EULAR European Congress of Rheumatology

EULAR 2022
1–4 June 2022

Abstracts

The EULAR Journal
Annals of the Rheumatic Diseases publishes original work on all aspects of rheumatology and disorders of connective tissue. Laboratory and clinical studies are equally welcome.
EULAR 2022 Abstracts Reviewers

ABHISHEK, Abhishek (UK)
ABLIN, Jacob (ISR)
ADAMI, Giovanni (ITA)
ALIVERNINI, Stefano (ITA)
ALLAART, Cornelia (NLD)
ALPIZAR-RODRIGUEZ, Deshiré (MEX)
ANTON, Jordi (Spain)
APPEL ESBENSEN, Bente (DNK)
ARAUJO, Filipe (PRT)
ASKLING, Johan (SWE)
ATSUMI, Tatsuya (JPN)
AVCIN, Tadej (SVN)
AYAN, Gizem (CAN)
BACKHOUSE, Mike (UK)
BAERWALD, Christoph (DEU)
BALINT, Peter (HUN)
BASU, Neil (USA)
BELIZNA, Cristina (FRA)
BENAVENT, Diego (Spain)
BENNIT, Sarah (UK)
BERTI, Alvise (ITA)
BERTSIAS, George (GRC)
BILGIN, Emre (Turkey)
BISSET, Hans (NLD)
BLOOM, Em (Turkey)
BLOCKMANS, Daniel (BEL)
BLUEML, Stephan (AUT)
BRUYERE, Olivier (BEL)
BRUCE, Ian (UK)
BRUYERE, Olivier (BEL)
BUKILICA, Mirjana (SRB)
BULTINK, Irene E.M. (NLD)
CAFARO, Giacomo (ITA)
CAILLOTTO, Frederic (FRA)
CAPORALI, Roberto (ITA)
CARDIEL, Mario (MEX)
CARMONA, Loreto (Spain)
CARRON, Philippe (BEL)
CARUBBI, Francesco (ITA)
CASTREJON, Isabel (Spain)
CANETE, Juan D. (Spain)
CHANDRAN, Vinod (CAN)
CHAPMAN, Victoria (UK)
CHAPURLAT, Roland (FRA)
CHIGHIZOLA, Cecilia (ITA)
CHINOY, Hector (UK)
CHRIST, Lisa (CHE)
CID, Maria (Spain)
CIUREA, Adrian (CHE)
CIURTIN, Coziana (UK)
CLARKE, Alex (UK)
COATES, Laura (UK)
CODREANU, Catalin (ROU)
COHEN SOLAL, Martine (FRA)
COHEN, Bernard (FRA)
CONSOLARO, Alessandro (ITA)
COPE, Andrew (UK)
COSTANTINO, Félicie (FRA)
COSTEDOAT-CHALMEAU, Nathalie (FRA)
CROWSON, Cynthia S. (USA)
DAIEN, Claire (FRA)
DE BARI, Cosimo (UK)
DE BENEDETTI, Fabrizio (ITA)
DE COCK, Diederik (BEL)
DE VLAM, Kurt (BEL)
DEANE, Kevin (USA)
DE JACO, Christian (ITA)
DEL GALDO, Francesco (UK)
DEN BROEDER, Alfons (NLD)
DENTON, Christopher (UK)
DIETER, Wiek (DEU)
DIFRESEKELI, Haner (Turkey)
DISTLER, Oliver (CHE)
DOLEZALOVA, Pavla (CZE)
DORIA, Andrea (ITA)
DUFTNER, Christina (AUT)
DUREZ, Patrick (BEL)
DÖRNER, Thomas (DEU)
E. VOLL, Reinhard (DEU)
EATHAKKATU ANTONY, Benny (AUS)
EDWARDS, Christopher (UK)
ELEWAUT, Dirk (BEL)
ELKAYAM, Ori (ISR)
ELS, Mateus (PRT)
ENGLUND, Martin (SWE)
FANOURIAKIS, Antonios (GRC)
FERREIRA, Ricardo (PRT)
FILIPPOU, Georgios (ITA)
FILLATREAU, Simon (FRA)
FINCH, Axel (CHE)
FINZEL, Stephanie (DEU)
FIRINU, Davide (ITA)
FISCHER-BETZ, Rebecca (DEU)
FITZGERALD, Oliver (IRL)
FOELL, Dirk (DEU)
FONTESTS, Francisca (PRT)
FRAGOUILIS, George (GRC)
GAFFNEY, Karl (UK)
GALLOWAY, James (UK)
GARCIA DE YEBENES, Maria Jesus (Spain)
GATTO, Mariele (ITA)
GALLOUX-VIALA, Cecile (FRA)
GENEVA, Stéphane (CHE)
GENSLER, Lianne (USA)
GIACOMELLI, Roberto (ITA)
GIANNETTI, Laetitia (FRA)
GUANABENS, Nuria (Spain)
GUINNESS, Iolo (FRA)
GUINARSSON, Iva (SWE)
HARAOUI, Boulos (CAN)
HASSELI, Rebecca (DEU)
HAUGEN, Ida Kristin (NOR)
HEBRICH, Christian (UK)
HELLWELL, Philip (UK)
HERMANN, Walter (DEU)
HERRERO-BEAUMONT, Gabriel (Spain)
HERRICK, Ariane (UK)
HÖPELER, Kirsten (DEU)
HOFMANN-VOLD, Anna-Maria (NOR)
HOLERS, V. Michael (USA)
HOLLICK, Rosemary (UK)
HOLROYD, Christopher (UK)
HORNNEFF, Gerd (DEU)
INGLEGNOLI, Francesca (ITA)
IONESCU, Ruxandra (ROU)
JAVAIY, Kassim (UK)
JUDE, Pierre-Antoine (FRA)
KERSCHBAUMER, Andreas (AUT)
KITZ, Uta (DEU)
KLOPPENBURG, Margreet (NLD)
KOCHE, Agnes (CHE)
KOK, Marc (NLD)
KORTEKAAS, Marion (NLD)
KOUTSIANAS, Christophos (UK)
KROON, Feline (NLD)
KRÖNKE, Gerhard (DEU)
KUO, Chang-Fu (TWN)
KUROWSKA-STOLARSKA, Mariola (UK)
LAMBOVA, Sevdalina (BGR)
LAMOT, Lovro (HRV)
LAMPRECHT, Peter (DEU)
LANDEWE, Roberto (NLD)
LAU, CS (HKG)
LAUPER, Kim (CHE)
LIEW, Jean (USA)
LORIES, Rik (BEL)
LOZA, Estibaliz (Spain)
LUBRANO, Ennio (ITA)
MAKRI, Souzi (CYP)
MANDL, Peter (AUT)
MARIETTE, Xavier (FRA)
MATHEW, Ashish J. (IND)
MAURO, Danielle (ITA)
MCBETH, John (UK)
MCGRAGGLE, Dennis (UK)
MERRIMAN, Tony (NZA)
METSIOS, George (UK)
MOLTO, Anna (FRA)
MOSCA, Marta (ITA)
MOSOR, Erika (AUT)
MUHAMMAD, Nisar (UK)
MYASOEDOVA, Elena (USA)
NAJM, Aurelie (UK)
NAVARRO, Victoria (Spain)
NDOSSI, Mwidi (UK)
NIKIPHOROU, Elena (UK)
NIMMERJAHN, Falk (DEU)
OLIVÉ, Alejandro (Spain)
OMETTO, Francesca (ITA)
OROZO, Gislue (UK)
OSTERGAARD, Mikkel (DNK)
PADOVANO, Leonid (SWE)
PAKOZDI, Angela (UK)
PENNE, Isabelle (BEL)
PENTEK, Marta (HUN)
PEREZ-RUIZ, Fernando (Spain)
PIANTONI, Silvia (ITA)
PIMENTEL SANTOS, Fernando (PRT)
PODDUBNYY, Denis (DEU)  
PRIMDAHL, Jette (DNK)  
PROFT, Fabian (DEU)  
PROTOPOPOV, Mikhail (DEU)  
PUTRIK, Polina (NLD)  
QUARTUCCIO, Luca (ITA)  
RAMIREZ, Giuseppe A. (ITA)  
RAMOS CASALS, Manuel (Spain)  
RAUSCH OSTHOFF, Anne-Kathrin (CHE)  
REGIERER, Anne (DEU)  
REYNOLDS, Gary (UK)  
RIEMEKASTEN, Gabriela (DEU)  
RITSCHL, Valentin (AUT)  
RIVELLESE, Felice (UK)  
RIZZI, Marta (DEU)  
RODRIGUES MANICA, Santiago (PRT)  
ROENIG, Sebastian (Spain)  
ROEOFS, Anke (UK)  
ROMAO, Vasco C. (PRT)  
ROTH, Johannes (DEU)  
RUARO, Barbara (ITA)  
RUBBERT-ROTH, Andrea (CHE)  
SAG, Erdal (Turkey)  
SALVARANI, Carlo (ITA)  
SCHULZE-KOOPS, Hendrik (DEU)  
SCHAFER, Valentins Sebastian (DEU)  
SELLAM, Jeremie (FRA)  
SENGUPTA, Raj (UK)  
SENOLE, Ladislav (CZE)  
SEPPIANO, Alexandre (PRT)  
SHERWOOD, Joanna (DEU)  
SHOENFELD, Yehuda (ISR)  
SHOOP-WORRALL, Stephanie (UK)  
SIEPER, Joachim (DEU)  
SIVERA, Francisca (Spain)  
SKAFENKO, Alla (DEU)  
SPARKS, Jeffrey (USA)  
SPIERINGS, Julia (NLD)  
STENOVA, Emoke (SVK)  
STRANGFELD, Anja (DEU)  
STUDENIC, Paul (AUT)  
SVENSSON, Camilla (SWE)  
SWART, Joost F. (NLD)  
SYTSKE, Anne Bergstra (NLD)  
SZUCS, Gabriella (HUN)  
SZEKANEZ, Zoltan (HUN)  
TASCHONNE, Anne-Katherine (DEU)  
TAYLOR, Peter C. (UK)  
TOEBERK, Klaus (DEU)  
TERRIR, Benjamin (FRA)  
TOES, Reinaldus (NLD)  
TOPLAK, Natasa (SVN)  
TROLDBORG, Anne Margrethe (DNK)  
UHLIG, Till (NOR)  
VAN DE SANDE , Marleen (NLD)  
VAN DER GEEEST, Kornelis (NLD)  
VAN DER HELM, Annette (NLD)  
VAN DER HORST-BRINSMA, Irene (NLD)  
VAN GAALEN, Floris A. (NLD)  
VAN LAAR, Jacob (NLD)  
VAN ONNA, Marloes (NLD)  
VAN TUBERGEN, Astrid (NLD)  
VAN WELLI, Salima (NLD)  
VENCOSK, Jiri (CZE)  
VERSTAPPEN, Suzanne (UK)  
VIEIRA-SOUZA, Elsa (PRT)  
VLIET VLIELAND, Thea (NLD)  
VONKEMAN, Harald (NLD)  
WEBERS, Casper (NLD)  
WESTHOVENS, Rene (BEL)  
WINCUP, Chris (UK)  
WITTOEK, Ruth (BEL)  
YAZICI, Yusuf (USA)  
ZIMBA, Olena (UKR)  
ZIGON, Polona (SVN)  

EULAR wishes to express its sincerest thanks to all abstract reviewers for their most appreciated collaboration.
Contents

Scientific Abstracts

Welcome Address
EULAR 2022 Abstracts Reviewers

Oral Presentations

OP0001  Addressing the effect of Placebo, Nocebo and Contextual factors in RMDs........ 1
OP0002  Bench to Bedside: The complement system in rheumatic diseases .................. 1
OP0003  Breaking the barriers: gut, lung and skin in arthritis pathogenesis ................... 2
OP0004  Does AI really help me diagnosing RMDs?......................................................... 3
OP0006  Is gender sufficiently studied in RMDs?.............................................................. 4
OP0008–OP0015 Plenary Abstract Session ..................................................................... 5
OP0024–OP0031 AxSpA drug treatment: new and old drugs.......................................... 9
OP0032–OP0039 Clinical aspects in Psoriatic Arthritis ................................................... 17
OP0042–OP0049 From risk assessment to societal outcomes ......................................... 23
OP0050–OP0057 Infection-related and other orphan rheumatic disorders ..................... 29
OP0058–OP0065 Managing chronic pain in RMDs ....................................................... 33
OP0066–OP0073 Modern biological treatment in RA ..................................................... 38
OP0074–OP0081 Adaptive immunity (T cells and B cells) in rheumatic diseases / Innate immunity in rheumatic diseases .............................................................................................................................. 46
OP0082–OP0089 Rheumatoid arthritis - aetiology, pathogenesis and animal models .... 50
OP0090–OP0097 Rheumatoid arthritis - prognosis and prediction ............................... 55
OP0098  The Yin and Yang of scleroderma and vasculitis .............................................. 60
OP0099  Microbiome and SpA ......................................................................................... 65
OP1000–OP1007 The role of the synovial microenvironment during onset and progression of arthritis .................. 65
OP1008–OP1015 Exploring the origin of inflammation in spondyloarthritis ................. 66
OP1016–OP1017 Translational and Clinical Research in Crystal Arthritis ...................... 108
OP1018–OP1019 Vaccination against SARS-CoV-2 ....................................................... 113
OP1020–OP1021 Vessels glowing in the dark .................................................................. 120
OP1022–OP1023 Active Ageing: new perspectives for RMD patients? ......................... 125
OP1024–OP1025 Modern technology for precision medicine ................................. 126
OP1026–OP1027 Rheumatology in Europe ................................................................... 127
OP1028–OP1029 Vaccination in rheumatic diseases with lessons from COVID ........... 127
OP1030–OP1031 sJIA vs AOSD: Two names one disease? What have we learnt so far ... 128
OP1032–OP1033 Autoinflammation over the course of a lifetime .................................. 128
OP1034–OP1035 Challenges of fibromyalgia ............................................................... 129
OP1036–OP1037 Long-COVID ..................................................................................... 130
OP1038–OP1039 Strengths and weaknesses of experimental models: Moving from animals to human clinical trials .......................................................................................................................... 131
OP1040–OP1041 Improving outcomes for children with JIA ........................................... 141
OP1042–OP1043 New developments in OA .................................................................. 146
OP1044–OP1045 Novel etiopathogenic aspects in SLE and Sjögren's syndrome ........ 152
OP1046–OP1047 Osteoporosis ....................................................................................... 157
OP1048–OP1049 Outcome of COVID-19 in Rheumatic Diseases ................................ 161
OP1050–OP1051 Emerging treatment strategies in PsA ................................................. 167
OP1052–OP1053 RA treatment: modern strategies and new molecules ....................... 174
OP1054–OP1055 RA: Clinical aspects and comorbidities - II ........................................ 181
OP1056–OP1057 Recent novelties in SLE/Sjögren and APS? ........................................ 185
OP1058–OP1059 The early bird gets the worm .............................................................. 190
OP1060–OP1061 Sjögren syndrome: from biopsy to lymphoma ..................................... 197
OP1062–OP1063 Crystal arthritis .................................................................................... 199
Late breaking abstracts

LB0001
LB0002
LB0003
LB0004
LB0005
LB0006

Poster Tours

POS0001–POS0011 Challenges in measuring and predicting RMDs
POS0012–POS0017 Challenging cases to make you think
POS0018–POS0028 Chronic pain - Mechanisms, epidemiology, and treatment
POS0029–POS0039 Genomics, functional genomics and genetic basis of inflammatory arthritis
POS0050–POS0060 Immunity in Rheumatic Diseases
POS0061–POS0071 Lung involvement in Rheumatic Diseases
POS0072–POS0082 New therapeutic avenues in psoriatic arthritis
POS0092–POS0102 Pathogenesis of SLE, Sjögren's and antiphospholipid syndrome
POS0103–POS0113 Rheumatoid arthritis – prognosis, predictors and outcome
POS0114–POS0123 Systemic lupus erythematosus, Sjögren's syndrome and anti-phospholipid syndrome
POS0124–POS0134 Through the looking glass
POS0135–POS0145 Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases
POS0146–POS0154 Clinical aspect of spondyloarthritis
POS0155–POS0163 Health services research: scoping the landscape
POS0164–POS0173 Improving our care and understanding of paediatric RMDs
POS0174–POS0182 New insights into the associations of outcomes and biomarkers in OA
POS0183–POS0193 New options in SLE-Sjögren and APS
POS0194–POS0204 Outcome of COVID-19 in patients with rheumatic diseases
POS0205–POS0214 RA comorbidities
POS0215–POS0224 Recent advances in orphan rheumatic diseases
POS0225–POS0233 Remodelling in OA
POS0234–POS0243 Rheumatoid arthritis: JAKi and beyond
POS0244–POS0253 Small vessels on fire
POS0254–POS0264 Vaccination against SARS-CoV-2
POS0265–POS0275 Achy-Breaky vessels
POS0276–POS0285 Advances in Crystal Arthritis
POS0286–POS0295 All you want to know about bDMARDs in RA
POS0296–POS0306 AxSpA: About treatments and outcomes
POS0307–POS0316 Clinical aspects in Psoriatic Arthritis
POS0317–POS0325 Mortality, Co-morbidity and disease burden
POS0326–POS0333 New data on pathophysiology of spondyloarthritis including psoriatic arthritis
POS0334–POS0343 New insights into the management of JIA
POS0344–POS0351 Novel molecular regulators of bone turnover
POS0352–POS0362 Systemic Lupus Erythematosus: monitoring and management
POS0363–POS0373 Telemedicine what does it tell us
POS0374–POS0382 What’s new in scleroderma and myositis?

POSTERS only

POS0383–POS0396 Genomics, genetic basis of disease and functional genomics
POS0397–POS0403 Adaptive immunity (T cells and B cells) in rheumatic diseases
POS0404–POS0406 Innate immunity in rheumatic diseases
POS0407 Osteo arthritis, aetiology, pathology and animal models
POS0408–POS0448 Rheumatoid arthritis - aetiology, pathogenesis and animal models
POS0449–POS0450 Spondyloarthritis - aetiology, pathogenesis and animal models
POS0451–POS0466 SLE, Sjögren's and APS - aetiology, pathogenesis and animal models
POS0467–POS0490 Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
POS0491–POS0494 Vasculitis - aetiology, pathogenesis and animal models
POS0495–POS0497 Basic and translational science in paediatric rheumatology
Basic and translational pain science ................................. 503
Rheumatoid arthritis - prognosis, predictors and outcome ........................................ 504
Rheumatoid arthritis - comorbidity and clinical aspects ........................................... 556
Rheumatoid arthritis - biological DMARDs .......................................................... 587
Rheumatoid arthritis - non biologic treatment and small molecules ...................... 604
SLE, Sjögren's and APS - treatment ................................................................. 633
SLE, Sjögren's and APS - clinical aspects (other than treatment) ......................... 644
Vasculitis - large vessel vasculitis ........................................................................... 683
Vasculitis - small vessel vasculitis .......................................................................... 702
Scleroderma, myositis and related syndromes ......................................................... 711
Spondyloarthritis – treatment .................................................................................. 765
Spondyloarthritis - clinical aspects (other than treatment) .................................... 783
Psoriatic arthritis – treatment .................................................................................. 815
Psoriatic arthritis - clinical aspects (other than treatment) .................................... 854
Osteoarthritis ........................................................................................................... 881
Osteopetrosis ............................................................................................................ 898
Crystal diseases, metabolic bone diseases other than osteoporosis ...................... 905
Infection-related rheumatic diseases .................................................................... 917
COVID-19 ............................................................................................................... 923
Pain in rheumatic diseases, including fibromyalgia ................................................. 981
Spine, mechanical musculoskeletal problems, local soft tissue disorders ............ 982
Paediatric rheumatology ......................................................................................... 983
Other orphan diseases ............................................................................................ 1001
Diagnostics and imaging procedures ...................................................................... 1030
Public health, health services research, and health economics .......................... 1041
Epidemiology, risk factors for disease or disease progression ............................... 1045
Validation of outcome measures and biomarkers .................................................. 1069
Rehabilitation ......................................................................................................... 1071
Education ................................................................................................................ 1072
Educational cases ..................................................................................................... 1075
Genomics, genetic basis of disease and functional genomics .............................. 1136
Adaptive immunity (T cells and B cells) in rheumatic diseases .............................. 1143
Innate immunity in rheumatic diseases .................................................................. 1153
Osteoarthritis, aetiology, pathology and animal models ......................................... 1157
Bone diseases, aetiology, pathology and animal models .......................................... 1161
Rheumatoid arthritis - aetiology, pathogenesis and animal models ..................... 1162
SLE, Sjögren's and APS - aetiology, pathogenesis and animal models .................. 1183
Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models .......................................................... 1193
Vasculitis - aetiology, pathogenesis and animal models .......................................... 1201
Basic and translational science in paediatric rheumatology ................................. 1207
Basic and translational pain science ..................................................................... 1208
Rheumatoid arthritis - prognosis, predictors and outcome .................................... 1209
Rheumatoid arthritis - comorbidity and clinical aspects ........................................ 1246
Rheumatoid arthritis - biological DMARDs ......................................................... 1289
Rheumatoid arthritis - non biologic treatment and small molecules .................... 1318
SLE, Sjögren's and APS - treatment ...................................................................... 1339
SLE, Sjögren's and APS - clinical aspects (other than treatment) ......................... 1353
Vasculitis – large vessel vasculitis .......................................................................... 1414
Vasculitis – small vessel vasculitis .......................................................................... 1430
Scleroderma, myositis and related syndromes ......................................................... 1449
Spondyloarthritis – treatment ............................................................................... 1500
Spondyloarthritis - clinical aspects (other than treatment) .................................... 1517
Psoriatic arthritis – treatment ................................................................................. 1562
Psoriatic arthritis - clinical aspects (other than treatment) .................................... 1590
Osteoarthritis .......................................................................................................... 1611
Osteoporosis ............................................................................................................ 1627
Crystal diseases, metabolic bone diseases other than osteoporosis .................... 1641
Infection-related rheumatic diseases ..................................................................... 1655
COVID-19 ............................................................................................................... 1660
Health Professionals in Rheumatology Abstracts

Oral Presentations

OP0007-HPR  “Not another pill!” Integrative pain management approaches ................................................. 4
OP0016-HPR–OP0123-HPR  HPR: From prevention to management ................................................................. 76
OP0198-HPR  How do we overcome the research-to-practice gap? Implementation of evidence into the rheumatology practice ................................................................. 131
OP0207-HPR–OP0214-HPR  HPR interventions on the spotlight ................................................................. 136
OP0295-HPR  Lifestyle and Disease activity in inflammatory arthritis ...................................................... 196
OP0296-HPR  Complexity of care in RMD: intersection between health and social care .......................... 197
OP0299-HPR  Facilitating work participation — why and how? ................................................................. 198
OP0301-HPR  Digital-Health and Tailored Interventions for Improving Patients’ Adherence: Opportunities and Challenges .................................................................................................................. 200
OP0308-HPR  Keeping the “Dark clouds” away: Psychological distress and RMDs ................................. 204

Poster Tours

POS0040-HPR–POS0049-HPR  HPR Poster Tour: Moving together towards person-centred care ................. 235

POSTERS only

POS1470-HPR–POS1492-HPR  HPR Measuring health (development and measurement properties of PROs, tests, devices) ........................................................................................................................................... 1081
POS1493-HPR–POS1495-HPR  HPR Epidemiology and public health (including prevention) ....................... 1092
POS1496-HPR–POS1510-HPR  HPR Interventions (educational, physical, social and psychological) ........... 1093
POS1511-HPR–POS1543-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) .......................................................................................................................... 1101
POS1544-HPR–POS1553-HPR  HPR Service developments, innovation and economics in healthcare .... 1117
POS1554-HPR–POS1559-HPR  HPR Professional education, training and competencies ........................... 1122
POS1560-HPR–POS1561-HPR  HPR Interdisciplinary research ........................................................................ 1126

Publication Only

AB1523-HPR–AB1533-HPR  HPR Measuring health (development and measurement properties of PROs, tests, devices) ........................................................................................................................................... 1864
AB1534-HPR  HPR Epidemiology and public health (including prevention) ................................................. 1869
AB1535-HPR–AB1543-HPR  HPR Interventions (educational, physical, social and psychological) ........... 1869
AB1544-HPR–AB1554-HPR  HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative) .......................................................................................................................... 1873
AB1555-HPR–AB1562-HPR  HPR Service developments, innovation and economics in healthcare .... 1878
AB1563-HPR–AB1566-HPR  HPR Professional education, training and competencies ........................... 1881
AB1567-HPR  HPR Interdisciplinary research ................................................................................. 1883

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

OP0005-PARE  How to maintain your quality of life after an RMD diagnosis ................................................. 3
OP0040-PARE–OP0041-PARE  In dialogue with the expert: axSpA and Sjogren’s syndrome .................... 28
OP0189-PARE  From childhood to adulthood - growing up with an RMD ................................................. 125
OP0200-PARE–OP0206-PARE  From abstract to concrete – the variety of activities of PARE organizations ................................................................. 132
OP0298-PARE  Enhancing research through patient involvement ......................................................... 198
OP0303-PARE–OP0304-PARE  The COVID-19 pandemic – what did we learn? ........................................ 201
OP0310-PARE  Volunteering for the RMD Community ......................................................... 205

Poster Tours
POS0083-PARE–POS0091-PARE  PARE Poster Tour 1 .................................................................................. 262
POS0352-PARE–POS0361-PARE  PARE Poster Tour 2 .................................................................................. 429

POSTERS only
POS1562-PARE–POS1568-PARE  Patient information and education ................................................................. 1127
POS1569-PARE  Building patient led organisations ......................................................................................... 1130
POS1570-PARE  Arthritis research ............................................................................................................... 1131
POS1571-PARE–POS1573-PARE  Innovations in arthritis health care .............................................................. 1132
POS1574-PARE  Psychosocial support .......................................................................................................... 1133
POS1575-PARE  Work and rehabilitation ..................................................................................................... 1133
POS1576-PARE–POS1579-PARE  Best practice campaigning ........................................................................ 1134

Publication Only
AB1568-PARE–AB1581-PARE  Patient information and education ................................................................. 1883
AB1582-PARE  Building patient led organisations ......................................................................................... 1889
AB1583-PARE–AB1585-PARE  Arthritis research ........................................................................................... 1890
AB1586-PARE  Innovations in arthritis health care ......................................................................................... 1891
AB1587-PARE  Work and rehabilitation ...................................................................................................... 1892

Author Index .................................................................................................................................................. 1893
Addressing the effect of Placebo, Nocebo and Contextual factors in RMDs

**OP0001** "I WILL NEVER FORGET THE SHAME I FELT": A SURVEY TO PEOPLE WITH A RHENUMATIC DISEASE ABOUT INVALIDATION FROM HEALTH PROFESSIONALS AND OTHER PEOPLE

A. Marques1,2,3, A. Silva3,3, J. Vicente4,5, E. Mateus6, R. J. O. Ferreira1,2, 1Centro Hospitalar e Universitário de Coimbra, Rheumatology, Coimbra, Portugal; 2Nursing School of Coimbra, Health Sciences Research Unit; Nursing (UCISA: E); Coimbra, Portugal; 3Nursing School of Coimbra, Professor, Coimbra, Portugal; 4Portuguese League against Rheumatic Diseases (LPCDR), Executive Board, Lisbon, Portugal; 5Portuguese Association of Fibromialgia (APJOF), Executive Board, Lisbon, Portugal

**Background:** The term invalidation refers to the patients’ perception that their medical condition is not recognised, either in denying, lecturing, not supporting or not acknowledging the condition. This may be felt from health professionals themselves but also from family, friends, at work and in other social areas, imposing great suffering. [1] The European Alliance of Associations for Rheumatology (EULAR) has made efforts to raise awareness for the burden imposed by rheumatic and musculoskeletal conditions (RMDs) and promote the best quality of care, including recognition and psychosocial support. However, it is unclear how frequent and severe the problem remains nowadays.

**Objectives:** The aims of this national survey were: (i) to identify the levels of invalidation and lack of understanding felt by adults with RMDs from health professionals and other people, (ii) to investigate the relationship between invalidation, sociodemographic characteristics and disease; and (iii) to understand its impact on people’s life and health outcomes.

**Methods:** An online survey was developed by the national health professionals in rheumatology and patients’ organisations and opened between May and December of 2021. The questionnaire included demographic and disease information, the Illness Invalidation Inventory (3*I),[1] with additional questions in a Likert format and open questions for a detailed understanding of the phenomenon. The 3*I is composed of 8 items, measured from 1 (=never) to 5 (=very often), forming two factors: Discounting (mean of 5 items; lower scores indicating more discounting) and Lack of understanding (mean of 3 items; Higher scores representing higher lack of understanding). Quantitative data were analysed using descriptive statistics. Associations were tested with a t-student and ANOVA one-way test (Bonferroni correction). Open responses were categorised using the content analysis technique, and themes were defined a posteriori.

**Results:** From the > 1500 responses obtained, 1410 responses were filled out completely (mean age of 46 years [SD=11], 95% females, 60% with FM, among which 59% were diagnosed in the last 5 years). Invalidation was reported by 86% of the participants and 70% rated ≤5 on a scale from 0 (nothing) to 10 (totally) on feeling understood by other people. Invalidation was mostly felt from family (56%), health professionals (48%), friends (39%), and social environment (38%). The impact of this invalidation is mainly on the psychological well-being (58%), also reducing seeking health care (41%) and therapeutic adherence (17%), affecting work (41%), and to a less extent, (family) relations (31%).

**Conclusion:** Invalidation is a source of suffering, affecting well-being and health outcomes. Specific awareness and educational campaigns are needed to target this problem on different play-actors.

**REFERENCES:**

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4969

**Bench to Bedside: The complement system in rheumatic diseases**

**OP0002** LOW COMPLEMENT LEVELS IN THE FIRST TRIMESTER PREDICT DISEASE FLARE IN SLE PREGNANCY: A NETWORK META-ANALYSIS ON 532 PATIENTS.

M. Radin1, F. Crisafulli2, I. Cecchi1, E. Klumb3, G. De Jesús4, M. A. Saavedra4, G. V. Reyes-Navarro3, L. Iaccarino5, M. Larosa5, G. Moroni5, F. Tamborini5, D. Roccatello1, L. Andreoli4, C. Chighizola5, S. Sciascia1, 1University of Turin, Clinical and Biological Sciences, Turin, Italy; 2University of Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 3Università dello Stato del Rio Janeiro, Rheumatology Department, Rio de Janeiro, Brazil; 4Hospital de Especialidades Dr. Antonio Fraga Mouret, Rheumatology Department, Mexico City, Mexico; 5Università Autónoma de Puebla, School of Medicine Puebla Campus, Puebla, Mexico; 6Università di Padova, Rheumatology Unit, Padova, Italy; 7Humanitas University, Department of Biomedical Sciences, Rozzano, Italy; 8ASST G. Pini & CTO, Pediatric Rheumatology, Milano, Italy

**Background:** The complement system is a key-player in the pathogenesis of systemic lupus erythematosus (SLE); its decreases correlate with disease activity and precedes flare. Since synthesis of complement proteins increase during gestational course, it is debated whether complement levels exert a prognostic role in pregnant women with SLE.

**Objectives:** We performed a network meta-analysis to assess the prognostic role of complement in pregnant SLE women, to evaluate the possible role of complement fluctuations during pregnancies.

**Methods:** Data from available prospective studies (Jan 2002-Dec 2020) investigating pregnancies in at least 50 SLE patients, excluding miscarriages before 12 weeks, were pooled together. After a systematic literature search, corresponding authors of 19 retrieved studies meeting inclusion criteria were invited to contribute with additional data, including complement levels [6 months before pregnancy, at conception, 1st trimester (T1), 2nd trimester (T2), 3rd trimester (T3) and 3 months after delivery].

**Results:** A total of 532 SLE women from four eligible studies were included in the analysis [1-4]. Lupus Nephritis (LN) was diagnosed in 237 patients (44.5%) and Antiphospholipid Syndrome in 68 (12.8%). A total of 170 patients (32%) experienced a flare during pregnancy, defined as need of new Immunosuppressants or increase of prednisone > 8mg/day. Patients with LN had significantly lower mean levels of complement (C3 at conception; C3 and C4 at T1; C3 after 3 months of delivery; C4 at all timepoints except for C4 at T3). SLE patients who experienced flares during pregnancy had significantly lower mean levels of complement (all timepoints for both C3 and C4). Table 1 shows the mean C3 and C4 levels in different timepoints according to diagnosis and flare during pregnancy. The lowest levels of complement were observed in patients with a concurrent diagnosis of LN and presence of flare, particularly during the T1 (Figure 1). Nevertheless, both in LN and flare groups the lowest levels of C3 and C4 were documented at T1.

**Figure 1.** Periods of responses per type of disease for the eight items of the Illness Invalidation Inventory.

**Figure 1.** Percentages of responses per type of disease for the eight items of the Illness Invalidation Inventory.
Breaking the barriers: gut, lung and skin in arthritis pathogenesis

OP0003 DOES IMMUNOSUPPRESSIVE THERAPY IMPROVE GASTROINTESTINAL SYMPTOMS IN PATIENTS WITH SYSTEMIC SCLEROSIS?

L. Stamm1, A. Garaiman1, N. Zampatti1, M. O. Becker1, C. Bruni1, R. Dobrota1, M. Ethal1, S. Ismail1, S. Jordan1, A. Tut1, O. Distler1, C. Mihai1
1 University Hospital Zürich, University of Zurich, Rheumatology, Zürich, Switzerland;
2 Azienda Ospedaliero Universitaria Careggi, University of Florence, Experimental Medicine, Division of Rheumatology, Florence, Italy; 3 National Research Center, Internal Medicine, Cairo, Egypt; 4 University Hospital Zürich, University of Zurich, Gastroenterology, Zürich, Switzerland

Background: The gastrointestinal (GI) tract is frequently affected in systemic sclerosis (SSc), leading to considerable morbidity and even mortality. While important progress has been made in the last years regarding treatment of SSc, there is no disease-modifying treatment available for SSc-related GI involvement.

Objectives: We aimed to identify, in an observational cohort study of real-life patients with SSc, an association between immunosuppressive therapy and the severity of GI symptoms, measured by the University of California at Los Angeles / Scleroderma Clinical Trial Consortium Gastro-Intestinal Tract instrument 2.0 (UCLA GIT 2.0).

Methods: We selected patients from our EUSTAR centre who met the 2013 ACR/EULAR classification criteria for SSc and had at least two visits with completed UCLA GIT 2.0 questionnaires, with an interval of 12±3 months between visits. We defined the first visit with a completed UCLA GIT 2.0 questionnaire as baseline visit. Immunosuppressive therapy was defined as exposure for at least 6 months between the two visits to at least one of the following drugs, regardless of indication: mycophenolate mofetil (MMF), cyclophosphamide, methotrexate, azathioprine, leflunomide, glucocorticoids (>10mg/d prednisone-equivalent), rituximab, tocilizumab, and abatacept. The study outcome was the UCLA GIT 2.0 score at the follow-up visit. We performed multivariable linear regression with this outcome as dependent variable and immunosuppressive therapy during follow-up, immuno-suppressive therapy before baseline, baseline UCLA GIT 2.0 score and several baseline parameters selected by clinical judgment as potentially influencing GI symptoms, as independent variables. Multiple imputation was implemented to handle missing values.

Results: We included 209 patients. Baseline characteristics were: 83.2% female, median (IQR) age 59.0 (48.6, 68.2) years, median disease duration 6.0 (2.7, 12.5) years, 40 (19.1%) diffuse cutaneous SSc, median baseline UCLA GIT 2.0 score 0.19 (0.06, 0.43). Of these, 71 patients were exposed to immunosuppressive therapy during the observation period had, compared to patients without such treatment, overall more severe SSc, higher prevalence of treatment with proton pump inhibitors, similar UCLA GIT 2.0 scores at baseline and at follow up and tendentially less severe GI symptoms at baseline and follow up by medical history. In multivariable linear regression, immunosuppressive therapy, lower body mass index, longer disease duration and lower baseline UCLA GIT 2.0 score were significantly associated with lower (better) UCLA GIT 2.0 scores at follow-up (Table 1).

Baseline factors associated with the total UCLA GIT 2.0 score at the end of the observation period. Multiple linear regression model with imputation for missing variables. N=209 patients

Conclusion: Immunosuppressive treatment was associated with lower UCLA GIT 2.0 scores, which suggests potential effects of immunosuppressants on GI manifestations in patients with SSc. These results need verification in additional studies and randomised controlled clinical trials.

REFERENCES:

Disclosure of Interests: Lea Stamm: None declared, Alexandru Garaiman: None declared, Norina Zampatti: None declared, Mike O. Becker Speakers bureau: Mepha, MSD, Novartis, GSK, Bayer and Vifor, Consultant of: Mepha, MSD, Novartis, GSK, Bayer and Vifor, Grant/research support from: Mepha, MSD, Novartis, GSK, Bayer and Vifor, Cosimo Bruni Speakers bureau: Actelion, Eli-Lilly, Boehringer-Ingelheim, Grant/research support from: Abbvie, EUSTAR, Gruppo Italiano Lotta alla Sclerodermia (GILS), SCTC, Rucsandra Dobrota
Does AI really help me diagnosing RMDs?

**OP0004**

**AUTOMATED RECOGNITION AND MONITORING OF DORSAL SKIN FOLDS BY A CONVOLUTIONAL NEURAL NETWORK AS A POTENTIAL DIGITAL BIOMARKER FOR JOINT SWELLING IN PATIENTS WITH RHEUMATOID ARTHRITIS**

T. Hügle1, L. Caratsch2, M. Matteo Caorsi2, J. Maglione3, D. Dan1, A. Dumusc1, M. Blanchard1, G. Kalweit1, M. Kalweit1, 4Lausanne University Hospital, CHUV, Department of Rheumatology, Lausanne, Switzerland; 4L2F, Informatics, Lausanne, Switzerland; 5Ecole Polytechnique Fédérale de Lausanne (EPFL), Informatics, Lausanne, Switzerland; 4Lausanne University Hospital, CHUV, Division of Rheumatology, Lausanne, Switzerland; 6University of Freiburg, Department of Computer Science, Freiburg, Germany

**Background:** To monitor rheumatic diseases, digital biomarkers such as wearables are of increasing interest, but they lack disease specificity.

**Objectives:** In this study, we apply convolutional neural networks (CNN) to real world hand photographs in order to automatically detect, extract and analyse dorsal finger fold lines as a correlate of proximal interphalangeal (PIP) joint swelling in patients with rheumatoid arthritis (RA).

**Methods:** Hand photographs from 190 RA patients were taken by a smartphone camera in a standardized manner. PIP joints were categorised as either swollen or not swollen based on clinical judgement and ultrasound. Images were automatically preprocessed by cropping PIP joints and extracting dorsal finger folds. Subsequently, metrical analysis of dorsal finger folds was performed and a CNN was trained to classify the dorsal finger lines into swollen versus non-swollen joints. Representative horizontal finger folds were also quantified in a subset of patients before and after resolution of PIP swelling and in patients with disease flares, respectively.

**Results:** In swollen joints, the number of automatically extracted double-contoured, deep skinfold imprints was significantly reduced compared to non-swollen joints. The joint diameter / deep skinfold ratio was significantly higher in swollen (4.1, SD 1.4) versus non-swollen joints (2.1, SD 0.6). The CNN model successfully differentiated swollen from non-swollen joints based on finger fold patterns with a validation accuracy of 0.84. A heatmap of the original images obtained by an extraction algorithm confirmed finger folds as the region of interest for correct classification. After significant response to DMARD +/- corticosteroid therapy, longitudinal metrical analysis as a digital biomarker in RA showed a decrease of the mean diameter/ finger fold length (finger fold index, FFI) from 3.03 (SD 0.68) to 2.08 (SD 0.57). Conversely, the FFI increased in patients with a flare of joint swelling.

**Conclusion:** Automated preprocessing and the application of CNN algorithms in combination with longitudinal metrical analysis of dorsal finger fold patterns extracted from real world hand photographs might serve as a digital biomarker in RA.

**Disclosure of Interests:** Thomas Hügle Shareholder of: Areton SA., Speake rs bureau: Multiple. Not relevant for this work., Leo Caratsch: None declared, Matteo Matteo Caorsi Employee of: MC is an employee of L2F., Jules Maglione: None declared, Maria Dan: None declared, Alexandre Dumusc Speakers bureau: Multiple. Not relevant for this work., Leo Caratsch: None declared, Matteo Matteo Caorsi Employee of: MC is an employee of L2F., Jules Maglione: None declared, Maria Dan: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.565

How to maintain your quality of life after an RMD diagnosis

**OP0005-PARE**

**DEVELOPMENT OF CONVERSATION AIDS: HOW TO GET THE MOST OUT OF YOUR RMD APPOINTMENT AND ADVANCE YOUR QUALITY OF LIFE**

P. Ronsse, Msc1, P. Pennings, Msc2, B. Maat1, I. Hest3, F. Van Eeckelen1, H. Van de Weijer1, I. Schoonen-Nuitten1, G. Willemsen-de Mey Msc1, 1National Association ReumaZorg Nederland, Patientexpert and Coordinator at the Department of Patient participation and Communication, Nijmegen, Netherlands; 2National Association ReumaZorg Nederland, Coordinator at the Department of Patient participation and Communication, Nijmegen, Netherlands; 3National Association ReumaZorg Nederland, Patientpartner at the department of Patient participation and Communication, Nijmegen, Netherlands; 4Bravis Medical Centre, Rheumatology Nurse at the Department of Rheumatology, Roosendaal, Netherlands; 5National Association ReumaZorg Nederland, President of the Board, Nijmegen, Netherlands

**Background:** Having a Rheumatic and Musculoskeletal Disease (RMD) has a big impact on your daily life, work, relationships and quality of life. It can cause various complaints, problems and questions. Research shows that people with an RMD are often insufficiently aware that they can talk about these challenges with their RMD professional. They also don't realise that these challenges matter when making a fitting choice for treatment. It also appears that RMD professionals do not sufficiently take into the account the priorities of their patient, when a treatment choice has to be made. This is unfortunate because research shows that people who decide together with their RMD professional make better informed treatment choices. They are also more likely to adhere to their treatment or medication use. A conversation aid can help people to become aware of the most important challenges or problems in their daily lives with an RMD. These uncovered challenges and problems can set the agenda for a good conversation in the RMD consultation room. Together with the RMD professional the conversation can focus on ways to deal with or treat these challenges or problems.

**Objectives:** To develop a conversation aid for people with an RMD that allows them to become aware of the most important challenges in their life with an RMD and that guides them in how to discuss these aspects with an RMD professional.

**Methods:** In the first step a review was made of all important aspects of a patient's life with an RMD. The outcome measures of ICHOM for inflammatory arthritis1 and hip- and knee osteoarthritis2 formed the starting point for this review. This was complemented with additional outcomes as measured in Dutch RMD apps and patient dashboards of Dutch hospitals. In the second step, the list of outcomes was assessed by means of a survey among Dutch patients with an RMD. The third step was to discuss the complete list with important outcomes with the Dutch rheumatology department of the Bravis Medical Centre. A first draft version of the conversation aids was made. This draft version was evaluated by patientpartners of the National Association ReumaZorg Nederland (RZN) and the Bravis Medical Centre.

**Results:** A total of 4 conversation aids (https://reumazorgnederland.nl/samen-beslissen-gesprekskaarten/) were made. Each aid addressing a main category of challenges with an RMD. Each main category was divided into 5 sub-categories. The 4 conversation aids are:

- **Disease:** Concerning the sub-categories: Disease activity, pain, fatigue, medication & side effects and knowledge about the disease.
- **Daily activity:** Concerning the sub-categories: Work/school, personal care, household & family, mobility, and spare time.
Lifestyle: Concerning the sub-categories: Activity, food, stress & relaxing, smoking, and weight.

Relationships and well-being: Concerning the sub-categories: Social contacts, intimate relationships & pregnancy & wish for children, incomprehension, loneliness, and gloom.

To advance Shared Decision Making (SDM), a separate conversation aid was made with tips and tricks for having a good conversation with your RMD professional:

• A good conversation: tips and tricks for preparing a conversation with your RMD professional. As well as tips and tricks that can be used during and after your conversation.

In Figure 1 the conversation aid with main category lifestyle is presented.

Figure 1. Example of the conversation aid with main category Lifestyle.

Conclusion: A consultation aid can advance a good conversation and therefore SDM, between people with an RMD and their RMD professional. A patient organization can play an important role in developing a consultation aid.

REFERENCES:
[1] ICHOM, Inflammatory Arthritis: Inflammatory Arthritis – ICHOM Connect

Acknowledgements: The voice of people with an RMD played a crucial role in the development of these consultation aids. We would like to thank everyone, including Bravis Medical Centre, for their feedback throughout the process.

Disclosure of Interests: None declared.


Is gender sufficiently studied in RMDs?

"Not another pill!" Integrative pain management approaches.

Table 1. Association between occupational silica exposure (by quartile) and HRCT lung abnormalities

<table>
<thead>
<tr>
<th>HRCT abnormality</th>
<th>OES (Quartiles)</th>
<th>Unadjusted OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial hilar lymphadenopathy</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>4.1 (1.2 to 13.9)</td>
<td>6.3 (1.4 to 27.7)</td>
<td></td>
</tr>
<tr>
<td>Interal lung disease</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>6.3 (1.5 to 26.6)</td>
<td>6.5 (1.3 to 32.6)</td>
<td></td>
</tr>
<tr>
<td>Emphysema</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>6.4 (1.6 to 24.7)</td>
<td>2.9 (0.6 to 13.7)</td>
<td></td>
</tr>
</tbody>
</table>

Disclosures of Interests: None declared.


Cleansing Activities, Dusty Clothes Laundry and Talcum Handling are Underestimated Major Sources of Exposure to Crystalline Silica in Women with Rheumatoid Arthritis

J. Siqueur,1,2; C. Cavallin,3,4; A. Lescoat,5; P. Y. Brillet,5; L. Sese6; H. Nunes6; M. C. Boissier1,2; L. Semerano1,2; A. Bouillet1,2; L. Lefebvre1,2

Avicenne Hospital, Rheumatology, Bobigny, France; Université Sorbonne Paris Nord, UMR 1125 Inserm, Bobigny, France; Université Paris Dauphine, IRISOS, UMR CNRS-INRAE 7170-1427 Paris, France; Science Po, Laboratoire Interdisciplinaire d’évaluation des politiques publiques (LIEPP), Paris, France; CHU Rennes, Rheumatology, Rennes, France; Avicenne Hospital, Radiology, Bobigny, France; Avicenne hospital, Physiology, Bobigny, France; Avicenne Hospital, Respiratory, Bobigny, France.

Background: Inhalation of crystalline silica (cSiO2) is associated with rheumatoid arthritis (RA). Research on cSiO2 has historically focused on professional exposures and on male workers. However, cSiO2 ubiquitously present in the environment, substantial exposure can take place in both men and women, in other professional activities and even beyond occupational context.

Objectives: To identify the main sources of exposure to crystalline silica in a series of RA patients not selected based on their professional activity, and to assess the association between silica exposure and disease features.

Methods: The Dust Exposure Life-Course Questionnaire (DELCQ) is a novel tool that longitudinally quantifies both occupational and non-occupational lifetime exposure to crystalline silica. The DELCQ was previously validated in a representative sample of the general French population that serves as control source for studies in specific diseases. The DELCQ was administered to 87 consecutive patients with RA, exposure scores were compared between cases and age-, sex- and smoking status-matched controls (1:4). The main sources of silica exposure were identified in cases and controls and source-specific exposure levels compared. The association between DELCQ scores and disease variables in cases was tested using multivariable analysis.

Results: In women with RA, the main sources of crystalline silica exposure were cleaning activities, dusty clothes laundry and talcum powder handling, with higher exposure levels from these sources vs. the general population (p<0.005).

In the whole series of RA patients, high silica exposure was independently associated with interstitial lung disease (OR 6.5 (95% CI: 1.3 to 32.6)) and mediastinal lymphadenopathy (OR 6.3 (95% CI: 1.4 to 27.7).

Conclusion: Cleaning activities, dusty clothes laundry and talcum handling are underestimated sources of crystalline silica exposure that are overrepresented in women with RA compared to the general population and may contribute to the pathogenesis of the disease.

Table 1. Association between occupational silica exposure (by quartile) and HRCT lung abnormalities

<table>
<thead>
<tr>
<th>HRCT abnormality</th>
<th>OES (Quartiles)</th>
<th>Unadjusted OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medial hilar lymphadenopathy</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>4.1 (1.2 to 13.9)</td>
<td>6.3 (1.4 to 27.7)</td>
<td></td>
</tr>
<tr>
<td>Interal lung disease</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>6.3 (1.5 to 26.6)</td>
<td>6.5 (1.3 to 32.6)</td>
<td></td>
</tr>
<tr>
<td>Emphysema</td>
<td>Q1-Q3 (ref)</td>
<td>(ref)</td>
<td>(ref)</td>
</tr>
<tr>
<td>Q4</td>
<td>6.4 (1.6 to 24.7)</td>
<td>2.9 (0.6 to 13.7)</td>
<td></td>
</tr>
</tbody>
</table>

Disclosures of Interests: None declared.


"Not another pill!" Integrative pain management approaches.

OP00067+HPR AN EPIDEMIOLOGICAL STUDY OF FOOT AND ANKLE PAIN AND HEALTH-RELATED JOB LOSS IN ADULTS OVER 50: CROSS-SECTIONAL FINDINGS FROM THE HEAP COHORT

D. Jobanputra1, L. Cherry2, K. Walker-Bone3, C. Price1, S. D’angelo5, G. Ntani5, on behalf of Health & Employment After Fifty. 1University of Southampton School of Medicine, Faculty of medicine, Southampton, United Kingdom; 2University of Southampton, School of Health sciences, Southampton, United Kingdom; 3University of Southampton, MRC Versus Arthritis Centre for Musculoskeletal Health and Work, Southampton, United Kingdom

Background: Foot and ankle pain (FAP), particularly that of musculoskeletal origin, is increasingly prevalent in our aging populations. Moreover, governments need people to work to older ages to reduce the costs of pensions and welfare benefits. It is not currently known however whether people with FAP are able to keep working or to what extent it pushes people out of work. We investigated this question in older working adults.

Objectives: To determine whether FAP is associated with HRJL amongst older working adults.

Methods: Health And Employment After Fifty is a longitudinal population-based cohort inceptioned 2013 to investigate health and retirement. At follow-up two years later, people were asked to complete a full-body mannequin which included the ankles/feet. Mannequins were coded: foot/ankle pain (FAP) with pain at other sites; pain elsewhere but not FAP; and no pain. Two years later, participants were asked whether they had left paid work entirely or partly because of health problems. Amongst those with HRJLs, 73 had no pain, 54 had pain involving FAP, 108 had pain not involving FAP . After adjusting for age and sex, people with FAP had 83% increased risk of HRJL compared to people with no pain (HR=1.83, 95% CI 1.29-2.61), whilst those with pain NOT involving FAP had 34% increased risk of HRJL.
A NOVEL SITE-SPECIFIC PEGYLATED IL-2 WITH POTENT AND TREG-SELECTIVE ACTIVITY IN VIVO

M. Ikeda1, S. Yamaguchi2, M. Murakami2, S. Takaoka2, Y. Sakaguchi2, S. Yasui2, K. Iijima2, K. Nanya2, H. Onodera2, T. Amano3, 1Kyowa Kirin Co., Ltd., R&D division, Sunto-gun, Shizuoka, Japan; 2Kyowa Kirin Co., Ltd., R&D division, Sunto-gun, Shizuoka, Japan; 3Kyowa Kirin Co., Ltd., R&D division, Machida-shi, Tokyo, Japan

Background: Decreased regulatory T cells (Tregs) and Treg dysfunction are hallmarks of a variety of autoimmune and inflammatory diseases. While low-dose IL-2 therapy induces Treg expansion in vivo and has clinical benefits in some diseases (e.g., SLE and chronic graft-versus-host disease [GVHD]), there are many concerns about adverse events due to low Treg-selectivity. Furthermore, frequent dosing is needed due to the short half-life.

Objectives: We discovered a novel site-specific PEGylated IL-2 variant, KKC80, with high Treg selectivity and a long half-life in vivo, which overcomes the issues of low-dose IL-2 therapy.

Methods: Based on the co-crystal structure of wild-type IL-2 and its heterotrimERIC receptor (PDB ID: 2ERJ), copper-amido acids that were to be PEGylated sites were substituted with oAzZLys, an azide-containing lysine derivative. The PEG molecule was site-specifically attached to oAzZLys-incorporated IL-2 by copper-free click chemistry. The binding property to the IL-2 receptors were measured by surface plasmon resonance (SPR). In vitro, Treg selectivity was evaluated by the IL-2-dependent proliferation activity of Tregs and NK cells from human peripheral blood mononuclear cells (PBMCs). In vivo pharmacological activity was assessed after the single subcutaneous administration in cynomolgus monkeys, and the selected features for RNA-Seq, DNA methylation and GWAS data were calculated according to serum PEGylated IL-2 concentration. Efficacy in mouse xenogenic GVHD model using human PBMC-transplanted NOG mice and in monkey DTH model were evaluated.

Results: A novel PEGylated IL-2, KKC80 (human IL-2 desA1/C125S/I126oAzZLys, W-shaped 80kDa PEG) was discovered by optimizing the PEGylation site and PEG structure based on Treg selectivity and PK. SPR analysis showed that the binding affinity of KKC80 to CD25 was moderately decreased from wild-type IL-2, while binding affinity of KKC80 to IL-2Rα was remarkably decreased due to a significant change of the association rate constant. In vitro, wild-type IL-2 activated both Tregs and NK cells in the same concentration range, whereas KKC80 selectively activated Tregs. The Treg selectivity of KKC80 was comparable to another IL-2 mutein, Flc-IL-2 V91K. KKC80, but not Flc-IL-2 V91K, retained its biological activity, even in the presence of a large amount of recombinant soluble CD25, which mimicked the endogenous decoy receptor for IL-2. In monkeys, KKC80 selectively increased peripheral blood Tregs in a dose-dependent manner; the average maximum rate of increase of Treg count in animals treated with 0.01, 0.03, 0.1, 0.3 and 1 mg/kg was 1.5, 3.5, 26, 50 and 154-fold, respectively; in contrast to Tregs, the rates of increase of conventional CD4+ T, CD8+ T and NK cells were low. The Treg increase peaked on day 8 or 11 and lasted for over day 29. KKC80 showed a more sustained upregulation of functional Treg markers (e.g., Foxp3 and CD25) in comparison to Flc-IL-2 V91K. The half-life of KKC80 was calculated as 83.5 to 150h. At high doses, inflammation-related adverse effects, including increased CRP (≥0.3 mg/kg) and deterioration of general conditions (1 mg/kg) were observed. In the mouse xenogenic GVHD model, KKC80 ameliorated GvHD symptoms and suppressed multiple tissue inflammation markers. Decreased soluble CD25 and IFN-γ were also confirmed, suggesting that Treg-mediated anti-inflammatory effect by KKC80 administration were exerted in vivo. In the monkey DTH model, KKC80 suppressed skin inflammation and antibody production.

Conclusion: Among next-generation IL-2 variants, KKC80 showed a best-in-class biological profile for Treg activation. A drastic and sustained increase of Tregs with high Treg-selectivity and anti-inflammatory effects were observed in vivo. These data suggest that in comparison to current IL-2 therapy, KKC80 provides superior therapeutic index and efficacy in patients with autoimmune and inflammatory diseases.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.369
Two-tailed pairwise Wilcoxon-rank sum test results are shown. Plots show median, with error
z-score analyses were performed for 286 pSS, 351 SLE and 94 UCTD patients and 254 HCs.
further disease manifestations. Together these findings underpin the role of B cell hyperactivity in pSS, that culminates in an altered ASC compartment.

Conclusion: Anti-Ro60+ patients present a specific inflammatory signature regardless of their disease suggesting that a dual approach targeting both Ro-associated RNAs and anti-Ro60 autoantibodies should be considered.

REFERENCES:

Disclose of Interests: None declared.

Figure 1. Three genes common to RNA-seq, DNA methylation and GWAS analysis char
acterize anti-Ro60+ patients. (A) ATP10/MX1/PARP14 z-score analyses were performed for 731 patients and 254 HCs according to anti-Ro60 expression. (B) ATP10/MX1/PARP14 z-score analyses were performed for 286 pSS, 351 SLE and 94 UCTD patients and 254 HCs. Two-tailed pairwise Wilcoxon-rank sum test results are shown. Plots show median, with error bars indicating interquartile range. (pSS: primary Sjögren’s syndrome, SLE: systemic lupus erythematosus, UCTD: undifferentiated connective tissue disease, HCs: healthy controls).

Figure 1. (A) Frequencies and absolute numbers of antibody-secreting cells (ASC) are increased in pSS patients and (B) correlate with salivary gland focus scores. (C) More mature CD28+ ASCs are associated with focus scores and (D) higher pro-inflammatory levels of CXCR3.

REFERENCES:


ressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 2015.

Disclosur of Interests: None declared.

OP0010
A MORE MATURE PLASMA CELL AND PLASMABLAST COMPARTMENT IS ASSOCIATED WITH DISEASE MANIFESTATION IN PRIMARY SJÖGREN’S SYNDROME

T. D. Steinmetz, G. M. Verstappen1, H. Bootma1, F. G. M. Kroese.1. University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands

Background: Sjögren’s syndrome (pSS) is an autoimmune disorder often associated with fatigue, dry eyes and dry mouth symptoms and characterized by chronic inflammation of moisture-producing glands like salivary and lacrimal glands (1). Auto-antibodies, B cell infiltration of affected glands and lymphoma development are signs for B cell hyperactivity in pSS (1-3). The B cell effector branch, namely antibody-secreting cells (ASC) like plasmablasts and plasma cells, can sustain autoimmune pathogenicity over long time periods by secretion of auto-antibodies (4,5).

Objectives: Since B cell hyperactivity is an important pathogenic feature in pSS, antibody-secreting cells as B effector cells are studied to characterize their abundance, maturation stage and inflammatory properties and relate them to pSS manifestations.

Methods: Peripheral blood mononuclear cells (PBMC) from pSS patients and healthy individuals were subjected to spectral flow cytometry phenotyping. CD27+CD38+ ASCs were analyzed with a comprehensive TSNE approach as well as based on expression of ASC markers. This includes markers described for maturity like CD19, CD138, CD28, Blimp1 and HLA-DR and markers relevant for ASC survival like Mc1 and BCMA. The pro-inflammatory status of the cells was assessed by CXCR3 and CXCR4 expression and their immune regulatory properties with markers like IL-10 and Lag-3. ASC properties like maturity state were correlated to characteristic pSS disease-associated features.

Results: Patients with pSS had higher frequencies and absolute numbers of ASCs than healthy controls. ASCs displayed a higher degree of maturation in pSS. ASC frequencies and their maturity state, for example reflected by CD19 down-regulation or increased CD28 expression (6), correlated with several pSS disease characteristics like ANA titers, focus scores and ocular scores indicating glandular impairment. Additionally, more mature ASCs that express low amounts of CD19 had increased Mc1 levels indicating prolong survival of these cells. The maturation state of ASCs was associated with CXCR3+ ASC frequencies in pSS patients. Expression levels of anti-inflammatory IL-10 and pathogenic CXCR3 by ASCs in pSS patients was negatively correlated. tSNE related clusters enriched for ASCs from pSS patients were more mature but also had higher expression levels of CXCR3.

Conclusion: Circulating ASCs in pSS are more abundant and have a more mature phenotype compared to healthy individuals. Their frequencies and degree of maturation could be linked to pSS disease features. Prolonged survival and pro-inflammatory status might further increase the impact of circulating ASCs on disease manifestations. Together these findings underpin the role of B cell hyperactivity in pSS, that culminates in an altered ASC compartment.

REFERENCES:


Disclosur of Interests: None declared.

OP0011
HIGHLY DIFFERENTIATED CD4 AND CD8 T EFFECTOR MEMORY CELLS RE-EXPRESSION CD45RA (TEMRA) ARE ASSOCIATED WITH ACTIVE DISEASE REFRACTORY TO ANTI-TNF THERAPY IN RHEUMATOID ARTHRITIS

1. University College London, Rheumatology, London, United Kingdom; 2. University College London, Experimental and Translational Medicine, Division of Medicine, London, United Kingdom

Background: Highly differentiated T cells have been reported to be enriched in rheumatoid arthritis (RA) compared to healthy individuals. The role of terminally differentiated T effector memory re-expressing CD45RA (Temra) in RA pathogenesis and disease activity is still unclear, including whether they can be used as a marker of sustained disease activity in RA patients receiving anti-TNF therapy.

Objectives: To investigate whether the frequency of peripheral blood Temra can be used as a biomarker to identify disease refractory to anti-TNF therapy in RA, if they correlate with inflammation in anti-TNF treated patients, and whether they associate with a flare following tapering anti-TNF.

Methods: RA patients on anti-TNF therapy were recruited from rheumatology clinic (cross-sectional cohort). Clinical data and whole blood were collected.
Patients were stratified based on disease activity. Remission was defined as no recorded DAS28-CRP $\leq 2.4$, no swollen joints, no C-reactive protein (CRP) of $>5\text{mg/L}$, and on a stable DMARD dose and no reported disease flare/loss of remission in the 6 months prior. Non-remission was defined as any other disease activity which does not fulfill the remission definition. Patients on abatacept, or methotrexate monotherapy and healthy volunteers were recruited as comparison groups. A separate cohort of anti-TNF patients (longitudinal cohort) who have been in remission on a stable dose of anti-TNF for 6 months and no use of corticosteroids in the last 6 months, was also recruited. Whole blood was obtained prior to dose tapering (dose halving) and at the point of a flare. Whole blood was processed by gradient centrifugation to obtain peripheral blood mononuclear cells (PBMC). PBMC were stained with fluorochrome-conjugated antibodies for multi-parameter flow cytometry. Analysis was performed on live lymphocytes using FlowJo software version 10.8. Two-tailed Mann-Whitney U test or unpaired t-test were used to obtain unadjusted values, analysis of variance (ANOVA) of log-transformed data was used to obtain age-adjusted values, Spearman's rank correlation was used to compare correlation between Temra and CRP.

**Results:** RA patients (36 anti-TNF, 12 abatacept, 16 methotrexate monotherapy) and 14 healthy individuals were recruited. There was a higher proportion of CD4 (age-adjusted $p = 0.004$) and CD8 Temra (age-adjusted $p = 0.0007$) in RA patients on anti-TNF with persistent disease activity compared to those who had achieved remission. These differences were confirmed when analysing absolute numbers of CD4 and CD8 Temra. Unexpectedly, the difference in Temra frequency between remission and non-remission RA was not observed in patients treated with methotrexate or abatacept. The median CD4 and CD8 Temra frequencies in RA patients in remission with all treatments studied were similar to healthy individuals.

Temra were not observed to increase with age in the anti-TNF, abatacept, or methotrexate cohorts in contrast to previous reports in healthy individuals. The frequency of CD4 and CD8 Temra correlated with CRP only in patients on anti-TNF (CD4 Temra Spearman $r = 0.5185$, $p = 0.001$, and CD8 Temra Spearman $r = 0.5040$, $p = 0.005$).

There was an increase in CD4 ($p = 0.003$) but not CD8 Temra at 3 months in patients who flared on tapering anti-TNF compared to those who remained in remission (Figure 1).

**Conclusion:** Increased CD4 and CD8 Temra frequency were associated with persistent disease activity in anti-TNF treated patients but not with other DMARD therapies (abatacept and methotrexate). CD4 Temra increased in those who flared on tapering anti-TNF. These results suggest that Temra may play a role in driving persistent disease activity refractory to anti-TNF therapy rather than merely a marker of inflammation.

**References:**


**Disclosure of Interests:** Su-Ann Yeo: None declared, James Kimpton: None declared, Muhammad Shipa: None declared, Eleanor Hawkins: None declared, Anne Akbar Grant/research support from: AA has received funding from the Leo Sun Foundation (Denmark), Michael Ehrenstein Consultant of: MRE has received consultancy fees from Galapagos and Sanofi, Grant/research support from: MRE has received financial grants from GlaxoSmithKline.

**DOI:** 10.1136/annrheumdis-2022-eular.1726

---

**Figure 1.** Percentage (%) change in CD4 and CD8 Temra between baseline (pre-taper) and 3 months after anti-TNF tapering. CD4 or CD8 Temra were calculated using FlowJo software version 10.8. Two-tailed Mann-Whitney U test or unpaired t-test were used to obtain unadjusted values, analysis of variance (ANOVA) of log-transformed data was used to obtain age-adjusted values, Spearman’s rank correlation was used to compare correlation between Temra and CRP.

**Acknowledgements:** SAY is funded by research grants from Versus Arthritis, Royal College of Physicians/Rosetrees Trust, Newcastle University College London Hospitals Biomedical Research Centre and UCLH Charities.
Disclosure of Interests: Faye Cooles Speakers bureau: AstraZeneca: December 2021, Jessica Tarn: None declared, Dennis Lundgren: None declared, Najib Naaman: None declared, Alice Lin: None declared, Ben Millar: None declared, Nicola Maney: None declared, Nishanthi Thalayasingam: None declared, Vincent Bondet: None declared, Darragh Duffy: None declared, Michael Barnes: None declared, Graham Smith: None declared, Sandra Ng: None declared, David Watson: None declared, Rafael Henkin: None declared, Andrew Cope: None declared, Louise Reynard: None declared, Arthur Pratt: None declared, RA-MAP Consortium: None declared, John Isaacs Speakers bureau: speaker/consulting fees from AbbVie, Gilead, Roche and UCB, Grant/research support from: JDF discloses research grants from Pfizer, Janssen and GSK.

DOI: 10.1136/annrheumdis-2022-eular.1126

OP0013

LOSS OF SYNOVIAL TISSUE MACROPHAGE HOMEOSTASIS PRECEDES RHEUMATOID ARTHRITIS CLINICAL ONSET

M. Hanlon1, M. Canavan1, N. Neto2, Q. Song1, P. Gallagher4, R. Mullan2, C. Hurson2, B. Moran1, M. Monaghan2, S. Nagal3, D. Veale1, U. Fearon1.

1Trinity Biomedical Sciences Institute, Molecular Rheumatology Research Group, Dublin 2, Ireland; 2Trinity Biomedical Sciences Institute, Mechanical and Manufacturing Engineering, Dublin, Ireland; 3Janssen Research and Development Spring House, Immunology & Discovery Sciences, Philadelphia, United States of America; 4St. Vincent’s University Hospital, EULAR Centre of Excellence, Centre for Arthritis & Rheumatic Diseases, Dublin, Ireland; 5Tallaght University Hospital, Rheumatology, Dublin, Ireland; 6St. Vincent’s University Hospital, Department of Orthopaedics, Dublin, Ireland; 7Trinity Biomedical Sciences Institute, Translational Immunology, Dublin, Ireland

Background: Synovial tissue macrophages significantly contribute to Rheumatoid Arthritis, yet the precise nature/function of macrophage subsets within the inflamed joint remains unexplored.

Objectives: To fully explore the spectrum of distinct macrophage activation states residing within the synovium of RA, at risk and healthy individuals.

Methods: Single-cell synovial tissue suspensions from RA (n=44), IAR (n=5), HC (n=11), PaA (n=11) and OA (n=4) were obtained, and synovial macrophage subsets examined by advanced multiparameter flow cytometric analysis, bulk RNA-sequencing, metabolic and functional assays.

Results: Multidimensional analysis identifies enrichment of CD206+CD163+ synovial-tissue macrophages co-expressing CD40 in the RA joint compared to healthy synovial-tissue, with frequency of CD206+CD163+CD40+ macrophages associated with increased disease activity and treatment response. In contrast, CX3CR1-expressing macrophages which form a protective barrier in healthy synovium are significantly depleted in RA. Importantly, this signature of enriched CD40 expression coupled with depleted CX3CR1 expression is an early phenomenon, occurring prior to clinical manifestation of disease in individuals ‘at-risk’ of RA (IAR). RNAseq and metabolic profiling of sorted RA synovial-macrophages identified that this population is transcriptionally distinct, displaying unique inflammatory, phagocytic and tissue-resident gene signatures, paralleled by biologically stable profile as indicated by NAD(P)H emission. Functionally CD206+CD163+ RA macrophages are potent producers of pro-inflammatory mediators (reversed by CD40-signalling inhibition) and induce an invasive phenotype in healthy synovial-fibroblasts. These findings identify a distinct pathogenic population of synovial-tissue macrophage involved in shaping the immune response in RA. Crucially, this signature is present pre-disease representing a unique opportunity for early diagnosis and therapeutic intervention.

Conclusion: We have identified a novel population of tissue-resident macrophages in the RA synovium which are transcriptionally/metabolically distinct and capable of contributing to disease pathology. Uncovering the molecular patterns and cues that transform this immunoregulatory macrophage population into a dysfunctional inflammatory activation state may provide opportunities to reinstate joint homeostasis in RA patients.

Disclosure of Interests: Megan Hanlon: None declared, Mary Canavan: None declared, Nuno Neto: None declared, Qingxuan Song Employee of: Employee of Janssen Pharmaceuticals, Phil Gallagher: None declared, Ronan Mullan: None declared, Conor Hurson: None declared, Barry Moran: None declared, Michael Monaghan: None declared, Sunil Nagal Employee of: Employee of Janssen Pharmaceuticals, Douglas Veale Consultant of: Janssen, Eli Lilly, Pfizer, Ursula Fearon Consultant of: Janssen, Eli Lilly, Pfizer


OP0014

CTLA4-IG INDUCES TOLEROGENIC PROPERTIES OF DENDRITIC CELLS BY ALTERING CELLULAR METABOLISM

P. Goutakoli2, G. Papadaki1, S. Papanikolaou1, G. Vatsellias1, G. Bertias1, P. Verginis1, P. Sidiropolous1, 1Laboratory of Rheumatology, Autoimmunity and Inflammation, Medical School, University of Crete, Heraklion, Greece; 2Institute for Bioinnovation-IBI, Biomedical Sciences Research Center “Alexandros Fleming”, Athens, Greece; 3Greek Genome Center, BRFAA, Athens, Greece; 4Clinic of Rheumatology, Clinical Immunology, University Hospital of Heraklion, Heraklion, Greece; 5Division of Basic Sciences, Medical School, University of Crete, Heraklion, Greece

Background: Dendritic cells (DCs) are well-recognized for their dual role either for T cell activation (1) or for inducing T cells tolerance (2). Their ability to modulate T-cell responses has made them an interesting tool for the immunotherapy of autoimmune diseases (3). Cytotoxic T lymphocyte antigen 4 (CTLA4) is a negative co-stimulatory molecule, which binds to CD80/CD86 on DCs. CTLA4 induces its immunoregulatory function through trans-endocytosis resulting in impaired co-stimulation (4), or through the induction of indoleamine-pyrole-2,3-dioxygenase (IDO) enzyme (5). Moreover, it has been demonstrated that CTLA4-IG impairs the autophagic machinery of DCs and therefore suppresses DC inflammatory function (6). Nevertheless, the molecular mechanisms underlying the CTLA4-mediated immunomodulatory phenotype, require a more comprehensive understanding.

Objectives: In this study we focused on tolerogenic DCs (tolDCs) and we applied CTLA4-IG as a tool to induce them. We aim to assess the immunoregulatory potential of CTLA4-mediated tolDCs and to investigate thoroughly the intracellular pathways that are involved in the induction of tolerance.

Methods: Healthy human monocytes were isolated from peripheral blood and differentiated into monocyte-derived dendritic cells (DCs). After 6 days, immature DCs activated with LPS were treated with CTLA4-IG or IgG control for 18 hours. The anti-inflammatory function of DCs was validated using RT-PCR and flow cytometry and DCs propensity to RNA sequencing. The metabolic pathways were studied using a Seahorse bioanalyzer.

Results: CTLA4-IG treated DCs showed significantly decreased HLA-DR, CD80/CD86 expression as compared to IgG-treated controls (n=4, p=0.0294, n=5; p=0.0079). Moreover, IL6 and TNFα mRNA expression, hallmark of inflammatory cytokines secreted by DCs, was reduced upon CTLA-4-IG (n=5, p=0.0079). To elucidate the pathways involved in DC reprogrammung upon CTLA4-IG treatment, we performed RNA sequencing and we concluded with 1270 differentially expressed genes (p-value<0.05 counts>10). Interestingly, transcriptomic analysis revealed that the majority of genes (n=900) participated in metabolic processes, specifically in OXPHOS pathway and mitochondrial function. To further support the above metabolic changes, we performed Seahorse assays and confirmed that tolDCs had lower basal OXPHOS and decreased ATP production compared with mature DCs. Furthermore, expression of phosphorylated mammalian target of rapamycin (mTOR) and AKT1, central regulators of metabolism, was increased in CTLA4-mediated tolDCs (n=3, p=0.0308 and p=0.0347).

Conclusion: Herein we confirmed that CTLA4 restricts the pro-inflammatory properties of activated DCs. RNA-seq analysis revealed that this anti-inflammatory deviation of DCs is characterized by the modification of the expression of genes implicated in cellular metabolism. Metabolic experiments confirmed that CTLA4-mediated tolerized DCs have reduced OXPHOS and ATP production, whereas, mTOR signaling is upregulated. In future experiments, we will investigate the mechanism that CTLA4 may promote metabolic changes thus contributes to the immunoregulatory phenotype of DCs and could represent a therapeutic target.

References:


Acknowledgements: This research is co-financed by Greece and the European Union (European Social Fund- ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning» in the context of the project “Strengthening Human Resources Research Potential via Doctorate Research” (MIS-5000432), implemented by the State Scholarships Foundation (IKY).

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4389

OP0015

PRONFLAMMATORY MONOCYTES AND MACROPHAGES IN SYNOVIAL FLUID AND BURSAL TISSUE OF PATIENTS WITH POLYMIALGIA RHEUMATICA: POTENT PRODUCERS OF IL-6 AND GM-CSF

W. F. Jemyl1, R. Reitsema1, A. Zhang1, M. Sandovici1, A. Boots1, P. Heeringa2, E. Brouwer1, K. Van der Geest1.

1University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 2University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, Netherlands

Background: Polymyalgia rheumatica (PMR) is a common, rheumatic inflammatory disease. Inflammation of bursae and tendon sheaths is a characteristic finding for Bioinnovation-IBI, Biomedical Sciences Research Center “Alexandros Fleming”, Athens, Greece; 3Greek Genome Center, BRFAA, Athens, Greece; 4Clinic of Rheumatology, Clinical Immunology, University Hospital of Heraklion, Heraklion, Greece; 5Division of Basic Sciences, Medical School, University of Crete, Heraklion, Greece
in patients with PMR. Glucocorticoid treatment remains the mainstay treatment for PMR. A study published in 1996 reported that macrophages dominate the inflammatory infiltrate in the glenohumeral synovium of PMR patients, suggesting the importance of these cells in the pathogenesis of PMR. However, the functional and phenotypical heterogeneity of the tissue-infiltrating macrophages in PMR remains obscure. Although treatment with anti-IL-6 receptor (tocilizumab) has shown promising results, it is unclear whether macrophages contribute to IL-6 production in PMR. Additionally, anti-GM-CSF receptor therapy (mavrilimumab), recently shown to be efficacious in the closely related disease giant cell arteritis, may also be useful for the treatment of PMR.

Results:

On macrophage markers (CD68, CD86, CD64, CD206 and FRβ), macrophage polarization were included in the flow cytometry analysis. Immunohistochemistry of bursal tissue biopsies was focused on macrophage markers (CD68, CD86, CD64, CD206 and FRβ) and proinflammatory cytokines (IL-6 and GM-CSF), which were scored semi-quantitatively. Double immunofluorescence stainings were performed to determine the expression of IL-6 and GM-CSF by tissue-infiltrating macrophages in bursal tissue. Results: Monocytopenia were detected in the SF of PMR patients. The proportion of classical monocytes was significantly lowered (p = 0.001) in SF versus PB, while the proportion of intermediate monocytes was significantly elevated (p = 0.001). The expression of CD206 was significantly elevated (p = 0.001) but not FRβ in SF monocytopenia, suggesting GM-CSF skewed phenotype. In bursal tissue, macrophages displayed mixed ‘M1’/‘M2’ traits with high expression of all macrophage polarization markers. Proinflammatory cytokines IL-6 and GM-CSF were highly expressed throughout the bursal tissue biopsies. Double immunofluorescence staining confirmed the expression of IL-6 and GM-CSF by the infiltrating macrophages.

Conclusion: SF monocytopenia and bursal tissue macrophages show a pro-inflammatory phenotype in PMR. Moreover, tissue-infiltrating macrophages show a prominent IL-6 and GM-CSF response in PMR. Our data add to the rationale of targeting IL-6 and GM-CSF as treatment options in PMR.

References:


Acknowledgements: This work was supported by a research grant from FONERUM Foundation for Research in Rheumatology. The PMR Research On disease Mechanisms In Synovium (PROMIS) study was also funded by the Rheumatology Grant (Dutch Society for Rheumatology) and Mandema Stipend (University Medical Center Groningen).

Disclosure of Interests: William Febry Jiemy: None declared, Rosanne Reitsma: None declared, Anqi Zhang: None declared, Maria Sandovici: None declared, William Febry Jiemy: None declared, Rosanne Reitsma: None declared, Anqi Zhang: None declared, Maria Sandovici: None declared, Jan van der Geest Consultant of: K. van der Geest (University Medical Center Groningen). Pernille Heeringa: None declared, Rosanne Reitsma: None declared, Anqi Zhang: None declared, Maria Sandovici: None declared, Jan van der Geest Consultant of: K. van der Geest (University Medical Center Groningen).

AxSpA drug treatment: new and old drugs

A. Deodhar1, E. Van den Bosch2, D. Poddubnyy3, W. P. Makymowych4, D. Van der Heijde5, T. H. Kim6, M. Kishimoto7, Y. Duan8, Y. Li8, A. Parang8, P. Wung8, I. H. Song9,10, Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Portland, OR, United States of America; 2Ghent University, VIB Center for Inflammation Research, Internal Medicine and Pediatrics, Ghent, Belgium; 3Charité Universitätsmedizin, Gastroenterologie, Infectious Diseases and Rheumatology, Berlin, Germany; 4University of Alberta, Medicine, Edmonton, Alberta, Canada; 5Leiden University Medical Center, Rheumatology, Leiden, Netherlands; 6Hanyang University Hospital, Rheumatology, Seoul, Korea, Rep. of (South Korea); 7Kyorin University School of Medicine, Nephrology and Rheumatology, Tokyo, Japan; 8AbbVie Inc., Immunology, North Chicago, IL, United States of America

Background: Janus kinase (JAK) inhibitors have been recognized as a potential therapeutic option in ankylosing spondylitis (r-axSpA).1 Upadacitinib (UPA), a JAK inhibitor, has demonstrated efficacy and safety in the treatment of AS2; however, no JAK inhibitor studies have been conducted in non-radiographic axSpA (nr-axSpA) to date.

Objectives: To assess the efficacy and safety of UPA in patients (pts) with active axSpA.

Methods: SELECT AXIS 2 (NCT04169373) was conducted under a master protocol comprising two independent studies, one in an AS population with an inadequate response to biologic disease-modifying antirheumatic drugs and one in an nr-axSpA population. The nr-axSpA study is a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial that enrolled adults ≥18 years with a clinical diagnosis of nr-axSpA (who also fulfilled 2009 ASAS classification criteria for axSpA but did not meet the radiologic criterion of modified New York criteria), who had obvious signs of active inflammatory consistent with axSpA on MRI of the sacroiliac (SI) joints and/or high sensitivity C-reactive protein (hs-CRP) > upper limit of normal (2.87 mg/L) at screening, and who had BASDAI and pt’s assessment of total back pain scores ≥14 based on a 0 to 10 numeric rating scale at study entry. Pts were randomized 1:1 to receive oral UPA 15 mg once daily (OD) or PBO during a 52-week (wk) double-blind treatment period. The primary endpoint was ASAS40 response at wk 14. Multiplicity-controlled secondary endpoints assessed at wk 14 included BASDAI50, ASAS ID (<1.3), ASDAS LDA (<2.1), ASDAS PR, and the change from baseline (Δ) in ASDAS (CRP), SPARCC MRI SI joint inflammation score, total and nocturnal back pain, BASFI, ASQoL, ASAS HI, BASMI, and MASES. Treatment-emergent adverse events (TEAEs) were reported through wk 14 for pts who received ≥1 dose of study drug.

Results: Of 314 pts randomized at baseline, 313 received study drug (UPA 15 mg, n=156; PBO, n=157) and 295 (94%) received study drug through wk 14. Baseline demographic and disease characteristics were balanced across treatment groups and consistent with an active nr-axSpA population (58% female; mean age 42.1 years; mean BASDAI 6.9; mean hs-CRP 12.1 mg/L).

AOP0016

Efficacy and Safety of UPA in Patients with Active Non-radiographic AxSpA: Spondylarthritis: A Double-Bind, Randomized, Placebo-Controlled Phase 3 Trial

A. Deodhar1, E. Van den Bosch2, D. Poddubnyy2, W. P. Makymowych4, D. Van der Heijde5, T. H. Kim6, M. Kishimoto7, Y. Duan8, Y. Li8, A. Parang8, P. Wung8, I. H. Song9,10, Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Portland, OR, United States of America; 2Ghent University, VIB Center for Inflammation Research, Internal Medicine and Pediatrics, Ghent, Belgium; 3Charité Universitätsmedizin, Gastroenterologie, Infectious Diseases and Rheumatology, Berlin, Germany; 4University of Alberta, Medicine, Edmonton, Alberta, Canada; 5Leiden University Medical Center, Rheumatology, Leiden, Netherlands; 6Hanyang University Hospital, Rheumatology, Seoul, Korea, Rep. of (South Korea); 7Kyorin University School of Medicine, Nephrology and Rheumatology, Tokyo, Japan; 8AbbVie Inc., Immunology, North Chicago, IL, United States of America

Disclosure of Interests: William Febry Jiemy: None declared, Rosanne Reitsma: None declared, Anqi Zhang: None declared, Maria Sandovici: None declared, William Febry Jiemy: None declared, Rosanne Reitsma: None declared, Anqi Zhang: None declared, Maria Sandovici: None declared, Jan van der Geest Consultant of: K. van der Geest (University Medical Center Groningen).
A significantly higher ASAS40 response rate at wk 14 was achieved with UPA vs PBO (45% vs 23%; P<0.0001; Figure 1). Statistical significance was also achieved in the first 12 of the 14 multiplicity-controlled secondary endpoints (ie, all endpoints except BASMI and MASES) and at wk 14 for UPA compared with PBO (P<0.001; Figure 1). The proportion of pts who experienced a TEAE was similar between treatment groups (UPA, 48%; PBO, 46%). Serious TEAEs and TEAEs leading to discontinuation were reported in 4 (2.6%) pts treated with UPA and 2 (1.3%) pts treated with PBO, respectively. Few pts had serious infection or herpes zoster (each 2 [1.3%] pts on UPA; each 1 [0.6%] pt on PBO, respectively). Uveitis was reported in 1 (0.6%) pt on PBO who had a history of uveitis and none on PBO. No malignancy other than non-melanoma skin cancer, major adverse cardiovascular events, venous thromboembolic events, inflammatory bowel disease (IBD), or death were reported in the study; 1 event of basal cell carcinoma occurred with PBO.

**Conclusion:** UPA 15 mg QD demonstrated significantly greater improvements in disease activity, pain, function, quality of life, and MRI-detected SI joint inflammation than PBO after 14 wks of treatment in pts with active nr-axSpA. The safety profile of UPA was consistent with what has been observed with other inflammatory musculoskeletal diseases,3–5 and no new risks were identified. These results support the potential use of UPA in pts with active nr-axSpA.

**REFERENCES:**

**Acknowledgements:** AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship.

**Medical writing support was provided by Julia Zolotarjova, MSc, MWC, of AbbVie.**

**Disclosure of Interests:** Atul Deodhar Consultant of: AbbVie, Amgen, Aurinia, BMS, Celgene, GSK, Janssen, Lilly, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, GSK, Lilly, Novartis, Pfizer, and UCB, Robert van den Bosch Speakers bureau: AbbVie, Ecolab, Celgene, GSK, Novartis, Lilly, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Celgene, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Denis Poddubnny Speakers bureau: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, BMS, MSD, Novartis, and Pfizer, Walter P Mak-smowycz Consultant of: AbbVie, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Novartis, and Pfizer, Désirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, UCB, Employee of: Director of Imaging Rheumatology BV, Tae-Hwan Kim Speakers bureau: AbbVie, Celtrion, Kirin, Lilly, and Novartis, Mitsumasa Kishi- môto Consultant of: AbbVie, Amgen Antares Aesthetics Pharma, Asah-Kasei Pharma, Asutum Pharma, Ayurmed Pharma, BMS, Chugai, Daichi Sankyo, Eisai, Gilead, Jans- sen, Kyowa Kirin, Lilly, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, Teijin Pharma, and UCB, Yuanjuan Duan Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, YiHan Li Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Aileen Pangan Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, Peter Wung Shareholder of: May own AbbVie stock or options, Employee of: AbbVie, In-Ho Song Shareholder of: May own AbbVie stock or options, Employee of: AbbVie. DOi: 10.1136/annrheumdis-2022-eular.2534

**OP0017**

**RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY**

**Table 1. Recapture of first treatment response before or after switching to open label IXE after 104 weeks among placebo (ixekizumab withdrawal)-treated patients who experienced a flare and retreated.**

<table>
<thead>
<tr>
<th>Total patients who flared and were switched to open-label ixekizumab withdrawal (N=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (ixekizumab withdrawal)</td>
</tr>
<tr>
<td>Number of patients who experienced a flare and retreated (N=28)</td>
</tr>
<tr>
<td>ASDAS disease activity status</td>
</tr>
<tr>
<td>Recaptured response before open label ixekizumab withdrawal (n=16 weeks)</td>
</tr>
<tr>
<td>Recaptured response with open label ixekizumab withdrawal (≥16 weeks)</td>
</tr>
</tbody>
</table>

**Objectives:** Here, we describe the final results of pts re-randomized to either placebo (PBO; IXE Withdrawal) or IXE, who experienced flare, and recaptured response before or after open label retreatment during COAST-Y.

**Methods:** COAST-Y (NCT03129100) is a Phase 3, long-term extension study that included a double-blind, PBO-controlled, randomized withdrawal-retreat- ment period (RWP). Eligible pts who completed an originating study (COAST-V, -W, or -X) entered a 24-week (Wk) lead-in period and received 80 mg IXE every 2 (Q2W) or 4 wks (Q4W) (the treatment regimen at the end of the originating study); pts receiving PBO at the end of COAST-X were assigned to IXE Q4W in COAST-Y. Pts who achieved remission (Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3 (inactive disease; ID) at least once at Wk 16 or 20, and >2.1 (low disease activity; LDA) at both visits) were randomized 2:1 at Wk 24 to continue IXE (as per lead-in period) or withdrawn to PBO. Pts who subsequently experienced flare (ASDAS ≥2.1 at 2 consecutive visits or ASDAS >3.5 at any visit) were switched to open label IXE Q2W or Q4W at the next visit (same as lead-in period).

**Results:** Time to first flare was analyzed using the Kaplan-Meier method with treatment comparison performed using log-rank test. The observed proportion of pts who recaptured ASDAS LDA and ID were summarized for pts who experienced flare and were retreated with open label IXE.

**Conclusion:** Pts continuously treated with IXE were less likely to experience flare vs pts on PBO (IXE withdrawal). The vast majority of pts withdrawn from IXE to PBO recaptured at least LDA and over half met ID with IXE retreatment. This may provide support for pts who require interruption in therapy.

**Acknowledgments:** This study was sponsored by Eli Lilly and Company. Medical writing services were provided by Edel Hughes, PhD and Suneet Sood, PhD of Eli Lilly and Company, and was funded by Eli Lilly and Company.

**Disclosure of Interests:** Robert B.M. Landewé Consultant of: Rheumatology Consultancy BV, AbbVie, UCB, Pfizer, Eli Lilly and Company, Novartis, and Celgene, Denis Poddubnny Speakers bureau: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and UCB Pharma, Consultant of: AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and UCB.
Pharma, Grant/research support from: AbbVie, Eli Lilly and Company, Merck Sharp & Dohme, Novartis, and Pfizer, Proton Rahman Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, and UCB; Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Merck, Novartis, Pfizer, and UCB.

Methods: Eligible patients had r-axSpA and high disease activity (BASDAI ≥4), NSAID failure and risk factors for radiographic spinal progression: C-reactive protein >5 mg/L and/or ≥1 syndesmophyte(s). The trial consisted of two phases: a 12-week initiation phase followed by a 108-week controlled treatment period, in which patients participating rheumatologist and included patients.

Disclosure of Interests: Fabian Proft Speakers bureau: AMGEN, AbbVie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: Novartis, Grant/research support from: Novartis, UCB, Lilly, Burkhard Mucbe Speakers bureau: UCB Pharma, AMGEN, Consultant of: UCB Pharma, AMGEN, Valeria Rios Rodriguez Speakers bureau: AbbVie, Falk e.V., Murat Torgutalp: None declared, Mikhail Popotopov Consultant of: Novartis, Joachim Listing: None declared, Maryna Verba: None declared, Uta Kiltz: None declared, Jan Brandt-Juergens: None declared, Maren Sieburg: None declared, Swen Holger Jaki: None declared, Joachim Sieper Speakers bureau: AbbVie, Janssen, Merck, Novartis, Consultant of: Abbvie, Janssen, Lilly, Merck, Novartis, UCB, Denis Poddubnyy Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, and Pfizer.


Table 1. Baseline characteristics of randomized patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>GOL+CEL N=54</th>
<th>GOL alone N=55</th>
<th>All patients N=109</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, male</td>
<td>n (%)</td>
<td>value</td>
<td>value</td>
</tr>
<tr>
<td>Age, years</td>
<td>Mean (SD)</td>
<td>54</td>
<td>40 (74.1)</td>
</tr>
<tr>
<td>C-reactive protein &gt;5 mg/L</td>
<td>Mean (SD)</td>
<td>54</td>
<td>39.9 (9.9)</td>
</tr>
<tr>
<td>BASDAI</td>
<td>Mean (SD)</td>
<td>54</td>
<td>19 (35.8)</td>
</tr>
<tr>
<td>BASMI</td>
<td>Mean (SD)</td>
<td>54</td>
<td>45 (83.3)</td>
</tr>
<tr>
<td>ASDAS-ESCR</td>
<td>Mean (SD)</td>
<td>54</td>
<td>6.2 (1)</td>
</tr>
<tr>
<td>Presence of ≥1 syndesmophyte(s)</td>
<td>n (%)</td>
<td>54</td>
<td>27 (50)</td>
</tr>
<tr>
<td>mSASSS</td>
<td>Mean (SD)</td>
<td>54</td>
<td>13.5 (16.9)</td>
</tr>
</tbody>
</table>
Background: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. In a phase 2b study, BKZ showed rapid results in the treatment of ankylosing spondylitis (AS) patients.

Objectives: To assess efficacy and safety of BKZ vs placebo (PBO) in pts with active AS up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 2.

Methods: BE MOBILE 2 (NCT03928743) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, met modified New York criteria and had active AS (BASDAI ≥4, spinal pain ≥4) at BL, Pts were randomised 2:1; BKZ 160 mg Q4W; PBO. From Wk 16, all pts received BKZ 160mg Q4W. Primary and secondary efficacy endpoints were assessed at Wk 16.

Results: Of 332 randomised pts (BKZ: 221; PBO: 111), 322 (97.0%) completed Wk 16 and 313 (94.3%) Wk 24. BL characteristics were comparable between groups: mean age 40.4 yrs, symptom duration 13.5 yrs; 72.3% pts male, 85.5% HLA-B27+. 16.3% TNFi-experienced. At Wk 16, the primary (ASAS40: 44.8% BKZ vs 22.5% PBO; p<0.001) and all ranked secondary endpoints were met (Table 1). Responses with BKZ were rapid, including in PBO pts who switched to BKZ at Wk 16, and increased to Wk 24 (Figure 1; Table 1). Substantial reductions of hs-CRP by Wk 2 and MRI SIJ and spine inflammation by Wk 16 were achieved with BKZ vs PBO (Table 1). At Wk 24, ≥50% pts had achieved ASDAS <2.1 (Figure 1).

Over 16 wks, 120/221 (54.3%) BKZ pts had at least one TEAE vs 48/111 (43.2%) PBO; three most frequent on BKZ were nasopharyngitis (BKZ: 7.7%; PBO: 3.6%), headache (4.1%; 4.5%) and oral candidiasis (4.1%; 0%). No systemic candidiasis was observed. Up to 16 wks, incidence of SAEs was low (1.8%; 0.9%); no MACE or deaths were reported; 2 (0.9%) IBD cases occurred in pts on BKZ.

Conclusion: Dual inhibition of IL-17A and IL-17F with BKZ in pts with active AS resulted in rapid, clinically relevant improvements in efficacy outcomes vs PBO. No new safety signals were observed.1,2

REFERENCES:

Table 1. Efficacy at Wks 16 and 24

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>BL</th>
<th>Wk 16</th>
<th>Wk 24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO</td>
<td>BKZ 160 mg Q4W</td>
<td>PBO</td>
</tr>
<tr>
<td></td>
<td>N=111</td>
<td>N=221</td>
<td>N=111</td>
</tr>
<tr>
<td>ASAS40††† (NRI)</td>
<td>-</td>
<td>25 (22.5)</td>
<td>99 (44.8)</td>
</tr>
<tr>
<td>n (%)</td>
<td>-</td>
<td>63 (56.8)</td>
<td>119 (53.8)</td>
</tr>
<tr>
<td>ASAS40 in TNFi-naive†††</td>
<td>-</td>
<td>22 (23.4)</td>
<td>84 (45.7)</td>
</tr>
<tr>
<td>n (%)</td>
<td>-</td>
<td>56 (59.6)</td>
<td>100 (54.3)</td>
</tr>
<tr>
<td>BASDAI CRIB†‡‡‡ [MI]</td>
<td>6.5 (0.1)</td>
<td>6.5 (0.1)</td>
<td>-19.0 (0.2)</td>
</tr>
<tr>
<td>mean (SE)</td>
<td></td>
<td>-3.3 (0.2)</td>
<td>-3.3 (0.1)</td>
</tr>
<tr>
<td>ASAS PR†‡‡‡ [NRI]</td>
<td>-</td>
<td>7 (8)</td>
<td>53 (24.0)</td>
</tr>
<tr>
<td>n (%)</td>
<td>-</td>
<td>28 (25.2)</td>
<td>56 (25.3)</td>
</tr>
<tr>
<td>ASDAS-MI†‡‡‡ [NRI]</td>
<td>-</td>
<td>6 (5.4)</td>
<td>57 (25.8)</td>
</tr>
<tr>
<td>n (%)</td>
<td>-</td>
<td>43 (38.7)</td>
<td>67 (30.3)</td>
</tr>
<tr>
<td>ASAS 5/6† [NRI]</td>
<td>-</td>
<td>16 (14.4)</td>
<td>94 (42.5)</td>
</tr>
<tr>
<td>n (%)</td>
<td>-</td>
<td>57 (51.4)</td>
<td>107 (48.4)</td>
</tr>
<tr>
<td>BASFI CRIB†‡‡‡ [MI]</td>
<td>5.2 (0.2)</td>
<td>5.3 (0.2)</td>
<td>-11.0 (0.2)</td>
</tr>
<tr>
<td>mean (SE)</td>
<td>6.8 (0.2)</td>
<td>6.6 (0.1)</td>
<td>-19.0 (0.2)</td>
</tr>
<tr>
<td>Nocturnal spinal pain CRIB†‡‡‡ [MI]</td>
<td></td>
<td>-3.3 (0.2)</td>
<td>-3.7 (0.3)</td>
</tr>
<tr>
<td>mean (SE)</td>
<td>8.5 (0.4)</td>
<td>9.0 (0.3)</td>
<td>-3.2 (0.3)</td>
</tr>
<tr>
<td>SF-36 PCS CRIB†‡‡‡ [MI]</td>
<td>34.6 (8.0)</td>
<td>34.4 (6.6)</td>
<td>5.9 (0.8)</td>
</tr>
<tr>
<td>mean (SE)</td>
<td>10.6 (0.8)</td>
<td>10.8 (0.6)</td>
<td></td>
</tr>
<tr>
<td>BASMI CRIB†‡‡‡ [MI]</td>
<td>3.8 (0.2)</td>
<td>3.9 (0.1)</td>
<td>-0.2 (0.1)</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>3.8 (0.2)</td>
<td>3.9 (0.1)</td>
<td>-0.2 (0.1)</td>
</tr>
<tr>
<td>Enthesitis-free state†‡‡‡ [NRI]</td>
<td></td>
<td>22 (32.8)</td>
<td>68 (51.5)</td>
</tr>
<tr>
<td>n (%)</td>
<td></td>
<td>33 (49.3)</td>
<td>70 (53.0)</td>
</tr>
<tr>
<td>ASDAS40 in TNFi-experienced† [NRI]</td>
<td></td>
<td>3 (17.6)</td>
<td>15 (40.5)</td>
</tr>
<tr>
<td>n (%)</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ASDAS-CRP CRIB†‡‡‡ [MI]</td>
<td>3.7 (0.1)</td>
<td>3.7 (0.1)</td>
<td>-0.7 (0.1)</td>
</tr>
<tr>
<td>mean (SE)</td>
<td>6.7 (6.3)</td>
<td>6.5 (8.2)</td>
<td>6.0 (6.3)</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>3.3 (4.9)</td>
<td>3.8 (5.3)</td>
<td>0.0 (1.4)</td>
</tr>
<tr>
<td>geometric mean (median)</td>
<td>5.8 (77.1)</td>
<td>7.4 (10.7)</td>
<td>1.1 (6.9)</td>
</tr>
</tbody>
</table>

Randomised set; *Primary endpoint; †Secondary endpoint; ‡N=94; ³N=184; ⁴MASES=0 in pts with BL MASES ≥0; ⁵N=47; ⁶N=132; ⁷N=17; ⁸N=37; ⁹In pts in MRI sub-study; ¹⁰N=82; ¹¹N=43; ¹²N=79; ¹³N=83; ¹⁴Nominal p values not shown.
This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

Disclosure of Interests: Désirée van der Heijde Consultant of: Abbvie, Bayer, MSD, Cyno, Eisaï, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Employee of: Imaging Rheumatology BV (Director), Xeno- fon Baraliakos Speakers bureau: Abbvie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, Paid instructor for: Abbvie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, Consultant of: Abbvie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, Maxime Dougados Consultant of: Abbvie, Eli Lilly, Novartis, Merck, Pfizer, and UCB Pharma, Grant/research support from: Abbvie, Eli Lilly, Novartis, Pfizer, and UCB Pharma, Matt Brown Speakers bureau: Novartis, Consultant of: Pfizer, Clementia, Ipsen, Regeneron, Grey Wolf Therapeutics, Grant/research support from: UCB Pharma, Denis Poddubnyy Speakers bureau: Abbvie, BMS, Eli Lilly, MSD, Novartis, Pfizer, and UCB Pharma, Consultant of: Abbvie, Biocad, Eli Lilly, Gilead, GSK, MSD, Novartis, Pfizer, and UCB Pharma, Grant/research support from: Abbvie, MSD, Novartis, Pfizer, and Filip van den Bosch Speakers bureau: Abbvie, Bristol Myers-Squibb, Celgene, Janssen, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: Abbvie, Amgen, Janssen, Merck, Novartis and UCB Pharma, Hui Xu: None.

Background: Exposure reveals sex differences in physiology, disease presentation and response to treatment in axial spondyloarthritis (axSpA). Pooled data from four randomized controlled trials demonstrated reduced treatment efficacy and response to treatment in axial spondyloarthritis (axSpA). However, real-life evidence confirming these data in large cohorts is scarce. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

Objectives: To investigate sex differences in treatment response and drug retention rates in clinical practice among patients with axSpA.

Methods: Data from biologic-naïve axSpA patients initiating a TNFi in the EuroSpA registries were pooled. In the primary analysis, propensity-score weighting was applied to assess the causal effect of sex on clinically important improvement (CII) according to ASDAS-CRP at 6 months. A generalized linear regression model was used to estimate the causal risk difference (RD) and relative risk (RR) on sex. Possible covariates influencing the outcome were determined a priori and selected based on availability in the database (<20% missing). The final model included country, age and TNFi start year. In the secondary analysis, drug retention was assessed over 24 months of follow-up by Kaplan-Meier curves and log-rank test.

Results: In total, 6,451 axSpA patients with available data on ASDAS-CRP at baseline and 6 months were assessed for treatment response. Baseline characteristics are shown in the Table 1. In the adjusted analysis, the probability for females to have CII was 15% (RR, 0.85; 95% confidence interval [CI], 0.82 to 0.87).
0.89) lower compared to males and the difference in probability for having CII was 9.4 percentage points (RD: 0.094; 95% CI, 0.069 to 0.12). The survival analysis included 28,608 axSpA patients with available data on retention rates. The TNFI 6/10/24-month retention rates were significantly lower in females (81%/69%/58%) compared to males (89%/81%/72%), see Figure 1.

<table>
<thead>
<tr>
<th>Table 1.</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD), Median [IQR] or percentages</td>
<td>Mean (SD), Median [IQR] or percentages</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>42.0 (12.1)</td>
<td>41.4 (12.3)</td>
</tr>
<tr>
<td>Fulfilment of mNYC</td>
<td>66%</td>
<td>80%</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>2.0 (1.0, 7.0)</td>
<td>3.0 (1.0, 9.0)</td>
</tr>
<tr>
<td>TNFI start year</td>
<td>72%</td>
<td>98%</td>
</tr>
<tr>
<td>Start 1999-2009</td>
<td>26%</td>
<td>27%</td>
</tr>
<tr>
<td>Start 2010-2013</td>
<td>37%</td>
<td>36%</td>
</tr>
<tr>
<td>Start 2014-2016</td>
<td>30%</td>
<td>27%</td>
</tr>
<tr>
<td>BASDAI, mm</td>
<td>59 (20)</td>
<td>54 (21)</td>
</tr>
<tr>
<td>BASMI, mm</td>
<td>48 (25)</td>
<td>46 (24)</td>
</tr>
<tr>
<td>ASDAS, units</td>
<td>3.5 (0.9)</td>
<td>3.5 (1.0)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>6.7 (2.5, 16.0)</td>
<td>11.9 (4.0, 25.0)</td>
</tr>
<tr>
<td>SJC (0-28)</td>
<td>0 [0, 0]</td>
<td>0 [0, 0]</td>
</tr>
<tr>
<td>TJC (0-28)</td>
<td>0 [0, 2]</td>
<td>0 [0, 1]</td>
</tr>
<tr>
<td>VAS pain, mm</td>
<td>63 (22)</td>
<td>59 (24)</td>
</tr>
<tr>
<td>VAS fatigue, mm</td>
<td>65 (25)</td>
<td>59 (28)</td>
</tr>
</tbody>
</table>

mNYC, modified New York criteria; TNFI, tumor necrosis factor inhibitor; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale.

Figure. Sex differences in 24-month retention rates in first-line tumor necrosis factor inhibitors. In patients with axial spondyloarthritis in EvosPA (N=10288; log-rank test: p=0.001).

Conclusion: Treatment efficacy and retention rates are lower among female patients with axSpA initiating their first TNFI. Females presented with lower C-reactive protein levels and higher scores on patient reported outcomes at baseline, reflecting differences in disease expression. Recognizing these sex differences is of relevance for customized patient care and may improve patient education.

REFERENCES:

Acknowledgements: Novartis Pharma AG and IQVIA for supporting the Euro-SpA collaboration.

Disclosure of Interests: Pasono Hellamand Grant/research support from: Novartis, Marlene G.H. van de Sande Speakers bureau: UCB, Consultant of: Abbvie, Eli Lilly, Novartis and UCB, Grant/research support from: Novartis, Janssen, UCB and Eli Lilly, Yannick Bonnafe Grant/research support from: Novartis, Hans Christiansen, Thomas Klausch: None declared, Michael Nurmohamed Speakers bureau: Abbvie, AstraZeneca, Biogen, BMS, Galapagos, Janssen, Motlenyi, Pfizer, UCB and speaker fees from Abbvie, Biogen, Galapagos, GSK, Janssen, Pfizer, R-Pharma and UCB, Grant/research support from: BMS, GSK and UCB, Dan Nordström Consultant of: Abbvie, Biogen, BMS, Lilly, Novartis, Pfizer, Roche and UCB, Anna-Mari Hokkanen Grant/research support from: MSD, Maria Jose Santos Speakers bureau: Abbvie, AstraZeneca, Lilly, Novartis and Pfizer, Elsa Vieira-Sousa Speakers bureau: MSD, Celgene, Novartis, Janssen, Abbvie and Pfizer, Consultant of: MSD, Celgene, Novartis, Janssen, Abbvie and Pfizer, Grant/research support from: MSD, Celgene, Novartis, Janssen, Abbvie and Pfizer, Anne Gitte Loft Consultant of: Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: Novartis, Bente Glintborg Grant/research support from: Pfizer, Abbvie and BMS, Mikkel Overgaard Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Sandoz, Pfizer, Roche, Sanofi and UCB, Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, BMS, Merck, Celgene and Novartis, Ulf Lindström: None declared, Johan K Wallman Consultant of: Wallmark Laboratories: Abbvie, Amgen, Celgene, Eli Lilly and Novartis, Brittte Michelsen Grant/research support from: Novartis, Adrian Ciurea Speakers bureau: Abbvie and Novartis, Michael J. Nisens Speakers bureau: Abbvie, Eli Lilly, Janssens, Novartis and Pfizer, Consultant of: Abbvie, Eli Lilly, Janssens, Novartis and Pfizer, Catalin Codreanu Speakers bureau: Abbvie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis and Pfizer, Consultant of: Abbvie, Amgen, Boehringer Ingelheim, Ewopharma, Lilly, Novartis and Pfizer, Corina Mogosan Speakers bureau: Abbvie, Ewopharma, Lilly, Novartis and Pfizer, Consultant of: Abbvie, Ewopharma, Lilly, Novartis and Pfizer, Gary Macfarlane Grant/research support from: GSK, Gareth T. Jones Grant/research support from: Abbvie, Pfizer, UCB, Amgen and GSK, Karin Laas Speakers bureau: Amgen, Janssen and Novartis, Ziga Rotor Speakers bureau: Abbvie, Novartis, MSD, Medis, Biogen, Eli Lilly, Pfizer, Sanofi, Lek and Janssens, Matthias Tomsic Speakers bureau: Abbvie, Amgen, Biogen, Eli Lilly, Janssens, Medis, MSD, Novartis, Pfizer, Sanofi and Sandoz-Lek, Isabel Castrojen Speakers bureau: Eli Lilly, BMS, Janssen, MSD and Abbvie, Consultant of: Eli Lilly, BMS, Janssen, MSD and Abbvie, Manuel Pombo-Suarez Consultant of: Abbvie, MSD and Roche, Björn Gudbjörnsson Speakers bureau: Amgen and Novartis, Consultant of: Amgen and Novartis, Arni Jon Geirsson: None declared, Erik Kristianslund: None declared, Jílí Vencovský Speakers bureau: Abbvie, Argenx, Boehringer-Ingelheim, Eli Lilly, Gilead, MSD, Novartis, Octapharma, Pfizer, Roche, Sanofi and UCB, Consultant of: Abbvie, Argenx, Boehringer-Ingelheim, Eli Lilly, Gilead, MSD, Novartis, Octapharma, Pfizer, Roche, Sanofi and UCB, Lucie Nekvindová: None declared, Semmi Gulie: None declared, Berrin Zengin: None declared, Merete Lund Hetland Grant/research support from: Abbvie, Biogen, BMS, Celtrion, Eli Lilly, Janssen Biologics B.V. Lundbeck Fonden, MSD, Medac, Pfizer, Roche, Roche, Samsung Biopics, Sandoz and Novartis, Irene van der Horst-Bruinsma Speakers bureau: BMS, Abbvie, Pfizer and MSD, Consultant of: Abbvie, UCB, MSD, Novartis and Lilly, Grant/research support from: MSD, Pfizer, Abbvie and UCB.


TREATMENT WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IS ASSOCIATED WITH RETARDATION OF RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 10-YEAR RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT

M. Torpatak1, V. Rios Rodriguez2, A. Dilibarany3, F. Proch3, M. Popotopov3, M. Verba1, J. Rademacher1, H. Haibel1, J. Sieper1, M. Rudwaleit2, D. Poddubny1, C. chaired—Universitätsmedizin Berlin, corporate member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases, and Rheumatology (including Nutrition Medicine), Berlin, Germany;2Moscow City Clinical Hospital, Department of Internal Medicine, Moscow, Russian Federation;3University of Bielefeld, Department of Internal Medicine and Rheumatology, Bielefeld, Germany.

Background: There are conflicting data regarding effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA) The analysis of the first 2-year of the GERSpIC showed that higher NSAID intake may retard new bone formation in r-axSpA. It remained, however, unclear, whether cyclooxygenase-2 selective inhibitors (COX2I) might have a stronger effect than non-selective (NS) ones and if the effect could be observed also in r-axSpA.

Objectives: To investigate the effect of NSAIDs (COX2I and NS) intake on radiographic spinal progression in patients with axSpA.

Methods: Based on availability of at least two sets of spinal radiographs during 10-year follow-up, 243 patients with early axSpA (130 and 113 nr- and r-axSpA, respectively) from GERSpIC were included in this analysis. The patients contributed a total of 540 2-year radiographic intervals. Radiographs were scored by 3 trained and calibrated readers according to modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). Final mSASSS was calculated as mean of 3 paired readers, and progression was defined as absolute mSASSS change score over 2 years. NSAID type, daily dose, and frequency of intake were recorded at visit. The ASAS index of NSAID intake (0-100) counting both dose and duration of intake was calculated for intervals. The association between NSAID intake
Evidence-Based Research, Copenhagen, Denmark; Odense University Hospital, Research Unit of Rheumatology, Department of Clinical Research, Odense, Denmark; Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; Randers Regional Hospital, Department of Rheumatology, Randers, Denmark; Odense University Hospital, Department of Rheumatology, Odense, Denmark; University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; Aalborg University Hospital, Department of Rheumatology, Aalborg, Denmark; Aalborg University, Department of Clinical Medicine, Aalborg, Denmark.

Background: Traditionally, biologics are maintained lifelong at standard dose in patients with inflammatory arthritis (IA) when sustained low disease activity (LDA) is reached. However, evidence of possible tapering is emerging but data on the optimal approach is lacking.

Objectives: The primary outcomes at 18 months follow-up are:

- Superiority: The proportion of patients reduced to ≤50% of their baseline biologic dose.
- Equivalence: Disease activity (rheumatoid arthritis [RA] and psoriatic arthritis [PsA]): Disease Activity Score28-C- Reactive Protein [DAS28-CRP] and axial spondyloarthritis [axSpA]: Anklyosing Spondylitis Disease Activity Score [ASDAS]).

Methods: The BIODOPT trial was a randomised, open-label, equivalence trial (EudraCT 2017-001970-41). Eligible patients were adults with RA, PsA, or axSpA in LDA on stable biologic doses during ≥12 months. The randomisation ratio was 2:1 (tapering:continuation) stratified by diagnosis, centre, and repeated biologic failures. In the tapering group, the biologic dosing interval was prolonged by 25% every four months until flare or discontinuation. The continuation group was kept on their baseline biologic dosing interval; however, a small increase was allowed (as usual practise) if requested by the patient. The sample size calculation was based on a pre-defined equivalence margin of ±0.5 disease activity points (score of the minimal important difference in DAS28-CRP [±1.2] or ASDAS [±1.1]) yielding a power of 87% for 180 enrolled patients. All analyses were based on the intention-to-treat population. Continuous outcomes were analysed with repeated-measures linear mixed-effects models with group, diagnosis, centre, repeated biologic failures, time point, and the interaction between group and time as fixed factors and the baseline value of the relevant variable as a covariate. Categorical outcomes were analysed using logistic regression with missing data imputed as trial failures.

Results: Between May, 2018, and March, 2020, 142 patients were enrolled of which 95 were randomised to tapering and 47 to continuation; inclusion was closed in April 2020 due to national implications of the coronavirus pandemic. At 18 months, significantly more patients in the tapering group (35 patients [37%]) achieved a significant reduction in their biologic dose (≥50%) compared to the continuation group (one patient [2%]), absolute risk difference (RD) 35%, 95%CI: 24% to 45%, p=0.001. Table 1. Furthermore, disease activity at 18 months was within the equivalence margins of ±0.5, mean difference between groups 0.08, 95%CI: -0.12 to 0.29; Table 1 and Figure 1. Flares were more frequent in the tapering group (39 [41%] vs 10 [21%], RD 0.20, 95%CI: 0.04 to 0.35, p=0.011) but managed with rescue therapy (e.g. biologic dose escalation or glucocorticoids) as only one patient (1%) in the tapering group and three patients (6%) in the continuation group lost therapeutic response and were switched to another biological agent.

Table 1. Comparison at 18 months in the ITT population

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Tapering group</th>
<th>Continuation group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=95</td>
<td>N=47</td>
<td></td>
</tr>
<tr>
<td>Group difference</td>
<td>p-value</td>
<td></td>
</tr>
<tr>
<td>Primary outcome:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics reduced to ≤50%, n (%)</td>
<td>35 (37%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Disease activity, LSiMeans (SE)</td>
<td>1.84 (0.15)</td>
<td>1.75 (0.16)</td>
</tr>
<tr>
<td>Key secondary outcomes:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remission2, n (%)</td>
<td>63 (66%)</td>
<td>33 (70%)</td>
</tr>
<tr>
<td>Low disease activity3, n (%)</td>
<td>79 (83%)</td>
<td>41 (87%)</td>
</tr>
<tr>
<td>Flares4, n (%)</td>
<td>39 (41%)</td>
<td>10 (21%)</td>
</tr>
</tbody>
</table>


Conclusion: Across IA conditions, a significant reduction of biologic dose is possible with disease activity-guided tapering while maintaining a similar disease activity state compared to continuation of biologic as usual care.

Acknowledgements: The authors thank patients, research personnel, and the patient research partners for their contribution to the BIODOPT trial, data manager JHW for technical support and for uploading the concealed allocation.
A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG

A. Deodhar1, A. Kvitiz2, M. Magrozy3, J. A. Walsh4, P. J. Mease5, M. Greenwald6, R. Calheiro7, F. Kianifard8, C. Elam9, K. Nagar10, A. Winseck1, L. G. Senslei11, 1Oakmer Health & R.C. University, Rheumatology, Portland, United States of America; 2Altona Center for Clinical Research, Altona Arthritis and Osteoporosis Center, Duncansville, United States of America; 3University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Rheumatology, Cleveland, United States of America; 4University of Utah School of Medicine and Salt Lake City Veterans Affairs Medical Center, Rheumatology, Salt Lake City, United States of America; 5Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America; 6Desert Medical Advances, Rheumatology, Palm Desert, United States of America; 7Novartis Pharmaceuticals Corporation, Rheumatology, East Hanover, United States of America; 8Novartis Pharmaceuticals Corporation, Biosciences, East Hanover, United States of America; 9Novartis Pharmaceuticals Corporation, Clinical Research, East Hanover, United States of America; 10Novartis Healthcare Pvt Ltd, Biosciences, Hyderabad, India; 11University of California, Department of Medicine, San Francisco, United States of America.

Background: Ankylosing spondylitis (AS) is a chronic, systemic inflammatory condition characterized by inflammatory back pain and is associated with extra-musculoskeletal manifestations and systemic comorbidities. Although biologic therapies for AS are available, no dose escalation studies are available in patients who have inadequate response to SEC 150 mg.

Objectives: The ASLep study (NCT03350815) estimated the difference in clinical response to SEC 300 mg vs 150 mg at Week (Wk) 52 in patients with AS who failed to achieve Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease status on SEC 150 mg at Wk 16.

Methods: In this randomized, double-blind, parallel-group, multicenter, phase 4 study, 322 patients with AS who were assigned to receive open-label SEC 150 mg administered per the label for 16 Wks (period 1). At Wk 16, patients who did not achieve inactive disease (ASDAS < 1.3) at Wks 12 and 16 were randomized 1:1 in a double-blind manner to SEC 150 mg or escalated to SEC 300 mg q4w to Wk 52 (period 2). The primary efficacy variable was achievement of ASDAS < 1.3 and the primary analysis time point was Wk 52. Secondary efficacy variables were achievement of ASDAS clinically important improvement ≥ 1.1, 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI50), Assessment of SpondyloArthritis international Society responses (ASAS20, ASAS40, and ASAS partial remission), and change from baseline in BASDAI, ASAS Health Index (ASAS-HI), and the Functional Assessment of Chronic Illness Therapy – Fatigue Scale (FACIT-F). Safety was evaluated by incidence of treatment-emergent adverse events (TEAEs) within Wk 52. No statistical hypothesis tests for superiority or equivalence were planned in the protocol and none were performed.

Results: Of 279 patients receiving SEC 150 mg who completed the 16-wk open-label period 1, 22 (79%) achieved ASDAS < 1.3 at Wks 12 or 16 and continued receiving SEC 150 mg; 207 patients did not attain ASDAS < 1.3 at Wk 12 and Wk 16 and initiated period 2. Demographics and baseline disease characteristics were balanced between patients randomized to SEC 150 mg and SEC 300 mg, including the proportion of patients who were TNFi naive (SEC 150 mg: 73 [72.3%]; SEC 300 mg: 73 [69.5%]) (Table 1). Approximately 60% of patients in either SEC group were HLA-B27 positive. After having an inadequate response to SEC 150 mg through Wk 16, patients receiving either dose of SEC experienced similar improvements at Wk 52 in disease activity as measured by achievement of ASDAS < 1.3, ASDAS clinically important improvement ≥ 1.1, BASDAI50, ASAS20, ASAS40, and ASAS partial remission; and mean changes in BASDAI, quality of life as measured by ASAS HI, and fatigue as measured by FACIT-F (Figure 1). The incidence of TEAEs through Wk 52 was similar between patients receiving SEC 300 mg (63.4%) and 150 mg (68.6%).

Disclosure of Interests: Line Uhrenholt Speakers bureau: Abbvie, Eli Lilly, Jansen, and Novartis, Robin Christensen: None declared, Lene Dreyer Speakers bureau: Eli Lilly, Galderma and Janssen, Grant/research support from: BMS (outside the present work), Ellen-Margrethe Hauge Speakers bureau: Abbvie, Eli Lilly, and Galapagos, (OCAY -18-774-OFIL).

References:

2. Novartis Pharmaceuticals Corporation, Clinical Research, Altoona Arthritis and Osteoporosis Center, Duncansville, United States of America; 3University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Rheumatology, Cleveland, United States of America; 4University of Utah School of Medicine and Salt Lake City Veterans Affairs Medical Center, Rheumatology, Salt Lake City, United States of America; 5Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America; 6Desert Medical Advances, Rheumatology, Palm Desert, United States of America; 7Novartis Pharmaceuticals Corporation, Rheumatology, East Hanover, United States of America; 8Novartis Pharmaceuticals Corporation, Biosciences, East Hanover, United States of America; 9Novartis Pharmaceuticals Corporation, Clinical Research, East Hanover, United States of America; 10Novartis Healthcare Pvt Ltd, Biosciences, Hyderabad, India; 11University of California, Department of Medicine, San Francisco, United States of America.
Table 1. Demographics and Baseline Disease Characteristics of Patients in Period 2 (safety set)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Secukinumab 150 mg → 300 mg</th>
<th>Secukinumab 150 mg → 150 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>48.5 (14.1)</td>
<td>47.0 (13.7)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>43 (42.6)</td>
<td>52 (49.5)</td>
</tr>
<tr>
<td>BMI, mean (SD), kg/m²</td>
<td>32.0 (5.8)</td>
<td>32.1 (7.7)</td>
</tr>
<tr>
<td>HLA-B27 positive, n (%)</td>
<td>60 (59.4)</td>
<td>65 (61.9)</td>
</tr>
<tr>
<td>Time since axial symptom onset, mean (SD)</td>
<td>13.9 (11.7)</td>
<td>14.0 (12.5)</td>
</tr>
<tr>
<td>Time since diagnosis of AS, mean (SD), years</td>
<td>4.7 (8.6)</td>
<td>5.1 (9.7)</td>
</tr>
<tr>
<td>TNF naïve, n (%)</td>
<td>73 (72.3)</td>
<td>73 (69.5)</td>
</tr>
<tr>
<td>History of extra-axial involvement, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peripheral arthritis</td>
<td>34 (33.7)</td>
<td>30 (28.6)</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>29 (28.7)</td>
<td>31 (29.5)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>13 (12.9)</td>
<td>17 (16.2)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>14 (13.9)</td>
<td>14 (13.3)</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>7 (6.9)</td>
<td>4 (3.8)</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>2 (2.0)</td>
<td>1 (1.0)</td>
</tr>
</tbody>
</table>

AS, ankylosing spondylitis; BMI, body mass index; TNF, tumor necrosis factor inhibitor.

Conclusion: Patients with AS who did not achieve inactive disease by Wk 16 after receiving SEC 150 mg experienced similar clinical response and safety through Wk 52 regardless of dose escalation to SEC 300 mg or continuation on SEC 150 mg.

Acknowledgements: This study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Richard Karpowicz, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.

Disclosure of Interests: Atul Deodhar Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and Sanofi, Speakers bureau: AbbVie, Celgene, Flexion, Genzyme, GSK, Eli Lilly, Horizon, Merck, Novartis, Pfizer, Sanofi, and UCB, Consultant of: AbbVie, Boehringer Ingelheim, Flexion, Gilead, Janssen, Pfizer, Regeneron, Sanofi, and Sun Pharma, Marina Magrey Consultant of: Eli Lilly and Novartis, Grant/ research support from: AbbVie, Amgen, and UCB, Jessica A. Walsh Consultant of: Amgen, Lilly, Novartis, and UCB, Grant/research support from: AbbVie and Pfizer, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Maria Greenwald Consultant of: Galapagos, Eli Lilly, Janssen, and Pfizer, Grant/research support from: UCB Pharma, AbbVie, Amgen, and Novartis.

Differential in Period 2 (safety set)

Background: The differential contribution of IL-6 and IL-17 pathways to the pathogenesis of psoriatic arthritis (PsA) is not fully understood. Upadacitinib (UPA), an oral JAK inhibitor, was more effective than placebo (PBO) in improving key clinical manifestations of PsA in two global phase 3 trials, SELECT-Psa1 (non-biological DMARD-IR, nbDMARD-IR) and SELECT-Psa2 (biological DMARD-IR, bDMARD-IR).3,4 Targeted proteomic analysis suggested that UPA modulates multiple biological pathways in innate and adaptive immune systems via direct and indirect inhibition of key regulators, including IL-6 and IL-17 pathways, with a possible shift from Th1 predominance in nbDMARD-IR PsA to a more Th17 bias in bDMARD-IR PsA.3,4

Objectives: We assessed the relationship between IL-6 and IL-17 pathway modulation and different clinical outcomes after UPA treatment in nbDMARD-IR and bDMARD-IR PsA patients.

Methods: A subset of patients was randomly selected from SELECT-Psa1 (n=74 of UPA 15 mg QD, n=74 of PBO) and PsA 2 studies (n=90 of UPA 15 mg QD, n=81 of PBO). Serum levels of IL-6, IL-17A, IL-17F, and beta-defensin 2 (BD2) proteins were measured at baseline, week 2, and week 12 by validated immunoassays. The quantitative cytokine measurements were transformed as log10, and PASI score was transformed as log10 (x+1) prior to analysis. A Repeated Measure Mixed Linear Model was used to compare UPA versus PBO treatment effects in overall selected patients and between responders and non-responders defined by PASDAS score ≤ 3.6 (Minimal Disease Activity, MDA) and PASI75 at week 12, respectively. The relationships between cytokines and clinical outcomes (PASI) and DAS28-CPRO were assessed by Pearson’s correlation at baseline and after treatment.

Results: In nbDMARD-IR PsA patients, baseline IL-17A, IL-17F, and BD2 levels were measured at baseline, week 2, and week 12 by validated immunoassays. The quantitative cytokine measurements were transformed as log10, and PASI score was transformed as log10 (x+1) prior to analysis. A Repeated Measure Mixed Linear Model was used to compare UPA versus PBO treatment effects in overall selected patients and between responders and non-responders defined by PASDAS score ≤ 3.6 (Minimal Disease Activity, MDA) and PASI75 at week 12, respectively. The relationships between cytokines and clinical outcomes (PASI) and DAS28-CPRO were assessed by Pearson’s correlation at baseline and after treatment.

References:
Background: Fatigue, one of the top 3 patient (pt)-reported symptoms of psoriatic arthritis (PsA) and a recent PsA outcome domain,\(^1\) causes impaired health-related quality-of-life, diminished productivity, and disability.\(^2,3\) Although the origins of fatigue are multifactorial, inflammation is hypothesized to play an important role.\(^4\) In pts with active PsA, treatment with guselkumab (GUS) led to clinically meaningful and sustained improvements in fatigue through 1 year in DISCOVER-1 (D1) and DISCOVER-2 (D2).\(^5\)

Objectives: To identify 1) factors associated with fatigue and 2) factors associated with change in fatigue among pts with PsA treated with GUS.

Methods: In the Phase 3 D1 (N=381, biologic-naive and tumor necrosis factor inhibitor-experienced) and D2 (N=739, biologic-naive) studies, pts with active PsA despite standard therapies and/or biologic disease-modifying antirheumatic drugs were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or placebo (PBO) with crossover to GUS 100 mg Q4W at W24. The pt-reported Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale measured fatigue (scored 0-52). In these post-hoc analyses of D1 and D2 pts, a principal component analysis (PCA) was performed using W0 data to identify the underlying baseline factors associated with fatigue. Additionally, linear regression analyses were performed to identify covariates associated with change in fatigue from W0 to W24.

Results: In 1120 pts (mean age 47 yrs, mean disease duration 5.9 yrs, 48% female), mean FACIT-Fatigue scores at baseline ranged from 29.1 to 31.4 (vs 43.6 for the general US population).\(^6\) PCA showed that 62% of the variability in fatigue could be explained by 3 components (Figure 1). The first component, explaining 34% of variability in fatigue, largely comprised systemic disease activity and function measures such as pain, pt global assessment of disease activity (PtGDA), physician’s global assessment of disease activity, and Health Assessment Questionnaire-Disability Index (HAQ-DI). The second component, explaining 16% of variability, comprised joint manifestations including swollen joint count (SJc) and tender joint count (TJc). Skin involvement as assessed by Psoriasis Area and Severity Index (PASI) and systemic inflammation (C-reactive protein [CRP]) could explain 12% of the variability in fatigue (Figure 1 and Table 1). In a multivariate linear regression analysis, after adjusting for effects from other variables, improvement in CRP, physical function in fatigue (Figure 1 and Table 1). In a multivariate linear regression analysis, after adjusting for effects from other variables, improvement in CRP, physical function, and HAQ-DI were significantly associated with fatigue improvement from W0 to W24.

Table 1. PCA of Pts With Active PsA in D1+D2 (N=1120; Pooled W0 data): Factor Loading Estimates by Covariates

<table>
<thead>
<tr>
<th>Component 1: Systemic Disease Activity and Function</th>
<th>Component 2: Joint Manifestations</th>
<th>Component 3: Skin Involvement and Inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td>PsA disease duration, yr</td>
<td>0.10</td>
<td>0.14</td>
</tr>
<tr>
<td>PASI total score (0-72)</td>
<td>0.22</td>
<td>0.23</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>0.36</td>
<td>-0.13</td>
</tr>
<tr>
<td>HAQ-DI score (0-3)</td>
<td>0.73</td>
<td>-0.09</td>
</tr>
<tr>
<td>Pain (0-10 VAS)</td>
<td>0.83</td>
<td>-0.35</td>
</tr>
<tr>
<td>PGA (0-10 VAS)</td>
<td>0.82</td>
<td>-0.36</td>
</tr>
<tr>
<td>Physician global assessment of disease activity (0-10 VAS)</td>
<td>0.65</td>
<td>-0.18</td>
</tr>
</tbody>
</table>

SJC (0-66) | 0.50 | 0.74 | 0.12 |
| TJC (0-66) | 0.54 | 0.70 | -0.18 |

VAS=Visual Analog Scale.

Conclusion: Among pts with PsA, measures of systemic disease activity and function, followed by joint manifestations, and skin involvement/inflammation accounted for 62% of the variability in fatigue. The large residual effect (38%) that was unexplained by the current model suggests the need for further research to identify additional factors (eg, distinct molecular pathways) contributing to the fatigue reported by PsA pts.

REFERENCES:

Disclosure of Interests: Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCBD, Grant/research support from: Janssen and Novartis, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Immagen, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Genentech, Janssen, Merck, Novartis, Pfizer and UCB, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Yan Liu Shareholder of: 3 Johnson & Johnson, Employee of: Janssen Research & Development, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Chenglong Han Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC.


OP0026  CLINICAL AND IMAGING-BASED CHARACTERIZATION OF A PROSPECTIVE COHORT OF PATIENTS WITH AXIAL PSORIATIC ARTHRITIS (AXIAL PSA). GESPECTIC-AXIAL PSA: RESULTS OF AN INTERIM ANALYSIS

H. Käding1, S. Lüders1, M. Protopopov1, J. Rademacher1, V. Rios Rodriguez2, L. Spiller1, M. Torgutalp1, D. Poddubnyy1, F. Proft1. 1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany. 2German Rheumatism Research Centre, Epidemiology unit, Berlin, Germany

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease, which is subsumed together with axial spondyloarthritis (axial SpA) under the umbrella term spondyloarthritides, whose clinical presentations are very heterogeneous. Axial involvement (axial PsA) has been described to be present in 34% of PsA patients [1] and has been systematically investigated only retrospectively or in cross-sectional studies [2]. Although axial PsA seems to have similar characteristics to axial SpA, it is not clear whether axial PsA and axial SpA, are a spectrum of the same disease with different expression patterns or different diseases with great similarities.

Objectives: To prospectively investigate the clinical and imaging morphology patterns in a well-defined cohort of patients with axial PsA from the German Spondyloarthritis Inception Cohort (GESPECTIC).

Methods: Prospective, longitudinal, observational study of patients with an imaging confirmed diagnosis of axial PsA. In addition to clinical and laboratory characterization, conventional radiographs and magnetic resonance imaging (MRI) - scans of the entire spine and sacroiliac joints (SIJs) are performed at the baseline visit and patients are followed up every 6 months according to a predefined protocol. After 2 years, additional imaging (X-ray and MRI) is performed for follow-up. In this interim analysis baseline data are presented.

Results: Between August 2019 and December 2021, 85 axial PsA patients were included. The mean age was 45.2 ± 12.9 years with a proportion of 55.3% female patients. Periphal involvement was present in 43 (50.6%) patients. HLA-B27 was positive in 39 (45.9%), and C-reactive protein was elevated (>5mg/l) in 27 (31.8%) patients. Inflammatory back pain (IBP) present, n (%) 64 (75.3%). Peripheral Involvement, n (%) 43 (50.6%). Nail Involvement, n (%) 39 (45.9%). BASFI (mean ± SD), 0-10 3.8 ± 2.5. BASDAI (mean ± SD), 0-10 4.9 ± 2.0. ASDAS-CRP (mean ± SD) 2.8 ± 1.0. ASDAS (mean ± SD) 14.5 ± 9.2. HLA-B 27 positive, n (%) 39 (45.9%). CRP >5mg/l, n (%) 27 (31.8%).

Table 1. Characteristics of patients with axial PsA

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Axial PsA (n=85)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years (mean ± SD)</td>
<td>45.2 ± 12.9</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>47 (55.3%)</td>
</tr>
<tr>
<td>Inflammatory back pain (IBP) present, n (%)</td>
<td>64 (75.3%)</td>
</tr>
<tr>
<td>Peripheral Involvement, n (%)</td>
<td>43 (50.6%)</td>
</tr>
<tr>
<td>Nail Involvement, n (%)</td>
<td>39 (45.9%)</td>
</tr>
<tr>
<td>BASFI (mean ± SD)</td>
<td>3.8 ± 2.5</td>
</tr>
<tr>
<td>BASDAI (mean ± SD)</td>
<td>4.9 ± 2.0</td>
</tr>
<tr>
<td>ASDAS-CRP (mean ± SD)</td>
<td>2.8 ± 1.0</td>
</tr>
<tr>
<td>ASDAS (mean ± SD)</td>
<td>14.5 ± 9.2</td>
</tr>
<tr>
<td>HLA-B 27 positive, n (%)</td>
<td>39 (45.9%)</td>
</tr>
<tr>
<td>CRP &gt;5mg/l, n (%)</td>
<td>27 (31.8%)</td>
</tr>
</tbody>
</table>

ASDAS-CRP =Ankylosing Spondylitis Disease Activity Score - CRR BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index, CRP = C-reactive protein, DAPSA = Disease Activity in Psoriatic Arthritis-Score, PASI = Psoriasis Area Severity Index, PsA = Psoriatic arthritis, SD = standard deviation.

Conclusion: In the here presented interim analysis of the baseline data of our prospective cohort study of patients with an imaging-based diagnosis of axial PsA, it is shown that these patients are less frequently HLA-B27 positive and more frequently female when compared to previously described cohorts of “classical” axial SpA patients. Noteworthy, nearly 20% of the patients showed an isolated spinal involvement without active or structural changes in the SIJs.

REFERENCES:

Acknowledgements: The GESPECTIC-axial PsA cohort is partially supported by an independent research grant from Novartis. We would especially like to thank C. Höppner, C. Lorenz, and all referring rheumatologists for their tireless support.

Disclosure of Interests: Henriette Käding: None declared, Susanne Lüders: None declared, Mikhail Protopopov: None declared, Judith Rademacher: None declared, Valeria Rios Rodriguez: None declared, Laura Spiller: None declared, Murat Torgutalp: None declared, Denis Poddubnyy: None declared, Fabian Profi Speakers bureau: AMGEN, AbbVie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, UCB.
Background: Common comorbidities of psoriatic arthritis (PsA) and psoriasis (PsO) are cardiovascular (CV) disease and metabolic syndrome (MetS). Risk of CV disease may be associated with increased risk of future malignancies. Tofacitinib is a JAK inhibitor for treatment of PsA and has been investigated for treatment of PsO.

Objectives: To examine baseline (BL) CV risk and its association with incidence rates (IRs) of major adverse CV events (MACE) and malignancies in tofacitinib-treated patients (pts) with PsA and PsO.

Methods: Analysis included data from 3 (Phase [P]3/long-term extension [LTE]) trials of pts with PsA and 7 (P2/LTE) trials of pts with PsO receiving ≥1 dose of tofacitinib (5 or 10 mg twice daily). IRs (pts with events/100 pt-yrs) for MACE and malignancies (excluding non-melanoma skin cancer) were stratified by: history of coronary artery disease (HxCAD [≥1 of myocardial infarction, coronary heart disease, coronary artery procedure or stable angina pectoris]); BL 10-yr atherosclerotic CV disease (ASCVD); and BL MetS (≥3 of hypertension, raised triglycerides, reduced high-density lipoprotein cholesterol, high waist circumference or high fasting glucose levels).

Results: Of 783 and 3663 pts with PsA and PsO, total tofacitinib exposure was 2036 and 8950 pt-yrs, and median duration of exposure was 3.0 and 2.4 yrs, respectively. In pts with PsA and PsO, 5.0% and 2.5% had HxCAD, respectively; in those without HxCAD, >20% had intermediate/high BL 10-yr ASCVD risk (Figure 1). At BL, 40.9% and 32.7% of pts with PsA and PsO had MetS, respectively. IRs of MACE were greatest in pts with PsA and PsO who had HxCAD/high BL 10-yr ASCVD risk (Table 1). In the PsA cohort, 5/6 pts with MACE had MetS, respectively. IRs of malignancies in pts with PsA were greatest in those with intermediate/high BL MetS (Table 1). In the PsO cohort, IRs of malignancies was notably greater in pts with PsO were greatest in those with intermediate/high BL MetS (Table 1). In the PsA cohort, 5/6 pts with MACE had BL MetS. IRs of MACE and malignancies were stratified by: history of coronary artery disease, ASCVD-pooled cohort equations calculator (only in pts without HxCAD); and BL 10-yr atherosclerotic CV disease (ASCVD-pooled cohort equations calculator [only in pts without HxCAD]); and BL 10-yr atherosclerotic CV disease (HxCAD [≥1 of myocardial infarction, coronary heart disease, coronary artery procedure or stable angina pectoris]); BL 10-yr atherosclerotic CV disease (ASCVD) risk (ASCVD-pooled cohort equations calculator only in pts without HxCAD); and BL MetS (≥3 of hypertension, raised triglycerides, reduced high-density lipoprotein cholesterol, high waist circumference or high fasting glucose levels). Conclusion: In tofacitinib-treated pts with PsA and PsO, raised CV risk and MetS at BL were potentially associated with higher IRs of MACE and malignancies. Our findings support assessing CV risk in pts with PsA and PsO and enhanced monitoring for malignancies in those with raised CV risk.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Emma Mitchell, CMC Connect, and funded by Pfizer Inc.

Disclosure of Interests: Lars Erik Kristensen, Speakers bureau: AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Eli Lilly, Janssen, MSD, Novartis, Pfizer Inc and UCB; Grant/research support from: Biogen, Janssen, Novartis and UCB; Bruce Strober, Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, MSD, Novartis, Pfizer Inc and UCB; Consultant: AbbVie, Biocad, Gilead Sciences, GlaxoSmithKline, Kline, Janssen, MSD, Novartis, Pfizer Inc and UCB; Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Emma Mitchell, CMC Connect, and funded by Pfizer Inc.

Disclosure of Interests: Lars Erik Kristensen, Speakers bureau: AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Eli Lilly, Janssen, MSD, Novartis, Pfizer Inc and UCB; Grant/research support from: Biogen, Janssen, Novartis and UCB; Bruce Strober, Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, MSD, Novartis, Pfizer Inc and UCB; Consultant: AbbVie, Biocad, Gilead Sciences, GlaxoSmithKline, Kline, Janssen, MSD, Novartis, Pfizer Inc and UCB; Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Emma Mitchell, CMC Connect, and funded by Pfizer Inc.

Table 1. IRs of MACE and malignancies in pts with PsA and PsO receiving tofacitinib, stratified by HxCAD, BL 10-yr ASCVD risk and BL MetS

<table>
<thead>
<tr>
<th>MACE</th>
<th>PsA</th>
<th>PsO</th>
<th>PsA</th>
<th>PsO</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N(n1)</td>
<td>IR (95% CI)</td>
<td>n/N(n1)</td>
<td>IR (95% CI)</td>
<td>n/N(n1)</td>
</tr>
<tr>
<td>HxCAD</td>
<td>Yes</td>
<td>1/380[0]</td>
<td>0.97 (0.02, 5.38)</td>
<td>3/983[0]</td>
</tr>
<tr>
<td>No</td>
<td>5/744[5]</td>
<td>0.25 (0.08, 0.59)</td>
<td>20/3570[10]</td>
<td>0.22 (0.13, 0.34)</td>
</tr>
<tr>
<td>BL 10-yr ASCVD risk category</td>
<td>High risk (&gt;20%)</td>
<td>1/35[1]</td>
<td>0.12 (0.01, 2.32)</td>
<td>7/179[4]</td>
</tr>
<tr>
<td>No</td>
<td>1/91[1]</td>
<td>0.42 (0.01, 2.32)</td>
<td>2/400[0]</td>
<td>0.19 (0.02, 0.67)</td>
</tr>
<tr>
<td>BL MetS</td>
<td>Yes</td>
<td>5/320</td>
<td>0.60 (0.20, 1.40)</td>
<td>10/1197</td>
</tr>
<tr>
<td>No</td>
<td>1/463</td>
<td>0.08 (0.00, 0.44)</td>
<td>13/2468</td>
<td>0.20 (0.11, 0.38)</td>
</tr>
</tbody>
</table>

Follow-up time calculated up to the day of the first event and subject to risk period of 28 days beyond the last dose of study drug.

CI, confidence interval; N, total pts; n, pts with MACE/malignancies; n1, pts with MACE/malignancies and BL MetS.
Background: Minimal disease activity (MDA) is a treatment target in psoriatic arthritis (PsA) that takes both clinical manifestations (joints, skin and enthesis) and the patient perspective into account (1). In a previous study we have shown that achieving MDA in the first year is associated with better quality of life (QoL) regardless whether this was achieved early or late in the first year (2). However, the impact of achieving MDA within the first year on the long-term is lacking.

Objectives: To compare quality of life at 1, 2 and 3 years between PsA patients who achieve MDA in the first year and those who do not.

Methods: Newly diagnosed, DMARD naïve PsA patients with oligo- or polyarthritis and at least 3 years of follow-up, participating in the Dutch southwest Early PsA cohort (DEPAR) were included. In short the DEPAR is an observational cohort of newly diagnosed PsA (3). Study visits took place at 3, 6, 9, 12, 18, 24 and 36 months after diagnosis. Patients were categorized in three groups by achievement of MDA in the first year:

- Sustained MDA, includes patients who were in MDA at both their 9- and 12-month visit;
- Non-sustained MDA, includes patients who achieved MDA in the first year but did not sustain it at both 9- and 12-months;
- No MDA, includes patients who did not achieve MDA in the first year.

To measure QoL at 1, 2 and 3 years the Short form-36 (SF-36) questionnaire was used. Descriptive statistics were used to compare QoL.

Results: We included 243 patients (51% male) of whom 113 (47%) were classified as sustained MDA, 64 (26%) as non-sustained MDA and 66 (27%) as no MDA. At baseline, patients had a mean age of 52.7 years and median symptom duration of 9.3 months. Patients in the no MDA group seemed to be older, were more often female and had a longer symptom duration (Table 1). QoL of sustained MDA patients was comparable to the general Dutch population (4) after 1, 2 and 3 years of follow-up. However, patients who did not achieve MDA in the first year had a lower QoL compared to the sustained MDA group and these differences persist in the years thereafter (Figure 1). The physical as well as the mental QoL domains were worse in the no MDA group compared to the other groups.

Table 1. Baseline characteristics of patients categorized by MDA group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Sustained MDA</th>
<th>Non-sustained MDA</th>
<th>No MDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>51.8 ± 13</td>
<td>51.8 ± 14</td>
<td>55.3 ± 13</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>69 (61)</td>
<td>33 (52)</td>
<td>21 (32)</td>
</tr>
<tr>
<td>Symptom duration (months)</td>
<td>8.5 (4-24)</td>
<td>8.1 (3-28)</td>
<td>12.9 (5-51)</td>
</tr>
<tr>
<td>Disease activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swollen joint count (68)</td>
<td>3 (2-5)</td>
<td>4 (1-6)</td>
<td>4 (2-6)</td>
</tr>
<tr>
<td>Tender joint count (68)</td>
<td>3 (1-6)</td>
<td>4 (2-8)</td>
<td>8 (4-13)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>95 (84)</td>
<td>58 (91)</td>
<td>56 (85)</td>
</tr>
<tr>
<td>BSA in case of psoriasis (%)</td>
<td>3 (2-4)</td>
<td>3.3 (14-5)</td>
<td>3 (15-6)</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>29 (26)</td>
<td>28 (44)</td>
<td>38 (58)</td>
</tr>
<tr>
<td>LEI in case of enthesitis</td>
<td>1 (1-2)</td>
<td>2 (1-2)</td>
<td>2 (1-4)</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.38 (0.19-0.75)</td>
<td>0.75 (0.5-1)</td>
<td>1 (0.75-1.38)</td>
</tr>
<tr>
<td>VAS global</td>
<td>31 (15-56)</td>
<td>46 (23-65)</td>
<td>59 (50-77)</td>
</tr>
<tr>
<td>VAS pain</td>
<td>28 (12-52)</td>
<td>50 (26-66)</td>
<td>69 (53-80)</td>
</tr>
</tbody>
</table>

Results are shown as mean ± standard deviation, n (%) or median (interquartile range). BSA: Body Surface Area; LEI: Leeds Enthesitis Index; HAQ: Health Assessment Questionnaire; VAS: visual analogue scale.

Over the years, treatment was intensified in all groups, with biologicals use after three years at 18%, 25% and 31% in the sustained MDA, non-sustained MDA and no MDA group, respectively.

Figure 1. (A) 1 year, (B) 2 year and (C) 3 year quality of life scores, measured with the SF-36 domains, for MDA groups and compared with the general Dutch population norms (4). (D) percentage of patients who use biologicals over time per MDA group.

Conclusion: Failure to achieve MDA in the first year after PsA diagnosis is associated with worse quality of life outcomes that persist over the years despite more intensified treatment.

REFERENCES:

Acknowledgements: This study was funded by UCB Pharma. UCB was involved in the development of the research question. UCB was not involved in the evaluation of the results or drafting of the abstract.

Disclosure of Interests: None declared.

sensitivity and specificity of diagnostic screening tools for PsA. Musculoskeletal ultrasonography (MSUS) has been shown to be a reliable tool for diagnosing PsA, even in preclinical situations. However, the use of MSUS screening by dermatologists in the early detection of PsA has not been studied so far.

**Objectives:** The purpose of this study was to assess the accuracy of early PsA identification by dermatologists who have been previously trained in MSUS utilizing an innovative handheld-ultrasound device (Butterfly IQ).

**Methods:** Twelve dermatologists have been trained in MSUS (2) previously by a newly designed curriculum. Six working at the clinic for Dermatology and Allergology of the University Hospital Bonn, while the remaining six serve in private practices. The MSUS training curriculum focused mainly on detecting joint effusion and synovial hyperperfusion in all joints. After successful training, these colleagues were provided with handheld-ultrasound devices in order to screen 140 psoriasis patients presenting with arthralgia. Dermatologists were asked to determine whether or not the patient had PsA based on the medical history, clinical examination, and GEPARD questionnaire. Subsequently a MSUS exam of up to three painful joints was conducted by the dermatologists using the provided handheld-ultrasound devices. The post MSUS decision was also recorded. All prescreened patients were then referred to blinded board-certified rheumatologists with MSUS certification (EFSUMB level II and III), which repeated medical history, clinical examination and MSUS. We investigated the impact of MSUS on the sensitivity and specificity of early PsA diagnosis by comparing dermatologists’ pre- and post-ultrasound PsA suspicion with the final diagnosis determined by the rheumatologist.

**Results:** In total, 140 patients were enrolled. PsA was detected in 24 cases. The sensitivity of dermatologists’ pre-MSUS PsA suspicion was 81.0% while the specificity was 54.5%. After conducting MSUS the sensitivity and specificity of early PsA diagnosis by comparing dermatologists with MSUS certification (EFSUMB level II and III) repeated medical history, clinical examination and MSUS. We investigated the impact of MSUS on the sensitivity and specificity of early PsA diagnosis by comparing dermatologists’ pre- and post-ultrasound PsA suspicion with the final diagnosis determined by the rheumatologist.

**Conclusion:** We were able to demonstrate that targeted MSUS performed by dermatologists increases specificity while decreasing sensitivity, perhaps leading to three painful joints was conducted by the dermatologists using the provided handheld-ultrasound devices. The post MSUS decision was also recorded. All prescreened patients were then referred to blinded board-certified rheumatologists who have been previously trained in MSUS utilizing an innovative handheld-ultrasound device (Butterfly IQ).

**Disclosure of Interests:** None declared.

**REFERENCES:**


SEROLOGICAL COLLAGEN BIOMARKERS CAN DIFFERENTIATE PATIENTS WITH PSORIASIS FROM PSORIATIC ARTHRITIS

S. S. Groen1,2, S. Holm Nielsen1,2, A. C. Bay-Jensen3, M. Rastå, D. Ganatra4, K. Oikonomopoulou5, V. Chandran1,2, University of Copenhagen, Biomedical Sciences, Copenhagen; Denmark; Nordic Bioscience, ImmunoScience, Herlev, Denmark; Nordic Bioscience, ImmunoScience, Herlev, Denmark; Technical University of Denmark, Biotechnology and Biomedicine, Kgs. Lyngby, Denmark; Krembi Research Institute, Schroeder Arthritis Institute, Toronto, Canada; Institute of Medical Science, Department of Medicine, Division of Rheumatology; Department of Laboratory Medicine and Pathobiology; Toronto, Canada.

Methods: Patients with PsA (n=87, median age 42.01 ±12.20, 44% female) underwent a full rheumatologic assessment to exclude PsA and patients with PsA (n=99, mean ±SD age 45.94 ±12.47, 49% female) were recruited at the Toronto Western Hospital, Canada, after appropriate ethics approval. ECM remodelling was estimated using as indices serological anabiotic biomarkers quantifying formation of type III, IV, and VI collagen (PRO-C3, PRO-C4, and PRO-C6 respectively), and catabolic biomarkers measuring degradation of type I, III, IV and VI collagen (C1M, C3M, C4M, C6M respectively). Data are presented as mean ± standard deviation (SD). Statistically significant difference between the two groups was calculated by Mann-Whitney U test and a p-value below 0.05 was considered significant. Area under the receiver operating characteristic (ROC) curve (AUC) analysis was performed to describe the discrimination accuracy of each biomarker between the two patient groups.

Results: Patients with PsA presented higher levels of C1M, C3M, C6M, and PRO-C6 compared to PsC (p<0.0460-p<0.0009, Figure 1 A, B, D, G), while biomarkers levels of C4M, PRO-C3, and PRO-C4 were not significantly different between PsC and PsA patients (Figure 1 C, E, F). Moreover, C1M and C6M were able to separate between PsC and PsA patients with an AUROC=0.6277 (p=0.0027) and AUROC=0.6446 (p=0.0010), respectively, indicating that these biomarkers may be markers of joint involvement (Figure 1 H, I).

Conclusion: This work provides evidence that serum degradation biomarkers of type I and VI collagen were able to differentiate patients with PsA from PsC and may be potential biomarkers of inflammatory systemic musculoskeletal involvement. These findings suggest that serological biomarkers may be used to identify the 25% of psoriasis patients that have PsA.

Disclosure of Interests: Sneige Skovlund Groen: None declared, Signe Holm Nielsen Employee of: Signe Holm Nielsen is employed by Nordic Bioscience, Anne-Christine Bay-Jensen Shareholder of: Anne C. Bay-Jensen holds stock in Nordic Bioscience, Employee of: Anne C. Bay-Jensen is employed by Nordic Bioscience, Mozghan Rasti: None declared, Darshini Ganatra: None declared, Katerina Oikonomopoulou: None declared, Vinod Chandran: None declared.


From risk assessment to societal outcomes

AN ECONOMIC WINDOW OF OPPORTUNITY FOR PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 5-YEAR COST-EFFECTIVENESS ANALYSIS OF THE CARERA TRIAL

S. Pazoni1, V. Stoufen1, D. De Cock1, M. Doumen1, D. Bertrand1, J. Joly2, R. Westhovens1,2, P. Verschueren1,2, on behalf of CareRA study group.
1Katholieke Universiteit Leuven, Development and Regeneration, Leuven, Belgium; 2UZ Gasthuisberg Campus, Rheumatology, Leuven, Belgium.

The CareRA trial showed that remission induction with methotrexate (MTX) and glucocorticoid (GC) bridging in a treat-to-target setting is cost-effective up to 2 years in early rheumatoid arthritis (eRA) patients. Our aim was to determine the cost-effectiveness of the CareRA (COBRA-Slim) trial in low- and high-risk populations over 5 years. No other studies have evaluated the CareRA compared to the other Step-Up: TSU)

Methods: 322 eligible patients, 252 were included in CareRA plus, of which 203 completed the trial. Patients were randomly assigned to receive MTX and a step-down GC scheme (COBRA-Slim) compared to (a) the same combination with either sulfasalazine (COBRA-Classic) or leflunomide (COBRA-Avant-Garde) in high-risk patients and (b) MTX without GCs (Tight-Step-Up TSU) in low-risk patients up to 5 years.

Results: Of 322 eligible patients, 252 were included in CareRA plus, of which 203 completed the trial. Rates of disease control (DAS28-CRP<2.6) at year 5 in high-risk patients were 68%, 72%, and 64% in the Classic, Slim and Avant-Garde group respectively (p=0.63) and related total costs were €11 358.39 (CI 7 776.84-14 939.93), €5 340.34 (CI 3 607.63-7 075.11) and €11 752.47 (CI 7 776.84-14 939.93), €5 340.34 (CI 3 607.63-7 075.11) and €11 752.47 (CI 7 776.84-14 939.93) for TSU. In the low-risk group, Classic (ICER €723.82) and Avant-Garde (ICER €411.17) were more expensive and less effective compared to Slim. Multiple imputation was used to handle missing data and non-parametric bootstrapping with 25000 iterations of random sampling with replacement to calculate confidence intervals (95% CIs).

Results: Of 322 eligible patients, 252 were included in CareRA plus, of which 203 completed the trial. Rates of disease control (DAS28-CRP<2.6) at year 5 in high-risk patients were 68%, 72%, and 64% in the Classic, Slim and Avant-Garde group respectively (p=0.63) and related total costs were €11 358.39 (CI 7 776.84-14 939.93), €5 340.34 (CI 3 607.63-7 075.11) and €11 752.47 (CI 7 776.84-14 939.93) for TSU. In the low-risk group, Classic (ICER €723.82) and Avant-Garde (ICER €411.17) were more expensive and less effective compared to Slim. Multiple imputation was used to handle missing data and non-parametric bootstrapping with 25000 iterations of random sampling with replacement to calculate confidence intervals (95% CIs).
Conclusion: The combination of MTX with a GC bridging scheme (COBRA Slim) was more cost-effective (less expensive with comparable disease control) than more intensive step-down combination strategies or a conventional step-up approach 5 years after initial treatment. Over 5 years, around one-fifth of all patients, were in need of starting biological treatment and the transition to a bDMARD was later in COBRA Slim. These results point out the possibility of an early "economic" window of opportunity for diminishing costs long-term while still maintaining optimal disease control.

Disclosure of Interests: None declared

OP0033
EFFECTIVENESS OF NON-PHARMACOLOGICAL INTERVENTIONS TO PROMOTE WORK PARTICIPATION IN PEOPLE WITH RMDs: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Butin1, C. Weber2, S. Verstappen3, R. Christensen4, L. Falcone5, H. Bijlsma6, G. R. Burmester7, A. Boonen8

Background: Work participation among people with rheumatic and musculoskeletal diseases (RMDs) remains reduced when compared to the general population. A EULAR taskforce was established to agree on Points to Consider (PtC) to support people with RMD in healthy and sustainable work participation. Non-pharmacological interventions (NPI) could have an important role in improving work participation in RMDs. However, a comprehensive evidence synthesis of the effectiveness of NPIs in people with RMDs is lacking.

Objectives: To summarise the literature on effectiveness of NPIs on work participation in people with RMDs.

Methods: A search in four databases (MEDLINE, EMBASE, CENTRAL and Cinahl) was performed. Randomized Controlled Trials (RCTs) and Longitudinal Observational Studies (LOS) assessing non-pharmacological/non-surgical interventions until August 2020 were screened. Studies including people with any RMD (except low back pain or work-related RMDs) and assessing a work participation outcome domain (sick leave, work status, presenteeism) were considered eligible. For qualitative evidence synthesis, RCTs and LOS were considered. For quantitative evidence synthesis, only RCTs were considered. For each randomized comparison, standardised mean differences (SMDs) were calculated for the three outcome domains and used as effect size in the meta-analyses; i.e. a negative SMD favouring the NPI over control. Next, Mixed Effects Meta-Regression Analyses were performed, with random effects for randomised comparisons, and a fixed effect factor for the stratified subgroups of clinical interest. Subgroups within diseases (musculoskeletal pain disorders vs. other types of RMDs), risk status for sick leave at baseline (on sick leave or at risk for sick leave; not at risk for sick leave; a combination; or not specified) and single vs. multiple component NPIs were pre-defined. Risk of Bias (RoB) of RCTs was assessed using the Cochrane tool.

Results: Out of 8,864 records, 64 studies (71 treatment comparisons) were included. Studies usually included a mixed population of several RMDs (42%). Most NPIs were conducted in a clinical setting (n=44, 62%) and NPIs usually had multiple components (n=57, 80%), such as vocational support combined with physical training (n=18, 25%). Sick leave was the most frequently reported outcome domain (n=56, 88%). In the qualitative syntheses, 30%/50%/29% of interventions were considered plausible in improving sick leave, work status and presenteeism, respectively.

In the quantitative synthesis, NPIs (37 RCTs, 42 comparisons with mostly moderate to high RoB) showed small to moderate effect sizes, favouring NPIs over comparators for sick leave (SMD=-0.23, 95%CI -0.33 to -0.13), work status (SMD=-0.38, 95%CI -0.63 to -0.12) and presenteeism (SMD=-0.25, 95%CI -0.39 to -0.12). The forest plot for sick leave is shown (Figure 1).

Subgroup analyses for sick leave revealed that, compared to control, NPIs were not effective in musculoskeletal pain disorders, in contrast to the other types of RMDs. For both other subgroup analyses (baseline risk for sick leave; single vs. multicomponent NPI), NPIs improved sick leave similarly in subgroups compared to the control. Subgroup analyses for work status and presenteeism had generally similar effects in subgroups, but the interpretation requires caution in view of the small number of comparisons. Of note, clinical and methodological heterogeneity between studies was substantial, with some concerns about methodological quality related blinding and completeness of follow up.

Disclosure of Interests: None declared

OP0034
IXEKIZUMAB IMPROVES SIGNS, SYMPTOMS, AND QUALITY OF LIFE IN PATIENTS WITH AXIAL SPA IRRESPECTIVE OF DISEASE DURATION: RESULTS FROM THE COAST-V, COAST-W AND COAST-X TRIALS

V. Navarro-Compán1, J. D. Reveille2, R. Rahman3, J. Maldonado-Cocco4, M. Magniet4, R. Bole4, D. Sandoval4, S. Y. Park4, A. Kronbergs6, M. Rudwaleit7

Background: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting interleukin-17A,1 has demonstrated superior efficacy to placebo (PBO) in the treatment of patients (pts) with radiographic axial spondyloarthriti
(r-axSpA) (COAST-V [NCT02696785]; -W [NCT02696798], and non-radio-
graphic axial spondyloarthritis (nr-axSpA) (COAST-X [NCT02757352]).

Objectives: Assess treatment response to IXE categorised by disease duration since symptom onset (<5 years, yrs), ≥5yrs in pts with nr-axSpA and nr-axSpA up to 52 Weeks (Wks).

Methods: Pts fulfilled ASAS classification criteria for r-axSpA or nr-axSpA and were randomised to receive 80mg subcutaneous IXE every 2Wks or 4Wks, or PBO (16Wks COAST-V/W; 52Wks COAST-X). Data were summarized by disease duration and treatment in eligible intent-to-treat (ITT) pts. Wk16 treatment compar-
sions were conducted using Cochran-Haenszel-Mantel test and ANCOVA. Missing data were handled using non-responder imputation and modified baseline obser-
vation carried forward, for categorical and continuous endpoints, respectively.

Results: Table 1 presents pt demographics and baseline characteristics. Data is from pooled IXE pts. In pts with nr-axSpA <5yrs symptom duration, ASAS40 response was achieved by 51.5% at Wk16 and 60.6% at Wk52, compared to 36.9% at Wk16, significantly different to PBO (p=0.012), and 40.5% at Wk52, in pts with ≥5yrs symptom duration. In pts with nr-axSpA <5yrs symptom duration, ASAS40 response was achieved by 42.5% at Wk16, significantly different to PBO (p=0.012), and 54.8% at Wk52, compared to 36.0% at Wk16 and 41.4% at Wk52 in pts with ≥5yrs symptom duration (Figure 1). In pts with nr-axSpA <5yrs symptom duration, ASDAS LDA <2.1 response was achieved by 39.4% at Wk16 and 48.5% at Wk52, compared to 27.5% at Wk16, significantly different to PBO (p=0.001), and 35.6% at Wk52 in pts with ≥5yrs symptom duration. In pts with nr-axSpA <5yrs symptom duration, ASDAS LDA <2.1 response was achieved by 32.9% at Wk16, significantly different to PBO (p=0.003), and 46.9% at Wk52, compared to 23.9% at Wk16 and 36.9% at Wk52 in pts with ≥5yrs symptom duration. At Wk16, in pts with nr-axSpA pts <5 and ≥5yrs symptom duration, the Change from Baseline (CFB) in SF-36 Physical Component Sum-
mary (PCS) Score (LSM±SE) was 7.91 (±1.52), compared to 6.81 (±0.40) in pts with ≥5yrs symptom duration. In pts with nr-axSpA and ≥5yrs symptom duration, this score was 8.95 (±0.95) compared to 7.07 (±0.73) in pts with ≤5yrs symptom duration, both were significantly different to PBO (r-axSpA: p<0.001; nr-axSpA: p=0.037).

Table 1. Patient demographics and Baseline Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Pts with r-axSpA</th>
<th>Pts with nr-axSpA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&lt;5yrs (Ns=33)</strong></td>
<td><strong>≥5yrs (Ns=30)</strong></td>
<td><strong>&lt;5yrs (Ns=73)</strong></td>
</tr>
<tr>
<td>Age (years)</td>
<td>33.1 (8.15)</td>
<td>45.1 (12.12)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>26 (78.8)</td>
<td>245 (80.1)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>7 (21.2)</td>
<td>61 (19.9)</td>
</tr>
<tr>
<td>Age at axSpA onset (yrs)</td>
<td>30.4 (8.29)</td>
<td>27.0 (9.06)</td>
</tr>
<tr>
<td>ASDAS score, mean (SD)</td>
<td>3.87 (0.79)</td>
<td>4.03 (0.82)</td>
</tr>
<tr>
<td>BASDAI score, mean (SD)</td>
<td>7.16 (1.64)</td>
<td>7.25 (1.35)</td>
</tr>
<tr>
<td>SF-36 PCS, mean (SD)</td>
<td>34.02 (7.73)</td>
<td>32.86 (7.63)</td>
</tr>
</tbody>
</table>

Abbreviations: IXE=ixekizumab, n=number of pts in specified category, Ns=number of pts in each subgroup, SD=standard deviation.

Conclusion: Efficacy response to the therapy with IXE was observed in both subgroups based on disease duration (<5 and ≥5yrs) with more robust responses in the ≥5yrs subgroup.

REFERENCES:

Disclosure of Interests: Victoria Navarro-Compan Speakers bureau of AbbVie, Janssen, Eli Lilly and Company, Novartis, Pfizer and UCB, Paid instructor for: AbbVie, Janssen, Eli Lilly and Company, Novartis, Pfizer and UCB, Consultant of: AbbVie, Eli Lilly and Company, Novartis, Pfizer and UCB, Grant/ressearch support from: ASAS: Research grant 2018 and 2021, Novartis: Research grant 2021 (Payment to institution), John D Reveille Speakers bureau of Eli Lilly and Company and UCB Pharma, Consultant of: UCB Pharma, Grant/research support from: Eli Lilly and Company, Proton Rahamn Speakers bureau of Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, and Pfizer., Paid instruc-
tor for: Advisory Board: Abbott, AbbVie, Amgen, Bristol-Myers Squibb, Cel-
gen, Eli Lilly and Company, Janssen, Novartis, Pfizer., Grant/research support from: Janssen and Novartis, Jose Maldonado-Cocco Speakers bureau of Pfizer, Merck Sharp Dohme, Wyeth, Sanofi Aventis, Novartis, Bristol-
tol Myers Squibb, Roche, Shering-Plough, Abbvie, UCB, Gilead., Consultant-
of: Pfizer, Merck Sharp Dohme, Wyeth, Sanofi Aventis, Novartis, Bristol
Myers Squibb, Roche, Shering-Plough, Abbvie, UCB, Gilead., Marina Magrey Speakers bureau of Novartis, AbbVie, Eli Lilly and Company., Consult-
holder of: Eli Lilly and Company, Company of: Eli Lilly and Company, Martin Rudwaleit Speakers bureau of Abbvie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly and Company, Novartis, Pfizer, UCB., Paid instructor for: AbbVie, Eli Lilly, Novartis, UCb., Consultant of: UCB, Grant/research support from: Galapa-
gos, UCB, Novartis.


Figure 1. ASAS40 Response Rates for patients with r-axSpA (COAST-V/W) and nr-axSpA (COAST-X) Symptom Duration <5 and ≥5yrs up to Week 52, ITT, NR: Significantly greater response of IXE vs PBO at Week 52 (p<0.001), Abbreviations: PBO: placebo; IXE: ixekizumab; NR: nonresponder imputation; ITT: intent-to-treat (popula-
tion), ASAS, Assessment of Spondyloarthritis International Society.
We examined: 1. the total effect of latitude on age at diagnosis at hospital and country level (Main model); 2. the amount of the total effect that is mediated by patient factors at the patient and hospital level (Model A); and 3. the amount of the total effect that is mediated by country factors at the country level (Model B). In each model we disentangle the effect in different measurement levels. For example, a patient level variable can vary at the patient, hospital and country level.

**Results:** We included 39,782 patients nested in 94 hospitals nested in 17 countries. The mean age at diagnosis per country ranged from 39 to 55 years. The study spanned a range of latitude between 9.9 and 55.8 degrees (i.e. from Nigeria to the United Kingdom). In the main model, we confirmed the association between latitude and age at diagnosis and found that it only occurred at the country level (not at the hospital level). Per degree increase in country latitude, the average age at diagnosis per country increased by 0.23 years (95% credibility interval: 0.07, 0.40). At the hospital level however, this effect was negligible: β=0.04 (95% 0.16; 0.20). The associations between latitude and several factors found at the country level, but these patient factors only associated with age at diagnosis at the patient level, not at the country (or hospital) level (Model A). This means patient-factors did not explain the association between latitude and age at diagnosis at the country level (main effect changed from 0.23 before to 0.37 after inclusion of patient factors). In model B latitude associated with most country factors (except GDP per capita). Even though none of these variables separately were significantly associated with age at diagnosis, inclusion of the set of country level factors reduced the country level effect of latitude on age at diagnosis from 0.23 to almost zero: β=0.033 (±0.51; 0.37). Sensitivity analyses with age at symptom onset as outcome provided similar results.

**Conclusion:** Patients living close at the equator indeed get RA far earlier than those living closer to the poles. We here suggest that, rather than due to variation in patients’ characteristics, this latitude gradient is a country level phenomenon explained by indicators of countries’ socioeconomic status, and not by patient specific genetic or environmental factors. This big data analysis in a worldwide prevalence cohort provides a direct link between countries’ levels of welfare and the onset of RA.

**Disclosure of Interests:** Systoke Anne Bergstra Grant/research support from: Pfizer, Alexander Sperianio Speakers bureau: Novartis, Consultant of: UCB, Arvind Chopra: None declared, Lai-Ling Winchow: None declared, David Sytske Anne Bergstra Grant/research support from: Pfizer, Alex. One thing we Matlab: None declared, Karen Solomon-Escoto: None declared, Xanthia Matthijisen: None declared, Robert B.M. Landewe Shareholder of: Director of Rheumatology Consultancy BV, Consultant of: Honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Eli-Lilly, Novartis, Pfizer, UCB Pharma. DOI: 10.1136/annrheumdis-2022-eular.877

**OP0036 CLINICALLY SUSPECT ARTHRALGIA PATIENTS WITH A LOW LEVEL OF EDUCATIONAL ATTAINMENT HAVE AN INCREASED RISK TO DEVELOP INFLAMMATORY ARTHRITIS**

S. Khidr 1, E. Van Mulligen 2, A. Van der Helm-Van Mil 1, H. Van der Helm-Leiden, Rheumatology, Leiden, University Medical Centre, Leiden, Rheumatology, Leiden, Netherlands; 2Erasmus Medical Centre, Rotterdam, Netherlands

**Background:** Cross-sectional studies on educational levels have shown that inflammatory arthritis (IA) and rheumatoid arthritis (RA) are more prevalent among people with a lower educational attainment. Studies on educational attainment in individuals at risk for RA could shed light on the influence of socioeconomic factors on RA development, which is divided in an asymptomatic and symptomatic pre-RA stage. To our knowledge, longitudinal studies on educational attainment and IA-development in symptomatic individuals at risk of RA are lacking.

**Objectives:** To determine the association between educational attainment and progression from clinically suspect arthralgia to IA and to perform mediation analysis to elucidate these effects.

**Methods:** 600 consecutive patients presenting with clinically suspect arthralgia were followed for the development of IA, identified at joint examination by rheumatologists during median follow-up of 25 months. Educational attainment was defined as low (lower general secondary education), medium, or high (college or university education). Contrast enhanced 1.5T MRI of hand and foot were made at baseline and were evaluated for synovial fluid/oedema/vascular remodelling by a blinded reader. Association between educational attainment and IA-development was studied with cox-regression analysis. To evaluate if subclinical joint inflammation is intermediary in the path of educational attainment and IA-development, a three-step mediation analysis was performed, before and after correction for age. Results: Patients with a low level of educational attainment were older, had a higher BMI, and smoked more often compared to patients with a high educational level. Low educational attainment was associated with increased IA-development (HR=2.5, 95%CI=1.4-4.7; p=0.003; see Figure 1), also after correction for age, BMI and smoking-status (HR=2.1, 95%CI=1.03-4.4; p=0.041). Moreover, patients with a lower educational level had higher levels of subclinical inflammation at presentation, which associated with a higher risk of progression to IA. Mediation analyses revealed that the association between lower educational attainment and IA-development reduced when adding the level of subclinical inflammation (HR=1.8, 95%CI:0.9-3.5; p=0.073), suggesting that the association between educational attainment and IA-development is partly mediated by higher levels of subclinical inflammation. Mediation analysis with age correction provided similar results.

**Figure:** Progression from clinically suspect arthralgia to inflammatory arthritis (IA), according to educational attainment

**Conclusion:** This is the first evidence that lower educational attainment of patients with arthralgia is associated with a higher risk of developing arthritis. This is partly caused by more severe subclinical joint inflammation. Further research into the role of socioeconomic factors on the development of RA is warranted.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4374
is diagnosed, and it indicates that a window of opportunity exists to expedite referral to specialist care and the diagnosis of RA.

Background: Strong biologic rationale supports both vitamin D and marine omega-3 (n-3) fatty acids for prevention of autoimmune disease (AD). Within the randomized, double-blind, placebo-controlled VITAL (Vitamin D and Omega-3 Randomized Controlled Trial), we tested the effects of these supplements on AD incidence. We previously reported results after 5.3 years of randomized follow-up showing overall protective effects for vitamin D on AD incidence (HR 0.78, 95% CI 0.61-0.99) and suggestive results for n-3 fatty acids (HR 0.85, 95% CI 0.64-1.10). Objectives: We aimed to test effects of these supplements with two more years of post-intervention follow-up in VITAL.

Methods: VITAL enrolled and randomized men and women (age ≥50 and ≥55 years, respectively) in a 2-by-2 factorial design to vitamin D₃ (2000 IU/d) and/or n-3 fatty acids (1000 mg/d) or placebo and followed for median 5.3 years. Here, we followed participants for another 2 years of observation to assess for sustained effects. Incident AD diagnoses were reported by participants annually and confirmed by medical record review by expert physicians using existing classification criteria. The primary endpoint was total incident AD, including rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), autoimmune thyroid disease (AITD), psoriasis, and all others. Pre-specified secondary endpoints included individual common AD; and probable AD. Cox models calculated hazard ratios (HR) for incident ADs.

Results: Of 25,871 participants randomized, 71% self-reported non-Hispanic Whites, 20% Black, 9% other racial/ethnic groups, 51% women, mean age was 67.1 years. During 7.5 years median follow-up, confirmed AD was diagnosed in 167 participants in vitamin D arm vs 198 in vitamin D placebo arm, HR 0.89 (0.72-1.10). Incident AD was confirmed in 187 in n-3 fatty acid arm and 187 in n-3 fatty acid placebo arm, HR 0.89 (0.72-1.01). For vitamin D, HRs trended toward reduction for RA 0.67 (0.37-1.21), PMR 0.69 (0.46-1.03) and psoriasis 0.57 (0.33-0.99). For n-3 fatty acids, HRs trended toward reduction for RA 0.67 (0.37-1.21), PMR 0.69 (0.46-1.03) and AITD 0.57 (0.33-0.99). Vitamin D’s effect on AD incidence was stronger in those with body mass index (BMI) < 25 (HR 0.65, 0.44-0.96) than ≥ 25 kg/m² (p interaction 0.01).

Conclusion: Supplementation for 5.3 years with 2000 IU/day vitamin D (compared to placebo), followed by 2 years of observational follow-up, significantly reduced overall incident AD by 21% in older adults. HRs for RA, PMR and psoriasis trended toward reduction with vitamin D, with stronger effect in those with normal BMI. Supplementation with 1000 mg/day n-3 fatty acids did not significantly reduce total AD.

REFERENCES:

Table 1. Hazard Ratios for Primary and Secondary Endpoints, by Randomized Assignment to Vitamin D/Placebo (Left), N-3 Fatty Acids/Placebo (Right) a

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>Vitamin D (N=12,927)</th>
<th>Placebo (N=12,944)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p</th>
<th>N-3 Fatty Acids (N=12,933)</th>
<th>Placebo (N=12,938)</th>
<th>Hazard Ratio (95% CI)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary: Confirmed AD</td>
<td>156</td>
<td>198</td>
<td>0.79 (0.64-0.97)</td>
<td>0.03</td>
<td>167</td>
<td>187</td>
<td>0.89 (0.72-1.10)</td>
<td>0.27</td>
</tr>
<tr>
<td>Secondary: Confirmed + probable AD</td>
<td>265</td>
<td>321</td>
<td>0.83 (0.70-0.97)</td>
<td>0.02</td>
<td>271</td>
<td>315</td>
<td>0.86 (0.73-1.01)</td>
<td>0.06</td>
</tr>
<tr>
<td>Excluding subjects with any pre-randomization AD</td>
<td>127</td>
<td>162</td>
<td>0.79 (0.62-0.99)</td>
<td>0.04</td>
<td>141</td>
<td>148</td>
<td>0.95 (0.75-1.20)</td>
<td>0.66</td>
</tr>
<tr>
<td>Confirmed AD</td>
<td>211</td>
<td>270</td>
<td>0.78 (0.65-0.94)</td>
<td>0.007</td>
<td>232</td>
<td>249</td>
<td>0.93 (0.78-1.11)</td>
<td>0.41</td>
</tr>
<tr>
<td>Excluding first 2 years follow-up</td>
<td>86</td>
<td>130</td>
<td>0.65 (0.50-0.87)</td>
<td>0.003</td>
<td>104</td>
<td>112</td>
<td>0.92 (0.71-1.21)</td>
<td>0.56</td>
</tr>
<tr>
<td>Confirmed AD</td>
<td>147</td>
<td>205</td>
<td>0.72 (0.58-0.89)</td>
<td>0.002</td>
<td>172</td>
<td>180</td>
<td>0.95 (0.77-1.17)</td>
<td>0.63</td>
</tr>
<tr>
<td>Individual AD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA</td>
<td>19</td>
<td>27</td>
<td>0.67 (0.37-1.21)</td>
<td>0.18</td>
<td>16</td>
<td>29</td>
<td>0.55 (0.30-1.01)</td>
<td>0.06</td>
</tr>
<tr>
<td>PMR</td>
<td>39</td>
<td>57</td>
<td>0.69 (0.46-1.03)</td>
<td>0.07</td>
<td>46</td>
<td>50</td>
<td>0.92 (0.61-1.37)</td>
<td>0.67</td>
</tr>
<tr>
<td>AITD</td>
<td>27</td>
<td>18</td>
<td>1.50 (0.82-2.71)</td>
<td>0.19</td>
<td>17</td>
<td>28</td>
<td>0.61 (0.33-1.12)</td>
<td>0.11</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>20</td>
<td>35</td>
<td>0.57 (0.33-0.99)</td>
<td>0.05</td>
<td>34</td>
<td>21</td>
<td>1.62 (0.94-2.79)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

a Analyses from Cox regression models controlled for age, sex, race, and other (n-3 fatty acid or vitamin D) randomization group b Confirmed AD.
Disclosure of Interests: Karen Costenbader Consultant of: Astra Zeneca, Glaxo Smith Kline, Neurontin, Grant/research support from: Merck, Exagen, Gilead, Nancy Cook: None declared, I-min Lee: None declared, Jill Hahn: None declared, Joseph Walter: None declared, Vadim Bubes: None declared, Gregory Kotler: None declared, Nicole Yang: None declared, Sonia Friedman: None declared, Erik Alexander: None declared, JoAnn Manson: None declared.


OP0039

RISK OF ARRHYTHMIA AMONG NEW USERS OF HYDROXYCHLOROQUINE: A LONGITUDINAL, POPULATION-BASED COHORT STUDY ON NEWLY DIAGNOSED RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

M. R. Hoque1,2, N. Lu2, N. Daltarian2, J. Esdaile2,3, H. Xie1,2, J. A. Avila-Zubiate1,3, Simon Fraser University, Faculty of Health Sciences, Burnaby, Canada;2Arthritis Research Canada, Arthritis Research Canada, Vancouver, Canada;3University of British Columbia, Division of Rheumatology, Department of Medicine, Vancouver, Canada

Background: Previous findings on hydroxychloroquine (HCQ) use and the risk of arrhythmia are contradictory and low-level evidence-based results. Additional research is required to evaluate the safety profile of HCQ to arrhythmia in managing rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

Objectives: To assess the association between HCQ initiation and risk of incident arrhythmia among newly diagnosed RA and SLE patients.

Methods: All patients with incident RA or SLE and no arrhythmic events or ant-arrhythmic medications and no HCQ use prior to disease index date in British Columbia, Canada, between January 1997 and March 2015 were identified using administrative databases. HCQ initiator and HCQ non-initiator groups were identified and matched 1:1 by propensity scores using baseline confounders on demographics including presence of RA or SLE disease and duration of disease prior to the index date of HCQ initiators or non-initiators, comorbidities, other medications, and healthcare utilization. Matching was done within the same calendar year to account for a potential secular trend in HCQ use and risk of arrhythmia. Outcomes were any new arrhythmias, atrial fibrillation, abnormal electrocardiogram including prolonged QT syndrome and conduction disorder, and other unspecified arrhythmias during follow-up. We used Cox proportional hazard models with death as a competing event to assess the association of HCQ initiation and the outcomes.

Results: We identified 11,518 HCQ initiators (10,655 RA and 863 SLE patients, mean ± SD age 55.9 ± 15.1 years, 76.1% female) and 11,518 HCQ non-initiators (10,639 RA and 879 SLE patients, mean ± SD age 56.0 ± 16.2 years, 76.4% female) after 1:1 propensity score matching. Over the mean follow-up of eight years, there were 1,610 and 1,646 incident arrhythmias in the HCQ initiator and non-initiator groups, respectively. The crude incidence rates of arrhythmia were 17.5, and 18.1 per 1,000 person-years, respectively. Cumulative risk of incident arrhythmias for HCQ initiators and non-initiators over the follow-up time.

Figure 1. Cumulative risk of incident arrhythmias for HCQ initiators and non-initiators over the follow-up time.

Conclusion: There is no increased risk of any type of arrhythmia among new users of HCQ in RA and SLE patients. We believe the results of this large cohort study will add to the confidence with which HCQ can be used in RA and SLE management.

Disclosure of interests: None declared.


In dialogue with the expert: axSpA and Sjögren’s syndrome

OP0040-PARE

THE WEBINAR SERIES FOR THE PATIENTS “PREGNANCY AFTER DIAGNOSING ANKYLOSIS SPONDYLITIS”

O. Krichevskaya1, T. Dubinina1, N. Klimenchenko2, N. Shatalova3.

1V.A. Nasonova Research Institute of Rheumatology, Laboratory of axial spondyloarthritis, Moscow, Russian Federation; 2National medical research center for obstetrics, gynecology and perinatology named after academician V.I. Kulakov, Obstetric department of pathology of pregnancy, Moscow, Russian Federation; 3Russian ankylosing spondylitis association, Directorate, Moscow, Russian Federation

Background: Having been diagnosed with ankylosis spondylitis (AS), 68.2% of females in Russia reconsider their plans for pregnancy, with 13% giving up motherhood altogether out of fear for their own and their child’s potential health problems. However, most females allow pregnancy while experiencing emotional discomfort and anxiety.

Objectives: To shed more light on the mutual influence of AS and pregnancy, AS pregnancy outcomes, clinical course of AS as well as medication options during AS and lactation.

Methods: From 03/2021 to 12/2021 an on-line series of eight webinars was conducted together with the patients’ Russian ankylosing spondylitis association. Each webinar included lectures of one or two rheumatologists and an obstetrician; furthermore, the series included the presentations of a physical therapy instructor (with the demonstration of exercises) and of a breast-feeding specialist. After the lecture each speaker answered the audience’s questions. Topics of rheumatologists’ lectures were “AS and pregnancy: problem introduction,” “What do we know about AS genetics,” “Features of pregnancy planning” (included therapy issues for men with AS who are planning to father a child), “Rheumatologist prenatal and postnatal care” (included the analysis of AS clinical manifestations such as potential changes in back pain type).

Contemporary approaches to AS pregnancy treatment: A brochure for the patients with the main provisions of the lectures had been developed in support of the series.
Results: Webinars scored 703±192 views (by 29.01.2022). According to the ques-
tionnaire survey of the audience, 43.8% first knew that it was necessary to plan
AS pregnancy minimum 3-6 months before conception; 25% – that conception is
optimal during remission or low AS activity; 31.3% – that medical therapy can be
continued during pregnancy; 18.8% – that it is necessary to inform the obstetri-
cian about AS diagnosis and therapy received. 80% of the participants are fully
satisfied with the information provided by the web series; 13.3% – reported not to
had received enough information.
Conclusion: The interest in webinars shows that the choice of the form and the
information provided was successful. The content of the series can be used to
develop FAQ-section on the patient's website 'Ankylosing Spondylitis Associa-
tion'. In 2022, lectures will continue taking into account patients' feedback.
are changed after diagnosing ankylosing spondylitis (AS). AS female patients'
attitude to the use of as medications during pregnancy planning
Disclosure of Interests: None declared.

Infection-related and other orphan rheumatic disorders

J. Henes1, J. B. Kuemmerle-Deschner1, T. Krickau2, T. Kallinich1, F. Dressier1, G. Horneff2, F. Meier12, I. Foeldvari9, F. Weller-Heinemann10, B. Kortus-Goetze11, M. Hufnagel12, J. Rech13, P. Oommen14, J. Weber-Arden13, N. Blank11, 1University Hospital Tubingen, Centre of
Interdisciplinary Rheumatology, Immunology and Auto-inflammatory
Diseases and Department of Internal Medicine 2, Tuebingen, Germany;
2University Hospital Tuebingen, Department of Pediatrics, Division of
Pediatric Rheumatology, Tuebingen, Germany;
3Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany;
4Charité University Medicine Berlin, Department of Pediatrics, Division of
Pulmonology, Immunology and Critical Care Medicine, Berlin, Germany;
5Hannover Medical School, Division of Pediatric Pneumology, Allergology
and Neonatology, Hannover, Germany;
6Asklepion Clinic Sankt Augustin, Asklepion Clinic Sankt Augustin, Sankt Augustin, Germany;
7University Hospital Frankfurt, Goethe University, Frankfurt am Main, Division of
Rheumatology, Frankfurt am Main, Germany;
8Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational
Medicine and Pharmacology TMP, Frankfurt am Main, Germany;
9Centre for Pediatric and Adolescence Rheumatology Hamburg, Centre for Pediatric
and Adolescence Rheumatology Hamburg, Hamburg, Germany;
10Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany;
11University of Marburg, Division of Nephrology, Marburg, Germany;
12University Medical Center, Medical Faculty, University of Freiburg, Department of Pediatrics
and Adolescent Medicine, Freiburg, Germany;
13Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen,
Department of Internal Medicine 3 - Rheumatology and Immunology,
Erlangen, Germany;
14Heinrich-Heine-University Düsseldorf, Clinic of
Pediatric Hematology, Oncology and Clinical Immunology, Division of
Pediatric Rheumatology, Düsseldorf, Germany;
15Novartis Pharma GmbH
16University Hospital Heidelberg, Rheumatology, Heidelberg, Germany

Background: Familial Mediterranean Fever (FMF) is a chronic disease char-
terized by recurrent attacks of fever as well as serositis and bears the risk of
serious complications (e. g. amyloidosis). Treatment of FMF according to EULAR
aims to control acute attacks and subclinical inflammation as well as to improve
patient’s quality of life. Clinical data indicate that the inhibition of interleukin-1β
with canakinumab (CAN) is effective in controlling and preventing flares in FMF
patients2.

Objectives: The present study explores the long-term efficacy and safety of
canakinumab in routine clinical practice conditions in pediatric (age ≥2 years)
and adult FMF patients.

Methods: RELIANCE is a prospective, non-interventional, multi-center, obser-
vation study based in Germany with a 3-year follow-up period. Patients with
clinically confirmed FMF diagnosis who routinely receive canakinumab are
enrolled in order to evaluate effectiveness and safety of canakinumab. Disease
activity and remission by physicians’ assessment, disease activity, fatigue and
impact on social life by patients' assessment, inflammatory markers and AIDAI
(Auto-Inflammatory Diseases Activity Index) score were recorded at baseline
and assessed at 6-monthly intervals within the 3-year observation period of
the study.

Results: This interim analysis of FMF patients (N=74) enrolled by December
2021 includes baseline as well as 6- to 24-month data. Mean age in this cohort
was 25 years (2–61 years) and the proportion of female patients was 51 %
(N=38). At baseline, median duration of prior CAN treatment was 1.0 years (0–6
years).

At month 24, physician ratings report around 63% of patients in disease remis-
sion and patient-reported disease activity (mean PPA) decreased from moderate
(3.0) to low (2.6) during the observation period. Other disease activity parame-
ters also decreased (Table 1). A total of 18 serious adverse events were reported,
of which 2 (1 case of tonsilllectomy and 1 case of tachycardia) were classified as
drug-related.

Disclosure of Interests: None declared.

SJÖGREN EUROPE: REVIEW OF ITS FIRST THREE YEARS OF ACTIVITY

A. Grosjean1, L. Stone1, C. Bouillot1, A. Vieira1, K. Antonopoulou1, J. Koewelijn-Tukker1, M. Oosterbaan1
1Sjögren Europe, Federation of European Sjögren’s patient associations, Bienne, Switzerland

Background: Sjögren Europe was founded on 23 February 2019 by several
European patient organisations representing Sjögren’s patient to help to address
the lack of visibility, attention, and solutions for Sjögren’s.

Objectives: To show the first achievements and contributions of the federation.

Methods: Sjögren Europe’s purpose is to promote the advancement of knowledge,
research, information, treatment, and care, to foster patient involvement and partic-
ipation in research and any other relevant area, to increase awareness, identify
the different unmet needs and articulate patient voices throughout Europe.

Results: Finding one’s bearings and the right rhythm during the first years of
an organisation’s life is a challenge in itself. The Covid-19 pandemic has made
this process even more difficult. Our first goal was to organise a first face-to-face
European patient conference. This meeting had to be postponed. However, we
were able to adapt and develop a range of activities.

We organised a series of informative webinars on different topics by leading Euro-
pcean experts for patients and others interested in the subject. We have organised
various awareness campaigns such as a campaign for Sjögren Awareness Month in
2021 for which we have created 2 awareness videos and published several testi-
monials. We also created a 3-axis campaign about fatigue for World Sjögren’s Day
2021 which won the Best Practice Award at the 2021 PARE Conference, and during
which we shared the patients’ perspective on fatigue in publications in 13 languages
on social media. We published a booklet about fatigue developed by a specialist
and produced 3 informative leaflets for patients. We also subtitled 2 videos made by
one of our members in 10 European languages to disseminate quality information
that many patients miss. We have been involved in various research projects, work-
ing groups and patient panels and have been able to bring the patient perspective
to various stakeholders on many occasions.

Conclusion: Despite the limited contacts, we were able to create strong links
and rich discussions that stimulated our creativity. Sjögren Europe has become
a privileged partner, recognised, and appreciated by the various stakeholders.
Patients with Sjögren’s are better represented at the supranational level. It is
our members, the national patient organisations, who by their trust give us
our legitimacy. In return, Sjögren Europe has been able to inject a new energy
and dynamism that can be felt at the different national levels and that opens
up many perspectives and opportunities. We have been able to strengthen our
presence and visibility with patients on social networks, where our audience is
constantly growing, as well as in the rheumatology field with researchers,
clinicians, industry, and associations such as EULAR. The resumption of face-
to-face contacts is eagerly awaited to consolidate the links already created
and to feed the richness, relevance, originality and diversity of our discussions
and activities.

Disclosure of Interests: None declared.
Table 1. Baseline characteristics and 4th interim analysis data of patients with FMF

<table>
<thead>
<tr>
<th># patients, N</th>
<th>% of patients with days absent from work/school during last 6 months</th>
<th>% of patients with days absent from work/school during last 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>22 (45)</td>
<td>23 (72)</td>
<td>12 (63)</td>
</tr>
<tr>
<td>2.0 (0.0; 7.0)</td>
<td>2.0 (0.0; 10)</td>
<td>2.0 (0.0; 10)</td>
</tr>
<tr>
<td>5.0 (0.0; 10)</td>
<td>4.0 (0.0; 10)</td>
<td>4.0 (0.0; 10)</td>
</tr>
<tr>
<td>27 (50)</td>
<td>28 (80)</td>
<td>8 (67)</td>
</tr>
</tbody>
</table>

**Conclusion:** Intermediate data of FMF patients from the RELIANCE study, the longest running real-life canakinumab registry confirm efficacy and safety of long-term canakinumab treatment.

**REFERENCES:**

**Disclosure of Interests:** Jörg Henes Consultant of: Novartis, Abbvie, Sobi, Roche, Janssen, Boehringer-Ingelheim, Grant/research support from: Novartis, Abbvie. J. B. Kueemmerle-Deschner Consultant of: Novartis, Abbvie, Sobi, Roche, Janssen, Lilly, MSD, Mylan, Pfizer, Roche, Schering-Plough, BMS, Merck Sharp & Dohme. Jörg Henes Consultant of: Novartis, Abbvie, Sobi, Roche, Janssen, Lilly, MSD, Mylan, Novartis, Roche, Sanofi, UCB, Grant/research support from: Novartis, Abbvie, Sobi, Roche, Boehringer-Ingelheim, Roche, Grant/research support from: Novartis, UCB, Tocilizumab (TCZ) for the treatment of FMF – TOFFIFE.

**Methods:** The TOFFIFE study was a placebo-controlled, double-blinded, randomized trial to investigate the efficacy and safety of TCZ in patients with colchicine resistant (cr)FMF. The physician’s global assessment of disease activity (PGA) based on a 5 point-scale for 6 symptoms (range 0-24) was used as a clinical score and had to be ≤2 at screening. Patients were randomized 1:1 to either receive monthly TCZ intravenously with 8 mg/kg bodyweight or placebo over a period of 24 weeks. Patients with inadequate response after week 12 had the opportunity to receive open label TCZ at week 16. The primary endpoint was the number of patients achieving an adequate response to treatment at week 16, defined as a PGA ≤ 2 + normalized ESR or CRP (the item that led to inclusion had to be normalized) + normalized SAA. Secondary endpoints included normalization of SAA during treatment and safety of TCZ in FMF patients.

**Results:** 25 patients were randomized with a median age of 31 years (range 18-53y), of which 14 (56%) were female. At week 16, which was the timepoint for the primary end point, 2 (15.4%) patients in the TCZ arm reached the primary end point with a PGA ≤ 2 and normalization of SAA and CRP and/or ESR but none of the patients in the placebo arm. Therefore, the superiority of TCZ compared to placebo could be shown concerning the pre-specified significance level of α = 0.02 (p = 0.089). SAA levels normalized with TCZ but not with PBO. This difference between TCZ und PBO was highly significant; SAA p < 0.015. At week 28 with 17 remaining patients and after having had the opportunity for a rescue treatment at week 16, the responder rates (PGA ≤ 2 + normalization of SAA, ESR and/or CRP) were 25% (n=1) in those patients who changed from placebo to TCZ (n=4) and 20% (n=2) in those patients who continued with placebo (n=10). Of note, all 3 patients remaining on PBO were non-responders (p = 0.842). In 75% of patients (n=3) CRP and in 50% of patients (n=2) normalized after changing to TCZ. No new safety aspects occurred.

**Conclusion:** In this first randomized, placebo-controlled study in patients with active crFMF TCZ therapy was lower than expected due to very strict response criteria; patients had to achieve a complete remission with a PGA ≤2 (on a 0-24 scale) and normalization of the inflammatory parameters (CRP/ESR and SAA). This required no or only mildest symptoms during the last 4 weeks. A larger multicenter study is therefore justifiable and needs to clarify the benefit of TCZ treatment in FMF.
Disclosure of Interests: Jörg Henes Speakers bureau: SOBI, Novartis, Roche/Chugai, Consultant of: SOBI, Novartis, Roche/Chugai, Grant/research support from: SOBI, Novartis, Roche/Chugai, Sebastic Sau: None declared, David M. Koller: None declared, Claudia Keker: None declared, Christoph Meisner: None declared, Martin Krusche Speakers bureau: SOBI, Novartis, Roche/Chugai, Ina Kötté Speakers bureau: SOBI, Novartis, Roche/Chugai, Consultant of: SOBI, Novartis, Roche/Chugai, Theodoros Xentidis: None declared, Hendrik Schulze-Koops Speakers bureau: SOBI, Novartis, Roche/Chugai, Ina Kötté Speakers bureau: SOBI, Novartis, Roche/Chugai, Consultant of: SOBI, Novartis, Roche/Chugai, Eugen Feist Speakers bureau: SOBI, Novartis, Roche/Chugai, Consultant of: SOBI, Novartis, Roche/Chugai. DOI: 10.1136/annrheumdis-2022-eular.1428

Cytokine Profile, Hyperferritinemia, and Multi-Visceral Involvement Characterise Macrophage Activation Syndrome Complicating Adult Onset Still's Disease. Results from a Multidimensional Evaluation

P. Rusconi1, F. Ursini1, O. Berarducci1, F. Masedu2, E. Bozzaia Cassone3, S. Naldi1, I. Di Cola4, C. Di Muzio4, L. De Stefano5, E. Di Nino1, F. Sensini1, L. Nobiletti3, M. Womersley3, S. Bugatti1, M. Vomero5, S. Iagnocco4, C. Montecucco1, R. Giacomelli3, P. Cipriani2, 1University of Udine, Department of Biotechnological and Applied Clinical Sciences, Udine, Italy; 2Aima Mater Studium University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy; 3University of Pavia, Rheumatology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Istituto Ortopedico Rizzoli, Department of Clinical and Surgical Sciences, Bologna, Italy; 5University of Rome Campus Biomedico, Rheumatology and Immunology Unit, Department of Medicine, Rome, Italy; 6Università degli Studi di Torino, Dipartimento Scienze Cliniche e Biologiche, Turin, Italy

Background: Adult-onset Still’s disease (AOSD) is a rare multigenic autoimmune inflammatory disease of unknown aetiology burdened by life-threatening, such as macrophage activation syndrome (MAS) [1]. Considering the poor outcome of MAS patients, previous works tried to assess predictive factors of its occurrence during AOSD [2]. However, an integrated evaluation of clinical features with biomolecules, may help to characterise the pathogenic mechanisms of the disease and its complications, is still missing.

Objectives: To multidimensionally characterise MAS complicating AOSD considering cytokine profile, inflammatory markers, and multi-visceral involvement of the disease. To perform a high-dimensional phenotypic analysis of circulating immune cells in AOSD patients with and without MAS. To assess interferon (IFN)-related pathways in AOSD synovial tissues by a bulky RNA sequencing.

Methods: We included 34 patients with AOSD, 12 of which were complicated or not with MAS. Patients were divided suggesting that IFN-α, IL-1Ra, IL-1β, and IL-6 are the pivotal cytokines in the pathophysiology of acute pericarditis and its recurrence [5]. This report presents the interim analysis of clinical trial with goflikicept (original, fusion protein, heterodimer, binding IL-1α and IL-1β) in patients with IRP. Trial registration: ClinicalTrials.gov, NCT04692766.

Objectives: To evaluate the efficacy and safety of goflikicept treatment in patients with IRP.

Methods: Subjects with recurrence (n=9) or in inter-recurrence period (n=13) were enrolled in the run-in period of 12 weeks for treatment with NSAIDs and/or colchicine for 24 weeks for treatment with corticosteroids (CS).

Dose finding approach was applied, where subjects from the first cohort (n=10) received subcutaneous goflikicept 80 mg every 2 weeks, subjects from the second cohort (n=12) - 240 mg load within the first week, 80 mg within the second week, thereafter 80 mg every second week for the next 12 weeks. After 12 weeks, patients were randomized to goflikicept or placebo. Primary endpoint was the time to the first pericarditis recurrence. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. At the end of the run-in responders proceeded into the double-blind, placebo-controlled randomized-withdrawal (RW) period, where received goflikicept 80 mg every 2 weeks or placebo. Primary endpoint was the time to the first pericarditis recurrence. In case of recurrence, the patients were unblinded, patients from placebo group treated with goflikicept. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.

Results: Treatment response was achieved in 8 of 9 patients, enrolled with recurrence and all patients enrolled without recurrence remained in remission at Day 4. There were no new recurrence events on goflikicept therapy, despite NSAIDs/colchicine combination. In case of recurrence, the patients were unblinded, patients from placebo group retreated with goflikicept. According to interim analysis plan efficacy/safety analysis included only unblinded data during the run-in period.
Conclusion: The first data show ability to achieve and maintain IRP remission on golfiticcept monotherapy with favorable risk-benefit ratio. Final data will be provided.

REFERENCES:

Acknowledgements: This study is sponsored by R-Pharm JSC.


OP0046 EVALUATION OF THE EFFICACY OF TOPICALLY APPLIED TACROLIMUS IN THE TREATMENT OF ORAL ULCERS IN BEHCET’S DISEASE: A DOUBLE BLIND PLACEBO CONTROLLED STUDY

M. Hassanien1, A. Moshrif2, M. Galal3, F. Abuzaid3, D. Fathalla4, E. Talaat1. 1Assiut University, Rheumatology, Assiut, Egypt; 2Al-Azhar University, Periodontology, Assiut, Egypt; 3Al-Azhar University, Oral Medicine, Periodontology, Assiut, Egypt; 4Assiut University, Pharmacy, Assiut, Egypt.

Rheumatology, Assiut, Egypt; Al-Azhar University, Oral Medicine, Periodontology, Assiut, Egypt; Assiut University, Pharmacy, Assiut, Egypt

Background: Treatment of Behcet disease (BD) associating oral ulcers is still challenging despite the advances in the systemic treatment modalities.

Objectives: We aimed to evaluate the clinical efficacy of topical Tacrolimus for treatment of BD.

Methods: In this double blind placebo controlled trial, forty BD patients with persistent active oral ulceration were equally randomized into group I (20 patients received oral colchicine plus topically applied tacrolimus) and group II (20 patients received oral colchicine plus placebo oral gel). All participants were evaluated based on Behcet's Disease Current Activity Form (BDCAF), Ulcer Severity Score (USS) and visual analog scale (VAS) before treatment, and at four-time points post-treatment (15 days, 1st, 2nd and 3rd months).

Results: USS was significantly lower in group I after 2 weeks (p= 0.037) and 3 months (0.025) than in group II. USS was significantly lower in group I after 3 months of follow up regarding to the number of ulcers (p=0.014), ulcer size (p=0.022), and duration (p=0.009). BDCAF showed significant improvement in 3 months follow up within each group (p<0.001 for both groups), while there was insignificant difference between both groups(p=0.347).

Conclusion: Topical Tacrolimus has been proven to be a safe and effective adjunctive therapy in the management of oral ulcerations in BD.

Disclosure of Interests: Manal Hassanien: None declared, Abdelhfeez Moshrif Speakers bureau: Amgen, Jansen, Novartis, Mostafa Galal: None declared, Fathy Abuzaid: None declared, Dian Fathalla: None declared, Esraa Talaat: None declared.


OP0047 IMPAIRED JAK-STAT PATHWAY IN PATIENTS WITH PYODERMA GANGRENSOSUM

T. Demirci Yildirim1, A. Kahraman Akalp1, A. Köken Arıç1, F. Oner1, S. Akar1, I. San1, A. M. Nallı1, Dokuz Eylul University, Faculty of Medicine, Rheumatology, İzmir, Turkey; 2Izmir Katip Celebi University, Pathology, İzmir, Turkey; 3Izmir Katip Celebi University, Rheumatology, İzmir, Turkey

Background: Pyoderma gangrenosum (PG) is an inflammatory disease with an unknown etiology. Currently there is an unmet need in the field of PG. In recent years, JAK/STAT pathway have been shown to have an important role in the etiology of inflammatory conditions particularly in the field of dermato-rheumatology. However, current data on JAK/STAT pathway in PG is significantly limited.

Objectives: Herein we aimed to investigate the JAK/STAT signaling pathway in the skin biopsies of PG patients and compared with psoriasis (PSO) and healthy subjects (HS).

Table 1. Summary of the findings

<table>
<thead>
<tr>
<th>Age, mean ± SD</th>
<th>Healthy Subjects (n=26)</th>
<th>Pyoderma Gangrenosum (n=31)</th>
<th>Psoriasis (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women/men (%)</td>
<td>60.3 ± 18.3</td>
<td>58.1 ± 16.1</td>
<td>46.5 ± 18.4</td>
</tr>
<tr>
<td>Dermal staining</td>
<td>14/12</td>
<td>18/13</td>
<td>15/20</td>
</tr>
<tr>
<td>Moderate positive, n (%)</td>
<td>23 (88.4)</td>
<td>6 (19.4)</td>
<td>24 (68.5)</td>
</tr>
<tr>
<td>Strongly positive, n (%)</td>
<td>3 (11.5)</td>
<td>24 (77.4)</td>
<td>11 (31.5)</td>
</tr>
<tr>
<td>TYK2</td>
<td>12 (46.1)</td>
<td>1 (3.2)</td>
<td>2 (5.7)</td>
</tr>
<tr>
<td>Negative, n (%)</td>
<td>0 (0)</td>
<td>3 (12.9)</td>
<td>1 (2.8)</td>
</tr>
<tr>
<td>Moderate positive, n (%)</td>
<td>18 (69.2)</td>
<td>18 (58.1)</td>
<td>11 (31.4)</td>
</tr>
<tr>
<td>Strongly positive, n (%)</td>
<td>8 (30.8)</td>
<td>8 (26.8)</td>
<td>21 (60)</td>
</tr>
<tr>
<td>STAT3</td>
<td>14 (53.9)</td>
<td>28 (90.4)</td>
<td>34 (97.2)</td>
</tr>
<tr>
<td>Negative, n (%)</td>
<td>0</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Moderate positive, n (%)</td>
<td>12 (46.1)</td>
<td>1 (3.2)</td>
<td>2 (5.7)</td>
</tr>
<tr>
<td>STAT5</td>
<td>18 (69.2)</td>
<td>15 (48.4)</td>
<td>21 (60)</td>
</tr>
<tr>
<td>Negative, n (%)</td>
<td>8 (30.8)</td>
<td>16 (51.6)</td>
<td>0</td>
</tr>
<tr>
<td>Moderate positive, n (%)</td>
<td>14 (53.9)</td>
<td>26 (83.9)</td>
<td>29 (82.9)</td>
</tr>
<tr>
<td>Strongly positive, n (%)</td>
<td>0</td>
<td>0</td>
<td>20 (57.2)</td>
</tr>
<tr>
<td>Nuclear part of epidermis</td>
<td>Negative, n (%)</td>
<td>22 (84.6)</td>
<td>1 (3.2)</td>
</tr>
<tr>
<td>TYK2</td>
<td>4 (15.4)</td>
<td>10 (32.2)</td>
<td>6 (17.1)</td>
</tr>
<tr>
<td>Negative, n (%)</td>
<td>0</td>
<td>20 (64.6)</td>
<td>27 (72.2)</td>
</tr>
<tr>
<td>Moderate positive, n (%)</td>
<td>2 (6.5%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Strongly positive, n (%)</td>
<td>16 (61.5%)</td>
<td>8 (26.6%)</td>
<td>5 (14.3%)</td>
</tr>
</tbody>
</table>

Data were shown means±SD and n (%), *= significant expression HS vs PG, **= significant expression HS vs PSO.
Methods: 31 patients with PG, 35 patients with PSO and 26 HS were included. Immunochemical methods were used to evaluate the expression of JAK1, JAK2, JAK3, Tyrosine Kinase 2 (TYK2), STAT1, STAT3, STAT4, STAT5, and STAT6. JAK/STAT proteins and epidermis the staining intensity was recorded as ‘positive’ or ‘negative’. The epidermal part is divided into cytoplasmatic and nuclear parts and staining intensity recorded by semi-quantitatively as follows: negative, mildly positive, moderately positive and strongly positive.

Results: In total, there were 92 biopsies. Dermal staining was significant for all the JAK/STAT proteins for patients with PG and PSO when compared to HS. On the other hand, there were no differences in the staining patterns of PG and PSO. For the investigation of cytoplasmatic parts of epidermis JAK1, STAT3, and STAT4 were highly expressed in the PG and PSO, STAT6, and TYK2 were only significantly overexpressed in psoriasis. JAK3 was overexpressed in healthy skin, PG and psoriasis. The assessment of the nuclear part of epidermis TYK2 and STAT3 were highly expressed in the PG and PSO. JAK1 was overexpressed in PG versus PSO in cytoplasmatic parts of the epidermis (p=0.001), TYK2 and STAT6 were highly expressed in the PSO versus PG. The summary of the findings is given in Table 1.

Conclusion: In this study, the JAK/STAT inflammatory pathway is significantly activated in PG patients which is adding up new information to the current literature. Considering the unmet need in PG targeting of this pathway could be beneficial for the treatment of refractory PG.

Disclosure of Interests: None declared.


OP0048 FIRST INTERIM ANALYSIS OF THE INTERNATIONAL X-LINKED HYPOPHOSPHATEMIA (XLH) REGISTRY: ADULT POPULATION BASELINE CHARACTERISTICS

K. Brief, J. Liu, A. Williams, S. Wood. Hôpital Cochin, Service de Rhumatologie, Centre de Référence des Maladies Rares du Métabolisme du Calcium et du Phosphate Filière OSCAR, AP-HP, Paris, France; 2Kyowa Kirin International Marlow Office, Nephrology | EMEA, Marlow, Buckinghamshire, United Kingdom; 3Kyowa Kirin International Marlow Office, Nephrology | EMEA, Marlow, Buckinghamshire, United Kingdom; 4Kyowa Kirin International Marlow Office, Nephrology | EMEA, Marlow, Buckinghamshire, United Kingdom

Background: X-Linked Hypophosphatemia (XLH) is a rare, progressive, lifelong, hereditary phosphate wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity. Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment and other medical interventions on patient outcomes. The multicentre, international, XLH patient registry was established to address this lack of information in XLH to help inform future clinical practice.

Objectives: To report data from the first interim analysis of the International XLH Registry (NCT03193476), focusing on baseline characteristics of adults (aged ≥18 years) [1].

Methods: The International XLH Registry was initiated August 2017 to collect information on the natural history of XLH and will run for 10 years, aiming to address this lack of information in XLH to help inform future clinical practice. The analysis of this young population treated with conventional therapy highlights the frequency of musculoskeletal involvement (osteoarthritis, enthesopathies, etc). The information collected within this rare-disease registry during these 10 years provides an exciting opportunity to integrate large-scale real-world evidence into clinical practice, with the aim of improving the care and quality of life of people living with this debilitating disease.

REFERENCES:

Acknowledgements: The authors acknowledge the contribution of all members of the International XLH Registry Steering Committee.


OP0049 FURTHER CHARACTERIZATION OF clinical AND LABORATORY FEATURES OCCURING IN VEXAS SYNDROME IN A LARGE-SCALE ANALYSIS OF MULTICENTER CASE-SERIES OF 116 FRENCH PATIENTS

S. Georgin-Lavialle1, B. Terrier2, K. Olivier3, A. Mekinian4, on behalf of fench VEXAS Syndrome Investigators.

116 patients with VEXAS syndrome. Frequency and median of parameters and vital status, from diagnosis to the end of the follow-up.

Results: Main clinical features were skin lesions (83.5%), non-infectious fever (63.6%), weight loss (62%), lung involvement (49.6%), ocular symptoms (38.8%), relapsing chondritis (36.4%), venous thrombosis (34.7%), lymph nodes (33.9%), and arthralgia (27%). Hematological disease was present in 58 cases (50%), considered as myelodysplastic syndrome (MDS, n = 58) and monoclonal gammopathy of unknown significance (n = 12). UBA1 mutations included p.M411T (44.8%), p.M411V (30.2%), p.M414L (18.1%), and splice mutations (6.9%). After a median follow-up of 3.0 years, 18 patients died (15.3%), from infectious origin (n = 9) and MDS progression (n = 9). Unsupervised analysis identified 3 clusters: cluster I (47%) with mild-to-moderate disease; cluster 2 (16%) with underlying MDS and higher mortality rates; cluster 3 (37%) with constitutional manifestations, higher C-reactive protein levels and less frequent chondritis. Five-year survival probability of survival was 84.2% in cluster 1, 50.5% in cluster 2, and 89.6% in cluster 3. UBA1 p.Met414Leu mutation was associated with a better prognosis.

Conclusion: VEXAS syndrome displays a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.

Disclosure of Interests: None declared.


Managing chronic pain in RMDs

H. Haibel1, J. Sieper2, D. Poddbubny1,2, V. Rios Rodriguez1, F. Proft1, J. Rademacher1,3, S. Igel1, P. Martus4, C. Stein5.

1Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Rheumatology, Berlin, Germany; 2German Rheumatism Research Center, Epidemiology, Berlin, Germany; 3Berlin Institute of Health, Clinician Scientist Program, Berlin, Germany; 4Tübingen, Clinical Epidemiology and Statistics, Tübingen, Germany; 5Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Anesthesiology and Intensive Care, Berlin, Germany

Background: Patients with chronic inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of chronic degenerative joint diseases (e.g. osteoarthritis; OA) suffer from recurrent pain, restricted function

Disclosure of Interests: None declared.

and reduction of daily activities. The current standard of intraarticular (i.a.) therapy is the injection of steroids, which can increase risk of infection, cartilage degenerations, and other well-known systemic side effects. A novel approach without such complications could be the activation of peripheral opioid receptors, e.g. by i.a. application of small, systemically inactive doses of morphine.

**Objectives:** The aim of this randomized placebo-and active drug controlled double blind trial was to investigate reduction of pain in chronic knee arthritis patients following i.a. injections of morphine, a standard steroid (triamcinolone), or placebo. The primary hypothesis was that i.a. morphine results in significantly lower pain scores than placebo. The primary outcome parameter was reduction of the Visual Analogue Scale (VAS) pain at day 7.

**Methods:** Adult patients with chronic knee arthritis because of osteoarthritis (OA) or inflammatory arthritis (IA, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, oligoarticular or monarticular) and a high level of pain (VAS pain ≥ 4 out of 10) at baseline received a single dose of either morphine 3mg i.a., or triamcinolone 40mg i.a., or placebo (NaCl 0.9%) i.a.. Patients were monitored closely throughout the entire study period with a total of 4 visits over weeks and documented pain in the morning and evening in a patient’s diary. Safety data was collected during the entire study period. P-values were calculated using two-sided T-Tests.

**Results:** 114 patients were screened, 93 were treated and 89 (96%) completed day 7. Of these n= 61 (66%) were diagnosed with OA and n= 32 (34%) with IA. 48 (52%) patients were female, mean age was 58.5 (SD 14 years) and mean disease duration 6.7 years (median 2 years, range <1 year – 42 years, IQR <1 – 10 years). The mean VAS pain improvement at day 7 for morphine, triamcinolone and placebo was -22.8, -37.7, and -19.8 respectively. The differences were not significant (p=0.69) for placebo vs. morphine, but significant for placebo vs. triamcinolone and for triamcinolone vs. morphine (p=0.013 and p=0.006). Mean improvements of the everyday pain documentation are shown in Figure 1. During the study period, there were no serious adverse events and 45 adverse events, most of them were mild.

**Conclusion:** In this randomized, placebo and active controlled double blind trial a single dose of 3mg i.a. administered morphine did not lead to significant improvements in comparison to placebo and was inferior to triamcinolone at day 7. The same was true during the first 7 days as shown in the pain documentation in patient diaries. These data does not support the use of i.a. morphine for pain reduction in patients with chronic arthritis.

**Disclosure of Interests:** Hildrun Haibel Speakers bureau: AbbVie, MSD, Janssen, Roche and Pfizer, Consultant of: Roche, Boehringer, Janssen, MSD, Novartis, and Sobi, Grant/research support from: BMBF Neuroimpa 01EC1403F, Joachim Sieper Speakers bureau: Abbvie, Janssen, Lilly, Merck,Novartis, UCB, Consultant of: Abbvie, Lilly, Merck, Novartis, UCB, Denis Poddubnyy Speakers bureau: AbbVie, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, and Pfizer, Valeria Rios Rodriguez: None declared, Fabian Platt Speakers bureau: Abbvie, BMS, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: Abbvie, BMS, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: Abbvie, Novartis, Judith Rademacher: None declared, Sabrina Igel: None declared, Peter Martus: None declared, Christoph Stein Grant/research support from: BMBF Neuroimpa 01EC1403F.

**DOI:** 10.1136/annrheumdis-2022-eular.1602

---

**Scientific Abstracts**

**TRENDS FOR OPIOID PRESCRIPTIONS AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES BETWEEN 2006-2020**

J. Y. T. Huang, D. Jenkins, B. B. Birle Yi, J. Benitez-Aurioles, N. Peel, M. Lunt, W. Dixon, M. Jans, University of Manchester, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Manchester, United Kingdom; University of Manchester, Division of Informatics, Imaging and Data Science, Manchester, United Kingdom; University of Manchester, NIHR Greater Manchester Patient Safety Translational Research Centre, Manchester, United Kingdom

**Background:** Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of the most common indications for prescribed opioids despite there being little evidence on opioid prescribing and the benefit of long-term use in RMDs.

**Objectives:** To investigate national UK opioid prescribing trends by studying the patterns of opioid prescribing in new users with the following six RMDs: rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), systemic lupus erythematosus (SLE), osteoarthritis (OA) and fibromyalgia.

**Methods:** Patients aged 18 years and older with a diagnosis of RA, PsA, AxSpA, SLE and OA with a new episode of opioid use without cancer in the Clinical Practice Research Datalink (CPRD) were included between 01/01/2006 and 31/12/2020. CPRD is a database of anonymised UK primary care electronic health records representative of the national population. New opioid users were defined as individuals with RMDs who had a new episode of opioid use in a 2-year time window up to 6 months before or after an RMD diagnosis. Rates of new opioid users were calculated by dividing the number of new opioid users with an RMD per year by the number of eligible patients registered in CPRD per year. Age- and gender-standardised rates for new opioid users were obtained using direct standardisation for each RMD. Rates of opioid prescriptions among new users for each RMD were calculated by dividing the number of opioid prescriptions among new users with an RMD in the year they had new opioid episodes by patient-years of the new users with an RMD. Trends for the rates in the study period were tested using negative binomial regression. Significant change points were identified by looking at the points where the derivative (i.e. rate of change) of the trends for the rates crossed zero. Recurrent opioid users were defined as patients who had at least 3 opioid prescriptions issued within 3 months after a new opioid episode.

**Results:** This study included 21,505 RA patients, 8,392 PsA patients, 4,491 AxSpA patients, 4,508 SLE patients, 944,078 OA patients, and 33,829 fibromyalgia patients, who had new opioid episodes between 2006-2020. Whilst the overall trend for RA (2.7 vs 3.9), PsA (1.0 vs 1.8) and fibromyalgia (3.7 vs 8.3) has significantly increased over 15 years, from 2018 onwards, trends of new opioid users appeared to stabilise/decrease (Figure 1). The year 2018 was found to be a significant decreasing change point in the trends of new opioid users for RA, AxSpA, and SLE, whilst this was 2013 in OA and 2019 for fibromyalgia. Opioid prescription rates among new opioid users increased in SLE (4.3 vs 5.4), OA (4.6 vs 4.9) and fibromyalgia (5.6 vs 6.5) but decreased in RA (5.7 vs 5.3) from 2006 to 2020, despite fluctuations in the rates observed in this period. The highest proportions of recurrent opioid users among the 6 RMDs were patients with RA (32.6%) and fibromyalgia (31.9%).

**The number of new opioid users per 10000 persons**

[Graph showing trends for opioid prescriptions among patients with RMDs between 2006-2020]

**Figure 1.** Trends for new opioid users by RMD, 2006-2020.
Conclusion: RA, PsA and fibromyalgia had an overall increase in new opioid users since 2006. The slight decrease in the trends of new opioid users among most of the RMDs after 2016 may reflect an increasing awareness of the opioid epidemic. The high proportions of recurrent opioid users in RA and fibromyalgia patients highlight the importance of exploring the safety of long-term opioid use and effective pain interventions for patients with RMDs.

REFERENCES:

Acknowledgements: This work was funded by a FOREUM grant (grant ID: 125059), MJ is funded through an NIHR Advanced Fellowship (NIHR301413). Thanks to the CPRD fob holders in our centre, Ruth Costello and Ramiro Bravo, for downloading the data.

Disclosure of Interests: Joyce (Yun-Ting) Huang: None declared, David Jenkins: None declared, Belay Birle Yimer: None declared, Jose Benitez-Aurioles: None declared, Niels Peek: None declared, Mark Lunt: None declared, William Dixon Consultant of: WGD has received consultancy fees from Abbvie and Google, Meghna Jani: None declared.


THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION


Objectives: To assess efficacy of tofacitinib, adalimumab (ADA) and placebo (PBO) on residual pain in pts with RA and PsA with abrogated inflammation, using a network meta-analysis (NMA).

Methods: Data were pooled from 9 randomised clinical trials of pts with RA (NCT00960440/NCT00847613/NCT00813407/NCT00855644/NCT00853385/ NCT00968859/NCT02187055) or PsA (NCT01877660/NCT01882439). This analysis included pts who received ≥1 dose of tofacitinib 5 mg twice daily (BID). ADA 40 mg once every 2 weeks or PBO with background therapy, and had abrogated inflammation (swollen joint count [SJC] = 0 and C-reactive protein [CRP] <6 mg/L) at Month (M)3. ADA was included in NCT00960440/NCT00847613/NCT00813407/NCT00855644/NCT00853385/NCT00968859/NCT02187055/NCT01877660/NCT02187055 performed tofacitinib/ADA non-inferiority/superiority comparisons. Primary outcome was pt assessment of pain (visual analogue scale [VAS]) 0 [no pain] – 100 mm [most severe pain]) at M3; scores were summarised descriptively; treatment comparisons were assessed by Bayesian NMA on individual pt-level data, accounting for within-trial imbalances and treatment effect modifiers.

Results: Abrogated inflammation at M3 was achieved in 14.1% (328/2330), 14.9% (207/1397) of RA and 22.7% (54/238), 29.2% (31/106) and 12.7% (30/236) of PsA pts receiving tofacitinib, ADA and PBO, respectively. RA pts receiving tofacitinib/ADA had lower SJC and longer disease duration vs pts receiving PBO. PsA pts receiving tofacitinib had a longer disease duration and higher Pain VAS vs pts receiving ADA/PBO. In both groups, a lower % of female pts received tofacitinib/ADA vs PBO (Table 1). Observed median (Q1; Q3) values for Pain VAS at M3 were 170 (6.0; 310), 19.0 (70; 310) and 33.5 (70; 48.0) in RA and 24.0 (8.0; 44.0), 21.0 (9.0; 49.0) and 27.0 (8.0; 52.0) in PsA pts treated with tofacitinib, ADA or PBO, respectively. Differences between active treatments and PBO were less prominent in PsA vs RA pts, per posterior probability values (Fig).

Conclusion: In this NMA, pts with RA and PsA achieving abrogated inflammation with tofacitinib or ADA at M3 had greater residual pain reduction vs those receiving PBO. This may imply that tofacitinib/ADA have analgesic benefits beyond those related to inflammation reduction.

REFERENCES:

Table 1. Demographics and baseline characteristics of pts with abrogated inflammation at M3

<table>
<thead>
<tr>
<th></th>
<th>RA (N=328)</th>
<th>ADA* 40 mg G2W (N=87)</th>
<th>PBO (N=20)</th>
<th>Tofacitinib 5 mg BID (N=54)</th>
<th>ADA* 40 mg G2W (N=31)</th>
<th>PBO (N=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs, mean (SD)</td>
<td>50.7(12.8)</td>
<td>49.2(13.9)</td>
<td>50.0(12.1)</td>
<td>49.1(14.5)</td>
<td>49.1(15.0)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>79.0%</td>
<td>81.9%</td>
<td>87.0%</td>
<td>79.6%</td>
<td>78.1%</td>
<td></td>
</tr>
<tr>
<td>Weight, kg, mean (SD)</td>
<td>68.9(16.9)</td>
<td>68.4(17.3)</td>
<td>72.5(18.3)</td>
<td>68.0(16.3)</td>
<td>67.9(16.3)</td>
<td></td>
</tr>
<tr>
<td>Disease duration, yrs, median (Q1; Q3)</td>
<td>4.8(1.4; 9.5)</td>
<td>5.0(1.6; 11.1)</td>
<td>3.8(2.2; 7.0)</td>
<td>3.9(2.4; 7.5)</td>
<td>3.9(2.4; 7.9)</td>
<td></td>
</tr>
<tr>
<td>SJC, median (Q1; Q3)</td>
<td>8.0(7.0; 14.0)</td>
<td>8.0(6.0; 12.0)</td>
<td>8.0(6.0; 12.0)</td>
<td>8.0(6.0; 12.0)</td>
<td>8.0(6.0; 12.0)</td>
<td></td>
</tr>
<tr>
<td>CRP, mg/L, median (Q1; Q3)</td>
<td>8.0(6.0; 15.7)</td>
<td>8.0(6.0; 15.7)</td>
<td>8.0(6.0; 15.7)</td>
<td>8.0(6.0; 15.7)</td>
<td>8.0(6.0; 15.7)</td>
<td></td>
</tr>
<tr>
<td>Pain VAS, median (Q1; Q3)</td>
<td>57.0(39.0; 72.7)</td>
<td>57.0(35.0; 69.0)</td>
<td>57.0(30.5; 67.0)</td>
<td>57.0(30.5; 67.0)</td>
<td>57.0(30.5; 67.0)</td>
<td></td>
</tr>
</tbody>
</table>

*ADA was included in NCT00853385/NCT02187055/NCT01877668; NCT02187055 performed tofacitinib/ADA non-inferiority/superiority comparisons, N, number of pts; Q1, 1st quartile (25th percentil); G2W, once every 2 weeks; Q3, 3rd quartile (75th percentil); SD, standard deviation.


OP0053

LUMBAR MECHANICAL TRACTIONS IN RADICULAR PAIN OF DISCUS ORIGIN: A PROSPECTIVE CONTROLLED RANDOMIZED TRIAL OF SUPERIORITY ON 428 PATIENTS IN REIMS HOSPITAL UNIVERSITY RHEUMATOLOGY SERVICE

E. Bernhard1, A. Hittinger1, I. Charlot-Lambrecht1, M. Geoffroy1, L. Pauvele1, B. Lois2, C. Clément1, H. Delaplace3, J. H. Salmon1, 1CHU of Reims - Maison Blanche Hospital, Rheumatology, Reims, France

Background: Medical cares guidelines for lumbosciatic pains are well codified in several country: NSAIDs, analgesics and physical therapy associated, at physician's discretion, to lumbar epidural infiltrations. Lumbar mechanical tractions have not a clear identified place in the lumbosciatic pain treatment. It is empirically realized in France's several medical centers. However, no current literature studies have shown a significant efficacy of lumbar mechanical tractions in this indication. Most of the time, studies presented a lack of power or methodological bias. (1,2)

Objectives: The aim of this study is to demonstrate the superiority of lumbar traction associated with standard treatment (epidural injections, analgesics, NSAID) compared to medical treatment alone in lumbosciatic pains of discal origin.

Methods: We performed a monocentric interventional prospective superiority study from 2013 to 2021, randomized controlled in the rheumatology unit of Reims University Hospital. Patients included had to present a lumboradicular pain, with a concordant discal hernia on MRI or scanner, and to be naive of any lumbar surgery. We recorded demographical and clinical data at baseline and during the follow up. After their consent, patients were randomized between the traction group and the medical group. The medical group received the standard treatment (NSAIDs, analgesics) associated with at least 2 epidural infiltrations. The traction group received the standard treatment, infiltrations and at least 3 lumbar tractions. Treatment was considered as effective if there was a pain diminution at least 25 % between baseline and at 1 month. Patients were assessed on their pain at baseline, at 1 month and at 3 months of their treatment. Pain was assessed using a visual analog scale on lumbar and radicular localisation.

Superiority analysis has been performed by using the Chi-2 test.

Results: Four hundred eighty-two patients were included: 207 patients in the lumbar traction group, 210 patients in the medical treatment alone group and 11 patients with missing data. The male/female sex ratio was 1.39:1. The patients suffered from 49.52% (205 patients) right and 50.48% (209 patients) left lumboradiculalgia, mostly L5 (41% or 172 patients) and S1 (50% or 207 patients). The pains evaluation at one month was recorded for 377 patients: 190 in traction group (50.3%) and 187 in medical group (49.7%). Two hundred twelve/377 (56.2%) patients had a pain reduction of at least 25 % at one month: 117/377 patients in traction group (31%) and 95/377 in medical group (25%). Twenty/377 patients (5%) were operated on before the one-month recall. Therefore, patients treated with lumbar traction had a significant reduction in pain (p=0.0036) compared to patients with medical treatment alone.

Conclusion: This study is one of the first randomized controlled studies highlighting the superiority of lumbar traction in combination with standard treatment compared to medical treatment alone.

References:

Disclosure of Interests: None declared.


OP0054

REDUCING THE BURDEN OF LOW BACK PAIN: RESULTS FROM A NEW MICROSIMULATION MODEL

J. Kopec1, E. C. Sayre2, J. Cibere3, L. Li4, H. Wong5, A. Okhmatovskaya5, J. Esdaile3, 1Arthritis Research Canada, School of Population and Public Health, University of British Columbia, Vancouver, Canada; 2Arthritis Research Canada, Vancouver Coastal Health Research Institute, Vancouver, Canada; 3Arthritis Research Canada, Department of Medicine, University of British Columbia, Vancouver, Canada; 4Arthritis Research Canada, Department of Physical Therapy, University of British Columbia, Vancouver, Canada; 5University of British Columbia, School of Population and Public Health, Vancouver, Canada; 6McGill University, McGill Clinical and Health Informatics, Montréal, Canada; 7Arthritis Research Canada, Department of Medicine, University of British Columbia, Vancouver, Canada

Background: Low back pain (LBP) has been the leading cause of disability worldwide for the past 30 years. In 2019, LBP was responsible for 64 million years lived with disability (YLDs) [1].

Objectives: The purpose of the present study was to project and compare the impact of three strategies for reducing the population health burden of LBP: weight loss, ergonomic interventions, and an exercise program.

Methods: We have developed a microsimulation model of LBP in Canada using a novel simulation platform, SimYouLate. The initial population was derived from Cycle 1 (2001) of the Canadian Community Health Survey (CCHS). We modeled an open population with 20 years of age and older. Key variables included age, sex, education, body mass index (BMI), type of work, having a back problem, pain level in persons with back problems, and exercise. The effects of interventions on the risk of LBP were obtained from the CCHS for the effect of BMI, the Global Burden of Disease Study for occupational risks, and a published meta-analysis for the effect of exercise. All interventions lasted from 2021 to 2040. Strength of the interventions varied over a wide range. YLDs were defined as LBP prevalence multiplied by disability weight. The population health impact of the interventions was calculated as a difference in YLDs between the base-case scenario and each intervention scenario expressed as YLDs averted per intervention unit and as % of total LBP-related YLDs.

Results: In the base-case scenario, LBP in 2020 was responsible for 424,900 YLDs in Canada and the amount increased to 460,312 YLDs in 2040. The effects of the interventions on YLDs were as follows: 27993 (95% CI 23,373, 32,614) YLDs averted over 20 years per 0.1 unit change in log-transformed BMI (10.5% change in BMI) among overweight and obese individuals, 19,416 (16,275, 22,557) YLDs averted per 1% reduction in the proportion of workers exposed to occupational risks, and 26,058 (22,455, 29,661) YLDs averted per 1% increase in the proportion of eligible patients with back problems participating in the exercise program. Table 1 shows the intervention impact as % of total LBP-related YLDs and Figure 1 shows YLD-equivalence between the interventions. A one unit reduction in BMI per year among the overweight and obese individuals would be approximately equivalent in terms of disability reduction to an effective ergonomic intervention in 35% of at-risk workers and an exercise intervention in 27% of eligible patients with back problems over the same period (Figure 1).

Table 1. YLDs averted between 2021 and 2040 as % of total LBP-related YLDs, according to intervention type and level, in persons aged 20+ in Canada

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Effect (%)</th>
<th>95% LCL</th>
<th>95% UCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in BMI per year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.1</td>
<td>1.4</td>
<td>-1.4</td>
<td>4.1</td>
</tr>
<tr>
<td>0.3</td>
<td>4.8</td>
<td>2.2</td>
<td>7.3</td>
</tr>
<tr>
<td>0.5</td>
<td>6.3</td>
<td>3.9</td>
<td>8.8</td>
</tr>
<tr>
<td>1.0</td>
<td>8.5</td>
<td>6.0</td>
<td>11.0</td>
</tr>
<tr>
<td>3.0</td>
<td>11.9</td>
<td>9.4</td>
<td>14.4</td>
</tr>
<tr>
<td>5.0</td>
<td>13.5</td>
<td>10.9</td>
<td>16.0</td>
</tr>
<tr>
<td>Reduction in occupational exposure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20%</td>
<td>5.2</td>
<td>1.9</td>
<td>8.5</td>
</tr>
<tr>
<td>60%</td>
<td>9.5</td>
<td>6.4</td>
<td>12.7</td>
</tr>
<tr>
<td>80%</td>
<td>13.8</td>
<td>10.6</td>
<td>16.9</td>
</tr>
<tr>
<td>Increase in exercise participation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20%</td>
<td>6.6</td>
<td>2.8</td>
<td>10.4</td>
</tr>
<tr>
<td>40%</td>
<td>12.4</td>
<td>8.7</td>
<td>16.0</td>
</tr>
<tr>
<td>60%</td>
<td>18.1</td>
<td>14.5</td>
<td>21.7</td>
</tr>
<tr>
<td>80%</td>
<td>23.9</td>
<td>20.1</td>
<td>27.6</td>
</tr>
<tr>
<td>100%</td>
<td>29.6</td>
<td>25.5</td>
<td>33.7</td>
</tr>
</tbody>
</table>

LCL: lower confidence limit. UCL: upper confidence limit.

Figure 1. Equivalence between BMI, ergonomic and exercise interventions in terms of their impact on YLDs. Each point represents a specific number of YLDs averted. Values on the y-axis show reduction in % of workers at risk and increase in % exercising that are required to achieve the same reduction in YLDs as the corresponding reduction in BMI shown on the x-axis.
Background: Low back pain is the most common musculoskeletal problem which negatively affects functional capacity and quality of life during pregnancy (1). So, from the beginning of pregnancy, pregnant women should be supported by appropriate exercise approaches recommended as first-line therapy to reduce the complaints about low back pain (2, 3). Although there are different opinions about the type, intensity and frequency of exercise in order to improve functional capacity in pregnant women with low back pain, there are no comparative studies on the diversity and length of the exercise program.

Objectives: The aim of this study was to compare the effects of supervised, long and multivariaty an exercise program (LEP) and a short exercise program (SEP), planned based on core stabilization and in line with the needs of pregnant women, on functional capacity and quality of life.

Methods: A total of 27 pregnant women complained about low back pain, without obstetric and medical complications were included in this study. Detailed sociodemographic and obstetric characteristics were recorded. Back pain intensity, functional capacity and the quality of life were determined by the Visual Analogue Scale (VAS), 6-minute walk test and Short Form-36 Quality of Life Questionnaire. All outcome measures were assessed at baseline, at 24 and 32 weeks of pregnancy. Starting from the 16th week of pregnancy to the 32nd week, for 6 weeks, 2 days a week, under the supervision of a physiotherapist, a stabilization-based exercise program consisting of posture training, upper extremity, lower extremity, abdominal and pelvic floor strengthening and emotional role limitation and pain-related quality of life in the short term and is more effective in terms of increasing functional capacity in the long term than SEP during pregnancy. In this respect; our study will guide clinicians to create individually exercise programs for the needs of pregnancy.

REFERENCES:


[2] Cordingly 1, 2, 3, 4 University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2 Manchester University Hospital NHS Trust, National Institute for Health Research Biomedical Research Centre, Manchester, United Kingdom; 3 Manchester University Hospitals Trust, Royal Manchester Children’s Hospital, Manchester, United Kingdom; 4 Children’s Mercy Kansas City, Division of Developmental and Behavioral Health, Kansas City, United States of America; 5 University of Manchester, Manchester Centre for Health Psychology, Manchester, United Kingdom


THE COMPARISON OF EFFECTS OF TWO DIFFERENT EXERCISE PROGRAM ON FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN PREGNANT WOMEN WITH LOW BACK PAIN

E. Üzelpasaci1, T. Akbayrak1, 1Hacettepe University, Physical Therapy and Rehabilitation, Ankara, Turkey

Background: Pain communication should be an integral part of every clinical consultation, particularly in paediatric rheumatology where children/young people often present complex long-term conditions in which chronic pain is a feature. Researchers investigating pain communication in paediatric healthcare encounters have been focused on healthcare professionals, yielding inconsistent findings about the occurrence and nature of pain discussions with children/young people. There has been limited research examining children/young peoples’ own communication experiences and perspectives on this in the literature to date.

Objectives: The objective of this study was to investigate children/young peoples’ experiences and perceptions of communicating about pain with paediatric rheumatology healthcare professionals in the UK.

Methods: Twenty-six children/young people were recruited from three UK paediatric rheumatology centres. Data were collected using semi-structured telephone interviews between April–October, 2021. A framework analysis approach was used to explore similarities and divergences in participants’ narrative accounts.

Results: The mean age of children/young people was 14.0 years (SD=3.6 years, Range= 6-18 years, 58% female). Diagnoses included; Juvenile Idiopathic Arthritis, Chronic Regional Pain Syndrome, diffuse idiopathic chronic pain, localised idiopathic pain, hypermobility (including Ehlers Danlos Syndrome) and Raynaud’s disease. Findings are organised into four themes.

1) Nature and focus of appointments. Children/young people talked about pain with several professionals from the team. Participants reported that pain conversations predominantly occurred during physical examinations.

2) Co-ordination of pain communication. Children/young people identified how professionals mostly started pain conversations. They explained how they were often asked to verbally rate pain rather than use a written assessment tool. For some, questions about pain were directed to parents. Participants reported that this was problematic as parents “can’t feel” pain.

3) Reflections on pain communication. There were expectations that pain should always be asked about as it was considered a main reason for a consultation. Participants discussed how these conversations gave them an opportunity to “get it off their chest” and made them feel “reassured” that professionals “care” Being asked about pain reminded them that they were different to peers and they were concerned it could highlight “something else is wrong”. Children/young people talked about how it became easier to talk about pain with familiar professionals.

4) Moving forward after pain communication. Children/young people discussed how professionals could give mixed messages about how to manage pain at home following consultations, offering advice which was difficult to put into practice (e.g. “doing too much” vs “not doing enough”). Children/young people expressed their need to discuss the emotional as well as the physical effects of their pain.

Conclusion: These study findings highlight a range of effective and ineffective pain communication approaches from the experiences and perspectives of children/young people. These will be used to create recommendations for improving the communication of chronic pain in paediatric rheumatology in the future, in a way that is acceptable and valuable to children/young people.

Acknowledgements: The authors would like to thank the children/young people for kindly taking the time to share their experiences and perceptions about their interactions with healthcare professionals in paediatric rheumatology. The views expressed herein are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the UK Department of Health. This work was supported by a Foundation Fellowship award from Versus Arthritis (Grant 22433). Aspects of this work were also supported by funding from the Centre for Epidemiology Versus Arthritis (Grant 201800) and the NIHR Manchester Biomedical Research Centre.

Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2022-eular.1162
RESPONSE TO INJECTION CAN PREDICT OUTCOMES OF FEMOROACETABULAR IMPINGEMENT

E. Campos Marting1, D. Almeida Gomes2, H. De Brito Fontana3, D. Araujo Fernandes4, F. De Souza Neves5, 1Federal University of Santa Catarina, Department of Surgery, Florianópolis, Brazil; 2Federal University of Santa Catarina, Department of Morphological Sciences, Florianópolis, Brazil; 3Federal University of Santa Catarina, Internal Medicine Department, Florianópolis, Brazil

Background: Femoroacetabular impingement syndrome (FAIS) is a highly prevalent painful disorder that is considered a risk factor for hip osteoarthritis. In order to relieve pain and improve cartilage preservation, surgery is often performed. However, many operated patients do not show satisfactory outcomes. Reliable diagnostic tests that can inform prognosis of surgery in patients with FAIS are needed for optimized indications and contraindications to surgery.

Objectives: This systematic review aimed to answer the following question: “Can the response to intra-articular anesthetic injections be used to predict surgical outcomes in patients with FAIS?”

Methods: This study was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) statement. Embase, CINAHL, LilACS, PubMed, SCOPUS, SPORTDiscuss, The Cochrane Library, and Web of Science databases were screened. All studies that assessed the capability of the response to intra-articular anesthetic injections in predicting surgical outcomes for patients with FAIS were considered eligible. Study selection and data collection were performed by three independent reviewers. Risk of bias of the included studies was assessed through the QUIPS tool.

Results: Seventeen articles were selected for full-text reading, of which 6 were considered eligible and included for analysis [1-6]. A summary of the studies’ descriptive characteristics can be found in the Table 1. A high risk of bias due to study attrition and the presence of confounding factors was observed for all included studies. Five out of six studies [1-4,6] presented “high risk” of bias associated to the prognostic factor measurement. A high overall risk of bias was evidenced by QUIPS for all studies (Figure 1). From 6 included studies, 5 indicated that the response to intra-articular injections can be useful in the prediction of surgical outcomes [2-6].

Conclusion: Although there seems to be some evidence supporting the use of intra-articular anesthetic injections to predict surgical outcomes in patients with FAIS, it is not conclusive. Future studies taking into account the various possible sources of bias in prognostic studies are needed. Standardizing and optimizing injection protocols as well as post-injection pain assessment and outcomes measurements are also essential to fill this gap.

REFERENCES:

Disclosure of Interests: None declared.

Table 1.

<table>
<thead>
<tr>
<th>Author</th>
<th>Mean Age</th>
<th>N (Female)</th>
<th>Injection Content</th>
<th>Time for pain assessment after injection (Way)</th>
<th>Intervention group (Score used)</th>
<th>Follow-up time after surgery</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ayeni</td>
<td>? (16-62)</td>
<td>52 (30)</td>
<td>Bupivacaine + prednisolone</td>
<td>Daily for 2 weeks (provocative activities)</td>
<td>42 with any pain relief (10)</td>
<td>6 months (mHHS)</td>
<td>Likelihood Ratio of reaching &gt;70 points (LR) for responders was 1.15; LR for nonresponders was 0.57 (p=0.05)</td>
</tr>
<tr>
<td>Chinzei</td>
<td>36.7 ± 14.7</td>
<td>49 (27)</td>
<td>Lidocaine</td>
<td>2 weeks (?)</td>
<td>30 with &gt;50% of pain relief (19)</td>
<td>12 months (mHHS)</td>
<td>Good responders showed better mHHS, pre- and post-operatively (p=0.026) 100% of good responders surpassed the MCID, while only 1/3 of poor responders achieved it</td>
</tr>
<tr>
<td>Gao</td>
<td>36.5 (16-65)</td>
<td>78 (41)</td>
<td>Lidocaine + betamethasone</td>
<td>10 min and 1 week (routine tasks)</td>
<td>33 with &gt;50% of pain relief (3)</td>
<td>22.8 ± 9.7 months (mHHS)</td>
<td>Correlation between iHOT after injection and iHOT at 12 months after surgery (n=0.784 p&lt;0.01)</td>
</tr>
<tr>
<td>Krych</td>
<td>37.6 ± 14.0</td>
<td>319 (?)</td>
<td>Variable</td>
<td>2 weeks, reporting the relief of the first 24h (?)</td>
<td>70 with &gt;50% of pain relief (26)</td>
<td>11–30 months (HOS and mHHS)</td>
<td>For Tönnis grade 1 patients, good responders had higher HOS-SS (p=0.03)</td>
</tr>
<tr>
<td>Li</td>
<td>38.6 ± 14.9</td>
<td>60 (33)</td>
<td>Lidocaine + ropivacaine</td>
<td>30 min (physical tests)</td>
<td>12 months (mHHS and iHOT-12)</td>
<td>Correlation between iHOT after injection and iHOT at 12 months after surgery (n=0.784 p&lt;0.01)</td>
<td></td>
</tr>
<tr>
<td>Mujahed</td>
<td>? (16-65)</td>
<td>242 (?)</td>
<td>Lidocaine + betamethasone</td>
<td>? (?)</td>
<td>120 with any pain relief (88)</td>
<td>24 months (HOS and mHHS)</td>
<td>Responders had greater improvement (p&lt;0.05) in all metrics, except for MCID at mHHS (p=0.24)</td>
</tr>
</tbody>
</table>
Background: The optimal first-line treatment of patients with early rheumatoid arthritis (ERA) is not established.

Objectives: To compare clinical and radiographic outcomes of active conventional therapy (ACT) with each of three biological therapies with different modes of action.

Methods: In this investigator-initiated, randomized, open-label, blinded-assessor study (NCT01491815), patients with treatment-naive ERA with DAS28>3.2 and RF+/ACPA+/CRP>10mg/L, were randomized 1:1:1:1 to methotrexate combined with one of three biologic treatments; 1) oral prednisolone (tapered quickly; discontinued at w36); or: sulfasalazine, hydroxychloroquine and mandatory intra-articular (IA) glucocorticoid injections in swollen joints (ACT); 2) certolizumab-pegol (CZP); 3) abatacept (ABA) with concomitant conventional therapy (csDMARD + glucocorticoids), superiority regarding CDAI remission rates was demonstrated for abatacept and tocilizumab-pegol, and not for tocilizumab. Radiographic progression was low and similar between treatments.

Results: 812 patients were randomized. Adjusted CDAI remission rates at w48 were: 59.3% (ACT), 52.6% (CZP), 50.6% (ABA) and 51.9% (ABA). CDAI remission, w48 Ref 13.1% (3.5 to 22.5) 22.6% Ref 13.1% (3.5 to 22.5) 13.1% (3.5 to 22.5) 22.6% Ref 13.1% (3.5 to 22.5)

Values are mean (SD), if not otherwise indicated. §Finns patients randomised to TCZ-MTX, but not receiving it due to unavailability, are not included. *Values are estimated adjusted marginal means and estimated marginal differences against ACT with 95% CI. ITT: intention to treat. Superiority compared with ACT was demonstrated.

No new safety signals were reported. Total numbers of serious adverse events (% patients with ≥1 event) were for ABA 21 (8.3%), CZP 28 (12.4%), TCZ 20 (9.2%) and ACT 23 (10.7%).

Conclusion: Compared with active conventional therapy (csDMARD + glucocorticoids), superiority regarding CDAI remission rates was demonstrated for abatacept and tocilizumab-pegol, and not for tocilizumab. Radiographic progression was low and similar between treatments.
PROFOUND ANTICOAGULANT EFFECTS OF INITIAL ANTIRHEUMATIC TREATMENTS IN EARLY RHEUMATOID ARTHRITIS PATIENTS: A NORD-STAR SPIN-OFF STUDY


Background: Patients with rheumatoid arthritis (RA) are at an increased risk of venous thromboembolism. Thus far, there have not been any comparative studies investigating the effects of initial antirheumatic treatments in very early RA patients.

Objectives: To assess the effects of different initial treatments on hematologic parameters in patients with early RA.

Methods: NORD-STAR is an international, multicentre, open-label, assessor-blinded, phase 4 study where patients with newly diagnosed RA started methotrexate (MTX) and were randomised 1:1:1:1 to a) conventional treatment (either prednisolone tapered to 5mg/day, or sulfasalazine combined with hydrochloroquine and intra-articular corticosteroids), b) certolizumab pegol, c) abatacept, d) tocilizumab.

Results: The mean age of investigated patients was 51.8 (±12.7) years and 58.3% were female. At baseline patients had an average DAS28 score of 4.6 (±0.9) and had elevated levels of investigated coagulation biomarkers: Factor I + 2, fibrinogen, D-dimer and parameters of the two global hemostatic assays, i.e., endogenous thrombin potential (ETP) and overall hemostasis potential (OHP).

These biomarkers decreased significantly at 12 and 24 weeks in patients in all groups (Table 1). Overall fibrinolytic potential (OFP) was decreased and clot lysis time (CLT) was prolonged at baseline, demonstrating impaired fibrinolytic activity in early RA. The reduction of coagulation parameters was significantly higher in biological treatment arms in comparison to the standard MTX treatment arm. In addition, tocilizumab was more effective compared to certolizumab and abatacept (Figure 1), which was expected considering the direct inhibitory effect of this drug on the IL-6 synthesis and consequently the coagulation activation as well. After 24 weeks of treatment with methotrexate and tocilizumab, the average fibrinogen of patients was reduced by 63% vs 31% and 36% in the certolizumab and abatacept groups, respectively. The changes in DAS28 and the changes in fibrinogen had a correlation of 0.385 which did not reach statistical significance.

Table 1. Measurements are marked with * if p<0.05, ** if p<0.01, *** if p<0.001

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>W12</th>
<th>W24</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor 1 + 2 (µmol/L)</td>
<td>270.25 (149.4)</td>
<td>190.36 (108.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fibrinogen (g/L)</td>
<td>4.64 (15)</td>
<td>3.61 (16)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>D-dimer (mg/L)</td>
<td>2.17 (3.0)</td>
<td>0.83 (0.23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>OHP (Abs-sum)</td>
<td>157.38 (64.9)</td>
<td>120.62 (68.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>OCP (Abs-sum)</td>
<td>369.52 (58.8)</td>
<td>305.04 (101.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lag time (s)</td>
<td>304.5 (71.1)</td>
<td>306.8 (71.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Slope</td>
<td>0.07 (0.02)</td>
<td>0.06 (0.03)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Max Abs</td>
<td>1.17 (0.3)</td>
<td>1.00 (0.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CLT (s)</td>
<td>1405 (356)</td>
<td>1377 (377)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ETP (mM/mn)</td>
<td>1480 (471)</td>
<td>1395 (395)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peak (nm)</td>
<td>231 (78)</td>
<td>223 (68)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lagtime (min)</td>
<td>4.06 (2.1)</td>
<td>3.28 (1.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peak (min)</td>
<td>7.40 (2.2)</td>
<td>6.61 (1.5)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Figure 1. Decrease of fibrinogen over time
EXPOSURE TO SPECIFIC TUMOR NECROSIS FACTOR INHIBITORS AND RISK OF DEMYELINATING AND INFLAMMATORY NEUROPATHY IN PATIENTS WITH INFLAMMATORY ARTHRITIS. A COLLABORATIVE OBSERVATIONAL STUDY ACROSS FIVE NORDIC RHEUMATOLOGY REGISTERS

B. Deloignier¹, T. I. Kopp², E. Arkema¹, K. Hellegren¹, S. Aarestad Provan³, H. Relas⁴, K. Aaltonen⁵, N. Trokovic⁶, B. Gudbjornsson⁷, G. Grönfeldt³, E. Kristianslund⁶, L. Dreyer⁵, J. Asking⁴, K. Arvidsson, Stockholm, Sweden; ¹Copenhagen University Hospital - Rigshospitalet, The Danish Multiple Sclerosis Registry, Department of Neurology, Glostrup, Denmark; ²Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway; ³Helsinki University Hospital and Helsinki University, ROB-FIN, Department of Medicine and Rheumatology, Helsinki, Finland; ⁴Ministry of Social Affairs and Health, ROB-FIN, Pharmaceuticals Pricing Board, Helsinki, Finland; ⁵University of Iceland, Centre for Rheumatology Research, Landspitali University Hospital, and Faculty of Medicine, Reykjavik, Iceland; ⁶Aalborg University, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark; ⁷DANBIO Registry, DANBIO Registry, Copenhagen, Denmark

Background: Though rare, studies have reported increased risk of neurological events including demyelinating disease of CNS (DML), multiple sclerosis (MS), and inflammatory neuropathy (INP) in patients with inflammatory joint disease treated with tumor necrosis factor inhibitors (TNFi). More in-depth investigations are required to elucidate the association between TNFi and neurological events in these patients, especially whether rates differ across type of TNFi mode of action.

Objectives: To estimate the incidence of neurological events in patients with rheumatoid arthritis (RA) and spondyloarthritits (SpA, including axial spondyloarthritis and psoriatic arthritis) starting treatment with TNFi across five Nordic countries. To compare the incidence of neurological events in etanercept (ETN)-treated patients to patients treated with other TNFi (oTNFi).

Methods: We defined treatment cohorts of patients initiating TNFi between 2001 and 2018 from clinical rheumatology registers in Denmark (DK), Finland (FI), Iceland (IS), Norway (NO), and Sweden (SE). One patient could contribute to more than one treatment episode. Demographic data (sex, age), co-medication (methotrexate) and clinical variables (CRP, disease duration <1 year, 1 to 5 years, >5 years) were extracted and used as covariates. We estimated crude incidence rates (IR) for neurological events and subtypes (ICD-10 codes: MS: G35, DML: G35, G36.8-9, G37.1, G37.2, G37.5, G37.8-9, H46, H48.1, G04.8-9, INP: G610, G618.9), all countries pooled. We compared risk of neurological events between patients treated with ETN and oTNFi using Cox regression with time since treatment start, adjusted for the above covariates, robust standard errors, and stratified by country.

Results: We included 52,682 treatment starts, in 33,885 RA patients (DK 8,259, FI 3,765, IS 723, NO 13,533, SE 19,785, 75% women, mean age 56 years) and 46,549 treatment starts in 10,594 SpA patients (7,000, FI 2,885, IS 962, NO 2,684, SE 15,241; 47% women, mean age 45 years). Numbers of DML, MS, INP and all neurological events, person-years (pyrs), and INP: G610, G618.9, all countries pooled. We compared risk of neurological events between patients treated with ETN and oTNFi using Cox regression with time since treatment start, adjusted for the above covariates, robust standard errors, and stratified by country.

Conclusion: The incidences of DML and MS were lower in RA compared to SpA patients, while rates of INP were similar in both patients' groups. There was no evidence of differences in these rates between ETN and oTNFi. The findings are of importance from a safety perspective for patients starting TNFi.

Acknowledgements: NordForsk and Foreum partially funded this research project.

Disclosure of Interests: Bénédicte Deloignier: None declared, Tine Iskov Kopp Paid instructor for: T. I. Kopp has served on scientific advisory board from Novartis, Consultant of: T. I. Kopp has received support to congress participation from Biogen, Grant/research support from: T. I. Kopp has received support to congress participation from Biogen, Elizabeth Arkema: None declared, Karin Hellegren: None declared, Sella Aarstad Provan: None declared, Sella Aarstad Provan: None declared, Heikki Relas Paid instructor for: Abbvie, Pfizer, Kalle Aaltonen: None declared, Nina Trokovic: None declared, Björn Gudbjornsson Speakers bureau: Novartis ...
Background: The ongoing coronavirus disease 2019 (COVID-19) pandemic and subsequent waves still represent a healthcare issue. Their impact on the treat-to-target (T2T) strategy in rheumatoid arthritis (RA) patients has been seldom investigated. Difficult access to rheumatologist outpatient clinic, laboratory and imaging investigations as well as nationwide containment measures could potentially affect disease activity and tight-control strategy. Recently, we reported how a telephone-based tight control strategy ensured satisfactory management of RA treated with targeted therapies during the first wave of the pandemic [1]. However, the performance of our different patterns of healthcare delivery across different pandemic waves has not been studied yet.

Objectives: To analyze the impact of different patterns of healthcare delivery on remission of RA patients treated with targeted therapies during the first wave (2020) and second/third waves (2021) of pandemic compared to the pre-pandemic period (2019).

Methods: In this observational real-life study, data of our cohort of RA patients treated with biologic or targeted synthetic drugs were extracted from a longitudinal registry. Clinical Disease Activity Index (CDAI) was analyzed in the same period from 22nd of February to 16th of May for three consecutive years: before the pandemic (2019), during the first wave (2020), and during the second/third waves (2021). During the first wave, patients could choose whether to receive home drug delivery or to maintain their face-to-face visits, in the other periods only in-person visits were delivered. A generalized linear model with the binomial error was fitted to evaluate the difference in the proportion of patients in CDAI remission. Quantile regression was used to compare the median of CDAI in difficult-to-treat (D2T) patients [2]. In both models, the correlation of different measurements on the same patient was considered.

Results: In the pre-pandemic period (2019), 407 RA patients were included in this study. During the first wave (2020) we analyzed 450 patients, of whom 359 patients chose in-person visits, while 91 patients home drug delivery and virtual visit. Finally, 540 patients were included in 2021 (second/third wave). The percentages of patients in CDAI remission were similar in the three periods (prevalence ratio 1.07, p-value 0.423 between 2020 and 2019, and 1.01, p-value 0.934 between 2021 and 2019). The CDAI remission rate was 40.55% (N=163), 43.18% (N=155) and 40.82% (N=220) in 2019, 2020 and 2021 respectively. The disease activity profile during the three periods is reported in detail in Table 1 below. Among our cohort of D2T patients, the median value of CDAI before (2019), during the first wave (2020), and during the second/third wave (2021) changed significantly (p= 0.053 between 2020 and 2019 and p=0.006 between 2021 and 2019).

Conclusion: Although the pandemic has imposed changes in our healthcare delivery, these different strategies seem to be effective in ensuring satisfactory management of RA treated with targeted therapies. The approaches modulated in the context of the different periods have been a feasible compensation for ensuring disease control even in D2T patients.

REFERENCES:

DISCLOSURE OF INTERESTS: Angela Flavia Luppino: None declared. Gilberto Cincinelli: None declared, Francesca Inegnoi: None declared, Annalisa Orenti: None declared, Ennio Giulio Favalli Speakers bureau: Galapagos, BMS, Lilly, Pfizer, Novartis, Paid instructor for: Roche, MSD, Consultant of: AbbVie, Lilly, Galapagos, Janssen, Patrizia Boracchi: None declared, Roberto Caporali Speakers bureau: Abbvie, Amgen, BMS, Celtrion, Galapagos, Lilly, Pfizer, Fresenius-Kabi, MSD, UCB, Roche, Janssen, Novartis, Sandoz, Consultant of: Abbvie, Amgen, BMS, Celtrion, Galapagos, Lilly, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz.


---

**Table 1.**

<table>
<thead>
<tr>
<th>RA patients</th>
<th>CDAI 2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. missing</td>
<td>N (%)</td>
<td>No. missing</td>
<td>N (%)</td>
</tr>
<tr>
<td>Remission</td>
<td>163</td>
<td>85</td>
<td>155</td>
</tr>
<tr>
<td>Low</td>
<td>101</td>
<td>89</td>
<td>140</td>
</tr>
<tr>
<td>Moderate/</td>
<td>88</td>
<td>89</td>
<td>64</td>
</tr>
<tr>
<td>high</td>
<td>21.89%</td>
<td>178.3%</td>
<td>170.7%</td>
</tr>
</tbody>
</table>

**Conclusion:** Although the pandemic has imposed changes in our healthcare delivery, these different strategies seem to be effective in ensuring satisfactory management of RA treated with targeted therapies. The approaches modulated in the context of the different periods have been a feasible compensation for ensuring disease control even in D2T patients.
methylprednisolone group reduced dose compared with the maximum dose group. The primary endpoint was non-inferiority in the achievement of SDAI remission at the end of treatment. A total of 300 patients were enrolled in the study. Among them, 291 started methylprednisolone and were included in the analysis. The mean age was 57.7±15.2 years, female was 74.6%, and the mean disease duration from the diagnosis of RA was 22.1±56.2 days. Anti-CCP antibody was positive in 221 (73.0%) and the mean SDAI at study enrollment was 26.5±12.4. At week 24, with the mean dose of methylprednisolone 12.6±2.9 mg/day, 108 patients (37.1%) achieved remission according to SDAI and continued MTX monotherapy. 134 patients (46.0%) were randomised and started adalimumab with 88 patients in the maximum tolerable dose group and 66 patients in the reduced dose group. At week 48, the remission achievement rates were 38.4% and 44.8%, respectively, with the adjusted risk difference of the reduced dose group to the maximum tolerable dose group of 6.4% (-7.0% to 19.8%, 90% CI), which met the criterion for noninferiority. No significant difference was found in health assessment questionnaire disability index ≤0.5 (59.1% vs 62.0%, respectively, p=0.72) and in radiological remission rates (modified total Sharp score ≤0.5, 66.3% vs 62.0%, respectively, p=0.59). Adverse drug reactions tended to be more frequent in the maximum tolerable dose group than in the reduced dose group (22.1% vs 9.1%, respectively, p=0.06).

Conclusion: The MIRACLE randomised study demonstrated that, in patients with inadequate response to methylprednisolone, the efficacy of adalimumab with reduced dose of concomitant methylprednisolone was not inferior to that with maximum tolerable dose of methylprednisolone with better safety profile.

Disclosure of Interests: Hiroya Tamai Speakers bureau: Eisai, Grant/ research support from: Eisai, Kei Ikeda Speakers bureau: AbbVie, Eisai, Eli Lilly, Novartis, Gilead, Asahi Kasei, Kowa Company, Ltd., Consultant of: MOCHIDA PHARMACEUTICAL CO., LTD, Tsutomu Kojima Speakers bureau: AbbVie, Eisai, Pfizer, Eli Lilly, Boehringer-Ingelheim, Chugai, Eli, Lilly, Mitsubishi-Tanabe, Nippon-kayaku, Novartis, Pfizer, Sanofi, UCB, Grant/ research support from: Asahi Kasei, AbbVie, Ayumi, Boehringer-Ingelheim, Chugai, Elii, Lilly, Mitsubishi-Tanabe, Sanofi, UCB, Yuku Kaneko Speakers bureau: Asahi Kasei, Astellas, Ayumi, Pfizer, AbbVie, Eli Lilly, Mitsubishi-Tanabe, Novartis, UCB, Grant/research support from: AbbVie, Chugai, Eisai, Mitsubishi-Tanabe, UCB.

DOI: 10.1136/annrheumdis-2022-eular.4

OP0063

OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN MODERATE TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS PATIENTS INADEQUATELY CONTROLLED BY METHOTREXATE (MTX-IR): RESULTS FROM THE PHASE 3 RANDOMIZED CONTROLLED TRIAL, CREDO 2

V. Strand1, E. Choy2, E. Nasonov3, T. Laitayna4, A. Lila4, S. Kuzikina4, M. Samsonov5, E. Feist5, Stanford University, Division of Rheumatology/RheumatoLOGY, Palo Alto CA, United States of America, 2Cardiff University, CREATE Centre, Section of Rheumatology, Cardiff, UK, United Kingdom, 3V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation, 4V. Nasonova Research Institute of Rheumatology, Tromboinflammation, Moscow, Russian Federation, 5R-Pharm, Medical, Moscow, Russian Federation, 6Helios Fachklinik Wiesbaden-Gommern, Helios Clinic, Rheumatology, Vogelsang-Gommern, Germany

Background: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients with moderate to severely active RA treated with OKZ vs adalimumab (ADA) or placebo in a phase 3 randomized controlled trial (RCT) (ClinicalTrials.gov number, NCT02760407).

Objectives: To assess the effect of OKZ treatment compared with placebo and ADA in patient global assessment of disease activity (PGA), pain, physical function (HAQ-DI), fatigue (FACIT-F) and health related quality of life (SF-36 physical (PCS) and mental (MCS) component summary and domain scores) and work participation (WPS-RA) at week 12.

Methods: 1848 patients receiving MTX were randomized to receive SQ injections: 1) OKZ 64 mg every 2 weeks (q2w, n=464), 2) OKZ 64 mg q4w (n=479), 3) ADA 40 mg q4w (n=462) and 4) placebo q2w (n=243). At week 14, non-responders: subjects without ≥ 20% improvements in both swollen and tender joint counts, added rescue medication (sulfasalazine and/or hydroxychloroquine) to study treatment. Between groups differences in least-squares mean (LSM) changes from baseline were analyzed.

Results: At week 12, treatment with both OKZ doses and ADA resulted in statistically greater LSM changes from baseline than placebo across all PROs, including 7 of 8 domains of SF-36 with exception of role emotional (Table 1 and Figure 1). Reported work and household work impairments, days productivities were reduced by half and missed household work days because of arthritis were all improved (p<0.01) with OKZ and ADA treatment. PROs further improved to week 24 in the active treatment arms. Post hoc analyses demonstrated that a higher proportion of patients receiving both doses of OKZ as well as ADA reported improved ≥ minimum clinically important differences vs placebo (p<0.01) across all PROs, indicating clinically meaningful benefits on an individual patient basis. Estimates of numbers needed to treat indicated that between 5 and 10 patients would need to be treated to achieve these benefits. More patients in both OKZ groups reported scores ≥ normative values in PGA, HAQ-DI and SF-36 PCS scores; with ADA in PGA and HAQ-DI.
Table 1. Mean baseline PROs and LSM changes to week 12

<table>
<thead>
<tr>
<th>Prognostic index</th>
<th>Baseline, mean (standard deviation)</th>
<th>12 weeks LSM changes (standard error)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-36 MCS</td>
<td>42.9(11.4)</td>
<td>43.9(11.3)</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>31.8(7.0)</td>
<td>31.6(7.2)</td>
</tr>
<tr>
<td>FACIT-F</td>
<td>26.7(10.7)</td>
<td>27.3(10.4)</td>
</tr>
<tr>
<td>HAQ-DI*</td>
<td>1.7(0.58)</td>
<td>1.7(0.60)</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>5 (2-9)</td>
<td>6 (3-12)</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>4 (2-9)</td>
<td>4 (3-12)</td>
</tr>
<tr>
<td>Fatigue, VAS</td>
<td>48.5 (28.8)</td>
<td>49.0 (25.9)</td>
</tr>
<tr>
<td>Patient pain, VAS</td>
<td>50.2 (25.6)</td>
<td>50.2 (25.6)</td>
</tr>
<tr>
<td>Pain-VAS</td>
<td>67.5(21.0)</td>
<td>67.5(21.0)</td>
</tr>
<tr>
<td>HAQ-DI*</td>
<td>1.7(0.58)</td>
<td>1.7(0.60)</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.97 (0.66)</td>
<td>1.0 (0.64)</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>6 (3-10)</td>
<td>6 (3-12)</td>
</tr>
<tr>
<td>Concomitant csDMARD</td>
<td>52.5%</td>
<td>50.4%</td>
</tr>
<tr>
<td>Patient pain, VAS</td>
<td>50.2 (25.6)</td>
<td>50.2 (25.6)</td>
</tr>
<tr>
<td>Fatigue, VAS</td>
<td>48.5 (28.8)</td>
<td>49.0 (25.9)</td>
</tr>
<tr>
<td>ESR (median, IQR)</td>
<td>23 (12-40)</td>
<td>23 (12-40)</td>
</tr>
<tr>
<td>CRP (mg/l, median, IQR)</td>
<td>8.9 (4-22)</td>
<td>10 (4-24)</td>
</tr>
</tbody>
</table>
| Treatment with both doses of OKZ resulted in similar, statistically significant improvements across PROs vs placebo in MTX-IR patients with moderate to severely active RA, comparable to ADA, that were clinically meaningful. **Conclusion:** Treatment with both doses of OKZ resulted in similar, statistically significant improvements across PROs vs placebo in MTX-IR patients with moderate to severely active RA, comparable to ADA, that were clinically meaningful.

**Acknowledgements:** R-Pharm funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and in the writing, review, and approval of the abstract. No honoraria or payments were made for authorship.

**Disclaimer of Interests:** Vibeke Strand Consultant of: Abbvie, Amgen, Arena, AstraZeneca, Bayer, BMS, Bohringer, Ingehelm, Chemocentryx, Celtrion, Galapagos, Genentech/Roche, Gilead, GSX, Horizon, Inmedix, Janssen, Kiniska, Lilly, Novartis, Pfizer, Regeneron, Rheos, R-Pharm, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Spherox, SUCB, Ernest Choy Consultant of: Abbvie, Amgen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, RPharm, Roche, Sanofi, and UCB.

**and UCB, Evgeny Nasonov Consultant of: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Tatiana Lisitsyna: None declared. Alexander Lilia Consultant of: Abbvie, Amgen, Bayer, Biotechnos, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, RPharm, Roche, Sanofi, Stada, Viatris and UCB, Sofia Kuzkina Employee of: R-Pharm, Mikhail Samsonov Employee of: R-Pharm, Eugen Feist Consultant of: Abbvie, Eli Lilly, Galapagos, Medac, Novartis, Sanofi, Sobi, R-Pharm, Grant/ research support from: Eli Lilly, Novartis, Pfizer.**

95% CI = 1.24-1.58), higher DAS28 (OR=1.21, 95% CI =1.15-1.26), HAQ (OR=1.46, 95% CI =1.33-1.61), pain (OR=1.104, 95% CI =1.012-1.077) and fatigue (OR=1.017, 95% CI =1.014-1.021). In the multivariable logistic regression model, female sex, younger age, higher HAQ, pain and fatigue at baseline were independent predictors of multiple treatment switching. Similar results were found for all three multi-switch definitions. Several comorbidities (i.e. heart failure, ischemic heart disease, malignancy, renal failure) were associated with a lower risk for multiple treatment switching, suggestive of medical contraindications for b/tsDMARDs.

**Conclusion:** In this large national observational cohort, multiple treatment switching, indicative of difficult to treat RA, was observed in a significant proportion of patients, ranging between around 2 to 7% during the first 5 years from time of diagnosis. Risk factors include female gender, younger age, higher HAQ, pain and fatigue at the time of RA diagnosis, suggesting increased attention to this challenging group of patients.

**Disclosure of Interests:** Emma Bjerreson Wittersen: None declared, Daniela Di Giuseppe: None declared, Johan Asking Grant/research support from: Karolinska Institutet has entered into agreements between Karolinska Institutet (as principal investigator) with Abbvie, BMS, MSD, Eli Lilly, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB, mainly regarding safety monitoring of anti-rheumatic therapies., Katerina Chatzidionysiou Consultant of: consultancy fees from Eli Lilly, AbbVie and Pfizer.


---

**Table 1. Baseline variables associated with GP1111 withdrawal (RA shown below, similar findings for PsA and AxSpA)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate</th>
<th>Age- and gender adjusted</th>
<th>Multivariate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p-value</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>RA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female gender</td>
<td>0.9 (0.6-1.3)</td>
<td>0.4</td>
<td>-</td>
</tr>
<tr>
<td>Age, years</td>
<td>1.0 (0.9-1.0)</td>
<td>0.9</td>
<td>-</td>
</tr>
<tr>
<td>Baseline VAS, mm</td>
<td>1.0 (1.0-1.1)</td>
<td></td>
<td>1.0 (1.0-1.1)</td>
</tr>
</tbody>
</table>

The risk of GP1111 withdrawal was lower in originator-naïve patients in patients with RA and PsA: HR 0.4 (95% CI 0.2-0.9), p-value 0.01) and HR 0.1 (0.1-0.6, p=0.01), but not significantly for AxSpA 0.56 (0.27-1.13, p=0.1). Across all indications, lower disease activity at baseline (DAS28/ASDAS remission) was associated with higher retention (Table 1).

**Conclusion:** Biosimilar-to-biosimilar infliximab switch was effective and well-tolerated in >1,500 real-world patients. Retention was higher in originator-experienced switchers and patients, who were in remission at the time of the switch, suggesting retention to be more affected by patient-related than drug-related factors.

**REFERENCES:**


**Acknowledgements:** We thank departments reporting to the DANBIO registry.

**Disclosure of Interests:** Hafsa Nabi Grant/research support from: Research grant from Sandzol, who had no influence on the analysis, interpretation and presentation of data., Merete L. Hettand Speakers bureau: Biogen, Celtrion, Janssen Biologics B.V, MSD, Pfizer, Samsung Bioepis, Consultant of: Biogen, Celtrion, Janssen Biologics B.V, MSD, Pfizer, Samsung Bioepis, Grant/research support from: AbbVie,
Adaptive immunity (T cells and B cells) in rheumatic diseases / Innate immunity in rheumatic diseases.

**OP0066** IMPACT OF DIAGNOSIS AND TREATMENT OF TROPHERYMA WHIPPLEI INFECTION IN PATIENTS WITH PRE-EXISTING CHRONIC INFLAMMATORY RHEUMATIC DISEASES: DATA FROM THE NATIONAL TW-IRD REGISTRY


1-Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, Toulouse, France; 2-Cochin Hospital, AP-HP, Paris, Ile de France; 3-Rare Autoimmune Systemic Diseases, Internal Medicine, Paris, France; 4-Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France; 5-Hospital center, Loire Vendée Ocean, Rheumatology, Les Sables-d'Olonne, France; 6-LÉBOCAGE Hospital, University Hospital of Dijon, Rheumatology, Dijon, France; 7-Jean Minjoz Hospital, University Hospital of Besançon, Rheumatology, Besançon, France; 8-Cochin Hospital, AP-HP, Paris, Rare Disease Reference Centre, Internal Medicine, Paris, France; 9-Hôpital Lariboisière, AP-HP, Paris, Rheumatology, Paris, France; 10-Hôpital University of Saint-Etienne, Rheumatology, Saint-Etienne, France; 11-University Hospital of poitiers, Rheumatology, Poitiers, France; 12-University Hospital of Clermont Ferrand, Rheumatology, Clermont Ferrand, France; 13-Bichat - Claude-Bernard Hospital, AP-HP, Paris, Rheumatology, Paris, France; 14-University Hospital of Montpellier, Rheumatology, Montpellier, France; 15-Louis-Mourier Hospital, AP-HP, Colombes, Rheumatology, Colombes, France; 16-Lanobiloière Hospital, AP-HP, Paris, Rheumatology, France; 17-University Hospital of Pau, Rheumatology, Pau, France; 18-Pierre-Bénite Hospital, University Hospital Lyon, Rheumatology, Lyon, France; 19-University Hospital of Rouen, Rheumatology, Rouen, France; 20-Purpan Hospital, Federal Institute of Biology (IFB), University Hospital, Toulouse, Biology, Toulouse, France; 21-Hautepierre Hospital, University Hospital of Strasbourg, Rheumatology, Strasbourg, France; 22-Pierre-Paul Riquet University Hospital, Toulouse & Toulouse III University - Paul Sabatier, Rheumatology, France

**Background:** Tropheryma whippelii (Tw) infection is a rare condition, characterized by inflammmatory joint symptoms in more than 75% of the cases, which can lead the physician to diagnose chronic inflammatory rheumatic diseases (IRD) and to initiate DMARDs. DMARDs are often ineffective and may reveal digestive symptoms that treatment of Tw infection has a favorable impact on rheumatologic and extra-rheumatologic manifestations attributed to IRD.

**Objectives:** To validate this hypothesis, we initiated a registry with the objectives to (1) record all the cases of IRD and associated DMARDs in two dynamic risk periods: the period from the index date until first filling of antidepressants (if it occurred) and the period after filling of antidepressants. We used the first filling of antidepressants as proxy for depression reported in the scientific literature. (2) In patients with stroke, depression defined as filling of antidepressants or a diagnosis with associated increased mortality risk and the risk is similar for both definitions of depression. (3) Objectives: We used the first filling of antidepressants as proxy for depression with the objective to describe the mortality risk associated with depression in patients with incident RA.

**Methods:** We included patients diagnosed with incident RA (index date) from the nationwide DANBIO register (4) from January 1, 2008 to September 30, 2016. Participants were identified by unique personal registration numbers. Included patients were without a recorded filling of methotrexate (Anatomical Therapeutic Chemical code L01BA01) and antidepressants (N06A) in the Danish National Prescription Register or recorded hospital contacts with RA and depression (International Classification of Diseases (version 10) codes M05, M06, F32) in the Danish National Patient Register, three years prior to the index date. From the index date, we defined depression as first filling of antidepressants and collected death dates from the Danish Civil Registration System. The participants were followed until December 31, 2016. We calculated and compared the hazard rate ratios (HRR) by modelling filling of antidepressants.

**Results:** We included 11,071 RA patients followed for median 59 years, and 1,095 (10%) filled prescriptions for antidepressants. The median age at diagnosis was 61 years, 66% were female, and 64% diagnosed with seropositive RA. Adjusted HRR was highest in the age group <55 years but also increased between 55-70 years, 70-75 years, among females and males, and in patients diagnosed with seropositive and seronegative RA (Table 1). The cumulative mortality is seen in Figure 1.

**References:**
3. Acknowledgements: Clab Rhumatismes In Et Inflammations.
4. Disclosure of Interests: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1248
Table 1.

<table>
<thead>
<tr>
<th>Strata</th>
<th>HRR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>4.10 (2.01-8.40)</td>
</tr>
<tr>
<td>55-70</td>
<td>3.17 (2.37-4.28)</td>
</tr>
<tr>
<td>&gt;70</td>
<td>4.15 (2.71-6.32)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4.85 (3.63-6.43)</td>
</tr>
<tr>
<td>Female</td>
<td>4.88 (3.35-7.35)</td>
</tr>
<tr>
<td>RA diagnosis</td>
<td></td>
</tr>
<tr>
<td>Seropositive (M05)</td>
<td>3.73 (2.99-4.65)</td>
</tr>
<tr>
<td>Seronegative (M06)</td>
<td>2.85 (2.07-3.91)</td>
</tr>
</tbody>
</table>

Figure 1.

Conclusion: Depression, defined as first filling of antidepressants, was associated with more than six-fold increased mortality risk in patients with incident RA.

REFERENCES:


Acknowledgements: The study was supported by the Danish Rheumatism Association.

Disclosure of Interests: None declared.


DISTINCT STROMAL AND IMMUNE CELL INTERACTIONS SHAPE THE PATHOGENESIS OF RHEUMATOID AND PSORIATIC ARTHRITIS

A. Floudas1, C. Smith2, O. Tynan1, N. Neto3, V. Krishna4, S. Wade1, M. Hanlon1, C. Cunningham1, V. Marzaol1, M. Canavan1, J. Fletcher2, S. Cole4, L.Y. Hao4, S. Nagpal1, M. Monaghan1, D. Veale1, U. Fearon1, 1 Trinity Biomedical Sciences Institute, Molecular Rheumatology, Dublin, Ireland; 2 Trinity Biomedical Sciences Institute, Translational Immunology, Dublin, Ireland; 3 Trinity Centre for Biomedical Engineering, Mechanical and Manufacturing Engineering, DUBLIN, Ireland; 4 Janssen Research & Development, Immunology, Philadelphia, United States of America; 5 UELAR Centre of Excellence, Centre for Arthritis and Rheumatic Diseases, Dublin, Ireland

Background: Rheumatoid (RA) and psoriatic arthritis (PsA) are common autoimmune and autoinflammatory diseases of unknown aetiology characterised by complex synovial pathology with a detrimental effect on the patient’s quality of life. Significant differences in pathophysiology may explain distinct clinical manifestations and account for differential responses to specific therapeutics. Recent implementation of single cell transcriptomic analysis of sorted synovial cells has revealed the diverse cellular landscape of the RA synovial stromal and immune cell compartments, however, a complete analysis of immune and stromal cells in tandem, for RA and PsA patient synovial tissue has not been performed.

Objectives: To combine novel scRNA transcriptomic approaches and ex vivo assays in order to: identify differences in the cellular landscape of RA and PsA synovial tissue inflammation and immune—stromal cell interactions that drive pathology in RA and PsA.

Methods: Single cell transcriptomic profiling of 178,000 synovial tissue cells from 5 PsA and 4 RA patients, importantly, without prior sorting of immune and stromal cells. This approach enabled the generation of a unique cell atlas of intact synovial tissue identifying immune and stromal cell interactions. State of the art data integration and annotation techniques identified and characterised 18 stromal and 14 immune cell clusters. Bioinformatic examination of cell-cell communication via construction of receptor-ligand interaction networks with further in vitro validation of stromal and immune crosstalk through flow cytometric analysis, multiplex ELISA and mitochondrial single cell metabolic profiling by multiphoton and florescent lifetime imaging microscopy, seahorse.

Results: Following quality control and data integration the PsA and RA cellular landscape was generated and nine mega clusters indicative of fibroblasts, endothelial cells, pericytes, macrophages, dendritic cells (DC), B cells, plasma cells, T cells and NKT consisting of several sub clusters were identified. Distinct points of transcriptomic deviation and convergence between RA and PsA were identified for each of the major cell types of the joint. Specifically, cell cycle and trajectory analysis revealed that only a fraction of synovial T cells are actively proliferating. Additionally, the differential usage of immunoglobulin light chains by memory and plasma cells indicates that plasma cells are potentially not derived from the local memory B cell pool of the synovial tissue. Importantly, we report distinct fibroblast and endothelial cell transcriptomes indicating differentially abundant subpopulations in RA and PsA characterised by distinct transcription factor usage and signalling pathway enrichment. Specifically transcriptomic imputation analysis revealed abundance of invasive FAP+THY1+ regulated by transcription factor TEAD1 in RA compared to PsA synovial tissue. In order to identify potential cell-cell communication driving inflammation in RA and PsA, novel receptor-ligand interaction networks were generated and downstream of the receptor, target characterisation was performed. Herein we identify RA-specific synovial T cell-derived TGF-β1 and macrophage IL-1β synergy in driving the transcriptional profile of FAP+THY1+ invasive synovial-fibroblasts, expanded in RA compared to PsA synovial tissue biopsies (Figure 1). Ex vivo treatment of RA patient synovial fibroblasts identified TGF-β and IL-1β synergy as a major driver of IL-6 production, fibroblast activation and adhesion molecule expression. Interestingly, the aforementioned proinflammatory changes of RA patient synovial fibroblasts were coupled with significant alterations in mitochondrial eccentricity and size and a marked metabolic adaptation towards a strongly glycolytic profile (Figure 1).

Figure 1.

Figure 1. Immunostromal cell crosstalk as a driver of synovial inflammation. A. Abundance of fibroblast clusters in RA and PsA patient synovial biopsies. B. Expansion and percentage of positive cells per fibroblast cluster for FAP and TGF-β. C. Scatterplots showing the relation between THY1 and FAP expressing cells before and after their isolation for RA and PsA fibroblast cluster 1 and 3 (PsA/RA ratio). FAP and THY1 fibroblasts with significantly different abundences between RA and PsA are indicated by green (higher in RA) and blue (higher in PsA) boxes. D. Frequency of fibroblasts clusters in PsA and RA patient synovial biopsies (top left). E. Clusters are summed in the and outliers only (more than 3 SD), symbols represent individual samples. F. Csa. Correlation depicting the top shared and downstream target interaction for enriched in PsA synovial fibroblast cluster 1 and RA fibroblast cluster 3. G. Representative images of the patient synovial fibroblasts' mitochondrial and metabolic analysis. H. Simultaneous fibroblast activity and protein synthesis within isolated fibroblasts of RA and PsA patients (Modified from the Journal of Cell Science).
Conclusion: Disrupting specific immune and stromal cell interactions offers novel opportunities for targeted therapeutic intervention in RA and PsA.

Disclosure of Interests: Achilleas Floudas: None declared, Conor Smith: None declared, Orla Tynan: None declared, Nuno Neto: None declared, Vinod Krishna Employee of: Janssen Pharmaceuticals, Sarah Wade: None declared, Megan Hanlon: None declared, Clare Cunningham: None declared, Viviana Marzaioli: None declared, Mary Canavan: None declared, Jean Fletcher: None declared, Suzanne Cole Employee of: Janssen Pharmaceuticals, Ling-Yao Hsu Employee of: Janssen Pharmaceuticals, Sunil Nagpal Employee of: Janssen Pharmaceuticals, GSK, Michael Monaghan: None declared, Douglas Veale Consultant of: Janssen, Eli Lilly, Pfizer, Ursula Fearon Consultant of: Janssen, Eli Lilly, Pfizer.

DOI: 10.1136/annrheumdis-2022-eular.1811

INCLUSION OF PATIENT RESEARCH PARTNERS IN REMEDY – A RESEARCH CENTER FOR TREATMENT OF RHEUMATIC AND MUSCULOSKELETAL DISEASES

M. Skare1, A. T. Tvedt,2, H. A. Zangi1, S. Lillegraven1, E. Haavardsholm1, I. Leichting2, A. Fryxelius3, I. Kjeken4, Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway;5The Norwegian Rheumatism Association, The Norwegian Rheumatism Association, Oslo, Norway

Background: Active collaboration between patients and researchers in development and implementation of scientific projects is important to ensure a good match between patient’s preferences and the scientific focus in research, contribute to more patient-oriented health research agendas, enhance patient friendly design of research projects, and creating support for implementation (1). Such involvement is strongly advocated by EULAR and is often a prerequisite to receive funding for clinical research projects. At Diakonhjemmet Hospital in Norway, the division of rheumatology and research has for many years worked to involve patient research partners (PRPs) in research. A patient advisory board was established in 2007, led by a person (20% position) who herself has a rheumatic disease. In eight years from 2022, the division will receive funding from the Norwegian Research Council to establish and host a clinical research center for treatment of Rheumatic and Musculoskeletal diseases – the REMEDY center.

Objectives: To describe how involvement of PRPs are organised within the REMEDY center.

Methods: An organisation map was developed as part of the application for funding. The leader of the patient advisory board, together with three senior researchers, were involved in several rounds of discussions on how PRP involvement should be organised in the center, and also in meetings with the larger research group.

Results: The organisation of REMEDY is shown in Figure 1.

Figure 1. Organisation of REMEDY.

1.All partners, including The Norwegian Rheumatism Association, (the largest patient organisation in the field), are represented at the Center Board. This ensures patient involvement at the strategic level, including setting research agendas and priorities.
2.The Center is led by a centre director and two co-directors, of which one has a specific responsibility of PRP-involvement.
3.The Centre Executive Committee (CEC) consist of the Center Director and co-directors, the WP leaders, the leader of the patient advisory board, the key senior scientific staff members of the partner institutions involved in the center and senior staff members deemed appropriate by the Centre Director.
4.The patient advisory board, consisting of 10-15 PRPs, is central within the center. Members of the board will be involved in all research projects, collaborating with researchers to improve design, methodology, research outcomes and implementation. The board provides a platform for the members for education, development, and exchange of knowledge and experience.
5.There are seven work packages (WPs) in REMEDY, each approaching the knowledge needs within rheumatic and musculoskeletal diseases (RMDs) treatment from different angles, and with international collaborators. WP7 (Empowerment of the individual) will provide a platform for the Patient advisory board, facilitating input from PRPs to all WPs. The chair of the EULAR study group for collaborative research is an international collaborator in WP7.

The leader of the Patient Advisory board has a 50% position. Additionally, there is funding for board activities, and for PRP involvement in initial project phases, whereas PRP activities are included in applications for external funding.

Conclusion: The REMEDY center is organised to ensure involvement of PRPs at all organisational levels, from individual research trials to the strategic and operational management of the center.

REFERENCES:

Disclosure of Interests: None declared.


INTERVENTION WITH METHOTREXATE IN ARTHRALGIA AT RISK FOR RHEUMATOID ARTHRITIS TO REDUCE THE DEVELOPMENT OF PERSISTENT ARTHRITIS AND ITS DISEASE BURDEN (TREAT EARLIER): A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL

D. Kribbeker,1, M. Verstappen2, B. van Dijik3, Y. Daakik4, L. Burgen5, A. Boer5, Y. Jung Park5, M. De Wit6, K. Visser6, M. R. Koek6, E. Molenaar7, P. de Jong8, S. Böhringer8, T. Huizinga9, C. Allaart1, E. Niemantsverdriet1, A. van der Helm-Vl5, Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; Reinier de Graaf Gasthuis, Rheumatology, Delft, Netherlands; Yagia Hospital (Leyweg), Rheumatology, Den Haag, Netherlands; Maasstad Hospital, Rheumatology, Rotterdam, Netherlands; Groene Hart Hospital, Rheumatology, Gouda, Netherlands; Erasmus MC, Rheumatology, Rotterdam, Netherlands; Leiden University Medical Center (LUMC), Biomedical Data Sciences, Leiden, Netherlands

Background: Rheumatoid arthritis (RA) is the most common autoimmune disease, and requires long-term treatment to suppress inflammation. Currently, methotrexate is initiated as first-line treatment when arthritis becomes clinically apparent with joint swelling. However, disease processes begin long before and become clinically recognizable when patients develop symptoms. We hypothesized that the ‘at risk phase’ of symptoms and subclinical joint-inflammation is a therapeutic window to permanently modify the disease course.

Objectives: We studied if intervention in the pre-arthritis phase of arthralgia and subclinical joint inflammation prevents the development of clinical arthritis or reduces the burden of disease.

Methods: In this randomised, double-blind, 2-year proof-of-concept trial, adults with arthritis clinically suspected of progressing to RA and MRI-detected subclinical joint-inflammation, recruited from all rheumatology outpatient-clinics in the south-west Netherlands, were randomly assigned (1:1) to a single intramuscular glucocorticoid injection (120 mg) and a one-year course of oral methotrexate (up to 25 mg/week), or placebo injection and placebo tablets. Subsequently, participants were followed for another year without study medication. The primary endpoint was the development of clinically detectable arthritis (fulfilling the 2010 RA-criteria or involving ≥2 joints) that persisted for at least 2 weeks. Patient reported physical functioning, along with symptoms and workability, were key secondary endpoints and measured 4-monthly. Additionally, the course of MRI-detected inflammation was studied (the sum of tenosynovitis, synovitis, osteitis, scored with the RA-MRI Scoring (RAMRIS) method). All participants entered the intention-to-treat analysis. We performed two prespecified subgroup analyses. Firstly, analyses were restricted in participants with high risk of clinical arthritis development (PPV >70%). Secondly, analyses were stratified for ACPA-status. The trial is registered with the Netherlands Trials Registry (NTR4853 trial NL4999).

Results: From April 16th, 2015 to September 11th, 2019, we randomly assigned 236 participants to treatment (n=119) or placebo (n=117). After 24 months, arthritis free survival was similar in both groups (80% versus 82%, HR 0.81 (95%CI 0.45-1.46)). Physical functioning improved more in the treatment-group during the first months and remained better (mean between-group difference over two years HAQ -0.1(-0.2,-0.03;p=0.004). Similarly, pain (-9 on scale 0-100: (95%CI -1.48)). Physical functioning improved more in the treatment-group during another year without study medication. The primary endpoint was the development of clinically detectable arthritis (fulfilling the 2010 RA-criteria or involving ≥2 joints) that persisted for at least 2 weeks. Patient reported physical functioning, along with symptoms and workability, were key secondary endpoints and measured 4-monthly. Additionally, the course of MRI-detected inflammation was studied (the sum of tenosynovitis, synovitis, osteitis, scored with the RA-MRI Scoring (RAMRIS) method). All participants entered the intention-to-treat analysis. We performed two prespecified subgroup analyses. Firstly, analyses were restricted in participants with high risk of clinical arthritis development (PPV >70%). Secondly, analyses were stratified for ACPA-status. The trial is registered with the Netherlands Trials Registry (NTR4853 trial NL4999).
Conclusion: Methotrexate, the cornerstone treatment of RA, initiated at the pre-arthritis stage of joint symptoms and subclinical inflammation, did not prevent the development of clinical arthritis, but modified the disease course as measured by sustained improvement in MRI-detected inflammation, related symptoms and impairments. These findings of sustained disease modification may open up a new treatment landscape in a pre-arthritis phase of RA, where limitations can be just as severe as at the onset of clinical arthritis.

Acknowledgements: We thank Prof. dr. R. ten Cate, prof. dr. S. le Cessie and dr. A.M.J. Langers for their role in the Data Safety and Monitoring Board. We thank all participants, and all rheumatologist of the following hospitals: Albert Schweitzer Hospital, Alrijne Hospital, Erasmus Medical Center, Haven-policlinic Rotterdam, IJsseland Hospital, Iazia Hospital, Franciscus Gasthuis & Vlietland Hospital, Groene Hart Hospital, Haaglanden Medical Center (all locations), Haga Hospital, Langeland Hospital, Meander Medical Center, Maasstad, Hospital, Reinier de Graaf Gasthuis, Reumazorg Zuid-West Nederland and Spaarne Gasthuis. We acknowledge the team of treating rheumatologists and research nurses of the LUMC, in particular Dr F. J. van der Giesen. Our gratitude also goes to the PhD students who scored MRIs for trial screening, in particular Dr. H. W. van Steenbergen, Dr. R. M. ten Brink, Dr. D. M. Boeters, Dr. L. M. Mangrus, X.M.E. Matthijsen and F. Wouters. We thank Dr. M. Reijnierse, prof. dr. S. C. Cannegieter and prof. Dr. D. van der Heijde for their advice, and Dr. J. Schoones for his help with the systematic literature search. We acknowledge the funder of the study: NWO ZonMW grant (project number 95104004).

Disclosure of Interests: None declared.


OP0071 ASSOCIATION BETWEEN LONG-TERM EXPOSURE TO AIR POLLUTION AND IMMUNE-MEDIATED DISEASES: A POPULATION-BASED COHORT STUDY

G. Adami1, M. Pontalti1, C. Benini1, A. Fassio2, E. Bertoldo1, D. Gatti1, M. Rossini1,1. University of Verona, Rheumatology Unit, Verona, Italy

Background: Environmental air pollution has been associated with disruption of the immune system at a molecular level.

Objectives: The primary aim of the present study is to describe the association between long-term exposure to air pollution and risk of developing immune-mediated conditions.

Methods: We conducted a retrospective observational study on a nation-wide dataset of women and men. Diagnoses of various immune-mediated diseases were retrieved. Data on the monitoring of PM10 and PM2.5 concentrations were retrieved from the Italian institute of environment protection and research (ISPRA). The long-term average PMs concentrations were the exposure of interest. Every study subject was linked to a PMs exposure value, which resulted from the average concentration of urban, rural and near-traffic stations of the subject residency from January 2013 to November 2020. Patients were linked to the nearest air quality station through ZIP code centroids. Generalized linear models were employed to determine the relationship between autoimmune diseases prevalence and PM. The fully adjusted model included age, body mass index (BMI), menopause, glucocorticoid treatment, treatment with adjuvant hormone therapy for breast or prostate cancer, specialty of the physician that entered the data and macro-area of residency (stratified as a categorical variable: northern Italy, central Italy and southern Italy.

Results: 81,363 subjects were included in the study. We found a positive association between PM10 and the risk of autoimmune diseases (β +0.007, p 0.014). Every 10 µg/m3 increase in PM10 concentration was associated with an incremental 7% risk of having autoimmune disease. Exposure to PM10 above 30 µg/m3 and PM2.5 above 20 µg/m3 was associated with a 12% and 13% higher risk of autoimmune disease pooled together, respectively (aOR 1.12, 95% CI 1.05-1.20 and aOR 1.13, 95% CI 1.06-1.20). Exposure to PM10 was associated with an increased risk of rheumatoid arthritis (aOR 1.408, 95% CI 1.271-1.560) but no other autoimmune diseases, whereas exposure to high levels of PM2.5 were associated with an increased risk of rheumatoid arthritis (aOR 1.559, 95% CI 1.401-1.734), CTDs (aOR 1.147, 95% CI 1.024-1.286) and IBDs (1.206, 95% CI 1.028-1.415) but no other autoimmune diseases.

Conclusion: Long-term exposure to air pollution was associated with higher risk of developing autoimmune diseases, in particular rheumatoid arthritis, CTDs and IBD. Chronic exposure to levels above the threshold for human protection was associated with a 10% higher risk of developing immune-mediated diseases.
declared, Maurizio Rossini Shareholder of: Abbvie, Amgen, Bms, Eli Lilly, Galapagos, Novartis, Pfizer, Sandoz, Theramex, Ucb.


**OP0072**

SMILE-RA - SELF-MANAGEMENT INDIVIDUALISED LEARNING ENVIRONMENT IN RHEUMATOID ARTHRITIS

A. Bowsworth1. National Rheumatoid Arthritis Society, Patient Services, Maidenhead, United Kingdom

**Background:** An important but insufficient aspect of care in people with inflammatory arthritis (IA) is empowering them to acquire good understanding of their disease and build ability to deal effectively with the practical, physical and psychological impacts of it. This extends beyond drug therapy and emphasizes the ability to self-manage, with the right support, as an essential component of care. Good self-efficacy and coping skills reduce health and financial burden to the individual as well as the health service, benefiting society overall. Provision of excellent supported self-management education is at the heart of what NRAS does and it was due to the difficulty of getting Commissioners to fund our face-to-face group self-management that led to our building an e-learning programme to expand on and replace our 6-week programme.

**Objectives:** To co-create an intuitive, easy to use, modular e-learning programme, free for all and which health professionals (HCPs) could refer their patients to. This makes supported self-management and evidence-based education accessible to all, wherever they live. SMILE enables HCPs to meet both NICE guideline and quality standards in RA against which rheumatology units in England and Wales are currently audited, as well as EULAR Recommendations for self-management strategies in inflammatory arthritis.

**Methods:** In 2019 with initial funding in place, we worked with our provider to help us realise our goal of developing a state-of-the-art e-learning experience in a modular format for people with RA. The programme had to be 1) simple to use; 2) interactive; 3) innovative and engaging; 4) able to measure impact through achievement of learning objectives and use of a validated patient reported outcome measure. The programme also had to be integrable with our Salesforce database enabling us to collect data and target resources to individuals, driven by identified need.

**Results:** Delayed by COVID, we launched with 4 modules on 17/09/2021. The 4 modules comprise: Foundation Module covering the importance of self-management which has the RA Impact of Disease PROM embedded; Newly Diagnosed; Meet the Team and Managing Pain and Flares. A fifth module on Medications in RA will be launched 1st quarter 2022 and 4 further modules will be uploaded in 2022. To date (26/01/22), 760 people have registered, of which 313 have completed a baseline RAID and this reveals that <50% are achieving minimal acceptable state of 3 or less. Over 78% of registrants are not NRAS members, and 634 modules have been completed. Early indications are that almost all are achieving learning objectives. More data will be available by June 2022.

**Conclusion:** Early indications demonstrate that people are successfully engaging with the programme and we have marketing activity lined up to raise further awareness of the value of SMILE with both potential users and rheumatology teams in 2022. Massive workforce issues together with significant backlogs of existing patients caused by the pandemic, have restricted the ability of Teams to provide education and self-management support for their patients. SMILE offers high quality, evidence-based learning opportunities for their patients and has been co-created with health professionals and people with RA at every step. With remote consultations here to stay, the importance of patients having access to evidence based online learning which they can tailor to their specific needs and improve their self-efficacy is even more critical.

**Disclosure of Interests:** provided input to SMILE.

**REFERENCES:**


**Disclosure of Interests:** Svetlana Tugce Ulus: None declared, Fabian Proft Speakers bureau: Novartis, Lilly and UCB, as well as personal fees from AbbVie, Amgen, BMS, Hexal, Janssen, MSD, Pfizer and Roche, Grant/research support from: Novartis, Eli Lilly and UCB., Torsten Diekhoff Speakers bureau: MSD, Novartis and Eli Lilly., Valeria Rios Rodriguez Speakers bureau: AbbVie and Falk e.V., Judith Rademacher Grant/research support from: Berlin Institute of Health (BiH) during the conduct of this study (Clinician Scientist Programme), Mikhail Protopopov Grant/research support from: UCB, Sarah Ohrndorf: None declared, Denis Poddubnyy Speakers bureau: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, Bristol-Myers Squibb, Roche, UCB, Biocad, GlaxoSmithKline and Gilead, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis and Pfizer., Katharina Ziegeler Grant/research support from: Assessment of Spondyloarthritis International Society (ASAS) during the conduct of this study. DOI: 10.1136/annrheumdis-2022-eular.1794

Rheumatoid arthritis - aetiology, pathogenesis and animal models

**OP0074**

DISTINCT CIRCULATING LYMPHOCYTE SUBSETS DISTINGUISH FLARE FROM DRUG-FREE REMISSION IN RHEUMATOID ARTHRITIS

K. F. Baker1,2, F. Rayner1, H. Lemos3, D. McDonald1, G. Hulme1, R. Hussain1, J. Coxhead1, A. Pratt1,2, A. E. Anderson1, A. Fibby1, J. Isaacs1,2, Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom; 2Newcastle upon Tyne Hospitals NHS Foundation Trust, Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, United Kingdom; 3Newcastle University, Flow Cytometry Core Facility, Newcastle upon Tyne, United Kingdom; 4Newcastle University, Genomics Core Facility, Newcastle upon Tyne, United Kingdom

**Background:** Gender-specific differences in patients with axial spondyloarthritis (axSpA) are often seen in the clinical presentation and may differ in MRI findings. Male axSpA patients tend to show structural changes earlier, whereas in female axSpA patients the peripheral joints are more often affected. This can lead to a delay in axSpA diagnosis in women. For this reason, gender-specific data collection and establishment of gender-specific imaging criteria are of particular importance.

**Objectives:** To evaluate the diagnostic performance of different combinations of imaging markers to derive data-driven imaging criteria for MRI in axSpA, separately for men and women.

**Methods:** A total of 1194 patients were included in the study. Considering the exclusion criteria (available MRI image data sets, confirmed diagnoses), 684 patients (379 axSpA and 305 control group) were included for further statistical analysis. Two trained readers scored the MRI images separately for the presence of ankylosis, as well as erosion, sclerosis, fat metaplasia, and bone marrow edema differentiated for 3 regions: ventral/mid/dorsal for sacral-sided and iliac-sided sacroiliac joint. Chi² test was applied to compare lesion frequencies per group. Contingency table analysis was performed to assess diagnostic performances. The diagnostic performances were compared using the diagnostic odd ratio (DOR).

**Results:** Overall, 136 female and 243 male axSpA patients were included. Higher prevalence for ankylosis (24.3% vs. 74%) and fat metaplasia (58.8% vs. 42.6%) was shown in male axSpA patients; in contrast, sclerosis was more common in female axSpA patients (75.0% vs. 57.6%). No sex differences in frequency were shown for bone marrow edema and erosion. In male axSpA patients, the most significant difference in individual parameters was shown for ankylosis (DOR 40.1) compared with females (DOR 4.7). The detection of erosion and fat metaplasia as markers was also better in male axSpA patients (DOR 17.6 vs. 11.1 and 18.6 vs. 6.3). Sclerosis and bone marrow edema were better suited in female axSpA patients (DOR 3.0 vs. 2.5 and 5.0 vs. 3.7). Overall, diagnostic accuracy was improved when only lesions in the middle and dorsal articular compartments were considered.

**Conclusion:** The diagnostic performance of established image markers on MRI is significantly lower in female axSpA patients. This is especially true for ankylosis, which provides the risk for false-positive findings in women. Based on these findings, future revisions of imaging criteria may include gender-specific recommendations to improve diagnostic accuracy for male and female axSpA patients.

**REFERENCES:**


Background: Rheumatoid arthritis (RA) is characterised by relapsing joint and systemic inflammation, yet the immunopathological basis of these disease flares and their clinical prediction remain uncertain.

Objectives: Using mass cytometry and single cell RNA sequencing, we aimed to identify circulating lymphocyte subsets associated with RA flare, and identify potential cellular biomarkers to predict flare versus drug-free remission (DFR).

Methods: We analysed peripheral blood mononuclear cells (PBMCs) from patients recruited to the BioRRA study (Figure 1), a prospective clinical trial of conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) cessation.[1] Patients with RA in clinical (DAS28-CRP < 2.4) and ultrasound (absence of power Doppler signal in 7 joints) remission stopped csDMARDs, with flare defined as DAS28-CRP ≥ 2.4 during 6 month follow-up. A 44-marker mass cytometry panel was used to profile PBMCs from 36 patients (20 flare, 16 DFR) at two time points each (baseline, and flare onset / month 6 DFR). In a subset of patients (n = 12: 8 flare, 4 DFR), fluorescence-activated cell sorting of PBMCs was followed by single cell sequencing (n = 81,923 cells) incorporating 320 immune genes, 34 oligo-tagged surface protein antibodies, and TCR/BCR CDR3 sequence clones. Cells were defined as ≥2 cells with identical CDR3 nucleotide sequence, and clonal expansion as a significant increase in proportion from baseline to final study visit. Statistical significance was assessed after Benjamini-Hochberg multiple test correction (adj p < 0.05).

Results: Mass cytometry revealed 31 distinct cell clusters: notably, greater proportions of memory (CD45RO+PD1hi) CD4+ and CD8+ T cells, and memory (CD27hiCD21-) B cells, were observed at onset of flare versus baseline (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Mass cytometry (n = 20 flare + 16 DFR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contrast</strong></td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Flare onset vs baseline:</td>
</tr>
<tr>
<td>Flare patients</td>
</tr>
<tr>
<td>CD19+/CD27+/CD21+ memory B cells</td>
</tr>
<tr>
<td>Single cell RNAseq (n = 8 flare + 4 DFR)</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>Flare onset vs baseline:</td>
</tr>
<tr>
<td>Flare patients</td>
</tr>
<tr>
<td>Baseline</td>
</tr>
</tbody>
</table>

To better characterise these flare-associated subsets, single cell sequencing of CD45RO+PD1hi CD4+ and CD8+ T cells, and CD19+ B cells, was performed and identified 21 distinct clusters. CDR3 sequencing revealed significant clonal expansion (Fisher exact, adj. p < 0.05) at flare onset within five unique CD8+ clones (4 patients), one CD4+ clone (1 patent), and no B clones. Overall, there was a significantly greater proportion of IgA+ plasma cells at flare onset versus baseline. In contrast, a significantly lower proportion of CD25+/Foxp3+ regulatory T cells were present at csDMARD cessation (baseline) in subsequent flare versus DFR patients (Table 1), suggesting biomarker potential.

To further assess the predictive performance of CD4+ Tregs as a biomarker for flare versus DFR, we analysed PBMCs from an independent cohort of 50 patients (25 flare, 25 DFR) stopping csDMARDs in the ongoing BIO-FLARE study.[2] By flow cytometry, we confirmed a lower proportion of CD4+/CD25hi Tregs at baseline in flare vs DFR (median 4.74 versus 6.37%, Wilcoxon p = 0.037; AUC: 0.67). In this cohort, stopping csDMARDs only in patients with elevated (> 6.11% total CD4) baseline Tregs would have prevented drug cessation in 18/25 (72%) of flare patients; 9/25 (36%) of DFR patients would have continued csDMARDs unnecessarily.

Conclusion: We present a detailed longitudinal characterisation of circulating lymphocyte surface phenotype, gene expression, and clonal expansion in RA flare vs DFR. Furthermore our data, across two independent cohorts, suggests a role for CD4+ Tregs in promoting drug-free remission meriting further investigation, with potential for future clinical biomarker development.

REFERENCES:
[2] Rayner et al; BMC Rheumatology; 5:22

Acknowledgements: This work was funded by research grants from Wellcome Trust [102595/Z/13/A to KFB], Newcastle NIHR Biomedical Research Centre [HR316167/P00045 to KFB], British Society for Rheumatology [KFB], Academy of Medical Sciences [SOL022/1074 to KFB], Newcastle University Wellcome Trust Translational Partnership [KFB], Newcastle Hospitals Charity [8033 to KFB], and a National Institute for Health Research Clinical Lecture [CL-2017-01-004 to KFB]. Our work is supported by the Research into Inflammatory Arthritis Centre Versus Arthritis (RACE) (grant number 202298), and Rheuma Tolerance for Cure (European Union Innovative Medicines Initiative 2, grant number 777357). AJP and JD are named as inventors on a patent application by Newcastle University (Prediction of Drug-Free Remission in Rheumatoid Arthritis; International Patent Application Number PCT/GB2019/050902). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.

Disclosure of Interests: Kenneth F Baker Consultant of: Modern Biosciences Ltd; Grant/research support from: Pfizer; Genentech, Fiona Rayner: None declared, Henrique Lemos: None declared, David McDon-ald: None declared, Gillian Hulme: None declared, Raifqui Hussain: None declared, Jonathan Coxhead Speakers bureau: Tesaro, Arthur Pratt Grant/ research support from: Pfizer, Gilead, Amy E. Anderson: None declared, Andrew Filby Grant/research support from: Becton Dickinson, John Isaacs Speakers bureau: Abbott, Gilead, Roche, UCB, Grant/research support from: GSK, Janssen, Pfizer.

DOI: 10.1136/annrheumdis-2022-eular.1341

OP0075

FIBROBLAST/MACROPHAGE CROSSTALK VIA LACTATE: NEW THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS

V. Pucino1, M. Nefsa1, V. Gauthier2, S. A. Clayton3, A. Filer1, A. R. Clark1, K. Raza1, C. D. Buckley2. 1University of Birmingham, Inflammation and Ageing, Birmingham, United Kingdom; 2University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom

Background: The synovial membrane is the principal site of inflammation in rheumatoid arthritis (RA) and distinct subsets of fibroblasts and macrophages, with different effector functions, have been described within it [2]. Inflammation renders the RA synovial microenvironment hypoxic and acidic, with increased levels of lactate, the end product of glycolysis. Lactate acts as an immunomodulatory molecule within the synovium, interacting with lactate transporters present on fibroblasts and macrophages to regulate their function, movement and metabolism.

Objectives: To test whether dysfunctional crosstalk between fibroblasts and macrophages, driven by lactate, promotes the persistence of synovial inflammation.

Methods: Synovial tissues (n = 8) from patients fulfilling the 2010 ACR/EULAR RA criteria were obtained by ultrasound-guided synovial biopsy. Osteoarthritis (OA) synovial tissues of subjects undergoing joint replacement were used as control group. Monocarboxylate transporter 1 (MCT1) and MCT4 expression on fibroblasts and macrophages was assessed via confocal microscopy. We used RA synovial fibroblasts and monocyte-derived macrophages to test the effect of lactate in vitro. Migration was assessed in trans-well plates or via scratch test assays. Seahorse was used to evaluate metabolic pathways. IL6 production was measured by ELISA. Bioinformatic data were confirmed on publicly available scRNAseq datasets.

Results: We showed that: i) The expression of MCT1 and MCT4 which regulate lactate import and export respectively, is up-regulated upon inflammation. ii) Fibroblasts preferentially express MCT1, while MCT4 expression on macrophages is downregulated. iii) Lactate, at the concentration found in RA synovial fluid (10 mM), has divergent effects on the effector functions of these two cell types. In fibroblasts, lactate promotes IL6 production and cell motility; these effects are reduced by pre-treatment with a pan-lactate transporter inhibitor. In contrast macrophages respond to lactate by reducing migration, IL6 secretion and glycolysis.

Conclusion: The contrasting effects of lactate on macrophage and fibroblast migration, IL6 production and metabolism suggest that lactate represents a key
metabolite ensuring linked choreography between fibroblast and macrophage movement in the synovium which may become uncoupled in disease. We propose that dysfunctional crosstalk between these two cell types due to high lactate levels, promotes inflammation and the establishment of persistent disease in RA. Targeting lactate/MCT’s pathway may provide a novel therapeutic strategy, to restore cellular crosstalk and to reduce inflammation in RA patients.

**REFERENCES:**


**Disclosure of Interests:** Valentina Pucino: None declared, Meriam Nefa: None declared, Vincent Gauthier: None declared, Sally A Clayton: None declared, Andrew Filer Consultant of: Abbvie, Roche, Lilly, Janssen Mestag, Grant/research support from: Roche, UCB, Nascient, Mestag, GSK, Janssen, Andy R Clark: None declared, Christopher D Buckley Consultant of: GSK, Astra-Zenica, Roche, Pfizer, Lilly, Janssen Mestag, Grant/research support from: GSK, Roche, Pfizer, Janssen Mestag.

**DOI:** 10.1136/annrheumdis-2022-eular.2323

---

L-ARGININE REPROGRAMS OSTEOCLAST PURINE METABOLISM AMELIORATING BONE LOSS IN RHEUMATOID ARTHRITIS

S. Cao¹,², R. Song¹,², X. Meng¹, K. Kachler¹, M. Fuchs², X. Meng³, Y. Li², V. Taudte³, M. Kunz⁴, U. Schlotzer-Schrehardt⁵, U. Schleicher⁶, X. Chen⁷, G. Schett⁸, A. Bozec⁹.¹

**Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Internal Medicine**

3–Rheumatology and Immunology Erlangen, Germany; Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Department of Rheumatology, Shanghai, China; Friedrich-Alexander University of Erlangen-Nürnberg, Chair of Medical Informatics, Erlangen, Germany; Friedrich-Alexander University of Erlangen-Nürnberg, Institute of Experimental and Clinical Pharmacology and Toxicology, Erlangen, Germany; Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Department of Ophthalmology, Erlangen, Germany; Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Klinisches Institut – Klinische Mikrobiologie, Immunologie und Hygiene, Erlangen, Germany

**Background:** Bone erosion is a clinical feature of rheumatoid arthritis related to disease severity and poor functional prognosis. Excessive osteoclast differentiation and insufficient osteoblast function are the main reasons for the erosive process in RA. Our previous investigation indicated that L-arginine supplementation not only diminished arthritic inflammation in the serum-induced arthritis (K/BxN) model but also decreased inflammatory joints osteoclast numbers (1).

**Objectives:** In the present study, we aim to investigate the metabolic action of L-arginine supplementation in RA, especially on periarticular bone erosion and systemic bone loss. We plan to depict the metabolic features of TNFα induced inflammatory osteoclasts after in vitro L-arginine supplementation.

**Methods:** Three murine arthritis models (serum-induced arthritis (K/BxN) model, collagen-induced arthritis (K/BxN) model, and TNFα mice model) were analyzed in the study. L-arginine was supplemented within the drinking water after the arthritis induction. The parameters (porcine skeleton (spine) and peripheral skeleton (tibia)) from the respective group were quantified by µCT. HE and TRAP staining were performed to address further the erosion area and osteoclast numbers in periarticular sites. In vitro osteoclast differentiation was conducted with or without L-arginine treatment, in the presence or not of TNFα activation. Seahorse and SCENITH analyses were adopted to delineate the metabolic features.

**Results:** In the RNA-Seq data by immunohistochemistry showing the presence of DKK3+ sublining fibroblasts in refractory rather than responder patients.

**Conclusion:** These data strongly demonstrated that L-arginine ameliorates bone erosion in RA through metabolic reprogramming and perturbation of purine metabolism in osteoclasts. L-arginine might therefore benefit RA therapy by reducing joint inflammation and also ameliorating bone destruction.

**REFERENCES:**


**Disclosure of Interests:** Shan Cao: None declared, Rui Song: None declared, Xinyi Meng: None declared, Katerina Kachler: None declared, Maximilian Fuchs: None declared, Xinyu Meng: None declared, Yixuan Li: None declared, Verena Taude: None declared, Meik Kunz: None declared, Ursula Schlotzer-Schrehardt: None declared, Ulrike Schleicher: None declared, Xiaoxiang Chen Speakers bureau: AbbVie, Roche and Novartis, Georg Schett Speakers bureau: AbbVie, BMS, Celgene, Janssen, Eli Lilly, Novartis, Roche and UCB, Aline Bozec: None declared. **DOI:** 10.1136/annrheumdis-2022-eular.4338

---

SYNOVIAL RNA-SEQ ANALYSIS OF THE R4RA TRIAL IDENTIFIES SIGNATURES OF TREATMENT RESISTANCE AND REFRACTORY STATE IN RHEUMATOID ARTHRITIS

A. Surace¹,², E. Sciacca³,², K. Goldmann³,², F. Rivellese¹,², C. Cubuk¹,², G. Giorgi³,², L. Fossati-Jimack³, M. Ahmed³, E. Prediletto³, M. Bombardieri³, M. Lewis¹, C. Fitzalis³, on behalf of R4RA investigators. ¹Queen Mary University of London, Centre for Experimental Medicine and Rheumatology, London, United Kingdom; ²Queen Mary University of London, Centre for Translational Bioinformatics, London, United Kingdom

**Background:** Although up to 5-20% of rheumatoid arthritis (RA) patients do not respond to all current medications including biologic therapies, relatively little is known about the underlying pathogenic mechanisms driving non-response. In the first biopsy-driven randomized clinical trial in RA (R4RA)¹, patients, in whom synthetic-DMARDs and at least one anti-TNF drug were not effective, were randomised 1:1 to rituximab (RTX) or tocilizumab (TOC) with a balanced stratification based on their synovial B-cell rich/poor signature, and response was assessed at 16 weeks. Non-responders were subsequently allowed to switch to the alternative drug with 48-week follow-up.

**Objectives:** Investigate mechanisms of response and non-response to RTX and TOC through deep molecular (RNA-sequencing) profiling of synovial tissue.

**Methods:** RNA-Seq from baseline synovial tissue biopsies of patients who received RTX (n=88) or TOC (n=94) at any point in the trial was analysed for differentially expressed genes and associated modules between responders and non-responders. Response was defined as 50% improvement in clinical disease activity index (CDAI) score. Patients who had received both drugs during the trial were subdivided into RTX only responders (pro-RTX, n=9), TOC only responders (pro-TOC, n=12) and refractory patients (no response to both RTX & TOC, n=32) and analysed for differential gene expression and performed gene module analysis.

**Results:** 16825 genes were significantly differentially expressed between RTX responders compared to non-responders, with a predominance of antigen presentation as well as T- and B-cell genes being associated with response, while non-response was linked to fibroblast associated genes. Comparison between TOC responders and non-responders identified fewer (85) differentially expressed genes, however lymphocyte and immunoglobulin genes were also high in the synovial tissue of TOC responders similar to RTX responders, while non-responders genes and modules also included a fibroblast signature. The cross-over study design enabled comparison of rituximab-specific responders (pro-RTX), tocilizumab-specific responders (pro-TOC) and refractory patients (non-responders to both RTX & TOC, n=32) in a 3-way analysis (see Figure 1). This identified 1980 genes upregulated both in pro-RTX and pro-TOC patients, 175 genes exclusive to the pro-RTX group and 306 to the pro-TOC group, while 1277 genes were exclusive to the refractory group. While leukocyte modules and genes dominated RTX & TOC response, the refractory state was strongly associated with fibroblast genes and modules. We confirmed the observed expansion of fibroblasts from the RNA-Seq data by immunohistochemistry showing the presence of DKK3+ sublining fibroblasts in refractory rather than responder patients.
were measured with TruCount, qPCR, and multiplex suspension assay, respectively. The absolute number of circulating immune cells, clock gene expression, and serum cytokine levels were measured at the end of the study. GCs suppressed diurnal variation in RA, but not in HD. IL-6 showed circadian variation in HD only. The following cytokines were tested for circadian rhythms: IL-2, IL-4, IL-10, IL-12, IL-23, IL-17A, IFN-γ, IL-12/23, GM-CSF, IL-6, TNF-α, IL-1β, IL-8, IL-12, IL-13, and IL-17F. Notably, IL-17A and IL-17F showed circadian rhythms in HD only.

**Conclusion:** We found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.

**Conclusion:** In patients with RA, we found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.

**Conclusion:** In patients with RA, we found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.

**Conclusion:** In patients with RA, we found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.

**Conclusion:** In patients with RA, we found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.

**Conclusion:** In patients with RA, we found a certain loss of circadian rhythms and the establishment of "inflammatory" rhythms. GC treatment in patients with RA resulted in three different types of effects on circadian rhythms: 1) restoration of rhythms of immune cells; 2) dampening of circadian oscillations; and 3) establishment of "inflammatory" rhythms in RA. GC treatment in patients with RA could be used to diagnose and treat the disease.

**References:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** We thank all participants for their contribution. We thank our clinical study team: Manuela Jakstadt, Lisa Ehlers, Alexandra Damerau, Annamarie Lang, Moritz Pfeiffenberger, Gabriela May, and Pierre-Louis Krauß.
Background: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that belongs to a class of targets devoid of catalytic function, thus deemed “undruggable” by standard modalities such as small molecule inhibitors or biologics. STAT3 can be activated by various receptor- and non-receptor tyrosine kinases, playing a critical role in activation pathways triggered by cytokines, hormones, and growth factors, making it an attractive target for the treatment of inflammatory diseases.

Objectives: Kymera has developed heterobifunctional molecules that selectively target STAT3 for degradation and elimination by the ubiquitin-proteasome pathway. We sought to evaluate the pharmacologic potential of these STAT3 degraders through in vitro and in vivo studies relevant to human autoimmune disease, including murine collagen-induced arthritis.

Methods: We evaluated the impact of STAT3 degraders on the activation of human monocytes, dermal fibroblasts, CD4+ T cells, and PBMC by LPS, IL-6/IL-6R, IL-21, IL-23, as well as anti-CD3/CD28 plus a cocktail of cytokines and antibodies. STAT3 degradation and pSTAT3 inhibition were determined in comparison to a JAK1/2 small molecule inhibitor. Inhibition of cytokines, chemokines, and collagen release, as well as Th17 (CD4+CD25-+CXCR6+) and Treg (CD4+CD25+CD127lowFOXP3+) expansion were used as readouts.

Results: STAT3 degraders showed broad and potent activity in vitro against TLR receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner dependent on STAT6 receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner dependent on STAT6 receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner dependent on STAT6 receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner dependent on STAT6 receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1. STAT3 degradation in CD4+ T cells robustly inhibited the development of Th17 cells, abrogating IL-17, IL-22, IL-8/CXCL8, and TNFα production, and increased Treg numbers in a manner dependent on STAT6 receptor and cytokine-induced activation of immune and stromal cells, including soluble receptor release such as MCP-1/CLL2 and Collagen1a1.

Conclusion: These data demonstrate the broad activity of STAT3 degradation in alleviating autoimmune inflammation in models relevant to human disease. Targeted protein degradation of STAT3 thus represents a novel therapeutic approach to treating autoimmune/autoinflammatory diseases such as rheumatoid arthritis.


References:
Rheumatoid arthritis - prediction and prognosis

**OP0082**

**DISCORDANCE BETWEEN DAS28ESR AND PRESENCE OF ULTRASOUND POWER DOPPLER DURING EARLY TREATMENT IS ASSOCIATED WITH DISTINCT CLINICAL AND IMAGING PHENOTYPES AT PRESENTATION**

R. Shukla1,2, R. Wakefield2,3, P. Emery2,4, D. Plant2,3, M. H. Buch1,2,3, University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, NIHR Biomedical Research Centre, Manchester, United Kingdom; 3University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 4Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

Background: Discordance between DAS28ESR and musculoskeletal ultrasound (MSUS) detected power Doppler synovitis (PDUS) is well-recognised and may lead to under/over-treatment. We hypothesise that clinical and imaging features at diagnosis associate with early discordance of DAS28-PDUS and change in DAS28-PDUS status following DMARD treatment.

Objectives: To identify pre-treatment clinical factors associated with discordance and change in DAS28-PDUS status during early treatment in an early RA trial cohort.

Methods: The VEDERA trial randomised 120 treatment-naive, new-onset RA patients to either first-line etanercept + methotrexate (ETN-MTX) or methotrexate treat-to-target (MTX-TT) regime with escalation to ETN-MTX if not in DAS28ESR remission at week 24. Clinical and MSUS assessments were completed at baseline, weeks 12, 24 and 48. DAS28ESR ≤ 2.6 and DAS28 > 2.6 categorised remission and active disease respectively. PDUS presence was defined as total PDUS score ≥ 1. Active concordance (AC) was defined as active disease with PDUS while active discordance (AD) was defined as active disease without PDUS. Remission concordance (RC) was defined as DAS28ESR remission without PDUS remission discordance (RD) was defined as DAS28ESR remission with PDUS. Bayesian multinomial logistic regression (posterior estimate and 95% credible intervals reported) was used to address the study objectives with AC as the comparator group.

Results: At baseline all patients had active disease (moderate or high DAS28ESR) in line with trial eligibility - 68% (91/130) were AC and 32% (39/120) were AD. Compared to AD patients, AC patients were older median age 53 (vs 44), had higher DAS28ESR (5.90 vs 5.16) and CRP (11.66mg/L vs 3.6mg/L), as well as a higher presence of greyscale (GS - 100% vs 67%), power Doppler tenosynovitis (PDTS - 78% vs 49%) and erosions (20% vs 0) (p < 0.01). Figure 1 illustrates the pre-treatment proportions and change in group proportions at each timepoint, revealing an early shift of AC to AD (36% by week 12) or RC (22% by week 12) but persistence of those in AD from baseline at subsequent timepoints (64% at week 12). Baseline characteristics associated with each group compared to the comparator AC group (at weeks 12, 24 and 48) are reported in Table 1. For AD versus AC these were lower CRP at week 12 and female sex at week 24. For RC versus AC these were lower CRP and allocation to ETN-MTX at week 12, allocation to ETN-MTX and presence of PDTS at week 24 and younger age at week 48. For RD versus AC these were presence of PDTS at week 24 and male sex at week 48.

Table 1. Baseline characteristics associated with longitudinal discordance vs concordance. AC is the comparator group. Results in posterior estimate with 95% credible intervals reported.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Week 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>AD vs AC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>0.53 (-0.44 to 1.48)</td>
<td>1.52 (0.51 to 2.59)</td>
<td>0.71 (0.17 to 1.25)</td>
</tr>
<tr>
<td>CRP</td>
<td>-0.05 (-0.1 to 0.01)</td>
<td>-0.01 (-0.04 to 0.05)</td>
<td>0.00 (0.02 to 0.02)</td>
</tr>
<tr>
<td>PDTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>-0.06 (-0.09 to 0.01)</td>
<td>-0.02 (-0.06 to 0.03)</td>
<td>-0.06 (-0.13 to -0.03)</td>
</tr>
<tr>
<td>CRP</td>
<td>-0.05 (-0.10 to -0.01)</td>
<td>0.01 (-0.04 to 0.02)</td>
<td>0.02 (0.04 to 0.02)</td>
</tr>
<tr>
<td>ETN-MTX</td>
<td>1.57 (1.27 to 2.44)</td>
<td>1.26 (0.23 to 2.33)</td>
<td>0.91 (0.20 to 1.85)</td>
</tr>
<tr>
<td>PDTS</td>
<td>0.58 (-0.5 to 1.68)</td>
<td>1.23 (0.20 to 2.29)</td>
<td>0.86 (0.27 to 1.83)</td>
</tr>
<tr>
<td>AD vs AC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>0.23 (-1.26 to 1.72)</td>
<td>0.9 (0.41 to 2.26)</td>
<td>-1.59 (-2.34 to -0.85)</td>
</tr>
<tr>
<td>PDTS</td>
<td>1.00 (0.65 to 2.69)</td>
<td>1.79 (0.44 to 3.33)</td>
<td>0.95 (0.29 to 2.77)</td>
</tr>
</tbody>
</table>

Conclusion: DAS28ESR and PDUS discordance and concordance have distinct clinical and imaging phenotypes at presentation. Baseline active concordance and discordance respond differently to treatment – a sizeable proportion of former triation into active discordance early on and the latter persist in the face of effective treatment. Understanding the basis for these phenotypes is essential to facilitate optimal aggressive treatment and/or alternative management strategies.

REFERENCES:

Disclosure of Interests: None declared.


**OP0083**

**HAND AND FOOT MRI IN CONTEMPORARY UNDIFFERENTIATED ARTHRITIS: IN WHICH PATIENTS IS MRI VALUABLE TO DETECT RHEUMATOID ARTHRITIS EARLY? – A LARGE PROSPECTIVE STUDY**

N. den Hollander1, M. Verstappen1, N. Sidhu1, E. van Mulligen2, M. Reijnierse3, A. van der Helm-van Mil1,4, Leiden University Medical Center; Rheumatology, Leiden, Netherlands; 2Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands; 3Leiden University Medical Center, Radiology, Leiden, Netherlands

Background: Identifying patients that will develop rheumatoid arthritis (RA) among those presenting with undifferentiated arthritis (UA) remains a clinical dilemma. Although magnetic resonance imaging (MRI) is helpful according to EULAR-recommendations, this has only been determined in UA-patients not fulfilling 1987-RA-criteria, whilst part of these patients are currently considered as RA because they fulfill the 2010-criteria.

Objectives: We studied the predictive value of MRI for progression to RA in the current UA-population: i.e. not fulfilling RA-classification-criteria (neither 1987- nor 2010-criteria), and not having an alternate diagnosis. Additionally, the value of MRI was studied in patients with a clinical diagnosis of UA, regardless of the classification-criteria.

Methods: Two UA-populations were studied: criteria-based-UA as described above (n=405) and expert-opinion-based-UA (n=564), i.e. UA indicated by treatment-naïve, new-onset RA because they fulfill the 2010-criteria.

Results: Among criteria-based-UA-patients (n=405), 21% developed RA. MRI-detected synovitis and MRI-detected tenosynovitis were predictive. MRI-detected tenosynovitis was independently associated with RA-progression (OR 2.79; 95% CI 1.40-5.58), especially within ACPA-negative UA-patients (OR 2.91; 1.42-5.96). Prior risks of RA-development for UA-patients with mono-/oligo-/polyarthritis were 3%, 19%, 46%, respectively. MRI-results changed this risk most within the oligoarthritis-subgroup: PPV was 27% and NPV 93%. Similar results were found in expert-opinion-based-UA (n=564).

Conclusion: MRI is most valuable in ACPA-negative UA-patients with oligoarthritis; a negative MRI could aid in preventing overtreatment.

Disclosure of Interests: None declared.

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

Digital spatial profiling reveals distinct synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]

REFERENCES:

To assess the impact of clinical classification of remission on synovial tissue macrophage transcriptomic signatures of sustained remission in Rheumatoid Arthritis patients at risk of disease flare after treatment cessation.

S. Perniola1,2, B. Tolusso1,3,4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, L. Bui4, M. A. D’Agostino5,6, M. Kurowska-Stolarska3, E. Gremese1,2,3,7, S. Alivernini1,3,5,6.

Disclosure of Interests: None declared, Laura Bui: None declared, Maria Antonietta D’Agostino: None declared, Simona Perniola: None declared, Barbara Tolusso: [1]
both for rituximab and tocilizumab, MCP-counter analysis showed significantly higher CD8 T-cells in responders to rituximab and higher macrophage-monocytes and myeloid dendritic cells (mDC) in responders to tocilizumab (Figure 1a). Moreover, when patients were classified according to MCP-counter scores, B-cell poor patients (MCP-counter B cell score <median value) showed significantly higher response rates to tocilizumab, while no difference was found in B-cell rich patients (Figure 1c). In contrast, macrophage and myeloid dendritic cell (mDC) rich individuals showed higher responses to tocilizumab (Figure 1d). Combined scores for lymphoid and myeloid cells demonstrated that patients poor in B-cells but rich in macrophages/mDC had a significantly higher response to tocilizumab (77% responders to tocilizumab vs 14% responders to rituximab, p=0.017, OR 16.48, 95%CI 1.29-1000.5) (Figure 1e). By analysing disease activity over time from baseline to week 16, we found a statistically significant interaction effect between treatments and time in B-cell poor (p=0.003), T-cell poor (p=0.022), mDC rich (p=0.029) and B-cell poor/Macrophages-mDC rich patients (p=0.006) (Figure 1f-g-h). Finally, by applying MCP-counter on matched pre-and post-treatment biopsies, rituximab-treated patients showed a significant reduction of B-cells, T-cells and monocyte/macrophages, while tocilizumab-treated patients showed a significant reduction of monocyte/macrophages, T-cells, but also neutrophils, myeloid dendritic cells and, interestingly, an increase in fibroblast signature (Figure 1i).

Conclusion: In silico deconvolution of the synovial tissue identify pre-treatment lymphoid cell lineages associated with response to rituximab and myeloid cells for tocilizumab. The longitudinal analysis of matched pre- and post-treatment synovial biopsies indicated that both medications have an effect on synovial immune cells, but tocilizumab can also affect stromal cells.

REFERENCES:


Acknowledgements: We would like to thank all patients and the R4RA recruiting centres and principal investigators http://www.r4ra-nihr.wsrh.qmul.ac.uk/recruiting_centres.php We would also like to acknowledge the UK National Institute of Health Research for funding the R4RA trial (grant reference: 11/100/78) and Versus Arthritis for providing infrastructure support through the Experimental Arthritis Treatment Centre (grant number: 20022). Disclosure of Interests: None declared.


OP0086

ANTIBODIES AGAINST ADVANCED GLYCATION END-PRODUCTS (ANTI-AGE) DISTINGUISH PATIENTS WITH A MORE INFLAMMATORY PROFILE AND WORSE OUTCOME IN SERONEGATIVE RHEUMATOID ARTHRITIS

T. J. van Wesemael1, M. D. van den Beukel2, A. T. W. Hoogslag3, T. Huizinga3, R. Toes1, L. A. Trouw2, D. van der Woude4 1Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Leiden University Medical Center (LUMC), IMMUNOCHEMATOLOGY AND BLOOD TRANSFUSION, Leiden, Netherlands

Background: In rheumatoid arthritis (RA) around two-thirds of patients are autoantibody-positive for rheumatoid factor, anti-citrullinated protein antibodies (ACPA) and/or anti-carbamylated protein antibodies (anti-CarP). The remaining seronegative subgroup of RA is clinically heterogeneous and thus far, biomarkers predicting the disease course in these patients are lacking. Therefore, we set out to investigate the value of a new/different autoantibody in rheumatoid arthritis directed against advanced glycation end-product (AGE) modified proteins (anti-AGE). AGEs are a marker of oxidative stress, and anti-AGE have been described in multiple diseases including diabetes, and hypertension.

Objectives: To investigate the prevalence of anti-AGE in RA and non-RA arthritis patients, as well as their association with clinical parameters and disease outcome in RA.

Methods: In 648 RA patients and 538 non-RA arthritis patients from the Leiden Early Arthritis Clinic anti-AGE IgG antibody levels were measured using an in-house fetal calf serum (FCS) ELISA based assay using native FCS as control. The cutoff for positivity was set as the mean optical density plus two times the standard deviation of 80 healthy controls. Radiological progression was measured with the Sharp van der Heijde score (SHS) on yearly basis and the association with anti-AGE was assessed with a multivariate normal regression model.

Results: Anti-AGE was found in 299 (46%) of RA patients versus 163 (30%) of non-RA arthritis patients. Interestingly, 67 (34%) of completely seronegative (RF-, ACPA- and anti-CarP-negative) RA patients were positive for anti-AGE. Within RA, anti-AGE-positive patients had significantly higher ESR (median anti-AGE-positive: 38, anti-AGE-negative: 32, p=0.001) and CRP (median anti-AGE-positive: 19, anti-AGE-negative: 17, p<0.001), indicating an more inflammatory profile in these patients. Radiographic progression, was significantly higher in anti-AGE+ patients (Figure 1A, B=1.05, p<0.001). Since ACPA and anti-CarP (in ACPA-patients) are associated with radiological progression, the analysis was first stratified for ACPA-status. In the anti-AGE+ACP+ patients a significant association with SHS was found (Figure 1B: B=1.04, P<0.001), indicating that anti-AGE is associated with radiological progression in ACPA-negative patients. Next, the ACPA-negative stratum was also stratified for anti-CarP. Interestingly, SHS was significantly higher in all anti-AGE+ groups compared to the autoantibody-negative group.

Conclusion: Almost half of the RA patients are anti-AGE positive including a substantial part of otherwise completely seronegative RA patients. Anti-AGE antibodies are associated with inflammatory parameters and radiologic progression in seronegative RA patients. Therefore, although these autoantibodies are not specific for RA, anti-AGE could potentially identify patients with a more inflammatory phenotype and more severe disease outcome in “classic” autoantibody-negative RA patients.

Figure 1. Erosion scores according to the presence of autoantibodies. Figure 1A. Median erosion scores assessed by Sharp van der Heijde method (SHS) during the disease course stratified for anti-AGE. A significant difference was found between anti-AGE-negative patients and anti-AGE-positive patients (B=1.05, p<0.001) Figure 1B. Median erosion scores assessed by SHS during the disease course stratified for anti-AGE and anti-citrullinated protein antibodies (ACPA). SHS was significantly higher in all autoantibody-positive groups compared to the anti-AGE-ACPA- group.

Disclosure of Interests: None declared.


OP0087

INTEGRATED SYSTEMS ANALYSIS OF THE GUT MICRBIOTA PHENOTYPES IN THE RHEUMATOID ARTHRITIS

J. Qiao1,2,3, S. X. Zhang1,2,3, M. J. Chang2,3,4, S. Song1,2,3, R. Zhao1,2,3, T. Cheng1,2,3, Y. Zhang1,2,3, X. Li1,2,3, 1The Second Hospital of Shanxi Medical
**Background:** Patients with rheumatoid arthritis (RA) displays extreme dysbiosis in microbiota. However, such dysbiosis is difficult to characterize owing to the high-dimensional complexity of the gut microbiota.\(^1\,\text{2}\)

**Objectives:** The aim of this study was to discover the enterotype characters of intestinal flora in RA.

**Methods:** Fecal samples from 145 RA patients were collected for bacterial 16S rRNA genes sequencing. Mathematical modeling using Dirichlet multinomial mixtures (DMM) was applied to describe the variability in the microbiome data and cluster samples into enterotypes. The alpha-diversity, beta-diversity and the microbiome composition of the gut microbiome were used to define the difference of gut microbiota profiles between different enterotypes. The nonredundant taxonomic biomarkers for each enterotype were selected by using LEfSe. Inflammatory biomarkers (ESR, CRP), auto-antibodies(ACPA, MCV), peripheral lymphocytes subsets and cytokines were analyzed in our cohort using the Kruskal-Wallis test.

**Results:** Laplace approximation of DMM indicated two significantly distinct bacterial microbiota structures (RAE1 and RA E2) existed in the dataset (Figure 1a). Principal co-ordinates analyses confirmed that these two microbiota states explained a reasonable proportion of observed variance in microbiota composition(ANOSIM R2 = 0.267, p < 0.001; Figure 1b), with distinct bacterial genus distribution of in each enterotype (Figure 1c). RA E1 were primarily dominated by Prevotella while RA E2 by Bacteroides. Interestingly, Chao1, ACE, Shannon and Simpson revealed a higher alpha diversity in Prevotella-enriched enterotype (p < 0.001, Figure 1d). Fourteen selected taxonomic biomarkers at different phylogenetic levels showed great discriminant ability, with Log10 LDA score > 4.0 (Figure 1e-g). Further, inflammatory biomarkers (ESR, CRP) and auto-antibodies(ACPA, MCV) as well as the number of T, B and CD4+T, CD8+T were significantly higher in RA E2 than in RA E1 (p < 0.05). But CD6+T were consistent in RA E1 and RA E2 (p > 0.05, Figure 2h). But CD8+T were significantly higher in RA E2 than in RA E1 (p < 0.05).

**Conclusion:** Despite RA gut microbiota being of different dysbiosis, two patterns of dysbiosis, designated as RA-enterotypes, were predominant among the RA patient cohort. RA E2 exhibited a loss of Prevotella but a growth of Bacteroides, while RA E1 presented the opposite results.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**Acknowledgements:** This work was supported by the National Natural Science Foundation of China (No. 82001740).

**DOI:** 10.1136/annrheumdis-2022-eular.3429
variable) using a generalized estimating equation (GEE) model in STATA/IC 14.0.In NOAR.

**Results:** A total of 2119 participants (2440 radiographs) were identified with both genetic and radiographic data available. 66.2% of these patients were female and 33.3% were anti-CCP positive. Median age of onset was 54.5 and 74.9% satisfied the American College of Rheumatology (ACR) 1987 criteria for rheumatoid arthritis.

A total of 113 different non-HLA SNPs associated with radiographic outcome in RA were identified from the literature. Of these, 102 were successfully identified within NOAR and 91 were deemed to be independent SNPs based on R² of 0.6. 14 SNPs were found to be significantly associated with the presence of erosions within NOAR (Table 1).

### Table 1. SNPs found to be associated with radiographic severity within NOAR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chromosome</th>
<th>SNP (single nucleotide polymorphism)</th>
<th>Odds ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL2RB</td>
<td>2</td>
<td>rs743777</td>
<td>1.23 (1.01, 1.05)</td>
<td>0.0398</td>
</tr>
<tr>
<td>IL15</td>
<td>4</td>
<td>rs828117</td>
<td>0.82 (0.67, 1.00)</td>
<td>0.0451</td>
</tr>
<tr>
<td>IL4</td>
<td>5</td>
<td>rs2243250</td>
<td>1.36 (1.08, 1.70)</td>
<td>0.0394</td>
</tr>
<tr>
<td>FOXO3</td>
<td>6</td>
<td>rs12212047</td>
<td>0.75 (0.58, 0.97)</td>
<td>0.0278</td>
</tr>
<tr>
<td>OPG</td>
<td>8</td>
<td>rs2073618</td>
<td>0.79 (0.64, 0.98)</td>
<td>0.0295</td>
</tr>
<tr>
<td>TRAF1</td>
<td>9</td>
<td>rs10760130</td>
<td>1.33 (1.06, 1.65)</td>
<td>0.0118</td>
</tr>
<tr>
<td>TRAF1</td>
<td>9</td>
<td>rs10818488</td>
<td>1.32 (1.06, 1.64)</td>
<td>0.0141</td>
</tr>
<tr>
<td>TRAF1</td>
<td>9</td>
<td>rs2900180</td>
<td>1.32 (1.07, 1.61)</td>
<td>0.0079</td>
</tr>
<tr>
<td>IL4r</td>
<td>16</td>
<td>rs1805010</td>
<td>1.25 (1.01, 1.56)</td>
<td>0.0393</td>
</tr>
<tr>
<td>IL16</td>
<td>16</td>
<td>rs1805011</td>
<td>1.31 (1.03, 1.66)</td>
<td>0.0260</td>
</tr>
<tr>
<td>LGALS9</td>
<td>17</td>
<td>rs3763959</td>
<td>1.32 (1.03, 1.59)</td>
<td>0.0260</td>
</tr>
<tr>
<td>SOST</td>
<td>17</td>
<td>rs4792909</td>
<td>1.34 (1.09, 1.65)</td>
<td>0.0052</td>
</tr>
<tr>
<td>IL1RA3</td>
<td>19</td>
<td>rs1033294</td>
<td>0.80 (0.65, 0.98)</td>
<td>0.0334</td>
</tr>
<tr>
<td>MMP9</td>
<td>20</td>
<td>rs11908352</td>
<td>0.70 (0.57, 0.85)</td>
<td>0.0005</td>
</tr>
</tbody>
</table>

**Conclusion:** 113 non-HLA SNPs have been previously reported to be associated with radiographic outcome in RA. Of these, only ~15% also showed an association in NOAR, the largest cohort with genetic and radiographic outcome data worldwide. Interestingly, rs2243250, a SNP located on chromosome 5 (IL4), previously found to be associated in a small Egyptian cohort, has been replicated in NOAR.(2) Current work consists of assessing the added clinical value of a genetic risk score based on HLA and non-HLA markers in predicting radiographic outcome when combined with clinical/serological/demographic markers.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3586

**Figure 1.** Heatmap representation of selected GO BP pathways in responders/non-responders.
Conclusion: Machine learning models based on transcriptomic functional pathways can accurately predict response to tofacitinib. Our study could contribute to improve the treatment customization and the optimization of RA treatment strategy toward a personalized approach. Furthermore, these findings may help to understand the mechanisms underlying the clinical response to JAK inhibitors.

Disclosure of Interests: None declared.

The Yin and Yang of scleroderma and vasculitis

PO0090
PRECLINICAL STUDIES OF A NOVEL CATHEPSIN C INHIBITOR IN MPO-ANCA-ASSOCIATED VASCULITIS MODEL

A. Ishizu1, M. Taniguchi2, S. Arai2, Y. Nishibata2, S. Masuda2, U. Tomaru2, T. Shimizu4, W. Sinko4, T. Nagakura4, Y. Terada4, 1Hokkaido University, Faculty of Health Sciences, Department of Medical Laboratory Science, Sapporo, Japan; 2Hokkaido University, Faculty of Health Sciences, Department of Medical Laboratory Science, Sapporo, Japan; 3Hokkaido University, Faculty of Medicine and Graduate School of Medicine, Department of Pathology, Sapporo, Japan; 4Modulus Discovery, Inc., Research & Development, Tokyo, Japan

Background: MPO-ANCA-associated vasculitis (MPO-AAV) is a systemic small vessel vasculitis with the production of MPO-ANCA in the serum. This disease develops necrotizing and crescent glomerulonephritis (NCGN) and peritubular capillaritis-mediated interstitial damages in the kidneys, and pulmonary hemorrhage due to capillaritis in the lungs. Recent studies have revealed that neutrophil extracellular traps (NETs) induced by MPO-ANCA are critically involved in its pathogenesis, and neutrophil elastase (NE) plays an essential role in the formation of NETs. Cathepsin C (CatC) functions as a key enzyme in the activation process of several neutrophil serine pro- teases (NSPs) such as NE, proteinase 3 and cathepsin G by converting the inactive forms of the NSPs to the active forms by digesting dipeptides at the N-terminus of the enzymes.

Objectives: Although glucocorticoids and immunosuppressive drugs used as the standard of cares can lead remission in MPO-AAV patients, there are remaining unmet medical needs such as severe side effects, resistance to the treatment and relapse. Therefore, development of new therapeutic strategies is awaited. The aim of this study is to demonstrate the efficacy of MOD06051, a novel CatC inhibitor, against MPO-AAV, using an MPO-AAV rat model established previously.

Methods: In vitro studies: CatC and NE inhibitory activity was measured using recombinant enzymes and fluorescent substrates. Cellular NE activity in the granulocytes differentiated from the primary human bone marrow-derived hematopoietic stem cells under the presence or absence of MOD06051 was determined using fluorescent substrates. In vivo studies: 4-week-old Wistar Kyoto (WKY) rats were immunized with human MPO according to Little’s protocol. The rats were divided into three groups (n=8 in each group), and vehicle (0.5% methylcellulose) or MOD06051 (0.3 or 3 mg/kg bid) was orally administered every day for 42 days. All rats were euthanized at the end of the study for serological and histological evaluations.

Results: In vitro studies: MOD06051 inhibited the enzymatic activity of human recombinant CatC with an IC50 value of 1.5 nM, and no other cathepsins nor NE inhibition was observed at 10 μM. The NE activity in primary human granulocytes was suppressed by MOD06051 with an IC50 value of 18 nM.

In vivo studies: MPO-ANCA was induced in all groups at the same level. The percentage of affected glomeruli including those with NCGN, NET-forming neutrophils in the peripheral blood and glomeruli, and glomerular neutrophil counts were significantly suppressed by MOD06051 treatment in a dose-dependent manner. Furthermore, hematuria score, urinary NGAL (Neutrophil Gelatinase-Associated Lipocalin), tubular erythrocyte cast counts, and pulmonary hemorrhage foci were significantly decreased in the 3 mg/kg of MOD06051 treated group with the similar trends in 0.3 mg/kg group.

Conclusion: MOD06051 showed specific inhibition of CatC activity. This compound suppressed the serine proteases activation in primary human neutrophils and NET formation in the MPO-AAV model rats, resulting in amelioration of MPO-ANCA-induced tissue destruction, including NCGN and tubular interstitial damages in the kidneys, and disorder of alveolar septal capillaries in the lungs. MOD06051 appears to be a promising agent for treatment of MPO-AAV patients.

REFERENCES:


Scientific Abstracts
Background: ANCA-associated vasculitides (AAV) are characterized by recurrent, chronic small vessel inflammation and deleterious organ damage. The main targets of ANCA are myeloperoxidase (MPO) and proteinase 3 (PR3). ANCA, B cells and the complement system are crucial to AAV pathogenesis, as evidenced by the clinical benefit of B cell depletion with rituximab and, more recently, the C5a receptor antagonist avacopan. While ANCA in serum have been studied extensively, phenotypic and functional characteristics of the underlying B cell responses remain largely unknown.

Objectives: To develop a flow cytometry-based technique for identifying MPO-specific B cells in the circulation of MPO-positive AAV patients in order to characterize this B cell response and its potential contribution to disease pathogenesis.

Methods: Human neutrophil-derived MPO was conjugated to two different fluorochromes and used to identify MPO-specific B cells by flow cytometry. An antigen-specific staining protocol was developed and validated using MPO- and PR3-specific hybridoma cells. MPO-specific B cells were phenotypically characterized and isolated from the peripheral blood of AAV patients by fluorescence-activated cell sorting (FACS) and cultured as single cells. MPO-specificity was confirmed by ELISA on culture supernatants. B cell receptor (BCR) sequences were obtained from MPO-positive clones by full length ARTISAN-PCR and confirmed by ELISA on culture supernatants. B cell receptor (BCR) sequences were obtained from MPO-positive clones by full length ARTISAN-PCR and confirmed by ELISA on culture supernatants. B cell receptor (BCR) sequences were obtained from MPO-positive clones by full length ARTISAN-PCR and confirmed by ELISA on culture supernatants. B cell receptor (BCR) sequences were obtained from MPO-positive clones by full length ARTISAN-PCR and confirmed by ELISA on culture supernatants.

Results: The newly developed, differential antigen labelling approach successfully identified MPO-specific but not PR3-specific hybridoma cells. Subsequently, we detected MPO-specific B cells in the circulation of MPO-positive AAV patients at a frequency of up to 1:1000 B cells. FACS sorting and single cell culture yielded an enrichment of MPO-specificity (>80%). Notably, the majority of isolated, MPO-specific B cells (60-95%) displayed an IgM memory phenotype, which corresponded to the presence of anti-MPO IgM in plasma. The remainder of the MPO-specific cells were mainly IgG memory B cells and few naive cells. BCR sequencing revealed a polyclonal IgM response with diverse V-gene usage, consisting of both germine and highly mutated clones. Generation of mAb (n=9) confirmed MPO specificity by inhibition ELISA both germine and somatically mutated clones. Interestingly, anti-MPO IgM mAb showed a high capacity for complement factor deposition upon MPO binding. MPO-specific complement assays with IgG- and IgM-depleted patient plasma showed that anti-MPO IgM activated complement much more efficiently than anti-MPO IgG.

Conclusion: We demonstrate the direct ex vivo identification, isolation and characterization of MPO-specific B cells in human AAV. Intriguingly, we observed a remarkable expansion of MPO-specific, IgM-expressing memory B cells in patients. This so far unrecognized, active IgM-compartment may be clinically relevant, as both mAb and plasma-derived polyclonal MPO-specific IgM strongly activated complement, a pathway thought to play a central role in AAV. Next to these novel insights into autoreactive B cell biology in AAV, our findings now provide new opportunities for studying auto-reactive B cell responses in different clinical phases of AAV, amongst which active disease, remission and (imminent) relapse.

Disclosure of Interests: None declared.
Background: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of multisystem inflammatory diseases of the small blood vessels, characterized by leukocytoclastic inflammation of small blood vessels and triggered by production of ANCA autoantibodies [1]. Due to the multorgan involvement and relapsing nature, AAV is among the systemic autoimmune rheumatic diseases with the highest morbidity and mortality [1, 2].

Objectives: To evaluate the risk of severe infection and infection-related mortality among patients with newly diagnosed AAV.

Methods: We conducted an age- and gender-matched cohort study of all patients with incident AAV between January 1, 1997 and March 31, 2015 using administrative health data from British Columbia, Canada. Primary outcome was the first severe infection after AAV onset necessitating hospitalization or occurring during hospitalization. Secondary outcomes were total number of severe infections and infection-related mortality.

Results: We identified 549 AAV patients and matched them with 5,480 non-AAV individuals from the general population, yielding 184 and 509 first severe infections during 2,539 and 33,342 person-years follow-up, respectively. The crude incidence rate ratios for first severe infection and infection-related mortality were 5.03 (95% CI, 4.25-5.96) and 3.72 (95% CI, 2.44-5.67), respectively. The corresponding adjusted hazard ratios were 3.77 (95% CI 2.94-4.85) and 3.84 (95% CI, 2.13-6.91). AAV patients had an increased risk of a greater total number of severe infections with crude rate ratio of 4.99 (95% CI, 4.42-5.62) and adjusted rate ratio of 3.32 (95% CI, 2.73-3.74).

Conclusion: AAV is independently associated with increased risks of first severe infection (3.8-fold), a greater total number of severe infections (3.2-fold) and infection-related mortality (3.8-fold).

REFERENCES:

Table 1. Risk of severe infection in AAV relative to non-AAV during follow-up

<table>
<thead>
<tr>
<th>AAV cohort</th>
<th>Non-AAV cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=549</td>
<td>N=5,480</td>
</tr>
<tr>
<td>No. of events</td>
<td></td>
</tr>
<tr>
<td>IR per 1,000 person-years</td>
<td></td>
</tr>
<tr>
<td>IRR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Age and gender adjusted HR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>All but GC adjusted HR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Fully adjusted HR* (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Post-AAV total number of severe infections</td>
<td></td>
</tr>
<tr>
<td>Infection episodes</td>
<td></td>
</tr>
<tr>
<td>IR per 1,000 person-years</td>
<td></td>
</tr>
<tr>
<td>IRR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Age and gender adjusted rate ratio (95% CI)</td>
<td></td>
</tr>
<tr>
<td>All but GC adjusted rate ratio (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Fully adjusted rate ratio* (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Infection-related mortality</td>
<td></td>
</tr>
<tr>
<td>No. of infection-related death events</td>
<td></td>
</tr>
<tr>
<td>IR per 1,000 person-years</td>
<td></td>
</tr>
<tr>
<td>IRR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Age and gender adjusted HR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>All but GC adjusted HR (95% CI)</td>
<td></td>
</tr>
<tr>
<td>Fully adjusted HR* (95% CI)</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: AAV, Antineutrophil cytoplasmic antibody-associated vasculitides; IR, incidence rate; IRR, incidence rate ratio; HR, hazard ratio; CI, confidence interval.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.31

OP0094 IDENTIFICATION OF NEW AUTOANTIGENS IN PATIENTS WITH SYSTEMIC SCLEROSIS THROUGH IMMUNOPRECIPITATION COMBINED WITH LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

J. B. Vulteira1,2, D. Blockmans3,4, P. De Haes5,6, S. Vanderschueren3,4, P. Verschueren1,2, K. G. Claeyse7, W. Wuyts8,10, J. L. Lenaerts9, E. De Langhe1,2, X. Bossuyt3,11,12,13, KU Leuven, Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium; University Hospitals Leuven, Rheumatology, Leuven, Belgium; KU Leuven, Microbiology, Immunology and Transplantation, Laboratory for Clinical Infectious and Inflammatory Disorders, Leuven, Belgium;4 University Hospitals Leuven, General Internal Medicine, Leuven, Belgium;5 KU Leuven, Microbiology, Immunology and Transplantation, Leuven, Belgium;6 University Hospitals Leuven, Dermatology, Leuven, Belgium;7 KU Leuven, Neurosciences, Laboratory for Muscle Diseases and Neuropathies, Leuven, Belgium;8 University Hospitals Leuven, Neurology, Leuven, Belgium;9 KU Leuven, Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and Thoracic Surgery, Leuven, Belgium;10 University Hospitals Leuven, Respiratory Diseases, Leuven, Belgium;11 KU Leuven, Microbiology, Immunology and Transplantation; Clinical and Diagnostic Immunology, Leuven, Belgium;12 KU University Hospitals Leuven, Laboratory Medicine, Leuven, Belgium

Background: In up to 20% of patients with systemic sclerosis (SSc) none of the established SSc-specific autoantibodies are present [1]. Notwithstanding, in many of these patients high-titer autoantibodies can be detected on the HEp-2 indirect immunofluorescence assay (HEp-2 IFA) which suggests the presence of an autoantibody to an intracellular protein expressed by the HEp-2 cell line. Immunoprecipitation of unlabelled cell extract followed by gel-free liquid chromatography tandem mass-spectrometry analysis has the potential to identify new autoantigens in an unbiased manner.

Objectives: To identify new autoantigens through immunoprecipitation combined with liquid chromatography-tandem mass spectrometry (IP + LC-MS/MS) in HEp-2 IFA-positive patients with SSc in whom none of the established SSc-specific autoantibody specificities are present.

Methods: Forty-nine patients from the University Hospitals Leuven that fulfilled the EULAR-ACR 2013 classification criteria for systemic sclerosis or LeRoy and Medsger's criteria for early systemic sclerosis and who were negative on the EIA CTD Screen (Thermo Fisher Scientific, United States), which includes centromere protein B, topoisomerase I, RNA polymerase III, fibrillarin, PM-Scl and U1 ribonucleoprotein, were identified. Immunoprecipitation was performed by incubation of sera of these patients (1:30 in 300 µl Tris-buffered saline) with Pierce A/G magnetic beads, subsequent cross-linking with bissulfosuccinimidyl suberate (BSS) followed by incubation with nuclear extract of HeLa cells (100-150 µg) overnight at 4°C. The eluted protein was analyzed through liquid chromatography with tandem mass spectrometry. Mass spectrometry data were matched against the Uniprot Homo Sapiens database with the Mascot search engine. Candidate autoantigens were confirmed through immunoprecipitation followed by western blot of the eluate with target-specific polyclonal rabbit antibodies or western blot of recombinant protein incubated with sera of the index patients.

Results: We identified multiple new autoantigens, including the THO complex subunit 1 (THOC1) and other subunits of the THO complex in 3 patients, nuclear valosin-containing protein like-2 (NVL) in 2 patients, nucleolar and coiled-body phosphoprotein 1 (NOLC1) and multiple interacting proteins in 1 patient, probable 28S rRNA (cytosine(4447)-C)-methyltransferase (NPD2) in 1 patient, telomeric repeat-binding factor 2 (TERF2) and TERF2-interacting protein (TERF2IP) in 1 patient and regulator of chromosome condensation 1 (RCC1) in 1 patient. The new targets were confirmed through immunoprecipitation-western blot or western blot of recombinant protein incubated with sera (Figure 1). Furthermore, in 10 patients known SSc-associated autoantigens were strongly immunoprecipitated including multiple Th/To subunits in 5 patients, RuvBL1/2 in 2 patients, multiple PM-Scl subunits in 2 patients (who both were negative on the EIA CTD Screen), and fibrillarin in 1 patient (who was also negative on the EIA CTD).

Figure 1.
Immunoprecipitation-western blot with target-specific rabbit polyclonal antibody (1/500-2000 dilution), numbers corresponding to order of description of patients, HC healthy control, NE nuclear extract. RP recombinant protein WB-RP western blot of recombinant protein was reproduced with different batches of lot (B).

Conclusion: Multiple new autoantigens were identified and confirmed in patients with SSc without previously identified autoantibody specificity. Further evaluation of reactivity against the newly identified autoantigens in patients with SSc with known autoantibody specificities and other cohorts is required. IP + LC-MS/MS can identify new and established autoantigens in patients with SSc.

REFERENCES:

Disclosure of Interests: Jean-Baptiste Vulsteke: None declared, Daniel Blockmans: None declared, Petra De Haes: None declared, Steven Vanderschueren: None declared, Patrick Verschueren: None declared, Krist G Claes: None declared, Wim Wuys Grant/research support from: Boehringer-Ingelheim, Galapagos, Roche, Jan Leo Lenaerts: None declared, Ellen De Langhe: None declared, Xavier Bossuyt Consultant of: Inova Diagnostics, Thermo Fisher Scientific. DOI: 10.1136/annrheumdis-2022-eular.593

OP0095  SINGLE-CELL RNA SEQUENCING REVEALS POTENT ANTI-INFLAMMATORY AND ANTIFIBROTIC ACTIVITIES OF DIMETHYL-ALPHA-KETOGLUTARATE ON EXPLANTED SKIN FROM PATIENTS WITH SYSTEMIC SCLEROSIS

B. Burja1,2, D. Paul1, R. Gerber3, S. G. Edalat1, M. Elhai4, E. Pacher4, R. S. Zingg5, P. M. Pramotton5, S. F. Madsen6, K. Buernki6, G. Costanza6,7, M. Whitlefield1, A. C. Bay-Jensen1,5, M. Tomics3, G. Kania2, H. Behraue4, O. Distler8, Z. Rota9, M. Robinson3, K. Lakota2,9, M. Frank1,9, Ziga Rotar2,9, M. Robinson3, Katja Lakota: None declared, Michael Whitfield: None declared, Anne-Christine Bay-Jensen: None declared, Rahel S. Zingg: None declared, Francesca Michela Pramotton: None declared, Sofie Falkenløve Madsen: None declared, Kristina Buerki: None declared, Giampietro Costanza: None declared, Reto Gerber: None declared, Elena Pachera: None declared, Rahel S. Zingg: None declared, Michael Whitfield: None declared, Anne-Christine Bay-Jensen: None declared, Snézna Sodin-Semrl: None declared, Matija Tomics: None declared, Gabriela Kania: None declared, Hubert Rehrauer: None declared, Olivier Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, None declared, Sam G. Edalat: None declared, Muriel Elhai Speakers bureau: BMS, Eliana Pacher: None declared, Rahel S. Zingg: None declared, Francesca Michela Pramotton: None declared, Sothe Falkenløve Madsen: None declared, Kristina Buerki: None declared, Giampietro Costanza: None declared, Michael Whitfield: None declared, Anne-Christine Bay-Jensen: None declared, Snézna Sodin-Semrl: None declared, Matija Tomics: None declared, Gabriela Kania: None declared, Hubert Rehrauer: None declared, Olivier Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: Abbvie, Acelorion, Alimed, Amgen, AnaMar, Arro, AstaZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltényi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Ziga Rotar: None declared, Mark Robinson: None declared, Katja Lakota: None declared, Mojca Frank Bertoncelj: None declared.

Background: Activated fibroblasts are the main drivers of skin fibrosis in Ssc. We have recently identified dimethyl alpha-ketoglutarate (dm-aKG) as a potential repressor of myofibroblast differentiation and profibrotic activity in cultured skin fibroblasts.

Objectives: To further analyse the clinical translation of our findings by investigating the antifibrotic capacity of dm-aKG on explanted skin biopsies from SSc patients.

Methods: We cultured forearm punch skin biopsies from SSc patients (n=10) for 24h ex vivo in the presence/absence of 6 mM dm-aKG. Thereafter, skin biopsies (n=4) were dissociated into single cells using a combined mechanical-enzymatic dissociation protocol, followed by single cell (sc)RNA-seq library preparation (10X Genomics) and sequencing (Illumina, NovaSeq6000, 50,000 reads/cell). We mapped the scRNA-seq reads to the reference genome GRCh38.p13 and analysed the data with R/Bioconductor tools. We deconvoluted cell types in bulk skin transcriptomes from SSc cohorts (GSE: 45485, 50795, 9285, 32415) using human skin scRNA-seq data1. The secretion of IL-6, procollagen-1, PRO-C1 (N-terminal type I collagen pro-peptide), C1M (MMP-degradation fragment of type I collagen), and fibrinectin (FBN-C) from cultured skin (n=10) was measured in supernatants by ELISA. We analysed gene and protein expression in TGFIα-activated healthy and Ssc dermal fibroblasts (DF, n=10) treated or not with dm-aKG using qPCR, Western blot and ELISA. Contractile properties of DF were assessed by gel contraction assay. Traction forces generated by DF were determined by reference-free traction microscopy.

Results: Dissociated cultured Ssc skin exhibited comparable cell yield and viability in the presence (20,203; 89%) and absence (25,280; 93%) of dm-aKG, respectively. scRNA-seq skin analysis included 20,869 high quality single cell profiles segregating into 10 distinct skin cell populations (Figure 1A). This analysis demonstrated decreased proportion of fibroblasts and increased proportion of keratinocytes in dm-aKG treated skin (p<0.05, Figure 1B). Among skin cell types, skin fibroblasts exhibited the largest amount of differentially expressed genes upon dm-aKG treatment (44%, n=779, x-fold=0.5, FDR=0.05), suggesting that these cells are key targets of dm-aKG therapy in Ssc skin. We identified inflammatory/cytokine signalling (hub genes IL6, STAT1) and extracellular matrix (ECM) organization (hub genes MMP1, ITG8) as top downregulated biological processes in fibroblasts in dm-aKG treated Ssc skin (Figure 1C), coinciding with a decreased abundance of proinflammatory skin fibroblast subpopulation. Specifically, these cells were identified as the main source of IL6 (Figure 1D) and were enriched in Ssc skin as revealed by deconvolution analysis of skin transcriptomes. Furthermore, dm-aKG reduced the secretion of IL-6, procollagen-1 and C1M, but not pro-C1 and FBN-C, from cultured skin explants. In cultured DF, dm-aKG blocked the inflammatory (IL6, pSTAT3), profibrotic (aSMA, Fibronectin, Procollagen-1, Pro-C1) and contractile activities, and significantly diminished traction forces exerted by DF on the matrix substrate.

Conclusion: Dm-aKG broadly interferes with inflammatory and ECM organizational activities of skin fibroblasts in culture and in explanted skin from SSc patients. These results confirm that dm-aKG might represent a potential new therapeutic approach for efficient targeting of skin inflammation and fibrosis in Ssc.

REFERENCES:

Acknowledgements: This work was supported by a research grant from FONREU Foundation for Research in Rheumatology and University Medical Centre Ljubljana.

Disclosure of Interests: Blaž Burja: None declared, Dominique Paul: None declared, Reito Gerber: None declared, Sam G. Edalat: None declared, Muriel Elhai Speakers bureau: BMS, Elena Pacher: None declared, Rahel S. Zingg: None declared, Francesca Michela Pramotton: None declared, Sofie Falkenløve Madsen: None declared, Kristina Buerki: None declared, Giampietro Costanza: None declared, Michael Whitfield: None declared, Anne-Christine Bay-Jensen: None declared, Snézna Sodin-Semrl: None declared, Matija Tomics: None declared, Gabriela Kania: None declared, Hubert Rehrauer: None declared, Olivier Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: Abbvie, Acelorion, Alimed, Amgen, AnaMar, Arro, AstaZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltényi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Ziga Rotar: None declared, Mark Robinson: None declared, Katja Lakota: None declared, Mojca Frank Bertoncelj: None declared.


OP0096  CAN IMMUNOGLOBULINS G FROM SYSTEMIC SCLEROSIS PATIENTS INFLUENCE THE SECRETOME OF DERMAL FIBROBLASTS?

A. Chepil1,2, M. Duhamele2, S. Viver1, L. Guibert1,4, D. Dubucquoi1,4, D. Launay1, M. Salzetz3, V. Sobranski3,2, University of Lille, Univ Lille, Inserm, CHU Lille, U1286 - INFINTE - Institute for Translational Research in Inflammation, F-59000 Lille, France, Lille, France, CHU de lille, CHU Lille, Dptement de Medecine Interne et Immunologie Clinique, Centre de Reference des Maladies Auto-immunes Systemiques Rares du Nord et Nord-Ouest de France (CeRAIN0), F-59000 Lille, France, Lille, France, CHU de lille, CHU Lille, Univ Lille, Univ Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, F-59000 Lille, France, Lille, France, CHU
Background: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc) [1]. Recently, it has been showed that immunoglobulins G (IgG) from SSc promoted proinflammatory and profibrotic phenotype in monocyte secrete (2). Fibroblasts (FB) are key effectors cells in SSc and data on FB proteins secretion in the presence of IgG from SSc patients are lacking. While recognized as potent biomarkers, the pathogenic role of Aab is much more debated.

Objectives: To explore the FB secretome in the presence of purified IgG from SSc patients

Methods: Normal dermal FB were cultured in the presence of purified IgG from patients with diffuse cutaneous SSc (dcSSc), limited cutaneous SSc (lcSSc) or healthy controls (HC). After 72 h of culture, the cell supernatants were collected, centrifuged and passed through a filter to remove the cells. After proteins digestion, secretome was explored using mass spectrometry coupled with liquid chromatography (LC-MS/MS). Analysis of variance (ANOVA) and hierarchical clustering were used to identify proteins responses patterns.

Results: Proteomic identified and quantified 1268 proteins, among them 377 were significant after ANOVA. SSC and HC secreteome appeared distinct. Hierarchical clustering on significant proteins after ANOVA showed 3 distinct groups of patients secreteome: a first group including mostly dcSSc anti-topoisomerase-I (ATA) positive (dcSSc ATA+) patients, a second group including mostly dcSSc ATA negative (dcSSc ATA-) patients, a third group more heterogeneous including the majority of HC, lcSSc anti-centromere positive (lcSSc ACA+) patients and dcSSc ATA- patients (Figure 1A). The comparison of FB secretome in the presence of purified IgG from dcSSc ATA+ vs IgG HC revealed 203 differentially expressed proteins (DEP) (Figure 1B). The enriched Gene Ontology (GO) terms upregulated in IgG dcSSc ATA+ vs IgG HC were involved in endocytic vesicle lumen, vesicle lumen, extracellular matrix or glycosaminoglycan binding. The comparisons of IgG dcSSc ATA+ vs IgG HC and IgG lcSSc ACA+ vs IgG HC revealed 85 and 15 DEP, respectively. Follistatin, amyloid beta A4 protein, myosin-9 and calreticulin were commonly overexpressed in the 3 subtypes of SSc. 40 proteins were DEP, respectively. Follistatin, amyloid beta A4 protein, myosin-9 and calreticulin were commonly overexpressed in the 3 subtypes of SSc. 40 proteins were DEP, respectively. Follistatin, amyloid beta A4 protein, myosin-9 and calreticulin were commonly overexpressed in the 3 subtypes of SSc. 40 proteins were DEP, respectively.

Conclusion: Using sensitive proteomic approach, we identified that purified IgG from SSc patients modified FB secreteome in a subtype dependent manner. The data support the pathogenic role of Aab in SSc.

References:

Disclosure of Interests: None declared.
Microbiome and SpA

OP0098 PREDICTING TREATMENT OUTCOME IN PATIENTS WITH SPONDYLOARTHRITIS USING MICROBIOTA ANALYSIS

L. Ameri1, T. Ströwig1, T. R. Lesker1, T. Witte2, 1Helmholtz Centre for Infection Research, Microbial Immune Regulation, Braunschweig, Germany; 2Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany

Background: Autoimmune-related rheumatic diseases such as rheumatoid arthritis (RA) and spondyloarthritis (SpA) are caused by an interplay of various factors including genetics, environmental factors and lifestyle. Among them, the intestinal microbiome has been suggested to influence disease initiation and progression. While the pathogenic connection between the microbiome and autoimmunity remains ambiguous, there is evidence that, for instance, microbiota-derived antigens cross-react with autoantibodies triggering an immune response and disease development1. However, other hypothesis such as the leaky gut model have been explored2. In addition to this potential involvement in disease initiation, microbial signatures have been identified to predict treatment outcome, as shown for the first-line medication Methotrexate (MTX) in RA patients3. Objectives: Our study aimed to longitudinally compare gut microbiota composition between treatment-naïve patients with different forms of rheumatic disorders from disease onset to remission/relapse to identify i) disease-specific signatures and ii) their impact on therapeutic responses. Methods: Patients with new onset of rheumatic disorders as well as their household members were recruited in the RheumaVOR cohort. The patients presented without treatment with steroids or DMARDs. The diagnosis was made by experienced rheumatologists. Native and stabilized fecal samples were collected, and 16S rRNA amplicon sequencing was performed to determine microbiota composition. Patients with non-inflammatory rheumatic disorders served as controls, whereas treatment was initiated in patients with inflammatory rheumatic diseases. Clinical data of patients was recorded including monitoring of medication and treatment response. Results: A total of 422 fecal samples were analyzed from patients diagnosed with different forms of immune-mediated rheumatic diseases, non-inflammatory rheumatic diseases as well as from household controls (Table 1). Using 16S rRNA amplicon sequencing, we did not detect any clustering of patient groups during disease onset based on the microbiota composition (Figure 1A). However, PsA patients responding to MTX (MTX-R) (=patients in DAPSA remission 3-6 months after MTX initiation or patients showing partial response) and patients not in remission (MTX-NR) differed in microbiota composition between treatment-naïve patients with different forms of rheumatic disorders from disease onset to remission/relapse to identify i) disease-specific signatures and ii) their impact on therapeutic responses.

Disclosure of Interests: None declared.

REFERENCES:

Table 1. Overview of RheumaVOR samples analyzed in this study

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>total number of samples</th>
<th>MTX treatment</th>
<th>no remission</th>
<th>response data available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Household controls</td>
<td>188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-inflammatory rheumatic diseases (NHD)</td>
<td>110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis (RA)</td>
<td>33</td>
<td>28</td>
<td>11</td>
<td>6 11</td>
</tr>
<tr>
<td>Psoriatic arthritis (PsA)</td>
<td>47</td>
<td>34</td>
<td>13</td>
<td>12 9</td>
</tr>
<tr>
<td>Axial spondylarthropathy (axSpA)</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reactive arthritis (ReA)</td>
<td>9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In total</td>
<td>422</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Microbiome analysis of RheumaVOR fecal samples. A: Analysis of beta diversity (PCoA) using Bray-Curtis distances. B: Alpha diversity of PSA patients receiving MTX as first-line medication. P values represent an unpaired nonparametric Mann–Whitney test, *p < 0.05.
Disclosure of Interests: Dornatien Anang: None declared, Tamara H.Ramwadhoeb: None declared, Janine Hahnlein: None declared, Bo van Kuik: None declared, Smit Noortje: None declared, Krijn P. van Lienden: None declared, Mario Maas: None declared, Danielle Gerlag Employee of: Employee of UCB Pharma. UCB Pharma was not involved in this study, Paul-Peter Tak Employee of: Employee of Candel therapeutics. Candel therapeutics was not involved in the study, Niek de Vries: None declared, Lisa van Baaren: None declared. 

Exploring the origin of inflammation in spondyloarthritis

OP0100 IL-17A BLOCKADE MODULATES DISEASE SPECIFIC IMMUNE AND STROMAL PATHWAYS IN PERIPHERAL SPONDYLOARTHRITIS SYNOVITIS

R. Fiechter1, L. van Mens1, I. Hammoura1, H. de Jong1, D. Pots1, I. Fluri1, S. Tas1, D. Baeten1, M. G. H. van de Sande1, N. Yeremenko1. 1Amsterdam UMC, location AMC, Rheumatology and Clinical Immunology / Experimental Immunology, Amsterdam, Netherlands

Background: The cellular and molecular mechanisms driving inflammation and structural remodelling in spondylarthropathies (SpA) remain largely unknown, though the IL-23/IL-17 pathway can contribute to synovial inflammation and radiographic progression.

Objectives: To investigate the molecular pathways affected by IL-17A blockade (IL-17Ai) with secukinumab in SpA synovitis, and assess if this response is tissue- and/or treatment-specific.

Methods: Synovial biopsies were obtained from peripheral SpA patients by needle arthroscopy before and after 12 weeks of IL-17Ai with secukinumab (n=12), and analyzed by RNA-sequencing and qPCR. We performed pathway enrichment analysis of the differentially expressed genes (DEGs) to identify pathways modulated after treatment. We compared the synovial tissue response in patients with psoriatic arthritis (PsA) in our cohort (n=7) with open source gene expression data of skin biopsies of psoriasis patients receiving secukinumab (n=22) [1] and of synovial biopsies of PsA patients receiving IL-12p40/IL-23p40 blockade (n=7) [2].

Results: IL-17Ai significantly modulated the expression of 1255 genes (549 up- and 706 down-regulated, FDR 0.1) in the synovium at week 12 compared to baseline (Figure 1). Genes downregulated upon IL-17Ai were significantly enriched in GO terms and KEGG pathways related to immune and inflammatory responses, including neutrophil and monocyte chemotaxis, TNF-mediated, NF-kB-, Wnt-, and JAK-STAT signalling pathways, and, importantly, bone-remodelling responses, such as osteoblast and osteoclast differentiation. Upregulated genes are enriched in JNK-, MAPK-, Wnt-, and PI3K-Akt signalling and negative regulation of osteoblast differentiation. We validated differential expression of selected genes from several pathways by qPCR, including: IL1B, p=0.027; CXCL6, p=0.020; ADAMTS4, p=0.002; MMP3, p=0.020; and CHRD2L2, p= 0.039.

To assess if this response is tissue- and/or treatment-specific, we compared changes in gene expression by IL-17Ai in PsA synovium versus psoriatic skin, and in the PsA synovium after IL-17Ai versus IL-12p40/IL-23p40 blockade. While many inflammation-related GO terms and KEGG pathways were over-represented in both tissues and treatments, NF-kB-, JAK-STAT-, and PI3K-Akt-signalling were enriched in DEGs in both skin and synovium after IL-17Ai, whereas JNK cascade, IL-17 signalling pathway and Th17 cell differentiation were over-represented in DEGs after IL-17Ai in the synovium specifically. Remarkably, IL-17Ai, but not IL-12p40/IL-23p40 blockade, modulated multiple bone-remodeling related pathways. Also, IL-17Ai modulated ossification and collagen catabolic process terms in PsA synovium and psoriatic skin in the opposite direction: these terms were over-represented in downregulated genes in synovium, but in upregulated genes in skin. Accordingly, genes upregulated after IL-17Ai were enriched in negative regulation of osteoblast differentiation in the synovium, but in positive regulation of osteoblast differentiation in the skin.

Conclusion: These first in vivo human data provide molecular confirmation of previously reported animal data [3] that demonstrated down-modulation of disease-relevant immune and stromal pathways in the synovium in response to IL-17Ai.

REFERENCES:

Disclosure of Interests: Renée Fiechter: None declared, Leonie van Mens: None declared, Ihsan Hammoura: None declared, Henriëtte de Jong: None declared, Desire Pots: None declared, Inka Fluri: None declared, Sander Tas: None declared, Dominique Baeten Employee of: Current employee of UCB Pharma, Mariëne G.H. van de Sande Consultant of: Novartis and AbbVie, Grant/Research support from: Janssen, Novartis and Eli Lilly, Nathalya Yeremenko: None declared.


OP0101 MECHANICAL LOAD-INDUCED BHLHE40 PROMOTES INFLAMMATORY ARTHRITIS

E. Gracey1, 2, I. Cambre1, E. Gillis1, F. Stappers1, G. Planckaert1, 3, A. Bozee4, D. Elewaut1, 2, 3
1Ghent University, Department of Internal Medicine and Pediatrics, Ghent, Belgium; 2Vlaams Instituut voor Biotechnologie, Center for Inflammation Research (IRC), Gent, Belgium; 3Ghent University Hospital, Orthopedics, Gent, Belgium; 4University Hospital Erlangen, Department of Medicine, Erlangen, Germany; 2Ghent University Hospital, Rheumatology, Gent, Belgium

Background: Force induced microdamage to joint tissue is hypothesized to trigger inflammatory events in the joint leading to arthritis. Patients with inflammatory arthritis, such as rheumatoid arthritis (RA) and spondyloarthropathies (SpA), are found to have inflammation in “mechanical hotspots” and mechanical loading in mouse models of these diseases is pro-arthritisogenic [1-7]. To date, the molecular mechanism involved in converting force to a biological signal that promotes arthritis is not known.

Objectives: This study aims to identify stretch induced genes in synovial fibroblasts, and the effect of these “mechano-sensitive” genes on arthritis.

Methods: Human synovial fibroblasts were stretched in vitro for 4hrs using the FlexCell system and analysed by microarray. Top stretch induced genes were measured in RA, SpA and healthy synovial tissue by qPCR. Patient synovium was further analysed by immunohistochemistry and collagenease digestion. Bhlhe40 deficient mice were subjected to collagen induced arthritis (CIA) and KBxN serum transfer arthritis (STA). FACS was performed on ankle synovium. uCT was performed on whole ankles, with morphological changes scored by blinded readers, and calcaneus erosions by customs scripts in Fiji.

Results: 600 genes were found to be differentially expressed in stretched synovial fibroblasts (fold change > +/-1.5, adjusted p<0.05). 25% of these genes were found to be transcription factors, which included BHLHE40. BHLHE40 mRNA was elevated in the synovial tissue of RA/SpA vs healthy subjects (1.56 fold change), and BHLHE40 protein was widely detectable in synovial fibroblasts and macrophages (Figure 1). Bhlhe40 deficient mice were completely protected against CIA (incidence: 0% vs 40%, n=30 per group), but Bhlhe40 deficiency was not blocked the generation of anti-collagen antibodies. Bhlhe40 deficient mice were partially protected against STA (peak clinical score at day 7: 5.2 vs 8.8, n=15 per group), with reduced synovial macrophage (CD11b+Ly6G-F4/80+) and neutrophil (CD11b+Ly6G+) frequency observed in the arthritic Bhlhe40 deficient mice compared to wildtype controls. Bhlhe40 had no impact on bone erosions with STA.

Figure 1. Heatmap of differentially expressed genes (DEGs) and pathway enrichment analysis of changes in peripheral SpA synovium 12 weeks after anti-IL-17A treatment (IL-17Ai). A. Hierarchical cluster analysis of the top 100 most significant DEGs (FDR < 0.1) modulated by IL-17Ai separates pre- and post-treated groups. Normalized and scaled log2 gene expression levels are shown. B. Pathway enrichment analysis through DAVID. Enriched (p < 0.05) gene ontology terms from IL-17Ai-induced up- and down-regulated DEGs in peripheral SpA synovium are shown.
Conclusion: BHLHE40 was identified as a force-induced gene in synovial fibroblasts and was found to be upregulated in patients with inflammatory arthritis. Importantly, Bhlhe40 strongly promotes joint inflammation in murine models of arthritis and uncouples systemic autoimmunity from joint tissue inflammation. Thus, we have identified BHLHE40 as a novel regulator of mechanical load-associated inflammation.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Top 5 synovial fibroblast (SF) marker genes.

<table>
<thead>
<tr>
<th>Cluster</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>PRG4 SF</td>
<td>PR4A</td>
</tr>
<tr>
<td></td>
<td>CSN1S1</td>
</tr>
<tr>
<td></td>
<td>MMP3</td>
</tr>
<tr>
<td></td>
<td>CRTAC1</td>
</tr>
<tr>
<td></td>
<td>HTRA1</td>
</tr>
<tr>
<td>CXCL12 SF</td>
<td>APOE</td>
</tr>
<tr>
<td></td>
<td>CXCL12</td>
</tr>
<tr>
<td></td>
<td>CCL2</td>
</tr>
<tr>
<td></td>
<td>PTGDS</td>
</tr>
<tr>
<td></td>
<td>CD74</td>
</tr>
<tr>
<td></td>
<td>COMP</td>
</tr>
<tr>
<td></td>
<td>COL1A1</td>
</tr>
<tr>
<td></td>
<td>POSTN</td>
</tr>
<tr>
<td></td>
<td>CILP</td>
</tr>
<tr>
<td></td>
<td>PTN</td>
</tr>
<tr>
<td></td>
<td>MFAP5</td>
</tr>
<tr>
<td></td>
<td>SFRP2</td>
</tr>
<tr>
<td></td>
<td>APOD</td>
</tr>
<tr>
<td></td>
<td>CXCL14</td>
</tr>
<tr>
<td></td>
<td>CFD</td>
</tr>
</tbody>
</table>

Conclusion: We were able to compare the synovium of the most common chronic inflammatory joint diseases on various levels for the first time. The findings set the path for future diagnostic, prognostic, and therapeutic approaches in inflammatory joint diseases.

REFERENCES:

Disclosure of Interests: None declared

**OP0103**

**GENE EXPRESSION PATTERNS RETRIEVED FROM SINGLE CELL RNA SEQUENCING REVEAL PHENOTYPIC TRAITS IN PATIENTS WITH PSORIATIC ARTHRITIS INITIATING TUMOUR NECROSIS FACTOR ALPHA INHIBITOR AND INTERLEUKIN-17 INHIBITOR**

M. Skougaard; C. Drachmann; Z. R. Stisen; S. B. Ditte; L. E. Jessen; L. E. Kristensen; Bispebjerg and Frederiksberg Hospital, The Parker Institute, Copenhagen, Denmark; Aarhus University Hospital, Department of Clinical Immunology, Aarhus, Denmark; Bispebjerg and Frederiksberg Hospital, Copenhagen Center for Translational Research, Copenhagen, Denmark; Technical University of Denmark, Department of Health Technology, Section of Bioinformatics, Kgs. Lyngby, Denmark

**Background:** Patients with Psoriatic Arthritis (PsA) suffer from heterogeneous debilitating symptoms caused by immune-mediated inflammation. However, great diversity in clinical response to available medical therapies targeting the immune response in PsA complicates treatment decision-making.

**Objectives:** The primary objective of the study was to evaluate gene expression profiles at baseline in responders versus non-responders of Tumour Necrosis Factor alpha inhibitor (TNFi) and Interleukin-17 inhibitor (IL-17i), respectively, to examine the foundation for future improved PsA patient stratification.

**Methods:** Single cell RNA sequencing (scRNAseq) was included to evaluate the transcriptome in responders versus non-responders of Tumour Necrosis Factor alpha inhibitor (TNFi) and Interleukin-17 inhibitor (IL-17i). Peripheral blood mononuclear cells (PBMCs) was isolated for scRNAseq and Disease Activity Score in PsA (DAPSA) retrieved in 40 PsA patients; 20 initiating TNFi and 20 initiating IL-17i. Responders and non-responders were stratified based on 50% improvement after 4-months (DAPSA50). The BD Rhapsody Whole Transcriptome Approach [1] was applied to prepare cDNA libraries sequenced to a depth of approximately 50,000 reads pr. cells on the Illumina NovaSeq 6000. The Seurat pipeline [2] was implemented for the analysis of gene expression on single cell level.

**Results:** A total of 273,515 cells were retrieved after initial quality control. Comparing patient demographics and characteristics at baseline revealed no difference between groups (Table 1). Dimensionality reduction with principal component analysis and additional clustering analysis indicated different phenotypic traits of responders and non-responders to TNFi and IL-17i (Figure 1).

**Conclusion:** High-dimensional data, retrieved from scRNAseq combined with bioinformatic data modelling and clinical knowledge, is important and should possibly be implemented to explore PsA disease heterogeneity and for better stratification of PsA patients prior to initiating available medical therapies.

**REFERENCES:**


**Disclosure of Interests:** Marie Skougaard Speakers bureau: has received speaking fees from Janseen, Abbvie; Research support from: has received research funding from Eli Lilly, Pfizer, The Danish Rheumatism Association and the Danish Psoriasis Association., Clara Drachmann: None declared, Zara Rebecca Stisen: None declared, Sissie B. Ditte: None declared, Leon Eyrich Jessen: None declared, Lars Erik Kristensen: Speaker bureaux: from Pfizer, Abbvie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals, Consultant of: from Pfizer, Abbvie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals, Grant/research support from: from Novo, UCB, Eli Lilly; Novartis and Abbvie

**DOI:** 10.1136/annrheumdis-2022-eular.3511

---

**OP0104**

**EXPANDED CD8+ T CELL CLONES FROM HLA-B*27+POSITIVE PATIENTS WITH SPONDYLOARTHROPATHIES SHOW SIGNS OF ANTIGEN-EXPERIENCE**

J. Rademacher; K. Deschler; S. Lacher; A. Huth; M. Utz; S. Krebs; H. Blum; E. Beltrán; D. Podubny; K. Dormair; Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Germany Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany; Berlin Institute of Health (BIH), BIH Biomedical Innovation Academy, BIH Charité (Junior) (Digital) Clinician Scientist Program, Berlin, Germany; Ludwig-Maximilians-Universität München, Institute of Clinical Neuroimmunology, Biomedical Center and Hospital of the LMU Munich, Munich, Germany; Gene Center of the LMU Munich, Germany, Laboratory for Functional Genome Analysis (LAFUGA), Berlin, Germany; German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany

**Background:** The pathogenesis of Spondyloarthritides (SpA) remains unknown but its strong association with some alleles of HLA-B*27 is peculiar. The arthritogenic antigen hypothesis assumes the existence of specific peptides presented by risk-conferring HLA-B*27 alleles to antigen-specific CD8+ T cells, which then initiate or sustain autoimmune reactions. Several studies analyzing T cell receptor (TCR) repertoire found preferred TCR chains and motifs in the hypertvariable complementary determining region (CDR) 3, but analyzed only TCR β-chains in bulk analyses<sup>1,2</sup>

**Objectives:** To analyze full sequence information of TCR including matching α- and β-chains from single CD8+ T cells and characterize the transcriptions of expanded and non-expanded clonotypes in synovial fluid (SF) of SpA patients.

**Methods:** We included 17 patients with active spondarthritis: 10 patients with HLA-B*27 positive (B27pos) SpA, 4 with HLA-B*27 negative (B27neg) SpA and 3 rheumatoid arthritis (RA) patients. Antigen-experienced CD8+ T cells were sorted out of SF by flow cytometry. Single cell sequencing was performed for all patients to
analyze matching TCR α- and β-chains. For 7 patients (3 B27pos SpA, 2 B27neg SpA, 2 RA), additionally whole transcriptome analyses were performed.

Results: We found strong biases when analyzing α- and β-chains of TCR Variable regions and CDR1 and CDR2 sequences (Figure 1 a,b): AV21, AV12-2, and AV17 were highly enriched in B27pos SpA as compared to B27neg subjects. Amongst the highest expressed clones, we could confirm enrichment for previously described TRBV genes as BV19, BV5-1 and BV6-2. We examined TCR αβ combinations and focused on those detected in at least three different B27pos SpA but not in any of the B27neg patients (Figure 1 c-f). The combinations TRBV19/TRAV21 and TRBV6-2/TRAV21 were most likely specific for B27pos SpA but not in any of the B27neg patients (Figure 1 c-f). The combinations and focused on those detected in at least three different B27pos SpA but not in any of the B27neg patients (Figure 1 c-f). The combinations TRBV19/TRAV21 and TRBV6-2/TRAV21 were most likely specific for B27pos SpA but not in any of the B27neg patients (Figure 1 c-f).

Sequences of CDR3 loops, which predominantly interact with HLA-bound antigenic peptides, revealed striking common structural motifs in α- and β-chains. Focusing on the most prominent TRAV21 chains pairing with TRBV19, 5-1 and 6-2 chains, revealed identical sequences in different patients and striking common structural motifs in α- and β-CDR3 sequences in other patients. Such marked similarities in the antigen-recognition loops of the β-chains associated with TRAV21 suggest common or highly similar antigens.

Gene expression levels provided evidence that expanded cell populations had tissue resident memory (TRM) phenotypes (elevated expression of activation, migration and tissue retention markers, downregulated genes characteristic for T cell egress), while this phenotype was not very pronounced in non-expanded cells. Furthermore, markers for T cell exhaustion and apoptosis were elevated in expanded cells of B27pos SpA patients.

Conclusion: Analysis of single antigen experienced CD8+ T cells from SF of B27pos SpA patients revealed significant clonal expansions and common motifs in the CDR loops. Two of the four CDR1 and CDR2 loops were highly homologous suggesting that these loops interact with α-helices of HLA-B*27. Common motifs in CDR3 loops of expanded clonotypes suggest recognition of a limited set of antigenic peptides presented by HLA-B*27. Many of the expanded clonotypes showed a TRM phenotype, were exhausted and on the way to become apoptotic, which suggests that these clones had sustained contact to specific antigens.

REFERENCES:

Acknowledgements: We thank all patients included in this study for their participation. This work was funded by the German Research Foundation (DFG) through grants DO 420/4 to KDo, PO 2124/2-1 to DP, and SyNergy (EXC 2145 SyNergy – ID 390857198) to KDo. Judith Rademacher and Katharina Deschler contributed equally. JR is participant in the BIH-Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health. The authors would like to thank Martina Seipel for excellent technical assistance, Sabrina Sron for patient recruitment and study coordination, and Hildrun Habel, Mikhail Protopopov, Fabian Proft, Valeria Rios Rodriguez and Laura Spiller for recruiting patients for this study.

Disclosure of Interests: None declared


Figure 1. Distinct TCRαV chain usage in expanded clones from HLA-B27 positive SpA patients. A,B Mean number of all productive TRAV (A) and TRBV (B) genes used in expanded, antigen-experienced CD8+ T cell clones (>1% of all cells) from SF of 10 B27pos, 4 B27neg SpA and 3 B27neg RA patients. C-F TRAV chains paired with TRBV19 (C), TRBV5-1 (D), TRBV6-2 (E), or TRBV chains paired with TRAV21 (F) with corresponding TRAV sequences grouped into expanded clones (frequency ≥2) from all 10 B27pos SpA. Number of chains are 1250 (C), 868 (D), 1220 (E), and 4006 (F).
SOLUBLE PD-1 PROMOTES LOCAL IL-17A PRODUCTION IN THE INFILTRATING MICROENVIRONMENT IN SPA

E. Rasmussen1, R. Østgaard2, M. Hvild3, U. Syrbe1, D. Poddubnyy5, B. Deleuran1, A. Aarhus University, Department of Biomedicine, Aarhus University, Department of Rheumatology, Department of Rheumatology, Aarhus, Denmark; 2Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Rheumatology, Berlin, Germany; 3Skjæbye Sygehus, Department of Rheumatology, Aarhus, Denmark

Background: Programmed death 1 (PD-1) is an immune checkpoint receptor expressed by activated T-cells. Activation of the PD-1 pathway reduces T cell activation and inflammation. Targeting PD-1 in cancer can result in autoimmune disease, which highlights the importance of this pathway in balancing inflammation. Both PD-1 and its ligands are present in soluble (s) forms, and we have previously shown that sPD-1 is associated to bone erosions in rheumatoid arthritis. Spondyloarthritis (SpA) is characterized by both bone erosions and bone formation. Current evidence suggests an important interaction between the PD-1 pathway and the proinflammatory cytokine IL-17A. IL-17A is central in promoting inflammation in SpA and direct osteoclast activation leading to bone erosion. We have previously demonstrated that the PD-1 ligand, PD-L2, reduces osteoclast formation under inflammatory conditions.

Objectives: We aimed at investigating the interplay between the PD-1 pathway and IL-17A in relation to inflammation and bone homeostasis in patients with SpA.

Methods: From early SpA patients, plasma was collected at baseline and after 1 year of treatment with Adalimumab. From chronic SpA patients, plasma, synovial fluid (SF), peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were collected. Plasma and PBMCs were also collected from healthy controls (HC) for comparison. Disease activity was measured by ASDAS and progression by inflammation and new bone formation in the total spine.

Facet joint biopsies were collected from SpA patients during surgery for correction of rigid hyperkyphosis. Levels of sPD-1 and sPD-L2 were measured in plasma and SF. Surface expression of PD-1 and CCR6 was evaluated on PBMCs and SFMCs. Levels of IL-17A were measured in the supernatant from stimulated PBMC cultures with recombinant human (rh)PD-1. Facet joint biopsies were stained for the presence of PD-1, PD-L1, PD-L2 and CCR6.

Results: Plasma levels of sPD-1 and sPD-L2 were equally increased in both early and chronic SpA compared to HC. Plasma levels of sPD-1 and sPD-L2 did not change following one year of treatment. In chronic SpA patients, sPD-1 levels were higher in SF than in plasma. Levels of sPD-1 and sPD-L2 in plasma and SF did not correlate with any disease activity scores or progression. Expression of PD-1 on the cell surface of PBMCs from SpA patient was comparable to healthy controls. On SFMCs, PD-1 expression was increased, supporting continuous T-cell activation in the local microenvironment. After stimulation with anti CD3/CD28, SpA PBMCs produced more IL-17A when cultured with rhPD-1 compared to healthy control PBMCs.

Conclusion: Plasma levels of the PD-1 family is unaffected by addition of anti-TNFα antibody treatment in SpA. The early SpA cohort had a low degree of proliferation in structural changes in the observation period, which could explain the lack correlation with sPD-1 and sPD-L2 and disease progression. Soluble PD-1 is high in the inflamed microenvironment, where it may result in increased IL-17A production. Collectively, these data suggest that the PD-1 pathway could play a role in the pathogenesis of SpA, acting in the inflamed microenvironment.

Disclosure of Interests: None declared


NEW INSIGHTS IN THE GENOMIC “GRAMMAR” OF RHEUMATOID ARTHRITIS

I. Papageorgiou1, M. Zervou2, G. Zisios2, D. Vlachakis3, G. Bertias3, G. Goulielmis4, E. Eliopoulos5, 1Agricultural University of Athens, Department of Biotechnology, Athens, Greece; 2University of Crete, School of Medicine, Heraklion, Greece

Background: Rheumatoid arthritis (RA) is a complex disease, caused by a combination of genetic, epigenetic and environmental factors common to other related autoimmune diseases including Multiple Sclerosis (MS) and Systemic Lupus Erythematosus (SLE) [1]. Using state of the art Bioinformatics tools we are able to formulate an ensemble (an ensemble of associated components or “ensemble grammar”) for each disease and distinguish important differences and common aspects in a specific group of disease such as ensembles of autoimmune diseases [2].

Objectives: To create, collect and evaluate the most credible and unique gene variants, epigenetic variants and single nucleotide polymorphisms (SNPs) causing the basis of an immune disease (the genomic grammar of the disease), which could potentially assist in the process of the RA disease prevention, diagnosis and treatment [3].

Methods: RA related publications from the PubMed have been analyzed using data mining and semantic techniques towards extracting the candidate causative SNPs. The extracted knowledge has been filtered, evaluated, annotated, and classified in a structured database which also includes GWAS information regarding SNPs. Additional clinical, genomic, structural, functional and biological information was also extracted from biological databases including dbSNP, LitVar, ClinVar and OMIM and cross-correlated with other available autoimmune disease related SNP databases, including the Demetra application, Epione application and Panacea application databases [3, 4].

From gene to function: genetic basis of rheumatic diseases
Results: A holistic genetic map of the studied autoimmune diseases with more than 2000 related SNPs has been estimated and specific sub-clusters with crucial nodes have been identified across the RA, SLE and MS diseases. Based on these results, the three studied autoimmune diseases share a 10% common SNPs genetic background (Figure 1 and Table 1) [5]. The optimal genomic grammar of the RA contains 1682 SNPs, with 73% responding to non-coding regions and 27% responding to coding regions of more than 1,300 genes, pseudogenes, primers and promoters. RA also shares 464 common SNPs with SLE and 113 with MS.

Table 1. Common Related Genes based on the analyzed SNP targets in the studied disease.

<table>
<thead>
<tr>
<th>A/A</th>
<th>Gene / Region</th>
<th>A/A</th>
<th>Gene / Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>ADAM33</td>
<td>2.</td>
<td>LOC285626</td>
</tr>
<tr>
<td>3.</td>
<td>ADIPOQ</td>
<td>4.</td>
<td>MIR3142HG</td>
</tr>
<tr>
<td>5.</td>
<td>CD40</td>
<td>6.</td>
<td>MIR469A</td>
</tr>
<tr>
<td>7.</td>
<td>CIITA</td>
<td>8.</td>
<td>MTHR</td>
</tr>
<tr>
<td>9.</td>
<td>CTLA4</td>
<td>10.</td>
<td>MTND5</td>
</tr>
<tr>
<td>11.</td>
<td>FCRL3</td>
<td>12.</td>
<td>NCF1</td>
</tr>
<tr>
<td>13.</td>
<td>HLA-DPB1</td>
<td>14.</td>
<td>NLRP1</td>
</tr>
<tr>
<td>15.</td>
<td>HLA-DRA</td>
<td>16.</td>
<td>NOS3</td>
</tr>
<tr>
<td>17.</td>
<td>HLA-DQ</td>
<td>18.</td>
<td>NRG2C1</td>
</tr>
<tr>
<td>19.</td>
<td>IL17A</td>
<td>20.</td>
<td>PADI4</td>
</tr>
<tr>
<td>21.</td>
<td>IL1RN</td>
<td>22.</td>
<td>PDCD1</td>
</tr>
<tr>
<td>23.</td>
<td>IL2</td>
<td>24.</td>
<td>PON1</td>
</tr>
<tr>
<td>25.</td>
<td>IL23R</td>
<td>26.</td>
<td>STAT4</td>
</tr>
<tr>
<td>27.</td>
<td>IL6</td>
<td>28.</td>
<td>TGFBI</td>
</tr>
<tr>
<td>29.</td>
<td>IL7R</td>
<td>30.</td>
<td>TLR9</td>
</tr>
<tr>
<td>31.</td>
<td>IRAK1</td>
<td>32.</td>
<td>TNF</td>
</tr>
<tr>
<td>33.</td>
<td>VDR</td>
<td>34.</td>
<td>TNFRSF1A</td>
</tr>
<tr>
<td>35.</td>
<td>IRF5</td>
<td>36.</td>
<td>TVK2</td>
</tr>
<tr>
<td>37.</td>
<td>KIF5A</td>
<td>38.</td>
<td>UCP2</td>
</tr>
<tr>
<td>39.</td>
<td>LEP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Three class Venn diagram of the genomic grammar between RA, MS and SLE.

Conclusion: The identification of the optimal genomic grammar in RA will help towards understanding the nature of the disease. Specific genetic targets via determined SNPs could act as biomarkers that aid in forming the right diagnosis [6].

REFERENCES:


Disclosure of Interests: None declared

OP0110
CELL-TYPE-SPECIFIC TRANSCRIPTOME ARCHITECTURE UNDERLYING THE ESTABLISHMENT AND EXACERBATION OF SYSTEMIC LUPUS ERYTHEMATOSUS

M. Nakano1,2, M. Ota1,2, Y. Takeshima1, Y. Iwasaki1, H. Hatano1,2, Y. Nagafuchi1,2, K. Kim1,2, S. Y. Bang1, H. S. Lee1, H. Shoda1, X. Zhang3, S. C. Bae4,5, C. Terasaki6,7,12, K. Yamamoto1,4, K. Ishigaki1,2, K. Fujio.1,2,3,4,5,6,7

1Graduate School of Medicine, the University of Tokyo, Department of Allergy and Rheumatology, Tokyo, Japan; 2RIKEN Center for Integrative Medical Sciences, Laboratory for Autoimmune Diseases, Yokohama, Japan; 3Graduate School of Medicine, the University of Tokyo, Department of Functional Genomics and Immunological Diseases, Tokyo, Japan; 4RIKEN Center for Integrative Medical Sciences, Laboratory for Human Immunogenetics, Yokohama, Japan; 5Kung Hee University, Department of Biology, Seoul, Korea, Rep. of (South Korea); 6Kung Hee University, Department of Biomedical and Pharmaceutical Sciences, Seoul, Korea, Rep. of (South Korea); 7Hanyang University Hospital for Rheumatic Diseases, Department of Rheumatology, Seoul, Korea, Rep. of (South Korea); 8Hanyang University, Institute for Rheumatology Research, Seoul, Korea, Rep. of (South Korea); 9First Affiliated Hospital, Anhui Medical University, Department of Dermatology, Hefei, China; 10Anhui Medical University, Institute of Dermatology, Hefei, China; 11RIKEN Center for Integrative Medical Sciences, Laboratory for Statistical and Translational Genomics, Yokohama, Japan; 12Shizuoka General Hospital, Clinical Research Center, Shizuoka, Japan; 13The School of Pharmaceutical Sciences, University of Shizuoka, The Department of Applied Genetics, Shizuoka, Japan

Background: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unknown etiology involving multiple immune cells and has diverse clinical phenotypes. This heterogeneous nature has hampered a better understanding of SLE pathogenesis and the development of effective therapeutic agents. While recent single-cell RNA sequencing studies of SLE identified several important cell subpopulations, they were limited by sparse expression information at single-cell level and small sample sizes.

Objectives: This study aimed to elucidate the dysregulated gene expression pattern linked to multiple clinical statuses of SLE with a fine cellular resolution and higher sensitivity. We also attempted to resolve a complex interaction between risk variants and the transcriptome dysregulation seen in SLE patients.

Methods: We conducted a large-scale bulk transcriptome study of 6,386 RNA-sequencing data including 27 puriﬁed immune cell types in peripheral blood from 136 SLE and 89 healthy donors in the Immune Cell Gene Expression Atlas from the University of Tokyo (ImmuneXUT) cohort. At enrolment, SLE patients have diverse clinical manifestations (diseases unique to organ involvement and treatment proﬁles) and 22 patients were re-evaluated after belimumab treatment.

Results: We ﬁrst proﬁled two distinct cell-type-specific transcriptomic signatures: disease-state and disease-activity signatures, reﬂecting disease establishment and exacerbation, respectively.

Moreover, we demonstrated cell-type-speciﬁc contributions to diverse organ involvement, e.g., Th1 for mucocutaneous, monocyte-lineage cells for muscle-skeletal, neutrophil-lineage cells for renal activity, respectively.

We also observed the strong associations of disease-activity signatures with treatment effect: (i) belimumab suppressed activity signatures from B-lineage cells, especially in good responders and (ii) mycophenolate mofetil substantially suppressed activity signatures from plasmablast, Th1, and central memory CD8 cells.

However, through stratified LD score regression using large-scale SLE GWASs, we revealed that disease-activity signatures were less enriched around SLE risk variants than disease-state signatures. Consistent with this result, the directions of SLE risk alleles’ expression quantitative trait locus (eQTL) effects were significantly concordant with the directions of disease-state signatures, but not with those of activity signatures. These ﬁndings suggested that the current genetic case-control studies may not well capture clinically vital biology linked to drug target discovery for SLE. Meanwhile, we also detected some examples of activity signatures that might contribute to the disease risk by modulating risk allele’s eQTL effects.

Disclosure of Interests: None declared


Figure 1. Manhattan plots for cis-expression quantitative trait loci (eQTL) analysis performed on 85 synovial samples (top) and 51 blood samples (middle). Tissue interaction eQTL (bottom) show significant differences between tissues (p < 5x10^-7).

OP0111
INTEGRATION OF GWAS AND EPIGENETIC STUDIES IDENTIFIES NOVEL GENES THAT ALTER EXPRESSION IN THE MINOR SALIVARY GLAND IN SJOGREN’S DISEASE


1Oklahoma Medical Research Foundation, Genes and Human Disease Research Program, Oklahoma City, United States of America; 2University of Mississippi Medical Center, Department of Medicine, Division of Rheumatology, Jackson, Mississippi; 3University of Oxford, Department of Clinical Genetics, and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom; 4University of North Carolina at Chapel Hill, School of Public Health, Department of Epidemiology, Chapel Hill, North Carolina; 5University of California, San Francisco, Department of Medicine, Division of Rheumatology, Oakland, California; 6University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, California; 7University of Washington, Department of Medicine, Division of Rheumatology, Seattle, Washington; 8University of Oxford, Oxford University Hospitals, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom; 9University of California, San Francisco, CHC Rheumatology Center, Department of Medicine, Division of Rheumatology, San Francisco, California; 10Geisinger Health, Department of Medical and Biomedical Informatics, Danville, Pennsylvania; 11University of California, San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, California; 12Oktoberfeld Zentrum für Medizinische Forschung, Institut für Klinische Genetik, der Universität Erlangen-Nürnberg, Erlangen, Germany; 13Memorial Sloan-Kettering Cancer Center, Department of Medicine, Division of Hematology, New York, New York; 14University of California, San Francisco, Department of Medicine, Division of Immunology, San Francisco, California; 15University of Oxford, Nuffield Department of Medicine, Ronald-Baillot-Institute for Rheumatology Research, Oxford, United Kingdom; 16University of California, San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, California; 17University of California, San Francisco, Department of Medicine, Division of Rheumatology, San Francisco, California

Disclosure of Interests: None declared

Figure 1. Identification of eQTL effects. This figure shows the eQTL effects identified by the eQTL analysis. The x-axis represents the log2 of the odds ratio (OR), and the y-axis represents the expression level of the gene. The color of the points indicates the direction of the eQTL effect, with red indicating upregulation and blue indicating downregulation. The size of the points is proportional to the significance of the eQTL effect. The eQTLs identified by the analysis are shown in red, and the eQTLs identified by the literature are shown in blue. The eQTLs identified by the analysis are significantly different from those identified by the literature, indicating the potential for novel gene identification.
Background: Sjogren's disease (SjD) is an autoimmune disease characterized by reduced function of exocrine glands (i.e., salivary and lacrimal glands). Epithelial cell damage resulting from lymphocytic infiltration has been implicated in SjD etiology [1]. How genetic and epigenetic changes influence epithelial-immune cell interactions in SjD pathogenesis remain understudied.

Objectives: Evaluate the role of SjD risk loci in salivary gland tissue to gain insights into the potential genes involved in salivary gland dysfunction.

Methods: SNPs from 16 regions with SNP-SjD associations (P<5x10^-8) in our GWAS study (3232 SjD cases and 3566 controls) were interrogated for eQTLs using genotype-Tissue Expression (GTEX) minor salivary gland data. Subsequent analysis identified genes that were both eQTLs in minor salivary gland and significantly expressed in RNA-seq and ATAC-seq data from the submaxillary salivary gland epithelial cell line, A253. Pathway enrichment analysis was performed using gProfiler on the genes where coexpression of eQTL, RNA-seq, and ATAC-seq data was observed. To further validate the results, we performed transcriptome-wide association study (TWAS) analysis using GWAS summary statistics and minor salivary gland eQTL data.

Results: In total, 5884 genome-wide significant SNPs from 16 SjD risk loci were identified as potential minor salivary gland eQTLs using two discovery thresholds: p(FDR)<0.05 provided by eQTL study (3566 SNPs) and p(FDR)<0.05 and p<0.05 in eQTL study (2318 SNPs). Further analysis revealed 10 SjD risk loci with SNPs that were minor salivary gland eQTLs for a total of 155 unique genes that had a coalescence of RNA- and ATAC-seq data in A253 cells. Many SNPs altered the expression of the nearest gene to the risk allele (i.e., index gene), such as IRFS and TNPO3 on chromosome 7 at 128Mb; however, this locus had 12 additional genes that were eQTLs in minor salivary gland. In contrast, other loci had no reported eQTLs for the index gene, but several reported eQTLs for other genes, such as TYK2 on chromosome 19 at 10Mb that showed no change in TYK2 expression but eQTLs for 8 distant genes, including ICAM1. Pathway enrichment analysis revealed an enrichment in Butyrophilin (BTN) family interactions (R-HSA-8851 (Padj=1.56E+10-5), including the BTN2A1, BTN2A2, BTN3A1, BTN3A2 and BTN3A3 gene cluster in the MHC region. In further support, TWAS of the minor salivary gland and the SjD GWAS summary statistics (after Bonferroni correction) showed association between SjD and TWAS (p=1.24x10^-42), as well as many other loci in the MHC region. In addition, several loci including index genes on chromosome 17 were significant, peaking at RP11-259G18.1 (p=4.43x10^-10).

Conclusion: This study shows that SjD-associated risk alleles influence disease by altering gene expression in immune cells and minor salivary glands. Further, our analysis suggests that altered gene expression in the minor salivary gland extends beyond the identified minor salivary gland index genes and their neighboring regions. Interestingly, we observed minor salivary gland eQTLs for several BTN family genes, which act as cell-surface binding partners to regulate cell-cell interactions, including interactions between epithelial cells and activated T cells [3]. Future work will assess chromatin-chromatin-interactions within the 10 SjD risk loci in salivary gland cells and tissues to map local chromatin regulatory networks that regulate gene expression. Additional transcriptome-wide studies of SjD minor salivary gland tissues will provide further insights into how altered gene expression in the salivary gland influences SjD pathology.

REFERENCES:

Disclosure of Interests: Farhang Aghakhani: None declared, Mandi M Wiley: None declared, Bhuvan Khatri: None declared, Kandice L Tessneer: None declared, Astrid Rasmussen: None declared, Simon J Bowman Consultant of: Abbvie, Galapagos, and Novartis in 2020-2021., Lida Radfar: None declared, Roald Omdal: None declared, Marie Wahren-Herlenius: None declared, Blake W. Smith: None declared, Jacob Fontaine: None declared, Maureen Rischmueller: None declared, Patrick M Gaffney: None declared, Judith A. James: None declared, Lars Ronnblom: None declared, R Hal Scofield: None declared, Xavier Mariette: None declared, Marta Alarcón-Riquelme: None declared, Wan Fai Ng: None declared, Kathy Sivils Employee of: Current employee of Janssen, Gunnar Nordmark: None declared, Unmesh Deshmukh of: None declared, A Darise Farris: None declared, Christopher Les: None declared


OPO112

THE EVER-LARGEST ASIAN GWAS FOR SYSTEMIC SCLEROSIS AND TRANS-POPULATION META-ANALYSIS IDENTIFIED SEVEN NEW LOCUS AND A CANDIDATE CAUSAL SNP IN A CIS-REGULATORY ELEMENT OF THE FCGR REGION

Y. Ishikawa1, N. Tanaka1, Y. Asano2,3, M. Koderad2, Y. Shirai2,2, M. Akahoshid2, M. Hasegawad, T. Matushita2, S. Kuzuyoshii, S. Motegid, H. Yoshifujid, A. Yohashikii, T. Kohimotoc, K. Takagii, A. Okaa, M. Kandaa, Y. Tanaka1, Y. Ito1, K. Nakano6, H. Kasamatsu5, A. Utsunomiyaii, A. Sekiguchii, H. Niro, M. Jinnd, K. Makinoc, T. Makinoni, H. Ihn7, M. Yamamotoc, C. Suzuki1, H. Takahashii, E. Nishaid2,3, A. Moritai1, T. Yamamoto2, M. Fujimoto2, Y. Kondob, D. Goto2, T. Sunand2, N. Ayazudai, H. Yanagidaii, T. Horitai, T. Atsumaii, H. Endo2, Y. Shima2, A. Kumanogochii, J. Hirata2, N. Otoroi, H. Suesugii, Y. Koike1, K. Tomizukai, S. Yoshino1, X. Liu1, S. Ito1, K. Hikino1, A. Suzuki1, Y. Momozowaa, I. Ikegawa2, Y. Tanakaa, O. Ishikawaa, K. Takeharai, T. Torii1, S. Sato1, Y. Okada3, T. Mimori2, F. Matsuod, M. Matusuda1,3, I. Imotod, T. Kuroyod, H. Yamasahii, K. Omhrui1, C. Teraii,4,4, 4RKEN Center for Integrative Medical Sciences, The Laboratory for Statistical and Translational Genetics, Yokohama, Japan; 2Tokohu University Graduate School of Medicine, Department of Dermatology, Sendai, Japan; 3The University of Tokyo, Department of Dermatology, Tokyo, Japan; 4Chukyo Hospital, Japan Community Health Care Organization, Department of Dermatology, Nagoya, Japan; 5Nippon Medical School Graduate School of Medicine, Department of Allergy and Rheumatology, Tokyo, Japan; 6Kyushu University, Faculty of Medicine, Department of Medicine and Biosysytematic Science, Fukuoka, Japan; 7Faculty of Medical Sciences, University of Fukushima, Department of Dermatology, Fukushima, Japan; 8Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Department of Molecular Pathology of Skin, Faculty of Medicine, Kanazawa, Japan; 9School of Medicine, University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; 10Gunnma University Graduate School of Medicine, Department of Dermatology, Maebashi, Japan; 11Graduate School of Medicine, Kyoto University, Department of Rheumatology and Clinical Immunology, Kyoto, Japan; 12Aichi Cancer Center Research Institute, Division of Molecular Genetics, Nagoya, Japan; 13Tokyo Women’s Medical University, Adachi Medical Center, Tokyo, Japan; 14Tokai university the institute of medical sciences, NA, Tokyo, Japan; 15Faculty of Medical Sciences, University of Fukui, Department of Dermatology, Fukui, Japan; 16Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Department of Molecular Pathology of Skin, Faculty of Medicine, Kanazawa, Japan; 17Newcastle University Graduate School of Medicine, Department of Dermatology, Newcastle, United Kingdom; 18Nagoya University Graduate School of Medicine, Department of Dermatology, Nagoya, Japan; 19Sapporo Medical School Graduate School of Medicine, Department of Dermatology, Sapporo, Japan; 20University of Tsukuba, Department of Dermatology, Sapporo, Japan; 21University of Tsukuba, Department of Dermatology, Sapporo, Japan; 22Fukuoka Medical University, School of Medicine, Department of Dermatology, Fukuoka, Japan; 23National Hospital Organization, Utsunomiya Hospital, Department of Dermatology, Tochigi, Japan; 24Faculty of Medicine and Graduate School of Medicine, Hokkaido University School of Medicine, Department of Dermatology, Sapporo, Japan; 25Sapporo Medical School Graduate School of Medicine, Department of Dermatology, Sapporo, Japan; 26Graduate School of Medicine, Osaka University, Department of Dermatology, Osaka, Japan; 27Faculty of Medicine, University of Tsukuba, Department of Internal Medicine, Tsukuba, Japan; 28National Hospital Organization, Utano National Hospital, Department of Clinical Immunology, Kyoto, Japan; 29Faculty of Medicine and Graduate School of Medicine, Hokkaido University School of Medicine, Department of Dermatology, Sapporo, Japan.
rs6697139, located within trans-population meta-analysis, respectively. One of Japanese novel risk SNPs, (4)
33University of Occupational and Environmental Health, Japan, The First Department of Internal Medicine, School of Medicine, Kitakyushu, Japan; 34Torii Clinic; NA, Maizuru, Japan; 35Jluknai Takeada General Hospital, NA, Kyoto, Japan; 36Graduate School of Medicine, Kyoto University, Center for Genomic Medicine, Kyoto, Japan; 37Institute of Medical Science, The University of Tokyo, Laboratory for Gene Technology, Human Genome Center, Tokyo, Japan; 38Graduate School of Frontier Sciences, The Research Center for Molecular Science, University of Shizuoka, The Department of Applied Genetics, Shizuoka, Japan
Background: Genome-wide association studies (GWASs) have identified 29 disease-associated single nucleotide polymorphisms (SNPs) for systemic sclerosis (SSc) in non-human leukocyte antigen (HLA) regions (1-7). While these GWASs have clarified genetic architectures of SSc, study subjects were mainly Caucasians limiting application of the findings to Asians.
Objectives: The study was conducted to identify novel causal variants for SSc specific to Japanese subjects as well as those shared with European population. We also aimed to clarify mechanistic effects of the variants on pathogenesis of SSc.
Methods: A total of 114,108 subjects comprising 1,499 cases and 112,609 controls were enrolled in the two-stage study leading to the ever-largest Asian GWAS for SSc. After applying a strict quality control both for genotype and single nucleotide polymorphisms (SNPs), imputation was conducted using the reference panel of the phase 3v5 1,000 genome project data combined with a high-depth whole-genome sequence data of 3,256 Japanese subjects. We conducted logistic regression analyses and also combined the Japanese GWAS results with those of Europeans (6) by an inverse-variance fixed-effect model. Polygenicity and enrichment of functional annotations were evaluated by linkage disequilibrium score regression (LDSC), Haplotype and IMPACT programs. We also constructed polygenic risk score (PRS) to predict SSc development.
Results: We identified three (FCRLA-FCGR, TNFAIP3, PLD4) and four (EOMES, ESR1, SLC12A5, TP1P2) novel loci in Japanese GWAS and a trans-population meta-analysis, respectively. One of Japanese novel risk SNPs, rs6697139, located within FCGR gene clusters had a strong effect size (OR 2.05, P=4.9x10^{-11}). We also found the complete LD variant, rs10917688, was positioned in cis-regulatory element and binding motif for an immunomodulatory transcription factor IRF8 in B cells, another genome-wide significant locus in our trans-ethnic meta-analysis and the previous European GWAS. Notably, the association of risk allele of rs10917688 was significant only in the presence of the risk allele of the IRF8. Intriguingly, rs10917688 was annotated as one enhancer-related histone marks, H3K4me1, in B cells, implying that FCGR gene(s) in B cells may play an important role in the pathogenesis of SSc. Furthermore, significant heritability enrichment of active histone marks and a transcription factor C-Myc were found in B cells both in European and Japanese populations by LDSC and IMPACT, highlighting a possibility of a shared disease mechanism where abnormal B-cell activation may be one of the key drivers for the disease development. Finally, PRS using effects sizes of European GWAS moderately fit in the development of Japanese SSc (AUC 0.520), paving a path to personalized medicine for SSc.
Conclusion: Our study identified seven novel susceptibility loci in SSc. Downstream analyses highlighted a novel disease mechanism of SSc where an interactive role of FCGR gene(s) and IRF8 may accelerate the disease development and B cells may play a key role on the pathogenesis of SSc.

REFERENCES:

Disclosure of Interests: None declared

FUNCTIONAL GENOMICS IN PRIMARY T CELLS AND MONOCYTES IDENTIFIES MECHANISMS BY WHICH GENETIC SUSCEPTIBILITY LOCI INFLUENCE SYSTEMIC SCLEROSIS RISK

D. Gonzalez Serna 1, C. Shi2, M. Kerick 1, J. Hankinson 2, J. Ding 3, A. McGovern 4, M. Tulino 5, N. Ortego 6, J. L. Callejas-Rubio 7, J. Martin Ibanez 2, G. Orozo 2, 3, Institute of Parasitology and Biomedicine Lopez-Neyra, Consejo Superior de Investigaciones Cientificas (IPBLN-CSIC), Granada, Spain; 4The University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom; 5The University of Manchester, Division of Infection, Immunity & Respiratory Medicine, Manchester, United Kingdom; 6Institute for Biosanitary Research of Granada, Department of Internal Medicine, Hospital Universitario San Cecilio, Granada, Spain; 7Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

Background: Systemic sclerosis (SSc) is a complex autoimmune disease with a strong genetic component. However, the underlying mechanism by which genetics increase disease risk is still unknown. The most recent GWAS studies have identified 27 independent signals associated to SSc [1]. However, the majority of these signals affect regulatory elements that can regulate genes often located hundreds of kilobases away.

The challenge in the post-GWAS era is to use functional genomics to translate genetic findings into patients' benefit, particularly in disease-relevant cell types.

Objectives: In this study we use chromatin conformation and gene expression analysis in patient derived primary cells and healthy individuals to assess potential mechanisms by which GWAS variants increase disease risk. We identify the potentially affected genes in a cell type specific manner and potential drug targets already in use or with potential for re-purposing.

Methods: Promoter capture Hi-C (pHi-C) and RNA sequencing experiments were performed in a total of 15 CD4+ T cells and CD14+ monocytes samples each isolated from peripheral blood from SSc patients and healthy controls. We linked SSc-associated variants with their target genes and performed differential expression and differential interaction analyses between both cell types. Potential drug targets were identified using a protein-protein interaction model and queried against the OpenTargets database.

Results: We linked SSc-associated loci to 39 new potential target genes, confirming 7 previously assigned genes. We highlight novel causal genes, such as CXCR5 as the most probable candidate gene for the DDX6 locus (Figure 1). We confirm some previously linked SSc genes such as IRF8, STAT4, or CD247 which interestingly showed cell type specific interactions. We also identified 15 potential drug targets already in use in other similar immune-mediated diseases that could be repurposed for SSc treatment. Furthermore, we observed that interactions are directly related with the expression of important genes implicated in cell type specific pathways.

Figure 1. Promoter Capture Hi-C interactions linking the DDX6 GWAS loci with the promoter of CXCR5 in CD4+ T cells and CD14+ monocytes. CD4+ T cells show significantly stronger interactions as well as CXCR5 gene expression.
Conclusion: Our study reveals potential causal genes for SSC-associated loci, some of them acting in a cell type specific manner, suggesting novel drug targets and biological mechanisms that may mediate SSC pathogenesis.

REFERENCES:

Acknowledgments: This work was supported by the Spanish Ministry of Science and Innovation (grants RTI201810332-B-100 and SAF2015-66761-P), the Cooperative Research Thematic Network (RETICS) programme (RD16/0012/0013) (RIER) from Instituto de Salud Carlos III (ISCIII, Spanish Ministry of Economy, Industry and Competitiveness), the Wellcome Trust (award references 207491/Z/17/2 and 215207/Z/19/Z), Versus Arthritis (award reference 217754), and the NIHR Manchester Biomedical Research Centre. DGS was supported by the Spanish Ministry of Economy and Competitiveness through the FPI programme (SAF2015-66761-P).

Disclosure of Interests: None declared


OP0114 IDENTIFICATION AND FUNCTIONAL PREDICTION OF LONG NONCODING RNA RELATED TO CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASES

F. Dai1, Q. B. Zhang3, Y. X. He1, Y. P. Tang1, T. Y. Lei1, Y. Jiang1, Y. F. Qiao1. 1Institute of Rheumatology and Immunology, Research Center of Hyperuricemia and Gout, Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China; 2Institute of Rheumatology and Immunology, Research Center of Hyperuricemia and Gout, Department of Geriatrics, the Affiliated Hospital of North Sichuan Medical College, Nanchong, China

Background: Recently, the role of long noncoding RNA (IncRNA) in rheumatic immune diseases has attracted widespread attention1. However, knowledge of IncRNA in connective tissue disease-associated interstitial lung disease (CTD-ILD) is limited.

Objectives: To explore the expression profile of IncRNA in peripheral blood mononuclear cells (PBMCs) of CTD-ILD patients and the possible mechanisms of significantly differentially expressed IncRNA involved in CTD-ILD, especially systemic sclerosis (SSc)-ILD and rheumatoid arthritis (RA)-ILD.

Methods: LncRNA microarray analysis was used to identify the pattern of IncRNA dysregulation between CTD-ILD and connective tissue disease without associated interstitial lung disease (CTD-NILD). Differential genes were identified by bioinformatic analysis. Relative expression levels of five differentially expressed IncRNAs in 120 SSc and RA patients with or without ILD were detected by quantitative reverse-transcription PCR (qRT-PCR).

Results: The differential gene expression analysis revealed 46 IncRNAs were upregulated while 194 IncRNAs were downregulated in the CTD-ILD group compared to the CTD-NILD group (Figure 1). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses identified several significant biological processes and signaling pathways, including NF-kappa B signaling pathway, IL-17 signaling pathway, Toll-like receptor signaling pathway, B cell receptor signaling pathway. qRT-PCR confirmed that the selected target genes were differentially expressed in different groups. In particular, the ENST00000604692 expression level was significantly higher in the ILD than the NILD group (p<0.05, Figure 1); T311354 and arginase-1 were significantly higher in SSc than RA group; Furthermore, the area under receiver operating characteristic curve for ENST00000604692 in predicting ILD from NILD was 0.797 (Figure 1).

Conclusion: This research has demonstrated, for the first time, the specific profile of IncRNA in PBMCs of CTD-ILD patients and the potential signal pathways related to the pathogenesis of CTD-ILD. ENST00000604692 can effectively distinguish ILD group from NILD group, which may be a diagnostic indicator of CTD-ILD, especially SSc-ILD and RA-ILD.

REFERENCES:

Disclosure of Interests: None declared


OP0115 MTDNA D-LOOP VARIANT M.16519C INCREASES THE RISK OF RAPID PROGRESSION OF KNEE OSTEOARTHRITIS: A META-ANALYSIS AND FUNCTIONAL STUDY

A. Duru-Sotuel1, M. Fernandez-Moreno1, T. Hermida Gomez1, P. Ramos-Lourou1, S. Retarado-Fernandez2, V. Suarez-Ulloa2, V. Babosa-Barreiro3, N. Oreiro4, C. Vaamonde-Garcia1, J. Vazquez-Garcia1, F. J. Blanco2, I. Rego-Perez2 on behalf of Grupo de investigación en Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), As Xubias, 15006, A Coruña, España; Servicio de Reumatología, A Coruña, Spain; Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), As Xubias, 15006, A Coruña, España; 3Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), As Xubias, 15006, A Coruña, España; 4Plataforma de Bioinformática, A Coruña, Spain; 5Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), As Xubias, 15006, A Coruña, España; 6Unidad de Apoyo a la Investigación, A Coruña, Spain

Background: The development of a tool capable of identifying patients suffering the rapid progressive knee Osteoarthritis (RPOA) was established as a goal to implement prevention strategies and to include them in clinical trials. Previous studies showed that mitochondrial DNA (mtDNA) variation plays a role in the incidence and progression of OA, but their influence on the development of RPOA is unknown.

Objectives: To find out new mtDNA variants related to RPOA in order to develop a predictive model based on genetic and clinical variables.

Methods: We used data from three independent prospective cohorts of patients: the Osteoarthritis Initiative (OAI) (N=1102) and the pooling of two European cohorts as replication cohort (N=706): the Cohort Hip and Cohort Knee (CHECK) and the Prospective Cohort of Osteoarthritis from A Coruña (PROCOAC). We classified the patients based on the following criteria:
- Rapid progressors (N Discovery=268, N Replication=107), subjects with baseline KL grade 0-1 and increase up to KL2/3 during 48-month follow-up; or baseline KL grade 2 and increase up to KL grade 4 during the follow-up.
- Non-rapid progressors (N Discovery=827, N Replication=992), subjects with the same baseline characteristics as rapid progressors, but with a slower or no evolution over time.

mtDNA variants were screened in the OAI by in-depth sequencing. Resulting variant was analyzed in the replication cohort by mini-sequencing techniques. Appropriate statistical approaches adjusting for confounding variables followed by a meta-analysis were applied.

Disclosure of Interests: None declared

We developed a functional study using two types of mitochondrial cybrids carrying the most common haplogroup H: one harboring the mtDNA variant m.16519C and the other the wild type m.16519T. Cybrids were used to assess mitochondrial biosynthesis and mitochondrial fitness/fusion by gene expression analyses, as well as cell viability under oxidative stress and mitochondrial reactive oxygen species (ROS) production.

Results: The in-depth sequencing of mtDNA showed the D-loop variant m.16519C significantly overrepresented in rapid-progressors [OR=1.506; 95% CI=0.848-2.675; p=0.162]. The analysis of this variant in the replication cohort showed a similar significant trend (OR=1.647; 95% CI=1.013-2.678; p=0.043). The logistic regression model revealed that, regardless of the different clinical variables, the variant m.16519C was significantly associated with RPOA in the OAI cohort (OR=1.559; 95% CI=1.125-2.161; p=0.008) (Table 1). The development of this model in the replication cohort showed a similar trend that bordered the statistical significance (OR=1.506; 95% CI=0.848-2.675; p=0.162) (Table 1). The subsequent meta-analysis for both ORs showed the variant m.16519C significantly associated with RPOA (OR=1.58; 95% CI=1.22-2.05; p<0.0027) (Figure 1).

Table 1. Binary regression model including clinical variables and m.16519C in both cohorts.

<table>
<thead>
<tr>
<th>Variable</th>
<th>A. Denmark</th>
<th>B. Ostergaard, R. Christensen, B. A. Esbensen</th>
<th>A. Copenhagen OAI</th>
<th>B. Copenhagen OAI (n=16519C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>0.0248 1</td>
<td>0.054 1</td>
<td>0.054 1</td>
<td>0.057 1</td>
</tr>
<tr>
<td>BMI</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
</tr>
<tr>
<td>WOMAC</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
</tr>
<tr>
<td>Age (y)</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
</tr>
<tr>
<td>BMI</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
</tr>
<tr>
<td>WOMAC</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
<td>0.0519 1</td>
</tr>
</tbody>
</table>

BMI: Body Mass Index; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; OR: Odds Ratio; CI: confidence interval; *: statistical significance declared at P < 0.05

Figure 1. Forest plot of the meta-analysis of the ORs of the two predictive models

Cybrids harboring the mtDNA variant m.16519C showed lower levels of PGC-1α (p=0.0024) and FIS1 (p=0.0519) than cybrids with the wild type. Cybrids harboring the variant m.16519C showed lower average cell survival under oxidative stress conditions (23.42±8.88 vs 115.7±64.1; p=0.0043), as well as higher mitochondrial ROS production.

Conclusion: D-loop variant m.16519C increases the risk of developing a rapid progression of knee OA. Among the effects caused by this variant both mitochondrial biogenesis and fission/fusion processes, as well as cell survival under oxidative stress conditions and mitochondrial ROS production seem to be affected.

Disclosure of Interests: None declared


HPR: From prevention to management

OP0016-HPR PATIENTS’ EXPERIENCES OF GROUP-BASED COGNITIVE BEHAVIOURAL THERAPY FOR INSOMNIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A QUALITATIVE STUDY

K. M. Latocha 1, K. Leppen 1,2, J. Jennum 3,4, M. Østergaard 1,2, R. Christensen 1,2, B. A. Esbensen 1,4, 1Copenhagen University Hospital - Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Glostrup, Denmark; 2Copenhagen University Hospital - Rigshospitalet, Copenhagen Center for Cancer and Organ diseases, Department of Oncology, Copenhagen, Denmark; 3University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 4Copenhagen University Hospital - Rigshospitalet, Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Glostrup, Denmark; 5Copenhagen University Hospital - Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Glostrup, Denmark; 6Copenhagen University Hospital - Bispebjerg and Frederiksberg, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Copenhagen, Denmark; 7University of Southern Denmark, Department of Clinical Research, Faculty of Health Sciences, Odense, Denmark

Background: Despite disease-modifying anti-rheumatic drugs, residual arthritic-related symptoms and burdens are still common in patients with rheumatoid arthritis (RA)1. In addition, insomnia – characterised by reduced sleep quantity and quality – is highly prevalent, occurring in up to 70% of patients with RA2. Insomnia is associated with increased pain, fatigue, and depressive symptoms. Cognitive behavioural therapy for insomnia (CBT-I) is recommended first-line treatment for chronic insomnia3 but has not been evaluated in patients with RA until now.

Objectives: The objective of this study was to explore patients’ experiences of CBT-I and how the components of CBT-I are incorporated in their sleep management.

Methods: Participants were patients with RA who had received CBT-I as experimental treatment for insomnia in a randomised controlled trial (RCT)4. Data were collected during an individual face-to-face interview using a semi-structured interview guide. The analysis was based on reflexive thematic method by Braun and Clarke5.

Results: Eleven participants (10 women and one man) from the intervention group of the RCT were interviewed. Prior to inclusion in the RCT, they had insomnia complaints for 8 years (median; interquartile range: 3/20 years).

Five themes emerged: 1) When knowledge contributes to an altered perception of sleep referring to the reduced misperception and increased motivation that followed sleep education, 2) Overcoming habits and perceptions to accelerate sleep onset referring to barriers related to sleep behaviour and mindset and how stimulus control was enabling them to find meaningful behaviour and rhythm, 3) The sleep window of challenges in learning how to sleep right referring to that payoff from sleep restriction did not come easily or by magic, and commitment led to progress and gave them confidence to continue, 4) Relaxation becomes a behavioural habit and goes beyond sleep referring to a means to achieve a relaxed body and mind and how they thereby copped better with RA-related symptoms, and 5) Break the cycle and regain control referring to how awareness of a vicious cycle was central to their perception of sleep and how trust in one’s own accomplishment was crucial to reducing worrying (See Figure 1).

Disclosure of Interests: None declared

REFERENCES:
[1] PMID: 29251034
[2] PMID: 25620673
[3] PMID: 28875581

Figure 1. The five themes with quotes from participants

Overall, the participants experienced CBT-I as challenging and demanding but at the same time meaningful. The participants considered persistency, stringency, and inflexibility necessary to succeed. After the intervention, the participants had continued using those components that enabled them individually to further improve their sleep.

Conclusion: The process towards eliminating insomnia was a bodily experience and involved a changed mindset that altered behaviour and cognitions.
OCT0118-HPR FROM CURING TO COPING: EXPLORING TASK-SHIFTING BETWEEN NORWEGIAN RHEUMATOLOGISTS AND OCCUPATIONAL THERAPISTS IN THE CARE OF HAND OSTEARTHRITIS

S. Zink1, I. Kjeken1, M. Feiring1,2, Diakonhjemmet Hospital, Norwegian National Advisory Unit on Rehabilitation in Rheumatology, Oslo, Norway; 2Oslo Metropolitan University, Department of Physiotherapy, Oslo, Norway

Background: Task-shifting between physicians and other health professionals is increasingly used as a strategy to optimise health care services. However, there is a lack of evidence regarding task-shifting within the field of rheumatology, specifically hand osteoarthritis (HOA). HOA is a highly prevalent rheumatic joint disease, and the number of people living with debilitating HOA will continue to rise in the coming decades. HOA is diagnosed based on clinical examination and the first choice of treatment is non-pharmacological. Despite this, patients with HOA are increasingly referred to rheumatologists (RTs) in specialist care, contributing to long wait times and bottlenecks within the health care service. A possible solution to this challenge is task-shifting to occupational therapists (OTs).

Objectives: To explore the process of task-shifting in the care of patients with HOA between RTs and OTs in a Norwegian health care context.

Methods: This is a multi-centre qualitative study. Individual semi-structured interviews were conducted in-person or digitally with RTs and OTs between December 2020–June 2021. They were audio-recorded and transcribed verbatim. Reflexive Thematic Analysis was employed to analyse the data, and carried out in NVivo.

Results: In total, 17 participants were interviewed: 9 RTs and 8 OTs. Majority of respondents were female (n = 14), had an average of 20.5 years of experience and were 48.5 years old. Interviews lasted on average 90 minutes, (range: 45–120 minutes). The analysis resulted in 5 main themes

1) Attitudes towards task-shifting of HOA care: Both RTs and OTs were overwhelmingly positive about task-shifting and reported OTs to be better suited for caring for patients with HOA than RTs. There was agreement amongst RTs that generally, they had little to offer HOA patients besides information.

2) Desirability of caring for HOA: RTs felt no occupational “ownership” of the HOA diagnosis due to the lack of curative medical treatment, and would prefer HOA patients to be seen by an OT. OTs on the other hand perceived themselves as a profession with tools, skills and competencies that would benefit patients with HOA.3) Practical and theoretical knowledge: OTs and RTs viewed different kinds of knowledge as central for task-shifting. Respondents emphasised that OTs must have good anatomical knowledge of the hand and confidence in identifying differential diagnoses that could potentially be more serious. Lack of knowledge lead to insecurity and hampered successful implementation of task-shifting.

4) Communication between RTs and OTs: RTs perceived OTs to be passive in communicating their willingness and competence in caring for this patient group. They expressed a wish for more “self-promotion” from OTs. OTs and RTs viewed communication between them as essential for task shifting. Good communication, understanding and inquisitive conversations acted as facilitators.

5) The importance of informal interpersonal relationships in the workplace: Informal interpersonal relationships facilitated trust and subsequent task-shifting between RTs and OTs. Personal relations directly affected engagement in the task-shifting process.

Conclusion: The findings show a unanimous wish for HOA care to be shifted from RTs to OTs. Attitudes towards HOA as a diagnosis, interpersonal relationships between RTs and OTs, and knowledge are key facilitators and barriers affecting this process. The findings contribute to the growing body of knowledge on strategies used to optimise health care services and can be used in the design and implementation of new care pathways for patients with HOA.

REFERENCES:

Acknowledgements: The authors thank the participants for generously sharing their experiences and the patient research partners for invaluable perspectives and contributions.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4527

OCT0118-HPR GAMING FOR ADHERENCE TO MEDICATION USING E-HEALTH IN RHEUMATOID ARTHRITIS (GAMER) STUDY – A RANDOMISED CLINICAL TRIAL

B. Pouls1,2, C. Bekker2, J. E. Vriezekolk1, S. van Dulmen3,2, B. van den Beemt1,2, 1Sint Maartenskliniek, Department of Rheumatology Research, Nijmegen, Netherlands; 2RadboudUMC, Radboud Institute for Health Sciences, Nijmegen, Netherlands; 3Netherlands Institute for Health Services Research, Healthcare Communication, Utrecht, Netherlands

Background: Effectiveness of pharmacological therapy in rheumatoid arthritis (RA) is limited by inadequate medication adherence. Medication adherence can be influenced by implicit attitudes of personal medication needs and concerns about adverse consequences. We targeted these implicit attitudes using a serious puzzle game. Objectives: To assess the effectiveness of a serious game compared to usual care to improve adherence to disease modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA).

Methods: A multicentre randomised clinical trial was performed with a 3 month follow-up period.[1] Inclusion criteria were adulthood, RA diagnosis, use of DMARDs and possession of a smartphone/tablet. All participants received usual care. In addition, intervention participants were invited to play the serious puzzle game at will. The game was designed to influence players’ attitudes toward medication.[2] Collected data consisted of serious game play data, Compliance Questionnaire in Rheumatology (CQR), Beliefs about Medication Questionnaire (BMQ), Health Assessment Questionnaire (HAQ) and Rheumatoid Arthritis Disease Activity Index (RADAI).

Primary outcome was DMARD implementation adherence at three months assessed as the difference in proportion of non-adherent patients (<80% taking adherence) between intervention and control group using the discriminant function of the CQR using the Chi-squared test. Two sample t-tests and Wilcoxon rank-sum test were performed to test for differences on secondary outcomes between study groups where appropriate.

Results: 229 participants were randomised and 186 participants completed the study. Of the 85 intervention participants, 70 (82%) played the serious game for at least one hour. The serious game was played a median of 36 sessions with an average playtime of 25 minutes leading to a median overall playtime of 9.7 hours. A total of 59 (69%) intervention participants showed at least 40 days of gaming activity. Control group adherence (54%) and intervention group adherence (63%) based on the dichotomised CQR-score did not differ at three months (p = 0.26) (see Table 1). Neither was there a significant difference in CQR continuous score (p = 0.20), beliefs about medication differential score (p = 0.43) or clinical outcomes (HAQ: p = 0.97; RADAI: p = 0.90) (see Table 1).

Table 1. Study outcomes at end-point (3 months)

<table>
<thead>
<tr>
<th>Primary outcome</th>
<th>Control group (n=101)</th>
<th>Intervention group (n=85)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent</td>
<td>55 (54)</td>
<td>52 (63)</td>
<td>0.26</td>
</tr>
<tr>
<td>no, (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary medication outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CQR continuous</td>
<td>75 ± 12</td>
<td>73 ± 11</td>
<td>0.20</td>
</tr>
<tr>
<td>mean ± SD</td>
<td>4.8 ± 4.2</td>
<td>5.3 ± 4.7</td>
<td>0.43</td>
</tr>
<tr>
<td>BMQ-Specific NCD score</td>
<td>2.5 [1.2 – 4.0]</td>
<td>2.5 [1.5 – 4.2]</td>
<td>0.90</td>
</tr>
<tr>
<td>mean ± SD</td>
<td>2.5 [1.2 – 4.0]</td>
<td>2.5 [1.5 – 4.2]</td>
<td>0.90</td>
</tr>
<tr>
<td>Secondary clinical outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RADAI score</td>
<td>0.8 [0.3 – 1.4]</td>
<td>0.6 [0.3 – 1.4]</td>
<td>0.97</td>
</tr>
<tr>
<td>median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAQ score</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: no. – number; SD – standard deviation; CQR – Compliance Questionnaire on Rheumatology; BMQ – Beliefs about Medication questionnaire; IQR – interquartile range* Percentages of the total number of participants excluding missing data.
Conclusion: This multicentre randomised clinical trial showed that a serious puzzle game aimed at reinforcing a positive attitude towards DMARDs was frequently played during three months. Playing the game did not improve medication adherence nor influenced beliefs about medication or clinical outcomes in RA patients.

REFERENCES:
[1] https://www.trialregister.nl/trial/7217

Disclosure of Interests: Bart Pouls: None declared, Charlotte Bekker: None declared, Johanna E. Vriezekolk: None declared, Sandra van Dulmen: None declared, Bart van den Bent Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly


Objective: To explore differences between patients with a low to moderate (<5%) vs. high to very high ≥5% mSCORE who accepted vs. declined a follow-up screening consultation in terms of CV risk factors not included in the mSCORE between patients with low to moderate vs. high or very high risk in triglycerides OR 1.70 (95% CI 1.20-2.28) and high waist circumference for women, OR 11.90 (95% CI 4.64-30.52). However, no significant differences were found between the two groups in the multivariate analysis.

Conclusion: Eight out of ten patients with RA accepted the first invitation to a CV screening consultation, and 2/3 of the patients with high or very high risk for CV death adhered to a follow-up invitation. This study could not identify differences between patients with high risk SCORE who accepted vs. declined a follow-up CV screening. There is a need to explore barriers and facilitators for patients’ adherence to CV screening.

REFERENCES:

Disclosure of Interests: None declared


Objectives: To explore the systematic CV risk assessment for patients with RA; ii) explore differences between patients with high risk who accepted vs. declined a follow-up screening and iii) explore differences in additional CV risk factors not included in the mSCORE between patients with low vs. high risk.

Methods: Data from all outpatients with RA connected to the Danish Hospital for Rheumatic Diseases in the period 2011-2021 were retrieved from the national rheumatology quality database, DANBIO. Differences between patients with mSCORE (≥5%) who accepted vs. declined a follow-up consultation in terms of triglycerides, long-term blood sugar, lifestyle factors (alcohol consumption, physical activity level and waist circumference) and measures of disease impact (pain, fatigue, patient global assessment, HAQ and EQ-5D-5L) were analysed using Wilcoxon rank sum test and Fisher’s exact test for groups. Crude and multiple regression analyses using the same explanatory variables, were performed to explore differences between patients with a low to moderate (<5%) vs. high to very high (≥5%) risk.

Results: Data were retrieved from 2,222 patients, of which 1,608 (72%) had been invited to screening consultations. 614 (28%) had not been invited and of these 139 (23%) were 75 years or older. 354 (22%) declined and 1,254 (78%) patients accepted the invitation. The patients who declined the invitation were older (mean 78.37 (SD 14.82) vs. mean 63.40 (SD 10.88) and had longer disease duration (mean 15.4 (SD 12.05) vs. mean 10.11 (SD 10.64)) compared to patients who had participated in a CV screening consultation. After excluding patients above 70 years of age, 888 patients remained, including patients with known CV disease or diabetes mellitus. Of these, 162 (18%) had a high or very high risk for CV death within ten years and 93 (57%) of these accepted a follow-up screening consultation. There were no significant differences between patients with a mSCORE ≥ 5% who accepted vs. declined a follow-up consultation in any of the studied variables. In the crude analyses, a significant difference was only found between patients with low to moderate vs. high or very high risk in triglycerides OR 1.70 (95% CI 1.20-2.28) and high waist circumference for women, OR 11.90 (95% CI 4.64-30.52). However, no significant differences were found between the two groups in the multivariate analysis.

Conclusion: Eight out of ten patients with RA accepted the first invitation to a CV screening consultation, and 2/3 of the patients with high or very high risk for CV death adhered to a follow-up invitation. This study could not identify differences between patients with high risk SCORE who accepted vs. declined a follow-up CV screening. There is a need to explore barriers and facilitators for patients’ adherence to CV screening.

REFERENCES:

Disclosure of Interests: None declared

HPR: From prevention to management

**OP0121-HPR**

**THE SELF- AND SHARED-MANAGEMENT OF JIA: A NEW FRAMEWORK FOR RESEARCH, POLICY, AND PRACTICE**

S. Stones1,2, V. Swallow1,3, L. Milnes1. 1University of Leeds, School of Healthcare, Leeds, United Kingdom; 2Envision Pharma Group, Engage, Scientific Solutions, Willslow, United Kingdom; 3Sheffield Hallam University, Department of Nursing & Midwifery, Sheffield, United Kingdom

**Background:** Juvenile idiopathic arthritis (JIA) is a complex long-term condition requiring lifelong management [1]. Children and young people (CYP) should be empowered to manage their health and wellbeing (H&W) from diagnosis [2], while families should be supported in their shared-management role [3]. Self- and shared-management (SSM) interventions can be used to develop SSM capacity [4]; however, few studies have explored SSM in this population.

**Objectives:** To develop a framework to promote JIA SSM, applicable to CYP families, and professionals involved in their healthcare, wellbeing, and education.

**Methods:** Using a realist approach [5] and underpinned by the individual and family self-management theory [6], evidence syntheses and a qualitative study were undertaken to identify, test, and refine a series of theories promoting JIA SSM. The theories developed and tested were referred to as ‘question theories’, akin to programme or intervention theories, written at a middle level of abstraction to map theory for future research. Twenty stakeholder were interviewed using a teacher-learner cycle approach. Data were analysed using hybrid deductive-inductive thematic analysis and were integrated into a framework promoting JIA SSM at a higher level of abstraction.

**Results:** Six refined question theories outlining the mechanisms by which the SSM of JIA is likely to transpire, and the different contexts under which interventions achieve their desired outcomes, were developed, and assimilated into a new, JIA-SSM framework. Within the framework, four levels of context related to SSM were identified. These were at an individual and interpersonal level of CYP, families, and professionals across healthcare, wellbeing, and education, and voluntary sectors. Individual healthcare plans can also act as shared-management tools to facilitate communication between CYP, families, and professionals across healthcare, wellbeing, and education.

**Conclusion:** The JIA-SSM framework encourages a shift towards a multi-intervention, multi-disciplinary, multi-agency approach which works with CYP and families in equipping them with the knowledge, skills, and behaviours to competently manage their H&W. Further research is recommended to apply and validate this framework in practice, to aid future design, delivery, evaluation, and implementation of SSM interventions in JIA.

**REFERENCES:**


**Acknowledgements:** The authors would like to thank everyone who participated in this study. This study was funded by the University of Leeds as part of a School of Healthcare PhD studentship.

**Disclosure of Interests:** Simon Stones Consultant of: SRS has served as a consultant for 67 Health, Ampersand Health, Envision Pharma Group, Janssen, On The Pulse Consultancy, Parexel, Sheffield Hallam University, and the University of Aberdeen. Employee of: SRS is employee of Envision Pharma Group and owns stock options in Envision Pharma Group., Veronica Swallow: None declared, Linda Milnes: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1301

**OP0122-HPR**

**DEVELOPMENT OF A SMARTPHONE APPLICATION FOR TREATMENT OF HAND OSTEOARTHRITIS – HAPPY HANDS**

A. T. Tveter1, T. Blanck1, S. Nyheim2, M. Maarnes1, B. Christensen1, S. J. Pedersen1, C. Varsi3, I. Kjesen. 1Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway; 2The Norwegian Rheumatism Association, The Norwegian Rheumatism Association, Oslo, Norway; 3University of Oslo, Faculty of Medicine, Oslo, Norway; 4University of South-Eastern Norway, Faculty of Health and Social Sciences, Drammen, Norway

**Background:** International recommendations state that all patients with hand osteoarthritis (HOA) should receive education and training in ergonomic principles, use of assistive devices and hand exercises as first-line treatment [1]. However, research shows that the quality-of-care service in general is sub-optimal for this patient group, with few patients receiving recommended first-line treatment before being referred to specialist healthcare [2].

**Objectives:** To make recommended treatment available for patients with HOA by developing a user-friendly self-management application (HAPPY Hands).

**Methods:** The development process was conducted four phases: 1) information needs analysis and patient interviews; 2) app illustrations and prototype development; 3) heuristic evaluation; and 4) pilot-testing.

Two patient research partners were involved in developing the content of the app. Researchers, in collaboration with experienced clinicians, the patient research partners and professional film photographers and animators, developed short informational videos and animations. Illustrations and a prototype of the app was developed in five two-week iterations by the University Center for Information Technology at the University of Oslo (Figure 1). Digital meetings were conducted at the end of each two-week iteration, where illustrations and prototype were discussed with developers, researchers, and patient research partners, informing the next iteration. The HAPPY Hands app will be pilot tested in 70 participants with HOA, simultaneously assessing the feasibility and usability of the app.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4343

**OP0123-HPR**

**INVESTIGATION ON THE EFFECTS OF UPPER EXTREMITY HOME EXERCISES ON GRIP STRENGTH, RANGE OF MOTION, ACTIVITY PERFORMANCE AND FUNCTIONALITY IN INDIVIDUALS WITH SCLERODERMA**

E. L. Sahin1, S. Y. Cetin1, A. Ayhan2, A. Akdeniz University, Physiotherapy and Rehabilitation, Antalya, Turkey; 2Antalya Health Sciences University, Rheumatology, Antalya, Turkey

**Background:** International recommendations state that all patients with hand osteoarthritis (HOA) should receive education and training in ergonomic principles, use of assistive devices and hand exercises as first-line treatment [1]. However, research shows that the quality-of-care service in general is sub-optimal for this patient group, with few patients receiving recommended first-line treatment before being referred to specialist healthcare [2].

**Objectives:** To make recommended treatment available for patients with HOA by developing a user-friendly self-management application (HAPPY Hands).

**Methods:** The development process was conducted four phases: 1) information needs analysis and patient interviews; 2) app illustrations and prototype development; 3) heuristic evaluation; and 4) pilot-testing.

Two patient research partners were involved in developing the content of the app. Researchers, in collaboration with experienced clinicians, the patient research partners and professional film photographers and animators, developed short informational videos and animations. Illustrations and a prototype of the app was developed in five two-week iterations by the University Center for Information Technology at the University of Oslo (Figure 1). Digital meetings were conducted at the end of each two-week iteration, where illustrations and prototype were discussed with developers, researchers, and patient research partners, informing the next iteration. The HAPPY Hands app will be pilot tested in 70 participants with HOA, simultaneously assessing the feasibility and usability of the app.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.21826

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.21826
Background: Scleroderma is an autoimmune disease that affects the skin and internal organs such as joints, muscles, and heart and lungs. Hand involvement in individuals with scleroderma leads to functional disability. Loss of grasping ability and impaired hand mobility may be one of the important factors affecting the daily living activities of patients with scleroderma. Although hand rehabilitation is not supported by strong levels of evidence, it has been the subject of studies, and a number of interventions have been described in patients with scleroderma, but no established guidelines for rehabilitation have been established. Passive and active stretching has been shown to help the patient maintain joint range of motion, strengthen tendons and muscles, especially when fibrotic retraction is present. Literature has been shown that self-administered home programs to be beneficial. In addition, evidence-based rehabilitation interventions for the upper extremity in scleroderma are limited.

Objectives: The aim of the study is to examine the effects of upper extremity exercises on joint range of motion, grip strength, activity performance and functionality in patients with scleroderma.

Methods: 46 SSC patients (42 female, 4 male) with an average age of 55.5±21.1±15.4 were included in the study. Patients were randomized into intervention (group 1) and control (group 2) groups. Group 1 received upper extremity home exercise for 5 days a week for 8 weeks. Group 2 received principles of joint protection education program. Goniometric measurement was used to evaluate the upper extremity range of motion. Dinamometer and pinchmeter was used to evaluate the hand grip and pinch strength. Canadian Occupational Performance Measure (COPM) was used to evaluate the activity performance and satisfaction. Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), Duruo§u§ Hand Index (DHI), and Score for Assessment and Quantification of Chronic Rheumatic Affectations of the Hands (SACRAH) was used to evaluate the upper extremity and hand functionality. All evaluations were performed at baseline and at the end of the 8th week.

Results: When the groups were compared before training, there was no significant difference (p>0.05). In post-training comparisons, there was a significant difference in shoulder, elbow, forearm, wrist and fingers range of motion (p: 0.00-0.04); hand grip and pinch strength (p: 0.00-0.02); CPM performance-satisfaction (p: 0.00); SACRAH total and subparameters (p: 0.00), DASH and DHI (p: 0.00) in Group 1. There was a significant difference in shoulder, elbow and fingers range of motion (p: 0.00-0.04); pinch strength (p: 0.00); SACRAH total and subparameters (p: 0.00); DASH and DHI (p: 0.00) in Group 2. Comparing the groups for post-training, Group 1 was found to be superior in terms of shoulder flexion and rotations, elbow extension and deviations, fingers flexion, extension and abduction (p: 0.00-0.04); pinch strength (p: 0.00-0.04); SACRAH total and subparameters (p: 0.00-0.04).

Conclusion: As a result of our study, upper extremity home exercise program has a positive effect on ROM, hand grip and pinch strength, activity performance and functionality. In rehabilitation programs, upper extremity exercises—not only hand exercises—may be effective to increase ROM, grip strength, activity performance and functionality.

REFERENCES:

Disclosure of Interests: None declared

Pregnancy outcomes in rheumatic diseases

Background: Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects women in their childbearing years. Previously, we demonstrated that fetal and maternal mortality has declined in SLE patients over the years, however little is known about morbidity (1).

Objectives: To determine the proportion of fetal and maternal morbidity in SLE deliveries compared to non-SLE deliveries in a US nationwide study over a decade.

Methods: We used retrospective data from the National Inpatient Sample database to identify all delivery related hospital admissions of patients with and without SLE from 2008 to 2017 using ICD-9 (710.0) and 10 (M32*) codes. Fetal morbidity indicators included preterm delivery and intrauterine growth restriction. 21 indicators of severe maternal morbidity were identified using the standard CDC definition: these are unexpected outcomes of labor and delivery that result in significant short- or long-term consequences to a woman's health (2). Descriptive statistics and their 95% confidence intervals were calculated using sample weights from the dataset.

Results: Among the 40 million delivery-related admissions, 51,161 patients (10,297 unweighted) were reported to have SLE. SLE patients were more likely to be older and have more comorbidities compared to non-SLE patients (Table 1). Patients with SLE had a higher risk of fetal morbidity, including intrauterine growth restriction (8.0% vs 2.7%) and preterm delivery (14.5% vs 7.3%) than patients without SLE. Amongst the CDC maternal morbidity indicators - SLE patients faced a greater risk of blood transfusion, puerperal cerebrovascular disorders, acute renal failure, ectropion or DIC, cardiovascular and peripheral vascular disorders, and general medical issues than those without SLE (Figure 1).

Table 1. Characteristics of deliveries with and without Systemic Lupus Erythematosus

<table>
<thead>
<tr>
<th></th>
<th>SLE deliveries</th>
<th>Non-SLE deliveries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent (%)</td>
<td>(95 % CI)</td>
<td>(95 % CI)</td>
</tr>
<tr>
<td>N</td>
<td>51,161* (10,297)</td>
<td>40,000,000*</td>
</tr>
<tr>
<td>Age (years)</td>
<td>30.05 (29.92, 30.18)</td>
<td>28.19 (28.14, 28.24)</td>
</tr>
<tr>
<td>Race</td>
<td>White 46.15 (44.83, 47.47)</td>
<td>52.43 (51.74, 53.11)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>18.48 (17.40, 19.60)</td>
<td>21.45 (20.81, 22.10)</td>
</tr>
<tr>
<td>Other</td>
<td>10.69 (9.93, 11.50)</td>
<td>11.11 (10.76, 11.47)</td>
</tr>
<tr>
<td>Insurance</td>
<td>Medicare 5.32 (4.83, 5.86)</td>
<td>0.7 (0.96, 0.75)</td>
</tr>
<tr>
<td></td>
<td>Medicaid 38.2 (37.00, 39.41)</td>
<td>43.79 (42.40, 44.39)</td>
</tr>
<tr>
<td></td>
<td>Private insurance 51.84 (50.55, 53.13)</td>
<td>49.8 (49.15, 50.45)</td>
</tr>
<tr>
<td></td>
<td>Self-pay 1.39 (1.13, 1.70)</td>
<td>2.74 (2.57, 2.92)</td>
</tr>
<tr>
<td></td>
<td>No charge 0.04 (0.02, 0.12)</td>
<td>0.13 (0.09, 0.18)</td>
</tr>
<tr>
<td></td>
<td>Other 3.21 (2.84, 3.63)</td>
<td>2.84 (2.73, 2.95)</td>
</tr>
<tr>
<td>Elixauser</td>
<td>0 (&quot;no obs&quot;)</td>
<td>80.56 (80.32, 80.80)</td>
</tr>
<tr>
<td></td>
<td>1 to 4 97.84 (96.50, 98.12)</td>
<td>19.4 (19.16, 19.64)</td>
</tr>
<tr>
<td></td>
<td>5+ 2.16 (1.88, 2.50)</td>
<td>0.04 (0.03, 0.04)</td>
</tr>
</tbody>
</table>

*Population weighted values are listed.

Figure 1. Fetal and severe maternal morbidity outcomes in Systemic Lupus Erythematosus (SLE) and non-SLE patients. Cardiovascular and peripheral vascular disorders include acute myocardial infarction, aneurysm, amniotic fluid embolism, cardiac arrest/ventricular fibrillation, heart failure, pulmonary edema/acute heart failure, sickle cell disease with crisis, air and thrombotic embolism, and conversion of cardiac rhythm. General medical issues include hysterectomy, shock, sepsis, adult respiratory distress syndrome, and severe anesthetic complications, temporary tracheostomy, and ventilation.

Conclusion: Our study demonstrates that fetal morbidity and severe maternal morbidity occur at a higher rate in patients with SLE compared to those without, even in this most recent decade. This work can help inform physicians to counsel and manage patients with SLE during pregnancy and its planning.

REFERENCES:
### Background

Pregnancy is a topic of fundamental importance for women living with autoimmune rheumatic diseases (ARD). Efforts at national and international levels have been put in the collection and harmonization of data in order to implement an evidence-based management of pregnant patients.

### Objectives

The P-RHEUM.I study was designed as a nationwide, web-based longitudinal observational cohort study to collect data about pregnancy in ARD in 26 centers in Italy. The study started in May 2018 and has been supported by the Italian Society for Rheumatology.

### Methods

Pregnant patients with a definite rheumatic disease according international criteria were enrolled up to gestational week (GW) 20. The course of maternal disease activity, the use of medications, fetal and maternal complications, and newborn outcomes (EPDQol questionnaire) were collected for each trimester, as well as pregnancy outcome, mode of delivery, neonatal complications, and maternal and children’s follow-up to 6 months after delivery, including the screening for post-partum depression by means of EPDS (Edinburgh Postnatal Depression Scale).

### Results

As of December 2021, 758 pregnancies had been enrolled, 205 (27%) ongoing and 553 (73%) with outcome. Pregnancy loss occurred in 54 (9.8%) cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases. Table 1 reports on cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases. Table 1 reports on cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases. Table 1 reports on cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases. Table 1 reports on cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases. Table 1 reports on cases (40 spontaneous miscarriages; 6 voluntary terminations). Live births were 495 (89.5%), perinatal death occurred in 4 (0.7%) cases.

### Acknowledgements

This work was supported by the Dean’s Diversity Award at Weill Cornell Medicine. Katharine Kayla J Glaser: None declared, Deanna Jannat-Khah: Shareholder of: at Weill Cornell Medicine.

### REFERENCES


### CONCLUSION

Continuous variables are expressed as median (interquartile range); *gestational hyperten-

### Disclosure of Interests

None declared.

### Table 1

<table>
<thead>
<tr>
<th>PREGNANCIES WITH LIVE BIRTHS, EXCLUDING PERINATAL DEATHS</th>
<th>Total pregnancies (n=495)</th>
<th>RA pregnancies (n=69)</th>
<th>SLE pregnancies (n=93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at conception (years)</td>
<td>34 (31 - 37)</td>
<td>34 (35 - 32)</td>
<td>34 (31 - 36)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6.1 (2.2 - 11.1)</td>
<td>7.1 (4.3 - 11.6)</td>
<td>9.3 (5.9 - 15.9)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>431 (87.8%)</td>
<td>53 (79.1%)</td>
<td>75 (80.6%)</td>
</tr>
<tr>
<td>Never smokers</td>
<td>358 (73.8%)</td>
<td>53 (80.3%)</td>
<td>66 (71.7%)</td>
</tr>
<tr>
<td>Body Mass Index &gt;30</td>
<td>45 (9.5%)</td>
<td>7 (10.3%)</td>
<td>5 (5.8%)</td>
</tr>
<tr>
<td>Arterial Hypertension</td>
<td>6 (1.2%)</td>
<td>0 (0%)</td>
<td>2 (2.2%)</td>
</tr>
<tr>
<td>Time to pregnancy (months)</td>
<td>3 (1 - 6)</td>
<td>3 (1 - 6)</td>
<td>3 (1 - 10)</td>
</tr>
<tr>
<td>Physician-reported flares in the 12 months prior to conception</td>
<td>107 (22%)</td>
<td>22 (34.4%)</td>
<td>13 (14.8%)</td>
</tr>
<tr>
<td>Physician global assessment at enrolment (VAS 0-100)</td>
<td>5 (0 - 17)</td>
<td>5 (0 - 20)</td>
<td>4 (0 - 10)</td>
</tr>
<tr>
<td>Patient global health at enrolment (VAS18 7 - 30)</td>
<td>10 (5 - 29)</td>
<td>10 (5 - 25)</td>
<td></td>
</tr>
<tr>
<td>EuroQol at enrolment (-1.6 - 1)</td>
<td>1 (0.8 - 1)</td>
<td>1 (0.8 - 1)</td>
<td>1 (0.8 - 1)</td>
</tr>
<tr>
<td>Fares during pregnancy</td>
<td>35 (71%)</td>
<td>6 (8.7%)</td>
<td>7 (7.5%)</td>
</tr>
<tr>
<td>Hypertensive disturbances*</td>
<td>8 (1.7%)</td>
<td>1 (1.6%)</td>
<td>6 (6.6%)</td>
</tr>
<tr>
<td>Delivery at term (37 GW)</td>
<td>410 (85.1%)</td>
<td>53 (77.9%)</td>
<td>74 (80.4%)</td>
</tr>
<tr>
<td>Spontaneous vaginal delivery</td>
<td>173 (38.9%)</td>
<td>23 (33.8%)</td>
<td>23 (25.3%)</td>
</tr>
<tr>
<td>Congenital malformations</td>
<td>11 (2.4%)</td>
<td>2 (3.1%)</td>
<td>1 (1.1%)</td>
</tr>
<tr>
<td>Small for gestational age (SGA)</td>
<td>24 (4.9%)</td>
<td>1 (1.4%)</td>
<td>9 (9.9%)</td>
</tr>
<tr>
<td>Breastfeeding in the first 4 weeks after delivery</td>
<td>341 (79.7%)</td>
<td>45 (77.6%)</td>
<td>59 (76.9%)</td>
</tr>
<tr>
<td>EPDS score at risk for post-partum delivery</td>
<td>22 (14.1%)</td>
<td>0 (0%)</td>
<td>3 (10.3%)</td>
</tr>
</tbody>
</table>

### Continuous variables are expressed as median (interquartile range); *gestational hypertension/preeclampsia/HELLP syndrome/eclampsia.

### Conclusion

Multiple factors may have contributed to the high rate of live births, including good disease control before and during pregnancy thanks to the use of anti-rheumatic drugs and low frequency of general risk factors. SLE pregnancy was affected by a higher frequency of complications (hypertensive disturbances, SGA babies) as compared to RA pregnancy. Nearly 80% of patients breastfed in the first month after delivery. For the first time, data about the screening questionnaire for post-partum depression were collected, showing at least 1 out 10 patients can be at risk.

### REFERENCES

maternal country of birth, BMI, smoking in early pregnancy, educational level, and disposable income in the year before pregnancy.

**Results:** Women with SpA (n=1394) were found to be at increased risk of several adverse outcomes compared to general population comparators (n=13932), as displayed in the Figure. Women with SpA had an increased risk of gestational diabetes (adjusted RR 1.88 [95% CI 1.10; 2.56]), elective and emergent Cesarean delivery (adjusted RR 1.54 [95% CI 1.32; 1.79] and 1.23 [95% CI 1.02; 1.48], respectively), and moderately preterm birth (adjusted RR 1.52 [95% CI 1.18; 1.97]). An association was seen with both spontaneous and medically indicated preterm birth, but the increase was only significant for spontaneous preterm birth. The risk estimate for preeclampsia was also increased, but failed to reach significance (adjusted RR 1.32 [95% CI 0.96; 1.81]). Infants to mothers with SpA were not more likely to be born SGA, but there was a slightly increased risk estimate of infection during their first year of life (adjusted RR 1.23 [95% CI 0.98; 1.53]).

**Background:** Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about the impact of the disease and its treatment on pregnancy.

**Objectives:** The aim of the study was to determine the factors associated with adverse pregnancy outcome in women with RA.

**Methods:** All RA patients (diagnosis according to the Rheumatologist) included in the national multicenter GR2 cohort from 2015 to June 2021 were included in the analysis. Patients could be included either with a pregnancy wish (i.e., preconceptional period) or because of a clinical pregnancy (<12 weeks of gestation). The main endpoint was favorable pregnancy outcome, a composite outcome defined as a live birth at term ≥ 37 gestation weeks of a healthy newborn with a weight greater than the 10th percentile. Disease activity was defined by a DAS28-CRP score > 3.2 at least once during pregnancy. We performed a multilevel logistic regression model, in which we considered patient and center random effects (patient random effect for some women included in the cohort two times). We used a multiple imputation procedure to address missing data among the explanatory variables. Results are presented as an odds ratio (OR) with confidence interval (CI).

**Results:** Among the 167 pregnancies in women with RA included in the GR2 cohort, 92 were retained for analysis of obstetrical outcome. Of these, 43 (46.2%), 8 (7.9%), 40 (43.5%) were exposed to corticosteroid, NSAID and biologics at least once during pregnancy, respectively. A moderate or severe disease activity at least once during pregnancy was found in 20 (21.8%) pregnancies. A live birth was found in 83 (90.2%) women, including 69 (83.1%) full-term births. Early miscarriages were observed in 9 (0.1%) women. A caesarean section was performed in 22 (23.9%) cases.

A favorable pregnancy outcome was found in 52 (56.5%) of the women. Unfavorable pregnancy outcome was mainly due to prematurity and small for gestational age, observed in 14 (16.9%) and 17 (20.5%), respectively. The multivariate model adjusted for age, BMI, nulliparity, active disease during pregnancy, smoking, and exposure to biologics and corticosteroids during pregnancy found an association between an unfavorable pregnancy outcome and nulliparity (OR 6.2 95% CI [2.1-17.8] p = 0.002), age (OR (per year) 1.9 95% CI [1.0-3.9] p = 0.02) and exposition to corticosteroids during pregnancy (OR 3.2 95% CI [1.9-5.6] p = 0.04).

**Conclusion:** This study provides original results on pregnancy in women with RA. It found a favorable pregnancy outcome in 56.5% of women. Unfavorable pregnancy outcome was associated with age, nulliparity and corticosteroids use during pregnancy, which argues for their careful use during pregnancy.

**REFERENCES:**

**Table 1. Multilevel logistic regression model: factors associated with unfavorable pregnancy outcome in women with RA.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate analyses</th>
<th>Multivariate analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.09 (1.01-1.19)</td>
<td>0.036</td>
</tr>
<tr>
<td>BMI</td>
<td>0.93 [0.83-1.04]</td>
<td>0.196</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>4.18 [1.66-10.53]</td>
<td>0.003</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.08 [0.29-3.36]</td>
<td>0.966</td>
</tr>
<tr>
<td>Disease activity</td>
<td>1.06 [0.40-2.81]</td>
<td>0.911</td>
</tr>
<tr>
<td>Corticosteroids**</td>
<td>2.45 [1.05-5.68]</td>
<td>0.039</td>
</tr>
<tr>
<td>Biologics**</td>
<td>1.05 [0.11-3.54]</td>
<td>0.589</td>
</tr>
</tbody>
</table>

* Moderate or severe disease activity at least once during pregnancy. ** Use at least once during pregnancy.
Methods: Pregnant and non-pregnant patients with an established diagnosis of SAD were consecutively enrolled. Pregnant patients were included in a tight monitoring protocol for high risk pregnancies, and treatments were checked every month. The following data were collected separately: demographic, epidemiological and demographic characteristics, disease duration and type of medications. Each patient completed the following anonymous questionnaires: the 8-item Morisky Medication Adherence Scale (MMAS-8) and Hospital Anxiety and Depression Scale (HADS) to assess the presence of anxiety and depression. With regard to MMAS-8, we assessed adherence to hydroxychloroquine (HCQ) and to other disease modifying antirheumatic drugs (DMARDs) separately. We considered a score ≥ 6 as indicator of good adherence. Vitamins and dietary supplements were not considered.

Results: A total of 80 pregnant women and 72 non-pregnant women were enrolled. Clinical data and results of the questionnaires are summarized in Table 1.

Demographic and clinical characteristics and the number of therapies received didn’t seem to influence treatment adherence. Fifty patients (32.8%) suffered an adequate pregnancy counselling; anxiety seems to be one determinant of low adherence despite being closely monitored in a dedicated clinic for high risk pregnancies and prescribed medications; nevertheless, 25% of patients didn’t take therapies adequately prescribed. Most (i.e. adalimumab, infliximab, golimumab) are monoclonal antibodies, which have shown no increase in risk of encephalopathy, microcephaly or polymicrogyria. This indicates that the reported CCAs may have been related to undiagnosed genetic alterations or were associated with underlying maternal disease, although a definitive relationship cannot be ruled out.

Conclusion: Except for vedolizumab, no special safety signal was identified regarding occurrence of CMs after exposure to non-TNFis. Based on available information, no firm conclusions can be made regarding observed CCA cases in vedolizumab group.

REFERENCES

Acknowledgements: We would like to thank C. Zaccaria and L. Piccolo for their contributions to access and interpreting data from EudraVigilance database. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

Disclosure of Interests: Nafise Ghalandari: None declared, Hubertina Johanna Maria Josephina Crijns: None declared, Jorrie Bergman: None declared, R. Dolhain Speakers bureau: UCB, Roche, Abbvie, Genzyme, Novartis, Lilly, Janssen.

OR: odds ratio; CI: confidence interval; CM: congenital malformation; TOPFA: termination of pregnancy due to fetal anomaly anomaly; *After adjusting for maternal age, stratified ORs are presented for patients who had no reported teratogen exposure during pregnancy.

Pattern of CMs were reviewed by a clinical geneticist. Except for vedolizumab, no specific CM patterns were observed. For vedolizumab four cases of corpus callosum agenesis (CCA) were reported (versus null in CZP and other investigated non-TNFis). Three of the CCA cases were associated with other neurological CMs such as a neural tube defect, microcephaly and polymicrogyria. This indicates that the reported CCAs may have been related to undiagnosed genetic alterations or were associated with underlying maternal disease, although a definitive relationship cannot be ruled out.

Conclusion: Except for vedolizumab, no special safety signal was identified regarding occurrence of CMs after exposure to non-TNFis. Based on available information, no firm conclusions can be made regarding observed CCA cases in vedolizumab group.

Table 1. Characteristics of the cohort

<table>
<thead>
<tr>
<th>Age at study entry (years, mean ±SD)</th>
<th>35.8±4.3</th>
<th>40.1±12.2</th>
<th>0.001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease duration (years, mean ±SD)</td>
<td>8.5±6.6</td>
<td>8.6±9.1</td>
<td>n.s.</td>
</tr>
<tr>
<td>Number of tablets/day (mean ±SD)</td>
<td>4.3±1.6</td>
<td>4.1±1.8</td>
<td>n.s.</td>
</tr>
<tr>
<td>Number of assumptions/day (mean ±SD)</td>
<td>1.4±0.6</td>
<td>1.6±0.8</td>
<td>n.s.</td>
</tr>
<tr>
<td>Score MMAS for HCQ (mean ±SD)</td>
<td>5.19±0.3</td>
<td>6.39±0.2</td>
<td>0.018</td>
</tr>
<tr>
<td>Score MMAS for other DMARDs (mean ±SD)</td>
<td>6.99±0.2</td>
<td>6.38±0.2</td>
<td>0.039</td>
</tr>
<tr>
<td>Patients with good adherence to HCQ (%)</td>
<td>38/50 (76.0%)</td>
<td>34/50 (68.0%)</td>
<td>0.044</td>
</tr>
<tr>
<td>Patients with good adherence to medications (%)</td>
<td>53/71 (74.6%)</td>
<td>37/60 (61.7%)</td>
<td>n.s.</td>
</tr>
<tr>
<td>Patients with low adherence to HCQ (%)</td>
<td>22/50 (44.0%)</td>
<td>23/50 (46.0%)</td>
<td>0.44</td>
</tr>
<tr>
<td>Patients with low adherence to medications (%)</td>
<td>18/50 (36.0%)</td>
<td>23/50 (46.0%)</td>
<td>0.39</td>
</tr>
<tr>
<td>Anxiety (%)</td>
<td>20 (25%)</td>
<td>30 (41.7%)</td>
<td>0.029</td>
</tr>
<tr>
<td>Depression (%)</td>
<td>11 (13.7%)</td>
<td>19 (26.4%)</td>
<td>0.051</td>
</tr>
</tbody>
</table>
higher fetal than maternal levels. Certolizumab (a pegylated Fab fragment) and etanercept (a fusion protein) display the lowest passage. Thus, depending on the TNFi subtype, the risk of immunosuppression may differ, and some offspring may be exposed to supra-therapeutic doses of TNFi. Therefore, the risk of serious infections in offspring by TNFi subtype needs to be clarified.

**Objectives:** We evaluated the risk of serious infections leading to hospitalization in offspring born to mothers with chronic inflammatory diseases who used TNFi during pregnancy depending on whether they had low or high placental transfer.

**Methods:** In this population cohort study, we identified offspring born in 2011-2019 to women with a prior diagnosis of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and/or inflammatory bowel diseases in the IBM MarketScan commercial database using commercial claims only. Women were included if they had been continuously enrolled within MarketScan with medical and pharmacy coverage for ≥12 months prior to delivery and had a child linked to them. TNFi exposure was defined as ≥1 filled prescription and/or infusion procedure code during pregnancy. Exposure was further categorized into high (i.e. infliximab, adalimumab, golimumab) and low (i.e. certolizumab, etanercept) placental transfer ability. Serious infections were ascertained based on ≥1 hospitalization with infection as the primary diagnosis in the offspring’s first year of life. We performed multivariable time-to-event analysis using a Cox proportional hazards model, adjusting for maternal age at delivery, chronic inflammatory disease diagnosis, maternal co-morbidities (pre-gestational diabetes, asthma), pregnancy complications (gestational diabetes, preterm birth), and other drug use (corticosteroids and non-biologic DMARDs).

**Results:** We identified 26,088 offspring, among whom 2,902 (11.1%) were exposed to TNFi during pregnancy. The majority of offspring (1,506; 51.9%) were born to mothers with inflammatory bowel diseases. Out of the 2,902 offspring with TNFi exposure, 797 (27.5%) and 2,105 (72.5%) were low and high placental transfer drugs, respectively. The frequency of serious infections was 1.3% and 1.8% in those offspring exposed to TNFi with low and high placental transfer, respectively. The incidence rate (IR) of serious infections in offspring exposed to TNFi with high vs. low placental transfer was, respectively, 2.27 (95% confidence interval, CI 1.61, 3.12) cases per 100-person-years at risk vs. IR 1.59 cases per 100-person-years at risk (95% CI 0.76, 2.92). In multivariable analyses, the adjusted hazard ratio for serious infections with the use of TNFi with high versus low placental transfer was 1.20 (95% CI 0.54, 2.54).

**Conclusion:** Although children exposed to high transfer TNFi may have a higher risk of serious infection, we saw no clear excess risk of serious infections in children exposed in utero to TNFi with high versus low placental transfer due to the wide confidence interval.

**REFERENCES:** None declared

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1038

---

**Table 1. Demographic, clinical characteristics and semen parameters**

<table>
<thead>
<tr>
<th>MTX naive</th>
<th>Controls</th>
<th>MTX chronic</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total, n</td>
<td>18</td>
<td>25</td>
<td>5</td>
</tr>
<tr>
<td>Age, mean</td>
<td>36.52</td>
<td>34.56</td>
<td>36.80</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(33.65-39.39)</td>
<td>(32.75-36.36)</td>
<td>(31.95 – 41.64)</td>
</tr>
<tr>
<td>MTX dose mg/week</td>
<td>16.52</td>
<td>18.00</td>
<td></td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(14.54 – 18.49)</td>
<td>(14.59 – 21.40)</td>
<td></td>
</tr>
<tr>
<td>Sperm concentration x 10^6/mL</td>
<td>84.27</td>
<td>64.31</td>
<td>92.56</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(44.27-123.83)</td>
<td>(42.55 – 86.35)</td>
<td>(60.45 – 124.66)</td>
</tr>
<tr>
<td>Progressive motility*, %</td>
<td>63.20</td>
<td>60.11</td>
<td>56.95</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(55.44-70.95)</td>
<td>(51.05-62.85)</td>
<td>(34.82 – 65.97)</td>
</tr>
<tr>
<td>Semen volume, mean mL</td>
<td>2.93</td>
<td>2.90</td>
<td>3.12</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(2.09-3.76)</td>
<td>(2.08-3.71)</td>
<td>(2.51-3.73)</td>
</tr>
<tr>
<td>(95% CI)</td>
<td>(1.55-3.44)</td>
<td>(1.56-3.33)</td>
<td>(1.59-3.53)</td>
</tr>
</tbody>
</table>

*Comparisons between pre and post exposure samples were tested using a paired t-test. **Comparisons between pre, post exposure and healthy controls were tested using a one way analysis of variance.

**Conclusion:** This is the largest prospective study ever conducted to evaluate the impact of MTX on semen parameters in men diagnosed with IMDs. We demonstrated that exposure to MTX did not result in statistically significant different semen parameters. Based on semen parameters, our findings suggest that MTX therapy can be continued in men diagnosed with an IMD and a wish to become a father.

**REFERENCES:**


---

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1345
RA: Clinical aspects and comorbidities - I

PREVALENCE AND COMORBIDITIES OF RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN SPAIN: A RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS USING NATURAL LANGUAGE PROCESSING

J.A. Román Iovra1, I. De la Morena2, N. Costas Torrío2, B. Safont2, J. Fernández-Melón3, B. Nuñez4, L. Silva Fernández5, L. Cobríal Méndez6, L. Lojo7, B. López-Muñiz8, E. Trallero9, M. Lopez Lasanta10, R. M. Veiga Cabello11, M. D. P. Ahijado Guzman12, D. Benavent12, D. Vilanova12, R. Castellanos Morein12, S. Lujan Valdés12 on behalf of RA-W-ILD Study Group. 1Hospital Universitario La Fe, Rheumatology Unit, Valencia, Spain; 2Hospital Clínico Universitario, Rheumatology Unit, Valencia, Spain; 3Hospital Clínico Universitario, Pulmonary Unit, Valencia, Spain; 4Hospital Universitario Son Espases, Rheumatology Unit, Palma de Mallorca, Spain; 5Hospital Universitario Son Espases, Pulmonary Unit, Palma de Mallorca, Spain; 6Hospital Universitario Infanta Leonor, Rheumatology Unit, Madrid, Spain; 7Hospital Universitario Infanta Leonor Pulmonary Unit, Madrid, Spain; 8Hospital Universitario Vall D’Hebron, Rheumatology Unit, Barcelona, Spain; 9Hospital Universitario Fuenlabrada, Rheumatology Unit, Madrid, Spain; 10SAVANA Group, Medical, Madrid, Spain; 11Bristol Myers Squibb, HEOR, Madrid, Spain; 12Bristol Myers Squibb, Medical, Madrid, Spain

Background: Interstitial lung disease (ILD) is one of the most frequent extra-articular manifestations of rheumatoid arthritis (RA) and leads to a significantly increased risk for morbidity and mortality compared with RA alone [1]. The analysis of Electronic Health Records (EHRs) using machine learning (ML) and Natural Language Processing (NLP) holds great promise to better characterize the disease in real-world settings.

Objectives: This study aims to a) estimate the prevalence of RA in Spain, b) determine the frequency of RA-ILD among RA patients, and c) describe the demographic and clinical characteristics in RA/RA-ILD patients.

Methods: Observational, retrospective, and multicenter study based on the secondary use of unstructured clinical data in EHRs from 6 Spanish hospitals between January 1, 2014 and December 31, 2019. The free-text information from patients’ records was captured with SAVANAs EHRread, a validated NLP technology which extracts clinical information from EHRs and standardizes it into a SNOMED-CT-based clinical terminology [2]. The study population comprised all adult patients ≥18 years with RA in the selected period and sites. Descriptive statistics were presented in summary tables. Prevalence was calculated dividing the total number of patients with RA over the total number of attended patients. This analysis was performed by age and sex.

Results: Among all attended patients in the participating hospitals within the study period, 11,163 patients with RA were identified; of these, 8.6% (n = 959) had RA-associated ILD (RA-ILD). The age-adjusted prevalence of RA is shown in Figure 1. The estimated prevalence (95% CI) in the overall population was 0.49 (0.37-0.60), being 0.26 (0.19-0.32) in males and 0.71 (0.54-0.87) in females. Most patients in the RA (73.9%; n = 8,250) and RA-ILD populations (63.3%, n = 607) were female (Table 1). The median age (Q1, Q3) was 60.8 (49, 74) and 67 (56, 77) years in the RA and RA-ILD groups, respectively. Regarding disease course, the time from RA to ILD diagnosis was 276 (3.7, 73.2) months.

Most comorbidities presented higher rates in the RA-ILD population, as shown in Table 1. Among patients with available ILD subtype information (n = 618), the most common was usual interstitial pneumonia (29.8%; n = 184).

Table 1. Demographics and comorbidities in the RA and RA-ILD patient populations

<table>
<thead>
<tr>
<th></th>
<th>RA* N=11,163</th>
<th>RA-ILD N=959</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8,250 (73.9)</td>
<td>607 (63.3)</td>
</tr>
<tr>
<td>Male</td>
<td>2,913 (26.1)</td>
<td>352 (36.7)</td>
</tr>
<tr>
<td>Age at first mention of disease (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>61 (49, 74)</td>
<td>67 (56, 77)</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>4369 (39.1)</td>
<td>316 (33)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3851 (34.5)</td>
<td>320 (33.4)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2970 (26.6)</td>
<td>248 (25.9)</td>
</tr>
<tr>
<td>Infections</td>
<td>2119 (18.1)</td>
<td>238 (24.2)</td>
</tr>
<tr>
<td>Bone fracture</td>
<td>1875 (16.8)</td>
<td>210 (21.9)</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>1275 (11.4)</td>
<td>150 (15.6)</td>
</tr>
<tr>
<td>Malignancies</td>
<td>1006 (9)</td>
<td>156 (16.3)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>993 (8.9)</td>
<td>184 (19.2)</td>
</tr>
<tr>
<td>Depression</td>
<td>825 (7.4)</td>
<td>100 (10.5)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Obesity</td>
<td>732 (6.6)</td>
<td>90 (9.4)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Depression</td>
<td>2129 (19.1)</td>
<td>328 (34.2)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2970 (26.6)</td>
<td>248 (25.9)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3851 (34.5)</td>
<td>320 (33.4)</td>
</tr>
<tr>
<td>Malignancies</td>
<td>1006 (9)</td>
<td>156 (16.3)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>993 (8.9)</td>
<td>184 (19.2)</td>
</tr>
<tr>
<td>Depression</td>
<td>825 (7.4)</td>
<td>100 (10.5)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Obesity</td>
<td>732 (6.6)</td>
<td>90 (9.4)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Depression</td>
<td>2129 (19.1)</td>
<td>328 (34.2)</td>
</tr>
</tbody>
</table>

Acknowledgements: RA-W-ILD Study Group

Disclosure of Interests: None declared.

Conclusion: This pioneering study is the first to characterize RA-ILD using NLP methodology in a multicenter setting. By analyzing readily available real-world data in patients EHRs, we were able to estimate the prevalence of RA in the Spanish population and describe the demographic and clinical characteristics of patients with RA/RA-ILD.

REFERENCES:

Figure 1. Estimated age-adjusted population prevalence for rheumatoid arthritis


THE DECREASE OF MUSCLE MASS BY THE BEHAVIORAL RESTRICTION OF COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. Tada1, Y. Yamada2, K. Mandai3, Y. Matsumoto4, N. Hidaka5, 1Osaka City General Hospital, Orthopaedic Surgery, Osaka, Japan; 2Osaka City University Medical School, Orthopaedic Surgery, Osaka, Japan; 3Osaka Sanenaiik Nakatsu Hospital, Orthopaedic Surgery, Osaka, Japan; 4Osaka City University Graduate School of Human Life Science, Medical Nutrition, Osaka, Japan

Table 1. Demographics and comorbidities in the RA and RA-ILD patient populations

<table>
<thead>
<tr>
<th></th>
<th>RA* N=11,163</th>
<th>RA-ILD N=959</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8,250 (73.9)</td>
<td>607 (63.3)</td>
</tr>
<tr>
<td>Male</td>
<td>2,913 (26.1)</td>
<td>352 (36.7)</td>
</tr>
<tr>
<td>Age at first mention of disease (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>61 (49, 74)</td>
<td>67 (56, 77)</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>4369 (39.1)</td>
<td>316 (33)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3851 (34.5)</td>
<td>320 (33.4)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>2970 (26.6)</td>
<td>248 (25.9)</td>
</tr>
<tr>
<td>Infections</td>
<td>2119 (18.1)</td>
<td>238 (24.2)</td>
</tr>
<tr>
<td>Bone fracture</td>
<td>1875 (16.8)</td>
<td>210 (21.9)</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>1275 (11.4)</td>
<td>150 (15.6)</td>
</tr>
<tr>
<td>Malignancies</td>
<td>1006 (9)</td>
<td>156 (16.3)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>993 (8.9)</td>
<td>184 (19.2)</td>
</tr>
<tr>
<td>Depression</td>
<td>825 (7.4)</td>
<td>100 (10.5)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Obesity</td>
<td>732 (6.6)</td>
<td>90 (9.4)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>773 (6.9)</td>
<td>39 (4.1)</td>
</tr>
<tr>
<td>Depression</td>
<td>2129 (19.1)</td>
<td>328 (34.2)</td>
</tr>
</tbody>
</table>

*RA includes patients in the RA-ILD population. *Patients’ age when either RA or ILD was first detected in the EHRs. RA = rheumatoid arthritis, ILD = interstitial lung disease
Background: We previously reported the prevalence of sarcopenia and body compositions at patients with rheumatoid arthritis (RA)\(^1\). The behavioral restriction of COVID-19 pandemic influenced for the lifestyle of people included patients with RA.

Objectives: The change of exercise and daily life activity of patients with RA were investigated and body composition and muscle function were compared pre- and post-behavioral restriction.

Methods: We used the date from prospective observational study (CHIKARA study; UMIN000023744). 70 from 100 patients with RA were followed up and evaluated the change of exercise and daily life activity by visual analog scale. They were measured the muscle mass, fat mass, basal metabolic rate by body composition analyzer and grip strength as muscle function. The relationship between the change of exercise and daily life activity and body composition was investigated by univariate analysis.

Results: Mean age was 69.7 years (women n=57, men n=13). The rate of decrease of exercise by <25%, 25–50%, and 51%< were 37%, 21%, and 9%, respectively (mean:20% decrease). Whereas, the rate of decrease of daily life activities by <25%, 25–50%, and 51%< were 70%, 21%, and 9%, respectively (mean:44% decrease). Muscle mass at post-behavioral restriction decrease significantly compared that at pre-behavioral restriction activities (34.0kg vs 34.7kg, P<0.001). Fat mass at post-behavioral restriction increase significantly compared that at pre-behavioral restriction (16.2kg vs 15.5kg, P=0.014). Grip strength at post-behavioral restriction decrease significantly compared that at pre-behavioral restriction (16.2kg vs 17.2kg, P=0.028). The change of exercise was significantly positively correlated with the change of muscle mass and basal metabolic rate (R=0.273, P=0.021 and R=0.256, P=0.033, relatively) at Table 1.

Table 1. Univariate analysis of the changes in daily living activities or exercise and those in body composition or muscle function

<table>
<thead>
<tr>
<th>Change of daily living activities</th>
<th>Change of exercise</th>
<th>R</th>
<th>P value</th>
<th>R</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Δ Weight (kg)</td>
<td></td>
<td>-0.123</td>
<td>0.311</td>
<td>-0.131</td>
<td>0.279</td>
</tr>
<tr>
<td>Δ Fat mass (kg)</td>
<td></td>
<td>0.140</td>
<td>0.311</td>
<td>0.273</td>
<td>0.021</td>
</tr>
<tr>
<td>Δ Fat percentage (%)</td>
<td></td>
<td>-0.061</td>
<td>0.144</td>
<td>-0.076</td>
<td>0.539</td>
</tr>
<tr>
<td>Δ Fat percentage (%)</td>
<td></td>
<td>-0.003</td>
<td>0.982</td>
<td>-0.018</td>
<td>0.884</td>
</tr>
<tr>
<td>Δ Basal metabolic rate (kcal)</td>
<td></td>
<td>0.201</td>
<td>0.095</td>
<td>0.256</td>
<td>0.033</td>
</tr>
<tr>
<td>Δ Grip strength (kg)</td>
<td></td>
<td>0.117</td>
<td>0.336</td>
<td>0.037</td>
<td>0.762</td>
</tr>
<tr>
<td>Δ Walk speed (m/s)</td>
<td></td>
<td>0.169</td>
<td>0.161</td>
<td>0.139</td>
<td>0.250</td>
</tr>
</tbody>
</table>

Δ, change from pre- to post-behavioral restriction; BMI, body mass index; Analyzed by Spearman's rank correlation coefficient.

Conclusion: Muscle mass and grip strength decrease and fat mass increase in patients with RA by the behavioral restriction of COVID-19 pandemic. Muscle mass and basal metabolic rate decrease in patients without exercise habits. Maintenance of muscle mass might be important during the COVID-19 pandemic.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.553

OP0134

ACTIVE RHEUMATOID ARTHRITIS AND ASSOCIATED COMORBIDITIES INCREASE RISK OF DEMENTIA: A POPULATION-BASED COHORT STUDY

C. Kodishala1, C. A. Hülschizer1, V. Kronzer1, J. M. Davis III2, V. K. Ramanan3, M. Vassilaki4, M. Mielke2,3, C. S. Crowson1,2, E. Myasoedova1,2.

Methods: This retrospective population-based cohort study included residents of Olmsted County, MN, who were ≥50 years when they met 1987 ACR criteria for incident RA in 1980-2014. All individuals were followed until death/migration or 12/31/2019. Patients with dementia before RA incidence were excluded (n=12). Incident dementia was defined as two relevant ICD-9/10 codes at least 30 days apart. Risk factors including socio-demographics, RA disease characteristics and medications, cardiovascular/cerebrovascular disease (CVD) risk factors and other comorbidities were abstracted from medical records. Any CVD was defined as coronary heart disease (i.e., angina pectoris, coronary artery disease, myocardial infarction, coronary revascularization procedures, cerebrovascular or stroke or heart failure (HF). Association of individual risk factors with incident dementia was examined using Cox proportional hazard models. Three models were utilized: Model 1, adjusting for age, sex, and calendar year of RA incidence; Model 2, adding smoking, obesity, hypertension, diabetes mellitus, and hyperlipidemia to the first; and Model 3, adding any CVD to the second. Time-dependent covariates were used to represent factors that developed during follow-up.

Results: The study included 886 patients with RA (mean age 65 years, 65% females). During the follow-up period (median=8.5 years), 103 patients developed dementia. Mean age at the diagnosis of dementia was 82.3 (72 years). The cumulative incidence of dementia increased by 2-3% every 5 years after the diagnosis of RA. Older age at RA incidence (Hazard Ratio (HR) 1.14 per 1 year increase, confidence interval (CI): 1.12-1.17) was consistently associated with risk of dementia. Presence of rheumatoid nodules (HR 1.76, CI: 1.05-2.95), large joint swelling (HR 2.11, CI: 1.33-3.34), hypertension (HR 1.84, CI: 1.19-2.85), HF (HR 2.72, CI: 1.29-5.74), and depression (HR 2.23, CI: 1.36-6.7) at baseline or during the first year after RA incidence were significantly associated with risk of dementia. Large joint swelling (HR 2.03, CI: 1.14-3.60), any CVD (HR 2.25, CI: 1.38-3.86), anxiety, (HR 1.86, CI: 1.16-2.97), and depression (HR 2.63, CI: 1.76-3.93) at any time during the disease increased the risk of dementia. Among CVD conditions, stroke (HR 3.16, CI: 1.84-5.43) and HF (HR 1.82, CI: 1.10-3.00) significantly increased risk of dementia. After adjusting for CVD risk factors (Model 2), or CVD risk factors plus any CVD (Model 3), all the covariates listed above were still significantly associated with the risk of dementia.

Conclusion: Apart from age, CVD (particularly hypertension), depression and anxiety, which are universally recognized risk factors for dementia, we observed that clinically active RA was associated with an elevated risk of dementia incidence among RA patients. Studies are ongoing to further evaluate the role of systemic inflammation and its interactions with other risk factors in dementia overall and by dementia subtype in patients with RA.

REFERENCES:

Acknowledgements: This work was supported by grants from the National Institutes of Health, NIAMS (R01 AR46849 and NI4 (R01 AG068192, R01 AG034676).

Disclosure of Interests: Chankaya Kodishala: None declared, Cassidy A Hulschizer: None declared, Vanessa Kronzer: None declared, John M Davis III Grant/research support from: Pfister, Vijay K Ramanan: None declared, Maria Vasiliadis: Abbott Laboratories, Johnson and Johnson, Merck, and Amgen, Consultant of: F. Hoffmann-La Roche Ltd, Grant/research support from: F. Hoffmann-La Roche Ltd and Biogen, Michelle Mielke Consultant of: Biogen, Brain Protection Company, and LabCorp, Cynthia S. Crowson: None declared, Elena Myasoedova: None declared

OP0135

RISK OF CARDIOVASCULAR EVENTS UNDER JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL DATA FROM THE GERMAN RABBIT REGISTER

Y. Meissner1, K. Albrecht1, J. Kekow2, S. Zinke1, H. P. Tony4, M. Schaef er1, A. Strangfeld1, 1German Reumatisches Research Centre Berlin, Epidemiology and Health Services Research, Berlin, Germany; 2Helios Fachklinik Vogelsang-Gommern, Rheumatology, Vogelsang-Gommern, Germany; 3Private Practice, Rheumatology, Berlin, Germany; 4Uniklinikum Würzburg, Medizinische Klinik 2 Rheumatologie/Klinische Immunologie, Würzburg, Germany

Background: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about the cardiovascular (CV) safety of the Janus kinase inhibitor (JAK) tofacitinib and required changes in labelling. These actions were based on results of the post-authorisation safety trial Oral Surveillance(1).

Objectives: To analyse major cardiovascular events (MACE) under treatment with JAKI, tumor necrosis factor inhibitors (TNFi) or conventional synthetic
disease-modifying anti-rheumatic drugs (csDMARDs - bionaive) in patients with rheumatoid arthritis (RA) observed in daily rheumatological care.

Methods: Data from patients enrolled in the biologics register RABBIT with treatment episodes from 01/2017 - 04/2021 were included. Incidence rates (IR) of MACE per 100 patient-years (PY) with 95% confidence intervals (CI) and adjusted risk ratios (RR) were calculated for all and for high-risk patients (age ≥ 50 years and ≥ 1 CV risk factor). Poisson regression analysis was adjusted for age, sex, smoking, disease activity, prior therapies, glucocorticoids and comorbidities.

Results: Starting from 2017, 2030 JAKi, 2338 TNFi and 871 csDMARD initiation were documented. Patients with a JAKi start were slightly older, more often women and had a longer RA disease duration (Table 1). The proportion with positive autoantibodies was higher than in the TNFi and csDMARD group, the physical function was lower, and they had received more previous biologic treatments. Characteristics of high-risk patients are also given in the Table 1.

In total, 28 incident MACE were reported. Patients under treatment with JAKi, TNFi and csDMARD showed comparable IR for MACE between 0.26 and 0.41 events per 100 PY (Figure 1). High-risk patients showed higher IRs. The median time under treatment was 10 months on JAKi and TNFi, and 12 months on csDMARDs. The majority of events were reported in the first year after treatment start. In the adjusted analyses, JAKi (RR 0.94 [95% CI 0.39; 2.28]) and csDMARDs (RR 0.85 [0.25; 2.88]) did not show a significantly increased risk for MACE compared with TNFi in unselected patients, and also not in high-risk patients (JAKi: RR 0.90 [0.37; 2.17]; csDMARDs: RR 0.61 [0.16; 2.28]).

Acknowledgements: RABBIT is supported by a joint, unconditional grant from AbbVie, Amgen, BMS, Fresenius-Kabi, Galapagos, Hexal, Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, Viatris and UCB.

Disclosure of Interests: Yvette Meissner Speakers bureau: Pfizer, Katinka Abrecht: None declared, Jörn Kelow: None declared, Silke Zirke Speakers bureau: Biogen, Galapagos, UCB, Lilly, Consultant of: AbbVie, Biogen, Galapagos, Novartis, Hans-Peter Lyon Consultant of: AbbVie, Astra-Zeneca, BMS, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, Martin Schaefer: None declared, Anja Strangfeld Speakers bureau: AbbVie, Amgen, BMS, Celtrion, Janssen, Lilly, Pfizer, Roche, Sanofi, UCB.


Table 1. Patient characteristics at the start of a JAKi, TNFi or csDMARD.

<table>
<thead>
<tr>
<th></th>
<th>ALL PATIENTS</th>
<th>HIGH RISK PATIENTS*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>JAKi TNFi</td>
<td>csDMARD</td>
</tr>
<tr>
<td># treatment starts</td>
<td>2030</td>
<td>2338</td>
</tr>
<tr>
<td>Age</td>
<td>59.9 ± 11.6</td>
<td>576 ± 13.0</td>
</tr>
<tr>
<td>Women</td>
<td>1573 (77.5)</td>
<td>1707 (73.0)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>12.6 ± 9.6</td>
<td>8.9 ± 6.5</td>
</tr>
<tr>
<td>Rheumatoid factor/ACPA positive</td>
<td>1531 (79.2)</td>
<td>1672 (74.2)</td>
</tr>
<tr>
<td># previous bDMARDs</td>
<td>2.0 ± 1.8</td>
<td>0.7 ± 1.2</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>4.2 ± 1.4</td>
<td>4.5 ± 1.4</td>
</tr>
<tr>
<td>Percentage of full physical function</td>
<td>63.3 ± 24.1</td>
<td>68.6 ± 22.4</td>
</tr>
<tr>
<td>Glucocorticoids/μ10mg/d</td>
<td>170 (73.5)</td>
<td>235 (101.5)</td>
</tr>
<tr>
<td>BMI &gt;30kg/m²</td>
<td>565 (28.2)</td>
<td>631 (27.4)</td>
</tr>
<tr>
<td>Sum of comorbidities</td>
<td>2.9 ± 2.5</td>
<td>2.6 ± 2.4</td>
</tr>
<tr>
<td>Current smokers</td>
<td>461 (26.3)</td>
<td>617 (28.5)</td>
</tr>
<tr>
<td>Previous smokers</td>
<td>551 (31.4)</td>
<td>692 (31.9)</td>
</tr>
</tbody>
</table>

Values are given as mean ± standard deviation or number (percentage). *Age ≥50 years and ≥ 1 CV risk factor (hypertension, coronary heart disease, diabetes, hyperlipoproteinemia, current smoking).

Figure 1. Incidence rates of MACE per 100 patient-years by treatment group.

Conclusion: IR of MACE in patients receiving JAKi in a real-world setting was lower than the IR reported for tocilizumab in the Oral Surveillance study. We found no evidence of an increased risk of MACE with JAKi compared to TNFi, although patients in the JAKi group were older and had longer disease duration.

REFERENCES:

OP0137

ABDOMINAL OBESITY MAY CONFUSE THE ACCURACY OF CARDIOVASCULAR RISK PREDICTION IN RHEUMATOID ARTHRITIS; CAN CORONARY ATHEROSCLEROSIS IMAGING AND BIOMARKERS HELP?

G. Karpouzas1,2, S. Ormseth3, E. Hernandez2, M. Budoff4, 1Harbor-UCLA Medical Center, Rheumatology, Torrance, United States of America; 2The Lundquist Institute, Rheumatology, Torrance, United States of America; 3Harbor-UCLA Medical Center, Cardiology, Torrance, United States of America; 4The Lundquist Institute, Cardiology, Torrance, United States of America

Background: Accurate cardiovascular risk stratification is essential in rheumatoid arthritis (RA) care. RA patients who are overweight incur greater total and cardiovascular mortality compared to those who are overweight or obese.

Objectives: We explored whether abdominal obesity impaired the accuracy of risk prediction estimates in RA patients without known cardiovascular disease (CVD). We further interrogated the potential utility of coronary atherosclerosis assessment and serum levels of related cardiac damage biomarkers to optimize risk prediction in obese RA patients.

Methods: In a single-center observational study, 150 participants with coronary CT angiography for atherosclerosis evaluation and prospective follow-up for cardiovascular events over 6.0±2.4 years were assessed. Framingham cardiovascular risk score was computed at baseline. Obesity was defined as waist circumference >88 cm in females and >102 cm in males. Serum highly-sensitive C-reactive protein (hsCRP) values were sequentially change in AUC, net reclassification index (NRI) and integrated discrimination improvement (IDI).

Results: A significant interaction between Framingham cardiovascular risk score and obesity was observed (p=0.032). Lower estimates were seen in obese [AUC 0.660, 95%CI 0.487-0.832] vs. non-obese RA patients [AUC 0.952, 95%CI 0.897-1.007, p=0.002, Figure 1A]. Likewise, risk estimates were lower in patients with higher (>22.1 ng/ml) vs. lower (>22.1 ng/ml) leptin [AUC 0.618, 95%CI 0.393-0.842 vs. 0.874, 95%CI 0.772-0.976 respectively, p=0.042, Figure 1B]. In obese patients, sequential addition of the highest hsCtN levels and extensive atherosclerotic plaque presence (SIS>5) to a base model including Framingham risk score, significantly improved risk prediction estimates based on changes in NRI [0.193 95%CI 0.517-1.574], IDI [0.188, 95%CI 0.060-0.526], as well as AUC [0.179, 95%CI 0.058-0.378, p=0.002]. The final, combined model accurately predicted 83.9% of incident cardiovascular events (Figure 1C).

Conclusion: Obesity significantly reduced cardiovascular risk estimate accuracy in patients with RA. The optimization of cardiac risk stratification with the help of non-invasive assessment of coronary atherosclerosis burden and related cardiac damage biomarkers in the serum may warrant further study.


OP0138

RISK OF CANCER AFTER BIOLOGIC AND TARGETED SYNTHETIC DMARDS INITIATION IN PATIENTS WITH RHEUMATIC DISEASES AND A HISTORY OF PRIOR MALIGNANCY: DATA FROM THE BIOBADASER REGISTRY

J. Molina Collada1,2, F. Sánchez-Alonso3, C. Bohorquez4, C. Díaz-Torne5, C. Perez-García, J. M. Blanco2, P. Vela-Casasempere6, I. Castrejon1,2, 1Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid, Spain; 2Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Rheumatology, Madrid, Spain; 3Unidad de investigación, Sociedad Española de Reumatología, Madrid, Spain; 4Hospital Principé de Asturias, Rheumatology, Madrid, Spain; 5Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain; 6Hospital del Mar, Rheumatology, Barcelona, Spain; 7Hospital de Basurto, Rheumatology, Bilbao, Spain; 8Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain

Background: Patients with a history of cancer are routinely excluded from randomized controlled trials. As consequence, data on the safety of biologic disease modifying antirheumatic drugs (bDMARDS) and targeted synthetic (ts) DMARDS are limited. Although real world data from various national registries have not provided evidence of increased cancer recurrence, additional data from real-world registries may help to confirm safety of non-TNFi bDMARDS and tsDMARDS regarding cancer recurrence to guide treatment decisions.

Objectives: To compare the risk of incident malignancy with exposure to different bDMARDS and tsDMARDS in patients with rheumatic diseases and a prior malignancy.

Method: The BIOBADASER is a national Spanish registry on patients initiated on biologic DMARDs (bDMARDS) and targeted synthetic (ts) DMARDS. Our objective was to compare the risk of cancer after bDMARDs (bDMARDS) and tsDMARDS (tsDMARDS) initiation in patients with rheumatic diseases and a history of cancer.

Results: A total of 17,202 patients were included, of whom 1,289 (7.5%) had a history of cancer. The risk of cancer after bDMARDS initiation was 1.69-fold higher than after tsDMARDS initiation (HR 1.69, 95%CI 1.14-2.50, p=0.009). The risk of cancer was higher in patients with RA (HR 2.14, 95%CI 1.30-3.51, p=0.004) compared to patients with psoriatic arthritis (HR 0.91, 95%CI 0.54-1.54, p=0.72). The risk of cancer was lower in patients with higher CRP levels (HR 0.75, 95%CI 0.61-0.94, p=0.01) compared to patients with lower CRP levels.

Conclusion: The risk of cancer after bDMARDs initiation is higher than after tsDMARDS initiation in patients with rheumatic diseases and a history of cancer. The risk of cancer is higher in patients with RA compared to patients with psoriatic arthritis. The risk of cancer is lower in patients with higher CRP levels compared to patients with lower CRP levels.


DOI: 10.1136/annrheumdis-2022-eular.1885
Methods: The study population comprised patients with a prior malignancy from the BIOBADASER 3.0 up to 2021. BIOBADASER is a large national drug safety registry of patients with rheumatic diseases starting treatment with any bDMARD or tsDMARD and followed thereafter at the time an adverse event or a change in biological therapy occurs. Incident cancer was defined as any cancer (new primaries, local recurrence or metastases) during the exposure classified according to Meddra dictionary. Incidence rate ratios of cancer per 1000 patients-year (PY) and 95% CI were estimated. Rates of incident cancer in tsDMARDs and other bDMARDs versus anti-TNF treated patients were compared.

Results: A total of 9,129 patients treated with bDMARDs and tsDMARDs are included in BIOBADASER 3.0 at the time of the study. Of them, 352 with a prior history of malignancy at time of enrollment were selected for analysis (Figure 1). Overall, there were 32 incident malignancies (17 solid cancer, 14 non-melanoma skin cancer and 1 melanoma). The overall rate of incident malignancy was 271 (95% CI 18.6-38.3) events/1,000 PY, ranging between none events/1000 PY in RA to JAKi [0.6 (95% CI 0.1-2.5)], anti-CD20 [0.3 (95% CI 0.1-1.4)], anti-IL6 [1.2 (95% CI 0.5-3.4)] or anti-IL17A [1.3 (95% CI 0.5-3.6)] versus anti-TNF therapy. The rate of different types of cancer (melanoma, non-melanoma skin cancer or solid tumors) did not differ between the different treatment groups when compared to anti-TNF therapy (Table 1).

Table 1. Baseline characteristics and rate of incident cancer.

<table>
<thead>
<tr>
<th></th>
<th>Anti-TNF (n = 185)</th>
<th>JAKi (n = 61)</th>
<th>Anti-CD20 (n = 61)</th>
<th>Anti-IL6 (n = 68)</th>
<th>Anti-CTLA-4 (n = 47)</th>
<th>Anti-IL17 (n = 39)</th>
<th>Total (n=352)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>129 (69.7)</td>
<td>49 (80.3)</td>
<td>43 (70.5)</td>
<td>54 (79.4)</td>
<td>34 (72.3)</td>
<td>21 (53.9)</td>
<td>247 (70.2)</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>64.4 (13.1)</td>
<td>66.7 (13.1)</td>
<td>67.8 (10.0)</td>
<td>70.5 (11.6)</td>
<td>71.8 (10.4)</td>
<td>59.5 (14.6)</td>
<td>65.3 (13.0)</td>
</tr>
<tr>
<td>Start treatment age, mean (SD)</td>
<td>60.0 (12.9)</td>
<td>64.8 (12.8)</td>
<td>65.7 (9.6)</td>
<td>67.3 (11.3)</td>
<td>62.8 (12.7)</td>
<td>56.9 (14.5)</td>
<td>61.6 (12.8)</td>
</tr>
<tr>
<td>Disease duration, median (IQR)</td>
<td>6.7 (3.0-13.1)</td>
<td>12.3 (7.4-19.6)</td>
<td>10.0 (3.1-19.4)</td>
<td>8.5 (4.5-16.8)</td>
<td>8.4 (4.7-16.1)</td>
<td>7.0 (2.9-15.5)</td>
<td></td>
</tr>
<tr>
<td>Time of follow-up months, mean (SD)</td>
<td>23.1 (25.3)</td>
<td>15.9 (13.3)</td>
<td>11.5 (2.5)</td>
<td>16.8 (17.6)</td>
<td>23.7 (22.6)</td>
<td>18.4 (15.5)</td>
<td>17.8 (18.2)</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td>4.9 (2.0)</td>
<td>5.2 (2.2)</td>
<td>5.1 (2.0)</td>
<td>5.5 (2.1)</td>
<td>6.1 (2.6)</td>
<td>6.9 (2.6)</td>
<td>5.2 (2.1)</td>
</tr>
<tr>
<td>Prior malignancy</td>
<td>Non-lymphoproliferative (solid or melanoma), n (%)</td>
<td>174 (94.5)</td>
<td>58 (95.1)</td>
<td>54 (88.5)</td>
<td>65 (95.6)</td>
<td>46 (97.9)</td>
<td>36 (92.3)</td>
</tr>
<tr>
<td>Lymphoproliferative, n (%)</td>
<td>9 (4.9)</td>
<td>3 (4.9)</td>
<td>13 (21.3)</td>
<td>4 (5.9)</td>
<td>4 (8.5)</td>
<td>5 (12.8)</td>
<td>29 (8.2)</td>
</tr>
<tr>
<td>Metastatic cancer, n (%)</td>
<td>2 (1.1)</td>
<td>2 (3.3)</td>
<td>2 (3.3)</td>
<td>1 (1.5)</td>
<td>3 (6.4)</td>
<td>0 (0.0)</td>
<td>7 (2.0)</td>
</tr>
<tr>
<td>New cancer diagnosis, n (%)</td>
<td>18</td>
<td>2</td>
<td>2</td>
<td>5</td>
<td>5</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>Time of exposure, sum (years)</td>
<td>470.1</td>
<td>91.6</td>
<td>163</td>
<td>104.9</td>
<td>96.8</td>
<td>63.8</td>
<td>171.6</td>
</tr>
<tr>
<td>Rate of incident cancer (per 1,000 PY)</td>
<td>0.6 (1.2-5.8)</td>
<td>218 (5.5-87.8)</td>
<td>12.3 (1-41.9)</td>
<td>47.7 (19.8-114.5)</td>
<td>51.7 (25-124.1)</td>
<td>0 (0.0)</td>
<td>7.1 (18.6-38.3)</td>
</tr>
</tbody>
</table>

Figure 1. Flowchart of patients included.

Conclusion: The risk of incident cancer in patients with rheumatic diseases and a prior malignancy does not differ according to the type of bDMARD and tsDMARD exposure.

Disclosure of Interests: None declared


Background: Chronic joint diseases impair the quality of life. This occurs not only by the deformity generated, but also by the pain and disability produced by them (1, 2). There are a limited number of studies on joint diseases and sexuality (3, 4). Besides, many lack a control group and do not explore the different areas of sexuality (5-10).

Objectives: To describe the prevalence of sexual dysfunction (SD) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PA). To compare the results obtained between the two diseases and a healthy population. To analyse the factors associated with SD in the 3 populations.

Methods: Cross-sectional observation study. Patients diagnosed of PA (CASPAR criteria and RA (EULAR/ACR 2010 criteria), followed in outpatient Rheumatology offices of two different university hospitals of the same geographical area, were consecutively included. The following variables were collected: age, gender, year of diagnoses, perceived health, marital status, level of education, employment situation and the annual level of income), as well as (history of depression and active treatment of mental health disease). The results were compared against healthy individuals, acting as a control group. Only adult patients, of any sexual orientation, were included. The CSFQ-14 questionnaire, which evaluates changes in sexual function due to the disease or its medication, was applied. This questionnaire studies 4 different domains in both genders (pleasure, desire, arousal, orgasm and pain during orgasm) and in addition, it evaluates orgasm completion in women and erection in men. A regression model was created to estimate the influence of the collected variables on the obtained results.

Results: 188 patients were included (52.7% women and 47.3% men); 72 of them were diagnosed of PA and 27 of RA. Moreover, 30.43% of the patients with RA, 48.15% of the patients with RA and 5.88% of the control group had scores on the CSFQ-14 test in the SD range. SD was found related to being diagnosed of PA and RA (p < 0.001), age (p < 0.001), employment status (p < 0.001) and the annual level of income (p = 0.002). On the CSFQ-14 test, men had a mean score 7.5 points higher than women, although this score decreased to 6.15 points in men with PA. Furthermore, patients with PA and RA had a mean score 8.2 points lower than the control group. All of the domains of the CSFQ-14 questionnaire were negatively affected by having PA or RA (p < 0.001). The estimated odds ratio of having SD was 8.7 times higher in patients diagnosed of PA and 10 times higher in patients diagnosed of RA.

Conclusion: Patients with RA or PA have a deteriorated sexual life when compared to a healthy population. This detriment affects all of the domains of the sexual sphere (pleasure, desire, arousal and orgasm). As shown in previous studies, age, gender, perceived health, employment situation and economic status, are related to the risk of suffering from SD. Therefore, these factors must be considered when attending this area of our patient’s health. The CSFQ-14 questionnaire provides a complete approach to sexual health and can be a tool for the management of chronic joint diseases.

REFERENCES:
Remission, flares and predictive factors in SLE, Sjögren and anti-phospholipid syndrome

IMPACT OF TIME TO REMISSION, FLARES AND TIME ON IMMUNOSUPPRESSIVES ON THE ESTIMATED GLOMERULAR FILTRATION RATE IN LUPUS NEPHRITIS

K. Tselios1, D. D. Gladman2, M. B. Urowitz2,3, McMaster Lupus Clinic, Department of Medicine, Hamilton, Canada; 3University Health Network, Schroeder Arthritis Institute, Toronto, Toronto, Canada; 4University of Toronto, Department of Medicine, Toronto, Canada

Background: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease in lupus nephritis (LN). However, the impact of these factors on the rate of glomerular filtration rate (GFR) deterioration is not known.

Objectives: To determine the impact of time to remission, flares and time on immunosuppressives after remission on the estimated GFR in LN.

Methods: Patients with LN based on biopsy or abnormal proteinuria (>0.5g/day) with or without hematuria or pyuria or casts for two consecutive visits were retrieved from the Toronto Lupus Clinic long-term longitudinal database. Individuals with advanced chronic kidney disease at baseline (eGFR<52ml/min/1.73m²) were excluded. All patients were followed for at least 5 years. The primary outcome was any decrease of the estimated GFR on an annual basis (slope). Remission was defined as proteinuria<0.5g/24h, inactive urinary sediment and serum creatinine ≤120% of the baseline value. Flare was defined as any abnormal proteinuria (>0.5g/day) or increase in serum creatinine (SCR) from normal to abnormal or >120% of the baseline value after remission. Slopes of eGFR changes (standard error) were calculated using Ordinary Least Square method in each complete remission/flare group. Linear Mixed model was performed to account for factors associated with deterioration of eGFR.

Results: Out of 418 eligible patients, 209 (50%) achieved remission within the first year from LN diagnosis, 102 (24.4%) within the 2nd and 3rd years, 70 (16.7%) after 3 years and 37 (8.9%) never achieved remission. Regarding flares, 82 patients (19.6%) never flared, 75 (18%) had one flare and 261 (62.4%) had two or more flares. The trajectory and annual slope of eGFR according to time to remission and number of flares is shown in the Figure 1.

Conclusion: Complete remission after 3 years or no remission is associated with a significant decrease in eGFR, while remission during the 2nd and 3rd year from LN diagnosis is not associated with significant decrease of renal function over time. Patients with one flare did not have significant impact on their renal function. Patients with 2 or more flares had a significant decrease of eGFR over 20 years, even after adjustment for other covariates. Time on immunosuppressives after complete remission is protective against eGFR decline. Our findings emphasize the importance of rapid remission and flare prevention by prolonged maintenance treatment with immunosuppressives to optimize renal outcomes.

Acknowledgements: The University of Toronto Lupus Clinics is supported by grants from Lupus Ontario and Lupus Canada and donations from the Marissa and Lou Rocco, the Diana and Mark Bzozko and the Stacey and Mark Krembil Families.

Disclosure of Interests: Konstantinos Tselios: None declared, Dafna D Gladman Consultant of: AstraZeneca, Jindong Su: None declared, Murray B Urowitz Consultant of: GlaxoSmithKline, AstraZeneca, Merck, Bayer, UCB, Grant/ research support from: GlaxoSmithKline


TREAT TO TARGET IN SYSTEMIC LUPUS ERYTHEMATOSUS FROM THE PATIENTS’ PERSPECTIVE – RESULTS FROM AN INTERNATIONAL PATIENT SURVEY

J. Mucke1, D. Pencheva2, A. Parra Sanchez, K. Kramer1, M. Schneider1, I. Bulbink1, University Hospital Dusseldorf, Polyclinic and Hiller Research Unit, Dusseldorf, Germany; 2Medical University of Sofia, Department of Physiology and Pathophysiology, Sofia, Bulgaria; 3Medical University of Sofia, University Clinical Hospital “St. Ivan Rilski”, Sofia, Bulgaria; 4Amsterdam Rheumatology and Immunology Center, Department of Rheumatology, Amsterdam, Netherlands; 5Patient Research Partner, Amsterdam, Netherlands

Background: Treat-to-target (T2T) is a generally accepted treatment concept in rheumatology care. It is assumed that T2T could significantly improve systemic lupus erythematosus (SLE) care and the patients’ outcomes. However, T2T has not yet been studied systematically and clinical trials are currently in preparation [1]. Furthermore, the patients’ opinion on T2T has barely been taken into account.

Objectives: As the success of T2T is largely determined by the involvement of patients, it was our aim to investigate the attitude towards, need, and willingness of SLE patients to participate in a T2T study and to identify possible obstacles.

Methods: A questionnaire on T2T, its acceptance, the need and willingness to participate in a T2T trial and possible obstacles for T2T was designed by the authors in cooperation with patient research partner and performed in the Netherlands (NL), Austria (AU), Germany (GE) and Bulgaria (BG). The web-based survey consisted of 13 questions with single and multiple answers and/or free text. After back-and-forth translation from German to Dutch and Bulgarian, it was distributed among members of the patient organizations of NL, GE, AU, BG via newsletter (GE, AU, BG), personal invitation (NL) and a closed Facebook group (BG). Castor Electronic Data Capture (NL) and SoSci-Survey (GE, AU, BG) were used as platforms.

Results: A total of 863 patients (n=316 NL, n=271 GE, n=232 BG, n=44 AU) with self-declared diagnosis of SLE completed the questionnaire. 93.3% were female, 52.2% were 41-60 years old. The disease duration was longer than 10 years in 54.8%, 12.4% had a disease duration of 0-2 years. Regarding the satisfaction with the current health status, 58.2% were somewhat to all the way satisfied, 29.3% were not at all or hardly satisfied. 65.5% were satisfied with their current therapeutic treatment, 14.8% where not at all or hardly satisfied.
48.4% declared being currently in remission, 13% did not know if they were in remission. As most important treatment goal, normalization of quality of life was chosen most frequently (37.4%) followed by prevention of organ damage (24.6%) and the absence of disease activity (22.6%).

Regarding shared decision making, the majority reported to be somewhat to all the way involved in treatment decisions (82.1%) while 20.7% where hardly or not at all involved.

As most difficult decisions in T2T and shared decision making, respondents named the start of new SLE medication (37.9%) and to change medication while feeling good (39.4%). An increase in the dose of glucocorticoids to reach remission was difficult for 22.7%.

The majority of patients considered research of T2T in SLE useful (55.4% all the way, 29.8% somewhat useful) and 67% would probably or definitely participate in such scientific research. The perceived advantages and disadvantages of T2T are depicted in Figure 1.

**Figure 1.** Consequences of T2T rated as advantage or disadvantage by SLE patients.

**Conclusion:** Despite many SLE patients being satisfied with their treatment and health status, T2T is considered an important subject to be studied in clinical trials. Advantages did outweigh possible disadvantages of T2T with the possibility of more doctors’ visits and the prescription of a new drug as biggest disadvantage. Quality of life named as most important treatment goal emphasizes its importance as outcome parameter. Most patients would be willing to participate in a trial about T2T.

**REFERENCES:**

[1] Mucke J, Kuss O, Brinks R, Schanze S, Schneider M, LUPUS-BEST-treat-to-target. Figure 1 are depicted in Figure 1.

**Disclosure of Interests:** Johanna Mucke Speakers bureau: AbbVie Deutschland GmbH & Co. KG, Bristol Myers Squibb, Celgene GmbH, Chugai Pharma Germany GmbH, Gilead Sciences Inc., GSK, Janssen-Cilag GmbH, Lilly, Chugai, 45 Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taipei, Taiwan, Republic of China; University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines; People's Hospital Peking University Health Science Center, Department of Rheumatology and Immunology, Tainan, Taiwan, Republic of China; University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines; People's Hospital Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China; University of Malaya, Department of Medicine, Faculty of Medicine, Kuala Lumpur, Malaysia; Tokyo Women's Medical University, Institute of Rheumatology, Tokyo, Japan; Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China; St Vincent's Hospital, Department of Rheumatology, Melbourne, Australia; Teaching Hospital Kandy, Division of Nephrology, Kandy, Sri Lanka; Tan Tock Seng Hospital, Department of Rheumatology, Allergy & Immunology, Tan Tock Seng, Singapore; Keio University, Department of Rheumatology, Department of Internal Medicine, School of Medicine, Tokyo, Japan; Hanyang University Hospital for Rheumatic Diseases, Department of Rheumatology, Seoul, Korea, Rep. of (South Korea); Liverpool Hospital, Rheumatology Department, Liverpool, NSW, Australia; University of New South Wales, Ingham Institute of Applied Medical Research, Sydney, NSW, Australia; Finders Medical Centre, Department of Rheumatology, Bedford Park, SA, Australia; Eli Lilly Pty Ltd, Rheumatology Division, Sydney, NSW, Australia; North Shore Hospital, Department of Medicine, Auckland, New Zealand; Singapore General Hospital, Department of Rheumatology, Singapore, Singapore; Greenlane Clinical Centre, Department of Rheumatology, Auckland, New Zealand; Middlemore Hospital, Department of Rheumatology, Auckland, New Zealand; University of the Philippines Department of Rheumatology, Quezon City, Philippines; University of Occupational and Environmental Health, The First Department of Internal Medicine, School of Medicine, Kitakyushu, Japan; The University of Hong Kong, Division of Rheumatology & Clinical Immunology, Department of Medicine, Pok Fu Lam, Hong Kong (SAR)

**Background:** Lupus low disease activity state (LLDAS) attainment has been reported to be associated with reduced damage accrual, flare, and mortality, as well as improved quality of life, in cohorts of SLE patients with established disease. Whether these associations are present in recent-onset disease is less well known.

**Objectives:** To evaluate the associations of LLDAS attainment with outcomes in patients with recent-onset SLE.

**Methods:** Data from a 13-country longitudinal SLE cohort (ACR/SLECC criteria) were collected prospectively between 2013 and 2020 using standard templates. Organ damage and flare were captured using SLICC Damage Index and SLEDAI Flare Index, respectively, LLDAS was defined as Golder et al., 2019 [1]. An inception cohort was defined based on duration since SLE diagnosis<1 year at enrolment. Patient characteristics between inception and non-inception cohorts were compared using Wilcoxon rank-sum (continuous variables) or Pearson's Chi-squared tests (categorical variables). Survival analyses were performed to examine the association between LLDAS attainment and damage accrual and flare.

**Results:** The study cohort included 4,106 patients of whom 680 (16%) were recruited within 1 year of SLE diagnosis (inception cohort). Compared to the non-inception cohort inception cohorts patients were significantly younger, had higher disease activity (SLEDAI-2K and physician global assessment), used more glucocorticoids and immunosuppressants but had less organ damage at enrolment and only 86 (13.6%) patients accrued damage during a median 2.2 years follow-up (Table 1).

**Table 1.**

<table>
<thead>
<tr>
<th></th>
<th>Non-inception cohort</th>
<th>Inception cohort</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to LLDAS attainment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at enrolment (years), median (IQR)</td>
<td>40 (31, 51)</td>
<td>33 (25, 44)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at diagnosis (years), median (IQR)</td>
<td>28 (21, 38)</td>
<td>33 (25, 43)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SLE duration at enrolment (years), median (IQR)</td>
<td>10 [5, 16]</td>
<td>1 [0, 1]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Study duration (years), median</td>
<td>2.5 [10, 5.4]</td>
<td>2.2 [0.9, 3.7]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>3155 (82.1%)</td>
<td>623 (91.6%)</td>
<td>0.68</td>
</tr>
<tr>
<td>Asian ethnicity, n (%)</td>
<td>3037 (89.1%)</td>
<td>595 (88.1%)</td>
<td>0.49</td>
</tr>
<tr>
<td>Prednisolone (PND) use - ever, n (%)</td>
<td>2865 (83.6%)</td>
<td>620 (91.2%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time adjusted mean (TAM) PND - mean (IQR)</td>
<td>5.0 (2.2, 8.6)</td>
<td>6.2 (3.2, 10.3)</td>
<td>0.08</td>
</tr>
<tr>
<td>Cumulative PND (g), median (IQR)</td>
<td>14.9 (5.9, 38.6)</td>
<td>3.8 (11.1, 8.6)</td>
<td>0.26</td>
</tr>
<tr>
<td>Anti-Malarial use - ever, n (%)</td>
<td>2669 (77.9%)</td>
<td>569 (83.3%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Immunosuppressant use - ever, n (%)</td>
<td>2367 (69.1%)</td>
<td>521 (76.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>MSS (TAM-SLEDAI-2K), median (IQR)</td>
<td>2.8 (12.4)</td>
<td>3.1 (16.9, 5.0)</td>
<td>0.02</td>
</tr>
<tr>
<td>TAM-PGA, median (IQR)</td>
<td>0.4 (0.2, 0.7)</td>
<td>0.4 (0.3, 0.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mild/moderate/severe flare ever, n (%)</td>
<td>1789 (52.2%)</td>
<td>391 (57.5%)</td>
<td>0.012</td>
</tr>
<tr>
<td>Organ damage accrual, n (%)</td>
<td>620 (90.7%)</td>
<td>121 (17.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline damage, n (%)</td>
<td>1730 (50.5%)</td>
<td>195 (28.7%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LLDAS-earliest at least once, n (%)</td>
<td>2637 (78.2%)</td>
<td>492 (73.9%)</td>
<td>0.014</td>
</tr>
<tr>
<td>≤50% time in LLDAS (LLDAS-5), n (%)</td>
<td>1612 (50.6%)</td>
<td>256 (41.1%)</td>
<td>0.014</td>
</tr>
</tbody>
</table>
Significantly fewer inception cohort patients were in LLDAS at enrolment than the non-inception cohort (29 vs. 51%, p<0.001). However, 74% of inception and 78% of non-inception cohort patients achieved LLDAS at least once during follow-up. Limiting analysis only to patients not in LLDAS at enrolment, time to first LLDAS attainment was assessed: inception cohort patients were 60% more likely to attain their first LLDAS (HR = 1.60 (95%CI: 1.40, 1.82), p<0.001) than non-inception cohort patients. LLDAS attainment was significantly protective against flare in the inception cohort (HR, 95% CI) and non-inception cohort (HR, 95% CI) trends. Towards protection against damage accrual in association with LLDAS in the inception cohort were not significant. Consistent with our LLDAS is protective from damage accrual (inception cohort), significant protection from damage accrual was not observed, due to low rates of damage accrual in the first years after SLE diagnosis.

REFERENCES:
1 Golder, V., et al., Lupus low disease activity state as a treatment endpoint


Background: Intercurrent infections are presumed potential triggers of systemic lupus erythematosus (SLE) disease flares. However, most of the evidence is obtained from a limited number of observational studies, and the results of these studies are conflicting. Objectives: To determine whether intercurrent infections are a risk factor for disease flares in SLE.

Methods: Demographic and clinical characteristics of 203 SLE patients from the Amsterdam SLE cohort were collected at baseline, and at the start of an intercurrent infection that either was or was not followed by a flare within three months. Major and minor flares were defined as, respectively: infections for which hospital admission or intravenous antibiotic therapy was required, and infections (proven or not proven, but highly likely based on clinical symptoms and/or response to therapy) for which hospital admission was not warranted. SLE flares were defined as an increase in disease activity requiring intensification of immunosuppressive therapy. Flares were categorized as major or minor depending on fulfillment of a predefined set of criteria. Incidence rates for infections, flares, and infections followed by a flare within three months were calculated using Poisson regression. Descriptive analyses were performed where appropriate. Proportional hazard models with recurrent events and time-varying covariates were used to estimate the hazard ratio of SLE flares.

Results: Table 1 shows the demographic and clinical characteristics of all 203 SLE patients. Fifty-six major infections occurred in 1060 patient years, and 670 minor infections occurred in 1008 patient years. The incidence rates of major and minor infections were 5.3 per 100 patient years (95% CI: 4.1 – 6.9) and 63.9 per 100 patient years (95% CI: 59.3 – 69.0), respectively. In total, 198 flares occurred within 1060 patient years. The incidence rate of flares is 18.7 per patient years (95% CI: 16.3 – 21.5), 3.6 per 100 patient years (95% CI: 2.6 – 4.9) for major and minor flares, respectively. The incidence rate of minor infections followed by a flare within three months were 0.7 per 100 patient years (95% CI: 0.3 – 1.4) and 2.3 per 100 patient years (95% CI: 1.5 – 3.4). Intercurrent infections (major and minor) were associated with the occurrence of SLE flares (major and minor; HR: 1.9, 95% CI:1.3 – 2.9) (Figure 1). The hazard ratio for a major SLE flare following a major infection was 7.4 (95% CI: 2.2 – 24.6). Major infections were not associated with the occurrence of minor flares.

Table 1. Baseline demographic and clinical characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>SLE patients (n = 203)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, Female, n (%)</td>
<td>184 (91)</td>
</tr>
<tr>
<td>Age, years (median (IQR))</td>
<td>40.0 (20.0 – 47.0)</td>
</tr>
<tr>
<td>Caucasian ethnicity, n (%)</td>
<td>137 (68)</td>
</tr>
<tr>
<td>SELENA-SLEDAI2k damage index (median (IQR))</td>
<td>1.0 (0 – 2)</td>
</tr>
<tr>
<td>Disease duration, years (median (IQR))</td>
<td>6 (11 – 11)</td>
</tr>
<tr>
<td>History of:</td>
<td></td>
</tr>
<tr>
<td>Biopsy proven lupus nephritis, n (%)</td>
<td>38 (19)</td>
</tr>
<tr>
<td>Renal insufficiency (eGFR &lt; 45), n (%)</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>7 (3)</td>
</tr>
<tr>
<td>Malignancy, n (%)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>Stroke, n (%)</td>
<td>12 (6)</td>
</tr>
<tr>
<td>Asplenia, n (%)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>Treatment variables:</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids, n (%)</td>
<td>106 (52)</td>
</tr>
<tr>
<td>Antimalarials, n (%)</td>
<td>151 (74)</td>
</tr>
<tr>
<td>Immunosuppressants, n (%)</td>
<td>88 (52)</td>
</tr>
<tr>
<td>NSAIa.s, n (%)</td>
<td>67 (33)</td>
</tr>
</tbody>
</table>
Methods: The creation process was composed of three phases: first, SLE-T2T was conceived as a web-based application with a specific task - to generate decision-making process3. SLE-T2T is an online CDSS tool designed to help rheumatologists to apply a T2T strategy in the management of SLE patients. A general sketch was conceived as a web-based application with a specific task - to generate appropriate treatment advice based on entered patients’ data. A general sketch of the program was made, and general consensus was achieved with regards to the desired functionalities. In the development phase, a beta version of SLE-T2T was conceived using a free integrated development environment, and based on the desired functionalities. In the decision-making process3. SLE-T2T is an online CDSS tool designed to help rheumatologists to apply a T2T strategy in the management of SLE patients.

Objectives: We aimed to design and develop a first prototype of SLE-T2T, and test its usability for the implementation of a treat-to-target strategy in the management of patients with SLE.

Methods: The creation process was composed of three phases: first, SLE-T2T was conceived as a web-based application with a specific task - to generate appropriate treatment advice based on entered patients’ data. A general sketch of the program was made, and general consensus was achieved with regards to the desired functionalities. In the development phase, a beta version of SLE-T2T was conceived using a free integrated development environment, and based on the desired functionalities. In the decision-making process3. SLE-T2T is an online CDSS tool designed to help rheumatologists to apply a T2T strategy in the management of SLE patients.

Objectives: We aimed to design and develop a first prototype of SLE-T2T, and test its usability for the implementation of a treat-to-target strategy in the management of patients with SLE.

Methods: The creation process was composed of three phases: first, SLE-T2T was conceived as a web-based application with a specific task - to generate appropriate treatment advice based on entered patients’ data. A general sketch of the program was made, and general consensus was achieved with regards to the desired functionalities. In the development phase, a beta version of SLE-T2T was conceived using a free integrated development environment, and based on the desired functionalities. In the decision-making process3. SLE-T2T is an online CDSS tool designed to help rheumatologists to apply a T2T strategy in the management of SLE patients.

Objectives: We aimed to design and develop a first prototype of SLE-T2T, and test its usability for the implementation of a treat-to-target strategy in the management of patients with SLE.
Results: A total of 302 patients were enrolled in this study. The mean age was 32±12 years old, and 202 (66.9%) were female (Table 1). Patients were followed up for a median of 36 months. During the follow-up period, there were 62 thrombotic events, with 40 (13.2%) venous and 22 (7.2%) arterial thrombosis. The 1-, 3-, and 5-year thrombosis risks were 8.9%, 16.9%, and 21.3% respectively (Figure 1A). The Harrell c-indexes for predicting thrombosis of aGAPSS, Padua score, and Caprini score were 0.56 (95% CI, 0.52-0.60), 0.58 (95% CI, 0.54-0.62), and 0.61 (95% CI, 0.57-0.65) respectively. The model predicting venous thrombosis with the best discrimination was Padua score whose Harrell c-index was 0.64 (95% CI, 0.60-0.68), and the model predicting arterial thrombosis with the best discrimination was Caprini score whose Harrell c-index was 0.62 (95% CI, 0.56-0.68). The calibration curves illustrated that the calibration for predicting thrombosis within 3 years after diagnosis of all the 3 models was poor (Figure 1B-D).

Table 1. Demographic characteristics and clinical manifestations at baseline

<table>
<thead>
<tr>
<th></th>
<th>N=302</th>
<th>N=302</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean±SD</td>
<td>32±12</td>
<td>Clinical manifestations</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>202 (66.9)</td>
<td>Venous thrombosis, n (%) 156 (51.7)</td>
</tr>
<tr>
<td>Disease duration (months), median (Q1, Q3)</td>
<td>11.50 (3.00, 44.00)</td>
<td>Deep venous thrombosis, n (%) 112 (37.1)</td>
</tr>
<tr>
<td>Secondary to SLE, n (%)</td>
<td>73 (24.2)</td>
<td>Pulmonary embolism, n (%) 70 (23.2)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>59 (19.5)</td>
<td>Visceral venous thrombosis, n (%) 12 (4.0)</td>
</tr>
<tr>
<td>Hyperlipidemia, n (%)</td>
<td>151 (50.0)</td>
<td>Cranial venous sinus thrombosis, n (%) 13 (4.3)</td>
</tr>
<tr>
<td>BMI, mean±SD</td>
<td>23.96±3.89</td>
<td>Arterial thrombosis, n (%) 113 (37.4)</td>
</tr>
<tr>
<td>LA positive, n (%)</td>
<td>241 (79.8)</td>
<td>Stroke/TIA, n (%) 62 (20.5)</td>
</tr>
<tr>
<td>aGPL positive, n (%)</td>
<td>208 (68.9)</td>
<td>Myocardial infarction, n (%) 14 (4.6)</td>
</tr>
<tr>
<td>a2GPI positive, n (%)</td>
<td>242 (80.1)</td>
<td>Arterial thrombosis of lower extremities, n (%) 22 (7.3)</td>
</tr>
<tr>
<td>Triple aPL positive, n (%)</td>
<td>165 (54.6)</td>
<td>Visceral arteriosclerosis, n (%) 18 (6.0)</td>
</tr>
<tr>
<td>Obstetric manifestations, n (%)</td>
<td>N=202</td>
<td>Thrombocytopenia, n (%) 118 (39.1)</td>
</tr>
<tr>
<td>Pregnancy morbidity</td>
<td>103 (51.0)</td>
<td>Valvar lesions, n (%) 24 (7.9)</td>
</tr>
<tr>
<td>Early miscarriages (&lt;10 weeks)</td>
<td>13 (6.4)</td>
<td>None declared</td>
</tr>
<tr>
<td>Fetal death (&gt;10 weeks)</td>
<td>68 (33.7)</td>
<td>None declared</td>
</tr>
<tr>
<td>Preeclampsia, edema and placental dysfunction</td>
<td>36 (17.8)</td>
<td>None declared</td>
</tr>
</tbody>
</table>

Figure 1. The Kaplan-Meier curve and the calibration curve of 3 prediction models within 3 years after diagnosis. A: The Kaplan-Meier curve of venous, arterial and both venous and arterial thrombosis. B: The calibration curves for venous thrombosis. C: The calibration curves for arterial thrombosis. D: The calibration curves for both venous and arterial thrombosis.

Conclusion: The ability of aGAPSS, Padua score and Caprini score to predict thrombosis in APS patients is relatively poor. Construction of a new prediction model specifically for APS patients is required to help with early prevention and treatment.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3074

OP1146

ISOLATED ANTI-RO52 ANTIBODIES IN SJÖGREN’S SYNDROME: A MILDLY INFLAMMATORY PHENOTYPE AT HIGHER RISK FOR FIBROTIC ORGAN INVOLVEMENT

S. Fonzetti1, F. Ferro1, G. La Rocca1, G. Fulvio1, I. C. Navarro Garcia1, G. Governato1, V. Donati1, M. Mosca1, C. Baldini1. 1University of Pisa, Rheumatology Unit, Clinical and Experimental Medicine, Pisa, Italy; 2Unit of Pathological Anatomy 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

Background: Autoimmune response against the Ro antigen (Ro52 and/or Ro60 subunits) represents a distinctive serological hallmark in primary Sjögren Syndrome (pSS). The double positivity for anti-Ro52 and anti-Ro52 has been associated with a higher glandular inflammation and B-cell hyperactivity. By contrast, the clinical significance of isolated anti-Ro52 antibodies in pSS remains controversial. Objectives: To investigate the association between isolated anti-Ro52 antibodies and glandular and extra-glandular pSS features in order to explore whether anti-Ro52 antibodies may help to identify a specific subset of pSS.

Methods: In this retrospective study we included unselected pSS patients prospectively followed at our Unit between 2012 to 2021. Of them, anti-Ro/SSA positive patients were identified and stratified by the presence of anti-Ro52 isolated, anti-Ro52 isolated and both anti-Ro60 and anti-Ro52. Demographics, clinical, biological and histological data were compared between the three groups. Data were presented as mean±SD, or percent frequency as appropriate. Intergroup comparisons were made using the t-test/Mann–Whitney test for continuous variables and Fisher’s exact test for categorical variables.

Results: Out of a study cohort of 432 pSS patients, we included 300 anti-Ro/SSA positive patients (21 M, 279 F, mean age 57±14 yrs) followed for a mean follow-up of 6.5±6.7 years. Of them, 59/300 (19.7%) presented isolated Ro52 antibodies, 214/300 (71.3 %) both anti-Ro60 and anti-Ro52 and 27/300 (9%) had isolated Ro60 antibodies. At diagnosis, patients with anti-Ro52 alone were older than those with double positivity (57±13±2 yrs vs 48.8±13.8, p=0.0001) and presented a lower focus score (FS) in their minor salivary gland biopsies (MSGBs) (p=0.9±1.0 vs 1.6±0.9, p=0.02). No differences in demographic and glandular infiltrate were detected between anti-Ro52 alone and anti-Ro60 alone patients. Similarly, the three subgroups did not differ in oral and ocular function tests as well as in the patient reported outcomes (ESSPRI, OHIP and OSDI). Salivary gland ultrasonography showed a decreasing trend of the OMERACT scoring system with the highest grade detected more commonly in anti-Ro60 and anti-Ro52 patients and the lowest grade in anti-Ro60 alone. Regarding extraglandular manifestations significant differences were observed among the three subgroups as shown in the heat map (Figure 1). Patients with anti-Ro52 alone presented the highest frequency of interstitial lung disease (ILD) and primary biliary cirrhosis (PBC) and the lowest prevalence of lymphadenopathy, anti-La/SSB and hyper-IgG (p<0.05). By contrast, patients presenting anti-Ro52 in association with anti-Ro60 had a prominent B cell hyperactivity with higher levels of serum IgG, anti-La SSB antibodies and Rheumatoid factor positivity (p<0.05). Finally, patients with isolated anti-Ro60 presented a milder disease activity and an ESSDAI (3.4±4.5 vs 6.3±4.8 vs 5.2±5.1, p=0.009) significantly lower than the other two subgroups.

Conclusion: Patients with isolated anti-Ro52 seems to represent a specific subset of pSS with milder tissue focal inflammation but at higher risk for systemic fibrotic changes, particularly in the lungs. The identification of molecular pathogenetic processes, common to both isolated anti-Ro52 pSS and other anti-Ro52 positive connective tissue diseases may offer new insights into our understanding of disease etiology, and facilitate the development of targeted therapeutic approaches.
Background: Accurate and practical outcome measures for clinical trials in systemic lupus erythematosus (SLE) are lacking. The SLE Disease Activity Score (SLE-DAS) is a recently validated 17-item instrument, with high accuracy and sensitivity in SLE disease activity. The SLE-DAS definitions of remission and low disease activity (LDA) were newly validated in the clinical setting. These definitions may constitute accurate and easy to apply endpoints for SLE trials.

Objectives: (1) To evaluate the ability of SLE-DAS remission and LDA definitions to discriminate drug from placebo in SLE phase 3 trials; (2) To determine if attainment of these SLE-DAS targets are associated with better health-related quality of life (HR-QoL).

Methods: Post-hoc analysis of the merged study population in the BLISS-52 and -76 trials (NCT00424476; NCT00103884) of intravenous belimumab versus placebo for moderate to severe SLE disease activity. We analyzed the British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy (FACIT) and 36-item Short Form Survey (SF-36) trial data. The fulfillment of SLE-DAS remission and LDA definitions were retrospectively assessed from the individual participants’ data. Proportion of patients attaining SLE-DAS Boolean remission (defined as absence of all SLE-DAS clinical items and prednisone ≤5mg/day) and LDA (defined as SLE-DAS ≤2.48 and prednisone ≤7.5mg/day) was compared with placebo (N=1684).

Results: A total of 1684 SLE patients were included: 562 on placebo, 559 on belimumab 1mg/Kg and 563 on belimumab 10mg/Kg. At week 52, significantly more patients attained SLE-DAS LDA on belimumab 10mg/Kg as compared with placebo (10.1% vs 13.0%, OR=1.289, p<0.001). In the BILAG, Physician Global Assessment, Functional Assessment of Chronic Illness Therapy and Medical Outcomes Survey Short Form (SF-36) trial data, the fulfillment of SLE-DAS remission and LDA definitions were significantly better in patients treated with belimumab as compared with placebo at week 52 (Table 1). Importantly, none of the patients achieving SLE-DAS remission on belimumab 10mg/Kg as compared with placebo (10.1% vs 14.7%, OR=1.532, p=0.019) or patients achieving SLE-DAS LDA on belimumab 10mg/Kg and 563 on belimumab 10mg/Kg as compared with placebo (13.0% vs 17.9%, OR=1.459, p<0.001, and 13.0% vs 21.7%, OR=1.532, p<0.001, respectively). Likewise, more patients attained SLE-DAS remission on belimumab 10mg/Kg as compared with placebo (10.1% vs 14.7%, OR=1.532, p=0.019) (Table 1). Importantly, none of the patients achieving SLE-DAS remission or LDA presented a new BILAG A or more than 1 new B domain score, neither a worsening in PGA≤0.3.

Table 1. Attainment of SLE-DAS Boolean remission and LDA at week 52 in BLISS-52 and BLISS-76 trials, according to the treatment groups (n=1684).

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>Belimumab 1mg/Kg</th>
<th>Belimumab 10mg/Kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE-DAS remission</td>
<td>10.1%</td>
<td>12.7%</td>
<td>14.7%</td>
</tr>
<tr>
<td>(n=211)</td>
<td>(0.89-1.86)</td>
<td>0.178</td>
<td>1.069-2.195</td>
</tr>
<tr>
<td>SLE-DAS LDA</td>
<td>13.0%</td>
<td>17.3%</td>
<td>21.7%</td>
</tr>
<tr>
<td>(n=295)</td>
<td>(1.95-2.95)</td>
<td>0.023</td>
<td>1.349-2.545</td>
</tr>
</tbody>
</table>

Discussion: SLE-DAS remission and LDA showed discriminant validity for identifying patients receiving active drug in clinical trials. These treatment targets are associated with better HR-QoL and lower fatigue.

REFERENCES:

Acknowledgements: The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for granting access to the data from the BLISS-52 and 76 trials through the Clinical Study Data Request consortium.

Disclosure of Interests: None declared.


Spondyloarthritis in practice: imaging, outcome assessment and comorbidities

V. Navarro-Compañón1, A. Boel2, A. Boonen3, P. J. Mease4, M. Dougeois5, U. Kiltz6, R. B. M. Landewe1, D. van der Heijde1 on behalf of The ASAS axSpA core measurement set working group. 1Hospital La Paz, IdiPaz, Rheumatology, Madrid, Spain; 2LUMC, Rheumatology, Leiden, Netherlands; 3UMC+, Rheumatology, Maastricht, Netherlands; 4Swedish Medical Center/Providence St. Joseph Health and the University of Washington, Rheumatology, Seattle, United States of America; 5Cochin Hospital, Rheumatology, Paris, France; 6Rheumazentrum Ruhrgebiet, Ruhr-Universität, Rheumatology, Bochum, Herne, Germany; 7Rheumatologist, Zuiderland MC, Rheumatology, Heerlen, Netherlands

Background: Recently, the core domains of the 20-years-old core outcome set for ankylosing spondylitis were updated. The next step is to define the measurement core set, which includes at least one instrument for each domain.

Objectives: To define the instruments for the ASAS-OMERACT core outcome set for axial spondyloarthritis (axSpA).

Methods: The scientific committee invited an international working group representing all key stakeholders (patients, rheumatologists, health professionals and pharmaceutical industry). The instrument selection process is presented in Figure 1.

Figure 1. Development process to determine the core measurement set

Results: The updated core measurement set for axSpA is shown in Table 1. This includes seven instruments for six domains that are mandatory for all trials: ASDAS and NRS patient global assessment for disease activity, NRS total back pain for pain, composite index for morning stiffness, NRS fatigue for fatigue, BASFI for physical function, and ASAS Health Index for overall functioning and health. There are 9 additional instruments for disease modifying drugs (DMARDs): two MRI activity scores (SPARCC SIJ and SPARCC spine) for disease activity, the three extra-musculoskeletal manifestations uveitis, IBD and psoriasis assessed as recommended by ASAS, the three peripheral manifestations (4 swollen joint count, MASES and Dactylitis count) and mSASSS for structural damage. The imaging outcomes are mandatory to be included at least in one trial for a drug that is considered to be a DMARD. The other instruments specific for DMARDs should be included in every trial. This core set is applicable to patients with radiographic and non-radiographic axSpA. Furthermore, other instruments were also endorsed by ASAS and can additionally be used in axSpA trials: BASDAI, CRP, Berlin MRI-SIJ and MRI-spine activity scores for disease activity, NRS back pain at night for pain, severity (BASDAI Q6) and duration (BASDAI Q6) for morning stiffness, SF-36 for overall functioning and health, 66 swollen joint count and SPARCC enthesis for peripheral manifestations and MRI-SIJ erosions scores (SPARCC SSS) for structural damage.
**Table 1. Updated core measurement set for axial spondyloarthritis.**

<table>
<thead>
<tr>
<th>Domain</th>
<th>Instrument</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease activity</td>
<td>ASDAS</td>
</tr>
<tr>
<td>Pain</td>
<td>NRS total back pain (BASDAI Q2)</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>Severity and duration (BASDAI (Q5-Q6)[2])</td>
</tr>
<tr>
<td>Fatigue</td>
<td>NRS fatigue (BASDAI Q1)</td>
</tr>
<tr>
<td>Physical function</td>
<td>BASFI</td>
</tr>
<tr>
<td>Overall functioning &amp; health</td>
<td>ASAS Health Index</td>
</tr>
<tr>
<td>Additional instruments mandatory for disease modifying drugs trials</td>
<td></td>
</tr>
<tr>
<td>Disease activity</td>
<td>SPARCC MRI-SI</td>
</tr>
<tr>
<td>Extra-musculoskeletal manifestations</td>
<td>psoriasis (ASAS CRF)[2]</td>
</tr>
<tr>
<td>Peripheral manifestations</td>
<td>44 Swollen joint count</td>
</tr>
<tr>
<td>Structural damage</td>
<td>mSASSS*</td>
</tr>
</tbody>
</table>

**REFERENCES:**


**Conclusion:** The previous core measurement set has been updated and endorsed by ASAS for the use in all axSpA trials.


**Background:** Patients (pts) with axial spondyloarthritis (axSpA) are classified into radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA) based on the presence or absence of radiographic sacroiliitis. Approximately 20% to 80% of newly diagnosed axSpA pts have nr-axSpA and 8% to 40% progress to r-axSpA over the next 10 years.

**Methods:** PROOF was a global, real-world, prospective, observational study conducted in rheumatology clinical practices in 29 countries across 6 different geographic regions. The study enrolled adults with chronic back pain for ≥6 months and onset before 45 years of age. This analysis included pts diagnosed with axSpA who also fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axSpA. Study visits occurred at baseline (BL) and yearly thereafter. Baseline and follow-up radiographs were evaluated for pts with initial nr-axSpA diagnosis independently by 2 central readers according to the modified New York criteria. In the case of disagreement on the classification (nr-axSpA vs r-axSpA), images were adjudicated by a third reader.

**Results:** Among 2633 enrolled pts, 2165 (82%) were diagnosed with axSpA and fulfilled the ASAS classification criteria. Among these, 1612 (74%) were classified as having r-axSpA (1050 [65%]) or nr-axSpA (562 [35%]) by central reading. The majority of nr-axSpA pts (77%) fulfilled the ASAS classification criteria due to positive findings on imaging (plus ≥1 SpA feature) and 23% were classified according to the clinical arm. A total of 246 nr-axSpA pts who had ≥1 follow-up SIJ radiograph were included in this analysis. Among these 246 pts, progression from initial nr-axSpA to r-axSpA at any of the follow-up visits was observed in 40 pts (16%) over 5 years. Mean time to radiographic progression was 2.4 years (range from 0.9 to 5.1 years) in descriptive analysis (Kaplan-Meier curve shown in Figure 1). In model 1 of the Cox regression analysis, male gender (HR: 3.16 [95% CI: 1.22–8.17]; P = 0.0174), fulfilment of the imaging arm (HR: 6.64 [1.37–32.25]; P = 0.0188), and good response to NSAIDs, (HR: 4.66 [1.23–17.71]; P = 0.0237), were significantly associated with progression to r-axSpA (Figure 1). In model 2, HLA-B27 positivity showed a significant association with progression (HR: 3.99 [1.10–14.49]; P = 0.0353; Figure 1).

**Conclusion:** In this study, 16% of nr-axSpA pts progressed to r-axSpA within 5 years. The mean time to disease progression was 2.4 years. Predictors of radiographic progression were male gender, good response to NSAIDs, and fulfilment of the imaging arm as well as HLA-B27 positivity.

**REFERENCES:**

Disclosure of Interests: Denis Poddubnyy Speakers bureau: AbbVie, Bristol Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Boceld, Eli Lilly, Gilead, GlaxoSmithKline, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, and Pfizer, Joachim Sieper Speakers bureau: AbbVie, Janssen, Merck, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Lilly, Merck, Novartis, Pfizer, and UCB, Servet Akar Speakers bureau: AbbVie, Lilly, MSD, Novartis, Pfizer, Roche, Janssen, and UCB, Consultant of: AbbVie, Lilly, MSD, Novartis, Pfizer, Roche, Janssen, and UCB, Santiago Muñoz-Fernández Speakers bureau: AbbVie, BMS, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, BMS, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Lilly, MSD, Novartis, Pfizer, Roche, Janssen, and UCB, Consultant of: AbbVie, Lilly, MSD, Novartis, Pfizer, Roche, Janssen, and UCB, Grant/research support from: AbbVie, Lilly, MSD, Novartis, Pfizer, Roche, Janssen, and UCB, Siemens Healthineers Consultant of: AbbVie, Amgen, Merck, and Janssen, Employee of: AbbVie, Robert Diekhoff Paid instructor for: Novartis, MSD, CANON, Consultant of: AbbVie, Eli Lilly, Mikhail Propotopov, none declared, Elisabeth Altmära Consultant of: AbbVie, Fabiana Ganz Shareholder of: Owns AbbVie stock or stock options, Employee of: AbbVie, Robert Inman Consultant of: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and Sandoz, Grant/research support from: AbbVie, Amgen, and MSD.

Methods:

An international task force was established combining radiologists and rheumatologists / orthopedics alike which are sometimes not completely known or understood.

Objectives: This project aimed to develop practical consensus recommendations for the standardized communication around imaging of sacroiliac joints and spine for diagnostic purposes in patients with suspected axSpA or their management in clinical practice.

Results:

This project aimed to develop practical consensus recommendations for the standardized communication around imaging of sacroiliac joints and spine for diagnostic purposes in patients with suspected axSpA or their management in clinical practice.

Background: Clinicians face uncertainties in their daily practice when requesting imaging examinations for patients with suspected axial spondyloarthritis (axSpA) or when producing an imaging report because the requirements and desired information of radiologists and rheumatologists / orthopedics alike are sometimes not completely known or understood.

Objectives: This project aimed to develop practical consensus recommendations for the standardized communication around imaging of sacroiliac joints and spine for diagnostic purposes in patients with suspected axSpA or their management in clinical practice.

Methods: An international task force was established combining radiologists (n=13) and rheumatologists / orthopedics alike (n=13) from the Assessment of SpondyloArthritis International Society (ASAS), two members of Young ASAS and a patient representative. The task force defined the project’s aims and developed a project statement. Then, considering published literature and the work of other groups, two survey rounds were designed, and all ASAS members invited to respond.

first, to identify items for further consideration, second, to consider the detail of information to be communicated. Finally, ASAS members discussed the recommendations proposed by the task force during the ASAS annual workshop in January 2022 and voted regarding endorsement of the recommendations.

Conclusion: These ASAS recommendations provide guidance for requesting and reporting imaging examinations in the context of axSpA and for standardizing and enhancing communication between rheumatologists and radiologists to improve diagnosis and patient care.


Figure 1. ASAS recommendations for requesting and reporting imaging in patients with suspected axSpA.

Conclusion: These ASAS recommendations provide guidance for requesting and reporting imaging examinations in the context of axSpA and for standardizing and enhancing communication between rheumatologists and radiologists to improve diagnosis and patient care.


Figure 1. ASAS recommendations for requesting and reporting imaging in patients with suspected axSpA.

Conclusion: These ASAS recommendations provide guidance for requesting and reporting imaging examinations in the context of axSpA and for standardizing and enhancing communication between rheumatologists and radiologists to improve diagnosis and patient care.


Figure 1. ASAS recommendations for requesting and reporting imaging in patients with suspected axSpA.
Background: Ankylosing spondylitis (AS) tends to develop at a relatively young age and is characterized by long-term disease progression (1). During that time, various radiographic changes occur in the spine, which eventually lead to disability in the patient’s lifetime (2). Although the duration of the disease, aging, and passage of time are predicted to be highly associated with spinal progression of AS, it is difficult to predict its progression in the spine of patients.

Objectives: We aimed to find ways to predict spinal progression over time in patients with AS and analyze its associated clinical factors.

Methods: Data from the medical records from a single center were extracted between 2001 and 2018. We analyzed the data on patients who fulfilled the modified New York Criteria for AS and had two or more sets of radiographs taken during the observation period. The modified Stote Ankylosing Spondylitis Spinal Score (mSASSS) was estimated by two independent radiologists. Group-based trajectory modeling (GBTM) was used to classify patients into distinct subgroups of longitudinal mSASSS. And when these trajectories and statistically associated factors acted on a patient, which group the patient was most likely to belong to was predicted using a decision tree analysis.

Results: Data on 1,125 patients were analyzed, and the trajectories were divided into three groups based on duration of the disease. The progression trend of patients with AS identified in this study is expected to be helpful in the treatment and management of patients with AS.

Conclusion: We identified three patterns of radiographic progression according to duration of the disease. The progression trend of patients with AS identified in this study is expected to be helpful in the treatment and management of patients with AS in actual clinical settings.

REFERENCES:
a similar performance on the validation and test datasets for the detection of active inflammatory changes fulfilling the ASAS definition. The model for the detection of structural changes indicative of axSpA showed good performance on the validation dataset with an AUC of 0.90 (0.82-0.96) for the detection of structural changes and an overall accuracy of 85%. The associated sensitivity and specificity were 95% and 75%, respectively. The model showed reasonable generalization to new data with an AUC of 0.89 (0.81-0.96) and an accuracy of 79%; the sensitivity and specificity were 85% and 78%, respectively. Overall, the model performed close to the individual human experts - Figure 1.

Conclusion: The developed framework allowed the detection of active inflammatory and structural changes indicative of axSpA on MRI. This approach may be used as an assistant tool in the diagnostic workflow.

Acknowledgements: GESPIC-AS has been financially supported by the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung - BMBF). GESPIC-Crohn has been supported by the Clinical Research Unit grant from the Berlin Institute of Health (BIH). GESPIC-Uveitis has been supported by a research grant from Abbvie. OptiRef has been supported by a research grant from Novartis. The Assessment of Spondyloarthritis International Society (ASAS) has supported the project with a research grant and provided access to the MRI images of the ASAS classification cohort. We want to thank colleagues who performed annotation of the images from the ASAS classification cohort: Pedro Machado, Mikkel Ostergaard, Suzanne Juhl Pedersen, Ulrich Weber. Further, we thank Torsten Karge for the development of the scoring interface for ASAS images. Joel Paschke for development of the scoring interface for ASAS images. LCA is grateful for her participation in the BIH Charité-Junior Clinician and Clinician Scientist Program and KKB is grateful for his participation in the BIH Charité–Junior Clinician and Clinician Scientist Program.

Disclosure of Interests: None declared,

DOI: 10.1136/annrheumdis-2022-eular.1416
Comorbidity clusters in ankylosing spondylitis (AS) occur more frequently than in the general population and are associated with higher morbidity and mortality. Some comorbidities may occur together, making one more likely in the presence of another, and different combinations of comorbidities may have differential considerations for AS management and outcomes.

**Objectives:** To examine the association of baseline comorbidities with disease activity and functional status in AS.

**Methods:** We used baseline data from the Prospective Study Of Ankylosing Spondylitis (POSA) cohort, a multicenter, prospective cohort from five centers (4 in the US, 1 in Australia). AS patients ≥ 18 years fulfilling mNRA criteria for AS (≥ 4/10) and non-criteria comorbidities and extra-musculoskeletal manifestations (EMMs, N=2) within 3 years of enrollment (prespecified on the baseline case-report form) and only those occurring in ≥1% were included. Undocumented comorbidities were assumed to be absent if missing in <15% of patients, and those missing in >50% of patients were excluded. Comorbidity clusters were identified using K-median clustering. The optimal number of clusters was determined using scree plot of the sum of squared errors and “elbow” on the graph line. Baseline characteristics of the clusters were compared, and associations with disease activity and functional status measures (primary outcomes: ASDAS-CRP and BASFI) were examined using linear regression adjusted for age and sex.

**Results:** There were 1,270 AS patients included with a mean age of 44.6 ±14.3 years, 74.1% males, and 81.2% whites. Mean AS symptom duration was 20.6±5.6 years, 81.6% HLAB27 positive, and CRP elevated in 27.5% of patients at baseline. Depression was the most prevalent comorbidity (31.4%) followed by hypertension (26.1%); uveitis was the most common EMM (30.4%). The five clusters included depression (27%), no comorbidities (22%), hypertension (21%), uveitis (20%), and asthma/low bone mass (10%) (Figure 1). The cluster with no comorbidities was significantly younger, with lower symptom duration (p<0.001). Females had higher odds of being in the depression (OR=2.00, 95% CI 1.38-2.90) and uveitis (OR=2.09, 95% CI 1.41-3.11) clusters compared to the cluster with no comorbidities. The number of comorbidities and clusters with depression and hypertension were significantly associated with worse disease activity and functional status (Table 1).

**Conclusion:** Distinct comorbidity clusters were identified in AS patients in the POSA cohort. In addition to the number of comorbidities, the type of comorbidity seems to be important. Depression and hypertension clusters seem to be associated with worse disease activity and function.

**Disclosure of Interests:** None declared.
Background: Presence of vertebral corner inflammation (VCI) increases the likelihood of a new syndesmophyte in the same vertebral corner (VC) in patients with r-axSpA. It was suggested that subsequent vertebral corner fat deposition (VCFD) partially explains this effect. However, this has not been formally tested.

Objectives: To determine how much of the effect of VCI on the development of new syndesmophytes is explained by new VCFD.

Methods: Two datasets (SIAS cohort, ASSERT clinical trial) were analyzed. Patients with r-axSpA were assessed at baseline (T0), an intermediate visit (T1) (SIAS: 1 year; ASSERT: 24 weeks) and the end of follow-up (T2) (SIAS: 2 years; ASSERT: 102 weeks). Syndesmophytes were assessed on whole spine low dose CT (SIAS) or spinal radiographs (ASSERT) at T0 and T2 and considered present if seen by ≥2 of 2 readers. VCI (T0) and VCFD (T0 and T1) on spinal MRI were present if seen by ≥2 of 3 readers (SIAS) or 2 of 2 readers (ASSERT). VCs with VCFD or a syndesmophyte at baseline were excluded. We used the counterfactual approach to decompose the total effect of VCI at T0 (binary exposure) on the formation of a new syndesmophyte in the same VC at T2 (binary outcome) into the effect that is explained (natural indirect effect, NIE) and the effect that is not explained (natural direct effect, NDE) by new VCFD (binary mediator) at T1. Because there was no interaction between the exposure and mediator (p=0.86 for SIAS; p=0.82 for ASSERT), the average NIE (aNIE) and average NDE (aNDE) are reported. The aNIE, aNDE and total effect, expressed as absolute increase in risk, were estimated in R using the ‘mediation’ package, which takes into account the 2-level structure of the data (VCs nested within patients).

Results: In total, 49 patients (2,667 corners) in SIAS and 168 patients (2,918 corners) in ASSERT were included. A new VCFD occurred at T2 in 124/2,667 (5%) corners in SIAS and 912/9,154 (9%) corners in ASSERT (Table 1). New VCFD at T1 was also uncommon (SIAS: 4%; ASSERT: 2%), but occurred more often in corners with (SIAS: 12%; ASSERT: 18%) than without VCI at T0 (SIAS: 3%; ASSERT: 1%). Applying the mediation formula, in SIAS, the presence of VCI at T0 increased the probability of a new syndesmophyte in the same VC at T2 by 9.3% [total effect (95% CI)=9.3% (4.5, 15.0)]. There was only a 0.2% increase in this probability that was mediated by the formation of new VCFDs at T1 [aNIE=0.2% (-0.4, 1.0)]. In contrast, 9.1% of the increase in probability remained unexplained [aNDE=9.1% (4.3, 15.0)]. This means that only 2% (0.2/9.3) of the total effect of VCI on the formation of new syndesmophytes was explained by new VCFD [% mediated=2.0% (-4.1, 13)]. In ASSERT, the total effect was somewhat lower than in SIAS [total effect=7.3% (2.0, 16.0)], and again the aNIE was small [aNIE=0.8% (-2.0, 3.0)], and the aNDE composed most of the total effect [aNDE=6.5% (1.3, 14.0)]. The proportion of the total effect explained by VCFD (0.8/7.3=10% (-3.1;44)) was larger than in SIAS but still non-significant.

Conclusion: In these two datasets we see that VCI only infrequently leads to syndesmophyte formation via visible VCFD.

Table 1. Marginal and conditional probabilities

| VCI T0 | New VCFD T1 | New SYND T2 | n | P (SYND|VCI, VCFD) | P(VCFD|VCI) |
|--------|-------------|-------------|---|------------------|----------|
| 0      | 0           | 0           | 2302 | P (SYND|1,0)       | P(VCFD|1)   |
| 0      | 0           | 1           | 90  | =90/2392=0.038  | =74/2466=0.30 |
| 0      | 1           | 0           | 70  | P (SYND|0,1)       | 4/70=0.057 |
| 0      | 1           | 1           | 152 | P (SYND|0,1)       | P(VCFD|1)   |
| 1      | 0           | 0           | 25  | 25/25+177=0.141 | =24/201=0.119 |
| 1      | 0           | 1           | 19  | P (SYND|1,1)       | 5/24=0.208 |

| ASSERT | VCI T0 | New VCFD T1 | New SYND T2 | n | P (SYND|VCI, VCFD) | P(VCFD|VCI) |
|--------|--------|-------------|-------------|---|------------------|----------|
| 0      | 0      | 0           | 2660 | P (SYND|1,0)       | P(VCFD|1)   |
| 0      | 0      | 1           | 76  | =76/2736=0.028  | =35/2771=0.013 |
| 0      | 1      | 0           | 34  | P (SYND|0,1)       | 1/34=0.029 |
| 0      | 1      | 1           | 112 | P (SYND|1,0)       | P(VCFD|1)   |
| 1      | 0      | 0           | 11  | 11/121=0.091    | =26/147=0.177 |
| 1      | 0      | 1           | 21  | P (SYND|1,1)       | 5/26=0.192 |

VCI, vertebral corner inflammation; VCFD, vertebral corner fat deposition; SYND, syndesmophytes; T0, baseline; T1, intermediate visit; T2, end of follow-up; n, number of vertebral corners; P, probability

Disclosure of Interests: Rosalinde Stal: None declared, Alexandre Seprano Speakers bureau: Novartis, Consultant of: UCB, Sofia Ramiro Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: Abbott, Eli Lilly, MSD, Novartis, Pfizer, UCB, Sanofi, Grant/research support from: AbbVii, Galapagos, MSD, Novartis, Pfizer, UCB, Floris A. van Gaalen Consultant of: Novartis, MSD, AbbVie, Bristol Myers Squibb, Eli Lilly, Grant/research support from: Stichting vrienden van Sole Mio, Stichting ASAS, Jacobus Stichting, Novartis, UCB, Pedro Machado Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, Xenotron Baraliakos: None declared, Rosaline van den Berg: None declared, Monique Reinjiere Grant/ research support from: reader for ASAS CLASSIC study, Juergen Braun: None declared, Robert B.M. Landewé Consultant of: AbbVie, Amgen, BMS, GSK, Janssen, Eli Lilly, Novartis, Pfizer, UCB, Désirée van der Heijde Consultant of: AbbVie, Gilead, Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Grant/research support from: Dutch Rheumatism Association DOI: 10.1136/annrheumdis-2022-eular.1587

The treatment and outcome of scleroderma

OP0156 TOCILIZUMB USE IN SYSTEMIC SCLEROSIS: SYSTEMATIC REVIEW AND META-ANALYSIS

R. Dos-Santos, E. Guadalope, D. Fernández Fernández², I. González Fernández³, M. Sanchez-Wonenburger¹, P. Castro-Santamaría¹, A. Mata¹, J. L. Puga Guzmán¹, E. Perez-Pampín¹, A. Souto Vilas¹, A. Mera Varela¹.¹Clinical University Hospital in Santiago de Compostela, Rheumatology Department, Santiago de Compostela, Spain; ²Universidade de Santiago de Compostela, Medicine Department, Santiago de Compostela, Spain

Background: Systemic sclerosis (SSc) is a low-prevalent autoimmune disease with a heterogeneous presentation. Skin involvement is the most frequent symptom and its treatment is orphan, only attending at Raynaud’s phenomenon and classic immunosuppressive therapy for fibrosis. Lung implication is still remaining as the first cause of death. Interstitial lung disease (ILD) is the most frequent presentation and treatments most used includes cyclophosphamide and mycophenolate. In 2021, the Food and Drug Administration (FDA) approved the first biologic therapy for ILD-SSc, tocilizumab (TCZ), based on 2 clinical trials. To assess TCZ efficacy in SSc, either in ILD or skin involvement. Methods: A systematic literature review was made using Medline, Embase, Cochrane Library and the Web of Science databases. Search strategy focused in synonyms of SSc and TCZ, also including MeSH terms. A random-effects model meta-analysis was performed to evaluate TCZ efficacy, when comparable measures were found. Clinical trials, observational studies and case-series were eligible.

Results: Search strategy identified 1036 articles, finally 13 studies were eligible for the review. Regarding the effect of TCZ in SSc skin involvement, measured by the modified Rodnan Skin Score (mRSS), a non-significant 40% improvement in mRSS and change in mean mRSS was reported (OR 1.22 [0.74-2.01], p=0.43 and SMD -0.69 [-1.48-0.10], p=0.09, respectively). About ILD-SSc, a significant non-worsening 10% Forced Vital Capacity (FVC) was reported in patients treated with TCZ (OR 0.45 [0.23-0.86], p=0.02) (Figure 1). As well, a non-significant Diffusing capacity for carbon monoxide (DLCO) was observed in patients treated with TCZ (SMD -0.06 [-1.48-0.17], p=0.12).

REFERENCES:
Conclusion: Our study is the first review and meta-analysis of SSc patients treated with TCZ. This result shows that TCZ could delay the worsening of ILD-SSc, being one therapeutic alternative to classical immunosuppressive therapy. Further studies are needed for better disease understanding and TCZ implications in other organ impairment.

REFERENCES:

Disclosure of Interests: None declared

Figure 1.

CONCLUSION OF THE SENSCIS TRIAL

Objective: To analyse the rate of decline in FVC and the effect of nintedanib on FVC decline in subjects with risk factors for a rapid decline in FVC in the SENSCIS trial.

Methods: In post-hoc analyses of data from the SENSCIS trial, we analysed the rate of decline in FVC (mL/year) over 52 weeks in all subjects and in those with early SSc (<18 months since first non-Raynaud symptom), elevated inflammatory markers (C-reactive protein ≥6 mg/L and/or platelets ≥330 x 10^9/L), or significant skin fibrosis using two approaches (modified Rodnan skin score [mRSS] 15-40 or mRSS >16) at baseline. We also analysed the rate of decline in FVC over 52 weeks in subjects with one of these risk factors and dcSSc.

Results: Of 575 subjects analysed, 79 (13.7%) had <18 months since first non-Raynaud symptom, 210 (36.5%) had elevated inflammatory markers, 172 (29.9%) had mRSS 15-40 and 118 (20.5%) had mRSS >18. Of 299 subjects with dcSSc, 29 (9.7%) had <18 months since onset of first non-Raynaud symptom, 129 (43.1%) had elevated inflammatory markers, 162 (54.2%) had mRSS 15-40 and 118 (39.5%) had mRSS >18. In the placebo group, the rate of decline in FVC over 52 weeks was numerically greater in subjects with these risk factors for rapid decline in FVC compared with all subjects (Figure 1). Across the subgroups, the rate of decline in FVC was numerically lower in subjects treated with nintedanib than placebo (Figure 1).

Figure 1. Rate of decline in FVC (mL/year) over 52 weeks in (A) all patients and in patients with risk factors for rapid decline in FVC at baseline and (B) all patients and in patients with dcSSc and risk factors for rapid decline in FVC at baseline in the SENSCIS trial.

Conclusion: The SENSCIS trial included a broad range of subjects with a fibrotic ILD complicating SSc, including those with risk factors for a rapid decline in FVC. In the placebo group, subjects with these risk factors had a more rapid decline in FVC over 52 weeks compared with the overall trial population. By targeting fibrosis with nintedanib, the rate of decline in FVC in patients with risk factors for FVC decline was reduced in patients treated with nintedanib compared with placebo.

Acknowledgements: The SENSCIS trial was funded by Boehringer Ingelheim. Toby Maher and Masataka Kuwana were members of the SENSCIS trial Steering Committee.

Disclosure of Interests: Dinesh Khanna Shareholder of: Stocks - Eicos Sciences, Inc, Consultant of: AbbVie, Acceleron, Actelion, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos NV, Genentech/Roche, Gilead, GlaxoSmithKline, Horizon Therapeutics, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Prometheus, Sanofi-Aventis, Thely, United Therapeutics, Grant/research support from: Bayer, Bristol-Myers Squibb, Horizon Therapeutics, Immune Tolerance Network, National Institutes of Health, Pfizer, Employee of: Leadership/Equity position – Chief Medical Officer - CivBioP-harma/Eicos Sciences, Inc, Toby Maher Speakers bureau: Boehringer Ingelheim, Galapagos, Genentech, Consultant of: AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, Galactus, GlaxoSmithKline R&D, IQVIA, Pfizer, Respiwant, Roche, Theravance and Versacote, Grants/
research support from: AstraZeneca, GlaxoSmithKline, Elizabeth Volkman Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim, Corbus, Forbixus, Horizon Therapeutics, Servier, Pfizer, Roche, Consultant of: Boehringer Ingelheim, Mylan, Janssen, Medsenic, Prometheus, Sanofi, Roche, Grant/ research support from: Alpine Immunosciences, Medsenic, OSE Immuno- therapeutics, Vanessa Smith Speakers bureau: Actelion Pharmaceuticals, Boehringer-Ingelheim Pharma GmbH&Co, Janssen-Cilag NV, UC Biopharma SpI, Consultant of: Abbvie, AstraZeneca, Boehringer Ingelheim, CSL Behring, Novartis, Grant/research support from: Boehringer Ingelheim, Janssen, Michael Kreuter Speakers bureau: Boehringer Ingelheim and Roche, Consultant of: Boehringer Ingelheim and Roche, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Lilly, Medscape, Merck Sharp & Dohme, Roche, Paid instructor for: Boehringer Ingelheim, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Masataka Kuwana Speakers bureau: AbbVie, Asahi Kasei Pharma, Astellas, Boehringer Ingelheim, Chugai, Eisai, GlaxoSmithKline, Janssen, Nippon Shinyaku, Ono Pharmaceuticals, Tanabe-Mitsubishi, Consultant of: AstraZeneca, Boehringer Ingelheim, Corbus, Kissei, Medsenic, Grant/ research support from: Boehringer Ingelheim, MBL, Ono Pharmaceuticals, Christian Stock Employee of: Christian Stock is an employee of Boehringer Ingelheim, Margarida Aves Employee of: Margarida Aves is an employee of Boehringer Ingelheim, Steven Sabemovski Employee of: Steven Sabemovski is an employee of Boehringer Ingelheim, Christopher P Denton Speakers bureau: Boehringer Ingelheim, Janssen, Consultant of: Abbvie, Acceleron, Boehringer Ingelheim, Corbus, CSL Behring, GlaxoSmithKline, Roche, Grant/research support from: ARXX Therapeutics, GlaxoSmithKline, Horizon Therapeutics, Servier DOi: 10.1136/annrheumdis-2022-eular.769

### OP0158

**COHORT ENRICHMENT STRATEGIES FOR PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS FROM EUSTAR**


**Background:** Enrichment strategies from clinical trials for progressive systemic sclerosis-associated interstitial lung disease (SSc-ILD) have been partly successful but have not been tested in a real life cohort.

**Objectives:** Analyse the accuracy, representativeness and feasibility of enrichment strategies in SSc-ILD patients from the EUSTAR cohort.

**Methods:** We applied the inclusion criteria of major recent SSc-ILD trials (focuSSced, SLS II and SENSCIS) in SSc-ILD patients and assessed progressive ILD, defined as absolute change in forced vital capacity (FVC) and as significant progression (FVC decline >10%) over time. Data were compared to all trials.

**Results:** In total, 2258 SSc-ILD patients were included, with 31.2% meeting SENSCIS criteria, 5.8% SLS II, 16% focuSSced criteria and 529 (6.7%) not meeting any criteria (Table 1). In the first 12+3 months, a slow FVC decline of −0.1% was seen in the total, unselected cohort and in patients fulfilling SENSCIS criteria. Patients fulfilling criteria from focuSSced showed a strong FVC decline of −3.7%. Notably, patients enriched for SLS II criteria showed FVC improvement of +2.3% (Figure 1). Similarly, compared to the total unselected cohort, the number of significant progressive events was numerically higher in patients fulfilling focuSSced criteria, the same for SENSCIS criteria and even slightly lower for patients fulfilling the SLS2 criteria.

**Table 1. Demographics and baseline clinical characteristics of EUSTAR patients.**

<table>
<thead>
<tr>
<th>Age, years (SD)</th>
<th>Not fulfilling any criteria (n=1529)</th>
<th>focuSSced (n=36)</th>
<th>SLS II (n=122)</th>
<th>SENSCIS (n=704)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>38.4 (12.9)</td>
<td>51.5 (12.5)†</td>
<td>51.2 (12.7)</td>
<td>54.2 (13.8)†</td>
</tr>
<tr>
<td>Disease duration, months (SD)</td>
<td>156.3 (99.4)</td>
<td>16.1 (13.9)</td>
<td>40.7 (25.2)</td>
<td>39.4 (23.9)†</td>
</tr>
<tr>
<td>DLCO, % predicted (mean, SD)</td>
<td>597 (43.8)</td>
<td>36 (100)</td>
<td>85 (65)</td>
<td>35 (55)†</td>
</tr>
<tr>
<td>ATA, n (%)</td>
<td>735 (51.1)</td>
<td>24 (67)</td>
<td>65 (89)</td>
<td>370 (56)</td>
</tr>
<tr>
<td>mRSS, mean (SD)</td>
<td>9.5 (8.3)</td>
<td>21 (6.5)</td>
<td>13 (9.6)</td>
<td>11 (3.2)</td>
</tr>
<tr>
<td>GERO, n (%)</td>
<td>1002 (65.9)</td>
<td>25 (69)</td>
<td>92 (70)</td>
<td>430 (62)</td>
</tr>
<tr>
<td>ESR, mean (SD)</td>
<td>27 (20.5)</td>
<td>43.1 (23)</td>
<td>29.6 (19.6)</td>
<td>24.7 (20.7)</td>
</tr>
<tr>
<td>MMF, n (%)</td>
<td>75 (16.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>52 (22)</td>
</tr>
<tr>
<td>MTX, n (%)</td>
<td>42 (9.2)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>20 (9)</td>
</tr>
<tr>
<td>FVC % predicted, mean (SD)</td>
<td>85.7 (22.8)</td>
<td>88 (13.6)</td>
<td>66 (9.1)</td>
<td>88 (19.8)</td>
</tr>
<tr>
<td>DLco, % predicted, mean (SD)</td>
<td>58.9 (21.5)</td>
<td>16 (12)</td>
<td>94 (14.6)</td>
<td>59 (14.2)</td>
</tr>
</tbody>
</table>

**ACKNOWLEDGEMENTS:** We thank all EUSTAR collaborators.

**Disclosure of Interests:** Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Cathrine Brunborg: None declared, Paolo Airò Speakers bureau: Bristol-Myers-Squibb, Boehringer Ingelheim, Consultant of: Bristol-Myers-Squibb, Grant/research support from: Boehringer Ingelheim, László Czirjak Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, László Czirjak Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, László Czirjak Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, László Czirjak Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, László Czirjak Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Boehringer Ingelheim, Consultant of: CSL Behring, GSK, Roche-Chugai, Johnson & Johnson, Boehringer Ingelheim, Consultant of: CSL Behring, GSK, Roche-Chugai, Johnson & Johnson, Boehringer Ingelheim, Grant/research support from: CSL Behring, Boehringer Ingelheim, GSK, Roche-Chugai, Sanofi Genzyme, Mengtao

1National & Kapodistrian University of Athens Medical School, Rheumatology, Greece
2National & Kapodistrian University of Athens Medical School, Rheumatology, Greece
3Spedali Civili di Brescia, Reumatologia e Immunologia Clinica, Brescia, Italy
4Nasonova Institute of Rheumatology, Rheumatology, Moscow, Russia
5Medical School of Pécs, Department of Rheumatology and Immunology, Pécs, Hungary
6University of Firenze, Rheumatology, Firenze, Italy
7Hôpital Claude Huriez, University of Lille, Internal Medicine and Clinical Immunology, Lille, France
8Peking Union Medical College Hospital (West Campus), Rheumatology, Beijing, China
9University Hospital Zurich, University of Zurich, Rheumatology, Zurich, Switzerland
10University of Medical Center Schmoeckel-Holstein, Rheumatology and Clinical Immunology, Lubeck, Germany
11National & Kapolstrian University of Athens Medical School, Rheumatology, Athens, Greece
12Università della Campania “Luigi Vanvitelli”, di Medicina di Precisione, Napoli, Italy
13Medical University of Bialystok, Rheumatology and Internal Medicine, Bialystok, Poland
14Descartes University, APHP Cochin Hospital, Rheumatology, Paris, France

**Table 1.** Demographics and baseline clinical characteristics of EUSTAR patients.
Background: Several rheumatologic diseases such as SLE and Rheumatoid arthritis are well known to increase cardiovascular risk. Scleroderma is well known to cause microvascular dysfunction, which can cause microvascular Coronal artery disease (CAD). However, Scleroderma is not classically associated with microvascular CAD.

Objectives: We wanted to study the association of both microvascular and macrovascular CAD and Myocardial infarction (MI) in Scleroderma patients using the NIS (National inpatient sample) of the United States (US).

Methods: We included adult patients admitted to teaching hospitals with a primary or secondary diagnosis of Scleroderma from the National inpatient sample (NIS) of 2016, 2017, and 2018. The NIS is the largest publicly available all-payer inpatient care database in the United States, containing data on more than seven million hospital stays. After coding for the relevant variables based on the ICD-10 coding system, we performed univariate and multivariate logistic regression analysis to determine if Scleroderma was associated with CAD and MI. As there was no ICD-10 code for macrovascular CAD, we used Percutaneous intervention (PCI) and Coronary artery bypass grafting (CABG) to indicate the presence of macrovascular CAD. Four separate models with outcomes as CAD, MI, PCI, and CABG were created.

Results: A total of weighted 57,739 (95% CI 55,787-59,692) hospitalizations with Scleroderma were included. Only 0.1% of CAD and MI patients had a history of Scleroderma. On univariate logistic regression, Scleroderma was not associated with an increased risk of CAD (OR 0.82, 95% CI 0.79-0.86, P<0.01). After adjusting for age, sex, race, family history of CAD, dyslipidemia, diabetes, hypertension, and smoking, Scleroderma was associated with CAD (OR 1.40, 95% CI 1.34-1.47, P<0.01) (Table 1) and MI (OR 1.13, 95% CI 1.02-1.25, P=0.01) but not with PCI (OR 0.86, 95% CI 0.73-1.01, P=0.07) or CABG (OR 0.79, 95% CI 0.61-1.03, P=0.09).

Conclusion: CAD in Scleroderma is due to the combined effect of Scleroderma itself and traditional cardiovascular risk factors. In our large epidemiologic study, Scleroderma was associated with CAD and MI despite adjusting for the traditional risk factors for CAD, which is consistent with our current understanding of Scleroderma. Scleroderma is suspected of causing recurrent coronary microvascular inflammation and ischemia, which leads to ischemic necrosis and myocardial fibrosis (1). Other mechanisms include coronary Raynaud phenomenon and vasculitis. The lack of association of PCI and CABG with Scleroderma likely suggests that CAD in Scleroderma is mostly microvascular. Potential limitations of our study are its retrospective nature and the lack of catheterization data. Cardiovascular diseases account for 12% of mortality, and CAD accounts for 5% mortality in Scleroderma patients (2). Therefore, care for Scleroderma patients should involve aggressive management of Scleroderma and the risk factors for CAD.

Table 1. Multivariate logistic regression model for CAD

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.03 (1.03-1.03)</td>
<td>0.000</td>
</tr>
<tr>
<td>Female</td>
<td>0.50 (0.50-0.51)</td>
<td>0.000</td>
</tr>
<tr>
<td>Race</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Whites</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>African American</td>
<td>0.82 (0.81-0.83)</td>
<td>0.000</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0.79 (0.78-0.81)</td>
<td>0.000</td>
</tr>
<tr>
<td>Asian/pacific islander</td>
<td>0.75 (0.73-0.76)</td>
<td>0.000</td>
</tr>
<tr>
<td>Native American</td>
<td>0.98 (0.93-1.04)</td>
<td>0.718</td>
</tr>
<tr>
<td>Others</td>
<td>0.91 (0.87-0.95)</td>
<td>0.000</td>
</tr>
<tr>
<td>Family history of MI</td>
<td>1.72 (1.69-1.75)</td>
<td>0.000</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>2.18 (2.17-2.20)</td>
<td>0.000</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.70 (1.69-1.71)</td>
<td>0.000</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.08 (2.07-2.10)</td>
<td>0.000</td>
</tr>
<tr>
<td>Nicotine dependence</td>
<td>1.34 (1.33-1.35)</td>
<td>0.000</td>
</tr>
<tr>
<td>Scleroderma</td>
<td>1.40 (1.34-1.44)</td>
<td>0.000</td>
</tr>
</tbody>
</table>
Results: Eight subgroups were defined by the autoantibody status (Table 1). Three of the subgroups (1, 2 and 6) have overlapping autoantibodies, while four are almost monospecific (3, 4, 5 and 7), and one (8) has patients negative for tested autoantibodies. Figure 1 represents the significant associations between HLA-DRB1 alleles and the eight subgroups. Heliotrope rash and Gottron’s sign were significantly more frequent in subgroup 3 (OR: 2.95% CI [1.14-8.4]), OR: 2.69% CI [1.35-9.8], respectively). 4. OR: 12 95% CI [3.8-75], OR: 78 95% CI [2.8-33], respectively) and 7 (OR: 22 95% CI [5.3-38], OR: 10 95% CI [3.1-65], respectively), and Raynaud’s phenomenon was significantly more frequent in subgroup 6 (OR: 3.3 95% CI [12-11]).

![Forest plot of significant associations of HLA-DRB1 alleles](image1.png)

Figure 1. Forest plot of significant associations of HLA-DRB1 alleles with autoantibody-defined subgroups. Scandinavia includes patients from Denmark, Norway, and Sweden.

Conclusion: Our study reveals that certain subgroups of IIM patients are characterized by overlap of myositis-specific and -associated autoantibodies, which in turn are associated with different HLA-DRB1 alleles including potential novel associations. These results point to different disease mechanisms in the subgroups, as well as suggest that IIM classification could be improved by integrating broader serological and genetic data.

Acknowledgements: We thank all the patients who participated in the study.

Disclosure of Interests: Valerie Leclair: None declared, Angeles Shunashy Galindo-Feria: None declared, Simon Rothwell: None declared, Olga Krystiskova: None declared, Heiman Mann: None declared, Louise Pyndt Dierichsens: None declared, Helena Andersson: None declared, Martin Klei: None declared, Sarah Tansley: None declared, Neil McHugh: None declared, Janine Lamb: None declared, Jiri Vencovsky: Speakers bureau: Abbvie, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Novartis. Consultant of: Abbvie, Argenx, Boehringer Ingelheim, Eli Lilly, Gilead, Octapharma, Pfizer, UCB, Consultant of: Abbvie, Argenx, Boehringer Ingelheim, Eli Lilly, Gilead, Octapharma, Pfizer, UCB, Grant/research support from: Abbvie, Hector Chinoy: None declared, Marie Holmqvist: None declared, Leonid Padyukov: None declared, Ingrid E. Lundberg: Shareholder of: Roche and Novartis. Consultant of: Corbus Pharmaceuticals, Inc, Astrazeneca. Bristo Myler's Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezar, Orphazyme, and Janssens, Grant/research support from: Astra Zeneca, Lina M. Diaz-Gallo: None declared


<table>
<thead>
<tr>
<th>Autoantibodies</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Jo1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anti-PeMsc1</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>107</td>
</tr>
<tr>
<td>Anti-SAE1</td>
<td>9</td>
<td>0</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>31</td>
</tr>
<tr>
<td>Anti-MDA5</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>22</td>
</tr>
<tr>
<td>Anti-PL7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>20</td>
</tr>
<tr>
<td>Anti-RA2</td>
<td>5</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Anti-RA2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Anti-TIF1</td>
<td>10</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>92</td>
</tr>
<tr>
<td>Anti-Mi2</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>75</td>
</tr>
<tr>
<td>Anti-DAE1</td>
<td>6</td>
<td>0</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>32</td>
</tr>
<tr>
<td>Anti-NKP2</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Anti-MDA1</td>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Anti-PRP</td>
<td>6</td>
<td>0</td>
<td>32</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>40</td>
</tr>
<tr>
<td>Anti-PL12</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>Anti-PMScl</td>
<td>11</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>119</td>
</tr>
</tbody>
</table>

Table 1. Autoantibody-defined subgroups using an unsupervised cluster analysis.

Acknowledgements: We thank all the patients who participated in the study.

Disclosure of Interests: Valerie Leclair: None declared, Angeles Shunashy Galindo-Feria: None declared, Simon Rothwell: None declared, Olga Krystiskova: None declared, Heiman Mann: None declared, Louise Pyndt Dierichsens: None declared, Helena Andersson: None declared, Martin Klein: None declared, Sarah Tansley: None declared, Neil McHugh: None declared, Janine Lamb: None declared, Jiri Vencovsky: Speakers bureau: Abbvie, Boehringer Ingelheim, Eli Lilly, Gilead, MSD, Novartis. Consultant of: Abbvie, Argenx, Boehringer Ingelheim, Eli Lilly, Gilead, Octapharma, Pfizer, UCB, Grant/research support from: Abbvie, Hector Chinoy: None declared, Marie Holmqvist: None declared, Leonid Padyukov: None declared, Ingrid E. Lundberg: Shareholder of: Roche and Novartis. Consultant of: Corbus Pharmaceuticals, Inc, Astrazeneca. Bristo Myler’s Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezar, Orphazyme, and Janssens, Grant/research support from: Astra Zeneca, Lina M. Diaz-Gallo: None declared

Immunosuppressants* 269 (58.6) 107 (58.8) 39 (11.2) 115 (77.7) 40 (70.2) 130 (58.0) 700 (49.4) <0.001
Number of patients 459 182 348 148 57 224 1418

Dermatomyositis Polymyositis Inclusion Body Myositis Anti-synthetase syndrome Necrotizing myositis Overlap syndrome All IIM p-value
Antimalarials 99 (21.6) 7 (3.8) 0 (0.0) 25 (16.9) 1 (1.8) 64 (28.6) 196 (13.8) <0.001
Biologics** 17 (3.7) 7 (3.8) 0 (0.0) 13 (8.8) 2 (3.5) 22 (9.8) 61 (4.3) <0.001

Abatacept (5), TNF inhibitors (4), Iclocizumab (3), Belinumab (3), Secukinumab (1). ***JAK(10) and PDE4 inhibitors (2)

* Methotrexate (278), Mycophenolate Mofetil (258), Azathioprine (125), Cyclosporine (38), Tacrolimus (28), Leflunomide (23), Sulfasalazine (14), Cyclophosphamide (9).
** Rituximab (44), Abatacept (5), TNF inhibitors (4), Iclocizumab (3), Belinumab (3), Secukinumab (1).

Background: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous autoimmune disorders with limited standardized treatment protocols. Objectives: To evaluate frequency and patterns of various treatments used for IIM based on disease subtype, world region, and organ involvement.

Methods: Cross-sectional data from the international CoVAD self-report e-survey was extracted on Sep 14th, 2021. Patient details included demographics, IIM subtypes (dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM)), antisyntethase syndrome (ASSD), nécrotizing myositis (NM) and overlap myositis (OM)).

Results: In 1418 patients with IIM, median age was 61 years [IQR 49-70], 62.5% were females, median disease duration was 6 years [IQR 3-11], most common subset was DM (32.4%).

The most used treatments were IS (49.4%, including Methotrexate 19.6%, Mycophenolate Mofetil 18.2%, Azathioprine 8.8%, Cyclosporine 2.7%, Tacrolimus 2%, Leflunomide 1.6%, Sulfasalazine 1%, and Cyclophosphamide 0.6%), followed by CS (40.8%), antimalarials (13.8%) and IVIG (9.4%). Biologics were used in 4.3% of patients.

Treatment patterns differed significantly by IIM subtypes with a higher frequency of IS (77.7%) and CS (63.4%) in ASSD; antimalarials (29.6%) and biologics (9.8%) in OM and IVIG use in NM (24.6%) (Table 1). Also, treatment patterns were different in regions of the world (Figure 1), with a higher frequency of CS use in Europe (60.5%) and IS use in South America (77.2%). Antimalarials were most used in Asia (19.4%), while IVIG use was most common in Oceania (16.9%). Dyspnea was associated with higher use of IS (69.9%) and CS (85.8%) (p<0.001), whereas dysphagia was negatively associated with IS (39.7%) and CS (32.7%) likely due to a higher proportion in IBM patients reporting dysphagia.

Multivariable logistic regression analysis showed an association of IS with the remission, and some clinical features (dyspnea, fatigue, and muscle weakness).

Conclusion: IIM treatment patterns differ significantly by disease subtypes, world regions and organ involvement, highlighting the need for unified international consensus-driven guidelines.

References:

Disclosure of Interests: None declared

OP0162 EFFICACY AND SAFETY OF LENABASUM IN THE PHASE 3 DETERMINE TRIAL IN DERMATOMYOSITIS

V. Werth1, B. White2, N. Degtuck3, K. Hally4, S. Constantine5, R. Aggarwal1,6, D. Fiorentino7, I. E. Lundberg8, C. V. Oddis9, University of Pennsylvania, Dermatology, Philadelphia, United States of America;1 Corbus Pharmaceuticals, Clinical Operations, Norwood, United States of America;2 Corbus Pharmaceuticals, Clinical Operations, Norwood, United States of America;3 University of Pittsburgh, Department of Rheumatology, Pittsburgh, United States of America;4 Stanford University, Department of Medicine, Stanford, United States of America;5 Karolinska Institutet, Division of Rheumatology, Department of Medicine, Stockholm, Sweden

Background: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported outcomes, and biomarkers in a Phase 2 study of DM patients with active skin disease.

Objectives: To evaluate the efficacy and safety of lenabasum in a Phase 3 double-blind study in DM.

Methods: DM patients ≥ 18 years old with active skin with or without muscle involvement were enrolled in 55 sites in North America, Europe, and Asia-Pacific. Stable doses of background immunosuppressants were allowed. Subjects were randomized 2:1:2 to lenabasum 20 mg BID, lenabasum 5 mg BID, or placebo BID for 52 weeks, with visits ≤ 8 weeks apart. The study was stopped after all subjects completed Week 28. Some subjects had completed Week 52 by then. The primary efficacy endpoint was Total Improvement Score (TIS) at Week 52 for lenabasum 20 mg BID vs placebo.

Results: 175 subjects (69 lenabasum 20 mg BID, 35 lenabasum 5 mg BID, 71 placebo BID) received study drug; 167 completed Week 28, and 103 completed Week 52. The most common reasons for study discontinuation were TIS at Week 52, for lenabasum 20 mg BID vs placebo.

Conclusion: Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported outcomes, and biomarkers in a Phase 2 study of DM patients with active skin disease.

Table 1. Current Treatments for IIM, Stratified by Disease Subtypes

<table>
<thead>
<tr>
<th>Dermatomyositis</th>
<th>Polymyositis</th>
<th>Inclusion Body Myositis</th>
<th>Anti-synthetase syndrome</th>
<th>Necrotizing myositis</th>
<th>Overlap syndrome</th>
<th>All IIM</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>459</td>
<td>182</td>
<td>348</td>
<td>148</td>
<td>224</td>
<td>1418</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressants*</td>
<td>269 (56.8) 107 (58.8) 39 (12.2)</td>
<td>115 (75.3) 40 (52.2) 130 (59.0) 719 (49.4)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>208 (48.0) 81 (46.8) 32 (9.7)</td>
<td>90 (63.4) 52 (59.3) 103 (50.0) 546 (40.8)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antimalarials</td>
<td>99 (21.6) 7 (3.8) 0 (0.0)</td>
<td>25 (16.9) 1 (1.8) 64 (28.6) 196 (13.8)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous Immunoglobulins</td>
<td>54 (11.8) 16 (8.8) 19 (5.5)</td>
<td>10 (6.8) 14 (24.6) 20 (8.9) 133 (9.4)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics**</td>
<td>17 (3.7) 7 (3.8) 0 (0.0)</td>
<td>13 (8.8) 2 (3.5) 22 (9.8) 61 (4.3)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others***</td>
<td>6 (1.3) 0 (0.0) 0 (0.0)</td>
<td>1 (0.7) 0 (0.0) 5 (2.2) 12 (0.8) 0.098</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Methotrexate (278), Mycophenolate Mofetil (258), Azathioprine (125), Cyclosporine (38), Tacrolimus (28), Leflunomide (23), Sulfasalazine (14), Cyclophosphamide (9).
** Rituximab (44), Abatacept (5), TNF inhibitors (4), Iclocizumab (3), Belinumab (3), Secukinumab (1).
*** JAK(10) and PDE4 inhibitors (2)
5.12. Corticosteroids were used by 48.1% and 38.0%, immunoglobulins by 5.8% and 7.0%, and other immunosuppressives by 51.0% and 54.9%, and monoclonal antibodies by 8.7% and 7.0% of lenabasum and placebo groups at baseline, respectively. The primary efficacy endpoint was not met - mean (SD) TIS score was 28.3 (19.75) vs 27.2 (19.23) at Week 28 for lenabasum 20 mg BID vs placebo, p = 0.3311, MMRM. Week 52 values were 40.6 (16.88) vs 34.8 (19.94), p = 0.2290. When analyses were restricted to subjects with muscle weakness at baseline (MMT8 < 142), TIS scores and treatment differences were greater and reached nominal statistical significance at Week 40, p = 0.0172. Mean (SD) improvements in CDASI activity score were numerically greater but not statistically different between lenabasum 20 mg BID group vs placebo at Week 28 [-7.1 (7.76) vs -5.8 (8.88) points, p = 0.2775] and Week 52 [-10.0 (9.45) vs -6.2 (12.8) points, p = 0.0932]. When restricting analysis of participants without muscle weakness (MMT8 = 150), improvement in CDASI activity score was greater in the lenabasum 20 mg BID group vs placebo at Week 28, p = 0.0461, and Week 52 p = 0.0059.

Treatment-emergent AEs (TEAEs) occurred in 87.0%, 85.7%, and 87.3% of lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo groups, with no deaths. Related TEAEs leading to withdrawal of study product were infrequent, occurring in 1.4%, 0%, and 2.0% of subjects in the same groups. Serious TEAEs occurring in ≥ 1 subject in any group. TEAE occurring in ≥ 10% of lenabasum 20 mg BID vs placebo at baseline (MMT8 < 142), TIS scores and treatment differences were greater and reached nominal statistical significance at Week 40, p = 0.0172. Mean (SD) improvements in CDASI activity score were numerically greater but not statistically different between lenabasum 20 mg BID group vs placebo at Week 28 [-7.1 (7.76) vs -5.8 (8.88) points, p = 0.2775] and Week 52 [-10.0 (9.45) vs -6.2 (12.8) points, p = 0.0932]. When restricting analysis of participants without muscle weakness (MMT8 = 150), improvement in CDASI activity score was greater in the lenabasum 20 mg BID group vs placebo at Week 28, p = 0.0461, and Week 52 p = 0.0059.

Conclusion: Although, primary or secondary endpoints were not met in the study, subgroup analysis of patients with muscle weakness and without muscle weakness, showed improvement in muscle strength and rash, respectively in lenabasum 20 mg BID group vs placebo. Lenabasum was administered safely and was well-tolerated in this study.


OP0163 A MATRIX PREDICTION MODEL FOR THE SIX-MONTH MORTALITY RISK IN PATIENTS WITH ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED PROTEIN-5 POSITIVE DERMATOMYOSITIS

A. J. Tang1,2, F. Y. Tang3, Z. M. Ouyang1, J. Lin1, Z. H. Yang1, L. J. Yang1, X. N. Wei1, Q. H. Li1, J. J. Liang1, D. H. Zheng1, L. Dai1, Y. Q. Mo1,2 1Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Department of Rheumatology, Guangzhou, China; 2Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, Department of Rheumatology, Shanghai, China; 3Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Department of Respiratory, Guangzhou, China; 4Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Departments of Radiology, Guangzhou, China

Background: Recently, the autoantibody recognizing melanoma differentiation-associated gene 5 (anti-MDAS) is of the greatest concern as a specific autoantibody of dermatomyositis (DM), since it delineates a unique clinical phenotype of DM with a high risk of life-threatening lung complications. Considering routine clinical characteristics at baseline are still desired candidates for...
screening potential mortality predictors, in order to as early as possible stratify the mortality risk in anti-MDA5 positive DM patients before making therapeutic strategies.

**Objectives:** To investigate the baseline independent risk factors for predicting 6-month mortality of anti-MDA5-positive DM patients and develop a matrix prediction model formed by these risk factors.

**Methods:** This was a real-world prospective observational study. The hospitalized patients with DM were included if they fulfilled the criteria including: aged over 18 years old; diagnosed as having DM according to the criteria proposed by Bohan and Peter or the modified Sontheimer definitions; and positive anti-MDA5 which was determined by both line immunoassay testing and enzyme-linked immunosorbent testing. The primary outcome was all-cause 6-month mortality after enrolment. A novel matrix prediction model was built with the mortality risk probability.

**Results:** There were 82 DM patients enrolled (mean age of onset 50±11 years and 63% female), with 40 (49%) showing positive anti-MDA5. Gottron sign/papules (OR: 5.135, 95%CI: 1.489–17.708), arthritis (OR: 5.184, 95%CI: 1.455–18.467), interstitial lung disease (ILD, OR: 7.034, 95%CI: 1.157–42.785), and higher level of C4 (OR: 1.010, 95%CI: 1.002–1.017) were independent associates with positive anti-MDA5 in DM patients. Anti-MDA5-positive DM patients had significant higher 6-month all-cause mortality than those with anti-MDA5-negative (30% vs. 0%). Among anti-MDA5-positive DM patients, compared to the survivors, non-survivors had significantly advanced age of onset (59±6 years vs. 46±9 years), higher rates of fever (75% vs. 18%), positive carcinoma embryonic antigen (CEA, 75% vs. 14%), higher level of ferritin (median 2858 μg/L vs. 619 μg/L, all p<0.05). Multivariate COX regression showed ferritin ≥1250 μg/L (HR: 10.4, 95%CI: 1.8–59.9), fever (HR: 11.2, 95%CI: 2.5–49.9), and positive CEA (HR: 5.2, 95%CI: 1.0–25.7) were independent risk factors of 6-month mortality.

According to the matrix prediction model, anti-MDA5-positive DM patients could be stratified into three subgroups based on various probabilities of predicted mortality: (i) High-risk: eight patients with two of the above three features (including fever, serum ferritin ≥1250 μg/L, and positive CEA) had high predicted mortality probability with 64%–85% (three red grids in Figure 1A), and the actual mortality was 75% (n=6) with 60%, 100%, and 100% respectively in three red grids (Figure 1B). Five patients with all of three features had extremely high predicted mortality probability with 97% (95%CI: 70%–100%), the dark red grid in Figure 1A, and the actual mortality was 100% in Figure 1B; (ii) Moderate-risk: nine patients with one of the above three features had moderate predicted mortality probability with 11%–29% (three yellow grids in Figure 1A), and the actual mortality was 11% (n=1) with 0%, 0%, and 17% respectively in three yellow grids (Figure 1B); (iii) Low-risk: eighteen patients with none of the above three features had low predicted mortality probability with 2% (95%CI: 0.2%–20%, the green grid in Figure 1A), and the actual mortality was 0% in the green grid (Figure 1B).

**Conclusion:** Baseline characteristics of fever, positive CEA, and ferritin ≥1250 μg/L are risk factors for 6-month all-cause mortality in anti-MDA5-positive DM patients. A novel matrix prediction model composed of these three clinical indicators is firstly proposed to provide a chance for exploration of individual treatment strategies in anti-MDA5-positive DM subgroups with various probabilities of mortality risk.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3009

---

**Translational and Clinical Research in Crystal Arthritis**

**OP0164**

**A POPULATION-BASED, PROSPECTIVE METABOLOMICS STUDY IN THE UK BIObANK IDENTIFIES GLYCOPROTEIN ACETYL as a NOVEL BIOMARKER OF INCIDENT GOUT**

A. Joshi1, N. McCormick2, C. Yokose3, N. Lu4, H. Choi3, 1Massachusetts General Hospital, CTEU, Mongan Institute, Department of Medicine, Boston, United States of America; 2Massachusetts General Hospital, Division of Rheumatology, Allergy and Immunology, Boston, United States of America; 3Arthritis Research Canada, Arthritis Research, Vancouver, Canada

**Background:** Serum urate (SU) level is the strongest known causal predictor of clinical gout, but only ~20% with prolonged hyperuricemia develop gout, motivating the need for additional biomarkers for risk prediction and stratification. The metabolome represents a compelling intermediate trait between genome and phenotype to elucidate disease mechanisms. Multiple cross-sectional studies of prevalent gout from men in Asia have been conducted, but no prospective data for incident gout (prediagnostic metabolome) are available.

**Objectives:** Our objectives were to (1) conduct a discovery-based metabolome-wide study to identify novel biomarkers of incident gout; and (2) replicate novel metabolomic biomarkers of gout in independent samples.

**Methods:** We conducted a prospective cohort analysis of 105,703 UK Biobank (UKB) participants (46% males, mean age 57.2 years) with targeted NMR metabolomic profiling (N=168 metabolites, including routine lipids and amino acids) available from baseline samples (2006-10), and no prior diagnosis of gout or urate lowering therapy use. Incident cases of gout were documented from linked medical records until gout diagnosis, death, or end of study period (Dec 31/19). We used Cox proportional hazards models to obtain hazard ratios (HR) and 95% confidence intervals (CIs) per standard deviation (SD) increase in each of the 168 metabolites to determine associations with incident gout. To replicate our findings, we assessed association of metabolome-wide significant metabolites in a replication set, restricted to 4,804 non-overlapping participants who provided blood in the repeat assessment visit (2012-13).

**Results:** During a median 10.4 years follow-up, we documented 1,367 cases of incident gout in the discovery set. After correction for multiple comparisons, glycoprotein acetyl (GlycA) were positively associated with risk of incident gout (multivariable HR per 1SD increase = 1.34 (1.27 to 1.41), P= 0.04x10^-3) after adjusting for age, sex, and lifestyle and clinical covariates (Table 1). This association persisted even after SU adjustment (HR 1.07, P= 0.0091). In the replication set, among 4,804 participants followed for a median of 6.8 years, we documented 22 cases. In this dataset, we replicated GlycA association with incident gout (multivariable HR per 1SD increase =1.56 (1.08 to 2.25), P= 0.017).

**Conclusion:** In this large-scale, prospective metabolomics study, we identified and independently replicated our findings that plasma levels of GlycA are associated with incident gout in UKB participants. GlycA is novel for gout, though this pro-inflammatory biomarker has predicted risk of other cardiometabolic-inflamatory phenotypes, independent of CRP. These findings may provide insight into the metabolic-inflammatory pathogenesis of gout, with implications for risk prediction, even beyond SU, but call for further investigation with more extensive metabolome profiling and external replication.

**Table 1. Association of glycoprotein acetyl (GlycA) with risk of incident gout in the UK Biobank**

<table>
<thead>
<tr>
<th>Model</th>
<th>Univariable HR, (95% CI)</th>
<th>Multivariable HR, (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Discovery (N= 105,703)</strong></td>
<td><strong>Per Standard deviation:</strong></td>
<td><strong>P</strong></td>
</tr>
<tr>
<td>GlycA, per SD</td>
<td>1.48 (1.41 to 1.60)</td>
<td>3.7x10^-03</td>
</tr>
<tr>
<td><strong>Categorized as quintiles:</strong></td>
<td>1.0 Ref</td>
<td>1.0 Ref</td>
</tr>
<tr>
<td>GlycA, Q1</td>
<td>1.43 (1.13 – 1.80)</td>
<td>0.0002</td>
</tr>
<tr>
<td>GlycA, Q2</td>
<td>2.06 (1.66 – 2.56)</td>
<td>4.88x10^-16</td>
</tr>
<tr>
<td>GlycA, Q3</td>
<td>2.53 (2.05 – 3.12)</td>
<td>4.15x10^-08</td>
</tr>
<tr>
<td>GlycA, Q4</td>
<td>3.70 (3.02 – 4.52)</td>
<td>3.21x10^-10</td>
</tr>
<tr>
<td>GlycA, Q5</td>
<td>1.65 (1.19 to 2.29)</td>
<td>0.0027</td>
</tr>
</tbody>
</table>

1 Hazard ratios (HR) and 95% confidence intervals (CIs) obtained after adjusting for the first 4 genomic principal components (controlling for population stratification), age, sex, fasting (<4 hrs, >4 hrs and >8 hrs and >12 hrs), smoking (never, former, current), freq of alcohol, BMI, diabetes (yes/no) and hypertension at baseline (yes/no).

**REFERENCES:**

[1] Kettunen; PMID 30571186

**Disclosure of Interests:** Amit Joshi: None declared, Natalie McCormick: None declared, Chio Yokose: None declared, Na Lu: None declared, Hyon Choi Consultant of: Ironwood, Selecta, Horizon, Takeda, Vaxart, Grant/research support from: Ironwood, Horizon

**DOI:** 10.1136/annrheumdis-2022-eular.4213
Background: Studies have confirmed that JAKs-STATs signaling pathway is involved in the pathogenesis of a variety of autoimmune inflammatory diseases, and has been transformed into the treatment of rheumatic diseases. So far, the research of JAKs-STATs in the mechanism of gout is very limited.

Objectives: To determine whether JAKs-STATs pathway is involved in the pathogenesis of gouty inflammation.

Methods: 1. The transcription and protein phosphorylation levels of 4 JAKs (JAK1, JAK2, JAK3, and Tyk2) and 7 STATs (STAT1, stat2, STAT3, STAT4, STAT5a/5b and STAT6) in PBMCs of 100 gout patients (concluding acute gout (AG) and intermittent gout (IG) patients 50 cases, respectively) and 50 healthy subjects (HC) were measured; 2. To detect the changes of JAK3-STAT5 signal pathway in synovium of rat ankle model of gouty inflammation; 3. To explore the changes of JAK3-STAT5 signal pathway in synovium of gouty inflammation model after colchicine treatment.

Results: 1. The phosphorylation levels of JAK3 and STAT5 in PBMCs, the plasma IL-2 level in the AG group were all significantly higher than those in the HC group (P <0.05, respectively); while there were no differences with respect to the other JAKs and STATs molecules between the two groups (P>0.05, respectively); 2. JAK3 and STAT5 phosphorylation levels in synovial tissue of rat ankle, cytokine IL-1β and IL-2 productions in synovial fluid of rat ankle from gout model were all significantly increased (P<0.05, respectively; Figure 1A-F); 3. Phosphorylation levels of JAK3 and STAT5, p-JAK3, p-STAT5a and GAPDH protein expression from the three groups.*P <.05, **P<.01, ***P <.001, significantly different from Control group; #P<.05, ##P<.01, ###P<.001, significantly different from MSU group. G. IL-2 and IL-7 levels in plasma of acute gout (AG), intermittent gout (IG) and healthy individuals (HC) were detected using ELISA. *P<.05, **P<.01, ***P<.001, significantly different from Control group; #P<.05, ##P<.01, ###P<.001, significantly different from MSU group. H. JAK3 and STAT5 mRNA, protein levels in PBMCs of AG, IG, and HC groups were measured by qRT-PCR and Western blotting, respectively. *P<.05, **P<.01, ***P<.001.

Conclusion: IL-2-JAK3-STAT5 signaling pathway is involved in the regulation of gouty inflammation. Colchicine could treat gouty inflammation through inhibiting IL-2-JAK3-STAT5 pathway; JAK3 is expected to be a therapeutic target for acute gouty inflammation.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular1202

Figure 1. JAK3-STAT5 participates in the pathogenesis of gouty inflammation. In vivo experimental protocol (A-F): A. Male Wistar rats were used. The model Colchicine group was intragastrically administered with 0.104 mg/kg/d colchicine solution, and the Control group was intragastrically administered with the same amount of saline. After 3 days of continuous intragastric administration, the right ankle joint was injected with MSU (8 mg/100 μl) or PBS (100 μl) to establish a gout arthritis model (MSU group) or Control group. B. Representative photographs of ankles 12 h after MSU or PBS injection. C. Representative microscopic photos of ankle tissue sections from Control, MSU and Colchicine groups. D. Representative confocal laser scanning images showed JAK3 protein and its phosphorylated protein staining in ankle tissues in the three groups. Areas staining positive for JAK3 protein are shown in green. Regions staining positive for p-JAK3 protein are shown in red. E. IL-1β and IL-2 production in ankle flushing was detected by ELISA. F. p-JAK3, p-STAT5a and CoCl2 protein expression from the three groups. **P<.01, ***P<.001.
followed from baseline up to 10 years or until gout diagnosis, death, or end of study period (Dec 31/19).

We calculated 10-year cumulative incidence of gout according to baseline SU category and CKD status and evaluated their individual and joint impact on gout risk using multivariable Cox proportional hazards models. We further assessed for additive and multiplicative interactions\(^3\) between levels of SU and inverted eGFR, on a standardized continuous scale per SD.

**Results:** We included 458,244 individuals (45% male, mean age 56.5 years), of whom 6,559 had CKD at baseline, and documented 5,847 cases of incident gout over 4,442,866 person-years.

10-year cumulative incidence of gout ranged from 0.2% (baseline SU < 5 mg/dL) to 33% (baseline SU ≥ 10 mg/dL), and in each category incidence was higher for those with CKD than without (Table 1; Figure 1-left). Multivariable hazard ratio (HR) for the joint effect of CKD and highest SU level (≥ 10 mg/dL), compared to non-CKD and lowest SU (<5 mg/dL), was 242 (95% CI 189 to 309) (Figure 1-right).

There was a significant additive interaction between continuous SU and eGFR (relative excess risk due to interaction = 0.16 [0.09 to 0.24], \(p < 0.001\)), with HRs of 3.7 (3.6 to 3.8) per SD increase of SU, 1.2 (1.2 to 1.3) per SD increase of inverted eGFR, and 4.1 (3.9 to 4.2) for their joint effect. Their multiplicative interaction was also significant (\(p < 0.001\)).

**Conclusion:** These large prospective cohort data suggest CKD presence enhances the effect of elevated SU levels on risk of incident gout. They support roles of CKD-associated factors beyond SU in developing gout, such as reduced AMPK activity levels and altered inflammatory factors in CKD, which warrant further investigation.

**REFERENCES:**
[1] PMID 34556489
[2] PMID 34554658

Disclosure of Interests: Natalie McCormick: None declared, Leo Lu: None declared, Chio Yokose: None declared, Amit Joshi: None declared, Yujing Zhang: None declared, Hyon Choi Consultant of: Ironwood, Selecta, Horizon, Takeda, Kowa, and Vaxart., Grant/research support from: Ironwood and Horizon


**OP0167**

ULTRASOUNDOGRAPHY IN THE PREDICTION OF GOUT FLARES: A 12-MONTH PROSPECTIVE OBSERVATIONAL STUDY

E. Cipolletta\(^1\), A. Abhishek\(^2\), J. Di Battista\(^1\), W. Grassi\(^1\), E. Filippucci\(^1\).

\(^1\)Polytechnic University of Marche, Department of Clinical and Molecular Sciences, Ancona, Italy; \(^2\)University of Nottingham, Academic Rheumatology, Nottingham, United Kingdom

**Background:** Gout flares are a distinctive feature of gout. Although imaging techniques, such as ultrasonography (US), can visualise monosodium urate (MSU) crystals and synovial inflammation and estimate their burden, the role of imaging in predicting gout flares has not been fully investigated.

**Objectives:** To evaluate whether US findings indicative of MSU deposits and subclinical inflammation predict gout flares over 12 months.

**Methods:** Participants with gout on urate-lowering therapy (ULT) for at least the preceding six months were enrolled consecutively in this 12-month prospective, observational, single-centre study.

A nested case-control analysis was performed. Cases were participants with at least one gout flare in the follow-up period while controls did not self-report any gout flare. Clinical assessment was scheduled at 6-month intervals. In addition, at baseline, each patient underwent an US examination using a standardised scanning protocol including the following sites: knees, ankles, 1st metatarsophalangeal joints, elbows, wrists and 2nd metacarpophalangeal joints. The US findings indicating MSU deposits [i.e., aggregates, double contour (DC) sign and tophi] and inflammation [i.e., Power Doppler (PD) signal] were identified according to the 2015 Outcome Measure in Rheumatology definitions (Figure 1).

**Figure 1.** Summed scores were calculated for each US finding. During follow-up visits, patients were asked to report any gout flares using an internationally-validated definition\(^1\).

**Conclusion:** Multivariable logistic regression analysis was used to measure the association between baseline US findings and the occurrence of gout flares over 12 months. US scores were tested separately, including the following covariates: age, gender, disease duration, presence of subcutaneous tophi, current serum urate>360 μmol/l, increasing dose of ULT during the study period and ongoing flare prophylaxis. In addition, multivariable zero-inflated Poisson regression analysis was used to investigate the association between US findings and the number of flares over 12 months.

**References:**

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1102

**OP0168**

DEVELOPMENT OF AN ULTRASOUND SCORING SYSTEM FOR CPPD EXTENT: RESULTS FROM A DELPHI PROCESS AND WEB-RELIABILITY EXERCISE BY THE OMERACT US WORKING GROUP

S. Sirotti\(^1\), A. Adinolfi\(^2\), A. Damian\(^2\), F. Becce\(^3\), T. Cazenave\(^4\), E. Cipolletta\(^2\), S. N. Christiansen\(^5\), A. Delle Sedie\(^6\), M. Diaz\(^7\), F. Fugis\(^1\), E. Filippucci\(^1\), H. B. Hammer\(^8\), P. Mandl\(^9\), D. Maccarter\(^10\), M. Micu\(^11\), I. Möller\(^10\), M. A. Mortada\(^11\), G. Mouterde\(^12\), E. Naredo\(^13\), P. Porta\(^14\), A. Regnato\(^15\), G. Sakellariou\(^16\), W. A. Schmincke\(^17\), C. A. Scigli\(^18\), T. Serban\(^19\), V. Vlad\(^20\), F. A. Vreju\(^21\), R. Wakefield\(^22\), P. Zufferey\(^23\), P. Sarzi-Puttini\(^24\), I. A. lagnocco\(^25\), C. Pineda\(^26\), R. Keen\(^27\), M. A. D’agostino\(^28\), L. Terslev\(^29\), G. Filippou\(^30\) on behalf of OMERACT

\(^1\)Luigi Sacco University Hospital, Rheumatology Department, Milan, Italy; \(^2\)University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; \(^3\)University of Milan, Department of Experimental and Clinical Medicine, Division of Rheumatology, Firenze, Italy; \(^4\)Lausanne University Hospital, Department of Diagnostic and Interventional Radiology, Lausanne, Switzerland; \(^5\)Psychophysical Rehabilitation Institute, Rheumatology Unit, Buenos Aires, Argentina; \(^6\)Polytechnic University of Nottingham, Academic Rheumatology, Nottingham, United Kingdom

**Background:** CPPD is a common and disabling joint disease with an uncertain and unpredictable course. A scoring system for CPPD may be a useful tool to better understand joint damage and to predict its future progression and treatment needs.

**Objectives:** To develop an ultrasound scoring for CPPD, specifically for subchondral bone erosions, using a Delphi process and a web-reliability exercise that involved rheumatologists and radiologists.

**Methods:** \(n = 10\) rheumatologists and 10 radiologists were invited to participate in a Delphi process. Initially, a preliminary list of bone erosions was generated, following the Outcome Measure in Rheumatology (OMERACT) work. After a 1-week period, the list was revised and the group agreed on the final list of erosions. In the second phase, a web-reliability exercise was conducted using an anonymous online questionnaire.

**Results:** A total of 200 subchondral bone erosions were identified and scored. The radiologists agreed on 194 erosions (97%) and the rheumatologists on 189 erosions (94%). The agreement was high among radiologists (k = 0.87, CI = 0.78-0.96) and among rheumatologists (k = 0.79, CI = 0.68-0.89).

**Conclusion:** A comprehensive list of bone erosions was generated and scored by radiologists and rheumatologists. This list will be used to develop a scoring system for CPPD, which will be evaluated in a further study.
Marche,”Carlo Urbani” Hospital, Rheumatology Unit, Department of Clinical and Molecular Sciences, Jesi, Italy; 7Copenhagen University Hospital Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatic and Spine Diseases, Rigshospitalet, Copenhagen, Denmark; 8Pisan University Hospital, Rheumatology Unit, Pisa, Italy; 9University Hospital Fundación Santa Fe de Bogotá, Rheumatology Unit, Bogota, Colombia; 10University of Turin, Academic Rheumatology Centre, Department of Clinical and Biological Science, Torino, Italy; 11University of Oslo, Dronninghjemmet Hospital, Department of Rheumatology, Oslo, Norway; 12Medical University of Vienna, Division of Rheumatology, Vienna, Austria; 13North Valley Hospital, Rheumatology Department, Whitefish, United States of America; 14Rehabilitation Clinical Hospital Cluj-Napoca, Division of Rheumatology, Cluj-Napoca, Romania; 15Instituto Pao de Reumatologia, Rheumatology Department, Barcelona, Spain; 16Zagazig University Hospital, Rheumatology Department, Zagazig, Egypt; 17Hospital Center University De Montpellier, Rheumatology Department, Montpellier, France; 18Hospital Universitario Fundación Jiménez Díaz, Rheumatology Department, Joint and Bone Research Unit, Madrid, Spain; 19Santa Maria Maddalena Hospital, Interdisciplinary Pain Medicine Unit, Occhiobello, Italy; 20Rhode Island Hospital, Warren Alpert Medical School of Brown University, Division of Rheumatology, Department of Medicine, Providence, United States of America; 21University of Pavia, IRCCS Policlinico San Matteo Foundation Istituti Clinici Scientifici Maugeri, Division of Rheumatology, Pavia, Italy; 22Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany; 23University of Milan - Bicocca, School of Medicine, Milan, Italy; 24Società Italiana di Reumatologia, Epidemiology Research Unit, Milan, Italy; 25Hospital La Colletta, Rheumatology Department, Genoa, Italy; 26Saint Mary Hospital, Rheumatology Department, Bucuresti, Romania; 27University of Medicine and Pharmacy of Craiova, Rheumatology Department, Craiova, Romania; 28University of Leeds, Chapel Allerton Hospital, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 29University of Lausanne, Rheumatology Department, Lausanne, Switzerland; 30University of Turin, Academic Rheumatology Centre, Department of Clinical and Biological Sciences, Torino, Italy; 31Instituto Nacional de Rehabilitación, Division of Musculoskeletal and Rheumatic Diseases, Ciudad de México, Mexico; 32The University of Western Australia, School of Medicine, Murdoch, Australia; 33Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Rheumatology Department, Roma, Italy; 34Copenhagen University Hospital Rigshospitalet, Center for Rheumatology and Spine Diseases, København, Denmark


Introduction
Rheumatoid arthritis is a chronic inflammatory disease that affects joints, muscles, and connective tissues, producing pain and disability. Early diagnosis and effective treatment are crucial to minimize joint damage and improve quality of life. Crystal deposition, particularly calcium pyrophosphate dihydrate (CPPD), is a common feature in patients with rheumatoid arthritis and can lead to joint pain, stiffness, and functional impairment. The diagnosis of CPPD is often challenging due to the asymptomatic nature of early CPPD deposition.

Objective
The aim of this study was to develop a scoring system for CPPD disease based on available literature and expert opinion.

Methods
We reviewed the literature on CPPD disease using PubMed and other online databases to identify relevant studies. We also conducted a survey among experts in the field to assess the reliability of the proposed system. The survey included 53 questions, focusing on the evaluation of joint involvement, clinical features, and the correlation with patients’ symptoms. The survey was distributed to 32/41 members of the OMERACT US-CPPD working group. The survey results were analyzed using descriptive statistics and correlation analysis.

Results
The survey was completed by 31 members, and 25/31 (92.6%) of the respondents found the scoring system to be a useful tool for clinical practice and research. The system was found to be reliable in static images. The next step of the validation process is to assess the reliability of the scoring system in a patient-based exercise. This study represents a fundamental step in the OMERACT process of validating US as an outcome measure instrument, and above proposed scoring system will hopefully provide a useful tool for clinical practice and research.

Conclusion
The survey findings suggest that the proposed scoring system is a reliable and useful tool for the diagnosis and management of CPPD disease. Further studies are needed to validate the system in a patient-based exercise.

References
1. Fashad S, Ramahi A, Murphy A, Aleatany Y, Khanna P. University of Michigan, Rheumatology, Ann Arbor, United States of America


INTRODUCING DISCONTINUATION ALLOPURINOL – A QUALITATIVE IMPROVEMENT (QI) INITIATIVE

S. Farshad1, A. Ramahi1, A. Murphy1, Y. Aleatany1, P. Khanna1. University of Michigan, Rheumatology, Ann Arbor, United States of America

Background: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain, when left untreated. Allopurinol is often used as long-term urate lowering therapy. Discontinuation of allopurinol leads to worsening flares, disability, poor quality of life, and frequent use of acute care facilities. Recent data revealed that 56% of hospitalized patients had allopurinol discontinued during an episode of acute gout flare, suggesting an unmet need for ongoing provider education (1). Gout flares are 14 times more likely to develop in patients who have allopurinol discontinued upon admission to the hospital (2).

Objectives: We performed a qualitative analysis of the current rate of discontinuation of allopurinol during hospitalizations at an academic hospital in order to develop a QI model.

Methods: We leveraged our electronic health records (EHR) to obtain data on gout patients admitted to the university hospital from 2019-2020, with IRB approval. Patients on allopurinol as an active home medication that was discontinued during hospitalization and/or after hospital discharge were included to calculate the rate of discontinuation. Lean thinking methodology with A3 process mapping for root cause analysis (RCA) was utilized. We identified stakeholders involved in medication reconciliation – nurses and various providers, including trainees, and invited them to participate in an anonymous survey to understand the rationale behind allopurinol discontinuation during hospitalization. Next, we created countermeasures and actionable recommendations that could be implemented at an institutional level.

Results: A total of 2138 patients who were hospitalized had allopurinol listed as an active home medication. Of these, 364 (17%) did not receive allopurinol during hospitalization. Based on the survey data, providers chose to discontinue allopurinol due to the following factors – acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. The RCA revealed layers of reasoning at various levels of the medication reconciliation process which impacted the decision-making algorithm. This in turn led to discontinuation during the admission and subsequent omission of allopurinol after discharge. Several low- and high-impact recommendations emerged as countermeasures, including a) pharmacy involvement at admission medication reconciliation, b) creation of a clinical practice guideline, and c) automated routing by EHR to standardized guidelines when allopurinol was discontinued on admission (Figure 1).

Figure 1: Implementation of allopurinol discontinuation during hospitalization at an academic hospital.

QUALITATIVE IMPROVEMENT (QI) INITIATIVE

S. Farshad1, A. Ramahi1, A. Murphy1, Y. Aleatany1, P. Khanna1. University of Michigan, Rheumatology, Ann Arbor, United States of America


OP0169

INPATIENT DISCONTINUATION OF ALLOPURINOL – A QUALITATIVE IMPROVEMENT (QI) INITIATIVE

S. Farshad1, A. Ramahi1, A. Murphy1, Y. Aleatany1, P. Khanna1. University of Michigan, Rheumatology, Ann Arbor, United States of America

Background: Gout is a chronic inflammatory arthritis induced by hyperuricemia and manifested by recurrent acute flares of debilitating joint pain, when left untreated. Allopurinol is often used as long-term urate lowering therapy. Discontinuation of allopurinol leads to worsening flares, disability, poor quality of life, and frequent use of acute care facilities. Recent data revealed that 56% of hospitalized patients had allopurinol discontinued during an episode of acute gout flare, suggesting an unmet need for ongoing provider education (1). Gout flares are 14 times more likely to develop in patients who have allopurinol discontinued upon admission to the hospital (2).

Objectives: We performed a qualitative analysis of the current rate of discontinuation of allopurinol during hospitalizations at an academic hospital in order to develop a QI model.

Methods: We leveraged our electronic health records (EHR) to obtain data on gout patients admitted to the university hospital from 2019-2020, with IRB approval. Patients on allopurinol as an active home medication that was discontinued during hospitalization and/or after hospital discharge were included to calculate the rate of discontinuation. Lean thinking methodology with A3 process mapping for root cause analysis (RCA) was utilized. We first identified stakeholders involved in medication reconciliation – nurses and various providers, including trainees, and invited them to participate in an anonymous survey to understand the rationale behind allopurinol discontinuation during hospitalization. Next, we created countermeasures and actionable recommendations that could be implemented at an institutional level.

Results: A total of 2138 patients who were hospitalized had allopurinol listed as an active home medication. Of these, 364 (17%) did not receive allopurinol during hospitalization. Based on the survey data, providers chose to discontinue allopurinol due to the following factors – acute gout flare, renal impairment, gastrointestinal issues, cytopenia, drug interactions, NPO status, and always discontinued the medication. The RCA revealed layers of reasoning at various levels of the medication reconciliation process which impacted the decision-making algorithm. This in turn led to discontinuation during the admission and subsequent omission of allopurinol after discharge. Several low- and high-impact recommendations emerged as countermeasures, including a) pharmacy involvement at admission medication reconciliation, b) creation of a clinical practice guideline, and c) automated routing by EHR to standardized guidelines when allopurinol was discontinued on admission (Figure 1).
**OP0170** PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF A TRANSDERMAL ALKALINIZING AND PAIN-RELIEVING TREATMENT FOR REDUCING PAIN ASSOCIATED WITH AN ACUTE GOUT FLARE

P. Khanna¹, R. Beal², ¹University of Michigan, Rheumatology Clinic | Taubman Center, Ann Arbor, United States of America; ²Dyve Biosciences, Management, Camarillo, United States of America

**Background:** Monosodium urate (MSU) deposition is pathognomonic for gouty arthropathy. MSU crystal formation and dissolution is affected by pH and theoretically, alkalinizing agents (eg, sodium bicarbonate, NaHCO₃) that raise the joint microenvironment pH, could facilitate MSU crystal dissolution and decrease the pain of an acute gout flare. However, oral NaHCO₃ use is fraught with intolerable gastrointestinal side effects.

**Objectives:** To determine if NaHCO₃ in a patented transdermal formulation could effectively and safely reduce the pain of an acute gout flare.

**Methods:** A Phase 2a prospective, double-blind, randomized, placebo-controlled study enrolled 418 subjects across 20 US sites. Patients with a diagnosis of gout using ACR/EULAR criteria (Score ≥ 8), ages 18-75, history of ≥ 2 gout flares in 12 months prior to randomization and on stable doses of urate lowering therapy were included. Exclusion criteria were BMI > 40kg/m², > 12 gout flares in the year prior to randomization, history of rheumatoid arthritis, psoriatic arthritis, evidence of septic arthritis, acute polyarticular gout (≥ 4 joints), and arthritis of any other cause. Patients were randomized to receive placebo lotion or transdermal NaHCO₃. Upon flare they initiated colchicine (1.2mg followed by 0.6mg 1 hour later) and applied study product to the limb of the affected joint. Outcome measures included pain-numerical rating scale (NRS, 0-10), time to resolution of pain (50% reduction), rescue medication use, joint tenderness, and physical function (PROMIS PF-20). Data were collected in patient diaries for the pain and PROMIS measures at several time points from baseline through Day 7, as were adverse events. Statistical analyses utilized ANCOVA (baseline pain as a covariate), Kaplan-Meier curves for homogeneity, and two-proportion z-test, all with α = 0.05.

**Results:** 98 patients had a gout flare during the 14-month study period. Those in the active arm (ITT, N=48) had an overall responder rate of 94.5% vs. 79.3% (p=0.01) in the placebo arm (ITT, N=50) over the 7-day follow up. Rescue medication use was lower in the active arm vs. placebo (6.3% vs. 20.0%, p=0.02); and PROMIS PF-20 showed greater improvements over 7 days (22.2 vs. 16.7 points, p=0.05). The most common adverse event was hypertension (14.2%) with no significant difference between arms. Per protocol analyses were conducted to adjust for adherence on Day 1 for time to resolution of pain (Figure 1) and additional 24hr endpoints (Table 1).

**Conclusion:** Transdermal NaHCO₃ reduced the pain intensity and duration of an acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and a reduction in rescue medication use. The lack of adverse events makes this topical a promising therapeutic choice; especially during debilitating acute gout flares in patients with concomitant comorbidities.

**REFERENCES:**

**Figure 1.** Time to resolution of pain (per protocol population, n = 57)

<table>
<thead>
<tr>
<th>Time (Days)</th>
<th>Active (n=28)</th>
<th>Placebo (n=29)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>100%</td>
<td>98%</td>
<td>0.99</td>
</tr>
<tr>
<td>1</td>
<td>80%</td>
<td>67%</td>
<td>0.13</td>
</tr>
<tr>
<td>2</td>
<td>77%</td>
<td>60%</td>
<td>0.18</td>
</tr>
<tr>
<td>3</td>
<td>70%</td>
<td>55%</td>
<td>0.24</td>
</tr>
<tr>
<td>4</td>
<td>67%</td>
<td>50%</td>
<td>0.28</td>
</tr>
<tr>
<td>5</td>
<td>60%</td>
<td>40%</td>
<td>0.36</td>
</tr>
<tr>
<td>6</td>
<td>55%</td>
<td>30%</td>
<td>0.43</td>
</tr>
<tr>
<td>7</td>
<td>50%</td>
<td>20%</td>
<td>0.50</td>
</tr>
</tbody>
</table>

*p = 0.03

# Table 1. Key 24hr Endpoints (Per Protocol, n = 57)

<table>
<thead>
<tr>
<th>Time (Days)</th>
<th>Median Time to Resolution (hrs)</th>
<th>Change in 24hr PROMIS PF-20 score</th>
<th>Physician-assessed moderate-to-severe joint tenderness</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>24</td>
<td>16.7</td>
<td>28.0%</td>
</tr>
<tr>
<td>1</td>
<td>72</td>
<td>9.4</td>
<td>57.1%</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
</tbody>
</table>

*p ≥ 50% reduction in pain; K-M Est.; Subjects using rescue medication, discontinuing study drug, or missing pain scores censored. Consists of 20, 0-5-point questions; higher scores indicate better function. Likert-0 (no pain), 1 (pain), 2 (wincing), 3 (wincing and withdrawal).
and prevents ADA development against biologics, co-administering MTX with pegloticase in uncontrolled gout pts is of interest. A small open-label study of pegloticase-oral MTX suggested an increased efficacy rate, so a randomized controlled trial (RCT) was conducted to compare pegloticase with/without MTX immunomodulation.

**Objectives:**

To determine safety/efficacy of oral MTX as co-therapy with pegloticase for sustained urate-lowering response in a randomized placebo (PBO) controlled trial.

**Methods:**

Pegloticase+MTX and pegloticase+PBO co-therapy were compared in uncontrolled gout pts (sUA≥7 mg/dL, ULT failure/intolerance, and ≥1 of the following: ≥1 tophus, ≥2 flares in past yr, chronic gouty arthritis). Primary endpoint was the proportion of Month 6 treatment responders (sUA<6 mg/dL for ≥80% of the time during Wks 20-24). Key exclusion criteria included MTX contraindication, immunosuppressant use, G6PD deficiency, and renal impairment (eGFR<40 mL/min/1.73 m²). Pts were randomized: 2:1 to oral MTX (15 mg/wk) or PBO. Following a 4 wk MTX/PBO run-in, pegloticase was initiated (Day 1). Both pegloticase (biweekly 8 mg infusions) and MTX/PBO were administered over 52-wks (treatment period). Efficacy was examined in the intent-to-treat population (ITT, all randomized pts); safety (AEs, laboratory values) in the safety population (all pts receiving ≥1 dose blinded MTX/PBO). Treatment was discontinued if pre-infusion sUA≥6 mg/dL for 2 consecutive visits Wks 2 or later.

**Results:**

152 pts (88.8% male) were randomized at 42 sites; 100 to pegloticase+MTX, 52 to pegloticase+PBO. 4 MTX, 3 PBO pts discontinued before first pegloticase dose; 26 MTX, 30 PBO pts who received pegloticase discontinued treatment at or before Wk 24. The primary endpoint was met with a 6-month response rate of 71.0% (71/100) vs 38.5% (20/52) in the MTX vs PBO co-therapy groups (p<0.0001; modified ITT [all pts receiving ≥1 pegloticase dose]: 74.0% [71/96] vs 40.8% [20/49], p<0.0001). In the first 24 wks of therapy, 81.3% vs 95.8% experienced ≥1 AE (Table 1), with gout flare in 66.7% (64/96) vs 69.4% (34/49) of MTX vs PBO pts. Infusion reactions (IRs) were more frequent in the PBO group (30.6%) than in the MTX group (3.1% plus anaphylaxis [NIAD/FAAN criteria] in 1 MTX pt). A single cardiovascular event of cardiac arrest occurred in 1 MTX pt ≥2 wks after pegloticase infusion 3 (deemed unrelated to study drug by site investigator). MTX-associated AEs 4 did not occur more frequently in the MTX group (Table 1).

**References:**


4. MTX package insert

**Disclosure of Interests:** John Botson Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Grant/research support from: Horizon Therapeutics, Alinea, Lg, Sobi., Jeff Peterson Grant/research support from: Horizon Therapeutics, Naval Parikh Grant/research support from: Horizon Therapeutics, Stephen Ong Grant/research support from: Horizon, Novo Nordisk, Sanofi, Lilly, NIH/Mount Sinai, Dan La Speakers bureau: Abbvie, Grant/research support from: Horizon Therapeutics, Katie Obermeyer Shareholder of: Horizon Therapeutics, Brian LaMureaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Stephen Sainati Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Sunee Grewal Speakers bureau: Horizon Therapeutics, UCB, Glaxo Smith Kline, Grant/research support from: Horizon Therapeutics, Amar Majhoo Speakers bureau: Abbvie, Amgen, BMS, Horizon Therapeutics, Jansen, Glaxo Smith Kline, Astra Zeneca, Grant/research support from: Horizon Therapeutics, John Tessar Grant/research support from: Horizon Therapeutics, Michael E. Weinblatt Consultant of: Horizon Therapeutics

**References:**

Table 1. Predictors of antibody response to COVID-19 vaccine

<table>
<thead>
<tr>
<th></th>
<th>Unvaccinated</th>
<th>Partially vaccinated</th>
<th>Fully vaccinated</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA Controls</td>
<td>N</td>
<td>28 447</td>
<td>568 940</td>
</tr>
<tr>
<td></td>
<td>Women, %</td>
<td>71.3</td>
<td>71.3</td>
</tr>
<tr>
<td></td>
<td>Age (years)</td>
<td>67.8 [34.2 to 88.3]</td>
<td>67.8 [34.2 to 88.4]</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>/</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>/</td>
<td>1.1</td>
<td>13.7</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>/</td>
<td>0.1</td>
<td>10.3</td>
</tr>
<tr>
<td>Other csDMARD</td>
<td>/</td>
<td>0.2</td>
<td>10.7</td>
</tr>
<tr>
<td>Prednisolone, all in %</td>
<td>12.5</td>
<td>2.0</td>
<td>12.2</td>
</tr>
<tr>
<td>TNF/ /</td>
<td>16.9</td>
<td>0.1</td>
<td>17.2</td>
</tr>
<tr>
<td>abatacept/ /</td>
<td>15.6</td>
<td>0.0</td>
<td>15.6</td>
</tr>
<tr>
<td>tocilizumab/ /</td>
<td>3.0</td>
<td>0.0</td>
<td>3.0</td>
</tr>
<tr>
<td>rituximab, all in %</td>
<td>2.2</td>
<td>0.1</td>
<td>2.1</td>
</tr>
<tr>
<td>COVID-19 hospitalisation</td>
<td>N</td>
<td>65</td>
<td>727</td>
</tr>
<tr>
<td></td>
<td>Median [IQR] days of follow-up</td>
<td>102 [62 to 137]</td>
<td>115 [88 to 146]</td>
</tr>
<tr>
<td>Rate per 1000 PY</td>
<td>10.4 (8.0 to 13.4)</td>
<td>4.7 (4.3 to 5.1)</td>
<td>5.5 (3.0 to 10.0)</td>
</tr>
<tr>
<td>Adjusted HR</td>
<td>1.08 (1.44 to 2.46)</td>
<td>1 (Ref.)</td>
<td>1.08 (1.44 to 2.46)</td>
</tr>
</tbody>
</table>

*Unrestricted research grants have been received från Roche and starting grants from the Swedish Rheumatism Association.

**Disclosures of Interests:** Martina Frodlund Consultant of: Consultancy fees from Eli Lilly, AbbVie and Pfizer, Anna Södergren: None declared, Eva Klingberg: None declared, Anders Bengtsson: None declared, Lars Klareskog: Grant/Research support from: Research grants from Pfizer, BMS, Affibody, Sonoma Biotherapeutics, Melihia C Kapetanovic: None declared.

**Acknowledgements:** Frequency (%) of individuals with good antibody response to COVID-19 vaccine

**Background:** Patients with rheumatoid arthritis (RA) may have impaired immunogenicity to COVID-19 vaccines.

**Objectives:** To investigate the incidence of COVID-19 infection and hospitalisation in unvaccinated and vaccinated patients with RA compared with matched individuals; and secondarily in patients with RA according to DMARD treatment.

**Methods:** Danish nationwide matched cohort study from January to October 2021. Patients with RA were identified in DANBIO and matched 1:20 with individuals from the general population on age, sex, and vaccination status (month and exact type of vaccination). Primary and secondary outcomes were COVID-19 hospitalisation (Danish National Patient Register) and positive SARS-CoV2 PCR test (Danish COVID-19 Surveillance Register), respectively. Stratified by vaccination status, incidence rates (IRs) per 1000 person years (PY) and comorbidity-adjusted hazard ratios (aHRs) in cause-specific Cox models were calculated with 95% confidence intervals. Using the Aalen-Johansen estimator, the cumulative incidence of COVID-19 hospitalisations was visualised according to RA and vaccine exposure status.

**Results:** Regardless of vaccination status, patients with RA had increased incidence of COVID-19 hospitalisation compared to matched individuals (Table 1). However, the absolute risk was 0.20% for unvaccinated patients at 60 days and 0.08% for comparators, whereas it remained below 0.05% at 180 days of follow-up in both groups when fully vaccinated (Figure 1). Increased SARS-CoV2 infection rates were seen only among unvaccinated patients with RA (Table 1). Unadjusted analyses showed increased incidence of COVID-19 hospitalisation among rituximab-treated compared with conventional DMARD treated: unvaccinated HR 4.71 (1.98 to 11.18) and vaccinated HR 11.69 (2.07 to 68.06). However, the proportions of patients with previous cancer and treated with prednisolone were higher among the rituximab treated.

**Conclusion:** The incidence of COVID-19 hospitalisation was increased for both unvaccinated and vaccinated patients with RA compared with controls. Importantly, the parallel decreasing risk for patients with RA suggests a comparable decrease in risk for vaccinated patients with RA.
relative benefit of vaccination. Less favourable outcomes among rituximab-treated patients with rheumatic diseases, such as vasculitis or systemic connective tissue diseases, early or during treatment, may impair response to vaccines, in particular those targeting B or T cells directly (1).

Objectives: The aim of this study is to evaluate the B and T-cell mediated immune response to mRNA vaccination in patients with systemic autoimmune diseases, such as systemic lupus erythematosus and other rheumatoid patients that needs to be further promoted. However, the immunosuppressive drugs used to treat rheumatic diseases may impair response to vaccines, in particular those targeting B or T cells directly (1).

Methods: Twenty-eight consecutive patients under treatment with rituximab (RTX, n=11) or belimumab (BEL, n=17) and 13 age/sex matched controls (non-rheumatic healthcare personnel) were enrolled in the study. Nobody presented anti-SARS-CoV-2 antibodies related to previous viral contact and all were negative at the molecular swab monthly control. All patients and controls received mRNA vaccines and were tested three to four weeks after complete vaccination. All RTX patients started vaccination within 5 months from the last infusion, and all but one of them were B-cell depleted. Anti-SARS-CoV-2 VBD total antibodies were analysed by a diagnostic assay (Elecys, Roche) while T-cell response was evaluated using the IGRA test (Euroimmun). A subgroup of BEL-patients was tested with pseudovirus neutralizing capacity in belimumab-exposed B cells, by comparing with controls and each other. Secondary we evaluated the in vitro effective neutralizing capacity in belimumab-exposed patients.

Results: Detectable anti-SARS-CoV-2 VBD antibodies were documented in 1/11 RTX patients versus 16/17 BEL patients (p<0.0001). The median concentration was significantly lower than that observed in controls (39.6 AU/ml vs 113 AU/ml, p<0.0001). A very low titer of anti-RBD antibodies were documented only in 1 out of 11 patients in the RTX subgroup (0.93 U/ml, positive if >0.79 U/ml) and the patient was the only one who showed an initial B-cell recovery (CD19+ B-cells 5 cells/µl). Anti-RBD antibodies were documented in 16 out of 17 patients in the BEL subgroup. The median anti-RBD antibody titer in patients receiving BEL was 243 (77.5-940.4) U/ml, and it was significantly lower compared to the controls (p=0.002).

The IGRA test was positive in 8/11 (72.7%) RTX patients vs 16/17 (94.1%) BEL patients (p=0.7), with interferon release comparable to controls subjects (p=0.2).

Six patients with BEL were also stratified according to total antibodies (lgG+IgA+IgM) against-RBD into high responders (>800 AU/ml, n=3) and low responders (≤45 AU/ml, n=3) and tested with pseudovirus neutralization assay. Two thirds of low titer group of patients treated with the Wuhan-Hu1 strain at medium-low titer (IC50 =102) but were almost ineffective in inhibiting the B.1.1.7 entry into target cells (IC50 =10). Regarding high responders, while two patients were able to inhibit both the strains at medium-high titer (approximately IC50 =103 for Wuhan-Hu1 and B.1.1.7), one patient neutralized only the WT strain.

Conclusion: B-cell targeting therapies do not preclude SARS-CoV-2 vaccination since a cellular immunity can raise even in the absence of circulating B cells. Most importantly, the immunogenicity of COVID-19 vaccination in SLE patients treated with belimumab is supported. However, patients showing the lowest humoral response to vaccine could remain at higher risk of infections, due to low neutralizing capacity.

REFERENCES:
Conclusion: Compared to no medication, some immunomodulatory therapies resulted in markedly lower Ab levels at all timepoints. In IRD patients, a past SARS-CoV-2 infection resulted in strikingly increased immunogenicity, as did mRNA-1273 (vs BNT162b2) increases with age. Interaction terms with medications: medication in combination th. vs medication as monoth.

Table 1. The OR of being above a given Ab threshold, regardless of the threshold. Ref. levels: mean age, no medication, no past SARS-CoV-2 inf., BNT162b2. Included in model but not shown: diagnosis, infrequently used medication (all non-signify.)

<table>
<thead>
<tr>
<th>Weeks post full vac.</th>
<th>4</th>
<th>12</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>0.96 (0.94 – 0.97)</td>
<td><strong>0.98 (0.96 – 0.996)</strong></td>
<td>0.98 (0.97 – 1.00)</td>
</tr>
<tr>
<td>mRNA-1273 (vs BNT162b2)</td>
<td>3.28 (2.34 – 4.61)</td>
<td><strong>3.96 (2.83 – 5.54)</strong></td>
<td><strong>3.94 (2.93 – 5.50)</strong></td>
</tr>
<tr>
<td>csDMARD$^3$</td>
<td>1.27 (0.67 – 2.41)</td>
<td>1.78 (0.94 – 3.35)</td>
<td>1.70 (0.86 – 3.36)</td>
</tr>
<tr>
<td>TNF$^2$</td>
<td>0.46 (0.28 – 0.71)</td>
<td><strong>0.30 (0.19 – 0.48)</strong></td>
<td><strong>0.13 (0.081 – 0.22)</strong></td>
</tr>
<tr>
<td>IL-18/17/23$^a$</td>
<td>0.97 (0.54 – 1.75)</td>
<td>1.04 (0.57 – 1.89)</td>
<td>0.89 (0.49 – 1.64)</td>
</tr>
<tr>
<td>JAK$^a$</td>
<td>0.38 (0.16 – 0.91)</td>
<td><strong>0.36 (0.16 – 0.91)</strong></td>
<td><strong>0.53 (0.22 – 1.28)</strong></td>
</tr>
<tr>
<td>RTX$^a$</td>
<td>0.078 (0.013 – 0.46)</td>
<td><strong>0.078 (0.015 – 0.42)</strong></td>
<td><strong>0.16 (0.037 – 0.71)</strong></td>
</tr>
<tr>
<td>ABA$^a$</td>
<td>0.14 (0.039 – 0.51)</td>
<td><strong>0.007 (0.022 – 0.33)</strong></td>
<td><strong>0.006 (0.017 – 0.27)</strong></td>
</tr>
</tbody>
</table>

Interactions$^5$

- Apcvaccine$^3$
- csDMARD/ombi
- TNF$^2$/ombi
- IL-18/17/23$^a$/ombi
- JAKi/ombi
- RTX$^a$/ombi
- ABA$^a$/ombi

$^*$ p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. $^†$ Medication as monoth. vs no medication $^‡$ Interaction terms showing how OR of mRNA-1273 (vs BNT162b2) increases with age $^§$ Interaction terms with medications: medication in combination th. vs medication as monoth.
Objectives: To compare the persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses between IMID patients using immunosuppressive medication and healthy controls and identify predictors of antibody decline.

Methods: We included patients with inflammatory joint- and bowel diseases on immunosuppressive medication and healthy controls enrolled in the prospective observational Nor-VaC study. Serum samples were collected at two time points following two dose SARS-CoV-2 vaccination (first assessment within 6–48 days and second within 49–123 days). Sera were analysed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Anti-RBD <200 BAU/ml were defined as low levels. The estimated percent reduction in anti-RBD standardised to 30 days was calculated and factors associated with reduction were identified in multivariable regression models.

Results: A total of 1097 patients (400 rheumatoid arthritis, 189 psoriatic arthritis, 189 spondyloarthritis, 129 ulcerative colitis, 190 Crohn’s disease) (median age 54 years [IQR 35–58]; 83% women) and 133 controls (median age 45 years [IQR 35–56]; 56% women) provided blood samples within the defined intervals (median 19 days [IQR 15–24] and 97 days [86–105] after second vaccine dose). Antibody levels were significantly lower in patients compared to controls at both assessments, with median anti-RBD 1468 BAU/ml [IQR 500–5062] in patients and 5514 BAU/ml [2528–9580] in controls (p<0.0001) and 298 BAU/ml [IQR 28–2870] in controls (p<0.0001), at first and second assessment respectively. Figure 1 show antibody levels at both assessments after medication group. At the second assessment, anti-RBD antibody levels decreased below 200 BAU/ml in 452 (41%) patients and in 1 (0.8%) control (p<0.0001) (Table 1). The percentage change in anti-RBD levels were -86 % in patients and -77 % in controls (p<0.0001). The majority of patients using rituximab had low antibody levels at both assessments, Figure 1. In the multivariable regression analysis, patients had a greater decline in anti-RBD levels compared to controls \(\beta_{-6.4} \) (-8.4, \(-7.2\)) respectively (p<0.001). Use of tumor necrosis factor inhibitors in mono- or combination therapy was associated with the greatest decline compared to controls, \(\beta_{-8.4} \) (-8.4, \(-6.2\)) respectively (p<0.001).

Conclusion: Within four months after the second vaccine dose, anti-Spike antibody levels declined considerably in both IMID patients and controls. Patients had lower antibody levels at the first assessment and a more pronounced decline compared to controls, and were consequently more likely to have low antibody levels four months after the second vaccine dose. Our results support that IMID patients lose humoral protection and need additional vaccine doses sooner than healthy individuals.

Table 1. Serological response in patients and controls

<table>
<thead>
<tr>
<th>Anti-RBD antibodies (BAU/ml)</th>
<th>Controls (n=133)</th>
<th>Patients (n=1097)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(&lt;5, n (%))</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5-19, n (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>20-199, n (%)</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>200-1999, n (%)</td>
<td>25 (19)</td>
<td>89 (67)</td>
</tr>
<tr>
<td>(\geq 2000), n (%)</td>
<td>71 (53)</td>
<td>398 (36)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Ingrid Egeland Christensen: None declared, Ingrid Jys: None declared, Anne Therese Tveten: None declared, Joe Sexton: None declared, Trung T. Tran: None declared, Siri Mjaaland: None declared, Grete B. Kro: None declared, Tore K. Kvien Speakers bureau: Amgen, Celtirion, Egis, Evapharma, Ewopharma, Hikma, Oktai, Sandoz, Sanofi, Consultant of: Abbvie, Amgen, Biogen, Celtirion, Eli Lilly, Gilead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Grants to institution (Dialonhjemmet Hospital): Abbie, Amgen, BMS, MSD, Novartis, Pfizer, UCB, David Worren: None declared, Jørgen Jahnssen Speakers bureau: AbbVie, Astra Pharma, Boehringer Ingelheim, BMS, Celtirion, Ferring, Gilead, Hikma, Janssen Cilag, Meda, MSD, Napp Pharma, Novartis, Ordon Pharma, Pfizer, Pharmacosmos, Roche, Takeda, Sandoz, Consultant of: AbbVie, Boehringer Ingelheim, BMS, Celtirion, Ferring, Gilead, Janssen Cilag MSD, Napp Pharma, Novartis, Ordon Pharma, Pfizer, Pharmacosmos, Takeda, Sandoz, Unimedic Pharma, Grant/research support from: Abbvie, Pharmacosmos, Ferring, Ludwig A. Munteh Speakers bureau: Novartis, Celligene, Espen Haavardsdahl: None declared, John Torgils Vaage: None declared, Gunnveig Groedelan Speakers bureau: Bayer, Sanofi Pasteur, Thermo Fisher, Consultant of: Consulting fees from the Norwegian System of Compensation to Patients and AstraZeneca, Fridjof Lund-Johansen: None declared, Kristin Kaassen Jergensen Speakers bureau: Roche, BMS, Consultant of: Celtirion, Norgine, Stine Watterdal Syversen: None declared, Guro Libov Goll Speakers bureau: AbbVie, Pfizer, UCB, Sandoz, Ordon Pharma, Novartis, Consultant of: Pfizer, AbbVie, Sella Areastad Provau: None declared DOI: 10.1136/annrheumdis-2022-eular.2054

OP0177 IMMUNOGENICITY INDUCED BY TWO AND THREE DOSES OF THE BNT162B2 mRNA VACCINE IN PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND IMMUNOCOMPETENT CONTROLS: A LONGITUDINAL MULTI-CENTER STUDY

V. Furer1, T. Eviatar1, H. Peleg2, D. Hagin3, T. Freund4, D. Levatovsky5, D. Paran1, I. Kaufman4, A. Broyle4, A. Polacheck1, O. Eliouf4, J. Feld6, A. Haddad7, T. Gazitz7, M. Elias8, N. Hijaze9, F. Kharouf10, S. Gertel11, S. Nevo5, S. Perl12, D. Zisman13, O. Eliakham14, 1Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Rheumatology, Tel Aviv-Yafo, Israel; 1Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Allergy and Clinical Immunology Unit, Department of Medicine, Tel Aviv, Israel; 2Hadassah University Hospital, Rheumatology, Jerusalem, Israel; 1Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Carmel Medical Center, Rheumatology, Haifa, Israel

Background: Data on the kinetics of the immune response to SARS-CoV-2 vaccination in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.

Objectives: To evaluate the kinetics of the immune response induced by two and three doses of the BNT162b2 mRNA vaccine in adult patients with AIIRD and immunocompetent controls.

Methods: A prospective multicenter study investigated the antibody response to the BNT162b2 vaccine by serial measurement of serum anti-SARS-CoV-2
S1/S2 IgG titers at the following time points: 2-6 weeks (AllRD n=720, controls n=122) and six months (AllIRD n=628, controls=116) after the second vaccine dose, and 2-6 weeks after the third vaccine dose (AllIRD n=169, controls n=45). A seropositive response was defined as a detectable anti-S1/S2 IgG titer ≥ 15 BAU/ml. T-cell immune response was evaluated in a sample of patients (n=28) and controls (n=9) by intracellular staining of S-stimulated CD4+ T-cells for TNFα and IFNγ production.

**Results:** The two-dose vaccine regimen induced a higher humoral response in controls compared to patients, as reflected by the post-vaccination seropositivity rates of 100% vs 84.72%, p=0.0001, and 96.55% vs 74.26%, p=0.001 at 2-to-6 weeks and at 6 months, respectively. The decline of S1/S2 IgG titers within six months was similar in controls and patients. Following the 3rd vaccine, the seropositivity rate increased to 80.47% and 100% in AllRD and control groups, p=0.0028, with a significantly higher increase of S1/S2 IgG titers in controls compared with AllIRD patients, 284.09±76.58 vs 219.39±15.65 BAU/ml, p=0.0016. At all-time points, S1/S2 IgG titers were significantly lower in AllRD patients compared with controls (Figure 1).

We further investigated the impact of therapies on the vaccine’s immunogenicity (Figure 1). Glucocorticoids (GC) were associated with a significantly lower seropositivity rate and lower S1/S2 IgG titers compared to controls at all time points. Monotherapy with methotrexate (MTX) was associated with a comparable to controls humoral response at all time points. Anti-cytokine biologics (TNFi, IL6i, IL17i) were associated with an initial high seropositivity rate, similar to controls, followed by a steeper decline at 6 months, 79.82% vs 96.55%, p=0.0001, and restoration of seropositivity after the 3rd vaccine dose in all patients. JAKi were associated with a mildly decreased seropositivity rate after the 2nd vaccine dose and similar to controls response after the 3rd vaccine dose. Abatacept was associated with a reduced immunogenicity after the 2nd vaccine dose, but was restored to 100% seropositivity after the 3rd vaccine dose. Rituximab (RTX) significantly blunted the humoral response at all time points, with a seropositivity rate of 42% after the 2nd vaccine dose, 29% at 6 months, and with increase to 40% after the 3rd vaccine dose. A third of the RTX-treated patients who were seronegative after two vaccine doses, seroconverted after the 3rd dose. The multivariate model for predicting the seropositive response to vaccination found that higher S1/S2 IgG titers after the 2nd vaccine dose was associated with a higher seropositivity rate following the 3rd vaccine dose, OR 1.027 (1.008-1.045), p=0.0027, and that treatment with RTX was associated with a 14.3-fold risk for a negative humoral response, p=0.0001. Cellular immune response, evaluated mainly in RTX treated patients, was preserved prior to and after the 3rd vaccine dose and was similar to controls.

**Conclusion:** Over a six-month period, the two dose BNTb262 vaccination was associated with a similar extent of waning of the humoral immune response in AllRD patients and controls. The 3rd vaccine dose restored the response in all controls and in patients treated with MTX monotherapy, anti-cytokine biologics, abatacept, and JAKi. Treatment with GC and RTX was associated with an impaired humoral response at all time points.

**Acknowledgements:** We would like to thank the statistician Mr Yishai Friedlander and Mr Yoram Neufeld for their valuable assistance.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2074

**OP0178**

**COVID-19 BREAKTHROUGH INFECTIONS IN VACCINATED PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES AND CONTROLS – DATA FROM TWO PROSPECTIVE COHORT STUDIES**

L. Boekel1, E. Stalmans1, L. Wiese2, F. Hooijberg1, Y. Besten1, M. Leeuw1, S. Atiq1, L. Kummer1, K. van Dam1, M. Steenhuis1, Z. van Kempen1, J. Killestein1, W. Lems3, S. Tas1, R. van Vollenhoven1, M. Nurmoohamed1,5, M. Boers1, M. van Ham1, T. Rispens1, T. Kuipers1, F. Eftimov4, G. M. Boers1,6, M. van Ham3, T. Rispens3, T. Kuijpers7, F. Eftimov4, G. N. J. Wolbink1,5 on behalf of The T2B! immunity against SARS-CoV-2 study group, 1Reade, Locatie Dr Jan Van Breemenstraat, Rheumatology, Amsterdam, Netherlands; 2Amsterdam UMC, locatie AMC, Neurology and Neurophysiology, Amsterdam, Netherlands; 3Sanquin Research and Landsteiner Laboratory, Immunopathology, Amsterdam, Netherlands; 4Amsterdam UMC, locatie VUMc, Neurology, Amsterdam, Netherlands; 5Amsterdam Rheumatology and Immunology Center, Rheumatology and Clinical Immunology, Amsterdam, Netherlands; 6Amsterdam UMC, locatie VUMc, Epidemiology and Data Science, Amsterdam, Netherlands; 7Amsterdam UMC, locatie AMC, Pediatric immunology, Amsterdam, Netherlands

**Background:** Concerns have been raised regarding risks of COVID-19 break-through infections in vaccinated patients with immune-mediated inflammatory diseases (IMIDs) treated with immunosuppressants, but data on COVID-19 breakthrough infections in these patients are still scarce.

**Objectives:** The primary objective was to compare the incidence and severity of COVID-19 breakthrough infections with the SARS-CoV-2 delta variant between fully vaccinated IMID patients with immunosuppressants, and controls (IMID patients without immunosuppressants and healthy controls). The secondary objective was to explore determinants of breakthrough infections.

**Methods:** In this study we pooled data collected from two large ongoing prospective multi-center cohort studies (Target to bi (T2Bi) study and ARC study). Clinical data were collected between February and December 2021, using digital questionnaires, standardized electronic case record forms and medical files. Post-vaccination serum samples were analyzed for anti-RBD antibodies (T2Bi study only) and anti-nucleocapsid antibodies to identify asymptomatic breakthrough infections (ARC study only). Logistic regression analyses were used to assess associations with the incidence of breakthrough infections. Multivariable models were adjusted for age, sex, cardiovascular disease, chronic pulmonary disease, obesity and vaccine type.

**Results:** We included 3207 IMID patients with immunosuppressants and 1810 controls (985 IMID patients without immunosuppressants and 825 healthy controls). The incidence of COVID-19 breakthrough infections was comparable between patients with immunosuppressants (5%) and controls (5%). The absence of SARS-CoV-2 IgG antibodies after COVID-19 vaccination was independently associated with an increased incidence of breakthrough infections (P=0.044). The proportion of asymptomatic COVID-19 breakthrough cases that were additionally identified serologically in the ARC cohort was comparable between IMID patients with immunosuppressants and controls; 66 (10%) of 695 patients vs. 64 (10%) of 647 controls. Hospitalization was required in 8 (5%) of 149 IMID patients with immunosuppressants and 5 (6%) of 86 controls with a COVID-19 breakthrough infection. Hospitalized cases were generally older, and had more comorbidities compared with non-hospitalized cases (Table 1).

**Hospitalization rates were significantly higher among IMID patients treated with anti-CD20 therapy compared to IMID patients using any other immunosuppressant (3% [23%] of 13 patients vs. 5% [4%] of 128 patients, P 0.041; Table 1).**

**Table 1. Determinants of the severity of COVID-19 breakthrough infections.**

<table>
<thead>
<tr>
<th>Group - no. (%)</th>
<th>Ambulatory care</th>
<th>Hospitalized</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMID patients with immunosuppressants</td>
<td>141 (64)</td>
<td>(62)</td>
</tr>
<tr>
<td>IMID patients without immunosuppressants</td>
<td>49 (22)</td>
<td>3 (23)</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>32 (14)</td>
<td>2 (15)</td>
</tr>
</tbody>
</table>

**Patient characteristics**

| Age, years – mean (SD) | 51 (14) | 60 (11) |
| Female sex – no. (%) | 143 (64) | 4 (31) |

**Comorbidities – no. (%)**

| Cardiovascular disease | 17 (8) | 5 (39) |
| Chronic pulmonary disease | 17 (8) | 4 (31) |
| Diabetes | 15 (7) | 3 (23) |
| Obesity | 34 (15) | 5 (39) |
| Immunosuppressants– no. (%) | 34 (15) | 5 (39) |

**Conclusion:** The incidence of COVID-19 breakthrough infections in IMID patients with immunosuppressants was comparable to controls, and infections were mostly mild. Anti-CD20 therapy might increase patients’ susceptibility to severe COVID-19 breakthrough infections, but traditional risk factors also continued to have a critical contribution to the disease course of COVID-19. Therefore, we argue that most patients with IMIDs should not necessarily be seen as a risk group for severe COVID-19, and that integrating other risk factors should become standard practice when discussing treatment options, COVID-19 vaccination, and adherence to infection prevention measures with patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4704
### Objectives:
To investigate the clinical profile of SARS-CoV-2 breakthrough infections among double and triple vaccinated patients with IRD.

### Methods:
Data from the German COVID-19-IRD registry, collected by treating rheumatologists between February 2021 and January 2022 were analysed.

Patients double or triple vaccinated against COVID-19 ≥14 days prior to proven SARS-CoV-2 infection were identified, and type of IRD, vaccine, immunomodulation, comorbidities and outcome of the infection were compared with 737 unvaccinated IRD-patients with COVID-19.

### Results:
In total, 271 cases of breakthrough infections were reported, 250 patients (91%) had received two doses of vaccines, 21 (9%) patients three. More than 70% of the patients received Pfizer/Biontech vaccine for the first, second and third vaccination. The median time from second/third vaccine dose to infection was 148 days (range 14-302) days. Most of the patients were diagnosed with inflammatory joint diseases (Table 1). Most of the patients were treated with methotrexate (Table 1). The use of Januskinase inhibitors(i) was more frequently reported in double vaccinated patients (10.4% vs 4.8%), whereas tumor necrosis (TNF)i were reported more often in triple vaccinated patients (33.3% vs 22.8%). Hospitalisation rate was higher in unvaccinated IRD-patients than in vaccinated ones, while mortality rate was similar in unvaccinated and double vaccinated patients. Although the rate of comorbidities and median age were higher in triple-vaccinated patients, infected patients showed a lower rate of hospitalisation, neither COVID-19 related complications, nor the need of oxygen treatment or death.

### Conclusion:
In this cohort of triple-vaccinated IRD patients no fatal courses and no COVID-19 related complications were reported, although median age and rate of comorbidities were higher compared to double-vaccinated and unvaccinated patients. These results support the general recommendations to reduce the risk of severe COVID-19 disease by administering three doses of vaccine, especially in patients with older age, presence of comorbidities, and on immunomodulatory treatment.

### Disclosure of Interests:
None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3386

---

**Table 1: Profile of vaccinated IRD patients**

<table>
<thead>
<tr>
<th></th>
<th>Number (737)</th>
<th>%</th>
<th>Number (250)</th>
<th>%</th>
<th>Number (21)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>478</td>
<td>64.9</td>
<td>158</td>
<td>63.2</td>
<td>13</td>
<td>61.9</td>
</tr>
<tr>
<td>BMI</td>
<td>26.8 (17-53)</td>
<td></td>
<td>26.7 (17-55)</td>
<td></td>
<td>25.4 (18-41)</td>
<td></td>
</tr>
<tr>
<td><strong>Inflammatory rheumatic disease (multiple selections possible)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory joint diseases</td>
<td>561</td>
<td>75.9</td>
<td>186</td>
<td>74.4</td>
<td>16</td>
<td>76.2</td>
</tr>
<tr>
<td>Connective tissue diseases</td>
<td>101</td>
<td>12.8</td>
<td>30</td>
<td>12</td>
<td>2</td>
<td>9.6</td>
</tr>
<tr>
<td>Vasculitis</td>
<td>71</td>
<td>9.6</td>
<td>22</td>
<td>8.8</td>
<td>3</td>
<td>14.3</td>
</tr>
<tr>
<td>Other IRD</td>
<td>63</td>
<td>8.5</td>
<td>29</td>
<td>11.6</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td><strong>Immunomodulation (multiple selections possible)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid</td>
<td>212</td>
<td>28.8</td>
<td>67</td>
<td>26.8</td>
<td>5</td>
<td>23.8</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>270</td>
<td>36.6</td>
<td>90</td>
<td>36</td>
<td>8</td>
<td>38.1</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>19</td>
<td>2.6</td>
<td>7</td>
<td>2.8</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td>3</td>
<td>0.4</td>
<td>1</td>
<td>0.4</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>50</td>
<td>6.8</td>
<td>7</td>
<td>2.8</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>72</td>
<td>10.7</td>
<td>23</td>
<td>9.2</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>20</td>
<td>2.7</td>
<td>9</td>
<td>3.6</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>JAKI</td>
<td>54</td>
<td>7.3</td>
<td>26</td>
<td>10.4</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td>TNF</td>
<td>158</td>
<td>21.4</td>
<td>57</td>
<td>22.8</td>
<td>7</td>
<td>33.3</td>
</tr>
<tr>
<td>Abatacept</td>
<td>9</td>
<td>1.2</td>
<td>3</td>
<td>1.2</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Rituximab</td>
<td>21</td>
<td>2.8</td>
<td>11</td>
<td>4.4</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td>Other biologics</td>
<td>59</td>
<td>7.9</td>
<td>32</td>
<td>12.8</td>
<td>2</td>
<td>9.6</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>15</td>
<td>2</td>
<td>4</td>
<td>1.6</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Immunoglobulins</td>
<td>2</td>
<td>0.3</td>
<td>1</td>
<td>0.4</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Apremilast</td>
<td>4</td>
<td>0.5</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>1</td>
<td>0.1</td>
<td>1</td>
<td>0.4</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>No immunomodulation</td>
<td>74</td>
<td>10</td>
<td>22</td>
<td>8.8</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td>No/low disease activity</td>
<td>625</td>
<td>84.8</td>
<td>223</td>
<td>85.2</td>
<td>18</td>
<td>85.7</td>
</tr>
<tr>
<td>Moderate/high disease activity</td>
<td>102</td>
<td>13.8</td>
<td>27</td>
<td>10.8</td>
<td>3</td>
<td>14.3</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular diseases</td>
<td>329</td>
<td>44.6</td>
<td>130</td>
<td>52</td>
<td>13</td>
<td>61.9</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>76</td>
<td>10.3</td>
<td>25</td>
<td>10</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>43</td>
<td>5.8</td>
<td>21</td>
<td>8.4</td>
<td>2</td>
<td>9.5</td>
</tr>
<tr>
<td>Chronic renal failure</td>
<td>40</td>
<td>5.4</td>
<td>16</td>
<td>6.4</td>
<td>4</td>
<td>19</td>
</tr>
<tr>
<td>Cancer/history of cancer</td>
<td>15</td>
<td>2.0</td>
<td>10</td>
<td>4</td>
<td>3</td>
<td>14.3</td>
</tr>
<tr>
<td>COPD</td>
<td>25</td>
<td>3.4</td>
<td>10</td>
<td>4</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>ILD</td>
<td>16</td>
<td>2.2</td>
<td>7</td>
<td>2.8</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>7</td>
<td>0.9</td>
<td>1</td>
<td>0.4</td>
<td>1</td>
<td>4.8</td>
</tr>
<tr>
<td>No comorbidity</td>
<td>254</td>
<td>34.5</td>
<td>97</td>
<td>38.8</td>
<td>5</td>
<td>23.8</td>
</tr>
<tr>
<td><strong>Complications due to COVID-19</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalisation</td>
<td>135</td>
<td>18.3</td>
<td>29</td>
<td>11.6</td>
<td>2</td>
<td>9.5</td>
</tr>
<tr>
<td>Oxygen treatment</td>
<td>114</td>
<td>15.5</td>
<td>24</td>
<td>9.6</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Invasive ventilation</td>
<td>25</td>
<td>3.4</td>
<td>9</td>
<td>3.6</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Death</td>
<td>16</td>
<td>2.2</td>
<td>7</td>
<td>2.8</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>
Vessels glowing in the dark

OP0180
EFFECT OF AVACOPAN ON RELAPSE RATES AND RELAPSE-FREE TIME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS, RESULTS OF THE PHASE 3 ADVOCATE STUDY

P.A. Merkel1, H. Yue2, E. deGoma2, P. Bekker2, D. Jayne3. 1University of Pennsylvania, Division of Rheumatology, Philadelphia, United States of America; 2ChemoCentryx, Clinical, San Carlos, United States of America; 3University of Cambridge, Department of Medicine, Cambridge, United Kingdom

Background: For patients with ANCA-associated vasculitis, both failure to achieve remission and relapse after achieving remission are associated with worse long-term outcomes. Avacopan, an oral selective inhibitor of the C5a receptor, is approved for the treatment of ANCA-associated vasculitis. The phase 3 ADVOCATE study tested daily avacopan as a substitute for a standard oral glucocorticoid taper regimen. At week 26, the avacopan group achieved a remission rate (72.3%) comparable to the prednisone group (70.1%) and superior sustained remission at Week 52 (65.7% avacopan vs. 54.9% prednisone groups, respectively [1]). The median (mean) total glucocorticoid dose from all sources was 400 mg (1349 mg) in the avacopan group versus 2939 mg (3655 mg) in the prednisone group, representing 86% (83%) lower glucocorticoid exposure in the avacopan group. Compared with the prednisone group, the avacopan group showed a reduction in the proportion of patients who relapsed after achieving remission and, among patients who achieved remission, a longer time to relapse (1).

Objectives: To further characterize efficacy, additional post-hoc analyses compared the avacopan and prednisone groups regarding i) failure to achieve remission and ii) relapse after achieving remission.

Methods: ADVOCATE, a phase 3, randomized, double-blind, controlled trial in 330 patients, evaluated the efficacy and safety of avacopan. Patients with ANCA-associated vasculitis (new-onset or relapsing disease) were randomized to receive avacopan 30 mg twice daily, or a standard 20-week oral glucocorticoid taper regimen. At week 26, the avacopan group achieved a remission rate (72.3%) comparable to the prednisone group (70.1%) and superior sustained remission at Week 52 (65.7% avacopan vs. 54.9% prednisone groups, respectively [1]). The median (mean) total glucocorticoid dose from all sources was 400 mg (1349 mg) in the avacopan group versus 2939 mg (3655 mg) in the prednisone group, representing 86% (83%) lower glucocorticoid exposure in the avacopan group. Compared with the prednisone group, the avacopan group showed a reduction in the proportion of patients who relapsed after achieving remission and, among patients who achieved remission, a longer time to relapse (1).

Discussion of Interests: Peter A. Merkel Consultant of: AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, CSL Behring, Dynacure, EMDSerono, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Immagene, InfraRx, Janssen, Kiniksa, Kyverna, Magenta, MiroBio, Neutrolis, Novartis, Pfizer, Regeneron, Sparrow, Takeda, Talaris.

Conclusion: In the phase 3 ADVOCATE study of ANCA-associated vasculitis, more patients in the avacopan group compared to the prednisone group achieved remission, and fewer in the avacopan group relapsed after achieving remission. Patients receiving avacopan had a longer relapse-free time compared to the prednisone group. These post-hoc sensitivity analyses provide additional evidence of the efficacy of avacopan for the treatment of ANCA-associated vasculitis.

REFERENCES:

Background: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly characterized by proximal muscular pain and stiffness. Although PMR is associated with systemic inflammation, prolonged glucocorticoid therapy and probably cardiovascular diseases, previous studies have not shown increased mortality. However, the number of studies is limited.

Objectives: The aim of this study was to determine whether PMR is associated with increased mortality in a large PMR cohort followed prospectively for a period of 35 years.

Methods: All patients diagnosed with PMR according to the criteria of Bird between 1987 and 1997 in the county of Aust-Agder, Southern Norway, were identified. Further details about the inclusion process have been published previously [1]. Patients in the prospective part of this study were followed until death or December 31, 2021. Standard mortality ratios (SMR) were calculated using population data (age- and gender-matched) from Statistics Norway as reference. Difference in survival between men and women was estimated using the Kaplan-Meier method. The study was approved by the regional ethics committee.

Results: A total of 296 patients were included. Among these were 200 (67.6%) females, and the mean age at diagnosis was 71.9 (SD 8.4). The vast majority, 277 patients (93.6%), were deceased at the censoring date of December 31, 2021. Mean observation time for all patients was 13.8 years (95% CI 12.8-14.7). The overall SMR was 1.05 (95% CI 0.93-1.18), for females 1.14 (95% CI 0.99-1.31) and for men 0.91 (95% CI 0.73-1.11). SMRs and mean survival times are presented in Table 1. The Kaplan-Meier survival curve showed no pronounced difference in survival between men and women (Figure 1).

Table 1. Standard Mortality Ratios.

<table>
<thead>
<tr>
<th>Age at diagnosis</th>
<th>Observed</th>
<th>Expected</th>
<th>SMR 95% CI</th>
<th>Mean survival time 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;60</td>
<td>31</td>
<td>67.8</td>
<td>0.46</td>
<td>0.28-0.76; 76.3</td>
</tr>
<tr>
<td>60-69</td>
<td>91</td>
<td>162.6</td>
<td>0.56</td>
<td>0.39-0.79; 77.9</td>
</tr>
<tr>
<td>70-79</td>
<td>123</td>
<td>139.4</td>
<td>0.91</td>
<td>0.71-1.13; 81.1</td>
</tr>
<tr>
<td>≥80</td>
<td>51</td>
<td>380.3</td>
<td>1.33</td>
<td>0.9-1.87; 69.4</td>
</tr>
</tbody>
</table>

Men
2 years 185 9 8.29 1.09 0.53-1.99
5 years 436 17 2.13 0.81 0.49-1.27
10 years 788 36 4.36 0.82 0.59-1.13
25 years 1272 83 88.57 0.94 0.75-1.16

Women
2 years 392 11 12.76 0.86 0.45-1.50
5 years 934 32 35.80 0.89 0.62-1.25
10 years 1678 68 74.03 0.92 0.72-1.16
25 years 2687 172 156.21 1.10 0.95-1.28

*Years*: refer to calculated survival time from date of diagnosis; *Observed*: number of deaths in the PMR cohort; *Expected*: number of expected deaths in age-matched, sex-matched, and year-matched background Norwegian Population.

Conclusion: To our knowledge, this is the first prospective study following a large PMR cohort from diagnosis to death. In women, overall mortality (SMR) was increased compared to the general Norwegian population. This tendency to increased mortality in women was observed during the last decades of the study period. Furthermore, increased SMR was observed in patients aged <60 at time of diagnosis and in men the first 2 years after diagnosis, although with wide confidence intervals due to the limited number of deaths in these subsets.

REFERENCES:

Disclosure of Interests: None declared


**OP0182**

**SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAN TRIAL**

N. Venhoff[1], W. A. Schmidt[2], R. Bergner[3], J. Rech[3], L. Unger[3], H. P. Tony[4], M. Mendelsson[5], C. Sieder[6], M. Maricots[7], J. Thiel[8], Vasculitis Center Freiburg, Medical Center - University of Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; Immunmanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany; Klinikum der Stadt Ludwigshafen, Medizinische Klinik A, Ludwigshafen, Germany; Friedrich-Alexander Universität (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Germany; Städtisches Klinikum Dresden, Medical Department 1, Dresden, Germany; Rheumatology and Clinical Immunology Oberduerrbachtstr, Department of Medicine 2, Wuerzburg, Germany; Novartis Pharmaceuticals Corporation, Rheumatology, New Jersey, United States of America; Novartis Pharma GmbH, Rheumatology, Nuernberg, Germany; Medical University of Graz, Division of Rheumatology and Immunology, Department of Internal Medicine, Graz, Austria

Background: Little is known about glucocorticoid-sparing agents in giant cell arteritis (GCA) except for IL-6 inhibition. Secukinumab (SEC) has shown significant improvements in the signs and symptoms of IL-17A driven medical conditions such as plaque psoriasis, psoriatic arthritides, and axial spondyloarthritis. It has a favourable long-term safety profile.[1,2] Objectives: TITAN is the first randomised controlled trial investigating the potential efficacy, safety, and tolerability of SEC in GCA patients (pts).

Methods: This phase 2, randomised, double-blind, placebo (PBO) controlled, multicentre, proof-of-concept trial enrolled pts (aged ≥50 years) with new onset (diagnosed within 6 weeks (wks) of baseline) or relapsing (diagnosed >6 wks from baseline) GCA, naïve to biological therapy. Pts were randomised (1:1 to SEC 300 mg or PBO initially administered wks 1 and 4 wks thereafter). The efficacy endpoint was 52 wks of continuous treatment. The primary endpoint was a Bayesian analysis of the proportion of pts with sustained remission until Wk 28. The secondary endpoints included time to first GCA flare after baseline, and proportion of pts with withdrawal due to adverse events (AEs) during the study period.

Results: Out of 52 randomised pts (SEC n=27; PBO n=25), 71.2% (n=37) completed study treatment (SEC, 81.5%; PBO, 60.0%). Overall, 42 (80.8%) pts had new onset GCA and 10 (19.2%) pts had relapsing GCA at baseline. Proportion (posterior median with 95% credibility interval) of SEC pts in sustained remission until Wk 28 was higher with SEC, 70.1% (51.6%-84.9%), than with PBO, 20.3% (12.4%-30.0%); odds ratio (posterior median with 95% credibility interval), 9.31 (3.54-26.29) (Table 1). Until Wk 52, proportion (95% confidence interval) of GCA pts with sustained remission was 59.3% (38.8%-77.6%) in SEC group and 8.0% (1.0%-26.0%) in PBO group (Table 1). Median (95% credible interval) time to first GCA flare after baseline was not reached for GCA pts treated with SEC and was 197.0 (101.0-280.0) days for PBO (Figure 1). Overall, treatment-emergent adverse events (AEs) occurred in 98.1% (SEC vs PBO, 100.0% vs 96.0%). Two pts in each SEC and PBO groups had AEs that led to study drug discontinuation and 1 pt in each group had AEs that led to death (not treatment-related). There were no new or unexpected safety signals identified with SEC treatment.

Table 1. Proportion of GCA patients with sustained remission (Full analysis set) until Week 28 and 52

<table>
<thead>
<tr>
<th>Proportion of pts</th>
<th>Secukinumab</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N=27)</td>
<td>(N=25)</td>
<td></td>
</tr>
<tr>
<td>Median percentage (95% credibility interval), Wk 28</td>
<td>70.1% (51.6%, 84.9%)</td>
<td>20.3% (12.4%, 30.0%)</td>
</tr>
<tr>
<td>Percentage (95% confidence interval), Wk 52</td>
<td>59.3% (38.8%, 77.6%)</td>
<td>8.0% (1.0%, 26.0%)</td>
</tr>
</tbody>
</table>

The full analysis set comprises all pts to whom study treatment has been assigned by randomisation and who received at least one dose of randomised study treatment (secukinumab or placebo). GCA, giant cell arteritis; N, number of pts in each treatment group in the full analysis set, pts, patients; Wk, Week.

*Figure 1. Kaplan-Meier survival curve.*
Conclusion: SEC demonstrated a higher sustained remission rate and longer time to first GCA flare vs PBO through 52 wks in pts with GCA. This proof-of-concept phase 2 study supports further development of SEC as a potential treat-
ment in combination with 26 wk glucocorticoid taper for pts with GCA.

REFERENCES:


Disclosure of Interests:

DOI: 10.1136/annrheumdis-2022-eular.806

OP0183 VALIDITY OF THE EULAR RECOMMENDATIONS ON THE USE OF ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS

E. Fernández-Fernández1, I. Monjo1, D. Peiteado1, A. Balisa1, E. de Miguel1, 1La Paz University Hospital, Rheumatology, Madrid, Spain

Background: The EULAR recommendations for the use of imaging in large ves-
sel vasculitides establish that an imaging test supported by clinical pre-test proba-
bility (PTP) is sufficient for the diagnosis of giant cell arteritis (GCA).

Objectives: To determine the validity of the EULAR recommendations on the use of Colour doppler ultrasound (CDUS) in GCA after calculating the PTP based on the Southern pre-test probability score (SPTPS).

Methods: We collected data of all patients referred to our fast-track clinic between 2016 and 2020. The SPTPS was calculated and classified as low (LR), intermediate (IR) and high risk (HR) according to the values obtained by its authors, <9, 9-12 and >12, respectively. All patients underwent a CDUS of the temporal arteries with their common, parietal and frontal branches, and the most also axillary (86.5%), subclavian and carotid arteries. Other diagnostic tests were performed when deemed necessary by the responsible physician. TAB was performed in 34 patients (11.4%), PET-CT in 48 (16.2%) and other imaging tests such as AngioMRI or AngioCT in 8 (2.7%). The gold standard diagnosis was made according to the physician's criteria after at least nine months of follow-up.

Results: Of the 297 referred patients, 97 (32.7%) were diagnosed with GCA. The SPTPS area under the ROC curve was 0.787. The LR category included 105 patients (35.4%), of which 10 (8.5%) had GCA. The LR category included 125 patients (42.1%), 40 with GCA (32%) and 85 without (68%). The HR category included 67 patients (22.5%), 47 with GCA (70.1%). In 4 of the 97 patients with GCA, the CDUS was negative and the diagnosis was confirmed with PET-CT. On the other hand, 6 of the 200 included patients without GCA (3%) had a false positive result of CDUS.

There were 93 patients classified as LR with negative CDUS, and 1 of them had a final clinical diagnosis of GCA. Of the 46 patients classified as HR with positive CDUS, 1 was a false positive diagnosis of GCA. And, within the IR group, of the 84 patients with negative CDUS one had a final GCA diagnosis and of those with positive CDUS 2 were not GCA (Figure 1). Therefore, the combined use of SPTPS + CDUS only misclassified 5/297 cases (<2%).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.979

OP0184 PREVALENCE OF SUBCLINICAL GIANT CELL ARTERITIS IN PATIENTS WITH POLYMyalgia Rheumatica

E. de Miguel1, P. Macchioni2, E. Conticini3, C. Campochiaro4, R. Karalilova5, S. Monti6, C. Ponte7, G. Klinowski8, I. Monjo9, P. Falsettì9, A. Tomelleri4, Z. Batalova9, A. Hocevar9 on behalf of GCA/PMR study group, 1Hospital Universitario La Paz, Rheumatology, Madrid, Spain; 2Department of Rheumatology, IRCCS-S.Maria Nuova, Rheumatology, Reggio Emilia, Italy; 3Department of Medicine, Surgery and Neurosciences, University of Siena, Rheumatology, Siena, Italy; 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnitRAR), San Raffaele Scientific Institute, Rheumatology, Milan, Italy; 5Medical University of Plovdiv, University Hospital Kaspela, Rheumatology, Plovdiv, Bulgaria; 6IRCCS Policlinico S Matteo Fondazione, University of Pavia, Rheumatology, Pavia, Italy; 7Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte EPE, Rheumatology, Lisboa, Portugal; 8Department of Rheumatology, IRCCS-S.Maria Nuova, Rheumatology, Emilia Romagna, Italy; 9University Medical Centre Ljubljana, Rheumatology, Ljubljana, Slovenia

Background: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of patients with GCA, however the prevalence of subclinical GCA in PMR has not yet been widely studied.

Objectives: The aim of our multicenter, prospective study was to determine the prevalence of subclinical GCA in newly diagnosed PMR, using vascular ultra-
sound (US) as a diagnostic tool.
Methods: Eight European centers participated in the study. The studied cohort represented consecutive newly diagnosed patients with PMR who fulfilled 2012 EULAR/ACR Provisional Classification Criteria for Polymyalgia Rheumatica without symptoms or signs suggestive for GCA. All patients underwent ultrasound (US) of both hips and shoulders, as well as four bilateral arterial territories (i.e. temporal, common carotid, subclavian and axillary arteries). Patients with positive halo signs were considered to have subclival GCA. An inima-metal thickness ≥0.34 mm for frontal and parietal TA, 0.42mm for common TA, and ≥1 mm for common carotid, axillary and subclavian arteries for positive result. Clinical demographic and laboratory characteristics of the PMR pure group were compared with the PMR/GCA patient group.

Results: A total of 258 patients were included, 137 (53.1%) females with a mean age of 73±8.4 years. Table 1 shows the main differences in PMR patients with and without subclinical GCA. The only statistical significant difference between the two groups was the higher prevalence of morning stiffness > 40 minutes in the pure PMR group (p=0.05). A halo sign was found on least one of the examined arteries in 56/258 patients (21.7%). The different subtypes of vessel involvement were available in 216 cases. Data compatible with the diagnosis of GCA was found in 41 cases (19%): 10 (24.3%) had only temporal artery involvement (“cranial” GCA), 27 (65.8%) had a mixed form with both cranial and extra-cranial arteries in 56/258 patients (21.7%).

Table 1. Clinical and demographic characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PMR study</th>
<th>PMR without GCA</th>
<th>PMR with GCA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>73.05 (6.43)</td>
<td>72.91 ± 8.36</td>
<td>73.52 ± 8.62</td>
</tr>
<tr>
<td>Sex (female/ male)</td>
<td>137/21</td>
<td>105/95</td>
<td>32/38</td>
</tr>
<tr>
<td>Bilateral shoulder pain</td>
<td>249/162</td>
<td>199/97</td>
<td>50/64</td>
</tr>
<tr>
<td>Hip pain</td>
<td>209/82</td>
<td>163/80</td>
<td>46/82.2</td>
</tr>
<tr>
<td>Neck pain</td>
<td>158/31</td>
<td>125/33</td>
<td>33/53.7</td>
</tr>
<tr>
<td>Morning stiffness*</td>
<td>227/86</td>
<td>192/90</td>
<td>45/80.4</td>
</tr>
<tr>
<td>Weight/loss</td>
<td>68/27</td>
<td>49/24</td>
<td>70/53.3</td>
</tr>
<tr>
<td>Fever</td>
<td>30/11</td>
<td>20/8.0</td>
<td>15/53.7</td>
</tr>
<tr>
<td>Periphereal arthritis</td>
<td>72/29</td>
<td>90/29</td>
<td>12/23.9</td>
</tr>
<tr>
<td>Pitting edema</td>
<td>92/13</td>
<td>39/13</td>
<td>10/31.6</td>
</tr>
<tr>
<td>Duration symptoms (weeks)</td>
<td>8.2/0.67</td>
<td>7.8/0.17</td>
<td>7.7/0.85</td>
</tr>
<tr>
<td>C-Reactive protein (mg/L)</td>
<td>5.1/0.47</td>
<td>4.1/0.34</td>
<td>5.7/0.63</td>
</tr>
<tr>
<td>ESR (mm/hour)</td>
<td>56.8/2.66</td>
<td>58.9/2.47</td>
<td>65.7/2.75</td>
</tr>
</tbody>
</table>

Figure 1. Subtypes of subclinical GCA in PMR in 216 patients with cranial and extra-cranial examination

Conclusion: One fifth of PMR patients without symptoms or signs of GCA have ultrasound findings consistent with the diagnosis of GCA. Subclinical GCA in PMR shows a predilection for extra-cranial artery involvement.

REFERENCES:

Acknowledgements: To the GCA/PMR study group

Figure 1. Clinical Trial Schema

Results: Between 11/2018 and 11/2020 we enrolled 30 patients (mean age 74 years, 60% females, 50% new-onset disease, 77% temporal artery biopsy-proven, 47% imaging-proven). The mean ESR and C-reactive protein (CRP) at screening were 45 mm/hour and 48 mg/L respectively. The initial prednisone dose was 60 mg (n = 7), 50 mg (n = 1), 40 mg (n = 7), 30 mg (n = 6) and 20 mg (n = 9). All patients entered remission within 4 weeks of baseline. The primary endpoint was achieved by 23 (77%) patients (Table 1). The mean (SD) cumulative prednisone dose in these 23 patients was 1052 (390) mg. After a mean period of 16 weeks, 7 (23%) patients relapsed (Table 1). All relapses but one occurred after the completion of the study prednisone taper. Overall, 6 of the 7 patients with relapse received a second prednisone taper over 8 weeks. Of these 6 patients, 4 achieved and maintained remission for the remainder of the trial period, and 2 withdrew from the study after having a second relapse. One patient with relapse received a second prednisone taper over 26 weeks and stayed in remission until the end of the study. The mean (SD) cumulative prednisone dose in the 7 patients with relapse was 1883 (899) mg (Table 1). Overall, 4 (13%) participants developed a serious adverse event (Table 1). No cases of ischemia-related visual symptoms including permanent vision loss occurred during the study.

Table 1. Efficacy and Safety Outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>GCA patients (n = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
</tr>
<tr>
<td>Sustained, prednisone-free remission by week 52</td>
<td>23.0 (76.7)</td>
</tr>
<tr>
<td>Cumulative prednisone dose (mg) at week 52, mean (SD)</td>
<td>1051.5 (390.3)</td>
</tr>
<tr>
<td>Relapse</td>
<td>70 (23.3)</td>
</tr>
<tr>
<td>Time to relapse, weeks: mean (SD)</td>
<td>15.8 (14.7)</td>
</tr>
<tr>
<td>Prednisone dose (mg/day) at relapse, mean (SD)</td>
<td>2.1 (5.2)</td>
</tr>
<tr>
<td>Cumulative prednisone dose (mg), mean (SD)</td>
<td>1883.1 (699.2)</td>
</tr>
<tr>
<td>Clinical manifestations at relapse</td>
<td></td>
</tr>
<tr>
<td>Cranial symptoms</td>
<td>4 out of 7 patients</td>
</tr>
<tr>
<td>Ischemic visual symptoms</td>
<td>0 out of 7 patients</td>
</tr>
<tr>
<td>PMR symptoms</td>
<td>4 out of 7 patients</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>4.0 (13.3)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>1</td>
</tr>
<tr>
<td>COVID-19</td>
<td>1</td>
</tr>
<tr>
<td>Fragility fracture</td>
<td>1</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>1</td>
</tr>
</tbody>
</table>

Values represent number and (%) unless otherwise specified. SD, standard deviation; PMR, polymyalgia rheumatica

Conclusion: These results suggest that 12 months of TCZ in combination with 8 weeks of prednisone could be efficacious for inducing and maintaining disease remission in patients with GCA. Confirmation of these findings in a randomized controlled trial is required.

Disclosure of Interests: Sebastian Unizony Consultant of: Kiniksa, Sanofi, Janssen, GSK, Grant/research support from: Janssen, Genentech, Mark Matza: None declared, Adam Jarvie: None declared, Ana Fernandes: None declared, John H. Stone Consultant of: Roche/Genentech, Grant/research support from: Roche/Genentech

SENSITIVITY TO CHANGE OF DIFFERENT ULTRASOUND SCORES IN A PROSPECTIVE FOLLOW-UP OF NEW-ONSET TREATMENT-NAÏVE GCA PATIENTS.

B. D. Nielsen1,2,3, P. Therkildsen2,3, K. Keller2,3, L. C. Gormsen4, I. Hansen2,3, E. M. Hauge2,3, 1The Regional Hospital Horsens, Department of Medicine, Horsens, Denmark; 2Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 3Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; 4Aarhus University Hospital, Department of Nuclear Medicine and PET Centre, Aarhus, Denmark

Background: The role of ultrasound (US) for monitoring giant cell arteritis (GCA) is not clarified. Follow-up assessment of number of halos (halo count) and different quantitative scores based on intima media complex (IMC) measurement of halos, have demonstrated potential to show sensitivity to change (STC)1. Including IMC of normalized arteries in such scores may reduce the risk of missing new arteritic lesions and assessment bias towards a response. We aimed to evaluate US scores based on halo features and scores based on IMT measurements of all assessed arteries.

Objectives: To compare different US score’s 1) STC after institution of treatment and 2) correlation with disease activity.

Methods: In a prospective cohort of new-onset GCA patient, pre-treatment diagnostic evaluation including US and PET/CT and subsequently temporal artery biopsy (TAB) was performed per protocol. All patients were started on 60 mg of prednisolone and followed a routine tapering. Follow-up visits including clinical evaluation, blood tests, US, the physician’s and patient’s global NRS (0-10) were performed after 8 weeks, 24 weeks and in a subgroup (n=24) at 15 months. US of temporal, carotid and axillary arteries included assessment of halo and IMC measurement in all arteries.

For each visit, max IMC, max halo IMC, sum IMC, sum halo IMC, mean IMC and halo count were calculated for all and for temporal (TA) and large vessels (LV) separately. Accordingly, halo IMC scores only included positive arteries whereas other IMC scores included all arteries assessed.

The change from baseline was assessed by Student’s t-test. Standard response means (SRM=mean(visit-baseline)/SE Δ) were computed for each timepoint as STC estimates. Correlation with disease activity markers was assessed by Spearman’s correlation. A p<0.05 was considered statistically significant.

Results: In total 47 patients were included (60% women, mean (CI) age 67 (62-69) years, mean (CI) CRP 75 (63-89)). Baseline US was positive(+) in 94% (72% TA+, 72% LV+), PET/CT in 96% (77% cranial arteries, 85% large vessel vasculitis) and TAB+ in 72% of patients. All patients completed the per protocol planned follow-up visits. Two patients experienced a relapse at week 8 and 10 patients at week 24. All US outcomes improved during follow-up and was apparent by week 8 (Table 1) and forward. However, only scores including TA consistently showed statistically significant change from baseline to follow-up. In accordance the magnitude of change as expressed by SRM was large in TA, whereas SRM in LV was small (Figure 1).

All TA based US scores showed significant moderate-strong correlation with disease activity markers (CRP, patient and physician global NRS). Some LV based US scored showed weak correlation with CRP but otherwise did not correlate with clinical disease activity.

Table 1.

Table: US score changes during follow-up

<table>
<thead>
<tr>
<th>Baseline (IQR)</th>
<th>Δw8 (SE)</th>
<th>Δw24 (SE)</th>
<th>Δm15 (SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halo count TA</td>
<td>2 (0-4)</td>
<td>-1.68 (.28)</td>
<td>-1.70 (.30)</td>
</tr>
<tr>
<td>LV</td>
<td>1 (0-2)</td>
<td>-0.04 (.11)</td>
<td>0.00 (.11)</td>
</tr>
<tr>
<td>Sum IMC TA</td>
<td>4 (2-6)</td>
<td>-1.72 (.30)</td>
<td>-1.70 (.34)</td>
</tr>
<tr>
<td>LV</td>
<td>0.8 (0-1.8)</td>
<td>-0.72 (.08)</td>
<td>-0.69 (.11)</td>
</tr>
<tr>
<td>Sum halo IMC TA</td>
<td>1.9 (1.6-2.5)</td>
<td>-0.90 (.14)</td>
<td>-0.81 (.15)</td>
</tr>
<tr>
<td>LV</td>
<td>1.5 (0-2.8)</td>
<td>-0.33 (.12)</td>
<td>-0.13 (.11)</td>
</tr>
<tr>
<td>Max IMC TA</td>
<td>2.6 (1.6-4.4)</td>
<td>-1.05 (.14)</td>
<td>-0.81 (.15)</td>
</tr>
<tr>
<td>LV</td>
<td>3.5 (2.8-4.0)</td>
<td>-0.33 (.17)</td>
<td>-0.15 (.14)</td>
</tr>
<tr>
<td>Max halo IMC TA</td>
<td>5.5 (4.6-6.3)</td>
<td>-1.23 (.24)</td>
<td>-1.04 (.24)</td>
</tr>
<tr>
<td>LV</td>
<td>1.9 (1.6-2.5)</td>
<td>-0.90 (.14)</td>
<td>-0.81 (.15)</td>
</tr>
<tr>
<td>Mean IMC TA</td>
<td>0.5 (0-4.0)</td>
<td>-0.17 (.03)</td>
<td>-0.14 (.03)</td>
</tr>
<tr>
<td>LV</td>
<td>1.2 (0.9-1.6)</td>
<td>-0.16 (.06)</td>
<td>-0.04 (.05)</td>
</tr>
<tr>
<td>Max halo IMC TA</td>
<td>0.5 (0-0.6)</td>
<td>-0.29 (.04)</td>
<td>-0.26 (.05)</td>
</tr>
<tr>
<td>LV</td>
<td>1.2 (0-1.6)</td>
<td>-0.27 (.09)</td>
<td>-0.09 (.08)</td>
</tr>
<tr>
<td>Mean IMC TA</td>
<td>0.32 (0.27-0.43)</td>
<td>-0.11 (.01)</td>
<td>-0.10 (.02)</td>
</tr>
<tr>
<td>LV</td>
<td>0.88 (0.7-1.03)</td>
<td>-0.9 (0.3)</td>
<td>-0.04 (.03)</td>
</tr>
</tbody>
</table>

Baseline medians, Δ mean difference from baseline. Bold indicates p<0.05.

Conclusion: STC was maintained in US scores that included all assessed arteries hereby reducing potential assessment bias. These findings confirm US as a potential tool for monitoring treatment response.

REFERENCES:
2 Seitz L, et al. Rheumatology 2021

Acknowledgements: The authors would like to thank Morten Frydenberg for statistical support.

Disclosure of Interests: Berit Dalsgaard Nielsen Speakers bureau: Roche, Paid instructor for: Roche, Consultant of: Sanofi, Philip Therkildsen: None declared, Kresten Keller: None declared, Lars Christian Gormsen: None declared, Ib Hansen: None declared, Ellen-Margrethe Hauge Speakers bureau: AbbVie, Sanofi, Sobi, MSD, UCB, Consultant of: AbbVie, Sanofi, Sobi, MSD, UCB, Grant/research support from: funding to Aarhus University Hospital from Roche, Novartis, Abbvie DOI: 10.1136/annrheumdis-2022-eular.2283
Methods: Patients with a diagnosis of TAK, attending our clinics between Jan 2000 and May 2019 were identified. Those who satisfied either ACR or Sharp’s classification or ULEAR PRINTO PRES criteria and/or had angiographic evidence of Takayasu’s arteritis with a minimum 2 follow up visits were included. Patients who received upfront biologics were excluded. The patients were matched for parameters statistically different among three groups using propensity score analysis. Clinical details at the index visit defined as the time of initia- tion of first IS and follow up visits were prospectively recorded and retrospectively noted from electronic medical records. The primary outcomes were attainment of complete remission and relapses. Disease activity was assessed by Indian Takayasu arteritis score (ITAS), C-reactive protein and angiograms. Relapse was defined as ITAS-Δ (CRP) ≥ 2 and/or progression in angiograms and/or escalation of steroid dose and/or switching of IS due to active disease. The baseline variables of patients receiving AZA, MMF and MTX were compared using chi square test or Mann Whitney U test. The comparative efficacy of IS to induce complete remission was calculated using logistic regression and presented as odds ratio (95% CI). The cumulative risk of relapse was calculated using Cox-proportional hazards model with hazards ratio and 95% confidence interval (CI) after adjusting for duration of symptoms and juvenile onset disease. The patients were censored at the time of relapse or time of switching to another IS or last follow up whichever was the earliest. ARA was arbitrary chosen as the reference drug for all the analysis. The missing values (visits) were not included in analysis and the last observation was carried forwards. Data after switching of immuno-suppressant of interest till the last follow up visit was analysed descriptively. All analysis were done for matched and unmatched patient groups. The results of matched and unmatched cohort were similar, hence the results of unmatched groups are presented here.

Results: Overall, 234 patients satisfying inclusion criteria including 53 (22.6%), 156 (66.7%) and 25 (10.7%) patients receiving AZA, MMF, MTX respectively were studied. Complete remission (CR) was attained in 183 (78.2%) patients after initiating steroids and IS. 79.2%, 77.6% and 80% of patients receiving AZA, MMF or MTX respectively achieved CR yielding an odds ratio of 1.10 (0.52-2.37), p= 0.80 and 0.96 (0.29-3.12), p= 0.94 for MMF and MTX as compared with AZA. CR was sustained in 22 (52.4%), 80 (66.1%) and 11 (55%) of patients on AZA, MMF and MTX respectively. When compared with AZA, adjusted hazards ratio (AHR) of relapse was 1.51 (0.79-2.89), p=0.21 and 2.45 (1.00-5.99), p= 0.05 with MMF and MTX after adjusting for juvenile onset disease, type 1 and type 4 disease by angiography. The frequency of remission in patients who received MMF was significantly higher in patients who presented with type 4 disease (96%) as compared with the patients who had other types on angiography (74%), p=0.017. Conversely, 63.6% of patients with type 1 disease responded to MMF which was significantly lower than 81.3% of patients with other angiographic types (p=0.037) while no such differential response was observed for A2A or MTX. Treatment of steroid dose and/or switching of IS due to active disease. The baseline variables of patients receiving AZA, MMF and MTX were compared using chi square test or Mann Whitney U test. The comparative efficacy of IS to induce complete remission was calculated using logistic regression and presented as odds ratio (95% CI). The cumulative risk of relapse was calculated using Cox-proportional hazards model with hazards ratio and 95% confidence interval (CI) after adjusting for duration of symptoms and juvenile onset disease. The patients were censored at the time of relapse or time of switching to another IS or last follow up whichever was the earliest. ARA was arbitrary chosen as the reference drug for all the analysis. The missing values (visits) were not included in analysis and the last observation was carried forwards. Data after switching of immuno-suppressant of interest till the last follow up visit was analysed descriptively. All analysis were done for matched and unmatched patient groups. The results of matched and unmatched cohort were similar, hence the results of unmatched groups are presented here.

Conclusion: In our patients with TAK, all the three IS were comparable in inducing remission. Azathioprine was equal to MMF but superior to MTX in maintaining relapse free sustained response. The efficacy of MMF differed across various angiographic types of disease.

REFERENCES: None

Disclosure of Interests: None declared


Active Ageing: new perspectives for RMD patients—

From childhood to adulthood - growing up with an RMD

NEW JIA-AT-NRAS RESOURCE MEDICINES IN JUVENILE IDIOPATHIC ARTHRITIS

D. Wilson1, 1National Rheumatoid Arthritis Society, JIA, Maidenhead, United Kingdom

Background: Biologics have been commissioned by the NHS for use to treat JIA since 2014. Many of the original biologics that were first developed have since lost exclusivity, allowing other manufacturers to produce highly similar versions (biosimilars). This difference between the originator and the biosimilar has caused confusion within the patient community, especially in how it has been communicated to them. Parents found the concept of biosimilars confusing and wanted more information about this, recommending that written material be provided. Previous conversations with healthcare professionals, parents and young people living with JIA had also found there was a lack of written information on all JIA medications so we looked into how this gap could be filled.

Objectives: Produce a new resource to clarify the confusion about the biosimilars and originators for the JIA patient community. Explain the different medications to treat JIA in a patient/parent friendly format so it can be easily referred
to. Easy to see the different categorisation of the medications e.g. pain management, DMARDS, biologics and targeting synthetic DMARDS and include information regarding how they are taken, how often and usage.

Methods: Knowing there was a need for this information, a focus group was convened with young people with JIA, parents of children with JIA and healthcare professionals. From this focus group and separate conversations with healthcare professionals it very quickly became apparent a resource not only covering medications for JIA but detailing the wider JIA journey was needed. This resource would need to cover each step from diagnosis to a young person taking control of their disease management. It would also cover how the complexity of the immune system means that some children/youth people respond differently to medication; help them to learn about the unpredictability of the disease and to take control of managing their disease, particularly as they move onto adult rheumatology services. NRAS worked collaboratively with health writer and healthcare professionals to make sure this new resource covered all the topics that were discussed at the focus group and detailed all the medications used to treat JIA, including information on the issue of differentiating between biologics and biosimilars.

Results: The medicines in JIA booklet is now freely available to all parents, young people and healthcare professionals from the jia.org.uk website. The addition of visuals makes the information easier to navigate, clearer to understand and helps to illustrate the JIA journey. Along with the medicine directory which details all the medications to treat JIA.

Conclusion: The feedback NRAS has received from both healthcare professionals and parents has been very positive:

“We think that they’re absolutely fantastic, they cover everything, and I’m so pleased I’ve got these to give to parents and children.” Paediatric Rheumatology Nurse Haywood Hospital

“This is brilliant and much needed. Great piece of work much appreciated by all of us.” Lead Nurse Nottingham Children and Young People’s Rheumatology Service

“This has been my absolute saviour! It gives you support on administering the medicines and made me feel right at ease after reading it”. Parent of child with JIA

REFERENCES:


Figure 1. JIA-at-NRAS: Medicines in JIA resource
Cure (European Union Innovative Medicines Initiative 2, grant number 777357). INB is funded by the NIHR Manchester BRC. This article/paper/report presents independent research funded/supported by the NIHR Leeds BRC and the NIHR Guy’s and St Thomas’ BRC. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Disclosure of Interests: Md Yuzaufl Md Yusof: None declared, James Robinson: None declared, Vinny Davies: None declared, Dawn Wild: None declared, Michael Morgan: None declared, John Taylor: None declared, Jasser El-Sherbiny: None declared, David Morris: None declared, Lu Lu: None declared, Andrew Rawstron: None declared, Maya H Buch: None declared, Darren Plant: None declared, Heather Cordell: None declared, John Isaacs: None declared, Ian N. Bruce: None declared, Paul Emery Speakers bureau: Roche, Consultant of: Roche, Grant/research support from: Roche, Anne Barton: None declared, Timothy Vyse: None declared, Jennifer Barrett: None declared, Edward Vital Consultant of: Roche, Grant/research support from: Roche, Ann Morgan Speakers bureau: Roche, Heather Chugai, Consultant of: GSK, Roche, Chugui, AstraZeneka, Regeneron, Sanofi, Vitor, Grant/research support from: Roche, Kiniksa Pharmaceuticals

DOI: 10.1136/annrheumdis-2022-eular.48

Vaccination in rheumatic diseases with lessons from COVID

OP0192

SEREOLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-COV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY

I. Jysse1, A. T. Tverete1, J. Sexton1, I. E. Christensen1, T. T. Tran2, S. Mjaaland3, D. J. Warren4, T. K. Kvien5, K. H. Bjørlykke6, G. B. Kro7, J. Jahnsen5, L. A. Munthe8, E. A. Haavardsholm9, J. T. Vaage10, G. Grodeland10, F. Lund-Johansen11, S. Aarestad Provan11, K. J. Jørgensen12, G. L. Goll13, S. W. Syversen14, Dkakonhjemnet Hospital, Division of Rheumatology, Research, Oslo, Norway; 1Oslo University Hospital, Immunology, Oslo, Norway; 2Norwegian Institute of Public Health, Infectious Diseases and Immunology, Oslo, Norway; 3Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway; 4Akershus University Hospital, Gastroenterology, Larenosg, Norway; 5Oslo University Hospital, Microbiology, Oslo, Norway

Background: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy have an inadequate serologic response following two-dose SARS-Cov-2 vaccination, and a standard vaccination strategy of three doses for this patient group is currently under implementation in several countries. However, the serological response and safety of this strategy has not been evaluated.

Objectives: To assess serological response and safety of a three-dose vaccination strategy in IMID patients on immunosuppressive therapy as compared to standard two-dose vaccination of healthy controls.

Methods: The prospective observational NorVac study (NCT04798625) enrolled adult patients on immunosuppressive therapy for inflammatory joint- and bowel diseases. Healthy controls were health care workers from participating hospitals. All participants received standard vaccines according to the national vaccination program with three doses in patients and two doses in controls. The third dose was offered to IMID patients >4 weeks after the second dose. Analysis of antibodies binding the receptor-binding domain of the SARS-CoV-2 Spike protein was performed prior to, and 2-4 weeks after the second and third vaccine doses. Levels were compared across groups by Mann-Whitney U tests and multi-variate linear regression was used to identify predictors of response.

Results: Overall, 961 patients (315 rheumatoid arthritis, 156 spondyloarthritides, 171 psoriatic arthritis, 132 ulcerative colitis and 182 Crohn’s disease) (median age 54 years [IQR 43-64]; 56 % women) and 227 controls (median age 44 years [IQR 32-55]; 83 % women) were included in the present analyses. TNF monotherapy was used by 399 patients, 229 used TNF in combination with other immunomodulators, 189 methotrexate monotherapy, 39 vedolizumab, 32 JakI and 73 patients used other drugs. Patients on rituximab were not included. Patients were vaccinated with Pfizer BNT162b2 (54 % patients, 14 % controls), Moderna mRNA-1273 (16 % patients, 40 % controls) or a combination of vaccines (30 % patients, 46 % controls). Patients received the third vaccine, dose a median of 120 (IQR 102-143) days after the second dose. After two doses, median anti-Spike antibody levels were significantly lower in patients (861 BAU/ml [IQR 418-4275] than controls (6318 BAU/ml [IQR 2468-9857], p<0.001) (Figure 1). Following the third dose, patients achieved antibody levels comparable to the two-dose vaccinated controls (median 5480 BAU/ml [IQR 1081-12069], p=0.28) (Figure 1). In the patients anti-Spike antibody levels increased by a median of 2685 BAU/ml (IQR 265-9129) from the second to the third dose. Main factors associated with increased antibody level after the third dose were younger age (β -87.7 (p=0.002)), and vaccine status (mRNA-1273 vaccine (β 5549 (p<0.001)) or a combination of vaccines (β 43673 (p<0.001)). Adverse events were reported by 438 (48 %) of patients after the third dose as compared to 471 (54 %) after the second dose and 193 (78 %) of controls. Disease flares were reported by 42 (5 %) and 69 (8 %) patients after the second and third dose, respectively.

Conclusion: This study suggests that a third vaccine dose for immunosuppressed patients closes the gap in serological response between patients and
the healthy population. Antibody levels following the three-dose regimen in IMID patients were comparable to healthy controls vaccinated twice, and no new safety issues emerged. This finding was consistent across all diagnoses and treatment groups, supporting the implementation of a three-dose vaccine regimen as standard in the IMID population.

Disclosure of Interests: Ingrid Jyssum: None declared, Anne Therese Tveten: None declared, Joe Sexton: None declared, Ingrid E. Christensen: None declared, Trung T. Tran: None declared, Siri Mjaaland: None declared, David J. Warren: None declared, Tore K. Kvien Speakers bureau: Amsen,Celltion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz, Sanofi, Consultant of: Abbvie, Amgen, Biogen, Celtion, Eli Lilly, Gilead, Mylan, Novartis, Pfizer, Sandoz, Sanofi, Grant/research support from: Grants to institution (Dakonhetemmet Hospital); Abbvie, Amgen, BMS, MSD, Novartis, Pfizer, UCB, Krstin Hammersboen Bjorklykke: None declared, Grete B. Kro: None declared, Jorgen Jahnssen Speakers bureau: Abbvie, Astro Pharma, Boehringer Ingelheim, BMS, Celtion, Ferrig, Gilead, Hikma, Janssen Cilag, Meda, MSD, Napp Pharma, Novartis, Orion Pharma Pfizer, Pharmacosmos, Roche, Takeda, San- doz, Consultant of: Abbvie, Boehringer Ingelheim, BMS, Celtion, Ferrig, Gilead, Janssen Cilag MSD, Napp Pharma, Novartis, Orion Pharma Pfizer, Pharmacosmos, Takeda, Sandoz, Unimedic Pharma, Grant/research support from: Abbvie, Pharmacosmos, Ferrig, Ludwig A. Munthe Speakers bureau: Novartis, Cellgene, Espen A Haavardsolm: None declared, John Torgils Vaage: None declared, Gunnveig Grodeland Speakers bureau: Bayer, Sanofi Pasteur, Novartis, Cellgene: None declared, Despina Eleftheriou Speakers bureau: Sobi, Charalam- pia Papadopoulou Speakers bureau: Sobi, Pierre Quartier Speakers bureau: Sobi, Abbvie, Chugai-Roche, Lilly, Novartis, Pfizer, Consultant of: Abbvie, Pfizer, Roche, Sanofi, Novartis, Novimmune, Grant/research support from: Sobi, Abbvie, Pfizer, Roche, Sanofi, Novartis, Novimmune, Consultant of: Sobi, Abbvie, Pfizer, Roche, Sanofi, Napar, Consultant of: Abbvie, Pfizer, UCBL, Sandoz, Orion Pharma, Novartis, Consultant of: Pfizer, Abbvie, Silje Watterdal Syversen: None declared DOI: 10.1136/annrheumdis-2022-eular.1230

sJIA vs AOSD: Two names one disease? What have we learnt so far

OP0193

EFFICACY AND SAFETY OF EMAPALUMAB, AN ANTI-INTERFERON GAMMA MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) WHO HAD FAILED HIGH-DOSE GLUCOCORTICOIDS

F. De Benedetti1, A. Grom2, P. Brogant, C. Bracaglia3, M. Pardeo1, G. Marucci1, D. Eleftheriou1, C. Papadopoulou1, P. Quartier1, J. Anton4, R. Frederiksen2, V. Asnaghi1, C. de Min1,1; Dipartimento Pediatrico Bambino Gesu’; RCCS, Division of Rheumatology, Rome, Italy; 2Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, United States of America; 3Great Ormond Street Hospital NHS Foundation Trust, UCL Institute of Child Health, London, United Kingdom; 4Necker Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, IMAGINE Institute, RAISE Reference Center, Pediatric Immuno-Hematology and Rheumatology Unit, Paris, France; 5University of Barcelona, Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, Barcelona, Spain; 6Swedish Orphan Biovitrum AG (Sobi), Clinical Science, Basel, Switzerland

Background: MAS is a severe, life-threatening complication of rheumatic diseases that occurs most frequently in patients with SJIA. The mainstay of treatment for MAS is high dose glucocorticoids (GCs); however, GCs do not provide adequate control in all patients. Additional treatments are used without a standardized approach; however, morbidity and mortality remain high. Data from animal models of MAS and from observational studies in patients suggest that overproduction of IFNγ is a driver of the hyperinflammation observed in MAS; neutralization of IFNγ has been shown to reverse the signs and symptoms of MAS in murine models, and high IFNγ levels are strongly correlated with laboratory parameters of disease severity in patients.

Objectives: To assess the efficacy and safety of intravenous (IV) infusions of emapalumab, a fully human, anti-IFNγ monoclonal antibody, in patients with MAS in SJIA.

Methods: Open-label, single-arm, phase 2 study (NCT03311854) that included patients with MAS (2016 ACR/EULAR criteria) in SJIA who had failed high-dose IV GCs and other treatments. Emapalumab was initiated at a dose of 6mg/kg on Day 0 and continued at 3mg/kg every 3 days until Day 15, and then twice weekly until Day 28 to ensure rapid and complete IFNγ neutralization after initiating treatment. As per protocol, 10 infusions were planned over the 4 weeks; however, treatment could be shortened if MAS remission was achieved earlier, or extended if required to achieve remission. Complete resolution (CR) was defined as resolution of clinical signs and symptoms of MAS according to the investigator, and normalization of laboratory parameters relevant to MAS. All patients were followed up for 4 weeks after the last infusion of emapalumab and offered to enter a 1-year, follow-up study (NCT02689899).

Results: Fourteen patients (10 females) were enrolled (11 in Europe, 3 in the USA). Several patients had previously received cyclosporine A and/or anakinra, in addition to high-dose GCs. Six patients received emapalumab until Day 28. Seven patients discontinued emapalumab early due to MAS remission (as per investigator’s assessment); one patient received treatment up to Day 38. Emapalumab treatment rapidly neutralized IFNγ, as documented by CXCL9 levels. A CR was achieved by 13/14 patients during the study. One patient stopped emapalumab after 3 doses because of achievement of MAS remission as per investigator’s assessment, but lactate dehydrogenase levels remained >1.5× upper limit of normal. At Week 8, 11/14 patients had a CR; 2 achieved a CR during the study, but not at Week 8, because of a single laboratory parameter abnormality in each patient. Overall, all measured laboratory parameters related to MAS activity rapidly improved with emapalumab treatment. GCs were tapered in all patients by Week 8 (≥30% reduction, n=12; GC dose ≤1mg/kg/day, n=8). Administration of anakinra for the treatment of underlying SJIA was maintained/introduced during the study, as required. No patients discontinued treatment for safety reasons. One treatment-related serious adverse event was reported (cytomegalovirus reactivation that resolved with antiviral treatment). All patients entered the long-term, follow-up study and were alive at last visit.

Conclusions: Emapalumab administration led to rapid IFNγ neutralization, was efficacious in controlling MAS in all patients, and was well tolerated with a favorable safety profile. These results support the pathogenic role of IFNγ in MAS in SJIA and the therapeutic value of IFNγ neutralization in MAS patients who have failed high-dose GCs.


Autoinflammation over the course of a lifetime

OP0194

COMBINATION ANAKINRA AND TOCILIZUMAB TO TREAT REFRACTORY MACROPHAGE ACTIVATION SYNDROME TRIGGERED BY ADULT-ONSET STILL’S DISEASE.

E. Alveyn1, A. Rutherford1. King’s College London, Centre for Rheumatic Disease, Department of Immunology Biologics, London, United Kingdom

In this study, we assessed the efficacy and safety of emapalumab in a cohort of patients with SJIA who had failed high-dose GCs. We found that emapalumab rapidly neutralized IFNγ, achieved CR in 13 out of 14 patients, and was well tolerated with a favorable safety profile. These results support the pathogenic role of IFNγ in MAS in SJIA and the therapeutic value of IFNγ neutralization in MAS patients who have failed high-dose GCs.
Background: Adult-onset Still’s disease (AOSD) is associated with the development of macrophage activation syndrome (MAS) [1], sometimes termed secondary haemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory state with high mortality. Successful management of AOSD and MAS is contingent on early identification and treatment of the syndromes and any triggers, with aggressive immunosuppression in acutely unwell patients [2].

Objectives: To describe the case of a patient with newly diagnosed AOSD who developed severe MAS requiring ICU admission and immunosuppression with high-dose glucocorticoids, tocilizumab and anakinra.

Methods: Case report.

Results: A 24-year-old woman attended hospital with a 4 month history of fever, arthralgia, rash and later dry cough. She became hypoxic and was admitted to the ICU for ventilation and vasopressor support. Imaging revealed splenomegaly, pleural effusions and lung consolidation but there was no response to antibiotics and no clear evidence of infection. Cytomegalovirus (CMV) DNA was initially absent, with IgG avidity indicating prior exposure. Bloods confirmed significant inflammatory markers (CRP 107 mg/L, ferritin 6154 µg/L, ESR 477 mm/hr) without disordered haemostasis. A bone marrow aspirate showed no haemophagocytosis. After extensive investigation a diagnosis of AOSD was made given the fulfilment of the Yamaguchi criteria and absence of evidence of an alternative driver of inflammation.

The patient deteriorated further, with deranged liver chemistry, rising CRP, triglycerides and ferritin (>100,000 µg/L), and trilineage cytopenia raising concern for MAS. This was managed by treating the presumed trigger (AOSD) with intravenous methylprednisolone (IVMP, 3x 500mg then 32mg daily) and anakinra (100mg twice daily). She developed a CMV viraemia that progressed despite aciclovir and later ganciclovir, which was switched to foscarnet and CMV immunoglobulin. The viraemia then stabilised and improved.

Due to persistent pyrexia, tachycardia, and elevated inflammatory markers, further IVMP (3x250mg), increased anakinra doses (100mg IV TDS) and intravenous immunoglobulin (2x60g) were given. A repeat bone marrow biopsy was consistent with MAS and testing for HLA-associated genes was negative. The patient became increasingly hypoalbuminaemic and oedematous, developing acute kidney injury requiring continuous haemofiltration in the ICU. Anakinra was increased to 500mg daily in divided doses. The blood counts improved transiently, before the ferritin rose sharply again, with fevers and broad-spectrum antimicrobials continuing. Cytofine profile testing at this point revealed significant elevation in IL-1β and IL-6. Tocilizumab 8mg/kg fortnightly was added to existing therapy.

After tocilizumab initiation the inflammatory markers, blood counts and clinical state improved, though the patient remained hypertensive despite numerous antihypertensives. She left the ICU ten weeks after initial presentation. Corticosteroids and anakinra were weaned and she was discharged on tocilizumab monotherapy. Renal function did not return, and she continues outpatient haemodialysis.

Conclusion: The evidence base for effective therapies in MAS is poor. Reports exist of the use of either anakinra or tocilizumab [3] but not both agents in combination. In this case, cytofine blockade with both agents produced significant clinical improvement in a critically unwell patient.

REFERENCES:

Acknowledgements: We acknowledge the kind permission of the patient for her case to be used for educational purposes, and to all those involved in her care during the acute admission.

Disclosure of Interests: None declared


Challenges of fibromyalgia

Table 1. Highlighting primary baseline data, primary and secondary endpoints, main differences regarding invasive procedures and medical specialists consulted during seven years follow up.

<table>
<thead>
<tr>
<th></th>
<th>Fibromyalgia, n=86</th>
<th>Non-fibromyalgia, n=151</th>
<th>P-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>52.5 (13.7)</td>
<td>52.8 (18.6)</td>
<td>0.432</td>
</tr>
<tr>
<td>Female, %</td>
<td>80</td>
<td>54</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Social economic support of any kind, %</td>
<td>62</td>
<td>20</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Rheumatic inflammatory disease, %</td>
<td>28</td>
<td>42</td>
<td>0.028</td>
</tr>
<tr>
<td>Number of different courses at hospital, Mean (SD)</td>
<td>12.7 (0.9)</td>
<td>9 (0.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Number of diagnoses, Mean (SD)</td>
<td>6 (0.3)</td>
<td>4 (0.2)</td>
<td>0.003</td>
</tr>
<tr>
<td>Numbers of admissions to hospital, Mean (SD)</td>
<td>2.1 (0.3)</td>
<td>1.9 (0.2)</td>
<td>0.550</td>
</tr>
<tr>
<td>Number of Medications, Mean (SD)</td>
<td>7.1 (0.5)</td>
<td>6.1 (0.3)</td>
<td>0.057</td>
</tr>
<tr>
<td>Number of Pain Medications, Mean (SD)</td>
<td>1.6 (1.1)</td>
<td>1.2 (0.1)</td>
<td>0.014</td>
</tr>
<tr>
<td>Invasive procedures total, %</td>
<td>78</td>
<td>60</td>
<td>0.003</td>
</tr>
<tr>
<td>Joint surgery other (including arthroscopies), %</td>
<td>30</td>
<td>17</td>
<td>0.026</td>
</tr>
<tr>
<td>Gastroscopy, %</td>
<td>37</td>
<td>14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Colonoscopy, %</td>
<td>38</td>
<td>21</td>
<td>0.004</td>
</tr>
<tr>
<td>Psychiatry, %</td>
<td>20</td>
<td>7</td>
<td>0.006</td>
</tr>
<tr>
<td>Abdominal Surgery, %</td>
<td>43</td>
<td>30</td>
<td>0.042</td>
</tr>
<tr>
<td>Pain centre, %</td>
<td>13</td>
<td>3</td>
<td>0.017</td>
</tr>
<tr>
<td>Endocrinology, %</td>
<td>40</td>
<td>21</td>
<td>0.003</td>
</tr>
<tr>
<td>Gastroenterology, %</td>
<td>30</td>
<td>13</td>
<td>0.003</td>
</tr>
<tr>
<td>Neurology, %</td>
<td>42</td>
<td>28</td>
<td>0.029</td>
</tr>
</tbody>
</table>

Acknowledgements: Study data were collected using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at OPEN (Open Patient Data Explorer Network), Odense University Hospital, Region of Southern Denmark.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.468

Accepted Article
Background: Patients with fibromyalgia (FM) suffer from high symptom burden and few available treatments. EULAR evidence-based recommendations for the management of FM state that optimal management should focus on prompt diagnosis, patient education and non-pharmacological treatments. A recent systematic review of mindfulness- and acceptance-based interventions for patients with FM showed small to moderate beneficial health effects. We tested a 10-session group-based mindfulness- and acceptance-based intervention, the Vitality Training Programme, followed by low threshold physical exercise counselling in primary health care, compared to treatment as usual (TAU) for patients diagnosed with FM.

Objectives: To explore possible changes in health status in a group of FM patients, two years after participation in a multicomponent rehabilitation programme.

Methods: A total of 170 patients with confirmed FM diagnosis according to ACR 2011-criteria were randomised, 85 to intervention and 85 to control. Self-reported data were collected electronically at baseline, 3 and 12 months. There were no statistically significant health effects in any disease-related variables at 12 months. However, there were significant between-group differences in patients’ tendency to be mindful. All patients were asked to complete the same questionnaires two years after completion of the intervention group. Because the TAU-group had been offered the same programme after 12 months, only data from the intervention group was included in this study. Primary outcome was Patient Global Impression of Change (PGIC), scored as 1= much worse, through 4= no change, to 7=much better. Values 6 and 7 were considered clinically relevant improvement. Secondary outcomes were self-reported pain, fatigue, sleep quality, psychological distress, mindfulness, physical activity, motivation and barriers for physical activity, and work participation. Mean changes from baseline to two years were analysed by paired sample t-tests.

Results: Totally, 48 (56.5%) of the patients who had been randomised to the intervention group responded to the questionnaires, 94% female, median (range) age 47 (28 to 54), symptoms duration 12 (5 to 33) years. Only seven patients reported clinically relevant improvement on PGIC; 32 (67%) reported the change, to 7=much better. Values 6 and 7 were considered clinically relevant. The improvement seen in patients’ tendency to be mindful at 12 months was sustained (p=0.012). Only 58% of patients reported clinically relevant improvement on PGIC; 32 (67%) reported the change, to 7=much better. Values 6 and 7 were considered clinically relevant.

Conclusion: Two years after participation in a multicomponent rehabilitation programme comprising mindfulness and acceptance training and physical activity counselling, FM patients still reported high symptom burden and no improvement in their health status. The increased tendency to be mindful was not reflected in improvements in disease-related outcomes. It was not possible to compare groups (intervention and TAU), because the TAU-group had been offered the intervention before the two-years data collection. However, there was a worse-ening of symptoms, which might have been the case without any intervention.

REFERENCES:

Acknowledgements: Patient research partners Elisabeth Baerheim and Astrid Andreassen

Disclosure of Interests: None declared


Long-COVID

OP0097

POST-TRAUMATIC STRESS DISORDER AND SYMPTOMS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES DURING THE COVID-19 PANDEMIC: PRELIMINARY RESULTS FROM THE PERMAS STUDY

G. Fulvio1, V. Pedrinelli2, G. Andreozzi3, F. Treniti1, S. Fantasia2, S. Fonzetti1, C. Fustini2, M. Da Rio1, G. Cappellato2, C. Cigolini2, D. Schiliro1, M. Matti1, L. Scagnellato1, A. Valevich1, F. Fattorini1, I. C. Navarro Garcia1, I. Palla3, V. Lorenzoni1, A. Gaglio1, C. Carmassi2, C. Tani1, G. Turchetti1, L. Dell'Oss2, M. Mosca2, University of Pisa, Rheumatology Unit, Department of Clinical and Experimental Medicine, Pisa, Italy; 2University of Pisa, Psychiatric Clinic, Department of Clinical and Experimental Medicine, Pisa, Italy; 3Institute of Management, Scuola Superiore SantAnna, Pisa, Italy

Background: The COVID-19 pandemic, with its uncertainties, fears of contagion, mass lockdowns and containment measures, has dramatically impacted on people’s everyday lives leading to an increased risk of mental disorders, particularly Post-Traumatic Stress Disorder (PTSD). Despite evidence in general population and healthcare workers, scant data emerged on vulnerable populations, such as patients with chronic diseases, particularly rheumatic and musculoskeletal diseases (RMDs), who also encountered difficulties in the management and treatment of their disorders.

Objectives: To assess PTSD and post-traumatic stress symptoms in a sample of patients with RMDs, during the COVID-19 pandemic in Italy.

Methods: PERMAS is a monocentric prospective observational study led by the Rheumatology Unit, the Psychiatric Clinic and the Institute of Management of the School of Advanced Studies. Patients with a RMD diagnosis, consecutively enrolled from May 2021 to January 2022. In the visit, sociodemographic characteristics and psychopathological data were collected through online survey, whereas clinical data were collected by physician. The survey included the Trauma and Loss Spectrum- Self Report (TALS-SR) and the Impact of Event Scale- Revised (IES-R), aimed to assess symptomatological PTSD and post-traumatic stress symptoms related to the impact of the COVID-19 pandemic.

Results: A total of 194 eligible patients, with a mean age of 50.3±12.17 years, was included: 142 (73.19%) were females; 112 (57.74%) patients reported connective tissue diseases (CTD), 63 (32.47%) arthritis and 19 (9.8%) vasculitis. A total of 33 (17%) subjects reported a symptomatological PTSD by means of the TALS-SR. The prevalence of Partial PTSD (defined by at least 2 out of the 4 criteria for DSM-5 diagnosis of the disorder) was 56.7%, with significant higher rates among females (90, 81.8%) with respect to males (20, 18.2%) (p=.013). Accordingly, a IES-R mean total score of 21.90 ± 15.98 was found in the total sample and a gender difference emerged, with higher mean scores among females rather than males (23.42 ± 16.26 vs 21.90 ± 15.98, p=0.031).

Conclusion: The present findings point out high prevalence rates of symptomatological PTSD among patients suffering from RMDs, highlighting the potentially traumatic burden of the COVID-19 pandemic in this particular population, especially among females, suggesting the need of further investigations to address tailored prevention and intervention strategies.

REFERENCES:
How do we overcome the research-to-practice gap? Implementation of evidence into the rheumatology practice

OP0198-HPR DEVELOPMENT OF AN INTERDISCIPLINARY NURSE-COORDINATED SELF-MANAGEMENT INTERVENTION (INSELMA) FOR PATIENTS WITH INFLAMMATORY ARTHRITIS

J. Prindahl1,2,3, K. M. Latocha1, A. Bremander1,2,5, O. Hendriks1,2, M. Østergaard1,2, L. Andersen6, K. V. Jensen6, B. A. Esbensen5,7,1 University of Southern Denmark, Department of Regional Health Research, Odense, Denmark; 2Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; 3Sønderborg Sygehus, University Hospital of Southern Denmark, Aabenraa, Denmark; 4Patient research partner, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital - Rigshospitalet, Glostrup, Copenhagen, Denmark; 5Lund University, Department of Clinical sciences, Lund, Sweden; 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Glostrup, Glostrup, Denmark; 7University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark; 8Patient research partner, Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark

Background: Up to 30% of patients with inflammatory arthritis (IA) do not respond sufficiently or tolerate the pharmacological treatment. Consequently, they may experience a substantial impact of their arthritis in everyday life. Even patients in remission or low disease activity state are at risk of substantial arthritis related symptoms and burden. These patients may need coherent interdisciplinary self-management support to manage symptoms and life with the chronic condition to increase their quality of life. A previous EU-ILAR review on the effectiveness of self-management interventions in patients with IA (1) found that well-structured self-management programmes were lacking or were poorly reported.

Objectives: This study aimed to develop a nurse-coordinated interdisciplinary self-management intervention, delivered in routine clinical care, for patients with inflammatory arthritis and with a substantial impact of their arthritis to support their self-management ability.

Methods: The study was planned across two Danish hospitals following the British Medical Research Councils (MRC) framework for developing and evaluating Complex Interventions (2). The development process consisted of four phases: 1) a comprehensive scoping review on patients support needs and elements in self-management interventions; 2) six workshops involving health professionals (rheumatologists, nurses, physiotherapists, occupational therapists, a social worker and a psychologist) and 2 patient representatives from the two hospitals and staff from primary health care, 40 people in total; the workshops focused on ideas for the content, outline of the intervention and needs for competence development of the staff; 3) self-management, self-efficacy, health literacy and principles of Acceptance and Commitment therapy (ACT) were selected as theories to tailor the intervention and 4) development of a manual through recurrent feedback from patient research partners, clinicians and the involved researchers. Two patient research partners with IA were involved in all phases of the development of the intervention.

Results: A six month nurse-coordinated interdisciplinary self-management intervention was developed (Figure 1) consisting of: 1) an initial holistic assessment is carried out by a coordinating outpatient nurse. Patients are asked to identify up to five important activities they are unable to perform or having difficulty with in accordance with the Patient Specific Functional Scale; 2) a goal-setting and action planning process involving the patient, relatives and the coordinating nurse; 3) Ongoing support to achieve the goals. The opportunities for support include individual consultations by the coordinating nurse (telephone, online or face-to-face, 2-5 hours in total), and a maximum of four consultations by a physiotherapist and/or an occupational therapist. Also, support from primary care, and an online session by a social worker about social support opportunities are offered. Two team conferences led by the coordinating nurse can be held during the intervention period. A status consultation will be held after 6 months. A manual for the initial screening, inclusion, detailing the intervention, outcomes and additional materials to support the intervention was developed. Competence development of the health professionals who are to deliver the intervention was planned and completed.

Conclusion: A nurse-coordinated interdisciplinary self-management intervention (INSELMA) was developed and described based on MRC’s framework for the development of Complex Interventions. The intervention is ready for feasibility testing before adaptation and test in a subsequent Randomized Controlled Trial. REFERENCES:


Disclosure of Interests: None declared, Chiara Tani: None declared, Giuseppe Turchetti: None declared, Valevich: None declared, Federico Fattorini: None declared, Inmaculada Conesa Zeneca: None declared, Laura Scagnellato: None declared, Anastasiya Fustini: None declared, Mattia Da Rio: None declared, Gabriele Cappellato: Giovanni Fulvio: None declared, Virginia Pedrinelli: BMJ 2021;374:n2061

Strengths and weaknesses of experimental models: Moving from animals to human clinical trials

OP0199 RADIONIC SIGNATURES REFLECT TREATMENT RESPONSE TO NINTEDANIB IN PRECLINICAL LUNG FIBROSIS MODEL

D. Lau1,2,3, J. Schniering2, H. Gabrys1, M. Maciukiewicz2,3, M. Brunner2,3, O. Distler2, T. Frauenfelder2, S. Tanandini-Lang1, B. Maurer1,2,1 University Hospital Bern, Department of Rheumatology and Immunology, Bern, Switzerland; 2University of Bern, Department for Biomedical Research (DBMR), Bern, Switzerland; 3University Hospital Zurich, University of Zurich, Center of Experimental Rheumatology, Zurich, Switzerland; 4Helmholtz Zentrum München, Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center, Munich, Germany; 5University Hospital Zurich, University of Zurich, Department of Radiation Oncology, Zurich, Switzerland; 6University Hospital Zurich, University of Zurich, Institute of Diagnostic and Interventional Radiology, Zurich, Switzerland

Background: Responses to anti-fibrotic drugs in preclinical disease models are difficult to quantify by histological analysis of single tissue sections. Quantitative in-depth analysis of imaging data, termed “radiomics,” may represent a more reliable and accurate measure of treatment response since the pathology of the whole organ is captured.

Objectives: To study the potential of µCT-derived radiomic features to reflect response to Nintedanib in the bleomycin (BLM)-induced murine model of fibrosing interstitial lung disease.

Methods: All C57BL/6J mice from both study groups were intratracheally instilled with 2U/kg BLM on day 0 to induce lung fibrosis. Nintedanib was administered daily by gavage at 60mg/kg for two weeks starting from day 7 (n=15). Controls received equivalent treatment with vehicle-only (n=19). Whole lung µCT scans (SkyScan 1176, Bruker) of each animal were acquired at baseline (day 0), pre-treatment (day 7), and post-treatment (day 21). The Ashcroft score was assessed on Sirius Red stained lung sections post-treatment. Lung volumes in µCTs were defined semi-automatically in MIM Software (6.9.2), followed by extraction of radiomic features with our in-house developed software Z-Rad (73.1). Each data set contained 1’386 features, describing image characteristics with histogram, texture, and wavelet functions. Data pre-processing involved removal of features sensitive to intra- and interobserver delineation variability (ICC<0.75), highly correlated features (Pearson’s r>0.95), and features not...
significantly changing between days 0 and 7 (p<0.05). Agglomerative clustering of radiomic temporal trajectories was performed on the Nintedanib group to identify distinct feature clusters. The identified feature sets were then used to plot average feature value trajectories for both study groups in each cluster. To identify features significantly different between a) Nintedanib vs. control, and b) pre- vs. post-treatment, Mann-Whitney U and Wilcoxon signed-rank tests were used, respectively. Samples were pooled from two independent experiments.

**Results:** Evaluation of tissue sections did not show a significant treatment-induced reduction of fibrosis with average Ashcroft scores of 3.7 (±2.5 s.d.) and 3.9 (±1.7 s.d.) in Nintedanib and control samples, respectively (p>0.05). Radiomics data analysis revealed two feature clusters in Nintedanib samples, composed of 52 features (cluster 1) and 96 features (cluster 2), the trajectories of which were then plotted for both study groups. In cluster 1, feature value trajectories significantly decreased in both Nintedanib and control group between pre- and post-treatment (p<0.001), whereas feature values in cluster 2 remained flat (p>0.05). Importantly, Nintedanib-treated mice displayed a much more pronounced feature value decrease post-treatment in cluster 1 compared to the control group (p<0.05). Here, feature values post-treatment resembled pre-disease baseline conditions in the Nintedanib group (p<0.05), whereas the control group remained significantly different from baseline (p<0.01). Cluster 1 was composed of 6 histogram, 11 texture, and 35 wavelet features, emphasizing the role of high-dimensional metrics for the detection of differences.

**Conclusion:** Histological quantification of lung fibrosis accounts only for a small fraction of the whole pathology in a spatially heterogeneous disease. We demonstrated that μCT-derived radiomic features identified significant differences on imaging level following Nintedanib treatment, which we could not reliably detect on tissue level using Ashcroft scoring. These findings hold great potential for the development of novel read-outs for improved stratification of anti-fibrotic treatment effects in preclinical models.

**Acknowledgements:** This study received funding support from the Swiss Lung Association.

**Disclosure of Interests:** David Lauer Shareholder of: Roche (no relation to project), Employee of: Former employee of Roche (no relation to project), Janine Schnier-None declared, Hubert Gabrys: None declared, Malgorzata Maciukiewicz: None declared, Matthias Brunner: None declared, Oliver Distler Speakers bureau: Speaker fees in the area of systemic sclerosis and related complications from Bayer, Boehringer Ingelheim, Janssen, Mediscpe, Consultant of: Consultancies in the area of systemic sclerosis and its complications with Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Anxo, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Mitleny Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Grant/research support from Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Thomas Frauenfelder: None declared, Stephanie Tanadin-Ng: None declared, Brita Maurer Speakers bureau: Received speaker fees from Boehringer-Ingelheim as well as congress support from Medtalk, Pfizer, Roche, Actelion, Mepha, and MSD, Consultant of: Consultancies with Novartis, Boehringer Ingelheim, Janssen-Clag. Has a patent mi-29 for the treatment of systemic sclerosis issued (US201479389, EP2033143), Grant/research support from: Had grant/research support from AbbVie, Protagen, Novartis Biomedical Research.

**DOI:** 10.1136/annrheumdis-2022-eular.572

---

**From abstract to concrete – the variety of activities of PARE organizations**

**OP0200-PARe**

**BARING IT ALL: A REPORT ON THE SEXUAL AND REPRODUCTIVE HEALTH EXPERIENCES OF WOMEN WITH INFLAMMATORY ARTHRITIS, RHEUMATIC AND PSORIATIC DISEASES**

L. Proulx1, S. Ketelaars2, R. Marion2, A. Scali3, 1Canadian Arthritis Patient Alliance, Patient Organisation, Ottawa, Canada; 2Canadian Spondylitis Association, Patient Organisation, Toronto, Canada; 3Canadian Association of Psoriasis Patients, Patient Organisation, Ottawa, Canada; 4Canadian Psoriasis Network, Patient Organisation, Toronto, Canada

Baring It All: a report on the sexual and reproductive health experiences of women with inflammatory arthritis, rheumatic and psoriatic diseases

**Background:** Inflammatory arthritis and psoriasis commonly affect women in the prime of their lives with significant impacts on sexual, reproductive and mental health. There have been some efforts to provide educational resources and other support by patient organizations globally but no broad efforts to evaluate patient needs and experiences throughout their lives and disease course.

**Objectives:** The Canadian Arthritis Patient Alliance, Canadian Association of Psoriasis Patients, Canadian Psoriasis Network and Canadian Spondylitis Association co-developed and launched the Women’s Sexual and Reproductive Health Survey on International Women’s Day 2021. Findings were analyzed in the report, Baring It All: A survey and recommendations on sexual and reproductive health needs of women+ with rheumatic, inflammatory and psoriatic diseases.

**Methods:** Survey participants were asked about their experiences with:

- sexual health
- family planning
- perimenopause/ menopause
- pain
- mental health
- accessing care and treatments (including paying for medications)

A total of 439 people across Canada who identified as female (women+) living with inflammatory arthritis, rheumatic, and psoriatic diseases participated. Results were analyzed to provide a national picture and insights based on Canadian geography, age, and identification as a member of a racialized community and/or as LGBTQ2S+.

**Results:** Over 60% of survey participants indicated that they did not have enough information about sexual health and their condition(s) and identified information needs relating to managing the impact of fatigue on their sex life, advice on improving sex drive, and sexual positions comfortable for their body as priorities. Less than half of survey participants indicated receiving counseling from a doctor before pregnancy. Many participants expressed a need for information about medication safety during pregnancy and breastfeeding and managing the impact of pain. Two in five survey participants (40%) indicated they were currently experiencing symptoms of perimenopause or menopause; however, only half of them (21%) indicated they understood how menopause affects their condition(s). Over 50% of participants indicated they understand how menopause affects bone health. Though 91% of survey participants indicated that they can honestly discuss pain with their healthcare provider, only 58% feel like their healthcare provider relates to the pain they experience from their condition. The vast majority (87%) of survey participants worry about the impact of their condition on their mental health, yet only 16% of participants identified having a mental health professional (e.g., psychologist, psychiatrist, social worker) as part of their care team.

**Conclusion:** There are several unmet needs in accessing care and information throughout the lives of women+ living with inflammatory arthritis, psoriatic and rheumatic diseases. A shift in models of care to focus on patient needs could assist patients in navigating a range of difficult decisions, such as choosing safe medications for pregnancy and breastfeeding, reconciling health, work and parenting demands, understanding menopause, accessing mental health support, and managing pain. A sex and gender lens can be used in the creation of resources and policies to support people with these condition(s).

**REFERENCES:**

**Disclosure of Interests:** Laurie Proulx Grant/research support from: Laurie Proulx is 2nd vice president of the Canadian Arthritis Patient Alliance, a patient run, volunteer-based organization that receives project funding from pharmaceutical companies. CAPA received unrestricted educational grants from UCB Canada for this project. Survey design & data analysis, report preparation and dissemination were carried out independently by CAPA, CAPP, CPN, and CSA. Rachael Manion Grant/research support from: Shannon Ketelaars is the Executive Director of the Canadian Spondylitis Association (CSA), a national charitable not-for-profit that receives project funding from the pharmaceutical sector. CSA received unrestricted educational grants from UCB Canada for this project. Survey design & data analysis, report preparation and dissemination were carried out independently by CAPA, CAPP, CPN, and CSA. Antonella Scali Grant/research support from: Antonella Scali is the Executive Director of the Canadian Association of Psoriasis Patients (CAPP) and the Canadian Skin Patient Alliance, both of which are national not-for-profit patient organizations that receive project funding from pharmaceutical companies. CAPP received unrestricted educational grants from UCB Canada for this project. Survey design & data analysis, report preparation and dissemination were carried out independently by CAPA, CAPP, CPN, and CSA. Rachael Manion Grant/research support from: Rachael Manion is the Executive Director of the Canadian Association of Psoriasis Patients (CAPP) and the Canadian Skin Patient Alliance, both of which are national not-for-profit patient organizations that receive project funding from pharmaceutical companies.

**DOI:** 10.1136/annrheumdis-2022-eular.1178

---

**OP0201-PARe**

**DEVELOPMENT THROUGH CO-CREATION OF A PERSONALIZED, MULTIMODAL, PHYSIOTHERAPIST-LED, WORK-ORIENTED INTERVENTION TO INCREASE WORK ABILITY IN WORKING PEOPLE WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS.**

N. Bakker1, J. Knoop2, N. Hutting1, Y. Heerkens3, J. Engels4, J.B. Staaij5, M. van der Leeden6, A. Boonen2, J. Tiggeloven6, N. Schuur2, T.P.M. Vliet Vlieland1, S. van Weely1, 1Leiden University Medical Center, Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden, Netherlands; 2HAN University
Background: Although work ability is considered a key element of quality of life for working people, work is underexposed in current treatment in people with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA). Most people with RA or axSpA attend a physiotherapist (PT). Physiotherapy can effectively improve physical fitness, which is associated with work ability. Therefore, PTs might play an important role in optimizing work ability of people with RA or axSpA.

Objectives: Developing a personalized, multimodal, PT-led, work-oriented intervention for working people with RA or axSpA who have a reduced work ability, through a co-creation process.

Methods: A systematic co-creation process with all relevant stakeholders was conducted following the Medical Research Council (MRC)-framework for complex interventions (see Figure 1). In step 1, all relevant clinical guidelines and treatment protocols were assessed. Based on the results of this assessment, a draft version of the intervention was developed, consisting of mandatory (i.e., work-oriented intake, patient education, exercise therapy, referral-roadmap of work-related professionals) and optional treatment modalities (i.e., workplace-intervention, self-management course). In step 2, focus groups with people with RA/axSpA, PTs and occupational/rheumatology experts were organized and indicated that the intervention was feasible and that the developed intervention collaboration. After revision of the draft intervention, the intervention was tested for applicability, Netherlands and Rheumatology, Amsterdam, Netherlands; 4 Maastricht University Medical Center, Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands; 5 General Board Member Axial SpA Foundation, not applicable, not applicable, Netherlands

Background: The National Rheumatoid Arthritis Society (NRAS) follows best practice, evidence-based standards in all we do. Huge strides have been made in the diagnosis and treatment of Rheumatoid Arthritis (RA), but impact on quality of life can be significant and for many, RA remains hard to come to terms with. Anxiety and depression are frequent co-morbidities seen in RA, and this can impede people’s ability to acquire knowledge of their disease together with supported self-management skills and coping strategies.

Objectives: The aim of Right Start (RS) is to improve outcomes of the recently diagnosed with RA through a framework of emotional, educational and peer support and access to high quality supported self-management resources tailored to individual need. RS also enables us to dispel myths and unhelpful health beliefs so that people get the ‘right start’ on their journey with RA to maximise health outcomes. A diagnosis of an incurable disease treated with life-long strong drugs is a life-changing event and without the right support it can be an isolating and emotionally very challenging experience for both the individual and their close family. We also wanted to give an opportunity for people to acquire understanding of the key role that support and self-management can play in improving quality of life, giving people back some control over their symptoms. Our goal was also to create a quick and easy way for HCPs to refer their patients to Right Start in a consented and GDPR compliant way.

Methods: HCPs are able to refer their patients via the ‘Refer a patient’ button on our website which takes them to a simple form which is filled in and submitted to NRAS with the patient’s consent. NRAS receive the referral and the form is integrated with our Salesforce database, and we contact the patient. RS involves a simple, 4-step process and the individual receives: A call (up to 1 hr) with a member of our helpline; 1:1 peer support (phone/Teams/Zoom) from trained volunteers with RA and access to 24/7 online community support; a tailored package of hard copy information with e-links/video/webinars of interest sent by post; further follow up available from helpline and individual peer support. RS enables health professionals to meet their responsibilities against NICE Quality Standard 33, Statement 3, (patient education and access to self-management resources) on which they are audited through National Early Inflammatory Arthritis Audit (NEIIA). RS is included in the NICE shared learning database of best practice examples. RS also supports the EULAR Recommendations for implementation of self-management strategies for patients with inflammatory arthritis.

Results: Since launch at BSR 2019, over 90 UK rheumatology units have referred over 435 patients to this service. Approx. 1/3rd cannot be contacted and after 3 attempts a letter and newly diagnosed pack are sent, inviting contact at future date. Anecdotally people are highly satisfied with this service and a number of units are referring multiple patients where the service is embedded in the patient pathway. To gather empirical data on the impact of the service NRAS has partnered with Manchester University to undertake an Enhanced Right Start pilot in 5 UK rheumatology units involving the use of validated patient reported outcome and experience measures from users recruited, and quantitative/qualitative data from health professionals. The pilot is due to commence recruitment in early Feb, 2022. Meantime, referrals to the standard service continue to grow.

Conclusion: Workforce shortages in all posts within the multi-disciplinary team, i.e. during the pandemic resulted in HCPs under immense pressure and time-poor. With a large backlog of patients has meant it’s extremely difficult for HCPs to meet Quality Standards and goals of audit. Feedback informs that HCPs find Right Start a beneficial service to refer their patients to and people with RA have found it more than helpful. We anticipate that the results of the Enhanced Right Start Service Pilot (see Results) will provide additional evidence to support HCP patient-referral to this service.

Acknowledgements: I would like to acknowledge the support of a number of UK consultant rheumatologists in the early stages of the development of this service, in particular Dr. James Galloway.

Disclosure of Interests: Ailsa Bosworth Speakers bureau: Where I have in the past the honorarium has been paid to NRAS not to me personally, Grant/research support from: Unrestricted educational grants have been paid to NRAS by a number of pharmaceutical companies in the last year, Clare Jacklin Speakers bureau: Where I have in the past the honorarium has been paid to NRAS not to me personally, Grant/research support from: Unrestricted educational grants have been paid to NRAS by a number of pharmaceutical companies in the last year.


OP0202-PARE NRAS NEW2RA RIGHT START SERVICE FOR PEOPLE RECENTLY DIAGNOSED WITH RA

A. Bosworth1, C. Jacklin2, National Rheumatoid Arthritis Society, Services, Maidenhead, United Kingdom; National Rheumatoid Arthritis Society, Services, Maidenhead, United Kingdom

Background: The National Rheumatoid Arthritis Society (NRAS) follows best practice, evidence-based standards in all we do. Huge strides have been made in the diagnosis and treatment of Rheumatoid Arthritis (RA), but impact on quality of life can be significant and for many, RA remains hard to come to terms with. Anxiety and depression are frequent co-morbidities seen in RA, and this can impede people’s ability to acquire knowledge of their disease together with supported self-management skills and coping strategies.

Objectives: The aim of Right Start (RS) is to improve outcomes of the recently diagnosed with RA through a framework of emotional, educational and peer support, and access to high quality supported self-management resources tailored to individual need. RS also enables us to dispel myths and unhelpful health beliefs so that people get the ‘right start’ on their journey with RA to maximise health outcomes. A diagnosis of an incurable disease treated with life-long strong drugs is a life-changing event and without the right support it can be an isolating and emotionally very challenging experience for both the individual and their close family. We also wanted to give an opportunity for people to acquire understanding of the key role that support and self-management can play in improving quality of life, giving people back some control over their symptoms. Our goal was also to create a quick and easy way for HCPs to refer their patients to Right Start in a consented and GDPR compliant way.

Methods: HCPs are able to refer their patients via the ‘Refer a patient’ button on our website which takes them to a simple form which is filled in and submitted to NRAS with the patient’s consent. NRAS receive the referral and the form is integrated with our Salesforce database, and we contact the patient. RS involves a simple, 4-step process and the individual receives: A call (up to 1 hr) with a member of our helpline; 1:1 peer support (phone/Teams/Zoom) from trained volunteers with RA and access to 24/7 online community support; a tailored package of hard copy information with e-links/video/webinars of interest sent by post; further follow up available from helpline and individual peer support. RS enables health professionals to meet their responsibilities against NICE Quality Standard 33, Statement 3, (patient education and access to self-management resources) on which they are audited through National Early Inflammatory Arthritis Audit (NEIIA). RS is included in the NICE shared learning database of best practice examples. RS also supports the EULAR Recommendations for implementation of self-management strategies for patients with inflammatory arthritis.

Results: Since launch at BSR 2019, over 90 UK rheumatology units have referred over 435 patients to this service. Approx. 1/3rd cannot be contacted and after 3 attempts a letter and newly diagnosed pack are sent, inviting contact at future date. Anecdotally people are highly satisfied with this service and a number of units are referring multiple patients where the service is embedded in the patient pathway. To gather empirical data on the impact of the service NRAS has partnered with Manchester University to undertake an Enhanced Right Start pilot in 5 UK rheumatology units involving the use of validated patient reported outcome and experience measures from users recruited, and quantitative/qualitative data from health professionals. The pilot is due to commence recruitment in early Feb, 2022. Meantime, referrals to the standard service continue to grow.

Conclusion: Workforce shortages in all posts within the multi-disciplinary team, i.e. during the pandemic resulted in HCPs under immense pressure and time-poor. With a large backlog of patients has meant it’s extremely difficult for HCPs to meet Quality Standards and goals of audit. Feedback informs that HCPs find Right Start a beneficial service to refer their patients to and people with RA have found it more than helpful. We anticipate that the results of the Enhanced Right Start Service Pilot (see Results) will provide additional evidence to support HCP patient-referral to this service.

Acknowledgements: I would like to acknowledge the support of a number of UK consultant rheumatologists in the early stages of the development of this service, in particular Dr. James Galloway.

Disclosure of Interests: Ailsa Bosworth Speakers bureau: Where I have in the past the honorarium has been paid to NRAS not to me personally, Grant/research support from: Unrestricted educational grants have been paid to NRAS by a number of pharmaceutical companies in the last year, Clare Jacklin Speakers bureau: Where I have in the past the honorarium has been paid to NRAS not to me personally, Grant/research support from: Unrestricted educational grants have been paid to NRAS by a number of pharmaceutical companies in the last year.


OP0202-PARE FATIGUE IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A SCOPING REVIEW ON ITS DEFINITION, MEASUREMENT INSTRUMENTS, DETERMINANTS, IMPACT AND INTERVENTIONS

E. Beckers1,2, K. Hermans1,2, A. van Tubergen1,2, A. Boonen1,2, Maastricht University Medical Center, Internal Medicine, Division of Rheumatology, Maastricht, Netherlands; 3 Maastricht University, Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands

Background: Fatigue is one of the most important symptoms of patients with rheumatic and musculoskeletal diseases (RMDs) and numerous studies on fatigue in patients with RMDs have been published. However, no overview exists
of all topics relevant to understand and manage fatigue in patients with rheumatoid arthritis (RA), spondyloarthritides (SpA, including psoriatic arthritis (PsA)), osteoarthritis (OA) and fibromyalgia (FM).

**Objectives:** To scope published reviews on aspects of fatigue identified by patients in a preceding initiative as relevant for care and mapped to the following research areas: 1) definitions for fatigue, 2) measurement instruments for fatigue, 3) determinants of fatigue, 4) impact of fatigue, and 5) effect of interventions on fatigue in patients with RMDs of interest.

**Methods:** A methodological framework for scoping reviews was followed. A systematic literature search was performed in five bibliographical databases. Data selection followed by data extraction was done by two independent researchers.

***Figure 1.* Determinants of fatigue and the related minimal number of underlying studies within reviews

Included reviews were categorized in Cochrane reviews (CRs), non-Cochrane systematic reviews (SRs) or narrative reviews (NRs). Data extraction was performed hierarchical based on review type (CRs followed by SRs and NRs) and year of publication. SRs and NRs were excluded if there was overlap in the underlying studies within the reviews. Data synthesis accounted for hierarchy in level of evidence by review type (CRs were considered as best evidence followed by SRs and NRs). For each research area and stratified per type of RMD, a narrative synthesis was performed. Two meetings were organized with a patient panel to discuss the results from a patient perspective.

**Results:** The scoping review included 144 reviews (18 CRs, 42 SRs and 84 NRs). RA was addressed most frequently (60/144 (42%)), Fatigue was a secondary outcome in the majority of these reviews.

No agreed upon definition for fatigue in any of the RMDs was found. Across reviews, there was agreement that fatigue is a complex multifactorial and highly subjective symptom, including various subtypes with specific characteristics. Reviews discussed 23 generic and 3 disease-specific self-reported outcome instruments to measure fatigue in RA, SpA and FM, but no reviews on outcome instruments for OA were found. Four of these 23 (17.4%) instruments included validated cut-off values to diagnose or classify excessive fatigue.

Numerous factors were associated with fatigue (Figure 1), but the study design (often cross-sectional) hindered studying causality. Across RMDs, pain, physical function, and depressive symptoms were the most frequently studied disease related factors; gender and stress the most frequent contextual factors related to fatigue. The strength of association was small or moderate, but mostly not reported. Work disability was one of the most frequently studied consequences of fatigue in RMDs, followed by impact on pain, physical activity and stress. Strength of these associations was not reported.

Finally, both pharmacological and non-pharmacological interventions, including physical activity-based and psychological interventions, generally had a small positive effect on fatigue in RMDs. No reviews described the effect of pharmacological interventions on fatigue in OA.

All results were relatable for the patient panel and some missing aspects were pointed out. The patient panel advised to develop a research agenda to specifically diagnose and treat excessive fatigue in RMDs, as continuing the current path is likely to increase publications about fatigue, but unlikely to change patients’ lives.

**Conclusion:** This scoping review emphasizes the complexity of fatigue. Only a minority of the reviews had a primary focus in fatigue, whereas to patients this prominent symptom deserves specific attention.

**REFERENCES:**


**Acknowledgements:** The authors thank the patient panel for their helpful contribution to this scoping review.

**Disclosure of Interests:** None declared

The active participation of 13 PRPs with well-defined roles and responsibilities ensures the preservation of the patient perspective during the entire duration of the project. Together they form the HIPPOCRATES Patient Advisory Council (PAC). PRPs are represented in the project’s management team, in all work packages and in the External Advisory Board. Three patient organisations support the project: GRAPPA-EU (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and EULAR CARE (People with Arthritis/Rheumatism in Europe) as consortium partners, and EUROPSO (European Federation of Psoriasis Patients’ Associations). EURAP is co-leading the work package focusing on Communication, Dissemination, Exploitation and Sustainability, and especially those activities targeting patients, PRPs (regular educational sessions), patient organisations and the general public. Finally, people with PsA will be recruited for a large European cohort study (HIPPOCRATES Prospective Observational Study, HPOS) which aims to identify clinical and molecular risk factors for developing PsA.

Results from the PRP survey were positive. Almost all PRPs have been invited to their work package meetings and included in email exchanges, and all feel well-included in their assigned groups and roles. Nevertheless, it was reported that some PRPs may be reluctant to raise their voice or to be involved in discussions at virtual meetings. This was one of the topics addressed during the online workshop, together with discussions on ethics and recruitment strategies for HPOS.

**Conclusion:** It has been central to the HIPPOCRATES ethos that highly experienced PRPs were involved from its initial conception. PRPs with leading responsibilities in patient organisations or representing relevant academic backgrounds have contributed substantially to the definition of research priorities and will have active ongoing engagement in the interpretation and implementation of future results. By demonstrating the pervasive benefit of the patient voice throughout the project, HIPPOCRATES will be an example for future projects in RMD and health research.

**Acknowledgements:** Meaningful patient involvement is critical to successful international grant applications: the case of the HIPPOCRATES consortium ("Health initiatives in Psoriasis and Psoriatic arthritis ConsorRTium European States")

Lars Werner on behalf of the HIPPOCRATES Patient Advisory Council (PAC)

**Disclosure of Interests:** Lars Werner Speakers bureau: Novartis, Janssen, LEO Pharma, Consultant of: Novartis, Janssen, LEO Pharma, B-I, UCB, Grant/ research support from: Novartis, Janssen, LEO Pharma, UCB, AbbVie, Sanofi, B-I, BMS, Pfizer, Employee of, LEO Pharma, AbiVie

**DOI:** 10.1136/annrheumdis-2022-eular.1510

**OP0206-PARE FOOD COMMUNITIES**

P. Del Pin, 1, Gentoffe, The Danish Rheumatism Association, Gentofte, Denmark

**Background:** In recent years the focus on healthy food and lifestyle has become a more important part of everyday life for many – with or without RMD. Many NGO-initiatives engaging citizens cooking and eating together has seen the light of day; people meet to talk, laugh and have a good time while making a healthy meal. The kitchen is an often discussed topic among the volunteers and members of The Danish Rheumatism Association. “Simple” tasks as opening a can of beans or cutting bread can be complicated for people with RMDs. The fundamentals of cooking are different for this group of people; hence the idea of communities around “arthritis friendly” food unfolded during fall 2019.

**Objectives:** The main objective is to create “food communities” for people with RMDs, helping them to get a better understanding of how to make “arthritis friendly food”; dispel the myth that it is expensive and hard, and to give them inspiration to find working positions with assistive devices - resulting in a healthier lifestyle which is important to keep the inflammation low and the quality of life high.

**Methods:** To obtain these objectives, a dietitian is facilitating 6 three hour “courses” guiding the participants through healthy cooking – each course with a different theme/subject which is introduced through a short presentation. Two volunteers are responsible for booking kitchen facilities (often school kitchens which is free of charge), coordination with the dietitian and making sure everything runs smoothly and that the atmosphere is top-notch. An occupational therapist is joining the group one time to ensure optimal working positions and introducing and demonstrating assistive devices.

**Conclusion:** The main goals is to create more sustainable and lasting (more than 6 facilitated courses) communities, which is why an important part of the volunteer’s responsibility is to initiate a talk about the opportunity of meeting without a dietitian. The 6 facilitated courses aim to give the group the ability to find recipes (provided by DRA) and being comfortable cooking with ingredients that the average Dane might not use very often. Furthermore, our assumption is that the group creates social bonds and therefore an interest in keeping these relations.

**Results:** About twenty groups all around Denmark has been a part of the course so far. The feedback from the participants is extremely good – they feel they are learning in an inspiring environment while having a great time with their new acquaintances. Unfortunately, only one of the groups has become a community that exists after the facilitated courses. One of the reasons is, without a doubt, that most of the groups have been affected by different Covid-19 restrictions which has had an impact on the level of social bonding and feeling of ownership. But most participants feel that the dietitian is crucial for further engagement.

**Conclusion:** The concept has been very successful in terms of creating a course that imparts useful knowledge about “arthritis friendly” food and lifestyle for people with RMD’s. It seems we need to make corrections to create the base for sustainable communities; small changes that helps the group visualizing how to overcome the challenge of the absence of a dietitian, the logistics of grocery shopping for a group etc. We plan to leave out the dietitian from the fifth of the six courses to prepare the group to establish their own “food community” with lots of healthy food, learning experiences and high spirit.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1736

**OP0205-PARE GREEK RMDs PATIENT’S NEED FOR SELF-MANAGEMENT AND THE USE OF NEW TECHNOLOGIES: THE CASE STUDY OF THE HELLENIC LEAGUE’S AGAINST RHEUMATISM SUPPORT LINE**

N. Malliou, 1, K. Antonopoulou, 1, Hellenic League Against Rheumatism, ELEANA/HELAR, Thessaloniki, Greece; 2Hellenic League Against Rheumatism, ELEANA/HELAR, Athens, Greece

**Background:** The Hellenic League Against Rheumatism (ELEANA/HELAR) offers psychosocial support to its members, patients with RMDs, their families and everyone else that’s interested in RMDs. More than 5000 members from all over Greece, with local ELEANA/HELAR groups in major cities such as Athens, Patras, Karditsa, Trikala, Thessaloniki and others. The helpline has been receiving incoming calls from patients with RMDs, members of ELEANA, their relatives and others that are interested in RMDs or are requesting information.

**Objectives:** This case study aimed at outlining that self-management is the main reason for incoming calls to ELEANAs helpline and secondly that during the pandemic and even after lockdown measures being lifted patients still use the online support offered thus making it apparent that digitalization is not a trend anymore but a necessity.

**Methods:** Empirical data from the helpline were gathered through the day-to-day helpline registry. This is a detailed registry containing basic info on demographics of the callers, reasons for calling and outcome of communication. Descriptive statistics as well as qualitative data have been used such as observations of the trained staff of the helpline.

**Results:** From 543 incoming calls, 49.91% were about self-management and the rest 50.09% were calls requesting information, 52.40% of self-management calls were about psychological issues (anxiety, depressive symptoms) and the rest were about treatment (adherence), such as the use of medication, alternative treatments, medical issues and questions on RMDs. 40.96% of patients with RMDs called again the helpline to follow up and 61.25% used online tools to communicate with the helpline both times. Psychologists receiving calls observed that patients needed counseling regarding their self-management, especially during the pandemic and that even though lockdown is lifted they keep on requesting online communication instead of face-to-face meetings.

**Conclusion:** The above findings show that digitalization is not a trend rather than a necessity in the self-management of RMDs. Patients seem to find it easier receiving support online and the requests for online support for their anxiety, depressive symptoms, difficulties in managing their medication makes it clear that more emphasis needs to be put on self-management programs.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1510

**Figure 1 Multiple layers of patient involvement in HIPPOCRATES**
HPR interventions on the spotlight

**OP0207-HPR**  
**EFFECT OF FOOT ORTHOSES IN REDUCING PAIN IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A 12-MONTH RANDOMISED CLINICAL TRIAL**


1University of Newcastle, College of Health, Medicine and Wellbeing, Callaghan, Australia; 2Faculty of Physical Education and Sport, Charles University, Department of Physiotherapy, Prague, Czech Republic; 3Queen Margaret University, Podiatry, Edinburgh, United Kingdom; 4Hunter Medical Research Institute, Statistics, New Lambton Heights, Australia

**Background:** Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children and adolescents [1]. The manifestation of JIA may include joint swelling, tenderness, and painful limitation with joint motion. Only few studies have explored the effect of foot orthoses (FOs) alone in children with JIA [2,3]. These studies showed FOs can reduce pain in children with JIA, however, further research with larger sample sizes and longer follow-ups are needed [4]. Prescribing FOs on the same day of the initial assessment may promote early clinical and targeted intervention, which is the gold standard approach in paediatric rheumatology.

**Objectives:** This single blinded multicentre randomised clinical trial (RCT) aims to investigate the effect of customised prefabricated FOs in reducing pain amongst children and adolescents with JIA.

**Methods:** Overall, 66 children and adolescents with JIA presenting with foot symptoms were recruited from the Sydney Children's Hospital Network (Westmead and Randwick) and John Hunter Children's Hospital (Newcastle). The primary outcome measure was pain with a minimal clinical significance of 8mm on the visual analogue scale (VAS). Participants were randomly allocated to receive either customised prefabricated or sham FOs. The trial intervention was a low-density Slimflex Simple device that was customised at chair-side. The control (sham) device was made of 2mm flat leather board with no corrective modifications. Standardised tests such as the Foot Posture Index, navicular drift and drop were used to identify biomechanical abnormalities. The FOs were worn for a total of 12 months, with data collected at baseline, 4 weeks, 3, 6 months, and 12 months.

**Results:** Reduction in self-reported pain was statistically and clinically significant at 4-weeks (p<0.018, -14.92 [-27.30, -2.55]) and 3 months (p<0.001, -28.93 [-40.90, -16.96]) post intervention in favour of the trial group. The 6- and 12-month follow-ups were not statistically or clinically significant. Parent reported pain was statistically and clinically significant at the 3-month (p<0.001, -21.92 [-33.16, -10.67]) in the reduction of pain in favour of the trial group. However, parent reported pain was not statistically significant at the 4-week, 6- and 12-month follow-ups. These results are similar to child reported pain with a p-value of less than 0.001 and average coefficients twice that of the clinical significance cut-off for VAS pain in paediatric rheumatology. The trial intervention was safe and tolerated well by participants with high compliance and adherence rates.

**Conclusion:** Results of this clinical trial indicate customised preformed FOs can be effective in reducing pain and in children with JIA experiencing foot and ankle symptoms. Significant clinical effects appear to be within the first 3-months of intervention prescription and reduce beyond 6 months. Overall, this paediatric intervention was safe, inexpensive, well tolerated and can be easily implemented as part of the multidisciplinary paediatric rheumatology care.

**REFERENCES:**


**Acknowledgements:** We would like to acknowledge all parents and children for their precious time.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.854

---

**OP0208-HPR**  
**EFFECT OF AN 8-WEEK SPECIALIZED PHYSICAL THERAPY PROGRAM ON SEXUAL HEALTH IN FEMALE PATIENTS WITH SYSTEMIC SCLEROSIS AND IDIOPATHIC INFLAMMATORY MYOPATHIES: A PILOT STUDY**

B. Heřmánková1, M. Štorkánová1, H. Štorkánová1, M. Tomčíková3, M. Tomčík4, B. Heřmánková1, M. Štorkánová1, K. Pavélka1, L. Šenolt1, J. Vencovský3, R. Bečvář1, M. Tomčík1,2, Institute of Rheumatology, Department of Rheumatology, Prague, Czech Republic; 2Faculty of Physical Education and Sport, Charles University, Department of Physiotherapy, Prague, Czech Republic; 3First Faculty of Medicine, Charles University, Department of Rheumatology, Prague, Czech Republic.

**Background:** Systemic rheumatic diseases like systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM) may affect all aspects of life, including sexual health however, no non-pharmacological treatment has been proposed to date.

**Objectives:** This is the pilot project aiming to investigate the effect of an 8-week physical therapy program on sexual function in women with SSc and IIM.

**Methods:** In total, 12 women with SSc and 4 women with IIM, who fulfilled the ACR/EULAR 2013 criteria for SSc and the Bohan/Peter 1975 criteria for DM/PM, respectively, were enrolled in the study. Based on patient’s possibilities and willingness to participate in the program, they were divided into an intervention group (IG) (6 SSc/2 IIM, mean age: 46.8±3.1 years) and a control group (CG) (6 SSc/2 IIM, mean age: 46.3±3.0 years). The IG underwent the 8-week tailored physiotherapy program, including the pelvic floor exercise and physiotherapy of musculoskeletal problems subjectively limiting the patient’s sexual function (1hour supervised physiotherapy twice weekly), whereas the control group received no specialized therapy. At weeks 0 and 8, all patients filled in questionnaires assessing sexual function: Female Sexual Function Index (FSFI), Brief Index of Sexual Functioning for Women (BISF-W); sexual quality of life: Sexual Quality of Life Female (SQoL-F); functional ability: Health Assessment Questionnaire (HAQ); quality of life: Medical Outcomes Short Form-36 (SF-36) and depression: Beck’s Depression Inventory-II (BDI-II). At the baseline, patients in IG were assessed by a physician (medical history, mRSS, ESSG activity score, MITAX, MYOACT) and by a physiotherapist (pelvic floor function assessment–PERFECT scheme, MMT-8, Functional Index-II). Normality of data was tested, and inter-group analysis was performed with 2-way ANOVA and intra-group analysis by Friedman’s test.

**Results:** Compared to observed statistically significant deterioration in CG over the period of weeks 0–8, we found statistically significant improvement in both intervention questionnaires: FSFI (p=0.043), BISF-W (p<0.040), functional status: HAQ (p=0.018), and quality of life: SF-36 Physical Component score (0.050). Only numerical improvement in IG compared to numerical deterioration in CG, which has not reached statistical significance, was observed in SQoL-F, BDI-II, and SF-36 Mental Component Score.

**Conclusion:** Our physiotherapy program not only prevented the natural course of progressive deterioration of functional abilities, but also led to a significant improvement in sexual function and overall quality of life in women with SSc and IIM. Physical therapy might become one of the possible therapeutic treatments for sexual problems in women with SSc and IIM.
Background: There is a well-known variability in the quality of rehabilitation provided to patients with rheumatic and musculoskeletal diseases (RMDs). Elements to be improved are a higher standardization of the core content, optimal patient participation in goal setting and continuation of the process in tailored follow-up. More knowledge is needed on critical features for successful delivery of improvement programs in rehabilitation.

Objectives: To investigate how a team-based quality improvement program was implemented and how it influenced the quality in RMD rehabilitation.

Methods: This convergent mixed methods study is nested within a stepped-wedge, randomized controlled trial where providers at 8 rehabilitation-centers delivered traditional programs in the control phase (T1), and added the BRIDGE quality improvement program in the intervention phase (T2). The BRIDGE program addressed a dialog-based, multidisciplinary approach to support the patients’ self-management, comprising motivational interviewing, goal setting, plans for rehabilitation, feedback and monitoring of progress, and tailored follow up. Providers answered 19 structure indicators from a quality indicator (QI) set for RMD rehabilitation [1] at T1 and T2, and a program-fidelity checklist with 18 items at T1 and T2 (both scores range 0-100, 100=best). Qualitative data was collected in three focus groups (FG) with the BRIDGE providers, and analyzed using reflexive thematic analysis. Integration and discussion of findings from the different data sources are ongoing, in our research group.

Results: Median summary pass rate for the structure QIs for all centers increased from 59 to 90% between T1 and T2. Program-fidelity was high, with a median summary score of 94% (range 61–100%), but lowest for program-components related to follow-up and communication with external services. Themes developed from the FG interviews reflected that variations in how the program was implemented related to features of the providers and institutions. More specific; the delivery of high-quality rehabilitation depended on the degree to which the providers trained their communication skills, used available tools to support their practice, and grounded their interventions in professional reasons. Critical organisational features at the institutions were dedicated time for team-work based on the patients’ plans for self-management, and sufficient attention to needs for involvement of next of kin or external services. Additionally, better program-implementation occurred if providers experienced an institutional culture for quality improvement, such as educational initiatives from the leaders. Preliminary integration of data is summarized in Figure 1. Congruent evidence in both quantitative and qualitative findings addressed the sustained needs for better quality in the area of follow-up across levels of care. However, the qualitative findings provided expanded insights on variability also in initial parts of the rehabilitation process. Presumably, these variations in delivery reported in interviews are important for the effectiveness of a quality improvement program, but difficult to capture in questionnaires.

Conclusion: To target specific strategies for quality improvement, we suggest a combined attention not only to recommended care reflected in quality indicators and measurable aspects of fidelity, but also to contextual factors, including the providers’ confidence and skills needed to provide a high-quality delivery of all components in a rehabilitation improvement program.

REFERENCES:

Disclosure of Interests: None declared

Figure 1. Complementary viewpoints on how the BRIDGE program was provided and how it influenced the quality of rehabilitation.

Conclusion: To target specific strategies for quality improvement, we suggest a combined attention not only to recommended care reflected in quality indicators and measurable aspects of fidelity, but also to contextual factors, including the providers’ confidence and skills needed to provide a high-quality delivery of all components in a rehabilitation improvement program.

REFERENCES:

Acknowledgements: We would like to thank Yvonne Peters for her involvement in the study design and data collection.

Disclosure of Interests: None declared
EXPERIENCES DURING THE COVID-19 PANDEMIC AMONG PEOPLE WITH INFLAMMATORY ARTHRITIS. “REOPENING IS SOMEWHAT HARDER THAN LOCK-DOWN” - A QUALITATIVE INTERVIEW STUDY

L. Lund1, M. Law1, O. Hendrick2, K. Schreiber2, B. Glintborg2, R. Petersen2, C. Pischelke3, W. Fick3, J. Primdahl3,1, University College UC SYD, Esbjerg, Denmark, Research Center of Applied Health Science (SuPra), UC SYD, Esbjerg, Denmark, Esbjerg, Denmark, Esbjerg, Denmark; 2Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark, Department of Regional Health Research, University of Southern Denmark, Odense, Denmark, Sønderborg, Denmark; 3DANBIO and Copenhagen Rheumatology Research Center (COPECare), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, University Hospital Copenhagen Rigshospitalet, Glostrup, Denmark, Department of Clinical Medicine, Faculty of health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, Copenhagen, Denmark; 4Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark, Patient Research Partner, Sønderborg, Denmark, 5University Hospital of Southern Denmark, Aabenraa, Denmark, Sygehus Sønderjylland, Aabenraa, Denmark, Aabenraa, Denmark

Background: People with inflammatory arthritis (IA) treated with conventional or biological immunosuppressive disease-modifying anti rheumatic drugs (DMARDs), were initially concerned to have an increased risk of severe illness from SARS-CoV-19 (COVID-19) infection compared to the general population. Although recent studies have not confirmed this, people with IA have reported high level of anxiety and self-isolation during the pandemic (1). Only few studies have qualitatively explored how people with IA experience the impact the COVID-19 pandemic and the SARS-CoV-19 vaccinations.

Objectives: To explore how people with IA experienced restrictions during the COVID-19 pandemic and the possible impact of vaccination on their protection against COVID-19 and their everyday lives.

Methods: Semi-structured in-depth interviews were conducted via telephone or video with 19 people with IA in May – August 2021, shortly after they were enrolled in the national COVID-19 vaccination programme (all Danish citizens >18 years of age invited for SARS-CoV-19 vaccination, free of charge, with timing depending on age and comorbidities). At the same time, society gradually reopened after a complete lock-down. Qualitative content analysis, inspired depending on age and comorbidities). At the same time, society gradually reopened after a complete lock-down. Qualitative content analysis, inspired by Graneheim and Lundman (2), was applied to analyse the data. Two patient research partners were involved in development of the study protocol, an interview guide and in the interpretation of findings.

Results: The participants’ age ranged from 21 to 64 years, median 50 years. 7 male and 12 female, all diagnosed with IA (Psoriatic arthritis n=4, Axial Spondyloarthritis n=4, Rheumatoid arthritis n=9, and Juvenile arthritis n=2) and 14 were treated with DMARDs. Two had not accepted vaccination. The analysis derived five themes: 1: “Changing and divergent information”: The participants experienced there was an overload of general information reflecting that par - 2: “Impact on everyday life”: They took self-imposed precau - 3: “Position in society and the vaccination programme”: emphasizing that participants were affected by the inconsistent announcements from authorities whether they were considered to be in particular risk or not, and some expressed concerns regarding the DMARDs influence on the effect of the vaccine and 5: “Reopening is somehow harder than lock-down”: A societal spirit of being “in this together” emerged through the lock-down and some were concerned that fewer restrictions during reopening of the society would put them in higher risk of a COVID-19 infection and force them to continue self-isolation.

Table 1. Quotation to illustrate the findings

<table>
<thead>
<tr>
<th>Quotation</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>“...you felt like one in the crowd and then everything is easier. Even though it was difficult. But then; it was difficult for all of us. It had nothing to do with my rheumatic disease...we were in this together...But it was harder when the reopening started. Because it’s like; I’m back on the platform and can’t just jump on the train, can’t go anywhere, that is...I’m just not quite ready to jump into society like everyone else...”</td>
<td>Participants felt isolated during lockdown and were more connected during the lockdown. Reopening forced them to adjust their lives.</td>
</tr>
</tbody>
</table>

Conclusion: The COVID-19 pandemic affected the everyday lives of people with IA due to the authorities' restrictions and further self-imposed precautions throughout lock down and reopening of society. People with IA experienced a lack of consistent information and felt alone to assess their own SARS-Cov-19 infection risk.

REFERENCES:

Disclosure of Interests: None declared

PATIENT ASSESSMENT CHRONIC ILLNESS CARE (PACIC) AND ITS ASSOCIATIONS WITH QUALITY OF LIFE AMONG SWISS PATIENTS WITH SYSTEMIC SCLEROSIS – A MIXED METHODS STUDY

A. Kocher1, 2, M. Simon1, 2, A. A. Dwyer1, 4, C. Blatter1, J. Bogdanovic1, P. Künzli-Heule1, 3, P. Villiger1, D. Dan1, O. Dister4, U. Walker4, D. Nicca1, 1
1Institute of Nursing Science (INS), University of Basel, Department Public Health (DPH), Basel, Switzerland; 2Inse Ipital, Bern University Hospital, Department of Nursing, Bern, Switzerland; 3Connell School of Nursing, Boston College, Chestnut Hill, Massachusetts, United States of America; 4Munn Center for Nursing Research, Massachusetts General Hospital, Boston, Massachusetts, United States of America; 5Cantonal Hospital St. Gallen, Department of Gastroenterology/Hepatology and Department of Nursing, St. Gallen, Switzerland; 6Medical Center, Monblijou, Bern, Switzerland; 7Lausanne University Hospital, University of Lausanne, Service of Rheumatology, Lausanne, Switzerland; 8University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland; 9University Hospital Basel, Department of Rheumatology, Basel, Switzerland; 10Institute for Epidemiology, Biostatistics and Prevention, University of Zurich, Department of Global and Public Health, Zurich, Switzerland

Background: Variable disease presentation and symptom burden in patients living with systemic sclerosis (SSc) require a chronic care approach including competent, coordinated, multidisciplinary collaboration as well as self-manage -

Methods: We employed an exploratory sequential mixed methods design (Figure 1). First, we conducted a cross-sectional quantitative survey (n=101 Swiss patients) using the Patient Assessment of Chronic Illness Care (PACIC)20) and Systemic Sclerosis Quality of Life (SScQol)3 questionnaires. Because PACIC has not been used in the context of SSc, we used the Mokken model to test the construct validity of the PACIC scale and its subscales. After excluding five problematic items, H coefficients were strong for the subscales and the global scale (0.52) suggesting a robust unidimensional scale.

Table 1. Research Overview

<table>
<thead>
<tr>
<th>Research Overview</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective 1: Assess the construct validity of the PACIC scale and its subscales.</td>
</tr>
<tr>
<td>Objective 2: Examine the associations between the PACIC scale and its subscales with SScQol2.</td>
</tr>
</tbody>
</table>

Figure 1. Schematic of the explanatory, sequential mixed methods design

Next, we used data from individual patient interviews (n=4) and one patient focus group (n=4) to further explore care experiences of people living with SSc with a focus on the PACIC dimensions.

Results: The mean overall PACIC-15 score was 3.0 / 5.0 (95% CI: 2.8–3.2), indicating care was ‘generally not’ aligned with the CCM. Lowest subscale scores related to ‘goal setting/ tailoring’ (mean = 2.5, 95% CI: 2.2–2.7) and ‘problem solving/contextual counselling’ (mean = 2.9, 95% CI: 2.7–3.2) (Table 1). No significant associations were identified between the mean PACIC-15 and SScQol scores.

Disclosure of Interests: None declared
INTRODUCTION

Background: The number of new treatments available in rheumatology continues to increase. Kinase inhibitors, or jakinibs, pose an added challenge due to the variety and because they are oral. The most important role of the rheumatology nurse is patient education, especially on how to take the medication. It is recommended to instruct the patient on preventive measures for infectious diseases (dental and hand hygiene, HPV, social distance, etc.). Recommendations will allow a practical approach to the management of jakinibs by nurses and enjoy an adequate consensus among potential users.

Disclosure of Interests: José María Martín Martin Speakers bureau: Lilly, Consultant of: Lilly, Grant/research support from: Galapagos, Silvia García-Díaz Grant/research support from: Galapagos, Amparo Molina Grant/research support from: Galapagos, Carmen Domínguez Grant/research support from: Galapagos, Loreto Carmona: None declared, Laura Cano García Grant/research support from: Galapagos.

Objectives

To establish practical, evidence-based nursing recommendations for the management of people with RA undergoing treatment with jakinibs.

Methods

To reach an evidence-based consensus we used systematic review and Delphi survey. A multidisciplinary panel of experts was formed with 6 rheumatology nurses, 2 rheumatologists, 1 psychologist, 1 dietician-nutritionist and 1 patient on treatment with jakinibs. This panel met on 2 occasions and was kept informed at all times of the progress of the project through the Miro platform. At the preparatory meeting the scope and users, structure and PICOt questions were established (these included efficacy and adverse effects, infections, cardiovascular risk, surgery, vaccination, pregnancy and breastfeeding, interactions and switches between jakinibs).

The steering group made recommendations based on the issues raised at the first meeting. Only those that achieved 85% in favour were included as items in a Delphi survey. The Delphi survey was sent to all members of the society nurses and rheumatologists (n=60). Voting ranged from 0 to 10 (strongly disagree to strongly agree). Items with more than 75% agreement in the first round did not proceed to a second round.

RESULTS

Table 1 shows the recommendations with their level of evidence and level of agreement after the Delphi (n=40; 67%). One item with only 50% agreement was rejected and did not proceed to a second round.

Table 1. Recommendations for the management of RA patients on treatment with jakinibs.

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Level of evidence</th>
<th>Degree of agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before starting treatment with a jakinib, it should be confirmed that the patient has no contraindications.</td>
<td>5</td>
<td>100%</td>
</tr>
<tr>
<td>The patient’s efficacy and outcome expectations for the drug should be explored and those that need to be adjusted.</td>
<td>5</td>
<td>85%</td>
</tr>
<tr>
<td>It should be indicated that a double dose should not be taken if one is missed.</td>
<td>4</td>
<td>100%</td>
</tr>
<tr>
<td>As with other DMARDs, the patient should be instructed that close management will follow.</td>
<td>5</td>
<td>99%</td>
</tr>
<tr>
<td>The use of contraception and discontinuation of the drug is recommended in case of gestational desire or unplanned pregnancy.</td>
<td>3</td>
<td>96%</td>
</tr>
<tr>
<td>It is recommended to explain the warning signs of infection: fever, blisters, burning pain in the ribs, itching when urinating, productive cough, diarrhoea, pus-filled wounds, plegmon.</td>
<td>1a</td>
<td>100%</td>
</tr>
<tr>
<td>It is recommended to instruct the patient on preventive measures for infectious diseases (dental and hand hygiene, HPV, social distance, etc.).</td>
<td>1a</td>
<td>89%</td>
</tr>
<tr>
<td>Vaccination against common germs in immunocompromised persons and shingles with the current vaccine is recommended.</td>
<td>1a</td>
<td>93%</td>
</tr>
<tr>
<td>CV risk factors should be monitored, and the patient trained for signs of thrombosis, HF or ischaemic heart disease.</td>
<td>1a</td>
<td>89%</td>
</tr>
<tr>
<td>Close monitoring of elderly patients (CV risk, infections) is recommended.</td>
<td>2</td>
<td>100%</td>
</tr>
<tr>
<td>Emphasis on adherence is recommended for jakinibs to be effective.</td>
<td>3</td>
<td>100%</td>
</tr>
<tr>
<td>Before surgery, discontinuation of jakinib should be scheduled depending on the type of surgery and comorbidities.</td>
<td>3</td>
<td>89%</td>
</tr>
</tbody>
</table>

CONCLUSION

These recommendations will allow a practical approach to the management of jakinibs by nurses and enjoy an adequate consensus among potential users.

Disclosure of Interests: José Maria Martin Martin Speakers bureau: Lilly, Consultant of: Lilly, Grant/research support from: Galapagos, Silvia García-Díaz Grant/research support from: Galapagos, Amparo Molina Grant/research support from: Galapagos, Carmen Domínguez Grant/research support from: Galapagos, Loreto Carmona: None declared, Laura Cano García Grant/research support from: Galapagos.

DOI: 10.1136/annrheumdis-2022-eular.5005

OP0214-HPR

EDUCATIONAL NEEDS AMONG HEALTH PROFESSIONALS IN RHEUMATOLOGY: LOW AWARENESS OF EULAR OFFERINGS AND UNFAMILIARITY WITH COURSE CONTENT AS A MAJOR BARRIER – A EULAR FUNDED EUROPEAN SURVEY


Objectives

To establish awareness of EULAR offerings and unfamiliarity with course content as major barriers among health professionals in rheumatology.

Methods

A survey was conducted among health professionals in rheumatology including physicians, nurses, and other healthcare professionals. A questionnaire was designed to assess their awareness of EULAR offerings and their familiarity with course content. The questionnaire included questions on their awareness of EULAR offerings, their familiarity with course content, and their willingness to participate in EULAR courses.

RESULTS

The survey revealed that only a small proportion of respondents were aware of EULAR offerings. Furthermore, most respondents reported a lack of familiarity with course content. These findings indicate a need for increased awareness and education among health professionals in rheumatology.

CONCLUSION

These findings highlight the importance of increasing awareness and education among health professionals in rheumatology. Efforts should be made to improve awareness of EULAR offerings and to increase familiarity with course content. This may include the development of outreach strategies, the provision of educational materials, and the implementation of educational programs.
Background: Health professionals in rheumatology (HPRs) should participate in post-graduate or continuous education to update and advance their knowledge and skills. This can improve patient outcomes and increase quality of care. EULAR aims to become a leading provider of postgraduate education for HPRs.

Objectives: The aims of this study were to evaluate the current motivations for participating in postgraduate education of HPRs, identify barriers and facilitators for participation in postgraduate education, and evaluate participation in the current educational offerings of EULAR for HPRs across Europe.

Methods: An online survey was developed and distributed in collaboration with the EULAR Standing Committee of Education and Training (ESCET) and the Paediatric Rheumatology European Society (PRoE5). The questionnaire was translated by national HPR representatives in 24 languages to cover the 23 national member organisations. Barriers were assessed using 5-point Likert scales, higher scores representing higher barriers. Quantitative data was analysed using descriptive statistics. In addition, we ran the Latent Dirichlet Allocation (LDA) on the answers to the open questions. LDA is an unsupervised probabilistic topic modelling technique that extracts the meanings of a large number of documents.

Results: The online questionnaire was accessed 3,588 times but only 667 complete responses were recorded. HPRs from 34 European countries responded to the survey; 80% of whom were women. The highest-ranked educational need was prevention, including lifestyle interventions and professional development. Although EULAR was well known among HPRs, only 32.1% of HPRs in adult care and 15.2% of HPRs in paediatric care had ever heard of the EULAR School of Rheumatology (Table 1 A).

The main barriers to participation in EULAR's educational offerings were identified by HPRs in adult care and in paediatric care (respectively) as: the unfamiliarity with the course content (3.46 [±1.35]; 3.69 [±1.28]) and English language (2.59 [±1.50]; 2.80 [±1.34]).

Conclusion: EULAR is well-known by HPRs in Europe; however, awareness of educational offerings is low and barriers to participation are numerous. To become the leading provider of postgraduate training by 2023, EULAR could use a "franchise" model that can be tailored to local conditions. This could be achieved by strengthening national organisations by actively involving them in the development of training programs and disseminating these programs and offerings through their networks.

REFERENCES:

Disclosures of Interests: Lisa Sperl: None declared, Tanja Stamm: None declared, Claudia Naimer-Stach: None declared, Mwidimi Ndosi: None declared, Polina Pchelinskova: None declared, Jette Primdahl: None declared, Polina Putrik: None declared, Claudia Naimer-Stach: None declared, Mwidimi Ndosi: None declared, Polina Pchelinskova: None declared, Jette Primdahl: None declared, Polina Putrik: None declared, Anne-Kathrin Rausch Osthoff: None declared, Hana Smucrova: None declared, Andrea Marques: None declared, Jorit Meesters: None declared, Rikke Helene Moe: None declared, Ellen Mohnott: None declared, Erika Mosor: None declared, Claudia Naimer-Stach: None declared, Mwidimi Ndosi: None declared, Polina Pchelinskova: None declared, Jette Primdahl: None declared, Polina Putrik: None declared, Anne-Kathrin Rausch Osthoff: None declared, George E. Fragoulis: None declared, Ricardo J. O. Ferreira: None declared, Ricardo J. O. Ferreira: None declared, George E. Fragoulis: None declared, Ricardo J. O. Ferreira: None declared, George E. Fragoulis: None declared.
Improving outcomes for children with JIA

**OP0215**
WHAT DOES THE PATIENT WELL-BEING VAS TELL US WHEN THE PHYSICIAN GLOBAL ASSESSMENT SCORE IS ZERO? ANALYSIS OF A LARGE MULTINATIONAL DATASET

M. Buronne1, R. Naddes1, F. Fidelini2, C. Trinicianti3, C. Herrera Mora4, C. Malagon5, A. Ibañez6, O. Arguedas7, N. Ruperto1, A. Ravelli1, A. Consolaro1,2

1IRCCS Istituto Giannina Gaslini, Clinic of Paediatrics and Rheumatology, Genoa, Italy; 2Gianna Gaslini Institute, University of Genova, Genova, Italy; 3Hospital de Niños Roberto Gilbert Elizalde, Reumatología, Guayaquil, Ecuador; 4Hospital Universitario Simon Bolivar, Clínica Infantil Colsubsidio, Bogota, Colombia; 5National Institute Salud del Nino, Rheumatology, Lima, Peru; 6Hospital Nacional De Niños Dr. Carlos Saenz Herrera, Immunology, San José, Costa Rica

Background: Parent- and child-reported outcomes (PCROs) are measures that reflect the parent and child perception of rheumatic disease course and effectiveness of therapeutic interventions. Among PCROs for the assessment of patients with juvenile idiopathic arthritis (JIA), the most widely adopted is the patient/patient global evaluation or well-being visual analogue scale (WB-VAS). Several studies in JIA have highlighted the discrepancies in the assessment of the disease status between the physician and the parent/patient. This difference might be due to the WB-VAS measuring a broader construct than the physician (clinical assessment).

Objectives: To evaluate, in a large multinational sample of JIA patients, the disease characteristics of subjects considered as inactive by the physician with an increased WB-VAS score.

Methods: Data from the multinational dataset of patients enrolled in the Epidemiology Treatment and Outcome of Childhood Arthritis (EPOCA) study were analyzed. We have included only subjects with a PGA score of 0. PCROs were collected through the juvenile arthritis multidimensional assessment report (JAMAR). We compared demographic features, socio-economic status, level of education, subtype of JIA diagnosis and the main PCROs (pain level, presence of morning stiffness, count of joints with swelling or pain, functional ability, disease activity level, ongoing therapy, presence of medications side effects and health related quality of life measured with the pediatric rheumatology quality of life (PRQL) scale) between subjects with WB-VAS ≤1 and > 1.

Results: A total of 3537 patients were sorted into two groups according to the WB-VAS score: 2862 subjects were included in a first group (WB-VAS ≤1); 675 in a second one (WB-VAS > 1). Respectively, 17.6% and 18.1% of families belonged to the lower socio-economic status, 70.5% and 71% to the intermediate, 11.9% and 10.8% to the higher. The percentages of patients in the three levels of education was not different in the two groups: 20.2% and 22% in the intermediate, 11.9% and 10.8% to the higher. The percentages of patients in the three levels of education was not different in the two groups: 20.2% and 22% in the intermediate, 11.9% and 10.8% to the higher. The percentages of patients in the three levels of education was not different in the two groups: 20.2% and 22% in the intermediate.

Conclusion: We have analyzed the variables that might determine a difference between the physician's assessment of inactive disease and the parent/patient’s perception of well-being. In particular the socio-economic status, level of education, and gender representation seem not to impact on the general perception of well-being, while pain seems to have the greatest influence on the parent/patient quality of life assessment. Finally, children with lower WB-VAS score were younger at disease onset.

**REFERENCES**

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4624

**OP0216**
DEVELOPMENT, REFINEMENT AND WEIGHTING OF CANDIDATE CRITERIA FOR AXIAL DISEASE IN JUVENILE SPONDYLOARTHRITIS: AN INTERNATIONAL COLLABORATION

P. Weiss1,2, T. G. Brandon1, A. Aggarwal3, R. Burgos-Vargas4, R. A. Colber5, G. Hornet6, R. Laxer7, R. K. Minden8, A. Ravelli1, N. Ruperto1, J. Smith1, M. L. Stolli1, S. M. Tse9, F. van den Bosch10, W. P. Maksymowych11,12, R. G. Lambert13, D. M. Biko10,13,14, N. A. Chauvin15, M. L. Francais16,17, J. L. Jaremko13, N. Herregods18, O. Kasapcopur19, M. Yildiz20, A. M. Hendry21, Children’s Hospital of Philadelphia, Department of Pediatrics, Division of Rheumatology, Philadelphia, United States of America; 2Perelman School of Medicine at the University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, United States of America; 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Departments of Medicine - (Incl. Obstetric Medicine and Adult Rheumatic Fever), Auckland, New Zealand; 4Asklepios Clinic Sankt Augustin, General Pediatrics, Sankt Augustin, Germany; 5Ghérit University, Department of Pediatric Rheumatology, Ghent, Belgium; 6The Hospital for Sick Children, Department of Paediatrics, Division of Rheumatology, Toronto, Canada; 7St. Michael’s Hospital, Medicine, Toronto, Canada; 8German Rheumatism Research Center, Epidemiology Unit, Berlin, Germany; 9IRCCS Istituto Giannina Gaslini, Direzione Scientifica, Genoa, Italy; 10IRCCS Istituto Giannina Gaslini, Clinica Pediatrica e Reumatologia, Genoa, Italy; 11University of Wisconsin-Madison, Department of Pediatrics, Madison United States of America; 12University of Alabama-Birmingham, Department of Pediatrics, Division of Rheumatology, Birmingham, United States of America; 13Ghérit University and VIB Center for Inflammation Research, Department of Internal Medicine and Pediatrics, Ghent, Belgium; 14University of Alberta, Department of Medicine, Edmonton, Canada; 15CARE Arthritis, Rheumatology, Edmonton, Canada; 16University of Alberta, Department of Radiology and Diagnostic Imaging, Edmonton, Canada; 17University of Pennsylvania, Department of Radiology, Philadelphia, United States of America; 18Children’s Hospital of Philadelphia, Department of Radiology, Philadelphia, United States of America; 19Penn State Health, Department of Radiology, Hershey, United States of America; 20Ghérit University Hospital, Department of Radiology and Nuclear Medicine, Ghent, Belgium; 21Istanbul University-Cerrahpasa Medical School, Istanbul, Turkey; 22Istanbul University-Cerrahpasa, Pediatric Rheumatology, Istanbul, Turkey; 23Middelmore Hospital, General Medicine - (Incl. Obstetric Medicine and Adult Rheumatic Fever), Auckland, New Zealand

Background: The lack of pediatric classification criteria for axial disease is a major impediment to the conduct of clinical trials for juvenile spondyloarthritis (JSpA).

Objectives: We aimed to develop classification criteria for axial JSpA that will enable identification of a more homogeneous group of patients with SpA and axial disease for entry into observational or clinical trials. These criteria are not intended to capture all possible subjects, but instead most patients with shared key features of axial disease. Treatment and diagnostic decisions should adhere to evidence-based recommendations.

Methods: 304 cases with JSpA and suspected axial disease from 6 international centers were collected on a standardised case report form (CRF) that was reviewed by an independent team of experts in musculoskeletal imaging. Candidate criteria were developed in an earlier phase of the project through an iterative process that included an international Delphi exercise for item generation, systematic literature review, and an item reduction exercise. Using the preliminary candidate criteria, 14 international clinical SpA experts scored and ranked ordered 20 representative SpA cases. During four, 3-hour virtual meetings, the clinical expert panel reviewed the interrater reliability of case ranking, refined the criteria definitions and domain levels, and participated in a multi-criterion decision consensus methodology exercise to generate relative weights of the criteria. The expert panel assessed whether the criteria weighting was in accordance with their consensus clinical judgment as a test of face validation of the weighting/scoring system and revisions were made as necessary. Next, 30 cases from the derivation cohort were scored and ranked using the relative weights for each category and domain. Each expert independently determined the score or “threshold” below which they were no longer confident enough that a patient had axial disease to enroll the child in a Phase 3 randomized clinical trial of a drug with unclear efficacy and safety. Results of this exercise were discussed and a provisional threshold score for classification was achieved by consensus.

Results: The preliminary axial disease criteria for JSpA included the PRINTO provisional criteria for enthesitis/spondylitis-related JIA or a rheumatologist diagnosis of SpA as obligatory entry criteria as well as additive weighted criteria for 7 domains (SpA active inflammation on imaging, SpA structural lesions on imaging, pain chronicity, pain pattern, pain location, morning stiffness, and genetics) (Figure 1). Interrater reliability of the pre-consensus meeting case rankings was poor
Figure 1. Axial juvenile spondyloarthritis (AxJSpA) classification criteria domains and levels. The first ring represents the domains and the items branching out are the levels moving from highest level (closest to center) to lowest level (furthest from center) in each domain. Assigned weights are shown below each item description.

Conclusion: Using an iterative process, the JSpA axial disease criteria definitions were refined, preliminary weights were generated, and a provisional threshold score for classification was determined. The most heavily weighted domains were active inflammation and structural lesions on imaging. Imaging typical of sacroiliitis was necessary, but not sufficient without any clinical criterion, to surpass the axial disease classification threshold.

Disclosure of Interests: Pamela F. Weiss Consultant of: Pfizer Novartis Biogen Lilly

(Accessed < SSK in the past fiscal year), Timothy G. Brandon: None declared, Amita Aggarwal: None declared, Ruben Burgos-Vargas Speakers bureau: not in the last three years Novartis, Consultant of: Not in the last four years BMS, Lilly, Novartis, Robert A. Colbert: None declared, Gerd Hornemann Speakers bureau: Pfizer, Novartis, Janssen, Chugai, Abbvie, BMS, Lilly, Grant/research support from: Pfizer, Novartis, MSD, Chugai, Roche, Abbvie, Rik Joos Speakers bureau: Galapagos, Pfizer, Abbvie, Novartis, Amgen, BMS, Lilly, Grant/research support from: Pfizer, Novartis, Lilly, M. Fasshauer6, K. Minden7,8, I. Foeldvari9, C. Rietschel10, D. Windschall11,12, R. Trauzedel13, M. Hufnagel14, D. Foel15, R. Berendes16, G. Boeschow17, P. Oomen18, F. Dressler19, G. Hornet20,1 Kinderklinik Sankt Augustin, Pediatric Rheumatology, Sankt Augustin, Germany;2 Cologne University Hospital, Pediatrics, Köln, Germany;3 Olghospital and Women's Clinic, Pediatric Rheumatology, Stuttgart, Germany;4 Professor Hess Klinik, Pediatric Rheumatology, Bremen, Germany;5 Universitäts-Kinderklinik, Pediatric Rheumatology, Tübingen, Germany;6 Klinikum St. Georg, Leipzig, Pediatric Rheumatology, Leipzig, Germany;7 Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Institut der Leibniz-Gemeinschaft, Pediatric Rheumatology, Berlin, Germany;8 Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Pediatric Rheumatology, Berlin, Germany;9 Center for Pediatric Rheumatology, Pediatric Rheumatology, Hamburg, Germany;10 Clementine Hospital Pediatric Rheumatology, Frankfurt am Main, Germany;11,12 St.-Josef-Stift Sendenhorst, Northwest German Center for Rheumatology, Clinic of Paediatric and Adolescent Rheumatology, Sendenhorst, Germany;13,14 Martin-Luther-University Halle-Wittenberg, Medical Faculty, Halle, Germany;15 Helios Hospital Berlin-Buch, Pediatrics, Berlin, Germany;16 Universitätsklinikum Freiburg, Pediatric Rheumatology, Freiburg im Breisgau, Germany;17 Münster University Hospital, Pediatric Rheumatology, Münster, Germany;18 Children’s Hospital St. Mary’s, Pediatric Rheumatology, Landshut, Germany;19 Hospital Carl-Thiem-Klinikum Cottbus, Pediatric Rheumatology, Cottbus, Germany;20 Universitätsklinikum Düsseldorf, Pediatric Rheumatology, Düsseldorf, Germany;21 Medizinische Hochschule, Pediatric Rheumatology, Hannover, Germany

Background: Tocilizumab (TCZ) has been approved for treatment of juvenile idiopathic arthritis (JIA) for 10 years. Objectives: Evaluation of 12-month efficacy and safety of TCZ compared to TNF inhibitors (TNFi).

Methods: BIKER WA 29358 is a 5-year multi-centre prospective, observational cohort study including polyarticular JIA patients in Germany starting treatment between 2015 and 2020 with TCZ and matched 1:1 by date of treatment start and region to patients starting an approved TNFi. Clinical disease activity (JADAS10), JADAS MDA (≤3.8) remission (≤3.0), safety and drug adherence at 12 months were assessed and compared between cohorts.

Results: The analysis included 342 participants with 12-month treatment data (TCZ n=171; TNFi n=171). TCZ was used as 2nd line biologic in the majority of patients (84%) while TNFi were mostly 1st line biologics (86%). Patients starting TCZ had a longer disease duration. Efficacy was demonstrated by a marked decrease in JADAS10 in both cohorts (TCZ vs. TNFi at baseline: 15.0±6.7 vs. 14.6±4.3; at month 12: 3.8±6.5 vs. 3.4±4.5). Proportions of patients in TCZ TNFi cohorts achieving JADAS remission at 12 months were 48%/41% in 1st line biologic users and 32%/33% in 2nd line biologic users. JADAS MDA was achieved in 64%/69% in 1st line and 52%/58% in 2nd line users of TCZ/TNFi. After 12 months of treatment JADAS10 (mean ±SD) was higher in the 2nd line TNFi cohort compared to the 1st line (4.5±6.5 vs. 3.2±4.3), similar to patients receiving TNFi. Patients receiving 2nd or 1st line TCZ (4.0±5.2 vs. 2.9±4.4). Patients receiving TCZ or TNFi as first biologic reached JADAS10 remission and MDA numerically more frequently but not statistically significant compared to 2nd line users. Safety was assessed based on adverse event (AE) reporting. 57 (33%) patients in the TCZ cohort and 43 (25%) patients in the TNFi cohort reported AE. The AE
rate was significantly higher in the TCZ cohort (69 vs. 44.8/100 patient years, RR 1.5495% CI 1.1-2.0, p=0.006, Wald-test). There were 6 serious AE in the TCZ and 3 in the TNFi cohort. Injection site reactions were more common in the TNFi cohort (9 vs. 1, p=0.043). No further differences were identified to date. There was no death and no opportunistic infection.

In the TCZ cohort, 32 patients discontinued treatment, 27 due to lack of efficacy, while in the TNFi cohort only 6 patients discontinued treatment. Treatment discontinuation was more frequent among the 2nd biologic users (n=29; 17.4%) than in first line users (n=9; 5.1%).

Conclusion: In this first interim analysis, treatment targets were reached with similar frequency after 12 months of treatment with TCZ or TNFi. TCZ was used predominantly as 2nd line biologic. Higher rates of remission /MDA were observed in 1st line compared to 2nd line biologic users. Although more AE were reported in the TCZ cohort, the occurrence of serious AE and infections was comparable in both cohorts. No new safety signals were identified. Observation is ongoing.

Disclosure of Interests: Ariane Klein Speakers bureau: Novartis fee chairing a lunch symposium, Angela Zimmer: None declared, Toni Hosbach: None declared, Frank Weller-Heinemann: None declared, Sandra Hansmann: None declared, Kirsten Minden Speakers bureau: Honoraries from Novartis, Pfizer, Medac, Ivan Foeldvari: None declared, Christoph Rietschel: None declared, Daniel Windschall Speakers bureau: Pfizer, Novartis, Abbvie, MEDAC, Canon, Grant/research support from: Novartis, Pfizer, Ralf Trauzedel: None declared, Markus Hufnagel: None declared, Dirk Foell: None declared, Rainer Berendes: None declared, Gundula Boeschow: None declared, Principals C. P. Oommen, P. Oommen: None declared, J. Klotzsche, F. Dressler, I. Foeldvari, D. Foell, G. Horneff, T. Hosbach, T. Kallinich, J. Kuermerie-Deschner, I. Liedmann, K. Moenkemoeller, M. Niewerth, C. Siemer, F. Weller-Heinemann, D. Windschall, K. Minden, C. Sendler, H. Heinrich Heine University Düsseldorf, Department of Paediatric Oncology, Haematology and Clinical Immunology, Düsseldorf, Germany; German Rheumatism Research Center Berlin, Epidemiology Unit, Berlin, Germany; Medizinische Hochschule Hannover, Paediatric Rheumatology, Hannover, Germany; Hamburg Centre for Pediatric and Adolescence Rheumatology, Paediatric Rheumatology, Hamburg, Germany; University Hospital Münster, Department of Paediatric Rheumatology and Immunology, Münster, Germany; Asklepios Kinderklinik St. Augustin, Centre for General Paediatrics and Neonatology, St. Augustin, Germany; Olghospital Stuttgart, Center for Pediatric Rheumatology, Stuttgart, Germany; Charité - Universitätsexinischen Berlin, Department of Paediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Berlin, Germany; University Hospital Tübingen, Department of Pediatrics, Division of Pediatric Rheumatology, Tübingen, Germany; German Rheumatism Research Center Berlin, Epidemiologic Unit, Berlin, Germany; Köln-Klinik Köln - Kinderkrankenhaus Amsterdamer Str, Paediatric Rheumatology, Köln, Germany; German Center for Child and Adolescent Rheumatology, Paediatric Rheumatology, Garmisch-Partenkirchen, Germany; Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Paediatric Rheumatology, Bremen, Germany; St. Josef-Stift Sendenhorst, Clinic for Paediatric and Adolescent Rheumatology, Sendenhorst, Germany.

Background: Psychiatric comorbidities can be a significant additional burden in chronic diseases. The most common chronic inflammatory rheumatic disease in children and adolescents is juvenile idiopathic arthritis (JIA). Data on mental illness in children and adolescents with JIA are heterogeneous.

Objectives: To assess the frequency of depressive and anxious symptoms in patients with JIA compared to healthy peers.

Methods: Data were analysed from JIA patients and healthy controls of the same age included in the inception cohort of newly diagnosed children and adolescents with JIA (ICON). Depressive symptoms (using the Patient Health Questionnaire (PHQ-9, score 0-27) and anxious symptoms (Generalised Anxiety Disorder Scale (GAD-7, score 0-21) were captured 7 or 9 years after inclusion in ICON in patients aged thirteen years or older at the time of filling in these questionnaires. Symptom severity for both instruments was assessed by sum score with the following cut-off values: PHQ-9 score < 5; none, 5-9: mild, 10-14: moderate, 15-19: severe, ≥ 20: very severe. GAD-7 Score < 5; none, 5-9: mild, 10-14: moderate, ≥ 15: severe. Disease parameters such as Physician Global Assessment of Disease Activity (PhGA Disease Activity, numerical rating scale, (NRS),(0-10, 0=best), joint count (n) and patient-reported outcomes on functional limitations (C/CHAQ, score 0-3, 0=best), Patient Global Assessment of Well-being (PGA Well-being), pain and fatigue (NRS, 0-10, 0=best) were also documented.

Results: The analysis included 344 patients, 157 (45.6%) < 18 years old (mean 15.5 ± 1.6 years, 64.3% female), 187 (54.4%) ≥ 18 years old (mean 21.5 ± 2.1 years, 65.2% female) and 224 control subjects, 115 (51.3%) < 18 years old (mean 15.2 ± 1.5 years, 60% female), 109 (48.7%) ≥ 18 years old (mean 21.4 ± 1.9 years, 58.7% female). Almost 40% of patients had oligoarthritis (26% persistent OA, 12.5% extended OA), 27% rheumatoid factor (RF)-negative polyarthritis, 6% psoriatic arthritis, 17% enthesis-related arthritis; 3% each had systemic JIA and RF-positive polyarthritis. In the total cohort, 14% of patients and 7% of controls had a PHQ-9 ≥ 10 and 10% of patients and 2% of controls had a GAD-7 ≥ 10. Within the categories of JIA, the rate of a PHQ-9 ≥ 10 ranged from 9.3% (oligoarthritis extended) to 22.2% (psoriatic arthritis).

Patients aged ≥ 18 years had higher scores for both PHQ-9 (≥ 10: 18.7%) and GAD-7 (≥ 10: 14.4%) compared to patients < 18 years (PHQ-9 < 5: 8.3%, GAD-7 < 10: 5.1%).

In patients < 18 years with PHQ-9 ≤ 10 versus ≥ 10, there were no significant differences in either PHGA disease activity (0.5±3.6 / 0.8±1.6, p=0.673) or joint count (0.5±3.6 / 0.5±1.6, p=0.999). In contrast, there was a significant difference in PHGA disease activity (0.8±1.5 / 1.6±1.4, p=0.005) but not in joint count (0.7±3.1 / 0.8±1.3, p=0.850) in patients ≥ 18 years with PHQ-9 < 10 versus PHQ-9 ≥ 10.

Female patients were more often found to have higher scores for depression and anxiety than male patients (PHQ-9 ≥ 10: female 17.5%, male 7.4%, GAD-7 ≥ 10: female 13.5%, male 4.1%) and patients more often had higher scores for depression than controls (PHQ-9 ≥ 10: female patients 17.5%, female controls 8.3%, male patients 7.4%, male controls 4.4%). The difference in the proportion of female patients with GAD-7 ≥ 10 (13.5%) compared to control subjects (2.3%) was remarkable, but in male patients this proportion (4.1%) was only slightly higher than in male controls (2.2%).

Conclusion: Depressive and anxious symptoms are common in adolescents and young adults with JIA, especially in females. In the continuous care of these patients, standardised diagnostic tools should be implemented to detect
these comorbidities, to optimise therapy and thereby reduce the burden of dis-
ease. Further research is needed to identify possible predictors of the develop-
ment of depression and anxiety in JIA patients in order to pursue preventive ap-
proaches.

Disclosure of Interests: Prasad Oommen: None declared, Jens Klotsche: None declared, Frank Dressler: None declared, Ivan Foeldvari: None declared, Dirk Foell: None declared, Gerd Hornett Speakers bureau: Pfizer, Novartis, Janssen, Chugai, Abbvie, Grant/research support from: Pfizer, Novartis, MSD, Chugai, Roche, Abbvie, Toni Hospach Consultant of: SOBI, Novartis, Tilmann Killinch: None declared, Jasmin Kuehmerie-Deschner: None declared, Ina Liedmann: None declared, Kirsten Moenkemoeller: None declared, Martina Niewerth: None declared, Caroline Siemer: None declared, Frank Weller-Heinemann: None declared, Daniel Windschall: None declared, Kirsten Minden Speakers bureau: AbbVie, Pfizer, Novartis, Claudia Sengler: None declared


HIGH INCIDENCE OF MIS-C AND OTHER AUTOIMMUNE DISEASES AFTER SARS-COV-2 INFECTION COMPARED TO COVID-19 VACCINATION IN PEDIATRIC POPULATION FROM SOUTH CENTRAL EUROPE

M. Bizjak,1 N. Emerici,1 M. Zajc Avramovic,1 T. Vesel Tjašnik,1 G. Markelj1, S. Della Padella,2 E. Conversano,2 V. Berce3, N. Toplak4, A. Taddio5,6, T. Ascioni7,8

1University Children's Hospital, University Medical Centre Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia; 2IRCCS “Burlo Garofolo”; Institute for Maternal and Child Health, Trieste, Italy; 3University Medical Centre Maribor, Division of Pediatrics, Maribor, Slovenia; 4University of Ljubljana, Faculty of Medicine, Pediatrics, Ljubljana, Slovenia; 5University of Trieste, Faculty of Medicine and Surgery, Trieste, Italy

Background: In contrast to adults, children are less likely to develop serious disease upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) but are at increased risk for inflammatory and autoimmune dis-
eases linked to the virus (1). The reported incidence of multisystem inflammatory syndrome in children (MIS-C) varied from 0.2 to 11.4/100,000 persons under 21 years (2,3). It is yet unknown whether MIS-C can recur after SARS-CoV-2 rein-
fec tion or COVID-19 vaccination.

Objectives: To estimate the incidence and describe the spectrum of inflam-
matory and autoimmune diseases linked to SARS-CoV-2 infection and coro-
navirus (COVID-19) vaccination in pediatric patients from two neighbouring South Central European countries and regions, Slovenia and Friuli Venezia Giulia (FVG), Italy.

Methods: We performed a multi-centre prospective cohort study of all chil-
dren and adolescents (under 18 years) newly diagnosed with MIS-C or other inflammatory/autoimmune diseases linked to SARS-CoV-2 infection, who were admitted to the pediatric tertiary care hospitals in Slovenia or FVG, Italy during the period from January 1, 2020, to December 31, 2021. These hospitals serve a combined population of 587,053 children and adolescents. Only patients who had positive anti-SARS-CoV-2 antibodies and/or pos-
itive SARS-CoV-2 PCR test within 3 months prior to disease onset were considered for estimating the disease incidence. We obtained the number of patients with serious adverse events (SAE) after COVID-19 vaccination and the number of patients with severe COVID-19 in the same population. This study was conducted as a part of the EU interregional Italy-Slovenia project CATTEDRA (Cross border cooperation for innovative diagnosis of rare diseases in paediatrics).

Results: 192 children and adolescents were diagnosed with inflammatory and autoimmune diseases linked to SARS-CoV-2 (Figure 1). Median age at diagnosis was 11.9 years (IQR 7.6 –14.7). All included patients were White. Incidence of MIS-C was one in 921 children and adolescents after SARS-
CoV-2 infection and one in 5870 of all children and adolescents. Cumulative incidence of MIS-C since the start of the pandemic was 17/100,000 children and adolescents. Until December 31, 2021, 92,139 children and adolescents (15.7 %) received at least one dose of COVID-19 vaccine. Three patients pre-
sented with inflammatory/autoimmune disease after COVID-19 vaccination, including 2 patients with MIS-C and one patient with myositis. All 3 had evi-
dence of recent SARS-CoV-2 infection in form of positive anti-N SARS-CoV-2 antibodies. In the same period, 15 children and adolescents were hospital-
ised with severe COVID-19. Seven patients from our cohort were vaccinated against COVID-19 median 8 months after MIS-C and further 6 patients had a SARS-CoV-2 reinfection 3–14 months after MIS-C. None of them experienced SAE or recurrence of MIS-C.

Conclusion: MIS-C was the most common manifestation and its incidence in this predominantly white population was higher than previously reported. Based on our limited experience, MIS-C does not seem to recur after SARS-
CoV-2 reinfection or COVID-19 vaccination, however long-term data are lacking. Autoimmune diseases were much more common after SARS-CoV-2 infection than after COVID-19 vaccination. Hospitalisations due to MIS-C were seven times as frequent as hospitalisations due to severe COVID-19 in children.

REFERENCES:

Disclosure of Interests: None declared


CRITERIA ASSOCIATED WITH TREATMENT DECISIONS IN JUVENILE IDIOPATHIC ARTHRITIS WITH A FOCUS ON ULTRASONOGRAPHY: RESULTS FROM THE JIRECHO COHORT.

S. Mahmoud1, S. Jousse-Joulin1, A. Saraux2, P. Dusser2, C. Borocci2, C. Galletti3, A. von Scheven4, M. Hofers5, B. Bader-Meunier6, F. Aeschlimann7, S. Breton5, L. Sparsa6, C. Aurélia7, G. Mouterde8, L. Rossis9, V. Devauchelle-Pensec10, 1CHU Brest, Rhumatologie, Brest, France; 2Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Pediatric Rheumatology, Paris, France; 3Lausanne University Hospital, Pediatric Immuno-Rheumatology of Western Switzerland, Geneva, Switzerland; 4Hôpital Necker-Enfants- Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Service d’immunologie, hémato logie, rhumatologie pédiatriques, Paris, France; 5Hôpital Necker-Enfants-Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Radiologie Pédiatique, Paris, France; 6CH Multihosp, Rheumatologie, Mulhouse, France; 7Hôpital Arnaud de Villeneuve, Service de Pédiatrie Générale, Infectieux et Immunologie Clinique, Montpellier, France; 8CH Montpellier, Rheumatologie, Montpellier, France

Background: Treatment of children with juvenile idiopathic arthritis (JIA) is a major challenge in paediatric rheumatology. The presence of synovitis, which is difficult to detect in children, is associated with structural damage. Musculoskele-
tal ultrasonography (MSUS) can be used in JIA patients to reveal subclinical synovitis.

Objectives: Our aim was to determine if the use of MSUS is associated with therapeutic modifications in JIA. Secondary outcomes were to identify other fac-
tors associated with therapeutic modifications.

Methods: We conducted an observational study based on the JIRECH
o multicentre cohort that was developed to provide a systematic MSUS fol-
low-up for JIA patients. Follow-up occurred every six months and included clinical and US examinations. We included children who underwent MSUS of the elbows, wrists, second metacarpophalangeal joints, knees and ankles. Synovitis in US was defined by the presence of joint effusion and/or synovial hypertrophy in B-mode (a grade 1) associated or not with Doppler signals (a grade 1). US was performed by expert sonographers in the field of JIA who previously participated in the study of the reliability of

Figure 1. Inflammatory and autoimmune diseases linked to SARS-CoV-2 and severe COVID-19 in pediatric population in Slovenia and FVG, Italy


Disclosure of Interests: None declared


References:
the OMERACT paediatric US synovitis definitions and scoring system in JIA (1). Clinical and biological data, disease activity score and information on therapeutics were collected.

Results: We included 112 patients with 185 visits in total. Three groups of patients were defined according to their therapeutic status: increased(22%) decreased(14%) and stable(64%) treatment. First, we compared patients with treatment escalation with the other patients. Patients with “increased treatment” had more synovitis in B-mode US than the other patients (80% vs. 65%, p=0.06). There was no difference for the presence of synovitis in Power Doppler (PD) US (30% vs. 25%, p=0.4). Patient’s and physician’s visual analogue scan (VAS) scores were significantly higher in patients with therapeutic escalation [3.3 vs 1.7, p<0.01 and 3.6 vs 1.6, p<0.0001] as well as disease activity score and inflammatory biological markers. Then, we compared patients with therapeutic de-escalation with the other patients. There was no difference in the presence of synovitis in US when compared with patients with stable treatment (62% vs. 69%, p=0.5) but there was less synovitis in B-mode ≥ grade 2 (8% vs. 24%, p=0.05).

We performed ROC curves analysis that showed that the sensitivity and specificity of the US in B-mode was similar to the physician’s VAS, disease score activity or inflammatory biological markers (Figure 1).

Figure 1. ROC curves for clinical and biological items and US in B-mode in patients with treatment escalation

Conclusion: In our study, MSUS of ten joints was not statistically associated with treatment escalation or de-escalation in B-mode and PD in patients with JIA.

REFERENCES:

None declared


Table 1. Resolution of axial and peripheral disease symptoms and JIA ACR responses at the end of TP1 and 2

<table>
<thead>
<tr>
<th>Clinical response, mean (SD) change from BL (unless otherwise stated)</th>
<th>TP1-Wk 12</th>
<th>End of TP2*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEC (N=52)</td>
<td>SEC (N=22)</td>
<td>PBO (N=22)</td>
</tr>
<tr>
<td>JSpADA index</td>
<td>-2.4 (1.7)</td>
<td>-2.7 (1.7)</td>
</tr>
<tr>
<td>JSpADA Schöber, %</td>
<td>58.3</td>
<td>100.0</td>
</tr>
<tr>
<td>Inflammatory back pain, %</td>
<td>77.8</td>
<td>100.0</td>
</tr>
<tr>
<td>FABER test, %</td>
<td>52.6</td>
<td>100.0</td>
</tr>
<tr>
<td>Clinical sacroiliitis, %</td>
<td>53.3</td>
<td>100.0</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>-2.2 (1.9)</td>
<td>-2.5 (2.1)</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>-0.2 (0.8)</td>
<td>-0.2 (1)</td>
</tr>
<tr>
<td>JIA ACR30, %</td>
<td>84.6</td>
<td>90.9</td>
</tr>
<tr>
<td>JIA ACR50, %</td>
<td>78.8</td>
<td>81.8</td>
</tr>
<tr>
<td>JIA ACR70, %</td>
<td>65.4</td>
<td>69.2</td>
</tr>
<tr>
<td>JIA ACR90, %</td>
<td>32.7</td>
<td>45.5</td>
</tr>
<tr>
<td>JIA ACR100, %</td>
<td>26.9</td>
<td>36.4</td>
</tr>
<tr>
<td>Inactive disease, %</td>
<td>38.5</td>
<td>50.0</td>
</tr>
<tr>
<td>CRP</td>
<td>-0.4 (0.5)</td>
<td>-0.4 (0.7)</td>
</tr>
<tr>
<td>CRP, median (SD) change from BL</td>
<td>-1.8 (3.87)</td>
<td>-5.8 (3.83)</td>
</tr>
<tr>
<td>JADAS-27</td>
<td>-9.6 (7.5)</td>
<td>-11.0 (8.9)</td>
</tr>
<tr>
<td>Resolution of enthesitis*, %</td>
<td>78.6</td>
<td>83.3</td>
</tr>
<tr>
<td>Resolution of dactylitis*, %</td>
<td>50</td>
<td>66.7</td>
</tr>
</tbody>
</table>

*End of TP2 is based on individual pts’ last visit at TP2. **At BL, in TP1, enthesitis (n= 46); dactylitis (n=5). In TP2, no of pts who had presence at BL and showed complete resolution at the end of TP2: enthesitis, SEC 14, PBO 18; dactylitis, SEC 3, PBO 0. CRP C-reactive protein

Conclusion: In pts with ERA, SEC demonstrated longer time to disease flare with PBO and exhibited rapid and sustained improvement of axial and peripheral manifestations up to Wk 104.

REFERENCES:
Disclosure of Interests: Niccolo Ripuerto Speakers bureau: Eli Lilly, GlaxoSmithKline, Pfizer, SOBI and UCB, Paid instructor for: Eli Lilly and Pfizer, Consultant of: Ablynx, Amgen, Astrengea-Medimine, Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research (CHR), Cellgene, Domain therapy, Eli Lilly, EMG Serono, GlaxoSmithKline and Vifor Pharma, Janssen, Novartis, Pfizer, SOBI and UCB, Grant/research support from: Bristol Myers and Squibb, Eli Lilly, F Hoffmann-La Roche, Novartis, Pfizer and SOBI, Ella Cherkotok: None declared, Joke Dehoorne Speakers bureau: Abbvie, Roche, Consultant of: Abbvie, Roche, Pfizer, Grant/research support from: Abbvie, Roche, Gerd Hornseth Speakers bureau: Novartis, Pfizer, Janssen, Grant/research support: from Pfizer, Novartis, Roche, MSD, Tilburg Kallinich Speakers bureau: Roche, Ingrid Louw Speakers bureau: Pfizer, Abbvie, BMS, Consultant of: Pfizer, Abbvie, Janssen, Amgen and Cipla, Sandrine Compeyrot-Lacassagne: None declared, Bernard Lauwereys Employee of: UCB Pharma, Neil Martin: None declared, Katherine Marzan Grant/research support from: Novartis, Sanofi, William Knibbe Speakers bureau: Novartis, Amgen, UCB, Abbvie, Ruiwe Min Shareholder of: Novartis, Employee of: Novartis, Xuan Zhu Shareholder of: Novartis, Employee of: Novartis, Sarah Whelan Shareholder of: Novartis, Employee of: Novartis, Luming Pricop Shareholder of: Novartis, Employee of: Novartis, Alberto Martini Speakers bureau: Aurinia, Bristol Myers and Squibb, Eli Lilly, EMG, Janssen, Pfizer, Roche and Serono, Consultant of: Aurinia, Bristol Myers and Squibb, Eli Lilly and EMG, Daniel J Lovell Consultant of: Astra Zeneca, Boehringer Ingelheim, GSK, Hoffman LaRoche, Novartis, UBC, Grant/research support from: Astra Zeneca, Boehringer Ingelheim, GSK, Hoffman LaRoche, Novartis, UBC, Hermine Brunner Consultant of: Novartis, Grant/research support: from Novartis

Identification of causal genes and mechanisms by which genetic variation mediates juvenile idiopathic arthritis susceptibility using functional genomics and CRISPR-Cas9

A. Frantzesko1, V. Malyshева2, C. Shi1, J. Ding1, J. Bowes1,4, W. Thomson1,4, S. Eyre4, M. Spivakov2,3, G. Orozco1,4. 1University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 2MRC London Institute of Medical Sciences, Functional Gene Control Group, Epigenesis Section, London, United Kingdom; 3Imperial College London, Institute of Clinical Sciences, Faculty of Medicine, London, United Kingdom; 4Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom

Background: We recently performed the largest juvenile idiopathic arthritis (JIA) genome-wide association study (GWAS) to date. Disease-associated loci contain multiple single nucleotide polymorphism (SNPs), and the majority map to non-coding enhancers, making it challenging to define causal variants and genes. Functional genomics datasets in disease-relevant tissues have shown to be essential for the functional interpretation of GWAS loci. In particular, capture Hi-C (CHi-C) has been successful in detecting chromosomal interactions linking GWAS loci to their target genes. However, such datasets are lacking in JIA.

Objectives: The aim of this study is to bridge this gap and advance the knowledge of the biological mechanisms that underpin susceptibility to JIA, by integrating GWAS with public epigenomics datasets and in-house generated CHi-C from JIA patients. We focus on CD4+ T-cells, which have been shown to be one of the most relevant cell types in JIA. In addition, we use CRISPR-Cas9 to validate the regulatory effect of prioritised variants on their predicted target genes.

Methods: Credible SNP sets for the top JIA risk loci (P < 5x10^-8) were annotated using EpiMap data. Low input whole genome promoter CHi-C (PCHi-C) was performed on CD4+ T-cells isolated from blood from 3 JIA oligoarthritis patients, and data was analysed using CHiCAGO. GWAS and PCHi-C data were combined to prioritise causal genes using the Capture Hi-C Omnibus Gene Score (COGS) pipeline. We subsequently employed CRISPR activation (CRISPRa) and CRISPR interference (CRISPRi) in Jurkats to assess whether prioritised JIA variants were capable of regulating the expression of the interacting genes.

Results: 614 credible SNPs (out of 735) were found to overlap active enhancers in CD4+ T-cells, and were prioritized for further analysis.

We identified numerous significant chromatin interactions in 19 out of 44 non-MHC JIA associated loci, linking JIA SNPs mapping to T-cell enhancers to a total of 61 target genes and revealing potential novel disease pathways. Moreover, COGS prioritised a total of 7 genes (RGS14, ERAP2, HIK1, CCRM1, CCR2L1, CCR2 and CCR3).

A JIA associated locus on chromosome 3 contains 39 SNPs. It maps to an intragenic region and the causal gene/s are unclear. Our PCHi-C data revealed that this JIA locus presents chromatin interactions with the promoters of several genes, such as CCR2L1, CCR2, CCR3 and CCR5, three of which were prioritised by COGS. Two variants were selected for further analysis: rs79815064, which had the highest posterior probability, and rs8005404, the only variant within a CD4+ T-cell enhancer linked to surrounding gene activity. When both SNPs were targeted with CRISPRa and CRISPRi, we observed an increased and decreased expression, respectively, of CCR2L1, CCR2, CCR3 and CCR5, confirming their role in disease. These genes belong to the chemokine receptor family and are important regulators of the inflammatory response.

Conclusion: Our work shows how functional genomics can help identify biological mechanisms by which GWAS variants increase risk of JIA, which in turn will benefit patients through personalised medicine and the identification of therapeutic targets.

REFERENCES:

Disclosure of Interests: Antonio Frantzesko: None declared, Valeria Malyshева: None declared, Chenfu Shi: None declared, James Ding: None declared, John Bowes: None declared, Wendy Thomson: None declared, Stephen Eyre: None declared, Mikhail Spivakov: Shareholder of: co-founder and shareholder of EnhancDSD Genomics Ltd, Gisela Orozco: None declared

New developments in OA
synovial tissue inflammation from joint explants or biopsies can be useful. However, an ongoing challenge in using semi-quantitative assessments of synovitis is the disagreement between human pathologist scores of the same sample. We previously developed and validated a computer vision algorithm to automatically count each cell nucleus in an H&E-stained synovial whole slide image and yield a value of cell density, defined as mean nuclei count per mm² of tissue.

Objectives: We sought to develop methods to distinguish OA from RA based on machine learning analysis of histologic features on H&E-stained synovial tissue samples.

Methods: We measured 14 pathologist-scored histology features (137 RA and 152 OA patients) and computer vision quantified cell density (60 RA and 147 OA patients) in H&E stained synovial tissue samples from total knee replacement arthroplasty explants. A random forest model was trained using disease state (OA vs RA) as classifier and histology features and/or cell density as inputs, and feature importance scores for the model were calculated.

Results: Synovium from patients with RA exhibited increased lymphocytic inflammation, lining hyperplasia, neutrophils, detrus, plasma cells, Russel bodies, binucleate plasma cells, sub-lining giant cells, synovial lining giant cells, and fibrin (all p<0.001), while synovium from patients with OA had increased mast cells and fibrosis (both p<0.001). Fourteen pathologist-scored features allowed for discrimination between RA and OA samples, producing a macro-averaged area under the receiver operating curve (AUC) of 0.85. This discriminatory ability was comparable to that of the computer vision score of cell density alone (AUC = 0.88). Combining the pathologist scores with the cell density metric improved the discriminatory power of the model (AUC = 0.91).

The three most important features in this combined model were mast cells followed by cell density and fibrosis (Figure 1). AUC values for each individual feature are provided in Table 1. The optimal cell density threshold to distinguish RA from OA synovium was 3,400 cells per mm², which yielded a sensitivity of 0.82 and specificity of 0.82.

Table 1. Area under receiver operating characteristic curves (AUC) of the synovial features in distinguishing RA and OA patients

<table>
<thead>
<tr>
<th>Feature</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Automated Cell Density</td>
<td>0.88</td>
</tr>
<tr>
<td>Fibrosis</td>
<td>0.84</td>
</tr>
<tr>
<td>Mast cells</td>
<td>0.80</td>
</tr>
<tr>
<td>Lining hyperplasia</td>
<td>0.78</td>
</tr>
<tr>
<td>Lymphocytic inflammation</td>
<td>0.69</td>
</tr>
<tr>
<td>Fibrin</td>
<td>0.68</td>
</tr>
<tr>
<td>Plasma cells</td>
<td>0.66</td>
</tr>
<tr>
<td>Detrus</td>
<td>0.64</td>
</tr>
<tr>
<td>Binucleate plasma cells</td>
<td>0.60</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0.60</td>
</tr>
<tr>
<td>Synovial giant cells</td>
<td>0.58</td>
</tr>
<tr>
<td>Sub-lining giant cells</td>
<td>0.57</td>
</tr>
<tr>
<td>Russell bodies</td>
<td>0.56</td>
</tr>
<tr>
<td>Germinal centers</td>
<td>0.51</td>
</tr>
<tr>
<td>Mucoid change</td>
<td>0.50</td>
</tr>
</tbody>
</table>

Figure 1. Importance of synovial features in distinguishing RA and OA synovium

Feature importance scores for supervised machine learning model including all 14 pathology scores and the computer vision-generated cell density.

Conclusion: H&E-stained images of RA and OA TKR explant synovium are distinct. We identified cell density, mast cells and fibrosis as the three most important features for making this distinction, with RA being characterized by increased cell density, low mast cells, and low fibrosis. Cell density greater than 3400 per mm² of tissue yields a sensitivity of 0.82 and a specificity of 0.82 for distinguishing RA from OA. In the future, this can have clinical and research applications as this technique removes the requirement for subjective selection of a certain field of interest, is reproducible, and is scalable as it does not require technical expertise of a pathologist.

REFERENCES:


Acknowledgements: This work was supported by the C. Ronald MacKenzie Young Scientist Endowment Award, the Leon Lowenstein Foundation, and the Kellen Scholar Award supported by the Anna Marie and Stephen Kellen Foundation.

Results: The proteomic analysis resulted in the identification of 558 proteins (10,466 peptides) in the serum samples. A label-free quantification algorithm was employed to quantify 468 proteins in the samples. Hierarchical clustering of the data showed the differences in protein abundance were more relevant longitudinally (BL to 24M) than in cross-sectional comparisons between the three groups under study (N, P or S). Sixty-three proteins were significantly altered (fold change >=1.5, p<0.05) when comparing BL to 24M in the N group (15 increased and 48 decreased), 53 in the P group (20 increased and 33 decreased) and 93 in the S group (19 increased and 74 decreased). Interestingly, two different endotypes were detected at baseline in the N and S groups, based on these protein modulations.

The overlapping of these proteomic profiles was analyzed between groups and is shown in the Figure 1. Proteins modulated specifically in the N group may be associated with mechanisms related with joint repair. On the other hand, six proteins (including two apolipoproteins) were increased at 24M only in the P group. Finally, 30 proteins were modulated only in the S group: five of them increased and 25 decreased. Remarkably, this latter group includes lubricin, chaperones and proteins related with proteoglycan binding, such as COMP, fibronectin or histidine-rich glycoprotein.

Figure 1. Circulating proteins identified as modulated after 24M follow-up in 45 patients from the APPROACH cohort that progressed in structure (S group; n=15), pain (P group; n=15) or did not progress (N group; n=10). The numbers with arrows indicate those proteins that decrease (arrow pointing down) or increase (arrow pointing up) compared to baseline.

Conclusion: The modulation of specific protein profiles in serum were identified as associated with the progression in structure, pain or non-progression in patients from the APPROACH cohort. Proteomic changes found specifically in the S group may be interesting circulating markers of the structural affection occurring in the joint.

REFERENCES:

Conclusion: This study showed that certain comorbidities were diagnosed more often in patients exposed to knee or hip OA, and none were less frequently diagnosed in patients exposed OA. This suggests that the management of OA should consider the risk of other long-term conditions and that further research on causality between OA and comorbidity is needed.

REFERENCES:

Acknowledgements: We thank the Patient Research Participants members Jenny Cockshull, Stevie Vanhegan, and Irene Pitsillidou for their involvement in the project. We would like to thank the FOREUM for financially supporting the research.

Disclosure of Interests: None declared


Table 1. Comorbidities with significant HRs of exposure to knee or hip OA

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Knee OA</th>
<th>Hip OA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>1.33</td>
<td>1.29</td>
</tr>
<tr>
<td>Back pain</td>
<td>1.28</td>
<td>1.46</td>
</tr>
<tr>
<td>Cataract</td>
<td>1.27</td>
<td>6.09</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>1.30</td>
<td>1.64</td>
</tr>
<tr>
<td>Coronary heart disease</td>
<td>1.34</td>
<td>1.44</td>
</tr>
<tr>
<td>Gout</td>
<td>1.43</td>
<td>1.32</td>
</tr>
<tr>
<td>Hearing loss</td>
<td>1.34</td>
<td>2.03</td>
</tr>
<tr>
<td>Neck pain</td>
<td>1.58</td>
<td>1.16</td>
</tr>
<tr>
<td>Obesity</td>
<td>2.02</td>
<td>1.32</td>
</tr>
<tr>
<td>Sleeping disorder</td>
<td>1.33</td>
<td>2.03</td>
</tr>
<tr>
<td>Thromboplastic disease</td>
<td>1.40</td>
<td>1.94</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Knee OA</th>
<th>Hip OA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>1.29</td>
<td>1.02</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1.46</td>
<td>1.14</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>6.09</td>
<td>1.25</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>1.64</td>
<td>1.09</td>
</tr>
<tr>
<td>Sleep disorder</td>
<td>1.44</td>
<td>1.10</td>
</tr>
<tr>
<td>Solid malignancy</td>
<td>1.32</td>
<td>1.11</td>
</tr>
<tr>
<td>Spinal disc herniation</td>
<td>2.03</td>
<td>1.46</td>
</tr>
</tbody>
</table>

Conclusion: Our study suggests that prevention of weight gain from young adulthood to midlife in order to reduce overweight and obesity could have a major impact on reducing the burden of severe knee osteoarthritis and associated healthcare costs.

Figure 1. A. Proportion of Total Knee Arthroplasties in each trajectory category. B. Speculated patterns and associated percentages represents the proportion of Total Knee Arthroplasties that could be avoided if the participants followed the lower trajectory category i.e. TR2 followed TR1.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3619

Table 1. Reduction in TKA if individuals followed the trajectory that was one lower

<table>
<thead>
<tr>
<th>Population counterfactuals</th>
<th>Population at risk, n (%)</th>
<th>TKA under the original scenario, n (%)</th>
<th>TKA under the new scenario*, n (%)</th>
<th>Difference in risk, n (%)</th>
<th>PAF** (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>TR1</td>
<td>4811 (19.7)</td>
<td>124 (2.6%)</td>
<td>0</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>II TR2 followed TR1 trajectory and rate of TKA*</td>
<td>8943 (36.7)</td>
<td>379 (4.2%)</td>
<td>2.6% of 8943 = 233</td>
<td>145 (10.9)</td>
<td>379 (26.7, 473)</td>
</tr>
<tr>
<td>II TR3 followed TR2 trajectory and rate of TKA*</td>
<td>6526 (26.8)</td>
<td>416 (6.4%)</td>
<td>4.2% of 6526 = 274</td>
<td>142 (10.7)</td>
<td>26.8 (20.0, 31.2)</td>
</tr>
<tr>
<td>II TR4 followed TR3 trajectory and rate of TKA*</td>
<td>845 (3.5)</td>
<td>64 (7.6%)</td>
<td>6.4% of 845 = 54</td>
<td>10 (0.8)</td>
<td>31 (0, 60)</td>
</tr>
<tr>
<td>II TR5 followed TR4 trajectory and rate of TKA*</td>
<td>2466 (10.1)</td>
<td>253 (10.3%)</td>
<td>7.6% of 2466 = 187</td>
<td>66 (5.0)</td>
<td>20.2 (0, 36.3)</td>
</tr>
<tr>
<td>II TR6 followed TR5 trajectory and rate of TKA*</td>
<td>777 (3.2)</td>
<td>93 (12.0%)</td>
<td>10.3% of 777 = 80</td>
<td>13 (1.0)</td>
<td>0.4 (0, 10.0)</td>
</tr>
<tr>
<td>Total population</td>
<td>24368 (100)</td>
<td>1328 (5.4%)</td>
<td>952</td>
<td>376 (28.4)</td>
<td></td>
</tr>
</tbody>
</table>

* if the trajectory is changed. ** PAAt and related 95% CIs were calculated by the Statin package using the formula pKr = 1 + HR, where pKr is the proportion of total knee replacements observed in the ith obesity trajectory and HR is the hazard ratio (HR) associated with that category. PAFs were calculated using pKr and HR estimated from the entire sample. All HR, values were generated from Cox proportional hazards regression models adjusted for covariables (age at baseline, sex, country of birth, physical activity, smoking history, and comorbidity) and postestimation analyses.
New South Wales, St Vincent’s Clinical School, Sydney, Australia; The University of Western Australia, School of Human Sciences, Crawley, WA, Australia

Background: Overweight and obesity are associated with greater incidence and progression of the structural defects of knee osteoarthritis, but it is unknown if weight loss is of benefit.

Objectives: To describe the association between change in body mass index (BMI) and the incidence and progression of structural defects in knee osteoarthritis.

Methods: Scores from radiographic analyses of knees at baseline and at 4 to 5 years’ follow up were obtained from three independent data sets (the OA1 and MOST data sets from the United States from America, and the CHECK data set from the Netherlands). The exposure of interest was change in BMI from baseline to 4 to 5 years’ follow up. To investigate the incidence of structural defects of knee osteoarthritis, we selected a total of 9732 knees (from 5802 participants) that had a Kellgren-Lawrence (KL) grade of knee osteoarthritis at baseline of ‘none’ (0) or ‘doubtful’ (1) (the ‘incidence cohort’), and determined the odds of having a KL grade at follow-up of ‘minimal’ (2), ‘moderate’ (3), or ‘severe’ (4) (the ‘progression cohort’). To investigate progression, we selected a total of 6084 knees (from 3996 participants) that had a KL grade at baseline of ‘minimal’ (2), ‘moderate’ (3), or ‘severe’ (4) (the ‘progression cohort’), and determined the odds of increasing by 1 or more KL grades by follow up. The degradation of three individual structural features of knee osteoarthritis (i.e., joint space narrowing, osteophytes on the femoral surface, and osteophytes on the tibial surface), on both the medial and lateral sides of the knee, were also investigated in both the incidence and progression cohorts. Here, degradation was defined as an increase by 1 or more Osteoarthritis Research Society International (OARSI) grades.

Results: Change in BMI was positively associated with both the incidence and progression of knee osteoarthritis, as defined by KL grade. Specifically, for each one-unit change in BMI, the adjusted odds ratio for incidence was 1.05 (95% confidence interval [CI] 1.02 to 1.09), and for progression, the same adjusted odds ratio and 95% CI was also observed. Change in BMI was also positively associated with degradation (i.e., narrowing) of joint space on the medial but not the lateral side of the knee, with an adjusted odds ratio of 1.08 (95% CI 1.04 to 1.12) in the ‘incidence cohort’ and 1.08 (95% CI 1.03 to 1.12) in the ‘progression cohort’. Degradation of the tibial and femoral surfaces (i.e., osteophytes) was also seen on the medial but not the lateral side of the knee, but only in one of the two cohorts investigated (the ‘incidence cohort’), with an adjusted odds ratio of 1.07 (95% CI 1.03 to 1.12) for osteophytes on the femoral surface, and 1.05 (95% CI 1.01 to 1.09) for osteophytes on the tibial surface.

Conclusion: Each one-unit reduction in BMI is associated with a 5 to 8% decrease in the odds of the incidence and progression of the structural defects of knee osteoarthritis, with lower odds of structural degradation specific to the medial – not lateral – side of the knee.

Acknowledgements: We acknowledge the provision of datasets and/or research tools from three studies: the Osteoarthritis Initiative (OAI) Study; the Multicenter Osteoarthritis Study (MOST); and the Cohort Hip and Cohort Knee (CHECK) Study.

The OAI is a collaborative informatics system created by the National Institute of Mental Health and the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) to provide a worldwide resource to quicken the pace of biomarker identification, scientific investigation and OA drug development. The OAI data repository is housed within the National Institute of Mental Health (NIMH) Data Archive (NDA). For the MOST data set, we wish to acknowledge the contributions of the study participants, investigators and research staff involved. MOST is comprised of four (4) cooperative grants: U01 AG18820 David T. Felson (Boston University); U01 AG18832 James Torner (University of Iowa); U01 AG18947 Cara E. Lewis (University of Alabama at Birmingham); U01 AG19069 Michael C. Nevitt (University of California, San Francisco), funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by MOST investigators. This manuscript was prepared using MOST data and does not claim, infer, or imply endorsement by MOST, by the MOST investigators and their respective institutions or by the University of California of the Data Recipients’ use of the Data, of the entity or personnel conducting the research, or of any results of the research.

The CHECK study is funded by the Dutch Arthritis Foundation. Involved are Erasmus MC University Medical Center Rotterdam; Kenneren Gasthuis Haarlem; Leiden University Medical Center; Maastricht University Medical Center; Mar-tini Hospital Groningen; Allied Health Care Center for Rheumatology and Rehabilitation Groningen; Medical Spectrum Twente Enschede /Ziekenhuisgroep Twente Almelo; Reade Center for Rehabilitation and Rheumatology; St.Maartens-kliniek Nijmegen; University Medical Center Utrecht and Wilhelmina Hospital Assen.

Disclosure of Interests: Zubeyir Salis: None declared, Helen Keen: None declared, Blanca Gallego: None declared, Tian van Nguyen: None declared, Amanda Sainsbury Speakers bureau: ZS and AS own 50% each of the shares in Zuman International, which receives royalties for books AS has written and payments for presentations, and provides paid training for higher degree students. AS additionally reports receiving presentation fees and travel reimbursements from Eli Lilly and Co, the Pharmacy Guild of Australia, Novo Nordisk, the Dietitians Association of Australia, Shoalhaven Family Medical Centres, the Pharmaceutical Society of Australia, and Metagenics, and serving on the Nestlé Health Science Optifast VLCD advisory board from 2016 to 2018., Consultant of: ZS and AS own 50% each of the shares in Zuman International, which receives royalties for books AS has written and payments for presentations, and provides paid training for higher degree students. AS additionally reports receiving presentation fees and travel reimbursements from Eli Lilly and Co, the Pharmacy Guild of Australia, Novo Nordisk, the Dietitians Association of Australia, Shoalhaven Family Medical Centres, the Pharmaceutical Society of Australia, and Metagenics, and serving on the Nestlé Health Science Optifast VLCD advisory board from 2016 to 2018.


**OP0228 USE OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND RISK OF COMORBITIES IN PEOPLE WITH AND WITHOUT OSTEOARTHRITIS - A UK PRIMARY CARE DATABASE COHORT STUDY**

S. Swain1, A. Kamps2, J. Runhaar3, A. Dell’Isola4, A. Turkiewicz4, D. E. Robinson5, V. Y. Strauss5, C. Mallen5, C. F. Ku6, C. Coupland7, M. Doherty1, A. Sarmanova8, D. Prieto-Ahambra9, M. Englund10, S. M. A. Biema-Zeinstra11, W. Zhang1 on behalf of FOREUM OA Comorbidity Consortium. 1University of Nottingham, Academic Rheumatology, Nottingham, United Kingdom; 2Erasmus MC University Medical Center Rotterdam, 3Department of General Practice, Rotterdam, Netherlands; 2Erasmus MC University Medical Center Rotterdam, Department of General Practice, Rotterdam, Netherlands; 4Lund University, Department of Clinical Sciences Lund, Lund, Sweden; 5University of Oxford, NDORMS, Oxford, United Kingdom; 6Keele University, School of Medicine, Keele, United Kingdom; 7Chang Gung Memorial Hospital, Division of Rheumatology, Allergy and Immunology, Taiwan, Taiwan, Republic of China; 8University of Nottingham, Department of Primary Care, Nottingham, United Kingdom; 9University of Bristol, Musculoskeletal Research Unit, Bristol Medical School, Bristol, United Kingdom

Background: People with osteoarthritis (OA) are at higher risk of developing a wide array of comorbidities. Whether the use of non-steroidal anti-inflammatory drugs (NSAIDs) contributes to the increased risk of some incident comorbidities remains unknown.

Objectives: To examine the contribution of NSAIDs in the development of a wide range of comorbidities in people with and without OA.

Methods: This observational cohort study used the UK primary care Clinical Practice Research Datalink (CPRD) GOLD containing data on 20+ million people covering 937 practices. We identified 259,000 people with incident OA and 259,000 age (≥2 years), sex, and practice matched controls at 1:1 ratio. Controls were assigned the same index date (the date of first diagnosis of OA) as cases for the start of follow-up. Both cases and controls were further divided into two groups according to NSAID prescriptions at any time after the index date. This allowed us to examine both the main effect of each exposure and interaction between OA and NSAID exposure after the index date. People with an NSAID prescription before the index date were excluded from the study. NSAID exposure was defined as at least two prescriptions within 90 days. Exposure status of each participant was assessed every six months as yes, no (at the end of the study/outcome of interest). Changes in the exposure status after the index date were calculated, whichever came first. Comorbidities were grouped into 9 categories as cancer, cardiovascular disease (CVD), endocrine, psychological, renal, gastro-intestinal (GI), genitourinary, hepatic, and neurological conditions. Propensity scores for the prescription of NSAIDs were calculated using a logistic regression model including age, sex, body mass index (BMI), musculoskele-tal and pain related conditions covariates. The propensity score adjusted time varying exposure analysis was undertaken using a multivariate COX model and hazard ratio (HR) and 95% confidence intervals were calculated. Proportional hazard assumption was tested using Schoenfeld test. Smoking, alcohol, ever prescription of proton pump inhibitors (PPIs) and other comorbidities were included in the adjusted model. The additional contribution of NSAIDs
and OA towards the incident comorbidity was estimated using addictive inter-
action methods. We also investigated the individual risk across non-selective,
and COX-2 selective NSAIDs.

Results: The mean age was 59.4±12.8 years in people with OA and
60.2±12.8 years for controls with 57.7% being female. Nearly two thirds of
people with OA were prescribed NSAIDs as defined, compared to one third
in the control population. People with OA and exposed to NSAIDs had high-
est risk of developing psychological (1.51; 1.43,1.60), CVD (1.38; 1.33,1.43),
cancer (1.34; 1.25,1.44), GI (1.25; 1.16,1.34) and renal (1.17; 1.11,1.24)
comorbidities after adjusting for all the covariates and PPI drugs, compared
to the non-OA and non-NSAID group. (Figure 1) Interaction between OA
and NSAID was significant for cancer, GI, renal, hepatic, and neurological
outcomes. Within people with OA, non-selective NSAIDs increased the risk
of CVD (1.25; 1.20,1.30), cancer (1.11; 1.04,1.19), endocrine (1.15; 1.10,1.19),
renal (1.19; 1.13,1.26) and psychological (1.21; 1.15,1.28) comorbidities,
whereas COX-2 selective NSAIDs increased risk of incident CVD (1.34;
1.25,1.44), endocrine (1.13; 1.04,1.21), renal (1.25; 1.14,1.37), and psycho-
logical (1.21; 1.09,1.34) comorbidities.

Figure 1. Hazard ratio of developing different comorbidities (reference group: no OA and no
NSAIDs) OA- Osteoarthritis; NSAIDS- Non-steroidal anti-inflammatory drugs.

Conclusion: Use of NSAIDs among people with OA is associated with increased
risk of a wide variety of comorbidities. Non-selective and COX-2 selective
NSAIDs are both associated with increased risk of cardiovascular, renal, and
psychological comorbidities.

Acknowledgements: We thank the Patient Research Participants (PRP) mem-
bers Jenny Cockshull, Stevie Vanhegan, and Irene Pitsillidou for their involve-
ment since the beginning of the project. We would like to thank the FOREUM for
financially supporting the research.

Disclosure of Interests: Subhashisa Swain: None declared, Anne
Kamps: None declared, Jos Runhaar: None declared, Andrea Dell’Isola: None
declared, Aleksandra Turkiewicz: None declared, Danielle E Rob-
inson: None declared, Victoria Y Strauss: None declared, Christian Malle-
en: None declared, Chang-Fu Kuo: None declared, Carol Coupland: None
declared, Michael Doherty Consultant of: Consultant of: Advisory borads
on gout for Grunenthal and Mallinckrodt, Grant/research support from: Astra Zeneca
funded the Nottingham Sons of Gout study, Aliya Sarmanova: None declared, Daniel
Prieto-Alhambra Speakers bureau: paid speaker services from Amgen and UCB Biopharma., Consultant of: His department has received advisory
or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson, and
Johnson, and UCB Biopharma., Grant/research support from: Prof. Prie-
to-Alhambra’s research group has received grant support from Amgen,
Chesi-Taylor, Novartis, and UCB Biopharma., Martin Englund: None
declared, S.M.A. Bierna-Zeinstra: None declared, Weiya Zhang Speak-
ers bureau: Speakers bureau: Bioiberica as an invited speaker for EULAR
2016 satellite symposium, Consultant of: Consultant of: Grunenthal for
advice on gout management, DOI: 10.1136/annrheumdis-2022-eular.110

OP0229
OSTEOARTHRITIS OF THE KNEE, INFLAMMATION,
AND THE EFFECT OF ADALIMUMAB (OKINADA): A
RANDOMIZED PLACEBO-CONTROLLED TRIAL

W. P. Maksymowych1, 2, L. Bessette3, R. G. Lambert4, A. Carapellucci5, C.
T. Appleton6, 1University of Alberta, Medicine, Edmonton, Canada; 2CARE
ARTHRTIS LTD, Rheumatology, Edmonton, Canada; 3Université Laval,
Medicine, Quebec City, Canada; 4University of Alberta, Radiology, Edmonton,
Canada; 5Bone and Joint Institute, Medicine, London, Canada; 6Schulich
School of Medicine and Dentistry, Western University, London, Canada

Background: Cytokines such as tumor necrosis factor (TNF-α) have been
shown to elicit inflammatory and catabolic events in the joints of patients with
osteoarthritis. Recent RCTs demonstrated that TNF-α inhibition has no effect
on pain and MRI-detected synovitis or bone marrow lesions in patients with
erosive hand OA. However, the progression of bone erosions was reduced in a
subset of patients with more clinically swollen distal interphalangeal joints in one RCT. Consequently, it remains possible that TNF-α inhibition
may have beneficial effects in specific subgroups of patients with a high
inflammatory component.

Objectives: We aimed to evaluate the efficacy and safety of a TNF-α inhibitor,
adalimumab (ADA), in a proof-of-concept study in patients with inflammatory OA
of the knee.

Methods: OKINADA was a 52-week, randomized, double-blind, pla-
cebo-controlled, parallel-group study done at 11 sites in Canada
(NCT02471118). Eligible participants were adults (aged ≥18 years) with
a diagnosis of OA of the index knee and classified according to American
College of Rheumatology criteria, including radiological evidence of OA
(Kellgren-Lawrence grades 2 or 3) with clinical signs of knee effusion. Sub-
jects had persistent knee pain of ≥ one month duration with a pain score
of ≥ 4 (0-10 NRS) in the index knee at screening and baseline despite
delontventional treatment with maximum tolerated acetylamophene and/or
non-steroidal anti-inflammatory drug. Patients were randomly assigned
(1:1) to receive subcutaneous 40 mg ADA every 2 weeks or placebo
(PBO). Primary endpoint was the Outcome Measures in Rheumatology
and Osteoarthritis Research Society International set of responder cri-
teria (OMERACT-OARSI) at week 16 defined as: (1) improvement in pain
or function ≥50% and an absolute change ≥20 mm; or (2) improvement
of ≥20% with an absolute change ≥10 mm in at least two of the following
three categories: pain, function, and patient’s global assessment. Second-
ary endpoints included: the Knee Injury and Osteoarthritis Outcome Score
(KOOS) for the domains of pain, activities of daily living (ADL), OA symp-
toms, sport and recreation function (SRF), and knee-related quality of life
(QoL), patient’s global assessment of disease status (PGAD), investigator
global assessment of disease status (IGAD), and expanded Target Joint
Assessment (TJA) score.

Results: A total of 59 patients were randomized (29 to PBO, 30 to ADA). The
primary endpoint was not met: OMERACT-OARSI combined (ADA: 9 [30.0%]
vs PBO: 7 [24.1%], p=0.62). For KOOS pain, ≥20% improvement was noted in
11 (36.7%) ADA vs 7 (24.1%) PBO patients (p=0.30), and ≥50% improve-
meth in 5 (16.7%) ADA vs 6 (20.7%) PBO patients (p=0.69). There were no signif-
cant treatment-group differences in baseline to 16-week change in continuous
secondary endpoints (ADA vs PBO: KOOS ADL 6.5 vs 8.4 (p=0.71), KOOS
QoL 10.1 vs 7.4 (p=0.66), KOOS symptoms 7.8 vs 11.5 (p=0.42), KOOS SRF
5.8 vs 7.7 (p=0.76), PGAD -1.0 vs 0.1 (p=0.10), IGAD -1.5 vs -2.1 (p=0.30), TJA
-2.4 vs -2.2 (p=0.67) or in lab markers (ESR, CRP). There were 11 withdrawals
(4 ADA, 7 PBO) of which 2 were for adverse events (1 ADA, 1 PBO) and 2 for
increasing knee pain (1 ADA, 1 PBO). No new safety signals were identified
and there were no serious adverse events.

References:
eet al. Rheumatology, 2006;
eet al. Rheumatology, 2006;.
Disclosure of Interests: Walter P Maksmowycz Speakers bureau: Abbvie, Janssen, Novartis, Pfizer, UCB, Consultant of: Abbvie, Boehringer Ingelheim, Celgene, Eli-Lilly, Galapagos, Novartis, Pfizer, UCB, Grant/ research support from: Abbvie, Novartis, Pfizer, UCB, Louis Bessette Speakers bureau: Amgen, BMS, Janssen, Roche, UCB, Abbvie, Pfizer, Merck, Lilly, Novartis, Sanofi, TEVA, Fresenius Kabi, Sandoz, Consultant of: Amgen, BMS, Janssen, Roche, UCB, Abbvie, Pfizer, Celgene, Lilly, Novartis, Sanofi, Gilead, TEVA, Fresenius Kabi, Sandoz, Grant/research support from: Abbvie, BMS, Janssen, Roche, UCB, Abbvie, Pfizer, Merck, Celgene, Sanofi, Lilly, Novartis, Gilead, Robert G Lambert Paid instructor for: Novartis, Amanda Carapellucci: None declared, C. Thomas Appleton Speakers bureau: Abbvie, Amgen, Bristol Myers Squibb, Celgene, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Organon, Pfizer, Hoffman LaRoche, Sandoz, Sanofi-Genzyme, UCB, Consultant of: Abbvie, Amgen, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Organon, Pfizer, Hoffman LaRoche, Sandoz, Sanofi-Genzyme, UCB, Grant/research support from: Abbvie, Fresenius Kabi, Novartis, Pfizer DOI: 10.1136/annrheumdis-2022-eular.3422

OP0230
ANTIHISTAMINE USE AND STRUCTURAL PROGRESSION OF KNEE OA: A POST-HOC ANALYSIS OF TWO PHASE III CLINICAL TRIALS
A. R. Bihlet1, C. P. Miller1, I. Byrjalsen1, J. R. Andersen2, M. Karsdal2, M. C. Baker3, T. R. Rao4. 1NBCD A/S, Herlev, Herlev, Denmark; 2Nordic Bioscience A/S, Herlev, Herlev, Denmark; 3Mobility Bio Inc., Palo Alto, Palo Alto, CA, United States of America; 4Stanford, Division of Immunology and Rheumatology, Stanford, United States of America

Background: Prior studies indicate that mast cells are involved in chronic inflammation and that their activation in the synovium may contribute to structural progression of osteoarthritis (OA), however the exact role of mast cells in structural progression of OA remains unclear. Antihistamines act by blocking histamine receptors, and current reports describing antihistamine use in OA patients suggest that antihistamines may reduce development of OA and lead to reduced risk of structural progression.

Objectives: We aimed to investigate whether antihistamine use during a two-year trial period was associated with differences in structural progression of OA, as compared with non-use.

Methods: This is a post-hoc analysis of two large phase III trials investigating oral salmon calcitonin in knee OA (NCT00486434 and NCT00704847). The primary outcome measure was structural progression defined as the change in minimum joint-space width measured by use of x-ray imaging from baseline to Year Two. In these trials, participants reported use of antihistamines, defined as medication coded with the ATC code R06A. In our study, we evaluated differences between groups of participants who reported use of antihistamines, versus those who did not, over the 2-year study period. Secondly, the duration of antihistamine use divided into categories of either no use, 1-49, 50-299 or >300 days of use was investigated to evaluate exposure-response relationships. The effect of use of antihistamines was evaluated using ANCOVA analysis adjusting for age, sex, BMI, and baseline JSW.

Results: Of a total study population of 2,206 participants, 1,485 completed the trial. Of these, 1,327 were non-users of antihistamines (mean age 64.4 years, 64.1% female, mean BMI 29.0 kg/m²) and 158 reported use of antihistamines (mean age 64.4 years, 64.1% female, mean BMI 28.1 kg/m²). Seventy-four participants reported use of antihistamines, defined as medication coded with the ATC code R06A.

Conclusion: Although the treatment was safe, short-term treatment with anti-TNFα therapy does not appear to provide clinically meaningful improvements in OA symptoms in patients with established radiographic knee OA. Analyses of structural endpoints will be reported when results are available.

REFERENCES:


OP0231
MASS CYTOMETRY DATA RECLASSIFY SYSTEMIC AUTOIMMUNE DISEASE PATIENTS IN PHENOTYPICALLY DISTINCTIVE GROUPS
P. Rybakowska1, S. van Gassen2, C. Perez-Sanchez3, A. Ibañez-Costa4, N. Varela1, R. Ortega Castro2, C. Fernández-Roldán1, J. Jiménez-Moleón4, N. Ortegón3, E. Raya4, R. Aguilar Quesada2, C. Lopez-Pedrera2, E. Collantes Estevez7, Y. Saeya7, M. Alarcon-Riquelme1, C. María8. 1GENYO, Centre for Genomics and Oncological Research Pfizer/University of Granada/Andalusian Regional Government, PTS, Genomic Medicine, Granada, Spain; 2VIB Center for Inflammation Research, Data Mining and Modeling for Biomedicine, Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium; 3Mammone Institute for Research in Biomedicine of Cordoba (IIMIBIC), Reina Sofia University Hospital/University of Córdoba, Córdoba, Spain; 4Servicio de Medicina Interna. Unidad de Enfermedades Autoinmunes Sistémicas, Departamento de Medicina, Universidad de Granada. Hospital Universitario San Cecilio, P.T.S. Granada, Granada, Spain; 5Servicio de Reumatología, Hospital Universitario San Cecilio, P.T.S. Granada, Granada, Spain; 6Biobanco del Sistema Sanitario Público de Andalucía, Andalusian Public Health System Biobank, Granada, Spain

Background: Systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSC), Sjögren's syndrome (SJS), mixed connective tissue disease (MCTD), primary antiphospholipid syndrome (PAPS) and undifferentiated connective tissue disease (UCTD) are classified as systemic autoimmune diseases (SADs). They are diagnosed based on different clinical and laboratory criteria. Due to their high internal heterogeneity and overlapping symptoms, SADs are difficult to diagnose. Therefore, molecular and cellular-based studies need to be undertaken to precisely classify the patients. Mass cytometry is a single-cell proteomics technology that measures approximately 50 markers per cell, thus it is a suitable tool to perform deep-phenotyping studies in SADs.

Objectives: Explore differences and similarities between SADs and build reclassification framework using high-dimensional cytometry data.

Methods: The whole blood samples collected from 129 individuals, including patients and controls were stained with a 39-plex antibody panel and acquired
in 9 batches on a CyTOF (HELIOS) instrument. Data were cleaned, and nor-
malized for batch effects using semi-automated cytof analysis pipeline. Cell
frequencies and median signal intensities (MSI) for each population were
extracted using FlowSOM for mononuclear cells (PBMC) and Phenograph
granulocytes. Secretion of 44 cytokines and chemokines were analyzed using
a multiplexed luminox assay. Diseases were compared by Kruskal-Wallis anal-
ysis and hierarchical clustering and reclassification was done using unsuper-
vised k-means clustering. Cytokine analysis across clusters was performed using
Kruskal-Wallis test.

**Results:** Differently expressed features were observed between patient groups.
regarding frequency of classical monocytes, B and T cell subpopulations,
mature and immature granulocytes and intensities of CD38, HLA-DR and CD95
across various populations. However, none of them were disease specific.
K-means clustering identified four patient clusters, which were composed by a
mixture of different diagnosis. Cluster C1 was characterized by increased levels
of circulating cells from PBMC compartment, and lower activation of different
populations of the T cell compartment. It presented lower frequency in multiple
granulocyte populations and the highest expression of CD95 and CD38. This
cluster was also associated with antimalarial and steroid treatment. Clusters C1
and C2 were exactly opposite to each other, cluster C3 was characterized by
intermediate features between C1 and C2 and cluster C4 could be considered
as undifferentiated, mixed group. Higher production of TNFα, IL-10 and IP-10
were found in patients from C1 compared to C2, suggesting more active pheno-
type in C1 and physiological one in C2. The cytokine levels were independent of
the treatment.

**Conclusion:** We constructed a patient reclassification framework using
cell frequencies and expression levels of functional markers. To our knowl-
edge this is the first time when 7 different SADs were compared using
mass cytometry. In agreement with other reports we did not detect any
disease-specific cellular markers. Distribution of diagnosis across different
clusters confirms diseases heterogeneity. Patients can be classified into
phenotypically similar groups, that could potentially benefit from the same
line of treatment.

**Acknowledgements:** This project has received funding from the Innova-
tive Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No
831434 (3TR) and The JU receives support from the European Union’s Horizon
2020 research and innovation programme and EFPIA. Also from No 115565
PRECIESADS.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1123

---

**OP0232 HIGH PLASMA C4D/C4 IDENTIFIES LUPUS NEPHRITIS PATIENTS WITH DISEASE MEDIATED BY ACTIVATION OF THE CLASSICAL COMPLEMENT PATHWAY**

A. Mongan1, P. Suri2, D. R. Arts3, E. Cahir-McFarland4, H. A. Kroon1,

1 Annexon Biosciences, Translational Medicine, San Francisco, United States of
America; 2 Annexon Biosciences, Research, San Francisco, United States of
America; 3Annexon Biosciences, Clinical Development, San Francisco, United States
of America; 4University of California, Department of Medicine, San
Francisco, United States of America

**Background:** Proliferative lupus nephritis (LN) involves immune complex depo-
sition in the kidney that can severely impact normal renal clearance mechanisms.
Immune complexes can activate C1q and the classical complement cascade,
and along with pathogenic anti-C1q antibodies (PACAs), may amplify inflam-
mation and disease progression. Martin et al reported that circulating C4d, a marker
of complement activation downstream of the C1 complex, correlated well with
C4d immunohistochemistry score in kidney tissue and could be a sensitive and
specific biomarker for diagnosing active LN.1

**Objectives:** To confirm and extend observations by Martin et al, and to extend
a link between C4d, C1q activation, and PACA levels to identify patients most
likely to have the classical complement pathway as a driving component of
disease. Such patients would be potential candidates for anti-C1q therapy,
such as ANX009, to dampen disease activity and slow disease progression
(NCT04535752).

**Methods:** Plasma samples were collected from a cohort of 40 LN patients
(20 with disease flare and 20 without disease flare) from the California
Lupus Epidemiology Study (CLUES), a multi-racial/ethnic cohort of indi-
viduals with physician-confirmed systemic lupus erythematosus, and 20
healthy controls (Table 1). A panel of complement factors, including 15 com-
plement protein and relevant complexes, were measured using an enzyme-
linked immunosorbent assay. Clinical disease activity was measured using

**Table 1. Patient Demographics**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Healthy Control(n=20)</th>
<th>LN Flare(n=20)</th>
<th>LN Without Flare(n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age (years)*</td>
<td>50 (31-60.8)</td>
<td>28.5 (26-34.5)</td>
<td>43.5 (33.5-52)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>Female 18 (90)</td>
<td>17 (85)</td>
<td>18 (90)</td>
</tr>
<tr>
<td>Demographics, n (%)</td>
<td>Caucasian 8 (40)</td>
<td>5 (25)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Hispanic 3 (15)</td>
<td>9 (45)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>African American 2 (10)</td>
<td>3 (15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian 8 (40)</td>
<td>7 (35)</td>
<td>8 (40)</td>
<td></td>
</tr>
<tr>
<td>Median UPCR (mg/mg)*</td>
<td>N/A</td>
<td>18 (13-6.5)</td>
<td>0.4 (0.2-0.6)</td>
</tr>
<tr>
<td>Median SLEDAI*</td>
<td>N/A</td>
<td>12 (9-16)</td>
<td>2 (2-4)</td>
</tr>
</tbody>
</table>

*Reported as median (IQR). LN, lupus nephritis; N/A, not applicable; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; UPCR, urinary protein/creatinine ratio.

**Results:** We observed evidence of coordinated complement activation in LN
patients relative to healthy controls. Specifically, levels of C4d and the C4d/C4
ratio were highly increased in LN patients with flare, while levels of C1q, C1s,
and C4 were decreased, consistent with activation of the classical comple-
ment pathway (increased activation and component consumption). The C4d/
C4 ratio also correlated with levels of PACA isoforms 1 and 3 that are known
to activate the classical pathway. Improvements in C4 and C4d/C4 ratio were
associated with improvements in proteinuria and SLEDAI following treatment
for disease flare, indicating their potential value as biomarkers of treatment
effect.

**Conclusion:** A subset of LN patients exhibited high C4d/C4 ratio along with
specific markers of classical pathway activation, indicating that the classical
complement pathway may be a driving component of their disease. Reduc-
tion in this ratio appears to correlate with treatment response, but its levels
are generally not normalized, suggesting an insufficient resolution of com-
plement-mediated inflammation by currently available treatments. Our data
support a clinical hypothesis that a subset of LN patients may benefit from a
precision medicine approach targeting the classical complement pathway
(Figure 1). This hypothesis will be evaluated in a forthcoming clinical trial
testing the subcutaneously administered C1q inhibitor ANX009 in patients
with active LN.

**Figure.** Unique Precision Medicine Strategy in Lupus Nephritis

**REFERENCES:**

Deposition in Kidneys and With Treatment Response in Lupus Nephritis

**Acknowledgements:** Supported by: Annexon Biosciences

**Disclosure of Interests:** Ann Mongan Employee of: Annexon Biosciences, Poo-
jan Suri Employee of: Annexon Biosciences, Maze Therapeutics, Dean Richard
Arts Shareholder of: Annexon Biosciences, Bristol Myer Squibb, Roche, Sanoll,
BMS, J.&J. Employee of: Annexon Biosciences, Ellen Cahir-McFarland Share-
holder of: Annexon Biosciences, Employee of: Annexon Biosciences, Biogen,
Henk-André Kroon Shareholder of: Annexon Biosciences, Employee of: Annexon
Biosciences, Yaisa Andrews-Zwilling Employee of: Annexon Biosciences, Shawn
Rose Employee of: Annexon, Johnson & Johnson, Sanjay Keswani Shareholder
of: Annexon Biosciences, Nura Bio, Biogen, Employee of: Annexon Biosciences, Nura
Bio, Maria Dal’Era Consultant of: GSK, AstraZeneca, Biogen, Annexon Biosciences,
Pfizer, Aurinia, Grant/research support from: Annexon Biosciences,
Interestingly, p16Ink4a seems to be associated with CD8 T cell infiltration, renal and systemic disease severity. These likely involve both the infiltrating immune and resident renal cell compartments. Cellular senescence is the irreversible arrest of the cell cycle through the accumulation of cyclin dependent kinase (CDK) inhibitors such as p16INK4a (CDKNA2). Senescent cells nevertheless remain metabolically active and undergoing morphological and physiological changes including the acquisition of a pro-inflammatory, pro-fibrotic senescence-associated secretory phenotype (SASP). Aberrant accumulation of senescent cells has been observed in renal aging and pathology. We recently described the presence of p16INK4a-positive cells (a senescence hallmark) in LN renal biopsies, and their association with baseline disease severity and 5 year outcome.

In addition, we observed a spatial co-distribution between tissue-infiltrating CD8 T cells, senescent kidney cells, suggesting a pathogenic functional interaction between them.

Objectives: We hypothesize that cellular senescence may contribute to tissue damage in a few different ways: (a) Presentation of senescence-associated antigens that attract and activate CD8 T cells. Alternatively, CD8 T cells may be summoned to the kidney by other means, and may contribute to senescence-induction through the secretion of certain cytokines; (b) Secretion of pro-fibrotic, pro-inflammatory molecules, and/or (c) Functional incapacitation of kidney cells, particularly renal progenitor cells, responsible for repairing and restoring kidney function upon damage. In parallel with our work on patient samples, we aim to establish a relevant pre-clinical model in which we may test for the effects of senescence and senescence-directed interventions, on kidney damage.

Methods: Here, we assess for whether the B6.Sle1.Sle2.Sle3 spontaneous lupus-prone mouse may serve as an appropriate model in which to study the role of cellular senescence. We evaluated the presence and distribution of p16INK4a-positive cells by immunohistochemistry, and tested for an association with CD8 T cell infiltration and renal and systemic disease, in a cohort of 21 B6.Sle1.Sle2.Sle3 female mice. This is now being followed-up by a systematic longitudinal study for the time of onset of different renal and systemic disease parameters, as compared to the detection of renal cell senescence in this well-characterized model.

Results: As observed in renal biopsies from LN patients, staining for p16INK4a-positive cells was heterogenous between mouse kidney samples. Interestingly, p16INK4a seems to be associated with CD8 T cell infiltration, renal impairment and damage, independently of age. This will now be confirmed using the “senescence-associated β-galactosidase” assay, the other classic measure of cellular senescence.

Conclusion: We report the occurrence of cellular senescence, and its correlation with CD8 T cell infiltration and disease severity, in the B6.Sle1.Sle2.Sle3 mouse model of lupus. These mice provide a pre-clinical model in which to test for the role of cellular senescence in the pathogenesis of LN in vivo (by the induction vs. selective elimination of senescent cells). They also serve as an alternative source (alongside patient samples) of cells for in vitro functional assays to test for the effects of senescent renal cells on CD8 T cells and vice versa.

REFERENCES:

Disclosure of Interests: Gaeil Tilman: None declared, Laura Watteyne: None declared, Delphine Nolf: None declared, Caroline Bouzin: None declared, Frederic Houssiau Grant/research support from: Grant from GSK, Nisha Limaye: None declared.
Objectives:

Nature. However, the DNAm patterns in purified immune cell populations are aberrant DNA methylation (DNAm) pattern with a predominant interferon signature. MTA3 activity.

Conclusion:

(p=0.03) in B cells.

Methods:

related to PLSCR1 B cells and hypomethylation in all but PARP9 methylation in granulocytes (p<0.0001) in non-coding clusters located on chromosome 22 downstream of TRAF5, and in non-coding clusters with no genic association. The non-gene methylated CpGs with 1360 genes in the promoter region restricted to differential methylation >10% and ≥2 DMCs, of which 1087 were hypermethylated. Of these, the most significantly hypermethylated CpGs in the promoter region included CAYBR, TPMRSS7, SLC6A2, KLK10/KLK11, WIZ, LPAR1, ZNF365B and IL1R1 (Figure 1). Top hypomethylated genes included IFI44L and MX1. Inguinity Pathway Analysis (IPA) predicted top upstream regulators in B cells to be IL4, TNF and IFNG. In addition, we identified 1437 DMCs associated with ncRNA and 4626 DMCs with no genic association. The non-gene associated DMCs were related to 275 non-coding clusters. Top non-coding clusters were in proximity to BMP7, ARHGFE10, PRDM1, RIN2 and CCR6, which themselves were differentially methylated. IPA predicted IL2, CD40LG and NFKB1 as the most important upstream regulators for neighbouring genes of non-coding clusters.

Pyrosequencing confirmed B cell hypermethylation in SLE patients is widespread, and hypomethylation in all but CD4 T cells, monocytes, granulocytes and B cells in SLE patients compared to healthy controls (HC).

Results:

Overall, SLE patients with active LN compared to HCs exhibited DMCs in 22, 46, 312 and 78,068 probes in CD4 T cells, monocytes, granulocytes and B cells, respectively. In CD4 T cells, monocytes and granulocytes, the majority of DMCs were hypomethylated and related to interferon-regulated genes. In B cells, the majority of DMCs were hypermethylated with 1960 genes in the promoter region restricted to differential methylation >10% and ≥2 DMCs, of which 1076 were hypermethylated. Of these, the most significantly hypermethylated CpGs in the promoter region included CAYBR, TPMRSS7, SLC6A2, KLK10/KLK11, WIZ, LPAR1, ZNF365B and IL1R1 (Figure 1). Top hypomethylated genes included IFI44L and MX1. Ingenuity Pathway Analysis (IPA) predicted top upstream regulators in B cells to be IL4, TNF and IFNG. In addition, we identified 1437 DMCs associated with ncRNA and 4626 DMCs with no genic association. The non-gene associated DMCs were related to 275 non-coding clusters. Top non-coding clusters were in proximity to BMP7, ARHGFE10, PRDM1, RIN2 and CCR6, which themselves were differentially methylated. IPA predicted IL2, CD40LG and NFKB1 as the most important upstream regulators for neighbouring genes of non-coding clusters.

Pyrosequencing confirmed B cell hypermethylation in CXCR5, DDR1, MT3, Rab30 and glycoprotein in IFI44L, LGALS3BP and PARP9 was stable at follow-up as well as in patients with inactive and never-LN. Patients in the active LN group exhibited significantly more pronounced hypermethylation in PLCSCR1 in CD4 T-cells, granulocytes and B-cells compared to the other patient groups. Greater j2 microglobulin, anti-DNA antibodies and disease activity were significantly associated with greater B cell CXCR5 hypermethylation (p<0.001), IFI44L hypermethylation in all but CD4 T cells, LGALS3BP hypermethylation in granulocytes (p<0.0001), PARP9 hypermethylation in all but B cells and PLCSCR1 hypermethylation in all but monocytes. Proteinuria was related to PLCSCR1 hypermethylation in all but monocytes, as well as hypermethylation at the non-coding cluster in chromosome 3 (p=0.05) and MT3 (p=0.03) in B cells.

Conclusion: B cell hypermethylation in SLE patients is widespread, and may indicate a novel mechanism for SLE pathogenesis. Differential methylation of several interferon-regulated genes may be associated with disease activity.

Disclosure of Interests: None declared

DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL DISTINCT IMMUNE NETWORKS STRATIFY ORGAN INVOLVEMENT AND RESPONSE TO B CELL

M. Shipa1, L. Santos Ribeiro1, D. Nguyen1, A. Embleton-Thirsk4, M. Parvaz2, D. Isenberg2, C. Gordon2, M. Ehrenstein1. 1University College London, Department of Ageing, Birmingham, United Kingdom; 2University of Birmingham, Rheumatology Research Group- Institute of Inflammation and Ageing, Birmingham, United Kingdom; 3University of Manchester, Manchester, United Kingdom; 4University of Liverpool, Comprehensive Clinical Trials Unit, London, United Kingdom; *University of Birmingham, Rheumatology Research Group- Institute of Inflammation and Ageing, Birmingham, United Kingdom

Background: The results from the double-blind BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We sought to identify biomarkers of response to belimumab after rituximab to aid a personalised approach to therapy for SLE.

Objectives: To identify biomarkers of clinical response to belimumab after rituximab in the BEAT-lupus trial.

Methods: We constructed a model utilising a range of clinical, routine and exploratory laboratory data, from the BEAT-lupus trial to identify variables at baseline (screening) that could predict a major clinical response (MCR, defined as reduction to BILAG C in all domains, steroid dose of ≤7.5mg/day & SLEDAI<2, without anti-dsDNA antibody component) at 24 weeks. Relevant serum autoantibodies and cytokines were assayed by ELISA/Simoa, and interferon signatures and BAFF expression measured by RT-PCR. A linear mixed model was applied to longitudinal data collected during the trial stratified by treatment and clinical response. An independent cross-sectional lupus cohort was recruited to validate biomarker association with organ involvement.

Results: A major clinical response (MCR) was achieved in 48% (10 responders, 11 non-responders) of patients who received belimumab after rituximab compared to 35% (8 responders, 15 non-responders) in the placebo group (i.e. rituximab alone), added to tapered standard of care, at 52 weeks. Baseline serum IgA2 anti-dsDNA antibody levels emerged as the only positive predictor of attaining MCR in belimumab treated patients (AUROC 0.8, 95% confidence interval [CI] 0.7 -1.0), but negatively predicted MCR in the placebo arm (AUROC 0.2, CI 0.1-0.4). At baseline, 77% and 85% of patients were positive for serum IgA2 anti-dsDNA antibodies in belimumab and placebo arms respectively, which reduced to 30% at 52 weeks in the belimumab group but remained unchanged with placebo (Fisher exact test, p=0.007). In striking contrast, the percentage of patients who remained IgG anti-dsDNA antibody positive from baseline to 52 weeks were similar between the belimumab and placebo group, despite the serum levels significantly falling in the belimumab group (1). A significant reduction in serum IgA2 anti-dsDNA antibody levels at 24 and 52 weeks from baseline was only observed in belimumab responders (Figure 1).

Conclusion: SGECs in the inflammatory milieu of pSS are characterized by induction of autophagy and pro-survival mechanisms, and by expression of adhesion molecules. These changes correlate with SS infiltration with immune cells and with histologic disease severity. Among clinically available therapies, the JAK/STAT inhibitor baricitinib effectively reduced autophagy, countered the state of maladaptive activation of SGECs, and restored epithelial cell homeostasis. Transcriptomics and metabolomics studies are ongoing to dissect the specific mechanisms responsible for these beneficial effects.

REFERENCES:

Disclosure of Interests: Serena Colafrancesco Speakers bureau: Novartis. Sobi, Grant/research support from: Eli Lilly, cristiano alessandri: None declared, Fabio Pfizer Massimo Fusconi: None declared, Francesca Romana Spinelli Speakers bureau: Novartis. Disclosure of Interests: None declared, Roberta Priori: None declared, Federicco Giardina: None declared, angelica gatt tamelata: None declared, raffaella izzo: None declared, Bruna Cerbelli: None declared, Federico Giardina: None declared, Serena Colafrancesco Speakers bureau: Novartis.

The number of circulating IgA2-secreting (but not total) plasmablasts (p=0.032) and T follicular helper cells (p=0.031) were significantly reduced at 52 weeks in the belimumab treated arm compared to placebo. Elevated serum IgA2 anti-dsDNA antibody levels were also associated with active renal disease irrespective of treatment arm (odds ratio, OR 3.2, CI 1.7-5.8, p<0.001). In contrast, serum IgA1 anti-dsDNA antibody (OR 1.3, CI 1.0-1.7, p=0.042) and interferon-alpha levels (OR 1.4, CI 1.0-2.0, p=0.041), and interferon transcriptional signature (OR 1.1, CI 1.0-1.3, p=0.027) showed a modest association with mucocutaneous disease activity; but did not predict response to B cell targeted therapy. Patients with a high baseline serum IL-6 were less likely to achieve an MCR irrespective of therapy (OR 0.4, CI 0.2-0.9, p=0.033). The associations between serum IgA2 and IgA1 anti-dsDNA antibody levels and active renal and mucocutaneous disease respectively were confirmed in an independent cross-sectional lupus cohort.

Conclusion: IgA2 anti-DNA autoantibodies is a biomarker of response to belimumab after rituximab, and of active renal disease, in systemic lupus erythematosus. Our study reveals distinct molecular networks associated with renal and mucocutaneous involvement, and response to B cell targeted therapies, which could guide precision targeting of current therapies for this heterogeneous disease.

REFERENCES:

Acknowledgements: This research was supported by Versus Arthritis (grant number 20873) and the UCLH Biomedical Research Centre (BRC). GSK provided belimumab free of charge, as well as additional funding. GSK had no role in this research and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results. Versus Arthritis and the UCLH BRC reviewed the relevant grant proposals and monitor progress of relevant aspects of the study but did not play any role in the analyses, interpretation of data, or decision to submit results.

Disclosure of Interests: Muhammad Shipa: None declared, Liliana Santos Ribeiro: None declared, Dao Nguyen: None declared, Andrew Embleton-Thirsk: None declared, Mariea Parvaz: None declared, David Isenberg Consultant of: Received consultancy fees from Astra Zeneca, Eli Lilly, Merck Serono, Servier and UCB. , Caroline Gordon Speakers bureau: Speakers’ bureau for GSK and
Background: In cases of systematic lupus erythematosus (SLE) that lead to surgery due to the development of heart diseases such as valvular disease, ischemic heart disease and aortic aneurysm, early detection and careful monitoring is important. The absence of background diseases or immunopathological examination of the myocardial tissue in SLE cases with cardiovascular lesions demonstrates the lack of knowledge in this area. In recent years, however, there have been reports of neutrophil extracellular traps being involved in the fulminant onset of SLE.

Objectives: This study aimed to analyze clinically and immunohistopathologically the pathophysiology of heart diseases associated with SLE.

Methods: We performed left atrial appendage resection in 34 patients, including patients with cardiovascular lesions, who underwent heart surgery for SLE complications from 2012 to 2021. Tissue analysis was conducted in 9 cases. The left atrial appendage, in cases of non-collagen valvular disease, was used as the control. Tissue staining of cardiomyocytes was carried out by adding anti-neutrophil extracellular (NE) antibodies (Abs) to anti-human IgG antibody (Ab), anti-IgM, anti-CL Abs was 55.6%, which was higher than the 25.5% observed in previous SLE patients. In this study, anti-SS-A and anti-RNP Abs tended to be relatively numerous. An example of immunohistochemical staining of IgG in the left atrial appendage is presented (Figure 1a). IgG deposits were not observed on the left side of the myocardial fibers in the control group, whereas IgG deposits were observed on the right side in the SLE group. Deposits were also observed in tissues that were not located in the affected areas. The presence or absence of tissue deposition in the myocardial fibers and clinical findings in 2 cases of the control group and 9 cases of the SLE complication group are reported in Table 1. IgG deposits were found in the myocardial fibers of 6 of the 9 patients in the SLE complication group, and deposits were found in the left atrial appendage tissue regardless of the type of heart disease, suggesting a potential change in the pathophysiology of heart diseases associated with SLE.

Results: Of the 34 SLE patients, 14 had valvular disease, 8 had ischemic heart disease and 12 had aortic aneurysms. Preoperative SLE activity was relatively stable with only 1 patient below the CH50 standard and 6 patients above the anti-DNA Ab standard. The Ab positivity rate for the patients in this study was higher than that of the 687 SLE patients who were previously tested in 2019. The presence of anti-CL Abs was 55.6%, which was higher than the 25.5% observed in previous SLE patients. In this study, anti-SS-A and anti-RNP Abs tended to be relatively numerous. An example of immunohistochemical staining of IgG in the left atrial appendage is presented (Figure 1a). IgG deposits were not observed on the left side of the myocardial fibers in the control group, whereas IgG deposits were observed on the right side in the SLE group. Deposits were also observed in tissues that were not located in the affected areas. The presence or absence of tissue deposition in the myocardial fibers and clinical findings in 2 cases of the control group and 9 cases of the SLE complication group are reported in Table 1. IgG deposits were found in the myocardial fibers of 6 of the 9 patients in the SLE complication group, and deposits were found in the left atrial appendage tissue regardless of the type of heart disease, suggesting a potential change in the pathophysiology of heart diseases associated with SLE.

Conclusion: In SLE patients who developed cardiovascular lesions and required surgery, immunological abnormalities may occur in the myocardial tissue even if serum complement and anti-DNA Ab levels are stable.

REFERENCES:

Disclosure of Interests: None declared


Osteoporosis
different anti-osteoporotic drugs on fracture. In sensitivity analyses we generated 1:1 matched cohorts of patients with prescription of bisphosphonates, denosumab, teriparatide or without any pharmacological prescription at baseline and 1:1 matched cohort based on the T-score variation over the time (increase in T-score vs decrease or stability in T-score values).

**Results:** Data from 50,862 women were available. Among these, 3,574 individuals had at least 2 consecutive visits. The crude fracture rate was 919.1/1,000 person-year for non-treated patients. The crude fracture rate in bisphosphonate users was 72.1/1,000 person-year, in denosumab users was 58.2/1,000 person-year and in teriparatide users was 19.3/1000 person-year. Overall, we found that bisphosphonates were associated with a 30% lower risk of fracture compared to no treatment (aHR 0.70, 95% CI 0.50-0.98), denosumab and teriparatide were associated with 60% and 90% lower risk of fracture, respectively (aHR 0.43, 95% CI 0.24-0.75 and aHR 0.09, 95% CI 0.01-0.70). Bisphosphonate use was associated with a lower risk of fracture only after one year of treatment. In Figure 1 are presented the Kaplan Meier curves free from fragility fracture after propensity score matching.

**Conclusion:** In conclusion, we found that all anti-osteoporotic medications effectively reduced the risk of fracture in the real-life. Bisphosphonate’s effect on fracture risk was apparent only after the first year of treatment. Our findings do not support the use of bisphosphonates in patients at imminent risk of fracture.

**Disclosure of Interests:** Giovanni Adami Shareholder of: Theramex, Galapagos, IRENE GAVIOLI: None declared, Angelo Fassio: None declared, Camilla Benini: None declared, Eugenia Bertoldo: None declared, Ornella Viapiana: None declared, Davide Gatti: None declared, Maurizio Rossini Shareholder of: Abbvie, Amgen, Bms, Eli Lilly, Galapagos, Novartis, Pfizer, Sandoz, Theramex, Ucb.
**Results:** A total of 140 patients were recruited. The mean age of the patients, who were mostly female (80.7%), was 58.7 ± 12.5 years at baseline. BLE and RA were the most common diagnoses. At baseline, 45.0% and 38.6% of the patients had previous fracture, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years was documented. The baseline clinical characteristics, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years were compared with patients with rheumatic diseases on long term GC from 7 regional hospitals who had dual-energy X-ray absorptiometry (DXA) and HR-pQCT done were invited to have a follow-up assessment. X-rays were repeated. The occurrence of new fragility fracture after 5 years was documented. The baseline clinical characteristics, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years follow-up period (incident fracture group) were compared with patients who did not experience a fragility fracture (control group).

**Results:** A total of 140 patients were recruited. The mean age of the patients, who were mostly female (80.7%), was 58.7 ± 12.5 years at baseline. BLE and RA were the most common diagnoses. At baseline, 45.0% and 38.6% of the patients had previous fracture, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years were compared with patients with rheumatic diseases on long term GC from 7 regional hospitals who had dual-energy X-ray absorptiometry (DXA) and HR-pQCT done were invited to have a follow-up assessment. X-rays were repeated. The occurrence of new fragility fracture after 5 years was documented. The baseline clinical characteristics, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years were compared with patients who did not experience a fragility fracture (control group).

**Results:** A total of 140 patients were recruited. The mean age of the patients, who were mostly female (80.7%), was 58.7 ± 12.5 years at baseline. BLE and RA were the most common diagnoses. At baseline, 45.0% and 38.6% of the patients had previous fracture, aBMD, FRAX and HR-pQCT parameters in patients who experienced a new fragility fracture after 5 years were compared with patients who did not experience a fragility fracture (control group).
Disclosure of Interests: Giovanni Adami Shareholder of: Galapagos, Thera-
rex, Camilla Benini: None declared, Angelo Fassio: None declared, Eugenia
Bortolito: None declared, Ombretta Viapiana: None declared, Davide Gatti: None
declared, MaurizioRossiniShareholderof: Abbvie, Amgen, Bms, Eli Lilly, Galap-
agos, Novartis, Pfizer, Sandoz, Theraxem, Ucb.
DOI: 10.1136/annrheumdis-2022-eular.533

OP0243

OSTEOPOROSIS CASE-FINDING IN PEOPLE UNDERGOING ROUTINE DIAGNOSTIC CT SCANS ALMOST TRIPLED THE RATE OF OSTEOPOROSIS TREATMENT AT 12 MONTHS. A RANDOMISED, MULTI-CENTRE FEASIBILITY STUDY USING WAITING ROOM FRAX, OPPORTUNISTIC CT BONE DENSITY AND VERTEBRAL FRACTURE ASSESSMENT VERSUS USUAL CARE.

K. Poole1, D. Chappell2, J. Brown2, J. Flemming4, L. Shepstone4, T. Turmezei2, A. Wagner2, K. Willoughby2, S. Kaptoge2,1, University of Cambridge School of Clinical Medicine, Medicine, Cambridge, United Kingdom;2Addenbrooke’s Hospital, Rheumatology, Cambridge, United Kingdom;3University of Bristol, Clinical Science at North Bristol, Bristol, United Kingdom;4Cambridge Institute of Public Health, Public Health and Primary Care, Robinson Way, United Kingdom;5Norwich Clinical Trials Unit, Statistics, Norwich, United Kingdom;6Norfolk & Norwich University Hospital, Radiology, Norwich, United Kingdom;7Norwich Clinical Trials Unit, Health Economics, Norwich, United Kingdom

Background: Up to 40% of all diagnostic computed tomography (CT) scans include views of the spine or hips. Among older people, osteoporosis or vertebral fractures have been found in 30% of such CT scans. Our PHOENIX interventionrepresents CT scan taking for other reasons to identify fractures and measure bone density as an ‘added extra’. Early detection and treatment of osteoporosis in CT-attending patients could improve health outcomes.

Objectives: To determine the feasibility and efficacy of PHOENIX versus usual care in a multi-centre, randomised, pragmatic study conducted in Eastern Eng-
land involving our Cambridge Specialist Hospital ‘hub’ and four regional General Hospitals ‘spokes’.

Methods: Study design of a pragmatic, multicentre, randomised control trial (RCT) comparing PHOENIX (intervention) to Usual Care (control). Participants receiving PHOENIX were offered bone active treatment based on NOS 2009 guidelines for osteoporosis with a bone mineral density (BMD) threshold for bone active therapeutic intervention. Both groups were offered bisphosphonates if osteoporosis was diagnosed.

Results: From 1828 invites, 595 participants consented to participate of whom 423 (71%) were allocated to intervention and 172 (29%) to usual care.Baseline characteristics were well-matched (p=0.50-0.99). Of the participants in two groups: 361 (36%) women had commenced their AI prior to their cancer diagnosis. A significant reduction in fractures pre (13%) versus post (0%) was demonstrated (p=0.021). There was an overall increase in BMD in those women who were offered bone active therapy in the intervention group (p=0.074).

Conclusion: Osteoporosis treatment rates were almost tripled by screening people attending for routine diagnostic CT scans with waiting room FRAX, CT-bone densitometry and vertebral fracture analysis. This study provides real-world evidence of the success of 2017 consensus statement in lowering fracture risk. Though there has been data for positive impact on BMD decline with this approach, evidence for fracture preven-
tion has been limited. This study suggests the success of lowering bone active therapy threshold employing alternative risk modelling strategy for women with breast cancer commenced on AI. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.

REFERENCES:
ciated Bone Loss (AIBL) in postmenopausal women with hormone sensitive

OP0244

AROMATASE INHIBITORS AND FRAC TURE PREVENTION – DO NEW GUIDELINES WORK IN REAL WORLD?

A. Mirza1, Z. Win Naing1, P. Khonsari1, H. Khan1, P. Rezai1, A. K. Abbas2, M. Nisar1,1, Luton & Dunstable University Hospital, Rheumatology, Luton, United Kingdom

Background: 2,261,419 women were diagnosed with breast cancer worldwide in 2020. For postmenopausal women with hormone sensitive disease, aromatase inhibi-
tors (AI) are recommended for their mortality benefit. However, AI bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. In 2017, a consensus statement of 7 international bone and cancer societies was published proposing an algorithm based on clinical risk factors and different bone mineral density (BMD) threshold for bone active therapeutic intervention.

Objectives: To determine the real-world impact of the 2017 consensus guide-
lines on AIBL and whether bone sparing therapy utilising proposed risk stratifica-
tion model is effective in fracture prevention.

Methods: Over a 7-year study period, 1001 women were prescribed AI at our uni-
versity teaching hospital. The new guidelines were adopted in July 2017. We split the participants in two groups: 361 (36%) women had commenced their AI prior to the adoption of guidelines and 640 (64%) were in the post implementation group. First group were offered active bone treatment based on NOS 2009 guidelines whereas the second group followed the 2017 consensus guidelines. Women with osteoporosis were all offered treatment, however the difference in guideline is pertinent to osteopenia and we compared the results of that group.

Results: 1001 women were included. Mean age was 64 years (range 29-93), 929 (93%) were Caucasian, 57 (6%) were Asian and 15 (1%) were Afro-Caribbean. 723 women (72%) had invasive ductal carcinoma and 863 women (86%) were postmenopausal. At diagnosis, 428 women (43%) had node positive disease and 35 women (4%) had metastases. 91 women (9%) had sustained fractures prior to their cancer diagnosis. 276 women (28%) were offered oral bisphosphonates based on DEXA result, with 58 (6%) offered parental therapy.

First group: 361 women had a baseline DEXA with a mean left neck of femur (LNOF) BMD of 0.889 g/cm² (range 0.593-1.001). 276 women (76%) had a repeat DEXA after a mean of 3 years. In the treatment group, LNOF mean BMD remained relatively unchanged from 0.831 g/cm² to 0.812 g/cm² at the repeat DEXA (p=0.94). Of the 174 women with osteopenia, 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with a mean LNOF BMD of 0.890 g/cm² (range 0.512-1.390), 216 (33%) women were normal, 322 (50%) had osteopenia and 107 (17%) had osteoporosis.

Of the women with osteopenia, 127 (39%) women were offered treatment and 56 women had a repeat DEXA after a mean of 3 years. In the treatment group, LNOF mean BMD remained relatively unchanged from 0.822 g/cm² to 0.829 g/cm² at the repeat DEXA (p=0.6169).

Of the 322 women with osteopenia, 8 (2.5%) women had a fracture.

Conclusion: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. Though there has been data for positive impact on BMD decline with this approach, evidence for fracture prevention has been limited. This study showcases the success of lowering bone active therapy threshold employing alternative risk modelling strategy for women with breast cancer commenced on AI. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.
OP0245

ASSOCIATION OF BARIATRIC SURGERY WITH THE RISK OF FRACTURE IN PATIENTS WITH OBESITY: A META-ANALYSIS OF REAL-WORLD EVIDENCE

S. Hussain1, J. Klugarova2, M. Klugar2.
1Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; 2Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC: JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Background: Evidence from published epidemiological studies found inconsistent evidence on the association of bariatric surgery with fracture risk.

Objectives: To evaluate the impact of bariatric surgery on fracture risk.

Methods: Electronic databases PubMed, and Embase were searched for studies assessing the association between bariatric surgery and fracture risk by two independent investigators. The study search period was from inception to September 2021. Study selection, data extraction, and risk of bias were assessed by investigators independently. Newcastle-Ottawa Scale (NOS) was used to assess the risk of bias. The primary outcome was to compute the pooled fracture risk in patients with obesity who underwent bariatric surgery. Secondary outcomes include fracture risk based on follow-up duration and sites of fracture (hip, upper limb).

Results: This meta-analysis was based on seven studies with a total of 156233 patients with a mean age of 41.65 ± 10.63 years. Included studies were of low certainty as per the GRADE rating system. Evidence from published epidemiological studies found inconsistent evidence on the association of bariatric surgery with fracture risk.

Subgroup analysis based on follow-up duration also revealed a significantly higher fracture risk with a RR of 1.75 (95% CI: 1.34 – 2.30), p = 0.03 for studies with a follow-up period of >5 years. Likewise, analysis based on fracture sites revealed a significantly higher risk of hip fracture RR 1.34 (95% CI: 1.03 – 1.75), p = 0.03 (Figure 2). Evidence was of low certainty as per the GRADE rating system.

Conclusion: The current study found that bariatric surgery was associated with increased fracture risk. Clinicians should also evaluate the bone health profiling of the patients before the surgery.

REFERENCES:

Disclosure of Interests: None declared


OP0246

TO SCAN OR NOT TO SCAN (BOTH HIPS) – A BRISTOL EXPERIENCE

A. Anilkumar1, S. Saeed2, E. Elsayed1, C. N. R. Jayatilleke1, S. Webber2, M. A. Roy1.
1University Hospitals Bristol and Weston NHS Foundation Trust, Adult Rheumatology, Bristol, United Kingdom; 2University Hospitals Bristol and Weston NHS Foundation Trust, Adult Rheumatology, Weston, United Kingdom

Background: The current International Society of Clinical Densiometry (ISCD) recommendation for bone densitometry practice is that single hip measurement is sufficient in clinical practice, as there is overall a good correlation between the two hips bone mineral densities (BMD) (1) (2). However, discordance in individual T-scores and BMD between the two hips due to increasing age and osteoarthritis (3)-(5) is well recognised.

Objectives: To identify whether discordant hip BMD values would lead to differences in the FRAX risk assessment score between the two hips, and thereby impact treatment decisions in clinical practice.

Methods: We looked at all DXA scans performed at our centre for 2 months between 23/7/21 and 23/9/21. Cases in which both hips were scanned and anti-resorptive treatment was advised were included in our study. The femoral neck with the lower BMD is used to calculate the FRAX score and this was referred to as the ‘reported’ hip. The FRAX score for ‘reported’ and ‘unreported’ hip were calculated and the T-score of the spine was also noted. Our local treatment threshold is set at 20% for a major osteoporotic fracture and 5% for hip fracture. Cases of difference in scores crossing the 20%/5% FRAX threshold were highlighted and reviewed in more detail.

Results: DXA scans were performed in 328 patients over the 2 month period, of which 201 patients had both of their hips scanned. Of these, 50 patients were advised to start anti-resorptive treatment. The majority of the treatment decisions (80%; 39/50 cases) were based on the hip/femoral neck BMD value, while 40% (20/50 cases) were based on the spine T-score.

Where the treatment decision was based on hip/femoral neck BMD, 20% (6/30 cases) were found to have a FRAX risk above the treatment threshold at one hip only, meaning that treatment may not have been offered if both hips had not been scanned. Similarly, where treatment was advised based on spinal T-scores, 20% (4/20 cases) had a FRAX risk above treatment threshold at one hip only.

Mean age across these 10 cases with a discordant FRAX risk between the two hips was 72 years (range 59 – 83); 80% (8/10) were female. Steroid use and chronic inflammatory co-morbidities were the predominant indications for these DXA Scans.

Conclusion: A significant proportion of patients in our cohort (20%; 10/50) may not have been offered treatment if only one hip was scanned. Scanning both hips does not require much additional time and can help mitigate the risk of undertreating patients. The recommendation for best practice for DXA BMD measurements should be reviewed to consider lumbar spine and dual hip BMD as standard of care.

REFERENCES:

Disclosure of Interests: Aishwarya Anilkumar: None declared, Sadaf Saeed: None declared, Ehsan Elsayed: None declared, Chandrin N. R. Jayatilleke: None declared, Stuart Webber: None declared, Mathew A. Roy Consultant of: Worked as a paid consultant for Kyowa Kirin.


Outcome of COVID-19 in Rheumatic Diseases
Table 1. COVID-19 test results, hospitalization, invasive mechanical ventilation, and mortality

<table>
<thead>
<tr>
<th></th>
<th>Tested for</th>
<th>Hospitalized</th>
<th>% of tested</th>
<th>% of tested</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>COVID</td>
<td>COVID+</td>
<td>IMV</td>
<td>mortality</td>
</tr>
<tr>
<td>All pts</td>
<td>1,101,431</td>
<td>128,962</td>
<td>19,704</td>
<td>1,001 (0.8%)</td>
</tr>
<tr>
<td>Pts without selected IMIDs</td>
<td>1,049,007</td>
<td>123,943</td>
<td>18,729</td>
<td>959 (0.8%)</td>
</tr>
<tr>
<td>Pts with selected rheumatologic IMIDs</td>
<td>28,411 (2.5%)</td>
<td>2,974</td>
<td>578 (19.4%)</td>
<td>27 (0.9%)</td>
</tr>
<tr>
<td>Pts with other selected IMIDs</td>
<td>24,013 (2.2%)</td>
<td>2,045 (8.5%)</td>
<td>397 (19.4%)</td>
<td>15 (0.7%)</td>
</tr>
</tbody>
</table>

Selected rheumatologic IMIDs = RA, SpA, PsA, SLE, PsG, SSc; Other selected IMIDs = IBD, MS.

Figure 1. Odds ratio (OR) for selected risk factors for COVID-19 positive test, hospitalization, IMV, and mortality

**Conclusion:** This analysis of COVID+ patients (n=1,101,431) from a large US health care system analyzes outcomes of patients with and without IMIDs; the majority were rheumatologic IMIDs. Patients with IMIDs had a similar rate of hospitalization, IMV, and death as those without IMIDs. The strongest associations with COVID-19 severity included heart failure and age. Spondyloarthritids was weakly associated with favorable outcomes whilst other conditions, including COVID-19 severity, were not worse than those of non-IMID patients. csDMARDS and corticosteroids were weakly associated with hospitalization and RTX with increased mortality. Other therapies were not associated with severe adverse outcomes.

**Acknowledgements:** Philip Mease and Qi Wei contributed equally and share first authorship. Swedish Medical Foundation and Pfizer investigator-initiated study grant.

**Disclosure of Interests:** Philip J Mease Speakers bureau: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Consultant of: Abbvie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagen, Janssen, Novartis, Pfizer, Sun Pharma, UCB, Grant/ research support from: Abbvie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, Swedish Medical Foundation, UCB, Qi Wei Grant/research support from: Pfizer, Swedish Medical Foundation, Michael Chioleani Speakers bureau: Pfizer, BMS, Takeda, Abbvie, Janssen, Medtronic, Consultant of: Pfizer, Lilly, Janssen, Arena, Medtronic, BMS, Abbvie, Grant/research support from: Takeda, Pfizer, Novartis, Swedish Medical Foundation, Lulu Iles-Shih Grant/research support from: Pfizer, Swedish Medical Foundation. Jennifer Hadlock Grant/research support from: Pfizer, Swedish Medical Foundation

**DOI:** 10.1136/annrheumdis-2022-eular.2163

**OP0248**

**SEVERE COVID-19 OUTCOMES AMONG PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: A POPULATION-BASED STUDY**

S. Marocotto, Z. A. Fazal1,2, J. Tan1,3, N. Lu1, A. Hoens1,4, D. Lacalle1,5, J. Kopper1,6, H. Xie1,7, J. M. Loree1,7, J. Essalih1,8, J. A. Avila-Zubileta1,3, Arthritis Research Canada, N/A, Vancouver, Canada; 2University of British Columbia, Faculty of Land and Food Systems, Vancouver, Canada; 3University of British Columbia, Faculty of Science, Vancouver, Canada; 4University of British Columbia, Department of Physical Therapy, Vancouver, Canada; 5University of British Columbia, School of Population and Public Health, Vancouver, Canada; 6University of British Columbia, Divisions of Rheumatology, Department of Medicine, Vancouver, Canada; 7University of British Columbia, School of Population and Public Health, Vancouver, Canada; Simon Fraser University, Faculty of Health Sciences, Burnaby, Canada; 8University of British Columbia, Division of Medical Oncology, Department of Medicine, Vancouver, Canada; 9BC Cancer, N/A, Vancouver, Canada

**Background:** Individuals with autoimmune rheumatic diseases (ARDs) may be at greater risk of severe COVID-19 outcomes than individuals in the general population.

**Objectives:** This study assesses the risk of COVID-19-related hospitalization, intensive care unit (ICU) admission, and COVID-19-specific mortality in patients with ARDs compared to matched general population comparators.

**Methods:** We conducted a population-based cohort study, using administrative datasets from British Columbia, Canada (February 2020-August 2021). Among all test-positive SARS-CoV-2 adults, we used ICD codes to identify all individuals with an ARD: rheumatoid arthritis (RA), psoriasis/psoriatic arthritis (PsO/PsA), ankylosing spondylitis (AS), and systemic autoimmune rheumatic diseases (SARDs), including systemic lupus erythematosus (SLE), Sjögren’s syndrome, systemic sclerosis, myositis, and adult systemic vasculitides. Individuals with an ARD were matched 1:5 to general population test-positive SARS-CoV-2 individuals on age (±5 years), sex, month/year of initial positive SARS-CoV-2 test, and health authority. Conditional logistic regression models adjusting for socioeconomic status, Charlson comorbidity index, hypertension, rural address, and number of previous COVID-19 PCR tests were performed to assess risk of COVID-19-related hospitalizations, ICU admissions, and COVID-19-specific mortality (mortality with primary ICD code for COVID-19).

**Results:** The risk of COVID-19-related hospitalization was significantly increased for patients with ARDs overall (aOR: 1.30) (Table 1). Within ARDs, the patient group at greatest risk of hospitalization was adult systemic vasculitides (aOR: 2.18). The risk of ICU admission was significantly increased for patients with ARDs overall (aOR: 1.30). Within ARDs, the patient group at greatest risk of ICU admission was those with AS (aOR: 2.03). The risk of COVID-19-specific mortality was significantly increased for patients with ARDs overall (aOR: 1.24). Within ARDs, the patient group at greatest risk of COVID-19-specific mortality was those with AS (aOR: 2.15).
Table 1. Risk of severe COVID-19 outcomes among patients with ARDs

<table>
<thead>
<tr>
<th>ARDs (6,279)</th>
<th>n (%)</th>
<th>aOR (95% CI)</th>
<th>ICUs (8,591)</th>
<th>n (%)</th>
<th>aOR (95% CI)</th>
<th>COVID-19-specific mortality</th>
<th>n (%)</th>
<th>aOR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARDs comparators (31,130)</td>
<td>2,843 (9.1)</td>
<td>1.00</td>
<td>807 (2.6)</td>
<td>1.00</td>
<td>847 (2.7)</td>
<td>1.00</td>
<td>789 (2.5)</td>
<td>1.00</td>
</tr>
<tr>
<td>RA</td>
<td>321 (15.5)</td>
<td>1.34</td>
<td>95 (4.6)</td>
<td>1.30</td>
<td>103 (5.0)</td>
<td>1.18</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsOpSAs (2,695)</td>
<td>1,052 (78)</td>
<td>1.00</td>
<td>332 (2.5)</td>
<td>1.00</td>
<td>309 (2.3)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AS</td>
<td>51 (8.6)</td>
<td>1.36</td>
<td>20 (3.8)</td>
<td>2.03</td>
<td>13 (2.5)</td>
<td>2.15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA comparators (10,197)</td>
<td>1,151 (11.3)</td>
<td>1.00</td>
<td>336 (3.3)</td>
<td>1.00</td>
<td>400 (3.9)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsOpSAs comparators (13,411)</td>
<td>525 (3.9)</td>
<td>1.30</td>
<td>142 (9.6)</td>
<td>1.19</td>
<td>149 (9.9)</td>
<td>1.24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sjögren’s</td>
<td>76 (9.5)</td>
<td>1.00</td>
<td>26 (2.2)</td>
<td>1.00</td>
<td>31 (2.5)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myositis (30)</td>
<td>57 (16.7)</td>
<td>3.18</td>
<td>14 (2.9)</td>
<td>1.00</td>
<td>15 (3.2)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myositis comparators (150)</td>
<td>12 (8.0)</td>
<td>1.00</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;5 *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitides (82)</td>
<td>25 (30.5)</td>
<td>2.18</td>
<td>8 (9.8)</td>
<td>1.70</td>
<td>&lt;5 *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitides comparators (404)</td>
<td>64 (15.6)</td>
<td>1.00</td>
<td>21 (5.2)</td>
<td>1.00</td>
<td>16 (4.0)</td>
<td>1.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results for systemic sclerosis not presented; sample size too small. *Unable to be calculated (small sample size).
2021 were included. An ordinal severity outcome was defined as: 1) not hospitalised, 2) hospitalised without death, and 3) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics (age, sex, time period of infection), comorbidities (hypertension, other cardiovascular disease [CVD], chronic obstructive lung disease [COPD], asthma, other chronic lung disease, chronic kidney disease, cancer, smoking, obesity, diabetes mellitus [DM]), rheumatic skin disease (PsO, PsA, axSpA), physician-reported disease activity, and medication exposure (methotrexate, leflunomide, sulfasalazine, TNFi, IL17i, IL-23/IL-12 + 23i, Janus kinase inhibitors [JAKi], apremilast, glucocorticoids [GC] and NSAIDs). Age-adjustment was performed employing four-knot restricted cubic splines. Country-adjustment was performed using random effects.

Results: A total of 5008 individuals with PsO (n=921), PsA (n=2263) and axSpA (n=1824) were included. Mean age was 50 years (SD 13.5) and 51.8% were male. Hospitalisation (without death) was observed in 14.6% of cases and 1.8% died. In the multivariable model, the following variables were associated with severe COVID-19 outcomes: older age (Figure 1), male sex (OR 1.53, 95%CI 1.29-1.82), CVD (hypertension alone: 1.26, 1.02-1.56; other CVD alone: 1.99, 1.22-2.94; vs no hypertension and no other CVD), COPD or asthma (1.75, 1.32-2.32), other lung disease (2.56, 1.66-3.97), chronic kidney disease (2.32, 1.50-3.59), obesity and DM (obesity alone: 1.36, 1.07-1.71; DM alone: 1.85, 1.39-2.47; obesity and DM 1.89, 1.34-2.67; vs no obesity and no DM), higher disease activity and GC intake (remission/low disease activity and GC intake: 1.96, 1.66-2.32; moderate/severe disease activity and no GC intake: 1.35, 1.05-1.72; moderate/severe disease activity and GC intake 2.30, 1.41-3.74; vs remission/low disease activity and no GC intake). Conversely, the following variables were associated with less severe COVID-19 outcomes, including IL-17i, IL-23/IL-12 + 23i, JAKi and apremilast.

Conclusions: More severe COVID-19 outcomes in PsO, PsA and axSpA are largely driven by demographic factors (age, sex), comorbidities, and active disease. None of the DMARDs typically used in PsO, PsA and axSpA, were associated with severe COVID-19 outcomes, including IL-17i, IL-23/IL-12 +23i, JAKi and apremilast.

Acknowledgements: We thank all the contributors to the COVID-19 PsoProtect, GRA and EULAR Registries. Disclosure of Interests: None declared DOI: 10.1136/annrheumdis-2022-eular.1753
Background: RA has been associated with poor COVID-19 outcomes, but few studies have investigated outcomes in RA features such as interstitial lung disease.

Objectives: To assess COVID-19 outcomes in patients with RA overall, and those with and without ILD, compared to general population comparators.

Methods: A multicenter, retrospective cohort study was conducted at Mayo Clinic (19 hospitals and affiliated outpatient centers in 4 states) and Mass General Brigham (14 hospitals and affiliated outpatient centers in New England). Consecutive patients with RA meeting ACR/EULAR criteria and a positive COVID-19 test from March 1, 2020 through June 6, 2021 were matched 1:5 on age, sex, race, and COVID-19 test date with general population comparators without RA. RA features assessed included: RA-ILD per Borgantz criteria [1], duration, rheumatoid factor (RF), cyclic citrullinated peptide antibody (CCP), bone erosions, and treatments. The primary outcome was a composite of hospitalization or death following COVID-19 diagnosis. We used multivariable Cox regression to investigate the association of RA, and features such as ILD, with COVID-19 outcomes compared to matched comparators.

Results: We analyzed 582 patients with RA and 2892 comparators without RA, all with COVID-19. Mean age was 62 years, 51% were female, and 79% were White. Mean RA duration was 11 years, 67% were seropositive (52% RF+ and 54% CCP+), 27% had bone erosions, 28% were on steroids, and 79% were on DMARDs. 50/582 (9%) patients with RA had ILD. The COVID-19 hospitalization or death rate for RA patients was higher than comparators (3.6% per 1,000 days [95% CI 2.3-3.8] vs. 1.9 per 1,000 days [95% CI 1.7, 2.1]), respectively. Overall, RA patients had a 53% higher risk of hospitalization or death than comparators after adjustment (95% CI 1.20-1.94).

Among those with RA-ILD, the hospitalization or death rate was significantly higher than comparators (10.9 [95% CI 6.7-15.2] vs. 2.5 per 1,000 days [1.8-3.2], respectively). RA-ILD was associated with nearly 3-fold higher risk for hospitalization or death than comparators (multivariable HR 2.84 [95% CI 1.64-4.91], Table 1). There was a significant interaction between RA/comparator status and presence/absence of ILD for risk of severe COVID-19 (p<0.001, Figure 1). The elevated risk for severe COVID-19 was similar for RA subgroups defined by serostatus or bone erosions.

Table 1. Frequencies, proportions, and hazard ratios for COVID-19 outcomes, comparing all RA patients, and subgroups with or without RA-ILD, to matched comparators.

Table: Frequencies, proportions, and hazard ratios for COVID-19 outcomes, comparing all RA patients, and subgroups with or without RA-ILD, to matched comparators.

<table>
<thead>
<tr>
<th>COVID-19 Outcomes</th>
<th>All RA Patients (n=582)</th>
<th>RA Patients with-Comparators (n=50)</th>
<th>Out ILD (n=532)</th>
<th>Unadjusted HR (95% CI)</th>
<th>Adjusted HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalization, n (%)</td>
<td>121 (21)</td>
<td>24 (48)</td>
<td>97 (18)</td>
<td>402 (14)</td>
<td></td>
</tr>
<tr>
<td>Unadjusted HR (95% CI)</td>
<td>1.58 (1.22, 1.96)</td>
<td>2.65 (1.71, 4.09)</td>
<td>1.43 (1.12, 1.82)</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>Adjusted* HR (95% CI)</td>
<td>1.45 (1.14, 1.83)</td>
<td>2.35 (1.38, 4.06)</td>
<td>1.31 (1.00, 1.70)</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>26 (4)</td>
<td>9 (18)</td>
<td>17 (3)</td>
<td>63 (2)</td>
<td></td>
</tr>
<tr>
<td>Unadjusted HR (95% CI)</td>
<td>1.72 (0.98, 3.01)</td>
<td>8.82 (2.07, 37.07)</td>
<td>1.13 (0.56, 2.29)</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>Adjusted* HR (95% CI)</td>
<td>1.24 (0.66, 2.32)</td>
<td>13.94 (4.30, 47.32)</td>
<td>0.75 (0.35, 1.63)</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>Hospitalization or death, n (%)</td>
<td>126 (22)</td>
<td>25 (50)</td>
<td>101 (19)</td>
<td>419 (14)</td>
<td></td>
</tr>
<tr>
<td>Unadjusted HR (95% CI)</td>
<td>1.66 (1.33, 2.07)</td>
<td>3.01 (1.93, 4.70)</td>
<td>1.47 (1.14, 1.89)</td>
<td>Ref.</td>
<td></td>
</tr>
<tr>
<td>Adjusted* HR (95% CI)</td>
<td>1.53 (1.20, 1.94)</td>
<td>2.84 (1.64, 4.91)</td>
<td>1.34 (1.02, 1.77)</td>
<td>Ref.</td>
<td></td>
</tr>
</tbody>
</table>

*Adjusted for age, sex, race, and smoking

Figure 1. Multivariable hazard ratios for the composite outcome of hospitalization or death from COVID-19, comparing all RA and subgroups by serostatus, bone erosions, and ILD to matched comparators without RA.

Conclusion: We confirmed that RA was associated with severe COVID-19 outcomes compared to the general population. We found evidence that ILD may be an effect modifier for the relationship between RA and severe COVID-19 outcomes, but RA subgroups defined by serostatus and bone erosions had similarly elevated risks. These findings suggest that ILD or its treatment may be a major contributor to severe COVID-19 outcomes in RA.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-ratapi2
Background: There is a paucity of data in the literature about the outcome of patients with idiopathic inflammatory myopathy (IIM) who have been infected with SARS-CoV-2.

Methods: Data on demographics, number of comorbidities, region, COVID-19 time period, physician-reported disease activity, anti-rheumatic medication exposure at the clinical onset of COVID-19, and COVID-19 outcomes of IIM patients were obtained from the voluntary COVID-19 Global Rheumatology Alliance physician-reported registry of adults with rheumatic disease (from 17 March 2020 to 27 August 2021). An ordinal COVID-19 severity scale was used as primary outcome of interest, with each outcome category being mutually exclusive from the other a) hospitalization, b) hospitalization (and no death), or c) death. Odds ratios (OR) were estimated using multivariable ordinal logistic regression. In ordinal logistic regression, the effect size of a categorical predictor can be interpreted as the odds of being one level higher on the ordinal COVID-19 severity scale than the reference category.

Results: Complete hospitalization and death outcome data was available in 348 IIM cases. Mean age was 53 years, and 223 (64.1%) were female. Overall, 167/348 (48.0%) people were not hospitalized, 136/348 (39.1%) were hospitalized (and did not die), and 45/348 (12.9%) died. Older age (OR=1.59 per decade of life, 95%CI 1.32-1.93), male sex (OR=1.63, 95%CI 1.00-2.64; versus female), high disease activity (OR=4.05, 95%CI 1.29-12.76; versus remission), presence of two or more comorbidities (OR=2.39, 95%CI 1.22-4.68; versus none), prednisolone-equivalent dose >7.5mg/day (OR=2.37, 95%CI 1.27-4.44; versus no glucocorticoid intake), and exposure to rituximab (OR=2.60, 95%CI 1.23-5.47; versus csDMARDs only) were associated with worse COVID-19 outcomes (Table 1).

Table 1. Multivariable logistic regression analysis of factors associated with the ordinal COVID-19 severity outcomes. AZA, azathioprine; CI, confidence interval; combi, combination; CSA, ciclosporin; CYC, cyclophosphamide; DMARD, disease-modifying anti-rheumatic drug; b/tsDMARD, biologic/targeted synthetic DMARD, csDMARD, conventional synthetic DMARD; HQC, hydroxychloroquine; IVlg, Intravenous immunoglobulin; LEF, leflunomide; MMF, mycophenolate mofetil; mono, monotherapy; MTX, methotrexate; OR, odds ratio; Ref, reference; RTX, rituximab; SSZ, sulfasalazine; TAC, tacrolimus.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95%CI) P-value</th>
<th>OR (95%CI) P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per decade)</td>
<td>1.59 (1.32-1.93)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.63</td>
<td>0.048</td>
</tr>
<tr>
<td>Prednisolone-equivalent dose</td>
<td>One</td>
<td>1.40</td>
</tr>
<tr>
<td>&gt;7.5mg/day</td>
<td>0.779</td>
<td>0.011</td>
</tr>
<tr>
<td>IVlg</td>
<td>0.41</td>
<td>0.093</td>
</tr>
<tr>
<td>DMARDs</td>
<td>High</td>
<td>4.05</td>
</tr>
<tr>
<td>csDMARD only</td>
<td>Region</td>
<td>(1.29-7.26)</td>
</tr>
<tr>
<td>No DMARD</td>
<td>Ref</td>
<td>NA</td>
</tr>
<tr>
<td>b/tsDMARD mono or combi - HQC, RTX, LEF, SSZ</td>
<td>(0.90-3.75)</td>
<td>1.84</td>
</tr>
<tr>
<td>CSA/CYC/TAC combi (except RTX)</td>
<td>North America</td>
<td>0.435</td>
</tr>
<tr>
<td>b/tsDMARDs</td>
<td>Other</td>
<td>0.429</td>
</tr>
<tr>
<td>AZA mono</td>
<td>Time period</td>
<td>4.25</td>
</tr>
<tr>
<td>AZAMMF mono</td>
<td>(2.21-4.16)</td>
<td></td>
</tr>
<tr>
<td>RTX or b/tsDMARDs</td>
<td>Before 15 June</td>
<td>1.22</td>
</tr>
<tr>
<td>RTX mono or combi</td>
<td>1.60</td>
<td>0.012</td>
</tr>
</tbody>
</table>

Conclusion: These are the first global registry data on the impact of COVID-19 on IIM patients. Older age, male gender, higher comorbidity burden, higher disease activity, higher glucocorticoid intake and rituximab exposure were associated with worse outcomes. These findings will inform risk stratification and management decisions for IIM patients.

REFERENCES: None

Disclosure of Interests: Su-Ann Yeoh: None declared, Milena Gianfrancesco: None declared, Saskia Lawson-Tovey: None declared, Kimmie Hyrich Speakers bureau: AbbVie unrelated to this work, Grant/research support from: Pfizer, BMS, hospitalization (and no death) to this work, Anja Strangfeld Speaker: Abbvie.

Objectives: To investigate factors associated with severe COVID-19 outcomes in patients with IIM.
Methods: An observational cohort study design was used. The population included adults in England with new diagnoses of inflammatory arthritis between May 2018 and March 2021 who enrolled in NICEAIA. The outcomes were hospitalization due to COVID-19 (primary admission reason or nosocomial acquisition) and death due to COVID-19 (COVID-19 stated on a death certificate), identified via linkage with secondary care records. Hazard ratios were calculated using Cox proportional hazards models, with adjustment for patient factors (age, gender, smoking status, and comorbidity) and disease factors (seropositivity, 28-joint disease activity score, patient-reported disability (HAQ), and functional impact (MSK-HQ)) recorded at baseline. Individuals were considered at risk from the date of diagnosis or February 2020 (whichever was later) and censored at a COVID-19 event, death or May 2021 (whichever was sooner).

Results: 14,127 patients were included. The mean age was 57 years; 62% were female; 19% were current smokers, while 29% were ex-smokers. The frequency of comorbidities at baseline were: hypertension (19%), diabetes mellitus (9%), and lung disease (9%). Overall, 20% had two or more comorbidities. Rheumatoid factor or CCP antibodies were positive in 56%. At presentation, mean scores for DAS28 were 4.6 (+/- 1.5), 1.1 (+/- 0.7) for HAQ, and 25 (+/- 11) for MSK-HQ. Initial DMARD therapy was known for 13,682/14,127 patients: methotrexate was the most common DMARD therapy (48%), followed by hydroxychloroquine (23%), and sulfasalazine (11%).

There were 143 COVID-19 hospital admissions and 47 deaths, corresponding to incidence rates per 100 person-years for hospitalisation: 0.94 [95% CI: 0.79-1.10] and death: 0.31 [95% CI: 0.23-0.41]. Increasing age, male gender, diabetes, hypertension, lung disease and smoking status all predicted COVID-19 hospitalisation and death. Higher baseline DAS28 predicted COVID-19 hospitalisation (HR 1.24 [95% CI: 1.10-1.39]) and mortality (HR 1.33 [95% CI: 1.09-1.63]). Higher HAQ predicted both COVID-19 hospitalisation and death. Seropositivity was not a significant predictor of any COVID-19 event, nor was MSK-HQ. In unadjusted models, corticosteroids associated with COVID-19 death (HR 2.29 [95% CI: 1.02-5.13], and sulfasalazine monotherapy associated with COVID-19 hospitalisation (HR 1.93 [95% CI: 1.04-3.56]). In adjusted models, associations for corticosteroids and sulfasalazine were no longer significant. Only age, smoking status, and comorbidities independently predicted COVID-19 events.

Conclusion: The burden of COVID-19 amongst early arthritis patients was substantial during the pandemic, with concerns about the use of csDMARDs and corticosteroids. Patient characteristics and rheumatoid disease severity at diagnosis appear to be the more important predictors of COVID-19 events than initial treatment strategy. An important limitation is that we have not looked at treatment changes over time, and must acknowledge that many patients, especially those recruited in 2019, may have changed therapy prior to the pandemic.

References:

Disclosure of Interests: Maryam Adas: None declared, Mark Russell Speakers bureau: has received speaker fees and educational grants from AbbVie, Celgene, Chugai, Genentech, Gilead, Janssen, Eli Lilly, Pfizer, Roche and UCB

OP0254

FACTORS ASSOCIATED WITH THE SEVERITY OF COVID-19 INFECTION IN PATIENTS WITH SPONDYLOARTHRITIS: RESULTS OF THE FRENCH RMD COVID-19 COHORT

L. Perrot1, L. Boyer2, R. M. Filpo2, H. Marotta1, E. Pertuiset1, C. Miceli Richard3, T. Thomas4, R. Seror5, P. Chazerain6, R. Nicolas4, C. Richet7, T. Pham8, 1Arts University, AHPM, Rheumatology, Marseille, France; 2Arts University, University, AHPM, Rheumatology, Marseille, France; 3Arts University, AHPM, Rheumatology, Marseille, France; 4Arts University, AHPM, Rheumatology, Marseille, France; 5Arts University, AHPM, Rheumatology, Marseille, France; 6Arts University, AHPM, Rheumatology, Marseille, France; 7Arts University, AHPM, Rheumatology, Marseille, France; 8Arts University, AHPM, Rheumatology, Marseille, France

Background: To our knowledge, no published work has described precisely the severity and evolution of SARS-CoV-2 infection in patients with spondyloarthritis (SpA). Data on COVID-19 from cohorts of patients with immune-mediated inflammatory diseases concern small samples of SpA.

Objectives: Our objective was to describe the severity and course of COVID-19 in a large cohort of patients with SpA, including axial SpA (axSpA) and psoriatic arthritis (PsA), and to identify factors associated with severe forms.

Methods: Patients: Individuals recruited in the French RMD COVID-19 cohort (observational, national, multicenter cohort) with a diagnosis of COVID-19 (clinical, PCR, CT or serology) were included.

Data collected: demographics, type of SpA, comorbidities, treatments, severity of COVID-19. Severity of COVID-19 was graded according to care needed: mild = outpatient care; moderate = non-intensive hospital treatment; severe = intensive care admittance or death. Moderate or severe outcomes were collected.

Statistical analyses: Logistic regression models were used to identify factors associated with these severe forms. All variables with p < 0.20 in the univariate analysis were proposed in the multivariate model. Treatment variables (non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate (MTX), sulfasalazine (SLZ), TNF inhibitors (TNFi), IL-17 inhibitors (IL-17i) and IL-23 inhibitors (IL-23pi)) were included in the models, even if p>0.20.

Results: Between March 2020 and April 2021, 626 SpAs reported COVID-19 with a mild course in 508 cases (81.1%), moderate in 93 cases (14.8%), and severe in 25 cases (3.9%), including 6 deaths. The cohort analyzed included 349 women (55.8%), mean age 49.3 ± 14.1 years, mean BMI 27.1 ± 5.4 with 403 axSpA (64.4%), 187 PsA (29.5%) and 36 other SpA, duration of disease 11.3 ± 9.8 years; 352 (56.2%) had at least one comorbidity, of which obesity (23.6%), hypertension (15.5%), and smoking status (10.4%) were the most frequent. Among them, 104 were treated with NSAIDs (16.6%), 186 with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) including 156 MTX, and 460 (73.5%) with biological DMARDs (379 TNFi, 57 IL-17i, 15 IL-23pi/p40i, 9 others).

The following variables were associated with severe COVID-19 outcomes: age, body mass index, chronic obstructive lung disease, cardiovascular disease, diabetes, hypertension, interstitial lung disease, renal failure, and corticosteroids intake.

The factors independently associated with severe COVID-19 outcomes were corticosteroid intake (3.15 [CI95%: 1.46-6.78], p = 0.004), and age (OR = 1.06 [CI95%: 1.04-1.08], p < 0.001) while anti-TNF (OR = 0.26 [CI95%: 0.09-0.78], p = 0.01) was protective. NSAIDs intake (OR = 0.97 [CI95%: 0.49-1.86]), SLZ (OR = 0.28 [CI95%: 0.60-1.03]), or anti-IL17 (OR = 0.37 [CI95%: 0.10-1.31]) was not associated with infection severity.

Conclusion: The course of COVID-19 was mild for the majority of SpA patients (81.1%). Corticosteroid intake was associated with more severe COVID-19 outcomes, whereas TNF inhibitors were found to be protective.

Disclosure of Interests: None declared

OP0255

BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BECOME, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

J. F. Merola1, I. McInnes2, C. T. Ritchlin3, P. J. Mease4, R. B. Landewé5, A. Asahina6, Y. Tanaka6, R. B. Warren7, L. Gosses8, D. D. Gladman9,10, F. Behrens11, B. Ink12, A. Assudani13, R. Bajracharya14, J. Coare15, L. Coates16,17, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America; 1University of Georgia, Institute of Infection, Immunity and Inflammation, Glasgow, United Kingdom; 2University of Rochester, Department of Medicine, Rochester, United States of America; 3University of Rochester, Department of Medicine, Rochester, United States of America; 4University of Arizona, School of Medicine, Phoenix, United States of America; 5University of Toronto, Schroeder Arthritis Institute and Providence St. Joseph Health, Seattle, United States of America; 6Amsterdam Rheumatology & Clinical Immunology Center, Department of Clinical Immunology & Rheumatology, Amsterdam, Netherlands; 7Zuyderland MC, N/A, Heeren, Netherlands; 8The Jikei University School of Medicine, Department of Dermatology, Tokyo, Japan; 9University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; 10University of Toronto, Schroeder Arthritis Institute, Toronto, Canada; 11University of Toronto, Schroeder Arthritis Institute, Toronto, Canada; 12Goethe University, Rheumatology University Hospital and Franhofer Institute for Translational Medicine & Pharmacology ITMP, Frankfurt am Main, Germany; 13UCB Pharma, N/A, Slough, United Kingdom; 14UCB Pharma, N/A, Raleigh, United States of America; 15University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom; 16Oxford University
Background: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. BKZ has shown sustained efficacy and tolerability up to 152 weeks in a phase 2b study in patients (pts) with active psoriatic arthritis (PsA).1

Objectives: To assess efficacy and safety of BKZ vs placebo (PBO) in pts with active PsA and prior inadequate tumour necrosis factor inhibitor (TNFi) response in the 16-wk pivotal phase 3 study, BE COMPLETE.

Methods: BE COMPLETE (NCT03895581) comprises a 16-wk double-blind, PBO-controlled period. Pts were aged ≥18 yrs, had a diagnosis of adult-onset, active PsA with ≥3 tender joints and ≥3 swollen joints, and inadequate response or intolerance to treatment with 1 or 2 TNFi. Pts were randomised 2:1 to BKZ 160 mg Q4W or PBO. From Wk 16, pts were eligible to enter an open-label extension, receiving BKZ 160 mg Q4W. The primary endpoint was a ≥50% improvement in American College of Rheumatology response criteria (ACR50) at Wk 16. Primary and ranked secondary efficacy endpoints were assessed at Wk 16.

Results: Of 400 randomised pts (BKZ: 267; PBO: 133), 388 (97.0%) completed Wk 16 (BKZ: 263 [98.5%]; PBO: 125 [94.0%]). Baseline characteristics were comparable between groups: mean age 50.5 yrs, weight 86.0 kg, BMI 29.8 kg/m², time since diagnosis 9.5 yrs; 475% pts were male.

At Wk 16, the primary endpoint (ACR50: 43.4% BKZ vs 6.8% PBO; p<0.001; Figure 1) and all ranked secondary endpoints (HAQ-DI CIB, PASI90, SF-36 PCS CIB and MDA response) were met (all p<0.001; Table 1). The ACR50 response was rapid with separation from PBO observed from Wk 4 (nominal p<0.001).

Additional outcomes, including ACR20/70, TJC, and PASI75/100, demonstrated numerical improvement with BKZ compared to PBO at Wk 16 (all nominal p<0.001; Table 1).

Table 1. Disease characteristics at baseline and efficacy at Wk 16

<table>
<thead>
<tr>
<th></th>
<th>PBO N=133</th>
<th>BKZ 160 mg Q4W N=267</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TJC</td>
<td>19.3 (14.2)</td>
<td>18.4 (13.5)</td>
<td>-</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>10.3 (8.2)</td>
<td>9.7 (7.5)</td>
<td>-</td>
</tr>
<tr>
<td>SJ C</td>
<td>63.0 (22.0)</td>
<td>60.5 (22.2)</td>
<td>-</td>
</tr>
<tr>
<td>mean (SD)</td>
<td>61.7 (24.6)</td>
<td>58.3 (24.2)</td>
<td>-</td>
</tr>
<tr>
<td>PASI50</td>
<td>8.5 (6.9)</td>
<td>10.1 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prior TNFi</td>
<td>45 (33.8)</td>
<td>91 (34.1)</td>
<td>-</td>
</tr>
<tr>
<td>n (%)</td>
<td>63 (47.4)</td>
<td>109 (40.8)</td>
<td>-</td>
</tr>
<tr>
<td>≥3 to ≤10%</td>
<td>25 (18.8)</td>
<td>67 (25.1)</td>
<td>-</td>
</tr>
<tr>
<td>&gt;10%</td>
<td>8.5 (6.9)</td>
<td>10.1 (9.1)</td>
<td>-</td>
</tr>
<tr>
<td>PASI30</td>
<td>5.0 (4.4)</td>
<td>6.8 (4.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDA Response</td>
<td>9 (6.8)</td>
<td>116 (43.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR20/70</td>
<td>6 (6.8)</td>
<td>121 (68.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR50/70</td>
<td>1.0 (0.8)</td>
<td>71 (26.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TJC CIB (MRI)</td>
<td>-2.4 (0.9)</td>
<td>-10.9 (0.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASI30 (N=267)</td>
<td>9 (10.2)</td>
<td>145 (82.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(median [SD])</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASI50 (N=267)</td>
<td>4 (4.5)</td>
<td>103 (58.5)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Acknowledgements: This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

Disclosure of Interests: Joseph F: Merola Paid instructor for: Amgen, Abbvie, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB Pharma, Consultant of: Amgen, Abbvie, Biogen, BMS, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB Pharma, lain McInnes Consultant of: Abbvie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, Grant/research support from: BMS, Boehringer Ingelheim, Celgene, Janssen, UCB Pharma, Christopher T. Ritchlin Consultant of: Amgen, Abbvie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer and UCB Pharma, Grant/ research support from: Abbvie, Amgen and UCB Pharma, Philip J Mease Speakers bureau: Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma, Consultant of: Abbvie, Amgen, BMS, Boehringer Ingelheim, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma and UCB Pharma, Grant/ research support from: Abbvie, Amgen, BMS, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma and UCB Pharma, Robert B. Landewé Speakers bureau: Abbott, Amgen, BMS, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB Pharma, and Wyeth, Akihiko Asahina Grant/research support from: Abbvie, Amgen, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Pfizer, Sun Pharma, Taiko Pharma, Tori Pharmaceutical, and UCB Pharma, Yoshiya Tanaka Speakers bureau: Abbvie, Amgen, Astellas, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Eisai, Eli Lilly, Gilead, Mitsubishi-Tanabe, and YL Biologics, Consultant of: Abbvie, Ayumi, Daiichi-Sankyo, Eli Lilly, GSK, Sanofi, and Taisho, Grant/ research support from: Asahi-Kasei, Abbvie, Boehringer-Ingelheim, Chugai, Coro- rona, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi-Tanabe, and Takeda, Richard B. Warren Paid instructor for: Astellas, DICE, GSK, and Union, Consultant of: Abbvie, Almirall, Amgen, Arena, Astellas, Avillion, Biogen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi,
and UCB Pharma, Grant/research support from: AbbVie, Amgen, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer; Samsung Bioepis, Sanofi-Aventis, and UCB Pharma, Grant/research support from: Amgen, Galapagos, Lilly, Pfizer, and Sandoz, Dafna D Gladman Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Medac, Novartis, Pfizer, and UCB Pharma, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Galapagos, Janssen, Moonlake, Novartis, and UCB Pharma, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Jansen, Novartis, Pfizer, and UCB Pharma DOI: 10.1136/annrheumdis-2022-eular.2265

Objectives: To assess inflammation and structural lesions. Follow-up 68Ga-FAPI-04 was also correlated with various composite scores of PsA. Hand MRI scans were performed in patients with PsA compared to healthy controls (p < 0.0001). Active pain in peripheral as well as axial joints as measured on a visual analogue scale highly correlated with PsA compared to healthy controls (p < 0.0001). Active pain in peripheral as well as axial joints as measured on a visual analogue scale highly correlated with PsA compared to healthy controls (p < 0.0001). Active pain in peripheral as well as axial joints as measured on a visual analogue scale highly correlated with PsA compared to healthy controls (p < 0.0001). Active pain in peripheral as well as axial joints as measured on a visual analogue scale highly correlated with PsA compared to healthy controls (p < 0.0001).

Results: The crude IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignancies were substantial. The IR of haematological malignances (during 59 827 person-years) among TNFi treated PsA, resulting in a crude incidence rate (IR) of 67 per 100 000 person-years. The corresponding IR was 91 (63 events) for biologics-naive PsA from the CRR, and 118 (172 events) for biologics-naive PsA from NPR. This resulted in a pooled IR of 0.97 (0.69 to 1.37) for TNFi treated vs. biologics-naive PsA patients from the CRR, and 0.84 (0.64 to 1.10) vs. biologics-naive PsA patients from the NPR. The pooled IR of haematological malignances in PsA overall vs. the general population was 1.35 (1.17 to 1.52). Throughout, the results were largely similar for lymphoid and myeloid malignancies (Figure 1). The crude IR of haematological malignancies were substantially across different TNFi agents.
Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease with heterogeneous musculoskeletal manifestation (arthritis, spondylosis, enthesitis, dactylitis) and extra-musculoskeletal manifestation (skin and oral involvement). Patients with PsA have a poorly defined clinical course, sometimes with periods of mild disease activity and others with exacerbations that require aggressive treatment. The novel IL-17A inhibitor izokibep is a unique IL-17A inhibitor with extraordinary potency and small molecular size designed to overcome the limitations of monoclonal antibodies such as poor tissue distribution.

**Objectives:** To assess efficacy, safety, pharmacokinetics and immunogenicity of izokibep versus placebo.

**Methods:** This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-groups, dose-finding trial studying bi-weekly 80 mg or 40 mg izokibep administered subcutaneously versus placebo until Week 16 (Period 1) and dose-controlled treatment until Week 46 (Period 2). PsA patients had to have ≥3 swollen and ≥3 tender joints of the 66/68 joint count, and an inadequate response to previous NSAIDs, csDMARDs or TNF inhibitor therapy. The primary endpoint was to evaluate ACR50 responses of 80 mg bi-weekly versus placebo at Week 16. Key secondary endpoints were ACR20/50/70 response rates up to Week 16 and least squares mean difference from placebo in mean tender joint count (TJC) at Week 16. The mean PsA disease duration was 7.1 (SD 7.8) years. 13% failed previous TNF inhibitor treatment and 80% received a concomitant csDMARD.

At Week 16, the confirmatory primary endpoint ACR50 response rate was met (p=0.0003). ACR50 response rate was 52% in the 80 mg group, 46% in the 40 mg and 13% in the placebo group. The ACR20/50/70 response rates up to Week 16 by treatment group are presented in Figure 1.

**Conclusion:** In this large five-country cohort study, we did not observe any increased risk of haematological malignancies overall, nor for lymphoid and myeloid types, in patients with PsA treated with TNFi. By contrast, there were signals of a moderately increased underlying risk of haematological malignancies, both of lymphoid and myeloid types, in patients with PsA overall as compared to the general population. The findings are of importance from a patient information perspective.

**Acknowledgements:** We would like to acknowledge the NordForsk and FOREUM, and especially the patient representatives of the NordForsk collaboration for their valuable contribution to this study.

**Disclosure of Interests:** René Cordtz: None declared, Johan Asklind Consultant of: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Consultant/research support from: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Bénédicte Delcolgne: None declared, Karin Ekström Smedby: None declared, Eva Baecklund: None declared, Christine Ballegaard: None declared, Pia Isomäki Speakers bureau: AbbVie, Sanofi, and UCB, Grant/research support from: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, and ViforPharma, Consultant of: AbbVie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Grant/research support from: Pfizer, Kalle Aaltonen: None declared, Björn Gudbjörnsson Speakers bureau: Novartis, not related to this work, Consultant of: Novartis, not related to this work, Thorvardur Love Speakers bureau: Celgene, Sella Aa. Provan: None declared, Brigitte Michelsen Grant/research support from: Novartis, not related to this work, Joe Sexton: None declared, Lene Dreyer Speakers bureau: Eli Lilly, Gaelderma and Janssen, Grant/research support from: BMS, not related to this work, Karin Heilglen: None declared

**DOi:** 10.1136/annrheumdis-2022-eular.403

---

**Table 1. SJC and TJC by visit until Week 16**

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo Q2W</th>
<th>40 mg Q2W</th>
<th>80 mg Q2W</th>
<th>Placebo Q2W</th>
<th>40 mg Q2W</th>
<th>80 mg Q2W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1</td>
<td>N=44</td>
<td>N=44</td>
<td>N=47</td>
<td>N=44</td>
<td>N=44</td>
<td>N=44</td>
</tr>
<tr>
<td>8</td>
<td>9.2 (6.4)</td>
<td>10.1 (7.0)</td>
<td>10.4 (6.4)</td>
<td>16.4 (11.3)</td>
<td>16.7 (10.3)</td>
<td>17.0 (8.7)</td>
</tr>
<tr>
<td>12</td>
<td>8.4 (7.4)</td>
<td>7.3 (6.5)</td>
<td>6.7 (7.1)</td>
<td>14.9 (10.0)</td>
<td>13.3 (9.5)</td>
<td>13.8 (10.7)</td>
</tr>
<tr>
<td>16</td>
<td>7.7 (7.2)</td>
<td>6.0 (7.2)</td>
<td>5.6 (6.2)</td>
<td>14.1 (11.8)</td>
<td>12.5 (11.6)</td>
<td>11.2 (9.2)</td>
</tr>
<tr>
<td>24</td>
<td>6.0 (6.2)</td>
<td>3.5 (4.1)</td>
<td>3.7 (4.7)</td>
<td>10.5 (7.5)</td>
<td>9.0 (10.5)</td>
<td>7.4 (7.2)</td>
</tr>
<tr>
<td>52</td>
<td>5.1 (5.2)</td>
<td>2.6 (3.4)</td>
<td>2.3 (3.4)</td>
<td>10.9 (8.7)</td>
<td>8.1 (8.9)</td>
<td>6.0 (6.7)</td>
</tr>
<tr>
<td>104</td>
<td>5.0 (5.7)</td>
<td>2.4 (3.7)</td>
<td>1.7 (2.7)</td>
<td>10.7 (9.1)</td>
<td>7.1 (7.7)</td>
<td>5.6 (6.8)</td>
</tr>
</tbody>
</table>

There was a dose-response relationship and a fast onset of response. No serious or severe adverse events occurred during Period 1. The three most frequently affected System Organ Classes (SOCs) were SOC General disorders and administration site conditions comprising mainly mild injection site reactions or erythema followed by SOC Infections and infestations and SOC Metabolism and nutrition disorders. One mild, transient vulvovaginal candidiasis infection with active treatment was reported. Apart from injection site reactions there were no apparent differences in the occurrence of adverse events between active and placebo patients.

**Conclusion:** In this phase 2 study, izokibep showed a dose-dependent high degree of efficacy in patients with active PsA having failed previous treatment. Overall, izokibep was well tolerated. These data strongly support further clinical development.

**REFERENCES:** None

**Acknowledgements:** AbbVie AB, Sweden, and ACELRYFIN Inc, USA, funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of this publication. All authors participated in the drafting, review, and approval of this publication.

**Disclosure of Interests:** Frank Behrens Shareholder of: Pfizer, Sanofi, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, Speakers bureau: Amgen, Horizon, Lilly, Novartis, Pfizer, Sanofi, Genzyme, Flexion, AbbVie, Consultant of: AbbVie,
Boehringinger Ingelheim, Flexion, Janssen, Pfizer, Sanofi, Regeneron, SUN Pharma Advanced Research, Gilead Sciences, Inc., Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Roche, Alan Kivitz, Peter C. Taylor Consultant of: AbbVie, Pfizer, Sanofi, Janssen, Bristol Myers Squibb, Fresenius, Galapagos, Gilead, Gilead Sciences, Inc., Grant/research support from: Celgene and Galapagos, Dieter Wetzel Consultant of: Acino, AbbVie, Biotest, Cheplapharm, CSL Behring, Mundipharma, Roche, Sandoz, Templier, Nikolai C Brun Employee of: AbbVie AB, Jan Brand-Juergens Speakers bureau: Abbvie, Pfizer, Roche, Novartis, Lilly, MSD, UCB, BMS, Janssen, Bristol, Medac, Gilead, AbbVie, Pfizer, Roche, Sanofi-Aventis, Novartis, Lilly, MSD, UCB, Janssen, Medac, Gilead, AbbVie, Edt Drescher: None declared, Eva Dokoupilova: None declared, Anna Rowska-Osuch: None declared, Nadia Abdel-Kader Martin Speakers bureau: Pfizer in 2011, Kurt de Vlam Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, UCB, Paid instructor for: Amgen, Galapagos, UCB, Consultant of: Eli Lilly, Johnson & Johnson, Novartis Galapagos, UCB, Grant/research support from: Celgene DOI: 10.1136/annrheumdis-2022-eular.536

Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19 subunit, demonstrated joint and skin efficacy in patients with active psoriatic arthritis (PsA) in the Phase III DISCOVER-1/2 trials. 1,2 Minimal disease activity (MDA), a multi-domain composite outcome, is a clinically relevant measure of therapeutic response in PsA. 3 However, response dynamics across diverse clusters of bio-naïve patients with PsA were described for each cluster (Table 1). Missing data were not imputed.

<table>
<thead>
<tr>
<th>Cluster</th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
<th>C4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, N</td>
<td>201</td>
<td>97</td>
<td>209</td>
<td>64</td>
</tr>
<tr>
<td>Age, years</td>
<td>46.1 ± 12.2</td>
<td>45.5 ± 11.5</td>
<td>46.1 ± 11.3</td>
<td>47.0 ± 11.1</td>
</tr>
<tr>
<td>Female, %</td>
<td>47.8</td>
<td>55.7</td>
<td>36.4</td>
<td>43.8</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29.4 ± 6.3</td>
<td>29.2 ± 6.5</td>
<td>28.9 ± 5.4</td>
<td>28.7 ± 5.7</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>13.9 ± 2.4</td>
<td>18.1 ± 1.6</td>
<td>14.4 ± 2.0</td>
<td>19.9 ± 2.1</td>
</tr>
<tr>
<td>PsA disease duration, years</td>
<td>5.5 ± 5.8</td>
<td>5.3 ± 5.7</td>
<td>5.2 ± 5.9</td>
<td>5.8 ± 5.9</td>
</tr>
<tr>
<td>TJC (0–68)</td>
<td>10.7 ± 5.4</td>
<td>10.6 ± 5.0</td>
<td>10.1 ± 6.2</td>
<td>21.1 ± 12.2</td>
</tr>
<tr>
<td>SJC (0–66)</td>
<td>5.5 ± 5.8</td>
<td>5.3 ± 5.7</td>
<td>5.2 ± 5.9</td>
<td>5.8 ± 5.9</td>
</tr>
<tr>
<td>29.8</td>
<td>26.8</td>
<td>29.7</td>
<td>24.9</td>
<td></td>
</tr>
<tr>
<td>PASI score (0–72)</td>
<td>8.6 ± 8.9</td>
<td>7.8 ± 8.0</td>
<td>10.6 ± 12.0</td>
<td>13.1 ± 14.6</td>
</tr>
<tr>
<td>Dactylitis, %</td>
<td>42.8</td>
<td>43.2</td>
<td>35.4</td>
<td>71.9</td>
</tr>
<tr>
<td>Dactylitis score (0–20)</td>
<td>7.6 ± 6.9</td>
<td>6.4 ± 1.9</td>
<td>2.0 ± 4.4</td>
<td>11.7 ± 15.2</td>
</tr>
<tr>
<td>Dactylitis count (0–20)</td>
<td>2.1 ± 4.0</td>
<td>0.9 ± 1.7</td>
<td>1.3 ± 2.8</td>
<td>6.0 ± 6.8</td>
</tr>
<tr>
<td>Enthesitis, %</td>
<td>11.6</td>
<td>14.3</td>
<td>47.0</td>
<td>22.7</td>
</tr>
<tr>
<td>LEI (0–4)</td>
<td>1.3 ± 1.6</td>
<td>1.7 ± 1.8</td>
<td>1.5 ± 1.7</td>
<td>3.6 ± 2.0</td>
</tr>
<tr>
<td>HAQ-DI (0–3)</td>
<td>1.3 ± 0.6</td>
<td>1.5 ± 0.5</td>
<td>0.9 ± 0.6</td>
<td>1.5 ± 0.5</td>
</tr>
<tr>
<td>PASI (0–100 VAS)</td>
<td>68.3 ± 17.8</td>
<td>78.2 ± 14.1</td>
<td>57.6 ± 21.6</td>
<td>73.7 ± 15.8</td>
</tr>
<tr>
<td>Pain (0–100 VAS)</td>
<td>62.1 ± 17.0</td>
<td>74.3 ± 13.7</td>
<td>50.8 ± 21.3</td>
<td>67.2 ± 15.2</td>
</tr>
</tbody>
</table>

Data points are mean values. CRP, C-reactive protein.

Results: This analysis included 571 of 669 patients receiving GUS and identified four distinct response clusters (C1–4; Table 1). Mean age and body mass index (BMI) were similar across clusters; C3 had a lower proportion of female patients. Relative to C3, a high burden of BL disease was observed in C4 across clinical measures and patient-reported outcomes (PROs), and across PROs only in C2. Through Week 52, MDA response rates were highest in C3 and lowest in C4, yet all clusters showed continuous improvement in mean values across all MDA domains (Figure 1). In C3, all individual domain thresholds were rapidly reached. C1 and 2, met PASI threshold and showed a substantial reduction in SJC while other domains varied. In C1 and 2, improvement in clinical measures paralleled that of C3; however, PROs appeared to take longer to resolve. Responses were slowest in C4, though improvements were substantial for the high BL disease burden. Improvement in pain, PROs and HAQ-DI occurred earlier in C1 than C2.

Conclusion: Machine learning identified four clusters of GUS-treated PsA patients based on differing response patterns in individual MDA domains. Response types may differ due to BL disease burden, especially in patients with higher pain, PtGA and functional disability scores. These results offer an innovative, complementary approach to identifying treatment response patterns across diverse clusters of bio-naïve patients with PsA, which may facilitate clinical decision-making.

REFERENCES:

Disclosure of Interests: Alen Zabotti Speakers bureau: AbbVie, Amgen, Cenegen, Lilly, Novartis and UCB, Grant/research support from: Novartis, Sarah Ohrdmorb Speakers bureau: Sarah Ohrdmorb has received speaker fees or travel expense reimbursements from AbbVie, BMS, Janssen, Novartis and Pfizer.

William Tillett Speakers bureau: William Tillett has received research funding, consulting and/or speaker fees from AbbVie, Amgen, Celgene, Janssen, Lilly, MDS, Novartis, Pfizer and UCB.


Background: Power Doppler ultrasound (PDUS) is a sensitive non-invasive imaging tool that allows the visualisation of articular and periarticular inflammation in patients with psoriatic arthritis (PsA).1, 2 A large randomised clinical trial that showed the responsiveness of the global OMERACT-EULAR ultrasound synovitis score (GLOESS) in PsA and confirmed the rapid and continued benefits of secukinumab through 52 weeks.3,4

Objectives: To report the distribution of ultrasound-detected synovitis at joint level, by degree of severity at baseline and over time, and the contribution of each core component of GLOESS, synovial hypertrophy (SH) by grayscale (GS; B-mode) and power Doppler (PD) signal, to the composite PDUS at Week 12 (Figure 1). Similar patterns were observed with PD signal in this dataset. The distribution of synovitis by grade of severity was responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset. The distribution of synovitis by grade of severity was responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset. The distribution of synovitis by grade of severity was responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset.

Methods: This was a 52-week study with a 12-week double-blind, placebo-controlled treatment period followed by a 12-week open-label period and a 6-month open-label extension secukinumab treatment period. The number of joints with synovitis measured by GLOESS2 was assessed up to Week 52. The assessments included distribution of synovitis based on composite PDUS score across 24 pairs of joints (with worse score of the pair of joints used) by grade of severity (0-3) and change from baseline to Week 52 in each core component of GLOESS.3,4 Data are presented as observed.

Results: A total of 166 patients (mean age, 46.7 years; males, 45.2%) were enrolled, of which 90% (75/83) of secukinumab and 83% (69/83) of placebo participants completed 52 weeks. The mean (SD) number of PDUS detected synovitis at baseline was 9.2 (4.9) and 10.2 (5.2) in the secukinumab and placebo group, respectively. The most frequent locations with synovitis at baseline were: wrist, metatarsophalangeal (MTP) joints and metacarpophalangeal (MCP) joints (Table 1). An early and continued improvement in GLOESS was observed in both secukinumab and placebo-secukinumab groups after switching to active therapy, as previously reported at Week 12 and through Week 52.5 Among the two core components of GLOESS, SH was mainly responsible for the change in GLOESS from baseline to Week 52, in contrast with PD signal in this dataset. The distribution of synovitis by grade of severity showed that MTP joints, wrist, knee, MCP1/2 and tibiotarsal joints mostly contributed to the composite PDUS at Week 12 (Figure 1). Similar patterns were observed over 52 weeks.

Table 1. Proportion of patients with PDUS detected synovitis at baseline

<table>
<thead>
<tr>
<th>Synovitis joint, data presented as n (%)</th>
<th>Secukinumab (N=83)</th>
<th>Placebo (N=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wrist</td>
<td>66 (80)</td>
<td>66 (80)</td>
</tr>
<tr>
<td>MTP2</td>
<td>56 (69)</td>
<td>60 (72)</td>
</tr>
<tr>
<td>MTP3</td>
<td>58 (70)</td>
<td>60 (72)</td>
</tr>
<tr>
<td>MTP4</td>
<td>52 (63)</td>
<td>52 (62)</td>
</tr>
<tr>
<td>Knee</td>
<td>46 (55)</td>
<td>59 (71)</td>
</tr>
<tr>
<td>MCP1</td>
<td>36 (45)</td>
<td>50 (60)</td>
</tr>
<tr>
<td>MCP2</td>
<td>35 (42)</td>
<td>46 (55)</td>
</tr>
<tr>
<td>MCP5</td>
<td>30 (36)</td>
<td>41 (49)</td>
</tr>
</tbody>
</table>

Data for top nine pairs of joints with most frequently detected power Doppler ultrasound (PDUS) synovitis are presented here. Synovitis was assessed by a OMERACT-EULAR composite PDUS score >0 for each paired joint (irrespective of right or left side). The OMERACT-EULAR composite PDUS score (for individual joints) ranged from 0 to 3 and was composed of the two core components synovial hypertrophy and power Doppler. N, total number of randomised patients; n, number of evaluable patients.

Conclusion: The distribution of synovitis at baseline reflected a predominance of small joints (fingers and hands) and large joints (wrist and knee) and were mostly responsive to secukinumab over time in the ULTIMATE trial. Synovial hypertrophy was the most responsive core component of GLOESS driving an early and continued reduction of synovitis with secukinumab through Week 52. This finding could be useful to select a restricted number of joints in future ultrasound trials in PsA.

REFERENCES

69% and 73%: adjusted difference 5% (Bayesian 95% credible interval: -10% to 19%), confirming NI. The mean percentage %DDD was respectively 53% and 91% at month 12 (Figure 1). At 12 months, 58 (72%) patients of the tapering group were successfully tapered, of whom 23 (28%) discontinued their TNFi. The cumulative incidence of flares was 85% in the tapering and 78% in the no-tapering group (p=0.32). Start or escalation of concomitant medication was more frequent in the tapering group, significantly so for NSAID use: csDMARDs (only for PsA): 1 (2%) vs. 1 (5%) (p=0.64); NSAIDs: 44 (54%) vs. 10 (24%) (p=0.002); glucocorticoids: 24 (30%) vs. 7 (17%) (p=0.13). For serious adverse events, similar results were seen. The risks of grade 3/4 infections and injection site reactions were respectively 46% and 23% lower in the tapering group than the no-tapering group.

Table 1. Baseline characteristics of T2T strategy treated PsA and axSpA patients with or without tapering.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>T2T with tapering (N=81)</th>
<th>T2T without tapering (N=41)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>42(52%)</td>
<td>22(54%)</td>
</tr>
<tr>
<td>Axial spondylarthropathy</td>
<td>39(48%)</td>
<td>19(46%)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>28(35%)</td>
<td>20(49%)</td>
</tr>
<tr>
<td>Disease duration at inclusion, mean (SD)</td>
<td>50(14)</td>
<td>52(15)</td>
</tr>
<tr>
<td>CASPAR Criteria, n (%)</td>
<td>34(81%)</td>
<td>17(77%)</td>
</tr>
<tr>
<td>ASAS Criteria, n (%)</td>
<td>35(90%)</td>
<td>17(89%)</td>
</tr>
<tr>
<td>Disease activity, mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsA</td>
<td>1.60(1.26)</td>
<td>1.63(0.98)</td>
</tr>
<tr>
<td>axSpA</td>
<td>1.34(0.87)</td>
<td>1.21(0.61)</td>
</tr>
<tr>
<td>Duration of current bDMARD use, years, median (IQR)</td>
<td>2(1-6)</td>
<td>2(2-7)</td>
</tr>
<tr>
<td>Current bDMARD use, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>62(77%)</td>
<td>28(68%)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>10(12%)</td>
<td>6(15%)</td>
</tr>
<tr>
<td>Certolizumab Pegol</td>
<td>2(2%)</td>
<td>2(2%)</td>
</tr>
<tr>
<td>Golimumab</td>
<td>2(2%)</td>
<td>2(2%)</td>
</tr>
<tr>
<td>Infliximab</td>
<td>5(6%)</td>
<td>5(12%)</td>
</tr>
</tbody>
</table>

Conclusion: A T2T TNFi tapering strategy is non-inferior to a T2T strategy without tapering with regard to the proportion of patients still in LDA at 12 months and results in a substantial reduction of TNFi use, albeit with slightly more use of other medication.

Acknowledgements: We thank all the patients who were willing to participate in this study and the rheumatologists in the Sint Maartenskliniek Nijmegen and Woerden for participation in patient recruitment and data collection; S.R. van de Plassche, A.H. Verkerk and M. den Broeder for data collection and entering; M. Roelofs, I. Cillessen, C. Kleinveld, I. van Neste for aiding with study coordination; D. van Aggelen, D. Rotteveel, L. Schiersbergen for aiding with laboratory implementation and procedures; B.J.F. van de Bemt and M. Flendrie for being part of the data safety monitoring board.

Disclosure of Interests: Celia Michielsen: None declared, Nathan den Broeder: None declared, Frank van den Hoogen: None declared, Elien Mahler: None declared, Steven Teerenstra: None declared, Désirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cystone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, L.M. Verhoef: None declared, Alftons den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Gilead


PREVALENCE AND PREDICTORS OF ACHIEVING SUSTAINED REMISSION IN PSORIATIC ARTHRITIS

O. Palsson1,2, J. T. Einasonsson1, J. K. Wallman1,2, T. Love1,2
B. Gudbjornsson1, 2, M. C. Kapetanovic1, 2, Lund University Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Skåne, Sweden; University of Iceland, Faculty of Medicine, Reykjavik, Iceland; Lundspitali University Hospital, Department of Science, Reykjavik, Iceland; Landspitali University Hospital, Centre for Rheumatology Research, Reykjavik, Iceland

Background: Increased availability and a wide selection of b/tsDMARDs with different mode of action has made long-term remission a realistic treatment goal in psoriatic arthritis.

Objectives: To estimate the prevalence and possible predictors of sustained remission in patients with psoriatic arthritis (PsA) treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) in Sweden.

Methods: All patients initiating treatment with bDMARDs or tsDMARDs for PsA in Sweden and registered in the national Swedish Rheumatology Quality Register (SRQ) were included. Data on disease and treatment characteristics from the start of the first b/tsDMARD (baseline) and all registered subsequent visits were extracted from SRQ. Sustained remission (SR) was defined as DAS28-CRP ≤ 2.6, DAPSA28 ≤ 4 or the evaluator’s global assessment of disease activity (0-4 on a Likert scale) = 0, during at least two consecutive visits over at least six months. To compensate for factors that may temporarily raise disease activity measures, such as concurrent infections, one visit with higher disease activity was allowed if the treatment regimen was not altered at that point and if less than two years between adjacent visits in remission. A sensitivity analysis was performed with a more stringent SR definition, not allowing any such visits with higher disease activity. Logistic regression was used to identify possible predictors of SR.

Results: 5 459 PsA patients with 50 811 visits were included in the analysis. According to DAS28-CRP, 78% of patients achieved a state of remission at some point, and 49% achieved SR at least once. When the more stringent DAPSA28 remission criteria were applied, 27% of patients reached a state of remission at some point, and 11% ever achieved SR. Corresponding figures using the evaluator’s global assessment were 64% and 34% for ever reaching remission or SR, respectively (Figure 1). The sensitivity analysis rendered similar results with a ≤3% difference from the main results for all outcomes. Higher age at start of the first b/tsDMARD therapy was associated with a lower likelihood of SR, but males were significantly more likely to achieve SR than females (OR 1.79-2.63 for reaching SR depending on the remission criteria used).

Figure 1. Proportion of patients achieving sustained and non-sustained remission at any point after SRQ registration.

Conclusion: Despite increased availability and a wider selection of b/tsDMARDs with different modes of action, a considerable proportion of PsA patients receiving such treatments never achieve a state of remission, and less than half ever achieve a more extended period of sustained remission. Males are more likely than females to enter sustained remission.
Disclosure of Interests: Olafur Palsson: None declared, Jon Thorrell Einars-son: None declared, Johan K Wallman Consultant of: Consultancy fees from AbbVie, Amgen, Celgene, Eli Lilly and Novartis (unrelated to the present work), Thorvardur Love: None declared, Bjorn Vodabjornsson Speakers bureau: Lecture fee from Amgen and Novartis (unrelated to the present work), Melina C Kapetanovic: None declared


RA treatment: modern strategies and new molecules

OP0263

FAVORABLE BALANCE OF BENEFIT AND HARM OF LONG-TERM, LOW-DOSE PREDNISOLONE ADDED TO STANDARD TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS AGED 65+: THE PRAGMATIC, MULTICENTER, PLACEBO-CONTROLLED GLORIA TRIAL


1Amsterdam UMC, locatie VUMc, Rheumatology; Epidemiology & Data Science, Amsterdam, Netherlands; 2Carol Davila University, Rheumatology, Bucharest, Romania; 3Medical Centre Leeuwarden, Rheumatology, Leeuwarden, Netherlands; 4Maassstad Hospital, Rheumatology, Rotterdam, Netherlands; 5Faculdade de Medicina e Hospital da Universidade de Coimbra, Rheumatology, Coimbra, Portugal; 6Antonius Ziekenhuis, Rheumatology, Sneek, Netherlands; 7Meander Medical Center, Rheumatology, Amersfoort, Netherlands; 8Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 9Reumazorg Flevoland, Rheumatology, Emmeloord, Netherlands; 10Northwest Clinics, Rheumatology, Alkmaar, Netherlands; 11Institute of Medicine, University of Debrecen Faculty of Medicine, Rheumatology, Debrecen, Hungary; 12Charité – University 8 Medicine Berlin, Rheumatology and Clinical Immunology, Berlin, Germany; 13Piešťany, National Institute for the Rheumatic Diseases, Piešťany, Slovakia (Slovak Republic); 14Amsterdam UMC, locatie VUMc, Epidemiology & Data Science, Amsterdam, Netherlands; 15Department of Internal Medicine, University of Genoa, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Genoa, Italy; 16Medical Center Leeuwarden, Rheumatology, Leeuwarden, Netherlands; 17Amsterdam UMC, locatie VUMc, Rheumatology, Amsterdam, Netherlands.

Background: Low-dose glucocorticoid (GC) therapy is widely used in RA but the true balance of benefit and harm is still unknown.

Objectives: We studied the effects of prednisolone (5mg/day, 2 years) in RA patients aged 65+, requiring adjustment of antitherapeutic treatment (DAS28≥2.60).

Methods: Pragmatic double-blind placebo-controlled randomized trial; all co-treatments and changes therein were allowed during the trial except long-term open label GC; Ca/D supplementation was advised in all patients. Minimal exclusion criteria were tailored to seniors.

Harm outcome: the number of patients with ≥1 serious adverse event (SAE), or ≥1 ‘other adverse event of special interest’ (other AESI). Other AESI comprised any AE (except worsening of RA) causing study discontinuation, and GC-specific events (Table 1).

Table 1. Adverse events of special interest (AESI).*

<table>
<thead>
<tr>
<th>Events by protocol-defined category</th>
<th>placebo (n=225)</th>
<th>prednisolone (n=224)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAE</td>
<td>other AESI</td>
<td>SAE</td>
</tr>
<tr>
<td>Infection</td>
<td>26</td>
<td>16</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Other</td>
<td>20</td>
<td>10</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>Symptomatic fracture</td>
<td>11</td>
<td>4</td>
</tr>
<tr>
<td>New onset</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Cataract</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Other†</td>
<td>43</td>
<td>35</td>
</tr>
<tr>
<td>Total</td>
<td>80</td>
<td>63</td>
</tr>
</tbody>
</table>

*AESI: Compares serious adverse events (SAE) and other AESI, defined by protocol. †’Other’ other AESI: non-serious AE outside of the above predefined categories, but associated with premature discontinuation.

Benefit outcomes: improvement in disease activity (DAS28) and joint damage progression (Sharp/van der Heijde).

Results: We randomized 451 RA patients in 7 EU countries, 449 received the intervention; of these 63% prednisolone vs 61% placebo patients completed 2 years of follow up. Discontinuations were similar in both groups: for AE (14%) and active disease (4%); the remainder mostly for trial fatigue and covid-related access issues (20%). Mean time on study drug was 19 (SD 8) months. 70% of patients were female, mean age was 72 (max 88) years, RA duration 11 years; 67% were RF+, 56% ACPA+, 96% had joint damage on radiographs: mean score 20, median 8. Mean DAS28 was 4.5. Most patients (79%) were on current DMARD treatment, including 14% on biologics; 47% had previously used GC, 14% changed DMARD therapy at baseline. Patients had mean 2.1 active comorbidities, and used median 7 drugs.

Benefit: Disease activity rapidly declined to stabilize after 1 year (Figure 1), and was lower on prednisolone (adjusted mean difference in DAS28 over 2 years: 0.37, 95% CL 0.23, p=0.0001). The contrast in early (3-month) response was larger in 331 patients adherent to protocol on stable treatment: mean difference in DAS28 0.62 (95% CL 0.44), more responders on prednisolone (Figure 1). Significant time-treatment interaction in secondary analyses suggested a decrease in contrast after the first year, most likely caused by significantly more changes in DMARD treatment on placebo. Joint damage progression over 2 years was significantly lower on prednisolone: mean 0.6 (SD 1.9) v 1.8 (6.4) score points on placebo, difference 1.2 (95% CL 0.2, p=0.02).

Harm: 80% prednisolone vs 49% placebo patients experienced the harm outcome: adjusted RR 1.24, 95% Cl 1.04, p=0.02; number needed to harm 9.5 (Table 1). During the study 1 v 2 patients died, and 3 v 0 died within 5 months of discontinuation. Per 100 patient-years, AE totaled 278 in prednisolone vs 206 in placebo patients, and the difference was most marked for infections (Table 1); these were mostly mild or moderately severe. Other GC-specific AESI were rare without relevant differences.

Conclusion: Add-on low dose prednisolone has beneficial long-term effects on disease activity and damage progression in senior RA patients on standard treatment. The tradeoff is a 24% increase in patients with mostly mild to moderate AE, suggesting a favorable balance of benefit and harm.
Cardiovascular Events in the Tofacitinib Clinical Programme

David A. Lippin

Aims and Methods: Cardiovascular (CV) events are an important measure of patient safety in RA clinical trials. Tofacitinib (TOF) is a JAK inhibitor approved for the treatment of RA. This Pooled Adenopathy and Cardiac Events Analysis (PACE) study investigated the incidence of major adverse cardiovascular events (MACE) using the TOF dataset from the PACE study and the wider tofacitinib RA clinical programme.

Background: PACE (NCT02585258) was a phase III, double-blind, placebo- and MTX-controlled, 4-year trial comparing the safety and efficacy of TOF 5 mg (n=2015) or 10 mg (n=2425) twice daily versus placebo (n=1008) and MTX 10 mg (n=1005) twice weekly versus MTX 20 mg (n=1010) twice weekly in previously MTX-naive patients with active RA. The first safety assessment occurred after 1 year, when the study was stopped early due to an increased incidence of MACE in the TOF 10 mg group and a risk of mortality in the TOF 20 mg group. This analysis includes data from the 3-year follow-up data analysis (January 2018).

Objectives: To evaluate the incidence of MACE in the TOF 5 mg and 10 mg twice daily treatment groups using data from the PACE study and the wider tofacitinib RA clinical programme.

Methods: Data from PACE were pooled with data from the wider tofacitinib RA clinical programme (24
double-blind, placebo-controlled studies). MACE were defined as: all-cause mortality, MI, or CHD. Risk was defined as age ≥50 years, male gender, ≥1 CV risk factor, and/or a 10-year risk of MACE ≥15%.

Results: The overall cohort included 7964 patients (average tofacitinib 5 mg BID, n=3969; average tofacitinib 10 mg BID, n=3995). Of these, 3125 (39.2%) patients were included in the CV risk-enriched cohort (average tofacitinib 5 mg BID, n=1614; average tofacitinib 10 mg BID, n=1511). In both treatment arms, as expected, higher proportions of patients in the CV risk-enriched cohort had a HxCAD or a high 10-year predicted risk of MACE at BL vs the overall cohort (Table 1).

Table 1. Proportions of pts with a HxCAD and pts without a HxCAD

<table>
<thead>
<tr>
<th>HxCAD</th>
<th>Overall cohort</th>
<th>CV risk-enriched cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>No HxCAD</td>
<td>(N=3969)</td>
<td>(N=1614)</td>
</tr>
<tr>
<td>No HxCAD</td>
<td>61 (1.5)</td>
<td>61 (3.8)</td>
</tr>
<tr>
<td>HxCAD</td>
<td>65 (1.6)</td>
<td>60 (4.0)</td>
</tr>
</tbody>
</table>

Conclusions: In the overall cohort, adjudicated MACE most commonly occurred in patients with a HxCAD (IR [95% CI] 0.98 [0.02, 5.47] and 1.05 [0.13, 3.78], respectively) vs the CV risk-enriched cohort (IR 0.72 [0.46, 1.09] and 0.67 [0.46, 0.93], respectively), and were similar between treatment arms. MACE IRs were lower than reported in the CV risk-enriched cohort (pts aged ≥50 yrs with ≥1 additional CV risk factor [current smoker, hypertension, HDL-cholesterol <40 mg/dL, diabetes mellitus, history of myocardial infarction (MI) or coronary heart disease (CHD)]). Data were summarised by average tofacitinib 5 or 10 mg daily (BID; average total daily dose of <15 or ≥15 mg, respectively). Incidence rates (IRs; pts with first events/100 pt-ys) for adjudicated MACE were calculated. MACE IRs were stratified by pt’s BL CV risk profile: pts were first categorised by history of coronary artery disease (HxCAD), then pts without a HxCAD were categorised by 10-year risk of MACE, per the ASCVD-PCE risk calculator with a 1.5 multiplier applied.

The overall cohort included 7964 patients (average tofacitinib 5 mg BID, n=3969; average tofacitinib 10 mg BID, n=3995). Of these, 3125 (39.2%) patients were included in the CV risk-enriched cohort (average tofacitinib 5 mg BID, n=1614; average tofacitinib 10 mg BID, n=1511). In both treatment arms, as expected, higher proportions of patients in the CV risk-enriched cohort had a HxCAD or a high 10-year predicted risk of MACE at BL vs the overall cohort (Table 1).

Table 1. Proportions of pts with a HxCAD and pts without a HxCAD

<table>
<thead>
<tr>
<th>HxCAD</th>
<th>Overall cohort</th>
<th>CV risk-enriched cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>No HxCAD</td>
<td>(N=3969)</td>
<td>(N=1614)</td>
</tr>
<tr>
<td>No HxCAD</td>
<td>61 (1.5)</td>
<td>61 (3.8)</td>
</tr>
<tr>
<td>HxCAD</td>
<td>65 (1.6)</td>
<td>60 (4.0)</td>
</tr>
</tbody>
</table>

Conclusions: In the overall cohort, adjudicated MACE most commonly occurred in patients with a HxCAD (IR [95% CI] 0.98 [0.02, 5.47] and 1.05 [0.13, 3.78], respectively) vs the CV risk-enriched cohort (IR 0.72 [0.46, 1.09] and 0.67 [0.46, 0.93], respectively), and were similar between treatment arms. MACE IRs were lower than reported in the CV risk-enriched cohort (pts aged ≥50 yrs with ≥1 additional CV risk factor [current smoker, hypertension, HDL-cholesterol <40 mg/dL, diabetes mellitus, history of myocardial infarction (MI) or coronary heart disease (CHD)]). Data were summarised by average tofacitinib 5 or 10 mg daily (BID; average total daily dose of <15 or ≥15 mg, respectively). Incidence rates (IRs; pts with first events/100 pt-ys) for adjudicated MACE were calculated. MACE IRs were stratified by pt’s BL CV risk profile: pts were first categorised by history of coronary artery disease (HxCAD), then pts without a HxCAD were categorised by 10-year risk of MACE, per the ASCVD-PCE risk calculator with a 1.5 multiplier applied.

The overall cohort included 7964 patients (average tofacitinib 5 mg BID, n=3969; average tofacitinib 10 mg BID, n=3995). Of these, 3125 (39.2%) patients were included in the CV risk-enriched cohort (average tofacitinib 5 mg BID, n=1614; average tofacitinib 10 mg BID, n=1511). In both treatment arms, as expected, higher proportions of patients in the CV risk-enriched cohort had a HxCAD or a high 10-year predicted risk of MACE at BL vs the overall cohort (Table 1).

Table 1. Proportions of pts with a HxCAD and pts without a HxCAD

<table>
<thead>
<tr>
<th>HxCAD</th>
<th>Overall cohort</th>
<th>CV risk-enriched cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>No HxCAD</td>
<td>(N=3969)</td>
<td>(N=1614)</td>
</tr>
<tr>
<td>No HxCAD</td>
<td>61 (1.5)</td>
<td>61 (3.8)</td>
</tr>
<tr>
<td>HxCAD</td>
<td>65 (1.6)</td>
<td>60 (4.0)</td>
</tr>
</tbody>
</table>
Conclusion: In the tofacitinib RA clinical programme, MACE were largely associated with BL CV risk in the overall cohort, consistent with results of ORAL Surveillance, although results should be interpreted with caution due to low pt-yrs of exposure in some pt groups. Noting this limitation, these findings emphasise the importance of assessing and addressing BL CV risk when treating pts with RA.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Kirsten Woollcott, CMC Connect, and funded by Pfizer Inc.


DOI: 10.1136/annrheumdis-2022-eular.879

**COMPARISON OF THE EFFECT OF DIFFERENT JANUS KINASE INHIBITORS ON ACTIVATION, FUNCTION AND PROPERTY OF NK CELLS TO CONTROL CANCER CELL LINES PROLIFERATION: AN EX VIVO AND IN VITRO STUDY.**

L. Meudec,1,2, P. Richebé,1, J. Pascaud1, X. Mariette1,2, G. Nocturne1,2, 1Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR T184, Université Paris-Saclay, Kremlin-Bicêtre, France; 2AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, Kremlin-Bicêtre, France

**Background:** Janus kinase inhibitors (JAKI) are effective targeted synthetic DMARDs licensed in rheumatoid arthritis (RA) and in other immune-mediated diseases. Among the adverse events described, the increased risk of herpes zoster is specific to this therapeutic class but variable depending on the drug, especially lower with filgotinib (FilGLO). Recently the ORAL Surveillance study highlighted an increased risk of lymphoma and lung cancer with tofacitinib (TOFA) in RA patients older than 50 years with cardio-vascular risk factors. Because of their antitumor and antiviral role, especially against herpes viruses, effect of JAKI on NK cells may play a causal role in these adverse events. Our working hypothesis is that the different JAKI could have a differential impact on the activation and function of NK cells leading to the variability of the tolerance profiles observed between the molecules.

**Objectives:** To evaluate the phenotypic and functional impact of JAKI on NK cells.

**Methods:** We first performed ex vivo phenotypic analyses of NK cells in RA patients treated with TOFA or baricitinib (BARI) in comparison with patients treated with methotrexate (MTX). To go deeper, we phenotyped sorted NK cells from healthy donors after 6 days of culture with 4 JAKI (TOFA, BARI, upadacitinib (UPA) and FilGLO) or control (DMSO). We used 3 different doses carefully chosen to mimic in vivo exposure (therapeutic concentration (therap) defined as mean concentration in patients at the licensed dose, intra-therapeutic (infra, mean -2SDS) and supra therapeutic concentration (supra, mean +2SDS)). Thirdly, we stimulated sorted NK cells from healthy donors exposed to TOFA or BARI at theraph and supra concentrations with anti-NKp30 crosslinking to assess NK cells function: intra-cellular IFNγ/TNF production and degranulation (CD107a). Finally, we challenged sorted NK cells from healthy donors exposed in vitro to TOFA or BARI at theraph and supra doses with 2 different tumor cells line to assess degranulation and cytotoxicity: a lung cancer line A549 and a lymphoma cell line SU-DHL-4.

**Results:** Twenty-eight RA patients were included in the ex vivo assay (12 MTX, 6 TOFA, and 10 BARI). Patients under TOFA and not under BARI had a significant reduced CD69 (an activation marker) expression on NK cells (p<0.05) compared to MTX. After in vitro culture of NK cells with JAKI, we confirmed the negative impact of JAKI on NK cells activation (CD69), maturation markers (CD57, Tim3) and activating receptor (NKp30), more pronounced with TOFA and UPA (Figure 1A). After crosslinking with anti-NKp30, NK cells exposed to TOFA produced significantly less IFNγ/TNF and expressed less CD107a compared to DMSO (p<0.005). There was a non-significant trend for a dose-effect (Figure 1B). BARI did not induce any significant effect. Lastly, when NK cells were co-cultured with the cancer cell lines, previous exposition to TOFA but not to BARI led to a significant reduction of CD107a expression on NK cells (p<0.005) and to reduced cytotoxicity (p=0.05) of NK cells versus A549 at theraph dose. Studies regarding SU-DHL-4 are still in progress.

**Figure 1.** Impact of in vitro exposure to JAKI at theraph and supra dose on NK cells regarding phenotype (A) and function after crosslinking (B).

**Conclusion:** JAKI have a phenotypic and functional dose-effect impact on NK cells activation, both in ex vivo and in vitro experiments. TOFA has more impact than other JAKI on NK cells phenotype and function and has the property to impair the control of proliferation of lung cancer and lymphoma cell lines by NK cells. The question remains open if this mechanism could explain the increased risk of lung cancer and lymphoma observed with TOFA in the ORAL surveillance trial.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2640
Background: The recently presented "ORAL Surveillance Study" has suggested increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to a comparator TNF-inhibitor (TNFi). Currently, there is limited real world evidence for the tolerability and safety of JAKi.

Objectives: To assess the safety of JAKi compared to other biologic agents in rheumatoid arthritis (RA) patients in a real-world population, by evaluating treatment discontinuation for AEs.

Methods: Pooled patient database from 16 national RA registries from across Europe, Quebec (Canada), Turkey, and Israel were used. Treatment discontinuation due to AEs by treatment groups, JAKi versus (vs) TNFi and JAKi vs OMA, were compared as an overall measure of tolerability and safety of JAKi.

Results: 90,478 treatment courses were included in the analysis (Table 1). We observed similar crude incidence rate of treatment discontinuation due to AEs between JAKi and TNFi, but less in JAKi vs OMA (Figure 1). The fully adjusted hazard rate of treatment stop for AEs was higher in women (HR = 1.29 (95% CI 1.21 – 1.37)) and in JAKi vs OMA (HR = 1.08 (95% CI 0.97 – 1.20)). The rate of treatment stop for AEs was higher in women (HR = 1.29 (95% CI 1.21 – 1.37)) and with an increasing number of previous b/tsDMARDs (HR = 1.50; 1.48; 1.68 for 1, 2, and 3 or more previous b/tsDMARDs, respectively).

Conclusion: After adjusting for potential confounders, the rate of treatment discontinuation for AEs was comparable between JAKi and OMA or TNFi. Treatment discontinuation for AEs comprises a wide range of AEs; future analyses will be performed to investigate specific AEs, such as cancer, serious infections or major adverse cardiovascular events.

REFERENCES:

Disclosure of Interests: Eric Nham: None declared, Romain Aymon: None declared, Denis Mongin: None declared, Sytanne Anne Bergstra: None declared, Denis Choquette: speaker/consulting fees from AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Celltrion, UCB, and Janssen Pharmaceutica

Figure 1. Comparison of cumulative incidence of treatment discontinuation for adverse events in JAKi, TNFi, and OMA group.

Table 1. Baseline characteristics of the study population

<table>
<thead>
<tr>
<th></th>
<th>JAKi1</th>
<th>OMA2</th>
<th>TNFi3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(BARI, FILGO,TOFA,UPA)</td>
<td>(ABA, ANAK, SARI, TOCI)</td>
<td>(ADA, CERT, ETAN, GOL, INF)</td>
</tr>
<tr>
<td>n</td>
<td>9208</td>
<td>16737</td>
<td>64533</td>
</tr>
<tr>
<td>Treatment duration* (yrs)</td>
<td>0.7 [0.2, 1.7]</td>
<td>1.1 [0.4, 2.8]</td>
<td>1.5 [0.5, 3.9]</td>
</tr>
<tr>
<td>Age</td>
<td>57.5</td>
<td>56.8</td>
<td>53.2</td>
</tr>
<tr>
<td>Female (%)</td>
<td>81.3</td>
<td>80.7</td>
<td>73.2</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>9.9</td>
<td>13.1</td>
<td>10.7</td>
</tr>
<tr>
<td>Seropositivity (%)</td>
<td>78.7</td>
<td>75.9</td>
<td>69.8</td>
</tr>
<tr>
<td>Previous b/tsDMARD (%)</td>
<td>34.0</td>
<td>30.8</td>
<td>59.7</td>
</tr>
<tr>
<td>0</td>
<td>20.9</td>
<td>25.9</td>
<td>24.3</td>
</tr>
<tr>
<td>1</td>
<td>16.6</td>
<td>21.7</td>
<td>10.4</td>
</tr>
<tr>
<td>2 or more</td>
<td>28.5</td>
<td>21.5</td>
<td>5.6</td>
</tr>
<tr>
<td>Concomitant GC (%)</td>
<td>44.6</td>
<td>50.7</td>
<td>41.3</td>
</tr>
<tr>
<td>Concomitant CSDMARD (%)</td>
<td>22.6</td>
<td>22.0</td>
<td>28.8</td>
</tr>
<tr>
<td>MTX</td>
<td>9.5</td>
<td>9.7</td>
<td>13.1</td>
</tr>
<tr>
<td>Other</td>
<td>50.5</td>
<td>52.5</td>
<td>43.5</td>
</tr>
<tr>
<td>CRP</td>
<td>17.4</td>
<td>15.9</td>
<td>14.7</td>
</tr>
<tr>
<td>DAS 28</td>
<td>13.2</td>
<td>13.3</td>
<td>12.3</td>
</tr>
<tr>
<td></td>
<td>23.7</td>
<td>22.9</td>
<td>22.6</td>
</tr>
<tr>
<td></td>
<td>4.7</td>
<td>4.7</td>
<td>4.6</td>
</tr>
</tbody>
</table>

1BARI (baricitinib; 44.41%), FILGO (filgotinib; 0.23%), TOFA (tofacitinib; 49.59%), UPA (upadacitinib; 5.78%); 2ABA (abatacept; 39.96%), ANAK (anakinra; 2.64%), SARI (sarilumab; 3.14%), TOCI (tocilizumab; 52.55%); 3ADA (adalimumab; 31.00%), CERT (cetuximab; 8.33%), ETAN (etanercept; 38.83%), GOL (golimumab; 9.36%), INF (infliximab; 12.56%).
speaker honoraria from Sandoz, Abbvie, Eli-Lilly, Pfizer, Roche, Grünenthal, Biogen, Celgene, Galina Lukina Speakers bureau: GVL has received speaker fees from AbbVie, Lilly, Novartis, MSD, Roche, Pfizer, Dan Nordström Consultant of: DCON has acted as consultant for AbbVie, BMS, MSD, Lilly, Novartis, Pfizer, Roche and UCB, Karel Pavelka Speakers bureau: KP has received honoraria for lectures: MSD, Pfizer, Roche, Eli Lilly, Medac, UCB, SOBI, Biogen, Sandoz, Via- tris, Manuel Pombo-Suarez Speakers bureau: MPS reports advisor and speaker honoraria from Janssen, Lilly, MSD, Novartis, Sanofi, Consultant of: Stated above, Ziga Rutar Speakers bureau: ZR has received fees for speaking/consult- ing from several companies among them Pfizer, AbbVie, and Eli Lilly, Consult- ant of: Stated above, Maria Jose Santos Speakers bureau: MJS has received speaker fees from AbbVie, AstraZeneca, Lilly, Novartis and Pfizer, Delphine Courvoisier: None declared, Kim Lauper Speakers bureau: KL reports speakers fees for Pfizer, Viatris and Cellerion, Consultant of: KL reports consulting fees for Pfizer, Axel Fönh Speakers bureau: AF reports honoraria and consultancies from Pfizer, BMS, MSD, Eli-Lilly, AbbVie, Galapagos, Mylan, UCB, Viatris, Consul- tant of: Stated above, Grant/research support from: AF reports grants from Pfizer INC, AbbVie, Galapagos, Eli Lilly


REFERENCE:

while 341 (0.9%) in JAK-inhibitors and 571 (0.2%) in anti-TNF treated patients were VTE. Disproportionality analyses identified an increased risk of reporting VTE events in JAK-inhibitors compared to anti-TNF (DVT: ROR = 3.99 [95%CI: 3.15-5.04], PE: ROR = 3.47 [2.90-4.13], Figure 1). This risk was not modified after stratification by age or sex. No increased ROR for MACE was found.

**Figure 1.**

**Conclusion:** Based on real-world data, the analysis did not identify an increase in declaration of MACEs with JAK-inhibitor compared to anti-TNF whereas we could observe more than three times declarations of VTE in Vigibase with JAK-inhibitors compared to anti-TNF.

**REFERENCES:**


**Disclosure of Interests:** None declared

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2686

---

**Table 1. Summary of results from biomarker analyses**

<table>
<thead>
<tr>
<th>Tier</th>
<th>Biomarker</th>
<th>Key results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tier 1</td>
<td>C-reactive protein</td>
<td>• No association with VTE in any treatment arm at BL or M12</td>
</tr>
<tr>
<td></td>
<td>D-dimer</td>
<td>• Higher M12 levels were prospectively associated with greater risk of subsequent VTE with tofacitinib 10 mg BID</td>
</tr>
<tr>
<td></td>
<td>Thrombopoietin</td>
<td>• For D-dimer, the same effect was observed with tofacitinib 5 mg BID</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Treatment specificity of effects could not be established</td>
</tr>
<tr>
<td>Tier 2</td>
<td>Factor VIII</td>
<td>• Two biomarkers with no known relationship to VTE (angiotensin and TNFSF13B) showed significant associations with pulmonary embolism in the tofacitinib 10 mg BID arm</td>
</tr>
<tr>
<td></td>
<td>Thrombin-antithrombin complex</td>
<td>• Treatment specificity of effects could not be established for either analyte</td>
</tr>
<tr>
<td></td>
<td>Tissue factor pathway inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
to VTE. Individual VTE risk should be considered when making decisions about initiation or maintenance of tofacitinib treatment.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Julia King, CMC Connect, and funded by Pfizer Inc.


Table 1. Adrenal insufficiency signs and symptoms.

<table>
<thead>
<tr>
<th></th>
<th>prednisolone (n=60)</th>
<th>placebo(n=72)</th>
<th>change after 3 months</th>
<th>end of trial</th>
<th>change after 3 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue (unusual)</td>
<td>15</td>
<td>1</td>
<td>13</td>
<td>–1</td>
<td>1</td>
</tr>
<tr>
<td>Appetite loss</td>
<td>5</td>
<td>–1</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>7</td>
<td>2</td>
<td>6</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Dizziness</td>
<td>3</td>
<td>2</td>
<td>10</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Systolic RR &lt; 90</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Muscle pain</td>
<td>19</td>
<td>19</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Nausea</td>
<td>5</td>
<td>–3</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Hypotension</td>
<td>2</td>
<td>–1</td>
<td>4</td>
<td>–2</td>
<td>–2</td>
</tr>
<tr>
<td><strong>Sum</strong></td>
<td>1.1 (1.1)</td>
<td>0.2 (1.3)</td>
<td>0.9 (1.3)</td>
<td>0.0 (1.3)</td>
<td>0.0 (1.3)</td>
</tr>
</tbody>
</table>

* Systolic RR < 90 or diastolic RR < 60. **Mean (SD)

No differences were seen in ACTH or cortisol levels: mean (SD) ACTH was 5.8 (4.1) in 23 prednisolone patients, and 5.1 (3.7) in 24 placebo patients; cortisol 296 (113) vs 310 (166), cortisol/ACTH 67 (40) vs 77 (54). Two prednisolone and one placebo patient had cortisol levels below 80. No evidence of clinical hypoadrenalism during further follow-up. 199 patients qualified for the disease flares sample, 99 prednisolone and 100 placebo; 4 patients failed on prednisolone tapering vs 31 on placebo, relative risk 1.43 (95% CI 0.99; 2.07; p=0.07).

Conclusion: Tapering prednisolone moderately increases disease activity to placebo levels (mean still at low disease activity levels) and numerically increases the risk of flare without any evidence of adrenal insufficiency. This suggests that withdrawal of low dose prednisolone is feasible after 2 years of administration.

REFERENCES:
RA: Clinical aspects and comorbidities - II.

OP0271 INCREASED RISK OF DEMENTIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONWIDE POPULATION-BASED COHORT STUDY

Y. Eun1, K. D. Han2, S. Y. Kang3, S. Lee4, H. S. Cha5, E. M. Koh6, J. Lee7, H. Kim8,9, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Republic of South Korea; 2Soongsil University, Department of Statistics and Actuarial Science, Seoul, Korea, Republic of South Korea; 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea, Republic of South Korea; 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medical Humanities, Seoul, Korea, Republic of South Korea

Background: There have been conflicting results of previous studies on the association between rheumatoid arthritis (RA) and the risk of dementia.

Objectives: In this study, we aimed to investigate the association between RA and dementia in a large nationwide population-based cohort.

Methods: Among patients diagnosed with RA between 2010 and 2017, patients who had undergone a national health examination within two years prior to RA diagnosis were included in the study (n = 138,592). Control group included age- and sex-matched non-RA controls who received a health check-up at the same time as RA patients (n = 692,960). The primary outcome of the study was incident dementia, which was defined by an ICD-10 code and the use of dementia medications. Kaplan-Meier curves and Cox proportional hazards regression analysis were used for the analysis.

Results: Mean follow-up duration of the study was 4.7 ± 2.2 years. RA patients had a 1.2 times higher risk of dementia than controls (adjusted hazard ratio [aHR] 1.19, 95% CI 1.16–1.23). In patients with RA, the aHR for Alzheimer's disease (aHR 1.24, 95% CI 0.84; 1.85) was higher than that of vascular dementia (aHR 1.10, 95% CI 0.99–1.21). In a stratified analysis according to age, gender, lifestyle factors and comorbidities, the association between RA and dementia was consistently found.

Conclusion: In a large nationwide population-based cohort, RA was associated with an increased risk of incident dementia. Appropriate evaluation of dementia is required when cognitive impairment occurs in RA patients. Further studies are needed to explore potential confounders.

Disclosure of Interests: None declared

OP0272 PREDNISONE USE AND THE INCIDENCE OF HYPERGLYCEMIA OR DIABETES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A 10-YEAR SUB ANALYSIS OF THE BEST STUDY.

J. van der Pol1, S. A. Bergstra2, T. Huizinga3, C. Allaart4, 1Leiden University Medical Center, Rheumatology, Leiden, Netherlands

Background: Use of prednisone in rheumatoid arthritis has been questioned because it may trigger side effects such as hyperglycemia and diabetes.

Objectives: To assess whether in RA the use of prednisone is associated with the development of hyperglycemia and diabetes.

Methods: The BeSt study is a multicenter, assessor-blinded randomized controlled 10-years follow-up trial in 508 non-diabetic early RA patients. Patients were randomised to 4 dynamic DMARD treatment strategy groups: 1) sequential monotherapy, 2) step-up combination therapy, 3) initial combination therapy including prednisone (60 mg/day, tapered to 7.5 mg/day in 7 weeks) and 4) initial combination therapy with infliximab. In groups 1, 2 and 4, prednisone had a maximum dose of 75 mg/day by protocol. Treatment was steered at disease activity score (DAS) ≤2.4. We performed a GEE over time to assess whether current prednisone use or cumulative prednisone dose were associated with hyperglycemia (glucose levels ≥7.8) and cox regression analyses to investigate the relationship between cumulative prednisone dose, previous prednisone use and diabetes (defined as either use of anti-diabetic medication or two instances of a glucose ≥11.1) assessed at 3-monthly visits. All analyses were adjusted for potential confounders.

Results: In total, 33/508 patients (6.5%) developed diabetes during the trial; 12 of these (36%) had received prior treatment with prednisone (any dose). Median (IQR) duration of prednisone use in all 508 patients was 9 (15) months and cumulative doses ranged from 0 to 27942 mg. The mean cumulative dose ranged from 55.5 mg in group 1 to 6170.0 mg in group 3. Previous prednisone use or cumulative prednisone dose was associated with hyperglycemia or diabetes, with effect sizes ranging from a hazard ratio of 0.588 (95% CI 0.285; 1.21) for the association between any previous dose and diabetes to an odds ratio of 1.04 (95% CI 0.978; 1.13) for the association between cumulative prednisone dose and diabetes (Table 1). To identify potential causes for these results, we investigated the relationship between DAS and the same outcomes. We found a higher DAS was significantly associated with development of diabetes, but not with hyperglycemia.

Table 1. The relationship between prednisone dose, DAS and glucose levels, hyperglycemia and diabetes

<table>
<thead>
<tr>
<th>GEE hyperglycemiaa</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any prednisone dose1</td>
<td>0.949</td>
<td>0.805; 1.12</td>
</tr>
<tr>
<td>Cumulative dose1</td>
<td>1.03**</td>
<td>1.01; 1.06</td>
</tr>
<tr>
<td>DAS1</td>
<td>1.24</td>
<td>0.94; 1.65</td>
</tr>
<tr>
<td>Cox Regression diabetes (any of the definitions)</td>
<td>0.588</td>
<td>0.285; 1.21</td>
</tr>
<tr>
<td>Any prednisone dose2</td>
<td>0.996**</td>
<td>0.972; 1.01</td>
</tr>
<tr>
<td>Cumulative dose2</td>
<td>1.60</td>
<td>1.13; 2.26</td>
</tr>
</tbody>
</table>

C: confidence interval; GEE: Generalized Estimating Equations; OR: odds ratio; HR: hazard ratio; DAS: disease activity; hyperglycemia: glucose level above 7.8 mmol/L; diabetes: random glucose level above 11.1 mmol/L at least two time points; odds ratio per 500mg cumulative prednisone increase: adjusted for DAS, age, diabetes and BMI; adjusted for cumulative prednisone dose, age, gender and BMI; adjusted for DAS, age and BMI

Conclusion: In early RA patients, cumulative dose nor any previous prednisone use was associated with the risk of hyperglycemia or diabetes. A higher DAS was significantly associated with increased risk of development of diabetes. Potential risks of prednisone may have been mitigated by suppression of DAS.

Disclosure of Interests: Joy van der Pol: None declared, Systeke Anne Bergrsta Grant/research support from: Pfizer, Thomas Huizinga: None declared, Cornelia Allaart Grant/research support from: The BeSt study was supported by a government grant from the Dutch Insurance Companies, with additional funding from Schering-Plough B.V. and Janssen B.V.

OP0273 CHARACTERISTICS OF PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN FRANCE

S. Hecquet1,2, A. Combier2, A. Steelandt2, M. Pons3, D. Wendling4, A. Molto5, D. Breschard6, Y. Allainore7, J. Avouac8, Centre Hospitalier Regional Universitaire de Besancon, Rheumatology, Besancon, France; 2University of Franche-Comté, UR 4267 PEPITE, Besancon, France; 3Cochin Hospital, Rheumatology, Paris, France

Background: Recently, EULAR has proposed a definition of difficult-to-treat rheumatoid arthritis (D2TRA). However, descriptive data on D2TRA are scarce and only one Japanese publication details the D2TRA encountered in routine practice, no similar work has been done in Europe so far.

Objectives: To describe D2TRA patients encountered in France according to two definitions and evaluate their therapeutic responses to different targeted therapies.

Methods: We reviewed all patients with RA treated in day hospital at Cochin University Hospital between 2020 and 2021. We divided our population into two groups of patients, a D2TRA group and a non-D2TRA group. This division was made on the same population according to two different definitions of D2TRA, resulting in four patient groups. The first definition is the one proposed by EULAR (EULAR D2TRA) defining D2TRAs as RAs with failure of ≥2 csDMARDs (with different mechanisms of action) after failing csDMARD therapy. The second definition as D2TRA patients who have failed at least two targeted therapies, without pre-judging the mechanism of action (non-EULAR D2TRA). We analyzed clinical characteristics and evaluated their response to different targeted therapies. Disease activity was assessed using the DAS for 28 joints (DAS28) at the latest visit.

Results: In total, we included 320 patients, we identified 76 EULAR D2TRA patients (mean age 59 years, 87% female) with 244 of corresponding non-DTRA patients (mean age 60 years, 85% female) and 120 non-EULAR D2TRA patients (mean age 58.7 years, 87% female) with 200 of corresponding non-DTRA (mean age 61 years, 85% female). Compared to non-D2TRA patients, there were significantly more D2TRA patients from low socioeconomic backgrounds in both D2TRA groups. In the EULAR-D2TRA group, compared to the non-D2TRA, there were significantly more patients with diabetes (14% vs 6%, p=0.024). D2TRA patients in both groups had significantly more rheumatoid factor (RF), interstitial lung disease (ILD) and a higher DAS28 than non-D2TRA patients. No difference was noted regarding ACPA and erosions. We observed a lower proportion of remission in both D2TRA groups than in non-D2TRA group (21% in EULAR-D2TRA vs 34% in non-D2TRA, p=0.034 and 23% in non-EULAR D2TRA vs 36% in non-D2TRA, p=0.024). There were significantly fewer patients on Methotrexate in the non-EULAR D2TRA group compared to the non-D2TRA group (53% vs 64%, p=0.046). In the non-EULAR D2TRA group, there were significantly more patients in remission on Rituximab than on TNF inhibitors (41% vs 5%, p=0.0032). We did not observe a significant difference in achieving remission in patients on JAK inhibitors or IL-6 inhibitors in the two groups of D2TRA.
**Objectives:**

- Hospitalisation for tuberculosis and other opportunistic infections in patients with inflammatory joint diseases before and after the introduction of biological therapy.

**Methods:**

- All patients hospitalized in Western Australia in the period 1980–2015 over 2 decades of biological therapies (including TNF inhibitors, IL-1 receptor antagonist, IL-6 receptor antagonist, and JAK inhibitors).
- Assess the impact of biological therapy on the incidence of opportunistic infections.

**Results:**

- The incidence of opportunistic infections decreased significantly after the introduction of biological therapy.
- Tuberculosis was the most common opportunistic infection, followed by fungal and mycobacterial infections.
- The incidence of opportunistic infections was higher in the pre-biological therapy period.

**Conclusion:**

- Biological therapy has significantly reduced the incidence of opportunistic infections in patients with inflammatory joint diseases.
- Further studies are needed to evaluate the long-term impact of biological therapy on the incidence of opportunistic infections.

**Disclosure of Interests:**

- None declared.

**References:**


**Table 1. Diagnostic codes applied to define conditions and opportunistic infections in hospital discharge database.**

<table>
<thead>
<tr>
<th>Condition</th>
<th>ICD9CM</th>
<th>ICD10AM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuberculosis</td>
<td>117.0-117.9</td>
<td>D17.0-17.9</td>
</tr>
<tr>
<td>Other mycobacterium</td>
<td>031.x</td>
<td>B59.x</td>
</tr>
<tr>
<td>Cryptococcosis</td>
<td>117.5</td>
<td>B45.5</td>
</tr>
<tr>
<td>Aspergillosis</td>
<td>117.4</td>
<td>B44.9</td>
</tr>
<tr>
<td>Histoplasmosis</td>
<td>115</td>
<td>A51.9</td>
</tr>
<tr>
<td>Mycosis</td>
<td>114.0-114.9</td>
<td>B35.0-35.9</td>
</tr>
<tr>
<td>Pneumocystis</td>
<td>136.3</td>
<td>B59.3</td>
</tr>
<tr>
<td>Cytomegalovirus disease</td>
<td>078.5</td>
<td>B25.0</td>
</tr>
<tr>
<td>Influenza</td>
<td>487.x, 488.x</td>
<td>B00.0-09.0</td>
</tr>
<tr>
<td>Varicella</td>
<td>052.x</td>
<td>B01.0</td>
</tr>
</tbody>
</table>

**Table 2. Clinical data of patients with D2TRA**

<table>
<thead>
<tr>
<th>NON D2TRA RA n=200</th>
<th>NON-EULAR D2TRA RA n=120</th>
<th>p-value</th>
<th>NON D2TRA RA n=244</th>
<th>EULAR D2TRA RA n=76</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low socioeconomic level</td>
<td>69 (35)</td>
<td>61 (31)</td>
<td>0.005</td>
<td>91 (37)</td>
<td>39 (51)</td>
</tr>
<tr>
<td>TJC (0-28), mean (SD)</td>
<td>3.4 (2.6)</td>
<td>4.9 (5.6)</td>
<td>0.0167</td>
<td>3.5 (4.5)</td>
<td>5.6 (6.5)</td>
</tr>
<tr>
<td>SJC (0-28), mean (SD)</td>
<td>2.4 (3.1)</td>
<td>3.5 (4.3)</td>
<td>0.0067</td>
<td>2.6 (3.3)</td>
<td>3.5 (4.3)</td>
</tr>
<tr>
<td>CRP in mg/dl, mean (SD)</td>
<td>6 (9.5)</td>
<td>7.5 (12.1)</td>
<td>0.2128</td>
<td>6.1 (9.9)</td>
<td>7.9 (12.3)</td>
</tr>
<tr>
<td>Remission</td>
<td>71 (36)</td>
<td>28 (23)</td>
<td>0.024</td>
<td>83 (34)</td>
<td>16 (21)</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
<td>156 (76)</td>
<td>105 (88)</td>
<td>0.037</td>
<td>193 (79)</td>
<td>68 (89)</td>
</tr>
<tr>
<td>Anti-CCP positive, n (%)</td>
<td>152 (76)</td>
<td>101 (84)</td>
<td>0.099</td>
<td>188 (77)</td>
<td>66 (87)</td>
</tr>
<tr>
<td>Erosion, n (%)</td>
<td>114 (57)</td>
<td>69 (58)</td>
<td>0.016</td>
<td>138 (56)</td>
<td>46 (60)</td>
</tr>
<tr>
<td>Intestinal Lung Disease, n (%)</td>
<td>16 (8)</td>
<td>19 (16)</td>
<td>0.041</td>
<td>17 (7)</td>
<td>18 (24)</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>84 (42)</td>
<td>64 (53)</td>
<td>0.064</td>
<td>101 (41)</td>
<td>66 (51)</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>6 (4.9)</td>
<td>5.5 (3.4)</td>
<td>0.416</td>
<td>6 (4.6)</td>
<td>5.3 (3.6)</td>
</tr>
<tr>
<td>Dose (mg), mean ± SD</td>
<td>128 (64)</td>
<td>63 (53)</td>
<td>0.046</td>
<td>149 (61)</td>
<td>42 (55)</td>
</tr>
<tr>
<td>Dose (mg), mean ± SD</td>
<td>173 (4.25)</td>
<td>175 (3.3)</td>
<td>0.786</td>
<td>173 (4.5)</td>
<td>18.1 (5.1)</td>
</tr>
</tbody>
</table>

**Conclusion:**

- The complication of managing RA patients can be explained by socio-economic status and the presence of comorbidities such as diabetes and ILD. Our work suggests that D2TRA patients have less Methotrexate and better response to Rituximab.

**Disclosure of Interests:**

- None declared.

**References:**


**Acknowledgements:**

- Supported by an unrestricted grant from the Arthritis Foundation of Western Australia.

**DOI:**

status were extracted from the electronic medical record. Descriptive statistics were used to summarize disease features. A Kaplan-Meier curve was created to evaluate survival, and a Cox proportional hazards model was created to identify predictors of survival.

Results: 42 RA-ILD patients underwent LTx. The majority of patients were male (57.1%), seropositive (91.4%), with a mean RA disease duration of 12.9 years at LTx (Table 1). Over the study period, 16 (36%) patients died. Compared with patients who had survived, deceased patients were slightly older at the time of transplantation (59.0±9.7 vs. 57.3±11.5, respectively), and were more likely to have usual interstitial pneumonia (UIP) in the lung explant (87.7% vs. 56.0%, p < 0.05). The median follow up was 2.3 years (IQR 1.3, 4.7), and median survival time was 5.3 years (IQR 2.7–7.6; Figure 1). In the univariate Cox proportional hazards analysis, there was a relationship between the presence of UIP pathology and increased mortality, although this did not reach significance (HR 7.13, p = 0.06).

The shaded area represents the 95% confidence interval. Median time to death was 5.3 years (IQR 2.7–7.6). Kaplan-Meier survival curve for RA-LTx patients from time of LTx to death, or censor.

Table 1. Disease features of study cohort*

<table>
<thead>
<tr>
<th>Feature</th>
<th>All patients (N=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at LTx</td>
<td>58.0±10.7</td>
</tr>
<tr>
<td>Female</td>
<td>18 (42.9)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.7±4.2</td>
</tr>
<tr>
<td>Race–Caucasian</td>
<td>28 (66.7)</td>
</tr>
<tr>
<td>Ethnicity–Hispanic</td>
<td>11 (26.2)</td>
</tr>
<tr>
<td>Smoking, ever</td>
<td>17 (40.4)</td>
</tr>
<tr>
<td>Pack years</td>
<td>6.5±12.8</td>
</tr>
<tr>
<td>RA disease duration at LTx (years)</td>
<td>12.9±11.4</td>
</tr>
<tr>
<td>ILD Before/Concurrent to RA*</td>
<td>12 (28.6)</td>
</tr>
<tr>
<td>Erosive</td>
<td>11 (40.7)</td>
</tr>
<tr>
<td>Seropositive*</td>
<td>32 (91.4)</td>
</tr>
<tr>
<td>Pathology–UIP</td>
<td>28 (68.3)</td>
</tr>
<tr>
<td>Pathology–NSIP</td>
<td>7 (17.0)</td>
</tr>
<tr>
<td>Pathology–Other</td>
<td>13 (31.7)</td>
</tr>
<tr>
<td>FVC% at time of LTx</td>
<td>46.9±14.0</td>
</tr>
<tr>
<td>DLCO% at time of LTx</td>
<td>34.4±17.9</td>
</tr>
<tr>
<td>Post-Transplant Rheumatology Follow-Up</td>
<td>20 (47.6)</td>
</tr>
</tbody>
</table>

*Values are N(%) or mean ±SD #ILD diagnosis was made within 12 months of RA diagnosis

**RF or CCP

Figure 1. Kaplan-Meier survival curve for RA-LTx patients from time of LTx to death, or censor. The shaded area represents the 95% confidence interval. Median time to death was 5.3 years (IQR 2.7–7.6).

Conclusion: This single-center study of RA-ILD patients who underwent LTx demonstrated a median survival time comparable to other LTx cohorts. There appeared to be a relationship between the presence of a UIP pattern, and increased risk of mortality, though the small sample size may have precluded the ability to reach statistical significance. Future prospective studies are needed to validate these findings. Understanding the disease features of RA patients who undergo LTx may facilitate the early identification of RA patients at the greatest risk of developing progressive fibrosing phenotype.

References:
2. Acknowledgements: Dr. Jeffrey Gornbein (biostatistics)
3. Disclosure of Interests: Amir Razmjou: None declared, Elizabeth Volkmann Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim, Kadmon, Horizon, Forbius, Veen a Ranganath Grant/research support from: BMS, Mallinckrodt

RA predicted class assignment; those with higher perceived risk were more likely to belong to class 1. On average, the predicted uptake of treatment profiles estimating prevention candidates: abatacept, atorvastatin, hydroxychloroquine; tolerogenic cell-based therapy; and no treatment would be 50%, 10%, 9%, 18% and 0%, respectively. Finally, the maximum acceptable risk participants were willing to accept were 81%, 25% and 3% point increases in risk of mild side effects, serious infection, and serious side effects, respectively, for medicines that would reduce their risk of developing RA in the upcoming two years from 60% to 20%.

Conclusion: Effective preventive treatments for RA were acceptable to FDRs asked to assume a 60% chance of developing RA. Mode and frequency of treatment administration had a greater impact on treatment choices for participants with a lower perceived risk of RA. These findings are informative for target product profile development, endpoint selection, benefit-risk assessment, regulatory approval, and development of informational resources for those at risk of RA.

REFERENCES:

Acknowledgements: On behalf of the PREFER project. PREFER received funding from the IMI 2 Joint Undertaking (grant No. 115966), which receives support from the EU’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA). This abstract and its contents reflect the view of the presenter and not the view of PREFER, IMI, the European Union or EFPIA. K. Raza is supported by the NIHR Birmingham Biomedical Research Centre.

Disclosure of Interests: Gwenda Simons: None declared, Jorien Veldwijk: None declared, Rachael DiSalvatore Shareholder of: Johnson & Johnson, Employee of: Janssen Research and Development, Matthias Engbericht Speaker’s bureau: Abbvie, Chugai, Eli Lilly, Novartis, Roche, Sanofi, Mundipharma, Paid instructor for: Abbvie, Chugai, Roche, Consultant of: Abbvie, Novartis, Roche, Sanofi, Grant/research support from: Roche, Chugai, Christine Radawski Shareholder of: Eli Lilly & Company, Employee of: Eli Lilly & Company, Larissa Valor: None declared, Jenny Humphreys: None declared, Ian N. Bruce: None declared, Karim Raza Consultant of: Abbvie, Sanofi, Grant/research support from: Bristol-Myers Squibb, Marie Falahae: None declared


PERSISTENT EXCESS OF STROKE EVENTS IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY FROM HORDALAND, NORWAY FROM 1972 TO 2014

C. L. Aasling1,2, J. Iland3, G. S. Tell3,5, H. Naess5, T.W. Nystand4, B. T. Svanes3 on behalf of BeaBiRD - Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease. 1Haraldsplass Deaconess Hospital, Department of Internal Medicine, Bergen, Norway; 2University of Bergen, Department of Clinical Science, Bergen, Norway; 3University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway; 4Western Norway University of Applied Science, Department of Health and Social Science, Bergen, Norway; 5Norwegian Institute of Public Health, Division of Mental and Physical Health, Bergen, Norway; 6Haukeland University Hospital, Department of Neurology, Bergen, Norway; 7University of Bergen, Department of Clinical Medicine (K1), Bergen, Norway; 8Stavanger University Hospital, Centre for Age-Related Medicine, Stavanger, Norway; 9Haukeland University Hospital/Health Bergen, Department of Rheumatology, Bergen, Norway

Background: Patients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD), including stroke [1]. After the introduction of biological DMARDs in 1999 and the treat to target strategy, more patients reach low disease activity and remission, which is associated with lower CVD risk [2]. Few previous studies have examined stroke occurrence in RA patients before and after these improvements in RA management.

Objectives: To investigate stroke events in RA patients diagnosed before and after 1999 compared with the total population.

Methods: We included 771 RA patients diagnosed during 1972-1998 and 1050 during 1999-2013 at the main rheumatological department of Hordaland county, Norway. The total population of the same county and time period were used as a comparison cohort. Data on stroke events were obtained from regional cardiovascular registries or hospital patient administrative systems during 1972-2014. Aggregated counts of stroke events and population counts from the comparison cohort were used to estimate expected counts of stroke hospitalisation in the RA cohort per 5-year age group, sex and calendar year. We then estimated standardised event ratios (SERs) by Poisson regression as a measure of excess stroke events in RA patients compared with the total population.

Results: In total, 152 stroke events occurred in 112 RA patients diagnosed during 1972-1998 over 15137 person-years of follow-up and 86 stroke events in 70 RA patients diagnosed during 1999-2013 over 8672 person-years of follow-up. RA patients diagnosed in the later period were on average 2.1 years older (56 years) at RA diagnosis, but the proportion of women was similar in both groups. Both RA patients diagnosed before and after 1998 had an excess of stroke events compared with the total population (SER 1.20, 95% CI 1.00-1.44 and SER 1.22, 95% CI 1.05-1.42 respectively). RA patients younger than 60 years of age did not appear to have significant excess stroke events in either group.

Conclusion: These results indicate a similar excess of stroke events in RA patients diagnosed before and after 1999. This warrants continued awareness regarding stroke prevention in RA patients, even after the recent improvements in RA treatment.

REFERENCES:
Background: The prevalence of the musculoskeletal immune-related adverse events (irAEs) is probably underestimated, as most studies report only severe side effects. The largest prospective study with systematic monitoring by a rheumatologist, for musculoskeletal irAEs, revealed that seroconversion is difficult to achieve in SLE to date.

Objectives: The main objective was to describe each type of musculoskeletal irAE: prevalence, clinical features, treatment regimen, ICI drug, time of occurrence and management of musculoskeletal irAEs. The secondary objectives were to describe irAEs/course ant to investigated tumor response at 3 months after introduction of ICI according to irAEs/grade, clinical features, pain patterns and the treatments used to manage musculoskeletal irAEs.

Methods: We conducted a retrospective study among patients who received ICI from 07/27/2014 to 05/08/2020 at the medical oncology department of the Institut Paoli-Calmettes, Marseille, France. All medical files were systematically reviewed by a rheumatologist who collected clinical features, time of occurrence, treatment regimen, irAEs management, course, outcomes and tumor response 3 months after introduction of ICI.

Results: In our cohort of 927 patients treated with ICI for a solid tumor, 118 patients (12.7%) presented a musculoskeletal irAE. Their median age was 66.5, 61% were male, and they mainly had a lung (57.6%) or urological cancer (27.1%). The most frequently involved ICI was an anti PD-1. Arthralgias and myalgias were the most frequent musculoskeletal irAEs (76.3%) and inflammatory rheumatic features were reported in 36 patients (30.5%) with elevated acute phase reactants and negative immunological markers. The median time of onset was 2 months (IC 95% 1.8; 2.7). Musculoskeletal irAEs were mainly mild and no deaths were related. Painkillers were the most widely used treatments (86.4%). Systemic corticosteroids were used in 38 patients (32.2%) with a mean dose of 43 ± 35 milligrams/day. Among the inflammatory rheumatic features, 20 (55.5%) were treated with systemic corticosteroids and 8 with csDMARDs (16.7%). bDMARDs were not used in our cohort. Musculoskeletal irAEs resulted in discontinuation of the responsible ICI in 23 patients (19.5%). The majority of the musculoskeletal irAEs (79.7%) resolved within a median time of 3 months (IC 95% 2.2;4.0). Tumor response at 3 months did not differ according to musculo-skeletal irAE severity, type of manifestation (arthralgias/myalgias versus inflammatory rheumatic features), pain patterns (mechanical versus inflammatory) or irAE treatments.

Conclusion: Our single-center cohort is the largest to our knowledge to describe all musculoskeletal irAEs in patients treated with ICI without focusing on severe or inflammatory manifestations. These musculoskeletal irAEs are frequent, mostly mild and well tolerated, resolving and allowing possible continuation of ICI treatment. Collaboration between oncologists and rheumatologists should be further encouraged to determine whether all musculoskeletal irAEs, even non-severe and non-inflammatory ones, are associated with a good tumor response to ICI.

REFERENCES:

Disclosure of Interests: None declared

Disclosure of Interests: None declared

Background: Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE). Severe (proliferative) forms of LN are treated with an induction immunosuppressive therapy (IST), followed by a maintenance IST, to target remission and avoid relapses. The optimal duration of maintenance IST for proliferative LN is unknown.

Objectives: The WIN-Lupus trial tested whether IST discontinuation after 2-3 years of LN proliferative was non-inferior to IST continuation for 2 more years.

Methods: WIN-Lupus is an investigator-initiated academic randomized controlled trial, conducted in 28 French centers. Patients on maintenance IST with azathioprine or mycophenolate mofetil for a minimum of 2 years and a maximum of 3 years, and who were taking Hydroxychloroquine, were randomized (1:1) between 2 groups: IST continuation and IST discontinuation. The primary endpoint was the relapse rate of proliferative LN at 24 months. Secondary endpoints were the rate of severe SLE flares, survival without renal relapse or severe flare, adverse events, kidney function, disease activity, corticosteroid exposure, patient-reported outcomes and medico-economic impact.

Results: Between 2011 and 2016, 125 patients were screened and 96 were randomized in the trial: 48 in the IST continuation group, 48 in the IST discontinuation group. In the per-protocol population, a relapse of proliferative LN occurred in 5/40 (10.4%) patients with IST continuation and in 12/45 (25%) patients with IST discontinuation (difference 14.8%, 95%CI [-19;31.5]). Non-inferiority was not demonstrated for relapse rate. Time to renal relapse did not differ between groups (p=0.092). Severe SLE flares (renal or extra-renal) were less frequent in patients with IST continuation compared to IST discontinuation (5/40 vs 14/44 patients, p=0.035). IST discontinuation was associated with lower health-related costs. Adverse events did not differ between groups.

Conclusion: Non-inferiority of maintenance IST discontinuation after 2 to 3 years was not demonstrated for renal relapse. IST discontinuation was associated with a higher risk of severe SLE flare.

REFERENCES:

Acknowledgements: This study is supported by the Lupus Réseau (CGLR).

Disclosure of Interests: No conflict declared.
The impact of anifrolumab on neuropsychiatric manifestations of depression and suicidality in patients with systemic lupus erythematosus


Background: Neuropsychiatric (NP) disease is more common in patients with systemic lupus erythematosus (SLE) than in the general population. Increased incidence of NP events (depression and suicidality) has been reported with biologic therapies, including SLE therapies. Depression and suicidality were evaluated in patients with SLE treated with anifrolumab, a type I interferon receptor antibody, in the TULIP-1 and TULIP-2 trials.

Objectives: To understand the impact of anifrolumab treatment on NP manifestations (depression and suicidality) in patients with SLE relative to standard therapy using pooled data from the TULIP trials.

Methods: TULIP-1/-2 were randomized, placebo-controlled, 52-week trials of intravenous anifrolumab every 4 weeks in patients with moderate to severe SLE despite standard therapy. Patients with active severe or unstable NP SLE were excluded. Patients who received ≥1 dose of anifrolumab 300 mg or placebo were analyzed for depression and suicidality. The Personal Health Questionnaire Depression Scale-8 (PHQ-8) and Columbia Suicide Severity Rating Scale (C-SSRS) were used to assess clinical depression and suicidal ideation and behavior, respectively. Incidence of adverse events (AEs) within the standardized Medical Dictionary for Regulatory Activities query of depression (excluding suicide and self-injury) and antidepressant use at baseline and during the study were also assessed.

Results: In the TULIP pooled analysis, 360 patients received anifrolumab and 365 received placebo. Mean PHQ-8 scores were in the mild range (25 to <10); 9.7 in both groups at baseline (Table 1). Excluding patients taking antidepressants, mean PHQ-8 scores were 9.5 in the anifrolumab group and 9.7 in the placebo group at baseline. No clinically meaningful worsening in mean PHQ-8 scores was observed from baseline to Week 52 in the anifrolumab (–2.0) or placebo (–1.3) groups; excluding patients taking antidepressants, mean changes in PHQ-8 were –2.0 and –1.2, respectively. Depression AEs during the study were reported in 11 anifrolumab-treated patients (3.1%) and 9 patients who received placebo (2.5%). At baseline, antidepressant use was comparable between groups (anifrolumab group, 7 patients [1.9%]; placebo group, 9 patients [2.5%]). During the study, 8 anifrolumab-treated patients (2.2%) and 12 patients who received placebo (3.3%) used antidepressants; 1 (0.3%) and 4 (1.1%) patients, respectively, initiated antidepressant therapy during the study (1 in the placebo group stopped therapy). Suicidal ideation or behavior, as assessed by C-SSRS, during the study was reported in 5 anifrolumab-treated patients (1.4%) and 11 patients who received placebo (3.0%). Excluding patients taking antidepressants, suicidal ideation or behavior during the study was reported in 4 anifrolumab-treated patients (1.1%) and 9 patients who received placebo (2.5%) (Figure 1).

Conclusion: Patients with SLE treated with anifrolumab did not experience increased depression, suicidality, or need for antidepressants when compared with standard therapy, irrespective of baseline antidepressant use.

REFERENCES:

Table 1. Absolute changes in biomarkers for treatment phase completers*

| Table 1. Absolute changes in biomarkers for treatment phase completers* |
| Change from BL |
| n=54 | n=102 | n=58 | n=24 | n=44 | n=50 |
| Anti-dsDNA (IU/mL) | -9 (83, 1) | -51 (155, -3) | -5 (41, 0) | -9.5 (197, -2) | -55 (-329, -2) | -6.5 (-57, -1) |
| C3 (mg/dl) | 8.5 (8.0, 21) | 15 (0, 30) | 15 (6.0, 11) | 6 (5.5, 19.5) | 11 (7.2, 27) | 7.5 (5.5, 23) |
| C4 (mg/dl) | 2 (0.5) | 2 (2.0) | 2 (2.0) | 2 (2.4) | 2 (2.0) | 2 (2.0) |
| B cells and B-cell subsets (cells/ml) |
| CD19* | -57,570 (-193,946, -44,240) | -57,399 (-152,403, -12,562) | -41,343 (-105,789, 23,819) | -11,932 (-77,822, 45,773) | -48,783 (-151,528, -15,603) |
| CD20* | -58,112 (-110,681, -31,269) | -57,428 (-142,803, -18,639) | -40,773 (-95,658, 25,547) | -3986 (-143,321, -15,063) |
| Naïve CD20+CD27- | -60,025 (-112,623, -51,316) | -61,405 (-152,861, -28,496) | -62,477 (-142,009, -16,191) | -22,210 (-72,131, 28,335) |
| Activated CD95* | -61,006 (-120,810, -56,663) | -59,900 (-147,003, -42,880) | -60,245 (-152,877, -30,635) | -68,210 (-204,912, -35,687) |
| Memory CD20+CD27+ | 9,586 (1,500, 30,983) | -15,076 (-42,880, -6,376) | 5532 (-146, 14,393) | -13,927 (-24,816, -3064) |

*Excluded from analysis: all pts who discontinued the investigational product before Wk 52 and BEL/ST pts if discontinued before Wk 104, and BEL/PBO and BEL/RXT pts who re-started BEL after Wk 53; t=101; n=57.

Table 1. PHQ-8 Summary

| n=360 | n=365 | n=360 | n=365 |
| Anifrolumab 300 mg | Placebo | Anifrolumab 300 mg | Placebo |
| Anifrolumab 300 mg | Placebo |
| n | Mean* | SD | Changea | n | Mean* | SD | Changea |
| Baseline | 341 | 9.7 | 6.26 | – | 348 | 9.7 | 6.11 | – |
| Week 24 | 295 | 7.6 | 5.89 | –2.1 | 303 | 8.0 | 6.00 | –1.5 |
| Week 52 | 266 | 7.8 | 5.99 | –2.0 | 261 | 7.9 | 6.03 | –1.3 |

*Percentages are based upon all patients included in the analysis within the respective pool and treatment group.

Acknowledgements: Writing assistance by Andrea Y. Angstadt, PhD (Fishawack Health). This study was sponsored by AstraZeneca.

Background: Mycophenolate mofetil (MMF) or low-dose intravenous cyclophosphamide (CYC) are recommended as initial (induction) treatment in many recommendations for the management of lupus nephritis (LN), and randomized controlled trials have shown their similar efficacy. However, there is little to no real-world data.

Objectives: We conducted the real-world analysis to compare the efficacy and safety of MMF and CYC for the induction treatment of LN.

Methods: Our patients came from PKUFH SLE cohort, a single-center longitudinal observational cohort set up in 2007, and only patients received initial remission induction therapy for initial or recurrence LN were analyzed. The primary outcome measure was complete renal remission (CR) as defined by (proteinuria <500 mg/24 hours and serum creatinine within 10% from baseline in 12 month. All statistical analyses were performed with SPSS 26.0 and two sides p < 0.05 was considered statistically significant.

Results: The 237 LN patients with a median age of 35.0 years had a mean duration of disease of 5.2 years. Of these, 97 patients received CYC, 98 patients received oral MMF, and 42 patients received other immunosuppressive agents or combination therapy. The CR rate in 6-month in MMF was significantly higher than CYC group (CR 57.6% vs 45.2%, p=0.005), and that also applied to 12 month (74.7% vs 66.3%, p=0.001). MMF group patients had lower serum creatinine (7.6±4.15 vs. 9.3±3±29, p=0.012), lower glucose, and lower albumin (11.4±3.9 vs. 11.2±5.6, p=0.05), and lower 24-hour protein level (0.4±0.7 vs. 0.7±1.0, p=0.017) than CYC group. However, MMF did not show superior to CYC in the LN induced remission (6 month:87.5% vs 73.7%, p=0.064, 12 month:87.7% vs 90.8%, p=0.632) after propensity score matching, just as the Kaplan-Meier analysis showed (Figure 1). Chinese patients usually adopted lower dose MMF (78.8% 15g/d) compared Caucasian populations, and which was also effective.

Conclusion: Mycophenolate mofetil vs cyclophosphamide for treatment of lupus nephritis: a single-center cohort real-world analysis

X. Zhang1, H. Huang1, D. Gao1, Y. Fan1, Z. Zhang1, 1Peking University First Hospital, Rheumatology and Clinical Immunology Department, Beijing, China

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.8894

References:


Disclosure of Interests: None declared


OP0284 IMMUNOPHENOTYPIC CHARACTERIZATION OF PERIPHERAL BLOOD-DERIVED B LYMPHOCYTES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING B-CELL TARGETED THERAPY WITH ANTI-BLYS

L. Petrella1, C. Di Mario2,3, M. R. Gigante1, A. Paglioni1, V. Varragno1,4, M. A. D’Agostino1,3, S. Alvernini1,2, B. Toluoso1, E. Gremese1,3,4,5, Division of Clinical Immunology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; 2Immunology Research Core Facility – Gemelli Science and Technology Park (GSTE), Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; 3, Università Cattolica del Sacro Cuore, Rome, Italy; 4Division of Clinical Immunology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; 5, Università Cattolica del Sacro Cuore, Rome, Italy

Background: Belimumab, the first biological drug approved for the treatment of patients with Systemic Lupus Erythematosus (SLE), is a fully human IgG1 monoclonal antibody directed against BlsY (B Lymphocyte Stimulator). BlsY inhibition is associated with a reduction in circulating B subsets and short-lived plasmacells.

Objectives: The aim of this study was to characterize the B cell phenotype in SLE patients at baseline and after B-cell targeted therapy with Belimumab in a cohort of active SLE patients.

Methods: Fifty-four SLE patients diagnosed according to the 2012 SLICC criteria (49 females, mean age 40.6±12.3 years, disease duration 12.3±9.0 years, SLEDAI-2K 6.6±3.1) who received belimumab were enrolled. Phenotyping of peripheral blood (PB)- derived B lymphocytes (using as phenotypic markers IgD, CD27 and CD38) was performed at six (T6) and twelve (T12) months in 38 SLE patients, together with the expression of BAFF and BAFF-R by flow cytometry.

Results: In the whole SLE cohort, a reduction over time was observed in the percentage of CD19+T0:11.6±6.1% vs T6:6.4±3.3%, p<0.01;T12:4.2±3.4% ,p<0.01 and naïve B cells (IgD-CD27pos) T0:55.8±28.7% vs T6:34.9±22.2%, p<0.01;T12:30.0±19.4%;p<0.04) and an increase of switched memory B cells (IgD-CD27pos) T0:21.0±20.2% vs T6:37.5±21.4% ,p<0.01;T12:42.2±21.7% , p<0.02) after B-cell targeted therapy with anti-Blys. Moreover, a reduction of IgD+CD27pos memory B cells at T6(p=0.01) was observed. Conversely, BAFF and BAFF-R expression in peripheral blood-derived CD19+ cells remained unchanged during therapy with anti-Blys. Stratifying SLE patients based on severe (renal and/or neurological) and mild (articular and/or cutaneous) organ involvement, a significant reduction of CD19+ pos percentage[T0:10.7±4.6% vs 6.6±8.2, p<0.03;T12:4.5±3.3%,p=0.03) and naïve B cells (IgD-CD27pos) [T0:61.0±24.6% vs T6:38.9±17.5%,p=0.01;T12:36.9±16.0%,p=0.03] was found in SLE patients with mild organ involvement and a significant increase of switched memory B cell subsets in both subgroups [severe T0:24.1±25.0% vs T6:44.9±27.4%,p<0.01] (mild T0:19.1±19.3% vs T6:31.2±12.7%,p<0.01). Evaluating the B cell subsets regarding the response to treatment (based on the reduction of the SLEDAI-2K), a significant reduction of naïve B cells was observed at T6 in both SLE group,[responders T0:55.4±29.3% vs T6:32.3±19.9%,p<0.01] (no responders T0:63.1±14.1% vs T6:41.4±3.5%,p<0.05) and switched memory B cells[responders T0:22.4±21.2% vs T6:39.6±19.4%,p<0.01] (no responders T0:20.6±26.1% vs T6:38.6±35.3%,p<0.05), with a significant higher percentage at baseline of switched memory B cells in responder SLE than in no-responder SLE group (22.4±21.2% vs 20.6±26.1%, p=0.02). ROC curve analysis of IgD-CD27pos subset [AUC(95% CI):0.761 (0.566-0.957) p=0.023] identified a cut-off of 9.94% associated with response at 6 months. Moreover, having a IgD-CD27pos rate ≥9.94% [OR:4.5(95% CIs:0.9-17.2)]; and the presence of anti-dsDNA antibod- ies at baseline[OR:5.295(95% CIs:1.2-22.12)], identified SLE patients who achieved early response within 6 months from belimumab therapy initiation.

Conclusion: Anti-Blys therapy significantly impacts on the composition of peripheral blood B-cell subpopulations in SLE patients in relation with the distinct organ involvement. Moreover, baseline immunological features and IgD-CD27pos B cell subset rate are novel putative biomarkers of response to anti-Blys in SLE patients.

References:
VOCLOSPORIN IS EFFECTIVE IN ACHIEVING PROTEINURIA TREATMENT TARGETS IN LUPUS NEPHRITIS DEFINED BY EULAR/ERA RECOMMENDATIONS

1Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Germany; 2Aurinia Pharmaceuticals Inc., Medical Affairs, Victoria, Canada

Background: The novel calcineurin inhibitor voclosporin was approved in 2021 for the treatment of adult patients with active lupus nephritis (LN) in combination with background immunotherapy. Voclosporin has a favorable metabolic profile and a consistent dose-concentration relationship, eliminating the need for therapeutic drug monitoring.

The Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to significantly higher complete renal response rates in AURA-LV at 24 weeks (32.6% vs 19.3%; odds ratio [OR] 2.03; p=0.046) and in AURORA 1 at 52 weeks (40.8% vs 22.5%; OR 2.65; p<0.0001) of treatment in patients with LN.

Objectives: The European League Against Rheumatism and European Renal Association (EULAR/ERA) published updated treatment recommendations for LN with targeted reductions in proteinuria over the course of the first year of therapeutic intervention. Here we report on a post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies based on these updated response criteria.

Methods: AURA-LV and AURORA 1 enrolled patients with biopsy-proven active lupus nephritis (Class III, IV, or V or III/IV) and proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V). Pooled data included 288 patients in the voclosporin (23.7 mg BID) group and 266 patients in the control group, with all patients receiving MMF (target dose 1 g BID) and low-dose steroids (target dose 2.5 mg/day by week 16 according to protocol-defined steroid taper). We assessed the following EULAR/ERA treatment targets: ≥25% reduction in urine protein creatinine ratio (UPCR) by 3 months, ≥50% reduction in UPCR by 6 months, UPCR ≤0.7 mg/mg by 12 months, and steroid dose ≤7.5 mg/day by 3, 6, and 12 months.

Results: Within the first 3 months of treatment, 79.4% of patients in the voclosporin group and 62.4% of patients in the control group achieved ≥25% reduction in UPCR (odds ratio [OR] 2.25; 95% confidence interval [CI] 1.52, 3.33; p<0.0001). The percentage of patients achieving a reduction of ≥50% in UPCR by 6 months was also significantly greater in the voclosporin group compared to control (66.0% vs 47.0%; OR 2.03; CI 1.35, 2.83; p<0.0001). After 12 months of treatment, 52.6% and 33.1% of patients receiving voclosporin and control, respectively, had achieved a UPCR ≤0.7 mg/mg (OR 2.52; CI 1.75, 3.63; p<0.0001). Given the protocol-defined steroid taper, at both 3 and 6 months, a similar proportion (>90%) of patients in both groups had achieved the recommended steroid dose, with 89.6% and 82.8% in the voclosporin and control groups, respectively, on the recommended dose at 12 months.

The proportion of patients meeting all three UPCR targets during the one-year study period and having a steroid dose ≤7.5 mg/day at 12 months was 37.3% in the voclosporin group and 23.3% in the control group (OR 1.97; CI 1.43, 3.10; p<0.0001).

Conclusion: The addition of voclosporin to a background regimen of MMF and low-dose steroids in patients with LN significantly increased the likelihood of achieving the 3-, 6-, and 12-month UPCR targets of therapy recommended by EULAR/ERA.

REFERENCES:


Development and Preliminary Validation of the SJÖGREN’S Tool for Assessing Response (STAR): A Consensual Composite Measure for Assessing Treatment Effect in Primary SJÖGREN’S SYNDROME

R. Seror1,2, G. Baron3,4, M. Camus5, D. Corne6,7, E. Peromedeau1,8, J. B. Bowman9,10, M. Bombardi11, R. Bootma12, J. E. Gottenberg11,12, B. Fiser13,14, W. Hueber15,16, J. van Roon17, V. Devauchelle-Pensec18, P. Gergely19, X. Mariette1,2, R. Porcher20 on behalf of NECESSITY WP5 STAR Development Participants. Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Rheumatology, Le Kremlin Bicêtre, France; 2Université Paris-Saclay INSERM UMR1184, Centre for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, France; 3Assistance Publique-Hôpitaux de Paris, Hôtel Dieu Hospital, Statistics, Paris, France; 4Université Paris Descartes Sorbonne Paris Cité, INSERM U1153, Centre de Recherche en Épidémiologie et StatistiqueS, Paris, France; 5CHU de Brest, Rheumatology, Brest, France; 6Université de Brest, UMR1227 Inserm, LBAI, Brest, France; 7Milton Keynes University Hospital, Rheumatology, Milton Keynes, United Kingdom; 8University Hospitals Birmingham and University Hospital Birmingham, Rheumatology, Birmingham, United Kingdom; 9William Harvey Research Institute, Queen Mary University of London, Experimental Medicine and Rheumatology, London, United Kingdom; 10University of Groningen, University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 11CHU de Strasbourg, Rheumatology, Strasbourg, France; 12CNRS, UP13572, Université de Strasbourg, Institut de Biologie Moléculaire et Cellulaire, Centre National de Référence pour les Maladies Auto-Immunes Systémiques Rares, Strasbourg, France; 13Université Hospitals Birmingham NHS Foundation Trust, National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Rheumatology Research Group, Birmingham, France; 14University of Birmingham, Institute of Inflammation and Ageing, Birmingham, France; 15Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland; 16Université Medical Center Utrecht, Utrecht University Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, Utrecht, Netherlands; 17Novartis Institutes for Biomedical Research, Rheumatology, Basel, Switzerland; 18Assistance Publique-Hôpitaux de Paris, Hôtel Dieu Hospital, Centre d’épidémiologie clinique, Paris, France

Background: Today, there are still no DMARDs licensed for primary Sjögren Syndrome (pSS) patients. Among the explanations, are the limitations of current outcome measures used in clinical trials: e.g; high placebo response rate, evaluation of either symptoms or systemic activity, and important features not being assessed. The NECESSITY consortium (https://www.necessity-h2020.eu), including pSS experts from academia, pharmaceutical industry and patient groups formed to develop a new composite responder index, the SJOgren’s Tool for Assessing Response (STAR) that solve the issues of current outcome measures in pSS and is intended for use in clinical trials as an efficacy endpoint.

Objectives: To develop a composite responder index in primary Sjögren’s syndrome (pSS): the STAR.

Methods: To develop the STAR, the NECESSITY consortium used data-driven methods, based on 9 randomized controlled trials (RCTs), and consensus techniques, involving 78 experts and 20 patients. Based on reanalysis of rituximab trials (TRACTISS and TEARS) and literature review, the Delphi panel identified a core set of domains to include in the STAR, with their respective outcome measures. STAR options combining these domains were designed and proposed to the panel to select and improve them. For each STAR option, sensitivity to change was estimated by the C-index (derived from Effect size) in all 9 RCTs. Delphi rounds were run for selecting STAR among these options. The Delphi panel also voted to classify trials as positive, negative or “in between” in regards to primary but also key secondary endpoints. For the options remaining before the final vote, meta-analyses of the RCTs were performed separately for positive and “in between” trials together, and for negative trials.

Results: The Delphi panel identified 5 core domains (systemic activity, patient symptoms, lachrymal gland function, salivary gland function and biological parameters), and 227 STAR options, combining these domains, were selected to be tested for sensitivity to change. After two Delphi rounds, meta-analyses of the 20 remaining options were performed. The candidate STAR was selected by a final vote based on metrological properties and clinical relevance. In positive/in between trials, candidate STAR detected a difference between arms (OR 3.29, 95%-CI [2.07,5.22], whereas it did not in negative trials (OR 1.53, 95%-CI [0.81,2.91]).

Conclusion: The candidate STAR is a composite responder index, including in a single tool all main disease features, and is designed for use as a primary endpoint.
in pSS RCTs. Its rigorous and consensual development process ensures its face and content validity. The candidate STAR showed good specificity and sensitivity to change. The candidate STAR will be prospectively validated in a dedicated three arms RCT of the NECESSITY consortium that will evaluate combination of synthetic DMARDs (hydroxychloroquine + leflunomide or hydroxychloroquine + mycophenolate vs placebo). We encourage the use of STAR in any ongoing and future trials.

Table 1. Candidate STAR

<table>
<thead>
<tr>
<th>Domain</th>
<th>Point</th>
<th>Definition of response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic activity</td>
<td>3</td>
<td>Decrease of clinESSDAI ≥ 3</td>
</tr>
<tr>
<td>Patient reported outcome</td>
<td>3</td>
<td>Decrease of ESSPRI ≥ 1 point or ≥ 15%</td>
</tr>
<tr>
<td>Lachrymal gland function</td>
<td>1</td>
<td>Schirmer:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If abnormal score at baseline: increase ≥ 5 mm from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If normal score at baseline: change to normal or worse</td>
</tr>
<tr>
<td>Ocular Staining Score:</td>
<td></td>
<td>If abnormal score at baseline: decrease ≥ 2 points from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If normal score at baseline: change to normal or worse</td>
</tr>
<tr>
<td>Salivary gland function</td>
<td>1</td>
<td>Unstimulated Whole Salivary Flow:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If score &gt; 0 at baseline: increase ≥ 25% from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If score &lt; 0 at baseline: any increase from baseline or worse</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ultrasound:</td>
</tr>
<tr>
<td>Biological</td>
<td>1</td>
<td>Decrease ≥ 25% in total Hocevar score from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Serum IgG levels: decrease ≥ 10%</td>
</tr>
<tr>
<td>Candidate STAR responder</td>
<td>≥ 5</td>
<td>Rheumatoid Factor levels: decrease ≥ 25%</td>
</tr>
</tbody>
</table>

ESSDAI: EULAR Sjögren syndrome disease activity index, ESSPRI: EULAR Sjögren syndrome patient reported index, IgG: Immunoglobulin G.

Acknowledgements: NECESSITY WPS STAR development participants: Suzanne Arends (University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen 9700 RB, Netherlands), Francesca Barone (Centre for Translational Inflammation Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK), Aïn Björk (Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden), Cécile Boullet (Centre de Recherche pour l’Immunologie et les Maladies Auto-immunes du Centre Inserm, Paris, France), Mari-Antonio Begona, Johan Brun, Valko Butyna, Laurent Chiche, Troy Daniels, Paul Emery, Robert Fo, Roberto Giacomelli, John Gonzales, John Green, Robert Moots, Susumu Nishiyama, Elizabeth Price, Christophe Richez, Caroline Shibsoski, Roser Solans Laque, Muthiah Srinivasan, Peter Olsson, Tsutomu Takeuchi, Frederick Vivino, Paraski Voulgari, Daniel Wallace, Ava Wu, Wen Zhang. We thank the anonymous patients from the NECESSITY Patient Advisory Group and the Sjögren Foundation for their valuable contribution to the Delphi process. We thank EW StClair and AN BAER who generated the barmercno data and made them publicly available.

Disclosure of Interests: Raphaèle Seror Consultant of: GlaxoSmithKline, Boehringer, Janssen and Novartis, Grant/research support from: GlaxoSmithKline and Amgen, Gabriel Baronti: None declared, Marine Camus: None declared, Divi Comes Consultant of: GlaxoSmithKline, Bristol Myers Squibb, Janssen, Amgen, Pfizer and Roche, Elodie Perreau: None declared, Simon J. Bowman Consultant of: Abbvie, Astra Zeneca, Galapagos and Novartis Pharmaceuticals, Michelle Bombardieri Consultant of: UCB, Amgen/Medimmune, Janssen, and GlaxoSmithKline, Grant/research support from: Amgen/Medimmune, Janssen, and GlaxoSmithKline, Hendrik Bootsma: None declared, Jacques-Eric Gotterberg Consultant of: Abbvie, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Pfizer, Roche, Sanofi, Novartis, MSD, CSL-Behring and Genzyme, Grant/research support from: Bristol Myers Squibb, Novartis, Bristol Myers Squibb, Janssen, Amgen, Pfizer and Roche, Freeloe Perreau: None declared, Simon J. Bowman Consultant of: Abbvie, Astra Zeneca, Galapagos and Novartis Pharmaceuticals, Michelle Bombardieri Consultant of: UCB, Amgen/Medimmune, Janssen, and GlaxoSmithKline.

The early bird gets the worm

OPO287

LONGITUDINAL ASSESSMENT OF THE ULTRASOUND GOUT LESIONS USING THE VALIDATED OMERACT SEMI-QUANTITATIVE SCORING SYSTEM

S. N. Christiansen, M. Østergaard, O. Slot, V. Fana, L. Teresli

Background: In gout, ultrasound (US) is a promising tool to detect changes in monosodium urate (MSU) deposits during urate-lowering therapy (ULT). The OMERACT US group has developed definitions of gout-specific US lesions[1] and a semi-quantitative scoring system for US lesions representing MSU deposition (tophus, double contour (DC) and aggregates)[2], but the responsiveness of lesions when applying this scoring system has not yet been assessed.

Objective: The primary aim of the study was to evaluate the responsiveness of gout-specific US lesions in patients receiving treat-to-target ULT using both a binary (present/absent) and the OMERACT-defined semi-quantitative (0–3) scoring system. The secondary aims were to determine the most responsive US measure for MSU deposition at patient level and the optimal joint/tendon set for monitoring lesions.

Methods: US (28 joints, 14 tendons) was performed in microscopically verified gout patients treated with ULT for ≥ 12 months. US images and videos of pathologies were stored. Tophus, DC and aggregates were scored binarily and semi-quantitatively. Individual lesion-scores were calculated at patient level as well as combined crystal sum scores. Standardised response means (SRM) for lesions when scored binarily and semi-quantitatively were calculated at patient and joint/tendon level.

Results: 48 patients with three-patient follow-up for 12 months. Plasma urate levels were effectively lowered during follow-up (Table 1). US showed statistically significant decreases in tophus and DC sum scores, both when scored binarily and semi-quantitatively.
Table 1. Course and SRMs of US scores during 12 months’ follow-up

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>6-months’ follow-up</th>
<th>12-months’ follow-up</th>
<th>P-value*</th>
<th>SRM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>Median [IQR]</td>
<td>Mean</td>
<td>Median [IQR]</td>
<td>Mean</td>
</tr>
<tr>
<td>P-urate (mmol/L)</td>
<td>0.49</td>
<td>0.48 [0.42–0.56]</td>
<td>0.33</td>
<td>0.32 [0.29–0.36]</td>
<td>0.31</td>
</tr>
<tr>
<td>SQ ultrasound scoring (0–3), [possible range]</td>
<td>DC sum score, [0–84]</td>
<td>5.5</td>
<td>3 [1; 8]</td>
<td>3.7</td>
<td>2 [0; 5]</td>
</tr>
<tr>
<td></td>
<td>Tophus sum score, [0–126]</td>
<td>9.5</td>
<td>6 [4; 11]</td>
<td>8.2</td>
<td>5 [3; 9]</td>
</tr>
<tr>
<td></td>
<td>Aggregates sum score, [0–126]</td>
<td>12.2</td>
<td>10 [7; 16]</td>
<td>12.6</td>
<td>10 [7; 16]</td>
</tr>
<tr>
<td></td>
<td>SQ-TD-sum score, [0–210]</td>
<td>15.0</td>
<td>10 [6; 16]</td>
<td>11.9</td>
<td>8 [5; 12]</td>
</tr>
<tr>
<td></td>
<td>SQ-TDA-sum score, [0–336]</td>
<td>27.2</td>
<td>22 [14; 30]</td>
<td>24.6</td>
<td>18 [12; 28]</td>
</tr>
<tr>
<td>Tophus sum score, [0–126], [possible range]</td>
<td>Binary-TDA-sum score, [0–112]</td>
<td>9.7</td>
<td>8 [5; 11]</td>
<td>8.6</td>
<td>7 [4; 10]</td>
</tr>
<tr>
<td></td>
<td>Aggregates sum score, [0–42]</td>
<td>4.4</td>
<td>3 [2; 6]</td>
<td>4.7</td>
<td>4 [2; 6]</td>
</tr>
<tr>
<td></td>
<td>DC sum score, [0–84]</td>
<td>1.8</td>
<td>1 [0; 3]</td>
<td>1.1</td>
<td>1 [0; 2]</td>
</tr>
<tr>
<td></td>
<td>Tophus sum score, [0–42]</td>
<td>3.4</td>
<td>2 [1; 4]</td>
<td>3.0</td>
<td>2 [1; 3]</td>
</tr>
<tr>
<td></td>
<td>Aggregates sum score, [0–42]</td>
<td>4.4</td>
<td>3 [2; 6]</td>
<td>4.7</td>
<td>4 [2; 6]</td>
</tr>
<tr>
<td></td>
<td>Binary-TDA-sum score, [0–70]</td>
<td>5.3</td>
<td>3 [2; 6]</td>
<td>4.2</td>
<td>3 [1; 4]</td>
</tr>
<tr>
<td></td>
<td>Binary-TDA-sum score, [0–112]</td>
<td>9.7</td>
<td>8 [5; 11]</td>
<td>8.6</td>
<td>7 [4; 10]</td>
</tr>
</tbody>
</table>

Acknowledgements: The Danish Rheumatism Association is acknowledged for financial support of the salary of SNC.

Disclosure of Interests: Sara Nysom Christiansen Speakers bureau: SNC has received speaker fees from BMS and GE, Grant/research support from: SNC has received funding from Novartis, Mikkel Østergaard Speakers bureau: MØ has received research support and/or consultancy/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Gilead, Galapagos, Hospira, Jansen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth., Grant/research support from: MØ has received research support and/or consultancy/speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Centocor, GSK, Gilead, Galapagos, Hospira, Jansen, Merck, Mundipharma, Novartis, Novo, Orion, Pfizer, Regeneron, Schering-Plough, Roche, Takeda, UCB and Wyeth., Olie Slot: None declared, Victoria Fana: None declared, Rene Terslev Speakers bureau: LT has received speakers’ fees from Abbvie, MSD, Novartis, Roche, Pfizer, GE, BMS and Jansen.


OP0288 IMPACT OF CARDIOVASCULAR RISK ON THE DIAGNOSTIC ACCURACY OF THE ULTRASOUND HALO SCORE FOR GIANT CELL ARTERITIS

J. Molina Collada1,2, L. López Gómez1, L. Castrejon1,2, J. C. Nieto González1,2, J. Martinez-Barrio1,2, A. M. Anzola1, J. Rivera1,2, J. M. Alvaro-Gracia1,2, J. J. C. Nieto González1,2, L. López Gómez1,2

1Hospital General Universitario Gregorio Marañón, Rheumatology, Madrid; Spain;
2Instituto de Investigación Sanitaria Gregorio Marañón (IISGM), Rheumatology, Madrid, Spain

Background: The ultrasonographic (US) Halo Score provide a quantitative measure of the extent of vascular inflammation in patients with giant cell arteritis (GCA). High Halo Scores correlate with systemic markers of inflammation, rate of ocular ischaemia and may help to firmly diagnose GCA with high specificity. However, an increase in the intima media thickness (IMT) in patients with elevated cardiovascular risk (CVR) may lead to false-positive US findings.

Objectives: Our aim is to evaluate the impact of CVR on the diagnostic accuracy of the US Halo Score in patients with suspected GCA.

Methods: This is a retrospective observational study of patients suspected of having GCA and referred to our US fast track clinic. All patients underwent exam within 24 hours per protocol. The IMT was measured in gray scale mode in cranial and extra-cranial (carotid, subclavian and axillary) arteries and the Halo Score was also determined to assess the extent of vascular inflammation. GCA diagnosis was confirmed after 6-month follow-up by the referring clinician. The European Society of Cardiology (ESC) Guidelines on CV Disease Prevention in clinical practice were used to define different categories of CVR. Patients were classified as very high, high, moderate or low CVR according to the Systemic Coronary Risk Evaluation (SCORE) obtained using the ESC CVD Risk Calculator app for mobile devices. Comparison between groups was performed and the diagnostic accuracy of the Halo Score in patients according to CVR was evaluated using ROC curves.

Results: Of the 157 patients referred to our US fast track clinic (67.5% female, mean age 73.7 years), 47(29.9%) had GCA confirmed after 6-month follow-up. There were no differences in CVR between patients with and without GCA (mean SCORE 20.6 [21.6] vs 18.7 [21]; p=0.601). Among patients without GCA, high/extra-cranial artery IMT was significantly higher in patients with high/very high CVR (0.835 (CI95% 0.756-0.914), slightly greater in patients with low/ moderate CVR (0.965 [CI95% 0.911-1]) versus patients with high/very high CVR (0.798 [CI95% 0.702-0.895]) (Figure 1). A statistically weak positive correlation was found between the Halo Score and the SCORE (r 0.245; p=0.002).

Discussion: The Danish Rheumatism Association is acknowledged for financial support of the salary of SNC.
Table 1. Measurements of IMT in cranial and extracranial arteries and Halo Score values according to CVR

<table>
<thead>
<tr>
<th>Artery IMT mm, mean (SD)</th>
<th>Patients with GCA n=47</th>
<th>Patients with low/moderate CVR n=110</th>
<th>p</th>
<th>Patients with GCA n=47</th>
<th>Patients with low/moderate CVR n=110</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Patients with high/very high CVR n=37(78.7%)</td>
<td>Patients with low/moderate CVR n=97(21.3%)</td>
<td></td>
<td>Patients with high/very high CVR n=79(78.1%)</td>
<td>Patients with low/moderate CVR n=31(28.2%)</td>
<td></td>
</tr>
<tr>
<td>Superficial temporal artery (both)</td>
<td>0.66(0.25)</td>
<td>0.45(0.11)</td>
<td>0.025</td>
<td>0.35(0.09)</td>
<td>0.32(0.07)</td>
<td>0.354</td>
</tr>
<tr>
<td>Frontal branch (both)</td>
<td>0.42(0.18)</td>
<td>0.31(0.15)</td>
<td>0.005</td>
<td>0.26(0.05)</td>
<td>0.28(0.06)</td>
<td>0.577</td>
</tr>
<tr>
<td>Parotid branch (both)</td>
<td>0.43(0.17)</td>
<td>0.35(0.12)</td>
<td>0.102</td>
<td>0.27(0.04)</td>
<td>0.28(0.09)</td>
<td>0.173</td>
</tr>
<tr>
<td>Carotid artery (both)</td>
<td>0.88(0.21)</td>
<td>1.26(0.6)</td>
<td>&lt;0.001</td>
<td>0.83(0.16)</td>
<td>0.74(0.13)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Subclavian artery (both)</td>
<td>0.86(0.31)</td>
<td>1.26(0.5)</td>
<td>0.001</td>
<td>0.74(0.18)</td>
<td>0.63(0.13)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Axillary artery (both)</td>
<td>0.92(0.38)</td>
<td>1.26(0.73)</td>
<td>0.001</td>
<td>0.72(0.16)</td>
<td>0.59(0.15)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Halo Score, mean (SD)</td>
<td>18.5(8.8)</td>
<td>17.2(10.6)</td>
<td>0.69</td>
<td>9.38(5.93)</td>
<td>6.1(5.22)</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Figure 1. Diagnostic accuracy of the Halo Score for a clinical diagnosis of GCA after 6-month follow-up in (A) all GCA suspected patients, (B) patients with high/very high CVR and (C) patients with low/moderate CVR.

Conclusion: High CVR may influence the diagnostic accuracy of the US Halo Score leading to false-positive findings in these patients. Higher IMT values may be found in extracranial arteries of subjects with high/very high CVR without GCA. Thus, CVR should be taken into consideration in the US vascular assessment of patients with suspected GCA. These results need to be confirmed in larger cohorts to develop a modified US Halo Score applicable to patients with high CVR.

Disclosure of Interests: None declared.


OP0290

SHORT-AND LONG-TERM EFFICACY OF ULTRASOUND-GUIDED NEEDLE FRAGMENTATION OR LAVAGE (BARBOTAGE) IN SYMPTOMATIC SHOULDER CALCIFIC TENDONITIS REFRACTORY TO SUBACROMIAL STEREOID INJECTION. PROSPECTIVE LONGITUDINAL STUDY OF 181 PATIENTS.

E. Casado1, S. Garcia-Cirera1, S. Retamozo1, M. Rusilov1, E. Costa Moya1, L. Lluis1, J. Calvet1, J. Gratacos-Masmitja1. University Hospital Parc Tauli, ISPT Research Institute, Rheumatology, Sabadell, Spain

Background: Rotator cuff calcific tendinopathy is a common cause of shoulder pain and disability in young patients. Despite anesthetics or steroid injection some patients still experience symptoms and may require surgery. Ultrasound-guided fragmentation or lavage are minimally invasive techniques that can be used instead of surgery to remove calcification and improve symptoms. However, evidence is poor because of most of published studies are retrospective or with few patients.

Objectives: To assess the short and long-term efficacy of ultrasound guided needle fragmentation or lavage (barbotage) in a large cohort of patients with symptomatic shoulder calcific tendinosis refractory to previous subacromial steroid injection.

Methods: Prospective study, including all consecutive patients referred to a Rheumatology out-patient clinic between Jul 2008-Dec 2020 because of symptomatic (visual analog scale or VAS≥4) calcific tendinosis of the rotator cuff refractory to at least one subacromial corticosteroid injection. After informed consent, all patients were treated with minimally invasive ultrasound-guided technique: fragmentation between Jul 2008-Dec 2013 or lavage (barbotage) between Jan 2014-Dec 2020. Corticoids were injected in the subacromial-subdeltoid bursa in all patients after procedure. Shoulder pain (VAS) and shoulder X-ray were assessed at baseline and after 4 months since the intervention. A new clinical assessment was made after 12 months or when clinical relapse occurred.

Results: One hundred and eighty-one subjects (56 men and 125 women), were included in the study. Mean age was 49.7 years (range 29–72). Mean duration of symptoms was 33.0 months (2–150), with mean VAS 7.6±1.5. Right shoulder was the location most frequently affected (66.3%). Mean size of calcification by X-ray was 13.7 mm (5–40), 55 patients (30.4%) underwent fragmentation, 115 (63.5%) lavage and 11 (6.1%) both techniques. There were not significant differences between groups at baseline. 4 months after procedure, mean VAS pain was 4.5±3.8 and 82.9% of subjects experienced a X-ray resolution (56.8%) or size reduction (26.1%) of the calcification. A clinical relapse occurred in 73 patients (40.3%) in the first 4 months of follow up, and in 33 patients (18.2%) between months 4 and 12. Symptoms disappeared in most of patients with a new steroid injection. Only 31 patients (17.1%) required a second fragmentation or lavage, and 13 patients (7.2%) a rotator cuff surgery. Any patient suffered local or systemic complications after fragmentation or lavage. Patients treated with lavage had higher shoulder pain when clinical relapse (mean VAS 6.5 vs 4.0; p<0.01) and needed more frequently a new steroid injection (54.8% vs 34%; p<0.004) or ultrasound guided-procedure (17.5% vs 13.1%; p=0.008). There were no significant differences between both techniques in the radiographic resolution or size decrease of the calcification.

Conclusion: Ultrasound guided needle fragmentation and lavage (barbotage) are effective and safe at short and long-term to treat patients with symptomatic shoulder calcific tendinosis, avoiding surgery in more than 90% of cases. Fragmentation seems to have better clinical outcomes than lavage.

REFERENCES:

Disclosure of Interests: None declared.


OP0291

WHICH INFLAMED TISSUES EXPLAIN A POSITIVE SQUEEZE TEST OF THE METATARSOPHALANGEAL JOINTS? A LARGE IMAGING STUDY TO UNDERSTAND THE HUMAN NAIL UNIT IN METATARSOPHALANGEAL ARTHRITIS

B. van Dijk1, Y. Dakkak1, D. Krijbolder1, J. van Zeben2, I. Tchetverikov3, M. Reijnierse4, A. van der Helm-van Mil 1,5.

1Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Franciscus Gasthuis & Vleuteland, Rheumatology, Rotterdam, Netherlands; 3Albert Schweitzer Hospital, Rheumatology, Dordrecht, Netherlands; 4Leiden University Medical Center (LUMC), Radiology, Leiden, Netherlands; 5Erasmus University Medical Center, Rheumatology, Rotterdam, Netherlands

Background: The squeeze test of metatarsophalangeal (MTP-)joints is frequently used, because it is easy and cheap, and is traditionally perceived as a test for synovitis. Besides classic intra-articular synovitis also tenosynovitis and intermetatarsal bursitis (IMB) represent synovial inflammation, albeit juxta-articularly located. Both are frequently present in RA and occasionally in other arthritides. However, the contribution of IMB to MTP squeeze test positivity is unknown and the contribution of tenosynovitis has only been partially studied.

Objectives: To assess whether tenosynovitis and IMB contribute to a positive MTP squeeze test.

Methods: 192 early arthritis patients and 693 CSA-patients underwent the MTP squeeze test and foot XRF at first presentation. MRI measurements in aged-matched healthy controls were used to define positivity for synovitis, tenosynovitis and IMB. Logistic regression was used; multivariable models adjusted for sex and simultaneous presence of inflammation features.

Results: In early arthritis patients synovitis (OR 4.8 (95%CI 2.5–9.5), tenosynovitis (2.4 (1.2–4.7)) and IMB (1.7 (1.2–2.6)) associated with positivity of the MTP squeeze test. Synovitis (3.2 (1.4–7.2)) and IMB (3.9 (1.7–8.8)) remained associated in multivariable analyses. Of patients with a positive MTP squeeze test, 79% had synovitis or IMB: 12% synovitis, 15% IMB and 52% both synovitis and IMB. IMB patients, subclinical synovitis (3.0 (2.0–4.7)), tenosynovitis (2.7 (1.6–4.6)) and IMB (1.7 (1.2–2.6)) associated with MTP squeeze test positivity. In multivariable analyses, synovitis remained independently associated (2.5 (1.5–4.1)) whilst tenosynovitis (1.5 (0.8–2.9)) and IMB did not (1.2 (0.8–1.8)). Of patients with a positive MTP squeeze test, 39% had synovitis or IMB: 10% synovitis, 15% IMB and 13% both synovitis and IMB.

Conclusion: Besides synovitis also IMB contributes to pain upon compression in early arthritis, presumably due to its location between MTP joints. This is the first evidence showing that a positive MTP squeeze test positivity is not only explained by intra- but also juxta-articular inflammation.
SCORING STRUCTURAL DAMAGE IN RHEUMATOID ARTHRITIS BY ULTRASOUND: RESULTS FROM A DELPHI PROCESS AND WEB-RELIABILITY EXERCISE BY THE OMERACT US WORKING GROUP


1 Medical University of Vienna, Division of Rheumatology, Vienna, Austria; 2 Luigi Sacco University Hospital, Rheumatology Department, Milan, Italy; 3 University of Western Australia, School of Medicine and Pharmacology Fiona Stanley Hospital Unit, Perth, Australia; 4 Park-Klinik Weensee Academic Hospital of the Charité, Department of Internal Medicine, Rheumatology and Clinical Immunology, Berlin, Germany; 5 Universitat de Barcelona, Instituto Poal de Reumatologia, Barcelona, Spain; 6 Università Politecnica delle Marche, Clinica Reumatologica, Jesi, Italy; 7 Hospital Universitario Severo Ochoa, Rheumatologia, Madrid, Spain; 8 Hospital of Bruno (SABES-ASDAA), Department of Rheumatology, Bruno, Italy; 9 University of Pisa, Rheumatology Unit, Pisa, Italy; 10 Clinical Division of Internal Medicine II, Medical University of Innsbruck, Department of Internal Medicine, Innsbruck, Austria; 11 Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway; 12 University of Oslo, Faculty of Medicine, Oslo, Norway; 13 University of Turin, Academic Rheumatology Centre, Department of Clinical and Biological Science, Turin, Italy; 14 Mid Yorkshire NHS Trust, Department of Rheumatology, Yorkshire, United Kingdom; 15 Hospital Universitario Fundacion Jimenez Diaz, Universidad Autonoma, Department of Rheumatology and Bone and Joint Research Unit, Madrid, Spain; 16 Immnuel Krankenhaus Berlin, Medical Centre for Rheumatology, Berlin-Buch, Germany; 17 Copenhagen University Hospital at Koge, Department of Rheumatology, Copenhagen, Denmark; 18 Ultrasound Center and Institute for Rheumatology, Basel, Switzerland; 19 The Chinese University of Hong Kong, Division of Rheumatology, Department of Medicine and Therapeutics, Hong-Kong, Hong Kong (SAR); 20 National Institute of Rheumatology and Physiotherapy, Department of Rheumatology, Budapest, Hungary; 21 Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rheumatology Unit, Roma, Italy

Background: Structural damage in rheumatoid arthritis (RA) includes bone erosion, cartilage change, and joint malalignment; historically evaluated with conventional radiography. Ultrasound (US) has been shown to be a valid tool for evaluating both cartilage change and bone erosion.

Objectives: To obtain agreement on definitions and develop semiquantitative scoring systems for assessing structural damage by US and to validate these in a web-based reliability exercise.

Methods: A Delphi survey of statements was prepared by an OMERACT US Working Group task force (USWG) based on a previously published systematic literature review (1) and circulated between group members, including definitions on normal US appearance of joint components, definitions of elementary lesions and scoring systems for bone erosions and joint malalignment. Definitions and a US scoring system for scoring cartilage damage were recently developed and validated by the USWG (2). After agreement was achieved (≥75% of grades 4-5 on 1-5 Likert scale) on the statements, still images of metacarpophalangeal and proximal interphalangeal joints 2-5 in healthy controls and in RA patients with varying degrees of pathology were acquired by the USWG members. A dataset of 100 anonymized images, representing various grades of the 3 components of structural damage was created and utilized in 2 rounds of a web-based exercise. Intra- and inter-reader reliability of the scoring systems was assessed by kappa statistics.

Results: 19 USWG members needed 4 Delphi rounds to reach agreement on a total of 9 statements. 4/12 statements were approved in the first, 2/6 in the second, 1/5 in the third and 2/2 in the fourth round. Final scoring systems and representative images are shown in Table 1 & Figure 1. 22 members participated in the web-based reliability exercise. The intra-reader reliability was almost perfect for bone erosion (kappa: 0.87) and cartilage change (kappa: 0.83) and substantial for malalignment (kappa: 0.72). The inter-reader reliability was almost perfect for bone erosion (kappa: 0.85) and cartilage change (kappa: 0.79) and substantial for malalignment (0.62).

Table 1. Final definitions of scoring systems of elementary lesions of structural damage in rheumatoid arthritis

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Definition</th>
<th>Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone erosion</td>
<td>A 4-grade semiquantitative scoring system can be used to score erosions as follows: grade 0. intact cortical bone; grade 1. single small erosion (diameter: &lt;2mm); grade 2. single large erosion (diameter: &gt;2mm) or 2 small erosions; grade 3. 2 large erosions or &gt;3 erosions, regardless of size. Both longitudinal and transverse scans should be considered, and the largest measure chosen for each erosion.</td>
<td>100%</td>
</tr>
<tr>
<td>Cartilage change</td>
<td>A 3-grade semiquantitative scoring system can be used to grade hyaline cartilage change as follows: grade 0. normal cartilage; grade 1. minimal change: focal thinning or incomplete loss of cartilage; grade 2. severe change: diffuse thinning or complete loss of cartilage.</td>
<td>80% (2)</td>
</tr>
<tr>
<td>Malalignment</td>
<td>A 3-grade semiquantitative scoring system can be used to grade malalignment as follows: 0. normal alignment; 1. subluxation or partial dislocation, where the two bone endings are malaligned so that one bone ending is dislocated from its normal position, but still within the articulation; 2. luxation or total dislocation, where the luxated bone ending moves beyond the articulation and the opposing bone ending. Bone position may be compared with a contralateral or similar intact joint if available.</td>
<td>94%</td>
</tr>
</tbody>
</table>

Conclusion: This first attempt to create a composite US instrument based on scoring systems encompassing all aspects of structural damage, demonstrates that US is a reliable tool for evaluating and scoring bone erosion, cartilage change and malalignment in the finger joints of RA patients.

REFERENCES:

Disclosure of Interests: Peter Mandl Speakers bureau: AbbVie, Janssen, Lilly, Novartis, Consultant of: AbbVie, Janssen, Lilly, Novartis, Grant/research support from: AbbVie, BMS, Novartis, Janssen, Lilly, MSD, UCB, Irina Gesell: None declared, Georgios Filipou: None declared, Silvia Sirotti: None declared, Lene Tesklev Speakers bureau: Novartis, Pfizer, UCB, Janssen, GE, Carlos Pineda: None declared, Helen Keen Speakers bureau: Roche, AbbVie, Janssen, Consultant of: Sanofi, Marina Backhaus: None declared, David Andrew Bong: None

Figure 1. Representative images of the scoring systems for bone erosion (A), cartilage change (B) and malalignment (C)
declared, Eduardo Cipolletta: None declared, PAZ COLLADO: None declared, Christian Dejaco Speakers bureau: Roche, AbbVie, Sanofi, Lilly, Pfizer, Novartis, Janssen, Galapagos, Consultant of: Roche, AbbVie, Sanofi, Lilly, Pfizer, Novartis, Janssen, Galapagos, Andrea Delles Sedie Speakers bureau: Abbvie, Amgen, Lilly, MSD, Novartis, UCB, Paid instructor for: Abbvie, Amgen, Lilly, MSD, Novartis, UCB, Consultant of: Abbvie, Amgen, Lilly, MSD, Novartis, UCB, Christina Dauther: None declared, Hilde Berner Hammer: None declared, Annamaria Iagnocco: None declared, Zunaid Karim: None declared, Ingrid Möller Speakers bureau: Bristol-Myers Squibb, Ibsa, Pfizer, Galapagos, Esperanza Naredo Speakers bureau: Abbvie, Pfizer, Lilly, Novartis, Janssen, Celgene GmbH, Paid instructor: Novartis, Consultant of: Novartis, Lilly, Grant/research support from: Lilly, Pfizer, Wolfgang A. Schmidt: None declared, Marc Szukliarek: None declared, Giorgio Tamborrini: None declared, Priscilla C Wong: None declared, Emilio Filipucci Speakers bureau: Abbvie, Amgen, Bristol-Myers Squibb, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Union Chimique Belge Pharma, Peter Balint Speakers bureau: Abbvie, Janssen, Lilly, Novartis, Maria-Antonieta DAgostino: None declared


OP0292 CLASSIFICATION OF PSORIATIC ARTHRITIS, SERONEGATIVE RHEUMATOID ARTHRITIS, AND SEROPOSITIVE RHEUMATOID ARTHRITIS USING DEEP LEARNING ON MAGNETIC RESONANCE IMAGING

L. Felle1, S. Bayat1, A. Kleyer2, F. Fagri3, L. Kapseen3, M. Schiereth4, T. Meenderink5, K. Brenning1, K. Tasclier2, G. Krönke3, M. Uder1, M. Sticherling2, S. Bickelhaupt3, G. Schett2, A. Maier1, F. Roemer3, D. Simon2
1University of Erlangen-Nuremberg, Computer Science, Erlangen, Germany; 2University Clinic Erlangen, Rheumatology, Erlangen, Germany; 3University Hospital Erlangen, Radiology, Erlangen, Germany; 4University of Erlangen-Nuremberg, Artificial Intelligence in Biomedical Engineering, Erlangen, Germany; 5University Clinic Erlangen, Dermatology, Erlangen, Germany

Background: While MRI evaluation of joints has been primarily used to quantify inflammation at a cross-sectional and longitudinal level, less is known about the potential of MRI in distinguishing different patterns of inflammation in the various forms of arthritis.

Objectives: To evaluate (i) whether deep learning using neural networks can be trained to distinguish between seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) based on structural inflammatory patterns on hand magnetic resonance imaging and (ii) to assess if psoriasis patients with subclinical inflammation fit into such patterns.

Methods: ResNet 3D [1] neural networks were trained to distinguish (i) RA+ vs. PsA, (ii) RA- vs. PsA and (iii) RA+ vs. RA- with respect to hand MRI data. Diagnosis of patients was determined using the following guidelines: ACR/EULAR 2010 [2] for RA and CASPAR [3] for PsA. Results from T1 coronal, T2 coronal, T1 coronal axial fat at suppressed contrast-enhanced (CE) and T2 fat suppressed axial sequences were used. The performance of such trained networks was analyzed by the area-under-the-receiver-operating-characteristic curve (AUROC) with and without imputation of demographic and clinical parameters (Figure 1A). Additionally, the trained networks were applied to psoriasis patients without clinical signs of PsA.

Conclusion: Deep learning can be successfully applied to differentiate MRI inflammatory patterns related to RA+, RA-, and PsA. Early changes in psoriasis patients can be recognized by neural networks and are characterized by a pattern that allowed the networks to classify them as PsA.

REFERENCES:

Acknowledgements: The study was supported by the Deutsche Forschungsgemeinschaft (DFG-FOR2886 PANDORA and the CRC1181 Checkpoints for Resolution of Inflammation). Additional funding was received by the Bundesministerium für Bildung und Forschung (BBMF; project MASCARA), the ERC Synergy grant 4D Nanoscope, the IML funded projects HIPPOCRATES and RTCure, the Emerging Fields Initiative MIRA-CLE of the Friedrich-Alexander-Universität Erlangen-Nürnberg and the Else Kröner-Memorial Scholarship (DS, no. 2019_EKMS.27). Furthermore, infrastructural and hardware support was provided by the d.hip Digital Health Innovation Platform.

Disclosure of Interests: None declared


OP0293 PHOTOREALISTIC DEPICTION OF RHEUMATIC PATHOLOGIES BY CINEMATIC RENDERING FACILITATES DISEASE UNDERSTANDING OF PATIENTS WITH RHEUMATIC DISEASES

M. Pachowsky1,2, H. Morf3, D. Simon1,2, V. Schönaus1,2, L. Valor3,2, J. Knitza1,3, K. Engel4, M. Uder1, A. Huerer1,4, G. Schett2,3, A. Kleyer2 "On behalf of https://www.medizin3.uk-erlangen.de/en/research/research-main-focus/research-group-pd-dr-a-kleyer-and-pd-dr-d-simon/

1University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany; 2Waldkrankenhaus Erlangen, Klinik für Orthopädie und Unfallchirurgie, Erlangen, Germany; 3Deutsches Zentrum Immuntherapie, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nuremberg, Erlangen, Germany; 4Siemens, Siemens Healthineers AG, Erlangen, Germany; 5University Hospital Erlangen, Institute of Radiology, Erlangen, Germany; 6Klinikum Nürnberg/Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Klinik für Innere Medizin 5, Rheumatologie, Nürnberg, Germany
Background: Treatment success of a rheumatic disease crucially depends on whether a patient is sufficiently informed about the disease[1]. Visual methods are suitable for explaining diseases[2]. Cinematic rendering (CR) is a new method that allows to segment standard medical images into images that illustrate disease pathologies in a photorealistic way. As such, CR provides new opportunities to visualize diseases and but could therefore be a valuable tool for patients with rheumatic and musculoskeletal disease (RMD)[3].

Objectives: We questioned, if it is possible to apply CR on images from structural lesions of patients with rheumatoid arthritis (RA), Psoriatic Arthritis (PsA) and axial Spondyloarthritis (axSpA) and to test whether such images are helpful to patients with RMDs to understand their disease process. application in doctor-patient communication.

Methods: We selected conventional computed tomography (CT) and high-resolution peripheral CT (HR-pQCT) from patients with rheumatoid arthritis (RA), Psoriatic Arthritis (PsA) and axial Spondyloarthritis (axSpA) that showed typical changes of the respective disease. HR-pQCT measurements were performed in RA and PsA at the Rheumatology Department. CT Measurements of the spine in an axSpA patient was provided from AH. All images were segmented to CR images using a prototype software by the manufacturer Siemens Healthineers. In a prospective study on consecutive patients with RA, PsA, axSpA these images were used to explain the depicted pathomoronic pathologies and compared to conventional imaging in a structured doctor-patient interview. In the last step, patients filled in a quantitative questionnaire (Likert Scale 1-5) about their perspectives answering following questions: Did you understand your disease in the provided Cinematic Rendering images? Did you understand your disease better through the presentation using Cinematic Rendering images than with a normal X-ray image? Do you think it would be reasonable to use this type of Cinematic Rendering to improve patients’ understanding of their disease? Descriptive statistical methods were used.

Results: CR images of rheumatic diseases were successfully generated from above mentioned imaging data (CT, HR-pQCT). Bone erosions, osteophytes, enthesiophytes, osteoporosis and anklylosis of the spine could be visualized in photorealistic detail. Figure 1 shows examples of a images of a patient with RA and axSpA with typical bone changes. 65 patients (23 RA/23 PsA/19 axSpA; f 55%) were guided through CR images of their respective disease by an experienced rheumatologist, followed by completing the questionnaire mentioned above. Patients stated that CR was very helpful to understand their disease process (4.39±0.15), that understanding diseases by CR was better than the one obtained by conventional radiographs (4.43±0.20) and that they considered such technology helpful for improving disease understanding (4.35±0.09).

Conclusion: CR seems to be a promising teaching tool for RMD patients facilitating an improved understanding of their disease process and in consequence my also improve adherence of RMD patients to their anti-rheumatic treatment.

REFERENCES:

Acknowledgements: Siemens Healthineers /Dr.Klaus Engel for providing CR expertise

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1463

OP0294 REDUCED JOINT SYNOVITIS ASSESSMENT VERSUS THE GLOBAL EULAR OMERACT SYNOVITIS SCORE (GLOESS) TO PREDICT THE RESPONSE TO SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: EXPLORATORY RESULTS FROM THE ULTIMATE TRIAL

M A Diogoeting1, M. Boers2, G. Schett3, P. G. Conaghan4, E. Naredo5, P. Mand6, P. Carron7, M. Backhaus8, A. López-Rodriguez9, P. Hanova10, P. Goyanka11, B. G. Sahoo12, C. Gai11le13, W. Bao14, Catholic University of Sacred Heart, Department of Rheumatology, Rome, Italy; 2Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Data Science, Amsterdam, Netherlands; 3FAU Erlangen-Nürnberg and Universitätssklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany; 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 5Hospital Fundación Jiménez Díaz and Autónoma University, Department of Rheumatology and Joint and Bone Research Unit, Madrid, Spain; 6Medical University of Vienna, Division of Rheumatology, Vienna, Austria; 7University Hospital Ghent, Department of Rheumatology, Ghent, Belgium; 8Park-Klinik Weissensee, Department of Internal Medicine-Rheumatology and Clinical Immunology, Berlin, Germany; 9PSQAPS Clinical and Research Psoriasis Center, Dermatologico Country, Guadalajara, Mexico; 10Institute of Rheumatology, Department of Experimental Rheumatology, Prague, Czech Republic; 11Novartis Healthcare Pvt Ltd, Clinical Project Management, Hyderabad, India; 12Novartis Healthcare Pvt Ltd, Biostatistics and Pharmacometrics, Hyderabad, India; 13Novartis Pharma AG, Immunology, Hepatology and Dermatology, Global Medical Affairs, Basel, Switzerland; 14Novartis Pharmaceuticals Corporation, Analytics- Global Medical Affairs, East Hanover, United States of America

Background: The combined use of B-mode ultrasound (US) and Power Doppler (PD; combination termed as PDUS) allows visualisation of morphological and pathophysiological changes of the synovium. ULTIMATE (NCT02662985) was the first large, randomised, double-blind, placebo-controlled PDUS phase IIb study in psoriatic arthritis (PsA), to demonstrate that Global OMERACT EULAR Synovitis Score (GLOESS), a US score at patient level, was sensitive to detect the early and continuous decrease in synovitis in a multicenter setting using different US devices and examiners. However, the US assessment for GLOESS was time-consuming owing to the number of joints assessed.

Objectives: To investigate the value of various reduced joint sets to predict the validated GLOESS score.

Methods: ULTIMATE was a 52-week study with a 12-week double-blind, placebo-controlled period followed by 12-week open-label (OL) treatment and 6-month OL extension period. In the ULTIMATE trial, GLOESS for the 24 paired joints was calculated, with a potential score ranging between 0 to 144. A Spearman’s rank correlation matrix and a Cluster Image Map were constructed to identify highly correlated joint clusters based on the composite PDUS scores. Based on the different approaches (best correlation, model optimization, etc.), representative joints were then selected from each group, which yielded several corresponding combinations of joints. Linear models were developed with these reduced joint sets as predictors of GLOESS, using data from 60% of patients randomly selected from the
ULTIMATE study. The remaining 40% data were used for model validation and diagnostics.

Results: Five models were established with reduced pairs of joint sets (9–13 pairs). The joints included in each linear model are summarized in Table 1.

All five models of reduced joint sets showed high correlation with GLOESS score of $R^2 \approx 0.95$. Figure 1 depicts all the 5 models of reduced joint sets demonstrating changes very close to that of validated GLOESS.

Table 1. Joints included across five linear models, indicated by green shading

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Elbow</td>
<td>MTP2</td>
<td>MTP1</td>
<td>MTP1</td>
<td>MTP1</td>
<td>MTP5</td>
</tr>
<tr>
<td>Knee</td>
<td>DIP4</td>
<td>DIP3</td>
<td>DIP2</td>
<td>DIP2</td>
<td>DIP5</td>
</tr>
<tr>
<td>MTP2</td>
<td>MCP5</td>
<td>MCP4</td>
<td>MCP4</td>
<td>MCP4</td>
<td>MCP4</td>
</tr>
<tr>
<td>MTP1</td>
<td>MCP2</td>
<td>MCP1</td>
<td>MCP1</td>
<td>MCP1</td>
<td>MCP1</td>
</tr>
<tr>
<td>MCP5</td>
<td>DIP5</td>
<td>DIP3</td>
<td>DIP3</td>
<td>DIP3</td>
<td>DIP3</td>
</tr>
</tbody>
</table>

N. number of joint pairs used in model. DIP, distal interphalangeal; MCP, metacarpophalangeal; MTP, metatarsophalangeal; PIP, proximal interphalangeal

Conclusion: All models of reduced joint sets for PDUS-detected synovitis predicted GLOESS well. The next steps will be to document responsiveness and ability to discriminate between active and placebo treatment.

REFERENCES:

Disclosure of Interests: Maria-Antonieta D’Agostino Speakers bureau: Abbvie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Janssen, Novartis, Roche, Sanofi, and UCB, Maarten Boers Consultant of: BMS, GSK, Novartis, Pfizer, Consultant of: BMS, GSK, Novartis and Pfizer, Georg Schett Speakers bureau: Abbvie, BMS, Celgene, Janssen, Lilly, Novartis, Roche and UCB, Philip G Conaghan Speakers bureau: Abbvie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Consultant of: Abbvie, AstraZeneca, BMS, Eli Lilly, Galapagos, Gilead, Novartis and Pfizer, Espe-ranza Naredo Speakers bureau: Abbvie, BMS, Celgene GmbH, Janssen, Lilly, Novartis, Pfizer, Roche, UCB, Grant/research support from: Honoraria for clinical trials from Abbvie, BMS and Novartis; Research Grants from Lilly; Peter Mandl Speakers bureau: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Grant/research support from: Abbvie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Roche and UCB., Philippe Carron Speakers bureau: Abbvie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Consultant of: Abbvie, Bristol Myers Squibb, Celgene Corporation, Eli Lilly, Gilead, Merck Sharp Dohme, Novartis, Pfizer, and UCB, Grant/research support from: Merck Sharp Dohme, Pfizer and UCB, Marina Backhaus Speakers bureau: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: BMS, Gilead, Jonsson, MSD, Novartis, Pfizer, Roche, UCB, Alejandro Lopez-Rodriguez Speakers bureau: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Consultant of: Eli Lilly, GSK, Janssen, Novartis, Roche and UCB, Petra Hanova: None declared, Punt Goyanka Employee of: Novartis, Braja Gopal Sahoo Employee of: Novartis, Corine Gaillez Shareholder of: Shareholder of Novartis and BMS, Employee of: Novartis, Webin Bao Employee of: Novartis.


Lifestyle and Disease activity in inflammatory arthritis

---

**OP0295-HPR**

THE EFFECT OF GROUP-BASED COGNITIVE BEHAVIOURAL THERAPY FOR INSOMNIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED TRIAL

K. M. Letocha1,2, K. Løppenthin1,4, M. Østergaard1,4, P. Jennum5, 5, M. L. Hetland1,4, H. Røgind6, T. Lundbak7, J. Midtgaard4,7, R. Christensen2,8; 1Department of Clinical Neurophysiology, Glostrup, Denmark; 2Copenhagen University Hospital - Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Glostrup, Denmark; 3Copenhagen University Hospital - Bispebjerg and Frederiksberg, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Copenhagen, Denmark; 4Copenhagen University Hospital - Rigshospitalet, Centre for Cancer and Organ Diseases, Department of Oncology, Copenhagen, Denmark; 5University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 6Copenhagen University Hospital - Rigshospitalet, Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Glostrup, Denmark; 7Copenhagen University Hospital - Bispebjerg and Frederiksberg, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Copenhagen, Denmark; 8Copenhagen University Hospital - Rigshospitalet, Centre for Cancer and Organ Diseases, Department of Oncology, Copenhagen, Denmark; 9University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 10Copenhagen University Hospital - Rigshospitalet, Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Glostrup, Denmark; 11Copenhagen University Hospital - Bispebjerg and Frederiksberg, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Copenhagen, Denmark; 12Copenhagen University Hospital - Rigshospitalet, Centre for Cancer and Organ Diseases, Department of Oncology, Copenhagen, Denmark; 13University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 14Copenhagen University Hospital - Rigshospitalet, Danish Center for Sleep Medicine, Department of Clinical Neurophysiology, Glostrup, Denmark; 15Copenhagen University Hospital - Bispebjerg and Frederiksberg, Section for Biostatistics and Evidence-Based Research, the Parker Institute, Copenhagen, Denmark.

**Table 1.** Primary and key secondary outcomes at week 7 and week 26, and differences between treatment groups (based on the ITT population)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>CBT-I n=31</th>
<th>Usual care n=31</th>
<th>Difference between groups (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>At week 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep efficiency (PSG, %)</td>
<td>88.7 (1.8)</td>
<td>83.7 (2.0)</td>
<td>5.0 (-0.4 to 10.4)</td>
<td>0.068</td>
</tr>
<tr>
<td>At week 26</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sleep efficiency (PSG, %)</td>
<td>84.8 (1.9)</td>
<td>86.3 (2.0)</td>
<td>-1.5 (-7.0 to 3.9)</td>
<td>0.577</td>
</tr>
<tr>
<td>Total sleep time (PSG, minutes)</td>
<td>376.5 (11.8)</td>
<td>394.8 (12.8)</td>
<td>-18.1 (-52.5 to 16.4)</td>
<td>0.392</td>
</tr>
<tr>
<td>Sleep onset latency (PSG, minutes)</td>
<td>14.2 (2.2)</td>
<td>10.0 (2.4)</td>
<td>4.2 (2.2 to 10.7)</td>
<td>0.197</td>
</tr>
<tr>
<td>Wake after sleep onset (PSG, minutes)</td>
<td>52.1 (10.7)</td>
<td>41.5 (11.6)</td>
<td>10.6 (-20.7 to 41.9)</td>
<td>0.505</td>
</tr>
<tr>
<td>Insomnia severity (ISI 0-28)</td>
<td>76.0 (7.7)</td>
<td>174.0 (7.7)</td>
<td>-98.0 (-118.0 to -78.0)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sleep quality (PSG 0-21)2</td>
<td>5.9 (0.5)</td>
<td>11.0 (5.0)</td>
<td>-5.2 (-6.6 to -3.8)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fatigue (BRADF-MQ 0-70)</td>
<td>24.0 (1.4)</td>
<td>36.4 (1.4)</td>
<td>-12.4 (-16.5 to -8.4)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RA impact of disease (RAID 0-10)</td>
<td>4.2 (0.2)</td>
<td>5.5 (0.2)</td>
<td>-1.4 (-1.9 to -0.80)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Depressive symptoms (HADS-D 0-21)</td>
<td>3.8 (0.5)</td>
<td>6.5 (0.5)</td>
<td>-2.7 (-4.1 to -1.3)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Values are reported as least squares means (standard errors) by group, while the differences between groups are reported with 95% confidence intervals. 1Polysomnography, 2Insomnia Severity Index, 3Pittsburgh Sleep Quality Index, 4Bristol Rheumatoid Arthritis Fatigue - Multidimensional Questionnaire, 5Rheumatoid Arthritis Impact of Disease, 6Hospital Anxiety and Depression Scale - Depression.
Background: Insomnia is highly prevalent in patients with rheumatoid arthritis (RA) and may exacerbate symptoms and burdens, such as fatigue, depressive symptoms, and pain. Cognitive behavioural therapy for insomnia (CBT-I) has been shown to produce positive effects on sleep in other clinical populations. However, CBT-I has not previously been investigated in patients with RA.

Objectives: The primary objective was to compare the effect of nurse-led group-based CBT-I to usual care on sleep efficiency, measured by polysomnography (PSG) immediately after the intervention (i.e. seven weeks after baseline) in patients with RA. Secondary objectives included comparing the longer-term effect of CBT-I on sleep and RA-related outcomes at 26 weeks' follow-up.

Methods: In a randomised controlled trial, using a parallel group design, the experimental intervention was six weeks' CBT-I, the control comparator was usual care. CBT-I was delivered face-to-face by a CBT-I trained nurse. The primary analyses were based on the intention-to-treat (ITT) population; missing data were statistically handled using repeated-measures linear mixed effects models adjusted for the level at baseline.

Results: The ITT population consisted of 62 patients (89% women), with an average age of 55 years (SD 10), DAS28-CRP of 3.4 (SD 1.0), Insomnia Severity Index (ISI) score of 18.9 (SD 4.4) and median Patient Global Assessment score of 55 (IQR 28;71). When primary outcome was measured by PSG at week seven, sleep efficiency was 88.7% in the CBT-I group, compared to 83.7% in the control group (difference: 5.0 [95% CI -0.4 to 10.4]; p=0.068) (See Table 1). Secondary outcomes measured by PSG had not improved at week 26 either. However, for all secondary sleep and RA-related patient-reported outcomes, there were statistically highly significant differences between CBT-I and usual care e.g. insomnia (ISI: -9.8 [95% CI -11.8 to -7.9]), RA impact of disease (RAID: -1.4 [95% CI -1.9 to -0.80]; and Patient Global Assessment (-13.0 [95% CI -20.9 to -5.1]) at 26 weeks' follow-up.

Conclusion: Nurse-led, group-based CBT-I for two hours per week for six weeks, did not improve objectively measured sleep efficiency or any other outcomes measured by PSG. However, CBT-I showed long-term improvement on patient-reported outcomes such as fatigue, impact of disease, depression, pain, and Patient Global Assessment – a finding that could have important clinical implications.

Acknowledgements: We thank the participants for their time and commitment and the patient research partners for valuable insight into the process and content of the trial.

Disclosure of Interests: None declared


Complexity of care in RMD: intersection between health and social care

Sjögren syndrome: from biopsy to lymphoma
score ≥ 1/4 mm²) corresponds to 3 scoring points out of 4 needed to reach a positive classification for SS [1]. Moreover, there is increasing evidence that salivary gland biopsy can provide prognostic information regarding systemic involvement and the development of lymphoma in the context of the disease.

**Objectives:** The aim of this study was to analyze the minor salivary gland (MSLG) biopsy findings of a large SS cohort and to examine their associations with disease specific laboratory markers, clinical and patient associated parameters.

**Methods:** We included all patients from two large rheumatological medical departments in Germany having undergone a diagnostic MSLG between 01/2010 and 12/2019. The data have been collected partly in a retrospective and party in a prospective manner. Next to the examination of histological results we focused on activity and chronicity parameters of the underlying disease, autoantibodies, presence of systemic and haematological involvement, as well as on current and previous comorbidities. The statistical analyses included sensitivity and specificity examinations via receiver operating characteristics (ROC), correlation analyses, Mann-Whitney-U-Tests and ANOVA.

**Results:** In total, 678 patients have been included (615 ♀, median age 55 years [47-63, IQR]), 306 patients (45.1%) had a positive focus score. The remaining 372 patients with a negative focus score served as a control group. There were significant correlations between the level of the focus score and nicotine use (p=0.002), hypergammaglobulinemia [1.27 [0.7-1.33, IQR] vs. 0.73 [0.0-0.76, IQR]; p=0.001], ANA positivity [1.18 [0.11-1.3, IQR] vs. 0.64 [0.1-1.34, IQR]; p<0.001] and rheumatoid factor positivity (p=0.001). Moreover, focus score levels correlated significantly with disease modifying antirheumatic treatment [1 [0-2.34, IQR] vs. 0.87 [0-1.8, IQR]; p=0.004] and weakly significantly with erythrocyte sedimentation rate (r=0.235, p=0.001).

Within the group of patients with primary SS there were significant correlations between the level of the focus score and presence of systemic involvement [2 (1.1 - 4, IQR) vs. 1.44 (1-2.62, IQR); p=0.015], glandular involvement [4 (2.98-6.2, IQR) vs. 0.72 (1-6.3, IQR); p=0.007] and haematologic manifestations (p=0.002). SSA-antibodies showed the best diagnostic performance compared to MSLG, as examined by ROC (Table 1).

**Table 1. Diagnostic value of SSA-antibodies, Sicca, Schirmer’s and Saxon’s test compared to minor salivary gland biopsy findings (reference focus score ≥ 1/4 mm²)**

<table>
<thead>
<tr>
<th></th>
<th>Specificity</th>
<th>Sensitivity</th>
<th>Area under the curve</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSA-Ro antibodies</td>
<td>88.2%</td>
<td>43.4%</td>
<td>0.658</td>
</tr>
<tr>
<td>Sicca</td>
<td>15%</td>
<td>91.9%</td>
<td>0.535</td>
</tr>
<tr>
<td>Schirmer’s test</td>
<td>27.3%</td>
<td>73%</td>
<td>0.507</td>
</tr>
<tr>
<td>Saxon’s test</td>
<td>57.3%</td>
<td>39%</td>
<td>0.541</td>
</tr>
</tbody>
</table>

Interestingly enough, among 159 patients who were admitted due to the diagnosis of primary fibromyalgia (FM), 63 (39.6%) could be diagnosed with SS on the basis of histologic findings and the ACR-EULAR classification criteria.

**Conclusion:** By examining one of the largest cohorts in the literature we could show that MSLG biopsy findings not only play a key role in the classification and diagnosis of SS, but could also provide important information regarding the presence of a systemic, glandular or haematological involvement. Furthermore, MSLG can help differentiate patients with FM and other chronic pain disorders from patients with subclinical SS who suffer primarily from chronic pain.

**REFERENCES:**

**Disclosure of Interests:** None declared


**OP0298-PARE**

**OP0299-HPR**

**Facilitating work participation – why and how?**

Enhancing research through patient involvement_____
Background: The Covid-19 pandemic has meant a modification of the patterns of the doctor-patient relationship, favoring online visits and reducing face-to-face visits. Likewise, the implementation of Patient-Reported Outcomes (PROs) that do not require the intervention of the doctor in our clinical practice and that given their close relationship with the clinical activity of chronic inflammatory joint diseases (CIJD) has favored an empowerment of patients and can allow the development of the online visit.

Objectives: Know the use and acceptance of patients with CIJD: rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthropathies (SpA) of a non-face-to-face online visit, through a digital environment.

Methods: Patients were included in a platform called Rheumanet for access by username and passwords (https://www.laconsolidadeterredes.com/). At the time of inclusion, demographic variables were collected: date of birth, sex, level of education (primary education, secondary education, vocational training, further education and higher education), distance from the hospital to the patient’s home, and clinical variables such as diagnosis: RA, PsA or SpA, as well as the duration of the disease. Prior to the appointment, patients were encouraged to complete a PRO survey to assess their clinical situation: Routine Assessment of Patient Index Data 3 (RAPID3) for RA, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for SpA and RAPID3 Index and/or BASDAI for the PsA. Both the RAPID3 and BASDAI were scored for the patient’s knowledge and assigned to a color scale based on disease activity in green (remission or low activity), orange (moderate activity) or red (severe activity). Likewise, they were ordered to express through a free text what they would tell us as if they were in a face-to-face consultation. Complementary tests (analytical, radiological studies and others) are obtained simultaneously from the medical records and a joint assessment of the visit is carried out.

Results: Between September 1, 2020 and January 31, 2022, a total of 248 patients (113 RA, 53 PsA and 82 PsA) were included in the platform. 172 (69.3%) patients used the digital platform and made at least one non-face-to-face visit during follow-up. The number of online visits made by each patient ranged from 1 to a maximum of 13 visits. 80 patients (70.7%) suffered from RA, 40 (75.4%) from PsA and 52 (63.4%) from PsA. The number of patients who made non-face-to-face visits was 38 (72.3%) for a disease duration of <5 years and 137 (64.5%) for >5 years. When the ages of the patients were analyzed, the number of patients who made visits was 75 (73.5%) between 18 and 30 years old, 50 (67.7%) between 30 and 50 and 47 (66.4%) from 50 years. According to the degree of activity of the disease, 75 patients were in remission or low activity at some point during the visits, 63 patients with moderate activity and 34 with severe activity. The distribution according to level of education was: 11 (6.3%) primary education, 21 (12.2%) secondary education, 37 (21.5%) vocational training, 63 (36.6%) further education and 40 (23.2%) higher education. The number of online visits was higher in patients who lived at a distance of 50 km or more from the hospital, reaching 100% of the visits in this subgroup of patients.

Conclusion: The online visit through a digital platform through PROs is well accepted by our population with CIJD, especially in the young population, with a higher cultural level and whose home is far from the hospital. The online visit was made by patients regardless of the severity of their disease activity. Speed and ease of use using PROs already known and their close relationship with the clinical activity of CIJD has favored an empowerment of patients and can allow the development of the online visit.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3887

Crystal arthritis

Disclosure of Interests: None declared
Digital-Health and Tailored Interventions for Improving Patients’ Adherence: Opportunities and Challenges

Methods: We systematically searched the following databases: Embase, PubMed, Cochrane Central, CINAHL, Web of Science, Clinicaltrials.gov, and the International Clinical Trials Registry Platform (ICTRP). Eligible articles reported adherence rates to eHealth tools in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), spondyloarthropathy (SpA), osteoarthritis (OA), and gout. Included texts were screened individually. Finally, quality assessment was done with the Newcastle-Ottawa scale (NOS) and the PEDro scale.

Results: The literature search resulted in 7027 articles. After deduplication, 4219 articles were screened for eligibility, and 47 articles were included. We found highest adherence rates in studies applying electronic diaries (81.8%), followed by text messages (79.9%), web-based platforms (74.6%), activity trackers (73%), and smartphone applications (65.5%). Highest adherence was reported in studies on patients with OA (79.7%), followed by patients with gout (73.7%), RA (71.3%), ankylosing SpA (67%), and JIA (59%). Demographic characteristics did not seem to affect patient adherence. Based on frequency of data entering, a time interval of once-daily showed highest adherence rates (72.6%), followed by entering data more than once a day (72.3%) and once a week (67.7%), or longer (59.2%). Adherence declined with longer study duration.

Conclusion: Our literature review identified declining adherence levels with longer study duration, and highest adherence rates for patients with OA, making use of electronic diaries, and requesting once-a-day completion. OA studies had an overall shorter duration than RA studies, which could be an explanation as to why OA studies had an overall higher adherence. Lower adherence rates were reported in studies on patients with chronic arthritis to eHealth tools.

Figure 1. Linear regression model of adherence based on study duration per disease. X = study duration (days); Y = adherence (%). Y = -0.0332X + 71.84. Light blue = RA, yellow = OA, dark blue = JIA, red = gout, green = SpA, white = >1 disease

Table 1. Included studies. Adh = adherence SA = smartphone app, ED = electronic diary, AT = activity tracker, OP = online platform, TM= text message. JIA= Juvenile Idiopathic Arthritis, PsA = Psoriatic Arthritis, SpA = Spondyloarthritis, OA = osteoarthritis, RA = Rheumatoid arthritis

---

Rheumatology across boundaries

Methods: AxSpA patients in the patient-based SPARTAKUS cohort study in southern Sweden (non-axSpA AxSpA [n=axSpA] n=86, ASAS criteria; AS n=168, modified New York criteria) self-reported their history of prior urolithiasis (no/yes). Faecal (F) calprotectin and ASCA (anti-Saccharomyces cerevisiae antibodies) in serum were measured by commercially available ELISAs (Calpro AS; ORGENTEC Diagnostika). For a subgroup of patients (n=164), presence of gut dysbiosis was also assessed by the OA-MAP Dysbiosis Test (Genetic Analysis). Demographics, disease/treatment characteristics, comorbid IBD and the gastrointestinal biomarkers (F-calprotectin/ASCA/dysbiosis) were compared between patients with versus without prior urolithiasis. Finally, the same biomarkers were also compared between patients with versus without urolithiasis history, after exclusion of subjects with known IBD.

Results: Urolithiasis history was reported by 13% (n=33) of the axSpA patients, and comorbid IBD was significantly more common in this group (27% versus 6.8%, p<0.001; Table 1). F-calprotectin levels were also significantly higher among patients with prior urolithiasis, as was presence of gut dysbiosis (Table 1). ASCA seropositivity did not differ between the groups. Moreover, prior urolithiasis was associated with longer disease duration and AS-phenotype. After exclusion of cases with comorbid IBD, urolithiasis history was reported by 10% (24 of 230 patients). F-calprotectin elevation ≥100 mg/kg remained significantly associated with urolithiasis history also in this population, while only being numerically increased when assessed as a continuous variable (p=0.053; Figure 1). Gut dysbiosis also remained associated with prior urolithiasis in the non-IBD population (56% [9 of 16 patients with prior urolithiasis] versus 30% [40 of 132 patients without], p=0.037), whereas ASCA status did not differ between the groups (data not shown).
Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>No, n=221</th>
<th>Yes, n=33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>115 (52%)</td>
<td>23 (70%)</td>
</tr>
<tr>
<td>Age, years</td>
<td>50 (13)</td>
<td>59 (12)*</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>25 (14)</td>
<td>31 (14)*</td>
</tr>
<tr>
<td>AS (versus nr-axSpA)</td>
<td>141 (64%)</td>
<td>27 (62%)*</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>15 (6.8%)</td>
<td>9 (27%)*</td>
</tr>
<tr>
<td>ASAS 3-month NSAID score</td>
<td>31 (40)</td>
<td>37 (48)</td>
</tr>
<tr>
<td>Ongoing bDMARD therapy</td>
<td>87 (39%)</td>
<td>16 (49%)</td>
</tr>
<tr>
<td>bDMARD therapy ever</td>
<td>113 (51%)</td>
<td>20 (61%)</td>
</tr>
<tr>
<td>ASAS-ESR</td>
<td>1.8 (1.0)</td>
<td>1.9 (0.8)</td>
</tr>
<tr>
<td>BASFI</td>
<td>2.0 (2.1)</td>
<td>2.7 (2.6)</td>
</tr>
<tr>
<td>BASMI</td>
<td>2.9 (1.5)</td>
<td>4.3 (2.1)*</td>
</tr>
<tr>
<td>F-Calprotectin, mg/kg</td>
<td>58 (97)</td>
<td>115 (176)</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>29 (49)</td>
<td>39 (152)</td>
</tr>
<tr>
<td>F-Calprotectin ≥100 mg/kg</td>
<td>28 (14%)</td>
<td>320 (2%)*</td>
</tr>
<tr>
<td>ASCA IgG ≥10 U/ml</td>
<td>12 (5.7%)</td>
<td>4 (13%)</td>
</tr>
<tr>
<td>Gut dysbiosis †</td>
<td>45 (21%)</td>
<td>10 (33%)</td>
</tr>
</tbody>
</table>

Mean (SD) or n (%) if not otherwise stated. † GA-Map Dysbiosis Test, dysbiosis index ≥3. *

Conclusion: The current results lend support to the hypothesis that the increased urolithiasis risk in axSpA may be driven by gut inflammation/pathology. Prospective studies are, however, needed to assess the causality.

REFERENCES:

Figure. Comparison of F-calprotectin levels (A) and share of patients with elevated F-calprotectin ≥100 mg/kg (B) between axSpA patients without known comorbid IBD versus with prior urolithiasis. Comparisons by Student t-test of Log10-transformed values (A) and Chi2-test (B), respectively. In the box-plots (A), lines represent medians, boxes 25th and 75th percentiles, whiskers 10th and 90th percentiles, and dots 5th and 95th percentiles.

Disclosure of Interests: Johan K Wallman Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Pfizer, Elisabeth Mogard Consultant of: Novartis, Jonas Sagard: None declared. Lars Erik Kristensen Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Mercck Sharp & Dohme, Novartis, Pfizer, UCB Pharma, Elisabeth Lindqvist: None declared, Tor Olloffson Consultant of: Eli Lilly, Merck Sharp & Dohme


The COVID-19 pandemic – what did we learn?

S. Trope1, R. M. Flipo2, ANDAR, Direction, Paris, France; 2Centre Hospitalier Universitaire de France, Department of Rheumatology, LILLE, France

Background: Has the COVID-19 crisis overwhelmed health democracy? This question may have arisen since extraordinary measures taken in response to the pandemic were developed almost exclusively by scientific expert committees. Citizens, patients, patient organizations, healthcare professionals, and even experts from these committees have recognized a lack of health democracy in the decision-making process regarding the COVID-19 response in France. Indeed, patient voices were barely heard during the early stages of the pandemic; yet inclusive dialogue is crucial for building trust and adherence to policy. Moreover, patients also need to be assisted in handling the overabundance of COVID-19 information, particularly misleading and false information, referred to as an “infodemic” by the WHO.

Objectives: To show a practical and effective application of health democracy in rheumatology through collaboration between patient associations and rheumatologists during the COVID-19 pandemic. To collect, select, analyze, and translate COVID-19 literature to provide rheumatoid arthritis (RA) patients with useful, convenient and quality educational materials that answer patients’ medical, scientific and daily life questions. This initiative is consistent with patient-centered COVID-19 response.

Methods: At the instigation of a patient association in October 2021, a working group was established to develop a COVID-19 patient education resource to meet the expectations and needs of RA patients. The working group consisted of health professionals and patients identified by the partner patient organization. A committee of rheumatologists checked the reliability and accuracy of the scientific and medical information. A committee of patients assessed materials’ relevance, readability, and understandability. Materials were written in lay language without distorting the meaning of the scientific data. The methodology is detailed in Figure 1.

Results: The document is available to download on www.polyarthrite-andar.com (number of unique visits on the webpage for the last version: 1176). A printed version was also provided directly to patients by rheumatologists. To provide up-to-date information, the brochure was updated 7 times between the first edition in January 2021 and the last version in August 2021. This last version included 49 questions. Each update was announced to all members of the patient organization in its monthly newsletter (number of newsletter’s subscribers: 1863; number of followers: Facebook=2632; Twitter=1382; Instagram=921; LinkedIn=590; Youtube=2907). The “MediCal” newsletter (number of newsletter’s subscribers: 1863; number of followers: Facebook=2632; Twitter=1382; Instagram=921; LinkedIn=590; Youtube=2907). The “Medical and scientific questions” section provided reliable and expert-reviewed information about the virus, protective measures, testing, vaccination, integrating RA specificities and medical, scientific and daily life questions. This initiative is consistent with patient-centered COVID-19 response.

Conclusion: This initiative demonstrates the benefits that can be achieved by greater collaboration between patients and healthcare professionals to address population health problems. The patient could be an active contributor in improving disease management of his peers. This patient education tool is a good example of the relevance of the motto of ‘nothing about us, without us’. The
OP0305-4 PARE 1 THE EMERGING EULAR NETWORK (EMEUNET) PEER-REVIEW MENTORING PROGRAM: TEN YEARS OF INNOVATIVE INITIATIVE.


Background: In 2012, the Emerging EULAR (European Alliance of Associations for Rheumatology) Network (EMEUNET) started a mentoring program in collaboration with the editorial board of top-leading journals in rheumatology, the Annals of the Rheumatic Diseases (ARD) and a few years later RMD Open, with the aim of improving peer reviewing skills of young researchers (mentees). In this program, now in its 6th edition, senior reviewers (mentors) critically discuss manuscripts submitted to ARD or RMD Open with mentees. At the end of the program, senior reviewers certify the capability of mentees to independently conduct a good quality review. The program is organized by members of the EMEUNET Peer Mentoring Subcommittee, including facilitating communication within the groups. Several strategies, such as face-to-face meetings and periodic videoconferences, were implemented recently, following the outcome of a previous survey among mentees.

Objectives: To assess the experienced benefits and challenges of the EMEUNET Peer Mentoring program of young rheumatologists and researchers and their mentors.

Methods: In November 2021, a survey was sent by email to mentors and mentees who successfully completed the first five editions of the program (launched between 2012 and 2019), asking for demographics, and potential benefits and challenges of the program. Felt change in peer-review skills before and after the program were rated on a scale from 0 (no skill) to 10 (perfect skill). Results were analysed descriptively.

Results: A response rate of 55% for mentors (11/20) and 43% for mentees (37/87) was obtained. Mentors had a mean(SD) age of 52(9.5) years, 64% were male and 7 different nationalities were included. Mentees had a mean age of 34(3.7), 43% were male and 16 nationalities were included. Mentees/mentors from all the editions were included, although recent editions were somewhat overrepresented. Almost all respondents said their overall experience with the program was positive (46/47), that the objectives of the peer-reviewing mentoring program were met (46/47) and that they would recommend the program to others (44/45).

Mentors indicated an initial average peer-review skill level of 5.2(1.8) for content and 4.2(1.9) for form, which improved by 2.7(1.3) points, respectively. Interestingly, improvement scores of the mentees paralleled those of mentors: content and form were initially rated at 4.9(1.7) and 5.1(1.8) and improved by 2.6(1.3) and 2.7(1.7), respectively. Nine out of ten mentors said the program had helped them improve their own skills (i.e., peer-reviewing, mentoring, and teaching). The number of peer reviews after completion of the program varied quite significantly between mentees (median 10, IQR 9.5-29). For most mentees, the number of peer-reviews stayed the same (18/32) or increased (12/32). Fifteen out of 32 respondents said they were invited as an independent reviewer for ARD and/or RMD Open after completion of the program. Potential benefits and challenges of the program are depicted in Figure 1. Added value mentioned by both mentors and mentees was the opportunity to contribute to high quality peer-review standards and improve their skills. Challenges reported by mentors were communication with mentees, short deadlines, and the program being time-consuming; challenges for mentees were the communication with their mentor, deadlines and insufficient clarity of the process.


How to review a manuscript

Figure 1. Rating of potential benefits and downsides of the program. X-axis: items of the survey; Y-axis: the number of respondents (10/11 mentors and 35/37 mentees).

Conclusion: After 5 editions over 10 years, the EMEUNET Peer-Review Mentoring Program continues to be a highly valued opportunity in the field of rheumatic diseases, as both mentors and mentees experience a significant impact on their skills. Areas for improvement were identified (e.g., communication, deadlines) and will be addressed in future editions.
Interstitial lung disease in RMDs.

## IMPACT OF INFLAMMATION ON INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS - AN ANALYSIS OF THE GERMAN BIOLOGICS REGISTER RABBIT

### Background
Ten percent of patients with prevalent rheumatoid arthritis (RA) develop an interstitial lung disease (ILD), which is associated with higher mortality (1). A previous study identified high/moderate disease activity, but not CRP, as a risk factor for RA-ILD (2).

### Objectives
To analyse whether systemic inflammation (CRP and ESR) and/or disease activity measured with a composite score (DAS28-ESR) are associated with the occurrence of ILD in patients with RA.

### Methods
Data from RA patients observed in the biologics register RABBIT until 10/2020 were included. Patients with incident ILD were selected as cases and matched 1:5 to controls using a modified risk-set sampling (controls had no ILD during the entire observation time). Matching criteria were age, sex, RA duration, date of enrolment and observation time. Odds ratios (OR) and 95% confidence intervals (CI) were computed by conditional logistic regression and adjusted for factors identified by a directed acyclic graph (DAG), namely smoking, rheumatoid factor (RF), chronic obstructive pulmonary disease, number of biologics until index date (date of ILD-diagnosis in cases, date after the respective observation time in controls) and mean glucocorticoid dosage (12 months prior index date). For the regression, CRP and ESR were log-transformed due to their skewed distribution, and missing values were addressed by multiple imputations (n=10).

### Results
Out of 19,148 RA patients enrolled since 2001, 133 patients with incident ILD were identified. Half of the ILDs were diagnosed by computed tomography (n=67), 8% by x-ray (n=10) and in 42% the method was unknown (n=56). At baseline, cases and controls had a mean age of 61 years, 68% were female, and mean RA disease duration was 9 years. Differences were observed in smoking status (59% ever smokers in cases vs. 48% in controls), RF positivity (84% vs. 72%) and the sum of comorbidities (means 3.1 vs. 2.3). During the 12 months prior to the index date, mean values of CRP and especially ESR were significantly higher in cases compared to controls. This difference was not observed for DAS28 (Figure 1, upper figures). Furthermore, more cases than controls were in a high inflammatory status, but not in at least moderate disease activity (Figure 1, lower figures). The adjusted regression analyses confirmed these results: CRP and ESR were significantly associated with incident ILD both at the time of diagnosis and in the 12 previous months, and results were even more pronounced with elevated CRP and ESR, which was not the case for DAS28 (Table 1).

### Conclusion
In contrast to other data, our analyses found that markers of systemic inflammation, but not the DAS28 composite score, are associated with the occurrence of incident ILD in patients with RA and can be predictors for the development of RA-ILD. Therefore, in a treat-to-target approach, rheumatologists should pay particular attention to controlling systemic inflammation.

### Acknowledgements
We would like to thank all mentors, EMEUNET and working group members that helped shaping the EMEUNET peer-reviewing program throughout the years, and the ARD and RMD Open journals for their kind and generous support.

### Disclosure of Interests
None declared.

### References
1. DOI: 10.1136/annrheumdis-2022-eular.1539
2. PMID: 30591251

<table>
<thead>
<tr>
<th>At index date</th>
<th>Crude OR (95% CI)</th>
<th>Adjusted OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP5 vs. CRP&lt;5</td>
<td>1.55 (1.25 – 1.92)</td>
<td>1.55 (1.24 – 1.94)</td>
</tr>
<tr>
<td>CRP5 vs. CRP&lt;5</td>
<td>2.43 (1.55 – 3.81)</td>
<td>2.41 (1.49 – 3.88)</td>
</tr>
<tr>
<td>ESR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR&gt;21 vs. ESR≤21</td>
<td>1.56 (1.22 – 2.00)</td>
<td>1.56 (1.21 – 2.01)</td>
</tr>
<tr>
<td>DAS28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28≥3.2 vs. DAS28&lt;3.2</td>
<td>1.17 (1.01 – 1.35)</td>
<td>1.16 (0.99 – 1.35)</td>
</tr>
<tr>
<td>DAS28≥3.2 vs. DAS28&lt;3.2</td>
<td>1.31 (0.86 – 1.99)</td>
<td>1.32 (0.85 – 2.06)</td>
</tr>
<tr>
<td>Within 12 months prior to index date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP5 vs. CRP&lt;5</td>
<td>1.41 (1.14 – 1.75)</td>
<td>1.38 (1.09 – 1.74)</td>
</tr>
<tr>
<td>ESR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR&gt;21 vs. ESR≤21</td>
<td>2.60 (1.59 – 4.27)</td>
<td>2.60 (1.54 – 4.41)</td>
</tr>
<tr>
<td>DAS28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28≥3.2 vs. DAS28&lt;3.2</td>
<td>1.65 (1.26 – 2.16)</td>
<td>1.69 (1.21 – 2.26)</td>
</tr>
<tr>
<td>DAS28≥3.2 vs. DAS28&lt;3.2</td>
<td>2.43 (1.53 – 3.86)</td>
<td>2.35 (1.45 – 3.81)</td>
</tr>
</tbody>
</table>

### Table 1. Results of the conditional logistic regression for the risk of ILD.
Results: In unadjusted analyses eight ACPA reactivities were found associated with PF development (p<0.05-0.001). The number of ACPA reactivities was related to PF development, both in crude and adjusted models (p<0.05 for both). In models concomitantly adjusted for the three SNPs (rs35705895, rs111521887 and rs2609255) respectively, in addition to mentioned adjustments the number of ACPA reactivities (p<0.05 for all three nmodels), Vim60-75 (p<0.05, in all three models), Fjb162–78 (72) (p<0.001-p<0.05) and F4-CIT-R (p<0.01-p<0.05) were all found significantly associated to PF development irrespective of the SNPs.

Conclusion: The development of PF in an inception cohort of RA patients was associated both with risk genes and, independently of the risk genes, the presence of certain ACPA, and the number of ACPA reactivities.

REFERENCES:

Acknowledgements: I have no acknowledgements to declare. The staff and patients at the departments of rheumatology in northern Sweden.

Disclosure of Interests: None declared

Keeping the "Dark clouds" away: Psychological distress and RMDs.

OP0308-HPR MORE THAN HALF OF RA PATIENTS WITH A LIFETIME HISTORY OF MOOD DISORDERS WERE ANXIOUS AND DEPRESSED DURING THE COVID-19 PANDEMIC: RESULTS FROM THE CANADIAN EARLY COHORT (CATCH) STUDY

S. J. Bartlett, O. Schiel, M. F. Valois, G. Boire, G. Hazlewood, C. Thorne, D. Tin, C. Hitchon, J. Pope, E. Keystone, L. Bessette, V. Bykerk on behalf of the CATCH Investigators. McGill University & McGill University Health Centre, Medicine, Montreal, Canada; McGill University Medicine, Montreal, Canada; University of Sherbrooke, Rheumatology, Sherbrooke, Canada; University of Calgary, Rheumatology, Calgary, Canada; CARE, Rheumatology, Newmarket, Canada; University of Manitoba, Rheumatology, Winnipeg, Canada; Western University, Rheumatology, London, Canada; RheumKey, Rheumatology, Toronto, Canada; Laval University, Rheumatology, Quebec City, Canada; Hospital for Special Surgery, Rheumatology, New York; United States of America

Background: A growing number of studies indicate the considerable mental health impacts of the prolonged COVID-19 pandemic in the general population as chronic stress is a risk factor for the development of depression and anxiety. Mood disorders are more prevalent in RA and a history of anxiety or depressive disorders increases the risk of recurrence in the future.

Objectives: To compare trends in prevalence of anxiety and depressive symptoms, prior to and during the COVID-19 pandemic in RA patients with and without a lifetime history of mood disorders.

Methods: Data were from RA patients diagnosed and treated for RA in rheumatology clinics across Canada enrolled in the Canadian Early Arthritis Cohort (CATCH) Study. We estimated monthly trends in prevalence of clinically significant levels of anxiety and depression (PROMIS Depression and Anxiety 4a score 55+) from all visits between Mar 2019 and Jan 2022 and compared monthly trends in anxiety and depression in the year prior to (Mar 2019- Feb 2020) and during the pandemic (Mar 2020 to Jan 2022) stratified by lifetime history of mood disorders.

Results: 4,148 visits were completed from Mar 2019 to Jan 2022 in 1,644 RA patients with a mean (SD) age of 60 (14) and disease duration of 6 (4) years. 73% were women, 84% white, 60% had completed some post-secondary education, and 77% were in CDAI REM/LDA at the visit closest to the start of pandemic. 253 (15%) reported a lifetime history of depression and 217 (13%) a lifetime history of anxiety; 8% reported prior treatment for either.

Patients with a history of mood disorders had higher levels of depression and anxiety prior to and during the pandemic compared with patients without a history of mood disorders (Table 1). Proportions were highest during COVID waves in all and were substantially higher and more variable in people with a previous history of mood disorders as compared to those without a history (Figure 1). While depressive symptoms peaked early in the pandemic, anxiety increased with each wave, peaking in Wave 3 (May-Jun 2021).

Table 1. Prevalence of depression and anxiety symptoms prior to and during the COVID-19 pandemic in RA patients with and without a history of mood disorders.

<table>
<thead>
<tr>
<th>Period</th>
<th>Depression</th>
<th>Anxiety</th>
</tr>
</thead>
<tbody>
<tr>
<td>N observations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prepandemic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3/19 - 2/20)</td>
<td>3527</td>
<td>621</td>
</tr>
<tr>
<td>Pandemic</td>
<td>3610</td>
<td>538</td>
</tr>
<tr>
<td>(3/20 - 1/22)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No history</td>
<td>21%</td>
<td>51%</td>
</tr>
<tr>
<td>Prior History</td>
<td>(14%-30%)</td>
<td>(29%-64%)</td>
</tr>
<tr>
<td>No History</td>
<td>22%</td>
<td>53%</td>
</tr>
<tr>
<td>Prior History</td>
<td>(15%-29%)</td>
<td>(33%-78%)</td>
</tr>
</tbody>
</table>

Figure 1. During the first 22 months of the COVID-19 pandemic, the proportion of patients with depression and anxiety increased in all groups. More than half of those with a history of emotional distress had clinically significant levels of depression and anxiety; proportions were highest during COVID waves in all and were substantially higher in people with previous history as compared to those without a history (see Figure 1). Whereas depressive symptoms peaked early in the pandemic, anxiety increased with each wave, peaking in Wave 3 (May-Jun 2021).

Conclusion: Symptoms of anxiety and depression were common in Canadian adults with RA prior to and after the onset of the COVID-19 pandemic. Whereas others have found that high levels of depression and anxiety occurred early in the pandemic but declined fairly rapidly in the general population, emotional distress was not attenuated over time in this large cohort of RA patients. Individuals reporting lifetime history of mood disorders were more than twice as likely to report anxiety and depression, with depression peaking early in the pandemic and anxiety growing with each successive wave in the first year. The results demonstrate the importance of applying a lifetime perspective as previous episodes of anxiety and depression may be an important marker of increased vulnerability and recurrence in RA patients, particularly during the pandemic.

REFERENCES:

Acknowledgements: CATCH is supported through unrestricted research grants from: Amgen and Pfizer Canada since 2007; AbbVie Corporation since 2011; Medexus since 2013; Sandoz Canada since 2019; Fresenius Kabi Canada since 2021 and Organon Canada since 2021. Previous funding from Janssen Canada (2011-16); UCB Canada and Bristol-Myers Squibb Canada (2011-18); Hoffman La Roche Limited (2011-21); Sanofi Genzyme (2016-17); Eli Lilly Canada (2016-20); Merck Canada (2017-21) and Gilead Sciences Canada (2020-21)

Disclosure of Interests: None declared

New lessons for rheumatology in genomics medicine.

OP0309 WES ANALYSIS OF RARE FAMILIES POINTS TO A PATHOGENIC ROLE FOR THE CGAS/STING-TYPE I IFN AXIS IN SSC

P. Maus, V. Smith, T. Du Four, M. Vanhuyse, B. Lauwers, N. Limaye, De Duve Institute, UCLouvain, Genetics of Autoimmune Diseases & Cancer (GEDI), Brussels, Belgium; Ghent University Hospital, Department of...
Rheumatology, Ghent, Belgium; 2Cliniques Universitaires Saint-Luc, UCLouvain, Rheumatology Department, Brussels, Belgium; 3Grand Hôpital De Charleroi, Rheumatology Department, Charleroi, Belgium. 4Institute of Experimental and Clinical Research, UCLouvain, Rheumatology Pole, Brussels, Belgium

Background: Systemic sclerosis (SSc) is a rare (prevalence ±20/100,000), chronic condition characterized by vascular, immunological and connective tissue abnormalities. Genetic factors contribute to disease, as evidenced by a 15-fold increased relative risk in relatives of patients. Case-control studies have identified numerous associated loci; the identification and functional validation of risk alleles has however been elusive. No monogenic or oligogenic causes of SSc have been demonstrated, likely due to the infrequency of familial clustering (≤1.6% of cases) in this disease. We are fortunate to have access to DNA samples from five such families, with two affected first-degree relatives each. To our knowledge the only series of its kind.

Objectives: The goal of our research is to identify and functionally validate genes that drive SSc pathogenesis in these families, thereby shedding light on fundamental disease mechanisms. In light of the apparent lack of a multi-gene-phenotypic effect, we hypothesize that SSc may be transmitted as a di/oligogenic trait in these families, with two-to-a-few genes acting together to cause disease.

Methods: Whole exome sequencing (WES) was performed on all available blood-DNA (Figure 1). We filtered for variants that are (a) shared by both affected individuals within each family, (b) absent-to-rare in the general population, and (c) predicted to affect protein function by multiple in silico tools. Candidate gene prioritization and pathway analysis is followed by in vitro testing of a subset of SSc-variants, to assess for their effects on protein function. Where two strong candidate genes are identified in the same family, in vitro validation of both variants will be followed by the generation of single- vs. double-knock-in mice, to test for di/oligogenic effects of variant combinations on SSc-related phenotypes.

Results: WES yielded 23-45 genes per family with variants that satisfied the above criteria. Prioritization of candidates was based on systematic annotation of all 180 genes for expression pattern, function, and potential impact of the SSc-variants. Our data suggest familial SSc is genetically heterogeneous, with little sharing of candidates between families. We therefore assessed for pathways represented in gene-lists from multiple families, and found that participants in the cGAS/STING - type II-IFN axis are identified in all (Figure 1). This would prove to be more demanding than we had expected. After the conference, we continued with the introduction of the app to new volunteers as well as sending information and updated instructions to existing app-users. We have found that the introduction of this new app has been quite a success. We now have a platform for easy and fast communication to and between all our volunteers, as well as access to relevant news and important information from the organization about their roles and tasks as volunteers.

Conclusion: We report, for the first time, WES analysis of a familial SSc series of unprecedented size for this rare disease. The identification of potential "driver" gene variants in cGAS/STING-type I IFN signaling regulators across all families points to an important pathogenic role for this pathway in SSc.

Disclosure of Interests: Pierre Maus: None declared, Vanessa Smith: None declared, Tessa Du Four: None declared, Marie Vanthuyne: None declared, Bernard Lauwerys Shareholder of: UCB Pharma, Employee of: Currently an employee of UCB Pharma, Nisha Limaye: None declared.


Volunteering for the RMD Community

AN APP FOR VOLUNTEERS IN DENMARK

J. Lange 1. The Danish Rheumatism Association, Department of Volunteers, Gentofte, Denmark

Background: The Danish Rheumatism Association wanted to improve its communication with and between its volunteers. We had an existing system that worked like a database of information, but our volunteers found it difficult and lacking the needed information. Furthermore, they wanted to be in closer contact with other volunteers with similar functions in the organization to be able to share ideas and learn from each other.

Objectives: We wanted to find a platform with which we could increase the connectivity between our volunteers across the organization as well as making existing information more accessible for them. We also wanted an easier way of contact to our volunteers that did not require them to use their e-mails.

Methods: First we identified the tasks we wanted our “solution” to solve. Then we decided that the ideal tool for this probably would be an App that supported the connectivity as well as a “database” with documents and instructions in which we could present important and useful information to our volunteers. We searched the marked for platforms and invited three companies to make a presentation on how their product could support our ideas and wishes.

Results: We found, that instructing such a large group of people all at once proved to be more demanding than we had expected. After the conference, we continued with the introduction of the app to new volunteers as well as sending information and updated instructions to existing app-users. We have found that the introduction of this new app has been quite a success.

Conclusion: We found that instructing such a large group of people all at once proved to be more demanding than we had expected. After the conference, we continued with the introduction of the app to new volunteers as well as sending information and updated instructions to existing app-users. We have found that the introduction of this new app has been quite a success.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2241
206 ﻿
LB0001

Scientific Abstracts
(Table 1). To Wk 16, pts with ≥1 TEAE, BKZ: 59.9%; PBO: 49.5%; ADA: 59.3%. SAE
rate low (1.6%; 1.1%; 1.4%). Most frequent (≥5%) AEs for all arms: nasopharyngitis
(9.3%; 4.6%; 5.0%), URTI (4.9%; 6.4%; 2.1%), increased ALT (0.7%; 0.7%; 5.0%).
Candida infections: 2.6%, 0.7%, 0%; no systemic candidiasis. 2 malignancies (BKZ:
basal cell carcinoma; PBO: breast cancer stage 1); no MACE, uveitis, IBD or deaths.

BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS
WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY
& SAFETY FROM BE OPTIMAL, A PHASE 3,
MULTICENTRE, RANDOMISED, PLACEBOCONTROLLED, ACTIVE REFERENCE STUDY

I. Mcinnes1, L. Coates2 3, R. B. M. Landewé4 5, P. J. Mease6, C. T. Ritchlin7,
Y. Tanaka8, A. Asahina9, L. Gossec10, A. B. Gottlieb11, R. B. Warren12, B. Ink13,
D. Assudani13, J. Coarse14, R. Bajracharya13, J. F. Merola15. 1University of
Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, United
Kingdom; 2University of Oxford, Nuffield Department of Orthopaedics,
Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom;
3
Oxford University Hospitals NHS Trust, Oxford Biomedical Research Centre,
Oxford, United Kingdom; 4Amsterdam Rheumatology & Clinical Immunology
Center, Department of Clinical Immunology & Rheumatology, Amsterdam,
Netherlands; 5Zuyderland MC, N/A, Heerlen, Netherlands; 6University of
Washington, Swedish Medical Center and Providence St. Joseph Health,
Seattle, United States of America; 7University of Rochester, Department of
Medicine, Rochester, United States of America; 8University of Occupational and
Environmental Health, The First Department of Internal Medicine, Kitakyushu,
Japan; 9The Jikei University School of Medicine, Department of Dermatology,
Tokyo, Japan; 10Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France;
11
The Icahn School of Medicine at Mt Sinai, Department of Dermatology, New
York, United States of America; 12The University of Manchester, Manchester
NIHR Biomedical Research Centre, Manchester, United Kingdom; 13UCB
Pharma, N/A, Slough, United Kingdom; 14UCB Pharma, N/A, Raleigh, United
States of America; 15Brigham and Women's Hospital, Harvard Medical School,
Boston, United States of America
Background: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A.
Objectives: Assess BKZ efficacy and safety vs PBO in bDMARD-naïve pts with
active PsA to Wk 24 of BE OPTIMAL.
Methods: BE OPTIMAL (NCT03895203) comprises 16 wks double-blind
PBO-controlled and 36 wks treatment-blind. Pts were ≥18 yrs, bDMARD-naïve,
with adult-onset, active PsA, ≥3 tender and ≥3 swollen joints. Pts randomised
3:2:1, subcutaneous BKZ 160 mg Q4W:PBO:adalimumab (ADA; reference arm)
40 mg Q2W. From Wk 16, PBO pts received BKZ 160 mg Q4W. Primary endpoint:
ACR50 at Wk 16.
Results: 821/852 (96.4%) pts completed Wk 16 and 806 (94.6%) Wk 24. Mean age
48.7 yrs, BMI 29.2 kg/m2; since diagnosis: 5.9 yrs; 46.8% male. BL characteristics
comparable across arms. Primary endpoint met (Wk 16 ACR50: 43.9% BKZ vs
10.0% PBO, p<0.001; ADA: 45.7%; Figure 1). All ranked secondary endpoints met
at Wk 16 (Table 1). As early as Wk 2, ACR20 was higher in BKZ vs PBO (27.1%
vs 7.8%, nominal p<0.001; ADA: 33.6%). Outcomes continued to improve at Wk 24

Conclusion: Dual inhibition of IL-17A and IL-17F with BKZ in bDMARD-naïve
pts with active PsA resulted in rapid, clinically relevant improvements in musculoskeletal and skin outcomes vs PBO. No new safety signals observed.1,2
REFERENCES:
Disclosure of Interests: Iain McInnes Consultant of: AbbVie, BMS, Boehringer
Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, Grant/research
support from: BMS, Boehringer Ingelheim, Celgene, Janssen, UCB Pharma, Laura
Coates Consultant of: AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene,
Domain, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer, and
UCB Pharma, Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer, and UCB Pharma, Grant/

Table 1. Wk 16 and 24 efficacy

Other endpoints

Ranked endpointsb

BL

ACR50 [NRI],
n (%)
HAQ-DI CfB [MI],
mean (SE)
PASI90d [NRI],
n (%)
SF-36 PCS CfB [MI],
mean (SE)
MDA [NRI],
n (%)
vdHmTSS CfB (subgroup)h
[MI], mean (SE)
vdHmTSS CfB [MI],
mean (SE)
ACR20 [NRI],
n (%)
ACR70 [NRI],
n (%)
PASI100d [NRI],
n (%)
TJC CfB [MI],
mean (SE)
SJC CfB [MI],
mean (SE)

Wk 16

PBO
N=281

BKZ
160 mg Q4W
N=431

ADA
40 mg
Q2W
N=140†

–

–

–

0.89
-0.04
–

0.82
-0.03
–

0.86
-0.05
–

36.9
-0.6
5
-1.8
15.67
(1.80)i
13.31
(1.56)l

38.1
-0.5
14
-3.2
15.56
(1.69)j
13.44
(1.47)m

37.6
-0.7
1
-0.7
17.39
(2.89)k
14.55
(2.44)n

–

–

–

–

–

–

–

–

–

17.1
-0.7
9.5
-0.4

16.8
-0.6
9
-0.3

17.5
-1.1
9.6
-0.6

Wk 24

PBO
N=281

BKZ
160 mg Q4W
N=431

ADA
40 mg
Q2W
N=140†

28
-10
−0.09
(0.03)
4
(2.9)e
2.3
-0.5
37
-13.2
0.36
(0.10)i
0.31
(0.09)l

189
(43.9)
−0.26
(0.02)
133
(61.3)f
6.3
-0.4
194
(45.0)
−0.01
(0.04)j
0
(0.04)m

64
-45.7
−0.33
(0.04)
28
(41.2)g
6.8
-0.8
63
-45
−0.06
(0.08)k
−0.03
(0.07)n

67
-23.8
12
-4.3
3
(2.1)e
−3.2
(0.7)
−3.0
(0.5)

268
(62.2)
105
(24.4)
103f
(47.5)
−10.0
(0.5)
−6.6
(0.3)

96
-68.6
39
-27.9
14
(20.6)g
−10.9
-1
−7.5
-0.6

p value
(BKZ vs
PBO)

PBO→
BKZ
BKZ
160 mg Q4Wa 160 mg Q4W
N=431
N=281

ADA
40 mg
Q2W
N=140†

101
(35.9)
−0.28
(0.03)
86
(61.4)e
6.2
-0.5
106
(37.7)

196
(45.5)
−0.30
(0.02)
158
(72.8)f
7.3
-0.4
209
(48.5)

66
-47.1
−0.34
(0.05)
32
(47.1)g
7.3
-0.8
67
-47.9

<0.001c

–

–

–

0.001c

–

–

–

<0.001o

175
(62.3)
53
-18.9
60
(42.9)e
−9.4
(0.7)
−6.8
(0.4)

282
(65.4)
126
(29.2)
122
(56.2)f
−11.5
(0.5)
−7.2
(0.3)

99
-70.7
42
-30
26
(38.2)g
−11.8
-0.9
−7.9
-0.6

<0.001
<0.001c
<0.001
<0.001c
<0.001

<0.001o
<0.001o
<0.001o
<0.001o

Randomised set. Interim results. †Reference arm; study not powered for statistical comparisons of ADA to BKZ or PBO. aPBO→BKZ pts received PBO to Wk 16, switched to BKZ 160 mg Q4W
through Wk 24 (8 wks BKZ); bResolution of enthesitis/dactylitis in pts with LEI>0/LDI>0 at BL pooled with BE COMPLETE (Wk 16 LEI=0 BKZ: 124/249 [49.8%], PBO: 37/106 [34.9%], p=0.008;
LDI=0 BKZ: 68/90 [75.6%], PBO: 24/47 [51.1%], p=0.002); cContinuous outcome p values calculated with RBMI data; dPts with PSO and ≥3% BSA at BL; en=140; fn=217; gn=68; hPts with hs-CRP
≥6 mg/L and/or bone erosion at BL; in=221; jn=357; kn=108; ln=261; mn=416; nn=131; oNominal, not powered for multiplicity.


Background: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by immune mediated chronic arthritis which often requires treatment with conventional synthetic or biologic disease-modifying antirheumatic drugs (cs or b-DMARDs).

Methods: This Phase 3 multicenter, double-blind, withdrawal, efficacy, and safety study, enrolled patients (pts) age 2 to <18 years with extended oligo- or poly-articular JIA, ERA, or PsA, per ILAR criteria, and an inadequate response to ≥1 cs and/or b-DMARDs (NCT03773978). There were 3 periods: a 2-week (wk) pharmacokinetic/safety assessment (PKS), a 12-wk open-label lead-in (OLLI), and an up-to 32-wk double-blind withdrawal (DBW). Dosage and safety were confirmed in the PKS and then pts, including those from the PKS, enrolled in the OLLI, receiving age-based, oral, on daily doses of baricitinib. Pts with a JIA-ACR30 response at wk12, end of OLLI, entered the DBW to be randomized 1:1 to continued baricitinib or newly started placebo (PBO) and remained until flare or up to wk32. Primary endpoint was time to flare during the DBW. Secondary endpoints included JIA-ACR30/50/70/90 response rates at wk12, and proportion of pts with a flare during the DBW. Survival curves were estimated using the Kaplan-Meier method.

Results: Of 220 pts enrolled, 29 participated in the PKS, 219 entered the OLLI, and 163 entered the DBW. The JIA-ACR30/50/70/90 response at wk12 was 76.3%/83.5%/46.1%/20.1%, respectively. During the DBW, time of flare was significantly shorter with PBO vs baricitinib (hazard ratio 0.54 [95% CI 0.34, 0.85], p<0.001; Figure 1). The proportion of pts with a flare during the DBW was significantly lower for baricitinib vs PBO (14 (17.1%) vs. 41 (50.6%), p<0.001). In the PKS and OLLI periods, 126 (57.3%) pts reported ≥1 treatment emergent adverse event (TEAE), while 6 (2.7%) reported ≥1 serious adverse event (SAE); Table 1. In the DBW, 38 (46.9%) and 54 (65.9%) pts reported ≥1 TEAE for PBO and baricitinib, respectively, whereas those with ≥1 SAE were 3 (3.7%) and 4 (4.9%). The mean wks of exposure was higher in baricitinib vs PBO (14 (17.1%) vs 41 (50.6%), p<0.001). In the PKS and OLLI periods, 54 (65.9%) pts reported ≥1 SAE. The mean wks of exposure was higher in baricitinib vs PBO (14 (17.1%) vs 41 (50.6%), p<0.001). In the PKS and OLLI periods, 54 (65.9%) pts reported ≥1 SAE. The mean wks of exposure was higher in baricitinib vs PBO (14 (17.1%) vs 41 (50.6%), p<0.001).

Table 1. Safety data

<table>
<thead>
<tr>
<th>Events, N (%)</th>
<th>PKS and OLLI (N=220)</th>
<th>Events, N (%)</th>
<th>DBW Placebo (N=81)</th>
<th>DBW Baricitinib (N=82)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinuations due to AEs</td>
<td>2 (0.9)</td>
<td>2 (2.5)</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>most common TEAEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>19 (8.6)</td>
<td>11 (12.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>14 (6.4)</td>
<td>3 (3.7)</td>
<td>9 (11.0)</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>12 (5.5)</td>
<td>3 (3.7)</td>
<td>6 (7.3)</td>
<td></td>
</tr>
<tr>
<td>URTI</td>
<td>11 (5.0)</td>
<td>3 (3.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>11 (5.0)</td>
<td>5 (12.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>6 (2.7)</td>
<td>3 (3.7)</td>
<td>4 (4.9)</td>
<td></td>
</tr>
<tr>
<td>Joint Destruction</td>
<td>1 (0.5)</td>
<td></td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>1 (0.5)</td>
<td>0</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>IJA</td>
<td>1 (0.5)</td>
<td>0</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal Chest Pain</td>
<td>1 (0.5)</td>
<td>0</td>
<td>1 (1.2)</td>
<td></td>
</tr>
<tr>
<td>Decreased Appetite</td>
<td>1 (0.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potential opportunistic infections</td>
<td>6 (2.7)</td>
<td>2 (1.0)</td>
<td>2 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Candida</td>
<td>1 (0.5)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>1 (0.5)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>URTI= Upper Respiratory Tract Infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Conclusion: Baricitinib significantly reduced time to and frequency of JIA flares in pts with JIA versus PBO, and improved JIA-ACR scores in the majority of pts with JIA versus PBO, and improved JIA-ACR scores in the majority of pts with JIA versus PBO.

Methods: Two single centre, investigator-blinded, RCTs were conducted in patients with RA or Psoriatic arthritis (PsA) on stable doses of MTX without prior COVID-19 (CTRI reg. no. MIVAC: I/ CTRI/2021/07/05468 & MIVAC II: CTRI/2021/07/035007). In MIVAC I, unvaccinated patients were randomised (1:1) to hold or continue MTX for two weeks after each dose of the vaccine. MIVAC II included patients who had continued MTX during the first dose of ChAdOx1 and were randomised (1:1) to hold or continue MTX for 2 weeks after the second vaccine dose. The primary outcome for both the trials was the anti-Receptor Binding Domain (RBD) antibody titres measured four weeks after the second vaccine dose (per protocol analysis). Secondary outcome was the flare rate, defined as an increase in disease activity scores (DAS28/cDAPSA) or physician intent to hike DMARDs.

Results: 250 patients were randomized for MIVAC I and 178 for MIVAC II and after due exclusions, 158 and 157 were eligible for analysis respectively (Fig-1). In MIVAC I, median anti-RBD titres were significantly high in the MTX hold group [2484 (1050-4388.8) versus 1147.5 (433.5-2360.3)], p<0.001 but the flare rate was higher in the hold group (20 (25%) versus 6 (8%) p=0.005) compared to continue group. In MIVAC II median anti-RBD titres were significantly high for the MTX hold group [2553 (1792-4823) versus 990 (356-2252), p=0.001] when compared to continue group but there was no difference in the flare rate between the groups [9 (11.8%) and 4 (7.9%), p=0.15] (Table 1). Both sets were parallel studies in similar population, MTX hold arms across both the trials were compared for anti-RBD titres and flare. There was no difference in the anti-RBD titres [p=0.2] between the groups. In MIVAC I, 29 (36.25%) patients had reported flare in 19 (either first or second dose, 10 for both doses) when compared to MIVAC II where only 9 (11.84%) patients had reported flare after the second dose (P <0.001).

Conclusion: Holding MTX after both the doses or only after the second dose of ChAdOx1 yields higher anti-RBD antibody titres as compared to continuing MTX. Comparing across the trials, holding MTX only after the second dose appears to be non-inferior to holding MTX after both doses of the vaccine with a lesser risk of flare.

REFERENCES:

Acknowledgements: Acknowledgments to all participating investigators, patients and their families.

Table 1. Baseline demographics and key results

<table>
<thead>
<tr>
<th>Variable</th>
<th>MIVAC I</th>
<th>MIVAC II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=80</td>
<td>N=78</td>
</tr>
<tr>
<td>Age (Median (IQR))</td>
<td>48 (38.5-53.3)</td>
<td>49 (39-59)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>73 (91.3)</td>
<td>75 (96.2)</td>
</tr>
<tr>
<td>RA (%)</td>
<td>69 (86.3)</td>
<td>69 (93.2)</td>
</tr>
<tr>
<td>PsA (%)</td>
<td>11 (13.8)</td>
<td>6 (8.1)</td>
</tr>
<tr>
<td>DAS28 (≥5.1)</td>
<td>2.7 (2.4-3.2)</td>
<td>2.6 (2.3-3.2)</td>
</tr>
<tr>
<td>cDAPSA (≥3.5)</td>
<td>2.3 (2-4.5)</td>
<td>2.5 (1.3-3.8)</td>
</tr>
<tr>
<td>Prednisolone (%)</td>
<td>29 (36.3)</td>
<td>23 (31.1)</td>
</tr>
<tr>
<td>MTX mg/week†</td>
<td>175 (10-25)</td>
<td>15 (10-20)</td>
</tr>
<tr>
<td>Anti-RBD antibody titre post second dose (IU/mL)</td>
<td>&lt;0.001</td>
<td>2484 (1050-4388.8)</td>
</tr>
<tr>
<td>flare (%)</td>
<td>20 (25)</td>
<td>6 (8)</td>
</tr>
<tr>
<td>Post first dose</td>
<td>19 (23.8)</td>
<td>10 (13.3)</td>
</tr>
</tbody>
</table>

All analysis as per protocol population. †Median (interquartile range); Mann Whitney test; % (N): Fisher Exact test. Bolded if p<0.05.
Disclosure of Interests: Anu Sreekanth: None declared, Tery Skaria: None declared, Sheha Joseph: None declared, Rashwith Umesh: None declared, Manju Mohanan: None declared, Aby Paul: None declared, Sakir Ahmed: Speaker bureau; Sakir Ahmed had received honorarium as speaker from Pfizer, Dr Reddy's, Cipla, and Novartis unrelated to this Comment, Pankti Mehta: None declared, Seena Oomen: None declared, Janet Benny: None declared, Justin George: None declared, Anagha Paulose: None declared, K Narayanam: None declared, Sanjana Joseph: None declared, Anuroopa Vijayan: None declared, Kaveer Nalianda: None declared, Padmanabha Shenoy: None declared.

DOI: 10.1136/annrheumdis-2022-eular.5121a

Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric Tyk2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

E Morand1 2, M Pike3, J T Merrill4, R Van Vollenhoven5, V P Werth6, C Hobar7, N Delev8, V Shah9, B Sharkey10, T Wegman11, I Catlett12, S Banerjee13, S Singhal15, M Monash Health, Department of Rheumatology, Victoria, Australia; 2Monash University, Clinical Sciences, Victoria, Australia; 3MedPharm Consulting, Rheumatology, Raleigh, United States of America; 4Oklahoma Medical Research Foundation, Clinical Projects in the Arthritis & Rheumatology Program, Oklahoma City, United States of America; 5Amsterdam University Medical Centers, Clinical Immunology and Rheumatology, Amsterdam, Netherlands; 6University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Dermatology, Philadelphia, USA; 7Bristol Myers Squibb, Immunology & Fibrosis Development, Princeton, United States of America; 8Bristol Myers Squibb, Rheumatology Clinical Development Team, Princeton, United States of America; 9Bristol Myers Squibb, Innovative Medicine Operations, Princeton, United States of America; 10Bristol Myers Squibb, Global Biometrics and Data Sciences, Princeton, United States of America; 11Bristol Myers Squibb, Clinical Sciences, Princeton, United States of America; 12Bristol Myers Squibb, Dermatology, Princeton, United States of America; 13Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America

Background: Tyrosine kinase 2 (TYK2) mediates signaling of Type I interferons, IL-23, and IL-12, key cytokines involved in lupus pathogenesis. Deucravacinib (DEUC) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action, distinct from Janus kinase (JAK) 1/23 inhibitors, and has shown efficacy in psoriasis and psoriatic arthritis.

Objectives: Assess efficacy and safety of DEUC in patients with active systemic lupus erythematosus (SLE).

Methods: This was a 48-week (wk), randomized, double-blind, placebo (PBO)-controlled, phase 2 trial (NCT03325287). Eligible patients met SLICC criteria, were seropositive (ANA/anti-dsDNA/anti-Sm), and had a SLEDAI-2K score ≥6 and ≥1 BILAG index A or ≥2 BILAG B manifestations from the musculoskeletal, skin, or mucocutaneous domain. Patients on standard background medications were randomized 1:1:1:1 to PBO or DEUC 3 mg BID, 6 mg BID, or 12 mg QD. Oral corticosteroid tapering to 7.5 mg/day was required from wks 8-20; further tapering was optional from wks 32-40. The primary endpoint was the proportion of patients achieving SRI(4) at wk 32. Key secondary endpoints at wk 48 included SRI(4), BICLA, CLASI-50, and change from baseline in active (tender and swollen) joint count.

Results: A total of 363 patients were randomized, with baseline demographic and disease characteristics similar across treatment groups. Of randomized patients, 75% (76%) completed 48 wks of treatment. The primary endpoint at wk 32 was met, with significantly greater proportion of patients in DEUC 3 mg BID and 6 mg BID groups vs PBO achieving SRI(4) responses (PBO: 34.4%; DEUC 3 mg BID: 58.2%; P=0.0006; DEUC 6 mg BID: 49.5%; P=0.021; DEUC 12 mg QD: 44.9%; P=0.076). SRI(4) response was sustained across all DEUC groups up to 48 wks (Figure 1). At wk 48, the DEUC 3 mg BID group demonstrated statistical significance in BICLA, BILDA, CLASI-50, and active joint count, and the two other DEUC groups demonstrated clinically meaningful differences vs PBO (Figure 1). Rates of adverse events (AEs), serious AEs, and AEs of interest were similar between DEUC and PBO groups (Table 1). Most common AEs (≥10%) with DEUC were upper respiratory tract infection, nasopharyngitis, headache, and urinary tract infection. No deaths, major cardiac events, thrombotic events, systemic opportunistic infections, or active tuberculosis occurred. Malignancies were rare with similar rates across all groups. No meaningful abnormalities in mean levels of hematometry and chemistry laboratory parameters were observed.

Figure. Summary of key efficacy results

<table>
<thead>
<tr>
<th>AE, n(%)</th>
<th>Placebo</th>
<th>DEUC 3 mg BID</th>
<th>DEUC 6 mg BID</th>
<th>DEUC 12 mg QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 90</td>
<td>n = 91</td>
<td>n = 93</td>
<td>n = 89</td>
<td></td>
</tr>
<tr>
<td>AE</td>
<td>79 (87.8)</td>
<td>85 (93.4)</td>
<td>81 (87.1)</td>
<td>75 (84.3)</td>
</tr>
<tr>
<td>SAE</td>
<td>11 (12.2)</td>
<td>7 (7.7)</td>
<td>6 (6.6)</td>
<td>7 (7.9)</td>
</tr>
<tr>
<td>AEs leading to treatment</td>
<td>3 (3.3)</td>
<td>8 (8.8)</td>
<td>6 (6.5)</td>
<td>11 (12.4)</td>
</tr>
<tr>
<td>Discontinuation</td>
<td>Skinn-related AEs</td>
<td>12 (13.3)</td>
<td>15 (16.5)</td>
<td>32 (34.4)</td>
</tr>
<tr>
<td>Overall infections/ infestations</td>
<td>48 (53.3)</td>
<td>60 (65.9)</td>
<td>60 (64.5)</td>
<td>45 (50.6)</td>
</tr>
<tr>
<td>Infections of interest</td>
<td>1 (1.1)</td>
<td>1 (1.1)</td>
<td>2 (2.2)</td>
<td>1 (1.1)</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>4 (4.4)</td>
<td>3 (3.3)</td>
<td>3 (3.2)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Influenza</td>
<td>1 (1.1)</td>
<td>3 (3.3)</td>
<td>5 (5.4)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>COVID-19</td>
<td>3 (3.3)</td>
<td>3 (3.3)</td>
<td>5 (5.4)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>MACE</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Thrombotic events</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

*In is the number of patients who experienced an event. †Includes (≥8.6% in any arm) acne, rash, dermatitis acrocinematous, pruritus, skin lesion; urticaria. ‡Includes herpes zoster, herpes ophthalmicus, genital herpes zoster. ††Breast cancer, breast cancer, breast cancer, breast cancer, breast cancer. AE, adverse event; COVID-19, coronavirus disease 2019; DEUC, deucravacitinib; MACE, major adverse cardiac events; SAE, serious adverse event.

Conclusion: In patients with active SLE, DEUC showed statistically significant and sustained clinical efficacy in SRI(4), improvement across multiple composite and organ-specific measures up to 48 wks, and was well tolerated. DEUC shows promise as a novel therapy for SLE and warrants further investigation in phase 3 trials.

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julianne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Bristol Myers Squibb. The authors acknowledge Christina Crater, MD, who was employed by Bristol Myers Squibb at the time the study was conducted, for contributions to study conduct.

Disclosure of Interests: Eric Morand Consultant of: AstraZeneca, Bristol Myers Squibb, Biogen, Eli Lilly, EMD Serono, Genentech, Servier, and Novartis; Grant/ research support from: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Biogen, Eli Lilly, EMD Serono, Genentech, Janssen, and UCB; Marilyn Pike Consultant of: AstraZeneca, Bristol Myers Squibb, and Pfizer, Joan T. Merrill Consultant of: UCB, GlaxoSmithKline, AbbVie, EMD Serono, Renegen, Celgene/Bristol Myers Squibb, AstraZeneca, Amgen, Janssen, Lilly, Genentech, Aurinia, Astellas, Alexion, Sanofi, Zenas, and Prevention; Grant/research support from: GlaxoSmithKline and AstraZeneca; Ronald van Vollenhoven Consultant of: UCB, Pfizer, AbbVie, AstraZeneca, Biogen, Biotest, Celgene, Galapagos, Gilead, Janssen, Servier, Paid instructor for: Roche, Pfizer, Speakers bureau: UCB, Pfizer, AbbVie, Galapagos, Janssen, Grant/research support from: Bristol Myers Squibb, GlaxoSmithKline, Eli Lilly, UCB, Victoria P. Werth Consultant of: Celgene; Medimmune, Resolve, Genentech, Idera, Janssen, Lilly, Biogen, Bristol Myers Squibb, Gilead, Amgen, Medscape, Nektar, Incyte, EMD Serono, CSL Behring, Principa, Crisalis, Viela Bio, Argenx, Kirin, AstraZeneca, AbbVie, GSK, AstraZeneca, Cuge, UCB, Concept, Beacon Bioscience, Grant/research support from: Celgene, Janssen, Biogen, Gilead, AstraZeneca, Viela, Amgen, Lupus Research Alliance/BMS; Coburn Hobar Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Nikolay Delev Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Vaishali Shah Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Brian Sharkey Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Thomas Wegman Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Ian Catlett Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Subhashis Banerjee Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Shaalabh Singhal Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb

DOI: 10.1136/annrheumdis-2022-eular.5020a
Table 1. Efficacy results at week 12.

<table>
<thead>
<tr>
<th>Group</th>
<th>Placebo</th>
<th>Olarabrutinib 50 mg</th>
<th>Olarabrutinib 80 mg</th>
<th>Olarabrutinib 100 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>14</td>
<td>14</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>SLEDAI-2K NS</td>
<td>5 (35.7%)</td>
<td>7 (50.0%)</td>
<td>8 (61.5%)</td>
<td>9 (64.3%)</td>
</tr>
<tr>
<td>Treatment difference vs. PBO (%)</td>
<td>14.3%</td>
<td>25.8%</td>
<td>28.6%</td>
<td></td>
</tr>
</tbody>
</table>

Note: All evaluable patients at week 12 efficacy data were included in the efficacy analysis.
achieving clinical remission vs the comparator arm (16.7% vs 29.3%; HR 0.56; 95% CI 0.38–0.90; P=0.0158). The comparator arm required more additional GCs vs the SAR arm, mainly due to PMR flare (median difference in actual and expected cumulative dose 199.5 mg vs 0.0 mg; P=0.0189). The cumulative GC toxicity index scores numerically favored SAR but the difference was not statistically significant. PMR activity scores improved in the SAR arm vs the comparator arm (LS mean -15.57 vs 10.27, nominal P=0.0002). Patient reported outcomes (eg, physical and mental health component scores, disability index, etc) favored SAR (Figure 1). Incidence of treatment-emergent AEs (TEAEs) was numerically higher in the SAR arm vs the comparator arm (94.9% vs 84.5%) and included neutropenia (15.3%) and arthralgia (15.3%) in the SAR arm, and insomnia (15.5%) in the comparator arm. Conversely, the frequency of serious AEs was higher in the comparator arm vs the SAR arm (20.7% vs 13.6%). No deaths were reported.

### Table 1. Demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SAR + 14 wk GC taper (n=60)</th>
<th>Placebo + 52 wk GC taper (n=58)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median years (range)</td>
<td>69 (51–88)</td>
<td>70 (52–88)</td>
</tr>
<tr>
<td>Sex (female), n (%)</td>
<td>45 (75.0)</td>
<td>37 (63.8)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>50 (83.3)</td>
<td>48 (82.8)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>1 (1.7)</td>
<td>2 (3.4)</td>
</tr>
<tr>
<td>Not reported</td>
<td>9 (15.0)</td>
<td>8 (13.8)</td>
</tr>
<tr>
<td>PMR duration (diagnosis date to baseline),*</td>
<td>292 (78–3992)</td>
<td>310 (86–2764)</td>
</tr>
<tr>
<td>Any prior disease modifying anti rheumatic drugs, n (%)</td>
<td>5 (8.3)</td>
<td>10 (17.2)</td>
</tr>
<tr>
<td>CRP (mg/L), median (range)</td>
<td>6.8 (0.5–38.2)</td>
<td>5.7 (0.1–62.3)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate (mm/h), median (range)</td>
<td>25.0 (2.0–115.0)</td>
<td>22.0 (5.0–85.0)</td>
</tr>
</tbody>
</table>

*SAR n = 54; comparator n= 50.

**Conclusion:** SAR + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients, including clinically meaningful improvement in quality of life. Safety was consistent with the known safety profile of SAR.

**REFERENCES:**

[3] Lally 2016,

**Acknowledgements:** Medical writing support was provided by Vijay Kadoshi of Sanofi and funded by Sanofi.

**Disclosure of Interests:** Bhaskar Dasgupta Consultant of: Sanofi, Roche Chugai, Speakers bureau: Roche Chugai, Cipla, Grant/research support from: Sanofi, Roche, Abbvie, Sebastian Unizony Consultant of: Sanofi, Kiniksa, Janssen, Grant/research support from: Genentech, Kenneth J Warrington Paid instructor for: Chemocentryx, Grant/research support from: Eli Lilly, Kiniksa, GSK, Jennifer Sloane Larson Employee of: Sanofi, Angeliki Giannelou Shareholder of: Regeneron, Employee of: Regeneron, Chad Nivens Shareholder of: Regeneron, Employee of: Regeneron, Bolanie Akinlade Shareholder of: Regeneron, Employee of: Regeneron, Wanling Wong Employee of: Sanofi, Yong Lin Employee of: Sanofi, Frank Buttgerit Consultant of: Sanofi, Horizon Pharma, Roche, Galapagos, Abbvie, Novartis, Grant/research support from: Sanofi, Horizon Pharma, Roche, Galapagos, Abbvie, Novartis, Valerie Devauchelle-Pensec; None declared, Andrea Rubbert-Roth Consultant of: Sanofi, Speakers bureau: Sanofi, Roche, Robert Spiera Consultant of: Sanofi, GSK, Novartis, Chemocentryx, Roche-Genetech, Abbvie, Vera, Grant/research support from: GSK, Chemocentryx, Corbus, Inflax, Boehringer Ingelheim

**DOI:** 10.1136/annrheumdis-2022-eular.5004a
Challenges in measuring and predicting RMDs

CAN SINGLE IMPUTATION TECHNIQUES FOR BASDAI COMPONENTS RELIABLY CALCULATE THE COMPOSITE SCORE IN AXIAL SPONDYLARTHRITIS PATIENTS?


Background: In axial spondyloarthritis (axSpA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a key patient-reported outcome. However, one or more of its components may be missing when recorded in clinical practice.

Objectives: To determine whether an individual patient’s BASDAI at a given timepoint can be reliably calculated with different single imputation techniques and to explore the impact of the number of missing components and/or differences between missings of individual components.

Methods: Real-life data from axSpA patients receiving tumour necrosis factor inhibitors (TNFi) from 13 countries in the European Spondyloarthritis (EuroSpA) Research Collaboration Network were utilized [1]. We studied missings in BASDAI component-based on simulations in a complete dataset, where we applied and expanded the approach of Ramiro et al. [2]. Using three different single imputation techniques: possible middle value (i.e. 50) of the component and mean and median of the available components. Differences between the observed (original) and calculated scores were assessed and corrected classification of patients as having BASDAI<40 mm was additionally evaluated. For the setting with one missing component, differences arising between missing one of components 1-4 versus 5-6 were explored. Finally, the performance of imputations in relation to the values of the original score was investigated.

Results: A total of 19,894 axSpA patients with at least one complete BASDAI registration at any timepoint were included. 59,126 complete BASDAI registrations were utilized for the analyses with a mean BASDAI of 38.5 (standard deviation 25.9).

Calculating BASDAI from the available components and imputing with mean or median showed similar levels of agreement (Table 1). When allowing one missing component, >90% had a difference of ≤6.9 mm between the original and calculated scores and >95% were correctly classified as BASDAI<40 (Table 1). However, separate analysis of components 1-4 and 5-6 as a function of the BASDAI score suggested that imputing any one of the first four BASDAI components resulted in a level of agreement <90% for specific BASDAI values while imputing one of the stiffness components 5-6 always reached a level of agreement >90% (Figure 1, upper panels). As expected, it was observed that regardless of the BASDAI component set to missing and the imputation technique used, correct classification of patients as BASDAI<40 was less than 95% for values around the cutoff (Figure 1, lower panels).

Table 1. Level of agreement between the original and calculated BASDAI and correct classification for BASDAI<40 mm

<table>
<thead>
<tr>
<th>Component</th>
<th>Level of agreement with Dif≤6.9 mm (%)</th>
<th>Correct classification for BASDAI&lt;40 mm (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 missing component</td>
<td>Available: 93.9</td>
<td>Value 50: 73.9</td>
</tr>
<tr>
<td>2 missing components</td>
<td>Available: 83.7</td>
<td>Value 50: 40.7</td>
</tr>
<tr>
<td>3 missing components</td>
<td>Available: 71.9</td>
<td>Value 50: 28.1</td>
</tr>
</tbody>
</table>

*The levels of agreement with a difference (Dif) of ≤6.9 mm between the original and calculated scores were based on the half of the smallest detectable change. Agreement of >90% was considered as acceptable. **Correct classification of >95% was considered as acceptable.

Conclusion: BASDAI calculation with available components gave similar results to single imputation of missing components with mean or median. Only when missing one of BASDAI components 5 or 6, single imputation techniques can reliably calculate individual BASDAI scores. However, missing any single component value results in misclassification of patients with original BASDAI scores close to 40.

REFERENCES:

Acknowledgements: Novartis Pharma AG and IQVIA for supporting the EuroSpA collaboration.

Disclosure of Interests: Stylianos Georgiadis Grant/research support from: Novartis, Myriam Ryen Research support from: Novartis, O. Polysopoulos Grant/research support from: Novartis, Almut Scherer Grant/research support from: Novartis, Daniela Di Giuseppe: None declared, Gareth T. Jones Speaker’s bureau: Janssen, Grant/research support from: AbbVie, Pfizer, UCB, Amgen, GSK, Merete Lund Heland Grant/research support from: Abbvie, Biogen, BMS, Celtrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Fonden, MSD, Medac, Pfizer, Novartis, Sandoz, Sanofi, UCB, Consultant of: Abbvie, BMS, Boehringer-Ingleheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi, UCB, Consultant of: Abbvie, BMS, Boehringer-Ingleheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck.
Background: The rheumatoid arthritis impact of disease score (RAID) is a patient-reported outcome measure to evaluate the impact of rheumatoid arthritis (RA) on patients’ quality of life (1). While an adapted instrument has been developed for psoriatic arthritis (2), there are no comparable instruments for other inflammatory rheumatic diseases. Since the RAID includes generic questions on pain, functional capacity, fatigue, physical and emotional well-being, sleep disturbances and coping, it could be an informative instrument beyond RA.

Objectives: To analyse the performance of the RAID in ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), polymyalgia rheumatica (PMR), primary Sjögren’s syndrome (pSS), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) compared to RA.

Methods: From 2015 to 2019, a total of 12,398 patients reported the RAID in the National Database of the German Collaborative Arthritis Centres. We calculated the age- and sex-adjusted partial correlation (0.3-0.5 weak, 0.5-0.7 moderate, > 0.7 strong correlation) between the RAID score and five other patient- or physician-reported outcomes, namely patient global (PtGl) health status, PtGl disease activity, physician global (PhGl) disease activity, the World Health Organisation Well-Being Index (WHO-5), and the EuroQoL-5 Dimensions (EQ-5D). Furthermore, for each of the diagnoses the mean difference between the RAID and the other outcomes was compared with the respective differences for RA. The EQ-5D and WHO-5 were rescaled to match the scale of the RAID.

Linear regression model: The dependent variable is the difference between RAID score and five respective outcomes. Independent variables were sex, age and diagnosis with RA as the referent category. An effect of a diagnosis was defined as clinically relevant if the mean change of difference was at least one unit.
RAID (range 0-10). General linear regression was used to assess the age- and sex-adjusted effect of each diagnosis on the difference between the RAID and the other scores with RA as the referent diagnosis. We defined the effect of a diagnosis as clinically relevant if the mean change of difference was at least one unit.

Results: The mean RAID score in RA (3.6) was lower than in AS (4.0) and SSc (3.8) and higher than in SLE, PMR, pSS, IIM (Table 1). Across all diagnoses, the RAID correlated strongly with PtGl health status (0.72 to 0.83), moderately to strongly with PtGl disease activity (0.55 to 0.78) and WHO-5 (0.67 to 0.83), moderately with the EQ-5D (0.61 to 0.68), and weakly with PtGl disease activity (0.25 to 0.41). Small mean differences were found between the RAID and either PtGl disease activity (0 to -0.6), PtGl health status (-0.4 to -0.9) or WHO-5 (-0.7 to -1.3). A higher deviation was observed for EQ-5D (1.1 to 1.7) and PtGl disease activity (1.4 to 2.2). However, the discrepancies between the five outcomes and the RAID turned out to be similar across all diagnoses and, more importantly, comparable to RA. Linear regression revealed no clinically relevant effect of any of the diagnoses on the difference between RAID and the other outcomes (Figure 1).

Conclusion: The RAID score performed comparably well across all diagnoses investigated. These findings support the use of the RAID for measuring the impact of disease not only in RA, but also in AS, SLE, PMR, pSS, IIM and SSc.

REFERENCES:
[1] PMID: 21540201
[2] PMID: 24790067

Acknowledgements: We thank all participating rheumatologists and patients for their valuable contributions.

The National Database of the German Collaborative Arthritis centers is supported by the Association of Regional Cooperative Rheumatology Centres, the German Society for Rheumatology and joint contributions to the Rheumatological Training Academy and the German Rheumatism Research Centre by the following members of the Working Group of Corporate Members of the German Society for Rheumatology: AbbVie, AstraZeneca, BMS, GALAPAGOS, GSK, Lilly, Medac, MSD, Pfizer, Sanofi-Aventis and UCB.

Disclosure of Interests: Katja Thiele: None declared, Katinka Albrecht: None declared, Angela Zink: None declared, Martin Aringer: None declared, Kirsten Karberg: None declared, Susanna Spaethling-Mestekemper Speakers bureau: BMS, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Sanofi, UCB, Consultant of: AbbVie, Gilead, Glaxo, GSK, UCSB, Novartis, Ulrich von Hinüber: None declared, Johanna Callhoff Paid instructor for: Rheumatologische Fortbildungsakademie GmbH, Grant/research support from: Abbvie, AstraZeneca, BMS, GALAPAGOS, GSK, Lilly, Medac, MSD, Pfizer, Sanofi, UCB


POS0003 DEVELOPMENT AND VALIDATION OF A DISEASE SPECIFIC PATIENT REPORTED OUTCOME FOR GIANT CELL ARTERITIS

J. Robson1, C. Almeida1, J. Dawson1, A. Dures1, R. Greenwood1, C. Guly2, S. Mackie1,2, A. Bromhead3, S. Stern4, M. Nedosi1, University of the West of England - UWE Bristol, Health and Social Wellbeing, Stoke Gifford, United Kingdom; 1University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Infirmary, Bristol, United Kingdom; 2University of Oxford, Old Road Campus, Department of Public Health, Oxford, United Kingdom; 3University of Leeds, Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 4Leeds General Infirmary, Leeds Biomedical Research Centre, Leeds, United Kingdom

Background: Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents and biologics to control inflammation and protect sight.

Objectives: The aim of this study was to produce a validated disease specific PROM for patients with GCA, to capture the impact of GCA and its treatment on health-related quality of life.

Methods: Patients with clinician-confirmed GCA from the UK, either diagnosed in the last three years or with a flare in the last year, were included in the survey. A long form of 40 candidate GCA-Specific Items, each with a 5-point Likert scale, had previously been developed, based on a qualitative study with patients from the UK and Australia [1]. In this cross-sectional survey, patients completed the 40-item draft GCA-PROM alongside EQ5D-5L, CAT-PROS and self-report of GCA disease activity. Rasch and factor analysis were used in an iterative manner to determine the underlying construct validity of the new PROM. Items were fitted to the Rasch model to determine its construct validity, reliability, unidimensionality and statistical sufficiency of the total score from the scale. Factor analysis was used to establish certainty structure. Item reduction decisions were based on clinical importance, lack of fit to the Rasch model, and redundancy detected during principal component analysis. External validity was tested by comparing the scores of the newly validated GCA-PROM (i) in participants who self-identify as having active disease versus patients in remission (known groups validity) (ii) with scores derived from EQ5D-5L and CAT-PROS (convergent validity).

Results: The survey included 428 patients; 327 (76%) cranial GCA, 114 (26.6%) temporal artery ultrasounds, and 51 (11.9%) Positron Emission Tomography and Computed Tomography (PET-CTs) were reported as positive. 108 (25%) received second-line immunosuppressants, and 34 (7.9%) anti-IL-6 therapy. Active disease was reported in 197 (46%). Four factors (domains) were identified after deletion of 10 redundant items: Acute symptoms (8 items), Activities of daily living (7 items), Psychological (7 items) and Participation (8 items). The four domains were analysed as ‘super-items’ and shown to fit the Rasch model. The overall scale had an adequate fit to the Rasch model: $X^2 = 25.219$, DF=24, p=0.394 including reliability PSI=0.828. The raw-to-linear transformation scale was calibrated to enable parametric analyses if desired. Each domain was shown to have known-groups validity (p<0.001 patients reporting active versus inactive disease) and correlation with EQ5D-5L and CAT-PROS (Rs) ranging between 0.42 and 0.778.

Conclusion: The GCA-PROM is a new patient reported outcome measure for patients with GCA which demonstrates good internal and external validity.

REFERENCES:

Disclosure of Interests: Joanna Robinson Speaker: EULAR 2021 Symposium, Consultant of: Vifor Pharma Advisory board 2021, Grant/ research support from: Vifor Pharma StorPro grant, Celia Almeida: None declared, Jill Dawson: None declared, Emma Dures: None declared, Rosemary Greenwood: None declared, Catherine Guly: None declared, Sarah Mackie Speakers bureau: Roche/Chugui Educational talk on GCA, Consultant of: Roche/Chugui Sanofi

Azbviv (2021-)
AstraZeneca (2021-), Grant/research support from: Vifor Pharma StorPro 2020

Roche GCA Tolcizumab Registry 2019, Alison Bromhead: None declared, Steve Stern: None declared, Mwimidii Nedosi: None declared


POS0004 WHAT DOES WORSENING IN DAPSA DISEASE ACTIVITY MEAN FOR PATIENTS WITH PSORIATIC ARTHRITIS? AN ANALYSIS OF 222 PATIENTS

M. Souca1, J. S. Smolen1, C. Gorlier1, M. de Wit1, L. Coates1, U. Kalyoncu1, A. Ryusse-Witrand1, K. Leung1, R. Scrivo1, J. D. da Cañete1, P. Palominos1, S. Meisalu1, A. Balanescu1, U. Kiltz1, S. Aydin1, I. Gaydukova1, E. Demis1, B. Fautrel1, A. M. Orbai1, E. Lubrano1, L. Gosses1 on behalf of the ReFlap Study Group. Paris, ReFlap Study Group, Paris, France
Background: In psoriatic arthritis (PsA), disease activity states have been defined using the DAPSA (Disease Activity index for Psoriatic Arthritis) score (1). The disease activity states have been validated using structural progression as the gold standard (2). However, the worsening in DAPSA states has not been compared to the patient’s perspective.

Objectives: To assess the association between a worsening in disease activity (i.e., change in DAPSA disease activity category) versus the patient’s judgement of disease worsening.

Methods: ReFlap (NCT03119805) was a longitudinal study in 14 countries of consecutive adult patients with definite PsA and more than 2 years of disease duration. Patients were seen twice in the context of usual care, around 4 months apart (3). Worsening in disease activity between the 2 visits was defined as a transition to a more active disease category, based on the DAPSA categories ([remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA)] (1). This change was compared to (a) patient perceived-flares collected according to a patient-reported question: “At this time, are you having a flare of your psoriatic arthritis, if this means the symptoms are worse than usual?”; and (b) a worsening according to the MCID (Minimal Clinical Important Difference) question. The agreement between the definitions of worsening were calculated by frequency, Cohen’s kappa and prevalence adjusted bias adjusted kappa (PABAK). There was no imputation of missing data.

Results: Overall, 222 patients were analyzed: 127 (58.8%) were male, aged 53.5±12.3 years and with 10.8±8.3 years of disease duration. Disease activity was moderate: 35.9% had no current psoriasis skin lesions, mean tender joint count (TJC, 0-68) was 3.0±7.5, mean swollen joint count (SJC, 0-66) was 1.6±6.6, and mean DAPSA was 11.5±14.0. At 4.5±2.2 months follow-up, the proportion of DAPSA worsening was 40.1% [95% confidence interval, 33.9-46.7] (n=89). Most of the changes corresponded to patients going from remission to LDA (N=24, 27.0% of worsened patients) or from LDA to MDA (N=24, 27.0%).

Patient-reported flares were reported in 27.0% [21.6-33.2] (n=60), and MCID worsening was reported in 14.0% [33.9-46.5] (n=31). Figure 1 shows the distribution of patients with worsening in DAPSA category versus patient-defined worsening. Of the 89 patients who worsened according to DAPSA categories, 41 (46.1%) had self-perceived flares and 20 (22.5%) had worsening according to MCID. Among patients who worsened in DAPSA category, the mean change in DAPSA was higher in patients with self-perceived flares (increase of 14.3±12.3) compared with either patient flare or MCID worsening were 0.34 [0.21-0.46] (0.40) and 0.16 [0.05-0.27] (0.28), respectively.

Conclusion: After 4 months of follow-up, 40.1% patients with long-standing PsA had a change in DAPSA category corresponding to more active disease. Most of these changes reflected transitions from remission to LDA, or from LDA to MDA. Among patients changing DAPSA category, only 46.1% reported themselves in flare at the second visit and only 22.5% reported themselves as worsened by MCID, leading to only fair (for flares) to low (for MCID worsening) agreement between the assessments of worsening. It is important to assess both disease activity, and the patient’s perspective of flare.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1493

POS0055

BASELINE BIOMARKERS PREDICT BETTER RESPONSES TO DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS

O. Fitzgerald1, D. D. Gladman2, P. J. Mease3, J. S. Smolen4, L. Gao5, S. Hu5, M. Nowak6, S. Banerjee7, I. Catlett8, 9Conway Institute, University College Dublin (UCD), Rheumatology, Dublin, Ireland; 2University of Toronto, Rheumatology, Toronto, Canada; 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, United States of America; 4University of Rochester Medical Center, Allergy Immunology, and Rheumatology, Rochester, United States of America; 5Medical University of Vienna, Rheumatology, Wien, Austria; 6Bristol Myers Squibb, Immunoscience and Small Molecule, Princeton, United States of America; 7Bristol Myers Squibb, Bioinformatics, Princeton, United States of America; 8Bristol Myers Squibb, Clinical R&D, Princeton, United States of America; 9Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America; 10Bristol Myers Squibb, Dermatology, Princeton, United States of America

Background: Deucravacitinib (DEUC) is a novel, oral, selective TYK2 inhibitor with a unique allosteric mechanism of action that has demonstrated efficacy in patients with psoriasis (PsO) (1) and psoriatic arthritis (PsA). TYK2 mediates signalling of select immune cytokones, eg, interleukin (IL) 23, IL-12, and Type I interferons, whereas the related Janus kinases (JAK) 1/2/3 mediate signalling of a wider array of cytokones and mediators involved in inflammatory, developmen- tal, metabolic, and hematopoietic pathways. DEUC reduced inflammatory markers associated with skin and joint manifestations but did not result in laboratory abnormalities associated with injection of JAK1/2/3 in a PsA trial. (2)

Objectives: To identify baseline biomarkers that predict response to DEUC in patients with PsA.

Methods: The double-blind Phase 2 trial (NCT03881059) enrolled 203 patients with PsA randomised 1:1:1 to placebo (PBO), DEUC 6 mg once daily (QD), or 12 mg QD. Molecular profiling of baseline serum samples was performed by immunocassays, Clinical response at Week 16 was measured by ≥20% improvement from baseline in American College of Rheumatology Improvement Criteria (ACR) 20 and ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI) 75 scores.

Results: Biomarkers of the IL-23/T helper cell type 17 pathway, including IL-17A, IL-17–induced β-defensin 2 (BD2), and IL-19, were associated with higher PASI 75 responder group. When patients were dichotomised by median baseline biomarker level, higher clinical responses in both PASI 75 and ACR 20 were achieved in those with higher baseline overall biomarker levels in the DEUC-treated groups compared with the PBO group. Baseline expression of IL-23 biomarkers IL-17A, IL-19, and BD2 enriched ACR 20 response in patients treated with DEUC compared with PBO (OR=5.64, 6.68, and 4.99, respectively). While greater benef- it was observed in high-biomarker groups, the low-biomarker populations still manifested clinical responses although not significant (Figure 1).

Conclusion: Patients who had higher expression of IL-23 pathway biomarkers were more likely to benefit from DEUC compared with placebo in skin and joint manifestations of PsA. These results reinforce the value of TYK2 inhibition in patients with IL-23–mediated diseases. The potential value of IL-23-pathway markers in predicting higher responses to DEUC should be further explored in larger trials.

REFERENCES:
Acknowledgements: This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julianne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Parnippany, NJ, USA, and funded by Bristol Myers Squibb.

Disclosure of Interests: Oliver FitzGerald Consultant of: Consulting and/or speaker fees: Biogen, and Novartis, Grant/research support from: Research grants: BMS, Novartis, Pfizer, UCB, Lilly, Dafna D Gladman Consultant of: Consulting fees: AbbVie, Amgen, BMS, Galapagos, Gilead, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Philip J Mease Consultant of: Consulting and/or speaker fees: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Christopher T. Ritchlin Consultant of: Consultant: AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, Regeneron, Sun, UCB., Grant/research support from: Grants / Research Support: AbbVie, Amgen, UCB, Josef S. Smolen Consultant of: Consulting and/or speaker fees: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos-Gilead, Janssen, Merck-Sharpe-Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, and UCB, Grant/research support from: Research grants: AbbVie, AstraZeneca, Eli Lilly, Novartis, Lu Gao Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Sarah Hu Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Miroslava Nowak Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Subhashis Banerjee Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb., Ian Catlett Shareholder of: Bristol Myers Squibb., Employee of: Bristol Myers Squibb., Miroslava Nowak Shareholder of: Bristol Myers Squibb., Employee of: Bristol Myers Squibb, Ole-Christina Schranaja1, Jürgen Schmitt1, M. K. Brun1, K. K. Jørgensen3, N. Bolstad6, S. W. Syversen1.

Background: Ankylosing spondylitis (AS), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are distinct diseases with common molecular features such as an imbalance in fibrosis and fibrolysis and calciﬁed tissues. Type III, IV and VI collagens are abundant in connective tissue, and type I, II and X of the skeletal tissue. Blood biomarkers are available to measure ﬁbrolysis (C1M, C2M, C3M, C4M, C6M, C10C) and ﬁbrosis (PRO-C1, PRO-C2, PRO-C3, PRO-C4, PRO-C6) of these collagens.

Objectives: To proﬁle AS, PsA and SLE patients (pts) using blood biomarkers of collagen formation and degradation.

Methods: Baseline serum samples from consenting pts of the AS (NCT02437162/ NCT02438787), PsA (NCT0315828), and SLE (NCT02349061) studies were included in the analyses. Healthy donor samples were acquired from Discovery LS. Biomarkers were measured by immunoassays. Biomarker levels were compared by Kruskal-Wallis test. Before hierarchical clustering (Ward.D2), biomarker levels were log-transformed and standardized by median centering and scaling by median absolute deviation (MAD).

Results: When compared with healthy individuals, VICM was elevated in all indications (although markedly less so in SLE pts). The ﬁbrolysis marker PRO-C3 was elevated in all indications vs. healthy, while PRO-C4 and PRO-C6 were elevated only in AS and PsA. The ﬁbrolysis markers C3M, C4M and C6M were elevated in all indications. The cartilage ﬁbrolysis marker PRO-C2, but not C2M, was elevated in AS and PsA, but not in SLE, ps. The bone ﬁbrolysis marker PRO-C1 was at the level of healthy for all. The ﬁbrolysis marker C1M was elevated in all, while elevated C10C was seen only in PsA and SLE, pts (Table 1). Four clusters (C) of blood markers were extracted (Figure 1). C1 was characterized by low biomarker levels (68% of healthy, 1% of PsA, 3% of SLE pts). C2 was described by high levels of C10C and median levels of VICM (20% of healthy, 12% of AS, 19% of PsA, 42% of SLE pts). C3 was described by median biomarker levels (8% of healthy, 67% of AS, 48% of PsA, 46% of SLE pts). C4 had high biomarker levels (4% of healthy, 21% of AS, 31% of PsA, 9% of SLE pts).

Conclusion: Fibrosis and ﬁbrolysis blood biomarkers were signiﬁcantly elevated in AS, PsA and SLE pts. Subsets of pts from each indication were found in clusters with either low (C1/2), median (C3) or high (C4) levels of ﬁbrolysis/ﬁbrosis biomarkers. These ﬁndings may provide a ﬁrst step towards precision medicine for guiding the use of anti-inﬂammatory vs. anti-ﬁbrotic treatments in pts with rheumatological disorders.

Fig. Radar plot showing medians of standardized biomarker levels by cluster.

Table. Patient group description and ﬁbrolysis/ﬁbrosis biomarkers (ng/ml) in healthy and AS, PsA or SLE pts.


Background: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been suggested to predispose to anti-drug antibody formation (ADA), but characterization of biologically relevant HLA haplotypes, based on high-resolution genotyping, is lacking.

Objectives: To assess associations between HLA loci and formation of ADA to infliximab across different immune mediated inflammatory diseases.

Methods: Patients with immune mediated inflammatory diseases on infliximab therapy (N=612; 181 spondyloarthritis, 120 rheumatoid arthritis, 72 psoriatic arthritis, 114 ulcerative colitis, 80 Crohn’s disease and 45 psoriasis) participating in the Norwegian Drug Monitoring (NOR-DRUM) trials (1, 2), were included in the present analyses. Neutralising ADA were assessed with an automated fluorescence assay at each infusion. Next generation sequencing-based HLA typing was performed. Associations with ADA formation were assessed at locus, allele, haplotype and amino acid level. Peptide binding predictions for infliximab were performed.

Results: ADA were detected in 147 patients (24%). Significant associations were shown between ADA and several HLA loci, whereas conditional analyses indicated HLA-DQB1 (p=1.4x10−6) as the primary risk locus. Highest risk of ADA formation was seen for patients carrying at least one of the HLA-DQ2 haplotypes; DQB1*02:01–DQA1*05:01 and DQB1*02:02–DQA1*02:01 (OR 3.18, 95% CI 2.15 to 4.69, p=5.9x10−9) (Figure 1). These findings were consistent across different diagnoses (Table 1), and remained significant when adjusting for other possible predictors of ADA. Computational predictions indicated that both these HLA-DQ2 haplotypes could strongly bind two peptide motifs (INTVESEDI and VYACE-)

Table 1. HLA-DQ2 carrier frequencies according to the different disease phenotypes and for all diagnosis combined

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>HLA-DQ2 carrier-frequency among patients with ADA formation</th>
<th>HLA-DQ2 carrier-frequency among patients without ADA formation</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA (N=120)</td>
<td>0.316</td>
<td>0.134</td>
<td>0.02</td>
</tr>
<tr>
<td>PsA (N=72)</td>
<td>0.55</td>
<td>0.231</td>
<td>0.01</td>
</tr>
<tr>
<td>UC (N=114)</td>
<td>0.556</td>
<td>0.264</td>
<td>0.006</td>
</tr>
<tr>
<td>CD (N=80)</td>
<td>0.429</td>
<td>0.303</td>
<td>0.33</td>
</tr>
<tr>
<td>Ps (N=45)</td>
<td>0.867</td>
<td>0.267</td>
<td>0.009</td>
</tr>
<tr>
<td>All disease</td>
<td>0.469</td>
<td>0.217</td>
<td>5.9x10−9</td>
</tr>
</tbody>
</table>

Figure: Kaplan-Meier survival curve of time to ADA formation (median) for the significant HLA-DQB1*02:01-DQA1*05:01 carriers and HLA-DQB1*02:02-DQA1*02:01 carriers.

Conclusion: The risk of ADA to infliximab was three-fold higher in patients carrying the HLA-DQ2 risk haplotypes across diseases. A biological role for the HLA-DQ2 molecules encoded by the two different HLA-DQ2 risk haplotypes in the formation of ADA was further supported by peptide binding predictions. These novel findings provide promise for future incorporation of HLA-DQ2 testing to facilitate personalized treatment decisions.

REFERENCES:

Disclosure of Interests: Marthe Kirksether Brun: None declared, Kristin Hammbesen Bjerklykke: None declared, Marte K. Viken: None declared, Bitte Stenvik Employee of: is a former employee of UCB Pharma, Rolf A. Klaasen: None declared, Johanna Gehin: None declared, David J. Warren: None declared, Joe Sexton: None declared, Dystein Sanandanger: None declared, Cato Merk Speakers bureau: Novartis Norway, LEO Pharma, ACO Hud Norge, Cellgene, Abbvie, and Galderma Nordic AB., Consultant of: Novartis Norway, LEO Pharma, ACO Hud Norge, Cellgene, Abbvie, and Galderma Nordic AB., Tore K. Kiven Speakers bureau: Amgen, Celtrion, Evapharma, Gilead, Hikma, Mylan, Oktai, Pfizer, San- doz, Vie, UCB, Consultant of: Amgen, Celtrion, Evapharma, Gilead, Hikma, Mylan, Oktai, Pfizer, Sandoz, Sanofi, UCB, Grant/research support from: AbbVie, Amgen, BMS, Novartis, Pfizer, UCB, Esper A Haardsholm Speakers bureau: Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli-Lilly, and UCB, Consultant of: Pfizer, AbbVie, Celgene, Novartis, Janssen, Gilead, Eli-Lilly, and UCB, Jorgen Jahnsen Speakers bureau: AbbVie, Boehringer Ingelheim, BMS, Celtrion, Gil- led, Pfizer, Rolf A. Klaasen Speakers bureau: Pfizer, AbbVie, Rolf A. Klaasen, Janssen Cilag, Novartis, Orion Pharma, Pfizer, Roche, Sandoz, and Sanofi, Consultant of: AbbVie, Boehringer Ingelheim, BMS, Celtrion, Gilead, Hikma, Janssen Cilag, Novartis, Orion Pharma, Pfizer, Roche, Takeda, and San- doz, Guo Levik Goll Speakers bureau: Pfizer, AbbVie, Boehringer Ingelheim, Roche, Orion Pharma, Sandoz, Novartis, and UCB, Consultant of: Pfizer, Abb- Vie, Boehringer Ingelheim, Roche, Orion Pharma, Sandoz, Novartis, and UCB, Benedicte A. Lie: None declared, Kristin Kaassen Jorgensen Speakers bureau: Roche, BMS, Celtrion, and Norgine, Nils Bolstad Speakers bureau: Roche Pharmaceuticals and Novartis, Consultant of: Janssen, Stille Watterdal Syversen: None declared DOI: 10.1136/annrheumdis-2022-eular.5020

POS0008 THE UTILITY OF TRANS-BRONCHIAL LUNG BIOPSIES TO GUIDE THE TREATMENT IN PATIENTS WITH RHEUMATIC INFLAMMATORY DISEASES: A RETROSPECTIVE CROSS-SECTIONAL STUDY

M. Andersen1, T. K. Lund2, T. H. L. Jensen2, M. Iverson2, M. Perch2, B. Baslund2
1Copenhagen University Hospital Rigshospitalet, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; 2Copenhagen University Hospital, Rigshospitalet, Department of Cardiology, Section for Lung Transplantation and Respiratory Medicine, Copenhagen, Denmark; 3Copenhagen University Hospital, Rigshospitalet, Department of Pathology, Kobenhavn Ø, Denmark

Background: Rheumatic inflammatory disease associated interstitial lung disease (R-ILD) is associated with significant mortality and morbidity. On a patient level, imaging which is a cornerstone in diagnosing R-ILD may not be sufficient to determine the underlying cause of the imaging pathology or the degree of reversibility. Furthermore the preconce of comorbidity and differential diagnoses such as infections or malignancy needs to be taken into account when determining the therapeutic strategy. The role of transbronchial lung biopsies (TBB) in the diagnostic workup of R-ILD is unclear and TBB is not generally recommended.

Objectives: The study objective was to examine the utility of TBB to guide treatment in a population of patients with R-ILD referred for bronchoscopy.

Methods: All patients from the Department of Rheumatology, Rigshospitalet, Copenhagen, Denmark referred for a TBB on the suspicion of R-ILD, from 2002 to 2016 were identified. Patient demographics as well as smoking status, previous lung disease, pulmonary function test, CTD-diagnosis, imaging results and immunomodulatory therapy pre- and post-bronchoscopy were obtained.

Histology findings were used to dichotomize patients into high inflammatory group or low inflammatory group. The high inflammation group primarily consisted of non-specific interstitial pneumonia (NSIP), organizing pneumonia (OP), lymphocytic infiltrating pneumonia (LIP) and granulomatous inflammation whereas the low inflammation group primarily consisted of histological findings of usual interstitial pneumonitis (UIP) and biopsies describing fibrosis and/or sparse unspecific inflammation. Therapeutic consequence was defined as intensification of therapy. Differences in treatment intensification were calculated using a binominal logistic regression model. Differences in treatment intensification were calculated using a binominal logistic regression model adjusted for age, gender, smoking status, previous lung disease, diffusion capacity, rheumatologic diagnosis, c-reactive protein level prior to TBB. Covariates with P>0.1 were excluded by a stepwise ‘backwards’ elimination.

Results: 96 patients had TBB performed. Biopsies from 55 patients were categorized as high-inflammatory and 41 as low-inflammatory, respectively. In the high inflammatory group thirty-eight (69%) had their therapy intensified compared to 6 (14%) in the low-inflammatory group (P <0.01). TBB inflammation type was the only covariate that was significantly associated with treatment intensification.

No procedure related complications were registered.

Conclusion: TBB findings can guide treatment strategy in R-ILD patients with suspected activity in the pulmonary disease. TBB appears safe and could be a useful part of the workup in patients with inflammatory rheumatic diseases where clinical features, bloodsamples, imaging and/or pulmonary function test do not provide sufficient information to guide the therapeutic strategy.

REFERENCES:
Background: Monitoring disease activity in patients with inflammatory arthritis is essential for effective treatment. While the health assessment questionnaire (HAQ) is commonly used to assess physical function, additional functional tests, such as isometric grip strength and the Moberg Pick-Up-Test (MPUT), provide objective measures for hand function and allow assessing hand function across different diseases (1). It remains unclear to date, if measured hand function is already reflected by the HAQ, as the most widely used patient reported outcome measure of physical function in arthritis.

Objectives: To estimate the proportion of hand function and grip strength variability explained by HAQ, patient-reported hand function, and between-person variation in measured hand function in patients with inflammatory arthritis and non-arthritic controls.

Methods: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), psoriasis without PsA (PsO) and healthy controls (HC) were investigated. Subject characteristics (age, sex, disease) and HAQ were recorded. Hand function was assessed by vigiometric grip strength, MPUT, and a patient-reported tool (Michigan Hand Questionnaire, MHQ), Mixed pure-random-effect linear regression models were used to estimate the proportion of variance in measured hand function or grip strength explained by subject characteristics (age, hand dominance, sex, reported hand function, disease group).

Results: 298 subjects were tested, 101 with RA (Age: 59.1±13.3 years, BMI: 27.2±6.1 kg/m²), 92 with PsA (Age: 58.8±11.6 years, BMI: 29.8±6.1 kg/m²), 51 with PsO (Age: 47.3±14.1 years, BMI: 29.8±7.3 kg/m²), 52 HC (Age: 54.6±16.5 years, BMI: 25.2±3.3 kg/m²). Overall variation in grip strength is mostly accounted for by sex (59.8%), between-person variation (21.1%) and HAQ (11.3%) (Figure 1A). Overall variation in grip strength is mostly accounted for by sex (59.8%), between-person variation (21.1%) and HAQ (11.3%) (Figure 1B). Over-all variability explained by HAQ, as the most widely used patient reported outcome measure of physical function in arthritis.

Conclusion: While the variance in grip strength is mainly explained by sex and between-person variation for all subject groups, the proportions of explained variance for measured hand function is not similar between diseases. In all groups > 50% of the variation in measured hand function remains unexplained by the variables used. Especially in arthritis patients, HAQ explained less than 25% of the variance in measured hand function. Grip strength can be considered a poor surrogate for hand function in this context due to its large gender dependence. The explainability of MHQ variation largely by HAQ indicates that it has limited potential to provide further information beyond overall functional impairment. In contrast, the large between-person variation in MPUT likely indicates unexplored movement patterns of hand motion that may be further dissected using sensor-based analyses (2) and can help identify movement components a potential for an in-depth assessment of subtle hand-function alterations in inflammatory arthritis.

REFERENCES:

Table 1. Variance proportions for each of the four study groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Control</th>
<th>PsA</th>
<th>PsO</th>
<th>RA</th>
<th>Control</th>
<th>PsA</th>
<th>PsO</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hand function (MPUT)</td>
<td>3.4</td>
<td>39.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Grip strength</td>
<td>34.8</td>
<td>36.2</td>
<td>51.6</td>
<td>52.8</td>
<td>16.1</td>
<td>12.9</td>
<td>21.3</td>
<td>27.9</td>
</tr>
<tr>
<td>Age</td>
<td>0.0</td>
<td>13.8</td>
<td>0.0</td>
<td>0.7</td>
<td>8.4</td>
<td>8.4</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>HAQ</td>
<td>35.8</td>
<td>10.8</td>
<td>34.3</td>
<td>16.4</td>
<td>3.8</td>
<td>3.1</td>
<td>10.3</td>
<td>12.0</td>
</tr>
<tr>
<td>Dominant hand</td>
<td>0.6</td>
<td>0.2</td>
<td>0.0</td>
<td>0.0</td>
<td>3.5</td>
<td>0.6</td>
<td>1.3</td>
<td>1.2</td>
</tr>
<tr>
<td>Sex</td>
<td>12.1</td>
<td>0.0</td>
<td>0.0</td>
<td>4.3</td>
<td>64.2</td>
<td>68.9</td>
<td>63.7</td>
<td>55.0</td>
</tr>
<tr>
<td>Residual</td>
<td>13.3</td>
<td>0.0</td>
<td>14.1</td>
<td>25.8</td>
<td>3.9</td>
<td>4.0</td>
<td>3.4</td>
<td>5.0</td>
</tr>
</tbody>
</table>

Conclusion: While the variance in grip strength is mainly explained by sex and between-person variation for all subject groups, the proportions of explained variance for measured hand function is not similar between diseases. In all groups > 50% of the variation in measured hand function remains unexplained by the variables used. Especially in arthritis patients, HAQ explained less than 25% of the variance in measured hand function. Grip strength can be considered a poor surrogate for hand function in this context due to its large gender dependence. The explainability of MHQ variation largely by HAQ indicates that it has limited potential to provide further information beyond overall functional impairment. In contrast, the large between-person variation in MPUT likely indicates unexplored movement patterns of hand motion that may be further dissected using sensor-based analyses (2) and can help identify movement components a potential for an in-depth assessment of subtle hand-function alterations in inflammatory arthritis.

Acknowledgements: This study was supported by the German Research Council (SFB 1483 – Project-ID 442419336, INST 90 / 985-1 FUGG, FOR2438/2886; SFB1181), the German Ministry of Science and Education (project MASCARA), the European Union (H2020 GA 810316 - 4D-Nanoscope European Research Council Synergy Project) and Novartis Germany GmbH.

Disclosure of Interests: None declared


Figure 1. Overall (N=299) proportions of variance for (A) hand function by Moberg Pick-Up Test and (B) grip strength. Dominance = dominant hand, HAQ = health assessment questionnaire, ID = Individual, MHQ = Michigan Hand Questionnaire.

POS0010

THE PSORIATIC ARTHRITIS 5-THERMOMETER SCALES (PSA-STS): A NEW INSTRUMENT FOR ASSESSING THE STATUS OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS

F. Salafi1, M. Carotì2, S. Farah1, M. Di Carlo1. 1Università Politecnica delle Marche, Dipartimento Di Scienze Cliniche e Molecolari, Ospedale “Carlo Urbani”, Jesi, Italy; 1Università Politecnica delle Marche, Dipartimento di Scienze Radiologiche, Ospedali Riuniti, Ancona, Italy

Background: There are a variety of composite disease activity monitoring methods and patient-centered metrics available for psoriatic arthritis (PsA). The Psoriatic Arthritis 5-Thermometer scales (PsA-STS) is a new tool, proposed, with the aim of improving its diagnostic accuracy.

Objectives: The goal of this research was to evaluate data on the measurement qualities of the PsA-STS, a composite measure of disease activity in PsA patients, in a real-world scenario (Figure 1).

POS0009

SUBJECTIVE ASSESSMENT OF PHYSICAL FUNCTION DOES NOT SUFFICIENTLY EXPLAIN VARIANCE IN MEASURED HAND FUNCTION AND GRIP STRENGTH IN ARTHRITIS PATIENTS AND NON-ARTHRITIS CONTROLS

A. M. Liphardt1,2, K. Tascilar1,2, B. Coppers1,2, E. Manger1, L. Bieńiek1, S. Bayat1,2, D. Simon1,2, M. Sticherling1,2, J. Rech1,2, A. Hubeur1, G. Schett1,2, A. Kleyer1,2. 1University Hospital Erlangen & Friedrich-Alexander-University Erlangen-Nürnberg, Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; 2University Hospital Erlangen & Friedrich-Alexander-University Erlangen-Nürnberg, German Centre for Immunotherapy Erlangen, Germany; 3University Hospital Erlangen & Friedrich-Alexander-University Erlangen-Nürnberg, Dermatology, Erlangen, Germany; Klinikum Nürnberg, Internal Medicine 5 – Oncology and Hematology, Nuremberg, Germany

Disclosure of Interests: Martin Andersen Employee of: Novo Nordisk A/S: 2010-

DOI: 10.1136/annrheumdis-2022-eular.2240

Figure 1. The Psoriatic Arthritis 5-Thermometer scales (PsA-STS) scoring and calculation rule

Table 1. Variance proportions for each of the four study groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Control</th>
<th>PsA</th>
<th>PsO</th>
<th>RA</th>
<th>Control</th>
<th>PsA</th>
<th>PsO</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hand function (MPUT)</td>
<td>3.4</td>
<td>39.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.1</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Grip strength</td>
<td>34.8</td>
<td>36.2</td>
<td>51.6</td>
<td>52.8</td>
<td>16.1</td>
<td>12.9</td>
<td>21.3</td>
<td>27.9</td>
</tr>
<tr>
<td>Age</td>
<td>0.0</td>
<td>13.8</td>
<td>0.0</td>
<td>0.7</td>
<td>8.4</td>
<td>8.4</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>HAQ</td>
<td>35.8</td>
<td>10.8</td>
<td>34.3</td>
<td>16.4</td>
<td>3.8</td>
<td>3.1</td>
<td>10.3</td>
<td>12.0</td>
</tr>
<tr>
<td>Dominant hand</td>
<td>0.6</td>
<td>0.2</td>
<td>0.0</td>
<td>0.0</td>
<td>3.5</td>
<td>0.6</td>
<td>1.3</td>
<td>1.2</td>
</tr>
<tr>
<td>Sex</td>
<td>12.1</td>
<td>0.0</td>
<td>0.0</td>
<td>4.3</td>
<td>64.2</td>
<td>68.9</td>
<td>63.7</td>
<td>55.0</td>
</tr>
<tr>
<td>Residual</td>
<td>13.3</td>
<td>0.0</td>
<td>14.1</td>
<td>25.8</td>
<td>3.9</td>
<td>4.0</td>
<td>3.4</td>
<td>5.0</td>
</tr>
</tbody>
</table>

Conclusion: While the variance in grip strength is mainly explained by sex and between-person variation for all subject groups, the proportions of explained variance for measured hand function is not similar between diseases. In all groups > 50% of the variation in measured hand function remains unexplained by the variables used. Especially in arthritis patients, HAQ explained less than 25% of the variance in measured hand function. Grip strength can be considered a poor surrogate for hand function in this context due to its large gender dependence. The explainability of MHQ variation largely by HAQ indicates that it has limited potential to provide further information beyond overall functional impairment. In contrast, the large between-person variation in MPUT likely indicates unexplored movement patterns of hand motion that may be further dissected using sensor-based analyses (2) and can help identify movement components a potential for an in-depth assessment of subtle hand-function alterations in inflammatory arthritis.
Methods: A total of 155 PsA patients were enrolled between May 2018 and December 2021. Adult-onset PsA CASPAR criteria were used to classify patients affected by PsA, while ASAS criteria were used to classify patients affected by axial-PsA (axPsA). All patients completed the PsA-STs, a simple instrument with five “thermometers” that incorporate pain, fatigue, physical function, skin disorders, and depression into a single assessment of disease activity. Additional continuous measures of disease activity (e.g., DAPSA, PASDAS, CPDAI) and patient-reported outcomes (PROs) measures of disease health status (e.g., PSAID and SF-36) were analyzed as comparisons. Spearman’s correlations and cross-tabulations were used to examine concurrent validity. Receiver operating characteristic (ROC) curve method was used to assess discriminant validity. As an external criterion, the Minimal Disease Activity (MDA) levels were used.

Results: The 96 female and 59 male patients ranged in age from 20 to 79 years old and had been living with PsA for an average of 8.35±2 years (6 months to 22 years). The PsA-STs’ area under the ROC curve (AUC-ROC) was 0.944. (95% CI 0.895 to 0.974) (Figure 2). The PsA-5Ts had same discriminant validity as the DAPSA, CPDAI, PASDAS, and PSAID, but it was better than the SF-36 (p=0.001). PsA-STs subscales were highly significantly different between the MDA status (all p<0.0001) when categorizing patients into those who rated their condition as reaching MDA (Kruskal-Wallis test). PsA-STs were also shown to have a remarkable (p<0.0001) correlation with known PsA activity measurements.

Conclusion: For the evaluation of disease activity in PsA, PsA-STs is a useful alternative to continuous composite indices and other patient-centered assessments. The PsA-STs make data collection simpler, and they should be used in both clinical studies and everyday clinical treatment. In order to establish the tool’s clinical relevance, longitudinal construct validity, which concerns the measure’s capacity to identify a real change in health status as well as its accuracy in detecting changes of various magnitudes, must be addressed.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1829

Figure 2. ROC curve analysis (AUC-ROC curves values, standard error and 95% confidence intervals) for the discriminatory power of disease activity, according to the different composite disease activity indices (DAPSA; CPDAI and PASDAS) and patient-reported outcomes (PROs) measures (PsA-STs, PSAID and SF-36). Receiver operating characteristic curves illustrating the relationship between sensitivity and complement of specificity (100-specificity) in PsA for activity measures using MDA as an external indicator. A line that runs diagonally across the figure from lower left to upper right will have an area of 0.5; this represents an instrument that does not discriminate.

Figure 3A. Comparison of psychometric properties of four global measures of presenteeism in patients with osteoarthritis and inflammatory arthritis: A EULAR-PRO study. S. Verstappen1, A. Boonen2, S. Wilkinson3, B. Beaton2, A. Bosworth4, J. Canas da Silva5, G. Crepaldi6, S. Daddonna7, C. Holstetter8, C. Miha8, S. Ramiro9,10, G. Sakellariou11, S. Meisalu12, J. K. Wallman14, D. Lacaille15 on behalf of the EULAR-PRO Working Group At-Work Productivity Loss. 1The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Maastricht University Medical Center, 3Department of Internal Medicine, Maastricht, Netherlands; 4Institute of Work and Health, N/A, Toronto, Canada; 5NRRAS, N/A, Maidenhed, United Kingdom; 6Rheumatology and Osteoporosis, N/A, Lisbon, Portugal; 7Universidad degli Studi di Torino, Academic Rheumatology Centre, Turin, Italy; 8Private Practice, N/A, Paris, France; 9Patient Partner, NIA, Toronto, Canada; 10University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland; 11Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 12Zuyderland Medical Center, Department of Rheumatology, Heerlen, Netherlands; 13University of Pavia, Istituto Clinico Sciolfici Maugeri IRCCS, Pavia, Italy; 14East Tallinn Central Hospital, Rheumatology, Tallinn, Estonia; 15Lund University and Skane University Hospital, Rheumatology, Lund, Sweden; 16University of British Columbia, Arthritis Research Centre of Canada, Vancouver, Canada

Background: Work is an important outcome for people with inflammatory arthritis (IA including PsA, RA, AxSpA) and osteoarthritis (OA). It is known that people with IA and OA are at increased risk of sick leave and have to stop working early due to ill health. In addition to being at increased risk of becoming work disabled and increased absenteeism, high levels of presenteeism (i.e. reduced productivity/ limited ability to work due to ill health whilst at work) have also been reported.

Several instruments exist to measure presenteeism, including single-item global measures and multi-item instruments. In some studies using single-item global instruments may be more feasible. However, available global instruments differ in concept, recall period and reference. It is important to understand which of the measures have good psychometric properties before using them in clinical studies.

Objectives: To assess the psychometric properties of four global presenteeism instruments.

Methods: Patients with IA or OA were recruited via rheumatology outpatient clinics to a large international, longitudinal observational study including 8 European countries and Canada. Participants completed a survey at baseline, 1, 2, 3, 4, 6 and 12 weeks, 2, 3 and 6 months and 3 months. The four global measures of presenteeism included: Work Productivity and Activity Impairment Questionnaire (WPAI), Work Productivity Scale–Rheumatoid Arthritis (WPS-RA), Work Ability Index (WAI) and the Quality/Quantity questionnaire (QQtotal/10) scale. To facilitate score interpretation the WAI and QQtotal were reversed. Pain was measured using an 11-point Likert scale. Spearman correlations were calculated between the presenteeism measures and the Workplace Activity Limitations Scale (WALS), a validated multi-item measure of presenteeism, and HAQ to evaluate construct validity (validity: r <0.50=low; r 0.50-0.70=moderate; r >0.70=high). Test-retest reliability of the 4 presenteeism scales (baseline-1wk) was measured applying ICC in patients with stable disease (i.e. same pain score at baseline and 1wk) (reliability: ICC<0.40=poor; ICC 0.40-0.75=fair to good; ICC >0.75=excellent).

Responsiveness during 3 months was measured comparing patients with improvement in pain score (>1 point improvement in pain score (~MCID pain)) with patients with no change or worsening in pain score. The two groups were compared applying Mann Whitney U test.

Results: This international study included 550 patients with a mean age of 47.8 (SD 9.9) yrs and 61.4% were female. Mean (SD) disease duration since diagnosis was 10.8 (10.4) yrs and 91.2% had IA. Mean (SD) presenteeism scores at baseline were: WPAI=2.9 (2.7), WPS-RA=3.4 (2.7), WAI=2.7 (2.4); and QQtotal=3.1 (3.2). The correlations between the global measures and with WALS and HAQ were moderate to good, except for QQtotal and HAQ which was low (Table 1). In patients with the same stable pain scores at baseline-1wk (n=141) ICC scores were good to excellent, respectively: WPAI (0.771), WPS-RA (0.752), WAI (0.663), and QQtotal (0.650). An improvement in pain during the 3 month study duration was observed in 145/381 (38%) of the patients. In these patients a significant reduction in mean pain during the 3 month study duration was observed

Table 1.

<table>
<thead>
<tr>
<th>Measure</th>
<th>WPAI</th>
<th>WPS-RA</th>
<th>WAI</th>
<th>QQtotal</th>
<th>HAQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>WPRA</td>
<td>0.592</td>
<td>0.5184</td>
<td>0.6269</td>
<td>0.592</td>
<td></td>
</tr>
<tr>
<td>WPS-RA</td>
<td>0.592</td>
<td>0.5184</td>
<td>0.6269</td>
<td>0.592</td>
<td></td>
</tr>
<tr>
<td>WAI</td>
<td>0.5707</td>
<td>0.5217</td>
<td>0.6055</td>
<td>0.5669</td>
<td></td>
</tr>
<tr>
<td>QQtotal</td>
<td>0.5707</td>
<td>0.5217</td>
<td>0.6055</td>
<td>0.5669</td>
<td></td>
</tr>
<tr>
<td>HAQ</td>
<td>0.5707</td>
<td>0.5217</td>
<td>0.6055</td>
<td>0.5669</td>
<td></td>
</tr>
</tbody>
</table>

The correlations between the global measures and with WALS and HAQ were moderate to good, except for QQtotal and HAQ which was low (Table 1). In patients with the same stable pain scores at baseline-1wk (n=141) ICC scores were good to excellent, respectively: WPAI (0.771), WPS-RA (0.752), WAI (0.663), and QQtotal (0.650). An improvement in pain during the 3 month study duration was observed in 145/381 (38%) of the patients. In these patients a significant reduction in mean pain during the 3 month study duration was observed.
Challenging cases to make you think

POS0012

A NEW TNFRSF1A GENE MUTATION IN A TURKISH FAMILY WITH TNF RECEPTOR-ASSOCIATED PERIODIC SYNDROME (TRAPS).

T. S. Özlü1, B. Aslan1, V. Vayzı¹, F. Erbasan1, M. E. Terzioğlu1, 1Akdeniz University, Rheumatology Clinic, Antalya, Turkey

Background: Tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS) is a rare autosomal dominant autoinflammatory syndrome caused by pathogenic variants in the tumor necrosis factor receptor 1 (TNFR1) gene (TNF receptor superfamily member 1A, TNFRSF1A). For definitive diagnosis, genetic tests are needed to show variants in the TNFR1 gene (1). Information on genotype-phenotype relationships is limited due to the rarity of the disease.

Objective: This study presents novel R97S mutation in TNFRSF1A gene and relevant clinical findings in a patient with amyloidosis of unknown etiology and his sister.

Methods: Case; Proband 33-year-old male patient presented with swelling in the legs 9 years ago. In his history, he described muscle pain, unilateral eye redness, swelling and discharge, which occurred several times in 2-3 months and lasted for up to 2 weeks. Kidney biopsy was found to be consistent with AA amyloidosis. R97S mutation was found to be heterozygous. Colchicine was started at 2x0.5 mg per day. Despite colchicine treatment in the following years, acute phase reactants remained high, proteinuria continued at nephrotic level (50-60 mg in 24-hour urine), progressive deterioration of kidney functions, end-stage renal failure developed. Gene analysis was performed for other autoinflammatory diseases; R97S (Nucleotide change c.290_310dup heterozygous) mutation was detected in the TNFRSF1A gene.

Sister; 31-year-old female patient was admitted to our clinic after a heterozygous mutation in the TNFRSF1A gene was detected in her brother. In her history, she described muscle pain, edema, redness and discharge around the eyes, which occurred 1-2 times a year and lasted for about 2 weeks, especially triggered by the menstrual cycle. TNF (tumor necrosis factor) receptor-associated periodic syndrome mutation was found to be heterozygous positive R97S.

Father; The father of the first two cases started having sore throat, diarrhea, muscle pain, swelling around the eyes and fever attacks starting from the age of 29. Renal biopsy revealed apple-green birefringence with congo-red stain, which was indicative of amyloidosis. When he was 32 years old, peritonitis, diathesis was started first and then continued with hemodialysis due to end-stage renal disease. Three months after the start of hemodialysis, he died due to high fever, hypotension and septicemia.

Results: In this article, a novel mutation of TRAPS which has not been reported in the literature so far, is presented in a Turkish family. Our country is endemic for FMF disease, a study by Bilge et al. (2) demonstrated that mutation analysis of 9% of all subjects with FMF in our country provided negative results. In our opinion genetic analysis should be performed to detect other autoinflammatory diseases in cases that classical FMF attacks are not seen, as in this case series. These and similar cases followed as FMF are likely to be associated with other autoinflammatory diseases. Diagnosing these rare diseases will provide both appropriate and effective treatment options to patients and a better definition of the clinical feature - mutation relationship.

Reference:

Disclosure of interests: None declared.
a trial with intravenous immunoglobulin had been initiated inducing clinical stabilization.

We diagnosed Sjögren-like syndrome based on sicca symptoms and a suspicious submandibular salivary gland in sonography, without typical serology. Family history was negative for autoimmune diseases. The clinical findings pointed towards immunosuppression, prompting cytokine examination, lymphocyte phenotyping and genetic testing. Cytokines (IFN\(\gamma\), IL-2, IL-4, IL-10, IL-17) under immunosuppression with 20 mg prednisolone and 2 g of myco-phenolate were all low/below detection threshold. Flow cytometry showed no abnormalities except for a low CD20 (after Rituximab) and a slightly elevated T-reg count. Genetic testing revealed heterozygous variants in exon three (c.354C>G) and eight (c.927C>G) of \(AIRE\). The patient’s mother showed the same genotype - indicating that the variants in the patient are in cis - but is asymptomatic. (Figure 1)

**Conclusion:** To our knowledge this is the first report of a patient with thymoma and genetic variant(s) in the \(AIRE\) gene displaying several autoimmune diseases. Although clinical similarities between thymoma patients and APECED / APS1 are known (4), a genetic link between these 2 diseases has not yet been described. As rheumatic autoimmunity can be induced by either, rheumatologists should be aware of these potentially underlying causes.

An additional point of interest is the lack of autoimmunity in the mother with the same genetic variants, which suggests an additional environmental trigger (e.g. smoking, viral infection) in the patient.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4300

---

**Table 1. Characteristics of the AOSD patients**

<table>
<thead>
<tr>
<th>No.</th>
<th>Sex</th>
<th>Age (year)</th>
<th>Disease Duration (Month)</th>
<th>Main symptoms</th>
<th>Treatments before JAKi onset</th>
<th>JAKi</th>
<th>Steroids at onset</th>
<th>Concomitant treatment</th>
<th>Steroids at the end of F-U</th>
<th>F-U (month)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 M</td>
<td>26</td>
<td>29</td>
<td>Fever, polyarthritis</td>
<td>Pred+MTX</td>
<td>Tofacitinib</td>
<td>0</td>
<td>MTX</td>
<td>4</td>
<td>4</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>2 M</td>
<td>25</td>
<td>9</td>
<td>Fever, polyarthritis, rash, pulmonary hypertension</td>
<td>Pred+MTX</td>
<td>Baricitinib</td>
<td>16</td>
<td>MTX+Pred</td>
<td>12</td>
<td>4</td>
<td>F</td>
<td></td>
</tr>
<tr>
<td>3 M</td>
<td>38</td>
<td>12</td>
<td>Fever, polyarthritis, rash</td>
<td>Pred+MTX+CsA+NSAIDs+TNFi</td>
<td>Tofacitinib</td>
<td>24</td>
<td>Pred</td>
<td>12</td>
<td>3</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>4 M</td>
<td>21</td>
<td>216</td>
<td>Fever, polyarthritis</td>
<td>Pred+MTX+SASP+NSAIDs+TNFi</td>
<td>Baricitinib</td>
<td>4</td>
<td>Pred+MTX+</td>
<td>4</td>
<td>3</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>5 F</td>
<td>33</td>
<td>1</td>
<td>Fever, polyarthritis, rash, abnormal liver function tests</td>
<td>Pred</td>
<td>Tofacitinib</td>
<td>40</td>
<td>Pred</td>
<td>2</td>
<td>5</td>
<td>CR</td>
<td></td>
</tr>
<tr>
<td>6 F</td>
<td>47</td>
<td>7</td>
<td>Fever, polyarthritis, rash, abdominal pain</td>
<td>Pred</td>
<td>Tofacitinib</td>
<td>36</td>
<td>Pred</td>
<td>4</td>
<td>5</td>
<td>PR</td>
<td></td>
</tr>
<tr>
<td>7 F</td>
<td>25</td>
<td>1</td>
<td>Fever, polyarthritis, rash, heart failure</td>
<td>Pred</td>
<td>Tofacitinib</td>
<td>40</td>
<td>Pred</td>
<td>12</td>
<td>3</td>
<td>PR</td>
<td></td>
</tr>
</tbody>
</table>

Pred: prednisone; MTX: Methotrexate; SASP: salicylazosulphapyridine; CsA: ciclosporin A; NSAIDs: Non-Steroidal AntiInflammatory Drugs; TNFi: Tumor necrosis factor inhibitor. CR: complete remission; PR: partial remission; F: failure.

— Z. Chen1, J. Tan1, T. Cheng1, X. Wu1, J. Gu1, Z. Liao1. Third Affiliated Hospital of Sun Yat-sen University, Rheumatology and Immunology Department, Guangzhou, China

**Background:** Inappropriate activation of pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 or IL-18, is a pathogenic cornerstone in adult onset Still’s disease (AOSD). Beyond therapies targeting IL-1 and IL-6, Janus kinases (JAK) inhibitors have been suggested to be effective in refractory AOSD patients [1].

**Objectives:** To assess the efficacy and safety of JAK inhibitors in the treatment of AOSD patient refractory to, or with initial treatment.

**Methods:** This retrospective study was based on our single center of the department of rheumatology and immunology. The data was collected from the patients’ medical records using a standardized questionnaire and analyzed at different time points. The response to JAK inhibitors was categorized as complete remission (CR), partial remission (PR) or failure (F) [2].

**Results:** 7 patients were recruited (Table 1), including 4 refractory patients and 3 initial patients. Mean age at JAK inhibitor treatment start was 27.5 years for refractory patients and 35 years for initial patients; and mean disease duration was 66.5 months and 1 month respectively. All patients had fever and polyarthritits, 5 patients had rash. In addition, pulmonary hypertension, abnormal liver function tests, abdominal pain, and heart failure were also observed in our patients. Response to corticosteroids, conventional synthetic or biological Disease Modifying Anti-Rheumatic Drugs (DMARDs) had been considered inadequate in 4 refractory patients, Tofacitinib was added in the initial treatment for 3 patients for high disease activity. In total, baricitinib was used in 2 patients and tofacitinib in 5 patients. Steroids were concurrently used in 6 patients, MTX in three, SASP and NSAIDs in one. At a mean follow up of 3.8 months, complete remission was observed in one patient (with tofacitinib), partial remission was in 5 patients (4 patients with tofacitinib and one with baricitinib), and failure in one patient (with baricitinib). At the last visit, steroids could be decreased but not stopped in those 6 patients. Tolerance of JAK inhibitors was excellent, none infectious disease or other severe side effect were observed.

**Conclusion:** JAK inhibitors treatment may be helpful for some patients with refractory AOSD, or patients with severe disease activity at initial treatment. Different treatment responses were observed in these short series of cases, which might be due to the phenotype of patients. However, the scale of patients in our study was too low to draw a conclusion. Further study and additional information are needed to evaluate more precisely the risk-benefit ratio of this treatment, and a possible difference in efficacy among the different groups of patients or JAK inhibitors.

**REFERENCES:**

**Figure 1.** Electropherograms of the heterozygous patient, his heterozygous, asymptomatic mother and his asymptomatic father, who has a wildtype of \(AIRE\).
POS0015
BULLOUS SYSTEMIC LUPUS ERYTHEMATOSUS SUCCESSFULLY TREATED WITH MYCOPHENOLATE MOFETIL COMBINED WITH GLUCOCORTICOID: A CASE REPORT
H. Du1, J. Hu1, J. Su1, T. Wu1, R. Wu1, J. Zhu1. 1Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Department of Rheumatology and Immunology, Chengdu, China

Background: Bullous systemic lupus erythematosus (BSLE) is a rare subtype of systemic lupus erythematosus, accounting for less than 1% of systemic lupus erythematosus (SLE) [1]. It is common in adults aged 20 to 40, with female predominance [2]. Its skin manifestations are mainly tense blisters, especially involving oral and genital mucosa, Nissl's sign is mostly negative, blisters break and heal to form pigmentation of varying degrees, leaving no scar. At present, the main treatment is systemic application of corticosteroids combined with immunosuppressants. Here, we report a BSLE who successfully treated with mycophenolate mofetil (MMF) combined with glucocorticoid.

Objectives: To be vigilant in the early identification of BSLE, and through the treatment experience of this case, it can provide a basis for the use of Mycophenolate ester as the preferred drug for the treatment of BSLE in the future.

Methods: The clinical manifestation, laboratory test, treatment, and outcome were described.

Results: A 50-year-old female patient with systemic lupus erythematosus presented with wandering joint pain for 1 year and sporadic patchy erythema on eyelid, hands, and neck for 7 months. There are blisters on part of her erythema and normal skin, about 1mm-15mm in diameter, the blister fluid is cool, fusion is broken, and Nissl's sign is negative. She suffered from anemia, albuminuria, polyserous effusion and other system damage. Skin histopathology showed mild hyperkeratosis of epidermis, formation of subepidermal blisters and accumulation of a large number of neutrophils; direct immunofluorescence showed that the positive expressions of IgA, IgG and C3 were found in the basement membrane of the skin, leading to a diagnosis of BSLE. In the initial stage, patients were treated with high-dose glucocorticoid (160mg, qd) combined with immunosuppressants (thalidomide and hydroxychloroquine), but the number of blisters increased. After treatment with MMF (1g, bid), the skin lesions disappeared, joint pain relieved, anemia was corrected, and polyserous effusion was absorbed. She was followed up for half a year and there was no recurrence.

Conclusion: Patients with BSLE are often accompanied by multiple system damage [2], so it is critical to correctly identify BSLE and provide appropriate treatment as soon as possible. For patients who do not respond to single glucocorticoid therapy, combined with MMF can be used as the preferred drug for the treatment of BSLE in the future.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4186

Figure 1. Changes in laboratory test (A) WBC; (B) CRP; (C) ESR; (D) Ferritin. M0: baseline; M1: month 1; M3: month 3; M5: month 5.

Acknowledgements: None
Disclosure of Interests: None declared

Figure 1. BSLE. Blisters can be seen on the face, neck, armpits and arms. BSLE = bullous systemic lupus erythematosus.
The mean duration of diagnosis was 123.5±89.3 months. At least one autoim-
immune manifestation was observed in 80% of the patients. In the follow-up period,
40% of the patients developed arthritis. Involvement of lower extremity joints
such as knee and ankle was more prominent. While all patients were given 0.8g/
kg/3 weeks of intravenous immunoglobulin, 80% required immunosuppressive
therapy for autoimmune manifestations. The demographic and clinical character-
istics of the patients are summarized in Table 1.

**Conclusion:** Autoimmune diseases can be seen in patients with CVID, and
sometimes this may be the first presentation of CVID. Heterogeneous clini-
cal findings of the disease may lead to delay in diagnosis. Clinicians should be
more careful about the different manifestations of CVID to avoid delay in
diagnosis.

**Disclosure of Interests:** None declared


---

**Table 1. Autoimmune manifestations of common variable immunodeficiency patients**

<table>
<thead>
<tr>
<th>Case</th>
<th>Age/Sex</th>
<th>Symptom duration (years)</th>
<th>Diagnosis duration (years)</th>
<th>Sinopulmonary infection</th>
<th>GI infection</th>
<th>Other infections</th>
<th>Pulmonary</th>
<th>Involvement Extra pulmonary Granuloma</th>
<th>Autimmune manifestations</th>
<th>Cirrhosis of the liver</th>
<th>Lymphadenopathy</th>
<th>Splenomegaly</th>
<th>Immunosuppressive Treatment</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>36/F</td>
<td>12</td>
<td>6</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>nodule cerebral</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Steroid, AZA, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>2</td>
<td>43/F</td>
<td>11</td>
<td>6</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>’bronchietasis’</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>3</td>
<td>40/M</td>
<td>11</td>
<td>7</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Steroid, AZA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>4</td>
<td>25/M</td>
<td>4</td>
<td>3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>5</td>
<td>23/M</td>
<td>17</td>
<td>10</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>6</td>
<td>36/M</td>
<td>12</td>
<td>9</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>7</td>
<td>41/M</td>
<td>12</td>
<td>9</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>8</td>
<td>57/F</td>
<td>11</td>
<td>1</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>9</td>
<td>35/F</td>
<td>13</td>
<td>7</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
<tr>
<td>10</td>
<td>48/F</td>
<td>12</td>
<td>2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>nodule</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>Steroid, SSZ, MTX, LEF, CSA</td>
<td>Steroid, CSA</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared


**REFERENCES:**


**Disclosure of Interests:** None declared


---

**RESULTS:**

**Methods:** Concentric needle electromyography showed abnormal spontaneous
activity; small amplitude and often polyphasic motor unit action potentials, along
with increased recruitment pattern in tibial anterior, vastus lateralis, medial gas-
trocnemius, tibialis posterior and short head biceps femoris muscle in the left lower extremity. The findings were suggestive of myopathy. She underwent a muscle biopsy from the left deltoid muscle which showed dense perimysial and endomys-
ial lymphoplasmacytic inflammatory infiltrates with degenerating myofibers.

**RESULTS:**

**Methods:** Concentric needle electromyography showed abnormal spontaneous
activity; small amplitude and often polyphasic motor unit action potentials, along
with increased recruitment pattern in tibial anterior, vastus lateralis, medial gas-
trocnemius, tibialis posterior and short head biceps femoris muscle in the left lower extremity. The findings were suggestive of myopathy. She underwent a muscle biopsy from the left deltoid muscle which showed dense perimysial and endomys-
ial lymphoplasmacytic inflammatory infiltrates with degenerating myofibers.

**Disclosure of Interests:** None declared

### POS0018

**REDUCTION OF DIFFUSE NOXIOUS INHIBITORY CONTROL IN ACTIVE INFLAMMATORY RHEUMATISM: A DEMONSTRATION OF CENTRAL SENSITISATION**

A. P. Trouvin1,2, A. Simunek1, J. Coste1,2, T. Medkou2, S. Carvès1, D. Bouhassira2, S. Perrot1,2, 1Cochin University Hospital, Pain Medicine Department, Paris, France; 2INSERM, U982, Boullogne Billancourt, France; 3GHU Paris Centre – Cochin, Biostatistics and Epidemiology Unit, Paris, France; 4Ambroise Paré University Hospital, Pain Medicine Department, Boullogne Billancourt, France

**Background:** In rheumatoid arthritis (RA) and spondyloarthritis (Spa), persistent pain remains challenging. It is thought to result from central pain sensitisation, which can be measured by quantitative sensory testing (QST) and conditioned pain modulation (CPM).

**Objectives:** The main objective of the RAPID (Rheumatism Pain Inhibitory Descending pathways) study, was to assess descending pain modulation (through CPM paradigms) in patients with RA or Spa, comparing these patients with healthy sex- and age-matched controls. The secondary objectives were the measurement pain thresholds (heat and cold) in a non-articular, non-painful area in patients and controls as a means of detecting possible widespread hyperalgesia as another index of central sensitisation in our patients.

**Methods:** We included 50 RA and 50 Spa patients and 100 age- and sex-matched controls. We assessed clinical disease variables for patients, together with responses to various psychological questionnaires. All participants underwent QST with the determination of heat and cold pain thresholds (HPT -CPT) and CPM. In CPM, a conditioning stimulus was applied to a foot and the non-dominant hand in a randomised sequence. Descending pain control was assessed as the change in HPT (in °C) following a conditioning stimulus: the higher the CPM effect, the more efficient the inhibitory control.

**Results:** HPT and CPT were similar in patients and controls. Mean CPM effect was significantly weaker in patients than controls; 0.25°C (±2.57) and 2.79°C (±2.31) for patients and controls, respectively ($p<0.0001$) for conditioning on the foot; 0.57°C (±2.74) and 2.68°C (±2.12) ($p<0.0001$), respectively, for conditioning on the hand. The heat pain threshold was 42.35°C (±3.68°C) for patients and 41.54°C (±3.34°C) for healthy controls; this difference was not statistically significant. The cold pain threshold was 13.11°C (±10.04°C) for patients and 13.28°C (±9.34°C) for healthy controls; this difference was not significant. The weaker CPM effect in patients was associated with higher pain intensity. In all participants, a weak CPM effect was associated with high Central Sensitisation.

**Conclusion:** Diffuse noxious inhibitory control is weaker in patients with active chronic inflammatory rheumatism than in healthy subjects, supporting the hypothesis of central sensitisation.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2789

---

### POS0019

**CENTRAL SENSITIZATION IN PATIENTS WITH RHEUMATOID ARTHRITIS: ASSOCIATION WITH DISEASE ACTIVITY**

V. Bombela1, M. Stanislavchuk1, 1National Progov Memorial Medical University, Vinnytsya, Ukraine, Department of Internal Medicine #1, Vinnytsya, Ukraine

**Background:** Rheumatoid arthritis (RA) is the most common inflammatory arthropathy with a predominance of autoimmune mechanisms of pathogenesis and pain as the main clinical manifestation. Recent evidence has found showed that Central Sensitization (CS) may be a new mechanism for the formation of pain [1]. There is insufficient data on this phenomenon in patients with RA [2].

**Objectives:** To determine the prevalence of the phenomenon of CS in patients with RA and evaluate its association with disease activity.

**Methods:** The study involved patients with RA according to the ACR / EULAR criteria (2010). RA activity was determined by DAS-28, SDAI, CDAI, and the functional ability of patients - by HAQ. Visual analog scoring (VAS) were used to evaluate the intensity of pain. The radiological stage of RA was determined according to the Kellgren-Lawrence classification. The presence of the CS phenomenon was established using the Central Sensitization Inventory (CSI) (Mayer, T. G. et al., 2012), MS Excel and SPSS22 (© SPSS Inc.) software packages were used for statistical processing of results.

**Results:** 110 patients (84% of women) were included. The participants’ mean age was (MsSD) 53.5 ± 12.2 years, with a disease duration 8.5 ± 8.1 years. Among the examined, radiological stage I was detected in 16 (15%) patients, II - in 59 (53%), III - in 23 (21%), IV - in 12 (11%). According to the DAS28-ESR index, 56 (51%) patients had high activity (DAS 28-ESR: >5.1) and 54 (49%) patients had moderate activity (3.2 -DAS28-ESR ≤5.1). Mean values of SDAI and CDAI also showed high disease activity: 36.5 ± 10.2 and 33.3 ± 9.8, respectively. The average value of HAQ was 1.4 ± 0.7.

**Conclusion:** Sensitization is common in RA patients. The phenomenon of central sensitization is associated with higher disease activity, loss of functional ability and severity of pain.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2789

---

### POS0020

**PAIN PHENOTYPING IN PATIENTS WITH PSORIATIC ARTHRITIS AND HAND OSTEOARTHRITIS**

J. Vela1, J. L. Dreyer1, K. Kjær Petersen1, 1Aalborg University Hospital, Rheumatology, Aalborg, Denmark; 2Aalborg University, Clinical Institute, Aalborg, Denmark; 3Aalborg University, Centre for Neuroplasticity and Pain, Aalborg, Denmark

**Background:** Chronic pain is experienced by many patients with joint disease but underlying pain phenotypes including impact of concomitant fibromyalgia (cFM) have not been investigated in patients with psoriatic arthritis (PsA) and hand osteoarthritis (hand-OA).

**Objectives:** To investigate pain parameters (quantitative sensory testing) in patients with hand-OA and PsA using pressure pain thresholds (PPT), temporal summation of pain (TSP) and conditioned pain modulation (CPM) compared with healthy controls. Furthermore, to explore whether alternations in underlying pain mechanisms and psychological factors are associated with cFM compared to those patients without.

**Methods:** Patients with verified PsA or hand-OA and healthy controls underwent quantitative sensory testing using hand-held and cuff pressure algometry to measure PPT, TSP and CPM. Psychosocial factors were assessed via the Hospital Anxiety and Depression Scale, Pain Catastrophizing Scale, Pittsburgh Sleep
Abbreviations: cFM: Concomitant fibromyalgia; HADS: Hospital anxiety and depression.

### Table 1.

<table>
<thead>
<tr>
<th></th>
<th>Hand-OA</th>
<th>PsA</th>
<th>Controls</th>
<th>No cFM</th>
<th>cFM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects (%)</td>
<td>75</td>
<td>59</td>
<td>20</td>
<td>74</td>
<td>59</td>
</tr>
<tr>
<td>Females (%)</td>
<td>48 (64%)</td>
<td>39 (75%)</td>
<td>18 (90%)</td>
<td>43 (58%)</td>
<td>44 (75%)</td>
</tr>
<tr>
<td>Age, years</td>
<td>66.07 (17.33)</td>
<td>53.16 (11.62)</td>
<td>68.10 (8.32)</td>
<td>61 (11.53)</td>
<td>59 (11.56)</td>
</tr>
<tr>
<td>Pain intensity, 0 to 100</td>
<td>56.6 (18.3)</td>
<td>58.6 (18.0)</td>
<td>NA</td>
<td>55.3 (17.8)</td>
<td>60.0 (18.4)</td>
</tr>
<tr>
<td>Pain location</td>
<td>5.81 (4.35)</td>
<td>6.79 (4.66)</td>
<td>-</td>
<td>3.28 (2.79)</td>
<td>9.95 (3.33)</td>
</tr>
<tr>
<td>PainDETECT</td>
<td>4.34 (3.37)</td>
<td>5.55 (3.32)</td>
<td>1.79 (2.62)</td>
<td>4.12 (3.07)</td>
<td>5.83 (3.57)</td>
</tr>
<tr>
<td>Pain Catastrophing</td>
<td>16.52 (26.26)</td>
<td>16.95 (7.80)</td>
<td>3.75 (5.23)</td>
<td>15.03 (8.42)</td>
<td>18.88 (8.44)</td>
</tr>
<tr>
<td>Temporal summation</td>
<td>2.68 (2.35)</td>
<td>2.51 (1.91)</td>
<td>1.13 (1.34)</td>
<td>2.24 (1.74)</td>
<td>3.07 (2.53)</td>
</tr>
<tr>
<td>Conditioned pain modulation, kPa</td>
<td>3 (16)</td>
<td>8 (18)</td>
<td>19 (14)</td>
<td>6 (18)</td>
<td>4 (16)</td>
</tr>
</tbody>
</table>

### Results:

Patients with cFM (58%) had greater scores of depression, anxiety, catastrophizing, disability and reduced sleep quality when compared to patients without cFM. Limiting the analysis to patients without cFM yielded a similar result.

Patients with cFM had greater TSP, painDETECT, disability, catastrophizing and reduced sleep quality, than patients without, indicating greater degree of sensitisation, psychosocial burden, and disability.

### Conclusion:

Patients with hand-OA and PsA experienced a greater degree of pain facilitation and psychosocial impact when compared with controls. Patients with cFM had greater TSP, painDETECT, disability, catastrophizing and reduced sleep quality, than patients without, indicating greater degree of sensitisation, psychosocial burden, and disability.
Continuous, neuropathic and intermittent. The value for each descriptor is plotted. The descriptors are divided into four categories: affective, activity (BDCAF < 4), comitant FMS diagnosis was more prevalent in the high disease activity group (72%) compared to low disease activity (37.7%). The prevalence of FM in the IBD cohort was 17/196 (8.7%) 95% CI 5% – 13%, of patients with high disease activity. Concomitant FMS diagnosis was more prevalent in the high disease activity group (52%) than the low disease activity group (29%) (p=0.04). The mean mBDCAF of patients with FMS was 2.09 ± 1.3 compared to 1.53 ± 1.3 in patients without FMS (p=0.047).

Figure 1. Pain Descriptors by Disease Activity

Affective descriptors
Continuous descriptors
Neuropathic descriptors
Intermittent descriptors

Figure 1. Pain descriptors from the SF-MPQ-2 stratified by high (BDCAF ≥4) and low disease activity (BDCAF <4). Descriptors are rated no pain to the worst pain over (0 – 10). The median value for each descriptor is plotted. The descriptors are divided into four categories: affective, continuous, neuropathic and intermittent.

Conclusion: This the first study to describe the pain experience of a UK population of BS patients. The majority of patients experience moderate to severe chronic MSK pain. Severe generalised MSK pain is more prevalent in those with high BS disease activity. We have demonstrated a relationship between high disease activity, worse pain intensity, and comorbid FMS. Our findings pose new questions into the research of pain in BS. Further studies are required to explore the mechanism of generalised pain and its correlation with disease activity.

Disclosure of Interests: None declared


PREVALENCE AND IMPACT OF FIBROMYALGIA SYNDROME IN A CORPUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE

L. Guida1, S. Sirotti2,3, G. Filippou4, A. Dell’era4, D. Gridavilla4, M. E. Romano5, D. Ventura4, G. M. C. La Paglia4, S. Farah4, S. Ardizzone4, P. Sarzi-Puttini2,3
1Luigi Sacco University Hospital, Gastroenterology Department, Milan, Italy; 2Luigi Sacco University Hospital, Rheumatology Department, Milan, Italy; 3University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 4Polytechnic University of Marche, Rheumatology Department, Jesi, Italy

Background: Fibromyalgia (FM) is a common chronic disorder characterized by widespread pain, fatigue, sleep disturbances and functional symptoms, reaching a prevalence of 2–3% worldwide. It can present as a comorbidity in patients with concomitant chronic disease and can have a significant impact on the quality of life. There are very few studies on the prevalence and the impact of FM in patients with inflammatory bowel disease (IBD).

Objectives: The aims of this study were to assess the prevalence of FM in a cohort of patients with IBD, and to evaluate the impact of FM on the quality of life of those patients.

Methods: Consecutive patients with IBD were enrolled from August to November 2021 in two IBD units, patients with severe disease activity according to the Crohn’s disease activity index (CDAI) and to the Mayo score for UC, or with other concomitant chronic diseases were excluded. Clinical and demographic data and Patient Reported Outcomes (PROs) (Widespread Pain Index (WPI), Symptom Severity Score (SSS)), IBD Questionnaire (IBD-Q), Depression anxiety stress scales-21 (DASS-21), Functional Assessment of Chronic Illness Therapy-Fatigue (FACT-F), Impact of event scale-revised (IES-R), Pittsburgh Sleep Quality Index (PSQI)) were collected. FM was diagnosed according to 2011 ACR classification criteria by an expert rheumatologist. Mann-Whitney test, chi-square test, and Student t test were used for statistical analyses. A multivariate analysis was performed to estimate the effect of independent variables (BMI, age, CRP, CDAI, Mayo score, WPI, DASS-21, FACT-F, PSQI) on patients’ quality of life (IBD-Q). A p value < 0.05 was considered as significant.

Results: A total of 196 IBD patients were enrolled (86 female (44%) with a mean age of 50 ± 15 yo), 105 with Crohn’s disease (CD) and 91 with ulcerative colitis (UC). 147 patients were in remission, 35 had low disease activity and 14 moderate disease activity. The overall prevalence of FM in the IBD cohort was 17/196 (8.7%) 95% CI 5% – 13%, 10 (11.6%) women and 7 (6.3%) men; with a prevalence of 7.6% (8/105) in CD and 9.9% (9/91) in UC.

In Table 1 are indicated the characteristics of patients with IBD + FM and IBD alone. No significant demographic and clinical differences between the two groups were detected.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>IBD + FM (n=17)</th>
<th>IBD without FM (n=179)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male (%)</td>
<td>10/7 (59%/41%)</td>
<td>75/102 (42%/58%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>56.8 ± 13</td>
<td>48.5 ± 17</td>
<td>0.06</td>
</tr>
<tr>
<td>BMI (SD)</td>
<td>21 ± 8.7</td>
<td>23.7 ± 4.8</td>
<td>0.46</td>
</tr>
<tr>
<td>CD (FU) (%C)</td>
<td>8 (47%)/9 (53%)</td>
<td>97 (54%)/82 (46%)</td>
<td>0.57</td>
</tr>
<tr>
<td>CRP, median (SD)</td>
<td>0.16 mg/dL ± 2.8</td>
<td>0.2 mg/dL ± 1.5</td>
<td>0.87</td>
</tr>
<tr>
<td>IBD remission</td>
<td>14 (82%)</td>
<td>133 (74%)</td>
<td>0.33</td>
</tr>
<tr>
<td>IBD low disease activity</td>
<td>1 (6%)</td>
<td>34 (19%)</td>
<td></td>
</tr>
<tr>
<td>IBD moderate disease activity</td>
<td>2 (12%)</td>
<td>12 (7%)</td>
<td></td>
</tr>
<tr>
<td>Ongoing conventional treatment</td>
<td>6 (35%)</td>
<td>70 (39%)</td>
<td>0.27</td>
</tr>
<tr>
<td>Ongoing biological treatment</td>
<td>11 (65%)</td>
<td>112 (63%)</td>
<td>0.42</td>
</tr>
</tbody>
</table>

The quality of life among IBD patients and IBD + FM patients, assessed with IBD-Q, appear significantly lower (p <0.001) in the second group. Similar results were obtained evaluating depression, anxiety, stress, chronic fatigue, and patients’ discomfort (Table 1).
The multivariate analysis demonstrated that the variables influencing the quality of life (IIB-Q) were the disease activity (CDAI) (p <0.0256), the chronic fatigue (FACT-F) (p <0.0061) and sleep disturbances (PSQI) (p <0.0440), for CD; while for UC the only variable that correlated with IIB-Q was the disease activity (Mayo score) (p <0.0129).

**Conclusion:** FM is a common disorder especially in patients with other comorbid chronic diseases. This study reported a prevalence of FM of 8.7% in IBD patients without any significant differences between CD and UC. Moreover, the comorbidity of FM in IBD can have a considerable impact on quality of life and on measures of disease severity, with worst values in all PROs measurements.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3862

---

POS0024

**PREDICTION OF SPONTANEOUS IMPROVEMENT IN PATIENT REPORTED OUTCOME SCORES IN OSTEOARTHRITIS USING MARKERS OF JOINT TISSUE TURNOVER**

M. Mukundan\(^1\), A. C. Bay-Jensen\(^2\), J. Samuels\(^1\), M. Kandsal\(^3\), S. Abramson\(^1\).

\(^1\)NYU Grossman School of Medicine, Division of Rheumatology, Department of Medicine, New York, United States of America; \(^2\)Nordic Bioscience, ImmunoScience, Herlev, Denmark

**Background:** Osteoarthritis (OA) is a chronic disease characterized by pain and disability. There is no modifying treatment approved for OA today. This may be attributed to the difficulty generating a robust response based on patient-reported outcomes (PROs) linked to the drug mode of action. There is a need in drug development to test and validate biomarkers that objectively relate to PROs or even predict changes in PROs. Biomarkers of cartilage and bone turnover are associated with structural and symptomatic progression\(^1\). In addition, recent findings suggest that a subset of OA patients have elevated serum levels of C-reactive protein metabolites (CRPM), which is predictive of radiographic progression\(^2,3\).

**Objectives:** This explorative study aimed to investigate the association between PROs and markers of joint tissue formation and degradation in patients with either high or low levels of CRPM. In particular, whether levels could predict spontaneous improvement in PROs.

**Methods:** 146 knee OA patients, 62% women, from the NYU cohort were included. Mean (SD) age, 62.5 (10.1); BMI, 26.6 (3.6); 32% NSAID users; and 67.6% with radiographic OA (KL≥2). PROs were recorded at baseline (BL) and 2 years (FU), and the current investigation was: WOMAC pain, stiffness, and function. The mean (SD) for WOMAC pain, stiffness, and function were 35.4 (22.9), 40.8 (25.7), and 41.7 (28.3) mm on a 100 mm scale. Twenty-one healthy individuals were included as a reference. Eight serum biomarkers of type I, II, III, and IV collagen degradation (C1M, C2M, C3M, C4M) and formation (PRO-C1, PRO-C2, PRO-C3, and PRO-C4) as well as the inflammatory biomarker CRPM, were assessed at baseline. LN-transformed data was adjusted for race, sex, age, BMI, and NSAID use when comparing OA to controls and in the pre-contrast chronic diseases. This study reported a prevalence of FM of 8.7% in IBD patients without any significant differences between CD and UC. Moreover, the comorbidity of FM in IBD can have a considerable impact on quality of life and on measures of disease severity, with worst values in all PROs measurements.

**Conclusion:** Levels of the joint tissue markers were subtle compared to controls. However, the markers, together with sex and BMI, could predict symptomatic improvement. This may provide novel insight into the link between tissue turnover and PROs.

**REFERENCES:**


**DOI:** 10.1136/annrheumdis-2022-eular.5209

---

POS0025

**PREVALENCE OF ATTENTION DEFICIT HYPERACTIVITY DISORDER AMONG ADULT PATIENTS WITH FIBROMYALGIA**

S. Noyano\(^1\), W. Berrios\(^2\), I. Gandino\(^1\), E. Soriano\(^1\), J. Rosa\(^1\).

\(^1\)Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina; \(^2\)Hospital Italiano de Buenos Aires, Neurology, Buenos Aires, Argentina

**Background:** Fibromyalgia (FM) and attention deficit hyperactivity disorder (ADHD) share some clinical features, and a reduced dopamine function has been proposed for both disorders. ADHD is a chronic condition, marked by persistent inattention, impaired concentration, hyperactivity, impulsivity, emotional lability, anxiety and disorganized behaviour. High rates of comorbidity between ADHD and FM have been reported, as well as some evidence that patients with both conditions experience heightened disease severity.

**Table. Prediction of symptomatic regressive OA in patients with symptomatic knee OA.** Multiple variate logistic regression including In-transformed biomarkers and baseline clinical characteristics (age, gender, race, BMI and NSAID use). Not adjusted for multiplicity.

<table>
<thead>
<tr>
<th>Regressive vs. stable OA</th>
<th>ALL</th>
<th>Low CRPM</th>
<th>High CRPM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>20 mm change(^1)</td>
<td>20 mm change(^1)</td>
<td>20 mm change(^1)</td>
</tr>
<tr>
<td>WOAMC pain n [%](^2) Predictors</td>
<td>61 (41.0)</td>
<td>35 (44.3)</td>
<td>26 (50.0)</td>
</tr>
<tr>
<td>C4M, Age, BMI</td>
<td>0.73 (0.60 – 0.84)</td>
<td>0.73 (0.62 – 0.83)</td>
<td>0.79 (0.58 – 0.92)</td>
</tr>
<tr>
<td>P</td>
<td>0.0042</td>
<td>0.056</td>
<td>0.024</td>
</tr>
<tr>
<td>WOAMC stiffness n [%](^2) Predictors</td>
<td>57 (47.4)</td>
<td>33 (48.5)</td>
<td>24 (45.8)</td>
</tr>
<tr>
<td>C2M</td>
<td>0.67 [0.53 – 0.79]</td>
<td>None</td>
<td>0.85 [0.64 – 0.96]</td>
</tr>
<tr>
<td>P</td>
<td>0.020</td>
<td>0.0007</td>
<td></td>
</tr>
<tr>
<td>WOAMC function n [%](^2) Predictors</td>
<td>61 (27.8)</td>
<td>35 (22.7)</td>
<td>26 (34.6)</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>0.83 [0.63 – 0.95]</td>
<td>0.0074</td>
</tr>
</tbody>
</table>

\(^1\)Regressive disease was defined as 10 or 20 mm or more decrease in VAS pain, WOMAC pain, stiffness or function, and 30 mm or 60 mm or more decrease in WOMAC total, over two-years. \(^2\)Rate of regression in percentage in each of the sub-populations.
Objectives: Our purpose was to determine the prevalence of ADHD symptoms in patients with FM and to assess the relationship with disease impact.

Methods: Consecutive patients, older than 18 years, with diagnosis of FM (ACR 2016 criteria) without known cognitive impairment, seen at the Rheumatology Unit between April 2018 and December 2019, were included. At inclusion visit the collected data included Revised Fibromyalgia Impact Questionnaire (FIQ-R) and Health Assessment Questionnaire, Argentine version (HAQ-A). During the Neurology visit, the following tests were performed: Montreal Cognitive Assessment (MoCa) test for evaluating the presence of cognitive impairment, Connors Continuous Performance Test II (CPT II) for the assessment of ADHD, and Wender-Utah Rating Scale (WURS) to retrospectively assess childhood ADHD symptoms. Univariate analysis was performed using t-tests for normally distributed continuous variables, and Wilcoxon rank sum test for non-normally distributed continuous variables. A chi-square or Fisher test was used when appropriate for categorical variables. Predictors that were found to be related to ADHD (p ≤ 0.20) were then entered into a multivariable logistic regression model.

Results: 60 patients with FM and 71 matched controls without FM or known cognitive impairment were included. FM patients’ characteristics are shown in Table 1. 61.7% (n=37) of the patients with FM tested positive for adult ADHD. In 48.6% (18/37) of them, the diagnosis had been missed in childhood. Participants with both FM and a positive adult ADHD screening test did not score significantly higher on the FIQ-R (52.3, SD= 16.1 vs. 47.9, SD= 12.3; p= 0.2693) and HAQ-A (0.693, SD= 0.455 vs. 0.521, SD= 0.428; p=0.1523) compared with patients without ADHD. Retrospectively assessed childhood ADHD was significantly associated with adult persistence (OR 55.1, CI=3.6 to 842.6, p=0.004).

Table 1. Clinical and demographic characteristics of patients with FM.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n=60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>53 (88.3)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>58.3 (14.2)</td>
</tr>
<tr>
<td>Time from diagnosis (years), mean (SD)</td>
<td>5.2 (5)</td>
</tr>
<tr>
<td>Scholarity (years), mean (SD)</td>
<td>12.9 (3.4)</td>
</tr>
<tr>
<td>HAQ-A, mean (SD)</td>
<td>0.627 (0.449)</td>
</tr>
<tr>
<td>FIQ-R, mean (SD)</td>
<td>50.6 (14.8)</td>
</tr>
<tr>
<td>Cognitive complaint, n (%)</td>
<td>34 (56.7)</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>26 (43.3)</td>
</tr>
<tr>
<td>Anxiety, n (%)</td>
<td>27 (45)</td>
</tr>
<tr>
<td>Concomitant personality disorders</td>
<td>39 (65)</td>
</tr>
</tbody>
</table>

Patients with FM had significantly higher prevalence of cognitive impairment (43.3% vs. 16.9%; p=0.0001), childhood ADHD symptoms (31.7% vs. 14.1%; p=0.016) and adult ADHD symptoms (61.7% vs. 23.9%; p<0.0001) than the control group (Figure 1).

Conclusion: The co-occurrence of adult ADHD in FM was highly prevalent. In nearly half of the patients the diagnosis had been overlooked during childhood and it was associated with adult persistence. The prevalence of cognitive impairment, and childhood and adult ADHD was higher in patients with FM compared with the control group. ADHD was not associated with the FM impact. Evaluation of ADHD symptoms in patients with FM is important for recognition and treatment of this comorbidity.

REFERENCES:

Disclosure of Interests: None declared
Background: Musculoskeletal pain is an important feature in patients (pts) with anterior acute uveitis (AAU), as a symptom of spondyloarthritis (SpA). Fibromyalgia (FM), which is more prevalent in pts with chronic inflammatory diseases, has a widely recognized effect on both differential diagnosis and evaluation of outcome measures in FM. The role of enthesitis in FM patients is not clear. The aim of this study was to estimate the prevalence of primary FM and comorbid FM and SpA in a cohort of pts with AAU, and to compare clinical and ultrasonographic findings in SpA pts with (SpA FM+) and without (SpA FM-) concurrent FM and SpA.

Methods: 146 pts were diagnosed with AAU from 2017 to 2019, and 143 pts were included in this study. A complete rheumatologic assessment, including 68/66 peripheral joint count, Leeds Enthesitis Index (LEI) and Manchester Ankylosing Spondylitis Enthesitis Score (MASES), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Fibromyalgia Impact Questionnaire (FIQ) was performed. Using an Esaote MyLabClass, 18-6MHz linear multifrequency transducer, 6 entheses (lateral epicondyle, distal quadriiceps insertion, proximal and distal patellar tendon insertions, superior iliac crest insertion, Achilles tendons and plantar fascia) were evaluated bilaterally for the presence of any elementary lesion, structural damage and active enthesitis, according to OMERACT definitions. Pts were classified as having SpA and/or FM according to ASAS criteria and 2010 ACR diagnostic criteria for FM, respectively.

Results: 103 pts were diagnosed with anterior acute non granulomatous uveitis (AANGU) and 49 with anterior acute granulomatous uveitis (AAGU) (FM 93/59, age 46.2±12.3 years, BMI 25±5.1, disease duration 43.8±85.2 months). 14 pts (9.2%) met the ACR criteria for FM, of whom 8 pts had concomitant FM and SpA. All FM pts had AANGU. FM pts showed significantly higher enthesitis count and report worse disease activity and function scores (Table 1). Fulfillment of ASAS criteria was associated with FM (p<0.004).

Table 1. Demographic and clinical data of FM patients (results for continuous variables expressed as mean ± standard deviations, for discrete variables as n° and percentage)

<table>
<thead>
<tr>
<th>Variable</th>
<th>FM+ (14)</th>
<th>FM- (138)</th>
<th>p</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>48 ±11.7</td>
<td>46 ±12.4</td>
<td>0.569</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>10 (71.4%)</td>
<td>83 (69%)</td>
<td>0.409</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>24.7±5.5</td>
<td>25 ±5 2</td>
<td>0.831</td>
<td></td>
</tr>
<tr>
<td>AANGU</td>
<td>14 (100%)</td>
<td>89 (64.5%)</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>SpA</td>
<td>8 (57%)</td>
<td>30 (22%)</td>
<td>0.004</td>
<td>4.8 (1.6 – 14.9)</td>
</tr>
<tr>
<td>ax-SpA</td>
<td>6 (43%)</td>
<td>18 (13%)</td>
<td>0.004</td>
<td>5 (1.6 – 16.1)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>2 (14.3%)</td>
<td>9 (6.5%)</td>
<td>0.268</td>
<td></td>
</tr>
<tr>
<td>IBP</td>
<td>7 (50%)</td>
<td>19 (14%)</td>
<td>0.001</td>
<td>6.3 (2 – 19.9)</td>
</tr>
<tr>
<td>Buttok pain</td>
<td>9 (64%)</td>
<td>24 (17%)</td>
<td>&lt;0.001</td>
<td>8.6 (2.63 – 278)</td>
</tr>
<tr>
<td>History of enthesitis</td>
<td>7 (50%)</td>
<td>20 (14.5%)</td>
<td>0.001</td>
<td>5.8 (1.9 – 18.6)</td>
</tr>
<tr>
<td>T/C</td>
<td>2.6 ± 3.8</td>
<td>0.6 ± 1.8</td>
<td>0.072</td>
<td></td>
</tr>
<tr>
<td>LEI</td>
<td>1.9 ± 1.2</td>
<td>0.5 ± 1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>MASES</td>
<td>3.8 ± 3.4</td>
<td>0.8 ± 2</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>BASDAI</td>
<td>5.1 ± 1.7</td>
<td>1.8 ± 1.7</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>BASFI</td>
<td>2 ± 4</td>
<td>0.6 ± 1.2</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>FIOQ</td>
<td>0.6 ± 0.6</td>
<td>0.3 ± 0.8</td>
<td>0.176</td>
<td></td>
</tr>
<tr>
<td>FIOQ2</td>
<td>4.2 ± 2.3</td>
<td>1.1 ± 1.5</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>FIOQ3</td>
<td>1.9 ± 2.4</td>
<td>0.4 ± 1.3</td>
<td>0.044</td>
<td></td>
</tr>
<tr>
<td>FIOQ4</td>
<td>38.9 ± 13.5</td>
<td>16.2 ± 13.9</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

SpA FM+ pts more frequently reported an history of enthesitis (75% vs 23.3%, p=0.011 OR 9.9 (95% CI 1.6 – 62.2) and buttok pain (75% vs 33.3%, p=0.034 OR 6 (95% CI 1.02 – 35.3)) when compared with SpA FM-, while no significant differences in LEI, MASES, joint count, and inflammatory back pain (IBP), as well as in sex, age and BMI were observed.

BASDAI, FIOQ and FIOQ4 were increased in SpA FM+ (6±1.1 vs 3.4±1.8 p<0.001, 4.3±2.1 vs 1.7±2.2 p= 0.005 and 43.6±11.4 vs 24.6±15.5 p=0.003 respectively).

Abnormal US findings were detected in 35/38 SpA pts (92.1%), without significant differences in elementary lesions and structural damage between SpA FM+ and SpA FM-. At patient-level, a significantly higher percentage of SpA FM+ pts had at least one active enthesitis, as compared with SpA FM- (25% vs 3.4%, p = 0.048).

Conclusion: Comorbid FM was frequent in SpA associated with AANGU, affecting both clinical presentation and outcome measures, whereas no FM patients were found in the AAGU group. In our cohort the role of ultrasonography in discriminate SpA FM+ from SpA FM- is not clear.

REFERENCES:

Disclosure of Interests: None declared
Genomics, functional genomics and genetic basis of inflammatory arthritis

**CHARACTERISING THE CLINICAL AND RADIOLOGICAL PHENOTYPE OF PSORIATIC ARTHRITIS: A CLASS I AND II HLA ALLELES STUDY**


**Background:** Psoriatic arthritis (PsA) is a heterogeneous disease affecting multiple tissues including skin and joints. Few studies have fully explored the association between class I and II HLA alleles and different clinical and radiological manifestations.

**Objectives:** To examine the association between different class I and II HLA alleles and certain PsA phenotypes.

**Methods:** Cross-sectional study including patients with PsA over 18 years. All patients fulfilled the CASPAR classification criteria for PsA. Demographic, clinical, laboratory and radiology data were gathered including variables related to joint phenotype, type of skin involvement and response to biologics.

**Results:** A total of 246 patients were included. Mean age of the cohort was 59.8 years and 53% were men. Average arthritic disease duration was 12.4 years. A total of 39.8% patients had axial involvement and 90.7% peripheral, being the polyarticular the most frequent subtype in 48% of cases. Considering the skin, mean disease duration was 22.2 years, being the plaque psoriasis the most frequent subtype in 75.2% of cases. 44.3% of the patients presented a history of dactylitis whilst 24% presented enthesitis. Uveitis was reported in 3.7% of patients and Cohn’s disease in 0.4%. 30.9% of PsA patients had erosions in the hand or feet x-ray. More than half (59.3%) were treated with bDMARDs with a median exposure of 2 different drugs.

**Conclusion:** In our cohort, we have confirmed previously described associations in the literature and found new significant associations with clinical and radiographic PsA manifestations including class II HLA analysis.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4618

**Table 1. HLA class I and II alleles with frequencies greater than 5%**

<table>
<thead>
<tr>
<th>HLA</th>
<th>ALELE</th>
<th>N</th>
<th>FREQUENCY (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-A</td>
<td>02:01</td>
<td>79</td>
<td>23.87</td>
</tr>
<tr>
<td></td>
<td>01:01</td>
<td>51</td>
<td>15.41</td>
</tr>
<tr>
<td></td>
<td>29:02</td>
<td>29</td>
<td>8.76</td>
</tr>
<tr>
<td></td>
<td>03:01</td>
<td>26</td>
<td>7.85</td>
</tr>
<tr>
<td>HLA-B</td>
<td>27:05</td>
<td>31</td>
<td>9.06</td>
</tr>
<tr>
<td></td>
<td>44:03</td>
<td>26</td>
<td>7.6</td>
</tr>
<tr>
<td></td>
<td>51:01</td>
<td>22</td>
<td>6.43</td>
</tr>
<tr>
<td></td>
<td>08:01</td>
<td>21</td>
<td>6.14</td>
</tr>
<tr>
<td>HLA-C</td>
<td>07:01</td>
<td>39</td>
<td>11.78</td>
</tr>
<tr>
<td></td>
<td>06:02</td>
<td>38</td>
<td>11.48</td>
</tr>
<tr>
<td></td>
<td>04:01</td>
<td>34</td>
<td>10.27</td>
</tr>
<tr>
<td></td>
<td>12:03</td>
<td>32</td>
<td>9.67</td>
</tr>
<tr>
<td>HLA-DR</td>
<td>07:01</td>
<td>60</td>
<td>18.13</td>
</tr>
<tr>
<td></td>
<td>01:01</td>
<td>37</td>
<td>11.18</td>
</tr>
<tr>
<td></td>
<td>03:01</td>
<td>28</td>
<td>8.46</td>
</tr>
<tr>
<td>HLA-DQ</td>
<td>05:01</td>
<td>60</td>
<td>19.8</td>
</tr>
<tr>
<td></td>
<td>02:02</td>
<td>49</td>
<td>16.17</td>
</tr>
<tr>
<td></td>
<td>03:01</td>
<td>39</td>
<td>12.87</td>
</tr>
<tr>
<td></td>
<td>02:01</td>
<td>29</td>
<td>9.57</td>
</tr>
</tbody>
</table>

HLA-B*27:05 (OR 2.3, CI 95% 1.01-5.47) and HLA-C*02:02 (OR 2.8, CI 95%, 1.08-7.35) were associated with axial involvement. HLA-DRB*03:01 (OR 3.1, CI 95%, 1.22-8.36) and HLA-DQ*02:01 (OR 3.24, CI 95%, 1.3-8.82) were associated with the polyarticular subtype, HLA-B*08:01 (OR 5, CI 95%, 1.81-14.33), HLA-C*07:01 (OR 2.65, CI 95%, 1.19-5.76) and HLA-DQ*02:01 (OR 2.55, CI 95%, 1.03-6.11) with enthesitis; HLA-A*02:09 (OR 2.68, CI 95%, 1.12-6.75) and HLA-A*11:01 (OR 2.77, CI 95%, 1.06-7.78) with dactylitis; HLA-C*06:02 (OR 2.33, CI 95%, 1.09-5.06) with nail psoriasis; HLA-C*04:01 (OR 3.52, CI 95%, 1.18-9.64) with palmoplantar psoriasis; HLA-C*06:02 (OR 4.5, CI 95%, 1.3-23.7) and HLA-C*12:03 (OR 3.59, CI 95%, 1.05-19.05) with plaque psoriasis and HLA-A*24:02 (OR 3.03, CI 95%, 1.17-792) with erosions. No association was found between alleles and bDMARD resistant PsA patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3104

**Clin. Transl. Immunology**

**Table 1. Median mSASSS in patients with AS and factors associated with severe radiographic damage**

<table>
<thead>
<tr>
<th>Factor</th>
<th>β</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral joint involvement</td>
<td>-0.221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at enrollment</td>
<td>0.818</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total ankylosis</td>
<td>1.105</td>
<td>1.97x10^-06</td>
</tr>
</tbody>
</table>

In our cohort, we have confirmed previously described associations in the literature and found new significant associations with clinical and radiographic PsA manifestations including class II HLA analysis.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4618
Genomics, functional genomics and genetic basis of inflammatory arthritis

**FUNCTIONAL GENOMIC INVESTIGATION OF THE ANKYLOSING SPONDYLITIS ASSOCIATED LOCUS RUNX3**

C. Cohen1, D. Simoné1, C. Selmi1, P. Bowness1, P. B. Wordworth1, M. Vecellio1.

**Background:** Ankylosing Spondylitis (AS), is a highly heritable disease with >100 genomic loci incriminated. Among these, RUNX3, a transcription factor (TF) involved in diverse immunological processes, is robustly (10−15) associated.

**Methods:** We have extensively investigated the single nucleotide polymorphism (SNP) rs4648889 located in a 2kb regulatory locus upstream of the RUNX3 promoter. We have demonstrated that the association between AS and this SNP can be explained by allele-specific effects on TF recruitment (including IRF4, IRF5 and the NuRD complex) that alter gene expression, specifically in CD8+ T-cells, and having a crucial role in CD8+ T-cells function. Further, we have recently shown a clear chromatin looping event between the region encompassing SNP rs4648889 and the RUNX3 promoter confirming the functional role of this variant.

**Objectives:** The purpose of this work is: (1) to better characterise the chromatin looping landscape of the whole AS-associated RUNX3 genomic locus and (2) to determine the single-cell expression of the RUNX3-related genes identified previously.

**Results:**

1. In addition to the recent results published, 3C-qPCR experiments revealed a high interaction frequency between the distal promoter of RUNX3 and an intrinsic region (called Int2), overlapping open chromatin and TF binding sites. This was highly reproducible in both cell lines analysed.
2. Four different clusters were identified in CD8+ T-cells obtained from AS peripheral blood via 10x sc-seq based on the expression of RUNX3 and RUNX3-related genes expression profile in CD8+ T-cells.
3. Comparing results obtained through HOCOMOCO and Remap databases resulted in a list of 68 unique TFs. Many of these are key regulators of adaptive immune responses, cellular metabolism, and pluripotency.

**Conclusion:** This study provides experimental evidence that survivin defines a plausible functional role in AS, probably by regulating gene transcription and DNA looping. These observations are critically important in defining dysregulated pathways and potential therapeutic drug targets.

**REFERENCES:**


**DISCLOSURE OF INTERESTS:**

Cara Cohen: None declared, Davide Simoné: None declared, Carlo Selmi Speakers bureau: Speakers fee (AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Lilly, Lilly, Janssen, MSD, Novartis, Pfizer, Sanofi-Genezyme), Consultant of: Consulting (AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Lilly, Janssen, MSD, Novartis, Pfizer, Sanofi-Genezyme), Grant/research support from: Research support (AbbVie, Amgen, Janssen, Pfizer), take Bowness Grant/research support from: Grant (BMS, GSK, Paul Bryan Wordsworth: None declared, Matteo Vecellio: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1134

**FUNCTIONAL ROLE OF SURVIVIN IN ORGANIZATION OF BIVALENT CHROMATIN REGIONS AND CONSEQUENCE FOR ARTHRITIS-RELEVANT GENE EXPRESSION**

V. Chandrasekaran1, M. I. Bokarewa1, N. Opara1, K. M. Andersson1, G. Katona1, M. Erlandsd1, M. Jensen1, A. Damdimopoulos1.
1. Institute of Medicine, University of Gothenburg, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden; 2. University of Gothenburg, Department of Chemistry and Molecular Biology, Gothenburg, Sweden

**Background:** Bivalent chromatin (BvCR) is characterized by the presence of simultaneous active and repressive modifications on histone H3 proteins. Influencing expression of the genes, BVCR determine cell fate and direct differentiation and lineage commitment in primary T cells and contribute to autoimmunity. Survivin is highly expressed during T cell division and in effector Th1 cells contributing to aggravation of autoimmune inflammation. Survivin can physically bind to DNA, specifically to Threonine-3 of histone H3 (1). Thus, functional, and mechanistic data point to a potential chromatin regulatory role for survivin, potentially acting in combination with histone epigenetic modifications (EMs).

**Objectives:** The goal of our study is to establish the colonization of survivin in BVCR and to deduce functional effects of this collaboration on chromatin organization and gene expression.

**Methods:** Chromatin from CD4+ T cells of 14 female subjects was immunoprecipitated with survivin antibodies and histone H3K27ac, H3K27me3, H3K4me3 antibodies, and coupled with DNA sequencing (ChiPseq, Hissee2000, Illumina). BVCR were identified as exact overlaps of the three histone EM peaks and the overlapping regions were searched for co-localization with survivin using the ‘ChiPPeakAnno’ Bioconductor package. Tag counts K27me3/K27ac were defined as inactive/poised BVCR, while tag count K27me3+K27ac were identified as active BVCR. Motif search was done through the MEME tool, and high/ moderate complexity motifs with E-value >10e-5 were selected and scanned through the HOCOMOCO database to identify consens thematic transcription factors (TF) found in TFs co-localized with the BVCR and identified through Remap database. To identify survivin sensitive genes, CD4+ T cells were treated with survivin inhibitor YM155 and a list of reproducible DEG (log2FC[0.4], |1| expression) was mapped and analysed for clustering with BVCR.

**Results:** Co-localization of survivin ChiP peaks with individual H3-peaks was significantly less frequent compared to overlap with all three (a3-H3 BVCR (7.1 vs 29.8%, p=8.9e-10). Overlap of a3-H3 peaks not containing survivin was less frequent (34%) compared to those which contained survivin (68%). Notably, survivin peak size was 5.5-fold higher when co-localized with a3-H3 peaks, compared to no, or any single H3 (p=2.2e-16). In contrast, no size difference for any of the H3 EM peaks was found.

Further analysis of two non-redundant groups of BVCR that contain (survivin-a3H3, n=4085), and not containing survivin-a3H3 (n = 2131) demonstrated that survivin was mostly associated with inactive BVCR (OR1.29, p=6.6e-6), while no such specificity was found for BVCR with no survivin. Additionally, survivin containing BVCR contained abundant binding sites matching known consensus TF motifs. No sequence-specific motifs were identified in BVCR with no survivin. Comparison of results obtained through HOCOMOCO and Remap databases resulted in a list of 68 unique TFs. Many of these are key regulators of adaptive immune responses, cellular metabolism, and pluripotency. Differentially expressed genes mapped to BVCR demonstrated enrichment for cellular hormone metabolic processes, regeneration and DNA biosynthesis.

**Conclusion:** This study provides experimental evidence that survivin defines binding specificity in bivalent chromatin regions being associated with regulation of cellular metabolism and renewal of CD4+ T cells that are functionally important to resist autoimmunity.

**REFERENCES:**


**DISCLOSURE OF INTERESTS:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4856

**GENETIC INVESTIGATION OF TUMOUR NECROSIS FACTOR INHIBITOR IMMUNOGENICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS**

C. F. Yang1, N. Nair1, K. Hyrich1, A. G. Wilson2, J. Isaac1, A. Morgan3, A. Barton1, D. Plant1.
1. The University of Manchester, Centre for Genetics and Genomics, Manchester, United Kingdom; 2. The University of Manchester, Centre for Epidemiology, Manchester, United Kingdom; 3. University College Dublin, School of Medicine & Medical Science, Conway Institute, Dublin, Ireland

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the synovial joints. Tumour Necrosis Factor inhibitor (TNFi) therapy has transformed the clinical management of RA. However, monoclonal antibody derived TNFi is associated with development of immunogenicity and subsequent loss of therapeutic effects. Previous studies have observed associations between certain HLA alleles and TNFi immunogenicity. For example
HLA-DQA1 and HLA-DRB1 have been associated with immunogenicity in inflammatory bowel disease [1,2] and RA [3,4], respectively.

**Objectives:** The aims of this study were to identify associations between HLA alleles and immunogenicity to TNFi in an observational cohort of RA patients and to replicate findings from previous studies.

**Methods:** Anti-drug antibody titres were measured using radioimmunoassay in serum samples from RA patients participating in Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS). An anti-drug antibody titre of ≥12 AU/mL following six months on treatment was used to define positive immunogenicity. Genotype data were generated using Illumina HumanCoreExome Arrays. Standard quality control (QC) was applied prior to HLA imputation using SNP2HLA software before low minor allele frequency markers were removed. Logistic regression was used to study the association between HLA alleles and immunogenicity, whilst the omnibus test was applied to amino acid positions; sex and concurrent conventional synthetic DMARD use were included as a covariate in all the models.

**Results:** In total, 445 RA patients were analysed, 377 patients (70 immunogenicity events) were underdosing adalimumab therapy and 68 corticosteroid (30 immunogenicity events) therapy, following QC, 162 HLA alleles and 361 amino acids positions were available for analysis. The strongest HLA allele association was observed for HLA-DQA1*03 when all patients were analysed (OR = 0.61; 95% CI = 0.43 – 0.86; p-value = 5e-3) and 26 (p-value = 5e-3) within the HLA-DQA1 gene were significantly associated with immunogenicity events. When both drugs were analysed separately, they produced similar effect size for HLA-DQA1*03 association; patients treated with adalimumab (OR = 0.59; 95% CI = 0.38 – 0.88; p-value = 1e-2) and corticosteroids (OR = 0.52; 95% CI = 0.24 – 1.1; p-value = 1e-1). Another strong association was found for HLA-DRB1*04:01 (OR = 0.62; 95% CI = 0.44 – 0.88; p-value = 7e-3) and the amino acid position of 180 (p-value = 7e-3) and 33 (p-value = 7e-3) of HLA-DRB1 gene. Additionally, the similar protective effect between the two presented alleles suggested possibility of linkage disequilibrium, upon investigation the r² between the 2 alleles is 0.69.

**Conclusion:** The current study increases the evidence for association between immunogenicity development with HLA-DQA1 and HLA-DRB1 alleles in patients receiving monoclonal antibody derived TNFi therapy. Further well powered studies are now required to determine the utility of HLA markers as a potential tool to aid the clinical management of RA.
Methods: CD4+ and CD8+ T cells were isolated from peripheral blood from 10 healthy controls and 48 PsA patients and from 6 PsA synovial fluid samples. We performed RNA-seq and ATAC-seq on these two cell types to analyse the global patterns of gene expression and chromatin activity.

Results: We find subtle differences between PsA patients and healthy controls in cells isolated from blood. RNA-seq analysis identified only a handful of differentially expressed genes whilst ATAC-seq analysis identified only 28 differentially loci. On the other hand, T cells isolated from synovial fluid showed significant differences compared to T cells isolated from patient’s blood. Interestingly, we find that CD4+ T cells as well as CD8+ T cells more differently expressed genes compared to CD8+ T cells (1168 vs 346 Log2FoldChange > 1, FDR < 0.01). Genes overexpressed in synovial CD4+ T cells are more strongly enriched for immune pathways such as cytokine signaling and T cell proliferation compared to synovial CD8+ T cells.

We also find that synovial CD4+ T cells highly overexpress MHC class II genes (Figure 1).

Conclusion: This preliminary analysis suggests that T cells isolated from peripheral blood do not seem to differ significantly between PsA patients and healthy controls. In contrast, cells isolated from synovial fluid are highly specialized and activated. Moreover, these cells do not resemble canonically activated T cells which means that this state can not be easily emulated in vitro.

This study indicates the importance of not only studying GWAS loci in relevant primary cells from patients, but also that attention needs to be given to cells isolated from the affected tissue.

REFERENCES:

A total number of 63 RA patients according to the 1987 ACR criteria were included non-steroidal antiinflammatory drugs (NSAIDs) and glucocorticosteroids (GCS), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and original biological DMARDs. There were no patients treated with conventional target DMARDs or biosimilar DMARDs. SPSS was used for statistical analysis.

Results: RA PB showed statistically significant overexpression of miR-223 (58.73%) when compared to HCs and only miR-223 expression levels could be used to differentiate RA patients from HCs (ρ=0.008). RA SF showed overexpression of miR-146a (in 70.83%, ρ=0.007), miR-155 (in 79.17%, p=1.63x10^-4) and of miR-223 (in 79.17%, p=1.64x10^-3) when compared to HCs and the studied miRNAs could be used to differentiate RA patients from HCs (p=4.8x10^-1, p=8.0x10^-3, and p=2.8x10^-4, respectively). When we analyzed the correlation between the expression of miRNAs and the ongoing treatment we found a statistically significant correlation between the PB expression levels of miR-223 and the use of NSAIDs and GCS (ρ=0.015 and p=0.04, respectively) and the SF expression levels of miR-146a and miR-155 and the use of NSAIDs (ρ=0.011 and 7.98x10^-4, respectively) and GCS (ρ=0.039 and p=0.009, respectively). The use of csDMARDs and bDMARDs did not show correlation with the PB nor the SF expression of the studied miRNAs.

Conclusion: The correlation between the systemic miR-223 and the local miR-146a and miR-155 expression with the NSAIDs and GCS treatment could be due to the effect of these treatment compounds on the cells lines from which the studied miRNAs origin. In our study there was no correlation between miRNA expression and the use of biological and conventional DMARDs. Further analysis with larger sets including pre- and posttreatment samples is needed to confirm if altered miRNA expression could be influenced by the treatment regimen as well as if miRNAs could serve as biomarkers for treatment response in the clinical practice.
Conclusion: This MR study does not support a causal effect of genetically determined adiponectin levels on the risk of developing RA in both European and East Asian populations. By using multiplicative MR to account for possible shared genetic predictors between circulating adiponectin levels and BMI we have shown that circulating adiponectin is not causally linked to RA risk after adjustment for BMI.

REFERENCES:

Acknowledgements: We would like to thank Maria Nethander, Jari Martikainen and Malin Östensson from the Bioinformatics Core Facility at the Sahlgrenska Academy for bioinformatics. We would also like to thank all study participants who agreed to have their DNA used for genetic testing and all the people involved in the study who made their data publicly available.

Disclosure of Interests: None declared

POS0038 GENOMICS OF JAK-STAT SIGNALING IN VENOUS THROMBOEMBOLISM
S. Haynen1, A. L. L. Nielsen1, P. Ovist1, T. W. Krastrup1, 1Aarhus University, Department of Biomedicine, Aarhus, Denmark

Background: Janus kinase inhibitors (JAKi) have been associated with an increased risk of venous thromboembolism (VTE) [1]. VTE comprises deep vein thrombosis and pulmonary embolism and is associated with complications such as recurrent VTE, post thrombotic syndrome, pulmonary hypertension, and death. These concerns limit the use of JAKi-based therapy. To improve risk stratification and drug development, it is crucial to understand the possible implication of dysregulated JAK-signaling in the pathogenesis of VTE.

Objectives: The objective of this study is to clarify the putative genomic vulnerability associated with dysregulated JAK-STAT signaling in VTE.

Methods: We are systematically mine and analyze large-scale genomic datasets generated from studies comparing VTE patients with healthy controls. Using VTE genome-wide associated (GWA) summary statistics we evaluate the representation of genes encoding the JAK-STAT pathway (KEGG hsa04630) in associated loci and assess their association to VTE. Further, we examine the genetic VTE risk burden in the chromatin interactome of STAT family transcription factors (TFs). We extract available STAT family (STAT-1) TF binding site (TFBS) consensus DNA motifs (JASPAR database) and assess the association of genes containing STAT family TFBS within their promotor sequence (TSS < 2000bp) to VTE. Through mining of deposited OMICs data from VTE patients, we examine molecular characteristics related to JAK-STAT signaling, including potential enrichment of STAT family TFBS among query promoter sequences of differentially expressed genes (DEGs).

Results: We do not observe a significant overrepresentation of JAK-STAT genes (n=162) among genes annotated to VTE significant GWA loci (n=147, p=0.48). Similarly, the JAK-STAT gene set show no cumulative association to VTE (p=0.98). Applying the same gene set association approach to the STAT target gene sets (n=4570) does not reveal significant association between VTE and STAT1 (n=18, p=0.17) and STAT3 (n=48, p=0.20) target gene sets. At the functional molecular level, we do not see any significant overlap between molecules acting in the JAK-STAT pathway and DEGs (n=507, p=0.06) or differentially abundant proteins (DAPs; n=35, p=0.57). However, we observe a significant overlap between downregulated DEGs (n=362) and the STAT1:STAT2 heterodimer target gene set (n=2155, n=48, p=0.0001) including downregulation of IL-27RA and CCND3 (Figure 1). Supporting the biological relevance of this finding, we find a weak but statistically significant enrichment of STAT1 TFBS motifs in the promoter sequence of downregulated DEGs compared to non-DEGs (p=0.02).

Figure 1. Overlap between STAT1:STAT2 heterodimer gene set and differently expressed genes (DEGs) in venous thromboembolism (VTE)

Conclusion: Here, we provide a coherent approach to assess the genomic basis for the reported association between JAKi treatment and VTE. Our preliminary data suggest that genes under transcriptional control of STAT family TFs may be dysregulated in VTE patients. It is conceivable, that the genomic actions of JAKi is overlapping with the molecular risk profile of VTE. CCND3 is especially interesting because VTE occurs in up to 10% of patients treated with cyclin-dependent kinase inhibitors such as Palbociclib [2]. Obviously, genomic data mining alone cannot guide medical decision making concerning the use of JAKi. However, our results provide a basis for further investigation of adverse events seen with JAKi.

REFERENCES:

Disclosure of Interests: Stine Haynen: None declared, Ane Langkilde-Lauritsen Nielsen: None declared, Per Ovist: None declared, Tue Wenzel Kragstrup Speakers bureau: Speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and Abbvie., Consultant of: Consultancy fees from Bristol-Myers Squibb and Gilead, Grant/research support from: Research grants from Gilead., Employee of: Co-founder and clinical developer in iBio tech ApS.

POS0039 MONOYE TRANSCRIPTOMICS AND TARGETED PROTEOMICS DEFINE HETEROGENEOUS SUBGROUPS IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND SUBCLINICAL ATHEROSCLEROSIS
L. Woodrige1,2, E. Chocano1,2, P. Ashford3, G. Robinson4, K. Waddington1,2, A. Rahman1, C. Orengo3, E. Jury4, I. Pineda Torra1, 1Centre for Cardiometabolic and Vascular Science, Division of Medicine, UCL, London, United Kingdom; 2Centre for Rheumatology Division of Medicine, UCL, London, United Kingdom; 3Institute of Structural and Molecular Biology, Biosciences, UCL, London, United Kingdom; 4University of Dundee, Dundee, United Kingdom
Background: Systemic lupus erythematosus (SLE), a chronic, inflammatory autoimmune disease, predominantly affects women with a 9:1 female: male incidence. Cardiovascular disease (CVD) is a leading cause of mortality in SLE via accelerated atherosclerosis: the build-up of cells and lipids in the vascular wall and the main pathology underlying CVD.

Objectives: To define molecular profiles of SLE with subclinical atherosclerosis using multi-omics data analysis and clinical data in a well-characterised cohort of CVD-free SLE women.

Methods: Multi-omics analyses were conducted to explore the molecular signatures of SLE patients with (SLE-P) and without (SLE-NP) subclinical atherosclerosis defined by non-invasive ultrasound scanning of the carotid and femoral arteries. SLE blood CD14+ monocyte transcriptomes were investigated by bulk RNA-sequencing (SLE-P N=13, SLE-NP N=8), and targeted serum cardiometabolic and cardiovascular proteomics (OLINK) were used to expose matched protein expression (SLE-P N=17, SLE-NP N=20) (no difference in disease activity between groups). Bioinformatics approaches, including pathway and disease module enrichment analyses and extended protein-protein interaction networks, further defined molecular profiles of SLE patients with atherosclerosis from patients that remained plaque-free. Gene signature-derived interferon (IFN) scores were applied to investigate heterogeneous subgroups within the cohort as a measure of inflammation.

Results: Distinct monocyte gene and protein expression profiles were identified in SLE and enriched in biological pathways relating to extracellular matrices, including purinergic and cytokine signalling. Lipid regulatory mechanisms were enriched in SLE-P, whereas SLE-NP patient's transcriptome and proteome profiles were defined by pathways relating to inflammation. Specifically, the type-I IFN pathway was exclusively reduced in SLE-P compared to SLE-NP. IFN scores derived from published responsive gene expression signatures stratified patients into significantly distinct subgroups (high versus low IFN-response, p=0.0001) with 66% (N=14) of patients showing high IFN expression across multiple signatures not associated with age, ethnicity, or disease activity. However, IFN scores did not predict the presence of sub-clinical atherosclerosis and further heterogeneity was revealed with 46% of SLE-P patients showing a low IFN response (N=6). Further, a measure of plaque lipid content (echogenicity) was inversely correlated with IFN score (grey scale median, p=0.03, r=−0.8) which may reflect distinct plaque phenotypes between these subgroups relating to clinical presentation and risk of cardiovascular events.

Conclusion: Lipid dysregulation is a key mechanism that drives atherosclerosis pathology and genes and proteins relating to lipid metabolism distinguished SLE patients with and without subclinical atherosclerosis. Differences in levels of interferons and other inflammatory molecules may contribute to unique patterns of gene expression between SLE patients. A distinct subset of SLE-P patients showed low interferon expression, which may be suggestive of a dampened immune response in early subclinical CVD. Further elucidating the complexity of lipid dysregulation, inflammation and immune function in atherosclerosis in SLE will help improve patient stratification towards investigating the efficacy of anti-atherosclerotic therapies.

Disclosure of Interests: None declared


HPR Poster Tour: Moving together towards person-centred care

A long-list of 134 initial candidate questionnaire items was developed from the individual themes. These items were reviewed by a qualitative working group of patient research partners, researchers and clinicians to reduce duplication and ambiguity of items. The resulting 62 items were tested and refined by piloting with patient research partners, iterative rounds of cognitive interviews with patients with a range of rheumatic conditions from the UK, USA and Australia, and a linguistic translatability assessment, to define a draft questionnaire of 40 items.

Disclosure of Interests: Susan Bridgewater Grant/research support from: Vifor Pharma, Michael A Shepherd Grant/research support from: Vifor Pharma, Jill Dawson: None declared, Pamela Richards: None declared, Christine Silverthorne: None declared, Nwidi Ndosi: None declared, Celia Almeida: None declared, Rachel J Black: None declared, Jonathan T.L. Cheah: None declared.
OUTCOME MEASURES IN RHEUMATOLOGY APPLIED IN SELF-MANAGEMENT INTERVENTIONS TARGETING PEOPLE WITH INFLAMMATORY ARTHRITIS - A SYSTEMATIC REVIEW OF OUTCOME DOMAINS AND MEASUREMENT INSTRUMENTS

C. Hansen¹, B. A. Ebsen², A. De Thurah³, R. Christensen⁴, M. De Wit⁵, P. F. Cromhout⁶. "Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup, Denmark; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Glostrup, Denmark; University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; Aarhus University Department of Clinical Medicine, Aarhus, Denmark; Bispebjerg and Frederiksberg Hospital, Section for Biostatistics and Evidence-Based Research, the Parker Institute Copenhagen, Denmark; Odense University Hospital, Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense C, Denmark; 6Outcome Measures in Rheumatology ‘OMERACT’, Patient Research Partner, Amsterdam, Netherlands

Background: Self-management refers to the patient’s ability to manage a large range of consequences such as symptoms, medication, emotions, and preferable lifestyle changes coherently with living with a chronic disease. Evaluating the effect of interventions targeting to improve people with inflammatory arthritis (IA) self-management is a challenge because self-management interventions are complex and consensus on important outcomes is lacking. Solutions to these issues could be to consensus on a Core Outcome Set (COS) describing what outcomes are relevant and should be applied in future studies hereby lessening the heterogeneity between future studies. The purpose of this study was therefore to take the first actions in identifying possible candidate outcomes for such a COS.

Objectives: The aim was to identify, and map applied outcome domains and outcome measurement instruments from previous trials measuring the effect of self-management interventions targeting people with IA.

Methods: We performed an informative systematic literature review following guidance from the Handbooks described by ‘Outcome Measures in Rheumatology’ (OMERACT) and Core Outcome Measures in Effectiveness Trials (COMET) initiatives. Randomized and non-randomized trials describing their experimental intervention as “self-management” and included a population of adults (≥18 years) with at least 50% diagnoses with IA (Rheumatoid arthritis, Psoriatic arthritis, Spondyloarthritis) was included. Both screening of possible trials and data extraction was performed independently by two reviewers. Extracted data included: study characteristics, outcome domains and the corresponding measurement instruments. During analysis two reviewers simultaneously grouped and categorized domains and subdomains, and two senior researchers approved the categorization.

Results: Searches was performed 2021.02.08 on online databases, trial registries, conference abstracts and references of included trials. From a total of 2,502 records, we included 38 trials published between 1988 and 2021. The interventions were heterogeneous and patients primarily female, diagnosed with Rheumatoid arthritis, and a calculated mean age of 54 years. We identified 12 different outcome domains and sub-domains, covering 39 subdomains, collected with 119 different measurement instruments. The most frequently applied outcome domains were self-efficacy, pain, physical functioning/disability, anxiety and depression, quality of life, fatigue, global assessment/disease activity and coping. Please see Figure 1 for all outcome domains and sub-domains. The applied measurement instruments varied within each outcome domain with up to 10 different instruments applied to measure the same domain. Instruments were predominantly patient-reported outcomes.

Conclusion: The outcome domains and measurement instruments used in self-management trials were widely diverse and differ from the current general OMERACT Core Outcome Sets (COS) for IA conditions. Further steps towards the establishment of a COS to be reported in all self-management intervention trials will enhance the relevance and the subsequent impact on the body of evidence from these trials.

REFERENCES: The protocol was registered in PROSPERO (ID CRD42021238749).


HOW DOES WEEKLY SUPERVISED GROUP EXERCISE CONTRIBUTE TO FULFILLING EXERCISE RECOMMENDATIONS IN PATIENTS WITH AXIAL SpondyloArthritis?

B. Hilberdink¹, M. Carbo², D. Paap³, S. Arends³, 4, T. P. M. Vliet Vlieland⁵, F. Van der Giesen¹, A. Spoorenberg¹, 4, S. Van Weely³. ¹Leiden University Medical Center, Department of Orthopaedics, Rehabilitation and Physical Therapy, Leiden, Netherlands; ²University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; ³Saxion University of Applied Sciences, Department of Physical Therapy, Enschede, Netherlands; ⁴Medical Center Leeuwarden, Department of Rheumatology, Leeuwarden, Netherlands; ⁵Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands

Background: Supervised group exercise (SxE) has been recommended for people with axial spondyloarthritis (axSpA) since decades, but the proportion and type of axSpA patients that engage in SxE is unknown. In addition, the 2018 EULAR recommendations for physical activity advocate that people with axSpA should engage in aerobic, strength and mobility exercises according to public health physical activity guidelines. However, it is unclear if SxE contributes to fulfilment of these exercise recommendations.

Objectives: To compare characteristics, health status and fulfilment of exercise recommendations between axSpA patients with and without SxE.

Methods: Cross-sectional data from three Dutch axSpA study cohorts were analysed: two cohorts with patients recruited at rheumatology outpatient clinics (n=196 and n=153) in which participation in SxE was recorded (yes/no) and one cohort with only SxE participants (n=128). Assessments included sociodemographic and disease characteristics, health status (ASAS Health Index), spinal mobility and the ‘short questionnaire to assess health enhancing physical activity’
(SQUASH). The SQUASH was used to determine fulfilment of the public health recommendations for leisure-time aerobic exercise (≥150 min/week of moderate-intensity or ≥75 min/week of vigorous-intensity exercise) and for strength and mobility exercises (≥2 sessions/week). Differences between patients with and without SGE were analysed using the Mann-Whitney U test and the Chi-Square test. Multivariate regression models were performed to correct the association between SGE and fulfilment of the exercise recommendations for age, sex, employment and health status.

Results: In the two outpatient axSpA cohorts, 17 of the 349 patients (5%) participated in SGE. The total group of SGE participants (n=145) was significantly older, had longer disease duration, was less frequently employed, used less disease related medication and had worse spinal mobility than the patients without SGE (n=332). There were no significant differences in health status. AxSpA patients with SGE performed more minutes per week of aerobic exercise (median 420; IQR 285-660) than patients without SGE (median 283; IQR 120-540), p < 0.001. As shown in Figure 1, SGE participants fulfilled the recommendations for moderate-intensity aerobic exercise (89% vs. 69%, p < 0.001) and for strength and mobility exercise (44% vs. 29%, p < 0.01) more often than patients without SGE. However, the recommendation for vigorous-intensity aerobic exercise was fulfilled less often by the SGE participants (5% vs. 12%, p = 0.05). After correcting for age, sex, employment and health status, the differences in fulfilment of the moderate-intensity aerobic and strength and mobility exercise recommendations remained significant.

![Figure 1. Differences in meeting exercise recommendations between axSpA patients with and without SGE.](image)

**Conclusion:** SGE is used by just few and especially older axSpA patients and contributes to fulfilling recommendations for moderate-intensity aerobic as well as mobility and strength exercise. However, both in patients with and without SGE, only a minority fulfilled the recommendations for vigorous-intensity aerobic and strength and mobility exercises. Therefore, future promotion of physical activity should focus on implementing these types of exercise.

**Acknowledgements:** The authors would like to thank ASAS and the Dutch Arthritis Society for supporting the three cohorts.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.

**Disclosure of Interests:** Bas Hilberdink: None declared, Marlies Carbo: None declared, Davy Paap: None declared, Suzanne Arends: None declared, T.P. M. Bas Hilberdink: None declared, Marlies Carbo: None declared.
Background: Assessments should be standard in individual as well as group physical therapy. The Ankylosing Spondylitis Association of Switzerland has translated the EULAR recommendations for physical activity (PA) in a concept for group exercise therapy, which, in addition to guidelines in all four fitness dimensions (aerobic, strength, flexibility, neuromotor function), also includes PA counselling and regular fitness assessments for the planning and documentation of the individual therapy progress as well for quality monitoring of the exercise groups.

Objectives: To evaluate the feasibility of the selected assessments across all four fitness dimensions, rating the acceptance, practicability, and integration by physiotherapists (PTs) and people with axSpA.

Methods: A feasibility study was conducted in four pilot exercise therapy groups. PTs performed the assessment battery, consisting of a) the Chester Step Test (CST) for aerobic fitness; b) the modified Core Strength Test for core strength; c) the Bath Ankylosing Spondylitis Metrology Index (BASMI) for spinal mobility and d) the Short Leg Strength Test (SLST) for balance, with the participants of the exercise therapy groups. Subsequently, the PTs and the participants with axSpA rated the acceptance, practicability, and integration by means of questionnaires. Acceptance was operationalised as satisfaction and perceived applicability, practicability was operationalised as feasibility and comprehensibility, and integration was operationalised as usefulness and repeatability. An ordinal scale with four answer options (very good, good, moderate, bad) and a free text field for comments was used. The categories ‘very good’ and ‘good’ were interpreted as positive evaluation. The feasibility of the assessments was defined based on three levels (I-III): with a positive evaluation of >80% (level I) a specific assessment was considered suitable, with a positive evaluation of 50-80% (level II) adjustments were necessary, with a positive evaluation of ≤50% (level III) a specific assessment was not considered suitable for group exercise therapy and a new choice had to be made.

Results: The BASMI was rated level I by people with axSpA and PTs, no adaptations were necessary. The CST was rated level I by people with axSpA and level II by PTs (too time consuming and failure-prone software), resulting in the adaptation that the test can now be performed without software, and a training will make the testing PTs more efficient. The modified Core Strength Test was rated level I by people with axSpA and level II by PTs (instructions unclear, leading to adaptations in the instruction manual). The SLST was rated level I by people with axSpA and level II by PTs (instruction “standing on one leg as long as possible” not useful for persons without balance deficit), leading to the adaptation that the test can be stopped after 60 seconds as the normal values are below that threshold.

Conclusion: From patient perspective, the feasibility of the tests was evaluated positive in terms of acceptance, practicability and integration (all level I). From PTs perspective some adaptations were necessary (level II, except BASMI). After the adaptations, the assessment battery can now be used in group exercise therapy for individuals with axSpA. In this way, the individual fitness status can be evaluated, leading to adaptations in the instruction manual. The SLST was rated level I by people with axSpA and level II by PTs (instructions unclear, leading to adaptations in the instruction manual). The BASMI was rated level I by people with axSpA and PTs, no adaptations were necessary, with a positive evaluation of >80% (level I) a specific assessment was considered suitable, with a positive evaluation of 50-80% (level II) adjustments were necessary, with a positive evaluation of ≤50% (level III) a specific assessment was not considered suitable for group exercise therapy and a new choice had to be made.

Acknowledgements: We thank all participants and the SVMB for their support.

Disclosure of Interests: None declared


POS0045-HPR | HEALTHCARE PROFESSIONALS’ ATTITUDE TOWARDS REMOTE MONITORING

E. E. Kyvernberg Thomassen1, A. T. Tveter1, E. Kristianslund1, J. I. Berg2, N. Österäs1,2. Diakonhjemmet Hospital, National Advisory Unit on Rehabilitation in Rheumatology (NKRR), Oslo, Norway;2. Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway.

Background: The pandemic has accelerated the use of remote monitoring of patients (1), but there is still lack of knowledge in regards to barriers and facilitators of using remote monitoring among health care professionals. Patients with rheumatic diseases are monitored frequently by healthcare professionals, and follow-up strategies with less hospital visits could reduce the resource use.

Objectives: To explore healthcare professionals’ attitude, facilitators and barriers on use of remote monitoring in a specialist healthcare setting.

Methods: Approximately 100 employees at a department of rheumatology at a specialist healthcare setting were invited to complete an anonymous 22-item questionnaire in December 2021. To ensure anonymity, demographic data were limited to age (under/over 45 years of age) and current position (doctor, nurse, allied healthcare/leaders/secretaries). In addition, participants completed questions on frequency of use of video consultation, phone consultation and patient-reported software. For investigating attitudes, facilitators and barriers the participants also responded to 16 statements related to perspectives on the use of remote monitoring in patients with low and stable disease activity using a 10-point numeric rating scale (NRS) from 0=“Strongly disagree” to 10=“Strongly agree”. We developed the statements as facility or barriers for the use of video consultations and remote monitoring based on facilitators and barriers identified in previous research (2-4). The statements that had median score for agreement >8 were categorized as either facilitator or barrier and presented with median score and interquartile range (IQR).

Results: Seventy (70%) participants completed the questionnaire. In the study sample 44 % were under the age of 45, 35 % were doctors, 36 % nurses and 28 % were allied health professionals, secretaries, or leaders. None used video consultation on a daily basis, while 6 % used phone consultation daily. The participants had a positive attitude towards the use of remote monitoring in patients with low and stable disease activity (median: 9 (IQR: 8-10). For the remaining 7 statements the median scores were close to 5 – which indicates that they cannot be regarded as neither facilitators nor barriers. The remaining statements focused on appropriate internet connection, patients underreporting, scepticism towards new software and mistrust in technical systems. The facilitators and barriers for remote monitoring with median score >6 among healthcare professionals are presented with box-plots including median score and IQR in Figure 1.

Conclusion: Health care professionals showed positive attitudes towards the use of remote monitoring. Main facilitators on use of remote monitoring were: patients saving time, the belief of remote monitoring being part of future health care, remote monitoring being integrated with patient record system, patients wish to use remote monitoring and patient feeling less burdened by not visiting hospital. The main barriers were the inability to physically examine the patients and limitations related to the use of video consultation.

REFERENCES:

Disclosure of Interests: None declared


POS0046-HPR | THE EFFECT OF MEDITATION, MINDFULNESS, AND YOGA IN PATIENTS WITH RHEUMATOID ARTHRITIS

L. Slagter1, K. Demyttenaere2, D. De Cock1,2. 1KU Leuven, Skeletal Biology and Engineering Research Centre, Leuven, Belgium; 2KU Leuven, Psychiatry Research Group, Leuven, Belgium; 3KU Leuven, Clinical and Experimental Endocrinology, Leuven, Belgium.

Background: Non-pharmacological approaches additional to the pharmacological treatment of rheumatoid arthritis (RA) may include meditation, as well as yoga and mindfulness. These mind-body therapies (MBTs) create an interaction between the mind and body to enhance overall health. MBTs are perceived as valuable in RA management, but the extent of this contribution is unclear, as well as patients subgroups who benefit most from these MBTs.

Objectives: To investigate the effects of meditation, mindfulness, and yoga in patients with RA in a systematic literature review.

Methods: A search was performed in 4 databases (PubMed, Embase, Web of Science (core collection), Chinese and Korean collections) for studies. All studies were screened by two independent reviewers, via title/abstract/full text. Studies included any form of meditation, mindfulness and/or yoga as an intervention
Table 1. Overview of included studies

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Intervention</th>
<th>Country</th>
<th>Outcome</th>
<th>Author (year)</th>
<th>Intervention</th>
<th>Country</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yoga</td>
<td>Mindfulness</td>
<td>USA</td>
<td>QoL, depression, pain, anxiety</td>
<td>Dash (1994) Yoga</td>
<td>USA</td>
<td>physiologic</td>
<td>chain (2007) MBSR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Badhoo (2009) Yoga</td>
<td>UAE</td>
<td>QoL, Disease activity</td>
<td>Davis (2015) MAAT</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bosch (2009) Yoga</td>
<td>USA</td>
<td>Functional, physiological, depression, pain</td>
<td>Fogarty (2015) MBSR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Singh (2011) Yogic package (incl. India meditation)</td>
<td>India</td>
<td>Disease activity, pain, anxiety, pain</td>
<td>Fogarty (2019) MBSR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Telles (2011) Yoga</td>
<td>India</td>
<td>Disease activity</td>
<td>Relaxation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Evans (2011) Iyengar Yoga</td>
<td>USA</td>
<td>QoL, disease activity, pain, fatigue, sleep quality</td>
<td>Bagheri-Naserni-Benson Relaxation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Greysen (2019) Yoga</td>
<td>USA</td>
<td>Functional, depression, pain, fatigue, sleep quality</td>
<td>Yazdani (2017) PMR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gautam (2020) Yoga-based lifestyle</td>
<td>India</td>
<td>QoL, Disease activity, physiological</td>
<td>QoL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ganesan Yoga</td>
<td>India</td>
<td>Disease activity, physiological</td>
<td>QoL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gautam (2021) Yoga</td>
<td>India</td>
<td>Disease activity, Disease activity, physiological</td>
<td>QoL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Puksic (2021) Yoga</td>
<td>Croatia</td>
<td>QoL, depression, anxiety, pain, fatigue, stress</td>
<td>QoL</td>
</tr>
</tbody>
</table>

MBT = Mindfulness-Based Cognitive Therapy; PMR = Progressive muscle relaxation; MBSR = Mindfulness-based stress reduction, MERT = mindfulness-based emotion regulation therapeutic program; MAAT = mindfulness-based emotion regulation therapeutic program QoL= quality of life

for patients with RA. Animal studies, case reports, non-English articles, qualitative studies, conference abstracts and articles without full text access were excluded. Each study was assessed for quality.

**Results:** Out of the 1,527 records, 23 studies were included after screening (Table 1). There was considerable heterogeneity, both in applied interventions and outcome measurements. All MBTs showed limited beneficial effects on psychological outcomes, such as vitality, functioning, and mental health, as well as on disease activity markers. Mindfulness-based interventions mainly reduced the subjective disease activity (e.g., joint tenderness/pain), rather than objective disease activity (e.g., swollen joints/CRP). RA patients with recurrent depression seemed to benefit more from these non-pharmacological therapies than patients without recurrent depression.

**Conclusion:** This systematic literature review found that MBTs have added value in RA management, especially for patients with depressive symptoms. These non-pharmacological approaches as an addition to treatment can be a way to diminish polypharmacy in specific RA patient populations.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2113

GOALS AND ACTION PLANS ACROSS TIME AND PLACE IN PERSON-CENTRED REHABILITATION - A QUALITATIVE STUDY EXPLORING THE IMPORTANCE OF CONTEXT

L. Eegn, J. Thuesen, 1, 2, 3, University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sanderborg, Denmark; 1University of Southern Denmark; Danish Knowledge Centre for Rehabilitation and Palliative Care, Nyborg, Denmark; 2University College Absalon, Center for Nutrition and Rehabilitation, Naestved, Denmark

**Background:** Person-centeredness is increasingly addressed in relation to rehabilitation interventions (1). Collaborative goal setting and action plans are key elements in person-centered rehabilitation (2). There is a lack of knowledge about how person-centered goals and action plans developed during inpatient rehabilitation are experienced by the patients after discharge.

**Objectives:** This aim of the study was to explore how rheumatic patients experience the relevance of goals and action plans after discharge from an inpatient rehabilitation stay.

**Methods:** Individual narrative interviews were conducted with eight patients with a rheumatic disease three to five weeks after discharge from a two-week inpatient rehabilitation stay. A convenience sampling strategy was applied. In order to the exploratory nature of the study, we strived for variety in diagnoses, age and gender (3). One male and seven female patients participated, aged between 40 and 60 years. Six of the participants were active at the labor market and two were retired. Data collection, analysis and interpretation of data were performed within a phenomenological-hermeneutic framework inspired by Paul Ricoeur's interpretative philosophy (4).

**Results:** The analysis derived one core theme: 'The relevance of goals and action plans is contextual' and three subthemes: 'The hospitalization - a protected bubble,' 'Being at home - a harsh reality' and 'Need for support after discharge.' The participants expressed that during the admission there was time and peace to exercise and to take a rest. They were relieved from everyday duties, and received support from the interdisciplinary team in how to exercise and during conversations where they focused on management of their symptoms and illness. Back home after discharge, the participants experienced how their everyday life differed from the hospital context. They found it challenging to work further with goals and actions plans in their everyday life. They described in particular challenges with incorporation of new habits in everyday life, challenges they were not prepared for. On challenging days with pain and fatigue, the participants missed having someone to talk to. The participants suggested involvement of their relatives to support action plans and called for follow-up support to enable them to continue working to achieve their goals and action plans after discharge. They suggested support by telephone calls from a nurse from the hospital after one, two or three months after discharge to ask how they felt. They believed that it would be motivating and could support the outcomes of the admission.

**Conclusion:** Goals and actions plans are relevant for rheumatic patients, but must be adapted to the patient's everyday life. There is a need to plan during the hospitalization how goal and action plans can be transferred to the rheumatic patient's everyday life after discharge from a rehabilitation stay. Likewise, there is a need for follow-up support after discharge to support the patients to pursue their goals and cope with challenges in everyday life.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2223

HEALTHCARE PROFESSIONALS’ EXPERIENCES OF LIFESTYLE MANAGEMENT IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS – A QUALITATIVE STUDY

K. Drake af Hagelsrum1, E. Mogard2, A. Bremernd3, E. Lindqvist2, I. Larsson4, 5, 6, 7, Halmstad University, School of Health and Welfare, Halmstad, Sweden; 3Lund University, Section of Rheumatology, Department of Clinical Sciences Lund, Lund, Sweden; 4Skane University Hospital, Department of Rheumatology, Lund, Sweden; 5Spenhult, Research and Development Centre, Halmstad, Sweden; 1University of Southern Denmark, Department of Regional Health Research, Odense, Denmark; 1University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sanderborg, Denmark

**Background:** Rheumatoid Arthritis (RA) is a chronic inflammatory systemic disease that mainly affects joints and with symptoms such as stiffness, pain, and increased fatigue. RA also appears to be an independent risk factor for accelerated atherosclerosis with an increased risk of cardiovascular diseases,
why national and international guidelines recommend proper pharmacological treatment together with a healthy lifestyle (1). Supporting people with early RA to achieve and maintain a healthy lifestyle is therefore of great importance. However, few studies have explored healthcare professionals’ views of working with lifestyle management. A healthy lifestyle does not only have the potential to lower cardiovascular risk but may also improve a person’s quality of life.

Objectives: The aim of this study was to explore healthcare professionals’ experiences of lifestyle management in patients with early RA.

Methods: In this explorative qualitative study, individual interviews were conducted with 20 healthcare professionals who had a mean of 16 years of professional experience in the field of working with patients with RA. An interview guide with open-ended questions was used e.g.: “How do you work with lifestyle changes in patients with RA?” and “What theories do you use to support lifestyle changes?” Qualitative content analysis was used, where three categories emerged: “The importance of a well-functioning organization,” “The importance of teamwork” and “The importance of person-centered care” and nine subcategories, representing the overall content of the interviews (Table 1).

<table>
<thead>
<tr>
<th>Categories Subcategories</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The importance of a well-functioning organization</td>
<td>Supportive leadership</td>
</tr>
<tr>
<td></td>
<td>Priority of lifestyle management</td>
</tr>
<tr>
<td></td>
<td>Competence development in lifestyle management</td>
</tr>
<tr>
<td>The importance of teamwork</td>
<td>Interdisciplinary team</td>
</tr>
<tr>
<td></td>
<td>Professional expertise in lifestyle habits</td>
</tr>
<tr>
<td></td>
<td>Structured approach to lifestyle management</td>
</tr>
<tr>
<td>The importance of person-centered care</td>
<td>Individually tailored lifestyle management</td>
</tr>
<tr>
<td></td>
<td>Shared decision-making</td>
</tr>
<tr>
<td></td>
<td>Patient engagement</td>
</tr>
</tbody>
</table>

Results: Healthcare professionals’ experiences of lifestyle management in patients with early RA included the importance of a well-functioning organization with supportive leadership, priority of lifestyle management, and competence development in lifestyle management. The importance of teamwork was emphasized including interdisciplinary team, professional expertise in lifestyle habits, and structured approach to lifestyle management. The healthcare professionals also highlighted the importance of person-centered care with individually tailored lifestyle management, shared decision-making, and patient engagement.

Conclusion: Healthcare professionals’ experiences of lifestyle management in patients with early RA reveal that commitment from both the management, the team, and the patient is important.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.914

Immunity in Rheumatic Diseases

POS0050 B CELL CHARACTERISTICS AT BASELINE PREDICT HUMORAL RESPONSE UPON SARS-COV-2 VACCINATION AMONG PATIENTS TREATED WITH RITUXIMAB

A. L. Stefaniski1,2, H. Rincon-Arevalo1,2,3,4, E. Schrezenmeier2,5,6, K. Karberg6, F. Szelinski1,2, J. Ritter1,5, B. Johannesdoerer1, H. Schrezenmeier1,6, C. Ludwig1, Y. Chen1,2, A. Claußnitzer1, A. Lino1, T. Dörner1,5.

Charité Universitätsmedizin Berlin, Rheumatology and Clinical Immunology, Berlin, Germany; 2Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), ein Institut der Leibniz-Gemeinschaft, B Cell Biology, Berlin, Germany; 3Universidad de Antioquia UdA, Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Instituto de Investigaciones Médicas, Medellin, Colombia; 4Charité Universitätsmedizin Berlin, Nephrology and Medical Intensive Care, Berlin, Germany; 5Berlin Institute of Health, BIH Academy, Berlin, Germany; 6RheumaPraxis Steglitz, Outpatient Office, Berlin, Germany; 7Ulm University Hospital, Institute of Transfusion Medicine and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen, Ulm, Germany

Background: Vaccination is considered efficient in controlling infections incl. SARS-CoV-2. Prior studies showed that patients receiving rituximab (RTX) with low B cell counts are at increased infectious risk (1) and risk of inadequate vaccination responses (2, 3). Thus, the ability to further define and predict vaccination responses in these patients may guide their optimal protection.

Objectives: To assess predictive biomarkers of vaccination responses upon SARS-CoV-2 vaccination in RTX treated patients.

Table 1. Number and % of respondents per each question and per each response category.

<table>
<thead>
<tr>
<th>Questions</th>
<th>Total number of respondents</th>
<th>Number of respondents (%) per each Likert scale point</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>To a high degree</td>
</tr>
<tr>
<td>Confidence in the nurse</td>
<td>358</td>
<td>315 (88%)</td>
</tr>
<tr>
<td>Clarity of nurse-communication</td>
<td>358</td>
<td>315 (88%)</td>
</tr>
<tr>
<td>Profit from the diagnostic</td>
<td>338</td>
<td>189 (56%)</td>
</tr>
<tr>
<td>Perceived need for further</td>
<td>357</td>
<td>39 (11%)</td>
</tr>
<tr>
<td>examinations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: The patients were confident in the nurse-conducted diagnostic process and had profited from the diagnostic consultation focused on the explanation of FM and current treatment options. Thus, specially trained nurses contribute to the effectiveness of the FM diagnostic process and to patients’ satisfaction. This facilitates patients’ timelier access to treatment options.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.914
Methods: B cell characteristics before vaccination were evaluated to predict responses in 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. 11 patients with rheumatoid arthritis on other therapies (RA), 11 kidney transplant recipients (KTR) and 15 healthy volunteers (HC) served as controls. A multidimensional analysis of B cell subsets and a correlation matrix were performed to identify predictive biomarkers.

Results: Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were validated at baseline. Here, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) comprised naïve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27−/IgD−) B cells (Figure 1). Moreover, there was a positive correlation between neutralizing antibodies and absolute B cell numbers with B cells expressing HLA-DR and CXCR5 (involved in antigen presentation and germinal center formation) as well as an inverse correlation with CD95 expression and CD21low expression (marker for activation and exhaustion) on B cells.

Conclusion: Substantial repopulation of naïve B cells upon RTX therapy appears to be essential for an adequate vaccination response requiring germinal center formation. In contrast, expression of exhaustion markers (CD21 low, CXCR5-, CD95+) indicate negative predictors of vaccination responses. These results may guide optimized vaccination strategies in RTX treated patients clearly requiring antigen-inexperienced B cells for appropriate protection.

REFERENCES:


None declared

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eeular.275

POS0051

DIFFERENTIAL PHARMACODYNAMIC ALTERATIONS ACROSS TREATMENT WITH ABATACEPT OR ADALIMUMAB IN MTX-INADEQUATE RESPONDERS PATIENTS WITH EARLY RA: WHOLE BLOOD RNA-SEQ ANALYSIS OF THE EARLY AMPLE STUDY

C. Wu, Y. Li, N. Ray, M. A. Maldonado, R. Schafer, S. L. Bridges, W. Rigby, Y. Bykerk, J. Buckner, J. Liu. 1Bristol Myers Squibb, Translational Bioinformatics, Princeton, United States of America; 2Parexel International, IV/A, Durham, United States of America; 3Bristol Myers Squibb (at the time of analysis), Global Drug Development, Princeton, United States of America; 4Bristol Myers Squibb, Clinical R&D, Immunoscience, Princeton, United States of America; 5Bristol Myers Squibb, Translational Medicine, Princeton, United States of America; 6Hospital for Special Surgery, Department of Medicine, New York, United States of America; 7Dartmouth-Hitchcock Medical Center, Rheumatology Section, Department of Medicine, Lebanon, United States of America; 8Hospital for Special Surgery, Division of Rheumatology, New York, United States of America; 9Benaroya Research Institute at Virginia Mason, Center for Translational Immunology, Seattle, United States of America

Background: Despite advances in available novel pharmacologic agents for RA,1 the dearth of effective response predictors for specific therapies remains an unmet need. To inform clinical decision making, it is critical to define molecular signatures of these therapeutic agents by investigating their mechanisms of action (MoAs) and differential impacts on patients' immune systems. Adalimumab and abatacept are biologic DMARDs with distinct MoAs used to treat RA. A better understanding of the differential pharmacodynamic (PD) changes of these 2 agents may provide guidance for the selection of treatment options.2 The Early AMPLE (Abatacept versus adalimumab parison in bioLogic-naïve RA subjects with background MTX) study compared treatment with abatacept or adalimumab in a population of patients with early RA to explore differential PD effects; abatacept treatment resulted in numerically higher efficacy responses vs adalimumab after 24 weeks of treatment.3

Objectives: To investigate PD changes in response to treatment with abatacept or adalimumab, and to identify and differentiate the impact of each drug on modulation of immune cells at the molecular level.

Methods: The phase 4 Early AMPLE trial (NCT02557100) was a head-to-head comparison of treatment response to either abatacept or adalimumab in patients with early RA with an inadequate response to MTX, high anti-citrullinated protein antibody titers, and RF positivity, with or without shared epitope. Whole blood RNA sequencing (RNA-Seq) was conducted on samples collected from patients at different visits (day 1; weeks 4, 8, 16, 24, 28, 32, 40, 48). Differential gene expression analyses were performed using Limma-voom pipeline in R, adjusting for batch effect and sex. Over-representation tests were used to identify enriched Gene Ontology pathways. xCell, a gene signatures–based method learned from thousands of pure cell types, was applied for immune cell type deconvolution and enrichment analysis.

Results: PD and association analyses were performed for 14,540 protein-coding genes in 684 RNA-Seq samples (79 patients with RA at 9 visits). Baseline association analysis showed that 248 differentially expressed genes and 6 cell cycle–related pathways were significantly associated with baseline SDAI score. After treatment, gene-enrichment analysis demonstrated that twice as many genes and pathways were significantly altered in the adalimumab- vs abatacept-treated arm. Abatacept treatment decreased immune cell cycle gene expression while adalimumab treatment increased expression of these genes. The increases due to adalimumab were reversed after switching to abatacept (open-label period). Using gene signatures to identify key immune cell subsets (Figure 1), adalimumab therapy increased expression of genes defining several key immune cell types involved in RA disease development, including dendritic cells, T cells, and B cells; these effects were also reversed after switching to abatacept.

Conclusion: The differential gene expression seen after treatment with abatacept or adalimumab was noted in genes identified as correlating with RA disease activity. These findings may inform on the mechanism for the relatively greater clinical improvements seen with abatacept vs adalimumab in the Early AMPLE study. Abatacept treatment may selectively modulate genes that are relevant to disease pathology/progression, with the potential to restore the immune homeostasis dysregulated in RA. Our findings warrant further studies to investigate the potential positive correlation between RA-relevant PD effects and better therapeuetic outcomes.

REFERENCES:

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Medical writing and editorial assistance were provided by Joanna Wright, DPhil, at Caudex, and was funded by Bristol Myers Squibb.

Results: Regarding the role of TAng in vasculopathy, the frequencies of these cells were significantly lower in patients with RA-ILD+, SSc-ILD+ and other AD-ILD+, as well as with IPF in relation to HC (p<0.001, respectively, Figure 1). No differences between RA-ILD+ patients, SSc-ILD+ patients and HC were found (Figure 1). With respect to TAng involvement in fibrosis, TAng frequencies were similar in patients with RA-ILD+, SSc-ILD+, other AD-ILD+ and those with IPF (Figure 1). Nevertheless, patients with RA-ILD+ and SSc-ILD+ showed significantly lower TAng frequencies than those with RA-ILD+ and SSc-ILD+, respectively (p=0.006 and p=0.044, respectively, Figure 1). In this line, a TAng frequency of TAng was found in SSc-ILD+ and RA-ILD+ patients in relation with those with IPF (p<0.001 and p=0.003, respectively, Figure 1). Moreover, TAng frequency did not show significant correlation with EPC frequency in the whole cohort of AD-ILD+ patients.

Conclusion: TAng play a relevant role in the lung vasculopathy of RA-ILD+, SSc-ILD+ and other AD-ILD+. Interestingly, circulating TAng may be considered as a useful biomarker of the presence of ILD in patients with RA and SSc.

REFERENCES:

Acknowledgements: VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL18/01); SR-M is supported by funds of the RETICS Program (RD16/0012/0009) from Instituto de Salud Carlos III (ISCIII), co-funded by the European Regional Development Fund; RL-M is a recipient of a Miguel Servet type I programme fellowship from ISCIII, co-funded by the European Social Fund, ‘Investing in your future’(grant CP16/00033).

Disclosure of Interests: Verónica Pullito-Cueto: None declared, Sara Remuzgo-Martínez: None declared, đổntella Fernandez: None declared, Belén Atienza-Mateo: None declared, Virginia Portillo: None declared, Víctor Manuel Mora-Cuesta: None declared, David Iturbe Fernández: None declared, Leticia Lera-Gómez: None declared, Javier Rodriguez Carrio: None declared, Diana Prieto-Peña: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Corrales: None declared, Oreste Gualillo: None declared, Jose Manuel Cifrián-Martínez: None declared, Raquel López-Mejías: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD, GSK, Grant/research support from: Abbvie, MSD, Janssen, Roche.

frequency of IgG and only a few patients had antibodies of more than one isotype targeting PL12, PL7 or EJ. The majority of anti-Ro52 positive IIM patients (n=52) only harbored IgG isotype. The combination of anti-Ro52 and anti-aARS autoantibodies was found in IIM patients (anti-Jo1 (n=19), -PL12 (n=2), -PL7 (n=3), and -EJ (n=4)). Most patients with such combination had anti-Ro52 IgG together with anti-aARS IgG or IgM in combination with IgA and/or IgM. The exception was observed for three anti-Jo1 positive patients who had the combination anti-Ro52 IgG with only anti-Jo1 IgM and one anti-PL7 positive patient who had anti-Ro52 IgA together with anti-PL7 IgA and IgG.

Conclusion: The frequency of the different autoantibody isotypes seems to be autoantigen dependent. Our results suggest that for anti-Ro52 autoantibodies in IIM it could be important to investigate additional autoantibody isotypes, as some patients only harbor autoantibodies of IgM or IgA isotypes but not IgG. The clinical relevance of the different antibody isotypes still needs to be determined.

REFERENCES:

Table 1. Total number of individuals and percentage (n (%)) in each group for each of the isotypes and antigens.

<table>
<thead>
<tr>
<th>anti-Jo1</th>
<th>anti-PL12</th>
<th>anti-PL7</th>
<th>anti-EJ</th>
<th>anti-Ro52</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG</td>
<td>61(16.7)</td>
<td>1(0.6)</td>
<td>7(1.9)</td>
<td>1(0.6)</td>
</tr>
<tr>
<td>IgA</td>
<td>20(5.5)</td>
<td>0(0.0)</td>
<td>2(1.2)</td>
<td>1(0.6)</td>
</tr>
<tr>
<td>IgM</td>
<td>56(15.3)</td>
<td>1(0.6)</td>
<td>2(1.3)</td>
<td>1(0.3)</td>
</tr>
</tbody>
</table>

Acknowledgements: ScilLifeLab facilities Autoimmunity and Serology Profiling and Human Antibody Therapeutics (Drug Discovery and Development), IIM project EUOPEN, This project has been funded from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning McGill University, Kungliga Tekniska Hogeskoalan, Diamond Light Source Limited.

Disclosure of Interests: Charlotta Pregger Grant/research support from: IIM project EUOPEN, Grant no 875510, Antonella Notarnicola: None declared, Cecilia Hellstrom: None declared, Edvard Wikgren Grant/research support from: IIM project EUOPEN, Grant no 875510, Ingrid E. Lundberg Shareholder of: Roche and Novartis, Consultant of: Corbus Pharmaceuticals Inc, Astra Zeneca, Bristol Myers’ Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezar, Orphazyme, and Janssen, Grant/ research support from: Astra Zeneca, Per-Johan Jakobsson Shareholder of: Gesynta Pharma, Consultant of: UCB, Grant/research support from: Gesynta Pharma, Helena Persson Employee of: Affibody AB, Susanne Gräslund Grant/ research support from: UCB, Grant/research support from: Gesynta Pharma, Consultant of: UCB, Grant/research support from: IMI project EUOPEN, Grant no 875510.


POS0054 DYSFUNCTION OF REGULATORY B CELLS IN GIANT CELL ARTERITIS (GCA)

M. Stöcker1,2,3, U. Kiltz1,3, J. Braun1,3, B. Wilde1,1, Rhabdomyosarcoma Ruhrgebiet, Rheumatologic, Bochum, Germany; 2Augusta-Krankenanstalt Bochum, Pneumology and Infectious Diseases, Bochum, Germany; 3Ruh-Universität Bochum, Rheumatologie, Bochum, Germany; 4University Hospital Essen, Nephrology, Essen, Germany

Background: The pathophysiology of GCA is not clearly understood, but most research has pointed towards a major role of T cells with proinflammatory Th1 and Th17 cells as dominant drivers of disease. The role of B cells in the pathogenesis of GCA has not been much studied to date.

Objectives: To study the role of proinflammatory T cell mediators and anti-inflammatory regulatory B cells (Bregs) as their counterpart in patients with GCA compared to healthy controls (HC).

Methods: GCA Patients and HC were recruited prospectively and included after informed consent. Peripheral blood mononuclear cells were freshly isolated from whole blood and included into 3 experimental setups, using flow cytometry and fluorescent antibodies: (i) pro-inflammatory T cell mediators (IL-2, GMCSF, IL-17a, IFN-y), (ii) granzyme B production of Bregs after stimulation with different agents (anti-human IgG + IgM, IL-21, anti-CD40L) and (iii) the IL-10 production of Bregs were measured. Disease activity was defined as unequivocal evidence of cranial symptoms of GCA and/or increased concentrations of C-reactive protein and/or halo sign, leading to a change in therapy according to the treating rheumatologist. Statistical comparisons between groups were performed by the Mann-Whitney-U-Test and Spearman's rank correlation.

Results: A total of 47 GCA patients (14 with active disease and 33 in remission) and 49 HC were included (Table 1). CD4+ T cells of GCA patients with active disease produced less IFN-y than HC (p=0.016, Figure 1a). There was also a trend towards lower expression of IL-2 (p=0.18), GMCSF (p=0.1) and IL-17a (p=0.18) by CD4+ T cells from GCA patients compared to HC. Bregs of GCA patients produced lower amounts of granzyme B after stimulation with anti-human IgG and IgM compared to HC, and this was similar in active patients (p=0.04, Figure 1b) and in quiescent patients (p=0.021, Figure 1b). With other stimuli, including IL-21 and anti-CD40L, there was also a trend towards a lower expression. The IL-10 production of Bregs did not show substantial differences between groups. Importantly, the dose of glucocorticoids did not influence cytokine production of T-cells or B-cells.

Table 1. Demographics

<table>
<thead>
<tr>
<th>Variables</th>
<th>GCA Patients (n=47)</th>
<th>Healthy Controls (n=49)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>71(54-83)</td>
<td>65(45-86)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td>31 female (65.9)</td>
<td>40 female (81.6)</td>
</tr>
<tr>
<td>Disease activity</td>
<td>14 active disease</td>
<td>NA</td>
</tr>
<tr>
<td>Therapy</td>
<td>Prednisolone: n=29 none</td>
<td>Methotrexat: n=23 Toolcumab: n=13</td>
</tr>
<tr>
<td>Dosage of prednisolone</td>
<td>None: n=18</td>
<td>1-7.5 mg/d: n=15 &gt; 7.5 mg/d: n=14</td>
</tr>
</tbody>
</table>

1a: Interferon gamma expression of CD4+ T-cells / 1b: Granzyme B expression of Breg after anti-human IgG + IgM stimulation

Conclusion: The in vitro cytokine production of proinflammatory CD4+ T cells and anti-inflammatory Bregs after stimulation, especially regarding granzyme B production, showed some differences between patients and HC. A lower granzyme B production was found in patients with active disease indicating a lack of Breg-mediated suppressive capacity towards pro-inflammatory T cells. This finding may play a role in the pathogenesis of GCA.

REFERENCES:

Disclosure of Interests: Marian Stöcker: None declared, Uta Kiltz Speakers of: IMI project EUOPEN, Grant no 875510, Antonella Notarnicola: None declared, Cecilia Hellstrom: None declared, Edvard Wikgren Grant/research support from: IIM project EUOPEN, Grant no 875510, Ingrid E. Lundberg Shareholder of: Roche and Novartis, Consultant of: Corbus Pharmaceuticals Inc, Astra Zeneca, Bristol Myers’ Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kezar, Orphazyme, and Janssen, Grant/ research support from: Astra Zeneca, Per-Johan Jakobsson Shareholder of: Gesynta Pharma, Consultant of: UCB, Grant/research support from: Gesynta Pharma, Helena Persson Employee of: Affibody AB, Susanne Gräslund Grant/ research support from: UCB, Grant/research support from: IMI project EUOPEN, Grant no 875510. DOI: 10.1136/annrheumdis-2022-eular.1980

Figure 1a: Interferon gamma expression of CD4+ T-Cells / 1b: Granzyme B expression of Breg after anti-human IgG + IgM stimulation
POS0055

**TFN-α REGULATION OF MIR-29B EXPRESSION IN CD14+PBMS AND ITS RELEASE OF PROINFLAMMATORY CYTOKINES IN RHEUMATOID ARTHRITIS**

D. Yun 1, D. Liu 1, Q. Gu 2

1The First Affiliated Hospital of Xi’an Medical University, Department of Rheumatology and Immunology, Xi’an, China; 2Luoyang Central Hospital Affiliated to Zhengzhou University, Department of Orthopedics, Luoyang, China

**Background:** It was found that the expression of mir-29b was significantly up-regulated in PBMs, and we tried to clarify TFN-α. The production of proinflammatory cytokines was induced by increasing the expression of mir-29b in CD14 + PBMs in patients with rheumatoid arthritis (RA), and by using TFN-α that the expression of mir-29b was significantly upregulated with the release of pro-inflammatory cytokines. **Methods:** (1) Cell experiment: PBMs from RA patients were collected and extracted for CD14 + cell expression labeling. Different doses of TNF-α were used to induce the expression of mir-29b in CD14 + PBMs and then produced pro-inflammatory cytokines. **Results:** The expression of TFN-α was significantly up-regulated in PBMs, and we tried to clarify TNF-α. The supernatant of cell culture was measured using a V-plex human cytokine 30-plex kit. (2) Grouping experiment of clinical intervention: 21 patients with RA diagnosis and 15 healthy volunteers were divided into three groups. TFN-α inhibitor group: RA patients treated with TFN-α inhibitor were collected (n=15); IL-6 monoclonal antibody group: RA patients treated with tocilizumab (n=6); Control group: healthy volunteers (n=15) were used as normal controls. PBMc was extracted from TNF-α inhibitor group for 6 months, IL-6 monoclonal antibody group for 6 months, and control group, respectively, to observe the difference of Mir-29b expression in CD14+PBMs of the three groups. **Conclusion:** The expression of mir-29b was dose-dependent and time-dependent with the incubation of TFN-α, and there was a significant difference (P < 0.05). Compared with the control group, the overexpression of mir-29b also led to an increase in the expression levels of a wide range of chemokines and proinflammatory cytokines (including IL-1α, IL-1β, TNF-α, IL-6, IFN-γ and IL-8) (P < 0.05). The expression of TFN-α in RA patients treated with TFN-α inhibitor was significantly reduced compared with that treated with Tocutuzumab (P<0.05). **Conclusion:** TFN-α inflammatory factors can induce the overexpression of mir-29b in RA patients, and then producing a large number of proinflammatory cytokines, which can aggravate the inflammation mechanism of RA. In RA patients, TFN-α inhibitors may partially reduce the inflammatory response through the TFN-α/CD14+PBMs/Mir-29b signaling pathway. Therefore, more attention should be paid to the expression of Mir-29b in TFN-α and CD14+PBMs in clinical practice, which may accurately indicate the state of immune disease in patients, and provide a basis for more accurate judgment of prognosis and the course of immunotherapeutic, as well as optimization of immunotherapy programs.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1817

POS0056

**GLOBAL STEROID METABOLISM IN MACROPHAGES: SHAPING INFLAMMATORY FUNCTION AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS**


1Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom; 2Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom; 3Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom; 4Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom

**Background:** Macrophages are key drivers of joint destruction and disease pathophysiology in rheumatoid arthritis (RA), where their inflammatory function is influenced by steroid hormones such as androgens and glucocorticoids (GCs). Local bioavailability of these steroids is determined by both systemic adrenal/gonadal synthesis and local metabolism in peripheral target tissues. The inflammatory regulation and function of steroid hormone metabolism, by key rate limiting enzymes in chronic inflammatory diseases such as RA remain poorly defined and could present new therapeutic targets.

**Objectives:** Characterise regulation of global steroid metabolism in macrophages in RA and determine its contribution to androgen and GC availability, macrophage function and disease activity.

**Methods:** Bulk and single-cell gene expression sequencing of FACS-sorted macrophages were analysed using previously published datasets from RA patients (27 female, 8 male) (1, 2). Gene expression of rate limiting steroid metabolism enzymes were assessed in macrophages and their subsets and correlated to clinical parameters of disease activity. Primary human monocyte-derived macrophages were polarised to non-inflammatory (M-CSF 20 ng/ml) and inflammatory activated (M-CSF 20 ng/ml, IFNy 20 ng/ml, TNF-α 10ng/ml) subsets and treated with active or inactive metabolites of GCs (cortisol/cortisone 100nmol/l) and androgens (androstenedione/testosterone/DHEA 100nmol/l; DHT 10nmol/l). Metabolism and functional effects were assessed in primary cultures and RA synovial fluids by liquid chromatography mass spectrometry, RT-qPCR and ELISA.

**Results:** Significant differentially expressed genes (DEGs) were identified in the GC and androgen metabolism pathways in synovial macrophages when stratified for high and low disease activity by DAS28-ERCP Expression of the GC-activating enzyme HSD11B1 and androgen activating enzyme SRD5A1 were significantly increased and positively correlated with disease severity. The androgen activating enzyme AKR1C3 was significantly suppressed and negatively correlated with disease severity. SRD5A1 and HSD11B1 expression were localised to S100A12+ macrophage and SPP1+ subsets associated with active RA, whilst AKR1C3 was primarily expressed by MerTK+ and TREM2+ subsets associated with RA remission. Inflammatory activation of primary macrophages decreased AKR1C3, and increased HSD11B1 and SRD5A1 expression. This result was in a shift in intracellular production of active GCs and androgens favouring increased levels of the active GC cortisol and the potent androgen DHT. The resulting changes in steroid ratios in inflammatory activated macrophages resulted in lower expression and release of the pro-inflammatory mediators TNF-α, IL-6 and IL-12 indicating functional significance. In vivo, metabolic changes favouring increased GC activation and reduced androgen activation correlated with disease severity determined by DAS28-CRP.

**Conclusion:** We have shown for the first time a role for macrophages and their tissue subsets in the inflammatory metabolism and activation of GCs and androgens in RA, which influence macrophage function and disease activity. Targeting these key metabolic pathways represents a novel route to modifying and suppressing disease activity and joint destruction in chronic polyarthritis.

**REFERENCES:**


**Acknowledgements:** This research was funded by the Wellcome Trust (ef/215243/Z/19/Z).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.782

POS0057

**INDUCIBLE REGULATORY SYNOVIAL MACROPHAGES: A PROOF-OF-CONCEPT STUDY FOR A CELL-BASED TARGETED THERAPY FOR RHEUMATOID ARTHRITIS**

A. Small 1, K. Lowe 1, A. Ferrante 1, M. Smith 1, S. Proudman 1, H. Weedon 1, M. Wechalekar 2, 3Flinders University, College of Medicine and Public Health, Bedford Park, Australia; 2SA Pathology, Department of Immunopathology, North Adelaide, Australia; 3Flinders University, School of Medicine and School of Biological Sciences, Adelaide, Australia; 4Royal Adelaide Hospital, Department of Rheumatology, Adelaide, Australia; 5University of Adelaide, School of Medicine, Adelaide, Australia; 6Flinders Medical Centre, Department of Rheumatology, Bedford Park, Australia

**Background:** Infiltration of monocyte-derived macrophages into the synovial tissue (ST) is a hallmark of rheumatoid arthritis (RA) pathology. These macrophages promote inflammation, local joint effusion, and joint damage via the release of cytokines, oxygen reactive species, and tissue damaging enzymes. However, balancing these, are the ‘regulatory’ macrophages with inflammation-resolving properties, characterised by expression of CD206 and MerTK, dominant within the ST of healthy individuals as well as RA patients in remission (1). Indeed, these cells are believed to actively contribute to the maintenance of remission.
Macrophages are known to exhibit remarkable phenotypic plasticity and understanding the role of this characteristic in regulating inflammation and pathology remains a major challenge, as does the characterization of factors in the microenvironment that control such macrophage characteristics. Importantly, whether the infiltrating, inflammatory macrophages of the RA ST similarly exhibit such phenotypic plasticity, and whether this occurs during the process of remission, remains to be studied.

**Objectives:** We investigated the phenotypic plasticity of inflammatory synovial macrophages from patients with RA in vitro, investigating their ability to convert from an inflammatory macrophage population into ‘regulatory’ CD206/MerTK+ macrophages. These findings will provide a proof-of-concept as to the utility of these macrophage for a cell-based therapy in resolving inflammation in patients with RA, and will likely extend our understanding of the mechanisms of action of currently used therapeutics.

**Methods:** Synovial fluid (SF) mononuclear cells were obtained from patients with active early RA (<1 year; fulfilling 2010 ACR/EULAR classification criteria). Cryopreserved SFMCs were cultured for 48hr in the presence of 10ng/mL interferon(IFN)γ, 50ng/mL dexamethasone, 10μg/mL Infliximab, or diluent. Following culture, cells were immunostained and analysed using a Beckman Coulter CytoFLEX flow cytometer and FlowJo software. SF macrophages were characterised by expression of CD14, CD45, CD68 (Figure 1A), and proportions of CD206/MerTK+ macrophages measured.

**Figure 1. Synovial fluid CD68+ macrophage plasticity in vitro.** (A) Gating strategy depicting CD68+CD45−CD14+SF macrophage determination. (B) Proportions of CD206 and MerTK-expressing SF macrophages after 48hr culture in the presence of 10ng/mL interferon (IFN)γ, 50ng/mL dexamethasone or 10μg/mL Infliximab, or diluent. Data are representative of 5 individual experiments. Data were analysed by two-way ANOVA followed by Dunnett’s multiple comparison test. *p<0.05.

**Results:** Prior to culture, the CD68+ macrophage populations present in SF were found to be predominantly CD206/MerTK+. After 48 hours of culture, in the absence of any stimulus, there was an increase in proportions of CD206/MerTK+ macrophages. Treatment with either dexamethasone or anti-TNF (Infliximab) resulted in a further increase in proportions of CD206/MerTK+ M2-like macrophages. In contrast, culture with IFNγ induced a reduction in this population. Importantly, we found that the generated CD206/MerTK+ macrophages were phenotypically stable in culture following removal of these differentiating agents.

**Conclusion:** Our findings demonstrate that inflammatory SF cells are indeed able to polarise to regulatory, CD206/MerTK+ macrophages in vitro. The findings provide further mechanistic insights into the basis for the therapeutic benefits of glucocorticoids and TNF inhibitors, as well as providing initial proof-of-concept in the use of regulatory macrophages as a cellular-based therapy or therapeutic target for patients with RA.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4129

**POS0059**

**IDENTIFICATION OF NOVEL BIOMARKERS OF DISEASE ACTIVITY IN SYSTEMIC AUTOIMMUNE DISEASES THROUGH NEXT GENERATION PROTEOMICS**

C. Lopez-Pedreira1, L. Muñoz-Barrera1, A. Escudero Contreras1, M. Á. Aguirre-Zamorano1, P. Ortiz Buitrago1, C. López-Medina1, J. Calvo Gutierrez1, R. Ortega Castro1, F. U. Pilari1, I. Sanchez-Pareja1, M. C. Abalos-Aguilera1, N. Barbarroja Puerto1, E. Collantes Estevez1, C. Perez-Sanchez1, 1MIMIC/IIMBIC/ Reina Sofia Hospital/University of Cordoba, Rheumatology, Cordoba, Spain

**Background:** Systemic autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) are characterised by aberrant autoimmune and inflammatory processes, which are directly associated with the development and progression of these disorders. Novel biomarkers associated with the severity of these diseases are needed to better characterise and monitor their progression as well as to develop new and more effective therapeutic strategies.

**Objectives:** To identify common and distinctive novel biomarkers of disease activity in SLE and RA using high-throughput proteomics.

**Methods:** Serum samples from 170 patients, including 100 RA and 70 SLE, were profiled with the diagnostic technology ‘proteomeX’ extension assay’ from Olink, which analysed the levels of a panel of 92 inflammatory proteins. The methodology involves protein-specific antibodies linked to DNA-encoded tags which are amplified by RT-PCR.

Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and Disease activity score in 28 joints (DAS28) were assessed in SLE and RA patients respectively to characterise the disease status of all patients. Pearson’s correlation studies were performed using molecular information and clinical data to identify biomarkers of disease activity in each disease (FDR<0.05). Gene ontology enrichment analysis were performed to gain insight about the biological meaning of the biomarker signatures.

**Results:** SLE patients were characterised by an average SLEDAI of 5.2 (min-max, 0-29) while RA patients exhibited an average DAS28 of 4.6 (min-max, 15-78). Correlation studies revealed 14 proteins directly associated with SLEDAI in SLE patients, including ADA, CCL25, CD40, CDCP1, CSF1, FGF21, FLT3L, IL10RB, LAP-TGFβ1, MMP20, OPG, SLAMF1, TNFRSF9 and uPA. The subsequent enrichment analysis revealed that those molecules were associated with pathways such as cytokine-cytokine receptor interaction and MAPK signalling. In RA patients 26 proteins were directly correlated with DAS28 including AXIN1, BNGF, CASP8, CCL23, CD40, CSF1, CXCL9, CXCL10, CXCL11, EN-RAGE, FGF23, GDFN, HGF, IL10RB, IL15RA, IL6, IL7, IL9, IL20, IL23, LAP-TGFβ1, MCP3, OPG, SLAMF1, TNFRSF9 and TWEAK which were enriched in biological pathways such as chemokine-chemokine receptor interaction and Jak-STAT signalling.

The levels of five pro-inflammatory mediators were commonly associated with the disease activity status of both diseases such as IL10RB (receptor for IL10, IFNL2 and IFN3), CSF1 (macrophage colony-stimulating factor 1 receptor), SLAMF1 (Signaling lymphocytic activation molecule), TNFRSF9 and OPG (both, tumor receptor factor ligand superfamily members), suggesting a key common role of these molecules in the underlying molecular mechanisms associated with both diseases.

**Conclusion:** The analysis of the inflammatory profile of systemic autoimmune diseases with novel high-throughput proteomic technologies in non-invasive samples allow the identification of relevant biomarkers associated with the disease activity, which can improve the monitoring of the disease and the development of new targeted therapies.

**Acknowledgements:** Supported by ISCIII (PI12/005991 and RICOR-R21/0002/0033) co-financed by FEDER, Fundación Andalucía de Reumatología (FAR) and Consejería de Conocimiento, Investigación y Universidad de la Junta de Andalucía (P20_01367).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4733
with non-specific LBP without SpA-features or MRI findings suggestive of axSpA. Diagnosis of axSpA was based on multidisciplinary team conference consensus after 3.5 years of follow-up (3). Plasma levels of 10 lectin pathway proteins (MBL, H-ficolin, M-ficolin, MASP-1, MASP-2, MASP-3, MAP44, and MAP19) were measured by immunossays developed in-house.

**Results:** Patient characteristics are shown in Table 1. Plasma levels of lectin pathway proteins L-ficolin, M-ficolin and CL-L1 differed significantly in the patient groups (p = 0.03). L-ficolin and M-ficolin were elevated in axSpA-patients compared with patients with SpA-features without axSpA and non-specific LBP patients (Figure 1). CL-L1 was elevated in axSpA-patients and patients with SpA-features without axSpA compared with non-specific LBP patients (Figure 1). No significant differences were observed for MBL, H-ficolin, MASP-1, MASP-2, MASP-3, MAP44, and MAP19. L-ficolin levels correlated with CRP in axSpA-patients (Spearman’s r=0.58, p=0.004). M-ficolin levels correlated weakly with CRP in non-specific LBP patients (Spearman’s r=0.36, p=0.003). Lectin pathway protein levels did not correlate with disease activity (ASDAS).

**Table 1. Patient characteristics**

<table>
<thead>
<tr>
<th></th>
<th>axSpA</th>
<th>Not axSpA</th>
<th>Non-specific low back pain</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=23)</td>
<td>(n=55)</td>
<td>(n=64)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age, years (range)</td>
<td>32 (19-40)</td>
<td>33 (19-41)</td>
<td>32 (18-39)</td>
<td>0.75*</td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>10 (43)</td>
<td>37 (67)</td>
<td>26 (41)</td>
<td>0.01</td>
</tr>
<tr>
<td>HLA-B27 positive, n (%)</td>
<td>17 (74)</td>
<td>11 (20)</td>
<td>5 (8)</td>
<td>0.00*</td>
</tr>
<tr>
<td>Inflammatory back pain, n (%)</td>
<td>18 (78)</td>
<td>38 (71)</td>
<td>31 (50)</td>
<td>0.17</td>
</tr>
<tr>
<td>Good response to NSAID</td>
<td>14 (61)</td>
<td>17 (31)</td>
<td>0.97</td>
<td></td>
</tr>
<tr>
<td>Saccoritinitis on MRI acc. ASAS, n (%)</td>
<td>22 (96)</td>
<td>45 (62)</td>
<td>0.11</td>
<td></td>
</tr>
<tr>
<td>Elevated CRP, n (%)</td>
<td>3 (13)</td>
<td>7 (13)</td>
<td>0.97</td>
<td></td>
</tr>
<tr>
<td>ASDAS (range)</td>
<td>2.5 (12-3.7)</td>
<td>2.3 (0.8-3.8)</td>
<td>0.52*</td>
<td></td>
</tr>
</tbody>
</table>

* compared by Kruskal-Wallis test. † all three groups compared by Chi2 test. ‡ compared by Mann Whitney U test.

**Conclusion:** L-ficolin and M-ficolin are increased in patients with axSpA when compared with relevant control cohorts of patients with LBP or with SpA-features without axSpA. Our findings support a potential pathogenic role for complement in axSpA, however, further studies are needed to elucidate the diagnostic potential of the specific complement proteins.

### REFERENCES:


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3846

**POS060**

**MEASUREMENTS OF COMPLEMENT ACTIVITY SPECIFICALLY THOUGH THE LECTIN-OR THE CLASSICAL PATHWAY IN PATIENTS WITH SLE**

M. C. L. Larsen1, A. Trolldborg1,2,3, E. Toonen2, L. Hurley1, Z. Prohászka4,5, L. Cervenak1, A. G. Hansen2, S. Thiel2, Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 2Aarhus University, Department of Biomedicine, Aarhus C, Denmark; 3Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; 4Hycult Biotech, R&D Department, PB Uden, Netherlands; 5Semmelweis University, Department of Internal Medicine and Haematology, Budapest, Hungary; 6Semmelweis University-Edvöd Loránth Research Network (Office for Supported Research Groups), Research Group for Immunology and Haematology, Budapest, Hungary

**Background:** In systemic lupus erythematosus (SLE), the complement system (CS) is activated and thought to occur primarily through the classical pathway (CP) [1]. Traditionally, when diagnosing SLE or assessing disease activity, measurement of low C3 or C4 are used as proxies for complement activation [2]. However, measurement of C3 and C4 does not differentiate which complement pathway initiated the activation (i.e., the lectin pathway (LP), the CP, or the alternative pathway) [1, 3].

**C1-esterase inhibitor (C1inh) is one of the key regulators of the CS. C1inh is the exclusive inhibitor of the active CP enzymes C1r and C1s [4], and the major inhibitor of active LP enzymes MASP-1 and MASP-2 [5]. A possible way of assessing complement activation through a specific pathway, is by measuring activated enzymes complexed with C1inh in plasma, as these complexes only exist after complement enzyme activation.

**Objectives:** Our aim was to investigate and unravel LP and CP complement activation in SLE, by measuring the protein complexes MASP1/C1inh (LP specific activation) and C1r/C1inh (CP specific activation). Furthermore, we aimed to investigate whether there is an association between complement activity, disease activity (SLEDAI) and disease manifestations (lupus nephritis (LN)).

**Methods:** A cross sectional cohort of 150 patients with SLE fulfilling the 1997 ACR classification criteria for SLE were included from the out-patient clinic at the department of Rheumatology, Aarhus University Hospital (AUH), Denmark. Disease manifestations and disease activity using SLEDAI score was assessed at inclusion. Fifty healthy individuals included at the Blood bank, AUH, were used as controls. Both C1s/C1inh and MASP1/C1inh complexes were measured in all samples using two newly developed sandwich ELISAs (C1s/C1inh: cat# HK9399; MASP1/C1inh: Cat#3001). Hycult Biotech, Uden, The Netherlands. EDTA-samples from both SLE patients and controls were measured in duplicates.

**Results:** When comparing SLE patients to controls, we observed a difference in complement activation through the LP, where a lower mean MASP1/C1inh plasma concentration was observed (p<0.01). C1s/C1inh concentrations were significantly increased in active SLE patients (SLEDAI >6) when compared to SLE patients with low disease activity (SLEDAI <6, p<0.01) and correlated with SLEDAI score (r=0.285, p<0.01). C1s/C1inh concentrations were increased in SLE patients with active LN compared to non-active LN, however this not statistically significant (p=0.09).

No differences in MASP1/C1inh plasma concentrations were observed between active SLE patients and patients with low disease activity (p=0.11), nor did we observe a significant correlation with disease activity (r=0.12, p=0.13). In active LN, plasma concentrations of MASP1/C1inh were significantly elevated compared to non-active LN (p=0.02).

**Conclusion:** Our data suggest that the CP and the LP is activated in SLE. CS is generally activated in active SLE disease, whereas activation of the LP might be more specific to particular disease manifestations like LN.

Our findings warrant further research into activation of the specific pathways in relation to specific disease manifestations in SLE.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2482
Lung involvement in Rheumatic Diseases

**POS0051** THE RISK OF LUNG CANCER IN RHEUMATOID ARTHRITIS AND IN RELATION TO AUTOANTIBODY POSITIVITY AND SMOKING

K. Chatzidionysiou1, D. Di Giuseppe1, J. Söderling1, A. Catrina1, J. Asklund1,2,3
1Karolinska Institute, Rheumatology Division, Department of Medicine Solna, Stockholm, Sweden; 2Karolinska Institute, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden

**Background:** Lung cancer is a common malignancy in rheumatoid arthritis (RA)1-3. Since smoking is a risk factor for both (seropositive) RA and lung cancer, it remains unclear whether RA, in itself, increases lung cancer risk.

**Objectives:** The aim of this study was to examine whether and to what extent the increased risk of lung cancer in RA may (or may not) be attributable to smoking, and to examine this association, both in terms of absolute and relative risks, specifically in relation to RA serostatus.

**Methods:** We performed a population-based cohort study of RA patients and individually matched general population reference individuals identified in Swedish registers and from the EIRA early RA study, prospectively followed for lung cancer occurrence 1995 through 2018. We calculated incidence rates and performed Cox regression to estimate hazard ratios (HR) including 95% confidence intervals (CI) of lung cancer, taking smoking and sero-status into account.

**Results:** Overall, we included 44,101 RA patients (590 incident lung cancers, 56 per 100,000, and 216,495 matched general population individuals (1,691 incident lung cancers, 33 per 100,000), corresponding to a crude HR (95% CI) of 1.76 (1.60-1.93). In subset analyses this increased risk remained after adjustment for smoking (HR=1.77, 95% CI 1.06-2.97). Compared to general population subjects who were never smokers, RA patients who were ever smokers had almost 7 times higher risk of lung cancer.

Positive autoantibody status was associated with an at least doubled risk of lung cancer in ACPA positive patients (vs. ACPA negative patients) and double seropositive (vs. double seronegative) patients after adjusting for comorbidities and smoking (Table 1).

The average absolute five-year risk of lung cancer counting from RA diagnosis was 1.3% in ever-smoking seropositive RA. At 20 years the risk was almost 3% in RA overall, and over 4% for patients who were ever smokers and had at least one autoantibody.

**Conclusion:** RA seropositivity is a strong and at least seemingly independent risk factor for lung cancer in RA. The absolute risks point to the potential for regular lung cancer screening, at least in seropositive RA.

**REFERENCES:**

**Disclosure of Interests:** Katerina Chatzidionysiou Consultant of: consultancy fees from Eli Lilly, AbbVie and Pfizer, Daniela Di Giuseppe: None declared, Jonas Söderling: None declared, Anca Catrina: None declared, Johan Asklund: Research support from Karolinska Institutet has entered into agreements between Karolinska Institutet (JA as principal investigator) with AbbVie, BMS, MSD, Eli Lilly, Pfizer, Roche, Samsung Bioepis, Sanofi and UCB, mainly regarding safety monitoring of anti-rheumatic therapies.

**DOI:** 10.1136/annrheumdis-2022-eular.600

Table 1. Number of events, person-years of follow-up, number of deaths per 100,000 person-years, and relative risk of lung cancer according to autoantibody status in the EIRA sub-cohort. Five Hazard ratios are presented: a) crude; b) adjusted for age, sex, index year, country of residency (model A); c) age, sex, index year, county of residency and comorbidities (renal failure, heart failure, ischemic heart disease, COPD, respiratory infections, hospitalization) (model B) c) all the above plus smoking (model C) and d) model C with packet-years instead of smoking ever vs. never.

<table>
<thead>
<tr>
<th>No of events/100 000 person years</th>
<th>Crude Hazard ratio (95% CI)</th>
<th>Model A Hazard ratio* (95% CI)</th>
<th>Model B Hazard ratio** (95% CI)</th>
<th>Model C Hazard ratio*** (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF</td>
<td>30 (49,440; 60.7)</td>
<td>6</td>
<td>2.78 (1.16-6.69)</td>
<td>3.01 (1.25-7.26)</td>
</tr>
<tr>
<td>(N=2060)</td>
<td></td>
<td></td>
<td>2.82 (1.17-6.82)</td>
<td>2.44 (1.01-5.95)</td>
</tr>
<tr>
<td>ACRA</td>
<td>30 (49,440; 12.1)</td>
<td>6</td>
<td>3.13 (1.30-7.51)</td>
<td>3.43 (1.42-8.25)</td>
</tr>
<tr>
<td>(N=2060)</td>
<td></td>
<td></td>
<td>3.22 (1.33-7.77)</td>
<td>2.88 (1.19-6.95)</td>
</tr>
<tr>
<td>RF and/or ACRA</td>
<td>34 (49,440; 60.7)</td>
<td>2</td>
<td>6.38 (1.53-26.56)</td>
<td>7.62 (1.83-31.83)</td>
</tr>
<tr>
<td>(N=2060)</td>
<td></td>
<td></td>
<td>7.20 (1.72-30.11)</td>
<td>6.29 (1.51-26.30)</td>
</tr>
<tr>
<td>RF and ACRA positive vs. double negative</td>
<td>26 (38,592; 674)</td>
<td>2</td>
<td>6.67 (1.58-28.08)</td>
<td>7.98 (1.87-33.50)</td>
</tr>
<tr>
<td>(N=1680)</td>
<td></td>
<td></td>
<td>7.08 (1.67-29.98)</td>
<td>6.21 (1.47-26.33)</td>
</tr>
</tbody>
</table>

**Conclusion:** Despite a high morbidity-mortality rate, there are no definite strategy for subclinical interstitial lung disease (ILD) screening in patients with rheumatoid arthritis (RA).

**Disclosure of Interests:** Pierre-Antoine Juge Speakers bureau: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Consultant of: Bristol Myers Squibb, Benjamin Granger: None declared, Marie-Pierre Debray: None declared, Esther Ebstein: None declared, Fabienne Louis-Sidney: None declared, Joanna KEDRA: None declared, Tracy Doyle: None declared, Raphael Borie: None declared, Arnaud Constantin Consultant of: Abbvie, Amgen, Biogen, BMS, Boehringer Ingelheim, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Mylan, Novartis, Pfizer, Procter & Gamble, Roche, Sanofi, UCB, Viatris, Bernard Combe Consultant of: Abbvie, BMS, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer.
Table 1. Demographics and baseline clinical characteristics of EUSTAR patients

<table>
<thead>
<tr>
<th>Disease duration</th>
<th>≤15 years</th>
<th>&gt;15 years</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>s (n=460)</td>
<td>(n=550)</td>
<td>(n=752)</td>
<td>(n=488)</td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>55 (13.5)</td>
<td>53 (14.1)</td>
<td>57 (13.1)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>123 (26.2)</td>
<td>115 (20.9)</td>
<td>112 (14.9)</td>
</tr>
<tr>
<td>DcSSc, n (%)</td>
<td>228 (56.4)</td>
<td>262 (45.8)</td>
<td>311 (45.4)</td>
</tr>
<tr>
<td>AFA, n (%)</td>
<td>236 (53.4)</td>
<td>293 (59.5)</td>
<td>374 (52.8)</td>
</tr>
<tr>
<td>HRSS, mean (SD)</td>
<td>12.3±10.1</td>
<td>10.4 (8.3)</td>
<td>9.4 (8.1)</td>
</tr>
<tr>
<td>GERD, n (%)</td>
<td>273 (58.7)</td>
<td>353 (64.4)</td>
<td>482 (64.4)</td>
</tr>
<tr>
<td>ESR, mean (SD)</td>
<td>124.2 (21.7)</td>
<td>24.2 (19.5)</td>
<td>26.2 (19.9)</td>
</tr>
<tr>
<td>MMP, n (%)</td>
<td>33 (16.6)</td>
<td>43 (25.2)</td>
<td>37 (20.4)</td>
</tr>
<tr>
<td>MX1, n (%)</td>
<td>19 (10)</td>
<td>17 (10)</td>
<td>19 (10.6)</td>
</tr>
<tr>
<td>Any Is, n (%)</td>
<td>81 (36.8)</td>
<td>89 (47.1)</td>
<td>82 (40.8)</td>
</tr>
<tr>
<td>FVC % pred, mean (SD)</td>
<td>86 (20.9)</td>
<td>87 (21.6)</td>
<td>86 (21.4)</td>
</tr>
<tr>
<td>DLCO % pred, mean (SD)</td>
<td>58 (19.3)</td>
<td>59 (19.3)</td>
<td>59 (19.9)</td>
</tr>
<tr>
<td>NYHA class ≥3, n (%)</td>
<td>84 (18.6)</td>
<td>78 (14.6)</td>
<td>125 (17.5)</td>
</tr>
</tbody>
</table>

Figure 1. FVC decline >10% and composite FVC and DLCO decline in the first and second 12+/-3 months within the four subgroups segregated by disease duration.

Conclusion: It was long believed that ILD burned out in late disease stages. In our analysis of ILD progression by four disease duration categories, we showed that ILD frequently progressed also in late disease stages. This has important implications for clinical practise, as SSc patients need to be regularly monitored for ILD progression independent of disease duration.

Disclosure of Interests: Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Rohe, Consultant of: Actelion, ARFX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Rohe, Grant/research support from: Boehringer Ingelheim, Katharina Brunborg: None declared, Paolo Aiò Speakers bureau: Bristol-Myers-Squibb, Boehringer Ingelheim, Consultant of: Bristol-Myers-Squibb, Roche, Janssen, CSL Behring, Lidia P Ananyeva Speakers bureau: Boehringer Ingelheim, Grant/research support from: Boehringer Ingelheim, Laszlo Czirják Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Actelion (now GSK), MSD, Novartis, Pfizer, Rohe, Lilly, Grant/research support from: Boehringer Ingelheim, Actelion (now GSK), MSD, Novartis, Pfizer, Seren Guidducci: None declared, Eric Hachulla Consultant of: Pfizer, Roche, Boehringer Ingelheim, Consultant of: Pfizer, Roche, Chugai, Bristol-Myers Squibb, Abbvie, MSD, Grant/research support from: Novartis.

POS0064 INTERSTITIAL LUNG DISEASE ASSOCIATED WITH PRIMARY SJÖGREN’S SYNDROME IS FREQUENTLY PROGRESSIVE

1Oslo University Hospital, Rheumatology, Oslo, Norway; 2Oslo University Hospital, Radiology, Oslo, Norway; 3Oslo University Hospital, Respiratory Medicine, Oslo, Norway; 4Oslo University Hospital, Radiology, Oslo, Norway.

Background: Intestinal lung disease (ILD) in primary Sjögren’s syndrome (pSS) has been reported to be present in 10–15% of patients, but pSS-ILD behavior over time is not well characterized. 

Objectives: Assess the pattern of ILD in pSS, its disease behavior and factors associated with disease progression in a well-characterized pSS-ILD cohort.

Methods: All pSS patients from the Oslo University Hospital (OUH) were included if ILD was diagnosed on HRCT. Clinical characteristics, lung function tests including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) and ILD pattern on HRCT assessed by a radiologist were evaluated. We determined ILD progression, defined as absolute FVC decline >5% or absolute DLCO decline >10% over 12 +/−6 months and increasing extent of ILD on HRCT observed over the treatment period. Factors associated with disease progression were chosen based on expert opinion. Descriptive analyses were conducted.

Results: Of 702 pSS patients followed at OUH, we identified 60 pSS patients with ILD with 33 having follow-up of 12 months (Table 1). Patients with pSS-ILD were characterized by high number of males (18%) and by frequent other extra-pulmonary organ involvement (48%) (Table 1). Mean time from pSS diagnosis to ILD diagnosis was 74 years. In 67% ILD was diagnosed after pSS, in 13% simultaneously, in 11% before pSS diagnosis and in 9% unknown. In total, 28 (47%) were diagnosed with lymphoproliferative interstitial pneumonia (LIP) and 32 (53%) with reticular pattern on HRCT. Mean time follow-up of 10.9 months (SD 4.2), 7/33 (21%) showed a FVC <5% decline, 9/32 (28%) a DLCO >10% decline and 12 (36%) had at least one of these defined lung function declines on standard of care treatment. Treatment was registered as ever used and by any indication. Over an observation period of 15.4 (SD 10.6) years, 27/47 (45%) showed any ILD progression on HRCT. HRCT pattern was not associated with risk of >10% DLCO decline or ILD progression on HRCT. >5% FVC decline occurred more frequently in LIP compared to other patterns (LIP: 6/17 (35%) vs 1/16 (6%), p=0.041). Factors significantly associated with ILD progression on lung function included higher baseline FVC (99% (SD16.4) vs 87% (SD14.9), p=0.032), higher DLCO (81% (SD13.1) vs 67% (SD17.4), p=0.020), increased CRP (2/10 (20%) vs 0/16 (0%), p=0.045) and presence of polyneuropathy (2/9 (22%) vs 1/17 (6%), p=0.045).

Conclusion: A substantial number of patients with pSS-ILD progressed during the time of observation. This highlights the importance of close monitoring and active consideration of treatment options in pSS-ILD. Recommendations for disease management including screening, diagnosis, disease monitoring and treatment for pulmonary involvement in pSS are lacking to date, but are highly needed.

Disclosure of Interests: Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Håvard Frethiem Consultant of: Bayer, Grant/research support from: Jansen, Phares, Pharmibio, Brigham and Women’s Hospital, Department of Pulmonary Medicine, Consultant of: Boehringer Ingelheim, Lerang: None declared, Helena Anderson: None declared, Øyvind Midveldt: None declared, Torhild Garen: None declared, Mike Durham Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim and Roche, Grant/research support from: Boehringer Ingelheim and Roche, Tornd M Aalakken Speakers bureau: Boehringer Ingelheim, Øyvind Palm: None declared, Øyvind Molberg: None declared.


POS0065 EPIDEMIOLOGY OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS IN FRANCE: A NATION-WIDE POPULATION-BASED STUDY OVER 10 YEARS

A. Mageau1, B. Crestani2, J. F. Timfi3, T. Papo1, K. Sacre1.  
1Université de Paris Bichat, Médecine Interne, Paris, France; 2Université de Paris Bichat, Pneumologie, Paris, France; 3Université de Paris Bichat, Réanimation Medica, Paris, France.

Background: Data regarding interstitial lung disease (ILD) in the setting of systemic lupus erythematosus (SLE) are limited.

Objectives: We used a nation-wide database to determine the incidence and the prevalence of ILD in SLE patients.

Methods: Characteristics of all SLE inpatients admitted between 2011 and 2012 in France were analyzed through the French medico-administrative database. Features associated with the presence of ILD were studied. Cox proportional hazard model was used to look for the impact of ILD on survival from the first stay to 2020. The incidence rate of ILD in SLE was estimated by analysing the onset of ILD from 2013 to 2020 in SLE patients who had no evidence of ILD in 2013.

Results: Between 2011 and 2012, 10,460 SLE patients had at least one hospital stay and could be traced until 2020. Among them, 1,34 (1.2%) had an ILD diagnosis at baseline. The frequency of ILD in SLE was higher in patients who had an associated autoimmune disease – such as Sjögren’s syndrome or systemic sclerosis (29.9% vs 5.9%; p<0.0001). ILD was associated with an increased risk of death in SLE after adjustment on comorbidities in the multivariable analysis (HR [CI95] 1.992 [1.420-2.794]; p<0.0001). Among the 31,029 SLE patients with no evidence of ILD at baseline, ILD occurred in 795 SLE patients (2.6%) between 2013 and 2020. The incidence rate of ILD in SLE was 10.26 for 1000 patient-years [CIRK: 10.24-10.28].

Conclusion: In SLE, ILD is exceedingly rare, often associated with another systemic autoimmune disorder and appears as a major risk factor for death.

Disclosure of Interests: Arthur Mageau: None declared, Raphael Borie Grant/research support from: Roche Boehringer Ingelheim, Bruno Crestani: None declared, Jean-Francois Timsit: None declared, Thomas Papo: None declared, Karim Sacre: None declared, Jean-Francois Timsit: None declared, Thomas Papo: None declared, Bruno Crestani: None declared, research support from: Roche Boehringer Ingelheim.


Table 1. Clinical characteristics, demographics and outcome of pSS with ILD

<table>
<thead>
<tr>
<th>pSS-ILD</th>
<th>n=60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at pSS diagnosis, y (SD)</td>
<td>50 (21.9)</td>
</tr>
<tr>
<td>Time from pSS to ILD diagnosis, y (SD)</td>
<td>74 (8.9)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>11 (18)</td>
</tr>
<tr>
<td>Anti-SSA AB, n/50 (%)</td>
<td>46 (92)</td>
</tr>
<tr>
<td>Increased CRP, n/7 (%)</td>
<td>7 (15)</td>
</tr>
<tr>
<td>Low complements, n/49 (%)</td>
<td>5 (10)</td>
</tr>
<tr>
<td>Extra-pulmonary involvement, n/46 (%)</td>
<td>22 (48)</td>
</tr>
<tr>
<td>Deceased, n (%)</td>
<td>10 (17)</td>
</tr>
<tr>
<td>Pulmonary involvement</td>
<td></td>
</tr>
<tr>
<td>FVC% predicted (SD)</td>
<td>91 (18.7)</td>
</tr>
<tr>
<td>FVC decline&gt;5%, n/33 (%)</td>
<td>7 (21)</td>
</tr>
<tr>
<td>DLCO% predicted (SD)</td>
<td>70 (20.7)</td>
</tr>
<tr>
<td>DLCO decline &gt;10%, n/32 (%)</td>
<td>9 (28)</td>
</tr>
<tr>
<td>ILD progression on HRCT, n/47 (%)</td>
<td>27 (45)</td>
</tr>
<tr>
<td>Treatment during follow up</td>
<td></td>
</tr>
<tr>
<td>Rituximab, n (%)</td>
<td>11 (18)</td>
</tr>
<tr>
<td>Any other immunosuppressive, n (%)</td>
<td>20 (33)</td>
</tr>
<tr>
<td>Hydroxychloroquine, n (%)</td>
<td>16 (27)</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>4 (6)</td>
</tr>
<tr>
<td>Lung transplant, n (%)</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>

POS0066 THE PHENOTYPE OF MIXED CONNECTIVE TISSUE DISEASE PATIENTS HAVING ASSOCIATED INTERSTITIAL LUNG DISEASE

G. Boleti1, S. Reiseter2, A. M. Hoffmann-Vold3, A. Mirouel2, P. Cacoub2, M. Matsuuc-Cernici2,5, M. Silván-Santo10, J. E. Fonseca2,9, V. Riccieri2, E. Le Tallec10, A. Lescoat10, J. L. Tandai11, I. Castelví11, P. Airo12, M. Kuzwana13, H. Kavosti11, J. Avouac11,15, Y. Allarone11,15, 1Université de Paris, Hôpital Cochin, Rheumatology, Paris, France; 2Martina Hansen Hospital, Department of Rheumatology, Barum, Norway; 3Oslo University Hospital, Rheumatology, Oslo, Norway; 4Groupe Hospitalier Pitité-Salpêtrière, AP-HF, F-75013, Department of Internal Medicine and Clinical Immunology, Paris, France; 5Inserm, 6Inserm, 7Inserm, 10Inserm, 11Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France.

Background: Mixed connective tissue disease (MCTD) is a rare autoimmune condition characterized by Raynaud’s phenomenon, positivity of autoantibodies
Objectives: To compare two distinct populations of MCTD patients with and without associated ILD and to identify predictive factors for lung progression and severe outcomes.

Methods: International multicenter retrospective study (12 tertiary hospitals). To be included, patients were required to fulfill at least one MCTD international classification criterion (4). ILD was defined by the presence of typical chest high-resolution computed tomography (HRCT) abnormalities. Patients were divided into two groups: with or without ILD, at a ratio of 1:1 and matching on disease duration (+/- 2 years).

Results: 300 patients were included. Mean age at MCTD diagnosis was 39.7±15.4 years and 191 (63.7%) were women. At baseline, we identified several variables associated with the presence of ILD: at older age (42.2 vs 37.5 years, p=0.01), scleroderma-like phenotype (38.7 vs 27.3%, p=0.03), upper gastro-esophageal (GI) symptoms (54.7 vs 30.7%, p<0.001), forced vital capacity (FVC) <80% (80.4 vs 95.3%, p<0.0001), diffuse opacity for carbon monoxide (DLCO) <80% (62.4 vs 74.8%, p=0.0001), anti-topoisomerase antibodies (6 vs 0 patients, p<0.01), SSA/Ro antibodies positivity (29.3 vs 19.3%, p=0.02), cryoglobulinemia (5.3 vs 13.0%, p=0.04) and elevated C-reactive protein (CRP) >5mg/L (5.4 vs 27.8%, p<0.001). Among the previous variables older age (OR 1.03, 95% CI 1.01 to 1.05), upper GI symptoms (OR 1.92, 95% CI 1.12 to 3.32) and CRP >5mg/L (OR 6.75; 95% CI 1.7-26.4, p=0.006).

Conclusion: In this large international cohort of patients with MCTD, we identified several factors associated with ILD development. Our findings highlight a high risk of mortality in MCTD-ILD patients and that digital ulceration seems to be at risk of more progressive ILD.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1351
Results: The median (IQR) age of the patients was 52.0 (43.5-58.5) years and 60 (75.0%) were women. Baseline median score of whole lung-QILD and most severe zone-QILD were 28.1% (19.1-43.8) and 68.0% (45.5-81.8), respectively, and QILD score showed significant correlations with pulmonary function tests (r=-0.349, p=0.002 for % predicted forced vital capacity; and r=-0.381, p=0.001 for % predicted diffusing capacity for carbon monoxide). The individual time-estimated yearly ∆QILD score between first 2 visits presented that approximately half of the patients showed improvement or stability in QILD scores; however, when patients were sorted by visual assessment in IILD subtype on HRCT, approximately two-thirds of the patients with usual interstitial pneumonia (UIP) pattern were aggraved in QILD scores and less than half of subjects with nonspecific interstitial pneumonia and organizing pneumonia were aggraved (Figure 1, 80% for UIP vs. 44.4% for non-UIP, p=0.013). There was no immunosuppressive drugs related to meaningful improvement in QILD scores during first 2 visits. Notably, we observed significant aggravation of QILD scores in sarcoid patients (n=7, median time-estimated whole lung-yrary QILD 20.3 (2.7-38.4)) compared with sarcoid non-users (n=73, median time estimated whole lung-yrary ∆QILD -1.2 (-8.3-6.5)). Among 80 patients, 6 (7.5%) were died due to various lung complications. Higher baseline QILD scores were noted in deaths (median whole lung-QILD 45.4 (32.9-56.5)) than in survivors (median whole lung-QILD 26.9 (19.0-42.4)), albeit not significant (p=0.084). Poor survival rate was observed in patients with high grade of ground glass opacity by visual assessment in right upper lobe (log-rank test, p=0.042). Among subgroup of patients with 3 serial HRCT scans (n=41), dynamic changes of four distinct patterns (improving, worsening, convex, and concave) were observed.

Methods: Overall chest HRCT, lung function and skin score changes were evaluated in 33 consecutive dSSc-patients before and after aHSCT during yearly routine follow-up between January 2000 and September 2016. Two independent radiologists blindly assessed the ILD extent using semi-quantitative Goh and Wells method (2), the widest esophageal diameter (WED) and the esophageal volume (EV) on HRCT. Patients were retrospectively classified as radiological responders or non-responders at 24 months after aHSCT according to the stability or a 5% or more decrease of HRCT IILD extent. Two by two time point comparisons after versus before aHSCT were performed using linear regressions.

Results: Twenty-four months after aHSCT, HRCT median [IQR] IILD (2 [-10.3; 0] points, p=0.0002) and ground-grass opacities (-2.1 [-8.3; 0] points, p=0.02) extent scores had improved, with 18 patients radiological responders (probability of response 0.78, 95% CI (0.580,0.90), whereas median WED (from 24.5 [18.29] to 28 [19.33] mm; p= 0.005) and EV (from 19 [13.30] to 30 [13; 58] mm2, p=0.01) increased significantly. Kaplan-Meier analyses showed a trend towards better 5 years survival rates (100% versus 60%; HR 0.23 95%CI 0.03 to 1.62, P = 0.11) among radiological responders versus non-responders at 24 months.

Conclusion: Real-world data analysis confirmed significant HRCT SSc-ILD improvement 24 months after aHSCT, although esophageal dilatation worsened requiring specific attention.

REFERENCES:

Disclosure of Interests: None declared


Figure 1. Cleveland dot plot of individual time-estimated yearly ∆QILD during first 2 visits.

Conclusion: The changes in QILD score in IIM-ILD are dynamic and present different by visual assessment. QILD score has the potential for evaluation of the severity changes, prognosis and medication response in patients with IIM-ILD.
Table 1. Adverse events (irrespective of causality) reported over 52 weeks in patients with ICSSC and ILD in SENSCIS and SENSCIS-ON.

<table>
<thead>
<tr>
<th>SENSCIS</th>
<th>SENSCIS-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nintedanib (n=135)</td>
<td>Placebo (n=142)</td>
</tr>
<tr>
<td>Initiated nintedanib (n=98)</td>
<td></td>
</tr>
</tbody>
</table>

Most frequent adverse events*

<table>
<thead>
<tr>
<th></th>
<th>SENSCIS</th>
<th>SENSCIS-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea</td>
<td>104 (77.0)</td>
<td>43 (30.3)</td>
</tr>
<tr>
<td>Nausea</td>
<td>45 (33.3)</td>
<td>20 (14.1)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>33 (24.4)</td>
<td>16 (11.3)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>21 (15.6)</td>
<td>29 (20.4)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>18 (13.3)</td>
<td>19 (13.4)</td>
</tr>
<tr>
<td>Skin reaction</td>
<td>11 (8.1)</td>
<td>18 (12.7)</td>
</tr>
<tr>
<td>Cough</td>
<td>17 (12.6)</td>
<td>25 (17.6)</td>
</tr>
<tr>
<td>Adverse event(s) leading to permanent treatment discontinuation</td>
<td>25 (18.5)</td>
<td>12 (8.5)</td>
</tr>
</tbody>
</table>

Adverse event(s) leading to dose reduction

<table>
<thead>
<tr>
<th></th>
<th>SENSCIS</th>
<th>SENSCIS-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 (34.8)</td>
<td>5 (3.5)</td>
<td>17 (13.3)</td>
</tr>
</tbody>
</table>

Most frequent adverse events*

<table>
<thead>
<tr>
<th></th>
<th>SENSCIS</th>
<th>SENSCIS-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhoea</td>
<td>104 (77.0)</td>
<td>43 (30.3)</td>
</tr>
<tr>
<td>Nausea</td>
<td>45 (33.3)</td>
<td>20 (14.1)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>33 (24.4)</td>
<td>16 (11.3)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>21 (15.6)</td>
<td>29 (20.4)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>18 (13.3)</td>
<td>19 (13.4)</td>
</tr>
<tr>
<td>Skin reaction</td>
<td>11 (8.1)</td>
<td>18 (12.7)</td>
</tr>
<tr>
<td>Cough</td>
<td>17 (12.6)</td>
<td>25 (17.6)</td>
</tr>
<tr>
<td>Adverse event(s) leading to dose reduction</td>
<td>47 (34.8)</td>
<td>5 (3.5)</td>
</tr>
</tbody>
</table>

Adverse event(s) leading to dose reduction

<table>
<thead>
<tr>
<th></th>
<th>SENSCIS</th>
<th>SENSCIS-ON</th>
</tr>
</thead>
<tbody>
<tr>
<td>47 (34.8)</td>
<td>5 (3.5)</td>
<td>17 (13.3)</td>
</tr>
</tbody>
</table>

Conclusion: The change in FVC in patients with ICSSC and ILD who received nintedanib over 52 weeks, and the safety profile of nintedanib, in SENSCIS-ON were similar to that observed in patients with ICSSC and ILD who received nintedanib in SENSCIS. These analyses support a continued effect of nintedanib on slowing decline in FVC and the ability to manage adverse events of nintedanib in patients with ICSSC and ILD over the longer term.

Acknowledgements: The SENSCIS-ON trial was funded by Boehringer Ingelheim.

Disclosure of Interests: Yannick Allanore Consultant of: Abbvie, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Medscin, Mylan, Prometheus, Roche, Sanofi, Grant/research support from: Alpine Immunosciences, Medscin, OSE Immunotherapeutics, Dinesh Khanna Shareholder of: Stocks - Eicos Sciences, Inc., Consultant of: AbbVie, Acceleron, AstraZeneca, Bayer, Boehringer Ingelheim, MSKCC, Netherlands Cancer Institute, Galapagos NV, Genentech/Roche, Gilead, GlaxoSmithKline, Horizon Therapeutics, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Prometheus, Sanofi-Aventis, Theraflu, United Therapeutics, Grant/research support from: Bayer, Bristol-Myers Squibb, Horizon Therapeutics, Immune Tolerance Network, National Institutes of Health, Pfizer, Employee of: Leadership/Equity position – Chief Medical Officer - Civico Pharma/Eicos Sciences, Inc, Vanessa Smith Speakers bureau: Actelion Pharmaceuticals, Boehringer-Ingelheim Pharma GmbH&Co, Janssen-Cilag NV, UCB Biopharma Sprl, Consultant of: Boehringer-Ingelheim Pharma GmbH&Co, Janssen-Cilag NV, Grant/research support from: Belgian Fund for Scientific Research in Rheumatic diseases (FWRO), Boehringer Ingelheim Pharma GmbH&Co, Janssen-Cilag NV, Research Foundation - Flanders (FWO), Martin Aringer Speakers bureau: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Galapagos, GlaxoSmithKline, Lilly, MSD, Novartis, Otsuka, Pfizer, Roche, Sanofi, UCB, Consultant of: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Galapagos, GlaxoSmithKline, Lilly, Pfizer, Roche, Sanofi, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Lilly, Medscape, Merck Sharp & Dohme, Roche, Paid instructor for: Boehringer Ingelheim, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Masataka Kuwana Speakers bureau: Abbvie, Asahi Kasei Pharma, Astellas, Boehringer Ingelheim, Chugai, Eisai, GlaxoSmithKline, Janssen, Nippon Shinyaku, Ono Pharmaceuticals, Takeda-Mitsubishi, Consultant of: AstraZeneca, Boehringer Ingelheim, Corbus, Mochida Kissei, Grant/research support from: Boehringer Ingelheim, MBL, Ono Pharmaceuticals, Peter A Merkel Consultant of: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ChemoCentryx, CSL Behring, Dynacure, EMD Serono, Forbuis, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Immagene, InflaRx, Janssen, Kiniksa, Kyverna, Magneta, MirBio, Neutrolis, Novartis, Pfizer, Regeneron, Sparrow, Takeda, Talaris, Grant/research support from: Boehringer Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Eics, Forbuis, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Sanofi, Takeda, Alexandra James Employee of: Alexandra James is an employee of Elderbrook solutions GmbH that is contracted by Boehringer Ingelheim, Steven Sambevski Employee of: Steven Sambevski is an employee of Boehringer Ingelheim, Margarida Alves Employee of: Margarida Alves is an employee of Boehringer Ingelheim, Christopher P Denton Speakers bureau: Boehringer Ingelheim, Janssen, Consultant of: Abbvie, Acceleron, Boehringer Ingelheim, Corbus, CSL Behring, GlaxoSmithKline, Roche, Grant/research support from: ARXX Therapeutics, GlaxoSmithKline, Horizon Therapeutics, Servier, DOI: 10.1136/annrheumdis-2022-er754

Background: Pulmonary interstitial disease (ILD) is very common in connective tissue disease (CTD). Different subtypes display significant differences in prognosis. Pirfenidone (PFD), the targeted anti-fibrosis and anti-inflammatory drug, started to apply in CTD-ILD, while its strategy of combination with immunotherapy, bridging time and service time are worth discussing.

Objectives: To evaluate the efficacy and safety of PFD combined with immuno-suppressant (IS) in the treatment of several CTD-ILD.

Methods: 111 CTD-ILD patients were involved from Aug 2019 to Dec 2021 (ClinicalTrials.gov Identifier NCT04928586), including systemic sclerosis (SSc, n=30), inflammatory myopathy (IM, n=51), rheumatoid arthritis (RA, n=17) and other CTDs (such as systemic lupus erythematosus, spondylitis, n=13). Patients were treated with relative stable dose of glucocorticoid (GC) and/or IS since screening. After the evaluation of HRCT, pulmonary function (FVC%) and changes in SSc, IIM, RA and other CTD-ILD from baseline.

(B) changes in SSc, IIM, RA and other CTD-ILD from baseline. *p < 0.05, compared to no PFD treatment group.

Figure 1. The changes of FVC% and DLco% in PFD treated CTD-ILD for 24 weeks. (A) FVC% changes in SSc; IIM, RA and other CTD-ILD from baseline. (B) DLco% changes in SSc, IIM, RA and other CTD-ILD from baseline.
New therapeutic avenues in psoriatic arthritis

**POS0072**

**CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS**


**Department:** University of British Columbia, Vancouver, Canada; 2Arizona Arthritis & Rheumatology Associates, Rheumatology, Phoenix, United States of America; 3Michigan Medicine Rheumatology Clinic, University of Michigan Medical School, Rheumatology Internal Medicine, Ann Arbor, United States of America; 4Brigham and Women's Hospital, Division of Rheumatology and Immunology, Harvard Medical School, Dermatology and Medicine, Boston, United States of America; 5Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America; 6Drexel University College of Medicine, Rheumatology, Philadelphia, United States of America; 7McGill University, Pediatrics, Montreal, Canada; 8JSS Medical Research, Inc, Scientific Affairs, Montreal, Canada; 9University of Saskatchewan, Community Health and Epidemiology, Saskatoon, Canada; 10Janssen Research & Development, LLC, Immunology, San Diego, United States of America; 11Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; 12Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy-les-Moulineaux, France; 13University of New South Wales, Sydney, Australia; 14Swedish Medical Center/ Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, United States of America

**Background:** Psoriatic arthritis (PsA) patients (pts) with differing baseline (BL) characteristics may vary in their response to treatment. In the phase 3 DISCOVER-1 and DISCOVER-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of life at Week (W) 24 in pts with PsA.1,2 Clinical responses across these disease domains were maintained or increased with GUS at W52,3,4 regardless of BL pt demographics, disease characteristics, or conventional synthetic disease-modifying antirheumatic drug (csDMARD) use.5 Durable efficacy with GUS through W100 across multiple disease domains was observed.6

**Objectives:** Assess both BL predictors of, and by BL pt subgroups, GUS efficacy across PsA disease domains through W100 of DISCOVER-2.

**Methods:** Biologic-naïve adults with active PsA despite standard therapies were enrolled in DISCOVER-2 (swollen joint count [SJC] ≥5 & tender joint count [TJC] ≥5, C-reactive protein [CRP] ≥0.6 mg/dL). Pts were randomized: 1:1 to GUS 100 mg at W0, W4, then QW (PBO) or placebo (PBO).7 GUS effects on joint, skin, enthesitis, dactylitis, spinal pain, and disease severity endpoints (change in Disease Activity in PsA [PsA-DAPSA], SJC, and TJC scores; Psoriasis [PsO] Area Severity Index [PSI] score) were compared with BL pts (psA-DAPSA, SJC, TJC, CRP level, %BSA, and PALI score) at W100.

**Results:** 442 (90%) GUS-randomized pts completed study treatment through W100.7 Among the BL predictors of long-term GUS efficacy assessed (see above), only PsA duration (p=0.032), SJC (p<0.001), and TJC (p<0.001) were significant predictors of long-term (BL to W100) GUS score change.8-10 Significant predictors of long-term (BL to W100) GUS score change included %BSA (p=0.002), PALI (p=0.008), and PsA-DAPSA use (p=0.014) with significant predictors of long-term (BL to W100) GUS score change and none significantly predicted long-term PALI score change. In pooled GUS pts (Figure 1), statistically significant improvements from BL to W100 in PsA-DAPSA, SJC, TJC, and PALI scores were observed across both BL strata, including those indicating more extensive or severe disease, in pooled GUS Q4W+Q8W pts (Figure 1, p<0.001) and within each dosing group. Similar improvements were observed for other continuous endpoints assessed (change in Psoriatic Arthritis Disease Activity Score [PsADAS], SJC, TJC, spinal pain, and dactylitis score).

**Conclusion:** GUS significantly improved PsA signs and symptoms through W100 across all BL subgroups evaluated, including pts with highly active disease, and regardless of dosing regimen.

**REFERENCES:**


**Disclosure of Interests:** Iain McInnes Shareholder of: Causeway Therapeutics and Evelo Compugen, Consultant of: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Cababetia, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB, Grant/research support from: Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Roche, and UCB, John Tesser Speakers bureau: AbbVie, Amgen, BMS, Eli Lilly, Janssen
and Pfizer, Consultant of: AbbVie, Eli Lilly, Gilead, Janssen, Novartis, and Pfizer, Grant/research support from: AbbVie, Amgen, BMS, Celgene, CoreVitas, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Arena, Biogen, Bristol Myers Squibb, DermaVant, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC (a wholly owned subsidiary of Johnson & Johnson), Emmanuel Rlampakis Consultant of: Janssen, Employee of: JSS Medical Research, Natalie Shift Shareholder of: AbbVie, Gilead, Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC (a wholly owned subsidiary of Johnson & Johnson), Alexia Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Frederic Lavié Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Paul Bird Speake Bureau: AbbVie, Eli Lilly, Gilead, Janssen, MSD, Pfizer, and UCB, Consultant of: Eli Lilly, Gilead, Janssen, Novartis, and Pfizer, Philip J Mease Speakers Bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Immagine, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB.

**POS0073**

**COMPARISON OF TIME FROM METHOTREXATE INITIATION TO START OF A BIO/TARGETED DISEASE MODIFYING ANTIRHEUMATIC DRUG (b/tsDMARD) IN PSORIATIC ARTHRITIS VERSUS RHEUMATOID ARTHRITIS. A NATIONWIDE REGISTER-BASED STUDY.**

U. Lindström1, D. Di Giuseppe2, S. Exarchou1, G. M. Alenius2, T. Olofsson3, E. Klingberg4, L. T. H. Jacobsson5, J. Askling6, J. K. Wallman3, Sahlgrenska Academy at University of Gothenburg, Rheumatology and Infarmnation Research, Gothenburg, Sweden; Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden; Lund University, Rheumatology, Department of Clinical Sciences, Malmö, Malmö, Sweden; Umeå University, Department of Public Health and Clinical Medicine/Rheumatology, Umeå, Sweden; Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden

**Background:** In Sweden, methotrexate (MTX) is recommended as first-line DMARD for both psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Whereas in RA the use of MTX monotherapy is supported by efficacy data from placebo-controlled trials. Therefore, the use of MTX in PsA is mostly based on clinical experience and results from studies not primarily designed to evaluate MTX efficacy.

**Objectives:** To compare time from MTX initiation until start of a biological or targeted synthetic DMARD (b/tsDMARD), as marker of insufficient MTX response, in previously DMARD-naïve, incident cases with PsA and matched, corresponding, reference subjects with RA.

**Methods:** Patients with PsA, having collected a prescription of MTX as their first ever DMARD any time between 2011 through 2018, and with a first ever MTX diagnosis in the Swedish National Patient Register within two years prior to this date, were included. Each individual was required to have a visit in rheumatology, but no visit in dermatology, within 6 weeks prior to MTX initiation, to ensure that PsA rather than psoriasis was the main reason for MTX treatment. For each individual with PsA, a corresponding individual with incident RA was identified, matched on sex, age, and year of MTX initiation. Only PsA cases with an identified RA comparator were included. All individuals with a diagnosis indicating axial spondyloarthritids prior to MTX start were excluded. The data were enriched through linkage to other national registers.

**Results:** Time until start of a b/tsDMARD was compared for PsA and RA through crude survival curves and conditional Cox-regression, crude and adjusted for comorbidity, level of education and patient global health. The crude survival curves for time from MTX initiation until start of a b/tsDMARD were identical for PsA and RA, Figure 1A. The adjusted HR for starting a b/tsDMARD in PsA compared with RA was 0.99 (95% CI 0.90-1.09). No calendar time trends were observed (Figure 1B and C).

**Conclusion:** In this study, the risk of escalating treatment from MTX, by adding or switching to a b/tsDMARD, was identical in PsA cases and matched RA controls. This supports a good response to MTX in PsA, similar to that in RA. Due to the matching, neither the results from the PsA nor the RA populations may be fully generalizable.

**Disclosure of Interests:** Ulf Lindström: None declared, Daniela Di Giuseppe: None declared, Sofia Exarchou Consultant of: AbbVie, Amgen, Janssen, Novartis, Grant/research support from: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer, Gerd-Marie Alenius: None declared, Tor Olofsson Consultant of: Merck Sharp & Dohme, Eva Klingberg: None declared, Lennart T.H. Jacobsson Speakers Bureau: Janssen, Eli Lilly, Novartis, Consultant of: Janssen, Eli Lilly, Novartis, Johan Askling Grant/research support from: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Pfizer, Pfizer, Samsung Bioepis, Sanofi, and UCB. Johan K Wallman Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Grant/research support from: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer DOI: 10.1136/annrheumdis-2022-eular.85

POS0074

**IMMUNOLOGICAL DIFFERENCES BETWEEN PSA PATIENTS WHO ARE TUMOR NECROSIS FACTOR INHIBITOR-NAIVE AND WHO HAVE INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITORS**


1University of Glasgow, Institute of Infection, Immunity and Inflammation, 2Wayne State University, Detroit, MI, USA, 3Mayo Clinic, Rochester, MN, USA, 4University of Michigan, Ann Arbor, MI, USA, 5Brigham and Women’s Hospital, Boston, MA, USA, 6University of Kentucky, Lexington, KY, USA, 7University of Buffalo, Buffalo, NY, USA, 8Rush University, Chicago, IL, USA, 9University of Colorado School of Medicine, Aurora, CO, USA, 10University of Gothenburg, Gothenburg, Sweden, 11Paracelsus Medical University Munich, Munich, Germany, 12Janssen Research & Development, LLC, Titusville, NJ, USA, 13University of Alabama at Birmingham, Birmingham, AL, USA, 14University of California San Diego, La Jolla, CA, USA, 15University of Minnesota, Minneapolis, MN, USA.
Background: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve & who have inadequate response to TNFi (TNFi-IR) may guide treatment choices. In DISCOVER-1, benefit of the IL-23/17 pathway in TNFi-IR pts was seen in adults with active PsA. The Phase 3b COSMOS study of GUS Q8W vs PBO in TNFi-IR PsA pts corroborated these findings.2

Objectives: Assess baseline (BL) molecular differences between TNFi-naïve & -IR PsA pts & investigate GUS pharmacodynamic (PD) effect on cytokine expression over time in the cohorts.

Methods: Serum samples collected from consenting biomarker substudy pts in DISCOVER-1 (TNFi-naïve [n=101] & -IR [n=117]), DISCOVER-2 (TNFi-naïve [n=150]), & COSMOS2 (TNFi-IR [n=76]) were analyzed for selected serum cytokine levels. TNFi-IR pts in this post-hoc analysis had active PsA & discontinued 1-2 TNFi due to inadequate efficacy; these pts required a TNFi-specific washout period prior to starting GUS. PD effect of GUS Q8W on cytokine levels was assessed. Differential BL cytokine expression compared between the TNFi-IR & TNFi-naïve cohorts with available cytokine levels & clinical response (Psoriasis [PsO] Area & Severity Index 75% improvement from BL [PSA75] & American College of Rheumatology 20% improvement [ACR20]). GUS effect on cytokine levels were analyzed with a General linear model & Spearman linear regression.

Results: BL pt demographics, disease characteristics, & conventional synthetic disease-modifying antirheumatic drug (csDMARD) use were comparable between TNFi-naïve (DISCOVER-1 & -2, N=251) & -IR (DISCOVER-1 & COSMOS, N=93) pts, with differences in mean PASI score (8.9 vs 12.5), swollen joint count (SJC) (11.7 vs 10.3), PsA duration (16.7 vs 20.4 yrs; Table 1). BL serum IL-22 & TNFs for pooled treatment groups were higher in TNFi-IR than -naïve pts (p<0.05). At W24, GUS reduced IL-22, IL-17A/IL-6, C-reactive protein (CRP), & serum amyloid A protein to similar levels for pooled treatment groups.

Conclusions: Elevated BL IL-22 expression & association between BL IL-22 levels & W24 PASI75 response, & a W24 trend for an association between upregulated BL IL-22 & ACR20 response, in TNFi-IR pts seen in this exploratory analysis, may suggest increased involvement of the IL-23/17 pathway in TNFi-IR pts. GUS showed comparable & significant PD effects for TNFi-naïve & -IR pts consistent with observed clinical responses.

Disclosure of Interests: Stefan Siebert Speakers bureau: AbbVie, Biogen, GSK, Janssen, Novartis, UCB, Consultant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, GSK, Janssen, Novartis, and UCB, Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Georg Schett Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, Novartis, and UCB, Siba P Raychaudhuri Speakers bureau: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Warner Chen Shareholder of: Janssen, Research Centre, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), Sheng Gao Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC (a wholly owned subsidiary of Johnson & Johnson), May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Frederic Lavie Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Elke Theander Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC (a wholly owned subsidiary of Johnson & Johnson), Marlies Neuhold Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC (a wholly owned subsidiary of Johnson & Johnson), Alexis Kollmeyer Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC (a wholly owned subsidiary of Johnson & Johnson), Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant/research support from: Janssen and Novartis, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Innategene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, GSK, Janssen, Monthlake, Novartis, Pfizer, and UCB, Consultant/research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB


Table 1. BL demographics, disease characteristics, & drug use in TNFi-naïve & -IR cohorts with available cytokine data in DISCOVER-1 & COSMOS.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>TNFi-naïve (N=251)</th>
<th>TNFi-IR (N=93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>47.2 (13.3)</td>
<td>48.5 (11.1)</td>
</tr>
<tr>
<td>Female, (%)</td>
<td>132 (52.6)</td>
<td>46 (49.5)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>29.6 (6.1)</td>
<td>30.3 (6.4)</td>
</tr>
<tr>
<td>Median (range) CRP (mg/dL)</td>
<td>0.9 (0.0-12.9)</td>
<td>1.0 (1.0-12.3)</td>
</tr>
<tr>
<td>Log2 IL-22/TNFα (pg/mL)</td>
<td>2.0 (1.4) / 1.1 (0.6)</td>
<td>2.5 (1.5) / 1.9 (1.2)</td>
</tr>
<tr>
<td>Log2 IL-17A/IL-6 (pg/mL)</td>
<td>-0.4 (1.5) / 1.7 (1.5)</td>
<td>-0.1 (1.7) / 2.0 (1.5)</td>
</tr>
<tr>
<td>SJC [0-66]</td>
<td>11.7 (7.1)</td>
<td>10.3 (8.3)</td>
</tr>
<tr>
<td>TJC [0-68]</td>
<td>20.3 (13.1)</td>
<td>20.6 (14.2)</td>
</tr>
<tr>
<td>PsA duration (yrs)</td>
<td>5.8 (5.9)</td>
<td>9.8 (8.2)</td>
</tr>
<tr>
<td>PsO duration (yrs)</td>
<td>16.7 (12.8)</td>
<td>20.4 (12.0)</td>
</tr>
<tr>
<td>PsO Body surface area (%)</td>
<td>14.8 (16.6)</td>
<td>19.1 (21.3)</td>
</tr>
<tr>
<td>Investigator’s Global Assessment score [0-4]</td>
<td>2.3 (2.3)</td>
<td>2.3 (2.3)</td>
</tr>
<tr>
<td>PASI score [0-72]</td>
<td>8.9 (10.6)</td>
<td>12.5 (10.0)</td>
</tr>
<tr>
<td>Enthesitis [Y], (%)</td>
<td>160 (63.7)</td>
<td>58 (62.4)</td>
</tr>
<tr>
<td>csDMARD use [Y], (%)</td>
<td>164 (65.3)</td>
<td>62 (66.7)</td>
</tr>
<tr>
<td>Corticosteroid use [Y], (%)</td>
<td>45 (17.9)</td>
<td>19 (20.4)</td>
</tr>
<tr>
<td>Methotrexate use [Y], (%)</td>
<td>136 (54.2)</td>
<td>54 (58.1)</td>
</tr>
</tbody>
</table>

Data are mean (SD) unless otherwise noted. *Ps with serum CRP level ≥0.3 mg/dL, SJC ≥3, & TJC ≥3 (to mimic D1 inclusion criteria). JC= tendon joint count.
Background: Treatment options for psoriasis (PsO) and psoriatic arthritis (PsA) have evolved significantly since the era of biologics. Clinical trials (mainly placebo-controlled for 12 to 16 weeks) are inadequate to assess the relative long-term efficacy of biologics and are often insufficient regarding safety.

Objectives: To assess the long-term persistence of different biologic classes to treat PsA and PsO.

Methods: This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to the hospital discharge database. We included, in two sub-cohorts, all adults with PsA and those with PsO, who were new users of biologics (not in the year before the index date) during 2015-2019. We excluded patients hospitalised for PsO in the PsA cohort and for PsA in the PsO cohort in the year before the index date. Persistence was defined as the time from biologic initiation to discontinuation and was estimated by the Kaplan-Meier method. Comparison of persistence by biologic class involved using propensity score-weighted Cox models (IPTW) and adjustment on specific systemic non-biologics (time-dependant variables).

Results: We included 6,531 patients with PsA (mean age 49±13 years, 45% male); 4,974 (76%) starting a TNF inhibitor, 803 (12%) an IL12/23i and 754 (12%) an IL17i. Overall 3-year persistence rates were 36% and 41% for PsA and PsO (Figure 1). After IPTW and adjustment, IL17i was associated with higher persistence than TNFi for PsA (weighted hazard ratio [HRw] 0.70, 95% confidence interval [CI] 0.68-0.73) and lower persistence than IL12/23i for PsO (HRw 0.76, 95% CI 0.72-0.80), with no difference observed for PsA. IL17i also has better persistence than IL12/23i for PsA, with IL17i persistence being higher than TNFi (16% vs 12%) and IL12/23i (16% vs 12%). Overall 3-year persistence rates were 36% and 41% for PsA and PsO (Figure 1). After IPTW and adjustment, IL17i was associated with higher persistence than TNFi for PsO (weighted hazard ratio [HRw] 0.70, 95% confidence interval [CI] 0.58-0.85) and PsO (HRw 0.78, 95%CI 0.73-0.83) and than IL12/23i for PsA (HR 0.69, 95CI 0.55-0.87). We found no difference between IL17i and IL12/23i for PsO. IL12/23i had better persistence than TNFi for PsO (HR 0.76, 95%CI 0.72-0.80), with no difference observed for PsA.

Conclusion: This real-life study suggests a higher persistence of IL17i than TNFi for PsA and PsO. IL17i also has better persistence than IL12/23i for PsA, with no difference for PsO. However, the persistence rates of all biologics remained globally low at 3 years.

Disclosure of Interests: Laura Pina Vegas: None declared, Laetitia Penso: None declared, Emilie Sbidian: None declared, Pascal Claudiepeire: Speakers bureau: P. Claudiepeire has been an investigator for Roche Chugai, Sanofi Aventis, Celgene, Pfizer, MSD, Novartis and BMS., Consultant of: P. Claudiepeire has received consulting fees from Abbvie, Amgen, Pfizer, Roche-Chugai, BMS, MSD, UCB, Novartis, Janssen, Lilly, Galapagos, Celgene (less than $10,000 each)


REFERENCE:

POS0076

DRUG SURVIVAL OF BIOLOGICS AND NOVEL IMMUNOMODULATORS FOR RHEUMATOID ARTHRITIS, AXIAL SPONDYLOPATHRITIS, PSORIATIC ARTHRITIS, AND PSORIASIS - A NATIONWIDE COHORT STUDY FROM THE DANBIO AND DERMBIO REGISTRIES


1Copenhagen University Hospital - Bispebjerg, Department of Dermatology, Copenhagen, Denmark; 2The Parker Institute, Department of Rheumatology, Frederiksberg, Denmark; 3Aalborg University Hospital, Department of Rheumatology, Aalborg, Denmark; 4Gentofte Hospital, Department of Dermatology and Allergy, Hellerup, Denmark; 5TeaLand University Hospital, Department of Dermatology, Roskilde, Denmark; 6Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark; 7Holbæk Hospital, Department of Rheumatology, Holbæk, Denmark

Background: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis [1-4].

Objectives: The objective of this study was to examine the real-life drug survival of biologics and novel small-molecule therapies across various disease entities such as RA, AxSpA, PsA, and psoriasis.

Methods: We performed a nationwide cohort study using the prospective nationwide registries DANBIO and DERMBIO, comprising all patients treated with biologics or novel small-molecule therapies for RA, AxSpA, PsA, and psoriasis between January 2015 through May 2021 (DANBIO) and November 2009 to November 2019 (DERMBIO). Drug survival was visualized using Kaplan-Meier curves, and Cox proportional hazards models were used to calculate adjusted Hazard Ratios (HRs) with 95% confidence intervals (CIs) for risk of discontinuing therapy.

Results: The study comprised a total of 12,080 patients (17,903 treatment series), including 5,104 RA patients (7,867 series), 2,157 AxSpA patients (3,016 series), 2,551 PsA patients (3,313 series), and 2,577 psoriasis patients (3,707 series). In confounder-adjusted models drug survival in RA was highest for rituximab followed by baricitinib, etanercept and tocilizumab respectively. For AxSpA drug survival was high for golimumab compared to all other drugs, followed by secukinumab and etanercept and lowest for infliximab. For PsA tofacitinib and infliximab had the lowest drug survival compared to all other drugs. All other drugs performed almost equally well with a tendency of a generally higher drug survival for golimumab, followed by secukinumab and ixekizumab. For psoriasis drug survival was generally highest for guselkumab.

Conclusion: Differing treatment responses to drugs with various types of action across RA, AxSpA, PsA and psoriasis emphasize that although these diseases have many overlaps in their pathogenesis, there is a need for an individualized treatment approach that considers the underlying disease, patient profile, and treatment history.

REFERENCES:

Acknowledgements: We acknowledge the substantial contribution of the academic hospitals and private clinics and their physicians that report data to DANBIO and DERMBIO.

Disclosure of Interests: Alexander Egeberg Speakers bureau: AbbVie, Almirall, Leo Pharma, Zuelig Pharma Ltd., Galapagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals, Consultant of: AbbVie, Almirall, Leo Pharma, Zuelig Pharma Ltd., Galapagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan,
Bristol-Myers Squibb, and Janssen Pharmaceuticals, Grant/research support from: Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Sanofi, Sanofi Genzyme, and LEO Pharma., Paid instructor for: Dr. LE Kristensen has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma., and has served as a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, and Sanofi, Sanofi Genzyme, and LEO Pharma., and has received research and educational grants from Novartis, Sanofi, Janssen Cilag, and LEO Pharma., Grant/research support from: Dr. Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, Sanofi, and Janssen pharmaceuticals, Grant/research support from: Dr. Thyssen has been a paid speaker for AbbVie, Eli Lilly, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis, grants/research support from: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis., Consultant of: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis., Consultant of: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis., Consultant of: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis., Consultant of: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis., Consultant of: Dr. Rasmussen has been a paid speaker for AbbVie, Almiril, and LEO Pharma. Consulting, or serving on expert/advisory boards with AbbVie, Almiril, Janssen Cilag, and Eli Lilly. He served as investigator for Janssen Cilag, UCB, and Novartis.
Background: Evidence demonstrates sex differences in disease presentation, physical function, treatment response and drug retention in patients with psoriatic arthritis (PsA). Data from observational cohort studies indicate female sex is associated with reduced effectiveness of tumor necrosis factor inhibitors (TNFis)1,2. Although, conflicting results are also reported3,4. We sought to validate prior studies using data from a large multinational cohort based on real-life clinical practice.

Objectives: To investigate sex differences in treatment response and drug retention rates in clinical practice among patients with PsA, treated with their first TNFi.

Methods: Data from biologic-naïve PsA patients initiating a TNFi in the EuroSpA registries were pooled. In the primary analysis, propensity-score weighting was applied to assess the causal effect of sex on low disease activity (LDA) according to DAS28-CRP at 6 months. A generalized linear regression model was used to estimate the causal risk difference (RD) and relative risk (RR) of sex on LDA. Possible covariates influencing the outcome were determined a priori and selected based on availability in the database (<20% missing). The final covariates included were country, age, conventional synthetic disease-modifying antirheumatic drug use at baseline and TNFi start year. In the secondary analysis, drug retention was assessed over 24 months of follow-up by Kaplan-Meier curves and log-rank test.

Results: In total, 7,679 PsA patients with available data on DAS28-CRP at 6 months were assessed for treatment response. Baseline characteristics are shown in the Table 1. In the adjusted analysis, the probability for females to have LDA was 17% (RR, 0.83; 95% confidence interval [CI], 0.81 to 0.85) lower compared to males and the difference in probability for having LDA was 13 percentage points (RD, 0.13; 95% CI, 0.11 to 0.15). The survival analysis included 18,599 PsA patients with available data on retention rates. The TNFi 6/12/24-month retention rates were significantly lower in females (81%/68%/56%) compared to males (89%/80%/69%), see Figure 1.

Table 1. Baseline characteristics of all biologic-naïve PsA patients treated with their first TNFi and available DAS28-CRP at 6 month, data pooled across all countries

<table>
<thead>
<tr>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD), median [IQR] or percentages</td>
<td>Mean (SD), median [IQR] or percentages</td>
</tr>
<tr>
<td>Age (years)</td>
<td>49.7 (12.5)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>4.0 [1.0, 10.0]</td>
</tr>
<tr>
<td>1999-2009</td>
<td>29%</td>
</tr>
<tr>
<td>2010-2013</td>
<td>26%</td>
</tr>
<tr>
<td>2014-2016</td>
<td>25%</td>
</tr>
<tr>
<td>2017-2020</td>
<td>20%</td>
</tr>
<tr>
<td>Concomitant csDMARD</td>
<td>75%</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>4.4 (1.12)</td>
</tr>
<tr>
<td>DAPSA28</td>
<td>32 (16)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>7.0 [3.0, 17.0]</td>
</tr>
<tr>
<td>SJC (0-28)</td>
<td>3.0 [0.0, 6.0]</td>
</tr>
<tr>
<td>TJC (0-28)</td>
<td>6.0 [2.0, 10.0]</td>
</tr>
<tr>
<td>VAS pain, mm</td>
<td>61 (23)</td>
</tr>
<tr>
<td>VAS fatigue, mm</td>
<td>62 (26)</td>
</tr>
</tbody>
</table>

Data are as observed, mean (SD), median [IQR] or percentage. TNFi, tumor necrosis factor inhibitor; csDMARD, Conventional synthetic disease-modifying antirheumatic drugs; DAS28-CRP, Disease Activity Score 28-joint count C reactive protein; DAPSA28, Disease Activity in PsA 28; CRP, C-reactive protein; SJC, swollen joint count; TJC, tender joint count.

Conclusion: Treatment efficacy and retention rates are lower among female patients with PsA initiating their first TNFi. Females presented with higher 28-tender joint count and higher scores on patient reported outcomes at baseline, reflecting differences in disease expression. Recognizing these sex differences is of relevance for customized patient care and may improve patient education.

REFERENCES:
Comparing Methotrexate Monotherapy with Methotrexate Plus Leflunomide Combination Therapy in Psoriatic Arthritis: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial (COMPLETE-PSA)


Methods: Patients with a clinical diagnosis of PsA and active disease (≥2 swollen joints) were included in this randomised, placebo-controlled, double-blind trial. Patients were randomised (1:1) to MTX plus LEF or MTX plus placebo. Patients received MTX 15mg/week for four weeks and thereafter 25mg/week, combined with two LEF 10mg tablets or two placebo tablets daily. The primary outcome was the difference between the MTX plus LEF group and the MTX plus placebo group on the psoriatic arthritis disease activity score (PASDAS) at week 16 adjusted for baseline PASDAS. Key secondary outcomes included safety and the achievement of minimal disease activity (MDA) criteria and PASDAS low disease activity (LDA) (≤3.2).

Results: A total of 78 PsA patients (MTX + LEF n=39; MTX + placebo n=39) were included. The mean age was 53.1 (SD=12.8) years and 36% (n=28) of the patients were female. The mean PASDAS at baseline was 4.9 (SD=1) in both treatment groups. Table 1 shows that MTX plus LEF was superior to MTX plus placebo at week 16 (PASDAS 3.1, SD=1.4 vs 3.7, SD=1.3; treatment difference= -0.6, 90% CI -1.0 to -0.1, one-sided P-value=0.025). Similar and significant results were found for achievement of MDA criteria (59% vs 33%, one-sided P-value=0.013) and PASDAS LDA (59% vs 35%, one-sided P-value=0.019) (Figure 1 and Table 1). Other favorable and significant outcomes for the MTX plus LEF group included -among others- the improvement in swollen joint count (SJC) (median [IQR] = 3 [-5, -2] vs -2 [-4, 0], one-sided P-value=0.039) and the proportion of patients with active psoriasis (i.e. body surface area score >0) at week 16 (44% vs 68%, one-sided P-value=0.014).

Generally mild adverse events and treatment discontinuation (MTX+LEF n=21; MTX + placebo n=33) occurred more frequently in the MTX plus LEF group.

Table 1. Primary and secondary outcomes at week 16

<table>
<thead>
<tr>
<th>Primary endpoint</th>
<th>MTX + LEF (N=39)</th>
<th>MTX + placebo (N=39)*</th>
<th>Absolute difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PASDAS at week 16</td>
<td>3.1 (1.4)</td>
<td>3.7 (1.3)</td>
<td>-0.6 (-1.0, -0.1)</td>
<td>0.025</td>
</tr>
<tr>
<td>Fulfilling MDA criteria, N (%)</td>
<td>23 (59)</td>
<td>13 (35)</td>
<td>24% [6, 42]</td>
<td>0.019</td>
</tr>
<tr>
<td>SJC66, change from baseline, N (%)</td>
<td>23 (59)</td>
<td>12 (33)</td>
<td>26% [7, 44]</td>
<td>0.013</td>
</tr>
<tr>
<td>TC66, change from baseline, N (%)</td>
<td>23 (59)</td>
<td>12 (33)</td>
<td>26% [7, 44]</td>
<td>0.013</td>
</tr>
</tbody>
</table>

Discussion of Interests: Michelle L. M. Mulder: None declared, Johanna E. Vriezekolk speaks on behalf of Eli Lilly Netherlands BV and Galapagos Biopharma Netherlands BV, Tamara van Hal speaks on behalf of Eli Lilly and Novartis, Grant/research support from: support for attending meetings from UCB (personal funding), Lieske Nieboer: None declared, Nathan den Broeder: None declared, E.M.G.J. de Jong receives funding from AbbVie, Almirall, Janssen Pharmaceutica, Novartis, Lilly, Celgene, Leo Pharma, Sanofi, UCB and Galapagos (all funding is not personal but goes to the independent research fund of the department of dermatology of Radboud university medical centre Nijmegen, the Netherlands), Consultant of: AbbVie, Almirall, Janssen Pharmaceutica, Novartis, Lilly, Celgene, Leo Pharma, Sanofi, UCB and Galapagos (all funding is not personal but goes to the independent research fund of the department of dermatology of Radboud university medical centre Nijmegen, the Netherlands), Grant/research support from: AbbVie, Novartis, Janssen Pharmaceutica, Leo Pharma and UCB for research on psoriasis, Altons van den Broeder: None declared, Frank van den Hogen: None declared, Philip Helliwell speaks on behalf of Pfizer, Abbvie, Novartis and Janssen, Consultant of: Eli Lilly, Mark Wenink: None declared


Conclusion: MTX plus LEF combination therapy resulted in a significantly greater improvement in disease activity according to PASDAS and MDA than treatment with MTX monotherapy in patients with PsA after 16 weeks. In addition, a greater improvement in psoriasis was found for the combination group. However, there are indications that MTX plus LEF combination is less well tolerated than MTX monotherapy.

Acknowledgements: We would like to thank all the patients that participated in this study; all rheumatologists from the Sint Maartenskliniek that helped with the patient inclusion; our patient partners and especially R. van den Griek; Dr. E. Mahler for her suggestions and advice with regard to the study design; Dr. C. Popa and Dr. D. Teigt for being members of our data safety monitoring board and the rheumatology nurses of our center for their assistance with collecting the data.

Disclosur of Interests: Michelle L.M. Mulder: No conflicts of interest, Johann E. Vriezekolk: speaks on behalf of Eli Lilly Netherlands BV and Galapagos Biopharma Netherlands BV, Tamara van Hal: speaks on behalf of Eli Lilly and Novartis, Grant/ research support from: support for attending meetings from UCB (personal funding), Lieske Nieboer: None declared, Nathan den Broeder: None declared, E.M.G.J. de Jong: receives funding from AbbVie, Almirall, Janssen Pharmaceutica, Novartis, Lilly, Celgene, Leo Pharma, Sanofi, UCB and Galapagos (all funding is not personal but goes to the independent research fund of the department of dermatology of Radboud university medical centre Nijmegen, the Netherlands), Consultant of: AbbVie, Almirall, Janssen Pharmaceutica, Novartis, Lilly, Celgene, Leo Pharma, Sanofi, UCB and Galapagos (all funding is not personal but goes to the independent research fund of the department of dermatology of Radboud university medical centre Nijmegen, the Netherlands), Grant/research support from: AbbVie, Novartis, Janssen Pharmaceutica, Leo Pharma and UCB for research on psoriasis, Altons the Nden Broeder: None declared, Frank van den Hogen: None declared, Philip Helliwell: speaks on behalf of Pfizer, Abbvie, Novartis and Janssen, Consultant of: Eli Lilly, Mark Wenink: None declared


Does Methotrexate Impact Ustekinumab Immunogenicity in Patients with Active Psoriatic Arthritis? A Post Hoc Analysis of Samples from a Randomized, Placebo-Controlled Trial.

S. Molthae Poo1,2,3, M. Henke1, T. Uischenhoefer1, F. Behrens1,2,3,4, M. Köhler1,2,3,4, H. Burkhardt1,2,3, S. Schifftmann1,3, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany; 2University Hospital Frankfurt, Rheumatology, Frankfurt am Main, Germany; 3Fraunhofer Cluster of Excellence for Immune-Mediated Diseases CIMD, Frankfurt, Germany; 4Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

Background: The formation of antidrug-antibodies (ADA) may reduce treatment efficacy or provoke discontinuation due to adverse reactions. Subsequent alterations in the drugs’ pharmacodynamics, pharmacokinetics, safety, and efficacy are often unpredictable and can impede clinical discourse. Recent studies gave us some insights regarding the role of ADA formation against the monoclonal IL-12/23 antibody ustekinumab (UST) and the impact of concomitant MTX treatment on immunogenicity in psoriatic arthritis (PsA) patients [1,2]. Valid measurement of ADA, particularly of neutralizing ADA (nADA) is essential to understand UST-associated immunogenicity and may help to predict clinical outcomes.

Objectives: To examine the impact of concomitant MTX on UST-immunogenicity in patients with active psoriatic arthritis (PsA).

Methods: Plasma samples were collected from a randomized controlled trial in patients with active PsA, treated with open UST and placebo-controlled methotrexate over a 52 weeks. We compared samples of 112 patients treated with UST and MTX against non-treated samples.
either UST and MTX (n=58) or UST and placebo (n=54). Plasma samples were obtained shortly before UST injection at weeks 0, 4, 16, 40, and 52. Immunogenicity testing was performed as described by our group elsewhere [2], in a multi-tiered manner with ELISA and surface plasmon resonance analysis for the detection and quantification of ADA and UST, respectively. Neutralizing capacity was characterized in a cell-based assay. For statistical analysis, a two-way ANOVA with Sidak correction for multiple comparisons was used.

**Results:** Over the 52 weeks treatment period, 10 (18 %) of patients in the placebo cohort developed UST-specific ADA with one patient having non-neutralizing ADA, whereas 15 (27 %) subjects in the MTX cohort generated UST-specific ADA with 2 patients having non-neutralizing ADA. The ADA rates and concentrations at the different time points (Figure 1A, B) did not differ significantly between MTX and non-MTX users (p> 0.05). Furthermore, the presence of UST-specific ADA was not associated with decreased UST levels (Figure 1C).

**Conclusion:** The presented data yielded no statistically significant difference in ADA detection between the two analyzed groups. Our findings suggest that concomitant MTX had no impact on UST immunogenicity in PsA patients.

**References:**

**Acknowledgements:** Sorwe Mojtahed Poor received research support from the German Society of Rheumatology (DGRh e.V.)

**Disclosure of Interests:** Sorwe Mojtahed Poor: None declared, Marina Henke: None declared, Thomas Ulshoefer: None declared, Frank Behrens Grant/research support from: Janssen, Michaela Köhm Grant/research support from: None declared, Thomas Ulshoefer: None declared, Frank Behrens Grant/Sorwe Mojtahed Poor: None declared, Marina Henke: Disclosure of Interests:

**Figure 1.** (A) ADA prevalence (%), (B) mean concentration (µg/ml) of confirmed ADA with 95% confidence interval and (C) mean UST concentration (µg/ml) with 95% confidence interval in the MTX cohort (UST/MTX: n=58) and placebo cohort (UST/pc: n=54) overall and with confirmed ADA (ADA+), respectively, at week (w) 0, 4, 16, 40, and 52.

**Conclusion:** The presented data yielded no statistically significant difference in ADA detection between the two analyzed groups. Our findings suggest that concomitant MTX had no impact on UST immunogenicity in PsA patients.

**References:**


**Acknowledgements:** Sorwe Mojtahed Poor received research support from the German Society of Rheumatology (DGRh e.V.)

**Disclosure of Interests:** Sorwe Mojtahed Poor: None declared, Marina Henke: None declared, Thomas Ulshoefer: None declared, Frank Behrens Grant/research support from: Janssen, Michaela Köhm Grant/research support from: None declared, Thomas Ulshoefer: None declared, Frank Behrens Grant/Sorwe Mojtahed Poor: None declared, Marina Henke: Disclosure of Interests:

**Figure 1.** The prognostic factors associated with non-remission/LDA status in PsA pts

**Conclusion:** In real practice remission/LDA can be seen in 60% of PsA pts treated mostly with bDMARDs. But about 40% of PsA pts still have HAD/ModA despite going through therapy. It is a combination of clinical features at baseline that are associated with remission or LDA nonachievement. M±SD, Me [Q25; Q75], Min-Max, %, t-test, Pearson-r, Mann-Whitney tests, ORs with 95% CI were performed. All p<0.05, were considered to indicate statistical significance.

**Results:** At 1 year of therapy 116 pts of 292 (39.7%) have HDA/ModA by DAPSA. Remission/LDA was reached in 176 pts (60.3%), 110 of them (62.5%) were treated with bDMARDs. Comparative analysis in both groups and one-factor model of logistic regression showed the following features at BL were associated with non-remission/LDA status: TJC>3 (p<0.001), SJC>5 (p<0.001), CRP> 10 mg/l (p<0.001), HAQ>0.5 (p<0.001), presence of enthesitis (p<0.001), dactylitis (p<0.001), BMI>30 (p<0.002) and had to be treated with sDMARDs. PsA pts with combination of these clinical features at first visit have more chance to non-remission/LDA status in comparison to PsA pts without them, OR with CI 95% (Figure 1).

**Odds Ratio 95% Confidence Interval**

**Figure 1.** The prognostic factors associated with non-remission/LDA status in PsA pts

**Conclusion:** In real practice remission/LDA can be seen in 60% of PsA pts treated mostly with bDMARDs. But about 40% of PsA pts still have HAD/ModA despite going through therapy. It is a combination of clinical features at BL: TJC>3, SJC>5, CRP>10mg/l, HAQ>0.5, presence of enthesitis, dactylitis, BMI>30kg/m² and sDMARDs therapy - that constitutes a prognostic factor with negative impact on achievement remission/LDA after 1 year of treatment.

**References:**


**Acknowledgements:** The Russian PsA Registry study group.

**Disclosure of Interests:** Elena Loginova Speakers bureau: Janssen, Tatiana Korotova Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Janssen, Lilly. Celgene, JSC BIOCAD and Novartis-Sandoz, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Novartis, Svetlana Glukhova: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.424

**Figure 1.** The prognostic factors associated with non-remission/LDA status in PsA pts

**Conclusion:** In real practice remission/LDA can be seen in 60% of PsA pts treated mostly with bDMARDs. But about 40% of PsA pts still have HAD/ModA despite going through therapy. It is a combination of clinical features at baseline that are associated with remission or LDA nonachievement. M±SD, Me [Q25; Q75], Min-Max, %, t-test, Pearson-r, Mann-Whitney tests, ORs with 95% CI were performed. All p<0.05, were considered to indicate statistical significance.

**Results:** At 1 year of therapy 116 pts of 292 (39.7%) have HDA/ModA by DAPSA. Remission/LDA was reached in 176 pts (60.3%), 110 of them (62.5%) were treated with bDMARDs. Comparative analysis in both groups and one-factor model of logistic regression showed the following features at BL were associated with non-remission/LDA status: TJC>3 (p<0.001), SJC>5 (p<0.001), CRP> 10 mg/l (p<0.001), HAQ>0.5 (p<0.001), presence of enthesitis (p<0.001), dactylitis (p<0.001), BMI>30 (p<0.002) and had to be treated with sDMARDs. PsA pts with combination of these clinical features at first visit have more chance to non-remission/LDA status in comparison to PsA pts without them, OR with CI 95% (Figure 1).

**Odds Ratio 95% Confidence Interval**

**Figure 1.** The prognostic factors associated with non-remission/LDA status in PsA pts

**Conclusion:** In real practice remission/LDA can be seen in 60% of PsA pts treated mostly with bDMARDs. But about 40% of PsA pts still have HAD/ModA despite going through therapy. It is a combination of clinical features at BL: TJC>3, SJC>5, CRP>10mg/l, HAQ>0.5, presence of enthesitis, dactylitis, BMI>30kg/m² and sDMARDs therapy - that constitutes a prognostic factor with negative impact on achievement remission/LDA after 1 year of treatment.

**References:**


**Acknowledgements:** The Russian PsA Registry study group.

**Disclosure of Interests:** Elena Loginova Speakers bureau: Janssen, Tatiana Korotova Speakers bureau: Pfizer, MSD, Novartis, AbbVie, Janssen, Lilly. Celgene, JSC BIOCAD and Novartis-Sandoz, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Novartis, Svetlana Glukhova: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.423
Background: In SELECT-Psa 1, patients (pts) with psoriatic arthritis (PsA) and an inadequate response or intolerance to ≥1 non-biologic disease-modifying antirheumatic drug showed improvement in the signs and symptoms of PsA with upadacitinib 15 mg (UPA15) or 30 mg (UPA30); an oral Janus Kinase (JAK) inhibitor, through week (wk) 56.1

Objectives: To evaluate the efficacy and safety of UPA and UPA vs adalimumab (ADA) at wk 104 from the ongoing long-term extension of SELECT-Psa 1.

Methods: Pts received UPA15, UPA30, ADA 40 mg, or placebo (PBO) for 24 wks, at which point, PBO pts switched to UPA15 or UPA30. Efficacy endpoints were analyzed using non-responder imputation (NRI) and as observed (AO) (binary endpoints) or mixed-effect model repeated measures and AO (continuous endpoints), with nominal P-values shown, for continuous UPA and ADA treatment groups. Treatment-emergent adverse events were summarized for pts who received ≥1 dose of study drug using a visit-based cut-off at wk 104.

Results: 1704 pts received ≥1 dose of study drug. At wk 104, 25.4% of pts had discontinued study drug. The proportions of pts who achieved ACR20/50/70, MDA, PASI75/90/100, and resolution of enthesitis or dactylitis showed consistent responses, or further improvements, from wk 56 to wk 104 (Table 1). ACR20/50/70 and MDA responses, as well as mean change from baseline (BL) in HAQ-DI, patient’s assessment of pain, BASDAI, and ASDAS, were greater with UPA vs ADA. Mean change from BL in modified total Sharp/van der Heijde Score (mTSS) was generally similar across groups and comparable to wk 56.1 The safety profile of UPA was generally comparable to ADA (Figure 1) and consistent with wk 56 data. Rates of serious infection, herpetic zoster, lymphopenia, and elevated CPK remained numerically higher with UPA30 vs UPA15; rates in both UPA groups were higher vs ADA. Rates of malignancies, MACE, or VTE were similar across groups, and consistent with wk 56 data. Two deaths were reported with UPA15, 1 with UPA30, and 1 with ADA.

Table 1. Efficacy Endpoints at Week 104

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>UPA15</th>
<th>UPA30</th>
<th>ADA</th>
<th>NRI (%)</th>
<th>AO (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of Pts (%)a</td>
<td>NRI AO</td>
<td>NRI AO</td>
<td>NRI AO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR20</td>
<td>49.0 67.9</td>
<td>87.9 63.4</td>
<td>85.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR50</td>
<td>35.6 67.4</td>
<td>95.9 73.9</td>
<td>71.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR70</td>
<td>38.0 74.4</td>
<td>93.5 75.4</td>
<td>85.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative Disease Activity (MDA)</td>
<td>42.0 54.8</td>
<td>45.9 56.8</td>
<td>50.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASI75b</td>
<td>57.9 73.4</td>
<td>64.2 78.6</td>
<td>69.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASI90c</td>
<td>46.7 59.0</td>
<td>53.3 60.6</td>
<td>56.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resolution of enthesitis by LDI5</td>
<td>53.3 67.5</td>
<td>52.9 72.0</td>
<td>72.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change from BLd</td>
<td>MMRM AO</td>
<td>MMRM AO</td>
<td>MMRM AO</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Assessment Questionnaire - Disability Index (HAQ-DI)</td>
<td>-0.55 -0.57 -0.55</td>
<td>-0.59 -0.45 -0.49</td>
<td>-0.47</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient’s assessment of pain (numeric rating scale)</td>
<td>-3.3 -3.5 -3.4</td>
<td>-3.6 -3.0 -3.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</td>
<td>-3.0 -3.2 -3.3</td>
<td>-3.6 -2.7 -2.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ankylosing Spondylitis Disease Activity Score (ASDAS)</td>
<td>-1.6</td>
<td>-1.8 -1.9</td>
<td>-2.1 -1.5 -1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modified Total Sharp/van der Heijde Score (mTSS)</td>
<td>0.03 0.01</td>
<td>0.01 0.11</td>
<td>0.11</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACR20/50/70, ≥20%/50%/70% improvement in American College of Rheumatology criteria; ACR, adalimumab; AO, as observed; BL, baseline; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesis Index; MMRM, mixed effect model repeated measurement; NRI, non-responder imputation; PASI75/90/100, ≥75%/90%/100% improvement in Psoriasis Area and Severity Index; pts, patients; UPA, upadacitinib; Data shown as NRI and AO for binary endpoints. For pts with psoriasis affecting ≥3% of body surface area at BL, for pts with LEI >0 at BL; resolution LDI=0. Data shown as MMRM (LS mean) and AO (mean) for continuous endpoints. For pts with psoriatic spondylitis at BL, nominal P-value ≤0.05. UPA15 or UPA30 vs ADA for NRI and MMRM; AO descriptive only.

Conclusion: In PsA pts, efficacy responses were similar or greater with UPA15 or UPA30 vs ADA at wk 104, and indication of radiographic progression was maintained. No new safety signals were identified with long-term exposure to UPA up to 2 years.

REFERENCES:
Psoriatic arthritis (PsA) is characterized by a range of musculoskeletal and extra-articular disease manifestations. Composite indices are valuable tools to assess the multidimensional nature of PsA. The Psoriatic Arthritis Disease Activity Score (PASDAS)\(^2\) provides robust assessment of both joint and skin domains but is cumbersome to use in clinical practice. The Disease Activity Index for Psoriatic Arthritis (DAPSA)\(^2\) is relatively easy to use but does not assess skin disease.

**Methods:** Using pooled data from the phase 3 DISCOVER-1 and DISCOVER-2 studies of guselkumab (GUS) for the treatment of active PsA,\(^3,4\) (1) Describe the rate of achievement of a new composite endpoint combining DAPSA low disease activity (LDA; score ≤14, including remission) and Investigator Global Assessment (IGA) of psoriasis score ≤1 (range = 0 [clear] to 4 [severe]); (2) Determine whether earlier (Week [W] 16) DAPSA LDA + IGA ≤1 is predictive of future achievement of minimal disease activity (MDA) or American College of Rheumatology (ACR) 50 response criteria; and (3) Contrast the performance of DAPSA LDA + IGA ≤1 with that of PASDAS LDA (score ≤3.2).

**Results:** Patients (pts) with active PsA despite standard therapies (DISCOVER-1: ≥3 swollen + ≥3 tender joints; CRP ≤0.3 mg/dL; ≥30% prior history of up to 2 TNF inhibitors; DISCOVER-2: ≥5 swollen + ≥5 tender joints; CRP ≤0.6 mg/dL; all pts with biologic-naïve) were randomized 1:1:1 to GUS 100 mg at W0, W4, then Q4W or Q8W or placebo (PBO) to crossover to GUS Q4W at W24. In both studies, efficacy of GUS vs PBO was compared at W24 (primary endpoint). The number (%) of pts with PASDAS LDA + IGA ≤1 was determined at W24 for pts randomized to GUS or PBO. For all GUS-randomized pts, baseline variables associated with PASDAS LDA + IGA ≤1 and PASDAS LDA at W16 and the predictive value of W16 PASDAS LDA + IGA ≤1 or PASDAS LDA for achieving ACR50, MDA, and PASDAS LDA at W52 were assessed using logistic regression models.

**Figure:** Composite response at W16 are predictive of Achievement of ACR50, MDA, and PASDAS LDA at W52

**Disclosures of Interest:** Wolf-Henning Boehncke Speakers bureau: AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, and UCB, Consultant of: AbbVie, Almirall, Janssen, Leo, Lilly, Novartis, and UCB, Alice G Gottlieb Consultant of: AnaptysBio, Avocet Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb Co., Incyte, GSK, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical Industries, Inc., UCB, and Dermavant, Grant/research support from: Boehringer Ingelheim, Incyte, Janssen, Novartis, UCB, Xbiotech, and Sun Pharma, Enrique Soriaño Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Alexis Ogide Consultant of: AbbVie, Amgen, BMS, Celgene, CorEvitas, Gilead, Happily Healthy, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Pfizer and Novartis and to Forward from Amgen, Olga Ziouzina Consultant of: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, Pfizer, UCB, Celtrion, and Fresenius-Kabi, Emmanouil Rapsomakis Consultant of: Janssen, Employee of: JSS Medical Research, Xie Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Marilise Marrache Shareholder of: Johnson & Johnson, Employee of: Janssen Inc, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB.

DOI: 10.1136/annrheumdis-2022-eular.1070

**REFERENCES:**


---

**PARE Poster 1**

**P00083-PARE**

DRIVING IMPROVEMENT IN AXIAL SPONDYLOARTHRITIS SERVICES: THE USE OF QUALITY IMPROVEMENT APPROACHES AND TOOLS

D. Webb\(^1\), R. Barnett\(^2\), L. Davies\(^3\), \(1\) National Axial Spondyloarthritis Society, CEO, London, United Kingdom; \(2\) Bath, Health, Bath, United Kingdom; \(3\) Salford, NHS Transformation Unit, Salford, United Kingdom

**Background:** Quality Improvement (QI) methods have been used in healthcare since the late 1980s across a wide range of healthcare settings. However, in the UK they have not been applied widely within rheumatology including axial Spondyloarthritis (axial SpA). In 2017, the UK healthcare regulator, NICE, produced a national clinical guideline for axial SpA, but there was no mechanism to encourage uptake of its recommendations. The National Axial Spondyloarthritis Society created a programme to use QI approaches to help encourage uptake of the Guidelines and act as a catalyst for wider improvement in axial SpA care.

**Objectives:** To encourage service improvement in axial Spondyloarthritis care through the use of quality improvement theory and methods.

**Methods:** In late 2019 six rheumatology departments were selected to participate in the first cohort. The programme design was underpinned by:

- A framework for management grounded in systems theory\(^1\)
- A learning system that brings healthcare organisations together\(^2\)
- A set of tools to develop, test and implement changes: the Model for Construct Improvement3.

The teams met four times for training in QI methods, plus team-based online coaching. They had time to develop their projects and networking opportunities to share their data and experiences of implementation.

We conducted a qualitative review of the programme in year one. We interviewed 31 programme participants and reviewed programme documentation.

**Results:**

The review found that:

- A proven QI framework provides a strong basis to build improvement
- A competitive programme helps foster motivation and accountability
- The programme provides the time to use tools to understand the problem and construct improvement aims
- Measurement is key to understand improvement and to create a story of change
- Collaboration and engagement is key within the team and with other stakeholders.
- The teams have:
  - Trained community-based physiotherapists, leading to improved rheumatology referrals
  - Implemented an inflammatory back pain pathway from primary care
  - Introduced an MRI spine IBP protocol to reduce variation in imaging
  - Established a tertiary referral service which has improved time to diagnosis

---

**Figure:** Composite response at W16 are predictive of Achievement of ACR50, MDA, and PASDAS LDA at W52
• Implemented mental health interventions for patients and reduced the percentage of patients with abnormal scores
• Established a pathway for physiotherapy self-referral and reduced Did Not Attend rates
• Used audit to make the business case for an extended scope practitioner

Conclusion: Despite the challenges posed by the Covid-19 pandemic, a structured QI programme has enabled clinicians to stay engaged and implement physiotherapy-led, rediagnostic delay and improve care.

REFERENCES:

Disclosure of Interests: Dale Webb Grant/research support from: Grant funding from AbbVie, Biogen, Lilly, Janssen, Novartis & UCB; Rosie Barnett: None declared, Lucy Davies: None declared

DOI: 10.1136/annrheumdis-2022-eular.4749

POS0084-PARE IMPACT OF OSTEOARTHRITIS ON PATIENT QUALITY OF LIFE: IS THERE AN EVOLUTION BETWEEN THE 2013 AND 2021 LARGE-SCALE SURVEYS – STOP OSTEOARTHRITIS CONDUCTED IN FRANCE AND BELGIUM?

L. Grange, C. Mathy, A. F. Lailloua, G. Chales, L. Seidell, A. Alberi, L. Lories, Y. Henriot, O., CHU Grenoble Alpes/Hôpital SUD, Rheumatology Department, Echirrolles, France; 1Association Francaise de Lutte Antirhumatisme A.F.L.RA, President, Paris, France; 2 Princess Paola Hospital, Vivalia, Department of Physical Therapy and Rehabilitation, Marche-En-Famenne, Belgium; 3 Osteoarthrosis Foundation, Treasurier, Belgium; 4 Association Francaise de Lutte Antirhumatisme A.F.L.RA, Voorzitter, Paris, France; 5 Association Francaise de Lutte Antirhumatisme A.F.L.RA, Treasurer, Paris, France; 6 Liège University Hospital, Department of Biostatistics, Liège, Belgium; 7 University Hospitals Leuven, Belgium, Skeletal Biology and Engineering Research Center, KU Leuven and Division of Rheumatology, Leuven, Belgium; 8 Princess Paola Hospital, Vivalia, Belgium, Department of Physical Therapy and Rehabilitation, Marche-En-Famenne, Belgium; 9 Osteoarthrosis Foundation, President, Boncelles, Belgium; 10 University of Liège, MusculoSkeletal Innovative Research Lab (mSKIL), Liège, Belgium

Background: Osteoarthritis (OA) is the most common form of arthritis, affecting more than 500 million people globally. OA is characterized by chronic mechanical pain and stiffness in the joints, limiting patient physical activities, leading to sedentarism, and disability. The results of the French web-based survey “Stop OA” (N=4227 participants) conducted in 2013 were presented at EULAR 2014. They evidenced the heavy burden of OA in France.

Objectives: The survey was repeated in France/Belgium between 2019 and 2021 (N=3465). This study aimed at assessing the impact of OA on patient quality of life and looking at a potential evolution between the two surveys.

Methods: Participants were invited to complete the survey questionnaire online via the website www.stop-arthrose.org. The questions focused on demographic and socio-economic aspects, history of the disease, physical activities, beliefs about OA, its impact on daily life, assessment of health status and the consequences, as well as the needs and expectations of the participants.

Results: 3465 questionnaires (France N = 2822, Belgium N = 643) were thus collected between September 2019 and January 2021. The average filling time of the survey was 40 minutes. In the 2021 survey, 80.8% of participants (mean age 60 years, 80.3% women) declared that OA had a negative impact on their morale and 64.1% that they had a deteriorated self-image due to the disease. 25% of participants thought that difficulties in their couple were caused by OA and 33% reported problems in sexual life. 24.8% found it hard to cope with the disease impact, and 33% reported problems in sexual life. 24.8% found it hard to cope with the disease impact, and 33% reported problems in sexual life.

Conclusion: OA represents a real burden that affects the mental health of patients, their relationships and the quality of their sleep. There has been no improvement of OA impact in patient quality of life between the two surveys (i.e., 8 years). This reflects the lack of resources for research to find new treatments and implement evidence-based therapeutic strategies in the current medical practice. A better understanding of these repercussions will allow effective strategies to be adopted in order to deal with these issues.

REFERENCES:

Acknowledgements: Acknowledgements to expenscience, Labhra, UBSA, and Tilmans laboratory for their institutional support

Disclosure of Interests: LAURENT GRANGE Speakers bureau: Expanscope, IBSA, Consultant of: Lohmann & Rauscher, Grünenthal, MSD, Grant/research support from: Thuaune, Stéphane Renier, Christine Mathy; None declared, Françoise Alliot Launois: None declared, Gerardo Chales: None declared, Laurence Seidel: None declared, Adelin Albert: None declared, Rik Lories Speakers bureau: Abbvie, Boehringer-Ingelmein, Celgene, Eli-Lilly, Galapagos, Janssen, Kabi-Fresenius, MSD, Novartis, Pfizer, Sandoz, Biosipic (Samumed) and UCB, Consultant of: Abbvie, Amgen (formerly Celgene) Eli-Lilly, Galapagos, Janssen, Kabi-Fresenius, MSD, Novartis, Pfizer, Sandoz, Biosipic (Samumed) and UCB, Yves Henrotin Consultant of: Tilmans, Nestlé, Wobenzym, Genequins, Expenscience, Lahra, Biobe


POS0085-PARE CURRENT NEEDS, IMPACT AND PERSPECTIVE OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS

P. Plazuelo-Ramos1, L. Loza2.1, Coordinadora Española de Asociaciones de Espondiloartritis, Presidencia, Fuenlabrada, Spain; 2Instituto de Salud Musculosquelética, Rheumatology, Madrid, Spain

Background: The impact of spondyloarthritis (SpA) and psoriatic arthritis (PsA) is enormous.

Objectives: To analyse in patients with SpA and PsA current 1) needs; 2) disease impact, and 3) patients’ opinion on treatments, patients-physicians relationship, and disease information.

Methods: National survey promoted by CEADE (Spanish Coordinator of Spondyloarthritis Associations). A multidisciplinary working group composed by 1 rheumatologist, 2 patients members of CEADE with SpA and PsA and a methodologist was established. They designed a structured survey (20 minutes long), in electronic format to be answered by patients with SpA and PsA, aged 18 years or above. The survey was launched on April 28, 2021, using CEADE channels to communicate with members and followers, and was closed on June 30, 2021. Sociodemographic and clinical variables were collected (age, sex, disease duration treatments), and variables related to the objectives. A descriptive analysis was performed.

Results: The survey included 543 patients with SpA (55% ankylosing spondylitis, 45% women, 81 aged 48-64 years, 25% with biological therapies) and 291 patients with PsA (89% women, 73% aged 48-64 years, 40% with biological therapies). In the last month, the reported level of fatigue, morning stiffness and sleep problems of patients with SpA and PsA was considerable. In a scale from 0 (no symptoms) to 10 (high level of symptoms) the means were greater than 8. Almost 80% of patients with SpA described low back pain within the last month and 82.5% of patients with PsA pain, stiffness and/or arthritis on the knees, ankles, feet and/or hands, and 51% dactylitis. Regarding to daily activities, practicing exercise and house cleaning were the most affected ones among patients with SpA and PsA. We found that 70%-74% of these patients were concerned about pain and almost 60%-66% about loss of mobility and autonomy. The impact of the disease on work was in general very high very high. The level of satisfaction with treatments was low in SpA, mean 5.5 (scale from no satisfaction to 10 very satisfied), and moderate in PsA, mean 6.2. Across treatments, the level of satisfaction was higher with biological therapies compared with classical synthetic disease modifying antirheumatic drugs in both disease groups. Many patients (70.2% with SpA and 66% with PsA) are used to live with pain every day. Many of the survey participants (over 50%) hope that treatments will help them recover their quality of life and improve pain, stiffness and fatigue. Oral treatments are preferred over subcutaneous and intramuscular drugs in SpA and PsA. Patients also consider that oral treatments have more positive influence on adherence to treatments. A total of 22% of surveyed patients with SpA and 14% with PsA said that their rheumatologists never asked them about the factors that limit their life, 14.3% and 6% that they never talked about the impact of the disease on quality of life, and 43.8% (SpA) and 31.2% (PsA) that they do not stablish treatment objectives with the rheumatologist. Almost 30% of participants stated that they would like to have more time to express and discuss doubts and concerns with their rheumatologist, and around 25% would like to have more follow-up visits.

Table 1 describes the most used.
In addition, oral corticosteroids (OCS) and other immunosuppressants can expose patients with SLE to severe adverse events. However, little is known about the relative importance of SLE treatment outcomes including symptom control or the extent to which treatment risks are tolerated in exchange for this.

**Objectives:** To quantify the relative importance of different SLE treatment outcomes and the trade-offs patients are willing to make between these outcomes.

**Methods:** This online discrete choice experiment (DCE) assessed how treatment choices varied with treatment outcomes. Subjects were US adults (≥18 years) with a self-reported diagnosis of moderate-to-severe SLE (≥6 months) who experienced ≥1 flare in the past year and were taking ≥1 SLE treatment. Treatment outcomes included four benefits on: 1) fatigue levels, as in the Functional Assessment of Chronic Illness Therapy (FACT)–Fatigue, described the degree of tiredness felt by a patient in the previous 7 days, while not experiencing a flare and despite adequate sleep or rest, 2) joint and 3) non-joint pain levels as measured using the Brief Pain Inventory–Short Form (BPI-SF) scale; scores of 2, 5, and 8 correspond to mild, moderate, and severe worst daily pain on a scale of 0 (no pain) to 10 (worst imaginable pain), and 4) skin rash and itch levels, as in SLE-QOL, indicated how much patients were troubled by sore, painful, stingy, or itchy skin in the previous 7 days. Treatment outcomes also included three risks: 1) risk of infections (1% decrease), 2) risk of mild-to-moderate side effects to avoid being ‘extremely troubled’ by skin rash and itch (Table 1).

**Conclusion:** This real-world patient preference assessment provides insights into the relative importance of SLE treatment outcomes and willingness to tolerate SLE treatment risks. These results can guide endpoint prioritization in SLE clinical studies and inform the evaluation of SLE treatments.


**DOI:** 10.1136/annrheumdis-2022-eular.830

---

**Table 1. Maximum acceptable risk of mild-to-moderate oral corticosteroid side effects**

<table>
<thead>
<tr>
<th>Attribute levels</th>
<th>Maximum Acceptable</th>
<th>Increase in Risk* [95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue A little bit</td>
<td>50.06% [32.41, 67.71]</td>
<td></td>
</tr>
<tr>
<td>Somewhat</td>
<td>47.51% [29.92, 65.09]</td>
<td></td>
</tr>
<tr>
<td>Very much</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Skin rash and itch Not at all</td>
<td>73.81% [51.51, 96.11]</td>
<td></td>
</tr>
<tr>
<td>Moderately</td>
<td>50.84% [32.37, 69.35]</td>
<td></td>
</tr>
<tr>
<td>Extremely</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Joint pain (1-level decrease) Not at all</td>
<td>15.63% [11.24, 20.02]</td>
<td></td>
</tr>
<tr>
<td>Moderately</td>
<td>9.18% [6.06, 12.31]</td>
<td></td>
</tr>
<tr>
<td>Extremely</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Risk of infections (1% decrease) Not at all</td>
<td>2.99% [1.53, 4.45]</td>
<td></td>
</tr>
<tr>
<td>Moderately</td>
<td>1.72% [0.97, 2.47]</td>
<td></td>
</tr>
</tbody>
</table>

*Calculated using an error-component multinomial logit model.

**Figure 1. Marginal utilities associated with changes in SLE treatment outcomes**

**Conclusion:** This real-world patient preference assessment provides insights into the relative importance of SLE treatment outcomes and willingness to tolerate SLE treatment risks. These results can guide endpoint prioritization in SLE clinical studies and inform the evaluation of SLE treatments.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2302

---

**Table 1. Sources and formats of information about the disease.**

<table>
<thead>
<tr>
<th>Source of information</th>
<th>SpA</th>
<th>PsA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social networks</td>
<td>184 (33.9%)</td>
<td>68 (23.4%)</td>
</tr>
<tr>
<td>Patients associations</td>
<td>158 (29.1%)</td>
<td>77 (26.5%)</td>
</tr>
<tr>
<td>Scientific societies</td>
<td>70 (12.9%)</td>
<td>36 (12.4%)</td>
</tr>
<tr>
<td>Websites created by rheumatologists</td>
<td>165 (30.4%)</td>
<td>82 (28.2%)</td>
</tr>
<tr>
<td>Physician</td>
<td>197 (36.3%)</td>
<td>117 (40.2%)</td>
</tr>
<tr>
<td>Nurse</td>
<td>33 (6.1%)</td>
<td>10 (3.4%)</td>
</tr>
<tr>
<td>Other/s</td>
<td>11 (2.0%)</td>
<td>7 (2.6%)</td>
</tr>
<tr>
<td>Format</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graphic or visual illustrations</td>
<td>184 (33.9%)</td>
<td>78 (26.8%)</td>
</tr>
<tr>
<td>Podcasts</td>
<td>47 (8.6%)</td>
<td>12 (4.1%)</td>
</tr>
<tr>
<td>Video</td>
<td>175 (32.2%)</td>
<td>72 (24.7%)</td>
</tr>
<tr>
<td>Written information (brochures, magazines, newspapers)</td>
<td>200 (37.8%)</td>
<td>100 (34.4%)</td>
</tr>
<tr>
<td>Newsletters</td>
<td>148 (27.3%)</td>
<td>72 (24.7%)</td>
</tr>
<tr>
<td>Chatbots</td>
<td>8 (1.5%)</td>
<td>2 (0.7%)</td>
</tr>
<tr>
<td>Other/s</td>
<td>10 (1.8%)</td>
<td>6 (0.7%)</td>
</tr>
</tbody>
</table>

**Conclusion:** Current impact of SpA and PsA on daily life is still very high. There are areas for improvement in the doctor-patient relationship and on disease treatments.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2302

---

**Figure 1. Marginal utilities associated with changes in SLE treatment outcomes**

**Conclusion:** This real-world patient preference assessment provides insights into the relative importance of SLE treatment outcomes and willingness to tolerate SLE treatment risks. These results can guide endpoint prioritization in SLE clinical studies and inform the evaluation of SLE treatments.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2302

---

**Table 1. Sources and formats of information about the disease.**

<table>
<thead>
<tr>
<th>Source of information</th>
<th>SpA</th>
<th>PsA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social networks</td>
<td>184 (33.9%)</td>
<td>68 (23.4%)</td>
</tr>
<tr>
<td>Patients associations</td>
<td>158 (29.1%)</td>
<td>77 (26.5%)</td>
</tr>
<tr>
<td>Scientific societies</td>
<td>70 (12.9%)</td>
<td>36 (12.4%)</td>
</tr>
<tr>
<td>Websites created by rheumatologists</td>
<td>165 (30.4%)</td>
<td>82 (28.2%)</td>
</tr>
<tr>
<td>Physician</td>
<td>197 (36.3%)</td>
<td>117 (40.2%)</td>
</tr>
<tr>
<td>Nurse</td>
<td>33 (6.1%)</td>
<td>10 (3.4%)</td>
</tr>
<tr>
<td>Other/s</td>
<td>11 (2.0%)</td>
<td>7 (2.6%)</td>
</tr>
<tr>
<td>Format</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graphic or visual illustrations</td>
<td>184 (33.9%)</td>
<td>78 (26.8%)</td>
</tr>
<tr>
<td>Podcasts</td>
<td>47 (8.6%)</td>
<td>12 (4.1%)</td>
</tr>
<tr>
<td>Video</td>
<td>175 (32.2%)</td>
<td>72 (24.7%)</td>
</tr>
<tr>
<td>Written information (brochures, magazines, newspapers)</td>
<td>200 (37.8%)</td>
<td>100 (34.4%)</td>
</tr>
<tr>
<td>Newsletters</td>
<td>148 (27.3%)</td>
<td>72 (24.7%)</td>
</tr>
<tr>
<td>Chatbots</td>
<td>8 (1.5%)</td>
<td>2 (0.7%)</td>
</tr>
<tr>
<td>Other/s</td>
<td>10 (1.8%)</td>
<td>6 (0.7%)</td>
</tr>
</tbody>
</table>

**Conclusion:** Current impact of SpA and PsA on daily life is still very high. There are areas for improvement in the doctor-patient relationship and on disease treatments.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2302
and increasing their ability to manage the disease. Furthermore, the pilot project aimed to close an important gap in the Swiss health care system.

**Methods:** A questionnaire was designed to measure the change in self-management abilities and the health status of patients. The questionnaire was given to patients at three points in time (t1=enrolment of patient, t2=last session of the self-management programme and t3= two months after the last session) and contained several validated scales such as the heiQ, Self-Efficacy for Managing Chronic Disease 6-item Scale, RADAi-5 and EQ-5D-5L. Descriptive statistics were applied to analyse the data by comparing the mean values of all relevant indicators at three points in time.

**Results:** In total 52 patients were enrolled in the pilot project. 48 patients completed the programme and 35 took part in the follow-up questionnaire. Overall, the results show a positive trend in self-management abilities and an improvement in the patients’ current health status. The slight increase in knowledge remained until the follow-up. Significant changes are seen in Skill and Technique Acquisition as well as in Self-Monitoring and Insight of the disease, which are two important components of self-management. Other components such as the knowledge and constructive attitudes and approaches also underwent a small but positive change that lasts up to two months after the last session of the self-management programme. Self-improvement improved as well, but with a slight decrease during the follow-up. The disease activity also declined slightly over time. The results also indicate a small and steady improvement of the current health status. Using a visual analogue scale as part of the EQ-ED-EL, participants evaluated their current health status as 69 (t=1), 73 (t=2) and 74 (t=3). The quality of life has improved too, but the change doesn’t seem to be relevant. Furthermore, the use of health services indicates a slight decline after taking part in the self-management programme.

**Conclusion:** The comprehensive self-management programme designed by the Swiss League against Rheumatism embedded in outpatient rheumatological and general practitioner clinics proved to be successful. The three components of self-management in particular, i.e., knowledge, motivation to take action and skills to manage the disease improved significantly. The results also show a positive trend in the patients’ current health status, their quality of life and a decline in disease activity. However, based on the study design, it cannot be concluded that there is a correlation between the improved health status/quality of life and the self-management programme. For this purpose, a control group would be necessary to evaluate the programme’s effect on the health status and quality of life of people with rheumatic disease. Nevertheless, this pilot project represents an important foundation on which further services and programmes to strengthen self-management in rheumatology can be developed.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2576

**Table 1. Avg assessment scores* by month, mean (SD)**

<table>
<thead>
<tr>
<th>Month</th>
<th>Pain Intolerance</th>
<th>Fatigue</th>
<th>Sleep Disturb</th>
<th>Physical Func</th>
<th>Depression</th>
<th>Anxiety</th>
<th>Social Isolation</th>
<th>Emot Support</th>
<th>Anger</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Period</td>
<td>62.9 (8.5)</td>
<td>60.3 (9.7)</td>
<td>37.7 (7.6)</td>
<td>62.4 (10.5)</td>
<td>61.9 (10.2)</td>
<td>40.9 (9.8)</td>
<td>61.5 (12.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2021</td>
<td>62.7 (8.5)</td>
<td>60.2 (9.3)</td>
<td>38.9 (8.5)</td>
<td>62.4 (10.5)</td>
<td>61.9 (10.2)</td>
<td>38.1 (8.3)</td>
<td>59.6 (14.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>June</td>
<td>62.6 (8.9)</td>
<td>60.9 (9.5)</td>
<td>38.3 (7.8)</td>
<td>62.4 (10.5)</td>
<td>61.9 (10.2)</td>
<td>39.3 (10.3)</td>
<td>60.2 (10.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>July</td>
<td>62.7 (8.5)</td>
<td>60.8 (10.2)</td>
<td>38.1 (7.9)</td>
<td>61.0 (7.8)</td>
<td>62.4 (10.5)</td>
<td>39.4 (9.7)</td>
<td>62.4 (9.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aug</td>
<td>62.5 (8.5)</td>
<td>60.7 (10.4)</td>
<td>38.5 (8.5)</td>
<td>57.7 (10.3)</td>
<td>57.2 (11.1)</td>
<td>36.9 (12.2)</td>
<td>53.3 (19.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sep</td>
<td>62.4 (8.5)</td>
<td>60.3 (9.7)</td>
<td>37.3 (7.6)</td>
<td>58.7 (8.0)</td>
<td>57.7 (11.3)</td>
<td>68.1 (12.8)</td>
<td>57.8 (12.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct</td>
<td>62.1 (8.5)</td>
<td>60.3 (9.7)</td>
<td>37.3 (8.0)</td>
<td>59.9 (8.5)</td>
<td>62.3 (9.0)</td>
<td>64.3 (10.3)</td>
<td>57.3 (11.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nov</td>
<td>62.6 (8.6)</td>
<td>60.3 (9.7)</td>
<td>36.9 (8.5)</td>
<td>59.1 (8.8)</td>
<td>61.3 (6.8)</td>
<td>61.4 (10.9)</td>
<td>58.6 (11.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dec</td>
<td>62.9 (8.3)</td>
<td>60.4 (9.6)</td>
<td>37.4 (8.1)</td>
<td>60.7 (8.4)</td>
<td>63.8 (5.3)</td>
<td>65.1 (7.5)</td>
<td>38.5 (13.5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PROMIS measures scored 0-100; mean 50 for general US population; 1SD = 10 points

**Acknowledgements:** This work was partially supported through a Patient-Centered Outcomes Research Institute (PCORI) award (PPRN-1306-04811). All statements in this poster, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee.

**Disclosure of Interests:** Kelly Gavigan: None declared, Esteban Rivera: None declared, Jeffrey R. Curtis Consultant of: Gilead, Novartis, and Samsung, Grant/ research support from: AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, Shilpa Venkatachalam: None declared, Laura Stratford: None declared, David Curtis: None declared, W. Benjamin Nowell Grant/research support from: William B. Nowell is the Principal Investigator on grants/contracts from AbbVie, Eli Lilly and Company, and PCORI, and an employee of the Global Healthy Living Foundation (GHLF). GHLF receives grants, sponsorships and contracts from pharmaceutical manufacturers.
The IMPORTANCE OF ACCURATE INCIDENCE AND PREVALENCE ESTIMATES FOR FAMILIES OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

R. Beesley, 1, 2, 3, 4, 5. Juvenile Arthritis Research, JAR Project, Tonbridge, United Kingdom

Background: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of auto-immune disorders characterised by chronic joint inflammation, affecting children and young people (CYP) under the age of 16. Recent analysis in the UK [1] has provided an update to the estimated incidence and prevalence rates of JIA.

Objectives: Whilst the policy and health-care benefits of accurate incidence and prevalence rates are understood, this patient- and parent-led qualitative project sought views from parents of CYP with JIA to understand whether knowing accurate estimates of incidence and prevalence are important to them.

Methods: Parents of CYP with JIA, all members of a small online group on social media, were asked whether knowing accurate rates of JIA were important to them, and why. Responses were collated and summarised.

Results: Whilst a few respondents felt it did not matter to them what the overall rates of JIA were, focusing instead on their own personal experience with the condition, the majority did want to know and gave consistent reasoning. They advised that, when your child is diagnosed with JIA, it is a very isolating experience. Most people have never heard of the condition before, and being told your child has arthritis is a frightening time (especially if you then become aware of some of the significant long-term effects, such as potential continuation of disease into adulthood and possible joint damage, and the side effects of treatment, and social impacts of the disease [2, 3]). Whilst direct support is available to families affected by JIA (www.jarproject.org), understanding prevalence rates can help reduce mental health burdens on patients and parents and reduce feelings of isolation.

Families also advised that they want to know numbers of children with JIA as so we collectively can get a better understanding of the cause, the trends, and the possible reasons behind changes. Knowing accurately the numbers of children with JIA can help to raise awareness; current lack of awareness in society and primary care contributes to delays in diagnosis and potentially worse clinical outcomes [4]. In addition they reported the need for appropriate resourcing of paediatric rheumatology and support services, and the political and financial discussions that must take place to enable that to happen need to be supported by evidence.

Conclusion: Overall, parents do want to know how many other children have JIA. It takes some of the isolation and anxiety away to know you are not alone. It matters because knowing there are other parents in the same situation as you can help reduce anxiety and loneliness. It matters, because knowing there are researchers focussing on JIA helps remind you that work is underway to better understand JIA, its causes, and improved treatments which will eventually lead to improved care for children with the condition. It matters, because it can help target resources appropriately. It matters, because raising awareness is more effective if we know how many people are affected by a chronic condition. And it matters, because as improved treatments are developed we want to be able to see the number of children categorised as having active JIA to reduce and health outcomes for each child to improve.

REFERENCES:


Disclosure of Interests: None declared


THE ORGANISATION, IMPACT, AND INFLUENCE OF PATIENT ADVISORY BOARD REPRESENTATION IN PRIVATE REHABILITATION INSTITUTIONS – AN EXPLORATIVE CROSS-SECTIONAL STUDY

J. Sagen1, E. Bæresund2, A. E. Simonsen3, A. Habberstad4, I. Kjeken1, H. Dagfinrud1, R. H. Moe5, 6. The Deacon's Home Hospital, Norwegian National Advisory Unit on Rehabilitation in Rheumatology, Oslo, Norway; 2Oslo University Hospital, Oslo, Norway, Department of Digital Health Research, Division of Medicine, Oslo, Norway; 3Raysumnetet Rehabilitation Center, Patient Advisory Board, Jarem, Norway; 4The Norwegian Federation of Organisations of Disabled People, Research and Patient Participation, Oslo, Norway

Background: Patient participation (PP) organised as patient advisory boards (PABs) is a statutory part of health care institutions in Norway (1). There is limited agreement on how to engage PABs in a meaningful manner (2). More knowledge on how PAB representatives experience patient engagement (PE) is needed.

Objectives: To explore how PAB representatives engage in PABs with regard to organisation, influence, and impact on decision-making processes and service delivery.

Methods: PAB representatives recruited from rehabilitation institutions, representing all four health regions in Norway completed a PE evaluation tool. The tool is tested for reliability and content validity with good results and comprises 35 items including four main domains: policies and practices, participatory culture, collaboration, and influence and impact that provided responses about PE-levels (3). Categorical data were summarized to modal scores using frequencies and percentages, and response categories were collapsed from five to three. The collapsed categories were divided into PE-levels: barrier, intermediate, and facilitator (Table 1). Free-text responses were analysed according to principles of manifest content analysis, summed up, and used to complete the results of the scores. Free text responses were analysed using Quirkos version 2.4.

Results: Of the 150 contacted PAB representatives, 47 (32%) responded. PAB representatives’ mean age was 60.5 (min-max 30-80), 62% were female and a majority (81%) had prior experience with PP. The results showed that 75% of the participants agreed that patient-centered care was strengthened as a result of PE. Three out of four main domains scored indicating a facilitating PE-level (Table 1). The domain, influence and impact scored with an intermediate PE-level. Regarding influence and impact, half of the participants did not know how PE input had influenced management decisions, and 60% had rarely identified any PE contributions. The results from free text analyses showed that PE was coded as a facilitator seven times, and as a barrier to PE 26 times. The most frequent barrier was exclusion of PAB (13 codes), and the most coded facilitator was inclusion of PAB (3 codes).

Conclusion: Findings indicate that PAB representatives are satisfied with how rehabilitation institutions organise PABs. Unclear adherence to the values and principles of PP may hinder influence and visibility from PE contributions.

REFERENCES:


Table 1

<table>
<thead>
<tr>
<th>Item</th>
<th>Domain</th>
<th>Modal PE-level</th>
<th>Mode</th>
</tr>
</thead>
<tbody>
<tr>
<td>125</td>
<td>5 Policies and practices Facilitating</td>
<td>125 (53.2)</td>
<td>(18-37)</td>
</tr>
<tr>
<td>199</td>
<td>8 Participatory culture Facilitating</td>
<td>199 (53)</td>
<td>(14-35)</td>
</tr>
<tr>
<td>35</td>
<td>2 Collaboration Facilitating</td>
<td>35 (36.5)</td>
<td>(14-19)</td>
</tr>
<tr>
<td>125</td>
<td>6 Influence and impact Intermediate</td>
<td>125 (44.4)</td>
<td>(10-30)</td>
</tr>
</tbody>
</table>

Questions not presented in the table consist of background items, items related to final thoughts, and five questions with free text fields. A yes or no question related to the domain policies and practices is not included in the table.

Before collapsed, 15 items were valued: Strongly disagree, disagree, neither agree nor disagree, agree, strongly agree. Most items valued 1-5: never, seldom, some of the time, all of the time, don’t know.

Acknowledgements: The authors acknowledge all participants who took part in this study, VIRKE and UNICARE rehabilitation organisations for cooperation, and DAM Foundation for funding.

Disclosure of Interests: None declared

MIG-NETWORK - A NETWORK FOR PEOPLE WITH RHEUMATISM AGED 35-55 YEARS.

B. Schmidt Andersen1, 2, Gitteforeningen, Friviligafdelingen, Gentotto, Denmark

Background: The MIG network (“MIG” is a shortening for “Middi i gigt” which means “In the middle of Reumatism” as well as mid-life. MIG also means “ME” in Danish

The existing offers and activities in the Danish Rheumatism Association are primarily targeted towards the age group above 60 years. Often, younger members find it difficult to feel at home and see themselves as part of that particular age group. They miss activities where they can meet up with their peers, who are going through the same challenges in life.

Objectives: The objectives of the MIG network is to create a forum for people with rheumatism, who are roughly between 35 and 55 years old. The network focuses on life with rheumatism and how to keep the balance between job, family life and the disease. The ultimate goal was to create a community based on networking, shared experiences and relevant knowledge from both each other and health professionals.

Methods: First of all, the age group needed to be involved right from the start, so we initially made a series of interviews to learn about their needs and wishes. Then we gathered a group of five volunteers, who agreed to participate in defining the objectives and activities and to start up the network. The network consists of the following:

I) an online based network with monthly webinars on the platform Zoom, where different health professionals talks about relevant subjects. The obvious advantage being, that people could participate from all over the country, from their sofa, not needing to dress up and travel after a long day of obligations.

II) The Danish Rheumatism Association have created an App for their volunteer community. In this app we offered the members of MIG “a room of resources” where they can find news on the latest research and other relevant news. The members can also ask questions and share written advice and good ideas with each other.

III) Last, but not least it was important for the volunteers to offer physical meet-ups, where they can find news on the latest research and other relevant news. The volunteers have enjoyed the professional presentations and found them to be very useful. At the same time, they gained useful tools to make it easier to live a life with rheumatism. But it has been difficult to create an intimate space. For many, it is difficult to share private feelings of uncertainty and inadequacy on camera in a Zoom meeting. It has been difficult to create an intimate space. For many, it is difficult to share private feelings of uncertainty and inadequacy on camera in a Zoom meeting. The “room of resources” on our App has only worked and engaged a very small group of people, in spite of a great effort from our volunteers.

The physical meetings have been a great success. And they have covered a need that wasn’t met before. The participants have enjoyed the professional lectures, but enjoyed the social networking even more. So now the meetings have less lectures and more networking in the program. As living with a chronic disease can make the whole family and network suffer, we also met the need to invite next of kin to join the meetings and have arranged for them to have their own workshop with a Psychologist.

Conclusion: The MIG network makes sense! And it has met a need for people with a chronic disease to meet up with peers in the same life situation. It has proven to be more difficult than intended to create an online community, whereas the physical meetings have created strong relations on a completely different level. The network continues with both the digital and the physical activities nationally. The goal is also to recruit volunteers locally, so that they can initiate local activities.

REFERENCES: None

Disclosure of Interests: None declared


Pathogenesis of SLE, Sjöns and antiphospholipid syndrome

POS0092 HETEROGENEITY OF THE TYPE I INTERFERON SIGNATURE AMONG ANTIIPHOSPHOLIPID SYNDROME PATIENTS: A CLUSTER AND CORRESPONDENCE ANALYSIS APPROACH

I. Cecchi1, M. Radin1, A. Barinotti1, S. G. Foddal1, E. Rubini1, A. Suárez2, D. Roccato1, S. Sciascia1, J. Rodriguez-Carrio2, 1University of Turin, Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, University of Turin, Italy, Turin, Italy; 2University of Oviedo, Area of Immunology, Department of Functional Biology, Faculty of Medicine, University of Oviedo, Oviedo, Spain, and Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, Oviedo, Spain

Background: Type I Interferons (IFN) are central players in the pathogenesis, disease activity and evolution of several autoimmune conditions. To date, a limited number of evidences is available on the specific role of IFN activation in antiphospholipid antibodies (aPL) positive patients, including aPL carriers, primary antiphospholipid syndrome (PAPS) and those APS subjects who presented with an associated autoimmune disease (secondary APS, SAPS), such as systemic lupus erythematosus (SLE).

Objectives: The aim of this study was to evaluate the differential expression of IFN stimulated genes (ISG) among different subsets of aPL positive subjects and SLE patients.

Methods: For the purpose of the study, a total of 112 patients attending the San Giovanni Bosco Hospital (Turin, Italy) were enrolled, including 31 PAPS, 25 SAPS, 27 SLE patients without aPL, 29 aPL carriers (mean age 48.3±13.3 years, 76% female). Nineteen subjects were also recruited as healthy controls (HCs).

Complete demographic, clinical, and laboratory data were collected at the time of the inclusion. Gene expression was evaluated by RT-PCR in whole blood for the following genes: IFI6, IFI44, IFI44L, MX1, IFI27, OAS1 and RSAD2. Normalized gene expression levels (Z-scores) were averaged into a global IFN signature (IFN score). Differences were measured by Krukal-Wallis tests and associations among genes were studied by cluster and correspondence analyses. Correlations among genes were plotted by network analyses.

Results: An overall activation of ISG was noted across APS subsets, but certain differences were noted among genes. Whereas some ISG were already upregulated in the aPL positive group compared to HC (IFI44, IFI44L, MX1, IFI27, OAS1 and RSAD2, all p<0.050), other ISG were only in increased SLE (IFI6), MX1 differed between SLE and SAPS, and IFI27 and OAS1 showed differences between PAPS and SLE. The composite IFN score revealed qualitative differences in the IFN pathway activation across APS subsets, being elevated in aPL carriers/PAPS groups compared to HC (both p<0.050) and increasing in SLE (p=0.010) and SLE (p=0.001) groups. Network analyses (Figure 1A) revealed qualitative differences in the gene-gene correlation networks: (i) weaker structures were found in HCs and aPL carriers, compared to stronger and higher degree networks in SLE and SLE groups; and (ii) the influence of each node was different across groups.

Unsupervised cluster analysis identified 3 clusters (I to III) based on ISG patterns (Figure 1B). Clusters usage differed among APS subsets, thus correlating clinical status (Figure 1C). Distinct groups of ISG positively correlate to aPS/PT IgG titre in aPL carriers and PAPS groups (all rho=0.500), whereas no associations were retrieved in SLE or SLE. No associations with previous thrombotic events were observed in any subset, although IFN composite score and several ISG correlate with the number of thrombotic recurrences under anticoagulation (all rho=0.400). No associations with GAPPS were observed.

Figure 1.
Conclusion: An overall IFN pathway activation has been observed in aPIL positive patients and across all APS subsets. Qualitative and quantitative differences across the APS spectrum can be identified, leading to the identification of distinct IFN signatures with different clinical value.

REFERENCES:

Disclosure of Interests: None declared


ASSESSMENT OF HISTOLOGICAL FEATURES OF CHRONICITY OF MINOR SALIVARY GLAND BIOPSY IN PATIENTS WITH PRIMARY SJOGEN’S SYNDROME

S. Garcia-Cirena1, L. C. Galisteo S, J. Rotamoz1, M. Moreno E, E. Casado1, M. Rusihol Gonzalez, J. Gratacos-Masmitja1, J. Calvet1, ParcTauli Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí, Rheumatology, Sabadell, Spain

Background: The origin of the histological chronic inflammation of the salivary gland in patients with primary Sjogren’s Syndrome (pSS) is questionable. It is probably a consequence of both, the evolution of the disease itself and aging.

Objectives: This study aims to evaluate histological data of chronicity of minor salivary gland biopsy with clinical characteristics and time of evolution in a series of patients with pSS.

Methods: A cross-sectional study including 98 subjects fulfilling the ACR-EULAR 2017 classification criteria for pSS. All patients underwent a minor salivary gland biopsy requested as per clinical practice. We collected the age at diagnosis and at biopsy, xerostomia and xerophthalmia evolution time, and stimulated and unstimulated salivary flow as a clinical data. We informed the following features in the minor salivary gland biopsy: the focus score (positive if ≥ 1), atrophy, fibrosis and adiposity all graded in negative, mild, moderate, and severe stages according to pathological criteria.

Results: This study included 98 patients with pSS. The median of all recruited parameters are shown in Table 1. Only 2 patients presented severe fibrosis and adiposity, so we did not consider them for the analysis. Both, the age at diagnosis and at biopsy are significantly higher between none, mild and moderate stages in the three biopsy parameters. The age at biopsy increased in negative, mild, and moderate stages, in median, 10, 9 and 6 years in atrophy, fibrosis and adiposity respectively. Although more evolution time is observed in atrophy and fibrosis regarding classification categories, it does not reach statistical significance. Focus score is associated with atrophy as a high percentage in severe stage shows negative biopsy (78% vs 22%, p = 0.046) while in negative, mild, and moderate atrophy display a positive biopsy (61%, 73% and 64%, respectively). Furthermore, we observe a significant OR of 8.75 [1.7-68] for negative, 6 [1.25-30] for mild, and 3 vs 2 and 1.75 for fibrosis). Regarding adiposity, a linear statistically significant association is observed for every stage (3.5, 1.65 and 0.7, p< 0.001). No differences in the stimulated salivary flow are shown.

Table 1. Description of variables included in the study.

<table>
<thead>
<tr>
<th>Categories</th>
<th>N(%)</th>
<th>Median(IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis(-years)</td>
<td>55.220 (51.097, 58.407)</td>
<td></td>
</tr>
<tr>
<td>Age at biopsy(-years)</td>
<td>57.719 (53.851, 61.333)</td>
<td></td>
</tr>
<tr>
<td>Xerostomia(months)</td>
<td>19.614 (10.480, 35.121)</td>
<td></td>
</tr>
<tr>
<td>Xerophthalmia(months)</td>
<td>21.487 (8.148, 38.735)</td>
<td></td>
</tr>
<tr>
<td>Focus score(positive)</td>
<td>63 (64.3%)</td>
<td></td>
</tr>
<tr>
<td>USF (ml/15 min)</td>
<td>2.000 (1.400, 3.000)</td>
<td></td>
</tr>
<tr>
<td>SSF (ml/5 min)</td>
<td>4.500 (3.000, 5.000)</td>
<td></td>
</tr>
<tr>
<td>Atrophy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>28 (28.7%)</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>37 (38.1%)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>23 (23.7%)</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>9 (9.3%)</td>
<td></td>
</tr>
<tr>
<td>Fibrosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>29 (30.5%)</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>40 (42.1%)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>26 (27.4%)</td>
<td></td>
</tr>
<tr>
<td>Adiposity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>39 (41.1%)</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>38 (40%)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>18 (18.3%)</td>
<td></td>
</tr>
</tbody>
</table>

USF: Unstimulated salivary flow, SSF: Stimulated salivary flow

Conclusion: An older age both, at diagnosis and at biopsy are associated with a severe stage of atrophy, fibrosis, and adiposity. Patient with severe atrophy shows less positive focus score, which might be noticed for biopsy interpretation

Disclosure of Interests: None declared


Figure 1. ALPN-303 treatment significantly reduces serum autoantibody titers and renal immune complex deposition in the inducible bm12 mouse model of lupus. *p<0.05, **p<0.01, ***p<0.001 by the Kruskal-Wallis test.

Conclusion: ALPN-303 is an engineered, potent BAFF/APRIL antagonist that continues to consistently demonstrate encouraging immunomodulatory activity and efficacy in vitro and in vivo, as further demonstrated in the SRBC immunization and bm12 lupus models, with superiority to WT TACI-Fc and anti-CD20 comparators. ALPN-303 may thus be an attractive development candidate for
the treatment of multiple autoimmune and inflammatory diseases, particularly B cell- and/or autoantbody-related diseases such as SLE, Sjögren’s syndrome, and other connective tissue diseases. A Phase 1 study of ALPN-303 in adult healthy volunteers (NCT02934484) is ongoing.

REFERENCES:


**POS0095**

CAMK4 CONTROLS T REGULATORY CELL METABOLISM AND DEFINES THEIR FUNCTION AND STABILITY IN SYSTEMIC LUPUS ERYTHEMATOSUS

M. Scherlinger1,2, W. Pan3, R. Hidas4, A. Boulogoura5, M. Vukelic1,6, G. Tsokos5,6.
1Beth Israel Deaconess Medical Center (BIDMC), Rheumatology, Boston, United States of America; 2Hôpital de Hautepiere - Hôpitaux Universitaires de Strasbourg, Rheumatology, Strasbourg, France; 3Albert Einstein College, Rheumatology, Bronx, United States of America

Background: Calcium/CaM-dependent protein kinase IV (CaMKIV) is a serine kinase expressed in CD4 T cells whose activity is increased in patients with active systemic lupus erythematosus (SLE). We have shown that CaMK4 negatively impacts T regulatory (Treg) cell function in SLE, but the underlying mechanism remains unclear. Recent data suggest that CaMK4 impacts cellular metabolism.

Objectives: Investigate how CaMK4 impacts Treg cell metabolism and its potential effect on Treg cell function.

Methods: We harvested CD62L+CD4+ T cells from wild-type (WT) or Camk4-/- mice and differentiated them in vitro into Treg (iTreg) cells. We assessed iTreg metabolism using Seahorse XF analyzer and mass spectrometry (metabolomics). Gene expression was assessed at the mRNA (RT-qPCR) and at the protein level (Western Blot), Phosphofructokinase activity was assessed by a colorimetric assay (Achrom). In vitro gene knockdown was conducted by transfecting a guide RNA (gRNA) in CRISPR/Cas9-expressing T cells. T cell function was evaluated by in vitro immunosuppressive assay and in vivo by the adoptive transfer of T conventional T and iTreg cells (8:1 ratio) in Rag1-/- mice to induce inflammatory colitis. The relevance of CaMK4 in SLE was evaluated in vivo using a T-cell specific knockdown of CaMK4 in the B6.1pr mouse model, and in humans by culturing SLE patient T cells with KN-93, a CaMK4 specific inhibitor.

Results: iTreg cells from Camk4-/- mice had decreased glycolysis and increased mitochondrial metabolism compared to WT T cells. Metabolomics studies suggested decreased activity of the rate-limiting glycolysis enzyme phosphofructokinase (PFK), while PFKF mRNA and protein levels were similar. Using a phosphofructokinase knockdown, we observed decreased activity of the rate-limiting glycolysis enzyme phosphofructokinase (PFK), while PFKF mRNA and protein levels were similar. While PFKP mRNA and protein levels were similar, PFKP knockdown significantly improved iTreg function in vitro and in vivo using an adoptive CD4+ T cell transfer in Rag1-/- mice (collitis model). Interestingly, iTreg lacking PFKP were transferred Rag1-/- mice were less likely to lose FoxP3 expression and to produce IL-17A, demonstrating higher Treg stability in an inflammatory environment. A translational basis, lupus-prone B6.1pr mice with a T-cell specific Camk4 knockdown displayed significantly less lupus manifestations. In vitro, CD4+ T cells had decreased PFKP activity, which correlated to healthy donors, and PFKP activity correlated with the SLE disease activity index (SLEDAI, r = 0.47; p < 0.05). Finally, culture of SLE CD4+ T cells with KN-93 led to a significant decrease in PFKP activity (p < 0.001).

Conclusion: Increased CaMK4 activity in human SLE mediates Treg dysfunction and instability by altering PFKF activity. Restoring normal Treg metabolism by inhibition of CaMK4 or its downstream target PFKP represents a novel strategy for the treatment of SLE.

Acknowledgements: Marc Scherlinger is financially supported by the Société Française de Rhumatologie (SFR), Philippe, Monahan & Arthurs Sachs foundations.

Disclosure of Interests: None declared


**POS0096**

Sjögren’s Disease and Systemic Lupus Erythematosus: DXD6-CXCR5 Risk Intervals Reveal Common SNPs with Functional Significance in Immune and Salivary Gland Cells

1University of Oklahoma Health Sciences Center, Oklahoma City, United States of America; 2University Hospitals; 3Birmingham NHS Foundation Trust, Rheumatology Department, Birmingham, United Kingdom; 4University of Oklahoma Health Sciences Center, College of Dentistry; 5Oral Diagnostics and Radiology Department, Oklahoma City, United States of America; 6Salt Lake University Hospital Department of Internal Medicine, Clinical Immunology Unit, Stavanger, Norway; 7Karolinska Institutet, Department of Medicine, Stockholm, Sweden; 8University of Bergen, Department of Clinical Science, Bergen, Norway; 9National Institute of Dental and Craniofacial Research, Salivary Disorder Unit, Bethesda, United States of America; 10Hannover Medical School, Department of Rheumatology and Immunology, Hannover, Germany; 11Haukeland University Hospital, Department of Rheumatology, Bergen, Norway; 12University of Adelaide, Discipline of Medicine, Adelaide, Australia; 13Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Research Program, Oklahoma City, United States of America; 14Uppsala University, Department of Medical Sciences, Uppsala, Sweden; 15University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, United States of America; 16US Department of Veterans Affairs Medical Center, US Department of Veterans Affairs Medical Center, Oklahoma City, United States of America; 17Université Paris-Saclay, Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR1184, Le Kremlin Bicêtre, France; 18Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, United Kingdom; 19Medical University of South Carolina, College of Medicine, Charleston, United States of America

Background: Sjögren’s Disease (SjD) and Systemic Lupus Erythematosus (SLE) are autoimmune diseases with several shared characteristics and similar genome-wide significant associations with the DXD6-CXCR5 locus. DXD6 suppresses interferon-stimulated gene expression and CXCR5 regulates T cell functions impotted in autoimmunity.

Objectives: To identify and characterize functional SNPs in the DXD6-CXCR5 interval.

Methods: ImmunoChip data from European populations (3785 SLE cases; 1916 SjD cases; 6893 controls) were imputed and SNP-trait associations tested. Bayesian statistics defined a credible SNP set that was refined using bioinformatic analyses (RegulomeDB, Haploreg, ENCODE, promoter capture Hi-C, eQTLs, etc.). Electrophoretic mobility shift assays (EMSA) and luciferase expression assays were used to test allele-specific SNP function in EBV-transfected B cells, Jurkat cells, and EBV-transfected T cells, and the risk allele significantly increased protein binding and promoter/enhancer region of DDX6, and rs4938572, rs4936443, rs7117261, and rs4938573 in the promoter/enhancer region of DXD6. Risk allele of rs4938572 also increased promoter activity in A2B5 cells (p<0.01), but had no effect on promoter or enhancer activity in B cells. SNP rs4936443 showed no promoter or enhancer activity in immune cells, but the risk allele showed
significant promoter and enhancer (p<0.001) activity in A253 cells. SNP rs7117261 showed decreased enhancer activity in EBV B cells, T cells, and A253 cells (p<0.05) and increased promoter activity in A253 cells (p<0.001). SNP rs4938573 also showed decreased promoter activity in EBV B cells, T cell and A253 cells (p<0.05). decreased promoter activity in EBV B cells (p<0.05), and increased enhancer activity in A253 cells (p<0.0001). Overall, A253 cells exhibited more allele-specific effects on promoter and enhancer activity across the five SNPs compared to tested immune cells. In addition to DDx6 and Cxcr5, rs57494551 and/or rs4938572 are reported eQTLs for several other genes of interest in the local chromatin regulatory network: IL10RA in T cells, TRAPPC4 in salivary gland and activated macrophages, and long non-coding (Inc)RNA AP002954.1 in T cells and whole blood. 3C-qPCR in EBV B and A253 cells showed that the two regulatory regions carrying rs4938572 or rs57494551 interacted with a region upstream of DDx6 that includes AP002954.1. Hi-C data showed looping between AP002954.1 and the regulatory region carrying rs4938572 and rs57494551 in T cells.

Conclusion: SJ and SLE share similar genomic architecture across the DDx6-CXCR5 risk interval with several common SNPs showing immune and salivary gland cell-type-specific allele effects on protein binding and/or enhancer/promoter activity. Extensive bioinformatic analyses suggest that the SNPs likely work within the local chromatin regulatory network to regulate cell type-specific expression of several genes on the interval. Ongoing studies will use 3C-qPCR to assess allele-specific chromatin interactions between the SNPs and these genes in different cell types, and CRISPR to determine how the risk alleles alters expression.


Table 1. Knock-down and knock-in genes significantly associated with the pSS transcriptomic signatures

<table>
<thead>
<tr>
<th>Type of experiment</th>
<th>Similarity score</th>
<th>Genes</th>
<th>Number of genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knock-in</td>
<td>IFNG, DUSP28, IFNB1, LYN, BCL2L2, TNFRSF1A, CD40, BCL10, NLK, ZNF398, SLC32A2</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td>Knock-down</td>
<td>SLC25A14, GOLM4, DTYMK, DCXR, RRM2, IMPA1, CLB, F2, CABS9, ID1, ISD1, UBAIP1, HGD2A, UFD1L, SOD2, ITG1, PRLK2, HIST2H2BE, NISCH, TEAD4, MT2X, TYK2, GTF2B, NDUFS7, NNT, ACADSB, GSTPI, HOMER2, SORBS3, PC2K2, PHB2, PDKX, TES, TRAPPC2, TXB6, HOX6, KIF2C, MED1, NSF2E, CD14, BECN1, TM9SF3, EFS3, PRMT3, KD, PKN2, SUCL2A2, CD44, GNR, SP3, ATP5J2, MYCBP2, TRAF7, POLA2, ADRB2, PGM31, PPRRS2C, PMAIP1, ETFA, ANKR3D7, SPECTC1</td>
<td>41</td>
<td>61</td>
</tr>
</tbody>
</table>

Type I and II interferons were highly ranked (similarity score >99), and their overexpression mimicked the disease signature. CD40 appeared also as a very relevant target (similarity score = 98.8). Three drugs had a significant negative similarity score: amoxicillin (-88.69, p=0.0019), amoylocine (-88.28, p=0.0026), and droxinostat (-85.42, p=0.0027). Droxinostat is a HDAC inhibitory. HDAC activity has been shown to be an essential element of the coactivation system for IFN-induced gene regulation and the IFN-induced innate immune response.

Conclusion: This first drug repositioning transcriptomic approach in Sjögren’s syndrome confirms the interest of targeting interferons and identifies histone deacetylases as potential therapeutic targets.


Centre de Ressources Biologiques de l’Hôpital Bichat: Sarah Tubiana Johan G. Brun for contributing to the Norwegian cohort.
LINC01871, IMPLICATED IN SJÖGREN’S DISEASE PATHOGENESIS, IS REGULATED BY INTERFERON-G AND CALCINEURIN SIGNALING

M. L. Joachims1, B. Khatri1, C. Li1, K. L. Tessner1, J. Icea1, A. M. Stolarczyk1, N. Means1, K. Grundahl1, S. Glenn1, J. Kelly1, D. Lewis1, L. Radlarska1, D. Stone1, J. Guthridge2,3,7, J. A. James2,3,7, R. H. Scofield2,7, G. B. Wiley1, J. Wren4, P. M. Gaffney4, C. Montgomery5, K. Sivilis5, A. Rasmussen6, A. D. Farris7, I. Adrianto8, C. Lessard8, 1Oklahoma Medical Research Foundation, Genes and Human Disease Research Program, Oklahoma City, United States of America; 2Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Research Program, Oklahoma City, United States of America; 3University of Oklahoma Health Sciences Center, Department of Pathology, Oklahoma City, United States of America; 4University of Oklahoma College of Dentistry, Department of Oral and Maxillofacial Pathology, Oklahoma City, United States of America; 5University of Oklahoma College of Dentistry, Oral Diagnosis and Radiology Department, Oklahoma City, United States of America; 6University of Oklahoma Health Sciences Center, Dean McGee Eye Institute, Department of Ophthalmology, Oklahoma City, United States of America; 7University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, United States of America; 8US Department of Veterans Affairs Medical Center, Department of Pathology, Oklahoma City, United States of America; 9Henry Ford Health System, Center for Bioinformatics, Department of Public Health Sciences, Oklahoma City, United States of America

Background: Sjögren’s disease (SjD) is an autoimmune disease characterized by exocrine gland dysfunction. Long non-coding RNAs (IncRNAs) are a functionally diverse class of non-protein coding RNAs that are longer than 200 nucleotides. Our previous study using whole blood RNA-seq found that IncRNA, LINC01871, is overexpressed in SjD relative to controls [1]. CRISPR-Cas9 targetting of the LINC01871 promoter region yielded a LINC01871−/− clone with altered expression of many genes implicated in immune regulation [1].

Objectives: The goal of this study was to analyze the gene expression perturbations resulting from the loss of LINC01871 and to characterize the regulation of LINC01871 in both the LINC01871−/− clone and primary human T cells in response to immune stimuli.

Methods: Programmed and LegendsPlex bead assays were used to compare surface and secreted protein expression changes, respectively, in LINC01871−/− cells and the parental HS2B2 cells. Parental HS2B2 T cells, LINC01871−/− cells, Kasumi-3 myeloid cells, and primary human T cells were stimulated in vitro and changes in gene expression were measured over time using qRT-PCR. Responses to interferons (IFN) were assessed using universal type I IFN (IFN-α), IFN-β, and IFN-γ. TCR signaling responses were assessed using PMA/Ionomycin (PMA/I) or anti-CD3/CD28 stimulations in the presence or absence of the calcineurin inhibitor, FK506.

Results: Previous RNA-seq analysis found 1166 differentially expressed (DE) transcripts (log2FC ≥1 or ≤-1; p < 0.05) in LINC01871−/− cells compared to parental HS2B2 cells, including many prominent immune regulatory genes. Changes in the basal expression of 7 proteins in LINC01871−/− cells were confirmed using flow cytometry (significantly decreased: CD8a (p=0.0004), CD30 (p=0.0008), CXCR3 (p=0.0002), HLA-DR (p=0.02), significantly increased: CD226 (p=0.0059) and CD44 (p=0.024)). Analysis of LINC01871−/− cells revealed a growth inhibition in LINC01871−/− cells (p=0.0014 at 72h), in which multiple secreted growth and adhesion factors were significantly reduced: GM-CSF (p=2.0e-06), M-CSF (p=2.7e-09), IGBP4 (p=1.2e-07), s-ICAM1 (p=0.015), MMP9 (p=3.0e-14), and MMP2 (p=6e-08). In contrast, the IL-6 cytokine family member, IL6, was significantly increased in LINC01871−/− cells (p=1.0e-07). Because HS2B2 cells were not responsive to all IFNs, IFN-mediated regulation of LINC01871 expression was examined in the Kasumi-3 myeloid cell line. While LINC01871 expression was not modulated by type I IFN stimulation, it was robustly responsive to IFNγ treatment. Since LINC01871 was expressed in T cells and implicated in T cell pathways, responses to TCR signaling pathways were characterized in HS2B2 cells or purified primary human T cells treated with PMA/I. In both cell types, LINC01871 exhibited a prolonged decrease in expression that was abrogated by concurrent treatment with FK506, indicating that LINC01871 is regulated by calcineurin signaling. Treatment of primary human T cells with anti-CD3/CD28 to mimic true TCR engagement resulted in a modest decrease of LINC01871 expression at early time points, followed by an increase in expression with longer stimulation (2d).

Conclusion: Our findings suggest that LINC01871 is a potential mediator of the dysregulated T cell inflammatory response pathways implicated in SjD pathogenesis. LINC01871 influences the expression of many important immune cell genes and growth factors, is inducible by IFNγ, and is regulated directly by calcineurin signaling and TCR ligand engagement. Although LINC01871 functions are still unknown, observed LINC01871 overexpression in whole blood of SjD cases and after prolonged TCR stimulation in primary human T cells suggests that it could be a biomarker of SjD.

REFERENCES:

Disclosure of Interests: Michelle L. Joachims: None declared, Bhuvan Khatiri: None declared, Candice L. Tessnee: None declared, Kathleen E. Icea: None declared, John Ice: None declared, Anna M. Stolarczyk: None declared, Nicole L. Means: None declared, Kiel Grundahl: None declared, Stuart Glenn: None declared, Jennifer Kelly: None declared, David Lewis: None declared, Lida Radfar: None declared, Donald Stone: None declared, Joel Guthridge: None declared, Judith A. James: None declared, Rhai Saltif: None declared, Graham B. Wiley: None declared, Johnathan Wren: None declared, Patrick M. Gaffney: None declared, Courtney Montgomery: None declared, Kathy Sivilis: Employee of: Current employee of Janssen, Astrid Rasmussen: None declared, Daree Farris: None declared, Indra Adrianto: None declared, Christopher Lessard: None declared


THE CELLULAR METABOLISM OF SLE NK CELLS IS PRIMARILY ALTERED AT THE LEVEL OF MITOCHLONDRIAL RESPIRATION

N. Fluder1, M. Humbel1, F. Bellanger1, A. Horisberger1, C. Fenwick1, C. Ribi1, D. Comte1, 1Lausanne University Hospital, Immunology and Allergy, Lausanne, Switzerland

Background: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease, involving the development of autoreactive cells and autoantibodies. National Killer (NK) cells are innate immune cells that mediate the interaction between the innate and adaptive immune system, however their role in SLE is incompletely understood. SLE NK cells are decreased in peripheral blood, exhibit reduced cytotoxicity, and impaired cytokine production (1, 2). Furthermore, SLE NK cells present phenotypic alterations: increased expression of CD38 and altered upregulation of SLAMF7 after activation (3). To date, few studies evaluated the molecular mechanisms underlying NK cell dysfunction in SLE.

Objectives: We examined immune metabolic alterations of SLE NK cells.

Methods: NK cells of cryopreserved PBMC from SLE patients were isolated. Glycolysis and OXPHOS were studied using XF®e96 Seahorse. Expression of metabolic receptors (CD71, GLUT-1, CD98), mitochondrial function (mitochondrial membrane potential, mass) and calcium influx were investigated

Disclosure of Interests: None declared

REFERENCES:

by FACS. Mitochondrial structure was evaluated by electron and confocal microscopy. **Results:** First, we examined the cellular metabolism of SLE NK cells compared to healthy cells. We observed that OXPHOS is significantly increased in SLE NK cells (Figure 1A), whereas glycolysis was normal (Figure 1B). Furthermore, the mitochondrial mass and membrane potential (by FACS (Figure 1C) and confocal microscopy) were increased in SLE. Electron microscope imaging showed profound alterations in SLE NK cell mitochondrial ultrastructure (Figure 1D). No significant differences in the expression of key metabolite transporters involved in mitochondrial fueling (CD71, GLUT-1, CD98) was observed in SLE NK cells compared to healthy controls. Second, we examined how ligation of DARA and ELO influences the metabolism of healthy NK cells. Our data showed that ELO primarily enhances NK cell OXPHOS (Figure 1E), whereas DARA mainly increases glycolysis. Consistently, ELO also increases mitochondrial membrane potential and expression of metabolite transporters CD71, GLUT-1 and CD98. Next, we examined the effect of DARA and ELO on SLE NK cells. While stimulation with DARA adequately increases glycolysis in SLE NK cells, engagement with ELO fails to properly increase OXPHOS (Figure 1F), expression of cell surface transporters, mitochondrial membrane potential and mass. **Conclusion:** Our data suggest that SLE NK cells exhibit alterations in cellular metabolism, primarily involving mitochondrial respiration. In contrast, glucose metabolism is similar to that of healthy NK cells. Additionally, ELO and DARA mediate the activation of healthy NK cells through the engagement of different metabolic pathways: OXPHOS and glycolysis, respectively. Therefore, priming SLE NK cells with ELO is unable to adequately engage their dysfunctional mitochondrial respiration. These findings provide important insights on the alteration present in SLE NK cells and contribute to a better understanding of the pathogenesis of the disease. **REFERENCES:**


**POS0100** ACTIVATION OF THE CELLULAR INTEGRATED STRESS RESPONSE IN LABIAL SALIVARY GLANDS FROM SJÖGREN’S SYNDROME PATIENTS.


1Universidad de Chile, Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Facultad de Medicina, Santiago, Chile; 2Ohio University, Edison Biotechnology Institute, Athens, Ohio, United States of America; 3Universidad de Chile, Departamento de Biología Médica, Facultad de Medicina, Santiago, Chile; 4Universidad San Sebastián, Facultad de Odontología, Santiago, Chile; 5Clínica Indisa, Reumatología, Santiago, Chile; 6Universidad Mayor, Escuela de Odontología, Facultad de Ciencias, Santiago, Chile

**Background:** Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by inflammation of the exocrine glands and severe symptoms of eye and mouth dryness. Disorders in the saliva secretion process have been associated with oxidative and endoplasmic reticulum (ER) stress in combination with inflammatory responses. The integrated stress response (ISR) is a mechanism that allows cells to modify their gene expression program to restore homeostasis and promote their survival against various extrinsic and intrinsic stress signals, such as hypoxia, nutrient deprivation, viral infections, inflammatory factors (cytokines, chemokines, inflammasomes), and accumulation of unfolded proteins in the ER, among others (1). The ISR is regulated by four kinases: PERK, PKR, HRI and GCN2, that dimerize and autophosphorylate to become active and each one responds to different stress stimuli. The signaling pathways that are activated in response to stress factors stimulate the phosphorylation of eIF2α, which causes a transient inhibition of global protein synthesis and induction of synthesis of some specific genes like ATF4 and Nrf2. ATF4 induces the transcription of genes involved in metabolism and nutrient uptake, redox status, and regulation of apoptosis. Dephosphorylation of eIF2α in the ISR termination signal to restore protein synthesis is mediated by the PP1 complex, which recruits the catalytic subunit PP1c and one of its two regulatory subunits: GADD34 or CREP.

**Objectives:** To evaluate the presence and functional state (phosphorylation) of the ISR sensing kinases: PERK, PKR, HRI and GCN2; the levels of eIF2α/p-eIF2α and the key ISR transcription factors ATF4 and Nrf2, as well as subunits of the complex involved in the ISR termination: PP1c, GADD34 and CREP in labial salivary glands (LSG) of SS-patients. **Methods:** Biopsies of LSG from 12 SS-patients and 11 control subjects were studied. The levels of mRNA, protein and phospho (p)-protein of the ISR components were determined by RT-qPCR and Western blotting. **Results:** Our results show increased levels of p-PERK/PERK ratio (11/11), p-PKR (7/11), p-PKR/PKR ratio (7/11), p-eIF2α (5/11) and ATF4 (11/11) in LSG from SS-patients compared to control subjects. No significant changes were found in mRNA levels of HRI, GCN2, and GADD34 between LSG from SS-patients and control subjects. Decreased protein levels of HRI (8/12), p-GCN2 (6/11), eIF2α (6/11), p-eIF2α (6/11), Nrf2 (11/12), and p-NRF2 (12/12) were found in LSG showing scarce parenchyma and high fibrosis and fat infiltration. On the other hand, PP1c and CREP showed decreased mRNA and protein levels in all SS-patients LSG. Interestingly, Ro autoantibodies and focus score were negatively correlated with PP1c and Nrf2 mRNA and protein levels whereas positively correlated with PKR mRNA levels. **Conclusion:** The overexpression and activation of some ISR kinases together with the decrease in the PP1c/CREP the integrated stress response (ISR) is a key mechanism of activation of ISR, resulting in p-eIF2α to remain activated in LSG from SS-patients. This would explain the high protein levels of ATF4 and of target genes involved in the antioxidant response in LSG from SS patients suggesting that ISR activation plays a key role in pro-survival response to cellular stress.

**REFERENCES:**


**Acknowledgements:** This study was supported by Fondecyt-Chile 1210055; Enlace-VID Universidad de Chile [EN04/20 to MJG]; Fondecyt Iniciación 11201058 and PhD fellowship Conicyt Chile. **Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.313
Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder, characterized by a remarkable heterogeneity of clinical presentations. Glomerulonephritis (GN) remains a leading cause of morbidity and mortality in SLE, influencing long-term prognosis. The alteration of both innate and adaptive immune responses plays a pivotal role in SLE pathophysiology [1]. B lymphocytes are mainly involved in SLE through the production of autoantibodies but recent evidence suggests an effector role of these cells in cytokine production. IL-40 is a recently discovered cytokine, produced by B cells and involved in their homeostasis, that may participate in the pathogenesis of B-mediated autoimmune diseases, such as SLE [2].

Objectives: The purpose of this study was to evaluate the role of IL-40 in the pathogenesis of SLE, with a specific focus on renal involvement.

Methods: Peripheral blood and urine samples were collected from 10 consecutive SLE patients and 10 healthy controls; kidney biopsy specimens were obtained from 3 SLE patients and 3 controls. The concentration of IL-40 in serum and urine samples was evaluated by ELISA. IL-40 production by monocytes, B cells and T cells was assessed by flow cytometry at day 0 and after in vitro stimulation. Immunohistochemistry on kidney tissue was also performed to evaluate IL-40 expression.

Results: IL-40 levels were reduced in the serum of patients with active GN. This reduction was further observed in the serum of patients with previous GN. In the serum of active SLE patients, without renal involvement, the concentration of IL-40 did not change significantly compared to controls. Urinary levels of IL-40 showed no significant changes compared to controls. Consistently, immunohistochemistry on kidney showed the expression of IL-40 only in SLE patients (Figure 1). Flow cytometric analysis on T cells, B cells and monocytes isolated from peripheral blood of SLE patients with active GN did not show production of IL-40.

Conclusion: To the best of our knowledge this is the first demonstration of IL-40 expression at kidney level in SLE associated nephritis. These preliminary data suggest an active role of IL-40 in SLE, with specific focus on active kidney disease. Our results highlight a potential use of IL-40 as a marker of active GN, although its specific mechanism of action needs to be further elucidated.

REFERENCES:

Disclosure of Interests: Chiara Rizzo: None declared, Lidia La Barbera: None declared, Marianna Lo Pizzo: None declared, Leila Mohammadnezhad: None declared, Vincenzo Luca Lentini: None declared, DENISE DONZELLA: None declared, Francesco Ciccia Speakers bureau: Lilly, pfizer, novartis, celgene, abb-

Rheumatoid arthritis prognosis, predictors and outcome

**POS0103**
IN RHEUMATOID ARTHRITIS, THE ASSOCIATION BETWEEN ANTI-MODIFIED PROTEIN ANTIBODIES AND LONG-TERM OUTCOMES IS DOMINATED BY THE EFFECT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES

T. J. Van Wesemael1, M. Verstappen1, R. Knevel1, A. Van der Helm-van Mil1, T. Huizinga1, R. Toes1, D. Van der Woude1. Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands

**Background:** In rheumatoid arthritis (RA) many patients harbor autoantibodies against posttranslationally modified proteins (anti-modified protein antibodies (AMPA)); anti-citrullinated protein antibodies (ACPA), anti-carnbamylylated protein antibodies (anti-CarP) and anti-acetylated protein antibodies (AAPA). All three AMPA have been described to be associated with an increase in radiographic joint damage and ACPA also with a lower chance of obtaining sustained drugfree remission (SDFR). However, it is unclear whether the effects of these autoantibodies are independent of each other, and whether testing for all three AMPA offers additional information regarding these clinical outcomes.

**Objectives:** To investigate the individual and combined associations of AMPA with radiological progression and SDFR in RA.

**Methods:** In 612 RA patients from the Leiden Early Arthritis Clinic, we measured ACPA IgG with anti-CCP2- assays, anti-CarP IgG using homocitrullinated and native (as a control) fetal calf serum, and AAPA IgG by means of novel assays consisting of cyclic peptides with either acetylated or norleucine residues (as a control). Sharp–van der Heijde scores (SHS) were determined in 2685 sets of radiographs with yearly intervals for 7 years. The association of AMPA with SHS was assessed with a multivariate normal regression model. SDFR was defined as the absence of clinical synovitis after discontinuation of DMARD treatment. The association of SHS with autoantibody-status was assessed with Kaplan-Meier curves. The very small number of patients single-positive for ACPA (n=4, 1%) precluded analyses in this subgroup.

**Results:** The prevalence of autoantibodies is shown in Table 1. A higher SHS was found in patients with autoantibodies compared to patients without antibodies, and in triple-positive versus single-positive patients (Figure 1A, p=0.04). To investigate if the higher SHS was due to the number of autoantibodies or a specific autoantibody, analyses were stratified for all three AMPAs. Interestingly, no difference was found in SHS between all ACPA-positive strata (Figure 1B). In the ACPA-negative stratum, a significant difference was found between patients with zero antibodies and solely anti-CarP (p=0.02).

**Table 1. Prevalence of autoantibodies in 612 rheumatoid arthritis patients in the EAC cohort**

<table>
<thead>
<tr>
<th>Autoantibody status</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACPA-positive</td>
<td>316 (52)</td>
</tr>
<tr>
<td>Anti-CarP-positive</td>
<td>270 (44)</td>
</tr>
<tr>
<td>AAPA-positive</td>
<td>208 (34)</td>
</tr>
<tr>
<td>ACPA-AAPACarP+</td>
<td>255 (42)</td>
</tr>
<tr>
<td>ACPA-AAPACarP-</td>
<td>46 (7)</td>
</tr>
<tr>
<td>ACPA-AAPACarP+</td>
<td>4 (1)</td>
</tr>
<tr>
<td>ACPA-AAPACarP-</td>
<td>37 (6)</td>
</tr>
<tr>
<td>ACPA+AAPACarP+</td>
<td>66 (11)</td>
</tr>
<tr>
<td>ACPA+AAPACarP-</td>
<td>0 (0)</td>
</tr>
<tr>
<td>ACPA+AAPACarP+</td>
<td>167 (27)</td>
</tr>
</tbody>
</table>


The chance to obtain SDFR was lower in all antibody-positive groups compared to the autoantibody-negative group. Moreover less triple-positive antibody-positive patients than single-antibody-positive patients achieved SDFR (p<0.001), Figure 1C. After stratification for AMPA, no difference was found in the percentage of SDFR in all ACPA-positive strata, or in the ACPA-negative stratum, Figure 1D.

**Conclusion:** In ACPA-positive patients, the presence of other AMPA influences neither radiographic progression, nor the chance of SDFR. Thus, long-term clinical phenotype in RA is particularly dependent on the presence of ACPA, and less on the presence of other AMPA. Therefore, there appears to be no added value of testing the other AMPA for predicting clinical outcome in ACPA-positive patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.881

**POS0104**
ACPA-NEGATIVE AND ACPA-POSITIVE RA-PATIENTS ACHIEVING DISEASE RESOLUTION DEMONSTRATE DISTINCT PATTERNS OF MRI-DETECTED JOINT-INFLAMMATION

M. Verstappen1, X. Matthijssen1, S. Connolly2, M. A. Maldonado2, T. Huizinga1, A. Van der Helm-van Mil1,3. Leiden University Medical Center, Rheumatology, Leiden, Netherlands; Bristol Myers Squibb, Immunology and Fibrosis, Philadelphia, United States of America; Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands

**Background:** Sustained DMARD-free remission (SDFR), the sustained absence of clinical-synovitis after DMARD-discontinuation, is increasingly achievable in RA. However, prevalence differs significantly between ACPA-negative (40%) and ACPA-positive RA (5-10%). In addition, early-DAS-remission (DAS<2.6) associates with SDFR in ACPA-negative RA but not in ACPA-positive RA. Based on these differences, we hypothesized that longitudinal patterns of local tissue-inflammation (synovitis/tenosynovitis/osteitis) might also differ between ACPA-negative and ACPA-positive RA-patients achieving SDFR.

**Objectives:** With the ultimate aim to increase understanding of disease-resolution in RA, we studied MRI-detected joint-inflammation over time in relation to SDFR-development in ACPA-negative RA and ACPA-positive RA.

**Methods:** 198 RA-patients (94 ACPA-negative and 104 ACPA-positive) underwent repeated MRIs (0/4/12/24-months) and were followed on SDFR-development. The course of MRI-detected total-inflammation, and synovitis/tenosynovitis/osteitis individually, were compared between RA-patients who did and did not achieve SDFR, using Poisson-mixed-models. 170 ACPA-positive RA-patients from the AVERT-1 were studied as ACPA-positive validation-population.

**Results:** In ACPA-negative RA, patients achieving SDFR had similar baseline total inflammation-levels, which declined 2.0-times stronger in the first-year of DMARD-treatment (IRR 0.50, 95%CI;0.32-0.77 , p<0.01) compared to patients without SDFR. This stronger decline was seen in tenosynovitis/synovitis/oesteitis. In contrast, ACPA-positive RA-patients achieving SDFR, had already lower inflammation-levels (especially synovitis/oesteitis) at disease-presentation (IRR 0.45, 95%CI;0.24-0.86, p=0.02) compared to non-SDFR patients, and remained lower during follow-up (p=0.02). Similar results were found in the ACPA-positive validation-population.

**Conclusion:** Compared to RA-patients without disease-resolution, ACPA-positive RA-patients achieving SDFR have less severe joint-inflammation from diagnosis onwards, whilst ACPA-negative RA-patients present with similar inflammation-levels but demonstrate a stronger decline in the first year of DMARD-therapy. These different trajectories suggest that mechanisms underlying resolution of RA-chronicity in both RA-subsets might be different and indicates the relevance of the total inflammatory-load in ACPA-positive RA.

**REFERENCES:**
IMMUNOLOGICAL AND TISSUE DERIVED BIOMARKERS OF EARLY RESPONSE IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS TREATED WITH JAK-INHIBITORS

S. Perniola1,2, B. Tolusso2, C. DI Mario2,3, M. Gessi4, D. Bruno1,2, S. Alivernini2,3,5, E. Gremese1,2,3.

1Clinical Immunology Unit, Fondazione Policlinico Universitario ‘A. Gemelli’/IRCCS, Rome, Italy; 2Immunology Research Core Facility, Gemelli Science and Technology Park (GSTep) - Fondazione Policlinico Universitario ‘A. Gemelli’/IRCCS, Rome, Italy; 3Department of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy; 4Institute of Pathology, Fondazione Policlinico Universitario ‘A. Gemelli’/IRCCS, Rome, Italy; 5Division of Rheumatology, Fondazione Policlinico Universitario ‘A. Gemelli’/IRCCS, Rome, Italy.

Background: Among Janus kinase inhibitors (JAKI) approved for Rheumatoid Arthritis (RA) treatment, tofacitinib and baricitinib are considered as pan-JAKi (pJAKI) while upadacitinib and filgotinib are selective anti-JAK1 (sJAK1) drugs. To date, despite >30% of RA patients exposed to JAKI achieve DAS28-CRP remission at 12 weeks, there is still lack of predictive biomarkers of response in RA treated with distinct JAKI.

Objectives: To determine whether pre-treatment immunological and synovial tissue features can predict clinical improvement in moderate-to-severe RA treated with JAKI.

Methods: Among 174 RA patients treated with JAKI, 84 underwent peripheral blood (PB) drawing and US-guided synovial tissue (ST) biopsy. Demographic, clinical and immunological features were collected for each patient at baseline and after 12 weeks. The distribution of PB-derived B lymphocytes subsets was assessed by flow cytometry, using CD27/IgD classification. Synovitis degree assessment was determined using Krenn score (KSS) by trained pathologist, blinded to clinical characteristics.

RESULTS: Among enrolled RA patients, 82.7% was treated with pJAKI and 17.3% with sJAKI. Moreover, 35.6% of RA patients was b/ts-DMARDs naïve, 18.4% b/ts-DMARDs non-responder and 46.0% was difficult-to-treat (D2T) RA. In the whole cohort, 49.2% and 50.8% of RA patients achieved DAS28-CRP and CDAI low disease activity (LDA), respectively, after 12 weeks of JAKI treatment. Moreover, 37.7% and 5.9% of RA patients achieved DAS28-CRP and CDAI remission (REM), respectively, after 12 weeks of JAKI treatment regardless to JAKI category. Considering the immunological profile, RA patients achieving CDAI LDA were more likely rheumatoid factor (60.0%) and ACPO positive (60.5%) compared to RA patients not achieving this outcome (RF: 40.0%, p= 0.03 and ACPO: 39.5%, p= 0.02). Considering PB-derived B cell phenotype, b/ts-DMARDs naïve RA achieving DAS28-CRP LDA at 12 week had pre-treatment lower unwrapped memory B (IgDposCD27neg) cell rate (6.91±7.70%) compared to b/ts-DMARDs naïve RA not achieving the same outcome (13.2±5.68%, p= 0.009). ROC analysis identified a cut-off value of 6.89% for IgDposCD27neg cells discriminating b/ts-DMARDs naïve RA achieving DAS28-CRP LDA at 12 week [AUC: 0.174±0.086; p= 0.008; OR(95%CIs): 18.20 (1.761-188.069)]. Furthermore, b/ts-DMARDs naïve RA achieving DAS28-CRP REM at 12-week follow up visit, had PB enrichment of naïve B cells (IgDposCD27neg: 68.08±17.38%) and lower percentage of unwrapped memory B lymphocytes (5.10±4.29%) compared to RA not achieving the same outcome (IgDposCD27neg: 54.68±16.16%, p= 0.05; IgDposCD27neg: 13.96±8.34%, p= 0.001) [IgDposCD27neg cut-off: 62.6%, AUC:0.727±0.101, p= 0.05; OR(95%CIs): 7.33 (1.272-42.294); IgDposCD27pos cut-off: 6.89%, AUC: 0.139±0.073, p= 0.002; OR(95%CIs): 12.37 (1.828-83.767)]. Interestingly, considering the D2T RA subgroup, patients achieving DAS28-CRP LDA at 12 week follow up had lower rates of PB-derived IgDposCD27neg B cells (3.83±0.96%) compared to RA not achieving the same outcome (7.25±2.83%, p= 0.04; cut-off: 5.46%, AUC: 0.083±0.095, p= 0.041). Considering the pre-treatment synovitis degree, b/ts-DMARDs naïve RA achieving CDAI LDA status had significantly higher KSS at baseline (3.8±2.2) compared to RA not achieving the same outcome [1.7±1.4, p= 0.02; KSS cut-off: 3.00, AUC: 0.795±0.087; p=0.018; OR(95%CIs): 14.0 (1.39-141.49)]. Finally, no significant associations were observed between PB-derived B cell subpopulations rate and synovitis degree both in the whole RA cohort as well as stratifying patients for disease phase.

Conclusion: Pre-treatment immunological profile, peripheral blood-derived B cell phenotype and synovitis degree are associated with the early achievement of at least DAS28-CRP/CDAI LDA in RA patients receiving JAKI despite their selectivity.

REFERENCES:

Disclosure of Interests: None declared


THE MCP2 AND WRIST PLUS 2 TENDORS ARE THE MOST AFFECTED AND RESPONSIVE JOINTS/TENDONS OUT OF THE ’US7 SCORE’ IN PATIENTS WITH RHEUMATOID ARTHRITIS – AN OBSERVATIONAL STUDY

A. F. Podewski1, A. M. Glimm1, I. Fischer1, G. Brün1, P. Hanov1, H. B. Hammer1, A. B. Ag1, E. A. Haavardshol1, S. Ramiro6, G. R. Burmester1, M. Backhaus1, S. Ohrndorf1 on behalf of AG Ohrndorf - Imaging (Development and Evaluation of Imaging Approaches in Rheumatic Diseases).

1Charité Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 2Universitätsklinikum Leipzig, Department of Endocrinology, Nephrology, Rheumatology, Leipzig, Germany; 3Biostatistics Tubingen, Biostatistics, Tubingen, Germany; 4MC Groep Hospitals, Department of Rheumatology, Lelystad, Netherlands; 5First Faculty of Medicine, Department of Rheumatology, Prague, Czech Republic; 6Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway; 7University of Oslo, Faculty of Medicine, Oslo, Netherlands; 8Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 9Zuyderland Medical Center, Department of Rheumatology, Heerlen, Netherlands; 10Park-Klinik Weilbensee, Department of Internal Medicine - Rheumatology and Clinical Immunology, Berlin, Germany

Background: There is no international consensus on an optimal ultrasound scoring system in patients with rheumatoid arthritis (RA) yet.

Objectives: To assess the musculoskeletal ultrasound score on seven joints (‘US7 score’) (1) for the identification of the most frequently pathologic and
responsive joint regions during 3 and 6 months of therapy in order to optimize the score. Furthermore, to evaluate the impact of disease duration on the performance of the score.

Methods: RA patients were recruited from 54 German rheumatology centers when starting or changing DMARD therapy. Patients were assessed by the US7 score in grayscale (GS) and power Doppler (PD) at baseline, after 3 and 6 months. The frequency of pathologic joint/tendon regions and their responsiveness to therapy were assessed including the comparison of palmar vs. dorsal regions.

Differences between the palmar and the dorsal sides were analyzed using Chi-square test, the gradings of the US-joint inflammation were compared between baseline, 3 months, and 6 months by Friedman test with Dunn test as post-hoc test.

We used standard response mean to determine the responsiveness of possible reduced scores and linear regression to assess the amount of information retained from the original score. Analyses were also performed separately for early and established RA.

Results: A total of 435 patients (n=138 early RA) were included (56.5 (SD 13.1) years old, 8.2 (9.1) years disease duration, 80% female). The wrist, palmar MCP2, extensor digitorum communis (EDC) and carpi ulnaris (ECU) tendons out of 7 joints were most frequently affected by GS/PD synovitis/tendonovitis (wrist: 45%/43%; MCP2: 35%/28%; EDC: 30%/11% and ECU: 25%/11%) and significantly changed within 6 months of therapy (all p≤0.003 in GS/PD).

The dorsal vs. palmar side of the wrist by GS/PD (p<0.001) and the palmar vs. dorsal side of the finger joints by PD (p<0.001) were more frequently pathologic. The reduced US7 score (GS and PD: dorsal MCP2, dorsal wrist, EDC and ECU, only GS: palmar MCP2) showed therapy response (SRM 0.433) after 6 months and retained 76% of the information of the full US7 score. No major differences between the groups of early and established RA could be detected.

Conclusion: The wrist, MCP2, EDC and ECU tendons were most frequently pathologic and responsive to therapy, representing an optimized score for monitoring of RA patients for both early and established RA and should therefore be included in comprehensive scores for monitoring RA patients.

REFERENCES:

Acknowledgements: We thank Gabriella Schmittat for logistic support in the study.

Disclosure of Interests: Annika Franziska Podewski: None declared, Anne-Marie Glimm: None declared, Imma Fischer: None declared, George Bryum: None declared, Petra Hanova: None declared, Hilde Berner Hammer: Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer and UCB, Espen A for AbbVie, Anna-Birgitte Aga: Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer bureau: Paid speaker for Lilly, Novartis and AbbVie, Employee of: Advisory board declared, Petra Hanova: None declared, Hilde Berner Hammer: Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer and UCB, Esper A Haavardsholm: None declared, Sofia Ramiro: Speakers bureau: AbbVie, Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer and UCB, Cespen A Haavardsholm: None declared, Sofia Ramiro Speakers bureau: AbbVie, Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, Sanofi, Consultant/research support from: AbbVie, Galapagos, Novartis, Pfizer, UCB, Gerd Rödiger Burmester: None declared, Marina Backhaus Speakers bureau: Speaker fee from AbbVie, BMS, Galapagos, UCB, Novartis, Sarah Ohrndorf: None declared.


ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIES

R. Alten, C. Rauch2, M. Chartier1, M.T. Nurmohamed1, S. Connolly, M. H. Buch2, P. Peichl4, X. Mariette1, Y. Patel16, S. Marsal1, R. Caporali12,13, H. Griffiths7, R. Sanmarti15, B. Bannert16, Y. Elbe27, K. Lozenz18,19, 1Schlosspark-Klinik, University Medicine Berlin, Department of Internal Medicine, Rheumatology, Berlin, Germany; 2Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany; 3Bristol Myers Squibb, MESP France – Market Access, Rueil-Malmaison, France; 4ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands; 5Bristol Myers Squibb, Global Drug Development, Princeton, United States of America; 6University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 7University of Manchester, Division of Musculoskeletal & Dermatological Sciences, Manchester, United Kingdom; 8Evangelical Hospital, Department of Internal Medicine, Vienna, Austria; 9Université Paris-Scalay, AP-HP Hospital Bicêtre, INSERM UMR1184, Department of Rheumatology, Le Kremlin Bicêtre, France; 10Hull Royal Infirmary, Rheumatology, Hull, United Kingdom; 11Hospital Universitari Vall d’Hebron, Rheumatology, Barcelona, Spain; 12University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 13G. Pini Hospital, Clinical Rheumatology Unit, Milan, Italy; 14University Hospital Geelong, Barwon Rheumatology Service, Geelong, Australia; 15Hospital Clinico de Barcelona, Rheumatology Department, Barcelona, Spain; 16Universitätsspital Basel, Rheumatologische Universitätsklinik, Basel, Switzerland; 17Significance, Biostatistics, Paris, France; 18Bristol Myers Squibb, Immunology and Fibrosis, Princeton, United States of America

Background: The goal of treatment for RA is achieving low disease activity and/or remission1–3; however, disease course and management can be complicated by additional factors that may be influenced by serostatus. Anti-citrullinated protein antibodies (ACPAs) and RF contribute to a more severe RA disease pattern4 and may be useful in predicting response to treatment.4 ACTION (AbataCept T In OutNe clinical practice; NCT02109666) and ASCORE (Abatacept SubCutaneous in Routine Clinical Practice; NCT02090556) were 2-year, international, observational, prospective, multicenter studies of IV and SC abatacept, respectively, for the treatment of RA in routine clinical practice.5,6 Previous analyses have shown that ACPA/RF double-positive serostatus was associated with better treatment outcomes compared with ACPA/RF double-negative serostatus.4,6

Objectives: To assess the independent effect of ACPA or RF single seropositivity among patients with RA on achieving remission after treatment with abatacept for 2 years, and to compare outcomes among patients with single versus double serostatus.

Methods: This post hoc analysis included patients from ACTION and ASCORE who were initiated IV (body weight-adjusted dosing) or SC abatacept (125mg once weekly), respectively. Patients were stratified by baseline ACPA/RF status: ACPA+/RF− (ACPA+ only), ACPA−/RF+ double positive (+/+), ACPA−/RF− (RF+ only), and ACPA−/RF− double negative (−/−). DAS28 (CRP) and CDAI remission rates (defined as ≤2.6 and 0–2.8, respectively) at 2 years for patients who were ACPA+ or RF+ only at baseline were assessed and compared with those who were +/+ and −/−. Patients with missing baseline ACPA/RF status were excluded. Last observation carried forward efficacy analyses were used to impute missing values.

Results: This analysis included 1679 patients from ACTION (ACPA+ only, n = 98; +/+ or −/−, n = 1028; RF+ only, n = 161; and −/−, n = 392) and 1748 patients from ASCORE (ACPA+ only, n = 184; +/+ or −/−, n = 1079; RF+ only, n = 142; and −/−, n = 343). Across studies and serogroups, baseline demographics and disease characteristics were similar (data not shown). In both ACTION and ASCORE, a higher proportion of patients who were only ACPA+ achieved DAS28 (CRP) and CDAI remission at 2 years compared with patients who were +/+. In contrast, a lower proportion of patients who were only RF+ achieved DAS28 (CRP) and CDAI remission at 2 years compared with patients who were +/+ (Figure 1). Additionally, a similar proportion of patients who were only ACPA+ achieved DAS28 (CRP) and CDAI remission at 2 years compared with patients who were −/−. In contrast, a lower proportion of patients who were only RF+ achieved DAS28 (CRP) and CDAI remission at 2 years compared with patients who were +/+.

Conclusion: In this post hoc analysis of real-world data from ACTION and ASCORE, ACPA positivity was associated with an increased likelihood of achieving DAS28 (CRP) and CDAI remission at 2 years. Patients who were ACPA+ only were as likely to achieve remission as +/+ patients, suggesting that RF serostatus had less influence than ACPA serostatus on remission status at 2 years. In line with this, patients who were RF+ only were less likely to achieve remission at 2 years. This is the first large, real-world study to show that ACPA positivity plays a more important role than RF positivity in achieving remission whilst on abatacept. These results highlight the importance of assessing baseline ACPA status when considering treatment options for patients with RA.

REFERENCES:
A. Brkic 1,2, K. Łosi 1,3, A. H. Prripp 1,4, M. Korkosz 3,5, G. Haugeberg 1,2.

Background: A recent meta-analysis by Ferreira et al. (2020) has questioned the validity of using Patient Global Assessment (PGA) to define remission in the Boolean remission criteria (4-variable remission, 4vR) [1]. This is because PGA, which presumptively reflects a patient’s perception of disease activity, is influenced by both inflammatory and non-inflammatory mechanisms, thus questioning the validity of PGA-related remission definitions when treating patients to target using anti-inflammatory drugs. Further, the impact of PGA differs in the various definitions and algorithms developed to define remission in rheumatoid arthritis (RA).

Objectives: This study aims to examine remission rates by applying different definitions of remission in an outpatient cohort of RA patients and illuminate the impact of PGA on Boolean remission.

Methods: Data were obtained during 2019 from RA patients followed at an outpatient clinic in Southern Norway. The composite disease activity scores simple disease activity index (SDAI), clinical disease activity index (CDAI), and disease activity score with 28 joint count with C-reactive peptide (DAS28(3) and with PGA DAS28(4)), as well as Boolean 4vR and without PGA the 3-variable remission (3vR) were used to define remission. Cut-off remission values for CDAI, SDAI, and DAS28 are ≤2.8, ≤3.2, and ≤2.6, respectively. 4vR is attained when PGA ≤10, C-reactive peptide (CRP) ≤10 mg/L, SJCD ≥8, and TJC28 ≤1, while 3vR when CRP ≤10 mg/L, TJC28 and SJCD ≤1. Remission rates for 4vR were also calculated with the PGA cut-offs of ≤20, 30, 40, 50, 60, 70, 80, 90.

Results: In Figure 1, proportion rates of remission for DAS28(3), DAS28(4), CDAI, SDAI, 3vR, and 4vR with different PGA cut-offs are presented. The proportion of remission was 73% for DAS28(3), 67% for DAS28(4), 37% for CDAI, 38% for SDAI, 23% for 4vR, 65% for 3vR. When comparing the different remissions proportion rate with various cut-offs of PGA in 4vR, SDAI and CDAI lie between a cut-off of ≤20 and ≤30, while DAS28(3), DAS28(4), and 3vR all lie beyond a cut-off of ≤90.

Conclusion: Our data highlights that there is a great variation in remission rates for the different remission definitions, with DAS28(3) having the highest (73%) and the original Boolean remission the lowest (23%) remission rate. While RA patients in DAS28 remission may still have swollen joints, RA patients with no swollen and tender joints and normal CRP may not achieve Boolean remission because of even a minor elevation of PGA above ten, which may not only reflect inflammatory mechanisms. We question the value of using remission definitions where PGA has a large impact when used in ordinary clinical practice to treat patients to remission. Further studies are warranted to illuminate which remission definitions should be used both in studies and in ordinary clinical practice when treating patients with anti-inflammatory drugs.

Is it time for a paradigm shift to focus more on objective than subjective measures reflecting disease status and disease activity when aiming for remission daily clinical practice?
POSO109 IMPACT OF EARLY AGE AT MENOPAUSE ON DISEASE OUTCOMES IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS: RESULTS FROM A LARGE OBSERVATIONAL COHORT OF KOREAN PATIENTS WITH RHEUMATOID ARTHRITIS


1Chung-Ang University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea); 2Seoul National University Bundang Hospital, Division of Rheumatology, Department of Internal Medicine, Seongnam, Korea, Rep. of (South Korea)

Background: The increased prevalence of rheumatoid arthritis (RA) in women has led to studies exploring how female reproductive factors affect disease outcomes in women RA. While a few studies have investigated how early menopause (EM) affects RA outcomes, they had relatively small sample size and have shown inconsistent results [1, 2]. Moreover, none has evaluated the association between age at menopause and longitudinal changes in validated disease activity indices or patient-reported outcomes (PROs) of RA.

Objectives: We aimed to assess the differences in clinical outcomes between RA patients with EM (age at menopause <45 years) and usual menopause (UM) (age at menopause ≥45 years), and identify potential impact of EM on longitudinal changes in RA activity and PROs during follow-up period.

Methods: A total of 2,878 postmenopausal women with RA were included from the Korean Observational Study Network for Arthritis, a nationwide prospective RA cohort of Korea. Each patient was examined at baseline and for 5 consecutive years using the simplified disease activity index (SDAI), health assessment questionnaire-disability index (HAQ-DI), and other PROs. Among patients with a baseline SDAI >11, generalized estimating equation (GEE) analyses were performed to evaluate the impact of EM on longitudinal changes in RA activity and PROs during follow-up period.

Results: The EM group (N=437) was younger than the UM group (N=2,441) [58.0±9.5 vs. 60.8±8.0 years, p<0.001], but RA duration was similar between the two groups. The EM group had higher education level and was more likely to be seronegative at enrolment. Moreover, the EM group demonstrated higher disease activity [SDAI 15.4±11.7 vs. 13.9±10.0, p=0.011] and patient-reported visual analogue scale (VAS) scores for global assessment, fatigue, and sleep disturbance (all p<0.05), and worse EQ-5D-VAS [59.9±22.2 vs. 63.0±19.5, p=0.006] at baseline. The rate of previous fracture and neoplastic disease, especially uterine/cervical neoplasm, was higher while that of hypertension was lower among the EM group. The GEE model revealed that EM significantly influenced the rate of SDAI change (β=1.265, p=0.004), after adjusting for age, RA duration, biologic use, and SDAI at baseline. The EM group was also significantly associated with increase in HAQ-DI (β=0.088, p=0.003), and decrease in EQ-5D utility value (β=-0.031, p=0.016) during 5-year follow-up period.

Conclusion: RA patients with EM demonstrate higher disease activity and poorer health-related quality of life. EM significantly affects longitudinal changes in disease activity and PROs in RA.

REFERENCES:

Table 1. Longitudinal analysis of predictors of the SDAI, HAQ-DI, and EQ-5D utility value over time using a GEE model among patients with a baseline SDAI>11.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Independent variables</th>
<th>Regression coefficient (β) (95% CI) P</th>
</tr>
</thead>
<tbody>
<tr>
<td>SDAI</td>
<td>Age</td>
<td>0.013 (-0.024-0.049)</td>
</tr>
<tr>
<td></td>
<td>RA duration</td>
<td>0.084 (0.046-0.122)</td>
</tr>
<tr>
<td></td>
<td>Baseline SDAI</td>
<td>0.580 (0.531-0.630)</td>
</tr>
<tr>
<td></td>
<td>Biologic use</td>
<td>0.196 (-0.924-1.315)</td>
</tr>
<tr>
<td></td>
<td>Early menopause</td>
<td>1.265 (0.412-2.117)</td>
</tr>
<tr>
<td></td>
<td>Follow-up time</td>
<td>-1.806 (-1.964--1.647)</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>Age</td>
<td>0.027 (0.004-0.009)</td>
</tr>
<tr>
<td></td>
<td>RA duration</td>
<td>0.011 (0.009-0.014)</td>
</tr>
<tr>
<td></td>
<td>Baseline HAQ-DI</td>
<td>0.678 (0.638-0.711)</td>
</tr>
<tr>
<td></td>
<td>Biologic use</td>
<td>0.044 (0.033-0.122)</td>
</tr>
<tr>
<td></td>
<td>Early menopause</td>
<td>0.092 (0.030-0.154)</td>
</tr>
<tr>
<td></td>
<td>Follow-up time</td>
<td>-0.004 (-0.016-0.007)</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>Age</td>
<td>0.052 (0.031-0.073)</td>
</tr>
<tr>
<td></td>
<td>RA duration</td>
<td>-0.003 (-0.004--0.002)</td>
</tr>
<tr>
<td></td>
<td>Baseline EQ-5D utility</td>
<td>0.532 (0.492-0.572)</td>
</tr>
<tr>
<td></td>
<td>Value</td>
<td>0.021 (0.002-0.040)</td>
</tr>
<tr>
<td></td>
<td>Early menopause</td>
<td>-0.033 (-0.059--0.006)</td>
</tr>
<tr>
<td></td>
<td>Follow-up time</td>
<td>0.010 (0.005-0.015)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

in pts in NA vs RoW (Figure 1). Incidence and risk of MACE were higher with tofacitinib vs TNFi in both NA and RoW (Figure 1). In NA, MACE IRs were higher for tofacitinib 5 mg BID vs TNFi in pts with a HxCAD, and tofacitinib 10 mg BID vs TNFi for pts with a high 10-yr risk of MACE; pts with low or borderline 10-yr MACE risk had no MACE across tofacitinib groups (Figure 1). Compared with NA, similar trends for MACE were generally observed across treatments in RoW, particularly for intermediate, borderline and low CV risk categories (Figure 1).

### Table 1. Percentages of pts in NA and RoW with a HxCAD and pts without a HxCAD categorised by 10-yr risk of MACE, per ASCVD-pooled cohorts equation risk calculator with a 1.5 multiplier applied

<table>
<thead>
<tr>
<th>NA</th>
<th>RoW</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tofacitinib</strong></td>
<td><strong>Tofacitinib</strong></td>
</tr>
<tr>
<td>5 mg BID</td>
<td>10 mg BID</td>
</tr>
<tr>
<td>(N=402)</td>
<td>(N=409)</td>
</tr>
<tr>
<td>HxCAD, n (%)</td>
<td>HxCAD, n (%)</td>
</tr>
<tr>
<td>Low (&lt;5%)</td>
<td>60 (14.9)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>131 (32.6)</td>
</tr>
<tr>
<td>Borderline</td>
<td>49 (12.2)</td>
</tr>
<tr>
<td>High (≥20%)</td>
<td>97 (24.1)</td>
</tr>
<tr>
<td>(≥7.5–&lt;20%)</td>
<td>131 (32.6)</td>
</tr>
<tr>
<td>(≥5–&lt;7.5%)</td>
<td>60 (14.9)</td>
</tr>
<tr>
<td>Low (&lt;5%)</td>
<td>7 (1.7)</td>
</tr>
</tbody>
</table>

### HxCAD was defined as any history of MI, coronary heart disease, stable angina pectoris or

### Missing data 7 (1.7) 8 (2.0) 5 (1.2) 10 (0.9) 11 (1.1) 11 (1.1)

### Low (<5%) 60 (14.9) 54 (13.2) 65 (15.0) 253 (24.0) 218 (20.8) 250

### Tofacitinib 5 mg BID 10 mg BID (N=402) 10 mg BID (N=1019)

### TNFi 5 mg BID 10 mg BID (N=409) 10 mg BID (N=1053)

### HxCAD, n (%)

### No HxCAD: 10-yr risk of MACE, n (%)

### High (≥20%)

### Intermediate (≥7.5–<20%)

### Borderline (≥5–<7.5%)

### Low (<5%)

### Missing data 7 (1.7) 8 (2.0) 5 (1.2) 10 (0.9) 11 (1.1) 11 (1.1)

### HxCAD was defined as any history of MI, coronary heart disease, stable angina pectoris or coronary artery procedures.

### United States, Puerto Rico and Canada.

### For pts randomised to TNFi group, adalimumab and etanercept were administered in NA and RoW, respectively.

### In NA, MACE IRs were higher for tofacitinib 5 mg BID vs TNFi in pts with a HxCAD, and tofacitinib 10 mg BID vs TNFi for pts with a high 10-yr risk of MACE; pts with low or borderline 10-yr MACE risk had no MACE across tofacitinib groups (Figure 1). Compared with NA, similar trends for MACE were generally observed across treatments in RoW, particularly for intermediate, borderline and low CV risk categories (Figure 1).

### Conclusion: This post hoc analysis of data from ORAL Surveillance suggests that differences in MACE IRs across geographic regions are largely driven by HxCAD and high BL CV risk scores in NA vs RoW. Results should be interpreted with caution due to low pt and event numbers, particularly restricting the evaluation of tofacitinib vs TNFi in NA and RoW. Noting this limitation, these findings emphasise the importance of assessing and addressing BL CV risk when treat-

### Allergy, Hamilton, Canada; 11Catholic University of the Sacred Heart, Rome, Italy; 12Park-Klinik Weissee,

### REFERENCES:


### Acknowledgements:

Studied sponsored by Pfizer Inc. Medical writing support was provided by Tanya Guha, CMC Connect, and funded by Pfizer Inc.

### Disclosure of Interests:


### Disclosure of Interests:


### Rheumatology, T oronto, Canada; 2Department of Rheumatology, Heerlen, the Netherlands; 3Amsterdam Rheumatology Center, Department of Rheumatology, Amsterdam, Netherlands; 4Novo Medical School, Department of Rheumatology, Lisbon, Portugal; 5Conway Institute for Biomolecular Research, School of Medicine, University College Dublin, Dublin, Department of Rheumatology, Dublin, Ireland; 6Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup and Department of Clinical Medicine, University of Copenhagen, Department of Rheumatology, Copenhagen, Denmark; 7University of Alberta, Department of Rheumatology, Alberta, Canada; 8Tel Aviv Sourasky Medical Center and the “Sackler” Faculty of Medicine, Tel Aviv University, Department of Rheumatology, Tel Aviv, Israel; 9Southlake Regional Health Centre, University of Toronto, Department of Rheumatology, Toronto, Canada; 10McMaster University, Departments of Medicine and Pediatrics, Divisions of Rheumatology, Clinical Immunology and Allergy, Hamilton, Canada; 11Catholic University of the Sacred Heart, Department of Rheumatology, Rome, Italy; 12Park-Klinik Weissee,

### Science Abstracts
Background: A Treat-to-Target approach (T2T) is broadly considered to lead to better clinical outcomes and recommended in patients with RA. However, very few studies have analyzed the effect of T2T on radiographic progression, and any such studies have provided inconsistent results.

Objectives: To investigate whether meticulously following a treat-to-target (T2T)-strategy in daily clinical practice leads to lower radiographic progression in RA.

Methods: Patients from the multicenter RA-BIODAM cohort with ≥2 consecutive visits with radiographs available were included. In RA-BIODAM patients were enrolled as they were initiating a new csDMARD/dMARD treatment were followed-up with the intention to benchmark and intensify treatment. The primary outcome of this analysis was the change in Sharp-van der Heijde score (SvdH, 0-448), assessed every 6 months, using average scores from 2 readers (scores with known chronological order). Following a DAS44-T2T remission strategy, which was defined at each 3-month visit, was the main variable of interest. Patients were categorized based on the proportion of visits in which T2T was followed according to our definition: very low (≤40% of the visits, low (>40%, <62.5%), high (≥62.5%, ≤75%) and very high (>75%). Radiographic progression at 2 years was visualized across groups by cumulative probability plots. Per 3-month interval T2T could be followed zero, one or two times (in a total of 2 visits). Associations between the number of visits with T2T in an interval and radiographic progression, both in the same and in the subsequent 6-month interval, were analysed by generalised estimating equations, adjusted for age, gender, disease duration and country.

Results: In total, 511 patients were included (mean (SD) age: 56 (13) years; 76% female). After 2 years, patients showed on average 2.2 (4.1) units progression (median:1 unit). Mean (SD) 2-year progression was not significantly different across categories of T2T: very low: 2.1 (2.7) units; low: 2.8 (6.0); high: 2.4 (4.5); very high: 16 (2.2) (Figure 1). Meticulously following-up T2T in a 3-month interval neither reduced progression in the same 6-month interval (parameter estimates (for yes vs no): +0.15 units (95%CI: -0.04 to 0.33) for 2 vs 0 visits; and +0.08 units (-0.06;0.22) for 1 vs 0 visits) nor did it reduce progression in the subsequent 6-month interval (Table 1).

Table 1. Effect of following DAS44-remission-T2T strategy on 6-month radiographic progression over 2 years

<table>
<thead>
<tr>
<th>T2T during 3 months on radiographic progression</th>
<th>Change in radiographic damage (regression coefficient (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>in the same 6-month period</td>
<td>N=506</td>
</tr>
<tr>
<td>2 visits vs 0 followed</td>
<td>0.15 (-0.04; 0.33)</td>
</tr>
<tr>
<td>1 visit vs 0 followed</td>
<td>0.08 (0.06; 0.22)</td>
</tr>
<tr>
<td>T2T during 3 months on radiographic progression</td>
<td></td>
</tr>
<tr>
<td>in the subsequent 6-month period</td>
<td></td>
</tr>
<tr>
<td>2 visits vs 0 followed</td>
<td>-0.09 (-0.28; 0.10)</td>
</tr>
<tr>
<td>1 visit vs 0 followed</td>
<td>-0.10 (-0.24; 0.05)</td>
</tr>
</tbody>
</table>

Conclusion: In this daily practice cohort, more meticulously following T2T principles did not result in more reduction of radiographic progression than a somewhat more liberal attitude toward T2T. One possible interpretation of these results is that the intention to apply T2T already suffices and that a more stringent approach does not further improve outcome.

Acknowledgements: BIODAM was financially supported by an unrestricted grant from AbbVie.
Background: Flares are an inherent part of the rheumatoid arthritis (RA) disease course and may impact clinical and patient outcomes. The ability to predict flares between clinic visits based on real-time longitudinal patient-generated data could potentially allow for timely interventions to avoid disease worsening. For intensively-collected patient-generated data, machine learning methods offer benefits over traditional statistical tools for accurate prediction, but examples in rheumatology are sparse.

Objectives: Investigate the feasibility of using machine learning methods to classify self-reported RA flares based on a small dataset of daily symptom data generated on a smartphone app.

Methods: We used data from the Remote Monitoring of Rheumatoid Arthritis (REROMA) study, which aimed to improve monitoring of disease severity in RA. Patients tracked daily symptoms (pain, fatigue, function, sleep, coping, physical and emotional wellbeing) on a 0-10 numerical rating scale, duration of morning stiffness, and weekly flares on the REROMA smartphone app for three months. The outcome was the binary yes/no answer to the weekly flare question “Have you experienced a flare in the last week?” Several summaries of the eight daily symptom scores collected in the week leading up to the flare question (the exposure period) were used as predictors. These included the mean, min, max, standard deviation and slope. Where exposure periods overlapped, the intersecting symptom reports were allowed to correspond to multiple outcomes. We fitted three binary classifiers: logistic regression +/- elastic net regularization, a random forest and naïve Bayes. The models were benchmarked using the R package mlr3 and 10-fold cross-validation, with two participants comprising the test and the remaining 18 the training set.

Finally, the performance of the classifiers was evaluated according to the area under the curve (AUC) of the receiver operating characteristic curve. The model with the highest AUC in the test dataset was considered as the best final model.

Results: Twenty patients tracked daily symptoms over three months. 60% were female, all but one were white British, and mean age was 56.9±11.1 years. The median number of days in the study was 81 (interquartile range (IQR) 80, 82). The collected data comprised an average of 69.6 daily reports and 10.5 weekly reports per participant over the study period. Participants reported a median of 2 flares (IQR 0.75-4.25) resulting in 57 flares in total. Classifier performances are visualized in Figure 1. The best performing model was logistic regression with elastic net with an AUC of 0.82. At a cut-off point requiring specificity to be 0.80, the corresponding sensitivity to detect flares was 0.60 for this model, meaning that the prediction model correctly identified three in every five self-reported flares, and four in every five non-flares. At this cut-off, the positive predictive value, i.e. the probability that those with a predicted flare indeed go on to have a flare was 53%. The negative predictive value, i.e. the probability that those with a predicted non-flare indeed do not experience a flare, was 85%.

Conclusion: Predicting self-reported flares based on daily symptom scorings in the preceding week using machine learning methods was feasible, although regularized logistic regression outperformed the other machine learning methods in this small dataset. The perceived advantage of machine learning may therefore be attributed to overfitting. It is possible that the observed predictive accuracy will improve as we obtain more data.

Disclosure of Interests: Julie Gandrup: None declared, David A Selby: None declared, William Dixon Consultant of: Received consultancy fees from Abbvie and Google


Figure 1. Performance of binary flare classifiers fitted to data from the REMORA study: Logistic regression with and without regularization, naïve Bayes and random forest.
time \((F(4,141) = 0.712, p=0.585)\). Figure 1 shows the estimated trajectories of DSAS2-ESR scores over 12 months time for the three health literacy groups. Patients with “several health literacy limitations” were prescribed prednisolone significantly more often (52.4%) than patients with “some health literacy limitations” (21.2%) or “good health literacy” (22.2%) over time \((p=0.019)\). Patients with “some health literacy limitations” were prescribed conventional DMARDs more often (72.7%) than patients with “good health literacy” (38.9%; \(p=0.008\)) There was no difference in biological DMARDs use between the health literacy groups.

**Conclusion:** We found that among patients with RA, those with several health literacy limitations have higher disease activity scores over time and use prednisolone significantly more often than patients with higher health literacy levels. No difference was observed in biological DMARD use. These results grant more insight into the role of health literacy for treatment and outcomes in patients with RA and supports existing research in other chronic diseases.

**REFERENCES:**


**Disclosure of Interests:** None declared


**Systemic lupus erythematosus, Sjogren’s syndrome and anti-phospholipid syndrome**

**POS0114**

**COMPUTATIONAL IDENTIFICATION OF SLE PATIENT RECORDS USING DATA-DRIVEN CLINICAL FINGERPRINTS**

M. Barbero Mota, J. L. Gamboa, J. M. Still, C. M. Stein, V. K. Kawai, T. A. Lasko. Vanderbilt University Medical Center, Department of Biomedical Informatics, Nashville, TN, United States of America; Vanderbilt University Medical Center, Department of Medicine, Nashville, TN, United States of America

**Background:** Systemic lupus erythematosus (SLE) is a chronic relapsing autoimmune disorder that is challenging to diagnose due to its heterogeneous presentation of a combination of non-specific clinical manifestations and laboratory findings. This heterogeneity and lack of granularity is a major cause of treatment failure. With the advent of precision medicine, there is a need for accurate methods to identify cases of SLE in large clinical databases, and to recognize constellations of pathological characteristics (or fingerprints) that allow a better understanding of the disease. Computational phenotype discovery aims to solve this problem by using unbiased, data-driven machine learning methods to disentangle the fingerprints of disease that hide within the noisy, sparse and incomplete electronic health record data.

**Objectives:** To generate data-driven phenotypic fingerprints of SLE and validate them by assessing their ability to distinguish records of patients with SLE vs. ‘near miss’ patients without the disease.

**Methods:** Records of 716 patients that published, expert-curated algorithms [1] indicated as likely SLE patients were reviewed by 3 clinicians and labeled as positive (490 records), negative (261), or indeterminate (55). Those labeled positive by an algorithm but negative by clinician chart review were considered ‘near misses’ and should be among the more difficult cases to classify. We trained an ElasticNet (regularized logistic regression) model to distinguish the true positive records from the near misses and evaluated it under 10x cross validation.

Inputs to the predictive model were the projections of each patient record into the space of 2000 latent variables. These features had been inferred separately by an unsupervised machine-learning algorithm from a much larger dataset of 646,716 randomly sampled temporal cross sections of 63,775 longitudinal records of patients with an antinuclear antibody test. Each of the 2000 variables constitutes the phenotypic fingerprint of an unobserved, independent potential disease mechanism. Formally, they represent linear combinations of demographic data, laboratory test results, billing code intensities, and medication exposures [2].

**Results:** Our predictive model achieved an area under the Receiver Operating Characteristic Curve of 0.90, 95% CI: [0.879, 0.922], an area under the Precision-Recall Curve of 0.94, 95% CI: [0.926, 0.954], and an Integrated Calibration Index of 0.074, 95% CI: [0.067, 0.080]. The model selected 61 of the 2000 potential latent mechanisms to distinguish positive SLE records from near-misses. All of the phenotypes selected to be predictive exhibit high face-validity from a clinical interpretation perspective. They include recognizable patterns of variables representing different clinical features of SLE (Figure 1).

**Source Fingerprint S-1497**

**POS0115**

**SERUM PROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 (PCSK9) AND CARDIOVASCULAR RISK IN SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL COHORT STUDY**

C. C. Mok, K. L. Chan, L. Y. Ho, S. M. Tse, C. H. To. Pok Oi Hospital, Medicine, Hong Kong, China; 2Kau Oi Hospital, Medicine, Hong Kong, China

**Objectives:** To study the effect of serum PCSK9 on major cardiovascular adverse events (MACEs) in Chinese patients with systemic lupus erythematosus (SLE),

**Methods:** Consecutive patients who fulfilled ACR 1997 criteria for SLE and consented for a biomarker study between 2009 and 2012 were included. Stored serum samples from these patients were assayed for the levels of PCSK9 using a commercial ELISA kit (OKBB00903, Lot# 1344, Aviva Systems Biology, San Diego, US). New MACEs (acute coronary syndrome, ischemic stroke, peripheral vascular disease) documented by imaging and angiographic studies over time was evaluated. Patients were stratified into high/low PCSK9 groups according to the best cut-off level by ROC analysis for the prediction of these events. The cumulative incidence of new MACEs and mortality over time was studied by Kaplan-Meier's analysis and compared between the high and low PCSK9 subgroups. Cox regression was performed to study the effect of the PCSK9 subgroups on new MACEs and mortality, adjusted for other confounding factors.

**Results:** 539 SLE patients were studied (93% women, age 41.9±14.0 years; disease duration 106±90.4 months at entry). The mean PCSK level at baseline was 539 SLE patients were studied (93% women, age 41.9±14.0 years; disease duration 106±90.4 months at entry). The mean PCSK level at baseline was
PLASMA AND CEREBROSPINAL FLUID NEUROFILAMENT LIGHT CONCENTRATIONS REFLECT NEURONAL DAMAGE IN SYSTEMIC LUPUS ERYSHEMATOSUS

K. Zervides,1,2 S. Janelidze,2 J. Nystedt5, B. Gullstrand1, P. Nilsson5, P. Sundgren4,1, A. Bengtsson6, O. Hansson7, A. Jonsen1, Lund University, Skåne University Hospital, Department of Clinical Sciences, Rheumatology, Lund, Sweden; 2Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 3Lund University, Clinical Memory Research Unit, Department of Clinical Sciences, Neurology, Lund, Sweden; 4Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 5Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 6Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 7Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 8Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden; 9Lund University, Skåne University Hospital, Memory Clinic, Malmö, Sweden; 10Lund University, Skåne University Hospital, Memory Clinic, Malmö, Sweden

Background: Neuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear [1-2]. Neurofilament light (NFL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal damage and reach abnormal levels in various neurological disorders [3]. NFL is sparsely studied in SLE [4-7].

Objectives: To explore plasma and CSF concentrations of NFL in SLE patients and investigate the associations between NFL and nervous system involvement, including cognitive dysfunction, imaging findings on magnetic resonance imaging (MRI), laboratory and clinical abnormalities, and to compare the NFL levels of SLE patients with those present in healthy controls.

Methods: In this cross-sectional study, 72 consecutive SLE out-patients and 26 healthy controls, all female, aged <55 years, underwent MRI and neurocognitive testing. NFL concentrations in plasma from all individuals and in CSF from 32 patients were measured with single-molecule array technology. Patients were assessed by a rheumatologist and neurologist to define neuropsychiatric involvement of lupus erythematosus (NPSLE) according to three attribution models.

Results: Plasma and CSF NFL concentrations correlated strongly (r=0.72, p<0.001). Plasma NFL concentrations were higher in SLE patients, both with and without neuropsychiatric involvement, compared with healthy controls (Figure 1A-D). Plasma and CSF NFL concentrations did not differ between NPSLE and non-NPSLE patients (Figure 1B-D). Larger white matter lesion volumes correlated with higher CSF NFL concentrations in patients aged 18-30 (r=0.80, p=0.005). Higher plasma NFL concentrations correlated with lower simple attention scores (r=-0.42, p=0.007), and were associated with dysfunction of psychomotor speed (p=0.012) and verbal memory (p=0.024). SLICC/ACR-Damage Index ≥1 was independently associated with higher plasma NFL concentrations when adjusting for age, SLE Disease Activity Index-2000 ≥1, low complement C3 levels, a history of renal involvement or anti-dsDNA, and ongoing treatment (β=0.080, 95% CI 0.009-0.15, p=0.028).

Conclusion: Higher plasma NFL concentrations in NPSLE and non-NPSLE patients may indicate a higher degree of neuronal damage in SLE in general, particularly in the lower age group, corresponding with cognitive impairment and organ damage development. NFL may serve as an indicator of neuronal damage in SLE in further studies.

REFERENCES:
The study included 106 patients, 93 women, 13 men) with a median age of 48 (41-58) and a median SLE duration 227 months (124-330). At the last evaluation median SLEDAI was 0 (0-2) and median SLICC was 1 (0-1). According to Zen definitions of remission, 51 patients (48%) and 20 (19%) also fulfilled the criteria of clinical remission off corticosteroids and complete remission respectively. Nevertheless, in 24 patients (22.7%) [PGA-PHA], 25 patients. Patients in the discordant group were older (median 58 years, IQR 49-62 vs 46, IQR 39-57; p=0.0043) and less frequently achieved the definition of clinical remission off corticosteroids (n=4, 16.7% vs n=24, 57.3%; p=0.001; OP6,7; CI95% 2.1-21) than concordant. No differences were found in gender, SLE duration, serology, disease activity or damage and other treatment. Data about differences in PROs between two groups are reported in Table 1: discordant patients had a worse performance in all the PROs included. At multivariate analysis SF-36 Physical Component Summary (PCS) resulted associated with PGA-PHA, p=0.0001).

Table 1. Data are expressed as median and interquartile range (IQR) and compared using Mann-Whitney test.

<table>
<thead>
<tr>
<th>Group</th>
<th>Median (IQR)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGA-PHA &lt;25</td>
<td>TOTAL</td>
<td>CONCORDANT</td>
</tr>
<tr>
<td>PGA-PHA ≥25</td>
<td>N=106 (%)</td>
<td>N=82 (%)</td>
</tr>
<tr>
<td>VAS-pain [0-100]</td>
<td>10 (0-30)</td>
<td>10 (0-20)</td>
</tr>
<tr>
<td>SF-36 Physical</td>
<td>50 (37.5-53)</td>
<td>51 (44-54)</td>
</tr>
<tr>
<td>SF-36 Mental</td>
<td>48 (38-55)</td>
<td>51 (40-55)</td>
</tr>
<tr>
<td>SF-36 Component</td>
<td>Summary (PCS)</td>
<td>STAI-Y1 [20-60]</td>
</tr>
<tr>
<td>DISCORDANT</td>
<td>TOTAL</td>
<td>N=82 (%)</td>
</tr>
</tbody>
</table>

Conclusion: In our study we found that, even in patients considered in remission, in more than 20% of patients there is a considerable discordance between the global disease assessment reported by patients and their physicians. Patients that had a higher PGA also presented worse score at PROs. Our data seems to confirm that potential causes for discordance could be more related to the presence of non-inflammatory processes, depression, or anxiety than clinical manifestations or damage related to SLE.

REFERENCES:

Disclosure of Interests: None declared
SLE-DAS for Patient Reported Outcomes, namely health-related quality of life (HR-QoL) and fatigue needs to be assessed.

**Objectives:** To evaluate if the attainment of SLE-DAS remission and LDA states is associated with improvements in HR-QoL and fatigue.

**Methods:** Post-hoc analysis of the merged study population in the BLISS-52 and -76 trials (NCT00424476; NCT00410384) of intravenous belimumab versus placebo for moderate to severe SLE disease activity. We analysed the Functional Assessment of Chronic Illness Therapy (FACIT) and 36-Item Short Form Survey (SF-36) trial data. Fulfilment of SLE-DAS remission (defined as absence of all SLE-DAS clinical items and prednisone ≤5mg/day) and LDA (defined as SLE-DAS≤2.48 and prednisone ≤5mg/day) definitions were retrospectively assessed from the individual participants' data. Mean changes from study baseline to week 52 in FACIT and SF-36 physical component summary (PCS) and mental component summary (MCS) and domain scores were compared between patients attaining at week 52 the SLE-DAS remission vs non-remission and the SLE-DAS LDA vs non-LDA using multivariate regression analysis adjusted for baseline scores.

**Results:** A total of 1684 SLE patients were included. Few patients were in SLE-DAS remission (0.5%) and LDA (0.8%) at study entry. At week 52, 12.5% patients attained SLE-DAS remission and 17.5% attained SLE-DAS LDA. Mean improvements in SF-36 PCS and MCS scores were greater in patients that attained SLE-DAS remission vs non-remission (5.4 vs 3.4, and 4.6 vs 2.7, respectively; multivariate p<0.005 for both) and SLE-DAS LDA vs non-LDA (5.0 vs 3.4 and 4.6 vs 2.6, respectively; multivariate p<0.005 for both), at week 52 (Figure 1). Similarly, improvements in all individual domain scores were greater in SLE-DAS remission vs non-remission patients (all multivariate p<0.005) and SLE-DAS LDA vs non-LDA patients (all multivariate p<0.005) (Figure 1). Importantly, improvements in the summary scores and in all the individual domain scores largely exceeded the minimum clinically important differences (MCIDs) of 2.5 and 5 points, respectively, in those patients attaining SLE-DAS remission or LDA.

**Conclusion:** Attainment of SLE-DAS remission and LDA is associated with meaningful improvement in HR-QoL and fatigue.

**REFERENCES:**

**Acknowledgements:** The authors would like to thank GlaxoSmithKline (Uxbridge, UK) for granting access to the data from the BLISS-52 and 76 trials through the Clinical Study Data Request consortium.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3634

---

**NEUROLOGICAL INVOLVEMENT IN A MONOCENTRIC COHORT OF PATIENTS WITH SERONEGATIVE ANTIPHOSPHOLIPID SYNDROME**

L. Rapino1, S. Truglia1, S. Mancuso2, M. De Michele2, D. Tonì2, I. Bertò2, M. Soricè2, R. Missiù2, A. Capozzi2, C. Alessandri2, F. Contì2, [1] La Sapienza Università di Roma - Policlinico Umberto I, Medicina Interna e Specialità Mediche - Reumatologia, Roma, Italy; [2] La Sapienza Università di Roma - Policlinico Umberto I, Emergenza e Accettazione - Unità di Terapia Neurovascolare, Roma, Italy; [2] La Sapienza Università di Roma - Policlinico Umberto I, Medicina Sperimentale - Medicina Clinica e Molecolare, Rome, Italy

**Background:** The nervous system is affected in a relevant number of patients with antiphospholipid syndrome (APS), being responsible for high morbidity and mortality rates. The identification of neurological manifestations is crucial since those symptoms may benefit from anticoagulation treatment. Noteworthy, the prevalence and the characteristics of neurological manifestations in the subset of patients with “seronegative APS” (SN-APS) still need to be investigated.

**Objectives:** The aim of this study was to assess the neurological involvement in patients with SN-APS. Secondly, association between non-conventional antiphospholipid antibodies (aPL) and clinical characteristics were investigated.

**Methods:** We included all consecutive patients referred to the Lupus Clinic and to the Stroke Unit of our Hospital, presenting clinical features consistent with a diagnosis of APS despite the evidence of persistently negative tests for anti-cardiolipin antibodies (aCL), anti-β2 glycoprotein 1, and lupus anticoagulant. Patients with an identified cause of thrombosis and/or pregnancy morbidity were excluded. Patients' sera were analyzed for the detection of aCL using thin layer chromatography (TLC), while ELISA test was used to detect antibodies directed against the anti-vimentin/cardiolipin complex (aVim/CL).

**Results:** From January 2015 to October 2019, 40 patients with SN-APS and neurological involvement were enrolled. Clinical and demographic characteristics are reported in Table 1. Thirty-three patients (82.5%) resulted positive for at least one non-conventional test (62.5% positive on two occasions) while 17.5% were negative. The occurrence of aCL by TLC immunostaining was 33/40 (82.5%), while a Vim/CL were found in 10/40 (25%). Double positivity for aCL by TLC-immunostaining and aVim/CL was observed in 8/40 patients (20%). Patients who tested positive for non-conventional aPL on two occasions had a five-fold increased risk of developing venous thrombosis (LR 5.24; p=0.022). The positivity for aCL by TLC immunostaining determined an augmented risk of sinus vein thrombosis (LR 5.49; p=0.019) while positivity for aVim/CL raised the likelihood of epilepsy (LR 4.133; p=0.042). Almost all (16/18, 88%) patients with ischemic stroke resulted positive at least one test, 15 tested positive for aCL by TLC-immunostaining and 3 for aVim/CL. In this subset of patients, the positivity for non-conventional aPL on two occasions determined an increased risk of venous thrombosis (LR 8.905; p=0.0033) and recurrent stroke (LR 6.321; p=0.012). In particular, those who tested positive for aVim/CL were at higher risk of developing recurrent stroke (LR 6.659; p=0.01).

**Table 1.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients N=40 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male</td>
<td>35/5</td>
</tr>
<tr>
<td>Mean age in years (S.D.)</td>
<td>48 (12.5)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>34 (85)</td>
</tr>
<tr>
<td>Arterial</td>
<td>23 (57.5)</td>
</tr>
<tr>
<td>Venous</td>
<td>17 (42.5)</td>
</tr>
<tr>
<td>Recurrent</td>
<td>13 (32.5)</td>
</tr>
<tr>
<td>Pregnancy morbidity</td>
<td>12 (34.3)</td>
</tr>
<tr>
<td>Recurrent miscarriage</td>
<td>11 (31.4)</td>
</tr>
<tr>
<td>Foetal deaths</td>
<td>2 (5.7)</td>
</tr>
<tr>
<td>Premature births</td>
<td>2 (5.7)</td>
</tr>
<tr>
<td>Thrombosis + Pregnancy morbidity</td>
<td>6 (17.1)</td>
</tr>
<tr>
<td>Neurological manifestations Stroke</td>
<td>18 (45)</td>
</tr>
<tr>
<td>Recurrent stroke</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Venous sinus thrombosis</td>
<td>5 (12.5)</td>
</tr>
<tr>
<td>Headache</td>
<td>18 (45)</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>Transverse myelitis</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Other manifestations</td>
<td>3 (7.5)</td>
</tr>
<tr>
<td>Livedo reticularis</td>
<td>5 (12.5)</td>
</tr>
<tr>
<td>Low platelets</td>
<td>3 (7.5)</td>
</tr>
</tbody>
</table>

**Conclusion:** The nervous system is one of the most frequently affected in APS, however only few data exist about prevalence, characteristics and outcome of its involvement in SN-APS patients. In this work, using TLC immunostaining and ELISA for aVim/CL, we identified non-conventional aPL antibodies in 62.5% SN-APS patients. This subset of patients presented a wide spectrum of neurological manifestations, with frequencies and features that resemble those observed in APS patients. Furthermore, we demonstrated the association between non-conventional aPL and neurological manifestations, such as sinus vein thrombosis, recurrent stroke and epilepsy. In conclusion, testing for non-conventional aPL antibodies may contribute to the evaluation of the stratification of risk for neurological manifestations in SN-APS.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3804

---

To summarize, the study on SLE-DAS remission and LDA showed that patients achieving these states had significant improvements in HR-QoL and fatigue, with improvements in SF-36 PCS and MCS scores exceeding the minimum clinically important differences (MCIDs) of 2.5 and 5 points, respectively. The authors concluded that the attainment of SLE-DAS remission and LDA is associated with meaningful improvement in HR-QoL and fatigue.

The study on neurological involvement in SN-APS patients highlighted the significant impact of non-conventional antiphospholipid antibodies on the risk of neurological complications, including recurrent stroke and epilepsy. The authors emphasized the importance of detecting these antibodies to better understand and manage the neurological manifestations associated with SN-APS.
Background: In SLE patients, episodes of high disease activity state (HDAS, SLEDAI≥20) are associated with worse outcomes even if only experienced once. We investigated whether attainment of the lupus low disease activity state (LLDAS, SLEDAI<10) is similarly protective from damage accrual and flare in both ‘HDAS-ever’ and ‘HDAS-never/not LLDAS’BL groups (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Conditions</th>
<th>HDAS-never/not LLDAS BL</th>
<th>HDAS-ever</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with organ damage accrual</td>
<td>212 (18.8%)</td>
<td>269 (27.5%)</td>
</tr>
<tr>
<td>Patients with flare</td>
<td>394 (35.5%)</td>
<td>119 (12.5%)</td>
</tr>
<tr>
<td>≥6-months sustained LLDAS</td>
<td>688 (56.6%)</td>
<td>713 (66.4%)</td>
</tr>
<tr>
<td>≥50% cumulative time in LLDAS</td>
<td>371 (33.1%)</td>
<td>182 (16.8%)</td>
</tr>
<tr>
<td>Longitudinal associations with organ damage accrual</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flare</td>
<td>0.54 (0.41,0.71), p&lt;0.001</td>
<td>0.49 (0.36,0.67), p&lt;0.001</td>
</tr>
<tr>
<td>＞12-months sustained LLDAS</td>
<td>0.69 (0.45,1.01) , p&lt;0.001</td>
<td>0.43 (0.26,0.73), p&lt;0.001</td>
</tr>
</tbody>
</table>
| ≥12 months sustained LLDAS                     | 0.54 (0.31,0.94), p<0.03 | 0.29 (0.11,0.47), p<0.01

Conclusion: Sustained or majority LLDAS was less achievable in SLE patients after an episode of HDAS in HDAS-ever compared to HDAS-never patients, but protective associations of LLDAS against organ damage accrual and flare were similar regardless of HDAS. LLDAS attainment is protective from adverse outcomes even after high disease activity.

Acknowledgements: We thank all patients participating in the Asia Pacific Lupus Collaboration (APLC) cohort, and all data collectors for their ongoing support for APLC research activities.

The APLC has received unrestricted project grants from AstraZeneca, BMS, Eli Lily, Janssen, Merck Serono, and UCB to support data collection contributing to this work.

Disclosure of Interests: Rangi Kandane-Rathnayake: None declared, Vera Goldner: None declared, Warawit Loutheennoo: None declared, Yi-Hsing Chen Speakers bureau: Pfizer, Novartis, Abbvie, Johnson & Johnson, BMS, Roche, Lilly, Astellas, MSD, Gilead, Janssen, Merck Serono, and UCB to support data collection contributing to this work.

The APLC has received unrestricted project grants from AstraZeneca, BMS, Eli Lilly, Janssen, Merck Serono, and UCB to support data collection contributing to this work.

The APLC has received unrestricted project grants from AstraZeneca, BMS, Eli Lilly, Janssen, Merck Serono, and UCB to support data collection contributing to this work.

We thank all patients participating in the Asia Pacific Lupus Collaboration (APLC) cohort, and all data collectors for their ongoing support for APLC research activities.

The APLC has received unrestricted project grants from AstraZeneca, BMS, Eli Lilly, Janssen, Merck Serono, and UCB to support data collection contributing to this work.
CNS demyelinating syndromes in systemic lupus erythematosus: results from “Attikon” lupus cohort

1. National and Kapodistrian University of Athens, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece; 2. National and Kapodistrian University of Athens, 2nd Department of Neurology, Attikon University Hospital, Athens, Greece; 3. National and Kapodistrian University of Athens, 2nd Department of Radiology, Attikon University Hospital, Athens, Greece; 4. Asklepion General Hospital, Department of Rheumatology, Asklepion General Hospital, Athens, Greece; 5. Hannover Medical University, Division of Immunology and Rheumatology, Hannover, Germany; 6. University of Ioannina, Rheumatology Clinic, University Hospital of Ioannina, Ioannina, Greece.

Background: Central nervous system (CNS) demyelinating syndromes that occur in the context of SLE may represent a manifestation of neuropsychiatric lupus, or an overlap of SLE and multiple sclerosis (MS). The differential diagnosis between the two entities has important clinical implications, because the therapeutic management differs between the two conditions.

Objectives: To characterize CNS demyelinating syndromes in a large SLE cohort as neuropsychiatric SLE or SLE-MS overlap, using a multidisciplinary approach and existing diagnostic (MS) and classification criteria (SLE).

Methods: Patients from the ‘Attikon’ lupus cohort (n=707) were evaluated for demyelinating syndromes. Clinical, laboratory and neuroimaging data were recorded for each patient. Following multidisciplinary evaluation and application of criteria, the demyelinating syndrome was attributed to either SLE or MS. Patients with transverse myelitis were not included in this study.

Results: We identified 26 patients with demyelinating syndromes (3.7%) with mean age at diagnosis 46.9 (SD 12.3) years and median disease duration at last follow-up 60 (IQR 52) months. Of them, 12 were diagnosed as primary SLE-demyelination (46.2%) and 14 as overlap SLE-MS (53.8%). The two groups did not differ with respect to rheumatologic and neurologic manifestations, or serologic data. The mean (SD) ADC value of MALT lesions was significantly lower than the ADC of fatty substitution did not differ in MALT lymphoma and in no-MALT pSS glands.

Background: Salivary MALT lymphoma represents the major complication of primary Sjögren’s Syndrome (pSS). However, the early recognition of MALT lymphoma may be challenging due to its indolent, slow clinical course.

Objectives: 1. to identify salivary gland ultrasonographic (SGUS) features and magnetic resonance (MRI) abnormal findings with Diffusion Weighted imaging (DWI) and Apparent Diffusion Coefficient (ADC) of MALT in pSS patients. 2. To evaluate the correlation between salivary gland ultrasonography (SGUS) and MRI in pSS patients with suspected lymphoma.

Methods: consecutive patients with pSS (2016 ACR/EULAR criteria) and suspected MALT lymphoma undergoing histological examination were included in this cross sectional study from September 2017 to November 2021. The US echostucture of each gland on B-mode images was graded using the latest 2019 OMERACT semiquantitative SGUS scoring systems (0-3). Sonographic features of focal lesions were described. Conventional MRI techniques (i.e. T1WI, T2WI, and STIR images) combined with MR sialography was performed in all the cases. DWI was acquired at b-value 0, 500 and 1000. ADC values were calculated. Patients’ clinical and histological data were collected. Data were presented as means±SD, or percent frequency as appropriate. Intergroup comparisons were made using the t-test/Mann–Whitney test for continuous variables and Fisher’s exact test for categorical variable.

Results: 45 pSS (mean age, S.D=55±15 yrs) were included. MALT lymphoma was histologically confirmed in 14/45 pSS patients and, specifically in 18/180 major salivary glands (17 parotid and 1 submandibular gland). At SGUS examination, MALT salivary glands presented an OMERACT grade 3 in 16/18 and a grade 2 in 2/18, significantly higher than the OMERACT scoring observed in no-MALT pSS glands (p=0.001). The sonographic features more commonly detected in MALT were: hypoecochic macroareas with posterior enhancement, presence of septa or hyperechogenic strands and anacral intraacusal vascularization. At MRI, 15/18 (83.3%) MALT lymphoma appeared as intraglandular solid lesions: 9/15 (60%) were solid-cystic lesions and 6/15 (40%) were solid lesions without cystic changes. The frequency of solid lesions in pSS patients without lymphoma was 3/124 (2.4%), significantly lower than in MALT-pSS. Furthermore, 15/18 (83.3%) MALT lymphoma showed glandular fatty substitution. The presence of fatty substitution did not differ in MALT lymphoma and in no-MALT pSS glands. The mean (SD) ADC value of MALT lesions was significantly lower than the ADC of the parotid glands in pSS lymphoma (0.63±0.07 × 10⁻³ mm²/s vs 1.1±0.19 × 10⁻³ mm²/s, p=0.001). A negative correlation between SGUS OMERACT score and mean glandular ADC values (r=−0.776, p<0.001) was found; patients with OMERACT score 3 presented the lowest mean salivary gland ADC when compared to the other OMERACT scores (0-2) (p<0.001).

Conclusion: OMERACT semiquantitative SGUS scoring systems and MRI with DWI represent promising complementary tools in the differential diagnosis of pSS MALT lymphoma, particularly useful to guide parotid biopsy. Patients with an OMERACT score 3 in their SGUS deserve a careful screening for lymphoma.

Disclosure of Interests: None declared.


Through the looking glass

Diagnostic value of liver stiffness as marker of hepatic marker of hepatic amyloid deposition in systemic amyloidosis

A. F. Brunger, J. Bibe1, H. Blokji, R. Van Rheenen, G. Rans, B. Hazenberg, H. L. A. Nienui1 on behalf of Amyloidosis Center of Expertise, University Medical Center Groningen, Groningen, The Netherlands; University Medical Center Groningen, Rheumatology & Clinical Immunology, Groningen, Netherlands; University Medical Center Groningen, Gastroenterology, Groningen, Netherlands; University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, Netherlands; University Medical Center Groningen, Internal Medicine, Groningen, Netherlands.

Disclosure of Interests: None declared.


Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4172
Background: Hepatic involvement in AL amyloidosis is often asymptomatic but does affect prognosis and should be taken into account during follow-up. An increased plasma level of alkaline phosphatase (ALP) or increased liver span are part of the conventional diagnostic criteria for establishing hepatic involvement of AL amyloidosis, but these markers are nonspecific. 18F-labeled serum amyloid P component (SAP) scintigraphy is a specific and sensitive method to establish hepatic involvement but is not widely available. Liver stiffness measured by transient elastography is increased in AL amyloidosis patients with hepatic involvement and could be useful in establishing liver involvement and monitoring treatment response in AL amyloidosis.

Objectives: To assess the diagnostic value of liver stiffness (LS) for liver involvement in AL amyloidosis and the utility of LS to monitor treatment effect using SAP scintigraphy as gold standard.

Methods: LS was measured prospectively in 49 treatment naive patients with systemic AL amyloidosis and 9 patients with wild type transthyretin amyloidosis (ATTRwt) with cardiomyopathy (cardiac controls). In addition, LS was longitudinally measured in 10 AL amyloidosis patients of whom 9 patients had liver involvement. SAP scintigraphy, laboratory assessments including ALP and measurement of liver span was performed in all patients.

Results: Of the 49 patients, 27 patients had liver involvement (of whom 24 also had heart involvement), 10 patients had heart involvement, 12 patients had no heart or liver involvement. Median LS was significantly higher in AL amyloidosis patients with liver involvement (22.8 kPa, range 4.3-75), than in AL amyloidosis patients without liver involvement (6.3 kPa, range 4.4-35.8) (p=0.00). Also a significant difference was seen between AL amyloidosis patients with liver involvement (22.8, range 4.3-75) versus, heart involvement (9.0, range 4.5-35.8) (p=0.02), no liver or heart involvement (5.7, range 4.4-10.1) (p=0.0001), and ATTRwt patients (2.9 kPa, range 4.0-14.6) (p=0.01). Furthermore, LS values seemed to significantly decrease over time in AL amyloidosis patients with liver involvement with a good hematologic response to treatment.

Conclusion: LS is a non-invasive tool which seems to be useful in clinical practice to establish liver involvement in patients with AL amyloidosis. In addition, it is a promising marker in the follow up of AL amyloidosis patients for establishing hepatic response over time.

REFERENCES:
Disclosure of Interests: None declared

Table 1. Abnormalities found on FDG-PET/CT scans

<table>
<thead>
<tr>
<th>Abnormality</th>
<th>No abnormality found on any scan (%</th>
<th>One or more abnormalities found on any scan (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No PET/CT result obtained</td>
<td>3 (2.5)</td>
<td>56 (47.8)</td>
</tr>
<tr>
<td>One or more abnormalities</td>
<td>59 (48.8)</td>
<td>59 (48.8)</td>
</tr>
</tbody>
</table>

* Fifteen of these abnormalities were found on the second PET/CT, the rest was found on the first scan. 11 abnormalities on the second PET/CT were the same as the one seen on the first scan, and 7 abnormalities resolved after the first scan. One scan can show multiple abnormalities, from different categories.

Follow-up action occurred in 21 (26.6%) patients, consisting of referral to a specialist or reassessing and/or scheduling diagnostics directly by the treating rheumatologist. In 5 (6.3%) patients, the rheumatologist followed-up. In 17 (21.5%) patients a consultation with a different specialist was scheduled. In five patients surgical/invasive intervention took place. In one patient a hemi-thyroidectomy was performed revealing a follicular adenoma. This resection was complicated by a persistent recurrent laryngeal nerve paresis and hoarseness. In a second, an intra-uterine myometrectomy took place. In a third, a colonoscopy was performed revealing two low-grade adenomas. In a fourth a benign cyst in the neck was extracted. A fifth patient underwent spinal marginal myotomy which turned out to be a benign schwannoma.

Nine patients (7.4%) were suspected of malignancy, none turned out to be malignant. Six clinical malignancies (bladder, penile, lymphoma, 2 melanoma and prostate) that developed during follow-up were all negative on baseline FDG-PET/CT. The malignancies were diagnosed after an interval of between 5 and 34 months (mean 13 months).

Conclusion: Whole-body FDG-PET/CT-scanning for arthritis imaging in RA patients results in frequent incidental extra-articular findings, while some who apparently had normal scans developed malignancies.

REFERENCES:
Disclosure of Interests: None declared

POS0125 EXTRA-ARTICULAR FINDINGS WITH FDG-PET/CT IN RHEUMATOID ARTHRITIS PATIENTS: MORE HARM THAN BENEFIT.

E. Ultin1, A. Den Broeder2, N. Boers3, M. Gothardt4, M. Bouman5, R. B. M. Landewe6, H. Den Broeder7, N. Van Herwaarden8,9, S. M. Maarstekinklens10, Rheumatology, Nijmegen, Netherlands, 1Sint Maartenskliniek, Rheumatology, Nijmegen, Netherlands, 2Radboud University Medical Center, Radiology, Nuclear Medicine & Institute for Molecular Life Sciences, Nijmegen, Netherlands, 3Rijnstate, Rheumatology, Arnhem, Netherlands, 4Amsterdam UMC, location VUmc, Rheumatology and Clinical Immunology, Amsterdam, Netherlands, 5Radboud University Medical Center, Pharmacology-Toxicology, Nijmegen, Netherlands

Background: Whole-body Positron Emission Tomography with CT-scan using fluorine-18 fluorodeoxyglucose (18F-FDG) is occasionally used in Rheumatoid Arthritis (RA) patients. Reasons to use FDG-PET/CT-scans are to diagnose arthritis or guide decisions on systemic therapy. As FDG uptake in affected joints may reflect disease activity [1], FDG-PET/CT might also detect malignancies, but the frequency of incidental findings and the proportion of relevant malignant disease that could be missed are currently unknown.

Objectives: To study the malignancy screening performance of whole-body FDG-PET/CT in longstanding RA patients with low disease activity.

Methods: FDG-PET/CT-scanning was done in the intervention arm of the Dose REduction Strategy of Subcutaneous TNF-inhibitors (DRESS) study, a randomized controlled trial on dose-tapering of biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) [3]. Baseline and if applicable follow-up whole-body FDG-PET/CT-scans were performed in consenting patients in the tapering arm to assess predictive value of subclinical PET-arthritis for risk of flaring [4]. The scans were also read by experienced nuclear medicine specialists independently after they were performed for any unexpected extra-articular finding, conform routine clinical care.

The reference standard was clinical diagnosis of malignancy during the 3 year follow-up. Prevalence of extra-articular abnormalities, follow-up, and received treatments were summarized post-hoc.

Results: 121 scans were made in 79 patients. Extra-articular abnormalities were found in 59/121 (48.8%) scans (Table 1) in 45/79 (57%) patients.

Disclosure of Interests: None declared

POS0126 UTILITY OF THE SUBCHONDRAL BONE ATTENUATION COEFFICIENT OF THE SACRIOILIAC MARGINS TO DIFFERENTIATE SPONDYLOARTHRITIS AND OSTEOSITIS CONDENSANS ILI

A. Terrier1, O. Fakhri2, M. Chouk3, C. Prati3, D. Wendling3, S. Aubry2, F. Verheoven5,6,7, CHU Besancon, Musculoskeletal Imaging, Besancon, France; 8CHU Besancon, Rheumatology, Besancon, France; 9CHU Besancon, Rhenium, Besancon, France; 10Université de Franche Comte, EA 4267 PEPITE, Besancon, France

Background: Differentiating ankylosing spondylitis (AS) from osteitis condensans ili (OCI) remains challenging for clinicians.

Objectives: The aim of this study was to determine whether Subchondral Bone Attenuation Coefficient of the Sacroiliac margins (SBAC-SI) is different in AS, OCI and diffuse idiopathic skeletal hyperostosis (DISH).

Methods: A monocentric retrospective observational study was performed at a French University Hospital. Patients included were followed for AS, DISH or OCI and underwent CT scan including sacroiliac joint. Patients with tumor lesion of bone or a history of pelvic radiotherapy were excluded. AS and OCI patients were matched with a control of the same age and sex. All scans were acquired on the same CT-scan unit (Somatom 64 definition AS+, Siemens Healthineers, Erlangen, Germany), with a slice thickness of 0.625mm. In the coronal oblique plane of the SIJ, three slices (anterior, middle and posterior) and four quadrants per joint were defined. Twenty-four identical circular regions of interest (ROIs) (30 mm2), 8 per slice, were manually placed separately subcortical to the SIJ, four on the sacral side and four on the iliac side. The distance between the circle of the ROI and the cortical bone was 2 to 3mm. An overall score was obtained from...
the sum of all ROIs. For every ROI, an Attenuation Coefficient was measured and expressed in Hounsfield Unit. The total SBAC-SI score was the sum of the 24 ROI. The sacral and iliac SBAC-SI scores were the sum of the sacral or the iliac ROI.

Results: Thirty AS and AS controls, 31 DISH, 29 OCI and OCI controls were included. SBAC-SI score was 9727 (±2430) in the OCI group (p<0.001), 3563 (±1860) in the AS group, 3899 (±1937) in the DISH group, 4224 (±1693) in the AS control group and 5445 (±1205) in the OCI control group. A threshold of 7500 HU had the best discriminative value between OCI and AS (youden index: 0.89). In AS, disease duration is negatively associated with SBAC-SI (r = -0.623; p < 0.01) and HLA B27 is associated with lower SBAC-SI (6523 [5198, 7137] vs 2809 [1568, 3371]; p < 0.001).

Conclusion: SBAC-SI is significantly different between AS and OCI and could help to distinguish these two diseases.

Figure 1. Distribution of the Subchondral Bone Attenuation Coefficients of the Sacroiliac Margins of the 24 ROI in the anterior (A), middle (B) and posterior (C) slices in the coronal oblique plane of the sacroiliac joints

Disclosure of Interests: None declared

POS0127 QUANTITATIVE ASSESSMENT OF FINGER VASCULARITY IN SYSTEMIC SCLEROSIS PATIENTS WITH RAYNAUD’S PHENOMENON USING ULTRASOUND VASCULAR IMAGING

K. Nam, F. Mendoza Ballesteros, C. Wessner, T. Alawih, F. Forsberg, Thomas Jefferson University, Department of Radiology, Philadelphia, United States of America; Thomas Jefferson University, Scleroderma Center and Jefferson Institute of Molecular Medicine, Philadelphia, United States of America; Thomas Jefferson University, Department of Medicine, Division of Rheumatology, Philadelphia, United States of America

Background: In patients with Systemic Sclerosis (SSc), vasculopathy plays an important pathophysiological role and it is almost universally expressed as Raynaud’s Phenomenon (RP). Assessment of vasculopathy/microangiopathy is crucial for early diagnosis of SSc and also is considered in the SSc classification criteria. Currently, this evaluation is performed by nailfold capillaroscopy. However, nailfold capillaroscopy is limited to the nail fold area and is mainly qualitative since is based on the shape, size, and density of the observed capillaries. Quantification: The objective of this study is to detect and quantify finger vascularity of SSc patients with RP using four ultrasound vascular imaging techniques. Additionally, the diagnostic performance of quantified finger vascularity was assessed.

Methods: This prospective IRB approved study has enrolled 20 SSc patients fulfilling the 2013 ACR/EULAR classification criteria and presenting RP. Age and sex matched normal volunteers (16 subjects) without RP were also enrolled. All fingers except thumbs were imaged at room temperature in the seated position. The blood flow of each finger was evaluated on the dorsal (showing nail) and on the ventral (showing palm) sides using an i24LX8 probe (9-24 MHz) on an Aplio 800 system (Canon Medical Systems, Tustin, CA, USA). Blood flow images were obtained using color Doppler imaging (CDI), power Doppler imaging (PDI), monochrome Superb Microvascular Imaging (cSMI), and color-coded Superb Microvascular Imaging (cSMI) keeping the same imaging settings for all subjects. The percent area of vascularity observed by each technique was quantified offline by counting pixels of blood flow in a 5 x 5 mm square centered at the nail fold for the dorsal side and in a 1 x 1 cm square from the fingertip for the ventral side using Matlab (MathWorks, Natick, MA, USA). The percent vascularity areas from dorsal and ventral sides were averaged over fingers, then t-tests and receiver operating characteristic (ROC) analyses were performed (Youden Index) to assess the diagnostic ability of the different methods and to classify disease status (RP-SSc from normal controls), allowing to assign diagnostic accuracy.

Results: Two patients' data were excluded due to technical errors. The data from 18 RP-SSc patients and 16 normal volunteers were analyzed. The percent vascular areas in patients with RP were significantly lower than those in normal volunteers at both dorsal (p < 0.03) and ventral (p < 0.01) for each imaging technique. The ventral side vascularity showed a higher diagnostic accuracy compared to the dorsal side. Among the four imaging techniques, CDI showed the highest diagnostic accuracy. The mean percent areas by CDI were 6.8 ± 7.1% (mean ± standard deviation) and 15.3 ± 8.9% on the dorsal side (p < 0.01) and 5.3 ± 5.6% and 16.7 ± 7.4% on the ventral side (p < 0.0001) for RP patients and normal volunteers, respectively. The ventral side vascularity by CDI showed the highest diagnostic accuracy of 90% with 88% specificity and 78% sensitivity.

Conclusion: Ultrasonic vascular imaging demonstrated the potential to quantitatively microangiopathy of RP-SSc. Additionally, the mean percent vascular area averaged across the fingers showed to be accurate (70 to 90%) to differentiate patients with RP-SSc from normal controls, albeit based on small sample size.

REFERENCES:

Disclosure of Interests: None declared

B. Atienza-Mateo, A. del Peral Fanjul, V. Pulito-Cueto, D. Prieto-Peña, A. González-Gay, R. Blanco, Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain; IDIVAL, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, Santander, Spain

Background: Ocular manifestations of Behçet's disease (BD) are globally recognized and widely studied [1]. Vascular lesions are also frequent but less explored [2]. Microvascular involvement may be clinical (as Raynaud's phenomenon) or subclinical. Vascular microcirculation is studied with Nailfold Capillaroscopy (NFC) that may show capillary abnormalities such as dilated loops, megacapillaries and microhemorrhages. Endothelial progenitor cells (EPCs) have been implied in the pathogenesis of multiple cardiovascular disorders and vasculitis, including BD and could be used as biomarkers. Objectives: To assess the microvascular involvement and EPCs in patients with BD.

Methods: Observational study of unselected consecutive patients with BD assessed in a national referral center from March to May 2021. All patients fulfilled the 2014 ICBD criteria [2]. They were evaluated sequentially with a scheduled clinic visit after signing an informed consent. The main variables collected were a) periangual capillaries features (loop diameter, tortuosity, vascular density, microhemorrhages and blood flow), and b) serum EPCs levels. NFC was performed from the second to fifth fingers of both hands using a 500x magnification digital microscope. The following features were considered abnormal: diffuse enlarged capillaries (>2 capillaries with a diameter of 20-50 µm in at least 2 different fingers), megacapillaries (>50 µm in diameter), reduced vascular density (<9 capillaries/mm or avascular areas), diffuse microhemorrhages (>2 hemorrhages in at least 2 different fingers) and granular/slow flow. NFC were studied in unselected BD patients in whom instant blood samples were available and compared with sex- and age-matched healthy controls (HC). EPCs from peripheral venous blood were quantified by direct flow cytometry and characterized by simultaneous expression of cell surface markers of stemness (CD34), immaturity (CD133), endothelial (CD144), megacapillaries (>2 capillaries with a diameter of 20-50 µm in at least 2 different fingers) and granular/slow flow. NFC were studied in unselected BD patients in whom instant blood samples were available and compared with sex- and age-matched healthy controls (HC). EPCs from peripheral venous blood were quantified by direct flow cytometry and characterized by simultaneous expression of cell surface markers of stemness (CD34), immaturity (CD133), endothelial commitment (CD309) and a low expression of the pan-leukocyte marker (CD45).

Results: From a cohort of 120 patients with BD, 42 were evaluated during the period of the study (Table 1). NFC was performed in the 42 cases, being abnormal in 54.8% of them. The most common findings were capillary loop dilatation (45.2%), capillary tortuosity (31%), megacapillaries (21.4%) and microhemorrhages (16.7%) (Table 1). Instant blood samples to study EPCs levels were available in 18 BD patients and 12 HC. The median [IQR] frequency of EPCs levels in BD patients in whom instant blood samples were available and compared with sex- and age-matched healthy controls (HC). EPCs from peripheral venous blood were quantified by direct flow cytometry and characterized by simultaneous expression of cell surface markers of stemness (CD34), immaturity (CD133), endothelial commitment (CD309) and a low expression of the pan-leukocyte marker (CD45).
Table 1. Collected data of 42 patients with Behçet’s disease.

<table>
<thead>
<tr>
<th>Demographic data</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women/Men</td>
<td>19 (45.2)/23 (54.8)</td>
</tr>
<tr>
<td>Age (years), mean ± SD</td>
<td>47.86±12.99</td>
</tr>
<tr>
<td>Clinical vascular involvement</td>
<td>n (%)</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>4 (9.52)</td>
</tr>
<tr>
<td>Superficial thrombophlebitis</td>
<td>1 (2.38)</td>
</tr>
<tr>
<td>Arterial aneurysms</td>
<td>2 (4.76)</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>3 (7.14)</td>
</tr>
<tr>
<td>Arterial thrombosis</td>
<td>1 (2.38)</td>
</tr>
<tr>
<td>Raynaud’s phenomenon</td>
<td>10 (23.81)</td>
</tr>
<tr>
<td>Nailfold capillaroscopy Findings</td>
<td>n (%)</td>
</tr>
<tr>
<td>Abnormal</td>
<td>23 (54.8)</td>
</tr>
<tr>
<td>Dilated loops (20-50 µm) ≥2 in at least 2 fingers</td>
<td>19 (45.2)</td>
</tr>
<tr>
<td>Megascapillaries (&gt;50 µm) ≥2 in at least 2 fingers</td>
<td>9 (21.4)</td>
</tr>
<tr>
<td>≥2 in at least 2 fingers</td>
<td>3 (7.1)</td>
</tr>
<tr>
<td>Capillary tortuosity</td>
<td>13 (31)</td>
</tr>
<tr>
<td>Microthromboses</td>
<td>7 (16.7)</td>
</tr>
<tr>
<td>≥2 in at least 2 fingers</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Reduced vascular density</td>
<td>3 (7.1)</td>
</tr>
<tr>
<td>Granular flow</td>
<td>1 (2.4)</td>
</tr>
</tbody>
</table>

Conclusion: Microvascular involvement is common in BD and can be easily assessed by NFC. Furthermore, EPCs quantification may be a useful serum biomarker of the disease.

REFERENCES:

Acknowledgements: We acknowledge all the patients who participated in the study.

Disclosure of Interests: Belén Atienza-Mateo Speakers bureau: Pfizer, Celgene, Novartis, Sanofi, Janssen, UCB, Eli Lilly, Grant/research support from: Abbvie, Roche, Alfonso del Peral Fanjul: None declared, Diana Preto-Peña Speakers bureau: Abbvie, Amgen, Bristol-Myers, Celgene, MSD, Novartis, Roche, Ricardo Blanco Speakers bureau: Abbvie, Agen, Bristol-Myers, Celgene, MSD, Novartis, Pfizer, Roche and Sanofi., Grant/research support from: Abbvie, Roche


POS029
TO CONTRAST OR NOT TO CONTRAST? ON THE ROLE OF CONTRAST ENHANCEMENT IN HAND MRI STUDIES OF PATIENTS WITH RHEUMATOID ARTHRITIS
G. Rübsam1, M. Frenken1, A. D. Mewes1, K. L. Radke1, L. Le2, L. Wilms1, S. Neubling2, D. Abrar1, P. Severin1,2, Heinrich Heine University Düsseldorf, Institute of Diagnostic and Interventional Radiology, Düsseldorf, Germany; 2Ludwig Maximilian University, Institute for Medical Information Sciences, Biometry and Epidemiology, Munich, Germany; 3Aachen University Hospital, Department of Diagnostic and Interventional Radiology, Aachen, Germany; 4Heinrich-Heine University, Department and Hiller Research Unit of Rheumatology, Duesseldorf, Germany; 5Ruhr-University Bochum, Rheumazentrum Ruhrgebiet Herne, Germany

Background: Currently, clinical indications for application of gadolinium-based contrast agents (GBCA) in magnetic resonance imaging (MRI) are increasingly being questioned1. Rheumatoid arthritis is a disease which is characterised by joint inflammation and due to various existing therapies, early diagnosis and sensitive monitoring is beneficial for assessing disease progression, therapy response and optimizing the individual therapy.

Objective: This study aimed to evaluate the necessity of contrast enhancement in MRI of the hand in patients with rheumatoid arthritis (RA).

Methods: 31 patients with RA (mean age, 50±14 years [range, 18–72 years]) from the German ArthroMark cohort underwent morphologic high-field MRI scans on a clinical 3T scanner. MRI studies were analyzed based on (1) the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)2 and (2) the GBCA-free RAMRIS version, termed RAMRIS Sine-Gadolinium-For-Experts (RAMRIS-SAFE), in which synovitis and tenosynovitis were assessed using the short-tau-inversion-recovery (STIR) sequence instead of the post-contrast T1-weighted sequence.

Results: Correlation between RAMRIS and RAMRIS-SAFE in terms of Spearman’s ρ was almost perfect (ρ=0.976; p<0.001). The synovitis subcores, as based on RAMRIS and RAMRIS-SAFE, were equally strongly correlated (ρ=0.937; p<0.001), while the tenosynovitis subcores were less strongly correlated (ρ=0.380 p=0.035). Inter-rater reliability in terms of Cohen’s κ was high (0.963 ≤ κ ≤ 0.925).

Conclusion: In conclusion, RAMRIS-SAFE as the GBCA-free version of the well-established RAMRIS is a patient-friendly and resource-efficient alternative for assessing disease-related joint changes in RA. As patients with RA are subject to repetitive GBCA applications, non-contrast imaging protocols should be considered.

REFERENCES:

Table 1. Composition of both scores: RAMRIS-SAFE and RAMRIS

<table>
<thead>
<tr>
<th>Magnetic Resonance Imaging Feature</th>
<th>Anatomic Location</th>
<th>MRI Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erosion</td>
<td>All carpal bones and metacarpal bases</td>
<td>coronal T1, coronal T1</td>
</tr>
<tr>
<td>Synovitis</td>
<td>MCP (II-V)</td>
<td>coronal STIR, coronal STIR</td>
</tr>
<tr>
<td>Tenosynovitis</td>
<td>MCP (II-V) joints</td>
<td>coronal axial T1, T1 + contrast</td>
</tr>
<tr>
<td>Joint space narrowing</td>
<td>MCP joints (II-V)</td>
<td>coronal axial T1, coronal axial T1</td>
</tr>
</tbody>
</table>

Abbreviations are “RAMRIS” (rheumatoid arthritis MRI scoring system), “RAMRIS-SAFE” (RAMRIS sine gadolinium for experts), “MCP” (metacarpophalangeal), and “STIR” (Short-Tau-Inversion-Recovery).
Disclosure of Interests: Gesa Rübsam: None declared, Miriam Frenken: None declared, Alexander Dieter Mewes: None declared, Karl Ludger Radke: None declared, Lien Le: None declared, Lena Wilms: None declared, Daniel Abrar: None declared, Philipp Sewerin: Speakers bureau: None declared, Lien Le: None declared, Lena Wilms: None declared, Sven Nebelung: None declared, Daniel Abrar: None declared, Philipp Sewerin: Speakers bureau: None declared, Lien Le: None declared, Lena Wilms: None declared, Sven Nebelung: None declared, Daniel Abrar: None declared, Philipp Sewerin: Speakers bureau: None declared, Lien Le: None declared, Lena Wilms: None declared, Sven Nebelung: None declared, Alexaner Dieter Mewes: None declared, Karl Ludger Radke: None declared.

Exemplary imaging features (erosion, osteitis, synovitis, tenosynovitis, and joint space narrowing) that are scored semiquantitatively based on RAMRIS, shown in (i) unenhanced MRT T1-weighted sequence (left column), (ii) STIR sequence (middle column), and enhanced T1-weighted postcontrast sequence (right column).

Results: Comparing the analyses of all phases of the OA cohort with those of the RA cohort, 14 of 51 features were identified as significantly different (p < 0.05). The most significant accumulation in metacarpophalangeal joints (MCP) has high specificity and diagnostic odds ratio (DOR) for RA patients (91%, 4.32). Patients in the OA cohort showed an increase in the signal at the muscle-tendon junction in the forearm (80% sensitivity, DOR 3.11). A comparison of the RA and CTD cohorts revealed 24 significant differences, most prominent changes in the nail bed in RA (100% specificity, DOR 8.27) and a punctate accumulation pattern in P2 (86% specificity, DOR 2.81) for the CTD cohort. Comparing the RA and CTD cohorts, 22 features were significantly different. The strongest differences were found in the PIP joints of RA patients (78% sensitivity, DOR 2.97) and in the nail bed of CTD patients (100% specificity, DOR 8.18). In the cumulative PV images a high specificity for a secondary Raynaud’s syndrome in CTD patients was found compared to RA (97%, DOR 17.7) and OA (91%, DOR 5.9). Further, DIP signals for OA compared to CTD show significant differences (76% sensitivity, DOR 2.73).

Conclusion: The present work demonstrates the detection and localization of specific, significant features in NIR-FOI of patients with different rheumatic diseases and can thus make an important contribution to diagnosis and optimization of therapy. In future, multivariate analysis and artificial intelligence algorithms can combine these features to further improve the diagnostic value.

Acknowledgements: Funded by the Federal Ministry of Education and Research (grant nb.: 13GW0341A)

Methods: NIR fluorescence imaging comprised 360 images/6 min. after injection of the dye. Analysis of patients with the clinical diagnosis of OA and CTD was performed on a separate cohort of patients. The analysis was performed on both hands in three time periods (P1-3) after injection in two independent passes. In some cases, Prima Vista images (PVI), representing the sum of images 1-240 were also analyzed (n = 45, 33, 33 for OA, RA, CTD). Signals compared to the background were assessed as positive or negative (Figure 1).

The data were analyzed statistically.
Background: Patients with psoriasis (PsO) report musculoskeletal (MSK) pain without clinical findings of inflammation. Ultrasound (US) is more sensitive than clinical evaluation in detecting synovitis and enthesitis, and we have previously found that patients with PsO and pain more often have US signs of inflammation in joints and entheses than patients without pain (1), indicating possible psoriatic arthritis (PsA). Whether the area of reported pain in these patients correspond to inflammation by US has not yet been investigated.

Objectives: In patients with PsA with self-reported MSK pain, to investigate if the area of reported of pain corresponds to synovitis and/or enthesitis.

Methods: PsO patients with self-reported MSK pain (n=79, Table 1), recruited from a Danish nationwide survey, were evaluated in one of four rheumatology departments with grey-scale (GS) and color Doppler (CD) US of 48 joints and 12 entheses, applying the OMERACT scoring systems (2) for US synovitis (defined as GS score ≥2 or CD≥1) and enthesitis (defined as ≥1 GS inflammatory finding (hypoechogenicity/thickening) and CD score ≥1). Patients indicated the location of current pain in 21 areas on a homunculus, out of which shoulder (joint), elbow (joint and common extensor enthesis), hand (wrist and MCP, PIP, and DIP-joints 1-5), knees (joint and quadriceps- and patellar entheses), feet (ankle and MTP-joints 1-5) and heel (Achilles- and plantar fascia entheses) were evaluated by US, see Figure 1. Association between self-reported pain and US inflammation (synovitis/enthesitis) was explored using Fisher’s exact test and odds ratios (OR) for 2x2 tables. Agreement was calculated using Cohen’s kappa (κ).

Table 1. Population characteristics (n=79)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>57</td>
<td>47 (46-66)</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>28.4</td>
<td>24.8-34.8</td>
</tr>
<tr>
<td>Disease duration PsO (years)</td>
<td>25</td>
<td>11-39</td>
</tr>
<tr>
<td>Swollen joint count (0-68)</td>
<td>0.0-1</td>
<td>0-0.5</td>
</tr>
<tr>
<td>Tender joint count (0-68)</td>
<td>2.0</td>
<td>0-0.5</td>
</tr>
<tr>
<td>Tender enthesis count (0-16)</td>
<td>1.0</td>
<td>0-0.5</td>
</tr>
<tr>
<td>Synovitis Area and Severity Index (0-72)</td>
<td>1.5</td>
<td>0.2-4.2</td>
</tr>
<tr>
<td>Pain VAS (0-100)</td>
<td>3.1</td>
<td>1-6</td>
</tr>
<tr>
<td>CRP (mMol/l)</td>
<td>2.1</td>
<td>0.5-4.1</td>
</tr>
<tr>
<td>Global VAS (0-100)</td>
<td>16</td>
<td>4-45</td>
</tr>
<tr>
<td>Pain VAS (0-100)</td>
<td>20</td>
<td>5-39</td>
</tr>
<tr>
<td>Health Assessment Questionnaire (0-3)</td>
<td>0.25</td>
<td>0.00-0.69</td>
</tr>
<tr>
<td>DAS28-28 (0-100)</td>
<td>1.6</td>
<td>1.5-2.6</td>
</tr>
<tr>
<td>Disease Activity in Psoriatic Arthritis (0-164)</td>
<td>5.2</td>
<td>4.1-20.7</td>
</tr>
</tbody>
</table>

Numbers are median (IQR) or no. (%). CRP: C-reactive protein, DAS28: Disease Activity Score 28 joints, VAS: Visual Analog Scale

Results: Of the areas examined by US, pain was most frequent in the knees (41% of patients), while US inflammation was most frequent in the hand/wrist (55%). In total, US inflammation was found in 72% patients (synovitis in 71%, enthesitis in 17%). In 47% of patients, US inflammation was found in one or more of the painful sites. Figure 1 shows 2x2 tables of pain versus US inflammation in different areas and corresponding ORs and κ-values. Self-reported pain was significantly related to US inflammation in that area, both overall (OR=3.1, p=0.001) and for the specific areas of the left hand (OR 3.1, p=0.03) and right elbow (OR 18.3, p=0.01). Agreement between self-reported pain and US inflammation, as measured by κ, was overall low, κ = 0.18 (95% confidence interval 0.10-0.27), with highest agreement found for the right elbow (κ = 0.30 (0.0-0.68)). Pain only in areas not examined by US (back/hips/breastbone/jaw) was indicated by 16% of patients.

Conclusion: While US signs of synovitis and enthesitis is frequent in patients with PsO and pain, concordance between US inflammation and the specific location of pain is only seen in half of the patients.

REFERENCES:

Disclosure of Interests: Sara Kamp Felbo Grant/research support from: Amgen/Celgene, Lene Terslev Speakers bureau: AbbVie, Janssen, Roche, Novartis, Pfizer, MSD, BMS and GE, Inge Juul Sorensen: None declared, Oliver Hendricks Speakers bureau: AbbVie, Pfizer and Novartis, Dorota Kuettel: None declared, Rasmus Lederballe Pedersen: None declared, stavros chrysides: None declared, Michel Östergaard Speakers bureau: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandzö, Sanofi and UCB, Grant/research support from: AbbVie, BMS, Celgene, Novartis DOI: 10.1136/annrheumdis-2022-eular.7241

Figure 1. Self-reported pain versus ultrasound (US) inflammation in different areas, and in all areas considered together, presented as 2x2 tables and corresponding odds ratios (OR, p-value) (Fisher’s exact test), and agreement (Cohens Kappa (κ))(95% confidence interval)).
**Table 1. Elementary ultrasound lesions and joints to be scanned for each included pathology**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Sites to scan</th>
<th>US elementary lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td>II-IV MCPs</td>
<td>Synovial Hypertrophy (SH), Power Doppler (PD), erosions</td>
</tr>
<tr>
<td></td>
<td>Wrist</td>
<td>Proximal patellar tendon enthesis</td>
</tr>
<tr>
<td>PsA</td>
<td>II-III MCPs</td>
<td>Peritendinitis, Enthesitis, Soft tissue oedema, Tenosynovitis, Soft tissue oedema</td>
</tr>
<tr>
<td></td>
<td>V MP</td>
<td>Achilles tendon enthesis, Proximal patellar tendon enthesis</td>
</tr>
<tr>
<td>CPPD</td>
<td>Knees (meniscus and Hyaline Cartilage)</td>
<td>CPP deposits</td>
</tr>
<tr>
<td></td>
<td>Wrist (triangular fibrocartilage) complex</td>
<td>Double contour, tophi</td>
</tr>
<tr>
<td>Gout</td>
<td>Any involved sites</td>
<td>CPP deposits, SH, PD</td>
</tr>
<tr>
<td>OA</td>
<td>I MTP</td>
<td>SH, PD</td>
</tr>
<tr>
<td>OA</td>
<td>Involved sites</td>
<td>Osteophytes, Cartilage changes</td>
</tr>
<tr>
<td>PMR</td>
<td>Shoulders</td>
<td>Bursitis, Arthritis, Rotator cuff integrity</td>
</tr>
</tbody>
</table>

![Figure 1. The final algorithm](image)

**Conclusion:** The diagnostic algorithm produced in this pilot study correctly classified patients with the most prevalent RMDs in clinical practice. A longitudinal study on included pathology.

**References:**


**Disclosure of Interests:** None declared


**POS0133 HIGH-RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY FOR THE EVALUATION OF BONE EROSIONS OF METATARSOPHALANGEAL JOINTS IN RHEUMATOID ARTHRITIS: A PILOT STUDY**

J. Meinhardt, R. Klose-Jensen, J. Therkildsen, B. Langdahl, E. M. Hauge, K. Keller, Aarhus University Hospital, Department of Rheumatology, Aarhus N, Denmark; Aarhus University Hospital, Department of Clinical Medicine, Aarhus N, Denmark; Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Aarhus N, Denmark

**Background:** Bone erosion in rheumatoid arthritis (RA) is most commonly detected in the wrist, metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints. High-resolution peripheral quantitative computed tomography (HR-pQCT) has successfully been used to quantify bone erosions in the wrist and MCP joints. A recent study highlights that HR-pQCT of only two MCP joints has equal accuracy to detect erosive disease in RA patients compared to conventional radiography (CR) of the hands, wrists, and feet (44 joints). However, no study has evaluated the MTP joints by HR-pQCT.

**Objectives:** To characterize the localization, size and frequency of erosions in the 4th and 5th MTP joints. Furthermore, to evaluate the sensitivity for the detection of erosion in the 4th and 5th MTP joints by HR-pQCT, compared to CR.

**Methods:** This single-centre cross-sectional study included 42 patients with established RA (disease duration ≥ 5 years). The right foot was imaged by HR-pQCT in a 2.7 cm long region corresponding to the 4th and 5th MTP joint. Blinded to patient data, the number and volume of bone erosions by HR-pQCT were measured and scored according to the SPECTRA criteria. CR of 44 joints was evaluated according to the Sharp/van der Heijde (SHS) method.

**Results:** The patients (62% women) had a median disease duration of 12 years (interquartile range (IQR): 7 – 20). HR-pQCT of the 4th and 5th MTP joints identified erosions in 38 (90%) patients. The total erosion volume (Vtot) was 2610 mm³ in all quadrants of the 4th and 5th MTP joints. Erosions were most frequently found at the lateral aspect of the 5th metatarsal head (MH), including 1261 mm³ (48%) of Vtot (Figure 1). CR of 44 joints detected erosions in 30 (71%) patients with a median SHS erosion score of 9 (5 – 28). The sensitivity and specificity (95% CI) of classifying patients with erosive RA by HR-pQCT and CR is displayed in Table 1. McNemar’s test showed a significantly higher sensitivity of patients classified as having erosive RA by HR-pQCT of the 4th and 5th MTP joints than by CR of 44 joints (4.6, p = 0.03).

**Table 1. Comparing CR and HR-pQCT for classifying patients as having erosive RA, and for identifying erosions in the 4th and 5th MTP joints.**

<table>
<thead>
<tr>
<th></th>
<th>CR Hands, wrists, and feet</th>
<th>CR Hands, wrists, and feet</th>
<th>Total</th>
<th>Sensitivity (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erosive RA</td>
<td></td>
<td></td>
<td>27</td>
<td>11</td>
</tr>
<tr>
<td>Non-erosive RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosive RA</td>
<td></td>
<td></td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Non-erosive RA</td>
<td></td>
<td></td>
<td>27</td>
<td>3</td>
</tr>
<tr>
<td>Erosive RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-erosive RA</td>
<td></td>
<td></td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>38</td>
<td>4</td>
</tr>
</tbody>
</table>

Conventional Radiography (CR), High-resolution peripheral Quantitative Computed Tomography (HR-pQCT), Metatarsophalangeal (MTP), Rheumatoid Arthritis (RA), Confidence Interval (CI).

**Conclusion:** This is the first study to evaluate erosions with HR-pQCT of the 4th and 5th MTP joints, including a comparison to CR. Erosions were frequent at the lateral aspect of the MTP joints, suggesting that mechanical and biomechanical demands may play a role in the development of erosions in the MTP joints. The superiority of HR-pQCT compared to CR for detecting erosions provide a basis for larger studies assessing bone changes in the MTP joints.

**References:**


**RELATIONSHIP BETWEEN RETINAL VASCULAR DENSITY DETECTED THROUGH OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND INTIMAL MEDIAL THICKNESS: A NEW POTENTIAL MARKER OF CARDIOVASCULAR INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS**

S. Ferrigno1, P. Conigliaro1, S. Longo2, C. Nesli3, A. Di Stefano4, E. Santilli5, C. Giannini6, S. Rizza7, M. Federici8, M. Cesareo9, A. Bergamin10. 1University of Rome Tor Vergata, Rheumatology, Allergology and Clinical Immunology, Department of ‘Medicina dei Sistemi’, Rome, Italy; 2University of Rome Tor Vergata, Internal Medicine, Department of ‘Medicina dei Sistemi’, Rome, Italy; 3University of Rome Tor Vergata, Ophthalmology Unit, Department of Experimental Medicine and Surgery, Rome, Italy.

**Background:** Systemic Lupus Erythematosus (SLE) patients have a 3-fold risk of CV events compared to the general population, mainly due to accelerated atherosclerosis that is not completely explained by the presence of traditional CV risk factors. Individuals with increased intimal medial thickness (IMT) carry a higher risk to develop carotid atherosclerosis. Accordingly, IMT acts as a marker of subclinical atherosclerosis. In recent studies, SLE patients showed a significant higher IMT compared to healthy subjects. On the other side, SLE retinal involvement can be detected in 7-29% of cases, it is characterized mainly by retinal vasculopathy and it can be a marker of systemic vascular involvement. Optical Coherence Tomography Angiography (OCTA), a new diagnostic technique that can visualize retinal blood flow and evaluate the Fovea Avascular Zone (FAZ), has been investigated as an instrument for early detection of subclinical retinal vascular impairment in SLE.

**Objectives:** Aim of this study is to examine a possible correlation between IMT and retinal vascular impairment assessed through OCTA in SLE.

**Methods:** We recruited SLE patients fulfilling 2019 EULAR/ACR classification criteria. Patients with other rheumatic, ophthalmological diseases, diabetes or history of CV diseases were excluded. We also collected patients’ demographic and clinical data, including sex, age, smoking habit, BMI, systolic and diastolic blood pressure (BP), C-Reactive Protein (CRP), total cholesterol, LDL, HDL, triglycerides. All patients underwent an ophthalmological evaluation, including OCTA estimation of superficial and deep retinal vessel density (VD), considering both the whole image and the foveal region, and FAZ area. Carotid ultrasound (US) comprising IMT assessment was also performed. Statistical analysis was accomplished using unpaired t-test or Mann Whitney U test, Pearson or Spearman rank correlation when appropriate.

**Results:** We enrolled 37 SLE patients; demographic, clinical and US data are displayed in Table 1. Nine patients (24.3%) had uncontrolled arterial hypertension. According to US evaluation, carotid plaques were detected in six patients (16.2%). OCTA data were correlated with IMT values showing a negative correlation between IMT and both superficial and deep fovea VD (p=0.003, r=-0.4) and p=0.004, r=-0.4), while a positive correlation was found with FAZ area (p=0.02, r=0.4).

**Table 1. Demographic, clinical and US data of the study population**

| Female sex (%) | 28 (75.6) |
| Age, yrs | 49.2±14.7 |
| Smokers n(%) | 12 (32.4) |
| BMI | 25.1±5.2 |
| SBP, mmHg | 118.5±15.7 |
| DBP, mmHg | 73.2±11.6 |
| IMT, μm | 549.6±124 |

**Discussion:** Retinal vascular impairment in SLE has been associated with IMT, atherosclerotic plaques and some CV risk factors as hypertension, hypertriglyceridemia and CRP levels. Search for new markers of preclinical CV damage in SLE is currently ongoing and OCTA might be an additional instrument to assess preclinical cardiovascular involvement in SLE.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5119

**Biomarkers in pathogenesis, monitoring and treatment of rheumatic diseases**

**DOWNSCALING OF MIR-885-5P AS A KEY EFFECTOR IN CUTANEOUS LUPUS ERYTHEMATOSUS PATHOGENESIS**

S. Domingo1, C. Solé-Marçal1, T. Moline1, B. Ferrer1, J. Cortés-Hernández1.

1VHIR - Vall d’Hebron Institut de Recerca, Luperus Unit, Rheumatology, Barcelona, Spain; 2VHIR - Vall d’Hebron Institut de Recerca, Pathology, Barcelona, Spain; 3Hospital Universitari Vall d’Hebron, Pathology, Barcelona, Spain.

**Background:** Skin involvement is common in systemic lupus erythematosus (SLE), with up to 70% of patients developing skin lesions at some point during the course of their disease. Moreover, cutaneous lesions are the first sign of systemic disease in 20% of SLE patients [1]. Skin requires a regulated and undisrupted miRNA profile for a correct development and function. Studies show that miRNAs play a pathogenic role in autoimmune skin diseases such as Psoriasis [2]. Understanding of the role of deregulated miRNAs in CLE may enhance our knowledge about CLE pathogenesis which is currently not understood.

**Objectives:** Identify differentially expressed miRNAs in skin lesions to determine new markers for CLE pathogenesis.

**Methods:** Paired skin biopsies from CLE lesional (n=20) and non-lesional skin (n=20) were obtained. MiRNA microarray screening was performed using TaqMan MicroRNA Array. Validation was performed in a new cohort of FFPE skin samples by qRT-PCR (n=20). In situ hybridization was performed to identify the skin cell type involved in selected miRNAs. Next, in vitro experiments using primary skin and immune cells were performed in order to discover their role in CLE pathogenesis. A microarray screening and luciferase assay were performed to find mir-885-5p altered gene expression, molecular pathways and target genes.

**Results:** mir-885-5p was found downregulated in CLE lesional skin (-4.45 fold, p<0.01, respectively). Results were confirmed in a validation cohort. In situ hybridization revealed mir-885-5p was located in the epidermal keratinocytes in CLE non-lesional skin. Healthy keratinocytes presented an increased mir-885-5p expression compared with other relevant cell types such as fibroblasts (p<0.001) or PBMHCs (p<0.001). Moreover stimulation with IFNα and UVB promoted a marked long-lasting downregulation of mir-885-5p (IFNα, 24h -67 fold (p<0.001); UVB, 24h -70 fold (p<0.001)).

**Conclusion:** Downregulation of mir-885-5p in CLE may represent a new hallmark of CLE pathogenesis.
We also found that C1q could increase basal OCR, ATP-coupled OCR, max in synovial macrophages. but not TNF- 

Results: Transcripts for inflammatory cytokines were quantified by RT-PCR. Mitochondrial protein expression was detected by flow cytometric analysis and immunoblotting. Besides, C1q could increase the expression of IL-1β and TNF-α but not TNF-α secreted by synovial macrophages, which represents a novel therapeutic target in RA.

REFERENCES: 


Disclosure of Interests: None declared

POS0136
COMPLEMENT C1Q PROMOTES MITOCHONDRIA RESPIRATION AND SECRETION OF IL-6 AND IL-1 
BUT NOT TNF-Α BY SYNOVIAL MACROPHAGE IN RHEUMATOID ARTHRITIS

Y. Jiang1,2, B. Wu1, T. Huang2, Y. Liu1, Z. Hu1, T. Zhao2, Y. Pan1, W. Cornelia1,2
1Third Affiliated Hospital of Sun Yat-sen University, Department of Rheumatology and Immunology, Guangzhou, China; 2Stanford University, Department of Immunology and Rheumatology, Palo Alto, United States of America; 3Mayo Clinic, Department of Rheumatology and Immunology, Rochester, United States of America

Background: Complement C1q (C1q), predominantly synthesized by myeloid cells such as macrophages, has elusive functions in the pathogenesis of rheumatic arthritis (RA). Binding to its receptor gC1qR, C1q can activate mitochondria, the dysfunction of which may result in tissue inflammatory disease [1]. Bone marrow derived macrophages in RA patients have elevated OXPHOS activity [2], while the reason remains to be discovered.

Objectives: The objectives of the study were to explore the expression of C1q and its receptor gC1qR in synovial macrophages in RA and whether C1q contributes to tissue inflammation via affecting pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and mitochondria respiration in synovial macrophages.

Methods: Tissue transcriptome analysis for C1q (C1qA, C1qB and C1qC), C1q receptors (including gC1qR) in rheumatoid synovium and pro-inflammatory cytokines (IL-6, IL-1β and TNF-α) in rheumatoid synovium and synovium macrophages were quantified by RT-PCR. Concentrations of C1q in the plasma of RA and healthy controls (HC) were analyzed by ELISA and the correlation between plasma C1q and disease activity measured by DAS28 were calculated. gC1qR protein expression was detected by flow cytometric analysis and immunoblotting. Synovial macrophages were isolated and stimulated with or without C1q for 24h. Function of gC1qR was analysed by knockdown experiment using siRNA. Transcripts for inflammatory cytokines were quantified by RT-PCR. Mitochondrial respirometer was evaluated with Seahorse Bioscience XF96 analyzer by adding test agents in order of 1, oligomycin; 2, FCCP; 3, anti-mycin A/rotenone. Total trend and each segmentation of oxygen consumption rates (OCR) were shown after treated with C1q, n=6. * P < 0.05; ** P < 0.01; *** P < 0.001.

Disclosure of Interests: Yutong Jiang Grant/research support from: Basic and Applied Basic Research Fund Project of Guandong Province [2021A1515111172], Bowen Wu: None declared, Tao Huang: None declared, Yan Liu: None declared, Zhaolan Hu: None declared, Tuantuan Zhao: None declared, Yunfeng Pan: None declared, Weyand Cornelia: None declared

POS0137
FREQUENCIES OF WNT PATHWAY GENE VARIANTS ASSOCIATED WITH ANTI CARBAMYLATE PROTEIN IN EARLY RHEUMATOID ARTHRITIS

M. Acevedo-Godoy1, S. J. Perdomo2, W. Bautista-Molano2, L. Chilla2, O. J. Calixto1, J. M. Bello-Gualterio1, C. Pomerro-Sanchez3,4, Hospital Militar Central, Rheumatology and Immunology Department, Clinical Immunology Group, Bogota, Colombia; 2Universidad El Bosque, Cellular and Molecular Immunology Group/ INMUUBO, Bogota, Colombia; 3Universidad Militar Nueva Granada, School of Medicine, Clinical Immunology Group, Bogota, Colombia

Background: Increased bone resorption and impaired bone formation characterize the pathogenesis of rheumatoid arthritis (RA). Wnt/β-catenin pathway regulates osteoblast function. Since bone mineral density (BMD) and RA joint destruction are partially inherited, we studied the association of Dickkopf-1 (DKK-1), sclerostin (SOST), Kremen-1 and lipoprotein receptor-related protein-5 (LRP-5) genes single nucleotide polymorphisms (SNP) with RA in 232 individuals.

Objectives: To establish the genotypic frequency of variants of the DKK-1, rs1896368, rs1896367, rs1528873), SOST (rs6503475), Kremen-1 (rs132274) and LRP-5 (3736228) genes in patients with early RA (eRA) and first degree relatives (FDR). A bivariate analysis was conducted in eRA and FDR. A logistic regression was performed.

Methods: Colombian individuals were matched by age and gender. Serological and clinical indices were measured. Variants associated with the Wnt pathway: DKK-1, SOST, LRP-5, and Kremen were analyzed using High Resolution Melting and confirmed by Sanger sequencing. A bivariate analysis was conducted in eRA and FDR. A logistic regression was performed.

Results: 232 individuals were evaluated; 66 eRA patients, 50 FDR, and 116 HC. For eRA, 78.8% were female, with a median age 52 years (IQR: 38,8-56). Higher levels of CRP: 4,2 (IQR: 1,8-11,6), RF: 30,2 (IQR: 1,2-74,1), and CCP: 7,81 (IQR: 7,81-104,9) and anti-Carbamylate protein (CarP): 17,6 (IQR: 12,3-31,8) were observed.
Among eRA, FDR, and HC genotypic frequencies are listed in Table 1. There were significant differences among DKK-1 rs1896367, GG native and GA, p=0.001. Meanwhile, the relationship between synovial fluid immune cells and HC was not significant. Our work demonstrates that RASFs from different endotypes display imprinted memory of their original synovial tissue when maintained in culture over several months. We also demonstrated that imprinted memory typical of RASF isolated from B-cell rich LM synovial tissues can be dynamically modulated in FPI-RASF following co-culturing with RA B cells. Finally, consensus gene modules based on FPI vs LM RASF gene signatures were able to inform response/resistance to targeted biologic therapies.

REFERENCES:

Disclosure of Interests: None declared.

POS0138
RHEUMATOID SYNOVIAL FIBROBLASTS DISPLAY IMPRINTED MEMORY OF THEIR SYNOVIAL ENDOTYPE WHICH CAN BE PLASTICALLY MODULATED BY B-CELLS CROSSTALK

E Prefidietto1, C Cubuik2, E Pontarini1, F Rivelese1, A Nerviani1, D Lucchesi1, M Caliste1, E Corsiero1, R Hands1, M Lewis1, C Pitzalis1, M Bombardieri1
1William Harvey Research Institute, Queen Mary University of London, Centre for Experimental Medicine & Rheumatology, London, United Kingdom

Background: Despite advances in the treatment of Rheumatoid Arthritis (RA), synethetics and biologicals drugs are ineffective in ~40% of patients. The origin of this refractoriness is unclear, but several clues point at the synovial microenvironment (SE) and the relative cellular heterogeneity between patients. We previously described the existence of different RA endotypes such as the lympho-lymphoid, LM, which is B-cell rich and the fibro-paucicellular, FPI, which is devoid of B-cells. While there is clear evidence that the co-culture between stromal and immune cells in rheumatoid joints is critical for the perpetuation of chronic inflammation and autoimmunity, it is currently unknown whether transcriptional signatures identified in synovial fibroblasts (SFs) derived from different RA endotypes are driven by “imprinted” properties of the SFs or are shaped by the interaction with infiltrating immune cells in the RA joints.

Objectives: i) to identify “imprinted” vs “inducible” RASFs gene signatures through the comparison of freshly isolated SFs and primary established SFs cultures obtained from LM vs FPI RA synovial biopsies and ii) to investigate the identified RASF signature as predictive biomarkers of disease evolution and of response to conventional and biological DMARDs.

Methods: We performed flowcytometry and single cell RNA sequencing (sc-RNAseq) on SFs obtained from LM and FPI biopsies, in isolation or in co-culture with RA B cells. Next, supernatant has been screened trough Multiplex and ELISA. Furthermore, we compared our results to publicly available sc-RNAseq datasets on freshly isolated SFs and to our bulk-RNAseq data from clinical trials patients.

Results: Hierarchical clustering from sc-RNAseq transcriptional profiling of LM vs FPI RASF - after several cell passages - identified profoundly different gene signatures: whereby LM-RASF were characterised by genes involved in inflammation, proteoglycan formation and integrin binding. FPI-RASF were defined by genes related to collagen biosynthesis. Comparing the above signatures with those of freshly isolated RASF we identified both imprinted (i.e. maintained through several in vitro passages) and inducible (i.e. loss after long term culture) gene signatures. Notably, RA B-cells co-cultured with FPI-RASF profoundly altered the FPI-RASF transcriptional profile including the ex novo expression of gene signatures typical of LM-RASF. Consensus gene modules constructed on LM vs FPI RASF imprinted gene signatures could be tracked in longitudinal whole tissue bulk RNA-seq data obtained from both early arthritis and established RA and were associated with synovial pathotype-specific histological and clinical features. Finally, modulation of FPI-RASF related genes following B-cell depletion identified poor responders to Rituximab in the RA4RA randomised clinical trial.

Conclusion: Our work demonstrates that RASFs from different endotypes display imprinted memory of their original synovial tissue when maintained in culture over several months. We also demonstrated that imprinted memory typical of RASF isolated from B-cell rich LM synovial tissues can be dynamically modulated in FPI-RASF following co-culturing with RA B cells. Finally, consensus gene modules based on FPI vs LM RASF gene signatures were able to inform on response/resistance to targeted biologic therapies.
worsening symptoms (339 vs 222 g/ml, p=0.002). CXCL10 levels in patients with improved symptoms showed a decreasing trend between phenotypes from KOA > KOA2 > KOA3 > KOA4. Regarding macrophages, low expression of chemokine receptor CXCR4 and CXCR7 on macrophages was associated with improved symptoms regardless of KOA phenotype.

Conclusion: We identified four KOA phenotypes differing in immune cell percentage and activation associated with different clinical trajectories. Low expression of chemokine receptors CXCR4 and CXCR7 on macrophages and high CXCL10 in SF was linked to KOA symptom improvement. How these phenotypes can be targeted for therapeutic intervention is a key question.

Acknowledgements: None declared


POS0140

PREDICTING OUTCOMES IN SYSTEMIC SCLEROSIS: STRATIFICATION BY AUTO-ANTIBODIES OUTPERFORMS CUTANEOUS SUBSETTING IN THE EUSTAR COHORT

M. Elhali1,2, M. Boubya3, N. Sritirathan4, A. Babir-Gurman5, E. Siegert5, E. Hachulla6, J. De Vries-Bouwstra7, G. Riemekasten8, J. H. W. Distler9, 15

54.4±13.8 years, mean disease duration: 7.9±8.2 years. In the prospective

PARTICIPATE IN SLE PATHOGENESIS

M. Scherliger1,2, V. Guillotin3,4, P. Vacher5, I. Douchet6, E. Lazaro6,7, C. Riche2,8, P. Blanco7,8, 4

3Strasbourg University Hospital, Rheumatology, Strasbourg, France; 5Bath Israel Deaconess Medical Center (BIDMC), Harvard, United States of America; 6Chu Bordeaux - Site Pellegrin, Intensive Care, Bordeaux, France; 7ImmunoConcept Lab CNRS UMR 5164, UMR 5164, Bordeaux, France; 8INSERM, U1218, Bordeaux, France; 9Chu Bordeaux - Site Pellegrin, Rheumatology, Bordeaux, France; 10Chu Bordeaux - Site Pellegrin, Immunology, Bordeaux, France

Background: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown that in human SLE, platelets interact with T regulatory cells and repress their immunosuppressive functions through its impact on neutrophil functions, and lupus pathogenesis.

Methods: Patients from the EUSTAR database were classified either as (i) limited cutaneous, diffuse cutaneous and sine scleroderma (based on the recording made by the treating physician) or (ii) according to autoantibodies with the following subclassifications: (1) no specific autoantibodies, (2) isolated ANA, (3) auto-centreome antibodies, (4) anti-Scl70 antibodies and (5) anti-RNA polymerase III antibodies or (iii) according to combination of cutaneous subset and auto-antibodies. The respective performance of each model to predict overall survival (OS), progression-free survival (PFS), disease progression and different organ involvements was assessed and the three models were compared by the area under the receiver operating characteristic curve (AUC 95%CI) and the net reclassification improvement (NRI). Missing data were imputed through multiple imputation using chain equations.

Results: In all, 10'711 patients were included: 84.6% females, mean age: 54.4±13.8 years, mean disease duration: 79±8.2 years. In the prospective

analysis (n=6'467 to 7'829 according to the outcome), after a mean follow-up of 56 months and a mean of three visits per patient, we did not identify any difference in AUC between the cutaneous-based model and the antibody-based model for prediction of OS and disease progression. However, the NRI showed a significant improvement in prediction of OS (0.57 [0.46-0.71] vs. 0.29 [0.19-0.39]) and disease progression (0.36 [0.29-0.46] vs. 0.21 [0.14-0.28]) at 4 years using the antibody-based model. Regarding prediction of each organ involvement in longitudinal analyses, the antibody-based model showed better performance than the cutaneous-one for renal crisis (AUC: 0.719 [0.696-0.742] vs. 0.664 [0.643-0.685]), with the highest association observed in the kidneys.

Conclusion: Auto-antibody status outperforms the common cutaneous subsetting to risk-stratify SSC patients in the EUSTAR cohort. This easily performed subclassification using autoantibodies specific status can be used by the clinicians to risk-stratify their patients and to adapt disease monitoring in routine practice.

Disclosure of Interests: Muriel Elhai Speakers bureau: BMS outside of the submitted work, Marouane Boubya: None declared, Nanthara Sritirathan: None declared, Alexandra Babir-Gurman: None declared, Elise Siegert: None declared, Eric Hachulla: None declared, Jeska De Vries-Bouwstra: None declared, Gabriela Riemekasten: None declared, Jörg H.W. Distler: None declared, Douglas Weale: None declared, Eduardo Rosato: None declared, Francesco Del Gado: None declared, Fabian A Mendoza: None declared, Daniel First Consultant of: Abbie, Novartis, Pfizer, R-Pirm, Grant/research support from: Emerald, Kadmon, PICOIR, Pfizer,Prometheus, Talaris, Mitsubishi, Carlos De la Puente Bujidos: None declared, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Janssen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Armand Gabrielli: None declared, Olivier Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: Abbiev, Acceleron, Alimed, Amgen, AnaMar, Anxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Prometheus, Roche, Santor, Sanofi-Aventis, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Coralie Bloch-Queyrat: None declared, Yannick Allanore Consultant of: Actelion, Arthritis Association of Southern California, Arthritis Association, Los Angeles, United States of America; 7Arthritis Research Campaign, London, UK; 8Arthritis Research Campaign, London, UK; 9Associated with tight closure and CRCl on macrophages was associated with improved symptoms regardless of KOA phenotype.

Conclusion: We identified four KOA phenotypes differing in immune cell percentage and activation associated with different clinical trajectories. Low expression of chemokine receptors CXCR4 and CXCR7 on macrophages and high CXCL10 in SF was linked to KOA symptom improvement. How these phenotypes can be targeted for therapeutic intervention is a key question.

Acknowledgements: None declared


POS0141

PLATELET-SELECTIN PRIME LUPUS NEUTROPHILS TO PRODUCE MITOCHONDRIAL ROS AND PARTICIPATE IN SLE PATHOGENESIS

C. Riche2, P. Bianco2, 1

1Strasbourg University Hospital, Rheumatology, Strasbourg, France; 2Bath Israel Deaconess Medical Center (BIDMC), Harvard, United States of America; 3Chu Bordeaux - Site Pellegrin, Immunology, Bordeaux, France

Background: Risk-stratification is key in a heterogeneous disease like systemic sclerosis (SSc). Until now, SSc patients are stratified according to the extent of skin involvement into limited cutaneous, diffuse cutaneous and sine scleroderma subtypes. However, this classification remains inaccurate to capture disease heterogeneity. Autoantibodies are found in more than 90% of the patients and can be detected before onset of the disease. Among them, three predominant and heterogeneous. Autoantibodies are found in more than 90% of the patients and can be detected before onset of the disease. Among them, three predominant and differentiated cutaneous, diffuse cutaneous or sine scleroderma (based on the record-
SLE disease activity index (SLEDAI-2K), and patients were considered active if SLEDAI-2K ≥ 6. Platelet-neutrophil aggregates were identified as (platelet) CD61+ (neutrophil) CD66b+ cells using flow cytometry on fresh blood samples. Single-cell cytosolic calcium and ROS imaging was performed by incubating cell with either a fluorescent calcium dye (cali-520), or a mitochondrial specific dye (MitoSox). Coverslips were mounted in an Affitfluor cell chamber positioned on the stage of an inverted epifluorescence microscope (Olympus, IX70). Mitochondrial polarization of human neutrophil was evaluated by incubating cells with TMRE (100 nm) for 30 minutes. Platelet-free plasma was isolated by two speed centrifugations (3500xg) of EDTA-anticoagulated blood and stored for subsequent evaluation of soluble P-selectin (using ELISA) and (platelet-derived) microparticle P-selectin (using flow cytometry).

**Results:** In healthy donors (HD) and patients with SLE, circulating neutrophils expressed significantly higher levels of the P-selectin ligand CD15s compared to lymphoid subsets (p < 0.001), predicting platelet/neutrophil interactions. In contrast to HD and patients with inactive SLE, those with active disease had a significant increase of circulating platelet-neutrophil aggregates (p < 0.05), and these aggregates correlated with the SLEDAI (r = 0.59, p < 0.001). The incubation of human neutrophils with recombinant P-selectin induced a strong intracellular calcium signaling which was inhibited by preincubating neutrophil with anti-PSGL1 antibody (blocking P-selectin/CD15s interaction) or with a Syk kinase inhibitor. Similarly, P-selectin induced a mitochondrial ROS release in a CD15s- and Syk-dependent manner. Interestingly, incubation of neutrophils with anti-dsDNA IgG and P-selectin induced mitochondrial depolarization, which was absent with either stimulus alone. Soluble and platelet-derived microparticle P-selectin levels were significantly increased in patients with active SLE compared to inactive patients or healthy donors (p < 0.05 and p < 0.001, respectively). In a longitudinal analysis of SLE patients, soluble and microparticle P-selectin levels closely followed clinical (SLEDAI) and biological (Cr) levels markers of SLE disease activity.

**Conclusion:** P-selectin levels are increased in active SLE and follow hallmark of disease activity. P-selectin induces calcium/mitochondrial ROS signaling in lupus neutrophils which are key players in SLE pathogenesis. We hypothesize that the inhibition of P-selectin pathway might be a promising target in SLE.

**REFERENCES:**

**Disclosure of Interests:** None declared

ANOSSA). Details, at the gener level, IIM patients had a higher abundance of Entero-coccus, Veillonella, Streptococcus, et al. and a lower abundance of Roseburia, Lachnospira, Klebsiella, et al (Figure 1D, p < 0.05). In IIM patients, Fusobacteriota correlated positively with the ratio of Th1 cells (Figure 1E, p < 0.01), and there was a significant positive correlation between Synergistota and B lymphocyte (Figure 1E, p < 0.01). Besides, Euryarchaeota and Cyanobacteria were both positively and significantly related to IL-6, IFN-γ and C-reactive protein (CRP) (Figure 1E, p < 0.001).

**Conclusion:** Richness and diversity of intestinal flora in IIM patients were impaired, which might participate in the pathogenesis of IIM by disturbing lymphocyte subpopulations and cytokines. Regulating intestinal flora and restoring homeostasis might become a critical therapeutic methods of IIM.

**REFERENCES:**


**Acknowledgements:** This work was supported by the National Natural Science Foundation of China (No. 82001740).

**Disclosure of Interests:** None declared.

**DOIs:**

**POS0144**

NOVEL ANTIBODY BIOMARKERS THAT PREDICT FAILURE TO ACHIEVE EARLY AND SUSTAINED DISEASE REMISSION OR LOW DISEASE ACTIVITY AFTER INTENSIVE FIRST-LINE THERAPY IN RHEUMATOID ARTHRITIS

P. Vandormael, A. Pues, E. Sleurs, J. Liesenborgs, P. Verschueren, V. Somers, Hasselt University, Biomedical Research Institute, Immunology and Infection, Diepenbeek, Belgium; Hasselt University, Expertise Centre for Digital Media, Computational Science, Diepenbeek, Belgium; KU Leuven, University Hospital Leuven, Rheumatology, Leuven, Belgium

**Background:** Current EULAR guidelines for the management of rheumatoid arthritis (RA) recommend the use of classical synthetic disease-modifying anti-rheumatic drugs (csDMARDs), combined with short-term use of glucocorticoids (GC) as first-line therapy. Still, finding out which patients will show a poor response to such intensive first-line therapy is currently based on trial and error. Therefore, we recently performed a screening for novel antibody biomarkers that could predict the lack of response to csDMARD/GC combination therapy, resulting in identification of antibodies to 6 novel University Hasselt (UH)-RA antigens.

**Objectives:** The aim of this study was to validate these novel antibody biomarkers for their potential to identify at baseline, which RA patients fail to reach remission (rem-), or low disease activity (LDA), after intensive csDMARD therapy.

**Methods:** Presence of antibodies to the identified UH-RA antigens was measured using ELISA in 179 baseline samples from participants of the CareRA trial, which evaluated the efficacy of different first-line combination therapies. Baseline antibody reactivity was correlated with remission or LDA, over a two-year follow-up period, according to the Disease Activity Score based on 28 joints with C-reactive protein (DAS28CRP), the DAS28 with erythrocyte sedimentation rate (DAS28ESR), and the clinical/simplified disease activity index (CDAI/SDAI).

**Results:** Baseline antibody reactivity against a panel of 3 antigens was higher in patients failing to reach DAS28CRP (31 vs 15%, p=0.007) or DAS28ESR (30 vs 14%, p=0.007) remission at week 8, or those failing to reach SDAI (36 vs 17%, p=0.018) or CDAI (37 vs 17%, p= 0.01) LDA at week 8, compared to RA patients that did reach these respective disease states. Baseline antibody reactivity correlated with lack of DAS28CRP remission after 8, 16 and 52 weeks of first-line therapy, and was present in one in three DAS28CRP rem-patients, and in one in two DAS28CRP rem-patients that were seronegative for RF and ACPA. For each of the remission criteria studied (DAS28CRP, DAS28ESR, SDAI and CDAI), baseline antibody reactivity against these antigens was significantly higher in RA patients that did not maintain sustained remission (resp. 25 vs 12%, p=0.029; 24 vs 11%, p=0.041; 24 vs 4%, p=0.009; 24 vs 4%, p=0.011), or sustained LDA (resp. 29 vs 13%, p=0.007; 27 vs 11%, p=0.008; 29 vs 14%, p=0.018; 29 vs 14%, p=0.013) between week 8 and week 52, compared to patients that did reach these respective disease states.

**Conclusion:** We have identified a set of 3 antibody biomarkers that predict the failure to achieve early and sustained remission and LDA in response to intensive first-line RA therapy. Therefore, the presence of these antibodies might indicate the need for another first-line treatment option in a personalized medicine approach.

**REFERENCES:**


**Disclosure of Interests:** Patrick Vandormael: None declared. Astrid Pues: None declared. Ellen Sleers: None declared. Jori Liesenborgs: None declared. Patrick Verschueren Speakers bureau: Eli Lilly, MSD, Galapagos, Roularta, Consultant of: Galapagos, Gilead, Pfizer, Sidekick Health, Eli Lilly, Nordic Pharma. ABBVIE, Celltrion, BMS, UCSB, Grant/research support from: Holder of the Pfizer Chair for Management of Early Rheumatoid Arthritis at KU Leuven, Veerie Somers Grant/research support from: research grant from Pfizer.

**DOIs:**


**POS0145**

CLINICAL RESPONSE TO RITUXIMAB IS ASSOCIATED WITH PREVENTION OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EPITHELIAL RESTORATION AS MEASURED BY MOLECULAR PATHOLOGY: RESULTS FROM THE TRACTISS TRIAL IN PRIMARY SJOGREN’S SYNDROME

E. Pontarini, F. Chowdhury, E. Sciaccia, S. Grigoriadou, W. Murray-Brown, F. Rivellese, D. Lucchesi, K. Goldmann, L. Fossati-Jimack, E. Jaworska, G. M. Ghirardi, A. Nervianni, P. Emery, W. F. Ng, N. Sutcliffe, A. Tappuni, M. Lewis, S. Arends, L. De Wolff, H. Bootsma, C. Pitzalis, S. J. Bowman, M. Bombardieri, William Harvey Research Institute, Queen Mary University of London, Experimental Medicine and Rheumatology, London, United Kingdom; University of Leeds, Chapel Allerton Hospital, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; Newcastle University, Translational and Clinical Research Institute, Newcastle-upon-Tyne, United Kingdom; Bart’s Health NHS Trust, Royal London Hospital, London, United Kingdom; Institute of Dentistry, Queen Mary University of London, Oral Immunobiology and Regenerative Medicine, London, United Kingdom; University of Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; University of Leeds, School of Medicine, University Hospitals Birmingham NHS Foundation Trust, Rheumatology Department, Birmingham, United Kingdom

**Background:** The TRial for Anti-B-Cell Therapy in patients with pSS (TRAC-TISS) is the largest multi-centre, placebo-controlled, phase-III trial with the administration of 2 cycles of Rituximab (RTX) or placebo at week 0 and 24, with trial clinical endpoints at week 48. Despite the primary endpoints (30% reduction in fatigue or oral dryness) were not met, RTX treated patients showed an improvement in secondary endpoints, such as unstimulated whole salivary flow

**Disclosure of Interests:**

None declared, Ellen Sleurs: None declared, Jori Liesenborgs: None declared, Patrick Verschueren: Speakers bureau: Eli Lilly, MSD, Galapagos, Roularta, Consultant of: Galapagos, Gilead, Pfizer, Sidekick Health, Eli Lilly, Nordic Pharma. ABBVIE, Celltrion, BMS, UCSB, Grant/research support from: Holder of the Pfizer Chair for Management of Early Rheumatoid Arthritis at KU Leuven, Veerie Somers Grant/research support from: research grant from Pfizer.

**DOIs:**

Clinical aspect of spondyloarthritides.

**POS0146**

**INCREASED RISKS OF AORTIC REGURGITATION AND ATRIAL FIBRILLATION IN RADIOPHORIC AXIAL SPONDYLOARTHRITIS PATIENTS: A 10 YEAR NATIONWIDE COHORT STUDY**

H. K. Min¹, K. Y. Kang², S. H. Lee², S. Park³, M. Park³, Y. S. Hong³, M. Y. Kim², S. H. Park¹.

¹Konkuk University Medical Center, Rheumatology, Seoul, Korea; ²Republic of (South Korea); ³Seoul National University Hospital, Hospital, Seoul, Korea; ⁴The Catholic University of Korea Incheon St. Mary’s Hospital, Rheumatology, Incheon, Korea; ⁵University of California, San Francisco, Departments of Medicine, Pharmacology and Population Health Sciences, San Francisco; ⁶Hamri Pharmacy, Data Science Team, Seoul, Korea; ⁷The Catholic University of Korea Seoul St. Mary’s Hospital, Rheumatology, Seoul, Korea; ⁸Republic of (South Korea).

Background: Radiographic axial spondyloarthritis (r-axSpA) has increased risk of cardiovascular disease. Other cardiac manifestations such as conduction disturbance and valvular diseases were also suggested as co-morbidities in r-axSpA patients, however, the risk of these cardiac manifestation in r-axSpA was seldomly evaluated in large cohort.

Objectives: To compare the incidences of aortic regurgitation, atrial fibrillation (AF), and aortic and/or mitral valve diseases in r-axSpA patients and the general population (GP).

Methods: National Health Insurance Services data were used in this study. r-axSpA patients (N = 8,877) and the age- and sex-matched GP (N = 26,631) were followed at 3 time points, over 48 weeks, from the TRACTISS cohort, in order to identify mechanisms of response/resistance to B cell depletion.

Methods: 29 psS patients randomised to RTX or placebo arm consented for salivary gland biopsies at week 0, 16 and 48. Patients received two 1000mg cycles of RTX or placebo at week 0 and 24. SG focus score, inflammatory aggregate area fraction, B-cells (CD20+), T-cells (CD3+), follicular dendritic cells (FDCs) (CD21+) and plasma cells (CD138+) density were assessed using quantitative digital image analysis. RNA sequencing with deconvolution and pathway analysis was performed to identify genes signatures and consensus gene modules as biomarkers of disease evolution and response/resistance to therapy.

Results: Placebo-treated SGs showed worsening of SG inflammation highlighted by the increase of aggregate size, B-cell density, development of new FDC networks, and a higher ectopic GC prevalence over 48 weeks, compared to RTX-treated patients. No difference in focus score, total T-cell and plasma cell infiltration was observed. RTX downregulated genes involved in immune cell recruitment and inflammatory aggregate organisation (e.g. CXCL13, CC19 and PDGDC1). Gene signature-based analysis of 35 immune cell types using XCell highlighted how RTX blocked class-switched and memory-B-cells accumulation in SGs over 48 weeks. Pathway analyses confirmed the downregulation of leukocyte migration, MHC-II antigen presentation, and T-cell co-stimulation immunological pathways, such as the CD40 receptor complex pathway. Among RTX-treated patients, only CRESS-responders demonstrated prevention of worsening B cell-driven molecular pathology signatures over time and a significant improvement in UWSF, in parallel with the upregulation of molecular pathways associated to SG restoration of the glandular epithelium. None of the above effects were observed at week 16 after the first RTX cycle.

Conclusion: Two RTX infusions repeated at week 24 exerted beneficial effects on salivary SG inflammatory infiltration in psS by downregulating involved genes in immune cell recruitment, activation and organisation in ectopic GCs. Conversely, all the above parameters showed significant improvement in placebo treated patients over 48 weeks demonstrating progression of SG immunopathology.

Clinical responders to RTX based on CRESS response criteria were characterised by preservation of exocrine function which appear driven by SG epithelial restoration.

REFERENCES:


Disclosure of Interests: None declared


**POS0147**

**DETERMINANTS OF GENERAL HEALTH AND HEALTH RELATED QUALITY OF LIFE IN AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSEORIATIC ARTHRITIS: RESULTS FROM THE ASAS-PERSPA STUDY**

H. Santos¹, ², R. Henriques¹, M. Dogados¹, C. Lopez-Medina², H. Canhão²,³, P. M. Machado²,³, F. Pimentel Santos²,³.

¹Universidade do Porto, Institute of Rheumatology, Porto, Portugal; ²Nova Medical School, EpiDoc Unit, Comprehensive Health Research Center, Lisbon, Portugal; ³University College of London, Centre for Rheumatology and Department of Neuromuscular Diseases, London, United Kingdom; ⁴Centro Hospitalar Lisboa Ocidental, Hospital de Egas Moniz, Rheumatology, Lisbon, Portugal.

Background: Axial Spondyloarthritis (axSpA), peripheral Spondyloarthritis (pSpA) and Psoriatic arthritis (PsA) are different types of SpA, with large heterogeneity in clinical manifestations. It is crucial to understand which are the determinants of health-related quality of life (HRQoL) and general health (GH, global functioning and health) in axSpA, pSpA and PsA, which can lead to differential approaches for treatment, to attain better outcomes.

Objectives: This study aims to identify and compare determinants of HRQoL and GH in axSpA, pSpA and PsA, using data from the ASAS-Perspa Study.

Methods: Data from the ASAS-Perspa Study, a cross-sectional and multicenter study with 24 participating countries, was used. Patients with either axSpA, pSpA or PsA were enrolled. Sociodemographic, lifestyle, anthropometric, and clinical characteristics were collected. Univariable and multivariable regression models for the three groups were performed separately, to explore factors associated with HRQoL, assessed by EuroQoL-5 Dimensions 3 level (EQ-5D), and similar analysis was performed for GH, assessed by the Assessment of SpondyloArthritis international Society Health Index (ASAS-HI).

Results: 4185 patients were included in the analyses. For the final models, only patients with complete data were included (results summarized in Table 1). Regarding HRQoL, worse HRQoL in axSpA was associated with female gender, fibromyalgia (FM), peripheral disease (PD), worse function and higher disease activity (DA) and patient's self-reported (PGA) in pSpA with worse function, higher DA and higher non-steroidal anti-inflammatory drugs intake score (NSAIDs-IS), and in PsA with female gender, axial involvement, worse function, higher DA and glucocorticoid therapy. On the contrary, better HRQoL was calculated by the Kaplan–Meier method and Cox regression analysis.

Disclosure of Interests: None declared

associated in axSpA with a history of uveitis, in pSpA with older age (with a trend in axSpA and PsA, but not statistically significant) and in PsA with biologic therapy. Regarding GH, in axSpA, worse GH was associated with female gender, FM, PD, worse function and higher DA and PGA, in pSpA, with female gender, inflammatory bowel disease, worse function, treatment with conventional synthetic disease-modifying anti-rheumatic drug and higher NSAID-IS, in PsA with female gender, alcohol intake, FM, axial involvement, worse function and higher DA. On the contrary, better GH was associated in axSpA with university education (UE), higher BMI and higher NSAID-IS, in pSpA with UE, and in PsA with older age and UE.

Table 1. Factors associated with HRQoL and GH stratified by diagnostic category (summarized)

<table>
<thead>
<tr>
<th>EQ-5D</th>
<th>ASAS-HI</th>
</tr>
</thead>
<tbody>
<tr>
<td>axSpA</td>
<td>pSpA</td>
</tr>
<tr>
<td>R²=0.548</td>
<td>R²=0.520</td>
</tr>
</tbody>
</table>

| Female gender | 0.146 | 0.017 | <0.001 | 0.001 | <0.001 |
| Age | 0.054 | 0.048 | 0.076 | 0.056 | 0.496 | 0.003 |
| University education | 0.090 | 0.875 | 0.039 | 0.044 | <0.001 |
| BMI | 0.428 | 0.116 | 0.207 | 0.004 | 0.646 | 0.309 |
| Ever alcohol intake | 0.072 | NS | 0.796 | 0.531 | 0.539 | 0.035 |
| Fibromyalgia | <0.001 | 0.473 | 0.052 | <0.001 | 0.692 | <0.001 |
| URO | 0.028 | NS | 0.892 | NS | NS | 0.225 |
| IBD | NS | NS | 0.341 | NS | 0.025 | 0.657 |
| Axial disease | NS | 0.867 | 0.003 | NS | NS | 0.006 |
| Peripheral disease | 0.039 | NS | NS | <0.001 | NS | NS |
| PGA | <0.001 | NS | <0.001 | NS | <0.001 | NS |
| BASFI | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| ASDAS-CRP | <0.001 | NS | <0.001 | NA | 0.001 | NA |
| DAS44-CRP | NS | <0.001 | <0.001 | NA | 0.001 | NA |
| csDMARD | 0.362 | 0.296 | 0.233 | 0.002 | 0.035 | 0.226 |
| bDMARD | 0.491 | 0.896 | 0.021 | 0.921 | NS | NS |
| Glucocorticoids | 0.295 | 0.988 | 0.035 | 0.692 | 0.803 | 0.814 |
| NSAID intake score | 0.998 | <0.001 | 0.659 | 0.011 | 0.028 | 0.685 |

NS – not significant in univariable model; NA – not applicable; * - colinear with DAS44-

Conclusion: In all types of SpA, DA and function are major determinants of HRQoL, passible of tight monitoring and therapeutic intervention. In GH, besides DA and function, socio-demographic factors, like gender and education, also play an important role, in all forms of SpA, highlighting the importance of a holistic approach of the individual patient in order to achieve better outcomes.

Acknowledgements: The authors would like to thank all ASAS-PerSpA investigators and members of the scientific committee.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.936

POS0148 SPARCC, MASES, LEI AND MEI INDEXES CAPTURE DIFFERENT PATIENTS WITH ENTHESITIS IN AXIAL SPONDYLOARTHRITIS, PERIPHERAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS.

R. E. M. Granados1, M. L. Dadehesa Pineda1, M. Á. Puche Larrubia1, M. Dougdos2, E. Collantes Estevez2, C. López-Medina1,2

1Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Rheumatology, Cordoba, Spain; 2Cochin Hospital, Rheumatology, Paris, France

Background: Spondyloarthritis, (axial (axSpA), peripheral (pSpA)) and psoriatic arthritis (PsA) share enthesis as a hallmark clinical feature. Reliable clinical instruments have been developed to assess enthesitis: Spondyloarthritis Research Consortium of North America Enthesitis (SPARCC), Leeds Enthesitis Index (LEI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and MEI (Mander Enthesitis Index). Since these four indexes include different enthesis locations, they may capture a different number of patients with enthesitis in the different SpA entities. The prevalence of patients with at least one enthesitis across the three groups differs depending on the use of SPARCC, LEI, MASES and MEI indexes; c) to evaluate the level of agreement between these indexes for detecting patients with at least one enthesitis in axSpA, pSpA and PsA populations.

Methods: PerSpA was a multinational observational, cross-sectional study with 24 participating countries worldwide. A total of 4185 patients with a diagnosis of axSpA (2719), pSpA (433) and PsA (1033) according to the Rheumatologist’s opinion were included in this analysis. Information on the location of enthesitis collected during the study visit was used according to the SPARCC, LEI, MASES and MEI indexes.

The prevalence of patients with at least one enthesis according to the different indexes was compared across the diseases (axSpA, pSpA and PsA), and pairwise agreement between indexes were evaluated using the Cohen's kappa in the global population and in the three groups.

Results: Out of 36 locations, the most prevalent enthesitis in the overall population were the lumbar spinous processes (6.5%), the thoracic spinous processes (4.9%) and the insertion of the Achilles tendon right (4.8%) and left (3.9%). A total of 10.7%, 8.3%, 13.5% and 17.2% of patients in the overall population showed at least one enthesitis according to the SPARCC, LEI, MASES and MEI indexes, respectively. Figure 1 shows that, among patients with axSpA, MEI and MASES indexes capture the majority of patients with at least one enthesitis (98.7% and 82.4%, respectively), while in pSpA and PsA, MEI and SPARCC are the indexes which capture the majority of patients with enthesitis (100% and 84.6% for MEI and SPARCC in pSpA, and 97.3% and 77% for MEI and SPARCC in PsA, respectively). In PsA, the LEI only captured 57.2% of the patients with at least one enthesis. In the total population, MASES and MEI showed the strongest agreement for patients with at least one enthesis (absolute agreement 96.3%; Cohen's kappa: 0.86). Similarly, among axSpA patients, MASES and MEI showed an almost perfect agreement (97.3%; 0.90), while LEI and MEI showed a moderate agreement (90.4%; 0.54). In pSpA patients, SPARCC and MEI showed the strongest agreement (97.2%; 0.90), as well as among PsA patients (95.4%; 0.82). However, MASES and SPARCC showed a less agreement in PsA patients (94.2%; 0.67).

Conclusion: The most prevalent locations of enthesitis on the global SpA population are the lumbar spinous processes, the thoracic spinous processes and Achilles tendon. MEI and MASES are the two index that capture more patients with enthesitis in axSpA, while MEI and SPARCC are the two index that capture more patients in pSpA and PsA. The LEI index may underestimate the prevalence of enthesitis in these patients. MASES and MEI showed the largest level of agreement in the overall population and in axSpA, while MEI and SPARCC showed the largest level of agreement in pSpA and PsA. These results suggest that the prevalence of enthesitis across entities differs depending on the disease and on the use of the different index.

REFERENCES:

Disclosure of Interests: None declared

WHAT IS BACKFILL? - DETAILED CT / MRI ANALYSIS OF NEW BONE FORMATION IN AXIAL SPONDYLOARTHRITIS

T. Diekhoff1, C. Niedermeier1, F. Prof1, D. Poddubny2, K. G. Hermann1.  
1Charité Universitätsmedizin Berlin, Clinic for Radiology, Berlin, Germany; 2Charité Universitätsmedizin Berlin, Division Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany

Background: Several magnetic resonance imaging (MRI) findings of the sacroiliac joint space in axial spondyloarthritis (axSpA) were previously described such as inflammation or fatty metaplasia inside an erosion, i.e. “backfill”. However, it is incompletely understood if one or all of these changes represent calcified bone matrix.

Objectives: This study aims to one-by-one link the aforementioned changes to computed tomography (CT) measurements and to understand, which of those findings represents new bone formation.

Methods: Out of 178 patients from two prospective studies that included CT and MRI of the sacroiliac joints all patients with the final diagnosis of axSpA were selected. MRI was screened by two senior musculoskeletal radiologists in consensus for joint-space related MRI findings and grouped into three categories, Type A: hyperintense in STIR and hypointense in T1 (inflammation inside erosion), Type B: hypointense in both sequences and Type C: hypointense in STIR and hyperintense in T1 (backfill). By using image fusion techniques and one-by-one comparison, the Hounsfield Units (HU) of those lesions as well as normal cartilage and spongious and cortical bone were measured in CT.

Results: Ninety-nine patients with axSpA were identified and 48 Type A, 88 Type B and 84 Type C lesions were assessed. Please see Figure 1 for CT measurements. The HU values of cartilage were 73.6±15.0, spongious bone 188.0±69.9, and normal cartilage and spongeous and cortical bone were measured in CT.

Conclusion: All joint space lesions (Type A to C) show calcified matrix and, thus, resemble new bone formation with gradually more calcified matrix in Type C lesions, i.e. typical backfill. Therefore, the nomenclature of those lesions should be critically re-assessed.

Disclosure of Interests: None declared


Figure 1. CT Measurements of cartilage, bone and lesions.

ANAGING Spondylitis RELATED STRUCTURAL CHANGES IN THE SPINE INDEPENDENTLY INFLUENCE PATIENT REPORTED PHYSICAL FUNCTION IN MEN BUT NOT IN WOMEN. A COMPREHENSIVE CROSS-SECTIONAL ANALYSIS OF BATH ANKYLING SPONDYLITIS FUNCTIONAL INDEX AND ITS RELATION TO SEX

M. Hallström1,2, E. Klingberg1,2, A. Deminger1,2, J. Backman Renman3, M. Geijer3,5, H. Forsblad-D'elia1,2. 1Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; 2Department of Rheumatology and Inflammation Research, Gothenburg, Sweden; 302

Introduction: Ankylosing spondylitis (AS) is an inflammatory disease that may result in structural changes in the spine. In the Bath Ankylosing Spondylitis Functional Index (BASFI), higher scores correlate with lower functional capacity. This study aims to one-by-one link the aforementioned changes to computed tomography (CT) measurements and to understand, which of those findings represents new bone formation.

Objectives: This study aims to one-by-one link the aforementioned changes to computed tomography (CT) measurements and to understand, which of those findings represents new bone formation.

Methods: Out of 178 patients from two prospective studies that included CT and MRI of the sacroiliac joints all patients with the final diagnosis of axSpA were selected. MRI was screened by two senior musculoskeletal radiologists in consensus for joint-space related MRI findings and grouped into three categories, Type A: hyperintense in STIR and hypointense in T1 (inflammation inside erosion), Type B: hypointense in both sequences and Type C: hypointense in STIR and hyperintense in T1 (backfill). By using image fusion techniques and one-by-one comparison, the Hounsfield Units (HU) of those lesions as well as normal cartilage and spongious and cortical bone were measured in CT.

Results: Ninety-nine patients with axSpA were identified and 48 Type A, 88 Type B and 84 Type C lesions were assessed. Please see Figure 1 for CT measurements. The HU values of cartilage were 73.6±15.0, spongious bone 188.0±69.9, and normal cartilage and spongeous and cortical bone were measured in CT.

Conclusion: All joint space lesions (Type A to C) show calcified matrix and, thus, resemble new bone formation with gradually more calcified matrix in Type C lesions, i.e. typical backfill. Therefore, the nomenclature of those lesions should be critically re-assessed.

Disclosure of Interests: None declared


Figure 1. CT Measurements of cartilage, bone and lesions.

Table 1. Multiple linear regression analysis exploring factors associated with BASFI

<table>
<thead>
<tr>
<th>All</th>
<th>Men</th>
<th>Women</th>
</tr>
</thead>
<tbody>
<tr>
<td>R²</td>
<td>0.58</td>
<td>0.62</td>
</tr>
<tr>
<td>B (95% CI)</td>
<td>p-value</td>
<td>B (95% CI)</td>
</tr>
<tr>
<td>Age</td>
<td>0.06 (0.04;0.08)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI</td>
<td>0.05 (0.01;0.09)</td>
<td>0.024</td>
</tr>
<tr>
<td>ASDAS CRP</td>
<td>1.04 (0.71;1.43)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>mSASSS</td>
<td>0.03 (0.02;0.04)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.34 (0.24;0.43)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Tenderness</td>
<td>0.17 (0.07;0.26)</td>
<td>0.001</td>
</tr>
<tr>
<td>Women</td>
<td>-0.29 (-0.74;0.17)</td>
<td>0.214</td>
</tr>
</tbody>
</table>
Background: There is growing interest in reproductive issues in patients with Spondyloarthritis (SpA) and Psoriatic arthritis (PsA).

Objectives: To describe a real-life cohort of prospectively-followed pregnancies in SpA and PsA patients, focusing on obstetric outcome and on flare during pregnancies and post-partum.

Methods: Data on SpA and PsA pregnancies prospectively-followed in 2 European pregnancy clinics from 2010 to 2021 were retrospectively analysed. Disease activity was assessed using ASDAS-CRP or DAS28-CRP according to the main involvement (peripheral or axial). Disease flare was defined as the need to treatment modification (introduction or increase ≥5mg/day of prednisone, introduction of cDMARD or bDMARD). Miscarriages were excluded from the analysis of flares.

Results: Data on 122 pregnancies (53 PsA and 69 ‘other’ SpA: 39 axialSpA, 20 undifferentiated SpA, 6 IBD-related SpA, 4 reactive arthritis) in 102 patients (median age at conception: 34 [IQR: 31-36] years; median disease duration: 72 [24-132] months) were collected. We recorded 98 (86%) live births and 16 (14%) miscarriages (8 missing data). Cesarean section was performed in 15/98 (15%) cases. Median week of gestation at delivery was 39 [38-40]; 8 preterm births (<37 week of gestation) and 2 severe preterm births (<34 week of gestation) occurred. There was no difference between PsA or ‘other’SpA concerning pregnancy outcome and route of delivery.

Fourty-two pregnancies (40%) had at least 1 flare during pregnancy; 7 pregnancies had more than 1 flare. Overall, there were 13, 24 and 12 flares in the 1st, 2nd and 3rd trimester, respectively. A higher frequency of patients with axial involvement was observed in the ‘flare’ group as compared to pregnancies without flare (83% vs 59%, p=0.02) (Table 1).

Table 1. Comparison between ‘flare’ and ‘without flare’ groups.

<table>
<thead>
<tr>
<th></th>
<th>FLARE (42)</th>
<th>WITHOUT FLARE (64)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at conception (years)</td>
<td>33 (31-37)</td>
<td>33 (31-35)</td>
<td>0.88</td>
</tr>
<tr>
<td>Disease duration at conception (months)</td>
<td>71 (24-120)</td>
<td>60 (24-137)</td>
<td>0.74</td>
</tr>
<tr>
<td>PsA (n)</td>
<td>13 (31%)</td>
<td>31 (48%)</td>
<td>0.11</td>
</tr>
<tr>
<td>‘other’SpA (n)</td>
<td>29 (69%)</td>
<td>33 (52%)</td>
<td>0.11</td>
</tr>
<tr>
<td>Axial involvement (n)</td>
<td>35 (83%)</td>
<td>38 (59%)</td>
<td>0.02</td>
</tr>
<tr>
<td>Peripheral involvement (n)</td>
<td>30 (%)</td>
<td>54 (%)</td>
<td>0.17</td>
</tr>
<tr>
<td>bDMARDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any time before pregnancy</td>
<td>16 (38%)</td>
<td>19 (30%)</td>
<td>0.49</td>
</tr>
<tr>
<td>Stop at pregnancy test/1st trimester</td>
<td>8 (19%)</td>
<td>6 (9%)</td>
<td>0.09</td>
</tr>
<tr>
<td>Start/continue 1st trimester</td>
<td>7 (17%)</td>
<td>10 (16%)</td>
<td>0.89</td>
</tr>
<tr>
<td>Start in 2nd trimester</td>
<td>5 (12%)</td>
<td>0</td>
<td>0.02</td>
</tr>
<tr>
<td>Start in 3rd trimester</td>
<td>2 (5%)</td>
<td>0</td>
<td>0.30</td>
</tr>
<tr>
<td>Post-partum flare</td>
<td>11/34 (32%)</td>
<td>22/49 (45%)</td>
<td>0.36</td>
</tr>
</tbody>
</table>

Continuous variables were compared using Mann-Whitney test; categorical variables were compared using Chi-square with Yates’ correction or Fisher’s exact test.

Medications resumed to treat flare were steroids (29 pregnancies), csDMARDs (14 pregnancies) and TNF-inhibitors (7 pregnancies: 5 during the 2nd and 2 during the 3rd trimester).

A post-partum flare was registered in 33/83 (40%) of cases, without difference between ‘flare’ group vs ‘without flare’ group (Table 1), as well as between PsA vs ‘other’SpA pregnancies (47% vs 33%, p=0.2).

Conclusion: In this cohort of SpA pregnancies, 40% experienced a flare during pregnancy and 40% during post-partum. Flares occurred more frequently in the 2nd trimester and especially in patients with axial involvement, requiring the start of a TNF-inhibitor during the 2nd or the 3rd trimester in 7 pregnancies. Having a flare during pregnancy was not associated with a post-partum flare.

Disclosure of Interests: None declared

Table 1. Frequency of Spinal MRI lesions According to SIJ Imaging Positive for AxSpA

<table>
<thead>
<tr>
<th>MRI Spinal Lesions, N (%)</th>
<th>MRIglobal SIJ+ (n=19)</th>
<th>MRIglobal SIJ- (n=32)</th>
<th>P value</th>
<th>MRIglobal SIJ+ and/or mNY+ (n=22)</th>
<th>MRIglobal SIJ- and mNY- (n=29)</th>
<th>P value</th>
<th>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</th>
<th>MRIglobal SIJ- SpA Diagnosis- (n=15)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI Spinal Lesions, N (%)</td>
<td>MRIglobal SIJ+ (n=19)</td>
<td>MRIglobal SIJ- (n=32)</td>
<td>P value</td>
<td>MRIglobal SIJ+ and/or mNY+ (n=22)</td>
<td>MRIglobal SIJ- and mNY- (n=29)</td>
<td>P value</td>
<td>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</td>
<td>MRIglobal SIJ- SpA Diagnosis- (n=15)</td>
<td>P value</td>
</tr>
<tr>
<td>MRI Spinal Lesions, N (%)</td>
<td>MRIglobal SIJ+ (n=19)</td>
<td>MRIglobal SIJ- (n=32)</td>
<td>P value</td>
<td>MRIglobal SIJ+ and/or mNY+ (n=22)</td>
<td>MRIglobal SIJ- and mNY- (n=29)</td>
<td>P value</td>
<td>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</td>
<td>MRIglobal SIJ- SpA Diagnosis- (n=15)</td>
<td>P value</td>
</tr>
<tr>
<td>MRI Spinal Lesions, N (%)</td>
<td>MRIglobal SIJ+ (n=19)</td>
<td>MRIglobal SIJ- (n=32)</td>
<td>P value</td>
<td>MRIglobal SIJ+ and/or mNY+ (n=22)</td>
<td>MRIglobal SIJ- and mNY- (n=29)</td>
<td>P value</td>
<td>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</td>
<td>MRIglobal SIJ- SpA Diagnosis- (n=15)</td>
<td>P value</td>
</tr>
<tr>
<td>MRI Spinal Lesions, N (%)</td>
<td>MRIglobal SIJ+ (n=19)</td>
<td>MRIglobal SIJ- (n=32)</td>
<td>P value</td>
<td>MRIglobal SIJ+ and/or mNY+ (n=22)</td>
<td>MRIglobal SIJ- and mNY- (n=29)</td>
<td>P value</td>
<td>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</td>
<td>MRIglobal SIJ- SpA Diagnosis- (n=15)</td>
<td>P value</td>
</tr>
<tr>
<td>MRI Spinal Lesions, N (%)</td>
<td>MRIglobal SIJ+ (n=19)</td>
<td>MRIglobal SIJ- (n=32)</td>
<td>P value</td>
<td>MRIglobal SIJ+ and/or mNY+ (n=22)</td>
<td>MRIglobal SIJ- and mNY- (n=29)</td>
<td>P value</td>
<td>MRIglobal SIJ+ SpA Diagnosis+ (n=17)</td>
<td>MRIglobal SIJ- SpA Diagnosis- (n=15)</td>
<td>P value</td>
</tr>
</tbody>
</table>

**Conclusion:** TNFi are effective at improving BASMI in patients with axSpA, in a real-life setting. This effect is mainly explained by the reduction in disease activity. However, a direct effect of TNFi on BASMI could also be demonstrated, when disease activity was measured by BASDAI, suggesting that ASDAS captures additional factors that can influence spinal mobility. These potential factors deserve further investigation, but they could for example include biomechanical properties of tendons and myofascial tissue.

**Disclosure of Interests:** Ana Sofia Pinto: None declared, Bohao Yao: None declared, Claire Harris: None declared, Pedro Machado: Speakers bureau: Received consulting/speaker’s fees from Abbvie, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, Consultant of: Received consulting/speaker’s fees from Abbvie, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript.

**DOI:** 10.1136/annrheumdis-2022-eular.3876

POS0513

**MRI SPINAL LESIONS IN PATIENTS WITHOUT MRI OR RADIOGRAPHIC LESIONS IN THE SACROLIAC JOINTS TYPICAL OF AXIAL SPONDYLOARTHROPATHIES**

W. P. Maksymowych1, M. Østergaard2, X. Baraliakos3, P. Machado4, S. J. Pedersen5, U. Weber6, I. Eshed7, M. De Hooge7, J. Sieper8, D. Podobny9, M. Rudwaleit9, D. Van der Heijde10,11, R. G. Lambert10,11 on behalf of ASAS MRI Imagine, 1University of Alberta, Medicine, Edmonton, Canada; 2Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; 3Rheumazentrum Ruhrgebiet Heme, Rheumatology, Heme, Germany; 4University College London, Rheumatology, London, United Kingdom; 5Practice Buchsbaum, Rheumatology, Schaffhausen, Switzerland; 6Sheba Medical Center, Radiology, Tel Aviv, Israel; 7University Hospital Gent, Rheumatology, Ghent, Belgium; 8Charité – Universitätsmedizin, Rheumatology, Berlin, Germany; 9Klinikum Bielefeld, Rheumatology, Bielefeld, Germany; 10Leiden University Medical Center, Rheumatology, Leiden, Netherlands; 11Amsterdam University Medical Centers; Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; 12Zuyderland MC, Rheumatology, Heeren, Netherlands; 13University of Alberta, Radiology, Edmonton, Canada

**Background:** There are limited data as to the frequency of spinal lesions on MRI in patients without MRI or radiographic features typical of sacroiliac joint (SIJ) disease and to what degree spine MRI might enhance diagnostic evaluation.

**Objectives:** To assess the frequency of MRI lesions of the spine in the ASAS-Classification Cohort according to the presence of MRI SIJ lesions typical of axSpA and/or radiographic sacroiliitis (mNY+).

**Methods:** MRI spine lesions were recorded by ≥9 readers in an eCRF that captures global assessment of the spine ("Is the MRI consistent with axSpA yes/no") (yes=MRI global spine+ and detailed anatomical-based scoring of each discovertebral unit plus lateral and posterior structures. Independently, readers globally assessed SIJ scans for active and/or structural lesions typical of axSpA. We compared the frequency of MRIglobal spine+ and frequencies of different types of spinal lesions according to the presence/absence of axSpA on global evaluation of SIJ scans by ≥5 of 9 readers (MRIglobal SIJ+ and mNY+ sacroiliitis using Fisher’s exact test. Analysis was also stratified by rheumatologist diagnosis.

**Results:** Among 51 cases with SIJ as well as spine MRI, we recorded 108 MRI global SIJ+ and 12 (23.5%) and 7 (13.7%) had MRI global spine+ by ≥2 and ≥5 reader agreement, respectively. MRI global spine+ occurred significantly more frequently in the presence of mNY+ sacroiliitis and MRIglobal SIJ but was also recorded in 4 of 32 (12.5%) (≥2 readers) and 1 of 32 (3.4%) (≥5 readers) cases that were MRI global spine- and x-ray negative, all 4 cases being diagnosed with axSpA. Moreover, vertebral corner BME lesions, but not spinal structural lesions, were significantly more frequent in MRIglobal SIJ+ cases that had been clinically diagnosed as axSpA versus non-axSpA (Table 1).

**Conclusion:** Spinal lesions on MRI indicative of axSpA per majority read occurred in about 3% of patients without positive imaging in the SIJ. Frequency of spinal BME lesions was higher in cases with negative SIJ imaging but clinically diagnosed with axSpA.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4151

POS0514

**INFLAMMATION IS ASSOCIATED WITH INCIDENT HYPERTENSION IN PATIENTS WITH AXIAL SPONDYLOARTHROPATHIES: A LONG-TERM FOLLOW-UP STUDY**

J. L. H. Shi1, S. H. M. Lam2, H. So3, E. Li4, T. K. Li5, C. C. Szeto2, L. S. Tam2,1

1The Chinese University of Hong Kong, Medicine & Therapeutics, Hong Kong, China; 2The Chinese University of Hong Kong, Medicine & Therapeutics, Hong Kong, Hong Kong (SAR)

**Background:** Axial spondyloarthritis (axSpA) patients have increased risks of developing cardiovascular diseases (CVD) compared to the general population. Hypertension (HT) as the most common CV risk factor in these patients. Whether chronic, low-grade inflammation predispose to the development of incident hypertension in axSpA remained uncertain.

**Objectives:** To examine the association between markers of systemic inflammation and incident hypertension in axSpA patients.

**Methods:** A cohort analysis was performed in patients with axSpA who had been followed since January 2001. Patients diagnosed with hypertension and/or on anti-hypertensives at baseline were excluded. The primary outcome was first diagnosis of HT occurring between January 2001 and December 2020. Three different CVD risk scores including Framingham risk score (FRS), QRISK3 and SCORE were computed at baseline. Baseline demographic data and clinical inflammatory markers, medications, and the occurrence of incident HT was assessed using time-varying Cox proportional hazard models after adjusting for baseline CVD risk scores.
Results: 413 patients [34(25-43) years, male: 319 (77.2%)] were recruited. After a median follow up of 12 (6-17) years, 58 patients (14%) developed incident HT (IHT-group). In baseline multivariable Cox regression analysis, ESR and CV risk scores were significantly associated with developing IHT (p<0.05) (Table 1). Using time-varying multivariate analysis, higher inflammatory burden (ESR≥20) was significantly associated with developing HT after adjusting for FRS and SCORE respectively. Use of csDMARDs was significantly linked to develop IHT after adjusting for baseline FRS, while a trend suggesting that csDMARDs was associated with an increased risk of HT after adjusting for baseline SCORE was observed (Table 2).

Table 1. Multivariable analysis with Cox proportional hazard regression for the baseline predictors of incident HT.

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HR (95%CI)</strong></td>
<td><strong>p-value</strong></td>
</tr>
<tr>
<td><strong>BASDAI≥5</strong></td>
<td>1.44 (0.78, 2.67)</td>
</tr>
<tr>
<td><strong>ESR</strong></td>
<td>1.01 (1.00, 1.02)</td>
</tr>
<tr>
<td><strong>BASFI</strong></td>
<td>1.03 (1.00, 1.02)</td>
</tr>
<tr>
<td><strong>Baseline disease duration</strong></td>
<td>1.04 (1.00, 1.08)</td>
</tr>
<tr>
<td><strong>Symptom duration</strong></td>
<td>1.01 (0.98, 1.05)</td>
</tr>
<tr>
<td><strong>FRS</strong></td>
<td>1.05 (1.03, 1.08)</td>
</tr>
</tbody>
</table>

Table 2. Multivariable analysis with Cox proportional hazard regression for the time-dependent predictors of incident HT.

<table>
<thead>
<tr>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HR (95%CI)</strong></td>
<td><strong>p-value</strong></td>
</tr>
<tr>
<td><strong>BASDAI≥5</strong></td>
<td>1.53 (0.84, 2.78)</td>
</tr>
<tr>
<td><strong>ESR</strong></td>
<td>1.01 (1.00, 1.02)</td>
</tr>
<tr>
<td><strong>BASFI</strong></td>
<td>1.03 (0.99, 1.15)</td>
</tr>
<tr>
<td><strong>Baseline disease duration</strong></td>
<td>1.04 (1.00, 1.08)</td>
</tr>
<tr>
<td><strong>Symptom duration</strong></td>
<td>1.01 (0.98, 1.05)</td>
</tr>
<tr>
<td><strong>FRS</strong></td>
<td>1.05 (1.03, 1.08)</td>
</tr>
</tbody>
</table>

Conclusion: Higher baseline and time-varying inflammatory burden predict the development of IHT in addition to traditional CV risk scores in axSpA patients. While exposure to csDMARDs may be associated with the development of IHT, NSAIDs and biologic DMARDs use were not associated with the development of IHT.

REFERENCES:

Table 2a. Multivariable analysis with Cox proportional hazard regression for the time-dependent predictors of incident HT.

<table>
<thead>
<tr>
<th>Time-dependent HR (95%CI)</th>
<th>p-value</th>
<th>Time-dependent HR (95%CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ESR</strong></td>
<td>2.24 (1.04, 4.82)</td>
<td>0.04*</td>
<td>2.16 (1.00, 4.68)</td>
</tr>
<tr>
<td><strong>csDMARDs</strong></td>
<td>1.05 (1.01, 1.08)</td>
<td>0.008*</td>
<td>1.24 (1.09, 1.41)</td>
</tr>
</tbody>
</table>

Table 2b.

_**Proportion Mediated, %**_

<table>
<thead>
<tr>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Effect Estimate (OR), 95% CI</strong></td>
<td><strong>Proportion Mediated, %</strong></td>
</tr>
<tr>
<td><strong>Indirect (Mediation) Effect</strong></td>
<td></td>
</tr>
<tr>
<td>Education (high school or less)</td>
<td>1.01 (0.98 to 1.03)</td>
</tr>
<tr>
<td>Poverty</td>
<td>1.07 (1.04 to 1.10)</td>
</tr>
<tr>
<td>Alcohol consumption (# drinks/week, continuous)</td>
<td>0.99 (0.96 to 1.01)</td>
</tr>
<tr>
<td>DASH diet score (continuous; higher scores = less adherence)</td>
<td>1.05 (0.96 to 1.01)</td>
</tr>
<tr>
<td>Body mass index (continuous)</td>
<td>1.25 (1.14 to 1.37)</td>
</tr>
<tr>
<td>Diuretic use</td>
<td>1.03 (1.01 to 1.05)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>1.10 (1.04 to 1.16)</td>
</tr>
<tr>
<td><strong>Direct Effect</strong></td>
<td></td>
</tr>
<tr>
<td>0.94 (0.69 to 1.30)</td>
<td>-15.2%</td>
</tr>
<tr>
<td><strong>Total Effect</strong></td>
<td>1.49 (1.12 to 1.98)</td>
</tr>
</tbody>
</table>

DASH-Dietary Approaches to Stop Hypertension; *p=0.52, **p=0.83*.

Among men, CKD was the largest mediator (46%), followed by poor diet (20%) and diuretic use (14%). BMI (12%) and poverty (0.5%) mediated smaller proportions of the racial difference among men compared to women. Mediators of racial differences in hyperuricemia closely agreed with gout results.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4206
Conclusion: Current experiences of PRPs involving in research

1.Current experiences of PRPs involvement in research
   Researcher experiences of involving PRPs
   Patient experiences of being involved as PRPs

2. The role of PRP in registries and research
   Complementary perspectives between researchers and PRPs
   The aim of patient involvement in research
   Consider professional and social backgrounds

3. Points to consider for involving PRPs in research
   Provide PRPs education and training
   A welcoming environment for PRPs to contribute
   Give PRPs a voice in research committees
   Identify questions that are most relevant to patients
   Select the most relevant outcomes to patients
   Improve recruitment strategies
   Analyze, interpretation and dissemination of results
   Recruitment of PRPs from ethnic minorities

4. PRP involvement in different phases of the research process
   Researcher
   Recruiting PRPs from ethnic minorities
   Identifying questions that are most relevant to patients
   Selecting the most relevant outcomes to patients
   Improving recruitment strategies
   Analyzing, interpretation and dissemination of results
   Limited financial resources

5. Barriers to involving PRPs in research
   Researchers' preconceptions of patient's ability to be involved in research
   Challenging to ask patients to help analyze quantitative data
   Recruiting PRPs from ethnic minorities

Table 1. Overview of themes, sub-themes, and presence of theme according to which focus group discussion.

<table>
<thead>
<tr>
<th>Theme</th>
<th>Sub theme</th>
<th>Focus Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Current experiences of PRPs involvement in research</td>
<td>Researcher experiences of involving PRPs</td>
<td>X</td>
</tr>
<tr>
<td>2. The role of PRP in registries and research</td>
<td>Patient experiences of being involved as PRPs</td>
<td>X</td>
</tr>
<tr>
<td>3. Points to consider for involving PRPs in research</td>
<td>Complementary perspectives between researchers and PRPs</td>
<td>X</td>
</tr>
<tr>
<td>4. PRP involvement in different phases of the research process</td>
<td>The aim of patient involvement in research</td>
<td>X</td>
</tr>
<tr>
<td>5. Barriers to involving PRPs in research</td>
<td>Consider professional and social backgrounds</td>
<td>X</td>
</tr>
</tbody>
</table>

Figure 1. The empirical research cycle - basis for discussion of the role, opportunities & challenges for patient research partners in registry and observational drug study research. X/Y indicates the number of votes for including PRPs at the respective stage.

Conclusion: There is room and much appreciation of PRP involvement in registry research. Researchers and PRPs could use the strategies proposed in this study to define PRP roles and plans of ongoing and future studies.

Disclosure of Interests: Paul Studenic; None declared, Mandeep Sekhon; None declared, Loreto Carmona; None declared, Maarten de Wit; None declared, Elena Nikphorou Speakers bureau: Celtrion, Pfizer, Sanofi, Gilead, Galapagos, Abbvie, Eli Lilly, Grant/research support from: Pfizer, Eli Lilly

For patients with DER, vaccination coverage significantly increased from 47 % to 87 % for FLU (p<0.001), from 73 % to 82 % for Pnc (p<0.001), from 57 % to 79 % for Hep B (p<0.001) and from 34 % to 67 % overall (p<0.001) (Figure 1).

Similarly, the vaccination coverage in IBD patients significantly increased from 76 % to 87 % for FLU (p<0.001), from 73 % to 82 % for Pnc (p<0.001), from 57 % to 73 % for Hep B (p<0.001) and from 34 % to 74 % overall (p<0.001) (Table 1).

Table 1. Vaccine coverage in 2018 vs. 2021 in patients with IMID

<table>
<thead>
<tr>
<th></th>
<th>FLU (%)</th>
<th>Pnc (%)</th>
<th>Hep B* (%)</th>
<th>TT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p-value &gt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>p-value &gt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>p-value &gt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td></td>
</tr>
<tr>
<td>p-value &gt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td>p-value &lt; 0.001</td>
<td></td>
</tr>
</tbody>
</table>

*recommended in all senescent IMID patients with IBD and patients at risk for other IMIDs.

Conclusion: The implementation of a vaccination tool integrated in the EMR coincided with a significant increase in vaccination rates and also in the total amount of IMID patients that were fully vaccinated according to guidelines. Quite likely, the suboptimal vaccination rate measured in 2018 and the COVID-19 pandemic also raised awareness among patients and healthcare professionals about the importance of following vaccination guidelines.

Disclosure of Interests: Johanna Joly: None declared, Barbara Neerinckx Grant/research support from: Pfizer, Kurt De Vlam Speakers bureau: Celgene Eli Lilly, Galapagos, Novartis, UCB, Consultant of: Celgene, Eli Lilly, Amgen, AbbVie, Galapagos, Novartis, UCB, Grant/research support from: Celgene and Galapagos. Liselotte Fieren: None declared, Els De Dycker: None declared, Tine Vanhoutvin: None declared, Petra De Haes Speakers bureau: Celgene, GSK, Novartis, Consultant of: Celgene, GSK, Novartis, Paul De Munter Grant/research support from: Sanofi-Pasteur, Joao Sabino Speakers bureau: Abbvie, Falk, Takeda, Janssen, Fresenius, Consultant of: Janssen, Ferring, Grant/research support from: Galapagos, Severine Vermeire Speakers bureau: Abbvie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Roberts Clinical Trials, Second Genome, Shire, Sunovion, Takeda, Theravance, Tilots Pharma AG, Consultant of: Abbvie, Abivax, Agomab, Arena Pharmaceuticals, Avaxia, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dr Falk Pharma, Ferring, Galapagos, Genentech-Roche, Gilead, GSK, Hospira, Janssen, Mundipharma, MSD, Pfizer, Prodigest, Progenity, Prometheus, Roberts Clinical Trials, Second Genome, Shire, Sunovion, Takeda, Theravance, Tilots Pharma AG, Grant/research support from: Abbvie, J&J, Pfizer, Galapagos, Takeda, Marc Ferrante Speakers bureau: Abbvie, Amgen, Biogen, Boehringer Ingelheim, Falk, Ferring, Janssen, Lameprot, MSD, Mylan, Pfizer, Sandoz, Takeda, Truvion Healthcare, Consultant of: Abbvie, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Medtronic, MSD, Pfizer, Sandoz, Takeda, Thermo Fisher, Grant/research support from: Abbvie, Amgen, Biogen, Janssen, Pfizer, Takeda, Viatris, Patrick Verschueren Speakers bureau: Eli Lilly, MSD, Galapagos, Roularta, Consultant of: Eli Lilly, Nordic Pharma, Galapagos, Gilead, Pfizer, Abbvie, Celgene, Celltrion, BMS, UCB, Pfizer, Sidekick Health, Grant/research support from: Pfizer.


POS0158 ADHERENCE TO TELEMONITORING DISEASE ACTIVITY BY ELECTRONIC PATIENT REPORTED OUTCOMES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A PROSPECTIVE COHORT STUDY


1Amsterdam Rheumatology & Immunology Center, Reade, Rheumatology, Amsterdam, Netherlands; 2Amsterdam UMC Location VUMc, Department of Epidemiology & Data Science, Amsterdam, Netherlands

Background: The use of electronic patient reported outcome measures (ePROMs) enables telemonitoring disease activity in patients with inflammatory arthritis in between consultations. However, recent telemonitoring studies report declining long-term adherence to reporting ePROMs1-7. What factors are associated with a decline in adherence is not known.

Objectives: To investigate the factors that are associated with adherence to telemonitoring by an ePROM in patients with inflammatory arthritis.

Methods: We performed a prospective cohort study in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) at Reade Amsterdam, The Netherlands. Patients telemonitored their disease activity weekly for 6 months with a modified Multidimensional Health Assessment Questionnaire including the Routine Assessment of Patient Index Data 3 (RAPID3) that was completed in the "MijnReuma" Reade smartphone application. Adherence was defined as the percentage of weeks completed with ePROM and time to dropout as 4 weeks nonscoring. Based on literature and through expert meetings, 13 baseline factors were selected to assess their association with dropout through multivariable Cox-regression analysis. The association with the system usability score (measured at 3 months, 1-100) was analyzed with a linear regression for patients who dropped out in month 1, month 2-3 and month 4-6.

Results: A total of 220 consecutive patients was included (mean age 54, 55% females, median disease duration 9 years), of which 99 had RA, 81 PsA, and 40 AS. Adherence to telemonitoring declined from 81% (week 1) to 39% (week 26). Median time to dropout was 17 weeks; a total of 141 patients (64%) stopped
telemonitoring their disease activity. Women had a higher chance to dropout over time compared to men (HR 1.6, p=0.02). The reported usability of the app was higher for patients who were adherent throughout the study (82%) compared to patients who dropped out in the 1st month (68%; p<0.001), 2nd-3rd month (71, p=0.001) and 4th-6th month (78, p=0.18).

**Conclusion:** Women stopped reporting the ePROM sooner than man and the usability score of the app differed between the adherence and drop-out group. Future research is needed to investigate if the association between the usability score of the app and adherence is causal, and thus if improvements in the usability will lead to lower dropouts. Furthermore, we will perform focus group discussions to identify why women tend to dropout sooner, since this is in contrary to previous research.

**REFERENCES:**


<table>
<thead>
<tr>
<th>Variable</th>
<th>HR</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>1.58</td>
<td>1.06; 2.36</td>
<td>0.02</td>
</tr>
<tr>
<td>Higher education</td>
<td>1.36</td>
<td>0.92; 2.02</td>
<td>0.13</td>
</tr>
<tr>
<td>Biological usage</td>
<td>1.18</td>
<td>0.83; 1.68</td>
<td>0.35</td>
</tr>
<tr>
<td>High medication adherence</td>
<td>1.14</td>
<td>0.80; 1.63</td>
<td>0.47</td>
</tr>
<tr>
<td>Diagnosis (relative to RA)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsA</td>
<td>1.14</td>
<td>0.77; 1.69</td>
<td>0.53</td>
</tr>
<tr>
<td>AS</td>
<td>1.09</td>
<td>0.63; 1.90</td>
<td>0.76</td>
</tr>
<tr>
<td>Smartphone usage</td>
<td>1.08</td>
<td>0.94; 1.23</td>
<td>0.29</td>
</tr>
<tr>
<td>Charlson Comorbidity index</td>
<td>1.05</td>
<td>0.78; 1.40</td>
<td>0.76</td>
</tr>
<tr>
<td>Resident in Amsterdam</td>
<td>1.02</td>
<td>0.72; 1.44</td>
<td>0.03</td>
</tr>
<tr>
<td>Disease duration</td>
<td>1.01</td>
<td>0.99; 1.02</td>
<td>0.49</td>
</tr>
<tr>
<td>Interaction patient-physician</td>
<td>1.00</td>
<td>0.92; 1.09</td>
<td>1.00</td>
</tr>
<tr>
<td>Self-management</td>
<td>1.00</td>
<td>0.98; 1.02</td>
<td>0.72</td>
</tr>
<tr>
<td>Age</td>
<td>0.99</td>
<td>0.96; 1.02</td>
<td>0.39</td>
</tr>
<tr>
<td>RAPID3</td>
<td>0.97</td>
<td>0.89; 1.06</td>
<td>0.51</td>
</tr>
</tbody>
</table>

**Table 1. Hazard ratios for dropout**

**Figure 1.** Percentage weekly completed ePROMs during the study.

**Disclosure of Interests:** Jim Wiegèl: None declared, Bar Seppen: None declared, Marieke ter Wee: None declared, Michael Nurmohamed: None declared, W.H. Bos Grant research support from: novartis and sanofi genzyme. DOI: 10.1136/annrheumdis-2022-eular.2610

**POS0159**

**SEX-RELATED DISPARITIES IN HEALTHCARE UTILIZATION IN PATIENTS WITH INFLAMMATORY ARTHRITIS: A POPULATION-BASED STUDY**

S. Taranum1, 2, J. Widdiffe3, 4, F. Wu3, S. Johnson3, 6, P. Rochon3, L. Eder1, 2, 5

1Women’s College Hospital, Women’s College Research Institute, Toronto, Canada; 2University of Toronto, Medicine, Toronto, Canada; 3Sunnybrook Research Institute, Health Sciences Research, Toronto, Canada; 4ICES, Statistics, Toronto, Canada; 5Toronto Western Hospital, Rheumatology, Toronto, Canada; 6Mount Sinai Hospital, Rheumatology, Toronto, Canada

**Background:** Delayed diagnosis of inflammatory arthritis (IA) such as rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) is associated with joint damage and disability. So regular timely assessment by both family physicians and specialists is necessary for favorable disease outcomes. Sex (biology) and gender (socio-cultural) related factors influence clinical patterns of IA, patient behavior and their interaction with care providers. This influence could be reflected in patterns of healthcare utilization.

**Objectives:** To compare patterns of musculoskeletal (MSK)-related healthcare utilization before and after diagnosis between male and female patients with IA in Ontario, Canada.

**Methods:** We assembled 3 inception cohorts of adult RA, AS and PsA patients diagnosed between April 2010 and March 2017 using Ontario health administrative data. MSK-related healthcare utilization patterns in terms of visits to physicians, MSK imaging and laboratory tests were assessed yearly for 3 years before and after the diagnosis date, and compared between male and female patients. Among individuals ≥ 66 years, prescriptions for rheumatic drugs (NSAIDs, corticosteroids, csDMARDs, advanced therapy (bDMARDs and tsDMARDs)) and opioids were ascertained. Regression models were used to compare healthcare utilization indicators between males and females after adjusting for demographics and comorbidities.

**Results:** A total of 41,277 patients with RA (69% females), 8,150 patients with AS (51% females) and 6,446 patients with PsA (54% female) were analyzed. Male patients were significantly older than female patients only in the RA cohort (mean age M 60.4 y, F 57.1 y). Multimorbidity, depression and osteoporosis were more common in female patients and cardiovascular disease in male patients across the 3 cohorts.

Similar trends of sex-related differences were observed in all three cohorts. Female patients were more likely to visit rheumatologists and family physicians than male patients especially in earlier pre-diagnosis periods (Figure 1). Male patients were more likely to visit emergency department immediately before diagnosis. A similar female predominance was observed in imaging modalities of X-rays and ultrasounds (adjusted ORs for F:M 1.15 - 1.25 for X-rays and 1.07 - 1.44 for ultrasounds), and laboratory tests before diagnosis (adjusted ORs for F:M 1.10 to 2.17 across the three cohorts).

Overall DMARD prescription patterns in older male and female patients were similar across the three cohorts except more csDMARD prescriptions in female AS patients (Table 1). Female RA patients were more likely to use NSAIDs and opioids.

**Table 1. Odds ratios for prescription patterns in inflammatory arthritis for older female to male patients after diagnosis**

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Adjusted Odds Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>csDMARD</td>
</tr>
<tr>
<td>Yr 1</td>
<td>1.00 (0.92, 1.09)</td>
</tr>
<tr>
<td>Yr 2</td>
<td>1.00 (0.92, 1.08)</td>
</tr>
<tr>
<td>Yr 3</td>
<td>1.05 (0.97, 1.14)</td>
</tr>
<tr>
<td>Advanced therapy</td>
<td></td>
</tr>
<tr>
<td>Yr 1</td>
<td>0.99 (0.78, 1.25)</td>
</tr>
<tr>
<td>Yr 2</td>
<td>1.17 (0.99, 1.39)</td>
</tr>
<tr>
<td>Yr 3</td>
<td>1.23 (1.05, 1.45)</td>
</tr>
<tr>
<td>NSAID</td>
<td></td>
</tr>
<tr>
<td>Yr 1</td>
<td>1.14 (1.04, 1.25)</td>
</tr>
<tr>
<td>Yr 2</td>
<td>1.1 (0.99, 1.23)</td>
</tr>
<tr>
<td>Yr 3</td>
<td>1.16 (1.04, 1.30)</td>
</tr>
<tr>
<td>Opioid</td>
<td></td>
</tr>
<tr>
<td>Yr 1</td>
<td>1.39 (1.22, 1.58)</td>
</tr>
<tr>
<td>Yr 2</td>
<td>1.51 (1.32, 1.72)</td>
</tr>
<tr>
<td>Yr 3</td>
<td>1.46 (1.27, 1.68)</td>
</tr>
</tbody>
</table>

Bolded results are statistically significant (p < 0.05). Odds ratios for female to male patients adjusted for age, residence, income quintiles, comorbidities and access to rheumatologists.

**Conclusion:** Female patients with IA have higher MSK-related healthcare utilization which may indicate biological differences in disease course or sociocultural differences in healthcare seeking behavior between male and female patients.

**REFERENCES:** N/A

**Acknowledgements:** Dr. Sanjana Taranum received funds from the Enid Walker Graduate Student Award for Research in Women’s Health for this study.
Dr. Widdifield receives support from the Arthritis Society Stars Career Development Award (STAR-19-0610).

Dr. Johnson has been awarded a Canadian Institutes of Health Research New Investigator Award.

Dr. Paula Rochon holds the RTOERO Chair in Geriatric Medicine at the University of Toronto.

Dr. Lihi Eder has been awarded Early Researcher Award from the Ontario Ministry of Research, Innovation and Science and Canada Research Chair (Tier 2) in Inflammatory Rheumatic Diseases.

Disclosure of Interests: Senjana Tarannum: None declared, Jessica Widdifield: None declared, Fangyun Wu: None declared, Sindhu Johnson: None declared, Paula Rochon: None declared, Lihi Eder Grant/research support from: UCB, AbbVie, Pfizer, Janssen, Novartis, Eli Lilly, Sandoz Advisory board: AbbVie, Pfizer, Janssen, Novartis, Eli Lilly


**POS0160** THE EMPLOYMENT GAP IN PEOPLE WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES COMPARED WITH THE GENERAL POPULATION: A SYSTEMATIC LITERATURE REVIEW

S. Verstappen1, A. Boonen2, N. Goodson3, C. Webens3, M. Butink2, N. Betteridge4, T. Stamm5, D. Wiek6, A. Woolf7, H. Bijlsma8, G. R. Burmester9 on behalf of the EULAR Task Force on Work. 1The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Maastricht University Medical Center, Department of Internal Medicine, Maastricht, Netherlands; 3Liverpool University NHS Foundation Trust, Department of Rheumatology, Liverpool, United Kingdom; 4Neil Betteridge Associates, N/A, London, United Kingdom; 5Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria; 6Patient Research Partner, People with Arthritis and Rheumatism (PARE) - EULAR, N/A, N/A, Germany; 7Bone and Joint Research Group, Royal Cornwall Hospital, Turo, United Kingdom; 8University Medical Center Utrecht, Dept of Rheumatology & Clinical Immunology, Utrecht, Netherlands; 9Charité - Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Background: Many people with rheumatic and musculoskeletal diseases (RMDs) experience problems at work and some may even have to stop working due to ill health. In most countries, RMDs are a major cause of worker productivity loss. The peak age of onset of many adult onset RMDs is between ~30-50 years, meaning that the majority of patients are still in employment when diagnosed with their chronic disease. Uncertainty about employment prospects and job attainment is also a major concern for young adults with juvenile idiopathic arthritis (JIA) for whom their first job may influence their future employment prospects. From both a societal and patient perspective it is important to gain an understanding about the impact of juvenile and adult onset RMDs on work outcomes.

Methods: A systematic literature review (SLR) was conducted to compare work outcomes in people with various RMDs (i.e. JIA, RA, PsA, AxSpA, SSc, SLE, gout, FM, and OA) with the general population or healthy controls as part of the EULAR Task Force on work. A search for eligible observational studies was performed in Medline, Embase and PsycInfo between 2000 and May 2021. Work outcomes were categorized according to employment status, work disability/ stopped working due to ill health, absenteeism, presenteeism and other.

Results: 541 abstracts were extracted and screened for eligibility. Results of 65 studies fulfilling the inclusion criteria were evaluated for this study, including 28 prospective/retrospective longitudinal cohort studies, 34 cross-sectional studies and 3 (nested) case-control studies. The majority of the studies were conducted in Europe (63.1%), Germany (26.2%) followed by OA (15.4%), SLE (15.4%), AxSpA (12.3%), FM (9.2%), mixed population (7.7%), JIA (7.7%), PsA (3.1%), SSc (1.5%), and gout (1.5%). In papers reporting disease duration (n=38), the majority of the study population had established disease (76.3%). Several work outcomes were evaluated with some papers reporting more than one work outcome: employment/work status (41.5%), unemployment (9.2%), work disability/pension or stopping work due to ill health (38.5%), absenteeism (22.0%), presenteeism (10.8%), and other (e.g. reduced working hours) (29.2%). Fifty-two papers applied statistical tests (e.g. indirect standardisation, logistic regression analysis, Cox regression analysis) to compare work outcomes in people with RMDs with a control/general population. The percentage of papers reporting the work outcome to be worse, not significantly different or better in the RMD population compared to the control population (n papers included per work outcome; %) was, respectively: employment/work status (n=26; 73.1%, 23.0%, 3.8%), unemployment (n=6; 66.7%, 33.3%, 0%), work disability/stopping work (n=22; 90.3%, 9.4%, 0%), absenteeism (n=26; 92.3%, 7.7%, 0%), presenteeism (n=8; 67.5%, 12.2%, 0%), other (n=19; 84.2%, 15.8%, 0%).

Conclusions: Despite better disease management during the last two decades there is still a significant employment gap between people with RMDs and the general population. It is therefore essential that health professional organisations, policy makers, patient organisations and employers should collaborate to minimize the employment gap and optimize employment opportunities among people with juvenile and adult onset RMDs.

Disclosure of Interests: Suzanne Verstappen Consultant of: EUCOSHA, Grant/research support from: BMS, AbbVie, Pfizer, EULAR, Annelies Boonen Speakers bureau: Abbvie / Galapagos, Consultant of: Galapagos, Nicola Goodson Consultant of: UCB, Lilly, Abbvie, Novartis and Janssen, Grant/research support from: Novartis, Casper Webers: None declared, Maarten Butink: None declared, Neil Betteridge Consultant of: Amgen, Eli Lilly, EULAR, GAIPA, Grunenthal, Heart Valve Voice and Sanofi, Tonja Stamm Consultant of: AbbVie and Sanofi, Genzyme, Grant/research support from: AbbVie and Roche, Dieter Wiek: None declared, Anthony Woof: None declared, Hans Bijlsma: None declared, Gerd Rüdiger Burmester: None declared


**POS0161** WORK STATUS IN PATIENTS WITH INFLAMMATORY RHEUMATIC MUSCULOSKELETAL DISEASES: RESULTS OF A BELGIAN COMPARATIVE STUDY

A. S. De Craemer1,2,3 I. Desimpele2,3 L. Delmeze2,3, L. Deroo1,2,3, T. Renson1,2,3, S. De Mitsu2,3, V. Smith1,2,3, P. Jacques1,2,3, D. Elewaut1,2,3, P. Carron1,2,3, F. Van den Bosch1,2,3, Ghent University Hospital, Rheumatology, Ghent, Belgium; 2Ghent University, Internal Medicine and Pediatrics, Ghent, Belgium; 3VIB-UGent, Center for Inflammation Research, Ghent, Belgium

Background: Inflammatory Rheumatic Musculoskeletal Diseases (RMD) constitute a heterogeneous group of chronic disorders with a potential major individual and socio-economic burden. RMD patients often report work-related difficulties (e.g. productivity loss, sick leave, work disability) which contribute significantly to indirect costs and may lead to additional premiums or exclusion when contracting private insurances. However, work-related epidemiological data in Belgium date back to a pre-biologics era, albeit that diagnosis, management and treatment strategies have dramatically improved in the last decade.

Objectives: To investigate actual work participation status of inflammatory RMD patients in Belgium, and to benchmark these data to the general Flemish population.

Methods: During an outpatient visit at the rheumatology clinic of Ghent University Hospital, a tertiary hospital in the Flemish region, adult patients with spondyloarthritides (SpA), rheumatoid arthritis (RA), and systemic sclerosis (SSc) were questioned on their socio-economic status. Employment rate, weekly working hours and work disability were evaluated among a representative sample of all RMD patients. In 2018 national Health Interview Survey.

Results: Among the 483 patients, 262/275 (95%) SpA, 83/102 (62%) RA, and 83/106 (78%) SSc were at a work-productive age (<65 y/o). Table 1 summarises socio-demographic and clinical characteristics.

**Table 1.**

<table>
<thead>
<tr>
<th>SpA (n=262)</th>
<th>RA (n=63)</th>
<th>SSc (n=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>148 (56%)</td>
<td>59 (24%)</td>
</tr>
<tr>
<td>Age (y)</td>
<td>40.7±11.0</td>
<td>53.5±10.8</td>
</tr>
<tr>
<td>Symptom duration (y)*</td>
<td>7.8 (4.7-15.7)</td>
<td>3.3 (1.1-5.8)</td>
</tr>
<tr>
<td>Age at diagnosis (y)</td>
<td>32.6±11</td>
<td>48.3±12</td>
</tr>
<tr>
<td>Biomarker</td>
<td>170 (70%)</td>
<td>52 (82%)</td>
</tr>
<tr>
<td>Disease activity†</td>
<td>1.9±1.0</td>
<td>2.1±1.0</td>
</tr>
<tr>
<td>Functional index**</td>
<td>2.3±2.2</td>
<td>67±14</td>
</tr>
<tr>
<td>EQ-SD scale</td>
<td>0.79±0.22</td>
<td>0.80±0.18</td>
</tr>
<tr>
<td>Biologics treatment</td>
<td>123 (58%)</td>
<td>15 (24%)</td>
</tr>
<tr>
<td>Educational level</td>
<td>123 (58%)</td>
<td>15 (24%)</td>
</tr>
<tr>
<td>Low</td>
<td>100 (38%)</td>
<td>36 (57%)</td>
</tr>
<tr>
<td>High</td>
<td>232 (82%)</td>
<td>27 (43%)</td>
</tr>
<tr>
<td>Classification criteria</td>
<td>ASAS</td>
<td>46 (73%)</td>
</tr>
<tr>
<td>Disease activity†</td>
<td>axSpA: 192 (73%)</td>
<td>70 (27%)</td>
</tr>
</tbody>
</table>

† HLA B27 (SpA), RF/ACPA (RA), SSc-related auto-antibodies (SSc); †† ASDAS-CRP (SpA), DAS28 (RA), mRSS (SSc). *Disease duration from first non-Rayneud phenomenon in SSc. **BASFI (SpA), Michigan Hand Outcomes Questionnaire (RA).
Crude employment rates were 82% in SpA, 56% in RA and 63% in SSc. Age- and sex-adjusted employment rates (indirect standardization) were respectively 75%, 68%, and 66%, corresponding to a standardized employment ratio of 1.00 (95% CI 0.87 – 1.14) for SpA, 0.89 (0.64 – 1.24) for RA, and 0.88 (0.67 – 1.15) for SSc.

SpA patients worked 39.5±10.9h/week, compared to 40.9±16.9h in RA and 33.0±12.4h in SSc (p=0.003). Flemish employees worked on average 39.7h (full-time) and 25.7h (part-time) per week.

In the working population, 48% of SpA patients, 53% RA and 78% SSc reported sick leave in the previous year, compared to 42% in Flanders. Long-term work disability was reported by respectively 10%, 17% and 20% of patients (p=0.03) compared to 9% in the reference population.

The median retention time on the labour market was not significantly different between SpA (42.1 years), RA (42.1 years) and SSc (41.2 years) (p=0.94, Figure 1).

Figure 1. retention time on the labour market since start of patient’s professional career.

Conclusion: Our data refute the common perception that patients with RMDs, especially inflammatory joint diseases, have significantly worse work outcomes compared to the general population. In an era of early diagnosis and treatment, more recent datasets could be used to realistically estimate the odds of these important health economic outcomes.

Acknowledgements: The Ghent University Hospital is member of the Flemish Network on rare connective tissue diseases and of the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNECT).

Disclosure of Interests: None declared


POS0162 HOW ACCURATELY CAN WE IDENTIFY RHEUMATOID ARTHRITIS BY ICD-10 CODES? A LINKAGE OF CROSS-SECTIONAL SURVEY DATA WITH CLAIMS DATA

J. Calhoff1,2, K. Albrecht1, U. Marschall3, F. Hoffmann4. 1German Rheumatism Research Centre, Epidemiology and Health Services Research, Berlin,.; 2Charité – Universitätsmedizin Berlin, Institute for Social Medicine, Epidemiology and Health Economics, Berlin, Germany; 3BARMER Institute for Health System Research, , Wuppertal, Germany; 4Universität Oldenburg, Health Services Research, Oldenburg, Germany

Background: Claims data from health insurance companies are a valuable source in health services research to provide insights on health care provision for an unsampled patient collective. However, the available ICD-10 diagnoses have been collected for billing purposes and their validity is not clear.

Objectives: The aim of this analysis was to assess the positive predictive values (PPV) of a ICD-10 diagnosis of rheumatoid arthritis (RA) and additional criteria (specific medication, measurement of inflammatory markers, contact to a rheumatologist) in German claims data using patient-reported confirmed diagnosis as reference/gold standard.

Methods: Within the PROCLAIM project (Linking Patient-Reported Outcomes with CLAims data for health services research In Rheumatology), data from a large German statutory health insurance with 6.6 million persons aged 18 to 79 were used. We identified a random sample of persons for which an ICD-10 code for RA (M05/M06) was available in at least two quarters in outpatient care. The sample was stratified for age (18 to 49, 50 to 64, 65 to 79 years), sex and to reference value for healthy people. The number of steps per day and the time spent in MVPA were collected. Univariable meta-regression models have been computed to assess the possibility that the study characteristics may act as effect modifiers on the final meta-analysis estimate. The primary outcome is the level of physical activity evaluated with a wearable device as a number of daily steps and MVPA. The secondary outcome is the comparison of both a number of steps and MVPA to reference value for healthy people. The number of steps per day and the time spent in MVPA considered as a mean or median were collected. Missing information was calculated from available data when possible.

The reference value for steps was 7000 steps per day, this value was derived by WHO guidelines [2]. MVPA reference value was of 150 min/week and was derived by WHO guidelines [3].

Conclusion: The ICD-10 codes M05 and (less optimal) M06 have high PPVs and are therefore feasible to identify RA in claims data. The prerequisite of specific medication seems to be the most useful one in identifying RA.

Acknowledgements: Supported by the Federal Ministry of Education and Research (grants 01E1405 and 01E1902A).

Disclosure of Interests: Johanna Calhoff Paid instructor for: Rheumatologische Fortbildungsakademie GmbH. Grant/research support from: Abbvie, AstraZeneca, BMS, GSK, Galapagos, Lilly, Medac, MSD, Pfizer, Sanofi, UCB, Katinka Albrecht: None declared, Ursula Marschall Employee of: Employee of BARMER, Falk Hoffmann: None declared

DOI: 10.1136/annrheumdis-2022-eular.1133

POS0163 USEFULNESS OF WEARABLE DEVICES TO ASSESS PHYSICAL ACTIVITY IN NON-INFLAMMATORY AND INFLAMMATORY RHEUMATIC DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS

H. Ogazi1, R. Agarinis2, D. Azzolina1, F. Todino1, M. Binutti2, A. Zabotti2, D. Gregori1, L. Quartuccio1. 1Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padova, Padua, Italy; 2Division of Rheumatology, Department of Medicine, Udine, Italy

Background: In the last years, the rise of personalized medicine has grown up. So, patient-oriented wearable technologies have been developed. Wearable devices (WD) are useful to collect objective data related to physical activity. In the management of rheumatic musculoskeletal disorders (RMDs) a regular physical activity is an important recognized non-pharmacological intervention [1].

Objectives: This systematic review aims at evaluating how the use of WDs impacts physical activity in patients with non-inflammatory and inflammatory rheumatic diseases.

Methods: A systematic review and meta-analysis were performed. A comprehensive search of articles was performed in the following databases: MEDLINE via PubMed, EMBASE, CINAHL, and Scopus. A random-effect meta-analysis has been carried out on the number of steps and moderate to vigorous physical activity (MVPA). Univariable meta-regression models have been computed to assess the possibility that the study characteristics may act as effect modifiers on the final meta-analysis estimate. The primary outcome is the level of physical activity evaluated with a wearable device as a number of daily steps and MVPA. The secondary outcome is the comparison of both a number of steps and MVPA to reference value for healthy people. The number of steps per day and the time spent in MVPA considered as a mean or median were collected. Missing information was calculated from available data when possible.

The reference value for steps was 7000 steps per day, this value was derived by a literature review commissioned by the Public Health Agency of Canada on the number of steps/day suitable for adults [2]. MVPA reference value was of 150 min/week and was derived by WHO guidelines [3].
Results: An overall of 1788 studies was considered in the title/abstract screening. In the analysis, 51 articles were included, with an overall of 7488 participants. Twenty-two studies considered MVPA outcome alone, 16 studies number of steps alone and 13 studies reported information on both outcomes. The results of this meta-analysis show that there is a high level of heterogeneity, 99%, according to dia gnosis. Recommended threshold for daily steps was reached for MVPA (36.35, 95% CI 29.39-43.31) but not for daily steps (>1092.60, 95% CI 1640.42-534.77), with fibromyalgia reporting a higher number (6290, 95% CI 5109.85-7381,62) of daily steps compared to other RMDs. Patients affected by chronic inflammatory arthritis seem to fare better in terms of daily steps than the other categories. Patients with rheumatoid or other chronic arthritis reported a higher number of steps, respectively 6361 (95% CI 5382.51; 7430.35) and 6290.14 (95% CI 5198.65; 7381.62).

Non-elderly people showed a higher overall level of physical activity compared to the elderly, 6796.11 (95% CI 5974.12; 7618.13) versus 5431.85 (95% CI 4633.76; 6229.95). Non-elderly group show higher level of physical activity than the elderly, 6796.11 (95% CI 5974.12; 7618.13) versus 5431.85 (95% CI 4633.76; 6229.95). Non-elderly group show higher level of physical activity than the elderly, 6796.11 (95% CI 5974.12; 7618.13) versus 5431.85 (95% CI 4633.76; 6229.95).

Results: 2015) and benign, or likely benign, classified variants were removed. Filters were then applied to remove variants with an allele frequency >1% (based on gnomAD), depth <30 and genotype quality <80 were removed. Rarity and pathogenicity scores and manual inspection on IGV, a candidate list of 25 genes remained. The number of variants in >=2 CNO genes with variants in ≥2 CNO genes were found.

Conclusion: RMDs suffer of low level of physical activity and WUDs are useful and affordable instruments to support the increase of WUDs. Can be used in daily monitoring of physical activity in RMDs.

REFERENCES:

Improving our care and understanding of paediatric RMDs

POS0165 WHOLE EXOME SEQUENCING TO IDENTIFY RARE INFLAMMATORY VARIANTS IN AN IRISH COHORT WITH CHRONIC NONBACTERIAL OSTEOMYELITIS (CNO)

D. O’Leary1,2, O. Killeen1,2, A. G. Wilson1, 1UCD, Centre for Arthritis Research, Dublin, Ireland; 2Children’s Health Ireland, National Centre for Paediatric Rheumatology, Dublin, Ireland

Background: Chronic nonbacterial osteomyelitis (CNO) is a rare inflammatory disease affecting bone which predominantly occurs in the paediatric population. It is frequently associated with pustulosis, psoriasis, inflammatory bowel disease and arthritis, in particular enthesitis-related arthritis. Activation of the NLRP3 inflammasome has been implicated in both human and mouse models of the disease.

Objectives: To identify a candidate list of rare, deleterious variants in known inflammatory genes in an Irish cohort with CNO.

Methods: 41 unrelated Irish children with CNO were recruited. Whole exome sequencing was performed on blood using Agilent SureSelect XT Human All Exon V6 kits and Illumina HiSeq 3000 with 150bp paired-end reads. Reads were aligned to the hg19 reference genome. After preprocessing, variants were hard filtered using quality by depth (QD) > 2.0, read depth (DP) >10 and genotype quality (GQ) >30. Synonymous variants and variants with MAF > 0.01 were excluded from further analysis. Remaining variants were filtered against existing databases of genes known to be associated with inborn errors of immunity, autoimmunity or autoinflammation. The Gene Damage Index (GDI) was used to identify genes which are least tolerant to variance and CADD phred-like scores to identify variants predicted to be deleterious. Genes with variants in >2 CNO patients were included in the candidate list and variants manually checked using the Integrative Genomics Viewer (IGV).

Results: After filtering low-quality, synonymous and common variants, 17293 variants were filtered against a database of 581 known inflammatory genes. 350 rare variants in 201 genes predicted to be intolerant to variance were identified. After excluding those present in one individual only, ranking by CADD phred-like scores and manual inspection on IGV, a candidate list of 25 genes remained. The same variant in IL17RA, NLRP1 and KMT2D was present in 3 unrelated individuals (Table 1). IL17RA belongs to the Th17 pathway which is involved in psoriasis pathogenesis. NLRP1 is implicated in several autoinflammatory diseases including psoriasis. Rare variants identified in these genes are most likely to be disease-causing. All the individuals carrying these variants in IL17RA or NLRP1 have psoriasis. One individual with IL17RA variant has 1°-degree family history of psoriasis. Rare variants predicted to be deleterious were found in two individuals in each of the following genes in the IL-17 signalling/Th17 differentiation pathway: IL17RB, IL17RE, IL25, HIF1A (Table 1). This suggests that the Th17 pathway may play a role in disease pathogenesis in a proportion of children with CNO.

Conclusion: IL17 +/- in the IL-17 signalling/Th17 differentiation pathways, and NLRP1 provide targets for further investigation in CNO. The role of these candidate genes may be further elucidated through gene-pathway-based burden analysis against a matched control population.

REFERENCES:
Table 1.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Gene</th>
<th>Variant</th>
<th>Effect</th>
<th>CADD</th>
<th>CNO MAF</th>
<th>gnomAD MAF</th>
<th>OR</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>16</td>
<td>IL17RA</td>
<td>22-17586757&gt;T&gt;C</td>
<td>Nonsynonymous p.W020R</td>
<td>24.5</td>
<td>0.04</td>
<td>0.0034</td>
<td>11.06</td>
<td>0.003</td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>NLRP1</td>
<td>17-5462417&gt;C&gt;A</td>
<td>Nonsynonymous p.G033H</td>
<td>26.2</td>
<td>0.04</td>
<td>0.0058</td>
<td>6.47</td>
<td>0.01</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>KIMF2D</td>
<td>12-49434409&gt;G&gt;A</td>
<td>Nonsynonymous p.P2382S</td>
<td>21.3</td>
<td>0.04</td>
<td>0.0056</td>
<td>6.75</td>
<td>0.01</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>IL17RB</td>
<td>3-53889368&gt;G&gt;A</td>
<td>Nonsynonymous p.G117R</td>
<td>29.7</td>
<td>0.024</td>
<td>0.0061</td>
<td>4.05</td>
<td>0.09</td>
</tr>
<tr>
<td>40</td>
<td>IL17RE</td>
<td>3-9957033&gt;C&gt;A</td>
<td>Nonsynonymous p.L400M</td>
<td>24.9</td>
<td>0.024</td>
<td>0.0086</td>
<td>3.19</td>
<td>0.13</td>
</tr>
<tr>
<td>43</td>
<td>IL25</td>
<td>14-23845076&gt;G&gt;A</td>
<td>Nonsynonymous p.R117H</td>
<td>34</td>
<td>0.024</td>
<td>0.0085</td>
<td>3.02</td>
<td>0.15</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>H6F1A</td>
<td>14-62187212&gt;G&gt;C</td>
<td>Nonsynonymous p.V74L</td>
<td>23.7</td>
<td>0.024</td>
<td>0.0026</td>
<td>9.9</td>
<td>0.02</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


POS0166 POLYARTICULAR JIA HAS A DISTINCT CO-INHIBITOR RECEPTOR PROFILE AMONG OTHER JIA SUBTYPES

E. Sanı1,2, Z. Balık3, S. Sener1, U. Kaya Akca1, S. Demir1, M. Kasap-Cuceoglu1, E. Atalay1, S. Boccutu1, T. Vural1, Y. Bilginer1, B. Deleuran3,4, S. Özen1,2. 1Hacettepe University Faculty of Medicine, Department of Pediatric Rheumatology, Ankara, Turkey; 2Hacettepe University, Pediatric Rheumatology Unit, Translational Medicine Laboratories, Ankara, Turkey; 3Aarhus University, Institute of Biomedicine, Aarhus, Denmark; 4Aarhus University Hospital, Department of Rheumatology, Ankara, Denmark

Background: Juvenile idiopathic arthritis (JIA) is the most common inflammatory joint disease in children, driven by continuous T-cell activation.[1] T cell activation is counter-balanced by signals generated by co-inhibitory receptors (co-IRs) such CTLA-4, PD-1, LAG-3, and TIM-3.[2]

Objectives: We aimed to identify the role of co-IRs in the pathogenesis of different subtypes of JIA.

Methods: In total, we included 107 patients with oligoarticular JIA (n=67), polyarticular JIA (n=12), enthesitis related arthritis (n=17), systemic JIA (n=11) and healthy controls (HC, n=10). We collected plasma samples from the patients during the active phase of their disease. We measured the soluble plasma levels of co-IRs by commercial pre-defined cytokometric bead array kits and their cellular expression by flow cytometry in blood mononuclear cells. We compared the plasma levels and cellular expressions of different co-IRs within different JIA subgroups.

Results: IL-2 levels were lower than HC in all JIA subgroups. The polyarticular JIA group distinguished from the four different JIA subgroups, having different co-IR pattern. In this specific subgroup, CTLA4, PD-1 and 4-1BB levels were higher than other groups. Polyarticular JIA is the more chronic and severe form of JIA, especially when compared to oligoarticular JIA. (Figure 1).

Conclusion: This is the first report studying the effects of different co-IRs in different subtypes of JIA. Polyarticular JIA patients had a different co-IR profile, having more CTLA-4, PD-1 and 4-1BB in their plasma than the other subtypes of JIA.

REFERENCES:

Acknowledgements: This work was supported by a research grant from FOREULIM Foundation for Research in Rheumatology


POS0167 A PROTEOGENOMIC MAP OF NATURAL KILLER CELLS IN OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

O. Kniichtet1,2, G. Guerra3, M. F. Mashreghi4, T. Kallinich5,6, T. Rückerl1, C. Romagnani1,2. 1Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Innate Immunity, Berlin, Germany; 2Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Berlin, Germany; 3Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Therapeutic Gene Regulation, Berlin, Germany; 4Charité Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Berlin, Germany; 5Deutsches Rheuma-Forschungszentrum (DRFZ), an Institute of the Leibniz Association, Chronic inflammation in Childhood, Berlin, Germany; 6Charité Universitätsmedizin Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany

Background: Natural Killer (NK) cells are innate lymphocytes which are specialised for recognising stressed cells, classically divided into cytotoxic (CD56dim) and cytokine-producing (CD56bright) populations. During oligoarticular Juvenile Idiopathic Arthritis (oligo-JIA), an unknown trigger induces the recruitment of peripheral immune cells into synovial joints, which in turn creates a chronic inflammatory environment. This can result in joint contractures and extraarticular complications, highlighting the requirement for early disease intervention. The contribution of NK cells toward immunopathology during the early stages of disease and in subsequent arthritic flares is unknown, providing a potential avenue for understanding disease course and therapeutic intervention.

Objectives: We aimed to assess the contribution of NK cells to the early pathogenesis of oligo-JIA by identifying inflammatory signatures present in patient synovia, and which signals could induce them.

Methods: Peripheral blood (PB) and synovial fluid (SF) were drawn from 4 patients at the first clinical presentation of oligo-JIA. Flow-cytometry Activated Cell-Sorting (FACS) was used to unbiasedly isolate NK cells (CD3-CD7+), and single cell RNA-sequencing (scRNA-Seq) paired with
**Table 1. Mean differences between different locations for each imaging technique**

<table>
<thead>
<tr>
<th>Imaging technique</th>
<th>Location</th>
<th>Overall mean difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFUS</td>
<td>Centre - Contralateral</td>
<td>-0.34 (-0.46, -0.22)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Contralateral</td>
<td>-0.30 (-0.40, -0.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>(mm)</td>
<td>Centre - Outer</td>
<td>-0.35 (-0.46, -0.24)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Outer</td>
<td>-0.31 (-0.40, -0.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Centre - Inner edge</td>
<td>-0.04 (0.10, 0.22)</td>
<td>0.168</td>
</tr>
<tr>
<td>MSI</td>
<td>Centre - Contralateral</td>
<td>0.06 (0.03, 0.10)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Contralateral</td>
<td>0.06 (0.03, 0.09)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Centre - Outer</td>
<td>0.04 (0.01, 0.07)</td>
<td>0.012</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Outer</td>
<td>0.03 (0.00, 0.06)</td>
<td>0.028</td>
</tr>
<tr>
<td></td>
<td>Centre - Inner edge</td>
<td>0.01 (0.00, 0.02)</td>
<td>0.291</td>
</tr>
<tr>
<td>LDI</td>
<td>Centre - Contralateral</td>
<td>44.8 (24.4, 65.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Contralateral</td>
<td>47.9 (21.0, 74.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Relative perfusion</td>
<td>Centre - Outer</td>
<td>19.1 (10.3, 27.9)</td>
<td>0.039</td>
</tr>
<tr>
<td>units</td>
<td>Inner edge - Outer</td>
<td>24.8 (6.7, 42.9)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>Centre - inner edge</td>
<td>-3.5 (20.3, 13.2)</td>
<td>0.679</td>
</tr>
<tr>
<td>IRT</td>
<td>Centre - Contralateral</td>
<td>0.58 (0.24, 0.91)</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Contralateral</td>
<td>0.44 (0.13, 0.75)</td>
<td>0.005</td>
</tr>
<tr>
<td>°C</td>
<td>Centre - Outer</td>
<td>0.44 (0.22, 0.66)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Inner edge - Outer</td>
<td>0.30 (0.09, 0.52)</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>Centre - Inner edge</td>
<td>0.14 (-0.05, 0.32)</td>
<td>0.153</td>
</tr>
</tbody>
</table>

The overall mean difference is the measurement of the first location minus the measurement from the second location (e.g. centre minus contralateral), averaged across the four visits.

Conclusion: Our results suggest non-invasive imaging can detect differences between healthy & unaffected skin in JLS. Whether each technique is only measuring activity & not damage requires further evaluation. The leading edge of lesions has historically been considered as most active compared to the centre. However, no difference was seen between centre & inner edge measurements suggesting that in future studies, imaging protocols can be simplified.

Acknowledgements: This study was funded by Scleroderma & Raynaud’s UK.

**Disclosure of Interests:** None declared

**DOI:** DOI: 10.1136/annrheumdis-2022-eular.4961

**POS0168 NON-INVASIVE IMAGING IN JUVENILE LOCALISED SCLERODERMA: HIGH-FREQUENCY ULTRASOUND, THERMOGRAPHY, LASER DOPPLER & MULTISPECTRAL IMAGING**

C. Pain, A. Murray, G. Dinsdale, A. Manders, J. Manning, A. Herrick. Alder Hey Children’s Hospital NHS Foundation Trust, Paediatric Rheumatology, Liverpool, United Kingdom; University of Manchester, Division of Musculoskeletal & Dermatological Sciences, Manchester, United Kingdom; Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; University of Manchester, Division of Population Health, Health Services Research and Primary Care, Manchester, United Kingdom; Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

**Background:** Outcome measures which can differentiate activity (inflammation) from damage (fibrosis/atrophy) would facilitate development of new treatment strategies in juvenile localized scleroderma (JLS) to target the inflammatory phase of the disease.

**Objectives:** To evaluate whether in JLS, non-invasive imaging modalities (high frequency ultrasounds (HFUS), multispectral imaging (MSI), laser doppler imaging (LDI) & infra-red thermography (IRT)) can detect differences between affected & non-affected skin, as a next step in developing these as outcome measures. Our hypothesis was that blood flow (and therefore temperature & oxygenation) would be increased in lesional skin.

**Methods:** Participants aged 4-17 were recruited from 3 paediatric rheumatology centres in the UK. For each participant, a single lesion was selected. HFUS (30MHz), MSI (bespoke camera and tuneable liquid crystal filter, coupled to custom analysis software, 500nm/710nm wavelengths), LDI and IRT imaging were performed at four sites relating to each location: two of affected skin (centre & inner edge of lesion) and two of non-affected skin (one cm from edge of lesion (‘outer’) & contralateral unaffected side). Imaging was performed at 4 visits at 3 monthly intervals. Mean values were compared between the four sites using data from all visits by mixed-effects linear regression to account for individual and repeated clustering.

**Results:** 24 participants completed all 4 visits and 1 attended 3. 20 participants aged 4-17 were recruited from 3 paediatric rheumatology centres in the UK. For each participant, a single lesion was selected. HFUS (30MHz), MSI (bespoke camera and tuneable liquid crystal filter, coupled to custom analysis software, 500nm/710nm wavelengths), LDI and IRT imaging were performed at four sites relating to each location: two of affected skin (centre & inner edge of lesion) and two of non-affected skin (one cm from edge of lesion (‘outer’) & contralateral unaffected side). Imaging was performed at 4 visits at 3 monthly intervals. Mean values were compared between the four sites using data from all visits by mixed-effects linear regression to account for individual and repeated clustering.

**Conclusions:** Synovial NK cells possess a significantly different transcriptomic identity compared with those in the periphery. However, though they share a gene signature that is most comparable to blood CD56bright NK cells, it is not identical. Uniquely activated subpopulations also provide the first evidence of NK cell activation during oligo-JIA pathogenesis, suggesting that these cells could hold therapeutic potential.

**Acknowledgements:** Stefanie Bartsch, Kathleen Necke, Carl-Christoph Goetzke, Anne Sae Lim von Stuckrad and all other members of the TargArt Consortium

**Disclosure of Interests:** None declared

**DOI:** DOI: 10.1136/annrheumdis-2022-eular.2024

**POS0169 OPEN-LABEL, LONG-TERM (10-YEAR) STUDY OF THE SAFETY OF ETANECORT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIPOARTICULAR, ENHETISIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS**

J. Vojnović, J. Dehoorne, V. Panaviene, G. Susić, G. Hornetf, V. Stanieviča, K. Kobusinska, Z. Zuber, B. Dobrzyńcika, A. Akkussa, T. Avcin, A. Martini, C. Borleñghi, E. Arthur, S. Y. Tatulyc, Z. Cangz, B. Vilão, R. Purtuf. Paediatric Rheumatology International Trials Organisation (PRINTO), Paediatric and Rheumatology, Genoa, Italy; Pfizer, I&I Medical Affairs, Buenos Aires, Argentina; Pfizer, Clinical Development and Operations, Peapack, United States of America; Pfizer, Clinical Development, Groton, United States of America; Pfizer, Global Biometrics and Data Management, Collegeville, United States of America; Pfizer, Global Product Development, Collegeville, United States of America

**Background:** CLIPPER2 was an 8-year, open-label extension of the phase 3b, multicenter, 2-year CLIPPER study of the safety and efficacy of etanercept (ETN) in the treatment of patients (pts) with juvenile idiopathic arthritis (JIA) categorized as extended oligoarticular arthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).

**Objectives:** The objective of this analysis was to describe the safety of ETN in this population after 10 years of follow up.

**Methods:** Pts (n=127) with eoJIA (2-17 years), ERA, or PsA (each 12-17 years) who received ≥1 ETN dose (0.8 mg/kg once weekly [max, 50 mg]) in CLIPPER were eligible to enter CLIPPER2. The primary outcome measure was the occurrence of malignancy. Long-term safety was assessed as the total incidence of events from CLIPPER baseline (BL) to month (mth) 120, frequency of events per 100 patient-years (EP100PY), and frequency of events in each study year.

**Results:** A total of 109/127 (86%) pts entered CLIPPER2; 99 (78%) continued in the active treatment period. At mth 120, 84 (86%) pts had completed the study; 27 (21%) while actively taking ETN; 7 (6%) had withdrawn from treatment due to low/inactive disease; 5 (4%) had re-stated ETN following an earlier withdrawal from treatment; and 45 (35%) had stopped ETN (but remained under observation); 25 (20%) pts permanently discontinued from the CLIPPER2 study. In CLIPPER/CLIPPER2, 1 case of malignancy (Hodgkin’s disease) was reported (1 pt with eoJIA in Year 3). There was 1 case of uveitis (1 pt with eoJIA in Year 6) and 3 of Crohn’s disease (2 pts with ERA, Year 1/Year 6, 1 pt with eoJIA, Year 5). There were 2 cases of opportunistic infections (both herpes zoster), and no deaths. Overall, there were 559 (81.82 EP100PY) treatment-emergent adverse events
314 ﻿

Scientific Abstracts

(TEAEs) excluding infections and injection-site reactions (ISRs). The overall
rate of TE serious infections was low (N=14; 2.05 EP100PY) (Table 1), with the
most common TE serious infection being gastroenteritis (N=2; 0.29 EP100PY).
The most frequently reported TEAEs (N [EP100PY]) were headache (28 [4.10]),
arthralgia (24 [3.51]), pyrexia (21 [3.07]), diarrhea (14 [2.05]), and leukopenia
(12 [1.76]). Overall, 39 patients reported serious AEs (excluding infections/ISRs).
The number and frequency (N [EP100PY]) of TEAEs (excluding infections/ISRs)
decreased over the 10-year study period from 193 [173.81] in Year 1 to 9 [27.15]
in Year 10. The number and frequency of TE infections and TE serious infections
also decreased over the 10-year study period. There was no clear trend of a
decrease over time for the incidence of TE serious AEs (Figure 1).
Table 1. ETN Safety Summary (from CLIPPER BL to mth 120),
N (EP100PY) (FAS)*
Total, n=12
PsA, n=29
ERA, n=38
eoJIA, n=60
(EXP=313.667 (EXP=206.971 (EXP=162.576 (EXP=683.214
PY)
PY)
PY)
PY)
TEAEs†
TE serious AEs†
TE ISRs
TE infections
TE serious infectionsǂ
Opportunistic infections§
TEAEs causing withdrawal†
TE infections causing
withdrawal

269 (85.76)
16 (5.10)
23 (7.33)
418 (133.26)
5 (1.59)
0
7 (2.23)
2 (0.64)

176 (85.04)
17 (8.21)
29 (14.01)
99 (47.83)
4 (1.93)
1 (0.48)
9 (4.35)
0

114 (70.12)
7 (4.31)
12 (7.38)
155 (95.34)
5 (3.08)
1 (0.62)
2 (1.23)
1 (0.62)

559 (81.82)
40 (5.85)
64 (9.37)
672 (98.36)
14 (2.05)
2 (0.29)
18 (2.63)
3 (0.44)

*While on active ETN treatment or within 30 days of last dose†Excluding infections/
ISRsǂGastroenteritis, 2 (0.29); acute tonsillitis, anal abscess, bronchopneumonia, gastrointestinal infection, helicobacter gastritis, influenza, peritonitis, pharyngitis, pyelocystitis, sepsis,
urinary tract infection, viral infection, all 1 (0.15)§Both herpes zosterEXP, exposure to ETN;
FAS, full analysis set; n, number of patients; N, number of events

Conclusion: ETN treatment to mth 120 was well tolerated in this patient population and consistent with the known safety profile. Frequency of TEAEs and
TE infections decreased over time. Over 10 years, there was 1 reported event of
malignancy and the overall rate of TE serious infections was low.
REFERENCES:
[1] NCT00962741/NCT01421069
Acknowledgements: Medical writing support was provided by Iain McDonald,
PhD, of Engage Scientific Solutions and was funded by Pfizer.
Disclosure of Interests: Jelena Vojinovic Speakers bureau: Abbvie, Roche,
Sandoz, Joke Dehoorne Speakers bureau: Abbvie, Roche, Consultant of: Abbvie, Roche, Violeta Panaviene: None declared, Gordana Susic: None declared,
Gerd Horneff Speakers bureau: Chugai, Eli-Lilly, Glaxo Smith and Kline, Janssen, Novartis, Pfizer, Roche and Sobi, Grant/research support from: Novartis,
Janssen, Roche, Valda Stanevicha Speakers bureau: Sandoz, Abbvie, Roche,
Katarzyna Kobusinska: None declared, Zbigniew Żuber: None declared, Bogna
Dobrzyniecka: None declared, Jonathan Akikusa: None declared, Tadej Avcin
Speakers bureau: AbbVie, Octapharma, and Takeda, Consultant of: AbbVie, Alexion, Octapharma, and Takeda, Alberto Martini Speakers bureau: Aurinia, Bristol
Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer, Roche, Consultant
of: Aurinia, Bristol Myers and Squibb, Eli-Lilly, EMD Serono, Janssen, Pfizer,
Roche, Cecilia Borlenghi Shareholder of: Pfizer, Employee of: Pfizer, Edmund
Arthur Employee of: Pfizer, Svitlana Y Tatulych Shareholder of: Pfizer, Employee
of: Pfizer, Chuanbo Zang Shareholder of: Pfizer, Employee of: Pfizer, Bonnie
Vlahos Shareholder of: Pfizer, Employee of: Pfizer, Nicolino Ruperto Speakers
bureau: Ablynx, Amgen, Astrazeneca-Medimmune, Aurinia, Bayer, Bristol Myers
and Squibb, Cambridge Healthcare Research (CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and Kline, Idorsia, Janssen, Novartis,
Pfizer, Sobi, UCB., Consultant of: Ablynx, Amgen, Astrazeneca-Medimmune,
Aurinia, Bayer, Bristol Myers and Squibb, Cambridge Healthcare Research

(CHR), Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, Glaxo Smith and
Kline, Idorsia, Janssen, Novartis, Pfizer, Sobi, UCB.
DOI: 10.1136/annrheumdis-2022-eular.53

POS0170

EXPERIENCES WITH COVID-19 INFECTIONS IN
GERMAN PEDIATRIC RHEUMATOLOGY CENTERS

G. Horneff1,2, F. Dressler3, D. Windschall4,5, S. Mrusek6, T. Hospach7,
A. Kühn8, M. Haller9, P. Von Bismarck10, W. Emminger11, P. Ruehmer12,
M. Hufnagel13, A. Klein1,2. 1Kinderklinik Sankt Augustin, Pediatrics,
Sankt Augustin, Germany; 2Kinderklinik Uniklinikum Köln, Pediatrics,
Köln, Germany; 3Medizinische Hochschule Hannover (MHH) Klinik für
Pädiatrische Nieren- Leber- und Stoffwechselerkrankungen, Pediatric
Rheumatology, Hannover, Germany; 4St. Josef-Stift Sendenhorst, Northwest
German Center for Rheumatology, Clinic of Paediatric and Adolescent
Rheumatology, Sendenhorst, Germany; 5Martin-Luther-University HalleWittenberg, Medical Faculty, Halle, Germany; 6Private Practive, Pediatrics,
Baden-Baden, Germany; 7Olgahospital and Women’s Clinic, Pediatric
Rheumatology, Stuttgart, Germany; 8Universitätsklinikum Halle (Saale),
Pediatric Rheumatology, Halle (Saale), Germany; 9Private Practice, Pediatrics,
Gundelfingen, Germany; 10Universität Kiel, Pediatrics, Kiel, Germany;
11
Universität Wien, Pediatrics, Wien, Austria; 12Helios Vogtland-Klinikum
Plauen, Pediatrics, Plauen, Germany; 13Universitätsklinikum Freiburg,
Pediatric Rheumatology, Freiburg im Breisgau, Germany
Background: Although the risk for severe COVID-19 progression in children is
low, this may be aggravated by the underlying disease and/or immunosuppressive drugs.
Objectives: We analyzed clinical data of COVID-19 cases among paediatric
patients with rheumatic diseases reported to the BIKER registry.
Methods: The main task of the German BIKER (Biologics in Pediatric Rheumatology) registry is to monitor the safety of biologics therapies in JIA. After the
onset of the COVID-19 pandemic, the survey was expanded with a standardized form to proactively interview all participating centers about the occurrence,
presentation, and outcome of SARS-CoV-2- infections in children with rheumatic
diseases. Interviews were conducted with 68 centers initially weekly and later
biweekly.
Results: A total of 68 centres participated in the survey. Clinical data from
194 COVID-19 cases reported to the BIKER registry from 41 German and
1 Austrian pediatric rheumatology institutions between February 2020 and
December 2021 were analyzed. Juvenile idiopathic arthritis (JIA, n=144)
was the most common diagnosis followed by genetic autoinflammation
(n=18; i.e. FMF, TRAPS, CAPS, HIDS, DADA2), systemic autoimmune diseases (n=11; i.e. SLE, dermatomyositis, vasculitis) and 16 with other rheumatic diseases (i.e. CRMO, Uveitis). 5 patients with no rheumatic disease
were excluded. 104 (54%) patients were receiving conventional DMARDs,
81 (43%) received biologics, mainly TNF inhibitors (n=66 (35%)). Of
the 189 rheumatic patients with SARS-CoV2 infection, 123 (63%) were
female. The mean age was 12.4+/-4.4 years in females and 13.2+/-4.1
in males. The duration of SARS-Co2 infection associated symptoms was
13.8+/-15.3 days (max. 113 days), in 35 (43%) patients they lasted for
> 12 days. 46 (24%) were asymptomatic. Patients with autoinflammation
and systemic autoimmunopathies reported more symptoms such as fever,
head and throat ache. 4 patients only complained about dyspnea. Only
3 patients were hospitalized and received Oxygen-supplementation. The
only patients admitted to ICU, received ventilation but succumbed. This
3½-year-old patient, initially diagnosed with systemic JIA, developed fatal
disease with intracranial edema and respiratory failure, as well as typical
pulmonary texture changes. Prior to her SARS-CoV-2 infection, the patient
was treated with MTX and low-dose steroids. Genetic testing revealed a
so far unrecognized congenital immunodeficiency. In the total JIA cohort,
treatment with corticosteroids, conventional DMARDs, biologics or combinations did not influence the number of reported symptoms or the favorable outcome of the cohort. However, the duration of symptoms was lower
in the TNF-treated cohort (10.4+/-6.4 days vs. 15.7 +/- 19.7 days). In the
cohort with autoinflammation, fever was observed in 11 (61%). Those 6
who received IL-1-inhibitors did not show a different outcome than those
12 who did not. No case of PIMS/MISC in children with rheumatic diseases
was reported.
Conclusion: Except for one patient with congenital immunodeficiency who died
from her COVID-19 infection, no case of severe COVID-19 was reported in our
cohort. At the time of infection, over 80% of patients in our cohort had been
treated with conventional DMARDs and/or biologics. This did not appear to have
a negative impact on the severity or outcome of SARS-CoV2 infection. Interestingly, no case of PIMS/MISC was observed.
Disclosure of Interests: Gerd Horneff Speakers bureau: Novartis, Pfizer,
Janssen, Grant/research support from: Pfizer, Novartis, Roche, MSD, Frank


Within the first 3 months after diagnosis, the treatment pathways proposed by the ProKind Commission [1] were followed in about three-quarters of patients: i) 5 (13%) received MTX and intra-articular glucocorticoid injections in more than 4 joints (IAGC) or bDMARD; ii) 8 (21%) received MTX and HDGC (no bDMARD, no IAGC); iii) 16 (42%) patients received MTX up to or at the 3FU (bDMARD, no IAGC); iv) 8 (21%) received MTX and HDGC (no IAGC, no bDMARD); v) 4 (10%) patients received MTX and IAGC up to or at the 3FU (no HDGC, no bDMARD, no IAGC). Nine (24%) patients were not treated with MTX or did not fit any of these categories, mostly due to starting bDMARD therapy in conjunction with HDGC or IAGC.

Conclusion: In the routine care of JIA patients with polyarthritis, the proposed treatment protocol and treat-to-target strategy are followed in most patients. At 3FU, improvements of JADAS10 and other outcomes were evident, with 41% having achieved inactive or minimal active disease. ProKind is funded by the Innovation Fund “Gemeinsamer Bundesausschuss”, FKZ: 01VSF18031.

References:

Acknowledgements: We are grateful to all physicians, medical professionals and everyone else who has so far contributed and supported the ProKind-Rheuma project.

Moreover, we want to express special gratitude to all patients and their parents for their participation.

Disclosure of Interests: Sascha Eulert: None declared, Kristina Vollbach: None declared, Klaus Tenbrock: None declared, Jens Klotsche: None declared, Ralf Trauzeddel: None declared, Kristen Minden: None declared, AlexandraRenner: None declared, Michael Rühlmann: None declared, Ralf Trauzeddel: None declared, Catharina Schütz: None declared, J. B. Kuenmerlei-Denisch: None declared, Anja Klein: None declared, Martin Ludwig: None declared, Julia Forst: None declared, Nikolas Hufnagel: None declared, Spasova Iliahi: None declared, Moritz Klaas: None declared, Ivan Foeldvari Consultant of: Addvisory board: Hexal, Novartis, Pfizer, Toni Hospach Consultant of: Advisory board: Sobi, Novartis, Moritz Klaas: None declared.

Disclosure of Interests: Sascha Eulert: None declared, Kristina Vollbach: None declared, Klaus Tenbrock: None declared, Jens Klotsche: None declared, Dirk Foeld Speakers bureau: Speaker fees/honoraria from Boehringer, Novartis, Werke.

*Based on non-missing values.

Table 1.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 5.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 6.

<table>
<thead>
<tr>
<th>Treatment Pathway</th>
<th>Total</th>
<th>At Baseline all</th>
<th>At Baseline with 3FU</th>
</tr>
</thead>
<tbody>
<tr>
<td>No treatment</td>
<td>673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX</td>
<td>157</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+HDGC</td>
<td>84</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+HDGC</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX+bDMARD+MDC+IAGC</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Background: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1 000 000 children (1). In adult patients there are significant differences between the clinical presentation of diffuse and limited subtypes (2). We reviewed clinical differences in presentation of subtypes in patients in the juvenile systemic scleroderma cohort study up to 2021.

Objectives: To study the clinical presentation of jSSc patients with diffuse (djSSc) and limited (ljSSc) subtypes.

Methods: We reviewed the clinical baseline characteristics of the patients, who were recruited to the juvenile scleroderma cohort study (jSScC) (3, 4) till 1st of December 2021. jSScC is a prospective cohort of jSSc patients who developed the first non-Raynaud’s symptom before the age of 16 years and are under the age of 18 years at the time of inclusion.

Results: 210 patients with jSSc were included in the cohort, 71% (n=152) had diffuse subtype. The median age at onset of Raynaud phenomenon was 10.4 years (7.3 – 12.9) and the median age at the first non-Raynaud symptom was 10.9 years (7.4 – 11.2). Median disease duration was 2.5 years (1 – 4). The median age at onset was 10.9 years (7.4 – 13.2). Median disease duration was 2.5 years (1 – 4.4) at the time of inclusion. The female/male ratio was significantly lower in the ljSSc subtype (3.7:1 versus 5:1, p<0.001). Antibody profile was quite similar, with the exception of a significantly higher number of anticientromere positive patients in the ljSSc (12% versus 2%, p=0.013). Decreased FVC < 80% was found in 10.9% of patients with ljSSc and 2.8% in djSSc patients (p=0.013). Decreased joint range of motion (64% versus 46%, p=0.019). Patients with ljSSc had significantly higher rate of cardiac involvement (13% versus 2%, p=0.001). Regarding patients with diffuse subtype, patients with more severe diffuse Rodnan Skin Score (mRSS) (16 versus 4.5, p<0.001), sclerodactyly (84% versus 60%, p<0.001), history of digital ulceration (62% versus 31%, p<0.001), decreased Body Mass Index (BMI) < -2 z score (20% versus 4%, p=0.003) and decreased joint range of motion (64% versus 46%, p=0.019). Patients with ljSSc had significantly higher rate of cardiac involvement (13% versus 2%, p=0.001).

Conclusion: In this jSSc cohort, the largest in the world, djSSc patients have a significantly more severe disease than ljSSc patients. Interestingly, we found no differences regarding interstitial lung disease and pulmonary hypertension.

REFERENCES:

Disclosure of Interests: None declared


L. Jaremko1, N. Herregods2, O. Kasacopur3, M. Yildiz4, A. M. Hendry5, W. F. Maksymowych6, 7.

1Children’s Hospital of Philadelphia, Department of Pediatrics, Division of Rheumatology, Philadelphia, United States of America;
2Children’s Hospital of Philadelphia, Section of Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany;
3German Rheumatism Research Center, German Rheumatism Research Center, Berlin, Germany;
4JSSc Collaborative Group, Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany;
5German Rheumatism Research Center, Department of Rheumatology, Mexico City, Mexico;
6NIH/NIAMS, Pediatric Translational Research Branch, Bethesda, United States of America;
7Asklepios Clinic Sankt Augustin, General Pediatrics, Sankt Augustin, Germany;
8Ghent University, Department of Pediatric Rheumatology, Ghent, Belgium;
9The Hospital for Sick Children, Department of Paediatrics, Division of Rheumatology, Toronto, Canada;
10St. Michael’s Hospital, Medicine, Toronto, Canada;
11German Rheumatism Research Center, Epidemiology Unit, Berlin, Germany;
12IRCORS Istituto Giannina Gaslini, Genoa, Italy;
13University of Wisconsin-Madison, Department of Pediatrics, Madison, United States of America;
14University of Alabama-Birmingham, Department of Pediatrics, Division of Pediatric Rheumatology, Birmingham, United States of America;
15Ghent University and VIB Center for Integrative Molecular Research, Department of Internal Medicine and Pediatrics, Ghent, Belgium;
16University of Alberta, Department of Radiology and Diagnostic Imaging, Edmonton, Canada;
17University of Pennsylvania, Department of Radiology, Philadelphia, United States of America;
18Children’s Hospital of Philadelphia, Department of Radiology, Philadelphia, United States of America;
19Penn State Health, Department of Radiology, Hershey, United States of America;
20Ghent University Hospital, Department of Radiology and Nuclear Medicine, Ghent, Belgium;
21Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul, Turkey;
22Istanbul University-Cerrahpasa, Pediatric Rheumatology, Istanbul, Turkey;
23Middlemore Hospital, General Medicine - (Incl. Obstetric Medicine and Adult Rheumatic Fever), Auckland, New Zealand;
24University of Alberta, Department of Medicine, Edmonton, Canada;
25CARE Arthritis, Rheumatology, Edmonton, Canada

Background: For classification in juvenile spondyloarthritides (JSpA), it is important to develop cut-offs for active and structural lesions typical of axial disease on MRI. The radiological criteria are readily available for adults, but the interpretation of these criteria is challenging in children because the growing sacroiliac joint (SIJ) looks different from the adult SIJ. The criteria developed for positive MRI in adults may not be applicable in JSpA.

Objectives: As part of a study developing classification criteria for axial disease in JSpA, we aimed to determine quantitative SIJ imaging lesion cut-offs for inflammatory and structural lesions typical of axial JSpA using majority imaging expert decision as the reference criterion.

Methods: Subjects were a retrospective cohort of children with SpA who met the provisionial Pediatric Rheumatology International Trials Organization criteria for enthesitis/spondylitis-related juvenile idiopathic arthritid or had a rheumatologist JSpA diagnosis. All subjects had symptom onset prior to age 18 years and underwent MRI as part of a diagnostic evaluation for axial disease. To enable SIJ quadrant-based scoring, all MRIs included semi-coronal slices through the cartilaginous part of the joint on fluid sensitive sequences and on T1-weighted sequences for the assessment of inflammation and structural lesions, respectively. MRIs were reviewed by 6 musculoskeletal imaging experts who were blinded to clinical details. MRI evaluation of the SIJ was based on standardized lesion definitions that were decided by consensus of the central imaging team and represented a mix of definitions from ASAS and the Juvenile Arthritis MRI Score Outcome Measures in Rheumatology working group. Using a web-based interface, raters globally assessed the presence or absence of lesions typical of axial SpA and performed SIJ quadrant or joint based scoring. Lesion scores were generated by averaging the scores of all raters. Sensitivity and specificity of lesion cut-offs were calculated using raters’ majority (≥4/6 raters) as the reference standard.

Results: Imaging from 243 subjects, 61% male, median age 14.9 years, had sequences available for detailed MRI scoring. Active inflammatory lesion typical of axial disease in JSpA was defined as bone marrow edema (BME) in at least 3 quadrants of the SIJ. Cut-offs were calculated with a high confidence (sensitivity of ≥ 0.80 or specificity of ≥ 0.80) as the reference criterion.

Conclusion: We propose data-driven cut-offs for active inflammatory and structural lesions on MRI typical of axial disease in JSpA that have high specificity and sensitivity using central imaging global assessment as the reference standard.
New insights into the associations of outcomes and biomarkers in OA.

Table 1. Performance of cut-offs for inflammatory and structural lesions of axial disease

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Definite active lesion</th>
<th>Structural lesion</th>
</tr>
</thead>
<tbody>
<tr>
<td>BME score ≥3</td>
<td>96.7 (92.5-100)</td>
<td>98.6 (87.9-99.9)</td>
</tr>
<tr>
<td>Definite structural erosion</td>
<td>93.5 (90.0-96.5)</td>
<td></td>
</tr>
<tr>
<td>Definite structural sclerosis</td>
<td>91.4 (84.3-99.8)</td>
<td></td>
</tr>
<tr>
<td>Definite structural ankylosis</td>
<td>91.4 (84.3-99.8)</td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: Pamela F. Weiss Consultant of: Pfizer Novartis
Biogen Lilly (All <5% in the past fiscal year), Timothy G. Brandon: None declared, Amita Aggarwal: None declared, Ruben Burgos-Vargas Speakers bureau: Not in the last three years, Novartis, Consultant of: Not in the last four years, BMS, Lilly, Novartis, Robert A. Colbert: None declared, Gerd Hornfeff Speakers bureau: Pfizer, Novartis, Janssen, Chugai, Abbvie, Grant/ research support from: Pfizer, Novartis, MSD, Chugai, Roche, Abbvie, Rik Janssen Speakers bureau: Pfizer, Novartis, Novartis, Amgen, BMS, Lilly, Grant/research support from: Pfizer, AbbVie, Roche, Ronald Lacer Consultant of: Abbvie, Novartis, Sobi, Sanofi, Eli Lilly Canada, Eli Lilly, Kirsten Minden Speakers bureau: Pfizer, Novartis, Consultant of: Pfizer, Novartis, Angelo Ravello Speakers bureau: Abbvie, Novartis, SOBI, Angeline, Reck- itt-Benker, Roche, Pfizer, Alexion, Grant/research support from: Novartis, Pfizer, Niccolino Rupert Speakers bureau: NR has received honoraria for consultations or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB, Consultant of: NR has received honoraria for consultations or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB, Grant/research support from: The IRCCS Istituto Giannina Gaslini (IGG), where NR works as full-time public employee has received contributions from the following industries in the last 3 years: Bristol Myers and Squibb, Eli-Lilly, F Hoffmann-La Roche, Novartis, Pfizer, Sobi. This funding has been reimbursed for the research activities of the hospital in a fully independent manner, without any commitment with third parties, Judith Smith Consultant of: Consulting panel of pediatric rheumatologists identifying issues in juvenile spondyloarthritids for Novartis. Paid < $5000, Matthew L. Stoll Consultant of: Currently consulting for 3 companies. None declared, Filip van den Bosch Speakers bureau: Abbvie, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, Paid instructor for: Amgen, Eli Lilly, Consultant of: Abbvie, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, Robert G Lambert Paid instructor for: Novarti, Consultant of: CARE Arthritis, Calix, Image Analysis Group, Novartis, David M. Biko Employee of: Merck (1998-2000), Nancy A. Chauvin Employee of: Forest Pharmaceuticals - Research scientist (1996) and Novartis - Pharmaceutical sales representative (1997), Michael L. Francavilla: None declared, Jacob J Laremko: None declared, Nele Herregods: None declared, Ozgur Kasacopur Speakers bureau: Pfizer, Abbvie, Novartis and Roche, Mehrdad Yildiz: None declared, Alison M. Hendry: None declared, Walter P Maksymowych Speakers bureau: Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, UCPharma, Consultant of: AbbVie, Boehringer Ingelheim, Amgen, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB Pharma, Grant/research support from: Abbvie, Novartis, Pfizer doi: 10.1136/annrheumdis-2022-eular.741
A COMPARISON OF ULTRASOUND-DETECTED PATHOLOGIES IN PERSONS WITH AND WITHOUT KNEE OSTEOARTHRITIS AND THE ASSOCIATIONS WITH PAIN

C. Dekkerhus1,2, A. Mathiessen3, F. Fjellstad1, B. Statwalksy-Christensen1, H. B. Hammer1, J. I. K. Haugen1,2, D. Kajnhrjemmet Hospital, Rheumatology, Oslo, Norway; 1University of Oslo, Faculty of Medicine, Oslo, Norway

Background: Ultrasound can evaluate osteophytes and synovitis in persons with knee OA. However, although the literature demonstrates a positive association between knee pain and synovitis, the instruments used to report pain, the number of patients included, the strengths of associations and the overall quality of the studies varies greatly (1).

Objectives: 1) To compare the degree of OA changes by ultrasound among people with and without clinical knee OA according to established classification criteria. 2) To study the associations between ultrasound findings and pain.

Methods: We included 286 of 300 participants from the NOR-HAND study, a hospital-based observational cohort after excluding participants with knee prosthesis or arthrodesis.

The participants reported the levels of knee/hip pain using the Western/Ontario McMaster University index (WOMAC) and marked their painful joints (including the bilateral knees) during the last 24 hours and last 6 weeks on two separate homunculi. An experienced rheumatologist (BS) examined whether the participants fulfilled the clinical ACR criteria for knee OA or not (n=7 missing).

A trained medical student performed the ultrasound examination of the knees using a General Electric (GE Logic E9 ultrasound machine with a 6-15Mz probe. Both knees were scored for 1) osteophytes in the medial and lateral tibia and femur on 0-3 semi-quantitative scales (0=no, 1-3 small, 2=medium, and 3=large), and 2) grey-scale synovitis on 0-3 semi-quantitative scales (Groen, 1=mild, 2=moderate, and 3=severe pathology). The highest score of osteophytes and grey-scale synovitis (range: 0-3) and the sum scores of both knees together (range: 0-24 for osteophytes and 0-6 for synovitis) were calculated.

We compared the degree of ultrasound pathologies in persons with vs. without clinical knee OA using Chi square tests and Mann-Whitney U test or T test as appropriate. The associations between ultrasound pathologies and pain scores were explored by logistic regression analyses, adjusted for age, sex and BMI. Generalized Estimating Equations were applied to account for two knees belonging to the same person.

Results: Knee osteophytes, but not grey-scale synovitis, were more common in persons with vs. without clinical knee OA (median sum score of osteophytes: 2 vs. 0, p<0.001) and were associated with higher levels of WOMAC pain (beta=0.18, 95% confidence interval (CI) 0.03-0.32). The same association to WOMAC pain was not found for synovitis (beta=0.03, 95% CI -0.33-0.40). However, in analyses on joint level, both osteophytes and synovitis were associated with pain in the same joint in both a short (24 hours) and longer term (6 weeks), with stronger associations for more severe ultrasound scores (Table 1).

Table 1. Associations between ultrasound pathologies and a) WOMAC pain and b) joint pain in the same joint previous 24 hours and c) previous 6 weeks, adjusted for age, sex and BMI.

<table>
<thead>
<tr>
<th>Pathology</th>
<th>WOMAC pain (both knees)</th>
<th>Joint pain (same joint)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a)</td>
<td>b)</td>
<td></td>
</tr>
<tr>
<td>Osteophytes (both knees)</td>
<td>0.18 (0.03-0.32)</td>
<td>0.91 (0.66-1.27)</td>
</tr>
<tr>
<td>Grey-scale synovitis (both knees)</td>
<td>0.03 (0.33-0.40)</td>
<td>0.23 (0.16-0.30)</td>
</tr>
</tbody>
</table>

Conclusion: Both osteophytes and grey-scale synovitis were associated with pain in the same joint, supporting the validity of ultrasound in knee OA. Grey-scale synovitis was commonly present in people not fulfilling the ACR criteria for clinical knee OA and seems to be less specific for clinical knee OA than osteophytes.

REFERENCES:
[1] doi 10.1016/j.joca.2016.03.004

Disclosure of Interests: Caroline Dekkerhus: None declared, Alexander Mathiessen: None declared, Caroline Fjellstad: None declared, Barbara Statwalksy-Christensen: None declared, Helmer Hammer: None declared, Ida K Haugen Consultant of: Novartis, Grant/research support from: Pfizer

HETEROGENOUS CARTILAGE DAMAGE SEEN ON MRI AMONG KNEES WITH KELLGREN-LAWRENCE 2 & 3 OSTEOARTHRITIS: WHAT ARE THE IMPLICATIONS FOR CLINICAL TRIALS?

M. Jarraya1, F. Roemer2, E. Ashbeck3, J. Lynch4, C. K. Kwoh5, A. Guermazi5.
1Massachusetts General Hospital, Radiology, Boston, United States of America; 2University of Erlangen-Nuremberg, Radiology, Erlangen, Germany; 3University of Arizona College of Medicine, Arthritis and Musculoskeletal Population Health Program, Tuscon, United States of America; 4UCSF, Epidemiology and Biostatistics, San Francisco, United States of America; 5VA Boston Healthcare, Radiology, Boston, United States of America

Background: The most recent update of the Global Burden of Disease figures (GBD 2013) estimated that 242 million people were living in the world with symptomatic and activity-limiting OA of the hip and/or knee. Many potential disease-modifying osteoarthritis drugs (DMOADs) have been investigated, but to date no DMOADs that slow or stop disease progression have been approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). A potential reason for the lack of demonstrated efficacy may be reliance on radiographs for defining structural inclusion and exclusion criteria for clinical trials, such as use of joint space width and Kellgren-Lawrence (KL) grade as surrogates for cartilage damage.

Table 1.

<table>
<thead>
<tr>
<th>Knee MRI Findings</th>
<th>Kellgren-Lawrence Grade</th>
<th>KL2 (n=2,318)</th>
<th>Percent</th>
<th>(95%CI)</th>
<th>KL3 (n=1,128)</th>
<th>Percent</th>
<th>(95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medial TFJ</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>52.4</td>
<td>(50.1, 54.6)</td>
<td>14.4</td>
<td>(12.2, 16.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal PT/FT</td>
<td></td>
<td>9.4</td>
<td>(8.2, 10.7)</td>
<td>2.6</td>
<td>(1.6, 3.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse PT lesion</td>
<td></td>
<td>32.1</td>
<td>(30.1, 34.2)</td>
<td>40.6</td>
<td>(37.5, 43.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse FT lesion</td>
<td></td>
<td>6.1</td>
<td>(5.0, 7.1)</td>
<td>42.5</td>
<td>(39.4, 45.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lateral TFJ</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>61.0</td>
<td>(58.8, 63.2)</td>
<td>53.6</td>
<td>(50.4, 56.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal PT/FT</td>
<td></td>
<td>16.4</td>
<td>(14.8, 18)</td>
<td>14.2</td>
<td>(12.1, 16.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse PT lesion</td>
<td></td>
<td>14.6</td>
<td>(13.1, 16.2)</td>
<td>12.1</td>
<td>(10.1, 14.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse FT lesion</td>
<td></td>
<td>7.9</td>
<td>(6.8, 9.1)</td>
<td>20.1</td>
<td>(17.6, 22.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medial/lateral TFJ</strong></td>
<td>(maximum score)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>34.8</td>
<td>(32.7, 36.9)</td>
<td>4.3</td>
<td>(3.0, 5.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal PT/FT</td>
<td></td>
<td>15.1</td>
<td>(13.5, 16.6)</td>
<td>1.2</td>
<td>(0.6, 1.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse PT lesion</td>
<td></td>
<td>36.9</td>
<td>(34.8, 39.0)</td>
<td>35.4</td>
<td>(32.4, 38.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse FT lesions</td>
<td></td>
<td>13.3</td>
<td>(11.8, 14.8)</td>
<td>59.1</td>
<td>(56.0, 62.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PFJ</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>22.0</td>
<td>(20.2, 23.9)</td>
<td>23.0</td>
<td>(20.3, 25.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal PT/FT</td>
<td></td>
<td>4.4</td>
<td>(3.5, 5.3)</td>
<td>3.9</td>
<td>(2.7, 5.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse PT lesion</td>
<td></td>
<td>24.9</td>
<td>(23, 26.9)</td>
<td>36.3</td>
<td>(33.3, 39.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse FT lesions</td>
<td></td>
<td>48.6</td>
<td>(46.2, 50.9)</td>
<td>36.9</td>
<td>(33.8, 40.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Whole knee</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td>9.8</td>
<td>(8.5, 11.1)</td>
<td>2.0</td>
<td>(1.1, 2.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal PT/FT</td>
<td></td>
<td>5.4</td>
<td>(4.4, 6.4)</td>
<td>1.0</td>
<td>(0.4, 1.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse PT lesion</td>
<td></td>
<td>28.8</td>
<td>(26.8, 30.8)</td>
<td>23.6</td>
<td>(20.9, 26.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diffuse FT lesions</td>
<td></td>
<td>55.9</td>
<td>(53.7, 58.2)</td>
<td>73.4</td>
<td>(70.6, 76.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of compartments with diffuse FT lesions</strong></td>
<td></td>
<td>0</td>
<td>44.0</td>
<td>(41.7, 46.3)</td>
<td>26.6</td>
<td>(23.8, 29.4)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>49.8</td>
<td>(47.5, 52.1)</td>
<td>48.9</td>
<td>(45.8, 52)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>5.8</td>
<td>(4.8, 6.8)</td>
<td>22.9</td>
<td>(20.3, 25.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0.4</td>
<td>(0.2, 0.7)</td>
<td>1.6</td>
<td>(0.9, 2.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Number of TFJ compartments with diffuse FT lesions</strong></td>
<td></td>
<td>0</td>
<td>86.7</td>
<td>(85.2, 88.2)</td>
<td>40.9</td>
<td>(37.8, 44.0)</td>
<td></td>
</tr>
<tr>
<td>1 (medial or lateral)</td>
<td>12.5</td>
<td>(11.0, 13.9)</td>
<td>55.5</td>
<td>(52.5, 58.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 (medial and lateral)</td>
<td>0.8</td>
<td>(0.4, 1.1)</td>
<td>3.5</td>
<td>(2.4, 4.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PT: Partial-thickness, FT: Full-thickness, TFJ: Tibiofemoral Joint, PFJ: Patellofemoral Joint
Objectives: To estimate the distribution of cartilage damage seen on knee MRI in a sample of knees with radiographic KL 2 and 3 OA that would potentially qualify for a DMOAD in KL3 knees.

Methods: We selected knees from the Osteoarthritis Initiative (OAI), a longitudinal cohort study of knees with or at risk of developing symptomatic radiographic OA, that met common structural inclusion criteria for DMOAD trial enrollment at OAI baseline: knees with radiographs centrally graded as KL 2 or 3 and medial minimum joint space width (mJSW) ≥ 1.5mm. A musculoskeletal radiologist with 10 years of experience in semi-quantitative MRI assessment scored knee cartilage damage in the medial and lateral femorotibial and patellofemoral compartments using WORMS (Whole-Organ Magnetic Resonance Imaging Score). Coronal intermediate weighted (IW) T2 and sagittal fat-suppressed IW T2 sequences on 3T MRI were used. The WORMS cartilage scores, which are based on both the extent and depth of cartilage damage, were collapsed into 4 categories: no cartilage damage (WORMS 0 and 1), focal partial or full-thickness (PT/FT) cartilage damage (WORMS 2 and 2.5), diffuse partial thickness (PT) cartilage damage (WORMS 5 and 6). We estimated the prevalence of each category of cartilage damage in KL2 and KL3 knees; 95% confidence intervals (CI) accounted for clustering at the participant-level since some participants contributed two knees to the analysis.

Results: We identified 2,372 participants contributing 3,446 knees with radiographic OA (KL 2 and 3) and medial mJSW ≥ 1.5mm. There were 2,318 KL2 knees and 1,128 KL3 knees. The distribution of cartilage damage in each compartment by KL grade is presented in Table 1. We found no cartilage damage in any compartments in 9.8% (95% CI: 8.5, 11.1) of KL2 knees and 2.0% (95% CI: 1.1, 2.9) of KL3 knees. Cartilage damage was absent in the medial tibialcompartment in 52.4% (95% CI: 50.1, 54.6) of KL2 knees, and 14.4% (95% CI: 12.2, 16.6) of KL3 knees; versus 61% (95% CI: 58.8, 63.2) of KL2 knees and 53.6% (95% CI: 50.4, 56.7) of KL3 knees in the lateral compartment. When medial and lateral compartments were combined, cartilage damage was absent in 34.8% (95% CI: 32.7, 36.9) of the KL2 knees, and 4.3% (95% CI: 3.0, 5.5) of the KL3 knees. Diffuse FT cartilage lesions in the medial compartment were found in 6.1% (95% CI: 5.0, 7.1) of KL2 knees and 42.5% (95% CI: 39.4, 45.6) of KL3 knees.

Conclusion: MRI screening prior to clinical trial enrollment may identify a substantial percentage of knees with normal cartilage, as well as knees with diffuse FT cartilage lesions that may not be responsive to DMOADs, depending on the mode of action of a given pharmacological compound.


POS0178 IMPPLICATIONS OF BRAIN ACTIVITY IN THE TREATMENT DECISION OF KNEE OSTEOARTHRITIS
F. Deidi1, 2, L. Tiao1, G. Martínez-Vilaveitia1, J. Pujol2, 3, L. Blanco-Hínojo4, 3, J. Deus1, 3, J. C. Monllau2, 6, J. Monfort1 on behalf of HOLOA group.1Hospital del Mar, Rheumatology, Barcelona, Spain; 2Municipal Institute of Medical Research, Grup de Recerca Cel·Luar en Inflamació i Cartílag., Barcelona, Spain; 3Hospital del Mar, MRI Research Unit, Department of Radiology, Barcelona, Spain; 4Hospital del Mar, Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Barcelona, Spain; 5Institut d’Investigació i Tecnologia en Enginyeria de les Imatges, Universitat Autònoma de Barcelona, Barcelona, Spain; 6Department of Clinical and Health Psychology, Barcelona, Barcelona, Spain; 7Hospital del Mar, Orthopaedic Department, BARCELONA, Spain

Background: Chronic pain related to knee osteoarthritis (KOA) is a common health problem and functional magnetic resonance imaging (fMRI) is a useful technique which can determine different brain activation (1). Objectives: The main purpose of our study was to observe whether there is different risk to central sensitization and different brain activation in patients with KOA according to the treatment followed (conservative (CNV) Vs. total knee replacement (TKR))

Methods: Patients diagnosed of primary KOA following a CNV treatment or undergoing TKR were recruited. Two groups were matched by age, sex and BMI. Clinical central sensitization was considered if patients presented spread tenderness, evaluated with an algometer, in more than 1 site of the extended peripatellar map (2) (notice that pain at points 3, 7 and 8 were not counted) fMRI testing involved pressure painful stimulation to the articular interline and to a commonly sensitized site (tibial surface, point 10).To evaluate the associations between central sensitization and risk to undergo a TKR logistic regression was performed to estimate OR and 95% confidence intervals (95%CI). Models were adjusted by sex, age and BMI (R (v.3.5.2).Whole-brain activation maps were compared between groups using Statistical Parametric Mapping software (SPM12 http://www.fil.ion.ucl.ac.uk/spm).

Results: Women have a significant higher risk to present central sensitization than men (OR 12.11 (95% CI 4.32-33.95) p-value:2.09*10-6), but no differences were observed between CNV or TKR groups (OR TRK 0.67 CI 0.24-1.98).

Table 1. The differences observed in brain activation between the treatment groups in the interline fMRI test (point 7) did not correspond to any specific brain...
area. However, TKR group showed a higher activation that implicated the region of the amygdala and anterior hippocampus during the tibial fMRI test (point 10).

Table 1. Central sensitization Odds Ratio (OR) with 95% Confidence Interval (95%CI)

<table>
<thead>
<tr>
<th>O.R. (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment</td>
<td>0.69 (0.24-1.98)</td>
</tr>
<tr>
<td>Sex</td>
<td>12.11 (4.32-33.95)</td>
</tr>
<tr>
<td>Age</td>
<td>0.72 (0.26-1.97)</td>
</tr>
<tr>
<td>BMI</td>
<td>1.88 (0.69-5.17)</td>
</tr>
</tbody>
</table>

Conclusion: Presenting central sensitization is not a risk for KOA patients to undergo a TKR, but the mechanism underlying sensitization in both treatment groups might be different, with amygdala playing an important role in TKR patients. The amygdala is an important element of the brain systems that both express emotions and modulate pain. The activation of the amygdala in response to pressure stimulation on a sensitized knee site is interpreted as a failure of the descending pain inhibitory systems, and the occurrence of a major emotional response during the painful experience in patients that ultimately received TKR.

References:

Extended peripatellar map including the points tested for tenderness, and brain areas differently activated between both treatment groups during painful stimulation to point 7 (interline) and point 10 (tibial surface, a commonly sensitized site).

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2067

THE EFFICACY AND SAFETY OF A FIXED-DOSE COMBINATION OF APOCYIN AND PAEONOL IN SYMPTOMATIC KNEE OA: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL

A. R. Bihlet1, I. Byrjalsen2, J. R. Andersen1, A. Metnik3, A. Reynolds4, N. Larkins5, P. Alexandersen6, H. Rovsing6, U. Schmidt7, R. Moots8,9, P. Kingo10, A. R. Bihlet1, I. Byrjalsen2, J. R. Andersen1, A. Metnik3, A. Reynolds4, N. Larkins5, P. Alexandersen6, H. Rovsing6, U. Schmidt7, R. Moots8,9, 1AKL Research and Development Ltd., Clinical Science, Stevenage, United Kingdom; 2AKL Research and Development Ltd., Clinical Science, Stevenage, United Kingdom; 3Sanos Clinic A/S, Vejle, Vejle, Denmark; 4Sanos Clinic A/S, Vejle, Vejle, Denmark; 5Sanos Clinic A/S, Vejle, Vejle, Denmark; 6Sanos Clinic A/S, Vejle, Vejle, Denmark; 7Sanos Clinic A/S, Vejle, Vejle, Denmark; 8Aintree Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom; 9University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 10NIHR Leeds, Biomedical Research Centre, Leeds, United Kingdom

Background: There is a great unmet need for the development of effective treatments to treat the symptoms of OA. Nuclear-Factor Kappa-B (NF-κB) and Nrf2 play a key roles in OA pathogenesis and have been identified as potential targets. A fixed-dose combination of apocynin and paenol in a ratio of 2:7 (APPA) has been shown to inhibit activation of NF-κB and upregulate Nrf2 [1].

Objectives: We report the results of a phase 2a study evaluating the efficacy and safety of APPA in patients with symptomatic knee OA.

Methods: The trial was a 28-day randomized, placebo-controlled, double-blind study comparing 800 mg of APPA twice daily with matched placebo capsules. Patients with radiographic knee OA K−grade 2−3, and a WOMAC pain score ≥40 and ≤30/100 of target knee at screening and baseline were randomized 1:1 to APPA or placebo. Main exclusion criteria included recent intrarticular surgery or injection therapy, hip pain greater than the target knee, and BMI ≥40 kg/m². The primary endpoint was change from baseline to Day 28 in the WOMAC pain score. Safety outcomes included reported adverse events (AE), clinical laboratory parameters, ECG, and vital signs.

A pre-defined subgroup analysis in subjects with a baseline PainDETECT score >12 indicated a positive effect. Accordingly, post-hoc analyses were undertaken to further assess the effects of APPA in subgroups of participants with higher disease severity.

Results: 152 participants were randomized, and 149 (98%) completed the trial. The mean (SD) WOMAC pain score at baseline was 55.3 (10.2). The two groups were comparable in terms of baseline pain score, gender, age, and BMI. The primary endpoint was not met, mean difference (MD) between APPA and placebo was -0.89 (95% CI: -5.62, 3.74, p=0.71, Figure 1A). Similarly, no significant differences were found on other key secondary endpoints (WOMAC Function and WOMAC total Figure 1B and C, respectively). APPA was well-tolerated and no differences in frequencies of reported AEs were noted, apart from a higher proportion of subjects reporting mild to moderate gastrointestinal discomfort reported with APPA compared to placebo (12% vs. 6.5%). In the pre-defined subgroup of participants with baseline PainDETECT ≥ 13 (N=45), the difference in mean change in pain from baseline favored the APPA group (MD: -11.20, 95% CI: -20.29 to -2.11, p=0.02). Analysis of participants >50 WOMAC pain at baseline (Group 1, N=95, Figure 1D), and a K−grade of the non-target knee >2 (Group 2, N=105, Figure 1E), and a combination of these two criteria (Group 3, N=64, Figure 1F) found a positive effect of APPA compared to placebo (Group 1 MD: -2.61, 95% CI: -8.98 to 3.76, p=0.42, Group 2 MD: -4.01, 95% CI: -9.35 to 1.33, p=0.14, and Group 3 MD: -8.32, 95% CI: -15.48 to -1.16, p=0.02).

Conclusion: Treatment with APPA 800mg twice daily for 28 days in patients with symptomatic knee OA overall was not associated with significantly improved outcomes compared to placebo. The treatment was well-tolerated and safe. Subgroup analyses, however, showed a significant effect of APPA in patients with moderate to severe OA, indicating that further research in the effects of APPA in appropriate patients is warranted.

REFERENCES:

DOI: 10.1136/annrheumdis-2022-eular.1175
Methods: Pain, stiffness, and physical function in patients with MSOA.

A mean (SD) age of 63 (6) and a mean (SD) BMI of 33 (5) kg/m². After 16 weeks, the PF J group lost more body weight (–3.9 kg, 95% CI –5.8 to –2.0; p < 0.001) and waist circumference (–4 cm, 95% CI –7 to –1; p = 0.01). HbA1c and fasting glucose improved in the PF J versus control group, but not significantly. LDL decreased by 0.38 mmol/l (95% CI 0.07 to 0.69; p = 0.02) and triglycerides by 0.32 (95% CI 0.01 to 0.63; p = 0.04) in favour of the PF J group. HDL and blood pressure remained unchanged. Of the patient reported outcome measures (PROMIS®) only fatigue showed a significant improvement. Body mass index (BMI) decreased by a baseline mean (SD) value of 55 for all the participants, fatigue improved a priori (95% CI 3.0 to 17.6)). Further, participants with constant pain at baseline also seem to benefit from GLAD over OLP (subgroup contrast: 10.0; p=0.01). KOOS pain points (95% CI 3.0 to 17.6)). Further, participants with constant pain at baseline also seem to benefit from GLAD over OLP (subgroup contrast: 10.0; p=0.01).

Conclusion: The 16-week “Plants for Joints” lifestyle program substantially decreased pain and stiffness and improved physical function in people with metabolic syndrome associated osteoarthritis of hip and/or knee. In addition, following the lifestyle program resulted in lower weight, fat mass and smaller waist circumference in comparison with usual care.

REFERENCES:
intermittent pain predicted beneficial effects of OLP, albeit the precision of the estimate was low. See Figure 1.

Figure 1. Forest plot showing the results of the subgroup analyses based on the intention-to-treat population with missing outcome data at week 9 replaced with the baseline observation (non-responder imputation). The full vertical line indicates the overall treatment effect, and the dashed line indicates zero effect. *24 GLAD and 26 OLP had no preference and are not included in the analyses, and 8 GLAD and 5 OLP had missing data; F1R study knee.

Conclusion: These results imply that GLAD should not be considered as a one-size-fits-all intervention. For patients who take analgesics for their knee pain or report constant knee pain, GLAD seems to yield clinically relevant benefits when compared to an open-label placebo. The results support a stratified recommendation of GLAD as management of knee OA.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2565

New options in SLE-Sjögren and APS

**POS0183**

THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS

M. A. Petri1, G. Bertsias2, M. Daniels3, N. L. Fox4, A. Hammerre, J. Harris1, H. Quasny8, C. Tani9, A. Askanase10.

Methods: The Be-SLE trial evaluated efficacy using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), adverse event (AE) and serious adverse events (SAE) incidence. The SLE Responder Index (SRI) is a composite measure including ≥4-point reduction in SLEDAI, no worsening in Physician global assessment (PGA), and no new organ manifestations at Week 52 (Wk 52).

Results: 1869 participants received BEL (n=1869) and 1217 received placebo (PBO) (n=1217). The efficacy and safety of BEL were maintained in multiple subgroups (Table 1; Appendix S1).

Conclusions: The efficacy of BEL was consistent across multiple patient subgroups, with higher response rates in pts with SELENA-SLEDAI score of ≥10, low C3 and/or C4 + anti-dsDNA ≥300 U/mL, and low C3 and/or C4 at baseline (Figure 1).

Disclosure of Interests: None declared

**REFERENCES:**


**POS0184**

EFFICACY OF BIIB059 ON SKIN MANIFESTATIONS IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 LLAC STUDY (PART A)

States of America; America; the production of Type I IFNs, pro-inflammatory cytokines, and chemokines. Part body targeting blood dendritic cell antigen 2 (BDCA2) that is expressed on pDCs, accumulate in the skin.4 Treatment with BIIB059, a humanized monoclonal anti-

**Objectives:** To further evaluate the effects of BIIB059 vs PBO in reducing skin disease activity, as measured by various CLASI-A response thresholds.

**Methods:** Adults with an SLE diagnosis according to the revised ACR 1997 SLE classification criteria, with ≥4 tender and ≥4 swollen joints (28-joint assessment), active skin disease (as defined by the SLE Disease Activity Index 2000 [SLEDAI-2K]), and positive anti-nuclear antibodies and/or anti-double-stranded DNA antibodies were enrolled. Participants were randomized to receive BIIB059 450 mg or PBO, administered subcutaneously every 4 weeks with an additional dose at Week 2. Improvements in skin disease were assessed in participants with baseline CLASI-A score ≥8. The proportion of participants achieving a ≥7-point reduction from baseline in CLASI-A score was assessed at Week 24, and CLASI-20, -50, -70, and -90 responses were assessed over time. Achievement of CLASI-A scores was also assessed at Week 24. These analyses used non-responder imputation with logistic regression, without correction for multiplicity. The proportions of participants achieving CLASI-A scores of 0–3 and with resolution of SLEDAI-2K skin rash at Week 24 were evaluated ad hoc in the same population. Non-responder imputation was applied to visits post treatment failure and treatment discontinuation. Improvement from baseline in British Isles Lupus Assessment Group index (BILAG-2004) A or B mucocutaneous domains was similarly assessed at Week 24. P-values were calculated based on the odds ratios (ORs) for BIIB059 compared with PBO.

**Results:** At Week 24, a significantly greater proportion of participants receiving BIIB059 (n=39) vs PBO (n=38) had a ≥7-point reduction in CLASI-A score from baseline to Week 24 [56.4% vs 34.2%, OR [95% confidence interval (CI)] 2.71 [1.03, 7.17], P=0.044]. Numerically greater proportions of participants receiving BIIB059 vs PBO achieved CLASI-50, CLASI-70, or CLASI-90 responses (Figure 1). Similarly, the proportion of participants who achieved CLASI-A scores of 0–1 was greater in the BIIB059 group vs PBO (25.6% vs 13.2%), as was the proportion who achieved CLASI-A scores of 0–3 (48.7% vs 28.9%). A greater proportion of BIIB059- vs PBO-treated participants had resolution of SLEDAI-2K skin rash at Week 24 (28.6% vs 10.7%), with similar findings seen in the BILAG-2004 mucocutaneous domain.

**Conclusion:** Numerically greater reductions in skin disease activity were consistently observed with BIIB059 treatment vs PBO in participants with SLE and active skin disease, supporting a potential benefit of BIIB059 treatment for skin manifestations in SLE.

**REFERENCES:**


**Acknowledgements:** The authors thank the LILAC investigators for their valuable contributions to this study. This study was sponsored by Biogen (Cambridge, MA, USA), and editorial support was provided by Selene Medical Communications (Macclesfield, UK), funded by Biogen.
**VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY**

A. Saxena, Y. K. O. Teng, C. Collins, N. England, H. Leher, NYU Langone Hospital, Internal Medicine, New York, United States of America; 2 Leiden University Medical Center (LUMC), Internal Medicine, Leiden, Netherlands; 3 Aurinia Pharmaceuticals, Medical Affairs, Victoria, Canada; 4 Aurinia Pharmaceuticals, Clinical Development, Victoria, Canada.

**Background:** Voclosporin (VCS), a novel calcineurin inhibitor, was approved in the US in January 2021 for the treatment of adult patients with active lupus nephritis (LN) in combination with background immunosuppressive therapy. The Phase 3 AURORA 1 study showed that the addition of VCS to mycophenolate mofetil (MMF) and low-dose steroids in patients with LN significantly increased rates of complete renal response at 52 weeks.

**Objectives:** Here we report the results of the completed continuation study, AURORA 2, which assessed the long-term safety and tolerability of VCS compared to placebo in patients with LN receiving treatment for an additional 24 months following completion of the AURORA 1 study.

**Methods:** Key inclusion criteria for the parent AURORA 1 study included a diagnosis of biopsy-proven active LN (Class III, IV, or V ± IIIb, IV) proteinuria ≥1.5 mg/mg (≥2 mg/mg for Class V) and estimated glomerular filtration rate (eGFR) >35 mL/min/1.73 m². Patients who completed AURORA 1 and who elected to be entered into AURORA 2 continued on the same blinded therapy as at the end of AURORA 1 (either VCS or placebo twice daily in combination with MMF and low-dose steroids). Safety and tolerability were monitored, and eGFR, serum creatinine (SCR), and urine protein creatinine ratio (UPCR) were also assessed.

**Results:** In total, 116 and 100 patients in the VCS and control arms enrolled in AURORA 2, with 92 (79.3%) and 73 (73.0%) patients in each respective arm receiving treatment to the end of AURORA 2. There were no unexpected safety signals in the VCS arm compared to control, with similar rates of serious adverse events reported in both arms (VCS [18.1%] vs. control [23.0%]; Table 1). Eight patients in each arm experienced serious adverse events of infection; serious coronavirus infections were observed in 2 patients in the voclosporin arm and 5 patients in the control arm. There were 4 and 2 adverse events by preferred term of renal impairment reported in the VCS and control arms, respectively, none of which were considered serious, and no reports of acute kidney injury by preferred term in either arm. There were no deaths in the VCS arm during AURORA 2; four deaths were reported in the control arm (pulmonary embolism [n=1], coronavirus infection [n=3]). Mean eGFR and SCR levels remained stable through the end of AURORA 2. The difference between the VCS and control arms in LS mean change from baseline in eGFR was 2.7 mL/min/1.73 m² at 4 weeks following study drug discontinuation (Figure 1). The mean reductions in UPCR observed in patients treated with VCS in AURORA 1 were maintained in AURORA 2 with no increase in UPCR noted at the follow-up visit 4 weeks after study drug discontinuation.

**Table 1. Overall Summary of Adverse Events**

<table>
<thead>
<tr>
<th>Event</th>
<th>Control (n=116)</th>
<th>Voclosporin (n=100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE</td>
<td>80 (80.0)</td>
<td>100 (86.2)</td>
</tr>
<tr>
<td>Renal Impairment</td>
<td>2 (2.0)</td>
<td>4 (3.4)</td>
</tr>
<tr>
<td>Acute Kidney Injury</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Treatment-related AE</td>
<td>21 (21.0)</td>
<td>28 (24.1)</td>
</tr>
<tr>
<td>Serious AE</td>
<td>23 (23.0)</td>
<td>21 (18.1)</td>
</tr>
<tr>
<td>Serious Treatment-related AE</td>
<td>2 (2.0)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>AE Leading to Study Drug Discontinuation</td>
<td>17 (17.0)</td>
<td>11 (9.5)</td>
</tr>
<tr>
<td>Death</td>
<td>4 (4.0)</td>
<td>0</td>
</tr>
<tr>
<td>Treatment-related Death</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Conclusion:** Voclosporin was well-tolerated over 3 years of treatment with no unexpected safety signals detected. Further, eGFR remained stable throughout the study period, and the significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. These data provide evidence of a long-term treatment benefit of VCS in patients with LN. Includes adverse events starting on or after the first dose of study drug in AURORA 2 up to 30 days after the last dose and all events of death reported during study follow-up. Adverse events were aggregated by System Organ Class and Preferred Term and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0. AE, adverse event.

**Disclosure of Interests:** Amit Saxena Speakers bureau: Aurinia Pharmaceuticals, Novartis, KezarBio, Grant/research support from: GSK.

**DOI:** 10.1136/annrheumdis-2022-eular.1820

Figure 1. LS Mean eGFR over Time

**Conclusion:** Voclosporin was well-tolerated over 3 years of treatment with no unexpected safety signals detected. Further, eGFR remained stable throughout the study period, and the significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. These data provide evidence of a long-term treatment benefit of VCS in patients with LN. Includes adverse events starting on or after the first dose of study drug in AURORA 2 up to 30 days after the last dose and all events of death reported during study follow-up. Adverse events were aggregated by System Organ Class and Preferred Term and coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 20.0. AE, adverse event.


**DOI:** 10.1136/annrheumdis-2022-eular.4162
Background: Lupus nephritis (LN) is one of the most severe organ manifesta-
tions of systemic lupus erythematosus (SLE) and constitutes an important cause of
morbidity and death among patients with SLE [1]. The associated renal injury, and
ultimately damage, is the result of an immune-mediated process which involves
leukocytes, immune complexes, complement and cytokines [2].

Objectives: Lupus nephritis (LN) is one of the most severe organ manifestations of
systemic lupus erythematosus (SLE) and constitutes an important cause of
morbidity and death among patients with SLE [1]. The associated renal injury, and
ultimately damage, is the result of an immune-mediated process which involves
leukocytes, immune complexes, complement and cytokines [2].

Methods: We analysed differentially expressed genes (DEGs), pathways and
their drugability via the Drug Gene Interaction database (DGIdb) [3] in active
LN (n=41) versus healthy controls (HC; n=497), and eQTLs in active or past
LN (n=87), based on validated (identified in two independent SLE populations) DEGs in SLE (n=350) vs HC (n=497), in whole blood collected within the frame of the European PRECISESADS consortium [4]. Genome-wide RNA-sequenc-
ing and genotyping was previously performed by illumina assays, and serum
levels of 17 cytokines and 18 autoantibodies were analysed using a Luminex assay, ELISA, IDS-SYS and SPLAPUS analyser [4].

Results: A total of 6 869 significant and validated DEGs were identified in active LN patients compared with HC. Of these, 1010 validated DEGs were tagged to 34 KEGG pathways including 24 DEGs with a fold change (FC) > 1.5, genes of 18 cis-eQTLs and 3 trans-eQTLs, and 1 gene from cytokines that differed signif-
ificantly between active LN and HC. Moreover, 2446 validated DEGs were tagged to 216 Reacome pathways included 85 DEGs with a FC > 1.5, genes of 21 cis-
eQTLs and 5 trans-eQTLs, and 1 gene from cytokines that differed significantly between active LN and HC. These genes could be targeted by 203 different drugs, with the proteasome inhibitor bortezomib interfering with cathepsin B (CTSB) reg-
ulation and cyclophosphamide interfering with the regulation of tumour necrosis factor receptor superfamily member 1A (TNFRSF1A) being of particular interest.

Conclusion: Integrated multilevel omics analysis in LN revealed a set of enriched pathways of potential interest for future drug investigation. A prospect for proteas-
osome inhibition was implicated.

REFERENCES:

Acknowledgements: The PRECISESADS Clinical Consortium Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5348
Atacicept is a fusion protein that blocks B-lymphocyte stimulator and a proliferation-inducing ligand, which are increased in patients with SLE. APRIL-SLE was a double-blind, placebo-controlled, Phase 2 study that randomized patients with moderate-to-severe systemic lupus erythematosus (SLE) to atacicept 75 mg, atacicept 150 mg, or placebo twice-weekly for 4 weeks, then weekly for 48 weeks.

**Results:** In total, 111 patients in the placebo group, 112 patients in the atacicept 75 mg group, and 62 patients in the atacicept 150 mg group completed 52 weeks of treatment; 27 other patients had already been withdrawn for various reasons; the protocol was discontinued prematurely due to 2 deaths from pneumonias. When treatment was discontinued, 62 of 144 patients in this group had completed 52 weeks of treatment; 27 other patients had already been withdrawn for various reasons; and, in the remaining 55 patients, treatment was stopped early as a safety precaution. Patients in the other two groups completed the protocol.

**Results:** In total, 111 patients in the placebo group, 112 patients in the atacicept 75 mg group, and 62 patients in the atacicept 150 mg group completed 52 weeks of treatment. The eGFR time course was stable for the atacicept groups compared to placebo in preventing new flares in patients with moderate-to-severe SLE; this effect has not been reported previously.

**Conclusion:** Results from this double-blind, placebo-controlled, Phase 2 study suggest a potential for improved renal function with atacicept treatment of patients with moderate-to-severe SLE.

**References:**


**Disclosure of Interests:** David Isenberg Consultant of: Professor Isenberg has consulted for Veratx, Servier, Asto-Zeneca, Idorsia, Merck Serono, and Amgen. His honoraria are passed on to a local arthritis charity, Celia J. F. Lin Shareholder of: Dr. Lin is an employee of Vera Therapeutics, Inc., Employee of: Dr. Lin is an employee of Vera Therapeutics, Inc., Amy Kao Shareholder of: Dr. Kao own stocks of Merck KGaA, Darmstadt, Germany, Employee of: Dr. Kao is an employee of EMD Serono Research & Development Institute, Inc (a business of Merck KGaA), Aida Arselan Aydemir Employee of: Ms. Aydemir is an employee of EMD Serono Research & Development Institute, Inc (a business of Merck KGaA), Caroline Gordon Speakers bureau: Dr. Gordon reports personal fees for speakers bureau from UCB, Consultant of: Dr. Gordon reports personal fees for honoraria from consultancy work from the Center for Disease Control and Prevention, Agen, Astra-Zeneca, AbbVie, EMD Serono, MGP, Sanofi, and UCB, Grant/research support from: Dr. Gordon reports an educational grant from UCB to Sandwell and West Birmingham Hospitals NHS Trust that supported previous research work unrelated to any specific drug (last payment July 2019).

**DOI:** 10.1136/annrheumdis-2022-eular.1924

---

**Table 1. Median Percent Change from Baseline of Estimated Glomerular Filtration Rate (eGFR) and Proteinuria at Week 52 – Safety Analysis Set**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo</th>
<th>Atacicept 75 mg</th>
<th>Atacicept 150 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>eGFR (mL/min)</td>
<td>n=110</td>
<td>n=111</td>
<td>n=62</td>
</tr>
<tr>
<td>median</td>
<td>-4.35</td>
<td>-1.69</td>
<td>0.57</td>
</tr>
<tr>
<td>UPCR (mg/mg)</td>
<td>n=108</td>
<td>n=108</td>
<td>n=63</td>
</tr>
<tr>
<td>median</td>
<td>6.29</td>
<td>-6.27</td>
<td>-12.72</td>
</tr>
<tr>
<td>UPCR (mg/mg)</td>
<td>n=12</td>
<td>n=15</td>
<td>n=8</td>
</tr>
<tr>
<td>median</td>
<td>26.11</td>
<td>-54.42</td>
<td>-12.15</td>
</tr>
</tbody>
</table>

eGFR-estimated glomerular filtration rate; UPCR-urinary protein/creatinine ratio. *Among patients with screening UPCR ≥0.2 mg/mg. †Enrollment in the atacicept 150 mg arm was discontinued prematurely (described in Isenberg et al., 2015).

**Figure 1. Median Change in eGFR. eGFR- estimated glomerular filtration rate; IQR-interquartile range**

**Conclusion:** Results from this double-blind, placebo-controlled, Phase 2 study suggest a potential for improved renal function with atacicept treatment of patients with moderate-to-severe SLE.

**References:**


**Disclosure of Interests:** David Isenberg Consultant of: Professor Isenberg has consulted for Veratx, Servier, Asto-Zeneca, Idorsia, Merck Serono, and Amgen. His honoraria are passed on to a local arthritis charity, Celia J. F. Lin Shareholder of: Dr. Lin is an employee of Vera Therapeutics, Inc., Employee of: Dr. Lin is an employee of Vera Therapeutics, Inc., Amy Kao Shareholder of: Dr. Kao own stocks of Merck KGaA, Darmstadt, Germany, Employee of: Dr. Kao is an employee of EMD Serono Research & Development Institute, Inc (a business of Merck KGaA), Aida Arselan Aydemir Employee of: Ms. Aydemir is an employee of EMD Serono Research & Development Institute, Inc (a business of Merck KGaA), Caroline Gordon Speakers bureau: Dr. Gordon reports personal fees for speakers bureau from UCB, Consultant of: Dr. Gordon reports personal fees for honoraria from consultancy work from the Center for Disease Control and Prevention, Agen, Astra-Zeneca, AbbVie, EMD Serono, MGP, Sanofi, and UCB, Grant/research support from: Dr. Gordon reports an educational grant from UCB to Sandwell and West Birmingham Hospitals NHS Trust that supported previous research work unrelated to any specific drug (last payment July 2019).

**DOI:** 10.1136/annrheumdis-2022-eular.1924
Table 1. Efficacy and safety of baricitinib in patients with SLE-BRAVE-I and -II

<table>
<thead>
<tr>
<th></th>
<th>SLE-BRAVE-I</th>
<th>SLE-BRAVE-II</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SRI-4 (W52)</td>
<td>116 (45.9)</td>
<td>126 (49.8)</td>
</tr>
<tr>
<td>SRI-4 (W24)</td>
<td>99 (39.1)</td>
<td>114 (44.8)</td>
</tr>
<tr>
<td>Severe flares (n, events)</td>
<td>38 (15.0)</td>
<td>34 (13.3)</td>
</tr>
<tr>
<td>HR for time to first severe flare (SFI)</td>
<td>NA &lt; 0.05 vs PBO &lt; 0.05</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid sparing</td>
<td>18 (7.1)</td>
<td>24 (9.4)</td>
</tr>
<tr>
<td><strong>SAE</strong></td>
<td>26 (10.3)</td>
<td>26 (10.2)</td>
</tr>
<tr>
<td><strong>TEAE</strong></td>
<td>116 (45.6)</td>
<td>120 (46.3)</td>
</tr>
<tr>
<td><strong>LLDAS (W52)</strong></td>
<td>29 (11.2)</td>
<td>210 (82.4)</td>
</tr>
<tr>
<td>Glucocorticoid sparing</td>
<td>35 (13.4)</td>
<td>29 (11.1)</td>
</tr>
<tr>
<td><strong>Lapse time to first severe flare</strong></td>
<td>116 (45.6)</td>
<td>120 (46.3)</td>
</tr>
<tr>
<td><strong>SAE</strong></td>
<td>29 (11.2)</td>
<td>210 (82.4)</td>
</tr>
<tr>
<td><strong>TEAE</strong></td>
<td>112 (47.1)</td>
<td>108 (42.1)</td>
</tr>
<tr>
<td><strong>SAE</strong></td>
<td>29 (11.2)</td>
<td>210 (82.4)</td>
</tr>
<tr>
<td><strong>TEAE</strong></td>
<td>121 (47.1)</td>
<td>108 (42.1)</td>
</tr>
</tbody>
</table>

**Results:** 91 patients diagnosed with SLE were included in the study. Of the total of patients included in the study, 64 were in current treatment with an antimalarial drug, with a mean of 9.09 (5.73) years of treatment, and a mean cumulative dosage of 613.16 (436.12) gr.

We analyzed the possible relationship between the QTC interval, the current treatment with antimalarial drugs, and the cumulated dosage of this medication. We corrected the lineal regression models by the years of disease evolution, the presence or absence of known heart disease, the women gender, and other treatments such as antiarrhythmics or beta-blockers.

We found a statistically significant association between taking antimalarial drugs and the elongated QTc interval (p=0.001). Nevertheless, in the multivariate analysis, we did not find a significant relationship between the ECG alterations and the treatment with antimalarial drugs.

**Figure 1.**

**Conclusion:** In our study, we did not observe a direct relationship between the intake of antimalarial drugs and the alteration of the corrected QT interval.

**REFERENCES:**

N/A

---

**Table 1.**

<table>
<thead>
<tr>
<th></th>
<th>NO antimalarial</th>
<th>YES antimalarial</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=27</td>
<td>n=64</td>
<td></td>
</tr>
</tbody>
</table>

**Heart disease**

<table>
<thead>
<tr>
<th></th>
<th>7 (25.93%)</th>
<th>5 (78.1%)</th>
</tr>
</thead>
</table>

**Cumulative dosage HCO (gr)**

<table>
<thead>
<tr>
<th></th>
<th>316.41 (457.28)</th>
<th>813.16 (436.12)</th>
</tr>
</thead>
</table>

**ECG disorders**

<table>
<thead>
<tr>
<th></th>
<th>5 (18.52%)</th>
<th>12 (18.75%)</th>
</tr>
</thead>
</table>

**Structural disorders**

<table>
<thead>
<tr>
<th></th>
<th>1 (3.7%)</th>
<th>6 (9.38%)</th>
</tr>
</thead>
</table>

**Electrical conduction disorders**

<table>
<thead>
<tr>
<th></th>
<th>2 (7.41%)</th>
<th>6 (9.38%)</th>
</tr>
</thead>
</table>

---

**Conclusion:** Although phase 2 data suggested BARI as a potential treatment for patients with SLE (2), the SLE-BRAVE-I and -II phase 3 study results were discordant for the primary outcome measure, with only SLE-BRAVE-I positive, making it difficult to elucidate benefit. Additional analyses are being performed to understand this discordance. No new safety signals were observed.

**REFERENCES:**


---

**Pos0191**

**Antimalarial Drugs and ElectrocadioGraphical Alterations in Patients with Systemic Lupus Erythematosus.**

C. Blesco Barcena1, S. Leal Rodriguez2, M. E. Acevedo2, E. Grau Garcia3, C. Pérez Peralta1, A. V. Huaylla Quispe1, M. De la Rubia Navarro1, P. Muñoz Martínez1, L. Mas Sanchez1, I. Martínez Cordellat1, C. Nájera Herranz1, C. Pávez Perales1, A. V. Huaylla Quispe1, M. De la Rubia Navarro1, P. Muñoz Martínez1, L. Mas Sanchez1, I. Martínez Cordellat1, C. Nájera Herranz1, R. Negueroles Albuixech1, F. Ortiz-Sanjuán1, E. Vicens Bernabeu2, I. Cánovas Olmo1, J. J. Frago Gil1, L. Gonzalez Puig1, J. E. Oliver Rodriguez1, J. Iwora Cortés1, J. A. Román Ivorra1, València, Servei de Reumatologia. Hospital Universitari y Politécnico La Fe, Valencia, Spain; 2València, Servei de Reumatologia. Institute Musculosquelàtico La Fe, Valencia, Spain

**Background:** During the first months of the Sars-CoV-2 pandemic, antimalarial drugs were the central axis of the treatment of patients with acute respiratory infection. After that, several studies reported a risk of prolongation of corrected QT interval (QTC) at the electrocardiogram (ECG).

**Objectives:** To analyze the possible relationship between the use of antimalarial drugs and the electrocardiographic alterations in patients diagnosed with SLE.

**Methods:** Cross-sectional study in patients diagnosed with SLE (SLICC 2012). In all of them, we performed a 12-lead ECG at rest. We measured the QT interval manually and automatically, and its correction was made according to the Hodge formula (QTC).

**Results:** Among patients included in the study, 64 were in current treatment with an antimalarial drug, with a mean of 9.09 (5.73) years of treatment, and a mean cumulative dosage of 613.16 (436.12) gr.

We analyzed the possible relationship between the QTC interval, the current treatment with antimalarial drugs, and the cumulated dosage of this medication. We corrected the lineal regression models by the years of disease evolution, the presence or absence of known heart disease, the women gender, and other treatments such as antiarrhythmics or beta-blockers.

We found a statistically significant association between taking antimalarial drugs and the elongated QTC interval (p=0.001). Nevertheless, in the multivariate analysis, we did not find a significant relationship between the ECG alterations and the treatment with antimalarial drugs.
IMPACT OF CORTICOSTEROID DISCONTINUATION ON SYMPTOM CONTROL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

1 InnoCentive Consulting Limited, London, United Kingdom; 2 Evidera, Waltham, United States of America; 3 Therapeutic Area Units, Idorsia Pharmaceuticals, Allschwil, Switzerland; 4 Evidera Ltd, Research, London, United Kingdom

Background: Corticosteroid (CS) treatment effectively reduces swelling and pain caused by inflammation in patients with systemic lupus erythematosus (SLE). However, prolonged CS treatment is associated with adverse events including weight gain, infections, bone loss, and premature atherosclerosis. CS treatment should be minimized to ≤5 mg/day prednisone or equivalents for chronic use and withdrawn when possible. Available data on the impact of CS discontinuation on patients with SLE are limited.

Objectives: To understand CS treatment patterns and impact of CS discontinuation on flares using a real-world cohort of patients with SLE from the United States.

Methods: This retrospective cohort study used the IBM MarketScan Commercial/Medicare supplemental claims database. Patients with SLE receiving CS who subsequently discontinued treatment during 2015 through 2019 were included. The index date was the completion date of the last CS prescription prior to discontinuation. The duration of CS exposure, daily oral CS dose, and CS medication types prescribed, converted into a prednisone-equivalent dose (PEQ), were evaluated during a 12-month pre-index (baseline) period. Outcomes were evaluated during the follow-up period, which started on the date of CS discontinuation and continued until health plan disenrollment or last day of data. Outcomes included flares, CS treatment restarts, and CS-free period prior to resuming therapy. A published algorithm, which draws on SLE-related healthcare resources and medication use, was used to identify and classify flares as mild, moderate, or severe.1 Multivariable Cox regression models evaluated the association between oral CS dose and occurrence of flare.

Results: Overall, 17,759 patients were included in the study (Table 1). The most frequently prescribed oral CS treatments were prednisone (62.7%) and methylprednisolone (23.8%). The mean (SD) duration of CS use prior to discontinuation between oral CS dose and occurrence of flare.

Disclosure of Interests: None declared

EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELUMUMAB/RTXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

1 University Medical Center Groningen, University of Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 2 GlaxoSmithKline, Clinical Science, Stevenage, Hertfordshire, United Kingdom; 3 GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, Hertfordshire, United Kingdom; 4 GlaxoSmithKline, R&D Biostatistics, Stevenage, Hertfordshire, United Kingdom; 5 GlaxoSmithKline, Clinical Development, Collegeville, PA, United States of America; 6 GlaxoSmithKline, R&D, Collegeville, PA, United States of America

Background: EULAR Sjögren’s syndrome disease activity index (ESSDAI) assesses systemic disease activity in patients (pts) with primary Sjögren’s syndrome (pSS); however, weaknesses include exclusion of patient-reported symptoms, tear and salivary gland function, and a marked placebo (PBO) response. Composite of Relevant Endpoints for Sjögren’s Syndrome (CRESS) is a recently developed composite outcome measure validated using data from three Phase 3 randomised controlled trials of pts with pSS.2 Concise CRESS (cCRESS) is used when ocular staining score and salivary gland ultrasonography are unavailable. ESSDAI was an endpoint in a Phase 2, PBO-controlled study, evaluating the safety and efficacy of belimumab (BEL) and rituximab (RTX) sequential administration (BEL/RTX), and BEL and RTX monotherapies in pts with pSS. Although the results numerically favoured BEL/RTX over PBO, this was not statistically significant.

Objectives: To evaluate the efficacy of BEL/RTX and monotherapies using cCRESS overall responses at Weeks (Wk) 24, 52, and 68 in all individual item responses at Wk 24 in pts with pSS who completed the Phase 2 study.

Methods: In the Phase 2, double-blind, 68-Wk study (NCT02631538) adults were randomised (2:2:2:1) into 4 treatment arms: BEL/RTX (n=24; weekly BEL 200 mg subcutaneous [SC] to Wk 24 followed by weekly PBO SC to Wk 52 + RTX 1000 mg intravenous [IV], Wk 8 + 10), BEL monotherapy (n=24; weekly BEL 200 mg SC to Wk 52), RTX monotherapy (n=29; RTX 1000 mg IV, Wk 8 + 10), or PBO (n=13). Pts were classified post hoc as cCRESS responders when ≥3 of the following 5 items were met: 1) Clinical (Clin)ESSDAI score ≤5 (low disease state); 2) decrease of ≥1 point or ≥15% from baseline (BL) in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI); 3) increase of ≥5 mm from BL in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score; 4) decrease of ≥25% in the rheumatoid factor (RF) titre from BL; or any increase from BL if score was 0 at BL); 5) decrease of ≥25% in the rheumatoid factor (RF) titre from BL, or decrease of ≥10% in IgG from BL.

Results: Of 86 randomised pts, 60 completed follow-up to Wk 68 (completer population) and were included in the analysis. Most pts were female (95%), n=57; mean (SD) age was 49.6 (13.0) years. BL disease characteristics are presented in the Table 1.

Table 1. Clinical, functional, and laboratory parameters at BL and cCRESS responders at Wks 24, 52, and 68 (completer population)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Commercial Health/Medicare Mean (SD)</th>
<th>PBO (n=8)</th>
<th>BEL/RTX (n=17)</th>
<th>BEL (n=19)</th>
<th>RTX (n=16)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt parameters at BL, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical ESSDAI</td>
<td>11.1 (3.76)</td>
<td>11.7 (5.47)</td>
<td>9.2 (3.77)</td>
<td>11.7 (4.78)</td>
<td></td>
</tr>
<tr>
<td>ESSPRI</td>
<td>6.4 (2.95)</td>
<td>6.0 (1.97)</td>
<td>6.5 (1.68)</td>
<td>5.9 (2.20)</td>
<td></td>
</tr>
<tr>
<td>Schirmer, mm/5 min</td>
<td>2.7 (3.25)</td>
<td>5.3 (6.44)</td>
<td>3.3 (3.16)</td>
<td>2.8 (3.15)</td>
<td></td>
</tr>
<tr>
<td>UWW, mm/min</td>
<td>0.1 (0.11)</td>
<td>0.1 (0.12)</td>
<td>0.1 (0.09)</td>
<td>0.1 (0.14)</td>
<td></td>
</tr>
<tr>
<td>RF, KU/L</td>
<td>60.8 (42.24)</td>
<td>30.9 (38.20)</td>
<td>370 (34.93)</td>
<td>105.0 (200.97)</td>
<td></td>
</tr>
<tr>
<td>cCRESS responders, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wk 24</td>
<td>3 (40.0)</td>
<td>9 (52.9)</td>
<td>7 (36.8)</td>
<td>5 (31.3)</td>
<td></td>
</tr>
<tr>
<td>Wk 52</td>
<td>4 (50.0)</td>
<td>10 (58.8)</td>
<td>8 (42.1)</td>
<td>4 (25.0)</td>
<td></td>
</tr>
<tr>
<td>Wk 68</td>
<td>1 (12.5)</td>
<td>6 (35.3)</td>
<td>7 (36.8)</td>
<td>3 (18.8)</td>
<td></td>
</tr>
</tbody>
</table>

At Wks 24 and 52, the proportion of cCRESS responders was numerically higher with BEL/RTX than with either BEL, RTX, or PBO, but the difference was not significant (Table 1). At Wk 68, the proportion of cCRESS responders was numerically higher with BEL/RTX than with RTX or PBO (Table 1). The 5 cCRESS items contributed relatively equally to total cCRESS response, with the highest response observed in the RFlg/ig and the lowest in the tear gland item (Schirmer’s test; Figure 1).


Table 1. Outcomes in patients with SLE treated with CS

<table>
<thead>
<tr>
<th>Measure</th>
<th>Commercial Health/Medicare Mean (SD) %</th>
<th>Prior to initial CS discontinuation</th>
<th>After initial CS discontinuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration CS use in days</td>
<td>100.6 (129.5)</td>
<td>26.6 (126.3)</td>
<td>28.0%</td>
</tr>
<tr>
<td>Oral CS dose tertile</td>
<td>≤5 mg/day 13.5%</td>
<td>6–20 mg/day 58.6%</td>
<td>56%</td>
</tr>
<tr>
<td>≥20 mg/day 28.0%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS treatment restart</td>
<td>73.2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No CS treatment ≥6 months</td>
<td>76.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any flare</td>
<td>90.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild to moderate</td>
<td>72.4%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>50.7%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number flares</td>
<td>6.9 (6.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CS, corticosteroid; SD, standard deviation.

Conclusion: Flares were common in patients with SLE who discontinued CS and most patients restarted CS treatment over an average follow-up of 28 months. Patients in the highest cumulative oral CS dose tertile were most at risk of disease flares following CS withdrawal.

REFERENCES


Scientific Abstracts
Outcome of COVID-19 in patients with rheumatic diseases

POS0194 MORBIDITY AND MORTALITY OF BREAKTHROUGH COVID-19 IN PATIENTS WITH IMMUNE MEDITATED CONDITIONS ON B CELL DEPLETING THERAPIES AND THE EFFECTS OF MONOCONAL ANTIBODY TREATMENT

C. Calabrese1, E. Kirchner2, M. E. Husni3, B. Moss2, A. Fernandez1, Y. Jin1, L. Calabrese1
1Cleveland Clinic, Cleveland, United States of America; 2Cleveland Clinic, Neurological Institute, Cleveland, United States of America; 3Cleveland Clinic, Dermatology, Cleveland, United States of America

Background: Among immunocompromised patients with immune mediated inflammatory diseases (IMIDs), those undergoing therapy with B cell depleting agents are among the most vulnerable to both severe COVID-19 disease and sub-optimal response to COVID-19 vaccines[1]. Numerous studies have documented suppressed humoral, but relatively maintained cell mediated, responses to COVID-19 vaccines in these patients. However, the clinical significance of such immunity in terms of protection from infection and its sequelae are poorly understood. We have analyzed a large cohort of vaccinated IMIDs patients undergoing B cell depletion therapy for the presence of breakthrough infection and assessed their outcomes.

Objectives: To define the frequency and outcomes of COVID-19 breakthrough infection in fully or partially vaccinated IMIDs patients receiving B cell depleting therapies. To assess the characteristics and risk factors for severe outcomes and death.

Methods: All pharmacy records from within a large health care system were electronically searched for patients undergoing B cell depleting therapies with approved monoclonal antibodies in 2020. Records with ICD codes for IMIDs agents are among the most vulnerable to severe COVID-19 disease and inflammatory diseases (IMIDs), those undergoing therapy with B cell depleting antibodies, dose and timing of B cell depleting therapy, and outcomes as assessed by an 8 point NIH ordinal scale. Univariate and multivariable logistic proportional-odds regression models were used to examine the risk factors for severe outcomes.

Results: A total of 1677 IMIDs patients were identified who received any B cell depleting monoclonal antibody and at least one COVID-19 vaccine in 2021. From this cohort 74 patients (4.4%) experienced a breakthrough COVID-19 infection. Among those with breakthrough infection patients 34 (46%) had a hematologic disease (RA 11, AV 15, SLE 2), 34 (46%) had CNS inflammatory disease (MS 32, 2 other), and 6 (8%) had immune hemolytic/malignant diseases. Four patients had a previous history of COVID-19 infection. Overall 24 (35%) were hospitalized with 11 patients requiring critical level care (15%) and 6 deaths (8%). All fatal cases had rheumatic diseases. Monoclonal antibodies were given as outpatient therapy to 21 patients and among these only 1 patient was hospitalized without requiring O2 and none died. In univariate analysis only number of comorbidities had a significant positive effect (p<.001) on severe outcomes (i.e. groups 1-4 vs. groups 5-8 Table 1) while monoclonal antibody therapy was associated with more favorable outcomes (p<.005 group 1-2 vs 3-8, Table 1). There were no associations between the dose, duration or timing of the B cell therapy, comorbid therapies including glucocorticoids, vaccine status (incomplete, complete, boosted) or date of vaccination with severe outcomes.

Conclusion: In IMIDs patients treated with B cell depleting therapies breakthrough infections are common with many experiencing severe outcomes. Concomitant comorbidities were associated with risk of severe disease. Monoclonal antibody therapy was used in only 28% but was associated with enhanced clinical outcomes with only 1 in 21 requiring hospitalization and zero mortality. This population of immunocompromised patients remains vulnerable to COVID-19 disease despite vaccination. More aggressive use of outpatient management with monoclonal antibody therapy and other preventive and therapeutic measures are urgently needed.

REFERENCE:

POS0195 PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS HAVE AN INCREASED RISK OF MORTALITY, MECHANICAL VENTILATION, AND HOSPITALIZATION FROM COVID-19

S. Brueng1, X. Lei3, H. Zhao2, J. Yazdany3, M. Chavez-Macgregor2, S. Giordano4, M. Suarez-Almazor5, Baylor College of Medicine, Section of Immunology, Allergy, and Rheumatology, Houston, United States of America; 2The University of Texas MD Anderson Cancer Center, Health Services Research, Houston, United States of America; 3University of California, San Francisco, Division of Rheumatology, San Francisco, United States of America

Background: Patients with systemic lupus erythematosus (SLE) may have an increased risk of mortality from COVID-19 due to underlying immunosuppression, comorbidities, and abnormalities in the innate immune system. Studies have shown that autoimmune diseases and some immunosuppressive agents are risk factors for hospitalization, ventilation, and mortality from COVID-19.

Objectives: To compare the outcomes of patients with or without SLE who were diagnosed with COVID-19 and to identify the factors associated with 30-day hospitalization, mechanical ventilation, and mortality. We hypothesized that patients with SLE had a higher risk of adverse outcomes.

Methods: This retrospective cohort study used the deidentified Optum COVID-19 Immunology Allergy, and Rheumatology, Houston, United States of America; 4University of California, San Francisco, Division of Rheumatology, San Francisco, United States of America

Results: A total of 1677 IMIDs patients were identified who received any B cell depleting monoclonal antibody and at least one COVID-19 vaccine in 2021. From this cohort 74 patients (4.4%) experienced a breakthrough COVID-19 infection. Among those with breakthrough infection patients 34 (46%) had a hematologic disease (RA 11, AV 15, SLE 2), 34 (46%) had CNS inflammatory disease (MS 32, 2 other), and 6 (8%) had immune hemolytic/malignant diseases. Four patients had a previous history of COVID-19 infection. Overall 24 (35%) were hospitalized with 11 patients requiring critical level care (15%) and 6 deaths (8%). All fatal cases had rheumatic diseases. Monoclonal antibodies were given as outpatient therapy to 21 patients and among these only 1 patient was hospitalized without requiring O2 and none died. In univariate analysis only number of comorbidities had a significant positive effect (p<.001) on severe outcomes (i.e. groups 1-4 vs. groups 5-8 Table 1) while monoclonal antibody therapy was associated with more favorable outcomes (p<.005 group 1-2 vs 3-8, Table 1). There were no associations between the dose, duration or timing of the B cell therapy, concomitant therapies including glucocorticoids, vaccine status (incomplete, complete, boosted) or date of vaccination with severe outcomes.

Conclusion: In IMIDs patients treated with B cell depleting therapies breakthrough infections are common with many experiencing severe outcomes. Concomitant comorbidities were associated with risk of severe disease. Monoclonal antibody therapy was used in only 28% but was associated with enhanced clinical outcomes with only 1 in 21 requiring hospitalization and zero mortality. This population of immunocompromised patients remains vulnerable to COVID-19 disease despite vaccination. More aggressive use of outpatient management with monoclonal antibody therapy and other preventive and therapeutic measures are urgently needed.

REFERENCE:

Disclosure of Interests: Cassandra Calabrese Speakers bureau: Sanofi-regeneron, Consultant of: Sanofi-regeneron, Elizabeth Kirchner Consultant of: Janssen, M Elaine Husni Consultant of: Abbvie, BMS, Novartis, Lilly, Pfizer, UCB, Regeneron, Janssen, Brandon Moss Consultant of: Biogen advisory board, Grant/research support from: Genentech/Roche and Novartis as part of investigators-initiated studies, Anthony Fernandez Consultant of: Abbvie, Novartis, Mallinckrodt, UCB, BMS, Bohringer Ingeheim, Alexion, Grant/ research support from: Research: Abbvie, Novartis, Pfizer, Corbus, Mallinckrodt, Yuxuan Jin: None declared, Leonard Calabrese Consultant of: Abbvie, ChemoCentryx, GSK, AstraZeneca, Consultant of: Sanofi, Jansen, Abbvie, ChemoCentrinx, GSK, AstraZeneca, BMS, Genentech
hospitalization, and mechanical ventilation after adjusting for age, sex, race and ethnicity. COVID-19 diagnosis quarter, insurance, region, severe obesity, smoking status, and comorbidities were considered only if coded or reported in an EMR up to 90 days after the positive RT-PCR. The patients' characteristics and the prognosis of COVID-19 were comparable for age, sex, race, COVID-19 diagnosis date (by quarter), insurance, region, severe obesity, smoking status, and skilled nursing facility stay three months before COVID-19 diagnosis. **Model 2 includes adjustments from model 1 and comorbidities (excluding SLE).**

**Conclusion:** Patients with SLE have an increased risks of mortality, mechanical ventilation, and hospitalization within 30 days of COVID-19 diagnosis. The risks decreased after adjustment for comorbidities but remained statistically significant for mechanical ventilation and hospitalization.

**Disclosure of Interests:** Sebastian Brueca: None declared, Xiudong Lei: None declared, Hui Zhao: None declared, Anna Moltó Consultant of: abbvie, MSD, BMS, Pfizer, Lilly, UCB, Gilead, Janssen, Novartis, Grant/research support from: UCB, Pierre Pinson: None declared, Nathanael Beeker: None declared, Christian Roux: None declared. DOI: 10.1136/annrheumdis-2022-eular.1558

**POS0196**

NINE PERCENT OF PATIENTS PRESENT WITH MUSCULOSKELETAL SYMPTOMS AFTER A SEVERE SARS-COV2 INFECTION: A DESCRIPTIVE ANALYSIS OF THE ASSISTANCE PUBlique - Hôpitaux DE PARIS CLINICAL DATA WAREHOUSE.

A. Moltó1, P. Pinson1, N. Beeker1, C. Roux1 on behalf of AP-HP COVID-19 Clinical Data Warehouse Initiative, 1AP-HP/Universities/INSERM COVID-19 Research Collaboration, AP-HP COVID Clinical Data Warehouse Initiative, Paris, France

**Background:** The main and most severe manifestation of the SARS-CoV2 infection is pneumonia, but other organ-specific symptoms have been described (myocarditis, encephalitis...), and some sparse cases have reported musculoskeletal (MSK) symptoms following such an infection. **Objectives:** to determine the prevalence of MSK symptoms appearing after a SARS-CoV2 infection.

**Methods:** This was an observational cohort based on data available at the Assistance Publique-Hôpitaux de Paris (APHP) Clinical Data Warehouse (which includes data from patients admitted in the 39 APHP hospitals). Data collected included both ICD-10 codes in discharge summaries, and 'key-words' search on electronic medical records (EMR). To be included in the analysis, patients had to have a positive RT-PCR for SARS-CoV2 performed in APHP and be admitted in any APHP department between 1st March 2020 until 31st December 2020. Patients with past history of any MSK condition were excluded. MSK conditions were considered only if coded or reported in an EMR up to 90 days after the positive RT-PCR. Demographics and disease characteristics including treatment were compared in both groups (MSK yes/no) by T-test or ChiSquare test, accordingly.

**Results:** Among the 55872 patients with a positive SARS-CoV2 RT-PCR performed in APHP, 17771 were admitted in APHP hospitals. Among them, 2170 had a previous history of MSK condition and were therefore excluded from this analysis. Among the remaining 15601 patients, 1370 (8.8%) presented with MSK symptoms. The most prevalent MSK symptoms were low back pain (32.9%), followed by joint pain (29.9%), radicular pain (20.2%) and joint effusion/arthritis (22.8%). Patients with MSK symptoms were older (67y vs. 64y, p<0.01), more frequently obese (25% vs. 20%, p=0.03), hypertensive (34% vs. 30%, p<0.01) and with diabetes (21% vs. 18%, p<0.01). There were no differences on gender nor on the ICU admission rate between groups (31% vs. 29%, NS); 30-days mortality was significantly lower in the MSK+ group probably due to selection bias (i.e. only patients who survived could present with MSK symptoms up to 90 days later) (7.8% vs. 16.9%, p<0.01). Treatment for SARS-CoV2 was slightly different in both groups, with higher corticosteroids (40.7% vs. 29.0%, p<0.01), antivirals (21.5% vs. 15.3%, p<0.01) and immunosuppressive drugs (8.5% vs. 4.5%, p<0.01) prescription rates in the MSK+ group.

**Conclusion:** MSK symptoms occurred in almost 9% of patients admitted to the hospital after a SARS-CoV2 infection, particularly in older and more comorbid patients. Further analysis evaluating the persistence of these symptoms is needed.

**Acknowledgements:** We would like to acknowledge all departments of Rheumatology of APHP.

**POS0197**

SARS-COV2 INFECTION CAUSED THROMBOSIS IN THE LUPUS MODEL WITH ANTIPHOSPHOLIPID ANTIBODY, WHEREAS COVID-19 ASSOCIATED THROMBOSIS WAS IRRELEVANT IN PATIENTS WITH POSITIVE ANTI-PHOSPHOLIPID ANTIBODY

S. Oba1, T. Hosoya1, D. Kawatani1, W. Lee1, M. Kamaya1, Y. Komiyama1, H. Iwai1, Y. Nakao1, S. Tohda3, S. Yasuda1. 1Tokyo Medical and Dental University, Department of Rheumatology, Bunkyo City, Japan; 2Tokyo Medical and Dental University, Department of Infection Control and prevention, Bunkyo City, Japan; 3Tokyo Medical and Dental University, Department of Laboratory Medicine, Bunkyo City, Japan

**Background:** Thrombosis is a unique complication in coronavirus disease 2019 (COVID-19). We have reported that elevated ferritin and D-dimer on admission were the risk factors of thromboses by analyzing the patients sequentially admitted to our hospital due to COVID-19 (1). However, we have not analyzed thrombotic complications in the view of the antiphospholipid antibodies (aPLs), which are frequently detected in the COVID-19 patients.

**Objectives:** To elucidate the thrombogenic effects of aPLs in COVID-19, we analyzed the development of thrombosis in three lupus models after SARS-CoV2 infection. Additionally, we evaluated the association of thrombotic events and the serum profile of aPLs in Japanese patients with COVID-19.

**Methods:** Three animal models of lupus (MRL/lpr/lpr, NZBxNZW F1 and NZWxBXS F1) were evaluated in this study. NZWxBXS F1 was also considered as a model of antiphospholipid syndrome (APS) since aPLs were detected with a high titer (2). Experimental SARS-CoV-2 infection was induced using mouse-passaged virus strain (3). The incidence of thromboses in the lungs and kidneys were identified by evaluating H&E staining and PTAH staining of paraffin-embedded sections. We have experienced 44 thrombotic events in 34 out of 594 patients admitted to our institute as a non-thrombotic COVID-19, 68 patients were selected to make a 1 to 2 matched-pair based on the propensity score. In total 102 patients, seven types of aPLs (anti-cardiolipin (CL) IgG/IgM, anti-β2GP1 IgG/IgA/IgM, and anti-phosphatidyl serine/prothrombin complex (PS/PT) IgG/IgM) were measured using specific ELISA kits. The patients' clinical characteristics and serological profile of aPLs were further evaluated.

**Results:** We identified the development of thromboses in the lungs or kidneys in 6 out of 12 (50%) NZWxBXS F1 mice after the SARS-CoV-2 infection, whereas no thrombosis was observed in non-infected mice. Further, there was no thrombosis in the other lupus models (0%) after the infection. These findings might suggest the pathogenic role of aPLs under the SARS-CoV2 infection.

**Conclusion:** Among our COVID-19 patients, 39 out of 102 (38%) were tested positive for one or more aPLs. The positive ratios of any aPLs were statistically different between the patients with or without thrombosis; anti-CL IgG (6.8% vs. 5.9%/ IgM (0% vs 5.9%), anti-β2GP1 IgG (21% vs. 15%)/IgA (8.8% vs 15%)/IgM (0% vs 15%), and anti-PS/PT IgG (0% vs 2.9%)/IgM (12% vs 13%), respectively. In addition, their titers were relatively lower than those observed in APS patients. The patients' characteristics and the prognosis of COVID-19 were comparable
regardless of the detection of any aPLs. These findings suggested that COVID-19 associated aPLs were irrelevant to thrombotic complications.

**Conclusion:** Thromboses were induced after the infection of SARS-CoV-2 only in the APS model. However, aPLs detected in COVID-19 patients have little impact on the development of thrombosis. SARS-CoV-2 infection might have a high risk of thrombosis, especially in APS patients, as shown in the case report (4). The discrepancy of its thrombogenic effects of aPLs might be explained by the low titer of the antibody or the diversity of antibody epitope. Further analyses are required to clarify the mechanisms of aPLs production and the development of thrombosis in COVID-19.

**REFERENCES:**


**Disclosure of Interests:** Seiya Oba: None declared, Tadashi Hosoya Speakers bureau: Janssen Pharmaceutical K.K. Daichi Sankyo Company, limited Asahi Kasei Corporation Ono pharmaceuticals Eisai Eli Lilly, Daiichi Kawata: None declared, Wenshi Lee: None declared, Mari Kamiya: None declared, Yoji Kamiya: None declared, Hideyuki Iwai: None declared, Yoko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared, Yoji Komiya: None declared, Hideyuki Iwai: None declared, Tadashi Hosoya: None declared, Yuko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared, Yoji Komiya: None declared, Hideyuki Iwai: None declared, Yuko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared, Yoji Komiya: None declared, Hideyuki Iwai: None declared, Yuko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared, Yoji Komiya: None declared, Hideyuki Iwai: None declared, Yuko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared, Yoji Komiya: None declared, Hideyuki Iwai: None declared, Yuko Nukui: None declared, Shuji Tohda: None declared, Shin-Kamiya: None declared.
Background: During the COVID-19 pandemic, it remains a major concern whether patients with rheumatic musculoskeletal disease treated with conventional (cs) or biologic (b) disease modifying drugs (DMARDs) exhibit an adequate immune response to the currently available SARS-CoV2 vaccines. There remains an urgent need for more data on SARS-CoV-2 vaccine efficacy to inform healthcare providers on the efficiency of the applied vaccination, potential need of and period for booster and/or re-vaccination.

Objectives: To assess and compare the efficacy of the SARS-CoV2 vaccines BNT162b2 vaccine (Pfizer/BioNTech) and mRNA-1273 vaccine (Moderna). The vaccines were administered as part of the Danish vaccine roll out and offered each with two doses and approximately four weeks apart.

Patients’ SARS-CoV2 IgG serum level was used as proxy to determine vaccination response.

Methods: We established the ‘Detection of SARS-CoV2 antibodies in Danish Inflammatory Rheumatic Outpatients’ study (DECODIR) as a longitudinal prospective cohort study. Patients with rheumatoid arthritis (RA), spondyloarthropathies (SpA) or psoriatic arthritis (PsA) receiving their outpatient treatment and monitored in the Danish DANBIO registry at the Danish Hospital for Rheumatic Diseases (DG), Sonderborg were included (April - June 2021).

Bloods, patient reported outcome measurements (PROMs), clinical data and treatment information (cs/bDMARD) were collected at baseline (prior to vaccination) and after six weeks and six months. SARS-CoV2 IgG levels in serum were assessed by ELISA (ThermoFischer), and manufacturer’s cut-off (>10 EliA U/mL) selected as definition of sufficient IgG response.

Associations between antibody response, age, gender, disease (RA/PsA/SpA), DMARD treatment (cs/bDMARD) and disease activity were tested using proportional odds regression and bootstrapped tests of medians. Results were reported using mean, median (IQR) and bootstrapped 95% confidence interval (CI) of the median.

Results: A total of 243 patients were included at baseline and after six weeks; at six months follow-up data were available for 233 patients.

After six weeks, vaccination was followed by a significant increase in IgG levels (median of <0.7 EliA U/mL at baseline versus 36.5 EliA U/mL). Patients treated with a combination of both csDMARD and bDMARD had significantly lower IgG levels compared to patients without any DMARD treatment (8.2 EliA U/mL vs 19.5 EliA U/mL (p<0.001)). Patients treated with oral prednisolone (any dose) showed significantly lower median IgG levels compared to patients without DMARD treatment (3.8 EliA U/mL vs 19.5 EliA U/mL (p<0.01)).

The actual measurements six months after baseline demonstrated a significant decrease of IgG levels for the whole study population (median of 16 EliA U/mL at six months vs 36.5 EliA U/mL at six weeks, p < 0.001) (Figure 1).

Conclusion: IgG levels decreased markedly six months after the initial double dose regimen. Patients treated with a combination of cs/bDMARD or oral prednisolone are at higher risk of inadequate vaccine response as measured by IgG level.

Our results support the decision for the need of a third booster vaccine in patients with inflammatory rheumatic diseases, especially in the case of cs/bDMARD combination treatment and prednisolone. The data may indicate a need for further revaccination in these patients.

REFERENCE: [1] Schreiber K. et al. Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases—an Interim Report from a Danish Prospective Cohort Study. Vaccines 2022, 10(1), 35.

Acknowledgements: We acknowledge all patients contributing to the DANBIO registry. The Danish Rheumatologic Biobank is acknowledged for handling and storage of biological material. Lab technician Charlotte Drachmann is acknowledged for her assistance.

Disclosure of Interests: Christine Graversgaard: None declared, Karen Schreiber Consultant of: UCB Advisory Board, Randi Petersen: None declared, Henning Jakobsen: None declared, Anders Bo Bojesen: None declared, Niels Steen Krogh: None declared, Bente Glintborg Grant/research support from: AbbVie, BMS, Pfizer, Merete Lund Hettland Grant/research support from: AbbVie, Biogen, BMS, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopis, Sandoz. MLH chairs the steering committee of the Danish Rheumatology Quality Registry (DANBIO), which receives public funding from the hospital owners and funding from pharmaceutical companies. MLH co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondyloarthritis based on secondary data and is partly funded by Novartis., Oliver Hendricks Grant/research support from: AbbVie, Novartis, Pfizer


Figure 1. IgG-level stratified by treatment

Similar to week 6, lowest response rates were found in patients treated with prednisolone or combination of csDMARD and bDMARD. After 6 months, the proportional odds model revealed significantly lower median IgG antibody level in patients who received Pfizer compared to Moderna (median 15 EliA U/mL (95%CI: 13-18) vs 44.5 EliA U/mL (95%CI: 36-83) (p<0.001).

Figure 1. Nelson-Aalen cumulative hazard estimate

Similar to week 6, lowest response rates were found in patients treated with prednisolone or combination of csDMARD and bDMARD. After 6 months, the proportional odds model revealed significantly lower median IgG antibody level in patients who received Pfizer compared to Moderna (median 15 EliA U/mL (95%CI: 13-18) vs 44.5 EliA U/mL (95%CI: 36-83) (p<0.001).
Background: Published data suggest no increased rate of flare of autoimmune inflammatory rheumatic diseases (AiIRD) after COVID-19 mRNA vaccination; however, the studies are limited by small sample size, short follow up or at risk of selection bias (voluntary physician reports or patient surveys).

Objectives: To study flares of AiIRD within three months of the first dose of an anti-SARS-COV2 mRNA vaccine.

Methods: A retrospective cohort study of consecutive AiIRD patients ≥ 12 years old, across six public hospitals in Singapore who received at least one dose of an mRNA (Pfizer/BioNTech or Moderna) vaccine. Data were censored at the first post-vaccine clinic visit when the patient had flared or if ≥ three months had elapsed since the first dose of the vaccine, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis and time to flare was examined using a Nelson Aalen cumulative hazard estimate (Figure 1).

Results: 2339 patients (74% Chinese, 72% female) of median (IQR) age 64 (53, 71) years were included in the interim analysis (Table 1). 2112 (90%) had recovered from a previous COVID-19 infection after 15K days. 60 (22.1%) were mild and self-limiting, 170 (62.5%) were mild-moderate. 56.6) days. 272 (10%) had the Pfizer/BioNTech vaccine and 195 (8%) had Moderna, with a median (IQR) interval of 21 (21, 23) days between the two doses. The most common AiIRD diagnoses were Rheumatoid arthritis (1063, 45%), Psoriatic arthritis (296, 12.6%) and Systemic lupus erythematosus (SLE) (288, 12.3%). 186 (8%) were treated with biologics/ targeted disease modifying agents. 2125 (91%) patients were in low disease activity or remission. Treatment was interrupted for vaccination in only 18 (0.8%) patients. Seven (0.3%) patients had previous COVID-19 infection.

Table 1. Patient characteristics

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Flares within 0–3 months of 1st vaccine dose (n=272, 72%)</th>
<th>Flares outside of 0–3 months after 1st vaccine dose (n=180, 55%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median years, IQR)</td>
<td>64 (53, 71)</td>
<td>65 (55, 71)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chinese</td>
<td>1386 (73)</td>
<td>129 (72)</td>
</tr>
<tr>
<td>Malay</td>
<td>193 (10)</td>
<td>20 (11)</td>
</tr>
<tr>
<td>Indian</td>
<td>195 (10)</td>
<td>26 (14)</td>
</tr>
<tr>
<td>Gender</td>
<td>1367 (72)</td>
<td>117 (65)</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer/BioNTech</td>
<td>1713 (92)</td>
<td>160 (90)</td>
</tr>
<tr>
<td>Moderna</td>
<td>149 (8)</td>
<td>18 (10)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>831 (44)</td>
<td>99 (36)</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus</td>
<td>269 (14)</td>
<td>9 (5)</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>225 (12)</td>
<td>29 (16)</td>
</tr>
<tr>
<td>Spondyloarthropathies</td>
<td>141 (7)</td>
<td>17 (9)</td>
</tr>
<tr>
<td>Sjogren’s Syndrome</td>
<td>114 (6)</td>
<td>8 (4)</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>94 (5)</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Baseline Physician Disease Activity</td>
<td>1007 (53)</td>
<td>63 (35)</td>
</tr>
<tr>
<td>Remission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low Disease-Activity</td>
<td>731 (39)</td>
<td>97 (54)</td>
</tr>
<tr>
<td>Moderate Disease Activity</td>
<td>134 (7)</td>
<td>20 (11)</td>
</tr>
<tr>
<td>High Disease Activity</td>
<td>15 (1)</td>
<td>2 (0)</td>
</tr>
</tbody>
</table>

452 (19%) flares were recorded during 9798.8 patient-months (4.6/100 patient-months, median (IQR) follow up duration 4.2 (3.3, 5.3) months), of which 272 (11.6%) patients flared within the 3-month period of interest and 180 (77%) flared outside of the 3-month period (Table 1). Median (IQR) time-to-flare was 40.5 (18, 56.6) days. 60 (22.1%) were mild and self-limiting, 170 (62.5%) were mild-moderate and 42 (15.4%) were severe. 190 (69.8%) of those who flared required escalation of treatment and 15 (5.5%) required hospital admission. 239 (10.2%) had improved disease activity after the vaccine.

On multivariate Cox regression analysis, patients in the oldest age tertile [median (IQR) interval of 74 (71, 79) years] were less likely to flare [HR 0.80 (95% CI 0.63, 1.00), p = 0.05] Patients with inflammatory arthritis (compared with connective tissue disease, vasculitis and others) and patients with baseline active disease were more likely to flare [HR 1.72 (95% CI 1.35, 2.20), p < 0.001 and 1.82 (95% CI 1.39, 2.39), p < 0.001 respectively]

Conclusion: There was a moderately high rate of AiIRD flares after mRNA vaccination; however, there was no clustering of flares in the immediate post-vaccine period to suggest causality. Older patients were less likely to flare, while those with inflammatory arthritis and active disease at baseline were more likely to flare.
Background: Significant gaps are present in the evidence of the spectrum and severity of COVID-19 infection in idiopathic inflammatory myopathies (IIM). IIM patients typically require immunosuppressive therapy, may have multiple disease sequelae, and frequent comorbidities, and thus may be more susceptible to severe COVID-19 infection and complications (1). The possibility of attenuated immunogenicity and reduced efficacy of COVID-19 vaccines due to concomitant immunosuppressive medication is a major concern in these patients, and there is little data available on COVID-19 vaccine breakthrough infections (BI) in IIM (2).

Objectives: This study aimed to compare disease spectrum and severity and COVID-19 BI in patients with IIM, other systemic autoimmune and inflammatory diseases (SAIDs) and healthy controls (HCs).

Methods: We developed an extensive self-reporting electronic-survey (COVAD survey) featuring 36 questions to collect respondent demographics, SAID details, COVID-19 infection history, COVID-19 vaccination details, 7-day post vaccination survey) featuring 36 questions to collect respondent demographics, SAID details, COVID-19 infection history, COVID-19 vaccination details, 7-day post vaccination adverse events and patient reported outcome measures using the PROMIS tool. After pilot testing, validation, translation into 16 languages on the online platform surveymonkey.com, and vetting by international experts, the COVAD survey was circulated in early 2021 by a multicenter study group of >110 collaborators in 94 countries. BI was defined as COVID-19 infection occurring more than 2 weeks after receiving 1st or 2nd dose of a COVID-19 vaccine. We analyzed data from the baseline survey for descriptive and intergroup comparative statistics based on data distribution and variable type.

Results: 10906 respondents [mean age 42 (30-55) years, 74% females and 45% Caucasians] were analyzed. 1,227 (11.2%) had IIM, 4,640 (42.6%) had other SAIDs, and 5,033 (46.2%) were HC. All respondents included in the final analysis had received a single dose of the vaccine and 69% had received 2 primary doses. Pfizer (39.8%) was the most common vaccine received, followed by Oxford/AstraZeneeca (13.4%) and Covishield (10.9%). IIM patients were older, had a higher Caucasian representation and higher Pfizer uptake than other SAIDs, and HC. A higher proportion of IIM patients received immunosuppressants than other SAIDs. IIMs were at a lower risk of symptomatic pre-vaccination COVID-19 infection compared to SAIDs (multivariate OR 0.6 (0.4-0.8)) and HCs (multivariate OR 0.39 (0.28-0.54)), yet at a higher risk of hospitalization due to COVID-19 compared to SAIDs [univariate OR 2.3 (1.2-3.5)] and HCs [multivariate OR 2.5 (1.1-5.3)]. BIs were very uncommon in IIM patients, with only 17 (1.4%) reporting BI. IIM patients were at a higher risk of contracting COVID-19 prior to vaccination than ≤2 weeks of vaccination [univariate OR 8 (4.1-15)] or BI [multivariate OR 4.6 (2.7-8.0)]. BIs were equaly severe compared to when they occurred prior to vaccination in IMs, and were comparable between IIM, SAIDs, and HC (Figure 1), though BI disease duration was shorter in IIMs than SAIDs (7 vs 11 days, p=0.027). 13/17 IIM patients with BI were on immunosuppressants.

Conclusion: IIM patients experienced COVID-19 infection less frequently prior to vaccination but were at a higher risk of hospitalization and requirement for oxygen therapy compared with patients with HC. Breakthrough COVID-19 infections were rare (1.4%) in vaccinated IIM patients, and were similar to HC and SAIDs, except for shorter disease duration in IIM.

REFERENCES:

Acknowledgements: The authors thank all members of the COVAD study group for their invaluable role in the collection of data. The authors thank all respondents for filling the questionnaire. The authors thank The Myositis association, Myositis India, Myositis UK, the Myositis Canada Network, Sanofi-Aventis, MSF, the Myositis Amsterdam Network, the Myositis UK Network, IM, Cure IBM, Sjögren’s India Foundation, EULAR PARE, and various other patient support groups and organizations for their invaluable contribution in the dissemination of this survey among patients which made the data collection possible. The authors also thank all members of the COVAD study group.

Disclosure of Interests: Latika Gupta: None declared, Leonardo Santos Hoff: None declared, Naveen R: None declared, Parkishit Sen: None declared, Samuel Katsuyuki Shinjo: None declared, Jessica Day Grant/research support from: JD has received research funding from CSL Limited; James B. Lilleker: None declared, Vishwesh Agarwal: None declared, Sinan Karde: None declared, Minchul Kim: None declared, Ashima Makot: None declared, Marnic Michert: None declared, Tamer A Gheta: None declared, Babur Salim: None declared, Tsvetelina Velikova: None declared, Abraham Edgar Gracia-Ramos: None declared, Ioannis Parodis Speakers bureau: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Consultant of: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Grant/research support from: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Albert Selva-O’Callaghan: None declared, Elena Nikiforou Speakers bureau: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Galil, Galapagos, AbbVie, Lilly, Consultant of: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Galil, Galapagos, AbbVie, Lilly, Grant/research support from: EN holds research grants from Pfizer and Lilly, Tulika Chatterjee: None declared, Al Lyn Tan Speakers bureau: ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCBB, Consultant of: ALT has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCBB, Arvind Nune: None declared, Lorenco Cavagna: None declared, Miguel A Saaavedra: None declared, Nelly Ziade Speakers bureau: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Consultant of: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Arvind Nune: None declared, Lorenco Cavagna: None declared, Miguel A Saaavedra: None declared, Nelly Ziade Speakers bureau: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Arvind Nune: None declared, Lorenco Cavagna: None declared, Miguel A Saaavedra: None declared, Nelly Ziade Speakers bureau: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Arvind Nune: None declared, Lorenco Cavagna: None declared, Miguel A Saaavedra: None declared, Nelly Ziade Speakers bureau: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Arvind Nune: None declared, Lorenco Cavagna: None declared, Miguel A Saaavedra: None declared, Nelly Ziade Speakers bureau: NZ has received honoraria for advisory boards and speaking for Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB., Arvind Nune: None declared.

S. Shoop-Worrall1,2, S. Verstappen1,2, W. Costello3,4, S. Angervale5,6, Y. Uziel7,8, C. Wouters9,10, N. Wulfraat11, R. Beesley12,13.

1 The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2The University of Manchester, Centre for Health Informatics, Manchester, United Kingdom; 3Manchester University NHS FT, NIHR Manchester BRC, Manchester Academic Health Science Centre, Manchester, United Kingdom; 4 European Network for Children with Arthritis, ENCA, Geneva, Switzerland; 5ICAN, ICAN Ireland, Bansha, Ireland; 6KAISZ, KAISZ, Amstterdam, Netherlands; 7Meir Medical Center, Pediatric Rheumatology Unit, Kefar Sava, Israel; 8Sacker School of Medicine, Department of Pediatrics, TelAviv, Israel; 9University Hospitals Leuven, Pediatric Rheumatology Division, Leuven, Belgium; 10KU Leuven University Hall, Department of Microbiology and Immunology, Leuven, Belgium; 11Wilhelmina Children’s Hospital (WKZ), Department of Pediatric Rheumatology, UMC Utrecht, Utrecht, Netherlands; 12Juvenile Arthritis Research, Juvenile Arthritis Research, Tonbridge, United Kingdom

Background: A major concern across rheumatology in recent years is how contracting COVID-19 may impact the control of rheumatic diseases.

Objectives: To quantify any difference in rheumatic disease control between those who did and did not contract COVID-19 between March and December 2020 and whether rheumatic disease control changed after COVID-19 was contracted.

Methods: Adults with rheumatic diseases recruited to the COVID-19 European Patient Registry, a patient-led, online, self-referred prospective cohort recruiting participants from around the globe, were included if enrolled between March and December 2020. Rheumatic disease control was self-reported weekly on a scale of 0 (very poor) to 10 (very well). Dates of contracting COVID-19 were self-reported.

Differences in rheumatic disease control trends between those who did and did not contract COVID-19 over the study period were tested via multilevel linear regression. Within those who contracted COVID-19, differences in rheumatic disease control trends were tested via segmented multilevel, multivariable linear regression, adjusting for month of COVID-19 contraction and with the interruption point set at the point of COVID-19 contraction.

Results: Of 3646 adults with rheumatic diseases, the majority were female (89%), most commonly from the UK (82%) and the most common rheumatic disease diagnosis was RA (63%). Between March and December 2020, 3% of the cohort contracted COVID-19 (n=103).

Over the study period, rheumatic disease control for adults who did not contract COVID-19 decreased weekly by 0.01 points (95% CI 0.01, 0.02, p<0.001). In those who contracted COVID-19, rheumatic disease control decreased weekly by 0.03 points (95% CI 0.2, 0.05, p<0.001), with a significant weekly difference of 0.86 points between groups (95% CI 0.28, 1.44, p=0.004) (Figure 1a).

Within those that contracted COVID-19, there were significant differences in rheumatic disease control trends before and after contracting COVID-19 (p=0.001). In the run up to contracting COVID-19, rheumatic disease control significantly decreased weekly by 0.03 points (95% CI 0.02, 0.04, p<0.001), dropped significantly by 0.53 points (95% CI 0.23, 0.83, p=0.001) at the point of COVID contraction and then stabilised with no further reductions or improvement in rheumatic disease control for the remainder of follow-up (p=0.831) (Figure 1b).

Conclusion: People who contracted COVID-19 had initial decreases in rheumatic disease control before contracting the virus, after which their disease control stabilised at a lower level. Those with disease flares should consider increased screening for COVID-19 and COVID-19 mitigation measures. The stabilising lower disease control post-COVID is concerning and should prompt further work into restoring disease control pre-COVID-19 levels.

Acknowledgements: The authors thank all of the participants and families involved in the international COVID-19 European Patient Registry, as well as the team of volunteers who helped translate the surveys. We also thank ENCA, PRES and representatives from the international rheumatology community for their expertise and support.

Disclosure of Interests: Stephanie Shoop-Worrall: None declared, Suzanne Verstappen: None declared, Wendy Costello: None declared, Saskya Angervale: None declared, Yosi Uziel: None declared, Carine Wouters: None declared, Wilco Wulfraat: Speaker bureau: Sobi, Grant/research support from: AbbVie, Richard Beesley: None declared


Figure 1. Trends in rheumatic disease control in those who did and did not contract COVID-19 between March and December 2020 a) overall and b) before and after contracting COVID-19.
POS0203  PREDICTIVE SEVERITY FACTORS OF COVID-19 IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES

1 Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander (SPAIN); 2 Hospital Universitario de Canarias, Rheumatology, Santa Cruz de Tenerife, Spain

Background: COVID-19 has become a common disease in patients with rheumatic immune-mediated diseases (R-IMID). A risk stratification of the patients at COVID-19 onset is important to predict possible unfavorable outcomes.

Objectives: To identify predictive severity factors in patients with COVID-19 with R-IMID.

Methods: Cross-sectional study in a single University Hospital. We included all consecutive patients with a R-IMID and COVID-19 up to November 6th, 2020. Confirmed infection was defined if the patient had a positive nasopharyngeal swab for SARS-CoV-2.

Results: We included 274 patients with R-IMID complicated with COVID-19. At COVID-19 onset, the main comorbidities, analytical values, underlying R-IMID and treatments received are shown in Table 1.

Conclusions: We identified various factors associated with a worse prognosis of COVID-19 in patients with R-IMID. This can help to identify which patients can present a worse course of the disease at the moment of the diagnosis.

Disclosure of Interests: David Martínez-López: None declared, Iván Ferraz-Amaro: None declared, Diana Prieto-Peña: None declared, Fabrício Benavides-Villanueva: None declared, Cristina Corrales-Selaya: None declared, Lara Sanchez-Bilbao: None declared, Alba Herrero-Morant: None declared, Carmen Álvarez-Requeuera: None declared, Martin Trigueros-Vazquez: None declared, Miguel A González-Gay Speakers bureau: Consultation fees/participation in company-sponsored speaker’s bureau from Abbvie, Pfizer, Roche and MSD, Grant/research support from: Dr. Miguel A. Gonzalez-Gay received grants/research support from Abbvie, MSD, and Roche, Ricardo Blanco Speakers bureau: Consultation fees/participation in company-sponsored speaker’s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Grant/research support from: Dr. Ricardo Blanco received grants/research support from Abbvie, MSD, and Roche.

DOI: 10.1136/annrheumdis-2022-eular.3978

Table 1. General features patients with R-IMID and COVID-19

<table>
<thead>
<tr>
<th>General features</th>
<th>Patients (n=274)</th>
<th>Critical COVID (n=21)</th>
<th>Patients (n=274)</th>
<th>Critical COVID (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>59 ± 18</td>
<td>76 ± 32.2 ± 13.4</td>
<td>46.7 ± 5.25</td>
<td>117 ± 8.6</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>185 (67)</td>
<td>11 (52.4)</td>
<td>4.9 ± 0.4</td>
<td>1.4 ± 0.7</td>
</tr>
<tr>
<td>CV risk factors, n (%)</td>
<td>(2.9) (3.1)</td>
<td>(14.3) (2.9)</td>
<td>179 ± 78</td>
<td>163 ± 72</td>
</tr>
<tr>
<td>-Current smoker</td>
<td>27 (10)</td>
<td>2 (9.5)</td>
<td>13.0 ± 18</td>
<td>12.5 ± 2.1</td>
</tr>
<tr>
<td>-Obesity</td>
<td>49 (18)</td>
<td>5 (23.8)</td>
<td>4.5 ± 2.5</td>
<td>4.9 ± 3.2</td>
</tr>
<tr>
<td>-Hypertension</td>
<td>119 (43)</td>
<td>18 (85.7)</td>
<td>11 ± 1</td>
<td>0.7 ± 0.5</td>
</tr>
<tr>
<td>-Diabetes Mellitus</td>
<td>36 (13)</td>
<td>5 (23.8)</td>
<td>426 ± 417</td>
<td>664 ± 469</td>
</tr>
<tr>
<td>-Dyslipidemia</td>
<td>119 (43)</td>
<td>15 (71.4)</td>
<td>257 ± 99</td>
<td>314 ± 143</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
<td>999 ± 1256</td>
<td>1890 ± 1893</td>
</tr>
<tr>
<td>-Chronic pulmonary disease</td>
<td>12 (4.4)</td>
<td>3 (14.3)</td>
<td>55 (20.1)</td>
<td>3 (14.3)</td>
</tr>
<tr>
<td>-Established cardiovascular disease</td>
<td>45 (16.4)</td>
<td>10 (47.6)</td>
<td>34 (12.4)</td>
<td>9 (42.9)</td>
</tr>
<tr>
<td>-Cancer</td>
<td>21 (8)</td>
<td>6 (28.6)</td>
<td>22 (8)</td>
<td>0</td>
</tr>
<tr>
<td>-Chronic kidney disease</td>
<td>27 (10)</td>
<td>6 (28.6)</td>
<td>8 (2.9)</td>
<td>1 (4.8)</td>
</tr>
<tr>
<td>-Chronic liver disease</td>
<td>11 (4)</td>
<td>3 (14.3)</td>
<td>12 (4.4)</td>
<td>3 (14.3)</td>
</tr>
<tr>
<td>Treatments received, n (%)</td>
<td></td>
<td></td>
<td>999 ± 1256</td>
<td>1890 ± 1893</td>
</tr>
<tr>
<td>-Methotrexate // Hydroxychloroquine</td>
<td>62 (23) // 50 (18)</td>
<td>3 (14.3) // 2 (9.5)</td>
<td>8 (2.9)</td>
<td>1 (4.8)</td>
</tr>
</tbody>
</table>
| -MTX: Methotrexate; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; SpA: Axial spondyloarthritids Adjusted by age, cardiovascular risk factors and comorbidities.

According to COVID-19 severity, patients were mild (n=209; 76.3%), moderate (n=35; 12.8%), severe (n=9; 3.3%) and critical (n=21; 7.7%). The predictive variables at COVID-19 onset related statistically to critical COVID were older patients, hypertension, dyslipidemia, previous cardiovascular disease, cancer, chronic kidney disease, and chronic liver disease. The only underlying R-IMID and treatment was polymyalgia rheumatica and Rituximab, respectively. Regarding analytical values were higher values of C-reactive protein, LDH, platelets and lymphopenia (Figure 1).

Figure 1. Predictive factors for critical COVID-19 in R-IMID (Multivariable analysis)

POS0204  RETROSPECTIVE STUDY OF THE COVID-19 COURSE IN CHILDREN WITH RHEUMATIC DISEASES: SINGLE CENTER EXPERIENCE

Z. Kolikhidova, I. Nikishina, V. Matkava, A. Shapovalenko, S. Arsenyeva, M. Kaleda, S. Salugina, E. Fedorov, T. Pachkoria, V. A. Nasonova Research Institute of Rheumatology, Pediatric Department, Moscow, Russian Federation

Background: The study of the features of the course and mutual influence of the new coronavirus disease COVID-19 and various rheumatic diseases (RD) in children can still give us new lessons, warnings and fears.

Objectives: To update the analysis in a retrospective study the course of COVID-19 in children with RD based on the results of two years of the pandemic. To analyze the impact of COVID-19 on the course of RD in children.

Methods: Retrospective analysis based on data from single center. The study included patients with RD and confirmed COVID-19 for 2 years (2020-2021).

Results: Were registered 320 cases of COVID-19 in children with RD. 158 (49%) patients were asymptptomatically infected, 162 (51%) had clinical symptoms. A detailed description of the groups is presented in Table 1. Clinical symptoms were fever (67%), anosmia (47%), chills (34%), cough (19%), arthralgia/myalgia (16%), dyspnea (5%), rash (2.5%), pneumonia (3%). In the majority of cases (98%), COVID-19 proceeded in mild to moderate severity. Hospitalization due to COVID-19 was required just in 5 cases. 2 children were admitted to the intensive care unit. First, an 11-year-old girl with sJIA with the history of recurrent episodes of MAS resolved by regular administration of canakinumab. 2nd, a 12-year-old girl with SpA/spondylitis, who received...
Table 1. Adverse events in patients with autoimmune disease-related ILDs in the SENSCIS and INBUILD trials in subgroups by sex and age at baseline.

<table>
<thead>
<tr>
<th>Diagnosis of RD</th>
<th>JIA non-systemic</th>
<th>sJIA</th>
<th>SLE</th>
<th>JDM</th>
<th>Scleroderma</th>
<th>Sjögren’s syndrome</th>
<th>Overlap syndrome</th>
<th>AIDs (CAPS, FMF, Behçet’s disease)</th>
<th>FOP (Fibrodermatosis ossificans progressive)</th>
<th>Treatment of RD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>110</td>
<td>34</td>
<td>6</td>
<td>9</td>
<td>8</td>
<td>15</td>
<td>8</td>
<td>0</td>
<td>1</td>
<td>23</td>
</tr>
</tbody>
</table>

Rituximab and 1 month later she developed the COVID-19 with MIS-like clinical picture, pneumonia with CT lesions. Both cases have a favorable outcome.

Table 1. Clinical characteristics of children with COVID-19 and RD

<table>
<thead>
<tr>
<th>Covid-19 with ILDs</th>
<th>Worsening of asymptomatic RD after Covid-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=162)</td>
<td>(n=156)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>96/66</td>
</tr>
<tr>
<td>Age, years (Me[25;75])</td>
<td>15 [8;17]</td>
</tr>
<tr>
<td>IgG Covid-19 positive</td>
<td>91 126</td>
</tr>
<tr>
<td>IgM Covid-19 positive</td>
<td>6 2</td>
</tr>
<tr>
<td>PCR Covid-19 positive</td>
<td>8 6 4</td>
</tr>
</tbody>
</table>

Conclusion: Our study suggests that the new coronavirus infection in most cases in children with RD, had mild or asymptomatic course, regardless of therapy with immunosuppressive drugs and bDMARD, except of 1 observation with the previous therapy of Rituximab. Worsening of RD after coronavirus infection developed in 15% of cases, regardless of its clinical manifestations. In 13 patients, the RD were started just after COVID-19. The explosive increasing of the incidence of a new strain of COVID-19 for a past month may change the current results and conclusions.

Disclosure of Interests: None declared


RA comorbidities

P00205

SAFETY AND TOLERABILITY OF NINTEDANIB IN PATIENTS WITH AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES (ILDs) IN SUBGROUPS BY SEX AND AGE

A. M. Hoffmann-Vold1, E. Volkmann2, Y. Allanore3, S. Assassi4, J. de Vries-Bouwstra5, V. Smith6, I. Tschoepe7, L. Loaiza8, M. Kanakapura9, O. Distler10 on behalf of The SENSCIS Trial Investigators and the INBUILD Trial Investigators. 1Oslo University Hospital, Department of Rheumatology, Oslo, Norway; 2University of California, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Los Angeles, CA, United States of America; 3Descartes University, APHP, Cochin Hospital, Department of Rheumatology A, Paris, France; 4University of Texas McGovern Medical School, Division of Rheumatology, Houston, TX, United States of America; 5Leiden University Medical Centre (LUMC), Department of Rheumatology, Leiden, Netherlands; 6Ghent University Hospital, Department of Rheumatology and Internal Medicine, Ghent, Belgium; 7Elderbrook Solutions, Statistics, Biebighem-Bissingen, Germany; 8Boehringer Ingelheim International GmbH, Patient Safety & PharmacoV. Corporate, Ingelheim am Rhein, Germany; 9Boehringer Ingelheim International GmbH, TA Inflammation Med, Ingelheim am Rhein, Germany; 10University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland

Background: Nintedanib slows the progression of fibrosing ILDs, with a safety profile characterised predominantly by gastrointestinal events.

Objectives: Assess the safety and tolerability of nintedanib in patients with autoimmune disease-related ILDs by sex and age.

Methods: The SENSCIS trial was conducted in patients with ILD associated with systemic sclerosis. The INBUILD trial was conducted in patients with progressive fibrosing ILDs other than idiopathic pulmonary fibrosis. Patients were randomised to receive nintedanib 150 mg bid or placebo. Dose reductions to 100 mg bid and treatment interruptions were permitted to manage adverse events (AEs). Data from all patients in SENSCIS and patients with autoimmune disease-related ILDs in INBUILD were pooled. In subgroups based on sex and age (<65 and ≥65 years) at baseline, we analysed AEs, irrespective of causality, over 52 weeks.

Results: Among 746 patients; 70.1% were female; 29.1% were aged ≥65 years. Mean (SD) exposure to nintedanib or placebo was 10.8 (3.2) and 11.1 (3.5) months in nintedanib or placebo group.

Table 1. Adverse events in patients with autoimmune disease-related ILDs in the SENSCIS and INBUILD trials in subgroups by sex and age at baseline.

<table>
<thead>
<tr>
<th>Female</th>
<th>Male</th>
<th>Age &lt;65 years</th>
<th>Age ≥65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Nintedanib (n=268)</td>
<td>Placebo (n=255)</td>
</tr>
<tr>
<td>Most frequent adverse events*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>198 (73.9)</td>
<td>77 (30.2)</td>
<td>73 (71.6)</td>
</tr>
<tr>
<td>Nausea</td>
<td>92 (34.3)</td>
<td>35 (13.7)</td>
<td>21 (20.6)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>73 (27.2)</td>
<td>22 (8.6)</td>
<td>12 (11.8)</td>
</tr>
<tr>
<td>Skin ulcer</td>
<td>3 (12.5)</td>
<td>7 (11.5)</td>
<td>37 (7.5)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>34 (12.7)</td>
<td>41 (16.1)</td>
<td>12 (11.8)</td>
</tr>
<tr>
<td>Weight decreased</td>
<td>34 (12.7)</td>
<td>13 (4.3)</td>
<td>9 (3.3)</td>
</tr>
<tr>
<td>Appetite loss</td>
<td>25 (10.8)</td>
<td>39 (15.3)</td>
<td>13 (12.7)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>30 (12.2)</td>
<td>31 (12.2)</td>
<td>9 (8.8)</td>
</tr>
<tr>
<td>Sleep-related disorders</td>
<td>23 (8.6)</td>
<td>15 (5.1)</td>
<td>3 (1.5)</td>
</tr>
<tr>
<td>Liver-related investigations, signs and symptoms</td>
<td>49 (18.3)</td>
<td>11 (3.9)</td>
<td>13 (12.7)</td>
</tr>
<tr>
<td>Worsening of RD</td>
<td>101 (37.7)</td>
<td>9 (3.5)</td>
<td>18 (17.6)</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>44 (16.4)</td>
<td>21 (8.2)</td>
<td>17 (16.7)</td>
</tr>
<tr>
<td>Serious adverse event(s)</td>
<td>57 (21.3)</td>
<td>53 (20.8)</td>
<td>40 (39.2)</td>
</tr>
</tbody>
</table>

n (%) of patients with ≥1 such adverse event over 52 weeks. Adverse events were coded based on preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA), except for live-related investigations, signs and symptoms, which was based on a standardised MedDRA query. *Adverse events reported in >10% of patients with autoimmune disease-related ILDs in the nintedanib or placebo group.
patients aged <65 and ≥65 years, respectively. The AE profile of nintedanib was similar between males and females, but nausea, vomiting, hepatic adverse events and dose reductions were more frequent in females. The AE profile of nintedanib was similar between patients aged <65 and ≥65 years, but nausea, decreased appetite, and weight loss were more frequent in patients aged ≥65 years. AEs leading to treatment discontinuation were more frequent in patients aged ≥65 years in both treatment groups. Serious AEs were more frequent in males and in patients aged ≥65 years in both treatment groups.

Conclusion: In patients with autoimmune-disease related ILDs, the AE profile of nintedanib in subgroups by sex and age was generally consistent with the known safety profile, but certain types of AE and dose reductions were more frequent in female patients, while serious AEs were more common in male patients.

Acknowledgements: The SENSCIS and INBUILD trials were funded by Boehringer Ingelheim. Oliver Distler was a member of the SENSCIS trial Steering Committee.


Background: Our findings suggest that 7% of RA patients present significant SGUS abnormalities according to OMERACT scoring system, associated with clinical sicca syndrome in 71% of cases. There was no significant association between the duration of rheumatoid arthritis and the OMERACT score (Spearman coefficient for correlation -0.028, p = 0.09). There was also no significant association found between the duration of sicca symptoms and the OMERACT score (Spearman coefficient for correlation 0.025 p = 0.89). This study highlights the importance of SGUS assessment in RA sicca patients to improve monitoring and follow-up in routine clinical practice.

REFERENCES:


Disclosure of Interests: None declared.


POS0207 UNRAVELING THE COMPLEX INTERACTION BETWEEN DISEASE ACTIVITY AND FATIGUE IN EARLY RA: A MEDIATION ANALYSIS WITH DATA FROM THE CARERA TRIAL

M. Doumer1,2, S. Pazmino1, D. Bertrand1, D. De Coo3,3 J. Joly2, R. Westhoven2,3 P. Verschueren2,2 “KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; “University Hospitals Leuven, Rheumatology, Leuven, Belgium; “KU Leuven, Laboratory of Clinical and Experimental Endocrinology, Leuven, Belgium

Background: Fatigue is recognized as one of the most important symptoms of rheumatoid arthritis (RA). Although inflammation is often proposed as the predominant pathophysiological mechanism, many patients with RA continue to experience fatigue despite inflammatory disease control. The relationship between RA disease activity and fatigue appears to be complex and is likely confounded by cognitive, emotional and social aspects.

Disclosure of Interests: None declared.

**Objectives:** To unravel the complex interaction between disease activity and fatigue in early RA.

**Methods:** Data were analyzed from the 2-year treat-to-target trial Care in early RA (CareRA), which compared different remission-induction DMARD regimens, either with or without bridging glucocorticoids, in treatment-naïve patients with early RA. Fatigue was measured on a visual analog scale (VAS) at every study visit. The association between inflammatory disease activity (DAS28-CRP) and fatigue (VAS) over time was studied with a multilevel mediation analysis, including as mediators the individual components of the DAS28-CRP, pain (VAS), disability (HAQ), psychosocial aspects (Short-Form 36 [SF-36]), illness perceptions (Revised Illness Perception Questionnaire [IPQ-R]), and sleep quality (Pittsburgh Sleep Quality Index [PSQI]).

**Results:** A total of 356 patients were included in these analyses, with a mean (SD) fatigue (VAS) of 48/100 (24) at study initiation. Although there was a consistently positive association between DAS28-CRP and fatigue over time, this association was fully mediated by patient global assessment (PGA) and pain, and to a lesser extent by SF-36 Mental Health and the PSQI global score (Figure 1). Full mediation implies the absence of a significant direct association between DAS28-CRP and fatigue after adjusting for these mediators. In addition, no mediating effect was found for tender/swollen joint counts or CRP.

![Figure 1. Mediation analysis of the association between DAS28-CRP and fatigue (VAS) over time.](image-url)

**Conclusion:** Our mediation analysis suggests that the relationship between disease activity and fatigue in early RA is complex and fully mediated by aspects of wellbeing like pain, mental health, sleep quality, and the patient’s overall assessment of disease. These results imply a mainly indirect relation between fatigue and inflammation. Clinicians should reserve specific attention for the psychosocial determinants of fatigue, particularly when no improvement is seen with DMARDs.

**Disclosure of Interests:** Michaela Doumen: None declared, Sofia Pazmino: None declared, Delphine Bertrand: None declared, Diederik De Cock: None declared, Johan Joly: None declared, Rene Westhoven: Speakers bureau: Honoraria for lectures.

- Celltrion
- Galapagos, Consultant of: - Celltrion
- Pfizer
- Eli Lilly, Consultant of: Sanofi
- Galapagos
- Pfizer

Grant/research support from: Pfizer Chair Management of Early Rheumatoid Arthritis at KU Leuven Belgium


**POS0208**

**STRESS AT HOME IS COMMON AND HAS SIGNIFICANT ASSOCIATION WITH MARRITAL STATUS, HIGHER DISEASE ACTIVITY, COMORBIDITIES, AND WORSE QUALITY OF LIFE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS: SINGLE CENTRE RESULTS FROM THE PRIME REGISTRY COHORT**

M. Haroon1, S. Asif1, S. Ullah1, F. Hashmi1, S. Javed1. 1Fatima Memorial Hospital & FMH College of Medicine and Dentistry; Department of Rheumatology, Lahore, Pakistan

**Background:** In chronic inflammatory diseases like rheumatoid arthritis (RA), psychological stress is widely recognised as an important risk factor to negatively affect the disease course. Perceived stress can potentially induce the disease exacerbation, but on the other hand, the disease itself might produce significant stress to patients thus the vicious circle is formed and maintained.

**Objectives:** We aimed to examine the prevalence of mental/emotional stress at home and its associations among patients with Rheumatoid arthritis. We addressed this question using real-world data from the PRIME registry.

**Methods:** This was a cross-sectional study conducted using data collected at the time of patient enrolment in the PRIME registry. The PRIME Registry is a large, independent, prospective, observational cohort initiated in October 2019 that comprises patients diagnosed with RA, SLE, PsA or AS by a rheumatologist, and is being actively followed up. IRB approval and informed consent was obtained. We assessed the data for RA patients. The clinical variables studied were gender, age, smoking habits, body mass index, education status, marital status, disease duration, comorbidities (using Charlson Comorbidity Index). Education status was stratified by whether participants completed secondary (high) school education. The SF-12 Physical Component Score (PCS-12) and Mental Component Score (MCS-12) was also measured. Evaluation of disease activity and severity was made as per internationally agreed definitions, such as: swollen joint counts, tender joint counts, deformed joint counts, and DAS-28. All participants were directly inquired at the interview during the time of patient enrolment about the presence or otherwise of mental/emotional stress at home, and to rate it from 1-3 (mild, moderate, severe). For better understanding and ease of statistical analysis, dichotomous variable was made with moderate-to-severe stress patients were categorised into one group and none-to-mild stress patients into second group.

**Results:** The data from consecutive 1016 RA patients (mean age 40.8±13 years, 78.6% female, disease duration of 65±67 months) was reviewed. Forty-nine percent of patients accepted to have moderate-severe stress at home. Female gender (p=0.003), low education status (p=0.050), being unmarried (p=0.051), and MCS, PCS, CCI (p<0.001) were associated with moderate-severe stress. However, no statistical association of age and disease duration was noted. On univariate analysis, significant association of moderate-severe stress at home was noted with deformed joint counts (p=0.003), higher DAS-28 scores (p<0.001), low education status (p=0.02) and being married (p=0.001). Weak statistical association of age (p=0.30), disease duration (p=0.12), low education status (p=0.14), female gender (p=0.24) was noted. On multiple logistic regression analysis, a significant association of moderate-severe stress at home was observed with higher DAS-28 scores (OR 2.38, CI 2.00-2.84, p<0.001), MCS-12 (OR 0.65, CI 0.61-0.69, p<0.001), comorbidities-CCI (OR 1.41, CI 1.15-1.74, p=0.001) and being unmarried (OR 0.55, CI 0.36-0.83, p=0.005). The final regression model resulted in a statistically significant improved association/prediction of worse moderate-severe stress at home (R square=71%). Following variables were included in multiple stepwise regression analysis: age, disease duration, gender, education status, marital status, comorbidities index, major trauma/stress in last one year, DAS-28, MCS-12 and PCS-12 scores.

**Conclusion:** Nearly half of the cohort was noted to have moderate-severe level of stress at home, and is associated with important adverse clinical outcomes. These findings demonstrate an important need for integration of rheumatologic, social workers and mental health services.

**Disclosure of Interests:** Muhammad Haroon: Speakers bureau: Novartis, Abbvie, Pfizer, Roche, Grant/research support from: Abbvie, Sadia Asif: None declared, Saadat Ullah: None declared, Farzana Hashmi: None declared, Saba Javed: None declared

DOI: 10.1136/annrheumdis-2022-eular.4234
Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease leading to significant increase in cardiovascular morbidity and mortality. Development of atherosclerotic lesions of the carotid arteries in RA patients is associated with the accumulation of traditional risk factors and immunoinflammatory disorders.

Objectives: To evaluate the detection rate of subclinical carotid atherosclerosis and clinical significance of immunoinflammatory markers in RA patients with low cardiovascular risk (CVR) in comparison with the control group.

Methods: The study included 275 RA patients (with low CVR and no established cardiovascular diseases) and a control group comprising 100 people without autoimmune diseases. The groups were comparable in terms of sex, age, traditional risk factors, and CVR value. CVR was calculated using the QRISK3 scale. All study participants had a low CVR (QRISK3<20%). All patients and control group members underwent carotid duplex ultrasonography. Atherosclerotic lesions of the carotid arteries were assessed by the detection of atherosclerotic plaque (ASP) - the cause of IMT ≥ 1.2 mm. Concentration of sICAM-1, sVCAM, and sCD40L in blood serum was determined by enzyme immunoassay using reagent kits and according to Bender MedSystems protocols (USA).

Results: Carotid ASP were observed more frequently in RA patients (27%) with low CVR than in the control group (17%), p=0.03. ASP were detected more frequently in men than in women with RA (50% versus 24%, p=0.01). The frequency of ASP in RA patients with low CVR did not depend on the disease’s stage or activity.

In RA patients, there was a significant correlation between carotid IMT and age (R=0.48), CVR value determined by QRISK3 (R=0.36), level of total cholesterol (R=0.28), LDL cholesterol (R=0.18), systolic blood pressure (R=0.37), diastolic blood pressure (R=0.38), p=0.05 in all cases. No correlation between carotid IMT and blood concentrations of sCD40L, sVCAM, and sICAM1 was found in RA patients or controls.

A higher concentration of sVCAM was detected in RA patients compared with the control group (1520 [945; 1915] ng/mL versus 790 [605; 1307] ng/mL, p=0.01), and in RA patients with carotid ASP compared with patients without carotid ASP (1680 [1460; 3350] ng/mL versus 1210 [865; 1810] ng/mL, p=0.01).

In RA patients with carotid ASP, sCD40L level was associated with carotid IMT (R=0.40, p=0.04) and cholesterol concentration (R=0.38, p=0.01). In RA patients without ASP, sCD40L level was associated with cholesterol concentration (R=0.41, p=0.02) and diastolic blood pressure level (R=0.3, p=0.04).

Conclusion: Subclinical atherosclerotic lesions of the carotid arteries were observed in a quarter of RA patients with low CVR and were detected at a significantly more frequent rate compared to the control group. The evaluation of carotid IMT is recommended for RA patients with low CVD. These results suggest that there is an association between carotid IMT and traditional CVR factors and immunoinflammatory markers in RA patients.

ASSOCIATION BETWEEN CARDIOVASCULAR OUTCOME AND RHEUMATOID ARTHRITIS: NATIONWIDE POPULATION-BASED COHORT STUDY

S. Kang1, K. D. Han2, S. Lee1, Y. Eun1, H. S. Cha1, E. M. Koh1, J. Lee1, H. Kim1.
1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea, Rep. of (South Korea); 2Shanxi Medical University, Department of Statistics and Actuarial Science, Seoul, Korea, Rep. of (South Korea)

Background: Many studies have shown increased risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). Despite a growing burden posed by CVD in RA patients, large scale studies which examined the association between characteristic of RA patients and CVD risks, and studies which adjusted for various confounding factors are lacking.

Objectives: This study aimed to investigate the association between CVD risk and RA in large-scale, nationwide cohort of Korean population, and to examine which characteristics of RA patients are associated with increased CVD risk.

Methods: We enrolled 136,469 patients with RA who participated in national health examinations within 2 years of RA diagnosis between 2010 and 2017 and non-RA controls matched by age and sex (n= 682,345). The cohort was followed until the end of 2019. The outcome was occurrence of myocardial infarction (MI) or stroke. MI was defined as one hospitalization or two outpatient visit with ICD-10-CM codes I21 or I22. Stroke was defined as one hospitalization with ICD-10-CM codes I63 or I64 and a claim for brain imaging (CT or MRI). The Cox proportional hazard model and Kaplan Meier curve were used for the analysis.

Results: Mean follow up duration was 4.7 years. The incidence rate of CVD was higher in RA group than control (MI: 3.20 vs 2.08; stroke: 2.84 vs 2.33 per 1,000 person-years). The risk of CVD was higher in RA patients. (MI adjusted HR 1.54, 95% CI 1.46-1.61; Stroke: adjusted HR 1.22, 95% CI 1.16-1.28). The association between RA and CVD was prominent in female (MI: adjusted HR 1.41 in male, 1.60 in female, p for interaction = 0.0293; Stroke: adjusted HR 1.13 in male, 1.27 in female, p for interaction = 0.03) and younger-age subgroups (MI: adjusted HR 2.9 in <40 years, 1.52 in 40-64 years, 1.51 in ≥65 years, p for interaction<0.0001; Stroke: adjusted HR 2.35 in <40 years, 1.21 in 40-64 years, 1.21 in ≥65 years, p for interaction = 0.0100) after adjusting for confounding variables. The association between RA and MI of risk was significant in those without DM. (adjusted HR 1.30 in DM, 1.61 in non-DM, p for interaction<0.0001; Stroke: adjusted HR 2.35 in <40 years, 1.21 in 40-64 years, 1.21 in ≥65 years, p for interaction = 0.0005)

Conclusion: RA patients had increased risk of CVD events compared to age- and sex-matched control group, and this association was stronger in female and younger-age subgroups. Therefore appropriate screening for CVD would be important in all RA patients including female and younger patients.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3579

THE REDUCTION OF TURICIBACTER IN GUT MICROBIOTA ASSOCIATED WITH SJOGREN'S SYNDROME SECONDARY TO RHEUMATOID ARTHRITIS

M. J. Chang1,2,3, S. X. Zhang3,2, J. Qiao3,4, Q. Wang3,5, R. X. Gu1, C. Wang3,2,3, Q. Yu6,3, P. F. He1, Shanxi Medical University, School of Management Shaxi Medical University, Taiyuan, China; 2Shanxi Medical University, Key Laboratory of Cellular Physiology, Taiyuan, China; 3Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 4The Second Hospital of Shanxi Medical University, The Second Hospital of Shaxi Medical University, Taiyuan, China; 5Shanxi Medical University, School of Basic Medical Sciences, Taiyuan, China; 6Shanxi Medical University, Medical Data Sciences, Taiyuan, China

Background: Secondary Sjogren's syndrome (SS) is a common extra-articular manifestation of rheumatoid arthritis (RA)1. RA patients with SS have different outcomes from those without SS2. However, the studies investigated the characteristics of gut microbiota in patients with RA and SS is limited.

Objectives: To investigate the characteristics of gut microbiome and the associations between flora and peripheral lymphocyte subpopulations in RA patients with or without Sjogren's syndrome.

Methods: A total of 326 samples from 145 RA patients without SS, 23 RA combined with SS patients(RA-SS) and 168 healthy controls (HCs) were recruited in this study from The Second Hospital of Shanxi Medical University (Taiyuan, Shanxi, China). The gut microbiota were investigated via 16s RNA sequencing and the peripheral T lymphocyte subsets of these participants were assessed by flow cytometry. The Wilcoxon rank-sum test was used to compare alpha diversity indices between groups. Differential abundance analysis was carried out the STAMP software. Spearman's correlation analysis was used to assess the correlations between the relative abundances of bacterial genera and clinical measures.

Results: Patients with RA and RA-SS exhibited a significant reduction in the richness and diversity of gut microbiota compared with those of HCs (Figure 1 A-B, p < 0.05), whereas there was no significant difference between RA and RA-SS patients. Principal co-ordinates analyses based on Bray Curtis distance suggested that these there microbiota states explained a definable proportion of observed variance in microbiota composition (ANOSIM R2 = 0.074, p < 0.001; Figure 1 C). Compared with HCs, 58 species of flora were discovered to be distinctly different in RA patients without SS at the genus level of which 6 species of flora unique to RA-SS patients were presented much fewer ([Eubacterium] halii_group, Anaerostipes, CAG-56, Fusobacterium, Turicibacter and Enterococcus). Among these RA-SS patients' unique species of flora, it seems that Turicibacter is the key species of flora, owing to whose has a positive correlation with most of lymphocytes such as T, B, CD4+T, CD8+T and NK cells suggesting a close association with intestinal immunity. (Figure 1 F-G, P<0.05)

Conclusion: RA patients with deficiency of Turicibacter in flora had higer occurrence of Sjogren's syndrome sjojgren's syndrome complication, which was correlated with peripheral lymphocyte subpopulations and cytokines.

Disclosure of Interests: None declared


EFFECT OF EARLY ETANERCEPT TREATMENT ON CIRCULATING LIPOPROTEINS DIFFERS TO TREATMENT WITH METHOTREXATE AND IS MODULATED BY CLINICAL DISEASE ACTIVITY

R. Shukla1,2, A. Burska3, P. Emery4, D. Plant2, M. H. Buch1,2,3, University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, NIHR Biomedical Research Centre, Manchester, United Kingdom; 3University of Leeds, Leeds Institute of Rheumatism and Musculoskeletal Medicine, Leeds, United Kingdom; 4Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

Background: A reduction in serum lipids such as total cholesterol (TC) and low-density lipoprotein (LDL) has been associated with increased risk of cardiovascular events in active RA, paradoxical to the general population4. The effect of DMARDs and active inflammation on lipid profiles has been investigated in RA

REFERENCES:

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740).
but detailed lipid profiling has been lacking in very early disease and across the spectrum of disease activity.

**Objectives**: In a treatment naïve early RA trial cohort, we sought to compare circulating lipid profiles between patients treated with first line etanercept + methotrexate (ETN-MTX) versus methotrexate treat-to-target (MTX-TT) regime and between clinical remission and high disease activity.

**Methods**: VEDERA trial (Very early Etanercept and Methotrexate versus Methotrexate with/without Delayed Etanercept in RA) randomised 120 treatment-naïve RA patients to either first-line ETN-MTX or MTX-TT regime with escalation to ETN-MTX if not in DAS28ESR remission at week 24. TC, triglycerides (TG), high density lipoprotein (HDL) and LDL were measured; apolipoproteins and atherogenic indices such as TC/HDL, atherogenic index of plasma (AIP) and apolipoprotein B/Ai ratio (aparatio) were calculated at baseline, weeks 12, 24 and 48. Linear mixed effects regression was used to test the effect of treatment on lipids and atherogenic indices in states of remission (DAS28-ESR ≤ 2.6) and high disease activity (DAS28-ESR > 5.1).

**Results**: Baseline clinical characteristics of individuals and lipid profiles including atherogenic indices were comparable between the two treatment groups (Table 1).

![Figure 1: Predicted trends in HDL and LDL in remission (left) vs high disease activity in MTX- TT and ETN-MTX groups](image)

**Conclusion**: Effect of early ETN treatment on HDL, and to a lesser extent LDL, differs from MTX and is modulated by clinical disease activity. Further investigations is needed to understand the basis for these findings and the clinical implication of observed differences in LDL and HDL. These data may indicate direct effect of therapies on the qualitative and functional components of metabolic lipid pathway.

**REFERENCES:**


**Disclosure of Interests**: None declared.


---

**Table 1. Baseline lipids (mmol/L) and atherogenic indices in VEDERA.**

<table>
<thead>
<tr>
<th></th>
<th>Total, N = 120</th>
<th>MTX- TT, N = 60</th>
<th>ETN-MTX, N = 60</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>4.69 (4.03,5.25)</td>
<td>4.70 (4.04,5.42)</td>
<td>4.69 (4.01,5.18)</td>
</tr>
<tr>
<td>TG</td>
<td>1.15 (0.90,1.41)</td>
<td>1.18 (0.92,1.32)</td>
<td>1.10 (0.89,1.55)</td>
</tr>
<tr>
<td>HDL</td>
<td>1.28 (1.04,1.53)</td>
<td>1.29 (1.04,1.57)</td>
<td>1.27 (1.05,1.48)</td>
</tr>
<tr>
<td>LDL</td>
<td>2.87 (2.22,3.27)</td>
<td>2.87 (2.22,3.19)</td>
<td>2.84 (2.01,3.29)</td>
</tr>
<tr>
<td>TC/HDL</td>
<td>3.53 (3.01,4.16)</td>
<td>3.53 (3.00,4.14)</td>
<td>3.58 (3.06,4.17)</td>
</tr>
<tr>
<td>AIP</td>
<td>-0.06 (-0.20,0.09)</td>
<td>-0.06 (-0.22,0.08)</td>
<td>-0.06 (-0.17,0.13)</td>
</tr>
<tr>
<td>Aporatio</td>
<td>0.63 (0.54,0.74)</td>
<td>0.62 (0.54,0.74)</td>
<td>0.64 (0.55,0.74)</td>
</tr>
</tbody>
</table>

In clinical remission, a lowering of atherogenic indices and TC, TG, LDL levels as well as a rise in predicted HDL levels were observed. In high disease activity, both HDL and LDL were increased along with the atherogenic indices TC/HDL-C, AIP and aporatio. However, the predicted values at different weeks did not reach statistical significance (not shown).

Treatmen with MTX-TT and ETN-MTX had opposing effects on predicted HDL levels in remission and high-disease activity (Figure 1). In remission, MTX-TT treatment resulted in a predicted rise in HDL whilst with ETN-MTX a small reduction was observed (estimate 0.004, p < 0.02). Similar trends were observed for HDL in high disease activity (p < 0.5). In remission, both treatments resulted in a reduction in LDL (p < 0.5), whilst in high disease activity ETN-MTX treatment resulted in a modest rise in LDL compared to MTX-TT (p < 0.06). At weeks 24 and 48, significant differences were observed in LDL values between treatment groups in high disease activity (estimate 0.57, p < 0.05 and estimate 1.13, p < 0.04 respectively).

---

**Figure 1**: Predicted trends in HDL and LDL in remission (left) vs high disease activity in MTX-TT and ETN-MTX groups

**Conclusion**: Effect of early ETN treatment on HDL, and to a lesser extent LDL, differs from MTX and is modulated by clinical disease activity. Further investigations is needed to understand the basis for these findings and the clinical implication of observed differences in LDL and HDL. These data may indicate direct effect of therapies on the qualitative and functional components of metabolic lipid pathway.

**REFERENCES:**


**Disclosure of Interests**: None declared.


---

**Recent advances in orphan rheumatic diseases**
Objectives: Describe disease characteristics, phenotypes, and performance of the 2011 CDC and 2019 ACR/EULAR classification criteria in patients with IgG4-RD in Norway.

Methods: Consenting, adult patients with a clinical diagnosis of IgG4-RD, seen at the Department of Rheumatology, Oslo University Hospital were included. Two experts (J.V., D.M.) assigned patients to phenotypes ("Pancreato-Hepato-Biliary", "Retroperitoneum and Aorta", "Head and Neck-Limited" or "Mikulicz and Systemic") based on pattern of organ involvement. Fulfillment of the CDC and classification criteria were assessed. Disease activity and damage were scored with the IgG4-RD responder index (IgG4-RD RI). We used descriptive statistics.

Results: We identified 60 patients with IgG4-RD (Table 1). Clinical characteristics were as expected, with approximately equal number of patients in each phenotype group. Of all patients diagnosed by expert opinion, 42 (70%) fulfilled the ACR/EULAR classification criteria. Reasons for not fulfilling the criteria were (i) failure to meet the inclusion criterion (n = 3) due to "atypical" organ involvement: tonsils (n = 1), nasal cavity (n = 1); coronary artery (n = 1); (ii) presence of ≥ 1 exclusion criterion (n = 5); fever (n = 1), leukaemia (n = 1), thrombocytopenia (n = 1), positive anti-MPO-ANCA (n = 3), anti-SSA (n = 1); and (iii) score < 20 points (n = 10). In the latter group, 8 (80%) were not biopsied, and 1 (10%) had only performed fine needle biopsy. Among the patients not meeting the inclusion criterion or having ≥ 1 exclusion criteria, 1 (33%) and 4 (80%) scored ≥ 20 points, respectively. Of all patients, 56 (93%) fulfilled CDC, with 32 (53%), 3 (17%) and 14 (23%) patients characterized as "definite", "probable" and "possible" IgG4-RD, respectively. Of the 18 patients not fulfilling the ACR/EULAR classification criteria, 15 (83%) fulfilled CDC (4 "definite", "probable", 8 "possible"). Of the 4 patients not fulfilling CDC, 1 fulfilled the ACR/EULAR classification criteria.

Conclusion: Despite expected clinical characteristics, phenotype distribution and fullfillment of CDC in our cohort, the performance of the ACR/EULAR classification criteria was lower than expected, especially in the "Retroperitoneum and Aorta" and "Head and Neck-Limited" phenotypes. This may have important implications for the comparability across studies and inclusion in future clinical trials.

References:

Disclosure of Interests: Jens Vikse Speakers bureau: Novartis, Consultant of: Novartis, Jupiter Life Science Consulting, Øyvind Midtvedt: None declared, Bjørn Tilde Svanes Fevang: None declared, Øyvind Palm: None declared, Torhild Garen: None declared, Katrine Brække Noehim: None declared, Gunstein Bakland: None declared, Marianne Wal lenius: None declared, Anna-Maria Hoffmann-Vold Speakers bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim


POS0216 CARDIAC SARCOIDOSIS: AN UNDERDIAGNOSED, LIFE-THREATENING YET TREATABLE DISEASE

P Webster 1, Y. Rochlani 2, K. Loupasakis 3. 1Montefiore Medical Center, Albert Einstein College of Medicine, Rheumatology, New York, United States of America; 2Montefiore Medical Center, Albert Einstein College of Medicine, Cardiology, New York, United States of America; 3Montefiore Medical Center, Albert Einstein College of Medicine, Rheumatology, New York, United States of America

Background: Cardiac sarcoidosis (CS) is potentially life-threatening and it typically causes heart failure, ventricular arrhythmia, AV block or sudden death. CS has been reported to account for 25% of sarcoidosis patient deaths, thus highlighting the importance of early diagnosis and treatment. Diagnostic challenges and lack of a unified screening approach make it difficult to estimate its prevalence. Immunosuppression is the mainstay of treatment, but there is paucity of data on optimal dose, duration and efficacy of steroids and synthetic (a) or biologic (b) disease-modifying anti-rheumatic drugs (DMARDs).

Objectives: To describe the demographic and clinical characteristics of our CS patients, and to study their clinical response to steroids, synthetic and biologic DMARDs.

Methods: A retrospective cohort study with a prospective ongoing phase was conducted. ICD-10 codes were used to identify patients over 18 years old with sarcoidosis and CS followed at Montefiore Medical Center from 2017 to 2021. The following variables were recorded: demographics (age, sex, ethnicity), BMI, smoking status, presenting manifestations, histopathology (cardiac and extracardiac), imaging, treatment (corticosteroids and s/bDMARDs), dose and duration of therapy, steroid-sparing effect, response to treatment based on clinical and imaging improvement (echocardiogram, cardiac MRI, PET).

Results: 220 patients with sarcoidosis were identified. 154 (70%) female and 124 (56.4%) Black. 42 out of 220 (19.1%) met diagnostic criteria for CS 1,2. Mean age of CS patients was 61.6 years. 23 (54.8%) were male and 24 (57.1%) Black. Heart

Table 1. Treatment of cardiac sarcoidosis

<table>
<thead>
<tr>
<th>Agent</th>
<th>Treated with DMARDs (N=21)*</th>
<th>Duration of treatment (months)</th>
<th>Max dose (mg, x)</th>
<th>Prednisone dose at 12 months (mg, x)</th>
<th>Response to treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate</td>
<td>16/21</td>
<td>16.0</td>
<td>16.9</td>
<td>3.67</td>
<td>14/16</td>
</tr>
<tr>
<td>(Weekly)</td>
<td>(76.1%)</td>
<td></td>
<td></td>
<td></td>
<td>(875%)</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>6/21</td>
<td>16.9</td>
<td>2000</td>
<td>5.1</td>
<td>3/6</td>
</tr>
<tr>
<td>Mycelotinol</td>
<td>(28.6%)</td>
<td></td>
<td></td>
<td></td>
<td>(50%)</td>
</tr>
<tr>
<td>Hydrochloroquin</td>
<td>1/21</td>
<td>7.5</td>
<td>400</td>
<td>5</td>
<td>1/1</td>
</tr>
<tr>
<td>(Daily)</td>
<td>(4.8%)</td>
<td></td>
<td></td>
<td></td>
<td>(100%)</td>
</tr>
<tr>
<td>Infliximab</td>
<td>1/21</td>
<td>6.0</td>
<td>5 (mg/kg)</td>
<td>5</td>
<td>1/1</td>
</tr>
<tr>
<td>(q 8 weeks)</td>
<td>(4.8%)</td>
<td></td>
<td></td>
<td></td>
<td>(100%)</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>2/21</td>
<td>10.0</td>
<td>40</td>
<td>7.5</td>
<td>2/2</td>
</tr>
<tr>
<td>(q 2 weeks)</td>
<td>(9.5%)</td>
<td></td>
<td></td>
<td></td>
<td>(100%)</td>
</tr>
</tbody>
</table>

*p < 0.05 by one-way ANOVA

*2 patients switched from MTX to MMF and 3 from sDMARDs to bDMARDs
failure (54.8%), arthralgias (47.6%) and heart block (28.6%) were the most common presenting manifestations. 28.6% had isolated CS. 5 (11.9%) underwent endomyocardial biopsy and 2 of them (40%) had histopathologic evidence of CS. Mean left ventricular ejection fraction (LVEF) was 40.6 % on echocardiogram, and 29 patients (69%) had PPM/ICD placed for arrhythmia prevention. 35 (83.3%) underwent cardiac MRI, 37 (88.1%) cardiac PET scan and 23 (62.3%) had a follow up PET. 33 (78.6%) CS patients were treated with corticosteroids for a mean duration of 17.3 months. 21 of them were also treated with sDMARDs and 3 were subsequently switched to bDMARDs (Table 1). Mean prednisone dose at 12 months was 4.8 mg/day. 11 patients (33%) were tapered off corticosteroids.

Conclusion: In our sarcoid patient population, the prevalence of CS is 19.1%, which is higher than previously reported in the literature, suggesting CS may be underdiagnosed. There was a greater proportion of male patients in the CS population (54.8%) than the generalized sarcoidosis population (30%). This indicates that males with sarcoidosis may be more likely to have cardiac involvement. Patients treated with sDMARDs had a high response rate as reflected by clinical and imaging improvement. Steroid-sparing effect is suggested by the low prednisone dose at 12 months (Table 1). Methotrexate was the most commonly used DMARD (76.2%). Randomized clinical trials are needed to establish robust guidelines for the treatment of CS.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1271

ALL-CAUSE AND CAUSE SPECIFIC MORTALITY AMONG PATIENTS WITH BEHÇET’S DISEASE VERSUS GENERAL POPULATION

A. Shin1, S. R. Choi2, Y. J. Ha1, Y. J. Lee3, E. B. Lee4, E. H. Kang5, 1Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam-si, Korea, Rep. of (South Korea); 2Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)

Background: Behçet’s disease (BD) is a systemic vasculitis with multiorgan involvement.

Objectives: To compare the risk of all-cause and cause specific mortality among patients with BD compared to general population

Methods: Using the 2002-2017 Korea National Health Insurance database, we conducted a cohort study among BD patients compared to general population matched on age and sex at a 1:5 ratio. The primary outcome was death of any cause, and the secondary outcomes were cause-specific mortality for top 5 causes of death. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), comparing BD patients versus general population.

Results: The PS-matched study cohort (mean age 42.1 years; 32.0% male) included 32288 BD patients and 161440 controls. During a mean follow-up of 9.6 years, 2214 deaths occurred. The HR [95%] for all-cause mortality was 10.6 [9.6-11.6]. The Top 5 causes of death derived from malignancy, cardiovascular disease, infection, respiratory disease, and injury: the HR [95%] for mortality from these causes were 8.5 [7.2-10.1], 10.8 [8.6-13.6], 14.6 [8.1-26.3], 12.0 [8.5-17.0], and 8.0 [5.0-13.0], respectively.

Conclusion: This population-based cohort study warns exceptionally heavy burden of the disease showing approximately 10 times higher mortality of BD patients compared to general population. In line with this, risk of cause specific mortality was also significantly higher among the BD patients, for 5 top causes of death.

Disclosure of Interests: None declared


DECREASED MIR-122-5P IN NEUTROPHIL-DERIVED EXOSOMES ATTENUATED IMMUNOREGULATORY FUNCTION ON MACROPHAGES BY TARGETING IRF5 EXPRESSION IN BEHÇET’S DISEASE

X. Yu1, C. Li2, J. Liu1, H. Chen1, W. Zheng1, 1Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Department of Rheumatology, Beijing, China; 2Shangqiu Hospital of Peking University, Department of Rheumatology, Beijing, China

Background: Behçet’s disease (BD) is a chronic systemic vasculitis characterized by the overactivation of neutrophils and macrophages. Exosomes are membrane-derived vesicles that mediate intercellular communications and neutrophil-derived exosomes account for the major portion of serum exosomes in BD. However, the role of neutrophil-derived exosomes in BD remains unknown.

Objectives: 1) To investigate the production of exosomes by BD neutrophils; 2) To elucidate the regulation of macrophage by BD neutrophil-derived exosomes; 3) To explore the mechanism of immunoregulatory functions of BD neutrophil-derived exosomes.

Methods: BD and healthy control (HC) neutrophil-derived exosomes were extracted and quantified. Human monocyte-derived macrophages (HMDM) were stimulated with BD and HC neutrophil-derived exosomes, and TNF-α and IL-6 production were examined. Differently expressed miRNAs in BD neutrophil-derived exosomes were analyzed using miRNA sequencing. LPS-induced HMDM were treated with miRNA mimics or inhibitors, and TNF-α and IL-6 production were detected. miRNA was overexpressed in macrophages, and RNA sequencing was performed to analyze regulating pathways. Dual-luciferase assays were performed to confirm miRNA-mRNA interaction.

Results: BD neutrophils produced a significantly lower level of exosomes than HC ones. Both BD and HC neutrophil-derived exosomes suppressed TNF-α and IL-6 production by macrophages, but to a lesser extent by BD neutrophil-derived exosomes. Six downregulated miRNAs were presented in BD neutrophil-derived exosomes, including mir-122-5p, mir-122-5p mimics inhibited IL-6 and TNF-α production while miR-122-5p inhibitor promoted IL-6 and TNF-α production by HMDMs. Overexpression of mir-122-5p attenuated TLR4 and IFN-γ signaling. mir-122-5p directly targeted 3'UTR of IRFS, the TF regulating TLR4 pathway and autocrine of IFN-γ, and downregulated IRF5 expression confirmed by dual luciferase assay. Knockdown of IRFS dampened IL-6 and TNF-α production in HMDMs.

REFERENCES:

Disclosure of Interests: None declared


EARLIER AND MORE AGGRESSIVE TREATMENT OF MAJOR ORGAN INVOLVEMENT WITH BIOLOGICS MAY PREVENT RELAPSES OR FURTHER NEW ORGAN INVOLVEMENT IN A SUBGROUP OF BEHÇET’S DISEASE PATIENTS

T. Bozkurt1, M. Karabacak2, H. Karataş1, S. Kutlu Ağaçkan2, T. Ergün3, H. Direskeneli4, F. Albaz-Oner6, 1Marmara University School of Medicine, Department of Internal Medicine, ISTANBUL, Turkey; 2Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, ISTANBUL, Turkey; 3Marmara University School of Medicine, Department of Dermatology, ISTANBUL, Turkey

Background: Conventional immunosuppressives (cIS) are the choice of treatment for major organ (ocular, vascular, central nervous (CNS) and gastrointestinal (GIS)) involvement to prevent relapses and organ damage in patients with Behçet's disease (BD).

Objectives: We aimed to investigate the rate of new major organ involvement in BD patients under cIS treatments during follow-up and to assess the characteristics and treatment protocols of these patients.

Methods: The files of 1114 patients diagnosed with BD and followed (1992-2019) in the Marmara University Behçet's Clinic were overviewed retrospectively. Patients with follow-up duration less than 6 months were excluded. A total of 806
patients, of whom 56% were male and included in the analysis. Demographic and clinical characteristics, follow-up and treatment data of the patients were recorded from files. Relapse of the same organ and/or major organ development during the follow-up period of patients receiving cSiS was defined as “event under cSiS.”

Results: Median age at diagnosis was 29 (10-65) years and median follow-up duration was 68 months (6-272). Genital ulcer, erythema nodosum and arthritis/arthralgia were more common in women, whereas papulopustular lesions, vascular, and ocular involvement were more common in men (p<0.005 for all). Presence of major organ involvement was 56.9% (n=459) and the frequencies of vascular, ocular, CNS and GIS involvement were 29.8%, 33.5%, 9.7%, and 2%, respectively. At diagnosis 232 (50.5%) patients had major organ involvement, whereas it developed in 227 patients during a follow-up of median 3 years (0.5 - 32) after diagnosis. Major organ involvement developed earlier in males compared to females (median 2 years vs 4 years, p = 0.012). In patients with a first-degree relative history of BD, major organ involvement also developed earlier, however without reaching significance (median 1 year vs 3 years) (p=0.066). 440 patients had follow-up data under cSiSs with the follow-up duration of median 65.5 months (6-272). Main reason for cSiS use was major organ involvement (86.8%), less frequent reasons were mucocutaneous disease (9.3%) and joint involvement (3.8%). An event under ISs (mainly relapses) occurred in 160 (36.4%) patients with median 23 months after cSiS initiation. Majority of events (68%) were relapses of the same major organ (Figure 1). The most commonly used cSiS agent was azathioprine (87%). Among patients having an event under cSiSs, 91% of the relapses and 75% of new major organ involvement developed under azathioprine treatment. In patients with an event under cSiSs, treatment mostly switched to other ISs such as cyclophosphamide, interferon-α, and high dose corticosteroids. In 22% of patients, azathioprine was switched to tumor necrosis factor (TNF) inhibitors.

Conclusion: In our study, major organ involvement developed in 57% of the 806 BD patients. We observed that disease course was more severe under cSiS treat-ment in male patients diagnosed at a younger age and with the history of familial BD. In one third (36%) of the patients under cSiS treatment, a relapse or a new major organ involvement developed despite the cSiS use, mainly under azathioprine. TNF-inhibitor use was approved for BD treatment within the last decade in Turkey. Therefore, azathioprine was switched to a TNF inhibitor in only 22%. Our results suggest that earlier and more aggressive treatment of major organ involvement with biologics may be an option in young male patients especially with the history of familial BD, who had the highest risk for severe disease course.

Disclosure of Interests: None declared

LONG-TERM SAFETY AND EFFECTIVENESS OF CANAKINUMAB IN CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES – 36-MONTH DATA FROM THE RELIANCE REGISTRY

J. B. Kuehmerle-Deschner1, B. Kortus-Goetze2, P. Ommern2, A. Janda3, J. Rech3, C. Schuetz4, T. Kalinich5, F. Weller-Heinemann5, G. Hornet6, I. Foeldvari7, F. Meier8,9, M. Borte10, T. Krickau11, J. Weber-Arden12, N. Blank13.1. University Hospital Tuebingen, Department of Pediatrics, Division of Pediatric Rheumatology, Tuebingen, Germany; 2. University of Marburg, Division of Nephrology, Marburg, Germany; 3. Heinrich-Heine-University Düsseldorf, Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Division of Pediatric Rheumatology, Düsseldorf, Germany; 4. Ulm University Medical Center Department of Pediatrics and Adolescent Medicine, Ulm, Germany; 5. Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; 6. Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Pediatrics, Dresden, Germany; 7. Charité University Medicine Berlin, Department of Pediatrics, Division of Pulmonology Immunology and Critical Care Medicine, Berlin, Germany; 8. Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Bremen, Germany; 9. Asklepios Clinic Sankt Augustin, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany; 10. Centre for Pediatric and Adolescence Rheumatology Hamburg, Centre for Pediatric and Adolescence Rheumatology Hamburg, Hamburg, Germany; 11. University Hospital Frankfurt, Goethe University, Frankfurt am Main, Division of Rheumatology, Frankfurt, Germany; 12. Fraunhofer Institute for Molecular Biology and Applied Ecology (IAME), Project Group Translational Medicine and Pharmacology TMr, Frankfurt, Germany; 13. Hospital St. Georg gGmbH Leipzig, ImmunoDeficiencyCenter Leipzig (IDC), Leipzig, Germany; 14. Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany; 15. Novartis Pharma GmbH, IZH, Nuernberg, Germany; 16. University Hospital Heidelberg, Rheumatology, Heidelberg, Germany

Background: The cryopyrin-associated periodic fever syndromes (CAPS) are hereditary monogenic autoinflammatory diseases with severe systemic and organ inflammation due to increased production of Interleukin-1β (IL-1β). The subcutaneously administered monoclonal antibody canakinumab (CAN) effectively inhibits IL-1β and results in rapid remission of CAPS symptoms in clinical trials as well as in real-life.

Objectives: The RELIANCE registry is designed to explore long-term safety and effectiveness of CAN under subcutaneous clinical practice conditions in pediatric (∗2 years) and adult patients with CAPS, including Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and neonatal onset multisystem inflammatory disease (NOMID)/chronic infantile neurological cutaneous and articular syndrome (CINCA).

Methods: This prospective, non-interventional, observational study with a 3-year follow-up enrols patients in Germany with clinically confirmed diagno-ses of CAPS routinely receiving CAN. In 6-monthly visits, clinical data, physician assessments and patient-reported outcomes are evaluated starting at baseline.

Results: 98 CAPS patients (52% female; 15 [15%] NOMID/CINCA subtypes) were enrolled by December 2021 (Table 1). At baseline, median age was 20 years and median duration of prior CAN treatment was 6 years. At the 36 months visit, 74% of patients reached disease remission by physicians’ assessment along with increasing rates of absent disease activity (patient’s assessment, median 2.0 at baseline and 0.0 month 36). In addition, patients reported low levels of fatigue (absent to mild/moderate: 87% at baseline and 95% at month 36). At baseline, CAPS impaired social life in 47% of patients (37% at month 36) and 33% (23% at month 36) reported days off from school/work. Lab parameters were within normal limits. Remission and disease control were sustained as evaluated parameters remained stable or even decreased over time.

Table 1. Patient and physician assessment of clinical CAPS disease activity and laboratory markers over time.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Baseline</th>
<th>12 months</th>
<th>36 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients in disease remission (physician assessment)</td>
<td>64 (68)</td>
<td>48 (70)</td>
<td>28 (74)</td>
</tr>
<tr>
<td>Patient’s assessment of current disease activity; 0–10, median (min; max)</td>
<td>2.0 (0; 7)</td>
<td>2.0 (0; 7)</td>
<td>0.0 (0; 6)</td>
</tr>
<tr>
<td>Patient’s assessment of current fatigue; 0–10, median (min; max)</td>
<td>3.0 (0; 9)</td>
<td>2.0 (0; 8)</td>
<td>10 (0; 8)</td>
</tr>
<tr>
<td>Number (%) of patients without impairment of social life by the disease</td>
<td>34 (53)</td>
<td>35 (65.0)</td>
<td>17 (63)</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>SAA (mg/dl); median 0.1</td>
<td>0.5 0.1</td>
<td>0.3 0.1</td>
</tr>
<tr>
<td>Number (%) of patients with disease-related symptoms prior to inclusion into the study</td>
<td>1.0</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Number (%) of patients with disease-related symptoms at baseline</td>
<td>12 months</td>
<td>36 months</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>75 (80)</td>
<td>14 (15)</td>
<td>19 (28)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>84 (89)</td>
<td>49 (52)</td>
<td>36 (52)</td>
</tr>
<tr>
<td>Conjunctivitis/Uveitis</td>
<td>63 (67)</td>
<td>27 (29)</td>
<td>21 (30)</td>
</tr>
<tr>
<td>Headache</td>
<td>68 (72)</td>
<td>30 (32)</td>
<td>30 (43)</td>
</tr>
<tr>
<td>Arthralgia/arthritis</td>
<td>80 (85)</td>
<td>32 (34)</td>
<td>30 (43)</td>
</tr>
<tr>
<td>Impairment of hearing</td>
<td>35 (37)</td>
<td>23 (25)</td>
<td>18 (26)</td>
</tr>
<tr>
<td>Trigger (cold, stress, infections, vaccinations, hormones)</td>
<td>71 (76)</td>
<td>32 (34)</td>
<td>21 (30)</td>
</tr>
</tbody>
</table>

Sae | Number of events | Incidence rate per 100 patient years |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; n. a., not annotated; SAA, serum amyloid A; SADRO, serious adverse drug reaction; SAE, serious adverse event*Incidence rate = number of events / 36,525 / sum of observation days (88,558–Abdominal pain, Alport’s syndrome, appendicitis, arthralgia, blister, cardiovascular disorder, chest pain, circular colitis, colonic perforation, diaphoresis, diabetes mellitus, dyspepsia, febrile convulsion, gastroenteritis, glomerulonephritis, haemophilia test positive, myalgia, oedema, pneumonia, premature delivery, skin discoloration, tonsillolithy, tonsillitis bacterial, tonsillitis streptococcal, vision blurred (all N=1 event), pyrexia (3 events)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics and interim analysis data of patients with TRAPS.

<table>
<thead>
<tr>
<th></th>
<th>Baseline (N=19)</th>
<th>12 months (N=15)</th>
<th>24 months (N=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number (%) of patients in disease remission (physician assessment)</td>
<td>9 (53)</td>
<td>11 (79)</td>
<td>4 (67)</td>
</tr>
<tr>
<td>Physician assessment of disease activity, percentage of absent/mild-moderate/severe rating</td>
<td>35 / 59 / 0</td>
<td>57 / 36 / 7</td>
<td>67 / 33 / 0</td>
</tr>
<tr>
<td>Patient’s assessment of current disease activity; 0–10, median (min; max)</td>
<td>1.5 (0; 8)</td>
<td>1.0 (0; 6)</td>
<td>0 (0; 7)</td>
</tr>
<tr>
<td>Patient’s assessment of current fatigue; 0–10, median (min; max)</td>
<td>1.0 (0; 8)</td>
<td>1.0 (0; 8)</td>
<td>0 (0; 8)</td>
</tr>
<tr>
<td>Number (%) of patients with days absent from work/school during last 6 months</td>
<td>5 (56)</td>
<td>4 (44)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Number (%) of patients with days absent from work/school during last 6 months</td>
<td>8 (44)</td>
<td>6 (40)</td>
<td>1 (14)</td>
</tr>
<tr>
<td>CRP, median (mg/dl)</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>SAA, median (mg/dl)</td>
<td>0.5</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>ESR, median (mm/h)</td>
<td>7.0</td>
<td>5.5</td>
<td>6.0</td>
</tr>
<tr>
<td>Number of events</td>
<td>9</td>
<td>24.2</td>
<td>0.0</td>
</tr>
<tr>
<td>Incidence rate per 100 patient years</td>
<td>0.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CRP: C-reactive protein; SAA: serum amyloid A; ESR: erythrocyte sedimentation rate; # Numbers/percentage do not sum up to N=19/100%, due to unknown weight of some patients.

Conclusion: The 36-month interim analysis of the RELIANCE study demonstrates that long-term canakinumab treatment is safe and effective in patients with CAPS, independent of subtype severity.

Disclosure of Interests: J. B. Kuermerle-Deschner Consultant of: Novartis, Abbvie, Sobi, Grant/research support from: Novartis, Abbvie, Sobi, Birgit Kortus-Goetz Pay instructor for: Novartis, Prasad Oommen Grant/research support from: Novartis, Ales Janda: None declared, Jürgen Rech Spezifikum bureau: Abbvie, Biogen, BMS, Chugai, GSK, Janssen, Lilly, MSD: Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Consultant of: Abbvie, Biogen, BMS, Chugai, GSK, Janssen, Lilly, MSD: Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Grant/research support from: Novartis, Sobi, Catharina Schuetz: None declared, Tilmann Kallinich Consultant of: Novartis, Roche, Grant/ research support from: Novartis, Frank Weller-Heinemann: None declared, Gerd HornfellSpezifikum bureau: Abbvie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Grant/research support from: Abbvie, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Ivan Feldstein Consultant of: Novartis, Hexal, Medac, Pfizer, Florian MeierSpezifikum bureau: Novartis, Michael Borte Grant/research support from: Pfizer, Shire, Tobias Krickau Spezifikum bureau: Novartis, Consultant of: Novartis, Giulia Weber-Arden Employee of: Novartis, Tobias Krickau Speakers bureau: Novartis, Consultant of: Novartis, Norbert Blank Consultant of: Novartis, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, Actelion, Boehringer-Ingehelm, Roche, Grant/ research support from: Novartis, Sobi, Catharina Schuetz: None declared, Jörg Henes Consultant of: Novartis, AbbVie, Sobi, Roche, Janssen, Boehringer-Ingehelm, Roche, Grant/ research support from: Novartis, Sobi, Catharina Schuetz: None declared, Jörg Henes Consultant of: Novartis, AbbVie, Sobi, Roche, Janssen, Boehringer-Ingehelm, Roche, Grant/ research support from: Novartis, Roche, Tilmann Kallinich Consultant of: Sobi, Roche, Grant/research support from: Novartis, Prasad Oommen Grant/research support from: Novartis, Michael Borte Grant/research support from: Pfizer, Shire, Markus Hufnagel Grant/research support from: Novartis, Ales Janda: None declared, Julia Weber-Arden Employee of: Novartis, J. B. Kuermerle-Deschner Consultant of: Novartis, Abbvie, Sobi, Grant/research support from: Novartis, Abbvie, Sobi.


POS0221
LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH TRAPS (TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME) – INTERIM ANALYSIS OF THE RELIANCE REGISTRY

N. Blank,1 C. Schuetz,2 J. Henes,3 T. Kallinich,4 R. Oommen,5 M. Borte5, M. Hufnagel1, A. Janda,6 J. Weber-Arden9, J. B. Kuermerle-Deschner6
1. University Hospital Heidelberg, Rheumatology, Heidelberg, Germany;
2. Technische Universität Dresden, Pediatrics, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany;
3. University Hospital Tübingen, Centre of Interdisciplinary Rheumatology, Immunology and Auto-inflammatory Diseases and Department of Internal Medicine 2, Tübingen, Germany;
4. Charité University Medicine Berlin, Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Berlin, Germany;
5. Heinrich-Heine-University Düsseldorf, Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Division of Pediatric Rheumatology, Düsseldorf, Germany;
6. Hospital St. Georg gGmbH Leipzig, ImmunodeficiencyCenter Leipzig (IDCL), Leipzig, Germany;
7. University Hospital Medical Center, Medical Faculty, University of Freiburg, Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, Freiburg, Germany;
8. University Hospital Ulm, Department of Pediatrics, Ulm, Germany;
9. Novartis Pharma GmbH, Hô, Nuenberg, Germany;
10. University Hospital Tübingen, Department of Pediatrics, Division of Pediatric Rheumatology, Tübingen, Germany.

Background: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is a rare hereditary autoinflammatory disease characterized by periodic fever as well as severe systemic and organ inflammation. Successful treatment was achieved with the interleukin-1β inhibitor canakinumab (CAN) in a pivotal phase 3 study, in which 45% of patients reached clinical remission after 16 weeks (primary endpoint). CAN has been approved and applied for the treatment of TRAPS patients since 2017.

Objectives: The present study explores the long-term efficacy and safety of CAN under routine clinical practice conditions in pediatric (age ≥2 years) and adult TRAPS patients.

Methods: RELIANCE is a prospective, non-interventional, multi-center, observational study based in Germany. Patients with clinically confirmed diagnosis of TRAPS who routinely receive CAN are enrolled in order to evaluate efficacy and safety of CAN under standard clinical practice conditions at baseline and at 6-month intervals.

Results: The interim analysis of TRAPS patients enrolled by December 2021 includes baseline (N=19, 1 patient with atypical TRAPS) and preliminary 24-month data. Of these patients, N=12 (63%) were females and median age at baseline was 16 years (3–43 years). Preliminary results indicate stable remission by physicians’ assessment and laboratory parameters. Disease control by patients’ assessment showed no major changes over time (Table 1). In total, N=7 adverse drug reactions were observed, of which none was classified as severe.

Conclusion: Baseline characteristics and interim data of TRAPS patients are available from the RELIANCE study. Further interim and end-of-study data will be analyzed to assess efficacy and safety of long-term treatment as well as dosing effects in TRAPS patients.

REFERENCES:
[2] Ilaris, INN-canakinumab (europa.eu)

POS0222
POLYARTICULAR ARTHRITIS AND ADULT-ONSET OSTEOLYSIS CAUSED BY MUTATIONS IN THE ASAH1 GENE: FARBER DISEASE CLINICAL PRESENTATIONS IN THE CONTEXT OF A FIRST-EVER NATURAL HISTORY STUDY

L. Seefried1, K. Crosby2, A. Solyom3,1 University of Wuerzburg, Musculoskeletal Center Wuerzburg, Wuerzburg, Germany;
2 Aceragen, Patient Engagement, Durham, United States of America;
3 Aceragen, Rare Disease Development, Basel, Switzerland

Background: Farber disease is frequently misdiagnosed as polyclarticular juvenile idiopathic arthritis or seronegative rheumatoid arthritis which leads to a delay in diagnosis for many patients. Farber disease is an ultra-rare lysosomal storage disease caused by mutations in the ASAH1 gene. The resulting deficiency of the acid ceramidase enzyme leads to accumulation of the pro-inflammatory and pro-apoptotic sphingolipid ceramide. Accumulation of ceramide throughout the body leads to the symptoms of Farber disease. Cardial symptoms include joint disease (polyarticular arthritis and contrac- tures), subcutaneous nodules, and a hoarse or weak voice due to laryngeal nodules. The phenotypic spectrum of Farber disease ranges from rapidly progressive disease causing death in infancy to moderate or slowly progressive disease with survival into late adulthood. Symptoms may vary in severity across patients and phenotypes.

Objectives: To further define the symptoms of Farber disease, including joint disease, subcutaneous nodules, dysphonia, and osteolysis, which can lead to referral to rheumatology or related specialties. To understand the clinical present- ation and broad phenotypic spectrum of this rare disease to aid in clinical diagnosis and reduce diagnostic delay.

Methods: The Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease (NCT03323841) was the first systematic clinical study of the natural history of Farber disease. The study collected retrospective and prospective data on living and deceased patients, including demographics, clinical presentation, phenotype, diagnostic history, and patient reported outcomes.
Results: 45 patients with Farber disease (27 living, 18 deceased) who had or had not undergone hematopoietic stem cell transplant (HSCT) were enrolled from 16 centers in 9 countries. A cohort of 24 living non-HSCT patients were followed prospectively. The patients represented the broad phenotypic spectrum of Farber disease, from rapidly progressive (severe) to slowly progressive (attenuated). In patients whose data was available for analysis, the average age of patients at enrollment was 72 years (range 1 to 28 years). The average age of onset of joint disease (arthritis and/or contractures) was 15 months (range 3 months to 7 years), of subcutaneous nodules was 13 months (range 3 months to 5 years), and of dysphonia was 13 months (range birth to 8 years). The average time from onset of symptoms to Farber disease diagnosis was 2 years (range <1 to 12 years). At baseline, the mean number of joints affected with active arthritis was 113 (range 0-36) and the mean number affected with contractures was 18 (range 0-38). 12.5% of patients were reported to have a bone disorder such as osteoporosis or osteomyelitis. The Child Health Assessment Questionnaire Disability Index ranging from 0 (no impairment) to 3 was used with mean scores of 2.62-3.00 across visits.

Conclusion: Data from the Farber disease natural history study further defined the cardinal symptoms, phenotypic spectrum, and high disease-related burden in patients with Farber disease. The large number of joints affected with arthritis or contractures reflects that patients with Farber disease are often referred to rheumatology and can be misdiagnosed with particular juvenile idiopathic arthritis or seronegative rheumatoid arthritis. Demographic information and number of patients enrolled indicate that Farber disease is likely not as rare as previously thought. ASAH1 genetic testing for adult and pediatric patients referred to the rheumatology clinic with symptoms including polyarticular arthritis, subcutaneous nodules, dysphonia, or osteomyelitis, may shorten the time to diagnosis in patients with Farber disease.


Table 1. Clinical and laboratory features of pts with FMF-AA according to AA-a burden

<table>
<thead>
<tr>
<th>Variables</th>
<th>G1 (n=79)</th>
<th>G2 (n=20)</th>
<th>G3 (n=14)</th>
<th>p1</th>
<th>p2</th>
<th>p3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age **</td>
<td>42.8±13</td>
<td>43.2±13</td>
<td>48.9±11</td>
<td>0.9</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Gender, male***</td>
<td>36 (45.6)</td>
<td>15 (75)</td>
<td>7 (50)</td>
<td>0.02</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Diagnosis age of AA-a *</td>
<td>30.7±13</td>
<td>34.1±14</td>
<td>34.9±15</td>
<td>0.3</td>
<td>0.3</td>
<td>0.9</td>
</tr>
<tr>
<td>Duration of AA-a *</td>
<td>13.8±9</td>
<td>10.8±6</td>
<td>14.3±8</td>
<td>0.15</td>
<td>0.8</td>
<td>0.2</td>
</tr>
<tr>
<td>Baseline CRP (mg/L)</td>
<td>20±13</td>
<td>24±19</td>
<td>13±7</td>
<td>0.4</td>
<td>0.05</td>
<td>0.07</td>
</tr>
<tr>
<td>PTH (pg/mL) II</td>
<td>3.8 (6.4)</td>
<td>12.6 (14)</td>
<td>5.6 (4)</td>
<td>0.03</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Cre (mg/dL)</td>
<td>0±0.4</td>
<td>5±1.5</td>
<td>1.8±1.3</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>0.6</td>
</tr>
<tr>
<td>e-GFR in</td>
<td>10±0.3</td>
<td>14±0.1</td>
<td>5±0.39</td>
<td>0.02</td>
<td>0.004</td>
<td>0.5</td>
</tr>
<tr>
<td>CRF at admission**</td>
<td>28±7 (38)</td>
<td>13±19 (68)</td>
<td>9±12 (75)</td>
<td>0.02</td>
<td>0.03 (6)</td>
<td>0.7</td>
</tr>
<tr>
<td>ESRD at admission**</td>
<td>7/62 (11)</td>
<td>6/18 (33)</td>
<td>4/11 (36)</td>
<td>0.03 (3)</td>
<td>0.03 (4.5)</td>
<td>0.9</td>
</tr>
<tr>
<td>C3/T3</td>
<td>10.2±17</td>
<td>10.6±11</td>
<td>13.9±16</td>
<td>0.3</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Trop I</td>
<td>9 (13)</td>
<td>23 (68)</td>
<td>75 (85)</td>
<td>0.4</td>
<td>0.005</td>
<td>0.1</td>
</tr>
<tr>
<td>pro-BNP I</td>
<td>288 (1040)</td>
<td>766 (1967)</td>
<td>4968</td>
<td>0.5</td>
<td>0.003</td>
<td>0.026</td>
</tr>
<tr>
<td>ESRD (overall)**</td>
<td>35 (45)</td>
<td>10 (50)</td>
<td>13 (93)</td>
<td>0.7</td>
<td>0.01 (11)</td>
<td>0.01 (7)</td>
</tr>
<tr>
<td>Duration of b-DMDAR</td>
<td>66±29</td>
<td>67±37</td>
<td>41.8±30</td>
<td>0.9</td>
<td>0.2</td>
<td>0.08</td>
</tr>
<tr>
<td>Mortality</td>
<td>8 (10)</td>
<td>3 (15)</td>
<td>6 (43)</td>
<td>0.5</td>
<td>0.006 (10)</td>
<td>0.1</td>
</tr>
</tbody>
</table>

Figure 1. Comparison of survival rate between G3 and G1 Log-Rank: p<0.007


Table POS0224

<table>
<thead>
<tr>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1-censores</td>
<td>Group 3-censores</td>
<td></td>
</tr>
</tbody>
</table>

A NOVEL TNFRSF1A MUTATION ASSOCIATED WITH TNP-RECEPTOR ASSOCIATED PERIODIC SYNDROME AND ITS METABOLIC SIGNATURE

J. Steiner1, A. Antebi1, A. Annibai1, T. Kubacki2. 1Max Planck Institute, Max Planck Institute for Biology of Ageing, Cologne, Germany; 2University Hospital Cologne, Cologne, Germany, Department II of Internal Medicine and Center for Molecular Medicine Cologne, Cologne, Germany

Background: Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominant syndrome characterized by prolonged episodes of fever, arthralgia, myalgia, abdominal pain and erythematous rash. We report a new mutation in the TNFRSF1A gene which is associated with TRAPS and AA-amyloidosis. Furthermore we analyzed the metabolic changes using a metabolomics approach.

Objectives: To describe a novel mutation in the TNFRSF1A gene that causes TRAPS.

Methods: Case series. For pathogenity predictions we used the PolyPhen-2 web-software2 and PROVEAN3. Metabolomics: Mass spectrometry was performed

## Table POS0224

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>42.8±13</td>
<td>43.2±13</td>
<td>48.9±11</td>
</tr>
<tr>
<td>Gender, male</td>
<td>36 (45.6)</td>
<td>15 (75)</td>
<td>7 (50)</td>
</tr>
<tr>
<td>Diagnosis age of AA-a</td>
<td>30.7±13</td>
<td>34.1±14</td>
<td>34.9±15</td>
</tr>
<tr>
<td>Duration of AA-a</td>
<td>13.8±9</td>
<td>10.8±6</td>
<td>14.3±8</td>
</tr>
<tr>
<td>Baseline CRP (mg/L)</td>
<td>20±13</td>
<td>24±19</td>
<td>13±7</td>
</tr>
<tr>
<td>PTH (pg/mL)</td>
<td>3.8 (6.4)</td>
<td>12.6 (14)</td>
<td>5.6 (4)</td>
</tr>
<tr>
<td>Cre (mg/dL)</td>
<td>0±0.4</td>
<td>5±1.5</td>
<td>1.8±1.3</td>
</tr>
<tr>
<td>e-GFR</td>
<td>10±0.3</td>
<td>14±0.1</td>
<td>5±0.39</td>
</tr>
<tr>
<td>CRF at admission</td>
<td>28±7 (38)</td>
<td>13±19 (68)</td>
<td>9±12 (75)</td>
</tr>
<tr>
<td>ESRD at admission</td>
<td>7/62 (11)</td>
<td>6/18 (33)</td>
<td>4/11 (36)</td>
</tr>
<tr>
<td>C3/T3</td>
<td>10.2±17</td>
<td>10.6±11</td>
<td>13.9±16</td>
</tr>
<tr>
<td>Trop I</td>
<td>9 (13)</td>
<td>23 (68)</td>
<td>75 (85)</td>
</tr>
<tr>
<td>pro-BNP I</td>
<td>288 (1040)</td>
<td>766 (1967)</td>
<td>4968</td>
</tr>
<tr>
<td>ESRD (overall)</td>
<td>35 (45)</td>
<td>10 (50)</td>
<td>13 (93)</td>
</tr>
<tr>
<td>Duration of b-DMDAR</td>
<td>66±29</td>
<td>67±37</td>
<td>41.8±30</td>
</tr>
<tr>
<td>Mortality</td>
<td>8 (10)</td>
<td>3 (15)</td>
<td>6 (43)</td>
</tr>
</tbody>
</table>

## References

1. Poser et al. 2022
2. Stein et al. 2022
3. Schmitt et al. 2022

## Conclusion

Data from the Farber disease natural history study further defined the cardinal symptoms, phenotypic spectrum, and high disease-related burden in patients with Farber disease. The large number of joints affected with arthritis or contractures reflects that patients with Farber disease are often referred to rheumatology and can be misdiagnosed with particular juvenile idiopathic arthritis or seronegative rheumatoid arthritis. Demographic information and number of patients enrolled indicate that Farber disease is likely not as rare as previously thought. ASAH1 genetic testing for adult and pediatric patients referred to the rheumatology clinic with symptoms including polyarticular arthritis, subcutaneous nodules, dysphonia, or osteomyelitis, may shorten the time to diagnosis in patients with Farber disease.
on patient plasma and healthy controls using an UHPLC system (Vanquish, Thermo Fisher Scientific, Bremen, Germany) coupled to an HRAM mass spectrometer (Q-Exactive Plus, Thermo Fisher Scientific GmbH, Bremen, Germany).

**Results:** A 44-year-old man (patient 1) presented to our hospital with abdominal pain, elevated inflammation parameters, renal failure and large proteinuria. Renal biopsy revealed AA amyloidosis. Further anamnesis showed he had suffered from recurrent attacks of abdominal pain with fever and elevation of inflammation markers since he was 16 years old. He also reported that his father, aunt, sister and daughter have had similar problems. His daughter (patient 2) reported recurrent episodes of abdominal pain. Since she was 11 years old and her 46-year-old sister (patient 3) reported similar symptoms starting at 12 years of age. Upon presentation patient 3 showed proteinuria of 2000mg/g creatinine (albuminuria 1500mg/g creatinine) strongly indicating early renal AA-amyloidosis. All symptomatic family members underwent genetic testing that revealed the yet uncharacterized TNFRSF1A-variant c.332A>G (p.Q111R). In silico analysis of the mutation by PolyPhen-2 software and PROVEAN classified the mutation as probably pathogenic culminating in the diagnosis of TRAPS. All patients received canakinumab for treatment and responded with normalization of the inflammatory parameters. Patient 3 showed a marked reduction of proteinuria after 6 months of treatment. Using a metabolomics approach we were able to detect 158 distinct metabolic compounds of which 32 were up- and 35 downregulated, respectively. Two patients were analyzed before and after treatment with canakinumab. The treatment with canakinumab, however, appears to have no effect on the metabolic changes caused by TRAPS. Significantly upregulated metabolic pathways included purine metabolism, glycolysis/glyconeogenesis, glutathione metabolism, pyrimidine metabolism and phenylalanine, tyrosine and tryptophan biosynthesis. Downregulated pathways included Aminoacyl-tRNA biosynthesis, arginine and proline metabolism, arginine biosynthesis among others.

**Conclusion:** Here we present a novel mutation in the TNFRSF1A gene that causes TRAPS and is associated with AA-amyloidosis. Canakinumab is an effective treatment in this variant and led to improvement in proteinuria in one of the patients with presumed early renal AA-amyloidosis. We observed significant changes in the metabolite in comparison to healthy controls. Treatment with canakinumab appeared to have no effect on these metabolic changes caused by TRAPS.

**REFERENCES:**


**Disclosure of Interests:** None declared. DOI: 10.1136/annhematids-2022-eular.1098

**Modelling in OA**

**POS0225**

**FLUIDIC SHEAR STRESS REDUCES TNF-α MEDIATED CARTILAGE DAMAGE IN A 3D MODEL OF DEGENERATIVE JOINT DISEASE**

D. H. Do Nguyen1, C. Lubahn1, T. Leeuw2, F. Buttgereit1, T. Gaber3, A. Damerau1 on behalf of AG Buttgereit.

**Background:** Pathomechanisms of degenerative joint diseases such as osteoarthritis (OA) ultimately result in the breakdown of cartilage tissue. To date, the exact underlying mechanisms of both cause and progression of OA remain unclear. Therefore, developing complex and long-lasting in vitro components of a human joint including cartilage, subchondral bone, synovial membrane and tendons that simulate the 3D architecture and the metabolic, hormonal and cellular interplay of the joint components is needed to study the long-lasting course of OA pathogenesis. Beside the impact of metabolic components and 3D architecture, mechanical forces are well-known to be key modulators of joint health, while abierant forces are primary etiological factors leading to cartilage degeneration.

**Objectives:** Here, we aimed to (i) develop a long-lasting human in vitro 3D cartilage model using alternated perfused cultivation and (ii) simulate TNF-α-mediated cartilage degradation. As a mechanical force we used the perfusion-mediated fluid shear stress (FSS) to enhance chondrogenesis and mimic FSS during joint movement.

**Methods:** Human bone marrow-derived mesenchymal stromal cells (MSC) were used to develop and to 3D cartilage model incubated in a bioreactor with a perfusion cycle that facilitates mechanical stimulation via FSS and daily sampling. Within the bioreactor, MSC mass cultures were subjected to FSS at 10 dyn/cm² by medium circulation three times a day for 1.5 hours. The approach of using optimized FSS rate, cycles and cultivation period of 18 days for MSC mass cultures was compared to a non-perfused control based on cell viability (live-dead and viability-assay), apoptosis (TUNEL-assay, caspase-3/7-activity, BCL2, BAX) metabolic activity (oxygen and glucose consumption, lactate production), chondrogenic gene expression (ACAN, COMP, COL2A1, COL1A1, COL2A1/COL1A1) and matrix metalloproteinase expression (MMP-1, -13).  

**Results:** Alternate perfused long-term cultivation at 10 dyn/cm² did not affect cell survival; it rather reduced apoptosis, did not affect oxygen consumption but reduced glucose consumption and lactate production and enhanced chondrogenic gene expression compared with reduced perfusion rates (MAP2K1 and COMP gene expression compared with non-perfused conditions). Mimicking pathophysiology of OA we simulated the 3D cartilage model with 100ng/mL TNF-α for 6 hours under non-perfused and perfused long-term cultivation with FSS at 10 dyn/cm² as a chemical stimulus. Compared to untreated perfused conditions, TNF-α stimulation (i) did not affect overall cell survival but enhanced apoptosis (demonstrating efficacy of stimulation), (ii) did not affect oxygen consumption and glycolysis, (iii) enhanced MMP expression and protected against TNF-α-mediated cartilage degradation.

**Acknowledgements:** This project is funded by Sanofi-Aventis Deutschland GmbH.

**Disclosure of Interests:** Duc Ha Do Nguyen: None declared, Christina Lubanh: None declared, Thomas Leeuw Employee of: Thomas Leeuw is a Sanofi employee and may hold shares and/or stock options in the company., Frank Buttgereit: None declared, Timo Gaber: None declared, Alexandra Damerau: None declared DOI: 10.1136/annhematids-2022-eular.948

**POS0226**

**DEFICIENT CHAPERONE-MEDIATED AUTOPHAGY CONTRIBUTES TO JOINT DAMAGE IN OSTEOARTHRITIS**

I. Lorenzo1, U. Nogueira-Recalde1, C. Garcia-Dominguez2, N. Oreiro2, J. A. Pinto Tasende3, M. LOTZ2, F. J. Blanco1,2, B. Caramés1, Instituto de Investigación Biomédica de A Coruña (INIBIC), Unidad de Biología del Cartílago, Grupo de Reumatología, A Coruña, Spain;1Complexo Hospitalario Universitario A Coruña, Grupo de Reumatología Clínica, A Coruña, Spain;3Scripps Research, Molecular Medicine, La Jolla, United States of America

**Background:** In Osteoarthritis (OA), defects in macroautophagy are evident and precede joint damage. Indeed, pharmacological activation of macroautophagy protects against joint damage and disease.

**Objectives:** Therefore, identifying hallmarks associated with specific autophagy subtypes could shed light to fundamental mechanisms of joint disease and facilitate the development of therapeutic strategies to prevent OA progression.

**Methods:** A gene expression analysis of 35 autophagy genes was performed from blood from a Prospective OA Cohort of A Coruña (PROCOAC) of non-OA (Age:61,44±1,16 years; BMI:25,25±5,02; Females, n=18) and knee OA subjects (Age:65,50±1,05 years; BMI:29,55±0,67; Females, n=18, OA grade III-IV) and by using SYBR green array. The differential expression of candidate genes in blood (n=30/group) and knee cartilage (Non-OA, n=12; Knee OA donors, n=21) was confirmed by using Taqman Technology. HSP90AA1, a chaperone mediated autophagy (CMA) mediator, and HSP90AB1, involved in key joint tissues (i.e. cartilage, meniscus, ACL and synovium) with different KL grades (0, 2, 4, 6, 8, 10 and 12 months old, n=3 each time) and surgically-induced OA mice (10 weeks after surgery, n=4 each) by immunohistochemistry. The functional consequences of HSP90AA1 deficiency on inflammation, oxidative stress, senescence and apoptosis were studied in human OA chondrocytes by gene and protein expression and flow cytometry. The potential contribution of CMA to chondrocyte homeostasis was studied by assessing the capacity of CMA to restore proteostasis upon macro-autophagy deficiency by ATG5 knockdown. To study the therapeutic potential of targeting CMA, HSP90AA1 was overexpressed in human OA chondrocytes.

**Results:** 16 autophagy-related genes were significantly downregulated in knee OA subjects (p<0.05). Macroautophagy-related genes ATG8L2, ATG12, ATG4B and MAP1LC3B were significantly downregulated (p<0.05). Interestingly, HSP90AA1 and HSPA5, CMA mediators involved in stress response and protein folding, were significantly downregulated (p<0.001). Confirmatory studies showed a downregulation of MAP1LC3B and HSP90AA1 in blood (p<0.001) and cartilage (p<0.05) from
Results: hASCs. After 12 weeks of implantation, rabbits were sacrificed for analysis. In order to possiblity of differentiating to complete cartilage, Fibrin only group and Fibrin filled with perfectly differentiated chondrocytes. Although Fibrin with hASCs MAP with hASCs group had the best healing and covered with hyaline cartilage. Moreover, histological assessment showed that implanted hASCs had been remained in target defect rather than dispersed to other sites of the knee. Dead fluorescent staining. The implanted cells were labeled with DiD for in vivo imaging cells to differentiate directly to chondrocytes.

Objectives: We developed biocompatible adhesive which enables implanted chondrogenic-enhanced hASCs being strongly fixed to the lesion site of defected cartilage, and thus, the implanted cells can survive lengthy in defect site allowing cells to differentiate directly to chondrocytes.

Methods: MAP was produced and purified for in vivo applications using a bacterial expression system as previously reported [1]. The cell encapsulated coacervate was formulated with two polyelectrolyte, the MAP and 723 kDa hyaluronic acid (HA). The DiD labeled cell was dispensed into the solution in which the MAP microdroplets with hyaluronic acid and subsequently gelated into microparticles, which is highly viscous and strongly adhesive. In vivo efficacy of MAP in rats - the osteochondral defects using stem cell therapy-based tissue engineering have been developed and used for more than 20 years; however, the low viability and high possibility of dispersion of injected cells to target defect sites have remained challenge. Mussel adhesive protein (MAP) receiving increasing attraction as functional underwater adhesive ability if the bioengineered MAP, therefore it could be applied on various environment of lesion site. Objectives: Background: Cartilage has limited intrinsic healing capacity, motivating the application of stem cells for regenerative therapies. Treaties to treat osteochondral defects using stem cell therapy-based tissue engineering have been developed and used for more than 20 years; however, the low viability and high possibility of dispersion of injected cells to target defect sites have remained challenge. Mussel adhesive protein (MAP) receiving increasing attraction as functional underwater adhesive ability if the bioengineered MAP, therefore it could be applied on various environment of lesion site.

Background: Cartilage has limited intrinsic healing capacity, motivating the application of stem cells for regenerative therapies. Treaties to treat osteochondral defects using stem cell therapy-based tissue engineering have been developed and used for more than 20 years; however, the low viability and high possibility of dispersion of injected cells to target defect sites have remained challenge. Mussel adhesive protein (MAP) receiving increasing attraction as functional underwater adhesive ability if the bioengineered MAP, therefore it could be applied on various environment of lesion site.

Methods: MAP was produced and purified for in vivo applications using a bacterial expression system as previously reported [1]. The cell encapsulated coacervate was formulated with two polyelectrolyte, the MAP and 723 kDa hyaluronic acid (HA). The DiD labeled cell was dispensed into the solution in which the MAP solution and the HA solution were mixed in a ratio of 7:3 (v/v). MAP formed liquid microdroplets with hyaluronic acid and subsequently gelated into microparticles, which is highly viscous and strongly adhesive. In vivo efficacy of MAP in rats - the osteochondral defects using stem cell therapy-based tissue engineering have been developed and used for more than 20 years; however, the low viability and high possibility of dispersion of injected cells to target defect sites have remained challenge. Mussel adhesive protein (MAP) receiving increasing attraction as functional underwater adhesive ability if the bioengineered MAP, therefore it could be applied on various environment of lesion site.

Results: Results: The fluorescence cell images exhibit the viability of cells under encapsulated condition in coacervate. The cell viabilities were determined with Live/ Dead fluorescent staining. The implanted cells were labeled with DiD for in vivo visualisation. After 7-10 days, fluorescent signals were more potently detected for MAP with hASCs group than Fibrin with hASCs group in osteochondral defect model. Implanted hASCs had been remained in target defect rather than dispersed to other sites of the knee. Moreover, histological assessment showed that MAP with hASCs group had the best healing and covered with hyaline cartilage-like tissue. The staining image shows that MAP with hASCs group were filled with perfectly differentiated chondrocytes. Although Fibrin with hASCs group had better healing, it was filled with fibrous cartilage which owes its flexibility and toughness. As MAP with hASCs group has higher possibility of differentiating to complete cartilage, Fibrin only group and Fibrin with hASCs group have failed to treat OA by rehabilitating cartilage. In order to clarify the evidence of remaining human cell proving efficacy of newly developed bioadhesive, human nuclear staining was proceeded with sectioned rabbit cartilage tissue. The results explicitly showed MAP with hASCs group have retained more human cells than Fibrin only and Fibrin with hASCs groups.

Conclusion: We investigated the waterproof bioadhesive supporting transplanted cells to attach to defect lengthy in harsh environment, which prevents cells from leaked to other region of cartilage. Collectively, the newly developed bio-adhesive, MAP, could be successfully applied in OA treatment as a waterproof bioadhesive with the capability of the strong adhesion to target defect sites. Our study suggests a new effective strategy for cartilage regeneration using MAP in tissue engineering fields.


Acknowledgements: This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health & Welfare, Republic of Korea (grant-number: HI20C009) and the National Research Foundation of Korea (NRF-2020R1A2C2002956 and 2019R1A1A01043778).

Disclosure of Interests: None declared


POS0228 HYPOXIA AND INHIBITION OF WNT SIGNALING PROMOTE EXPRESSION OF THE PROTECTIVE MOLECULE ANP32A IN CARTILAGE

J. Quintens1,2, F. M. F. Cornelis1, A. De Roover1, A. Escrivanò Núñez3, S. Monteagudo4, R. Lories1,2,5, CU Leuven, Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, Leuven, Belgium; UZ Leuven, Division of Rheumatology, Leuven, Belgium

Background: Osteoarthritis (OA) is the most common joint disorder and is characterized by cartilage damage. To date, no cure exists (1). Previously, an association between polymorphisms in the acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) gene and OA was described (2). Our group showed that ANP32A plays a key protective role in OA by preventing oxidative stress (3). In OA cartilage, ANP32A is downregulated as compared to non-OA cartilage (3).

Objectives: Taking together, we identified HSP90A, a marker of CMA, as a key regulator of chondrocyte homeostasis underlying a relevant mechanism in OA. A better definition of the cross-talk between CMA and macroautophagy defects might reveal its role as a hallmark of OA.

METHODS: In vivo efficacy of MAP in rats - the osteochondral defects were created on the patellar groove of distal femora in rats with sharp excision. After transplantation of human adipose derived stem cells (hASCs), the fluorescence images was taken in every 7 days. Animals were allocated into two groups as follows: MAP with hASCs; fibrin with hASCs. The MAP with chondro-induced hASCs were implanted on the osteochondral defect created in the patellar groove/condyle of OA-induced rabbits. Rabbits were allocated to three different groups as follows: Group 1 - Fibrin only; Group 2 - Fibrin with hASCs (1.5 x 10^5 chondro-induced hASCs); Group3; MAP with hASCs. After 12 weeks of implantation, rabbits were sacrificed for analysis.

RESULTS: The fluorescence cell images exhibit the viability of cells under encapsulated condition in coacervate. The cell viabilities were determined with Live/Dead fluorescent staining. The implanted cells were labeled with DiD for in vivo visualisation. After 7-10 days, fluorescent signals were more potently detected for MAP with hASCs group than Fibrin with hASCs group in osteochondral defect model. Implanted hASCs had been remained in target defect rather than dispersed to other sites of the knee. Moreover, histological assessment showed that MAP with hASCs group had the best healing and covered with hyaline cartilage-like tissue. The staining image shows that MAP with hASCs group were filled with perfectly differentiated chondrocytes. Although Fibrin with hASCs group had better healing, it was filled with fibrous cartilage which owes its flexibility and toughness. As MAP with hASCs group has higher possibility of differentiating to complete cartilage, Fibrin only group and Fibrin with hASCs group have failed to treat OA by rehabilitating cartilage. In order to

Background: Osteoarthritis (OA) affects 12% of the population, and yet we still have no disease-modifying treatment. Cartilage breakdown is the hallmark of OA, and patients suffer from pain and loss of joint function/independency, severely affecting quality of life. Therefore, there is a huge unmet clinical need. Receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a non-canonical WNT receptor that regulates the planar cell polarity pathway, controlling limb outgrowth. During skeletal development chondrocytes require ROR2 to undergo hypertrophy in the process of endochondral bone formation (1). Loss of function mutations in human causes Recessive Robinow Syndrome (limb shortening and brachydactyly type C, 2,3,4). Although absent from healthy adult articular cartilage, our initial studies identified high ROR2 expression in chondrocytes from patients with OA, suggesting a role in the disease process.

In a murine model of OA, blocking ROR2 in therapeutic regime using siRNA resulted in reduced cartilage destruction and rapid and sustained pain relief. Due to the limited expression pattern of ROR2 in adulthood, no systemic or local toxicity were expected, nor were any observed. We also found that blocking ROR2 supports cartilage formation in a human cartilage organoid model in nude mice using chondrocytes from patients with OA, and proposed ROR2 blockade as a potential disease-modifying OA treatment. The mechanism of action of ROR2 blockade was independent of modulation of canonical WNT signaling. YAP inhibition was required, but not sufficient, for the chondrogenic effect (4). Therefore, additional, yet unknown mechanisms must be involved downstream of ROR2 blockade.

Objectives: To study the phosphorylation events downstream of ROR2, to further our understanding of the mechanism of action of ROR2 blockade.

Methods: Phosphoproteomics (label free liquid chromatography tandem-mass spectrometry with TiO2 based phospho-enrichment), in vitro studies in cells, CRISPR.

Results: WNT5A is the most well established ligand for ROR2. We confirmed that WNT5A stimulation leads to time-dependent phosphorylation of ERK in C3H10T1/2 cells. We then deleted ROR2 in C3H10T1/2 cells by CRISPR, and performed phosphoproteomics analysis on wildtype (control) C3H10T1/2 cells and ROR2-CRISPR C3H10T1/2 cells stimulated with 100ng/ml recombinant WNT5A for 5 or 15 minutes. ROR2-dependant phosphorylation targets were defined as proteins differentially phosphorylated in control cells upon WNT5A stimulation, but that did not occur in ROR2-CRISPR cells.

Table 1. Predicted gene targets of the miR-320 family include members of the 14-3-3 gene family.

<table>
<thead>
<tr>
<th>miR-320 Family</th>
<th>Predicted Gene Targets</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-320</td>
<td>YAP</td>
</tr>
</tbody>
</table>

YAP phosphorylated by WNT5A in a ROR2-dependant manner. WNT5A/ ROR2 also modulated the YAP signaling pathway at other levels. KEGG analysis revealed that other pathways with known roles in the pathogenesis of OA were enhanced, including NF-kB, mTOR signaling and cellular senescence.

With the current technology, ROR2 blockade requires intra-articular injections of siRNA conjugated to atelocollagen every 5 days. Preliminary efficacy data of potentially longer-acting ROR2 blockers are promising.

Conclusion: ROR2 blockade has potential as a disease-modifying treatment for OA, resulting in cartilage protection and rapid and sustained pain relief in a murine model. Here, we studied the mechanism downstream of ROR2 blockade using a phosphoproteomics approach. We confirmed that YAP signaling was modulated by ROR2, and identified novel pathways and cellular processes regulated by WNT5A/ROR2. Further studies are needed to clarify their role downstream of ROR2 blockade in OA.

Our current siRNA-atelocollagen based technology requires intra-articular injections too frequently to be acceptable for patients. We are developing ROR2 blockade which can be administered systemically or intra-articularly not more often than every 3 months.

REFERENCES:


Disclosure of Interests: None declared, Jacob Wilson: None declared, Pedro Cutillas: None declared, Francesco Dell’Accio Consultant of: Samumegro - not related to this abstract, Grant/research support from: UCB - not related to this abstract.

Background: Knee osteoarthritis is the most prevalent chronic musculoskeletal debilitating disease. Current treatments are only symptomatic and to improve this, we need a robust prediction model to stratify patients at an early stage according to the risk of joint structure disease progression. Some genetic factors, including single nucleotide polymorphism (SNP) genes and mitochondrial (mt) DNA haplogroups/clusters, have been linked to this disease.

Objectives: For the first time, we aim to determine, by using machine learning, whether some SNP genes and mtDNA haplogroups/clusters alone or combined could account for knee osteoarthritis structural progressors.

Methods: Participants (901) were first classified for the probability of being structural progressors. Genotyping included SNP genes TP63, FTO, GPNL3, USP45, GDF5, SUPT3H, MCF2L, TGFα, mtDNA haplogroups H, J, T, U, others, and clusters HV, TJ, KU, C-others. They were considered for prediction with major risk factors of osteoarthritis, namely, age and body mass index (BMI). Seven supervised machine learning methodologies were evaluated. The support vector machine was used to generate gender-based models. The best input combination was assessed using sensitivity and synergy analyses. Validation was performed using 10-fold cross-validation as well as an external cohort (TASOAC).

Results: From 277 models, two were defined. Both used age and BMI in addition for the first one of the SNP genes TP63, USP45, GDF5, FTO with an accuracy of 85.0%; the second profits from the association of mtDNA haplogroups and SNP genes FTO and SUPT3H with 82.5% accuracy. The highest impact was associated with the haplogroup H, the presence of CT alleles for rs8044769 at FTO, and the absence of AA for rs10948172 at SUPT3H. Validation accuracy with the cross-validation (about 95%) and the external cohort (90.5%, 87.5%, respectively) was excellent for both models.

Conclusion: This study introduces a novel source of decision support in precision medicine, in which, for the first time, two models were developed consisting of i) age, BMI, TP63, USP45, GDF5, FTO and ii) the optimum one as it has one less variable, age, BMI, mtDNA haplogroup, FTO, SUPT3H. Such a framework is translational and type deconvolution and dissecting gene regulatory networks.

Acknowledgements: The authors would like to thank the Osteoarthritis Initiative (OAI) participants and Coordinating Center for their work in generating the clinical and radiological data of the OAI cohort and for making them publicly available. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. None of the authors are part of the OAI investigator team. Moreover, the authors are also grateful to the TOSOAC participants.

A special thanks to ArthroLab Inc. for having provided the MRI data used for classifying structural progressors for each individual.

Disclosure of Interests: Artohosein Bonakdari: None declared, Jean-Pierre Pelletier Shareholder of: ArthroLab Inc., Grant/research support from: Work supported in part by the Osteoarthritis Research Unit of the University of Montreal Hospital Research Centre and the Chair in Osteoarthritis from the University of Montreal. DOI: 10.1136/annrheumdis-2022-eular.4778
Conclusion: These data provide detailed insight into the cellular and molecular mechanisms underpinning subchondral bone and BMAT remodeling in OA. An expansion of pre-adipocyte populations along altered function of BMAT adipocytes might represent a previously unrecognized mechanism regulating subchondral bone sclerosis. TFs driving core gene regulatory networks might be promising therapeutic targets for knee OA.

REFERENCES:

Disclosure of Interests: None declared

POS0233  COMPARISON OF 3D QUANTITATIVE OSTEOARTHRITIS IMAGING BIOMARKERS: A STUDY USING PAIRED CT AND MR IMAGES FROM THE IMI-APPROACH STUDY.

A. Brett1, M. A. Bowes1, P. G. Conaghan1. 1Iompics Ltd. Clinical Applications, Manchester United Kingdom; 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

Background: MRI bone surface area and femoral bone shape (B-score) measures have been employed as quantitative endpoints in DMOAD clinical trials. The B-score (typical range -2 to +7) has been shown to be an objective, automated assessment of OA status, with clinical risk defined for current and future patient, functional limitation and total knee replacement. Computerized Tomography (CT) imaging is more commonly used for 3D visualization of bone anatomy due to its high bone-soft tissue contrast. Also, CT images are not subject to the geometric distortion in MR images due to the presence of inhomogeneities, a problem addressed in DMOAD clinical trials by positioning the knee near the magnet isocenter. Measurement of 3D joint space width (3DJSW) has been previously reported using CT images but is possible from MR images.

Objectives: To test the robustness of the B-score, bone area and 3DJSW imaging endpoints to the choice of imaging modality, we compared the results of automated analysis of CT and MR image pairs acquired at baseline and 24-month timepoints.

Methods: We used image data from the IMI-APPROACH exploratory, 2-year prospective cohort study. High resolution CT images were acquired at baseline and 24-months. These were matched with 3D T1w MR images with fat-sat or SE sequences. CT and MR images were acquired within a mean of 12 days of each other. Additional test-re-test MR images with repositioning were available from 37 subjects. Kelgren-Lawrence Grades (KLG) were read centrally from screening weight-bearing x-rays. Femur and tibia bones were automatically segmented with sub-voxel accuracy from CT or MR images using active appearance models, a machine learning model trained to search images (Imorphics, Manchester, UK). Bone area measurement was produced for MF.tAB, LT.tAB, MT.tAB and LT.tAB regions. Average 3DJSW was measured in central regions of the medial or lateral tibial plateaus, normal to the tibial surface. Linear regression was used to test for correlation between measures. Limits of agreement and systematic bias were tested using Bland-Altman analysis. Smallest detectable difference (SDD) for MR B-score was computed from test-re-test image pairs using Bland-Altman analysis. Images acquired from the same subject at both baseline and 24-month timepoints were treated as independent.

Results: Baseline and 24-month CT-MR pairs of the same knee were available from 231 and 203 subjects respectively. 338 were female knees (78%). KLG was KLG0 (19%), KLG1 (31%), KLG2 (30%), KLG3 (16%) and KLG4 (3%) with 5 knees ungraded (1%). SDD of the B-score measure was 0.227. Table 1 presents summary statistics for shape, area, and 3D JSW measures. Figure 1 shows linear regression and Bland-Altman analysis for B-score.

Table 1. Bland-Altman and linear regression statistics.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Bias [95% CI]</th>
<th>Limits of Agreement</th>
<th>R²</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-score</td>
<td>0.10</td>
<td>-0.90, 1.10</td>
<td>0.94</td>
</tr>
<tr>
<td>MF.tAB (mm²)</td>
<td>-54.98</td>
<td>-184.52, 74.56</td>
<td>0.96</td>
</tr>
<tr>
<td>LT.tAB (mm²)</td>
<td>-42.79</td>
<td>-130.56, 44.98</td>
<td>0.97</td>
</tr>
<tr>
<td>MT.tAB (mm²)</td>
<td>-5.86</td>
<td>-76.00, 64.38</td>
<td>0.96</td>
</tr>
<tr>
<td>LT.tAB (mm²)</td>
<td>-9.24, -2.48</td>
<td>-21.33, -42.44</td>
<td>0.97</td>
</tr>
<tr>
<td>Med 3DJSW (mm)</td>
<td>-23.90, -10.77</td>
<td>1.04, -0.32, 2.40</td>
<td>0.58</td>
</tr>
<tr>
<td>Lat 3DJSW (mm)</td>
<td>0.42</td>
<td>-1.30, 2.14</td>
<td>0.47</td>
</tr>
</tbody>
</table>

Conclusion: B-score measures were highly correlated with CT and showed good agreement with a relatively small bias of 0.1 suggesting that B-score may be measured reliably using either modality. All 4 area measures were highly correlated and showed negative bias (MR smaller). It is likely that the bone surface identified using MR and CT will be at slightly different positions within the bone/cartilage boundary. A consistent negative bias suggests the MR bone boundary is inside the CT boundary. This is consistent with the positive bias in favour of MR for 3DJSW. However, the MR-CT difference for medial 3DJSW is larger than for lateral 3DJSW, possibly due to a difference in knee pose during acquisition (fully extended for CT, flexed for MR) – the tibia is more externally rotated with respect to the femur in the fully extended knee.

Acknowledgements: IMI-APPROACH investigators and patients

DOI: 10.1136/annrheumdis-2022-eular.4796

Rheumatoid arthritis: JAKi and beyond_________

POS0234  HOW CLOSELY DO GERMAN RHEUMATOLOGISTS FOLLOW THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS WHEN MAKING THERAPEUTIC DECISIONS?

Y. Meissner1, D. Huschek1, A. Zink1, J. Kaufmann2, M. Bohl-Buehler1, A. Strangfeld3. 1German Rheumatism Research Centre Berlin, Epidemiology and Health Services Research, Berlin, Germany; 2Private Practice, Rheumatology, Ludwigsfeld, Germany; 3Private Practice, Rheumatology, Potsdam, Germany

Background: EULAR developed recommendations for the management of rheumatoid arthritis (RA) suggesting treatment escalation and changes at different stages of the disease to reach at least low disease activity with latest updates in 2015[1], 2016[2], and 2019[3]. The recommendation to consider adding a biologic disease-modifying anti-rheumatic drug (DMARD) – or, since 2016, a Januskinase inhibitor (JAKi) – after the first conventional synthetic (cs) DMARD had failed and if poor prognostic factors (PPF) are present, was strengthened 2019. Since then, it is recommended that a bDMARD or a tsDMARD should be added.
Table 1. Number and percentages of treatment changes at different stages of the disease.

<table>
<thead>
<tr>
<th>Patients with</th>
<th>1 previous csDMARD &amp; no PPF</th>
<th>1 previous csDMARD &amp; ≥1 PPF</th>
<th>2 previous csDMARDs</th>
<th>1 previous bDMARD/ JAKi</th>
<th>≥2 previous bDMARDs/ JAKi</th>
</tr>
</thead>
<tbody>
<tr>
<td>EULAR Recommendation change/add csDMARD</td>
<td>n=25</td>
<td>n=848</td>
<td>n=986</td>
<td>n=1,109</td>
<td>n=1,136</td>
</tr>
<tr>
<td>Period [I]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01/2014 – 12/2016</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>21 (84.0%)</td>
<td>594 (70.0%)</td>
<td>134 (13.6%)</td>
<td>199 (36.6%)</td>
<td>275 (52.9%)</td>
</tr>
<tr>
<td>bDMARD</td>
<td>4 (16.0%)</td>
<td>254 (30.0%)</td>
<td>852 (86.4%)</td>
<td>344 (63.4%)</td>
<td>245 (47.1%)</td>
</tr>
<tr>
<td>Period [II]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>01/2017 – 06/2020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>21 (60.0%)</td>
<td>109 (40.6%)</td>
<td>26 (74.2%)</td>
<td>43 (30.8%)</td>
<td>263 (57.7%)</td>
</tr>
<tr>
<td>bDMARD</td>
<td>14 (40.0%)</td>
<td>26 (33.3%)</td>
<td>9 (25.0%)</td>
<td>13 (30.8%)</td>
<td>70 (17.1%)</td>
</tr>
<tr>
<td>Period [III]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07/2020 – 04/2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>16 (50.0%)</td>
<td>469 (43.0%)</td>
<td>96 (8.5%)</td>
<td>261 (24.8%)</td>
<td>274 (21.6%)</td>
</tr>
<tr>
<td>bDMARD</td>
<td>21 (69.0%)</td>
<td>401 (37.0%)</td>
<td>121 (19.2%)</td>
<td>390 (37.0%)</td>
<td>706 (55.7%)</td>
</tr>
</tbody>
</table>

Methods: Data were used from the long-term observational cohort RABBIT, which enrolls patients with RA starting a bDMARD or JAKi, or a csDMARD after at least one previous csDMARD failure. According to the publication of the recommendations, periods from [I] 01/2014 – 12/2016, [II] 01/2017 – 06/2020 and [III] 07/2020 – 04/2021 were investigated. Patients who were in at least moderate disease activity (DAS28<3.2) were selected and analysed, if they started a csDMARD, a bDMARD, or a JAKi. Patients were further stratified by prior treatments and by the presence of PPF (≥4 swollen joints, positive rheumatoid factor or ACPA, erosions).

Results: Of the 15,150 patients with RA enrolled since 2007, 2,922 treatments were initiated in period [I], 4,580 in [II] and 415 in [III] (see Table 1). The proportion of patients with 1 previous csDMARD and 1 PPF who – in agreement with the recommendations – switched to bDMARD or JAKi, increased from 30% (only csDMARDs) in period [I] to 68% (bDMARDs + JAKi) in [III]. The proportions were even higher in patients with 2 previous csDMARDs (86% in [I], 93% in [III]). As recommended, JAKi were used more often as first line therapy (after csDMARD) in period [III].

Conclusion: JAKi have become more established, especially in bionaive patients, but have not reached the significance of biologics in certain patient groups. The early decision for a bDMARD or JAKi has been made more frequently in recent years, yet one third of patients did not receive the recommended treatment escalation. We cannot conclude from the data, which considerations led to the decision not to escalate. Of note, German rheumatologists should rather follow the German treatment guidelines, which are, however, very similar to the EULAR recommendations.

Acknowledgements: RABBIT is supported by a joint, unconditional grant from Abbvie, Amgen, BMS, Fresenius-Kabi, Galapagos, Hexal, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, VATRIS and UCB.

Disclosure of Interests: Yvette Meissner Speakers bureau: Pfizer, Doreen Hutschek: None declared, Angela Zink Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Jörg Kaufmann: None declared, Martin Bohi-Buehler Speakers bureau: 

Table 1. TEAEs of special interest, as-treated set

<table>
<thead>
<tr>
<th>TEAE, n (%) or rate per 100 PYE</th>
<th>FIL 200 mg (n=2267)</th>
<th>Total FIL (n=3691)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious AEs</td>
<td>1206 (53.2)</td>
<td>1472 (52.2)</td>
</tr>
<tr>
<td>EAE</td>
<td>211 (9.3, 22.5)</td>
<td>270 (19.9, 23.3)</td>
</tr>
<tr>
<td>Serious infectious AEs</td>
<td>80 (3.5)</td>
<td>101 (3.7)</td>
</tr>
<tr>
<td>EAE</td>
<td>1.5 (1.1, 1.9)</td>
<td>1.5 (1.2, 1.9)</td>
</tr>
<tr>
<td>Opportunistic infections</td>
<td>0.1 (0.0, 0.2)</td>
<td>0.1 (0.0, 0.2)</td>
</tr>
<tr>
<td>EAE</td>
<td>0 (0.1, 0.3)</td>
<td>0.1 (0.1, 0.3)</td>
</tr>
<tr>
<td>Active tuberculosis</td>
<td>0</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>EAE</td>
<td>0</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>0</td>
<td>0.1 (0.0, 0.3)</td>
</tr>
<tr>
<td>EAE</td>
<td>0</td>
<td>0.1 (0.0, 0.3)</td>
</tr>
<tr>
<td>Major adverse cardiovascular events</td>
<td>0</td>
<td>0.2 (0.0, 0.3)</td>
</tr>
<tr>
<td>EAE</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.4 (0.2, 0.6)</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
<td>0</td>
<td>0.2 (0.1, 0.4)</td>
</tr>
<tr>
<td>EAE</td>
<td>0.02 (0.0, 0.1)</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>Allergic systemic thrombotic events</td>
<td>0</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>EAE</td>
<td>0.02 (0.0, 0.1)</td>
<td>0.2 (0.1, 0.3)</td>
</tr>
<tr>
<td>Malignancy excluding NSMC</td>
<td>0</td>
<td>0.2 (0.0, 0.4)</td>
</tr>
<tr>
<td>EAE</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.4 (0.2, 0.4)</td>
</tr>
<tr>
<td>Gastrintestinal perforations</td>
<td>0</td>
<td>0.1 (0.0, 0.2)</td>
</tr>
</tbody>
</table>

*Except when any study had 0 event within the treatment, the Poisson model was not adjusted by study. PYE was defined as (last dose date – first dose date + 1)/365.25.

Positively adjudicated.

Adequately as deep vein thrombosis or pulmonary embolism.

NSMC, nonmelanoma skin cancer.

References:
[1] PMID: 24161836;
[2] PMID: 28264816;
[3] PMID: 31969328;
[4] PMID: 29968101;

EULAR treatment recommendations are indicated in green. *JAKi were not available. **Recommendation in period [I]: Addition of a bDMARD should be considered; in [II]: Addition of a bDMARD or a tsDMARD should be considered, current practice would be to start a bDMARD; in [III]: a bDMARD or a tsDMARD should be added. PPF, poor prognostic factor.

Background: The preferential Janus kinase-1 inhibitor FIL significantly improved signs and symptoms of RA in Phase 2 and 3 trials. FIL is approved for treatment of moderate to severe active RA in Europe and Japan. Integrated safety analysis of FIL with patient data through 2019 was presented at the 2020 ACR virtual meeting. 6

Objectives: To report updated, as-treated data from the FIL integrated safety analysis with increased study drug exposure.

Methods: Data were integrated from 2 Phase 2 (NCT01668641, NCT01894516), 3 Phase 3 (NCT02889796, NCT02873936, NCT02886728), and 2 long-term extension (LTE) (NCT02085700, NCT03025308) trials. Phase 2 and 3 LTE data were through Nov 2020 and Jan 2021, respectively. The as-treated analysis set included all available data for pts receiving ≥1 dose FIL 200 (FIL200) or 100 mg FIL 100 (FIL100).
(FIL100), including those rerandomized to FIL for LTE. Exposure-adjusted incidence rates (EAIRs) of treatment-emergent adverse events (TEAEs) and malignancies excluding NMSC (total FIL 0.5 to 0.6).

Results: 3691 pts received FIL200 or FIL100 for 8085.1 PYE (median 2.2, maximum 6.8 y). In the as-treated set, 61% of FIL200 and 45% of FIL100 pts received FIL for ≥2 y, 19% and 5% for ≥3 y, and 11% and 0.5% for ≥4.5 y, respectively. EAIRs for AESIs were comparable between doses (Table 1). EAIRs for AESIs tended to decrease since the previous update, except for venous thromboembolism (total FIL 0.1 to 0.2) and malignancies excluding NMSC (total FIL 0.5 to 0.6).

Conclusion: With 1 additional year of exposure since the 2020 report, FIL continued to be well tolerated with no new safety concerns emerging. EAIRs of TEAEs, including deaths, and AESIs remained stable or decreased since the 2020 report, except for slight increases in rates of NMSC and malignancies excluding NMSC. In the context of demonstrated efficacy, both FIL doses had an acceptable risk/benefit profile.


Acknowledgements: Funding for DARWIN 1 and 2 was provided by Galapagos NV, and funding for DARWIN 3, FINCH 1, 2, 3, and 4 was provided by Gilead Sciences, Inc., Foster City, CA. Funding for this analysis was provided by Gilead Sciences, Inc. The sponsors participated in the planning, execution, and interpretation of the research. Medical writing support was provided by Gregory Bez-korovainy, MA, of AlphaScientia, LLC, San Francisco, CA, and funded by Gilead Sciences, Inc., Foster City, CA.

Disclosure of Interests: Kevin Winthrop Consultant of: AbbVie, Bristol-Myers Squibb, Eli Lilly and Co., Galapagos NV, and funding for DARWIN 3, FINCH 1, 2, 3, and 4 was provided by Gilead Sciences, Inc., Foster City, CA. Funding for this analysis was provided by Gilead Sciences, Inc. The sponsors participated in the planning, execution, and interpretation of the research. Medical writing support was provided by Gregory Bez-korovainy, MA, of AlphaScientia, LLC, San Francisco, CA, and funded by Gilead Sciences, Inc., Foster City, CA.

Background: Vagus nerve stimulation (VNS) activates innate immunoregulatory reflexes that have been shown to reduce pro-inflammatory cytokines and clinical disease activity in subjects with rheumatoid arthritis (RA) 1. We now report 24-week efficacy and safety findings from this study.

Objectives: Determine the long-term safety and exploratory efficacy of neurostimulation using a novel, miniaturized VNS device in patients with multiple drug refractory RA who were previously enrolled in a first-in-human study.

Methods: The primary study enrolled active adult patients with active moderate-to-severe RA with incomplete response or intolerability to at least two biologic and/or targeted synthetic DMARDs having at least two different mechanisms of action. The study was enrolled in 2 Stages: Stage 1 (n=3) was open-label, and Stage 2 (n=11) was randomized and sham-controlled (Figure 1). Three weeks after MR implantation, the first 3 subjects in Stage 1 received active VNS for 1 minute, once per day (QD). Following safety review board approval, 11 patients in Stage 2 were implanted with the MR and randomized 1:1:1 into one of two active VNS groups (1 minute of VNS QD or 1 minute of active VNS 4 times per day [QID]) or a sham group. At Week 12, the blind was lifted, sham subjects were re-randomized and crossed over to either QD or QID active VNS dosing, and all actively treated subjects remained on their dosing through Week 24. Safety and tolerability were determined, and several secondary efficacy endpoints were evaluated measuring the change in disease activity from the start of active VNS to Week 24.

Results: There were no device-related adverse events from Week 12 through Week 24. Improvement in clinical disease activity was sustained through Week 24.
EULAR response criteria for DAS28-CRP at Week 24 (Table 1) vs. 5/10 at Week 12 (one Week 12 responder was lost to follow-up). Similarly, 6/9 patients in the original, active VNS treatment group met or exceeded the MCID in CDAI at Week 24 vs. 5/10 at Week 12. In the long-term extension, 1/4 sham crossover patients had both EULAR and CDAI response after 12 weeks of VNS (1/2 QD, 0/2 QID). Co-treatment with a b/tsDMARD was initiated in 2 subjects (Table 1). One crossover subject was treated with oral methylprednisolone at week 19 due to worsening RA disease activity. VECTRA composite scores and component analysis revealed an 18-point decrease in median multi-analyte disease activity index in the QD group over 24 weeks of VNS with a decrease in serum levels of several analytes in key component categories (IL-6, serum amyloid A, and VCAM-1). Erosion progression by hand MRI was stabilized or decreased in all but 1 of the stimulated patients at Week 24.

Table 1. Change in DAS28-CRP at Week 24

<table>
<thead>
<tr>
<th>Subject</th>
<th>Treatment</th>
<th>DAS28-CRP (MCID -1.2)</th>
<th>*added b/tsDMARD co-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>005-01</td>
<td>QD</td>
<td>-2.4</td>
<td></td>
</tr>
<tr>
<td>005-03</td>
<td>QD</td>
<td>-2.21</td>
<td></td>
</tr>
<tr>
<td>006-01</td>
<td>QD</td>
<td>-0.07</td>
<td></td>
</tr>
<tr>
<td>002-01</td>
<td>QD</td>
<td>-4.96</td>
<td>*</td>
</tr>
<tr>
<td>005-06</td>
<td>QD</td>
<td>-0.72</td>
<td>*</td>
</tr>
<tr>
<td>006-03</td>
<td>QD</td>
<td>-0.69</td>
<td></td>
</tr>
<tr>
<td>008-01</td>
<td>QD</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>008-03</td>
<td>QD</td>
<td>-3.14</td>
<td></td>
</tr>
<tr>
<td>008-04</td>
<td>QD</td>
<td>1.43</td>
<td></td>
</tr>
<tr>
<td>005-05</td>
<td>Sham to QD</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>006-04</td>
<td>Sham to QD</td>
<td>-0.78</td>
<td></td>
</tr>
<tr>
<td>006-02</td>
<td>Sham to QD</td>
<td>-0.22</td>
<td></td>
</tr>
<tr>
<td>008-02</td>
<td>Sham to QD</td>
<td>-0.09</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Improvements in clinical disease activity and pro-inflammatory cytokine suppression were maintained through 24 weeks of VNS treatment. Safety outcomes continue to support the risk/benefit profile of VNS as a treatment option for patients with multiple-drug refractory RA.

REFERENCES:

Acknowledgements: Authors wish to thank the patients for participating in this study


POS0237

MAJOR ADVERSE CARDIOVASCULAR EVENTS, MALIGNANCIES AND VENOUS THROMBOEMBOLISM BY BASELINE CARDIOVASCULAR RISK: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

M. H. Buch1, C. Charles-Schoeman2, J. Curtis3, M. Dougados1, D. L. Bhatt4, J. T. Giles5, S. R. Ytterberg6, G. G. Koch7, I. Vranic8, J. Wu1, C. Wang1, K. Kwok9, S. Menon10, J. L. Ravsa11, A. Yndestad12, C. A. Connell13, Z. Szekeczek14,1; University of Manchester and NIHR Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 2University of California, Division of Rheumatology, Department of Medicine, Los Angeles, CA, United States of America; 3University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, United States of America; 4Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Department of Rheumatology, Paris, France; 5PRES Sorbonne Paris-Cité, INSERM (U1153): Clinical Epidemiology and Biostatistics, Paris, France; 6Brigham and Women’s Hospital and Harvard Medical School, Department of Cardiovascular Medicine, Boston, MA, United States of America; 7Columbia University Vagelos College of Physicians and Surgeons, Division of Rheumatology, New York, NY, United States of America; 8Mayo Clinic, Division of Rheumatology, Rochester, MN, United States of America; 9University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States of America; 10Pfizer Ltd, Immunology and Inflammation, Tadworth, Surrey, United Kingdom; 11Pfizer Inc, Immunology and Inflammation, Groton, CT, United States of America; 12Pfizer Inc, Immunology and Inflammation, New York, NY, United States of America; 13Pfizer SLU, Immunology and Inflammation, Madrid, Spain; 14Pfizer Inc, Immunology and Inflammation, Oslo, Norway; 15University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary

Background: ORAL Surveillance was a post-authorisation safety study of tocilizumab vs TNF inhibitors (TNFi) in rheumatoid arthritis (RA) patients (pts) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to methotrexate (MTX). CV disease has overlapping risk factors with malignancies and venous thromboembolism (VTE), including older age, smoking, hypertension and diabetes.1,2

Objectives: To evaluate the impact of pts' baseline (BL) CV risk on the incidence and risk of major adverse CV events (MACE), malignancies and VTE in ORAL Surveillance.

Methods: Pts on stable MTX were randomised 1:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID) or a TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg once weekly). Incidence rates (IRs; pts with first events/100 pt-yrs) and hazard ratios (HRs; tofacitinib vs TNFi) were evaluated for adjudicated MACE (defined as CV death [excluding CV death due to pulmonary embolism (PE)], nonfatal MI and non-fatal stroke), malignancies (excluding NMSC) and VTE (including fatal/non-fatal deep vein thrombosis and PE). Across safety outcomes, IRs/HRs were stratified by BL CV risk score; pts were first categorised by history of coronary artery disease (HxCAD); pts without a HxCAD were further stratified by BL CV risk score categories (high ≥20%, intermediate ≥7.5–20%, borderline [≥5–<7.5%] and low [≤5%] risk), with a 1.5 multiplier applied per EULAR recommendations.3

Results: 4362 pts were included: tofacitinib 5 mg BID, n=1455; tofacitinib 10 mg BID, n=1456; TNFi, n=1451. In these treatment groups, during a median follow-up of 4.0 yrs, MACE was reported in 47 (3.2%), 51 (3.5%) and 37 (2.6%) pts, malignancies in 62 (4.3%), 60 (4.1%) and 42 (2.9%) pts, and VTE in 17 (1.2%), 34 (2.3%) and 10 (0.7%) pts, respectively. Approximately two-thirds of pts had intermediate to high CV risk, or HxCAD, and risk was well-balanced across treatment groups (Table 1). Across treatments, MACE and malignancies IRs were highest in pts with a HxCAD or high BL CV risk score (Figure 1). IRs/HRs for MACE, malignancies and VTE were generally higher with tofacitinib vs TNFi. Differences between tofacitinib vs TNFi in MACE and malignancy IRs/HRs were typically more pronounced in pts with a HxCAD or at least intermediate BL CV risk score, and less so in pts with lower BL CV risk score (Figure 1). In tofacitinib 10mg BID-treated pts, VTE IRs/HRs (vs TNFi) were clearly highest in pts with a HxCAD or high BL CV risk score; no association between VTE and BL CV risk scores was observed (Figure 1).

Table 1. Percentages of pts with a HxCAD and pts without a HxCAD categorised by BL CV risk scores, per ASCVD-PCE risk calculator4 with a 1.5 multiplier applied3

<table>
<thead>
<tr>
<th>Hx CAD, n (%)</th>
<th>Tofacitinib 5 mg BID (N=1455)</th>
<th>Tofacitinib 10 mg BID (N=1456)</th>
<th>TNFi (N=1451)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (&lt;5%)</td>
<td>313 (21.5)</td>
<td>353 (20.8)</td>
<td>296 (20.4)</td>
</tr>
<tr>
<td>Borderline</td>
<td>200 (13.7)</td>
<td>174 (12.0)</td>
<td>155 (10.7)</td>
</tr>
<tr>
<td>Intermediate</td>
<td>490 (33.7)</td>
<td>516 (35.4)</td>
<td>505 (34.8)</td>
</tr>
<tr>
<td>High (≥20%)</td>
<td>274 (18.8)</td>
<td>303 (20.8)</td>
<td>296 (20.4)</td>
</tr>
<tr>
<td>Missing data</td>
<td>17 (1.2)</td>
<td>19 (1.3)</td>
<td>16 (1.1)</td>
</tr>
</tbody>
</table>

HxCAD is defined as any history of MI, coronary heart disease, stable angina pectoris or coronary artery procedures n, number of pts with specified characteristics; N, number of evaluable pts.

References:
1. Koopman PNAS 2016
3. University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States of America;
4. Pfizer Ltd, Immunology and Inflammation, Tadworth, Surrey, United Kingdom;
and address CV risk in RA pts.

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Tanya Guha, CMC Connect, and funded by Pfizer Inc.


REFERENCES:

Conclusion: In this post hoc analysis of data from ORAL Surveillance, IRs for MACE and malignancies (excluding NMSC) were highest across treatments, and increased with both tofacitinib doses vs TNFi, in pts with a HxCAD or high BL CV risk score; a similar finding was observed for VTE IRs in pts treated with tofacitinib 10 mg BID. These findings support recommendations to regularly assess and address CV risk in RA pts.

BACKGROUND: During the pandemic, hydroxychloroquine (HCQ) became a household name, yet despite more than 70 years as a csDMARD treatment, relatively little is known about its overall side effect (SE) profile.

Objectives: To understand the types, severity, and rates of patient-reported side effects of HCQ in adults with RA, SLE, and other RMDs alone and in comparison with methotrexate (MTX).

Methods: Adult participants in the Forward Databank observational registry reported all medication use and medication side effects through biannual questionnaires from 1999 through 2021. Incident use of HCQ and MTX were measured at enrollment and longitudinally with additional reporting of severity of side effects, certainty of medication as cause of side effect, and affected body systems. We analyzed incident rates of side effects overall and by HCO and MTX categorical use, respectively: monotherapy, with concomitant use of another csDMARD, or with concomitant use of a bDMARD or tsDMARD. Finally, the likelihood of having any side effects was analyzed in Cox regression models by comparing HCO initiators to MTX initiation, and within each, combination MTX or HCQ with csDMARD or bDMARD to monotherapy; these findings support recommendations to regularly assess and address CV risk in RA pts.
models were adjusted for age, sex, RD Comorbidity Index, patient global, pain, disease duration, and number of csDMARDs used.

Results: Overall, 5874 patients initiated HCQ and 10420 initiated MTX, with RA as the predominant diagnosis. Mean baseline characteristics were similar for RA: 59 years old, 80% female and 12 years of RA duration. MTX was mostly used with other csDMARDs, while MTX was mostly used with bDMARDs. In the other RMD and SLE groups, most were on HCQ monotherapy. For all RMDs, SE incidence for HCQ (16 – 17%) was lower than MTX (26 – 39%). The Table 1 provides incidence rates by HCQ/MTX for any SE, those that force medication discontinuation, and SE leading to hospitalization. Reported SE rates were always higher for MTX vs. HCQ for all SE severity and diagnoses.

Conclusion: This is the largest study yet to review patient-reported SEs from HCQ and MTX in RA and other RMDs over a 20-year period. While validating SEs was beyond the scope of the current study, we found an overall low incidence of SEs from HCQ use, with an adjusted rate half of those reported for MTX, and that this low rate did not differ by diagnosis or concomitant DMARD use.

Disclosure of Interests: None declared

Table 1. Incidence rates (IR) per 1000 patient-years of SEs by diagnoses for HCQ and MTX initiators

<table>
<thead>
<tr>
<th>RA</th>
<th>SE</th>
<th>IR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any HCQ SE</td>
<td>12711</td>
<td>26 (23, 29)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mono HCQ</td>
<td>3397</td>
<td>28 (24, 33)</td>
<td>0.001</td>
</tr>
<tr>
<td>HCQ + csDMARDs</td>
<td>5473</td>
<td>28 (24, 33)</td>
<td>0.001</td>
</tr>
<tr>
<td>HCQ + bDMARDs</td>
<td>8471</td>
<td>22 (17, 27)</td>
<td>0.001</td>
</tr>
<tr>
<td>SE stopping HCQ</td>
<td>12711</td>
<td>13 (11, 15)</td>
<td>0.001</td>
</tr>
<tr>
<td>Mono MTX</td>
<td>5473</td>
<td>15 (12, 18)</td>
<td>0.001</td>
</tr>
<tr>
<td>HCQ + csDMARDs</td>
<td>8471</td>
<td>15 (12, 18)</td>
<td>0.001</td>
</tr>
<tr>
<td>HCQ + bDMARDs</td>
<td>8471</td>
<td>15 (12, 18)</td>
<td>0.001</td>
</tr>
<tr>
<td>HCQ SE hospitalization</td>
<td>10240</td>
<td>0.31 (0.12, 0.84)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Methods: Pts on stable MTX received tofacitinib 5 or 10 mg twice daily (BID) or a TNFi (etanercept 50 mg weekly or adalimumab 40 mg once every 2 weeks). Incidence rates (IRs; pts with first events/100 pt-yrs; PY) and 95% CIs were calculated for adjudicated VTE, DVT, and PE (overall by 6-month interval and for pts with/without history of VTE). For overall VTE, DVT and PE, numbers needed to harm (NNH); tofacitinib 5 or 10 mg BID vs TNFi were calculated post hoc. Multivariate Cox models were used post hoc to identify overall independent baseline (BL) risk factors for PE. Censoring time was a 28-day on-treatment period (minimum of last contact date or last study treatment date +28 days).

Results: Analysis included 1455, 1456 and 1451 pts receiving tofacitinib 5 mg BID, 10 mg BID and TNFi, respectively. Generally, across 6-month intervals to >54 months, VTE, DVT and PE IRs were numerically higher with both tofacitinib doses vs TNFi, and with tofacitinib 10 vs 5 mg BID; IRs were consistent across time (data not shown). Across treatments, VTE, DVT and PE IRs were higher in pts with vs without history of VTE; however, only a small number

Table 1. Multivariate Cox analyses to identify overall independent BL risk factors for PE across treatments

<table>
<thead>
<tr>
<th>BL covariate</th>
<th>HR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of VTE</td>
<td>7.06 (2.46, 20.25)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Antidepressanuse</td>
<td>2.94 (1.44, 6.02)</td>
<td>0.0038</td>
</tr>
<tr>
<td>Body mass index&gt;30kg/m²</td>
<td>2.97 (1.45, 6.32)</td>
<td>0.0041</td>
</tr>
<tr>
<td>Corticosteroid use</td>
<td>3.01 (1.40, 6.46)</td>
<td>0.0047</td>
</tr>
<tr>
<td>Proton pump inhibitor use</td>
<td>0.32 (0.15, 0.71)</td>
<td>0.0052</td>
</tr>
<tr>
<td>Male sex</td>
<td>2.16 (1.06, 4.48)</td>
<td>0.0340</td>
</tr>
<tr>
<td>Age &lt;65 yrs</td>
<td>2.00 (1.03, 3.88)</td>
<td>0.0401</td>
</tr>
<tr>
<td>Oral contraceptives/HRT use</td>
<td>3.56 (1.05, 12.10)</td>
<td>0.0422</td>
</tr>
<tr>
<td>History of hypertension</td>
<td>2.57 (0.98, 6.76)</td>
<td>0.0554</td>
</tr>
</tbody>
</table>

cBL antidepressanuse was an indicator of an underlying condition of depression, and subgroup analysis did not identify the difference in IRs for depression across treatments/Proxy for elevated BL disease activity; HRs for BL corticosteroid use were similar between all tofacitinib doses combined and TNFi; includes all BL corticosteroid use/Impact of sex on PE risk considered inconclusive/Multivariate Cox model using backward selection included treatment effects (not subject to model selection) and overall potential independent risk factors (those affecting PE IRs equally across treatments; subject to model selection) identified from a prior set of Cox regression analyses (which included treatment and a single candidate risk factor in each model fitting, cycling through a predetermined set of risk factors); cut-off for risk factor to stay in multivariate model was p<0.10; nominal p value and HR (95% CI) based on this model/HR, hazard ratio
of pts per treatment had history of VTE (Figure 1). NNH for tofacitinib 5 and 10 mg BID, respectively, vs TNFi were 763 and 198 PY for VTE, 1347 and 1068 PY for DVT, and 174 and 46 pts for PE. Identified BL risk factors for PE across treatments included history of VTE, antidepressant use, body mass index ≥30 kg/m², corticosteroid use, male sex, age ≥65 yrs, oral contraceptives/hormone-replacement therapy (HRT) use, and history of hypertension (Table 1).

**Conclusion:** Generally, in ORAL Surveillance, VTE, DVT and PE IRs were numerically higher for tofacitinib (10 > 5 mg BID) vs TNFi across 6-month intervals, and for pts with vs without history of VTE. Multivariate Cox models identified BL risk factors for PE that may help support future treatment decisions.

**Acknowledgements:** Study sponsored by Pfizer Inc. Medical writing support was provided by Emma Mitchell, CMC Connect, and funded by Pfizer Inc.


**Disclosure of Interests:** None declared

**Disclosure of Interests:** Patient Global assessment; CRP= C-reactive protein; ESR= erythrocyte sedimentation rate; TJC= tender joint count; SJC= Swollen joint Count; DAS28 = disease activity score based on the 28 joints; N= number. * Signifies p<0.05.  

**Table 1. Comparison of baseline demographic and clinical characteristics between 1st and 2nd generation tsDMARDs**  

<table>
<thead>
<tr>
<th>All population</th>
<th>Bio naive patients</th>
<th>Bio experienced patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1st generation tsDMARDs</strong></td>
<td><strong>2nd generation tsDMARDs</strong></td>
<td><strong>1st generation tsDMARDs</strong></td>
</tr>
<tr>
<td><strong>number</strong></td>
<td>433</td>
<td>1210</td>
</tr>
<tr>
<td>Age (years)</td>
<td>60.8 ± 12.6*</td>
<td>57.5 ± 13.1*</td>
</tr>
<tr>
<td>Gender (women)</td>
<td>304 (72.8%)</td>
<td>304 (72.8%)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.3 ± 15.3</td>
<td>74.2 ± 15.3</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>9.0 ± 8.9</td>
<td>10.0 ± 9.7</td>
</tr>
<tr>
<td>HAQ (0-3)</td>
<td>1.9 ± 0.6*</td>
<td>1.3 ± 0.8*</td>
</tr>
<tr>
<td>PGA (0-100)</td>
<td>63.5 ± 19.2</td>
<td>63.0 ± 21.5</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>12.8 ± 11.0</td>
<td>17.7 ± 10.7</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>25.3 ± 20.1*</td>
<td>22.5 ± 18.3*</td>
</tr>
<tr>
<td>TJC</td>
<td>8.8 ± 6.0</td>
<td>8.4 ± 5.7</td>
</tr>
<tr>
<td>SJC28</td>
<td>6.1 ± 4.6</td>
<td>5.9 ± 4.6</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.8 ± 10</td>
<td>4.7 ± 11</td>
</tr>
<tr>
<td>Bio-Experienced (yes)</td>
<td>226 (51.1%)</td>
<td>278 (60.2%)</td>
</tr>
<tr>
<td>N previous b/tsDMARDs</td>
<td>2.0 ± 1.9*</td>
<td>2.3 ± 2.2*</td>
</tr>
</tbody>
</table>
| Number given are mean ± SD or number, proportion. b=biologic; ts= targeted synthetic; HAQ= health assessment questionnaire, PGA= Patient Global assessment; CRP= C-reactive protein; ESR= erythrocyte sedimentation rate; TJC= tender joint count; SJC= Swollen joint Count; DAS28 = disease activity score based on the 28 joints; N= number. * Signifies p<0.05.
JAK INHIBITORS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: EXPLORING EARLY RESPONSE ON CENTRAL SENSITIZATION AND CATASTROPHISM SYMPTOMS

F. Salato1, M. Di Carlo1, M. Carotti2, L. Ceccharelli3, S. Fulginei1, S. Farah1, A. Giovangioni1, 1Università Politecnica delle Marche, Dipartimento Di Scienze e Molecolari, Ospedale “Carlo Urbani”; Jesi, Italy; 2Università Politecnica delle Marche, Dipartimento di Scienze Radiologiche, Ospedali Riuniti, Ancona, Italy; 3Azienda Ospedaliero-Universitaria Sant’Anna, Department of Interventional and Diagnostic Radiology, Ferrara, Italy

Background: Catastrophizing has been demonstrated to be linked with central sensitization (CS), although few studies have investigated the potential of interactions between catastrophizing and CS in patients receiving JAK inhibitors.

Objectives: To explore the link between changes in Simplified Disease Activity Index (SDAI) and changes in pain catastrophizing, pain intensity, neuropathic pain component (NPC) and CS symptoms that occur with the introduction of a novel treatment targeting the JAK/STAT signalling pathway.

Methods: 115 patients in an ongoing prospective observational analysis filled out questionnaires at the start and conclusion of the research, using the Pain Catastrophizing Scale (PCS) and Central Sensitization Inventory (CSI). The study included 22 patients on tofacitinib monotherapy (5 mg BD), 19 on tofacitinib and MTX, 17 on baricitinib monotherapy (4 mg OD), 17 on baricitinib and MTX, 17 on upadacitinib monotherapy (15 mg OD), 16 on upadacitinib and MTX, and 8 on filgotinib (200 mg OD) and MTX. The disease activity index was evaluated by the simplified disease activity index (SDAI). The US scoring system validated in the US-CLARA was used. The Semantic Questionnaire for Rheumatology (SOR) and PainDETECT questionnaire (PDQ), were used to assess pain severity and NPC. Using multivariable linear regression models, we investigated the connection between changes in SDAI and in CSI, PCS, PDQ, SQR and US score.

Results: At baseline, the percentage of RA patients who exceeded the thresholds for the presence of NPC (PDQ > 19 points) of the CSI (> 40 points) and PCS (> 30 points) were 43.5%, 36.5%, and 62.6%, respectively. After 4 weeks of treatment, the patient-reported scores and the disease composite index decreased significantly, SRO (p<0.0001), PDQ (p=0.0084), PCS (p=0.0066), CSI (p=0.0165) and SDAI (p<0.0001). The US score did not change significantly (5.25 to 5.03; p=0.248), SDAI achieved 10.6% remission and 15.2% low disease activity at week 4. Multivariate regression analysis indicated that changes in SDAI were exclusively connected to changes in catastrophizing (coefficient=0.500, P=0.0224).

Conclusion: After starting a Jak inhibitor, pain catastrophizing, but not articular inflammation on US, diminishes along with disease activity. These findings provide evidence to the concept of catastrophizing as a dynamic construct that may be adjusted by therapy aimed at reducing inflammatory disease activity and pain levels in the RA patient.

REFERENCES:

Table 1. Multivariate regression analysis, using SDAI (Simplified Disease Activity Index) changes as dependent variable.

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Coefficient</th>
<th>Std. Error</th>
<th>T</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Constant)</td>
<td>-0.7239</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACPA,titre</td>
<td>-0.0022410</td>
<td>0.002528</td>
<td>-0.0953</td>
<td>0.9242</td>
</tr>
<tr>
<td>Age, yrs</td>
<td>-0.09063</td>
<td>0.1028</td>
<td>-0.881</td>
<td>0.3803</td>
</tr>
<tr>
<td>BMI</td>
<td>-0.1600</td>
<td>0.2787</td>
<td>-0.574</td>
<td>0.5671</td>
</tr>
<tr>
<td>Disease duration, yrs</td>
<td>-0.1003</td>
<td>0.1611</td>
<td>-0.623</td>
<td>0.5347</td>
</tr>
<tr>
<td>Educational level, yrs</td>
<td>-0.1072</td>
<td>0.3703</td>
<td>-0.289</td>
<td>0.7728</td>
</tr>
<tr>
<td>Diff. CSI</td>
<td>0.3194</td>
<td>0.1984</td>
<td>1.610</td>
<td>0.1105</td>
</tr>
<tr>
<td>Diff. PDQ</td>
<td>0.07018</td>
<td>0.3726</td>
<td>0.188</td>
<td>0.8509</td>
</tr>
<tr>
<td>Diff US score</td>
<td>1.2248</td>
<td>0.7024</td>
<td>1.744</td>
<td>0.0842</td>
</tr>
<tr>
<td>Diff PCS</td>
<td>0.5009</td>
<td>0.2160</td>
<td>2.318</td>
<td>0.0224</td>
</tr>
<tr>
<td>Diff PDQ</td>
<td>0.1860</td>
<td>0.2271</td>
<td>0.819</td>
<td>0.4146</td>
</tr>
</tbody>
</table>

Abbreviations: ACPA= Anti-Citrullinated Protein/peptide Antibody; BMI= Body Mass Index; CSI= Central Sensitization Inventory; SRO= Semantic Questionnaire for Rheumatology; US=Ultrasonography; PCS= Pain Catastrophizing Scale; PDQ= PainDETECT Questionnaire.

THE EFFECT OF ANTIMALARIALS ON THE OVERALL SAFETY AND PERSISTENCE OF TREATMENT WITH BIOLOGIC AGENTS OR JAK INHIBITORS IN RHEUMATOID ARTHRITIS

M. Bredemeier1, A. Duarte1, M. Pinheiro1, B. Stadler2, J. C. Maceira2, R. Ranzza1, J. Miranda1, V. Valim3, G. Castro3, M. Bertolo4, M. D. F. Sauma1, V. Fernandes1, A. C. Medeiros-Ribeiro1, R. Botelho1, C. Brenol1, H. M. Da Silveira DE Carvalho1, S. Studart1, G. Da Rocha Castelan Pinheiro1, L. Rocha1, H. De Leon de Lima1, I. Pereira1, M. Ohira Gazzeta1, A. Kakehasi1, P. Louzada Jr1, A. L. S. Hayata1, F. Pina1, M. Pires Ferreira1, L. Balanini1, I. G. Silveira1, S. Kowalski1, D. Titton1, R. Mendonça Da Silva Chakr1, A. Ranzolin1, I. Laurindo1, R. Xavier1 on behalf of BiobadaBrasil. 1Brazilian Society of Rheumatology, Register BiobadaBrasil, São Paulo, Brazil

Background: Antimalarials (AM) are frequently part of the initial scheme of conventional synthetic DMARDs in the treatment of rheumatoid arthritis (RA), and have been associated with lower incidence of diabetes and better lipid profile in these patients (1). However, the role of AM in schemes involving biologic (b-) or targeted synthetic (ts-) DMARDs has been much less extensively studied. In addition, a recent large scale study (2) and a consensus article (1) casted doubt on the long-term cardiovascular safety of AM.

Objectives: To evaluate the association of concomitant use of AM with the overall safety and survival of treatment course among patients receiving one or multiple courses of bDMARDs or tsDMARDs.

Methods: BiobadaBrasil is a multicentric registry-based cohort study of Brazilian patients with rheumatic diseases starting their first bDMARD or tsDMARD (3). The present analysis includes RA patients recruited from Jan 2009 to Oct 2019, followed-up over one or multiple (up to six) courses of treatment (latest date, Nov 19, 2019). A treatment course is defined as a period during which the medication scheme does not change. The primary outcome was the incidence of serious adverse events (SAEs). Total and system-specific adverse events (AEs), treatment interruption for any reason, interruption due to AEs and due to inefficacy served as secondary outcomes. Negative binomial regression with generalized estimating equations (to calculate the incidence rate ratios [IRRs]) and extended (frailty) Cox proportional hazards models were used for statistical analyses (both types of analyses including time-varying covariates over multiple courses of treatment). Results: In total, 1316 patients (2335 treatment courses, 671 patient-years [PY]) were enrolled. The overall incidence of serious adverse events was 9.2/100 PY. AM were used over 354 courses (1254.5 PY) of therapy. The IRRs for the primary and secondary outcomes are presented in Table 1. AM were also associated with better treatment course survival (Figure 1), reducing the risk of interruption due to AEs (multivariate hazard ratio: 0.56, 95% CI: 0.39 to 0.81, P=0.002) and inefficacy (0.65, 0.48 to 0.87, P=0.003).

Disclosure of Interests: None declared
Table 1. Univariate and multivariate incidence rate ratios (IRRs) of adverse events comparing usage versus non-use (reference category) of antimalarials. Results are IRRs, 95% CIs, and P-values.

<table>
<thead>
<tr>
<th>Type of adverse event (n of events)</th>
<th>Crude analysis</th>
<th>Adjusted covariates*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serious adverse events (617)</td>
<td>0.60 (0.41 to 0.87), P&lt;0.007</td>
<td>0.51 (0.37 to 0.69), P&lt;0.001</td>
</tr>
<tr>
<td>Any adverse event (3494)</td>
<td>0.65 (0.54 to 0.77), P&lt;0.001</td>
<td>0.68 (0.57 to 0.81), P&lt;0.001</td>
</tr>
<tr>
<td>Cardiovascular†</td>
<td>1.04 (0.49 to 2.20), P&lt;0.001</td>
<td>1.06 (0.48 to 2.50), P&lt;0.001</td>
</tr>
<tr>
<td>Total (163)</td>
<td>0.90 (0.59 to 1.38), P&lt;0.002</td>
<td>0.93 (0.59 to 1.45), P&lt;0.737</td>
</tr>
<tr>
<td>Infections</td>
<td>0.78 (0.44 to 1.39), P&lt;0.404</td>
<td>0.53 (0.34 to 0.83), P&lt;0.006</td>
</tr>
<tr>
<td>Total (1400)</td>
<td>0.77 (0.61 to 0.96), P&lt;0.003</td>
<td>0.70 (0.56 to 0.94), P&lt;0.014</td>
</tr>
<tr>
<td>Hepatic</td>
<td>0.20 (0.07 to 0.64), P&lt;0.001</td>
<td>0.16 (0.04 to 0.57), P&lt;0.055</td>
</tr>
<tr>
<td>Total (34)</td>
<td>0.74 (0.29 to 1.92), P&lt;0.540</td>
<td>0.73 (0.26 to 2.00), P&lt;0.535</td>
</tr>
<tr>
<td>Dyslipidemia control-related</td>
<td>0.60 (0.31 to 1.13), P&lt;0.514</td>
<td>0.55 (0.28 to 1.06), P&lt;0.074</td>
</tr>
</tbody>
</table>

*Age, baseline DAS28, disease duration, gender, smoking, seropositivity (RF or anti-CCP), previous malignancy, interstitial lung disease, diabetes, hypertension, hypercholesterolemia, renal failure, ischemic cardiomyopathy, COPD, heart failure, concomitant use of each cs-, b-, and dMDMARDs, corticosteroids, starting year, osteoporosis, hepatitis B and C, and treatment sequence. †Excluding infections.

Conclusion: Among RA patients on treatment with bMDMARDs or tsMDMARDs, concomitant use of antimalarials reduced the incidence of serious and total AEs, including infections and hepatic AEs, and prolonged treatment course survival. No significant increase in the risk of cardiovascular AEs was observed.

REFERENCES:

Disclosure of Interests: None declared

Small vessels on fire

POS0244

ASSOCIATION OF PROTEINASE 3 GENE (PRPTN) VAL119ILE POLYMORPHISM (SNP RS351111) WITH RISK OF RELAPSE AMONG HOMOZYGOUS PATIENTS WITH PR3 ANCA-ASSOCIATED VASculITIS

M. Casal Moura1, Z. Deng2, S. Brooks2, W. Teal2, A. Hummel1, F. Fervenza3, C. Kallenberg1, C. Langford4, P.A. Merkel5, P.A. Monach6, P. See7, R. Spiera8, W. St. Clair9, J. H. Stone10, M. Prunotto11, P. Grayson12, S. Specks1. 1Mayo Clinic, 2Thoracic Disease Research Unit, Division of Pulmonary & Critical Care Medicine, Department of Medicine, Rochester, United States of America; 3National Institute of Health, Translational Autoinflammatory Diseases Section (TADS), NIAD/NIH, Bethesda, United States of America; 4Genentech Inc., a member of the Roche Group, I2O Technology & Translational Research, San Francisco, United States of America; 5Mayo Clinic, Division of Nephrology and Hypertension, Department of Medicine, Rochester, United States of America; 6University of Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 7Cleveland Clinic, Rheumatology, Cleveland, United States of America; 8University of Pennsylvania, Division of Rheumatology, Department of Medicine, Division of Clinical Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, Philadelphia, United States of America; 9University of Boston, Rheumatology, Boston, United States of America; 10Johns Hopkins Medicine, Rheumatology, Baltimore, United States of America; 11Weill Cornell Medical College, Hospital for Special Surgery, Rheumatology, New York, United States of America; 12Duke University, Rheumatology, Durham, United States of America. 13University of Geneva, Medicine, Geneva, Switzerland

Background: The frequency of the proteinase 3 gene (PRPTN) polymorphisms in patients with ANCA-associated vasculitis (AAV) is not well characterized. We hypothesize that PRPTN3 gene polymorphisms induce allostatic changes in PR3 conformation which may alter its interaction with ligands and PR3-ANCA during inflammation with potential implications for disease presentation and clinical outcomes.

Objectives: To analyze the association of PRPTN3 Val119Ile polymorphism (SNP rs351111) with risk of relapse among homozygous patients with PR3 ANCA-associated vasculitis.

METHODS: DNA variant calling for SNP rs351111 (chr.19:844020, c.355G>A) in PRPTN gene assessed the allelic frequency in patients with PR3-AAV included in the Rituximab versus Cyclophosphamide (RAVE) trial. This was followed by RNA-seq variant calling for SNP rs351111 (chr.19:844020, c.355G>A) in PRPTN gene assessed the allelic frequency in patients with PR3-AAV included in the Rituximab versus Cyclophosphamide (RAVE) trial. This was followed by RNA-seq variant calling to characterize the mRNA expression. We compared clinical presentation and outcomes between patients homozygous for PR3-Val119Ile and PR3-Val119.

RESULTS: Serum samples for DNA calling were available in 188 of the 197 patients with AAV in the RAVE cohort. 75 PR3-AAV patients had the allelic variant was found in 35 PR3-AAV patients: 13 patients were homozygous for PR3-Ile119 and 62 patients were heterozygous PR3-Val119Ile with an allele frequency threshold of 29.3 – 55.1% of reads (Figure 1A and 1B). RNA-seq was available for 89 patients and the mRNA expression corresponding to the allelic variant was found in 35 PR3-AAV patients: 13 patients were homozygous for PR3-Ile119 and 22 patients were heterozygous PR3-Val119Ile with an allele frequency threshold of 11.1 – 62.8% of reads (Figure 1A and 1C). The agreement between the DNA calling results and the mRNA expression of the 86 patients that overlapped was 100%. We found an additional homozygous patient for PR3-Val119 in which blood was not available for DNA calling.


Financial support: This study was funded by the School of Allied Health Postgraduate scholarship at the University of Limerick.

Acknowledgements: This work was funded by the School of Allied Health Postgraduate scholarship at the University of Limerick.

Disclosure of Interests: None declared

We compared the clinical presentation and outcomes of 74 patients with PR3-AAV: 13 homozygous for PR3-Ile and 51 homozygous for PR3-Val (Table 1). The frequency of severe flares at 18 months in homozygous PR3-Ile was ≥2x higher when compared with homozygous PR3-Val (46.2% vs. 19.6%, p=0.048). We found no differences in clinical presentation.

**Figure 1.** RAVE trial population distribution according to the zygosity status for PRTN3 gene (PR3 and MPO-ANCA patients) and DNA or RNA variant calling (panel A). Allelic frequency for rs351111, chr19:844020 (c.355G>A) in PRTN3 among patients with AAV (PR3 and MPO-ANCA) in the DNA (panel B) and RNA (panel C) variant calling.

| Table 1. Outcomes of patients with PR3-ANCA according with PRTN3 zygosity. |
|-----------------------------|-----------------------------|-----------------------------|
| PR3-ANCA (n=64)             | Homozygous PR3-Val (n=51)   | Homozygous PR3-Ile (n=13)   |
| **Remission, n (%)**        | 45 (88.2)                   | 13 (100)                    |
| Complete remission, n (%)   | 36 (70.6)                   | 10 (76.9)                   |
| Any flare 18 months, n (%)  | 30 (58.8)                   | 7 (53.8)                    |
| Severe Relapse 18 months, n (%) | 10 (19.6) | 6 (46.2) | 0.048 |

*Relapse was considered “Severe” if Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) > 3 or one major item as per the RAVE trial definition.

**Conclusion:** In patients with PR3-AAV the presence of PRTN3 Val allele polymorphism was associated with higher frequency of severe relapse. Further studies are necessary to understand the association of this observation with the risk of severe relapse.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4977

**POSO245**

**PROTEIN PROFILING IN PRE-SYMPTOMATIC ANCA-ASSOCIATED VASULITIS INDIVIDUALS.**

M. Brink, E. Berglin, A. J. Mohammd, A. Alexyenko, K. Lejon, S. Rantapää Dahlqvist, Umeå university, Public Health and Medicine/Rheumatology, Umeå, Sweden; Lund University, Clinical Sciences/Rheumatology, Lund, Sweden; University of Cambridge, Department of Medicine, Cambridge, United Kingdom; Karolinska Institute, Department of Microbiology, Stockholm, Sweden; Umeå universitet, Department of Clinical Microbiology, Umeå, Sweden

**Background:** Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a chronic relapsing condition, with unknown etiology.

**Objectives:** This study was undertaken to gain insight to the molecular processes and to find potential biomarkers in blood samples collected prior to the onset of symptoms of AAV.

**Methods:** The National Patient Register and Cause of Death register were searched for AAV-ICD codes and linked to the registers of five biobanks. Eighty-five AAV cases were included. For each case two controls matched for sex, age, and sampling date were included. Samples were analyzed using ELISAs for PR3- or MPO-ANCA specificities. Ninety-two protein markers were analyzed using Olink Inflammation panel (OLINK, Uppsala, Sweden) with 73 eligible after quality control.

**Results:** Eight protein markers were significantly altered between pre-AAV and controls, with higher levels of CCL23, CXCL5 (p< 0.01-0.05) and lower levels of Fli3L, STAMBPL, ADA, TNFB, CX3CL1 and IL-15RA (p< 0.01-0.05) in the pre-AAV individuals. Nine protein markers were found significantly associated with time to symptom onset; CXCL9, CD344, VEGFA, CXCL1, TNFSP5, CPG, CSF-1, IFN-gamma and DDAO (p< 0.01-0.05). In pre-AAV individuals, six proteins were associated with MPO-ANCA-positivity compared with the MPO-ANCA-negative pre-AAV individuals which showed no overlap with the seven proteins related to PR3-ANCA-positivity.

**Conclusion:** To our knowledge our study is the first to analyze for and identify protein markers before symptom onset in AAV. This allowed for further studies of underling cellular and molecular mechanisms in pre-AAV patients as well as the diversification into PR3-ANCA and MPO-ANCA subphenotypes.

**Disclosure of Interests:** Mikael Brink: None declared, Ewa Berglin: None declared, Aladdin J Mohammad Speakers bureau: Roche, Gsk, AMGEN; Vifor; Lilly, Consultant of: Roche & AMGEN, Andrey Alexeyenko: None declared, Kristina Lejon: None declared, Solbritt Rantapää Dahlqvist: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1207
systemic manifestations (19/34; 56%), or of both systemic and respiratory symptoms (11/34; 32%). All except one patient were receiving oral corticosteroids, at a median dosage of 25 mg/day (10-38). Mepo was started after a median of 14 months (6-23) from RTX initiation and after a median of 5 months (IQR 3-11) from the last RTX administration. Mepo was used at the dosage of 1000mg/4 weeks in 32/34 (94%), mostly for the control of respiratory manifestations (25/34, 74%). At the time of starting Mepo, the median BVAS was 4 (2-8), and the median prednisolone dose 10 mg/day (7-15). After a median follow-up of 28 months (IQR 23-33) from starting Mepo, the median BVAS decreased to 1.5 (IQR 0-4) and the median corticosteroid dosage to 5 mg/day (2.5-5), with 7/34 (21%) patients being off steroids. At last follow-up, most patients were off RTX (28/34), typically due to stable disease remission (20/34; 59%).

Both RTX and Mepo were well-tolerated; 5 patients had adverse events on RTX (none serious), and 5 on Mepo (including one serious infection).

Conclusion: Sequential use of RTX and Mepo seems to be effective for remission induction and maintenance in EGPA.


Table 1. Effectiveness of sequential RTX and Mepo in the 34 patients included in the study

<table>
<thead>
<tr>
<th>RTX beginning</th>
<th>Mepo beginning</th>
<th>Last follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median time elapsed (IQR)</td>
<td>-</td>
<td>14 months (6-23)</td>
</tr>
<tr>
<td>RTX beginning from Mepo</td>
<td>1g q2w (26/34); 100mg/4 weeks (32/34)</td>
<td>6 patients off RTX</td>
</tr>
<tr>
<td>Dosage (median, IQR), mg/day</td>
<td>375mg/m² for 4 weeks (8/34)</td>
<td>100mg/4 weeks (7-15)</td>
</tr>
<tr>
<td>Reason for treatment beginning (manifestations)</td>
<td>Systemic + respiratory (11/34); Only respiratory (3/34); Other (1/34)</td>
<td>Systemic (4/34); Remission maintenance (3/34);</td>
</tr>
<tr>
<td>BVAS (median, IQR)</td>
<td>9 (6-14)</td>
<td>4 (2-8)</td>
</tr>
<tr>
<td>Prednisolone dosage (median, IQR), mg/day</td>
<td>25 (10-38)</td>
<td>10 (7-15)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Alessandra Bettoli: None declared, Maria Letizia Urban: None declared, Federica Bello: None declared, Davide Fiori: None declared, Irene Mattioni: None declared, Giuseppe Lupalco: None declared, Florenzo Iannone: None declared, Allyson Egane: None declared, Luca Moroni: None declared, Lorenzo Dagna Consultant of: Consultation honoraria from GSK outside the current work, Marco Caminati: None declared, Simone Negri: None declared, Paolo Cameli: None declared, Marco Folci: None declared, Paola Toniati: None declared, Roberto Padoan: None declared, Olivier Flossmann: None declared, Roser Solans-Laqué: None declared, Laura Losappio: None declared, Jan Schroeder Consultant of: Advisory Board fees from AstraZeneca, whereas secondary outcome included the incidence of infectious events compared. Primary outcome was defined as relapse-free days from treatment initiation, whereas secondary outcome included the incidence of infectious events requiring hospitalization within 48 weeks from treatment initiation. Multivariable analysis was performed to assess the relationship between tapering pace and clinical outcomes.

Methods: In this multicenter (25 sites in Japan), observational, retrospective study of AAV, 541 patients who had initial or severe relapse were enrolled between January 2017 and June 2020. Of these, 500 patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) who entered in the GC dose, clinicians often taper it slower than recommended due to concerns of potential disease relapse. However, such slower taper may prolong GC exposure for the patients, increasing the risk of adverse events, particularly infection.

Objectives: The aims of our study were (1) to clarify GC dose tapering in the treatment of AAV in a real-world setting, in contrast to the EULAR recommendation of 2015 and (2) to compare the incidence of AAV relapse and severe infection between patients underdosing EULAR-recommended tapering and those undergoing slower tapering than the recommendation.

Background: Antineutrophil cytoplasmic antibody -associated vasculitis (AAV) is usually treated with combination of high-dose glucocorticoid (GC) and immunosuppressive agents, followed by tapering GC dose. Although the European League Against Rheumatism (EULAR) has specific recommendations for tapering the GC dose, clinicians often taper it slower than recommended due to concerns of potential disease relapse. However, such slower taper may prolong GC exposure for the patients, increasing the risk of adverse events, particularly infection.

Objectives: The aims of our study were (1) to clarify GC dose tapering in the treatment of AAV in a real-world setting, in contrast to the EULAR recommendation of 2015 and (2) to compare the incidence of AAV relapse and severe infection between patients underdosing EULAR-recommended tapering and those undergoing slower tapering than the recommendation.

Methods: In this multicenter (25 sites in Japan), observational, retrospective study of AAV, 541 patients who had initial or severe relapse were enrolled between January 2017 and June 2020. Of these, 500 patients with microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) who entered in GC tapering phase after successful induction treatment were included. These patients were then grouped on the pace of GC tapering, defined as the GC dose at 12 weeks after treatment initiation: (1) EULAR group: 7.5-10 mg/day of GC, according to the EULAR recommendation of 2015, and (2) SLOWER group: >10 mg/day of GC. Their baseline characteristics and clinical outcomes were compared. Primary outcome was defined as relapse-free days from treatment initiation, whereas secondary outcome included the incidence of infectious events requiring hospitalization within 48 weeks from treatment initiation. Multivariable analysis was performed to assess the relationship between tapering pace and clinical outcomes.

Results: There were 44 patients (12.6%) in the EULAR group and 290 (83.2%) in the SLOWER group. Regarding baseline characteristics, compared with the EULAR group, the SLOWER group had significantly higher serum C-reactive protein level (EULAR, 5.89 ± 6.89 mg/dL vs SLOWER, 7.56 ± 6.01 mg/dL; p = 0.03), as well as a trend toward higher Birmingham Vasculitis Activity Score
Subclinical PMR has a predilection for affection of large vessels, followed by isolated cranial pattern (i.e. isolated temporal artery involvement) and with clearly different pattern than classical GCA.

Conclusion: Subclinical GCA in PMR shows a principal isolated extra-cranial involvement and with clearly different pattern than classical GCA.

Acknowledgements: To the GCA/PMR study group

Subclinical PMR has a predication for affection of large vessels, followed by isolated cranial pattern (i.e. isolated temporal artery involvement) and with the mixed (cranial and extra-cranial) form. On the contrary, in classical GCA an isolated cranial involvement represents the more common pattern, followed by the mixed and finally isolated large vessel involvement.

Conclusion: Subclinical GCA in PMR shows a principal isolated extra-cranial involvement and with clearly different pattern than classical GCA.

Acknowledgements: To the GCA/PMR study group

Disclosure of Interests: None declared

---

Figure 1. Subtypes of vessel affection in Subclinical GCA in PMR and in classical GCA

Table 1. Clinical characteristics of patients of Cohort A (Subclinical GCA in PMR n = 41/216) and B (GCA in the fast-track clinic n = 97)

<table>
<thead>
<tr>
<th>Cohort A (n = 41)</th>
<th>Cohort B (n = 97)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex female (%)</td>
<td>17 (41.5%)</td>
</tr>
<tr>
<td>Age (years) mean ± SD</td>
<td>71±6.7</td>
</tr>
<tr>
<td>CRP mg/L</td>
<td>49.6±49.1</td>
</tr>
<tr>
<td>Polymygina rheumatica</td>
<td>41 (100%)</td>
</tr>
<tr>
<td>Constitutional symptoms</td>
<td>19 (46.5%)</td>
</tr>
</tbody>
</table>

---

POS0249

FIBROBLAST ACTIVATION PROTEIN AS A LINK BETWEEN INFLAMMATION AND VASCULAR REMODELING IN GIANT CELL ARTERITIS

S. Xu1, W. F. Jiem1, A. Boots1, Y. Van Sleen1, K. Van der Geest1, P. Heeringa2, E. Brouwer1, M. Sandoval1. 1University Medical Center Groningen, University of Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 2University Medical Center Groningen, University of Groningen, Department of Pathology and Medical Biology, Groningen, Netherlands

Background: Giant cell arteritis (GCA) can present with serious complications such as blindness, stroke and aortic aneurysm that are related to both inflammation and remodeling of the vessel wall. GCA frequently overlaps with polymyalgia rheumatica (PMR). The pathogenesis of GCA starts in the adventitia where fibroblasts are the major stromal cell population. A preliminary study reported the migration of adventitial fibroblasts to the intima, contributing to intimal hyperplasia. Such a role for adventitial fibroblasts in early stages of GCA was observed in an animal model. In patients with GCA and PMR, fibroblast activation protein (FAP) is involved in GCA vascularopathy due to its pro-inflammatory and pro-fibrotic effects.

Objectives: As a first step to unravel the contribution of FAP to the vasculopathy in GCA, we determined FAP plasma levels and FAP protein expression at the site of vascular inflammation in GCA.

Methods: Eight rheumatology European centers participated in the study. Cohort A represented consecutive newly diagnosed patients with PMR who fulfilled the 2012 EULAR/ACR Provisional Classification Criteria for Polymyalgia Rheumatica and had no symptoms or signs suggestive of GCA. Ultrasound (US) examination of four vessel territories (i.e. temporal, carotid, subclavian and axillary arteries) was performed bilaterally. Cohort B included all consecutive patients with the diagnosis of GCA evaluated on the fast-track clinic of one of the hospitals (HULP). The halo sign was considered as positive US finding for GCA. In addition, intima-media thickness of arteries was measured, with a cut-off 0.34 mm for temporal arteries (TA) frontal and parietal, 0.42 mm for common TA, and ≥1 mm for common carotid, axillary and subclavian arteries for positive result. The clinical characteristics of PMR patients were recorded and the frequency of subclinical GCA determined.

Results: Cohort A included 41 PMR patients with subclinical GCA. Cohort B was formed by 97 GCA. The characteristics of the patients are shown in the Table 1. Figure 1 shows the different subtypes of vessel involvement in patients with PMR and subclinical GCA and in patients of the fast-track clinic with the diagnosis of GCA in a single hospital.

Subclinical PMR can be a condition of serious complications such as blindness, stroke and aortic aneurysm that are related to both inflammation and remodeling of the vessel wall. GCA frequently overlaps with polymyalgia rheumatica (PMR). The pathogenesis of GCA starts in the adventitia where fibroblasts are the major stromal cell population. A preliminary study reported the migration of adventitial fibroblasts to the intima, contributing to intimal hyperplasia in GCA. Fibroblast activation protein (FAP) is a non-classical serine protease which can be present in both a membrane-bound form and a soluble form and has been demonstrated to promote inflammation and fibrosis in coronary artery disease and rheumatoid arthritis. We hypothesize that FAP is involved in GCA vascularopathy due to its pro-inflammatory and pro-fibrotic effects.

Objectives: As a first step to unravel the contribution of FAP to the vasculopathy in GCA, we determined FAP plasma levels and FAP protein expression at the site of vascular inflammation in GCA.

---

Science Abstracts

Methods: In our prospective cohort of GCA, PMR and healthy elderly (GPS), we measured the plasma FAP levels with ELISA in new-onset, treatment-naive GCA (N=62), and PMR (N=63) patients and 42 age-matched healthy controls (HC). In addition, we measured the plasma FAP levels at follow-up (3-months, 1-year, 1.5-year and treatment-free remission (TFR)). Temporal artery biopsies (TAB) from treatment-naive GCA patients (n=9) and non-GCA patients (n=9), aorta samples from GCA-related aneurysm (n=9) and atherosclerosis (n=11) were stained for FAP using immunohistochemistry. Immunofluorescence staining for CD90, CD68, αSMA and FAP was performed to detect FAP expression in fibroblasts, macrophages and vascular smooth muscle cells (VSMC), respectively.

Results: Baseline plasma FAP levels were significantly lower in GCA patients (52.72±2.93 ng/ml) than in PMR patients (66.42±2.86 ng/ml) and HC (80.47±3.38 ng/ml). FAP levels at baseline correlated inversely with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin (IL)-6, macrophage-associated protein YKL-40 (Chitinase 3-like 1/CHI3L1) levels and monocyte counts. Plasma FAP levels in GCA patients decreased even further at 3 months (37.23±2.10 ng/ml) upon glucocorticoid-induced remission, and 20 with MPA (19.2%). mtDNA levels were significantly elevated in AAV plasma (8.7±10^7 copies/ml plasma, 95% CI: 5.3±10^7 to 1.3 ±10^8), compared to HC plasma (6.7±10^7 copies/ml plasma, 95% CI: 5.4±10^7 to 9.1±10^7, p<0.0001). mtDNA levels in contrast did not differ between AAV (4.0±10^6 copies/ml plasma), 95% CI: 2.7±10^6 to 5.0±10^6) and HC (3.3±10^6 copies/ml plasma, 95% CI: 2.4±10^6 to 4.7±10^6, p=0.30). ROC analysis showed that a cut-off value of 1.3±10^7 mtDNA copy numbers differentiated between AAV and HC with 89.4% sensitivity, 82.6% specificity and an AUC of 0.94. For AAV patients with active AAV, a cut-off value of 2.9±10^7 mtDNA copy numbers differentiated between AAV and HC with 96.1% sensitivity, 98.9% specificity and an AUC of 0.99 (Figure 1a).

Conclusion: FAP expression is clearly modulated both in plasma and at the site of vascular inflammation in GCA and may represent a pathogenic link between the inflammatory and remodeling processes in GCA. As such, FAP may have utility as a biomarker and should be further investigated as target for therapeutic intervention.

REFERENCES:

POS0250 PLASMA MITOCHONDRIAL DNA AS A BIOMARKER IN THE DIAGNOSIS AND FOLLOW-UP OF ANCA-ASSOCIATED VASCULITIDES

S. Giaglis1, 2, D. Kyburz1, 2, J. Thiel1, N. Venhoff2, U. Walker1, 2
1University of Basel, Department of Biomedicine, Experimental Rheumatology Laboratory, Basel, Switzerland; 2University Hospital of Basel, Department of Rheumatology, Basel, Switzerland

Background: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) include granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (1, 2). ANCA recognize the antimicrobial proteins proteinase 3 (PR3) or myeloperoxidase (MPO) (1,2) and trigger the formation of neutrophil extracellular traps (NETs), which release DNA into the extracellular space and systemic circulation. This cell-free (cf)DNA induces endothelial damage, vascular inflammation and necrosis (3).

Objectives: The nature, diagnostic and prognostic value of cfDNA in AAV is still unknown. The aim of the present study was to examine the clinical utility of cfDNA quantification as a biomarker in AAV.

Methods: Total DNA was isolated from platelet-free plasma samples of healthy controls (HC) and consecutive AAV patients. Plasma and clinical data were collected at baseline and follow-up. Copy numbers were quantified by qPCR for mtDNA (ATP-6 gene) and nuclear (n) DNA (GAPDH gene) (4). Patients with eosinophilic GPA (EGPA) were excluded.

Results: Ninety-two HC (median age 51 ± 9, 48.2% female) and 104 AAV patients (median age 64 ± 10, 48% female, mean BVAS: 0; range: 0-40) were available for analysis. Eighty-four (80.8%) of these patients were diagnosed with GPA, and 20 with MPA (19.2%). mtDNA levels were significantly elevated in AAV plasma (8.7±10^7 copies/ml plasma, 95% CI: 5.3±10^7 to 1.3 ±10^8), compared to HC plasma (6.7±10^7 copies/ml plasma, 95% CI: 5.4±10^7 to 9.1±10^7, p<0.0001). mtDNA levels in contrast did not differ between AAV (4.0±10^6 copies/ml plasma, 95% CI: 2.7±10^6 to 5.0±10^6) and HC (3.3±10^6 copies/ml plasma, 95% CI: 2.4±10^6 to 4.7±10^6, p=0.30). ROC analysis showed that a cut-off value of 1.3±10^7 mtDNA copy numbers differentiated between AAV and HC with 89.4% sensitivity, 82.6% specificity and an AUC of 0.94. For AAV patients with active AAV, a cut-off value of 2.9±10^7 mtDNA copy numbers differentiated between AAV and HC with 96.1% sensitivity, 98.9% specificity and an AUC of 0.99 (Figure 1a).

With the exception of the peripheral nervous system involvement, there was no association of mtDNA elevation with any particular type of active organ involvement at the time of blood sampling. A positive correlation between all cell-free DNA species and anti-MPO antibody titres was observed, as expected (for cfDNA, nDNA and mtDNA - r=0.25, p=0.01; r=0.21, p=0.02; r=0.22, p=0.02, respectively).

AAV patients with active disease (BVAS>0) had a mean of 2.0±10^7 copies/ml of mtDNA in plasma which was higher compared to HC (p<0.0001) and AAV patients in remission (BVAS=0) (6.2±10^7 copies/ml, p<0.03). For nDNA on the other hand, there were similar levels in active disease as in remission (3.5±10^7 and 4.8±10^7 copies/ml, respectively; p=0.64) (Figure 1b).

Follow-up data were available for 27 AAV patients (median follow-up: 6 ± 6 months, IQR: 12). Longitudinal changes in mtDNA levels robustly correlated with changes in BVAS (r=0.56, p<0.002, Figure 1c).

Conclusion: The quantification of cell free mtDNA - but not nDNA - copy numbers allows a sensitive and specific distinction between healthy individuals and patients with active AAV. mtDNA levels correlate cross sectionally with disease activity in AAV patients. Plasma mtDNA quantification may therefore aid in the diagnosis of AAV and in monitoring AAV activity.

REFERENCES:

DISCLOSURE OF INTERESTS: None declared.

Background: Giant cell arteritis (GCA) is a chronic disease, and affected patients suffer from relapses and glucocorticoid (GC)-related toxicity. Targeted therapies are emerging with the aim of achieving better disease control and reducing GC exposure. Blocking IL-6 receptor with tocilizumab has been a major advance in the treatment of GCA. However, approximately 40% of patients treated with tocilizumab in combination with GCs experience a flare or tocilizumab-related adverse event. Blockade GM-CSF receptor α with mavrilimumab significantly reduced risk of relapse and improved sustained remission at week 26 vs placebo in Phase 2 trial. Not all patients satisfactorily respond to any therapy, indicating heterogeneity in leading pathogenic pathways among patients. For these reasons, it is crucial to understand the specific impact of targeted therapies on vascular lesions.

Objectives: In this study we investigated transcriptomic changes induced by tocilizumab or mavrilimumab in ex vivo cultured arteries from patients with GCA. Genes were selected for validation based on high level of expression and differential changes elicited between treatments. Of those, only 9 transcripts remained significant after correction for multiple comparisons, with a false discovery rate ≤0.05. 81 transcripts were differentially expressed in at least one comparison across groups (Figure 1A). 15 transcripts were lower, and 6 were higher in the mavrilimumab group vs placebo; 3 transcripts were lower, and 2 were higher in the tocilizumab group vs placebo. Most changes elicited between treatments were unique, but CXCL1 was common (Figure 1B). None remained significant after correction for multiple comparisons. The effects of mavrilimumab and tocilizumab on GNAS, CXCL1, IL8, IL2, IRF3, MRC1 and BCL6 expression by Nanostring were consistent with the effect assessed using real time PCR in the separate validation cohort (Figure 1C).

Conclusion: Mavrilimumab and tocilizumab have a different transcriptomic impact on cultured arteries from patients with GCA, with some overlapping effects, although differential effects may have been attenuated by prior GC use. A better understanding of the impact of targeted therapies on vascular inflammation is needed to improve treatment options for patients with GCA.

Disclosure of Interests: The authors would like to thank: the Genomics core facility of the Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Emily Plummer, PhD, Kiniksa Pharmaceuticals, for her invaluable contribution. The study was funded by Kiniksa Pharmaceuticals, Ltd. With support from: Fundació Clinic Barcelona, Fundació Privada Cellex, IDIBAPS, Universitat de Barcelona, Vasculitis Foundation, Marie Curie Actions, and Gobierno de España, Ministerio de Economía, Industria, y Competitividad.

mononuclear cells (PBMC) and vascular cells thus obtained were co-cultured for 7 days in different conditions. Vascular cells were cultured in the presence or absence of IFN-γ and tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6) and were treated with IL-6 for 72 hours. When cells reached confluence, they were cultured alone or with allogenic PBMC activated with anti-CD3/CD28 microbeads. After 7 days of culture, cells were separated with a treatment with EDTA and studied by flow cytometry.

**Results:** Confocal microscopy analyses of GCA arteries showed that neointima was mainly composed of myofibroblasts (MF) (α-SMA+Desmin+MHC11lowCD90+) in contact with CD45+ cells and that MF expressed HLA-DR, the phosphorylated form of STAT1 (pSTAT1) and in a lesser extent pSTAT3, strongly suggesting the activation of the IFN-γ signaling pathway rather than the IL-6 pathway. The phenotype of cultured vascular cells isolated from fresh TAB was consistent with MF. When MF were exposed to IFN-γ and TNF-α in vitro, their proliferation capacity decreased and their levels of expression of HLA-DR and CD86 increased (median fluorescence intensity [MF]) from 0 to 57 (p<0.03) and from 34 to 103 (p=0.03), respectively. In addition, co-cultures of MF and activated PBMC revealed that MF maintained the polarization of T cells into Th1 and Th17 cells (p≤0.001) and to a lesser extent into Th17 and Tc17 cells (p=0.03). This effect was even more significant when MF were previously exposed to IFN-γ and TNF-α but not when they were exposed to IL-6.

**Conclusion:** Our results show that myofibroblasts are present in the neointima of GCA patients and that these MF activate signalling pathways indicative of IFN-γ exposure. Moreover, these MF, especially when exposed to IFN-γ, maintain the polarization of T cells into Th1 and Th17 cells, which contributes to amplify the production of IFN-γ and thus initiate a pro-inflammatory amplification loop that likely participates in vascular inflammation and remodelling.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3546

**POS0253**

**PERSONALIZED RISK EVALUATION FOR OUTCOME PREDICTION IN ANCA ASSOCIATED VASCULITIS (AAV) USING LATENT CLASS ANALYSIS AND MACHINE LEARNING.**


**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1089

**Vaccination against SARS-CoV-2.**

E. G. Favalli1,2,3, A. Favalli1,2,3, G. Andrea1,2,3, G. Majoli1,2,3, E. Zagato4, M. Bombaci4, E. Pesce5, L. Donnici5,3, P. Gruarin6,5, M. Biggiogero6,7, S. Curti6,7, L. Mangarano6,7, F. Mutschis6,7, V. Beilacovic6,7, T. Faustino6,7, M. Crosti6,7, L. Marongiu3,5, F. Granucci6,7, S. Notabartolo6,7, A. Bandera2,8,9, A. Gori1,10, R. De Francesc10, S. Abrignani10, R. Caporal10,11, R. Grittani12 on behalf of MAINSTREAM Project. "ASST Pino Cito Institute, Division of Clinical Rheumatology, Milano, Italy; University of Milan, Department of Clinical Sciences & Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy; "INO M. Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milano, Italy; DiaPro, Diagnostic Bioprobes srl, Milan, Italy; Universe Italia dei Studi di Milano Bicocca, Department of Biotechnology and Biosciences, Milano, Italy; Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Infectious Diseases Unit,
Background: Rheumatic musculoskeletal diseases (RMD) are pathological conditions characterized by an impaired immunological system that is determinant both in the pathogenesis and in the inadequate response to infections. The use of disease-modifying anti-rheumatic drugs (DMARDs), which include conventional synthetic (cs) or biologic and targeted synthetic (bs) DMARDs, contribute to compromise immunological reactivity.

Objectives: To analyze the immune response to SARS-CoV-2 in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA) receiving treatment with DMARDs and to investigate the effect of the different classes of drugs on humoral and cellular response.

Methods: Patients were tested for anti-SARS-CoV-2 IgG, IgM and IgA antibodies to nucleoprotein (N) and receptor-binding domain (RBD) through ELISA and neutralization assays. Then, we performed a flow cytometry analysis of monocytes, NK cells, B and T lymphocytes from PBMCs of serologically positive patients. We also included a cohort of non-RMD individuals recovered from COVID-19 as a reference group of non-immunosuppressed subjects. A first recruitment occurred in May-June 2020 (T1) and a second recruitment, 3-4 months after (T2), allowed to evaluate the persistence of the antibody response over time and to investigate the cellular immune response to SARS-CoV-2 in RMD patients having resolved the infection.

Results: During T1, 358 patients with RA (n=200) or SpA (n=158) were recruited. Mean age was 52.8, 62% were female. All patients were treated with DMARDs: 299 with b/tsDMARDs and 59 received csDMARDs alone. One third was also receiving corticosteroids (CS). At T2, 36 subjects were recruited. We found a seroprevalence rate of 18.4%, which did not significantly differ between RA and SpA groups, and between patients treated with b/ts-DMARD or csDMARDs, either alone or in combination with CS (Table 1). Antibody levels of RMD patients were lower than non-RMD individuals (Figure 1), with CTLA4-Ig-treated patients having the lowest IgG levels. This difference was less marked in symptomatic RMD patients. 72% of seropositive patients elicited neutralizing sera. Despite an overall decrease in anti-RBD and anti-N titers, more than two-third of patients treated with b/tsDMARD had significant impaired antibody response compared to patients treated with other biologic and targeted synthetic disease modifying anti-rheumatic drugs (csDMARD).

Conclusion: Our data provide a comprehensive picture of the humoral and cellular immune responses to SARS-CoV-2 infection in RMD patients. We showed that DMARDs treatments did not alter a successful antibody response to the virus and did not hamper the antibody neutralizing ability. However, the magnitude of antibody response was slightly reduced compared to non-RMD individuals, especially in patients receiving CTLA4-Ig. We did not observe marked differences in the B- and T-cell populations between RMD patients compared to non-RMD individuals. However, in patients receiving anti-TNFα we found a higher relative abundance of effector adaptive population compared to other bDMARDs.

Disclosure of Interests: None declared.

Table 1. Predictors of good antibody response to two doses of COVID-19 vaccine defined as antibodies over the cut-off level for both spike antigens

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>p-value</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at vaccination (years)</td>
<td>-0.04</td>
<td>0.009</td>
<td>0.96</td>
<td>0.93-0.99</td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>-9.55</td>
<td>0.209</td>
<td>0.58</td>
<td>0.24-1.36</td>
</tr>
<tr>
<td>csDMARD at vaccination (yes/no)</td>
<td>-1.08</td>
<td>0.026</td>
<td>0.34</td>
<td>0.13-0.88</td>
</tr>
<tr>
<td>Prednisolone (mg/day)</td>
<td>-0.10</td>
<td>0.103</td>
<td>0.90</td>
<td>0.80-1.02</td>
</tr>
<tr>
<td>Rituximab dose (1000mg vs 500mg)</td>
<td>-0.01</td>
<td>0.370</td>
<td>0.99</td>
<td>0.99-1.00</td>
</tr>
</tbody>
</table>

**Conclusion:** Patients with IRD getting vaccinated with two doses of COVID19 vaccine during the treatment with rituximab have the ability to develop antibody response although the response is impaired. For each month passed after the last rituximab course and vaccination, participants have the highest chance of achieving a good antibody response.

**Acknowledgements:** Unrestricted research grants have been received from Roche and starting grants from The Swedish Rheumatism Association.

**Disclosure of Interests:** Martina Frodlund: None declared, Katarina Chatzidionysiou Consultant of: consultancy fees from Eli Lilly, AbbVie and Pfizer., Anna Bengtsson: None declared, Lars Klareskog Grant/research support from: has received unrestricted research grants from Roche and Pfizer. Martina Frodlund: None declared, Katarina Chatzidionysiou Consultant of: consultancy fees from Eli Lilly, AbbVie and Pfizer.

**Figure 1.** The change of good antibody response following two doses of COVID-19 vaccine in relation to time between the last rituximab course and vaccination.

**Table 1. Clinical characteristics stratified by anti-SARS-CoV-2 RBD response**

<table>
<thead>
<tr>
<th>Diagnostics</th>
<th>Negative (n=115)*</th>
<th>Positive (n=1023)*</th>
<th>p-value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age,median (IQR)</td>
<td>49(42, 58)</td>
<td>47(37, 58)</td>
<td>0.78</td>
</tr>
<tr>
<td>Female sex, no. (%)</td>
<td>108(94%)</td>
<td>952(93%)</td>
<td>0.78</td>
</tr>
<tr>
<td>Non-white, no. (%)</td>
<td>16(13.9%)</td>
<td>83(8.1%)</td>
<td>0.04</td>
</tr>
<tr>
<td>Diagnosis, no. (%)</td>
<td>22(19.1%)</td>
<td>469(45.8%)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

**Results:** We studied 1138 RMD patients on immunosuppression: most were female (93%) and white (91%) (Table 1). One-hundred and fifteen (10%) had anti-RBD response in the negative range at a median (IQR) of 29 days (28-34) following completion of vaccine series. A greater proportion of participants with negative response were non-white, received J&J vaccine, reported use of mycophenolate, rituximab, or glucocorticoids. Antibody response differed by immunosuppressive regimen, with those receiving rituximab having poorest response (Figure 1). Use of mycophenolate (aOR 9.9, p=0.001), rituximab (aOR 56.9, p=0.001), glucocorticoids (aOR 2.9, p=0.001) and receipt of J&J (aOR 3.13, p=0.039) were associated with negative antibody response.

**Table 1. Clinical characteristics stratified by anti-SARS-CoV-2 RBD response**

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>p-value</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age,median (IQR)</td>
<td>27(23.5%)</td>
<td>0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td>193(18.9%)</td>
<td>0.53</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>464(5.5%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mysitis</td>
<td>49(4.8%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>9(0.9%)</td>
<td>0.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td>16(1.8%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overlap connective tissue disease‡</td>
<td>24(23.6%)</td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine, no. (%) Pfizer/BioTech</td>
<td>548(53.6%)</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderna</td>
<td>438(42.8%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>J&amp;J</td>
<td>37(3.6%)</td>
<td>0.65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-biologic in regimen</td>
<td>725(70.9%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologic in regimen</td>
<td>5070(55.7%)</td>
<td>0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycophenolate**</td>
<td>120(11.7%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>29(2.8%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids**</td>
<td>284(27.8%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Withheld immunosuppression</td>
<td>260(39.6%)</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Negative defined as anti-RBD titer <0.8 U/mL. † Comparisons between negative and positive groups. ‡ Denotes a combination of two or more of the above conditions. ** Mycophenolate: mycophenolic acid and mycophenolate methyl. Corticosteroid: prednisone and prednisone equivalents.

**Figure 1.** Conclusion: Use of mycophenolate, glucocorticoids, rituximab and receipt of J&J vaccine were the strongest predictors of an attenuated antibody response to primary SARS-CoV-2 vaccination; these data support use of an additional primary dose in RMD patients.
Department of Laboratory, Tokyo, Japan;
Background: Department of Infectious Diseases, Tokyo, Japan

paucity of data about immunogenicity and safety of mRNA COVID-19 vaccines

the coronavirus disease 2019 (COVID-19) crisis. Whereas both of them have

(Pfizer-BioNTech) and mRNA-1273 (Moderna) have benefitted all countries amid

1273 (Moderna) compared with the BNT162b2 (Pfizer-BioNTech) in inflammatory

genicity and frequency of systemic adverse reaction of the SARS-CoV-2 mRNA-

Conclusion:

including methotrexate, mycophenolate, cyclophosphamide, and tacrolimus are

age, glucocorticoid dose (prednisolone > 7.5mg), use of immunosuppressants

izing antibody titres in patients with BNT162b2 were decreased more rapidly than

vs 61.8% vs 31.2%, p<0.001, respectively). In longitudinal measurement, neutral-

significantly higher in patients with mRNA-1273 and healthy controls than patients

with controls (242±136.4 vs. 387.8±57.3 BAU/ml, respectively; p<0.0001). No

anti-S1/S2 antibody titres were significantly lower in the AIIRD group compared

no change in disease activity. However, 3 patients had transient acute symptoms:

file was good, with 96.7% (n=88) of patients reporting mild or no side-effects, and

Results:

Objectives: We enrolled consecutive, previously uninfected patients with inflam-

ratory rheumatic diseases receiving mRNA vaccine including BNT162b2 and

mRNA-1273. Healthy participants receiving BNT162b2 were also recruited as

controls (242±136.4 vs. 387.8±57.3 BAU/ml, respectively; p<0.0001). No

anti-S1/S2 antibody titres were significantly lower in the AIIRD group compared

with controls (242±136.4 vs. 387.8±57.3 BAU/ml, respectively; p<0.0001). No

Cases of COVID-19 were documented during the 3-month follow-up.

Conclusion: Vaccination of juvenile-onset AIIRD patients demonstrated good

short-term safety and efficacy, high seropositivity rate, but lower anti-S1/S2

antibody titres compared to healthy controls. These results should encourage

age vaccination of adolescents with juvenile-onset AIIRD, even while on

REFERENCES:
[1] Fact sheet for healthcare providers administering vaccine emergency use
determination (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent
coronavirus disease 2019 (COVID-19) for 12 years of age and older dilute
before use for 12 years of age and older; Available from: www.cdcvaccine.com.
Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in
adolescents aged 5 through 11 years | FDA [Internet]. [cited 2022 Jan 3]. Available from: https://www.fda.gov/news-events/press-announcements/
fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age

POSO258
SAFETY AND IMMUNOGENICITY OF BNT162B2
MRNA COVID-19 VACCINE AMONG ADOLESCENTS
WITH RHEUMATOID MUSCULOSKELETAL DISEASES

M. Heshin-Bekenstein1,2, A. Ziv3,2, N. Toplak4, D. Kadishievich5, Y. Butbul6, E. Saiag7, G. Shefer8, O. Sharom9, S. Pel10, O. Elkayam10,
Y. Uziel10 on behalf of PFeS Vaccination Working Group. Dana Dwek Children's Hospital of Tel Aviv Sourasky Medical Center, Pediatric
Rheumatology Service, Tel Aviv, Israel; Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel; Meir Medical Center; Pediatric Rheumatology Unit, Kfar Saba, Israel; University Children's Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia; Tel Aviv Medical Center, Allergy and Clinical Immunology Unit, Tel Aviv; Meir Medical Center, Pediatrics, Kfar Saba, Israel; Ruth Rappaport Children's Hospital of Rambam Medical Center, Pediatric Rheumatology Service, Haifa; Tel Aviv Sourasky Medical Center, Hospital Management, Information and Operation Branch, Tel Aviv, Israel; Tel Aviv Sourasky Medical Center, Department of Endocrinology Metabolism and Hypertension, Tel Aviv, Israel; Tel Aviv Sourasky Medical Center, Rheumatology Department, Tel Aviv, Israel.

Background: Adolescents with juvenile-onset autoimmune inflammatory rheumatic diseases (AIIRD) could be at risk for disease flare secondary to SARS-CoV-2 infection or to withholding anti-inflammatory therapy. While vaccination can protect against COVID-19, safety and immunogenicity data regarding anti-
SARS-CoV-2 vaccines among adolescents with AIIRD are limited.

Objectives: This international, prospective, multicentre study evaluated the safety and immunogenicity of the BNT162b2 anti-SARS-CoV-2 vaccine among adolescents and young adults with juvenile-onset AIIRD, 80% of whom are on chronic immunomodulatory therapy.

Methods: Vaccine side effects, disease activity, and short-term efficacy were evaluated after 3 months in 91 patients. Anti-S1/S2 IgG antibody levels were evaluated in 37 patients and 22 controls, 2–9 weeks after the second dose.

Results: Ninety-one patients and 40 healthy controls were included. Safety profile was good, with 96.7% (n=88) of patients reporting mild or no side-effects, and no change in disease activity. However, 3 patients had transient acute symptoms: 2 following the first vaccination (renal failure and pulmonary haemorrhage) and 1 following the second dose (mild lupus flare vs. viral infection). Seroconversion was 97.3% in the AIIRD group compared with 100% among controls. However, anti-S1/S2 antibody titres were significantly lower in the AIIRD group compared with controls (242±136.4 vs. 387.8±57.3 BAU/ml, respectively; p<0.0001). No
cases of COVID-19 were documented during the 3-month follow-up.

Conclusion: Vaccination of juvenile-onset AIIRD patients demonstrated good short-term safety and efficacy, high seropositivity rate, but lower anti-S1/S2 antibody titres compared to healthy controls. These results should encourage age vaccination of adolescents with juvenile-onset AIIRD, even while on immunomodulation.

REFERENCES:

Disclosure of Interests: None declared.
**Acknowledgements:** We thank the families and adolescents who participated in the study. We thank Mr. Yishai Friedlander, MPH, for performing the statistical analysis. We thank Faye Schreiber, MS, for editing the manuscript.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4691

---

**A RANDOMIZED CLINICAL TRIAL OF 2-WEEK METHOTREXATE DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS VACCINATED WITH INACTIVATED SARS-COV-2 VACCINE**

C. Scognamiglio Renner Araujo1, A. C. Medeiros Ribeiro1, C. Saad1, K. Bonfiglioli1, D. S. Domiciano1, A. Yukie Shimabuco1, M. Rodrigues Silva1, E. Neves1, S. Pasoto1, T. Pedrosa1, L. Kanda Kupa1, G. Zou1, R. M. Pereira1, C. A. Silva1, N. Akawa1, E. Bonfa1 on behalf of COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS (CoronaRheum).

**Background:** Patients with rheumatoid arthritis (RA) on methotrexate have reduced vaccine responses. Temporary discontinuation has improved immunogenicity of anti-influenza vaccine, but this strategy has not been evaluated in anti-SARS-CoV-2 vaccines.

**Objectives:** To evaluate the effect on immunogenicity and safety of 2-week methotrexate (MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX maintenance in rheumatoid arthritis (RA) patients.

**Methods:** This was a single-center, prospective, randomized, investigator-blinded, intervention study (#NCT04754698, CoronaRheum), including adult RA patients (stable CDAI≤10, prednisone ≤7.5mg/day), randomized (1:1) to withdraw MTX (MTX-hold) for 2 weeks after each vaccine dose or maintain MTX (MTX-main), evaluated at D0, D28 and D69. Co-primary outcomes were anti-SARS-CoV-2 S1/S2 IgG seroconversion(SC) and neutralizing antibody (NAB) positivity at D69. Secondary outcomes were geometric mean titers (GMT) and flare rates. For immunogenicity analyses, we excluded patients with baseline positive IgG/NAb, and for safety reasons, those who flared at D28 (CDAI>10) and did not withdraw MTX twice.

**Results:** Randomization included 138 patients with 9 exclusions (5 COVID-19, 4 protocol violations). Safety evaluation included 60 (MTX-hold) and 69 (MTX-main) patients. Further exclusions: 27 patients [13 (21.7%), n=20 (30%), p=0.848] with positive baseline IgG/NAb and 10 patients (21.3%) in MTX-hold with CDAI>10 at D28. At D69, MTX-hold (n=37) had a higher rate of seroconversion than MTX-main (n=55) [29 (78.4%) vs 30 (54.5%), p=0.019], with parallel augmentation in GMT [34.2 (25.2-46.4) vs 16.8 (11.9-23.6), p=0.006]. No differences were observed for NAB positivity [23 (62.2%) vs 27 (49.1%), p=0.217]. At D28 flare, rates were comparable in both groups (CDAI, p=0.122; DAS28-ESR p=0.576), whereas CDAI>10 was more frequent in MTX-hold at D69 (p=0.024).

**Conclusion:** We provide novel data that 2-week MTX withdrawal after each Sinovac-CoronaVac vaccine dose improves anti-SARS-CoV-2 IgG response. The increased flare rates after second MTX withdrawal may be attributed to the short-term interval between vaccine doses. This strategy requires close surveillance and shared decision making due to the possibility of flares.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4890

---

**LONG-TERM HUMORAL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE**

K. Tasclar1, D. Simon1, A. Kleyer1, F. Fagni1, G. Krörke1, C. Meder2, P. Dietrich3, T. Otremba3, T. Kleim1, J. Möltner1, A. M. Lippard1, V. Schonau1, D. Bohn1, L. Schuster1, F. Hartmann1, J. Taubmann1, M. Leppikes1, A. Ramming1, M. Pachowsky1, F. Schuch1, M. Ronneberger2, S. Kleinert1, A. Hueber1, K. Manger1, B. Manger1, R. Atreya3, C. Berking1, M. Sticherling2, M. F. Neurath3, G. Schett1, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany; Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany; Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Department of Internal Medicine 1, Erlangen, Germany; Rheumatology Clinical Practice, Erlangen, Erlangen, Germany; Paracelsus University Nürnberg, Clinic for Internal Medicine 5, Nürnberg, Germany; Rheumatology Practice, Bamberg, Bamberg, Germany

**Background:** The first vaccine against SARS-CoV-2 was approved in December 2020. Immunogenicity of SARS-CoV2 vaccines in patients with immune-mediated inflammatory disease (IMID) have so far been evaluated in the 2-6 weeks after vaccination, but the long-term course of humoral response to vaccination is lacking. We have initiated a prospective dynamic cohort of IMID patients and healthy controls in February 2020 to monitor immune response to SARS-CoV-2 and respiratory infections including COVID-19 (1). Participants who contributed data starting from the 4 weeks before their first vaccination onwards were included in this analysis. Antibodies against SARS-CoV-2 spike protein were quantified with an ELISA from Euroimmun (Lübeck, Germany) with an optical density cutoff of 0.8. We fitted linear mixed-effect models for log-transformed antibody levels using time splines with adjustment for age and sex. Marginal mean antibody levels with 95% confidence intervals (CI) were estimated at selected time points for IMID patients and controls with double vaccination. We descriptively analyzed the observed antibody levels over time in cohort participants receiving two vaccinations vs. three vaccinations.

**Methods:** With a prospective cohort design, we recruited adult IMID patients and healthy controls in February 2020 to monitor immune response to SARS-CoV-2 in a large prospective cohort of IMID patients and non-IMID controls with a follow-up duration of up-to to 10 months after the first vaccine dose.

**Results:** Among 5076 cohort participants, 3147 IMID patients and healthy controls in February 2020 to monitor immune response to SARS-CoV-2 and respiratory infections including COVID-19 (1). Participants who contributed data starting from the 4 weeks before their first vaccination onwards were included in this analysis. Antibodies against SARS-CoV-2 spike protein were quantified with an ELISA from Euroimmun (Lübeck, Germany) with an optical density cutoff of 0.8. We fitted linear mixed-effect models for log-transformed antibody levels using time splines with adjustment for age and sex. Marginal mean antibody levels with 95% confidence intervals (CI) were estimated at selected time points for IMID patients and controls with double vaccination. We descriptively analyzed the observed antibody levels over time in cohort participants receiving two vaccinations vs. three vaccinations.
In IMID patients, age and sex-adjusted estimated marginal mean antibody levels waned after week 16 and were substantially reduced at all time points compared to the controls, finally dropping to the borderline range (1.01, 95%CI 0.86 to 1.19) at week 40 (Figure 1A, Table 1). A third dose was given to 128 (7%) of IMID patients with a poor response to 2 vaccine doses after a median 20 weeks of the second dose (IQR 10 to 26 weeks). After the third dose, antibody levels in IMID patients were comparable to those of healthy controls at 40 weeks who had three vaccine doses. These were also higher than that of IMID patients and controls who did not receive a third dose (Figure 1B).

Conclusion: Humoral response to vaccination against SARS-CoV-2 was weaker in IMID patients compared to controls at all time points after the first vaccine dose and practically disappeared after 1 year. IMID patients can still achieve a good antibody response with a third dose even after a weak response with two doses.

REFERENCES:

Disclosure of Interests: None declared

Table 1. Participant characteristics and antibody levels

<table>
<thead>
<tr>
<th>Healthy controls</th>
<th>IMID</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>1199</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>40.8 (13.5)</td>
</tr>
<tr>
<td>Follow-up, weeks, median (IQR)</td>
<td>31.1 (23.8-36.6)</td>
</tr>
<tr>
<td>Follow-up range, weeks,</td>
<td>16-46.1</td>
</tr>
<tr>
<td>Sex, n(%)</td>
<td>554 (46.2)</td>
</tr>
<tr>
<td>Vaccine intervals, median (IQR)</td>
<td>4.6 (3.0-6.0)</td>
</tr>
<tr>
<td>1st to 2nd dose</td>
<td>29.6 (26.9-36.4)</td>
</tr>
<tr>
<td>Diagnosis, n(%)</td>
<td>713 (36.6)</td>
</tr>
<tr>
<td>Spondyloarthritis</td>
<td>420 (21.5)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>219 (11.2)</td>
</tr>
<tr>
<td>Autoimmune disease, systemic†</td>
<td>107 (5.5)</td>
</tr>
<tr>
<td>Mean antibody levels after 1st dose</td>
<td>4.16 (3.89 to 4.45)</td>
</tr>
<tr>
<td>Week-8</td>
<td>8.39 (7.81 to 9.02)</td>
</tr>
<tr>
<td>Week-16</td>
<td>5.02 (4.73 to 5.33)</td>
</tr>
<tr>
<td>Week-32</td>
<td>2.14 (1.95 to 2.39)</td>
</tr>
</tbody>
</table>

† Systemic lupus, systemic sclerosis, Sjögren’s syndrome, vasculitis. Estimated marginal means adjusted for age and sex.

Figure 1.
less than 9 months. For the majority of RTX treated patients, the recommended six months since last RTX is insufficient to develop a humoral response to COVID-19 mRNA vaccines. Our data suggest that the current recommendations of a 6 months interval should be revised.

Conclusion: SARS-CoV-2 vaccination was safe for GCA/PMR patients and immunogenicity was comparable to other older individuals. However, patients using methotrexate and particularly >10mg/day prednisolone did show lower vaccine responses, which corroborates findings in older non-autoinflammatory patient populations. These patients may therefore be at higher risk of (potentially even severe) breakthrough SARS-CoV-2 infection.

Acknowledgements: This study was supported by the Dutch Vasculitis Foundation (Vasculitis stichting).

Disclosure of Interests: None declared


POS0263

RE-VACCINATION COMPARED TO BOOSTER COVID-19 mRNA VACCINATION SIGNIFICANTLY INCREASES THE SEROLOGICAL RESPONSE IN RITUXIMAB-TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES WITHOUT A PRIMARY DETECTABLE SEROLOGICAL COVID-19 VACCINE RESPONSE

C. Ammitzbøll1, 2, M. K. Thomesen3, 2, M. L. F. Hermansen1, S. R. Viis1, 4, J. B. Andersen1, A. D. Johansen1, F. Szabados1, C. M. Jørgensen1, 2, 4, M. C. L. Larsen1, C. Erikstrup1, 2, 3, E. M. Hauge1, 2, A. Trolberg1, 4, Aarhus University Hospital, Rheumatology, Aarhus, Denmark; 2Aarhus University, Clinical Medicine, Aarhus, Denmark; 3Aarhus University Hospital, Clinical Microbiology, Aarhus, Denmark; 4Aarhus University Hospital, Clinical Immunology, Aarhus, Denmark

Background: Reports of an impaired humoral response after COVID-19 vaccination in patients treated with rituximab (RTX) have raised particular concern for patients with inflammatory rheumatic diseases (IRD) receiving RTX (1). This calls for strategies to enhance a humoral response in RTX-treated patients. At present, there is no data on whether it is best to increase the humoral response with a third vaccine dose (a booster) or with a third and fourth dose (re-vaccination).

Objectives: In IRD patients treated with RTX, without a detectable humoral response after the first vaccination course (two shots), we aimed to investigate the difference of either a booster vaccine (dose 3) or a new re-vaccination course (dose 3+4) on the serological response of the COVID-19 mRNA vaccines.

Methods: We included 84 patients with IRD treated with RTX, all without measurable total SARS-CoV-2 antibodies after a full primary COVID-19 vaccination course (2 doses three weeks apart). All patients were offered a new re-vaccination course with the mRNA vaccine not used primarily (Pfizer/Biontec or Moderna). A small number of patients declined the re-vaccination, and received a booster with the mRNA vaccine used initially. Serum total antibodies were measured before and six weeks after the last dose against recombinant SARS-CoV-2 spike S1 protein (VITROS). In addition, CD19+ B-cells were measured at inclusion.

Results: Patient characteristics are in Table 1. The median age was 64 years; 68% were female with a disease duration of 5 years. Sixty-nine out of 84 were re-vaccinated (3+4 dose). Details previous exposure to RTX are given in Table 1. CD19+ B-cells were measurable in 12/81 at inclusion.

Table 1. Patient Characteristics

<table>
<thead>
<tr>
<th>Booster, n=15 Revaccination, n=69</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years median (IQR)</strong></td>
</tr>
<tr>
<td><strong>Female</strong></td>
</tr>
<tr>
<td><strong>47%</strong></td>
</tr>
<tr>
<td><strong>Disease duration, years (IQR)</strong></td>
</tr>
<tr>
<td><strong>ARCA-vasculitis</strong></td>
</tr>
<tr>
<td><strong>47%</strong></td>
</tr>
<tr>
<td><strong>ANCA-vasculitis</strong></td>
</tr>
<tr>
<td><strong>Rheumatoid Arthritis</strong></td>
</tr>
<tr>
<td><strong>Poly- Dermatomyositis</strong></td>
</tr>
<tr>
<td><strong>6%</strong></td>
</tr>
<tr>
<td><strong>SLE, Scleroderma, other diagnoses</strong></td>
</tr>
<tr>
<td><strong>No DMARD treatment</strong></td>
</tr>
<tr>
<td><strong>27%</strong></td>
</tr>
<tr>
<td><strong>Prednisone</strong></td>
</tr>
<tr>
<td><strong>Methotrexate</strong></td>
</tr>
<tr>
<td><strong>16%</strong></td>
</tr>
<tr>
<td><strong>Azathioprine</strong></td>
</tr>
<tr>
<td><strong>12%</strong></td>
</tr>
<tr>
<td><strong>Mycophenolate</strong></td>
</tr>
<tr>
<td><strong>12%</strong></td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
<tr>
<td><strong>9%</strong></td>
</tr>
<tr>
<td><strong>Rituximab treatment, (IQR)</strong></td>
</tr>
<tr>
<td><strong>Months from last RTX to vaccination</strong></td>
</tr>
<tr>
<td><strong>Number of infusions</strong></td>
</tr>
<tr>
<td><strong>7 (5 - 12)</strong></td>
</tr>
<tr>
<td><strong>Cumulative total dose, gram</strong></td>
</tr>
<tr>
<td><strong>6 (3.5 - 10)</strong></td>
</tr>
<tr>
<td><strong>Total treatment time with RTX, months</strong></td>
</tr>
<tr>
<td><strong>Patients with measurable CD19+ B-cells in peripheral blood</strong></td>
</tr>
<tr>
<td><strong>98%</strong></td>
</tr>
</tbody>
</table>

We found a combined seroconversion rate of 33% six weeks after the last shot. There was no statistical difference between the booster (38,5%) and the re-vaccination group (32,3%), p=0.67 (Pearson's chi-squared). IRD patients with a humoral response in the re-vaccination group had significantly higher levels of total SARS-CoV-2 antibodies (median(IQR) 306(49-444) AU/ml) compared to the booster group (14(4-15) AU/ml) p=0.02, Figure 1A. In multiple logistic regression model, we found that levels of CD19+ B-cells were the only variable able to predict a humoral response, Figure 1B. However, only 39% of the patients with...

REFERENCES:
a humoral response to vaccination had measurable CD19+ B-cells before vacci-
nation. We found no effect of age, sex, diagnosis, treatment, and RTX exposure on the chance of seroconversion in multiple logistic regression models when corrected for CD19+ B-cells.

Conclusion: We found that re-vaccination (dose 3+4) with COVID-19 mRNA vaccines favored a high humoral response in patients with IDR treated with RTX, who did not have a detectable humoral response after the first two vaccine doses, compared to a booster shot (dose 3). A detectable humoral response after re-vaccination was seen in more than half of the patients with no measurable CD19+ B-cells before vaccination. Presence of circulating CD19+ B-cells are a significant predictor of humoral response to mRNA COVID-19 vaccination.

REFERENCES:

Acknowledgements: The Danish Rheumatism Association - Gigtforeningen for funding the study.

Disclosure of Interests: None declared

POS0264
CHARACTERIZATION OF THE IMMUNE RESPONSE IN PATIENTS WITH INFLAMMATORY IMMUNE-MEDIATED DISEASES ON IMMUNOSUPPRESSIVE TREATMENT AFTER ONE MONTH OF SARS-COV-2 VACCINATION
A. Martínez-Felto1, P. Nozal1, M. Novella-Navarro2, E. Fernández-Fernández2, L. Del Pino Molina3, M. Casas Temprano3, I. Akabat Bousaid1, M. D. Martin Arranz4, A. Balsa5, C. Plascencia6, La Paz University Hospital, Immunology, Madrid, Spain; 2La Paz University Hospital, Rheumatology, Madrid, Spain; 3IdiPAZ, Lymphocyte Pathophysiology in Immunodeficiencies, Madrid, Spain; 4La Paz University Hospital, Gastroenterology, Madrid, Spain

Background: The relevance of studying immune response after SARS-Cov-2 vaccination in patients with inflammatory immune-mediated diseases (IMIDs) represents a deep concern regarding the risk estimation and management of patients with these diseases on immunomodulatory drugs. It is well known that certain treatments as anti CD20 therapies results in a diminished immunogenicity against common vaccines but it is a scarce data regarding the cellular protection obtained upon vaccination between patients with different IMID and between different treatments.

Objectives: To compare a potential detrimental on cellular and antibody-medi- ated protection upon SARS-CoV-2 vaccination in patients with IMID treated with immunosuppressive drugs.

Methods: We recruited 73 patients with rheumatoid arthritis-RA(n=49), spondylarthritis-SPA(n=19), inflammatory bowel disease-IBD(n=5), idiopathic juvenile arthritis-IAA(n=2) and heterogeneous group composed of sclerodermia, lupus, uveitis...(n=6). They were treated mainly with rituximab (n=27), TNFi (n=37) or JAKi (n=3). We collected data of age, sex, csDMARDs, previous SARS-CoV-2 infection, last RTX infusion and prednisone use. After one month of vaccination, we assessed the humoral response performing the Thermo Scientific EIA SARS-CoV-2-Sp1 IgG Test (positivity cut-off >0.70 IU/ml) which was also compared with the data of with 35 healthy controls. In addition, in 40 patients who had serum antibody levels under 100U/ml, we analysed the cellular response by the use of the QuantiFENOM SARS-CoV-2 Starter Pack (Quigain). A cut-off value of 0.15 IU/ml discriminate between positive or negative cell-mediated immune responses.

Figure 1. Concentration of total SARS-CoV-2 antibodies measured 6 weeks after COVID-19 re-vaccination or booster shot. A: Total antibody concentration presented by vaccination group: 1) d1 (booster) or 2) d3 (re-vaccination). The chart presents percent of patients with a positive total antibody measurement post-vaccination. Circles with straight line indicate mean concentration with confidence intervals. B: Total antibody concentration presented by pre-vaccination measurement of circulating CD19+ B-cells in peripheral blood. A) indicate booster and B) indicate re-vaccination group.

Figure 1

We compared differences among the different IMIDs and between the different immuno suppressive treatments through non-parametric test (p<0.05)

Results: Regarding demographic characteristics of patients, older patients (>56 years) and female sex were factors which were associated with low titles of serum antibodies. Anti-spike IgG antibodies were present in an 86% of the IMIDs patients and in 100% healthy controls with significant different IgG titre (median [IQR]): 51[11-184] vs 700[440-940]; p=0.0001.

The differences between (median [IQR]) serum antibody levels were statistically significant between IMID types: 33[1-138] in RA vs 94[34-191] in SpA vs 204[187-204] in IBD vs 133[61-204] in IJA vs 13[1.5-31.8] in the rest; p<0.04. Remarkably, patients with IBD who had the highest antibodies titles were the youngest compared with the other patients.

Target of the therapy played also an important role in serum antibody levels being these: 3.6 [0-7.51] in RTX patients vs 156 [45-204] in TNFi for 40 [18-58] in JAKi patients; p=0.0001. In those patients who the last infusion of rituximab was, at least, one year before vaccination presented CD19+ B-cells detected by flow cytometry and anti-spike IgG antibodies as well.

Cell-mediated responses to SARS-CoV-2 were positive in 33% of IMIDs patients, indeterminate in 3% and negative in 65% of the patients. Strikingly, out of the 33% positive patients, 85% were treated with RTX. A 61% of the RTX patients had inducible cell-mediated responses vs 14% of the patients treated with TNFi; p<0.01. On the other hand, there were no differences in cell-mediated responses between positive and negative antibody patients.

Conclusion: Titors of serum antibodies against spike protein of SARS-CoV-2 were lower in IMIDs patients than in controls. Patients with RTX had lower rates of positivity humoral response as well as lower serum titles than patients treated with TNF inhibitors regardless the patients age. Nevertheless, in those patients in whom RTX infusion was delayed because of vaccination they conserved a humoral response.

On the other hand, more patients treated with RTX had indiscernible cell-mediated responses compared with patients with TNFi.

Disclosure of Interests: ANA MARTINEZ-FEITO: None declared, Pilar Nozal: None declared, Marta Novella-Navarro: None declared, Elisa Fernández-Fernández: None declared, Lucía del pino molina: None declared, Milagros Casas Temprano: None declared, Ibittsam Akabat Bousaid: None declared, María Dolores Martín Arranz: None declared, Alejandro Balsa Speakers bureau: Pfizer, AbbVie, Lilly, Galapagos, Bios, Sandoz, Nordic, Gebro, Roche, UCB, Consultant of: Pfizer, AbbVie, Lilly, Galapagos, Bios, Sandoz, Nordic, Sanofi, UCB, Grant/research support from: AbbVie, Bios, Nordic, Gebro, Roche, UCB, Chamaida Plasencia Grant/research support from: AbbVie, Pfizer, UCB, Sandoz, Sanofi, Biogen, Lilly, Roche and Novartis

POS0265
SERUM PROTEOMICS IN GIANT CELL ARTERITIS IN RESPONSE TO A THREE-DAY PULSE OF GLUCOCORTICOID FOLLOWED BY TOCILIZUMAB MONOTHERAPY (THE GUSTO TRIAL)
L. Chrig1, A. Gloor2, F. Kollert1, S. Reichenbach1,2, P. Villiger3, Inselspital, Bern University Hospital, Department of Rheumatology and Immunology, Bern, Switzerland; 2Inselspital, Bern University Hospital, Department of General Internal Medicine, Bern, Switzerland; 3University of Bern, Institute for Social and Preventive Medicine, Bern, Switzerland; 4Medical Center Monbijou, Rheumatology, Bern, Switzerland

Background: Measuring disease activity in Giant Cell Arteritis (GCA) remains a challenge, particularly, if Tocilizumab (TCZ) is prescribed which blunts the acute phase response. A proteome analysis may not only serve to identify biomarkers, but also to shed light on pathophysiology. The sequential administration of Glu cocorticoids (GC) and TCZ as done in the GUSTO study (GCA treatment with ultra-short GC and TCZ) provides a unique opportunity to dissect the effects of GC and TCZ.

Objectives: To investigate the effects of pulse GC-treatment and of ensuing long-term TCZ monotherapy on serum proteins in GCA; to compare the sereo logical findings with clinical response; to search for proteins which are not under control of IL-6 and may be unstable as biomarkers of disease activity.

Methods: Eighteen patients with newly diagnosed GCA received 500 mg methy lprednisolone intravenously for 3 consecutive days (NCT03745586). Thereafter, GC treatment was discontinued and a single dose of TCZ (8 mg/kg body-weight) was administered intravenously, followed by weekly subcutaneous TCZ injections (162 mg) from day 10 until week 52. Serum samples were collected prior to treat ment (day 0), at day 3 (after GC treatment), day 10 and at weeks 4, 24, and 52

Achy-Breaky vessels.
POS0266  EFFECTIVENESS OF A SPACING-UP STRATEGY AFTER ONE-YEAR COURSE OF WEEKLY TOCILIZUMAB IN PATIENTS WITH GIANT CELL ARTERITIS: A SINGLE-CENTRE PROSPECTIVE STUDY

A. Tomelleri1, C. Campochiaro1, S. Sartorelli1, L. Mariotti1, E. Baldissera1, M. Matucci-Cerinic1, L. Dagna1. IRCCS San Raffaele Hospital, Unit of Immunology Rheumatology Allergy and Rare Diseases, Milan, Italy

Background: Although tocilizumab (TCZ) is extensively used for the treatment of giant cell arteritis (GCA), there is still uncertainty with regard to optimal treatment duration. The GIACTA open-label extension phase showed that 58% of patients treated with a 12-month course of weekly TCZ had a disease flare in the 2 years following therapy suspension, suggesting that some patients may need a more prolonged duration of this therapy.

Objectives: To evaluate efficacy and safety of low-dose TCZ maintenance in GCA patients who achieved remission after one year of standard TCZ therapy.

Methods: GCA patients eligible for TCZ according to the 2018 EULAR recommendations and who achieved remission after one year of weekly subcutaneous TCZ therapy were prospectively enrolled. TCZ was administered every-other-week (EOW) for additional 12 months, and eventually suspended. Patients were evaluated 4-monthly during TCZ therapy, and 1 and 6 months after TCZ suspension (Figure 1). In patients with large-vessel (LV) involvement at baseline, PET scan was performed 12 and 24 months after TCZ start. Primary outcome was relapse-free survival at month 6 since TCZ suspension. Relapse-free survival during TCZ therapy and imaging response at PET scan were also evaluated. Adverse events were recorded.

Results: 17 patients were enrolled (12 women, 71%; mean age 71.5±8.7 years). Disease features at diagnosis and TCZ start are listed in Table 1. Reasons for TCZ start were clinical or imaging disease flare (n=9), persistence of disease activity (n=5), and steroid-related adverse events (n=3). At TCZ start, median disease duration was 8 (3-22) months, serum C-reactive protein (CRP) was 13 (6-22) mg/L, daily prednisone (PND) dose was 25 (15-375) mg; 4 patients were already on methotrexate (MTX) which was maintained in 1 of them; 10 patients (59%) had LV involvement on PET scan. At TCZ EOW start, no patient was on PND and 1 patient was on MTX; MTX was added in another patient due to persistence of LV involvement at PET scan. All patients completed the 24-month TCZ course. Two patients (12%) had a polymyalgic flare while on EOW TCZ: one patient at month 1 and one patient at month 6; of note, one of them had a polymyalgic flare also while on weekly TCZ. Both flares were managed with a PND course with complete clinical remission. No patient had active LV involvement at 24-month PET scan. All patients completed the 24-month TCZ course. Two patients (12%) experienced a flare, which was successfully managed in all cases with weekly TCZ re-introduction; in 2 patients, a PND course was also started.

Conclusion: In this proof-of-concept study, low-dose TCZ maintenance in GCA showed excellent disease control, which was maintained in most patients after therapy suspension. Longer follow-up and replication in larger cohorts are required.

REFERENCES:
Disclosure of Interests: Alessandro Tomelleri: None declared, Corrado Campochiaro: None declared, Silvia Sartorelli: None declared, Letizia Mariotti: None declared, Elena Baldissara: Speakers bureau: Prof Lorenzo Dagna received honoraria as a speaker from Roche, Marco Matucci-Cerinic: None declared, Lorenzo Dagna: Consultant of: Prof Lorenzo Dagna received consultation honoraria from Roche

DOI: 10.1136/annrheumdis-2022-eular.784

**POS0267**

OUTCOMES DURING AND AFTER LONG-TERM TOCILIZUMAB TREATMENT IN PATIENTS WITH GIANT CELL ARTERITIS

M. Mata2, N. DAgincourt2, S. Mohan1, A. Pavlov1, J. Han1, J.H. Stone1, S. Unizony1, 1Massachusetts General Hospital - Harvard Medical School, Vascularitis and Glomerulonephritis Center, Boston, United States of America; 2Everest Clinical Research, Statistical Operations, Markham, Canada; 3Genentech, Inc., US Medical Affairs, South San Francisco, United States of America; 4Genentech, Inc., Biometrics, South San Francisco, United States of America

**Background:** Data on the long-term efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA), including incidence and timing of disease relapse after TCZ discontinuation, is limited.

**Objectives:** We aimed to evaluate the long-term outcomes of GCA patients treated with TCZ in a real-world setting.

**Methods:** Retrospective analysis of GCA patients treated with TCZ for >9 months at a single center between 2010-2021. Time to relapse and annualized relapse rate were assessed. Relapse was defined as the re-appearance of clinical manifestations of GCA that required treatment intensification regardless of the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels. Kaplan-Meier (KM) estimated relapse rates on TCZ were 10.5% and 14.9% at 12 and 18 months, respectively (Figure 1A). TCZ was discontinued due to long-term remission in 37 (64.9%) patients and after an adverse event in 6 (10.5%) patients. Of the 43 patients stopping TCZ due to remission or adverse event, 19 (44.2%) subsequently relapsed. KM estimated relapse rates after TCZ discontinuation were 30.4% and 44.0% at 12 and 18 months, respectively (Figure 1B).

**Results:** A total of 57 GCA patients were followed for a mean (SD) period of 3.4 (1.7) years. Baseline characteristics and treatments received are shown in Table 1. Patients were maintained on their initial TCZ course for a mean (SD) period of 2.0 (1.3) years. The initial TCZ course lasted >12 months in 50 (88%) patients. During the initial TCZ course, 8 (14.0%) patients relapsed. Kaplan-Meier KM estimated relapse rates on TCZ were 10.5% and 14.9% at 12 and 18 months, respectively (Figure 1A). TCZ was discontinued due to long-term remission in 37 (64.9%) patients and after an adverse event in 6 (10.5%) patients. Among the 43 patients stopping TCZ due to remission or adverse event, 19 (44.2%) subsequently relapsed. KM estimated relapse rates after TCZ discontinuation were 30.4% and 44.0% at 12 and 18 months, respectively (Figure 1B). Overall, 12 patients received more than one TCZ course. The aggregation of all TCZ courses (mean 2.5 years) and all periods off TCZ following the initial TCZ treatment (mean 0.9 years) showed that 11 (19.3%) patients relapsed while on TCZ and 20 (35.1%) patients relapsed during time off TCZ. An analysis adjusting for age, sex, prednisone dose at initiation of first TCZ course, and disease type (new onset vs. relapsing) at initiation of first TCZ course showed an annualized relapse rate (95% CI) of 0.1 (0.0-0.2) during TCZ treatment and 0.4 (0.3-0.7) off TCZ (rate ratio 0.2, p<0.0001). By the end of follow up, 42 (73.7%) patients were able to wean off prednisone. During the study, 12 serious adverse events occurred in 11 (19.3%) patients. Among those 12 events, 3 (25%) were related or possibly related to TCZ exclusively (i.e., osteoporotic fracture, diabetic ketoacidosis and stroke), and 2 (16.7%) to either TCZ or prednisone (i.e., pneumonia and sepsis).

**Conclusion:** Long-term TCZ treatment was efficacious in maintaining disease remission and sparing the use of prednisone in patients with GCA. Over 40% of patients stopping TCZ after long-term remission or adverse event relapsed following TCZ discontinuation.

**Table 1. Baseline characteristics and treatments**

<table>
<thead>
<tr>
<th>GCA patients (n = 57)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
</tr>
<tr>
<td>Female sex</td>
</tr>
<tr>
<td>New onset disease at TCZ initiation</td>
</tr>
<tr>
<td>Initial TCZ treatment</td>
</tr>
<tr>
<td>4 mg/Kg intravenously monthly</td>
</tr>
<tr>
<td>8 mg/Kg intravenously monthly</td>
</tr>
<tr>
<td>162 mg subcutaneously every 2 weeks</td>
</tr>
<tr>
<td>162 mg subcutaneously weekly</td>
</tr>
<tr>
<td>On prednisone at TCZ initiation</td>
</tr>
<tr>
<td>Prednisone dose (mg) at TCZ initiation, mean (SD)</td>
</tr>
<tr>
<td>Patients receiving &gt;1 TCZ course</td>
</tr>
<tr>
<td>Duration of initial TCZ course, mean (SD)</td>
</tr>
<tr>
<td>Total duration of TCZ treatment, mean (SD)</td>
</tr>
</tbody>
</table>

Values represent number and (%) unless otherwise specified. *Aggregated time on tocilizumab (TCZ) for those patients that received more than 1 TCZ course. GCA, giant cell arteritis; SD, standard deviation.

**Acknowledgements:** This study was sponsored by Genentech, Inc.


**DOI:** 10.1136/annrheumdis-2022-eular.1108

**POS0268**

INTRAVENOUS TOCILIZUMAB FOR THE TREATMENT OF GIANT CELL ARTERITIS: A PHASE IB DOSE-RANGING PHARMACOKINETIC BRIDGING STUDY

C. Schmitt1, L. Brockwell1, M. Giraudon1, M. Zucchetto1, L. Christ2, B. Bannert3, T. Daeke4, P. Villiger4, F. Hoffmann-La Roche Ltd, Clinical Pharmacology, Basel, Switzerland; 3K. Hoffmann-La Roche Ltd, Product Development – Immunology, Infectious Diseases, and Ophthalmology, Welwyn Garden City, United Kingdom; 4F. Hoffmann-La Roche Ltd, Pharmaceutical Sciences, Basel, Switzerland; 5Paraxel International, Biostatistics, Milan, Italy; 6Inselhospital, University Hospital Bern, Rheumatology and Immunology, Bern, Switzerland; 7USB - University Hospital Basel, Rheumatology, Basel, Switzerland; 8Medical Center Monbibiou, Rheumatology, Bern, Switzerland

**Background:** Subcutaneous (SC) tocilizumab (TCZ), a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, is approved globally for systemic juvenile idiopathic arthritis, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, adult systemic onset juvenile idiopathic arthritis, giant cell arteritis, and rheumatoid vasculitis.

**Objectives:** We aimed to evaluate the safety, tolerability, and pharmacokinetics of SC TCZ in adult patients receiving SC TCZ at a dose ranging from 8 to 164 mg.

**Methods:** Retrospective analysis of GCA patients treated with TCZ for >9 months at a single center between 2010-2021. Time to relapse and annualized relapse rate were assessed. Relapse was defined as the re-appearance of clinical manifestations of GCA that required treatment intensification regardless of the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) levels. Kaplan-Meier KM estimated relapse rates on TCZ were 10.5% and 14.9% at 12 and 18 months, respectively (Figure 1A). TCZ was discontinued due to long-term remission in 37 (64.9%) patients and after an adverse event in 6 (10.5%) patients. Among those 12 events, 3 (25%) were related or possibly related to TCZ exclusively (i.e., osteoporotic fracture, diabetic ketoacidosis and stroke), and 2 (16.7%) to either TCZ or prednisone (i.e., pneumonia and sepsis).

**Conclusion:** Long-term TCZ treatment was efficacious in maintaining disease remission and sparing the use of prednisone in patients with GCA. Over 40% of patients stopping TCZ after long-term remission or adverse event relapsed following TCZ discontinuation.

**Figure 1A. Time to relapse on initial TCZ treatment**

* Patients were censored if tocilizumab (TCZ) was discontinued for any reason or the patient was lost to follow-up.

**Figure 1B. Time to relapse after discontinuation of initial TCZ treatment**

* Time to relapse in patients that discontinued TCZ due to either long-term remission or an adverse event and who had follow-up beyond their TCZ discontinuation date. Patients were censored if TCZ was re-started for any reason other than relapse or the patient was lost to follow-up.

**Acknowledgements:** This study was sponsored by Genentech, Inc.


**DOI:** 10.1136/annrheumdis-2022-eular.1108
the treatment of giant cell arteritis (GCA), with once weekly injections, based on the GIACCTA trial.

**Objectives:** This Phase Ib study (NCT02892378) investigated the pharmacokinetics (PK), pharmacodynamics (PD), safety and exploratory efficacy of 2 doses of TCZ given intravenously (IV) in patients with GCA. The purpose was to explore an IV dose resulting in a minimum exposure level within the range of effective trough concentrations achieved with TCZ SC dosing in GCA and not exceeding the exposure of the well-tolerated 8 mg/kg IV every 4 weeks (Q4W) in rheumatoid arthritis (RA).

**Methods:** This study enrolled patients with GCA in Switzerland who had received ≥5 consecutive doses of TCZ IV 8 mg/kg (off label) Q4W and were in remission. Patients received 5 or 6 doses of TCZ IV 7 mg/kg Q4W in period 1 and, if still in remission, then received 5 or 6 doses of 6 mg/kg Q4W in period 2. Glucocorticoid use was at the investigator’s discretion. PK endpoints were maximum concentration (C_{max}), minimum (trough) concentration (C_{trough}), area under the curve (AUC) over a dosing interval (τ) and average concentration (C_{mean}) calculated as AUC/τ of TCZ after the last dose of each period. Other endpoints included PD markers (IL-6, soluble IL-6R [sIL-6R], C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]), safety (adverse events [AEs], serious AEs [SAEs]) and exploratory efficacy (rates of flare and remission).

**Results:** In 24 patients enrolled, median (range) age was 65.5 (57-90) years and the majority were female (62.5%). All patients had a history of elevated ESR and/or CRP and evidence of GCA by temporal artery biopsy and/or evidence of large vessel vasculitis at GCA diagnosis. The mean PK profile following TCZ IV 7 mg/kg Q4W in Period 1 was of a similar shape to mean PK profile following TCZ IV 6 mg/kg Q4W in Period 2, with a slightly lower exposure at the 6-mg/kg dose level (Figure 1). Compared with the 7-mg/kg dose, TCZ exposures (C_{max} and AUC) were on average 11.2% and 20.0% lower at the 6-mg/kg dose (Table 1). Mean IL-6 serum concentrations were elevated at baseline due to previous TCZ treatment and remained elevated throughout the study, with slightly higher concentrations in Period 1 (7 mg/kg) than Period 2 (6 mg/kg). Mean sIL-6R concentrations were elevated at baseline and comparable between the 2 doses at steady state. As expected for patients in remission, CRP levels and most ESRs were within the normal ranges at baseline and throughout the study. Overall, 22 patients (91.7%) had ≥1 AE; infections were the most frequently reported AEs. Two patients (8.3%) experienced a Grade ≥3 AE. The majority of AEs (70.8%) were TCZ-related. Four patients (16.7%) reported an SAE; 1 (pneumococcal pneumonia) was considered TCZ-related by the investigator and 3 led to treatment interruption. There were no deaths. No patients experienced a GCA flare, and all patients remained in remission throughout the study.

**Table 1. Steady-State PK Parameters of TCZ IV 7 and 6 mg/kg Q4W**

<table>
<thead>
<tr>
<th>PK Parameters, mean, median (range)</th>
<th>7 mg/kg IV (Period 1) n=22</th>
<th>6 mg/kg IV (Period 2) n=22</th>
</tr>
</thead>
<tbody>
<tr>
<td>C_{max} μg/mL</td>
<td>205</td>
<td>182</td>
</tr>
<tr>
<td>AUC_{day 7} μg/mL</td>
<td>197 (118-352)</td>
<td>178 (115-320)</td>
</tr>
<tr>
<td>AUC_{day 28} μg/mL</td>
<td>2100 (1120-4300)</td>
<td>1610 (921-3070)</td>
</tr>
<tr>
<td>C_{mean} μg/mL</td>
<td>76.9</td>
<td>61.5</td>
</tr>
<tr>
<td>C_{trough} μg/mL</td>
<td>76.0 (40.1-154)</td>
<td>57.5 (32.5-110)</td>
</tr>
<tr>
<td>C_{trough} μg/mL</td>
<td>35.3</td>
<td>22.7</td>
</tr>
<tr>
<td></td>
<td>372 (6.59-69.0)</td>
<td>22.7 (3.38-54.5)</td>
</tr>
</tbody>
</table>

AUC_{day 28} under the curve over a dosing interval (τ); C_{max}, maximum concentration; C_{mean}, mean concentration (AUC_{day 7}/τ); C_{trough}, minimum (trough) concentration; IV, intravenous; PK, pharmacokinetics; Q4W, every 4 weeks; TCZ, tocilizumab; *n=21 for C_{max}.

**Conclusion:** Both dose levels of TCZ-IV (6 and 7 mg/kg) Q4W were generally well tolerated in patients with GCA. The C_{max} and C_{mean} achieved with 6 mg/kg IV Q4W in patients with GCA were similar to those seen in patients with RA treated with 8 mg/kg IV Q4W, and C_{trough} was within the range observed in patients with GCA treated with once weekly and every 2 weeks SC dosing.

**Acknowledgements:** This study was sponsored by F. Hoffmann-La Roche Ltd. Employee of: F. Hoffmann-La Roche Ltd, Laura Brockwell Employee of: F. Hoffmann-La Roche Ltd, Mylene Giraudon Employee of: F. Hoffmann-La Roche Ltd, Mauro Zucchetto Employee of: Working for F. Hoffmann-LaRoche Ltd as an employee of Parexel International, Lisa Christ Shareholder of: Gilead Sciences and F. Hoffmann-La Roche Ltd, Consultant of: Bristol-Myers Squibb, Novartis, and Sanofi, Grant/research support from: Gilead Sciences, F. Hoffmann-La Roche Ltd, and Pfizer, Bettina Bannert: None declared, Thomas Daikeler Speakers bureau: Novartis, Consultant of: Advisory fees from Novartis, Grant/research support from: Research support from Novartis, Peter Villiger Speakers bureau: Roche, MSD, AbbVie, Pfizer, Novartis, Grünenthal, Amgen, Sanofi, Chuangui, BMS, and Gilead, Consultant of: Advisory fees from Roche, MSD, AbbVie, Pfizer, Novartis, Grünenthal, Amgen, Sanofi, Chuangui, BMS, and Pfizer, Grant/research support from: Research support from MSD, AbbVie, Pfizer, DOI: 10.1136/annrheumdis-2022-eular.898

**POS0269 RESULTS OF ONE YEAR OBSERVATIONAL EXTENSION OF THE BRIDGE-PMR STUDY, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL WITH RITUXIMAB IN POLYMALGIA RHEUMATICA.**

T. Bolhuis1, D. Marsman1, A. Den Broeder1, N. Den Broeder1, A. Van der Maas1, 1Sint Maartenskliniek, Rheumatology, Ubbergen, Netherlands

**Background:** Glucocorticoids (GC) are the cornerstone of treatment in Poly- myalgia rheumatica (PMR) [1]. However, they are associated with considerable toxicity and inefficacy in part of the patients. Rituximab (RTX) was effective for PMR in a 21-week randomized controlled trial (RCT), however results from longer follow-up is still absent [2].

**Objectives:** To assess, in a randomized double blinded fashion, the clinical and GC-sparing effects one year after RTX.

**Methods:** In the BRIDGE-PMR, an RCT of 38 recently diagnosed and 9 relapsing PMR (2012 EULAR/ACR classification criteria) patients recruited from the Sint Maartenskliniek, patients were randomly allocated in a 1:1 ratio and treated with 1x 1000mg RTX / placebo (PCB) iv, identical pre-medication and an accelerated GC tapering protocol. After the 21-week study, patients were assessed in a double blinded prospective extension study up to one year after infusion. The primary outcome at one year was between group difference in GC-free remission (PMR-activity score < 10). Analysis was performed with Fischer’s exact test and a two-tailed p-value < 0.05 was considered significant. Secondary outcomes were proportion of relapsing patients during the extension, proportion of patients with CRP > 5mg/l during the extension, cumulative GC dose, DMARD use, EQ-5D score, and adverse events (AE).

**Results:** The proportion of patients in GC-free remission after one year was significantly higher in the RTX group (48%, 11/23) compared to the PCB group (17%, 4/24), with an absolute difference of 31% (95%-CI 6-56), a relative risk of 2.9 (95%-CI 1.1-7.7), p=0.03. The secondary outcomes showed statistically significant differences in RTX versus PCB in median GC cumulative dose: 1595 versus 2302 mg (p = 0.04) and median PMR-AS: 6 versus 15 (p = 0.02) (Table 1 and Figure 1). No differences were seen in other secondary outcomes.
Table 1. Primary and Secondary Outcomes for Rituximab Versus Placebo Treatment One Year After Infusion

<table>
<thead>
<tr>
<th></th>
<th>Placebo [n=24]</th>
<th>Rituximab [n=23]</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission, number (%)</td>
<td>10 (42%)</td>
<td>15 (65%)</td>
<td>0.15</td>
</tr>
<tr>
<td>GC-free remission, number (%)</td>
<td>4 (17%)</td>
<td>11 (48%)</td>
<td>0.03</td>
</tr>
<tr>
<td>Cumulative GC dose 0-52 weeks, in mg</td>
<td>2302 (1595 - 2881)</td>
<td>1596 (1275 - 2260)</td>
<td>0.04</td>
</tr>
<tr>
<td>Cumulative GC dose 21-52 weeks, in mg</td>
<td>959 (91 - 1442)</td>
<td>160 (0 - 902)</td>
<td>0.10</td>
</tr>
<tr>
<td>Relapse patient 21-52 weeks, number (%)</td>
<td>14 (58%)</td>
<td>12 (52%)</td>
<td>0.77</td>
</tr>
<tr>
<td>PMR-AS**</td>
<td>15.25 (7.75 - 22.5)</td>
<td>6.3 (4.7 - 12.1)</td>
<td>0.02</td>
</tr>
<tr>
<td>CRP serum level, in mg/L</td>
<td>3.5 (2 - 5)</td>
<td>3 (1 - 4)</td>
<td>0.29</td>
</tr>
<tr>
<td>physicians' VAS, 0-10</td>
<td>2 (0.2 - 3.7)</td>
<td>1 (0 - 2)</td>
<td>0.08</td>
</tr>
<tr>
<td>Morning stiffness, in minutes</td>
<td>25 (4 - 60)</td>
<td>10 (0 - 30)</td>
<td>0.06</td>
</tr>
<tr>
<td>VSAM pam, 0-10</td>
<td>3 (1.45 - 6.4)</td>
<td>1.8 (0.7 - 5)</td>
<td>0.16</td>
</tr>
<tr>
<td>EQSD-5L, score at week 52#</td>
<td>0.71 (0.60 - 0.77)</td>
<td>0.71 (0.63 - 0.77)</td>
<td>0.87</td>
</tr>
<tr>
<td>EQSD-5L, change week 21-52#</td>
<td>0 (-0.03 - 0.09)</td>
<td>0.07 (-0.05 - 0.10)</td>
<td>0.56</td>
</tr>
<tr>
<td>Methotrexate use, number (%)</td>
<td>4 (17%)</td>
<td>2 (9%)</td>
<td>0.67</td>
</tr>
<tr>
<td>Adverse events, total, % of patients</td>
<td>8, 26%</td>
<td>6, 33%</td>
<td>0.75</td>
</tr>
</tbody>
</table>

Notes: * Relapse was defined as therapy intensification, based on either a) an increase in oral prednisolone, b) adding intramuscular methylprednisolone, or c) starting or switching a DMARD due to treatment inefficiency. ** Remission is based on the PMR-AS, calculated by oral prednisolone, b) adding intramuscular methylprednisolone, or c) starting or switching a DMARD due to treatment inefficiency. 

Conclusion: Efficacy of 1x1000 mg RTX in PMR was maintained up to 1 year follow-up, while also demonstrating a GC sparing effect. A larger trial, also assessing effect of on demand retreatment, is needed to confirm our results, and provide insight in which patients most likely benefit from RTX.

REFERENCES:

Disclosure of Interests: None declared


Figure 1. Cumulative GC Dose 0-52 Weeks, in mg


development of aortic aneurysm/dilatation in a prospective cohort of patients with biopsy-proven giant-cell arteritis: early identification of patients at risk.

J. Marco Hernandez1, A. García-Martínez1, S. Prieto-González2, A. Suso1, G. Espigol-Frigole1, P. Arguis1, R. Gilabert2, M. Alba2, J. Hernández-Rodríguez2, M. C. Cid1. 1Hospital Clínic de Barcelona, Vasculitis Research Unit, Barcelona, Spain; 2Hospital Clinic de Barcelona, Radiology Department, Barcelona, Spain

Background: Up to 10-33% of patients with giant-cell arteritis (GCA) develop aortic structural damage (ASD) (aneurysm or dilatation), typically involving the ascending aorta (1,2). Systematic use of imaging reveals radiological features of aortitis in 45-85% of patients at diagnosis (3). This finding has been associated with future aortic dilatation in retrospective studies (4). Objectives: To investigate the prevalence of thoracic ASD in a large prospective cohort of patients with GCA subjected to periodic imaging. To evaluate the association between features at diagnosis with ASD development.

Methods: Patients were included in the study if consented, had biopsy-proven GCA and met the 1990 ACR criteria for GCA classification. Patients were prospectively followed and treated according to uniform criteria. Since 1985 patients were subjected to systematic imaging screening aimed to detect thoracic ASD. Until November 2006 it consisted of a chest X-ray that was performed at least 4 years after diagnosis and repeated every 4 years. When aortic dilatation was minimal suspected, patients underwent contrast-enhanced computed tomography (CT) scan. Since November 2006, most of patients were prospectively studied with CT angiography at diagnosis, after 1 year and every 4 years. The diagnosis of ASD was confirmed by CT, defined as an aortic diameter > 4 cm at the ascending aorta or >4 cm at the aortic arch or the descending aorta. Data regarding demographic characteristics, cardiovascular risk factors, GCA symptoms, laboratory tests, chronic medication at time of GCA diagnosis and corticosteroid tapering were recorded. Kaplan-Meier survival plot was used to present the cumulated incidence of thoracic ASD over time and patients were censored at the time of ASD diagnosis or at the time of the last screening in those without ASD. We also investigated which variables present at the time of GCA-diagnosis were associated with future development of ASD. Patients were classified in two groups according to whether they developed ASD or not during a follow-up period of 8 ± 1 years from the time of diagnosis.

Results: Thoracic ASD was confirmed by CT in 58 patients (21.6% of the patients with systematic screening diagnosed from 1994 to 2018) after a median follow-up of 4.7 years (0.05-7.5). Ascending aorta was involved in 56 patients (96.5%), followed by the aortic arch in 11 patients (18.9%), and descending aorta in 5 (8.6%). 14 patients (24.1%) had more than 1 aortic segment involved. Figure 1 shows the number of patients with thoracic ASD detected during follow-up.

Disclosure of Interests: None declared


Figure 1. Thoracic ASD was detected within the first 4 years from GCA-diagnosis in 19 out of the 58 patients who developed ASD (32.7%) but was severe (≥ 50 mm) in only 3 (15.8% out of those 19 patients). Most ASD was detected between 5 and 9 years after GCA-diagnosis. Patients who developed ASD during follow-up experienced less often cranial ischemic symptoms (14.8% vs 41.1%; p=0.003) and polymyalgia (33.3% vs 51.8%; p=0.057), and less frequently had a previous diagnosis of hypertension (66.7% vs 79.3%; p=0.081). Age, sex, clinical or laboratory findings or chronic therapies used at time of GCA-diagnosis were not significantly different between groups. After multivariate analysis, the presence of cranial ischemic symptoms (HR 0.180, 95% CI 0.065-0.495, p=0.001) and polymyalgia rheumatica (HR 0.329, 95% CI 0.136-0.793, p=0.013) remained inversely associated with thoracic ASD development.

Conclusion: ASD is frequent and probably an underdiagnosed complication of GCA. There is no consensus yet regarding the optimal screening protocol during follow-up and early identification of patients at risk is crucial for this purpose. The presence of cranial ischemic symptoms or polymyalgia rheumatica were inversely associated with thoracic ASD development in our prospective cohort.

REFERENCES:

Disclosure of Interests: Both first co-authors contributed equally to this work. The research was supported by MVT3 2014/207492

Disclosure of Interests: None declared

**REFERENCES:**


**Acknowledgments:** on behalf of the Spanish Registry of Systemic Vasculitis (REVAS).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3134
Giant Cell Arteritis (GCA) is the most common form of primary systemic vasculitis in patients aged >50 years. It predominantly affects the cranial arteries; however, extra-cranial disease involving the aorta and its major branches can also be present. Currently, ultrasound of the temporal (TA) and axillary (AX) arteries is the first imaging modality recommended in patients with suspected predominantly cranial GCA. Nevertheless, other arteries such as facial (FA), occipital (OC), subclavian (SC), and common carotid (CC) arteries can also show vasculitic changes on ultrasound. However, there are still conflicting data to support the inclusion of these arteries in the routine ultrasound assessment of patients with suspected GCA.

**Objectives:** To assess the value of adding the evaluation of the FAs, OCs, SCs and CCs in the ultrasonographic diagnosis of patients with GCA.

**Methods:** Single-center observational retrospective study, using data from patients diagnosed with GCA registered at the Rheumatic Diseases Portuguese Registry (Reuma.pt). All patients underwent ultrasound of the TAs and AXs ± FAs, OCs, SCs or CCs at the time of diagnosis. The halo sign was considered a positive ultrasonographic finding for GCA. Only patients with the presence of halo sign in at least one of the arterial segments assessed were included. Binary logistic regression modelling was performed to explore associations between the presence of halo sign in different arterial segments.

**Results:** We included 84 patients, 57 (67.9%) females, with a mean ± standard deviation age at diagnosis of 75.6 ± 8.8 years. Halo sign was found in the TAs of 66/84 (78.6%) patients, AXs of 40/84 (47.6%) patients, FAs of 37/74 (50.0%) patients, OCs of 15/61 (24.6%) patients, SCs of 30/49 (61.2%) patients and CCs of 13/60 (21.7%) patients. Of the 44/84 patients with GCA without the presence of TA halo, 17/18 (94.4%) showed halo in the AXs, 1/18 (5.6%) in the FAs, 3/18 (16.7%) in the OCs, 15/17 (88.2%) in the SCs and 6/16 (37.5%) in the CCs. Of the 44/84 patients with GCA without the presence of AX halo, 43/44 (97.7%) showed halo in the TAs, 24/39 (61.5%) in the FAs, 12/32 (37.5%) in the OCs, 4/18 (22.2%) in the SCs and 3/33 (9.1%) in the CCs. A total of 83/84 (98.8%) patients had halo sign on the ultrasound of either the TA or AX arteries. The patient with normal TA and AX ultrasound had the presence of halo sign in the SCs. Table 1 shows the proportion of patients with positive TA and AX ultrasounds according to the presence of halo in the FA, OC, SC or CC arteries. Patients with involvement of the cranial arteries were more likely to have a TA halo (OR 30.6, 95% CI 3.8-247.3; OC: OR not applicable) and less likely to have an AX halo (OR 0.37, 95% CI 0.14-0.95; OC: OR 0.19, 95% CI 0.05-0.77). As opposed to patients with involvement of the extra-cranial arteries in whom the halo sign was more frequently found in the AXs (SC: OR 18.2, 95% CI 4.2-78.9; CC: OR 5.9, 95% CI 1.4-24.4) but not in the TAs (SC: OR 0.12, 95% CI 0.02-0.60; OC: OR 0.32, 95% CI 0.09-1.15).

**Table 1. Differences in the presence of halo sign in the temporal and auxiliary arteries according to the arterial segment affected.**

<table>
<thead>
<tr>
<th>Arterial segment with halo</th>
<th>Temporal arteries with halo</th>
<th>Auxiliary arteries with halo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facial arteries (n=37)</td>
<td>36/37 (97.3%)</td>
<td>13/37 (35.1%)</td>
</tr>
<tr>
<td>Occipital arteries (n=15)</td>
<td>15/15 (100.0%)</td>
<td>3/15 (20.0%)</td>
</tr>
<tr>
<td>Subclavian arteries (n=30)</td>
<td>26/30 (86.7%)</td>
<td>10/13 (76.9%)</td>
</tr>
<tr>
<td>Common carotid arteries (n=13)</td>
<td>7/13 (53.8%)</td>
<td>10/13 (76.9%)</td>
</tr>
</tbody>
</table>

**Conclusion:** Our results support the need to assess both TAs and AXs in patients with suspected GCA, resulting in a diagnostic sensitivity of 99%. Only by adding the evaluation of the SCs to the already recommended TAs and AXs increased the diagnostic sensitivity of ultrasound to 100%. All patients with a positive FA, OC or CC ultrasound for GCA also showed a halo sign in either the TAs or AXs. Hence, the additional assessment of these arteries did not improve the diagnostic yield of ultrasound and, therefore, should not be recommended in routine practice.

**Disclosure of Interests:** None declared

life-threatening disease complications. Certain population subsets seem to be at increased risk of developing such complications, such as elderly and/or immuno-compromised patients.

Objectives: To assess the persistence of immunity following SARS-CoV-2 mRNA vaccine and the magnitude of the humoral response after the booster dose in a cohort of patients affected by giant cell arteritis (GCA).

Methods: Patients with GCA regularly followed at the Rheumatology Department of the University of Pavia, Italy, who received a booster dose of SARS-CoV-2 mRNA vaccine (BNT162b2 Pfizer/BioNtech or mRNA-1273 Moderna) between October 1st and December 31st, 2021 were included. Humoral response was assessed by measuring SARS-CoV-2 Trimeric S (TSAs) and Neutralizing (NAbs) antibodies, with a cut-off of 33.8 Binding Antibody Units (BAU)/mL and 1:10 dilution, respectively. Blood samples from each patient were drawn at least 4 months after the second and three weeks after the third vaccine dose.

Results: Forty-two patients who received the booster dose of SARS-CoV-2 mRNA vaccine were enrolled. Thirty (71.4%) were females, mean age 73.2±4.7 years, disease duration 58±38 months, 19 (45.2%) had large-vessel vasculitis. Thirty-two (76.2%) were on glucocorticoids (GCs) at a mean dose ≥7.5 mg/day prednisone equivalents had negative NAbs before the third dose. Thirty-nine (55.3%) patients were on methotrexate (MTX) and 30 (71.4%) NAbs. The median TSAb titre was 134 BAU/mL (IQR 2080-2080) (p<0.001), while the median NAb titre increased 24-32 fold after the third vaccine dose. All patients developed TSAbs, even those with negative NAbs after the second dose.

Data regarding antibody response after the booster dose were available for 35 patients (83.3%). Blood collection occurred at a median of 25 days (IQR 24-32) after the third vaccine dose. All patients developed TSAbs, even those who did not respond to the previous shots. The median TSAb titre rose to 2080 BAU/mL (IQR 2080-2080) (p<0.001), while the median NAb titre increased from 1:10 to 1:320 (p<0.001). One patient (2.9%) treated with prednisone 8.75 mg/day plus MTX 12.5 mg/week did not develop NAbs. NAb levels were >7.5 mg/day prednisone equivalents seemed to blunt NAb levels along time: 28.6% patients on GCs ≥7.5 mg/day prednisone equivalents had negative NAbs before the third dose vs. 80.0% of those taking <7.5 mg/day (p=0.007) as well as lower NAb titres (Figure 1B).

Conclusion: In our cohort, most patients who seroconverted after the second dose of vaccine retained the humoral immunity, with excellent seroconversion rates following the booster dose. However, GCs, especially at doses ≥7.5 mg/day prednisone equivalents, may contribute to the waning of NAb titres. On the other hand, immunosuppressants like MTX, especially when combined with GCs, might impair the magnitude of the humoral response to the booster dose.

Disclosure of Interests: None declared


Figure 1. (A) TSAb levels before and after the booster dose among patients on GC + MTX. (B) NAb titres before and after the booster dose according to treatment with prednisone ≥7.5 mg/day or (C) MTX in combination with GCs or (D) MTX alone.
appropriate sequence of use of US and CR in patients with suspected CPPD: in case of a positive CR at any of the 3 sites (menisci and HC) no additional exam is necessary, and the same in case of a negative US in at least two sites; however in case of a negative CR, US could help in a statistically significant way to identify CPPD patients, and further in case of a positive US in a single site CR can offer additional information.


<table>
<thead>
<tr>
<th></th>
<th>US</th>
<th>SN</th>
<th>SP</th>
<th>PPV</th>
<th>NPV</th>
<th>ACC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MM</td>
<td>0.88</td>
<td>0.81</td>
<td>0.82</td>
<td>0.80</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>LM</td>
<td>0.88</td>
<td>0.73</td>
<td>0.76</td>
<td>0.86</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>HC</td>
<td>0.78</td>
<td>0.86</td>
<td>0.82</td>
<td>0.83</td>
<td>0.82</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.92</td>
<td>0.64</td>
<td>0.73</td>
<td>0.89</td>
<td>0.78</td>
<td></td>
</tr>
<tr>
<td>CR</td>
<td>MM</td>
<td>0.32</td>
<td>1</td>
<td>0.61</td>
<td>0.67</td>
<td></td>
</tr>
<tr>
<td>LM</td>
<td>0.40</td>
<td>0.96</td>
<td>0.91</td>
<td>0.63</td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>HC</td>
<td>0.48</td>
<td>0.93</td>
<td>0.85</td>
<td>0.68</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.54</td>
<td>0.92</td>
<td>0.88</td>
<td>0.66</td>
<td>0.73</td>
<td></td>
</tr>
<tr>
<td>US + CR</td>
<td>MM</td>
<td>0.68</td>
<td>0.81</td>
<td>0.82</td>
<td>0.88</td>
<td>0.84</td>
</tr>
<tr>
<td>LM</td>
<td>0.92</td>
<td>0.69</td>
<td>0.76</td>
<td>0.90</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>HC</td>
<td>0.87</td>
<td>0.82</td>
<td>0.80</td>
<td>0.89</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>Overall</td>
<td>0.92</td>
<td>0.56</td>
<td>0.67</td>
<td>0.88</td>
<td>0.75</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. evaluation of sequence of US and CR

Conclusion: US confirmed a high diagnostic accuracy in identifying patients affected by CPPD at knee level, while CR demonstrated a high specificity but a low sensitivity. Performing both diagnostic tests could make sense in case of a negative CR or in case of an inconclusive US (only one positive site). To our knowledge, this is the first study that investigates the role of the combination of the two exams in CPPD. Further studies in a large number of patients and in different joints would be helpful to address this point.

REFERENCES:

DISCLOSURE OF INTERESTS: None declared


POS0278 COMPARISON OF ULTRASOUND BEAM ATTENUATION BY CALCIUM PYROPHOSPHATE, HYDROXYAPATITE AND MONOSODIUM URATE CRYSTALS: A PROOF-OF-CONCEPT STUDY

E. Cheremushkina1,2, M. Eliseev1, O. Sheliabina1, A. Novikova3, S. Glukhova4.
1VA Nasonova Research Institute of Rheumatology, Laboratory of Laboratory Microcrystalline Arthritis, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Laboratory of Microcrystalline Arthritis, Moscow, Russian Federation; 3Laboratory Axial Spondyloarthritis, Moscow, Russian Federation

Background: Ultrasound (US) demonstrated to be reliable and accurate for the diagnosis of crystal induced arthropathies, especially gout and calcium pyrophosphate deposition disease (CPPD) and validated definitions for uric acid and calcium pyrophosphate deposition in joints were released by the Outcome Measures in Rheumatology (OMERACT) US group. Less is known regarding hydroxyapatite (HA) deposition disease (HAAD) and the role of US in the assessment of HA crystal deposition.

Objective: To assess the effect of colchicine, hydroxychloroquine, and methotrexate on cardiovascular outcomes (CVO) in CPPD pts.

Methods: The study included 305 pts with CPPD: 115 (37.7%) men, 190 (62.3%) women. The average follow-up period was 3.9±2.7 yrs. Among the factors influencing CVO were considered: gender, age, smoking, alcohol intake ≥20 standard doses/week, hypertension, history of cardiovascular disease (CVD);
computed tomography (CT) and dual-energy CT (DECT) in vivo[1]. The density of the agar-based lipogel background was intentionally increased to mimic the X-ray attenuation of hyaline cartilage (i.e., 100-120 HU at 120 kVp). Each crystal suspension was placed in a plastic container filled with US gel, next to the control (i.e., crystal-free background) calibration phantom. We acquired all US images using a Samsung RS80A system equipped with a high-frequency linear array transducer (4-18 MHz) set at the maximum frequency, by applying the same settings. All scans were performed by a single experienced sonographer, blinded to the crystal type and concentration. For each of the 16 crystal suspensions, at least two images were recorded both in the long- and short-axis views, the latter including the control phantom in the field of view. Interpretation of US images for the extent of US beam attenuation and the presence of acoustic shadowing was performed in consensus with a second experienced sonographer.

Results: None of the five CPP phantoms generated posterior acoustic shadowing or US beam attenuation regardless of CPP concentration. HA 31 mg/mL did not generate US beam attenuation, while HA 62, 92 and 123 mg/mL generated a progressively increasing US beam attenuation with posterior acoustic shadow clearly generated by HA 153 mg/mL. Similarly, MSU 90 mg/mL did not generate US beam attenuation, while HA 62, 92 and 123 mg/mL generated only a very faint US shadow clearly generated by HA 153 mg/mL. Conversely, MSU 195 mg/mL generated only a very faint US shadow clearly generated by HA 153 mg/mL. None of the five CPP phantoms generated posterior acoustic shadowing or US beam attenuation even if a clear posterior acoustic shadow was detectable only with MSU 420 and 500 mg/mL (Figure 1).

Conclusion: This proof-of-concept study confirmed that in the concentrations of crystals encountered in vivo, CPP do not generate posterior shadowing, while MSU and HA determine US beam attenuation proportionally to the concentration of the crystals. Being this a proof-of-concept study, attenuation of the US beam was assessed empirically and not in a quantitative or semi-quantitative way. However, this study highlights the potential of US to differentiate between CPP, MSU and HA crystals based on their appearance on gray scale imaging. Future studies should be carried out with different crystal concentrations, different US equipment and settings in order to create a scoring system for US beam attenuation that is actually lacking.

REFERENCES:

Disclosure of Interests: None declared

Background: Despite the disproportionately worsening disease burden of female gout in recent years and its frequent associations with key cardiovascular risk factors (more often than male gout), there remains a paucity of specific data about female gout, particularly about its impact on mortality and fatal coronary heart disease. Compared to women without history of gout or CHD, women with gout at baseline in 1982 tended to be older (mean age 7.8 (SD 7.6) years).

Methods: Using data from the Nurses’ Health Study (NHS), an ongoing prospective cohort study in which female nurses in the United States completed detailed mailed questionnaires regarding their medical history, lifestyle, and other risk factors at baseline and every two years thereafter, we prospectively analyzed the association between gout status and mortality, specifically in female gout to help curtail the rising disease burden of gout worldwide.

Results: These prospective data indicate that women with gout have a higher risk of all-cause mortality, which is primarily driven by higher risk of CVD deaths. These findings closely agree with the UK general population data of both sexes that showed unclosing mortality gap over the past two decades. Together, these findings provide support for rigorous cardiovascular risk factor modification specifically in female gout to help curtail the rising disease burden of gout worldwide.

Conclusion: These prospective data indicate that women with gout have a higher risk of all-cause mortality, which is primarily driven by higher risk of CVD deaths. These findings closely agree with the UK general population data of both sexes that showed unclosing mortality gap over the past two decades. Together, these findings provide support for rigorous cardiovascular risk factor modification specifically in female gout to help curtail the rising disease burden of gout worldwide.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3143
SUA decreased from mean 500 µmol/L at baseline to 311 µmol at 1 year and 324 µmol/L at year 2. Flares were seen in year 1 in 81.2% (155/186) and year 2 26.0% (45/173) of patients. The total sum of SUA changes over 2 years as a global measure for individual SUA fluctuation was related to flares in all 3-month periods during year 1 (Table 1) and for year 1 overall (Figure 1), but not for year 2.

**Table 1. Flares and fluctuation of serum urate (SUA) measures during defined observation periods.**

<table>
<thead>
<tr>
<th>Flare period (Mths)</th>
<th>N</th>
<th>Sum of all SUA changes (mean)</th>
<th>SUA change (mean)</th>
<th>&gt;30 µmol/L SUA change (% patients)</th>
<th>&gt;60 µmol/L SUA change (% patients)</th>
<th>&gt;90 µmol/L SUA change (% patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3</td>
<td>63 467*</td>
<td>141*</td>
<td>88.1</td>
<td>83.1</td>
<td>67.8</td>
<td></td>
</tr>
<tr>
<td>Flare + 148 369*</td>
<td>165 95.5</td>
<td>91.5</td>
<td>80.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-6</td>
<td>91 459*</td>
<td>19</td>
<td>39.8</td>
<td>28.2</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>Flare - 120 375</td>
<td>17</td>
<td>39.4</td>
<td>24.5</td>
<td>14.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-9</td>
<td>56 482*</td>
<td>10</td>
<td>49.0**</td>
<td>25.5</td>
<td>25.5</td>
<td></td>
</tr>
<tr>
<td>Flare - 155 386</td>
<td>26</td>
<td>26.5</td>
<td>15.5</td>
<td>15.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9-12</td>
<td>70 470*</td>
<td>4</td>
<td>32.2</td>
<td>16.9</td>
<td>11.9</td>
<td></td>
</tr>
<tr>
<td>Flare - 116 406</td>
<td>9</td>
<td>22.6</td>
<td>9.4</td>
<td>6.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-12</td>
<td>155 445*</td>
<td>193</td>
<td>98.0</td>
<td>94.0</td>
<td>90.7*</td>
<td></td>
</tr>
<tr>
<td>Flare - 36 345</td>
<td>160</td>
<td>91.7</td>
<td>86.0</td>
<td>75.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12-24</td>
<td>45 411</td>
<td>13</td>
<td>24.4</td>
<td>11.1</td>
<td>6.7</td>
<td></td>
</tr>
<tr>
<td>Flare - 128 449</td>
<td>14</td>
<td>25.8</td>
<td>11.7</td>
<td>4.7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*P<0.05, **P<0.01 for comparisons +/Flare

Other measures of SUA fluctuation (SUA change during periods, and exceeding thresholds of change) were generally not related to incidence of flares, neither were sensitivity analyses for incidence of flares in periods succeeding observed SUA fluctuations.

**Conclusion:** Fluctuation in SUA, defined as the total sum of mean SUA changes between all study visits, was related to gout flares during year 1. Our findings support that a pattern of SUA fluctuation is related to gout flares.

**Figure.** Fluctuation of serum urate and flare during months 0-12

**Disclosure of Interests:** Till Uhlig Speakers bureau: SOBI, Consultant of: Grünenthal, Lars Karoliussen: None declared, Joe Sexton: None declared, Tore K. Kvien Speakers bureau: AbbVie, MSD, UCB, Hospira/Pfizer, Eli-Lilly, Roche, Hickma, Onan, Sanofi, Celltrion, Sandzol, Biogen, Aegis, Ewop-harma, Mylan, Grant/research support from: BMS, Asprey Andre Harvardscholm Speakers bureau: Pfizer, UCB, Eli Lilly, Celgene, Janssen-Clag, AbbVie, Gilead, Fernando Perez-Ruiz Speakers bureau: Algorithm, Ayinlam, Astellas, Arthrit, Menarini, NMD, Parexel, Hilde Berner Hammer Speakers bureau: AbbVie, Lilly, Novartis

**DOE:** 10.1136/annrheumdis-2022-eular.1135

**POS0282 UPDATE ON COMPARATIVE CARDIOVASCULAR SAFETY OF FEBOXOSTAT VersUS ALLOPURINOL AMONG PATIENTS WITH GOUT**

A. Shin, Y. J. Ha, Y. J. Lee, E. B. Lee, E. H. Kang. 1. Seoul National University Bundang Hospital, Department of Internal Medicine, Seongnam-si, Korea, Rep. of (South Korea); 2. Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)

**Background:** Gout is associated with an increased risk of cardiovascular (CV) disease.

**Objectives:** To update comparative CV safety of febuxostat versus allopurinol among patients with gout

**Methods:** Using the 2011-2019 Korea National Health Insurance database, we conducted a cohort study comparing gout patients initiating febuxostat versus allopurinol, with study participants matched on a propensity score (PS) for 65 covariates at a 1:1 ratio. The primary outcome was composite CV outcome of myocardial infarction, coronary revascularization, and stroke. Secondary outcomes were CV and all-cause mortalities in addition to individual components of the primary outcome. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), comparing febuxostat versus allopurinol initiators.

**Results:** We included 160,930 febuxostat users PS-matched on 160,930 allopurinol users (mean age 59.3 years, 79.6% male). During a mean follow-up of 250 days, the incidence rate of the primary outcome was 2.27 and 2.06 per 100 person-years for allopurinol and febuxostat users respectively, with the PS-matched HR [95% CI] of 1.03 [0.95-1.12]. Analysis on secondary outcomes also showed a similar result except for all-cause mortality with a significantly reduced risk among febuxostat users with a PS-matched HR [95% CI] of 0.84 [0.78-0.91] (Table 1).

**Table 1. Comparative cardiovascular safety between febuxostat and allopurinol**

<table>
<thead>
<tr>
<th>Events</th>
<th>FY</th>
<th>HR <strong>95% CI</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Composite CV</td>
<td>2635</td>
<td>2.093</td>
</tr>
<tr>
<td>MI</td>
<td>468</td>
<td>0.84</td>
</tr>
<tr>
<td>Coronary</td>
<td>1085</td>
<td>0.84</td>
</tr>
<tr>
<td>Stroke or TIA</td>
<td>1490</td>
<td>0.77</td>
</tr>
<tr>
<td>Death</td>
<td>2558</td>
<td>0.84</td>
</tr>
</tbody>
</table>

*IR is per 100-person years, HR=incidence rate, HR=p-value, CIs=confidence interval, MI=myocardial infarction, FY=person-years, TIA=transient ischemic attack

**Conclusion:** This large population-based cohort study showed a similar CV safety profile between febuxostat and allopurinol users but found a 16% reduced all-cause mortality among febuxostat users compared to allopurinol, primarily derived from non-CV death reduction.

**Disclosure of Interests:** None declared

**DOE:** 10.1136/annrheumdis-2022-eular.2910

**POS0283 DOES A GOUT STIGMA AMONG RHEUMATOLOGISTS INFLUENCE PERCEPTIONS OF PATIENTS AND TREATMENT DECISIONS?**

N. L. Edwards, B. Lamoreaux, A. Magerman, J. Hunger, J. Vitriol.

1. University of Florida College of Medicine, Rheumatology, Gainesville, United States of America; 2. Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America; 3. Saint Joseph's University, Haub School of Business, Philadelphia, United States of America; 4. Miami University, Psychology, Oxford, United States of America; 5. Stony Brook University, Political Science, Stony Brook, United States of America

**Background:** Gout is an inflammatory condition caused by chronic hyperuricemia, often causing physical and emotional distress and a lower quality of life (QOL),1-4 Gout stigma is common and impactful,5 with physicians often perceiving gout as a “lifestyle” disease caused by personal dietary and exercise choices. Further, patients can internalize and anticipate this stigma, influencing how they seek healthcare and adhere to medical therapies.6

**Objectives:** This study investigated whether or not a gout stigma exists among rheumatologists and, if so, how it influences physicians’ perceptions of patients and treatment decisions. Rheumatoid arthritis (RA) was used as a comparator disease.

**Methods:** 106 practicing rheumatologists completed an online survey regarding perceptions of, experiences with, and recommendations for patients with controlled gout, uncontrolled gout, and rheumatoid arthritis (RA). Disease states were presented in random order. Each set of measures examined rheumatologists’ perceptions and judgments of each disease condition on a range of dimensions, including (a) perceptions of patient’s compliance with treatment recommendations and responsibility for their disease condition, (b) causal attributions for contributing factors to disease condition, and (c) efficacy of recommended treatment decisions. Answers were provided using a 7-point Likert scale (e.g., patient compliance: 1 = will not comply, 7 = will comply; patient responsibility for condition: 1 = not responsible, 7 = responsible). Prior to analyses, all responses were converted to a 0 to 1 scale for ease of comparison and interpretation.

**Results:** Responses regarding controlled and uncontrolled gout patients were not significantly different, so these two groups were pooled. Compared to patients with RA, rheumatologists perceived patients with gout as significantly more responsible for their disease (p<0.05) and significantly less likely to comply with prescribed treatment regimens (p<0.05, Figure 1). Further, rheumatologists perceived patient personal behavior, diet, BMI, and patient adherence as...
greater contributing factors to gout than to RA (all p<0.01). Similarly, change in diet, increased exercise, and weight loss were perceived as more beneficial for managing gout than RA (all p<0.01), and biological treatments were perceived as more effective for managing RA than gout (p<0.01).

Conclusion: Despite good intentions when treating gout patients, rheumatologists appear to have causal beliefs and illness perceptions that reflect negative gout-related stereotypes. Compared to RA patients, gout patients were perceived as being more responsible for their condition and were expected to be less compliant with medications and less likely to benefit from biological therapies. Interestingly, there were no differences in rheumatologists’ judgments between patients with controlled and uncontrolled gout, suggesting that their beliefs may refer to gout itself rather than the degree of control or management. Educating physicians, particularly rheumatologists, on the myths surrounding gout may improve clinical care and, therefore, patient outcomes.

REFERENCES:

Acknowledgements: Medical writing support was provided by Lissa Padnick-Silver, PhD, an employee of and stockholder in Horizon.

Disclosure of Interests: N. Lawrence Edwards Consultant of: Horizon Therapeutics, Astra Zeneca, and Selecta Biosciences, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Adam Magerman; None declared, Jeffrey Hunger: None declared, Joseph Vitriol: None declared.


POS0285

SUB-STANDARD CARE FOR PATIENTS WITH GOUT, DESPITE UPDATED GUIDELINES: A UK-WIDE, POPULATION-BASED COHORT STUDY

M. Russell1, A. Rutherford2, B. Ellis3, S. Norton1, A. Douiri2, M. Guillford2, A. Cole3, J. Galloway2. 1King’s College London, Centre for Rheumatic Diseases, London, United Kingdom; 2Imperial College Healthcare NHS Trust, Department of Rheumatology, London, United Kingdom; 3King’s College London, School of Population Health and Environmental Sciences, London, United Kingdom

Background: Treat-to-target urate-lowering therapy (ULT) is highly effective at preventing flares and improving quality of life for patients with gout. However, in 2012, only 27% of patients with gout in UK primary care received prescriptions for ULT within 12 months of diagnosis. Since then, EULAR and BSR gout management guidelines have been updated, to recommend that all patients with gout should have ULT discussed and offered to them, with uptitration of dosing until target urate levels are achieved. We investigated whether gout management has improved in recent years.

Objectives: To assess temporal trends in the initiation of ULT and attainment of serum urate targets following new gout diagnoses in UK primary care from 2004 to 2020.

Methods: The Clinical Practice Research Datalink (CPRD) Gold database was used to assess the management of patients with index diagnostic codes for gout in UK primary care between January 2004 and October 2020. We analysed the proportion of patients with the following outcomes within 12 months of diagnosis: i) initiation of ULT (allopurinol, febuxostat, benzbromarone, probenecid or sulfinpyrazone); ii) serum urate ≤360 µmol/L; iii) serum urate ≤300 µmol/L; iv) treat-to-target urate monitoring (defined as two or more urate ≤300 µmol/L). Interrupted time-series analyses (ITSA) were used to estimate the impact of updated EULAR and BSR gout management guidelines on these outcomes. Multivariate logistic regression was used to analyse predictors of ULT prescription and target attainment following new gout diagnoses.

Results: 129,972 patients had index gout diagnoses between January 2004 and October 2020, of whom only 37,529 (28.9%) had ULT initiated within 12 months of diagnosis. ULT initiation improved modestly over the study period, from 26.8% for those diagnosed in 2004 to 36.6% in 2019, decreasing to 34.7% in 2020 (Figure 1). Of patients diagnosed in 2020 who had a serum urate performed within 12 months of diagnosis, 36.0% attained a urate ≤360 µmol/L, while 17.1% attained a urate ≤300 µmol/L. Of all participants, 18.9% received treat-to-target urate monitoring. In ITSA models, no statistically significant improvements in ULT prescription or urate target attainment were observed after publication of updated
EULAR (2016) or BSR (2017) gout management guidelines, relative to before publication of these guidelines. In multivariate logistic regression models, comorbidities including chronic kidney disease, heart failure and obesity, and diuretic use were associated with increased odds of ULT initiation but decreased odds of attaining target urate levels by 12 months.

Conclusion: In this UK-wide study, we demonstrate that the initiation of ULT and attainment of serum urate targets following new gout diagnoses remain poor, despite the introduction of updated management guidelines. If the evidence-practice gap in gout management is to be bridged successfully, strategies to implement best practice gout care are urgently needed.

REFERENCES:

Acknowledgements: This work is independent research supported by the National Institute for Health Research (NIHR) Doctoral Fellowship, Dr Mark Russell, NIHR000967. This study is based in part on data from the Clinical Practice Research Datalink obtained under licence from the UK Medicines and Healthcare products Regulatory Agency.

Disclosure of Interests: Mark Russell Speakers bureau: Lilly; Menarini, Andrew Rutherford: None declared, Benjamin Douiri: None declared, Martin Gulliford: None declared, Andrew Rutherford: None declared, Benjamin Ellis: None declared, Sam Norton: None declared.

Disclosure of Interests: Chariq Meng: None declared, Divya Rajesh: None declared, Deanna Jannat-Khah Shareholder of: AstraZeneca, Cytodyn, Walgreens, Omar Bruce: None declared, Bridget Jivanelli: None declared, Vivian

All you want to know about bDMARDs in RA

POS0286

CAN PATIENTS WITH CONTROLLED RA RECEIVING ANY CLASS OF TARGETED THERAPY WITH METHOTREXATE (MTX) SUSTAIN DISEASE CONTROL AFTER TAPERING MTX? A SYSTEMATIC REVIEW AND META-ANALYSIS


Background: Patients with RA frequently struggle with intolerance of MTX and adherence to MTX remains highly variable. Guidelines conditionally recommend the tapering of MTX before tapering biologic (b)DMARDs, but acknowledge there is an absence of direct evidence. Prior reviews on this topic have focused on tapering of MTX from combination treatment with TNF-inhibitors(i) only. There have been no updated reviews addressing MTX tapering from other targeted therapies such as IL6-i or JAK-i, nor has there been a systematic review addressing this question.

Objectives: To determine the feasibility of tapering MTX to targeted therapy (bDMARDs or JAKi) alone in patients whose RA is controlled (LDA or remission).

Methods: A systematic literature search combining MeSH terms and key words was conducted in Medline, Embase and Cochrane Library for studies reporting remission outcomes after tapering MTX from targeted therapies in RA. Non-English and animal studies were excluded. Meta-analyses were conducted using random effects models. Forest and funnel plots were created and heterogeneity was calculated.

Results: Our search identified 5762 citations. After removal of duplicates and screening title/abstract using the COVIDENCE platform, 504 full-text articles were reviewed. Of the 10 articles meeting our inclusion criteria of tapering MTX to monotherapy with a targeted therapy, 3 studies tapered to etanercept, 3 to tocilizumab, 1 to tocilcitinib, 1 to adalimumab and 1 to abatacept monotherapy. Nine studies were RCTs and one was a long-term extension study (LTE) (Table 1). Disease duration was longer in 7 studies (6–11 years) and early in 3 studies (1–9 months). The MTX tapering strategy was gradual in 2 and rapid in 8 studies. Follow-up ranged from 3–18 months in RCTs, and up to 3 years in the LTE. Studies reporting outcomes up to 1 year after tapering had remission rates ranging 48–76%, but this dropped to 40% in one study reporting 18-month remission outcomes. Our meta-analysis conducted in 2000 RA participants from 10 studies showed that patients who tapered MTX to targeted therapy alone could maintain remission with an overall pooled OR of 0.81 (0.68, 0.97) (Figure 1). There was no heterogeneity among the studies in this group (I²=0.0%, p=0.788). Our funnel plot indicated high precision and potentially less publication bias. No significant difference in remission outcomes between early RA [OR 0.63 (0.33, 1.18)] and established RA [OR 0.84 (0.69, 1.03)] was observed.

Table 1. Included Studies

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>n</th>
<th>Early RA</th>
<th>Baseline treatment</th>
<th>MTX Taper Strategy</th>
<th>REM measure</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curtis 2020</td>
<td>253</td>
<td>no</td>
<td>ETA+MTX</td>
<td>Stop</td>
<td>SDAI</td>
<td>48 wks</td>
</tr>
<tr>
<td>Emery 2019</td>
<td>147</td>
<td>yes</td>
<td>ADA+MTX</td>
<td>Stop</td>
<td>SDAI</td>
<td>48 wks</td>
</tr>
<tr>
<td>Cohen 2019</td>
<td>533</td>
<td>yes</td>
<td>TOFA+MTX</td>
<td>Stop</td>
<td>DAS28-CP</td>
<td>48 wks</td>
</tr>
<tr>
<td>Emery 2019</td>
<td>411</td>
<td>yes</td>
<td>ETA+MTX</td>
<td>Taper 4 wks</td>
<td>DAS28</td>
<td>52 wks</td>
</tr>
<tr>
<td>Pablos 2019</td>
<td>165</td>
<td>no</td>
<td>TCZ+MTX</td>
<td>Stop</td>
<td>DAS28</td>
<td>28 wks</td>
</tr>
<tr>
<td>Pope 2019</td>
<td>88</td>
<td>no</td>
<td>CZP+DMARD</td>
<td>Stop</td>
<td>DAS28</td>
<td>18 mos</td>
</tr>
<tr>
<td>Kremer 2018</td>
<td>296</td>
<td>no</td>
<td>TCZ+MTX</td>
<td>Stop</td>
<td>DAS28</td>
<td>52 wks</td>
</tr>
<tr>
<td>Edwards 2017</td>
<td>272</td>
<td>no</td>
<td>TCZ+MTX</td>
<td>Taper 24 wks</td>
<td>DAS28</td>
<td>48 wks</td>
</tr>
<tr>
<td>Keystone 2016</td>
<td>205</td>
<td>no</td>
<td>ETA+MTX</td>
<td>Stop</td>
<td>DAS28</td>
<td>18 mos</td>
</tr>
<tr>
<td>Keystone 2018</td>
<td>140</td>
<td>yes</td>
<td>ADA+MTX</td>
<td>Stop</td>
<td>DAS28-CP</td>
<td>3 years</td>
</tr>
</tbody>
</table>

EUA etanercept, ABA abatacept, TOFA tocilizumab, TCZ tocilcitinib, CZP certolizumab pegol, ADA adalimumab, REM remission, wk week, mo month, DAS28 Disease Activity Score 28, SDAI Simplified disease activity index.

Conclusion: Patients with controlled RA have a high probability of maintaining disease control after tapering their MTX to targeted therapy alone, up to 18 months. This review may inform patients with controlled disease on any of a range of targeted therapies and MTX, but who are struggling with MTX-related adverse effects and wish to taper it. Longer follow-up studies with attention to radiographic, functional and patient reported outcomes are needed. The possibility of disease worsening must be discussed with the patient in advance with careful follow-up and prompt re-treatment of disease worsening.

REFERENCES:

Disclosure of Interests: Chariq Meng: None declared, Divya Rajesh: None declared, Deanna Jannat-Khah Shareholder of: AstraZeneca, Cytodyn, Walgreens, Omar Bruce: None declared, Bridget Jivanelli: None declared, Vivian
A PHASE III, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED CLINICAL TRIAL TO COMPARE BAT1806/BIBIB800, A PROPOSED TOCILIZUMAB BIOSIMILAR, WITH TOCILIZUMAB REFERENCE PRODUCT IN SUBJECTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE THERAPY

X. Leng,1,2 P. Leszczyński,3 S. Jeka,3 S. Liu,4 H. Liu,4 M. Miakisz,5 J. Gu,4 L. Kilasoria,3 M. Stanislavchuk9, X. Yang,7 Y. Zhou,7 Q. Dong,7 M. Mitroiu,6 J. Addison,7 X. Zeng,1* Peiking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China;2 Poznan University of Medical Sciences, Department of Rheumatology, Poznan, Poland;3 Clinic and Department of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Department of Rheumatology and Connective Tissue Diseases, Toruń, Poland;4 First Affiliated Hospital of Zhengzhou University, Department of Rheumatology and Immunology, Zhengzhou, China;5 Qilu Hospital of Shandong University, Department of Rheumatology, Jinan, China;6 Toruń Psychodnia Medyczne Centrum, Internal Medicine and Rheumatology, Nowa Sol, Poland;7 The Third Affiliated Hospital of Sun Yat-sen university, Department of Rheumatology, Guangzhou, China;8 Tbilisi Heart and vascular Clinic Ltd, Rheumatology, Tbilisi, Georgia;9 National Pirogov Memorial Medical University, Internal Medicine, Vinnytsya, Ukraine;10 Biothera Solutions Ltd., Medical Affairs, Guangzhou, China;11 Biothera Solutions Ltd., Research and Development, Guangzhou, China;12 Biogen International GmbH, Evidence Generation Biosimilars, Baar, Switzerland;13 Biogen Idec Ltd., Clinical Research, Maidenhead, United Kingdom;14 Peiking Union Medical College Hospital, Department of Rheumatology, Beijing, China

Background: BAT1806/BIBIB800 is a proposed biosimilar to reference tocilizumab (TCZ). A Phase III randomised, double-blind, active-controlled clinical trial was conducted as part of a biosimilar development programme. Objectives: To evaluate the efficacy, pharmacokinetics (PK), safety and immunogenicity of BAT1806/BIBIB800 in comparison with EU-sourced TCZ in subjects with inadequately controlled severe rheumatoid arthritis with inadequate response to methotrexate (MTX). Methods: The study was conducted at 55 centres in China and Europe, between June 2018 and January 2021. Eligible subjects were randomised in a 2:1:1 ratio to one of three treatment groups: (1) BAT1806/BIBIB800 up to Week 48, (2) TCZ up to Week 48, or (3) TCZ up to Week 24, followed by BAT1806/BIBIB800 from Week 24 to Week 48, administered intravenously every 4 weeks at a dose of 8mg/kg. The primary endpoint was the proportion of subjects achieving an ACR20 response at timepoints pre-specified to meet the requirements of different Regulatory Agencies: Week 12, for EMA; Week 24, for FDA and NMMPA. Equivalence margins applied to differences in ACR20 response rates in the BAT1806/BIBIB800 and TCZ treatment groups were pre-specified as follows: +/- 14.5% for EMA (95% confidence interval (CI)) -12.0%, 15.0% for FDA (90% CI); +/- 13.6% for NMMPA (95% CI). Secondary endpoints included pharmacokinetics, safety and immunogenicity. The ICH E9(R1) estimands framework including intercurrent events (related or unrelated to the COVID19 pandemic) was implemented for the ACR20 evaluation. A logistic regression model including ‘region’ (China and Eastern Europe) and ‘previous biologic or targeted synthetic DMARD use’ (Yes/No) as captured in Interactive Web Response System as stratification factors was utilised to assess equivalence for the primary endpoint. The difference in response rates was estimated and corresponding confidence intervals were derived to assess equivalence for the primary endpoint. This abstract presents results up to Week 24.

Results: In total, 621 subjects were randomised to receive BAT1806/BIBIB800 (N=312), TCZ (N=155), or TCZ followed by BAT1806/BIBIB800 (N=154). The groups were comparable in terms of baseline demographics and disease characteristics, including age, gender, disease activity and disease duration. The estimated proportions of subjects achieving an ACR20 response in the BAT1806/BIBIB800 vs. the TCZ groups, respectively, were 68.97% vs. 64.82% at Week 12 and 69.89% vs. 67.94% at Week 24. The estimated difference between ACR response rates was 4.15% (95% CI -3.63, 11.93) at Week 12, and 1.94% (90% CI 4.04, 7.32; 95% CI -5.18, 9.07) at Week 24. The CIs for the estimated differences between the treatment groups were within the pre-defined equivalence margins (Figure 1). The treatment groups were comparable in terms of serum trough levels, incidence of TEAEs and ADA/NAb positivity (Table 1).


DOI: 10.1136/annrheumdis-2022-eular.211

Table 1. Safety and Immunogenicity up to Week 24, and Pharmacokinetics at Week 24

<table>
<thead>
<tr>
<th></th>
<th>BAT1806/BIBIB800 (N=312)</th>
<th>TCZ (N=309)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>196 (63.4)</td>
<td>201 (64.4)</td>
</tr>
<tr>
<td>Related TEAE</td>
<td>151 (48.9)</td>
<td>148 (47.4)</td>
</tr>
<tr>
<td>Related Serious TEAE</td>
<td>13 (4.2)</td>
<td>11 (3.5)</td>
</tr>
<tr>
<td>Related Serious TEAE</td>
<td>7 (2.3)</td>
<td>2 (0.6)</td>
</tr>
<tr>
<td>Fatal TEAE</td>
<td>1 (0.3)</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>ADA positive a</td>
<td>42 (13.6%)</td>
<td>40 (13.2%)</td>
</tr>
<tr>
<td>NAb positive a</td>
<td>42 (13.6%)</td>
<td>43 (13.2%)</td>
</tr>
<tr>
<td>PK, n</td>
<td>271</td>
<td>276</td>
</tr>
<tr>
<td>Serum trough level (µg/mL), median (SD)</td>
<td>15.4 (12.1)</td>
<td>15.8 (12.3)</td>
</tr>
<tr>
<td>Serum trough level (µg/mL), geometric mean (CV%)</td>
<td>12.3 (140.3)</td>
<td>12.9 (121.3)</td>
</tr>
<tr>
<td>Below limit of quantification, n (%)</td>
<td>43 (15.9)</td>
<td>28 (10.1)</td>
</tr>
</tbody>
</table>

TEAE: treatment emergent adverse events a subjects with ≥1 ADA/NAb positive results up to week 24.

Conclusion: BAT1806/BIBIB800 has demonstrated equivalent efficacy at Week 12 and Week 24 and a similar PK, safety and immunogenicity profile as reference tocilizumab up to Week 24.

A CANADIAN RETROSPECTIVE CHART REVIEW EVALUATING CONCOMITANT METHOTREXATE DE-ESCALATION PATTERNS IN RA PATIENTS TREATED WITH BIOLOGIC OR TARGETED SYNTHETIC DMARDs

L. Bessette, B. Florica, P.A. Fournier, T. Girard, L. Naik, D. Sholter, P. Baer. 1 Faculty of Medicine - University Laval, Department of Medicine, Québec, Canada; 2 University of Toronto, Department of Internal Medicine, Toronto, Canada; 3 Abbvie Corporation, Medical Affairs, St-Laurent, Canada; 4 University of Saskatchewan, Department of Adult Rheumatology, Saskatoon, Canada; 5 University of Alberta, Department of Medicine, Edmonton, Canada; 6 Baer Weinberg MPC, Medicine, Scarborough, Canada

Background: Rheumatoid arthritis (RA) guidelines recommend methotrexate (MTX) as anchor therapy in combination with biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). However, its tolerability is challenging with a significant proportion of patients not adhering to their prescribed MTX regimen following a b/tsDMARD initiation. Rates of MTX tapering and withdrawal have been reported elsewhere but Canadian data are lacking.

Objectives: This multi-centre, retrospective chart-based cohort study assessed the frequency of MTX withdrawal or tapering following initiation of a b/tsDMARD in Canadian adults with RA.

Methods: Patients were eligible if they received MTX for ≥3 months before initiation of a b/tsDMARD that was then prescribed continuously for ≥18 months and was initiated in combination with MTX. Patients taking oral prednisone or equivalent at a dose >10 mg per day, and those whose b/tsDMARD was prescribed prior to 2014, were excluded.

Results: Data from 889 patients were included in the analysis. Mean age was 50.6 years and 72.6% were female. Mean time since diagnosis was approximately 8 years. Of the 46.1% of patients with a documented assessment of disease status at baseline, 62.7% of patients had high disease activity. Baseline mean (SD) MTX dose was 18.9 (6.63) mg/week, administered orally (57.4%), subcutaneously (41.3%), or intramuscularly (1.2%). Overall, 270 (30.4%) patients either tapered (123, 13.8%) or discontinued (147, 16.5%) their MTX within 2 years of initiating the b/tsDMARD. Methotrexate dose was unchanged for 582 (65.5%) subjects and increased for 37 (4.2%) subjects. The prescribed b/tsDMARD was most often a tumor necrosis factor inhibitor (TNFi, 52.1%), followed by a Janus kinase inhibitor (JAKI, 18.3%).

In the MTX Tapered group, the most common reasons for MTX dose change were planned tapering (36.6%) and adverse events (29.3%). In the MTX Increased group, insufficient clinical response (73.0%) was the most common reason provided for MTX dose change. Baseline factors associated with MTX dose discontinuation and tapering by multiple logistic regression analysis included a shorter time since diagnosis (Odds ratio (OR): 0.981; 95% confidence interval [CI]: 0.964 – 0.999; P=0.0401), use of non-DMARD medications excluding steroids (OR: 0.883; 95%CI: 0.503 – 0.929; P=0.0150) and a greater number of comorbidities (OR: 1.054; 95%CI: 1.001 – 1.100; P=0.0444). The mean (SD) weekly MTX dose at the end of the data extraction period was 14.13 (4.81) mg for the MTX Tapered group, with 109 (88.6%) subjects taking a weekly MTX dose ≥10mg. In the MTX Increased group, the mean (SD) weekly MTX dose was 22.3 (3.74) mg. Interpretation of the effect of MTX dose on disease activity, fatigue, pain and functional status is challenging due to missing data, but most patients in all 4 groups transitioned to low disease activity or remission during the study period.

Conclusion: Methotrexate withdrawal or tapering occurred in 30.4% of Canadians with RA within two years following b/tsDMARD initiation. There was no evidence of worsening disease activity in these patients. These proportion of Canadian RA patients who reduce or discontinue MTX after the initiation of a b/tsDMARD are generally consistent with those reported in other regions of the world.

Acknowledgements: AbbVie Corp. funded the research for this study and provided writing support for this abstract. AbbVie participated in the study design; study conduct and analysis; and writing, reviewing, and approving this abstract for submission. All authors had access to the data; participated in the development, review, and approval of the abstract; and agreed to submit this abstract to EULAR 2022. AbbVie and the authors thank all study investigators for their contributions and the patients who participated in this study. Medical writing support was provided by Judy drill PhD of Medpace Scientific and funded by AbbVie, LLC.


Figure 1. A conceptual framework of descriptions of the course and timeframe of adverse drug reactions reported by patients using a biologic for immune-mediated inflammatory diseases

Conclusion: We identified six themes in patient-reported descriptions of the course of ADRs of biologics. These themes provide information about ADRs on a broader level than the currently available information on nature and frequency. Information about ADRs enriched with details on the course is essential. A framework of ADRs may support healthcare professionals in improving clinical practice by discussing ADRs with patients and finding practical solutions in dealing with ADRs. This will ultimately lead to more optimised medical treatment.

REFERENCES:
Disclosure of Interests: Jette van Lint: None declared, Naomi Jessurun: None declared, Sander Tas Consultant of: Gebro, GSK, AbbVie, Galvani, Arthrogen, MeiraGTx, Galapagos, Grant/research support from: Pfizer, GSK, Celgene, BMS, AstraZeneca, Harald von Vekenman Speakers bureau: anthe, BMS, Celgene, Galapagos, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Grant/research support from: Abbvie, Sanofi-Genzyme, Frank Hoentjen Speakers bureau: served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celtnion, Teva, Sandoz and Dr Falk, Consultant of: Celgene, Grant/research support from: Funding (Grants/Honoraria): Dr Fr Janssen-Cilag, AbbVie, Takeda, Martin van Doorn Speakers bureau: Janssen, LEO Pharma, Pfizer, Novartis, Paid instructor for: LEO Pharma, Consultant of: AbbVie, Janssen, LEO Pharma, Pfizer, Genentech, Novartis, TEVA, MSD, Sanofi, AstraZeneca, Grant/research support from: Novartis, Janssen, Michael Nurmohamed Speakers bureau: Abbvie, Janssen, Celgene, Consultant of: AbbVie, Grant/research support from: Abbvie, Amgen, Pfizer, Galapagos, BMS, Bart van den Bermt Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen, Eli Lilly

**Table 1. Multivariate linear regression analysis of risk factor to inhibit the clinical response in patients with D2TRA.**

<table>
<thead>
<tr>
<th>β</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-0.037</td>
<td>-0.025</td>
<td>0.077</td>
</tr>
<tr>
<td>male</td>
<td>-0.047</td>
<td>-0.788</td>
</tr>
<tr>
<td>Disease durations (years)</td>
<td>-0.048</td>
<td>-0.028</td>
</tr>
<tr>
<td>RF (U/ml)</td>
<td>-0.082</td>
<td>-0.0004</td>
</tr>
<tr>
<td>Anti CCP antibody (U/ml)</td>
<td>0.111</td>
<td>-0.0005</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-0.063</td>
<td>-0.257</td>
<td>0.171</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.279</td>
<td>0.0589</td>
</tr>
<tr>
<td>MTX (mg/day)</td>
<td>0.136</td>
<td>-0.018</td>
</tr>
<tr>
<td>Glucocorticoid dose (mg/day)</td>
<td>0.669</td>
<td>0.174</td>
</tr>
<tr>
<td>Type of bDMARDs/JAKI</td>
<td>-0.088</td>
<td>-0.415</td>
</tr>
</tbody>
</table>

Conclusion: Drug retention rate and clinical efficacy of D2TRA patients were not different among IL-6Ri, abatacept and JAKI. D2TRA patient with functional disorder and high dosage of glucocorticoid were risk factor to inhibit the clinical response.

Disclosure of Interests: None declared

**Table 2.** A comparison of patient characteristics between IL-6Ri group, abatacept group and JAKi group.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>IL-6Ri</th>
<th>Abatacept</th>
<th>JAKi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56.3</td>
<td>57.2</td>
<td>55.1</td>
</tr>
<tr>
<td>Male (%)</td>
<td>62.5</td>
<td>60.2</td>
<td>67.0</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>4.5</td>
<td>5.0</td>
<td>4.0</td>
</tr>
<tr>
<td>RF (U/ml)</td>
<td>32.7</td>
<td>35.2</td>
<td>31.5</td>
</tr>
<tr>
<td>Anti CCP antibody (U/ml)</td>
<td>6.7</td>
<td>7.2</td>
<td>6.0</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>5.6</td>
<td>5.9</td>
<td>6.0</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.8</td>
<td>1.0</td>
<td>0.9</td>
</tr>
<tr>
<td>MTX (mg/day)</td>
<td>5.0</td>
<td>5.5</td>
<td>5.0</td>
</tr>
<tr>
<td>Glucocorticoid dose (mg/day)</td>
<td>10.0</td>
<td>10.5</td>
<td>10.0</td>
</tr>
</tbody>
</table>

Background: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients with moderate to severely active RA receiving OKZ or placebo in a phase 3 randomized controlled trial (RCT) (ClinicalTrials.gov number, NCT02760433).
Results: Baseline demographics and disease characteristics were comparable between groups. At week 12, treatment with OKZ q2w compared with placebo resulted in significantly greater LSM changes from baseline in Pain, HAQ-DI, FACIT-F, SF-36 PCS, MCS and 4 domains; with OKZ q4w in PTGA, Pain, SF-36 MCS and 4 domains (Table 1, Figure 1). Improvements reported at week 12 in PROs continued or increased with both doses of OKZ until week 24. Post hoc analyses demonstrated that a higher proportion of patients receiving OKZ reported improvements ≥minimum clinically important differences vs placebo (p<0.05) in FACIT-F, SF-36 PCS and MCS scores, indicating that these changes translated into clinically meaningful benefits on an individual patient basis. Numbers needed to treat to gain these benefits in fatigue and physical function ranged from 9.2 - 15.4 with OKZ q2w vs 10.5 - 13.3 with OKZ q4w, respectively.

Disclosure of Interests: Vibeke Strand Consultant of: Abbvie, Amgen, Arena, AstraZeneca, Bayer, BMS, Boehringer, Ingelheim, Chemocentryx, Celsitron, Galapagos, Genentech/Roche, Gilead, GSK, Horizon, Inmedix, Janssen, Kiniska, Lilly, Novartis, Pfizer, Regeneron, Rheos, R-Pharm, Samsung, Sanzod, Sanofi, Sciphir, Servier, Setpoint, Sorrento, Synthex, UCB, Erenzi, Nov. Consultant of: Abbvie, Amgen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, RPharm, Roche, Sanofi, and UCB., Grant/research support from: Bio-Cancer; Biogen, Novartis, Pfizer, Roche, Sanofi and UCB, Evgeny Nasonov Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Tatiana Listitsyna; None declared, Alexander Lilla Consultant of: Abbvie, Amgen, Bayer, Biotechnos, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, RPharm, Roche, Sanofi, Stada, Viatris and UCB, Grant/ research support from: Novartis, Pfizer, Sofia Kuzkina Employee of: R-Pharm, Mikhail Samsonov Employee of: R-Pharm, Eugen Feist Consultant of: Abbvie, Eli Lilly, Galapagos, Medac, Novartis, Novo, Sobi, R-Pharm, Grant/research support from: Eli Lilly, Novartis, Pfizer DOI: 10.1136/annrheumdis-2022-eular.1990

POS0292 INCREASE OF PRO-INFLAMMATORY CYTOKINES IS ASSOCIATED WITH ANTI-IDIOTYPE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB OR ADALIMUMAB

D. X. Xibille Friedrich1, S. M. Carrillo Vazquez2, J. Gonzalez Christen3, D. Vega Morales4, M. Garza Elizondo5, R. Hernandez2, J. E. Ortiz Panozo6, J. L. Montiel Hernandez7. 1Hospital General de Cuernavaca, Rheumatology, Cuernavaca, Mexico; 2Hospital Regional 1 de Octubre, Rheumatology, CDMX, Mexico; 3Universidad Autonoma del Estado de Morelos, Facultad de Farmacia, Cuernavaca, Mexico; 4Universidad Autonoma de Nuevo Leon, Rheumatology, Monterrey, Mexico; 5Hospital de Especialidades, Centro Medico Nacional S. XXI, Rheumatology, CDMX, Mexico; 6Instituto Nacional de Salud Publica, Epidemiology, Cuernavaca, Mexico

Background: A significant percentage of rheumatoid arthritis (RA) patients undergoing Infliximab (IFX) or Adalimumab (ADA) treatment develop antidrug antibodies with potential negative effects over their clinical activity; however, it is unknown if these anti-idiotype events could be associated with changes in cytokines levels

Objectives: To evaluate the association between blood cytokine levels, anti-idiotype events and clinical activity in RA patients treated with IFX or ADA

Methods: All patients complied with ACR/EULAR 2021 criteria for RA and received anti-TNFa agents. Blood samples were collected during the drug trough and kept at -75ºC until analysis. Clinical activity was based on DAS28-ESR. Specific anti-drug antibodies to IFX and ADA were evaluated by sandwich ELISA. Cytokine blood levels were quantified using a multiplex system or sandwich ELISA.

Results: 57 patients with RA were recruited, 17 treated with IFX and 40 with ADA. According to the presence of anti-drug antibodies and sub-optimal levels of the biologic drug, patients were classified as immunogenic (29.8%; n=17) and non-immunogenic (70.2%; n=40), the latter showed significantly higher ESR (p<0.001) and DAS28 (p<0.005). A significant association was seen between antidrug antibodies and increases of IFNg (2.1 OR, CI95%:1.2-3.8, p<0.01); MCP-1 (3.9 OR, CI95%:1.1-14.5, p<0.05); MIF (2.8 OR, CI95%:1.3-5.7, p<0.01) and TNFa 3.0 OR, CI95%:1.3-6.6, p<0.01 (see Table 1). Although anti-idiotpe events were more frequent in IFX treated patients (41%), a significant difference was not seen when comparing with ADA treated patients (25%).
392 ﻿

Scientific Abstracts

Table 1. Association analysis between anti-Idiotype events with cytokine
levels.

DAS28-CRP score, years since diagnosis, failed modes of action and transcriptional signatures.

Anti-Idiotype Crude results
events vs
OR (IC, 95%)

Table 1.

IL-1β
IL-6
IL-8
IL-10
IL-12p40
IL-17A
INFϒ
Leptina
MIF
MCP-1
TNFα
Anti-Idiotype
events vs
IL-1β
IL-6
IL-8
IL-10
IL-12p40
IL-17A
INFϒ
Leptina
MIF
MCP-1
TNFα

2.04 (1.26-3.30)
1.29 (1.02-1.64)
1.20 (0.80-1.79)
1.18 (0.91-1.51)
1.73 (1.09-2.76)
1.39 (0.95-2.02)
2.38 (1.37-4.12)
6.15 (0.77-48.72)
3.94 (1.07-14.48)
2.98 (1.34-6.62)
2.79 (1.38-5.63)
Crude results***
OR (IC, 95%)
1.07 (1.02-1.12)
1.02 (1.00-1.05)
1.02 (0.98-1.06)
1.02 (0.99-1.04)
1.05 (1.01-1.10)
1.03 (0.99-1.07)
1.09 (1.03-1.14)
1.19 (0.98-1.45)
1.14 (1.01-1.29)
1.11 (1.03-1.20)
1.10 (1.03-1.18)

p
0.004
0.03
0.37
0.20
0.02
0.08
0.002
0.09
0.04
0.007
0.004
p
0.004
0.03
0.37
0.20
0.02
0.08
0.002
0.09
0.04
0.007
0.004

Model 1* OR
(IC, 95%)
2.18 (1.27-3.74)
1.30 (1.00-1.69)
1.24 (0.81-1.88)
1.16 (0.89-1.53)
1.67 (1.00-2.80)
1.31 (0.90-1.91)
2.36 (1.32-4.23)
4.79 (0.63-1.07)
5.86 (1.28-26.65)
3.28 (1.38-7.78)
2.55 (1.27-5.14)
Model 1* OR
(IC, 95%)
1.08 (1.02-1.13)
1.02 (1.00-1.05)
1.02 (0.98-1.06)
1.01 (0.99-1.04)
1.05 (1.00-1.10)
1.03 (0.99-1.06)
1.08 (1.02-1.14)
1.16 (0.95-1.40)
1.18 (1.02-1.36)
1.12 (1.03-1.21)
1.09 (1.02-1.16)

p
0.005
0.04
0.32
0.26
0.04
0.15
0.004
0.12
0.02
0.007
0.008
p
0.005
0.04
0.32
0.26
0.04
0.15
0.004
0.12
0.02
0.007
0.008

Model 2** OR
(IC, 95%)
2.72 (1.41-5.24)
1.33 (1.03-1.72)
1.22 (0.79-1.90)
1.22 (0.92-1.62)
1.90 (1.12-3.22)
1.51 (1.01-2.25)
2.97 (1.57-5.61)
7.30 (0.78-68.37)
3.45 (0.87-13.68)
3.74 (1.47-9.49)
2.72 (1.30-5.71)
Model 2** OR
(IC, 95%)
1.10 (1.03-1.17)
1.02 (1.00-1.05)
1.01 (0.97-1.06)
1.01 (0.99-1.04)
1.06 (1.01-1.11)
1.03 (1.00-1.08)
1.10 (1.04-1.17)
1.20 (0.97-1.49)
1.12 (0.98-1.28)
1.13 (1.03-1.23)
1.10 (1.02-1.18)

p
0.003
0.02
0.35
0.15
0.01
0.04
0.001
0.08
0.07
0.005
0.008
p
0.003
0.02
0.35
0.15
0.01
0.04
0.001
0.08
0.07
0.005
0.008

*Model 1: Adjusted by age + Body mass index; **Model 2: Adjusted by Time since onset of disease + Time with biologic + complementary treatment with MTX; ***Adjusted to 10% increase
of cytokine.

Conclusion: Patients with antidrug antibodies to IFX or ADA had higher ESR
and DAS28 and a showed a significant association with higher levels of IFNg,
MCP-1, MIF and TNFa.
REFERENCES:
Disclosure of Interests: Daniel Xavier Xibille Friedmann Speakers bureau:
Lilly, Abbvie, Paid instructor for: Lilly, Abbvie, Consultant of: Lilly, Abbvie, Sandra
Miriam Carrillo Vazquez Speakers bureau: Abbvie, Roche, Paid instructor for:
Abbvie, Roche, Consultant of: Abbvie, Roche, Judith González Christen: None
declared, David Vega Morales Speakers bureau: Abbvie, Roche, Paid instructor
for: Abbvie, Roche, Consultant of: Abbvie, Roche, Mario Garza Elizondo Speakers bureau: Abbvie, Roche, Paid instructor for: Abbvie, Roche, Consultant of:
Abbvie, Roche, Ramiro Hernández: None declared, José Eduardo Ortíz Panozo:
None declared, José Luis Montiel Hernández: None declared

POS0293

IN VITRO RESPONSE TO DISEASE MODIFYING
ANTIRHEUMATIC DRUGS LINK MOLECULAR DRUG
TARGET WITH SYNOVIAL TRANSCRIPTIONAL
SIGNATURE

M. B. Kristensen1, U. Ahmadov1, M. A. Nielsen1,2, L. S. Kristensen1,
T. W. Kragstrup1,2. 1Aarhus University, Department of Biomedicine, Aarhus C,
Denmark; 2Aarhus University Hospital, Department of Rheumatology, Aarhus,
Denmark
Background: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA),
psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some disease modifying
antirheumatic drugs (DMARDs) have demonstrated efficacy in several of these
diseases (e.g. TNFα inhibitors) while others have not (e.g. IL-17A inhibitors in
RA). Furthermore, within each disease there are patient subgroups experiencing
different responses to the same drug, which underlines the need for further elucidation of pathogenic processes to guide personalized in IMIAs.
Objectives: Here we investigated if clinical features and synovial transcriptional signature could predict in vitro efficacy of specific DMARDs across different IMIAs.
Methods: Synovial fluid mononuclear cells (SFMCs) from patients with SpA
(n=13), RA (n=16), PsA (n=13), juvenile idiopathic arthritis (JIA) (n=7) or undifferentiated arthritis (n=5) were included. SFMCs from each patient were cultured
for 48 hours (drugs listed in Table 1). Culture medium and DMSO were used as
negative controls. In vitro drug response was assessed by measuring monocyte
chemoattractant protein 1 (MCP-1) by ELISA. SFMC baseline gene expression of
270 genes related to inflammation was measured using the NanoString nCounter
Human Inflammation V2 Panel. Drug responses (ΔMCP-1) were compared with
clinical diagnosis, serostatus in RA patients, HLA-B27 status in SpA patients,

Drug

Target

Adalimumab
Etanercept
Tocilizumab
Anakinra
Ustekinumab
Secukinumab
Tofacitinib
Baricitinib

TNFα
TNFα
IL-6
IL-1β
IL-12/23
IL-17A
JAK1/3
JAK2/3

Results: DMARDs with a similar molecular target had comparable effects on
ΔMCP-1. The TNFα inhibitors adalimumab and etanercept (r=0.86) had similar
drug responses, and so had the JAK inhibitors tofacitinib and baricitinib (r=0,71).
In contrast, drugs with different modes of action had diverse responses (Figure 1). High HLA-DRA gene expression associated with high responses to TNFα
inhibitors (both p<0.05). JAK inhibitors reduced MCP-1 secretion significantly
more in SFMCs from seropositive than seronegative RA patients (p<0.05).
Drug response was greater in SFMCs from patients with low DAS28-CRP
scores (DAS28-CRP <2.5) compared with patients with a high DAS28-CRP
score (DAS28-CRP >5.2) for TNFα inhibitors, tocilizumab and JAK inhibitors (all
p<0.05). Patients clustered with either an overall high or an overall low response
to almost all DMARDs, or with a significant response to only one or a few of
the DMARDs. Transcriptional signature of patient SFMCs primarily responding
to TNFα inhibitors was different compared with the signature of patient SFMCs
primarily responding to JAK inhibitors. Diagnosis, HLA-B27 status, failed modes
of action and years since diagnosis did not affect ΔMCP-1 in this in vitro setup.

Figure 1. Association between DMARD molecular target and in vitro response as measured
by change in MCP-1 secretion.

Conclusion: Similarities and differences in mode of action for 8 different
DMARDs were captured in drug response as measured by MCP-1 change in
SFMC cultures from 54 patients with inflammatory arthritis. We were able to identify interesting differences in gene expression when comparing cells responding
to TNF inhibitors to cells responding to JAK inhibitors. Drug responses were only
to a minor extent associated with clinical features.
Acknowledgements: Sincere thanks to Stinne Greisen, Malene Hvid, Maithri
Aspari and Amalie Broksø for continuous guidance during the laboratory work.
Disclosure of Interests: Mads Brüner Kristensen: None declared, Ulvi Ahmadov:
None declared, Morten Aagaard Nielsen: None declared, Lasse Sommer Kristensen: None declared, Tue Wenzel Kragstrup Shareholder of: Co-founder and
clinical developer in iBio tech ApS., Speakers bureau: Speaking fees from Pfizer,
Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and Abbvie., Consultant of: Consultancy fees from Bristol-Myers Squibb and Gilead., Grant/research support from:.
Research grants from Gilead.
DOI: 10.1136/annrheumdis-2022-eular.2512

POS0294

ARTIFICIAL INTELLIGENCE TO CONNECT THE
USE OF BIOLOGICS AND SMALL MOLECULES IN
RHEUMATOID AND PSORIATIC ARTHRITIS WITH A
MULTIDISCIPLINARY EVALUATION: A REAL WORLD
EVIDENCE APPROACH THROUGH NATURALLANGUAGE PROCESSING

P. Moranding1, F. Maffia1, F. Puggioni2, F. Motta3, M. Vecellio3, A. Costanzo4,
V. Savevski1, C. Selmi3. 1Humanitas Research Hospital - IRCCS, Artificial
Intelligence, Rozzano, Italy; 2Humanitas Research Hospital - IRCCS, Asthma,
Allergy, and Personalized Medicine, Rozzano, Italy; 3Humanitas Research


Background: The management of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is often relying on a multidisciplinary approach with different specialists evaluating the patient for treatment choices. The ultimate impact of such management on the use of systemic glucocorticoids and more innovative drugs such as biologics and small molecules, however, is unclear. Artificial intelligence tools, particularly natural language processing and machine learning, allow to manage large datasets and investigate associations between variables.

Objectives: To use a natural language processing approach to demonstrate whether a multidisciplinary approach to RA or PsA changes treatment choices.

Methods: We analysed the clinical notes of hospital encounters between 2017 and 2020 of patients with a terminated or ongoing care process at outpatient clinics included in the Humanitas Center for immune-mediated disease. To extract structured information from text data we used regular expressions (RegEx), a technique that allows to define elastic search patterns. RegEx were also used to detect negations to consider only affirmative citation of diseases or prescribed therapy. Care processes were described by binary flags which express the presence of RA or PsA and the prescription of glucocorticoids and biologics / small molecules for each patient. Working with only categorical data, we relied on the chi squared test to detect possible correlations between prescribed treatments and the characteristics of the care process, including whether a multidisciplinary evaluation had occurred.

Results: Our analysis included 1839 patients with RA (77% women, mean±standard deviation age 58±16 years) and 1652 patients with PsA (46% women, age 57±15 years), accounting for 5517 and 3992 outpatient visits with different specialists over the study period, respectively. Among patients with RA and PsA, 378 (22%) and 371 (25%) were prescribed biologics or small molecules, respectively, while 830 (47%) RA and 431 (29%) PsA cases received a prescription for systemic glucocorticoids during one of the visits and patients seen three of more times by the rheumatologists received significantly more biologics / small molecules. Importantly, 4.5% of patients with RA and 9.4% of patients with PsA were evaluated also by dermatology, gastroenterology, allergy and pulmonary disease specialists and these patients were treated more frequently with glucocorticoids (70% vs.47% for RA, P<0.001; 60% vs. 29% for PsA, P<0.001) as well as with biologics / small molecules (42% vs. 22% for RA, P<0.001; 58% vs. 25% in PsA, P<0.001).

Conclusion: Natural language processing and machine learning were applied to unstructured electronic clinical charts in a large Center dedicated to immune-mediated diseases and allowed to demonstrate that patients with RA or PsA undergoing multiple evaluations are more likely to receive biologics / small molecules. The occurrence of serious infections between groups (defined as infections requiring hospitalization and/or parenteral antibiotics). We deployed the nearest-neighbour matching algorithm (1:4), based on Propensity Score (PS), in order to adjust for non-randomization. The McNemar's test was used to compare the frequency of serious infection in the two groups.

Results: DEN group consisted of 36 patients were recruited, while the cohort of patients in noDEN group consisted of 547 individuals (Table 1). After PS matching only 58 patients were noDEN group, matched for disease duration, presence/absence of ACPA antibodies, baseline BMI, baseline DAS28 and daily prednisone dosage. In the matched cohort, we found an increase in terms of frequency of serious infections in DEN group, even if not statistically significant (Figure 1). All the infections were completely resolved after hospitalization and/or parenteral antibiotic treatment, without fatal events or irreversible complications. Both groups were not stratified for bDMARDs mechanism of action (MoA). Of note, in the DEN group Rituximab therapy was administered in 22% of patients, while in noDEN group in 12% of them.

Table 1. Patients’ characteristics at baseline.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>bDMARDs Only</th>
<th>bDMARDs + Denosumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>547</td>
<td>38</td>
</tr>
<tr>
<td>Age, y (mean±sd)</td>
<td>547</td>
<td>38</td>
</tr>
<tr>
<td>Disease duration, m (mean±sd)</td>
<td>472</td>
<td>38</td>
</tr>
<tr>
<td>PCR, mg/dL (mean±sd)</td>
<td>539</td>
<td>38</td>
</tr>
<tr>
<td>HAG, n (mean±sd)</td>
<td>516</td>
<td>38</td>
</tr>
</tbody>
</table>

Figure 1. Occurrence of serious infections at 12-months follow-up.

Conclusion: The occurrence of serious infections among RA patients receiving denosumab in combination with bDMARDs ± MTX for RA was not significantly increased compared to those receiving bDMARDs ± MTX alone at 12 months from treatment baseline. Further studies powered for detecting difference between bDMARDs MoA are necessary in order to assess the infection risk of denosumab co-administration.
AxSpA: About treatments and outcomes

Tofacitinib 5 mg BID was well tolerated over 48 Wks in pts with AS, and safety was consistent with the established safety profile of tofacitinib.

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Jennifer Arnold, CMC Connect, and funded by Pfizer Inc.

Disclosure of Interests: Atul Deodhar Consultant of: AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB, and various other pharmaceutical companies. Speakers bureau: AbbVie, Amgen, Eli Lilly, MSD, Novartis, Pfizer Inc and UCB. Consultant of: AbbVie, Amgen, Eli Lilly, MSD, Novartis, Pfizer Inc and UCB. Grant/research support from: Pfizer Inc, Jefrey Curtis Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), Eli Lilly, Janssen, Myriad, Pfizer Inc, Radius, LLC (formerly Corrona, LLC), El...

**Table 1. Clinical, functional, disease activity and serological parame- ters of naïve (n=72) and non-naïve (n=177) axSpA patients during the 24-month follow-up**

<table>
<thead>
<tr>
<th>T0</th>
<th>T6</th>
<th>T12</th>
<th>T24</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BASMI</strong></td>
<td><strong>(0-10, median)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naïve</td>
<td>2.0 (1.0-4.0)</td>
<td>2.0 (0.0-3.3)</td>
<td>1.0 (0.0-2.8)</td>
</tr>
<tr>
<td>non-naïve</td>
<td>4.0 (1.0-7.0)</td>
<td>4.0 (1.0-7.0)</td>
<td>2.0 (1.0-4.0)</td>
</tr>
<tr>
<td>p</td>
<td>p=0.03</td>
<td>p=0.04</td>
<td>ns</td>
</tr>
<tr>
<td><strong>HAQ-S</strong></td>
<td><strong>(0-6, median)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naïve</td>
<td>0.8 (0.5-1.3)</td>
<td>0.5 (0.0-1.0)</td>
<td>0.3 (0.0-1.0)</td>
</tr>
<tr>
<td>non-naïve</td>
<td>1.1 (0.8-1.5)</td>
<td>1.0 (0.4-1.3)</td>
<td>0.6 (0.4-0.9)</td>
</tr>
<tr>
<td>p</td>
<td>p=0.04</td>
<td>p=0.04</td>
<td>p=0.04</td>
</tr>
<tr>
<td><strong>ASDAS</strong></td>
<td><strong>(0-10, median)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naïve</td>
<td>3.3 (2.7-3.9)</td>
<td>2.1 (1.6-2.7)</td>
<td>2.0 (1.2-2.8)</td>
</tr>
<tr>
<td>non-naïve</td>
<td>3.7 (2.9-4.7)</td>
<td>2.9 (2.0-3.7)</td>
<td>2.1 (1.9-3.1)</td>
</tr>
<tr>
<td>p</td>
<td>ns</td>
<td>ns</td>
<td>p=0.04</td>
</tr>
<tr>
<td><strong>ESR</strong></td>
<td><strong>(0-25)(mm/h), median</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>naïve</td>
<td>14.0 (6.0-27.0)</td>
<td>10.0 (4.0-19.5)</td>
<td>8.0 (3.1-12.8)</td>
</tr>
<tr>
<td>non-naïve</td>
<td>18.5 (10.0-31.3)</td>
<td>15.0 (8.0-25.0)</td>
<td>12.0 (6.0-20.0)</td>
</tr>
<tr>
<td>p</td>
<td>p=0.04</td>
<td>p=0.04</td>
<td>p=0.04</td>
</tr>
</tbody>
</table>

**Legend:** BASMI: Bath Ankylosing Spondylitis Metascore Index; HAQ: Health Assessment Questionnaire modified for spondyloarthritis; ASDAS: Ankylosing Spondylitis Disease Activity Score; ESR: erythrocyte sedimentation rate

**Conclusion:** In a real-life clinical-setting, PROSPECT proved to be safe and effective in axSpA, mainly in naïve-patients, with a notable drug-retention-rate. No differences were observed between r-axSpA and nr-axSpA.
Background: Patients with axial spondyloarthritis (axSpA) in clinical remission tapered Tumor Necrosis Factor inhibitor (TNFi) therapy according to a clinical guideline and had 2 years’ follow-up [1].

Objectives: We aimed to investigate flare frequency, dose at which flare occurred, type of flare (clinical/ Bath ankylosing spondylitis disease activity index (BASDAI)/magnetic resonance imaging (MRI)) and predictors of flare.

Methods: Patients in clinical remission (BASDAI<40, physician global score<40 during tapering to discontinuation, but above half not before receiving 1/3 dose or less. Higher physician global score was the only independent predictor of flare after tapering to 2/3 dose (Odds ratio=1.19 (95% Confidence Interval=1.05-1.41); p=0.011) (Table 1). Changes in clinical and/or imaging variables in the 16 weeks prior to tapering did not predict flare (data not shown).

Conclusion: Almost all (99%) axSpA patients in clinical remission flared during tapering to discontinuation, but above half not before receiving 1/3 dose or less. Higher physician global score was the only independent predictor of flare.

Disclosure of Interests: Marie Wetterslev: None declared, Stylianos Georgiadi: None declared, Sara Nysom Christiansen Speakers bureau: BMS and GE, Grant/research support from: Novartis, Susanne Juhi Pedersen Speakers bureau: MSD, Pfizer, AbbVie, Novartis and UCB, Consultant of: AbbVie and Novartis, Grant/research support from: AbbVie, MSD, and Novartis, Inge Juul Sørensen: None declared, Merete Lund Hetland Consultant of: MSD, Biogen, Pfizer, Eli Lilly, Orion Pharma, CellTion, Samsung

Table 1. Prediction of flare within 16 weeks after tapering to 2/3 dose (n=74)

<table>
<thead>
<tr>
<th>Values are from timepoint of tapering from full dose to 2/3 dose</th>
<th>Univariate analyses</th>
<th>Final multivariable analyses*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Univariate analyses</td>
<td>(95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>Male gender</td>
<td>0.96</td>
<td>(0.25 - 4.14)</td>
</tr>
<tr>
<td>Age</td>
<td>1.00</td>
<td>(0.96 - 1.04)</td>
</tr>
<tr>
<td>Time since diagnosis</td>
<td>1.00</td>
<td>(0.95 - 1.06)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>0.70</td>
<td>(0.20 - 2.20)</td>
</tr>
<tr>
<td>HLA-B27 positive</td>
<td>0.66</td>
<td>(0.18 - 2.41)</td>
</tr>
<tr>
<td>Previous cDMARDs</td>
<td>1.28</td>
<td>(0.66 - 2.49)</td>
</tr>
<tr>
<td>Patient pain VAS</td>
<td>1.02</td>
<td>(0.98 - 1.06)</td>
</tr>
<tr>
<td>Physician global VAS</td>
<td>1.19</td>
<td>(1.04 - 1.41)</td>
</tr>
<tr>
<td>aBAS</td>
<td>1.66</td>
<td>(0.70 - 4.10)</td>
</tr>
<tr>
<td>mNYC positive</td>
<td>0.78</td>
<td>(0.29 - 2.09)</td>
</tr>
<tr>
<td>SPARRCC SJ inflammation Index</td>
<td>1.01</td>
<td>(0.90 - 1.12)</td>
</tr>
<tr>
<td>CANDEN Total Inflammation</td>
<td>0.95</td>
<td>(0.65 - 1.25)</td>
</tr>
<tr>
<td>SPARRCC SSS Erosion</td>
<td>1.11</td>
<td>(0.91 - 1.37)</td>
</tr>
<tr>
<td>CANDEN Fat</td>
<td>0.99</td>
<td>(0.96 - 1.02)</td>
</tr>
<tr>
<td>AUC (95% CI)</td>
<td>0.66 (0.54 - 0.78)</td>
<td></td>
</tr>
</tbody>
</table>

Predictors were selected by applying backward selection in stacked data. p-values by likelihood ratio tests. Bold indicates p-values<0.1 in univariate analyses. Predictors were selected by backward selection in stacked imputed datasets after applying a fixed weight to all observations, accounting for the average fraction of missing data across all variables under consideration. *Results were derived in non-imputed data (no missing values in selected predictors). CIs given as profile likelihood CIs, AUC estimated based on internal validation by bootstrapping with 1000 samples.ASASDA, Ankylosing Spondylitis Disease Activity Score; bDMARDs, biological disease modifying anti-rheumatic drugs; AUC, Area Under the receiver operating characteristic Curve; CANDEN, Canada-Denmark MRI scoring system of the spine in patients with axial spondyloarthritis; CI, confidence interval; mNYC, modified New York criteria; SJ, sacroiliac joint; SPARRCC SJ inflammation, Spondyloarthritis Research Consortium of Canada Sacroiliac joint inflammation; SPARRCC SSS, Spondyloarthritis Research Consortium of Canada Sacroiliac joint Structural Score; VAS, visual analogue scale.
Biopis, and Janssen Biologics IV, Grant/research support from: MSD, Biogen, Pfizer, Bristol-Myers Squibb, AbbVie, Roche and Novartis, Anne Duer: None declared, Michel Boesen Speakers bureau: None declared, Henrik Røgind: None declared, Mikkel Østergaard: None declared, None declared, Jakob Møllenbach Møller: None declared, Mads Bakkegaard: None declared, Cecile Heeg haarde Brahe: None declared, Henrik Steen Krogh: None declared, Bente Jensen: None declared, Ole Madsen: None declared, Jan Christensen: None declared, Annette Hansen Speakers bureau: speaker fees from Eli Lilly, Jesper Nørregaard: None declared, Henrik Regind: None declared, Mikkel Østergaard Speakers bureau: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Consultant of: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/ research support from: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli- Lilly, Hospira, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB DOI: 10.1136/annrheumdis-2022-eular.654

POS0299

EFFECT OF SECUKINUMAB ON RADIOGRAPHIC PROGRESSION AND INFLAMMATION IN SACRALIOLJC JOINTS AND SPINE IN PATIENTS WITH NON- RADIOGRAPHIC AXIAL SPONDYLARTHRITIS: 2-YEAR IMAGE OUTCOMES FROM A PHASE III RANDOMISED TRIAL

J. Braun1, R. Blancho2, L. Marzo-Ortega3, O. L. Genser4, A. Van den Bosch5, S. Hall6, K. Kameda7, B. Podubrany8, D. Van der Heijde9, T. Zhang10, A. Stefanska11, A. Readie12, H. Richards13, A. Deodhar14, 1Rheumazentrum Ruhrgebiet, Herne, and Ruhr-University Bochum, Department of Rheumatology, Bochum, Germany; 2Hospital Universitaries Marques de Valdecillo, IDIVAL, Division of Rheumatology, Santander, Spain; 3NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, LIRMM, University of Leeds, Leeds, United Kingdom; 4University of California, Department of Rheumatology, San Francisco, CA, United States of America; 5Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, VIB Center for Inflammation Research, Ghent, Belgium; 6Monash University, Department of Medicine, Melbourne, Australia; 7Toho University, Division of Rheumatology, Tokyo, Japan; 8Charité -Universitätmedizin Berlin, German Rheumatism Research Centre, Berlin, Germany; 9Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands; 10Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 11Novartis Pharmaceuticals Corporation, Rheumatology, New Jersey, United States of America; 12Novartis Ireland Limited, Rheumatology, Dublin, Ireland; 13Novartis Pharma AG, Rheumatology, Basel, Switzerland; 14Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Portland, United States of America

Background: Axial spondylarthrititis (axSpA) is characterised by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ bone marrow oedema as detected by magnetic resonance imaging (MRI) in patients (pts) with non-radiographic (nr) axSpA through 52 weeks in the PREVENT (NCT02696031) study.1

Objective: To report radiographic progression and the course of inflammation as assessed by X-ray and MRI of SIJ and spine over 2 years in the PREVENT study.

Methods: Study design and key endpoints have been reported earlier.1 In total, 555 pts were randomised (1:1:1) to receive SEC 150 mg, with (LD) or without loading (NL) doses, or placebo (PBO). Switch to open-label (OL) SEC or standard -label (SoC) was permitted after Week (Wk) 20. All pts (except those who switched to SoC) received OL SEC from Wk 52. Radiographs of the spine and SIJ were collected at baseline (BL) and Wk 104; MR images of the spine and SIJ were collected at BL, Wk 16, 52, and 104. Spinal radiographs were scored using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and SIJ radiographs according to modified New York criteria (mNY). Pts whose screening SI joint radiographs fulfilled mNY criteria during the eligibility reading session were excluded from the study. Spinal MRI images were assessed for signs of inflammation with the Berlin score. SIJ bone marrow oedema was assessed according to the Berlin Active Inflammatory Lesions Scoring. All images were evaluated in blinded fashion independently by 2 central readers. All data are reported from the Wk 104 reading session and are presented as observed.

Results: The vast majority (98%) of pts treated with SEC 150 mg (pooled LD and NL) showed no structural progression, defined as change in total mSASSS score ≤ smallest detectable change (SDC) of 0.76 (80% agreement level) over 2 years. At BL, 62 pts (43 in SEC, 19 in PBO) presented with ≥1 syndesmophytes (≥1 vertebral unit scored by ≥1 reader). Among these pts, 9 in SEC (20.9%) and 7 in PBO (36.8%) groups had developed ≥1 new syndesmophytes by Wk 104. Among 237 SEC and 117 PBO pts without syndesmophytes at BL, only 4 pts on SEC (1.7%) and 4 pts on PBO (3.4%) developed ≥1 new syndesmophytes by Wk 104. SEC radiographs showed that 88% of pts on SEC and 86% on PBO had no progression in SIJ (defined as change ≤ SDC (0.46) in total mNY score) by Wk 104. No patient had an increase in total mNYC score of 2 or more. When screening radiographs of eligible pts were scored alongside post-BL images in the final reading campaign, approximately 25% of pts (68/277 and 34/139) in the SEC and PBO groups, respectively) were evaluated as mNY-positive at screening (pts were considered mNY-positive if ≥1 reader evaluated them as mNY-positive). Of these, 11/68 pts in the SEC (16.2%) and 5/34 in the PBO (14.7%) groups were evaluated as mNY-negative at Wk 104. In the SEC and PBO groups, 202 (96.7%) and 102 (97.1%) pts who were mNY-negative at screening stayed negative through Wk 104, respectively. Only 7 pts in the SEC (3.3%) and 3 in the PBO (2.9%) groups who were mNY-negative at BL were scored as mNY-positive at Wk 104. In both groups, fewer pts progressed from mNY-negative to mNY-positive than had a change in the opposite direction (from positive to negative), resulting in an overall negative net progression.

Spinal inflammation on MRI (Berlin score) was low at BL with a mean of 0.62 in SEC and 1.07 in PBO groups with no meaningful change up to Wk 104 (mean of 0.56; SEC). SEC reduced SIJ bone marrow oedema score versus PBO at Wk 16 and Wk 52 with sustained reduction through Wk 104 in the overall patient population, with greater reduction in pts with BL score >2 (Figure 1).

Conclusion: Most pts initially randomised to SEC or PBO showed no radiographic progression through 2 years. There was some discrepancy between SIJ eligibility and efficacy reads. SEC reduced SIJ inflammation (bone marrow oedema) on MRI in pts with active nr-axSpA.

REFERENCES:


Figure. Mean change in SIJ bone marrow oedema score by MRI in the overall population and in patients with baseline score ≥2 through Wk 104.

**Disclosure of Interests:** Juergen Braun Speakers bureau: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Merck), Pfizer (Wyeth), Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, UCB, Eli Lilly, Consultant of: Abbvie (Abbott), Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, UCB, Eli Lilly, Grant/research support from: Abbvie (Abbott), Amgen, BMS, Boehringer,
Factors associated with secukinumab (SEC) retention in axial spondyloarthritiXTS (axSpA): results of the French retrosttiXtive study FORSYA

M. Dougdos1, J. Lucas2, E. Desfleurs3, P. Claudepierre4, P. Goupille5, A. Ruyssen-Witrand6, A. Saraux7, A. Tournadre6, D. Wendling8, C. Lukas9, 1Hôpital Cochin. Assistance Publique - Hôpitaux de Paris, Department of Rheumatology, Paris, France; 2RcTS Clinical Research Organization, Biostatistics, Lyon, France; 3Novartis Pharma SAS, Medical Affairs, Rueil Malmaison, France; 4Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Department of Rheumatology, Créteil, France; 5University Hospital of Tours, Department of Rheumatology, Tours, France; 6University Hospital of Toulouse, Rheumatology center, Toulouse, France; 7CHU Brest, Department of Rheumatology, Brest, France; 8CHU Clermont Ferrand, Department of Rheumatology, Clermont Ferrand, France; 9CHRU de Besançon, Department of Rheumatology, Besançon, France; 10University Hospital Montpellier, Department of Rheumatology, Montpellier, France

Background: While data on real-life SEC retention rate in patients (pts) with axSpA are accumulating, there are no data on predictive factors for this retention. Presence of objective sign of inflammation (OSI) is known to be predictive of efficacy of anti-TNFs and their retention in axSpA.

Objectives: To assess whether OSI were predictive of SEC retention at 1 year in axSpA.

Methods: French retrospective study collecting between October 2019 and September 2020 data from axSpA pts a) having initiated and received at least one dose of SEC between August 11th 2016 and August 31st 2018, b) with at least one a year follow-up period. Retention of SEC at 1 year was estimated by the Kaplan Meier (KM) method. OSI were defined by at least one of the following: CRP > N, MRI-inflammation at the sacroiliac or spine level. Preselected factors of SEC retention at 1 year (~1 OSI, age, sex, BMI, smoking, HLA B27, non-radiographic axSpA, past or present uveitis / Inflammatory Bowel Disease (IBD) / psoriasis / arthritis or synovitis, diagnostic delay, disease duration, SEC line of biological therapy, SEC maintenance dose, concomitant csDMARD / oral corticosteroids / proton pump inhibitor, history of depression / fibromyalgia) were analyzed by multivariate cox model regression. Only variables with <20% missing data were included in the model after imputation and stepwise selection (significance level for entering variables = 20%; for removing variables = 10%). OSI was forced into the model whatever its significance level or rate of missing data.

Results: In total, 906 pts from 47 centers (male: 42.2%, mean age: 46.2 ± 11.7 years, mean disease duration: 9.3 ± 9.1 years), were included in the analysis. At initiation of SEC, 86.3% of pts had ≥1 OSI and respectively 8.0%, 14.9% and 77.1% were in 1st, 2nd and ≥3rd line (L) of biological targeted synthetic DMDAR. The 1 year KM survival rate for SEC was 59% [95%CI:55%-62%] overall, 58% [54%-62%] and 63% [53%-73%] for pts with or without OSI, and was numerically greater in 1st L vs 2nd and ≥3rd L (70% [59%-81%], 62% [54%-70%], 57% [53%-61%] respectively). In multivariate analysis absence of OSI, lack of prior exposure to anti-TNF inhibitors, absence of IBD, and absence of history of depression were associated with a better SEC retention at 1 year (Table 1).

Table 1. Predictive factors of SEC 1 year retention identified by multivariate cox regression analysis (multiple imputation + stepwise selection)

<table>
<thead>
<tr>
<th>Predictive factors (* reference)</th>
<th>Still on SEC at 1 Year (%)#</th>
<th>HR [95% CI]</th>
<th>p vs ref</th>
<th>p type III</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1 objective sign of inflammation</td>
<td>No (N=165)*</td>
<td>60.8%</td>
<td>0.04</td>
<td>0.014</td>
</tr>
<tr>
<td>SEC treatment line</td>
<td>1st L (N=68)*</td>
<td>57.6%</td>
<td>1.67 [1.06; 2.62]</td>
<td>0.028</td>
</tr>
<tr>
<td>2nd L (N=132)</td>
<td>62.7%</td>
<td>1.53 [0.91; 2.57]</td>
<td>0.107</td>
<td></td>
</tr>
<tr>
<td>≥ 3rd L (N=676)</td>
<td>57.6%</td>
<td>1.67 [1.06; 2.62]</td>
<td>0.028</td>
<td></td>
</tr>
<tr>
<td>Past or present history of IBD</td>
<td>Yes (N=22)</td>
<td>40.9%</td>
<td>0.97 [1.01; 3.07]</td>
<td>0.047</td>
</tr>
<tr>
<td>History of depression or anti-depressive con-</td>
<td>No (N=716)*</td>
<td>60.8%</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>comitant treatment</td>
<td>Yes (N=160)*</td>
<td>54.5%</td>
<td>1.25 [0.97; 1.60]</td>
<td>0.090</td>
</tr>
</tbody>
</table>

# without imputation for missing datainterpretation HR > 1: the hazard of discontinuation at 1 year is X times higher vs reference

Conclusion: The overall retention of SEC at 1 year in daily practice at the time of its launch in France was 59% for axSpA patients and OSI, prior exposure to TNF inhibitors, IBD and history of depression were identified as predictive factors of SEC retention.

Acknowledgements: Authors thank the participating investigators, centers and patients. NOVARTIS Pharma France financially supported this study.


Scientific Abstracts
STRUCTURAL OUTCOMES IN THE SACROIILAC JOINT AFTER IXEKIZUMAB TREATMENT FOR 16 WEEKS IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY GENDER, HLA-B27, AND BASELINE MRI INFLAMMATION

W. P. Maksymowycz, X. Baraliakos, R. G. Lambert, R. B. M. Landewé, D. Sandałow, H. Cartier, J. Lisse, X. Li, M. Hojkă, M. Østergaard, Division of Rheumatology at the University of Alberta, Department of Medicine, Alberta, Canada; 2Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany; 3University of Alberta, Department of Radiology & Diagnostic Imaging, Alberta, Canada; 4Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology and Rheumatology, Amsterdam, Netherlands; 5Eli Lilly and Company; Lilly Corporate Center, Indianapolis, United States of America; 6Eli Lilly and Company, Immunology Medical, Brussels, Belgium; 7Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark

Background: Ixekizumab (IXE) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) together with significant repair of structural lesions in the sacroiliac joint (SIJ) on MRI. There is, however, a paucity of data as to which patients may be most responsive.

Objectives: We aimed to evaluate whether patients’ gender, HLA-B27 status, and presence of MRI inflammation impacted the effect of treatment with IXE versus placebo (PBO) on MRI structural lesions in the SIJ in patients with nr-axSpA.

Methods: Patients with active nr-axSpA, biologic-naïve (COAST-X, NCT02757352) were randomized 1:1:1 to ixekizumab 80 mg every 4 (Q4W) or 2 weeks (Q2W) or PBO. Structural lesions on SIJ MRI were assessed by the Spondyloarthritis Research Consortium of Canada (SPARC) MRI SIJ structural score (SSS). Treatment comparisons used analysis of covariance based on observed cases. SPARC SSS subgroup analyses were performed according to baseline gender, HLA-B27 status, and SPARC MRI SIJ bone marrow oedema (BME) ≤4 and ≥4 subgroups, which reflects a definite MRI for inflammation in the SIJ typical of nr-axSpA.

Results: Of 303 randomized patients, 266 patients (Q4W: n=85, Q2W: n=91, PBO: n=90) had an MRI scan at baseline and week 16. At baseline, SPARC SSS scores were consistently higher in males, and mostly higher in HLA-B27 and BME≥4 positive subgroups. Significant differences between patients treated with IXE versus PBO were observed for male patients, HLA-B27 positives, and those with baseline SPARC BME ≥4. Numerically similar changes were observed in female patients, with negative HLA-B27, and patients with SPARC BME<4, though not statistically significant.

Conclusion: Effects of IXE on structural repair are most evident in males, HLA-B27 positives, and patients with definite MRI inflammation at baseline.

Acknowledgements: Study was sponsored by Eli Lilly and Company Disclosure of Interests: Walter P. Maksymowycz Speakers bureau: AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Galapagos, Janssen, Novartis, Pfizer, and UCB and is Chief Medical Officer of CARE Arthritis Ltd, Grant/research support from: AbbVie, Novartis, Pfizer, and UCB, Xenon Baraliakos Grant/ research support from: Abbvie, Amergen, BMS, Chugai, Galapagos, Gilead, Eli Lilly and Company, MSD, Novartis, Pfizer, Roche, Sandzo, and UCB, Robert G. Lambert Consultant of: CARE Arthritis, Image Analysis Group, Parexel, and Pfizer, Robert B.M. Landewé Consultant of: AbbVie, Astra-Zeneca, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Galapagos, GlaxoSmith-Kline, Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Novartis, Pfizer, and UCB; and is director of Imaging Rheumatology BV, which is a registered company under Dutch Law, David Sandoval Shareholder of: Eli Lilly and Company. Employee of: Eli Lilly and Company, Hilde Carlier Shareholder of: Eli Lilly and Company, Jeffrey Lisse Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Xiaoqi Li Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Maja Horkin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company,该项研究的资助方为：AbbVie, BMS, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandzo, Sanofi, and UCB. Consultant of: AbbVie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly and Company, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandzo, Sanofi, and UCB, Grant/research support from: AbbVie, BMS, Merck, Celgene, and Novartis DOI: 10.1136/annrheumdis-2022-eular.2322

Table 1. MRI SIJ Structural Lesion Outcomes.

<table>
<thead>
<tr>
<th>Lesion</th>
<th>Analysis</th>
<th>Male (n=59)</th>
<th>Female (n=51)</th>
<th>Male (n=44)</th>
<th>Female (n=41)</th>
<th>Male (n=43)</th>
<th>Female (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erosion</td>
<td>BL mean</td>
<td>5.167</td>
<td>1.880</td>
<td>3.545</td>
<td>2.817</td>
<td>3.523</td>
<td>2.594</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>0.51 (0.20)</td>
<td>-0.11 (0.17)</td>
<td>-0.63 (0.18)</td>
<td>-0.11 (0.19)</td>
<td>-0.51 (0.18)</td>
<td>-0.32 (0.17)</td>
</tr>
<tr>
<td>Fat</td>
<td>BL mean</td>
<td>2.051</td>
<td>0.912</td>
<td>1.293</td>
<td>1.465</td>
<td>0.677</td>
<td>0.37</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.02 (0.09)</td>
<td>-0.03 (0.08)</td>
<td>0.29 (0.08)</td>
<td>0.03 (0.08)</td>
<td>0.21 (0.08)</td>
<td>0.04 (0.08)</td>
</tr>
<tr>
<td>Backfill</td>
<td>BL mean</td>
<td>1.154</td>
<td>0.167</td>
<td>0.663</td>
<td>0.415</td>
<td>0.791</td>
<td>0.303</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.20 (0.13)</td>
<td>0.01 (0.11)</td>
<td>0.39 (0.12)</td>
<td>0.01 (0.12)</td>
<td>0.34 (0.12)</td>
<td>0.14 (0.11)</td>
</tr>
<tr>
<td>Lesion Analysis</td>
<td>HLA-B27+ (n=44)</td>
<td>HLA-B27- (n=25)</td>
<td>HLA-B27+ (n=43)</td>
<td>HLA-B27- (n=26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosion</td>
<td>BL mean</td>
<td>3.620</td>
<td>2.100</td>
<td>3.467</td>
<td>2.543</td>
<td>3.515</td>
<td>1.827</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>0.27 (0.15)</td>
<td>-0.10 (0.24)</td>
<td>-0.49 (0.15)</td>
<td>-0.01 (0.25)</td>
<td>-0.50 (0.15)</td>
<td>-0.17 (0.24)</td>
</tr>
<tr>
<td>Fat</td>
<td>BL mean</td>
<td>1.578</td>
<td>1.020</td>
<td>1.328</td>
<td>2.783</td>
<td>1.285</td>
<td>0.462</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.06 (0.06)</td>
<td>-0.06 (0.10)</td>
<td>0.22 (0.06)</td>
<td>0.01 (0.10)</td>
<td>0.13 (0.06)</td>
<td>0.10 (0.10)</td>
</tr>
<tr>
<td>Backfill</td>
<td>BL mean</td>
<td>0.742</td>
<td>0.240</td>
<td>0.542</td>
<td>0.565</td>
<td>0.762</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.12 (0.10)</td>
<td>0.01 (0.16)</td>
<td>0.28 (0.10)</td>
<td>0.07 (0.10)</td>
<td>0.27 (0.10)</td>
<td>0.16 (0.10)</td>
</tr>
<tr>
<td>Lesion Analysis</td>
<td>BME ≥4 (n=50)</td>
<td>BME ≥4 (n=47)</td>
<td>BME ≥4 (n=48)</td>
<td>BME ≥4 (n=53)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erosion</td>
<td>BL mean</td>
<td>4.863</td>
<td>2.160</td>
<td>5.352</td>
<td>2.190</td>
<td>5.276</td>
<td>1.425</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>0.42 (0.19)</td>
<td>-0.06 (0.17)</td>
<td>-0.70 (0.23)</td>
<td>-0.23 (0.16)</td>
<td>-0.71 (0.20)</td>
<td>-0.19 (0.17)</td>
</tr>
<tr>
<td>Fat</td>
<td>BL mean</td>
<td>0.775</td>
<td>1.910</td>
<td>1.926</td>
<td>1.603</td>
<td>1.671</td>
<td>0.604</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.02 (0.08)</td>
<td>-0.02 (0.07)</td>
<td>0.54 (0.10)</td>
<td>-0.01 (0.07)</td>
<td>0.28 (0.08)</td>
<td>0.01 (0.07)</td>
</tr>
<tr>
<td>Backfill</td>
<td>BL mean</td>
<td>0.760</td>
<td>0.470</td>
<td>1.019</td>
<td>0.328</td>
<td>0.763</td>
<td>0.387</td>
</tr>
<tr>
<td></td>
<td>LS mean CFB (SE)</td>
<td>-0.21 (0.12)</td>
<td>0.01 (0.11)</td>
<td>0.41 (0.15)</td>
<td>0.11 (0.10)</td>
<td>0.49 (0.13)</td>
<td>0.05 (0.11)</td>
</tr>
</tbody>
</table>

CFB=change from BL, BL=baseline, LS=least squares.
Background: So far, no consensus has been reached on a definition of early axSpA. The ASAS-SPEAR (Spondyloarthritis EARly definition) project aims to develop a consensual definition. Therefore, it is important to know whether treatment earlier in the disease course compared to treatment of established disease leads to better outcomes in axSpA.

Objectives: To summarize the evidence on the relationship between symptom duration or the presence of radiographic damage and clinical response in patients with axSpA treated with NSAIDs, bDMARDs or tsDMARDs.

Methods: A SLR was conducted using Medline, EMBASE and the Cochrane Library (April 28, 2021), supplemented by hand-searches in the FDA website. Randomized controlled trials (RCTs) and cohort studies in patients with axSpA addressing the impact of symptom duration or disease duration and presence of radiographic damage on treatment response (to NSAIDs, b/tsDMARDs) were included. Based on a cut-off of symptom/disease duration or the absence/presence of radiographic damage, groups of ‘early’ and ‘established’ disease were compared. Treatment outcomes were measures of disease activity, function or quality of life.

Two reviewers independently identified eligible studies and extracted the data, including the risk of bias (RoB) assessment. For categorical outcomes we calculated relative risk (RR), relative risk ratio (RRR) and number needed to treat (NNT), and differences in differences (DID) for continuous outcomes.

Results: From the 8769 articles retrieved, 23 were included and 3 added by hand-search, most of them with low RoB. Nineteen studies (9 RCTs) compared groups based on symptom (n=6)/disease duration (n=13) and 7 studies (4 RCTs) based comparisons on absence/presence of radiographic damage in posthoc analyses.

When early axSpA was defined by symptom duration in RCTs (n=4), in patients with axSpA, early treatment was associated with higher RR and RRR and lower NNT for ASAS40 in two studies (Table 1); a third study showed that patients achieving ASDAS-ID and ASAS-PR had shorter symptom duration than those not achieving this. Lastly, in one study including patients with axSpA patients, no difference in treatment response was observed based on symptom duration. In most of the cohort studies using a definition based on symptom/disease duration (n=10), no association was found between symptom/disease duration and treatment response (n=8). Only in one cohort study, disease duration was a significant predictor of quality of life, and in another cohort study, it was a predictor of functional improvement.

Table 1. Assessment of treatment response in RCTs based on symptom duration

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Early vs established (years)</th>
<th>RR (early vs established)</th>
<th>RRR (95% CI)</th>
<th>NNT (early vs established)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASAS20</td>
<td>Langeweg 2014 axSpA</td>
<td>&lt;5 vs ≥5</td>
<td>1.5 vs 1.5</td>
<td>0.96 (0.53-1.73)</td>
<td>5.5 vs 4.8</td>
</tr>
<tr>
<td>ASAS40</td>
<td>Sieper 2012 n-axSpA</td>
<td>&lt;5 vs ≥5</td>
<td>8.2 vs 16.4</td>
<td>5.24 (1.24-22.41)</td>
<td>2.4 vs 9.1</td>
</tr>
<tr>
<td>Kay 2019 n-axSpA</td>
<td>&lt;5 vs ≥5</td>
<td>5.0 vs 3.3</td>
<td>1.52 (0.60-3.87)</td>
<td>2.1 vs 3.9</td>
<td></td>
</tr>
<tr>
<td>ASDAS-MI</td>
<td>Kay 2019 n-axSpA</td>
<td>&lt;5 vs ≥5</td>
<td>3.6 vs 3.5</td>
<td>1.01 (0.46-2.20)</td>
<td>2.1 vs 2.3</td>
</tr>
<tr>
<td>Study</td>
<td>Population</td>
<td>Symptom duration Responders Non responders</td>
<td>p value</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>ASDAS-ID</td>
<td>Sieper 2019 n-axSpA</td>
<td>6.1±6.2</td>
<td>8.3±6.1</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>ASAS-PR</td>
<td>Sieper 2019 n-axSpA</td>
<td>5.3±5.7</td>
<td>8.0±7.8</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

When early axSpA was defined based on disease duration or the presence of radiographic damage, there was no significant difference in response to treatment between early and established axSpA.

Conclusion: Studies addressing treatment response based on symptom duration or radiographic damage in axSpA are scarce. When defining early axSpA based on symptom duration, in n-axSpA, treatment with bDMARDs may lead to better outcomes compared to established axSpA whereas in axSpA there is no difference in response to treatment between early and established disease.

When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found between early and established disease.

Acknowledgements: The Assessment of Spondyloarthritis international Society (ASAS) supported Diego Benavent financially for this work.

Disclosure of Interests: Danie Capelusznik Speakers bureau: Bristol Myers Squibb, Pfizer, Grant/research support from: Pfizer, Diego Benavent Speakers bureau: Janssen, Roche, Grant/research support from: Novartis, Désirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma Director of Imaging Rheumatology bv.: Robert Landewé Consultant of: AbbVie, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, UCB, Denis Podubnyy Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmith-Kline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB, Grant/ research support from: AbbVie, Eli Lilly, MSD, Novartis, and Pfizer, Astrid van Tubergen Consultant of: Novartis, Galapagos, Grant/research support of: Novartis, Pfizer, UCB, Novartis, Louise Falcon: None declared, Victoria Navarro-Compañ Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Grant/ research support from: AbbVie, Novartis, Sofia Ramiro Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, and Janssen Consultant/research support from: AbbVie, Galapagos, Novartis, Pfizer, UCB DOI: 10.1136/annrheumdis-2022-eular.735

TREATMENT DECISIONS IN AXIAL Spondyloarthritis are MORE THAN TREAT TO TARGET

J. W. Bolt1,2, C. Aalbers1,2, L. H. Wiele2,1, L. Van Mens3,2, J. C. Van Denderen3,2, I. Van der Horst-Bruinisma1,2, L. Van Baarren1,2, R. B. M. Landewé1,2, M. G. H. Van de Sande1,2,1, Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam, Netherlands; 2Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands; 3Reade, Department of Rheumatology, Amsterdam, Netherlands; 4Radboud University Medical Centre, Department of Rheumatology, Nijmegen, Netherlands

Background: Several guidelines treating axial spondyloarthritis (axSpA) patients according to the ‘treat-to-target principles’ (T2T)1 although a clear target has not yet been defined. Disease activity measures, which are often used as targets, do not always reflect pure inflammatory disease activity. Currently it is not known if T2T is applied in axSpA clinical practice and what factors influence treatment decisions.

Objectives: To assess residual disease activity according to the physician's opinion, patient's opinion and disease activity measures and the subsequent treatment decisions made in axSpA patients.

Methods: This cross-sectional multicentre study included 249 patients with a clinical diagnosis of axSpA > 6 months. Remission and low disease activity according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI <1.9 and <3.5 respectively), physician's, and patient's opinion was assessed. Questionnaires including patient reported outcomes (PROs) such as the Patient Global Assessment (PGA) of disease activity, Bath Ankylosing Spondylitis Functional Index (BASFI), ASAS-Health Index (ASAS-HI), central sensitization inventory (CSI), Brief Illness Perception Questionnaire (B-IPQ), and satisfaction with treatment; or questions regarding motivations for treatment decisions were filled in by patients and physicians respectively.

Results: In this cohort, 115/249 patients were in remission according to the physician. Of these 115 patients, 67% (n=80) indeed perceived their disease as being inactive, but only 37% (n=43) reached remission according to the BASDAI. This shows a significant level of discrepancy in comparison with the physician's opinion. Of note, 30 (n=35) even reported a BASDAI >3.5. In 93% (n=107) treatment-intensity remained unchanged and in 6% (n=5) treatment was tapered. Physicians motivated that treatment was left unchanged in the majority of these patients because of remission (n=5, 10%) and disease activity (n=5, 25%), or complaints not related to axSpA (n=13, 12%). The latter two motives were most frequently mentioned for the patients with a BASDAI >3.5 (respectively n=13, 39% and n=9, 27%). Residual disease activity was present in 134/249 patients according to the physician's opinion and 67% (n=90) of these patients also perceived their disease as active. In 89% (n=119) BASDAI score was >1.9 and in 62% (n=83) >3.5. In 61% (n=51) of these patients with residual disease and a BASDAI >3.5, treatment remained unchanged, as well as in 84% (n=43) of the patients with a BASDAI between 1.9 and 3.5. Physician's most frequently mentioned motives for not changing treatment in the residual disease activity group were low disease activity achieved (n=29, 25%), the need to await the effect of the current treatment (n=23, 20%), or complaints that were not related to axSpA (n=9, 8%). The second (n=20, 39%) motive was most frequently mentioned for unchanged treatment in the BASAI >3.5 group and additionally, physicians mentioned that these patients had a preference to continue their current treatment despite high disease activity (n=5, 10%). Analyses of PROs showed significantly higher scores for PGA of disease activity, several subdomains of the B-IPQ, general fatigue and morning stiffness in patients with remission according to the physician despite a BASDAI >3.5.
compared to patients with residual disease according to the physician with a BASDAI <19.

**Conclusion:** This study shows that physicians in daily clinical practice do not always adjust treatment according to the T2T-principles in patients with residual disease activity when measured by BASDAI scores, either because low disease activity is achieved, because they classify the patient as being in remission, as having low disease activity, or because there was a need to await the efficacy of the current treatment. Further studies are needed to investigate if treatment choices made in clinical practice result in under-treatment of axSpA patients with worse outcome in comparison to the T2T approach.

**REFERENCES:**


**Disclosure of Interests:** J.W. Boit: None declared, Caroline Aalbers Speakers bureau: I am paid by Novartis as a speaker, Laura H Walet: None declared, Leonie van Mens: None declared, J.C. van Denderen: None declared, Irene van der Horst-Bruinsma

**Methods:** Data from the international ASAS Health Index Validation Study were used. Included patients had a diagnosis of SpA and fulfilled the ASAS classification criteria for axial/peripheral SpA. Patients were assessed at baseline, and for those who required a therapeutic change (initiation of NSAID, csDMARD or TNFi) due to high disease activity, a follow-up assessment was conducted. The current analysis included only those with a therapeutic change. Data on demographics, disease characteristics and disease activity (ASDAS, BASDAI, CRP) were available. Depressive symptoms were assessed with the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D, range 0-21 [best-worst]). HADS-D scores ≥8 and ≥11 indicated possible and probable depression, respectively. Change in depressive symptoms from baseline was compared between treatments (CS) and is associated with higher levels of pain and functional disability. Tofacitinib is oral JAK inhibitor approved for the treatment of AS. In pts with AS, greater improvements in fatigue were seen with tofacitinib vs placebo (PBO).

**Objectives:** To estimate the time to improvement in fatigue in pts with AS treated with tofacitinib.

**Methods:** This post hoc analysis used data from a Phase 3 trial (NCT03502816) in pts with AS receiving tofacitinib 5mg twice daily (BID) or PBO for 16 weeks; after Week (W)16, all pts received open-label tofacitinib until W48. Fatigue was assessed by Functional Assessment of Chronic Illness Therapy-Fatigue (FACT-F) total score (range 0–52; higher scores indicate less fatigue). A series of time to improvement analyses were performed using non-parametric Kaplan–Meier models.

**Results:** Overall, 269 pts were assessed; baseline demographics/disease characteristics have been previously reported. The median times to initial improvements in FACT-F total score were assessed based on different thresholds. The initial improvement event was defined as time to first improvement in FACT-F total score. For example, median time to initial improvement in FACT-F total score was significantly (p < 0.05) shorter in pts receiving tofacitinib 5mg BID vs PBO (Figure 1). For example, median time to
initial improvement of 30% in FACIT-F total score was 16 weeks in pts receiving tofacitinib 5 mg BID; however, in pts receiving PBO, the median time for this event was not achieved up to W16. More pts receiving tofacitinib 5 mg BID vs PBO experienced initial improvement events up to W16 (Table 1). For example, 36.1% of pts receiving tofacitinib 5 mg BID experienced 50% improvement of fatigue up to W16, compared with 19.9% of pts receiving PBO.

Table 1. Proportions of pts who experienced initial improvement events in FACIT-F total score up to W16

<table>
<thead>
<tr>
<th>Fatigue improvement threshold</th>
<th>Initial improvement, n (%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>25% Tofacitinib 5 mg BID PBO</td>
<td>82 (61.7)</td>
<td>0.0009</td>
</tr>
<tr>
<td>50% Tofacitinib 5 mg BID PBO</td>
<td>48 (36.1)</td>
<td>0.0031</td>
</tr>
<tr>
<td>75% Tofacitinib 5 mg BID PBO</td>
<td>30 (22.6)</td>
<td>0.0626</td>
</tr>
<tr>
<td>100% Tofacitinib 5 mg BID PBO</td>
<td>23 (17.3)</td>
<td>0.1233</td>
</tr>
</tbody>
</table>

N=133 (tofacitinib 5 mg BID); N=136 (PBO). aTest of equality over strata log-rank test, p<0.05

Conclusion: In pts with AS, initial improvements in fatigue, as determined by FACIT-F total score, occurred faster and were larger in magnitude with tofacitinib vs PBO up to W16. These results may help physicians better understand the speed and magnitude for fatigue benefit in pts receiving tofacitinib.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Lauren Hogarth, CMC Connect, and funded by Pfizer Inc.


Impact of the article on health 

POS0306

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: a double-blind, randomised, placebo-controlled phase 3 trial


1. Leiden University Medical Center, Rheumatology, Leiden, Netherlands;
2. Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany;
3. Charité Universitätsmedizin Berlin, Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany;
4. Oregon Health & Science University, Division of Arthritis & Rheumatic Diseases, Portland, OR, United States of America;
5. Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, and University of Toronto, Immunology; Toronto, Ontario, Canada;
6. Toho University, Internal Medicine, Tokyo, Japan;
7. Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Rheumatology and Clinical Immunology, Beijing, China;
8. AbbVie Inc., Immunology, North Chicago, IL, United States of America.

Background: Upadacitinib (UPA) was shown to be safe and effective through 2 years in patients (pts) with active ankylosing spondylitis (AS) naïve to biologic disease-modifying antirheumatic drugs (bDMARDs) in the pivotal phase 2/3 SELECT-Axis 1 trial.

Objectives: To assess the efficacy and safety of UPA in pts with active AS with an inadequate response (IR) to bDMARDs.

Methods: SELECT-Axis 2 (NCT04169373) was conducted under a master protocol and includes two separate studies (one for AS bDMARD-IR and one for non-radiographic axial spondyloarthropathies [n-axSpA]). The AS bDMARD-IR study is a randomized, double-blind, placebo (PBO)-controlled, phase 3 trial that enrolled adults ≥18 years with AS who met modified New York criteria, had BASDAI and pt’s assessment of total back pain scores ≥4 (numeric rating scale 0–10) at study entry, and had an IR to one or two bDMARDs (TNF inhibitor or IL-17 inhibitor). Pts were randomized 1:1 to receive oral UPA 15 mg once daily (QD) or PBO during the 14-week (wk) double-blind treatment period. The primary endpoint was ASAS40 response at wk 14. Multiplicity-adjusted secondary endpoints evaluated at wk 14 were improvements from baseline in disease activity (ASDAS CRP), ASDAS LDA (<1.3), ASDAS Lans<0.2, BASDAS05, ASAS20, and ASAS PR), pain (total and nocturnal back pain), function (BASFI), objective measure of inflammation (SPARCC MRI score of the spine), spinal mobility (BASMI), enthesitis (MASES), and quality of life (ASQoL and ASAS HI). Non-responder imputation incorporating multiple imputation (NRI-MI) was used to handle intercurrent events and missing data for binary endpoints. Cochran-Mantel-Haenszel (CMH) test and mixed-effect model for repeated measures (MIMM) were used for analyzing binary and continuous endpoints, respectively. Treatment-emergent adverse events (TEAEs) assessed through wk 14 are reported for pts who had ≥1 dose of study drug.

Results: All 420 randomized pts with active AS received assigned treatment (UPA 15 mg, n=211; PBO, n=209); 409 (97%) received study drug through wk 14. Baseline demographic and disease characteristics were generally similar between treatment groups and reflective of an active AS bDMARD-IR population (74% male; mean age 42.4 years; mean disease duration 7.7 years; 83% HLA-B27 positive; mean BASDAI 6.8). Significantly more pts achieved the primary endpoint of ASAS40 response at wk 14 with UPA vs PBO (45% vs 18%; P<0.0001; Figure 1). UPA showed onset of effect in ASAS40 as early as wk 4 (nominal P<0.05). All multiplicity-controlled secondary endpoints met statistical significance for UPA vs PBO at wk 14 across multiple clinical domains of AS (P<0.0001; Figure 1). The rate of TEAEs was similar between treatment groups through wk 14 (UPA, 41%; PBO, 37%). TEAEs led to discontinuation in 3 (1.4%) pts treated with PBO and none with UPA. Serious infections occurred with UPA (2.4%) but not with PBO and included 4 events of COVID-19 and 1 event of uveitis. Additional events of uveitis occurred in 1 (0.5%) pt on UPA and none on PBO. No malignancy, major adverse cardiovascular events, venous thromboembolic events, or death were reported with UPA; 1 event of malignancy was observed with PBO.

Conclusion: UPA 15 mg QD was significantly more effective than PBO over 14 wks of treatment in pts with active AS and IR to bDMARDs. No new safety risks were identified with UPA compared with its known safety profile. These findings are consistent with and complementary to those of SELECT-Axis 1 (bDMARD-naive AS population), and support the use of UPA in pts with active AS, including those who had a previous IR to bDMARD therapy.

REFERENCES:
Background: Psoriatic arthritis (PsA) and psoriasis are both strongly associated with impaired glycaemic control and type 2 diabetes. The risk of developing type 2 diabetes is estimated to be ~40% higher in PsA compared to controls [1]. However, these observational findings are susceptible to bias from reverse causality, insulin resistance and impaired glycaemic control are evident well over a decade before clinical onset of type 2 diabetes [2]. Therefore, whether impaired glycaemic control is a cause or consequence of PsA is unclear. Testing this hypothesis using traditional observational designs is challenging since longitudinal assessments of glycaemic control before PsA onset are often not available. Mendelian randomisation (MR) is an epidemiologic method that provides evidence about putative causal relationships between modifiable exposures and disease outcomes using genetic variants as instrumental variables. MR is less likely to be affected by confounding or reverse causation than conventional observational designs because genetic variants are randomly allocated at conception.

Objectives: To estimate the effect of genetically predicted glycaemic traits - glycaemic control may reduce PsA risk, although further studies are required to confirm these findings and to compare PsA directly against cutaneous only psoriasis.

Methods: We selected 320 independent (r²<0.01) genome-wide significant (p<5x10⁻⁸) variants as instruments for HbA1c from a UK biobank genome-wide association study (GWAS) of 3,448,182 individuals, and 14 variants for 2hG, 67 for FG and 38 for F1 from up to 200,622 individuals from a MAGIC consortium meta-analysis that adjusted for body mass index. Genetic associations for PsA were obtained from a GWAS comprising 3,609 cases (majority fulfilling CASPAR criteria) and 9,192 controls. Psoriasis data were obtained from 5,278 cases (96% European, defined using ICD and phenotypes) and 650,391 controls from the UK biobank, FinGen and BioBank Japan [3]. We used the inverse-variance weighted method to combine effect estimates from each variant using fixed-effect meta-analysis.

Results: Genetically predicted HbA1c increased risk of PsA (OR 1.18 per standard deviation (6.7 mmol/mol) increase in HbA1c; 95%CI 1.10, 1.26) and FG (OR 1.21 per SD (0.7 mmol/L) increase; 95%CI 1.04, 1.40) and 2hG (OR 1.21 per SD (0.6 mmol/L) increase; 95%CI 1.04, 1.40). Estimates were smaller when comparing PsA directly against cutaneous only psoriasis. Improving glycaemic control may reduce PsA risk, although further studies are required to confirm these findings and to compare PsA directly against cutaneous only psoriasis.

REFERENCES:

Acknowledgements: This work was supported by Versus Arthritis (grant number 21173, grant number 21754 and grant number 21755). This study provides supportive genetic evidence that impaired glycaemic control increases risk of PsA. By contrast, estimates were smaller when comparing psoriasis against controls with confidence intervals including the null. Improving glycaemic control may reduce PsA risk, although further studies are required to confirm these findings and to compare PsA directly against cutaneous only psoriasis.

Clinical aspects in Psoriatic Arthritis

---

Figure 1. Mendelian randomisation estimates of the effect of glycaemic traits on risk of psoriatic arthritis and psoriasis.

Conclusion: This study provides supportive genetic evidence that impaired glycaemic control increases risk of PsA. By contrast, estimates were smaller when comparing psoriasis against controls with confidence intervals including the null. Improving glycaemic control may reduce PsA risk, although further studies are required to confirm these findings and to compare PsA directly against cutaneous only psoriasis.
Background: Gusekumbab (GUS), a selective IL-23 inhibitor, is efficacious in treating bio-naive and TNFi-experienced active PsA patients (pts).1,2 In the COSMOS study of active PsA pts with lack of efficacy/intolerance, i.e., inadequate response (IR), to ≥2 TNFi, GUS demonstrated significantly greater response rates and mean improvements in PsA signs and symptoms vs. placebo (PBO) at Week (W) 24.3

Objectives: Evaluate baseline (BL) serum levels of pro-inflammatory biomarkers (CRP, serum amyloid A [SAA], TNFα, IFNγ, IL-6, IL-10, IL-17F, IL-17A, IL-22) and their relationship to BL disease activity, GUS treatment (tx), and clinical response in COSMOS TNFi-IR pts.

Methods: TNFi-IR pts ≥18 yrs with active PsA (≥3 swollen & ≥3 tender joint counts [SJC/TJC]) were randomized 2:1 to GUS 100 mg every 8 W (Q8W) through W44 or PBO with early escape (W16) or crossover (W24) to GUS Q8W. Samples for serum biomarker analyses, collected at W0, 4, 16, 24, and 48 from consenting pts, were compared with healthy controls (HC); independent of COSMOS TNFi-IR pts. Associations between early biomarker changes and BL disease activity, GUS tx, and clinical response at W24 were assessed.

Results: Among 285 COSMOS pts, 50/95 PBO and 100/190 GUS pts had available biomarker data. BL characteristics of the biomarker cohort were similar to the overall COSMOS population and well balanced across tx arms. At BL, levels of TNFα, IFNγ, IL-6, IL-10, IL-17A, IL-17F, and IL-22 were significantly upregulated in TNFi-IR pts vs. HC (Table 1). IL-6, CRP, and SAA levels were associated with BL joint disease severity per Disease Activity Score (DAS) 28 (CRP [≥3] in W24 with SJC [0-66]/TJC [0-68]). IL-17A and IL-17F levels were associated with BL PASI score. Through W24, significant decreases from BL levels in CRP, SAA, IL-6, IL-17A, IL-17F, and IL-22 were seen in GUS-, but not PBO-tx pts. Reductions in IL-17A, IL-17F and IL-22 with GUS were significant by W4, decreased further by W16, and were sustained through W24 and W48. In GUS-tx pts, serum levels of IL-17F (from W16) and IL-22 (from W4) were not significantly different vs. HC. At W48, reductions in these same markers were seen in PBO-tx pts who crossed over to GUS at W26/W44 (Figure 1; IL-17A, IL-17F, & IL-22 data shown). In these TNFi-IR pts, GUS-tx pts achieving ACR20 at W24 exhibited higher IL-22 and IFNγ levels at BL than nonresponders (NR). All other biomarkers evaluated were not significantly associated with ACR20 response to GUS. In the subset of pts with IGa of psoriasis assessed, BL IL-6 and SAA levels were upregulated in W24 ACR 0/1 responders (R) vs. NR in the GUS arm. ACR20 and IGA 0/1 R at W24 exhibited an earlier reduction in IL-6 expression (at W4) than did respective NR in the GUS arm. No BL biomarkers were associated with ACR50 or PASI75 responses to GUS at W24.

Table 1. Select Serum Biomarkers at BL in TNFi-IR pts vs. HC

<table>
<thead>
<tr>
<th>Biomarker, pg/mL</th>
<th>HC N=24</th>
<th>TNFi-IR N=50</th>
<th>Fold difference</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP</td>
<td>22.1 (1.5)</td>
<td>22.3 (2.2)</td>
<td>1.03</td>
<td>0.2835</td>
</tr>
<tr>
<td>SAA</td>
<td>21.7 (1.2)</td>
<td>22.0 (2.4)</td>
<td>2.1</td>
<td>0.0794</td>
</tr>
<tr>
<td>IL-6</td>
<td>0.07 (1.1)</td>
<td>0.98 (1.7)</td>
<td>3.9</td>
<td>0.0314</td>
</tr>
<tr>
<td>IL-10</td>
<td>-2.3 (1.1)</td>
<td>-1.7 (1.0)</td>
<td>1.9</td>
<td>0.0272</td>
</tr>
<tr>
<td>IL-17A</td>
<td>-2.1 (1.3)</td>
<td>-0.3 (1.5)</td>
<td>3.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IL-17F</td>
<td>0.05 (1.1)</td>
<td>1.3 (1.5)</td>
<td>2.4</td>
<td>0.0007</td>
</tr>
<tr>
<td>IL-22</td>
<td>1.9 (1.1)</td>
<td>3.1 (1.3)</td>
<td>2.4</td>
<td>0.0002</td>
</tr>
<tr>
<td>TNFα</td>
<td>0.5 (0.75)</td>
<td>0.7 (1.1)</td>
<td>1.8</td>
<td>0.0002</td>
</tr>
<tr>
<td>IFNγ</td>
<td>2.4 (0.84)</td>
<td>2.9 (1.3)</td>
<td>1.5</td>
<td>0.0259</td>
</tr>
</tbody>
</table>

Data are mean (SD); *p<0.05 and fold difference >1.44, adjusted for confounding factors age & sex.

Conclusion: GUS-tx TNFi-IR pts showed response-specific associations with BL biomarkers (IL-22, IFNγ, IL-6, and SAA). GUS resulted in decreased levels of elevated CRP, SAA, IL-6, IL-17A, IL-17F, and IL-22, while no significant change was observed with PBO tx. Reductions in these biomarkers were evident as early as W4 and approximated levels seen in HC from W16 onward (W4 for IL-22), suggesting apparent normalization of effector cytokines associated with the IL-23/Th17 axis following GUS tx.

REFERENCES:


DOI: 10.1136/annrheumdis-2021-220991.

POS0309
ARE PATIENTS' AND RHEUMATOLOGISTS' PERCEPTIONS OF THE BURDEN AND TREATMENT OF PsORIATIC ARTHRITIS ALIGNED? RESULTS FROM THE UPLIFT SURVEY

P. Richter1, W. Tillett2, A. Ogdie3, A. B. Gottlieb4, S. Jardon5, S. Richter5, A. Flower5, J. Merola6, 1Hôpital Lariboisière, AP-HP, Paris, France; 2University of Bath, Department of Pharmacy & Pharmacology, Bath, United Kingdom; 3University of Pennsylvania, Rheumatology, Philadelphia, United States of America; 4Ichan School of Medicine at Mount Sinai, Dermatology, New York, United States of America; 5Amgen Inc, Medical Affairs, Thousand Oaks, United States of America; 6Brigham and Women's Hospital, Dermatology, Boston, United States of America

Background: Alignment of patient and clinician goals and perceptions of psoriatic arthritis (PsA) burden and treatment are important to improving disease management.

Objectives: To describe patient and rheumatologist perceptions on factors contributing to PsA severity, treatment goals, and attributes of ideal therapy.

Methods: Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) was a multinational Web-based survey that included adults who reported a healthcare provider (HCP) diagnosis of PsA and/or psoriasis, as well as rheumatologists and dermatologists. This analysis focused on survey responses from patients with PsA and rheumatologists. Respondents ranked their top 3 contributing factors for PsA severity, treatment goals, and ideal attributes for therapy. Results were analyzed using the sum of scores.

Results: In all, 1256 patients with PsA and 450 rheumatologists completed the respective surveys between March and June 2020. An oligocarticular (≤4 joints involved) pattern of involvement was prevalent in 43.8% of patients (Table 1). Involvement of large joints (78.8%) was most common, followed by intermediate (9.3%) and small (51.8%) joints. Only half of patients reported seeing an HCP for PsA in the last year (Table 1). Patients and rheumatologists agreed that joint pain is a top factor contributing to disease severity; patients also ranked the impact on quality of life and type of symptoms as top factors whereas rheumatologists placed greater importance on the number of joints involved and joint erosion or deformity (Figure 1). Top treatment goals for patients were reducing joint pain and stiffness and stopping the progression of joint damage or erosion (Figure 1). Rheumatologists agreed that inhibiting progression of joint damage or erosion and reducing joint pain were among the top treatment goals, and they rated disease remission or low disease activity (LDA) as the most important goal (Figure 1). Rheumatologists identified consistent treatment goals for patients
regardless of degree of joint involvement (oligoarthritis vs polyarthritis). Patients and rheumatologists agreed that long-term safety and efficacy are key attributes of an ideal PsA therapy. The top attribute for patients was joint pain reduction, whereas achievement of remission or LDA was the top attribute identified by rheumatologists (Figure 1). Despite general alignment between patient and rheumatologist responses across metrics, 87.1% of patients reported they did not feel that their treatment goals matched those of their current HCP.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>UPLIFT Global PsA Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Subgroup N=1256</td>
</tr>
<tr>
<td>Age, mean (SD), years</td>
<td>42.9 (15.3)</td>
</tr>
<tr>
<td>Men, n (%)</td>
<td>674 (53.7)</td>
</tr>
<tr>
<td>Joint count, n (%)</td>
<td>4 joints (polyarthritis)</td>
</tr>
<tr>
<td>&gt;4 joints (polyarthritis)</td>
<td>706 (56.2)</td>
</tr>
<tr>
<td>≤4 joints (oligoarthritis)</td>
<td>550 (43.8)</td>
</tr>
<tr>
<td>Seen an HCP in the past year, n (%)</td>
<td>626 (49.8)</td>
</tr>
<tr>
<td>Type and location of practice, n (%)</td>
<td>UPLIFT Rheumatologists N=450</td>
</tr>
<tr>
<td>Single or solo specialty</td>
<td>267 (59.3)</td>
</tr>
<tr>
<td>Multi-specialty</td>
<td>183 (40.7)</td>
</tr>
<tr>
<td>Canada</td>
<td>41 (9.1)</td>
</tr>
<tr>
<td>France</td>
<td>53 (11.8)</td>
</tr>
<tr>
<td>Germany</td>
<td>50 (11.1)</td>
</tr>
<tr>
<td>Italy</td>
<td>52 (11.2)</td>
</tr>
<tr>
<td>Japan</td>
<td>50 (11.1)</td>
</tr>
<tr>
<td>Spain</td>
<td>51 (11.3)</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>50 (11.1)</td>
</tr>
<tr>
<td>United States</td>
<td>101 (22.4)</td>
</tr>
</tbody>
</table>

The N represents the total sample. The number of patients with data available may vary. *COVID-19 restrictions may have impacted a patient’s ability to have an HCP visit from March 2 to June 3.

Conclusion: In the UPLIFT survey, patients with PsA and their rheumatologists generally agreed on the top factors contributing to disease severity, treatment goals, and attributes of ideal PsA therapy. However, the majority of patients with PsA did not feel aligned with their current HCP regarding treatment goals. Development of methods for treatment goal discussion and alignment are important to promoting patient outcomes.

Acknowledgements: The authors gratefully acknowledge Hsiuan Lin Wu for data analysis.

This study was funded by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Kristin Carlin, BSPharm, MBA, of Peloton Advantage, LLC, an OPEN Health company, and Cathryn M. Carter, MS, employee of and stockholder in Amgen Inc.


EMD, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Serono, Sun, and UCB – consultant and/or investigator.

DOI: 10.1136/annrheumdis-2022-eular.1355

POS0310 DO AXIAL PSORIATIC ARTHRITIS PATIENTS MEET ASAS CLASSIFICATION CRITERIA FOR AXIAL SPONDYLOARTHRITIS?

F. Gubar1, T. Korotaeva1, E. Logina1, Y. Korsakova1, S. Glukhova2, I. V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritides and Psoriatic Arthritis, Moscow, Russian Federation; 2 I. V. A. Nasonova Research Institute of Rheumatology, Medical and Social Problems in Rheumatology, Moscow, Russian Federation

Background: There isn’t any generally accepted definition and diagnostic criteria for axial psoriatic arthritis (axPsA). According to most recent data, classification criteria for axial spondyloarthritis (axSpA) may not be applied to axPsA (1).

Objectives: To analyze, in clinical practice, whether axPsA patients (pts) meet classification criteria for axSpA and ankylosing spondylitis (AS).

Methods: 52 pts (MF=32/20), a hospital cohort, with PsA according to CASPAR criteria were observed. All pts had back pain at one time or another, which rheumatologist suspected to be axial involvement. Pts’ age 43.0 [35.0; 54.0], disease duration 3.4 yrs [0.2; 32.0]. Me BASDAI 5.3 [3.6; 7.0]; ASDAS-CPS 3.3 [2.2; 4.1]; DAPSA 36.3 [19.3; 50.5]; CRP 6.9 [0.1; 18.6] mg/L; ESR 31 [3; 99] mm/h. Enthesi- sis was found in 69.2% and dactylitis in 61.5% of pts. All pts had psoriasis with Me BSA (body surface area) of 4 [1; 8]. Me PASI (Psoriasis Area Severity Index) of 9.6 [5.6; 17.4]. Nail psoriasis was found in 38 (73.1%) pts, 40.4% of them had onycholysis. All pts were evaluated for presence of inflammatory back pain (IBP) by ASAS criteria. Pts underwent sacroiliac joint (SIJ) X-ray (pelvic radiographs), cervical and lumbar spine, hands and feet X-rays, so that 50 pts had complete sets of radiographs. Radiographic sacroilitis (rSI) was defined as bilateral grade ≥ 2 or unilateral grade ≥ 3. Pts without rSI underwent SI MRI on Philips Multiscan 1.5 T scanner. Active MRI sacroilitis (MRI-SI) was categorized using ASAS 2016 criteria. Radiographic spondylitis (rSp) was defined as ≥1 marginal/paramarginal syndesmophyte(s) of the cervical and/or lumbar spine. All radiographs and MRI results were interpreted by two experienced musculoskeletal radiologists. 45 pts underwent HLA B27 examination. Me [Q25; Q75] and Pierson-y2 tests were performed. All p<0.05 were considered to indicate statistical significance.

Results: IBP was found in 34 (66.7%) and rSI in 30 (57.7%) pts. 15 (30.0%) pts had rSI along with rSp, while in 15 (30.0%) pts rSI was without it, and 9 (18.0%) pts had rSp alone. 2 pts of the 17 examined, had MRI-SI, HLA B27 was present in 15 (33.3%) pts examined. 37 (71.2%) pts met ASAS criteria for axSpA as follows: 22 pts met the imaging arm (rSI or MRI-SI + ≥1 SpA feature), 5 pts met the clinical arm (HLA B27+ ≥ 2 other SpA features) and 10 pts met both of those. 10 (19.2%) pts didn’t meet ASAS criteria for axSpA: they had neither rSI/ MRI-SI nor HLA B27; however, 9 of them had syndesmophytes. 30 pts had rSI with 21 of them (40.4% of all pts) meeting modified New York (mNY) criteria for AS, because along with rSI, they had at least 1 of the 3 clinical criteria (IBP for > 3 months, limitation of lumbar motion in sagittal and frontal planes, limitation of chest expansion). The pts who met both CASPAR and mNY criteria, however, had typical axPsA features: 85.7% of them had polyarthritis with multiple joint erosions, 61.9% had osteology and/or juxtaarticular new bone formation, 61.9% dactylitis, 33.3% non-marginal asymmetrical syndesmophytes, 44.4% were HLA B27 negative, 43.3% didn’t have IBP: all pts developed psoriasis many years before the onset of PsA.

Conclusion: Among PsA pts with axial involvement there is an alternative phenotype group (18% of our cohort) with neither sacroilitis (rSI/MRI-SI) nor HLA B27. Such pts do not meet ASAS criteria for axSpA. The alternative phenotype is characterized by isolated spondylitis (syndesmophytes) without sacroilitis. Axial disease cannot be ruled out in PsA pts without spinal radiographs, regardless of symptoms. Pts meeting both CASPAR and mNY criteria and featuring typical axPsA symptoms cannot be diagnosed as having AS along with concomitant psoriasis, because axPsA patients with psoriasis seem to be two distinct diseases. There is an urgent need for a unified definition of axial involvement in PsA.

REFERENCES:


Disclosure of Interests: ELENA GUBAR: None declared, Tatiana Korotaeva Speakers bureau: Pfizer, MSD, Novartis, Abbvie, Janssen, Lilly, Celgene, JSC BIOCAD and Novartis-Sanofi, Elena Logina Speakers bureau: Novartis, Svetlana Glukhova: None declared


POS0311 FLARES IN PATIENTS WITH RECENT-ONSET PSORIATIC ARTHRITIS: PREDICTIVE MODEL BASED ON MACHINE LEARNING

R. Queiroz Silva1, D. Seoane-Mato2, A. Laiz4, E. Galindez-Agirregiokoa3, J. D. D. Cañete5, J. Gratacos-Masmitja6, X. Juanola-Roura7, J. Fiter2,1

E. Galindez-Agirregiokoa3, J. D. D. Cañete5, J. Gratacos-Masmitja6, X. Juanola-Roura7, J. Fiter2,1
Background: An important aspect in the clinical care of patients with PsA is to be able to predict the occurrence of a flare using tools and information that are readily available in daily clinical practice. This information would provide added value in disease management, yet, unfortunately, scarcely any studies provide it.

Objectives: To identify patient- and disease-related characteristics that make it possible to predict flares in recent-onset PsA.

Methods: We performed a multicenter observational prospective study (2-year follow-up, regular annual visits), promoted by the Spanish Society of Rheumatology [1]. The study population comprised patients aged ≥18 years who fulfilled the CASPAR criteria [2], with less than 2 years since the onset of symptoms. The intention at the baseline visit was to reflect the patient’s situation before disease onset, but progress was modified by the treatments prescribed in the rheumatology department. All patients gave their informed consent. The study was approved by the Clinical Research Ethics Committee of the Principality of Asturias.

Flares were defined as inflammatory episodes affecting the axial skeleton and/or peripheral joints (joints, digits or entheses) and diagnosed by a rheumatologist between the previous and the current visit. The dataset contained data for the independent variables from the baseline visit and from follow-up visit number 1. These were matched with the outcome measures from follow-up visits 1 and 2, respectively. We trained logistic regression models and a random forest–type machine learning algorithm to analyze the association between the outcome measure and the variables selected in the bivariate analysis (statistical significance was defined as p value <0.05). We used a confusion matrix to visualize the performance of the final model. This matrix shows the real class of the data items, together with the class predicted by the machine learning algorithm, and records the number of hits and misses.

Results: The sample comprised 158 patients. 14.6% were lost to follow-up. At the first follow-up visit, 37.6% of the patients who attended the clinic had age-adjusted Charlson comorbidity index and physical activity and positive for PsAID score and level of physical activity. The direction of the association was negative for flares between visits selected in this analysis were age-adjusted Charlson comorbidity index, physical activity, PsAID score, and level of physical activity. The results of the logistic regression analysis. The variables predicting flares between visits selected in this analysis were age-adjusted Charlson comorbidity index, PsAID score, number of digits with onychopathy, and level of physical activity. The direction of the association was negative for the Charlson index and physical activity and positive for PsAID score and onychopathy.

Table 1. Variables associated with flares between visits selected in the logistic regression analysis.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Regression coefficient</th>
<th>95% CI</th>
<th>p value (Wald test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age-adjusted Charlson comorbidity index</td>
<td>-4.655</td>
<td>(-7.021, -2.289)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PsAID score</td>
<td>2.212</td>
<td>(1.171, 3.254)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>No. of digits with onychopathy</td>
<td>1.420</td>
<td>(0.331, 2.511)</td>
<td>0.011</td>
</tr>
<tr>
<td>Level of physical activity</td>
<td>-1.221</td>
<td>(-1.87, -0.572)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

When the random forest machine learning algorithm was trained with these 4 variables, the order of importance (from more to less) attributed by the model was as follows: PsAID score, number of digits with onychopathy, age-adjusted Charlson comorbidity index, and level of physical activity. The percentage of hits in the confusion matrix was 78.38%.

Conclusion: PsAID score was the first variable in the predictive hierarchy generated in our model, supporting its importance in the management and follow-up of PsA patients.

References:


Acknowledgements: The authors would like to acknowledge José Luis Fernández-Sueiro for the conception of the study; José Miguel Carrasco for his contribution to the design of the study; Nuria Montero and Cristina Oliva for her contribution to data monitoring; Ana Serrano and Cristina Prunera for her contribution to data analysis; Thomas O’Boyle for the translation; and non-author investigators of Proyecto REAPSER Study Group.

Disclosure of Interests: None declared.


POS0312 REAL-WORLD EVIDENCE ON ASSESSING PSORIATIC ARTHRITIS BY DISEASE DOMAIN: AN EVALUATION OF THE COREVITAS PSORIATIC ARTHRITIS/SPONDYLOARTHROPATHY REGISTRY

P. J. Mease1, T. Blachley2, J. O’Brien3, N. Middaugh4, G. Krilocan5, S. Sykier6, D. Collier7, O. Agee8. 1Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Rheumatology, Seattle, United States of America; 2CorEvitas, LLC, Research, Waltham, United States of America; 3AmerGen Inc., Research, Thousand Oaks, United States of America; 4University of Pennsylvania, Rheumatology, Philadelphia, United States of America

Background: Psoriatic arthritis (PsA) is a burdensome, chronic disease that can impact patient functionality and quality of life. Real-world data are limited regarding the most common disease domain combinations in patients with PsA receiving biologic disease-modifying anti-rheumatic drugs.

Objectives: The objective of this study was to describe PsA disease domain frequency, the most common disease domain combinations of PsA manifestations, and pairwise disease domain prevalence in patients initiating treatment with tumor necrosis factor inhibitors (TNFIs) or interleukin-17 (IL-17) inhibitors.

Methods: The CorEvitas PsA/Spondyloarthropathy (SpA) Registry is a prospective, observational registry for patients with PsA or SpA under the care of a rheumatologist. The current analysis included adults with PsA who initiated treatment with a TNFi (adalimumab, etanercept, certolizumab pegol, infliximab, golimumab), etanercept (ETN; independent exploratory evaluation as a subset of the TNFI group), or an IL-17 inhibitor (ixekizumab, secukinumab) from January 2013 through December 2020. Baseline disease characteristics among the total population and by therapy group were examined for 6 PsA domains, including enthesitis (ET), dactylitis (DA), peripheral arthritis (PA), nail psoriasis (NP), axial arthritis (AX), and skin disease (SD). The top 5 most common domain combinations and pairwise combination of other concomitant disease domains within each domain subpopulation are presented.

Results: Among 1005 patients initiating treatment for PsA (mean age, 52.9 years; 57% female, 90% white), the prevalence of disease domains was PA (86%), SD (82%), NP (57%), ET (38%), DA (23%), and AX (20%); these proportions were similar among the therapy groups. The frequency of high skin disease (body surface area [BSA] ≥10%) at baseline was highest in IL-17 initiators (23% vs 16% for TNFI and 9% for ETN). TNFI (40%) and ETN (48%) were more frequently observed as first-line therapy compared with IL-17 inhibitors (14%). The most common disease domain combination overall (14%) was PA, NP, and SD; frequency of the top 3 most common domain combinations were similar among therapy groups (Table 1). Overall, PA and SD were the most common concomitant disease domains observed in each PsA disease domain subpopulation (Figure 1). Results were similar by therapy group (data not shown).

Table 1. Most common PsA domain combinations overall and by therapy

<table>
<thead>
<tr>
<th>Domain Combination</th>
<th>Ranking by Frequency (%)</th>
<th>Overall</th>
<th>TNFI</th>
<th>ETN</th>
<th>IL-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA, NP</td>
<td>SD 138 (14)</td>
<td>PA, NP</td>
<td>SD 91 (14)</td>
<td>PA, SD 17 (15)</td>
<td>PA, NP</td>
</tr>
<tr>
<td>PA, SD</td>
<td>ET, PA, NP</td>
<td>SD 84 (13)</td>
<td>ET, PA, NP</td>
<td>DA, SD 12 (13)</td>
<td>PA, NP</td>
</tr>
<tr>
<td>PA</td>
<td>ET, PA, NP, SD</td>
<td>ET, PA, NP, SD</td>
<td>ET, PA, NP, SD</td>
<td>DA, SD 9 (9)</td>
<td>PA, NP</td>
</tr>
<tr>
<td>NP</td>
<td>ET, PA</td>
<td>DA</td>
<td>SD 9 (9)</td>
<td>DA, SD 4 (4)</td>
<td>ET, PA</td>
</tr>
<tr>
<td>SD</td>
<td>DA</td>
<td>ET, PA</td>
<td>DA</td>
<td>DA, NP</td>
<td>ET, PA</td>
</tr>
</tbody>
</table>

#4 ET, PA, DA | DA, SD 7 (7) | ET, PA |
#5 DA, NP, PA, NP | ET, PA, NP | ET, PA, NP |

#6 DA, NP, PA, NP | SD 36 (8) | DA, NP, PA, NP |
#7 DA, NP, PA, NP | NP, SD 38 (6) | DA, NP, PA, NP |
#8 DA, NP, PA, NP | ET, PA, NP | DA, NP, PA, NP |
#9 DA, NP, DA, NP | NP, SD 38 (6) | DA, NP, PA, NP |
#10 DA, NP, DA, NP | ET, PA, NP | DA, NP, PA, NP |

Matching domain combinations are shaded across each therapy group. ET, enthesitis; DA, dactylitis; PA, peripheral arthritis; NP, nail psoriasis; AX, axial PsA; SD, skin disease; TNFI, tumor necrosis factor inhibitors; ETN, etanercept; IL-17, interleukin-17 inhibitors. *TNFIs includes ETN initiators.
**POS0313**

THE ASSOCIATION BETWEEN BODY COMPOSITION AND PHYSICAL ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: THE TRONDELAG HEALTH STUDY

A. A. Osman1, M. Hoff2, V. Viden3,4, 1Norwegian University of Science and Technology’s, Department of Clinical and Molecular Medicine, Trondheim, Norway; 2Norwegian University of Science and Technology’s, Department of Neuromedicine and Movement Science, Trondheim, Norway; 3St. Olav’s University Hospital, Department of Rheumatology, Trondheim, Norway; 4St. Olav’s University Hospital, Department of Immunology and Transfusion Medicine, Trondheim, Norway.

**Background:** Persons with psoriatic arthritis (PsA) have an altered body composition compared to the general population, including overweight, which may increase the risk of several comorbidities. However, the associations of physical activity (PA) with body composition among persons with PsA is not well described.

**Methods:** The study utilized data from the population-based Trøndelag Health Study (HUNT4, 2017-2019), where all inhabitants ≥ 20 years of age in northern Trøndelag were invited. Data comprised questionnaires, measurements, and blood sample analyses. Persons with PsA (n=291, CASPAR criteria) were identified from hospital case notes. The remaining participants with complete data for relevant variables (n=38 955) were used as controls.

**Results:** Patients with PsA had higher weight, body mass index, VFM and PBF than controls, and they were less physically active (Table 1). The interaction term between PsA and age was statistically significant in both models (p<0.05), showing that the difference in VFM and PBF with PsA compared to controls was relatively larger in persons < 40 years (VMF difference: 3.6kg (95% CI 1.4, 5.9kg) vs. ~1.1 kg in older age groups, PBF difference: 5.2% (1.9, 8.5%) vs. ~1.5% in older age groups).

The associations between PA and VFM or PBF were similar with and without PsA. In Model 1 (R²=0.17), moderate or high physical activity was significantly associated with lower VFM. The moderate activity group had 0.8 kg (0.7, 0.9kg, p<0.001) and the high activity group had 2.6 kg (2.5, 2.7, p<0.001) lower VFM compared to the low physical activity group. In Model 2 (R²=0.38), moderate or high physical activity was significantly associated with lower PBF. The moderate activity group had 1.4% (1.2, 1.5%, p<0.001) and the high activity group had 4.3% (4.1, 4.5%, p<0.001) lower PBF compared to the low physical activity group.

**Conclusion:** Patients with PsA had increased PBF and VFM, and moderate or high physical activity was associated with significant reductions in both endpoints. Physical activity may reduce the comorbidity burden among persons with PsA and should be a focus in clinical treatment plans.

**REFERENCES:**


**DISCLOSURE OF INTERESTS:** None declared.

**DOIs:** 10.1136/annrheumdis-2022-eular.2627

**Table 1. Demographic and clinical characteristics**

<table>
<thead>
<tr>
<th>Variable</th>
<th>PSa (n=291)</th>
<th>Controls (n=38 955)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (±SD)</td>
<td>58 (12)</td>
<td>53 (17)</td>
<td>p=0.001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>174 (59.8)</td>
<td>21 875 (56.2)</td>
<td>p=0.21</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>28 (9.7)</td>
<td>1 876 (4.8)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Cardiovascular disease, n (%)</td>
<td>11 (3.8)</td>
<td>1 349 (3.5)</td>
<td>p=0.77</td>
</tr>
<tr>
<td>Lung disease, n (%)</td>
<td>45 (15.5)</td>
<td>4 904 (12.6)</td>
<td>p=0.14</td>
</tr>
<tr>
<td>Cancer, n (%)</td>
<td>29 (10.0)</td>
<td>2 746 (7.1)</td>
<td>p=0.053</td>
</tr>
<tr>
<td>Alcohol (once a week/more), n (%)</td>
<td>71 (24.4)</td>
<td>8 234 (21.1)</td>
<td>p=0.18</td>
</tr>
<tr>
<td>Smoking (present/former), n (%)</td>
<td>208 (71.5)</td>
<td>20 915 (53.7)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Education (college or higher), n (%)</td>
<td>164 (56.4)</td>
<td>25 166 (64.4)</td>
<td>p=0.003</td>
</tr>
<tr>
<td>Height (cm), mean (±SD)</td>
<td>171 (9.1)</td>
<td>171 (9.2)</td>
<td>p=0.31</td>
</tr>
<tr>
<td>Weight (kg), mean (±SD)</td>
<td>83 (16.5)</td>
<td>79 (15.7)</td>
<td>p&lt;0.001</td>
</tr>
<tr>
<td>Body mass index (kg/m²), mean (±SD)</td>
<td>28.3 (4.7)</td>
<td>26.9 (4.5)</td>
<td>p=0.001</td>
</tr>
<tr>
<td>Percentage body fat, mean (±SD)</td>
<td>33.7 (9.8)</td>
<td>30.5 (9.3)</td>
<td>p=0.001</td>
</tr>
<tr>
<td>Visceral fat mass (kg), mean (±SD)</td>
<td>13.5 (5.5)</td>
<td>11.4 (5.4)</td>
<td>p=0.001</td>
</tr>
<tr>
<td>Physical activity</td>
<td>p=0.004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low</td>
<td>139 (47.8)</td>
<td>16 648 (42.8)</td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>104 (35.7)</td>
<td>14 491 (37.2)</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>48 (16.5)</td>
<td>7 816 (20.1)</td>
<td></td>
</tr>
</tbody>
</table>

**The associations between PA and VFM or PBF were similar with and without PsA. In Model 1 (R²=0.17), moderate or high physical activity was significantly associated with lower VFM. The moderate activity group had 0.8 kg (0.7, 0.9kg, p<0.001) and the high activity group had 2.6 kg (2.5, 2.7, p<0.001) lower VFM compared to the low physical activity group. In Model 2 (R²=0.38), moderate or high physical activity was significantly associated with lower PBF. The moderate activity group had 1.4% (1.2, 1.5%, p<0.001) and the high activity group had 4.3% (4.1, 4.5%, p<0.001) lower PBF compared to the low physical activity group.**

**Conclusion:** Patients with PsA had increased PBF and VFM, and moderate or high physical activity was associated with significant reductions in both endpoints. Physical activity may reduce the comorbidity burden among persons with PsA and should be a focus in clinical treatment plans.
### Table 1

<table>
<thead>
<tr>
<th></th>
<th>PsA vs HC</th>
<th>PsO vs HC</th>
<th>PsA vs PsO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Discovery Phase</td>
<td>Validation Phase</td>
<td>Discovery Phase</td>
</tr>
<tr>
<td>miR-93-5p</td>
<td>0.0001</td>
<td>&lt;0.0001</td>
<td>0.008</td>
</tr>
<tr>
<td>miR-29b-3p</td>
<td>0.0001</td>
<td>&lt;0.0001</td>
<td>0.004</td>
</tr>
<tr>
<td>miR-19b-5p</td>
<td>0.007</td>
<td>0.708</td>
<td>0.0002</td>
</tr>
<tr>
<td>miR-30a-5p</td>
<td>0.001</td>
<td>0.619</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>miR-141-5p</td>
<td>0.003</td>
<td>0.006</td>
<td>0.0001</td>
</tr>
<tr>
<td>miR-186-5p</td>
<td>0.014</td>
<td>0.990</td>
<td>0.975</td>
</tr>
<tr>
<td>let-7b-5p</td>
<td>0.009</td>
<td>0.0003</td>
<td>0.889</td>
</tr>
<tr>
<td>miR-29a-3p</td>
<td>0.043</td>
<td>0.001</td>
<td>0.005</td>
</tr>
<tr>
<td>miR-324-3p</td>
<td>0.138</td>
<td>1.000</td>
<td>0.257</td>
</tr>
<tr>
<td>miR-126-3p</td>
<td>0.014</td>
<td>0.169</td>
<td>0.013</td>
</tr>
<tr>
<td>miR-223-3p</td>
<td>0.169</td>
<td>0.872</td>
<td>0.617</td>
</tr>
<tr>
<td>miR-130a-3p</td>
<td>0.039</td>
<td>0.035</td>
<td>0.556</td>
</tr>
<tr>
<td>miR-140-3p</td>
<td>0.350</td>
<td>0.053</td>
<td>0.002</td>
</tr>
<tr>
<td>miR-155-5p</td>
<td>0.159</td>
<td>0.995</td>
<td>0.169</td>
</tr>
<tr>
<td>miR-21-5p</td>
<td>0.297</td>
<td>0.990</td>
<td>0.000</td>
</tr>
<tr>
<td>miR-144a-5p</td>
<td>0.706</td>
<td>0.004</td>
<td>0.936</td>
</tr>
<tr>
<td>miR-122-5p</td>
<td>0.980</td>
<td>0.734</td>
<td>0.695</td>
</tr>
</tbody>
</table>

**Rheumatology, Rheuma-Zentrum Wien-Oberlaa, Vienna, Austria;** Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Deutsches Zentrum för Immuntherapie, Erlangen, Germany; TAmiRNA GmbH, Vienna, Austria; Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Austria.

**Background:** MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression. Specific miRNA signatures have been identified in numerous diseases and may serve as potential biomarkers or new drug targets. Whether certain miRNA signatures are associated with psoriatic joint disease is currently unknown.

**Objectives:** To search for circulating miRNA signatures in psoriasis patients with subclinical joint disease and in patients with psoriatic arthritis (PsA).

**Methods:** Analyses of serum miRNA were done in three groups: (1) PsA patients fulfilling CASPAR criteria (PsA), (2) healthy controls without past or present signs of musculoskeletal disease (HC) and (3) psoriasis patients with musculoskeletal pain but no signs of clinical PsA (PsO). PsO and PsA patients received a hand MRI, which was scored according to PsAMRIS method. miRNA analysis of serum samples was performed stepwise using RT-qPCR (TAmiRNA Vienna). In the discovery phase 192 miRNA assays were analyzed in 48 samples (N=16 each group). In the validation phase 17 miRNAs (Table 1) were selected and analyzed in 94 samples (N=35 PsA, N=24 PsO, N=35 HC) based on results of discovery phase and previous reports in literature. Results presented as means/SD/median (IQR), p-values are adjusted for multiple testing.

**Results:** 51 PsA patients (age: 51.3±14.4 years; 56.9% females), 40 PsO patients (51.4±11.0; 37.5%) and 50 HC (51.0±10.5; 52.9%) were assessed. Duration of psoriasis was 12(25) years in PsA and 15(22.8) years in PsO. Duration of joint disease in PsA was 1.0(4.8) year. 51% of PsA and 5% of PsO patients were on biological disease modifying drugs (bDMARDs), 49% vs. 10% on conventional DMARDs. The most frequent findings in the MRI were erosions (PsA 59.6%; PsO 40%) and synovitis (PsA 49%; PsO 10% vs. 10% on conventional DMARDs). New bone formation on radiographs was detected in 39% of PsA and 13% of PsO patients. Significantly higher frequencies of tenosynovitis and enthesitis were observed on US compared to clinical examination alone.

**Conclusion:** PsA and PsO patients show miRNA signatures different from HC. Top candidate miRNA differentially regulated in PsA and PsO have been previously reported in alteration of bone metabolism and osteoarthritis indicating the intimate association of psoriatic inflammation with bone and cartilage changes.

REFERENCES:


DISCLOSURE OF INTERESTS: None declared.


Diagnosis of Psoriatic Arthritis with or without integration of Ultrasound

Y. Geng1, Z. Song2, X. Zhang1, X. Deng1, Y. Wang1, Z. Zhang1, 1Peking University First Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China

**Background:** Although the CASPAR criteria in the diagnosis of psoriatic arthritis (PsA) have been validated, CASPAR based on physical examination (PE) is not “gold standard.” The ultrasound (US) could improve the diagnostic accuracy as compared to clinical examination alone.

**Objectives:** To evaluate the diagnostic performance of CASPAR criteria for psoriatic arthritis (PsA) with or without integration of ultrasound (US).

**Methods:** The patients with a hint of PsA were enrolled. Tender and swollen joint counts, presents of enthesis and dactylitis were collected by physical examination (PE). US was performed to evaluate peripheral joints, entheses and tendons. The additional value of US to CASPAR criteria were analysed.

**Results:** 326 consecutive patients were enrolled, with 164 PsA and 162 non-PsA. Significantly higher frequencies of tenosynovitis and enthesis on US and new bone formation on X-ray were found in PsA than non-PsA patients (56.7% vs. 13.0%; 62.2% vs. 14.2%; 62.2% vs. 8.0%; p<0.01 for all). Logistic regression analysis showed that dactylitis (OR=12.0, p<0.01), family history of PsO/ PsA (OR=3.1, p<0.05), nail involvement (OR=3.5, p=0.01), new bone formation (OR=14.8, p=0.01) and tenosynovitis on US (OR=213, p<0.01) enthesitis on US (OR=217, p<0.01) were independent risk factors for PsA. Adding US tenosynovitis and/or enthesis to CASPAR criteria showed better performance by improving the specificity (91.4% vs. 67.9%) and meanwhile keeping sensitivity (92.1% vs. 96.3%). When replacing hand X-ray by US in CASPAR criteria, the sensitivity and specificity were comparable to CASPAR criteria adding with US. The diagnostic accuracy was 82.2% for CASPAR criteria based on PE, 91.7% for CASPAR integrated with US, and 91.4% for CASPAR with US to replace X-ray.

**Conclusion:** CASPAR criteria based on US improve the diagnosis utility of PsA than CASPAR criteria based on PE. US assessment is valuable in the diagnosis of PsA.

REFERENCES:

Assessment of Synovitis on US-Guided Synovial Membrane Biopsies is Contingent on Disease Phase and Predictive of Treatment Response in Naïve to Treatment Psoriatic Arthritis

D. Bruno1,2, B. Tolusso1,2, M. Gessi3, C. DI Mario1,4, M. R. Gigante5, L. Petricca5, D. Bruno1,2, B. Tolusso1,2, M. Gessi3, C. DI Mario1,4, M. R. Gigante5, L. Petricca5

Background: Ultrasound (US)-guided minimally invasive Synovial Tissue (ST) biopsy serves as a safe and well-tolerated procedure for basic and translational research on chronic inflammatory joint disease.

Objectives: (i) to assess the diagnostic value of the Krenn score (KSS) on ST samples obtained from US-guided biopsies in a large bio-samples dataset of patients with Psoriatic Arthritis (PsA) across different disease phases; (ii) to develop a multiparametric nomogram integrating clinical and histological characteristics enabling treatment response prediction in naïve to treatment PsA.

Methods: 410 patients fulfilling the CASPAR criteria for PsA who underwent US-guided ST biopsy were enrolled. At baseline, patients were categorized based on their disease phase and treatment: n=207 naïve to DMARDs; n=101 resistant to c-DMARDs; n=48 resistant to b-DMARDs and n=54 in sustained clinical and ultrasound remission or in low disease activity (LDA) state (DAPSA ≤ 4 or among 4-14, respectively). Clinical, demographic, and immunological characteristics were recorded for each patient. All ST specimens were stained with H&E and classified by a pathologist, blinded to clinical characteristics, using the Krenn score to assess ST inflammation degree (1) implemented with the determination of lymphocytes, plasma cells, granulocytes and tissue oedema presence. Each naïve to treatment PsA was treated according to the EULAR recommendations (2) and DAPSA remission rate at 6 months was recorded.

Results: Considering the whole enrolled cohort, the distribution of KSS was significantly different among patients across the different PsA phases (ANOVA p<0.001). In particular, among the different phases, KSS was significantly higher in b-DMARDs resistant (p<0.0001) and c-DMARDs resistant (p<0.0001) compared to remission/LDA disease patients as well as naïve to treatment PsA (p<0.0001). Interestingly, regardless to the disease phase, KSS of the biopsied joint directly correlated to disease activity in terms of DAPSA (r=0.476, p<0.001) and DAS28 scores (r=0.476, p<0.001). Considering the naïve to treatment PsA cohort, patients achieving DAPSA defined-LDA/remission had, before treatment, significantly lower KSS (p<0.001), lower rate of ST plasmacells presence (p<0.001) and shorter symptoms duration (p=0.01) as compared to naïve to treatment PsA not achieving this clinical outcome. Moreover, considering distinct clinical phenotype domains, naïve to treatment PsA patients with concomitant dactylitis and skin disease were less likely to achieve DAPSA LDA/remission (p<0.001), regardless of treatment scheme. On logistic regression, at baseline, having a KSS >5 (OR: 5.30 (95%CI 2.21-12.74) p<0.001), absence of plasma cells ST infiltrate (OR: 3.87 (2.11-7.10 95%CI) p=0.001), concomitant dactylitis (OR: 2.55 (95%CI 1.24-5.25) p=0.01) and skin involvement (OR: 2.06(95%CI 1.17-3.62) p=0.01) were independent factors associated with DAPSA score-LDA/remission achievement at 6 months. Finally, a multiparametric nomogram integrating baseline clinical and histological characteristics of naïve PsA enabling to predict up to 75% of probability to achieve DAPSA remission at 6 months was developed.

Conclusion: KSS is a reliable tool for synovial assessment in PsA, being contingent on disease phases, related to disease burden and included within a treatment response predictive multiparametric nomogram in naïve PsA.

REFERENCES:

Disclosures: None declared


Mortality, Co-morbidity and disease burden

WORLD MORTALITY OF SPONDYLOARTHROPSIS AND INFLAMMATORY BOWEL DISEASES IN 2015 AND ITS EVOLUTION BETWEEN 2001 AND 2015

O. Fahk1, C. Pratt1,2, D. Wending1,3, F. Verhoeven1,2, Centre Hospitalier Régional Universitaire de Besançon, Rheumatology, Besançon, France; 1UFR Santé, Université de Franche-Comté, EA 4267 ‘PEPITE’; Besançon, France; 2UFR Santé, Université de Franche-Comté, EA 4266 ‘EPILAB’; Besançon, France

Background: There is little epidemiological data on mortality in spondyloarthrits (SpA).

Objectives: To determine countries’ mortality rates of ankylosing spondylitis (AS) and psoriatic arthritis (PsA), as well as chronic inflammatory bowel diseases (IBDs), which are physiologically related to SpA, and to describe their evolution between 2001 and 2015.

Methods: We used mortality data from the World Health Organisation (WHO), freely available on its website, which shows the number of deaths classified by age, sex, and cause of death coded by ICD-10. The code M45 was used for AS, L405 for PsA, K56 for Crohn’s disease (CD), and K51 for ulcerative colitis (UC). Age-standardized mortality rates (ASMR) were constructed using the 2015 WHO reference population and are expressed as deaths per million inhabitants. Temporal trend analyses of ASMR were performed between 2001 and 2015, considering only countries with up to 3 years of missing data, using joinpoint regression.

Results: In 2015, the global ASMR of AS was 0.13 (0.11-0.14), ranging from 0.02 in Japan to 2.00 in Iceland (Figure 1A). The ASMR was 0.20 (0.18-0.23) for men and 0.07 (0.06-0.09) for women (p<0.001). The trend analysis did not show any significant variation between 2001 and 2015. The ASMR in Europe (0.17 (0.15-0.20)) was significantly higher than in North America (0.12 (0.09-0.14)) (p=0.008), South America (0.09 (0.06-0.12)) (p=0.001) and Asia (0.08 (0.05-0.10)) (p=0.001).

Figure 1. 2015 ASMR by country for ankylosing spondylitis (A), psoriatic arthritis (B), Crohn’s disease (C) and ulcerative colitis (D).
For PsA, the global ASMR in 2015 was 0.04 (0.03-0.05), ranging from 0.01 in Mexico to 0.13 in Greece (Figure 1B). The ASMR was 0.06 (0.04-0.07) for men and 0.03 (0.02-0.04) for women (p=0.01). The trend analysis showed a significant increase from 2001 to 2015 with a mean annual percent change (APC) of 5.94% (p=0.02). The ASMR in Europe (0.05 (0.03-0.06)) was significantly higher than in South America (0.02 (0.00-0.03)) (p=0.02).

For CD, the global ASMR in 2015 was 0.86 (0.82-0.89), ranging from 0.02 in Thailand to 5.25 in Luxembourg (Figure 1C). The ASMR was 0.41 (0.38-0.43) for men and 0.38 (0.36-0.41) for women (p=0.17). The trend analysis showed a significant decrease from 2001 to 2015 with a mean APC of -0.82% (p=0.049). The ASMR in Europe (1.12 (1.05-1.19)) was significantly lower than in North America (1.31 (1.21-1.41)) (p=0.001), but significantly higher than in Latin America (0.57 (0.51-0.64)) (p<0.0001) and Asia (0.27 (0.23-0.32)) (p<0.0001).

For UC, the global ASMR in 2015 was 0.76 (0.73-0.79), ranging from 0.03 in Thailand to 5.48 in Saint Lucia (Figure 1D). The ASMR was 0.37 (0.35-0.39) for men and 0.23 (0.21-0.24) for women (p>0.0001). The trend analysis showed a significant decrease from 2001 to 2015 with a mean APC of -12.9% (p<0.001). The ASMR in Europe (0.64 (0.57-0.71)) (p<0.0001), Africa (0.57 (0.41-0.72)) (p<0.0001), South America (0.84 (0.76-0.91)) (p=0.003), Asia (0.47 (0.93-1.06)) and Oceania (0.58 (0.38-0.79)) (p=0.003).

Conclusion: ASMR for IBD are higher than those for SpA and are decreasing over time, in contrast to SpA where they remain essentially stable. There are geographical disparities which must be interpreted with caution due to the declarative nature of the data.

Disclosure of Interests: None declared


POS0319

DISEASE BURDEN OF PRIMARY SJÖGRENS SYNDROME: A RETROSPECTIVE UNITED STATES CLAIMS DATABASE STUDY

L. Kalouche-Khalli1, R. Gandhi2, L. Hao3, E. Smolikina4, F. Schumacher5, 6

Sanofi Genzyme, MS Global Medical Affairs, Paris, France; 2Sanofi Genzyme, MS Medical Affairs, Cambridge, United States of America; 3Sanofi GenMed, RWE, Bridgewater, United States of America; 4Sanofi, Global HEVA Neuro Immunology, Amsterdam, Netherlands; 5Sanofi Translational Medicine and Clinical Pharmacy, Frankfurt, Germany

Background: Primary Sjögren’s syndrome (pSS) is a chronic and complex systemic autoimmune disease, primarily characterised by inflammation and progressive destruction of the exocrine glands (ie, autoimmune epithelitis) [1].

Objectives: We evaluated disease progression, treatment patterns, mortality, and healthcare resource utilization (HCRU) of pSS patients in the United States (US) to understand the real-world experiences of patients with pSS.

Methods: This retrospective cohort study utilised data from US Optum Clinfor matics claims database claims between 01 May 2000 and 31 December 2020. The study included pSS patient cohort and general population cohort, matched (1:1) on age, sex, and index date. Baseline period of 365 days prior to the index date was used for assessment of baseline comorbidities. Descriptive statistics were used to describe baseline characteristics, HCRU, and treatment pattern while multivariable models were used to assess hazard ratios (HRs) and risk factors.

Results: Overall, 23,168 patients with pSS (ICD-9 710.2 Sicca syndrome and ICD-10 M35.0 Sjögren Syndrome and excluding patients with Rheumatoid arthritis [RA], Systemic sclerosis [SS] and Systemic lupus erythematosus [SLE] diagnoses codes) were included in the cohort (mean SD age: 61.5 [15.3] years; females: 85%). At baseline, 79.4% and 8.2% of pSS patients had systemic complications and organ-specific autoimmune comorbidities, respectively. In a subset of the cohort including patients with at least 5 years of follow-up, by the end of 5 years 96.6% and 16.5% of patients developed systemic complications and organ-specific autoimmune comorbidities, respectively (Table 1). The most frequently occurring organ-specific autoimmune comorbidities over the 5-year follow-up included Graves disease (5.4%), Hashimoto disease (3.7%), and discoid/subacute cutaneous lupus erythematosus (3.5%). Mortality was reported in 7.4% of the patients during 5-year follow-up. Risk factors associated with higher mortality included systemic complications in renal (HR [95% CI]: 2.29 [2.08–2.52]), cardiovascualr (HR [95% CI]: 2.42 [2.19–2.67]), lungs (HR [95% CI]: 3.41 [3.41–4.09]) and haematological domains (HR [95% CI]: 2.83 [2.56–3.13]), non-Hodgkin’s lymphoma (HR [95% CI]: 2.58 [2.12–3.14]), and primary biliary cirrhosis (HR [95% CI]: 2.17 [1.60–2.96]). Corticosteroids (28.2%), hydroxychloroquine (15.7%), and cyclosporine (10.9%) were most frequently used medications. During the year following the first pSS diagnosis, defined as the first claim with the Sjögren Syndrome ICD code (index date), the mean all-cause healthcare costs have increased by 27% from $21,634 to $27,526 per patient per year.

Table 1. Occurrence of systemic complications and organ-specific autoimmune comorbidities over follow-up of 5 years

<table>
<thead>
<tr>
<th>Variable, n (%)</th>
<th>Baseline (N=6000)</th>
<th>Within 5 years (N=6000)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any systemic complication</strong></td>
<td>4,555 (75.9%)</td>
<td>5,806 (96.8%)</td>
</tr>
<tr>
<td>Articular involvement</td>
<td>3,176 (52.9%)</td>
<td>5,026 (83.8%)</td>
</tr>
<tr>
<td>Renal involvement</td>
<td>352 (5.9%)</td>
<td>1,165 (19.8%)</td>
</tr>
<tr>
<td>Cardiovascular complications</td>
<td>342 (5.7%)</td>
<td>826 (13.8%)</td>
</tr>
<tr>
<td>Muscles</td>
<td>1,390 (23.2%)</td>
<td>2,732 (45.5%)</td>
</tr>
<tr>
<td>Retinopathy</td>
<td>31 (0.5%)</td>
<td>123 (2.1%)</td>
</tr>
<tr>
<td>Lungs</td>
<td>373 (6.2%)</td>
<td>1,383 (23.1%)</td>
</tr>
<tr>
<td>Peripheral nervous system</td>
<td>766 (12.8%)</td>
<td>2,109 (35.2%)</td>
</tr>
<tr>
<td>Haematological</td>
<td>1,016 (16.9%)</td>
<td>2,507 (41.8%)</td>
</tr>
<tr>
<td>Glucuronic</td>
<td>542 (9.0%)</td>
<td>2,274 (37.9%)</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>212 (3.5%)</td>
<td>556 (9.3%)</td>
</tr>
<tr>
<td>Biological</td>
<td>153 (2.6%)</td>
<td>408 (6.8%)</td>
</tr>
<tr>
<td>Skin</td>
<td>517 (8.6%)</td>
<td>1,397 (23.1%)</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>374 (6.2%)</td>
<td>959 (16.0%)</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma</td>
<td>59 (1.0%)</td>
<td>131 (2.2%)</td>
</tr>
<tr>
<td>Any organ-specific autoimmune disease</td>
<td>464 (77%)</td>
<td>992 (16.5%)</td>
</tr>
</tbody>
</table>
Conclusions:  These results provide additional evidence that pSjS is associated with substantial morbidity and clinical burden supporting the need for safe and efficacious disease modifying treatment options in this patient population.

REFERENCES:

Acknowledgements:  Medical writing and editorial assistance were provided by Sanjeev Kallapari and Chiranjit Ghosh, PhD of Sanofi. This study was funded by Sanofi.


**EPIDEMIOLOGY AND HEALTHCARE RESOURCE UTILIZATION OF PATIENTS WITH EGPA IN THE UNITED KINGDOM**

J. Hwee, 1 O. Fu2, 1 H. Harper3, 1 K. Niranrathakumar2, 3 R. Goel3, 1 R. Jakes4, 1 GSK, Value Evidence Outcomes, Mississauga, Canada; 2 GSK, Value Evidence Outcomes, Collegeville, United States of America; 3 University of Birmingham, Institute of Applied Health Research, Birmingham, United Kingdom; 4 GSK, Epidemiology, London, United Kingdom

Background:  Eosinophilic granulomatosis with polyangiitis (EGPA) is characterized by eosinophilic inflammation of small with or without medium arteries. EGPA is a rare disease with varying prevalence and incidence rates globally. To date, limited information is available on the prevalence, incidence and burden of disease in the United Kingdom (UK).

Objectives:  The objectives were to estimate the prevalence and incidence of EGPA, and to describe the healthcare resource utilization (HCRU) among patients with EGPA in the UK.

Methods:  This retrospective database study used the UK-based Clinical Practice Research Datalink (CPRD)-AURUM database linked to the Hospital Episode Statistics (HES). Prevalence was estimated from 2005 to 2019, and incidence was estimated from 2006 to 2019. HCRU was assessed in the 12-months following the first recorded diagnosis of EGPA (index date), and included hospitalizations, emergency room visits, procedures, outpatient specialist visits, primary care visits, and oral corticosteroid use.

Results:  764 people were identified with EGPA in the UK. The prevalence of EGPA, reported in the database, increased from 22.7 to 45.6 per 1,000,000 persons from 2005 to 2019 (Figure 1), whereas the incidence of EGPA from 2006 to 2019 ranged from 2.28 to 4.00 per 1,000,000 person-years. 377 patients with EGPA were successfully linked to the CPRD-HES database. Patient characteristics were as follows: mean age (SD) was 57 years (14.2); 49% were male; 81% had asthma; and 11% had peripheral neuropathy prior to the index date. For patients with EGPA, 19% had an EGPA-related hospitalization and 50% had any-cause hospitalization within 1 year of the index date (Table 1). The mean length of stay was, 18 days and 16 days for EGPA-related and any-cause hospitalizations, respectively. 52% of patients with EGPA had undergone a medical procedure, 89% of patients with EGPA had an outpatient visit to a specialist. Almost all patients with EGPA visited a general practitioner within 1 year of their EGPA diagnosis (97%) and averaged 16.0 visits in 1 year. A significant proportion of the EGPA population were prescribed OCS; most EGPA patients had a prescription in the 0–3 months after the index date (64%), and patients on average had a prescription for OCS for 6 out of the 12 months after the index date.

Table 1.  HCRU among patients with EGPA

<table>
<thead>
<tr>
<th>HCRU</th>
<th>Number of patients N (%)</th>
<th>Number of events per patient, Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total EGPA cohort (N)</td>
<td>377</td>
<td></td>
</tr>
<tr>
<td>EGPA-specific hospitalizations</td>
<td>72 (19.10)</td>
<td>1.2 (1)</td>
</tr>
<tr>
<td>EGPA-specific hospitalizations</td>
<td>[1283]</td>
<td>178 (23.3)</td>
</tr>
<tr>
<td>length of stay</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any-cause hospitalizations</td>
<td>188 (49.87)</td>
<td>1.7 (1)</td>
</tr>
<tr>
<td>Any-cause hospitalizations/length of stay</td>
<td>[2993]</td>
<td>15.9 (23.7)</td>
</tr>
<tr>
<td>Any-cause A &amp; E visits</td>
<td>19 (5.04)</td>
<td>1.8 (2)</td>
</tr>
<tr>
<td>Any-cause outpatient visits</td>
<td>334 (88.59)</td>
<td>9.8 (7)</td>
</tr>
<tr>
<td>Any procedures undertaken</td>
<td>196 (51.59)</td>
<td>6.8 (6)</td>
</tr>
<tr>
<td>General Practitioner visits</td>
<td>366 (97.08)</td>
<td>16.0 (11)</td>
</tr>
</tbody>
</table>

A&E: Accident and Emergency; EGPA, eosinophilic granulomatosis with polyangiitis; HCRU, healthcare resource utilization.

Conclusion:  The prevalence of EGPA increased over the study period in the UK, and the data show significant HCRU within 1 year of the first recorded diagnosis of EGPA. Almost all of the patients with EGPA were found to frequently visit the primary care physician and seek specialist care, and almost half required hospitalization. Funding:  GSK [207888]

Acknowledgements:  Funding:  GSK [207888]

Disclosure of Interests:  Jeremiah Hwee Shareholder of:  GSK, Employee of:  GSK. Cingong Fu Shareholder of:  GSK, Employee of:  GSK, Lorraine Harper Speakers bureau:  Viopharm (2021), Roche (2017), Consultant of:  GSK (2021), Viopharm (2021), Grant/research support from:  Viopharm (researcher initiated project), MSD (researcher initiated project), Krishnaraj Niranrathakumar Consultant of:  Boehringer Ingelheim (Consultancy on real world evidence), Grant/ research support from:  AstraZeneca, Vifor and Boehringer Ingelheim (Investigator led grants), Ruchika Goel:  None declared, Rupert Jakes Shareholder of:  GSK, Employee of:  GSK.


**CO-MORBIDITY IN POLYMYALGIA RHEUMATICA**

M. Yates1, 2, A. Ittkihar Talib1, C. Aldus2, J. Brown3, 4, A. Macgregor1, 2, 1University of East Anglia, Centre for Epidemiology, Norwich, United Kingdom; 2Nortis and Norwich University Hospital, Rheumatology, Norwich, United Kingdom; 3Prescribing Services Limited, Eclipse, Buxton, United Kingdom; 4Litcham Medical Practice, General Practice, Litcham, United Kingdom

Background:  Polymyalgia rheumatica (PMR) is the most common autoimmune musculoskeletal condition in the developed world, with UK prevalence of 1.7% in those aged older than 55 years. Current guidelines recommend glucocorticoid treatment for one to two years. Since PMR affects older individuals and is associated with prolonged treatment with glucocorticoids, patients are at risk of developing or worsening co-morbidity.

Objectives:  This national study aimed to establish the prevalence of PMR from routinely recorded administrative care records from community-based primary care practices; secondly to calculate the most common comorbidities and their relative risk amongst those diagnosed with PMR.

Methods:  The ECLIPSE database covers over 230 patients across 2400 general practices in England and provides insights for enhanced clinical pathway management and to support patient safety in primary care. Routinely recorded diagnoses from primary care data are updated daily, along with administrative prescribing data. Using standardised nationally agreed disease coding frameworks, all diagnoses of PMR were retrieved from the live patient population of 23.3m individuals registered with general practices across England. Comorbidity was recorded similarly. Diagnoses of PMR were categorised in 12-month bands since their date of diagnosis to examine the rates of prednisolone prescription by time since diagnosis.

Results:  Amongst the 23.3 million patient care records there were 146,252 diagnoses of PMR, resulting in a prevalence of 2.2% for those aged older than 55 years. The average age of those with PMR was 77.5 years. There were between 9863 to 11036 diagnoses of PMR made each year over the past five years. The proportion of those receiving prednisolone were highest amongst those most recently diagnosed: 76.4% for those in the last year; 48.4% for those diagnosed between a year and two years ago; 33.0% for those diagnosed between two to three years ago; 28.8% for those diagnosed between three to four years ago, and 24.9% for those diagnosed between four to five years ago. On average each patient with PMR had 3.5 co-morbid conditions and was prescribed 5.4 different medications. The top ten co-morbid conditions were, in rank order: hypertension (53.6%), osteoarthritis (48.6%), anxiety and depression (275%), chronic kidney...
CARDIOVASCULAR RISK FACTORS AND RISK OF GIANT CELL ARTERITIS AND/OR POLYMyalGIA RHEUMATICA: RESULTS FROM THE FRENCH E3N COHORT STUDY

F. Barrière, C. Macdonald, S. Asclier, F. Artau, X. Mariette, M. C. Boutron-Ruault, Y. Nguyen, R. Serot, Université Paris-Saclay; UVSQ, Inserm, Institut Gustave Roussy; Exposome and Heredity Team, CESP, Villejuif, France; Centre Hospitalier Régional d’Orléans, Rheumatology, Orléans, France; Hôpital Lariboisière AP-HP, Rheumatology, Paris, France; Université Paris-Saclay; AP-HP, Hôpital Bicêtre, Rheumatology, Le Kremlin Bicêtre, France; Université Paris-Saclay, France, AP-HP, Hôpital Bicêtre, National Reference Center for Rare Systemic Autoimmune Diseases, INSERM UMR1184, Le Kremlin Bicêtre, France; AP-HP Nord, Hôpital Beaujon, Université de Paris, Internal Medicine, Clichy, France.

Background: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two associated inflammatory diseases with incompletely known common pathophysiological mechanism. Cardiovascular (CV) risk factors have been thought to play a role in the underlying chronic vascular inflammation involved in GCA and PMR pathophysiology. However, available data on CV risk factors are conflicting.

Objectives: To investigate the association between CV risk factors and the risk of GCA and/or PMR in a large prospective cohort of French women.

Methods: The E3N cohort study (Étude Épidémiologique auprès des femmes de la Mutuelle générale de l’Education Nationale) is a French prospective cohort including 98,995 French women born between 1925 and 1950, recruited in 1990. They completed biennial mailed questionnaires to update their health-related information. A validation study based on the use of a specific GCA/PMR questionnaire and medication reimbursement database was conducted prior to this study. The history of CV risk factors (hypertension, type 2 diabetes, dyslipidemia, and active smoking status and family history of cardiovascular disease) was self-reported at each questionnaire. Hazard ratios (HRs) and their 95% confidence intervals (95%CIs) for incident GCA and/or PMR were estimated by Cox proportional hazards regression models with age as the time scale. Multi-adjusted intervals (95% CIs) for incident GCA and/or PMR were estimated by Cox proportional hazards regression models with age as the time scale.

Results: The overall population included 79,804 women, during a total follow-up of 1,899,742 person-years. Among them, 399 incident GCA and/or PMR cases were identified (incidence 31/100,000 person-years): 282 GPMR alone, 112 GCA cases, and 5 patients who could not be classified. Incident GCA/PMR cases were diagnosed after a mean of 17.9 (± 5.2) years after recruitment. Mean age at diagnosis was 69 (± 7.2) years. Type 2 diabetes was inversely associated with the risk of incident GCA/PMR in age-adjusted and multivariable models (HR 0.41; 95%CI 0.2–0.9) in multivariate model. Other CV risk factors such as hypertension, smoking status, dyslipidemia, familial history of cardiovascular events were not associated with incident GCA/PMR (Table 1). The inverse association remained statistically significant when studying separately the risk of incident PMR (HR 0.3; 95%CI 0.09–0.91) but no longer with incident GCA (HR 0.5; 95%CI 0.1–2.0), probably due to a reduced statistical power.

Conclusion: Type 2 diabetes was associated with a decreased risk of subsequent GCA/PMR development. Further research should be carried out to determine potential mechanisms, and especially to analyze the respective role of diabetes itself and its treatments.

Acknowledgements: The authors are indebted to all participants for their continued participation. The authors would like to thank Pascale Gerbouin-Rerolle, Mariam Alyanakiyan, Sofiane Harizi and Roselyn Rima Gomes for their help on data management. The present work was performed using data from the Inserrm E3N cohort and support from the MGEN, Gustave Roussy, and the Ligue contre le Cancer for setting up and maintaining the cohort. The cohort was supported by a state grant ANR-10-COHO-0006 from the Agence Nationale de la Recherche within the Invesettsement dAvenir program. The present work was conducted thanks to a research grant from the Agence Régionale de Santé – Île de France. lementsed to declare.

Disclosure of Interests: None declared


Table 1. Hazard ratios for the risk incident GCA and/or PMR according to cardiovascular risk factors

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Non-Cases</th>
<th>GCA/PMR Cases</th>
<th>HR [95%CI]</th>
<th>M1</th>
<th>M2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=79,405</td>
<td>N=399</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never-smoker</td>
<td>42,274(53.2)</td>
<td>233 (58.4)</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Past smoker</td>
<td>30,824(38.8)</td>
<td>134 (33.6)</td>
<td>0.91 [0.74;1.13]</td>
<td>0.90 [0.73;1.12]</td>
<td>1.04 [0.72;1.51]</td>
</tr>
<tr>
<td>Current smoker</td>
<td>6,307(79)</td>
<td>32 (8.0)</td>
<td>1.00 [0.72;1.52]</td>
<td>0.85 [0.69;1.04]</td>
<td></td>
</tr>
<tr>
<td>High blood pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No hypertension</td>
<td>38,813 (48.9)</td>
<td>210 (52.6)</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>40,992 (51.1)</td>
<td>189 (47.4)</td>
<td>0.84 [0.69;1.03]</td>
<td>0.85 [0.69;1.04]</td>
<td></td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No diabetes</td>
<td>75,704(95.3)</td>
<td>386 (96.7)</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>3,707 (4.7)</td>
<td>13 (3.3)</td>
<td>0.41 [0.18;0.91]</td>
<td>0.41 [0.18;0.92]</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25 kg/m2</td>
<td>52,054(65.6)</td>
<td>269 (67.4)</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>≥ 25 kg/m2</td>
<td>27,351(34.4)</td>
<td>130 (32.6)</td>
<td>1.01 [0.82;1.25]</td>
<td>1.06 [0.85;1.31]</td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>43,944 (55.3)</td>
<td>237 (59.4)</td>
<td>Reference</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>33,169 (41.8)</td>
<td>147 (36.8)</td>
<td>1.17 [0.94;1.44]</td>
<td>1.18 [0.95;1.45]</td>
<td></td>
</tr>
<tr>
<td>Familial history of cardiovascular disease</td>
<td>No 64,878 (81.7)</td>
<td>336 (84.2)</td>
<td>Reference NA</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes 3,121 (3.9)</td>
<td>20 (5.0)</td>
<td>1.30 [0.85;2.09]</td>
<td>NA</td>
<td></td>
</tr>
</tbody>
</table>

M1: Adjusted for age and educational level educational level (< high school, up to 2 years of university, > 3 years of university). M2: M1+ smoking status, body mass index(kg/m2), hypertension, diabetes, dyslipidemia
CRP and ESR levels and drugs used were analyzed to identify the risk of having MACE in IA patients.

Results: A total of 17,732 (12,505 RA patients, 1,789 PsA patients and 3,893 AS patients) patients with IA were recruited. After a mean follow-up of 8.7 ± 3.1 years, 1,069 (6.0%) patients developed a first MACE. At baseline, the MACE group was older (68.12 vs 53.15, p < 0.001), had more traditional cardiovascular risk factors, higher levels of CRP (2.7 ± 1.5 vs 1.7 ± 1.3, p < 0.001) and ESR (57.8 ± 32.4 vs 42.5 ± 29.2, p < 0.001), and less exposure to biologic DMARDs (bDMARDs) (10% vs 3%, p < 0.001) and non-selective NSAIDs (nsNSAIDs) (63.4% vs 71.1%, p < 0.001). After adjusting for age, sex, baseline cardiovascular comorbidities using multivariable Cox regression analysis, IA patients with higher inflammatory burden (as reflected by the time-varying CRP [hazard ratio (HR) 1.11, 95% confidence interval (CI) 1.10–1.12, p < 0.001]) and ESR levels (HR 1.02, 95% CI 1.01–1.01, p < 0.001) and the use of steroid (HR 1.79–1.88) were independently associated with a higher risk of developing MACE (Table 1). In contrast, exposure to nsNSAIDs had a protective effect against MACE (HR 0.76, 95% CI 0.66–0.89, p < 0.001), while bDMARDs were not associated with MACE.

Table 1. Multivariable time-varying Cox regression models for the predictors of incidence of MACE in the IA patients (n=17732)

<table>
<thead>
<tr>
<th>Model 1†</th>
<th>Model 2‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variables</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>Male</td>
<td>1.92 (1.65–2.23)</td>
</tr>
<tr>
<td>Age</td>
<td>1.06 (1.05–1.06)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>1.04 (0.97–1.08)</td>
</tr>
<tr>
<td>Baseline DM</td>
<td>1.25 (0.95–1.64)</td>
</tr>
<tr>
<td>Baseline HT</td>
<td>1.77 (1.52–2.08)</td>
</tr>
<tr>
<td>Baseline LP</td>
<td>1.14 (0.92–1.41)</td>
</tr>
<tr>
<td>Time-varying inflammatory markers</td>
<td></td>
</tr>
<tr>
<td>ESR</td>
<td>1.02 (1.01–1.01)</td>
</tr>
<tr>
<td>CRP</td>
<td>0.93 (0.68–1.27)</td>
</tr>
<tr>
<td>CoxIL</td>
<td>0.71 (0.53–0.96)</td>
</tr>
<tr>
<td>nsNSAIDs</td>
<td>0.76 (0.66–0.89)</td>
</tr>
<tr>
<td>Steroids</td>
<td>1.18 (1.63–2.17)</td>
</tr>
</tbody>
</table>

Explanation: Increased inflammatory burden as reflected by elevated ESR and CRP level over time, and increased exposure to steroid were independently associated with increased risk of MACE, while the risk was significantly reduced with non-selective NSAIDs in IA patients.

Disclosure of Interests: None declared, Juha Sinisalo: None declared, Abbvie, Amgen and Pfizer, Kari Eklund: None declared, Javier Gracia Tabuenca: Bureau: Lecture free from Pfizer and Sanofi, Consultant of: Consulting fee from Roche, Consultant of: Consulting fee from Abbvie, Eli Lilly and Pfizer, Consultant of: Consultant for Abbvie, Eli Lilly, Pfizer, Roche and Vifor/Pharma., Grant/research support from: A research grant from Pfizer, Mika Helminen: None declared, The Kerola: None declared, Arnt Palomäki Speakers bureau: Lecture free from Pfizer and Sanofi, Consultant of: Consultant fee from Abbvie, Amgen and Pfizer, Kari Eklund: None declared, Javier Gracia Tabuenca: None declared, Juha Sinisalo: None declared.


Disclosure of Interests: None declared, Pla Isomäki Speakers bureau: Speaker or chair for AbbVie, Eli Lilly and Pfizer, Consultant of: Consultant for Abbvie, Eli Lilly, Pfizer, Roche and Vifor/Pharma., Grant/research support from: A research grant from Pfizer, Nina Mars: None declared, Mika Helminen: None declared, H. K. Aaramaa1, P. Isomäki1, N. Mars2, M. Helminen3,4, A. Kerola5, A. Palomäki6,7, K. Eklund,9 H. Graecu Tabuenca1,9, J. Sinisalo10 on behalf of FinGen. 1 Tampere University Hospital, Rheumatology Centre, Tampere, Finland; 2 Helsinki Institute of Life Sciences (HILIFE), Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland; 3 Tampere University Hospital, Iljas Research Services, Tampere, Finland; 4 University of Tampere, Faculty of Social Sciences, Health Sciences, Tampere, Finland; 5 Helsinki University Central Hospital, Inflammation Center, Rheumatology Division, Helsinki, Finland; 6 Turku University Hospital, Centre for Rheumatology and Clinical Immunology, Turku, Finland; 7 University of Turku, Faculty of Medicine, Turku, Finland; 8 University of Tampere, Faculty of Medicine and Health Technology, Tampere, Finland; 9 Helsinki University Central Hospital, Heart and Lung Center, Cardiology division, Helsinki, Finland

Background: Cardiovascular diseases (CVDs) are among the most common comorbidities in rheumatic diseases, causing also increased risk of MACE [1]. However, there is limited data on how the risk of CV comorbidities varies between different rheumatic diseases. Objectives: The aim of our study was to estimate the risk of certain CV comorbidities across rheumatic diseases. Methods: The ongoing FinGen project links nationwide healthcare register data with genome data. The study (data freeze 7) included 321,302 individuals and, from this group, we identified patients with seropositive (N=4293) and seronegative (N=1733) rheumatoid arthritis (RA), ankylosing spondylitis (AS, N=1247), psoriatic arthritis (PsA, N=1235), systemic lupus erythematosus (SLE, N=386), primary Sjögren’s syndrome (pSS, N=557) and gout (N=2178). Each patient was matched based on age, sex and municipality of residence with twenty individuals without any rheumatic conditions. The CV comorbidities studied were any CV disease (CVD), major coronary heart disease event (myocardial infarction and/or revascularization; CHD), ischemic stroke, atrial fibrillation and flutter (AF), deep vein thrombosis of lower extremities (DVT) and pulmonary embolism (PE), chronic heart failure (CHF) and valvular heart disease excluding rheumatic fever (VHD). From the prevalence of each CV disease among rheumatic disease cohorts, we calculated the risk ratio (RR) for each CV disease by comparing the prevalence of these diseases between rheumatic diseases and controls.

Results: The average age at the time of diagnosis ranged from 39.6 to 64.4 years, and the average duration of follow-up varied from 9 to 19.5 years in different rheumatic diseases. The risk for any CVD was elevated in all rheumatic disease cohorts with RR varying from 1.14 in seropositive RA to 1.65 in SLE. SLE patients carried the highest relative risk for CV comorbidities, demonstrating over 2.5-fold risk for DVT/PE (RR 3.57), stroke (RR 2.57), CHF (RR 2.64) and VHD (RR 2.98). At least two-fold risk compared to controls was identified for AF (RR 2.03), DVT/PE (RR 2.44) and CHF (RR 3.03) in patients with gout, for DVT/PE (RR 2.15) and CHF (RR 2.0) in patients with pSS, and for DVT/PE (RR 2.03) in patients with PsA. Seropositive and seronegative RA demonstrated similar CV risk profiles. In patients with seropositive or seronegative RA, PsA, pSS or SLE, DVT/PE demonstrated the highest RR's among various CV comorbidities.

Conclusion: The risk of CV comorbidities is increased in all studied rheumatic diseases, with the largest effects observed in patients with SLE and gout. Among CV comorbidities, DVT/PE displayed the largest effect sizes in several rheumatic diseases. The current results further strengthen the importance of evaluating and treating risk factors for CV comorbidities across rheumatic diseases, focusing also to the excess risk for thromboses.

Disclosure of Interests: None declared.
in waves 2–8 and knee pain in the same or previous wave of diagnosis were defined as having kOA (baseline). Participants with at least one body mass index (BMI) measurement and one follow-up assessment were included. Underweight/normal weight, overweight and obesity were defined using BMI <25 kg/m², 25–30 kg/m² and ≥30 kg/m², respectively. Education, occupation (current or last occupation if retired), wealth quintiles (all individual-based) and index of multiple deprivation quintiles (area-based) were used as SEP indicators. Outcome was the first self-reported kJRS (left or right knee) in waves 3–9. Cox proportional hazards models were used to investigate the associations of obesity and SEP with kJRS, controlling for baseline covariates. Person year follow up was calculated from baseline to either a) date of self-reported kJRS, b) loss to follow-up, c) end of follow-up (wave 9).

Results: The analysis sample included 1499 people who reported kOA and had ≥1 BMI measure (62.3% female; mean age 66.5y (SD 9.4); 96% white; 47% obese). Number of person-years included in the analysis was 8427. Over a mean follow-up of 4.7 years (SD 2.8), 144 (9.8%) reported having kJRS. Obese kOA patients were more likely to report kJRS than non-obese patients (adjHR 1.89 (95% CI 1.33, 2.68)), independent of age, gender, SEP, cardiovascular disease (self-reported) and HbA1c values (measured from collected blood samples). Education and occupation were not associated with kJRS. However, those living in the most deprived areas and with the least amount of wealth were less likely to undergo kJRS compared with the least deprived and wealthiest (HRs adjusted for age and gender 0.37 (95% CI 0.19, 0.73) and 0.55 (95% CI 0.33, 0.93), respectively). There was no evidence of interactions between obesity and SEP indicators.

Conclusion: Obesity increased the likelihood of undergoing kJRS in kOA patients. Therefore, reducing obesity in kOA patients may help to reduce the need for kJRS. Area-deprivation and lower wealth were associated with lower likelihood of kJRS. Taken together with findings from other studies which report associations between lower SEP and worse OA symptoms, our results suggest that there may be social inequalities in the provision of kJRS in England.

Table 1. The relationships between obesity at baseline and rates of knee joint replacement surgery over a mean of 4.7 (SD 2.8) years in follow-up in those with knee OA at baseline in the English Longitudinal Study of Ageing

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Adjusted for age and gender</th>
<th>Adjusted for age, gender, SEP, CVD and HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>ref (1.12, 2.17)</td>
<td>(1.77, 1.89)</td>
</tr>
<tr>
<td>Non-obesity</td>
<td>ref (1.17, 2.28)</td>
<td>(1.26, 2.50)</td>
</tr>
<tr>
<td>Obesity</td>
<td>ref (1.33, 2.68)</td>
<td>(1.33, 2.68)</td>
</tr>
<tr>
<td>Obesity</td>
<td>ref (1.77, 2.70)</td>
<td>(1.43, 2.91)</td>
</tr>
<tr>
<td>Overweight</td>
<td>ref (1.80, 2.71)</td>
<td>(1.38, 2.73)</td>
</tr>
<tr>
<td>Underweight/normal</td>
<td>ref (2.01, 2.11)</td>
<td>(1.44, 2.49)</td>
</tr>
<tr>
<td>weight</td>
<td>ref (2.13, 2.29)</td>
<td>(1.46, 2.69)</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval; SEP, socioeconomic position; CVD, cardiovascular disease; ref, reference category; BMI, body mass index.

Disclosure of Interests: None declared


New data on pathophysiology of spondyloarthritis including psoriatic arthritis

POS0326

THE TRANSCRIPTOMIC LANDSCAPE OF ACTIVE PSORIATIC ARTHRITIS: ACTIVATED INNATE IMMUNITY, EXTRACELLULAR MATRIX (ECM) TURNOVER, ABERRANT METABOLISM AND HEMOPOIETIC CELL - SKIN CROSSTALK.

A. Grivas1,2, M. Grigoriou1, G. Sentis2, A. Filia3, P. Katsimp1, V. Verginis3, B. Bournas2, National and Kapodistrian University of Athens, 4th Department of Internal Medicine, Athens, Greece; 1Biomedical Research Foundation of the Academy of Athens (BRFAA), Laboratory of Autoimmunity and Inflammation, Athens, Greece; 2Medical School, University of Crete, Heraklion, Greece

Laboratory of Immune Regulation and Tolerance, Division of Basic Sciences, Heraklion, Greece

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease whereby activated T lymphocytes and myeloid cells interact with tissue-resident cells in the skin and joints. Gene expression studies, mainly based on the microarray platforms, have provided an initial glimpse into disease pathogenesis highlighting, among others, the role of the TNFα and IL17 cytokine axis. Yet, the transcriptomic landscape of PsA remains largely unexplored, and the specific contribution of skin fibroblasts to disease pathogenesis remains elusive.

Objectives: To comprehensively characterize the gene expression profile in PsA, specifically in the blood and skin fibroblasts through next-generation RNA sequencing.

Methods: Peripheral blood (PB) was collected from PsA patients (n=30) after informed consent. Healthy individuals (HC) and patients with rheumatoid arthritis (RA) were used as healthy and disease controls (n=10/group) respectively. Psoriatic skin biopsies were obtained from a subset of three PsA patients and three HC. All PsA patients fulfilled the CASPAR criteria and displayed peripheral polyarthritis of moderate-to-high disease activity. Patient’s clinical and laboratory data were recorded at the time of sampling. Disease activity in PsA and RA was assessed using the Disease Activity Index for Psoriatic arthritis (DAPSA) and the Disease Activity Score-28 (DAS28), respectively. RNA from PB and skin fibroblasts was extracted. RNA libraries were prepared and sequenced. EdgeR package was used to call differentially expressed genes (DEGs). Statistical significance was set at p-value<0.05 and fold-change |FC| >1.5. Functional enrichment analysis and weighted gene co-expression network analysis (WGCNA) was implemented. Inference and analysis of blood immune cells-skin fibroblasts communication were performed with CellChat.

Results: 8 males and 22 female patients with PsA were included with median age 49 years old and median disease duration 4 years. The median DAPSA score was 44.3 and the median DAS28 score was 5.5 for RA patients, suggesting high disease activity in both groups. We found 46 DEGs in PsA versus HC blood (303 up- and 163 down-regulated). DEGs were significantly enriched in biological pathways related to immunity (i.e. inflammatory response, TNFα signaling via NFkB, IFNa & IFNγ response, complement, IL2 signaling), metabolism (i.e. oxidative phosphorylation, adipogenesis, fatty acid metabolism) and other signaling cascades of pathophysiologic relevance (i.e. WNTb catenin signaling, TGFβ signaling, MTORC1 signaling). WGCNA in blood revealed four gene modules containing highly correlated genes. These modules were enriched in myeloid leukocyte mediated immunity, neutrophil-mediated immunity, ECM and collagen metabolism, TGFβ and Pdgf signaling. Next, we characterized the ‘PsA specific activity signature’, taking the intersection of DEGs in PsA vs. HC and PsA vs. RA, which resulted in 67 DEGs enriched in response to TGF and Pdgf, ECM organization and degradation. CellChat analysis identified a higher number of interactions between blood immune cells and skin fibroblasts and increased strength of interactions in PsA compared to healthy state. Aberrant interactions between blood and skin fibroblasts in PsA included, among others, ligand-receptor pairs of the WNT, Notch, and GDF11 signaling pathways.

Conclusion: Our findings confirm the presence of an IFNγ signature and complement activation in PsA. The increased cardiometabolic burden and enhanced bone remodeling are reflected by the presence of pathways related to aberrant metabolism and ECM metabolism, respectively. The myeloid cell signature in active disease supports the emerging role of monocytes/macrophages in driving inflammation in PsA, while the aberrant blood-skin fibroblast interactions suggest a novel role for these resident cells in disease pathophysiology.

REFERENCES:


Disclosure of Interests: None declared


POS0327

IRISIN: A NEW MARKER OF SUBCLINICAL ATHEROSCLEROSIS, CARDIOVASCULAR RISK AND DISEASE ACTIVITY IN AXIAL SPONDYLOARTHROPATHY.

S. Remuzgo-Martinez1, J. Rueda-Gotor1, V. Putilo-Cueto1, R. López-Mejías1, A. Corrales1, L. Lera-Gómez1, R. Pérez-Fernández1, V. Portilla1, I. Gonzalez-Mazon1, R. Blanco1, R. Expósito1, C. Mata2, J. Llorca1, V. Hernández-Hernández1, C. Rodríguez-Lozano1, N. Barbarroja Puerto1.
Background: Axial spondyloarthritis (axSpA) is an inflammatory disease with detrimental effects on the health status of the individuals affected by this condition. axSpA patients also exhibit high cardiovascular (CV) risk, mainly due to accelerated atherosclerosis [2]. Interestingly, the adipokine irisin was described to play a beneficial role in several physiological and pathophysiological processes such as inflammation, angiogenesis, oxidative stress, as well as lipid and bone metabolism [3]. However, studies on the role of irisin in CV risk in the setting of axSpA or in the pathogenesis of axSpA are limited [4].

Objectives: In this study we evaluated the role of irisin as a genetic and serological biomarker of subclinical atherosclerosis and CV risk in a large cohort of patients with axSpA. We also assessed its role as a marker of axSpA susceptibility and severity.

Methods: 725 patients who fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axSpA were included in this study [5]. In these patients, the presence of subclinical atherosclerosis (plaques and/or abnormal carotid intima-media thickness values) was assessed by carotid ultrasound. Four irisin polymorphisms (rs16835198 G/T, rs3480 A/G, rs726344 G/A and rs1570569 G/T) were genotyped by TaqMan methods in all the patients and in 656 age, sex and ethnically-matched healthy controls. Additionally, serum irisin levels were determined by ELISA in all the patients. All analyses were performed using STATA v.11.1 statistical software, adjusting for potential confounding factors. The strength of associations is indicated as odds ratios (OR) [95% confidence intervals].

Results: Low levels of serum irisin were linked to the presence of plaques (p=0.002) and with atherogenic index values indicative of an adverse lipid profile (p=0.01). The minor alleles of rs3480 (G) and rs1570569 (T) were associated with higher values of Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients (p=0.01 in both cases). In this line, the frequency of the minor allele of rs1570569 (T) was higher in patients with ASDAS values ≥2.1 (indicative of high disease activity) (OR: 1.46 [1.08-1.97], p=0.01), while the minor allele of rs16835198 (T) was less frequent in this group of patients (OR: 0.73 [0.57-0.92], p=0.01).

Conclusion: Low serum irisin levels could be indicators of the presence of subclinical atherosclerosis, high CV risk and more severe disease in axSpA patients. In addition, irisin may also constitute a genetic biomarker of disease activity in axSpA.

REFERENCES:

Acknowledgements: This work was partially supported by grants from Instituto de Investigación Sanitaria IDIVAL (IVALA17/10), from the Asociación Cántabra de Reumatología’ awarded to FG. FG and JR-G are beneficiaries of a grant funded by ‘Instituto de Salud Carlos III’ (ISCIII) (PI12/000059). SR-M is supported by funds of the RETICS Program (RD16/0022/0009) from ISCIII, co-funded by the European Regional Development Fund. VP-C is supported by a pre-doctoral grant from IDIVAL (PREVAL18/01). RL-M is a recipient of a Miguel Servet type I programme fellowship from ISCIII, co-funded by the European Social Fund, ‘Investing in your future’ (grant CP16/00035).

Disclosure of Interests: Sara Remuzgo-Martinez: None declared, Javier Rueda-Gotor: None declared, Veronica Pulto-Cueto: None declared, Raquel López-Mejias: None declared, Alfonso Corrales: None declared, Leticia Lera-Gómez: None declared, Raquel Pérez-Fernández: None declared, Virginia Portilla: None declared, Iñigo González-Mazon: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant/research support from: Abbvie, MSD and Roche, Rosa Esposito: None declared, Cristina Mata: None declared, Javier Llorca: None declared, Vanessa Hernández-Hernández: None declared, Carlos Rodríguez-Lozano: None declared, Nuria Barbero Puerto: None declared, Rafaela Ortega Castro: None declared, Esther F. Vicente-Rabaneda: None declared, Cristina Fernández-Carballo: None declared, María Paz Martínez-Vidal: None declared, David Castro-Corredo: None declared, Joaquin Anino-Fernández: None declared, Diana Peiteado: None declared, Chamaida Plasencia: None declared, E Galindez: None declared, Maria L. Garcia Vivar: None declared, Nuria Vegas-Rengel: None declared, Irais Urionaguena: None declared, Oreste Gualliu: None declared, Juan Carlos Quevedo-Abeledo: None declared, Santos Castañeda: None declared, Ivan Ferraz-Amaro: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD, GSK, Grant/research support from: Abbvie, MSD, Janssen, Roche, Fernanda Genre: None declared.

between JAK inhibition and FLS function improvement at synovial level is not fully understood.

**Objectives:** To evaluate the effect of tofacitinib on spontaneous autophagic activity of PsA FLS, and to confirm its effect on anti-inflammatory and anti-invasive properties of PsA FLS and synovial explants.

**Methods:** This is an in vitro study. Patients with active PsA underwent ultrasound-guided synovial biopsy. Histological evaluation was performed according to Krenn’s synovitis score. FLS, PBMCs and synovial explants cultures were set up, and cells were treated in vitro with tofacitinib 1 µM or vehicle control for 24h. Protein levels in cellular homogenates were analysed by western blot for relevant autophagy markers. Autophagy was also studied by fluorescence microscopy using GFP-LC3. Chemokinases/cytokines levels into culture supernatants were quantified by ELISA. Migration assays were used to investigate the effect of tofacitinib on invasive properties of FLS. Differences were determined adopting the non-parametric Wilcoxon signed rank test.

**Results:** 16 patients with moderately active PsA were enrolled (Table 1). Mean (SD) Krenn’s synovitis score was 4.4, (1.9). Tofacitinib significantly increased LC3-II and ATG7 levels in PsA FLS compared to vehicle control, while p62 levels were not significantly affected, suggesting an increase in spontaneous autophagy activity, confirmed by LCS-autophagic vesicles count (Figure 1). No effect was highlighted in PBMCs and synovial explants cultures. Tofacitinib significantly reduced migration properties of PsA FLS, as well as MCP-1 and IL-6 release into FLS and synovial explants cultures supernatants.

**Conclusion:** The induction of autophagy by tofacitinib might permit a better functioning of PsA FLS, with a coherent reduction in pro-inflammatory and pro-inflammatory properties. This may contribute to the rationale for tofacitinib use in PsA management.

**REFERENCES:**
Conclusion: a global DNA hypermethylation was observed in patients with axSpA, both in T CD4 lymphocytes and monocytes. These modifications involved both the radiographic and non radiographic forms. These results were weakly correlated with disease activity and only in monocytes. Collectively, these changes in DNA methylation could alter recruitment of methyl binding proteins (MBP) that regulate chromatin structure and/or impair binding of transcription factors, resulting in down regulation of gene expression relevant to the pathogenesis of axSpA. We currently evaluated the level of expression of DNA methyltransferase (DNMT) and MBP proteins and specific DNA methylation status of the promoters of gene involved in inflammation such as TNFa.

Acknowledgements: This work was supported by a grant (APICHU) from CHU de Besançon

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1876

Differences in gut microbiota associated with lymphocyte subsets, cytokines and disease activity in ankylosing spondylitis

Z. Song1,2,3, S. X. Zhang1,2,3, T. Cheng1,2,3, R. Zhao1,2,3, J. Qiao1,2,3, S. Song1,2,3, Y. Li1,3, X. Li1,2,3, C. Wang1,2,3, 1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 3Shanxi Medical University, Key Laboratory of Cellular Physiology, Taiyuan, China

Background: Ankylosing spondylitis (AS), a common chronic inflammatory disease, is a prototype of spondyloarthritis affecting sacroiliac joints and spine with or without peripheral arthritis and other systemic symptoms [1]. Environmental factors, especially microorganisms have been suggested to implicate with AS pathogenesis [2].

Objectives: Utilizing 16S rRNA genes sequencing on the feces of untreated AS patients and healthy controls (HCs), our study aimed to provide an in-depth understanding of AS gut microbiota and identifying a feasible diagnostic strategy for AS.

Methods: Fecal samples were collected from 62 AS patients and 62 age-and-gender- matched HCs. Microbial genome was extracted from approximately 250mg fresh fecal samples from all participants using QIAamp PowerFecal DNA Kit (Qiaigen). The V3-V4 variable regions of bacterial 16S rRNA genes were sequenced with the Illumina MiSeq PE300 system. QiIME2 based pipeline was used to process the raw sequence data. Alpha and beta diversities were assessed using result from QiIME2, and comparisons of gut microbiome profile was performed using linear discriminant analysis (LDA) effect size (LEfSe) to examine differences between AS and HCs. R (version 4.0.1) was used for comparative statistics, and pearson’s correlation was used to assess the correlations between the relative abundances of bacterial genera and clinical parameters; correlations with p < 0.05 were considered significant.

Results: AS for alpha-diversity, ACE and Chao1 indices were lower in AS compared with those HCs (Figure 1A, p < 0.05), though no significant differences were observed in Shannon and Simpson index. Bray curits distance-based beta-diversity analysis revealed significant differences in the microbial community between AS and HCs (Figure 1B, p = 0.003, ANOSIM). Fecal microbial communities in AS differed significantly from those in HCs, driven by higher abundances of Escherichia-Shigella, Turicibacter, Enterococcus, et al. and a lower abundance of Agathobacter, Roseburia, Eubacterium_eligens_group, et al (Figure 1C, p < 0.05). There was a significant positive correlation between ESR and Klebsiella, Butyricicoccus, Roseburia, CRP and Faecalibacterium, Muribaculaceae, ASDAS-ESR score and Faecalibacterium, Ruminococcus, total lymphocyte cells and Agathobacter, Ruminococcus, T cell and Agathobacter, CD4+ T cell and Agathobacter, B cell and Agathobacter, Streptococcus, Th1 and Prevotella, CAG–352, Th2 and Agathobacter, Th17 and Prevotella, Agathobacter, IL-2 and Agathobacter, IL-4 and Agathobacter, IL-6 and Lachnospiraceae_ UCG–004, Muribaculaceae, IL-17 and Eubacterium_hallii_group, IFNgama and Phascolarctobacterium. There were negative correlations between total lymphocytes and Escherichia–Shigella, CD4+ T cell and Enterobacteriaceae, Th2 cell and Escherichia–Shigella, IL-10 and CAG–352, Ruminococcus (Figure 2, p < 0.05).

Figure 1. Feature of gut microbiota in AS patients and HCs. (A) Alpha-diversity assessed by richness (Chao1, ACE) and diversity (Shannon, Simpson). Median estimates compared across cohorts. (B) PCoA plot based on the Bray curits distance of gut microbiota samples from AS patients vs. HC group (p = 0.003, ANOSIM). (C) Panel demonstrated the average relative abundance of different genus in AS and HCs. (D) Distribution of gut microbiota at genus level.

Correlations between the relative abundance of significantly different bacteria and clinical variables. *p<0.05, **p < 0.01, ***p <0.001, ****p < 0.0001.

Conclusion: Human gut microbiome in patients with AS differed from that of the HCs. Characteristics of bacteria communities were associated with disease activity.

REFERENCES:

Acknowledgements: This project was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests: None declared

Background: Enthesis or inflammation of the tendon/ligament anchorage points is the cardinal lesion in spondyloarthritis (SpA)[1]. Several key mediators have been shown to have a role in SpA including TNFα, IL-23, IL-17A and IL-17F [1]. There is a need for new therapeutic agents to treat SpA as current therapeutics fail to adequately target all its manifestations. Janus kinase (JAK) inhibitors have shown promise as disease modifying drugs and by targeting signaling components shared amongst several inflammatory pathways may be advantageous in treating inflammatory diseases with complex overlapping pathologic mechanisms, as seen in SpA[2]. Upadacitinib is an oral selective JAK inhibitor (JAK1 over JAK2/3) which in phase II/III trials has shown efficacy for both psoriatic arthropathy and ankylosing spondylitis, suggesting specific JAK1 targeting may be superior[3, 4]. The role of JAK/STAT signaling in enthesis has not been extensively explored and given the importance of the enthesis in the development of SpA it is crucial to gain a mechanistic understanding of how JAK inhibitors affect entheseal inflammation.

Objectives: To determine if upadacitinib could suppress innate and adaptive immune responses in an in vitro human enthesis model and elucidate mechanisms of suppression.

Methods: Normal spinous process enthesis was obtained from patients undergoing spinal decompression or surgery for scoliosis correction as previously described[5]. Enthesis cells were subsequently isolated by mechanical digestion. Enthesal cells were stimulated with IFNγ (JAK1 activator) with and without upadacitinib and STAT1 activation measured by phos-flow cytometry. Enthesal T-cells were stimulated with anti-CD3, anti-CD2 with IL-23 and anti-CD3 with IL-17 with and without upadacitinib. IL-17A and TNFα were quantified using intracellular flow cytometry and ELISA of supernatants. Enthesal cells were also stimulated with LPS with and without upadacitinib, and IL-23 and TNFα quantified by ELISA.

Results: Upadacitinib inhibited phosphorylation of STAT1 in entheseal cells, following IFNγ stimulation (Figure 1-A). Following stimulation of entheseal T-cells upadacitinib inhibited both TNFα and IL-17A production as assessed by both ELISA and intracellular flow cytometry (Figure 1-B, 1-C). Upadacitinib did not attenuate LPS induced IL-23 or TNFα from entheseal myeloid cells.

Conclusion: Upadacitinib inhibition of entheseal T cell derived TNFα and IL-17A, therefore interrupting the IL-23/IL-17/TNFα axis so prominent in SpA, may offer a mechanistic explanation for upadacitinib’s efficacy treating enthesis.

REFERENCES:

Disclosure of Interests: Sami Gires: None declared, Charlie Bridgewood: None declared, Chi Wong: None declared, Tom Macleod: None declared, Dennis McGonagle Grant/research support from: The study is funded by an Abbvie research grant.

Conclusion: The findings reflect a possible relationship among the apical expression of CD71 in ileum with high levels of serum S IgA and activity, suggesting that retrotranscytosis mediated by this receptor might be a mechanism that mediate the intestine-joint axis in SpA.

Acknowledgements: The Ministry of Science, Technology, and Innovation - MinCiencias (Grants No. 68022 and 57442), Universidad El Bosque (PCI-2018-10300), Hospital Militar Central (Grant 2017-023), Clinicos IPS, Gastroadvanced, Fundación Instituto de Reumatología Fernando Chalem, in Bogota, Colombia and Biomedicina de Chihuahua, México

Disclosure of Interests: None declared


CIRCULATING NON-CLASSICAL CD14LOW/CD16+ MONOCYTES AND THEIR EXPRESSION OF ARGINASE-1 ARE ASSOCIATED WITH THE ACTIVITY OF AXIAL SPONDYLOARTHRITIS

T. Tyirnova1, A. Morenkova1, M. Tikhonova1, O. Chumasova2, N. Ilina3, A. Fedorov4, A. Sizikov2, A. Ostanin1, E. Chernykh1, 1Research Institute of Fundamental and Clinical Immunology, Laboratory of Cellular Immunotherapy, Novosibirsk, Russian Federation; 2Research Institute of Fundamental and Clinical Immunology, Department of Rheumatology, Novosibirsk, Russian Federation

Background: Human peripheral blood monocytes represent heterogeneous population and can be divided into three major populations, classical (CD14+CD16−), intermediate (CD14−CD16+) and non-classical (CD14−CD16+) monocytes. All three monocyte populations are thought to have different functional activity, including their pro- and anti-inflammatory activity. The ratio between monocyte populations could change in inflammatory conditions that it is thought to be important for the development of adequate immune responses. Axial spondyloarthritis (axSpA) being autoimmune diseases is currently classified as an autoinflammatory disease based on a strong inflammatory component. Axial spondyloarthritis (axSpA) being autoimmune diseases is currently classified as an autoinflammatory disease based on a strong inflammatory component. It is accepted that increased concentration of pro-inflammatory mediators can cause an impairment of myelopoiesis.

Objectives: The present study aimed to analyze the frequency of blood monocyte subpopulations and their expression of the suppressor molecule arginase-1 (Arg1) in patients with axSpA.

Methods: The study included 14 healthy donors and 19 axSpA patients aged 23 to 59 years, including 15 men and 4 women. Ankylosing Spondylitis Disease Activity Score (ASDAS) was used to assess disease activity and high activity was determined as ASDAS≥2.1. The disease duration at the time of the study was 12 years (median). Phenotypic analysis of blood monocytes was performed by flow cytometry based on CD14 and CD16 expression.

Results: The frequency of monocyte subpopulations in patients with low/moderate activity of axSpA did not differ from the donor group. Patients with high very high disease activity showed an increased relative number of non-classical CD14+CD16+ monocytes (vs donors pU=0.007). All donor monocyte subpopulations expressed suppressor intracellular molecule Arg1 with higher expression in intermediate and non-classical monocytes. The expression of Arg1 in CD14+CD16+ monocytes was significantly reduced in patients with high activity (vs donors Me 41.5 vs 76.5%, pU=0.01). Patients with the presence of peripheral articular manifestations of axSpA were characterized by a decreased Arg1 expression in non-classical monocytes compared with the donor group (pU=0.02). However, patients without peripheral manifestations demonstrated a significant reduction of Arg1 expression in all monocyte subpopulations (pU<0.05).

Conclusion: Shifting of monocyte subpopulation toward a higher number of non-classical monocytes with the decrease in the expression of the suppressor molecule Arg1 in the high activity of axSpA can play important role in terms of the possible involvement of monocytes in maintaining inflammation and its regulation in autoinflammatory disease.

The reported study was funded by State Budgeted Project (registration ID 122011800037-3).

Disclosure of Interests: None declared


New insights into the management of JIA

A. I. Rebolli Gímenez1, A. Alongí2, G. Giancane1, R. Naddeo1, N. Ruperto1, A. Consolaro1, A. Ravelli1 on behalf of Pediatric Rheumatology Internationals Trials Organization (PRINTO), 1Istituto Giannina Gaslini, Pediatric and Rheumatology Clinic, Genoa, Italy; 2Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Civico Di Cristina e Benfratelli, Pediatric Clinic, Palermo, Italy; 3Istituto Giannina Gaslini, Scientific Director, Genoa, Italy

Background: The ACR provisional criteria for defining inactive disease (ID) in Juvenile Idiopathic Arthritis (JIA) requires that the physician's global assessment of disease activity (PhGA) is marked as 0 on the visual analog scale (VAS). However, some investigators have noticed the tendency of some clinicians to mark the PhGA=0 even on resolution of active disease. Due to the fact that the PhGA and the count of active joints are the two main physician-centered measures included in ID criteria the analysis of their discordance may be of importance to address the issue.

Objectives: To investigate the frequency in which the physician provides a global assessment of disease activity (PhGA)0 and an active joint account (AJC)=0 in children with juvenile idiopathic arthritis (JIA) and search for determinants of divergence between the two measures.

Methods: Data were extracted from a multinational cross-sectional dataset of 7265 patients who had JIA by ILAR criteria, were recruited between 2011 and 2016 and had both PhGA and AJC recorded by the caring paediatric rheumatologist at the study visit. Determinants of discordance between PhGA and AJC=0 were searched for by multivariable logistic regression and dominance analysis.

Results: The PhGA was scored 0 in 1211 (32.4%) of 3668 patients who had an AJC=0 of 0. In 536 patients (14.6%) the PhGA was the single most frequent reason for not meeting the ID definition in patients with AJC=0. Independent associations with discordant assessment were identified for tender or restricted joint count>0, history of entheses, presence of active uveitis or systemic features, enthesitis-related or systemic arthritis, increased acute phase reactants, pain visual analog scale (VAS)>0, and impaired physical or psychosocial wellbeing. In dominance analysis, tender joint count accounted for 35,43% of PhGA variance, followed by an active joint account (AJC=0) (17 ,72%), restricted joint count>0 (16, 14%) and physical health score >0 (11,42%) (Figure 1).

Disclosure of Interests: None declared


Figure 1. Discrimination analysis of relative importance of predictive factors in explaining the variance in PhGA.
**Conclusion:** We found that many paediatric rheumatologists did not mark a score of 0 for patients who found not to have active joints. The presence of pain in joints not meeting the definition of active joint used in JIA was the main determinant of this phenomenon.

**REFERENCES:**


NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, GlaxoSmithKline, Idorsia, Janssen. Eli Lilly, Novartis, Pfizer, Sobi, UCBL. Consultant of: NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, GlaxoSmithKline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCBL.

**Conclusion:** In this study, we created a shorter pain coping scale for children (IPCSpar) and a novel scale for caregivers (IPCSpar). Both showed good validity and reliability.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1413

**POS0338**

**COURSE OF UVEITIS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE INCEPTION COHORT OF NEWLY DIAGNOSED PATIENTS WITH JIA (ICON-JIA) STUDY**


**1German Rheumatism Research Center Berlin, Epidemiology, Berlin, Germany; 2Medizinische Hochschule Hannover, Paediatric Rheumatology, Hannover, Germany; 3University Hospital Münster, Department of Paediatric Rheumatology and Immunology, Münster, Germany; 4Huband Centre for Pediatric and Adolescence Rheumatology, Paediatric Rheumatology, Hamburg, Germany; 5German Centre for Child and Adolescent Rheumatology, Paediatric Rheumatology, Gammsich-Partenkirchen, Germany; 6Asklepios Kinderklinik St Augsburg, Centre for General Paediatrics and Neonatology, St. Augsburg, Germany; 7Olghospital Stuttgart, Center for Pediatric Rheumatology, Stuttgart, Germany; 8Ostkreis – Universitätsmedizin Berlin, Department of Paediatric Respiratory Medicine, Immunology and Intensive Care Medicine, Berlin, Germany; 9Klinikum Köln – Kinderkrankenhaus, Paediatric Rheumatology, Köln, Germany; 10Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Paediatric Rheumatology, Bremen, Germany; 11St. Josef-Stift Sendenhorst, Clinic for Paediatric and Adolescent Rheumatology, Sendenhorst, Germany; 12Franziskus Hospital, Department of Ophthalmology, Münster, Germany.

**Background:** Uveitis is an extra-articular manifestation of Juvenile idiopathic arthritis (JIA) with a prevalence of up to 20% developing most frequently in young girls and patients positive for antinuclear antibodies (ANA). Untreated and uncontrolled uveitis may lead to vision-threatening complications and even blindness.

**Objectives:** The main objectives of the analyses were to determine the visual prognosis, uveitis complications and necessity of ocular surgery during the first five years of ocular disease. The likelihood of achieving an inflammation-free phase or even a remission without medication were investigated.

**Methods:** The Inception Cohort of Newly diagnosed patients with JIA (ICON) was initiated in 2010 in order to prospectively follow JIA patients up to 10 years after JIA disease onset. 953 Patients were assessed at enrolment, three-monthly during the first year, and six-monthly afterwards by a standardized phisician's patient's and patient's case report form including clinical parameters, treatment data and several laboratory parameters such as ESR, CRP or S100A12. Patients who developed uveitis underwent a regular ophthalmological assessment. The treatment ophthalmological for each patient was completed an additional questionnaire documenting the anterior chamber (AC) cell grade, current uveitis activity (UA) and UA during the previous three months, best corrected visual acuity (BCVA), uveitis-related complications, previous ocular surgery, current topical treatment
and clinical course of uveitis and additional parameters. Inactive uveitis was defined by AC cell grade of 0, quiescence of uveitis by inactive uveitis for at least 6 months, and remission by inactive uveitis for at least 6 months without topical steroids or systemic anti-inflammatory medication (steroids or DMARDs).

**Results:** A total of 133 children developed uveitis in the JIA disease course, of which 97 patients were documented via the ophthalmological questionnaire for at least two years resulting in a mean follow-up of 5.8 years (SD 1.8). 76% were female, 86% ANA positive, 70% oligoarthritis, and 22% rheumatoid factor negative polyarthritis and mean age at JIA onset was 3.1 (SD 2.1) and uveitis onset at 4.4 (SD 2.2) years. The mean duration between JIA onset and uveitis onset was 15.7 (SD 15.6) months. At least one ocular complication was reported for 24% of patients at first uveitis documentation and 47% of patients had at least one ocular complication until the five year follow-up. Among those, posterior synchiae (31%) and cataract (27%) were the most frequent, followed by an increased IOP (12%) with or without glaucomatous changes. Ocular surgery was rarely necessary, and visual acuity remained quite good in the majority of patients: After five years, >90% had BCVA of >0.4 LogMAR (Logarithm of the Minimum Angle of Resolution), and 63.5% even of >0.1 LogMAR. About half of the uveitis patients were already treated with DMARDs at uveitis onset. The rate of treatment with biological DMARDs increased from 10% at first uveitis documentation up to 20% at 5-year follow-up. Three in four patients were treated with topical steroids at first assessment, whereas this proportion decreased to 43%. 80 of 97 patients (83%) achieved uveitis quiescence during the first five years of disease, with more than 50% experiencing more than one episode (mean 1.5 episodes (SD 1.0)) during this time period. The mean duration of uveitis quiescence was 23.2 (SD 15.6) months. A total of 39 (40%) patients achieved uveitis remission during follow-up. The likeliness of remission was associated with a lower JIA disease activity (cJADAS10), lower erythrocyte sedimentation rate (ESR) and a higher age at JIA disease onset.

**Conclusion:** The rate of ocular complications is already remarkable at uveitis diagnosis, and increases during uveitis disease course despite anti-inflammatory treatment. However, the visual acuity frequently remains unaffected, and the majority of patients achieve uveitis quiescence and even 40% uveitis remission within 5 years of follow-up.

**Acknowledgements:** The ICON study is funded by a research grant of the Federal ministry of education and research (BMBF, FKZ 01ER0812, FKZ 01ER1504A-C)

**Disclosure of Interests:** Jens Klotsche: None declared, Claudia Sengler: None declared, Frank Dreßler: None declared, Dirk Föll: None declared, Ivan Foeßvar: None declared, Johannes-Peter Haas: None declared, Gerd Horneff: Speakers bureau: Pfizer, Novartis, Janssen, Chugai, Abbvie, Grant/research support from: Pfizer, Novartis, MSD, Chugai, Roche, Abbvie, Toni Hospach Consultant of: SOBI, Novartis, Tilmann Kallinich: None declared, Ina Liedmann: None declared, Kirsten Moenkemoeller: None declared, Martina Niewert: None declared, Frank Weller-Heinemann: None declared, Daniel Windschall: None declared, Arndt Heiligenhaus: None declared, Kirsten Minden: None declared, Karoline Baquet-Walscheid: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5073

**POS0337**

**DISTINCT CLUSTERS OF JIA AT METHOTREXATE INITIATION IDENTIFIED USING TOPOLOGICAL DATA ANALYSIS**

S. Shoop-Worrall1,2, K. Hyrich3,4, L. Wedderburn5,6, N. Geiffin7 on behalf of The CLUSTER Consortium, BSPAR-ETN Study, BCRD Study, CAPS, CHARMS. 1The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2The University of Manchester, Centre for Health Informatics, Manchester, United Kingdom; 3Manchester University NHS FT, NHS Manchester BRC, Manchester Academic Health Science Centre, Manchester, United Kingdom; 4UCL Great Ormond Street Institute of Child Health, University College London, Centre for Adolescent Rheumatology Versus Arthritis at UCL, London, United Kingdom; 5Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom; 6NIHR Great Ormond Street Hospital Biomedical Research Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom; 7University of Surrey, School of Health Sciences, Faculty of Health and Medical Sciences, Guildford, United Kingdom

**Background:** Stratified medicine requires the identification of unique strata of a disease within which to base prognostic and treatment decisions. Juvenile idiopathic arthritis (JIA) offers a unique challenge in its inherent heterogeneity. The current ILAR classification, whilst useful for clinical categorisation, does not correlate with treatment outcomes. Therefore, further refinement, clustering and correlation of patient characteristics with treatment response are urgently required.

**Objectives:** To identify novel, phenotypically consistent subgroups of children and young people (CYP) with JIA at the point of starting methotrexate, across 19 demographic and clinical variables. ILAR categories across clusters were not always indicators of disease activity or symptom burden. Future analyses will correlate MTX treatment response within each cluster to understand what role these combined factors may have on initial treatment response.

**Disclosures of Interests:** Stephanie Shoop-Worrall: None declared, Kimmie Hyrich: Speakers bureau: AbbVie, Grant/research support from: BMS, UCB, and Pfizer, Lucy Wedderburn: Grant/research support from: AbbVie and Sobi, Nophar Geiffin: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2714

**POS0338**

**TRANSITION COMPETENCE IN YOUNG PEOPLE WITH JUVENILE IDIOPATHIC ARTHRITIS HAS IMPROVED OVER TIME**

K. Minden1,2, M. Niewert1, S. Schalm1, J. Föllvari1, J. P. Haas1, G. Horneff1, D. Windschall2,3, T. Kallinich1, F. Dressler1, F. Weller-Heinemann1, R. Berendse1,2, T. Hospach2, M. Hufnagel3, M. Hailer4, S. Hansmann4, J. Klotzsche1. 1Charité Universitätsmedizin Berlin, Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany; 2Deutsches Rheuma-Forschungszentrum Berlin, Epidemiology, Berlin, Germany; 3Rheumatolog im Zentrum, Rheumapräxis München, München, Germany; 4Hamburger Zentrum für Kinder- und Jugendrheumatologie, Praxis, Hamburg, Germany; 5Deutsches Zentrum für Kinder- und Jugendrheumatologie, Kinderklinik Gamisch-Partenkirchen, Gamisch-Partenkirchen, Germany; 6Asklepios Kinderklinik St. Augustin, Zentrum für Allgemeine Pädiatrie und Neonatologie, St. Augustin, Germany; 7University of Cologne, Medical Faculty, Cologne, Germany; 8St.-Josef-Stift Sendenhorst, Clinic of Paediatric and Adolescent Rheumatology, Sendenhorst, Germany; 9Martin-Luther-University Halle-Wittenberg Medical Faculty, Halle, Germany; 10Medizinische Hochschule Hannover, Zentrum für Kinderheilkunde und Jugendmedizin, Hannover, Germany; 11Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Bremen, Germany; 12Kinderkrankenhaus

**Disclosure of Interests:**

This study shows substantial heterogeneity in JIA at the point of MTX initiation, with six clusters identified across 19 demographic and clinical variables. ILAR categories across clusters were not always indicators of disease activity or symptom burden. Future analyses will correlate MTX treatment response within each cluster to understand what role these combined factors may have on initial treatment response.
Background: In recent years, transition clinics have been set up at an increasing number of paediatric rheumatology sites in Germany to reduce identified deficits in the care of young people with rheumatic diseases. In addition, the German Rheumatic Diseases League (Deutsche Rheuma-Liga, DRL), the largest self-help organisation in Germany, has been offering support services for young people in transition since 2016, including the interactive website www.mein-rheumakind.de.

Objectives: To assess the transition competence of young people with juvenile idiopathic arthritis (JIA) and their knowledge of self-help services.

Methods: Cross-sectional data of the National Paediatric Rheumatology Database (NPRD) from 2016 to 2020 were used to evaluate the health-related transition competence of young people with JIA aged ≥16 years. Health-related knowledge and health-care competence were assessed using a modified self-report instrument on a 4-point Likert scale as part of routine documentation in the NPRD. Young people were also asked about their information behaviour and knowledge of new support services. Linear mixed models were used to determine whether health-related transition competence changed between 2016 and 2020, adjusted for disease duration.

Results: From the years 2016 to 2020, between 1908 to 2536 patients with JIA aged ≥16 years were annually recorded in the NPRD from 56 to 61 paediatric rheumatology sites. The annual patient collective comprised 34% 39% oligoarthritis, 23-26% RF-negative or RF-positive polyarthritis and 22-27% enthesis-related arthritis cases. In the years from 2016 to 2020, about one-third of patients had inactive disease (cJADAS=0) and about 60% had no functional limitation (CHAQ=0).

Over the years, the proportions of patients who rated their disease knowledge and health care competence as “very well” increased significantly in most areas. Although over time, no increase in numbers of patients seeking information about their disease outside of rheumatology consultations was recorded (2016: 22.8%; 2020; 20.9%), awareness of the DRL’s new website for young people with rheumatic diseases increased from 7.7% in 2016 to 26.9% in 2020. Compared to those who were unaware of the new website, those who knew about the website were more likely to have received care in rheumatology settings that offer transitional care (cJADAS=10 vs 1) and had a higher school attendance (51% vs 46%) and to be slightly older (17.6 vs 17.1 years).

Conclusion: The transition competence of young people with JIA seems to have improved over the last five years. During this time, more transition services were made available for young people with rheumatic diseases. However, most young people are not yet aware of these services. Moreover, the effectiveness of the different measures/interventions has yet to be evaluated.

REFERENCES:

Table 1. Health-related transition competence in JIA patients ≥16 years who participated in the NPRD

<table>
<thead>
<tr>
<th></th>
<th>2016</th>
<th>2018</th>
<th>2020</th>
<th>p (difference over time)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>N=2536</td>
<td>N=2068</td>
<td>N=1908</td>
<td></td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>6.7±4.9</td>
<td>7.2±5.0</td>
<td>7.6±5.1</td>
<td></td>
</tr>
<tr>
<td>DMARDs at documentation, %</td>
<td>57</td>
<td>62</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Disease-related knowledge (best answer)</td>
<td>N=1992</td>
<td>N=1598</td>
<td>N=1265</td>
<td></td>
</tr>
<tr>
<td>“very well”, % name of illness</td>
<td>35</td>
<td>42</td>
<td>42</td>
<td>0.001</td>
</tr>
<tr>
<td>names of medicines</td>
<td>54</td>
<td>59</td>
<td>56</td>
<td>0.717</td>
</tr>
<tr>
<td>what medicines are for</td>
<td>60</td>
<td>54</td>
<td>52</td>
<td>0.357</td>
</tr>
<tr>
<td>who to contact in case of health problems</td>
<td>65</td>
<td>65</td>
<td>65</td>
<td>0.015</td>
</tr>
<tr>
<td>influence of smoking, drugs, and alcohol</td>
<td>49</td>
<td>55</td>
<td>54</td>
<td>0.002</td>
</tr>
<tr>
<td>on disease</td>
<td>68</td>
<td>65</td>
<td>65</td>
<td>0.087</td>
</tr>
<tr>
<td>how to make a doctor’s appointment</td>
<td>42</td>
<td>46</td>
<td>49</td>
<td>0.031</td>
</tr>
<tr>
<td>which doctors are responsible after leaving paediatric care</td>
<td>N=1784</td>
<td>N=1443</td>
<td>N=1143</td>
<td></td>
</tr>
<tr>
<td>Health-care competence (best answer &quot;most of the time&quot;), % inform my doctor of any unusual changes in my health</td>
<td>66</td>
<td>72</td>
<td>69</td>
<td>0.038</td>
</tr>
<tr>
<td>keep my information about my illness</td>
<td>81</td>
<td>84</td>
<td>84</td>
<td>0.281</td>
</tr>
<tr>
<td>ask my own questions</td>
<td>51</td>
<td>56</td>
<td>55</td>
<td>0.016</td>
</tr>
<tr>
<td>answer the questions I am asked</td>
<td>69</td>
<td>73</td>
<td>74</td>
<td>0.014</td>
</tr>
<tr>
<td>take care of my health concerns and meeting needs</td>
<td>66</td>
<td>71</td>
<td>69</td>
<td>0.041</td>
</tr>
<tr>
<td>attend the consultation alone</td>
<td>59</td>
<td>61</td>
<td>61</td>
<td>0.599</td>
</tr>
<tr>
<td>speak up for myself and say what I need</td>
<td>64</td>
<td>68</td>
<td>68</td>
<td>0.537</td>
</tr>
</tbody>
</table>

Acknowledgements: The NPRD has been funded by the Federal Ministry of Health and the companies Abbvie, Chugai, ask, Novartis, Pfizer

Disclosure of Interests: Kirsten Minden Speakers bureau: Pfizer, Novartis, Consultant of: Pfizer, Novartis, Martina Berti; None declared, Susanne Schalm; None declared, Ivan Foeldvari: None declared, Johannes-Peter Haas: None declared, Gerd Horneff: None declared, Daniel Windschall Speakers bureau: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Grant/research support from: Pfizer, Novartis, Abbvie, Medac, Sobi, Canon, Tilmann Kallinich: None declared, Frank Dressler: None declared, Frank Weller-Heinemann: None declared, Rainer Bierer: None declared, Tori Hospach Consultant of: Sobi, Novartis, Markus Huñagel: None declared, Maria Haller: None declared, Sandra Hansmann: None declared, Jens Klotzsche: None declared


POS0339 POINTS TO CONSIDER AT THE EARLIEST STAGES OF THE DIAGNOSIS AND MANAGEMENT OF HEMOPHAGIC LYMPHOPHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME (HLH/MAS)

B. Shaakyoo1, A. Geerlings2, M. Wijejo2, K. Kernan1, E. Demirkaya2, A. Ravel1, R. Sinha1, R. Goldbach-Mansky3, F. De Benedetti4, R. Marsh1, S. Canoa1 on behalf of EULAR/ACR HLH/MAS Working Group, 1NAID/NIH, 2Translational Autoinflammatory Disease Section, Bethesda, United States of America; 3London Health Sciences Centre, Hematology/Oncology, London, Canada; 4University of Pittsburgh, Critical Care Medicine, Pittsburgh, United States of America; 5Istituto Giannina, Rheumatology, Genoa, Italy; 6Systemic JIA Foundation, Head, Cincinnati, United States of America; 7Ospedale Bambino Gesù, Rheumatology, Rome, Italy; 8Cincinnati Children’s Hospital Medical Center, Bone Marrow Transplantation and Immune Deficiency, Cincinnati, United States of America; 9The Children’s Hospital of Philadelphia, Rheumatology & Immune Dysregulation, Philadelphia, United States of America

Background: Hemophagic Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) are life-threatening systemic hyperinflammatory syndromes that occur in many contexts and are often called by many names. They nevertheless can progress rapidly, and early identification and management are critical for preventing organ failure and mortality.

Objectives: The purpose of this effort was to develop a series of ‘points to consider’ to assist clinicians at the earliest stages of evaluation and diagnosis, monitoring, and management of patients with HLH/MAS in order to improve patient outcomes.

Methods: A working group of adult and pediatric rheumatologists (14), hematologists/oncologists (4), immunologists (2), infectious disease specialists (2), intensivists (3), allied health care professionals (1), and patients/parents (2) formulated relevant research questions for a systematic literature review (SLR). We then used the SLR results, Delphi questionnaires, and consensus methodology to devise and refine overarching and specific ‘points to consider’ statements.

Results: The group arrived at six overarching statements and 24 specific points- to-consider-relevant to early decision-making in diagnostics, initial management, and monitoring of HLH/MAS. Major themes included the a) need for prompt recognition, evaluation, and management of underlying triggers and conditions, b) multi-disciplinary/expert input, and c) early, tailored intervention with the goals of halting disease progression and preventing life- and organ-threatening immunopathology.

Conclusion: The 2022 EULAR/ACR Points to Consider provide guidance on the initial evaluation, management, and monitoring of patients during the initial consideration of HLH/MAS.

Disclosure of Interests: Bita Shaakyoo: None declared, Ashley Geerlings: None declared, Marta Wijejo: None declared, Kate Kernan: None declared, Erkan Demirkaya: None declared, Angelo Ravel: None declared, Rashmi Sinha: None declared, Raphaele Goldbach-Mansky: Consultant of: SOBI, Novartis, Regeneron, IFM, Lilly, Pfizer, Fabrizio De Benedetti Consultant of: abbiev, sibi, novimmune, novartis, roche, sanofi, Grant/research support from: sibi novimmune novartis roche sanofi, Rebecca Marsh: None declared, Scott Cannsa Consultant of: Simcha Therapeutics, Grant/research support from: Immuvion therapeutics, AB2Bio Ltd, Novartis


POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS

N. Ruperto1, H. Brummer1, A. Berman1, F. Avila Zapata1, G. Hornern1, L. Wagner-Weiner1, A. Beirc1, R. Burgos-Vargas1, M. L. Gármar Gármar10, C. Goldenstein-Schainberg11, M. T. Terrier12, M. Askell13, R. Wong14, A. Martin15, D. J. Lovell16 on behalf of Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative

1Klinikum Stuttgart, Allgemeine und Spezielle Pädiatrie, Stuttgart, Germany; 2Universitätsklinik Freiburg, Zentrum für Kinder- und Jugendmedizin, Freiburg, Germany; 3Kinderärztpaarzugs Gündelfingen, Kinder- und Jugendheumatologie, Gündelfingen, Germany; 4Universitätsklinikum Tübingen, Klinik für Kinder- und Jugendmedizin, Tübingen, Germany

The transition competence of young people with JIA seems to have improved over the last five years. During this time, more transition services were made available for young people with rheumatic diseases. However, most young people are not yet aware of these services. Moreover, the effectiveness of the different measures/interventions has yet to be evaluated.
Background: For children with polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response or intolerance to initial treatment with MTX, treatment options include abatacept. Abatacept, a selective T-cell co-stimulation modulator, has a distinct mechanism of action from other current treatments for rheumatic diseases, and factors predicting clinical response can help determine optimal treatment strategy. Two phase 3 studies demonstrated the efficacy and safety of IV and SC abatacept in patients with pJIA and an inadequate response to other DMARDs.

Objectives: To determine baseline and post-baseline factors that may predict a clinical response in children and adolescents with pJIA treated with abatacept for 2 years.

Methods: Baseline demographic and disease characteristics and post-baseline factors (50% and 70% improvement in ACR criteria [ACR50, ACR70] at days 57 and 85) were analyzed using data from 2 phase 3 studies of abatacept treatment, both time to JADAS10-CRP ID and time to JADAS10-CRP remission were predicted (nominal ≤ 0.05) by age (≤ 11 years: hazard ratio 2.05 [95% CI, 1.45–2.91]) and SC route of administration (HR, 2.05 [95% CI, 1.35–3.10], respectively), Parient/Parental Global Assessment of well-being (≤ 35.86: HR, 1.88 [95% CI, 1.41–2.51]) and ≥ 43.16: HR, 2.05 [95% CI, 1.35–3.10], respectively), and Childhood HAQ-DI (CHAQ-DI; ≤ 0.63: HR, 2.23 [95% CI, 1.47–3.39] and ≤ 0.75: HR, 1.84 [95% CI, 1.24–2.73], respectively) (remission data shown in Figure 1). Disease duration ≤ 2 years from baseline (HR, 1.66 [95% CI, 1.25–2.21]) and SC route of administration (HR, 2.05 [95% CI, 1.45–2.91]) also predicted ID. Among the post-baseline factors, ACR50 at days 57 and 85 predicted both ID (HR, 1.57 [95% CI, 1.04–2.36] and HR, 1.88 [95% CI, 1.41–2.51], respectively) and remission (HR, 1.96 [95% CI, 1.11–3.45] and HR, 3.05 [95% CI, 1.47–6.34], respectively); ACR70 at day 57 also predicted ID (data not shown). Patients with predictive factors for age, hsCRP Parent/Parental Global Assessment of well-being, and CHAQ-DI, and with lower disease activity achieved ID and/or remission earlier than patients with high disease activity.

Conclusion: We identified baseline and post-baseline factors that predicted JADAS10-CRP ID and remission in patients with pJIA treated with abatacept for 2 years. Screening of abatacept-treated patients with pJIA for such factors may help predict earlier achievement of ID and/or remission.

References:

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Writing and editorial assistance were provided by Candice Judith Dcosta, MSc, of Caudex, funded by Bristol Myers Squibb. We would like to acknowledge Mara Becker, Duke Clinical Research Institute, Durham, NC, USA, for her contribution to the study analysis.

Disclosure of Interests: Nicolina Ruperto Speakers bureau: Honoraria for consultants or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Bristol Myers Squibb, Cambridge Healthcare Research, Celygen, Domain Therapeutic, Eli Lilly, EMD Serono, GlaxoSmithKline, Idiosa, inMed, Janssen, Novartis, Pfizer, Sobi, UCB, Consultant of: Honoraria for consultants or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Bristol Myers Squibb, Cambridge Healthcare Research, Celygen, Domain Therapeutic, Eli Lilly, EMD Serono, GlaxoSmithKline, Idiosa, inMed, Janssen, Novartis, Pfizer, Sobi, UCB, Hermine Breuner Speakers bureau: GlaxoSmithKline, Novartis, Pfizer, Consultant of: AbbVie, AstraZeneca-Medimmune, Biogen, Boehringer, Bristol Myers Squibb, Celygen, Cerocor, Eli Lilly, EMD Serono, F. Hoffmann-La Roche, GlaxoSmithKline, Idiosa, Janssen, Merck, Novartis, R-Pharm, Sanofi, Grant/research support from: The Cincinnati Children’s Hospital, where HRB works as a full-time employee, has received contributions from the following industries in the past 3 years: Bristol Myers Squibb, F. Hoffmann-La Roche, Janssen, Novartis, and Pfizer. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment to third parties, Alberto Berman Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Lilly, Novartis, Pfizer, Roche, Francisco Avila Zapata: None declared, Gerd Hornfell Speakers bureau: AbbVie, Chugai, Janssen, Novartis, Pfizer, Grant/research support from: AbbVie, Chugai, MSD, Novartis, Pfizer, Roche, Linda Wagner-Weiner Grant/research support from: Abbott, Bristol Myers Squibb, Merck, Pfizer, UCB, Alexander Belot Speakers bureau: Chugai, GlaxoSmithKline, Novartis, Roche (punctual scientific intervention), Grant/research support from: Boehringer Ingelheim, Merck (joint research project), Ruben Burgos-Vargas: None declared, Maria Luz Gamir Gamar: None declared, Claudia Goldenstein-Schanberg Speakers bureau: AbbVie, Chugai, Janssen, Novartis, Pfizer, Consultant of: AbbVie, Janssen, Novartis, Maria T. Terrier: None declared, Margarita Askelson Consultant of: Acerta Pharma, Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Robert Wong Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Alberto Martini Consultant of: AbbVie, Eli Lilly, EMD Serono, Idiosa, Janssen, Novartis, Pfizer, Daniel J Lowell Consultant of: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman LaRoche, Novartis, UBC (all contracts with employer, CCHMC), Grant/research support from: Bristol Myers Squibb, Janssen, Pfizer, Roche (all contracts with employer, CCHMC); NIH grants: NIAMS, NICHD


POSO341 CONSENSUS-DRIVEN DEFINITION FOR UNEQUIVOCAL SACROILIITIS ON RADIOGRAPHS IN JUVENILE SPONDYLOARTHRITIS

P. P. Weiss1,2, T. G. Brandon1, R. G. Lambert1, D. M. Biko1,2,3, N. A. Chauvin1, M. L. Francavilla1,4,5, N. Herregods1, A. M. Hendry2, W. P. Makemorewicz2, P. Caudex,1,2,3,4,5,6,7,8,9,10

1Perelman School of Medicine at the University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, United States of America; 2Children’s Hospital of Philadelphia, Department of Pediatrics, Division of Rheumatology, Philadelphia, United States of America; 3University of Alberta, Department of Radiology and Diagnostic Imaging, Edmonton, Canada; 4University of Pennsylvania, Department of Radiology, Philadelphia, United States of America; 5Children’s Hospital of Philadelphia, Department of Radiology, Philadelphia, United States of America; 6Penn State Health, Department of Radiology, Hershey, United States of America; 7Ghent University Hospital, Department of Radiology and Nuclear Medicine, Ghent, Belgium; 8Middlemore Hospital, General Medicine - (Incl. Obstetric Medicine and Adult Rheumatic Fever), Auckland, New Zealand; 9University of Alberta, Department of Medicine, Edmonton, Canada

Background: Radiographs are not a sensitive or reliable imaging tool for detection of early sacroiliitis in juvenile spondyloarthritis (JSaPa). However, radiographs are still commonly performed in some areas due to difficulty in accessing MRI. As such, radiographs were included in the imaging data considered for an axial disease classification criteria development study, but only when there was no suitable MRI available.

Objectives: We aimed to define criteria for unequivocal evidence of sacroiliitis on pelvic radiography in skeletally immature children and adolescents for use in classification criteria.

Methods: Subjects were a cohort of JSaPa patients with suspected axial disease. All subjects had symptom onset prior to age 18 years and underwent MRI as part of a diagnostic evaluation for axial disease; a subset of subjects also had a dedicated pelvic radiograph. Using a web-based interface, 6 musculoskeletal imaging experts, blinded to clinical details, reviewed the radiographs and graded them according to the modified New York (mNY) criteria. A two-way random effects intraclass correlation coefficient (ICC) was used to assess agreement. Next, the central imaging team underwent an iterative consensus process to define unequivocal evidence of sacroiliitis on pelvic radiography in skeletally immature children. Radiographs with at least two raters assigning a non-zero mNY grade were re-reviewed for the presence/absence of "unequivocal evidence of sacroiliitis" according to the consensus definition. Agreement was assessed with Fleiss’s kappa statistic with agreement interpreted as poor ≤0.40, fair 0.41-0.59, good 0.60-0.74, and ≥0.75 excellent. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) were calculated to assess performance of the novel definition using structural lesion typical of juvenile axial disease on MRI as the reference standard (erosion in ≥3 sacroiliac joint (SIJ) quadrants or at least one of the following lesions in ≥2 SIJ quadrants: sclerosis, fat lesion, backfill, ankylosis).

Results: Radiographs from 120 subjects, 61% male, median age 14.7 years (range 6.7-20.1 years), had an AP dedicated pelvic radiograph available for scoring. The ICC for mNY grade amongst 6 central raters was 0.80 (95% CI: 0.63-0.90). After multiple iterations and discussion, the consensus definition of unequivocal sacroiliitis by radiograph in skeletally immature children and adolescents was deemed "Unequivocal lesion (erosion, sclerosis, or ankylosis [partial or complete]) that must include at least one iliac bone. When sclerosis is present in isolation, if measurable, should extend ≥5mm from the joint surface. The decision may be influenced by the presence of other lesions, which in themselves do not suffice to meet the criterion." Sixteen radiographs were assessed using the consensus definition. 8 (50%) were rated as unequivocal sacroiliitis and Fleiss’ kappa statistic was good at 0.61 (95% CI: 0.41-0.80). Across raters, the sensitivity, specificity, PPV and NPV of the consensus definition on radiograph using structural lesions typical of sacroiliitis on MRI as the reference standard were 80% (95%CI: 44.4-97.5), 100% (95% CI: 54.1-100), 100% (95% CI: 54.1-100), 100% (95% CI: 54.1-100), 100% (95% CI: 54.1-100) and 75% (95% CI:33.9-96.8), respectively.

Conclusion: We propose a consensus-defined definition of unequivocal sacroiliitis by radiography in skeletally immature children and adolescents with good expert rater agreement. Additionally, the consensus-definition had moderate to high sensitivity and PPV and high specificity and NPV with typical structural lesions typical of sacroiliitis on MRI as the reference standard.

Disclosure of Interests: Pamela F. Weiss Consultant of: Pfizer
Biogen
Lilly
(All < $5k in the past fiscal year), Timothy G. Brandon: None declared, Robert G Lambert Paid instructor for: Novartis, Consultant of: CARE Arthritis, Calyx, Image Analysis Group, Novartis, David M. Biko Employee of: Merck (1998 to 2000), Nancy A. Chauvin Employee of: Forest Pharmaceuticals - Research scientist (1996) and Novartis - Pharmaceutical sales representative (1997), Michael L. Francavilla: None declared, Nele Herregods: None declared, Alison M. Hendry: None declared, Walter P Maksymowycz Speakers bureau: Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB Pharma, Grant/research support from: Abbvie, Novartis, Pfizer

Figure 1. Examples of radiographs with unequivocal evidence of sacroiliitis in skeletally immature children as indicated by definite erosions of both iliac bones (A and B) and definite iliac sclerosis (A).

Table 1. Rate of flare and duration related to aTNF between short- and long-weaning groups

<table>
<thead>
<tr>
<th>FLARE</th>
<th>Total (n=105)</th>
<th>Short (n=56)</th>
<th>Long (n=49)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of JIA patients flared during treatment (n=97)</td>
<td>24 (22.9)</td>
<td>9 (0.0)</td>
<td>24 (49.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Time to flare during aTNF weaning after starting (month)*</td>
<td>6.5 (4.5-14.5)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of JIA patients flared after DC aTNF (%)</td>
<td>50 (47.6)</td>
<td>34 (60.7)</td>
<td>16 (32.7)</td>
<td>0.004</td>
</tr>
<tr>
<td>Time to flare after stopping aTNF (month)*</td>
<td>6.2 (2.7-11.8)</td>
<td>6.9 (5.5-11.6)</td>
<td>0.270</td>
<td></td>
</tr>
<tr>
<td>Total number of patients who flared aTNF (%)</td>
<td>68 (64.8)</td>
<td>34 (60.7)</td>
<td>34 (69.4)</td>
<td>0.353</td>
</tr>
</tbody>
</table>

*Median (interquartile range), †included 6 patients who flare during weaning and after stopping aTNF, aTNF = anti-tumour necrosis factor

Figure 1. Examples of radiographs with unequivocal evidence of sacroiliitis in skeletally immature children as indicated by definite erosions of both iliac bones (A and B) and definite iliac sclerosis (A).
Conclusion: Duration of spacing out the aTNF therapy after achieving ROM may not minimize the flare rate or delay time to flare after stopping the therapy in JIA patients. Further validation in larger multinational longitudinal cohorts is required to confirm our initial findings.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3484

POS0343 TREATMENT PERSISTENCE AND ADHERENCE AMONG PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS RECEIVING ABATACEPT OR TNF INHIBITORS USING US CLAIMS DATA


Objectives: To evaluate treatment persistence and adherence at 12- and 18-month follow-up in patients with JIA newly initiating either abatacept or a TNF.

Methods: This analysis used data from the IQVIA PharMetrics Plus claims database from Jan 2008–Apr 2021. We identified patients with ≥ 1 claim of abatacept or TNFi treatment (adalimumab, etanercept, ≥ 12 months before index date, patients receiving abatacept or TNFi treatment ≤ 12 months prior to index date and patients initiating combined abatacept + TNFi treatment on the index date were excluded. Specific outcomes included: discontinuation (absence of a new prescription for index treatment within the gap of 5x treatment half-life), persistence rate (proportion of patients continuing index medication without any gaps exceeding 5x treatment half-life), and treatment adherence (defined as medication possession ratio [MPR, proportion of follow-up period where medication supply is available] and proportion of days covered [PDC, proportion of follow-up period where a patient is covered by a given drug]). All outcomes were reported at 12 and 18 months. All statistical analyses are descriptive with the intent for hypothesis generation.

Results: There were 2847 patients (abatacept, n = 111; TNFi, n = 2736) at 12-month follow-up; fewer completed the 18-month follow-up (2403 patients: abatacept, n = 94; TNFi, n = 2309). At index date, treatment groups were similar for sex, geographic location, and comorbidities (Table 1). Numerically higher persistence was observed in patients prescribed abatacept compared with TNFi overall at both time points. Abatacept persistence was higher than etanercept but similar to adalimumab (Figure 1). At 12 months, the percent of patients with PDC ≥ 0.8 was 57% for abatacept, 51% for adalimumab, and 38% for etanercept, while MPR ≥ 0.8 was 63% for abatacept, 55% for adalimumab, and 42% for etanercept. Patients prescribed abatacept had numerically greater proportions of PDC ≥ 0.8 (abatacept, 48%; adalimumab, 40%; etanercept, 29%) and MPR ≥ 0.8 (abatacept, 53%, adalimumab, 44%, etanercept, 33%) at 18 months.

Table 1. Baseline characteristics of patients with 12-month follow-up data

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Abatacept (n = 111)</th>
<th>TNFi (n = 2736)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>14.4 (3.8)</td>
<td>12.6 (4.6)</td>
</tr>
<tr>
<td>Female sex</td>
<td>89 (80.2)</td>
<td>1930 (70.5)</td>
</tr>
<tr>
<td>Geographic region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>43 (38.7)</td>
<td>865 (31.6)</td>
</tr>
<tr>
<td>Midwest</td>
<td>40 (36.0)</td>
<td>818 (29.9)</td>
</tr>
<tr>
<td>West</td>
<td>9 (8.1)</td>
<td>408 (14.9)</td>
</tr>
<tr>
<td>East</td>
<td>19 (17.1)</td>
<td>540 (19.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0 (0)</td>
<td>105 (3.8)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>9 (8.1)</td>
<td>275 (10.1)</td>
</tr>
<tr>
<td>COPD</td>
<td>11 (9.9)</td>
<td>323 (11.8)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>14 (12.6)</td>
<td>222 (8.1)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>14 (12.6)</td>
<td>321 (11.7)</td>
</tr>
<tr>
<td>Iridocyclitis</td>
<td>12 (10.8)</td>
<td>216 (7.9)</td>
</tr>
<tr>
<td>CCI score, mean (SD)</td>
<td>0.58 (0.73)</td>
<td>0.46 (0.68)</td>
</tr>
</tbody>
</table>

Data are shown as n (%) unless otherwise specified. *Subgroup disease under uveitis. CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease.

Conclusion: The present findings suggest that patients with JIA initiating abatacept treatment display numerically higher persistence and adherence compared with patients treated with TNFIs at both 12- and 18-months’ follow-up.

REFERENCES:


Acknowledgements: This study was sponsored by Bristol Myers Squibb. Medical writing and editorial assistance were provided by Ryan Miller, of Caudex, and were funded by Bristol Myers Squibb. Project analysis was provided by Akshay Vinod (Mu Sigma).


DOI: 10.1136/annrheumdis-2022-eular.1289

Figure 1. Cumulative probability of flare between the short- and long-weaning group after discontinuing aTNF therapy

Table 1. Baseline characteristics of patients with 12-month follow-up data

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Abatacept (n = 111)</th>
<th>TNFi (n = 2736)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>14.4 (3.8)</td>
<td>12.6 (4.6)</td>
</tr>
<tr>
<td>Female sex</td>
<td>89 (80.2)</td>
<td>1930 (70.5)</td>
</tr>
<tr>
<td>Geographic region</td>
<td></td>
<td></td>
</tr>
<tr>
<td>South</td>
<td>43 (38.7)</td>
<td>865 (31.6)</td>
</tr>
<tr>
<td>Midwest</td>
<td>40 (36.0)</td>
<td>818 (29.9)</td>
</tr>
<tr>
<td>West</td>
<td>9 (8.1)</td>
<td>408 (14.9)</td>
</tr>
<tr>
<td>East</td>
<td>19 (17.1)</td>
<td>540 (19.7)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0 (0)</td>
<td>105 (3.8)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>9 (8.1)</td>
<td>275 (10.1)</td>
</tr>
<tr>
<td>COPD</td>
<td>11 (9.9)</td>
<td>323 (11.8)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>14 (12.6)</td>
<td>222 (8.1)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>14 (12.6)</td>
<td>321 (11.7)</td>
</tr>
<tr>
<td>Iridocyclitis</td>
<td>12 (10.8)</td>
<td>216 (7.9)</td>
</tr>
<tr>
<td>CCI score, mean (SD)</td>
<td>0.58 (0.73)</td>
<td>0.46 (0.68)</td>
</tr>
</tbody>
</table>

Data are shown as n (%) unless otherwise specified. *Subgroup disease under uveitis. CCI, Charlson Comorbidity Index; COPD, chronic obstructive pulmonary disease.
Novel molecular regulators of bone turnover.

**POSS0344**

O-GlcNAcylation on NUP153 regulates the early stages of osteoclastogenesis through MYC nuclear translocation

Y. N. Li1, C. W. Chen1, T. Trinh-Minh1, Z. Honglin2, P. Hubel1, J. Pfannstiel3, G. Schett4, J. H. W. Distler3. 1University Hospital Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany; 2Xiangya Hospital, Central South University, Department of Rheumatology, Changsha, China; 3University of Hohenheim, Core Facility Hohenheim, Stuttgart, Germany

**Background:** Bone homeostasis is maintained by the balance between bone formation and resorption. In inflammatory arthritis, such as rheumatoid arthritis (RA), the pro-inflammatory environment promotes osteoclast differentiation and skews this balance towards bone resorption, leading to destructive bone erosion and bone loss. O-GlcNAcylation is one of the most common post-translational modifications, which attaches a single N-acetylglucosamine (GlcNAc) moiety to the serine or threonine of the target protein. O-GlcNAcylation is controlled by the activities of a single pair of enzymes: OGT, which facilitates de-O-GlcNAcylation of the target protein, and O-GlcNAcase, which removes GlcNAc from proteins. The activity of O-GlcNAcylation has been reported to be involved in several cellular events, such as transcription, translation, intracellular trafficking, and differentiation. We previously showed that the dynamics of O-GlcNAcylation are essential for osteoclast differentiation. TNF-α, a key pro-inflammatory factor in RA, intensifies the O-GlcNAcylation dynamics. Inhibition of OGT arrests osteoclast precursors at early stages, whereas OGA inhibition blocks osteoclast differentiation. However, the molecular mechanism of these regulations remains unclear.

**Objectives:** We aimed to identify the O-GlcNAcylation targets in osteoclast precursors in a pro-inflammatory milieu and to decipher the molecular mechanism of O-GlcNAcylation mediated regulation of osteoclastogenesis.

**Methods:** We first identified the O-GlcNAc-dependent molecular pathways in osteoclast precursors with pharmacological OGT and OGA inhibition by RNA sequencing. Then, we identified the O-GlcNAcylated proteins by mass spectrometry-based proteomics analysis and confirmed by immunoprecipitation. We found the potential molecular mechanism by combining the data from transcripomics and proteomics. The proposed mechanism was further validated through siRNA-mediated knockdown and high-content screening analysis.

**Results:** Our transcripomics data showed that OGT inhibition arrested osteoclast differentiation at early stages through interfering the cytokine signaling and metabolic adaption. The upstream analysis proposed MYC as the most potent regulator for the transcripomic profile under OGT inhibition. Recent studies proposed MYC as a master regulator for metabolic reprogramming during osteoclast differentiation. However, O-GlcNAcylation of MYC was not detected by mass spectrometry, suggesting indirect effects of O-GlcNAcylation on MYC signaling in osteoclast precursors. We detected upregulated levels of O-GlcNAc on NUP153, MTDH, RBM27, IFT207 upon RANKL+TNFα stimulation. An integrated analysis of transcripomic and proteomic data by Ingenuity Pathway Analysis indicated that NUP153 might regulate the most DEGs among all the identified targets and indicated potential of NUP153 to regulate nuclear shuttling of MYC. Subcellular fractionation and confocal microscopy showed enhanced MYC nuclear translocation upon RANKL+TNFα stimulation, which could be blocked by NUP153 knockdown or OGT inhibition. Functionally, knockdown of NUP153 arrested cells at similar stages to OGT inhibition and reduced bone resorption ability. Together, these results suggest a model, in which O-GlcNAcylation regulates the shuttling activity of the nuclear pore component NUP153 to control the access of MYC to the nucleus during osteoclast differentiation.

**Conclusion:** Our results indicated that OGT inhibition arrests osteoclastogenesis at early stages through hampering MYC-dependent metabolic adaption. NUP153 was proposed as the most potent O-GlcNAcylated target by multi-omics data integration. NUP153-mediated MYC nuclear trafficking is required for osteoclast differentiation. These findings reveal the molecular mechanism of O-GlcNAcylation-dependent osteoclastogenesis and provide therapeutic insights on targeting O-GlcNAcylation in pathologic bone resorption.

**Disclosure of Interests:** Yi-Nan Li: None declared, Chih-Wei Chen: None declared, Thuong Trinh-Minh: None declared, ZHU Honglin: None declared, Philipp Hubel: None declared, Jens Pfannstiel: None declared, Georg Schett: None declared, Jörg H.W. Distler: Shareholder of: 4D Science, Speakers bureau: Boehringer Ingelheim, Paid instructor for: Boehringer Ingelheim, Consultant of: Actelion, Active Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB, Grant/research support from: Anamar, Active Biotech, Array BioPharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB, Employee of: FibroCure DOi: 10.1136/annrheumdis-2022-eular.1161

**POSS0345**

Assessment of the effect of tofacitinib on bone marrow adipocytes and bone-forming osteoblasts under non-inflammatory and inflammatory conditions

**Background:** Systemic inflammation is the main factor underlying secondary osteoporosis in patients with rheumatoid arthritis (RA). The JAK inhibitors, such as Tofacitinib (Tofa), can control systemic inflammation and have beneficial effects on bone in various models. This might be due to direct effects on the bone microenvironment and not exclusively based on their anti-inflammatory function. Bone marrow adipocytes (BMA) are abundant in the bone microenvironment. The effect of JAK inhibitors on BMA is unknown, but evidence suggests that there is competition between human bone marrow-derived stromal cell (hBMSCs) differentiation routes towards BMA and osteoblasts (Ob) in osteoporosis.

**Objectives:** To determine in various models whether Tofa influences directly human cell commitment toward adipogenesis and osteoblastogenesis. Then, in a prospective pilot study, to investigate the potential effects of Tofa on bone marrow adiposity in patients with RA.

**Methods:** To study the effect of Tofa on cellular commitment, hBMSCs were cultured for 3 days in appropriate Ob- and BMA- differentiation media (Ob-3d and BM-3d), together with Tofa at 200, 400 (equivalent to a therapeutic dose of 5mg twice a day in RA patients) or 800 nM. To mimic inflammatory conditions, TNFα was added to the media at a dose of 1 ng/ml. This study was also conducted on mature BMAs and a similar treatment was applied for 6 days to mature BMA at 14 days of differentiation (BMA-20d). The impact of Tofa was determined by gene expression profile analysis, western-blot analysis and cell density monitoring. In parallel, in a pilot study of 9 RA patients treated with Tofa 5mg twice a day (TOFAT study; NCT04175886), proton density fat fraction (PDDF) was measured by MRI (Dixon technique) at the lumbar spine at the start of treatment and at 6 months.

**Results:** In non-inflammatory conditions, the gene expression of Runx2 decreased in Ob-3d treated with Tofa 400 and 800nM (p<0.05). Conversely, BMA-3d treated with Tofa (at 200, 400 and 800 nM) exhibited a substantial increase in the gene expression of PPARγ2 (the master regulator associated with lipid droplet formation) compared to controls (p<0.05). The increase in the expression of PPARγ2 was also confirmed at the protein level. In inflammatory conditions, BMA-3d and Ob-3d markers decreased considerably (PPARγ2 and RUNX2, respectively, p<0.05), but the addition of Tofa did not change the expression profiles of Ob-3d compared to TNFα controls. On the contrary, the analysis of PPARγ2 gene expression showed that Tofa limited the negative effect of TNFα on BMA differentiation (p<0.05). The positive effect of Tofa on mature adipocyte (BMA-20d) under inflammatory conditions was also supported by an increase in the density of differentiated BMAs (p<0.001). These findings were consolidated by an increase in PDDF at 6 months of treatment with Tofa in RA patients (+6.9%, p<0.01).

**Conclusion:** Overall, in vitro and clinical results suggest a stimulatory effect of Tofa on BMAs commitment and differentiation, which does not support a positive effect of Tofa on bone.

Background: The Paget's disease of Bone (PDB) is characterized by a chronic and focal disorder of bone remodeling. PDB is currently considered a complex and multifactorial disease, as a result of a synergistic association of genetic variants with environmental risk factors. The genetic component would explain certain epidemiological traits such as the predisposition to develop in certain ethnic groups and the strong tendency to family aggregation. The most important susceptibility gene for PDB is the Sequestosome-1 (SQSTM1) gene, which encodes a 440-amino-acid protein called p62 protein. SQSTM1 gene occurs in between 20 and 40% of patients with a family history of PDB, and 5 and 10% of patients with sporadic disease, according to the series studied. Thus far, 29 SQSTM1 mutations have been identified in patients with PDB.

Methods: The molecular study was carried out by sequencing the SQSTM1 gene (p62) in a population of 200 PDB affected patients and 200 hypernormal controls. An "in silico" functional analysis of the different genetic variants was performed using the information provided by the splicing prediction algorithms, the miRNA target prediction algorithms, the gene-specific algorithms for predicting pathogenicity (SIFT, PolyPhen, PMut) and the interspecific evolutionary conservation study. The statistical analysis was performed using SPSS statistical software Windows (v23) and the R software version 2.15.0 for Windows. The study was approved by the CEC (Hospital del Mar-Parc de Salut Mar (2007/2885/I)) and all participants signed an informed consent agreeing to participate in the study.

Results: The 27% of the PDB affected patients were carriers of different gene SQSTM1 mutations, being the most frequent identified the p.P392L, described in the 20% of cases. In terms of genotype-phenotype relation, being a carrier of gene SQSTM1 mutations is associated to a more severe phenotype based on a greater disease activity and a greater extent at diagnosis as well as higher complications during the course of it, without the presence of an associated familial history positive. In our patient cohort 17 mutations have been identified in coding regions of the SQSTM1, with six newly described "missense" genetic variants (p.R161W, p.H163Y, p.K238E, p.G262R, p.E274D,p.G405S), all of them associated to a greater susceptibility in the development of PDB and distributed in the different structural and functional domains of the p62 protein, being able to cause dysfunctions in the different cell signalling processes where intervenes apoptosis, autophagy, proteic degradation through the ubiquitin-proteasome system, the regulation of antioxidant response and the cell survival mediated by RANK-TRAF6-NF-kB signaling pathway), implicated in the pathogenesis of Paget's disease of bone.

Conclusion: In the molecular study of the SQSTM1 gene, seventeen mutations were identified in the coding regions of the gene, being six "missense" genetic variants of new description, associated all of them to a higher risk of developing PDB and distributed in different structural and functional domains of the p62 protein.

Disclosure of Interests: None declared, Adeline Ruyssen-Witrand: None declared, Carle Paul: None declared, This work has been supported by a Novartis grant, Arnaud Constantin: None declared, Patrice Dubreuil: None declared, Cristina Bulai Livideanu: None declared

Background: Osteoporosis is a mineral bone disease arising from the pre-dominance of osteoclastic bone resorption. Bisphosphonates which inhibit osteoclasts are commonly used in osteoporosis treatment, but are not without severe adverse effects like osteonecrosis of the jaw. The mechanisms behind the development of such phenomena is not well understood. Bone homeostasis is achieved through an intimate cross-talk between osteoclasts and osteoblasts. Thus, it is important to visualise activities of these cells simultaneously in situ. Currently, there are means to visualise osteoclast shape and numbers with tartrate-resistant alkaline phosphatase (TRAP) staining but no practical and accurate methods to quantify osteoclast activity in situ.

Objectives: This investigation aims to establish the use of ELF97, a substrate of TRAP, to visualise and quantify osteoclast activity. This provides vital clues to mechanisms of various bone disorders. TRAP dephosphorylation of ELF97 results in a detectable fluorescent product at areas of osteoclast activity.

Methods: Osteoclastic activity was initiated in zebrafish by inducing crush injuries in tail fin rays. Colocalisation of ELF97 fluorescence with osteoclast-specific DsRed in transgenic zebrafish, visualised under confocal microscopy, is used to further establish the specificity of ELF97 to sites of osteoclastic activity. Quantification is established by comparing fluorescence between wild type, osteoclast-deficient mutants and bisphosphonate-treated zebrafish. The utility of ELF97 will also be investigated in terms of the stability of the fluorescent product.

Results: The investigation revealed that ELF97 and DsRed fluorescence were found commonly at crush sites with osteoclastic activity. Wild type zebrafish had greater fluorescence compared to osteoclast-deficient (p<0.0001) and bisphosphonate-treated zebrafish (p<0.0001) after 7 and 14 days post-crush, revealing that fluorescence from ELF97 corresponds to expected osteoclastic activity. Fluorescence of tail fins treated with ELF97 did not diminish over a period of 21 days of storage, demonstrating its stability.

Conclusion: ELF97 is thus a useful means to visualise osteoclast activity, potentially crucial in more advanced investigations to understand bone disorders. It could be used in combination with other cellular markers in whole biological samples to study and experimentally manipulate bone remodelling.

Disclosure of Interests: None declared


POS0349
decoy receptor 3 and its signal pathway contribute to pathogenesis in primary gouty arthritis

Y. Jiang1, X. Liao1, S. B. Wang1, Y. X. He1, Y. F. Qing1 on behalf of Institute of Research Center of Gout and Hyperuricemia of the Affiliated Hospital, North Sichuan Medical College. 1Affiliated Hospital of North Sichuan Medical College, Department of Rheumatology, Nanchong, China

Background: Gouty arthritis (GA) is an autoimmune disease caused by the deposition of monosodium urate crystal (MSU) in the joints and surrounding tissues which lead to a series of complex inflammatory reactions and amplification reactions. The clinical symptoms of acute GA attack rapidly, but often alleviate spontaneously within 7 – 10 days, which is one of the significant characteristics different from other joint diseases or autoimmune diseases. However, the exact molecular mechanism of its inflammatory self limitation is still unclear. The biomechanical imbalance of Th1 / Th2 cells and the M1/ M2 polarization of macrophages may be involved in the inflammatory self limitation of gout[1]. Decoy receptor 3 (DCR3) can differentiate T cells into Th2 phenotype, promote M2 polarization of macrophages, and play the functions of immune regulation and repair[2]. DCR3 and its Signal Pathway are involved in the pathogenesis of tumors and a variety of autoimmune diseases, and have become an important research target of tumors and immune related diseases. However, studies on DCR3 related molecular pathway and GA are scarce, and the specific regulatory mechanism is unknown.

Objectives: To assess the contribution of DCR3 and its signal pathway to gout and the clinical importance of these genes in primary gouty arthritis.

Methods: The mRNA expression levels of DCR3 and its signal pathway (DR3, TL1A, Fas, Fasl, Ligh, Light, LtghtRNA) expression levels of DCR3 and its signal pathway (DR3gout and the clinical importance of these genes in primary gouty arthritis.nt research target of tumors and immune related diseases. However, studies on DCR3 related molecular pathway expression levels and laboratory features was analyzed in GA patients.

Results: The expression levels of DCR3, FasL were much lower in the AG and IG group than in the HC groups (p<0.05), and no significant difference was detected between AG and IG group than in the HC groups (p<0.05). The expression levels of DCR3 were much lower in the AG and IG group than in the HC groups (p<0.05), and much lower in the AG group than in the IG groups (p<0.05). The expression levels of TL1A were much higher in the AG group than in the IG and HC groups (p<0.05), and no significant difference was detected between IG and HC groups (p<0.05). The expression levels of Light, LightR were much lower in the AG group than in the HC groups (p<0.05), and no significant difference was detected between AG and IG groups, IG and HC groups (p<0.05). The expression levels of LtghtRNA were much higher in the AG group than in the HC groups (p<0.05), and no significant difference was detected between AG and IG groups, IG and HC groups (p>0.05). In GA patients, the levels of DcR3 related molecular pathway gene correlated with laboratory inflammatory and metabolic indexes.

Conclusion: Altered DCR3 and its signal pathway expression suggests that DCR3 related molecular pathway is involved in the pathogenesis of GA and participates in regulating inflammation and metabolism.

REFERENCES:

Acknowledgements: Institute of Research Center of Gout and Hyperuricemia of the Affiliated Hospital, North Sichuan Medical College

Disclosure of Interests: None declared


POS0350
micrornas associated with osteoporosis in patients with haemochromatosis arthropathy

S. Finzel1, A. Diendorfer2, B. Butzek3, M. Hackl2, R. Voltz, 1Freiburg im Breisgau, Department of Rheumatology and Clinical Immunology, University Medical Centre, Freiburg im Breisgau, Germany; 2TAmiRNA GmbH, Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria; 3Hämoblastose-Vereinigung Deutschland e. V, HVD, European Federation of Associations of Patients with Haemochromatosis EFAPH, Hattingen, Germany; 4Freiburg im Breisgau, Department of Rheumatology and Clinical Immunology, University Medical Centre, Freiburg im Breisgau, Germany

Background: Haemochromatosis arthropathy (HA) is one of the most frequent manifestations of hereditary haemochromatosis (HH). Moreover, frequency of osteoporosis is increased in HH. MicroRNAs (miRNAs) are small non-coding RNAs involved in gene silencing, and onset and progression of disease is often reflected in aberrant miRNA expression patterns including osteitis and osteoporosis. Active or passive release of miRNAs from cells enables minimal-invasive detection in biofluids such as plasma (“circulating miRNAs”).

Figure 1. Relative Expression of DcR3 related molecular pathway gene in the PBMCs of Patients. The expression levels of DCR3, FasL were much lower in the AG and IG group than in the HC groups (p<0.05). The expression levels of DCR3 were much lower in the AG and IG group than in the HC groups (p<0.05), and much lower in the AG group than in the IG groups (p<0.05). The expression levels of TL1A were much higher in the AG group than in the IG and HC groups (p<0.05). The expression levels of Light, LightR were much lower in the AG group than in the HC groups (p<0.05). The expression levels of LtghtRNA were much higher in the AG group than in the HC groups (p<0.05).

Acknowledgements: Institute of Research Center of Gout and Hyperuricemia of the Affiliated Hospital, North Sichuan Medical College

Disclosure of Interests: None declared

OBJECTIVES: We aimed to investigate whether circulating miRNAs involved in osteoporosis as well as liver disease in healthy elderly individuals are also elevated in patients with HH.

METHODS: Plasma of 28 HA patients homozygous for C282Y (60.71% female), 8 HA patients heterozygous for C282Y (50% female), and 12 controls (66.67% female), was analyzed using the osteomiR and the hepatomiR RT-qPCR kits. Levels were normalized using spike-in controls and non-parametric analyses were performed to associate miRNAs to other clinical parameters and test for differential regulation of miRNAs between the groups.

RESULTS: Even though mean age was different between the three groups (70.64, 52.38, 61.92 years), correlation analysis identified only weak or no associations to miRNA levels. In patients with osteoporosis (n=9, all female, all homozygous) miR-203a-3p, 214-3p (both bone-related), and 122-5p (liver-related) were significantly downregulated (Kruskal Wallis p=0.024, p=0.037, and p=0.00024). Interestingly, miR-122-5p also showed a clear trend for down-regulation in homozygous HH compared to heterozygous HH and controls (p=0.087).

CONCLUSION: This is the first study reporting miRNAs involved in osteoporosis and liver diseases in patients homozygous for C282Y.

DISCLOSURE OF INTERESTS: None declared


POSO351 NEITHER ANTI-CITRULLINATED PROTEIN ANTI-BODIES (ACPA) NOR POLYCLONAL lgG ARE ASSOCIATED WITH BONE MASS, IN ELDERLY MEN

M. Nurkkala1, M. Lagerquist1, P. Gupta1,2, D. Mellström1, C. Ohlsson1, C. Engdahl1,2, 1University of Gothenburg, CBU, Dept. of Rheumatology and Immunisation, Göteborg, Sweden; 2University of Gothenburg, CBU, Dept. of Internal Medicine, Göteborg, Sweden

BACKGROUND: Bone loss is associated with anti-citrullinated protein antibodies (ACPA) positivity in rheumatoid arthritis (RA) patients. This is shown in both in pre-clinical RA, and in more pronounced bone loss in serum positive patients compared to serum negative patients. Further, both ACPA and activated IgG stimulate osteoclastogenesis in vitro and in murine arthritis-mediated bone loss.

OBJECTIVES: Whether polyclonal IgG or autoantibodies are important for general bone architecture, and not only in arthritis-mediated bone loss, has not been determined but they may represent an important link between the immune system and bone.

METHODS: Polyclonal IgG and ACPA were measured with ELISA in serum of 600 elderly men (mean age 80.2±3.5 years), in the cohort MoS Gothenburg. In this cohort, bone was investigated with Dual-energy-x-ray absorptiometry (DXA) and high-resolution 3D peripheral quantitative computed tomography (HR-pQCT). In C57/Bl6 mice, high dose heat-activated polyclonal IgG was repetitively injected systemically or intraarticularly, and the bone was investigated with DXA and micro-CT.

RESULTS: No association was determined between existing serum polyclonal IgG and ACPA, with the measured bone parameters, not total bone density, trabecular or cortical bone in the MoS cohort. Systemic injection of activated IgG in mice did not affect general bone health, not total, trabecular, or cortical bone. Intraarticular injection of activated IgG was shown to give a local reduction in trabecular bone density of the tibia.

CONCLUSION: These data indicate that serum polyclonal IgG and ACPA do not influence general bone health in elderly men. However, in mice injection with activated IgG intraarticularly leads to a local reduction in trabecular bone mass. In conclusion, our data imply that ACPA and activated IgG need to be present in close connection to the bone, e.g., in the synovial area, to be able to mediate a reduction in bone mass.

DISCLOSURE OF INTERESTS: Merja Nurkkala: None declared, Marie Lagerquist: None declared, Priti Gupta: None declared, Dan Mellström: None declared, Claes Ohlsson Grant/research support from: Novo Nordisk, Cecilia Engdahl: None declared


PARE Poster Tour 2

POSO352-PARE PODCAST FOR RHEUMATISM SUFFERERS AND THEIR RELATIVES

M. Sibert1, T. Spichtig1, 1Swiss League Against Rheumatism, Communication, Zurich, Switzerland; 2Swiss League Against Rheumatism, Communication & Fundraising, Zurich, Switzerland

BACKGROUND: Two million people in Switzerland suffer from rheumatic diseases. The Swiss League against Rheumatism is committed to helping those affected. It provides them and their relatives with professional, neutral information on the subject of rheumatism. The Swiss League against Rheumatism has been publishing the podcast series “Rheumatism in person” since 2021. In it, affected people discuss relevant and current topics about living with rheumatism with experts. Another aim is to devote time to the personal experiences of sufferers. The pool of experts includes medical specialists, nutritionists, social counsellors and psychologists.

OBJECTIVES: The Swiss League against Rheumatism, as the national umbrella organisation, is expanding its communication services via the podcast in order to reach even more people with rheumatism in Switzerland. This makes it possible to increasingly address a younger, digital-savvy target group and to expand the service proposed for this target group. The podcasts are primarily aimed at people with chronic forms of rheumatism between the ages of 25 and 50 and their relatives in German-speaking Switzerland. A further aim is to bring the opinions of those affected to the attention of the public, as well as to provide information from specialists, thereby creating greater awareness of the disease.

METHODS: Each podcast episode is about 30 minutes long. According to experience, this length is the most popular with most listeners, whilst also allowing complex topics to be explored in depth. The podcasts are issued monthly. This enables listeners to be prepared for a fixed release date. The episodes are produced in cooperation with a podcast agency. The advantage of an agency lies in its expertise and experience, especially in the technical field. Funding for the podcast episodes can be secured from sponsors.

“When things get complicated – social counselling for rheumatism,” “Sport and rheumatism – anything but a contradiction?” or “Rare forms of rheumatism – lupus, EDS & co.” are popular episode titles, to name but a few.

The podcasts are available on various international podcast platforms. The episodes are distributed via blog posts, existing newsletters and social media (Facebook, Instagram and LinkedIn). External distribution channels are used in the form of the interviewees’ networks, the “Junge mit Rheuma” (young people with rheumatism) group, national patient organisations, cantonal/regional rheumatism leagues, the Swiss Society of Rheumatology and any media coverage attracted.

RESULTS: So far, the eleven episodes and accompanying trailer have been downloaded or streamed over 8,200 times by 5,300 unique listeners.

All eleven topics were of great interest. The episode on “Anti-inflammatory nutrition” generated the most downloads (1,550), closely followed by the episode on “The coronavirus pandemic with rheumatism,” which reached just under 1,300 downloads (as of 21 January 2022). On 15 March 2021, the podcast series also made it onto the podium of a well-known podcast chart in the field of medicine. This clearly shows that there is a need among rheumatism sufferers and their relatives to obtain information via podcasts.

The large quantity of positive feedback from patients, rheumatologists and other health professionals is particularly noteworthy. “From the first second: very interesting topics, well produced and a great voice,” shared a listener.

CONCLUSION: The podcast series has proved successful and will therefore be continued as a complementary communication tool for the Swiss League against Rheumatism. In addition to the episodes already released, another ten episodes are planned in German.

The Swiss League against Rheumatism is keen to extend the podcast series to the French-speaking part of Switzerland. The idea is therefore to include French episodes in 2022. There are specific plans to record three episodes, which will be broadcast in the second half of the year. The aim is to add more episodes to the French podcast series in the long term.

REFERENCES: None

More information: Podcast: Rheuma persönlich - Rheumaliga Schweiz

Disclosure of Interests: Monika Siber Grant/research support from: The Swiss League against Rheumatism has a sponsorship agreement with MSD Merck Sharp & Dohme AG and Pfizer AG for the production of the podcasts. The two companies have no influence on the content of the podcast. Tina Spichtig Grant/research support from: The Swiss League against Rheumatism has a sponsorship agreement with MSD Merck Sharp & Dohme AG and Pfizer AG for the production of the podcasts. The two companies have no influence on the content of the podcast.

THE POLITICAL WORK FOR BETTER TREATMENT OF MUSCULOSKELETAL DISEASES IN DANISH MUNICIPALITIES

K. Hammendon1 on behalf of The Danish Rheumatism Association, 1The Danish Rheumatism Association, Department for Politics and Knowledge, Gentofte, Denmark

Background: Historically most treatment of musculoskeletal diseases in Denmark has taken place in hospitals. Today, treatment is split between different sectors, where the requirements are widely different. Physiotherapists, occupational therapists and dietitians are, to a certain extent, no longer found in the rheumatic sections of the hospitals, but rather expected to take care of rehabilitating treatment in one of the 98 municipalities. With the clinical guidelines, the Health Authorities has indicated which treatment areas the individual groups of patients will benefit from – however, there is lack of provision of these in many of the municipalities across the country.

Objectives: To secure that treatment guidelines - within the field of musculoskeletal diseases - made by The National Board of Health, are transformed into national quality standards for treatment in the municipalities.

Methods: To ensure that patients get the treatment needed, we have worked with external consultants resulting in two research papers (visible at link) on the subject at hand. One paper mapped how many of the 98 municipalities provides each of four treatment guidelines made by The National Board of Health. The four being - weight loss, education and physical training for hip- and knee osteoarthritis, education and physical training for patients with back conditions and interdisciplinary treatment for people with pain conditions. The other paper uncovered the potential economic gains for the public sector by introducing the treatment guidelines.

The Danish Rheumatism Association has used these research papers as a significant driver for a large conference in October 2021 at the Danish Parliament – Christiansborg. Essential national politicians where present and they acknowledged the need for an increased focus on the treatment areas.

The results of the reports has also been shared with government officials, an existing commission on labor supply as well as municipalities etc.

In connection with the recently held elections in Danish municipalities and regions, we have reached out to the local politicians experiencing a gap in the offerings either directly or through local media which will hopefully result in an uplift of the focus. In addition, we have made debate posts with among others - unions sharing our point of view.

Results: Essential national politicians acknowledged the need for an increased focus on the treatment areas.

We hope that both from the municipalities as well as from a national level initiative will be taken to introduce a set of national quality standards within the field of musculoskeletal diseases because of our forceful approach.

Conclusion: The increased focus on treatment of musculoskeletal diseases is the result of strong collaboration between The Danish Rheumatism Association department for Politics and Knowledge, Internal Communications and external partners. We believe that our work can inspire other European NGO’s who has a need to increase their political agenda and awareness. We made a long-term goal, focus on the treatment areas.

We believe that our work in collaborating with The Danish Rheumatism Association will help us achieve the goals.

Acknowledgements: The Danish Rheumatism Association

Disclosure of Interests: None declared


LONGITUDINAL INVESTIGATION AND VISUALIZATION OF COURSE AND BURDEN OF ADVERSE DRUG REACTIONS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES USING TNFα-INHIBITORS

M. De Boer1, H. Gosselt2, J. Jansen3, M. Van Doorn1,2,3, F. Hoentjen4,5, M. Nurmohamed1, P. Spuls2, S. Tas3,4, H. Vonkeman5,10, N. Jessurun6

1University of Alberta, 2Radboud University, 3Centre for Human Drug Research, N/A, Leiden, Netherlands, 4Erasmus MC, Department of Dermatology, Rotterdam, Netherlands, 5Centre for Human Drug Research, N/A, Leiden, Netherlands, 6Amsterdam Rheumatology Immunology Centre (ARC), N/A, Amsterdam, Netherlands

Background: Patients are increasingly involved in the decision process regarding their medicines, but a discrepancy exists between the information provided and preferred. Information on adverse drug reactions (ADRs) relies on frequency, but little is known about the course and burden of ADRs.

Objectives: We aimed to investigate the course and burden of ADRs over time attributed to using TNFα-inhibitors in patients with inflammatory rheumatic diseases (IRDs) and to assess whether Sankey diagrams and polar plots are suitable to provide visualization of these aspects.

Methods: We used data of the Dutch Biologic Monitor [1], in which biologic users with an immune-mediated inflammatory disease filled out bimonthly surveys about ADRs experienced and specifically the ADR course and burden. ADRs were coded according to the MedDRA terminology. ADR course was scored as worsening, improving, remaining stable or resolving over time, with room to give a description. Furthermore, it was assessed whether an ADR was recurrent or not. Patients scored burden on a scale ranging from 1 (no burden) to 5 (very high burden). We selected patients with rheumatoid arthritis (RA), psoriatic arthritis or axial spondyloarthritis using a TNFα inhibitor (adalimumab, certolizumab pegol, etanercept, golimumab or infliximab). They also had to report an ADR belonging to the system organ classes ‘Infections and infestations’ or ‘Skin and subcutaneous tissue disorders’, or the high level term ‘Injection site reactions’ and completed ≥2 consecutive questionnaires (representing circa ≥4 months). These types of ADRs were chosen as they impose the highest burden for patients. [2]

Results: A total of 202 patients met the inclusion criteria (71.6% female, mean age 54.8 years (±12.7 years)). The majority of the patients (61.9%) was diagnosed with RA. Most frequently used TNFα inhibitors were adalimumab (37.1%) and etanercept (54.0%). In total 353 ADRs were reported, of which 76 (21.5%) were categorized as ‘Skin and subcutaneous tissue disorders’, 122 (34.6%) as ‘Infections and infestations’ and 155 (43.9%) as ‘Injection site reactions’. The course of the ADRs is visualized in Sankey diagrams (Figure 1a–c); the flows show possible ADR courses, the width of each is proportional to the number of ADRs following that course. Most skin reactions did not change during follow-up (25.0%, Figure 1a), only a few were recurrent. Most infections resolved over time (50.8%, Figure 1b), with some remaining stable and some being recurrent. Most injection site reactions (72.3%, Figure 1c) were recurrent, and resolved in only a minority of the patients (13.4%) during follow-up. The polar plots (Figure 1d–f) visualizes the burden of the ADRs over time. For skin reactions and infections a decreasing trend was observed, represented by fading of the colors to the periphery. Infections had the highest burden at the start of the ADR, indicated by the darker colors in the inner circle. Injection site reactions had a relatively low and stable burden over time, shown by the lighter colors continuing over the circles.

Conclusion: Skin reactions attributed to the use of TNFα-inhibitors by IRD-patients show a stable course over time with a slightly diminishing burden over time. Infections have the highest burden at start but decrease over time and most of them resolve during follow-up. Injection site reactions are mostly recurrent with a low and stable burden over time. We propose that Sankey diagrams and polar plots are suitable to visualize the course and burden of ADRs over time.

REFERENCES:


Disclosure of Interests: Merel de Boer: None declared, Helen Gosselt: None declared, Jurriaan Jansen: None declared, Martijn van Doorn: Speakers bureau: Merel de Boer: None declared, Helen Gosselt: None

Scientific Abstracts


POS0356-PARE

M. Nudel1. 1Mifrakim Tze’irim, None, Haifa, Israel

Since 2016 we had a dream to construct a self-management course for members of The Israeli association for RMDs patients Mifrakim Tze’irim. On September 2018, our CEO heard a lecture by Mrs. Mary Vella, the president of ARAM Malta, and the rest is history.

We approached PARE through AGORA for the Knowledge Transfer Program Grant, and got approved in February 2019. The need to develop such a course came from members of the association, as well as posts in Facebook groups. Concerns, fears, and uncertainties about how to live with a chronic illness.

Mitrakim Tz’eerim is committed to reaching out to children, youth, adults and seniors with autoimmune and inflammatory joint diseases and rare autoimmune and various inflammatory diseases and to their families. The association assists its members and provides them with support and available tools on a personal, family, and social level. Our goal is to act for increasing public awareness of these diseases and their day-to-day impact on patients, to expand knowledge and disseminate information about them, patient rights and innovations in treatment, as well as to promote access to a variety of advanced treatments and medications for the members.

Objectives: Providing tools for daily coping and optimal conduct in chronic illness situations in a wide range of aspects: a self-management triangle:

1. Medical / biological (better / helpful understanding of the situation)
2. Emotional (identify and manage the emotional impact)
3. Social (adjusting the way you manage your daily life)

METHODS:

1. Receiving a grant from PARE - The Knowledge Transfer Program Grant, through AGORA
2. Cooperation with ARAM - Arthritis & Rheumatism Association Malta
3. A study visits to Malta
4. Monitoring the process in Israel by ARAM
5. Founding a management team for the course
6. Localizing adaptation of the learned content for Israelis and introducing new content of our own
7. Promotion of the course to the association members, selecting participants
8. December 2019 the first course started. In 2020-2021 we had 3 more cycles of the course to the members. We had 40 participations
9. Following the pilot course - generating conclusions, lessons, and adjustment of the syllabus accordingly
10. Three more courses are planned for 2022

RESULTS:

1. Excellent feedback from ARAM during the control performed
2. Participants provided outstanding feedback on the course
3. Course graduates established designated WhatsApp groups for ongoing mutual support, thus creating empowerment circles, including periodic physical meetings

CONCLUSION:

1. In My Hands course provides a highly efficient and relevant toolbox.
2. The course should be continually offered to people coping with chronic diseases
3. Finger on the pulse - ongoing drawn conclusions to be implemented for adjusting the syllabus
4. The course should be promoted gently, since it marks a change in life, which can threat some people’s perception
5. We have expanded and offered participation to members of other patient associations that we collaborate with
6. Graduates of the course become ambassadors, spreading the benefits received by the course
7. Graduates of the course are a vivid example of the chance of improving your life even when you cope with chronic diseases
8. Graduates of the course influence their immediate circles to adapt and adopt changing habits

REFERENCES:

[1] In In Our Hand - Self Management Course - Israel Malta Report, Submitted to Pare 29.04.2020

ACKNOWLEDGEMENTS:

1. PARE, EULAR KTP
2. AGORA Board platform for South European organizations of Patients with RMDs
3. Mrs. Mary Vella, President, ARAM
4. Dr. Mariella Borg Buontempo, Consultant in public health medicine, Maltese Ministry for Health
5. Prof. Gleb Slobodin, Senior Rheumatologist, medical supervisor to the Israeli course
6. Mrs. Hily Wollach, Chairwoman of Mitrakim Tze’irim, and the Association Board members
7. The Israeli course Management Team and lecturers
8. Last but not least - Mitrakim Tze’irim members who took part in the courses

Disclosure of Interests: None declared


IN OUR HAND – SELF MANAGEMENT COURSE (FOR PEOPLE WITH CHRONIC RHEUMATIC DISEASES)

Figure 1. Summary diagrams and solar plots of the course and burden of eA skin and subcutaneous tissue disorders &ILD infections and reiterations and eA injection site reactions

M. Nudel1. 1Mifrakim Tze’irim, None, Haifa, Israel
Background: Patients with rheumatic diseases show impaired quality of life (QoL): disease activity, comorbidities and treatment-related side effects contribute to decrease physical, emotional, and social functioning. The COVID-19 pandemic challenges health care systems and patients with chronic conditions: hospital and outpatient clinics delayed access, unpredictable changes like non-adherence to medication, but also negative emotions, psychological conditions recognized as risk factors for the poor QoL [1-2].

Objectives: To describe the impact of the COVID-19 pandemic on the QoL of Italian patients with rheumatic diseases in the first period of the national lockdown.

Methods: APMARR (Associazione Nazionale Persone con Malattie Reumatologiche e Rare) invited Italian patients and caregivers to participate to an online structured survey in the period March–June 2020. Informed consent was retrieved. The questionnaire, promoted by the patient advocacy website, collected demographics, emotional and healthcare pattern information.

Results: 87.44% (N=215) complete questionnaires were retrieved (96.3% patients; 3.7% caregivers; 87.77% female; 2% aged <18 years, 16% aged 18-30 years, 82% aged >31 years; 0.53% missing data). Respondents were illustrative of the Patient Advocacy regional distribution (Puglia Region predominant). Rheumatoid arthritis regarded 29% of respondents, ankylosing spondylitis 17%, psoriasis 16%, remaining 38% other rheumatoid diseases. 96% of respondents were employed, 39% of which had to discontinue/change working activity during pandemics. 60% of respondents reported being worried about their disease. The deriving distress was the main cause of anxiety, which was not controlled even by compliance to the treatment plan (88%). 30% of respondents was worried about virus infection, Irritabilty, appetite and sleep disorders were also reported: anxiety had effects on irritability (46% sometimes more irritable) and sleep quality (38% always disturbed). GPs visits access was limited (40% considered it absent and 76% had to postpone it). Only 32% of specialist centers provided facilitated patterns of care.

Respondents suggested possible solutions to improve QoL during COVID-19 pandemic and over it. Psychologist support was suggested as useful by 44% of respondents to manage therapies and by 96% to enjoy daily life. The home infusion would be of support according to 44% of respondents (18% already got access to it). Patient Advocacy had a major role in the new care and life context: 80% would consider it useful to participate to and 81% was satisfied by the prompt and continuous support received during pandemics.

Conclusion: Similar results as far as distress were reported by Italian and foreign evidence, which demonstrated considerable COVID-19 related psychosocial burden in rheumatic disease patients [3-5]. Potential solutions are also with EULAR recent guidelines, which underlined how psychological interventions were found to reduce pain and fatigue even in difficult-to-treat patients [6] and how mental health needs should be periodically assessed, due to the link between better emotional well-being and better self-management [7]. Besides, the reported picture of reorganised care during pandemic corresponded to the real-world experience of the Italian Regions [8]. New approaches of care like home infusions and telemedicine supported by patient organisations should become routinary and may therefore benefit patients.

REFERENCES:
[1] https://www.tuh.ie/News/Tallaght-Hospital-to-take-the-lead-on-first-national-research-study-on-Vasculitis.html

Disclosure of Interests: None declared

fever syndrome” (PFS), “familial Mediterranean fever” (FMF), “cycloprogn
associated periodic syndrome” (CAPS), “tumor necrosis factor associated
periodic syndrome” (TRAPS), “adult onset of still’s disease” (AOSD) and
“systemic juvenile idiopathic arthritis” (sJIA). For every keyword, the top 20
videos in their order of relevance were included. Video duration, number of
views, likes, dislikes, comments and uploading source were extracted.

The quality of a video’s information was evaluated independently by two
physicians based on the modified global quality scale (GQS) (2). Subgroup
analyses were performed classifying healthcare professionals and patients
as target group.

Results: In total 140 videos were screened. We excluded 5 videos due to
language other than English, 7 duplicates and 23 not suitable ones. 105
videos met the inclusion criteria for further analysis. Video characteristics
are presented in Table 1. Based on the GQS, overall quality of videos for
patients was found to be low in 64,8%, intermediate in 27,6%, and high in
7,6% of videos. The quality of videos for professionals was similar: 54,3%
were judged to be of low, 23,8% of intermediate, and 21,9% of high quality
(Figure 1). Subgroup analyses focusing on videos for professionals found
sJIA videos to achieve the highest scores (31,6% with high quality) whereas
videos regarding CAPS were rated the least useful ones (15,4% with high
quality). In videos for patients, sJIA videos also ranked highest (42,1% with high
quality) whereas no high quality videos could be identified for TRAPS.
Videos are more often aimed at specialists such as doctors or medical stu-
dents (65.7%) and less often at affected patients or relatives (34.3%). Video
duration was significantly longer in videos targeting a professional audience
(p < 0.001). In videos for professionals, length was significantly correlated
with higher quality (p < 0.001).

Table 1. Video Characteristics

<table>
<thead>
<tr>
<th>Disease Syndrome</th>
<th>Total videos (n=105)</th>
<th>Patient videos (n=40)</th>
<th>Professional videos (n=65)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sJIA</td>
<td>23 (21.9%)</td>
<td>10 (25%)</td>
<td>13 (20%)</td>
</tr>
<tr>
<td>CAPS</td>
<td>15 (14.3%)</td>
<td>3 (7.5%)</td>
<td>12 (18.5%)</td>
</tr>
<tr>
<td>TRAPS</td>
<td>39 (37.1%)</td>
<td>7 (17.5%)</td>
<td>32 (50%)</td>
</tr>
<tr>
<td>AOSD</td>
<td>17 (16.2%)</td>
<td>5 (12.5%)</td>
<td>12 (18.5%)</td>
</tr>
<tr>
<td>Others</td>
<td>6 (5.7%)</td>
<td>2 (5%)</td>
<td>4 (6.2%)</td>
</tr>
</tbody>
</table>

![Figure 1. Quality Scale](image)

Figure 1. Quality Scale

Conclusion: YouTube as a source of information could have great potential
for rare diseases. However, this study demonstrates that the majority of videos
regarding AIDs is of limited quality and available videos more often adress users
with a professional medical background. Only a small proportion of existing vid-
eos provide understandable and useful information for AID patients.

REFERENCES:
terol102: 2070–2077

Disclosure of Interests: None declared


POSO360-PARE

EDUCATIONAL NEEDS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AND HEALTH
PROFESSIONALS IN RHEUMATOLOGY: A SWISS CROSS-SECTIONAL QUALITATIVE ANALYSIS

A Grosse1, 2, C Madelaine-Bonjour1, 3, University of Geneva, Patient Education, Geneva, Switzerland; 1Sjögren Europe, Federation of European Sjögren’s Patient Associations, Bienne, Switzerland; 2Lausanne University Hospital, Rheumatology, Lausanne, Switzerland

Background: The content and delivery of patient education (PE) should be indi-
vidualy tailored and needs-based for people with inflammatory arthritis1. There-
fore, a patient trained in PE joined forces with a rheumatology clinical nurse
specialist to explore the needs for the management of patients with RA in a
Swiss local context (rheumatology department of a university hospital).

Objectives: To identify the difficulties and needs of patients with RA regarding
their disease and its management in a local context, from both perspectives:
patients and health professionals (HPs).

Methods: We developed 2 different semi-structured questionnaires for each sur-
veyed group. They were distributed to 93 patients and 62 HPs during Summer
2020. Only the fully completed surveys were analysed. A qualitative analysis of
the answers to the open questions was carried out and the phenomena thus
identified were then quantified.

Results: We collected 38 patient (40%) and 35 HP (56%) questionnaires, and 23
patients (25%) and 21 HPs (34%) filled them completely out. Participants among
patients were mostly female (74%) with a mean (SD) age of 54.8 (10.9). Mean (SD)
number of years of illness after diagnosis was 11.9 (12,6). HPs were nurses (57.1%),
medical doctors (19%), occupational therapists (14,3%), physiotherapists (4.8%) and assistant nurses (4.8%).
Almost half of HPs (48%) and 39% of patients experience difficulties to talk about
sensitive topics like sexuality, financial or emotional difficulties.

A third of patients (30%) wished a more supportive attitude from HPs and
HPs (62%) would like patients to be more involved in their care, more speci-
cifically regarding autonomy and treatment adherence. A few HPs (9%) and
patients (19%) want to improve patient-centred and personalised care. Most
of HPs (81%) and patients (87%) state that they have no objection or reluc-
tance to PE being developed in the department. Some HPs see PE as an
additional workload (19%) and others as a tool to involve the patients more
in their care (43%).
HPs (43%) express a need for patient’s and disease’s management training
and wish to acquire additional tools and methods to better assist their patients
(43%). A third of them (33%) report a lack of communication, collaboration and
interdisciplinarity to support patients. Furthermore, due to the lack of time and
availability, 67% of them are not able to provide adequate time for meeting the
patients’ needs. Some HPs feel powerless to help their patients (19%). Some oth-
ers (18%) highlight the difference of perspectives and concerns between patients
and HPs.
Patients and HPs agreed on most of the main difficulties related to the disease
and follow-up. It should be noted that HPs were not aware of the difficulties
related to their patients’ sleep. The painful and distressing psychological and
emotional impact of RA is the difficulty most cited by patients (74%) and the
second most mentioned by HPs. More than half of patients (61%) have difficulty
managing their pain.

Conclusion: The results of this study confirm the need for PE in the depart-
ment. Communication is a challenge for both populations. HPs know their
patients well, but patients and HPs have different expectations regarding
disease’s management and follow-up. This work shows the importance of
analysing educational needs: it brings out dimensions of the disease and its
management that are sometimes hidden or underinvestigated. It thus helps
us to have a better understanding of the reality and difficulties as they are
experienced by people in order to propose appropriate solutions. This
work provides a basis for reflection and discussion for the future develop-
ment and implementation of a PE program, based on the paradigm of the
patient-HP partnership. In addition to being an example of an advanced
and successful patient-HP partnership, it also demonstrates the benefits of
such collaboration.

REFERENCES:
education for people with inflammatory arthritis. Annals of the Rheumatic

Disclosure of Interests: None declared

Systemic Lupus Erythematosus: monitoring and management

FACTORS ASSOCIATED WITH CHANGES IN COPING BEHAVIOUR IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS - A LONGITUDINAL STUDY OF THE LULU COHORT

E. Reutemann1, R. Brinks2, J. G. Richter3, R. Fischer-Betz4, B. Winkler-Rohlfing4, M. Aringer1, G. Chehab1
1Policlinic for Rheumatology & Hill Research Unit for Rheumatology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany; 2Chair for Medical Biometry and Epidemiology, Witten/Herdecke University, Faculty of Health/School of Medicine, Witten, Germany; 3German Lupus Self-Help Community, Wuppertal, Germany; 4Department of Medicine III, Division of Rheumatology, TU Dresden, Dresden, Germany

Background: Patients with Systemic Lupus Erythematosus (SLE) experience both physical and psychosocial restrictions that negatively impact their quality of life. Coping mechanisms have turned out to be important contributors to health-related outcomes, not only in SLE but also other chronic conditions. However, there is limited understanding of factors that enhance or hamper coping in SLE.

Objectives: To analyse parameters associated with longitudinal changes in coping behaviour in patients with SLE who take part in a long-term SLE patient cohort study.

Methods: Since 2001, the German nationwide SLE patient longitudinal (Lupus Langzeit ‘LuLa’) study annually administers self-reported questionnaires to SLE patients. In addition to demographic and the annually probed extended clinical data (e.g., medication, disease activity, fatigue, depression), in both 2009 and 2014 we assessed the Pain-related Self Statements Scale (PRSS) to perceive information related to coping behaviour. This includes ‘positive coping’ as well as catastrophizing as a dysfunctional form of coping behaviour.

Statistical analysis was accomplished by a linear regression model adjusting for age, pain, number of comorbidities and net income. The PRSS score difference from 2009 and 2014 was used as the dependent variable. Factors from the i) medical (infection, mood, fatigue), ii) activity (basic, leisure, sports), iii) intrinsic (depression, kinesiophobia, perceived health control), and iv) social participation categories were entered as independent variables.

Results: 272 patients (96.7% female) provided valid PRSS questionnaires in both 2009 and 2014. In 2009 the mean age in this cohort was 51 ± 12 years (SD 11.2) with an average disease duration of 16.2 years (SD 8.3). The mean reported lupus activity (VAS 0-10) during the last three months was 3.7 (SD 2.4). During the six-year observation period, the proportion of improvement (46.2%) and deterioration (47.4%) in coping score was almost balanced, while in catastrophizing score more participants improved (50.0%) than deteriorated (37.0%). A perceived high health-related control, thus the belief that health outcomes are contingent on personal behaviour, was associated with an improvement in the coping score [HLC, b=0.061 (95%-CI 0.014; 0.109), p=0.012]. Conversely, high external control convictions, e.g., the belief that doctors and other third parties determine health outcomes, were associated with a worse coping score [HLC, b=-0.090 (95%-CI -0.154; -0.028), p=0.006]. Deterioration in depression [ADS-L, b=0.015, (95%-CI 0.006; 0.023), p=0.002] and impaired social participation [IMET, b=0.043, (95%-CI 0.000; 0.085), p=0.050] were associated with a deterioration of catastrophizing, whereas better internal control [HLC, b=-0.046, (95%-CI -0.080; -0.012), p=0.009] was associated with its improvement.

Mucocutaneous involvement, fatigue, and the extent of physical activity were not significantly associated with either coping or catastrophizing scores in the regression analysis.

Conclusion: In line with data from other chronic diseases, our findings in a longitudinal SLE cohort emphasise the role of intrinsic factors, such as mental health status and self-efficacy, improving the quality of life in SLE patients via successful coping behaviour. Affirmative action measures and programs to improve social participation may yield additional benefits.

Acknowledgements: This research study is supported by unrestricted grants from GlaxoSmithKline, UCB Pharma and AstraZeneca.

Disclosure of Interests: Emily Reutemann: None declared, Ralf Brinks: None declared, Jutta G. Richter Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Rebecca Fischer-Betz Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Borgi Winkler-Rohlfing: None declared, Martin Aringer: None declared, Matthias Schneider Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study., Gamal Chehab Grant/research support from: GlaxoSmithKline and UCB Pharma for performing the LuLa-study.

DOI: 10.1136/annrheumdis-2022-eular.4974
clinical SLEDAI ≥5 and 98 (24.6%) had clinical SLEDAI 1-4. The mean total SLEDAI was 3.02±2.87 and PGA score was 0.60±0.53. A total of 178 patients (44.6%) had SDI score ≥1. The mean SIMPLE index was 25.6±12.8. SIMPLE index correlated significantly with clinical SLEDAI (ρ=0.75; p<0.001), total SLEDAI (ρ=0.75; p<0.001) and PGA score (ρ=0.41; p<0.001). At visit 3, 87 and 38 patients, respectively, had a drop in total SLEDAI score by ≥1 and ≥4, and the corresponding change in SIMPLE index was 35.3±13.7 to 25.0±10.1 (p<0.001) and 42.9±19.9 to 26.0±11.1 (p<0.001). Conversely, 103 and 29 patients, respectively, had an increase in total SLEDAI score by ≥1 and ≥4. The corresponding change in SIMPLE index was 23.5±11.3 to 25.7±10.1 (p=0.007) and 25.3±13.7 to 27.3±11.6 (p=0.27). Change in SIMPLE index from visit 1 to 3 correlated significantly with the change in total SLEDAI (ρ=0.35; p<0.001), clinical SLEDAI (ρ=0.19; p<0.001) and PGA (ρ=0.14; p=0.005). ROC analysis performed with pooled data from all the 3 visits showed that a SIMPLE index ≥34 points best predicted a clinical SLEDAI score of 1-4 (area under the curve [AUC] 0.72[0.68-0.75]; sensitivity 0.65; specificity 0.64), and ≥31 points best predicted a clinical SLEDAI score of ≥5 (AUC 0.84[0.77-0.91]; sensitivity 0.76, specificity 0.81).

Conclusion: The SIMPLE index shows a good correlation with SELENA-SLEDAI and PGA. It is also sensitive to change in SLEDAI and PGA score during subsequent visits. The SIMPLE index is a simple tool that enables patients to self-report disease activity and communicate with the health care team more efficiently.

Disclosure of Interests: None declared


POS0364 UNMET NEEDS IN THE TREATMENT OF EXTRA-RENAL FLARES IN SLE PATIENTS: REAL LIFE EXPERIENCE VS ARTIFICIAL APPROACH

M. Maffi1, L. Scagnellato1, A. Collesei2,3, E. Elefante1, C. Stagnaro1, F. Ferro1, L. Carli1, V. Signorini1, D. Zucchi1, F. Trentin1, C. Tani1, M. Mosca1,1University of Pisa, Rheumatology, Pisa, Italy; 2University of Padua, Surgery, Oncology and Gastroenterology, Padua, Italy; 3Familial Cancer Clinics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy

Background: Systemic lupus erythematosus (SLE) is a heterogeneous disease which can affect various organs and is characterized by different clinical phenotypes. While the treatment of renal involvement is quite standardized, the therapeutic approach to extra-renal manifestations is subjected to a degree of variability.

Objectives: 1. To describe extra-renal disease flares in terms of clinical phenotype and outcomes in SLE patients 2. To compare data from a real-life setting with a machine learning (ML) approach.

Methods: This study is a retrospective analysis of data from a monocentric cohort of SLE patients who experienced a disease flare between 2015 and 2020. Each flare was followed for one year and was classified according to the organ involvement and categorized according to the BILAG definition of flare. At baseline and at 3,6,12 months the following variables were collected: disease activity (SELENA-SLEDAI) and categorized according to the BILAG definition of flare. At baseline and during follow up were analyzed in terms of explained variance across the dataset’s Principal Components and clustered with a hierarchical unsupervised learning approach. A ML model based on neural networks was built to early detect flares’ therapeutic difficulty: it was validated after data augmentation to satisfy statistical requirements during the training phase.

Results: 66 extra-renal flare were investigated (Table 1); 5 flares (7.5%) were treated with glucocorticoid (GC) pulses and 61 (92.5%) with oral GC therapy, while an immunosuppressive (IS) treatment was prescribed in 44 flares (66.7%). The remission rate at 12 months for the whole group was 50%, with musculo-skeletal (MS) flares, mucocutaneous (MC) flares and others (neuropsychiatric, cardiopulmonary, constitutional, haematologic) that were respectively 63.6%, 31.3% and 41.2%, showing lower rate of remission for MC flares.

<table>
<thead>
<tr>
<th>NUMBER (%)</th>
<th>MUSCLE</th>
<th>MUCOCUT</th>
<th>CONSTITUTIONAL</th>
<th>CARDIOPULM</th>
<th>HEMATOM</th>
<th>NEURO</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>33 (50)</td>
<td>16 (24.2)</td>
<td>7 (10.6)</td>
<td>4 (6.1)</td>
<td>5 (76)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>SLEDAI at baseline median (IQR)</td>
<td>4 (10)</td>
<td>8 (9-10)</td>
<td>5 (5.5)</td>
<td>9 (5-12)</td>
<td>5 (5-6)</td>
<td>29 (29-29)</td>
</tr>
<tr>
<td>SLEDAI 12 mos median (IQR)</td>
<td>4 (10)</td>
<td>8 (9-10)</td>
<td>5 (5.5)</td>
<td>9 (5-12)</td>
<td>5 (5-6)</td>
<td>29 (29-29)</td>
</tr>
<tr>
<td>REMISSION 12 mos number (%)</td>
<td>33 (50)</td>
<td>21 (63.6)</td>
<td>5 (31.3)</td>
<td>4 (6.1)</td>
<td>2 (40%)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>NON RESPONSE 12 mos number (%)</td>
<td>17 (25.8)</td>
<td>8 (25)</td>
<td>5 (31.3)</td>
<td>28 (29.8)</td>
<td>1 (20%)</td>
<td>1 (100)</td>
</tr>
</tbody>
</table>

Figure 1. Flare clusters.

Conclusion: These data suggest that, in a real-life setting, the clinical response rate to therapy of patients with an extra-renal flare is not satisfactory, thus identifying an unmet need in the treatment of SLE and highlighting the absence of a standard treatment. Both the real-life data and the machine learning approach identify flares with MC manifestations as the most difficult to treat with the lower rate of remission after one year. Further prospective studies are necessary to improve the neural network model; ML techniques could help in the early identification of difficult to treat flares to be candidates for new and more aggressive therapeutic strategies for extra-renal manifestations.

Disclosure of Interests: None declared


POS0365 RELAPSES ARE COMMON IN SEVERE HEMATOLOGIC SLE: REAL-LIFE EXPERIENCE FROM THE “ATTIKON” LUPUS COHORT

G. S. Moysidou1, S. Flouda1, M. Kosmetatou1, N. Kapsala1, D. Tseronis1, M. Aggelakos1, T. Karageorgas1, D. Nikolopoulos1, K. Chavatzis1, A. Filippopoulou1, K. Zoupidou1, P. Katsimpi1, A. Fanourakis1, D. Boumpas1,1National and Kapodistrian University of Athens, 4th Department of Internal Medicine Attikon University Hospital, Athens, Greece

Background: Hematological manifestations are common in systemic lupus erythematosus (SLE), and are thought to result from immune-mediated peripheral cell destruction or bone marrow failure (1,2).

Objectives: To assess the clinical characteristics and outcomes of severe hematological disease in a large cohort of lupus patients.

Methods: Retrospective analysis of the “Attikon” lupus cohort (over 800 patients total) (3) for the identification of patients with a history of severe hematological manifestation. The latter were defined as: thrombocytopenia with a platelet count <30,000/mm3, hemolytic anemia with an hemoglobin <8 g/dL, neutropenia with less than 500 neutrophils/mm3, history of thrombotic microangiopathy (TMA) or macrophase activation syndrome (MAS). Treatments and long-term outcomes (relapses, mortality) were recorded.

Results: Among 300 patients with hematologic manifestations, 40 patients had severe disease. Most of them were women (75%). Mean age at SLE diagnosis was 41.1 years and mean disease duration at diagnosis of cytopenia was 3 “flare in polymorphic disease with mild activity” and cluster 4 “recurrent skin flares”. Interestingly, cluster 4 (recurrent skin flares) was associated with the lowest rate of remission at 12 months with respect to clusters 1, 2, and 3 (33% vs 40%, 76.5% and 56% respectively). Moreover the neural network model correctly predicts difficult to treat flares in up to 80% of the cases.

Table 1.

<table>
<thead>
<tr>
<th>WHOLE GROUP</th>
<th>MUSCLE</th>
<th>MUCOCUT</th>
<th>CONSTITUTIONAL</th>
<th>CARDIOPULM</th>
<th>HEMATOM</th>
<th>NEURO</th>
</tr>
</thead>
<tbody>
<tr>
<td>66</td>
<td>33 (50)</td>
<td>16 (24.2)</td>
<td>7 (10.6)</td>
<td>4 (6.1)</td>
<td>5 (76)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>SLEDAI at baseline median (IQR)</td>
<td>5 (5.5)</td>
<td>8 (9-10)</td>
<td>5 (5.5)</td>
<td>9 (5-12)</td>
<td>5 (5-6)</td>
<td>29 (29-29)</td>
</tr>
<tr>
<td>SLEDAI 12 mos median (IQR)</td>
<td>5 (5.5)</td>
<td>8 (9-10)</td>
<td>5 (5.5)</td>
<td>9 (5-12)</td>
<td>5 (5-6)</td>
<td>29 (29-29)</td>
</tr>
<tr>
<td>REMISSION 12 mos number (%)</td>
<td>33 (50)</td>
<td>21 (63.6)</td>
<td>5 (31.3)</td>
<td>4 (6.1)</td>
<td>2 (40%)</td>
<td>1 (100)</td>
</tr>
<tr>
<td>NON RESPONSE 12 mos number (%)</td>
<td>17 (25.8)</td>
<td>8 (25)</td>
<td>5 (31.3)</td>
<td>28 (29.8)</td>
<td>1 (20%)</td>
<td>1 (100)</td>
</tr>
</tbody>
</table>
Disclosure of Interests: None declared


POSO366 MODERATE RATES OF TREATMENT INTENSIFICATION IN SLE PATIENTS WITH RESIDUAL DISEASE ACTIVITY

O. Gioi1, M. Nikoloudaki2, K. Chavatza3, E. Kalav1, A. Elezoglu4, P. Sidiropoulos2, G. Bertias2, D. Boumpas2, A. Fanouriakis5, A. Asklepioi1 General Hospital, Department of Rheumatology, Athens, Greece; 1University Hospital Heraklion, Rheumatology, Clinical Immunology and Allergy, Crete, Greece; 2Attikon University Hospital, Athens, Greece; 3University Hospital Heraklion, Rheumatology, Clinical Immunology and Allergy, Crete, Greece; 4University Hospital Ana Kari, Athens, Greece; 5Axion Medical Center, Athens, Greece

Background: The treat-to-target (T2T) strategy has gained significant attention in SLE,1 whereas UPLAR has set remission or low disease activity as the goal of treatment.2 Nevertheless, the degree to which T2T is followed in real-life clinical settings has not been extensively studied.

Objectives: To assess the proportion of lupus patients with residual disease activity that had their therapy intensified during their most recent visit, identify associated factors, and assess the validity of the SLEDAI-2k as a predictor of therapy intensification.

Methods: Cross-sectional study of SLE patients who were evaluated in three tertiary centers in Greece during their last visit. Patients were categorized in four disease activity states (remission on and off treatment, low disease activity and non-optimally controlled), according to definitions used in previous studies.3 Intensification of treatment was defined as addition/increase of glucocorticoids (GC) or addition/increase of immunosuppressive (IS) agent (conventional or biologic). Logistic regression analysis was used to identify factors associated with treatment intensification and ROC analysis to calculate sensitivity, specificity of different SLEDAI-2k cut-off values to predict this escalation.

Results: 332 patients were included [93.1% female, mean (SD) age 48.5 (14.7) years, median (IQR) disease duration 6.5 (12.4) years]. Regarding disease activity states, 23.2% (n=77) of patients were in remission (off or on therapy), 36.7% (n=122) were in LDA, while 40.1% (n=133) were categorized as non-optimally controlled disease.

Within patients with residual disease activity, therapy intensification was offered to 25.6% and 48.9% of those with low disease activity and non-optimally controlled disease, respectively. In multivariable analysis, proteinuria (OR 6.78, 95% CI 2.06 – 22.23), arthritis (OR 5.48, 95% CI 3.20 – 9.40) and rash (OR 5.23, 95% CI 1.81 - 15.76), were associated with intensification of therapy. The AUC of the ROC analysis for total SLEDAI-2k to predict therapy escalation was 0.761, indicating only fair accuracy; the cut-off value with the best combination of sensitivity and specificity was 3 (sensitivity 87%, with a specificity of 55%). For clinical SLEDAI-2k, the respective AUC was marginally better (0.779), with a cut-off of 3 being associated with the best sensitivity (80%), with compromised specificity (64%)

Figure 1. ROC analysis of total and clinical SLEDAI to predict any increase in therapy

Conclusion: In real-life clinical settings, no therapy intensification was offered in more than half of patients categorized as non-optimally controlled disease. Total and clinical SLEDAI-2k showed only fair accuracy to predict therapy escalation, reflecting the role of additional parameters in the decision to escalate therapy in an individual patient.

REFERENCES:

Disclosure of Interests: None declared


POSO367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB

V. Werth1, J. Wissmar2, A. Strömbäck3, R. Tummalà4, C. Kleudel5, M. Albulescu5, University of Pennsylvania and CorporaI Michael J. Crescenz Veterans Administration Hospital, Department of Dermatology, Philadelphia, PA, United States of America; 2AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden; 3AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, MD, United States of America; 4AstraZeneca, BioPharmaceuticals R&D, Cambridge, United Kingdom

Background: Patients with cutaneous lupus erythematosus (CLE) experience disfiguring and painful lesions that can lead to psychological distress and significant impacts on quality of life.1 Treatment of patients with systemic lupus erythematosus (SLE) with anifrolumab, a type I interferon receptor antagonist, was associated with CLE Disease Area and Severity Index–Activity (CLASI-A) improvements compared with placebo through Week 52 in the phase 3 TULIP-1
and TULIP-2 SLE trials.2,3 CLASI assesses overall skin improvement and may be driven by erythema over the other components.4

Objectives: To better understand the effect of anifrolumab on mucocutaneous SLE manifestations by analyzing the individual domains of CLASI-A using pooled data from the TULIP trials.

Methods: TULIP-1 (NCT02444692) and TULIP-2 (NCT02444689) were randomized, double-blind, placebo-controlled, 52-week trials that evaluated efficacy and safety of intravenous anifrolumab administered every 4 weeks in patients with moderate to severe SLE despite standard therapy.5 In a post hoc analysis, individual CLASI-A domains (erythema, scale/hypertrophy, alopecia, and mucosa) were assessed at Week 24 (time point chosen to ensure adequate duration for improvement in slow-remitting manifestations [eg, scale, alopecia]) in 2 patient subgroups: 1) the “chronic” mucocutaneous subgroup (resembling chronic/discoid CLE), defined as patients with a baseline erythema score ≥4 and scale score ≥2, and alopecia score ≥1 or baseline mucosal lesions or ulceration score of 1; and 2) the “extended” mucocutaneous subgroup (resembling all CLE subtypes), defined as patients who met the “chronic” criteria or those who had a baseline erythema score ≥8.

Results: Across the pooled TULIP trials, 360 patients received anifrolumab 300 mg and 366 patients received placebo. In patients with assessments at Week 24 in the “chronic” (anifrolumab n=58, placebo n=50) and “extended” (anifrolumab n=104, placebo n=96) subgroups, anifrolumab led to a greater mean percent reduction from baseline compared to placebo in erythema (chronic: −63.6% vs −39.9%; extended: −63.7% vs −41.2%); scale/hypertrrophy (chronic: −72.2% vs −42.6%; extended: −45.3% vs −7.3%); anifrolumab-treated patients in both subgroups had no worsening in alopecia (chronic: 93.5% [95% CI 66.0%–96.0%] vs 95.3% [92/96]; or mucocutaneous (chronic: 95.0% [95% CI 67.0%–96.0%] vs 96.0% [48/50]; extended: 96.3% [103/107] vs 94.8% [91/96]) from baseline to placebo (Table 1).

Table 1. Skin Responses at Week 24 Compared With Baseline

<table>
<thead>
<tr>
<th>Criteria, n (%)</th>
<th>Chronic subgroup</th>
<th>Extended subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anifrolumab Placebo</td>
<td>Anifrolumab Placebo</td>
</tr>
<tr>
<td></td>
<td>Placebo Placebo n=107</td>
<td>Placebo n=96</td>
</tr>
<tr>
<td></td>
<td>300 mg (n=60)</td>
<td>50 mg (n=50)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Erythema score reduction</th>
<th>≥25%</th>
<th>53 (88.3)</th>
<th>32 (66.0)</th>
<th>93 (86.9)</th>
<th>68 (70.8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥50%</td>
<td>42 (70.0)</td>
<td>22 (44.0)</td>
<td>71 (66.4)</td>
<td>47 (49.0)</td>
<td></td>
</tr>
<tr>
<td>≥25%</td>
<td>59 (96.7)</td>
<td>18 (36.0)</td>
<td>61 (57.0)</td>
<td>23 (23.3)</td>
<td></td>
</tr>
<tr>
<td>≥10%</td>
<td>49 (81.7)</td>
<td>11 (22.0)</td>
<td>51 (47.2)</td>
<td>38 (39.6)</td>
<td></td>
</tr>
<tr>
<td>≥50%</td>
<td>46 (76.7)</td>
<td>28 (56.0)</td>
<td>51 (47.2)</td>
<td>31 (32.3)</td>
<td></td>
</tr>
<tr>
<td>No new/worsened lesions in any individual body area</td>
<td>44 (73.3)</td>
<td>26 (52.0)</td>
<td>81 (75.7)</td>
<td>56 (58.3)</td>
<td></td>
</tr>
</tbody>
</table>

Alopecia
| ≥1-point decreasea | 25 (41.7) | 19 (38.0) | 35 (32.7) | 27 (28.1) |
| No worsening | 56 (93.3) | 49 (98.0) | 102 (95.3) | 92 (95.6) |
| Mucosal lesion/ulceration | 25 (41.7) | 13 (26.0) | 39 (36.4) | 33 (34.0) |
| No worsening | 57 (95.0) | 48 (96.0) | 103 (96.3) | 91 (94.8) |

aIf baseline score ≥1. bIf baseline score =1.

Conclusion: In the phase 3 TULIP trials, SLE patients with mucocutaneous manifestations treated with anifrolumab experienced numerical improvements in erythema and scale/hypertrophy and no worsening in alopecia or mucous membrane CLASI-A domains compared with placebo, regardless of whether skin disease was classified by chronic or extended definitions. These encouraging data support further evaluation of anifrolumab in patients with CLE.

REFERENCES:


Figure 1. Efficacy-related survival of belimumab according to improvement or not of PGA at 3 months since treatment initiation.
Conclusion: In real-life setting, about 28% of SLE patients discontinue belimumab due to suboptimal treatment response per physician judgement, especially those with moderate-to-high activity and severe arthritis. Improvement in PGA at 3 months predicts long-term drug maintenance, therefore suggesting its value for patient monitoring. Our data confirm the very good tolerability of belimumab and identify hydroxychloroquine co-administration as a predictor for prolonged safety-related drug survival.

Acknowledgements: The study was partly funded by the Greek Rheumatology Society and the Greek Association of Professional Rheumatologists (ERE-EPREM) supported by Pfizer Global Medical Grants.

Disclosure of Interests: Mytro Nikoloudaki: None declared, Dionysis Nikolopoulou: None declared, SOFIA KOUTSOVITI: None declared, Irini Flouri: None declared, Noemín Kapsala: None declared, ARGYRO REPA: None declared, PELAGIA KATSIKMP: None declared, EVANGELOS THEOTIKOS: None declared, Sofia Pitsigavadki: None declared, Katerina Pateromichali: None declared, Anastasios Eskitzis: None declared, ANTÓNIA ELEZOGLOU: None declared, Prodomos Sidiropoulos: None declared, Antonis Fanouriakis: None declared, Dimitrios Boumpas: None declared, George Bertsias: None declared, Prodromos Sidiropoulos: None declared, Antonis Fanouriakis: None declared, ANTONIA ELEZOGLOU: None declared, Myrto Nikoloudaki: None declared, Dionysis Niko-

| Table 1. Characteristics of patients with QTc greater than or less than 440 ms and with an OHCLQ level greater than or less than 100 mcg/L. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | QTc >440 ms     | QTc ≤440 ms     | OHCLQ >100 mcg/L | OHCLQ ≤100 mcg/L |
| Age, mean (SD) | 64 (15)         | 56 (14.5)       | 0.007           |
| Female, n (%)  | 22 (96)         | 40 (95)         | 0.85            |
| QTc, mean (SD) | 454 (23.9)      | 416 (23.7)      | 0.0001          |
| Symptoms, n (%)| 4 (17)          | 4 (10)          | 0.77            |
| Heart rate, mean (SD) | 74 (10.3) | 67 (10.3) | 0.016 |
| Weight, mean (SD) | 69 (15.1) | 67 (15.6) | 0.61 |

Acknowledgements: El estudio fue apoyado con una beca de investigación de la Asociación para la Investigación en Reumatología de la Marina Baixa (AIRE-MB).

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4046
Results: Among 4,677 patients, the mean age at HCQ initiation was 52 years; 83% were female. The racial/ethnic composition included 51% non-Hispanic White, 19% Hispanic, 14% Asian, and 11% Black patients. 756 (16.2%) and 3,921 (83.8%) patients initiated HCQ with the primary definition of the treatment strategies >5 and ≤5mg/kg/day, respectively. The weighted kappa was 0.80 for SD-ICT reliability. 164 patients developed HCQ retinopathy (100 mild, 38 moderate, and 26 severe cases). The cumulative incidence of retinopathy over 18 years was 37.6% for >5 and 5.7% for ≤5mg/kg of HCQ in our primary analysis. The corresponding risk was 26.5% for >5 and 3.2% for ≤5mg/kg in our secondary analysis using >80% of prescription days. Compared with ≤5mg/kg of HCQ, the HRs of retinopathy were 9.65 (95% CI 5.73-16.65) and 10.79 (95% CI 6.40-20.07) for >5mg/kg using the primary and secondary definitions of HCQ dose categories, respectively (Figure 1).

Conclusion: The risk of HCQ retinopathy associated with long-term adherence to >5mg/kg dosing was high, approximately 10 times that of ≤5mg/kg dosing. However, most cases identified during the study were mild and pre-symptomatic, supporting the value of regular screening. These data should be incorporated into individualized discussions about long-term use of HCQ.

REFERENCES:

Table 1. Characteristics of the fifteen interviewees.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Prescribed medications</th>
<th>MASRI (0–100%)</th>
<th>CQR (0–100%)</th>
<th>Direct question (Y/N)</th>
<th>Intentional non-adherence (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PRED 96</td>
<td>61</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>HCO 96</td>
<td>77</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>AZA 96</td>
<td>81</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>HCO 90</td>
<td>58</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>HCO 100</td>
<td>54</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>PRED 70</td>
<td>65</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>HCO 70</td>
<td>69</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>AZA 20</td>
<td>72</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>HCO 96</td>
<td>74</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>PRED 96</td>
<td>66</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>AZA 80</td>
<td>63</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>PRED 96</td>
<td>54</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>HCO 92</td>
<td>58</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>PRED 100</td>
<td>84</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>HCO 100</td>
<td>74</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>PRED 90</td>
<td>67</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>MMF 98</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: April Jorge: None declared, Ronald Meller: None declared, Michael Marmor: None declared, Baijun Zhou: None declared, Jingbo Niu: None declared, Yuqing Zhang: None declared, Hyon Choi: Consultant of: Ironwood, Selecta, Horizon, Takeda, Kowa, and Vaxart., Grant/research support from: Ironwood and Horizon

CAN WE ENHANCE ADHERENCE TO MEDICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? RESULTS FROM A QUALITATIVE STUDY

S. Emamikia1, C. Gentline1, Y. Enman1, I. Parodis1,2,1 Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine, Solna, Sweden; 2 Örebro University, Department of Rheumatology, Faculty of Medicine and Health, Örebro, Sweden

Background: Medication non-adherence is common among patients with systemic lupus erythematosus (SLE) [1] and may lead to poor clinical outcomes [2,3]. Objectives: Our aim was to identify influential contributors to medication non-adherence to suggest interventions that could increase adherence.

Methods: Patients with SLE from two Swedish tertiary referral centres (N=205) participated in a survey assessing self-reported adherence to medications. Medication adherence was self-reported and measured using the generic instrument Medication Adherence Self-Report Inventory (MASRI) and the rheumatic disease-specific instrument Complianc Questionnaire Rheumatology (CQR). Responses were used to select patients for qualitative interviews (N=15). Verbatim interview transcripts were analysed by two researchers using content analysis methodology.

Results: The mean age of the interviewees was 39 years, 87% were women, and their mean SLE duration was 11.6 years. Patients’ medications and adherence levels are detailed in Table 1. We categorised reasons for non-adherence thematically into (i) patient-related e.g., unintentional non-adherence due to forgetfulness or intentional non-adherence due to disbelief in medications, (ii) healthcare-related e.g., untrustworthy relationship with the treating physician, authority fear, and poor information about the prescribed medications or the disease, (iii) medication-related e.g., fear of side-effects, and (iv) disease-related reasons e.g., lacking acceptance of a chronic illness or perceived disease quiescence. Interventions identified that healthcare could implement to improve patients’ adherence to medications included (i) increased communication between healthcare professionals and patients, (ii) patient education, (iii) accessible healthcare, preferably with the same personnel, (iv) smooth transition from paediatric to adult care, (v) regularity in addressing adherence to medications, (vi) psychological support, and (vii) involvement of family members or people who are close to the patient.

Table 1. Characteristics of the fifteen interviewees.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Prescribed medications</th>
<th>MASRI (0–100%)</th>
<th>CQR (0–100%)</th>
<th>Direct question (Y/N)</th>
<th>Intentional non-adherence (Y/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PRED 96</td>
<td>61</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>HCO 96</td>
<td>77</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>AZA 96</td>
<td>81</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>HCO 90</td>
<td>58</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>HCO 100</td>
<td>54</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>PRED 70</td>
<td>65</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>HCO 70</td>
<td>69</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>AZA 20</td>
<td>72</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>HCO 96</td>
<td>74</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>PRED 96</td>
<td>66</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>AZA 80</td>
<td>63</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>PRED 96</td>
<td>54</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>HCO 92</td>
<td>58</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>PRED 100</td>
<td>84</td>
<td>Y</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>HCO 100</td>
<td>74</td>
<td>N</td>
<td>Y</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>PRED 90</td>
<td>67</td>
<td>N</td>
<td>N</td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: April Jorge: None declared, Ronald Meller: None declared, Carol Conell: None declared, Baijun Zhou: None declared, Jingbo Niu: None declared, Yuqing Zhang: None declared, Hyon Choi: Consultant of: Ironwood, Selecta, Horizon, Takeda, Kowa, and Vaxart., Grant/research support from: Ironwood and Horizon

1 MASRI: Medications Adherence Self Report Inventory; CQR: Compliance Questionnaire Rheumatology; F/M: female/male; Y/N: yes/no; NA: not applicable; iv: intravenous; sc: subcutaneous; PRED: prednisolone; HCQ: hydroxychloroquine; AZA: azathioprine; MTX: methotrexate; MMF: mycophenolate mofetil; RTX: rituximab; BEL: belimumab; CVS: cyclosporine; * Y: Adherence accept to direct question; N: Non-adherence accept to direct question.

Conclusion: The reasons for medication non-adherence are complex and multifaceted. From the patients’ perspective, multiple different strategies could be implemented in healthcare with the goal of improving adherence, including increased communication, patient education and psychological support.

REFERENCES:

Acknowledgements: All authors would like to express our gratitude to the individuals who participated in the interviews and shared their thoughts, views, and opinions.

Disclosure of Interests: Sharzad Emamikia: None declared, Citern Gentline: None declared, Yvonne Enman: None declared, Ioannis Parodis Grant/research support from: Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffman-La Roche AG.
Background: Patients with systemic lupus erythematosus (SLE) are at increased risk of severe COVID-19 and the underlying disease complications and in need of immunosuppressants (IS). An alternative option would be to adopt telemedicine (TM) to maintain medical care while minimizing exposure. Despite being widely adopted during the pandemic, the evidence supporting the use of TM in rheumatology has been limited.

Objectives: We primarily aimed to evaluate the effectiveness to maintain disease activity control using TM delivered care compared to conventional in-person follow-up in patients with lupus nephritis (LN). The secondary objectives were to compare the patient reported outcomes, safety, and cost-of-illness from the patients’ perspective between the 2 modes of health care delivery.

Methods: This was a 1-year, single-center, RCT conducted at a regional hospital in Hong Kong. From May 2020, consecutive adult patients with a SLE according to the 2019 EULAR/ACR classification criteria followed up at the LN clinic were invited to participate in the study. Participants were randomized 1:1 to either TM (TM group) or standard FU (SF group). Patients randomized to receive TM FU were scheduled for a video consultation via a commercial software ZOOM. Patients in the SF group received standard in-person outpatient care. SLE disease activity at each consultation was assessed by SLEDAI-2k and physician global assessment (PGA).

Results: A total of 144 patients with LN were randomized and 3 patients self-withdrew from the study. The mean age was 44.5±11.4 years and the median time from diagnosis to randomization was 168 months (range: 1-528). Most of the patients had class III, IV or V LN (87.2%) and were on prednisolone (89.4%, median dose 5mg daily). Many of them (68.1%) were on IS. While 66.0% of the patients were in lupus low disease activity state (LLDAS), none had disease remission. There were no baseline differences, including demographics, SLEDAI-2k (TM: 3.8±3.3, SF: 3.2±2.2, p=0.13), PGA (TM: 6.2±5.6, SF: 4.6±5.9, p=0.13) and SLE damage index (TM: 1.1±1.3, SF: 0.8±1.1, p=0.10), between the 2 groups. At one year, 80.0% and 80.2% of the patients in the TM group and SF group were in LLDAS or remission respectively. SLE disease activity indices including SLEDAI-2k, PGA, proteinuria amount and serum anti-dsDNA level remained similar between the 2 groups. Within the study period, 28 (40%) patients in the TM group and 21 (29.6%) patients in the SF group had disease flare (p=0.20). There were no differences in the SF-36, lupusQoL and HADS scores between the 2 groups at the end of the study. The overall patient satisfaction score was higher in the TM group with a significantly shorter waiting time before seeing doctors. At the end of the study, 67.9% of the overall participants agreed to (versus 15.0% who did not agree) to use TM as a mode of future FU. The mean indirect costs of illness (HKD26,681 vs HKD12,016, p=0.20) and the out-of-pocket costs for health care services were similar between the 2 groups (TM: HKD13,547 vs SF: HKD12,297, p=0.08) in one year. The total number of FU was similar (TM: 60±20, SF: 67±17, p=0.40). However, significantly more patients in the TM group (29/70, 41.4% vs 47/11, 5.6%, p<0.01) requested change mode of FU. The proportion of patients requiring hospitalization during the study period was also higher in the TM group (TM: 23/70, 32.9% vs 11/71, 15.5%; p=0.02). After adjusting for age and prednisolone dosage, not being in LLDAS at baseline was the predictor of hospitalization (OR 3.4, 95%CI 1.20-9.65). None of the participants was tested positive for COVID-19.

Conclusion: The results of the study suggest that TM delivered care could help minimizing proportion of patients cared by TM required in-person visits or were hospitalized. Satisfaction in patients with LN compared to standard care. However, a significant proportion of patients cared by TM required in-person visits or were hospitalized. The results of the study suggest that TM delivered care could help minimizing exposure to COVID-19, but it needs to be complemented by physical visits, particularly in those with unstable disease.

Acknowledgements: We would also like to thank the University of Central Lancashire & East Lancashire Hospitals NHS Trust for granting us permission to use the LupusQoL questionnaire.

Disclosure of Interests: None declared.

Data entry, DANBIO-from-home solution

<table>
<thead>
<tr>
<th>Gender</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age strata, yrs</td>
<td>&lt; 40</td>
<td>40-60</td>
</tr>
<tr>
<td>Data entry, DANBIO-from-home solution</td>
<td>64</td>
<td>36</td>
</tr>
<tr>
<td>Age, yrs</td>
<td>&lt; 40</td>
<td>40-60</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>RA</td>
<td>AxSpa</td>
</tr>
<tr>
<td>Diagnosis, median (IQR)</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>Data entry, DANBIO-from-home solution</td>
<td>0.5 (0.125-1.0)</td>
<td>0.625 (0.125-1.25)</td>
</tr>
<tr>
<td>Data entry, DANBIO-from-home solution</td>
<td>62</td>
<td>52 (52-61)</td>
</tr>
</tbody>
</table>

Table 1.

| Data entry, DANBIO-from-home solution | N=33,776 |
| Gender | Male | Female |
| Age strata, yrs | < 40 | 40-60 | 61-80 | > 80 |
| Diagnosis | RA | AxSpa | PsA | Biologic treatment, yes* |
| Diagnosis, median (IQR) | 70 | 30 | 27 | 1 |
| Data entry, DANBIO-from-home solution | 0.5 (0.125-1.0) | 0.625 (0.125-1.25) |

Table 1.

| Data entry, DANBIO-from-home solution | N=33,776 |
| Gender | Male | Female |
| Age strata, yrs | < 40 | 40-60 | 61-80 | > 80 |
| Diagnosis | RA | AxSpa | PsA | Biologic treatment, yes* |
| Diagnosis, median (IQR) | 70 | 30 | 27 | 1 |
| Data entry, DANBIO-from-home solution | 0.5 (0.125-1.0) | 0.625 (0.125-1.25) |

Table 1.

| Data entry, DANBIO-from-home solution | N=33,776 |
| Gender | Male | Female |
| Age strata, yrs | < 40 | 40-60 | 61-80 | > 80 |
| Diagnosis | RA | AxSpa | PsA | Biologic treatment, yes* |
| Diagnosis, median (IQR) | 70 | 30 | 27 | 1 |
| Data entry, DANBIO-from-home solution | 0.5 (0.125-1.0) | 0.625 (0.125-1.25) |

Table 1.

| Data entry, DANBIO-from-home solution | N=33,776 |
| Gender | Male | Female |
| Age strata, yrs | < 40 | 40-60 | 61-80 | > 80 |
| Diagnosis | RA | AxSpa | PsA | Biologic treatment, yes* |
| Diagnosis, median (IQR) | 70 | 30 | 27 | 1 |
| Data entry, DANBIO-from-home solution | 0.5 (0.125-1.0) | 0.625 (0.125-1.25) |

Table 1.

| Data entry, DANBIO-from-home solution | N=33,776 |
| Gender | Male | Female |
| Age strata, yrs | < 40 | 40-60 | 61-80 | > 80 |
| Diagnosis | RA | AxSpa | PsA | Biologic treatment, yes* |
| Diagnosis, median (IQR) | 70 | 30 | 27 | 1 |
| Data entry, DANBIO-from-home solution | 0.5 (0.125-1.0) | 0.625 (0.125-1.25) |
Disclosure of Interests: Bente Glintborg Grant/research support from: AbbVie, BMS, Pfizer, Dorte Vendelbo Jensen: None declared, Lene Terslev Speakers bureau: AbbVie, BMS, Novartis, Pfizer, UCB, Janssen, Oliver Hendricks Grant/research support from: AbbVie, BMS, Novartis, Pfizer, Møller Sørensen: None declared, Niels Steen Krogh: None declared, Jette Nørgaard Bureau: Abbvie, BMS, Boehringer-Ingelheim, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Grant/research support from: Abbvie, BMS, Celgene, Merck, Novartis, Simon Horskjær Rasmussen: None declared, Mogens Pfeiffer-Jensen: None declared, Thomas Adelsten: None declared, Ada Colic: None declared, Kamilla Danelo: None declared, Malene Kildemand: None declared, Anne Gitte Lott Speakers bureau: AbbVie, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Heidi Lausten Munk: None declared, Jens Kristian Pedersen: None declared, René Østgård Speakers bureau: Abbvie, BMS, Boehringer-Ingelheim, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi and UCB., Grant/research support from: Abbvie, Christian Møller Sørensen, Jette Nørgaard Agerbo: None declared, Connie Ziegler: None declared, Mette Lund Helland Grant/research support from: AbbVie, Eli Lilly and Roche, Eli Lilly Denmark A/S, Jansen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopics, Sandoz

POS0374
MONITORING CHRONIC INFLAMMATORY MUSCULOSKELETAL DISEASES WITH A PRECISION DIGITAL COMPANION PLATFORM(TM)—RESULTS OF THE DIGIREUMA RASIBILITY STUDY

D. Benvent1, F. J. Núñez-Benjumea2, L. Fernández-Luque2, V. Navarro-Compañ1, M. Sanz3, E. Calvo Aranda3, L. Lojo3, A. Balsa1, C. Plasencia1,2 1Hospital Universitario La Paz, IdiPaz, Department of Rheumatology, Madrid, Spain; 2AdheraHealth Inc., Palo Alto, United States of America; 3Hospital Universitario Infanta Leonor, Department of Rheumatology, Madrid, Spain

Background: Patients with rheumatic and musculoskeletal diseases (RMDs) require a tailored follow-up that is limited by the capacity of healthcare professionals. Innovative tools need to be implemented effectively in the clinical care of patients with RMDs.

Objectives: To test the feasibility of a Precision Digital Companion Platform™ for real-time monitoring of disease outcomes in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).

Methods: Digireuma was a prospective study including patients with RA and SpA, using the digital Precision Digital Companion Platform, Adhera for Rheumatology (ISRCTN11896540). During a follow-up of 3 months, patients were asked to report disease specific electronic patient reported outcomes (ePROs) on a regular basis in the mobile solution. Two rheumatologists monitored these ePROs and, patients were contacted for online or face-to-face interventions when deemed necessary by clinicians (Figure 1). Assessment measures included patient global assessment (PGA) of disease activity, tender joint count (TJC), swollen joint count (SJC), Health Assessment Questionnaire (HAQ) and pain visual analogue scale (VAS), for patients with RA; VAS, PGA, TJC, SJC, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and ASAS Health Index (ASAS-HI), for patients with SpA. In addition, flares, changes in medication and recent infections were asked. Usability of the digital solution was measured by the Net-Promoter Score (NPS).

Results: Forty-six patients were recruited of whom 22 had RA and 24 SpA. Mean age was 48 ± 12 and 42 ± 9 years in the RA and SpA groups, respectively. 18/22 (82%) patients with RA and 9/24 (38%) with SpA were female. Among the total included patients, 41 (89%) completed the onboarding (18/22 (82%) RA, 23/24 (96%) SpA) and 37 (80%) submitted at least one entry. In the RA group who completed the onboarding (n=18) there were a total of 4019 total interactions (2178 questionnaire items, 648 accesses to educational units, 105 quizzes, 1088 rated messages), while patients with SpA (n=23) had a total of 3180 interactions (1637 questionnaire items, 684 accesses to educational units, 77 quizzes, 762 rated messages). ePROS measurements completion rates for RA and SpA patients that completed any data during follow-up are shown in Table 1. Patients with RA completed a median of 9.5 ePROS during follow-up, whereas patients with SpA completed a median of 3. Regarding alerts, 15 patients generated a total of 26 alerts, of which 24 were flares (10 RA, 14 SpA) and 2 were problems with the medication (1 RA, 1 SpA). 18 (69%) of the alerts were managed remotely, 5 (19%) required a face-to-face intervention and in 3 (12%) patients did not respond before the consultation. Regarding usability and patient satisfaction, 14 patients provided feedback. According to the NPS, 9/14 were considered promoters, 4/14 passives and 1/14 detractor. The overall rating of these 14 patients for the app was 4.3 out of 5 stars.

Table 1. Onboarded patient engagement with regards to e-PROs

<table>
<thead>
<tr>
<th>Rheumatoid Arthritis (n=18)</th>
<th>PGA</th>
<th>TJC</th>
<th>SJC</th>
<th>VAS</th>
<th>HAQ</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ePROs completed</td>
<td>1.5 (0.25, 3)</td>
<td>2 (0.25, 3)</td>
<td>2 (0.25, 3)</td>
<td>2 (0.25, 3)</td>
<td>2 (0.25, 3)</td>
<td>2 (1, 3)</td>
</tr>
<tr>
<td>Patients with ≥1 entry</td>
<td>13 (72.2)</td>
<td>13 (72.2)</td>
<td>13 (72.2)</td>
<td>12 (66.7)</td>
<td>13 (68.9)</td>
<td>16 (88.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Spondyloarthritis (n=23)</th>
<th>PGA</th>
<th>TJC</th>
<th>SJC</th>
<th>BASDAI</th>
<th>ASAS-HI Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>ePROs completed</td>
<td>1 (0.3)</td>
<td>1 (0.3)</td>
<td>1 (0.3)</td>
<td>1 (0.2)</td>
<td>1 (0.2)</td>
</tr>
<tr>
<td>Patients with ≥1 entry</td>
<td>16 (69.5)</td>
<td>16 (69.5)</td>
<td>16 (69.5)</td>
<td>16 (68.8)</td>
<td>14 (60.8)</td>
</tr>
</tbody>
</table>

Follow-up period was 3 months. Results are expressed in median (Q1, Q3) and in (%)

Conclusion: This study shows that the use of a digital health solution is feasible in clinical practice. Based on these preliminary results, the next step will be to further implement the Precision Digital Companion Platform, Adhera for Rheumatology, in a multicentric setting to analyze the added value for monitoring patients.

Acknowledgements: This study was funded with an unrestricted grant from Abbvie.

Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie and Novartis, Maria Sanz: None declared, Enrique Calvo Aranda Speakers bureau: Abbvie, LETICIA LOJO: None declared, Alejandro Baeta Speakers bureau: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic Pharma, Gebro, Roche, Sanofi, UCB, Consultant of: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic Pharma, Sanofi, UCB, Grant/research support from: Pfizer, Abbvie, BMS, Nordic Pharma, Gebro, Roche, UCB, Chaimada Plasencia Speakers bureau: Pfizer, Abbvie, Lilly, Sandzod, Sanofi, Biogen, Roche, Novartis, Grant/research support from: Pfizer y Abbvie.

Objectives:
The sudden emergence of SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and has catalyzed the rapid emergence of telemedicine. Our aim was to describe which parameters were used by rheumatologists to monitor patients with rheumatoid arthritis (RA) in teleconsultation during the first wave of the pandemic and identify the most relevant for decision making.

Methods:
Retrospective monocentric routine care cross-sectional study including RA patients seen in teleconsultation between March and September 2020. Available parameters assessing disease status were collected in teleconsultation files. Clinic intervention was defined by treatment escalation and/or the need for a rapid face-to-face consultation or day hospitalization.

Results:
143 RA patients were included (117 females, mean age of 58±16 years, mean disease duration of 14±11 years). The presence or absence of patient self-reported RA flares concerned 43/143 patients (30%). The presence of patient self-reported RA flares concerning 43/143 patients (30%). The presence of patient self-reported RA flares associated with a detailed evaluation of patient in teleconsultation: The presence (or number) of tender joints and swollen joints were more significantly reported in patients who presented a flare (39/43, 91% vs. 70/100, 70%, p=0.008 and 25/43, 58% vs. 23/100, 23%, p<0.001, respectively). Teleconsultation led to a clinician intervention in 22/143 patients (14%), representing 51% of patients with self-reported flares (22/43 patients). Therapeutic escalation was necessary in 13 patients: introduction or dose increase of corticosteroids in 8 patients, introduction or dose increase of methotrexate in 4 patients and introduction of hydroxychloroquine in 1 patient. Face-to-face consultation or day hospitalization were organized for 10 patients. Active disease was confirmed during this next face-to-face visit in 9 patients, with DAS28 ranging from 3.35 to 5.62, leading to therapeutic modification. The 133 other patients were seen in face-to-face consultation 6±2 months after the teleconsultation. No DMARD modification was recorded during this next face-to-face consultation.

Conclusion:
Our study identified patient reported RA flares and increased CRP values as 2 red flags in teleconsultation, independently associated with therapeutic modification and/or the need for a rapid face-to-face consultation. These indicators may help clinician’s decision making in teleconsultation.

Disclosure of Interests:
Jerome Avouac: Speakers bureau: Bristol Myers Squibb, PANOFI, galapagos, Lilly, Abbvie, Pfizer, Novartis, Biogen, Fresenius Kabi, Janssen, MSD, Roche-Chugui, Medac, Consultant of: galapagos, Abbvie, Pfizer, Bristol Myers Squibb, SANOFI, Nordic-Pharma, Grant/research support from: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Anna Moltó: None declared, CAMELIA FRANTZ: None declared, Sarah Wanono: None declared, Elise Descamps: None declared, Olivier Fogel: None declared, Alice Combier: None declared, Lucile Poioux: None declared, Corinne Miceli Richard: None declared, Yannick Allarone: None declared.


EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TELECONSULTATION DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC

J. AVOUAC1, A. MOLTÓ1, C. FRANTZ1, S. WANONO1, E. DESCAMPS1, O. FOGEL1, A. COMBIER1, L. POIUOX1, C. MICELI RICHARD1, Y. ALLARONE1, COCHIN HOSPITAL, RHEUMATOLOGY, PARIS, FRANCE

Background:
The relevance of early diagnosis in SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and has catalyzed the rapid emergence of telemedicine. Electronic consultation (e-Consults) is a tool for communication and a means for a rapid face-to-face consultation or day hospitalization.

Methods:
Available parameters assessing disease status were collected in teleconsultation files. Clinic intervention was defined by treatment escalation and/or the need for a rapid face-to-face consultation or day hospitalization.

Results:
143 RA patients were included (117 females, mean age of 58±16 years, mean disease duration of 14±11 years). The presence or absence of patient self-reported RA flares concerned 43/143 patients (30%). The presence of patient self-reported RA flares was mentioned in all medical files, followed by the presence and/or the number of tender joints (76%), the number of pain-related nocturnal awakenings (66%) and the CRP value (54%). Patient self-reported RA flares concerned 43/143 patients (30%). The presence of self-reported RA flares associated with a detailed evaluation of patient in teleconsultation: The presence (or number) of tender joints and swollen joints were more significantly reported in patients who presented a flare (39/43, 91% vs. 70/100, 70%, p=0.008 and 25/43, 58% vs. 23/100, 23%, p<0.001, respectively). Teleconsultation led to a clinician intervention in 22/143 patients (14%), representing 51% of patients with self-reported flares (22/43 patients). Therapeutic escalation was necessary in 13 patients: introduction or dose increase of corticosteroids in 8 patients, introduction or dose increase of methotrexate in 4 patients and introduction of hydroxychloroquine in 1 patient. Face-to-face consultation or day hospitalization were organized for 10 patients. Active disease was confirmed during this next face-to-face visit in 9 patients, with DAS28 ranging from 3.35 to 5.62, leading to therapeutic modification. The 133 other patients were seen in face-to-face consultation 6±2 months after the teleconsultation. No DMARD modification was recorded during this next face-to-face consultation.

Conclusion:
Our study identified patient reported RA flares and increased CRP values as 2 red flags in teleconsultation, independently associated with therapeutic modification and/or the need for a rapid face-to-face consultation. These indicators may help clinician’s decision making in teleconsultation.

Disclosure of Interests:
Jerome Avouac: Speakers bureau: Bristol Myers Squibb, PANOFI, galapagos, Lilly, Abbvie, Pfizer, Novartis, Biogen, Fresenius Kabi, Janssen, MSD, Roche-Chugui, Medac, Consultant of: galapagos, Abbvie, Pfizer, Bristol Myers Squibb, SANOFI, Nordic-Pharma, Grant/research support from: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Anna Moltó: None declared, CAMELIA FRANTZ: None declared, Sarah Wanono: None declared, Elise Descamps: None declared, Olivier Fogel: None declared, Alice Combier: None declared, Lucile Poioux: None declared, Corinne Miceli Richard: None declared, Yannick Allarone: None declared.


EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS IN TELECONSULTATION DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC

J. AVOUAC1, A. MOLTÓ1, C. FRANTZ1, S. WANONO1, E. DESCAMPS1, O. FOGEL1, A. COMBIER1, L. POIUOX1, C. MICELI RICHARD1, Y. ALLARONE1, COCHIN HOSPITAL, RHEUMATOLOGY, PARIS, FRANCE

Background:
The relevance of early diagnosis in SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and has catalyzed the rapid emergence of telemedicine. Electronic consultation (e-Consults) is a tool for communication and a means for a rapid face-to-face consultation or day hospitalization.

Methods:
Available parameters assessing disease status were collected in teleconsultation files. Clinic intervention was defined by treatment escalation and/or the need for a rapid face-to-face consultation or day hospitalization.

Results:
143 RA patients were included (117 females, mean age of 58±16 years, mean disease duration of 14±11 years). The presence or absence of patient self-reported RA flares concerned 43/143 patients (30%). The presence of patient self-reported RA flares was mentioned in all medical files, followed by the presence and/or the number of tender joints (76%), the number of pain-related nocturnal awakenings (66%) and the CRP value (54%). Patient self-reported RA flares concerned 43/143 patients (30%). The presence of self-reported RA flares associated with a detailed evaluation of patient in teleconsultation: The presence (or number) of tender joints and swollen joints were more significantly reported in patients who presented a flare (39/43, 91% vs. 70/100, 70%, p=0.008 and 25/43, 58% vs. 23/100, 23%, p<0.001, respectively). Teleconsultation led to a clinician intervention in 22/143 patients (14%), representing 51% of patients with self-reported flares (22/43 patients). Therapeutic escalation was necessary in 13 patients: introduction or dose increase of corticosteroids in 8 patients, introduction or dose increase of methotrexate in 4 patients and introduction of hydroxychloroquine in 1 patient. Face-to-face consultation or day hospitalization were organized for 10 patients. Active disease was confirmed during this next face-to-face visit in 9 patients, with DAS28 ranging from 3.35 to 5.62, leading to therapeutic modification. The 133 other patients were seen in face-to-face consultation 6±2 months after the teleconsultation. No DMARD modification was recorded during this next face-to-face consultation.

Conclusion:
Our study identified patient reported RA flares and increased CRP values as 2 red flags in teleconsultation, independently associated with therapeutic modification and/or the need for a rapid face-to-face consultation. These indicators may help clinician’s decision making in teleconsultation.

Disclosure of Interests:
Jerome Avouac: Speakers bureau: Bristol Myers Squibb, PANOFI, galapagos, Lilly, Abbvie, Pfizer, Novartis, Biogen, Fresenius Kabi, Janssen, MSD, Roche-Chugui, Medac, Consultant of: galapagos, Abbvie, Pfizer, Bristol Myers Squibb, SANOFI, Nordic-Pharma, Grant/research support from: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Anna Moltó: None declared, CAMELIA FRANTZ: None declared, Sarah Wanono: None declared, Elise Descamps: None declared, Olivier Fogel: None declared, Alice Combier: None declared, Lucile Poioux: None declared, Corinne Miceli Richard: None declared, Yannick Allarone: None declared.

ONE YEAR OF DIGITAL HEALTH APPLICATIONS (DiGA) IN GERMANY – RHEUMATOLOGISTS' PERSPECTIVES

J. G. Richter1, G. Chehab1, P. Stachwitz2, J. Hagen3, D. Larsen4, J. Knitz5, M. Schneider6, A. Voormann1, C. Specker7, 1Medical Faculty, Heinrich-Heine-University Duesseldorf, Policlinic for Rheumatology and Hiller Research Unit for Rheumatology, Düsseldorf, Germany; 2Health Innovation Hub of the Federal Ministry of Health, Health Innovation Hub of the Federal Ministry of Health, Berlin, Germany; 3Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3-Rheumatology and Clinical Immunology, Erlangen, Germany; 4German Society for Rheumatology, German Society for Rheumatology, Berlin, Germany; 5Clinic Essen-Mitte, Clinic of Rheumatology and Clinical Immunology, Essen, Germany

Background: Based on given legislation (§§ 33a and 139e SGB V, Social Code Book V) the German approach to digital health applications (Digitale Gesundheitsanwendungen, DiGA) allows reimbursed prescription of approved therapeutic software products (listed in the DiGA directory https://diga.bfarm.de/de/verzeichnis) for patients since October 6th, 2020.

Objectives: To evaluate the level of knowledge on DiGA among members of the German Society for Rheumatology (DGRh) after one year of DiGA under the conditions of the COVID-19 pandemic using the DiGA Toolbox of the ‘health innovation hub’ (hih), a think tank and sparring partner of the German Federal Ministry of Health.

Methods: Anonymous cross-sectional online survey using LimeSurvey (https://limesurvey.org). The survey was promoted by newsletters sent out to DGRh newsletter recipients and Twitter posts. Ethical approval was obtained.

Results: 75 valid participants reported that they care more than 80% of their working time for patients with rheumatic diseases. Most were working in outpatient clinics (54%) and older than 40 years of age (84%). Gender distribution was balanced (50%).

70% were aware of the possibility to prescribe DiGA. Most were informed on this for the first time via trade press (63%), and only 8% via the professional society. 46% expect information on DiGA from professional societies and the medical chambers (36%) but rarely from the manufacturer (10%) and the responsible ministry (4%). Respondents would like to be informed about DiGA via continuing education events (face-to-face 76%, online 84%), trade press (86%), and manufacturers’ test accounts (64%).

Only 7% have already prescribed a DiGA, 46% planned to do so, and 47% did not intend DiGA prescriptions. Relevant aspects for prescription are given in Figure 1.

Figure 1. Aspects relevant for DiGA prescriptions; sorted by importance/number of mentions (participants needed to pick their three most relevant aspects from a pre-given list)

68% believe that using DiGA / medical apps would at least partially be feasible and understandable to their patients. 83% thought that data collected by the patients using DiGA or other digital solutions could at least partially influence health care positively.

51% appreciated to get DiGA data directly into their patient documentation system resp. clinical electronic health record (EHR) and 29% into patients’ owned EHR.

Conclusion: DiGA awareness was high whereas prescription rate was low. Mostly, physician-desired aspects for DiGA prescriptions were proven efficacy and efficiency for physicians and patients, risk of adverse effects and health care costs were less important. Evaluation of patients’ barriers and needs are warranted. Our results will contribute to the implementation and dissemination of DiGA.


EVALUATION OF THE USE OF VIDEO CONSULTATION IN GERMAN RHEUMATOLOGY CARE BEFORE AND DURING THE COVID-19 PANDEMIC WAVES

J. Reiter1, G. Chehab1, P. Ares2, F. Mueliensiepen2, M. Weikert2, A. Voormann1, M. Schneider1, C. Specker7, J. G. Richter1, 1Medical Faculty, Heinrich-Heine-University Duesseldorf, University Clinic, Duesseldorf, Policlinic & Hiller Research Unit for Rheumatology, Duesseldorf, Germany; 2Immunologikum Hamburg, Rheumatologie & Klinische Immunologie, Hamburg, Germany; 3Faculty of Health Sciences, Brandenburg Medical School Theodor Fontane, Ruedersdorf, Center for Health Services Research, Brandenburg, Germany; 4MVZ für Rheumatologie Dr. Martin Welcker GmbH & RheumaDatenRhePort (RHADAR), Geschäftsführung, Planegg, Planegg, Germany; 5German Society for Rheumatology, German Society for Rheumatology, Berlin, Germany; 6Clinic Essen-Mitte, Clinic of Rheumatology and Clinical Immunology, Essen, Germany; 7Hamburg, Germany

Background: During the COVID-19 pandemic telemedicine tools rapidly and widely gained acceptance as indispensable management tools for the continuum of clinical care in rheumatic diseases. They have been adopted in position papers and guidelines for the management of rheumatic diseases in adult patients.

Objectives: Evaluation of the use of video consultation as one form of telemedicine before and during the COVID-19 pandemic and associated lockdowns among Rheumatology physicians in Germany. The survey results are expected to support the optimization and implementation of video consultation (VC) into routine clinical practice in rheumatology, providing long-term benefits for both parties, patients and their treating rheumatologists.

Methods: Cross-sectional nationwide online survey among German rheumatologists and rheumatologists in training. The survey was promoted by newsletters sent by means of mail and Twitter posts to members of the German Society for Rheumatology (n=1,650) and German Professional Society for Rheumatology (n=527).

Results: Reported data refer to 205 participants. The majority of respondents was male (59%), older than 40 years (90%) and specialized in internal medicine/rheumatology (85%).

They were divided into two groups: ‘digital users’ (38%) and ‘digital non-users’ (62%). Users employing telemedicine (TM) but never VC were defined as ‘TM-users’ (10%). Those using TM and VC were classified as ‘VC-users’ (27%). ‘Non-users’ negated the use of VC and TM respectively.

Knowledge on telemedicine was self-rated as 4 (median on a Likert Scale 1 (very high) to 6 (very low)) with a significant difference between user (VC-user 7±1.2, TM-user 3.2±1.1) and non-user (4.4±1.3).

The Figure 1 shows a significant increase in the use of VC during the lockdown periods. Even between the lockdown phases, VC use was higher than in the pre-pandemic phase.

Figure 1. Grouped patient numbers seen via VC during the pandemic waves

Reasons for VC non-use in TM-user and non-user were administrative/technical efforts (21%), lack of technical equipment (15%), time constraints (12%), time required for individual VC sessions (12%), inadequate reimbursement (11%), lack of demand from patients (11%), data security concerns (9%), poor internet connection (8%), and lack of scientific evidence (5%).

Based on the experience gained, physicians considered the following clinical situations to be particularly suitable for VC: follow-up visits (VC-user 79%, TM-user 62%, non-user 25%).
47%), emergency consultations (VC-user 20%, TM-user 33%, non-user 20%), and patients presenting for the first time (VC-user 11%, TM-user 19%, non-user 8%).

Table 1. Evaluation of the VC in comparison to other patient interaction (VC-user) on a Likert Scale with 1 (I agree completely) to 6 (I do not agree at all)

<table>
<thead>
<tr>
<th>VC is</th>
<th>Mean ± standard deviation (median)</th>
</tr>
</thead>
<tbody>
<tr>
<td>... comparable to a face to face meeting (n=52)</td>
<td>4.3 ± 1.4 (4.5)</td>
</tr>
<tr>
<td>... comparable to a telephone consultation (n=51)</td>
<td>3.3 ± 1.3 (3.0)</td>
</tr>
<tr>
<td>... suitable as an additional means of communication</td>
<td>2.3 ± 1.5 (2.0)</td>
</tr>
</tbody>
</table>

Table 1 (n=51) with the patient (n=51)

Conclusion: Despite the fact that the current pandemic situation, with social distancing and several lockdowns, provides an ideal environment for the implementation of new remote care forms such as VC, their use and acceptance remained below expectations. Given the reported decline in physician face-to-face consultations during the pandemic, these findings are even more concerning. The identified reasons for non-utilization should be addressed by policy makers, payers and medical societies to provide better foundations for future innovative care models.

Disclosure of Interests: Joana Reiter: None declared, Gamal Chehab: None declared, Peer Aries: None declared, Felix Muehlespiezen Speakers bureau: Novartis Pharma GmbH, Grant/research support from: Novartis Pharma GmbH & AbbVie Deutschland GmbH & Co. KG, Martin Welcker: None declared, Anna Voormann: None declared, Matthias Schneider: Speakers bureau: Astra-Zeneca; Biogen; BMS; Celgene; Chugai; GSK; Janssen-Cilag; Lilly; Pfizer; UCBB, Paid instructor for: Lilly; Consultant of: Abbvie; AstraZeneca; Boehringer-Ingehelm; GSK; Lilly; Novartis; Pfizer; Protagen; Roche; Sanofi-Aventis; UCB, Grant/research support from: Abbvie; Astra-Zeneca; GSK; UCB, Christof Specker: None declared, Jutta G. Richter: None declared


**POS0379** SMARTPHONE-ASSISTED PATIENT-INITIATED CARE VERSUS USUAL CARE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND LOW DISEASE ACTIVITY: A RANDOMIZED CONTROLLED TRIAL

B. Seppen1,2, J. Wiegel1,2, M. Ter Wee3, D. Van Schaaardenburg4, L. Roorda3, M. Boers5, M. Nurmoohamed1, W. H. Bos1,2, Amsterdam Rheumatology and Immunology Center | Reade, Rheumatology, Amsterdam, Netherlands; 2Amsterdam UMC, location VUMc, Rheumatology, Amsterdam, Netherlands; 3Amsterdam UMC, location VUMc, Rheumatology, Amsterdam, Netherlands; 4Amsterdam UMC, location VUmc, Rheumatology, Amsterdam, Netherlands; 5Amsterdam UMC, location AMC, Rheumatology, Amsterdam, Netherlands; 6Reade, Rehabilitation, Amsterdam, Netherlands

Background: Most patients with rheumatoid arthritis (RA) visit their rheumatologist every 3-6 months to evaluate their disease activity. This may be inefficient, as research shows that many patients have minimal disease activity.1 When patients monitor their disease and initiate care at the right moment, they may be able to reduce the number of clinic visits, with a lower health care burden and costs. We developed a smartphone app that allows patients to self-monitor their disease activity through a weekly assessment of patient index data (RAPID-3).

Objectives: To assess safety (non-inferiority in disease activity, DAS28) and efficacy (reduction in number of visits) of patient-initiated care assisted by a smartphone app compared to usual care.

Methods: A twelve month, randomized, non-inferiority clinical trial was conducted in RA patients with low disease activity, on stable treatment for at least 6 months prior to entry. Patients were randomized (1:1) to either app supported patient-initiated care with a scheduled follow-up consultation after a year (app-group), or usual care, see Figure 1. The primary outcomes were non-inferiority in terms of change in disease activity (ΔDAS28) after 12 months and the number of consultations with a rheumatologist.

Results: 102 of 103 randomized patients completed the study. The mean age was 58, 60 were female and the mean disease duration was 12 years. At baseline mean (SD) DAS28 was 1.67 (0.68) in the app group, and 1.54 (0.72) in the usual care group. After a year, the app group mean (SD) DAS28 was 0.27 (0.35) in the usual care group: the difference in ΔDAS28 was −0.04 in favor of the app group (95%CI:−0.39;−0.30) documenting non-inferiority. The number of rheumatologist consultations was significantly lower in the app group: mean (SD) 1.7 (1.8) vs 2.8 (1.4) visits/year; visit rate ratio: 0.82 (95% CI 0.47;0.81, p<0.001).

Conclusion: Patient-initiated care supported with self-monitoring via a smartphone app was non-inferior to usual care in terms of ΔDAS28 and led to a 38% reduction in rheumatologist consultations rate.

REFERENCES:

Disclosure of Interests: Bart Seppen: None declared, Jim Wiegel: None declared, Marieke ter Wee: None declared, Dirkjan van Schaardenburg: None declared, Leo Roorda: None declared, Maarten Boers: None declared, Michael Nurmoohamed: None declared, W.H. Bos Grant/research support from: AbbVie sponsored this trial


**POS0380** EFFECTIVENESS OF REMOTE CARE INTERVENTIONS: A SYSTEMATIC REVIEW INFORMING THE 2022 EULAR POINTS TO CONSIDER FOR REMOTE CARE IN RHEUMATOID AND MUSCULOSKELETAL DISEASES

A. Marques1,2, P. Bosch3, A. De Thurah4, L. Faizon4, C. Mukhtyar5, H. Bijlsma6, C. Dejaco7, T. Stamm8 on behalf of EULAR task force on Points to Consider for the remote care in rheumatic and musculoskeletal diseases. 1Higher School of Nursing of Coimbra, Health Sciences Research Unit Nursing, Coimbra, Portugal; 2Centro Hospitalar e Universitário de Coimbra, Rheumatology, Coimbra, Portugal; 3Medical University of Graz, Rheumatology and Immunology, Graz, Austria; 4Aarhus University Hospital, Rheumatology, Aarhus, Denmark; 5German Rheumatism Research Centre, Epidemiology and Health Sciences Research, Berlin, Germany; 6The University of Sheffield, School of Health and Related Research, Health Economics and Decision Science, Sheffield, United Kingdom; 7Nordiak & Norwich University Hospital, Rheumatology, Norwich, United Kingdom; 8UMC Utrecht, Rheumatology and Clinical Immunology, Utrecht, Netherlands; 9Hospital of Bruneck (ASASA-SABES), Rheumatology, Bruneck, Italy; 10Medical University of Vienna & Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria

Background: While the number of patients with rheumatic musculoskeletal diseases (RMDs) is increasing worldwide, there is no adequate increment in the number of health care professionals, leading to the urgent need for new forms of care to take pressure off health care systems.1 Telehealth comprises a number of different types of interventions with the scope of performing certain steps of care, ranging from diagnostics to follow-up visits, in a remote manner. The use of remote care is heterogeneous and guidance is needed to optimize the combination with conventional face-to-face (F2F) visits.

Objectives: To perform a systematic literature review (SLR) on different outcomes of remote care compared to F2F care, its implementation into clinical practice and to identify drivers and barriers in order to inform a task force formulating the European Alliance of Associations for Rheumatology (EULAR) Points to Consider for remote care in RMDs.

Methods: Prospective, retrospective, and qualitative studies testing different types of remote care in patients with RMDs were included. Medline, Embase and the Cochrane Library were searched through February 28th, 2021. Two reviewers independently performed standardized data extraction, synthesis, and risk of bias assessment.

Results: A total of 2,240 references were identified. Forty-seven studies, consisting of 26 randomized controlled trials, 8 prospective cohort studies, 8 cross sectional studies, and 5 qualitative studies were included. Fifty-one percent of the studies involved patients with inflammatory RMDs, including rheumatoid arthritis, and spondyloarthritis, while 49% were on patients with non-inflammatory conditions, such as osteoarthritis and fibromyalgia. Remote monitoring (n=35) was most frequently studied, with telephone/video calls being the most common mode of delivery (n=30). Thirty-four studies investigated outcomes of remote care in comparison to F2F care. The most frequently assessed outcomes concerned efficacy and user perception of remote care, with 34% and 21% of studies, respectively, reporting superior results for the remote care intervention.

Time savings and flexibility were reported as major drivers, while inadequate technical knowledge and concerns in data security were the main barriers to
Scientific Abstracts	﻿ 
implementing remote care. Implementation of remote care methods into clinical
practice was not reported by the included studies. The main limitations were the
heterogeneity of outcomes and interventions, and the substantial risk of bias
(50% of studies with high risk of bias).
Conclusion: Studies on remote care reported similar to partially better results
compared to F2F care concerning efficacy, and user perception outcomes, with
the limitation of heterogeneity and considerable risk of bias.
REFERENCES:
apps.who.int/iris/bitstream/handle/10665/311941/9789241550505-eng.
pdf?ua=1 accessed 10.01.2022.
prevalence, and years lived with disability for 354 diseases and injuries
for 195 countries and territories, 1990–2017: a systematic analysis for the
doi: https://doi.org/10.1016/S0140-6736(18)32279-7
Disclosure of Interests: Andrea Marques: None declared, Philipp Bosch: None
declared, Annette de Thurah Speakers bureau: Pfizer, Eli Lily, Grant/research
support from: Novartis, Yvette Meissner Speakers bureau: Pfizer, Louise Falzon:
None declared, Chetan Mukhtyar: None declared, Hans Bijlsma Speakers
bureau: Abbvie, Arthrogen, BMS, Lilly, MSD, Pfizer, Roche, Sun, UCB, Consultant of: Abbvie, Arthrogen, BMS, Lilly, MSD, Pfizer, Roche, Sun, UCB, Grant/
research support from: Roche, Sun, Christian Dejaco Speakers bureau: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sanofi, Consultant
of: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos, Sanofi, Grant/
research support from: Celgene, Pfizer, Tanja Stamm Speakers bureau: AbbVie,
Roche, Sanofi, Takeda, Consultant of: Abbvie, Sanofi, Grant/research support
from: Abbvie, Roche

POS0381

ALLOCATION OF VISITS ACCORDING TO NEED:
SCREENING RHEUMATOID ARTHRITIS PATIENTS
WITH PATIENT REPORTED OUTCOMES

B. Seppen1,2, S. Verkleij1, J. Wiegel1,2, M. Ter Wee3, M. Nurmohamed1,2,
W. H. Bos1,2. 1Amsterdam Rheumatology and Immunology Center | Reade,
Rheumatology, Amsterdam, Netherlands; 2Amsterdam UMC, locatie VUmc,
Rheumatology, Amsterdam, Netherlands; 3Amsterdam UMC, locatie VUmc,
Biostatistics and Data Science, Amsterdam, Netherlands
Background: Currently, patients with rheumatoid arthritis (RA) require frequent consultations to monitor their disease activity. However, since a majority of patients is in remission during routine follow up, it should be possible
to reduce the number of consultations for them.1 Patients that are meeting
their treatment goal, based on the results of their electronic patient reported
outcome measures (ePROMs), could be eligible to skip their visit. Research
revealed that patients who indicate to be in remission or have a low disease
activity (remission/LDA) on their ePROMs, such as the routine assessment
of patient index data (RAPID3), also have a low disease activity score 28
(DAS28).2 However, in clinical practice the decision to intensify treatment is
more complex than not meeting a DAS28 threshold. Therefore, ePROM-results should be compared with treatment intensifications to assess the safety
of screening with ePROMs.
Objectives: To assess the probability that patients with low scores on
disease activity assessment with ePROMs do not need medication
intensification.
Methods: This retrospective study compared results of three ePROMs
(RAPID3, patient acceptable symptom state (PASS) and asking patients
if they experienced a flare (flare question)) answered during routine care
with (disease modifying anti-rheumatic drug) DMARD or steroid intensifications collected from anonymised electronic medical records at Reade. We
calculated the positive predictive value (PPV) for not receiving a DMARD
or steroid intensifications within two weeks and three months for 1) being
in remission/LDA according to the RAPID3, 2) being in PASS and 3) not
reporting a flare. The secondary aim of the study was to assess which
combination of ePROM-results led to the best PPV for DMARD or steroid
intensifications.
Results: A total of 321 records were included that regarded 302 unique
patients (77% female, mean age (SD) was 60 (12) years). The PPV for not
receiving a DMARD or steroid intensification within 2 weeks of the RAPID3,
PASS and flare-question were 99%, 95% and 83%, respectively, and after
3 months 95%, 88%, 85%, for all test characteristics see Table 1. The combination of a RAPID3 < 2 and a negative flare-question resulted in a PPV
of 100%; this combination was present in 29% (93/321) of the total study
population.

445

Table 1. Predictive values of ePROMs for DMARD or steroid
intensifications
ePROMs
Direct (<2 weeks)
RAPID3
PASS
FLARE
RAPID3 + Flare
Follow up (<3 months)
RAPID3
PASS
FLARE
RAPID3 + Flare

PPV

Specificity

NPV

Sensitivity

99
95
93
100

99
85
74
100

28
42
52
36

37
71
83
29

95
88
85
96

95
75
62
96

39
54
63
39

40
74
85
39

All numbers are percentages. ePROMs: electronic Patient Reported Outcome Measures,
NPV: Negative Predictive Value, PPV: Positive Predictive Value, RAPID3: Routine Assessment
of Patient Index Data-3, PASS: Patient Acceptable Symptom State.

Conclusion: Our results show that the RAPID3, PASS and flare have a high
diagnostic accuracy to identify individuals that will not receive a DMARD or steroid intensification up to 3 months after their initial consultation and are therefore possibly eligible to skip their outpatient clinic visit. The combination of the
RAPID3 and the PASS yielded the best combination of diagnostic accuracy and
highest number of eligible patients.
REFERENCES:
[1] Haugeberg, G. et al. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of
patients in an ordinary outpatient clinic in southern Norway. Arthritis Res
Ther 17, 219 (2015).
[2] Wiegel J. et al. Reducing the Number of Outpatient Clinic Visits by Using the
Routine Assessment of Patient Index Data 3 as a Screening Tool [abstract].
Arthritis Rheumatol. 2021; 73 (suppl 10).
Disclosure of Interests: None declared

What’s new in scleroderma and myositis?
POS0382

RNA-SEQUENCING ANALYSIS TO IDENTIFY
POTENTIAL FUNCTIONAL PATHWAYS INVOLVED
IN SYSTEMIC SCLEROSIS PATHOGENESIS: OUR
PRELIMINARY EXPERIENCE

A. Spinella1, D. Lo Tartaro2, L. Gibellini2, M. Starnoni3, M. de Pinto1, G. Amati1,
G. De Santis2,3, A. Cossarizza2, C. Salvarani1,4, D. Giuggioli1,2. 1University
Hospital of Modena and Reggio Emilia, Modena, Italy., Scleroderma Unit,
Rheumatology Unit, Modena, Italy; 2University of Modena and Reggio Emilia,
Department of Medical and Surgical Sciences of Children and Adults,
Modena, Italy; 3University of Modena and Reggio Emilia, Division of Plastic
Surgery, Modena, Italy; 4University of Modena and Reggio Emilia, Department
of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant
Surgery, Oncology and Regenerative Medicine Relevance, Modena, Italy
Background: Systemic Sclerosis (SSc) is a connective tissue disease, characterized by endothelial dysfunction, autoimmunity abnormalities and fibrosis of
the skin and internal organs. The exact pathogenetic mechanisms that propagate SSc vasculopathy are still not completely understood. A complex network of
interactions between endothelial cells, pericytes, myofibroblasts, and the extracellular matrix (ECM) has been implicated but it is currently unclear what drives
the activation of fibroblasts and the increased ECM deposition responsible for the
fibrotic changes well known in SSc.
Objectives: Using RNA sequencing (RNA-seq), our goal was to identify potential functional pathways possibly involved in SSc pathogenesis and markers that
could potentially be used to better understand endothelial dysfunction and fibrosis mechanisms in SSc patients.
Methods: RNA-seq analysis was performed on RNA obtained from biopsies
from 3 SSc patients and 3 age- and sex-matched healthy controls (HC) enrolled
in our University Hospital between January 2019 and December 2020. The
samples were transferred to a labelled cryovial and immediately stored in liquid nitrogen. RNA extraction followed standard methodologies. RNA from each
sample was used to generate sequencing libraries that were sequenced according to proper transcriptomic analyses. To identify potential functional pathways
that could be involved in SSc pathogenesis, we performed gene set enrichment
analysis (GSEA) of differentially expressed genes (DEGs). GSEA was applied
on the entire list of genes that compose the RNA-seq expression matrix. Genes
were ranked based on their fold change calculated between groups of each pairwise comparison and analyzed by GSEA in pre-ranked mode. We adopted the


“classic” enrichment statistic, the recommended approach for RNA-seq data.

Results: According to GSEA analysis of DEGs applied to SSc and HC, we identified 305 DEGs that were upregulated or downregulated at least 2-fold. In particular, 175 genes were upregulated and 130 genes were downregulated. A marked upregulation of genes involved in Wnt signaling, including Wnt family members, was present in HC if compared with SSc. The upregulation of collagen type VI, extracellular matrix protein 2, vascular endothelial growth factor D, among others, was also observed. Conversely, a marked downregulation of late cornified envelope and of genes encoding for keratins, was present in HC versus SSc samples. GSEA revealed that HC were characterized, among others, by gene signatures related to stromal stem cells proliferation, cytokine-cytokine receptor interaction, macrophage-enriched metabolic network, whereas SSc tissues were enriched in signatures related to keratinization, cornification, retinoblastoma (RB) 1 and tumour suppressor (TP) S3 signaling. Figure 1 displays GSEA in HC vs SSc tissues.

Conclusion: According to our preliminary data, RNA-seq, differential gene expression and pathway analysis revealed that SSc patients show a discrete pattern of gene expression associated with keratinization, extracellular matrix generation, and negative regulation of angiogenesis and stromal stem cell proliferation. Further analysis on larger numbers of patients are needed; however, our results provide an interesting framework for the development of biomarkers representing vascular injury and fibrotic changes in SSc in order to explore potential future therapeutic targets.


PO50383

CLINICAL CHARACTERISTICS AND PROGNOSIS OF PATIENTS WITH SYSTEMIC SCLEROSIS SINE SCLERODERMA: DATA FROM THE INTERNATIONAL EUSTAR DATABASE.


1University of Rennes, CHU Rennes, Inserm, EHEBP, Institut d’Etudes en Santé, Environnement et Travail-UMR1085, Internal Medicine & Clinical Immunology, Rennes, France; 2University of Michigan, Division of Rheumatology and Scleroderma Program - Department of Internal Medicine, Ann Arbor, Michigan, United States of America; 3University of Erlangen-Nuremberg, Dpt of Internal Medicine, Erlangen, Germany; 4Ghent University Hospital, Department of Rheumatology, Gent, Belgium; 5University of Leeds, Institute of Rheumatic and Musculoskeletal Medicine and NIHR Biomedical Research Centre, Leeds, United Kingdom; 6University of Zagreb School of Medicine and University Hospital Centre, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia; 7Faculty of Medicine University of Belgrade, Institute of Rheumatology, Belgrade, Serbia; 8Emergency County Teaching Hospital, Department of Rheumatology, Cluj-Napoca, Romania; 9Lausanne University Hospital, Immunology and Allergy, Lausanne, Switzerland; 10St-Louis Hospital, AP-HP CRMR for Rare Systemic Autoimmune Diseases, Internal Medicine, Paris, France; 11Rikshospitalet University Hospital, Department of Rheumatology, Oslo, Norway; 12Arche Polytechnic University, University of Ancona, Institute of Clinical Medicine, Ancona, Italy; 13University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland; 14University of Michigan, Division of Rheumatology and Scleroderma Program - Department of Internal Medicine, Ann Arbor, Michigan, United States of America; 15Hôpital Cochin, AP-HP/CUP Service de Rhéumatologie, Paris, France

Background: LeRoy’s classification defines two main subsets of Systemic Sclerosis (SSc) based on the extent of skin fibrosis: limited cutaneous SSc (lcSSc) with skin thickening sparing the trunk and distal to the elbow and knees, and diffuse cutaneous SSc (dcSSc) with proximal and distal skin thickening. These two subsets notably differ in terms of survival and frequency of visceral involvement. dcSSc being a more frequent, more severe form with a higher frequency of visceral manifestations. SSc sine scleroderma (ssSSc) is a third subset initially described by Rodnan et al. and characterized by the absence of skin fibrosis but with the existence of SSc-associated visceral manifestations.

Objectives: This study aimed to characterise the main clinical features of patients with ssSSc in comparison with the lcSSc and dcSSc subsets within the international EUSTAR database.

Methods: All patients from the EUSTAR database fulfilling the ACR2013 or 1980 classification criteria for SSc were assessed by the modified Rodnan Skin score (mRSS) at inclusion and with at least one follow-up visit were eligible. Sine scleroderma (ssSSc) was defined by the absence of skin thickening (mRSS=0 and no sclerodactyly) at all available visits. The clinical characteristics of these ssSSc patients were compared to those of patients with lcSSc and dcSSc with similar disease duration at last follow-up visit. Descriptive statistics were applied.

Results: Among the 4263 patients fulfilling the inclusion criteria, 376 (8.8%) were classified as ssSSc. Among them, 40.3% had puffy fingers, 39.4% had interstitial lung disease (ILD), 16.1% had a history of scleroderma renal crisis at inclusion visit. At last available visit, in comparison with 708 lcSSc and 708 dcSSc with the same disease duration, ssSSc patients had a lower prevalence of previous or current digital ulcers (28.2% versus 53.1% in lcSSc (P<0.001) and 68.3% in dcSSc (P<0.001)), of joint synovitis (16.9% versus 24.3% in lcSSc (P<0.01) and 30.8% in dcSSc (P<0.001)), and of elevated sPAP on echocardiogram (15.2% versus 23.9% in lcSSc (P<0.01) and 28.7% in dcSSc (P<0.0001)). Despite similar disease duration, disease activity at follow up visit (assessed by the EScSG disease activity index 2001 and 2016) was lower in ssSSc in comparison with lcSSc and dcSSc. By contrast, the prevalence of ILD was almost similar in ssSSc and lcSSc (49.8% and 57.1% (P=0.03)) but significantly higher in dcSSc (75.0%, P<0.0001). Based on forced vital capacity, ILD was less severe in ssSSc in comparison with the other subsets (mean FVC 100% (SD=22)% vs versus 93% (SD=21) in lcSSc and 82% (SD=23) in dcSSc (P<0.0001 for both)). Anti-centromere antibodies were most represented in ssSSc (61.7% versus 41.9% in lcSSc (P<0.0001) and 16.3% in dcSSc (P<0.0001)), whereas the opposite distribution was observed for anti-Scl70 antibodies. Survival was significantly higher in ssSSc patients compared to lcSSc (P<0.05) and dcSSc (P<0.0001).

Conclusion: This study highlights that ssSSc patients account for almost 10% of SSc patients with milder disease severity compared to both lcSSc and dcSSc.

Acknowledgements: The authors thank all EUSTAR collaborators.

Disclosure of Interests: None declared, Susanne Huang: None declared, Patricia Carreira: None declared, Elise Siegert: None declared, Jeska de Vries-Bouwstra: None declared, Jörg H.W. Distler: None declared, Vanessa Smith: None declared, Francesco Del Galdo: None declared, Branimir Ancic: None declared, Nemanja Damjanov: None declared, Simona Rednic: None declared, Camillo Ribi: None declared, DOMINIQUE FARGE: None declared, Anna-Maria Hoffmann-Vold: Speakers bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim, Armando Gabrielli: None declared, Olivier Distler: None declared, Dinesh Khanna: None declared, Yannick Allanore: None declared DOI: 10.1136/annrheumdis-2022-eular.3773

PO50384

ULTRA SHORT ECHO TIME MRI (UTE) SEQUENCE IN THE ASSESSMENT OF INTERSTITIAL DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS: CORRELATION WITH DISSON TENSION AT CT AND WITH PULMONARY LUNG FUNCTION TESTS.

M. Orlandi1, N. Landini2, C. Nardi3, G. Morana2, S. Colagrande3, M. Matsu-Cerinic4,5, 6University of Florence, Experimental and Clinical Medicine, Division of Rheumatology, Firenze, Italy; 7Ca’ Foscillo General Hospital, Radiology, Treviso, Italy; 8University of Florence, Radiology, Firenze, Italy; 9RCCS San Raffaele Hospital, Immunology, Rheumatology, Allergology and Rare diseases, Firenze, Italy

Background: Interstitial lung disease (ILD) is the major cause of death in Systemic sclerosis (SSc). Computed tomography (CT) is the gold standard imaging
technique to diagnose ILD and to assess ILD prognosis. ILD extent assessment at lung CT has shown to correlate with functional lung capacity: extensive lung disease (>20%) correlate with significant lung capacity decline (forced vital capacity (FVC) <70%). In fact, associated with a higher mortality. Unfortunately, it is burdened by exposure to ionizing radiations that limits its use for the follow-up. For this reason, new MRI sequences were recently investigated, and Ultra Short Echo Time (UTE) emerged promising for ILD assessment.

**Objectives:** The aim of the study is to evaluate the reliability of an MRI-UTE sequence in the assessment of ILD extent in patients with SS in comparison with standard high-resolution CT images and to correlate the extension with pulmonary function tests (PFT).

**Methods:** Patients with SSc and ILD underwent a CT and UTE-MRI (1.5 T) acquisition on the same day. In the same week, they carried out PFT, with FVC and the diffusion capacity of carbon monoxide (DCLCO) evaluation. Two thoracic radiologists assessed consensus, on CT and UTE-MRI, the extent of ILD. Extensions were calculated as the mean percentage of lung involvement, evaluated at five levels, with an assumption of 5%: ILD extension was classified as limited (<20%) or extensive (>20% or 20% with FVC <70%). The ANOVA test was adopted to compare the CT and MRI extensions of the ILD. Correlations of the extent of CT and UTE-MRI alterations with FVC and DCLCO were calculated with Pearson’s correlation coefficient r. Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of UTE-MRI were also calculated for UTE-MRI in determining ILD extent.

**Results:** The mean ILD extension was 20.9% in CT and 17% in UTE-MRI (p-value=0.64). The correlation of ILD extension in CT with FVC and DCLCO was significant (r=-0.66 (p<0.001) and r=-0.59 (p<0.0008), respectively). The correlation of ILD extension in UTE-MRI with FVC and DCLCO was significant (r=-0.66 (p<0.001) and r=-0.57 (p<0.002), respectively). The UTE-MRI assessments agreed with CT in identifying limited or extensive ILD in 25/29 patients (19 limited and 6 extended) and discordant in 4 (1 limited and 3 extended) UTE-MRI test sensitivity and specificity in identifying extended ILD were high (86.4% (65.1% -97.1%) and 85.7% (42.1% -99.6%), respectively). PPV and NPV were 95.0% (75.4% -99.2%) and 85.7% (42.1% -99.6%), respectively.

**Conclusion:** UTE-MRI sequence, compared to CT, shows high correlation with PFR and comparable ability in identifying patients with extensive ILD. Therefore, UTE-MRI seems a promising imaging sequence for the evaluation of ILD extension in SSc patients.

**REFERENCES:**

**SOS388**
Objectives: The aim of our study was to examine whether eSCAR may detect subclinical myocardial fibrosis in SSc.

Methods: In this cross-sectional study conducted between 11/2020 and 02/2021, consecutive SSc patients from the University of Verona underwent cardiovascular disease (CVD) screening procedures including standard transthoracic echocardiography (TTE) and myocardial scars detection through the eSCAR technique. We excluded patients with prior history of structural heart disease and pulmonary hypertension. To validate eSCAR findings, we assessed myocardial function through global longitudinal strain (GLS) analysis by speckle tracking echocardiography (STE). We also conducted a case-control study comparing eSCAR findings in randomly selected SSc patients and non-SSc controls matched 1:1 for age, sex and number of CVD risk factors. The primary outcome was the proportion of patients with myocardial scars.

Results: Scar imaging echocardiography revealed that 42/82 (44%) SSc patients had myocardial scars involving a median [25th-75th percentile] of 4 [1-7] segments. PCA identified that myocardial scars localised mostly at the inferior and septal segments (inferoseptal pattern; Figure 1). STE validation confirmed that GLS was significantly reduced in SSc patients with inferoseptal scars (Table 1). Otherwise, all standard echocardiography measures were normal in both groups. In multivariable regression analysis, prior digital ulcerations \( \beta = 0.41, 95\% \text{ CI} 0.008 \text{ to } 0.809, p=0.045 \) and body mass index \( \beta = -0.06, 95\% \text{ CI} -0.113 \text{ to } -0.015, p=0.012 \) were both significantly and independently associated with inferoseptal myocardial scars. Myocardial scars were found in 38% of SSc patients and no matched controls \( p<0.0001 \).

<table>
<thead>
<tr>
<th>GLS global (%)</th>
<th>eSCAR-positive ( n=8 )</th>
<th>eSCAR-negative ( n=31 )</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GLS (basal)</td>
<td>-20.66 (9.91)</td>
<td>-20.09 (4.12)</td>
<td>0.720</td>
</tr>
<tr>
<td>GLS apical</td>
<td>-17.11 (2.60)</td>
<td>-19.31 (5.26)</td>
<td>0.015</td>
</tr>
<tr>
<td>GLS basal</td>
<td>-20.66 (1.91)</td>
<td>-20.09 (4.12)</td>
<td>0.720</td>
</tr>
<tr>
<td>GLS 1-chamber (%)</td>
<td>-20.66 (5.23)</td>
<td>-21.97 (3.69)</td>
<td>0.924</td>
</tr>
<tr>
<td>GLS 2-chamber (%)</td>
<td>-20.66 (3.29)</td>
<td>-20.42 (2.65)</td>
<td>0.895</td>
</tr>
<tr>
<td>GLS 3-chamber (%)</td>
<td>-17.11 (2.60)</td>
<td>-19.31 (5.26)</td>
<td>0.015</td>
</tr>
<tr>
<td>GLS septal</td>
<td>-22.68 (7.14)</td>
<td>-21.76 (7.04)</td>
<td>0.844</td>
</tr>
<tr>
<td>GLS inferior</td>
<td>-26.89 (7.79)</td>
<td>-23.65 (4.46)</td>
<td>0.581</td>
</tr>
<tr>
<td>GLS anterior</td>
<td>-26.89 (7.79)</td>
<td>-23.65 (4.46)</td>
<td>0.581</td>
</tr>
</tbody>
</table>

Data are reported as mean (S.D.). GLS, global longitudinal strain.

Conclusion: This simple ultrasound technique allows detection of myocardial dysfunction associated with scars in SSc patients, or its absence in matched controls. Patients with prior digital ulcerations and low body weight have the strongest association with inferoseptal myocardial scars. eSCAR may help detect subclinical myocardial fibrosis in SSc.

Disclosure of Interests: None declared DOI: 10.1136/ann-rheum-dis-2022-eular.838

RISK STRATIFICATION APPROACHES PERFORM DIFFERENTLY IN SSc-ASSOCIATED PAH IN EUSTAR

H. J. Borgelmann1,2, C. Brun1, P. Carreira3, P. Airot, C. P. Simeon-Aznar1, M. E. Truchetet, A. Girol1, A. Babik-Gurman4, M. Martin5, C. P. Denton3, A. Gabrieli6, H. Fretheim1, I. Barau7,8, H. Bitter, O. Midvedt8, K. Br6, K. Andressanen9, Y. Tanaka10, G. Bremelkasten11, U. Muller-Ladner12, M. Matucci-Cerinic13,11, I. Castelli12, E. Siegert11, E. Hachulla11, O. Distler1, A. M. Hoffmann-Vold1, H. Hospital of Southern Norway, Kristiansand, Department of Rheumatology, Kristiansand, Norway; 2University of Oslo, Institute of Clinical Medicine, Oslo, Norway; 3Azienda Ospedaliero Universitaria Careggi, University of Florence, Department of Experimental Medicine, Division of Rheumatology, Florence, Italy; 4University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland; 512 de Octubre University Hospital, Department of Rheumatology, Madrid, Spain; 6Azienda Ospedaliero Spedali Civil di Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 7University Vall d’Hebron Hospital, Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Barcelona, Spain; 8Bordeaux University Hospital, Rheumatology Department, Bordeaux, France; 9University of Verona, Rheumatology Section, Department of Medicine, Verona, Italy; 10Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Institute of Technology, B Shein Rheumatology Institute, Haifa, Israel; 11Potier’s University Hospital, Department of Internal Medicine, Poitiers, France; 12University College London Division of Medicine and Royal Free Hospital, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom; 13University Politecnica delle Marche, Departmento di Scienze Cliniche e Molecolari, Ancona, Italy; 14Oslo University Hospital, Rikshospitalet, Department of Rheumatology, Oslo, Norway; 15Oslo University Hospital, Rikshospitalet, Department of Cardiology, Oslo, Norway, 16University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, Kitakyushu, Japan; 17University of Lübeck, Department of Rheumatology, Lübeck, Germany; 18Justus-Liebig University Giessen, Campus Kirchhoff, Dept of Rheumatology and Clinical Immunology Bad Nauheim, Germany; 19Hospital San Raffaele Hospital, UNIRAR, Milan, Italy; 20Hospital de la Santa Creu i Sant Pau, Department of Rheumatology, Barcelona, Spain; 21Charit University Hospital, Rheumatology, Berlin, Germany; 22Hôpital Claude Huriez, University of Lille, Department of Internal Medicine and Clinical Immunology, Lille, France

Background: Pulmonary arterial hypertension (PAH) is a major clinical challenge in systemic sclerosis (SSc), and is associated with high mortality. Risk stratification provides an estimate for individual patient risk of 1-year mortality. The aim is to detect patients with the worst prognosis to optimize management strategies. Nine risk stratification approaches have been proposed in PAH, but have not been validated in SSc-PAH.

Objectives: To assess four risk stratification models and their performance to predict 1- and 3-year mortality and to identify the best risk assessment approach for SSc-PAH.

Methods: We included all patients with SSc diagnosed with PAH by right heart catheterization (RHC) from the European Scleroderma trial and research (EUSTAR) database from 2001 to February 2021. PAH was defined as mean pulmonary arterial pressure (mPAP) ≥25 mmHg, pulmonary artery wedge pressure (PAWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >3 Wood units (WU) in the absence of significant interstitial lung disease. We applied four different approaches for risk stratification at time of PAH diagnosis. Risk parameters included New York Heart Association (NYHA) class, 6-minute walk distance (6MWD), NT-proBNP or BNP, and echocardiographic and hemodynamic parameters with cut-off values based on the 2015 ESC/ERS Guidelines. Model 1 and 2 stratified patients into low, intermediate and high-risk categories; while Model 3 and 4 stratified the patients into four categories (low, intermediate-low, intermediate-high and high).

Model 1: Patients with ≥1 high-risk parameter were considered at high risk; with ≥1 intermediate-risk parameter at intermediate risk, otherwise at low risk

Model 2: Each variable was graded from 1 to 3 representing low to high risk. The mean of available risk parameters was rounded to the nearest integer to define the risk category

Model 3: Equalizes Model 2, but the intermediate risk group was divided into intermediate-low and intermediate-high based on the mean score.

Model 4: Stratifies patients into four risk categories based on the proportion of low-risk parameters

We performed analysis of 1- and 3-year mortality in patients with a minimum follow-up of 1 and 3 years, respectively.
Results: Of 911 patients who conducted RHC, 273 (30%) were diagnosed with SSc-PAH according to the inclusion criteria (Table 1). Median follow-up time was 2.8 years (IQR 1.3-5.3). The models varied in their ability to predict mortality (Figure 1). Model 1 and 4 either over- or underestimated mortality. Model 2 stratified patients according to the expected 1-year mortality of <5%, 5-10% and >10% suggested by the ESC/ERS Guidelines. Model 3, which divided the intermediate risk group in two different risk groups, segregated the risk of mortality further within this group.

Conclusion: Model 3 provides signals for a better risk stratification of patients with newly diagnosed SSc-PAH, with progressively increasing mortality across the categories. This may provide guidance for optimized management in clinical practice.

Acknowledgements: The authors thank all EUSTAR collaborators.

REFERENCES:
[1] Hoffmann-Vold, Rheum 2018

Disclosure of Interests: Hilde Jenssen Bjerkaker: None declared, Cosimo Bruni Speakers bureau: Actelion, Consultant of: Boehringer Ingelheim, Patricia Carreira: None declared, Paolo Anir Speakers bureau: Boehringer Ingelheim, Bristol-Myers-Squibb, Consultant of: Bristol-Myers-Squibb, Roche, Jansen, CSL Behring, Carolina Pilar Simeón-Aznar Speakers bureau: Janssen, Boehringer Ingelheim and MSD, Consultant of: Janssen, Boehringer Ingelheim, Marie-Elise Truchetet: None declared, Simeón-Aznar Speakers bureau: Janssen, Boehringer Ingelheim and MSD, Consultant of: Bristol-Myers-Squibb, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ARXX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/research support from: Boehringer Ingelheim

DOI: 10.1136/annrheumdis-2022-eular.975

POS0388 DEVELOPING A SCREENING TOOL FOR THE DETECTION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS: THE ILD-RISC RISK SCORE

O. Bruni1, L. Tofani1,2, H. Fretin2, S. Liem1, A. Velathuppillai3, H. J. Bjerkaker2, I. Barua4, I. Galetti5, A. Garaiman5, M. O. Becker2, A. M. Hoffmann-Vold6, J. De Vries-Bouwstra5, M. Vonk2, J. W. H. Distler8, M. Matucci-Cerinic1,9, O. Distler2, Careggi University Hospital, Rheumatology, Firenze, Italy; 1University Hospital Zürich, Rheumatology, Zürich, Switzerland; 2University of Florence, Department of Statistics, Computer Science, Applications, Firenze, Italy; 3Oslo University Hospital - Rikshospitalet, Rheumatology, Oslo, Norway; 4Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 5Radboud University Medical Center, Rheumatology, Nijmegen, Netherlands; 6Hospital of Southern Norway, Rheumatology, Kristiansand, Norway; 7Gruppo Italiano per la Lotta alla Sclerodermia, GILS, Milano, Italy; 8University Hospital Erlangen, Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany; 9San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy

Background: High resolution computed tomography (HRCT) is the gold standard for the diagnosis of systemic sclerosis associated interstitial lung disease (SSc-ILD). Although there is agreement in performing HRCT as a screening test at time of SSc diagnosis, some physicians do not regularly perform baseline HRCTs. In addition, it is unclear according to which criteria HRCTs should be repeated during the follow-up of baseline ILD negative patients.

Objectives: To develop a risk score for the presence of SSc-ILD (the ILD-RISC), to guide physicians in ordering both baseline and follow-up HRCTs.

Methods: The steering board included six SSc-ILD experts from referral centers, two fellows and a patient research partner. Items for regression analysis were selected according to face validity, feasibility, scientific background, and personal experience using the nominal group technique (NGT). The prediction model for the presence of ILD was developed from baseline visits of SSc patients from the six centers using multivariable logistic regression with backward selection. Patients were randomly divided into a derivation and validation cohort consisting of 66% and 34% of patients respectively. Patients with missing data in the selected covariates and in the ILD status (outcome) were excluded. After identifying a cut-off favoring sensitivity >85% from the ROC curve analysis, the derived ILD-RISC score was applied first in the validation cohort and then longitudinally in a cohort of SSc patients with negative baseline HRCT.

Results: The steering board selected 13 variables deemed important in the identification of Scc-ILD: sex, age, disease duration from first non-Raynaud's phenomenon symptom, skin subset (diffuse/limited), presence of esophageal symptoms, digital ulcers (DU) ever, arthritis ever, smoking ever, increased inflammatory markers, NYHA functional class, SSc autoantibody status (SSc_Ab), FVC% and DCO%, among 780/3240 patients fulfilling the inclusion criteria, 533 (43% ILD) and 247 (48% ILD) respectively constituted the derivation and the validation cohort. In the derivation cohort, a model including FVC%, DCO%, DU ever, age and Ssc_Ab (Table 1A) showed an OR of 133.9 (95% CI 53.4-335.9) and an AUC of 79.1% (95% CI 75.3-83.0%) for the presence of ILD on HRCT (Figure 1). An ILD-RISC score ≥0.3 showed sensitivity of 85.6% and specificity of 53.6%, NPV of 82.2% and PPV of 58.2%, which were replicated in the validation cohort (Table 1B). Among 819 patients with negative baseline HRCT, 170 (20.8%) developed ILD during a 3.8±3.0 years follow up (1998 visits). Longitudinally, the ILD-RISC score showed comparable sensitivity and specificity (Table 1B).

Table 1. Demographic and clinical characteristics of patients segregated by risk stratification (Model 3)

<table>
<thead>
<tr>
<th></th>
<th>All patients (n=273)</th>
<th>Low-risk (n=78)</th>
<th>Intermediate-low (n=118)</th>
<th>Intermediate-high (n=56)</th>
<th>High-risk (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>273</td>
<td>65 (10.7)</td>
<td>65 (10.3)</td>
<td>65 (10.7)</td>
<td>65 (10.8)</td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>273</td>
<td>230 (84)</td>
<td>64 (82)</td>
<td>98 (83)</td>
<td>48 (86)</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>263</td>
<td>221 (84)</td>
<td>60 (80)</td>
<td>99 (86)</td>
<td>47 (90)</td>
</tr>
<tr>
<td>NYHA 3 or 4, n (%)</td>
<td>261</td>
<td>155 (59)</td>
<td>12 (16)</td>
<td>75 (68)</td>
<td>49 (89)</td>
</tr>
<tr>
<td>NTproBNP, pg/ml (IQR)</td>
<td>111</td>
<td>1041 (280-1480)</td>
<td>215 (103-377)</td>
<td>763 (325-1418)</td>
<td>1992 (1051-5681)</td>
</tr>
<tr>
<td>6MWD, m (SD)</td>
<td>196</td>
<td>321 (124.1)</td>
<td>404 (124.1)</td>
<td>314 (99.9)</td>
<td>262 (128.6)</td>
</tr>
<tr>
<td>mRAP, mmHg (SD)</td>
<td>273</td>
<td>40 (11.9)</td>
<td>35 (8.8)</td>
<td>41 (11.5)</td>
<td>41 (10.8)</td>
</tr>
<tr>
<td>PAWP, mmHg (SD)</td>
<td>273</td>
<td>9 (3.2)</td>
<td>9 (3.0)</td>
<td>9 (3.4)</td>
<td>9 (3.2)</td>
</tr>
<tr>
<td>Cardiac index, L/min/m² (SD)</td>
<td>260</td>
<td>2.8 (0.8)</td>
<td>3.2 (0.7)</td>
<td>2.7 (0.8)</td>
<td>2.6 (1.0)</td>
</tr>
<tr>
<td>PVR, WU (SD)</td>
<td>273</td>
<td>7.4 (4.1)</td>
<td>5.3 (2.8)</td>
<td>7.9 (4.0)</td>
<td>7.9 (4.2)</td>
</tr>
</tbody>
</table>

Figure 1. 1- and 3-year mortality according to risk category in the four different models.
Table 1:

<table>
<thead>
<tr>
<th>AILD-RISC MODEL VARIABLES</th>
<th>OR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Digital ulcers, ever</td>
<td>2.058</td>
<td>1.347-3.145</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age</td>
<td>1.026</td>
<td>1.010-1.042</td>
<td>0.001</td>
</tr>
<tr>
<td>SSc, ATB</td>
<td>0.334</td>
<td>0.198-0.563</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anti-centromere</td>
<td>2.379</td>
<td>1.326-4.267</td>
<td>0.004</td>
</tr>
<tr>
<td>Anti-topoisomerase I</td>
<td>1.407</td>
<td>0.636-3.113</td>
<td>0.399</td>
</tr>
<tr>
<td>ANA/antiSCoL</td>
<td>1.558</td>
<td>0.916-7.135</td>
<td>0.073</td>
</tr>
<tr>
<td>None of the above</td>
<td>Comparator</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC%</td>
<td>0.590</td>
<td>0.979-1002</td>
<td>0.091</td>
</tr>
<tr>
<td>DLCO%</td>
<td>0.971</td>
<td>0.960-0.982</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**BILD-RISC SCORE**

<table>
<thead>
<tr>
<th>PERFORMANCE</th>
<th>Derivation cohort</th>
<th>Validation cohort</th>
<th>Longitudinal cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Patients/ILD patients</td>
<td>533/229</td>
<td>247/199</td>
<td>619/170</td>
</tr>
<tr>
<td>AUC, %, 95% CI</td>
<td>0.791 (75.3 – 83.0)</td>
<td>0.764 (710 – 82.7)</td>
<td>0.726 (68.8 – 76.2)</td>
</tr>
<tr>
<td>Sensitivity, %, 95% CI</td>
<td>85.6 (80.4 – 89.9)</td>
<td>85.7 (78.1 – 91.5)</td>
<td>80.4 (73.9 – 86.0)</td>
</tr>
<tr>
<td>Specificity, %, 95% CI</td>
<td>53.6 (47.8 – 59.3)</td>
<td>49.2 (40.3 – 58.2)</td>
<td>50.5 (48.2 – 52.9)</td>
</tr>
<tr>
<td>Negative Predictive Value, %</td>
<td>93.2 (77.2 – 88.1)</td>
<td>79.8 (68.2 – 87.1)</td>
<td>96.3 (94.7 – 97.4)</td>
</tr>
<tr>
<td>Positive Predictive Value, %</td>
<td>58.2 (52.7 – 63.5)</td>
<td>61.1 (53.2 – 68.5)</td>
<td>13.9 (11.8 – 16.1)</td>
</tr>
<tr>
<td>95% CI</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 1. Distribution of the ILD-RISC score between patients with and without IOL on HRCT, in the derivation and validation cohorts.**

Conclusion: We developed and validated the ILD-RISC score to predict the presence of IOL at time of diagnosis and evaluated its performance during follow-up. The ILD-RISC may be useful in routine practice when resources for HRCTs might be limited. In particular, it may also help to decide when to order HRCTs at follow up, thus limiting unnecessary HRCTs and reducing the burden for patients and institutions.

Disclosure of Interests: Comosino Bruni Speakers bureau: Actelion, Consultant of: Boehringer-Ingelheim, Eli-Lilly, Grant/research support from: New Horizon fellowship, FOREUM, EUSTAR, GILS, Lorenzo Tofani: None declared, Håvard Frethem: None declared, Sophie Liem: None declared, Aritha Velauthapillai: None declared, Hilde Jenssen Bjørkekjær: None declared, Imon Barua: None declared, Ilaria Galietti: None declared, Alexandru Garașan: None declared, Mike O. Becker Speakers bureau: Mepha, MSD, Novartis, GSK, Bayer and Viofor, Consultant of: Mepha, MSD, Novartis, GSK, Bayer and Viofor, Grant/research support from: Mepha, MSD, Novartis, GSK, Bayer and Viofor, Anna-Maria Hoffmann-Vold Consultant of: Actelion, ARFX therapeutics, Bayer, Jansen, MSD, Lilly, Roche, Boehringer-Ingelheim, Medscope., Jesika de Vries-Bouwstra Speakers bureau: Payment for presentations and educational events by Boehringer Ingelheim and Janssen, Consultant of: Janssen and Boehringer Ingelheim, Abbvie, Grant/research support from: Roche, Gelapagos and Janssen, ZonMW and ReumaNederland, Madelon Vonk: None declared, Jörg H.W. Distler Shareholder of: J.H.W.D. is stock owner of 4D Science and Scientific head of FibroCure., Grant/research support from: J.H.W.D. has received research funding from Anamur, Active Biotech, Array Biopharma, aTyr, BMW, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB, Marco Matucci-Cerinic Speakers bureau: Biogen, Bayer, Boehringer-Ingelheim, CSL Behring, Eli-Lilly, Consultant of: Actelion, Bioingen, Bayer, Boehringer-Ingelheim, CSL Behring, Eli-Lilly, Grant/research support from: Actelion, Oliver Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscope, Consultant of: Abbvie, Acceleron, Alimera, Amgen, AnaMar, Arno, AstroZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Millenyi Biotech, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim


**POS0389**

**MUSCULAR EXPRESSION OF CD163 AND MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I AS DIAGNOSTIC MARKERS IN IDIOPATHIC INFLAMMATORY MYOPATHIES**

B. Ghang1, B. Yoo2, S. J. Nam3.

1. Jeju National Univ Hospital, Rheumatology, Jeju-si, Korea, Rep. of (South Korea); 2. Asian Medical Center, Rheumatology, Seoul, Korea, Rep. of (South Korea); 3. Asian Medical Center, Pathology, Seoul, Korea, Rep. of (South Korea)

Background: Various inflammatory markers have been suggested for detecting idiopathic inflammatory myopathies (IMMs); however, their diagnostic utility remains inconclusive.

Objectives: Muscle tissues from patients diagnosed with IMMs from January 2001 to March 2017 in a tertiary hospital were investigated. Muscular expression of CD3, CD4, CD8, CD20, CD68, CD163, MX1, MHC class I, MHC class II, and HLA-DR in muscle biopsy specimens from patients with IMMs and controls were evaluated using immunohistochemical staining. Classification and regression tree analyses were used to classify patients with IMMs who met the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies (2017 EULAR/ACR criteria for IMMs) using various staining results as predictor variables.

Methods: Muscle tissues from patients diagnosed with IMMs from January 2001 to March 2017 in a tertiary hospital were investigated. Muscular expression of CD3, CD4, CD8, CD20, CD68, CD163, MX1, MHC class I, MHC class II, and HLA-DR in muscle biopsy specimens from patients with IMMs and controls were evaluated using immunohistochemical staining. Classification and regression tree analyses were used to classify patients with IMMs who met the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies (2017 EULAR/ ACR criteria for IMMs) using various staining results as predictor variables.

Results: Among the total 146 patients diagnosed with IMMs by expert neurologist or rheumatologist, 129 patients with IMMs met the 2017 EULAR/ACR criteria for IMMs. Histopathologic features consistent with IMMs using HE staining was observed in 104 of 129 (80.6%) patients who met the 2017 EULAR/ACR criteria for IMMs (dermatomyositis, n = 46/66, 69.7%; polymyositis n = 58/63, 92.1%; sensitivity 80.6%, specificity 100.0%). Muscular expression of CD163 (99.2% vs. 20.8%, p < 0.001) and MHC class I (876% vs. 23.1%, p < 0.001) were significantly higher in patients with IMMs who met the 2017 EULAR/ACR criteria for IMMs than in controls. Combined CD163 and MHC class I expression provided the most significant stratification for the control group (sensitivity 96.1%, specificity 94.5%). This combination was able to classify 15 of 17 (94.1%) patients who were diagnosed with IMMs by an expert physician but did not meet the 2017 EULAR/ACR criteria for IMMs.

Conclusion: Combined CD163 and MHC class I muscular expression may be useful in diagnosing IMMs.

Table 1. Sensitivity, specificity, and predictive values of various inflammatory marker expressions and their optimal combinations for the diagnosis of idiopathic inflammatory myopathies.

<table>
<thead>
<tr>
<th>Muscle biopsy features consistent with IMMs on H/E staining</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3 expression</td>
<td>91.5%</td>
<td>51.4%</td>
<td>77.6%</td>
<td>76.6%</td>
</tr>
<tr>
<td>CD163 expression</td>
<td>99.2%</td>
<td>79.2%</td>
<td>98.9%</td>
<td>95.3%</td>
</tr>
<tr>
<td>MHC class I on myofibers</td>
<td>87.6%</td>
<td>76.3%</td>
<td>88.3%</td>
<td>75.8%</td>
</tr>
<tr>
<td>HLA-DR on myofibers</td>
<td>69.8%</td>
<td>81.6%</td>
<td>88.2%</td>
<td>76.5%</td>
</tr>
<tr>
<td>MHC class II on myofibers</td>
<td>13.2%</td>
<td>72.3%</td>
<td>45.6%</td>
<td>29.6%</td>
</tr>
<tr>
<td>Combination of CD163 and MHC class I on myofibers</td>
<td>96.1%</td>
<td>94.5%</td>
<td>96.9%</td>
<td>93.2%</td>
</tr>
</tbody>
</table>

Acknowledgements: This work was supported by a research grant from the Jeju National University Hospital

Disclosure of Interests: None declared

Background: Anti-melanoma differentiation-associated gene 5–positive dermamyositis (MDAS DM) is a rare but distinct subtype of idiopathic inflammatory myopathy (IIM) that is characterized by high mortality due to rapid progressive interstitial lung disease (ILD). MDAS is a cytosolic protein and a family of retinoic-acid inducible gene-1 (RIG-1) like receptor, which functions as a virus RNA sensor and induces the production of type I interferons (IFN-I) and proinflammatory cytokines. This leads to the death of infected cells and the activation of the antigen-specific antiviral immune response. Although the pathogenesis of MDAS DM is largely unknown, a hypothesis that pathogenic involvement of anti–MDAS antibodies has been proposed. Recently, similarities have been noted between multifaceted features of COVID-19 and MDAS DM, which suggests shared underlying autoimmune mechanisms.

Objectives: To detect the critical actors in the pathogenesis of MDAS DM by gene expression analysis of peripheral blood.

Methods: Total of 31 DM cases were investigated, including anti-amylooid-β-TRNA synthetase positive (ARS) DM (n=12), MDAS DM (n=7, survivor=3) and others (n=12). Peripheral blood was drawn at baseline and 2 to 3 months after treatments. Total RNAs were then extracted with using PAXgene miRNA kit. After quantifying the expressions of transcripts by multiplex sequencing. And then, hierarchical clustering analysis, enrichment analysis using gene ontology (GO) terms, single sample gene set enrichment analysis (ssGSEA) and weighted gene co-expression network analysis (WGCNA) were performed.

Results: The hierarchical clustering with expression profiles of peripheral blood at baseline showed major 3 clusters. Interestingly, ARS DM cases were segregated into right side of the 3rd cluster while MDAS DM cases fell into 1st and 2nd clusters. ARS and MDAS DM were clearly discriminated if differentially expressed genes (DEGs) between these subtypes of DM were analyzed. By GO enrichment analysis, the terms, such as related to “defense response to virus” including “type1 interferon signaling pathway” were found in the DEGs. In the MDAS DM cases, ssGSEA revealed that genes of “FCγR receptor mediated phagocytosis pathway” or “complement and coagulation cascade” were significantly enriched and WGCNA showed that pathways of “T-cell antigen receptor signaling” or “lungs fibrosis” were significantly upregulated. Next, we also investigated the DEGs of peripheral blood at 2-3 months after treatment between survival and fatal cases in MDAS DM. We found that suppressing RIG-I like receptor and type 1 and type 2 interferon (IFN) signaling were the keys for survival.

Conclusion: MDAS is a key sensor of several RNA viruses including corona-virus families and also activate antiviral gene transcription such as type 1 IFN genes, leading to establish an antiviral host response. As the pulmonary damage of COVID-19 is known to be difficult to distinguish from the ILD associated with anti-MDAS DM, the life-threatening ILD of MDAS DM may be caused by the over-activation of RIG-I like receptor signaling via MDAS. The hypothesis is supported by our findings that the defining features of MDAS DM are activation of “type 1 IFN pathways” and antigen-specific antiviral immune responses including “FCγR receptor mediated phagocytosis pathway” or “T-cell antigen receptor signaling”. As the levels of anti-MDAS antibodies reported to be important prognostic parameter, it may be involved in pathogenesis of MDAS DM. As we found that suppression of type 1 and type 2 IFN signaling were the keys for survival, it seems to be reasonable to use inhibitors of Janus Kinases (JAK) for treatment of MDAS DM.

Disclosure of Interests: Yoshinobu Koyama Speakers bureau: Abbvie, Asahikasei, Aya-Mi, BMS, Eli-Lilly, Mitsubishi Tanabe, Grant/research support from: Abbvie, GSK, Yoshinari Sato: None declared, Moe Sakamoto: None declared

DOI: 10.1136/annrheumdis-2022-eular.1574
Objectives: To correlate tMRI scores for muscle edema, fascial edema, muscle atrophy, and fatty infiltration with consecutively collected manual muscle testing 8 (MMT-8) scores and muscle enzymes. To determine the role of baseline tMRI changes in achieving maximum muscle power during follow-up.

Methods: This is a retrospective analysis of a single-center myositis cohort. IIM patients (n=55) who underwent baseline tMRI (STIR and T1 sequences) at the time of diagnosis were included. Baseline demographic, clinical, and serological parameters were noted. MRI T1 weighted sequence and STIR sequence axial and coronal images were assessed for intramuscular and fascial edema, atrophy and fatty replacement using a semiquantitative score and the percentage of muscle involvement for each parameter was calculated. MMT-8 values and muscle enzyme levels which remained unchanged at least for 6 months during follow-up were noted for 42 patients. MMT-8 ≥74 was taken as near normal muscle power based on the fact that 75% of IIM patients in remission for a long duration achieved MMT-8 of≥74 in our cohort. Spearman correlation was done between clinical parameters, muscle enzymes, and tMRI scores. Baseline parameters of patients who achieved and did not achieve MMT-8≥74 were compared. Multiple linear regression was performed to assess the tMRI variables predicting a higher MMT-8 during follow-up.

Results: The median age was 36 (27.25-44.75) years, median duration of disease at presentation was 4 months (2-10), median duration of follow up was 24 months (6.75-38.25). Dermatomyositis, Polymyositis and Antisynthetase syndrome comprised of 58.2%, 7.3% and 30.9% cases respectively. Baseline muscle enzymes CPK(r=0.531), AST(r=0.535) and ALT(r=0.442) showed significant positive correlation(p<0.01) with muscle edema. Baseline MRI thigh scores (median, IQR) muscle edema% 22.41(5.65-63.33) 10.37(0.00-28.70) 0.070 fascial edema % 43.33(18.61-78.06)33.89(11.49-50.56)0.478 muscle atrophy % 2.22(0.28-20.83) 0.00(0.00-2.50) 0.081 fatty infiltration % 6.67(2.78-18.61) 0.56(0.00-3.61) 0.010

Conclusion: Low baseline MMT-8 and presence of muscle atrophy at baseline are predictors of poor outcome. Hence performing a baseline MRI will help in the prognosis.

Disclosure of Interests: None declared

ASSOCIATION BETWEEN GENETICALLY PREDICTED EXPRESSION OF TPMT AND AZATHIOPRINE ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY CONDITIONS

A. Davis1, A. Dickson1, L. Daniel1, P. Nepal1, J. Zanussi1, T. Miller-Fleming1,2, P. Straub1,2, W. Q. Wei2, G. Liu1, N. Cox3, A. Hung3, G. Feng3, C. M. Stein1, C. P. Chung1,2,1Vanderbilt University Medical Center, Department of Medicine, Nashville, United States of America; 2Vanderbilt University School of Medicine, Vanderbilt Genetics Institute, Nashville, United States of America; 3Vanderbilt University Medical Center, Department of Biomedical Informatics, Nashville, United States of America

Background: Azathioprine is a widely used immunosuppressant for the treatment of inflammatory conditions such as systemic lupus erythematosus (SLE), systemic vasculitis, dermatomyositis, and inflammatory bowel disease. However, its use is often limited by myelotoxicity. Variants in the gene encoding thiopurine-S-methyltransferase (TPMT), an enzyme in the metabolic pathway of azathioprine, increase the risk for myelotoxicity. We know little about the relationship between the genetically predicted expression of TPMT and side effects of azathioprine.

Objectives: To examine whether genetically predicted expression of TPMT in liver tissue is associated with azathioprine adverse effects.

Methods: We assembled a retrospective cohort of new users taking azathioprine for inflammatory conditions at a tertiary care center. We performed genotyping with Illumina Infinium Expanded Multi-Ethnic Genotyping Array plus custom content data, and we then used Michigan Imputation servers for genetic imputation and PrediXcan models trained with GTEx/Genotype-Tissue Expression Project version 8 data to impute TPMT expression in liver tissue. We specified nine groups of phenotypes (comprised of ICD9 and ICD10 codes) corresponding to known adverse effects of azathioprine. We then tested the association between the predicted expression of TPMT and these adverse events; for outcomes significant in the Wilcoxon ranksum tests (p=0.05), each case was reviewed in clinical records for confirmation. Finally, we grouped the predicted expression of TPMT in liver tissue into tertiles and conducted logistic regressions to assess the associations between predicted expression and side effects. We conducted a sensitivity analysis restricted to patients with EHR-reported white race.

Results: The cohort included 1034 patients (Table 1). Phenocodes for 3 side effects—leukopenia (n=29), skin cancer (n=13), and rash (n=52)—were identified as associated with predicted TPMT expression in liver tissue. Of these, cases of side effects attributed to azathioprine were validated by chart review: leukopenia (96.6%; n=28), skin cancer (92.3%; n=12), and rash (9.6%; n=5) and used for analysis. When assessed by tertile of predicted expression, patients in the highest tertile had lower odds of having leukopenia (OR=0.35, 95%CI: 0.12-0.98, p=0.045) and a trend towards higher odds for skin cancer, but the number of cases was small (OR=3.56, 95%CI: 0.73-17.27, p=0.115). Confirmed cases of rash attributed to azathioprine were too few for meaningful analysis. We found similar associations between tertile of predicted expression and side effects attributed to azathioprine were validated by chart review: leukopenia (96.6%; n=28), skin cancer (92.3%; n=12), and rash (9.6%; n=5) and used for analysis. When assessed by tertile of predicted expression, patients in the highest tertile had lower odds of having leukopenia (OR=0.35, 95%CI: 0.12-0.98, p=0.045) and a trend towards higher odds for skin cancer, but the number of cases was small (OR=3.56, 95%CI: 0.73-17.27, p=0.115). Confirmed cases of rash attributed to azathioprine were too few for meaningful analysis. We found similar associations between tertile of predicted expression and side effects attributed to azathioprine were validated by chart review: leukopenia (96.6%; n=28), skin cancer (92.3%; n=12), and rash (9.6%; n=5) and used for analysis. When assessed by tertile of predicted expression, patients in the highest tertile had lower odds of having leukopenia (OR=0.35, 95%CI: 0.12-0.98, p=0.045) and a trend towards higher odds for skin cancer, but the number of cases was small (OR=3.56, 95%CI: 0.73-17.27, p=0.115). Confirmed cases of rash attributed to azathioprine were too few for meaningful analysis.

Conclusion: This analysis suggests that PrediXcan may be useful for examining the association between gene expression and side effects of medications. Moreover, this approach successfully identified leukopenia as a side effect associated with predicted TPMT expression.

Disclosure of Interests: None to declare.

DOI: 10.1136/annhem-2022-eular.332
Background: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population which contributes to early mortality. However, CAD screening tools developed in the general population are less effective for estimating CAD risk in RA patients. This is mainly due to the differing contribution from traditional risk factors and the contribution from disease-specific factors. Understanding of the genetic basis of CAD has improved over recent years and shows promise for improving risk prediction in the form of genetic risk scores (GRSs), in particular with the development of the metaGRS approach, which combines multiple polygenic risk scores.

Objectives: This study hypothesise that the metaGRS approach can help us improve CAD risk prediction in patients with RA.

Methods: Patients were recruited from the Norfolk Arthritis Register (NORAF), a longitudinal observational study focused on the cause and outcome of inflammatory polyarthritis. Analysis was restricted to patients who satisfied the 2010 ACR criteria cumulatively over five years and had detailed clinical history at baseline and follow-up for ten years. We developed a prediction model based on traditional risk factors[1], and explored the inclusion of a metaGRS. We used a meta-analytic approach to calculate a new metaGRS for CAD, using the effect-sizes from three large-scale, genome-wide, and targeted GRSs derived from 1,745,179[2], 6,630,150[3], and 40,079 SNPs[4]. We tested the metaGRS in combination with available data on traditional risk factors in a subset of patients with available genetic data. Cox proportional hazards models were used to derive risk equations for evaluation of 10-year risk of CAD. We applied multiple imputations with chained equations to replace missing values. Calibration and discrimination were determined in a separate cohort of 423 individuals.

Results: A total of 2123 patients were included in the analysis with 136 incident cases of self-reported CAD (defined as a composite outcome of myocardial infarction, angina, heart attack, arrhythmia, angioplasty, and coronary artery bypass grafting). The model using only traditional risk factors achieved an AUC of 0.81 (95% CI 0.80, 0.82), with a calibration slope of 1.10, and explained approximately 71% (95% CI 69, 72%) of the variance of the outcome. The hazard ratio for age was found to be 1.00 (95% CI 0.99, 1.01) indicating risk remains the same across all age groups. Inclusion of a metaCADGRS improves the AUC to 0.82 (95% CI 0.80, 0.83), explains more of the variance at 71% (95% CI 79, 82%) but worsens calibration slope to 0.93. A likelihood ratio test indicates that the integrated model is a better fit (p = 0.04).

Conclusion: An integrated risk score, that combines traditional risk factors with a metaGRS, improves CAD prediction in patients with RA. Further research is required to better understand the role of heritable components contributing to CAD risk in RA patients. By refining the underlying GRS, we hope to further improve risk prediction, through this integrated approach.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.06

POS0096
IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

J. H. Jung1, A. Kim2, B. Y. Kim2, G. G. Song1. 1Korea University College of Medicine, Internal Medicine, Seoul, Korea, Rep. of (South Korea); 2CHA University School of Medicine, Medicine, Seongnam, Korea, Rep. of (South Korea)

Background: Characterizing differentially expressed genes (DEGs) of systemic lupus erythematosus (SLE) is necessary to understand immunogenic interactions, and how several key immune genes were closely associated with the susceptibility of SLE.

Objectives: This study aimed to identify DEGs in SLE using gene expression-based computational methodologies to analyze disease-immune interactions, which affect the development and progression of SLE.

Methods: Twenty-six patients with SLE and 46 healthy controls were selected from the Gene Expression Omnibus database. The significantly enriched immune and virus related gene lists were computed and visualized by using the DEGs from the Gene Set Enrichment Analysis. Quantification of 36 immune cells were performed in determining the impact of immune cells on the virus mediated immunity in SLE by using ImmQuant algorithm.

Results: Thirty nine upregulated and 57 downregulated were identified in SLE patient compared to the healthy controls. Upregulated genes were significantly implicated in Gene Ontology gene sets as cytokine mediated signaling, secretion, and exocytosis in immune response pathways. In addition, these genes were enriched in hepatitis C, influenza A, measles, Epstein-Barr virus, and...
Adaptive immunity (T cells and B cells) in rheumatic diseases

**POS0397**

**SSD6453, A NOVEL AND HIGHLY SELECTIVE BTK/JAK3 DUAL INHIBITOR IS EFFICACIOUS IN MULTIPLE PRE-CLINICAL MODELS OF INFLAMMATION**


1Simcere Pharmaceuticals, in vitro pharmacology, Shanghai, China; 2Simcere Pharmaceuticals, in vivo pharmacology, Shanghai, China; 3Simcere Pharmaceuticals, Pharmaceutical Chemistry, Shanghai, China; 4Simcere Pharmaceuticals, DMPK, Shanghai, China; 5Simcere Pharmaceuticals, R&D, Shanghai, China

**Background:** The mechanism of inflammatory diseases is complicated and dysfunction of multiple immune cells is thought to be directly related to the pathogenesis. Targeting either JAK-STAT or BCR signaling has been proven to offer solid clinical efficacy in multiple inflammatory diseases, such as rheumatoid arthritis (RA) and multiple sclerosis (MS). And the combination of BTK and JAK inhibitors demonstrated synergistic effects for the treatment of inflammation models in pre-clinical. JAK3 expression is largely restricted to leukocytes and involves functions in JAK1/JAK3 heterodimer in signal transduction, it might be a more effective and safer target. Meanwhile, both BTK and JAK3 possess a cysteine residue in their active site and this feature makes it possible to design a dual inhibitor. SSD6453 is a highly selective and irreversible JAK3/BTK dual inhibitor which may have synergistic effects for the treatment of RA and other inflammatory diseases such as MS. **Objectives:** To develop a potent, oral, highly selective JAK3/BTK inhibitor for treatment of multiple inflammatory diseases.

**Methods:** ADP-Glo based biochemical assays were performed to determine the enzymatic inhibitory effect and selectivity for JAK family. The target engagement was evaluated by IgM induced pBTK and IL-2 induced pSTAT5 in human PBMCs. In vivo efficacy was evaluated by rat collagen-induced arthritis (CIA) model and mice experimental autoimmune encephalomyelitis (EAE) models induced by MOG1-125 or MOG35-55, respectively. BTK occupancy in spleens post last dose 24h and IL-2 induced pSTAT5 in whole blood post last dose 0.5h were used to evaluate targets inhibitions. Osteoclast was stained by IHC in pathological section of rat paws. **Results:** In biochemical assays, SSD6453 inhibited BTK and JAK3 with the IC50 values of 3.4 nM and 1.1 nM, respectively. Notably, SSD6453 displayed high enzymatic inhibitory effect and selectivity for JAK family. **Conclusion:** SSD6453 is a novel and high selective BTK/JAK3 dual inhibitor, and demonstrated synergistic efficacy in multiple pre-clinic inflammation models. SSD6453 showed good pharmacokinetic characteristics and well-tolerant in multiple pre-clinical species, and is moving to IND in 2022.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1907

**POS0398**

**IDENTIFICATION OF THE HLA-B*51:01 IMMUNOPEPTIDOME IN BEHÇET’S DISEASE**


1Seoul National University College of Medicine, Internal Medicine, Seoul, Korea, Rep. of (South Korea); 2Seoul National University, Molecular Medicine and Biopharmaceutical Sciences, Seoul, Korea, Rep. of (South Korea)

**Background:** Immunopeptidomes are peptides, bound to human leukocyte antigens (HLA), that play a key role in immune responses. HLA-B*51:01 is an HLA allele associated with Behçet’s disease (BD)1. However, the characteristics and the role of HLA-B*51:01 immunopeptidome are not revealed in Behçet’s disease. **Objectives:** To investigate the difference of HLA-B*51:01 immunopeptidome between Behçet’s disease and healthy controls (HCs) and to select candidate peptides which have a pathogenic role in Behçet’s disease.

**Methods:** HLA-bound peptide profiles were established through analysis of plasma samples from HLA-B*51:01-positive BD patients and HCs. HLA class I molecules were immunoprecipitated, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed. Then, HLA-B*51:01-binding peptides were assessed in terms of binding affinity using NethMCpan. Finally, the motifs of human leukocyte antigens (HLA)-B*51:01-positive BD patients and HCs.
immunological characteristics of selected peptides were analyzed in BD patients and HCs, using ELISPot, flow cytometry, and dextramer staining.

**Results:** 2,306 peptides were present only in BD patients, while 3,145 peptides were detected only in HCs. Immunoepitope of BD patients preferentially showed hydrophobic amino acids at amino acid position 2 (Figure 1). Ten peptides were selected, which were confirmed to be preferentially expressed in BD patients compared with HCs. When bound to HLA-B*51:01 in monocyte-derived dendritic cells (MoDCs) or peripheral blood mononuclear cells, these peptides activated T cells and induced surface expression of CD69 and CD107, as well as the secretion of inflammatory cytokines such as interferon (IFN)-γ and tumor necrosis factor (TNF)-α.

**Conclusion:** HLA-B*51:01 immunoepitope may play a critical role in the development of BD by activating T cells and inducing the secretion of inflammatory cytokines.

**References:**

**Background:** Differentiation in the bone marrow (BM) is impaired in patients carrying mutation in the IKZF1 gene, coding for Ikaros a zinc-finger transcription factor. High Ikaros expression is on the contrary associated with systemic lupus erythematosus [1] and multiple myeloma [2]. Targeted treatment with iberdomide, a cerebellin modulator which enhances degradation of Ikaros and Aiolos, is under clinical investigation in multiple myeloma patients and systemic lupus erythematosus. However, consequences of the treatment on human early B cell development remain elusive. Immature B cells develop in the BM from hematopoietic stem cells. An intricate network of transcription factors regulates the maturation process. Ikaros and Aiolos regulate gene expression during B cell development. As reported in mice, Ikaros is essential for the commitment to the lymphoid lineage and later, together with Aiolos, ensures the transition from pre-BII large to pre-BII small cells.

**Objectives:** The impact of iberdomide on short term culture of BM-derived lymphocytes and in a unique in vitro modeling of early B cell development starting from cord blood (CB)-CD34+ progenitors [3, 4]. We used multi-dimensional spectrally flow cytometry (17-color pan-el) to dissect early B cell subpopulations.

**Results:** Iberdomide treatment led to enhanced degradation of Ikaros and Aiolos in both BM- and CB-derived cultures. Addition of iberdomide early (day 7) to the CB-derived culture impaired the specification to the lymphoid lineage and later also the commitment to the B cell lineage. These observations were confirmed by reduced E2A and PAX5 gene expression, respectively. Treatment with iberdomide on B cell precursors (pre- and pre-B cells, day 28 of culture) on one side it enhanced the proliferation of early progenitors resulting in increased amount of CD10+CD38+ lymphoid-committed cells. On the other side, it resulted in a accumulation of pre-B cells and inefficient development of immature B cells.

**Conclusion:** Iberdomide impairs the commitment to the lymphoid lineage by enhancing Ikaros’ degrada-tion. When targeting already committed B cells, iberdo-mide treatment undermines the transition of pre-BI large to pre-BII small cells due to increased Aiolos’ degradation, concomitantly impairing the development of immu-nate B cells. Our data can instruct immunological monitoring of patients treated with iberdomide, and provide insights in the mechanisms of the therapeutic efficacy.

**References:**

**Disclosure of Interests:** Iga Janowska: None declared, Jakov Kozhnechevich: None declared, Julian Staniek: None declared, Raquel Lorenzetti: None declared, Lukas Konstantinidis: None declared, Miriam Erlacher: None declared, Peter Schafer Employee of: BMS, Reinhard Voll: None declared, Jens Thiel Grant/research support from: BMS (former Celgene), Nils Venhoff: None declared, Marta Rizzi Grant/research support from: BMS (former Celgene)

**DOI:** 10.1136/annrheumdis-2022-eular.2867

**POS404**

**SEROUM ANTIBODIES TO TYPE I COLLAGEN IN PERIPHERAL ARTHRPATHY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE**

D. Abulagulayeva1, D. Mukhamedtseva1, O. Zinkevich2, N. Saphina3, M. Korovina3, A. Odincova3. Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation; 2 Kazan State Medical Academy, Central Research Laboratory, Kazan, Russian Federation; 3 Kazan State Medical University, biochemistry and clinical laboratory diagnosis, Kazan, Russian Federation; 4 Republican Clinical Hospital, gastroenterology, Kazan, Russian Federation

**Background:** Immunological disorders play an important role in the pathogenesis of inflammatory bowel disease (IBD). Type I collagen (COL1) is the main component of the intercellular matrix of connective tissue. It can be assumed that the immune disorders occurring in the production of autoantibodies to collagen play a role in the pathogenesis of arthropathy associated with IBD.

**Objectives:** To study the level of IgM and IgG to type I collagen (COL1) in peripheral arthropathy associated with IBD.
Methods: We prospectively included 91 patients with IBD [61 ulcerative colitis (UC), 30 Crohn's disease (CD)] and 30 healthy controls. 82 patients with IBD were in disease attack and 9 in the remission. Mean age in IBD was 36 [28; 47] years and in control group – 35 [24; 45]. Joint involvement (arthralgia, arthritis) was observed in 33 patients (36%). Affected joints were the knees 17 (51%), shoulders 6 (18%), feet 6 (18%), hands 5 (15%), elbows 4 (12%), ankles 3 (9%), wrists 2 (6%). Levels of serum IgM and IgG to COL1 were assessed by enzyme immunoassay.

Results: Levels of IgM to COL1 in active IBD (0.18 [0.10; 0.22] mg/ml; p<0.01) and in remission (0.15 [0.11; 0.20] mg/ml; p<0.05) were increased compared with healthy (0.09 [0.07; 0.12] mg/ml). There were no differences between stages of disease attack and remission (remission and exacerbation). IgM antibody levels to COL1 in patients with peripheral arthropathy 0.174 [0.12; 0.28] mg/ml were significantly higher in patients without joint involvement 0.12 [0.08; 0.19] mg/ml; p<0.01.

The levels of IgG to COL1 in active IBD 14.4 [10.22; 33.34] mg/ml; p<0.05 and in remission (28.82 [16.36; 78.8] mg/ml; p<0.005) were higher than in the control group 11.36 [6.93; 19.83] mg/ml. We didn't find any differences in IgG levels depending on the severity of disease. IgG levels to COL1 in patients with peripheral arthropathy 16.18 [9.46; 26.21] mg/ml were higher, than without them 12.78 [8.81; 28.31] mg/ml, also not significant.

Conclusion: In active IBD the level of serum antibodies of class IgM and IgG to COL1 increased compared with healthy. The maximum increase was found in the patients with peripheral arthropathy, which can be explained by the high content of this collagen in the structural components of the joints and by joint inflammation in patients by IBD.

Disclosure of Interests: None declared.


PSQ0403

DYNAMIC CHANGES IN AUTOACTIVE MEMORY B CELLS IN RHEUMATOID ARTHRITIS: KEY TO UNDERSTANDING IMMUNOLOGICAL DISEASE ACTIVITY

N. Blomberg1, H. Kristiansyo1, M. Verstappen1, S. Neppelenbroek1, A. S. B. Kampstra1, A. Van der Helm-van Mil1, R. Toes1, H. J. U. Scherer1, Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands

Background: Rheumatoid arthritis (RA) patients with autoantibodies against citrullinated antigens (ACPA) are characterized by poor chances to achieve sustained DMARD free remission. We have previously observed that autoactive ACPA-expressing memory B cells (MBC) display an activated phenotype and frequently maintain this state of activation during periods even in patients in clinical remission in whom inflammation is absent through treatment. Conceptually, these observations could reflect ongoing immunological activity. In fact, they indicate that most current therapeutic interventions do not induce immunological remission and could explain why disease frequently flares when treatment is stopped. ACPA-expressing MBC display the phenotype of recent germlinal centre emigrants, actively proliferating (Ki-67 positive), expressing CD69 and co-stimulatory markers CD80 and CD86, and the signature cytokine IL-6.[1] Notably, in autoantibody-positive individuals with arthralgia that did not progress to inflammatory arthritis within 2 years, the autoreactive B cells were readily detectable in the circulation and proliferated but lacked, in most cases, the upregulation of CD80 seen at the onset of disease. Now, we studied these autoactive B cells longitudinally in the ‘at-risk’ phase of clinically suspect arthritis (CSA) and in a population of patients in sustained (>1 year) drug-free remission (SDFR).

Objectives: To define dynamic changes of the ACPA-expressing B cell compartment throughout clinical disease stages with the aim to evaluate this response as a possibly predictive biomarker of immunological disease activity.

Methods: ACPA-expressing MBC were identified by flow cytometry in peripheral blood of RA patients with chronic disease or at disease-onset (treatment-naive), in ACPA-positive CSA patients ‘at-risk’ for RA, and in patients in SDFR. B cells were characterized by a combination of markers to classify B cell subpopulations and activation- and germinal centre related markers. Tnusus-toxoid-specific B cells were analysed in the same individuals as antigen-specific comparators.

Results: In patients in SDFR, significantly less autoreactive B cells expressed CD80 compared to active disease, while they persistently showed signs of proliferation similar to the phenotype observed in CSA patients that did not progress to RA. ACPA-specific plasmablasts (defined as CD20 CD22[+] ) were practically absent in SDFR and CSA non-progressors, while they were readily detectable in patients with RA at disease onset, during treatment, and in CSA-individuals that later progressed to RA. Notably, two arthritis patients that developed RA within one year showed high CD80 expression in the autoactive MBC compartment already in the ‘at-risk’ phase, whereas patients that so far did not progress to RA during the time of follow-up, showed less CD80-positive autoactive MBC.

Conclusion: The phenotype of autoreactive B cells is dynamic in different disease phases of RA. By studying extremes of clinical phenotypes (‘at-risk’ phase, disease onset, SDFR), we found evidence for dynamic expression of CD80 by ACPA-expressing MBC in relation to clinical disease stage. Intriguingly, CD80-positive B cells, but not CD80-negative B cells, have been shown to be able to differentiate into antibody secreting cells in mice.[2] Our finding that plasmablasts were practically absent in ACPA-positive arthritis patients that did not progress to RA and in SDFR would fit with this notion and suggests that in SDFR autoactive MBC lack, although actively proliferating, triggers that induce CD80 upregulation, differentiation to plasmablasts and, possibly, their active participation in processes causing joint inflammation. Based on this observation, it is possible that induction of this CD80 [ ] phenotype in autoreactive MBC may be an important step towards achieving immunological remission, a conceptual proxy for cure.

REFERENCES:

Disclosure of Interests: None declared.


PSQ0402

CLONALLY EXPANDED CD8+ CYTOTOXIC CD8+ T CELLS DEFINE THE T CELL INFILTRATE IN CHECKPOINT INHIBITOR-ASSOCIATED ARTHRITIS

R. Wang1,2, A. Singaraju3, K. E. Marks1, L. Shaki3, G. Dunlap1, A. Cunningham-Bussie1, S. R. Grieser1, L. Chen1, A. Tripkic1, M. Fein1, D. Todd1, L. Madarame1, S. Goodman7, E. Dicarlo9, E. Massarotti1, J. Sparks1, O. P. Hamnvik10, L. Min10, A. Bussel1, S. R. Greisen6, L. Chen1, A. Tirpak1, M. Fein1, D. Todd1, L. Madarame1, S. Goodman7, E. Dicarlo9, E. Massarotti1, J. Sparks1, O. P. Hamnvik10, L. Min10, A. H. Jonsson1, M. Brenner, K. K. Chan7, A. Bass1, L. Donlin4,8, D. Rao1, Briggs1. A. Women's Hospital and Harvard Medical School, Division of Rheumatology, Immunology and Microbial Pathogenesis, New York, United States of America; 2Well Cornell Graduate School of Medical Sciences, Graduate Program in Immunology and Microbial Pathogenesis, New York, United States of America; 3Harvard Medical School, Program in Biological and Biomedical Sciences, Boston, United States of America; 4Aarhus University Hospital, Department of Biomedicine / Department of Rheumatology, Aarhus, Denmark; 5Hospital for Special Surgery / Weill Cornell Medicine, Division of Rheumatology, New York, United States of America; 6Hospital for Special Surgery, HSS Research Institute, New York, United States of America; 7Hospital for Special Surgery / Well Cornell Medicine, Division of Pathology, New York, United States of America; 8Brigham and Women's Hospital and Harvard Medical School, Division of Endocrinology, Diabetes and Hypertension, Boston, United States of America

Background: Immune checkpoint inhibitor (ICI) therapies that promote T cell activation have improved outcomes for advanced malignancies yet can also elicit harmful autoimmune reactions. The T cell mechanisms mediating these iatrogenic autoimmune events remain unclear.

Objectives: To investigate the immunophenotype, transcriptomic feature and clonotypes of T cells from joints of patients affected by ICI-induced inflammatory arthritis (ICI-aria)

Methods: Detailed immunophenotyping was performed on mononuclear cells from synovial fluid and flow cytometry and flow cytometry to identify significantly altered populations in ICI-A compared to seropositive rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (p<0.05). Bulk RNA-seq was performed on altered SF CD8 T cell subsets from ICI-A, RA and PsA to investigate their transcriptomic features. Cytokine profile and pathways enriched in ICI-A CD8 T cells were examined using differentially expressed genes, intracellular staining, and in vitro culture. TCR clonotypes were examined using single cell RNA-seq of T cells from synovial fluid, tissue and blood of ICI-A.

Results: Compared to the autoimmune arthritis RA and PsA, ICI-aria joint tissues contained an expanded CD8+ CD127- CD8+ T cell subset that displays cytotoxic, effector, and interferon (IFN) response signatures. Expression of synovial T cells to Type I IFN, more so than IFN-γ, induced the CD38+ cytotoxic phenotype. Single cell transcriptomic and T cell repertoire (TCR) analyses indicated that the abundance of CD38+ CD8+ T cells in ICI-aria resulted from proliferation of a limited number of clones. The CD38+ population appeared distinct from dysfunctional T cells and clonally most related to TCFF+ memory populations. Comparison of synovial tissue from bilateral knees of the same patient demonstrated considerable sharing of TCR clonotypes among CD38+ CD8+ T cells between the two joints. Further, TCR clonotypes expanded in synovial fluid of ICI-aria patients were detected in circulating T cells, and circulating CD38+ CD8+ T cells are also expanded in ICI-aria patients.

Conclusion: These results define a distinct CD8 T cell subset in the synovial fluid and in the circulation of patients with ICI-A that may be directly activated by ICI therapy to mediate a tissue-specific autoimmune response.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4504
Innate immunity in rheumatic diseases

**POSIT044**

IFNα-MEDIATED METABOLIC REPROGRAMMING IN HUMAN SLE MONOCYTES INVOLVES PERTURBATIONS IN GLYCOLYTIC AND LIPID METABOLISM TO REGULATE INFLAMMATORY MARKERS AND CYTOKINES

C. Stathopoulou1, D. Konstantopoulos2, S. Papapikolaou3, G. Vatellases1, G. Panagopoulos4, P. Sidirovski1, G. Bertsias1, 2, 3

1University of Crete, Medical School, Heraklion, Greece; 2Institute of Molecular Biology and Biotechnology-IMBB, Foundation for Research and Technology Hellas, Heraklion, Greece; 3Institute for Bioinovation-IIB, Biomedical Sciences Research Center ‘Alexander Fleming’, Athens, Greece; 4Greek Genome Center, Biomedical Research Foundation of Athens, Athens, Greece; 5University General Hospital, Rheumatology Department, Heraklion, Greece

**Background:** Systemic Lupus Erythematosus (SLE) is a prototype interferonopathy characterized by multiple organ damage. Metabolomic analyses of patient-derived sera indicate distinct metabolic perturbations in oxidative and lipid metabolic pathways of healthy Mo, whereas SLE-Mo resemble unhealthy Mo. Additionally, transcripts associated with cholesterol biosynthesis were upregulated in IFNα-SLE-Mo, in turn being responsible for the metabolic shift of cells. IFNα-mediated metabolic shifts in Mo with correlated metabolic perturbations in human disease are of current interest as new therapeutic targets in SLE.

**Objectives:** Based on previous data indicating a prominent IFNα-gene signature in SLE monocytes even during disease remission, we herein sought to delineate the metabolic repercussion of IFNα signaling contributing to SLE autoimmunity.

**Methods:** Using transcriptional data, we compared the enriched metabolic categories of IFNα(+) and IFNα(-) SLE-Mo. In order to compare metabolic perturbations pertaining to SLE, we performed transcriptomic Gene Set Enrichment Analysis (GSEA) from vitro cultured IFNα-activated Mo. We supplemented the analysis with in vitro biochemical inhibition of the metabolic pathways arising from the GSEA and evaluated the effect on inflammatory markers of healthy IFNα-Mo.

**Results:** We found a statistically significant enrichment of transcripts associated with glycolytic metabolism and lipid biosynthetic and catabolic processes in both IFNα(+) SLE-Mo and healthy IFNα-Mo, but not in IFNα(-) SLE-Mo, which in turn resemble healthy-Mo. Additionally, transcripts associated with cholesterol biosynthetic processes such as PMVK, SLOSE, LDLR, and LSLR, MVK, FMNL were significantly upregulated in IFNα(+) SLE-Mo and healthy IFNα-Mo respectively. In accordance with either glycolysis or the use of 2-DG hexokinase inhibitor, or mevalonic acid synthesis with the use of fuvastatin, attested proinflammatory cytokine secretion (IL6, CXCL10) associated with IFNα-response in both IFNα(+) SLE-Mo and healthy IFNα-Mo.

**Conclusion:** Our results link IFNα-mediated metabolic shifts in Mo with corresponding metabolic perturbations found in SLE patient-Mo. Pending further confirmation with targeted metabolomics, these data further rationalize the use of IFNα blockade and also suggest the potential use of specific metabolites as novel therapeutic targets in SLE.

**REFERENCES:**


Disclosure of Interests: None declared, Raquel López-Mejías: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Comaría: None declared, Raquel Güell: None declared, José Manuel Cifrián-Martínez: None declared, Raquel López-Mejías: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD, GSK, Grant/research support from: Abbvie, MSD, Janssen, Roche.

DOI: 10.1136/annrheumdis-2022-eular.2271

**POSIT0405**

INCREASED LEVELS OF CELLULAR ADHESION MOLECULES ARE LINKED TO THE PRESENCE OF INTERTISSUAL LUNG DISEASE IN PATIENTS WITH AUTOIMMUNE DISEASES

V. Pulte-Cueto1, S. Remuzgo-Martínez2, F. Genre1, B. Aleneria-Mateo2, V. Portilla2, V. Mora-Cuesta2, L. Iturbe Fernández2, L. Lera-Gómez2, D. Prieto-Pería2, R. Blanco2, A. Conejas2, O. Guallido2, J. M. Cifrián-Martínez2, R. López-Mejías2, M. A. González-Gay2, IDIVAL, Hospital Universitario Marqués de Valdecilla, Department of Pneumology, Santander, Spain; 3Hospital Universitario Marqués de Valdecilla, Department of Pneumology, Santander, Spain; 4Servicio Galego de Saúde, Instituto de Investigación Sanitaria-Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; 5Universidad de Cantabria, School of Medicine, Santander, Spain; 6Department of Medicine and Psychiatry, Universidad de Cantabria, Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain; 7University of the Witwatersrand, Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, Johannesburg, South Africa

**Background:** Intercellular adhesion molecule-1 (ICAM-1) and E-Selectin are adhesion molecules considered as markers of underlying endothelial activity and damage. These molecules are known to play an important role in autoimmune disease (AD) [1]. Accordingly, they may contribute to the development of interstitial lung disease (ILD), one of the main causes of death in patients with AD [2]. In fact, they have been proposed as prognostic biomarkers in idiopathic pulmonary fibrosis (IPF) [3]. However, studies on the role of ICAM-1 and E-Selectin in the pathogenesis of AD-ILD* are scarce.

**Objectives:** To study the role of ICAM-1 and E-Selectin in the pathogenesis of AD-ILD*.

**Methods:** Peripheral venous blood was collected from 57 patients with AD-ILD* and three comparative groups: 45 AD-ILD* patients, 21 IPF patients and 21 healthy controls (HC). All the subjects were recruited from the Rheumatology, and Pneumology departments of Hospital Universitario Marqués de Valdecilla, Santander, Spain. ICAM-1 and E-Selectin levels were measured in serum samples by enzyme-linked immunosorbent assay.

**Results:** Higher levels of ICAM-1 and E-Selectin were found in patients with AD-ILD* compared to AD-ILD* patients (p<0.001 and p=0.001, respectively) and HC (p<0.001 in both cases). Likewise, IPF patients showed increased levels of ICAM-1 and E-Selectin in relation to AD-ILD* patients (p<0.001 and p=0.002, respectively) and HC (p<0.001 in both cases). However, no statistically significant difference in ICAM-1 and E-Selectin concentrations was observed between AD-ILD* and IPF patients.

**Conclusion:** Our study suggests that increased levels of ICAM-1 and E-Selectin are associated with the presence of ILD in AD patients.

**REFERENCES:**


Disclosure of Interests: Veronica Pulte-Cueto: None declared, Sara Remuzgo-Martinez: None declared, Fernando Genre: None declared, Beihén Aleneria-Mateo: None declared, Virginia Portilla: None declared, Victor Manuel Mora-Cuesta: None declared, David Iturbe Fernandez: None declared, Leticia Lera-Gomez: None declared, Diana Prieto-Peria: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD and Roche, Alfonso Comaria: None declared, Oreste Guallido: None declared, Jose Manuel Cifrián-Martinez: None declared, Raquel Lopez-Mejias: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, MSD, GSK, Grant/research support from: Abbvie, MSD, Janssen, Roche.

Methods: The expression of eRNAs in SF (n=9), stimulated with TNF (24h; 10 ng/μl) or left untreated, was detected by cap analysis of gene expression followed by sequencing (CAGEseq). To further investigate eRNA expression in SF, the expression of selected eRNAs and their linked coding genes (CXCL1, CCL2, IL6, CCL2, CXCL12, IL8) was analyzed by real-time PCR in SF that were stimulated with TNF (1, 3, 6, 24h; 10 ng/μl), IL1 (1, 24h; 1 ng/ml), or the Toll-like receptor agonists Pam3 (1, 24h; 1 ng/ml), pic (1, 24h; 10 μg/ml) and LPS (1, 24h; 100 ng/μl). Samples containing the untranscribed RNA were measured in parallel. To study eRNA regulation, SF were treated with the bromodomain inhibitor I-BET (1 μM; 24h), or silenced for the histone acetyltransferases CBP and p300 by transfection with antisense LNA gapmeRs (12.5 nM) prior to stimulation with TNF (1, 24h).

Results: We have selected four potential eRNAs for CCL2 and IL8, three for CXCL12, two for IL6 and CXCL1 and one for CCL20 from CAGEseq analysis. They were located upstream (eCCL2#1, eCCL2#2, eCXCL1#2, eCXCL12#3, elIL#1+2, elIL#4-1), downstream (eCCL2#3, eCCL2#4, eCXCL1#1, eCXCL12#1) and intronic (eCCL20, eCCL12#2) at distances between 300 bp to 35.6 kb relative to the transcription start sites of the corresponding coding genes. None of the eRNAs was present in all nine samples in CAGEseq data sets, indicating a patient-dependent variability in eRNA expression. The majority of eRNAs were not detected in unstimulated SF, with the exception of eRNAs for CXCL12. By performing TNF time course experiments (Figure 1), we have detected different patterns of eRNAs: (a) eRNAs, that peaked at 1h (eCCL20, elIL#2, eCCL2#1), (b) at 6h (eCXCL1#1), (c) or at 24h (elIL#1, elIL#8#3, elIL#4, eCXCL1#2) after stimulation, (d) eRNAs that were stably expressed over the time points (eCCL2#2, 3, 4), and (e) eRNAs that were down regulated by TNF.

Results.

Figure 1.

stimulation (eCXCL12#1, eCXCL12#3). All inflammatory stimuli induced eRNA expression in SF, with LPS and IL1, followed by TNF, being the most potent inducers of eRNAs. I-BET suppressed the TNF-induced expression of all eRNAs tested. The effects on the expression of eRNAs after silencing of p300 but not of CBP mirrored to a large extent those of the respective coding genes. 

Conclusion: In SF, the expression of some eRNAs is maintained for up to 24h, contradicting previous reports that eRNA expression is short-lived. Our data suggest that different eRNAs orchestrate the early and sustained expression of cytokines and chemokines in SF; eRNA expression is controlled by p300 and BET bromodomain proteins.

Disclosure of Interests: Larissa Moser: None declared, Miranda Houtman: None declared, Oliver Distler Consultant of: Abbvie, Britta Maurer Speakers bureau: Boehringer-Ingelheim, Consultant of: Novartis, Boehringer Ingelheim, Janssen-Cilag, Grant/research support from: AbbVie, Protagen, Novartis Bio-medical Research, Caroline Ospelt: None declared, Kerstin Klein Grant/research support from: Novartis Foundation for biomedical research (2019)

Osteoarthritis, aetiology, pathology and animal models

POS0407

OXysterol 7-ketocholesterol can re-program synovial tissue macrophages and support M1 polarization

W. Dravši, D. Legovič, B. Ćurko-Cofel, L. Fryklavá, E. Babaovic, T. Kehler, V. Persic, G. Laskarin.1 1Clinical Hospital Centre Rijeka, Clinical Department of Laboratory Diagnostics, Rijeka, Croatia; 2Orthopedic University Hospital Lovran, Orthopaedic University Hospital Lovran, Lovran, Croatia; 3Faculty of Medicine, University of Rijeka, Department of Physiology and Immunology, Rijeka, Croatia; 4Croatian Academy of Sciences and Arts, Department of Biomedical Sciences in Rijeka, Rijeka, Croatia; 5Faculty of Medicine, University of Rijeka, Department of Pathology, Rijeka, Croatia; 6Hospital for Medical Rehabilitation of Heath and Lung Diseases and Rheumatism “Thalassoatherapia-Opatija”; 7Hospital for Medical Rehabilitation of Heath and Lung Diseases and Rheumatism “Thalassoatherapia-Opatija”, Opatija, Croatia

Background: Oxidized low-density lipoprotein (oxLDL) particles support low-grade inflammation and have been found in synovial fluid from osteoarthritis (OA) joints [1]. Their component is 7-ketocholesterol (7-KC), which arises as the result of the oxidation of cholesterol [1]. 7-KC acts proinflammatory and it binds to Toll-like receptor (TLR) 4 expressed on macrophages [1]. Activation of TLR4 stimulates the classical macrophage maturation program, resulting in a specific phenotype of inducible nitric oxide synthase positive (iNOS+) and macrophage (M) 1 function, which produce pro-inflammatory cytokines and chemokines [2]. M2 macrophages are associated with wound healing by the production of arginase-1 [2,3]. Synovial macrophages are of critical importance in the symptomatology and structural progression of OA since M1 polarized macrophages accumulate in human OA synovial tissue during exacerbation [3]. However, it is not known whether 7-KC can re-program synovial tissue macrophages and support M1 polarization.

Objectives: We analyzed the influence of 7-KC on the polarization of CD68+ macrophages in the suspension of synovial mononuclear cells (SMCs) in respect to lipopolysaccharide (LPS), as M1 inducer.

Methods: Mature synovial tissue samples were obtained during arthroplasty of the knee (N = 56). Paraffin embedded tissue sections were labelled by double immunofluorescence using a combination of antibodies directed toward CD68 and iNOS, arginase-1, CCL2 or CCL22. Suspension of SMCs was prepared by enzymatic digestion of tissue samples using collagenase IV and gradient density centrifugation. We analyzed intracellular (iNOS, arginase-1, CCL2, and CCL22) and surface (CD91, mannose receptor, HLA-DR, CD80, CD86 and decy D6) antigens expression in CD68+ cells and CD16+ cells in the suspension of freshly isolated or 18 hour-cultured SMCs with 7-KC (25 μM), LPS (10 ng/ml), their combination or in the medium only.

Results: iNOS and CCL2 were more frequently labelled in lymphocyte clusters, while arginase-1 and CCL22 were labelled in synovial lining CD68+ cells. Phenotype of CD68+ cells did not change significantly after the 18 hour culture in the medium only, except the decrease of mannose receptor and CD91, when compared with freshly isolated cells. 7-KC increased the percentage of CD68 expressing CD68+ cells, whereas decreased surface expression of CD91 and chemokine decor D6, like in the culture with LPS, when compared with cells cultured in the medium only. 7-KC decreased the frequency of arginase-1+/CD68+ cells in the suspension and did not change iNOS+ in CD68+ cells, thus increasing the ratio of iNOS+/arginase-1+ in CD68+ subset. 7-KC was unable to increase CCL2 like LPS in comparison with cells cultured in the medium only. Neither 7-KC nor LPS affected CCL22 expression in the CD68+ subset.

Conclusion: These data provide a new perspective in understanding the polarization of macrophages toward the M1 phenotype mediated with oxysterol 7-KC in vitro.

REFERENCES:


Rheumatoid arthritis - aetiology, pathogenesis and animal models__

**POSO048**  TRANSFER OF HUMAN RHEUMATOID ARTHRITIS MONONUCLEAR CELLS INDUCES ARTHRITIS IN IMMUNODEFICIENT HLA-DR4 TRANSIENT MICE

J. Rupp1, J. Fessler1, S. Hayer1, B. Dreo1, A. Lackner1, P. Pasching2, W. Hebel1, P. Schlenke3, J. Thiel1, G. Steiner4, W. Cornelia5, M. Stradner1. 1Medical University of Graz, Division of Rheumatology and Immunology, Graz, Austria; 2Medical University of Vienna, Division of Rheumatology, Vienna, Austria; 3Städtisches Krankenanstaltengesellschaft m.b.H., Institut für Krankenhausthygiene und Mikrobiologie, Graz, Austria; 4Medical University of Graz, Department of Blood Group Serology and Transfusion Medicine, Graz, Austria; 5Mayo Clinic School of Medicine and Sciences, Division of Rheumatology, Department of Medicine, Rochester, United States of America

**Background:** Rheumatoid arthritis (RA) is a systemic autoimmune disease leading to erosive joint destruction, although the exact pathogenesis is still elusive, the strong association of certain HLA class II molecules, such as HLA-DRB1*0401 (HLA-DR4), suggest involvement of CD4+ T cells (1, 2). Mouse models of RA mimic specific aspects of the disease but are limited by the differences between human and murine immune systems.

**Objectives:** We aimed to establish a humanized mouse model (humice) carrying DR4+ RA PBMCs to study its role in the pathogenesis of RA without putting patients at risk.

**Methods:** Peripheral blood mononuclear cells (PBMC) of HLA-DR4 positive RA patients or controls were isolated and injected into NSG-Ab0 DR4 mice (NOD-scid IL2Rgamma-null mice lacking MHC class II while expressing the human HLA-DR4) to create humice. Human immune cell composition within humice was profiled using flow cytometry. Development of RA was monitored by examination of the joints and micro computed tomography analysis. Joints were analysed by histology regarding pannus formation, bone erosions, cartilage damage, and human cell infiltration.

**Results:** Transfer of RA PBMCs induced arthritis in humice recapitulating hallmark signs of RA including immune cell infiltration, pannus formation, increased osteoclastogenesis, cartilage damage, and bone erosions. Arthritis was dependent on the implanted human cells as NSG-Ab0 DR4 mice without transfer of human PBMCs did not develop arthritis. T-helper 1 (Th1) cells, dominated the human immune cell composition in humice, while regulatory T cells (Tregs) were diminished compared to donor PBMC composition. Mice humanized with cells from RA patients were more likely to develop inflammatory joint disease, compared to healthy HLA-DR4 positive controls (RA donor mice vs vs. healthy control 20%, p=0.00196). CTLA4-Ig treatment prevented arthritis development in this model (p=0.0035).

**Conclusion:** Humice carrying DR4+ RA PBMCs developed an RA-like erosive joint disease driven by the implanted human immune system. The data implies that the disease can be transferred by arthritogenic cells found in the peripheral blood of RA patients. This model will allow new insights into the pathogenesis of RA.

**REFERENCES:**

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.670

**POSO409**  INTESTINAL HIF1α EXPRESSION PROTECTS AGAINST EPITHELIAL CELL DEATH IN ARTHRITIS

P. Lyu1, J. Wen1, I. Stolzer2, A. Giessi1, R. Song1, X. Meng1, S. Cao1, C. Günther1, G. Schett1, A. Bozec1, 1Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany; 2Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Department of Ophthalmology, Erlangen, Germany

**Background:** While a so-called gut-joint axis is supported by many clinical observations, the current knowledge on such axis is mostly confined to descriptive and correlative data, e.g. showing the microbiota changes are associated with arthritis. In contrast, mechanistic data on how molecular changes in the intestinal epithelium influence the development of arthritis are scarce.

**Objectives:** To investigate, whether the mucosal barrier in the intestine determines the fate of the epithelial cell survival maintenance, influences the development of arthritis.

**Methods:** Intestinal hypoxia inducible factor (HIF)-1α expression was assessed before, at onset and during experimental arthritis and human rheumatoid arthritis (RA). Intestinal epithelial cell-specific HIF1α conditional knock-out mice were generated (HIF1αΔIEC) and subjected to collagen-induced arthritis (CIA). Clinical and histological courses of arthritis were recorded, and T and B cell subsets were analyzed in the gut and secondary lymphatic organs, and intestinal epithelial cells were subjected to molecular mRNA sequencing in HIF1αΔIEC and littermate control mice. Furthermore, pharmacologic HIF1α stabilization by PHD inhibitor was used for the treatment of arthritis.

**Results:** Intestinal HIF1α expression peaked at onset and remained high in experimental arthritis and RA. Conditionally deletion of HIF1α in gut epithelial cells strongly exacerbate arthritis and was associated with increased gut epithelial cell death, intestinal and lymphatic Th1 and Th17 activation. Mechanistically, HIF1α inhibits the transcription of necroptotic and apoptotic markers, which leads to a defect in the intestinal barrier integrity. Furthermore, treatment with HIF1α stabilization reinforced the gut epithelial cell survival and inhibited arthritis.

**Conclusion:** These findings show that the HIF1α regulating epithelial cell survival is critical for the breakdown of the intestinal barrier function in arthritis highlighting the functional link between intestinal homeostasis and arthritis.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.367

**POSO410**  THE ROLE OF IL-6 IN ENDOTHELIAL DYSFUNCTION: RHEUMATOID ARTHRITIS AND COVID-19, TWO PATHOGENIC MODELS IN COMPARISON

A. I. Celia1, C. Barbatii, T. Colasanti1, M. Speziali1, G. Pellegrino1, F. Natalucci1, F. M. Uccio1, E. Balboni1, C. Ciancarella1, G. Tripodi1, G. Buonocore1, F. Cecarelli1, F. Conti1, C. Alessandrini1. 1Arthritis Clinic, Department of Clinical internal, anaesthesiological and cardiovascular sciences, Sapienza University of Rome, Rome, Italy

**Background:** Rheumatoid arthritis (RA) is the most common systemic autoimmune disease that primarily affects joints but is also often characterized by extra-articular involvement. Cardiovascular diseases are the most important causes of sudden death in these patients, which present a risk of developing cardiovascular events increased by 48%. The causes of increased cardiovascular risk are several and not completely understood, but recent evidence supports the key role of endothelial dysfunction in pathogenesis. In this complex scenario, it is known that IL-6 receptors are present at the endothelial level and can be activated leading to endothelial dysfunction. SARS-CoV-2 is a coronavirus responsible for the disease called COVID-19. COVID-19 2019 (COVID-19) characterized by clinical manifestations ranging from a flu-like syndrome up to severe lung damage associated with systemic hyper cytokine syndrome that can lead to multiple organ failure and death. Therefore, both RA and COVID-19 are associated with an increased pro-thrombotic and cardiovascular risk and IL-6 might be crucial in the pathophysiological mechanisms of both diseases.

**Objectives:** The main hypothesis of this study was to evaluate the possible role of IL-6 as a promoter of endothelial dysfunction in RA and COVID-19.

**Methods:** In vitro experiments were conducted on the endothelial cell line EA.hy926. Cells were treated for 24 h with fetal bovine serum (FBS), a pool of RA patients' sera or a pool of COVID-19 patients' sera. The expression levels of adhesion molecules (VCAM-1/CD-106, ICAM-1/CD-54, P-Selectine/CD-62, E-selectine/CD-62l), apoptosis were analyzed using cytofluorimetric technique. In addition, we observed increased levels of both p62 and LC3 proteins after both rheumatoid arthritis and COVID-19 patients' sera treatment. The expression levels of IL-6, IL-10, IL-22, and the Mann-Whitney test for paired samples. P<0.05 values were considered statistically significant.

**Results:** EA. hy926 cells, when treated with both RA and COVID-19 patients' sera, showed increased levels of activation molecules and apoptosis compared to FBS treated cells. In addition, we observed increased levels of both p62 and LC3 proteins after both rheumatoid arthritis and COVID-19 patients' sera treatment. All these findings were reversible in the presence of TCZ. The results are presented in Figure 1.
Background: Optimal dosing of methotrexate (MTX) in rheumatoid arthritis (RA) remains challenging. To this end, monitoring of intracellular MTX polyglutamates (MTX-PGs) in red blood cells (RBCs) has been investigated as a potential marker of MTX (non-)response, with contradictory results. As enucleated, non-proliferative cells, mature RBCs lack regulated folate metabolism and are devoid of folylpolyglutamate synthetase (FPGS) activity catalyzing the conversion of MTX to MTX-PGs. Therefore, it has been argued that analysis of MTX-PG in immune-effector cells, represented by peripheral blood mononuclear cells (PBMCs), would be more relevant. However, no prospective study has been performed measuring MTX-PG levels in PBMCs nor in comparison with RBCs.

Objectives: To investigate the pharmacokinetics of MTX-PG accumulation in RBCs and PBMCs in newly diagnosed RA patients in the early phase of MTX treatment.

Methods: In a clinical prospective cohort study (Methotrexate Monitoring (NTR7149)), RA patients were administered MTX op to 25 mg/week, as described before. (1) At 1, 2, 3 and 6 months after start of therapy, blood was collected and RBCs were isolated by centrifugation and PBMCs after Ficoll density gradient centrifugation. MTX-PG\(n\) concentrations in these cells were analyzed using a UPLC-MS/MS method with including custom-made stable isotopes of MTX-PG\(n\) as internal standards. (2) UPLC-MS/MS measurements for MTX-PG\(n\) were performed with a Waters Acquity BEH C18 column coupled to an AB Sciex 6500+ with the ESI operating on the positive mode. MTX dosing and concomitant treatments were in conformity with clinical practice. (3) Results: 46 consecutive patients were included in this study; 76% female, mean age: 57.8 years, mean baseline DAS28-ESR: 3.5, as described before. (1) Mean dosage was 10.5 mg (SD: 1.5) at baseline, 16.3 mg (2.5) at month 1, 22.7 mg (4.5) at month 2, 19.5 mg (6.3) at month 3 and 19.1 mg (6.2) at month 6. MTX-PG accumulation in PBMCs and RBCs revealed a disparate profile in both MTX-PG distribution and absolute accumulation levels (Figure 1A). Remarkably, MTX-PG distribution in PBMCs was mainly composed of MTX-PG1 (58%), and to a lesser extent MTX-PG2 (27%) and MTX-PG3 (15%). Longer chain MTX-PG\(n\) were also detectable in PBMCs, but at lower levels (mean: 4.0–6.7 nmol/10^6 cells) than MTX-PG\(1\). Moreover, this MTX-PG distribution profile in PBMCs remained constant over a MTX therapy period of 6 months (Figure 1A). The RBC MTX-PG accumulation profile shows mainly MTX-PG1 and lower levels of MTX-PG2-5 at 1 month after the start of therapy. After 3 months of therapy, MTX-PG1 is the main PG-moiety with also MTX-PG2 being detected. This profile is largely similar after 6 months of therapy. With respect to total intracellular MTX-PG\(1-6\) accumulation, PBMCs had significantly (p<0.001) 10-20-fold higher levels than RBCs at all analyzed time points (Figure 1A/B). Total MTX-PG\(1-6\) levels in RBCs and PBMCs at all time points were weakly correlated (r=0.41, p<0.01) (Figure 1C).

Conclusion: Our data showed that treatment with RA and CoViD-19 patients' sera increase the activation and death of endothelial cells in vitro. The increased level of cells death is possibly due to a block of autophagy. The reversibility of the process after blocking IL-6 with TCZ co-treatment confirms the hypothesis that IL-6 can play a key role in the pathogenesis of endothelial damage in patients with RA and CoViD-19.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.691

Figure 1. Figures show the adhesion molecules levels (A), apoptosis levels (B), p62 and LC3II levels (C), in all experimental conditions. FBS 10% (cells treated with FBS at 10% concentration), S AR (cells treated with a pool of RA patients' sera); S Covid (cells treated with a pool of CoViD-19 patients' sera); FBS 10%+toci (cells co-treated with FBS at 10% concentration and TCZ); S AR+toci (cells co-treated with a pool of RA patients' sera and TCZ); S Covid+toci (cells co-treated with a pool of CoViD-19 patients' sera and TCZ).

Figure 1. Individual MTX-PG concentrations in PBMCs (A) and RBCs (B) during the first 6 months of MTX administration (note the different scaling of the y-axes). At 6 months, 36 patients were still on MTX treatment. Panel (C): Spearman's correlation plot of total MTX-PGs in RBCs versus PBMCs of all time points.

The disparate MTX-PG accumulation and distribution profiles in PBMCs versus RBCs of RA patients may be associated with the shorter life span of PBMCs and the low FPGS activity in RBCs. (4) No significant relation between MTX-PGs and DAS28 was found (data not shown).

Conclusion: This study shows that in newly diagnosed RA patients starting MTX therapy, MTX-PG concentrations in PBMCs are significantly 10-20-fold higher than in RBCs over a period of 6 months, with a disparate MTX-PG distribution profile in PBMCs (highest: MTX-PG1,) than RBCs (highest: MTX-PG3.).

REFERENCES:

Acknowledgements: Acknowledgements: We would like to thank all participating patients and Pfizer (grant 53233663 / WI230458). AmsterdamUMC (AI&II extension grant) and NVKC (Noyons grant 2018)

Disclosure of Interests: Renske Hebing Grant/research support from: Pfizer (grant 53233663 / WI230458), NVKC (Netherlands Society for Clinical Chemistry, Noyons grant 2018) and AmsterdamUMC (extension grant), Marry Lin: None
Methods: A mouse model of pulmonary fibrosis was induced by intratracheal injection of bleomycin (BLM)[2]. Model mice were randomly assigned to receive Sodium carboxymethyl cellulose (CMC) or different concentrations of IGU. HE staining and immunohistochemical staining were performed to observe the therapeutic effects of IGU on mouse fibrosis. TGF-β1 induced A549 EMT cell model was utilized to investigate the effects of IGU on EMT in vitro[3]. NLRP3 inflammasome was activated by the co-stimulation of TGF-β1+LPS+ATP (TLA) to evaluate the effects of IGU in vitro[4].

Results: We found that IGU resulted in favorable therapeutic outcomes by affecting the inflammation infiltration (Figure 1A) and collagen deposition (Figure 1B). Immunohistochemical results showed that IGU downregulated the levels of α-SM and NLRP3. Additionally, the markers of BLM-mediated EMT (Figure 1C) phenotype and NLRP3-activated (Figure 1D) phenotype in the lung were also attenuated after IGU administration. In vitro experiments, the results confirmed its anti-EMT effects of reducing the expression of interstitial proteins Vimentin and α-SMA and restoring the content of epithelial protein E-cadherin. Besides, IGU could inhibit NLRP3 activation by downregulating NLRP3 related marker proteins, reducing the secretion of IL-1β, and attenuating caspase-1 activity. We then found that IGU anti-EMT and anti-NLRP3 effect was accompanied by decreased ROS production.

Conclusion: IGU can inhibit the EMT process and NLRP3 inflammasome activation, reduce ROS production to ameliorate pulmonary fibrosis, which may provide new insights into the further application of IGU in Interstitial pulmonary fibrosis.

REFERENCES:

Disclosure of Interests: None declared.
DOI: 10.1136/annrheumdis-2022-eular.969
Objectives: To investigate the role of GaR-9 as a biomarker for disease severity in treatment naïve patients with early RA and to study aspects of Gal-9 effects on inflammatory RA FLS.

Methods: Soluble plasma Gal-9 was measured in patients with newly diagnosed, treatment-naive RA (n = 98) and in Healthy (HC) (n = 48) (Table 1). Over a 2-year period patients were randomized to either MTX alone or MTX and anti-TNF antibody treatments. Serial measurements of disease activity (DAS28CRP) were collected to evaluate the disease course. In another cohort of patients with established RA, plasma and synovial fluid samples were also examined for Gal-9 (n = 18). Table 1. Synovial fluid mononuclear cells (SFMC) from established RA patients were used to harvest RA FLS (n=7). Osteoarthritis FLS were used as disease controls and obtained from patients with knee OA undergoing joint replacement surgery (n = 5). Monocultures of synovial fluid derived FLS (SF-FLS) (n=6) and autologous co-cultures of SF-FLS and peripheral blood mononuclear cells (PBMC) were established (n=7) and subsequently analyzed by flow cytometry, MITT assay, and ELISA. In vitro, cultures were treated with a neutralizing anti-Gal-9 antibody.

Table 1.

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Early RA (n=98)</th>
<th>Established RA (n=18)</th>
<th>HC (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time after treatment initiation (months)</td>
<td>0</td>
<td>3</td>
<td>24</td>
</tr>
<tr>
<td>Disease activity DAS28CRP (0-10)</td>
<td>5.7 (5.1-6.4)</td>
<td>2.1 (1.8-3.2)</td>
<td>2.0 (1.8-2.7)</td>
</tr>
<tr>
<td>Gal-9 levels (pg/ml)</td>
<td>3315</td>
<td>2817</td>
<td>3094</td>
</tr>
<tr>
<td>Plasma</td>
<td>(2683-4421)</td>
<td>(2706-4250)</td>
<td>(2639-3411)</td>
</tr>
<tr>
<td>Synovial fluid</td>
<td>21246</td>
<td>21324</td>
<td>21348</td>
</tr>
</tbody>
</table>

Patient characteristics. Data are expressed as median with IQR range unless otherwise indicated.

Results: Patients with early and established RA had increased plasma levels of Gal-9 compared with HC (P < 0.05) (Table 1) and levels of Gal-9 correlated positively with swollen joint counts at baseline (rho = 0.344, P < 0.05). The levels remained unaffected by treatment with MTX alone or by a combination of MTX and anti-TNF antibodies. Gal-9 levels were markedly elevated in the synovial fluid of chronic RA patients compared with the corresponding plasma samples (P < 0.05) (Table 1). In vitro, a neutralizing Gal-9 antibody mediated a 40% decrease in MCP-1 secretion (P < 0.05) and a 30% decrease in IL-6 secretion (P < 0.05) in RA FLS mononucleates. In OA FLS, addition of anti-Gal-9 antibodies comparably decreased the production of both MCP-1 (P < 0.05) and IL-6 (P < 0.05). The changes in cytokine production were not attributable to reduction in the fraction of inflammatory FLS (CD34/PDPN+THY1), decreased viability or proliferation. We further investigated if the effect of neutralizing Gal-9 persisted in co-cultures between FLS and activated T cells. Also in vitro using neutralization of Gal-9, mediated a 40% reduction in both MCP-1 and IL-6 (P < 0.05, P < 0.05). Conclusion: Pretreatment plasma Gal-9 levels in patients with newly diagnosed RA were increased and correlated with baseline clinical disease activity but remained elevated during goal directed synovitis suppressive therapy. In addition, in vitro neutralization of Gal-9 decreased MCP-1 and IL-6 production in a subset of FLS linked to RA pathology. Collectively, these findings indicate that Gal-9 overexpression is a co-player in the causation of acute and persistent RA synovitis by enhancing pro-inflammatory FLS pathways.

Acknowledgements: We thank Karin Skovgård Sorensen (Dept. of Biomedicine, Aarhus University) for technical assistance concerning the ELISA data and the FACS Core Facility (Aarhus University, Denmark) for technical assistance regarding Flow cytometry. We thank medical doctors and nurses at the Department of Rheumatology, Aarhus University Hospital for helping to collect the patient samples. We kindly acknowledge the generous grants from Aarhus University and the FACS Core Facility (Aarhus University, Denmark) for technical assistance concerning the ELISA data and the FACS Core Facility (Aarhus University, Denmark) for technical assistance regarding Flow cytometry.

Disclosure of Interests: None declared.
23% of RA patients positive for 0-4 epitopes, 36% for 5-10 epitopes, and 41% for >10 epitopes (p=0.02). The one ICI-A patient who was also RF positive had 12 positive ACPA epitopes. There was no significant difference in the number of ACPA epitopes in ICI-A patients who were smokers vs. nonsmokers, RA-like vs. PMR-like, or who received ICI combination vs. ICI monotherapy. In the 3 ICI-A patients with synovial fluid samples, SF ACPA was not demonstrated.

**Table 1. Baseline Characteristics of ACPA+ ICI-A and RA Patients**

<table>
<thead>
<tr>
<th></th>
<th>ICI-A (N=12)</th>
<th>Early RA (N=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years, mean (SD)</td>
<td>71.0 (8.3)</td>
<td>48.2 (14.6)</td>
</tr>
<tr>
<td>Female Sex</td>
<td>7 (58%)</td>
<td>33 (85%)</td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>9 (75%)</td>
<td>27 (69%)</td>
</tr>
<tr>
<td>Symptom Duration in months, median [IQR]</td>
<td>3.7 [10,11.3]</td>
<td>6.7 [4.0,9.7]</td>
</tr>
<tr>
<td>RF Positive</td>
<td>1 (8%)</td>
<td>27 (69%)</td>
</tr>
<tr>
<td>ACPA level (units/mL), median [IQR]</td>
<td>42.2 [28.4,70.5]</td>
<td>250 [107.5,251.0]</td>
</tr>
<tr>
<td>Obese (BMI&gt;30)</td>
<td>3 (25%)</td>
<td>9 (23%)</td>
</tr>
<tr>
<td>Current/Past Smoker</td>
<td>8 (67%)</td>
<td>14 (36%)</td>
</tr>
<tr>
<td>Cancer Type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Melanoma</td>
<td>4 (33%)</td>
<td></td>
</tr>
<tr>
<td>Renal Cell Carcinoma</td>
<td>3 (25%)</td>
<td></td>
</tr>
<tr>
<td>ICI Regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-1-PD-L1</td>
<td>7 (58%)</td>
<td></td>
</tr>
<tr>
<td>CTLA-4-IP-1</td>
<td>5 (42%)</td>
<td></td>
</tr>
<tr>
<td>ICI-A Phenotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA-like</td>
<td>9 (75%)</td>
<td></td>
</tr>
<tr>
<td>PMR-like</td>
<td>3 (25%)</td>
<td></td>
</tr>
</tbody>
</table>

a Other cancer types in ICI-A patients included urothelial carcinoma (n=2), non-small cell lung cancer (n=2), and head and neck cancer (n=1).

**Conclusion:** ICI-A patients had lower ACPA titers and targeted fewer ACPA epitopes than early RA patients. It remains to be determined if ICI-A represents an accelerated model of RA pathogenesis with ICI triggering an early transition from pre-clinical to clinical disease. This would require sequential sampling and analysis.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1810

**Fig. 1.** Heat Map of ACPA repertoire in RA Patients and ICI-A Patients.

**Discussion of Interests:** None declared.

**Disclosure of Interests:** None declared.

**Doi:** 10.1136/annrheumdis-2022-eular.1812

---

**Table 1. Baseline Characteristics of ACPA+ ICI-A and RA Patients**

<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>ICI-A (N=12)</th>
<th>Early RA (N=39)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melanoma</td>
<td>4 (33%)</td>
<td></td>
</tr>
<tr>
<td>Renal Cell Carcinoma</td>
<td>3 (25%)</td>
<td></td>
</tr>
<tr>
<td>ICI Regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD-1-PD-L1</td>
<td>7 (58%)</td>
<td></td>
</tr>
<tr>
<td>CTLA-4-IP-1</td>
<td>5 (42%)</td>
<td></td>
</tr>
<tr>
<td>ICI-A Phenotype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA-like</td>
<td>9 (75%)</td>
<td></td>
</tr>
<tr>
<td>PMR-like</td>
<td>3 (25%)</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** ICI-A patients had lower ACPA titers and targeted fewer ACPA epitopes than early RA patients. It remains to be determined if ICI-A represents an accelerated model of RA pathogenesis with ICI triggering an early transition from pre-clinical to clinical disease. This would require sequential sampling and analysis.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1810

---

**POS418**

**DIFFERENTIAL MiRNA EXPRESSION AND ENDOTHELIAL CELL FUNCTION IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS**

Q. Tyman1, C. Cunningham1, M. Hanlon1, A. Floudas1, M. Canavan1, U. Fearon1, D. Veale1, Trinity Biomedical Sciences Institute, Molecular Rheumatology, School of Medicine, Dublin, Ireland; 2St.Vincent’s University Hospital, and University College Dublin, Centre for Arthritis and Rheumatic Disease, Dublin, Ireland

**Background:** Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) constitute forms of inflammatory arthritis (IA) characterised by enhanced angiogenesis, immune cell infiltration, and generation of a hypoxic microenvironment leading to an invasive synovial pannus that results in bone and cartilage destruction. However, significant differences in circulating biomarkers in addition to disease pathogenesis at the clinical, immunological, cellular, and molecular levels have been identified that differentiate the two pathotypes.

**Objectives:** The aim of this study was to examine circulating miRNA as cellular biomarkers that can distinguish RA form PsA and to evaluate the potential implication for disease pathogenesis. Furthermore, this study aimed to examine the differential effect of the joint microenvironment on endothelial cell (EC) function in both RA and PsA.

**Methods:** RA, PsA and healthy controls (HC) were recruited from St. Vincent’s University Hospital, and serum was collected. Multiplex analysis of 88 serum miRNAs was performed using the FirePlex miRNA Immunology-V2 panel (FirePlex Biochrks Inc). Receiver operator characteristic (ROC) curves were generated to determine specificity and sensitivity of specific miRNAs whilst DNA intelligent analysis (DIANA)-mirPath and STRING software were used to analyse pathways targeted by the dysregulated miRNAs. Additionally, human umbilical vein endothelial cells (HUVEC) were cultured with RA and PsA synovial fluid (SF). Angiogenesis, invasion, and cellular adhesion were quantified by Matrigel tube formation assays, wound healing assays, and adhesion assays. Real-time cellular bioenergetics was analysed in HUVEC in response to RA and PsA SF using the Seahorse XF96 Analysers.

**Results:** 7 miRNAs; miR-126-3p, miR-29b-3p, miR-22-3p, miR-223-3p, miR-320a, let-7g-5e, and let-7g-5p (allp<0.01), were significantly elevated in RA
Denmark

ovial fluid, the panel was able to identify podoplanin+/CD90+/FAPa+ synovial fibroblasts previously linked with joint inflammation. The panel was, furthermore, able to identify a podoplanin+/CD90+/HLA-DR+ population in the immortalized synovial fibroblasts.

Conclusion: The optimized flow cytometry panel presented here enables researchers to identify synovial fibroblasts subsets which have been linked with disease traits in rheumatoid arthritis. This panel could therefore both be useful as a supplement to transcriptomic data and as a primary interrogation tool when investigating fibroblast subsets and cell function on a protein level.

REFERENCES:

Figure 1: Synovial fibroblast subsets identified with a 10-color flow cytometry panel

POS0420

A 10-COLOR FLOW CYTOMETRIC PANEL FOR IDENTIFYING SYNOVIAL FIBROBLAST SUBSETS IN RHEUMATOID ARTHRITIS

S. Lomholt1, T. W. Kragstrup1,2.1 Aarhus University, Department of Biomedicine, Aarhus, Denmark; 2Silkeborg Regional Hospital, Diagnostic Center, Silkeborg, Denmark

Background: Synovial fibroblasts are key players in the disease pathology of rheumatoid arthritis and specific fibroblast subsets have been linked to joint inflammation and joint destruction[1]. These synovial fibroblasts can be cultured from both the easily obtained synovial fluid or the more time-consuming synovial biopsy or resection. Recently, cultured synovial fibroblasts from synovial fluid where confirmed to possess a similar phenotype to that of the synovial fibroblast podoplanin+/CD90+/HLA-DR+ subset from biopsies.[2]

The present advancement in our knowledge of synovial fibroblasts have been spearheaded through bulk and single cell RNA transcriptionics. Expensive techniques that may require supplementary identification of phenotype clusters and cell function on protein level.

Objectives: The objective of this work was to plan, optimise and test a multi-color flow cytometry panel for identification of known synovial fibroblast subsets linked to arthritis pathology. The primary focus was well established markers; podoplanin, CD90, CD55, HLA-DR, CD24 and fibroblast activation protein alpha (FAPA).

Methods: Several cell types were used in optimizing the panel. The majority of antibody titration was conducted on immortalized synovial fibroblasts from a patient with rheumatoid arthritis. Exclusion markers such as CD45 (blood leukocytes), CD34 (endothelial and monocytes/macrophages) were titrated on synovial fluid mononuclear cells and peripheral blood mononuclear cells. Finally, full panel testing on synovial fibroblasts cultured from synovial fluid was compared with immortalized synovial fibroblasts. All tests were carried out on a commercially available flow cytometer with 4-lasers (405, 488, 561 and 637nm) and 27 detectors.

Results: Several panel iterations were tested during the optimization process. Two markers, cadherin-11 and receptor activator of nuclear factor kappa-b ligand, were abandoned after testing different antibody clones for staining and several detaching solutions on fibroblasts prior to staining. Initial compensation issues were overcome by rearranging fluorochromes and using cells as CD90 compensation controls.

The final flow cytometry panel contained 10 markers; podoplanin, CD90, CD55, CD34, HLA-DR, FAPA, CD45, CD31, complement C3a receptor and a viability marker. Final testing on synovial fibroblasts cultured from synovial fluid yielded an acceptable viability > 90%. Within the synovial fibroblasts cultured from synovial fluid, the panel was able to identify podoplanin+/CD90+/FAPA+ synovial fibroblasts previously linked with joint inflammation. The panel was, furthermore, able to identify a podoplanin+/CD90+/HLA-DR+ population in the immortalized synovial fibroblasts.

Conclusion: The optimized flow cytometry panel presented here enables researchers to identify synovial fibroblasts subsets which have been linked with disease traits in rheumatoid arthritis. This panel could therefore both be useful as a supplement to transcriptomic data and as a primary interrogation tool when investigating fibroblast subsets and cell function on a protein level.

Acknowledgements: We would like to acknowledge the FACS Core Facility at Aarhus University, Denmark, and thank them for sparing throughout the optimization process.

Disclosure of Interests: Søren Lomholt: None declared, Tue Wenzel Kragstrup Shareholder of: i bio tech ApS., Speakers bureau: Speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and Abbvie., Consultant of: Consultancy fees from Bristol-Myers Squibb and Gilead., Grant/research support from: Gilead.


POS0422

A HISTORY OF CHLAMYDIAE INFECTION IN RHEUMATOID ARTHRITIS DEVELOPMENT

C. Lamachia1, R. Aymon1, B. Gilbert1, O. Studer1, K. Lauper1, A. Finckh1. Geneva University Hospital, Rheumatology, Geneva, Switzerland

Background: Current hypotheses for the ethiopathogenesis of rheumatoid arthritis (RA) postulate an infectious agent initiating autoimmunity, which is thought to be at the mucosal level. Chlamydiae infections have been previously associated to development of an acute inflammatory arthritis, which can become chronic in some patients. Chlamydia trachomatis was detected in synovial fluid and tissue of RA patients, at least in early disease, suggesting that this organism could be involved in initiating RA onset, at least in a subset of patients.

Objectives: To investigate the association between Chlamydiae infection and the development of autoimmunity and pre-clinical manifestations associated with RA.

Methods: This study was performed in an ongoing prospective study of individuals genetically at risk of developing RA, namely first-degree relatives of RA patients (RA-FDR). Individuals without clinical evidence of RA

serum compared to both PsA patients and HC, with ROC curve analysis demonstrating the predictive accuracy with which each miRNA differentiated between RA and PsA (all p<0.05). Biplot analysis further identified that three miRNAs, miR-21-3p, miR-22-3p, and miR-223-3p, demonstrated the greatest separation between RA and PsA (all p<0.05). DIANA and STRING analysis identified the P13K-Akt pathway as being the primary target of these 3 miRNAs with specific gene targets involved in this pathway including factors importantly associated with endothelial cell migration, proliferation, invasion, and angiogenesis. Next, we examined the effect of the joint microenvironment on endothelial cell function and demonstrated that PsA SF significantly enhanced EC tube formation (p<0.05) and EC leukocyte adhesion (p<0.05), with RASF only significantly inducing EC leukocyte adhesion. Finally, metabolic analysis of endothelial cells demonstrated that PsA SF significantly induced baseline glycolysis (p<0.05), baseline OCR (p<0.05), maximal respiratory capacity (p<0.05) and spare respiratory capacity (p<0.05), with no effect observed for RA SF.

Conclusion: Circulating miRNAs may be valuable as diagnostic biomarkers that can distinguish RA from PsA. Additionally, the joint microenvironment induces EC function and metabolic capacity, with these effects more pronounced in response to PsA SF compared to RA SF.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2119
are enrolled, and assessed yearly, clinically and biologically. We included all RA-FDRs who responded to a Chlamydiae infection questionnaire, and the exposure of interest was self-reported Chlamydiae infection. The primary outcome was autoimmunity associated with RA (seropositivity) defined by the presence of anti-citrullinated peptide antibodies (ACPA) and/or rheumatoid factors (RF) at the last visit. Seropositive inflammatory arthritis at the last visit was a secondary outcome. We used logistic regression to analyze univari- able and multivariable associations, adjusting for age and gender as potential confounders.

Results: A total of 1254 RA-FDRs were analyzed, of which 168 (13.4%) had developed seropositivity. The prevalence of self-reported Chlamydia infection was significantly higher in seropositive individuals as compared to controls (179% versus 9.8%, P < 0.01 (Table 1). A significant association between the self-reported history of Chlamydiae infection and the seropositivity was observed in both univariate and multivariate analyses (OR = 2.00, 95% CI: 1.27-3.09; OR = 1.91, 95% CI: 1.20-2.95, respectively). A sub-group of 48 RA-FDRs (4%) presented inflammatory arthritis in conjunction with seropositivity. This sub-group, considered at highest risk for RA, reported significantly more often prior infections with Chlamydiae than the negative subgroup (20.8% versus 10.5%, P < 0.05). The ORs for the association of self-reported history of Chlamydiae infection and inflammatory arthritis coupled to RA-associated autoimmunity were 2.23 (95% CI: 1.03-4.43, P < 0.01, univariate analysis) and 1.91 (95% CI: 0.88-3.82, P = 0.08, multivariate analysis).

Table 1. A potential association between a self-reported history of Chlamydiae infection and RA development

<table>
<thead>
<tr>
<th>Study Groups</th>
<th>Self-reported “Infection”</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA-FDR with self-reported chlamydia infection anamnesis (n = 1254)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seropositive RA-FDR (n=168)</td>
<td>30 (17.9%)</td>
<td>2.00 (1.27-3.09)</td>
<td>1.91 (1.20-2.95)</td>
</tr>
<tr>
<td>Seronegative RA-FDR (n=1063)</td>
<td>104 (9.8%)</td>
<td>2.23 (1.03-4.43)</td>
<td>1.91 (0.88-3.82)</td>
</tr>
<tr>
<td>RA-FDR with seropositive inflammatory arthritis (n=48)</td>
<td>10 (20.8%)</td>
<td>2.00 (1.27-3.09)</td>
<td>1.91 (1.20-2.95)</td>
</tr>
<tr>
<td>RA-FDR without seropositive inflammatory arthritis (n=1206)</td>
<td>127 (10.5%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1Logistic regression model adjusting for age and gender. 2Seropositive inflammatory arthritis was defined by being either: seropositive RA; seropositive “arthritis” (defined by at least one swollen joint at physical examination); seropositive with MSUS (musculoskeletal ultrasound) inflammatory activity. 

Conclusion: Our results suggest that a history of Chlamydiae infection may be a risk factor for the development of RA in a subset of individuals at genetic risk for the disease. Serological analyses to assess the prevalence of antibodies to Ch. trachomatis major outer membrane protein (MOMP) are under way to confirm these preliminary data.

REFERENCES:

Disclosure of Interests: Céline Lamacchia: None declared, Romain Aymon: None declared, Benoit Gilbert: None declared, Olivia Studer: None declared, Kim Lau Per Consultant of: KL reports consultant fees for Pfizer and speaker fees for Pfizer, Viatris and Celltrion, outside of the submitted work, Axel Finckh: None declared.


POS0423 CYCLIC CITRULLINATED PEPTIDE APAMTER TREATMENT ATTENUATES COLLAGEN INDUCED ARTHRITIS

S. Khatri1, J. Hansen1, N. Pedersen1, S. Gram-Nielsen2, A. Mendes3, I. Chronakis1, U. Keiding1, B. Réth1, M. H. Clausen1,5, T. W. Kragstrup5,6, K. Astakhova1,5,6,11, Technical University of Denmark, Chemistry, Lyngby, Denmark; 2Technical University of Denmark, Health Technology, Lyngby, Denmark; 3Technical University of Denmark, Food, Lyngby, Denmark; 4Karolinska Institutet and Karolinska University Hospital, Department of Medicine/Solna, Solna, Sweden; 5IBIO TECH A/S, R&D, Copenhagen, Denmark; 6Aarhus University, Biomedicine, Aarhus, Denmark

Background: Anti-citrullinated peptide antibodies (ACPA) appear 10–15 years before the diagnosis of rheumatoid arthritis (RA) and are associated with a more severe disease course. In previous work, we rationally designed and screened ACPA-binding peptide aptamer sequences in silico and constructed a nanoparticle with chitosan and hyaluronic acid (1). A development- al stage version of this nanoparticle was able to reduce disease activity in the collagen-induced arthritis (CIA) and the serum transfer arthritis mouse models (2).

Objectives: Here, we investigated the effect and potential toxicity of three different versions of the aptamer nanoparticle (loading of 20%, 10% and 5% aptamer, respectively) in the CIA rat model.

Methods: Wistar rats (males and females) were given a single intravenous dose (100 mg/kg) of type II collagen in PBS in the tail vein. The dosing was repeated three times with one day interval, followed by blood sample collection at day 7 after the initial collagen injection. To evaluate route of administration and dosing, we injected a single intravenous and subcutaneous dose (2.5 mg/kg) of aptamer-nanoparticles (A/N ratio 20%) in PBS in the tail vein/abdomen, and plasma concentration-time profiles were followed for 2 days after dosing with weekly blood sampling. To evaluate organ uptake, rats were given a single intravenous and subcutaneous dose (2.5 mg/kg) of aptamer-nanoparticles and nanoparticle controls without aptamer or PBS alone in the abdomen. The procedure was repeated once after 24 hours. Blood and urine samples were taken once a week. A group of 10 animals was sacrificed every week over a three-week period, and the organs were processed. To examine efficacy, rats were given a single subcutaneous dose (2.5 mg/kg) of aptamer-nanoparticles and nanoparticle controls without aptamer or PBS alone in the abdomen. The procedure was repeated once a week over a course of three weeks. Weight, joint measurement, blood, and urine samples were taken once a week. Paw swelling was measured on a weekly basis. In the plasma samples we measured CPEP2 and anti-collagen II by enzyme linked immunosorbent assay (ELISA).

Results: Using a rather high dose of collagen (100 mg/kg) via an intrave- nous administration route, ACPA was measurable in all CIA rats with rapid development of RA in 82% of the included animals. Intravenous administra- tion resulted in an immediate high plasma concentration post injection, which decreased rapidly to low levels. The s.c. administration route gave a steady, long-term aptamer release with a maximum availability 8 hours post-injection. After three aptamer-nanoparticle doses (2.5 mg/kg; either 20%, 10% or 5% aptamer), we observed a dose-dependent reduction in swollen joint count for the aptamer-nanoparticle treated groups (10 rats in each group) compared with the healthy control group (10 rats) (P-value = 2.1E-6). We observed decreased ACPA IgG levels in the rats treated with aptamer-nanoparticle. The decrease in ACPA levels correlated with the aptamer-nanoparticle having higher loading. Anti-collagen II IgG levels slightly increased towards the end of the study.

Conclusion: We developed and tested a novel peptide aptamer-based drug can- didate for seropositive rheumatoid arthritis in CIA rats. Over a 3-week course of treatment with subcutaneous administration of aptamer-nanoparticles, joint swelling was decreased during treatment, and completely reversed at the end of the observation period. The reduction of joint swelling was associated with decreased levels of ACPA in the blood.

REFERENCES:


Disclosure of Interests: D. Liu1, Y. Li2, Xi’an No.5 Hospital, Department of Rheumatology and Immunology, Xi’an, China; Xi’an No.5 Hospital, Department of Rheumatology and Immunology, Xi’an, China
Background: Rheumatoid arthritis (RA) is a prevalent common autoimmune disease characterized by chronic inflammation of the joint and synovial hyperplasia and progressive destruction of articular cartilage and bone, which seriously influences a patient’s quality of life. Interleukin-25 belongs to the IL-17 cytokine family newly identified. IL-25 is widely produced between tissues, and IL-25 is reported to play an anti-inflammatory role in autoimmune and inflammatory diseases through the downregulation of Th1 and Th17 cell responses[1]. However, the exact role of IL-25 in the pathogenesis of RA remains to be elucidated.

Objectives: Set up CIA model to evaluate IL-25 influence in RA disease. Determine the molecular mechanism of IL-25 how to regulate IL-17A, ROR-γt, and Th17.

Methods: ① Male DBA/1 mice (n=12) were induced with immunized intradermally twice with type II collagen (2 mg/ml) emulsified in Complete Freund’s adjuvant orIncomplete Freund’s adjuvant containing by tail intravenous injection. CIA model mouse was constructed. CIA were then divided into two groups, for the use of PBS (n=6) and IL-25 (0.5μg, n=6) respectively, and followed daily. After 42 days, mice were sacrificed and collected articular tissues, proceed pathological staining and pathological score of arthritis. ② Male DBA/1 mice were immunized with CII to induce arthritis and consecutively received rMIL-25 (1 μg/mice) or PBS for 5 days beginning from day 1 after the second immunization with CII, and the incidence of arthritis was calculated. Spleen CD4+ T cells were isolated from CIA mice using Mouse CD4+ T Cell Isolation Kit. Cells were stimulated with plate-bound anti-CD3 (5 μg/ml) plus anti-CD28 (2 μg/ml) in the presence or absence of recombinant mouse (rm) IL-25 (100 ng/ml) for 24 h. In some cases, control IgG (10 μg/ml) were added to the cultures. The expression of IL-17A were examined using ELISA assay and ROR-γt mRNA in the cells were measured by real-time quantitative qPCR.

Results: In vivo studies indicated that, the RA incidence and symptoms of arthritis in IL-25-treated mice were significantly decreased compared with PBS controls. Histopathologic examination showed that the knee joints of IL-25-treated mice with CIA exhibited a significant reduction in synovial hyperplasia, cartilage damage and bone erosion compared with PBS controls. The serum levels of IL-17A in IL-25-treated mice were markedly reduced compared with those in WT mice. RT-qPCR also demonstrated that the transcript levels of IL-17A and ROR-γt were decreased in the Spleen of IL-25-treated mice.

Conclusion: Systemic injection of IL-25 can reduce the onset of arthritis and joint injury in CIA mice. IL-25 can inhibit Th17 cells of CIA mice, and its target is to regulate IL-17 cytokines and Expression of ROR-γt mRNA. CIA protection is mediated by the inhibition of Th17 by IL-25.

REFERENCES:

Disclosure of Interests: None declared.


P00425
METABOLIC ALTERATIONS IN ACTIVATED FIBROBLAST-LIKE SYNOVIOCYTES FROM NON-INFLAMED SUBJECTS - MIMICKING EARLY STAGE OF RHEUMATOID ARTHRITIS

Y. Zhang1,2, A. Nguyen1, A. Rudin1, C. Maglio1,2,3, Sahlgrenska Academy, University of Gothenburg, Department of Rheumatology and Inflammation research, Gothenburg, Sweden; 1University of Gothenburg, Wallenberg Center for Molecular and Translational Medicine, Gothenburg, Sweden; 3Region Västra Götaland, Sahlgrenska University Hospital, Rheumatology Clinic, Gothenburg, Sweden

Background: Proliferative cells, such as inflamed cells, depend on altered metabolic pathways to support their active proliferation. Synovial samples from patients with rheumatoid arthritis (RA) show reprogramming of different metabolic pathways such as glucose and glutamine metabolism [1]. However, it is unknown which metabolic pathways are altered in the early phases of RA pathogenesis, when non-inflamed fibroblast-like synoviocytes (FLS) are activated to a pro-inflammatory state. Our group has created an in-vitro cell model using FLS from subjects without inflammatory arthritis (non-inflamed FLS) after activation with adiponectin and tumour necrosis factor (TNF) to mimic the early stage of RA [2].

Objectives: We aim to determine if the stimulation of non-inflamed FLS upregulates the expression of key enzymes involved in glucose and glutamine metabolism and how the inhibition of those enzymes affects FLS activation.

Methods: FLS (passage 8-8) were isolated from synovial tissues of patients without inflammatory arthritis or osteoarthritis who underwent diagnostic arthroscopy due to a previous injury. FLS were cultured in DMEM medium (high glucose and GlutaMAX) containing 10% FBS and stimulated by known FLS-activators, i.e. TNF, interleukin 1 beta (IL-1β), and adiponectin. For the inhibition experiments, cells were pre-treated with 25 mM 2-DG or 300 mM CB-839 for 4 hours before stimulation. Expressions of the enzymes were measured by western blot in whole-cell lysates and IL-6 was measured using ELISA in cell culture supernatants at 24 hours after stimulation. Cell proliferation was determined using MTT assay after 48 hours of stimulation.

Results: First, we compared the expression of hexokinase 2 (HK2), glutaminase C (GAC), and PFKFB3 in non-inflamed FLS before and after activation with adiponectin, TNF, and IL-1β. Expression of HK2 and GAC were upregulated in adiponectin- and TNF-activated FLS compared to unstimulated FLS. PFKFB3 was not affected by any of the stimuli. IL-1β did not affect the expression of the analysed enzymes (Figure 1A-C). As IL-1β did not affect the expression of metabolic enzymes, we continued stimulation only with adiponectin and TNF. TNF but not adiponectin significantly enhanced the proliferation of FLS without inhibition (Figure 1D). However, FLS proliferation was significantly reduced by pre-treatment with 2-DG, a glycolysis inhibitor, in unstimulated as well as TNF- and adiponectin-stimulated cells. CB-839, a glutaminase inhibitor, did not affect the proliferation of FLS (Figure 1D). Both TNF and adiponectin significantly upregulated the production of IL-6 in FLS. Pre-treatment with 2-DG significantly reduced the production of IL-6. CB-839 pre-treatment significantly reduced the production of IL-6 only in unstimulated FLS (Figure 1E).

Conclusion: Our results show that the expression of key enzymes regulating metabolic pathways can be enhanced by adiponectin and TNF in non-inflamed FLS. Moreover, we also show that inhibition of specific metabolic pathways can affect FLS activation differently depending on the cytokine stimulation. These results provide a deeper understanding of metabolic reprogramming in FLS in early RA.

REFERENCES:

Disclosure of Interests: None declared.


P00426
BRD3 REGulates THE INFLAMMATORY AND STRESS RESPONSE IN RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS

M. Maciukiewicz1,2,3, L. Mose1, K. Krosel1, T. Seifritz3, M. Tomsic4, B. Maurer1,2, O. Distler1, C. Ospelt1, K. Klein1,2, University Hospital Bern, Department of Rheumatology and Immunology, Bern, Switzerland; 1University of Bern, Department of BioMedical Research, Bern, Switzerland; 2University Hospital Zurich, University of Zurich, Center of Experimental Rheumatology, Department of Rheumatology, Zurich, Switzerland; 3University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia

Background: Small molecule inhibitors targeting members of the bromodomain and extra-terminal (BET) protein family (BRD2, BRD3, BRD4) have anti-inflammatory properties in rheumatoid arthritis (RA). BET proteins are readers of acetylated histone side chains and activators of transcription. BRD3 is an under-studied member of BET proteins.

Disclosure of Interests: None declared.

Objectives: To analyse individual functions of BET proteins and mechanisms underlying BET inhibition in RA synovial fibroblasts (SF).

Methods: The expression of BRD2, BRD3, and BRD4 was silenced by lentiviral transduction followed by TNF stimulation (10 ng/ml, 24h). Silencing was confirmed by Western blotting. Transcriptomes were determined by RNA-seq (Illumina NovaSeq 6000, n=3). Pathway enrichment analysis for KEGG and Reactome databases was conducted with significantly affected genes (a fold change > 1.5, FDR < 0.05). SF were treated with I-BET (1 µM) and TNF (10 ng/ml, 24h). Autophagy was evaluated by Western blotting using the conversion of LC3B as a marker (n=9). I-BET-induced global changes on post-translational histone modifications were analysed by mass spectrometry (Mod Spec, Active Motif; n=2; 120h protocol) and Western blotting (H3K27ac, H3K18ac, total acH3; n=7; 24h and 120h protocol). For this purpose, SF were stimulated with I-BET (1 µM) for 24h, and either co-stimulated with TNF (24h protocol), or washed with PBS, followed by a 24h stimulation with TNF 120h after the I-BET treatment (120h protocol).

Results: Silencing of BRD2 and BRD4 in SF was in contrast to silencing of BRD3, associated with high levels of cell death, and therefore not analyzed further. We detected 257 and 324 differentially expressed genes (DEG) that were affected by BRD3 silencing in unstimulated and TNF-stimulated SF, respectively. 105 DEG overlapped between the two groups. DEG were enriched in inflammatory pathways such as "TNF signaling pathway", "rheumatoid arthritis", " Toll-like receptor cascades", "MAPK signaling pathway", "IL-17 signaling pathway" and "signaling by interleukins". Furthermore, pathway enrichment analysis suggested a role for BRD3 in different stress-associated pathways, including "DNA repair", "chaperone mediated autophagy", "cellular responses to stress", and "autophagy". In line with the pathway enrichment analysis, I-BET induced levels of LC3B-II in unstimulated (4.3 fold, p=0.07) and TNF-stimulated (2.9 fold, p=0.07) SF, indicating a role of BET proteins in the regulation of autophagy. To further study the mechanisms underlying I-BET-mediated suppression of gene expression, we analyzed potential effects of I-BET on histone modifications. Mod Spec analysis indicated that I-BET induced profound changes in chromatin modifications, with a global reduction of acetylation on different histone side modifications. We confirmed some of these differences in independent samples. I-BET treatment reduced mean TNF-induced levels of total acH3 by 25.2% (120h; p=0.0303), of H3K18ac by 35.3% (24h; p=0.0028) and by 29.3% (120h; p=0.0373) and of H3K9ac by 41.7% (120h; p=0.0587).

Conclusion: BRD3 acts as an upstream regulatory factor that integrates the response to inflammatory stimuli and stress conditions in SF. Our data suggest that BET inhibitors do not only prevent the reading of acetylated histone side chains, but also directly affect the chromatin structure, in particular by downregulating BRD3, associated with high levels of cell death, and therefore not analyzed further. In addition, BET inhibitors do not only prevent the reading of acetylated histone side chains, but also directly affect the chromatin structure, in particular by downregulating BRD3, associated with high levels of cell death, and therefore not analyzed further.

Disclosure of Interests: Malgorzata Maciukiewicz: None declared, Larissa Moser: None declared, Monika Krosel: None declared, Tanja Seifritz: None declared, Matija Tomsic: None declared, Brita Maurer Speakers bureau: Boehringer-Ingelheim, Consultant of: Novartis, Boehringer Ingelheim, Janssen-Cilag, Grant/research support from: AbbVie, Protagene, Novartis Biomedical Research and Innovation Infrastructure, funded by the Operational Programme "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund).

Objectives: We investigated the presence on the surface of RA-MPs of antigens derived from post-translationally modified proteins (citrullinated peptides and carbamylated peptides). We assumed that these specific antigens carried on the surface of RA-MPs could participate in RA pathogenetic process.

Methods: We enrolled 20 RA patients naïve for biological therapy fulfilling the 2010 American College of Rheumatology RA criteria and 20 healthy controls (HC), matched for age and sex. For each patient, laboratory and clinical data were recorded and clinical indexes were measured. TJC, SJC, CDAI, VAS pain, CDAI, SDAI, DAS28. A fasting blood sample, obtained from RA patients and HC, was centrifugated in order to obtain platelet-poor plasma (PPP), rich in MPs. Thereafter, MPs in RA patients and HC were measured using nanoparticle tracking analysis. Later on, MPs were incubated with unconjugated anti-citrullinated/carbamylated proteins antibodies and processed by flow cytometry and western blot to evaluate the surface expression of citrullinated/carbamylated antigens.

Results: Nanoparticle tracking analysis revealed a significant increase of number of MPs in RA compared to HC. Moreover, densitometric analysis showed a significant higher expression of citrullinated antigens on MPs’ surface in RA than controls (p < 0.0001), while no substantial difference was found in the expression of carbamylated antigens. The data obtained were confirmed with the western blot which identified the cytoskeletal protein vimentin, the cytoplasmatic glycylcytic enzyme alpha-enolase1 and type II collagen as the main citrullinated and carbamylated proteins carried by MPs. Finally, a relevant correlation between the expression of citrullinated and carbamylated antigens and disease activity was found (Figure 1).

Conclusion: The results of this study confirm an important role of MPs in the pathogenesis of RA not only as markers of disease activity but also as possible inducers of autoimmunity.

Disclosure of Interests: None declared.


Figure 1. The figure shows: (A) concentration of MPs in RA patients and HC (nanoparticle tracking analysis); (B) expression of citrullinated and carbamylated antigens on MPs’ surface in RA patients (flow cytometry analysis); (C) expression of citrullinated antigens in RA patients and HC and correlation between expression of citrullinated and carbamylated antigens on MPs’ surface in RA patients and DAS28, CDAI, SDAI; (D) cytoskeletal protein vimentin, cytoplasmatic glycylcytic enzyme alpha-enolase1 and collagen type II (western blot).
Background: Accumulating evidence suggests that poor mental health is one of the most common comorbidities of both rheumatoid arthritis (RA) and osteoarthritis (OA) [1]. Even if underpinning RA and OA are different genetic, structural, mechanical, and immunologic pathways involved in their pathogenesis, poor mental health, and joint involvement are intertwined and negatively affect their mutual course by contributing to global disability. Thus, new insights into mechanisms that link these disorders are needed to identify new actionable biomarkers to drive more personalized therapeutic strategies. Amidst potential mediators, extracellular vesicles (EVs) play a central role in terms of communication between cells, they cross the blood-brain barrier and based on their cargo can affect the recipient cell function [2].

Objectives: To isolate EVs from synovial fluid (SF) in RA and OA patients and to evaluate if and how these EVs can alter in vitro synaptic transmission of murine hippocampal neurons.

Methods: In this cross-sectional pilot study, consecutive adult RA and primary OA who were referred to the Rheumatology Unit for aspiration of joint effusion were enrolled. Demographic and clinical variables and mental health rating scales were collected. Discarded SF were collected and EVs were isolated and analyzed by Malvern NanoSight NS300 system to obtain information on their number and size. Afterwards, DIV14 cultured wild-type hippocampal neurons were exposed for two hours to OA- and RA-EVs at low and high concentration EVs. Thus, miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs), which reflects glutamatergic and GABA-ergic activity respectively, were examined by exploiting patch-clamp recordings in the whole-cell configuration. Frequency and amplitude were analyzed to evaluate potential changes at the presynaptic or postsynaptic compartment. Mann Whitney test was used to compare two different samples.

Results: Eight RA patients (7 female, mean age 57 yrs), and 5 primary OA (4 female, mean age 60 yrs) were recruited for SF aspiration. The mean VAS pain was 7.25 in RA and 6.5 in OA. No statistically significant differences were found between the two groups in mean rating scale scores although patients affected by RA had more severe depressive symptoms (Montgomery Asberg Depression Rating Scale -MADRS- means scores: 16.57) with respect OA group (MADRS mean scores: 10). The Nanoparticle tracking analysis showed that RA-EVs were significantly more in number compared to OA-EVs (Figure 1 A), mimicking more inflammation, while no significant difference in size was observed. Analysis of miniature events revealed the occurrence of two different changes. High concentration of OA-EVs has led to an increased amplitude of excitatory events, meaning OA-EVs at low and high concentration EVs. Thus, miniature excitatory and inhibitory postsynaptic currents (mEPSCs and mIPSCs), which reflects glutamatergic and GABA-ergic activity respectively, were examined by exploiting patch-clamp recordings in the whole-cell configuration. Frequency and amplitude were analyzed to evaluate potential changes at the presynaptic or postsynaptic compartment. Mann Whitney test was used to compare two different samples.

Discussion: Our results suggest that SF-derived EVs from OA and RA patients lead to different specific changes of neurotransmission, with different concentration needed to alter neuronal spontaneous activity in post-synaptic and pre-synaptic compartment, respectively. EVs may provide insight into the pathogenesis of joint-brain communication in RA and OA, unraveling specific pathways thus allowing targeted therapies for neuropsychiatric involvement.

References:

Disclosure of Interests: Lavinia A. Coletto: None declared, Francesca Ingegnoli: None declared, Clara Cambria: None declared, Laura Cantone: None declared, Orazio De Lucia: None declared, Roberto Caporali Speakers bureau: Abbvie, Amgen, BMS, Celltrion, Galapagos, Lilly, Pfizer, Fresenius-Kabi, MSD, UCB, Roche, Janssen, Novartis, Sandoz, Consultant of: Abbvie, Amgen, BMS, Celltrion, Galapagos, Lilly, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz, Valentina Bollati: None declared, Massimiliano Buolli: None declared, Flavia Antonucci: None declared.


POS0431

PGDF-BB, TNF-α, and LT-β REGULATE FOLLICULAR DENDRITIC CELL DEVELOPMENT IN THE RHEUMATOID SYNOVION

M. Elshish1, R. El Sayed1, N. Ay2, E. Prediletto1, R. Hands2, L. Fossati-Jimack1, M. Bombardieri1, M. Lewis3, C. Pitzalis1.

1Experimental Medicine and Rheumatology, William Harvey Research Institute - Barts and The London School of Medicine and Dentistry - Queen Mary University of London, London, United Kingdom

Background: Follicular dendritic cells (FDCs) fundamentally contribute to the formation of synovial ectopic lymphoid-like structures in rheumatoid arthritis (RA) which is associated with poor clinical prognosis. Despite this critical role in RA pathogenesis, FDC development in the RA synovion has not been fully elucidated.

Objectives: To investigate the role of TNF-α/LT-β and PGDF-BB in the ontogeny of RA synovial FDCs and the differentiation of lymphoid and fibroid RA synovions.

Methods: RA Synovial tissues were obtained from the Pathobiology of Early Arthritis Cohort (PEAC) of the Centre for Experimental Medicine and Rheumatology of Queen Mary University of London. RNA-Seq analysis and confocal imaging of early and late FDC differentiation markers were carried out and the stromal cell subsets were sorted by flow cytometry. The stromal cell subsets were treated with TNF-α/LT-β and/or PGDF-BB and the expression of FDC differentiation genes was assessed by qPCR. Germinal centre reactions were setup in vitro using TNF-α/LT-β activated stromal cells, and antibody production by naive human B cells stimulated with anti IgM was measured by ELISA.

Results: Our results indicate that PGDF-BB induces the FDC marker CNA.42 on NG2+ uSMA+ type-1 pericytes, stimulates THY-1 and uSMA gene expression, and strongly correlates with fibroid synovits using RNA-Seq analysis. On the other hand, TNF-α/LT-β downregulate PGDFFr-β, THY-1, uSMA; induce CD21, FcγRIIB expression, and significantly correlate with lymphoid synovial phenotype. Ultrastructural examination of antigen trapping on TNF-α/LT-β-activated RA synovial fibroblasts (RASFs) showed periodically retained surface antigens and these fibroblasts were able to induce T cell independent B cell activation in vitro germinal centre reactions. The transition from an early PGDFFr-β+ pre FDCs to a late TNF-α/LT-β- responsive mature FDCs is promoted by PGDF-BB. PGDF-BB induces TNF-α/r expression in RASFs and facilitates B cell recruitment via pericyte CXCL13 expression and stromal cell migration.

Conclusion: To the best of our knowledge, this is the first report describing the crosstalks between PGDF-BB and TNF-α/LT-β in FDC development in the rheumatoid synovion and its association with the evolution of lymphoid and fibroid synovits. Selective targeting of this interplay could inhibit FDC differentiation and potentially ameliorate RA in clinically severe and drug-resistant patients.

Disclosure of Interests: None declared.


POS0432

MDCS IN THE INFLAMMATORY JOINT OF SKG MICE HAVE BOTH T CELL SUPPRESSIVE ABILITY AND OSTEOCLAST DIFFERENTIATION POTENTIAL


1Kobe University, Rheumatology and clinical Immunology, Chuo-Ku, Kobe, Hyogo, Japan; 2University of California, San Diego, Department of Medicine, San Diego, California, United States of America; 3Kobe University, Rheumatology and clinical Immunology, Chuo-Ku, Kobe, Hyogo, Japan.

Background: Myeloid-derived suppressor cells (MDCs) are heterogeneous immature myeloid cells with suppressive functions (1). It is known that MDCs are expanded in inflammatory sites after migrating from bone marrow (BM) or spleen. Rheumatoid arthritis (RA) is an autoimmune disease characterized as polyarthritis. Although previous reports indicate that MDCs are increased in BM
and spleen of arthritis model mice, detailed analysis of MDSCs in inflammatory joints is limited.

Objectives: The purpose of this study is to characterize the MDSCs in the joints of autoimmune arthritis.

Methods: We isolated CD11b+Gr1+ cells as MDSCs from joints (Jo-MDSCs), bone marrow (BM-MDSCs) and spleen (Sp-MDSCs) of arthritis-induced SKG mice, and investigated differential expressed genes (DEGs) among MDSCs from three tissues by microarray expression analysis. Furthermore, we analyzed the suppressive function of each MDSCs by investigating the effect of them on T cell-proliferation and the osteoclast differentiation of each MDSCs stimulated by M-CSF and RANKL.

Results: Microarray analysis revealed that Jo-MDSCs highly expressed immunosuppressive DEGs (Pdl1, Arg1, Eg2 and Egr3) compared to BM MDSCs or Sp MDSCs. In addition, Jo-MDSCs highly expressed NF-κB non-canonical pathway DEGs (Nkb2 and Relb), which are related to osteoclast differentiation. BM-MDSCs differentiated into osteoclasts but didn’t suppress T cell-proliferation and Sp-MDSCs suppressed T cell-proliferation but didn’t differentiate into osteoclasts. On the other hand, Jo-MDSCs was found to have both functions: T cell suppression and osteoclast differentiation potential.

Conclusion: Jo-MDSCs have a strong inhibitory effect on T cell proliferation and have the ability osteoclast differentiation potential.

REFERENCES:

Disclosure of Interests: None declared.

POS0433

POTENTIAL THERAPEUTIC EFFECTS OF NARINGENIN ON RA THROUGH SUPPRESSING P2X7R/NLRP3 MEDIATED PYROPTOSIS BY TARGETING ESR

H. Wang1, Y. Zhang1. 1Qilu Hospital, Department of Clinical Laboratory, Jinan, China

Background: Naringenin (NAR), a partial agonist on estrogen receptor, is naturally occurring flavonoids in grapes and grapefruits. We previously reported that NAR in patients with Rheumatoid arthritis (RA) have changed significantly [1]. However, the role and mechanism of action of NAR in RA remain unclear.

Objectives: This study aimed to determine the roles and mechanisms of NAR on RA and provides a basis for NAR to become a potential therapeutic agent for RA.

Methods: This study employed bovine type II collagen-induced arthritis (CIA) rats, in vitro mononuclear cells (MNCs) as models to explore the potential therapeutic effects and mechanisms of NAR on RA.

Results: Rats following NAR injections showed significantly alleviated CIA, while the proportion of NK cells decreased. After CIA rats were injected with both NAR and NK cells, the rats remained joint inflammation. NAR decreased the proportion of NK cells in RA MNCs. However, NAR did not directly affect the NK cell activation and their cytokine production. NAR suppress pyroptosis in THP-1 cells (Figure 1). The NAR activate the ESR1 in macroage. NAR significantly increased histone deacetylase 1 gene (HDAC1) activation in macroage. NAR significantly increased P2X7R expression and decreased NLRP3 expression in macroage.

Conclusion: NAR has therapeutic effects for CIA and RA through suppressing P2X7R/NLRP3 mediated pyroptosis by targeting ESR.

REFERENCES:

Disclosure of Interests: None declared.

POS0434

A NOVEL TARGET FOR TREATMENT OF INFLAMMATORY JOINT DISEASES

S. Lindquist1,2, H. Persson3, A. Roos3, L. Lundberg3, O. Hernel1,2, 1Umeå University, Clinical Sciences, Pediatrics, Umeå, Sweden; 2Lipum AB, Drug Discovery and Development Platform, Uppsala, Sweden; 3SciLifeLab, Drug Discovery and Development Platform, Uppsala, Sweden

Background: A significant number of patients with inflammatory joint disorders do not respond or experience a waning effect to currently available pharmaceuticals, which emphasizes a high medical need for new efficacious drugs operating through novel targets and modes of action. One unexplored novel target is Bile Salt-Stimulated Lipase (BSSL). We have shown that patients with rheumatoid arthritis (RA), psoriasis arthritis (PsA), and juvenile idiopathic arthritis (JIA) have increased BSSL plasma levels compared to healthy controls, and that these levels correlate with disease activity scores. Moreover, conventional BSSL knockout mice are protected from developing disease in several recognized in vivo arthritis models and antibodies targeting BSSL prevent or mitigate arthritis in rodent models.

Figure 1. Effect of NAR on RA in vitro and in vivo. A The chemical structures of NAR and Estrogen. B Flow cytometry assay of NK cells in MNCs with treatment of NAR. C The morphology of THP-1 cells with treatment of NAR. D Joint inflammation of CIA rats with treatment of NAR and NK cells. E The expression level of pyroptosis-related protein was tested by western blot (WB). F Pattern diagram explaining therapy mechanism of NAR to RA.
We have further shown that BSSL is secreted from activated granulocytes, binds to monocytes and stimulates their migration in vitro. With that knowledge, we developed a humanized anti-BSSL antibody (SOL-116) that blocks BSSL from binding to monocytes and we are now evaluating SOL-116 as candidate drug for treatment of chronic inflammatory joint diseases, including RA, PsA and JIA in man.

**Objectives:** The aim of the present study was to characterize SOL-116’s biological activity in vitro and verify the therapeutic efficacy in the pristane induced arthritis (PIA) rat model.

**Methods:** The affinity of SOL-116 to human, mouse and rat BSSL was measured by surface plasmon resonance biosensor technology. The epitope on human BSSL was mapped by hydrogen deuterium exchange mass spectrometry (HDX-MS) and confirmed by crystallization of SOL-116 Fab-fragments with human BSSL. For efficacy evaluation, arthritis was induced in DA rats by administration of pristane. SOL-116 at three different doses (10, 30 and 90 mg/kg) or vehicle control were administered subcutaneously on day 5, 10 and 15 after disease induction. Disease activity was evaluated daily from day 7 in a blinded fashion using a macroscopic scoring system of the four limbs. To gain knowledge about the mechanism of action, the effect of SOL-116 on BSSL induced cell migration was evaluated using a transwell migration assay.

**Results:** SOL-116 binds to human, mouse, and rat BSSL, although a single amino acid deviation in the BSSL epitope results in approximately 80-fold lower affinity to rodent compared to human BSSL protein. In the efficacy validation study, treatment with highest dose SOL-116 (90 mg/kg) significantly mitigated disease severity in the PIA rats (Figure 1A). The relatively high doses of SOL-116 were chosen to compensate the low affinity for rat BSSL. A decrease in disease severity was also seen with SOL-116 at 30 mg/kg and 10 mg/kg, indicating a dose response, albeit not statistically significant. The plasma concentration of SOL-116 at day 19 correlated significantly to the arthritis score (Figure 1B). Mechanistic studies show that BSSL stimulates migration of CD14+ monocytes, and that SOL-116 prevents this effect in a dose dependent manner.

**Conclusion:** The present study verifies that BSSL plays an important role in inflammation and that SOL-116 is a promising biologic drug candidate for novel treatment of chronic inflammatory joint diseases.


**Acknowledgements:** The authors are grateful to Mrs. Eva-Lotta Andersson for excellent technical assistance.


**POS0435 IMPACT OF COMBINATION THERAPY WITH CDSDMARDS ON THE EFFECTIVENESS OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS IN A REAL-LIFE SETTING: RESULTS FROM THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)**

B. Gilbert, D. Longin, E. Nham, D. Courvoisier, K. Lauper, C. Laedermann, F. Muller, A. Finckh, Geneva University Hospitals, Division of Rheumatology, Geneva, Switzerland; Centre for Musculoskeletal Research University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; Eli Lilly (Suisse) SA, Vernier, Switzerland; Kantonsspital, Division of Rheumatology, Aarau, Switzerland

**Background:** Management guidelines of RA suggest to administer biological or targeted synthetic DMARD (b/tsDMARD) in combination with conventional synthetic DMARD (csDMARD). Limited data exists about the impact of such csDMARD combination therapy (co-therapy) in real life settings, in particular for baricitinib use compared to other types of b/tsDMARD.

**Objectives:** To assess the impact of concomitant csDMARD prescription on b/tsDMARD maintenance, in a real-world setting.

**Methods:** This is a nested cohort study within the Swiss registry of RA patients (Swiss Clinical Quality Management (SCQM-RA)), of treatment courses with bDMARDs or baricitinib (BARI) initiated between 2017-09-01 and 2020-06-01, with at least one follow-up visit. We compared the time-to-drug-discontinuation (drug maintenance), as a measure of drug effectiveness of b/tsDMARDs, with or without csDMARD co-therapy. Our exposure of interest was the impact of csDMARD co-therapy compared to monotherapy in 3 categories of b/tsDMARDs: baricitinib (BARI), TNFi inhibitors (TNFi) and other modes of action bDMARDs (OMA). Co-therapy was defined as receiving at least one csDMARD during at least 40% of the b/tsDMARD treatment courses (TC) duration. Baseline characteristics were compared using t-tests or χ². Survival Kaplan-Meier curves, with Log-rank test, were used to assess time-to-discontinuation. Cox models were applied to obtain adjusted hazard ratios (HR) using age, BMI, corticosteroid treatment, CDAI score, disease duration, smoking, line of therapy, seropositivity, gender as covariates. Missing baseline CDAI values were imputed using linear model with quadratic regression time.

**Results:** 1065 TC were included (273 BARI, 319 OMA, 473 TNFi), about half of which were initiated with csDMARD co-therapy (Table 1). In the co-therapy groups, csDMARD were taken on average 98% of the TC duration. Methotrexate was the most prescribed csDMARD (Table 1). Even after adjustment, we found no difference in drug maintenance with and without concomitant csDMARD in the BARI group (crude p = 0.67; HR co-therapy 2.17, 95% CI [0.61;7.77], p = 0.16) and in the TNFi group (crude p = 0.13; HR co-therapy 1.24, 95% CI [0.56;2.74], p = 0.60). Adjusted drug maintenance with or without csDMARD was also similar in the OMA group, despite non-adjusted p-value in favor of monotherapy (Figure 1) (crude p = 0.007; HR co-therapy 0.66, 95% CI [0.25;1.80], p = 0.39).

**Conclusion:** Our data suggest that drug maintenance of BARI, OMA and TNFi, were not significantly modified by concomitant csDMARD therapy.

**Disclosure of Interests:** Benoit GILBERT Speakers bureau: Once for Lilly, outside of the presented work., Denis Mongin: None declared, Eric Nham: None declared, Delphine Courvoisier: None declared, Kim Lauper: None declared, Christophe Viatras and Cellinlon, outside of the submitted work., Consultant of: for Pfizer, outside of the submitted work., Cedric Laedermann Employee of: Currently employed by Eli Lilly., Rüdiger Müller: None declared, Axel Finckh Speakers bureau: Lilly, Grant/research support from: Research Grant by Lilly, to the rheumatology division.

**RESULTS:**

Cartilage degradation activity in SKG mice

- *Control* (untreated): Normal cartilage structure, no visible signs of degradation.
- *TNFα* + *ZyA*: Severe cartilage erosion, with visible loss of cartilage matrix.
- *ZyA*: Mild cartilage erosion.

**DISCUSSION:**

The results indicate that TNFα inactivation can significantly reduce cartilage degradation in SKG mice, demonstrating the potential efficacy of anti-TNFα strategies in RA-ILD treatment.

**CONCLUSION:**

The study highlights the importance of TNFα in RA-ILD and suggests that targeted anti-TNFα therapies may offer significant therapeutic benefits for this condition.
the concentration of inflammatory factors. Double luciferase reporter gene detection and rip detection confirmed mir-654-5p and Interaction between Circ_0003972.

REFERENCES:

Table 1. Table showing a summary of the results. Ct: confidence interval

<table>
<thead>
<tr>
<th>•Treatments</th>
<th>•ACAs</th>
<th>•AUC (CI 95%; p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>anti-IL17A 0.586 (0.504-0.668; 0.044)</td>
<td></td>
</tr>
<tr>
<td>CTZ</td>
<td>anti-IL17A 0.594 (0.512-0.767; 0.028)</td>
<td></td>
</tr>
<tr>
<td>ABA</td>
<td>anti-IL17A 0.569 (0.521-0.754; 0.023)</td>
<td></td>
</tr>
<tr>
<td>TCZ</td>
<td>anti-IL17A 0.657 (0.494-0.820; 0.049)</td>
<td></td>
</tr>
<tr>
<td>anti-IL17F 0.689 (0.651-0.827; 0.018)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>anti-IL18 0.698 (0.645-0.850; 0.013)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disclose of Interests: None declared.

PO5439
STROMAL B-CELL Crosstalk PROMOTES THE ESTABLISHMENT OF SYNOVIAL B CELL NICHEL THROUGH THE SELECTION, ACTIVATION OF NATURALLY OCCURRING EBV+ B CELLS

M. Caliste1, E. Prediletto1, E. Consiero1, L. Jagemann1, C. Pitzalis2, M. Bombardieri1, William Harvey Research Institute, Experimental Medicine & Rheumatology, London, United Kingdom.

Background: Rheumatoid Arthritis (RA) is characterized by the formation of ectopic lymphoid structures (ELS) in the synovial tissue, which can promote B cells activation and local production of autoantibodies. B cells exert an essential role in RA immunopathogenesis, as demonstrated by therapeutic effects of Rituximab (1). We previously showed that ELS in the RA joints frequently accumulate Epstein Barr virus (EBV)-infected B cells displaying evidence of both latent (LMP2A) and early lytic viral reactivation in locally differentiated plasma cells (PCs)(2). RA synovial fibroblasts (SFs) can sustain B cells activation, proliferation and maturation into high affinity antibodies producing cells, mimicking B cells physiological differentiation in germinal centres (3). Whether RASFs can also promote preferential selection of naturally-occurring EBV+ B cells is currently unknown.

Objective: Here, we aim to a) demonstrate SFs role in EBV+ B cells selection b) phenotypically characterize B cells after co-culture with SFs c) dissect the molecular mechanisms behind the B cells SFs crosstalk.

Methods: Long-term in vitro B cells SFs co-cultures have been established, followed by phenotypical characterization of B cells in flowcytometry. Supernatant were then screened by ELISA at different timepoints, to measure IgG, IgM and IgA production. EBV infection status on B cells were analysed by qRT-PCR after gDNA extraction. Single cells RNA sequencing was finally performed at 28 days of co-culture.

RESULTS: Preliminary results confirmed RASFs role in sustaining B cells activation and maturation, showing B cells survival up to 90 days, production of IgG and an increased IgG/IgM ratio overtime. Interestingly, we identified a particular B cells phenotype occurring in long term in vitro co-cultures, characterized by CD38 expression and the subdivision into two functional subsets, CD58+/CD23high and CD58+CD23low. These two subpopulations - previously described by Megyola et al. in in vitro EBV infected B cells - are characterized by two different functional states: an highly proliferating (CD58+/CD23high) population and an IL-6 producers (CD58+CD23low) one(4). We also observed that RASFs preferentially support EBV+ clones expansion, showing a preferential expression of EBV markers in CD58+CD23low cells. The high proliferation rate of these B cells allowed – on a specific experiment - the establishment of a cell line, named

Disclose of Interests: None declared.
“Carejavi,” that we are currently employing as tool for functional investigation of RASFs primed EBV+ B-cells. Finally, the transcriptomic analysis revealed the selection of a relatively small number of clonotype at the VDJ analysis at the end of co-culture. In addition, we observed the upregulation of genes related to GC formation (such as EB13, LTA and LTβ), B cells proliferation (mi67) and viral oncosogenic transformation (MYC).

Conclusion: Here, we demonstrated that RA SFs not only support B cells maturation and activation in local autoantibodies producing cells, but they are also able to preferentially induce selection and proliferation of EBV+ clones, characterized by a peculiar expression of CD56 and CD23. The molecular mechanisms behind this phenomenon are currently under investigation.

REFERENCES:

Disclosure of Interests: None declared.


POS0440 THE ANALYSIS OF THE INFLAMMATORY PROTEOME IN RHEUMATOID ARTHRITIS IDENTIFIES COMMON SIGNATURES ASSOCIATED WITH THE CLINICAL RESPONSE TO DMARDS AND TNFI THERAPIES


Background: Tyrosine kinases receptors MerTK and Axl have been implicated in the pathogenesis of several autoimmune diseases. Despite sharing significant structural homology and having common ligands, Axl and MerTK have distinct features and biological functions [1]. A growing body of evidence suggests that both Axl and MerTK play a crucial role in Rheumatoid Arthritis (RA) pathogenesis and progression and may be exploited as novel therapeutic targets [2]. However, numerous unanswered questions remain to be addressed.

OBJECTIVES:
1. To define common and distinct gene-partners of Axl/MerTK and quantify their expression in RA synovial tissue.
2. To assess the co-expression of Axl/MerTK by synovial cells.
3. To outline the longitudinal variation in Axl/MerTK expression upon treatment intervention.

Methods: Synovial tissue samples were collected by US-guided synovial biopsy from: i. Patients with early (<12 months) RA DMARDs/steroid-naïve (n=87); and ii. RA patients who failed the first-line biologic with TNF-inhibitors (TNFi) before and 16 weeks after receiving either Rituximab (RTX) or Tocilizumab (TOC) (n=164) [3]. Gene expression was obtained by bulk RNAseq performed on an Illumina HiSeq2500 platform. Axl/MerTK-modules were defined using STRING networks and the module expression determined by the mean z-score of regularized log transformed expression for all genes in the set. Axl, MerTK, CD55, CD90, CD68 protein expression was analysed by protein expression in immunofluorescence staining.

Results: Using STRING network analysis, we defined an Axl- and a MerTK-module composed of 31 predicted gene-partners of either Axl or MerTK. Thirteen genes were common to both modules and included the ligands Gas6 and ProteinS, and EGFR. Conversely, eighteen genes were uniquely present in the Axl-module (e.g., PIK3-family, IFG1R, IFNAR1 and STAT3) or the MerTK-module (e.g., Galectin3 and TULP; recently discovered MerTK ligands, FCGRA1/CD64, PTTP1 and MEGF10). Axl/MerTK-modules quantified in the early-arthritis treatment-naïve RNAseq dataset showed a significant negative correlation with the synovitis score (Axl r=-0.33, p=0.0152; MerTK r=-0.23, p=0.0003). There were twelve log transformed gene expression differences of the Lining showed notable heterogeneity between patients: they could express either Axl or MerTK alone, or co-express both. Axl was also present in most CD55+ Lining Fibroblast-Like-Cells (FLS) but not by CD90+ Sublining FLS while MerTK, as expected, was restricted to macrophages, including intra-aggregate tingible-body-macrophages. To define Axl and MerTK vary depending on disease stage and treatment exposure, we quantified their gene expression in active RA patients inadequately responding to TNFi, prior and 16 weeks after starting second-line biologic (RTX or TOC) [3]. Differently from the early-arthritis cohort, MerTK was significantly up-regulated in synovia characterised by higher degree of tissue inflammation (lympho-myeloid > diffuse-myeloid > pauci-immune, p<0.0001) and significantly positively correlated with several cytokines’ genes such as TNF, IL-6, CCL5 and IL-10. MerTK expression was dependent on clinical response to RTX but not TOC as assessed by EULAR response (dAS28CRP, good vs none/mod, FDRresp 0.048). Conversely, Axl expression compared with Cluster 2 (C2), where a signature of 16 chemokines was significantly enriched (CCL-3, -4, -10, -23, CXCL1, CXCL-10, -11, -5, -6, -9; MCP-1, -3, -4). Clinically, 25% of the non-responders’ patients was included in C2, while 75% was located in C1, suggesting that a prominent circulating chemokines profile prior therapy is associated with a poor clinical outcome. These data were similarly observed in patients before receiving DMARDs, where a signature of upregulated chemokines and pro-inflammatory mediators characterised a cluster with a high % of non-responding patients.

Conclusion: A pro-inflammatory signature, where chemokines are predominatiely up-regulated in the serum of RA patients before therapy, is associated with a poor clinical outcome. This newly identified signature, which deserves a more in-depth analysis, might be clinically useful guiding precision medicine and novel therapeutic approaches.

Acknowledgements: Supported by ISCIII (PI21/005991 y RICOR-RD21/0002/0033) co-financed by FEDER, Fundación Andalucía de Reumatología (FAR) and Consejería de Conocimiento, Investigación y Universidad de la Junta de Andalucía (P20_01367).

Disclosure of Interests: None declared.

GLPG4399: SELECTIVE SIK3 INHIBITION AS A NOVEL MODE OF ACTION FOR THE TREATMENT OF INFAMMATORY ARTHRITIC DISEASES (PRECLINICAL)

S. Lavazais,1 A. Pereira-Fernandes,2 C. Delachamaë,1 C. Jagerschmid1, M. Drennan,2 D. Merciris1, C. Peixoto1, M. Borgonovi1, N. Desroy,2 D. Amantini,1 S. De Vos,2 K. Nys2, Galapagos, SASU, Romainville, France; Galapagos, NV, Mechelen, Belgium.

Background: SIK3 is a serine/threonine kinase implicated in inflammatory pathways and contributing to the generation of IFN-γ and TNFα in peripheral blood. In the present study, we investigated the effect of GLPG4399, a selective SIK3 inhibitor, on human synovial tissue biopsies (ST) from patients with inflammatory arthritis.

Methods: Freshly digested ST tissue was assayed for IL-12 and IFN-γ protein production. ST cells were isolated by enzymatic digestion and then stained for multiple populations, demonstrating differential endocytosis associated with a shift in their metabolic profile. In addition, freshly digested ST cell suspensions were subjected to an optimized assay to evaluate endocytosis in multiple populations simultaneously without the need for cell sorting. Briefly, digested cells were incubated at 4°C (passive endocytosis) or 37°C (active endocytosis) in the presence of OxPhos inhibitors and then stained for multiple populations, demonstrating differential endocytosis.

Results: GLPG4399 was shown to be a SIK3 inhibitor with high selectivity against a panel of 370 kinases. The wide effect of SIK3 inhibition on key immune cell types was demonstrated by GLPG4399’s reduction of pro-inflammatory cytokines produced by monocytes, macrophages, dendritic cells, B and T lymphocytes. Immune phenotypic assays and in a lipopolysaccharide (LPS)-stimulated human whole blood assay by measuring the production of inflammatory cytokines. In vivo target engagement was evaluated in an acute LPS-stimulated cytokine release mouse model by measuring plasma tumour necrosis factor (TNF) levels. The therapeutic efficacy of GLPG4399 was evaluated in vivo in collagen-induced arthritis (CIA) and IL-23-induced psoriatic arthritis mouse models by assessing disease activity endpoints.

Conclusion: Our preclinical findings demonstrate the strong immunomodulatory effect of SIK3 inhibition in arthritis-relevant immune cell assays and highlight the significant preclinical efficacy of GLPG4399 in two experimental arthritis mouse models. The novel mechanisms of action of GLPG4399 represents a promising approach for the treatment of arthritis.


POS0443 INSIDE THE JOINT OF INFLAMMATORY ARTHRITIS PATIENTS: HANDLING AND PROCESSING OF SYNOVIAL TISSUE BIOPSYs FOR HIGH THROUGHPUT ANALYSIS

A. Floudas1,2, A. Gorman,2 N. Neto,3 M. Monaghan,3 Z. Elliott,2 U. Fearon,1,2 V. Marzocco1,2 1 Trinity Biomedical Sciences Institute, Molecular Rheumatology, Dublin, Ireland; 2 EULAR Centre of excellence, Centre for Arthritis and Rheumatic Diseases, St Vincent’s University Hospital, Dublin, Ireland; 3 Trinity Biomedical Sciences Institute, Trinity Centre for Biomedical Engineering, Dublin, Ireland

Background: Inflammatory arthritis (IA) is a chronic systemic autoimmune disease whose etiology is unknown, which afflicts the joints. While studies on immune cell populations in peripheral blood have been informative regarding potential immune cell dysfunction and possible patient stratification, there are considerable limitations in identifying the early events that lead to synovial inflammation. The joint, as the site of inflammation and the local microenvironment, exhibit unique characteristics that contribute to disease pathogenesis.

The limited availability of synovial tissue (ST) biopsies is a key incentive for the utilisation of high-throughput techniques in order to maximise information gain.

Objectives: This work aims to provide an overview of key methods and novel techniques that are used in the handling, processing and analysis of ST biopsies and the potential synergy between these techniques.

Methods: We describe the utilisation of high dimensionality flow cytometric analysis, single cell RNA sequencing, ex vivo functional assays, including T cell activation, endocytosis and two-photon fluorescent lifetime imaging microscopy (FLIM).

Results: When comparing different methods for ST cell suspension generation we observed that the combination of mechanical and enzymatic digestion resulted in the release of considerably higher numbers of total viable cells when compared to mechanical digestion alone, although consideration should be taken in the cleaving of extracellular markers, like CD27. We next compared two different cryopreservation methods that to that of freshly digested ST and observed similar viability and frequency of immune cells. Functional characterisation of ST cells can be challenging due to the high number of cells required for analysis, herein, we utilised the above protocols to establish ST viable cell suspensions and optimised different experimental approaches for phenotypic functional characterisation. To investigate the functional consequence of OxPhos inhibition on ST T-cell polyfunctionality, ex-vivo ST cell suspensions from IA patients were stimulated with PMA/ionomycin in the presence/absence of FCPP followed by metabolic profile characterisation via FLIM and high dimensionality flow-cytometric analysis for T cell-derived cytokines. Treatment with FCPP resulted in a decreased in T-cell polyfunctionality specifically in co-expression of TNF-α, IL-2, IFN-γ, IL-17A. -GM-CSF, an effect associated with a shift in their metabolic profile. In addition, freshly digested ST cell suspensions were subjected to an optimized assay to evaluate endocytosis in multiple populations simultaneously without the need for cell sorting. Briefly, digested cells were incubated in parallel at 4°C (passive endocytosis) and 37°C (active endocytosis) with DQ OVA (Ovalbumin). ST cells were then stained for multiple populations, demonstrating differential endocytosis capacity across pathotypes and disease controls. Finally, utilisation of novel bioinformatics analysis of RNAseq a data showed differential gene expression and pathway enrichment involved in IA pathogenesis and allowed for the comparison of cell specific enrichment scores and transcription factor usage based on pathotype and gender.

Conclusion: The introduction of new powerful techniques in the study of ST inflammation brings new challenges and significant opportunities. These approaches will accelerate our path towards understanding of the mechanisms involved in the pathogenesis of IA and lead to the identification of new avenues of therapeutic intervention.

Acknowledgements: We would like to thank all the patients who consented to be involved in this study.

Disclosure of Interests: None declared.

**POS0444**

PROFILING OF CIRCULATING MiRNAs IN DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS

J. Baloun1,2, A. Pekacova1,2, H. Mann1,2, J. Vencovsky2,4, K. Pavelek2,4, L. Šenolt1,2, 1Institute of rheumatology, Department of Experimental Rheumatology, Prague, Czech Republic, 11st Faculty of Medicine of Charles University, Department of Rheumatology, Prague, Czech Republic, 2Institute of rheumatology, Inpatient department, Prague, Czech Republic, 3Institute of rheumatology, Research Center, Prague, Czech Republic

**Background:** Biologic (b-) and targeted synthetic (ts-) disease-modifying anti-rheumatic drugs (DMARDs) have brought significant progress in the treatment of rheumatoid arthritis (RA), but a significant proportion of RA patients still remain symptomatic despite treatment according to current recommendations. These patients have recently been defined as “difficult-to-treat (D2T)” RA (1). There is evidence that miRNA expression may play a role in the diagnosis and therapy of RA (2).

**Objectives:** In a retrospective study, we analyzed patients’ blood samples prior to b-/ts-DMARD treatment and profiled circulating miRNAs to predict the development of D2T-RA.

**Methods:** A total of 36 patients fulfilling the EULAR definition of D2T-RA (1) (mean age 59.1±10.7 yrs, 78% females), 36 patients with RA in sustained clinical remission on b-/ts-DMARDs at two consecutive examinations 12 yrs apart (mean age 66.3±9.6 yrs, 78% females), and 36 healthy controls (mean age 61.1±7.7 yrs, 68% females) were included in the study. Blood samples were collected before initiation of b-/ts-DMARD. We profiled circulating miRNAs using the sequencing approach and differential expression analysis was performed using DESeq2 algorithm.

**Results:** The massive parallel sequencing of circulating miRNAs detected 814 quantifiable miRNAs and DESeq2 algorithm revealed 35 miRNAs with differential concentrations in patients who developed D2T-RA compared to patients with RA who achieved sustained remission or healthy controls. Out of these miRNAs, miR-16-5p (1.5x) and miR-451a (2.1x) were downregulated and miR-126-3p (1.4x) was upregulated in D2T RA patients compared to controls. In addition, miR-101-3p (1.5x) was downregulated in D2T RA compared to RA patients. Except for miR-101-3p, these miRNAs have been previously associated with RA and might predict development of D2T disease prior to initiation of b-/ts-DMARD therapy.

**Conclusion:** We found four miRNAs as potential biomarkers differentiating patients who are at risk to develop difficult-to-treat disease compared to patients who have a chance of sustained remission even before initiation of biologic or targeted synthetic DMARDs. Further studies with larger sample size are needed to validate these data.

**REFERENCES:**


**Disclosure of Interests:** Don Kimpel Speakers bureau: GSK, Consultant of: Auria, Krishna Kannan: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4673

**POS0445**

DISSECTING THE ROLE OF PLATELET FUNCTION IN INFLAMMATORY ARTHRITIS

D. Kimpel1, K. Kannan1, 1University of Virginia, Rheumatology & Immunology, Charlottesville, United States of America, 2University of Arkansas, Medicine, Little Rock, United States of America

**Background:** Inflammatory autoimmune diseases such as rheumatoid arthritis (RA) show an increase in atherosclerotic cardiovascular disease, and are commonly associated with an increase in platelet counts. Thus, platelets fill a central role in the tenet: Inflammation begets coagulation, and coagulation begets inflammation. We have previously reported that induction of arthritis by the Streptococcal cell wall component peptidoglycan polysaccharide (PGPS) results in increased platelet numbers, aggregation, activation, and increased expression of P-selectin (CD62-P) and of the costimulatory molecule CD40. These platelets are also more sensitive to stimuli such as ADP and thrombin, which induce dense granule release of serotonin and aggregation. We have also described increased P-selectin expression limited to the joints in mice with acute arthritis. Platelets, generally considered elements of the hemostatic system, are underestimated for their pro-inflammatory potential.

**Objectives:** To further understand the role of platelets in inflammatory arthritis, and distinguish their biochemical and adhesive features we set out to characterize the impact of modulating platelet activity in acute and chronic rodent models of arthritis.

**Methods:** Chronic inflammatory arthritis was induced in Lewis rats by a single i.p. injection of PGPS which results in an early phase non-T cell dependent arthritis, and a chronic T cell dependent phase after day 10. An acute inflammatory arthritis was induced in Balb/c mice by the same method. Joint scoring and volume measurement were carried out daily to determine an arthritis severity score. The role of platelets on PGPS arthritis was assessed using a) depletion of platelets using periodic intraperitoneal (IP) anti-platelet antibody, b) blockade of the integrin GPIb/IIIa with the monoclonal antibody (mAb) abciximab to inhibit activation and aggregation via vWF and fibrinogen. In the acute murine arthritis models, we previously described expression of CD62-P in joints and on platelets, the CD62-P knockout mice had no significant difference in arthritis severity. Conversely treatment of wild-type mice with the anti-CD41 to block GPIb resulted in suppression of the arthritis.

**Conclusion:** Platelet depletion had a dramatic impact on both acute and chronic phases of inflammatory arthritis, which is not unexpected given that platelets carry an array of pro-inflammatory and procoagulant mediators including IL-1, chemokines, vWF, and fibrinogen, as well as an array of adhesion molecules for binding to endothelium, leukocytes, and to other platelets. The increase in chronic arthritis severity despite inhibiting platelet aggregation by blockade of GPIb/IIIa was unexpected, but may have been due to increased platelet-endothelial binding or platelet-leukocyte aggregation thus exacerbating the chronic T cell phase. Lack of CD62-P appeared to have no influence on acute phase arthritis development. Interestingly anti-CD41, which blocks one part of the GPIb/IIIa integrin, was effective at ameliorating arthritis in the murine model. Platelets play an often underappreciated role in inflammatory processes, but understanding the mechanisms will require further description of the complex nature of these cellular elements which have dual inflammatory and hemostatic roles.

**Disclosure of Interests:** Don Kimpel Speakers bureau: GSK, Consultant of: Auria, Krishna Kannan: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4563

**POS0446**

ARP23 AS A LASP1 INTERACTION PARTNER REGULATES CELL-TO-CELL CONTACT FORMATION OF FIBROBLAST-LIKE SYNOVIOCYTES IN RA

D. Beckmann1, A. Krause2, U. Hansen1, H. Kiener2, J. Kremerskothen2, H. Ravenstät3, T. Pap1, A. Korb-Pap1, 1University Hospital Muenster, Institute of Musculoskeletal Medicine, Muenster, Germany; 2Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria; 3University Hospital of Muenster, Department of Nephrology and Rheumatology, Internal Medicine D, Muenster, Germany

**Background:** In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) undergo a stable transformation resulting in an aggressive phenotype mediating cartilage damage by increased levels of adhesion molecules. In this context, Lasp1 and the Arp2/3 complex are of interest because they modulate actin organization and focal adhesion turnover.

**Objectives:** In this study, the effects of Arp2/3 on cadherin-11 mediated cell-to-cell contact formation have been investigated using the arthritic hTNFtg mouse model.

**Methods:** Expression levels of Lasp1 and Arp2/3 protein complex were investigated in synovial tissue of wild type (wt) and hTNFtg hind paws by immunohistochemistry. Primary FLS were analyzed, respectively and co-immunoprecipitation experiments were performed. In addition, Lasp1+/− mice were interbred with hTNFtg animals and offspring were evaluated for disease progression and joint destruction. To further study the role of Arp2/3 in the function of the cadherin-11 adhesion complex, the effects of an Arp2/3 inhibitor (CK666) on cell-to-cell contact formation in FLS derived from hTNFtg and Lasp1−/− mice were assessed for severity of arthritis, and d) wild-type mice were pre-treated with a single ip injection of anti-CD41 (GPIb) antibody.

**Results:** Depletion of platelets in rats during the PGPS treatment resulted in amelioration of both the early and chronic phases of disease. We previously demonstrated that TNF is elevated in this model following PGPS injection, so for comparison animals were treated with infliximab, a monoclonal antibody to TNF, with equivalent suppression of both acute and chronic phases of disease. Abciximab, targeting the dual function adhesion and signaling molecule GPIb/IIIa, did not decrease arthritis, and in fact increased the severity of the chronic phase of arthritis. In the acute murine model, despite the previously described expression of CD62-P in joints and on platelets, the CD62-P knockout mice had no significant difference in arthritis severity. Conversely treatment of wild-type mice with the anti-CD41 to block GPIb resulted in suppression of the arthritis.

**Disclosure of Interests:** Don Kimpel Speakers bureau: GSK, Consultant of: Auria, Krishna Kannan: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4673
Results: upregulated Lasp1 levels were found in synovial tissue and FLS of hTNFtg compared to wt mice. Assays showed that Arp2/3 is part of the adhesion junction (AJ) machinery in FLS although Arp2/3 expression levels were not changed between the genotypes. In vivo evaluation of lasp1+ hTNFtg mice revealed a milder arthritis score, less cartilage degradation and reduced FLS attachment to articular cartilage compared to hTNFtg mice. In vitro, the loss of Lasp1 led to clear alterations in AJ arrangement indicated by altered β-catenin pattern. As expected, β-catenin expression was mainly located at adhesion sites between adjacent cells. In hTNFtg FLS, these structures were characterized by a zipper-like pattern. In contrast, these structures were disrupted in lasp1+ hTNFtg FLS. Interestingly, CK666 induced zipper-like structures in hTNFtg FLS comparable to the pattern found in lasp1+ hTNFtg cells. Furthermore, lasp1+ hTNFtg FLS showed decreased Src phosphorylation following PDGF stimulation in comparison to hTNFtg FLS.

Conclusion: Lasp1 represents an interesting target involved in RA-caused joint destruction, because its loss results in significantly reduced cartilage destruction and altered FLS contacts mediated by Arp2/3.

Disclosure of Interests: None declared.


POS0447 TREATMENT WITH UPADACITINIB IN RA PATIENTS FOR WHICH BIOLOGIC THERAPY FAILED

L. Robles Kirkegaard1, E. Rubio Romero1, P. León1, Servicio Andaluz Salud, Hospital Universitario Virgen del Roció, Sevilla, Spain

Background: Upadacitinib is a JAK inhibitor recently approved for rheumatoid arthritis treatment with promising results in its studies for severe moderate RA for which conventional therapies failed.

Objectives: To study and describe the evolution of patients diagnosed with RA and treated with Upadacitinib who had inadequate response to biological therapy in association or not with DMARDS and GC for 6 months.

Methods: A population of 23 patients (19 of them female) with RA on treatment with Upadacitinib was analyzed over 6 months. Using patient-reported outcomes (PROs) to measure disease activity by visual analogue scale (VAS), the HAQ Disability Index (HAQ-DiI), Disease Activity Score (DAS28), and morning stiffness duration. The age’s (average ± SD) = 53 ± 10 years and time of disease evolution (average ± SD) = 176 ± 23.3 years. Pretreatment HAQ (average ± SD) = 2.2 ± 0.5. All patients received previous biologic treatments and 61% (14 patients) combined therapy with DMARDS. Only 2 cases had no glucocorticoid treatment prior to treatment with Upadacitinib.

Results: In 3 months’ time, most patients (81%, n = 21) treated with Upadacitinib were able to reduce GC dose, and this reduction was maintained 6 months from the beginning of the treatment. After 3 months of treatment, most patients experienced an enhancement in DAS28 (89%, n = 18), with an average improvement in DAS28 of (± SD) 1.87±1.09 units. Regarding the pain (VAS), 67% of the patients showed improvement after 3 months (n=16), reaching 71% after 6 months (n=17). Sixty-eight percent of treated patients showed a reduction in morning stiffness after 3 months (n = 19), and this improvement increased up to 84% of treated patients at 6 months (n = 19). Side effects were observed in five patients, consisting of dizziness and nausea. In no case were they a reason for the withdrawal of the drug. Treatment was withdrawn in three patients due to primary failure.

Conclusion: Treatment with Upadacitinib allows GC dose reduction, as well as an improvement in DAS28, VAS and morning stiffness at three months and six of treatment. These data are in line with the evidence published in Upadacitinib pivotal studies, meaning a good alternative in the treatment of patients with moderate or severe RA.

REFERENCES:

Disclosure of Interests: None declared.


POS0457 SYNOVIAL TRANSCRIPTOMIC PROFILES CORRELATE WITH DISEASE ACTIVITY IN EARLY UNTREATED RHEUMATOID ARTHRITIS

C. Triaille1, T. Sokolova1, S. De Montjoie2, A. Nzeusuou Toukap2, L. Meric de Belletet2, A. Loriot3, B. Lauwersy3, P. Durez4, N. Limaye5, UCLOuvain Brussels; 4De Duve Institute UCLouvain, Service de rhumatologie, Bruxelles, Belgium; 5De Duve Institute UCLouvain, Computational Biology, Woluwe-Saint-Lambert, Belgium; 6De Duve Institute UCLouvain, Genetics of Autoimmune Diseases and Cancer, Woluwe-Saint-Lambert, Belgium

Background: Synovitis is the common feature across all individuals with a diagnosis of rheumatoid arthritis (RA). Yet, cellular and transcriptomic alterations occurring in RA synovium are highly variable among patients. So far, most data on clinical-tissue correlations either rely on hypothesis-driven approaches or are potentially biased by heterogeneous clinical characteristics (e.g. disease duration or disease-modifying antirheumatic drugs).

Objectives: We used transcriptomic profiling of synovial tissue from early, untreated rheumatoid arthritis patients (ERA) to 1/ identify the genes with the most variable expression among patients and 2/ explore the ability of unbiased (data-driven) approaches to define clinically relevant ERA subgroups.

Methods: Synovial biopsies were harvested from clinically involved joints of ERA patients using needle arthroscopy or ultrasound-guided biopsy. Data on disease activity were collected at inclusion. For each sample, 350ng total RNA was sent for RNASEquencing using a standardized protocol (Macrogen Europe). After quality control (Fast QC) and genome alignment (HiSat2), normalized read counts were analyzed on Glucone Omics Explorer. To focus on inter-sample heterogeneity, genes were filtered based on variance (\(\sigma_{\text{max}}\)). Unbiased approaches (Principal Component Analysis, Unsupervised Clustering) were applied to define patients’ clusters. Pathway enrichment analyses were performed on Metascap. CibersortX was used to extrapolate the immune cell subsets relative composition from gene expression data. All other statistical analyses were performed on GraphPad Prism v9.

Results: Total RNA was obtained from synovial biopsies from 74 patients. We first applied variance filtering to identify the genes whose expression showed the greatest variation between patients (n = 894 most variable genes). PCA analysis on the level of expression of these genes did not divide samples into distinct groups, instead yielding a continuous distribution broadly associated with baseline disease activity, as measured by DAS28CRP. Consequently, we used unsupervised clustering to allow for unbiased definition of two patient clusters (PicC: PicC1 (n=52) and PicC2 (n=22) based on their expression of these 894 genes. Pathway analysis of these genes revealed significant enrichment of immune system genes, in the Inflammatory response and Rheumatoid Arthritis pathways (gene cluster 1: GC1), B cell & plasma cell-related pathways (GC2) and metabolic processes-related genes (GC3). Interestingly, PicC1 and PicC2 were characterized by very different clinical features. More specifically, patients from the group with a strong B & plasma cell signature (PicC1) displayed higher baseline indices of all disease activity score components (median DAS28CRP: 5.56 vs 4.09; p-value = 0.0003). They also had higher rates of baseline radiological erosions (erosive disease in 34.6 % vs 10%; p-value = 0.0252) but similar rates of seropositive disease. In line with our pathway analyses, we found a higher signature (inferred relative frequency) of B & plasma cells, T cells and M1-like macrophages in PicC1 compared to PicC2 synovia. PicC2 synovia instead had relatively higher M2-like macrophage and resting mast cell signatures.

Conclusion: In this large synovial biopsy study, we found that synovial transcriptomic profiles in ERA patients distribute continuously based on the expression of inflammatory and immune cell transcriptomic activity. These transcriptomic signatures correlate strongly with systemic disease activity. Data on disease activity were collected at inclusion. For each sample, 350ng total RNA was sent for RNASEquencing using a standardized protocol (Macrogen Europe). After quality control (Fast QC) and genome alignment (HiSat2), normalized read counts were analyzed on Glucone Omics Explorer. To focus on inter-sample heterogeneity, genes were filtered based on variance (\(\sigma_{\text{max}}\)). Unbiased approaches (Principal Component Analysis, Unsupervised Clustering) were applied to define patients’ clusters. Pathway enrichment analyses were performed on Metascap. CibersortX was used to extrapolate the immune cell subsets relative composition from gene expression data. All other statistical analyses were performed on GraphPad Prism v9.

Acknowledgements: This work was funded in part by unrestricted grants from Cap48 (RTBF), the Fonds de la Recherche Scientifique (FNRS), and the Fund for Scientific Research in Rheumatology (FWRO/FRSR), managed by the King Baudouin Foundation. CT is funded by the FNRS and Fondation Saint-Luc (Cliniques Universitaires Saint-Luc). NL is a chercheur qualifié of the FNRS.

Disclosure of Interests: Clément Triaille: None declared, Tatiana Sokolova: None declared, Stéphanie de Montjoie: None declared, Adrien Nzeusuou Toukap: None declared, Laurent Meric de Bellet: None declared, Axelle Loriot: None declared, Bernard Lauwersy Shareholder of: BL owns shares (<15000€) in DNAlytics, Employee of: BL is currently employed at UCB Biopharma, Patrick Durez: None declared, Nisha Limaye: None declared.

Spondyloarthritis - aetiology, pathogenesis and animal models

CHARACTERISTICS OF GUT MICROBIOTA AND ITS RELATIONSHIP WITH LYMPHOCYTE SUBSETS AND CYTOKINES IN PATIENTS WITH UNDIFFERENTIATED SPONDYLOARTHRITIS

O. Wang1,2, S. X. Zhang3,4, J. Qiao3,4, X. Li1, Q. Yu1,6, P. F. He1,6, 1Shanxi Medical University, School of Basic Medical Sciences, Taiyuan, China; 2Ministry of Education, Key laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China; 3The Second Hospital of Shanxi Medical University, Department of Rheumatology and Immunology, Taiyuan, China; 4Shanxi Medical University, School of Management, Taiyuan, China; 5Shanxi Medical University, Medical Data Sciences, Taiyuan, China

Background: Gastrointestinal microbiota, particularly dysbiosis of gut microbiota composition have been correlated with the progression of autoimmune disorders, such as undifferentiated spondyloarthritis (USPA).

Objectives: This study aimed to identify the changed gut microbiota and its relationship with lymphocyte subsets and cytokines in USPA Patients.

Methods: A total of 210 participants were recruited in this study, comprising 105 USPA patients and 105 age and sex-matched healthy controls (HCs). Microbial genome was extracted from approximately 250mg fresh fecal samples from all participants using QI Amp PowerFecal DNA Kit (Qiagen). The V3-V4 variable regions of bacterial 16S RNA genes were sequenced with the Illumina MiSeq PE300 system. QIIME2 was used to process representative sequence clusters and beta diversity (bray distance). Biomarker species were identified based on STEMP between USPA and HC group. Correlations were analyzed with the Spearman rank correlation test.

Results: The alpha-diversity indices have no significant difference between two groups (P > 0.05, Figure 1A). Gut microbial community structure differed between USPA and HC, as revealed by ASV Bray–Curtis distances (P < 0.05, Figure 1B). As for composition of gut microbiota, there were the increased levels of Escherichia, Lactobacillus, Staphylococcus, and Prevotella and Enterobacter was negatively correlated with the absolute numbers of NK cell (P < 0.05, Figure 1F).

Conclusion: Gut dysbiosis in USPA patients mainly characterized by reduced the diversity and impaired abundance of the intestinal flora, which was closely related to the disturbance of lymphocyte subpopulations and cytokines.

REFERENCES:


Disclosure of Interests: None declared.


POS0450 TEMPORAL MIGRATION OF IMMUNE CELLS FROM PSORIATIC SKIN TO JOINTS INITIATING SYNOVIAL INFLAMMATION IN PSORIATIC ARTHRITIS

M. G. Raimondi1,2, S. Rauber1,2, C. Xu1,2, H. Mohammadiani1,2, M. Vogl1,2, C. G. Anchang1,4, A. Fius Rigal1,2, M. Lubert1,2, A. Leibens1,6, A. Soaso1,2, J. H. W. Distler1,2, U. Fearon5, D. Veale6, M. Stichinger7, J. D. D. Carhete6, G. Schett1,2, A. Ramming1,2, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; 2Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Deutsches Zentrum Arthromes, Erlich, Germany; 3University: Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; 4Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen, Germany; 5 Trinity College Dublin, Department of Molecular Rheumatology, Dublin, Ireland; 6University College Dublin, Centre for Arthritis and Rheumatic Disease, Dublin, Ireland; 7Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany; 8Hospital Clinic and IDIBAPS, Arthritis Unit, Rheumatology Department, Barcelona, Spain

Background: Spreading of inflammation from skin to joint is a key question behind the pathogenesis of psoriatic arthritis (PsA). Psoriasis (PsO), being one of the most prevalent skin diseases, usually anticipates joint manifestations, suggesting spreading of skin to joint disease, which happens in about 30% of the patients with psoriasis. To date, it is still obscure why the inflammatory process in some patients with PsO remains restrained to the skin, whereas in other patients it extents to tendons and joints.

Objectives: Using a pre-clinical model of PsA, we aimed to unveil the skin-joint axis, i.e. the spreading of psoriatic inflammation from the skin to the joints.

Methods: KAEDERED transgenic mice expressing a photo-convertible fluorescent reporter were used to assess cell trafficking from inflamed skin to other organs in animal models. Using a pre-clinical model of IL-23 overexpression (IL-23OE) induced PsA. Psoriatic skin lesions were irradiated with UV light to trigger the photoswitch from KAEDERED treated mice to KAEDEREDED. Migration to different organs was determined by flow cytometry. Imaging flow cytometry was used to characterize the type of cells migrating from the skin to the joints. Migrating cells were further characterized by single-cell RNA-sequencing (scRNAseq) and functional analyses.

Results: MRI imaging and histological evaluation of IL-23OE mice revealed skin inflammation preceding joint inflammation in both wild-type and KAEDERED transgenic mice. Specific leukocyte migration from the skin to the joints started shortly after the onset of skin inflammation and before onset of inflammation within the joints of KAEDERED transgenic mice. No migration was observed in healthy control animals. Other organs such as spleen or lymph nodes showed no model-dependent migration. Imaging flow cytometry revealed that the cells migrating to the joints were predominantly CD45+ CD11b+ cells. ScRNAseq analysis of sorted KAEDERED cells from inflamed joints confirmed that approximately 80% of the migrating cells were macrophages. Differential gene expression and pathway analysis revealed an imbalance between pro- and anti-inflammatory macrophages in the joints of experimental psoriatic arthritis.

Conclusion: We describe IL-23-mediated migration of skin-derived macrophages from the skin to the joints during the onset of experimental psoriatic arthritis. This process may explain the spreading from psoriatic skin to joint disease as these cells foster the development by local cytokine production once arrived in the joints.

REFERENCES:


Disclosure of Interests: None declared.

SLE, Sjögrens and APS - aetiology, pathogenesis and animal models

**DEFICIENCY OF PPM1A IN MACROPHAGE AGRGRAVATES PRISTANE-INDUCED LUPUS-LIKE DISEASE**

J. E. Kim1,2, E. Y. Kim1,3, S. Oh1,2, M. Lee1,2, D. Yoon1,2, H. J. Min1,2, H. S. Choi1,2, Y. G. Kim3, E. J. Chang1,2,4,5
1University of Ulsan College of Medicine, Biomedical Sciences, Seoul, Korea, Rep. of (South Korea); 2University of Ulsan College of Medicine, Stem cell Immunomodulation Research Center Seoul, Korea, Rep. of (South Korea); 3Asian Medical Center, Division of Rheumatology, Seoul, Korea, Rep. of (South Korea); 4University of Ulsan College of Medicine, Biochemistry and Molecular Biology, Seoul, Korea, Rep. of (South Korea)

**Background:** Protein phosphatase Mg2+/Mn2+-dependent 1A (PPM1A) is a phosphatase which regulates various intracellular cell signaling pathways including inflammation. We previously suggested that the inflammatory signal decreased the PPM1A protein level in macrophage and this reduction had correlation with the chronic inflammatory bone disease, implying the possible role of PPM1A in inflammatory responses of macrophage.

**Objectives:** In this study, we aimed to elucidate the potential role of PPM1A in macrophage to regulate inflammatory response during the disease progression of systemic lupus erythematosus.

**Methods:** We generated macrophage-specific conditional gene-knockout (PPM1Afl/fl;LysMCre) mice and developed a lupus-like disease with immune complex glomerulonephritis in these PPM1Afl/fl;LysMCre mice by intraperitoneal pristane injection. Mice serum was collected every 4 weeks after pristane injection. Serum anti-dsDNA IgG, anti-ssDNA IgG, interleukin-17 (IL-17) and tumor necrosis factor-α (TNF-α) were quantified by ELISA. After 41 weeks from pristane injection, histological changes in the kidney, spleen, and lung tissues were observed. To analyze M1/M2 polarization in vitro, LysMCre and PPM1Afl/fl;LysMCre mouse bone marrow-derived macrophages were cultured with lipopolysaccharide (LPS)/Interferon-α (IFN-α) or Interferon-γ (IFN-γ) or IL-4 to check M1 or M2 related genes.

**Results:** We found that macrophages of PPM1Afl/fl;LysMCre mice displayed different gene expression with LPS stimulation especially in M1/M2 related genes through the RNA-seq analysis and showed a decrease in both M1 and M2 polarization induced by LPS/IFN-γ or IL-4 stimulation. Notably, we found that PPM1Afl/fl;LysMCre mice with pristane injection showed a significant increase of anti-ssDNA IgG compared to LysMCre mice. PPM1Afl/fl;LysMCre mice showed severe lupus-like phenotypes such as global glomerular enlargement indicated by endocapillary proliferation and glomerular cellularity in kidney and lung inflammation accompanied by fibrosis, compared to LysMCre mouse by pristane injection. Together, serum IL-17 and TNF-α, which are proinflammatory cytokines, were increased in PPM1Afl/fl;LysMCre after pristane injection. These results indicate that PPM1A depletion in macrophage deteriorates inflammation and contributes to the tissue damage in lupus-like disease.

**Conclusion:** Our findings suggest that the deficiency of PPM1A in macrophages impairs M1/M2 macrophage polarization leading to an immune imbalance in lupus-like disease model, providing a potential link between the loss of function of PPM1A in macrophages and its molecular target for treatment of systemic lupus erythematosus.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.137

**EXPLORATORY IMMUNOPHENOTYPE OF THE TISSUE JUVENILE SJÖGREN’S SYNDROME REVEALS A DISREGULATION OF B AND T MEMORY CELL FREQUENCIES**

L. Martin-Gutierrez1,2, H. Peckham3, A. Radziszewska2,3, J. Peng2, O. Nette2, E. Jury1, C. Clurin3,1, University College London, Centre for Rheumatology Research, London, United Kingdom; 2University College London, Centre for Adolescent Rheumatology Versus Arthritis, London, United Kingdom

**Background:** Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands. Patients also present with other extraglandular manifestations such as arthritis, anaemia and fatigue or various organ and systems involvement. The disease is more frequent in women aged 30-50. However, in rare cases, the disease is seen in childhood and is known as juvenile SS (JSS) or childhood SS. Children have different clinical manifestations compared to adults, with dryness being less common, making the diagnosis very challenging.

**Objectives:** To investigate in depth the immune cell profile of patients with JSS for better understanding of disease pathogenesis.

**Methods:** Peripheral blood was collected from a cohort of patients with JSS who were attending appointments at UCLH clinics. None had received B-cell depletion therapy. Immune-phenotyping of 29 immune-cell subsets, including B and T cells, in peripheral blood from patients with JSS (n=10) and age and sex-matched healthy controls (n=10) was performed using flow cytometry as we have performed previously for patients with adult onset SS. Data were analysed using multiple t-tests and compared with the adult SS immune phenotype.

**Results:** Patients with JSS had an average age of 18 years (range 16-21) with an average age of disease onset at 14 years (range 12-18). Up to 60% of patients presented Anti-Ro autoantibodies while 50% presented Anti-La autoantibodies. Patients with JSS had an altered immune profile compared to age matched healthy controls (average of 18 years, range 15-25). In the B cell compartment,
JSS patients had higher frequencies of total CD19+ B cells (p=0.0044), Naïve B cells (CD19+IgD+CD27-) (p=0.0183) and b2m (CD19+HlgD-CD28+) (p=0.0490) whereas memory B cell subsets such as early b5m (CD19+HlgD-CD38+) and late b5m (CD19+HlgD-CD38-) were significantly reduced (p=0.0249, and p=0.0177, respectively), similar to the profile seen in patients with adult-SS. Interestingly, in the CD4+ T cell compartment, central memory (CD4+CD27+CD45RA-) T cells were significantly reduced (p=0.0001) but effector memory (CD4+CD27-CD45+) and effector memory-re-expressing-CD45RA (EMRA, CD4+CD27-CD45RA+) T cell subsets were significantly elevated (p=0.0171 and p=0.0022 respectively). These changes were not observed in adult-SS patients. Finally, unlike intraepithelial B-lymphocytes, serological parameters, such as, rheumatoid factor-, IgG- and ESR levels were significantly higher in JSS patients with presence of B-lymphocyte containing ducts, irrespective whether the labial or parotid gland was taken into account.

**Conclusions:** Presence of B-lymphocyte containing ducts is a specific finding in salivary gland biopsies of pSS patients and is associated with clinical parameters of pSS. Tofacoitinib containing ducts by using DIA could be used as an objective marker in the diagnostic histopathological work-up of patients suspected of pSS.

**References:**


RIIP buffer to obtain proteins. The protein levels of PRRs: NLPR3, TLR9, ZBP-1, and cGAS, as well as molecules activated downstream of cGAS and ZBP-1 such as TBK1, p-TBK1, p-STING, and STING were determined by Western blotting.

**Results:** The results show that the mitochondria of the glandular epithelial cells of NOD.B10Sn-H2b/J mice treated with vehicle (control) present alterations such as swelling, disruption of membranes and crest disorganization that previously were reported in patients with SS (1). Interestingly, tofacitinib treatment improves the architecture of mitochondria. On the other hand, the protein levels of PRRs such as NLPR3 and cGAS decreased in mice treated with tofacitinib, as well as pTBK1.

**Conclusion:** The altered morphology of mitochondria together with the increased protein levels of PRRs and downstream markers of these PRRs suggests release of mitochondrial DAMPs in submandibular glands of NOD. B10Sn-H2b/J mice. The improvement in mitochondrial morphology as well as the decrease in PRRs activation under tofacitinib treatment suggest a potential use of this anti-inflammatory agent in mitochondrial alterations associated with inflammation. Many questions remain to be addressed, such as determining which mitochondrial DAMPs might be being released and whether this is associated with impaired mitochondrial function in SS.

**REFERENCES:**


**A. Nagel1, M. Radziszewski1, B. Khatri1, M. M. Wiley1, A. M. Stolarczyk1, M. Loachims1, Q. Sun2, K. Kim3, S. C. Bae4,5, B. Tsao2, C. Lessard1.

**Disclosure of Interests:** None declared.

**DOI:** None declared.

**Disclosure of Interests:** None declared.

**References:**


**Acknowledgements:** This work was supported by Fondo de Investigación 11201056 and Fondo de Chile 1210055.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2110

**POS0456 AUTOPHAGY-RELATED LOCUS IN SLE AND THEIR ROLE IN NEUTROPHILS**

A. Nagel1, M. Radziszewski1, B. Khatri1, M. M. Wiley1, A. M. Stolarczyk1, M. Loachims1, Q. Sun2, K. Kim3, S. C. Bae4,5, B. Tsao2, C. Lessard1.


**Science, Seoul, Korea, Rep. of (South Korea);** L. Joachims1, Q. Sun2, K. Kim3, S. C. Bae4,5, B. Tsao2, C. Lessard1.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2496

**POS0457 LABIAL AND PAROTID SALIVARY GLAND HISTOPATHOLOGY IN PRIMARY SJÖGREN’S SYNDROME**

U. Nakehandari1, M. S. Van Ginkel1, B. Bootsma1, S. C. Liefers1, F. K. L. Spikker2, A. Visink3, B. Van der Vegt3, G. F. M. Kroese1

**Discord of Patients:**

1. University Medical Center Groningen, Rheumatology & Clinical Immunology, Groningen, Netherlands.
2. University Medical Center Groningen, Oral & Maxillofacial surgery, Groningen, Netherlands.
3. University Medical Center Groningen, Pathology & Medical Biology, Groningen, Netherlands.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2496

**Background:** Salivary gland involvement is a hallmark of disease in primary Sjögren’s syndrome (pSS). This is reflected by the prominent role of a positive biopsy within the ACR-EULAR classification criteria, which is solely based on the focus score (FS)1. In pSS all salivary glands might be involved in the disease process. For this reason, both labial and parotid salivary gland biopsies can be used for diagnosis and evaluation. Although nearly all clinical centres obtain labial gland biopsies for classification and diagnosis of pSS, a parotid biopsy is also a safe and effective procedure. Furthermore, it has a comparable diagnostic potential in pSS, might be associated with less morbidity, and may even detect presence of subclinical MALT lymphomas. However, histopathological differences between both types of salivary glands should potentially be taken into account.

**Objectives:** The aim of this study was to get histopathological insight in minor (labial) and major (parotid) salivary glands in pSS patients in comparison with non-SS sicca patients.

**Methods:** Both labial and parotid salivary gland biopsies were obtained from 99 patients. According to the expert opinion of three experienced rheumatologists, 36 patients were classified as pSS patients and 63 as non-SS sicca patients. Salivary gland biopsies were formalin fixed, paraffin embedded and serially sectioned at 3–4µm. Sections were stained with H&E and for CD3, CD20, CD45, CD3+, CD20+, CD45+, and CD20+ infiltrates compared to non-SS parotid salivary gland biopsies. Other histopathological parameters were comparable between the two types of salivary glands. In pSS patients, both labial and parotid salivary gland sections. Comparison of the two salivary gland types of non-SS sicca patients revealed more signs of inflammation in labial salivary glands as shown by a significantly higher FS, CD3+ “T-cells”, CD20+ “B-cells” and relative area of CD45+ infiltrates compared to non-SS parotid salivary gland biopsies. Other histopathological parameters were comparable between the two types of salivary glands. In pSS patients, a higher FS and relative area of CD45+ infiltrates was observed in labial gland biopsies compared to parotid gland biopsies. Nevertheless, relative and absolute CD20+ B-cell counts, GCs/mm² and LEVs/mm² were higher in parotid gland parenchyma.

**Conclusion:** This study shows in labial salivary gland biopsies of non-SS sicca patients more signs of (unspecific) inflammation compared to parotid biopsies. In parotid gland biopsies signs of B-cell hyperactivity, such as number of CD20+ B-cells, GCs/mm² and LEVs/mm², are more pronounced, compared to labial gland biopsies. These histopathological differences should be taken into consideration in diagnosis and classification of Sjögren’s disease.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2496

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2496
REFERENCES:
This study was financed by a grant from the National Institutes of Dental and Craniofacial Research (U01 DE015793 Salivary Biomarkers for Sjögren’s Syndrome Detection-Definitive Validation).
Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2022-eular.2567

POS0458
ENRICHMENT OF COMPLEMENT, IMMUNOGLOBULINS, AND AUTOANTIBODY TARGETS IN THE PROTEOME OF PLATELETS FROM PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
P. Linge1, A. Jern1, H. Tydén1, B. Gullstrand1, H. Yani2, C. Welinder3, R. Kahn1, A. Jonsen1, J. Sjöple1, A. Bengtsgon1, on behalf of Lund SLE Research Group, 1Lund University, Department of Clinical Sciences, Rheumatology, Lund, Sweden; 2Swedish National Infrastructure for Biological Mass Spectrometry, BioMS, Lund, Sweden; 3Lund University, Department of Clinical Sciences Lund, Lund, Sweden; 4Lund University, Division of Hematology and Transfusion Medicine, Lund, Sweden
Background: Systemic Lupus Erythematosus (SLE) is characterized by autoimmunity towards apoptotic/necrotic cells, complement activation and excessive amounts of circulating immune complexes. Platelets are recognized as immune cells that interacts with innate and adaptive immune functions. They are activated in SLE patients and contribute to an increased susceptibility to thrombosis [1]. Decreased platelet size has been observed in patients with SLE [2], but the mechanism(s) remains unclear. In this study, we have analyzed the complete proteome of platelets with normal and decreased size from SLE patients and from healthy controls (HC).
Objectives: Our aim was to find clues that could explain the morphological differences observed in platelets from SLE patients and to better characterize the role of platelets in SLE.
Methods: We included 23 consecutive patients with SLE, median SLEDAI-2K score was 2, and 10 HC. Blood count, serum complement levels and the presence of antiphospholipid or dsDNA antibodies were analyzed in all patients. Platelet size (forward scatter) and activation status (CD154, PAC1, CD32, PAR1, CD62P and Annexin V) was determined using flow cytometry. The proteome of 10 platelet isolates from SLE (five with smallest and the five with largest average size) and five HC were analyzed using liquid chromatography with tandem mass spectrometry (LC-MS/MS). Data were analyzed using ANOVA, t-test, hierarchical cluster analysis, protein interactions using the STRING software and correlation analysis using spearman correlation.
Results: We identified a total of 2572 proteins from the platelet isolates. Out of the identified proteins, 396 had significantly different levels, meeting an ANOVA q-value < 0.01. Pairwise t-test analysis, using a fold difference (FD) of > 1.5 and a p-value of ≤ 0.05 as cut off revealed significant differences in the distribution of proteins between groups. Platelets of both SLE groups (small and normal sized) shared higher levels of forty proteins and twenty proteins were reduced, compared to HC. Cytokine functions were overrepresentation in the group of reduced proteins, while proteins with higher levels in platelets from SLE patients included proteins associated with complement and autoantibody targets such as Beta-2-glycoprotein 1, Annexin A5, and Prothrombin. Platelets from SLE patients also shared an abundance in immunoglobulin proteins, with even greater accumulation in the normal sized platelets. Platelet heavy chain constant alpha 1 (r = -0.85, p=0.003), heavy constant mu (r = -0.64, p=0.05) and heavy constant gamma 3 (r = -0.80, p=0.008) are negatively correlated with complement C4 in serum and heavy constant gamma 2 (r = -0.648, p=0.049) with complement C3.
Conclusion: This study revealed an accumulation of complement proteins, immunoglobulins and known autoantigens in platelets from SLE patients compared to HC. The signature was largely independent of platelet size, but the mechanism(s) remains unclear. In this study, we have analyzed the complete proteome of platelets with normal and decreased size from SLE patients and from healthy controls (HC).
Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2022-eular.2567

POS0459
APTERM-BASED PROTEOMIC SCREENING IN IDENTIFICATION OF PATHOGENIC SIGNAL PATHWAY AND ASSOCIATED BIOMARKERS WITH ASSOCIATED WITH HISTOLOGICAL FINDINGS IN LUPUS NEPHRITIS
1Keio University School of Medicine, Division of Rheumatology; 2Department of Internal Medicine, Tokyo, Japan; 3Mitsubishi Tanabe Pharma Corporation Sohaku, Innovative Research Division, Tokyo, Japan
Background: The current gold standard for the diagnosis and classification, assessment of the severity of lupus nephritis (LN) is a renal biopsy. On the other hand, since the procedure is highly invasive, there is a pressing need to identify biomarkers for predicting the presence and its histological severity of LN.
Objectives: The purpose of this study was to elucidate the urine biomarkers for predicting the presence and the severity of histological findings of LN, and to search the pathogenic signal pathway.
Methods: Urine samples from 24 biopsy-proven active LN patients were initially screened for the levels of 1305 distinct human proteins using an aptamer-based-targeted proteomic assay. We developed histological scoring system based on ISN/RPS lesion definitions and classification, NIH activity and chronicity score. Two experienced evaluators assessed the histological scores. Cluster analysis and pathway analysis were performed.
Results: A total of 24 LN patients were included: 20 (83%) had a proliferative histological class (III or IV +/- V), 4 (17%) pure membranous (V). Through cluster analysis, several histological subgroups were extracted according to correlation with each histological finding, and proteins which correlated with each histological scores were analyzed. We focused on two subgroups: one in which including active glomerular histological findings (endocapillary hypercellularity, karyorrhexis, neutrophil infiltration, subendothelial deposits) and the other in which including interstitial histological findings (interstitial inflammation, interstitial fibrosis, tubular atrophy). Histological scores in the former group showed strong positive correlation with protein group which contained 59 proteins (Group A), including CCL21, CCLX10, VCAM1. Histological scores in the latter group correlated with another protein group which contained 85 proteins (Group B), including MCP-1, CCL11. Inguenity Pathway Analysis showed 16 pathways (PDGF Signalling, Granulocyte Adhesion and Diapedesis, etc) were upregulated in Group A and 11 pathways (IL-17 signalling, Fibrosis signalling pathway, etc) upregulated in Group B. Among group A and B urine proteins, those showed strong correlation between respective histological findings were validated with ELISA assays.
Conclusion: An aptamer-based-targeted proteomic assay screening by combining with renal histological scoring system suggested several urine proteins can predict the severity and the presence of major renal histological findings, and suggested to be related with the pathogenesis in patients with LN.
Disclosure of Interests: Kuzuo Hiramoto; None declared, Shuntaro Saito; None declared, Hironari Hanako; None declared, Katsuya Suzuki; None declared, Jun Kikuchi; Mitsubishi Tanabe Pharma Corporation Sohaku, Yoko Sugahara; Employee of; Mitsubishi Tanabe Pharma Corporation Sohaku, Fumihiko Takano; Employee of; Mitsubishi Tanabe Pharma Corporation Sohaku, Noriaki Miyoshi; Employee of; Mitsubishi Tanabe Pharma Corporation Sohaku, Hiroaki Fukui; Nobelis Sohaku, Hironari Hanaoka; None declared, Katsuya Suzuki; None declared, John Semple; None declared, Anders Bengtsson; None declared. DOI: 10.1136/annrheumdis-2022-eular.2698

POS0460
METABOLOMICS ACROSS AGE IDENTIFIES UNIQUE CHANGES IN THE SERUM METABOLIC PROFILE IN PATIENTS WITH SLE
G. Robinson1,2, A. Van Vlietje1,1, L. Martin-Gutierr2,1, I. Jenedberg1,2, C. Torra1,2, C. Curtin1,2, E. Jury1, University College London, Rheumatology, London, United Kingdom; 2University College London, Centre for Adolescent Rheumatology, London, United Kingdom; 3University College London Centre, for Cardiometabolic and Vascular Science, London, United Kingdom

Disclosure of Interests: Petrus Linge: None declared, Andreas Jern: None declared, Helena Tydén: None declared, Birgitta Gullstrand: None declared, Hong Yan: None declared, Charlotte Weilender: None declared, Robin Kahn: None declared, Andreas Jonsen Consultant of: Astra Zeneca and glaxosmithkline, John Sorensen: None declared, Christine Bengtsson: None declared. DOI: 10.1136/annrheumdis-2022-eular.2572

Disclosure of Interests: None declared.
Background: Cardiovascular disease (CVD) is a leading cause of mortality in patients with systemic lupus erythematosus (SLE, female:male ratio of 9:1) through accelerated atherosclerosis, the build-up of lipids and inflammation in the major artery walls, compared to age and sex matched healthy individuals. This is due to chronic inflammation, dyslipidaemia and other cardiometabolic defects that exacerbate with age (1). SLE women in aged of 35-44 increases the risk of coronary artery disease by 50 times and there is a 100-300-fold increased CVD-related mortality risk in young patients that develop SLE before the age of 18. Investigating metabolic defects in young patients and how they progress with age could help us understand the progressive mechanisms of atherosclerosis in SLE.

Objectives: To further investigate the hippocampal neurogenesis in lupus and determine its involvement in disease pathogenesis.

Methods: All experiments were performed in female NZB/NZW F1 and C57BL/6 (WT) mice at the age of 3 months (pre-nephritic) and 6 months (nephritic stage) (n=5-8/condition/experiment). Neurogenesis was assessed in sagittal sections of hippocampus by immunohistochemical staining (DCX, Sox2, GFAP, Iba1) and morphological criteria. RNA-sequencing was performed in hippocampal tissue followed by pathway and enrichment analysis. Apoptosis (cleaved-caspase 3) and immune cell infiltration (CD11b, CD45, Ly6G, Ly6C, MHC-II, CD4, CD8, B220, Iba1, CD80, CD86, Argiase-1, iNOS) were assessed by flow-cytometry. Cytokines levels were measured by Legendplex. Ex vivo assays were performed in adult hippocampal neural stem cells extracted by 2-month-old female WT mice.

Results: We identified a profound disruption (~2-fold) of hippocampal neurogenesis (decreased DCX+ cells) both at 3 and 6 month-old lupus mice together with decreased differentiated cells in both time-points, suggesting that lupus mice exhibit impaired neuronal differentiation. Although the number of the neuronal precursors radial gial-like cells (RGLs) was normal at pre-nephritic stage, lupus mice express increased number of both activated RGLs (Sox2+/GFAP+) and proliferating neuronal progenitors (Sox2+ cells) indicating enhanced self-renewal ability of neural precursors and augmented proliferation. Levels of cleaved-caspase 3 were elevated in lupus hippocampus supporting increased hippocampal apoptosis. Immunohistochemical and transcriptomic analysis of hippocampal tissue revealed a profound inflammatory response in lupus mice. Flow-cytometry analyses showed a pronounced immune cell trafficking in lupus hippocampus with a myeloid predominance –involving predominantly the microglia- both at early and late stages of the disease. Multiplex assays revealed elevated levels of IL-6 and IL-18 in lupus hippocampus. Ex vivo exposure of adult hNSCs to IL-6 or IL-18 promoted cell proliferation and induced apoptosis.

Conclusion: The NZB/W-F1 mouse model of SLE exhibits defective neurogenesis due to increased apoptosis, and decreased differentiation of neuronal progenitors. Inflammation in lupus hippocampus results in elevated levels of IL-6 and IL-18 with both cytokines negatively affecting the NSCs response. IL-6 and IL-18 may induce behavioral changes in NZB/W-F1 lupus mediated by altered neurogenesis and may represent therapeutic targets in NPSLE.

REFERENCES:

Acknowledgements: This project has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No 742390)

Disclosure of Interests: None declared.


POS0462 HYDROXYLQUORINE REDUCES THE TITERS OF ANTI-DOMAIN 1 ANTIBODIES OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES: RESULTS FROM THE APS ACTION CLINICAL DATABASE AND REPOSITORY ("REPOSIT")


POS0461 DISRUPTED HIPPOCAMPAL NEUROGENESIS MEDIATED BY IL-6 IS MIGHTY-10 INDUCE NEUROPSYCHIATRIC CHANGES IN MURINE LUPUS

D. Nikolopoulos1, T. Manolakou1, A. Polissaidis1, A. Fila2, Y. Koutmanis1, D. Boumpas2.2Biomedical research foundation academy of athens. Center for clinical, experimental surgery and translational research, Athens, Greece

Background: Systemic lupus erythematosus (SLE) frequently affects the nervous system (NSLE) in SLE patients, now largely only partly understood. We have previously characterized the behavioral phenotype of the NZW/F1 lupus-prone mouse which recapitulates the NPSLE phenotype exhibiting hippocampal-linked behavior including depressive-like disorder, anxiety and cognitive impairment both at early and late stages of the disease characterized by a profound hippocampal inflammatory response I.2 Defective hippocampal neural stem cell (hNSC) response is associated with cognitive dysfunction, depression and anxiety, all of which represent common neuropsychiatric features of both human and murine SLE.

Objectives: To further investigate the hippocampal neurogenesis in lupus and determine its involvement in disease pathogenesis.

Methods: Serum NMR metabolomics (>250 metabolites, Nightingale) covering glycolysis metabolites, amino acids and 130 lipid measures was performed on serum from a cohort of female SLE patients (n=164, 13-72 years of age, median 35) and matched healthy controls (HCs, n=120, 15-76 years of age, median 36) and analysed by linear regression and Venn analysis. Multiple t-tests (corrected for multiple comparisons by false discovery rate) were used to assess unique metabolic changes by age group between SLE patients and HCs (≥25, n=62/43; 26-49, n=50/46; ≥50, n=52/31) and dysregulated metabolic pathways were assessed using metaboanalyst software. The metabolic impact of disease activity measures and treatments was assessed by Spearman correlations and unpaired t-tests respectively.

Results: Twenty-five metabolites were significantly altered in all SLE age groups compared to HCs, dominated by atheroprotective high density lipoprotein (HDL) subunits and their surface-bound peptide, apolipoprotein(Apo) A1, all of which were downregulated in SLE compared to HCs (p<0.0001 in ages combined). In addition, the concentration of glycolycoprotein acetyls (GlycA, inflammatory biomarker) was increased in SLE in all age groups compared to HCs (p<0.0001 in ages combined). Importantly, ApoA1 correlated negatively with disease activity measures (SLEDAI, p=0.005; BILAG, p=0.0009; dDNA, p=0.03; ESR, p=0.0006) and positively with lymphocyte count (p=0.0003), whilst GlycA correlated positively with ESR (p=0.0001) and CRP (p<0.0001). Alternatively, metabolites unique to specific age groups in SLE compared to HCs included reduced amino acid subsets in the ≥25 age group, increased atherogenic very low density lipoproteins and reduced polyunsaturated fatty acids in the 26-49 age group, and increased atherogenic low density lipoproteins in the ≥50 age group. Separately, metabolites associated with the glycosylation pathway (p=0.004, metaboanalyst), including acetone, citrate, creatinine, glycerol, lactate and pyruvate, had significant positive correlations with age in SLE patients, but not in HCs. These metabolites were not significantly associated with disease activity measures. However, pyruvate (p=0.01) and lactate (p=0.009) were significantly upregulated in prednisolone treated patients, whilst citrate (p=0.002) and creatinine (p=0.005) were downregulated in hydroxylorochrome treated patients.

Conclusion: Increasing HDL (ApoA1) levels whilst maintaining low disease activity in patients with SLE from a young age could improve cardiometabolic risk and determine its involvement in disease pathogenesis.

REFERENCES:

Acknowledgements: This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (grant agreement No 742390)

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2827
of Propaedeutic and Internal Medicine, Laiko Hospital, Athens, Greece;
4University of Turin, Department of Clinical and Biological Sciences, Turin, Italy;
5University of Padua, Department of Cardiac Thoracic and Vascular Sciences, Padua, Italy;
6Universidad Nacional del Sur, Miniatura, Argentina; Unibertsitatea, Unidad de Investigación de Enfermedades Autoinmunes, Servicio de Medicina Interna, BioCruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Spain; 7New York University, Hospital for Joint Diseases, New York, United States of America; 8University of Milan, Clinical Rheumatology Unit, Milan, Italy; 9Université Laval, Medicine, Quebec, Canada; 10University of Cordoba, Systemic autoimmune diseases and chronic arthropathies IMIBIC-Reina Sofia Hospital, Cordoba, Spain; 11Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China; 12Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan; 13Universidade do Estado do Rio de Janeiro, Department of Obstetrics, Rio de Janeiro, Brazil; 14Northwell Health, Rheumatology, Great Neck, United States of America; 15University of Utah and Intermountain Healthcare, Department of Obstetrics, Salt Lake City, United States of America; 16University of Brescia, Rheumatology Unit, Brescia, Italy; 17Nancy University, Internal Medicine, Nancy, France; 18Johns Hopkins University School of Medicine, Rheumatology, Baltimore, United States of America; 19Hospital Universitario, 12 de Octubre, Rheumatology, Madrid, Spain; 20Hospital Cliníc de Barcelona, Department of Autoimmune Diseases, Barcelona, Spain; 21Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Rheumatology, Rosario, Argentina; 22University of Michigan, Division of Rheumatology, Ann Arbor, United States of America; 23University of Texas Medical Branch, Internal Medicine, Galveston, United States of America; 24University of Calgary, Division of Rheumatology, Calgary, Canada; 25University of Istanbul, Division of Rheumatology, Istanbul, Turkey; 26University College London, Department of Haematology, London, United Kingdom; 27Hospital for Special Surgery, Rheumatology, New York, United States of America; 28King’s College London, Vascular Risk and Surgery Section, London, United Kingdom

Background: Data on fluctuation of antibodies directed against domain 1 (anti-D1) of β2-glycoprotein I (β2-GPI) are scarce. Patients with antiphospholipid syndrome (APS) and all three criteria tests for antiphospholipid antibodies (aPL) display higher titers of anti-D1, which correlates with clinical events. Objectives: This project aims at evaluating predictors of the variation of anti-D1 titers over time in a large international cohort of persistently aPL positive patients. Methods: Anti-Phospholipid Syndrome Alliance For Clinical Trials and International Networking (APS ACTION) Registry was created to study the course of persistently aPL-positive patients with or without autoimmune disorders over at least 10 years. Inclusion criteria are positive aPL by Updated Sapporo Criteria display higher titers of anti-D1, which correlates with clinical events. Results: In this longitudinal study, 230 patients with anti-D1 tested at 4 time points were included (Table 1). Patients with thrombotic APS had anti-D1 titers significantly higher than those without thrombosis (p=0.029). Among 135 patients with at least one anti-D1 positive result, anti-D1 titers varied significantly over time (Friedman statistics: 508.5, p<0.0001; anti-D1 geometric mean at baseline 189.0; Table 1. Demographic and Clinical Characteristics of 230 APS ACTION Registry Patients with anti-D1 tested ≥3 time points during the follow-up

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Anti-D1 pos samples</th>
<th>Anti-D1 neg samples</th>
<th>p-value</th>
<th>Overall sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=135)</td>
<td>(n=95)</td>
<td></td>
<td></td>
<td>(n=230)</td>
</tr>
<tr>
<td>Age [years] [median (SD)]</td>
<td>42.3 (11.8)</td>
<td>48.8 (13.0)</td>
<td>0.0001</td>
<td>45.0 (12.7)</td>
</tr>
<tr>
<td>%Female (n)</td>
<td>71.9 (97)</td>
<td>65.3 (62)</td>
<td>0.358</td>
<td>69.1 (159)</td>
</tr>
<tr>
<td>Associated systemic autoimmune disease</td>
<td>39.3 (53)</td>
<td>44.2 (42)</td>
<td>0.539</td>
<td>41.3 (95)</td>
</tr>
<tr>
<td>APS without APS</td>
<td>19.3 (26)</td>
<td>34.7 (33)</td>
<td>0.010</td>
<td>25.7 (59)</td>
</tr>
<tr>
<td>Thrombotic APS</td>
<td>54.1 (73)</td>
<td>53.7 (51)</td>
<td>0.539</td>
<td>53.9 (124)</td>
</tr>
<tr>
<td>Obstetric APS</td>
<td>11.9 (16)</td>
<td>5.3 (5)</td>
<td>0.21</td>
<td>8.6 (121)</td>
</tr>
<tr>
<td>Thrombotic+obstetric APS</td>
<td>14.8 (20)</td>
<td>6.3 (6)</td>
<td>0.26</td>
<td>11.3 (26)</td>
</tr>
<tr>
<td>aCL IgG</td>
<td>89.5 (119/133)</td>
<td>25.5 (24/94)</td>
<td>&lt;0.0001</td>
<td>63.0 (143/227)</td>
</tr>
<tr>
<td>aCL IgM</td>
<td>36.1 (48/133)</td>
<td>27.7 (26/94)</td>
<td>0.234</td>
<td>32.6 (74/227)</td>
</tr>
<tr>
<td>Anti-β2GPI IgG</td>
<td>93.2 (124/133)</td>
<td>39.4 (47/94)</td>
<td>&lt;0.0001</td>
<td>70.9 (161/227)</td>
</tr>
<tr>
<td>Anti-β2GPI IgM</td>
<td>34.6 (46/133)</td>
<td>21.3 (20/94)</td>
<td>0.043</td>
<td>29.1 (66/227)</td>
</tr>
<tr>
<td>LA</td>
<td>82.6 (82/99)</td>
<td>59.5 (44/74)</td>
<td>0.001</td>
<td>72.8 (126/173)</td>
</tr>
</tbody>
</table>

Anti-D1 titers were significantly higher at baseline compared to T3 (p=0.029). In the 4 years of follow-up, 18 new thrombotic events occurred. Patients with double/triple aPL positivity displayed 12.5 fold increase [95%CI 7.4-20.0] in baseline anti-D1 titers. After adjustment for age, gender and number of positive aPL tests, the fluctuation of anti-D1 titers was associated with treatment with hydroxychloroquine (HQC) at each time-point. In particular, treatment with HQC, but not those with conventional immunosuppressors, was associated with a 1.3-fold decrease in anti-D1 titers [95%CI 1.1-1.5]. In the same multivariable model, incident vascular events were associated with a 1.5 fold increase of anti-D1 titers. A concomitant diagnosis of systemic lupus erythematosus did not affect the fluctuation of anti-D1 titers.

Conclusion: Treatment with HQC and vascular events during follow-up were identified as significant predictors of the fluctuation of anti-D1 antibody titers over time.

Disclosure of Interests: None declared.


POS0463 REENGINEERING CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TARGETED THERAPY OF LUPUS NEPHRITIS

C. Sole-Marcé1, T. Molina1, J. Cortés-Hernández2, 1Vall Hebron Institute Research, Lupus Unit - Rheumatology, Barcelona, Spain; 2Vall Hebron Institute Research, Pathology, Barcelona, Spain; 3Hospital Universitari Vall d’Hebron, Lupus Unit - Rheumatology, Barcelona, Spain

Background: Although the pathogenesis of lupus nephritis (LN) is not completely clear, it is known that the production of anti-dsDNA or anti-C1q antibodies is related to its activity [1]. Despite treatment, approximately 30-40% of patients continue to present a significant number of renal outbreaks [2]. Therefore, there is a growing interest in the development of more specific drugs. As B cells play a central role in the pathogenesis of SLE, the therapy CAR-T cells has been studied reporting good results for the prevention and also for as treatment in murine lupus models [3,4]. Recently, a new selective immunotherapy for autoimmune diseases has been demonstrated by modifying the T cells with a chimeric autoantigen receptor (CAAR) [5]. This novel therapeutic approach could be beneficial in LN with the aim of depleting only anti-DNA producing B cells. In this way, the benefits of anti-CD20 biologics would be obtained, but it would be much more specific, personalized and, surely, effective since only the self-reactive B cells would be destroyed.

Objectives: To study CAAR-Tcell anti-dsDNA and anti-C1q therapy in LN through in vitro experiments (primary cells and kidney organoids).

Methods: Synthesis of 6 CAAR anti-dsDNA that will be transfected in the primary T cells extracted from patients with LN and healthy controls (N = 10 per group). Through in vitro experiments their ability to lyse the B cells that produce anti-dsDNA or anti-C1q will be evaluated. The two CAAR-Tcell models that is most effective will be evaluated using kidney organoid models obtained from human samples.

Results: We engineered six human T cells models to express a chimeric autobody receptor (CAAR), consisting lupus nephritis autoantigen. As antigens for anti-DNA produced B cells, we designed Heparanase1/2, His-autoantibody receptor (CAAR), consisting lupus nephritis autoantigen. As antigens for anti-DNA produced B cells, we designed Heparanase1/2, His-autoantibody receptor (CAAR) [5]. This novel therapeutic approach could be beneficial in LN with the aim of depleting only anti-DNA producing B cells. In this way, the benefits of anti-CD20 biologics would be obtained, but it would be much more specific, personalized and, surely, effective since only the self-reactive B cells would be destroyed.

References:

Discussion: Most important clinical results will be presented. The results will be compared with previously published results.
anti-idDNA were Heparanase2 and alpha actinin1 CAAR-Tcells (selectivity of 75% vs 45%). C1q CAAR-T cells also presented specificity cytotoxicity for anti-C1q B cells (selectivity of 80%). In vivo imaging assay reveals that C1q or Heparanase2 CAAR-Tcells depleted completely B cells at 48 hours (ratio 1:10). Bcells:CAAR-Tcells. We developed 3D in vitro organoid culture using human kidney organoid and B cells from lupus nephritis patients. We evaluated Heparanase2 and C1q CAAR-Tcells using them and we demonstrated that C1q CAAR-Tcells could resolved better local kidney inflammation (reduction of IL6, TNF and INF cytokines levels).

Conclusion: Taken together, these results show that C1q CAAR-Tcells could be an effective and selective immune therapy for treatment of lupus nephritis. Currently, we are evaluated this therapy using NZW/F1 mouse models.

REFERENCES:

Acknowledgements: I have acknowledge Instituto de Salud Carlos III for their kind financial support (grant PI18/01917)

Disclosure of Interests: None declared.


Figure 1. Results from the proteomic analysis carried out on synovial tissues. A) Heatmap showing the differential protein profiles between synovial tissues (PsA and RA) and healthy controls (CTL), at FDR 0.01. B) Characteristic protein panel discriminating PsA and RA tissues (p-value < 0.01). C) Discriminant analysis performed using this protein panel.

Results: Lipid profiles in ST from PsA and RA were unequivocally distinguished by MALDI-MSI followed by PCA-DA, and were also different comparing with control tissues. Interestingly, several lipid species, including sphingomyelins, phosphatidylincholines (PC) and phosphatidylethanolamines (PE), presented the greatest separation power to classify RA and PsA tissue samples. ANOVA analysis found 35 lipid species significantly different among the study groups, most of them significantly increased in RA and PsA compared to controls. Particularly, 11 lipids showed higher levels in PsA tissues compared with RA, including several PC and PE. The spatial distribution of these PE species was associated with areas of the sublining layer with increased vascularity and inflammatory cell infiltrates, according to MALDI-MSI images. On the other hand, RA and PsA patients were also correctly classified based on the ST levels of all quantified lipid species according to PCA and clustering analysis. Finally, the proteomic analysis quantified around 2,500 distinct proteins in the ST, including several related with lipid metabolism. Near 300 proteins showed altered abundance in the pathological tissues compared to healthy controls (FDR 0.01%, Figure 1A), being the small subset increased in controls mainly extracellular matrix proteins. The comparison between RA and PsA ST led to the identification of a panel of 36 proteins discriminating the two tissues with high statistical significance (p-value <0.01). In this comparison, all proteins except two appeared increased in RA (Figure 1B). A discriminant analysis shows the usefulness of this protein panel to differentiate the two diseases (Figure 1C).

Conclusion: Our study shows distinct molecular profiles between RA and PsA synovial tissue and synovial fluid, and reports potential clinically useful lipid and protein markers for the differential diagnosis of these diseases.

Disclosure of Interests: None declared.


POS0465

UNSUPUPERVISED CLUSTERING ANALYSIS OF THE SERUM PROTEOME IDENTIFIES SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DISTINCTIVE DISEASE SEVERITY AND LUPUS NEPHROPATHY

G. Lopez-Pedrera1, M. Á. Aguirre-Zamorano1, L. Muñoz-Barrera1, I. Sanchez-Paredes2, F. U. Pillar1, M. C. Ábalos-Aguilera3, N. Barberroja Puerto1, E. Collantes Estevez1, R. Ortega Castro1, C. Perez-Sanchez1, JMBIC/Reina Sofia Hospital/ University of Cordoba, Rheumatology; Córdoba, Spain

Background: Systemic lupus erythematosus (SLE) is a remarkably heterogeneous autoimmune disease. Despite great efforts, our knowledge of serum protein patterns in severe SLE phenotypes is still limited.

Objectives: This study investigated the serum proteomic profile of SLE, in order to identify relevant clinical categories.

Methods: Proximity extension immunosassay (PEA, Olink) was used to assess the serum levels of one hundred and eighty-five inflammation and organ damage-related proteins in patients with SLE (n = 72) and age-matched healthy donors (HD) (n = 18). In parallel, an extensive clinical and analytical profile of recruited subjects was performed. To evaluate the contribution of molecular profiles to the disease severity, unsupervised clustering analyses were developed. Gene ontology enrichment analysis were
also carried out to interrogate the biological meaning associated with the molecular signatures identified.

**Results:** Several circulating proteins related to inflammation and organ damage were coordinately altered in the serum of SLE patients in relation to HD. Unsupervised clustering analyses differentiated 2 patients clusters presenting different proteomic profiles. Clinically, although no differences were found in terms of age or disease duration, patients belonging to cluster 1 were characterized by a significantly higher status of disease activity (SLEDAI > 6) and prevalence of positivity for anti-ENA and anti-dsDNA antibodies than patients belonging to cluster 2, along with preponderance of patients with biopsy-diagnosed lupus nephritis (LN), abnormal creatinine and proteinuria. Twenty-three serum proteins were found deregulated between clusters. Interestingly, in parallel to well-recognized inflammatory cytokines, chemokines and regulatory proteins of leukocyte activity [Interferon (IFN)-gamma, interleukin (IL)-1βRA, IL-20, sCD40, macrophage colony-stimulating factor-1 (CSF-1), leukemia-inhibitory factor receptor (LIF-R), monocyte chemotactic protein (MCP)-1, MCP-4, C-C motif chemokine (CCL)-4, C-X-C motif chemokine (CXCL)-5, CXCL-6, metalloproteinase (MMP)-1, programmed cell-death ligand (PD-L)-1, eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1)], a number of key proteins involved in renal damage, not previously reported in serum from SLE, were further found significantly deregulated in patients belonging to cluster 1 when compared with cluster 2 (kidney injury molecule 1 (KIM1), Linker for activation of T-cells family member-2 (LAT2), C-type natriuretic peptide (NPPC), ErbB-2 interacted protein (ERBB2IP)).

**Conclusion:** 1) This highly sensitive proteomic analysis in the serum of SLE identified molecular patterns distinguishing patients with high disease activity and active LN, and including several novel candidate proteins, whose exact role and suitability as biomarkers in SLE deserve further investigation. 2) Combination of novel and traditional disease-specific biomarkers may improve diagnosis and management of SLE.

**Acknowledgements:** Supported by ISCIII (PI12/005991 and RICOR-RD21/0002/0033) co-financed by FEDER. Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2022-eular.4467

**PO5466**

**RESISTANT STARCH DIET IMPROVES DISTINCT GUT MICROBIOTA STRUCTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME**

M. Pereira1, I. Kulyk2, S. Redanz1, W. E. Ruff3, T. M. Greiling4, T. M. Greiling4, C. Dehner5, W. E. Ruff3, T. M. Greiling4, Carina Dehner5, Odelya Pagovich6, M. Greiling7, Daniel Zegarra Ruiz7, Cassyanne Aguiar8, None declared, Daniel Zegarra Ruiz: None declared, Cassyanne Aguiar: None declared, M. Greiling: None declared, Carina Dehner: None declared, Odelya Pagovich: None declared, Sylvio Redanz: None declared, William E Ruff: None declared, Teri M Greiling: None declared, Haider A. Pathan: None declared.

**Background:** Fiber-poor diets are linked to a reduction in gut microbiota diversity and gut barrier integrity, which is thought to promote the susceptibility to chronic inflammatory disorders1,2. We have previously shown that dietary resistant starch (RS) improves lupus-like disease in a murine model of SLE3 through the modulation of microbiota composition. If similar microbiotic microbial community structures exist in subsets of SLE patients and if a RS intervention may be efficacious in those patients remains unclear.

**Objectives:** To test if the dietary RS content in SLE and SLE-related antiphospholipid syndrome (APS) affect gut microbial taxa associated with SLE in published cohorts to date.

**Methods:** We obtained stool and blood samples as well as diet history for up to 3 visits (0, 4 and 8 weeks) from 12 SLE (n=28) and 15 APS (n=44) patients as well as 20 controls (n=48) as previously published4. Microbiota composition was defined by 16S rRNA V4 region sequencing on the Illumina platform and correlated with dietary fiber content extracted from a diet questionnaire. We used the FDA reference list to determine dietary RS contents in patients’ regular diets and defined RS quantities as being low if less than 2.5 g/day and as medium if 2.5 to 15 g/day. None of the patients achieved high RS greater than 15 g/day. Mann-Whitney or Kruskal-Wallis tests were performed to compare bacteria relative abundances among the different groups. Simple linear regression was performed to relate the bacterial abundance to RS content and other metadata.

**Results:** Medium intake of RS was associated with beneficial *Bifidobacterium* spp. in SLE patients (p=0.016) but not APS (p=0.509). Instead, APS patients who consumed medium quantities of RS in their diets had less gut bacterial taxa that are capable of producing cardiolipins (among them *Collinsella*; p=0.009) and *Ruminococcus gnavus* (p=0.0142), a species previously associated with lupus nephritis5. A recent Japanese metagenome-wide study6 associated *Streptococcus* spp. and related redox reaction genes with SLE, which may also affect oxidative processes in APS7. We therefore also explored *Streptococcus* levels in SLE and APS patients and found unexpectedly a significant reduction of streptococci in a subset of APS (p<0.004) but not SLE patients (p=0.451) in medium compared to low RS dietary content. *Streptococcus* abundance was correlated with both *Collinsella* (R2=0.3141; p<0.0001) and *Ruminococcus gnavus* (R2=0.1687; p=0.0056) in APS patients. Conclusion: Medium compared to low RS quantities in the regular diets of SLE and APS patients were associated with unique alterations in gut microbiota structure. *Bifidobacterium* increased in SLE patients with diets containing medium RS whereas APS patients with medium RS carried less cardiolipin-synthesizing taxa and lupus-related pathobionts. In particular, *Streptococcus* species recently strongly associated with SLE and redox reactions in Japanese patients in a metagenome-wide study8, were significantly suppressed in APS patients on medium RS diets. This modulatory effect was not seen in SLE patients or control subjects consuming medium RS diets. Together, these findings support distinct dietary effects on autoimmune gut microbiomes depending on the disease state. They also suggest potential beneficial effects of increased RS content on gut microbiota in SLE and APS patients. Fully resolving gut microbial signatures and clinical characteristics in these patients may identify the ideal subset to benefit from an intervention trial with RS.

**REFERENCES:**

[6] Ruff et al., 2019, Cell Host Microbe 26, 1–14

**Disclosure of Interests:** The work was supported by grants from the National Institutes of Health (NIH) (R01AI118655, T32AI070709), Arthritis National Research Foundation, Arthritis Foundation, Lupus Research Alliance, and Maren Foundation.

**Disclosure of Interests:** Márcia Pereira: None declared, Iryna Kulyk: None declared, Sylvio Redanz: None declared, William E Ruff: None declared, Teri M Greiling: None declared, Carina Dehner: None declared, Odelya Pagovich: None declared, Daniel Zegarra Ruiz: None declared, Cassyanne Aguiar: None declared, Doruk Erkan: None declared, M. Greiling (Krieger Speakers bureau: Novartis, BMS, GSK, MSD, Grant) research support from: AbbVie, Employee of: Roche. DOI: 10.1136/annrheumdis-2022-eular.4786
Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models.

**DERSIMELAGON, A NOVEL ORAL MELANOCORTIN 1 RECEPTOR AGONIST, DEMONSTRATES DISEASE-MODIFYING EFFECTS IN PRECLINICAL MODELS OF SYSTEMIC SCLEROSIS**

M. Kondo1, T. Suzuki1, Y. Kawano1, S. Kojima2, M. Miyashiro1, A. Matsumoto1, G. Kania3, P. Bliszczuk4, R. Ross5, P. Mulipia, F. Del Gaddi6, Y. Zhang7, J. H. W. Distler2,4, Mitsubishi Tanabe Pharma Corporation, Research Unit/Immunology & Inflammation, Souyaku Innovative Research Division, Yokohama, Japan; 1Mitsubishi Tanabe Pharma Corporation, Discovery Technology Laboratories, Souyaku Innovative Research Division, Yokohama, Japan; 3University of Zurich, University of Zurich, Center of Experimental Rheumatology, Department of Rheumatology, Schlieren, Switzerland; 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, Leeds, United Kingdom; 5Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, Germany

**Background:** Activation of melanocortin 1 receptor (MC1R) is known to have broad anti-inflammatory and anti-fibrotic effects. The blemcin (BLM)-induced skin fibrosis model is well-established for systemic sclerosis (SSc). α-melanocortin-stimulating hormone, an endogenous ligand of MC1R, inhibits skin fibrosis and MC1R knock-out enhances skin fibrosis in this model. These pieces of evidence suggest that MC1R agonism has potential in the treatment of SSC.

**Objectives:** Dersimelagon phosphate (MT-7117) is an investigational small molecule that is an orally administered, selective agonist for MC1R. The purpose of this study is to investigate the potential of MT-7117 as a therapeutic agent for SSC by evaluating its efficacy and mechanism of action in complementary preclinical models. The expression and distribution of MC1R in the skin of SSC patients was investigated.

**Methods:** The effects of MT-7117 on skin fibrosis and lung inflammation were evaluated in BLM-induced SSC murine models that were optimized for prophylactic and therapeutic evaluation. Microarray-based gene expression analysis and serum protein profiling were performed to investigate the mechanism of action of MT-7117 in the BLM-induced SSc models. The effect of MT-7117 on TGF-β-induced activation of human dermal fibroblasts was evaluated in vitro. Immunohistochemical analyses of MC1R expression in skin samples from SSC patients were performed.

**Results:** Prophylactic treatment with MT-7117 (≥3 mg/kg/day p.o.) significantly inhibited the increase in collagen content of the skin, the serum level of surfactant protein D, and the weight of the lungs from BLM-induced skin fibrosis and lung inflammation model. Therapeutic treatment with MT-7117 (≥3 mg/kg/day p.o.) significantly suppressed skin thickening and the numbers of myofibroblasts in pre-established BLM-induced skin fibrosis model. Gene array analysis using the BLM-induced SSc model demonstrated changes in numerous categories related to macrophages, monocytes, and neutrophils, followed by endothelial cell-related categories after treatment with MT-7117. In the analysis that focused on molecular signaling pathways, triggering receptor expressed on myeloid cells-1, IL-6, and oncostatin M were identified in inflammation, and peroxisome proliferator-activated receptor that is related to fibrosis were all affected by MT-7117. Serum protein profiling using BLM-induced SSc model revealed that multiple SSc-related biomarkers including P-selectin, osteoprotegerin, cystatin C, growth and differentiation factor-15 and ST00A9 were suppressed by MT-7117. MT-7117 inhibited the activation of human dermal fibroblasts by suppressing TGF-β-induced ACTA2 (encoding α-smooth muscle actin) mRNA elevation in vitro. Immunohistochemical analyses showed that MC1R positivity was observed in 40 of 50 diffuse cutaneous SSc patients. MC1R was expressed by monocytes/macrophages, neutrophils, blood vessels (endothelial cells), fibroblasts, and epidermis (keratinocytes) in the skin of SSc patients.

**Conclusion:** MT-7117 demonstrates disease-modifying effects in preclinical models of SSc. Investigations of its mechanism of action and target expression analyses indicate that MT-7117 exerts its positive effects by affecting the pathologies of inflammation, vascular dysfunction, and fibrosis through inflammatory cells, endothelial cells, and fibroblasts. In view of its potent beneficial impact on all three main pathologies of SSc, MT-7117 is a potential therapeutic agent for the treatment of clinically challenging SSc, which has diverse and difficult to treat symptoms. A phase 2 clinical trial investigating the efficacy and tolerability of MT-7117 in patients with early, progressive diffuse cutaneous SSc is currently in progress.

**Disclosure of Interests:** Masahiro Kondo Employee of: Mitsubishi Tanabe Pharma Corporation, Tsurui Suzuki Employee of: Mitsubishi Tanabe Pharma Corporation, Yuko Kawano Employee of: Mitsubishi Tanabe Pharma Corporation, Shinji Kojima Employee of: Mitsubishi Tanabe Pharma Corporation, Masa-hiko Miyashiro Employee of: Mitsubishi Tanabe Pharma Corporation, Atsuhiko Matsumoto Employee of: Mitsubishi Tanabe Pharma Corporation, Gabriela Kania: None declared, Puzrmays Blyszczuk: None declared, rekha; None declared, Pani Mulipa: None declared, Francesco Del Gado Grant/research support from: Pfizer, F. Del Gando received fees and research support from Abbvie, AstraZeneca, Boehinger-Ingelheim, Capella, Chemomab, Kambom, Janssen and Mitsubishi-Tanabe., Yun Zhang: None declared, Jörg H.W. Distler Grant/research support from: Prof. J.H.W. Distler received consulting fees, lecture fees, and/or honoraria from Actelion, Active Biotech, Anamar, ARXX, AYt, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JBT Theobalds, Medac, Pfizer, SFDA, Richard Wiener, and Pfizer. Distler is stock owner of 4D Science and Scientific head of Fibrocure. DOI: 10.1136/annrheumdis-2022-eular.29

**EXTRACELLULAR VESICLES FROM SERUM OF MYOSITIS PATIENTS AS CIRCULATING BIOMARKERS AND DISEASE MEDIATORS**

S. Kivity1,2, H. Kravitz2,3, C. Cohen1, D. Margoulios1, M. Amar1, G. Kazimirsky1, D. Ozeri1, A. Dor1, C. Brodie2, Meir Medical Center, Rheumatology Unit, Kefar Sava, Israel; 2Tel-Aviv University, Sackler Faculty of Medicine, Tel-Aviv-Yafa, Israel; 3Bar-Ilan University, The Mina and Everard Goodman Faculty of Life Sciences, Ramat Gan, Israel; 4Tel-HaShomer The Sheba Medical Center, Zabludowicz Center for Autoimmune Disease, Ramat Gan, Israel; 5Tel-HaShomer The Sheba Medical Center, Department of Neurology, Tel-Aviv University, Ramat Gan, Israel

**Background:** Inflammatory myopathies (IM) are a heterogeneous group of disorders characterized by autoimmune inflammatory destruction of skeletal muscles. It is many times associated with lung, skin, and joint involvement. Identifying biomarkers that can differentiate IM from other muscle disorders may elucidate the pathophysiology of IM, guide novel therapies, monitor disease activity/response to treatments and predict prognosis. Exosomes are membrane-bound nanovesicles with diameters of 30-150 nm that contain multiple proteins, nucleic acids, and other molecules in a tissue- and cell-specific manner. Exosomes are secreted by a large variety of cells, play major roles in cell-cell interactions, and have recently emerged as circulating biomarkers in a variety of pathological conditions, including several autoimmune diseases.

**Objectives:** To characterize exosomes from serum of IM patients, analyze protein expression and study their potential mediators of disease pathologies.

**Methods:** Serum was collected from patients suffering from IM(n=5) and from patients suffering from Becker (BMD) and Duchenne (DMD) muscular dystrophies (n=6). Exosomes were isolated by Exoquick precipitation and analyzed for size distribution and by nanoparticle tracking analysis (NTA) and by Western blot for exosome markers. The effects of the isolated EVs on human satellite cell proliferation and differentiation and macrophage activation were examined.

**Results:** Exosomes from IM patients decreased human satellite cell proliferation (51%, P<0.01) and inhibited their myogenic differentiation as indicated by lower fusion index (24% inhibition, P<0.01) and expression of myosin heavy chain (72% inhibition, P<0.001). Similar results were obtained also with exosomes derived from DMD and BMD patients; however, their inhibitory effect was more pronounced on MyoD expression. Treatment of macrophages with exosomes from IM patients significantly increased the expression of IL-10 (3-fold, P<0.001), compared to exosomes of healthy controls and DMD patients. Another significant difference was in the expression of signaling molecules: Thus, exosomes from BMD patients increased the phosphorylation of Erk and p38, whereas a smaller effect was induced by IM exosomes. Conclusion: Exosomes from IM patients decrease satellite cell proliferation and myogenic differentiation compared to healthy exosomes. In addition, these exosomes increased the expression of IL-10 in macrophages. These effects are unique to exosomes of IM patients compared to muscular dystrophies. These promising results suggest that serum exosomes should be further investigated as a novel biomarker with potential therapeutic implications.

**Disclosure of Interests:** Ami: None declared, Gili Kazimirsky: None declared, D. Ozeri: Speakers bureau: BI, Abbvie, Lilly, Pfizer, Janssen, Neopharm, Grant/research support from: Sobi, Haya Kravitz: None declared, Coral Cohen: None declared, Darya Margoulios: None declared, Moshe Amar: None declared, Gila Kazimirsky: None declared, David Ozeri: Speakers bureau: Neopharm, Consultant of: Abbvie, Amir Dori: Grant/research support from: Biogen, Chaya Brodie: Grant/research support from: Biogen. DOI: 10.1136/annrheumdis-2022-eular.63

**ENDOTHELIAL RESPONSE TO MESENCHYMAL TRANSITION FACTORS ARE PART OF THE FIBROTIC PATHOGENESIS IN SYSTEMIC SCLEROSIS**

Y. H. Chiu1,2, J. Spierings1, J. M. Van Laar3, J. De Vries-Bouwstra3, M. Van Dijk1, R. Golschmeding1, 1University Medical Center Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, Netherlands; 2Tri-Service General Hospital, Division of Rheumatology/Immunology/Allergy, Taipei, Taiwan, Republic of China; 3Leiden University Medical Center, The Department of
Background: Systemic sclerosis (SSc) is a systemic autoimmune disease characterised by inflammation, vasculopathy and fibrosis. Several mechanisms, including endothelial to mesenchymal transition (EndMT) and cellular senescence, may be included in the fibrosis process, especially in response to inflammation and vasculopathy.

Objectives: Our study aimed to identify how EndMT and cellular senescence manifest in SSc skin fibrosis.

Methods: We performed a cross-sectional biobank study on formalin-fixed, paraffin-embedded skin biopsies from patients meeting the ACR/EULAR 2013 classification criteria for SSc. The extent of dermal fibrosis and inflammatory cell infiltration was scored on haematoxylin-eosin stained samples. Fibrosis severity was semi-quantified by the compactness of collagen bundles and scored from one to three. The presence of senescence was defined by P21 or P16 positivity without co-localised Ki-67. The expression of P16, P21, and CTGF on fibroblasts and endothelia was scored from zero to two. The semi-quantitative score was evaluated independently in the superficial and deep dermis by agreement of two researchers (MRD and YHD). EndMT was assessed by co-localisation of CD31 and α-SMA double staining by immunofluorescence, and enclosure of ERG positive endothelial cell nuclei by α-SMA stained cytoplasm under bright field. Lymph vessels were identified by D2-40 (podoplanin) staining, and density was assessed.

Results: In total, skin biopsies from 18 SSc patients and four age-matched healthy controls were investigated. The characteristics of the patients are listed in Table 1. The dermal fibrosis score revealed a correlation with modified Rodnan skin score (Figure 1A).

Table 1. Clinical features of 18 patients with systemic sclerosis

<table>
<thead>
<tr>
<th>Feature</th>
<th>Value (n (%))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>47 (21)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>11 (61)</td>
</tr>
<tr>
<td>Biopsy site, n (%)</td>
<td></td>
</tr>
<tr>
<td>Upper limb</td>
<td>3 (17)</td>
</tr>
<tr>
<td>Trunk</td>
<td>6 (33)</td>
</tr>
<tr>
<td>Lower limb</td>
<td>8 (44)</td>
</tr>
<tr>
<td>Type of SSc, n (%)</td>
<td></td>
</tr>
<tr>
<td>Limited cutaneous SSc</td>
<td>13 (72)</td>
</tr>
<tr>
<td>Diffuse cutaneous SSc</td>
<td>5 (28)</td>
</tr>
<tr>
<td>mRSS, median (IQR)</td>
<td></td>
</tr>
<tr>
<td>Anti-topoisomerase I antibody positive, n (%)</td>
<td>4 (9)</td>
</tr>
<tr>
<td>Anti-RNA polymerase 3 positive, n (%)</td>
<td>2 (11)</td>
</tr>
<tr>
<td>Anti-centromere positive, n (%)</td>
<td>3 (17)</td>
</tr>
</tbody>
</table>

SSc, systemic sclerosis; IQR, interquartile range; mRSS, modified Rodnan skin score.

Figure 1. (A) The modified Rodnan skin score (mRSS) was higher in skin biopsies with severe fibrosis. (B) While merging superficial and deep dermis semi-quantitative scores, increased senescence marker was associated with increased CTGF expression on fibroblasts. (C) Endothelial to mesenchymal transition (EndMT) was more in systemic sclerosis skin with out difference between groups with various fibrosis severity. (D) EndMT was associated with increased senescence markers on fibroblasts.

Senescence markers showed higher expression on fibroblasts from highly fibrotic dermis than healthy control. The median (IQR) percentage of P16 positive fibroblasts in dermis was 0.7 (0.5) in healthy controls, 0.9 (0.7) in grade one fibrosis, 0.3 (0.5) in grade two fibrosis, and 0.6 (4.6) in grade three fibrosis (p = 0.144). The median (IQR) percentage of P21 positive fibroblasts in dermis was 3.3 (7.0) in healthy controls, 10.3 (11.8) in grade one fibrosis, 33.2 (19.2) in grade two fibrosis, and 32.9 (40.7) in grade three fibrosis (p = 0.042). Moreover, increase of senescence markers on fibroblasts was associated with increased CTGF expression (Figure 1B). The density of blood and lymphatic vessels did not correlate with fibrosis severity. Still, the frequency of EndMT was significantly higher in patients with SSc, although it did not differ between groups with various fibrosis severity (Figure 1C). EndMT was not observed in lymphatic vessels (i.e. there was no co-localisation of D2-40 and α-SMA). Finally, the frequency of EndMT was increased with stronger fibroblast senescence (Figure 1D).

Disclosure of Interests: Yu-Hsiang Chiu: None declared, Julia Spiersing Grant/research support from: J. Spiersing has received a grant from Boehringer, Jacob M. van Laar Consultant of: J. M. van Laar has received honoraria from Abbvie, Axox Tx, Galapagos, Gesynta, Leadiant, and Roche., Grant/research support from: J. M. van Laar has received grants from Boehringer, Astra Zeneca, MSD, and Roche., Jeska de Vries-Bouwstra: None declared, Marijke van Dijk: None declared, Roel Goldschmeding: None declared.

DOI: 10.1136/annrheumdis-2022-eular.76
macrophages displayed a reduced expression of CD206 (p<0.05) and PD-L2 (p<0.01) markers compared to Fosl2fl/fl controls (n=5-9). Preliminary data indicated that Fosl2tg MHCII+ and CD36+ peritoneal macrophages showed a trend towards increased phagocytic activity compared to wt cells (n=3). Csf1RCreFosl2fl/fl peritoneal macrophages did not show a significant difference in phagocytic activity (n=3) compared to Fosl2fl/fl controls.

Conclusion: For the first time, we showed an increased expression of Fosl-2 and boosted phagocytic activity in SSc mDMD. scRNAseq analyses revealed upregulated phagocytosis-related genes with association to alternatively-activated macrophage polarization in different macrophage clusters in SSc-ILD lungs and lcSSc skin. Moreover, our animal data indicated an involvement of Fosl-2 regulating alternatively-activated macrophage polarization and phagocytosis. Therefore, targeting this alternative/pro-phagocytic phenotype represents an effective tool to counteract disease progression.

REFERENCES:

Disclosure of Interests: Amelia Hukara: None declared, Tracy Tabib: None declared, Michal Rudnik: None declared, Oliver Distler: Consultant of: Pfizer, Bristol Myers Squibb, tis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Regeneron, Pfizer and Kinka, Gabriela Kania: None declared, Robert Lafyatis: Consultant of: Pfizer, Bristol Myers Squibb, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Regeneron, Pfizer and Kinka, Gabriela Kania: None declared.
effect of PF1801 on the expression of antioxidant molecules in the myotubes was analyzed with quantitative real-time PCR.

**Results:** GLP-1R was expressed on the innervated muscle fibers of PM and CIM. The treatment with PF1801 in monotherapy or in combination with PSL suppressed CIM-induced muscle weakness and the muscle weight loss as well as the severity of histological myositis while the monotherapy with PSL did not suppress muscle weakness and muscle weight loss. PF1801 decreased the levels of inflammatory mediators such as HMGB1, TNF-α, and IL-6 in the serum of CIM. In vitro, PF1801 inhibited FASLG-induced myotube necroptosis and decreased the levels of HMGB1, TNF-α, and IL-6 in the supernatant. PF1801 activated AMPK and decreased the levels of PGAM5, which was crucial for FASLG-induced necroptosis of the myotubes. The inhibitory effect of PF1801 on myotube necroptosis was cancelled by compound C, an AMPK-kinase inhibitor, or MG132, a proteasome inhibitor, suggesting that PF1801 promoted ubiquitin-proteasome-mediated PGAM5 degradation through the activation of AMPK. Furthermore, PF1801 suppressed FASLG-induced reactive oxygen species (ROS) accumulation in myotubes, which was also crucial for the execution of necroptosis, through up-regulating the antioxidant molecules such as Nrf2/2, Hmox1, Gclm, and Nqo1.

**Conclusion:** GLP-1R agonist could be a novel therapy for PM that restores muscle strength as well as suppresses muscle inflammation through inhibiting muscle fiber necroptosis.

**REFERENCES:**


**Acknowledgements:** We thank Katsuko Yamasaki for the histological analysis.


**PO5047**

**INFLAMMATORY-PRIMED MUSCLE CELLS INFLUENCE MACROPHAGE CYTOKINE SECRETION IN A MYOSITIS CONTEXT**

B. Mccord1, R. Day1.1 Centre for Precision Healthcare, Division of Medicine, University College London (UCL), London, United Kingdom

**Background:** Sporadic inclusion body myositis (sIBM) is a progressive disease causing muscle weakness and mobility issues; however it is characterised by inflammatory and degenerative features; however there is no clear single cause for sIBM symptoms. Inflammatory factors include macrophage infiltration into muscle fibres and presence of high levels of inflammatory cytokines such as IFN-γ [1]. Degenerative features within muscle fibres include sarcoplastic inclusions containing aggregated PGAM5 and TDP-43 containing protein 43 (TDP-43) are two proteins that are found in inclusion bodies, and these have been suggested as sensitive diagnostic markers differentiating sIBM from other inflammatory myopathies [2]. Currently there is limited understanding of the pathogenic mechanisms underlying sIBM, and no effective treatments.

**Objectives:** The aim of this study is to investigate the interplay between inflammatory and degenerative features of sIBM with a focus on macrophage secreted factors, p62 and TDP-43 sarcomplastic aggregation. Firstly, to examine whether skeletal muscle cells that have previously been exposed to an inflammatory environment can in turn influence the inflammatory response of macrophages. Secondly, by investigating if macrophage-secreted inflammatory factors influence p62 and TDP-43 sarcomplastic aggregates. This will give insight into whether macrophage inflammation precludes skeletal muscle degeneration in an sIBM context in vitro versus vivo.

**Methods:** Primary human myogenic cells from healthy individuals were differentiated into myotubes for 7 days, with further 48-hour 20-ng/mL IL-1β and 750-ng/mL IFN-γ incubation to form inflammatory-primed myotubes. Conditioned media (CM) was collected from washed myotubes after 24 hours. 6x10^6 THP-1 cells/mL were differentiated to unprimed M(PMA) macrophages with 150-nM phorbol 12-myristate 13-acetate (PMA) for 24 hours, followed by 72-hour PMA-free rest. Inflammatory-primed M(IFN-γ) THP-1 were generated from M(PMA) with 48-hour IFN-γ and lipopolysaccharide (LPS) incubation. 20 % CM from myotubes was added to M(PMA) or M(IFN-γ-LPS) THP-1 for 24 hours, after washing and measuring IL-6 and TNFα release from macrophages via ELISA. 20 % CM from M(PMA) or M(IFN-γ-LPS) was added to myotubes for 48 hours before quantifying TDP-43 and p62 aggregates with image analysis.

**Results:** In M(IFN-γ-LPS) THP-1 secreted higher levels of IL-6 and TNFα than M(PMA), M(PMA) or M(IFN-γ-LPS) exposed to conditioned media from control or inflammatory-primed myotubes had no detectable TNFα secretion. For both M(PMA) and M(IFN-γ-LPS), addition of inflammatory-primed myotubes CM caused higher IL-6 secretion than adding control myotube CM. Incubating unprimed myotubes with M(PMA) or M(IFN-γ-LPS) CM had no effect on the presence, size, or frequency of p62 or TDP-43 sarcomplastic aggregates compared to control conditions.

**Conclusion:** Inflammatory priming myotubes with IL-1β and IFN-γ caused a response in macrophages that increased IL-6 production. However, CM from inflammatory-primed myotubes did not influence TNFα secretion from macrophages compared to control myotube CM. IL-6 has pleiotropic effects on skeletal muscle [3], promoting both hypertrophy and atrophy under different conditions. Therefore the effects of macrophage IL-6 upregulation on muscle is unclear. Culturing myotubes in unprimed or inflammatory-primed macrophage conditioned media did not influence p62 or TDP-43 sarcomplastic aggregation. This suggests macrophage secretory factors are not responsible for the sIBM degenerative features of p62 and TDP-43 aggregation.

**REFERENCES:**


**Disclosure of Interests:** None declared.

Conclusion: We provide experimental and clinical evidence that agonistic Abs may contribute to SRC. Novel therapies targeted at autoimmune hyperactivation of AT1R and ETAR might improve outcomes in severe cases of SRC.

REFERENCES:

Figure 1: Graph 1. Serum sST2 (a) and IL-33 (b) concentrations in patients with EKG abnormalities (EKG+) vs control group (EKG-)

Disclosure of Interests: None declared.

POS0475
ROLE OF IL-33/ST2 AXIS IN SYSTEMIC SCLEROSIS PATIENTS WITH ELECTROCARDIOGRAPHIC ABNORMALITIES
G. Pelegrino1, T. Colasanti1, M. Cadar1, L. Shen1, Y. Zhang1, Z. Honglin2, J. H. W. Distler1

Background: Electrocardiographic (EKG) abnormalities are described in 25-75% of Systemic Sclerosis (SSc) patients and they are associated with other systemic manifestations1 as well as with a worse prognosis.2 There is an increasing need for clinical and laboratory biomarkers to ameliorate the diagnostic approaches to patients with EKG abnormalities.3 In the last decade, many studies focused on the components of the interleukin (IL)-33/ST2 axis. Under physiological conditions, IL-33 is released by apoptotic cardiac cells, promoting a protective mechanism of cell survival, thanks to the binding with its transmembrane receptor ST2.4 During pathological cardiovascular events, an abnormal secretion of the IL-33 soluble receptor (sST2) by TH2 cells occurs. It binds IL-33 not allowing the physiological mechanism driven by the IL-33/ST2 binding previously described.4 For these reasons, sST2 has been proposed as a biomarker of cardiac injury in a variety of diseases.5 Objectives: Aim of this study was to analyse clinical and demographic parameters in a group of SSc patients, trying to define any possible feature associated with EKG abnormalities. Furthermore, the role of IL-33/ST2 axis components as biomarkers of cardiac injury in patients with SSc-related EKG abnormalities was evaluated, also assessing the possible correlation with serum concentration of NT-pro-BNP, a well-known cardiac injury biomarker in SSc.

Methods: Data from 277 SSc patients, fulfilling the 2013 ACR/EULAR classification criteria,6 attending our Scleroderma Clinic were retrospectively analysed. We selected patients with EKG trace and a blood sample available, collected after the SSc diagnosis. The sera levels of sST2 (ELISA Kit, Abcam), IL-33 (ELISA kit, RayBiotech) and NT-pro-BNP (ELISA Kit, Abcam) were measured. Patients with a history of heart diseases occurring before the diagnosis of SSc or features of secondary cardiac involvement (pulmonary arterial hypertension, severe interstitial lung disease or renal disease) were excluded.

Results: Forty-six SSc patients showed significant EKG abnormalities (rhythm and conduction disorders). Thirty-one SSc patients without pathologic finding at EKG traces were recruited as the control group. From the analysis of the clinical characteristic of the disease at the moment of serum collection, patients with EKG anomalies have more frequently both a diffuse form of disease (n=23; p=0.0007), and a mean value of mRSS higher than controls (11±9 vs 6±6; p=0.01), and a scleroderma “late” pattern at the nailfold capillaroscopy (n=12; p=0.0027). Significantly higher median values of serum levels of sST2 in SSc patients with EKG disorders compared to the control group (149 pg/mL, IQR 2383 vs 2560 pg/mL, IQR 1455; p=0.0002) were detected, while opposite results were found analyzing serum levels of IL-33 (2.89 pg/mL, IQR 101 vs 9 pg/mL, IQR 277; p=0.032) (Graph 1). Serum NT-pro-BNP median values were significantly higher in the group of patients with EKG abnormalities than in the control group (149 pg/mL, IQR 354 vs 26 pg/mL, IQR 62; p=0.0007). These values correlated with sST2 serum levels (rho Spearman correlation 0.37; p=0.0006).

Conclusion: SSc patients with EKG abnormalities showed an increased skin and vascular involvement with respect to the control group. These associations could help clinicians in clinically stratifying SSc patients at risk of EKG abnormalities. To our knowledge, this is the first report evaluating the serum concentration of sST2 in SSc patients. Based on these results, we can speculate on the role of this molecule as potential biomarkers of early cardiac injury during SSc, although further studies involving a larger cohort of patients are needed.

REFERENCES:
Background: Nuclear receptors (NR) are a family of transcription factors. Several members of the NR family are candidates for targeted intervention in inflammatory and fibrotic diseases (1-2). Testicular receptor 4 (TR4), also known as NR2C2, has been shown to regulate fundamental cellular processes such as differentiation, proliferation and growth factor signaling (3-4). However, its role in fibrotic diseases has not been investigated so far.

Objectives: The aim of the present study was to characterize the role of TR4 in the pathogenesis of fibrotic tissue remodeling in SSc and to interrogate its underlying mechanisms.

Methods: Expression of TR4 was quantified by RT-PCR, Western blot and immunofluorescence. The effects of TR4 knockdown on collagen production and myofibroblast differentiation were analyzed in cultured human fibroblasts and in three mouse models with fibroblast-specific knockout of TR4. RNA sequencing was performed in TGFβ-stimulated human dermal fibroblasts transfected with TR4 siRNA or non-targeting siRNA. The implication of TR4 in cytoskeleton regulation was analyzed by ROCK activity assays, stress fiber formation and quantification of the ratio of filamentous (F)-actin/globular (G)-actin. The functional role of ROCK and Gα12 was analyzed using small molecule inhibitors and siRNA, respectively.

Results: TR4 expression was upregulated in fibroblasts in the skin of SSc patients and fibrotic mouse models. The expression of TR4 was upregulated in a TGFβ/α-smooth muscle actin (α-SMA)-positive phenotype. TR4 knockdown inhibited Gα12-induced myofibroblast differentiation and collagen release, whereas overexpression of TR4 promoted fibroblast activation. Fibroblastspecific knockout of TR4 ameliorated experimental dermal fibrosis induced by bleomycin, adTBR and in scGvHD with decreases in dermal thickening, myofibroblast counts and hydroxyproline content. The RNASeq of TR4 knockdown fibroblasts stimulated with TGFβ identified 651 differentially expressed genes as compared to control fibroblasts. Differentially expressed genes included central profibrotic genes such as ACTA2, COL3A1, CCL12. gProfiler enrichment analysis of the TR4-DEGs revealed enrichment of multiple GO, GSEA and Reactome terms related to ECM release, cytoskeleton organization and Rho GTPases activity. Indeed, knockdown of TR4 ameliorated the induction of ROCK activity by TGFβ stimulation and reduced the shift in the ratio from globular (G) actin to filamentous (F). Knockdown of TR4 strongly reduced the expression of the G-protein alpha-12 (Gα12), ROCK inhibition by Y27632 or knockdown of Gα12 inhibited the induction of α-SMA and stress fiber formation induced by overexpression of TR4.

Conclusion: TR4 is upregulated in SSc in a TGFβ-dependent manner to promote fibroblast activation. Inhibition of TR4 interferes with TGFβ-induced activation of ROCK, prevents cytoskeletal remodeling and fibroblast-to-myofibroblast transition and ameliorates experimental fibrosis. As nuclear receptors are common targets for therapeutic intervention, TR4 may offer potential for antifibrotic therapies.

REFERENCES:

Disclosure of Interests: Lichong Shen: None declared, Yun Zhang: None declared, Jörg H.W. Distler: Shareholder of: stock owner of 4D Science, Consultant of: consultancy relationships with Actelion, Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Medac, Novartis, Pfizer, RuiYi and UCB, Grant/research support from: has received research funding from Anamar, Actelion, Biotech Array, Biopharma, ARXX, aTyr, Biotech, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Galapagos, GSK, Inventiva, Kinkisa, Sanofi-Aventis, Redx, UCB.

compound reported for this application has been sodium thiosulfate (STS), with often-contradictory results.

**Objectives:** To test the hypothesis, in pre-clinical studies, that polycarboxylic acids can induce calcium dissolution without skin toxicity, with the long-term aim of developing an effective topical treatment for cutis calcinosis.

**Methods:** We compared the metal ion-chelating agents citric acid (CA) and ethylenediaminetetraacetic acid (EDTA) - polycarboxylic acids with well-characterised chelation profiles – to STS for their ability to chelate calcium, without inducing cytotoxicity or inflammation (pro-inflammatory cytokine expression and release), using in vitro 2D (keratinocyte [HaCaT]; fibroblast [HCC23]) and recombinant human epidermal (RHE) models. The resultant data was subsequently used to predict therapeutic concentrations for assessment in a validated skin irritation model (SkinEthicTM; Episkin SA) and to assay maximal percutaneous absorption. At relative dermal concentrations, the dissolution performance of each chelator was further assessed using two different models of calcification: 1) pharmacological dissolution of a hydroxyapatite (HAp) tablet (1 and 2), and 2) dissolution of a calcified extracellular matrix laid down by mineralising SaOS2 in vitro monolayer culture (2).

**Results:** Incubation with CA, EDTA and STS induced cytotoxicity in both in vitro and in vivo cell lines studied at concentrations of >10 mM; only EDTA (10 mM) resulted in inflammatory cytokine release (IL8) from cells at these higher concentrations (of positive control, Lipo polysaccharide 10 mg/ml). When applied topically to RHE models as near-saturated solutions, none of the chelators were categorised as skin irritants. Due to differences in their relative aqueous solubility, higher concentrations of CA (1600 mM) and STS (1200 mM) could be delivered through the RHE model than EDTA (200 µM). Using a simple linear regression model, the rate of compound absorption was: CA, 0.43 ± 0.05; STS, 0.26 ± 0.03 and; EDTA, 0.05 ± 0.01 g/L/hr. At each time-point, the cumulative concentration of compound in the receptor media was CA > STS > EDTA. Incubation with chelators had no effect on the integrity of the RHE by standard histology. Based on the rate of percutaneous absorption, the dissolution performance of each chelator was tested at relative dermal concentrations for phosphate dissolution (mmoles) of HAp (CA, 9.61 ± 0.97; EDTA, 5.38 ± 0.28; 3.78 ± 0.58) and in the calcified in vitro model (Figure 1; CA, 3285 ± 105; STS, 947 ± 55; EDTA, 1714 ± 49), showing the superiority of CA in both model systems.

**Discussion:** Overall, this study highlights the promise of polycarboxylic acids, particularly CA, to target subcutaneous calcification, which are neither toxic nor inflammatory to the skin. Specifically, we have identified CA as a potentially more efficacious alternative to STS for the topical treatment of cutis calcinosis.

**References:**


**Disclosure of Interests:** Kyle Burgess: None declared, Richard Wimpenny: None declared, Alberto Salian: None declared, Ariane Herrick Speakers bureau: Janssen, Consultant of: Arena, Boehringer-Ingehelm, Camurus, CSL Behing, Gevanta, Grant/research support from: Genynta, Rachel Wat son Consultant of: NAOB, AbbVie, Grant/research support from: Walgreens Alliance Boots.


**POS0479**

**STAT3 DEGRADERS PROTECT FROM IMMUNOFIBROTIC CHANGES IN PRECLINICAL MODELS**

P. Blaszczuk1,2, G. Kania1, E. Pachera1, F. Rolski4, A. Hukara1, V. Tela4, M. Mayo1, V. Dixit1, B. Yang2, J. Gollob3, N. Mainolfi4, A. Slavin1, G. Hubeau3, O. Chambaz1, University of Rhode Island, Providence, United States of America; 2. University Medical Center, University Hospital, Switzerland; 3. Jagiellonian University Medical College, Department of Clinical Immunology, Cracow, Poland; 4. KYMERA THERAPEUTICS, INC., KYMERA THERAPEUTICS, INC., Watertown, United States of America.

**Background:** The ubiquitous-proteasome system (UPS) is the endogenous intracellular mechanism for maintaining protein homeostasis through protein degradation and turnover. Heterobifunctional small molecules are a new class of compounds that form a ternary complex with an E3 ligase and protein of interest leading to ubiquitination and subsequent degradation of the protein of interest in a process known as Targeted Protein Degradation. This new therapeutic modality enables targeting of "undruggable" proteins such as STAT3, a transcription factor activated in immunobiotic diseases.

**Objectives:** Kymera has developed heterobifunctional molecules that potently and selectively target STAT3 for degradation and elimination by the ubiquitin-proteasome pathway. The aim of these studies was to evaluate the therapeutic potential of pharmacologically removing STAT3 by targeted protein degradation in human cell types in vitro, and to prevent the development of skin and lung fibrosis in vivo.

**Methods:** Dermal fibroblasts obtained from healthy and systemic sclerosis patients activated with TGF-β were studied to analyse STAT3 degradation. Human dermal and endothelial cells (HAEcs) were activated with LPS, and their adhesive properties were measured in the microcapillary system by the ability to bind peripheral blood mononuclear cells (PBMCs) under shear stress. HAEcs proliferation was induced with VEGF. THP-1 cells and CD14+ monocytes were activated with IL-6 and LPS, and secreted cytokines were assessed by CBA. PBMCs were activated with LPS, IL-6, IL-21, or IL-23 alone (pSTAT3 induction), or with a combination of anti-CD3/CD8 beads and a pro-T17 cocktail comprised of cytokines and antibodies to evaluate the development of T17 and Treg phenotype by flow cytometry. Cytokines were analysed by ELISA. All cell types were pre-treated with STAT3 degraders 20h prior to experiment start. Intratracheal instillation of bleomycin was used to induce pulmonary fibrosis. Transgenic Tsk-1 mice were used as a model of spontaneous skin fibrosis.

**Results:** STAT3 degraders completely ablated STAT3 in all analyzed cell types with DC50 ranging from 0.25-0.6 nM. STAT3 degradation prevented TGF-β-induced formation of α-SMA-positive stress fibres and for contractility using collagen gel contraction assay. Assay contracture was also performed using human dermal smooth muscle cells. HAEcs adherent cell lines studied at concentrations of >10 mM; only EDTA (10 mM)

**Conclusion:** STAT3 degraders completely ablated STAT3 in various human cell types in vitro, and to prevent the development of skin and lung fibrosis in vivo.
POS0480

VITAMIN D AND ITS RECEPTOR (VDR) GENE EXPRESSION IN SKELETAL MUSCLE ASSOCIATE WITH DISEASE AND MUSCLE FUNCTION PARAMETERS IN IDIOPATHIC INFLAMMATORY MYOPATHIES

L. Veversová1, M. Vokurkova2, S. Oreska1,2, M. Štrpitovíček1,2, M. Klein1,2, T. Kropackova3, V. Horvatova1, M. Tomcik5, J. Ukopec4, B. Ukropcová1,4,5, J. Vencovsky1,4,5,1, Institute of Rheumatology, Department of Experimental Rheumatology, Prague, Czech Republic; 1First Faculty of Medicine, Charles University, Department of Rheumatology, Praha, Czech Republic; 2Faculty of Physical Education and Sport, Charles University, Department of Physiotherapy, Praha, Czech Republic; 4Biomedical Research Center, Slovak Academy of Sciences, Institute of Experimental Endocrinology, Bratislava, Slovakia (Slovak Republic); 5Faculty of Medicine, Comenius University, Institute of Pathophysiology, Bratislava, Slovakia (Slovak Republic)

Background: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders characterised, apart from extramuscular manifestations, by symmetrically progressive muscle weakness that may persist even after pharmacological suppression of inflammation, suggesting a significant involvement of nonimmune mechanisms. Low levels of vitamin D have been associated with autoimmune diseases. Vitamin D is essential for the maintenance of skeletal muscle, and mounting evidence supports its relation to muscle damage, regeneration, and energy metabolism.

Objectives: The aim was to analyse vitamin D and the mediators of its function in muscle tissue of IIM patients, and to associate it with muscle health parameters.

Methods: A total of 48 IIM patients (40 females, 6 males; mean age 56.7±12.4; disease duration 6.5±6.0 years; dermatomyositis (21), polymyositis (18), necrotizing myopathy (7) and 67 healthy controls (HC) (56 females, 11 males; mean age 50.9±14.7) were recruited. In total, 27 IIM patients participated in a 24-week intervention combining activities-of-daily-life, resistance and stability training [1]. Muscle biopsies from m. vastus lateralis (by Bergström needle) were obtained from 7 IIM patients before and after the 24-week training program, and from 13 control IIM patients, and 21 HC. Primary muscle cell cultures were established from these samples. Disease-associated parameters were evaluated by MYOACT/MITAX, MVI, HAS, HAQ, MMT8, FI-2 and CK, myoglobin, LD, ALT, AST, and CRP levels. Myostatin, as a myokine involved in muscle atrophy, was determined from serum samples by ELISA. Circulating concentrations of 25(OH) vitamin D (calcidiol) and active 1,25(OH) vitamin D (calcitriol) were measured by routine biochemical techniques. Gene expression of vitamin D receptor (VDR) and 25-hydroxyvitamin D 1-alpha-hydroxylase (CYP27B1), an enzyme catalysing calcidiol conversion to hormonally active calcitriol, was determined by real-time PCR in muscle tissue and primary muscle cell cultures. Data are presented as mean ± standard deviation.

Results: Decreased serum levels of active 1,25(OH)D were observed in IIM patients compared to HC (125.0±54.4 vs. 164.7±42 pmol/l; p<0.0001). No difference was found for 25(OH)D. The 24-week training program did not have an effect on 25(OH) D or 1,25(OH)D serum levels. 25(OH)D was significantly associated with CRP (r=-0.32, p=0.040), MITAX (r=-0.380, p=0.021) and HAQ (r=0.370, p=0.017) in IIM patients, even after correction for BMI, gliocorticoid (GC) and vitamin D daily supplementation dose. After 24 weeks of exercise, active 1,25(OH)D was positively associated with MMT8 (r=0.866, p=0.0001), FI2 (r=0.608, p=0.013) and HAQ (r=-0.537, p=0.032) (corrected for BMI, GC and vit.D supplementation). Numerically higher gene expression of VDR and CYP27B1 was found in muscle tissue and primary muscle cells in IIM compared to HC. After the 24-week training, gene expression of both VDR and CYP27B1 in primary muscle cells decreased (p=0.031 and p=0.078, respectively). Associations of gene expression with myostatin (IIM: r=0.519, p=0.023; HC: r=0.586, p=0.005), and CK (HC: r=0.484, p=0.031) were observed in muscle tissue. CYP27B1 gene expression in the muscle was also associated with myoglobin (HC: r=0.501, p=0.024), MMT8 (IIM: r=0.535, p=0.011) and VDR (IIM: r=0.581, p=0.012; HC: r=0.632, p=0.002).

Conclusion: Decrease of the biologically active form of vitamin D in circulation suggests a negative impact of its metabolism in IIM. Vitamin D serum levels associated with disease activity and muscle function parameters indicating an important role of vitamin D in physical fitness and disease manifestations in IIM patients.

REFERENCES:

Acknowledgements: This work was supported by the Ministry of Health of the Czech Republic grant nr. NU21-05-00322.

Disclosure of Interests: None declared.

Disclosure of Interests: Kristina Clark: None declared, Alice Cole: None declared, Xu Shiwenn: None declared, Voon Ong: None declared, Christopher D Buckley Employee of: founder of Mestag Therapeutics https://mestagtherapeutics.com/; Christopher P Denton: None declared.


POS0482

LONG NON-CODING RNA H19X IS A MEDIATOR OF ENDOTHELIAL CELL ACTIVATION IN SYSTEMIC SCLEROSIS

F. Tirelli1,2, E. Pachera1, R. Layfatis3, M. Huang4, S. Assassi4, E. Camarillo1, F. Zulian1, G. Kania1, O. Distler1
1University of Zurich, University Hospital Zurich, Department of Rheumatology, Center of Experimental Rheumatology, Zurich, Switzerland; 2University of Padova, Department of Woman’s and Child’s Health, Rheumatology and Biotechnology, Padova, Italy; 3Department of Medicine, Division of Rheumatology and Clinical Immunology, Pittsburgh, United States of America; 4University of Texas Health Science Center at Houston, McGovern Medical School, Department of Internal Medicine, Division of Rheumatology, Houston, United States of America.

Background: In one of our previous studies, we demonstrated that long non-coding RNA (IncRNA) H19X plays a crucial role in the development of TGFβ driven fibrosis in systemic sclerosis (SSc) and other fibrotic diseases.

Objectives: To define the functional relevance of H19X in endothelial cell (EC) activation as a decisive process in SSc vasculopathy.

Methods: Correlation H19X expression and microvascular gene signature was computed on bulk RNA-Seq data derived from SSc skin biopsies of patients enrolled in the multicentre Prospective Registry of Early Systemic Sclerosis cohort (PRESS, n=48 SSc vs. n=33 healthy controls, HCs). Single cell RNA sequencing (scRNA-seq) data were collected from 27 diffuse cutaneous SSc (dcSSc) and 10 HC skin biopsies. Single cells were barcoded and encapsulated in droplets using a 10X Genomics system. After CDNA synthesis, the libraries were prepared and sequenced using Illumina NovaSeq-500 platform. Seurat package in R (v.3.0) was used to perform data analysis. EC were identified by enrichment of EC markers CLDN5, VWF and PECAM1. One thousand five hundred eighty-three and 3398 EC were identified from HC and SSc patients, respectively. Cells were analysed for the expression of H19X and EC activation markers. Additionally, differential expression and pathway enrichment analysis between H19X expressing cells and H19X negative cells was carried out. The function of H19X was investigated in human dermal microvascular EC (HDMEC) by silencing, using locked nucleic acid antisense oligonucleotides (LNA GapMeRs). Gene expression was measured by qPCR. Protein levels of endothelial adhesion molecules were analysed by Western Blot. Endothelial adhesion was evaluated by co-culture of HDMEC and fluorescently labelled peripheral blood mononuclear cells (PBMCs).

Results: H19X expression was found significantly upregulated in SSc skin biopsies of the PRESS cohort (p<0.0001). The expression of H19X positively correlated with the microvascular endothelial cell gene signature in all subjects (SSc and HC, R=0.43, p<0.0001), confirming that H19X is expressed in this cell type. To determine if H19X might be an important factor in SSc EC dysfunction, scRNAseq was performed. This analysis revealed a significant upregulation of H19X in SSc EC as compared to HC EC (p=0.0095). H19X was found to be upregulated in several EC subclusters including arterial (SEMA3G, HEY1), capillary (CA4, RGCC), venous (ACKR1, Vcam1) and lymphatic (PROX1, LYVE1). H19X displayed highest expression in injured SSc EC and capillary SSc EC. Co-expression analysis of the scRNA-seq data revealed higher expression of several adhesion molecules in EC expressing H19X including, VCAM1, ICAM and JAM3. KEGG pathway analysis revealed that differentially expressed genes in H19X expressing cells were highly associated with the ‘Cell adhesion molecule’ pathway (p=2.20e-7). H19X silencing lead to a significant downregulation of mRNA levels of genes encoding adhesion molecules VCAM1 (n=7, p<0.05) and E-selectin (n=7, p<0.01) at 48h after transfection, VCAM1, but not E-Selectin, was also reduced at protein level as revealed by Western Blot (n=3). The functional relevance of H19X on endothelial adhesion was confirmed by PBMCs with H19X silenced HDMEC where we were able to demonstrate a significant decrease in leucocyte-to-endothelial cell adhesion (n=5, p<0.05).

Conclusion: Our results show that IncRNA H19X could contribute to EC activation in SSc vasculopathy, acting as a regulator of expression of adhesion molecules.

REFERENCES:

Disclosure of Interests: Francesca Tirelli: None declared, Elena Pachera: None declared, Robert Layfatis Consultant of: Pfizer, Bristol Myers Squibb, Boehringer Ingelheim, Formation. Sanofi, Boehringer-Ingelheim, Merck and Genentech/Roche, Grant/research support from: Corbus, Formation, Moderna, Regeneron, Pfizer and Kiniksa, Meng Hu: None declared, Shervin Assassi: None declared, Eva Camarillo: None declared, Francesco Zulian: None declared, Gabriela Kania: None declared, Oliver Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscop, Consultant of: Abbvie, Acceleron, Alcimed, Amgen, AnMar, AnxA, AstraZeneica, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Invetivka, Kymera, Lupin, Mitrenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur, Grant/research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim.


POS0483

THE EFFECT OF VITAMIN D3 AND α-TOCOPHEROL ACETATE IN THE PRECLINICAL MODEL OF SYSTEMIC SCLEROSIS

B. Doskailuk1, L. Zaiats2, R. Yatsyshyn3, Ivano-Frankivsk National Medical University, Pathophysiology; Ivano-Frankivsk, Ukraine; 1Ivano-Frankivsk National Medical University, Internal medicine #1 clinical immunology and allergology, Ivano-Frankivsk, Ukraine.

Background: The pathogenesis of systemic sclerosis (SSc) is characterized by complex damage of an organism due to the development of mechanisms of autoimmunity. Dysregulation of immune system, development of fibrosis, and vasculopathy play a significant role in this process.

Objectives: This study aimed to investigate the effect of antioxidant α-tocopherol acetate and immunomodulator vitamin D 3 in the preclinical model of SSc.

Methods: To perform this study, three groups of laboratory animals were formed: a control group (20 animals), an experimental group #1 (25 animals) and an experimental group #2 (25 animals). Experimental animals were mature laboratory rats of the Wistar line weighing 180-220 g. Modeling of SSc was performed in the experimental group #1 using sodium hyPOCHORONE (NaClO) according reported previously method [1]. Laboratory animals of the control group were injected with the isotonic solution according to the same scheme. In the experimental group #2, in addition to NaClO, laboratory rats received a solution of α-tocopherol acetate 10 mg / 100 g of body weight IV and a solution of vitamin D3 1000 UI / 100 g of body weight, IV for 3 weeks (second half of the experiment). The level of surfactant protein D (Elabscience SP-D ELISA-Kit), the vascular cell adhesion molecule (Elabscience VCAM-1 ELISA-Kit), and interleukin 13 (Elabscience IL-13 ELISA-Kit) was determined by enzyme-linked immunosorbent assay. ELISA was performed on an enzyme-linked immunosorbent assay STAT FAX 303 plus. Data distribution was evaluated with the Shapiro-Wilk test. Mann-Whitney U test and unpaired t test were used for comparisons between groups, a p-value <0.05 was considered statistically significant.

Results: The level of IL-13 (pg/ml) in the experimental group was higher than in the control (36.4, 56.23 vs 9.43, 4.01 (p<0.001). The serum concentration of SP-D (pg/ml) among the experimental group of laboratory animals was significantly higher compared to the control subjects 490,20 [228,75–568,73] vs 70,13±33,21, (p=0.05), VCAM-1 (pg/ml) was also higher in the experimental group VCAM-1 91.25 [85,63–143,75] vs 173,5±7,47, (p<0.05). The administration of vitamin D3 and α-tocopherol acetate has shown a positive effect for all three investigated parameters. We have found a statistical difference between the two experimental groups regarding IL-13, SP-D, and VCAM-1. The SP-D level in the experimental group #2 was 124.93 ± 18.96, which was significantly lower than in the experimental group #1 (p=0.04). The concentration of IL-13 and VCAM were also lower in the group of vitamins D3 and α-tocopherol acetate administration (22.88±5.11, p<0.001 and 38.73±12.13, p=0.02 respectively).

Conclusion: This study provided evidence that administration of vitamins D3 and α-tocopherol acetate, given in combination, has a beneficial effect on IL-13, SP-D, and VCAM-1 levels in the organism of the experimental animals.

REFERENCES:

Disclosure of Interests: None declared.


POS0484

LUNG ORGANOIDS: A NOVEL APPROACH TO STUDY THE MOLECULAR PATHOLOGY OF PULMONARY FIBROSIS IN SYSTEMIC SCLEROSIS

M. Aspar1, S. R. Greisen1,2, K. Soendergaard2, M. N. Dahl1,2, M. Hvid2, V. Ong3, D. Abraham3, B. Deleuran1 on behalf of Bent Deleuran's group.
1Aarhus University, Biomedicine, Aarhus, Denmark; 2Aarhus University Hospital, Rheumatology, Aarhus, Denmark; 3University College London, Division of Medicine, London, United Kingdom

Background: Pulmonary fibrosis is one of the major manifestations in Systemic Sclerosis (SSc) associated with high mortality. Mesenchymal transformation of the airway epithelial cells has been implicated as one of the causes for
developing pulmonary fibrosis. Though several animal models shed light towards some of these aspects, an in vitro airway epithelial model would provide a novel experimental platform for the understanding and molecular and genetic changes that occur in SSc associated pulmonary fibrosis.

Objectives: To establish a functional model for airway epithelium from patient with diffuse cutaneous SSc (dSSc) and healthy volunteers derived nasal stem cells. Subsequently to induce Epithelial Mesenchymal transformation (EMT). 

Methods: Nasal stem cells harvested from healthy volunteers (HV) and dSSc patients were differentiated into ciliated airway epithelium in an Air-Liquid Interface (ALI) using a transwell system. 4 HV cultures were then stimulated with TGF beta for 10 days at a basal stage and when differentiated. Markers of mesenchymal transformation including loss of E cadherin, and gain of N cadherin, fibronectin and vimentin were analysed by flow cytometry and image stream, and mean expression intensities given as (MFI). Secreted Type 1 collagen and fibronectin were measured by ELISA.

Results: Ciliated epithelial cultures could successfully be established from nasal stem cells (Figure 1). TGF beta induced a phenotypic change in the epithelial cells towards a mesenchymal one in HV cultures. This was observed by significantly increased expression of fibronectin and vimentin and loss of expression of E cadherin on the ciliated cells with 7 days of stimulation with TGF beta at a basal stage (Figure 1b). When cells, stimulated with TGF beta for 7 days, were analysed at Day 35 a similar trend was seen in their Delta MFI (Figure 1c). Stimulating the ALI cultures with TGF beta for 20 days completely repressed epithelial cell growth and disrupted their microstructure.

Conclusion: This novel ALI differentiated Airway epithelial model serves as a functional organoid to test various pulmonary manifestations of Systemic Sclerosis. The ability to induce Epithelial Mesenchymal Transformation of these cultures provides a proof of concept for TGF beta mediated fibrosis in dSSc. Moreover, this model can be utilized to explore, at the cell and molecular level, the impact of various autoantibodies and therapeutics on epithelial cells.

REFERENCES:

Disclosure of Interests: None declared.


Table 1. Demographic and clinical data of studied population

<table>
<thead>
<tr>
<th>Variable</th>
<th>SSc (n=70)</th>
<th>Healthy controls (n=35)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male</td>
<td>63 (90) / 7 (10)</td>
<td>31 (88.6) / 4 (11.4)</td>
<td>0.68</td>
</tr>
<tr>
<td>Age, yr.</td>
<td>48.9 ± 13.4</td>
<td>47.6 ± 14.0</td>
<td>0.63</td>
</tr>
<tr>
<td>Limited SSc/Diffuse SSc</td>
<td>44 (62.9) / 26 (37.1)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Disease duration, yr.</td>
<td>6.4 ± 4.0</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Modified Rodnan skin score</td>
<td>6.5 ± 9.6</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Active digital ulcers</td>
<td>15 (21.4)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>PVC (n=63)</td>
<td>80.9 ± 17.4</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>ILD</td>
<td>38 (54.3)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>PAH</td>
<td>4 (5.7)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Esophageal dyskinesia</td>
<td>42 (60)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Cardiac involvement</td>
<td>8 (11.4)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Autoantibodies</td>
<td></td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Anticentromere</td>
<td>13 (18.6)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Anti-topoisomerase-I</td>
<td>13 (18.6)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Nailfold capillarscopy, (n=61)</td>
<td></td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>SD Early</td>
<td>23 (37.7)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>SD Active</td>
<td>15 (24.5)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>SD Late</td>
<td>23 (37.7)</td>
<td>49 (70)</td>
<td></td>
</tr>
<tr>
<td>Calcium channel blockers in use</td>
<td>9 (12.9)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Phosphodiesterase-5 inhibitors in use</td>
<td>0 (0)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressors in use</td>
<td></td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>8 (11.4)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>3 (4.3)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>15 (21.4)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>3 (4.3)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>1 (1.4)</td>
<td>--</td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12 (17.1)</td>
<td>--</td>
<td></td>
</tr>
</tbody>
</table>

Data are mean ± SD or n (%) unless otherwise stated. FVC: forced vital capacity; ILD: interstitial lung disease; PAH: pulmonary arterial hypertension.

Figure 1. MP plasma levels in SSc patients vs healthy controls.
FIBROBLASTS UNDER IMMUNOFIBROTIC CONDITIONS

I. Kocherova1, E. Pachera, D. Nurznyska2, F. Di Meglio2, O. Distler2, P. Blyszczuk1, G. Kania3
1 University of Zurich, University Hospital Zurich, Department of Rheumatology, Center of Experimental Rheumatology, Zurich, Switzerland; 2 University of Naples “Federico II”, Department of Public Health, Naples, Italy

Background: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of mortality in patients with systemic diseases. Fibroblast activation, driven by the activator protein 1 family member Fos-related antigen 2 (FOSL2), represents a critical step in cardiac fibrogenesis. The existing antibiotic therapies, based on known fibrotic markers, failed to demonstrate efficacy against myocardial fibrosis.

Objectives: To identify new candidate targets implicated in cardiac fibrogenesis under immunofibrotic conditions.

Methods: Cardiac fibroblasts were isolated from the left atria of patients (n=5) undergoing heart transplantation due to HF associated with iDCM and from unaffected hearts of brain-dead donors (UDs, n=5). Protein identification and quantification was performed using liquid chromatography tandem-mass-spectrometry (LC–MS/MS). The data were analysed with MaxQuant v1.6.2.3 software. Bulk RNA sequencing (RNA-seq) was conducted using the Illumina HiSeq platform. Differentially expressed genes were identified using DESeq2. Additionally, we analysed publicly available single-cell (sc) RNA sequencing datasets (GSE109816, GSE121893) [1] on adult hearts from HF patients (n=6) and UDs (n=14) using Seurat package (V2.3.4). Specific gene knockdown was achieved by siRNA transfection of human foetal cardiac fibroblasts (HCFs, Sigma), untransfected HCFs stimulated with TGF-β (p<0.05) for 48-72h. The profibrotic marker expression levels were decreased in TGF-β-stimulated (n=4) and untreated (n=4): p<0.01) and TGF-β stimulated (p<0.01) but downregulated FOXL2 (p<0.05) and MXRA5 (p<0.01) in untreated HCFs, and also upregulated FOXL2 (p<0.05) and MXRA5 (p<0.01) in untreated HCFs and 72h after TGF-β stimulation (n=3, p<0.05).

Results: The LC–MS/MS analysis revealed 14 differentially expressed proteins (absolute log2FC>1, adj. p<0.05) in the HF group compared to UDs. The most upregulated protein in HF fibroblasts was dysferlin (DYSF, log2FC=5.78, adj. p<0.004), which is known to play a role in the sarcolemma repair of both skeletal muscle fibres and cardiomyocytes. Bulk RNA-seq analysis identified a total of 67 significantly differentially expressed genes (absolute log2FC>1, adj. p<0.05). The comparative analysis of bulk RNA-seq results and publicly available scRNA-seq datasets revealed two commonly upregulated genes in HF fibroblasts or their subclusters, encoding transcription factor FOXL2 (log2FC=3.51, adj. p<0.05) and matrix remodelling-associated protein MXRA5 (log2FC=2.91, adj. p<0.05). Further in vitro studies on HCFs (n=4) showed that TGF-β upregulated DYSF (p<0.001) and MXRA5 (p<0.01) but downregulated FOXL2 (p<0.05). Dysferlin silencing in HCFs (n=4) upregulated MXRA5 after 48h of TGF-β stimulation (p<0.05), downregulated ACTA2 (48h and 72h of TGF-β stimulation, p<0.05), and upregulated FOXL2 protein levels in untreated HCFs and 72h after TGF-β stimulation (n=3, p<0.05). MXRA5 knockdown (n=8) resulted in the upregulation of DYSF (p<0.05), ACTA2 (p<0.05) and COL1A1 (p<0.001) in untreated HCFs, and also upregulated DYSF (p<0.01) and COL1A1 (p<0.05) after 48h of TGF-β stimulation. FOXL2 silencing in HCFs (n=8) followed by 48h of TGF-β-stimulation downregulated MXRA5 (p<0.01) and ACTA2 (p<0.06), and upregulated DYSF (p<0.001) and COL1A1 (p<0.05). Candidate targets knockdown reduced cell viability in untreated (n=4, DYSF: p<0.01, MXRA5: p<0.001, FOXL2: p<0.01) and TGF-β-stimulated (n=4, DYSF: p<0.05, MXRA5: p<0.05, FOXL2: p<0.01) HCFs. ATP levels were decreased in TGF-β-stimulated HCFs after DYSF silencing (n=6, p<0.05).

Conclusion: Based on transcriptomics, proteomics and in vitro analysis of human cardiac fibroblasts, we identified DYSF, MXRA5 and FOXL2 as candidate targets implicated in profibrotic phenotype development, including profibrotic transcription factor FOXL2 regulation. These newly proposed candidates may serve as potential therapeutic targets for the treatment of cardiac fibrosis.

REFERENCES:

Disclosure of Interests: None declared.

System. Clinical features of the disease consist of skin thickening and internal organ involvement. Due to the heterogeneous nature of the disease, there is an unmet need of biomarkers for diagnosis, disease progression and response to treatment.

Objectives: The aim of this study was to explore new serum proteomic fingerprints of clinically defined forms of SSC.

Methods: Highly specific detection of nighty two proteins from a panel related to organ damage was performed, by using the breakthrough technology proximity extension immunoassay (PEA, Olink), in the serum of 72 patients with SSC and 18 age-matched healthy donors (HD). Main disease complications in the SSC cohort, including lung fibrosis, skin fibrosis, renal, vascular, and esophageal involvement were assessed, and prevalence of circulating autoantibodies was tested, along with standard demographic and inflammatory parameters. Unsupervised hierarchical clustering methodologies were applied to identify subgroups of patients based on their proteomic profiles. Gene ontology enrichment was used to investigate the biological meaning of the distinctive molecular signatures identified.

Results: Sixteen circulating proteins related to organ damage were coordinate- nately altered in the serum of SSC patients in relation to HD. Unsupervised clustering analyses differentiated 3 patients clusters presenting different proteomic profiles. Clinically, patients belonging to cluster 1 were characterized by a significant prevalence of multiple organ involvement (84%) in relation to clusters 2 (52%) and 3 (43%), mostly encompassing lung and skin fibrosis and esophageal dysmotility. Immunologically, cluster 1 further displayed the highest percentage of positivity for anti-scl70 antibodies. Nineteen serum proteins, not previously reported in the serum of SSC patients (BANK1, BID, CALR, ERBB2IP, FGR, FOXP1, INPPL1, MAAE, MAGED1, MAP4K5, NBN, NCF2, PRKAB1, RASSF2, ROR1, SMAD1, STXBP3, VASH1) were found deregulated between clusters, with a significant increase in the levels of all of them in cluster 1 compared with clusters 2 and 3. These deregulated pro- teins were mostly involved in biological processes such as cell proliferation, apoptosis, cell adhesion, migration, and immune response. Among them, two were functionally linked with cutaneous diseases [Cattelucin (CALR) and B-cell scaffold protein with ankryin repeats (BANK1)], two with digestive disorders [Tyrosine-protein kinase Fgr (FGR) and syntaxin-binding protein 3 (STXB P3)] and three with lung dysfunction [protein FosB (FOXP1), mothers against decapentaplegic homolog 1 (SMAD1) and forkhead box protein O1 (FOXP1)]. Interestingly, levels of some overexpressed proteins in C1 [B3H-interacting domain death agonist (BID), phosphatidylinositol 3,4,5-triphosphate 3-phosphatase 2 (INPPL1), Erbin (ERBB2IP), BANK1 and FOXP1] were further related to the positivity for anti-scl70, the specific SSC-autoantibody known to be mostly associated to a bad prognosis and multiple organ involve- ment in SSC patients.

Conclusion: 1) Stratification based on serum proteomic profile could be of use for a better clinical classification of SSC patients, adding new insights to the underlying pathophysiological mechanisms. 2) Combination of disease classifying autoantibodies with principal pathophysi- ological processes and serum proteomic profiles can help to elucidate and strengthen the diagnosis as well as the prognosis in SSC.

Acknowledgements: Supported by ISCIII (RICOR-RD21/0002/0033) co-fi- nanced with FEDER.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4180

POS0489 CCL24 SERUM CONCENTRATION CORRELATES WITH DISEASE ACTIVITY AND WORSE PROGNOSIS IN DIFFUSE CUTANEOUS SSC: A PROMISING BIOLOGICAL TARGET TO PREVENT DISEASE PROGRESSION

M. Segal Salto1, A. Mor2, F. Del Gaido3, Chemomab Therapeutics Ltd., R&D, Tel-Aviv, Israel; 1University of Leeds, Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

Background: Linking novel therapeutic targets for diffuse cutaneous Systemic Sclerosis (dcSSc) to markers of disease severity and clinical outcome will enable directing of specific and right therapeutic agents to the appropriate patient populations. Such correlation will also support patient stratification in clinical trials increasing their informative value and success rates. CCL24 is a chemokine within the Eotaxin family, that has been shown to have a dual pro-inflammatory and pro-fibrotic role in SSC. CCL24 and its receptor, CCR3, were found to be over-expressed in SSC skin and serum samples. In-vivo CCL24 blockade was associated with reduction of bleomycin induced skin and lung injury.

Objectives: We aimed to study the role of CCL24 in dcSSc using patient cohorts, by correlating its serum levels to disease activity markers and disease progression.

Methods: Retrospective and longitudinal dSSc patients' cohorts were ana- lyzed for CCL24 circulating levels, clinical measurement and disease related biomarkers.

Results: In a retrospective cohort of 56 dcSSc patients, CCL24 serum lev- els were significantly higher in patients that had positive anti topoisomerase antibody (ATA) compared to patients with negative ATA. In addition, within the ATA positive patients, ones that had high serum CCL24 levels (>1500 pg/ ml) also presented significantly higher fibrotic activity reflected by a higher enhanced liver fibrosis (ELF) score compared to ATA positive patients with low CCL24 (<1500 pg/ml). In a second longitudinal cohort of 66 patient, base- line CCL24 levels positively correlated with ELF score (r=0.42, p≤0.0005).

Patients with high baseline CCL24 serum levels were also more likely to experience lung disease progression, measured by reduction in forced vital capacity (FVC) during 12 months (7 out of 17 patients with CCL24 ≥ 1500 pg/ml had at least -5% reduction of FVC). Consistent with these data, patients with normal FVC at baseline (>80% predicted) who experienced worsening in the next 12 months (at least 7%) had a statistically significant higher baseline serum CCL24 (Average 2.275 pg/ml) compared to patients that had no worsening in FVC over time (average 962 pg/ml, p<0.001).

Interestingly, the same group showed an even steeper reduction in DLCO % predicted (-6.8% vs -0.2%, p<0.05).

Conclusion: We show here using two dcSSc patient cohorts, that CCL24 serum levels are correlated with disease activity and worse prognosis reflected by high fibrotic activity and deterioration of lung function over time. This reverse transla- tional study supports the role of CCL24 as a therapeutic target for dcSSc and it has informed a phase 2 study testing CM-101, a CCL24 neutralizing antibody, in dcSSc patients to be started in 2022.

Disclosure of Interests: Michal Segal Salto Employee of: Chemomab Thera- peutic Ltd., Adi Mor Employee of: Chemomab Therapeutics Ltd., Francesco Del Gaido Consultant of: Chemomab Therapeutic Ltd., Grant/research support from: Chemomab Therapeutic Ltd.

DOI: 10.1136/annrheumdis-2022-eular.4180

POS0490 USEFULNESS OF MHC-II IMMUNO-STAINING ON MUSCLE BIOSPIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES

M. Robert1, L. Lessard2, F. Fenouill3, A. Hot4, T. Laumonier3, A. Bouche5, B. Chazaud6, N. Streichenberger7, L. Gally7, 1Pierre Wertheimer Hospital, Service d’Electroneuromyographie et de pathologies neuromusculaires, Lyon, France; 2Pierre Wertheimer Hospital, Service d’Electroneuromyographie et de pathologies neuromusculaires, Lyon, France; 3Institute NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, UMR 5261 CNRS, U1315 Insem, Université Claude Bernard Lyon 1, Lyon, France; 4Institut NeuroMyoGène, Unité Physiopathologie et Génétique du Neurone et du Muscle, UMR 5261 CNRS, U1315 Insem, Université Claude Bernard Lyon 1, Lyon, France; 5Cancer Research Center of Lyon, UMR Insem 1052 CNRS 5286, Equipe « Fibrosome Tractation and Cancer », Lyon, France; 6Institut Hospital Is - Hôpitaux Universitaires de Lyon, Service d’Electromyographie et Musculation, Lyon, France; 7Hopitaux Universitaires de Genève (HUG), Laboratoire « Cell Therapy & Musculoskeletal Disorders », Département de Chirurgie Orthopédique, Genève, Switzerland

Background: Idiopathic inflammatory myopathies (IIMs) constitute a group of acquired muscular diseases that occur during childhood and adulthood, exhibit a variety of phenotypes and are potentially life-threatening. IIM diagnosis consid- ers clinical, serological, and histological data. Muscle pathological analysis of IIM patients gives relevant elements for the diagnosis (immune cell infiltrate, vascu- lar and connective tissues, as well as myofiber morphology). Immunohistochemistry (IHC) labeling for major histocompatibility complex class I (MHC-I), and C5b9, that are negative in normal muscle, appeared of interest in IIM diagnosis and the understanding of IIM pathogenesis. In normal muscle, myofibers are negative for MHC-II IHC. Its interest in the neuropathological exam of IIM muscle remains to be better characterized.

Objectives: This study aims to analyze the pattern of MHC-II expression in various IIMs.

Methods: A historical cohort was designed using the MYOLYON register (IIM patients diagnosed between 2016 and 2020 at the University Hospital of Lyon, France). Inclusion criteria were IIM diagnosis that was established histologically and available frozen muscle samples for additional analyses. Exclusion criterion was any treatment before muscle biopsy. Demographical data and final diagnosis were recorded using retrospective and historical records. A centralized, standardized, and blind analysis of muscle MHC-II immuno-staining was conducted to define the various patterns of MHC-II by myofibers and by capillaries. The study complied with ethical requirements.

Results: Seventy-three patients were included: 23 dermatomyositis (DM), 13 anti-synthetase syndrome (ASS), 13 immune-mediated necrotizing myopathies (IMM), 13 inclusion body myositis (IBM), and 11 overlap myositis (OM). MHC-II immuno-staining of myofibers or capillaries was abnormal for 91.8% of the ana- lyzed biopsies (Figure 1). The analysis of MHC-II myofiber immuno-staining
revealed distinguishable patterns according to IIM subtype: the labeling was diffuse in IBM (69.2%, n=8/13), perivascular in ASS (61.5%, n=8/13), and variable in OM (patchy for 27.3% n=3/11 or clustered for 36.4%, n=4/11). MHC-II immunostaining was negative in IMNM (94.6%, n=11/13) and in DM (47.8%, n=11/23). DM exhibiting positive MHC-II myofibers (n=12) were associated with the presence of anti-TIF1γ, anti-NXP2 and anti-SAE auto antibodies (n=5, n=3 and n=2, respectively). Among the 12 patients, there were juvenile cases (n=5, 41.7%) or DM associated with ongoing neoplasia (n=4, 33.3%). Three main architectures were described for capillaries: giant, leaky and capillary dropout. Patterns of MHC-II positive capillaries were the following: DM was characterized by capillary dropout (68.2%), IMM showed leaky capillaries (75.0%), IBM giant capillaries (66.7%), ASS exhibited both giant (61.5%) and/or leaky (58.3%) capillaries, while OM showed giant (63.6%) or/and leaky (80.0%) capillaries and capillaries dropout (60.0%).

Conclusion: The present work establishes the usefulness of MHC-II immunostaining for IIM diagnosis, and gives additional elements on the impairment of myofibers and capillaries in the various IIM subgroups. MHC-II expression is known to be induced by inflammatory cytokine such as interferon type II. This could be linked to myofiber and/or capillary impairment in some IIMs, such as IBM, ASS and OM. These results also support the implication of vasculopathy in IIM pathogenesis, with various structural and cellular consequences regarding the different subgroups. Finally, MHC-II immuno-staining in IIM muscle biopsies enables a foremost analysis of myofibers and capillaries, and represents an additional biomarker to distinguish IIM subgroups.

REFERENCES:
intracellular metabolomics, chromatim immunoprecipitation PCR, ATAC and RNA sequencing, and cytokine production assays. Arteries from GCA patients were evaluated with immunohistochemistry (IHC) to assess immunometabolic activation. Pharmacologic inhibition of immunometabolic changes underlying TI (ie, glycolysis) was evaluated ex vivo as a therapeutic strategy to suppress cytokine production.

Results: GCA monocytes exhibited hallmark molecular features of TI. Specifically, these included typical immunometabolic changes (eg, increased glycolysis and glutaminolysis through the TCA cycle), epigenetic changes promoting transcription of genes governing pro-inflammatory activation and enhanced IL-6 production upon inflammatory challenge. IHC revealed that GCA lesions are highly glycolytic microenvironments, and pharmacologic inhibition of glycolysis with 2-deoxy-glucose effectively dampened IL-6 production. 

Conclusion: This study reveals the deleterious potential of maladaptive TI in the pathogenesis of GCA, and the therapeutic potential of inhibiting TI for the treatment of this condition.

Acknowledgements: This study was supported by the Foundation for Research in Rheumatology (FOREUM Career Award 2020 to GC). GC is also supported by AIRC under MAFG 2018 (ID. 22136 project – P. Giuli Cavalli). EHA (European Haematology Association Physician Scientist Grant 2021); Italian Ministry of Health (GR-2018-12366385); SIMIT (Italian Society of Internal Medicine, G. Licata Award 2021).

Disclosure of Interests: Eleonora Cantoni: None declared, Ivan Merelli: None declared, Davide Stefanoni: None declared, Alessandro Tomelleri: None declared, Corrado Campochiaro: None declared, Elena Baldissera: None declared, Jorge Domínguez Andrés: None declared, Marco Matucci-Cerinic: None declared, Davide Stefanoni: None declared, Lorenzo Dagna Speake- r bureau: SANOFI, NOVARTIS, SOBI, Mihai Netea: None declared, Raffaella Molteni: None declared, Giuli Cavalli: None declared.


POS0493

1H-NMR BASED METABOLIC PROFILE OF PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA IN ACTIVE AND INACTIVE DISEASE STATE

O. Argyropoulou1, M. Karagiannakou, D. Palmadidas, B. Benaki, K. Tsezou, P. Vlachosianopoulos, E. Mikos, A. Tzivoglou, 1School of Medicine, National and Kapodistrian University of Athens, Greece; 2School of Pharmacy, National and Kapodistrian University of Athens, Department of Pharmaceutical Chemistry, Athens, Greece; 3University Hospital, Internal Medicine and Clinical Immunology department, Dijon-Bourgogne University Hospital, Dijon, France.

Background: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in the elderly. The disease is characterized by a remarkable heterogeneity in terms of clinical picture, histologic pattern of the affected vessels, pathogenetic mechanisms and treatment selection strategies. Approximately half of GCA patients present with polymyalgia rheumatica (PMR), while 20% of PMR patients will develop GCA during follow-up. Organ or life-threatening complications of GCA, include vision loss, strokes, aneurysm formation and accelerated atherosclerosis. The clinical heterogeneity along with the increased relapse rate, even under treatment and the fact that ESR and C-Reactive Protein are the only laboratory tools for the assessment of active disease suggest that the definition of new biomarkers with diagnostic, prognostic and predictive value is an unmet need (1). Among the high throughput approaches towards this direction, 1H NMR spectra of serum samples provides a direct, untargeted, and holistic metabolic profile offering a wealth of information that could be proved useful to discover outcome tools for the management of the disease (2).

Objectives: 1. To characterize and compare the metabolic profile of GCA/PMR serum samples, as captured in 1H NMR spectra, in 3-time points: diagnosis, 1 and 6 months of treatment with steroids (remission). 2. Evaluate whether 1H NMR-based metabolic profile from patients with GCA/PMR associate with response to treatment and 3. Identify potential discriminatory serum metabolic profiles correlating with disease activity.

Methods: One-hundred and ten serum samples from 50 consecutive patients (33-GCA and 17-PMR) were evaluated in the study. GCA serum samples consisted of 33 naive, 22 in 1 and 21 after 6 months of treatment (25 females, mean age 73.0 ± 6.1 years and 8 males, mean age 69.5 ± 4.9 years), while PMR of 15 naive, 10 in 1st and 8 respectively (9 females, mean age 65.0 ± 5.3 years and 8 males, mean age 77.0 ± 6.6 years). The serum metabolic profiles of patients were obtained at a 600 MHz NMR spectrometer and analysed by means of univariate and multivariate statistical methods.

Results: Multivariate analysis showed metabolic differences between GCA/PMR patients in activity and in remission using unsupervised principal component analysis (PCA: R2X= 0.698, Q2= 0.501) and supervised partial least squares discriminant analysis (PLS-DA: R2X= 0.596, Q2= 0.219) (Figure 1). In accordance with univariate analysis (p<0.05), the following discriminatory metabolites were identified: N-acetyl glycoproteins, 3-hydroxybutyric acid and phenylalanine were increased in inflammation, while choline, lipoproteins, and lipids were decreased in these patients.

Figure 1. (A) PLS-DA scores plot and (B) S-plot from OPLS-DA of 1H NMR profiling of GCA/PMR serum samples before treatment (green dots) and after 1 (red dots) and 6 months (black dots) of treatment. Characteristic metabolites in inflammation and remission are annotated and the corresponding p-values are given. PLS-DA: partial least square discriminant analysis, OPLS-DA: orthogonal partial least squares discriminant analysis.

Conclusion: 1H NMR-based serum metabolomics revealed a clear discrimination of GCA/PMR metabolic profiles before (active inflammation) and after treatment with steroids (remission), suggesting that the metabolic analysis may serve as a useful tool to identify potential biomarkers related to disease activity in both GCA and PMR, as well as give further insights into pathogenetic mechanisms mediating the inflammatory response. Further validation studies to dissect the clinical value of specific metabolites are ongoing in our laboratory.

REFERENCES:

Disclosure of Interests: None declared.


POS0494

ARTERIAL WALL DENDRITIC CELLS IN GIANT CELL ARTERITIS (GCA) AND POLYMYALGIA RHEUMATICA (PMR)

A. Ramon1,2, H. Greiger3,4, C. Cladière2, M. Ciudad2, P. Orrentí1, A. Bonnottete3, M. Samso3,2,3,4,5 Dijon University Hospital, Rheumatology, Dijon, France; 2Bourgogne Franche-Comté University, INSERM, EFS BFC, UMR 1098, RIGHT Graft-Host-Tumor Interactions/Cellular and Genetic Engineering, Dijon, France; 3Dijon University Hospital, Internal Medicine and Clinical Immunology department, Dijon-Bourgogne University Hospital, Dijon, France; 4Dijon University Hospital, Vascular Medicine department, Dijon-Bourgogne University Hospital, Dijon, France

Background: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease (1) associated in 16 to 21% of cases with giant cell arteritis (GCA). The association of these two conditions raises the question of a pathophysiological continuum between PMR and GCA. An early study reported mature arterial wall dendritic cells (DC) in patients with GCA or PMR leading, during GCA, to CD4+ T cell recruitment and the development of vasculitis (2). However, these data have never been confirmed in other studies. There are 3 main types of DC: plasmacytoid DC (expressing CD123), conventional DC (cDC) expressing CD141 (cDC1) or CD1c (cDC2) and monocyte-derived DC (moDC) expressing CD14. The aim of this study was to describe the arterial wall infiltrating DCs, their phenotype and maturation state, during PMR and GCA.

Methods: Using temporal artery biopsies (TAB) from patients with PMR, GCA and healthy controls, the level of expression of CD1, CD123, CCR7, CCR3, CCR4, CCR6, CCL18, CCL19, CCL20, CCL21, GM-CSF, CD8, CD68 and the percentage of CD83, CCR7, CCR6, CCL18, CCL19, CCL20, CD11c, GM-CSF, CD3 and CD68 gene expression was assessed by RT-PCR. Expression of markers of DC lineage (CD1c, CD14, CD1a, CD1b) and the expression of the maturation marker CD83 from the arterial wall were assessed. The level of expression of CCR3 and CCR7 from the arterial wall and also expressed CD14 and often CD68 but neither CD1c nor CD141, which could be explained by a monocytic/macrophage origin. TAB from GCA patients were characterized by a high level of expression of CCR3, CCR2 CCR6, CCL18, CCL19, CCL20, CD11c, GM-CSF, CD3 and CD68 gene. This expression was significantly higher (p<0.05) compared to the control and PMR groups. Confocal microscopy analyses of arteries from the PMR and controls did not detect the presence of DCs into the arterial wall. In addition, level of
expression of CD83, CCR7, CCL18, CCL19, CCL21 and CD68 genes in temporal arteries was comparable between PMR and healthy controls.

**Conclusion:** This work confirms the presence of mature CD209+CD83+CCR7+ DCs within the arterial wall in GCA. The phenotype of these DCs mainly fits with DC of monocytic origin (mo-DCs). However, both by RT-PCR and confocal microscopy, we did not identify DCs in the arterial wall of PMR patients. This discrepancy with previous work (3) could be explained by a better diagnosis of GCA in PMR patients since the development of imaging techniques.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4767
A STUDY ON THE IMMUNOREGULATORY ROLE OF THE PD1 PATHWAY IN JUVENILE IDIOPATHIC ARTHRITIS - PRELIMINARY RESULTS

A. Koutsonikoli, A. Taparkou, P. Pratsidou-Gertsi, V. Spourolopoulou, M. Trachana
Aristotle University of Thessaloniki, Pediatric Immunology and Rheumatology Reference Centre, 1st Pediatric Dept, Hippokratieio General Hospital, Thessaloniki, Greece

Background: The programmed cell Death protein-1 (PD1) pathway promotes self-tolerance, by inhibiting immune responses. The PD1 soluble form (sPD1), by antagonizing the binding of the membrane-bound PD1 with its ligands, may lead to the blocking of the pathway’s functions. Data regarding the role of the PD1 pathway in Juvenile Idiopathic Arthritis (JIA) are still limited.

Objectives: To investigate the immunoregulatory role of the PD1 pathway in JIA patients.

Methods: JIA patients and healthy controls participated in this study with peripheral blood (PB) and/or synovial fluid (SF) samples. sPD1 levels in serum and SF were determined by ELISA. The PD1 expression on T-helper (CD4+) and T-cytotoxic (CD8+) cells in PB and SF was analyzed by flow cytometry. A search for any association between the above biomarkers, as well as their relation with JIA activity was then performed. Inactive disease was defined according to Wallace criteria.

Results: 77 Caucasian patients (52 female) participated so far in this study, with a median (range) age of 13 (2-19) years; their JIA subtypes were: oligoarticular (33%), polyarticular (26%), psoriatic (12%), enthesitis-related (16%), systemic (10%) and undifferentiated (3%). Ten healthy children served as controls. As compared to controls, a subpopulation of these JIA patients (n=46) had a significantly higher median percentage of PD1+CD4+ (1.15 vs. 0.32%, p=0.029) and PD1+CD8 T cells (1.34 vs. 0.4%, p=0.006) in PB. In regard to the JIA status, patients with activity (n=33) had a significantly higher median percentage of both PD1+CD4+ and PD1+CD8 T cells in PB, as compared to those with inactive disease (n=13) (1.36 vs. 0.87%, p=0.034 and 2.03 vs. 0.45%, p<0.001, respectively).

Additionally, in a sample of the patients with disease activity (n=22), the median serum sPD1 level was statistically significantly higher, as compared to a sample of those with inactive JIA (n=10) (218.3 vs. 186.7pg/ml, p=0.035). In patients with concurrent serum and SF samples (n=7), the median sPD1 level was statistically significantly higher in the SF than in the serum (1104.4 vs. 773.4pg/ml, p=0.028).

No correlation was though found between the sPD1 levels and the PD1 cellular surface expression (n=16 PB/serum, n=11 SF).

Conclusion: These preliminary results indicated an sPD1 compartmentalization in active JIA, as sPD1 levels were more prominently raised in the inflamed joint than in the PB. A higher number of circulating T-helper and T-cytotoxic cells expressing PD1 were also detected in active JIA. Further investigation in a larger sample of JIA patients may verify these observations and contribute to unraveling the precise role of the PD1 pathway in the pathogenesis and persistence of the joint inflammation.

REFERENCES:

Disclosure of Interests: None declared.


Basic and translational pain science

MOLECULAR DOCKING AND PHARMACOLOGICAL ANALYSIS OF ALPHA-PHELLANDRENE IN CHRONIC PAIN: THE ROLE OF SEROTONERGIC SYSTEM

V. M. D. S. Pires, J. T. Ceciliinsky, L. D. S. Gomes, F. D. A. Oliveira, F. R. D. C. Almeida, F. University of Paraná, Pharmaceutical Sciences, Curitiba, Brazil; Universidade do Contestado, Pharmacy, Mafra, Brazil; Federal University of Piauí, Biochemistry and Pharmacology, Teresina, Brazil

Background: Pain is an unpleasant sensory and emotional experience that causes human suffering. Its prevalence has increased, as well as the abuse and dependence on strong opioids. The α-phellandrene is a terpene that exerts antinociceptive and immunostimulant effects, however, its mechanisms remain to be elucidated. In this way, bioinformatics may assist in developing new therapeutic approaches for pain management.

Objectives: To investigate the action of α-PHEL in chronic pain, focusing on the role of the serotonergic system, to develop a new therapeutic tool without the side effects of conventional drugs.

Methods: Molecular docking is an important method for the investigation of the mechanism of action of natural compounds. It is possible to evaluate the molecular dynamics, elucidating the stability of complexes. The software PyMOL and AutoDock Vina 1.5.7 were used to predict interactions of α-PHEL and 5-HT 2A receptor antagonist Ketanserin (0.3mg/kg, i.p.) or Saline (10mL/kg, p.o.). After 20min, they were treated with α-phell (6.25mg/kg, p.o.) and after 1h they were evaluated by the Von Frey test.

Results: The serotonergic system has a complex and important role in pain modulation especially through descending inhibitory pathways. The Molecular docking predicted the positioning of α-PHEL in the 5-HT 2A receptor, aiding the understanding of its biological activity. The analysis identified 9 key positions for the ligand binding in 5-HT 2A. The lowest Gibbs free energy ΔG= -6.9 kcal/mol. The negative binding energy indicates a strong and stable bond, therefore, α-PHEL has a high affinity for the receptor (Figure 1).

Excellent in vivo therapeutical effects were observed in the animal model of neuropathic pain. Regarding the pharmacological in vivo analysis, the α-PHEL significantly decreased the pain threshold (P<0.05), exhibiting an anti-hyper-sensitive effect. The inhibition of serotonergic transmission by pretreatment with Ketanserin significantly reduced the antinociceptive effect of α-PHEL in mice. The data indicate that α-PHEL exerts its antinociceptive effect on chronic neuropathic pain model by activation of the 5-HT2AR receptor. Its analgesic effect seems to be mediated by descending inhibitory serotonin system interfering with pain impulse transduction.

Conclusion: Chronic pain is often resistant to medical treatment and the chemoinformatics techniques may facilitate the discovery of new compounds, guiding towards specific molecular targets. The α-PHEL may act as a serotonergic agonist, reducing mechanical sensitivity. It is a promising compound for chronic pain treatment, with lower cost and fewer adverse effects than opioids. Further investigations are expected to highlight the in-depth effects of the interaction of α-PHEL with other receptor subtypes.

REFERENCES:

Disclosure of Interests: None declared.

Rheumatoid arthritis - prognosis, predictors and outcome

Table 1. Baseline inflammatory protein biomarkers and progression of joint damage over 5 years in rheumatoid arthritis

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
<th>P (corr)</th>
<th>OR</th>
<th>95% CI</th>
<th>P</th>
<th>P (corr)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6</td>
<td>1.83</td>
<td>1.11-3.01</td>
<td>0.018</td>
<td>0.14</td>
<td>1.62</td>
<td>0.96-2.75</td>
<td>0.072</td>
<td>0.58</td>
</tr>
<tr>
<td>MMP-1</td>
<td>1.96</td>
<td>0.92-2.66</td>
<td>0.10</td>
<td>0.65</td>
<td>1.44</td>
<td>0.84-2.47</td>
<td>0.19</td>
<td>0.96</td>
</tr>
<tr>
<td>MCP-3</td>
<td>1.64</td>
<td>1.01-2.65</td>
<td>0.045</td>
<td>0.99</td>
<td>1.14-3.49</td>
<td>0.016</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>CCL19</td>
<td>1.76</td>
<td>1.05-2.91</td>
<td>0.027</td>
<td>2.14</td>
<td>1.22-3.78</td>
<td>0.009</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>SLAMF1</td>
<td>1.64</td>
<td>1.05-2.57</td>
<td>0.031</td>
<td>1.61</td>
<td>1.02-2.56</td>
<td>0.047</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>TNFSF14</td>
<td>1.67</td>
<td>1.08-2.60</td>
<td>0.022</td>
<td>1.53</td>
<td>0.98-2.37</td>
<td>0.060</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>EN-RAGE</td>
<td>2.77</td>
<td>1.64-4.84</td>
<td>0.001</td>
<td>2.44</td>
<td>1.34-4.43</td>
<td>0.004</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>LIF</td>
<td>1.96</td>
<td>1.13-3.40</td>
<td>0.173</td>
<td>1.73</td>
<td>0.95-3.14</td>
<td>0.073</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>FGF-3L</td>
<td>0.60</td>
<td>0.36-0.98</td>
<td>0.040</td>
<td>0.68</td>
<td>0.40-1.14</td>
<td>0.15</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>DNGIR</td>
<td>0.72</td>
<td>0.42-1.25</td>
<td>0.259</td>
<td>0.69</td>
<td>0.37-0.27</td>
<td>0.53</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>CD8A</td>
<td>0.74</td>
<td>0.49-1.12</td>
<td>0.16</td>
<td>0.85</td>
<td>0.55-1.31</td>
<td>0.45</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
<tr>
<td>TRAIL</td>
<td>0.50</td>
<td>0.30-0.83</td>
<td>0.007</td>
<td>0.51</td>
<td>0.29-0.88</td>
<td>0.016</td>
<td>0.14</td>
<td>0.06-0.23</td>
</tr>
</tbody>
</table>

Conclusion: The new SynHelix ELISA measures precisely circulating degradation fragments of Helix-III peptide-containing collagen. Serum SynHelix levels are already increased in patients with low activity RA, values correlating modestly the degree of systemic inflammation. Larger longitudinal studies are needed to further evaluate the value of SynHelix to predict disease outcome in RA.


DOI: 10.1136/annrheumdis-2022-eular.159
Results: A total of 52 consecutive patients were studied: 29% developed IA after one year. At baseline, 25 patients had subclinical inflammation and 27 patients did not have subclinical inflammation. In these groups respectively 28% and 7% developed IA before the 4-month-visit and therefore did not have repeated MSUS. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months.

Objectives: To investigate whether sequential imaging at 4-months, in addition to baseline evaluation, is helpful in the risk stratification of arthralgia-patients.

Methods: Arthralgia-patients suspicious for progression to IA were included in the Rotterdam clinically suspect arthralgia cohort. At baseline and at 4-months a bilateral US-examination was performed of the joints and tendons in both hands and feet. Subclinical inflammation was defined as GS >1 and/or PD >0, this was scored according to the latest OMERACT-guidelines.[1, 2] Based on a large US study carried out in a symptom-free population, the cut-off value in MTP joints was considered present if GS ≥3 and/or PD ≥1.(3) Patients were followed for one-year on development of IA, identified with joint examination by experienced rheumatologists. The value of MSUS was studied separately for patients with and without subclinical joint inflammation at baseline. In a sensitivity analysis, ACPA-stratification was applied.

Results: A total of 52 consecutive patients were studied: 29% developed IA after one year. At baseline, 25 patients had subclinical inflammation and 27 patients did not have subclinical inflammation. In these groups respectively 28% and 7% developed IA before the 4-month-visit and therefore did not have repeated MSUS. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months. All patients with a negative MSUS at baseline, 26% achieved a positive MSUS at 4-months.

Conclusion: Within arthralgia patients with a positive MSUS at baseline, a negative MSUS after 4-months may be an incentive to exclude arthralgia-patients from further follow-up. Within the patients with a negative MSUS at baseline, repeating MSUS may induce more false positive than correct positive results.

REFERENCES:

Disclosure of Interests: None declared.

Results: bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. After bDMARDs introduction were compared with expected rates assuming no change in non-RA (Figure 1): the adjusted difference between the post- and pre-bDMARDs secular trends of 8-year CVD rates was 0.23 (p=0.06) for RA patients and -0.07 (p=0.33) for non-RA individuals (Table 1). However, we observed a reduction in the level of CVD rates among RA patients diagnosed in the post-bDMARDs period and no change in non-RA (Figure 1): the adjusted difference in level comparing points immediately before and after the intervention, and accounting for pre-intervention trend was -1.61 (p=0.03) in RA, while it was -0.02 (p=0.93) in non-RA (Table 1).

Conclusion: Arthritis onset after bDMARDs introduction is associated with a significant reduction in the risk of incident CVD events among RA patients, but not in the matched non-RA individuals.

Acknowledgements: We would like to thank the Ministry of Health of British Columbia and Population Data BC for providing access to the administrative data. All inferences, opinions, and conclusions drawn in this publication are those of the authors, and do not reflect the opinions or policies of the Data Stewards or the [British Columbia] Ministry of Health. No personal identifying information was made available as part of this study. Procedures used were in compliance with British Columbia’s Freedom in Information and Privacy Protection Act. Ethics approval was obtained from the University of British Columbia’s Behavioral Research Ethics Board (H15-00887).

Disclosure of Interests: None declared.


Table 1. Results of interrupted time-series analysis of incident CVD rates, adjusting for age, gender, chronic obstructive pulmonary disease, Romano Charlson Comorbidity Index, diabetes, angina, hypertension, chronic kidney disease, peripheral vascular disease, atrial fibrillation, glucocorticoid, non-steroidal anti-inflammatory drugs, CVD medications, fibrate, contraceptives, and aspirin use at disease diagnosis year, using stepwise model selection

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Parameter</th>
<th>RA</th>
<th>Non-RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unadj. Diff (95% CI)</td>
<td>Adj. Diff (95% CI)</td>
</tr>
<tr>
<td>CVD</td>
<td>Trend</td>
<td>-0.15 (-0.72, 0.42)</td>
<td>0.6086</td>
</tr>
<tr>
<td></td>
<td>Level (1 year post-intervention)</td>
<td>-1.36 (-3.17, 0.45)</td>
<td>0.1474</td>
</tr>
<tr>
<td></td>
<td>5 years post-intervention</td>
<td>-1.98 (-4.48, 0.55)</td>
<td>0.1332</td>
</tr>
</tbody>
</table>
Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th></th>
<th>Excess disability</th>
<th>No excess disability</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD) / N (%)</td>
<td>Mean (SD) / N (%)</td>
</tr>
<tr>
<td>N</td>
<td>200</td>
<td>338</td>
</tr>
<tr>
<td>Age, years</td>
<td>50.4 (10.7)</td>
<td>47.0 (12.8)</td>
</tr>
<tr>
<td>Women, N(%)</td>
<td>174 (87.0%)</td>
<td>252 (74.6%)</td>
</tr>
<tr>
<td>Fatigue VAS</td>
<td>59.3 (27.2)</td>
<td>46.5 (26.5)</td>
</tr>
<tr>
<td>DAS28-2C</td>
<td>4.04 (1.28)</td>
<td>3.99 (1.34)</td>
</tr>
<tr>
<td>AIMS anxiety</td>
<td>5.61 (2.25)</td>
<td>4.71 (2.27)</td>
</tr>
<tr>
<td>AIMS depression</td>
<td>4.47 (2.24)</td>
<td>3.47 (1.97)</td>
</tr>
<tr>
<td>Health Assessment Questionnaire</td>
<td>1.39 (0.64)</td>
<td>0.93 (0.81)</td>
</tr>
<tr>
<td>DAS28-2C</td>
<td>4.04 (1.28)</td>
<td>3.94 (1.34)</td>
</tr>
</tbody>
</table>

AIMS = Arthritis Impact Measurement Scales, DAS28-2C = two-component Disease Activity Score, SD = standard deviation, VAS = visual analogue scale

Conclusion: Disability resulting from RA is a complex phenomenon, arising from more than just joint inflammation. This analysis indicates that lack of social support, financial instability and lower physical fitness at symptom onset may explain the excess disability associated with RA. As only a small portion of the effect is mediated by PROMs, health and social inequalities may need to be targeted directly by interventions.

REFERENCES:


Disclosure of Interests: James Gwinnutt: None declared, Sam Norton: None declared, Kimme Hyrich Speakers bureau: Abbvie, Grant/research support from: Bristol-Myers Squibb, Pfizer, Mark Lunt: None declared, Bernard Combe: None declared, Adrie Kuyvenhoven: None declared, Bruno Fautrel: None declared, Suzanne Verstappen: None declared. DOI: 10.1136/annrheumdis-2022-eular.496
Conclusion: Contemporary UA has no excess mortality, in contrast to RA. So, besides milder disease at presentation within contemporary UA, also the long-term outcome mortality is more favorable and comparable to the general population. This supports the notion that contemporary UA-patients have intrinsically different characteristics than RA-patients, rather than representing an early stage of RA. Future studies are warranted to determine whether contemporary UA should be treated as RA; our results suggest that this population may deserve separate guidelines.

REFERENCES:

Disclosure of Interests: None declared.
DOI: 10.1136/annrheumdis-2022-eular.676

DIFFERENT BIOACTIVE LIPID PROFILES PREDICT RESPONSE TO TNF OR IL6 INHIBITORS IN RHEUMATOID ARTHRITIS: RESULT OF THE COREVITAS CERTAIN COMPARATIVE EFFECTIVENESS STUDY

M. Aloiabi1, R. Coras1, D. A. Pappas2, J. M. Kremer2, G. Thiele3,4, T. Mikuls4,5, M. Jain1, M. Guma3. 1University of California San Diego, Medicine, La Jolla, United States of America; 2CorEvitas, Medicine, NYC, United States of America; 3University of Nebraska Medical Center, Medicine, Omaha, United States of America; 4Omaha VA Medical Center, Medicine, Omaha, United States of America; 5VA San Diego Healthcare System, Medicine, San Diego, United States of America

Background: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier in the course of rheumatoid arthritis (RA) could help reach the goal of remission.

Objectives: We hypothesized that circulating bioactive lipids at baseline would identify specific metabolic profiles that predict patient response to therapy and define elements of metabolic pathobiology in arthritis.

Methods: Bioactive lipids were measured in plasma from two cohorts of RA patients from the CorEvitas (formerly known as Corrona) CERTAIN registry (1) at baseline prior to treatment with TNF inhibitors (all biologic naive, N=102) or anti-IL6 (all previously exposed to biologics, N=114). Response to treatment was categorized by minimal clinically important difference (MCID) in Clinical Disease Activity Index (CDAI) (2) at 6 months after treatment initiation. Patients had to have a 6 month follow up visit and plasma available at both the baseline and the 6 month time points. Liquid chromatography (LC) system coupled with high resolution Orbitrap mass spectrometer (LC/MS) was used for bioactive lipid profiling. Around 300 spectral features were identified as potential oxylipins by searching against an in-house MS/MS library. Logistic regression analyses were adjusted for gender, age and BMI was performed using R software.

Results: 102 patients (average age 54, standard deviation [SD] 12.6, 82% female [83], average BMI 29.7, SD 6.7, average CDAI 27.1, SD 13.7) starting anti-TNF therapy and 114 patients (average age 57, SD 13, 90% female [102], average BMI 30.5, SD 7.4, average CDAI 28.7, SD 13.8) starting tocilizumab were analyzed. Twenty-five bioactive metabolites discriminated between RA patients classified as anti-TNF responders (R, n = 74) and non-responders (NR, n = 28). Among these, the anti-inflammatory oxylipin maresin 2 was higher in R while the pro-inflammatory oxylipins 15d PGJ2 and 5,6-diHETE were higher in NR. Twenty different metabolites discriminated anti-IL6 R (n=73) and NR (n=41) as shown in Figure 1. The anti-inflammatory oxylipin 14-15EET was higher in R while the pro-inflammatory oxylipins 16-HETE and 15dEET were higher in NR.

Conclusion: Circulating bioactive lipid analysis using LC/MS provided a rapid analysis of a wide range of metabolites and can be used to describe metabolic signatures that predict response to therapies. These results lay the groundwork for more deliberate investigations novel metabolic-based interventions to predict response to therapy and reduce arthritis morbidity.

REFERENCES:

TAILORING ORAL THERAPY IN RHEUMATOID ARTHRITIS: THE TUTOR APP

M. Radin1, M. Arbrile1, I. Cecchi1, A. Barinotti1, S. Baldovino1, E. Menegatti1, D. Rossi1, S. Sciascia1, D. Roccatello1. 1University of Turin, Clinical and Biological Sciences, Turin, Italy

Background: Medication non-adherence has a significant impact on the health and well-being of individuals with chronic diseases. Indeed, with respect to important risk factors of Rheumatoid Arthritis (RA), such as cardiovascular risk factors, it is known that up to 50% of patients will stop taking medication for these conditions during the first year of prescription [1].

Objectives: To support the management of RA patients treated with Tofacitinib, we designed the TuTOR (Tailoring Tofacitinib Oral therapy in Rheumatoid arthritis) Mobile App.

Methods: A prospective-controlled study evaluated the impact of TuTOR App on medical adherence in 20 RA patients, that began treatment with Tofacitinib jointly with the App. We used a crossover design alternating Paper-Diary and TuTOR App, with monthly clinical assessments.

Results: Seventeen patients with RA (mean age at inclusion 59±19yrs; 88% females) the study. A statistically significant decrease of DAS28 was observed since the first month of therapy with Tofacitinib (mean DAS28 at baseline 3.9±1 vs. 1° month 3.1±1, p=0.0016). Similarly, Numerical Rating Scale (NRS) of perceived activity of disease (5.8±2.1 vs 3.7±2.5, p=0.02), and subjective fatigue (6.1±2.3 vs 4.3±2.6, p=0.01) progressively decreased. No differences were reported in DAS28 and in all the NRS between the use of the TuTOR App and the Paper-Diary: A significant decrease was observed also in HAQ during the follow-up (baseline 1.38±1.11 vs six months 0.89±0.9; p=0.01). Most of the patients (82%) when filling out the self-reporting questionnaires preferred the TuTOR App in helping them to remember to take the pills. Further 82% of patients used the TuTOR App regularly (vs.53% Paper-Diary) and 76% of patients would use it in the future (vs.53% Paper-Diary). Three patients suspended the therapy with Tofacitinib due to gastrointestinal intolerance.

Conclusion: Both digital- and paper-devices can help maximize the adherence to therapy, leading to an improvement in disease’s activity, highlighting the need of supports for medication adherence.

REFERENCES:
Table 1. Baseline demographic and clinical characteristics of the patients enrolled in the study, who completed follow-up. RA – Rheumatoid Arthritis

<table>
<thead>
<tr>
<th>Patients with RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N=17)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DEMOGRAPHICS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean ± S.D.)</td>
<td>59.4 ± 13.5</td>
</tr>
<tr>
<td>Sex (n; %)</td>
<td>M (2; 11.8), F (15; 88.2)</td>
</tr>
<tr>
<td>Ethnicity (caucasian; n; %)</td>
<td>16; 94</td>
</tr>
<tr>
<td>Ethnicity (Hispanic; n; %)</td>
<td>1; 6</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CLINICAL CHARACTERISTICS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (mean ± S.D.)</td>
<td>44.7±14.47</td>
</tr>
<tr>
<td>Follow-up length (years; mean ± S.D.)</td>
<td>6.33± 5.17</td>
</tr>
<tr>
<td>Positive Rheumatoid Factor (n; %)</td>
<td>17; 100</td>
</tr>
<tr>
<td>Positive Anti-Cyclic citrullinated peptides (n%; %)</td>
<td>15; 88.2</td>
</tr>
<tr>
<td>Structural articular damage at radiography (n; %)</td>
<td>11; 7</td>
</tr>
</tbody>
</table>

Table 2. Predictors of Persistent Rheumatoid Arthritis at 12 months

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Persistent RA</th>
<th>Persistent RA</th>
<th>Persistent RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95 CI)</td>
<td>OR (95 CI)</td>
<td>OR (95 CI)</td>
</tr>
<tr>
<td>n</td>
<td>708</td>
<td>708</td>
<td>707</td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.99 (0.98, 1.01)</td>
<td>0.99 (0.98, 1.01)</td>
<td>0.99 (0.97, 1.01)</td>
</tr>
<tr>
<td>Female gender</td>
<td>1.06 (0.57, 2.00)</td>
<td>1.06 (0.56, 1.99)</td>
<td>0.72 (0.30, 1.71)</td>
</tr>
<tr>
<td>RF positive</td>
<td>2.33 (1.44, 3.78)</td>
<td>2.45 (1.62, 3.98)</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
<tr>
<td>ACPA positive</td>
<td>-</td>
<td>-</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
<tr>
<td>DAS28 at baseline</td>
<td>1.27 (1.06, 1.52)</td>
<td>1.59 (1.24, 2.04)</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
<tr>
<td>Categorical DAS28</td>
<td>-</td>
<td>-</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
<tr>
<td>MDA (vs LDA)</td>
<td>-</td>
<td>-</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
<tr>
<td>HDA (vs LDA)</td>
<td>-</td>
<td>-</td>
<td>0.72 (0.30, 1.70)</td>
</tr>
</tbody>
</table>

**Background:** Early arthritis is an inflammatory disease with the potential to progress to persistent arthritis, such as established Rheumatoid Arthritis (RA) or other articular disease, to resolve spontaneously or remain undifferentiated for indefinite periods of time.

**Objectives:** To identify predictors of persistent RA after 12 months follow up in the Argentinean early arthritis clinic (CONAART).

**Methods:** We conducted an observational, prospective longitudinal study, including patients with early arthritis (at least 1 swollen joint with <2 years of evolution) who had at least one year of follow-up. Sociodemographic and clinical data and characteristics of the disease were recorded at baseline, at 3, 6 and 12 months. After 1 year of follow-up, each patient was classified according to diagnosis: self-limited arthritis, persistent non-erosive arthritis, or persistent erosive arthritis. The association between the different predictors of diagnosis at 12 months was evaluated using multiple logistic regression, adjusted by potential confounders. Rheumatoid Factor (RF) and Anti Citrullinated Peptide Antibodies (ACPA) were included in separate models in order to avoid multicollinearity. A value of p<0.05 was considered significant.

**Results:** We included 839 patients, 83% females, mean age of 57±14 years and mean disease duration of 8.2±6.2 months; 67.5% were rheumatoid factor positive and 59% ACPA positive. Disease characteristics at baseline were DAS28 5.1±1.4, swollen joints 6±5, erythrocyte sedimentation rate (ESR) 34±25 mm/h, C Reactive Protein (CRP) 4±6 and Health Assessment Questionnaire-Argentinean (HAQ-A) 1.2±0.8. After 12 months follow up, 11% of the patients were diagnosed as self-limited disease, whereas 89% were diagnosed as persistent disease. For the persistent disease, 34% presented radiograph erosions and therefore were catalogued as persistent erosive disease. The seropositivity for both, RF and ACPA, together with baseline DAS28, were the variables independently associated with the development of persistent disease at 12 months. [Model 1a: RF OR 2.33 (95% CI 1.44, 3.78) and DAS28 1.27 (1.06, 1.52); Model 2a: ACPA 2.61 (1.38, 4.93) and DAS28 1.59 (1.24, 2.04)]. (Table 1). In the patient prediction model, it can be observed that a patient with female gender, ACPA negative, and a low activity at baseline (DAS28 <3.1) presents a 62.3% of likelihood of developing persistent arthritis after 12 months, while a male patient, ACPA positive, with a high baseline activity level, the probability of having persistent disease rises to 97.5%. (Figure 1)
Results: Adjusted for optimism, the multinomial model achieves an accuracy of 50.7% (IQR: 50 – 51.3%), with calibration slopes of 0.57 (IQR: 0.569 – 0.579) and 0.534 (IQR: 0.525 - 0.544) for moderate and poor response, respectively. Figure 1 shows a comparison of odds ratios (OR) for the different outcome groups. The Health Assessment Questionnaire (HAQ) score is the biggest driver of both moderate and poor response. Previous biologic treatment also predicts poor but not moderate response. Compared to the multinomial model, a binary model, that discriminates poor from moderate and good responders, underestimates the effect size of HAQ.

Conclusion: The model predicts EULAR response groups moderately well but is poorly calibrated, which can partly be explained by the generally higher sample size requirement of multinomial modelling. In the multinomial model, moderate and poor response is largely driven by the same covariates, which leads to blurred boundaries between good and poor responders, when response groups are merged to create a binary problem. Future research should consider the most appropriate model choice to describe data, including the use of multinomial instead of binomial models. More research and bigger sample sizes are required to improve on this multinomial model.

Disclosure of Interests: Michael Stadler: None declared, Stephanie Ling: None declared, Nisha Nair: None declared, John Isaacs: Speakers bureau: Abbvie, Gilead, Roche, UCB, Grant/research support from: GSK, Janssen, Pfizer, Kiniksa Pharmaceuticals, Anthony G Wilson: None declared, Darren Plant: None declared, John Bowes: None declared, Anne Barton: Grant/research support from: Pfizer, Galapagos, Scipher Medicine, and Bristol Myers Squibb.


POS0510
INFLUENCE OF CMV INFECTION ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

A. Kippenhahn1, C. Baerwald2, C. Pitsch2, O. Sellert3. 1Rheumatology Unit, Clinic for Endocrinology, Nephrology and Rheumatology, Department of Internal Medicine, Neurology and Dermatology, University Hospital Leipzig, Leipzig, Germany; 2Institute of Medical Microbiology and Virology, Department of Virology, University Hospital Leipzig, Leipzig, Germany

Background: The causes of the onset and progression of rheumatoid arthritis (RA) are complex and not yet understood. Some studies suspect viruses as triggers of inflammatory processes (1). Increased numbers of immunomodulatory cells have already been detected in patients with RA infected with the cytomegalovirus (CMV) (2) (3). Understanding the role this infection has on RA-specific disease parameters could help clarify predisposing and prognostic factors.

Objectives: The aim of this study was to determine the relationship between CMV serostatus and disease activity in patients with rheumatoid arthritis.

Methods: We performed a retrospective study in adult patients diagnosed with RA. The data was collected between 2008 and 2021 in the rheumatological outpatient department of the University Hospital in Leipzig, Germany. The parameters examined included age, gender, CMV-IgG and CMV-IgM, and the following parameters to record the disease activity of RA: disease duration, joint erosions, rheumatoid factor, anti-CCP antibodies, CRP, disease activity score (DAS28), visual analog scale (VAS) for pain detection, Health Assessment Questionnaire (HAQ), medication with DMARDs and prednisolone.

Results: A total of 89 RA patients were included, 78.7% of them were female. The mean age was 61.44 ± 10.89 years and the mean duration of illness was 9.48 ± 9.13 years. 56.2% of the patients were CMV-IgG positive, 2.2% CMV-IgM positive. With an OR of 5.04 (95% CI 1.63-15.64), the CMV-IgG titer in women was significantly higher than in men (115.16 vs. 50.75).
p = 0.007). This has already been shown in other studies (4). One of the reasons discussed is the women's closer relationship with children at work. It has also been shown that among those medicated with DMARDs had significantly higher CMV-IgG titers (126.82 vs. 58.84 p = 0.036). This could be explained by an increased predisposition for CMV reactivation due to the intake of medication. Women with joint erosions were also more likely to be CMV-IgG positive (OR = 3.2; 95% CI 1.02-10.03) and had higher CMV-IgG titers (147.44 vs. 97.23 p = 0.024). Furthermore, seropositive RA women were significantly more likely to be CMV-IgG positive (p = 0.05). This association supports the assumption that CMV may play a role in the pathogenesis of RA.

Conclusion: The data presented shows that there is indeed a relationship between infection with CMV and parameters for disease activity in patients with RA. In summary, the integration of a CMV status determination into everyday clinical practice in patients with high disease activity could be quite useful and should be discussed.

REFERENCES:


Disclosure of Interests: None declared.


POS0511

PERIODONTAL STATUS BEFORE DIAGNOSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS PREDICTS CUMULATIVE DISEASE ACTIVITY IN YEARS AFTER TREATMENT INITIATION

A. Plachokova1, J. Fransen2, M. Koenders2, R. M. Thurlings2.

University Medical Center, Dentistry, Nijmegen, Netherlands; 2University Medical Center, Rheumatology, Nijmegen, Netherlands

Background: Transversal cohort studies demonstrated an association between periodontal disease (PD) and rheumatoid arthritis (RA), but it is unknown how this association evolves during the course and treatment of both conditions.

Objectives: In this study we compared RA and PD before and after RA diagnosis in patients versus controls and analyzed the relationships between disease course and treatment of both conditions.

Methods: Retrospective dental and RA data were analyzed of 95 RA patients from 10 years before up to 10 years after RA diagnosis. Dental data were acquired from general practices and matched healthy control patient data from the university dental college. PD was analyzed via radiographic assessment using the new periodontal classification system from 2017. The relationship was analyzed between PD and RA parameters and treatment.

Results: More RA patients had severe or very severe PD compared to matched healthy controls, already before RA diagnosis. The fraction of RA patients with severe/very severe PD increased from 23% before diagnosis to 43% 5-10 years after diagnosis. Patients with a more severe PD before RA diagnosis had more tooth loss at last dental follow-up and a higher cumulative DAS28 in the years after diagnosis. Two-thirds of patients with severe/very severe PD received appropriate dental care less frequently than advised by guidelines. Suboptimal dental care was associated with a higher cumulative DAS28.

Conclusion: PD occurs before RA diagnosis in a proportion of patients. This proportion increases in the years after diagnosis. PD is associated with a decreased response to treatment of RA. A significant number of RA patients with PD receives suboptimal dental care, which is associated with diminished response to RA treatment.

REFERENCES:

Figure 1. periodontitis severity in the years before RA diagnosis was scored from stage 1 to 4 (mild, moderate, severe, very severe) according the periodontal classification system from 2017. The time averaged DAS28 was calculated by taking the mean of the available DAS28 scores in the first 10 years after diagnosis and correcting this for the time intervals during which these were acquired. Linear regression analysis was performed. * = P < 0.05.

Acknowledgements: Jill Hadisurya, Julia van Bergen, Floris Scholle, Isabelle van Dorp, Sabine Oerlemans, Arakseya Zakaryan for data collection, Thea van Gaalen for data management.

Disclosure of Interests: None declared.


POS0512

ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS DETERMINES 2-YEAR RETENTION OF IV AND SC ABATACEPT IN PATIENTS WITH RA IN A REAL-WORLD SETTING

R. Alten1, C. Rauch2, M. Charter3, M. T. Nurmohamed4, S. Connolly5, M. H. Buch6,7, P. Peichi8, X. Mariette9, Y. Patel10, S. Marsal11, R. Caporali12,13, H. Griffiths14, B. Sammarti15, B. Bannert16, Y. Ebiz17, K. Lozenk18, Schlosspark-Klinik, University Medicine Berlin, Germany; 2Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany; 3Bristol Myers Squibb, MESS France - Market Access, Rueil-Malmaison, France; 4ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands; 5Bristol Myers Squibb, Global Drug Development, Princeton, United States of America; 6University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 7University of Manchester, Division of Musculoskeletal & Dermatological Sciences, Manchester, United Kingdom; 8Evangelical Hospital, Department of Internal Medicine, Vienna, Austria; 9Université Paris-Saclay, AP-HP, Hospital Bicêtre, INSERM UMR1184, Department of Rheumatology, Le Kremlin Bicêtre, France; 10Hull Royal Infirmary, Rheumatology Unit, Hull, United Kingdom; 11Hospital Universitari Vall d’Hebron, Rheumatology, Barcelona, Spain; 12University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 13G. Pini Hospital, Clinical Rheumatology Unit, Milan, Italy; 14University Hospital Geelong, Barwon Rheumatology Service, Geelong, Australia; 15Hospital Clinic de Barcelona, Rheumatology Department, Barcelona, Spain; 16Universitätsspital Basel, Rheumatologische Universitätsklinik, Basel, Switzerland; 17Significance, Biostatistics, Paris, France; 18Bristol Myers Squibb, Immunology and Fibrosis, Princeton, United States of America

Background: A treat-to-target approach for RA management is recommended. However, up to half of patients discontinue DMARD treatment within 18 months. Predictive biomarkers, such as anti-citrullinated protein antibodies (ACPA) and RF, may be useful to stratify patients to the most appropriate treatment. ACTION (Abatacept in routine clinical practice; NCT02109666) and ASCORE (Abatacept SubCutaneously in Routine Clinical Practice; NCT02090556) were 2-year, international, observational, prospective, multicenter studies of IV and SC abatacept, respectively, for the treatment of RA in routine clinical practice.
Retention has been previously reported in patients with double ACPA/RF seropositive RA compared with double ACPA/RF seronegative RA.3,4

Objectives: To assess the independent effect of ACPA or RF single seropositivity on abatacept retention in patients with RA receiving abatacept in a post hoc analysis of ACTION and ASCORE.

Methods: This post hoc analysis included patients aged ≥ 18 years, with active moderate-to-severe RA (ACR/EULAR 2010 criteria) who initiated IV (body weight–adjusted dosing) or SC (125 mg once weekly) abatacept.3,4 Patients were stratified by baseline ACPA/RF status: ACPA+/RF− (ACPA+ only), ACPA+/RF+ (RF+ only), and ACPA+/RF− double negative (−/−). Abatacept retention rate at 2 years was estimated by Kaplan–Meier (KM) analysis.

Results: Patients with ACPA/RF serostatus data from the ACTION and ASCORE studies (N = 1679 and N = 1748, respectively) were evaluated. Baseline demographic and disease characteristics were similar across studies and serostatus groups (Table 1). In patients with ACPA+ only RA, abatacept retention rates were similar to the +/- group and greater than the RF+ only and −/− groups (Figure 1). In ASCORE (Figure 1A), retention rates were significantly higher in ACPA+ only and +/- groups when compared with the −/− group. In contrast, retention rates for patients with RF+ only RA were not significantly different vs −/− patients. Results were similar in ACTION, although the higher retention in the ACPA+ group did not reach statistical significance (Figure 1B).

Conclusion: In this post hoc analysis of the real-world ACTION and ASCORE studies, ACPA positivity was associated with an increased likelihood of retention over 2 years. Patients with ACPA+ only RA were equally as likely to be retained on abatacept as patients with ACPA/RF double positivity. In contrast, patients with RF+ only RA were less likely to be retained on abatacept over 2 years. These findings suggest that ACPA positivity played a more important role than RF positivity in abatacept retention. The higher retention seen in patients with ACPA+ only vs RF+ only disease demonstrates the key role of ACPA in RA and supports the importance of precision medicine in treating patients.

References:

Disclosure of Interests: Rieke Alten Speakers bureau: Abbvie, Bristol Myers Squibb. Medical writing and editorial assistance was provided by Fiona Boswell, PhD, of Caudex, and was funded by Bristol Myers Squibb. Study management provided by Syneos (CRO).

Table 1. Baseline demographics and disease characteristics by ACPA/RF status for the ASCORE and ACTION studies

<table>
<thead>
<tr>
<th></th>
<th>ACPA+ only</th>
<th>RF+ only</th>
<th>−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n = 184)</td>
<td>(n = 142)</td>
<td>(n = 343)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>58.2 (11.8)</td>
<td>57.4 (13.5)</td>
<td>578 (13.9)</td>
</tr>
<tr>
<td>DAS28 (CRP)</td>
<td>4.4 (1.1)</td>
<td>4.4 (1.0)</td>
<td>4.8 (1.2)</td>
</tr>
<tr>
<td>CDAI</td>
<td>25.8 (12.0)</td>
<td>23.6 (10.9)</td>
<td>28.2 (13.2)</td>
</tr>
<tr>
<td>SDAI</td>
<td>272 (12.4)</td>
<td>24.4 (10.8)</td>
<td>29.7 (13.9)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>(n = 1028)</th>
<th>(n = 161)</th>
<th>(n = 392)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>58.4 (13.4)</td>
<td>58.5 (14.0)</td>
<td>570 (13.3)</td>
</tr>
<tr>
<td>DAS28 (CRP)</td>
<td>4.9 (1.1)</td>
<td>4.9 (1.0)</td>
<td>5.0 (1.1)</td>
</tr>
<tr>
<td>CDAI</td>
<td>29.2 (12.4)</td>
<td>28.7 (11.5)</td>
<td>30.1 (12.9)</td>
</tr>
<tr>
<td>SDAI</td>
<td>31.2 (13.4)</td>
<td>29.8 (11.5)</td>
<td>31.7 (13.4)</td>
</tr>
</tbody>
</table>

Data are mean (SD). Patients with missing data for baseline ACPA/RF status are excluded.

incidence was slightly higher in pts with vs without prior FIL exposure, with the exposure had numerically higher median lymphocyte levels at LTE baseline in both treatment groups, median laboratory lymphocyte levels remained relatively stable over 1 year with lymphocyte decreases observed in individual FIL-treated pts. Lymphocyte levels should be monitored. Objectives: To assess the effect of FIL on lymphocyte levels and lymphopenia in the FINCH 4 long-term extension (LTE) study in RA. Methods: Safety data of FIL 100 mg (FIL100) and 200 mg (FIL200) from LTE baseline to data cut off (01 June 2020) are reported overall and by prior FIL exposure for pts who received ≥1 FIL dose in FINCH 4 (NCT03025308; adults with RA who had completed FINCH Week 1/2/3). Adverse events (AEs) of lymphopenia were graded based on clinical severity; laboratory abnormalities (decreased lymphocytes) were graded per Common Terminology Criteria for Adverse Events v4.03 (CTCAE). Frequencies of both measures and exposure-adjusted incidence rates (EIRs) of AEs are reported. Median lymphocyte levels are reported to LTE Week 48. Results: The safety analysis set included 2729 pts (FIL200: n=1530; FIL100: n=1199). Of these, 75.4% (n=2058) had prior FIL exposure in FINCH 1/2/3. Incidence was slightly higher in pts with vs without prior FIL exposure, with the difference most apparent for Grade 2 decreases.

Of all pts receiving FIL 43 (1.6%) reported a lymphopenia AE; frequencies and EIRs of lymphopenia AEs were slightly higher with FIL200 (1.9%; EIR [95% CI]: 1.2 [0.9–1.4]) vs FIL100 (1.2%; 0.8 [0.4–1.3]). Most were Grade 1 or 2 in severity. Grade 3 lymphopenia AEs occurred in 4 (0.3%) vs 1 (<0.1%) pts receiving FIL200 vs FIL100. There were no Grade 4 AEs in either group. No serious AEs of lymphopenia or treatment discontinuations due to lymphopenia were reported. In total, 8 (0.3%) pts interrupted study treatment due to lymphopenia. Infection rates, but not serious infections, were slightly higher for pts with lymphopenia, however no relationship between lymphopenia severity and infection AE grade was seen.

Conclusion: In FINCH 4, lymphopenia AEs were infrequent but numerically greater with FIL200 vs FIL100, suggesting a dose–response relationship. While exposure at either dose may be associated with decreased lymphocytes, median lymphocyte levels were comparable in both groups and all remained within normal range at LTE Week 48, similar to observations in FINCH 1–3.

REFERENCES:

Acknowledgements: The authors would like to acknowledge Nadia Verbrug- gen and Peter-Jan Stiers for providing statistical analysis support. This study was co-funded by Galapagos NV (Mechelen, Belgium) and Gilead Sciences, Inc. (Foster City, CA, USA). Medical writing support was provided by Kristian Clausen, MPH, CMP, Aspire Scientific Ltd, Bollington, UK), and funded by Galapagos NV.

Disclosure of Interests: Jacques-Eric Gottenberg Consultant of: AbbVie, Bristol Myers Squibb, Galapagos, Gilead, Lilly, and Pfizer, Grant/research support from: Bristol Myers Squibb, and Pfizer, Gerd Rüdiger Burmester Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Lilly MSD, Pfizer, Roche, and Sanofi, Katrien Van Beneden Shareholder of: Galapagos NV. Employee of: Galapagos NV, Chris Watson Shareholder of: Galapagos Biotech Ltd, Employee of: Galapagos Biotech Ltd, Ineke Seghers Employee of: Galapagos NV, Vijay Rajendran Employee of: Galapagos NV, Lorenzo Dagna Consultant of: AbbVie, Amgen, AstraZeneca, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly and Company, Galapagos, GlaxoSmithKline, Janssen, Kiniksa Pharmaceuticals, Novartis, Pfizer, Roche, Sanofi-Genzyme, and Swedish Orphan Biovitrum (SOFI), Grant/research support from: Bristol Myers Squibb, Celltrion, Kiniksa Pharmaceuticals, Pfizer, and Swedish Orphan Biovitrum (SOFI), Maya H Buch Speakers bureau: Speaker fees paid to host institution by AbbVie, Consultant of: Consultant honoraria paid to host institution by AbbVie, Galapagos, Gilead, and Pfizer, Grant/research support from: Gilead and Pfizer.

DOI: 10.1136/annrheumdis-2022-eular.888

Table 1. Frequencies of treatment-emergent laboratory decreases in lymphocytes

<table>
<thead>
<tr>
<th></th>
<th>Prior FIL exposure</th>
<th>No prior FIL exposure</th>
<th>Overall</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=1195)</td>
<td>(n=863)</td>
<td>(n=335)</td>
<td>(n=1530)</td>
</tr>
<tr>
<td>FIL200</td>
<td>159 (13.3)</td>
<td>82 (9.5)</td>
<td>21 (6.3)</td>
<td>108 (0.1)</td>
</tr>
<tr>
<td>FIL100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

A treatment-emergent laboratory decrease in lymphocytes was defined as an increase of ≥1 toxicity grade from baseline at any time post-baseline up to and including the date of last study drug dose +30 days. Severity grades were defined per CTCAE (lower limit of normal: <0.8 x 10^9/L [Grade 1]; <0.8–0.5 x 10^9/L [2]; <0.5–0.2 x 10^9/L [3]; <0.2 x 10^9/L [4]).
treatment (Figure 1). Baseline DAS28-ESR, anti-citrullinated protein antibody (ACPA) and health assessment questionnaire (HAQ) score were the top predictors of good response to MTX using LASSO (Area Under the Curve [AUC] 0.79) and Random Forest models (AUC 0.68) in the external validation set. DAS28-ESR≤7.4, ACPA positive and HAQ≤2 provided the highest likelihood of response (Table 1). Among patients with 12-week DAS28-ESR≤3.2, at least 1 point improvement in DAS28-ESR baseline-to-12-week was predictive of achieving DAS28-ESR≤3.2 at 24 weeks.

Table 1. Matrix prediction model: Probability of achieving a good response to methotrexate at 24 weeks

<table>
<thead>
<tr>
<th>DAS28ESR</th>
<th>ACPA Status</th>
<th>HAQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤7.4</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td>&gt;7.4</td>
<td>Negative</td>
<td>Negative</td>
</tr>
</tbody>
</table>

Figure 1. Two patient class trajectories identified with latent class modeling of DAS28-ESR (N=775)

Conclusion: We have developed and externally validated a prediction model for response to MTX within 24 weeks in DMARD-naïve patients with RA, providing variably weighted clinical features and defined cut-offs for clinical decision-making. Trajectory of DAS28-ESR change over 24 weeks in patients with moderate-to-high RA disease activity at baseline who are starting MTX can be predicted by baseline DAS28-ESR, ACPA status and HAQ-score. Patients with at least 1 unit decline in DAS28-ESR within the first 12 weeks of treatment who have not achieved low disease activity by week 12, may be more likely to achieve low disease activity at 24 weeks. These parameters should be considered as part of the clinical decision-making process when initiating MTX in DMARD-naïve patients with RA.

REFERENCES:
[1] Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of the clinical decision-making process when initiating MTX in DMARD-naïve patients with RA who have not achieved low disease activity by week 12, may be more likely to achieve low disease activity by week 12, and are more likely to achieve low disease activity by week 12, and are more likely to achieve low disease activity by week 12.

Background: Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular disease, including venous thromboembolic events (VTE). The reason behind the increased VTE risk is incompletely understood, but inherent features of RA, such as RA specific autoantibodies, could potentially play a role. For example, studies have linked occurrence and levels of rheumatoid factor (RF) in the general population to increased VTE risk. We and others have demonstrated an association between ACPA and risk of late ischemic cardiovascular events. There are also potential mechanistic links; citrullinated fibrinogen (cFib) has been associated to clot stability.

Objectives: We aimed to examine the association between anti-modified protein antibodies (AMPAs) and risk of VTE in RA.

Methods: We included 2809 individuals newly diagnosed with RA and included in the Swedish EIRA study 1996-2009. Through linkage to nationwide health care registers we identified past and incident events of VTE based on validated ICD code algorithms. We centrally typed baseline sera for anti-CCP2, 20 different ACPA sub-specificities, RF isotypes, carbamylated antibodies and 10 additional post-translational modifications. We followed all individuals from RA diagnosis until 1 year after the first VTE event, migration, death or end of study (2020-12-31) whichever occurred first. We used a Cox regression to estimate hazard ratios (HR) with 95% confidence intervals (CI). Individuals with a history of a VTE event (n=27) at RA diagnosis were excluded.

Results: We included 2782 individuals; 72% were women, median age at RA diagnosis was 54 years (inter quartile range (IQR) 18 years) and median follow-up time was 15.8 (IQR 6.8) years. During follow-up 177 incident VTE events were observed corresponding to an incidence of 5.0 per 1,000 person years.

Conclusion: We have developed and externally validated a prediction model for response to MTX within 24 weeks in DMARD-naïve patients with RA, providing variably weighted clinical features and defined cut-offs for clinical decision-making. Trajectory of DAS28-ESR change over 24 weeks in patients with moderate-to-high RA disease activity at baseline who are starting MTX can be predicted by baseline DAS28-ESR, ACPA status and HAQ-score. Patients with at least 1 unit decline in DAS28-ESR within the first 12 weeks of treatment who have not achieved low disease activity by week 12, may be more likely to achieve low disease activity at 24 weeks. These parameters should be considered as part of the clinical decision-making process when initiating MTX in DMARD-naïve patients with RA.

REFERENCES: 

Disclosure of Interests: Helga Westerlund: None declared, Alf Kastbom: None declared, Johan Rönnelid: None declared, Monika Hansson: None declared, K. Skriner, K. Bang, L. Klaarekog, S. Sævaarsdottir, K. Lundberg, C. Grönrvald, J. Askling, Karolinska Institutet, Department of Medicine, Solna, Stockholm, Sweden; Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden; Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden; Karolinska Institutet, Institute of Environmental Medicine (IMM), Stockholm, Sweden; Thermo Fisher Scientific, Thermo Fisher Scientific, Uppsala, Sweden; Université Toulouse III, Institut toulousain des maladies infectieuses et inffamatatoires - INFINITY, Toulouse, France; Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Stockholm, Sweden; Leibniz Institute, German Rheumatism Centre, Berlin, Germany; Charité - Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; ORGENTEC Diagnostika GmbH, Research & Development, Mainz, Germany; University of Iceland, Faculty of Medicine, School of Health Sciences, Reykjavik, Iceland.
PLASMA CALPROTECTIN WAS ASSESSED IN MULTIPLE BIOLOGICAL TREATMENT STRATEGIES FOR EARLY RHEUMATOID ARTHRITIS

D. Stevens, M. Heiberg, A. Kazemi, R. Van Vollenhoven, J. Lampa, A. Rudin, K. Lund, M. L. Helland, M. Ostergaard, M. Nurmohamed, K. Hørslev-Petersen, D. Nordström, B. Gudbjornsson, T. Uhlig, E. A. Haavardsholm, H. B. Hammer, St. Olavs Hospital, Dept of Rheumatology, Trondheim, Norway; Diakonhjemmet Hospital, Dept of Rheumatology, Oslo, Norway; Amsterdam University Medical Center, Amsterdam Rheumatology Clinic, Amsterdam, Netherlands; Karolinska University Hospital, Dept of Rheumatology, Stockholm, Sweden; Sahlgrenska University Hospital, Rheumatology Clinic, Gothenburg, Sweden; Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands; Karolinska Institute, Dept of Rheumatology, Stockholm, Sweden; Rigshospitalet, Center for Rheumatology and Spine Diseases, Glostrup, Denmark; Amsterdam University Medical Center, Location VUMc, Amsterdam, Netherlands; Kong Chr’s Hospital for Rheumatic Diseases, Dept of Rheumatology, Grästen, Denmark; Helsinki University Hospital, Division of Internal Medicine and Rheumatology, Helsinki, Finland; University of Iceland, Centre for Rheumatology, Reykjavik, Iceland

Background: Plasma calprotectin is a sensitive inflammatory marker in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Plasma calprotectin has not previously been studied in a head-to-head clinical trial of multiple biological mechanisms of action versus active conventional therapy (ACT) with methotrexate and prednisolone.

Objectives: To assess the effect of treatment on plasma calprotectin levels in patients with early RA by determining the 24-week change in the four arms of the NORD-STAR Study, a large multicenter randomized head-to-head clinical trial of active conventional therapy, CZP+MTX: certolizumab-pegol and methotrexate, ABA+MTX: abatacept and methotrexate, T2C-MTX: tocilizumab and methotrexate.

Methods: Calprotectin was analyzed in plasma samples at baseline, week 4 and week 24 from 400 treatment naive patients with early RA in the NORD-STAR Study. Samples were analyzed using a calprotectin ELISA alkaline phosphatase (ALP) kit from CalproLab (Oslo, Norway) in a Dynex DS2 processing system (normal levels ≤910 µg/L). Patients were assessed by clinical CRP, 28 SJC/TJC, physician global) and patients’ reported assessments. Crude and adjusted linear regression analyses were performed in R 4.0.3 with calprotectin levels at week 24 as the outcome. The four arms were represented by three dummy variables. The adjustment variables were age, sex, anti-CCP status and country. Both analyses were adjusted for baseline calprotectin levels.

Results: At baseline, the mean time since diagnosis was 15.7 days (SD) (22.9), mean age 53.7 (15.0) years, ACPA positive 81%, and female 66%. Mean calprotectin levels were 1931 (1495) µg/L at baseline, 866 (951) µg/L at week 4, and 629 (681) µg/L at week 24. At baseline, normal calprotectin levels (<910 µg/L) were observed in 27% of all patients (ACT 22%, certolizumab-pegol and methotrexate 30%, abatacept and methotrexate 25%, tocilizumab and methotrexate 31%). At week 24, normal calprotectin levels were observed in 82% of all patients (ACT 68%, certolizumab-pegol and methotrexate 91%, abatacept and methotrexate 80%, tocilizumab and methotrexate 90%). Observed calprotectin levels at week 24 were significantly lower in patients treated with certolizumab-pegol and methotrexate -336µg/L (97) (p = 0.006) or tocilizumab and methotrexate -284 (99) (p < 0.004), versus ACT when adjusted for age, sex, anti-CCP status, baseline calprotectin level, and country; however, a significant difference was not observed in patients treated with abatacept and methotrexate -110 (96) (p = 0.25). The Figure 1 shows the average percentage change in calprotectin levels from baseline to week 24 for all treatment groups.

Conclusion: Calprotectin, a sensitive biomarker of inflammation, normalized in the majority of patients. The decline differed between treatment groups and was largest in patients treated with a TNF inhibitor and methotrexate, suggesting that calprotectin reflects the activity of specific inflammatory pathways rather than overall inflammation. The findings of this study should be further explored.


Acknowledgements: I would like to acknowledge the NORD-STAR Study group.

Disclosure of Interests: David Stevens: None declared, Marte Heiberg: None declared, Amirhossein Kazemi: None declared, Ronald van Vollenhoven: None declared, Jon Lampa: None declared, Anna Rudin: None declared, Kristina Lend: None declared, Merete Lund Huteland: None declared, Mikkel Ostergaard: None declared, Michael Nurmohamed: None declared, Kim Horslev-Petersen: None declared, Dan Nordström Consultant of: Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Björn Gudbjornsson: None declared, Tili Uhlig: None declared, Espen A Haavardsholm: None declared, Hilde Berner Hammer Speakers bureau: AbbVie, Novartis, and Lilly.

IgA ACPA levels in RA patients versus healthy controls. Rather than prioritizing specificity, as is done for diagnostic tests, we aimed to define reliably detectable amounts of IgA ACPA, with both sensitivity and specificity not under 79% – 3 µg/mL for total IgA ACPA; 2.46 µg/mL for IgA1 and 0.6 µg/mL for IgA2 ACPA.

**Results:** Serum levels of both IgA ACPA subclasses were elevated in individuals at-risk, with no significant difference to patients with established IgA ACPA-positive RA. Interestingly, 41.4% of IgA ACPA-negative patients had detectable amounts of IgA ACPA; IgA1 ACPA, but not IgA2 ACPA levels were higher in individuals at-risk who developed RA in the next 14 months than in those who did not (4.54 vs. 2.85 µg/mL, p=0.03); and the percentage of those developing RA was higher in IgA1 ACPA-positive at-risk individuals (64.3% versus 35.3%). Interestingly, during the transition to RA, in the majority of IgA ACPA-positive individuals a decline in IgA1 ACPA levels at the time of RA diagnosis (-26%; p=0.085), as well as in the first months after the RA diagnosis (-38%; p=0.0002) was observed. This observation was confirmed in an independent cohort. IgA2 ACPA declined only after the diagnosis (33%; 10-64%; p=0.037), and no significant change was observed for IgG ACPA.

**Conclusion:** Both IgA ACPA subclasses were elevated in individuals at-risk for RA. Positivity for IgA1 ACPA was associated with the progression to RA in the next 14 months. IgA1 ACPA levels declined in the months preceding the diagnosis of RA and in the months after the diagnosis, which might reflect pathophysiological events happening at the time of the disease outbreak.

**Acknowledgements:** We thank Holger Bank from Orgentec Diagnostika, Mainz for the supply of CCP-coated plates.

**Disclosure of Interests:** Maria V Sokolova: None declared, Fabian Hartmann: None declared, Daniela Sieghart: None declared, Günter Steiner: None declared, Arnd Kleyer: Speakers bureau: Novartis, Lilly, Consultant of: Lilly, Gilead, Novartis, Abbvie, George Schett: Speakers bureau: Abbvie, BMS, Celgene, Janssen, Eli Lilly. Ulrike Steffen: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1049

### Table 1. Exposure-adjusted incidence rate (95% CI) of AEs per 100 PYE by baseline BMI

<table>
<thead>
<tr>
<th>FIL dose (mg)</th>
<th>BMI (kg/m²)</th>
<th>PYE</th>
<th>25</th>
<th>25–30</th>
<th>≥30</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>75700.2</td>
<td>25</td>
<td>25–30</td>
<td>≥30</td>
</tr>
<tr>
<td>TEAEs</td>
<td>200</td>
<td>34.5 (32.0, 37.1)</td>
<td>35.7 (33.0, 38.6)</td>
<td>36.6 (33.7, 39.8)</td>
<td></td>
</tr>
<tr>
<td>Serious TEAEs</td>
<td>100</td>
<td>44.3 (40.4, 48.6)</td>
<td>43.0 (38.9, 47.5)</td>
<td>45.3 (41.1, 50.0)</td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>100</td>
<td>5.3 (4.4, 6.4)</td>
<td>5.8 (4.8, 7.1)</td>
<td>7.1 (5.8, 8.5)</td>
<td></td>
</tr>
<tr>
<td>Serious infections</td>
<td>100</td>
<td>7.6 (6.0, 9.4)</td>
<td>6.5 (5.0, 8.4)</td>
<td>8.1 (6.4, 10.2)</td>
<td></td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>200</td>
<td>0.3 (0.1, 0.7)</td>
<td>0.5 (0.3, 1.0)</td>
<td>0.5 (0.3, 1.0)</td>
<td></td>
</tr>
<tr>
<td>Malignancy excluding non-melanoma skin cancer</td>
<td>200</td>
<td>0.5 (0.3, 1.0)</td>
<td>0.7 (0.4, 1.3)</td>
<td>0.5 (0.3, 1.1)</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** FIL did not substantially affect CFB in BW or BMI. FIL200±MTX was generally more efficacious vs controls regardless of baseline BMI, and the rate of TEAEs was similar across baseline BMI subgroups.

**REFERENCES:**

[1] Tofacitinib SmPC

[2] Baricitinib SmPC

[3] Upadacitinib SmPC


**Acknowledgements:** The FINCH studies were funded by Gilead Sciences (Foster City, CA, United States). We thank the physicians and patients who participated in the studies. Medical writing support was provided by Debbie Sherwood, BSc (Aspire Scientific Ltd, Bollington, UK) and funded by Galapagos NV (Mechelen, Belgium).

**Disclosure of Interests:** Alejandro Balsa Speakers bureau: Abbvie, Galapagos, Gilead, Lilly, Nordic, Pfizer, Sandoz, and UCB, Consultant of: Abbvie, Galapagos, Lilly, Nordic, Pfizer, and UCB, Grant/research support from: Abbvie, Pfizer, UCB, Sieghfried Wassenberg Speakers bureau; Abbvie, MSD, Pfizer, and Sanofi, Consultant of: Abbvie, Gilead, Lilly, Novartis-iKo, Pfizer, and UCB, Grant/research support from: Pfizer, Alejandro Tournadre Speakers bureau: Fresenius-Kabi and Sanofi, Paid instructor for: Fresenius-Kabi, Consultant of: Abbvie, Fresenius-Kabi, Lilly, Novartis, and Sanofi, Grant/research support from: Novartis, Pfizer, and UCB, Hans-Dieter Orzechowski Employee of: Galapagos, Katrien


POS0519

RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE


1Harbor-UCLA Medical Center, Division of Rheumatology, Torrance, CA, United States of America; 2University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary; 3Uppsala University, Department of Medical Sciences, Uppsala, Sweden; 4University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Division of Rheumatology, Omaha, NE, United States of America; 5Brigham and Women’s Hospital and Harvard Medical School, Department of Cardiovascular Medicine, Boston, MA, United States of America; 6Pfizer Inc, Inflammation and Immunology, Collegeville, PA, United States of America; 7Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America; 8Mayo Clinic, Division of Rheumatology, Rochester, MN, United States of America

Background: Uncontrolled rheumatoid arthritis (RA) activity and acute disease flares are associated with higher risk of adverse outcomes such as cardiovascular (CV) disease, venous thromboembolism (VTE), malignancy, and infection.1-4

Objectives: To evaluate associations of acute and cumulative Clinical Disease Activity Index (CDAI) measurements with major CV, malignancy, or infectious adverse events (AEs) of special interest in ORAL Surveillance.

Methods: ORAL Surveillance (NCT02092467) was a post-authorisation safety study of tofacitinib vs TNF inhibitors (TNFi) in patients (pts) aged ≥50 yrs with active RA despite methotrexate (MTX), and ≥1 additional CV risk factor. Pts were randomised 1:1:1 to tofacitinib 5 or 10 mg twice daily (BID) or subcutaneous TNFi. Two post hoc analyses were performed: (1) a time-varying multivariate Cox model examined risks of major AEs when pts were in CDAI-defined low (>2.8–≤10; LDA), moderate (>10–≤22; MDA) or high (>22; HDA) disease activity vs remission (≤2.8). The Cox model also included pt demographics, medical history, and TNFi. Two post hoc analyses were performed: (1) a time-varying multivariate Cox model examined risks of major AEs when pts were in CDAI-defined low (>2.8–≤10; LDA), moderate (>10–≤22; MDA) or high (>22; HDA) disease activity vs remission (≤2.8).

Results: 4362 pts were included. Mean RA duration at BL was approximately 10 yrs. All pts were on MTX at BL, and 28% had previously been on one other synthetic disease-modifying antirheumatic drug (DMARD). Overall, 10% of pts had LDA, MDA or HDA vs remission, they were potentially at higher risk of developing major adverse CV events (MACE), VTE and non-serious infections (NSIs) excluding herpes zoster (HZ), but not malignancies, serious infections or HZ (Figure 1).

Similarly, mean CDAI AUC trended higher for MACE, VTE and NSIs (Table 1).

Table 1. Cumulative CDAI (from BL to event) for pts with vs without events (AUC/yr)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Pts with events</th>
<th>LS mean AUC/yr</th>
<th>n</th>
<th>LS mean AUC/yr</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MACE</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>42</td>
<td>6275.4</td>
<td>1336</td>
<td>4607.3</td>
<td>0.0018*</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>50</td>
<td>5237.4</td>
<td>1306</td>
<td>4482.6</td>
<td>0.1253</td>
</tr>
<tr>
<td>TNFi</td>
<td>36</td>
<td>5234.5</td>
<td>1312</td>
<td>4851.5</td>
<td>0.5069</td>
</tr>
<tr>
<td>VTE</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>15</td>
<td>6546.7</td>
<td>1363</td>
<td>4614.4</td>
<td>0.0293*</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>31</td>
<td>6698.2</td>
<td>1323</td>
<td>4458.5</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>TNFi</td>
<td>8</td>
<td>6423.6</td>
<td>1339</td>
<td>4839.4</td>
<td>0.1907</td>
</tr>
<tr>
<td>Malignancy excl. NMSC</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>59</td>
<td>5249.3</td>
<td>1319</td>
<td>4618.9</td>
<td>0.6551</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>55</td>
<td>4793.7</td>
<td>1301</td>
<td>4482.2</td>
<td>0.0077</td>
</tr>
<tr>
<td>TNFi</td>
<td>39</td>
<td>4561.4</td>
<td>1301</td>
<td>4206.1</td>
<td>0.6551</td>
</tr>
<tr>
<td>Serious infections</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>127</td>
<td>5710.2</td>
<td>1242</td>
<td>4577.5</td>
<td>0.0004</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>150</td>
<td>5425.2</td>
<td>1197</td>
<td>4476.4</td>
<td>0.0013</td>
</tr>
<tr>
<td>TNFi</td>
<td>105</td>
<td>6058.4</td>
<td>1240</td>
<td>4807.7</td>
<td>0.0003</td>
</tr>
<tr>
<td>HZ</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>175</td>
<td>5184.5</td>
<td>1199</td>
<td>4738.1</td>
<td>0.1101</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>163</td>
<td>5549.1</td>
<td>1186</td>
<td>4481.3</td>
<td>0.0002</td>
</tr>
<tr>
<td>TNFi</td>
<td>56</td>
<td>6767.7</td>
<td>1291</td>
<td>4875.5</td>
<td>0.0930</td>
</tr>
<tr>
<td>NSIs excl. HZ</td>
<td></td>
<td></td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tofacitinib 5mg BID</td>
<td>760</td>
<td>6608.3</td>
<td>463</td>
<td>5122.5</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>Tofacitinib 10mg BID</td>
<td>750</td>
<td>6587.8</td>
<td>426</td>
<td>5009.6</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td>TNFi</td>
<td>722</td>
<td>6737.6</td>
<td>521</td>
<td>5217.3</td>
<td>&lt;0.0001*</td>
</tr>
</tbody>
</table>

*p<0.10. Data collected after pts who were randomised to tofacitinib 10mg BID had their dose reduced to 5mg BID were included in the tofacitinib 10mg BID groupLS, least squares; n, number of pts in analysis of variance model
**Conclusion:** In ORAL Surveillance, the risk of MACE, VTE and NSIs excluding H2 appeared higher when pts had active disease than when in remission. Greater cumulative RA disease activity was seen in pts who suffered these AEs vs those who did not. Our findings support treat-to-target recommendations for RA.

**REFERENCES:**


**Acknowledgements:** Study sponsored by Pfizer Inc. Medical writing support was provided by Karen Thompson, PhD, CMC Connect, and funded by Pfizer Inc.

**Disclosure of Interests:** George Karpouzas Speakers bureau: Sanofi-Aventis, Janssen

**Table 1.** Proportion of pts receiving statins at BL, by CV risk category

<table>
<thead>
<tr>
<th>n/N (%)</th>
<th>Overall</th>
<th>Tofacitinib</th>
<th>Tofacitinib</th>
<th>TNFi</th>
</tr>
</thead>
<tbody>
<tr>
<td>High (&gt;20%)/HxCAD</td>
<td>525/1370 (38.3)</td>
<td>168/435 (38.6)</td>
<td>193/475 (40.6)</td>
<td>164/460 (35.7)</td>
</tr>
<tr>
<td>Intermediate (7.5–&lt;20%)</td>
<td>302/1511 (20.0)</td>
<td>110/490 (22.4)</td>
<td>94/156 (18.2)</td>
<td>98/505 (19.4)</td>
</tr>
<tr>
<td>Low-borderline (&lt;7.5%)</td>
<td>178/1429 (12.5)</td>
<td>66/313 (12.9)</td>
<td>7/54/46 (12.8)</td>
<td>55/479 (11.7)</td>
</tr>
<tr>
<td>Diabetes (yes)</td>
<td>320/789 (40.6)</td>
<td>112/251 (44.2)</td>
<td>114/272 (41.9)</td>
<td>95/266 (35.7)</td>
</tr>
</tbody>
</table>

**POS0520**

**ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE**


1. Columbia University Vagelos College of Physicians and Surgeons, Division of Rheumatology, New York, NY, United States of America; 2. University of California, Division of Rheumatology, Department of Medicine, Los Angeles, CA, United States of America; 3. University of Manchester and NHIR Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 4. Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Department of Rheumatology, Paris, France; 5. PRES Sorbonne Paris-Cité, INSERM (U1153): Clinical Epidemiology and Biostatistics, Paris, France; 6. University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary; 7. Mayo Clinic, Division of Rheumatology, Rochester, MN, United States of America; 8. University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States of America; 9. Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of America; 10. Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America; 11. Pfizer Turkey, Inflammation and Immunology, Istanbul, Turkey; 12. Pfizer SVL, Inflammation and Immunology, Madrid, Spain; 13. Pfizer Inc, Inflammation and Immunology, Oslo, Norway; 14. Pfizer Inc, Inflammation and Immunology, Collegeville, PA, United States of America; 15. Brigham and Women’s Hospital and Harvard Medical School, Department of Cardiovascular Medicine, Boston, MA, United States of America

**Background:** ORAL Surveillance (NCT02092467) was a post-authorisation safety study of tofacitinib vs tumour necrosis factor inhibitors (TNFi) in patients (pts) with rheumatoid arthritis (RA) aged ≥50 years (yrs) with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to methotrexate (MTX). Statins are used to treat coronary artery disease (CAD) and are recommended by the American College of Cardiology/American Heart Association (ACC/AHA) for the management of pts at risk of atherosclerotic CV disease (ASCVD),1 such as those with ≥75% 10-yr risk of major adverse CV events (MACE) or diabetes mellitus.

**Objectives:** To examine the association between baseline (BL) statin use and MACE in ORAL Surveillance.

**Methods:** Pts with RA on stable MTX were randomised 1:1:1 to receive tofacitinib 5 or 10 mg twice daily (BID) or TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg once weekly). Pts were stratified post hoc by BL statin use (yes/no). Pts were further categorised by history of CAD (HxCAD). BL CV risk score divided per ACC/AHA guidelines1 (for pts without HxCAD); 10-yr risk of MACE per the ASCVD-pooled cohort equations risk calculator2 with a 1.5 multiplier applied3, and separately by BL diabetes status. CV risk score/BL diabetes status categories were: high (>20%)/HxCAD (yes), intermediate (≥7.5%–<20%) or low-borderline (<7.5%), and diabetes status (yes). For the overall population and each treatment group, risk of MACE was compared between BL statin use (yes vs no) via Cox analyses for each CV risk category and diabetes status (yes). Incidence rates (IRs; pts with first events/100 pt-yrs) and hazard ratios (HRs; BL statin use: yes vs no) were evaluated for adjudicated MACE.

**Results:** Of 4362 pts (tofacitinib 5 mg BID, n=1455; tofacitinib 10 mg BID, n=1456; TNFi, n=1451), 497 had a HxCAD, and 3813 without a HxCAD had CV risk scores determined. 789 had BL diabetes. Overall, 1020 (23.4%) pts reported BL statin use. Across CV risk score categories for all treatment groups, <50% of pts received statins at BL, with statin use highest in the high/HxCAD category (35.7–40.6%) and pts with diabetes (35.7–44.2%) (Table 1). Across categories, no interpretable associations between BL statin use and MACE were found. However, in the overall population, MACE IRs were lower in pts with vs without BL statin use in the high/HxCAD category and in pts with diabetes (Figure 1). In pts receiving tofacitinib 5 mg BID and TNFi, MACE IRs were lower in pts with vs without BL statin use across all categories (Figure 1).

**N, number of pts in each category; n, number of pts receiving BL statins:**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>High (≥20%)/HxCAD</th>
<th>Intermediate (7.5–&lt;20%)</th>
<th>Low-borderline (&lt;7.5%)</th>
<th>Diabetes (yes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>525/1370 (38.3)</td>
<td>302/1511 (20.0)</td>
<td>178/1429 (12.5)</td>
<td>320/789 (40.6)</td>
</tr>
<tr>
<td>Tofacitinib 5 mg BID</td>
<td>168/435 (38.6)</td>
<td>110/490 (22.4)</td>
<td>66/313 (12.9)</td>
<td>112/251 (44.2)</td>
</tr>
<tr>
<td>Tofacitinib 10 mg BID</td>
<td>193/475 (40.6)</td>
<td>94/156 (18.2)</td>
<td>7/54/46 (12.8)</td>
<td>114/272 (41.9)</td>
</tr>
<tr>
<td>TNFi 5 mg</td>
<td>164/460 (35.7)</td>
<td>98/505 (19.4)</td>
<td>55/479 (11.7)</td>
<td>95/266 (35.7)</td>
</tr>
</tbody>
</table>

**Conclusion:** In this post hoc analysis of data from ORAL Surveillance, most pts did not receive BL statin treatment. This suggests suboptimal CV risk management, particularly in pts at high risk of CV events. There was no interpretable association...
between BL statin use and MACE. However, pts in the higher risk categories, particularly those receiving tofacitinib 5 mg BID, had lower MACE IRs in vs without BL statin use. This analysis did not take into account initiation or dose adjustment of statin treatment during the study, and had low yrs of exposure in some categories.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Lauren Hogarth, CMC Connect, and funded by Pfizer Inc.


RISKS OF SEVERE INFECTION AFTER THE INTRODUCTION OF BDMAARDS IN NEWLY DIAGNOSED RHEUMATOID ARTHRITIS PATIENTS: A POPULATION-BASED INTERRUPTED-TIME SERIES ANALYSIS

Y V. Zhou1,2, D. Lacailla1,3, N. Lu1, J. Kopec1,4, Y. Qian1, B. Nosyk1,2, J. A. Avila-Zubeta1,3, J. Eisdale1,2, H. Xie1,2, 1Arthritis Research Canada, Research, Vancouver, Canada; 2Simon Fraser University, Health Sciences, Burnaby, Canada; 3University of British Columbia, Department of Medicine, Vancouver, Canada; 4University of British Columbia, School of population and public health, Vancouver, Canada; 5University of British Columbia, Sauder School of Business, Vancouver, Canada; 6Center for Health Evaluation & Outcome Sciences, Research, Vancouver, Canada.

Table 1. Results of interrupted time-series analysis of FSI/ASI rates, adjusting for age, gender, chronic obstructive pulmonary disease, Romano Charlson Comorbidity Index, diabetes, chronic kidney diseases, alcoholism, cancer, prior hospitalization with infection and socio-economic status at disease diagnosis year, using stepwise model selection

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Parameter</th>
<th>RA</th>
<th>Non-RA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadj. Diff (95% CI)</td>
<td>Adj. Diff (95% CI)</td>
<td>Unadj. Diff (95% CI)</td>
</tr>
<tr>
<td></td>
<td>p-value</td>
<td>p-value</td>
<td>p-value</td>
</tr>
<tr>
<td>FSI</td>
<td>Trend</td>
<td>0.63 (0.03, 1.23) 0.0441</td>
<td>0.68 (0.09, 1.27) 0.0292</td>
</tr>
<tr>
<td>Level (1 year post-intervention)</td>
<td>0.50 (-2.02, 2.99) 0.6899</td>
<td>0.31 (-1.88, 2.49) 0.7847</td>
<td>0.41 (-0.21, 1.03) 0.2041</td>
</tr>
<tr>
<td>5 years post-intervention</td>
<td>3.01 (-0.85, 6.87) 0.1331</td>
<td>3.02 (-0.48, 6.52) 0.0986</td>
<td>0.73 (-0.24, 1.73) 0.4133</td>
</tr>
<tr>
<td>ASI</td>
<td>Trend</td>
<td>1.84 (0.83, 2.84) 0.0029</td>
<td>1.85 (0.81, 2.89) 0.0011</td>
</tr>
<tr>
<td>Level (1 year post-intervention)</td>
<td>-1.21 (-5.41, 3.00) 0.5763</td>
<td>-1.44 (-5.44, 2.56) 0.4850</td>
<td>0.16 (0.42, 2.49) 0.0085</td>
</tr>
<tr>
<td>5 years post-intervention</td>
<td>6.14 (0.26, 12.01) 0.0466</td>
<td>5.97 (0.02, 11.93) 0.0560</td>
<td>2.60 (10.8, 4.12) 0.0017</td>
</tr>
</tbody>
</table>

Figure 1. Unadjusted rates.

Background: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are effective in suppressing inflammation and preventing joint damage. But bDMARDs may be associated with increased risk of severe infection. Evidence on this is contradictory with some studies showing increased risk, whereas others reporting no significant changes.

Objectives: To determine the impact of the introduction of bDMARDs on severe infection among patients newly diagnosed with RA compared with non-RA individuals.

Methods: In this age- and gender-matched cohort study using administrative health data for the population of BC, Canada, all incident RA patients diagnosed between 1995–2007 were identified. Non-RA individuals were randomly selected from the general control population to match with RA. Incident RA/ non-RA individuals were then divided into quarterly cohorts according to their diagnosis date. Two outcomes were examined: (1) first severe infection (FSI) after RA onset necessitating hospitalization or occurring during hospitalization; and (2) all severe infections (ASI) after RA onset. We calculated the 8-year FSI and ASI rate for each cohort. We conducted interrupted time-series analyses to compare levels and trends of FSI and ASI in RA and non-RA individuals diagnosed.
during pre-bDMARDs (1995–2001) and post-bDMARDs (2003–2007) periods. Adjusted 8-year FSI and ASI rates for RA and non-RA cohorts diagnosed five years after bDMARDs introduction were compared with expected rates assuming no bDMARDs introduction, based on extrapolation of pre-bDMARDs trends. Results: A total of 60,226 and 588,499 incident RA/non-RA individuals were identified. We identified 8,954 FSI and 14,245 ASI in RA, and 56,153 FSI and 79,819 ASI in non-RA. The 8-year FSI rates among RA patients diagnosed in the pre-bDMARDs period decreased over time but leveled off among those diagnosed in the post-period (Figure 1). The adjusted difference between the post- and pre-bDMARDs secular trends of 8-year FSI rates was 0.68 (p=0.03) in RA and 0.03 (p=0.67) in non-RA (Table 1). The 8-year ASI rates among RA patients diagnosed in the pre-bDMARDs period decreased over time but increased significantly among those diagnosed in the post-period (Figure 1). The adjusted difference between the post- and pre-bDMARDs secular trends of 8-year ASI rates was 1.85 (p=0.001) in RA and 0.12 (p=0.29) in non-RA (Table 1). For RA cohort diagnosed 5 years after bDMARDs introduction, ASI rate increased by 20.4% than expected rates assuming no bDMARDs introduction. In contrast, ASI rate in non-RA increased by only 10.9%.

Conclusion: Arthritis onset after bDMARDs introduction is associated with an elevated risk of severe infection in RA patients, compared with matched non-RA individuals.

Acknowledgements: We would like to thank the Ministry of Health of British Columbia and Population Data BC for providing access to the administrative data. All inferences, opinions, and conclusions drawn in this publication are those of the authors, and do not reflect the opinions or policies of the Data Stewards or the [British Columbia] Ministry of Health. No personal identifying information was made available as part of this study. Procedures were used in compliance with British Columbia’s Freedom in Information and Privacy Protection Act. Ethics approval was obtained from the University of British Columbia’s Behavioral Research Ethics Board (H15-00887).

Disclosure of Interests: None declared.


**POS0522** ASSOCIATED FACTORS WITH PHYSICAL DYSFUNCTION OF ELDERLY-ONSET RHEUMATOID ARTHRITIS TREATED WITH A TREAT-TO-TARGET STRATEGY

T. Sugihara1,2,3, T. Ishizaki2, H. Baba3, T. Matsumoto4, K. Kubo5, M. Kamuya6,7, F. Hirano1,3, T. Hosoya1,3, M. Kojima1, N. Miyasaki3, M. Harigai4, T. Tokyo Metropolitan Geriatric Hospital, Department of Medicine and Rheumatology, Tokyo, Japan; 2Tokyo Metropolitan Institute of Gerontology, Human Care Research Team, Tokyo, Japan; 3Tokyo Medical and Dental University, Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo, Japan; 4St. Marianna University School of Medicine, Division of Rheumatology and Allergy, Department of Internal Medicine, Tokyo, Japan; 5National Center for Geriatrics and Gerontology, Department of Frailty Research, Center for Gerontology and Social Science, Nagoya, Japan; 6Tokyo Women’s Medical University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan; 7National Center for Geriatrics and Gerontology, Department of Frailty Research, Center for Gerontology and Social Science, Nagoya, Japan.

Background: Achievement of normal physical function is an important outcome for older patients. Previous studies of younger cohorts showed that age, comorbidities, and joint damage influenced the physical function of patients with RA who achieved clinical remission or low disease activity (LDA). We previously demonstrated that a treat-to-target (T2T) strategy for methotrexate (MTX)-naïve elderly-onset RA (EROA) was effective with an acceptable safety profile. It showed that 60.9% of 197 patients achieved HAQ Disability Index (HAQ-DI) ≤0.5 at three years by following the T2T strategy targeting LDA (1).

Objectives: We aimed to evaluate associated factors with HAQ-DI in the T2T strategy targeting LDA for patients with EORA during three-year observational period.

Methods: Treatment was adjusted to target LDA with conventional synthetic disease-modifying antirheumatic drugs (DMARDs), followed by biological DMARDs (bDMARDs) in 197 MTX-naive EORA patients (mean age 74.9 years) with moderate-to-high disease activity. HAQ-DI was evaluated at week 0, 24, 52, 76, 104, 128, and 156. To evaluate associated factors with SDAI and HAQ-DI over the 36-month follow-up, Bayesian hierarchical logistic regression modeling was applied for 1067 periods from the 197 patients.

Results: At baseline, the enrolled 197 patients with EORA who had normal physical function (HAQ-DI ≤0.5) in 29.4%, HAQ-DI >0.5 and ≤1.5 in 36.5%, and HAQ-DI ≥1.5 in 33.0%, and the mean age (standard deviation [SD]) in each group was 72.7 (5.9), 74.8 (7.3), and 75.6 (6.7), respectively. Baseline SDAI increased in the group with higher HAQ-DI. The proportions of patients with each comorbidity and estimated creatinine clearance at baseline were not significantly different across the 3 groups. In the multilevel logistic model, the association of MTX, bDMARDs, and GC use with changes in SDAI in each period was evaluated. Age, sex, comorbidities (chronic lung disease, cardiovascular disease, history of malignancy, osteoporosis, history of serious infections, and osteoarthritis) were included as inter-individual factors. The model indicated that the use of bDMARDs was associated with a reduction of the SDAI (ΔSDAI: −9.75, SD 0.75, p<0.001), while neither MTX (ΔSDAI: −1.25, SD 1.13, p=0.270) nor GCs (ΔSDAI: −0.78, SD 0.88, p=0.372) was associated with changes in SDAI Chronic lung disease (ΔSDAI: 4.64, SD 1.44, p<0.001) and osteoporosis (ΔSDAI: 3.78, SD 1.46, p=0.001) at baseline were associated with the increment of SDAI. The association of age, sex, the comorbidities, and MTX, bDMARDs, and GC use with physical function in each period was evaluated by the multilevel logistic model. The model indicated that older age (ΔHAQ-DI: 0.03, SD 0.01, p<0.001), chronic lung diseases (ΔHAQ-DI: 0.30, SD 0.10, p<0.001), and osteoporosis (ΔHAQ-DI: 0.30, SD 0.10, p<0.001) at baseline were associated with the increment of HAQ-DI. When the mean SDAI during the observation period was added to the model as an inter-individual factor, the associations of HAQ-DI with the chronic lung diseases and osteoporosis at baseline were not statistically significant.

Conclusion: These data indicate that bDMARDs had a central role in reducing disease activity in the T2T strategy targeting LDA in EORA patients. Chronic lung diseases and osteoporosis at baseline were associated with increase in disease activity and worsening of physical function. However, disease activity had a greater impact on physical function than the comorbidities at baseline.

REFERENCES:

**POS0523** FATIGUE TRAJECTORIES IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: A LONGITUDINAL ANALYSIS OF DATA FROM THE CAREA TRIAL

M. Doumen1,2, S. Pazmino1, D. Bertrand1, D. De Cock1,3, J. Joly2, R. Westhovens1,2, P. Verschueren1,2, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; 2University Hospitals Leuven, Rheumatology, Leuven, Belgium; 3KU Leuven, Laboratory for Clinical and Experimental Endocrinology, Leuven, Belgium.

Background: Fatigue is a common and impactful symptom of rheumatoid arthri-
tis (RA). Given its heterogeneous and unpredictable nature, studies on contribut-
ing factors of RA-related fatigue should include multidimensional measures of
Objectives: We aimed to explore the longitudinal course of fatigue and its predictors among patients with early RA starting DMARD therapy.

Methods: Data came from the 2-year treat-to-target trial Care in early RA (CareRA) and its 3-year extension. Fatigue was measured based on visual analog scale (VAS), Multidimensional Fatigue Inventory (MFI), and Short-Form 36 (SF-36). Longitudinal fatigue trajectories were identified with multivariable growth mixture modeling. Baseline and early predictors of trajectory membership, including treatment response, were studied with multinomial logistic regression adjusted for age, gender, and treatment type. Patient global assessment (PGA), pain (VAS), and disability (HAQ) were studied in separate models because of collinearity (Spearman r > 0.60). For all models, posterior probabilities of trajectory assignment were included in the regression as weights to account for classification uncertainty. Treatment response was defined, based on whether remission (DAS28-CRP < 2.6) was achieved by week 16 and sustained until year 2, as either early persistent response, secondary failure, or delayed response.

Results: In total, 356 and 244 patients were included in the 2-year and 5-year analyses, respectively. Mean (SD) fatigue (VAS) at inclusion was 48/100 (24). Four fatigue trajectories were identified: Rapid Improvement, Gradual Improvement, Transient Improvement, and Early Deterioration, consisting of 10%, 14%, 56%, and 20% of patients, respectively (Figure 1). Higher PGA, pain and HAQ at baseline were associated with increased probability of Rapid Improvement compared to Transient Improvement or Early Deterioration (Table 2). Secondary treatment failure and delayed treatment response strongly increased the probability of less positive fatigue trajectories when compared to early persistent response.

Conclusion: The longitudinal course of fatigue in early RA is dynamic but highly refractory, with less than 25% of patients making lasting improvements and 20% even experiencing worsening fatigue despite intensive DMARD therapy. Remarkably, a higher perceived disease impact at baseline was associated with an increased probability of fatigue improvement, possibly reflecting the fluctuating nature of this complex symptom. However, early inflammatory disease control appears to be the most important contributor to improved long-term fatigue outcomes, illustrating the far-reaching impact of the therapeutic window of opportunity in early RA.

REFERENCES:

Disclosure of Interests: Michaël Doumen: None declared, Sofia Pazmino: None declared, Delphine Bertrand: None declared, Diedrik De Cock: None declared, Johan Joly: None declared, Rene Westhovens Speakers bureau: - Celltrion - Galapagos - Gilead, Consultant of: - Celltrion - Galapagos - Gilead, Patrick Verschueren Speakers bureau: - MSD - Eli Lilly - Galapagos, Consultant of: - Sanofi - Galapagos - Gilead - Pfizer, Grant/research support from: Pfizer Chair Management of Early Rheumatoid Arthritis at KU Leuven Belgium


Table 1. Predictors of fatigue trajectory membership

<table>
<thead>
<tr>
<th>Trajectory</th>
<th>Gradual improvement</th>
<th></th>
<th>Transient improvement</th>
<th></th>
<th>Early deterioration</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
<td>p</td>
<td></td>
</tr>
<tr>
<td>Fatigue (0-100)</td>
<td>1.01 (0.99; 1.04)</td>
<td>0.32</td>
<td>0.99 (0.97; 1.01)</td>
<td>0.16</td>
<td>0.98 (0.96; 1.00)</td>
<td>0.07</td>
</tr>
<tr>
<td>PGA (0-100)</td>
<td>0.98 (0.95; 1.01)</td>
<td>0.11</td>
<td>0.96 (0.94; 0.99)</td>
<td>0.003</td>
<td>0.95 (0.92; 0.98)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tender joints (0-28)</td>
<td>1.00 (0.91; 1.13)</td>
<td>0.82</td>
<td>1.00 (0.91; 1.09)</td>
<td>0.97</td>
<td>0.99 (0.88; 1.11)</td>
<td>0.80</td>
</tr>
<tr>
<td>Swollen joints (0-28)</td>
<td>1.01 (0.90; 1.15)</td>
<td>0.82</td>
<td>0.99 (0.89; 1.09)</td>
<td>0.83</td>
<td>0.93 (0.81; 1.06)</td>
<td>0.30</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>1.00 (0.98; 1.01)</td>
<td>0.67</td>
<td>0.99 (0.98; 1.01)</td>
<td>0.36</td>
<td>1.00 (0.97; 1.02)</td>
<td>0.66</td>
</tr>
<tr>
<td>Pain (0-100)</td>
<td>0.99 (0.96; 1.02)</td>
<td>0.36</td>
<td>0.96 (0.94; 0.98)</td>
<td>0.002</td>
<td>0.95 (0.92; 0.98)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HAQ (0-3)</td>
<td>1.07 (0.52; 2.20)</td>
<td>0.86</td>
<td>0.55 (0.30; 1.01)</td>
<td>0.05</td>
<td>0.24 (0.11; 0.51)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SF-36 Mental Component Score (0-100)</td>
<td>1.00 (0.96; 1.04)</td>
<td>0.97</td>
<td>1.02 (0.99; 1.06)</td>
<td>0.23</td>
<td>1.02 (0.98; 1.06)</td>
<td>0.34</td>
</tr>
<tr>
<td>Treatment response</td>
<td>2.22 (0.78; 6.32)</td>
<td>0.13</td>
<td>3.87 (1.57; 9.55)</td>
<td>0.003</td>
<td>7.88 (2.68; 23.13)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Secondary failure</td>
<td>2.93 (0.70; 12.15)</td>
<td>0.14</td>
<td>6.82 (1.91; 24.44)</td>
<td>0.003</td>
<td>11.14 (2.33; 53.19)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Figure 1. Latent trajectories of fatigue evolution over the first 2 years in CareRA (n = 356).
Background: Composite disease activity ratings, which are used to assess the severity of rheumatoid arthritis (RA), may not effectively reflect the illness’s spatial impact on the hands. In RA, assessments of handgrip strength (HGs) and functional deficits are a kind of objective examination that focuses on the hands. Objectives: The goal of this study was to see if there was a link between joint inflammation and damage in the wrists and hands, as measured by ultrasound (US) and magnetic resonance imaging (MRI), functional disability as measured by hand-specific self-report questionnaires, and composite disease activity indices. Methods: Sixty-six female patients with RA were investigated (age 55.6 ± 12.2 years, range 20-80 years; disease duration 4.4 ± 3.0 years). The DAS28-CRP, the SDAI, the CDAI, and US and MRI scoring techniques such as the Ultra-Sound-Clinical Arthritis Activity (US-CLARA) and modified Simplified Rheumatoid Arthritis Magnetic Resonance Imaging Score (SAMIS) were all used as baseline assessments (mod SAMIS) (Figure 1). Without contrast injection, the mod SAMIS score was rated for the presence/absence and semiquantitative assessments of synovitis, bone erosion (ERO), and bone marrow edema (BME). All patients had HGs and completed the shortened Disability of Arm, Shoulder, and Hand Questionnaire (QuickDASH), the Arthritis Impact Measurement Scales hand and finger function subscale, and the upper extremity function sub-score of the ROAD. Results: The mod SAMIS total score and the US-CLARA had a strong correlation (rho=0.377, p=0.0018) for all patients. Among the SAMIS sub-indices, there was a significant relationship between mod SAMIS bone oedema (SAMIS-BME) and US-CLARA (rho=0.799, p<0.001) and mod SAMIS synovitis (SAMIS-synovitis) and US-CLARA (rho=0.539, p<0.001). There were also significant negative relationships between the HGs score and the mod SAMIS total score and US-CLARA (rho = -0.309, p=0.011 and rho = -0.775, p<0.0001, respectively). The HGs and disease activity composite indices, as well as hand-specific self-report questionnaires, were shown to have high relationships (p<0.0001) in individuals with RA. The hand and finger function sub-scales, as well as the mod SAMIS erosion (SAMIS-ERO) and HGs, exhibited no significant relationship. For each of the three components, interobserver agreement was good to excellent (intraclass correlation values = 0.713, 0.912, and 0.821, respectively) (synovitis, BME, and BM (Figure 2). Conclusion: BME and synovitis have an impact on upper-extremity function. The US-CLARA and mod SAMIS total score are promising solutions for semi-quantitative evaluation of joint inflammation and damage in RA. These shortened scores might cut down on image processing time in US and MRI-controlled RA investigations, as well as make using these imaging modalities in RA treatment response evaluation studies simpler.

REFERENCES:

Disclosure of Interests: None declared.

POS0525 ARE BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ASSOCIATED WITH WORK PARTICIPATION IMPROVEMENT IN EARLY RHEUMATOID ARTHRITIS? A SYSTEMATIC REVIEW AND META-ANALYSIS

M L Marques1,2, A Alunno3, L Falzon4, A Boonen5,6, S Ramiro1,7. 1Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Centro Hospitalar e Universitario de Coimbra, Rheumatology, Coimbra, Portugal; 3University of Uqulita, Internal Medicine and Nephrology Unit, MeSWA Department, Uquila, Italy; 4The University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Sheffield, United Kingdom; 5Maastricht University Medical Center, Internal Medicine, Maastricht, Netherlands; 6Maastricht University, Care and Public Health Research Institute (CAPHRI), Maastricht, Netherlands; 7Zuyderland MC, Rheumatology, Heerlen, Netherlands

Background: In early RA, the benefit of treatment with b-/tsDMARDs on work participation (WP), a top-three social role in RA, has seldom been studied. Objectives: To review the effect of treatment with b-/tsDMARDs on employment status (ES), presenteeism and sick leave (SL), in patients with early RA. Methods: A systematic literature review (SLR) was conducted in key electronic databases up to October 2021, to include RCTs assessing the effect of treatment with b-/tsDMARDs vs any comparator on ES, presenteeism and SL in patients with RA (≤3y). Two reviewers independently identified eligible studies and extracted data. Random-effects meta-analysis was only performed if ≥3 studies were conducted in comparable populations, assessing WP outcome similarly. Statistical heterogeneity was assessed with $I^2$.

Results: From 7129 records (65 full-text articles screened), 11 RCTs were included in the SLR (7 in csDMARD naïve patients; 2 in inadequate responder to csDMARDs; 1 bDMARD tapering after initial combination with MTX, and 1 strategy study). Large heterogeneity was found across WP outcomes, measured using instruments, interventions and comparators (Table 1), which together with insufficient data reporting hampered meta-analysis of most outcomes. For ES, to allow meta-analysis, all outcomes were converted to employment loss, for which individual study Odds ratios (OR) were computed. The pooled OR of 4 studies with 779 patients treated with adalimumab, infliximab or baricitinib (Figure 1) showed a lower likelihood of employment loss at weeks 58 to 104 in those treated with MTX+b-tsDMARDs compared to MTX+PBO (OR: 0.65; 95% CI:0.43-0.99). For presenteeism and SL, 33/40 (83%) between-group comparisons showed improvement in favour of b-tsDMARDs, but an effect size was reported or possible to compute for only 12 comparisons, of which 8 (67%) were statistically significant.

Figure 1. The modified simplified SAMIS magnetic resonance score (mod SAMIS) scoring spreadsheet. The MRI was graded for the presence/absence of synovitis and semiquantitative ratings of bone marrow oedema and bone erosion, without contrast injection.

Table 1. Comparison of Health Outcomes in Early RA (≤3 years) between csDMARD naïve patients and inadequate responders treated with b-/tsDMARDs.
**Table 1. Overview of between-group results**

<table>
<thead>
<tr>
<th>Author, Study name</th>
<th>Intervention (I) Comparator (C)</th>
<th>Follow-up (weeks)</th>
<th>Assessed Instrument</th>
<th>Assessed Outcome</th>
<th>Favour intervention (+ yes; - no)</th>
</tr>
</thead>
<tbody>
<tr>
<td>csDMARD naive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smolen 2006</td>
<td>IFX+MTX</td>
<td>54</td>
<td>SCMI</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>ASPIRE</td>
<td>PBO+MTX</td>
<td></td>
<td>SL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bejarano 2008</td>
<td>ADA+MTX</td>
<td>56</td>
<td>Weekly</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>PBO+MTX</td>
<td>SL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anis 2009</td>
<td>ETN+MTX</td>
<td></td>
<td>SL</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>COMET</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>van den Hoorn 2009</td>
<td>I: IFX+MTX</td>
<td>104</td>
<td>SCS1</td>
<td>+ vs C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C: seq.</td>
<td></td>
<td>Pres VAS (0-100)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BeSt monotherapy</td>
<td>C2: step-up comb.</td>
<td>Therapy + IFX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>vs C</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C3: initial comb.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>van Vollenhoven 2010</td>
<td>I: ADA+PBO</td>
<td>SCMI</td>
<td>+ vs C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C: PBO+MTX</td>
<td></td>
<td>SL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PREMIE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Emery 2016</td>
<td>ADA+MTX</td>
<td>24-26</td>
<td>OPTIMA + PROWD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBO+MTX</td>
<td>SL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wiland 2016</td>
<td>I: ETN25/MTX</td>
<td>117</td>
<td>WPAI-RA</td>
<td>39W &amp; 65 W + I</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>39W &amp; 65 W + I</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>vs C</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STRAND 2021</td>
<td>I: UPA 30</td>
<td>Overall</td>
<td>12</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>work</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IMPAIR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SELECT E2015</td>
<td>I: UPA 15</td>
<td>C: MTX</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IMPAIR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD inadequate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>responders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eriksson 2015</td>
<td>IFX + MTX</td>
<td>Registy</td>
<td>7 y</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Sweft</td>
<td></td>
<td></td>
<td>C: csDMARD + MTX</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fleischmann 2016</td>
<td>ADA+MTX</td>
<td>WPAI-RA</td>
<td>104</td>
<td>24.56 &amp; 104w</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AMPL6</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCMI – self composed multiple items;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCS1 – self composed single item;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WPAI – Work Productivity Activity Impairment questionnaire</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>/csDMARD-naive patients treated with MTX+b-mdsDMARDs compared to MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>monotherapy. The methodological heterogeneity and insufficient reporting hampers clear conclusions regarding the beneficial effects of b-SDMARDs on presenteeism and SL. Efforts to uniformize future studies with WP as outcome by following recently developed points to consider are crucial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** A protective effect against employment loss was observed in patients with early RA treated with MTX+b-mdsDMARDs compared to MTX monotherapy. The methodological heterogeneity and insufficient reporting hampers clear conclusions regarding the beneficial effects of b-SDMARDs on presenteeism and SL. Efforts to uniformize future studies with WP as outcome by following recently developed points to consider are crucial.

**REFERENCES:**

**Disclosure of Interests:** Mary Lucy Marques: None declared, Alessia Alunno: None declared, Louise Falcon: None declared, Annelies Boonen Speakers Bureau: Abbvie/Galapagos, Consultant of: Galapagos, Grant/research support from: Abbvie, Sofia Ramiro: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1363
Methods: In a single centre prospective observational cohort of anti-CCP positive individuals with new musculoskeletal symptoms but without clinical arthritis, 394 individuals with at least 3 available longitudinal datapoints including first, second and last recordings (progression excluded), were selected. Data on anti-CCP2 antibodies (CCP2), rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), early morning stiffness duration (EMS), tender joint count on examination (TJC28), health assessment questionnaire (HAQ), absence from work in the last 3 months (sick days), and ultrasound power Doppler signal (PD) grade ≥ 1 in small joints, were assessed. Mixed model analysis on repeated measures (MANOVA) were performed, missing data were not imputed.

Results: Of the 394 selected individuals, 82 (21%) progressed to IA. In those who progressed, last visit was at a mean (SD) of 6.1 (8) months prior to progression, and total follow-up duration was 33.7 months (26.7) versus 46.5 months (30.2) for those who did not.

Within group analysis: in the progresor group there was a significant increase in the value of biomarkers at the visit prior progression for CCP2+, RF+, EMS, HAQ, and the number of joints with a PD grade ≥ 1 (Figure 1, Table 1). For sick days from prior work last visit, the increase was non-significant.

Table 1. Mixed model ANOVA on repeated measures: pairwise comparison

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Analysis between groups</th>
<th>Analysis within groups</th>
<th>Within subject effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCP2</td>
<td>NP: 71 (108) P=0.001 F(2/257)=3</td>
<td>P=1.000 F(2/257)=4</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>RF</td>
<td>NP: 37 (73) P=0.001 F(2/165)=15</td>
<td>P=0.973 F(2/165)=0.084</td>
<td>P=0.001</td>
</tr>
<tr>
<td>ESR</td>
<td>NP: 11 (9) P=0.001 F(2/22)=1</td>
<td>P=0.614 F(2/22)=0.1</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>EMS</td>
<td>NP: 26 (68) P=0.010 F(2/710)=4</td>
<td>P=1.000 F(2/710)=0.018</td>
<td>P=0.011</td>
</tr>
<tr>
<td>TJC28</td>
<td>NP: 5.1 (15) P=0.001 F(2/784)=10</td>
<td>P=1.000 F(2/784)=0.005</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Number of sick days</td>
<td>NP: 0.7 (2) P&lt;0.001 F(2/218)=4</td>
<td>P=0.055 F(2/218)=0.05</td>
<td>P=0.001</td>
</tr>
<tr>
<td>PD ≥ 1</td>
<td>NP: 0.5 (0.6) P=0.105 F(2/249)=4.25</td>
<td>P=1.000 F(2/249)=0.009</td>
<td>P=0.086</td>
</tr>
<tr>
<td>HAQ</td>
<td>NP: 2 (6) P=0.204 F(2/236)=4</td>
<td>P=0.492 F(2/236)=0.021</td>
<td>P&lt;0.001</td>
</tr>
<tr>
<td>Number of joints</td>
<td>NP: 4 (13) P&lt;0.001 F(2/304)=10</td>
<td>P=0.049 F(2/304)=0.049</td>
<td>P=0.021</td>
</tr>
</tbody>
</table>

NP: Non progressors. P: progressors. P<: Partial p< for these results the assumption of homogeneity of variance was violated, as assessed by Levene’s test for equality of variances.

In the non-progresor group, only TJC28 and sick days showed significant decrease between first and last visit.

Between groups analysis showed significant differences at last visit for the following biomarkers -CCP2+, RF+, ESR, EMS, TJC28, and number of joints PD grade ≥ 1. The difference in HAQ and sick days was non-significant (Figure 1, Table 1). A significant difference was also shown in all visits for CCP2 + and RF +, and at the second visit for TJC28. For PD grade ≥ 1, differences at last visit within progresor group and between groups were only significant after selection of last visits < 3 months before progression.

Conclusion: These results show for the first time significant changes in relevant biomarkers prior to progression to IA with individual biomarkers having different trajectories. Clinical markers (EMS, TJC28, and HAQ) and ultrasound changed late, whilst immunological (CCP2 and RF values) and inflammation biomarkers (ESR) were different from baseline. These data provide valuable information for longitudinal monitoring of biomarkers, further analysis will show if these changes have predictive value for imminent progression to IA.

Disclosure of Interests: Laurence Duquenne: None declared, Kate Hamden: None declared, Leticia Garcia-Montoya: None declared, Navikiran Sidhu: None declared, Kulveer Mankia: None declared, Jacqueline Nam: None declared, Uber Delfin: None declared, Anna Zejden: None declared, Jesper Thygesen: None declared, Anne-Birgitte Blavnsfeldt: None declared, Bente Langhøj: None declared, Bente Mørk: Consultant of: BLL has worked as a consultant of Aarhus University Hospital from Danish Regions Medicine Grants, Roche, Novartis, and the Novo Nordic Foundation.

DOI: 10.1136/annrheumdis-2022-eular.1411

ANTICCP POSITIVE INDIVIDUALS AT RISK OF PROGRESSION TO INFLAMMATORY ARTHRITIS: WHAT HAPPENS TO BIOMARKERS PRIOR TO PROGRESSION?

L. Duquenne1,2, K. Hamden1,2, L. Garcia-Montoya1,2, N. Sidhu1,2, J. Nam1,2, K. Mankia1,2, P. Emery1,2, *University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, LEEDS, United Kingdom; †NIHR, Leeds Biomedical Research Centre, LEEDS, United Kingdom

Background: Although many predictors of progression to inflammatory arthritis (IA) have been identified at first visit in individuals at risk of developing IA, their fluctuation during follow-up is largely unknown.

Objectives: To describe the changes in relevant biomarkers, which precede arthritis development in anti-CCP positive at risk individuals.

Figure 1: Mixed model ANOVA on repeated measures
BACKGROUND: According to the current EULAR recommendations for the management of rheumatoid arthritis (RA), methotrexate (MTX) should be started as soon as RA is diagnosed and rapidly optimized to achieve remission. Nonetheless, it has been estimated that a difficult-to-treat (D2T) MTX disease occurs in 3-10% of RA patients. Herein, we hypothesized that D2T-RA can be prevented with an optimal MTX treatment in early stages.

OBJECTIVES: The main objective of this study was to demonstrate an association between successful optimization of MTX treatment within two years of RA diagnosis and development of a status of D2T-RA later in the disease course.

METHODS: In 2016 we started a ‘Refractory RA’ clinic at the Rheumatology Unit, University of Padua, Italy. In this retrospective cohort study conducted in December 2021, we enrolled patients fulfilling both the ACR/EULAR 2010 criteria for RA and the EULAR definition of D2T-RA diagnosed after 2000. We compared D2T-RA patients with non-D2T-RA controls from the same clinic having similar sex distribution and year of diagnosis. The primary outcome was the status of D2T-RA. The exposure was ‘MTX optimization’ after two years from diagnosis, as assessed with a numeric score (the sum of the following binary variables concerning MTX therapy: starting within 3, 12 or 24 months from diagnosis; adequate dose ≥15 mg weekly; treatment duration≥6 months; early intolerance≤3 months; range 0 to 6, with higher scores reflecting better optimization). We used multiple logistic regression analysis to examine the association (odds ratio (OR)) between MTX optimization scores and the outcome, controlling for potential modifiers (age, sex, body mass index, age at onset, and anti-citrullinated peptides antibodies (ACPA)).

RESULTS: There were 37 D2T RA patients and 107 non-D2T RA controls for the analysis (mean (SD) disease duration 12.8 (4.1) vs. 12.6 (4.6), p=0.621). Per protocol, gender (females 77.3% vs. 82.0%, p=0.247) and year of diagnosis (median [25th, 75th percentile]: 2008 [2004, 2011] vs. 2008 [2003, 2012]) were comparable between groups. Optimization of MTX therapy was poor overall, yet MTX optimization scores were significantly higher in D2T-RA than in non-D2T-RA patients (1.06 (0.21) vs. 0.56 (0.14), p<0.001). In multiple logistic regression, MTX optimization was protective against D2T-RA. Indeed, the likelihood of D2T-RA was decreased by 34%-54% according to MTX optimization scores. Other disease characteristics significantly associated with D2T-RA were an older age at diagnosis and female sex (Table 1). In December 2021 (last follow-up), D2T-RA patients were receiving a significantly higher daily dose of prednisone (4.3 (1.4) vs. 0.5 (0.2), p<0.001), and had a numerically greater burden of comorbidities (median 3 [1, 4] vs. 2 [1, 3], p=0.252) and disease activity (DAS28-ESR: 3.41 (0.40) vs. 2.6 (0.19), p=0.053) than non-D2T-RA patients.

Table 1. Early factors associated with difficult-to-treat rheumatoid arthritis (multivariable logistic regression)

<table>
<thead>
<tr>
<th>B</th>
<th>SE</th>
<th>P-value</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTX optimization score</td>
<td>-0.599</td>
<td>0.092</td>
<td>&lt;0.001</td>
<td>0.549</td>
</tr>
<tr>
<td>Age, years</td>
<td>0.033</td>
<td>0.008</td>
<td>&lt;0.001</td>
<td>1.034</td>
</tr>
<tr>
<td>Sex (female vs males)</td>
<td>0.723</td>
<td>0.287</td>
<td>0.012</td>
<td>2.061</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>-0.006</td>
<td>0.018</td>
<td>0.748</td>
<td>1.006</td>
</tr>
<tr>
<td>ACPA (positive vs negative)</td>
<td>0.431</td>
<td>0.2450</td>
<td>0.079</td>
<td>1.539</td>
</tr>
</tbody>
</table>

ACPA, anti-citrullinated peptide antibodies; B, unstandardised beta coefficient; BMI, body mass index; MTX, methotrexate; SE, standard error.

Conclusion: DT2-RA may be prevented by optimization of MTX therapy within two years of RA management.

REFERENCES:

Disclosure of Interests: Sascha Heckert: None declared, S. A. Bergstra, Y. Goekoop-Ruiterman, M. Güler-Yüksel, W. Lems, M. Van Oosterhout, T. Huizinga, C. Allaart, L. University Medical Center (LUMC), Leiden, Netherlands; H. Zagari, Rheumatology, Den Haag, Netherlands; Maastricht University, Rheumatology, Rotterdam, Netherlands; Amsterdam University Medical Center, Rheumatology Amsterdam, Netherlands; Groene Hart Hospital, Rheumatology, Gouda, Netherlands

Disclosure of Interests: Previous study was funded by a research grant from the Dutch College of Health Insurances with additional funding from Schering-Plough BV and Centocor Inc.

Molecular signature in sustained clinical remission induced by tocilizumab in patients with rheumatoid arthritis

N. Keio1, K. Suzuki1, K. Matsumoto2, H. Iijima3, S. Nakamura5, Y. Ishizawa4, J. Inamo1, M. Takeshita1, K. Yoshimoto1, Y. Kaneko1, T. Takeuchi1, K. Keio University, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tokyo, Japan; 2DNA Chip Research Inc, Research Division, Tokyo, Japan

Background: Clinical remission is a clinical goal in the treatment of rheumatoid arthritis (RA). Sustained, biologics-free and true remission is an unachieved goal of the “treat-to-target” approach in most patients, and the determinants for achievement are still unclear. In our recent prospective study using multiomics analysis, we proposed that a molecular signature in peripheral whole blood can be a predictor for subsequent disease activity or activities of daily living. We also showed that tocilizumab (TCZ) induced deep clinical remission associated with gene expression in peripheral CD4+ T cells.

Objectives: To consolidate and expand our hypothesis, we investigated the significance of molecular signatures in sustained remission in a larger scale cohort.

Methods: To build and validate the diagnostic model, we collected 73 peripheral blood samples from 30 patients with active RA, 30 patients in clinical remission induced by TCZ and 13 healthy controls. Then we collected another 23 samples at a point before TCZ was halted due to sustained clinical remission. In total, 96 samples were analyzed by a multiomics platform, which included RNA sequencing and comprehensive proteomics.

Results: We first developed an optimized partial least-squares regression (PLSR) model using data from 5,436 genes and 255 proteins extracted in our previous model. The odds ratio in the model clearly reflected the clinical state at a molecular level. To clarify the characteristics of the molecular signature at sustained clinical remission under TCZ continuation, 23 samples were applied to the model. The odds ratio was largely the same as that for clinical remission. Next, we investigated the association with disease flare after cessation of TCZ. At some points before cessation, the median odds ratio in patients who experienced disease flare after stopping TCZ tended to be higher than that in patients with sustained remission after stopping TCZ in the transcriptomics model but not in the proteomics model. Thirty-five differentially expressed genes were identified between the two groups under the conditions of a >1.5-fold change and P-value<0.05.

Conclusion: Our larger scale study validated the idea in our previous study that TCZ induces molecular remission. A certain substantial gap associated with the previous model. The odds ratio in the model clearly reflected the clinical state at a molecular level.

References:

Graphs:

Acknowledgements: We acknowledge funding by Chugai Pharmaceutical Co., Ltd.

Disclosure of Interests: Nobuhiko Kajio: None declared, Katsuya Suzuki Speakers bureau: AbbVie, AsahiKasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Gilead, Janssen, Mitsubishi Tanabe, Pfizer, Sanofi, Visa-tris, Consultant of: AbbVie, Asahi Kasei, Janssen, Pfzer, Grant/research support from: Chugai, Daiichi-Sankyo, Eli Lilly, Mitsubishi Tanabe, Ono, Takeda, Kotaro Matsumoto: None declared, Hiroshi Iijima: None declared, Seiji Nakamura: None declared, Yohei Ishizawa: None declared, Jun Inamo: None declared, Masaru Takeshita: None declared, Keiko Yoshimoto: None declared, Yuko Kaneko Speakers bureau: Chugai, Consultant of: Chugai, Grant/research support from: Chugai, Tsumoru Takeuchi Speakers bureau: Chugai, Consultant of: Chugai, Grant- research support from: Chugai.

DOI: 10.1136/annrheumdis-2022-eular.1680

Abatacept delays the development of RA—clinical results after 18 months from the randomized, placebo-controlled ARIAA study in RA-at-risk patients

J. Rech1, A. Kleyer1, M. Ostergaard2, M. Hagen2, L. Valor3, K. Tiscallar2, G. Krönke1, V. Schönau1, S. Kleinert1, X. Baraliakos1, J. Braun1, M. Fleck1, A. Rubbert-Roth1, F. Behrens1, M. Feuchtenberger1, M. Zanekin1, D. M. Koffler1, R. Völ1, E. Glaser1, A. Hueber1, E. Feist1, G. R. Burmester1, K. Karberg1, J. Strunk15, J. D. C. Hatele1, L. Senolt1, E. Naredo16, G. Schett1, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, University of Erlangen-Nuremberg, Department of Internal Medicine - 1 Rheumatology and Immunology, Erlangen, Germany; 2University Hospital Rigshospitalet, Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Copenhagen, Glostrup, Denmark; 3Rheumatology Clinical Practice Erlangen, Rheumatology, Erlangen, Germany; 4Ruhr University Bochum, Department of Rheumatology, Bochum, Germany; 5Rheumazentrum Ruhrgebiet, Rheumazentrum Ruhrgebiet, Herne, Germany; 6Asklepios Klinikum Bad Abbach, Klinik und Poliklinik für Rheumatologie, Klinikum, Immunologie, Bad Abbach, Germany; 7Kantonsspital St. Gallen, Klinik für Rheumatologie, St. Gallen, Switzerland; 8Rheumatology University Hospital Frankfurt, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP Fraunhofer Cluster of Excellence for Immunemediated Disease CIMD, Frankfurt, Germany; 9MED | BAYER OST GmbH, Fachbereich Rheumatologie, Burghausen, Germany; 10Immannel Klinikum Bernau, Herzzentrum Brandenburg, Abteilung Innere Medizin, Bernau, Germany; 11Uniklinik Köln, Studienzentrum der Klinik für Innere Medizin, Köln, Germany; 12Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany; 13Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Klinik für Innere Medizin 5, Schwerpunkt Onkologie / Hämatologie; Abteilung Rheumatologie, Nurnberg, Germany; 14Heilios Fachklinik Vogelsang-Gommern GmbH, Klinik für Rheumatologie, Vogelsang, Germany; 15Charité - Universitätsmedizin Berlin, Medizin, mit Schwerpunkt Rheumatologie/ Klinik and Immunologie, Berlin, Germany; 16Praxis für Rheumatologie und Innere Medizin, Rheumatologie, Berlin, Germany; 17Krankenhaus Porz am Rhein GmbH, Rheumaklinik, Köln (Porz), Germany; 18Hospital Clinic de Barcelona, Servicio de Reumatología, Barcelona, Spain; 19Institute of Rheumatology, Rheumatology, Prague 2, Czech Republic; 20Hospital Fundación Jiménez Díaz, Servicio de Reumatología, Madrid, Spain

Background: The development of RA is described by a preclinical phase of autoimmunity, that precedes clinical disease. This autoimmune phase is characterized by the presence of anti-modified protein antibodies that recognize citrullinated proteins (ACPA). A subset of individuals with ACPA develops RA, i.e. the disease onset with imaging signs of subclinical inflammation in the joints. As T cell mediated B cell activation is a key step in developing autoimmunity and RA, interventions that target this process may be useful for preventing the onset of RA. In this context, abatacept seems being an attractive therapeutic tool as it interrupts the activation of T cells and has a favourable safety profile in the treatment of RA.

Objectives: To test whether treatment of abatacept, as compared to placebo, delays the onset of RA in ACPA positive individuals with a high risk to develop RA.

Methods: ARIAA is an international, randomized double-blind placebo-controlled multi-center study in RA-at-risk individuals, being ACPA positive and showing MRI signs of inflammation. The study was composed of a 6 months treatment phase with either abatacept 125mg weekly or placebo and a 18 months observation phase with no treatment. Primary endpoint was the improvement of MRI inflammation after 6 months, secondary endpoints were the progression to RA after 6 and 18 months. The primary analysis was done on the ITT population and missing values were classified as treatment failures.

Results: Between November 2014 and December 2019 139 RA-at-risk individuals were included into ARIAA by 14 study sites (11 in Germany, 1 in the Czech Republic and 2 in Spain). Of them, 100 patients were randomized to receive either abatacept or placebo. Two patients were excluded and 98 patients could be evaluated for efficacy and safety. The primary endpoint was met: 61% of abatacept and 31% of placebo treated individuals (p=0.0043) improved in MRI inflammation. Furthermore, only 4 patients (8.2%) in the abatacept group but 17 patients in the placebo group (34.7%) progressed to RA after 6 months (p=0.0025). Even 1 year after cessation of treatment (18 months after inclusion) the number of patients progressing to RA was lower in the abatacept group (35%) than in the placebo group (57%; p=0.0421). With respect to safety, 12 serious adverse events (each one gastritis, cellulitis, pneumonia, tendinitis calcificans, rotator cuff syndrome,

Figure 1. Odds ratio in the partial least-squares regression model using transcriptomics (A) and proteomics (B) data from rheumatoid arthritis and healthy control groups

Conclusion: The clinical course of RA can be prolonged in ACPA positive individuals with high risk to develop RA. A 6 months treatment with abatacept seems being an attractive therapeutic tool as it delays the onset of RA.
cholelithiasis, peripheral artery disease, idiopathic pain syndrome, prostate cancer, penile neoplasme; trabecluometry, cataract surgery] were reported, with only one (pneumonia) being considered to be related to treatment.

**Conclusion:** Abatacept significantly reduces subclinical joint inflammation and delays the development of RA in at-risk individuals.

### Table 1.

<table>
<thead>
<tr>
<th></th>
<th>ABA</th>
<th>PBO</th>
<th>All</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females, N (%)</td>
<td>31 (83.3)</td>
<td>38 (79.6)</td>
<td>70 (71.4)</td>
</tr>
<tr>
<td>Age (yrs); mean (±SD)</td>
<td>51.3 (±10.8)</td>
<td>48.5 (±12.6)</td>
<td>49.9 (±11.7)</td>
</tr>
<tr>
<td>SJM (N); mean (±SD)</td>
<td>3.06 (± 3.75)</td>
<td>3.51 (± 4.42)</td>
<td>3.29 (±4.08)</td>
</tr>
<tr>
<td>VAS (mm) mean (±SD)</td>
<td>42.2 (±27.1)</td>
<td>42.8 (±33.2)</td>
<td>42.5 (±30.2)</td>
</tr>
<tr>
<td>VAS PG (mm) mean (±SD)</td>
<td>42.2 (±28.7)</td>
<td>43.0 (±30.8)</td>
<td>42.6 (±31.2)</td>
</tr>
<tr>
<td>MIR improvement, N (%)</td>
<td>30 (61.2)</td>
<td>15 (30.6)</td>
<td>45 (45.9)</td>
</tr>
<tr>
<td>RA at 12 months, N (%)</td>
<td>9 (4.2)</td>
<td>17 (34.7)</td>
<td>21 (21.4)</td>
</tr>
<tr>
<td>RA at 18 months, N (%)</td>
<td>17 (34.7)</td>
<td>28 (57.1)</td>
<td>45 (45.9)</td>
</tr>
</tbody>
</table>

**Acknowledgements:** The study was supported by BMS according to the items outlined in the IIS contract and the IMI funded project RTcure.

**Disclosure of Interests:** Jürgen Rech Consultant of: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD, Novartis, Roche, Sanofi, Sobi, UCB, Consultancy: Biogen, BMS, Chugai, GSK, Lilly, MSD, Novartis, Roche, Sanofi, Sobi, UCB, Grant/ research support from: Sobi, Novartis, Almir Sleyer Consultant of: BMS, Pfizer, Sanofi, Abbvie, Janssen, Medac, Novartis, Lilly Deutschland GmbH, Gilead, Amgen, Grant/research support from: Novartis, Lilly Deutschland GmbH, Mikkell Ostergaard: None declared, Melanie Hagen: None declared, Larissa Valor: None declared, Koray Tascilar: None declared, Gerhard Krönke: None declared, Andrea Rubbert-Roth: None declared, Frank Behrens: None declared, Axel Hueber: None declared, Eugen Feist: None declared, Gerd Rüdiger Burmester: None declared, Kirsten Karberg: None declared, Johannes Strunk: None declared, Juan de Dios Cadete: None declared, Ladislav Šenolt: None declared, Esperanza Naredo: None declared, Georg Schett: None declared, Kurt H. Mueller-Ladner U, Buch MH, McNines IB, van der Heijde D, van Laar JM. Ann Rheum Dis. 2021 Jan;80(1):31-35.


**DOR:** 10.1136/annrheumdis-2022-eular.1693

**POS0532**

**DRUG RETENTION OF BIOLOGICS OR JAK INHIBITORS IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: RESULTS FROM THE ANSWER COHORT**


1Osaka City University Graduate School of Medicine, Department of Clinical Immunology, Osaka, Japan; 2Osaka City University Graduate School of Medicine, Department of Orthopedic Surgery, Osaka, Japan; 3Kurashiki Sweet Hospital, Department of Health Information Management, Kurashiki, Japan; 4Graduate School of Medicine, Kobe University, Department of Advanced Medicine for Rheumatic diseases, Kyoto, Japan; 5Graduate School of Medicine, Kyoto University, Center for Cancer Immunotherapy and Immunobiology, Kyoto, Japan; 6Osaka University, Graduate School of Medicine, Department of Musculoskeletal Regenerative Medicine, Osaka, Japan; 7Graduate School of Medicine, Osaka University, Department of Respiratory Medicine and Clinical Immunology, Osaka, Japan; 8Kobe University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kobe, Japan; 9Kansai Medical University, First Department of Internal Medicine, Hirakata, Japan; 10Osaka Red Cross Hospital, Department of Rheumatology, Osaka, Japan; 11Nara Medical University, Rheumatology Clinic and Department of Orthopaedic Surgery, Nara, Japan; 12Osaka Medical and Pharmaceutical University, Department of Internal Medicine (IV), Takatsuki, Japan

**Background:** Difficult-to-treat rheumatoid arthritis (D2T RA) is defined as RA in which disease activity is uncontrolled despite the use of two or more biologics or Janus kinase inhibitors (JAKi) with different mechanisms of action (MOA). Objectives: To explore the optimal treatment strategy for D2T RA, we evaluated the drug retention, efficacy, and reasons for discontinuation of biologics or JAKi used for patients with D2T RA in a longitudinal multicenter cohort.

**Methods:** RA patients with clinical disease activity index (CDAI) >10 despite the use of at least two biologics or JAKi with different MOA and further treated with biologics or JAKi were included. The drug retention rates of biologics (TNFi, IL-6Ri, and CTLA4-Ig) or JAKi were estimated at 12 months using the Kaplan-Meier method and adjusted for potential confounders (age, sex, disease duration, concomitant MTX and PSL use, and the number of switched biologics or JAKi) using Cox proportional hazards models.

**Results:** A total of 251 treatment courses (TCs) from 167 patients were included (TNFi: 97 TCs, IL-6Ri: 67 TCs, CTLA4-Ig: 27 TCs, JAKi: 60 TCs). Baseline characteristics showed no difference in age, sex, disease duration, ACPA positivity, CDAI, and concomitant MTX and PSL use between the four groups. Drug retention excluding non-toxic reasons and remission was significantly higher in patients treated with JAKi or IL-6Ri than in patients treated with TNFi or CTLA4-Ig (P<0.0012). Multivariate analysis using Cox proportional hazards models demonstrated that discontinuation of the drug was associated with the use of TNFi or CTLA4-Ig (HR: 3.29, 95%CI: 1.15-9.42, P=0.027) and concomitant PSL use (HR: 1.14, 95%CI: 1.04-1.26, P=0.0084). In terms of disease activity evaluated with CDAI, no difference was observed between the four groups at 3 months (P=0.90), at 6 months (P=0.77), and at 12 months (P=0.75).

**Conclusion:** In patients with D2T RA, JAKi or IL-6Ri may have treatment advantages compared with TNFi or CTLA4-Ig.

**REFERENCES:**


Background: The Fibrosis-4 (FIB4) score, including age, transaminases and platelets, can detect severe fibrosis (F3-F4) in patients with Non Alcoholic Steato Hepatitis (NASH) and could be of interest in the follow-up of patients with RA. Indeed, platelets contribute to the pathophysiology of RA, transaminases are used in the liver monitoring of our treatments. In addition, retrospective data suggested the association between FIB4 and mortality in RA (1).

Objectives: We aimed to evaluate the value of the FIB4 score as a prognostic factor in RA in the prospective ESPOIR cohort.

Methods: Patients of the ESPOIR cohort diagnosed with RA according to ACR/EULAR criteria were included in our analysis. The formula for the FIB4 score is as follows: \[(\text{Age (years)} \times \text{AST (U/L)}) / \text{platelet count} (10^9/L) \times \text{ALT (U/L)} - 1\]. The analyses were based on linear mixed-effects models with a random effect on the subject to account for repeated measures throughout time.

Results: 633 of the 813 patients included met the ACR/EULAR criteria for RA and had a calculable FIB4 score. Median FIB4 was 0.75 (IQR: 0.53-0.99) and 61 patients (9.8%) had a high FIB4 score at baseline. Baseline FIB4 was significantly higher in patients with a chronic alcohol consumption (p=0.021) or viral hepatitis (p<0.001). In multivariate analysis, including the main baseline prognostic factors for progression of RA (swollen Joint Count, CRP, Presence of ACPA, Rheumatoid Factor and modified Sharp score), FIB4 was not independently associated with progression of DAS28 during 10 years of follow-up, unlike baseline CRP and SJC. Baseline FIB4 was not associated with the modified Sharp score at 10-year follow-up unlike age and the presence of ACPA (Table 1). FIB4 was not associated with mortality (p=0.77) or major adverse cardiovascular events (p=0.22) during the 10-year follow-up. No significant change in FIB4 score over time was associated with mortality (p=0.77) or major adverse cardiovascular events (p=0.22).

Conclusion: Our study was the first to evaluate the value of FIB4 in a prospective cohort of RA patients. The present prospective cohort study with a 10-year follow-up did not find a prognostic role of FIB4 in RA, in contrast to previous retrospective studies. Reassuringly, FIB4 score was not increased by DMARD treatment after 10 years of follow-up, confirming the absence of long-term DMARD-related hepatotoxicity.

REFERENCES:


Figure 1. Impact of baseline FIB4 score on DAS28, HAQ and total modified-Sharp score over time.

Acknowledgements: An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, Pfizer, Abbvie, Lilly, Sanofi also supported the ESPOIR cohort study. We also wish to thank Nathalie Rincheval (CHU Montpellier and EA 2415) who did expert monitoring and data management and all the investigators who recruited and followed the patients (F. Berenbaum, Paris-Saint Antoine, MC. Boissier, Paris- Bobigny, A. Cantagrel, Toulouse, B. Combe, Montpellier, M. Dougados, Paris-Cochin, P. Fardellone et P. Bournier Amiens, B. Fautrel, Paris-La Pitié, R. Filipo, Ville, Ph. Goupille, Tours, F. Lioté, Paris-Lariboisière, O. Vittecoq, Rouen, X. Mariet- te, Paris Bicêtre, P. Dieude, Paris Bichat, A. Saraux, Brest, T. Schaeverbeke, Bordeaux, J. Sibilia, Strasbourg) V. Devauchelle and C. Lukas for expert X-ray reading. Disclosure of Interests: None declared.

Disclosure of Interests: Daan van der Bijl: None declared, Tjardo Maarseveen: None declared, Andrew Cope Speakers bureau: Abbvie, BMS, Consultant of: Abbvie, BMS, Galvani/GSK, UCB, Janssen, Grant/research support from: BMS, UCB, Abraham Yann Eyerphyre, Janssen Pharmaceutical Companies of Johnson & Johnson, Rachel Knevel Grant/research support from: Pfizer.


OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS INITIATING THERAPY WITH ETANECIGHT, ADALIMUMAB, OR JANUS KINASE INHIBITORS

D. A. Pappas1,2, J. O’brien2, L. Guo3, Y. Shan2, J. Baker2, G. Kricorian4, S. Stryker5, D. Collier4, 1Columbia University, Department of Medicine, New York, United States of America; 2CorEvitas, LLC, Research, Waltham, United States of America; 3Philadelphia Veterans Affairs Medical Center, Rheumatology and Epidemiology, Philadelphia, United States of America; 4Amgen Inc., Research, Thousand Oaks, United States of America

Background: Ongoing debate exists regarding the optimal sequence of tumor necrosis factor inhibitors and Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA) as first-line biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) therapy following conventional therapies. The frequency of switching to another b/tsDMARD was similar across ETN ADA, and JAKis (tofacitinib, baricitinib, and upadacitinib).

Methods: Data on patients who initiated b/tsDMARD from 11/2012 to 6/2021 were obtained from the CorEvitas RA Registry, a prospective, multicenter, observational, disease-based registry. Patients ≥18 years with rheumatologist-diagnosed RA and 6- and/or 12-months’ (M) follow-up were included. We report descriptive statistics at baseline, persistency on therapy, escalation/de-escalation of therapy, details on patterns of drug switching, and effectiveness outcomes using regression models adjusted for baseline covariates (demographic/socio-economic/lifestyle characteristics, comorbidities, medication history, disease activity, and patient-reported outcomes). Outcomes were evaluated at 6M and 12M follow-up.

Results: First-line initiators of ETN, ADA, and JAKis with baseline and follow-up visits were identified: 803, 984, and 361 patients at 6M, respectively; 589, 749, and 264 patients at 12M, respectively. Baseline characteristics were similar among ETN, ADA, and JAKis initiators with the exception of disease duration, which was longer among first-line JAKi initiators (mean, 8.6 y) versus ETN (5.9 y) and ADA (5.8 y) initiators. Unadjusted mean improvement in Clinical Disease Activity Index (CDAI) was generally similar between groups at 6M and 12M (Table 1). Adjusted effectiveness results were similar at 6M and 12M (Figure 1). At 6M, 68% of ETN, 69% of ADA, and 67% of JAKi initiators remained on the same therapy; at 12M, 53% of ETN, 57% of ADA, and 57% of JAKi initiators remained on the same therapy. The frequency of switching to another b/tsDMARD was similar across initiators.

| Table 1. Patient Description at Time of Initiation and Unadjusted Disease Activity Results |
|-----------------------------------------------|-----------------|-----------------|-----------------|
| Age, years                                    | ETN             | ADA             | JAKis           |
| Female, n (%)                                 | 54.4 (12.8)     | 55.5 (12.1)     | 60.9 (12.5)     |
| BMI, kg/m²                                    | 30.4 (76)       | 31.3 (79)       | 30.8 (76)       |
| Duration of RA, years                         | 5.9 (76)        | 5.8 (73)        | 8.6 (10.0)      |
| Disease activity at 6M                        | 19.9 (14.3)     | 18.9 (12.7)     | 18.8 (13.2)     |
| mHAQ                                         | 0.5 (0.5)       | 0.5 (0.5)       | 0.5 (0.5)       |
| Disease activity decrease from BL at 6M       | 48.0 (28.8)     | 49.2 (28.5)     | 45.2 (29.2)     |
| CDAI                                         | 6.9 (13.6)      | 6.4 (12.1)      | 4.7 (12.3)      |
| mHAQ                                         | 0.1 (0.4)       | 0.1 (0.4)       | 0.1 (0.4)       |
| Disease activity decrease from BL at 12M      | 9.7 (30.2)      | 10.6 (28.4)     | 8.9 (29.5)      |
| CDAI                                         | 7.4 (13.5)      | 6.1 (13.0)      | 5.1 (13.0)      |
| mHAQ                                         | 0.1 (0.4)       | 0.1 (0.4)       | 0.1 (0.4)       |
| Disease activity decrease from BL at 12M      | 8.8 (29.7)      | 8.7 (30.1)      | 7.5 (28.6)      |
| CDAI                                         | 43.4           | 41.9            | 32.5            |
| 6M                                           | 41.0            | 39.6            | 38.3            |

*Baseline for combined population with 6M and 12M follow-up. \( \beta \) range: 0–100. \( \beta \) CDAI ≤10 among those with moderate or high disease activity at baseline. Data are mean (SD) unless otherwise specified. ADALUMAB: BL baseline; CDAI, Clinical Disease Activity Index; ETN: etanercept; JAKIS, Janus kinase inhibitors; LDA, low disease activity; M, months; mHAQ, modified Health Assessment Questionnaire; RA, rheumatoid arthritis; SD, standard deviation.

Conclusions: In this real-world study in patients initiating first-line b/tsDMARD therapy with ETN, ADA, or JAKIs, we did not observe differences in effectiveness outcomes.
REFINING THE SEROLOGICAL SCORES OF THE ACR/EULAR 2010 RHEUMATOID ARTHRITIS CLASSIFICATION CRITERIA: AN INTERNATIONAL STUDY


1KU Leuven, Department of Microbiology, Immunology and Transplantation, Leuven, Belgium; 2OLV Hospital, Department of Laboratory Medicine, Aalst, Belgium; 3OLV Hospital, Department of Rheumatology, Aalst, Belgium; 4Medical University of Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria; 5Ghent University, Department of Internal Medicine, Ghent, Belgium; 6Ghent University, Department of Diagnostic Sciences, Ghent, Belgium; 7National Institute of Locomotor disease and Disabilities, Department of Laboratory Medicine, Budapest, Hungary; 8Sahlgrenska University Hospital Gothenburg, Department of Clinical Immunology and Transfusion Medicine, Gothenburg, Sweden; 9University Medical Center Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 10Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping, Sweden; 11University Hospital Basel, Department of Laboratory Medicine, Basel, Switzerland; 12Kantonsspital Aarau, Department of Laboratory Medicine, Aarau, Switzerland; 13Centre Hospitalier de Luxembourg, Department of Laboratory Medicine, Luxembourg, Luxembourg; 14AZ Sint-Elisabeth, Department of Laboratory Medicine, Zottegem, Belgium; 15AZ Rivierenland, Department of Laboratory Medicine, Bornem, Belgium; 16AZ Sint-Lucas, Department of Laboratory Medicine, Bruges, Belgium; 17National Institute for Biological Standards and Control, NIBSC, Hertfordshire, United Kingdom; 18Centre Hospitalier de Luxembourg, Department of Rheumatology, Luxembourg, Luxembourg; 19Rheumazentrum Ostschweiz, Department of Rheumatology, St. Gallen, Switzerland; 20University Hospital Basel, Department of Rheumatology, Basel, Switzerland; 21Linköping University, Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping, Sweden; 22National Institute of Public Health and the Environment, Department of Clinical Immunology, Budapest, Hungary; 23University Hospital Ghent and VIB - Institute for Inflammation Research, Department of Rheumatology, Ghent, Belgium; 24Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Department of Rheumatology, Vienna, Austria; 25University Hospital Leuven, Department of Rheumatology, Leuven, Belgium; 26University Hospital Leuven, Department of Developmental and Regenerative KULeuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; 27University Hospital Leuven, Department of Laboratory Medicine, Leuven, Belgium

Background: Rheumatoid factor (RF) and anti-cyclic citrullinated protein/peptide antibodies (ACPA) are included in the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA)(1). Both markers are given the same weight in the criteria.

Objectives: As the performance characteristics differ significantly between RF and ACPA(2), we set out to refine the serological scores for RA classification.

Methods: Diagnostic samples from 398 RA patients and from 1073 diseased controls were evaluated with five RF assays (two RF IgM isotype-specific assays and three total RF assays) and five ACPA IgG assays from five different manufacturers.

Results: Firstly, we harmonized thresholds between manufacturers based on predefined specificity for low positive (at 92.5% specificity for RF and at 97.5% specificity ACPA) and high positive results (at 97.5% specificity RF and at 99.0% specificity for ACPA). Next, we determined likelihood ratios (LRs) for RF, ACPA, and combinations of both, for negative, low positive, and high positive results. The LR was higher for ACPA than for RF, for high positive results than for low positive results and for double positivity than for single positivity. Based on these data we refined the weights of serological scores for classification (Table 1).

Table 1. Refined weights of serological scores for RA classification

<table>
<thead>
<tr>
<th>RF negative</th>
<th>RF low positive</th>
<th>RF high positive</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACPA negative</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>ACPA low positive</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>ACPA high positive</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

Application of such refined serological weights significantly increased the area under the curve of receiver operating characteristics analysis to distinguish RA from controls, significantly reduced the serological scores in the controls as well as the number of RA misclassifications without affecting the diagnostic sensitivity. Besides, we showed that combining predefined specificity thresholds with the refined serological scoring, reduced manufacturer-dependent variability in RA classification impacting RA classification for controls from 18.0-29.0% by ACR/EULAR to 11.0-13.0% (significantly increasing specificity) and for RA patients from 67.8-74.0% to 67.6-71.5% (without significantly affecting sensitivity).

Conclusion: Serological weight factors for RA classification can be improved by taking into account the antibody type (RF versus ACPA), the antibody level, and single or double positivity.

REFERENCES:

Acknowledgements: We thank all participating diagnostic companies for the in-kind support of assays, their technical training and the constructive discussions. Furthermore, we are very thankful to the laboratory technicians of all participating laboratories for their most appreciated assistance in the performance of the RF/ACPA analyses.
KYBUN: None declared, Christopher Sjowall: None declared, Alf Kasbom: None declared, Rok Jese: None declared, Boja Jovanovic: None declared, Emese Virag Kiss: None declared, Peggy Jacques: None declared, Günter Stein Speakers bureau: Thermo Fisher, Consultant of: Thermo Fisher, Patrick Verschueren: None declared, Xavier Bossuyt Speakers bureau: Thermo Fisher, Consultant of: Thermo Fisher.


POS0537 MORTALITY IN RHEUMATOID ARTHRITIS: CHANGING CAUSES AND PREDICTIVE FACTORS. STUDY OF A COHORT FOLLOWED PROSPECTIVELY

C. Corrales-Selaya1, F. Benavides-Villanueva1, I. Ferraz-Amaro2, N. Vegas-Revenga3, V. Portilla1, R. Blanco1, M. A. González-Gay1, A. Corrales1

1Marqués de Valdecilla University Hospital, Nursing, Santander, Spain; 2Hospital Universitario de Canarias, Rheumatology, San Cristóbal de La Laguna, Spain; 3Hospital de Galdakao-Usansolo, Rheumatology, Galdakao, Spain; 4Marqués de Valdecilla University Hospital, Nursing, Santander, Spain

Background: Patients with Rheumatoid Arthritis (RA) present an increased risk of mortality. In the last decades, mortality rates tended to decrease but also cardiovascular (CV) events remained as the leading cause of death in most series (1). Objectives: To assess mortality rates and leading causes of death, as well as predictors of mortality related to disease activity in a prospectively followed cohort of RA patients. Methods: We conducted a prospective longitudinal study that included 673 RA patients from a single tertiary center. Univariate and multivariate Cox proportional hazards regression were used to identify predictors of mortality. Results: We studied 673 patients with RA (75% women), mean age 61±13 years. The main general characteristics, CV risk factors, RA disease activity data and current treatment are summarized in the Table 1.

Table 1. Baseline characteristics of 673 RA patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>61 (±13)</td>
</tr>
<tr>
<td>Female/Male</td>
<td>505 (75)/168 (25)</td>
</tr>
<tr>
<td>Past or Current smoker, n (%)</td>
<td>338 (50)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>226 (34)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>310 (46)</td>
</tr>
<tr>
<td>Diabetes Mellitus, n (%)</td>
<td>85 (13)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>310 (46)</td>
</tr>
<tr>
<td>BMI, kg/m² (mean±sd)</td>
<td>28±6</td>
</tr>
<tr>
<td>Abdominal circumference, cm (mean±sd)</td>
<td>97±15</td>
</tr>
<tr>
<td>Total/HDL/LDL cholesterol, mg/dl (mean±sd)</td>
<td>204±38/62±18/120±31</td>
</tr>
<tr>
<td>Disease duration, years (median, [IQR])</td>
<td>13 [10-20]</td>
</tr>
<tr>
<td>CRP, mg/l (median, [IQR])</td>
<td>3.0 [0.9-7.0]</td>
</tr>
<tr>
<td>ESR, mm/h (1st hour, median, [IQR])</td>
<td>12 [5-21]</td>
</tr>
<tr>
<td>Rheumatoid factor ACRA, n (%)</td>
<td>376 [51]</td>
</tr>
<tr>
<td>DAS28-ESR/DAS28-PCR (mean±sd)</td>
<td>3.18 ± 1.41/3.00 ± 1.23</td>
</tr>
<tr>
<td>NSAIDs / Prednisone, n (%)</td>
<td>265 [39] / 341 [51]</td>
</tr>
<tr>
<td>Prednisone dose, mg/day (median, [IQR])</td>
<td>5 [2-5]</td>
</tr>
<tr>
<td>JAK Inhibitors, n (%)</td>
<td>12 [2]</td>
</tr>
</tbody>
</table>

Conclusion: In a cohort of patients with RA followed prospectively in a tertiary hospital, infections and malignancies are the main cause of mortality rather than CV events. Disease activity parameters are associated with an increased risk of mortality in these patients with RA.


<Figure 1> Forest Plot of mortality (Univariate and multivariate analysis). Results expressed in logarithmic scale. Multivariate analysis: Disease activity related parameters adjusted by age, gender, disease duration, smoker, diabetes, hypertension and abdominal circumference. All models, ESR and CPR expressed value/10. (*) p<0.05.

DISCLOSURE OF INTERESTS: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2292

POS0538 PREDICTING VALUE OF CIRCULATING SEMAPHORIN 4A FOR RHEUMATOID ARTHRITIS PROGRESSION

J. Avouac1, E. Vandebeuque1, A. Combier1, L. Poiroux1, A. Steelandt1, M. Boisson1, V. Gonzalez2, A. Cauvet1, Y. Allanore1, 1Cochin Hospital, Rheumatology, Paris, France; 2Cochin Institute, INSERM U1016, Paris, France

Background: The lack of validated tools to predict rheumatoid arthritis (RA) disease course warrants the development of new reliable biomarkers. We have previously detected increased SEMA4A expression in endothelial cells, synovial tissue, and serum of patients with RA. In addition, SEMA4A serum levels correlated with multiple clinical, biological, and power doppler ultrasound markers of disease activity and angiogenesis (1).

Objectives: To evaluate the merit of circulating semaphorin 4A (SEMA4A) for the prediction of disease progression in RA patients.

Methods: Prospective monocentric observational study including consecutive RA patients between May 2016 and February 2018 with available SEMA4A concentrations, measured by quantitative ELISAs (Coud-Clone Corp, Katy, TX). Increased SEMA4A concentrations were defined as values >94 ng/mL, as previously reported (1). Patients were followed up on an annual basis until August 2021. Primary endpoints were the occurrence of patient-reported flares with swollen joints and the necessity to initiate or change a targeted biologic or synthetic disease-modifying anti-rheumatic drugs.

Results: A total of 101 patients (86 females, 84%) were included, with a mean age of 58±13 years and a mean disease duration of 14±11 years. During a follow-up period of 41±15 months, disease flares occurred in 38 patients and targeted therapy was added or modified in 26 patients because of insufficient disease control. Increased baseline SEMA4A levels were predictive of flares and treatment escalation (hazard ratio, HR: 2.43, 95% confidence interval, CI 1.07-4.68 and 2.73, 95% CI 1.24-5.96, respectively) (Figure 1A-B). Multivariate
Cox analyses confirmed that SEMA4A was an independent predictors of flares and treatment escalation (HR: 2.12, 95%CI 1.04-4.32 and 2.71, 95%CI 1.14-6.43, respectively), and revealed that DAS28-CRP and synovial hyperemia were independent predictors of flares. Baseline age, disease duration, ACPA or RF positivity, smoking status, presence of erosions, line of targeted DMARDs, treatment with corticosteroids and CRP levels were not predictive of these outcomes. SEMA4A maintained predictive of flares and treatment escalation in the 58 patients with a DAS28 <3.2 at baseline (HR: 3.68, 95%CI 1.33-10.17 and 3.50, 95%CI 1.02-12.01, respectively). Baseline SEMA4A levels also identified more active and difficult to treat patients who maintained higher mean DAS28-11 values during the follow-up period (Figure 1C). The highest predictive value of flares and treatment escalation was obtained with the combination of increased circulating SEMA4A and/or DAS28-3.2 and/or the presence of synovial hyperemia on power-doppler ultrasound (HR:4.88, 95%CI 1.41-78.94, respectively).

**Table 1. Cox proportional hazards model predicting time to remission**

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Univariate</th>
<th>Multivariable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sociodemographic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female gender</td>
<td>0.71 (0.60-0.84) &lt;.0001</td>
<td>0.87 (0.70-1.09) 0.2256</td>
</tr>
<tr>
<td>Post-secondary education</td>
<td>1.26 (1.08-1.47) 0.0039</td>
<td>1.04 (0.87-1.70) 0.6744</td>
</tr>
<tr>
<td>Ever smoked</td>
<td>0.87 (0.75-1.02) 0.076</td>
<td>0.93 (0.77-1.12) 0.4269</td>
</tr>
<tr>
<td>RA family history</td>
<td>0.89 (0.74-1.07) 0.2176</td>
<td>0.87 (0.70-1.70) 0.1817</td>
</tr>
<tr>
<td><strong>Disease characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive rheumatoid factor</td>
<td>1.01 (0.85-1.19) 0.9182</td>
<td>0.94 (0.78-1.14) 0.5381</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>0.62 (0.55-0.69) &lt;.0001</td>
<td>0.71 (0.61-0.83) &lt;.0001</td>
</tr>
<tr>
<td>Morning stiffness (&gt;30 mins)</td>
<td>0.71 (0.61-0.83) &lt;.0001</td>
<td>0.89 (0.73-1.08) 0.2366</td>
</tr>
<tr>
<td>Joint erosion</td>
<td>0.94 (0.77-1.14) 0.5225</td>
<td>0.87 (0.70-1.13) 0.1364</td>
</tr>
<tr>
<td>DAS28</td>
<td>0.77 (0.72-0.82) &lt;.0001</td>
<td>0.88 (0.80-0.96) 0.0048</td>
</tr>
<tr>
<td>Number of comorbidities</td>
<td>0.83 (0.77-0.88) &lt;.0001</td>
<td>0.88 (0.81-0.95) 0.0019</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologic or JAK inhibitor (time variant)</td>
<td>0.86 (0.71-1.03) 0.09</td>
<td>1.53 (0.63-3.69) 0.3485</td>
</tr>
<tr>
<td>LORA</td>
<td>0.83 (0.71-0.97) 0.0194</td>
<td>1.10 (0.90-1.34) 0.3593</td>
</tr>
</tbody>
</table>

**Figure 1. Kaplan Meier survival curve of time to remission.**

**Conclusion:** LORA and YORA patients had similar prognosis in terms of time to remission. At remission, LORA patients were more likely to be on a single csDMARD without biological or JAK inhibitor. Clinicians should take the same approach for all RA patients targeting remission regardless of age of onset.

**References:**


**Disclosure of Interests:** Xinyue Li Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Janssen, Medexus, Merck, Novartis, and Pfizer. Mohammad Movahedi Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Janssen, Merck, Novartis, and Pfizer. Mohammad Movahedi Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Janssen, Merck, Novartis, and Pfizer. Mohammad Movahedi Grant/research support from: OBRI was funded by peer reviewed grants from CIHR (Canadian Institute for Health Research), Ontario Ministry of Health and Long-Term Care (MOHLTC), Canadian Arthritis Network (CAN) and unrestricted grants from: Abbvie, Amgen, Janssen, Merck, Novartis, and Pfizer.

**DOI:** 10.1136/annrheumdis-2022-eular.2492
Background: Patients (pts) with rheumatoid arthritis (RA) are often administered glucocorticoids (GCs) as bridging therapy when initiating or adjusting disease-modifying antirheumatic drugs (DMARDs). Due to their systemic effects, short-term use of GCs at the lowest possible dose is recommended with rapid tapering. 

Objectives: We describe GC discontinuation patterns and the associated clinical outcomes in pts with RA receiving upadacitinib (UPA) or adalimumab (ADA).

Methods: SELECT-COMPARÉ is a randomized phase 3 trial of UPA vs placebo and ADA with a 48-week (wk) double-blind treatment period and a 10-year long-term extension in pts with RA receiving concomitant methotrexate (MTX) who had an inadequate response to MTX. Background GCs (≤10 mg/day prednisone or equivalent) were permitted and could be tapered or discontinued starting at wk 26 per physician discretion. This post hoc analysis included pts who received ≥1 dose of UPA 15 mg once daily or ADA 40 mg every other wk while on concomitant GCs at baseline. The proportion of pts with disease worsening (Clinical Disease Activity Index [CDAI] >2 and Disease Activity Score 28-joint count C-reactive protein [DAS28-CRP] >0.6) following GC discontinuation through follow-up is described. Maintenance of clinical response, including remission and low disease activity based on CDAI ≤2 and ≤10, respectively, as well as DAS28-CRP <2.6 and ≤3.2, were assessed among pts who discontinued GCs. Adverse events (AEs) were assessed before and after GC discontinuation through follow-up. Data were analyzed descriptively.

Results: Of 1,629 pts randomized, 978 (60%) used GCs at baseline; 128 (13%) discontinued use at/after wk 26 (UPA, n=97; ADA, n=31). Baseline demographics and clinical characteristics were broadly similar between pts who continued or discontinued GCs. Median follow-up time after GC discontinuation was 60 wks for UPA and 84 wks for ADA. At the time of GC discontinuation, a numerically higher proportion of pts treated with UPA vs ADA were in disease control (CDAI ≤2; 55% vs 32%; CDAI ≤10: 85% vs 68%; DAS28-CRP <2.6: 71% vs 48%; DAS28-CRP ≤3.2: 87% vs 62%) (Table 1). Few pts receiving UPA experienced disease worsening following GC discontinuation (1% CDAI increase >2; 7% DAS28-CRP increase >0.6) and none on ADA (Table 1). At 6 months follow-up after GC discontinuation, most pts treated with UPA and ADA maintained CDAI ≤2.8 (74% vs 88%) and ≤10 (92% vs 95%) and DAS28-CRP <2.6 (89% vs 85%) and ≤3.2 (91% vs 94%), respectively (Table 1). GCs were reintroduced (albeit usually temporarily) in 14% of pts on UPA and 19% on ADA (Figure 1). AEs were generally similar across treatment groups. Rates of serious infection before and after GC discontinuation were 0.8 (95% CI 0.0–4.2) and 1.5 (0.2–5.4) events per 100 patient-years (E1/100 PY) for UPA and 7.7 (16–22.4) and 0 E1/100 PY for ADA, respectively. Interpretation of results is limited by small pt numbers and different exposure times.

Conclusion: In pts who achieved disease control and discontinued GCs, disease control was maintained in almost all without worsening disease activity over time following GC discontinuation.

Table 1. Clinical outcomes of pts who discontinued GCs at/after wk 26

<table>
<thead>
<tr>
<th>Pts who discontinued GCs N=128</th>
<th>UPA</th>
<th>ADA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N (%)</td>
<td>n=97</td>
<td>n=31</td>
</tr>
<tr>
<td>CDAI</td>
<td>79/93 (85%)</td>
<td>21/31 (68%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>61/66 (92%)</td>
<td>18/19 (95%)</td>
</tr>
<tr>
<td>≤2.8 at withdrawal</td>
<td>51/93 (55%)</td>
<td>10/31 (32%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>32/43 (74%)</td>
<td>7/88 (88%)</td>
</tr>
<tr>
<td>Increase ≥2 any visit after withdrawal</td>
<td>1/93 (1%)</td>
<td>0</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>78/90 (87%)</td>
<td>18/29 (62%)</td>
</tr>
<tr>
<td>≤3.2 at withdrawal</td>
<td>58/64 (91%)</td>
<td>15/16 (94%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>64/90 (71%)</td>
<td>14/29 (48%)</td>
</tr>
<tr>
<td>≤2.6 at withdrawal</td>
<td>47/52 (89%)</td>
<td>11/13 (85%)</td>
</tr>
<tr>
<td>Increase ≥0.6 any visit after withdrawal</td>
<td>6/92 (7%)</td>
<td>0</td>
</tr>
</tbody>
</table>

*As a proportion of pts achieving outcome at GC discontinuation and with observed data 6 months post GC discontinuation.

Acknowledgements: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing assistance was provided by Julia Zolotarjova, MSc, MW of AbbVie Inc.

Disclosure of Interests: Roy M. Fleischmann Consultant of: AbbVie, Amgen, BMS, Galvani, Gilead, GSK, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; Grant/ research support from: AbbVie, Amgen, Astra-Zeneca, BMS, Flexion, Galvani, Gilead, GSK, Janssen, Eli Lilly, Novartis, Noven, Pfizer, Samumed, Selecta, Teva, UCB, Vela, and Vorso.; Bernard Combe Speakers bureau: AbbVie, BMS, Celltrion, Eli Lilly, Gilead-Galapagos, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche-Chugai. Consultant of: AbbVie, BMS, Celltrion, Eli Lilly, Gilead-Galapagos, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, and Roche-Chugai. Grant/research support from: Pfizer and Roche-Chugai, Andrew Ostor Consultant of: AbbVie, BMS, Eli Lilly, Gilead, Janssen, Novartis, Paradigm, Pfizer, Roche, and UCB.; Cesar Francisco Pacheco Tena Consultant of: Abb- Vie, Astra-Zeneca, Eli Lilly, Gilead, Janssen, Pfizer, Roche, R-Pharm, Sanofi, Regeneron, and UCB. Grant/research support from: AbbVie, Astra-Zeneca, Eli Lilly, Gilead, Janssen, Pfizer, Roche, R-Pharm, Sanofi, Regeneron, and UCB., Nasser Khan Shareholder of: May own AbbVie stock or stock options, Employee of: AbbVie, Jessica Suboticki Shareholder of: May own AbbVie stock or stock options, Employee of: AbbVie, Anna Shmagel Shareholder of: May own AbbVie stock or stock options, Employee of: AbbVie, Vanna Song Shareholder of: May own AbbVie stock or stock options, Employee of: AbbVie, Ivan Lagunes-Galindo Shareholder of: May own AbbVie stock or stock options, Employee of: AbbVie, Gerd Rüdiger Burmester Speakers bureau: AbbVie, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Pfizer, Roche, Sanofi, and UCB., Consultant of: AbbVie, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Pfizer, Roche, Sanofi, and UCB.


POSS541

Table 1. Clinical outcomes of pts who discontinued GCs at/after wk 26

<table>
<thead>
<tr>
<th>Pts who discontinued GCs N=128</th>
<th>UPA</th>
<th>ADA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n/N (%)</td>
<td>n=97</td>
<td>n=31</td>
</tr>
<tr>
<td>CDAI</td>
<td>79/93 (85%)</td>
<td>21/31 (68%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>61/66 (92%)</td>
<td>18/19 (95%)</td>
</tr>
<tr>
<td>≤2.8 at withdrawal</td>
<td>51/93 (55%)</td>
<td>10/31 (32%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>32/43 (74%)</td>
<td>7/88 (88%)</td>
</tr>
<tr>
<td>Increase ≥2 any visit after withdrawal</td>
<td>1/93 (1%)</td>
<td>0</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>78/90 (87%)</td>
<td>18/29 (62%)</td>
</tr>
<tr>
<td>≤3.2 at withdrawal</td>
<td>58/64 (91%)</td>
<td>15/16 (94%)</td>
</tr>
<tr>
<td>Maintained at 6 months post discontinuation*</td>
<td>64/90 (71%)</td>
<td>14/29 (48%)</td>
</tr>
<tr>
<td>≤2.6 at withdrawal</td>
<td>47/52 (89%)</td>
<td>11/13 (85%)</td>
</tr>
<tr>
<td>Increase ≥0.6 any visit after withdrawal</td>
<td>6/92 (7%)</td>
<td>0</td>
</tr>
</tbody>
</table>

*As a proportion of pts achieving outcome at GC discontinuation and with observed data 6 months post GC discontinuation.
Methods: Clinical (CDAI, SDAI, and DAS28-CRP) and laboratory data (CRP, ESR, CBC with differential, and Lipids) for all available patients enrolled in the SELECT-COMPARE phase 3 study were included in this post-hoc analysis (UPA: n = 623 [CDAI REM at wk26 = 23.8%]; ADA: n = 516 [CDAI REM at wk 26 = 14.2%]). Patients who switched treatment between weeks 14 and 22 due to not reaching at least 20% improvement in tender and swollen joints were classified as non-responders for CDAI REM at week 26. The predictive value of clinical and laboratory endpoints recorded at week 12 for determining CDAI REM status at week 26 was assessed by univariate logistic regression. We report the performance of each model as ROC AUC with a cutoff of 0.75 for meaningful predictive value.

Results: For both patients treated with UPA and those treated with ADA, clinical disease activity status measures (CDAI, SDAI, and DAS28-CRP) and relative change in disease activity measures (Percent Change [PCHG] in CDAI, PCHG in DAS28-CRP, and PCHG in SDAI) at week 12 resulted in the highest predictive performance for determining CDAI REM status at week 26 (Figure 1). In contrast, none of the selected standard laboratory measures (CRP, ESR, CBC with differential, and Lipids) reached a meaningful predictive value (ROC AUC < 0.75). Of note, cell numbers and changes in cell numbers (including Neutrophils, Lymphocytes, Basophils, Eosinophils, and Monocytes) at week 12 had no meaningful predictive value for determining CDAI REM at week 26.

Conclusion: This analysis suggests that standard laboratory measures (CRP, ESR, CBC with differential, and Cholesterol) at week 12 do not represent useful predictors for REM at week 26 in csDMARD-IR RA patients. In particular, blood cell numbers and the changes in these measures at week 12 do not provide additional predictive value in our analyses, contrasting with the results from Amarnani and colleagues. Hence, clinical disease activity levels and changes in these measures at week 12 remained adequate predictors of CDAI REM at week 26. Still, the absolute predictive performance of clinical measures remains suboptimal, highlighting the need to dedicate continued efforts to identify and validate improved predictors of long-term REM in RA.

REFERENCES:

Acknowledgements: AbbVie, Inc was the study sponsor, contributed to the study design, data collection, analysis & interpretation, and writing, reviewing, and approval of the final version.


Figure 1: Each point represents a patient which is plotted with his DAS 28 on horizontal axis; and positive or negative influence on probability response to TNFi treatment on vertical axis.
We aimed to build machine learning models based on simple clinical and biological data to predict patient response to MTX. The machine learning models developed in this study can predict RA patients’ response to methotrexate with a good accuracy exclusively using data available in clinical routine. It paves the way for personalized therapeutic strategies in rheumatoid arthritis.

REFERENCES:


Disclosure of Interests: None declared.


Table 1. Sensitivity, Specificity, PPV and NPV are computed on the ABIRISK validation cohort for each strategy

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC (ESPOIR)</th>
<th>AUC (ABIRIA)</th>
<th>STRATEGY 1 (high confidence in response)</th>
<th>STRATEGY 2 (high confidence in non-response)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity</td>
<td>Specificity</td>
<td>PPV</td>
<td>NPV</td>
</tr>
<tr>
<td>Overall TNF</td>
<td>0.72</td>
<td>0.65</td>
<td>18%</td>
<td>91%</td>
</tr>
<tr>
<td>(0.68-0.73)</td>
<td>(0.54-0.75)</td>
<td>(10%-27%)</td>
<td>(82%-98%)</td>
<td>(54%-95%)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>0.74</td>
<td>0.71</td>
<td>78%</td>
<td>95%</td>
</tr>
<tr>
<td>(0.68-0.75)</td>
<td>(0.57-0.82)</td>
<td>(44%-74%)</td>
<td>(63%-92%)</td>
<td>(36%-69%)</td>
</tr>
<tr>
<td>Monoclonal anti-TNF antibodies</td>
<td>0.74</td>
<td>0.71</td>
<td>37%</td>
<td>92%</td>
</tr>
<tr>
<td>(0.69-0.77)</td>
<td>(0.55-0.86)</td>
<td>(20%-55%)</td>
<td>(83%-100%)</td>
<td>(73%-100%)</td>
</tr>
</tbody>
</table>

Results: We included 435 patients from the ESPOIR cohort, 243 patients from the Leiden cohort and 143 patients from the tREACH cohort. Results of the model are displayed in Table 1. The variables automatically selected to perform prediction were Sex, DAS28, White blood cells, AST, ALT and lymphocytes. Our model performs well on unseen data, this result comes from the fact that we included two different cohorts in our training set which reduces the overfitting of our model and helps him generalize. Our model predicts a probability for a patient to respond to MTX. This probability is compared to a decision threshold to obtain the final binary outcome. Two decision thresholds were tested. The first prioritizes a high confidence when identifying responders (Strategy 1) while the second prioritizes a high confidence when identifying non-responders (Strategy 2). This second strategy would enable physicians to identify highly probable inadequate responders to methotrexate and propose them directly a targeted DMARD such as TNF inhibitors, while still treating more than 70% of patients with MTX as first-line treatment.

Conclusion: The machine learning models developed in this study can predict RA patients’ response to methotrexate with a good accuracy exclusively using data available in clinical routine. It paves the way for personalized therapeutic strategies in rheumatoid arthritis.

Disclosure of Interests: None declared.


Table 1. Sensitivity, Specificity, PPV and NPV are computed on the ABIRISK validation cohort for each strategy

<table>
<thead>
<tr>
<th>Drug</th>
<th>AUC (ESPOIR, LEIDEN)</th>
<th>AUC (T-REACH)</th>
<th>STRATEGY 1 (high confidence in responders)</th>
<th>STRATEGY 2 (high confidence in non-responders)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity</td>
<td>Specificity</td>
<td>PPV</td>
<td>NPV</td>
</tr>
<tr>
<td>Methotrexate (MTX)</td>
<td>0.68</td>
<td>0.65</td>
<td>18%</td>
<td>91%</td>
</tr>
<tr>
<td>(0.64-0.71)</td>
<td>(0.54-0.75)</td>
<td>(10%-27%)</td>
<td>(82%-98%)</td>
<td>(54%-95%)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>0.74</td>
<td>0.71</td>
<td>78%</td>
<td>95%</td>
</tr>
<tr>
<td>(0.68-0.75)</td>
<td>(0.57-0.82)</td>
<td>(44%-74%)</td>
<td>(63%-92%)</td>
<td>(36%-69%)</td>
</tr>
<tr>
<td>Monoclonal anti-TNF antibodies</td>
<td>0.74</td>
<td>0.71</td>
<td>37%</td>
<td>92%</td>
</tr>
<tr>
<td>(0.69-0.77)</td>
<td>(0.55-0.86)</td>
<td>(20%-55%)</td>
<td>(83%-100%)</td>
<td>(73%-100%)</td>
</tr>
</tbody>
</table>

Background: Methotrexate (MTX) is the first line of treatment for rheumatoid arthritis (RA) patients. Unfortunately, 30% to 40% of RA patients do not respond to MTX, resulting in uncontrolled joint pain and potential joint destruction. At the same time, many efficient second-line treatments exist and can be given to the inadequate responder patients. Predicting patient response to MTX before prescribing the treatment is therefore a major goal and could enable physicians to directly prescribe second-line treatments if inadequate response to MTX is predicted.

Objectives: We aimed to build machine learning models based on simple clinical and biological data to predict patient response to MTX.

Methods: We used data from the ESPOIR early arthritis (1) and Leiden cohorts (2) to train the models, and the tREACH cohort to validate the results. We included patients that fulfilled the EULAR/ACR 2010 criteria and that were treated with MTX in monotherapy as their first treatment for RA. The models take as input patient’s characteristics at treatment initiation and predict the therapeutic response, defined as the EULAR response score 3 to 12 months after treatment initiation. We evaluated four missing data imputation methods (median, mean, MICE, KNN); we used the backward feature selection algorithm to select the most relevant variables; and compared the performances of four models (Linear Regression, Random Forest, XGBoost, and Catboost) on the training set by cross-validated them using the Area Under the ROC Curve (AUCROC). The best model was then evaluated on the validation dataset.

Results: We included 435 patients from the ESPOIR cohort, 243 patients from the Leiden cohort and 143 patients from the tREACH cohort. Results of the model are displayed in Table 1. The variables automatically selected to perform prediction were Sex, DAS28, White blood cells, AST, ALT and lymphocytes. Our model performs well on unseen data, this result comes from the fact that we included two different cohorts in our training set which reduces the overfitting of our model and helps him generalize. Our model predicts a probability for a patient to respond to MTX. This probability is compared to a decision threshold to obtain the final binary outcome. Two decision thresholds were tested. The first prioritizes a high confidence when identifying responders (Strategy 1) while the second prioritizes a high confidence when identifying non-responders (Strategy 2). This second strategy would enable physicians to identify highly probable inadequate responders to methotrexate and propose them directly a targeted DMARD such as TNF inhibitors, while still treating more than 70% of patients with MTX as first-line treatment.

Conclusion: The machine learning models developed in this study can predict RA patients’ response to methotrexate with a good accuracy exclusively using data available in clinical routine. It paves the way for personalized therapeutic strategies in rheumatoid arthritis.

Disclosure of Interests: None declared.

39 patients started anti-JAK therapy and 21 with TNF-α inhibitors. The 33.34% of patients were under monotherapy, and the 46.67% previously had been treated with biological therapy. The 77.36% of the total number of patients was on the biological therapy at 6 months of follow-up, while the 22.64% discontinued at 6 months of follow-up (9 due to inefficacy and 3 due to adverse effects). 48 patients continued the treatment in the 6 months after, and 12 patients discontinued due to ineffectiveness or drug intolerance. Clinical activity, fatigue, disability and pain perception are shown in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>VISIT 0</th>
<th>VISIT 1</th>
<th>VISIT 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=60</td>
<td>N=57</td>
<td>N=45</td>
</tr>
<tr>
<td>Pain VAS</td>
<td>6 (2)</td>
<td>4 (3)</td>
<td>5 (3)</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.33 (0.61)</td>
<td>1.06 (0.64)</td>
<td>1.06 (0.69)</td>
</tr>
<tr>
<td>FACIT-fatigue</td>
<td>25.52 (12.19)</td>
<td>31.03 (12.9)</td>
<td>32.76 (12.46)</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.78 (1.2)</td>
<td>3.6 (1.33)</td>
<td>3.54 (1.44)</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>4.31 (1.06)</td>
<td>3.19 (1.14)</td>
<td>3.05 (1.28)</td>
</tr>
<tr>
<td>SDAI</td>
<td>22.72 (9.88)</td>
<td>13.58 (8.58)</td>
<td>12.97 (9.32)</td>
</tr>
<tr>
<td>CDAI</td>
<td>21.75 (9.62)</td>
<td>12.88 (7.96)</td>
<td>12.36 (9.11)</td>
</tr>
</tbody>
</table>

Using a mixed linear regression model the association among the fatigue, disability and pain perception with clinical activity was conducted, corrected by age, smoking habits, time of disease evolution, BMI, previous biological/anti-JAK therapy administration and current dose of steroids. We observed a significant association among clinical activity and fatigue (P<0.001), disability (P<0.001) and pain perception (P<0.001). The statistical analyses showed a significant association where a high fatigue is increased in cases with high pain perception (P<0.001) and high number of swollen joints (P=0.002), but not in high levels of CRP and ESR. Fatigue was higher in those cases whom discontinued treatment (P=0.044) regardless of which therapy was chosen. No effect of age, time of disease evolution, steroid dose, BMI or previous therapy and smoking habits in the PROs values was observed.

Conclusion: PROs would be helpful in the disease control in those cases where a remote monitoring is needed, since HAQ or FACIT-FATIGUE index showed a significant association with clinical activity index in RA. Because of its ease for shipping and handling, PROs, especially in professional, PROs could be a useful tool in the disease control. Its implementation in the remote monitoring of RA patient, as has been the case of Covid19 pandemic, results in an improvement of the clinic evaluation of RA patients due to required information to clinical management is reported, avoiding delays in the treatment of Covid19 pandemic.

Disclosure of Interests: None declared.


OBJECTIVES:

To evaluate the urinary metabolic profile of patients with rheumatoid arthritis and associate it with skeletal muscle loss.

METHODS:

We recruited patients aged 40–70 years with RA according to the 2010 ACR/EULAR classification criteria. We measured disease activity by the following variables regarding the aforementioned outcomes, without affecting the clustering process. We evaluated the corresponding weights and their influence on the proposed neural network.

RESULTS:

Data from a total of 1,277 patients were included in the analysis. When both continuous and discrete variables were integrated, discrete data were transformed using the one-hot encoding method, creating new variables according to the corresponding number of categories. Dissimilarity between groups was very low when considering only the continuous variables, and it increases when adding all the other variables; likewise, regardless of the clinical metric index used for labeling, the clustering organization remains (Figure 1a).

Figure 1. Clusters and heatmaps of variables’ weights

In the construction of the groups, the influence of the RF and ACPA positivity was confirmed; furthermore, the antinuclear antibodies (ANAs) delivered a significant effect, especially those with negative ANAs or positive ANAs with a homogeneous pattern, on disease activity (Figure 1b).

Conclusion: SOM, as well as other artificial neural networks (ANN) are important methods for clustering and 2D visualization, due to the multivariate nature of the clinical data and its difficult visualization in the generated n-dimensional hyper-space. The utilized labels confirm that the clustering is adequate when considering that there was an identical grouping behavior for those registers with similar characteristics and an equivalent disease activity score. The findings of this research provide insights into a potentially pivotal role of the influence of RF, ACPA, and ANAs and their interaction with the proposed outcome variables in the understanding and development of future classification or prediction models; based on artificial intelligence and big data methods rather than on classical epidemiological approaches.

REFERENCES:


Disclosure of Interests: None declared.


POS0545

A NEURAL NETWORK BASED CLUSTERING MODEL OF A COLOMBIAN COHORT OF RHEUMATOID ARTHRITIS PATIENTS

K. J. Franco-Cuevres1, K. Maladonado-Cañón2, L. F. Niño Vásquez2, G. Quintana López1,2,3,5; 1Universidad Nacional de Colombia, Reumavance research group. LSI research group, Bogotá, Colombia; 2Fundacion Santa Fe de Bogota University Hospital, Reumavance research group. Department of Internal Medicine, Bogotá, Colombia; 3School of Engineering - Universidad Nacional de Colombia, LSI research group. Department of Systems and Industrial Engineering, Bogotá, Colombia; 4School of Medicine - Universidad de los Andes, Department of Internal Medicine, Bogotá, Colombia; 5School of Medicine - Universidad Nacional de Colombia, Department of Internal Medicine, Bogotá, Colombia

Background: Rheumatoid Arthritis (RA) is a chronic disease characterized by inflammation and joint pain. In daily clinical practice, it is usual to have multiple variables of different nature to define the current state of the disease, the patient's risk profile, and the subsequent optimal treatment.

Objectives: We aimed to identify the most influential variables from a suitable multivariable clustering and its labeling for an outpatient clinic-based cohort of Colombian RA patients.

Methods: We execute a clustering model (Kohonen's self-organizing map – SOM), applied to 23 variables (17 continuous and 6 discrete) obtained from 14,811 related follow-up visit records hosted on a previously preprocessed database of a cohort with data prospectively collected between 2013 and 2020. The included variables were the disease activity indexes (DAS28-ESR/CRP, CDAI, and SDAI; as outcome variables), serological status (autoantibodies positivity), and patients' sociodemographic and clinical characteristics. Clustering method used for generating the groups was SOM with a size of 25 x 25 neurons and 10000 iterations. SOM allows us to generate the groups by the comparison of the Euclidean distance in the hyperspace generated by the dimensions composed by the variables. After clustering, a discrete label built upon the categorization of the disease activity allowed us to identify the behavior of the included

POS0546

URINARY METABOLOMIC BIOMARKER CANDIDATES FOR SKELETAL MUSCLE WASTING IN PATIENTS WITH RHEUMATOID ARTHRITIS

M. De Oliveira1, R. Cavalcheiro Do Espirito Santo1, R. Xavier1, P. Alabarse2, J. Miranda de Souza Silva1on behalf of Laboratory of Autoimmune Diseases - HCPA. 1Clinicas Hospital, Rheumatology, Porto Alegre, Brazil; 2University of California, Rheumatology, San Diego, United States of America; 3University Hospital Münster, University Hospital Münster, Münster, Germany

Background: Rheumatoid arthritis (RA) is an autoimmune disease that affects the joints, leading to chronic synovial inflammation and local tissue destruction. Extra-articular manifestations may also occur, such as changes in body composition. Skeletal muscle wasting is often observed in patients with RA, but methods for assessing loss of muscle mass are expensive and not widely available, limiting their use in clinical practice and their evaluation in longitudinal studies. Metabolomic analysis has shown great potential for identifying changes in the metabolite profile of patients with autoimmune diseases and can advance our understanding of pathogenic mechanisms, early diagnosis, treatment, and follow-up. In this setting, urine metabolomic profiling in patients with RA may be a useful tool to identify skeletal muscle wasting.

Objectives: To evaluate the urinary metabolic profile of patients with rheumatoid arthritis and associate it with skeletal muscle loss.

Methods: We recruited patients aged 40–70 years with RA according to the 2010 ACR/EULAR classification criteria. We measured disease activity by the
A. Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP). We determined muscle mass according to DXA-derived appendicular lean mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height^2). We performed urine mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height^2). We performed urine mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height^2). We performed urine mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height^2).

B. Figure 1. Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP). We determined muscle mass according to DXA-derived appendicular lean mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height^2). We performed urine metabolomic analysis by nuclear magnetic resonance (NMR) spectroscopy using the BAYESIL and MetaboAnalyst software packages. We performed principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA), followed by Spearman's correlation analysis. We set the significance level at p<0.05 for all analyses. We combined Receiver Operating Characteristic Curve (ROC) and logistic regression analyses to establish a diagnostic model.

Results: We included 90 patients with RA. Most patients were women (86.7%), with a mean age of 56.5 (SD, 7.3) years and a median DAS28-CRP of 3.0 (IQR, 1.0–3.0). We identified 15 metabolites that showed high variable importance in projection (VIP scores) by MetaboAnalyst. Of these, dimethylglycine (r=0.205; p=0.053), oxo-isovalerate (r=−0.203; p=0.055) and isobutyric acid (r=−0.249; p=0.018) were significantly correlated with ALMI. Based on low muscle mass (ALMI ≤5.0 kg/m² for women and ≤8.1 kg/m² for men), we established a diagnostic model with dimethylglycine (Area Under the Curve - AUC=0.65), oxo-isovalerate (AUC=0.49) and isobutyric acid (AUC=0.83), with significant sensitivity and specificity.

Conclusion: Isobutyric acid, oxo-isovalerate and dimethylglycine from the samples were associated with low skeletal muscle mass in patients with RA. These findings suggest that this group of metabolites may be further tested as biomarkers for identification of skeletal muscle wasting.

REFERENCES:

Disclosure of Interests: None declared.


POS0547 THE ADVANTAGE OF TIGHT CONTROL AND TREAT TO TARGET IN NEW-ONSET RA PATIENTS IN DAILY RHEUMATOLOGY PRACTICE: RESULTS FROM A CONTEMPORARY UNIVERSITY CLINIC INCEPTION COHORT

J. T. Einasson1, K. Fribjerger Pajalic1, C. Bengtsson1, E. Mogard1, E. Lindqvist1, C. Roseman1, O. Palsson1, J. K. Wallman1, T. Olsson1, M. C. Kapetanovic1, 1Lund University, Department of Clinical Sciences, Lund, Section for Rheumatology, Lund and Skåne University Hospital, Lund, Sweden, Lund, Sweden; 2Faculty of Medicine, University of Iceland, Reykjavík, Iceland, Faculty of Medicine, University of Iceland, Reykjavík, Iceland, Reykjavik, Iceland

Background: Since 2018, all patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skane University Hospital, Lund, Sweden, are offered to participate in a "tight control" and "treat to target" (TC+T2T) follow-up strategy. This strategy includes regular follow-up visits to a rheumatologist (at diagnosis and 3, 6, 12, 18, 24 months) plus physical/telephone consultations with a rheumatology nurse between physician visits, both with disease activity assessments and, if needed, adjustment/intensification of anti-rheumatic treatment aiming for remission.

Objectives: To explore the possible advantages of integrating this TC+T2T strategy over routine care, aiming more systematically for remission (DAS28<2.6 or CDAI≤2,8), in clinical practice of new-onset RA.

Methods: Patients followed by the TC+T2T strategy were compared to new-onset RA patients followed according to routine care at the same department and during the same period. Data on disease and treatment characteristics, as well as outcome measures during follow-up were retrieved from the Swedish Rheumatology Quality register (SRQ). In total, 156 patients with at least 3 months follow-up between 2018 and 2021 were included; 95 followed according to the TC+T2T strategy and 61 according to routine care. Percentage females/mean age at onset/mean symptom duration at diagnosis were 79%/57 years/4 months (TC+T2T) and 62%/62 years/7 months (routine care).

Results: Disease and treatment characteristics at inclusion (diagnosis) are summarized in the Table 1.

Table 1.

<table>
<thead>
<tr>
<th>TC+T2T group (n=95)</th>
<th>Controls (n=61)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swollen 28 joint count</td>
<td>6.6 (4)</td>
</tr>
<tr>
<td>Tender 28 joint count</td>
<td>8.2 (5)</td>
</tr>
<tr>
<td>ESR</td>
<td>48.1 (29)</td>
</tr>
<tr>
<td>CRP</td>
<td>21.3 (29)</td>
</tr>
<tr>
<td>DAS28</td>
<td>5.5 (1)</td>
</tr>
<tr>
<td>CDAI</td>
<td>24.5 (11)</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.01 (0.6)</td>
</tr>
<tr>
<td>Fatigue (VAS)</td>
<td>50.1 (29)</td>
</tr>
<tr>
<td>Pain (VAS)</td>
<td>75.9 (24)</td>
</tr>
<tr>
<td>ACPA positive (%)</td>
<td>77%</td>
</tr>
<tr>
<td>Radiographic changes in hands or feet at inclusion (%)</td>
<td>12%</td>
</tr>
<tr>
<td>Smoker (%)</td>
<td>16%</td>
</tr>
<tr>
<td>Methotrexate started at inclusion (%)</td>
<td>78%</td>
</tr>
<tr>
<td>Prednisolone started at inclusion (%)</td>
<td>100%</td>
</tr>
</tbody>
</table>

Mean and standard deviation (SD) if not otherwise stated.

References:

Disclosure of Interests: None declared.

The TC+T2T strategy resulted in greater improvements in DAS28 and CDAI scores from inclusion to 12 months follow up (p=0.025 and p=0.026; respectively; Figure 1). Beyond improvements in DAS28 and CDAI, a significant decrease in patient-reported outcomes (fatigue and pain) during 12 months from diagnosis was observed (Figure 1).

Conclusion: Compared to routine rheumatology practice, the implementation of a “tight control” and “treat to target” strategy resulted in a greater improvement in disease activity and an early and sustained improvement in patient-reported outcomes. Our results suggest that this type of strategy should be integrated into daily clinical practice of new-onset RA.

Disclosure of Interests: Jon Thrakkel Einarsson: None declared, Katarina Friberger Pajalic: None declared, Caroline Bengtsson: None declared, Elisabeth Mogard: None declared, Elisabet Lindqvist: None declared, Carmen Roseman: None declared, Olafur Palsson: None declared, Johan K Wallman Consultant of: Consultant of AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Grant/research support from: unrestricted grants from Pfizer and Roche.

None declared, Olafur Palsson: None declared, Johan K Wallman Consultant of: Consultant of AbbVie, Amgen, Celgene, Eli Lilly, Novartis, Grant/research support from: unrestricted grants from Pfizer and Roche.

Disclosure of Interests: J. Thrakkel Einarsson: None declared, K. Friberger Pajalic: None declared, C. Bengtsson: None declared, E. Mogard: None declared, E. Lindqvist: None declared, C. Roseman: None declared, O. Palsson: None declared, J. K. Wallman Consultant of: Consultant of AbbVie, Amgen, Celgene, Eli Lilly, Novartis. Pfizer, Tor Olofsson Consultant of: Consultant of MSD, Meliha C Kapetanovic Consultant of: Abbvie, Pfizer, GSK, Grant/research support from: unrestricted grants from Pfizer and Roche.


EVALUATION OF PHYSICIAN GLOBAL ASSESSMENT IN PATIENTS WITH BT/SDMARD THERAPY SELECTION ALIGNED WITH A MOLECULAR SIGNATURE RESPONSE CLASSIFIER RESULTS: AN ANALYSIS FROM THE STUDY TO ACCELERATE INFORMATION OF MOLECULAR SIGNATURES (AIMS) IN RHEUMATOID ARTHRITIS

E. Connolly-Strong1, L. Zhang2, S. Asgarian1. 1Scipher medicine, Medical Affairs, waltham, United States of America; 2Scipher medicine, Data Science, waltham, United States of America

Background: Despite drug therapies that improve lives, tens of millions of patients annually are prescribed therapy using a “trial and error” approach because, until recently, it was not possible to personalize treatment using a patient’s unique molecular profile. A blood-based molecular signature response classifier (MSRC) was shown to predict non-response to TNFi therapies in patients. MSRC integrates disease-associated RNA transcripts, and clinical features (anti-CCP, sex, BMI, PGA). A recent study demonstrated that patient response to treatment informed by MSRC was more or less responsive TNFi therapies.


Scientific Abstracts
Background: Rheumatoid arthritis (RA) is a kind of autoimmune disease characterized with chronic aggressive arthritis, presence of abnormal antibodies and persistent synovitis[1]. However, the pathogenesis of RA remained unclear by now. Several observations have showed that the breakdown of immune tolerance was involved in the development of RA. T follicular regulatory (Tfr) cells and T follicular helper (Tfh) cells, as a new subset of CD4+ T cell, can exert an opposite effect in the regulation of humoral immunity[2]. Intensive researches have showed that the imbalance of Tfr/Tfh cell is related to the pathogenesis and development of autoimmune disease. There is still a lack of understanding of the relationship between Tfr/Tfh and RA, which needs further exploration.

Objectives: To detect the expression of Tfh and Tfr cells in peripheral blood of patients with new-onset RA and healthy controls, and to explore the role of Tfh and Tfr cells in the pathogenesis and development of RA.

Methods: We enrolled 26 patients with new-onset RA who hospitalized at the Second Hospital of Shanxi Medical University from the June 2021 to the November 2021. And 17 age and gender-matched healthy adults were anticipated as controls. The absolute number of Tfh and Tfr cells in peripheral blood was detected by flow cytometry. Disease activity indicators were collected including erythrocyte sedimentation rate (ESR, mm/h) and Disease Activity Score in 28 joints (DAS28). Then we compared the expression of Tfr and Tfh cells between the patients and healthy controls and conducted the correlation analysis with disease activity.

Results: There was significant decreased level of Tfr cells in the patients with new-onset RA compared with healthy controls (P<0.001) and a lower ratio of Tfr/Tfh in the patients (P<0.01). The reduced Tfr cells and Tfr/Tfh were significant negative correlation with the disease activity indicators including ESR and DAS28. Statistical analyses were performed by the Spearman correlation analysis.

Conclusion: The results we investigated here showed that new-onset RA exhibited an imbalance of Tfr/Tfh, specifically reduced Tfr cells, compared with healthy controls, which were negatively correlated with higher disease activity in RA. It was likely that the imbalance of Tfr/Tfh in peripheral blood played an important role in the development of RA, which may be a target to treat RA.

Table 1. A summary of data of all enrolled patients with RA and healthy controls

<table>
<thead>
<tr>
<th>HC(n=17)</th>
<th>New-onset RA(n=26)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(years)</td>
<td>51.9±4.13</td>
<td>55.8±3.56</td>
</tr>
<tr>
<td>Sex(male/female)</td>
<td>4/13</td>
<td>7/19</td>
</tr>
<tr>
<td>ESR(mm/h)*</td>
<td>-</td>
<td>54.8±32.7</td>
</tr>
<tr>
<td>DAS28**</td>
<td>-</td>
<td>5.09±1.56</td>
</tr>
<tr>
<td>Tfh cell count(cell/UL)</td>
<td>43.156(23.775,106.638)</td>
<td>83.914(38.133,119.662)</td>
</tr>
</tbody>
</table>
| Tfr cell count(cell/UL) | 1.422(0.862,1.893) | 0.441(0.116,2.888) | 0.001 *
| Tfr/Tfh | 0.030(0.014,0.049) | 0.001(0.001,0.024) | 0.001 ** |

* Results are expressed as the mean ± standard error. ** Results are expressed as the median(IQI). Normally distributed continuous variables were analyzed by the independent-samples Student’s t-test. And nonparametric variables were analyzed by Mann-Whitney U test.

Figure 1. The differences of Tfr and Tfh cells in peripheral blood between the healthy controls and patients with RA. Tfr cells were higher in new-onset RA leading to an imbalance of Tfr/Tfh. Statistical analyses were performed by the Mann-Whitney U test. (P<0.05, **P<0.01)
**Methods:** The IMAGINE-more trial was designed as an extension protocol to the 2-year IMAGINE-RA randomised controlled trial (RCT). IMAGINE-RA included 200 RA patients, in clinical remission (DAS28-CRP<3.2 and no swollen joints), who received conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and investigated whether an MRI T2T strategy targeting absence of osteitis in combination with clinical remission (DAS28-CRP<3.2 and no swollen joints) could increase remission rates and prevent erosive progression compared with a conventional T2T strategy targeting clinical remission only. If target was not met, treatment was escalated according to a predefined treatment algorithm starting with increment in csDMARDs and then adding biologics. At the end of the study, participants were invited to participate in the IMAGINE-more follow-up study. Patients were managed in routine outpatient clinic and had three IMAGINE-more visits including clinical examination (year 3, 4 and 5) and more follow-up study. Patients were managed in routine outpatient clinic and had the end of the study, participants were invited to participate in the IMAGINE-more algorithm starting with increment in csDMARDs and then adding biologics. At target was not met, treatment was escalated according to a predefined treatment algorithm.

**Conclusion:** A 2-year MRI T2T strategy targeting absence of MRI osteitis combined with clinical remission as compared to a conventional clinical T2T strategy in RA patients had no effect on the long-term probability of achieving DAS28-CRP remission. These findings do not support the use of an MRI-guided strategy for treating patients with RA.

**REFERENCES:**

**Disclosure of Interests:** Signe Möller-Bisgaard Grant/research support from: AbbVie, Kim Herslev-Petersen: None declared, Daniel Glinatis: None declared, Bo Eljær: None declared, Merete L. Hetland: None declared, Jakob Möllenhack Möller: None declared, Robin Christensen: None declared, Sabrina Mai Nielsen: None declared, Mikael Boesen: None declared, Kristian Stengaard-Pedersen: None declared, Ole Madsen: None declared, Bente Jensen: None declared, Jan Alexander Villadsen: None declared, Ellen Margrethe Hauge: None declared, Oliver Hendriks: None declared, Hanne Merete Lindegaard: None declared, Niels Steen Krogh: None declared, Anne Grethe Jurik: None declared, Henrik Thomsen: None declared, Mikkel Østergaard Speakers bureau: Abbvie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Orion, Pfizer, Roche and UCBC, Consultant of: Abbvie, BMS, Boehringer-Ingehelm, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandz, Sanofi and UCBC, Grant/research support from: Abbvie, Amgen, BMS, Merck, Celgene and Novartis.

**DOI:** 10.1136/annrheumdis-2022-eular.3095

---

**Table 1. Primary and key secondary outcomes at 5 years**

<table>
<thead>
<tr>
<th>Primary endpoint</th>
<th>Conventional T2T</th>
<th>MRI T2T</th>
<th>Difference between groups</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=59</td>
<td>N=72</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28-CRP remission (DAS28-CRP&lt;2.6)</td>
<td>47 (80%)</td>
<td>54 (75%)</td>
<td>2.00 (0.76 to 5.28)</td>
<td>0.161</td>
</tr>
<tr>
<td>CRP&lt;2.6, No (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>1.79 (0.08)</td>
<td>1.94 (0.08)</td>
<td>-0.15 (-0.38 to 0.07)</td>
<td>0.176</td>
</tr>
<tr>
<td>Change from baseline MRI osteitis (RAMRIS)</td>
<td>-0.17 (0.58)</td>
<td>0.18 (0.54)</td>
<td>-0.35 (-1.96 to 1.25)</td>
<td>0.663</td>
</tr>
<tr>
<td>Change from baseline in HAQ</td>
<td>-0.02 (0.03)</td>
<td>0.05 (0.03)</td>
<td>-0.07 (-0.15 to 0.01)</td>
<td>0.080</td>
</tr>
</tbody>
</table>

Group estimates are presented as No. (%) for dichotomous data and least squares means (SE) for continuous data. For the primary endpoint, adjusted odds ratio and 95%CI between groups were calculated from a logistic regression model including a fixed factor for treatment arm, and an adjustment for propensity score as a covariate. For endpoints with continuous data, least squares mean differences between groups were calculated based on repeated-measures mixed linear models adjusted for baseline values and propensity scores.

**Results:** Fifty-nine patients in the MRI T2T arm and 72 patients in conventional T2T arm consented to participate. Of these, 47 patients (80%) in the MRI T2T group and 54 patients (75%) in the conventional T2T group reached the primary clinical endpoint (p=0.161) (Table 1 and Figure 1). No statistically significant T2T arm consented to participate. Of these, 47 patients (80%) in the MRI T2T group and 54 patients (75%) in the conventional T2T group reached the primary clinical endpoint (p=0.161) (Table 1 and Figure 1). No statistically significant differences between treatment strategies in key secondary outcomes were seen.

**Disclosure of Interests:**

**B. Li, J. Zhao, G. Li, Z. Zhang, 1 Peking University First Hospital, Rheumatology and Clinical Immunology Department, Beijing, China**

**Background:** Tumor necrosis factor inhibitors (TNFi) have been widely used in the treatment of RA. Few researches offered solid solution to predict the response of TNFi treatment. NETs formation (NEToxis) is a key process participant in RA. NETs and their components also work as a source of auto-antigens for RA.

**Objectives:** To explore the relationship between serum MPO-DNA complex, which is one of the components of NEToxis, and disease activity of RA, and to explore the possibility for serum MPO-DNA complex to predict the therapy response of anti-TNF therapy in RA patients.

**Methods:** RA patients were enrolled from a randomized controlled clinical trial (ESCORt study, ClinicalTrials.gov identifier: NCT02320630) conducted from Oct. 2014 to Oct. 2018. The clinical and demographic data and blood samples were collected at baseline and every 4 weeks. Serum levels of MPO-DNA complex were detected by a modified enzyme-linked immunosorbent assay (ELISA) kit. The Association between MPO-DNA complex level and disease activity was analyzed. The predictive value of baseline MPO-DNA complex for treatment response of RA patients was analyzed.

**Results:** 86 RA patients were enrolled. The level of serum MPO-DNA was higher in patients with high disease activity (HDA) than that in patients with medium disease activity (MDA) (1.0±0.32 vs. 0.86±0.29, p<0.001). After 4 weeks of treatments, the level of serum MPO-DNA complex decreased significantly (1.0±0.32 vs. 0.57±0.79 for ACR50 and 0.66-0.85 for ACR70, all p-value<0.05) and ΔMPO-DNA complex at week 4 against baseline MPO-DNA complex for treatment response of RA patients was analyzed.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3147
Table 1. Predictive ability of MPO-DNA for treatment response at week 12

<table>
<thead>
<tr>
<th>Measures</th>
<th>AU(C)(95%CIs) P</th>
<th>AUC difference</th>
<th>p</th>
<th>AU(C)(95%CIs) P</th>
<th>AUC difference</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>b-MPO-DNA</td>
<td>0.68(0.57-0.79)</td>
<td>0.003</td>
<td>Reference</td>
<td>-</td>
<td>0.77(0.66-0.85)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>b-ESR</td>
<td>0.48(0.36-0.61)</td>
<td>0.848</td>
<td>0.20</td>
<td>0.085</td>
<td>0.57(0.40-0.75)</td>
<td>0.332</td>
</tr>
<tr>
<td>b-CRP</td>
<td>0.55(0.40-0.70)</td>
<td>0.296</td>
<td>0.20</td>
<td>0.072</td>
<td>0.66(0.50-0.82)</td>
<td>0.244</td>
</tr>
<tr>
<td>AUC(95%CIs) P</td>
<td>AUC difference</td>
<td>p</td>
<td>AUC(95%CIs) P</td>
<td>AUC difference</td>
<td>p</td>
<td></td>
</tr>
<tr>
<td>∆MPO-DNA</td>
<td>0.73(0.63-0.83)</td>
<td>&lt;0.001</td>
<td>Reference</td>
<td>-</td>
<td>0.86(0.74-0.97)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>∆ESR</td>
<td>0.56(0.48-0.68)</td>
<td>0.33</td>
<td>0.17</td>
<td>0.017</td>
<td>0.64(0.48-0.80)</td>
<td>0.072</td>
</tr>
<tr>
<td>∆CRP</td>
<td>0.59(0.47-0.71)</td>
<td>0.14</td>
<td>0.14</td>
<td>0.056</td>
<td>0.66(0.53-0.83)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

Values are presented as areas under curve (95%CIs). Abbreviations: b-MPO-DNA/ESR/CRP: Serum MPO-DNA complex/ESR/CRP at baseline; ∆MPO-DNA/ESR/CRP: change of serum MPO-DNA/ESR/CRP at week 4 against baseline; ∆MPO-DNA/ESR/CRP%, reduction rate of serum MPO-DNA/ESR/CRP at week 4 against baseline.

Relationship between painless myocardial ischemia with level Willebrand factor (WVF) and inflammatory markers in patients with rheumatoid arthritis

O. Gallicuta1, M. Szumlas1,2, O. Bych1, V. Seheda1. Scientific and Research Institute of Invalid Rehabilitation (Educational Scientific Treatment Complex) of National Pirogov Memorial Medical University, Rheumatology, Vinnytsya, Ukraine; 2National Pirogov Memorial Medical University, Internal Medicine Chair #1, Vinnytsya, Ukraine; 3Vinnytsya Regional Center for Medical and Social Expertise, Neurology, Vinnytsya, Ukraine

Background: In a patient with rheumatoid arthritis (RA) manifestations of coronary heart disease occur gradually, at the same time “painless” myocardial ischemia is detected in 50 - 70% of cases according to the literature. According to modern ideas, the formation of endothelial dysfunction, development of early atherosclerosis and vascular thrombosis are closely associated with the increase level of von Willebrand factor (VWF) and inflammatory markers.

Objectives: The aim of this study was to investigate the frequency and duration of painless myocardial ischemia and its association with VWF levels and inflammatory markers in patients with RA.

Methods: 63 patients with RA (44 women) aged 27 - 65 years (mean age - 46.8 ± 9.8 years) and 69 age and sex-matched controls were examined. Serum levels of VWF, CRP and TNF-α were determined by enzyme-linked immunosorbent assays. Daily (Holter) ECG monitoring was performed by Holter ECG monitoring systems “DiaCard” registrar model 02100, software version 10.40, developed by JSC “Solvieg” (Ukraine).

Results: It was found, that the part of patients with painless myocardial ischemia among patients with RA was significantly higher (58.7%) than in the control group (13%). At the same time, in patients with RA the duration of painless myocardial ischemia was in averaged 10.9 ± 8.1 minutes per day. It was significantly more than in the control group 2.88±1.25 minutes per day (p<0.05). It was found, that in patients with RA there was an increased levels of VWF (162.2 ± 9.3% vs. 86.2 ± 2.7% in control). It was found, that the duration of painless myocardial ischemia had close correlations with VWF (r = 0.28), CRP (r = 0.41) and TNF-α, indicating the possible involvement of VWF and inflammatory markers in cardiovascular disease in RA patients.

Conclusion: The severity the duration of painless myocardial ischemia in RA patients is associated with elevated levels of VWF, CRP, and TNF-α, indicating the possible involvement of VWF and inflammatory markers in cardiovascular disease in RA patients.

References:

Disclosure of Interests: None declared.

New biomarkers in rheumatoid arthritis: role of homocysteinylated anti-alpha 1 antitrypsin antibodies

M. Speziali1,1, F. Ceccorelli1, F. Natafucchi2, A. I. Celia1, T. Colasanti1, C. Barbati2, G. Oliveri1, E. Babbonc1, F. Cianciancarci1, F. M. Ucc1, G. Buonucer12, G. Tripdl1, F. R. Spinelli1, F. Conti1, C. Alessandri1. 1Arthritis Clinic, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy

Background: Rheumatoid Arthritis (RA) is a multifactorial, chronic, systemic, inflammatory disease that can lead to progressive joint destruction (Alamanos et al, Autoimmun Rev 2005). Positivity for Rheumatoid Factor (RF) and antibodies against citrullinated proteins (ACPAs) is useful for diagnostic and prognostic purposes. Nevertheless, in about 20% of patients, it is not possible to detect the presence of these autoantibodies. This has led to the identification of new antibody specificities, such as antibodies directed against carbamylated proteins (Mastrangelo A et al, J Immunol Res 2015) and, more recently, against homocysteinylated alpha 1 antitrypsin (anti-HATA) (Colasanti T et al, J Autoimmun 2020).

Objectives: To evaluate the presence of anti-HATA in a large cohort of patients with RA and their correlation with serological, clinical and erosive bone damage assessed by musculo-skeletal ultrasound (US).

Methods: Consecutive outpatients with RA, diagnosed according to the 2010 ACR/EULAR criteria, were enrolled. Demographic and clinical-laboratory data were recorded, including FR and ACPA determination. Disease activity was assessed by DAS28. The presence of anti-HATA antibodies was investigated by homemade ELISA using native alpha 1 antitrypsin modified in vitro to obtain homocysteinylated alpha 1 antitrypsin. US assessment was performed at the level of bilateral metacarpophalangeal and proximal interphalangeal joints; the presence of erosions and inflammatory features was identified according to OMERACT definitions (Wakefield R et al, J Rheumatol 2005).

Results: The present analysis included 91 RA patients (M/F 22/69; mean age 62 years; mean disease duration 12.5 years). Overall, the prevalence of anti-HATA was 69.2%. Anti-HATA antibodies were found in 63/91 (69.2%) of the entire patient cohort, whereas 68/91 (74.3%) patients were positive for ACPA and 63/91 (69.4%) for FR. 41.4% of patients had concomitant positivity for the three autoantibodies (FR, ACPA, anti-HATA). The analysis of patients with triple positivity for related arthritis antibodies (FR, ACPA, anti-HATA) was particularly interesting: indeed, in this subgroup, 80% of patients presented erosive damage, compared to 42.1% of patients who did not present simultaneously the three autoantibodies (p=0.0001). Patients with simultaneous positivity for RF, ACPA and anti-HATA showed a more aggressive disease phenotype (p=0.0001). Finally, a positive correlation was also found between disease activity (expressed by DAS28) and total inflammatory and erosive ultrasonographic score (p<0.005 and p<0.001, respectively).

Conclusion: The results of the present study confirm a high prevalence of anti-HATA in RA patients; furthermore, patients with concomitant presence of anti-HATA, ACPA and RF showed a more aggressive disease phenotype, in terms of erosive damage. Our analysis underlines as the characterization of new antibody specificities in RA could help in the early diagnosis of this disease and in the characterization of the different severity degrees.

References:

Disclosure of Interests: None declared.

Clinical characteristics of patients with rheumatoid arthritis in pre-difficult-to-treat status

I. Yoshi1, N. Sawada2, T. Chijiwa3,3. 1Yoshii Hospital, Musculoskeletal Medicine, Shimano-City, Japan; 2Dohgo Onsen Hospital, Rheumatology, Matsuyama, Japan; 3Kochi Memorial Hospital, Rheumatology, Kochi,
Background: Patients with rheumatoid arthritis (RA) who have a difficult-to-treat condition (D2T RA) are often a burden to both patients and rheumatologists. Objectives: The aim of this study was to determine the risk factors for failure to treat RA patients with refractory conditions and to find them relevant to prevention.

Methods: Patients with RA who were treated under treat-to-target (T2T) strategy, more than one year were picked up. Their background characteristics such as sex, age, disease duration, anti-citrullinated polypeptide antibodies titer (ACPA), and disease duration were collected, and they simplified disease activity index (SDAI) score, Health Assessment Questionnaire Disability Index (HAQ) score, pain score measured by visual analog scale (PS), EuroQol 5th-dimensions score (EQ5D) were monitored every three months. Sharp/Van der Heijde score (SHS) was calculated annually. Difficult-to-treat status was determined in according to the EULAR definition of D2T RA [1], and pre-D2T RA status was determined as follows: (Category-1) a failure history of one kind of effect in biologic or targeted synthetic disease modifying anti-rheumatic drug (bsDMARD) and switched to another bsDMARD with other action mechanism or (Category-2) one or more of following status; mean SDAI score in recent three months exceeded 11 (MDA), three consecutive administration of glucocorticoid steroid no less than 7.5mg in prednisolone equivalent (GCS), rapid radiographic progression with 5 or more in SHS than last time (RRP), or decrease of EQ5D score less than -0.2 in recent 6 months (deEQ5D).

Results: A total of 47 in Category-1 and 491 patients in Category-2 were recruited. In Category-1 matched patients, female were 83.0% and mean age was 71.3. Mean SDAI score, HAQ score, PS, EQ5D score, and SHS at failure of bsDMARD (baseline) were 15.5, 0.457, 40.1, 0.811, and 72.9, respectively. Numbers of the first bsDMARD were 32 TNF inhibitors, 8 IL-6 inhibitors, 6 abatacepts, and 1 JAK inhibitor. Numbers of the second after the first were 13 IL-6 inhibitors and 19 JAK inhibitors after TNF inhibitor, whereas 3 TNF inhibitors, 2 abatacepts, and 3 JAK inhibitors after IL-6 inhibitor failure, 1 TNF inhibitor, 1 IL-6 inhibitor, and 4 JAK inhibitors after abatacept failure, and 1 TNF inhibitor after JAK inhibitor failure. In these, success counted 18 and failure counted 29. Significant risk factors for Category-1 failure were higher ACPA, higher SDAI score, higher HAQ score, and higher SHS at baseline (p<0.05). There was no significant difference between drugs.

Conclusion: Clinical background factors besides disease activity such as ACPA, SDAI score, and SHS at baseline were important for preventing fail-in-D2T_RA. However, most weighted factor was disease activity control after falling in MDA status. Tight disease activity control is the overriding factor.

REFERENCES:

Disclosure of Interests: None declared.


Figure 1. Predictive model of TNFi nonresponse based on NAPCD genes. (A) Volcano map of differential expressed genes; (B) Correlation heat map of gene modules and phenotypes, the red is positively correlated with the phenotype, blue is negatively correlated with the phenotype; (C) The shared 38 genes of TNFi response & nonresponse DEGs, among the WGCNA turquoise module and cell programmed death genes; (D) Consensus clustering matrix for k = 2. (E) The ROC curve of 33 genes; (F) LASSO regression of the 32 genes, except for CD46; (G) Nomogram for predicting TNFi nonresponse in TNFi treatment RA cohort, indicated five possible indicators (CAP5, CAPN10, ITGB4, NLRP2, and SLCA2B) were closely related to TNFi nonresponse.

Disclosure of Interests: None declared.


Background: The non-apoptotic programmed cell death genes (NAPCD) genes were closely related to TNFi nonresponse. To predict the possibility of TNFi response prior to prescription, we constructed a predictive model with R packages “limma” and “WGCNA” Then the enrichment analysis among the shared genes was performed through the KEGG, Reactome, and Metascape websites, and WebGestalt website. Following the confirmation of the non-apoptotic programmed cell death (NAPCD) genes in the shared genes with Student’s T-test. Furthermore, the TNFi treatment cohort was clustered based on the hub genes, making the receiver operating characteristic (ROC) curve analysis. Moreover, the least absolute shrinkage and selection operator (LASSO) model was constructed to identify the predictive genes.

Results: 2624 DEGs were identified significantly, including 161 upregulated genes and 2463 downregulated genes. One module with TNFi treatment was constructed in WGCNA, significant in both response and nonresponse. The gene signatures for TNFi nonresponse were collected from overlaps 2260 genes in above. And we found 38 NAPCD genes might play role in TNFi nonresponse, but reserved 33 genes which statistically significant with T-Test. 22 TNFi treated synovial samples in GEO database could be classified into response or nonresponse subgroups. The ROC curve showed that the AUC for 32 genes in these samples ranged from 0.7 to 0.9, expected for CD46. At last, the LASSO model indicated that CAP5, CAPN10, ITGB4, NLRP2, and SLCA2B could predict the TNFi nonresponse, as the risk score = CAP5 × 0.028 + CAPN10 × 0.064 + ITGB4 × 0.080 + NLRP2 × 0.317 + SLCA2B × 0.090 (Figure 1).
ALTERATION OF THE GUT MICROBIOTA IN CHINESE POPULATION WITH RHEUMATOID ARTHRITIS


The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; Shanxi Medical University, Key Laboratory of Cellular Physiology, Ministry of Education, Taiyuan, China;

Background: Rheumatoid arthritis (RA) is an aggressive immune-mediated joint disease characterized by synovial proliferation and inflammation, cartilage destruction, and joint destruction. Growing evidences suggests a chronic inflammatory response induced by gut microbiome critically contribute to the development of rheumatoid arthritis.

Objectives: The aim of this study was to evaluate and quantify differences in the composition of gut microbiota in RA patients and investigate the associations between flora and clinical variables in RA patients.

Methods: Fecal samples from 145 RA patients and 145 age- and gender-matched healthy controls (HCs) were collected for bacterial 16S rRNA genes sequencing. The alpha-diversity, beta-diversity and the microbial composition of gut microbiota in RA patients and HCs. The peripheral lymphocytes of these patients were assessed by flow cytometry, and inflammatory biomarkers (ESR, CRP), auto-antibodies(ACP, MCV) and cytokines measured by ELISA were recorded. Correlations between different taxa and clinical variables, were calculated by Spearman's rank test.

Results: Consistent with trends observed for diversity, patients with RA had a lower richness compared with those of HCs (p < 0.01, Figure 1a), suggesting gut microbiome was markedly less diverse in composition in RA. Bray curtis distance-based beta diversity analysis revealed significant differences in the microbial community between RA and HCs (ANOSIM, R=0.061, p=0.001, Figure 1b). Ten selected taxonomic biomarkers at different phylogenetic levels showed great discriminant ability, with Log10 LDA score > 4.0 (Figure 1c-g).

Conclusion: Specific gut microbiota may play an important role in the pathogenesis of RA, which may aid in the diagnosis or determination of the susceptibility of individuals to RA via detection of the gut microbiome.

REFERENCES:

ASSOCIATION BETWEEN ANTI CITRULLINATED PEPTIDES ANTIBODIES, BONE MINERAL DENSITY, AND FRACTURE RISK IN RHEUMATOID ARTHRITIS PATIENTS

O. Lamkhania1, H. Azzouzi1, I. Linda1, Mohamed I University, 1Rheumatology department, Oujda, Morocco

Background: Recent literature reported Anti Citrullinated Peptides Antibodies (ACPA) associated with bone loss in patients with rheumatoid arthritis (RA).

Objectives: To study if ACPA positivity was associated with bone mineral density and the ten-year probability of fracture (FRAX) in RA patients.

Methods: We performed a cross-sectional study on patients with RA diagnosis according to ACR-EULAR 2010 classification recruited from January 2021 till January 2022. Patients aged from 40 to 90 years were included. Those with prior cancer, hyperparathyroidism, hyperthyroidism, diabetes, chronic kidney disease, and cirrhosis were excluded. Clinical data and results of laboratory tests were collected simultaneously with bone mineral density (BMD) acquisition. The latter was measured with dual-energy X-ray absorptiometry (DXA). BMD of the femoral neck (FN) was used to calculate the ten-year probability of major osteoporotic fracture (FRAX MOF) and femoral neck risk fracture (FRAX FN). Patients were grouped by positivity or quartile of ACPA level (I-IV). We used logistic regression, parametric and non-parametric tests for statistical analysis with SPSS20.

Results: Eighty-two RA patients were enrolled. In total, 69 (84.1%) were women, 16 (19.5%) reported a previous personal fracture, and 37 (45.1%) had osteoporosis. Seventy-two (87.8%) patients were ACPA positive. The mean body mass index (BMI; kg/m²) and lumbar spine BMD in ACPA-positive patients were 25.44 ± 4.79 and 0.791 ± 0.138, respectively. We found a significant association between ACPA positivity and BMI over 25 (p = 0.01; OR = 0.132 [1.527; 6.785]). Comparison between ACPA positive/negative patients did not find a significant difference for osteoporosis, history of fracture, DASS28CRP, lumbar spine BMD, FN BMD, FRAX MOF BMD, and FRAX FN BMD. Lumbar spine BMD was significantly different (p = 0.035) among subgroups of ACPA levels, whereas there was no significant difference for FRAX MOF, FRAX FN, and FN BMD.

Conclusion: In this study, lumbar spine BMD was significantly different among subgroups of ACPA levels.

Disclosure of Interests: None declared.


A INFAMMATORY FACTOR-BASED NOMOGRAM PREDICTS FIRST REMISSION TIME OF RHEUMATOID ARTHRITIS PATIENTS WITH BASELINE GALECTIN-9

Z. Sun1,2, X. Liu3, F. Wang4, J. Sun5, Y. Gu7, Q. Che5, Q. Shu2, 6. Qilu Hospital, Cheelo College of Medicine, Shandong University, Department of Rheumatology, Jinan, China; 2Shandong Provincial Clinical Research Center for Immune Diseases and Gout, Department of Rheumatology Jinan, China; 3Tianjin Medical University General Hospital, Department of Rheumatology, Tianjin, China; 4Women and Children’s Hospital, Department of Hematology, Qingdao, China; 5Shandong Provincial Third Hospital, Department of Nephrology and Immunology Jinan, China; 6YanTaiShan Hospital, Department of Rheumatology and Immunology, Yantai, China

Background: Galectin-9 (Gal-9) is an immunoregulatory peptide involved in the development of RA. The aim of this study was to establish a predictive model for the first remission time of RA patients based on baseline Gal-9.

Objectives: To develop a predictive model for the first remission time of RA patients based on baseline Gal-9.

Methods: A total of 275 RA patients were enrolled in this study. The demographic and clinical characteristics of the patients are shown in Table S1. The first remission time was defined as the time from initial treatment to remission. Logistic regression analysis was used to identify the independent factors associated with remission.

Results: The median remission time was 3 months. The median baseline Gal-9 level was 12.1 ng/ml. The baseline Gal-9 level was significantly associated with remission (p = 0.001). The area under the ROC curve for baseline Gal-9 was 0.71 (p < 0.001).

Conclusion: The baseline Gal-9 level is a predictive factor for the first remission time of RA patients. The Gal-9-based nomogram may be a useful tool for predicting the first remission time of RA patients.

Disclosure of Interests: None declared.

Background: Rheumatoid arthritis (RA) is an autoimmune disease. The core treatment principle of RA is to achieve remission or low disease activity as soon as possible to ensure optimal outcomes. Predicting the first remission time according to the patient’s risk factors is very important for the choice of treatment scheme.

Objectives: We aimed to verify the prognostic value of inflammatory factors in RA and establish a nomogram based on Human Interleukin-6 (IL-6), Galectin-9 (Gal-9) and disease activity to predict the first remission time after conventional synthetic DMARDs treatment.

Methods: 184 RA active patients (DAS28-ESR > 3.2, ACR 1987 criteria or EUILAR 2010 criteria) were enrolled in the rheumatology department of Qilu Hospital of Shandong University from June 2014 to June 2020. 129 patients were assigned to the development cohort and 55 patients were assigned to the validation cohort randomly. Baseline clinical data and plasma were collected. The expressions of Tumour Necrosis Factor (TNF-α), Vascular Endothelial Growth Factor (VEGF), IL-6 and Gal-9 in plasma of RA patients were detected by ELISA. All patients were treated with csDMARDs and we recorded activity of each follow-up visit until 36 months. Lasso regression and Cox regression analysis were used to screen the 14 variables (including activity indices and cytokines) at baseline, and the prediction model was established to draw the nomogram.

Results: Patient age, CRP, IL-6, Gal-9, HAQ and DAS28-ESR were the significant prognostic factors in the lasso and Cox regression analyses, especially Gal-9. The multivariate analysis revealed that IL-6 ≤ 9.04 pg/ml (HR = 0.54, 95% CI: 0.31–0.95), Gal-9 ≤ 4490 pg/ml (HR = 0.43, 95% CI: 0.21–0.89) were independent protective factors. The cutoff values for the Cox regression analysis were used to screen the 14 variables (including activity indices and cytokines) at baseline, and the prediction model was established to draw the nomogram.

Conclusion: We constructed and validated a nomogram with baseline activity indices and cytokines that can predict first remission time in RA patients after csDMARDs treatment. Using this simple-to-use model with plasma Gal-9 ≥ 4490 pg/ml (HR = 0.21–0.89) were independent protective factors in the lasso and Cox regression analyses, especially Gal-9. The resulting model containing six factors had good discrimination ability in both the development cohort (C-index, 0.729) and the validation cohort (C-index, 0.710). Time-dependent ROC curve (Figure 2), calibration analysis (Figure 3) and decision curve analysis (DCA) show that the nomogram has significant discriminant power, stability and clinical practicability in predicting the first remission time.

Table 1. Univariate and multivariate analysis of factors associated with first remission time according to the Cox Proportional Hazards Model.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate HR (95%CI)</th>
<th>P-value</th>
<th>Multivariate HR (95%CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>≤ 45 vs. &gt;45</td>
<td>0.69</td>
<td>0.43-1.12</td>
<td>0.13</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>≤ 10 vs. &gt;10</td>
<td>0.87</td>
<td>0.53-1.42</td>
<td>0.37</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>≤ 9.04 vs. &gt;9.04</td>
<td>0.58</td>
<td>0.34-0.97</td>
<td>0.04</td>
</tr>
<tr>
<td>Gal-9 (pg/ml)</td>
<td>≤ 4490 vs. &gt;4490</td>
<td>0.37</td>
<td>0.18-0.73</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HAQ</td>
<td>≤ 5 vs. &gt;5</td>
<td>0.44</td>
<td>0.24-0.77</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>≤ 5.3 vs. &gt;5.3</td>
<td>0.50</td>
<td>0.34-0.93</td>
<td>0.02</td>
</tr>
</tbody>
</table>

REFERENCES:

Acknowledgements: Funded by ECCM Program of Clinical Research Center of Shandong University (No. 2021SDUCRCB010)

Disclosure of Interests: None declared.

recommendations are based on a previously validated Diet Quality Index, except for red meat (based on SDGI) and added sugars (based on World Health Organization guidelines from 2015 for sugar intake).

We used conditional logistic regression analysis to study the relation between NDS, its components, and RA. The NDS was divided into categories, defined as low (0–1), moderate (2–3) and high (4–5), with “low” as reference, and also assessed as a continuous variable. All models were adjusted for reported total energy intake, and potential misreporters of total energy intake were excluded.

We designed multivariable-adjusted models in which we included covariates that had been associated with diet and RA (smoking, alcohol and leisure time physical activity).

Results: In the study population, 172 RA cases were identified. Low red meat intake (<500 g/week) was significantly associated with a decreased risk of RA (Table 1). Compliance with the recommendations for fiber and vegetables and fruit was inversely associated with RA, with a similar trend for the total NDS (Table). In additional multivariable analysis, including both variables and relevant confounders, compliance with recommendations for red meat intake (odds ratio (OR) 0.43; 95% CI 0.22-0.85) and for fiber intake (OR 0.53; 95% CI 0.30-0.94) were both associated with a reduced risk of RA.

Table 1. Multivariable-adjusted odds ratios (ORs) describing the relation between New Diet Score (NDS) and its components and the risk of developing rheumatoid arthritis

<table>
<thead>
<tr>
<th>NDS components</th>
<th>Recommendation</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fish</td>
<td>≥4 P MJ</td>
<td>0.51</td>
<td>0.29–0.90</td>
</tr>
<tr>
<td>Vegetables and fruits</td>
<td>≥400/g/day</td>
<td>0.55</td>
<td>0.32–0.95</td>
</tr>
<tr>
<td>Fish</td>
<td>≥300/g/week</td>
<td>1.25</td>
<td>0.76–2.05</td>
</tr>
<tr>
<td>Added sugar</td>
<td>≤10%</td>
<td>1.10</td>
<td>0.68–1.78</td>
</tr>
<tr>
<td>Red meat (&lt;500 g/week)</td>
<td></td>
<td>0.42</td>
<td>0.22–0.81</td>
</tr>
<tr>
<td>NDS</td>
<td></td>
<td>0.10</td>
<td>0.01–0.80</td>
</tr>
<tr>
<td>0–1</td>
<td></td>
<td>1.00</td>
<td>(Ref)</td>
</tr>
<tr>
<td>2–3</td>
<td></td>
<td>0.65</td>
<td>0.38–1.10</td>
</tr>
<tr>
<td>4–5</td>
<td></td>
<td>0.67</td>
<td>0.30–1.46</td>
</tr>
<tr>
<td>Per point increment</td>
<td></td>
<td>0.82</td>
<td>0.67–1.00</td>
</tr>
</tbody>
</table>

Conclusion: These preliminary results indicate that low intake of red meat and higher fiber intake, in line with current recommendations, are independently associated with reduced risk of developing RA, suggesting that components found in meat and fiber-rich foods may affect early disease mechanisms.

Disclosure of Interests: None declared.


POS0561

PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH ‘ARTHRALGIA AT-RISK’ DEFINED ACCORDING TO THE RHEUMATOLOGIST AND THE NEW EULAR DEFINITION: A PILOT RETROSPECTIVE STUDY FOCUSED ON REFERRAL TO A STRUCTURED EARLY ARTHRITIS CLINIC

S. Grignaschi1,2, B. Xoo1, E. Bozzalla Cassione1,2, T. Luvar1, M. I. Greco1, I. Mazzucchelli1, S. Bugatti1,2, C. Montecucco1,2, A. Manzo1,2, Fondazione I.R.O.C.S. Policlinico San Matteo, Division of Rheumatology, Pavia, Italy; 2The University of Pavia, Department of Internal Medicine and Therapeutics, Pavia, Italy

Background: The phase preceding the development of rheumatoid arthritis (RA) may contain a novel window of opportunity for disease prevention and control. Investigation of this phase at population level remains, however, very challenging in epidemiological terms due to the rarity of the events. Patients seeking medical attention with arthralgia at-risk, defined by an expert rheumatologist (clinically suspect arthralgia, CSA) or by the recent EULAR definition represent an attractive platform for the identification of both seropositive and seronegative disease subsets.

Objectives: The objective of this study was to explore the prevalence and characteristics of patients with different types of arthralgia, focusing on referral to the screening visit of an early arthritis clinic (EAC) as a putative enrichment strategy for pre-RA.

Methods: EAC first referrals from January 1st 2019 to June 30th 2021 were systematically reviewed through a retrospective evaluation of medical charts. Patient’s history, comorbidities, PROs and clinical examination were recorded by two expert rheumatologists. Data was compared to immunological and radiological data. Arthralgia cases, sub-classified according to risk-definitions, were recorded. Categories at-risk, according to the rheumatologist’s opinion and the EULAR definition, were characterized and compared to other arthralgia cases for clinical characteristics, imaging data and autoantibody status.

Results: Of the 363 patients referred to the EAC, 178 were characterized by peripheral arthralgia (swollen joint count=0) at screening visit (49%). Of these patients, 130 cases were characterized by recent-onset arthralgia (ROA) (<12 months symptoms’ duration) (73% of the total), CSA, according to the rheumatologist’s opinion, was applicable to 71/178 total arthralgia patients (40%) and to 61/130 ROA patients (47%), recent-onset CSA, RO-CSA. Patients without
OBJECTIVES: early and precise diagnosis of RA.

AIM TO ASSESS WHETHER AUTOANTIBODIES TO NATIVE OR MODIFIED JP CAN BE USED FOR THE ACCURATE IDENTIFICATION OF UNTREATED EARLY RHEUMATOID ARTHRITIS PATIENTS.

BACKGROUND: CCp; aCCP) and rheumatoid factor (RF) appear years before clinical onset of RA. Autoantibodies to JP have been reported in up to 25% of patients with early rheumatoid arthritis.

METHODS: Antibodies to JP were analysed in serum from patients in three independent early RA cohorts as well as from population controls without rheumatic diseases (WINGA, Gothenburg and MFM-ÅUS, Malmö). The performance of the different antibodies was assessed in a blinded setting using a multianalyte bead-based assay. The study was approved by the regional ethics committee.

RESULTS: The novel biomarkers identified 22.5% of the patients with 99% specificity compared to other groups (13% vs 3%, p=0.03). After a stratification according to the fulfillment of the EULAR definition, both CSA and RO-CSA increased their differences compared to other groups regarding the elevation of C-reactive protein (CRP ≥0.5 mg/dl, p=0.006 and p=0.02 respectively). No epidemiological, clinical or imaging differences were observed through patient stratification according to current arthralgia at-risk definition in the real-life setting of an EAC. Both CSA and RO-CSA appears as suitable niches for the patient selection according to current arthralgia at-risk definition in the real-life setting of an EAC.

CONCLUSION: Results of our pilot study provide evidence of the applicability of patient selection according to current arthralgia at-risk definition in the real-life setting of an EAC. Both CSA and RO-CSA appears as suitable niches for the enrichment of primary immunological and serological risk factors for RA (RF/ACPA, hypogammaglobulinemia and C-reactive protein).

Disclosure of Interests: None declared.


**Table 1. Diagnostic capacity of the joint-specific antibodies**

<table>
<thead>
<tr>
<th>group of patients</th>
<th>aCCP+</th>
<th>RF+</th>
<th>JP+</th>
<th>sensitivity</th>
<th>specificity</th>
<th>AUC (ROC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EULAR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF and aCCP-neg patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BARFOT and TIRA-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF and aCCP-neg patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**REFERENCES:**


**Acknowledgements**: BARFOT study group.

**Disclosure of Interests**: Erik Lönnblom: None declared, Monica Leu Agelii: None declared, Outi Sarelia Employee of: Part time employee in Vacara AB, Ingrid Haas: None declared, Maria Andersson: None declared, J. Xu: None declared, R. Holmdahl: None declared, Gökhan Bergström: None declared, Anna-Karin H. Ekwall: None declared, Anna Rudin: None declared, Alf Kastbom: None declared, Christopher Sjowall: None declared, Binghe Xu: None declared, Lennart T.H. Jacobsson: None declared, Johan Viljanen: None declared, Jan Kihlborg: None declared, Inger Gjertsson: None declared, Rikard Holmdahl Shareholder of: Rikard Holmdahl the founder of Vacara AB.


**POS0563 INFLUENCE OF ACTIVE VERSUS PLACEBO CONTROL ON TREATMENT RESPONSES IN RANDOMIZED CONTROLLED TRIALS IN RHEUMATOID ARTHRITIS**

N. M. Stimakovs, A. Korschbaumer, J. S. Smolen, T. Stefanova, E. Chwala, D. Aletaha

**Background**: Randomised placebo controlled double-blind clinical trials are the mainstay of testing drugs for efficacy and safety and ultimately drug approval in medicine. They are performed to ensure the efficacy of the active intervention against the effects of interventions without expected efficacy (placebo). Patients have to be fully consented to the risk of being (randomly) allocated to placebo by good clinical practice guidelines. Knowledge about this risk may reduce the expectations about efficacy on both the patient and the investigator side. Once many therapeutic options are available, active control interventions are often used as comparators instead of placebo in trials. In such studies, placebo flow immunoassay [2] and screened approx. 350 peptides derived from JPs of interest. We included monoclonal antibodies as assay calibrators and determined limit of detection (LoD). To assess positivity for autoantibodies to JP of interest above LoD, we used SMAD (median absolute deviation) of the control populations as the cut-off.

**Results**: In the ERAp cohort, 5 autoantibodies discriminated RA patients from controls with 81% sensitivity and 100% specificity (Table 1). The same autoantibodies had 68% sensitivity and 98% specificity in the combined BARFOT and TIRA-2 cohorts. Together with RF and aCCP, only 2 of the 5 autoantibodies added statistically significant diagnostic value, increasing the sensitivity from 48% to 61% with 99% specificity. In aCCP- and RF-negative uEArA patients (n=536), the novel biomarkers identified 22.5% of the patients with 99% specificity compared to controls.

**Table 1. Diagnostic capacity of the joint-specific antibodies**

<table>
<thead>
<tr>
<th>group of patients</th>
<th>aCCP+</th>
<th>RF+</th>
<th>JP+</th>
<th>sensitivity</th>
<th>specificity</th>
<th>AUC (ROC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EULAR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF and aCCP-neg patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BARFOT and TIRA-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF and aCCP-neg patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**REFERENCES:**


**Acknowledgements**: BARFOT study group.

**Disclosure of Interests**: Erik Lönnblom: None declared, Monica Leu Agelii: None declared, Outi Sarelia Employee of: Part time employee in Vacara AB, Ingrid Haas: None declared, Maria Andersson: None declared, J. Xu: None declared, R. Holmdahl: None declared, Gökhan Bergström: None declared, Anna-Karin H. Ekwall: None declared, Anna Rudin: None declared, Alf Kastbom: None declared, Christopher Sjowall: None declared, Binghe Xu: None declared, Lennart T.H. Jacobsson: None declared, Johan Viljanen: None declared, Jan Kihlborg: None declared, Inger Gjertsson: None declared, Rikard Holmdahl Shareholder of: Rikard Holmdahl the founder of Vacara AB.

Effects are still in place by the mere expectation of a response, but one could hypothesise that the observable effect of each intervention may be higher simply because of patients’ awareness of an active treatment (i.e. no risk of placebo).

Here we investigated this hypothesis by comparing the effects of active controlled trials versus placebo controlled trials on the efficacy for the same therapeutic intervention in patients with rheumatoid arthritis (RA), in a systematic approach using all published trials in the field.

Objectives: To assess whether there is a systematic difference in response rates when investigating treatments in randomised controlled trials (RCTs) with active control compared to placebo control in RA clinical trials.

Methods: A systematic literature search was performed. We identified and matched RCTs that used comparable regimens, patient populations, background therapy and outcome reporting, but were different in terms of control group (active or placebo). Included studies were explored for potential risk of bias and mixed-model logistic regression was used to estimate odds ratios (OR) for achieving an American College of Rheumatology (ACR) 20, 50, and 70% response at week 12 in active-controlled studies compared to corresponding placebo-controlled studies.

Results: 7477 studies were screened, 576 of which underwent detailed review. Finally, 39 studies (45 study arms) were included for analysis. ACR response rates were higher in active controlled trials. The OR for achieving an ACR response when investigating the same treatment was consistently higher in studies with active control group than in corresponding studies with placebo control group: ORs were 1.64 (95% Confidence Interval, CI: 1.44-1.86; p<0.001) for ACR20 (Figure 1), 1.46 (95% CI: 1.28-1.71; p<0.001) for ACR50 and 1.61 (95% CI: 1.28-2.02; p<0.001) for ACR70 at week 12.

Conclusion: A systematic difference in response rates favouring head-to-head trials compared to placebo-controlled trials exists in RA clinical trials. This finding calls for consideration when interpreting and planning clinical trials and has implications for patients, investigators, sponsors and regulatory agencies.

References:

Acknowledgements: The authors thank B. Bierbaum for his assistance in building the underlying database for this project.

Disclosure of Interests: None declared.


Table 1. Factors Associated with PGA and PhGA in multivariate regression analysis

<table>
<thead>
<tr>
<th>PGA</th>
<th>PhGA(lij, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔR²</td>
<td>ΔR²</td>
</tr>
<tr>
<td>DAS28-3v-CRP</td>
<td>3.7 (1.9-5.5)</td>
</tr>
<tr>
<td>RAID</td>
<td>0.02</td>
</tr>
<tr>
<td>HAQ</td>
<td>7.7 (6.7-8.8)</td>
</tr>
<tr>
<td>ΔR²</td>
<td>0.61</td>
</tr>
<tr>
<td>ΔR²</td>
<td>5.6 (1.0-8.1)</td>
</tr>
<tr>
<td>H²</td>
<td>0.01</td>
</tr>
</tbody>
</table>

DAS28-3v-CRP: Disease Activity Score-3 variables C-Reactive Protein (CRP), Pain score, Health Assessment Questionnaire (HAQ), the Rheumatoid Arthritis Impact of Disease (RAID) total score, Hospital Anxiety and Depression Scale (HADS) scores, PGA and PhGA were collected. Disease Activity Score (DAS28-3v-CRP) was calculated and taken as the reference measure of current disease activity. Correlation between PGA and PhGA with other continuous variables was evaluated through Pearson’s Correlation Coefficient and variables with p<0.10 in univariate analysis were included in multivariable linear regression models.

Conclusion: PhGA is a closer representation of actual disease activity than PGA, thus providing a more valid basis for treatment decisions aimed at disease activity. These observations support the substitution of PGA by PhGA in the Boolean definition of remission as it would strengthen the representation of disease activity and significantly reduce the risk of overtreatment in comparison to current definitions. The consequences of this change upon the prediction of long-term function and structural stability warrant evaluation. The patient's perspective will remain central to disease management in the form of a distinct target.

References:

Figure 1. Forest plot showing ORs (with 95% CI) of achieving an ACR20 response at week 12 in studies with active control compared to studies with placebo control.

Should we use physician’s global to define remission in rheumatoid arthritis and consider a separate patient-centred target?

R. Teixeira, L. Saraiva, E. Santos, S.C. Barreira, P. Avila-Ribeiro, F. Campos Costa, J. Dinis de Freitas, F. Araujo, R. Freitas, J. Marona, S. Rodrigues-Manica, J.F. Ferreira, M. Couto, M. Guerra, R. J. O. Ferreira, J.A.P. Da Silva, C. Duarte, on behalf of RAID.PT, Coimbra University, Faculty of Medicine, Coimbra, Portugal; 2Centro Hospitalar Universitário de Coimbra, Rheumatology, Coimbra, Portugal; 3Polytechnic Institute of Viseu, Health School, Viseu, Portugal; 4Nursing School of Coimbra, Health Sciences Research Unit: Nursing, Coimbra, Portugal; 5Centro Hospitalar Universitário de Lisboa Norte, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Lisboa, Portugal; 6Centro Hospitalar Vila Nova de Gaia, Rheumatology; Vila Nova de Gaia, Portugal; 7Hospital de Santa Cruz, SCML, Rheumatology and Osteoporosis Unit; Lisboa, Portugal; 8Garcia de Orta Hospital, Rheumatology, almada, Portugal; 9Centro Hospitalar Cova da Beira, Rheumatology, Covilhã, Portugal; 10Hospital Egas Moniz, Centro Hospitalar Lisboa Ocidental Lisboa, Rheumatology, Lisboa, Portugal; 11Nova Medical School, CEDOC, Lisboa, Portugal; 12Health Unit of Guarda, Rheumatology, Guarda, Portugal; 13Beira Interior University, Faculty of Health Sciences, Covilha, Portugal; 14Centro Hospitalar Tondela-Viseu, Rheumatology, Viseu, Portugal; 15Faculty of Medicine Of Coimbra University, ICBR-Coimbra Institute for Clinical and Biomedical Research, Coimbra, Portugal

Background: The definitions of remission play a crucial role in the treat-to-target strategy in rheumatoid arthritis. The patient’s and physician’s global assessment (PGA/PhGA) of disease activity are considered in current definitions, but PGA has been criticized for its poor relationship with actual disease activity. This leads to a considerable risk of overtreatment in patients who are otherwise in remission but fail this target solely because of PGA. PGA near-remission. A dual-target strategy, excluding PGA from the definition of biological remission and the creation of a second target focused on disease impact has been proposed. Another proposal is to substitute PGA by PhGA with the purpose of strengthening the definition with a fourth variable capable of conveying relevant unaccounted factors, such as comorbidity.

Objectives: To assess the relationship of PGA and PhGA with objective measures of disease activity (DAS3v) and their impact upon near-remission and risk of overtreatment.

Methods: This is a cross-sectional analysis of data from RAID.PT, an observational prospective and multicenter study, including adult patients fulfilling RA classification criteria. Tender (TJC28) and swollen (SJC28) 28 joint counts, C-Reactive Protein (CRP), Pain score, Health Assessment Questionnaire (HAQ), the Rheumatoid Arthritis Impact of Disease (RAID) total score, Hospital Anxiety and Depression Scale (HADS) scores, PGA and PhGA were collected. Disease Activity Score (DAS28-3v-CRP) was calculated and taken as the reference measure of current disease activity. Correlation between PGA and PhGA with other continuous variables was evaluated through Pearson’s Correlation Coefficient and variables with p<0.10 in univariate analysis were included in multivariable linear regression models.

Results: We included 299 patients, 81.3% women, mean age of 57.4±12.0 years and disease duration 9.4±9.5 years. Average DAS28-3v-CRP 2.4 (±1.9). DAS28-CRP is the strongest factor associated with PhGA, explaining 45% of its variance. Inversely, it only explains 2% of the variance of PGA, which is more affected by disease impact. In this clinical cohort, 13% of patients were in full Boolean remission and 41% in PGA-near-remission. Only 49 of 123 patients in the latter group had a PhGA >1. Considering PhGA instead of PGA in the Boolean definition of remission would increase the proportion of remission from 13 to 37.5% of the whole cohort.

Disclosure of Interests: None declared.
Disclosure of Interests: None declared.

**Table 1. Associations between ethnicity and disease remission at three months in EIA patients**

<table>
<thead>
<tr>
<th>Model</th>
<th>Odds ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unadjusted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ethnic minority backgrounds</td>
<td>0.76 (0.62, 0.93)</td>
<td>0.01</td>
</tr>
<tr>
<td>Black</td>
<td>0.48 (0.34, 0.67)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Asian</td>
<td>0.74 (0.59, 0.93)</td>
<td>0.01</td>
</tr>
<tr>
<td>Mixed</td>
<td>0.61 (0.28, 1.35)</td>
<td>0.22</td>
</tr>
<tr>
<td>Other</td>
<td>1.09 (0.71, 1.68)</td>
<td>0.67</td>
</tr>
<tr>
<td>Age and sex-adjusted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ethnic minority backgrounds</td>
<td>0.78 (0.63, 0.96)</td>
<td>0.01</td>
</tr>
<tr>
<td>Black</td>
<td>0.49 (0.35, 0.69)</td>
<td>0.00</td>
</tr>
<tr>
<td>Asian</td>
<td>0.75 (0.60, 0.94)</td>
<td>0.01</td>
</tr>
<tr>
<td>Mixed</td>
<td>0.63 (0.28, 1.39)</td>
<td>0.25</td>
</tr>
<tr>
<td>Other</td>
<td>1.17 (0.71, 1.71)</td>
<td>0.63</td>
</tr>
<tr>
<td>Fully-adjusted</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All ethnic minority backgrounds</td>
<td>0.79 (0.65, 0.96)</td>
<td>0.02</td>
</tr>
<tr>
<td>Black</td>
<td>0.57 (0.41, 0.79)</td>
<td>0.001</td>
</tr>
<tr>
<td>Asian</td>
<td>0.76 (0.62, 0.93)</td>
<td>0.009</td>
</tr>
<tr>
<td>Mixed</td>
<td>0.63 (0.27, 1.68)</td>
<td>0.29</td>
</tr>
<tr>
<td>Other</td>
<td>1.04 (0.71, 1.54)</td>
<td>0.80</td>
</tr>
</tbody>
</table>

Conclusion: The results from this large cohort demonstrate that some minority ethnic groups are less likely to reach disease remission in the early months following an EIA diagnosis. Our results are not explained by delays in referral or treatment. Initial treatment strategies varied across ethnic groups. These data highlight the need for investigation into the possible drivers of these inequitable outcomes and reappraisal of EIA management pathways.

**References:**


Table 1. Results of multivariable logistic regression analysis for prediction of response (as defined by DAS28-CRP-based EULAR good or moderate responses) to methotrexate monotherapy in RA

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted OR (95% CI)</th>
<th>p-value</th>
<th>Adjusted OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.97 (0.93-1.00)</td>
<td>0.06</td>
<td>0.95 (0.91-0.99)</td>
<td>0.01</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.78 (0.37-1.62)</td>
<td>0.55</td>
<td>1.10 (0.20-1.19)</td>
<td>0.12</td>
</tr>
<tr>
<td>BMI</td>
<td>1.10 (0.81-1.54)</td>
<td>0.54</td>
<td>1.12 (1.03-1.22)</td>
<td>0.006</td>
</tr>
<tr>
<td>Presence of comorbidities</td>
<td>0.67 (0.31-1.44)</td>
<td>0.31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration</td>
<td>0.98 (0.79-1.22)</td>
<td>0.87</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline DAS28</td>
<td>1.11 (0.81-1.54)</td>
<td>0.54</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline HAQ</td>
<td>1.04 (0.66-1.64)</td>
<td>0.86</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline TJC</td>
<td>1.01 (0.96-1.05)</td>
<td>0.72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline CRP</td>
<td>0.97 (0.91-1.02)</td>
<td>0.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline ESR</td>
<td>1.01 (1.00-1.02)</td>
<td>0.27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline CRP</td>
<td>1.00 (0.99-1.01)</td>
<td>0.85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF positive</td>
<td>0.01 (0.11-0.85)</td>
<td>0.02</td>
<td>0.34 (0.12-0.98)</td>
<td>0.045</td>
</tr>
<tr>
<td>Anti-CCP positive</td>
<td>0.73 (0.27-1.99)</td>
<td>0.54</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX PG1 (16 weeks)</td>
<td>0.99 (0.94-1.04)</td>
<td>0.69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX PG2 (16 weeks)</td>
<td>0.98 (0.95-1.02)</td>
<td>0.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX PG3 (16 weeks)</td>
<td>0.99 (0.96-1.02)</td>
<td>0.43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX PG4 (16 weeks)</td>
<td>0.99 (0.95-1.03)</td>
<td>0.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum IL-6 (baseline)</td>
<td>0.99 (0.95-1.02)</td>
<td>0.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum MMP-3 (baseline)</td>
<td>1.00 (1.00-1.00)</td>
<td>0.48</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BM= Body Mass Index, CCP= Cyclic Citrullinated Peptides, CRP= C-reactive protein, DAS= Disease Activity Score, ESR= Erythrocyte Sedimentation Rate, HAQ= Health Assessment Questionnaire, MTX= Methotrexate, PG= polylutamate, OR=Odds Ratio, RF=Rheumatoid Factor, SJ= Swollen Joint Count, TJC= Tender Joint Count

Analysis 1: Patients’ responses and occurrence of DAS28 remission after 12 months - Univariate logistic regression models (Remission (DAS28-ESR < 2.6) after 12 months (1 yes vs. 0 no))

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q11A: yes vs. no</td>
<td>1.62 (1.27; 2.05)</td>
<td>&lt;0.001</td>
<td>1.74 (1.20; 2.52)</td>
<td>0.004</td>
</tr>
<tr>
<td>Q11C: yes vs. no</td>
<td>1.48 (1.15; 1.93)</td>
<td>0.001</td>
<td>1.66 (1.12; 2.43)</td>
<td>0.010</td>
</tr>
</tbody>
</table>

Analysis 2: Patients’ responses and occurrence of remission after 12 months - Adjusted ORs using logistic regression

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>p-value</th>
<th>OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q11A: yes vs. no</td>
<td>1.86 (1.24; 2.79)</td>
<td>&lt;0.001</td>
<td>2.04 (1.37; 3.03)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Q11C: yes vs. no</td>
<td>1.55 (1.17; 2.07)</td>
<td>&lt;0.001</td>
<td>2.04 (1.34; 3.05)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Conclusion: We provide a robust evidence that self-perceived general health at start of anti-TNF therapy predicts reaching remission at 12 months in pts with RA.
comorbidity history varied with disease activity (Table 1). By contrast, age, number of previous DMARDs, disease duration and smoking habits were relatively similar across categories of disease activity (Table 1).

Table 1. Median [Q1-Q3] or percentage for clinical characteristics in remission (DAS28-ESR≤2.6) and high disease activity (DAS28-ESR≥5.1) categories

<table>
<thead>
<tr>
<th>Variable</th>
<th>Remission</th>
<th>High disease activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (visits)</td>
<td>91,497</td>
<td>25,264</td>
</tr>
<tr>
<td>Age, years</td>
<td>69[53-72]</td>
<td>63[53-72]</td>
</tr>
<tr>
<td>Disease duration</td>
<td>10[4-18]</td>
<td>8[2-17]</td>
</tr>
<tr>
<td>N treatment courses</td>
<td>0[0-0]</td>
<td>0[0-1]</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td>Tender joint count, 28-joints (TJC)</td>
<td>0[0-0]</td>
<td>10[6-14]</td>
</tr>
<tr>
<td>Swollen joint count, 28-joints (SJC)</td>
<td>0[0-0]</td>
<td>7[4-10]</td>
</tr>
<tr>
<td>C-reactive protein (CRP)</td>
<td>3[1-4]</td>
<td>14[5-32]</td>
</tr>
<tr>
<td>Patient global assessment, PGA</td>
<td>13[4-27]</td>
<td>70[55-82]</td>
</tr>
<tr>
<td>Pain</td>
<td>12[4-27]</td>
<td>70[55-82]</td>
</tr>
<tr>
<td>ERS-RA</td>
<td>8[3-16]</td>
<td>12[5-23]</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>6%</td>
<td>7%</td>
</tr>
<tr>
<td>Diabetes</td>
<td>5%</td>
<td>13%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>39%</td>
<td>42%</td>
</tr>
<tr>
<td>Hypertensionism</td>
<td>23%</td>
<td>25%</td>
</tr>
<tr>
<td>Ever smoking</td>
<td>45%</td>
<td>50%</td>
</tr>
</tbody>
</table>

We observed 598 ACS events (in 554 patients) during the 6-month follow-up window. Comparing patients not in remission to patients in remission, adjusting for the covariates described above, indicated that not being in remission increased the risk of ACS occurrence (Figure 1). Similarly, there was an association between DAS28-ESR at the visit and the risk of ACS during the coming six months.

**Conclusion:** Being in RA remission at any visit is associated with a noticeably lower risk of ACS during the following months, suggesting that RA disease activity not only affects CVD risk in the longer term but also in the short term. **Acknowledgements:** NordForsk and Foreum partially funded this research project. **Disclosure of Interests:** Bénédicte Delcoigne: None declared, Sella Aarrestad project.

---

**POS0569**

**IDENTIFICATION OF JOINT LOCATIONS IN AN EARLY RHEUMATOID ARTHRITIS COHORT AS A CHARACTERISTIC OF DISEASE SEVERITY. DATA FROM THE ERA-CLINIQUE BRUSSELS COHORT**

L. Bricman1, S. Emilie1, T. Sokolova1, A. Avramovska1, P. Durez1, 1Cliniques Universitaires Saint-Luc– Université catholique de Louvain (UCL) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium

**Background:** Early RA patients (ERA pts) often present with different areas of joint involvement, but limited data exist to identify which specific joint locations may be indicative of greater disease severity.

**Objectives:** This analysis investigated the baseline (BL) prevalence of swelling in individual joint locations and their possible association with disease characteristics and prognostic factors in a cohort of ERA pts.

**Methods:** This analysis was based on data from the ERA UCLouvain Brussels cohort in which patients were included according the ACR/EULAR 2010 criteria, naïve to DMARDs and followed in our daily clinic. The physician assessed prevalence of baseline individual swollen joint status (present, absent) through a physical examination. The joint count includes 44 joints. Similarly, all patient and RA characteristics were analyzed. The association between BL swelling and disease characteristics was investigated for each individual joints.

**Results:** 453 ERA pts were analyzed, BL swelling was most frequently observed in the wrist (71.1%) followed by IPP 3 and 2 joints (52.5 and 50.1%). DAS4P 4.5 was more present in younger and MCP 2-4 in older pts. BL swelling in the large size joint (knee, elbow, shoulder and ankle), in the medium size joint (wrist) and the small size joint (only MCP3, IPP 1, 2 and MTP5) was highly associated with higher DAS28 (CRP)*. Pts with BL swelling MCP1, 3, 4; MTP 1, 2, 5 was associated with erosive disease*. In contrast, swelling of the knee was correlated with non erosive and also seronegative RA*. Swelling of many joints locations (knee, shoulder, ankle, MCP 1-5, MTP1, 5 and IPP 1, 2) were correlated significantly with a higher HAQ*. Only swelling of MTP1, 2, 5 was associated with the presence of ACPA antibodies*. No difference was observed for smoking habits and gender. (* p<0.001).

**Conclusion:** In our cohort of ERA, small joints swelling was associated with erosive and seropositive RA (only MTP). Swelling of the large joint and the wrist seems to be associated with higher disease activity. In ERA, a difference in joint location presentation may identify pts with poor prognostic factors to be eligible for an intensive treatment or a personalized treatment approach. Further analysis is planned to analyze the correlation with erosion in each joint location and response to Methotrexate.

**Acknowledgements:** This work was supported by CAP48/RTBF.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4460

---

**POS0570**

**UNSUPERVISED DEEP-LEARNING IDENTIFIES SIX CLINICAL SUBTYPES OF RHEUMATOID ARTHRITIS AT BASELINE THAT ASSOCIATE WITH M ETHOTREXATE FAILURE DURING FOLLOW-UP**

T. Maasen2, 3, M. Maurits1, T. Huizinga1, M. Reinders2, 3, E. Van den Akker1, 3, R. Knevel1, 4, 1Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Delft University of Technology (TU Delft), Bioinformatics Lab, Delft, Netherlands; 3Leiden University Medical Center (LUMC), Molecular Epidemiology, Leiden, Netherlands; 4Newcastle University, Rheumatology, Newcastle upon Tyne, United Kingdom

**Background:** Currently methotrexate (MTX) is the prevailing baseline treatment for Rheumatoid Arthritis (RA). Treatment response varies since RA is a highly heterogeneous disease. A tantalizing idea is that the factors causing clinical heterogeneity can already be elucidated at baseline.

**Objectives:** Disentangle clinical heterogeneity of RA patients at baseline to identify likely MTX failure during follow-up.

**Methods:** We constructed patient-specific profiles, featuring baseline clinical measurements which we split into three layers: 1) joint counts, 2) numerical hematology work up, and 3) categorical features (binary serological markers (aCCP, RF) and localization of joint inflammation and tenderness). We applied Z-score scaling on the numerical data and one hot encoding on the categorical features. To identify hidden structure across these layers we used Maui (Multi-omics Autoencoder Integration) [1], and Phenograph [2] for subsequent clustering of patients within the extracted latent space. We examined the most discriminatory features post-hoc with SHAP. With Kaplan Meier curves we assessed MTX efficacy using treatment switch as proxy for failure. We calculated hazard ratios (HR) with univariate Cox-regression.

**Results:** We had 944 RA patients with baseline health record data. MAUI identified 23 latent factors from 335 baseline variables. Phenograph showed 6 RA-subgroups (Table 1 & Figure 1). The baseline clusters (C) are characterized by a different joint involvement or lab value: C1 had a low aCCP-positive (37%) and high median ESR of 33. C1 had the most affected joints (primarily the small joints) with a swollen- (SJC) and tender joint count (TJC) of 15 and 19 respectively. C2 had moderate aCCP-positive (50%) and low median SJC=6 and TJC=9. C3 had MTP involvement, high aCCP-positive (64%), and low ESR=19 but relatively high joint counts; SJC=9 and TJC=12. C4 had no wrists, high aCCP-positive (65%), high ESR=28 and low joint counts; SJC=2, TJC=4. C5 had low lymphocyte numbers and a low median ESR=23, SJC=4 and TJC=3. C6 had MCP1 involvement, was mostly aCCP-positive (59%) and had a slightly higher median ESR=25, SJC=9 and TJC=11.
Clusters differed in MTX failure: 40%, 53%, 69%, 54%, 48% and 64% (for cluster 1-6, \( P = 3.2 \times 10^{-2} \)). Examining the local differences, we observed the biggest difference between C1 and C3 (HR 0.5 (95% CI 0.36-0.7), \( P = 4.4 \times 10^{-5} \)).

**Conclusion:** Using baseline data, we identified 6 putative novel RA subtypes which were associated with differences in MTX failure. Our study demonstrates the applicability of unsupervised deep learning and cluster analysis to elucidate hidden structure in the multi-modal EHR.

**REFERENCES:**
[2] Levine JH. doi:10.1016/j.cell.2015.05.047

**Disclosure of Interests:** Tjardo Maarseveen: None declared, Marc Maurits: None declared, Thomas Huizinga: None declared, Marcel Reinders: None declared, Erik van den Akker: None declared, Rachel Knevel Grant/research support from: Rachel received a grant from Pfizer.

**DOI:** 10.1136/annrheumdis-2022-eular.4600

---

**Table 1. Baseline characteristics of the different clusters**

<table>
<thead>
<tr>
<th></th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
<th>C4</th>
<th>C5</th>
<th>C6</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>224</td>
<td>179</td>
<td>171</td>
<td>162</td>
<td>116</td>
<td>92</td>
</tr>
<tr>
<td>Sex (F)</td>
<td>131 (59)</td>
<td>122 (68)</td>
<td>125 (73)</td>
<td>112 (69)</td>
<td>71 (61)</td>
<td>57 (62)</td>
</tr>
<tr>
<td>RF</td>
<td>95 (42)</td>
<td>89 (50)</td>
<td>106 (62)</td>
<td>107 (66)</td>
<td>68 (59)</td>
<td>55 (60)</td>
</tr>
<tr>
<td>aCCP</td>
<td>82 (36.6)</td>
<td>89 (50)</td>
<td>110 (64)</td>
<td>105 (65)</td>
<td>65 (56)</td>
<td>54 (59)</td>
</tr>
<tr>
<td>DAS44(3)</td>
<td>3.6 (2.7-4.2)</td>
<td>2.7 (2.2-3.1)</td>
<td>2.4 (1.9-2.9)</td>
<td>2.1 (1.7-2.6)</td>
<td>2.2 (1.9-2.6)</td>
<td>2.8 (2.4-3.2)</td>
</tr>
<tr>
<td>SJIC</td>
<td>15 (11-20)</td>
<td>6 (3-8)</td>
<td>9.6 (6-12)</td>
<td>2.1 (1-3.5)</td>
<td>4 (2.6)</td>
<td>4.6 (2.3)</td>
</tr>
<tr>
<td>ESR (mm/hr)</td>
<td>14 (19-27)</td>
<td>9 (6-12)</td>
<td>12.0 (9-18)</td>
<td>4 (2-6)</td>
<td>3 (2-6)</td>
<td>11 (7-13)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>63 (14)</td>
<td>60 (13)</td>
<td>53 (16)</td>
<td>59 (15)</td>
<td>63 (13)</td>
<td>58 (16)</td>
</tr>
<tr>
<td>MTX prescription</td>
<td>192 (85)</td>
<td>146 (81)</td>
<td>182 (80)</td>
<td>159 (80)</td>
<td>188 (75)</td>
<td>78 (85)</td>
</tr>
<tr>
<td>Follow up (days)</td>
<td>1308 (743-2060)</td>
<td>1458 (880-2567)</td>
<td>1821 (982-2566)</td>
<td>1590 (1022-2245)</td>
<td>1566 (787-2000)</td>
<td>1468 (832-2211)</td>
</tr>
<tr>
<td>Symptom duration (days)</td>
<td>124 (52-334)</td>
<td>155 (46-537)</td>
<td>155 (62-365)</td>
<td>217 (77-158)</td>
<td>186 (62-549)</td>
<td>105 (62-365)</td>
</tr>
</tbody>
</table>

Presented are binary variables as n(%) and continuous as median (Q1-Q3) or mean (SD).

---

**Figure 1.** Overview of the distinct RA-clusters: A) 2D UMAP, B) Kaplan Meier plot of MTX-probability across 8.6 years (defined by cluster with shortest follow up), C) SHAP plot of most discriminatory features per cluster.

---

**Table No. 1 Initial cytokine level of patients with early RA compared with healthy donors (pg/ml)**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients with RA(n=23)</th>
<th>Donors(n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1b</td>
<td>2.52 (2.21; 4.95)</td>
<td>0.07 (2.61; 4.9)</td>
</tr>
<tr>
<td>IL-1Pa</td>
<td>219.36 (100.399; 559.77)</td>
<td>150.64 (111.19; 253.83)</td>
</tr>
<tr>
<td>IL-2</td>
<td>7.12 (2.94; 23.12)</td>
<td>10.765 (5.53; 13.87)</td>
</tr>
<tr>
<td>IL-4</td>
<td>2.71 (2.23; 4.4)</td>
<td>3.315 (20.215; 8.5)</td>
</tr>
<tr>
<td>IL-5</td>
<td>6.05 (3.65; 7.66)</td>
<td>2.92 (0.2; 5.24)</td>
</tr>
<tr>
<td>IL-6</td>
<td>36.09 (20.38; 82.02)</td>
<td>7.78 (4.15; 0.193)</td>
</tr>
<tr>
<td>IL-7</td>
<td>33.83 (24.74; 64)</td>
<td>6.15 (0.5; 2.12)</td>
</tr>
<tr>
<td>IL-8</td>
<td>27.99 (22.92; 40.54)</td>
<td>12.47 (4.76; 16.25)</td>
</tr>
<tr>
<td>IL-9</td>
<td>23.01 (14.78; 46.54)</td>
<td>34.17 (26.3; 43.6)</td>
</tr>
<tr>
<td>IL-10</td>
<td>13.61 (5.24; 33.46)</td>
<td>13.22 (5.83; 37.47)</td>
</tr>
<tr>
<td>IL-12</td>
<td>38.14 (19.96; 82.98)</td>
<td>7.775 (2.24; 9.94)</td>
</tr>
<tr>
<td>IL-13</td>
<td>4.53 (0.01; 14.99)</td>
<td>16.695 (9.93; 22.44)</td>
</tr>
<tr>
<td>IL-15</td>
<td>0.37 (0.01; 2.83)</td>
<td>6.695 (3.82; 17.42)</td>
</tr>
<tr>
<td>IL-17</td>
<td>11.24 (5.81; 16.71)</td>
<td>22.87 (5.23; 90.3)</td>
</tr>
<tr>
<td>Eotaxin</td>
<td>263.51 (179.96; 422.95)</td>
<td>102.415 (19.39; 585.69)</td>
</tr>
<tr>
<td>FGF-basic</td>
<td>20.83 (15.79; 23.89)</td>
<td>27.25 (19.32; 44.31)</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>111.21 (86.27; 358.6)</td>
<td>285.345 (112.39; 1037.9)</td>
</tr>
<tr>
<td>IP-10</td>
<td>5616.05 (3123.44; 9901.46)</td>
<td>717.8 (188.68; 4064.81)</td>
</tr>
<tr>
<td>MCP-1</td>
<td>36.99 (19.81; 93.85)</td>
<td>48.595 (22.26; 120.74)</td>
</tr>
<tr>
<td>MIP-1α</td>
<td>9.51 (8.62; 10.09)</td>
<td>10.815 (8.84; 18.1)</td>
</tr>
<tr>
<td>MIP-1β</td>
<td>140.72 (116.05; 174.44)</td>
<td>66.045 (49.36; 99.42)</td>
</tr>
<tr>
<td>PDGF-BB</td>
<td>4975.53 (3031.33; 8994.55)</td>
<td>26024.51 (5854.75; 58715.04)</td>
</tr>
<tr>
<td>TNF-α</td>
<td>42.66 (34.01; 110.11)</td>
<td>38.9 (17.2; 64.87)</td>
</tr>
<tr>
<td>VEGF</td>
<td>84.02 (56.71; 160.84)</td>
<td>205.56 (63.85; 312.77)</td>
</tr>
</tbody>
</table>

\( p<0.05 \) from baseline.
Conclusion: The evaluation of the level of proinflammatory cytokines (IL-6, IL-17), chemokines IP-10, immunoregulatory cytokine IL-9 after 12 weeks and 24 weeks of the initiation of therapy allows to identify a group with the worst long-term prognosis.

Disclosure of Interests: None declared.


ARE WOMEN WITH RHEUMATOID ARTHRITIS REALLY LESS LIKELY TO ACHIEVE REMISSION WITH BIOLOGICS? A COHORT STUDY IN THE SWISS CLINICAL QUALITY MANAGEMENT COHORT

E. Vallejo-Yague1, J. N. Pfund1, T. Burkard1, C. Clair2,3, R. Micheroli4, E. T. New York, United States of America

Objectives: We aimed to compare the likelihood of achieving remission across men and women with RA, who started their first biologic or targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARDs).

Methods: This observational cohort study in the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry included adult RA patients who started their first b/tsDMARDs (from 1997 to 31/Apr/2018). Patient characteristics at start of the b/tsDMARDs were compared between men and women. Subsequently, logistic regression was used to assess the likelihood of achieving remission during the first year after b/tsDMARDs start, defined by disease activity score 28 (DAS28) <2.6, in men compared to women (reference group). Secondary analyses were adjusted for age and seropositivity as prognostic factors, and we investigated the role of potential mediators or factors that could explain the findings from the main analysis.

Results: The study included 3722 RA patients, of which 2839 (76.3%) were women and 883 (23.7%) were men. Compared to women, men were older at diagnosis and start of b/tsDMARDs, and had shorter time from diagnosis to the first b/tsDMARD (3.4 vs 5.0 years, p<0.001). At baseline (b/tsDMARD initiation), women had significantly more active disease activity (DAS28) and worse patient-reported outcomes (Health Assessment Questionnaire, tender joints). Concomitant osteoporosis and depression/anxiety were more frequent among women, while men had more frequent diabetes and prior or current smoking record. Physician’s global disease assessment and swollen joints were similar across groups. Compared to women, men were 21% more likely to achieve DAS28-remission, with an odds ratio (OR) 1.21, 95% confidence interval (CI) 1.02-1.42. Secondary analyses adjusting by for age and seropositivity did not change the findings (adjusted OR 1.24, 95% CI 1.05-1.46). Our analyses of potential mediators suggested that the observed effect may be explained by the shorter disease duration and lower DAS28 at treatment initiation in men versus women.

Conclusion: Men started b/tsDMARDs at an earlier stage of disease than women, particularly regarding disease duration and disease activity (DAS28) at b/tsDMARD initiation, and they presented higher odds of remission. This highlights the importance of an earlier treatment, and it suggests to target an earlier stage of disease in women to match the benefits observed in men.

Acknowledgements: We thank all patients and rheumatologists contributing to the SCQM registry, as well as the entire SCQM staff. A list of rheumatology offices and hospitals which contribute to the SCQM registry can be found at http://www.scqm.ch/institutions. A list of financial supporters of SCQM can be found at http://www.scqm.ch/sponsors. AMB acknowledges that her professorship is partly endowed by the Swiss National Pharmacy Association (PharmaSuisse) and the ETH Foundation.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4677

MUSCULOSKELETAL ULTRASOUND STUDIES ARE CRITICAL FOR DETECTING SERONEGATIVE INFLAMMATORY ARTHRITIS

C. Lin1, R. Chou2

1University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Buffalo, New York, United States of America

Background: The autoantibody status of rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP Ab) has gained widespread recognition for its role in the diagnosis of rheumatoid arthritis (RA) based on the latest diagnostic criteria for RA.1 However, in early disease, the rates of antibody expression have been reported as low as 50%, rendering early diagnosis of RA difficult. Furthermore, the nature of seronegative rheumatoid arthritis is unknown, though it is presumed to have less aggressive disease course as compared to its seropositive counterparts. Musculoskeletal (MS) ultrasound studies have been widely used in recent clinical practice to assess soft-tissue abnormalities of the joints and disease states in RA, such as synovitis and bone erosions. MS ultrasound studies were recently shown to be more sensitive to detect early synovial changes and erosions than other radiographic methods while maintaining cost-effectiveness.2 We hypothesize that MS ultrasound studies are more sensitive to detecting inflammatory changes in seronegative inflammatory arthritis, which is often subclinical in presentation.

Objectives: To assess the role of MS ultrasound studies in detecting early inflammatory changes in the joints and diagnosing seronegative inflammatory arthritis.

Methods: A retrospective electronic medical record review was performed of all patients at the two University at Buffalo rheumatology clinics who underwent MS ultrasound studies after complaining of multiple joint pain. All these patients were previously seen and evaluated by at least one other medical provider, who found no evidence of inflammatory arthritis on physical examination. These patients did not meet diagnostic criteria for rheumatoid arthritis due to a lack of gross joint swelling and/or positive serological makeup. As part of their clinical care, they were referred to obtain MS ultrasound studies to rule out inflammatory arthritis. All patients were de-identified at initial data collection. Information pertaining to the patients’ demographics (gender, age, ethnicity, etc.), 2) findings of MS ultrasound studies, and 3) serological studies (RF, anti-CCP Ab, HLA-B27) was collected and tabulated.

Results: Of the 363 patients who underwent MS ultrasound studies, 280 of them (77.1%) of them were found to have synovial hypertrophy [minimal = 23%, mild = 46%, moderate = 29%, severe = 2%] in bilateral MCP,PIP, carpal, and/MTP joints, therefore confirming a diagnosis of inflammatory arthritis. The average age of these 280 patients was 48.35 ± 14.86 years old at the time of diagnosis, with female to male ratio of 4.38:1. Surprisingly, of these 280 patients with evidence of inflammatory arthritis, 69 (24.8%) of them were found to have joint erosions with either MCP or MTP joints, supporting a diagnosis of advanced inflammatory arthritis with erosive disease. The erosions were predominantly located in MTP joints (77.1%) as compared to MCP joints (22.9%). Therefore, our findings clearly demonstrated distinct clinical and ultrasonography features of seronegative inflammatory arthritis (SNIA) as compared to erosive RA.

Conclusion: MS ultrasound studies are more sensitive to and critical for detecting inflammatory changes and joint damages in SNIA due to its subclinical presentation. Based on our findings, SN IA is underdiagnosed in individuals who complain of joint pain without gross synovitis. SNIA also likely has distinct pathophysiology that needs further characterization.

REFERENCES:


Table 1. Capacity of cardiovascular risk algorithms to detect presence of carotid plaque in rheumatoid arthritis patients

<table>
<thead>
<tr>
<th>Algorithms (cut-off points)</th>
<th>AUC</th>
<th>CI 95%</th>
<th>Superior limit</th>
<th>p</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO (5.25)</td>
<td>0.729</td>
<td>0.649</td>
<td>0.809</td>
<td>&lt;0.001</td>
<td>72.9%</td>
<td>64.8%</td>
</tr>
<tr>
<td>FRS-lipids (8.62)</td>
<td>0.684</td>
<td>0.601</td>
<td>0.767</td>
<td>&lt;0.001</td>
<td>67.8%</td>
<td>61.0%</td>
</tr>
<tr>
<td>FRS-BMI (11.55)</td>
<td>0.700</td>
<td>0.618</td>
<td>0.781</td>
<td>&lt;0.001</td>
<td>72.9%</td>
<td>61.0%</td>
</tr>
<tr>
<td>SCORE (15)</td>
<td>0.687</td>
<td>0.601</td>
<td>0.773</td>
<td>&lt;0.001</td>
<td>79.7%</td>
<td>45.7%</td>
</tr>
<tr>
<td>ACC/AHA (9.82)</td>
<td>0.687</td>
<td>0.604</td>
<td>0.770</td>
<td>&lt;0.001</td>
<td>62.7%</td>
<td>61.0%</td>
</tr>
<tr>
<td>QRISK3 (0.05)</td>
<td>0.733</td>
<td>0.654</td>
<td>0.811</td>
<td>&lt;0.001</td>
<td>71.2%</td>
<td>61.0%</td>
</tr>
</tbody>
</table>

AUC, area under the curve; WHO, World Health Organization; FRS, Framingham Risk Score; BMI, body mass index.
ACR/AHA showed AUC: 0.687 (0.604-0.770), cutoff point: 3.82, sensitivity: 62.7%, and specificity: 61.0%. QRISK showed AUC: 0.733 (0.654-0.811), cutoff point: 6.05, sensitivity: 71.2%, and specificity: 61.0%. All algorithms had a p-value <0.001 (Figure 1 and Table 1).

Conclusion: The WHO calculator was one of the best algorithms for the detection of CP, with the best positive and negative likelihood ratios; however, like the other algorithms, a lower cut-off point than the one established by official guidelines was needed to identify high-risk patients with the presence of CP, who were initially classified as low-moderate risk by the CVR algorithm.

REFERENCES:

Disclosure of Interests: None declared.
DOI: 10.1136/annrheumdis-2022-eular.5023
Background: Cardiovascular disease is the major cause of death in rheumatoid arthritis (RA) patients. Cardiovascular risk algorithms are used to estimate the probability for the development of a cardiovascular event in 10 years, according to patients’ characteristics, however, no algorithm existed for the Hispanic population until the World Health Organization (WHO) published the cardiovascular disease risk charts for 21 regions (1).

Objectives: To compare the capacity of the 2019 WHO algorithm and the 2013 American College of Cardiology/American Heart Association (ACC/AHA) algorithm for detecting the presence of carotid plaque (CP) in RA patients.

Methods: Cross-sectional study. We recruited a total of 164 patients with RA diagnosis, according to the 2010 ACR/EULAR classification criteria, aged 40-75 years. Patients with a previous cardiovascular event were excluded. Cardiovascular risk was evaluated with the 2019 WHO algorithm for the Mexican population and the 2013 ACC/AHA cardiovascular algorithm. The results were multiplicated by 1.5, according to current guidelines. A carotid ultrasound was performed to all study subjects by a certified radiologist blinded to clinical information. Distribution was evaluated with the Kolmogorov-Smirnov test. Correlations were performed with the Spearman-rho coefficient (rho). A ROC-curve analysis was performed for both algorithms. The areas under the curve (AUC) of the algorithms were compared using the method of DeLong.

Results: The presence of CP was detected in 59 (36.0%) patients. Demographic characteristics are shown in Table 1. There was a large positive correlation between the WHO and the ACC/AHA algorithms (rho=0.880, p<0.001). Both algorithms showed significant discrimination for the presence of CP in RA patients. The WHO algorithm had an AUC 0.729 (95% CI 0.649-0.809, p<0.001) and the ACC/AHA algorithm had an AUC 0.687 (95% CI 0.604-0.770, p<0.001). However, there was a difference when comparing both AUC, which was higher with the WHO algorithm (p=0.042) (Figure 1).

Table 1. Demographic characteristics of RA patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RA patients (n=164)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD</td>
<td>55.82 ± 8.94</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>157 (95.73)</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>27 (16.46)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>53 (32.32)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>58 (35.36)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>56 (34.15)</td>
</tr>
<tr>
<td>Active smoking, n (%)</td>
<td>19 (11.9)</td>
</tr>
<tr>
<td>WHO algorithm, median (IQR)</td>
<td>4.5 (3.0-9.0)</td>
</tr>
<tr>
<td>ACC/AHA algorithm, median (IQR)</td>
<td>3.75 (1.80-9.26)</td>
</tr>
<tr>
<td>Carotid plaque, n (%)</td>
<td>59 (36.0)</td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; T2DM, type 2 diabetes mellitus; WHO, world health organization; ACC/AHA, American College of Cardiology/American Heart Association.

Conclusion: Our results showed that although both algorithms had significant discrimination for the presence of CP, the 2019 WHO algorithm had a better capacity for the detection of CP than the 2013 ACC/AHA algorithm, for this specific Hispanic RA population. This could be attributed to the fact that the WHO algorithm was designed for 21 different regions, including the Mexican population.

REFERENCES:

Disclosure of Interests: None declared.
**PB0579**

**ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY**


1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 2Leeds Teaching Hospitals NHS Trust, Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom; 4University of Texas, Division of Rheumatology, Dallas, United States of America; 6Bristol Myers Squibb (at the time of analysis), Immunology and Fibrosis, Princeton, United States of America; 8Bristol Myers Squibb, Immunology and Fibrosis, Princeton, United States of America; 9Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 10Instituto de Rehabilitación Psicofísica, Department of Rheumatology, Buenos Aires, Argentina; 11Signifience, Biostatistics, Paris, France; 12Bristol Myers Squibb, Clinical Pharmacology and Pharmacoemetrics, Princeton, United States of America; 13Cognigen Corporation, a Simulations Plus company, Pharmacometrics, Buffalo, United States of America; 14Cognigen Corporation, a Simulations Plus company, Statistics, Buffalo, United States of America

**Background:** Infections are the most commonly reported AE observed in patients with RA treated with immunosuppressive therapies and can be clinically significant. A recent review reported differences in the risk of infection for some biologics such as tocilizumab and TNF inhibitors. Abatacept selectively modulates T-cell co-stimulation and is approved for the treatment of RA. In patients with polyarticular-course juvenile idiopathic arthritis, no association was found between higher serum abatacept exposure and the incidence of infection. This has not been evaluated for adult patients with RA.

**Objectives:** To determine if higher serum abatacept exposure during treatment with SC abatacept was associated with increased risk of infection in adult patients with RA.

**Methods:** AVERT-2 (Assessing Very Early Rheumatoid arthritis Treatment-2) was a randomized, placebo-controlled study of SC abatacept + MTX vs abatacept placebo + MTX in MTX-naïve, anti-citrullinated protein antibody–positive patients with early, active RA. A post hoc population pharmacokinetic (PK) analysis was performed using PK-evaluable patient data from the induction period (year 1) of AVERT-2. Association between steady-state abatacept exposure (min plasma concentration [Cmin], max plasma concentration [Cmax], and average plasma concentration [Cavg]), or compared with placebo (Figure 1A–C). Kaplan–Meier plots of probability vs time on treatment by abatacept exposure quartiles and Cox proportional-hazards models.

**Results:** PK of SC abatacept was defined as a linear 2-compartment model with first-order absorption and first-order elimination. The findings of the updated PK analysis were consistent with those reported in prior population analyses of abatacept PK in adults with RA. The final model included effects of baseline body weight, estimated glomerular filtration rate, sex, age, albumin, MTX use, NSAID use, SJC, and race on abatacept clearance. The only covariate with a clinically relevant effect was higher body weight, which caused an increase in clearance and volume. Infections occurred in a total of 330/693 (47.6%; serious, 1.6%) patients treated with abatacept, and 134/301 (44.5%; serious, 1.3%) with placebo during the first year of AVERT-2. In patients taking abatacept, the mean (SD) study exposure to abatacept was 376 (60) days, while mean (SD) prednisone equivalent dose was 6.7 (3.8) mg/day and mean (SD) MTX dose was 9.6 (3.0) mg/week. No exposure–response relationship was observed between the probability of first infection and steady-state abatacept exposure quartiles (Cmin, Cavg, and Cmax, or compared with placebo (Figure 1A–C). Kaplan–Meier assessment also showed no increase in risk of infection with concomitant use of MTX and glucocorticoids.

**Conclusion:** No association was found between initial infection and steady-state abatacept exposure (Cmin, Cavg, Cmax) or MTX and glucocorticoid use in patients with RA treated with SC abatacept.

**REFERENCES:**


**Acknowledgements:** This study was sponsored by Bristol Myers Squibb. Writing and editorial assistance were provided by Fiona Boswell, PhD, of Caudex, and was funded by Bristol Myers Squibb. Support was provided by Sandra Overfield as Protocol Manager, and Prema Sukumar and Renfang Hwang as Data Science Leads.

**Disclosure of Interests:** Paul Emery Consultant of: AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Samsung, Merck, Novartis, Pfizer, Grant/research support from: AbbVie, Bristol Myers Squibb, Eli Lilly, Novartis, Pfizer, Roche, Samsung, Roy Fleischmann Consultant of: Amgen, AbbVie, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Novartis, Pfizer, Grant/research support from: Amgen, Abb-Vie, Arthrosi, Biosplice, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Horizon,
TRENDS IN THE OCCURRENCE OF ISCHEMIC HEART DISEASE OVER TIME IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY FROM NORWAY OF 1821 PATIENTS FROM 1972 TO 2014

C. L. Alsing,1,2 T. W. Nystad,3,4 J. Iland,5,6 C. G. Gjesdal,2,3,4 H. Midtbø,2,3,4 G. Stjernvall,2,3,4 B. T. Toldrá,5,6 on behalf of RbA - Bergen group of Epidemiology and Biomarkers in Rheumatic Diseases.1 Haraldsplass Deaconess Hospital, Department of Internal Medicine, Bergen, Norway; 2University of Bergen, Department of Clinical Science, Bergen, Norway; 3Haukeland University Hospital, Department of Rheumatology, Bergen, Norway; 4University of Bergen, Department of Global Public Health and Primary Care, Bergen, Norway; 5Western Norway University of Applied Science, Department of Health and Social Science, Centre for Evidence-Based Practice, Bergen, Norway; 6Haukeland University Hospital, Department of Heart Disease, Bergen, Norway; 7Norwegian Institute of Public Health, Division of Mental and Physical Health, Bergen, Norway

Background: Previous studies have shown that rheumatoid arthritis is associated with a 1.5 to 2.0 times increased risk of acute myocardial infarction (AMI) and ischemic heart disease (IHD) compared with the general population [1,2]. RA treatment has improved vastly over the last two decades, due to the focus on early and aggressive treatment and the use of synthetic and biologic DMARDs. Several studies have documented higher rates of remission and better long-term outcomes in patients with early introduction of DMARDs [3]. This “window of opportunity” may also be a critical phase for intervention against the development of atherosclerosis in RA. There is little information about the occurrence of AMI and IHD in RA patients diagnosed after the introduction of modern RA treatment.

Objectives: To evaluate trends of AMI and IHD in RA patients compared with the general population over time.

Methods: We performed a retrospective cohort study of 1821 RA patients diagnosed from 1972 to 2013. The total population of Hordaland, Norway was used as a comparison cohort. Information on AMI and IHD events was obtained from hospital patient administrative systems or cardiovascular registries during 1972-2014. Aggregated counts of AMI, IHD and population counts of the comparison cohort were used to calculate expected counts of AMI and IHD in the RA cohort per 5-year age group, sex and calendar year. We then used Poisson regression with expected counts as an offset to estimate standardized event ratios (SER) as a measure of excess events.

Results: The difference in events (excess events) in RA patients compared with the general population declined on average 1.3% per year for AMI and 2.3% for IHD from 1972 to 2014. There was no significant excess AMI (SER 1.05, 95% CI 0.89–1.35) and IHD events (SER 1.02, 95% CI, 0.89–1.16) for RA patients diagnosed after 1998 compared with the general population.

Conclusion: RA patients have historically had an excess risk of IHD compared with the general population. Our study did not find excess AMI or IHD events in RA patients diagnosed after 1998. Our findings may reflect improved management of RA, CVD prevention or changes in the case-mix of RA patients over time.

REFERENCES:
protein antibodies (ACPA), clinical suspect arthralgia (CSA) and rheumatoid arthritis (RA) in a large population-based cohort.

**Methods:** Cross-sectional data were used from 17346 participants of the Dutch Lifelines Cohort Study, of whom baseline SAF and ACPA levels were available. The presence of CSA was determined using EULAR questions from the connective tissue disease screening questionnaire (CSQ). Individuals were divided into four groups: ACPA negative controls (n=17211), ACPA positive without CSA (n=49), ACPA positive with CSA (n=31) and defined RA (n=52). Multinomial regression was used to compare SAF levels and correct for potential confounders.

**Results:** SAF levels were higher in the ACPA positive with CSA group (OR 2.04, p=0.034) and the defined RA group (OR 3.10, p<0.001) compared to controls, but not in the ACPA positive without CSA group (OR 1.07, p=0.875). The difference in SAF levels remained statistically significant in the defined RA group after adjusting for age (OR 2.09, p=0.011), smoking status, renal function or HbA1c. In the ACPA positive with CSA group, the effect was found to be comparable (corrected for age: OR 2.09).

**Conclusion:** Our results indicate that ACPA positive individuals with CSA have elevated SAF levels, which is regarded as an early marker for oxidative stress and a possible indicator for development of cardiovascular disease. Therefore it is important to conduct further studies to explore if, in individuals with clinical suspect arthralgia, cardiovascular risk management should be considered in future clinical practice.

**REFERENCES:**


![Figure 1. The top chart shows SAF levels measured with the AGE reader in the 4 groups: ACPA negative controls, ACPA positive without CSA group, ACPA positive with CSA group and defined RA group. The lower picture shows the AGE reader we used from DiagnOptics Technologies BV, Groningen, the Netherlands.](https://www.diagnoptics.com/)

**Acknowledgements:** The Lifelines initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG), Groningen University and the Provinces in the North of the Netherlands (Drenthe, Friesland, Groningen).

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.172

**POSS0583**

**RHEUMATOID ARTHRITIS BENEFITS FROM FASTING AND PLANT-BASED DIET: AN EXPLORATORY RANDOMIZED CONTROLLED TRIAL (NUTRIFAST)**

A. M. Hartmann1,2, F. I. Kandil1,2, N. Steckhan1,2, T. Häupl1,2, C. S. Kessler1,2, A. Michalsen1,2, D. A. Koppold-Liebscher1,2, Christ–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Social Medicine, Epidemiology and Health Economics, Berlin, Germany;2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology and Allergology, Berlin, Germany;3Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Paediatric Oncology/Haematology, Otto-Heuener Kreislinikum, Charité Berlin, Berlin, Germany;4Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany;5Immanuel Hospital Berlin, Department of Internal and Integrative Medicine, Berlin, Germany

**Background:** Fasting has been shown to be beneficial in many diseases, including rheumatoid arthritis (RA). Among other effects, fasting stimulates ketogenic metabolism, induces autophagy, and harbors immunomodulatory functions. Recent studies have highlighted the role of the intestinal microbiota in the still unclear etiology of RA1. This could be a potential target for additional dietary therapy in RA.

**Objectives:** To investigate the effect of therapeutic fasting followed by a plant-based diet compared to standard dietary recommendations in patients with RA.

**Methods:** In this pilot study2 patients with RA were randomized to either a 7-day fast (≤250kcal/d) followed by 11 weeks of plant-based diet or to conventional nutritional counselling according to the recommendations of the German Society for Nutrition (Deutsche Gesellschaft für Ernährung, DGE) for 12 weeks. Disease activity and treatment response in RA (including Health Assessment Questionnaire, HAQ; EULAR Response Criteria, ACR Response Criteria) were measured at baseline (T0), day 7 (T1), 6 weeks (T2) and 12 weeks (T3).

**Results:** A total of 50 from S3 enrolled participants were included into the per-protocol analysis. The mean age was 51.96 ± 9.4 years with symptoms duration of 6.8 ± 8.1 years; 92% were females and 78% were ACPA and/or RF IgM positive. At baseline, participants presented HAQ 0.8 ± 0.5, DAS28CRP 4.0 ± 1.3, CRP 3.1 ± 3.8mg/L, and a BMI of 25.0 ± 3.7kg/m². The primary endpoint did not become significant. However, post-hoc analyses revealed clinically relevant improvements in the HAQ after 12 weeks in both the fasting and the DGE group (∆-0.29; 95% CI, -0.45 to -0.13; p=0.032; and ∆-0.23; 95% CI, -0.45 to -0.22; p=0.032, respectively). Furthermore, the effect already set on by day 7 in the fasting group compared to week 6 in the DGE group (Figure 1). This effect was independent of antibody status, delivery mode of the intervention or previous dietary forms. CV risk factors including weight and total cholesterol levels improved stronger in the fasting group compared to the DGE group (∆-3.9 kg vs. -0.7 kg; 95% CI, 1.4 to 5.0, p = 0.001 and ∆-18.60 mg/dL vs. ∆-6.44 mg/dL; 95% CI, 1.7 to 42.8, p = 0.007).

![Figure 1. EULAR and ACR Response until week 12 and HAQ up to 6 months. ACR, American College of Rheumatology; CI, confidence interval; HAQ, health assessment questionnaire.](https://www.acl.org/)

![Figure 2. POS0583].](https://www.acl.org/)
Conclusion: Fasting followed by a plant-based diet positively impacts disease activity and CV risk factors in RA, comparable to and no lesser than those of an anti-inflammatory diet according to the DGE. These results may open new perspectives by dietary interventions in an integrative therapeutic approach. Further confirmatory clinical studies with larger patient numbers are needed to confirm these exploratory findings.

REFERENCES:

Disclosure of Interests: Anika M. Hartmann: None declared, Farid I. Kandil: None declared, Nico Steckhan: None declared, Andreas Michalsen Paid instructor for: co-founder and instructor in the Academy of Integrative Fasting, Daniela A. Koppold-Liebscher

DOI: 10.1136/annrheumdis-2022-eular.452
Conclusion: The psychiatrist’s diagnosis was abnormal in 9 patients. This included one patient with major depression, one patient with moderate depression, and two patients with adjustment disorder. The Patient Health Questionnaire-9 (PHQ-9) and Center for Epidemiologic Studies Depression Scale (CES-D) questionnaires were used; a score of 10 or more on the PHQ-9 and 16 or more on the CES-D was considered for the diagnosis of RA complicated by psychiatric disorders.

Results: Forty-nine outpatients with RA who agreed to participate in this study were included. Age, gender, type of Disease-modifying anti- rheumatic drugs, prednisolone use, presence of diabetes, hypertension, dyslipidemia, and CRP were investigated. The Patient Health Questionnaire-9 (PHQ-9) and Center for Epidemiologic Studies Depression Scale (CES-D) questionnaires were used; a score of 10 or more on the PHQ-9 and 16 or more on the CES-D was considered a cutoff. The psychiatrist was blinded to the results of the questionnaire and conducted a structured interview in a separate room. The psychiatrist’s diagnosis was defined as the Gold Standard, and was compared with the PHQ-9 and CES-D. Results: Psychiatrist’s diagnosis was abnormal in 9 patients. This included one patient with major depression, one patient with moderate depression, two patients with minor depression, and two patients with adjustment disorder. The PHQ-9 had a specificity of 98%, a sensitivity of 33%, a positive predictive value of 75%, and a negative predictive value of 87%. The CES-D had a specificity of 82%, a sensitivity of 100%, a positive predictive value of 56%, and a negative predictive value of 100%.

Conclusion: The PHQ-9 and CES-D may be useful in screening for psychiatric disorders including associated with RA.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.627

POS0586
DIAGNOSIS OF MENTAL DISORDER COMPLICATED BY RHEUMATOID ARTHRITIS: A STUDY OF THE VALIDITY OF A PSYCHIATRIST’S DIAGNOSIS AND QUESTIONNAIRE METHOD

Y. Miwa1, H. Tomioka2, M. Hosaka3, Y. Mitamura1, 1Showa University School of Medicine, Division of Rheumatology, Department of Medicine, Tokyo, Japan; 2Showa University School of Medicine, Department of Psychiatry, Yokohama, Japan; 3Kasuyama Clinic, Department of psychosomatic medicine, Yamanshi, Japan

Background: It has been reported that about 15% of patients with rheumatoid arthritis (RA) have depression, and most of these studies have used questionnaire methods. Most of the studies have used questionnaires for depression. Because the depression questionnaire includes questions about physical symptoms, it is necessary to be careful in interpreting the results when there is an underlying disease. In addition, there are no studies on other mental disorders.

Objectives: In this study, we examined the validity of the questionnaire method for the diagnosis of RA complicated by psychiatric disorders.

Methods: Forty-nine outpatients with RA who agreed to participate in this study were included. Age, gender, type of Disease-modifying anti-rheumatic drugs, prednisolone use, presence of diabetes, hypertension, dyslipidemia, and CRP were investigated. The Patient Health Questionnaire-9 (PHQ-9) and Center for Epidemiologic Studies Depression Scale (CES-D) questionnaires were used; a score of 10 or more on the PHQ-9 and 16 or more on the CES-D was considered a cutoff. The psychiatrist was blinded to the results of the questionnaire and conducted a structured interview in a separate room. The psychiatrist’s diagnosis was defined as the Gold Standard, and was compared with the PHQ-9 and CES-D.

Results: Psychiatrist's diagnosis was abnormal in 9 patients. This included one patient with major depression, one patient with moderate depression, two patients with minor depression, and two patients with adjustment disorder. The PHQ-9 had a specificity of 98%, a sensitivity of 33%, a positive predictive value of 75%, and a negative predictive value of 87%. The CES-D had a specificity of 82%, a sensitivity of 100%, a positive predictive value of 56%, and a negative predictive value of 100%.

Conclusion: The PHQ-9 and CES-D may be useful in screening for psychiatric disorders including associated with RA.

Disclosure of Interests: None declared.


POS0587
TRAJECTORYs AND FACTORS INFLUENCING THE EVOLUTION OF HAND GRIP AMONG PATIENTS WITH RHEUMATOID ARTHRITIS

B. Squecioni1, B. Pereira1, M. Beauger2, M. Couderc3, F. Ladouce3, S. Malochet3, S. Mathieu4, P. Marie-Eva5, M. Soubrier4, A. Tournadre4; 1CHU Clermont-Ferrand, Rheumatology, Clermont Ferrand, France; 2CHU Clermont-Ferrand, Biostatistics department DRCI, Clermont-Ferrand, France

Background: Rheumatoid arthritis (RA) is characterized by an early reduced grip strength which persists over time despite the remission of the disease suggesting the presence of a sarcopenia.

Objectives: To study the evolution of the grip strength measured by the handgrip, by identifying different trajectories and associated factors.

Methods: Patients with active RA who visited the Rheumatology Department of Clermont-Ferrand University Hospital for initiating bDMARD were invited to participate to the longitudinal cohort RCVRIC analyzing cardiovascular risk and chronic inflammatory rheumatic disease. Within the RCVRIC cohort 175 RA initially underwent a handgrip determination. 143 patients had at least 2 handgrip measurements over 2 years, allowing analysis of trajectories by the “Group Based Trajectory Modeling” method. For the trajectories, handgrip was expressed in terms of percentage of the theoretical value defined according to age and sex. The clinical characteristics of the disease, the therapeutic response, and the body composition associated with each trajectory were analyzed.

Results: At inclusion, the handgrip was normal among only 4% of patients, with an alteration of 51% of its theoretical value. After 2 years of follow-up, a majority of patients improved their handgrip trajectory to reach an average of 68% of the theoretical one, but only 15.7% of the patients normalized their handgrip. Four trajectories have been identified along with associated factors:

1st trajectory consists of low handgrip with little improvement and was composed of: 9 patients (6.3%), median age 60 years [53.6;69.3], 88% women, disease duration 17.99 years [6.78;24.9], EAS 28 ESR 4.68 ± 1.29, and initial handgrip 21% of the theoretical value [8;24].

2nd trajectory shows good improvement (+72%) and was composed of: 70 patients (49%), median age 58.9 years [54.4;64.3], 84% women, disease duration 5.99 years [1.46;14.8], EAS 28 ESR 4.43 ± 1.07, and initial handgrip 32% of the theoretical value [17.8;46.4].

3rd trajectory shows moderate improvement (+25%) and was composed of: 43 patients (30%), median aged 60.7 years [45.7;69.4], 79% women, disease duration 3.5 years [1.25;9.9], EAS 28 ESR 4.0 ± 1.03 and initial handgrip 60% of the theoretical value [48.2;76].

4th trajectory shows high handgrip and was composed of: 21 patients (14.7%), 57% women, median age 57.9 years old [49.7;67.4], disease duration 3.81 years [2.14; 10.7], EAS 28 ESR 3.68 ±1.29 and initial hand grip 92% of the theoretical value [85; 100].

Significant differences at inclusion between the 4 trajectories were observed. The 4th trajectory was characterized by a higher proportion of men (p=0.05), lower disease activity (EAS 28 ESR (p=0.02), SDAI (p=0.04), better initial handgrip (p=0.03) and 6min walk test (p=0.0001), and a lower percentage of fat mass (p=0.04). In contrast, a higher disability (HAQ, p=0.002), a lower total lean body mass (p=0.001) and poorer therapeutic response (p=0.04) were noted in trajectories 1 and 2.

Conclusion: After 2 years of follow-up, a majority of patients improved their handgrip trajectory. However, very few patients normalized their hand grip. Four trajectories of handgrip were identified; the main indicators of hand grip’s improvement were the control of the disease activity, low functional disability, walking performance, a low percentage of fat mass and high lean mass.

REFERENCES:
SEASONALITY OF FLARE AND REMISSION PATTERNS IN RHEUMATOID ARTHRITIS: A POPULATION-BASED COHORT STUDY

R. Javed1, C. S. Crowson2, J. M. Davis III1, E. Myasoedova2,3. Mayo Clinic, Division of Rheumatology; Rochester, United States of America;4 Mayo Clinic, Division of Rheumatology; Department of Quantitative Health Sciences, Rochester, United States of America

Background: Flare of rheumatoid arthritis (RA) disease activity is an important aspect of RA disease experience for patients with RA, associated joint damage and comorbidity. Major advancements in treatment of RA in recent decades resulted in improving trends in RA disease activity and increasing rates of remission. However, flares in RA remain common and some patients are still unable to achieve remission. Disease-modifying antirheumatic drugs have a major impact on controlling RA disease activity, minimizing the likelihood of flares. The effect of environmental factors on the pattern of flares and remissions in RA is less studied. Previous studies showed conflicting results regarding the likelihood of flare and remission occurrence across the seasons of the year.

Objectives: To assess the seasonal pattern in the occurrence of flares and remissions in a population-based cohort of patients with RA.

Methods: This retrospective population-based cohort study included patients with RA (age ≥30 years) who met 1987 ACR criteria in 1988-2007. A retrospective review of each clinical visit in the medical records was performed to ascertain flare or remission status. A flare was defined as an episodic worsening of RA disease activity that leads to initiation, change or increase of treatment. Remission was defined as the absence of disease activity based on a tender joint count of 0, a swollen joint count of 0 and an ESR less than 10 mm/h. Seasons were defined as: winter (Dec, Jan, Feb), spring (Mar, Apr, May), summer (June, July, Aug) and autumn (Sep, Oct, Nov). All subjects were followed until death, migration or July 1, 2012. Generalized linear models with random effects accounts for multiple visits per patient were used for data analyses.

Results: The study included 650 RA patients (mean age 55.8 years; 69% female) with a mean follow-up of 10.3 years. In a total of 17,323 clinical visits, patients were flaring in 2887 (17%) visits. The incidence of RA flares was 15% higher in the spring than in the winter (OR 1.15: CI: 1.02-1.29, p=0.045) after adjusting for age, sex and RA duration. There was no change in flare pattern between winter and summer or autumn. Remission rate did not differ between the seasons. (3df test p=0.65).

Conclusion: Patients with RA were more likely to experience flares in spring as compared to winter, and there were no differences in flare rates for the rest of the seasons. Remission rates were similar between the seasons of the year. The reasons for this seasonal effect on flare pattern is unknown, and the role of patient-related and environmental risk factors remains to be investigated. Our findings on the seasonality in flare occurrence can be used to inform patients about the risk of RA disease flares throughout the year.

Disclosure of Interests: Rabia Javed: None declared, Cynthia S. Crowson: None declared, John M Davis III Grant/research support from: Received research grant from Pfizer for rheumatoid arthritis., Elena Myasoedova: None declared.


CARDBOVIDR DISEASE RISK IN INFLAMMATORY ARTHRITIS STILL ELEVATED IN 2021!

R. Raadtsen1, F. Hooijberg1, L. Boeke1, G. J. Wolbink1, W. Lems1,2, A. Van Kuijk1, M. Nurmohamed1,2. Amsterdam Rheumatology and Immunology Center, location Reade, Rheumatology, Amsterdam, Netherlands; Amsterdam Rheumatology and Immunology Center, location VU University Medical Center, Rheumatology, Amsterdam, Netherlands

Background: Patients with inflammatory rheumatic diseases as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA) are at higher risk for developing cardiovascular diseases (CVD) than the general population. This is due to a higher prevalence of ‘traditional’ CVD risk factors such as hypertension and dyslipidaemia, and the underlying systemic inflammation. During the past two decades, the burden of inflammation has been reduced by more efficacious anti-rheumatic treatment, leading to a reduced CVD risk, albeit still elevated in comparison to the general population. Therefore, it remains important to monitor the presence of CVD in rheumatic patients in systematically controlled cohorts.

Objectives: To evaluate whether, nowadays, the CVD risk of patients with inflammatory rheumatic diseases still differs from the general population.

Methods: In March 2020, all adult patients with an inflammatory rheumatic disease, from the Amsterdam Rheumatology and Immunology Center, location ‘Reade’ were systematically asked to participate in a prospective cohort study, which focused on the impact of the COVID-19 pandemic. The patients were compared with age and sex matched controls. In the third questionnaire, sent out in January 2021, questions regarding CV risk factors and comorbidities were added. Baseline characteristics and prevalence of CV risk factors and CVD were compared between RA, PsA, SpA patients, and healthy controls.

Results: 2050 consecutive patients with an inflammatory rheumatic disease (1312 RA patients, 353 PsA patients, 385 SpA patients), and 939 healthy controls completed the questionnaires (Table 1). The prevalence of at least one CV morbidity was more frequently reported in RA, PsA and SpA patients compared to healthy controls: 69 (5%), 24 (7%), 17 (4%) compared to 31 (3%), respectively. Events were primarily cardiac (i.e. myocardial infarction and coronary angioplasty). Inflammatory arthritis patients more often had hypertension or hypercholesterolemia than healthy controls, which were untreated in nearly half the cases. RA patients most often used anticoagulant medication.

Disclosure of Interests: None declared.


ASSOCIATIONS BETWEEN SELF-REPORTED RHEUMATOID ARTHRITIS, RHEUMATOID FACTOR POSITIVITY AND STRUCTURAL BRAIN PHENOTYPES IN UK BIOBANK

I. Stančič1, S. Siebert2, D. Mackay1, D. Lyall1. University of Glasgow, Public Health, Glasgow, United Kingdom; 3University of Glasgow, Infection Immunity & Inflammation, Glasgow, United Kingdom

Background: There is very limited research on structural brain health in people with rheumatoid arthritis (RA).

Objectives: To investigate whether there are differences in brain volume in people with self-reported RA or positive rheumatoid factor (RF+).

Methods: Cross-sectionally tested for associations with several MRI brain volume measures in UK Biobank (n=37,379 of whom 432 RA and 1833 RF+). The partially adjusted regression models controlled for age and sex, while the fully adjusted models further controlled for deprivation index, smoking status and alcohol consumption.
cardiometabolic diseases. For all subcortical volumes analyses we also controlled for total brain volume.

Results: Those that self-reported RA were more likely to have increased WMH (White Matter Hyperintensities) (β = 0.08, 95% CI: 0.022; 0.14, p<0.01), and smaller volumes of the amygdala (β = -0.07, 95% CI: -0.13; -0.005, p<0.05) and thalamus (β = -0.06, 95% CI: -0.12; -0.01, p<0.05) in the partially adjusted analyses. In the fully adjusted model only amygdala volume remained negatively associated with RA (β = -0.09, 95% CI: -0.16; -0.02, p<0.01).

Conclusion: We provide evidence of differences in structural brain phenotypes known to underpin cognitive and psychological health, in RA. Since the amygdala may play an important role in pain modulation and mental health, while WMH are associated with a higher risk of stroke, the observed differences may be of clinical relevance in RA which is associated with a higher prevalence of these conditions. Further research is required to confirm these findings and assess their functional implications.

Disclosure of Interests: None declared.


Table 1. Attributes and levels of treatment options

<table>
<thead>
<tr>
<th>Treatment attribute</th>
<th>Levels describing no treatment option</th>
<th>Levels describing treatment option</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chance of developing RA</td>
<td>60%</td>
<td>20%</td>
</tr>
<tr>
<td>Chance of mild side effects</td>
<td>0%</td>
<td>2%; 4%; 5%; 7%; or 10%</td>
</tr>
<tr>
<td>Chance of a serious infection due to treatment</td>
<td>0%</td>
<td>1%; 15%; 2%; 3%; or 5%</td>
</tr>
<tr>
<td>Chance of a serious side effect that is potentially irreversible</td>
<td>0.001%; 0.01%; 0.02%; 0.05% or 0.1%</td>
<td></td>
</tr>
</tbody>
</table>

Results: 289 FDRs (80 male) responded. The mean (SE) MAR for mild side effects, serious infection, and serious side effects was 29.08 (1.52), 9.09 (0.60) and 0.85 (0.27), respectively. Participants aged over 60 years were less tolerant of risk of serious infection than average (mean MAR - 2.06 (0.78)) and younger participants were more tolerant of risk of serious infection than average (mean MAR + 2.06 (0.78)). Risk of mild side effects was less acceptable to participants who perceived they were likely/very likely to develop RA (mean MAR - 3.34 (1.55)) than to those who did not (mean MAR + 3.34 (1.55)). Education level, health literacy, numeracy, IQP and BMO-G subscales were not predictors of risk tolerance.

Conclusion: Age and perceived risk of RA had a significant impact on FDRs tolerance for specific, but not all, included risks. Cognitive ability and beliefs about RA/medicine did not explain preference heterogeneity. This is informative for drug development and the development of tailored risk communication resources to support preventive approaches.

REFERENCES:

Acknowledgements: On behalf of the PREFER project. PREFER received funding from the IMI 2 Joint Undertaking (grant No. 115966), which receives support from the EU’s Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries and Associations (EFPIA). K. Raza is supported by the NIHR Birmingham Biomedical Research Centre.


POS0592 PREDICTING LIVER ENZYME ELEVATION IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TREATMENT WITH METHOTREXATE USING SUPERVISED MACHINE LEARNING

V. Gilvaz1, S. Surenradan2, M. Cb2, 1Rhode Island Hospital, Rheumatology, Providence, United States of America; 2Amita Hospital, Rheumatology, Kochi, India

Background: Methotrexate (MTX) is the most used disease-modifying anti-rheumatic drug (DMARD) in the treatment of rheumatoid arthritis (RA). (1) Chronic use of this medication warrants close laboratory monitoring given its propensity for liver damage and myelosuppression. (2) MTX associated hepatic dysfunction is a well-described adverse effect and has been seen in up to a quarter of
patients on long term treatment. (3) Recent advances in health care coupled with the extensive use of electronic health records (EHR) has resulted in the accumulation of large amounts of patient data. Approaches like machine learning (ML) allows us to leverage these large data sets to predict outcomes and support clinical decision making. (4) We hypothesized that a ML model trained on conventionally available EHR data would be able to identify patients at the greatest risk of developing MTX related hepatotoxicity.

**Objectives:** To develop a machine learning model to accurately predict liver enzyme elevation in rheumatoid arthritis (RA) patients on treatment with methotrexate (MTX) using electronic health record (EHR) data from a real-world RA cohort.

**Methods:** Demographic, clinical, biochemical, as well as prescription information from 569 RA patients were retrospectively collected. Liver transaminase elevation above the upper limit of normal following initiation of MTX, was the primary outcome. The total dataset was randomly split into a training (80%) and test set (20%) and used to develop a Random Forest Classifier model. The best model was selected after hyper-parameter tuning and fivefold cross-validation.

**Results:** 104 patients (18.2%) developed hepatic dysfunction while on MTX therapy. The best performing predictive model had an accuracy/F1 score of 0.87. The top ten predictive features were then used to create a limited feature model that retained most of the predictive accuracy, with an accuracy/F1 score of 0.86.

**Conclusion:** Our proof-of-concept study suggests the possibility of building a well-performing ML model to predict liver enzyme elevation in RA patients being treated with MTX. Similar ML models could be used to identify ‘high risk’ patients who can then be potentially targeted for closer monitoring with the aim of preventing these adverse outcomes. Conversely, patients at low risk can avoid extra outpatient visits, thereby reducing costs.

**REFERENCES:**


---

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1676

**POS0593**

THE COURSE OF FATIGUE AND ITS RELATION WITH INFLAMMATION DURING THE DEVELOPMENT OF RHEUMATOID ARTHRITIS: A LONGITUDINAL STUDY

S. Khidir1, F. Wouters1, E. Van Mulligen1,2, A. Van der Helm-van Mil1,2. 1Leiden University Medical Centre, Leiden, Rheumatology, Leiden, Netherlands; 2Erasmus Medical Centre, Rheumatology, Rotterdam, Netherlands

**Background:** Fatigue is a prominent and disabling symptom in patients with rheumatoid arthritis (RA), that is only partially explained by inflammation and responds poorly to DMARD-therapy. We hypothesized that inflammation explains fatigue to a larger extent in the phase of clinically suspect arthralgia (CSA), when clinical arthritis is still absent and fatigue has not yet become chronic.

**Objectives:** To study the course of fatigue in CSA during progression to RA and the association with inflammation at CSA-onset and at RA-diagnosis.

**Methods:** 600 consecutive CSA-patients were followed for RA-development (median follow-up 25 months). Additionally, 710 early RA-patients were studied at diagnosis. Fatigue was assessed every study visit and expressed on a scale of 0-100. The DAS44-CRP was used to measure inflammation (with SJC=0 in CSA). The course of fatigue over time was studied with linear mixed models. Associations between fatigue and inflammation were studied with linear regression, corrected for sex. Analyses were stratified by ACPA-status.

**Results:** In 88 CSA-patients who developed RA, pre-arthritis fatigue levels increased gradually with 7/year (95%CI= -2 to 16, p=0.13), towards 48 at RA-development. Fatigue decreased in CSA-patients who did not develop RA (-4/year, 95%CI= -6 to -3, p<0.001) (see Figure 1). At CSA-onset, inflammation was associated with fatigue (β=18, meaning 18 points more fatigue than the same healthy individual).

**Figure 1.** Course of fatigue in CSA-patients developing RA (A) and in CSA-patients not developing RA (B)

**Disclosure of Interests:** None declared.
per point increase DAS-score, 95% CI=7-28, p=0.001). This association was stronger than at RA-diagnosis (p=5, 95% CI=3-7, p<0.001). Fatigue-levels increased towards RA-development in both ACPA-subtypes, but were on average higher in ACPA-negative CSA than ACPA-positive CSA (mean difference in fatigue of 13, 95% CI=1-24, p=0.027). However, the association between fatigue and inflammation was stronger in ACPA-positive compared to ACPA-negative CSA.

Conclusion: Fatigue increased gradually during progression from arthralgia to clinical arthritis, and fatigue was better explained by inflammation in CSA than in RA. This implies a ‘phase-dependent relation’ between inflammation and fatigue.

REFERENCES: -

Disclosure of Interests: None declared.


POS0594 FACTORS ASSOCIATED WITH THE 6-MINUTE WALK TEST AMONG PERSONS WITH RHEUMATOID ARTHRITIS

I. S. Houge1,2, M. Hofte3,4, V. Videm1,5.
1Norwegian University of Science and Technology, Department of Molecular and Clinical Medicine, Trondheim, Norway; 2Levanger, Department of Rheumatology, Levanger, Norway; 3Norwegian University of Science and Technology, Department of Neumedicine and Movement Science, Trondheim, Norway; 4St. Olav’s University Hospital, Department of Rheumatology, Trondheim, Norway; 5St. Olav’s University Hospital, Department of Immunology and Transfusion Medicine, Trondheim, Norway

Background: Persons with rheumatoid arthritis (RA) are less physically active than the general population. A 6-minute walk test (6MWT) measures how far a person can walk in 6 minutes, testing overall functional capacity. This can inform clinicians before initiating potential interventions.

Objectives: To assess psychological, patient- and disease-related factors associated with 6MWT results among persons with RA.

Methods: Patients were recruited in 2019 and 2021 from the Rheumatology outpatient clinics at St. Olav’s Hospital and Levanger Hospital, Norway (n=225). They answered questionnaires, and a subgroup (n=86) performed a 6MWT according to guidelines from the American Thoracic Society (1). Diagnostic characteristics and medical history were collected from hospital records. Participants with data for 6MWT but missing data for other variables in the main model were excluded (n=7). Physical function was measured with the Modified Stanford Health Assessment Questionnaire (mHAQ, range 0-3, lower score indicating better physical function). For the patient global assessment (PGA) patients rated their overall disease activity in the past week on a 100 mm visual analogue scale; higher score indicates more symptoms. Presence of depressive symptoms was measured with the Hospital Anxiety Depression Index Depression score (HADS-D, range 0-21, higher score indicating more depressive symptoms). Perceived stress was measured with the Cohen’s Perceived Stress Scale, median (IQR) 15 (9, 19). Anxiety Depression Index Depression score, median (IQR) 3 (1, 4), Cohen’s Perceived Stress Scale, median (IQR) 15 (9, 19), Self-Efficacy for Exercise, median (IQR) 25 (20, 30). 6-Minute Walk Test (m), mean (±SD) 507 (±88).

Table 1. Patient characteristic

<table>
<thead>
<tr>
<th>characteristic</th>
<th>Rheumatoid arthritis patients (N=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex, n (%)</td>
<td>60 (76)</td>
</tr>
<tr>
<td>Age (years), median (IQR)</td>
<td>65 (55, 71)</td>
</tr>
<tr>
<td>Ever smoker, n (%)</td>
<td>49 (62)</td>
</tr>
<tr>
<td>Body mass index (kg/m²), median (IQR)</td>
<td>26.3 (23.6, 28.9)</td>
</tr>
<tr>
<td>Rheumatoid arthritis duration (years), median (IQR)</td>
<td>10 (5, 23)</td>
</tr>
<tr>
<td>Seropositive (anti-CCP and/or RF), n (%)</td>
<td>68 (86)</td>
</tr>
<tr>
<td>Uses conventional DMARDs, n (%)</td>
<td>67 (85)</td>
</tr>
<tr>
<td>Uses biological DMARDs, n (%)</td>
<td>42 (53)</td>
</tr>
<tr>
<td>Uses corticosteroids, n (%)</td>
<td>21 (27)</td>
</tr>
<tr>
<td>Cardiovascular disease (HT, angina, MI, arrhythmia or stroke), n (%)</td>
<td>38 (48)</td>
</tr>
<tr>
<td>Respiratory disease (COPD, CRP or asthma), n (%)</td>
<td>21 (27)</td>
</tr>
<tr>
<td>DAS28-ESR</td>
<td>2.3 (1.8, 2.9)</td>
</tr>
<tr>
<td>Modified Health Assessment Questionnaire, median (IQR)</td>
<td>0.38 (0.13, 0.63)</td>
</tr>
<tr>
<td>Physical global assessment (mm), median (IQR)</td>
<td>27 (12, 40)</td>
</tr>
<tr>
<td>Hospital Anxiety Depression Scale Depression score, median (IQR)</td>
<td>3 (1, 4)</td>
</tr>
<tr>
<td>Cohen’s Perceived Stress Scale, median (IQR)</td>
<td>15 (9, 19)</td>
</tr>
<tr>
<td>Self-Efficacy for Exercise, median (IQR)</td>
<td>25 (17, 30)</td>
</tr>
<tr>
<td>6-Minute Walk Test (m), mean (±SD)</td>
<td>507 (±88)</td>
</tr>
</tbody>
</table>

multiple regression with 6MWT as dependent variable. Model 1 included age (categorized into tertiles to improve model fit: <59, 59-89, or ≥70 years), sex, mHAQ, PGA, HADS-D, Cohen's Perceived Stress Scale. Self-Efficacy for Exercise, smoking habit and body mass index (BMI, categorized ≤25 or >25 kg/m²). Model 2 included only the variables significantly associated with 6MWT in Model 1, but keeping adjustment for sex. The regression coefficients of Model 2 were standardized.

Results: In model 1, the variables associated with 6MWT were mHAQ (p=0.04), Self-Efficacy for Exercise (p=0.001), BMI (p=0.01) and age (oldest versus youngest age tertile p<0.001, middle versus youngest age tertile p=0.11). Sex was not significantly associated with 6MWT (p=0.82). The standardized coefficients in Model 2 were: mHAQ -0.27 (p=0.002), Self-Efficacy 0.27 (p=0.002), categorized BMI -0.27 (p-value=0.002), middle age group versus youngest age group -0.17 (p=0.08), oldest age group versus youngest age group -0.55 (p<0.001), male gender 0.08 (p=0.33). The R² of Model 1 and Model 2 were 0.54 and 0.52 respectively.

Conclusion: Self-Efficacy for Exercise, mHAQ, BMI and age had the largest impact on 6MWT, explaining 52 % of the observed variation in 6MWT in a model adjusted for sex.


Disclosure of Interests: None declared.


POS0595 THE ASSOCIATION BETWEEN AXIAL AND PERIPHERAL BONE IN PATIENTS WITH RHEUMATOID ARTHRITIS, INCLUDING THE IMPACT OF EROSIIVE DISEASE. A HR-pQCT STUDY.

A. B. G. Blavnsfeldt1,2, R. Klose-Jensen3, J. Therkildsen1,2, K. Keller1,3, S. G. Hansen1,4, B. Langdahl2,5, E. M. Hauge1,2, 1Aarhus University Hospital, Rheumatology, Aarhus, Denmark; 2Aarhus University, Clinical Medicine, Aarhus, Denmark; 3Odense University Hospital, Endocrinology, Odense, Denmark; 4University of Southern Denmark, Research Unit of Rheumatology, Department of Clinical Research, Odense, Denmark; 5Aarhus University Hospital, Internal Medicine and Endocrinology, Aarhus, Denmark

Background: The severity of Rheumatoid Arthritis (RA) is associated with increased fracture risk (1). Areal bone mineral density (aBMD) by dual-energy absorptiometry (DXA) is the gold standard for diagnosis of osteoporosis as well as fracture risk assessment. High resolution peripheral quantitative computed tomography (HR-pQCT) of the distal radius yields volumetric BMD (vBMD) of trabecular and cortical bone compartments, as well as micro-architectural parameters and may prove useful for fracture risk prediction. The association between aBMD by DXA and HR-pQCT derived vBMD and microarchitecture have only been sparsely investigated in patients with RA, and it is not known if erosive disease, measured by the gold standard Heijde-modified Sharp Scores (HSS) (2) affects HR-pQCT derived parameters.

Objectives: To assess the associations between aBMD by DXA and bone parameters of the distal radius by HR-pQCT, in both male and female patients with RA, and the impact of erosive disease on the bone parameters of the distal radius.

Methods: We measured aBMD by DXA of the lumbar spine and hip, HR-pQCT of the distal radius and assessed HSS in 162 patients with RA. Using multivariate linear regression models, we explored the association between HSS and HR-pQCT parameters, adjusted for sex and age. The associations between aBMD by DXA and vBMD and microarchitecture by HR-pQCT were assessed by Spearman correlation coefficients, interpreted as negligible (0.00-0.10), weak (0.10-0.39), moderate (0.40-0.69), strong (0.70-0.89) or very strong (0.90-1.00).

Results: Mean age for the included patients was 63 years, 75% were women and median disease duration was 18 years. Erosive disease (HSS) was negatively associated with trabecular number and density, but not with cortical bone parameters. This association was stronger for HSS of the wrist joints, than for HSS of the hands and total HSS (Table 1). Trabecular density of the distal radius correlated moderately with aBMD at the total hip, and weakly with aBMD at the lumbar spine. Trabecular numbers also correlated moderately with aBMD at the total hip. Cortical bone parameters at the distal radius correlated weakly with aBMD at the hip, but only among women.
In the study, the authors investigated the effect of increased cholesterol content in macrophages and the role of inflammation in promoting foam cell formation. They found that serum cholesterol loading capacity on macrophages is linked to oxidized low-density lipoprotein (oxLDL) and C-reactive protein (CRP) in patients with rheumatoid arthritis (RA). The study also explored the role of anti-oxLDL IgG, pro-atherogenic cholesterol transport gene expression in THP-1 human monocyte cell line, and the potential of targeting LDL oxidation in dual seropositive patients.

**Methods:**

A two-stage moderated mediation model was used to explore whether the association between oxPL-apoB100, anti-oxLDL IgG, and PCSK9 with CLC was mediated by CRP and anti-oxLDL IgG. The study included a disease activity-steered cohort of patients with early rheumatoid arthritis. 

**Results:**

OxPL-apoB100, anti-oxLDL IgG, and PCSK9 were positively associated with CLC in dual seropositive patients. CLC was more strongly related to anti-oxLDL IgG and PCSK9 in patients with dual seropositivity compared to single seropositive patients.

**Conclusion:**

Oxidized LDL can directly influence CLC in dual seropositive RA patients, regardless of CRP. The study highlights the importance of targeting LDL oxidation in these patients to reduce atherosclerotic risk.

**References:**


**Disclosure of Interests:**


Published online: None.

INTO INFLAMMATORY ARTHRITIS CENTRE VERSUS ARTHRITIS, BIRMINGHAM, UNITED KINGDOM

Background: Risk of rheumatoid arthritis (RA) is 3-5 times higher in first-degree relatives (FDRs). Efforts are increasing to develop preventive interventions for this at-risk group. Risk perception is a key predictor of health behaviours, including FDRs’ interest in predictive testing and preventive intervention for RA. Effective risk communication is essential for RA prevention studies and clinical translation.

Objectives: To define variables associated with perceived risk of developing RA in FDRs of RA patients.

Methods: RA patients attending outpatient clinics (West Midlands, UK) were asked to invite their FDRs to complete a cross-sectional printed survey. Patients were also invited to complete a survey. Unique survey numbers enabled linkage of FDR and proband responses. FDRs’ perceived absolute risk, comparative risk, experiential risk, and worry about risk were assessed using 5-point Likert scales. Predictor variables included demographics, the Single Item Literacy Screener, Brief Illness Perception Questionnaire, Brief Approach/Avoidance Coping Questionnaire, Life Orientation Test Revised and the Short Health Anxiety Inventory. Patient predictors of FDR perceived risk included demographics, time since RA diagnosis and Rheumatoid Arthritis Impact of Disease Score. Outcome measure responses were grouped into ‘low’ and ‘high’ for regression analyses. Univariable analysis used independent samples T-tests, chi-square tests and Mann-Whitney U Tests. Backwards stepwise binary logistic regression examined the relationship between FDR characteristics and perceived risk of RA. Generalised Estimating Equations assessed whether patient variables predicted FDRs’ perceived risk.

Results: 396 FDRs returned a survey. Paired data from 213 patients were available for 292 of these FDRs. The distributions of risk perception scores are shown in Figure 1. All measures of perceived risk were inter-correlated (p<0.001; ranging from r=0.48 to r=0.80). 65.2% of FDRs perceived themselves to be ‘Likely’ or ‘Very Likely’ to develop RA in their lifetime. FDRs’ ethnic group, deprivation index, employment status, education level, smoking status, cohabitation with index patient status, coping style and dispositional optimism were not significantly different between high and low perceived risk groups. Characteristics significant in univariable analyses were used in multivariable analyses (Table 1). Children were 3.89 times more likely than siblings to perceive themselves at high risk of RA. Higher health anxiety scores were associated with increased perceived risk. Female gender, and beliefs that RA would last a long time, and cause higher concern and negative emotional impact predicted increased perceived risk. Higher perceptions of how well treatment would control RA was associated with a reduced likelihood of perceiving oneself at high risk. Index patient characteristics did not associate with FDRs’ risk perceptions.

Table 1. Multivariable analysis

<table>
<thead>
<tr>
<th>FDR Characteristic</th>
<th>Perceived Risk [Odds Ratio (95% Confidence Interval)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1.98 (1.19-3.27)</td>
</tr>
<tr>
<td>Female</td>
<td></td>
</tr>
<tr>
<td>Relationship to index patient</td>
<td></td>
</tr>
<tr>
<td>Child</td>
<td>2.80 (1.70-4.61)</td>
</tr>
<tr>
<td>Sibling</td>
<td>3.43 (2.04-5.78)</td>
</tr>
<tr>
<td>Illness</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>3.89 (2.24-6.75)</td>
</tr>
<tr>
<td>Low</td>
<td>2.26 (1.30-3.94)</td>
</tr>
<tr>
<td>Perceptions</td>
<td></td>
</tr>
<tr>
<td>Timeline</td>
<td>0.91 (0.81-1.01)</td>
</tr>
<tr>
<td>Treatment</td>
<td>0.87 (0.77-0.98)</td>
</tr>
<tr>
<td>Control</td>
<td>1.36 (1.13-1.63)</td>
</tr>
<tr>
<td>Concern</td>
<td>1.20 (1.02-1.40)</td>
</tr>
<tr>
<td>Emotion</td>
<td></td>
</tr>
<tr>
<td>Health Anxiety</td>
<td>1.04 (1.01-1.07)</td>
</tr>
</tbody>
</table>

Conclusions: FDRs’ perceived risk of RA was high. Key predictors included being a child of a patient with RA, higher health anxiety and lower perceptions of RA treatment control. An understanding of these predictors will inform the development of effective risk communication and preventive strategies.

REFERENCES:

Acknowledgements: S. Bunnewell and I. Wells are joint first authors.

Disclosure of Interests: None declared


PERSISTING PAIN IN RHEUMATOID ARTHRITIS: DO WE NEED TO RECONSIDER OUR IDEA OF PAIN ALLEVIATION DESPITE ANTI-INFLAMMATORY TREATMENT?

C. Baerwald1, E. Stemmler2, S. Gneucheti3, K. Jeromin3, C. Holland4, B. Fritz5, D. Adolf6, P. C. Taylor5, R. Baron6. 1University Hospital Leipzig, Department of Medicine, Neurology and Dermatology, Rheumatology Unit, Leipzig, Germany; 2AbbVie Germany GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany; 3AbbVie Deutschland GmbH & Co. KG, AbbVie Deutschland GmbH & Co. KG, Westbaden, Germany; 4StatConsult GmbH, Biometrics and Data management, Magdeburg, Germany; 5University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Headington, Oxford, United Kingdom; 6University Hospital Schleswig-Holstein, Division of Neurological Pain Research and Therapy, Department of Neurology, Kiel, Germany

Background: Pain significantly impacts life of patients with rheumatoid arthritis (RA). Besides articular pain due to systemic inflammation, neuropathic pain (NeP) represents another challenge that can pose a considerable burden on the life of patients.

Objectives: To investigate persisting pain in RA patients and to analyse NeP along with patient-reported outcomes (PROs).

Methods: PAIN-CONTROL is a prospective, non-interventional study in rheumatology centres in Germany. Inclusion criteria were fulfilment of the 2010 ACR/EULAR RA classification criteria, disease duration ≤ 8 yrs, DAS28 > 3.2, SJC > 3, CRP normal or above reference range, and pain rating ≥ 50 (0-100 VAS). Eligible subjects had to be scheduled for escalation of anti-inflammatory treatment according to national guidelines. At wk 24 subjects were allocated to three subgroups given DAS28-CRP change and VAS pain: i) reference group: VAS pain < 50 with either DAS28 improvement > 1.2 or DAS28 ≤ 3.2, ii) non-responders: DAS28 improvement ≤ 1.2 and DAS28 > 3.2 with or without pain alleviation, iii) persisting pain: VAS pain ≥ 50 with either DAS28 improvement > 1.2 or DAS28 ≤ 3.2. For groups 1 and 2 end of study was at week 24, patients with persisting pain continued until wk 48. Patients were assessed for NeP using a score of ≥ 19 in the painDETECT questionnaire (PD-Q) (3). Pain-related PROs, i.e. the Rheumatoid Arthritis Impact of Disease Questionnaire (RAID) and the Patient Health Questionnaire (PHQ-9), were analysed along with demographic background information (1,4). Descriptive results are presented as mean (SD) or mean (SD) | N | n (%) or n (%) | N | n (%), respectively.

Results: 567 subjects were analysed with the following distribution: Reference group 337 (59.4%), non-responders 102 (18.0%), and persisting pain 128 (22.6%), of which 115 patients were available at wk 48. Subgroups showed similar demographic baseline characteristics but differed in PROs (Table 1). Until wk 24, proportion of patients with NeP indication decreased in the reference group (-19.8%) and slightly in non-responders (-6.0%) and persisting pain group (-9.5%). Non-responders showed the highest NeP proportion at wk 24 (35.0%) (Table 1). Of 115 patients with
persisting pain at wk 24, 47 (40.9%) tested NeP negative at wk 48, 21 (18.3%) tested unclear, 28 (24.3%) were missing and 19 (16.3%) tested positive. Of the latter 9 patients (47.4%) still had persisting pain at week 48, whereas this was the case for 14 patients (29.4%) in the former group. Of the 49 (42.6%) of 115 patients with severe persisting pain at wk 24 reported pain alleviation at wk 48 and fulfillment of reference group criteria. RAID and PHQ-9 scores improved in the reference group but only slightly in the other two subgroups.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Reference group (N=337)</th>
<th>Non-responders (N=110)</th>
<th>Persisting pain (N=128)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (f/m)</td>
<td>233 (69.1%)</td>
<td>65 (63.7%)</td>
<td>87 (68.0%)</td>
</tr>
<tr>
<td>Age</td>
<td>57.1 (13.2)</td>
<td>59.9 (12.0)</td>
<td>57.1 (13.0)</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>2.5 (2.6)</td>
<td>2.7 (2.8)</td>
<td>2.5 (2.5)</td>
</tr>
<tr>
<td>PD-Q (≥ 19) (Bl)</td>
<td>82 (28.6%)</td>
<td>239 (14.8)</td>
<td>80 (13.8)</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>2.5 (2.6)</td>
<td>2.7 (2.8)</td>
<td>2.5 (2.5)</td>
</tr>
<tr>
<td>Age</td>
<td>57.1 (13.2)</td>
<td>59.9 (12.0)</td>
<td>57.1 (13.0)</td>
</tr>
<tr>
<td>Disease duration (yrs)</td>
<td>2.5 (2.6)</td>
<td>2.7 (2.8)</td>
<td>2.5 (2.5)</td>
</tr>
<tr>
<td>PD-Q (≥ 19) (Bl)</td>
<td>82 (28.6%)</td>
<td>239 (14.8)</td>
<td>80 (13.8)</td>
</tr>
<tr>
<td>Clinical arthritis duration</td>
<td>2.5 (2.6)</td>
<td>2.7 (2.8)</td>
<td>2.5 (2.5)</td>
</tr>
</tbody>
</table>

Conclusion: NeP is common among RA non-responders to anti-inflammatory treatment and in patients with persisting pain, meritng a routine NeP screening to more adequately address persisting pain in these patients. However, even late improvements (after 24 wks) regarding persisting pain seem likely during anti-inflammatory treatment.

REFERENCES:

Acknowledgements: Statistical analysis was performed under lead of Dr. Daniela Adolf of StatConsult GmbH, which was funded by AbbVie. Medical writing support was provided by Dr. Matthias Engelbrecht of Statosach, which was funded by AbbVie.

Disclosure of Interests: Christoph Baerwald Speakers bureau: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Grant/research funding: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Grant/research funding: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie., Consultant of: Prof. Christoph G. Baerwald has served as consultant to AbbVie and has received research funding and speaker fees from AbbVie.

Disclosure of Interests: None declared


PO600

ANGIOGENIC T-CELL DEPLETION OCCURS DURING THE EARLIEST PHASES OF RHEUMATOID ARTHRITIS LINKED TO SUBCLINICAL VASCULAR STIFFNESS

J. Rodríguez-Carrión a, M. Alperi-López2 a, P. López2, A. Pérez-Alvarez1, A. Suárez3 a.

1University of Oviedo, Área de Immunología, Oviedo, Spain;
2Instituto de Investigación Sanitaria del Principado de Asturias, Research Group on Basic and Translational Research on Chronic Inflammatory Diseases, Oviedo, Spain;
3Hospital Universitario Central de Asturias, Rheumatology, Oviedo, Spain;
4Hospital Universitario Central de Asturias, Neurology, Oviedo, Spain

Background: vascular insult accounts for the cardiovascular (CV) risk excess in rheumatoid arthritis (RA). Angiogenic T cells (Tang), which are responsible of vascular repair, have been described to be reduced in established RA with overt CV disease. However, whether Tang are altered during the earliest stage of the disease and related to subclinical CV findings is unknown.

Objectives: to evaluate circulating Tang levels in the very early stage of RA, including clinically suspect arthralgia (CSA), and their associations with subclinical CV endpoints (subclinical atherosclerosis and vascular stiffness).

Methods: 84 RA patients (2010 EULAR/ACR classification criteria), 14 CSA individuals (EULAR criteria) and 28 matched healthy controls (HC) were recruited. All patients were untreated at the time of sampling. Tang (CD3+CD31+CXCR4+) frequency was assessed by flow cytometry in peripheral blood samples. Plaque occurrence, cIMT and stiffness parameters were analyzed by Doppler ultrasound in internal carotid, middle cerebral and basilic arteries. Lipoprotein analyses were performed by NMR.

Results: Tang were decreased in RA and CSA groups compared to HC (both p<0.010). Whereas Tang frequency was negatively correlated with very low density lipoproteins features (cholesterol and triglyceride content, size distribution and particle number) in HC and positively with HDL (cholesterol content and particle number), these associations were lacking in RA.

Disclosure of Interests: All authors have declared no conflicts of interest.
and CSA groups. Tang levels were not related to individual traditional CV risk factors, body mass index, waist circumference (all p>0.050) nor with the modified SCORE (r=-0.070, p=0.542) or Framingham Risk Score (r=-0.013, p=0.970). On the contrary, disease activity accounted for the Tang depletion observed in RA (β[95% CI]: DSAS−: −0.436 [-0.306, −0.109], p<0.001; SDAI: −0.020 [-0.032, −0.008], p=0.002). Tang levels were unrelated to the duration of the symptoms both in RA and CSA. In RA patients, Tang frequency was not associated with atherosclerosis plaque occurrence (p=0.556) or cIMT (r=0.136, p=0.245). However, Tang paralleled stiffness parameters: vascular strain (VS, r=0.373, p=0.013), vascular distensibility (VD, r=0.479, p=0.004), vascular stiffness (VSI, r=0.400, p=0.007) and pressure-strain elastic modulus (PSEM, r=−0.373, p=0.013). Finally, Tang frequency was an independent predictor of stiffness parameters after adjusting for mSCORE, body mass index, DSAS−, RF and ACPA positivity: VS (β=0.415, p=0.035), VD (β=0.361, p=0.028), VSI (β=−0.322, p=0.033) and PSEM (β=−0.346, p=0.016).

Conclusion: Tang depletion is an early event along RA development, associated with disease-related parameters and unrelated to traditional risk factors. Tang may be the missing, functional link between disease activity and CV outcomes. Altered Tang levels may be an early biomarker of premature vascular stiffness during the first stages of the disease.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2350

POSO061 CRANIOCERVICAL JUNCTION INVOLVEMENT ASSESSED BY COMPUTED TOMOGRAPHY AND/OR MAGNETIC RESONANCE IMAGING IN INFLAMMATORY ARTHRITIS: SINGLE CENTER CASE-CONTROL STUDY

F. Yalçınkaya1, Ş. Parias1, E. Bilgin2, K. Karlı Oğuz3, U. Kalyoncu2
1Hacettepe University, Internal Medicine, Ankara, Turkey; 2Hacettepe University, Radiology, Ankara, Turkey; 3Hacettepe University, Rheumatology, Ankara, Turkey

Background: Cranio-cervical involvement is generally overlooked clinically.

Objectives: The aim of this study is to investigate cranio-cervical involvement in inflammatory arthritides and compare with patients without inflammatory arthritides.

Methods: In this retrospective analysis, cervical CT and/or MRI scans -taken for any reasons between 2010 and 2020 - of patients with rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) were included in the study database. The diagnosis of RA, AS, and PsA was confirmed by an experienced clinician with medical history, laboratory, and treatment history. Of these patients, those who underwent CT and/or MRI before the definitive diagnosis of inflammatory arthritides were included in the analyses. Demographic data of the included patients were recorded. Cranio-cervical involvements (anterior, posterior, lateral, and rotational atlantoaxial subluxation; vertical subluxation; subaxial subluxation; odontoid process involvement [resorption or pannus], atlantoaxial and atlanto-occipital involvement) were evaluated by an experienced radiologist on CT or MRI, as appropriate. Control group was consisted of consequent patients without inflammatory arthritides and who undergone cervical CT or MRI with any reasons out of trauma. p<0.05 was considered statistically significant.

Results: From a total of 4442 records (1558 individual patients), 459 patients (204 RA, 200 SpA, and 55 PsA patients) and 78 patients for control group were included in the study. In Table 1, comparison of RA, SpA and control groups for specific types of cranio-cervical involvements was given. The percentage of female gender and age at inclusion and exclusion criteria were used; For inclusion: 1) nodules with changing dimension on follow-up, 2) At least two nodules with different dimensions, 3) Cavitary nodule at any chest CT. For exclusion: 1) Solitary nodules OR all nodules ≤ 5mm and without follow-up OR no change on follow-up. biggest nodule was named as dominant nodule. Then, patients were grouped according to rheumatoid factor and anti-CCP status as seropositive (RF ± anti-CCP) and seronegative. Demographics, comorbidities, RA-specific treatments and nodule characteristics were compared.

Results: Of 680 RA patients who had pulmonary nodule in chest CT, 208 (30.6%) patients were classified as having pulmonary rheumatoid nodule.

Conclusion: Cranio-cervical junction involvement can often be detected in patients with inflammatory arthritis, especially in patients with RA. Odontoid process seems as the main target of inflammation. Cranio-cervical involvement has the potential to be overlooked clinically, and needs to be evaluated more carefully. Disclosure of Interests: None declared

POSO062 PULMONARY RHEUMATOID NODULES: DOES SEROLOGIC STATUS MATTER?

Y. Sankaya1, G. Sandal Uzun2, E. B. Atea1, S. Arslan1, M. Ekiç2, G. Durhan1, E. Bilgin3, U. Kalyoncu3, M. Arıyürek1, 2Hacettepe University, Radiology, Ankara, Turkey; 3Hacettepe University, Rheumatology, Ankara, Turkey

Background: The frequency of pulmonary rheumatoid nodules closely relates to the diagnostic modality and changes from <0.4% to 32%. Also, it is known that seropositive RA patients tend to have more extra-articular disease.

Objectives: We aimed to compare the disease and pulmonary rheumatoid nodule characteristics of seropositive and seronegative RA patients.

Methods: In this study, all RA patients - according to ICD-10 code - and had at least one chest computerized tomography (CT) were examined and revealed 4117 individual patients. First, RA diagnosis was confirmed according to the patients' history, physical examination, radiography and laboratory assessment. Then, chest CTs were examined by an experienced radiologist. To classify pulmonary nodules as "pulmonary rheumatoid nodules", following inclusion and exclusion criteria were used: For inclusion: 1) nodules with changing dimension on follow-up, 2) At least two nodules with different dimensions, 3) Cavitary nodule at any chest CT. For exclusion: 1) Solitary nodules OR all nodules ≤ 5mm and without follow-up OR no change on follow-up. Biggest nodule was named as dominant nodule. Then, patients were grouped according to rheumatoid factor and anti-CCP status as seropositive (RF ± anti-CCP) and seronegative. Demographics, comorbidities, RA-specific treatments and nodule characteristics were compared.

Results: Of 680 RA patients who had pulmonary nodule in chest CT, 208 (30.6%) patients were classified as having pulmonary rheumatoid nodule.

Conclusion: Cranio-cervical junction involvement can often be detected in patients with inflammatory arthritis, especially in patients with RA. Odontoid process seems as the main target of inflammation. Cranio-cervical involvement has the potential to be overlooked clinically, and needs to be evaluated more carefully.

Disclosure of Interests: None declared
Table 1. Comparison of demographic, disease and nodule characteristics of seropositive and seronegative patients (n=208)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Seropositive (n=167, 80.3%)</th>
<th>Seronegative (n=41, 19.7%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n(%)</td>
<td>113 (67.7)</td>
<td>28 (68.3)</td>
<td>0.94</td>
</tr>
<tr>
<td>Age at the time of CT (median, min-max)</td>
<td>61 (24-83)</td>
<td>59.7 (20-83)</td>
<td>0.28</td>
</tr>
<tr>
<td>Smoking (n=73)</td>
<td>26 (43.3)</td>
<td>4 (30.8)</td>
<td>0.40</td>
</tr>
<tr>
<td>- Never smoked</td>
<td>34 (56.7)</td>
<td>9 (69.2)</td>
<td></td>
</tr>
<tr>
<td>- Ever smoked</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comorbidity (n=188)</td>
<td>127 (84.7)</td>
<td>30 (78.9)</td>
<td>0.40</td>
</tr>
<tr>
<td>- Hypertension</td>
<td>72 (52.0)</td>
<td>18 (68.1)</td>
<td>0.91</td>
</tr>
<tr>
<td>- Diabetes (n=166)</td>
<td>25 (15.8)</td>
<td>7 (22.6)</td>
<td>0.79</td>
</tr>
<tr>
<td>- CAD (n=165)</td>
<td>30 (22.6)</td>
<td>7 (21.9)</td>
<td>0.93</td>
</tr>
<tr>
<td>- Heart Failure (n=164)</td>
<td>15 (11.4)</td>
<td>6 (18.8)</td>
<td>0.41</td>
</tr>
<tr>
<td>- COPD (n=163)</td>
<td>20 (15.2)</td>
<td>3 (2.2)</td>
<td>0.13</td>
</tr>
<tr>
<td>- Asthma (n=160)</td>
<td>15 (11.6)</td>
<td>5 (16.1)</td>
<td>0.54</td>
</tr>
<tr>
<td>- CKD (n=169)</td>
<td>20 (14.5)</td>
<td>8 (25.8)</td>
<td>0.22</td>
</tr>
<tr>
<td>- ILD (n=202)</td>
<td>54 (33.1)</td>
<td>10 (25.6)</td>
<td>0.37</td>
</tr>
<tr>
<td>RA-specific treatments (ever)</td>
<td>31.2 (24-83)</td>
<td>59.7 (20-83)</td>
<td>0.28</td>
</tr>
<tr>
<td>- Methotrexate (n=153)</td>
<td>105 (64.0)</td>
<td>12 (30.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>- Leflunomide (n=208)</td>
<td>117 (70.5)</td>
<td>25 (60.1)</td>
<td>0.06</td>
</tr>
<tr>
<td>- Hydrochloroquine (n=169)</td>
<td>65 (47.4)</td>
<td>11 (36.7)</td>
<td>0.28</td>
</tr>
<tr>
<td>- Sulfasalazine (n=167)</td>
<td>39 (29.0)</td>
<td>6 (27.3)</td>
<td>0.30</td>
</tr>
<tr>
<td>- TNF (n=112)</td>
<td>41 (38.9)</td>
<td>2 (9.5)</td>
<td>0.008</td>
</tr>
<tr>
<td>- Rituximab (n=124)</td>
<td>11 (9.9)</td>
<td>2 (8.0)</td>
<td>0.77</td>
</tr>
<tr>
<td>- Tocilizumab (n=136)</td>
<td>12 (11.9)</td>
<td>2 (10.5)</td>
<td>0.86</td>
</tr>
<tr>
<td>- Abatacept (n=120)</td>
<td>9 (8.5)</td>
<td>2 (8.7)</td>
<td>0.98</td>
</tr>
<tr>
<td>Number of nodules at baseline CT (median, min-max)</td>
<td>5 (1-48)</td>
<td>3 (1-27)</td>
<td>0.004</td>
</tr>
<tr>
<td>Diameter of dominant nodule (median, min-max)</td>
<td>8 (3-35)</td>
<td>6 (3-45)</td>
<td>0.011</td>
</tr>
<tr>
<td>Localization of dominant nodal</td>
<td>64 (38.3)</td>
<td>15 (36.6)</td>
<td>0.84</td>
</tr>
<tr>
<td>- Left or right?</td>
<td>64 (38.3)</td>
<td>12 (29.3)</td>
<td>0.48</td>
</tr>
<tr>
<td>- Left</td>
<td>51 (30.5)</td>
<td>16 (39.0)</td>
<td>0.28</td>
</tr>
<tr>
<td>- Upper, middle or lower?</td>
<td>52 (31.1)</td>
<td>13 (31.7)</td>
<td></td>
</tr>
<tr>
<td>- Upper</td>
<td>69 (43.3)</td>
<td>21 (51.2)</td>
<td></td>
</tr>
<tr>
<td>- Middle</td>
<td>22 (13.2)</td>
<td>7 (17.1)</td>
<td></td>
</tr>
<tr>
<td>- Lower</td>
<td>76 (45.5)</td>
<td>13 (31.7)</td>
<td></td>
</tr>
<tr>
<td>- Peripheral, central or subpleural</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Peripheral</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Central</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Subpleural</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cavitary</td>
<td>48 (28.7)</td>
<td>5 (12.2)</td>
<td>0.03</td>
</tr>
<tr>
<td>Calcification</td>
<td>54 (32.5)</td>
<td>12 (29.3)</td>
<td>0.69</td>
</tr>
</tbody>
</table>

CAD: Coronary artery disease, CKD: Chronic kidney disease.; ILD: Interstitial Lung Disease.

Conclusion: Autoantibodies seem to have impact on the characteristics of pulmonary rheumatoid nodules. As there were different prescription patterns were seen in our study, effects of these treatment differences needs to be determined.

REFERENCES: -

Disclosure of Interests: None declared

Conclusion: DB causes the greatest increase in HRV for healthy participants, while both DB and taVNS can equally elevate HRV in patients with RA and SLE, which support their use as a potential new treatment approach. However, their clinical effect needs to be investigated in future studies.

Acknowledgements: The authors thank patients and research personnel at Aalborg University Hospital.

Disclosure of Interests: None declared


Figure 1.

IN PATIENTS WITH RHEUMATOID ARTHRITIS, CLINICAL EXAMINATION OF THE FEET IS IMPORTANT FOR UNDERSTANDING INDIVIDUAL DISEASE BURDEN, BUT DOES NOT PROVOKE A CHANGE IN THERAPY IN MOST CASES

N. Leuchten1, C. Weinert1, M. Aringer1. University Medical Center and Faculty of Medicine TU Dresden, Division of Rheumatology, Department of Medicine III, Dresden, Germany.

Background: Disease activity scores like CDAI, SDAI or DAS28, are essential for measuring rheumatoid arthritis (RA) disease activity. These do not contain foot joints. However, foot pain is an important aspect of morbidity for RA patients, which leads to reduced mobility and quality of life.

Objectives: To analyse the impact of synovitis in ankle and metatarsophalangeal joints on RA scores and RA disease activity states.

Methods: Joint scores of 545 RA outpatients were followed from August 2004 through December 2020. Informed consent for the analysis of their routine data was obtained for every patient. The standard CDAI cut-offs used were CDAI ≤ 2.8 for remission (REM), CDAI > 2.8 - 10.0 for low disease activity (LDA), CDAI > 10.0 - 22.0 for moderate disease activity (MDA) and CDAI > 22.0 for high disease activity (HDA). Foot involvement (FI) was defined as having at least one swollen (SJ) or tender (TJ) foot joint in patients who ever had palpable synovitis in any of these joints. The visits were grouped according to the number of swollen joints (SJ 0-28). The mean Physician Global Assessment of disease activity (PhGA) was calculated for each SJ group and the difference between the mean PhGA in patients with and without FI (as defined above) was calculated for each SJ group (ΔPhGA). Statistical analysis was performed in IBM SPSS Statistics Version 28.0.1.0.

Results: A total of 7,577 visits of 545 patients were included, for a mean of 14 visits per patient. 413 (75.8%) of the patients were female, the mean age at visit was 59 years, mean disease duration was 13 years, 284 (52.1%) were ACPA positive. 247 (45.3%) were on biological DMARDs. The median CDAI at visit was 4.3 (interquartile range IQR 1.6 - 9.0), the median DAS28 was 2.56 (IQR 1.89 - 3.37), the median CRP was 2.5 (IQR 1.0 - 6.2) mg/L. At 2,853 (37.7%) visits the patient was in REM, at 3,134 (41.4%) visits in LDA, at 1,265 (16.7%) visits in MDA and at 324 (4.3%) visits in HDA. Patients with FI were more active and scored higher on CDAI (9.1 vs. 3.4, p<0.001) and DAS28 (3.19 vs. 2.45, p<0.001), even though the indices do not include the foot joints. This was mainly due to higher patient global assessment of disease activity (3.1 vs. 2.0, p<0.001). Involvement of the feet also led to a higher physician estimate of global disease activity. The mean difference of PhGA between patients with and without involvement of their feet (ΔPhGA) was meaningful for joint counts 0-10, with an unweighted mean ΔPhGA of 0.273. Of the 217 patients with FI, 3,776 visits were analyzed. For patients with FI, the potential change in disease activity was calculated by subtracting ΔPhGA from the CDAI at each visit. For 3,662 (97.0%) of the visits, this did not result in a change of disease activity state. For 90 (2.4%) visits, disease activity changed from LDA to REM, for 21 (0.6%) from MDA to LDA, and for only 3 (0.1%) visits from HDA to MDA. At 83 (1.1%) visits of a total of 59 (10.8%) patients, only swollen foot joints without tender foot joints were recorded.

Conclusion: Patients with foot involvement are more active and score disproportionally high on disease activity indices, even though these do not include foot joints. While patients suffer significantly from foot involvement, underestimating disease activity by not assessing the feet would have changed the disease activity state for 3.1% of the visits only. Palpable synovitis without tenderness, which would be missed by performing only a metatarsophalangeal squeeze test, was found at one in a hundred visits.

REFERENCES:

Disclosures: Nicolai Leuchten Speakers bureau: Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB. Consultant of: Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GSK, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB., Christoph Weinert: None declared, Martin Aringer Speakers bureau: AbbVie, Astra Zeneca, BMS, Boehringer Ingelheim, Chugai, Galapagos, GSK, HEXAL, Lilly, MSD, Mylan, Novartis, Otsuka, Pfizer, Roche, Sanofi, UCB., Consultant of: AbbVie, Astra Zeneca, BMS, Boehringer Ingelheim, Galapagos, GSK, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB.

DOI: 10.1136/annrheumdis-2022-eular.2747
S. Dieperink1, 2, B. Glintborg1, 2, 3, F. Mehney4, M. Nergaard4, T. Bentfield5, 6, C. Torp-Pedersen5, 7, 8, L. B. Oestergaard9, A. Petersen5, 6, M. L. Hetland1, 2, 3, 1Copenhagen University Hospital - Rigshospitalet, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopedics, Glostrup, Denmark; 2University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 3Copenhagen University Hospital - Rigshospitalet, DANBIO Registry, Glostrup, Denmark; 4Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus, Denmark; 5Copenhagen University Hospital - Amager and Hvidovre, Department of Infectious Diseases, Copenhagen, Denmark; 6Copenhagen University Hospital - North Zealand, Department of Cardiology, Hillerød, Copenhagen, Denmark; 7Aalborg University Hospital, Department of Cardiology, Aalborg, Denmark; 8University of Copenhagen, Department of Public Health, Copenhagen, Denmark; 9Copenhagen University Hospital - Herlev and Gentofte, Cardiovascular Research Center, Helleurop, Denmark; 10Statens Serum Institut, Department of Bacteria, Parasites and Fungi, Copenhagen, Denmark

Background: Staphylococcus aureus bacteremia (SAB) has high mortality and rheumatoid arthritis (RA) patients are at increased risk. The role of anti-rheumatic treatments and disease activity is unclear.[2,3]

Objectives: To explore the impact of treatment with glucocorticoids and biologic disease-modifying anti-rheumatic drugs (bDMARDs) and disease activity on the risk of SAB in RA patients.

Methods: Nestled case control study in a nationwide cohort of RA patients (DANBIO) with no history of SAB. Cases had a first-time microbiologically verified SAB between 2010-2018. Controls were incidence density matched (age and sex) at time of SAB (index date). We linked data from DANBIO (e.g. disease activity, anti-rheumatic treatment) to other national registries (comorbidities, prescriptions, socioeconomic status, etc.). Treatments were redeemed prescriptions or registrations in DANBIO (oral glucocorticoids, bDMARDs) 0-2 years before the index date. Dose of oral glucocorticoids was retrieved from either DANBIO or estimated from the latest prescription. Risk associated with treatment and disease activity was assessed by multivariate conditional logistic regression. For treatments, excess cases/10,000 exposed/year were calculated by multiplying the fully adjusted OR (95% CI) with the incidence rate in the cohort. Missing data was handled by multiple imputation.

Results: We identified 180 cases in 30,479 RA patients (IR 106.7/100,000 person-years) and matched 720 controls (53% women, median age 73 years, IQR 65; 80). For cases, orthopedic implants were frequent (53%/34% for cases/controls), many had recent surgery (38%/5%), longstanding RA (13 years (6; 21)/8 (4; 14)), joint erosions (48%/39%), moderate (29%/16%) or high (10%/77%) disease activity, and used glucocorticoids (41%/19%) and bDMARDs (31%/20%). Adjusted ORs were high for current use of glucocorticoids, especially for doses >10mg/day (OR=14.5 (4.0; 52.2)). For bDMARDs, adjusted OR was 1.9 (1.1; 3.8). Correspondingly, the treatments increased risk with 144 and 9 excess cases/10,000/year, respectively (Table 1). For disease activity, adjusted ORs were >1 (non-significant) for moderate and high disease activity compared with remission (Figure 1).

Table 1. Use of oral glucocorticoids and biologic disease-modifying anti-rheumatic drugs (bDMARDs) 0-2 years before the index date and risk of Staphylococcus aureus bacteremia (SAB)

<table>
<thead>
<tr>
<th>Glucocorticoids n (%)</th>
<th>SAB cases, n=180</th>
<th>Controls, n=720</th>
<th>OR (95% CI)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>67 (37)</td>
<td>452 (63)</td>
<td>ref</td>
</tr>
<tr>
<td>Yes</td>
<td>113 (63)</td>
<td>270 (38)</td>
<td>2.4 (1.5; 3.8)</td>
</tr>
<tr>
<td>Current usera</td>
<td>39 (22)</td>
<td>133 (19)</td>
<td>1.7 (0.9; 3.0)</td>
</tr>
<tr>
<td>Current daily dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;0-5 mg</td>
<td>44 (24)</td>
<td>108 (15)</td>
<td>2.1 (1.1; 3.8)</td>
</tr>
<tr>
<td>&gt;5-10 mg</td>
<td>18 (10)</td>
<td>26 (4)</td>
<td>3.5 (1.4; 8.6)</td>
</tr>
<tr>
<td>&gt;10mg</td>
<td>12 (7)</td>
<td>8 (1)</td>
<td>14.5 (4.0; 52.2)</td>
</tr>
<tr>
<td>bDMARDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>111 (62)</td>
<td>558 (78)</td>
<td>ref</td>
</tr>
<tr>
<td>Yes</td>
<td>69 (38)</td>
<td>162 (23)</td>
<td>1.9 (1.1; 3.2)</td>
</tr>
<tr>
<td>Current usera</td>
<td>14 (8)</td>
<td>18 (3)</td>
<td>2.1 (0.8; 5.8)</td>
</tr>
</tbody>
</table>

*Number of excess cases/10,000 exposed/year (confidence limits)

Conclusions: Oral glucocorticoids and bDMARDs increased relative risk of SAB, with number of excess cases being high for oral glucocorticoids (>10 mg/day) and low for bDMARDs. Disease activity had minor impact on the risk. This emphasizes that high dose glucocorticoids should be used with caution.

References:
[1] Dieperink SS, resubmitted after revision Jan 2022

Acknowledgements: We wish to acknowledge the valuable inputs from patient representative Pia Lüchau Pedersen who participated in the initial brainstorming phase that led to the hypotheses being tested in this study.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2749
BACKGROUND: Treat-to-target (T2T) is integral to international recommendations for managing patients with rheumatoid arthritis (RA), but its implementation in clinical practice is suboptimal. Understanding T2T barriers and facilitators may inform strategies for improving T2T implementation in RA.

OBJECTIVES: To review published evidence on barriers to and facilitators of T2T implementation in RA, and interventions designed to improve T2T implementation.

METHODS: Two systematic literature searches were conducted to identify barriers to or facilitators of, and interventions designed to improve, T2T implementation in RA (Jan 1, 2015–Mar 1, 2021 and Jan 1, 2010–Jul 1, 2021, respectively). The quality of each study was assessed using the appropriate Critical Appraisal Skills Programme (CASP) checklist. Barriers/facilitators and interventions were grouped into categories and summarized descriptively.

RESULTS: The barriers/facilitators literature search retrieved 235 articles. Seventy-seven of these, which described primary studies mentioning a total of 331 T2T barriers/facilitators in RA, were included in the analysis. The interventions literature search identified 451 articles, including 70 primary studies reporting a total of 56 unique interventions to improve T2T implementation in RA. The quality of the studies varied; however, most addressed at least half of the information evaluated in the CASP checklists. Barriers/facilitators were categorized into 18 key target areas for patients (n=7), healthcare professionals (HCPs; n=6), or patients and HCPs (n=5). These related to: HCPs’ or patients’ knowledge or perceptions; patients’ clinical or social conditions; patient–HCP communication or alignment; and time or resources (Figure 1). The 56 interventions were grouped into 18 types (Table 1). More than half of the interventions (n=30; 53.6%) were designed to improve or streamline disease activity or patient-reported outcome assessments or increase patient–HCP alignment on disease activity. Interventions designed to improve shared decision-making were also common (n=23, 41.1%); these included patient and HCP education (n=15), decision aids (n=7), and shared decision-making prompts (n=3). Of the 56 interventions, 20 (35.7%) reported improvements in T2T implementation and/or patient outcomes in RA. However, as most interventions were evaluated in single centers, their effectiveness, feasibility, and generalizability across other regions or healthcare settings were unclear.

Table 1. Interventions for improving T2T implementation in RA, by type

<table>
<thead>
<tr>
<th>Type of intervention</th>
<th>Number of unique interventions (n=66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic disease assessment recording</td>
<td>11</td>
</tr>
<tr>
<td>Disease assessment process/quality improvement initiative</td>
<td>8</td>
</tr>
<tr>
<td>Allied HCP-supported T2T strategy</td>
<td>8</td>
</tr>
<tr>
<td>Patient educational tools</td>
<td>7</td>
</tr>
<tr>
<td>Patient decision aid</td>
<td>7</td>
</tr>
<tr>
<td>HCP performance feedback</td>
<td>7</td>
</tr>
<tr>
<td>Integrated PRO assessment</td>
<td>6</td>
</tr>
<tr>
<td>Ultrasound assessment</td>
<td>5</td>
</tr>
<tr>
<td>HCP learning collaborative (structured learning sessions + performance feedback)</td>
<td>4</td>
</tr>
<tr>
<td>Patient PRO dashboard/visual feedback tool</td>
<td>4</td>
</tr>
<tr>
<td>Telehealth monitoring</td>
<td>3</td>
</tr>
<tr>
<td>HCP T2T/shared decision-making prompt</td>
<td>3</td>
</tr>
<tr>
<td>Nurse-led patient education</td>
<td>3</td>
</tr>
<tr>
<td>Multidisciplinary team program</td>
<td>3</td>
</tr>
<tr>
<td>HCP training</td>
<td>2</td>
</tr>
<tr>
<td>Patient telehealth education</td>
<td>2</td>
</tr>
<tr>
<td>HCP decision-making tool</td>
<td>1</td>
</tr>
<tr>
<td>Patient group sessions</td>
<td>1</td>
</tr>
</tbody>
</table>

*Interventions may be assigned to more than one category.

Conclusion: While practical methods designed to improve T2T implementation in RA are available, their effectiveness and feasibility will likely vary by region and healthcare setting. More primary research is required to identify the most relevant barriers/facilitators and prioritize the most appropriate interventions to optimize T2T implementation both globally and locally.

REFERENCES:
COVID-19 pandemic response to limit virus transmission was characterized by mandated lockdowns and quarantines, resulting in significant stressors for rheumatology patients and potentially threatening their disease.

**Objectives:** To examine factors associated with changes in rheumatoid arthritis (RA) disease activity and flares in the COVID-19 pandemic.

**Methods:** RA patients identified by ICD-9/10 codes and active email addresses within a University of California, Los Angeles (UCLA) Rheumatology database were sent surveys via email in July and November of 2020. The survey was UCLA Institutional Review Board approved and included electronic consent and questions related to perceptions of disease activity/remission via Routine Assessment of Patient Index Data 3 (RAPID3), flare frequency, RA flare questionnaire (RA-FQ), Perceived Stress Scale (PSS-4), and pandemic impact on stress (i.e. emotional state, apprehension, panic, helplessness, work, home, financial, and social distancing stress). Demographics were extracted from electronic medical records. Results were examined via descriptive analyses, Pearson correlations, and chi-square test for comparisons plus linear stepwise regressions where appropriate to evaluate the relationship between stress measures, RA disease activity, and flare frequency and severity.

**Results:** Among 5037 patients surveyed, 361 in July and 4676 in November,1128 (22.4%) responded. The study population demographics were: mean age of 57.5 ± 15.1 years, 79.4% female, racially diverse (69.6% Caucasian, 15.7% % LatinX, 9.5% Asian, and 4.9% Black), and 62% seropositive (CCP and/or RF). Perceived disease activity and remission remained stable in most patients with 719 reporting no flares, and 409 in current flares at the time of the survey (Table 1). A minority reported perceived increases in disease activity which were associated with multiple aspects of perceived stress. At survey completion, 346 had not experienced flares, 290 had experienced one flare, and 492 had experienced multiple flares. Use of DMARDs was associated with lack of flare versus current flare (77.8% versus 71.6%, p = 0.02). The use of conventional synthetic, biologic, or targeted synthetic DMARDs were not associated with flare while current corticosteroid use was associated with flare (9.3% without flare and 20.8% with flare, p < 0.0001). Current flare was associated with increased PSS-4 scores (odds ratio (OR): 1.17 (95% confidence interval: 1.12 – 1.22, p < 0.0001). Figure 1 describes the odds ratio of experiencing aspects of stress with the presence of RA flare.

**Table 1. Current RA flare at time of survey completion**

<table>
<thead>
<tr>
<th>Current Flare</th>
<th>Current Flare Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N=409</td>
</tr>
<tr>
<td>RA duration (mean ± SD) years</td>
<td>15.6 ± 12.3</td>
</tr>
<tr>
<td>Patient Global (mean ± SD), range 0-10</td>
<td>3.5 ± 2.5</td>
</tr>
<tr>
<td>Patient-Reported Remission, no. (%)</td>
<td>404 (57.1%)</td>
</tr>
<tr>
<td>RA-FQ Score, (mean ± SD), range 0-50</td>
<td>13.4 ± 11.4</td>
</tr>
<tr>
<td>Overall stress level (%)</td>
<td>5.2 ± 3.1</td>
</tr>
</tbody>
</table>

**Conclusion:** Collectively, our data indicate that a large proportion of patients with RA still lack early diagnosis despite dedicated early access to rheumatology care; from 2010 onwards, autoantibody-positive patients are diagnosed with a milder and less disabling disease, while autoantibody-negative patients are at increased risk of delayed diagnosis, and remain burdened with severe disease. Stressors related to perceived stress and disease activity/remission were associated with multiple aspects of perceived stress. At survey completion, 346 had not experienced flares, 290 had experienced one flare, and 492 had experienced multiple flares. Use of DMARDs was associated with lack of flare versus current flare (77.8% versus 71.6%, p = 0.02). The use of conventional synthetic, biologic, or targeted synthetic DMARDs were not associated with flare while current corticosteroid use was associated with flare (9.3% without flare and 20.8% with flare, p < 0.0001). Current flare was associated with increased PSS-4 scores (odds ratio (OR): 1.17 (95% confidence interval: 1.12 – 1.22, p < 0.0001). Figure 1 describes the odds ratio of experiencing aspects of stress with the presence of RA flare.

**Table 1. Current RA flare at time of survey completion**

<table>
<thead>
<tr>
<th>Current Flare</th>
<th>Current Flare Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N=409</td>
</tr>
</tbody>
</table>

**SD = standard deviation; No. = number; RA = rheumatoid arthritis; RAPID3 = routine assessment of patient index data 3; RA-FQ = rheumatoid arthritis flare questionnaire; PSS-4 = perceived stress scale; D/C = discontinued; DMARD = disease modifying antirheumatic drugs; csDMARD = conventional synthetic DMARD; bDMARD = biologic DMARD; tsDMARD = targeted synthetic DMARD**

**Conclusion:** In a large survey population of RA patients during the COVID-19 pandemic, multiple aspects of stress were found to correlate with RA disease activity and flare.

**Figure 1. Odds ratio of degree of stress relative to no stress**

**POS0609**

**STRESS-ASSOCIATED INCREASES IN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND FLARES DURING THE COVID-19 PANDEMIC**

D. Furst1, N. T. Morris1, A. O. Pham2, T. Woodworth3, D. Elashof3, J. Brook4, V. Ranganath1.

1University of California, Los Angeles, Rheumatology, Los Angeles, United States of America; 2University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, United States of America; 3University of California, Los Angeles, Medicine Statistics Core, Los Angeles, United States of America

**Background:** The novel coronavirus disease 2019 (COVID-19) pandemic has spurred global action. Beginning in March of 2020, the Southern California
Disclosure of Interests: Daniel Furst Consultant of: Corbus; Galapagos; Novartis; Agen; Grant/research support from: Actelion; Galapagos; National Institutes of Health; GlaxoSmithKline; Sanofi; Corbus; Pfizer; Novartis; Agen; Bristol Myers Squibb; Roche/Genentech; Nicolette T Morris: None declared, Angela G Pham: None declared, Thasia Woodworth: None declared, David Elashoff: None declared, Jenny Brook: None declared, Veeana Ranganath Grant/research support from: Bristol Myers Squibb; Mallinckrodt Pharmaceuticals DOI: 10.1136/annhumed-2022-eular-2886

POS0610 THE RELATIONSHIP BETWEEN SYSTEMIC MANIFESTATIONS OF RHEUMATOID ARTHRITIS AND THE STRUCTURAL GEOMETRY OF THE MYOCARDIUM

I. Feisikhanova1, D. Abdulginanueva 1, Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation

Background: In recent years, chronic inflammatory diseases, including rheumatoid arthritis (RA), have been perceived as independent risk factors for cardiovascular diseases. In addition to influencing the development of atherosclerosis, rheumatic diseases are accompanied by changes in the myocardium.

Objectives: to determine the relationship between systemic manifestations of RA and structural changes of the heart.

Methods: The 282 patients (240 women and 42 men) with verified RA were examined. In addition to standard diagnostic tests, all patients underwent echocardiography with tissue Dopplerography of the myocardium.

Results: Structural and geometric remodeling of the heart was detected in 146 patients (51.8%), of which 29 had concentric remodeling, 35 had concentric hypertrophy, and most often, 82 people had eccentric hypertrophy. The average age was 57.9±8.55 years in the group with cardiac remodeling and 47.2±11.92 years in individuals with normal heart geometry, respectively (p <0.0001). Among 136 patients (48.2%) with normal heart geometry, 39 people suffered from arterial hypertension, 73 patients had various systemic manifestations of rheumatoid arthritis (Sjogren’s syndrome, rheumatoid nodules and/or cryoglobulinemia). Among those with cardiac remodeling, arterial hypertension was diagnosed more often — in 107 people (p <0.0001), and systemic manifestations of rheumatoid arthritis — in 87 patients (p<0.1). A comparison was made between a group with eccentric hypertrophy (82 people) and a combined group of patients with concentric remodeling and eccentric hypertrophy (64 people). In the first group, the age was higher and amounted to 58.6±5.2 years, and in the second — 57.2±7.96 years (p<0.05). In the first group, systemic extra-articular manifestations of rheumatoid arthritis were found in 56 individuals (68.3%), and in the second group — in 33 people (51.6%) (p=0.04).

It is worth noting that in the second group, patients with concentric hypertrophy made the greatest contribution: out of 35 people, systemic manifestations of rheumatoid arthritis were detected in 23 people (65.7%), which is comparable to the frequency among people with eccentric hypertrophy. In this regard, for the research purpose, we combined individuals with normal geometry and concentric remodeling into one group (165 people), and patients with concentric and eccentric hypertrophy into another group (117 people). When compared, it was found that regardless of the type of myocardial hypertrophy these individuals are significantly more likely to suffer from systemic manifestations of rheumatoid arthritis: 53.9% and 67.5%, respectively (p=0.02).

Conclusion: the formation of myocardial hypertrophy in patients with rheumatoid arthritis is associated with more frequent development of extra-articular manifestations of this disease.

REFERENCES:

Disclosure of Interests: None declared DOI: 10.1136/annhumed-2022-eular-2959

POS0611 THE SIGNIFICANCE OF DETERMINING THE LEVEL OF THE ST-2 MARKER OF HEART FAILURE IN PATIENTS WITH RHEUMATOID ARTHRITIS

I. Feisikhanova1, D. Abdulginanueva 1, Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation

Background: The heart failure in patients with rheumatoid arthritis differs in its genesis from that in the general population. It has been established that the increased risk of congestive heart failure in patients with RA cannot be explained by the high frequency of risk factors for cardiovascular diseases, including coronary heart disease. While 80% of chronic heart failure in the general population is associated with classical risk factors for cardiovascular diseases, in RA these same predictors explain only 40% of cases.

Objectives: to establish the prevalence of diastolic dysfunction of preclinical signs of heart failure in patients with rheumatoid arthritis.

Methods: The 282 patients with verified rheumatoid arthritis were examined, including 240 women and 42 men. All patients underwent standard diagnostic tests, two-dimensional transthoracic echocardiography with tissue dopplerography of the myocardium, determination of the level of ST-2, stimulating growth factor, a marker of heart failure, in blood serum.

Results: The Tissue Dopplerography in combination with two-dimensional echocardiography allowed us to identify patients with diastolic myocardial dysfunction and form the following subgroups. 1 — with normal heart geometry and without diastolic myocardial dysfunction (91 people), 2 — with normal heart geometry and with diastolic dysfunction (45 people), 3 — with structural and geometric remodeling of the heart and without diastolic myocardial dysfunction (73 people), 4 — with structural -geometric remodeling of the heart and with diastolic dysfunction (73 people). Among patients with altered heart geometry (3rd and 4th subgroups), the prevalence of diastolic dysfunction was higher than among those with normal geometry (1st and 2nd subgroups): 50% and 33.1%, respectively (p=0.004). We conducted a comparison between the subgroups depending on the presence of diastolic myocardial dysfunction. The average age of patients with rheumatoid arthritis who showed signs of diastolic dysfunction with normal heart geometry was higher (54 [49; 57] years) than in the compared subgroup (45.5 [33.5; 53.5]) (p<0.0001). They also had significantly higher levels of the ST-2 marker, which indicates an early preclinical sign of heart failure: 70.1 [39.5; 106.5] and 42.2 [29.6; 61.5] ng/ml (p<0.1). Apparently, despite the absence of cardiac remodeling, with age, patients with rheumatoid arthritis are more likely to develop not only diastolic dysfunction, but also diastolic type of heart failure.

Conclusion: Thus, in patients with rheumatoid arthritis, it is advisable to conduct tissue Dopplerography in addition to standard echocardiography to detect diastolic dysfunction, which in these patients may develop in the absence of structural and geometric changes.

REFERENCES:

Disclosure of Interests: None declared DOI: 10.1136/annhumed-2022-eular-2979

POS0612 COMORBIDITIES IN RHEUMATOID ARTHRITIS DO NOT INFLUENCE BIOLOGICS DRUG RETENTION: DATA FROM THE NATIONAL HEALTH INSURANCE FUND OF TUNIS

S. Bousaid1, K. Saadaoui2, S. Rekki2, S. Jemmali2, S. Rahmouni2, H. Sahl2, M. Elleuch2, 1Hospital Rabta, Rheumatology, Tunis, Tunisia; 2Hospital Rabta, Rheumatology, Tunis, Tunisia

Background: the advent of biologics in the late 1990s radically changed the profile of inflammatory diseases, in particular rheumatoid arthritis (RA). The survival of these innovative therapies is an indicator, in clinical practice, of their long-term efficiency in patients with RA.

Objectives: To study the influence of comorbidities on biologics drug retention rates.

Methods: We conducted a cross-sectional, observational study. Data were identified from the files of the National Health Insurance Fund of Tunis. It included patients with RA on biologics. Epidemiological characteristics such as age, sex, and comorbidities, were collected. Comorbidities were assessed by the Charlson Comorbidity Index (CCI). The therapeutic maintenance rate at 12, 24, 36, and 48 months as well as the biologics survival were analyzed using Kaplan-Meier survival curves and compared using the Log-Rank test.

Results: Three hundred and seventy-four files were selected. The average age of our cohort was 55±12.54 years [20-90]. A female predominance was noted with a sex ratio M/F=0.147. The average duration of RA was 11.7±6.76 years.
Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease with a high cardiovascular risk, increasing the incidence of coronary artery disease, ventricular arrhythmias and sudden cardiac death (SCD). The annual incidence of SCD among the general population is 0.2%, and patients with RA are twice as likely to develop it as healthy people. The well-known predictors of the development of SCD among the variance of the QT interval and the alternation of the T-wave. Comorbidities were assessed by the CCI in 373 patients (99.7%). Ninety patients had an ICC of 0 and 103 patients had an ICC of 1. Only one patient had an ICC of 8. The median value of this score was equal to 1, the mean was 1.64 ± 1.48. Osteoporosis was the most observed comorbidity with 78 patients (20.9%). The study of drug survival according to the ICC did not show any significant differences between the different curves (p=0.809). The Hazard Ratio was 0.989. Similarly, we did not find a discriminating threshold for the Charlson score, allowing it to be decisive for the survival of biologic drugs.

Conclusion: This study did not identify the influence of comorbidities on the biologics survival during RA. Comorbidities can have an impact not only on our therapeutic choice but also on the efficacy and maintenance of biomedicines as well as the quality of life of patients and consequently the prognosis of RA (1).

The few studies that have looked at this subject have produced variable results.

REFERENCES:

Disclosure of Interests: None declared

POS0614 THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND FINANCIAL TOXICITY IN PATIENTS WITH RHEUMATOID ARTHRITIS REGISTRY

R. Inoue1, N. Vajima1,2,3, T. Matsui2,2, S. Tohma2,2, 1Showa University School of Medicine, Division of Rheumatology, Department of Medicine, Tokyo, Japan; 2National Hospital Organization Sagamihara National Hospital, Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, Kanagawa, Japan; 2Fukushima Medical University, Center for Innovative Research for Communities and Clinical Excellence, Fukushima, Japan; 3Fukuoka University, Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyotango, Japan; 2National Hospital Organization Sagamihara National Hospital, Department of Rheumatology, Kanagawa, Japan; 1National Hospital Organization Tokyo National Hospital, Department of Rheumatology, Tokyo, Japan

Background: As the number of rheumatoid arthritis (RA) patients using biologics increases, the health financial issues posed by biologics become more important. The health financial issues posed by biologics have been discussed using health economic indicators such as incremental cost-effectiveness ratios (ICERs), but have not been evaluated using the financial burden of medical expenses (financial toxicity). In the field of malignancies, evaluations using financial burden have been conducted and have shown that the stage of malignancy is associated with financial toxicity. It is not known whether disease activity and financial toxicity are similarly associated in RA patients.

Objectives: This study aims to evaluate the relationship between RA activity and financial toxicity in RA patients using biologics, who are especially likely to feel the financial burdens.

Methods: We conducted a cross-sectional study of biologic users enrolled in NinJa2020, a database of rheumatoid arthritis patients in Japan collected from April 1, 2020 to March 31, 2021. We defined the users of TNF inhibitor, IL-6 receptor antagonists, T-cell costimulation blocker, Janus kinase inhibitor and biosimilar as biologic users. The main exposure was the disease activity of RA and was measured using DAS28-CRP. Outcome measure was a financial toxicity and was measured using COMprehensive Score for Financial Toxicity (COST). This scale is a patient-reported outcome measure (PROM) consisting of 11 items. The responses are recorded on 5-point Likert Scales (ranging from 0 = strongly disagree to 4 = strongly agree). The score by domains ranges from 0 to 44. Higher scores indicated better results and lower financial toxicity. Multiple linear regression models adjusted for age, sex, disease duration, co-payments for anti-rheumatic drugs, work status, financial support systems were conducted to assess the relationship between the disease activity of RA and financial toxicity. As a result, this study intended to evaluate the relationship between RA activity and financial toxicity in RA patients using biologics, who are especially likely to feel the financial burdens.
secondary analysis, we excluded patients with zero copayments and performed the same analysis as in the main analysis. We used multiple imputation to deal with missing values.

Results: Among 15553 cases in the NinJa database, 649 cases for which RA disease activity and COST were available were included. The median age of the patients was 70 (interquartile range [IQR], 56 -77), 83.7% were female. The median copayment amount was ¥12978 per month (IQR 6372.4 to 24204.1). The median DAS28-CRP was 1.99 (IQR, 1.1 - 2.72). The median financial toxicity (COST score) was 21 (IQR 0-27) (Figure 1). In the main analysis using multiple linear regression, COST significantly decreased with disease activity of RA (per 1-pt DAS28-CRP, -1.16 [95% CI -2.04 - -0.28]). In the secondary analysis, COST significantly decreased with disease activity of RA (per 1-pt DAS28-CRP, -1.69 [95% CI -2.29 - -1.10]). Statistical significance was defined as a two-sided p-value < 0.05. All statistical analyses were conducted using STATA 17.0 (Stata Corp LP, College Station, TX). The National Hospital Organization’s research ethics committees evaluated and authorized the NinJa study.

Conclusion: High disease activity of RA was associated with high financial toxicity in biologic users. We reaffirmed the importance of financial considerations and empathy for RA patients using biologics, and suggested a potential demand for more financial support for RA patients who are refractory to treatment.

Disclosure of Interests: None declared


POS0615 CLINICAL DEMOGRAPHICS AND FACTORS AFFECTING DRYNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS

1Kanazawa Medical University, Department of Hematology and Immunology, Uchinada, Japan; 2Kanazawa University Hospital, Department of Rheumatology, Kanazawa, Japan; 3Kaga Medical Center, Department of Internal Medicine, Kaga, Japan; *Kim Clinic, Department of Internal Medicine, Saka, Japan

Background: Sjogren’s syndrome (SS) is known to coexist with rheumatoid arthritis (RA). However, the prevalence of RA with SS varies widely, from 2.4% to 30%, and some patients with RA without SS also show dryness. The prevalence and clinical demographies of dryness in patients with RA are not well recognized.

Objectives: The aim of this study was to clarify the prevalence, clinical demographics, and related factors of dryness in patients with RA who have not been diagnosed with (SS).

Methods: We enrolled 166 patients with RA (129 females, 37 males; mean age 65.8±14.3 years; disease duration 14.1±10.9 years; DAS28-CRP 2.30±0.92) who were not diagnosed with SS. We analyzed CRP, the estimated glomerular filtration rate (eGFR), RF, anti-CCP antibody, antinuclear antibody, anti-SS-A antibody (SSA), and disease activity score (DAS) 28-CRP, and identified treatments for RA. We used each question item of the EULAR SS Patient Reported Index (ESSPRI) to clarify dryness, somatic and mental fatigue, and pain. History of smoking, comorbidities, such as interstitial fibromyalgia, fibromyalgia, and psychiatric disorders, and narcotic and/ or psychotropic medication use were determined from the medical records. We defined patients with dryness as greater than or equal to one point, and those with severe dryness as greater than or equal to five points, of the visual analog scale (VAS).

Results: Dryness was observed in 93/166 (56.0%) patients and severe dryness was identified in 57/166 (34.4%) patients, and SSA was positive in 23/169 patients (13.9%). We divided our patients into dryness and non-dryness groups and compared their clinical demographics. The dryness group was relatively younger (64.0±14.5 vs. 68.1±13.8 years, p=0.052), had a female predominance (89.2% vs. 63.0%, p=0.001), had severe fatigue (4.06±2.59 vs 2.60±2.78, p=0.001), and had severe pain (3.52±2.41 vs. 2.73±3.22, p=0.020). However, there were no significant differences in other factors including lipid pattern. Twenty-seven RA patients receiving TCZ (8 mg/kg IV/q4w) were assessed at baseline and weeks 12, 24, and 52. Disease activity indexes, serum levels of ApoC3, ANGPLT4 and LPL, and lipoproteins serum concentrations were assessed in a post-treatment visit.

Results: Acute phase reactants and disease activity were significantly reduced during study visits and at the end of treatment after one year with TCZ. While total and LDL cholesterol initially increased in plasma concentration, then decreased to baseline, lipoprotein (a) was significantly lower, and HDL higher, than baseline at all visits. TG showed a trend to be significantly higher at 6 months (net increase 29 (95%CI -45-68) mg/dl, percentage increase 36 (95%CI -27-52) %, p=0.079). However, TG did not show significant differences at any visit compared to baseline levels. ANGPLT4 (baseline 387 ± 203 vs final 257 ± 32 wk52 ng/ml, p=0.079), and ApoC3 (baseline 10.1 ± 6.7 vs final 6.3 ± 3.7 mg/dl, p=0.023) were significantly lower at the end of the study (week 52) compared to their initial concentrations. LPL also showed a gradual decrease at each visit (baseline 349 ± 289 vs final 291 ± 197 mg/ml, p=0.57), although statistical significance was not reached (trend test p=0.56). The decrease in DAS28-ESR at each visit was not associated with the changes produced in the three molecules, thus showing that the decrease in the TG metabolism axis does not depend on the lower activity of the disease produced by TCZ. In contrast, the decline in ApoC3 was significantly correlated with the increase in TG at month 3 (Pearson r -0.494, p=0.037) but not at 6 and 12 months.

Conclusion: TCZ decreases serum levels of ANGPLT4, ApoC3 and LPL. At 3 months, the increase that occurs in TG seems to depend on the inhibition that TCZ exerts over ApoC3. Our findings suggest that the effect of TCZ on the lipid profile in patients with RA could be mediated by the modification that this drug exerts on the ANGPLT4-ApoC3-LPL axis.

Disclosure of Interests: Sergio Santos-Concepcion: None declared, Javier Castro-Hernández: None declared, Vanessa Hernández-Hernández: None declared, Cristina Luna-Gomez: None declared, Iván Ferraz-Amaro: Speakers bureau: Dr. Iván Ferraz-Amaro and Dr. Diaz-González would like to acknowledge that he has received grants/research supports from Abbott, Pfizer, Roche, Sanofi, Celgene, Grant/research support from: Dr. Iván Ferraz-Amaro and Dr. Diaz-González would like to acknowledge that he has received grants/research supports from Abbott, MSD, Jansen and Roche, as well as consultation fees from company sponsored speakers' bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, Federico Diaz-Gonzalez: Speakers bureau: Dr. Iván Ferraz-Amaro and Dr. Diaz-González would like to acknowledge that he has received grants/research supports from Abbott, MSD, Jansen and Roche, as well as consultation fees from company sponsored speakers' bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene, Consultant of: Dr. Iván Ferraz-Amaro and Dr. Diaz-González would like to acknowledge that he has received grants/research supports from Abbott, MSD, Jansen and Roche, as well as consultation fees from company sponsored speakers' bureaus associated with Abbott, Pfizer, Roche, Sanofi, Celgene.

Conclusion: MCP I synovitis is a major contributor to reduced grip force in patients with early RA during the first 5 years after diagnosis, independent of wrist synovitis, general pain and systemic inflammation. This underlines the importance of involvement of the thumb for impaired hand function in RA.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Relation between synovitis of individual MCP and PIP joints and grip force of the right hand (% of expected) in patients with early RA;

<table>
<thead>
<tr>
<th>MCP I</th>
<th>1-year follow-up</th>
<th>5-year follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>-10.8 (-17.1 to -4.4)</td>
<td>-8.0 (-14.8 to -1.2)</td>
<td>-8.2 (-16.4 to 0)</td>
</tr>
<tr>
<td>-7.5 (-13.9 to -1.1)</td>
<td>-6.0 (-10.6 to 6.4)</td>
<td>-0.6 (-8.2 to 9.5)</td>
</tr>
<tr>
<td>-7.4 (-13.6 to -1.3)</td>
<td>-13.9 (-14.4 to -8.8)</td>
<td>-4.5 (-13.4 to 4.5)</td>
</tr>
<tr>
<td>-8.9 (-18.5 to 0.7)</td>
<td>-8.8 (-25.7 to 8.1)</td>
<td>-4.0 (-22.1 to 14.0)</td>
</tr>
<tr>
<td>-2.5 (-12.6 to 7.8)</td>
<td>-2.6 (-15.6 to 11.2)</td>
<td>7.4 (-5.2 to 20.0)</td>
</tr>
<tr>
<td>2.0 (-6.4 to 10.9)</td>
<td>-16.4 (-16.9 to 10.7)</td>
<td>-5.1 (-23.3 to 13.2)</td>
</tr>
<tr>
<td>-0.8 (-7.7 to 6.2)</td>
<td>-3.9 (-13.3 to 5.5)</td>
<td>-3.2 (-16.2 to 9.8)</td>
</tr>
<tr>
<td>-5.6 (-12.1 to 1.0)</td>
<td>2.5 (-6.5 to 11.6)</td>
<td>1.9 (-9.0 to 12.9)</td>
</tr>
<tr>
<td>-4.1 (-11.8 to 3.6)</td>
<td>-1.9 (-12.8 to 9.0)</td>
<td>-0.1 (-14.2 to 14.1)</td>
</tr>
<tr>
<td>-7.2 (-16.0 to 1.7)</td>
<td>-10.3 (-22.8 to 2.3)</td>
<td>-5.6 (-21.2 to 9.9)</td>
</tr>
</tbody>
</table>

Table 2. Relation between synovitis of individual MCP and PIP joints and grip force of the right hand (% of expected) in patients with early RA; β (95% CI), adjusted for wrist synovitis, ESR and VAS pain

<table>
<thead>
<tr>
<th>MCP I</th>
<th>1-year follow-up</th>
<th>5-year follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>-10.8 (-17.1 to -4.4)</td>
<td>-8.0 (-14.8 to -1.2)</td>
<td>-8.2 (-16.4 to 0)</td>
</tr>
<tr>
<td>-7.5 (-13.9 to -1.1)</td>
<td>-6.0 (-10.6 to 6.4)</td>
<td>-0.6 (-8.2 to 9.5)</td>
</tr>
<tr>
<td>-7.4 (-13.6 to -1.3)</td>
<td>-13.9 (-14.4 to -8.8)</td>
<td>-4.5 (-13.4 to 4.5)</td>
</tr>
<tr>
<td>-8.9 (-18.5 to 0.7)</td>
<td>-8.8 (-25.7 to 8.1)</td>
<td>-4.0 (-22.1 to 14.0)</td>
</tr>
<tr>
<td>-2.5 (-12.6 to 7.8)</td>
<td>-2.6 (-15.6 to 11.2)</td>
<td>7.4 (-5.2 to 20.0)</td>
</tr>
<tr>
<td>2.0 (-6.4 to 10.9)</td>
<td>-16.4 (-16.9 to 10.7)</td>
<td>-5.1 (-23.3 to 13.2)</td>
</tr>
<tr>
<td>-0.8 (-7.7 to 6.2)</td>
<td>-3.9 (-13.3 to 5.5)</td>
<td>-3.2 (-16.2 to 9.8)</td>
</tr>
<tr>
<td>-5.6 (-12.1 to 1.0)</td>
<td>2.5 (-6.5 to 11.6)</td>
<td>1.9 (-9.0 to 12.9)</td>
</tr>
<tr>
<td>-4.1 (-11.8 to 3.6)</td>
<td>-1.9 (-12.8 to 9.0)</td>
<td>-0.1 (-14.2 to 14.1)</td>
</tr>
<tr>
<td>-7.2 (-16.0 to 1.7)</td>
<td>-10.3 (-22.8 to 2.3)</td>
<td>-5.6 (-21.2 to 9.9)</td>
</tr>
</tbody>
</table>

Conclusion: MCP I synovitis is a major contributor to reduced grip force in patients with early RA during the first 5 years after diagnosis, independent of wrist synovitis, general pain and systemic inflammation. This underlines the importance of involvement of the thumb for impaired hand function in RA.

REFERENCES:

Disclosure of Interests: None declared


Table 3. Relation between synovitis of individual MCP and PIP joints and grip force of the right hand (% of expected) in patients with early RA; β (95% CI), adjusted for wrist synovitis, ESR and VAS pain

<table>
<thead>
<tr>
<th>MCP I</th>
<th>1-year follow-up</th>
<th>5-year follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>-10.8 (-17.1 to -4.4)</td>
<td>-8.0 (-14.8 to -1.2)</td>
<td>-8.2 (-16.4 to 0)</td>
</tr>
<tr>
<td>-7.5 (-13.9 to -1.1)</td>
<td>-6.0 (-10.6 to 6.4)</td>
<td>-0.6 (-8.2 to 9.5)</td>
</tr>
<tr>
<td>-7.4 (-13.6 to -1.3)</td>
<td>-13.9 (-14.4 to -8.8)</td>
<td>-4.5 (-13.4 to 4.5)</td>
</tr>
<tr>
<td>-8.9 (-18.5 to 0.7)</td>
<td>-8.8 (-25.7 to 8.1)</td>
<td>-4.0 (-22.1 to 14.0)</td>
</tr>
<tr>
<td>-2.5 (-12.6 to 7.8)</td>
<td>-2.6 (-15.6 to 11.2)</td>
<td>7.4 (-5.2 to 20.0)</td>
</tr>
<tr>
<td>2.0 (-6.4 to 10.9)</td>
<td>-16.4 (-16.9 to 10.7)</td>
<td>-5.1 (-23.3 to 13.2)</td>
</tr>
<tr>
<td>-0.8 (-7.7 to 6.2)</td>
<td>-3.9 (-13.3 to 5.5)</td>
<td>-3.2 (-16.2 to 9.8)</td>
</tr>
<tr>
<td>-5.6 (-12.1 to 1.0)</td>
<td>2.5 (-6.5 to 11.6)</td>
<td>1.9 (-9.0 to 12.9)</td>
</tr>
<tr>
<td>-4.1 (-11.8 to 3.6)</td>
<td>-1.9 (-12.8 to 9.0)</td>
<td>-0.1 (-14.2 to 14.1)</td>
</tr>
<tr>
<td>-7.2 (-16.0 to 1.7)</td>
<td>-10.3 (-22.8 to 2.3)</td>
<td>-5.6 (-21.2 to 9.9)</td>
</tr>
</tbody>
</table>
M. Rojas-Giménez1, J. Calvo Gutierrez2, R. Ortega Castro3, M. L. Ladehesa Pineda4, A. Escudero Contreras1.1 Rheumatology Department, Córdoba, Spain; in mind that ILD is an important cause of death in our patients, we must actively assess whether the course and prognosis in both groups is also similar. Bearing in mind that ILD is an important cause of death in our patients, we must actively assess whether the course and prognosis in both groups is also similar. Bearing

Conclusion: Our study showed that comorbidity index was associated with a severe disease and signs of poor prognosis (erosions, coxitis, and atlanto-axial dislocation). This confirmed the hypothesis that comorbidity can be a threat to the improvement in the long-term prognosis in RA patients.

Disclosure of Interests: None declared


Disclosure of Interests: None declared


Table 1. Differential characteristics between the different groups

<table>
<thead>
<tr>
<th>Variables</th>
<th>RA with ILD (n=107)</th>
<th>RA without ILD (n=36)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, range (SD))</td>
<td>55.2 (±13.3)</td>
<td>57.2 (±12.5)</td>
<td>0.15</td>
</tr>
<tr>
<td>Age at diagnosis (mean, range (SD))</td>
<td>53.1 (±13.4)</td>
<td>55.4 (±13.4)</td>
<td>0.16</td>
</tr>
<tr>
<td>Sex</td>
<td>M: 63 (58.6%)</td>
<td>M: 14 (38.9%)</td>
<td>0.22</td>
</tr>
<tr>
<td>Erosions</td>
<td>15 (15.4%)</td>
<td>3 (8.3%)</td>
<td>0.08</td>
</tr>
<tr>
<td>Active rheumatoid factor (mean, range (SD))</td>
<td>56.2 (±13.2)</td>
<td>53.4 (±13.4)</td>
<td>0.13</td>
</tr>
<tr>
<td>Patient emotion (mean, range (SD))</td>
<td>3.1 (0-9)</td>
<td>3.2 (0-9)</td>
<td>0.84</td>
</tr>
<tr>
<td>Activity (mean, range (SD))</td>
<td>4.5 (3-7)</td>
<td>4.4 (3-7)</td>
<td>0.32</td>
</tr>
<tr>
<td>Disease activity scale (mean, range (SD))</td>
<td>4.5 (2-8)</td>
<td>4.4 (2-8)</td>
<td>0.42</td>
</tr>
<tr>
<td>Functional activity (mean, range (SD))</td>
<td>0.5 (0-2)</td>
<td>0.5 (0-2)</td>
<td>0.82</td>
</tr>
<tr>
<td>Comorbidities (mean, range (SD))</td>
<td>0.9 (0-3)</td>
<td>0.9 (0-3)</td>
<td>0.91</td>
</tr>
<tr>
<td>Radiographic erosions (mean, range (SD))</td>
<td>24.3 (0-72)</td>
<td>18.5 (0-72)</td>
<td>0.03</td>
</tr>
<tr>
<td>Erosions + coxitis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
<tr>
<td>Erosions + atlanto-axial arthritis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
<tr>
<td>Erosions + coxitis + atlanto-axial arthritis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
</tbody>
</table>

Results: There were 255 RA with sex ratio M/F at 0.2. The mean age was 58.92 ± 10.72 years [25-85]. The mean age at onset of disease was 43.76 ± 14.28 years [13-81]. The mean disease duration was 16.32 ± 13.4 [1-72]. Identified comorbidities were: hypertension (31.4%), lung disease (27.1%), diabetes (19.6%), cardiovascular disease (16.8%), gastrointestinal ulcer (9.2%), depression (8.8%), and chronic renal failure (8%). The mean RDCI was 1.14 ± 1.25 [0-6]. A statistically significant correlation was found between RDCI and age (r=0.277), RDCI and at disease onset (r=0.226), RDCI was not correlated to the disease duration (p=0.27). RDCI was not associated with the HAQ (p=0.4). RCDI was not significantly different in terms of sex (female: 1.2 vs male: 1.3, p=0.09). This comorbidity index was associated with the presence of extra articular manifestation (presence: 1 vs absence: 0.8, p=0.004). It was associated with pulmonary involvement (presence: 1.7 vs absence: 0.6, p<0.01). There was an association between the presence of radiographic erosions and RDCI (1.2 vs 1, p<0.001). RDCI was also associated with atlanto-axial dislocation (p=0.009) and with coxitis (p=0.009). Comorbidity index was statistically different between patients on biologic drugs and patients without biologic drugs (1.6 vs 0.9, p<0.01).

Conclusion: More than 40% of women with rheumatoid arthritis have a time-to-conception longer than 1 year: analysis of the prospective GR2 cohort

<table>
<thead>
<tr>
<th>Variable</th>
<th>RA with ILD (n=107)</th>
<th>RA without ILD (n=36)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, range (SD))</td>
<td>56.2 (±13.3)</td>
<td>58.7 (±14.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>Sex</td>
<td>M: 63 (58.6%)</td>
<td>M: 14 (38.9%)</td>
<td>0.22</td>
</tr>
<tr>
<td>Erosions</td>
<td>15 (15.4%)</td>
<td>3 (8.3%)</td>
<td>0.08</td>
</tr>
<tr>
<td>Active rheumatoid factor (mean, range (SD))</td>
<td>56.2 (±13.2)</td>
<td>53.4 (±13.4)</td>
<td>0.13</td>
</tr>
<tr>
<td>Patient emotion (mean, range (SD))</td>
<td>3.1 (0-9)</td>
<td>3.2 (0-9)</td>
<td>0.84</td>
</tr>
<tr>
<td>Activity (mean, range (SD))</td>
<td>4.5 (3-7)</td>
<td>4.4 (3-7)</td>
<td>0.32</td>
</tr>
<tr>
<td>Disease activity scale (mean, range (SD))</td>
<td>4.5 (2-8)</td>
<td>4.4 (2-8)</td>
<td>0.42</td>
</tr>
<tr>
<td>Functional activity (mean, range (SD))</td>
<td>0.5 (0-2)</td>
<td>0.5 (0-2)</td>
<td>0.82</td>
</tr>
<tr>
<td>Comorbidities (mean, range (SD))</td>
<td>0.9 (0-3)</td>
<td>0.9 (0-3)</td>
<td>0.91</td>
</tr>
<tr>
<td>Radiographic erosions (mean, range (SD))</td>
<td>24.3 (0-72)</td>
<td>18.5 (0-72)</td>
<td>0.03</td>
</tr>
<tr>
<td>Erosions + coxitis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
<tr>
<td>Erosions + atlanto-axial arthritis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
<tr>
<td>Erosions + coxitis + atlanto-axial arthritis</td>
<td>0.1 (0-2.3)</td>
<td>0.1 (0-2.3)</td>
<td>0.31</td>
</tr>
</tbody>
</table>

References:
Methods: All RA patients (diagnosis according to the Rheumatologist) included in the national multicenter GR2 cohort from 2015 to June 2021 were included in the analysis. Patients could be included either with a pregnancy wish (i.e., preconceptional period) or because of a clinical pregnancy (<12 weeks of gestation). For this analysis, only patients included preconceptionally were included. The main endpoint was time-to-conception, and the secondary endpoints were the number of subfertile patients (i.e., time-to-conception >12 months or non-achievement of pregnancy), as well as the number exposed to csDMARDs and biologics in the preconception period. We performed survival analyses, using a Cox model including a random effect for the center to account for heterogeneity of practices among participating centers. We used a multiple imputation to address missing data among the explanatory variables. Results are presented as a hazard ratio (HR) with confidence interval (CI) to assess associations between the factors studied and time-to-conception.

Results: Among the 167 patients with RA included in the GR2 cohort, 78 were selected for the main analysis of time-to-conception. Of these, 40 (51.3%) had a clinical pregnancy during follow-up. Subfertility was observed in 33 (42.3%) women and median time to conception was 19.1 months; mean preconception DAS28-CRP score was 2.3 (+/- 1.2). Patients were treated during the preconceptional period with NSAIDs, corticosteroids, csDMARDs and biotherapies in 10 (12.8%), 35 (44.9%), 24 (30.8%), and 32 (41.0%) cases, respectively. The multivariate model adjusted for age, BMI, DAS28-CRP, disease duration, ACPA positivity, and exposure to corticosteroids and biologics in the preconception period found an association between increased preconception delay and age (HR (per year) 1.12 95% CI [1.04-1.16], p < 0.01) as well as disease duration (HR (per year) 1.06 95% CI [1.02-1.15], p = 0.03).

Conclusion: This study provides original results on fertility in women with RA. It found a median time to conception of 19.1 months, with a subfertility rate of 42.3%, which is significantly higher than the general population[2]. In this context, it seems essential to discuss this topic from the beginning of the disease in women of childbearing age.

REFERENCES:

Table 1. Survival analyses (Cox model): factors associated with time-to-conception in women with RA.

<table>
<thead>
<tr>
<th>Univariate analyses</th>
<th>Multivariate analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude HR 95% CI p</td>
</tr>
<tr>
<td>Age</td>
<td>1.11 [1.04-1.18]</td>
</tr>
<tr>
<td>BMI</td>
<td>1.06 [0.99-1.16]</td>
</tr>
<tr>
<td>ACDA positivity</td>
<td>1.7 [0.9-3.39]</td>
</tr>
<tr>
<td>Disease duration</td>
<td>1.03 [0.98-1.08]</td>
</tr>
<tr>
<td>DAS28-CRP score</td>
<td>1.08 [0.81-1.45]</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>0.91 [0.51-1.60]</td>
</tr>
<tr>
<td>Biologics</td>
<td>1.52 [0.82-2.61]</td>
</tr>
</tbody>
</table>

Figure 1. Cumulative incidence curves for pregnancies in women with RA.

Acknowledgements: The GR2 Cohort is supported by the French Society of Rheumatology, the French Internal Medicine Society, and unrestricted grants including EU.

Disclosure of Interests: SABRINA HAMROUN: None declared, Marion Coudenc: None declared, Laure Gossec: None declared, Rene-Marc Filpo: None declared, Hubert MAROTTE. None declared, Christophe Richez Speakers bureau: CR has received consulting/speaker’s fees from Abbvie, Amgen, Astra Zeneca, Biogen, BMS, Celtrion, Eli Lilly, Galapagos, GSK, MSD, Novartis, and Pfizer, all unrelated to this manuscript., Aline Frazier-Mironer: None declared, Jérémie SELLAM: None declared, Elisabeth Gervais: None declared, Valerie Devauchelle-Pensec: None declared, Alban Deroux: None declared, Rakiba Belkhir: None declared, AZEDDINE DELLAL: None declared, Laetitia Dunois: None declared, Emmanuelle Chatelus: None declared, Nathalie Costeodat-Chalameau: None declared, Anna Molto: None declared.

Disclosure of Interests: POS622


POS622

ASSOCIATION OF DIURNAL FLUCTUATION OF THE SOLUBLE TOLL-LIKE RECEPTORS 2 (TLR2) WITH COMORBIDITY AND QUALITY OF LIFE IN WOMEN WITH RHEUMATOID ARTHRITIS

K. Zaichko1, N. Zaichko2. 1Vinnytsya National Pinogriv Medical University, Internal Medicine #2, Vinnytsya, Ukraine; 2Vinnytsya National Pinogriv Medical University, Clinical Biochemistry, Vinnytsya, Ukraine

Background: Disorders of circadian rhythms in the production of inflammatory mediators play an important role in the pathogenesis of rheumatoid arthritis (RA) [1]. Innate immune factors, in particular toll-like receptors 2 (TLR2), are involved in the formation of the inflammatory pattern in RA. Recently was shown that TLR2 play an important role in the development of atherosclerosis and hypertension [2]. Chronobiological aspects of innate immunity, in particular circadian rhythms of the soluble form of TLR2 (sTLR2) in RA and its comorbidity, requires further study.

Objectives: The aim of the study was to assess the daily variability of sTLR2 in RA patients depending on comorbid conditions and quality of life indexes.

Methods: In the study were enrolled 173 females with RA aged 45.9 (8.79) years and disease duration 7.96 (6.38) years. High activity of the RA (DAS28-ESR > 5.1) were registered in 114 (66%) cases, moderate activity (DAS28-3.2-5.1) - in 59 (34%) cases. 144 (83%) patients were seropositive by anticardiolipin antibodies (ACCP). Among enrolled subjects 140 (81%) had l-lil radiographic stage. There were 89 (51%) patients with comorbid pathologies, including arterial hypertension (AH) - 59 (34%). Serum sTLR2 level was determined at 8:00 and 20:00 using Cloud-Clone Corp kits (USA). All stages of the study were carried out in compliance with bioethical standards and provisions of the WHO, Helsinki Declaration of the General Assembly of the World Medical Association (1989), Bioethical protocol No 1, 01 November 2016. *Data are mean (SD) or %.

Results: In patients with RA, daily fluctuations in sTLR2 levels were detected: indexes at 8:00 to 20:00 were lower than at 8:00 (343 (93.7) vs 272 (99.2) ng/L, p<0.001). The mean difference between sTLR2 levels at 8:00 and 20:00 was -21.6 (12.3) %. In RA patients with AH, the average daily level of sTLR2 was higher (in 1.42 times, p <0.01) than in RA patients without AH. Differences between RA with AH and RA without AH groups were more significant in the evening sTLR2 level (320 (112) vs 246 (81.3) ng/L, p<0.01), than in the morning (378 (90.6) vs 321 (89.0) ng/L, p<0.05). In the group RA with AH decrease in sTLR2 in the evening was less than in the group RA without AH (1.36 times, p<0.05). An increase in sTLR2 at 20:00 was associated with a deterioration in mental health according to SF-36 (VT, SF, MH) in 1.2-1.3 times (highest quartile vs lowest quartile, p=0.01). An increase in sTLR2 at 8:00 was associated with a decrease in physical health PF, RP, BP and GH (in 1.3-1.6 times, p<0.01). Patients with high levels of sTLR2 showed more severe pain, impaired function, fatigue and sleep, decreased physical and emotional comfort, and control of symptoms according to RAID (in 1.3-1.4 times, p<0.01).

Conclusion: In RA patients daily fluctuations in sTLR2 levels has been registered with the decrease of this index in the evening. In the case of comorbid AH production of sTLR2 is higher, especially in the evening time. Differences of sTLR2 production are one of the factors that deteriorate the quality of life in patients with RA.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.3955

POS623

SUBCLINICAL ATHEROSCLEROSIS IS NOT RELATED WITH ACID URIC IN RHEUMATOID ARTHRITIS. STUDY OF 1005 PATIENTS OF A SINGLE UNIVERSITY HOSPITAL

F. Benavides-Villanueva1, C. Corrales-Selaya1, F. Ferraz-Amaro2, N. Vegas-Revenga3, V. Portilla, R. Bianco, M. A. González-Gay3, A. Corrales1, Marqués de Valdecilla University Hospital, Rheumatology, Santander, Spain; 1Hospital
Background: Rheumatoid Arthritis (RA) and Gout are associated with an increase of cardiovascular (CV) disease (1,2). Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of CV mortality (3). The association of serum uric acid (SUA) levels as an independent factor of subclinical Atherosclerosis and mortality in RA remains not fully clarified (4,5).

Objectives: In a wide cohort of patients with RA our aims were to assess the relationship of SUA with a) CV risk factors and b) presence of atherosclerosis.

Methods: Cross-sectional study including 1005 patients with RA from a Single University Center. The presence of Atherosclerosis (c-IMT and carotid plaque) was explored by Carotid Ultrasonography. The relationship between SUA and markers of subclinical atherosclerosis was studied through linear regression and logistic multivariate analysis.

Results: We studied 1005 RA patients (741 women, 74%), mean age 61±13. The main general features, CV risks factors, RA activity data and current therapy are summarized in Table 1.

Table 1. Main features of 1005 RA patients

<table>
<thead>
<tr>
<th>GENERAL FEATURES</th>
<th>RESULTS</th>
<th>GENERAL FEATURES</th>
<th>RESULTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean±SD</td>
<td>60±13</td>
<td>RA features</td>
<td></td>
</tr>
<tr>
<td>Female/ Male, n (%)</td>
<td>741 / 264 (28)</td>
<td>RA duration, years; mean±SD</td>
<td>17±12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CRP mg/L; median, [IQR]</td>
<td>3.0 [0.9-7.5]</td>
</tr>
<tr>
<td>CV risk factors</td>
<td></td>
<td>ESR, mm/ 1st hour; median, [IQR]</td>
<td>14 [6-24]</td>
</tr>
<tr>
<td>Past or Current smoker, n (%)</td>
<td>539 (54)</td>
<td>Past or Current smoker, n (%)</td>
<td>17±12</td>
</tr>
<tr>
<td>Obesity/ Dyslipidemia, n (%)</td>
<td>307 (31) / 560 (56)</td>
<td>Obesity/ Dyslipidemia, n (%)</td>
<td>28±(53)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>453 (45)</td>
<td>Hypertension, n (%)</td>
<td>492 (50)</td>
</tr>
<tr>
<td>Diabetes Mellitus, n (%)</td>
<td>127 (13)</td>
<td>Diabetes Mellitus, n (%)</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m2, mean±SD</td>
<td>28±9 / 9±15</td>
<td>BMI, kg/m2, mean±SD</td>
<td>3.3±1.5</td>
</tr>
<tr>
<td>Abdominal circumference cm; mean±SD</td>
<td></td>
<td>Abdominal circumference cm; mean±SD</td>
<td>3.1±1.3</td>
</tr>
<tr>
<td>Previous CV Events, n (%)</td>
<td>12±(12)</td>
<td>Previous CV Events, n (%)</td>
<td>4.8±1.4</td>
</tr>
<tr>
<td>Chronic Kidney Disease, n (%)</td>
<td>56 (6)</td>
<td>Chronic Kidney Disease, n (%)</td>
<td></td>
</tr>
<tr>
<td>Gout / using drugs for hyperuricemia, n (%)</td>
<td>20 (2)</td>
<td>Gout / using drugs for hyperuricemia, n (%)</td>
<td>201±97</td>
</tr>
<tr>
<td>Total cholesterol, mg/dl; mean±SD</td>
<td>201±39</td>
<td>Total cholesterol, mg/dl; mean±SD</td>
<td>708±157</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dl; mean±SD</td>
<td>61±17</td>
<td>LDL cholesterol, mg/dl; mean±SD</td>
<td>617±62</td>
</tr>
<tr>
<td>Uric acid, mg/dl; mean±SD</td>
<td>119±32</td>
<td>Uric acid, mg/dl; mean±SD</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ACPA: Anti–citrullinated protein antibody; BMI: Body mass index; CV: Cardiovascular; cIMT: carotid intima-media thickness; cm: centimeter; CRP: C-Reactive protein; DAS28:ESR or CRP; mean±SD: mean±standard deviation; CRP: C-Reactive protein; DAS28:ESR: Disease Activity Score-28 for Rheumatoid Arthritis with Erythrocyte Sedimentation Rate; DAS28:PCR: Disease Activity Score-28 for Rheumatoid Arthritis with C reactive protein; dt: deciliter; ESR: Erythrocyte Sedimentation Rate; HDL: high-density lipoprotein; IQR: Interquartile range; Kg: kilogram; LDL: Low-density lipoprotein; mg: milligram; m2: square meter; n: number; RA: Rheumatoid Arthritis; SD: Standard Deviation.

SUA as a dependent variable was significantly correlated with age, male gender and most of CV risk factors (body mass index, abdominal circumference and obesity) (single-variable analysis). Similarly, a significant beta coefficient, [95%CI] positive relationship with SUA was observed with hypertension (0.7 [0.5-0.8], p<0.001), diabetes (0.5 [0.2-0.7], p<0.001), dyslipidemia (0.2 [0.04-0.4], p=0.016), renal chronic insufficiency (1.5 [95CI 1.0-1.8], p<0.001) and previous CV events (0.8 [0.4-1.2], p<0.001). Subclinical Atherosclerosis, as dependent variable, was significantly correlated with SUA (single-variable analysis). In addition, SUA showed a positive significant beta coefficient, [95%CI] relationship with cIMT (18 [12-25], p<0.001) and the presence of carotid plaques (1.29 [17-1.42], p<0.001). However, statistical significance was not observed in the multivariable analysis adjusted by Classic CV Risk Factors.

Conclusion: In RA, SUA is related with most of CV risk factors. However, SUA is not associated with Subclinical Atherosclerosis.

REFERENCES:

Disclosure of Interests: None declared

**Table 1. Univariable analysis on baseline clinical characters and progression of subclinical atherosclerosis parameters**

<table>
<thead>
<tr>
<th></th>
<th>AP+</th>
<th>OR</th>
<th>p Value</th>
<th>95% CI</th>
<th>Multivariate model</th>
<th>OR</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptom duration</td>
<td>0.99</td>
<td>0.704</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF positive</td>
<td>0.99</td>
<td>0.692</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline Triglycerides</td>
<td>3.19</td>
<td>0.094</td>
<td></td>
<td>3.48</td>
<td>0.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FRS, 20%</td>
<td>5.97</td>
<td>0.031</td>
<td></td>
<td>5.65</td>
<td>0.500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ca-ESR</td>
<td>1.02</td>
<td>1.006</td>
<td></td>
<td>1.03</td>
<td>0.038</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 1. Group distribution of RA patients according to eGFR, n(%)**

<table>
<thead>
<tr>
<th>Group</th>
<th>eGFR &lt;60 ml/min/1.73 m²</th>
<th>60-89 ml/min/1.73 m²</th>
<th>90-109 ml/min/1.73 m²</th>
<th>≥110 ml/min/1.73 m²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I</td>
<td>16 (17.0)</td>
<td>52 (54.2)</td>
<td>20 (20.8)</td>
<td>8 (8.3)</td>
</tr>
<tr>
<td>Group II</td>
<td>22 (22.9)</td>
<td>39 (40.6)</td>
<td>20 (20.8)</td>
<td>15 (15.6)</td>
</tr>
<tr>
<td>Group III</td>
<td>29 (30.2)</td>
<td>29 (30.2)</td>
<td>22 (22.9)</td>
<td>16 (16.7)</td>
</tr>
</tbody>
</table>

The use of eGFRcyst showed that only 12 of 29 people in the first group had optimal (>90 ml/min/1.73 m²) eGFRcyst (p=0.031), and 17 patients entered the group with slightly decreased (60-89 ml/min/1.73 m²) eGFRcyst. A similar, but less significant situation (12 of 22 people and 10 patients, p=0.02) was also observed with eGFRcyst-cyst. In the second group of RA patients 19 patients corresponded to the chosen criteria in determination of eGFRcyst, and 8 patients entered groups (III and IV) with more severe decrease of renal function (2 patients were included into group I) (p=0.011). Significant differences in this group were also noted when comparing the proportions according to eGFRcyst with eGFRcyst-cyst (p=0.044). A probable decrease in renal filtration function with eGFRcyst (compared with the alternative use of eGFRcyst or eGFRcyst-cyst) can be observed in 11-18% of RA patients in group 1 (high/optimal renal function) and up to 10% of RA patients in group 2 (slight decrease). No significant differences were found using the three estimated CKD-EPI formulas in RA patients with moderate/significant decrease in GFR (p=0.05).

**Conclusion:** Currently, the overall diagnostic performance of the CKD-EPI equation based on creatinine and cystatin C may be the most optimal (in comparison with other calculated CKD-EPI formulas) in patients with RA, and may also be useful for confirming eGFRcyst results >60 ml/min/1.73 m².
Background: Currently, real-world data on rheumatoid arthritis (RA) treatment patterns in France are limited.

Objectives: The aim of this study was to describe, between 2013 and 2017, the sequence of therapies used in the treatment of patients with RA and to characterize RA treatment patterns using real-world data.

Methods: A non-interventional, longitudinal study was conducted using the Echantillon Généraliste des Bénéficiaires (EGB) between 1 January 2013 and 31 December 2017. EGB is a 1/97th representative random sample from the French National Healthcare Database (SDNS) which includes claims data covering 99% of the total French population. Treatment patterns, adherence and persistence of RA treatments were described in a cohort of patients with RA, identified between 2013 and 2017.

Results: Between 2013 and 2017, 2,553 patients with RA were identified, including 2,314 in 2017. Of the 2,314 patients identified in 2017 (mean age 66.2 ± 15.4 years; 73.7% female; mean Charlson comorbidity score 4.2), 1,102 (47.6%) had received no disease-modifying-anti-rheumatic drug (DMARD). Of these, 944 (85.7%) had received at least one symptomatic treatment, including 862 (91.3%) an analgesic, 509 (53.9%) an oral corticosteroid and 384 (40.7%) a non-steroidal anti-inflammatory drug. Of the 2,553 RA patients monitored between 2013 and 2017, 1,512 (59.2%) patients received a DMARD, of which 721 (47.7%) patients received only one treatment sequence, mainly methotrexate (n=529, 35.0%), and did not discontinue or switch treatment. Switching treatment to a targeted DMARD was reported for 42.6% of cases (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713), TNFi for 39.7% (n=100/252) and csDMARD for 42.6% (n=304/713)

Conclusion: Using data obtained from the EGB, this study estimated the number of patients with RA in France to be 307,612 in 2017. Approximately half of the patients identified in the EGB cohort were not treated with a DMARD. For a substantial proportion of patients receiving DMARDs, therapeutic escalation, a switch in treatment, or long-term corticosteroid co-therapy with an average daily dose greater than 5 mg were needed. Furthermore, median persistence for most targeted DMARDs was less than 2 years, and the early discontinuation rates of up to 46.6% suggest poor DMARD tolerance in many patients.

This study highlights that the medical need for RA treatment is not covered by current therapeutic strategies.
prescribed at the onset of the disease were more often TNFα blockers in gr C and rituximab in gr S.

Conclusion: According to our observations, the combination of RA with SJ/S leads to a milder course of the RA. Early diagnosis of SJ/S in RA pts is important for understanding the course of the disease and determining the prognosis.

Disclosure of Interests: None declared


## POS0630

### INCIDENCE AND ASSOCIATED FACTORS OF CANCER IN PATIENTS WITH RHEUMATOID ARTHRITIS


1Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey; 2Izmir Katip Çelebi University, Department of Public Health, Izmir, Turkey; 3Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology; Ankara, Turkey

Background: Rheumatoid arthritis (RA) is an autoimmune disease primarily characterized by joint inflammation along with systemic manifestations and increased risk of cardiovascular disease. Furthermore, it has been suggested that RA itself and medications administered might increase the risk of cancer.

Objectives: To assess cancer incidence in RA patients and factors associated with cancer development in RA patients.

Methods: In this single centre retrospective cohort study, the data of 2000 patients (76.3% female, mean age at the last follow-up: 59.5 ± 13.4 years) who were followed up between 2005 and 2020 and fulfilled 2010 ACR/EULAR classification criteria were scrutinised. Patients’ demographic, clinical and serological characteristics, and smoking history were recorded. Multivariable logistic regression analysis was performed to determine the associated factors with cancer development. The standardized incidence rate (SIR) was calculated by dividing the number of cancer cases observed in a given age and gender group by the expected number.

Results: After a median follow-up of 9 years, 71 (3.6%) patients were diagnosed with cancer and the number of patients with more than one malignancy was 5 (0.5%). Cancer types in each sex were demonstrated in Table 1. Seropositivity rate of the cohort was 86.0% and 376 out of 1102 (34.1%) patients were smokers. Glucocorticoids were the most common used agent in the treatment of RA (75.2%), followed by methotrexate (68%), hydroxychloroquine (65.1%), sulfasalazine (37.7%), lefunomide (35.5%), biological disease-modifying anti-rheumatic drugs (11.4%) and tofacitinib 4%. In multivariable logistic regression analysis performed of 1102 patients without missing data of smoking history, only smoking and age were independently associated with malignancy (Odds Ratios were 2.11 (95% Confidence Interval (CI) 1.07-4.14 and 1.04 (95% CI 1.02-1.07), respectively). Treatment modalities and RA-related clinical factors were not related to cancer development (data not shown). When compared with the 2017 Cancer Statistics of Turkey, the incidence of malignancy in our RA cohort was similar to the corresponding age and gender groups. The SIRs in male and female patients were calculated as 0.93 (95% CI: 0.82-1.05 p= 0.25) and 0.92 (95% CI: 0.77-1.09 p= 0.34), respectively.

<table>
<thead>
<tr>
<th>Table 1. Number of malignancy distribution by gender of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>------------------</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Breast, n (%)</td>
</tr>
<tr>
<td>Urogenital system, n (%)</td>
</tr>
<tr>
<td>Prostate, n (%)</td>
</tr>
<tr>
<td>Lung, n (%)</td>
</tr>
<tr>
<td>Lymphoma, n (%)</td>
</tr>
<tr>
<td>Thyroid, n (%)</td>
</tr>
<tr>
<td>Skin, n (%)</td>
</tr>
<tr>
<td>Colorectal, n (%)</td>
</tr>
<tr>
<td>Head and Neck, n (%)</td>
</tr>
<tr>
<td>Multipl Myeloma, n (%)</td>
</tr>
<tr>
<td>Others, n (%)</td>
</tr>
</tbody>
</table>

*Row Percent

Conclusion: Our results show that patients with RA do not require additional screening beyond the nationally recommended guidelines. Medications used, including tumor necrosis factor inhibitors, did not increase the risk of cancer. In conclusion, all patients with RA should receive standard age- and sex-appropriate cancer screening.

REFERENCES:

BACKGROUND: Patients with rheumatoid arthritis (RA) who have sarcopenia and stiff or painful joints might be at increased risk of falls and fractures.

OBJECTIVES: The present study aimed to prospectively identify the incidence of clinical fractures and associated risk factors in patients with RA in a cohort study named the TOMORROW (UMIN000003876) that started in 2010.

METHODS: We evaluated anthropometric parameters, bone mineral density (BMD), disease activity, RA medication at entry and observed the incidence of clinical fractures between patients with RA and Vo for ten years in 202 patients with RA (mean age, 58.6 ± 5.94) and 202 age- and sex-matched non-RA volunteers (Vo) (mean age, 57.4 ± 6.2). We compared the incidence of clinical fractures between patients with RA and Vo for ten years, and analyzed the risk factors for clinical fractures using Cox proportional hazard model.

RESULTS: The incidences of clinical fractures were 0.036 and 0.024/person-year in patients with RA and Vo, respectively. Cox proportional hazard model revealed that low BMD at the thoracic vertebrae (< 0.7 g/cm2) and history of fractures at any site were significant risk factors (HR 2.189, p=0.004, 1.866, p=0.022, respectively). Additionally, a mean GC dose (≥ 2 mg/day) at entry and during the ten-year period increased risk for fractures (HR 2.189, p=0.004, 1.866, p=0.022, respectively).

Conclusion: RA per se was not a risk factor for clinical fractures in this cohort. Low BMD at the thoracic vertebrae at entry and the use of GC with even low dose at entry and during ten years were significantly associated with an increased frequency of clinical fractures among patients with RA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4573

Table 1. Clinical and lymphoma related parameters and their distribution in the RA-DLBCL patients according to high and low expression of PD-L1 in tumour cells

<table>
<thead>
<tr>
<th></th>
<th>Entire cohort</th>
<th>High PD-L1 in tumour cells</th>
<th>Low PD-L1 in tumour cells</th>
<th>Pa-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥60, n (%)</td>
<td>85 (83)</td>
<td>4 (4)</td>
<td>81 (87)</td>
<td>0.35</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>61 (59)</td>
<td>6 (6)</td>
<td>55 (60)</td>
<td>0.70</td>
</tr>
<tr>
<td>EBV status, n (%)</td>
<td>4 (4)</td>
<td>0 (0)</td>
<td>4 (4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GCB, n (%)</td>
<td>30 (29)</td>
<td>2 (2)</td>
<td>28 (29)</td>
<td>0.04</td>
</tr>
<tr>
<td>Missing, n (%)</td>
<td>65 (63)</td>
<td>5 (5)</td>
<td>60 (61)</td>
<td>0.57</td>
</tr>
<tr>
<td>Ann Arbor stage III-V, n (%)</td>
<td>82 (79)</td>
<td>6 (6)</td>
<td>76 (79)</td>
<td>0.31</td>
</tr>
<tr>
<td>Missing, n (%)</td>
<td>4 (4)</td>
<td>1 (1)</td>
<td>3 (3)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RA highest disease severity group, n (%) | Yes | 25 (25) | 5 (5) | 20 (20) | 0.96     |

Active RA treatment, n (%) | Yes | 39 (38) | 4 (4) | 35 (37) | 0.22     |
| Missing, n (%) | 3 (3) | 1 (1) | 2 (2) | 0.96     |

Disclosure of Interests: None declared

myocardial abnormalities on cardiac magnetic resonance imaging (CMR) in an early RA cohort compared with control subjects, and improvement with DMARD treatment. Non-invasive assays for high-sensitivity troponin and NT-pro-BNP have been evaluated in RA cohorts. No study has investigated these in early, treatment-naive RA and in association with subclinical CMR findings.

Objectives: In a treatment-naive, early RA trial cohort, we examined serum cardiac markers of ventricular stretch (NT-pro-BNP) and myocardial injury (high-sensitivity troponin-I (hs-Tn-I)) and change with treatment, and whether these associated with cardiac MRI abnormalities.

Methods: In CADERA (a unique early RA RCT derived study), out of a total of 120 patients randomised to either first-line TNFi+MTX (n=60) or MTX and conventional synthetic DMARDs (n=60), 81 subjects with no previous history of CVD or diabetes and with only a maximum of 1 other traditional risk factor, underwent baseline and year 1 CMR. Corresponding levels of NT-pro-BNP (pg/ml) and hs-Tn-I (ng/L) were measured at baseline and year 1. CADERA reported CMR measures of vascular stiffness [aortic stiffness index (AoSI), and aortic distensibility (AD)]; tissue oedema/fibrosis [native T1 values (T1), myocardial extracellular volume (ECV), and late gadolinium enhancement (LGE)] and ventricular function [2]. Bayesian linear and logistic regression models with mixed effects for overall data were used to test association between serum cardiac markers and CMR parameters.

Results: CADERA trial already reported baseline demographics and comorbidity data of patients. The most common risk factor was smoking history (55%) followed by hypertension (7%) and family history of ischaemic comorbidity data of patients. The most common risk factor was smoking

<table>
<thead>
<tr>
<th>Measures of myocardial tissue oedema/fibrosis</th>
<th>Overall</th>
<th>Baseline</th>
<th>Year 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>LGE</td>
<td>0.56(0.1 to 1.11)</td>
<td>0.60(0.04 to 1.27)</td>
<td>0.54(0.13 to 1.17)</td>
</tr>
<tr>
<td>T1</td>
<td>-4.42(-10.5 to 1.5)</td>
<td>-3.8(-6.7 to 6.2)</td>
<td>-6.02(-14.9 to 3.15)</td>
</tr>
<tr>
<td>ECV</td>
<td>0.002(0.04 to 0.08)</td>
<td>0.001(0.05 to 0.07)</td>
<td>0.001(0.04 to 0.04)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Measures of vascular stiffness</th>
<th>Overall</th>
<th>Baseline</th>
<th>Year 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>AoSI</td>
<td>0.01(-0.23 to 0.25)</td>
<td>0.05(-0.22 to 0.33)</td>
<td>0.05(-0.33 to 0.42)</td>
</tr>
<tr>
<td>AD</td>
<td>-0.05(-0.23 to 0.13)</td>
<td>-0.02(-0.18 to 0.14)</td>
<td>-0.06(-0.37 to 0.25)</td>
</tr>
</tbody>
</table>

Conclusion: Our data suggest hs-Tn-I is within normal limits in a treatment-naive, RA cohort but with numerical differences that associated with presence of focal fibrosis on CMR. Modest numbers of those with focal fibrosis may account for normal range values for hs-Tn-I.

REFERENCES:

Disclosure of Interests: None declared

POS0634 SAFETY PROFILE OF BT/SDMARD IN RHEUMATOID ARTHRITIS PATIENTS WITH IMPAIRED GLOMERULAR FILTRATION RATE: AN ANALYSIS FROM THE GISEA REGISTRY.

M. Fornara1, F. Franceschini2, E. Greisme3, A. Caui4, M. Sebastiani5, C. Montecucco6, F. Conti7, M. Rossini8, R. Foti8, F. P. Cantatore9, E. Fusaro10, C. Lomater11, B. Frediani12, M. Govoni14, F. Atzeni15, R. Madonna16, S. D’angelo17, G. Ferraccioli18, G. Lapadula19, R. Caporali20, F. Iannone on behalf of the Gruppo Italiano di Studio sulla Early Arthritis-GISEA. 1Department of Emergency and Organ Transplantations, University of Bari “Aldo Moro”; Rheumatology Unit, Bari, Italy; 2ASST Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 3Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rheumatology, Roma, Italy; 4AOU and University of Cagliari, Rheumatology, Cagliari, Italy; 5University of Modena and Reggio Emilia, Rheumatology, Modena, Italy; 6IRCCS Policlinico S. Matteo Foundation, Rheumatology Unit, Pavia, Italy; 7Sapienza Università di Roma, Dpt. Scienze Cliniche, Internistiche, Anestesiologiche e Cardiovascolari, Roma, Italy; 8University of Verona, Policlinico Borgo Roma, Rheumatology, Verona, Italy; 9U.O. Reumatologia A.O.U. Policlinico V.E.

Table 1. Disease characteristics at b/t/SDMARD prescription of RA patients with impaired glomerular filtration rate (eGFR <60) and normal (eGFR>60) glomerular filtration rate

<table>
<thead>
<tr>
<th>Treatment</th>
<th>eGFR &lt;60</th>
<th>eGFR&gt;60</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-line b/t/SDMARD treatment</td>
<td>90 (31.3)</td>
<td>753 (34.5)</td>
</tr>
<tr>
<td>Second-line b/t/SDMARD treatment</td>
<td>72 (25)</td>
<td>487 (22.6)</td>
</tr>
<tr>
<td>Other-line b/t/SDMARD treatment</td>
<td>126 (43.8)</td>
<td>915 (42.5)</td>
</tr>
</tbody>
</table>

*p<0.05, p<0.01, p<0.001
Background: In real-life setting, a greater number of elderly rheumatoid arthritis (RA) patients with impaired glomerular filtration rate (GFR) needs treatment with biologic or target synthetic disease-modifying anti-rheumatic drugs (b/tsDMARD) to achieve disease control and reduce NSAIDs intake. Long-term observational data from the real-life on the use of b/tsDMARD in these patients are scarce.

Objectives: The aim of this study was to evaluate the retention rate of b/tsDMARD in RA patients with impaired GFR in real-life setting.

Methods: Data of RA patients treated with at least one b/tsDMARD were retrospectively analyzed form the national Italian GISEA registry from January 2016 to December 2021. Estimated-GFR (eGFR) was calculated with the Cockcroft-Gault equation at the time of any b/tsDMARD prescription. For the purpose of this study, patients were divided in two groups, patients with impaired GFR (eGFR ≤60) and patients with normal GFR (eGFR >60). The retention rate was calculated by the Kaplan-Meier method and compared between these two groups by a log-rank test.

Results: The study population included 2443 treatment-line with b/tsDMARD from 1888 patients (female 80.4%, age 57±12 years, mean baseline CDAl 17±12, FR/ACPA+ 69.5%) who started a new b/tsDMARD. Disease characteristics are shown in Table 1. 288 treatments with b/tsDMARD were started in patients with impaired eGFR and 2155 in patients with normal eGFR. Compared to patients with eGFR >60, patients with eGFR ≤60 showed higher HAQ-DI (1.3±0.8 vs 1±0.8, p<0.001) at the start of b/tsDMARD treatment. Glucocorticoids were more prescribed in patients with impaired eGFR (80.2% vs 72.8%, p<0.01), while csDMARDs were more prescribed in association with b/tsDMARD in patients with normal eGFR (83.1% vs 76.4%, p<0.01). Of note, CTLA4-Ig treatment was more prescribed in patients with impaired eGFR (26% vs 17.1%, p<0.05), while no difference in b/tsDMARD prescription was observed for other mechanism of actions. Drug survival was similar between RA patients with impaired eGFR [58.2%, mean survival time 35 months (C195% 31-39)] and RA patients with normal eGFR [55%, mean survival time 34.4 months (C195% 33-36), log rank: 0.88] (Figure 1). Cox regression model adjusted for age, sex and b/tsDMARD showed no impact of eGFR on drug survival (HR: 0.9 (C195%: 0.7-1.2).

Conclusion: Our data show that impaired eGFR seems to not influence the persistence of b/tsDMARD treatment in RA patients.

Disclosure of Interests: None declared


**Table 1.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>D2T RA (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>54.4</td>
</tr>
<tr>
<td>Female, %</td>
<td>91.1</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>31.6</td>
</tr>
<tr>
<td>Smoking</td>
<td>37.9</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td></td>
</tr>
<tr>
<td>Disease duration, months</td>
<td>13.9</td>
</tr>
<tr>
<td>RF positivity, %</td>
<td>92.4</td>
</tr>
<tr>
<td>ACPA positivity, %</td>
<td>59.5</td>
</tr>
<tr>
<td>PAI</td>
<td>10.1</td>
</tr>
<tr>
<td>EAM</td>
<td>32.9</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td>Number of previous bDMARDs, mean</td>
<td>2.89</td>
</tr>
<tr>
<td>Glucocorticoid therapy, mean dose per day (mg)</td>
<td>18.4</td>
</tr>
</tbody>
</table>

**REFERENCES:**


Disclosure of Interests: None declared


**Table 1.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>D2T RA (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>54.4</td>
</tr>
<tr>
<td>Female, %</td>
<td>91.1</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>31.6</td>
</tr>
<tr>
<td>Smoking</td>
<td>37.9</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td></td>
</tr>
<tr>
<td>Disease duration, months</td>
<td>13.9</td>
</tr>
<tr>
<td>RF positivity, %</td>
<td>92.4</td>
</tr>
<tr>
<td>ACPA positivity, %</td>
<td>59.5</td>
</tr>
<tr>
<td>PAI</td>
<td>10.1</td>
</tr>
<tr>
<td>EAM</td>
<td>32.9</td>
</tr>
<tr>
<td>Drugs</td>
<td></td>
</tr>
<tr>
<td>Number of previous bDMARDs, mean</td>
<td>2.89</td>
</tr>
<tr>
<td>Glucocorticoid therapy, mean dose per day (mg)</td>
<td>18.4</td>
</tr>
</tbody>
</table>

**REFERENCES:**


Disclosure of Interests: None declared

Rheumatoid arthritis - biological DMARDs.

**POS0638**

**PATIENT GROUPS IN RHEUMATOID ARTHRITIS IDENTIFIED BY DEEP LEARNING RESPOND DIFFERENTLY TO BIOLOGIC OR TARGETED SYNTHETIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS**

M. Kalwein, A. M. Burden, T. Hägg, T. Burkard. University of Freiburg, Department of Computer Science, Freiburg im Breisgau, Germany; ETH Zürich, Department of Chemistry and Applied Biosciences, Zürich, Switzerland; Lausanne University Hospital, Department of Rheumatology, Lausanne, Switzerland

**Background:** Cycling of biologic or targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) patients due to non-response is a problem preventing and delaying disease control.

**Objectives:** To assess and validate treatment response of b/tsDMARDs among RA patient groups identified by deep learning.

**Methods:** In the Swiss Clinical Quality Management of Rheumatic Diseases registry (SCQM), between 1998 and 2018, we identified all RA patients with a DAS28-erythrocyte sedimentation rate (esr) record within 6 months before the start of the first b/tsDMARD. This first-time b/tsDMARD was the cohort entry at which patients were clustered through several runs of deep embedded clustering. Features, measured at cohort entry, included demographics, RA disease burden/duration, life-style factors, and other RA medication. To increase robustness of the obtained clusters, we grouped similar patient clusters together (further referred to as groups). Our outcomes were b/tsDMARD stop due to non-response, and separately a ≥20% reduction in DAS28-esr (RA disease activity in 28 joints using esr measures) as a proxy for treatment response. We followed all patients from cohort entry until b/tsDMARD stop or a maximum of 15 months follow-up. We assessed comparative effectiveness of b/tsDMARDs (ref. adalimumab) using Cox proportional-hazard regression in each patient group by estimating hazard ratios (HR) with 95% confidence intervals (CI). We validated results obtained per patient group through stratified analyses according to most distinctive patient characteristics of the respective group, i.e. the characteristics that led to the respective grouping were also used to stratify the overall population by in this validation analysis.

**Results:** We obtained 24 clusters which comprised between 362 and 1481 patients (among 3516 unique patients). These clusters were grouped into 5 groups according to most distinct characteristics at b/tsDMARD initiation: 1) ≥2 csDMARDs and prednisone use, 2) male sex, 3) seronegativity, female sex, and no prednisone use, 4) rather low disease burden, 5) seropositivity, female sex, and a rather high disease burden/duration.

Comparative effectiveness results among validation strata confirmed comparative effectiveness results observed among the 5 groups: Patients with ≥2 csDMARDs and prednisone at b/tsDMARD initiation, men, as well as patients with a lower disease burden responded better to tocilizumab than to adalimumab (HRs of reaching ≥20% reduction in DAS28-esr: 5.46, 95% CI [1.76-16.94], HR 8.44 [3.43-20.74], and HR 3.64 [2.04-6.49], respectively). Furthermore, seronegative women without use of prednisone at b/tsDMARD initiation as well as seropositive women with a higher disease burden and longer disease duration had a higher risk of non-response with golimumab (HRs of b/tsDMARD discontinuation: 2.36 [10.03-5.40] and HR 5.27 [2.10-13.21], respectively) than with adalimumab.

**Conclusion:** Our results suggest that RA patient groups identified by deep learning may respond differently to individual first-line b/tsDMARDs. Thus, our results can possibly support the decision on the best choice of first-time b/tsDMARD for certain RA patients, which is a step forward towards personalizing treatment.

However, further research in other cohorts is needed to verify our results.

**Acknowledgements:** We thank all patients and rheumatologists contributing to the SCQM registry, as well as the entire SCQM staff. A list of rheumatologists working in hospitals which contribute to the SCQM registry can be found at http://www.scqm.ch/sponsors. A list of financial supporters of SCQM can be found at http://www.scqm.ch/sponsors. The professorship of Andrea M Burden is supported by PharmaSuisse and the ETH Foundation.

**Disclosure of Interests:** Maria Kalwein: None declared, Andrea Michelle Burden: None declared, Thomas Hägg: None declared, Novartis, Janssen, Eli Lilly, T. Hägg, E. Baecklund: None declared, T. Burkard: None declared, Pfizer, A. M. Burden: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.223

---

**POS0637**

**SAFETY OF B/TSDMARDS FOR RA AS USED IN CLINICAL PRACTICE - RESULTS FROM THE LAST DECADE OF THE ARTIS PROGRAM**

T. Frisell, H. Bower, E. Baecklund, D. Di Giuseppe, B. Delcoigne, N. Felletius, H. Forbisdal-D’ella, E. Lindqvist, U. Lindström, J. Askling. On behalf of the ARTIS Study Group. Karolinska Institutet, Medicin Solna, Clinical Epidemiology Division, Stockholm, Sweden; Uppsala University, Medical Sciences, Uppsala, Sweden; Swedish Medical Products Agency, - Uppsala, Sweden; Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Lund University, Section of Rheumatology, Department of Clinical Sciences Lund, Lund, Sweden; Skåne University Hospital, Department of Rheumatology, Lund, Sweden; Karolinska University Hospital, Rheumatology, Stockholm, Sweden

**Background:** While the relative efficacy of treatments can be demonstrated in relatively small studies with limited follow-up, most safety concerns are infrequent, requiring longer follow-up and larger populations. This is recognized by the regulatory framework, where data from pivotal randomized controlled trials are usually considered sufficient for demonstrating efficacy and non-toxicity, but post-approval safety studies are required for many years to fully evaluate drug-associated risks. Though such regulatory safety-studies often focus on one drug (vs. all others), clinical decision-making requires data across all available treatment options. Long-standing longitudinal clinical registries, like the Anti-Rheumatic Therapies in Sweden (ARTIS) database, thus have a key role in assessing the relative safety of b/tsDMARDs, allowing simultaneous comparison of all drugs used in clinical practice, with consistent definitions of treatment cohorts, follow-up, and outcomes.

**Objectives:** To assess incidence rates of critical safety endpoints for individual b/tsDMARDs used to treat RA, updating previously published reports and including more recently introduced treatments.

**Methods:** Nationwide cohort-based cohort study including all RA patients in Sweden registered as starting any b/tsDMARD between Jan 1st 2010 and Dec 31st 2019, and followed until Dec 31st 2020. The incidence rates of selected outcomes, identified through national healthcare registers, were compared between individual b/tsDMARDs while adjusting for a range of potential confounders (covering demographics, RA-related characteristics and disease activity, and comorbidity) using Inverse Probability of Treatment Weighting. Probabilities were predicted by multinomial logistic regression, regressing all covariates on treatment status. Exposure time was counted from treatment start until stop (> 90 days’ lag time), censored at emigration and death.

**Results:** There were clear differences between patients starting individual b/tsDMARDs, in particular with TNF inhibitors more often used as a first line b/tsDMARD; sarilumab, baricitinib, and tofacitinib predominantly used later in the treatment course; rituximab used more often for older patients, and non-TNF generally used more frequently for patients with higher disease activity or comorbidity. Expectedly, these differences translated into differences in the crude rate of safety endpoints. Several differences remained after confounder-adjustment (Table 1), including a higher rate of treatment discontinuation due to adverse events on baricitinib, tofacitinib, and sarilumab. Rituximab was associated with higher rates of several outcomes, but the confounder-adjustment markedly reduced risks and residual confounding likely explain most of the remaining increase. Baricitinib and tofacitinib were associated with higher rates of hospitalised herpes zoster, but not with similarly elevated rates of other serious infections. There were no clear differences in the rate of cardiovascular events or severe depression. Low number of events limit the comparison, in particular for sarilumab and tofacitinib.

**Table 1. Weighted incidence rate per 1,000 person-years of selected safety outcomes.**

<table>
<thead>
<tr>
<th>DMARD</th>
<th>N</th>
<th>Discont. due to adverse event</th>
<th>ACS Stroke</th>
<th>Liver disease infection</th>
<th>Hosp. Herpes zoster</th>
<th>Hosp. Depression</th>
<th>Any cause mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETA</td>
<td>8244</td>
<td>46</td>
<td>6.2</td>
<td>4.5</td>
<td>1.4</td>
<td>32</td>
<td>2.9</td>
</tr>
<tr>
<td>ADA</td>
<td>5069</td>
<td>46</td>
<td>5.9</td>
<td>5.6</td>
<td>1.1</td>
<td>36</td>
<td>3.5</td>
</tr>
<tr>
<td>INF</td>
<td>2832</td>
<td>50</td>
<td>8.2</td>
<td>5.8</td>
<td>3.1</td>
<td>43</td>
<td>3.2</td>
</tr>
<tr>
<td>GER</td>
<td>2072</td>
<td>54</td>
<td>6.6</td>
<td>4.7</td>
<td>2.5</td>
<td>34</td>
<td>3.6</td>
</tr>
<tr>
<td>GOL</td>
<td>1796</td>
<td>51</td>
<td>5.9</td>
<td>6.8</td>
<td>3.2</td>
<td>34</td>
<td>2.8</td>
</tr>
<tr>
<td>ABA</td>
<td>3254</td>
<td>56</td>
<td>7.3</td>
<td>4.7</td>
<td>1.9</td>
<td>36</td>
<td>2.3</td>
</tr>
<tr>
<td>RTX</td>
<td>3960</td>
<td>31</td>
<td>8.4</td>
<td>6.2</td>
<td>2.3</td>
<td>41</td>
<td>3.3</td>
</tr>
<tr>
<td>TCZ</td>
<td>2619</td>
<td>50</td>
<td>5.7</td>
<td>5.0</td>
<td>2.1</td>
<td>31</td>
<td>2.9</td>
</tr>
<tr>
<td>SAR</td>
<td>271</td>
<td>100</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>SYN</td>
<td>1265</td>
<td>69</td>
<td>3.0</td>
<td>4.2</td>
<td>1.4</td>
<td>37</td>
<td>8.8</td>
</tr>
<tr>
<td>TOPA</td>
<td>392</td>
<td>82</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>32</td>
<td>12.9</td>
</tr>
</tbody>
</table>

Note: Rates based on < 5 events set to 0.1.

**Conclusion:** We found large differences in the rate of treatment discontinuations due to adverse events across b/tsDMARDs, which were not generally mirrored by corresponding differences in the rates for specific serious adverse events.

**REFERENCES**

**Acknowledgements:** ARTIS has been or is currently supported by agreements with Abbvie, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, and Sanofi.

**Disclosure of Interests:** Thomas Frisell: None declared, Hannah Bower: None declared, Eva Baecklund: None declared, Daniela Di Giuseppe: None declared.
Bénédicte Delcoigne: None declared, Nils Feltelius: None declared, Elisabet Lindqvist: None declared, Ulf Lindström: None declared, Helena Forsblad-d’Elia: None declared, Bénédicte Delcoigne: None declared, Nils Feltelius Employee of: NF is employed by Gilead Sciences as a consultant. The views in this abstract may not represent the views of the MPA, Helena Forsblad-d’Elia: None declared, Elisabet Lindqvist: None declared, Ulf Lindström: None declared, Johan Askling Grant/research support from: Karolinska Institutet has entered into agreements with the following companies, as per Act IV: Abbvie, CMS, Eli Lilly, Galapagos, Janssen, Pfizer, Roche, Samsung Bioepis and Sanofi.


**POS0638**

**RECOMMENDATIONS FOR COST-EFFECTIVE USE OF BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN INFLAMMATORY ARTHRITIS: PRACTICAL RESULTS FROM AN INTERNATIONAL DELPHI STUDY**

C. Van der Tocht, B. Van den Bemt1,2, A. D'Aletaha, R. Alten, K. Chatzidiyouvi, J. Galloway, J. Isaac, D. Mullemam, P. Verschueren, A. Vutlo, P. Welsing, L. M. Verhoef, A. Den Broeder1,1,3, 3Saartenskliniek, Rheumatologie, Uibergen, Nederland; 3Saartenskliniek, Pharmacie, Uibergen, Nederland; 2Radboud University Medical Center, Clinical Pharmacy, Nijmegen, Nederland; 2Medical University of Vienna, Rheumatology, Vienna, Austria; 3Schlosspark-Klinik Charlottenburg, Rheumatologie, Berlin, Germany; 4Nya Karolinska, Rheumatology, Solna, Sweden; 5King’s College London, Rheumatology, London, United Kingdom; 6Newcastle University, Rheumatology, Newcastle, United Kingdom; 7Université de Tours - Faculté de droit, économie et sciences sociales, Rheumatology, Tours, France; 8UZ Gasthuisberg Campus, Rheumatology, Leuven, Belgium; 9Erasmus University Rotterdam, Pharmacy, Rotterdam, Nederland; 10UMC Utrecht, Rheumatology, Utrecht, Nederland; 11Erasmus University Rotterdam, Medical Center, Rotterdam, Nederland; 12Radboud University Medical Center, Rheumatologie, Nijmegen, Netherlands

**Background:** Biological and targeted synthetic disease modifying antirheumatic drugs (b/ts-DMARDs) are effective treatments for rheumatoid arthritis (RA), psoriatic arthritis (PsA) and spondyloarthritis (SpA), but associated with high costs. Therefore, various strategies for safe and cost-effective use of these drugs have been developed, such as tapering and biosimilar use. However, overruling recommendations on how clinicians or hospitals can use these strategies in clinical practice are absent.

**Objectives:** To develop evidence-based multidisciplinary recommendations on strategies for cost-effective use of b/tsDMARDs in the treatment of RA, PsA and SpA.

**Methods:** A task force was formed consisting of 13 experts in rheumatology, epidemiology and/or pharmacology from seven European countries. Relevant strategies for cost-effective use were collected and defined using one-to-one interviews with each task force member separately using an online form. Level of agreement varied from 0 (completely disagree) to 10 (completely agree).

**Results:** Twelve strategies for cost-effective b/tsDMARDs were identified and four overarching principles were formulated (Table 1). For 10 strategies, there was enough evidence available to form one or multiple recommendation(s). In total, 20 recommendations were formulated, focussing on: the use of loading doses (2); the use of biosimilars where available (2); combining a csDMARD with a b/tsDMARD to maximise efficacy (3); the use of disease activity guided dose-doses (2); the use of biosimilars where available (2); combining a csDMARD with a b/tsDMARD to maximise efficacy (3); the use of disease activity guided doses (2). In total, 20 recommendations were formulated, focussing on: the use of loading doses (2); the use of biosimilars where available (2); combining a csDMARD with a b/tsDMARD to maximise efficacy (3); the use of disease activity guided dose-doses (2); the use of biosimilars where available (2); combining a csDMARD with a b/tsDMARD to maximise efficacy (3); the use of disease activity guided doses (2).

**Conclusion:** These evidence-based recommendations provide caregivers in rheumatology with a consensus on strategies for cost-effective use of b/tsDMARDs in RA, PsA and SpA. Because high-quality evidence was limited, we were not able to formulate recommendations on all strategies.

**REFERENCES:**


**Disclosure of Interests:** Celeste van der Tocht: None declared, Bart van den Bemt Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz; Consultant of: Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz; Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sandoz; Rieke Alten Speakers bureau: Abbvie, CMS, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Paid instructor for: Abbvie, BMS, Celltrion, Galapagos, Janssen, Lilly, Novartis, Pfizer, Roche, Consultant of: Abbvie, BMS, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Orange, Grant/research support from: Abbvie, BMS, Celltrion, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche.


**POS0639**

**PHARMACOKINETIC BOOSTING TO ENABLE A ONCE-DAILY REDUCED DOSE OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS**

C. Van der Tocht, L. M. Verhoef1, B. Van den Bemt1,2, N. Den Broeder1,3, R. Ter Heine3, A. Den Broder1,3, 3Saartenskliniek, Rheumatologie, Uibergen, Nederland; 2Sint Maartenskliniek, Pharmacy, Ubbergen, Nederland; 4Sint Maartenskliniek, Pharmacy, Ubbergen, Nederland; 3Radboud University Medical Center, Clinical Pharmacy, Nijmegen, Netherlands; 4Radboud University Medical Center, Rheumatic Diseases, Nijmegen, Netherlands

**Background:** Tofacitinib is an effective drug for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). As tofacitinib is metabolized by the CYP3A4-enzyme, the manufacturer recommends to reduce the dose with 50% when combined with CYP3A4-inhibitors. This creates an opportunity to improve cost-effectiveness and patient experience by deliberately combining tofacitinib 5mg once daily with a registered CYP3A4-inhibitor, cocistatin.

**Objectives:** Primary: pharmacokinetic (PK) bioequivalence of tofacitinib 5mg and cocistatin 150mg once daily (intervention) to tofacitinib 5mg twice daily (control). Secondary: clinical efficacy (DAS28-CRP), safety, patient preference, and predictive modelling of long-term DAS28 and ACR20 response.

**Methods:** This open-label, cross-over, monocentre study (Sint Maartenskliniek, The Netherlands) included patients with RA or PsA, using tofacitinib 5mg twice daily for ≥ 14 days without co-medication affected by CYP3A4-inhibition. At the first sampling day, plasma samples of tofacitinib were collected pre-dose and 0.5, 1, 2, 3, 4, 6, 9 and 12 hours post-dose. Subsequently, patients switched treatment to tofacitinib 5mg and cocistatin 150mg once daily, and 2-6 weeks thereafter, another PK sampling was performed at the same timepoints and additionally at 24 hours post-dose. PK bioequivalence was defined as the 90% confidence interval of the average ratio of the individual mean ratio (GMR) falling between 0.80-1.25. Secondary endpoints included efficacy (change in mean DAS28-CRP between sampling days), safety, and patient preference (7-point Likert scale at study end). Additionally, differences between both regimens in DAS28 and probability of ACR20 response were predicted using a validated PK/PD model.

**Results:** Between September 2019 and March 2021, 27 participants were included. Twenty-five participants completed both PK measurements and were included in the primary analysis. The C1 GMR was 84.8%, 90% CI 75.1% to 95.6%. The difference in absolute DAS28-CRP was 0.05 (95% CI -0.50 to 0.59, intervention to control). There were no significant or relevant
differences in adverse events between both regimens. Patient preference was 56% for intervention (Likert 5-7), versus 18% for control (score 1-3). Median differences in predicted DAS28 and probability of ACR20 response were 0.03 (95% CI -0.16 to 0.22; intervention-control) and -0.01 (-0.07 to 0.05), respectively.

**Conclusion:** Due to slightly lower tofacitinib concentrations during combination therapy, pharmacokinetic bioequivalence could not formally be established. However, because of comparable short-term clinical efficacy and safety, a clear patient preference and no relevant differences in predicted DAS28 and ACR20-response at maximum efficacy, pharmacokinetic boosting seems an attractive strategy to improve cost-effectiveness of tofacitinib treatment.

**REFERENCES:**

### Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Participants (n=27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Female gender</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>GFR calculated by CKD-epi (ml/min/1.73m²)</td>
</tr>
<tr>
<td>Disease</td>
</tr>
<tr>
<td>• RA</td>
</tr>
<tr>
<td>• RF and/or ACPA positive (RA only)</td>
</tr>
<tr>
<td>• PsA</td>
</tr>
<tr>
<td>Disease duration (years)</td>
</tr>
<tr>
<td>Tofacitinib use ≤ 3 months</td>
</tr>
<tr>
<td>Concomitant csDMARD use</td>
</tr>
<tr>
<td>• methotrexate</td>
</tr>
<tr>
<td>• leflunomide</td>
</tr>
<tr>
<td>• infliximab</td>
</tr>
<tr>
<td>Previous bi/csDMARDs (n)</td>
</tr>
</tbody>
</table>

Either displayed as number (%), mean ± standard deviation or median (interquartile range). Percentages were calculated over the total number of participants unless indicated otherwise.

**Figure 1.** Visual representation of measured bioequivalence (A), and predicted difference in tofacitinib serum level during combination therapy (B) and probability of ACR response (C).

**A:** GMR (diamond) with 90% CI; vertical dotted lines: equivalence margin (80-125%). **B/C:** median predicted value (diamond) with 95% CI; vertical dotted line; post-hoc noninferiority margins (+0.6 for DAS28 and -0.1% for ACR20).

**Acknowledgements:** We thank the Radboud Technology Centre for Clinical Trials and Kasper Jolink for performing blood sampling for this study, and the Radboudumc Clinical Pharmacy for the tofacitinib serum level analysis.

**Disclosure of Interests:** Celeste van der Togt: None declared, L.M. Verhoef: None declared, Bart van den Berkt Manns bureaus: UCB; Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly, Nathan den Broeder: None declared, Rob ter Heine: None declared, Alfons den Broeder Grant/research support from: Aventis, Galapagos, Amgen en Eli Lilly, Nathan den Broeder: None declared, Bart van den Bemt: Speakers bureau: UCB, Pfizer, Sanofi-Département, Unité Rhumatologie, Unité Clinique Rhumatologie, Unité Clinique Gastroentérologie, Unité Clinique Gastroentérologie, Uni-Clinic and Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland; **Institut de Rhumatologie de Montréal, Montréal, Canada;** Cochin Hospital, Université de Paris, Rheumatology Department, Paris, France; **Sandorz Hesal AG, Rheumatology, Holzkirchen, Germany;** Cannock and Wolverhampton Hospitals, Rheumatology, Cannock, United Kingdom.

**Background:** COMPACT is a non-interventional study evaluating the effectiveness and safety in patients (pts) with rheumatoid arthritis (RA), axial-spondyloarthritis (axSpA) or psoriatic arthritis (PsA) treated with GP2015 (an etanercept [ETN] biosimilar) in real-world conditions.

**Objectives:** We present the effectiveness and safety data from the final analysis of the COMPACT study for all patient groups.

**Methods:** Pts aged ≥18 years on treatment with GP2015 were enrolled. Baseline visit corresponded with date of study inclusion and not with date of GP2015 treatment start. Pts were categorised based on prior treatment status: pts on conventional remission or low disease activity under treatment without reference ETN or biosimilar ETN (initial ETN: [iETN]) and switched to GP2015 (Group A) or pts who received non-ETN targeted therapies and switched to GP2015 (Group B) or biologic-naive pts who started GP2015 after conventional therapy failure (Group C) or DMARD-naive pts with recent diagnosis of RA considered suitable for treatment initiation with a biologic and started on treatment with GP2015 (Group D). Effectiveness assessments included Disease Activity Score 28-joint count Erythrocyte Sedimentation Rate (DAS28-ESR) or Ankylosing Spondylitis Disease Activity Score (ASDAS) until Month 12 after enrolment (baseline) in the study.

**Results:** Of the 1466 pts enrolled, 572 were switched from iETN (Group A), 171 were switched from other targeted therapies (Group B), 713 were biologic-naive (Group C), and 10 were RA DMARD-naive (Group D). Comorbidities were more frequent in pts with RA (68.7%) followed by pts with PsA (59.4%) and axSpA (52.1%). After 12 months of treatment with GP2015, pts with RA or PsA achieved comparable DAS28-ESR scores irrespective of whether they switched from iETN, or from other targeted therapies or were biologic-naive. At Month 12, the mean ASDAS scores were comparable between the treatment groups in pts with axSpA (Table 1). Across all pt groups, no major differences were observed in the disease activity scores between baseline and Month 12 which may be explained by the ongoing GP2015 treatment at the time of enrolment for an observed average of 138 days. Overall, the proportion of patients with at least one adverse event (AE) and serious AE (SAE) was 47.6% and 7.7% in pts who were switched from iETN, 56.7% and 9.9% in pts switched from other targeted therapies, 56% and 8.7% in biologic-naive pts, and 60% and 0% in DMARD-naive pts. Rate of injection site reaction was low across the groups (Figure 1).

**Table 1.** Effectiveness outcomes in patients treated with GP2015

<table>
<thead>
<tr>
<th>Effectiveness outcomes</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
<th>Group D</th>
<th>Overall (A-D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA DAS28-ESR, n, mean (SD)</td>
<td>2.5 (1.1)</td>
<td>2.6 (1.3)</td>
<td>2.5 (1.3)</td>
<td>2.5 (1.3)</td>
<td>2.6 (1.3)</td>
</tr>
<tr>
<td>Month 12</td>
<td>n=135</td>
<td>n=47</td>
<td>n=135</td>
<td>n=47</td>
<td>n=282</td>
</tr>
<tr>
<td>PsA</td>
<td>2.9 (1.6)</td>
<td>2.6 (1.6)</td>
<td>2.8 (1.4)</td>
<td>2.6 (1.5)</td>
<td>2.6 (1.5)</td>
</tr>
<tr>
<td>Month 12</td>
<td>n=32</td>
<td>n=13</td>
<td>n=30</td>
<td>n=11</td>
<td>n=163</td>
</tr>
<tr>
<td>AxSpA ASDAS, n, mean (SD)</td>
<td>2.6 (1.6)</td>
<td>2.6 (1.6)</td>
<td>2.3 (1.4)</td>
<td>2.3 (1.4)</td>
<td>2.4 (1.5)</td>
</tr>
<tr>
<td>Month 12</td>
<td>n=39</td>
<td>n=9</td>
<td>n=39</td>
<td>n=9</td>
<td>n=234</td>
</tr>
</tbody>
</table>

N, total number of patients in the treatment group; n, number of patients with available data at each time point, SD, standard deviation.

**POS0640 REAL-WORLD EFFECTIVENESS AND SAFETY OF GP2015 IN PATIENTS WITH RHEUMATIC DISEASES: FINAL RESULTS OF THE COMPACT STUDY**


**Disclosure of Interests:** Celeste van der Togt: None declared, L.M. Verhoef: None declared, Bart van den Berkt Manns bureaus: UCB; Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly, Nathan den Broeder: None declared, Rob ter Heine: None declared, Alfons den Broeder Grant/research support from: Aventis, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Gilead DOI: 10.1136/annrheumdis-2022-eular.1007
IN HEALTHY MALE SUBJECTS

**POS0642**

A RANDOMISED PHASE I PHARMACOKINETIC STUDY COMPARING HIGH-CONCENTRATION, LOW-VOLUME, AND CITRATE-FREE SB5 (40 MG/0.4 ML) WITH PRIOR SB5 FORMULATION, AND ADALIMUMAB BIOSIMILAR, IN HEALTHY MALE SUBJECTS

S. S. Ahn1, M. Lee1, Y. Baek2, S. Lee2, 1Samsung Bioepis Co., Ltd., Product Evaluation Team, Incheon, Korea, Republic of (South Korea); 2Samsung Bioepis Co., Ltd., Quality Evaluation Team, Incheon, Korea, Republic of (South Korea)

Background: SB5, an adalimumab (ADL) biosimilar, was developed in a low-concentration (40 mg/0.8 mL, SB5-LC) aligned with the reference ADL product. Pharmacokinetics (PK) equivalence of SB5 and reference ADL was demonstrated in a Phase I study conducted in healthy subjects. Equivalent efficacy and comparable safety between 40 mg/0.8 mL SB5 and 40 mg/0.8 mL reference ADL were demonstrated in a Phase III study conducted in patients with rheumatoid arthritis. High-concentration, low-volume, citrate-free SB5 (40 mg/0.4 mL, SB5-HC) has been developed as a part of life cycle management in line with the reference ADL formulation.

Objectives: To compare the PK, safety, and tolerability of the newly developed SB5-HC (40 mg/0.4 mL) to prior SB5-LC (40 mg/0.8 mL) in healthy male subjects.

Methods: This study was a randomised, single-blind, two-arm, parallel-group, single-dose study in healthy male subjects. Subjects were randomised in a ratio of 1:1 to receive a single dose of either SB5-HC or SB5-LC by subcutaneous injection on Day 1 and then observed for 57 days during which the PK, safety, and immunogenicity were evaluated. The serum concentration of ADL was measured using an enzyme-linked immunosorbent assay. The primary PK parameters were area under the concentration-time curve from time zero to infinity (AUC_{inf}), maximum serum concentration (C_{max}), and comparable safety between 40 mg/0.8 mL SB5 and 40 mg/0.8 mL reference ADL were demonstrated in a Phase III study conducted in patients with rheumatoid arthritis. High-concentration, low-volume, citrate-free SB5 (40 mg/0.4 mL, SB5-HC) has been developed as a part of life cycle management in line with the reference ADL formulation.

Results: Of 188 randomised subjects, 187 subjects were analysed as PK Analysis Set (PKS) (n=93 in SB5-HC and n=94 in SB5-LC). One subject was excluded from the PKS in SB5-HC group (major protocol deviation for not being withdrawn in the event of confirmed COVID-19). The geometric LSMeans ratios for the comparison of SB5-HC and SB5-LC for AUC_{inf} and C_{max} were 0.920 and 0.984, respectively, and the corresponding 90% CIs were within the pre-defined equivalence margin of 0.80 to 1.25 (Table 1), indicating the two treatment groups are bioequivalent. There were no deaths, serious adverse events or discontinuation of the study due to treatment-emergent adverse events (TEAEs) during the study.

Table 1. Comparison of Primary PK Parameters between the Treatments

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Treatment</th>
<th>Geometric LSMean Ratio</th>
<th>90% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_{inf} (h·μg/mL)</td>
<td>SB5-HC 2616.1</td>
<td>0.920</td>
<td>0.8262; 1.0239</td>
</tr>
<tr>
<td>SB5-LC 2844.3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C_{max} (μg/mL)</td>
<td>SB5-HC 4.1</td>
<td>0.984</td>
<td>0.9126; 1.0604</td>
</tr>
<tr>
<td>SB5-LC 4.1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: This study demonstrated PK equivalence between SB5-HC and SB5-LC in healthy subjects; SB5-HC and SB5-LC were generally well tolerated with similar safety profiles.

REFERENCES:


Disclosure of Interests: None declared.

DOI: 10.1136/annheumdis-2022-eular.1114
Table 1. Included studies.

<table>
<thead>
<tr>
<th>Author/year</th>
<th>n</th>
<th>Early RA</th>
<th>Mean Age Range</th>
<th>Baseline treatment</th>
<th>Tapering strategy</th>
<th>Comparison arm intervention</th>
<th>Remission outcome</th>
<th>Follow up</th>
</tr>
</thead>
<tbody>
<tr>
<td>van Mulligen 2020</td>
<td>189</td>
<td>No</td>
<td>56-57</td>
<td>csDMARD + TNFi vs TCZ</td>
<td>Taper csDMARD then TNFi vs TCZ</td>
<td>Taper in reverse order</td>
<td>CDAI &lt; 2.8</td>
<td>24 mos</td>
</tr>
<tr>
<td>Kaneko 2018</td>
<td>102</td>
<td>No</td>
<td>54-58</td>
<td>csDMARD + TNFi vs MTX</td>
<td>Stop TCZ</td>
<td>CS + DMARD vs MTX</td>
<td>DAS28 &lt; 2.6</td>
<td>104 wks</td>
</tr>
<tr>
<td>Bijlisma 2016</td>
<td>299</td>
<td>Yes</td>
<td>54</td>
<td></td>
<td>Gradual taper MTX then TCZ</td>
<td>Taper in reverse order</td>
<td>CDAI &lt; 2.6</td>
<td>104 wks</td>
</tr>
<tr>
<td>Emery 2015</td>
<td>176</td>
<td>Yes</td>
<td>45-49</td>
<td></td>
<td>Stop ABA</td>
<td>Gradual taper MTX</td>
<td>CDAI &lt; 2.6</td>
<td>18 mos</td>
</tr>
<tr>
<td>Takeuchi 2019</td>
<td>69</td>
<td>Yes</td>
<td>48-53</td>
<td></td>
<td>Reduce 2mg</td>
<td>Stop ABA</td>
<td>CDAI &lt; 2.6</td>
<td>48 wks</td>
</tr>
</tbody>
</table>

ABA abatacept, BARI baricitinib, CDAI Clinical disease activity index, csDMARDs conventional synthetic DMARDs, DAS28 Disease Activity Score 28, MTX methotrexate, SJC swollen joint count, TCZ tocilizumab, wks weeks, mos months.

REFERENCES:


Disclosure of Interests: Charis Meng: None declared, Diviya Rajesh: None declared, Deanna Jannat-Khah Shareholder of: AstraZeneca, CytoDyn, Walgreens, Omar Bruce: None declared, Bridget Jivanelli: None declared, Vivian Bykerk Consultant of: Amgen, Bristol Myers Squibb, Genzyme, Gilead, Janssen, Pfizer, Sanofi-Aventis, UCB, Grant/research support from: NIH (NIAID/NIAMS) grant 1UH2AR067691-01 GRANT11652401 and The Cedar Hill Foundation; institution received grants from Bristol Myers Squibb and Amgen

DOI: 10.1136/annrheumdis-2022-eular1264

SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL

P. Nash1, A. Kavanaugh2, M. H. Buch3, B. Combe3, L. Bessette5, I. H. Song2, T. Shaw2, Y. Song2, J. Suboticki4, R. M. Fleischmann5. 1School of Medicine, Griffith University, Brisbane, Australia; 2University of California San Diego, Rheumatology, San Diego, United States of America; 3University of Manchester & NIHR, Manchester Biomedical Research Centre, Manchester, United Kingdom; 4Montpellier University, Rheumatology, Montpellier, France; 5Université Laval, Centre Hospitalier de l’Université Laval, Laval, Canada; 6AbbVie Inc., Immunology, North Chicago, United States of America; 7AbbVie Inc., Immunology, Maidenhead, United Kingdom; aUniv of Texas Southwestern Med Center, Metroples Clinical Research Center, Dallas, United States of America

Background: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) and low disease activity (LDA). A greater proportion of patients with RA and inadequate response to methotrexate (MTX) receiving the JAK inhibitor, upadacitinib (UPA), achieved REM/LDA compared with adalimumab (ADA), both with background MTX, through 26 weeks in the phase 3, SELECT-COMPARE trial. 3

Objectives: We assessed sustainability of response over 3 years in UPA-treated patients with RA.

Methods: SELECT-COMPARE included a 26-week, double-blind, placebo (PBO)-controlled period, a 48-week, double-blind active comparator-controlled period, and an ongoing long-term extension for up to 10 years. Patients on background MTX received UPA 15 mg once daily, PBO, or ADA 40 mg every other week. Patients who did not achieve at least 20% improvements in tender and swollen joint counts (Weeks 14-22) or LDA (CDAI ≤10 at Week 26) were rescued from UPA to ADA or PBO/ADA to UPA. This post hoc analysis evaluated clinical REM (CDAI ≤2.8; SDAI ≤3.3), LDA (CDAI ≤10; SDAI ≤11), and DAS28(CRP) <2.6/≤3.2 at first occurrence (prior to treatment switch [rescue]), as well as over 3 years following initial response in patients randomized to UPA or ADA. For those patients who achieved REM/LDA, Kaplan-Meier was used to define the time from when the response was first achieved to the earliest date at which the response was lost at two consecutive visits, discontinuation of study drug, or losing response at the time of rescue. The predictive ability of time to CDAI REM/LDA was assessed using Harrell’s concordance (c)-index (range: 0 [all predictions wrong] to 1.0 [perfect predictive ability]). Non-responder imputation was used for missing data.

Results: Through 3 years, a significantly higher proportion of patients receiving UPA + MTX vs ADA + MTX achieved CDAI REM (47% vs 35%, p=0.001) as well as CDAI LDA (70% vs 60%, p=0.001). At 30 months after first occurrence of response, CDAI REM/LDA was sustained in 19%/42% of patients randomized to UPA and 10%/30% of patients randomized to ADA (Figure 1). Time to initial clinical response did not appear to be predictive of sustained disease control. The c-index for CDAI REM/LDA was 0.50/0.60 on UPA vs 0.49/0.56 on ADA. Through the last follow-up visit, 37%/58% of patients receiving UPA and 27%/48% on ADA remained in CDAI REM/LDA, respectively (Figure 2). Of patients who lost CDAI REM, 68% on UPA and 55% on ADA remained in LDA. Additionally, roughly similar proportions on UPA and ADA recaptured CDAI REM/LDA (UPA, 40%/17%; ADA, 48%/19%). Similar results were observed for REM/LDA based on SDAI and for DAS28(CRP) <2.6/≤3.2.

Conclusion: Among patients with inadequate response to MTX, a higher proportion receiving UPA + MTX achieved remission or LDA across disease activity measures vs ADA + MTX. UPA-treated patients demonstrated a consistently higher sustained response rate over 3 years compared to those receiving ADA. Furthermore, significant proportions of patients who lost response on either UPA or ADA were able to recapture remission or LDA.

REFERENCES:


Acknowledgements: AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. No honoraria or payments were made for authorship. Medical writing support was provided by Matthew Eckwuhl, PhD, of AbbVie.
Disclosure of Interests: Peter Nash Speakers bureau: AbbVie, BMS, Pfizer, Gilead/Galapagos, Sanofi, Celgene, Novartis, Lilly, Janssen, UCB, Samsung, MSD, Roche, Consultant of: AbbVie, BMS, Pfizer, Gilead/Galapagos, Sanofi, Celgene, Novartis, Lilly, Janssen, UCB, Samsung, MSD, Roche, Grant/research support from: AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, Grant/research support from: AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, Maya H Buch Speakers bureau: AbbVie, Boehringer Ingelheim, Eli Lilly, Merck-Serono, and Sanofi, Consultant of: AbbVie, Boehringer Ingelheim, Eli Lilly, Merck-Serono, and Sanofi, Pfizer: Roche, Chugai, Louis Bessette Speakers bureau: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Genentech, Roche, Sanofi, and Teva, Consultant of: Amgen, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Genentech, Sanofi, Eli Lilly, Novartis, Sandoz, Genentech, Fresenius Kabi, and Teva, Consultant of: Amgen, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Genentech, Sanofi, Eli Lilly, Novartis, Sandoz, Genentech, Fresenius Kabi, and Teva, Grant/research support from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Genentech, Sanofi, Eli Lilly, Novartis, Sandoz, Genentech, Fresenius Kabi, and Teva, In-Ho Song Shareholder of: Amgen Inc., Employee of: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Genentech, Sanofi, Eli Lilly, Novartis, Sandoz, Fresenius Kabi, and Teva, Grant/research support from: Amgen, BMS, Janssen, Roche, UCB, AbbVie, Pfizer, Merck, Genentech, Sanofi, Eli Lilly, Novartis, Sandoz, Genentech, Fresenius Kabi, and Teva, Tim Shaw Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Yanna Song Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Roy M. Fleischmann Consultant of: AbbVie, Amgen, Pfizer, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc., Sanofi-Aventis, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Janssen, Novartis, Pfizer Inc, Regeneron, Roche, Sanofi-Aventis and UCB.

REFERENCES:

RESULTS:
Of 193 patients included in the ITT population, we had outcome data on 176 (i.e. data from 17 patients were imputed): 114 (59%) had a clinical response to biologic therapy. In the HFLM group, 41 (64%) patients responded to treatment compared to 73 (56%) in the LFHM group, but the difference proved not to be statistically significant (Odds ratio, OR: 1.48, 95% confidence interval 0.72 to 3.05).

POS0644 IMPACT OF FIBRE AND RED/PROCESSED MEAT INTAKE ON TREATMENT OUTCOMES AMONG PATIENTS WITH CHRONIC INFLAMMATORY DISEASES INITIATING BIOLOGICAL THERAPY: A PROSPECTIVE COHORT STUDY
S. H. Overgaard1,2,3, S. Sorensen1,4, H. L. Munk1,2,3, A. B. Nexøe1,4,7, H. Glerup1,4, R. H. Henriksen1,4, T. G. Nielsen1, S. Pedersen1, S. Sabin2, L. Hvid1, J. A. Dahlérup1, C. L. Hvas1,12,13, K. W. Andersen1,13, A. Kristian Hvitfeldt1, O. H. Nielsen16, F. H. Bergenheim11, J. B. Brodersen11, B. L. Heitmann17,18, T. I. Halldórsson19, U. Holmskov4, A. Bygum10,20, S. H. Overgaard1,2,3, Silja Hvid Overgaard: None declared, Signe Sorensen: None declared, Heidi Lausten Munk: None declared, Anders Bathum Nexøe: None declared, Henning Glerup: None declared, Rikke Holm Henriksen: None declared.

Figure 1. Meta-analysis (random effects model) of the included Chronic Inflammatory Diseases (CIDs) on the ‘As Observed’ population comparing clinical response to biologics in patients with a high intake of fibre and low intake of red/processed meat (HFLM) versus patients with a low intake of fibre and high intake of red/processed meat (LFHM). The horizontal lines represent the OR ± 95% CI. Event= clinical response according to the specified CIDs. Event OR 95% CI: 10.1136/annrheumdis-2022-eular.1268

Conclusion: Overall, habitual HFLM intake did not affect the clinical response to biologic treatment across CIDs. However, a HFLM diet in RA patients might be more beneficial as those with completed baseline food frequency questionnaires enabling stratification into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). This was determined by the ratio of fibre to red/processed meat intake whereby HFLM constituted the upper tertile of the study sample and LFHM constituted the two lower tertiles of the study sample. The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14-16 weeks of treatment. Based on the ITT population, differences between the dietary phenotypes in terms of the clinical response rate were analysed (while adjusting for the specific CIDs) in logistic regression models.

DISCLOSURE OF INTERESTS:
None declared, Henning Glerup: None declared, Sija Hvid Overgaard: None declared, Signe Sorensen: None declared, Heidi Lausten Munk: None declared, Anders Bathum Nexøe: None declared, Rikke Holm Henriksen: None declared.


POS0645

LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4


1Eugen Feist Consultant of: Abbvie, BMS, Eli Lilly, Gilead Sciences, Galapagos, Medac, Novartis, Roche, Sanofi, Sobi, R-Pharm, Grant/research support from: BMS, Eli Lilly, Novartis, Roche, Evgeny Nasonov Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Michael Luggen Grant/research support from: AbbVie, Biogen, GSK, Lilly, R-Pharm, Sanum, and UCB, Saeed Fatenejad Shareholder of: Pfizer, INC, Consultant of: ICON and PPD contract research organizations, R-Pharm, Sergey Grishin Employee of: R-Pharm, Mikhail Samsonov Employee of: R-Pharm, Roy M. Fleischmann Consultant of: AbbVie, BMG, Gilead, Galvani, GSK, Janssen, Eli Lilly, Novartis, Pfizer, R-Pharm, UCBB.


POS0646

NON-MEDICAL SWITCHING FROM TOCILIZUMAB TO SARILUMAB IN RHEUMATOID ARTHRITIS PATIENTS WITH LOW DISEASE ACTIVITY

N. Den Broeder1,2, A. Den Broeder1, L. M. Verhoeft1, F. Van den Hoogen1, A. Van der Maas1, B. Van den Berft1, S. M. Maarten, Rotterdam, Netherlands; 2Radboumc, Radboud Institute for Health Sciences, Nijmegen, Netherlands

Background: Tocilizumab (TCZ) and sarilumab (SRL) are IL-6 receptor antagonists registered for the treatment of rheumatoid arthritis (RA). Data from extension of the ASCERTAIN trial showed that patients responding to blinded intravenous (IV) TCZ rarely experienced a loss of response when switching to open label SRL [1]. This within-class, between-drug switch has gained relevance given the recent pandemic-driven shortage of several BDMARDs including TCZ.

Objectives: To assess the efficacy and persistence of switching to sarilumab in RA patients responding well to tocilizumab.

Methods: SAARTOOS (SArilumab Actively Replacing TOcilizumab, an Open label Study) is an open, observational single arm study. RA patients doing well (DAS28-CRP<2.9 or <3.6 with clinical judgement of low disease activity) on stable dose (>6 months) of TCZ were offered to switch to SRL in clinical care (because of lower injection frequency). Patients who switched and consented were followed for 6 months. SRL was prescribed at a dose of 200mg. The SRL dosing interval was determined by doubling patient’s last TCZ dosing interval. All treatment decisions, including adjusting dose of or stopping SRL, were left to the treating physician. Co-primary outcomes were 1) the 90% confidence interval (CI) of DAS28-CRP change from baseline to month 6 compared to the non-inferiority
Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity and increased risk for disease progression. Recent publications indicate significantly lower efficacy of TNF inhibitors (TNFi) in RA patients with high RF levels compared with low/negative RF subgroup. Fab therapy with Certolizumab pegol (CZP), a PEGylated, Fc-free monoclonal antibody (mAb), has shown comparable efficacy and consistent serum levels irrespective of baseline RF. RF binds the Fc region of IgG1, complexes may likely explain the increased clearance of mAbs in patients with high RF titers and reported reduced TNFi efficacy.

## Table 1. Baseline characteristics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (n=168)</th>
<th>IFX (n=90)</th>
<th>ADL (n=48)</th>
<th>CZP (n=32)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years*</td>
<td>55.5(45.3-66)</td>
<td>57(46)</td>
<td>50(42-64)</td>
<td>50(42.5-64)</td>
<td>0.08</td>
</tr>
<tr>
<td>Body mass index, Kg/m²</td>
<td>24.5(21.9-29)</td>
<td>24.2(21.8-27.7)</td>
<td>24.7(23.5-30.3)</td>
<td>24.6(22.9-30.3)</td>
<td>0.3</td>
</tr>
<tr>
<td>Male, n(%)</td>
<td>28(17%)</td>
<td>14(15%)</td>
<td>9(19%)</td>
<td>5(17%)</td>
<td>0.2</td>
</tr>
<tr>
<td>Disease duration, years*</td>
<td>8.7(4.4-14.3)</td>
<td>8.4(4.4-14.3)</td>
<td>8.8(3.9-16)</td>
<td>9.7(5.1-12)</td>
<td>0.06</td>
</tr>
<tr>
<td>Smoking status, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
</tr>
<tr>
<td>Current/ever-smoker</td>
<td>66(39%)</td>
<td>22(48%)</td>
<td>49(54%)</td>
<td>15(46.9%)</td>
<td></td>
</tr>
<tr>
<td>Non-smoker</td>
<td>94(61%)</td>
<td>64(78%)</td>
<td>43(56%)</td>
<td>17(53.1%)</td>
<td>0.2</td>
</tr>
<tr>
<td>RF, n(%)</td>
<td>128(76%)</td>
<td>75(83%)</td>
<td>28(58%)</td>
<td>25(81%)</td>
<td>0.002</td>
</tr>
<tr>
<td>ACPA, n(%)</td>
<td>134(80%)</td>
<td>83(81%)</td>
<td>35(73%)</td>
<td>27(84%)</td>
<td>0.3</td>
</tr>
<tr>
<td>DAS28**</td>
<td>5.1(11.3)</td>
<td>5.4(11.3)</td>
<td>4.6(11.3)</td>
<td>4.9(11.3)</td>
<td>0.002</td>
</tr>
<tr>
<td>CRP levels*</td>
<td>7.3(21.8)</td>
<td>10.3(25.2)</td>
<td>5.1(10.1)</td>
<td>7.8(18.2)</td>
<td>0.1</td>
</tr>
<tr>
<td>Prior bDMARDs, n(%)</td>
<td>26(10%)</td>
<td>10(11%)</td>
<td>10(21%)</td>
<td>6(20%)</td>
<td>0.2</td>
</tr>
<tr>
<td>Methotrexate, n(%)</td>
<td>12(67%)</td>
<td>64(78%)</td>
<td>33(83%)</td>
<td>17(53%)</td>
<td>0.2</td>
</tr>
<tr>
<td>Other csDMARDs, n(%)</td>
<td>24(24%)</td>
<td>18(22%)</td>
<td>7(18%)</td>
<td>15(50%)</td>
<td>0.0008</td>
</tr>
<tr>
<td>Prednisone, n(%)</td>
<td>85(51%)</td>
<td>49(54%)</td>
<td>21(44%)</td>
<td>16(50%)</td>
<td>0.6</td>
</tr>
</tbody>
</table>

*Median and interquartile range; **mean and standard deviation

Table 1. Baseline characteristics.

**Persistent serum levels irrespective of baseline RF**

**DAS28-CRP change was 7 (3-10), during the study, 8 (36%) patients experienced a DAS28-CRP based flare** (and post-hoc the proportion of patients persisting to TCZ and 2 (9%) switched to baricitinib.

**Secondary outcomes included the CDAI, proportion of patients preferring TCZ, and 5 (25%) patients somewhat or strongly preferring SRL. In terms of (co-)medication, 4 (18%) patients required additional corticosteroids (oral or intramuscular), 5 (23%) patients switched back to TCZ and 2 (9%) switched to baricitinib.

**Conclusion:** Non-medical switching from tocilizumab to sarilumab in patients doing well on tocilizumab is associated with a non-negligible risk of flare and non-persistence.

**REFERENCES:**


**Disclosure of Interests:** Nathan den Broeder: None declared, Alfonso den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Glaxo, L.M. Verhoef: None declared, Frank van den Hoogen: None declared, Aatke van der Maas: None declared, Bart van den Bemt: Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly

**Scientific Abstracts**

**POS0647**

**DOES TNF INHIBITOR MOLECULAR STRUCTURE MATTER? ANALYSIS OF IMPACT OF BASELINE RHEUMATOID FACTOR TITERS ON DRUG LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS**


Institute for Health Research (IdiPAZ), Immuno-Rheumatology Research Group, Madrid, Spain; La Paz University Hospital, Department of Rheumatology, Madrid, Spain

**Background:** Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity and increased risk for disease progression. Recent publications indicate significantly lower efficacy of TNF inhibitors (TNFi) in RA patients with high RF levels compared with low/negative RF subgroup. Fab therapy with Certolizumab pegol (CZP), a PEGylated, Fc-free monoclonal antibody (mAb), has shown comparable efficacy and consistent serum levels irrespective of baseline RF. RF binds the Fc region of IgG1, the subtype used to engineer the majority of mAbs. Formation of large immune complexes may likely explain the increased clearance of mAbs in patients with high RF titers and reported reduced TNFi efficacy.


**Disclosure of Interests:** Nathan den Broeder: None declared, Alfonso den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Glaxo, L.M. Verhoef: None declared, Frank van den Hoogen: None declared, Aatke van der Maas: None declared, Bart van den Bemt: Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.2156

**POS0647**

**DOES TNF INHIBITOR MOLECULAR STRUCTURE MATTER? ANALYSIS OF IMPACT OF BASELINE RHEUMATOID FACTOR TITERS ON DRUG LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS**


Institute for Health Research (IdiPAZ), Immuno-Rheumatology Research Group, Madrid, Spain; La Paz University Hospital, Department of Rheumatology, Madrid, Spain

**Background:** Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity and increased risk for disease progression. Recent publications indicate significantly lower efficacy of TNF inhibitors (TNFi) in RA patients with high RF levels compared with low/negative RF subgroup. Fab therapy with Certolizumab pegol (CZP), a PEGylated, Fc-free monoclonal antibody (mAb), has shown comparable efficacy and consistent serum levels irrespective of baseline RF. RF binds the Fc region of IgG1, the subtype used to engineer the majority of mAbs. Formation of large immune complexes may likely explain the increased clearance of mAbs in patients with high RF titers and reported reduced TNFi efficacy.


**Disclosure of Interests:** Nathan den Broeder: None declared, Alfonso den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Glaxo, L.M. Verhoef: None declared, Frank van den Hoogen: None declared, Aatke van der Maas: None declared, Bart van den Bemt: Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.2156
Sex Differences in Adverse Drug Reactions in Patients with Immune-Mediated Inflammatory Diseases


Background: Women generally report more adverse drug reactions (ADRs) than men. Information on sex differences concerning the frequency and the nature of ADRs is still limited and sex differences are not considered in research on ADRs. Consequently, no sex specific distinction is made when reporting results of ADR analyses or when providing information to patients.

Objectives: To examine sex differences in regard to the nature and frequency of reported ADRs in patients with immune-mediated inflammatory disease (IMIDs) treated with adalimumab or etanercept.

Methods: Patients with rheumatoid arthritis (RA), psoriatic arthritis or axial spondyloarthritis using etanercept or adalimumab, were included from the Dutch Biologic Monitor (DBM). Questionnaires concerning experienced ADRs were filled out bimonthly. ADRs were coded according to Medical Dictionary for Regulatory Activities (MedDRA) terminology. Sex specific ADRs (e.g. concerning menstruation) were excluded. MedDRA Preferred Terms (PTs) were analyzed to assess the nature and frequency of ADRs. Only PTs that were reported at least four times were analyzed. Discrepancies in the distribution of the nature of reported ADRs between male and female patients were assessed using Fisher Freeman Halton with Monte Carlo simulation. Subsequently, differences in frequencies at PT level were examined using Fisher’s exact tests, corrected for multiple testing using Bonferroni correction.

Results: In total 748 consecutive patients were included of which the majority (59%) was female (Table 1). 362 participants (48%) reported at least one ADR during the study. Relatively more female patients (35%) reported at least one ADR compared to male patients (38%, p<0.001). In total 882 ADRs were reported comprising 264 distinct ADRs, of which the majority (74%) was reported by female patients. The ADR distribution differed significantly between male and female patients (p<0.025). ‘Injection site pruritus’ (p=0.004), ‘ Injection site inflammation’ (p=0.028), ‘Injection site hematoma’ (p=0.017), ‘ injection site erythema’ (p=0.026), ‘hematoma’ (p=0.011) and ‘cystitis’ (p=0.044) were reported relatively more often by female patients (Figure 1). These differences were no longer statistically significant upon correction for multiple testing.

Disclosure of Interests: Helen Gosselt: None declared. Jette van Lint: None declared. Sander Tas Consultant of: Gebro, GSK, AbbVie, Galvani, Arthogen/MearaGTX, Galapagos, Grant/research support from: Pfizer, GSK, Celgene.

Table 1. Demographics of included patients from the Dutch Biologic Monitor stratified on sex

<table>
<thead>
<tr>
<th>Participating</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>304</td>
<td>444</td>
</tr>
<tr>
<td>Age, mean ± SD</td>
<td>58.2 ± 11.9</td>
<td>56.6 ± 12.9</td>
</tr>
<tr>
<td>Indication, N(%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bechterew’s disease/axial SpA</td>
<td>71 (23.4)</td>
<td>39 (8.8)</td>
</tr>
<tr>
<td>Bechterew’s disease/axial SpA and PsA</td>
<td>4 (1.3)</td>
<td>8 (1.8)</td>
</tr>
<tr>
<td>Bechterew’s disease/axial SpA and RA</td>
<td>8 (2.6)</td>
<td>3 (0.7)</td>
</tr>
<tr>
<td>PsA</td>
<td>89 (29.3)</td>
<td>84 (18.9)</td>
</tr>
<tr>
<td>bDMARDs, N(%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>138 (45.4)</td>
<td>199 (44.8)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>159 (52.3)</td>
<td>232 (52.3)</td>
</tr>
<tr>
<td>Switched adalimumab/etanercept</td>
<td>7 (2.3)</td>
<td>13 (2.9)</td>
</tr>
<tr>
<td>Comedication, N(%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>107 (35.2)</td>
<td>250 (56.3)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>27 (8.9)</td>
<td>49 (11.0)</td>
</tr>
<tr>
<td>Thiopurines</td>
<td>3 (1.0)</td>
<td>10 (2.2)</td>
</tr>
<tr>
<td>Aminosalicylates</td>
<td>14 (4.6)</td>
<td>33 (7.4)</td>
</tr>
</tbody>
</table>

*p-value<0.05.

Figure 1. Top reported ADRs Percentages on the axis were calculated separately for sex, divided by the number of male or female patients with at least one ADR.
V. Mazurov1, M. Korolev2, A. Pristrom1, A. Kundyzer1, N. Soroka3, A. Kastanayan4, T. Povorova1, T. Plaksina1, O. Antipova1, D. Kretchikova1, S. Smakotina15, D. Tciupa16, Y. Plotnikova17, A. Zinkina-Orikhanova18, A. Ermeeva19, A. Lutski20.

1North-Western State Medical University n.a. I.I. Mechnikov, Department of Therapy and Rheumatology of Temporary Disability and Medical Care Quality Expertise named after E. E. Eichwald, Saint-Petersburg, Russian Federation; 2Federal Research Center Institute of Cytology and Genetics, Deputy Director for Clinical Issues, Novosibirsk, Russian Federation; 3Belarusian Medical Academy of Postgraduate Education, Department of Cardiology and Rheumatology, Minsk, Belarus; 4Belarus State Medical University, Department of Internal Diseases No.2, Minsk, Belarus; 5Rostov State Medical University, Department of Internal Diseases No.2, Rostov-on-Don, Russian Federation; 6Clinical Hospital Russian Railways-Medicine of the east of Saratov, Department of Cardiology, Saratov, Russian Federation; 7A. N. Semashko Nizhny Novgorod Regional Medical Center, Department of Rheumatology, Nizhny Novgorod, Russian Federation; 8Irkutsk City Clinical Hospital No.1, Medical Rheumatological Center, Irkutsk, Russian Federation; 9Regional Hospital No.4 of the City of Barnaul, Department of Rheumatology, Barnaul, Russian Federation; 10Perm Regional Clinical Hospital, Admission Department, Perm, Russian Federation; 11Kemerovo Regional Hospital, Education Department of Internal Medicine, Kemerovo, Russian Federation; 12City Clinical Emergency Hospital No 25, Regional Rheumatological Center, Kemerovo, Russian Federation; 13Kemerovo State Medical University, Department of Internal Medicine, Kemerovo, Russian Federation; 14City Clinical Hospital No 40, Department of Rheumatology, Kemerovo, Russian Federation; 15Rostov State Medical University, Department of Rheumatology, Krasnodar, Russian Federation; 16UKRAINE: 17Ulyanovsk Regional Clinical Hospital, Department of Rheumatology, Ulyanovsk, Russian Federation; 18BIOCAD, Clinical Development, Saint-Petersburg, Russian Federation; 19BIOCAD, Clinical Research, Saint-Petersburg, Russian Federation; 20BIOCAD, Medical Promotion, Saint-Petersburg, Russian Federation

Background: Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo. Here we present 1-year efficacy and safety data of the open-label period of the SOLAR study.

Objectives: To evaluate the efficacy and safety of levilimab in combination with methotrexate (MTX) in subjects with MTX resistant active RA.

Methods: The study was conducted at 21 clinical sites in Russia and Belarus. All randomized subjects had completed the study between November 2019 and October 2021. 154 adults, aged ≥ 18 years with confirmed diagnosis of RA were randomly assigned (2:1) to receive either levilimab, 162 mg, SC (LVL QW) or MTX (n=102) or placebo (PBO) + MTX (n=52). After W24 of the study all subjects randomly assigned (2:1) to receive either levilimab, 162 mg, SC (LVL QW) + MTX or PBO + MTX (n=257) and PBO/LVL Q2W arm (n=1). Those with DAS28- CRP ≥ 2.6 at W28 continued with placebo levilimab regimen + MTX: LVL QW/Q2W arm (n=75) and PBO/LVL QW arm (n=51).

The efficacy analysis was done in a population of all randomized subjects (n=154). Those with missing data due to study discontinuation or rescue therapy prescription were considered non-responders. Otherwise, the analysis was performed on complete cases. Safety was assessed through monitoring of adverse events (AEs) in a population of those, who received at least one dose of LVL (n=152). Two subjects randomized to receive placebo were discontinued within first 24 weeks of the study, thus did not receive any dose of levilimab and were excluded from safety analysis.

Results: Obviously, better response to the treatment was observed in LVL QW/Q2W arm as it was composed of those who had reached DAS28-CRP ≤ 2.6 at W24. At this time point 15/27 (55.6%) of them achieved ACR70/23/27 (85.2%) achieved DAS28-CRP remission (<2.6) and 7/27 (25.9%) achieved ACR/EULAR remission of RA. After switching to LVL Q2W, rates of ACR70 and DAS28-CRP < 2.6 did not significantly changed until W52: 17/27 (63.0%) and 21/27 (77.8%), respectively, yet the proportion of subject with ACR/EULAR2011 remission further increased and reached 12/27 (44.4%). LVL QW/Q2W arm was diminished by subjects who had achieved high response to treatment at W24 and composed LVL QW/Q2W arm. Thus, the ACR70, and remissions rate in this arm were close to zero at W24. However, continuation of LVL QW in those who had not achieved DAS28-CRP ≤ 2.6 at W24 induced ACR70 response in 37/75 (46.7%) and ACR/EULAR2011 remission in 8/75 (10.7%) at W52. The most common adverse events (reported in ≥5% of subjects) were blood cholesterol increase (30.3%), ALT increase (23.0%), lymphocyte count decrease (17.1%), ANC decrease (16.4%), blood triglycerides increase (13.8%), bilirubin increase (11.2%), AST increase (9.9%), WBC decrease (9.9%), IGRA with M.tb antigen positive (7.2%) and injection site reactions (6.9%). No deaths were reported.

Conclusion: Open label period confirmed the lasting efficacy and safety of levilimab in combination with MTX in subjects with MTX resistant active RA suggesting the possibility of switching to maintenance (Q2W) regimen of levilimab in those who achieved remission of RA at week 24.

Disclosure of Interests: All authors declare no conflict of interests.
Methods: BiobadaBrasil is a multicentric registry-based cohort study of Brazilian patients with rheumatic diseases starting their first bDMARD or tsDMARD (3). The present analysis includes RA patients recruited from Jan 2009 to Oct 2019, followed-up over one or multiple (up to six) courses of treatment necessarily involving a bDMARD or tsDMARD (latest date, Nov 19, 2019). Treatment course is defined as a period during which the medication scheme does not change, except for dose adjustments. Primary outcome was the incidence treatment interruption for any reason (except for pregnancy or disease remission), while interruption due to adverse events (AEs; including death) and due to inefficacy served as secondary outcomes. Incidence of serious adverse events (SAEs) also served as a secondary outcome. Extended (frailty) multivariate Cox proportional hazards models and negative binomial regression with generalized estimating equations (to calculate incidence rate ratios [IRR]s) were used for statistical analyses (both types of analyses including time-varying covariates over multiple courses of treatment).

Results: In total, 1316 patients (2335 treatment courses, 6508 patient-years [PY]) were enrolled. Of these, 160 patients (643 PY; 237 treatment courses) were ≤65 years old, mean age at starting treatment = 71 ± 5 yrs (84% female). Old age was not significantly associated with treatment interruption for any reason, but presented higher risk of interruption due to adverse events (after multivariate adjustment) and lower risk of stopping because of inefficacy (see Table 1). Older patients presented higher incidence of SAEs than younger ones (16.0 vs 8.4/100 PY, respectively; multivariate IRR: 2.06, 95% CI: 1.51 to 2.80, P<0.001). Among old patients, tocilizumab (HR: 2.73, 95% CI: 1.13 to 6.64, P=0.026), etanercept (2.13, 1.12 to 4.07, P=0.022), and infliximab (2.39, 1.19 to 4.79, P=0.014) presented higher risk of treatment termination as compared with adalimumab. In this subgroup (age ≥65 yrs), there was no significant difference in the risk of SAEs between different bDMARDs/tsDMARDs.

Table 1. Univariate and multivariate hazard ratios (HRs) of interruption of treatment course comparing older (≥65 years) versus younger patients (reference category). Results are HRs, 95% CIs, and P values.

<table>
<thead>
<tr>
<th>Cause of interruption (n of events)</th>
<th>crude analysis</th>
<th>adjusted covariates*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interruption - any reason</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1321)</td>
<td>0.96 (0.75 to 1.23)</td>
<td>0.76 (0.68 to 1.34)</td>
</tr>
<tr>
<td><strong>Interruption - adverse events</strong> (368)</td>
<td>1.03 (0.75 to 0.89)</td>
<td>0.91 (0.72 to 1.16)</td>
</tr>
<tr>
<td><strong>Interruption - inefficacy</strong> (680)</td>
<td>0.56 (0.39 to 0.80)</td>
<td>0.84 (0.53 to 1.34)</td>
</tr>
</tbody>
</table>

* Age, baseline DAS28, disease duration, gender, smoking, RF or anti-CCP previous malignancy, interstitial lung disease, diabetes, hypertension, hypercholesterolemia, renal failure, ischemic cardiomyopathy, COPD, heart failure, concomitant use of each cs-, b-, and tsD-MARDs, corticosteroids, starting year, osteoporosis, hepatitis B, C treatment sequence.

Conclusion: The overall risk of treatment interruption with biologic or targeted synthetic DMDAR is not higher in older patients. Higher risk of interruption due to AE was balanced by a lower risk of stopping treatment due to inefficacy. Older patients had a higher incidence of SAEs.

References:
4. Disclosure of Interests: None declared.

POS0651 IMPACT OF ADVERSE DRUG REACTIONS ON THE TREATMENT PATHWAYS OF EARLY RHEUMATOID ARTHRITIS PATIENTS


1. Netherlands Pharmacovigilance Centre Lareb, Research, 's-Hertogenbosch, Netherlands; 2. University of Twente, Department of Psychology, Health & Technology, Enschede, Netherlands; 3. Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, Netherlands; 4. Netherlands Pharmacovigilance Centre Lareb, Research, 's-Hertogenbosch, Netherlands; 5. Medisch Spectrum Twente, Rheumatology and Clinical Immunology, Enschede, Netherlands

Background: Rheumatoid arthritis (RA) patients frequently pass through several medications in order to achieve and maintain acceptable disease control. The clinical heterogeneity and variable course of the disease, plus the availability of multiple classes and subclasses of DMDARs may lead to very different and complex treatment sequencing in individual patients. Limited real-world data exists regarding treatment pathways among patients with RA. Adverse drug reactions (ADRs) belong to the stop reasons of medication, but the impact of ADRs on treatment pathways has not been quantified.

Objectives: To assess differences in treatment pathways between RA patients with and without adverse drug reactions (ADRs).

Methods: Single center retrospective observational study, using real-world data collected in the Dutch Rheumatoid Arthritis Monitoring (DREAM-RA) registry from Medisch Spectrum Twente (Enschede, the Netherlands). From all early RA patients enrolled between 16 July 2006 and 30 April 2020, the first four consecutive courses of treatment were assessed. Patients were selected from the DREAM early RA treat-to-target cohort. The use of corticosteroids per protocol was allowed but not considered as a DMDAR treatment. bDMARDs and tsDMARDs and a combination of these classes of DMDARs were considered as bDMARDs/tsDMARDs.

Results: In total, 372 RA patients (66.1% females) were assessed (Table 1). The average duration of treatment was shorter in patients that experienced at least one ADR (1.8 vs. 2.7 years, p<0.001), and the number of treatments was higher (3.5 vs. 2.5, p<0.001), than in those that experienced no ADR. Furthermore, there was a difference between these groups in the proportion of treatments with tsDMARD(s) and bDMARD(s) or a combination of the two (p<0.001). This was for the No ADR group respectively 93%; 1%; 6%, and for the ADR group respectively: 77%; 8%; 15%.

Table 1. Characteristics of patients with and without adverse drug reactions (ADRs) and treatment pathways

<table>
<thead>
<tr>
<th>Total, n (% of all patients)</th>
<th>Patients with ADRs</th>
<th>Patients without ADRs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients that received 1, 2, 3 or 4 treatments, n (%)</td>
<td>515 (40.6)</td>
<td>103 (41.9)</td>
</tr>
<tr>
<td>Duration per treatment in years, mean ±SD</td>
<td>2.4 ±2.9</td>
<td>2.4 ±2.8</td>
</tr>
<tr>
<td>Follow-up time in years, mean ±SD</td>
<td>6.6 ±3.8</td>
<td>6.3 ±3.3</td>
</tr>
<tr>
<td>Number of treatments stopped with treatment, n (% of total)</td>
<td>2.7 ±1.3</td>
<td>2.8 ±1.4</td>
</tr>
<tr>
<td>Number of patients stopped with treatment, n (% of total)</td>
<td>3.5 ±1.0</td>
<td>3.5 ±1.1</td>
</tr>
<tr>
<td>n = 87</td>
<td>n = 372 (100.0)</td>
<td></td>
</tr>
</tbody>
</table>

* p<0.001

Conclusion: Treatment pathways for patients with and without ADRs differ significantly. Patients that experience ADRs have shorter duration of treatments and have more consecutive treatments utilizing more bDMARDs.

References:


POS0652 LONG-TERM EFFECTIVENESS OF ULTRA-LOW DOSES OF RITUXIMAB IN RHEUMATOID ARTHRITIS


1. Sint Maartenskliniek, Rheumatology, Ubbergen, Netherlands; 2. Radboudumc, Radboud Institute for Health Sciences, Nijmegen, Netherlands; 3. Ziekenhuisgroep Twente (Hospital Group Twente), Rheumatology, Borne, Netherlands; 4. Maasstad Hospital, Rheumatology, Rotterdam, Netherlands; 5. Radboud University Medical Centre, Rheumatology, Nijmegen, Netherlands; 6. Reade, Rheumatology, Amsterdam, Netherlands

Background: The optimal rituximab (RTX) dose for the treatment of rheumatoid arthritis remains unclear. RTX treatment of 1000mg per 6 months and 2000mg per 8 months were shown to be similarly efficacious (1). The REDI trial showed the 6-month efficacy of continued treatment with 500mg and 200mg compared to 1000mg, though formal non-inferiority could not be established (2).

Objectives: To assess the long-term effects of ultra-low dose RTX (1x500mg and 1x200mg) in RA patients previously responding well to conventional low dose RTX (1x1000mg).


REFERENCES:
**Methods:** Patients from the REDO trial were invited to participate in this study. Treatment decisions were left at the discretion of the rheumatologist and patient. Disease activity (DAS28-CRP), and medication use (b/tsDMARD, csDMARD, glucocorticoids [GC]) were collected from start of the trial to censoring in April 2021. The primary outcome was disease activity, secondary outcomes were RTX persistence, RTX doses and intervals, and use of comedication. Disease activity was analyzed using a longitudinal mixed model with random intercepts to account for intra-patient correlations, in two ways: 1. By original randomization and stratification factors (RF/ACPA and csDMARD use), 2. By time-varying total RTX dose received in the year preceding each disease activity measurement, adjusted for current csDMARD or GC use, and RF/ACPA. The original DAS28-CRP non-inferiority (NI) margin of 0.6 was used.

**Results:** 118 out of 142 REDO patients were included in current analyses (Table 1) Reasons for exclusion were: continuing treatment elsewhere (n=3), no informed consent (n=8) and data yet to be collected in 2 study centers (n=12). Mean follow up was 3.2 years (total of 377 patient-years), with 7 patients switching to another b/tsDMARD (Figure 1) upon which they were censored from disease activity analyses.

**Table 1. Patient characteristics by original randomization**

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Disease duration (years)</th>
<th>Previous number of b/tsDMARDs used</th>
<th>Duration of rituximab use (years)</th>
<th>Concomitant csDMARD</th>
<th>Previous number of b/tsDMARDs used</th>
<th>Oral GC use at baseline</th>
<th>Baseline DAS28-CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
<td>Median (IQR)</td>
</tr>
<tr>
<td>56 (15)</td>
<td>14 (9-24)</td>
<td>17 (71%)</td>
<td>11 (6-15)</td>
<td>8 (2.2-2.5)</td>
<td>2 (2-2)</td>
<td>3 (1.3)</td>
<td>2.3 (0.9)</td>
</tr>
</tbody>
</table>

**Figure 1. Rituximab treatment persistence during follow up.**

Disease activity in both ultra-low dose groups was non-inferior to the 1000mg group, with a mean DAS28-CRP (95% CI) during follow-up of 2.2 (2.0-2.4) in the 1000mg group, 2.2 (2.1-2.4) in the 500mg group and 2.3 (2.2-2.5) in the 200mg group. Analyzed by received RTX dose, lower RTX dose was significantly associated with a higher DAS28-CRP: 0.15 (95% CI: 0.02-0.28) per patient-year and initiation rate of oral GC was 0.05 (0.03-0.08) per patient-year.

**Conclusion:** A majority of patients treated with ultra-low dose RTX remained on ultra-low doses for up to 4 years, while disease activity remained low and did not relevantly differ between RTX doses, either according to original randomization or by received dose. Switching to other b/tsDMARDs or use of GC was rarely required.

**REFERENCES:**


**Disclosure of Interests:** Nathan den Broeder: None declared, L.M. Verhoef: None declared, Yael A. de Man: None declared, Marc R Kok: None declared, R.M. Thuurings: None declared, W. van der Weele: None declared, Bart van den Bemt Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen and Eli Lilly, Frank van den Hoogen: None declared, Aatke van der Maas: None declared, Allons den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Gilead

**DOI:** 10.1136/annrheumdis-2022-eular.2903

**POS0653 CAN DOSAGE OF INFlixIMAB BE ADJUSTED TO 8 WEEK INTERVALS WITHOUT LOSING EFFICACY IN ARTHRITIS PATIENTS ON MAINTENANCE THERAPY WITH MORE FREQUENT INFUSIONS?**

E. Lindqvist1, B. Månsson1. 1Lund University Department of Clinical Sciences, Lund, Sweden

**Background:** Infliximab is usually given every 8 weeks. To increase dosage, the dose can be increased or the interval between infusions shortened. To minimize patient visits and workload for the medical staff during the Corona pandemic, we intended to change all infliximab infusions to 8 week intervals. For patients with inflammatory bowel disease, a trough level of serum (s-) concentration of infliximab of 3-7 µg/ml is recommended. In Rheumatology the usefulness of assessing s-concentration is controversial. (1, 2)

**Objectives:** To evaluate if 8 week interval infliximab dosage, with retained weekly dose, can be used in arthritis patients, without worsening of disease activity or general health and study if s-concentration of infliximab is related to disease activity and general health.

**Methods:** All arthritis patients on stable infliximab treatment were evaluated at the time for infliximab infusion. Disease activity, DAS28-CRP, VAS pain, global, fatigue, doctors’ global, HAQ, and ASDAS-CRP, BASFI for spondyloarthritis (SpA) patients were registered in the Swedish Rheumatology Quality registry (SRQ). Blood tests for CRP, ESR and s-concentration of infliximab were taken before infusion start. S-concentration was analysed at Karolinska Hospital, Solna, Sweden with an in-house ELISA. Antibodies were assessed if s-concentration was >0.5 µg/ml.

Patients with infusion intervals less than 8 weeks were recommended a switch to 8 week intervals with maintained weekly dose of infliximab. The new dose was given the same day and patients with changed doses were re-evaluated after 24 weeks. Paired samples T-test and Wilcoxon signed rank test for paired data were used for comparison of disease activity and general health after dosage change. Linear regression analyses were used to explore associations between s-concentration, disease activity and general health.

**Results:** Of 91 assessed patients, 66 with shorter intervals were recommended dosage change. The remaining 25 patients had infliximab every 8 weeks and served as controls. For baseline characteristics see Table 1. Dosage was changed in 58 patients and 90% (n=52) remained on 8 week intervals after 24 weeks, with a mean (SD) dose of infliximab of 5.3 (1.9) mg/kg. All assessed disease variables (DAS28-CRP, VAS pain, global, fatigue, Dr global, HAQ, and ASDAS-CRP, BASFI for spondyloarthritis (SpA) patients) remained unchanged (p=0.051 (pain) – 0.83) (Figure 1 A, B) while s-concentration was lower (p<0.001) at follow up. S-concentration of infliximab did not relate to disease activity neither at baseline nor at follow up (p=0.15-0.24). (Figure 1 C, D)

**Table 1. Patient characteristics at inclusion**

<table>
<thead>
<tr>
<th>Interval</th>
<th>Age years</th>
<th>Female sex</th>
<th>Disease duration, years</th>
<th>Clinical diagnosis: RA/JIA+arthritis UNS</th>
<th>SpA/Psa</th>
<th>Concentration infliximab µg/ml</th>
<th>Baseline ceruloplasmin µmol/l</th>
<th>Baseline CRP</th>
<th>BASFI</th>
<th>CRP</th>
<th>ESR</th>
<th>VAS pain</th>
<th>HAQ</th>
<th>ASDAS-CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-7 w, n=66</td>
<td>56 (15)</td>
<td>42 (64%)</td>
<td>20 (12)</td>
<td>14 (21)%/5% (8%)</td>
<td>31 (47%)/26% (24%)</td>
<td>16.6 (6-20)</td>
<td>0.38 (0.25-0.85)</td>
<td>0.38 (0.25-0.85)</td>
<td>0.38 (0.25-0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 w, n=25</td>
<td>58 (14)</td>
<td>41 (59%)</td>
<td>19 (12)</td>
<td>14 (21)%/5% (8%)</td>
<td>35 (51%)/26% (24%)</td>
<td>16.6 (6-20)</td>
<td>0.38 (0.25-0.85)</td>
<td>0.38 (0.25-0.85)</td>
<td>0.38 (0.25-0.85)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** Adjustment of infliximab dosage to every 8 weeks worked for a majority of the arthritis patients in this clinical setting without worsening of
EFFECTIVENESS OF ABATECT IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH RHEUMATOID ARTHRITIS.

R. Redondo Rodríguez1, F. Godoy-Narváez2, F. Morales-Garrido3, M. Rojas-Giménez4, C. M. Romero-Barco5, N. Mena-Vázquez1. Universidad de Málaga (HRUM), Málaga, Spain; Biomédica de Málaga (IBIMA), UGC de Reumatología, Hospital Regional de Málaga (HRUM), Málaga, Spain; Hospital Universitario de Jaén, UGC de Reumatología, Jaén, Spain; Hospital Universitario Clínico San Cecilio, UGC de Reumatología, Granada, Spain; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), UGC de Reumatología, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain; Hospital Clínico Universitario Virgen de la Victoria, UGC de Reumatología, Málaga, Spain

Background: Interstitial Lung Disease (ILD) is the most common lung involvement in rheumatoid arthritis (RA) and leads to increased morbidity and mortality. Some retrospective observational studies suggest that abatacept (ABT) could be effective and safe, although there are no clinical trials and prospectively collected data on ABT.

Objectives: To evaluate prospective the effectiveness and safety of ABT in patients with ILD associated RA (ILD-RA).

Methods: Design and Protocol: We performed a multicenter, prospective, observational study of patients with interstitial lung disease secondary to rheumatoid arthritis (ILD-RA) receiving ABT between 2015 and 2021. The patients were assessed using high-resolution computed tomography and lung function tests at the beginning of treatment (V0), at 12 months (V12), and at the end of follow-up in 2021 (Vf). The study was approved by the Ethics Committee (Code 1719-N-15).

Main variable: effectiveness of ABT according to evolution of ILD at the end of follow-up: (1) improvement (ie improvement of FVC ≥10% or DLCO ≥15% and no radiological progression), (2) no progression (stabilization or improvement in FVC ≤10% or DLCO <15% and no radiological progression), (3) progression (worsening of FVC >10% or DLCO >15% and radiological progression) or (4) death.

Other variables: clinical and analytical characteristics, treatments and safety (infections, hospitalization and mortality).

Statistical analysis: Cox regression analysis to identify factors associated with worsening of ILD-RA treated with ABT.

Results: Thirty-eight ILD-RA patients started ABT treatment during prospective follow-up. A total of 22/38 (57.9%) were men and the mean (SD) age was 61.9 (9.1) years. The mean (SD) evolution of ILD was 43.9 (30.0) months and the median (IQR) time with ABT was 17.0 (12.1-34.8) months. The baseline clinical-epidemiological characteristics and pulmonary progression of the patients are shown in Table 1. At the end of follow-up (fV) 28/38 (73.6%) had improvement/stabilization among the patients who were in combination with methotrexate compared to those who were in monotherapy (83.3% vs 39.1%; p=0.046). The baseline variables that were independently associated with progression-mortality of ILD-RA in fV were: baseline FVC [OR [95% CI], 0.895 [0.805-0.996]; p=0.042] and duration of ILD-RA [OR [95% CI], 1.204 [1.148-2.112; p=0.046]]. Two patients discontinued ABT during follow-up due to insufficient joint and pulmonary response.

Conclusion: More than half of the patients with ILD-RA treated with ABT manage to stabilize or improve their lung disease after a median follow-up of 17 months. Patients who worsen or die have lower baseline FVC values and ILD-RA with a longer evolution time.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3166

Table 1. Characteristics of patients with ILD-RA treated with Abatect.

<table>
<thead>
<tr>
<th>Variable</th>
<th>ILD-RA n=38</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline clinical-epidemiological characteristics</td>
<td></td>
</tr>
<tr>
<td>Sex, man, n (%)</td>
<td>22 (57.9)</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>66.1 (9.1)</td>
</tr>
<tr>
<td>Race, caucasian, n (%)</td>
<td>38 (100.0)</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
</tr>
<tr>
<td>No smoker, n (%)</td>
<td>23 (60.5)</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>15 (39.5)</td>
</tr>
<tr>
<td>Time of evolution RA, months, median (IQR)</td>
<td>139.1 [68.1-218.7]</td>
</tr>
<tr>
<td>RF, n (%)</td>
<td>36 (94.7)</td>
</tr>
<tr>
<td>Anti-CCP, n (%)</td>
<td>32 (84.2)</td>
</tr>
<tr>
<td>AANA, n (%)</td>
<td>8 (22.9)</td>
</tr>
<tr>
<td>Radiological pattern</td>
<td></td>
</tr>
<tr>
<td>UPI, n (%)</td>
<td>26 (68.0)</td>
</tr>
<tr>
<td>NSIP, n (%)</td>
<td>12 (32.0)</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
</tr>
<tr>
<td>DMARDs, n (%)</td>
<td>33 (86.8)</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>19 (50.0)</td>
</tr>
<tr>
<td>Leflunomide n (%)</td>
<td>11 (22.9)</td>
</tr>
<tr>
<td>Sulfasalazine, n (%)</td>
<td>2 (5.3)</td>
</tr>
<tr>
<td>Hydroxychloroquine, n (%)</td>
<td>6 (15.7)</td>
</tr>
<tr>
<td>Immunosuppressants, n (%)</td>
<td></td>
</tr>
<tr>
<td>Antifibrotic, n (%)</td>
<td>1 (2.6)</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>32 (84.2)</td>
</tr>
<tr>
<td>Corticosteroids, median (IQR)</td>
<td>5.0 (2.5-10.0)</td>
</tr>
<tr>
<td>Pulmonary progression (fV)</td>
<td></td>
</tr>
<tr>
<td>Improvement-Stabilization, n (%)</td>
<td>22 (73.6)</td>
</tr>
<tr>
<td>Progression-Mortality, n (%)</td>
<td>10 (26.4)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3166
Background: Advances in rheumatology and new therapeutic options have certainly impacted patient survival, changing the age range, from youth to seniors. The differences between the age groups could influence the evolution of the disease and the adverse events (AEs) related to the treatments. There are few real-world data on the safety and efficacy of treatments in different age groups.

Objectives: To evaluate the frequency of AEs and the survival of treatments according to the age in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

Methods: Retrospective, observational, multicenter study of real-life data of patients included in the BIOBADASAR 3.0 registry; exposed and not exposed to original biological treatments (b-DMARDs), biosimilars, targeted synthetic drugs (ts-DMARDs). The unexposed group received treatment with conventional disease-modifying drugs (cDMARDs). A Kaplan-Meier and Log Rank Test analysis was performed to study AEs-free survival and treatment in different age groups (young people <25; young adults 25-34; mature adults 34-65; old adults >65). Factors related to treatment survival were evaluated using Cox regression models.

Results: 5,297 patients were included, 80.3% female, mean age 43.7 years (SD 15.6) and median disease progression 14.3 [IQR: 11.5]. RA 4658 (87.9%); PsA 490 (9.25%) and EA 149 (2.8%). The main reason for treatment discontinuation was ineffectiveness, in 624 patients in the exposed group and in 53 (2.5%) patients in control group, followed by the presence of AEs in 352 (11.2%) and 63 (3.9%), respectively (p = 0.001). A mean Charlson Score of 0.298 (SD 0.6) in the exposed group and 0.306 (SD 0.7) in the control group (p = 0.095). Median EAS-free survival in the exposed group was 12.5 years [IQR 16.6] while in controls was 28 years [IQR 11]. p < 0.0001. Median AEs-free survival was 12 years (IQR 11) in young people, 11.5 years [IQR: 4.9] in young adults, 10 years [IQR: 3.25] in mature adults and 76 years [IQR: 6] in old adults with a difference statistically significant (p = 0.017). The exposed group presented a median treatment survival in years of 11.25 years [IQR: 10] in young people; 12.5 years [IQR: 4.7] in young adults, 75 years [IQR: 12.1] in mature adults and 4.5 years [IQR: 1.14] in old adults (p = 0.0001). Considering only the first line of treatment, a median survival of 11.5 years [IQR: 10] was evidenced in the age group <25; 12 years [IQR: 2] between 25-34 years old, 10 years [IQR: 12] in the group between 34-85 years old and 5.5 years [IQR: 1.4] in the group > 65 years old (p = 0.004). (Figure 1). Considering the second line of treatment, the differences between the groups were not statistically significant (p = 0.57). In the multivariate regression model for patients with RA, the factors with the greatest impact on treatment survival were female sex (HR 1.3, 95% CI 1.2-1.4), old age (HR 1.01, 95% CI 1.008-1.01), treatment with steroids (HR 1.19, 95% CI 1.11-1.12) and longer disease duration (HR 1.01, 95% CI 1.01 – 1.02).

Conclusion: In the present study we were able to demonstrate a greater occurrence of AEs in old adults and mature adults compared to young people and young adults. Conversely, survival for b-DMARDs and ts-DMARDs were greater in young and young adults. In patients with RA, female sex, corticosteroid therapy, old aged and longer disease duration were associated with treatment discontinuation.

REFERENCES:
[1] Souto A, et al. Rate of discontinuation and drug survival of biologic therapies in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased risk of adverse outcomes in patients with RA on biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b- or tsDMARDs) remains unknown.

Objectives: To evaluate the association between frailty and adverse outcomes in patients with RA exposed to b- or tsDMARDs.

Methods: Using the IBMWatson MarketScan Commercial Claims and Encounters Databases, we identified all patients with RA who filled new prescriptions (or received infusions) for TNFi antagonists (TNFi), non-TNFi biologics (rituximab, abatacept, tocilizumab) or Janssen Kinase inhibitors (JAKi) between 2008-2019. We used a 1-year lookback period without the use of these drugs to identify new users. The date of the first prescription within these three drug categories was the index date. Patients’ frailty risk score was calculated using the Claims-Based Frailty Index (CFI) [2], which estimates a deficit-accumulation frailty index using International Classification of Diseases codes, Current procedural Terminology codes, and Healthcare Common Procedure Coding System codes in administrative claims data in the 1-year baseline period. The index ranges from 0 (not at all frail) to 1 (severely frail). The primary outcome was time to serious infections (those requiring hospitalization); secondary outcomes: any infection (outpatient or inpatient encounters) and all-cause hospitalizations. Patients were followed until 1) outcome occurrence; 2) disenrollment; 3) >90 days elapsed (or >180 days for rituximab) without further fills of the first drug categories; 4) they filled/received infusions of b- or tsDMARDs from a different drug category; or 5) 2 years after index. Cox proportional hazards adjusting for demographics, calendar year, serious and/or opportunistic infections in the 12-months prior to index were used to estimate the adjusted hazard ratios (aHR) and 95% confidence intervals (CIs) for each outcome. In separate model, we additionally adjusted for comorbidity burden, and health care utilization (HCU).

Results: A total of 62,246 patients with RA met our inclusion criteria of whom 50,910 (82%) started TNFi as their first biologic, 9252 (15%) non-TNFi biologics, and 1811 (3%) JAKi. Among these, 3928 (6%) were considered frail. In multivariable analyses, frail patients had higher risk of serious infections compared to non-frail patients (aHR 2.37, 95% CI 2.05-2.74) which decreased to aHR 1.34, 95% CI 1.13-1.58 (Table 1) after adjusting for comorbidity burden and the HCU. Similarly, frailty was associated with increased of any infection (aHR 1.18, 95% CI 1.11-1.25), and all-cause hospitalizations (aHR 1.34, 95% CI 1.21-1.46) relative to non-frail individuals.

Table 1. Multivariable models evaluating the association between frailty status and inpatient infections as the outcome

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frail</td>
<td>2.37 (2.05, 2.74)</td>
</tr>
<tr>
<td>Model</td>
<td>1.34 (1.13, 1.58)</td>
</tr>
</tbody>
</table>

Conclusion: Frailty is an important predictor for the risk of adverse outcomes among patients with RA treated with b- or tsDMARDs. Our findings underscore the need for considering this parameter in patient evaluation (even among younger patients) in the clinic.

REFERENCES:

Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared


PO6056

SURVIVAL OF BARICITINIB VS ANTI-TNF AS THE FIRST BIOLOGICAL DRUG IN PATIENTS WITH RHEUMATOID ARTHRITIS, IN CLINICAL PRACTICE: RESULTS OF A LOCAL REGISTRY

J. Rosés1, A. Pons1, X. Barber2, J. M. Senabre-Gallego3, G. Santos Soler3, E. Soler-Giner4, J. A. Bernalló5, A. Raga6, C. Raya-Santos1, J. C. Cortés-Quiroz1, M. Lorente Betoret7, J. A. García-Gómez8 on behalf of AIRE-MB.

Background: Recently, it has been recognized that frailty and pre-frailty are common in patients with rheumatoid arthritis (RA) [1]. Whether frailty status portends an increased risk of adverse outcomes in patients with RA on biologic or targeted synthetic disease-modifying anti-rheumatic drugs (b- or tsDMARDs) remains unknown.

Objectives: To evaluate the association between frailty and adverse outcomes in patients with RA exposed to b- or tsDMARDs.

Methods: Retrospective study of patients with RA, treated with the first BIO-1, with BARI or TNFI, from September 2017 to December 2021. General data (current age, at diagnosis of RA and at the start of BIO-1) were collected; RA: evolution time, RF, ACPA; type of BIO-1: dose received, time in treatment, reason for withdrawal. Univariate analysis of drug survival was performed using Kaplan-Meier curves and the Long Rank test to differentiate by groups. For the multivariable study, Cox regression with proportional hazards.

Results: The study includes 96 patients with RA, who have started treatment for > 1 month with BIO-1: BARI (n: 63/66% patients) or TNFI (33/34% patients): women: 82 (96%), current mean age (SD): 62 (1) years, at diagnosis: 51 (1) years, at the start of BIO-1: 59 (1) years. 36 (37%) patients are ≥65 years old, the mean time
In ARI is 76 years and the time in BIO-1: 1.34 (2.2) years. BIO-1 was withdrawn in 34 (40%) patients: inefficacy: 17 (18%) patients, Complications: 14 (15%) Cardiovascular/thrombosis: 2 (2%), rash: 2 (2%), infection-neoplasia-immunogenicity: 1 (1%) patient in each, loss to follow-up: 5 (5%) and others: 2 (2%). When comparing the BARI vs. TNFI group, no differences were detected between the general data, the percentage of patients >65 years of age, or the mean time in treatment or the reasons for drug withdrawal (Table 1). However, survival in the BARI group was significantly superior to TNFI throughout the period (p=0.04; HR: 0.47, 95% CI: 0.24-0.91, p=0.026) (Figure 1A).

Table 1. Characteristics of patients who receive Baricitinib (BARI) or anti-TNF as first BIO-1 (TNFI).

<table>
<thead>
<tr>
<th></th>
<th>All</th>
<th>BARI</th>
<th>TNFI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>82</td>
<td>65</td>
<td>17</td>
</tr>
<tr>
<td>Current age, mean (SD)</td>
<td>62 (4.2)</td>
<td>63 (6.1)</td>
<td>59 (11)</td>
</tr>
<tr>
<td>Age at diagnosis RA, mean (SD)</td>
<td>51 (4.9)</td>
<td>52.5 (7.8)</td>
<td>48.6 (15.5)</td>
</tr>
<tr>
<td>Age at start of BIO-1, mean (SD)</td>
<td>59 (2.1)</td>
<td>60 (4.9)</td>
<td>55.9 (9.5)</td>
</tr>
<tr>
<td>≥65 years, n (%)</td>
<td>36 (37)</td>
<td>27 (43)</td>
<td>9 (27)</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
<td>77 (80)</td>
<td>54 (86)</td>
<td>23 (70)</td>
</tr>
<tr>
<td>ACPA positive, n (%)</td>
<td>74 (77)</td>
<td>50 (79)</td>
<td>24 (73)</td>
</tr>
<tr>
<td>Average time in BIO-1, years (DE)</td>
<td>1.34 (2.2)</td>
<td>1.85 (0.5)</td>
<td>1.32 (2.4)</td>
</tr>
<tr>
<td>BARI 2 mg, n (%)</td>
<td>-</td>
<td>23</td>
<td>-</td>
</tr>
<tr>
<td>Withdrawal of BIO-1, n (%)</td>
<td>38 (40)</td>
<td>20 (32)</td>
<td>18 (55)</td>
</tr>
<tr>
<td>-Concomitance</td>
<td>14 (16)</td>
<td>7 (13)</td>
<td>7 (21)</td>
</tr>
<tr>
<td>-Loss of efficacy</td>
<td>17 (18)</td>
<td>8 (13)</td>
<td>9 (27)</td>
</tr>
<tr>
<td>-Loss of follow up</td>
<td>5 (5)</td>
<td>5 (8)</td>
<td>-</td>
</tr>
<tr>
<td>-Other</td>
<td>2 (2)</td>
<td>-</td>
<td>2 (6)</td>
</tr>
</tbody>
</table>

Figure 1. Survival probability in patients with rheumatoid arthritis who receive the first BIO-1. A. Between TNFI drug vs Baricitinib. B. Between TNFI vs Baricitinib 2 mg or 4 mg.

In patients <65 years, the greatest survival of BARI is maintained (p=0.05), being significant in the first 24 months of treatment (p=0.02). In patients ≥65 years, significance was not reached throughout the overall period (p=0.5) and in the first 24 months of treatment (p=0.06). When comparing the BARI 2 mg (n: 23/36%) and 4 mg (n: 40/64%) groups, the 2 mg group is significantly older at RA diagnosis (73 [SD: 2] years vs 56 [SD: 3] years; p=0.0001) and at the start of BIO-1 (72 [SD: 14] years vs 54 [SD: 2.8] years; p=0.0001). However, survival in the BARI 2 mg group was significantly higher in the first 24 months (p=0.003) (Figure 1B): BARI 2 mg HR: 0.14, 95% CI; 0.04-0.56, p=0.005, HR BARI 4 mg: 0.44 (95% CI; 0.20-0.96, p=0.038).

Conclusion: Survival of BARI is superior to TNFI during the first 4 years of treatment, especially during the first 24 months of treatment. There are no differences between the cause that causes drug withdrawal. 3. The use of the 2 mg dose of BARI predominates in patients older than 65 years, with survival being greater than TNFI, especially in the first 24 months of treatment.

Acknowledgements: The study was supported by a research grant from the Marin Baixa Association for Research in Rheumatology (AIRE-MB).

Disclosure of Interests: None declared


TUMOR NECROSIS FACTOR BLOCKERS INDUCED SARCOIDOSIS: DESCRIPTION OF 31 CASES FROM THE FRENCH PHARMACOVIGILANCE DATABASE

M. Trenec1, B. Chemetren2, N. M. Silva3, C. Dolladilite4, J. Alexandre5, A. Dumont1, A. Nguyen1, H. De Boysson1, A. Aubad1, S. Deshayes1. 1University of Caen Normandie Hospital Center, Internal Medicine, Caen, France; 2University of Caen Normandie Hospital Center, Pharmacology, Caen, France

Background: Development of Tumor Necrosis Factor blockers (TNFBs) whose drug class has several mechanistic and pharmacologic sub-classes, have improved the management of autoimmune and inflammatory diseases, including sarcoidosis. With their increasing use, paradoxical reactions are described and one of the most frequent is sarcoidosis. However, the description of TNFb-induced sarcoidosis (TIS) remains poor, because reported in few and only short case-series.

Objectives: We aimed to better describe the clinical spectrum of TIS, and the differential involvement of TNFb sub-classes.

Methods: French pharmacovigilance database was used to collect data on TIS, excluding patients with previous idiosyncatic sarcoidosis. Statistical analyses were performed using the Mann-Whitney test for quantitative data and Fisher test for qualitative data. A p value < 0.05 was considered statistically significant.

Results: Data were obtained from 2002 to 2019 for infliximab, adalimumab, golimumab, certolizumab and etanercept. Thirty-one TIS patients were collected from the database, including 12 women (38%). In most cases, TNFb was introduced for ankylosing spondylitis (58%), psoriasis (19.3%) or rheumatoid arthritis (16.1%). Median age at TIS occurrence was 54 [43.5; 61.5] years, with a median time to onset of 24 [6.0; 72.0] months. The most frequent involved TNFb was etanercept (n=21, 67.8%). The two main clinical TIS manifestations were lymph node (n=27, 87.1%) and lung involvement (n=16, 51.6%). The culprit drug was discontinued in 26 (84%) patients, and a double-barreled inflammatory gun to control both initial and induced disorders was proposed in 19 of them (90.5 %), mostly glucocorticoids (n=13, 68.4%) alone or combined with methotrexate (n=3, 15.8%). Among the 14 patients with the available data, the TIS had completely resolved in 11 (78.6%); for all these lasts, the TNFb was discontinued. No significant differences were observed between the TNFb sub-classes of monoclonal antibodies or fusion proteins, regarding clinical presentation, median time to onset or outcome.

Conclusion: This second largest case-series shows that TIS are mostly encountered with etanercept, but without any difference in clinical or prognostic implications with the other TNFb-subclasses.

REFERENCES:

clustered in 9 groups, taking the next features in to account (Figure 1); the presence or absence of ADA, the height of ADA titers (higher or lower than 100AU/mL), emergent (early vs. late; cutoff week 28) and its persistence. Based on these features 397 (77%) patients were assigned to one of the groups. Due to missing data at crucial time points the remainder of patients were excluded. In the ‘High early’ and ‘High early LTF’ group was the rate of MTX use (adjusted odds ratio (AOR) 0.033 [95%CI 0.01-0.09] P<0.0001 respectively 0.79 [95%CI 0.03-0.22] P<0.0001), adalimumab concentration above Smg/mL (AOR 0.022 [95%CI 0.0-1.08] P<0.001 respectively 0.026 [95%CI 0.01-0.08] P<0.001 and low disease activity (DAS28 <3.2) at week 52 (AOR 0.191[95%CI 0.07-0.52] P<0.002 respectively 0.102 [95%CI 0.03-0.31] P<0.001) significantly lower, compared to the negative group. Furthermore, the failure rate was in both groups significantly higher (AOR 9.19 [95%CI 3.7-22.87] P<0.0001 respectively 23.94 [95%CI 8.1-70.53] P<0.0001). In contrast to forgoing studies, our data does not show any differences in clinical outcomes between groups with persistent and transient ADA response.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Total N=511</th>
<th>Follow-up</th>
<th>Demographics</th>
<th>Age mean SD</th>
<th>Female No (%)</th>
<th>Disease status</th>
<th>Disease duration median (IQR)</th>
<th>IgM rheumatoid factor + (%)</th>
<th>DAS28-score mean SD</th>
<th>Anti-citrullinated protein antibody + (%)</th>
<th>Erosive (%)</th>
<th>Methotrexate use no (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>78 (20-104)</td>
<td>53.7 ± 12.5</td>
<td>409 (79.8)</td>
<td>63 (23.2)</td>
<td>6 (7.3)</td>
<td>296 (16.6)</td>
<td>315 (73.2)</td>
<td>4.5 ± 1.6</td>
<td>378 (73)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: The majority of patients have an immune response to ADL. Based on ADA concentration, time point of emergence and its persistence, certain patterns of ADA response can be distinguished. Only high ADA concentration at early time points, causing low ADL concentration, are associated with unfavorable clinical effects. All the remaining distinctive patterns do not have any association with clinical outcomes. This suggests a regulated immune response in the majority of patients.

REFERENCES:

Disclosure of Interests: Sadaf Atiqi; None declared, Maureen Leeuw; None declared, Femke Holijah Berg; None declared, Laura Boekel; None declared, Floris Loeff; None declared, Karin Bloem; None declared, Charlotte Kriekskaert; None declared, Annick de Vries; None declared, Michael Nurmohamed
1.18, 95% CI 1.05-1.34) were associated with a higher risk of AE in exposed patients. Treatment survival was 15 years [IQR: 28] in unexposed group vs 4.7 years [IQR: 10] in exposed patients (p<0.0001). In the multivariate analysis, female sex (HR 1.15, 95% CI 1.05-1.26), older age (HR 1.0, 95% CI: 1.01-1.014), corticosteroid treatment (HR 1.16, 95% CI 1.09-1.2), the diagnosis of rheumatoid arthritis (HR 0.83 CI95% 0.75-0.93) was associated with a lower risk of suspension.

Conclusion: We found that the use of steroids and elderly patients are still being associated with a higher risk of presenting an AE and treatment discontinuing. This could be related to the fact that the use of steroids is frequently associated with active disease or severe conditions. Exposed patients have a lower AE-free survival and a lower treatment survival. This could be since unexposed patients have a longer follow-up time and a longer duration of their disease. This data from real-world Latin American patients of ten years of follow-up are extremely useful for monitoring and pharmacovigilance of biological therapies in patients with rheumatic diseases.

REFERENCES:

Disclosure of Interests: None declared


POS0661

MAJOR COST SAVINGS ASSOCIATED WITH BIOLOGIC DOSE REDUCTION IN PATIENTS WITH INFLAMMATORY ARTHRITIS

A. Behram1, S. Tariq1, J. Kumar1, L. Martin1, C. Bannon1, T. Duffy1, E. Murphy1, J. Stack1, M. Barry1, C. L. Murphy1,1 Connolly Hospital Blanchardstown, Rheumatology, Dublin, Ireland; 2 Mater Hospital, Rheumatology, Dublin, Ireland

Background: Anti-TNF drugs have dramatically improved the management of inflammatory arthritis (IA). Although the introduction of biosimilars has reduced the cost, chronic use of biologic agents has a high impact on healthcare expenditure. This study evaluated the cost effectiveness of a dose reduction strategy for the most commonly used anti-TNF drugs over a period of 10 years in patients with IA in remission.

Objectives: The purpose of this study was to explore whether patients with Inflammatory Arthritis (IA) (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS)) would remain in remission after 10 year period, following a reduction in biologic dosing frequency and to calculate the cost savings associated with dose reduction.

Methods: This prospective, non-blinded, non-randomised study was commenced in 2010. Patients with IA, Rheumatoid arthritis (RA),ankylosing spondylitis (AS), Psoriatic arthritis (PsA) who were in remission as defined by disease activity indices (DAS28<2.6, BASDAI<4), and were offered Anti TNF dose reduction. Patients on etanercept were reduced from 50mg weekly to fortnightly, adalimumab 40mg once monthly instead of fortnightly. Patients were assessed for disease activity at 1, 4 and 10 years following reduction in dosing frequency.

Cost saving was calculated by deducting the total annual cost of the biologic agent used over 10 years compared with the cost if the dosing interval had not changed.

Results: Seventy nine patients with inflammatory arthritis in remission were recruited. 57% had rheumatoid arthritis (n=45), 13% psoriatic arthritis (n=10) and 30% ankylosing spondylitis (n=24). 57% (n=45) were taking etanercept and 43% (n=34) adalimumab. The percentage of patients who maintained dose reduction at 10 years was 9% (n=7). Of the total 48 patients who were successfully dose reduced at year 1 (n=42), (69%, n=29) were able to maintain the dose reduction up to 4 years and 9% (n=7) maintained this dose reduction up to year 10. The estimated cost saving was €4,928 per patient per year. Estimated cost savings for 7 patients on reduced dose was €344,952.88 over 10 years.

Conclusion: Anti TNF dose reduction strategy in patients with IA results in substantial cost savings. Implementation of a dose reduction strategy while monitoring of disease activity reduces the financial impact of the use of biologic therapies. Further studies should be done to identify which patients are more likely to remain in remission while on dose reduction.

REFERENCES:

Disclosure of Interests: None declared


POS0662

BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS

A. L. Fedele1, F. Melpignano1, D. Bruno1, R. La Ferrara1, M. A. D’agostino1, Division of Rheumatology-Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgiche, Rome, Italy

Background: According to 2019 updated EULAR recommendations, therapy of Early Rheumatoid Arthritis (ERA) with biological disease-modifying antirheumatic drugs (bDMARDs) is advised in presence of poor prognostic factors, persistently moderate/high disease activity, high acute phase reactants, high swollen joint count, autoantibody positivity, presence of early erosions, failure of two/more conventional synthetic DMARD.

Objectives: To evaluate over time prevalence of bDMARD therapy and factors associated to rapid initiation in our Early Arthritis Cohort (EAC), comparing two different periods: from 2004 to 2012 and from 2012 to 2020. The last two years were not considered because of the adverse influence of COVID19 pandemic on early access to EAC and on timely scheduled visits.

Methods: A total of 281 ERA patients with less than 12 months of disease duration (53.9 years mean age, 75% female, 77% seropositive), followed according to the treat-to-target (T2T) strategy, were enrolled in the study. At baseline, and every three months, the ACR/EULAR core data set variables were recorded. At baseline and every year, hand and foot radiographs were examined according to modified Total Sharp score (mTSS). At each visit, clinical improvement and remission were evaluated according to EULAR criteria. The achievement of Comprehensive Disease Control (CDC) (28-joint Disease Activity Score using C reactive protein <2.6, Health Assessment Questionnaire <0.5 and change from baseline in mTSS ≤0.5) was assessed every year.

Results: We examined 164 patients from 2004 to 2012 and 117 subjects from 2012 to 2020. In the first group 72 patients (43.9%) initiated bDMARDs during the 8-year FU, with a mean delay of 41.8 months. In the second group 37 patients (31.6%) started biotechnological drugs over time, with a mean delay of 50.4 months.

Analyzing the period from 2004 to 2012, ERA patients starting bDMARDs were younger (p=0.04), in higher percentage ACPA positive (81.1%) and reached to a lesser extent CDC at 12months of FU (26.1%) compared to patients that didn’t initiate bDMARDs (60.9% ACPA positive, p=0.01; 63% achieving CDC, p=0.001, respectively).

Examining the period from 2012 to 2020, bDMARD-treated ERA patients were younger (p=0.06), in higher percentage AC(81.1%) and erosive at baseline (35.1%) compared to patients that didn’t initiate bDMARDs (64% ACPA positive, p=0.02; 17.5% erosive, p=0.04, respectively). As previously, patients in bDMARD reached to a lesser extent CDC at 12 month of FU (35.1%) compared to subjects not undergoing to biological therapy (55% achieving CDC, p=0.05). On multivariate analysis, AC positive was associated with initiation of bDMARD in both patient groups (p=0.02), whereas older age at onset and reaching CDC at 12 month were inversely associated (p=0.001; p<0.0001, respectively).

Conclusion: Despite the widest choice of bDMARDs currently available in the last 8 years, we did not observe an increase in the prescription of these drugs from 2012 to 2020. As in other ERA cohorts, bDMARD initiation is associated to poor prognostic factors, in particular AC positivity, presence of erosions at baseline and not achieving CDC at 12 months of FU. In the last 8 years, the decreased influence of disease duration at onset and of BMI could be a consequence of the improvement in strategies of early referral and control of modifiable risk factors.

Disclosure of Interests: None declared

Rheumatoid arthritis - non biologic treatment and small molecules

POSO663
THE USE OF EXPOSURE-ADJUSTED EVENT RATES VERSUS EXPOSURE-ADJUSTED INCIDENCE RATES IN ADVERSE EVENT REPORTING: INSIGHTS FROM FILGOTINIB INTEGRATED SAFETY DATA IN RHEUMATOID ARTHRITIS


Background: Reporting of treatment-emergent adverse events (TEAEs) in rheumatoid arthritis (RA) clinical trials can be summarized as exposure-adjusted incidence rates (EAIRs) or exposure-adjusted event rates (EAERs). Censored EAIR (EAIRc), weighing exposure up to a patient’s first event, is commonly reported; the three methods account for different exposures and/or multiple events, which can impact the outcome evaluation. Studies of filgotinib (FIL) in RA report safety data as EAIR/100 patient-years of exposure (PYE) for TEAEs, which is uncensored.

Objectives: To describe the outcome of long-term FIL integrated safety data in RA by applying different statistical methodologies: EAER, EAIRc and EAIR. Predefined adverse events of special interest (AESI) included serious infections (any), herpes zoster (HZ), major adverse cardiac events (MACE), malignancies (excluding nonmelanoma skin cancer [NMSC]), NMSC and venous thromboembolism (VTE). The number of patients with an event, number of events, EAER, EAIRc and EAIR were summarized. The data extraction date was January 2021 for the DARWIN 3 (NCT02085700) long-term extension (LTE) and November 2020 for the FINCH 4 (NCT03203508) LTE.

Results: In total, 3691 patients received ≥1 FIL dose for 8085 PYE. In this population, 176 serious infections were reported in 137 patients, 125 HZ events were randomised, blinded, to FIL200 + MTX, FIL100 + MTX, FIL200 alone, or FIL100 alone. At W24, the mTSS CFB in pts with BL yearly progression ≥5 or <5 was 0.84 and 0.22 in MTX-IR pts taking PBO + MTX, and 0.67 and 0.25 in MTX-naive pts taking PBO + MTX. At W52, the mTSS CFB in pts with BL yearly progression ≥5 or <5 was 0.67 and 0.22 in MTX-naive pts taking PBO + MTX. At W24, the mTSS CFB in pts with BL yearly progression ≥5 or <5 was 0.67 and 0.25 in MTX-naive pts taking PBO + MTX.

Table 1. Exposure-adjusted event and incidence rates for AESI

<table>
<thead>
<tr>
<th>Event Type</th>
<th>FIL200</th>
<th>FIL100</th>
<th>FIL combined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients/PYE</td>
<td>2627/5302.5</td>
<td>1647/2782.6</td>
<td>3691/8085.1</td>
</tr>
<tr>
<td>Serious infections</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.4 (0.3, 0.6)</td>
<td>0.3 (0.2, 0.5)</td>
</tr>
<tr>
<td>HZ</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.2 (0.1, 0.4)</td>
<td>0.2 (0.1, 0.4)</td>
</tr>
<tr>
<td>MACE</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
</tr>
<tr>
<td>VTE</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.4 (0.3, 0.6)</td>
<td>0.3 (0.2, 0.5)</td>
</tr>
<tr>
<td>Malignancies excluding NMSC</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
</tr>
<tr>
<td>NMSC</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
<td>0.3 (0.2, 0.5)</td>
</tr>
</tbody>
</table>

Data are rate (95% CI) unless otherwise stated.

Conclusion: These data confirm that using different methods to analyze FIL safety data (EAER, EAIRc, EAIR) does not result in different safety outcomes, reinforcing the previously reported FIL safety profile in patients with RA. As the AESI reported in the long-term safety database with FIL are rare, patients commonly have long exposure times before experiencing an event, which are often associated with end of treatment. As such, EAIRc, EAIR and EAIR are similar.

References:

Acknowledgements: This study was co-funded by Galapagos NV (Mechelen, Belgium) and Gilead Sciences, Inc. (Foster City, CA, USA). Medical writing support was provided by Iain Haslam, PhD (Aspire Scientific Ltd, Bollington, UK), and funded by Galapagos NV.

Disclosure of Interests: Patrick Durez Speakers bureau: AbbVie, Galapagos, and Lilly, Eugen Feist Speakers bureau: AbbVie; Galapagos, Lilly, Novartis, Pfizer, Roche, and Sobi, Consultant: of AbbVie; Galapagos, Lilly, Novartis, Pfizer, Roche, and Sobi, Grant/research support from: Lilly, Pfizer, and Roche, Ricardo Blanco Speakers bureau: AbbVie, Amgen, Bristol-Myers, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and Sobi, Consultant: of Astra-Zeneca, Galapagos, Janssen, Novartis, and Pfizer, Grant/research support from: AbbVie and Roche, Vijay Rajendran Employee of: Galapagos, Nadia Verbruggen Employee of: Galapagos, Katrien Van Beneden Shareholder of: Galapagos, Employee of: Galapagos, James Galloway Speakers bureau: AbbVie, Biogen, Galapagos, Janssen, Lilly, Novartis, Pfizer, Roche, and UCB, Consultant: of AbbVie, Galapagos, Galapagos, Janssen, Lilly, Novartis, and Pfizer, Grant/support research from: Astra-Zeneca, Celgene, Galilead, Janssen, Medicago, Novavax, and Pfizer.


POSO664
RADIOGRAPHIC CHANGE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ESTIMATED BASELINE YEARLY PROGRESSION ≥5 OR <5: POST HOC ANALYSIS OF TWO PHASE 3 TRIALS OF FILGOTINIB

Y. Tanaka1, T. Atsumi2, D. Aletaha3; R. B. M. Landewe4, B. Bartok5, A. Pechonkina6, Z. Yiri7, L. Han8, K. Emoto9, S. Kando10, V. Rajendran11, T. Takeuchi12. University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; 2Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Hokkaido, Japan; 3Medical University of Vienna, Division of Rheumatology, Department of Medicine, Wien, Austria; 4Amsterdam Rheumatology & Clinical Immunology Center (amC) & Zuyderland MC, Clinical Immunology and Rheumatology, Heerlen, Netherlands; 5Galapagos NV, Biostatistics, Foster City, United States of America; 6Gilead Sciences, Inc., Department of Clinical Research, Foster City, United States of America; 7Gilead Sciences, Inc., Biostatistics, Foster City, United States of America; 8Gilead Sciences K.K., Medical Affairs, Tokyo, Japan; 9Galapagos BV Inflammatory Diseases, Mechelen, Belgium; 10Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan.

Background: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice to prevent further rapid radiographic progression (RRP). In FINCH 1 (NCT02886728), filgotinib 200mg (FIL200) vs MTX (FIL100) reduced change in total Sharp score (mTSS) vs placebo (PBO) in pts with RA and inadequate response to MTX (MTX-IR).2 In FINCH 3 (NCT02886728), FIL200 and FIL100 reduced change in mTSS vs MTX monotherapy (MTX mono) in MTX-naive pts.3

Objectives: To evaluate, via post hoc analysis of 2 trials, filgotinib’s effects on radiographic progression vs MTX mono in pts with estimated baseline (BL) yearly progression ≥5 or <5 mTSS units/year.

Methods: The double-blind 52-week (W) FINCH 1 study randomised MTX-IR pts with moderate–severe active RA to FIL200 or FIL100, subcutaneous adalimumab (ADA) 40 mg, or PBO; at W24, PBO pts were randomised blinded to FIL200 vs FIL100; all took stable background MTX1. In FINCH 3, MTX-naive pts were randomised blinded, to Fil200 + MTX, FIL100 + MTX, FIL200 alone, or MTX mono for up to W52.2 This analysis examined subgroups by estimated BL yearly progression (BL mTSS/duration in years of RA diagnosis), based on ≥5 or <5 mTSS units/year,4 a threshold commonly used to define RRP. We assessed effects of filgotinib vs ADA or PBO in mTSS change from BL (CFB) at W24/W52 (using a mixed model for repeatable measurements) and percentages with no W24 progression (mTSS change ≥0.5, ≥0.5, ≤smallest detectable change [SDC], using Fisher’s exact test).

Results: At BL, 558/1755 MTX-IR and 787/1249 MTX-naive pts had BL estimated yearly progression ≥5. Median mTSS in pts with BL yearly progression ≥5 and <5 was 53.25 vs 5.00 respectively in the MTX-IR trial and 6.00 vs 2.50 in the MTX-naive trial. At W24, the mTSS CFB in pts with BL yearly progression ≥5 and <5 was 0.84 and 0.22 in MTX-IR pts taking PBO + MTX, and 0.67 and 0.25 in MTX-naive pts taking PBO. At W52, in pts with BL yearly progression ≥5, FIL200 + MTX reduced mTSS change vs PBO + MTX in the MTX-IR trial and vs MTX mono in the MTX-naive trial (Figure 1). At W24, among pts with estimated BL yearly progression ≥5, FIL200 + MTX increased odds of no
Table 1. Ratio of no radiographic progression at W24

<table>
<thead>
<tr>
<th></th>
<th>FINCH 1: MTX-IR</th>
<th>FIL200 + MTX</th>
<th>FIL100 + MTX</th>
<th>FIL200 mono MTX</th>
<th>ADA + MTX</th>
<th>PBO + MTX</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BL yearly progress</td>
<td>n = 139</td>
<td>n = 267</td>
<td>n = 139</td>
<td>n = 265</td>
<td>n = 91</td>
</tr>
<tr>
<td>% with no progression (≤0.5)</td>
<td>87.7</td>
<td>97.0</td>
<td>88.5</td>
<td>92.5</td>
<td>87.9</td>
<td>93.9</td>
</tr>
<tr>
<td>OR</td>
<td>2.22*</td>
<td>2.97*</td>
<td>2.40*</td>
<td>1.12</td>
<td>t</td>
<td>t</td>
</tr>
<tr>
<td>% with no progression (≤0.5)</td>
<td>80.4</td>
<td>91.8</td>
<td>81.3</td>
<td>88.3</td>
<td>80.2</td>
<td>89.4</td>
</tr>
<tr>
<td>OR</td>
<td>2.00*</td>
<td>1.75</td>
<td>2.11*</td>
<td>1.19</td>
<td>t</td>
<td>t</td>
</tr>
<tr>
<td>% with no progression (≤SDC [1.53])</td>
<td>91.3</td>
<td>96.1</td>
<td>92.1</td>
<td>96.6</td>
<td>92.3</td>
<td>95.6</td>
</tr>
<tr>
<td>OR</td>
<td>2.43*</td>
<td>3.35*</td>
<td>2.70*</td>
<td>1.82</td>
<td>t</td>
<td>t</td>
</tr>
<tr>
<td>FINCH 3: MTX-naïve</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIL200 + MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIL100 + MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIL200 mono MTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% with no progression (≤0.5)</td>
<td>86.9</td>
<td>94.0</td>
<td>83.5</td>
<td>93.7</td>
<td>89.6</td>
<td>95.7</td>
</tr>
<tr>
<td>OR</td>
<td>1.81*</td>
<td>2.17</td>
<td>1.38</td>
<td>2.03</td>
<td>2.34*</td>
<td>1.20</td>
</tr>
<tr>
<td>% with no progression (≤0.5)</td>
<td>78.2</td>
<td>93.6</td>
<td>72.7</td>
<td>84.1</td>
<td>80.0</td>
<td>87.9</td>
</tr>
<tr>
<td>OR</td>
<td>1.75*</td>
<td>1.25</td>
<td>1.26</td>
<td>1.3</td>
<td>1.89*</td>
<td>1.79</td>
</tr>
<tr>
<td>% with no progression (SDC [1.53])</td>
<td>93.7</td>
<td>97.8</td>
<td>91.7</td>
<td>96.8</td>
<td>95.7</td>
<td>96.6</td>
</tr>
<tr>
<td>OR</td>
<td>1.77</td>
<td>2.08</td>
<td>1.33</td>
<td>1.45</td>
<td>2.64</td>
<td>1.33</td>
</tr>
</tbody>
</table>

MTX-IR ORs are FIL vs PBO + MTX; MTX-naïve are FIL vs MTX. *Nominal P<.05. †Not applicable. ADMI, adalimumab; FIL, filgotinib; IR, inadequate response; mTSS, modified total Sharp score; MTX, methotrexate; OR, odds ratio; SDC, smallest detectable change; W, week.

Conclusion: These data suggest filgotinib’s inhibition of radiographic progression is numerically greater than MTX monotherapy in RA pts with high estimated BL yearly progression. In those with a more moderate estimated rate of progression, filgotinib suppressed progression comparably to ADA and/or MTX.

REFERENCES:


POS0665 DEVELOPMENT OF A BIOCHEMICAL TOFACITINIB ADHERENCE ASSAY IN RHEUMATOID ARTHRITIS: THE ORAL ADHERE STUDY

S. Church1, K. Hyrich2, K. Ogungbenro2, R. Unwin1, A. Barton3, J. Buith3,5
1Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Core Technology Facility, Grafton Street, Manchester, United Kingdom; 2Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; 3Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; 4Stoller Biomarker Discovery Centre and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology Medicine and Health, The University of Manchester, CityLabs 1.0 (3rd Floor), Nelson Street, Manchester, United Kingdom; 5NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; 6Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom

Background: Tofacitinib is a potent inhibitor of the JAK1/JAK3 tyrosine kinases effective in the treatment of rheumatoid arthritis (RA). Unlike biologic DMARDs, tofacitinib is administered orally. Oral administration offers a major benefit to patients, removing the risk of injection site reactions and previous research has shown that patients prefer an oral DMARD which may affect patient’s adherence (1). Non-adherence is a health behaviour that results in reduced response and increased healthcare costs but can be challenging to accurately measure. Direct tofacitinib measurement may be an accurate measure of adherence that could, in the future, be used in a clinical setting as part of a behaviour change intervention. Tofacitinib can be measured using High Performance Liquid Chromatography Selected Reaction Monitoring Mass Spectrometry (HPLC-SRM-MS). Previous tofacitinib studies have demonstrated an assay sensitivity of 0.1ng/ml may be sufficient for the detection of adherence following 5mg twice daily administration (2). Objectives: The aim of this study is to develop a HPLC-SRM-MS assay to measure biochemical tofacitinib adherence in patients with RA.

Methods: Human serum for method development was obtained from volunteers recruited to the collection of blood and urine samples from volunteers for the development of analytical methods study (UREC 12346) and the National Repository Study (REC 99/8/84) following informed consent. Samples were spiked with Tofacitinib/Tofacitinib-d3 and subjected to protein precipitation. LC-MS/MS analysis was performed on a TSQ Vantage triple quadrupole mass spectrometer coupled with an Acquity UHPLC system (Thermo Fisher Scientific, USA). Validation of the assay was tested as adapted from European Medicines Agency guidelines on Bioanalytical Validation. Specifically, the lower limit of quantification (LLOQ), carryover, accuracy, linearity, precision, recovery and stability of the assay was determined.

To investigate the ability of the assay to detect adherence, serum samples (n=10) of patients prescribed tofacitinib from the Biologics in Rheumatoid Arthritis (BRAAGS) were analysed (REC reference: 04/Q1403/37). Participants self-reported date and time of tofacitinib ingestion prior to venepuncture. Samples were analysed in triplicate.
Results: The assay demonstrated a tofacitinib LLOQ of 0.1 ng/ml, carryover of sample following injection of a 1000 ng/ml tofacitinib was <1%, linearity of r²=0.998, within run accuracy was between 81-85% at LLOQ and between 91-107% at all other levels. Between run accuracy was within 14.9% at LLOQ and within 0.2-5.5% of the nominal concentration at all other levels. Samples of tofacitinib spiked in whole blood and left at room temperature for seven days were within 0.98-10.25% of serum samples spiked on the day of analysis for all concentrations. To demonstrate the potential of the assay to determine adherence, all 10 BRAGGSS samples revealed tofacitinib levels above 0.1 ng/ml with CV<15% (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Sample ID</th>
<th>Time difference between self-reported tofacitinib ingestion and blood sample (hours)</th>
<th>Mean Tofacitinib CV (ng/ml, n=3) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>7.0</td>
<td>26.43 2.82</td>
</tr>
<tr>
<td>40</td>
<td>2.8</td>
<td>100.55 5.51</td>
</tr>
<tr>
<td>70</td>
<td>3.6</td>
<td>73.23 2.27</td>
</tr>
<tr>
<td>68</td>
<td>1.5</td>
<td>150.37 8.09</td>
</tr>
<tr>
<td>20</td>
<td>1.5</td>
<td>137.46 9.09</td>
</tr>
<tr>
<td>30</td>
<td>1.8</td>
<td>117.85 14.97</td>
</tr>
<tr>
<td>33</td>
<td>1.4</td>
<td>90.89 1.18</td>
</tr>
<tr>
<td>79</td>
<td>5.4</td>
<td>217.47 11.40</td>
</tr>
<tr>
<td>17</td>
<td>2.8</td>
<td>108.43 7.43</td>
</tr>
<tr>
<td>37</td>
<td>2.5</td>
<td>335.04 3.48</td>
</tr>
</tbody>
</table>

Conclusion: A novel tofacitinib LC-MS/MS assay has been developed. The ability of the assay to measure biochemical adherence has been explored. Further research to establish the sensitivity of the assay and the ability of the assay to detect non-adherence are required.


Acknowledgements: Financial support was provided as an Investigator Sponsored Research Grant from Pfizer Limited.

Disclosure of Interests: Stephanie Church Grant/research support from: Financial support was provided as an Investigator Sponsored Research Grant from Pfizer Limited. Kimmie Hyrich Speakers bureau: Honoraria as a speaker received from Abbvie, Grant/research support from: Financial support was provided as an Investigator Sponsored Research Grant from Pfizer Limited.

Baricitinib (BARI), an oral selective JAK 1/2 inhibitor, is approved in the EU (cohort A), or any bDMARD or tsDMARD (b/tsDMARDs; cohort B). Treatment initiation and changes are at the discretion of the patient or physician. Response rates for remission, low disease activity (LDA), moderate disease activity (MDA) or high disease activity (HDA) were determined using the Clinical Disease Activity Index (CDAI) at 12M. Quality of life using the EQ-5D-5L and patient reported outcome (PRO) measures for pain (pain visual analogue scale; VAS) and physical functioning (Health Assessment Questionnaire Disability Index; HAQ-DI) were also assessed at 12M. This pre-specified interim analysis reports descriptive 12M data using summary statistics, without any inferential testing.

Results: This analysis involved 1073 adult RA patients with a mean age (standard deviation; SD) of 59.1 (13.2) (cohort A) and 57.0 (13.9) yrs (cohort B), respectively, and a mean disease duration (SD) of 10.0 (9.1) (cohort A) and 8.9 (9.6) yrs (cohort B), respectively. At baseline, 50.9% of patients in cohort A and 31.2% in cohort B initiated treatment as a monotherapy. At 12M, 26.7% of patients in cohort A and 44.1% of patients in cohort B had discontinued treatment. The most common reason for discontinuation in both cohorts was primary non-response. At 12M, 24.1% of patients in cohort A and 16.6% in cohort B achieved CDAI remission (Figure 1). The mean CDAI reduction was -14.5 and -12.0, respectively in cohorts A and B. Mean reductions from baseline in physician global assessment (PhGA) and in patient global assessment (PGA) were -3.4 and -2.5, respectively in cohort A and -3.0 and -2.1, respectively in cohort B. Improvements from baseline in clinical disease activity index from baseline in cohort A and cohort B were -14.5 and -12.0, respectively in cohorts A and B. Mean CDAI remission at 12M was achieved by 24.1% of patients in cohort A and 16.6% in cohort B.

Figure 1. Percentage of pts in cohorts A and B achieving remission and LDA at 12M.

Conclusion: The majority of BARI-treated patients were in remission or had low disease activity and continued treatment at 12M.
Biogen, Eli Lilly and Company, Grant/research support from: Actelion, Biogen, Novartis, MSD, Andrew Ostor Consultant of: AbbVie, BMS, Roche, Janssen, Eli Lilly and Company, Novartis, Pfizer, UCB, Gilead, Paradigm, Liliana Zaremba-Pechmann:


Table 1. Baseline Characteristics Overall and by Response Status

<table>
<thead>
<tr>
<th>Statistic</th>
<th>Overall</th>
<th>Responders</th>
<th>Non-responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>61.6 (13.3)</td>
<td>63.9 (13.0)</td>
<td>59.8 (13.3)</td>
</tr>
<tr>
<td>Female</td>
<td>5,059 (76.1%)</td>
<td>2,096 (72.2%)</td>
<td>2,963 (79.1%)</td>
</tr>
<tr>
<td>Region</td>
<td>906 (13.6%)</td>
<td>366 (12.6%)</td>
<td>539 (14.4%)</td>
</tr>
<tr>
<td>SOUTH</td>
<td>4,063 (61.1%)</td>
<td>1,759 (60.7%)</td>
<td>2,304 (65.1%)</td>
</tr>
<tr>
<td>WEST</td>
<td>565 (8.5%)</td>
<td>255 (8.8%)</td>
<td>310 (8.3%)</td>
</tr>
<tr>
<td>Race</td>
<td>BLACK 597 (9.0%)</td>
<td>243 (8.4%)</td>
<td>354 (9.5%)</td>
</tr>
<tr>
<td>WHITE 4,305 (64.8%)</td>
<td>1,935 (66.7%)</td>
<td>2,370 (63.2%)</td>
<td></td>
</tr>
<tr>
<td>OTHER 166 (2.5%)</td>
<td>73 (2.5%)</td>
<td>93 (2.5%)</td>
<td></td>
</tr>
<tr>
<td>UNKNOWN 5,180 (83.8%)</td>
<td>649 (22.4%)</td>
<td>931 (24.8%)</td>
<td></td>
</tr>
<tr>
<td>Payor</td>
<td>COMMERCIAL 3,786 (56.7%)</td>
<td>1,516 (52.3%)</td>
<td>2,252 (60.1%)</td>
</tr>
<tr>
<td>MEDICARE 2,690 (39.0%)</td>
<td>1,294 (43.9%)</td>
<td>1,396 (37.5%)</td>
<td></td>
</tr>
<tr>
<td>MEDICAID 290 (4.4%)</td>
<td>111 (3.8%)</td>
<td>179 (4.8%)</td>
<td></td>
</tr>
<tr>
<td>CDAI 15.6 (10.4%)</td>
<td>113 (9.5)</td>
<td>189 (9.8)</td>
<td></td>
</tr>
<tr>
<td>CCI 1.4 (1.1)</td>
<td>1.1 (1.1)</td>
<td>1.4 (1.1)</td>
<td></td>
</tr>
<tr>
<td>BMI 30.4 (7.1)</td>
<td>29.7 (6.8)</td>
<td>30.9 (7.3)</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** We found that over half of patients qualified as MTX non-responders at approximately 6 months. Significant predictors of non-response were younger age, female gender, higher CDAI score and BMI. Maximizing improvement as quickly as possible and deploying more tailored escalation of care may be aided by identifying RA patients at higher risk of early MTX treatment failure.

**REFERENCES:**

Disclose of Interests: None declared, Kathry Starzyk: None declared, Mark Friedman: None declared, Joseph Menzin Grant/research support from: Grant support


Table 1. Levels of cytokines in RA patients receiving tocilizumab, pg/ml, Me [25;75 percentile].

<table>
<thead>
<tr>
<th>Cytokine</th>
<th>Initial</th>
<th>After 3 months of tocilizumab treatment</th>
<th>After 6 months of tocilizumab treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1β</td>
<td>0.07 [0.03;0.13]</td>
<td>0.05 [0.03;0.08]</td>
<td>0.08 [0.06;0.11]</td>
</tr>
<tr>
<td>IL-6</td>
<td>3.43 [2.44;11.02]</td>
<td>2.08 [1.32;3.85]</td>
<td>1.55 [1.32;2.07]</td>
</tr>
<tr>
<td>TNF-α</td>
<td>2.05 [1.48;3.19]</td>
<td>0.99 [0.49;2.05]</td>
<td>0.99 [0.49;2.62]</td>
</tr>
<tr>
<td>IL-10</td>
<td>2.56 [1.20;2.56]</td>
<td>2.10 [1.50;3.04]</td>
<td>2.41 [1.80;3.99]</td>
</tr>
<tr>
<td>IL-17</td>
<td>1.11 [0.47;2.41]</td>
<td>0.86 [0.36;1.76]</td>
<td>1.11 [0.66;1.76]</td>
</tr>
<tr>
<td>IL-21</td>
<td>3.47 [0.74;4.07]</td>
<td>2.30 [0.71;11.72]</td>
<td>1.37 [0.85;1.27]</td>
</tr>
<tr>
<td>IL-22</td>
<td>4.74 [1.19;4.96]</td>
<td>2.07 [0.50;5.93]</td>
<td>4.75 [7.45;10.46]</td>
</tr>
<tr>
<td>IL-23</td>
<td>2.76 [0.62;2.75]</td>
<td>1.18 [0.50;2.35]</td>
<td>1.69 [0.80;2.04]</td>
</tr>
<tr>
<td>IL-24</td>
<td>13.54 [7.34;46.27]</td>
<td>12.26 [4.41;17.94]</td>
<td>13.90 [8.80;20.80]</td>
</tr>
<tr>
<td>INF-α</td>
<td>1.11 [0.32;2.18]</td>
<td>0.31 [0.01;2.5]</td>
<td>0.42 [0.21;1.4]</td>
</tr>
<tr>
<td>IL-31</td>
<td>6.95 [3.85;17.72]</td>
<td>3.00 [1.50;7.83]</td>
<td>5.09 [3.85;6.33]</td>
</tr>
<tr>
<td>CD40L</td>
<td>72.77 [9.80;201.19]</td>
<td>15.31 [4.29;34.80]</td>
<td>40.17 [25.63;58.85]</td>
</tr>
</tbody>
</table>

*p<0.05 (comparing with initial concentration)

**Conclusion:** The data obtained indicate the efficacy of tocilizumab in patients with RA, including decreasing of disease activity and concentrations of clue pro-inflammatory cytokines. Further studies are needed to investigate pathogenic role of cytokine-mediated inflammation in RA and the efficacy of targeted oral medications on the course of the disease.

Disclose of Interests: None declared

**Disclosure of Interests:** None declared

**Objectives:** The OM1 RA Registry (OM1, Inc; Boston, MA) follows more than 210,000 RA patients in the US. The registry utilizes longitudinal electronic medical records from over 400,000 administrative claims starting from 2013. In this retrospective observational study, patients aged ≥18 years initiating MTX between 01 January 2014 and 01 August 2020 without previous bDMARD/tsDMARD utilization were identified. The first MTX date was the index date, with ≥1 Clinical Disease Activity Index (CDAI) measurement and ≥2 all-cause healthcare encounters required in the preceding 12 months (baseline). Patients initiating a bDMARD/tsDMARD within 30 days of the index date or with a history of other conditions where the same bDMARD/tsDMARDs are indicated were excluded. MTX non-response was defined as failing to attain remission or low disease activity (i.e., CDAI >10) within 4 to 8 months and/or the initiation of a bDMARD/tsDMARD within 8 months following the index date (with or without continuing MTX; non-response could include patients discontinuing MTX due to tolerability). Baseline characteristics were summarized with descriptive statistics. Multivariable logistic regression with age, gender, region, race, payor, year of index, the most recent CDAI and body mass index (BMI) measurements from the baseline, and Charlson comorbidity index (CCI) was used to investigate risk factors of non-response. P value was considered significant if <0.05.

**Results:** Among 6,648 eligible RA patients, 3,748 (56.4%) were classified as non-responders. Baseline characteristics are summarized in Table 1. Being female (OR=1.3), increasing baseline CDAI (OR: Low activity=1.9, moderate activity=8.1, high activity=23.9) and higher BMI (OR=1.01) were significantly associated with non-response.

**Conclusion:** We found that over half of patients qualified as MTX non-responders at approximately 6 months. Significant predictors of non-response were younger age, female gender, higher CDAI score and BMI. Maximizing improvement as quickly as possible and deploying more tailored escalation of care may be aided by identifying RA patients at higher risk of early MTX treatment failure.

**REFERENCES:**
Background: Thanks to improved treatment strategies, disease remission in rheumatoid arthritis (RA) patients has become more common. Therefore, current guidelines recommend to consider tapering DMARDs, including methotrexate (MTX), in patients who are in sustained remission. Previous research has shown that subcutaneous methotrexate (MTXsc) has a better bioavailability, efficacy and tolerability in active RA than oral MTX[1]. However, these advantages might be a disadvantage when tapering of MTXsc is considered.

Objectives: To compare the 1-year cumulative flare rates between established RA patients who taper subcutaneous and oral MTX.

Methods: Data from the Tapering strategies in Rheumatoid Arthritis (TARA) trial were used[2]. In this trial, established RA patients with a well-controlled disease, defined as Disease Activity Score (DAS)≤2.4 and swollen joint count (SJC)≤1, using ≥1 csDMARD and TNF-inhibitor (TNFi) were included. Participants were randomized into two groups which gradually tapered their csDMARD first followed by the TNFi, or vice versa. The csDMARD was tapered by reducing the dosage by a half at baseline, by a quarter at 3 months and was stopped at 6 months. Patients who tapered MTX were included in this analysis. If a disease flare (DAS>2.4 or SJC>1) occurred, the last effective therapy was restarted and intensified every 3 months, until DAS≤2.4 and SJC≤1. Following an intention-to-treat principle, flare rates were compared between patients who tapered subcutaneous and oral MTX, using a chi-square test. Two sensitivity analyses were performed where we 1) only included patients with a complete follow-up; and 2) assumed that patients developed a flare at the moment of drop-out.

Results: A total of 71 and 17 patients respectively used oral and subcutaneous MTX. The median disease duration was 5.9 years and 70% was female. The median MTX dosage for both administration routes was 20 milligrams per week. After 12 months, 53% of patients who tapered MTXsc developed a flare compared to 27% who tapered oral MTX (OR 3.1(10.91, 95%CI), p=0.037) (Figure 1). Respectively 68% and 67% of the patients who developed a flare and were using oral and subcutaneous MTX had a well-controlled disease 3 months after restarting their treatment (p=0.93). Both sensitivity analyses showed similar results.

Conclusion: Patients who tapered MTXsc have a higher chance at developing a disease flare compared to those who tapered oral MTX. This could be explained by a higher efficacy of MTXsc when similar dosages are used[1]. Alternatively, the better tolerability of MTXsc, especially regarding gastrointestinal side effects[1], may lead to a difference in adherence. When deciding to taper MTX, the administration route should be taken into account. Because of the increased risk of flare after tapering MTXsc, these patients could be monitored more closely than those tapering oral MTX.

REFERENCES:

Disclosure of Interests: None declared
Objectives: To evaluate impact of self-reported race on tofacitinib efficacy/safety in RA pts.

Methods: This post hoc analysis used pooled data from 8 Phase (P)2, 6 P3 and 1 P3b/4 randomised controlled trials (RCTs) of RA pts treated with tofacitinib 5 or 10 mg twice daily (BID), adalimumab (ADA; 40 mg once weekly), and placebo (PBO). Tofacitinib was stratified by self-reported pt race (White, Black, Asian, Other) at baseline (BL). Efficacy outcomes (Month (M)3: ∆DAS28-4(ESR) and ∆HAQ-DI) and safety outcomes (incidence rates (IRs) of adverse events (AEs) and serious AEs (SAEs)) were compared across the four racial groups (White/Black vs Asian/Other). A statistical model was used to compare IRs, adjusted for race, demographic and clinical factors, and regional efficacy or safety differences. To determine whether differences in safety or efficacy were driven by racial differences, a region-specific exploratory analysis was performed.

Results: A total of 6355 pts were included (White, n=4145; Black, n=213; Asian, n=1348; Other, n=649). White/Black and Asian/Other pts were more commonly enrolled from Europe (40.9%) and North America (68.1%), respectively. Across treatments, White, Black, Asian and Other pts most commonly enrolled from Europe (40.9%) and North America (68.1%), respectively. Most Other pts self-reported as Hispanic and/or Latino (52.4%), followed by mixed race (36.8%) and unspecified (5.2%). At M3, ACR50 rates were higher in Other vs White pts with tofacitinib, similar across racial groups with ADA, and numerically higher in Black vs White/Asian/Other pts with PBO (Figure 1); similarly, trends were seen with ACR20/70 and CDAI LDA rates (data not shown [DNS]). Across treatments (Figure 1; DNS), safety outcomes were broadly similar across treatment arms, with some higher IRs for AEs observed with Black/Other vs White/Asian pts (Table 1). Results should be interpreted with caution due to low pt numbers in some groups and the heterogenous nature of the Other pts group.

Table 1. AEs and SAEs, stratified by race

<table>
<thead>
<tr>
<th></th>
<th>White</th>
<th>Black</th>
<th>Asian</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>IR (95% CI)</td>
<td>IR (95% CI)</td>
<td>IR (95% CI)</td>
<td>IR (95% CI)</td>
</tr>
<tr>
<td>Tofacitinib N=1699; PBO N=1588.3</td>
<td>1150 (133.8, 150.3)</td>
<td>76 (192.4, 305.6)</td>
<td>382 (135.4, 165.9)</td>
<td>205 (197.1, 260.4)</td>
</tr>
<tr>
<td>AE</td>
<td>93 (14.3, 37.4)</td>
<td>15 (6.6, 27.5)</td>
<td>61 (8.6, 14.5)</td>
<td>7 (3.3, 10.8)</td>
</tr>
<tr>
<td>SAE</td>
<td>146 (10.7, 31.4)</td>
<td>19 (8.6, 14.5)</td>
<td>63 (11.3)</td>
<td>7 (3.3, 10.8)</td>
</tr>
<tr>
<td>Tofacitinib N=1126; 5 mg BID PBO N=1175.4</td>
<td>919 (176.1, 201.1)</td>
<td>48 (302.0, 575.8)</td>
<td>338 (159.9, 198.6)</td>
<td>122 (95.1, 150.8)</td>
</tr>
<tr>
<td>AE</td>
<td>103 (3.9, 10.5)</td>
<td>2 (0.1, 10.4)</td>
<td>47 (280.6, 345.1)</td>
<td>9 (0.1, 10.4)</td>
</tr>
<tr>
<td>SAE</td>
<td>81 (8.6, 27.5)</td>
<td>1 (0.1, 10.4)</td>
<td>51 (116.9, 206.5)</td>
<td>1 (0.1, 10.4)</td>
</tr>
<tr>
<td>Tofacitinib N=484; 10 mg BID PBO N=495</td>
<td>318 (124.5, 156.7)</td>
<td>16 (92.7, 263.4)</td>
<td>9 (6.6, 27.5)</td>
<td>1 (0.1, 10.4)</td>
</tr>
<tr>
<td>AE</td>
<td>31 (5.2, 10.8)</td>
<td>2 (0.1, 10.4)</td>
<td>51 (116.9, 206.5)</td>
<td>1 (0.1, 10.4)</td>
</tr>
<tr>
<td>SAE</td>
<td>31 (7.6, 21.9)</td>
<td>1 (0.1, 10.4)</td>
<td>44 (117.4, 216.9)</td>
<td>1 (0.1, 10.4)</td>
</tr>
</tbody>
</table>

Conclusion: Across racial groups, tofacitinib efficacy/safety was consistent with previous tofacitinib RA clinical programme findings. Some racial differences in clinical outcomes were observed, which may reflect regional practice norms or demographic differences. Future analyses should focus on the impact of socio-economic, cultural, genetic or practice-based differences that may underpin these results.

REFERENCES:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Kirsten Woolcott, CMC Connect, and funded by Pfizer Inc.


Branebrutinib (BMS-986195) is a highly potent and selective irreversible small-molecule covalent inhibitor of Bruton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase involved in the pathophysiology of immune-mediated diseases. Branebrutinib has the potential to be best in its class, as it achieves ~100% BTK occupancy in humans, sustained over a 24-hour dosing interval at low doses (≤ 10 mg once daily [QD]) despite its short half-life (≤ 2 hours), and demonstrates potent efficacy in murine models of immune-mediated diseases. 1 Branebrutinib is under clinical study in multiple autoimmune inflammatory disorders such as RA, systemic lupus erythematosus, primary Sjögren’s syndrome, and atopic dermatitis. In vitro drug-drug interaction (DDI) studies with branebrutinib predicted pharmacokinetic DDI potential with substrates of cytochrome P450 (CYP) and diphosphate glucuronosyltransferase.

**Methods:** Branebrutinib predicted pharmacokinetic DDI potential with substrates of cytochrome P450 (CYP) and diphosphate glucuronosyltransferase.

**Objectives:** To assess the DDI potential of branebrutinib when co-administered with potential concomitant medications and probe substrates of major drug-metabolizing enzymes (DMEs) and drug transporters.

**Methods:** DDI risk with branebrutinib was assessed in 3 single-sequence, cross-over clinical studies in healthy participants. In the first 2-part study, MTX was administered alone or with steady-state (SS) branebrutinib (9mg QD) in part 1; in part 2, caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin were taken with or without SS branebrutinib (9mg QD). In the second study, rosuvastatin was taken alone or with SS branebrutinib (9mg QD). In cycle 1 of the third study, the oral contraceptive (OC) loestrin (1.5 mg norethindrone/30 μg ethinyl estradiol) was taken with or without SS branebrutinib (9mg QD). In the second study, rosuvastatin was taken alone or with SS branebrutinib (9mg QD). In cycle 1 of the third study, the oral contraceptive (OC) loestrin (15mg norethindrone/30 μg ethinyl estradiol) was taken alone; in cycle 2, SS branebrutinib (9mg QD) was taken alone or with the OC.

**Results:** Weak DDI with montelukast (CYP2C8) was observed, leading to a mild increase in montelukast exposure (max concentration [Cmax] 56%; area under the curve [AUC] 27%). A mild increase in digoxin exposure (P-glycoprotein [P-gp] substrates; Cmax 57%; AUC, 21%) was also observed. There was no potential DDI with MTX (Table 1). No other clinically relevant DDIs with branebrutinib were observed. No serious AEs or other significant AEs occurred during these studies. All AEs were mild to moderate in intensity.

**Table 1. Results from clinical DDI studies of branebrutinib**

<table>
<thead>
<tr>
<th>Concomitant medication</th>
<th>Adjusted geometric mean ratios with (test) and without (reference) branebrutinib</th>
<th>DME or drug transporter tested Cmax ratio (90% CI)</th>
<th>AUC ratio (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipyridamole (0.25 mg)</td>
<td>1.57 (1.36–1.80)</td>
<td>1.21 (1.11–1.32)</td>
<td></td>
</tr>
<tr>
<td>MTX (75 mg)</td>
<td>BCRP, OATP1B1, OATP1B3, OAT1, OAT3, MRP2, MRP4</td>
<td>1.00 (0.92–1.09)</td>
<td>0.94 (0.90–0.99)</td>
</tr>
<tr>
<td>Pravastatin (40 mg)</td>
<td>1.25 (1.00–1.57)</td>
<td>1.06 (0.90–1.25)</td>
<td></td>
</tr>
<tr>
<td>Rosuvastatin (10 mg)</td>
<td>BCRP, OATP1B1, OATP1B3</td>
<td>0.81 (0.71–0.93)</td>
<td>0.96 (0.88–1.04)</td>
</tr>
<tr>
<td>Montelukast (10 mg)</td>
<td>CYP2C9</td>
<td>1.56 (1.24–1.95)</td>
<td>1.27 (1.10–1.47)</td>
</tr>
<tr>
<td>Caffeine (200 mg)</td>
<td>CYP1A2</td>
<td>0.98 (0.94–1.01)</td>
<td>1.16 (1.08–1.24)</td>
</tr>
<tr>
<td>Flurbiprofen (50 mg)</td>
<td>CYP2C9</td>
<td>1.06 (0.97–1.16)</td>
<td>1.12 (1.09–1.15)</td>
</tr>
<tr>
<td>Omeprazole (50 mg)</td>
<td>CYP3A4</td>
<td>1.00 (0.92–1.05)</td>
<td>1.07 (0.94–1.13)</td>
</tr>
<tr>
<td>Midazolam (5mg)</td>
<td>CYP3A4</td>
<td>0.95 (0.82–1.11)</td>
<td>1.00 (0.84–1.19)</td>
</tr>
<tr>
<td>Ethinyl estradiol (30 μg)</td>
<td>CYP3A4, CYP2C9, UGT1A1, UGT1A4</td>
<td>1.16 (1.09–1.23)</td>
<td>1.17 (1.12–1.22)</td>
</tr>
<tr>
<td>Norethindrone (1.5 mg)</td>
<td>CYP2C9</td>
<td>1.10 (1.04–1.15)</td>
<td>1.06 (1.01–1.12)</td>
</tr>
</tbody>
</table>

**Conclusion:** In all 3 studies, co-administration of SS branebrutinib was generally well tolerated. The only significantly potential DDIs with substrates of major DMEs or transporters were mild increases in montelukast (CYP2C8) and digoxin (P-gp) exposures.

RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE

C. Charles-Schoeman1, M. H. Buch2, M. Dougados3,4, D. L. Bhatt5, J. T. Giles6, S. R. Ytterberg7, G. G. Koch8, I. Vranic9, J. Wu10, C. Wang10, S. Menon10, J. L. Rivas11, A. Yndestad12, C. A. Connell10, Z. Szekanecz13, 1University of California, Division of Rheumatology, Department of Medicine, Los Angeles, CA, United States of America; 2University of Manchester and NIHR Manchester Biomedical Research Centre, Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom; 3Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Department of Rheumatology, Paris, France; 4PRES Sorbonne Paris-Cité, INSERM (U1153): Clinical Epidemiology and Biostatistics, Paris, France; 5Brigham and Women’s Hospital and Harvard Medical School, Department of Cardiovascular Medicine, Boston, MA, United States of America; 6Columbia University Vagelos College of Physicians and Surgeons, Division of Rheumatology, New York, NY, United States of America; 7 Mayo Clinic, Division of Rheumatology, Rochester, MN, United States of America; 8University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC, United States of America; 9Pfizer Ltd, Inflammation and Immunology, Tadworth, Surrey, United Kingdom; 10Pfizer Inc, Inflammation and Immunology, Groton, CT, United States of America; 11Pfizer Inc, Inflammation and Immunology, Madrid, Spain; 12Pfizer Inc, Inflammation and Immunology, Oslo, Norway; 13University of Debrecen, Division of Rheumatology, Faculty of Medicine, Debrecen, Hungary

Background: ORAL Surveillance (NCT02092467) was a post-approval safety study of tofacitinib vs TNF inhibitors (TNFi) in rheumatoid arthritis (RA) patients (pts) aged ≥50 yrs with ≥1 additional cardiovascular (CV) risk factor and an inadequate response to methotrexate (MTX).

Objectives: To identify independent risk factors for major adverse CV events (MACE) in ORAL Surveillance.

Methods: Pts on stable MTX were randomised 1:1:1 to receive tofacitinib 5 or 10mg twice daily (BID) or a TNFi (adalimumab 40mg every 2 weeks or etanercept 50mg once weekly). Incidence rates (IRs; pts with first events/100 pt-yrs) and hazard ratios (HRs; tofacitinib vs TNFi) were assessed for adjudicated MACE (total/fatal/non-fatal), sudden cardiac death, and total/fatal/non-fatal myocardial infarction (MI) and stroke. Post hoc univariate Cox model analyses identified potentially independent baseline (BL) risk factors for MACE across treatments; those with p<0.10 were entered into a multivariate Cox model using backward selection (p<0.10 stay criteria). MACE HRs were produced for subgroups for BL risk factors with p<0.05 in the final multivariate Cox model.

Results: 4362 pts were included (tofacitinib 5 mg BID, n=1455; tofacitinib 10 mg BID, n=1456; TNFi, n=1451). IRs for total/fatal/non-fatal MACE, sudden cardiac death, and total/fatal MI were higher with tofacitinib vs TNFi (Table 1). Fatal MI and stroke (including fatal/non-fatal events) IRs were similar across treatments (Table 1). Total MACE and MI IRs and risk were higher with tofacitinib vs TNFi (HRs >1) and higher for non-fatal MI for tofacitinib 5 mg BID (Table 1). Current smoking, aspirin use, history of chronic lung disease, history of diabetes, male sex and older age were BL risk factors for MACE. While MACE risk was generally higher with tofacitinib vs TNFi across all BL risk factors, increased risk was clearest in current/past smokers (vs never smoked) and aspirin users (vs non-users) (Figure 1). When and smoking status were considered in combination, pts aged ≥65 yrs or who had ever smoked had a particularly elevated MACE risk vs never smokers aged ≥50–65 yrs (Figure 1).

Table 1. MACE, MI and stroke IRs (pts with first events/100 pt-yrs; 95% CI) and HRs (tolfacitinib vs TNFi; 95% CI)

<table>
<thead>
<tr>
<th></th>
<th>Tofacitinib 5 mg BID (N=1455)</th>
<th>Tofacitinib 10 mg BID (N=1456)</th>
<th>TNFi (N=1451)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>IR (95% CI)</td>
<td>HR (95% CI)</td>
<td>IR (95% CI)</td>
</tr>
<tr>
<td>MACE</td>
<td>47 (0.67, 1.21)</td>
<td>1.24 (0.19, 1.19)</td>
<td>51 (0.78, 1.38)</td>
</tr>
<tr>
<td>Fatal MACE</td>
<td>14 (0.27, 0.45)</td>
<td>1.14 (0.35, 0.77)</td>
<td>19 (0.39, 1.63)</td>
</tr>
<tr>
<td>Non-fatal MACE</td>
<td>33 (0.44, 0.90)</td>
<td>1.29 (0.73, 2.17)</td>
<td>32 (0.45, 0.93)</td>
</tr>
<tr>
<td>Sudden cardiac death</td>
<td>10 (0.09, 0.35)</td>
<td>1.26 (0.48, 3.10)</td>
<td>13 (0.14, 0.45)</td>
</tr>
<tr>
<td>MI</td>
<td>19 (0.22, 0.57)</td>
<td>1.61 (0.80, 3.35)</td>
<td>19 (0.23, 0.61)</td>
</tr>
<tr>
<td>Fatal MI</td>
<td>0 (0.00, 0.07)</td>
<td>0.00 (0.01, 0.18)</td>
<td>3 (0.01, 0.31)</td>
</tr>
<tr>
<td>Non-fatal MI</td>
<td>18 (0.22, 0.57)</td>
<td>2.32 (1.02, 5.30)</td>
<td>16 (0.19, 0.53)</td>
</tr>
<tr>
<td>Stroke</td>
<td>18 (0.21, 0.55)</td>
<td>1.03 (0.53, 2.00)</td>
<td>18 (0.22, 0.58)</td>
</tr>
<tr>
<td>Fatal stroke</td>
<td>4 (0.02, 0.20)</td>
<td>0.00 (0.01, 0.15)</td>
<td>2 (0.00, 0.07)</td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>14 (0.15, 0.45)</td>
<td>0.80 (0.19, 4.13)</td>
<td>16 (0.19, 0.53)</td>
</tr>
</tbody>
</table>

*HR 95% CI excludes 1. Data collected after pts who were randomised to tofacitinib 10 mg BID had their dose reduced to 5 mg. BID were included in the tofacitinib 10 mg BID group. HRs (95% CI) were not informative when one of the treatments in the comparison had 0 events. Risk period was defined as time from first dose to last dose ±60 days or to the last contact date, whichever was earlier. CI, confidence interval; NI, non-informative.
Conclusion: MACE IFRs and risk were higher with tofacitinib vs TNFi in ORAL Surveillance. BL risk factor findings could aid identification of RA pts with potentially highest risk for MACE, with a view to informing treatment decisions.

Acknowledgements: Study sponsored by Pfizer Inc. Medication writing support was provided by Kirsten Woolcott, CMC Connect, and funded by Pfizer Inc.


DISCLOSURE OF INTERESTS: I have no disclosures to declare.

Disclosure of Interests: None declared.


POS0675 IMPACT OF PAST USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON JAK INHIBITOR TREATMENT FOR RHEUMATOID ARTHRITIS - DATA FROM THE FUKUI ISHIKAWA TOYAMA DATABASE OF RHEUMATOID ARTHRITIS

M. Konishi, I. Mizushima, M. Kawano, T. Murayama, S. Nakazaki, K. Shinoda, T. Kido, Y. Katsuki, H. Fujinaga, T. Watanabe, H. Motomura, I. Matsushita, Kanazawa University Hospital, Department of Rheumatology, Kanazawa, Japan; 11 Charité University Hospital, Department of Rheumatology, Berlin, Germany; 9 Galapagos NV, Biostatistics, Mechelen, Belgium; 10 Gedeon Richter, Novartis, Pfizer Inc and Roche, Employee of: Pfizer Ltd, Employee of: Pfizer Inc, Consultant of: Pfizer Inc, Employee of: Pfizer Inc, Carol A. Connell Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, Zoltán Székeczek Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lilly, Gedeon Richter, Novartis, Pfizer Inc and Roche, Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer Inc, Roche and Sanofi.

Background: Currently, five types of Janus kinase inhibitors (JAKis) are used for rheumatoid arthritis (RA) treatment. The number of cases in which multiple JAKis have been prescribed is increasing. However, the real-world efficacy and safety of JAKis and related factors require further evaluation.

Objectives: The primary objective of this study was to elucidate the impact of past use of disease-modifying anti-rheumatic drugs (DMARDs) on RA treatment using JAKis. The secondary objective was to investigate the safety profiles of these agents in a real-world setting.

Methods: Of the 303 JAKi-treated patients in the Fukui Ishikawa Toyama Database of RA included in this study, 30 had switched from one JAKi to another (JJ group), 214 switched from a biologic agent to a JAKi (BJ group), and 47 were switched from other or JAKi therapy to a JAKi therapy. The investigators evaluated baseline factors, treatment response, and JAKi continuation rates among the three groups. Factors related to JAKi discontinuation were assessed using Cox regression analysis. Furthermore, we investigated adverse events and reported them using exposure-adjusted incidence rates (EAR; incidence rates per 100 patient-years).

Results: Data from the 303 cases were analyzed (mean age = 63.6 years; female: 82.5%; mean RA duration, 176 months). Of the 303 patients, 118, 106, 50, and 29 were treated with tofacitinib, baricitinib, peficitinib, and upadacitinib, respectively, on initial observation. Rate of concomitant use with methotrexate and prednisolone was 52% and 49%, respectively.

Conclusion: JAKi discontinuation in Japan is influenced by factors including past use of DMARDs, disease severity, and adverse events. While JAKi was effective in patients with RA aged ≥75 y, treatment response was lower in patients with a past history of JAKi use.

Disclosure of Interests: I have no disclosures to declare.

DOI: 10.1136/annrheumdis-2022-eular.1234

POS0676 EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS AGED ≥75 YEARS: A POST HOC SUBGROUP ANALYSIS OF THE FINCH 4 LONG-TERM EXTENSION (LTE) STUDY

D. Aletha, R. Westhoven, B. Combe, E. J. Gottenberg, M. H. Buch, C. Caporali, J. A. Gómez-Puerta, P. Van Hoek, V. Rajendran, P. J. Stiers, T. Hendrikx, G. R. Burmester, T. Yanaka, M. University of Vienna, Department of Medicine III (Division of Rheumatology), Vienna, Austria; 2 University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium; 3 Montpellier University, Department of Rheumatology, Montpellier, France; 4 Strasbourg University Hospital, Department of Rheumatology, Strasbourg, France; 5 The University of Manchester, Centre for Musculoskeletal Research, Division of Musculoskeletal & Dermatological Sciences, Faculty of Medicine & Health, Manchester, United Kingdom; 6 The University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 7 Hospital Clinic of Barcelona, Department of Rheumatology, Barcelona, Spain; 8 Galapagos NV Clinical Development, Brussels, Belgium; 9 Galapagos NV, Vienna, Austria; 10 Charité University Hospital, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 11 University of Occupational and Environmental Health, Internal Medicine, Kitakyushu, Japan.

Background: Filgotinib (FIL) is a Janus kinase 1 preferential inhibitor for the treatment of moderate to severe rheumatoid arthritis (RA)1. The recommended dose for adults with RA is 200 mg (FIL200); however, a starting dose of 100 mg (FIL100) is recommended for those aged ≥75 years (y) in view of limited clinical experience1. An important consideration is the generally higher incidence of adverse events (AEs) in the elderly due to comorbidities.

Objectives: To evaluate the efficacy and safety of FIL100 and FIL200 in patients with RA aged ≥75 y.

Methods: FINCH 4 (NCT03025308) is an ongoing phase 3 open-label LTE study of FIL100 and FIL200 for RA. Eligible patients completed a prior phase 5 randomized, double-blind, study of FIL lasting 52 weeks (FINCH 1 or 2) or 24 weeks (FINCH 2). In this post hoc analysis, safety and efficacy were assessed in patients aged ≥75 and ≥75 y in FINCH 4. Efficacy measures were American College of Rheumatology (ACR)/20/50/70 responses, clinical disease activity index (CDAI) ≤10/≤2.8, disease activity score (DAS) ≤28 <2.6/≤3.2 and health assessment questionnaire-disability index (HAQ-DI).

Results: At LTE Week 48, 52% and 44% of patients aged ≥75 and ≥75 y, respectively, were on methotrexate. Baseline age group response rates for key efficacy measures at LTE Week 48 were generally maintained from LTE baseline (Figure 1) in patients with and without prior FIL exposure in FINCH 1–3, and were numerically higher with FIL200 vs FIL100. Mean change from baseline in mean DAS28-CRP: 1.48 ± 0.26 vs. 1.89 ± 0.62.

Conclusions: Past use of JAKis may contribute to decreased response and continuation rates for JAKi treatment. In this study, conducted in Japan, development of herpes zoster was found to be the most frequent adverse event among the priority survey items.

Acknowledgements: I have no disclosures to declare.

Disclosure of Interests: None declared.


Scientific Abstracts

612

Scientific Abstracts
HAQ-DI with FIL200 and FIL100 was 0.61 and 0.74 in those aged <75 y and 1.04 and 0.98 in those aged ≥75 y, respectively.


POS0677

CONSISTENCY IN TIME TO RESPONSE WITH UPADACITINIB AS MONOTHERAPY OR COMBINATION THERAPY AND ACROSS PATIENT POPULATIONS WITH RHEUMATOID ARTHRITIS

A. Rubbert-Roth1, B. Combe2, Z. Stojkovic2, S. Half1, B. Harasou1, S. Attar1, A. K. H. Ekkelenkamp1, Y. Song1, T. Shaw2, O. Nagy1, R. Xavier1, 1Cambridgeside St. Gallen, Rheumatology, St. Gallen, Switzerland; 2Montpellier University, Rheumatology, Montpellier, France; 3University of Debrecen, Rheumatology, Debrecen, Hungary; 4Monash University, Rheumatology, Melbourne, Australia; 5Institut de Rhumatologie de Montréal, Rheumatology, Montreal, Canada; 6King Abdulaziz University, Rheumatology, Jeddah, Saudi Arabia; 7University of Gothenburg, Rheumatology, Gothenburg, Sweden; 8AbbVie Inc., Immunology, North Chicago, United States of America; 9AbbVie Ltd., Immunology, Maidenhead, United Kingdom; 10Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Background: Upadacitinib (UPA) has demonstrated efficacy in patients with moderate-to-severe rheumatoid arthritis (RA) across various patient populations.1-4

Objectives: This post hoc analysis aimed to evaluate the consistency in time to achieving meaningful clinical response with UPA 15 mg + conventional synthetic (cs) DMARDs in biologic (b) DMARD-inadequate responder (IR) versus csDMARD-IR patients with RA as well as with UPA 15 mg monotherapy versus UPA 15 mg + csDMARDs in csDMARD-IR patients.

Methods: Patients originally randomized to UPA 15 mg once daily from four Phase 3 trials were included in this analysis: SELECT-BEYOND1 and SELECT-CHOICE2 (UPA 15 mg + csDMARDs in bDMARD-IR patients), SELECT-NEXT3 (UPA 15 mg + csDMARDs in csDMARD-IR patients), and SELECT-MONOTHERAPY4 (UPA 15 mg monotherapy in methotrexate-IR patients). Time to response was estimated using the Kaplan-Meier method for clinical outcomes over 24 weeks (26 weeks in SELECT-MONOTHERAPY). Clinical outcomes included achievement of 28-joint Disease Activity Score with C-reactive protein (DAS28[CRP]) ≤3.2; low disease activity (LDA) defined as Clinical Disease Activity Index (CDAI) ≤10 and Simple Disease Activity Index (SDAI) ≤11; and 50% improvement in American College of Rheumatology (ACR) core components and morning stiffness (MS) duration/severity. Data presented were as observed.

Results: Overall, 905 patients were included (SELECT-BEYOND: n=164; SELECT-CHOICE: n=303; SELECT-NEXT: n=221; SELECT-MONOTHERAPY: n=217). csDMARD-IR patients had a mean disease duration of 7.3 (SELECT- NEXT) or 7.5 years (SELECT-MONOTHERAPY); bDMARD-IR patients had a mean disease duration of 12.4 years, with a more refractory population (≥3 prior bDMARDs) in SELECT-BEYOND (23%) than SELECT-CHOICE (13%). In general, the median time to DAS28[CRP] ≤3.2, CDAI LDA, 50% improvement in ACR core components, and 50% improvement in MS duration/severity were consistent across the studies in bDMARD-IR and csDMARD-IR patients. For SELECT-BEYOND, SELECT-CHOICE, SELECT-NEXT, and SELECT-MONOTHERAPY, the median (95% CI) time to achieve DAS28[CRP] ≤3.2 was 12 (12, 16), 12 (8, 16), 12 (8, 16), 12 (8, 16), and 14 (8, 14) weeks, respectively (Figure 1), and the median time to achieve SDAI LDA was observed with UPA monotherapy [20 (14, 20) weeks] versus UPA + csDMARDs [12 (12, 16) weeks] in csDMARD-IR patients. Among bDMARD-IR patients, the median (95% CI) time to 50% improvement in pain was longer in SELECT-BEYOND versus SELECT-CHOICE 16 (12, 20) versus 8 (8, 12) weeks).

Conclusion: In diverse patient populations with RA, patients treated with UPA 15 mg, as monotherapy or with csDMARDs, generally demonstrated consistent
time to achieving DAS28(CRP) ≤3.2, CDAI LDA, and 50% improvement in clinical outcomes.

REFERENCES:

Acknowledgements: AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data. No honoraria or payments were made for authorship. Medical writing support was provided by A.W. Wilson, MSc, of 2 of the Nth (Cheshire, UK), and was funded by AbbVie.

Disclosure of Interests: Andrea Rubbert-Roth Consultant of: AbbVie; Amgen, Bristol-Myers Squibb, Chugai, Eli Lilly, Gilead, Janssen, Novartis, Roche, and Sanofi, Bernard Combe Speakers bureau: AbbVie, Bristol-Myers Squibb, Celtrion, Eli Lilly, Gilead/Galapagos, Janssen, Merck, Novartis, Pfizer, Roche/Chugai, and Sanofi, Zoltán Székanez Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gedeon Richter, MSD, Pfizer, Roche, Sanofi, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Gedeon Richter, MSD, Pfizer, Roche, Sanofi, and UCB, Stephen Hall Speakers bureau: Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, and research grants from AbbVie, Janssen, Merck, and UCB, Consultant of: E. Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, and research grants from AbbVie, Janssen, Merck, and UCB, Boulos Harouali Speakers bureau from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Suzan Altar: None declared, Anna-Karin E Hekwall Consultant of: AbbVie and Pfizer, Yanna Song Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Tam Shaw Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Osorlya Nagy Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Ricardo Xavier Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB


POS0678

CLINICAL OUTCOMES OF METHOTREXATE (MTX)-NAIVE RHEUMATOID ARTHRITIS (RA) PATIENTS ON FILGOTINIB (FIL) LONG-TERM EXTENSION (LTE) TRIAL INITIALLY ON FIL OR MTX DURING THE PHASE 3 PARENT STUDY (PS)

D. Aletha 1, R. Westhoven 1, T. Atsumi 2, Y. Tan 1, A. Pechonkina 3, Q. Gong 1, V. Rajendran 4, S. Strengholt 7, G. R. Burmester 8.

1Medical University of Vienna, Division of Rheumatology, Vienna, Austria; 2University Hospitals KU Leuven, Rheumatology Department, Leuven, Belgium; 3Hokkaido University, Department of Rheumatology, Hokkaido, Japan; 4Gilead Sciences, Inc., Clinical Development, Foster City, United States of America; 5Gilead Sciences, Inc., Biostatistics, Foster City, United States of America; 6Galapagos NV, Clinical Development, Mechelen, Belgium; 7Galapagos BV Medical Affairs, Leiden, Netherlands; 8Charité University Hospital Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Background: The preferential Janus kinase-1 inhibitor FIL is approved for treatment of moderate to severe active RA in Europe and Japan.

Objectives: In this post hoc, exploratory analysis, efficacy and safety of long-term treatment with FIL (± MTX) were assessed in MTX-naïve pts treated with FIL or MTX in the Phase 3 PS (NCT02886728).

Methods: Pts received FIL 200 mg (FIL200)+MTX, FIL 100 mg (FIL100)+MTX, FIL200 alone, or MTX alone up to 52W in PS. Those completing PS on study drug could enter LTE (NCT03023508; data cutoff: June 1, 2020). LTE completers were rerandomized, blinded, to FIL200 or FIL100; pts on FIL in PS remained on the same dose in LTE. MTX was washed out for 4W at LTE baseline (BL); pts could (re)start MTX and/or other conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) ≥4W after LTE first dosing. Efficacy data to LTE W48 and safety data are reported.

Table 1. EAIRs of TEAEs through June 2020

<table>
<thead>
<tr>
<th>Data Set</th>
<th>TEAE</th>
<th>FIL200+MTX</th>
<th>FIL100+MTX</th>
<th>FIL200 LTE</th>
<th>FIL100 LTE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>N=325</td>
<td>N=167</td>
<td>N=169</td>
<td>N=148</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n=230</td>
<td>n=117</td>
<td>n=124</td>
<td>n=105</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PYE=474.4</td>
<td>PYE=232.5</td>
<td>PYE=213.4</td>
<td>PYE=213.4</td>
</tr>
<tr>
<td></td>
<td>TEAE</td>
<td>49.7 (43.8, 56.5)</td>
<td>46.9 (38.9, 56.6)</td>
<td>49.9 (41.9, 56.6)</td>
<td>41.9 (38.2, 56.6)</td>
</tr>
<tr>
<td></td>
<td>Grade ≥3</td>
<td>7.2 (5.1, 10.0)</td>
<td>6.5 (5.3, 9.7)</td>
<td>10.2 (6.8, 15.1)</td>
<td>7.0 (4.2, 11.6)</td>
</tr>
<tr>
<td></td>
<td>Serious AE</td>
<td>5.9 (4.1, 8.5)</td>
<td>6.0 (3.6, 10.2)</td>
<td>8.9 (5.8, 13.6)</td>
<td>6.6 (3.9, 11.0)</td>
</tr>
<tr>
<td></td>
<td>Death</td>
<td>1.1 (0.3, 2.5)</td>
<td>0.4 (0.1, 1.3)</td>
<td>0.0 (0, 1.7)</td>
<td>0.0 (0, 1.7)</td>
</tr>
<tr>
<td></td>
<td>Infections</td>
<td>28.5 (24.0, 32.9)</td>
<td>29.7 (23.4, 37.5)</td>
<td>22.7 (16.6, 29.6)</td>
<td>28.6 (22.2, 34.1)</td>
</tr>
<tr>
<td></td>
<td>Opportunistic infections</td>
<td>0.2 (0.15)</td>
<td>0.0 (0.16)</td>
<td>0.0 (0, 1.7)</td>
<td>0.0 (0, 1.7)</td>
</tr>
<tr>
<td></td>
<td>Herpes zoster</td>
<td>0.8 (0.3, 2.2)</td>
<td>1.7 (0.6, 4.6)</td>
<td>0.8 (0.2, 3.4)</td>
<td>1.9 (0, 7.5)</td>
</tr>
<tr>
<td></td>
<td>MACE</td>
<td>0.6 (0.1, 1.8)</td>
<td>0.9 (0.2, 3.4)</td>
<td>0.4 (0, 1.6)</td>
<td>0.7 (0.2, 3.7)</td>
</tr>
<tr>
<td></td>
<td>VTE</td>
<td>0.2 (0.12)</td>
<td>0.4 (0.1, 1.3)</td>
<td>0.0 (0, 1.6)</td>
<td>0.1 (0, 1.7)</td>
</tr>
<tr>
<td></td>
<td>DVT/PE</td>
<td>0.6 (2, 0.2)</td>
<td>0.0 (0, 0.16)</td>
<td>1.7 (0.6, 4.5)</td>
<td>0.5 (0, 2.6)</td>
</tr>
<tr>
<td></td>
<td>Malignancies</td>
<td>0.6 (0.2, 0.2)</td>
<td>0.4 (0.1, 1.3)</td>
<td>0.8 (0.2, 3.4)</td>
<td>0.5 (0, 2.6)</td>
</tr>
<tr>
<td></td>
<td>NMISC</td>
<td>0.6 (0.2, 0.2)</td>
<td>0.4 (0.1, 1.3)</td>
<td>0.8 (0.2, 3.4)</td>
<td>0.5 (0, 2.6)</td>
</tr>
</tbody>
</table>

Figure 1: Conclusion: Overall, response rates improved from LTE BL to W48 for pts switched from PS MTX to FIL and decreased modestly for PS FIL pts. Rates of AEs of special interest were generally low and tended to be higher in pts maintained on FIL from PS. Safety findings in this subpopulation were comparable with the PS through W52 and with a 7-trial integrated safety analysis. Limitations: the LTE was not formally randomized at BL, the groups were of unequal size, and the switch from MTX to FIL for LTE was by design rather than based on disease activity.

REFERENCES:
MA, of AlphaScienG, LLC, San Francisco, CA; and funded by Gilead Sciences, Inc., Foster City, CA. Funding for this analysis was provided by Gilead Sciences, Inc., Foster City, CA.

Disclosure of Interests: Daniel Aletaha Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Medac, Merck, Merck & Dohme, Novartis, Pfizer, Roche, Sandoz, Sanofi/Genzyme, and UCB; Consultant of: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Medac, Merck, Novartis, Pfizer, Roche, Sandoz, and Sanofi/Genzyme.

Background: The preferential Janus kinase-1 inhibitor FIL is approved for treatment of moderate to severe active RA in Europe and Japan.

Objectives: Efficacy and safety of FIL were assessed in pts with IR to MTX who completed a Phase 3 trial (NCT02889796) and enrolled in an LTE (NCT03025308).

Methods: Pts completing the PS1 on study drug were eligible to enter the LTE (data cutoff: June 1, 2020). Median exposure: 2.2 years (y). Efficacy data to W48 are reported for 4 treatment groups (all with background MTX): pts receiving FIL 200 mg (FIL200) or FIL 100 mg (FIL100) in the PS and continuing their dose in LTE (FIL200/FIL200, FIL100/FIL100) and ADA pts randomized, double blind, to FIL200 or FIL100 for LTE (ADA/FIL200, ADA/FIL100); safety data are reported.

Results: As of June 1, 2020, 522/571 (91%) FIL200/FIL200, 502/570 (88%) FIL100/FIL100, 118/128 (92%) ADA/FIL200, and 115/130 (89%) ADA/FIL100 pts remained on study drug. LTE baseline disease characteristics were similar between groups: mean duration of RA approximately 8.7 y; DAS28(CRP) 2.55, and mean concurrent MTX dosage was 13.5 mg/week. Proportions of pts achieving ACR20/50/70, DAS28(CRP) <3.2, <2.6, and CDAI ≤10, ≤2.8 were generally maintained in all LTE groups through W48 (Figure 1).

Numerically greater proportions of pts met response criteria at W48 in the FIL200 groups vs FIL100, regardless of PS treatment. Treatment-emergent AEs (TEAEs), serious AEs, and AEs Grade 3 were largely comparable between groups and lowest in ADA/FIL100. There were 10 deaths (5 from each). Exposure-adjusted AEs rates (EAIRs)/10 pt-y of exposure for deaths were lower for FIL/FIL vs ADA/FIL.

Figure 1. Conclusion: During the LTE through W48, response rates generally were maintained for FIL/FIL and ADA/FIL pts. Though there were differences between LTE groups, safety was largely comparable and consistent with PS observations1 and previously reported results from 7 trials2, rates of AEs of special interest were low; all confidence intervals were overlapping. Limitation: the LTE was not formally randomized for comparison between FIL/FIL and ADA/FIL treatment groups, the groups were of unequal size, and the switch from ADA to FIL for LTE was by design, rather than based on disease activity.

Table 1. EAIRs of TEAEs in LTE, as of June 1, 2020

<table>
<thead>
<tr>
<th>TEAE</th>
<th>5PYE=859.4</th>
<th>8PYE=197.8</th>
<th>11PYE=852.3</th>
<th>14PYE=192.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIL200+MTX→FIL200+MTX</td>
<td>45±71</td>
<td>71±128</td>
<td>10m±570</td>
<td>13±130</td>
</tr>
<tr>
<td>2EAIR (95% CI)</td>
<td>429 (75.1)</td>
<td>49.9 (45.4, 54.9)</td>
<td>64 (11.5)</td>
<td>7.4 (5.8, 9.5)</td>
</tr>
<tr>
<td>TE serious AE</td>
<td>52 (9.1)</td>
<td>6.1 (4.6, 7.9)</td>
<td>6 (3.8, 11.3)</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Death</td>
<td>3 (0.5)</td>
<td>0.3 (0.1, 0.1)</td>
<td>1.0 (3.0, 4.0)</td>
<td>0.4 (0.1, 1.1)</td>
</tr>
<tr>
<td>TE infections</td>
<td>243 (42.6)</td>
<td>52 (40.6)</td>
<td>26 (20.3, 34.5)</td>
<td>249 (43.7)</td>
</tr>
<tr>
<td>TE serious infections</td>
<td>7 (1.2)</td>
<td>2 (1.6)</td>
<td>1.0 (3.0, 4.0)</td>
<td>15 (5.9, 2.6)</td>
</tr>
<tr>
<td>Opportunistic infections</td>
<td>2 (0.4)</td>
<td>0.8 (0.4, 1.7)</td>
<td>0.3 (0.3, 4.0)</td>
<td>1.0 (0.3, 3.7)</td>
</tr>
<tr>
<td>TE herpes zoster</td>
<td>16 (2.8)</td>
<td>5 (2.8)</td>
<td>1.9 (1.1, 3.0)</td>
<td>2.5 (1.6, 1.6)</td>
</tr>
<tr>
<td>TE MACE (adjudicated)</td>
<td>1 (0.2)</td>
<td>0</td>
<td>3 (0.5)</td>
<td>3 (0.3, 1.7)</td>
</tr>
<tr>
<td>TE DVT/PE (adjudicated)</td>
<td>3 (0.5)</td>
<td>0.3 (0.1, 0.1)</td>
<td>0.0 (0.1, 0.1)</td>
<td>0.4 (0.1, 1.1)</td>
</tr>
<tr>
<td>Malignancies (excluding NMSC)</td>
<td>5 (0.9)</td>
<td>0.6 (0.2, 1.4)</td>
<td>1.0 (0.5, 4.7)</td>
<td>0.5 (0.1, 1.2)</td>
</tr>
<tr>
<td>NMSC</td>
<td>3 (0.5)</td>
<td>0.3 (0.1, 0.1)</td>
<td>0.0 (0.1, 0.1)</td>
<td>0.2 (0.0, 0.8)</td>
</tr>
</tbody>
</table>

DVT, deep vein thrombosis; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PE, pulmonary embolism; TE, treatment-emergent
REFERENCES:

Acknowledgements: This study was funded by Gilead Sciences, Inc., Foster City, CA. Medical writing support was provided by Claudine Bittel, PhD, of AlphaScientia, LLC, San Francisco, CA; and funded by Gilead Sciences, Inc., Foster City, CA.


**PO5680 PHYSICIANS’ REASONS FOR PRESCRIBING JANUS KINASE INHIBITORS (JAKI) IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA), AND ASSOCIATED ALIGNMENT BETWEEN PHYSICIANS AND PATIENTS IN A REAL-WORLD CLINICAL SETTING**

1 University of Oxford, Nuffield Department of Orthopaedics, Oxford, United Kingdom; 2 Sorbonne Université - Assistance Publique Hôpitaux de Paris, Rheumatology Department, Paris, France; 3 Ghent University Hospital, Ghent and AZ Sint-Jans Brugge - Oostende AVE, Rheumatology, Bruges, Belgium; 4 University Hospital Complex of Pontevedra, Rheumatology Service, Pontevedra, Spain; 5 Maxima Medical Centre, Location Velhoven, Regional Rheumatology Center, Velhoven and Eindhoven, Netherlands; 6 MVZ für Rheumatologie, - Planegg, Germany; 7 Adelphi Real World, Rheumatology, Bollington, United Kingdom; 8 Galapagos NV, Medical Affairs, Mechelen, Belgium; 9 The University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; 10 Schlosspark Klinik, Department of Internal Medicine II, Berlin, Germany

Background: Shared decision making, a cornerstone of RA management1, allows physicians and their patients to make informed decisions about their treatment goals and choice of care. As new treatments become available, it is important to understand rheumatologists’ reasons for choosing JAKI, in addition to exploring alignment between rheumatologists and RA patients in terms of treatment choice and satisfaction.

Objectives: This survey evaluated rheumatologists’ clinical and patient centric reasons for choosing JAKI, in addition to exploring alignment between rheumatologists and RA patients in terms of treatment choice and satisfaction.

Methods: The Adelphi RA Disease Specific Programme2 is a large, multinational, point-in-time survey conducted amongst rheumatologists and their consecutive patients with RA in Europe (Belgium, France, Germany, Italy, Spain, UK) between January and October 2020. Physicians completed record forms for up to 10 consecutive RA patients, collecting demographic, clinical and treatment data, and reasons for current treatment choice. Patients were invited to complete a patient questionnaire to assess their satisfaction with ongoing treatment (5-point scale), and perceptions of shared decision making for the current treatment.

Results: 316 rheumatologists provided data for 3121 patients, of whom 1103 (36.2%) completed patient reported questionnaires. Overall, 67% were female, mean age was 53 years (SD 14), 23% had moderate-high disease activity score (DAS28 >3.2), 68% of patients were currently receiving either a biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD; defined here as advanced therapy, AT), 72% were on first line AT, overall, physicians and their patients were aligned that a conversation took place about a treatment decision (80%; n=2511), and this was a shared treatment decision (n=814, 75% net alignment). 15% of patients not taking an AT were reported to have a clinical condition warranting one; reasons for not taking AT included patients’ concerns about infection (24%), conventional synthetic DMARDs were tolerated and safe in the patient (18%), and patient dislike of infusions/injections (17%). Of 2143 patients receiving AT, 19% were prescribed JAKI; 57% as monotherapy, 43% as combination therapy. For physician stated reasons for choice of JAKI, factors were driven by both perceptions of clinical efficacy and onset of action, as well as factors relating to patient acceptability such as method of delivery and ease of use (Table 1). With respect to JAKI treatment (n=135 patient-physician pairs), 62% of physicians and their patients were aligned on satisfaction, however 30% of patients reported less satisfaction than their consulting physician (Figure 1).

Table 1. Physician stated clinical and patient centric reasons for prescribing a JAKI in their patients with RA (data are percentage of patients; n=397)

<table>
<thead>
<tr>
<th>Reasons for prescribing JAKI</th>
<th>Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Top 5 clinical reasons</strong></td>
<td></td>
</tr>
<tr>
<td>Strong overall efficacy</td>
<td>74</td>
</tr>
<tr>
<td>Fast onset of action</td>
<td>49</td>
</tr>
<tr>
<td>Inhibition of disease progression</td>
<td>42</td>
</tr>
<tr>
<td>Strong efficacy as monotherapy</td>
<td>39</td>
</tr>
<tr>
<td>Achievement of clinical remission</td>
<td>37</td>
</tr>
<tr>
<td><strong>Top 5 patient centric reasons</strong></td>
<td></td>
</tr>
<tr>
<td>Acceptability of method of delivery for the patient</td>
<td>39</td>
</tr>
<tr>
<td>Enabling patient to perform everyday tasks/activities</td>
<td>36</td>
</tr>
<tr>
<td>Ease of product use (for the patient)</td>
<td>33</td>
</tr>
<tr>
<td>Improvement or maintenance of quality of life</td>
<td>30</td>
</tr>
<tr>
<td>Improving patient’s mood/state of mind</td>
<td>14</td>
</tr>
</tbody>
</table>

Conclusion: Communicating the choice of pharmaceutical therapy to patients with RA has become increasingly complex for physicians with expansion of approved treatments. In this subgroup of patients on JAKI, the drug attributes considered as reasons for prescribing were driven by clinical factors as well as by patient centric attributes. Although communications between patients and physicians were largely aligned, better understanding of patient expectations might serve to improve messaging about treatment options and resulting satisfaction.

REFERENCES:

Figure. Level of alignment between physician and patient-reported satisfaction with JAKI

Acknowledgements: The study was funded by Galapagos NV (Mechelen, Belgium). We thank the physicians and patients who participated in this survey. Medical writing support was provided by Gary Sidgwick, PhD (Adelphi Real World, Bollington, UK) and publications management was provided by Aspire Scientific Ltd. (Bollington, UK), funded by Galapagos NV.

Disclosure of Interests: Peter C. Taylor Consultant of: AbbVie, Biogen, Bristol-Myers Squibb, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB, Grant/research support from: Celgene and Galapagos, Bruno Fautrel Consultant of: AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Celgene, Celtrion, Fresenius Kabi, Gilead, Janssen, Lilly, Medac, MSD, Mylan, NORDIC Pharma, Novartis, Pfizer, Roche, Sando, Sanofi-Genzyme, Sobi, and UCB, Grant/research support from: AbbVie, Lilly, MSD, and Pfizer, Yves Piette Consultant of: AbbVie, Galapagos, Grüneenthal, Novartis, Janssen, and Sandoz, Susana Romero-Yuste Speakers bureau: AbbVie, Amgen, Bristol-Myers Squibb, Grünenthal, Janssen, Kern Pharma, Lilly, Roche, Sandoz, Sanofi, and UCB, Consultant of: AbbVie, Bristol, Biogen, Fresenius, Galapagos, Gilead, Janssen, and Lilly, Grant/research support from: Bristol Myers Squibb, MSD, Novartis, and Pfizer, Jasper Broen Consultant of: Galapagos, Gilead, UCB, and Novartis, Martin Welcker Speakers bureau: Abb-Vie, Aescu, Amgen, Biogen, BMS, Berlin Chemie, GSK, Hexal, Janssen, Medac, MSD, Mundipharma, Mylan, Novartis, Pfizer, Nirens, Sanofi, and UCB, Consultant of: AbbVie, Bristol, Biogen, Fresenius, Galapagos, Gilead, Hexal, Roche, Sanofi, and UCB, Grant/research support from: AbbVie, Actelion, Boehringer, Galapagos, Gilead, GSK, Hexal, Novartis, and UCB, Elizabeth Holdsworth Employee of: Adelphi Real World, Monia Zignani Employee of:
Galapagos NV, Katrien Van Beneden Shareholder of: Galapagos NV. Employee of: Galapagos NV, Roberto Caporali Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celtrion, Fresenius Kabi, Galapagos, Gilead, Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celtrion, Galapagos, Gilead, Janssen, Lilly, and MSD, Rieke Alten Consultant of: AbbVie, Amgen, Biogen, Roche, Samsung Bioepis, Sanofi, and UCB.

Disclosure of Interests: Roberto Caporali Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Celtrion, Fresenius Kabi, Galapagos, Gilead, Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celtrion, Galapagos, Gilead, Janssen, Lilly, Novartis, and Pfizer, and Roche.


**POS0682**

**DRUG RETENTION RATE AND EFFECTIVENESS OF JAK INHIBITOR IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS**

S. Aino1,2,3, T. Okano1, K. Manda4, K. Crita4, Y. Yamada1, K. Mamoto1, T. Iida5,6, M. Tada7, K. Inui4, T. Koike8,9, H. Nakamura1. 1Osaka City University Medical School, Orthopaedic Surgery, Osaka, Japan; 2Osaka Social Medical Center, Orthopaedic Surgery, Osaka, Japan; 3Yodogawa Christian Hospital, Orthopaedic Surgery, Osaka, Japan; 4Osaka Saiseikai Nakatsu Hospital, Orthopaedic Surgery, Osaka, Japan; 5Kyorai Hospital, Orthopaedic Surgery, Osaka, Japan; 6Takahiro Clinic Orthopedic Surgery, Nishinomiya, Japan; 7Osaka City General Hospital, Orthopaedic Surgery, Osaka, Japan; 8Osaka City University Medical School, Center for Senile Degenerative Disorders (CSDD), Osaka, Japan; 9Shirahama Foundation for Health and Welfare, Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama, Japan

**Background:** Recently, the disease activity of rheumatoid arthritis (RA) was improved due to the ‘treat-to-target’ strategy. However, some patients remain various symptoms despite recommended treatment was performed. Then, the term of ‘difficult-to-treat RA (D2TRA)’ is widely recognized. Janus kinase inhibitor (JAKi) might be effective for D2TRA patients, because JAKi can simultaneously block the function of multiple cytokines.

**Objectives:** The aim of this study was to evaluate drug retention rate and effectiveness of JAKi in patients with D2TRA.

**Methods:** This study included 220 RA patients (tofacitinib 101, baricitinib 83, upadacitinib 20, peficitinib 14, filgotinib 2) treated with JAKi. Sixty-two patients were treated as first line bDMARDs/JAKi (1st group), 57 patients were treated as second line bDMARDs/JAKi (2nd group), 101 patients were treated as third and more bDMARDs/JAKi. In these 101 patients, 25 patients did not met D2TRA criteria (non-D2TRA group) and 76 patients met D2TRA criteria (D2TRA group). Drug retention rate and effectiveness of JAKi were evaluated during 24 weeks in each group.

**Results:** Usage rate of methotrexate was lower and dosage of glucocorticoid was higher in D2TRA group than in other groups (Table 1). Drug retention rate at 24 weeks was 87.1% (54/62) in 1st group, 80.1% (46/57) in 2nd group, 88% (22/25) in non-D2TRA group, 61.8% (47/76) in D2TRA group. Drug retention rate was lower in D2TRA group compared to 1st group, 2nd group and non-D2TRA group (p<0.01, p<0.01, p<0.01), there was no difference between DT2RA group and 2nd group or non-D2TRA group (p=0.95, p=0.48). SDAI was 22.9, 19.9, 18.3, 23.9 at baseline, 11.8, 11.9, 13.3, 14.4 at 4 weeks, 79, 11.3, 8.4, 13.3 at 12 weeks, 8.5, 11.5, 9.7, 12.6 at 24 weeks. CDAI was 213, 18.8, 176, 218 at baseline, 113, 12.5, 13.9 at 4 weeks, 75, 10.9, 8.0, 12.3 at 12 weeks, 8.1, 10.7, 8.6, 12.1 at 24 weeks. HAQ was 1.15, 0.99, 0.89, 1.39 at baseline, 0.84, 0.76, 0.93, 1.22 at 4 weeks, 0.79, 0.84, 0.77, 1.17 at 12 weeks, 0.76, 0.79, 0.76, 1.14 at 24 weeks. Improvement rate of HAQ at 24 weeks were 44.3%, 23.9%, 21.2%, 8.1%.

**Conclusion:** Drug retention rate of JAKi in treatment of D2TRA group were lower than that of 1st group, 2nd group, and non-D2TRA group. Clinical efficacy of JAKi in D2TRA group were not significantly different to 2nd group and non-D2TRA group. However, HAQ improvement was weak in D2TRA group.

**Disclosure of Interests:** None declared


**POS0683**

**LONG-TERM EFFICACY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO BDMAARDS: RESULTS FROM RA-BEYOND FOLLOWING 6.9 YEARS OF TREATMENT**

R. Caporali1, D. Aletaha2, R. Sanmartí3, T. Takeuchi4, D. Mo5, E. Halady6, L. Zaremba-Pechmann6, P. C. Taylor7. 1University of Milan, Department of Clinical Sciences & Community Health, Milan, Italy; 2Medical University of Vienna, Department of Medicine III, Vienna, Austria; 3Hospital Clinic de Barcelona and IDIBAPS, Rheumatology Department, Barcelona, Spain; 4Keio University School of Medicine, Division of Rheumatology, Tokyo, Japan; 5Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America; 6HaaPACS GmbH, HaaPACS GmbH, Schriesheim, Germany; 7University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

**Background:** Baricitinib (BARI), an oral selective Janus kinase 1/2 inhibitor, is approved for treatment of adults with moderately-to-severely active rheumatoid arthritis (RA). BARI demonstrated efficacy in patients (pts) with RA who have inadequate response to biologic disease-modifying antirheumatic drugs (bDMARD-IR) in a 24-week (wk) phase 3 study, RA-BEACON.1 BARI efficacy was evaluated up to 3 years (yrs) of treatment in a long-term extension (LTE) study, RA-BEYOND.2

**Objectives:** Disclose long-term efficacy of BARI 4 mg and 2 mg in bDMARD-IR pts in the completed study RA-BEYOND.

**Methods:** In RA-BEACON, pts were randomized 1:1:1 to BARI 4 mg, 2 mg, or PBO; pts with no response could be rescued after wk 16. Completers to wk 24 could enter with BARI 4 or 2mg RA-BEYOND for up to 360 wks (6.9 yrs). LTE data were analysed by treatment assigned at baseline in RA-BEACON as observed up to time of stepdown (if applicable), study discontinuation, or study completion, whichever occurred earlier. Efficacy response rates (ARR) were assessed as proportions of pts with observed data up to wk 360 for low-disease activity (LDA) (SDAI ≤ 11, DAS28-hsCRP < 3.2, CDAI ≤ 10), remission (REM) (SDAI ≤ 3.3, DAS28-hsCRP < 2.6, CDAI ≤ 2.8, Boolean), and physical functioning (HAQ-DI ≤ 0.5). No formal statistical comparisons were conducted.

**Results:** 156, 132, and 140 pts entered the LTE (4 mg, 2 mg, and PBO, respectively). Pts in BARI 4 and 2mg arms had higher LDA and REM RR vs PBO at LTE.
entry (wk 24) (Table 4). PBO-treated pts achieved comparable RR to pts in the BARI 4 mg arm by wk 48 (24 wks after switch to BARI 4 mg) and up to wk 360. Of pts enrolled to RA-BEYOND, approx. 50% in BARI 4 mg, 65% in 2 mg and 61% in PBO remained active at wk 156; 17%, 26% and 26% at wk 360, respectively. SDAI LDA RR were 47%/70% and 61%/74% for pts treated with BARI 4 mg and 2 mg, at wk 156 (yr 3)/360 (yr 6.9), respectively; SDAI REM RR were 15%/26% and 26%/26% for BARI 4 mg and 2 mg, at wk 156/360, respectively (Table 1). SDAI and CDAI had comparable RR. DAS-28 CRP LDA RR were similar to SDAI and CDAI, while REM RR were almost twice those of SDAI and CDAI. HAQ-DI ≤ 0.5 RR was 15%/26% (BARI 4 mg), 21%/15% (BARI 2 mg), and 9%/3% (PBO) at 3/6.9 yrs.

Conclusion: In observed data, BARI maintained efficacy and normative physical function bDMARD-IR population up to 6.9 yrs (360 wks).

REFERENCES:


Table 1. Efficacy outcomes in RA-BEYOND

<table>
<thead>
<tr>
<th>Time (wks)</th>
<th>PBO</th>
<th>BARI 4 mg</th>
<th>BARI 2 mg</th>
<th>REM</th>
</tr>
</thead>
<tbody>
<tr>
<td>wk 24</td>
<td>135/31 (23.0)</td>
<td>138/32 (23.2)</td>
<td>135/31 (23.0)</td>
<td>135/36 (4.4)</td>
</tr>
<tr>
<td>wk 48</td>
<td>128/61 (45.1)</td>
<td>129/58 (45.0)</td>
<td>128/58 (45.3)</td>
<td>128/14 (10.9)</td>
</tr>
<tr>
<td>wk 156</td>
<td>84/68 (47.4)</td>
<td>85/60 (47.3)</td>
<td>84/57 (47.3)</td>
<td>84/15 (17.0)</td>
</tr>
<tr>
<td>wk 360</td>
<td>61/80 (61.2)</td>
<td>62/60 (60.6)</td>
<td>61/58 (59.2)</td>
<td>61/25 (25.5)</td>
</tr>
</tbody>
</table>

N: Number of pts with observed data; n: Number of pts with response. a Number of wks from randomisation. b Treatment groups as assigned at randomisation.

RESULTS: 588 TNF-IR patients were included: 146 from BEYOND, 263 from CHOICE, and 159 from COMPARE. Mean duration since RA diagnosis was longer for BEYOND and CHOICE versus COMPARE. Cardiovascular (CV) risk factors were common among this refractory population (Table 1). ACR20/50/70 and disease activity outcomes observed in the TNFi-IR population were generally consistent with the overall BEYOND and CHOICE bDMARD-IR populations, and consistent across the three studies in the TNFi-IR subgroup (Figure 1). Improvements in PROs including HAQ-DI, fatigue, pain, and morning stiffness over 24 weeks were observed (data not shown). Pooled safety results reported 1574.8 patient-years (PY) of exposure in the TNFi-IR subgroup showed similar results to the overall BEYOND and CHOICE bDMARD-IR study populations, with EAErs of 3.1 events/100 PY for herpes zoster and 0.8 events/100 PY for adjudicated major adverse CV events, adjudicated venous thromboembolism (VTE), and malignancy excluding non-melanoma skin cancer. The EAEr of any AE leading to death was 1.4 events/100 PY.
**Table 1. Baseline characteristics of TNF-IR patients treated with UPA 15 mg**

<table>
<thead>
<tr>
<th></th>
<th>SELECT BEYOND (n=146)</th>
<th>SELECT CHOOSE (n=285)</th>
<th>SELECT COMPARE (ADA → UPA) (n=159)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female</strong> (%)</td>
<td>122 (83.6)</td>
<td>219 (83.3)</td>
<td>133 (86.3)</td>
</tr>
<tr>
<td><strong>Mean (SD) age, years</strong></td>
<td>56.6 (11.0)</td>
<td>55.5 (11.1)</td>
<td>53.9 (10.6)</td>
</tr>
<tr>
<td><strong>Mean (SD) duration of RA diagnosis, years</strong></td>
<td>13.2 (9.5)</td>
<td>12.5 (9.4)</td>
<td>8.2 (8.5)</td>
</tr>
<tr>
<td><strong>Concomitant csDMARDs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTX alone (%)</td>
<td>100 (70.4)</td>
<td>195 (74.1)</td>
<td>159 (100.0)</td>
</tr>
<tr>
<td>MTX and other csDMARDs (%)</td>
<td>20 (14.1)</td>
<td>25 (9.5)</td>
<td>0</td>
</tr>
<tr>
<td><strong>CV risk factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>72 (49.3)</td>
<td>109 (41.4)</td>
<td>68 (42.8)</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>22 (15.1)</td>
<td>34 (12.9)</td>
<td>17 (10.7)</td>
</tr>
<tr>
<td>Smoking (current/former past) (%)</td>
<td>68 (46.6)</td>
<td>109 (41.5)</td>
<td>55 (34.6)</td>
</tr>
<tr>
<td>Elevated LDL-C (≥3.06 mmol/L) (%)</td>
<td>38 (26.0)</td>
<td>52 (20.0)</td>
<td>48 (30.2)</td>
</tr>
<tr>
<td>Low HDL-C (≤1.55 mmol/L) (%)</td>
<td>80 (54.8)</td>
<td>171 (65.0)</td>
<td>88 (55.3)</td>
</tr>
</tbody>
</table>

*These patients received one bDMARD before entry into SELECT-COMPARE.* Remaining patients were intolerant to ≥1 prior TNFi.

**Conclusion:** In this post hoc subgroup analysis, TNF-IR patients treated with UPA 15 mg achieved clinically meaningful efficacy responses over 24 weeks, with safety consistent with the overall bDMARD-IR patient population in the Phase 3 program.

**REFERENCES:**


**Figure.** ACR20/50/70 and disease activity outcomes of UPA 15 mg in TNF-IR patients with RA

**Disclosure of Interests:** Roy M. Fleischmann Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Galvani, Gilead, GSK, Janssen, Novartis, Pfizer, and UCB; Grant/research support from: AbbVie, Amgen, Biopiluce, Bristol-Myers Squibb, Flexion, Gilead, Horizon, Eli Lilly, Galvani, Janssen, Novartis, Pfizer, Sanofi-Aventis, Selecta, Teva, UCB, Viela, and Voro; Louis Bessette Speakers bureau: AbbVie, Amgen, Bristol-Meyers Squibb, Celgene, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Teva, and UCB; Consultant of: AbbVie, Amgen, Bristol-Meyers Squibb, Celgene, Eli Lilly, Fresenius Kabi, Gilead, and Sanofi; Employee of: AbbVie, Amgen, Bristol-Meyers Squibb, Celgene, Eli Lilly, Fresenius Kabi, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Teva, and UCB; Jeffrey Sparks Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer; Stephen Hall Consultant of: AbbVie, Amgen, Bristol-Meyers Squibb, Eli Lilly, Galvad, Janssen, Merck, Novartis, and UCB; Grant/research support from: AbbVie, Amgen, Bristol-Meyers Squibb, Eli Lilly, Gilead, Janssen, Merck, Novartis, and UCB; Marjauh Jain Consultant of: AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer; Grant/research support from: AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer, Adriana Kakehashi Speakers bureau: AbbVie, Amgen, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer, Sanzod, and UCB; Consultant of: AbbVie, Amgen, Eli Lilly, Fresenius Kabi, Janssen, Novartis, Pfizer, Sanzod, and UCB, Yanna Song Shareholder of: AbbVie (may own stock or options), Employee of: AbbVie, Sebastian Meerwein Shareholder of: AbbVie (may own stock or options), Employee of: AbbVie, Ryan DeMasi Shareholder of: AbbVie (may own stock or options); Employee of: AbbVie, Jessica Suboticki Shareholder of: AbbVie (may own stock or options), Employee of: AbbVie, Andrea Rubbert-Roth Consultant of: AbbVie, AbbVie Deutschland, Amgen, Bristol-Myers Squibb, Chugai Pharmaceuticals, Eli Lilly, F. Hoffman-La Roche, Gilead Sciences, Janssen Global Services, Novartis, and Sanofi Pasteur

**DOI:** 10.1136/annrheumdis-2022-eular.1800
Results: 483 patients (369 female, 114 male) were included in the study, with available baseline PRO information for 481 patients. 6-months follow-up data were yet available from 279 patients. The baseline average age and disease duration were 58.0 (12.3) years and 9.0 (8.0) years, respectively, whereas the mean initial DAS28-CRP was 4.6 (1.0). At baseline, 60.8% of enrolled patients had previously been treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. Overall, PRO scores improved from baseline throughout month 6 with a considerable amelioration at month 3, which was maintained at month 6. Responses were rapid, with improvement already evident at month 1 (Table 1). The NRS pain as a crucial PRO in RA confirmed the previously described pattern of results seen for most of the other PROs (Figure 1).

Table 1. Baseline scores and average changes from baseline scores

<table>
<thead>
<tr>
<th>PRO</th>
<th>Baseline scores (SD)</th>
<th>Change from baseline - month 1 (SD)</th>
<th>Change from baseline - month 3 (SD)</th>
<th>Change from baseline - month 6 (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain (NRS)</td>
<td>481.6 (2.2)</td>
<td>393.2 -2.2 (2.3)</td>
<td>392.5 -2.5 (2.5)</td>
<td>258.2 -2.4 (2.4)</td>
</tr>
<tr>
<td>Fatigue (NRS)</td>
<td>481.5 (2.6)</td>
<td>393.9 -1.4 (2.3)</td>
<td>393.6 -1.6 (2.4)</td>
<td>259.1 -1.5 (2.3)</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>471.3 (3.6)</td>
<td>380.2 -0.2 (0.3)</td>
<td>376.2 -0.4 (0.4)</td>
<td>253.2 -0.2 (0.4)</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>439.8 (69.3)</td>
<td>316.3 -25.0 (55.3)</td>
<td>296.9 -29.6 (54.9)</td>
<td>179.3 -316.1 (51.7)</td>
</tr>
<tr>
<td>(duration, minutes)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>478.5 (2.7)</td>
<td>386.1 -18.2 (2.3)</td>
<td>393.2 -2.2 (2.6)</td>
<td>258.2 -2.2 (2.9)</td>
</tr>
<tr>
<td>PHQ-9</td>
<td>477.8 (5.2)</td>
<td>383.3 -19.3 (3.3)</td>
<td>381.2 -2.3 (4.0)</td>
<td>255.2 -2.2 (3.8)</td>
</tr>
<tr>
<td>RAID</td>
<td>466.5 (2.9)</td>
<td>393.7 -17.1 (1.8)</td>
<td>392.4 -2.0 (2.3)</td>
<td>258.3 -1.9 (1.9)</td>
</tr>
</tbody>
</table>

Conclusion: This interim analysis confirmed a meaningful improvement regarding included PROs that cover various RA-related symptoms, depressiveness and the impact of symptoms of RA on daily life.

REFERENCES:

Acknowledgements: AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and in the writing, review, and approval of the abstract. AbbVie and the authors thank all study investigators for their contributions and the patients who participated in this study. No honoraria or payments were made for authorship. The medical writing support was provided by Matthias Engbret, Freelance Healthcare Data Scientist (Eckert, Germany) and was funded by AbbVie. Statistical analyses were provided by Dr. Daniela Adolff of StatConsult GmbH (Magenburg, Germany) which was funded by AbbVie.

Disclosure of Interests: Torsten Witte Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Chugai, Gilead, Janseen, Lilly, MSD, Mylan, Novartis, Pfizer, Roche, and UCB, Uta Kiltz Consultant of: AbbVie, Bio- cad, Eli Lilly and Company, Grünenthal, Hexal, Janseen, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Amgen, Biogen, Fresenius, GSK, Hexal, Novartis, and Pfizer, Florian Haas Consultant of: AbbVie, Celgene, Novartis, and Pfizer, Grant/research support from: AbbVie, BMS, Cel- gene, Chugai, MSD, Novartis, Pfizer, Roche, and Sanofi Genzyme, Elke Rech- ers Consultant of: AbbVie, Chugai, Novartis, and UCB, Grant/research support from: AbbVie, Chugai, Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Ulrich Prothmann Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Chugai, Glaxo Smith Kline, Novartis, Pfizer, Roche, Sanofi, SOBI, and UCB, Daniela Adolf Consultant of: AbbVie, Bio- cad, Eli Lilly and Company, Grünenthal, Hexal, Janseen, MSD, Novartis, Pfizer, Roche, and UCB, Uta Kiltz Consultant of: AbbVie, Biogen, BMS, Celltrion, Gilead, Hexal, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, and UCB

Background: Upadacitinib (UPA) was previously evaluated in two Phase 2, randomized, controlled trials (RCTs) in patients (pts) with rheumatoid arthritis (RA) and inadequate response to tumor necrosis factor inhibitors (BALANCE-1) or methotrexate (BALANCE-2).

Objectives: To assess the final safety and efficacy of UPA in BALANCE-EX- TEND, a 312-week open-label extension (OLE) enrolling pts who completed either BALANCE-1 or BALANCE-2.

Methods: All pts initially received UPA 6 mg twice daily (BID). Increase to 12 mg BID was required for pts with <20% improvement in swollen or tender joint counts (S/TJC) at Week 6 or 12, and permitted for those not achieving Clinical Disease Activity Index (CDAI) low disease activity (LDA). Pts with <20% improvement in SJC or TJC at any two consecutive visits, discontinued. Return to 6 mg BID was permitted for safety or tolerability reasons. After January 2017, the 6 and 12 mg BID doses were replaced by 15 and 30 mg once-daily (QD) extend- ed-release equivalents. As-observed efficacy data are shown at Week 312 for three subgroups: pts who received 6 mg BID/15 mg QD throughout ("Titrated up"), those titrated up to 12 mg BID/30 mg QD for efficacy ("Titrated up"), and those titrated up to 12 BID/30 mg QD and then back to 6 mg BID/15 mg QD due to safety concerns ("Titrated up and down"). Exposure-adjusted adverse events (EAERs) per 100 patient-years (PY) of exposure were summarized from OLE Day 1 in all pts who received UPA (Any UPA).

Results: Overall, 493 pts entered the OLE, receiving UPA for ≤62 years (Never titrated, n=306; Titrated up, n=149; Titrated up and down, n=38), and 270 pts (54.8%) discontinued, mostly due to withdrawal of consent (16.8%; n=83) or AEs (14.6%; n=72). Mean (standard deviation) duration of UPA exposure was 3.8 (2.4) years (range <1–6.2 years); cumulative exposure was 1863 PY. The AE profile in pts receiving UPA 15 mg was generally similar to the Any UPA popula- tion, and to that observed in the Phase 3 UPA 15 mg clinical trial population (Table 1). Efficacy was maintained to Week 312, with 84.5% and 86.6% of pts in the Never titrated group achieving DAS28-CRP ≤3.2 and CDAI LDA, respectively (Figure 1).
Table 1. Summary of AEs in pts who received UPA 6 mg BID/15 mg QD in the OLE and in the UPA 15 mg Phase 3 study program

<table>
<thead>
<tr>
<th>Event</th>
<th>OLE (95% CI)</th>
<th>Phase 3 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any AE</td>
<td>138.4 (132.0, 145.0)</td>
<td>205.5 (202.5, 208.5)</td>
</tr>
<tr>
<td>Any SAE</td>
<td>78 (6.4, 8.6)</td>
<td>124 (11.7, 13.2)</td>
</tr>
<tr>
<td>AE leading to discontinuation</td>
<td>4.2 (3.2, 5.5)</td>
<td>4.9 (4.4, 5.3)</td>
</tr>
<tr>
<td>Death</td>
<td>0.4 (0.1, 0.9)</td>
<td>0.5 (0.4, 0.7)</td>
</tr>
<tr>
<td>Infection</td>
<td>49.2 (45.5, 52.9)</td>
<td>63.9 (62.3, 65.6)</td>
</tr>
<tr>
<td>Serious infection</td>
<td>1.4 (0.8, 2.2)</td>
<td>2.8 (2.4, 3.1)</td>
</tr>
<tr>
<td>Opportunistic infection</td>
<td>0.2 (0.0, 0.6)</td>
<td>0.3 (0.2, 0.4)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>2.0 (1.3, 3.0)</td>
<td>3.0 (2.6, 3.3)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>11.1 (6.6, 18)</td>
<td>3.0 (2.7, 3.4)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1.8 (0.3, 2.1)</td>
<td>2.1 (1.8, 2.5)</td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>1.7 (1.1, 2.6)</td>
<td>1.7 (1.4, 1.9)</td>
</tr>
<tr>
<td>Gastrointestinal perforation</td>
<td>0</td>
<td>0.1 (0.0, 0.1)</td>
</tr>
<tr>
<td>Any malignancy</td>
<td>1.2 (0.7, 1.9)</td>
<td>1.1 (0.9, 1.4)</td>
</tr>
<tr>
<td>Non-melanoma skin cancer (NMISC)</td>
<td>0.4 (0.1, 0.9)</td>
<td>0.4 (0.3, 0.5)</td>
</tr>
<tr>
<td>Excluding NMISC</td>
<td>0.8 (0.4, 1.4)</td>
<td>0.7 (0.6, 0.9)</td>
</tr>
<tr>
<td>Creatinine phosphokinase elevation</td>
<td>3.4 (2.5, 4.6)</td>
<td>4.4 (4.0, 4.9)</td>
</tr>
<tr>
<td>Hepatic disorder</td>
<td>4.1 (3.0, 5.3)</td>
<td>10.2 (9.5, 10.8)</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
<td>0.5 (0.2, 1.0)</td>
<td>0.3 (0.4, 0.6)</td>
</tr>
<tr>
<td>Major adverse cardiovascular event</td>
<td>0.5 (0.2, 1.0)</td>
<td>0.4 (0.3, 0.5)</td>
</tr>
</tbody>
</table>

*Multiple events occurring in the same pts are counted in the calculation of events/100 PY.

Conclusion: In this OLE, UPA treatment over ~312 weeks showed sustained long-term efficacy in pts with RA who had completed Phase 2 RCTs. Overall safety results showed that UPA was well tolerated over time; the types and frequencies of AEs were consistent with those in pts with similar populations of moderately to severely active RA receiving Janus kinase inhibitors.

Acknowledgements: AbbVie funded this study; contributed to its design; participated in data collection, analysis, and interpretation of the data; and participated in the writing, review, and approval of the abstract. AbbVie and the authors thank all study investigators for their contributions and the patients who participated in this study. No honoraria or payments were made for authorship. Medical writing support was provided by Dan Booth, PhD, of the Nth (Cheshire, UK), and was funded by AbbVie.

Disclosure of Interests: Alan Kivitz Shareholder of: Amgen, Gilead, GlaxoSmithKline, Novartis, Pfizer, and Sanofi (stocks or options); Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Flexion, Genzyme, Gilead, Hori-zon, Janssen, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sanofi Aventis, SUN Pharma Advanced Research, and UCIB, Grant/research support from: AbbVie, (his institution received fees for his role as a Principal Investigator in the study), Alvin F.Wells Consultant of: AbbVie, Juan Ignacio Vargas Consultant of: AbbVie, Grant/research support from: AbbVie (as a Principal Investigator in the study), Herbert S.B. Baraf Consultant of: Gilead and Janssen, Grant/research support from: AbbVie, Eli Lilly, Genentech, Gilead, and Janssen, Maureen Rischmuel-ler Consultant of: AbbVie, Bristol-Myers Squibb, CSL Behring, Eli Lilly, Gilead Sciences, Janssen Global Services, Pfizer, Sanofi US Services, and UCB Bio-sciences, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen Global Services, Novartis, Pfizer, Sanofi Pasteur Biologics, and UCIB Biosciences, Justin Klaff Shareholder of: AbbVie (may own stocks or options), Employee of: AbbVie, Nasser Khan Shareholder of: AbbVie (may own stocks or options), Employee of: AbbVie, Yihan Li Shareholder of: AbbVie (may own stocks or options), Employee of: AbbVie, Kyle Carter Shareholder of: AbbVie (may own stocks or options), Employee of: AbbVie, Alan Friedman Shareholder of: AbbVie (may own stocks or options), Employee of: AbbVie, Patrick Durez, Speaker's bureau: Eli Lilly and Galapagos.


EFFECTIVENESS OF UPADACITINIB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: ANALYSIS OF 6-MONTH REAL-WORLD DATA FROM THE UNITED RHEUMATOLOGY NORMALIZED INTEGRATED COMMUNITY EVIDENCE (UR-NICE(TM)) DATABASE

A. Gibofsky1, M. E. Pearson2, A. Concoff3, A. Shmagel4, P. Zueger4, Y. Song4, L. Smith5, G. W. Wright6,1. Well Cornell Medical College, Hospital for Special Surgery, New York, New York, United States of America; 2West Suburban Center For Arthritis, Rheumatology, Brookfield, Wisconsin, United States of America; 3Department of Rheumatology, Rheumatology, Hauppauge, New York, United States of America; 4 AbbVie Inc., Immunology, North Chicago, Illinois, United States of America; 5Association of Women in Rheumatology, Rheumatology, New York, New York, United States of America

Background: The efficacy of upadacitinib (UPA), an oral Janus kinase inhibitor (JAKI), in the treatment of rheumatoid arthritis (RA) has been demonstrated in the phase 3 SELECT clinical trial program. However, few real-world data have been reported to date.

Objectives: To assess the 6-month effectiveness of UPA in patients (pts) with RA initiating UPA treatment in clinical practice.

Methods: This observational study included US-based pts from the United Rheumatology Normalized Integrated Community Evidence (UR-NICE) database that initiated UPA 15 mg once daily from Aug 2019 to the data cut-off in Nov 2021. Pts with ≥6 months of baseline (BL) data before UPA initiation, and with Clinical Disease Activity Index (CDAI) score recorded at BL and 6 months (+45 days) after initiation, were included in the analysis. Effectiveness measures included CDAI score, Routine Assessment of Patient Index Data 3 (RAPID3), and Disease Activity Score in 28 joints based on C-reactive protein (DAS28-CRP); patient-reported outcomes (PROs) including Health Assessment Questionnaire-Disability Index (HAQ-DI), Pain, and Patient’s Global Assessment of Disease Activity (PGA); and Physician’s Global Assessment of Disease Activity (PhGA). Subgroup analyses were conducted by prior tumor necrosis factor inhibitor (TNFi) and tocilizumab (TOFA) treatment history.

Results: 363 pts were included in the analysis and most were female (80.2%) (Table 1). 140 (39%) received UPA monotherapy and 223 (61%) received UPA plus conventional synthetic (cs) disease-modifying antirheumatic drugs (DMARDs). 83% of pts received prior csDMARDs, 72% prior biologics (TNFi 55%), and 41% JAKIs (TOFA 39%). Overall, 46% (166/363), 23% (57/254), and 55% (95/173) of pts achieved LDA by CDAI, RAPID3, and DAS28-CRP, respectively, and 14% (51/363), 16% (39/245), and 36% (82/237) of pts achieved remission (REM) by CDAI, RAPID3, and DAS28-CRP, respectively. Results were similar regardless of prior TNFi or TOFA exposure, supporting UPA as an effective treatment option in clinical practice.

In this study, almost half (46%) of pts treated with UPA achieved CDAI LDA at 6 months and 14% achieved CDAI REM. Improvements in all PROs and PhGA were observed. Effectiveness of UPA was not impacted by prior TNFi or TOFA exposure, supporting UPA as an effective treatment option in clinical practice, including in pts with prior exposure to advanced therapy.

REFERENCES:
RESULTS OF AN OPEN-LABEL, RANDOMIZED, CONVENTIONAL SYNTHETIC DMARD (CSDMARD) RHEUMATOID ARTHRITIS PATIENTS RECEIVING A

**Objective:**
This exploratory study aimed to compare, in patients receiving conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) for treatment of RA, the effectiveness of combined use of csDMARD and denosumab vs csDMARD alone, in terms of inhibition of ER determined by HR-pQCT.

**Methods:**
Detail protocol of this open-label, randomized, parallel-group study has been published previously. RA patients with moderate or low disease activity and progressive ER were eligible, and were randomly assigned to receive denosumab in addition to the csDMARD (denosumab group) or to continued use of the csDMARD alone (csDMARD group). Denosumab was administered every 6 months during the 12-month study period. The primary endpoint was change of ER-depth at month 6 from baseline as the primary endpoint was −0.57 (−1.52, 0.39) in the denosumab group vs −0.22 (−0.97, 0.53) in the csDMARD group, respectively. At months 6 and 12, ER-depth, width, and volume (extension data) were numerically lower in the denosumab group than in the csDMARD group (Table 1). Compared with patients in the csDMARD group, those in the denosumab group had significantly higher volumetric bone mineral density (vBMD) at month 12. AE were reported in 12 (52.2%) and 13 (56.5%) of patients in the denosumab and csDMARD groups, respectively. The most common AE of denosumab groups was hypocalcemia (reported in 4), and all the events were causally related with denosumab.

**Conclusion:**
Our results suggest that adding denosumab to csDMARD therapy may help prevent ER, promote ER repair, and improve bone microstructure.

**References:**
Shiraishi: None declared, Konosuke Watanabe: None declared, Nozomi Ohki: None declared, AkitoOm Okada: None declared, Tomohiro Koga: None declared, Makoto Kobayashi Employee of: Daiichi Sankyo Co., Ltd. (retired at submission), Kengo Saito Employee of: Daiichi Sankyo Co., Ltd., Naoki Okubo Employee of: Daiichi Sankyo Co., Ltd., Atsushi Kawamaki Speakers bureau: Daiichi Sankyo Co., Ltd., Grant/research support from: Daiichi Sankyo Co., Ltd.


Table 1. Efficacy endpoints.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>50 mg</th>
<th>100 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PP</td>
<td>ITT</td>
<td>PP</td>
</tr>
<tr>
<td>Early discontinuations due to AE</td>
<td>1</td>
<td></td>
<td>9</td>
</tr>
<tr>
<td>ACR20 n (%)</td>
<td>4 (21%)</td>
<td>4 (20%)</td>
<td>9 (56%)</td>
</tr>
<tr>
<td>ACR50 n (%)</td>
<td>1 (5%)</td>
<td>1 (5%)</td>
<td>5 (31%)</td>
</tr>
<tr>
<td>ACR70 n (%)</td>
<td>1 (5%)</td>
<td>1 (5%)</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>-0.63</td>
<td>-0.60</td>
<td>-1.79</td>
</tr>
<tr>
<td>Mean change from baseline DAS28-ESR</td>
<td>-0.65</td>
<td>-0.59</td>
<td>-1.86</td>
</tr>
<tr>
<td>Low Disease Activity (DAS28-CRP ≤ 3.2) (%)</td>
<td>2 (11 %)</td>
<td>2 (10%)</td>
<td>4 (25%)</td>
</tr>
<tr>
<td>Categorical DAS28-CRP response n (%)</td>
<td>8 (42%)</td>
<td>8 (40%)</td>
<td>14 (88%)**</td>
</tr>
<tr>
<td>CDLA ≤ 10 n (%)</td>
<td>2 (11%)</td>
<td>2 (10%)</td>
<td>5 (31%)</td>
</tr>
<tr>
<td>CDLA Remission n (%)</td>
<td>0</td>
<td>0</td>
<td>3 (19%)*</td>
</tr>
</tbody>
</table>

* P < 0.05, ** P < 0.01 Chi-squared test ABX-464 versus placebo
Background: Current NICE guidance for rheumatoid arthritis (RA) states that glucocorticoids may be used for bridging therapy and to rapidly decrease inflammation in acute flares. However, a recommended route and dosage is not specified, and variation has been observed between individual departments as to whether or not steroids are administered. Glucocorticoids are associated with adverse events that can be severe, leading to a strong recommendation by the American College of Rheumatology to avoid long term use. It is therefore important to ascertain the efficacy of available routes and dosages of glucocorticoids to weigh against these risks.

Objectives: This review aimed to ascertain the optimal route and dose of corticosteroid for adults with early RA.

Methods: Papers included were full text, English language, randomised controlled trials that fulfilled the PICO criteria. The population was defined as adults with early RA with onset <2 years, the intervention corticosteroids of any route or dose, the comparator conventional DMARDs or placebo, and the primary outcome remission. Functional improvement and X-ray progression were considered as secondary outcomes. MEDLINE, Embase, Web of Science and Cochrane Central were searched. Screening of results and extracted data was carried out by both reviewers. During data extraction, outcomes were rounded to timepoints of 3, 6 and 12 months, and steroid doses were stratified into low (up to 10mg/day prednisolone or equivalent), medium (15-30mg) and high (>30mg). Meta-analyses were carried out in RevMan 5.4 when 3 or more studies measured the same outcome at the same dose and route. A funnel plot was generated to check for publication bias.

Results: Three papers measured DAS28 remission rate at 1 year, comparing DMARDs only to DMARDs plus low dose oral steroids. The Forest plot for this meta-analysis is shown in Figure 1. As p = 0%, a fixed effect method was used. This shows an odds ratio (OR) of 1.73 (95% CI 1.25, 2.39) favouring low dose steroids. Both analyses favoured steroids; for HAQ scores the standardised mean difference (SMD) was -0.69 (95% CI -1.66, 0.29), and for DAS28 the SMD was -0.36 (95% CI -0.58, -0.15). At 3 and 6 months there was a lack of available data for meta-analyses.

Conclusion: At 1 year, remission and improvement in function appear more likely if low dose steroids are used. Due to a lack of available data, non-oral routes, higher doses and X-ray progression could not be analysed. Studies were not designed to detect differences in adverse events. This highlights the need for further clinical research into steroid efficacy in early RA. As the meta-analyses suggest that glucocorticoids may be more effective in inducing remission in early disease than conventional DMARDs alone.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.22417

Figure 1. Forest plot showing the OR of DAS28 remission with low dose steroids and conventional DMARDs vs DMARDs only

EMULATING A TARGET TRIAL OF ADALIMUMAB VERSUS TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A COMPARATIVE EFFECTIVENESS ANALYSIS USING THE OPAL REAL-WORLD DATASET

C. Deakin1,2,3, B. De Stavola4, G. Littlejohn1,5, H. Griffiths1,6, S. Cicirelli1,7, P. Youssfi1,9, D. Mathers1,10, P. Bird1,11, T. Smith1, C. Osullivan1, T. Freeman12, D. Segelov1, D. Hoffman1, S. Seaman1,2,3,4, OPAL Rheumatology Ltd, Rheumatology, Sydney, Australia; 1University College London, Centre for Adolescent Rheumatology Versus Arthritis, London, United Kingdom; 2Great Ormond Street Hospital, National Institute of Health Research Biomedical Centre, London, United Kingdom; 3UCL Great Ormond Street Institute of Child Health, Population and Policy and Research and Teaching Department, London, United Kingdom; 4Monash University Clayton Campus, Departments of Medicine, Clayton, Australia; 5Barwon Rheumatology Service, Rheumatology, Geelong, Australia; 6Royal Melbourne Hospital, Rheumatology, Melbourne, Australia; 7Royal Prince Alfred Hospital, Rheumatology, Camperdown, Australia; 8The University of Sydney, Rheumatology, Camperdown, Australia; 9Georgetown Arthritis, Rheumatology, Newcastle, Australia; 10UNSW Sydney, Rheumatology, Sydney, Australia; 11Software 4 Specialists Pty Ltd, (S4S), Sydney, Australia; 12University of Cambridge, MRC Biostatistics Unit, Cambridge, United Kingdom

Background: There is increasing recognition of the complementary role for real-world evidence (RWE) in health care and regulatory decision-making. However, careful analysis is required when drugs are compared using observational data to account for differences between treatment groups. Electronic medical records (EMR) are an important source of real-world data (RWD), but outcomes are often recorded incompletely. We emulated a target trial of adalimumab (ADA) versus tocitinitib (TOF) in patients with rheumatoid arthritis (RA) using the OPAL dataset to illustrate the application of methodologies to address the challenges of non-random treatment assignment and incomplete data. The OPAL dataset is derived from EMR of 112 community-based rheumatologists around Australia, where practitioners have discretion to prescribe whichever b/tsDMARD they consider most clinically appropriate.

Objectives: To estimate the average treatment effect (ATE) of TOF compared to ADA at 3 and 9 months, defined as the difference in mean disease activity score (DAS28CRP), in patients with RA who are new users of a b/tsDMARD. This is equivalent to aiming to estimate the intention-to-treat effect in a randomised controlled trial.

Methods: OPAL patients diagnosed with RA were included if they initiated ADA or TOF between 1 October 2015 and 1 April 2021, were new b/tsDMARD users (no prior recorded b/tsDMARD use) and had at least 3 months of prior csDMARD treatment, and had at least 1 component of DAS28CRP recorded at baseline or during follow-up. Data were also extracted on baseline characteristics. Baseline characteristics were DAS28CRP, patient demographics, regional location, disease duration, prescriber characteristics (including gender, experience), prior recorded comorbidities, and prior and concomitant treatment with csDMARDs and oral corticosteroids. We used random forest multiple imputation to impute missing baseline and follow-up DAS28CRP components. Stable balancing weights (SBW) were then used to balance the treatment groups in terms of their

Figure 1. Forest plot showing the OR of DAS28 remission with low dose steroids and conventional DMARDs vs DMARDs only
baseline characteristics, including DAS28CRP (3). For each imputed dataset, the ATE at 3 months was estimated as the difference between the mean outcome in the two treatment groups after balancing (i.e. weighting) the sample, and then these estimates were averaged across the 10 imputed datasets. The ATE at 9 months was estimated similarly. The whole procedure was subsequently performed in 1000 bootstrap samples to estimate a 95% confidence interval (CI) for the ATEs using the percentile method (4).

Results: 842 patients were identified including n=569 treated with ADA and n=273 treated with TOF. After applying the SWB, the maximum difference between the mean of each baseline characteristic in the ADA and TOF groups was less than 0.03% of the corresponding standard deviation in the whole sample, indicating reasonable balance was achieved in this complex dataset. After weighting, mean DAS28CRP reduced from 5.3 at baseline (both ADA and TOF groups) to 2.6 and 2.3 at 3 and 9 months for ADA, and 2.4 and 2.3 at 3 and 9 months for TOF. The estimated ATE was -0.22 (95% CI -0.36, -0.03; p=0.02) at 3 months, indicating a modest but significant reduction in disease activity for patients on TOF. The estimated ATE was -0.03 (95% CI -0.19, 0.1; p=0.56) at 9 months, indicating no difference between groups.

Conclusion: DAS28CRP was significantly lower at 3 months for patients treated with TOF compared to ADA. However, 3 months of treatment with either drug led to substantive average reductions in mean DAS28CRP, consistent with remission. There was no difference between drugs at 9 months. Future work will estimate a per-protocol effect.

REFERENCES:

Acknowledgments: The authors acknowledge the members of OPAL, Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.

Disclosure of Interests: Claire Deakin: None declared, Bianca De Stavola: None declared, Geof Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: Abbvie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: Abbvie, Novartis, Eli Lilly, David Mathers: None declared, Shaun Seaman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shawn Seaman: None declared

DOI: 10.1136/annrheumdis-2022-eular.2515

Table 1. Classification of Selected Protein BMs

<table>
<thead>
<tr>
<th>Protein</th>
<th>BL to Week 14: ADA</th>
<th>BL to Week 14: UPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td></td>
</tr>
<tr>
<td>CCL3, CCL4, CXCL8, CCL9, CCL10, CXCL16, IL17A</td>
<td>FABP4, FLT3LG, IL12B, KITLG, MMP10, SPP1</td>
<td></td>
</tr>
<tr>
<td>CCL7, CCL8, CHI3L1, IL17A, IL18BP, MMP3, TNFSF9, TNFSF12B, FABP4, FGF21, KITLG, MMP10, PON3</td>
<td>CCL13, CCL19, CCL23, IL18R, IL1R1, IL2RA, MMP1, SLAMF1, SPP1, TNFSF11, TNFSF14</td>
<td></td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Claire Deakin: None declared, Bianca De Stavola: None declared, Geof Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: Abbvie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: Abbvie, Novartis, Eli Lilly, David Mathers: None declared, Shawn Seaman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shawn Seaman: None declared

**Acknowledgements:** The authors acknowledge the members of OPAL, Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.

**Disclosure of Interests:** Claire Deakin: None declared, Bianca De Stavola: None declared, Geof Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: Abbvie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: Abbvie, Novartis, Eli Lilly, David Mathers: None declared, Shaun Seaman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shawn Seaman: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2515

**Table 1. Classification of Selected Protein BMs**

<table>
<thead>
<tr>
<th>Protein</th>
<th>BL to Week 14: ADA</th>
<th>BL to Week 14: UPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td></td>
</tr>
<tr>
<td>CCL3, CCL4, CXCL8, CCL9, CCL10, CXCL16, IL17A</td>
<td>FABP4, FLT3LG, IL12B, KITLG, MMP10, SPP1</td>
<td></td>
</tr>
<tr>
<td>CCL7, CCL8, CHI3L1, IL17A, IL18BP, MMP3, TNFSF9, TNFSF12B, FABP4, FGF21, KITLG, MMP10, PON3</td>
<td>CCL13, CCL19, CCL23, IL18R, IL1R1, IL2RA, MMP1, SLAMF1, SPP1, TNFSF11, TNFSF14</td>
<td></td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Claire Deakin: None declared, Bianca De Stavola: None declared, Geof Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: Abbvie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: Abbvie, Novartis, Eli Lilly, David Mathers: None declared, Shaun Seaman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shawn Seaman: None declared

**Acknowledgements:** The authors acknowledge the members of OPAL, Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.

**Disclosure of Interests:** Claire Deakin: None declared, Bianca De Stavola: None declared, Geof Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD, Hedley Griffiths Consultant of: Abbvie and Eli Lilly, Sabina Ciciriello: None declared, Peter Youssef Speakers bureau: Abbvie, Novartis, Eli Lilly, David Mathers: None declared, Shaun Seaman: None declared, Dana Segelov: None declared, David Hoffman: None declared, Shawn Seaman: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2515

**Table 1. Classification of Selected Protein BMs**

<table>
<thead>
<tr>
<th>Protein</th>
<th>BL to Week 14: ADA</th>
<th>BL to Week 14: UPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td>CCL7, CCL8, CHI3L1, CCL13, CCL19, CCL23, FGF21, IL18, IL19A, IL18BP, IL1R1, IL2RA, MMP3, TNFSF11, VEGFA</td>
<td></td>
</tr>
<tr>
<td>CCL3, CCL4, CXCL8, CCL9, CCL10, CXCL16, IL17A</td>
<td>FABP4, FLT3LG, IL12B, KITLG, MMP10, SPP1</td>
<td></td>
</tr>
<tr>
<td>CCL7, CCL8, CHI3L1, IL17A, IL18BP, MMP3, TNFSF9, TNFSF12B, FABP4, FGF21, KITLG, MMP10, PON3</td>
<td>CCL13, CCL19, CCL23, IL18R, IL1R1, IL2RA, MMP1, SLAMF1, SPP1, TNFSF11, TNFSF14</td>
<td></td>
</tr>
</tbody>
</table>
Background: The phase 3 SELECT-CHOICE trial of patients with rheumatoid arthritis (RA) and prior inadequate response to biologic DMARD(s) (bDMARD-IR) demonstrated superiority of the JAK inhibitor upadacitinib (UPA) vs abatacept (ABA) in the mean change from baseline (BL) in DAS28 (CRP) and in the proportion achieving DAS28 (CRP) <2.6 at week 12, with higher incidence of serious adverse events reported in the UPA treatment group.

Objectives: To evaluate the impact of UPA vs ABA on individual components of composite measures of disease activity in SELECT-CHOICE.

Methods: In SELECT-CHOICE, a double-blind phase 3 trial, bDMARD-IR patients were randomly assigned to UPA 15 mg once daily or ABA, each with background conventional synthetic DMARDs, for 24 wks. For this post hoc analysis, the proportions of patients achieving improvement from BL through wk 24 in ACR core variables (including SJC, TJC, PtGA, Disease Activity Score 28 [DAS28], Physician Global Assessment [PGA], Patient Global Assessment [PGa], and hsCRP) and Boolean remission criteria were evaluated. Differences in the cumulative distributions of CDAI, DAS28 (hsCRP), SDAI, and ACR-n (the lowest percent change in TJC, percent change in SJC, or median of the other 5 ACR components) were determined using the Kolmogorov-Smirnov test and are reported as observed. For all other variables, non-responder imputation was applied for missing data. Nominal P values are provided throughout.

Results: A total of 616 bDMARD-IR patients with moderate to severe RA were randomized in SELECT-CHOICE (UPA 15 mg, n=303; ABA, n=309). BL demographic and disease characteristics were generally comparable between treatment groups, with a mean disease duration of approximately 12 years and mean CDAI of 39.6. At wk 12, more patients receiving UPA vs ABA achieved ≥50% improvements from BL in TJC66, PGA, and hsCRP, with comparable proportions observed between UPA and ABA for the remaining ACR components (Figure 1). At wk 24, similar proportions of patients receiving UPA and ABA achieved ≥50% improvements in all but the hsCRP component. Overall, 15% and 26% of patients on UPA compared with 6% and 15% on ABA demonstrated ≥50% improvements across all ACR components at wks 12 and 24, respectively. At wks 12 and 24, Boolean remission was achieved by 6% and 14% of patients on UPA vs 2% and 10% of patients on ABA, respectively; the proportion of patients in both treatment groups achieving the individual Boolean components were also reported (Table 1). While comparable at BL, cumulative distributions of CDAI, SDAI, DAS28 (hsCRP), and ACR-n were improved on UPA vs ABA at wk 12 (all nominal P <0.05); differences persisted for most measures at wk 24.

Table 1. Proportions of Patients Achieving Boolean Remission and Its Components at Week 12 and 24 (NRIs)

<table>
<thead>
<tr>
<th>Component</th>
<th>Week 12</th>
<th>Week 24</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>UPA 15 mg</td>
<td>ABA</td>
</tr>
<tr>
<td>n (%)</td>
<td>(N=303)</td>
<td>(N=309)</td>
</tr>
<tr>
<td><strong>Boolean Remission</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGA ≤ 10</td>
<td>19 (6)**</td>
<td>5 (2)</td>
</tr>
<tr>
<td>TJC ≤ 1</td>
<td>54 (18)**</td>
<td>29 (9)</td>
</tr>
<tr>
<td>SJC ≤ 1</td>
<td>89 (29)**</td>
<td>64 (21)</td>
</tr>
<tr>
<td>hsCRP ≤ 1 mg/dL</td>
<td>127 (42)**</td>
<td>106 (34)</td>
</tr>
<tr>
<td>ACR-n &lt; 0.5</td>
<td>257 (85)**</td>
<td>209 (68)</td>
</tr>
</tbody>
</table>

Nominal ***P <0.001, **P <0.01, *P <0.05 for UPA vs ABA, ABA vs abatacept; PGA, Patient’s Global Assessment of disease severity; UPA, upadacitinib.

Conclusion: In this post hoc analysis of bDMARD-IR RA patients, improvements in disease component measures were reported for both UPA and ABA through 24 weeks, with numeric differences noted for several components. Nominal higher attainment of Boolean remission and its components were observed through 24 weeks, with numeric differences noted for several components. Nominal differences in components of disease measures were reported for both UPA and ABA at wk 12 and 24, Boolean remission was achieved by 6% and 14% of patients on UPA compared with 6% and 15% on ABA demonstrated ≥50% improvements in all but the hsCRP component. Overall, 15% and 26% of patients on UPA compared with 6% and 15% on ABA demonstrated ≥50% improvements across all ACR components at wks 12 and 24, respectively. At wks 12 and 24, Boolean remission was achieved by 6% and 14% of patients on UPA vs 2% and 10% of patients on ABA, respectively; the proportion of patients in both treatment groups achieving the individual Boolean components were also reported (Table 1). While comparable at BL, cumulative distributions of CDAI, SDAI, DAS28 (hsCRP), and ACR-n were improved on UPA vs ABA at wk 12 (all nominal P <0.05); differences persisted for most measures at wk 24.
**Objectives:** To study if clinical response differs between advanced therapies that are initiated after stopping a JAKi.

**Methods:** Patients were included from the electronic platform “Tool for Administrative Reimbursement Drug Information Sharing” (TARDIS). Data from all Belgian RA patients on biologic and targeted therapy are collected here for drug reimbursement. Patients were selected for this analysis if they had stopped JAKi therapy and initiated a subsequent therapy. Patients were grouped by TNFi, T/B cell therapy, IL6i or JAKi therapy. The DAS28 response and proportion of patients in remission at the first follow-up (between 3 and 6 months) were compared between groups. Remission was defined as DAS28<2.6. Analyses were repeated in patients who were prescribed the stopped JAKI as first-line or as subsequent line therapy. Data were compared via χ², Anova and t-tests.

**Results:** In total, 1238 patients who had stopped JAKI therapy were included. TNFi, T/B cell therapy, IL6i or JAKi therapy was initiated in 36% (441/1238), 19% (233/1238), 18% (227/1238) and 27% (337/1238) respectively. Most baseline demographic and clinical characteristics differed between groups (Table 1).

<table>
<thead>
<tr>
<th>Table 1.</th>
<th>TNFi</th>
<th>BiT cell</th>
<th>IL6i</th>
<th>JAKi</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>441</td>
<td>233 (19%)</td>
<td>227</td>
<td>337</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>55±14</td>
<td>57±13</td>
<td>55±14</td>
<td>59±12</td>
<td>0.001</td>
</tr>
<tr>
<td>Gender (women)</td>
<td>323 (73%)</td>
<td>196 (82%)</td>
<td>257 (76%)</td>
<td>0.100</td>
<td></td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>74±15</td>
<td>79±17</td>
<td>75±15</td>
<td>75±11</td>
<td>0.111</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>9±8</td>
<td>10±9</td>
<td>11±9</td>
<td>11±9</td>
<td>0.002</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.0±0.7</td>
<td>0.6±0.7</td>
<td>0.5±0.6</td>
<td>0.8±0.5</td>
<td>0.353</td>
</tr>
<tr>
<td>PGA (0-100)</td>
<td>65±20</td>
<td>68±21</td>
<td>67±21</td>
<td>57±24</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>10±16</td>
<td>14±20</td>
<td>16±28</td>
<td>11±17</td>
<td>0.003</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>22±21</td>
<td>24±19</td>
<td>27±21</td>
<td>25±22</td>
<td>0.117</td>
</tr>
<tr>
<td>TJC28</td>
<td>6±6</td>
<td>6±6</td>
<td>6±6</td>
<td>7±6</td>
<td>0.001</td>
</tr>
<tr>
<td>SJC28</td>
<td>5±4</td>
<td>6±5</td>
<td>6±4</td>
<td>5±5</td>
<td>0.006</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.7±1.1</td>
<td>4.8±1.1</td>
<td>4.9±1.2</td>
<td>4.4±1.3</td>
<td>0.001</td>
</tr>
</tbody>
</table>

2nd line of therapy after initial JAKI therapy

211 (46%) 56 (24%) 52 (23%) 112 (33%) <0.001

**Discussion of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2779

**POS0695**

**EFFECT OF METHOTREXATE AND FOLIC ACID CO-COMMUNICATION IN ARTHRITIS**

E. Dailly1, M. Maalouf2, S. Peyrache1, A. Vanden-Bossche1, C. A. Arthaud1, S. Hodin1, H. Marotte2, R. Müller3,4, INSERM, U1059-SAINBOISE, University of Lyon, Saint-Etienne, France; 1University Hospital of Saint-Etienne, Rheumatology, Saint-Etienne, France; 2Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV Ludwig-Maximilians-University Munich, Munich, Germany; 4Rheumazentrum Ostschweiz, Rheumatology, St. Gallen, Switzerland

**Background:** Methotrexate (MTX) is the recommended first-line treatment for rheumatoid arthritis. Adjuvant-induced arthritis (AlA) is a robust model with a high prevalence of arthritis used to investigate arthritis. MTX reduces inflammation, but associated with adverse events, such as gastrointestinal, hepatic, and hematological toxicity (1). To reduce these side effects, folic acid (FA) is administrated at distance to MTX with no defined recommendation for its dosing (5-25mg/week) or time point of administration (2) (1-3 days after MTX application). Whether the complicated therapeutic regimen with MTX once a week and FA at another time point affects compliance is an open question. MTX is metabolized in polyglutamates derivates (MTX-PG), which is a biomarker of MTX efficacy as its half-life (1-4 weeks) is longer than MTX (4h) (3).

**Objectives:** The aim of this study was to assess efficacy and tolerance of co-administration of MTX and FA compared to FA applied one day after MTX in the AlA.

**Methods:** Female Lewis rat were randomly divided into three groups and received an injection of Mycobacterium butyricum defining day (D) 0 to induce arthritis. An historic AlA group was used as control. Treatment began on D9, one day before arthritis onset in this model. The first group rats were treated with MTX only (n=13), the second group received MTX and FA at the same day (n=14), and the third group received FA one day after MTX administration (n=14). MTX was administrated intraperitoneally (IP) at 1mg/kg every 3 days (4) and FA was delivered IP at 0.17mg/kg. Arthritic index (AI) and ankle circumference (AC) were monitored to assess arthritis.

**Results:** Arthritis developed at D10 in all groups. AI and AC were similar in MTX groups at the various time points. At D17, arthritis severity was lower in MTX groups (AI (mean and standard deviation): 1.4 ± 1.6; AC: 35 ± 7 mm) compared to AlA historic group (AI: 3.3 ± 0.6; AC: 42 ± 4 mm). Bone erosion and bone loss parameters were similar in all groups. Cortical porosity was around 0.40±0.15 and bone volume / total volume was around 0.22±0.13. MTX-PG1 was found at similar levels in MTX groups and correlated negatively with AI in MTX alone and MTX and FA at the same day groups (p<0.05 and p<0.01, respectively).

Finally, while red blood cells, platelets, hemoglobin, mean corpuscular volume, transaminases, and creatinine were found at a similar level in MTX groups.

**Conclusion:** Co-administration of MTX with FA on the same day is effective compared to FA application one day after MTX. MTX metabolism was not affected, as demonstrated by the MTX-PG concentrations. The biological tolerance between the protocols was comparable. Thus, co-administration of MTX and FA seems to be possible and may be more convenient to the patients and improve compliance at the end.

**REFERENCES:**


**Acknowledgements:** We thank Ghislaine Roux, Diane Denis and Valentine Berucus for their support in animal experiments. We thank Xavier Delavenne for MTX-PG dosage. We thank Nadia Boutahar for transaminases and creatinine dosage.

**Disclosure of Interests:** Elisa Dalix Grant/research support from: GEBSRO, Mathieu Maalouf Grant/research support from: GEBSRO, Sylvie Peyrache Grant/research support from: GEBSRO, Arnaud Vanden-Bossche Grant/research support from: GEBSRO, Charles-Antoine Arthaud Grant/research support from: GEBSRO, Sophie Hodin Grant/research support from: GEBSRO, Hubert MAROTTE Grant/research support from: GEBSRO, Nordic Pharma, Rüdiger Müller Grant/ research support from: GEBSRO, Nordic Pharma

**DOI:** 10.1136/annrheumdis-2022-eular.3150

**POS0696**

**DOES PREDNISONE USE DURING PREGNANCY IN WOMEN WITH RHEUMATOID ARTHRITIS INDUCE INSULIN RESISTANCE IN THE OFFSPRING?**

F. D. O. De Steenwinkel1, R. Dolain1, J. Hazes1, A. C. Hokken-Koelega1 on behalf of PARA. 1Erasmus University Medical Centre, Rheumatology, Rotterdam, Netherlands; 2Erasmus University Medical Centre, Sophia Children’s Hospital, Department of Paediatrics, Subdivision of Endocrinology, Rotterdam, Netherlands

**Background:** The use of long-term corticosteroids during pregnancy has been growing over the past decades. Corticosteroids can be given when an auto-inflammatory disease like rheumatoid arthritis (RA) is too active. Several studies have shown that long-term corticosteroids use in pregnancy is associated with an increased risk of maternal and fetal adverse outcomes, like preeclampsia, shorter gestational age, lower birth weight and rapid catch-up growth 1-3. These last two outcomes could influence the insulin resistance later in life4.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3150
Objectives: Does prednisone use in pregnant women with RA induces insulin resistance in the offspring?

Methods: 103 children were included after their mother had participated in a prospective cohort study on RA and pregnancy. 42 children were in utero exposed to prednisone and 61 were non-exposed. To assess insulin resistance, we measured Homeostasis Model of Assessment Insulin Resistance (HOMA-IR), serum adiponectin and lipid levels, corrected for body fat distribution.

Results: There was no difference in mean HOMA-IR (SD) between the children who were prednisone-exposed in utero (1.10 (0.84)) and those non-exposed (1.09 (0.49)). No difference was found in mean adiponectin (SD) level, 16.45 (4.06) µg/mL and 15.40 (3.59) µg/mL, respectively. Also no difference was found in body fat distribution or lipids such as total cholesterol, fasting triglyceride or high-density lipoprotein.

Conclusion: Children who are prednisone-exposed in utero have no increased risk for insulin resistance at the age of approximately 7-years. This finding, though reassuring, but further research has to be performed to evaluate if prednisone-exposure in utero has no other negative effects on the long-term and if insulin resistance remains absent in the future.

REFERENCES:

Table 1. Ophthalmological adverse events with JAK inhibitors

<table>
<thead>
<tr>
<th>BARICITINIB</th>
<th>TOFACITINIB</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=103</td>
<td>n=1308</td>
</tr>
<tr>
<td>Mean delay (in days)</td>
<td></td>
</tr>
<tr>
<td>Inflammatory involvement</td>
<td>2 (2) 26 (2) 190±197</td>
</tr>
<tr>
<td>Scleritis, n (%)</td>
<td>8 (8) 41 (32) 321±405</td>
</tr>
<tr>
<td>Corneal ulceration, n (%)</td>
<td>1 (1) 50 (4) 292±296</td>
</tr>
<tr>
<td>Uveitis, n (%)</td>
<td>2 (2) 11 (1) 172±244</td>
</tr>
</tbody>
</table>

Conclusion: Ophthalmological manifestations under JAK inhibit seem rare but not exceptional. The rheumatologist must be made aware of them in order to discuss the potential imputability of the treatment and to report these manifestations to the pharmacovigilance structures. A detailed history, exclusion of infections and pathological evaluation of the lesions are recommended to ensure that a differential diagnosis is not ignored. Topical treatments, and if necessary, discontinuation of the drug and switching to another targeted therapy may be considered. Discontinuation of JAKinhib appears to be warranted pending ophthalmologic advice.

Disclosure of Interests: None declared

Table 1. Changes in RA patient profile at initiation of first targeted therapy over a five-year period: analysis of the STRATEGE 1 and STRATEGE 2 studies.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>STRATEGE 1</th>
<th>STRATEGE 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52.6±12.5</td>
<td>56.4±13.6</td>
<td>0.0158</td>
</tr>
<tr>
<td>RA duration (years)</td>
<td>6.5±7.1</td>
<td>5.6±7.2</td>
<td>NS</td>
</tr>
<tr>
<td>Radiological signs</td>
<td>50.0%</td>
<td>48.0%</td>
<td>NS</td>
</tr>
<tr>
<td>Average MTX initiation (years)</td>
<td>4.6±4.3</td>
<td>4.3±5.3</td>
<td>NS</td>
</tr>
<tr>
<td>MTX per os</td>
<td>44.0%</td>
<td>28.9%</td>
<td>0.0088</td>
</tr>
<tr>
<td>mean dosage (mg/week)</td>
<td>16.2±3.6</td>
<td>16.0±4.1</td>
<td>NS</td>
</tr>
<tr>
<td>MTX subcutaneous</td>
<td>52.6%</td>
<td>70.6%</td>
<td>0.003</td>
</tr>
<tr>
<td>mean dosage (mg/week)</td>
<td>18.5±3.6</td>
<td>19.5±3.9</td>
<td>NS</td>
</tr>
<tr>
<td>Patients self-administration</td>
<td>53.8%</td>
<td>75.8%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Corticosteroid therapy</td>
<td>53.0%</td>
<td>50.6%</td>
<td>NS</td>
</tr>
<tr>
<td>mean dosage (mg/day)</td>
<td>8.1±4.3</td>
<td>9.5±5.8</td>
<td>NS</td>
</tr>
<tr>
<td>Mean DAS28</td>
<td>4.6±1.1</td>
<td>4.3±1.2</td>
<td>0.0074</td>
</tr>
<tr>
<td>Mean HAQ</td>
<td>1.4±0.9</td>
<td>1.0±0.7</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Table 1. At baseline (before b/tsDMARD initiation) STRATEGE 1 (N=117) STRATEGE 2 (N=180) p

<table>
<thead>
<tr>
<th>Parameter</th>
<th>STRATEGE 1</th>
<th>STRATEGE 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>52.6±12.5</td>
<td>56.4±13.6</td>
<td>0.0158</td>
</tr>
<tr>
<td>RA duration (years)</td>
<td>6.5±7.1</td>
<td>5.6±7.2</td>
<td>NS</td>
</tr>
<tr>
<td>Radiological signs</td>
<td>50.0%</td>
<td>48.0%</td>
<td>NS</td>
</tr>
<tr>
<td>Average MTX initiation (years)</td>
<td>4.6±4.3</td>
<td>4.3±5.3</td>
<td>NS</td>
</tr>
<tr>
<td>MTX per os</td>
<td>44.0%</td>
<td>28.9%</td>
<td>0.0088</td>
</tr>
<tr>
<td>mean dosage (mg/week)</td>
<td>16.2±3.6</td>
<td>16.0±4.1</td>
<td>NS</td>
</tr>
<tr>
<td>MTX subcutaneous</td>
<td>52.6%</td>
<td>70.6%</td>
<td>0.003</td>
</tr>
<tr>
<td>mean dosage (mg/week)</td>
<td>18.5±3.6</td>
<td>19.5±3.9</td>
<td>NS</td>
</tr>
<tr>
<td>Patients self-administration</td>
<td>53.8%</td>
<td>75.8%</td>
<td>0.0001</td>
</tr>
<tr>
<td>Corticosteroid therapy</td>
<td>53.0%</td>
<td>50.6%</td>
<td>NS</td>
</tr>
<tr>
<td>mean dosage (mg/day)</td>
<td>8.1±4.3</td>
<td>9.5±5.8</td>
<td>NS</td>
</tr>
<tr>
<td>Mean DAS28</td>
<td>4.6±1.1</td>
<td>4.3±1.2</td>
<td>0.0074</td>
</tr>
<tr>
<td>Mean HAQ</td>
<td>1.4±0.9</td>
<td>1.0±0.7</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
The baseline visits involved initiation of bDMARD therapy with 100% vs. 88.9% bDMARD (anti-TNF: 78.8% vs. 58.3%, anti-IL6: 8.7% vs. 12.8%, CTLA4 Ig: 11.5% vs. 16.7%, anti-CD20: 2.9% vs. 1.1%) and 0% vs. 11.1% bDMARD. Therapeutic decision concerning the bDMARD were (STRATEGE 1 vs STRATEGE 2): identical regimens maintained (pharmaceutical form + dosage): 69.2% vs. 76.1%; discontinuation: 4.3% vs. 2.2%; adjustment: 26.7% vs. 21.7% (with dose reduction: 18.2% vs. 93.5%) and/or change in pharmaceutical form (p.o. to SC): 54.5% vs. 0%.

Main reasons for adjusting treatment were (STRATEGE 1 vs STRATEGE 2): active RA: 86.1% vs. 77.8%; RA not in remission: 3.5% vs. 21.1%; exacerbation based on clinical laboratory parameters: 42.6% vs. 10%.

Conclusion: Over the five years, these results suggest a change in practices for RA patients with an inadequate response to MTX and initiating their first targeted therapy; now with earlier recourse to first targeted therapy, for less active RA, and more pronounced investigation of remission.

REFERENCES:

Acknowledgments: The authors wish to acknowledge RCTs for their contribution to the statistical analysis, the investigators, centres and patients.

Disclosure of Interests: Cécile Gaujoux-Viala Speakers bureau: Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCBB, Consultant of: Abbvie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCBB Pharma., Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Eric Senbel Speakers bureau: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Eric Senbel Speakers bureau: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi, Consultant of: Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi, Consultant of: Abbvie. Acknowledgements: None declared.

Disclosure of Interests: None declared.

Supported by Eli Lilly.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.
and methotrexate initiation in one arm, versus immediate introduction of MTX follow-
ing vaccination in the other arm. We analyzed disease activity based on DAS28-ESR at baseline (M0), 1, 2, 3, 6 and 12 months between the 2 groups. For structural progression, we performed a radiographic analysis of 79 RA patients included in the Montpellier center at baseline, 6 and 12 months. This analysis was performed by the same physician two times, blinded to the patient's group. Structural damage progress-
ion at 6 months and 1 year was assessed according to van-der-Heijde-modified Sharp score (vSHS) on radiographs performed at inclusion, at 6 and 12 months of follow-up. Comparisons of the means of activity scores and radiographic scores were made with the non-parametric Wilcoxon-Mann-Whitney test.

Results: Of the 276 patients randomized, 261 could be analyzed (131 in the IMMEDIATE group and 130 in the DELAY group). At inclusion, there were no significant differences in demographic, disease activity (DAS28-ESR), biological and radiographic characteristics between the 2 groups (Table 1).

There was a significant difference in the means of DAS28-ESR at 1 month between the DELAY and IMMEDIATE groups (3.96 ± 1.46 vs 3.41 ± 1.32; p<0.001, respectively). There was no significant difference in the means of DAS28-ESR between the 2 groups at 3 months (3.19 ± 1.46 in the 2 groups p=0.91), at 6 months (3.11 ± 1.42 vs 3.24 ± 1.43; p=0.46, respectively) and at 12 months (2.96 ± 1.34 vs 2.98 ± 1.26p=0.89). (Graphic). Similarly, there was no significant difference in mean radiographic scores at 6 months (2.00 ± 4.41 vs 1.80 ± 4.03 p=0.81) or at 12 months (2.25 ± 4.86 vs 2.00 ± 4.07p=0.93).

There was no significant variation between radiographic scores at 6 months compared to baseline in either group (mean difference 0.21 ± 0.52 vs. 0.36 ± 1.01, p=0.90) nor at 12 months compared to baseline (mean difference 0.40 ± 1.06 vs. 0.62 ± 1.58, p=0.85).

Conclusion: In patients with rheumatoid arthritis, initiation of methotrexate 1 month after PCV13 vaccination has no significant impact on RA activity and structural outcome at 1 year. Performing vaccinations 1 month before starting MTX can be proposed without significant impact on RA outcome at 1 year.
Table 1. Efficacy outcomes in RA-BEYOND

<table>
<thead>
<tr>
<th>LDA</th>
<th>REM</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>N/n (%)</td>
</tr>
<tr>
<td>RA-BEYOND entry</td>
<td></td>
</tr>
<tr>
<td>BAR1 2mg (BUILD)</td>
<td>197/109 (55.3)</td>
</tr>
<tr>
<td>BAR1 4mg (BUILD)</td>
<td>188/116 (59.3)</td>
</tr>
<tr>
<td>BAR4 4mg (BEAM)</td>
<td>412/288 (55.3)</td>
</tr>
<tr>
<td>Yr 3</td>
<td>156/120 (78.9)</td>
</tr>
<tr>
<td>BAR1 4mg (BUILD)</td>
<td>107/76 (71.0)</td>
</tr>
<tr>
<td>BAR4 4mg (BEAM)</td>
<td>222/166 (74.8)</td>
</tr>
<tr>
<td>Yr 7</td>
<td>61/50 (82.0)</td>
</tr>
<tr>
<td>BAR1 4mg (BUILD)</td>
<td>45/37 (77.1)</td>
</tr>
<tr>
<td>BAR4 4mg (BEAM)</td>
<td>64/57 (88.3)</td>
</tr>
</tbody>
</table>

N: Number of pts with observed data; n: Number of pts with response. *Time from randomization in originating studies. Entry to RA-BEYOND = wk 24 and wk 52; Yr 3 = wk 156 and wk 160; and Yr 7 = wk 360 and wk 364 of RA-BUILD and RA-BEAM, respectively.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-e4562
The text content of the document is too long to be included here. The document appears to be a scientific paper discussing the efficacy and safety of filgotinib in patients with rheumatoid arthritis (RA), particularly in those with 4 or <4 poor prognostic factors. The paper includes methods, results, and conclusions, along with a table comparing the results of different treatment groups.

Table 1. AEIs and AEIs of interest in BL 4 PP and <4 PP subgroups

<table>
<thead>
<tr>
<th>4 PP</th>
<th>&lt;4 PP</th>
</tr>
</thead>
<tbody>
<tr>
<td>FIL200</td>
<td>FIL100</td>
</tr>
<tr>
<td>(n = 191)</td>
<td>(n = 189)</td>
</tr>
<tr>
<td>ADISA</td>
<td>(n = 126)</td>
</tr>
<tr>
<td>W24 switch (n = 181)</td>
<td>(n = 284)</td>
</tr>
<tr>
<td>(n = 291)</td>
<td>(n = 291)</td>
</tr>
<tr>
<td>(n = 199)</td>
<td>before W24 switch (n = 294)</td>
</tr>
</tbody>
</table>

Values are n (%). **ADISA**, adalimumab; AE, adverse event; BL, baseline; DVT, deep vein thrombosis; FIL100, filgotinib 100 mg; FIL200, filgotinib 200 mg; GI, gastrointestinal; MACE, major adverse cardiac event; NMSS, nonmelanoma skin cancer; PBO, placebo; PE, pulmonary embolism; PP, poor prognostic factor; VTE, venous thromboembolism; W, week.

The table includes counts and percentages for various adverse events (AEIs) and adverse events of interest (AEIs of interest) in the FIL200 and FIL100 treatment groups. The table compares the occurrence of these events between BL 4 PP and <4 PP subgroups, with a focus on the W24 switch and before W24 switch.

References:

Disclosure of Interests:
None declared

Copyright: © 2022 the authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

SLE, Sjögren’s and APS – treatment

**DILEMMA OF BELIMUMAB THERAPY (DIS)**

CONTINUATION DURING PREGNANCY: RESULTS OF A RETROSPECTIVE STUDY IN EUDRAVIGILANCE

N. Ghahardari1, H. J. M. J. Crimplia, R. Dolhain, J. Hazes1, E. Van Puijenbroek1,2

1Erasmus MC, Rheumatology, Rotterdam, Netherlands; 2CBG-MEB, Pharmacovigilance, Utrecht, Netherlands; 3Lareb, Pharmacovigilance, ’s-Hertogenbosch, Netherlands

**Background:** Active systemic lupus erythematosus (SLE) and nephritis due to SLE contribute to poor pregnancy outcomes. (1, 2) A meta-analysis has shown a relative risk of 1.51 for miscarriage in SLE patients compared to women without SLE. (3) The risk is even higher if the disease is active during pregnancy (around 3-fold increase in pregnancy loss). (4) Corticosteroids, azathioprine, hydroxychloroquine, cyclosporine and tacrolimus are considered safe treatments. (5) However, these treatment options may still not be sufficient in patients poorly responsive to conventional therapies or patients who suffer from nephritis. (6) The only biologic authorized for SLE up to this date, belimumab, is currently not recommended for use during pregnancy due to lack of data. Provided that the health of the child begins with the health of the mother, pregnant patients face the dilemma of cessation or continuation of belimumab. If belimumab is stopped there will be a risk of SLE flare and its consequences for mother and foetus. Continuation is also not optimal because of the lack of knowledge on safety for use during pregnancy.

**Objectives:** To compare the reported foetal outcomes in SLE patients who stopped scheduled belimumab during the first trimester or thereafter (group B) and who continued scheduled belimumab during the first trimester or thereafter (group A). Belimumab was started according to the treatment guidelines of the regulatory agency/agencies or organizations with which the author(s) is/are employed/affiliated.

**Methods:** All belimumab-exposed pregnancy-related reports, were extracted from the EudraVigilance (EV) database until March 11th 2021. After case review, repeated cases, uninformative reports, non-medical elective abortions and foetal chromosomal abnormalities were excluded. Included pregnancies were divided into two groups (group A and B, as described above). Foetal outcomes were divided into live birth or foetal death (due to miscarriage or still birth) and were compared between both groups. Furthermore, neonatal outcomes, such as reporting rates of pre-term birth, low birth weight and major congenital malformations (CMs) were compared.

**Results:** No statistical difference in foetal death was observed between group A and B (reporting rates: 46.4% and 52.4%, respectively; p-value>0.05). Occurrence of major CMs, pre-term birth and low birth weight was higher - though not statistically different- in group A (Table 1).

**Conclusion:** Based on our data belimumab continuation during first trimester or thereafter does not result in higher reporting of foetal death. Therefore, continuation might be even preferable if the pregnancy is already exposed to belimumab. Since the analysis is based on spontaneous reports / retrospective data, additional studies are needed to confirm the results.

**REFERENCES:**


**Acknowledgements:** We would like to thank C. Zaccaria and L. Piccolo for their contributions to access and interpreting data from EudraVigilance database. The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies/organizations or with which the author(s) is/are employed/affiliated.

**Disclosure of Interests:** Nafise Ghahardari: None declared, Hubertina Johanna Maria Josephina Crimpi 1: None declared, Radboud Dolhain Speakers bureau: UCB, Roche, Abbvie, Genzyme, Novartis, Lilly. Grant/research support from: unrestricted research grants from: Dutch Arthritis Association, UCB Pharma, Galapagos, Johanna Hazes: None declared, Eugène van Puijenbroek: None declared.


**LONG-TERM HYDROXYCHLOROQUINE TREATMENT IMPROVES ESSPRI AND ESSDAI IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME**

N. Hashimoto1, T. Nakazawa2, T. Iwasaki3, T. Hashimoto1

1Hashimoto Rheumatology Clinic, Department of Rheumatology, Osaka, Japan; 2Osaka Saiseikai Nakatsu Hospital, Department of Rheumatology, Osaka, Japan; 3Keiseikai Medical Corporation, Department of Internal Medicine, Higashiosaka, Japan

**Background:** Primary Sjögren’s syndrome (pSS) is a chronic, systemic autoimmune disease typically affecting the salivary and lacrimal glands and producing symptoms of dry mouth, dry eyes, fatigue and pain. Hydroxychloroquine (HCQ) have been shown to have immunomodulatory and immunosuppressive effects, and currently have established roles in the management of rheumatoid arthritis and systemic lupus erythematosus (SLE). However, the use of HCQ in pSS is based on expert recommendations and in few studies with a low level of evidence. There are very few publications assessing HCQ use in a double-blind, randomized, and placebo-controlled studies. In Japan, HCQ is indicated for patients with SLE and cutaneous lupus erythematosus (CLE) and is off-label for pSS patients without CLE. Recently, ESSPRI and ESSDAI have been developed by the European League Against Rheumatism (EULAR) SS study group as standardized outcome tools for measuring patients’ reported symptoms and disease-specific activity. ESSDAI and ESSPRI have been proven to be valid and reliable, they have been used to select patients or as the primary or secondary outcome measures in clinical trials.

**Objectives:** The aim of this study was to examine the efficacy of HCQ in pSS at 8 and 52 weeks after treatment evaluated by ESSPRI and ESSDAI.

**Methods:** Twenty-six pSS patients (26 female, mean age 51.6 ± 13.6 years) with CLE who fulfilled the ACR/EULAR classification criteria for SS and/or the Japanese Ministry of Health and Welfare criteria for SS were studied. The clinical indexes were evaluated by ESSDAI, ESSPRI, IgG and CH50 before and after HCQ treatment at 8 and 52 weeks. ESSPRI components were calculated individually and as a single factor composed of the mean of the three components (pain, fatigue, and dryness: VAS 0-10). ESSDAI (0–123) proposes the evaluation of 12 domains or organ systems (constitutional, lymphadenopathy, glandular, articular, cutaneous, pulmonary, renal, peripheral nervous system, central nervous system, muscular, hematological and biological).

**Results:** ESSPRI and component of fatigue and pain were significantly lower at 8 and 52 weeks after treatment than HCQ pre-treatment (ESSPRI: 4.14±1.45 vs 3.38±1.57, 3.34±1.56, p<0.005, p=0.045, fatigue: 4.86±2.12 vs 3.68±1.96, 3.58±1.87, p=0.010, p=0.036, pain: 3.32±1.94 vs 2.09±1.60, 1.79±1.51, p=0.0043, p=0.0014). However, there was no significant difference in dryness component between HCQ pre-treatment and 8 and 52 weeks after treatment (4.41±2.09 vs 4.32±2.06, 4.21±2.39, p = 0.71, p = 0.94), and the amount of saliva produced by the gum test also showed no significant difference between pre-HCQ treatment and 52 weeks after treatment (6.21 ± 6.72 vs 8.24 ± 6.79 mL / 10 minutes, p = 0.45). There was also a significant decrease in ESSDAI and constitutional, articular, cutaneous and biological domain at 52 weeks after treatment compared to HCQ pre-treatment (ESSDAI: 4.14±1.45 vs 3.38±1.57, 3.34±1.56, p<0.005, p=0.045, constitutional: 1.4±1.50 vs 0.63±1.26, p=0.034, articular: 1.00±1.02 vs 0.21±0.63, p=0.0027, cutaneous: 2.86±3.27 vs 1.12±2.49, p=0.010, biological: 1.14±0.83 vs 0.79±0.86, p=0.014). An improvement of at least 1 point or more in ESSPRI and at least 3 points in ESSDAI compared to HCQ pr-treatment were observed in 63.6% and 31.8% at 8 weeks and 73.7% and 68.4% at 52 weeks after treatment. In addition, IgG was significantly decreased at 52 weeks after treatment compared to HCQ pre-treatment (4.38±1.38 vs 4.14±1.45, p=0.0005).

**Conclusion:** HCQ treatment improved pain such as arthritis, fatigue, constitutional and cutaneous manifestations, but was not effective for salivary function and dryness. HCQ treatment was useful in improving ESSPRI and ESSDAI, and long-term treatment increased the number of effective cases from 8 weeks treatment to 52 weeks. Further studies are needed.

**Disclosure of Interests:** None declared.

BACKGROUND: The goal of targeted treatment in patients with Systemic Lupus Erythematosus (SLE) is to achieve clinical remission or low disease activity, with the best quality of life, low damage rates and better survival.1,2 RELEASAR is a multicenter, cross-sectional study registry of ≥18 years SLE (ACR 97) patients.1,2 Rheumatology, Santa Fe, Argentina;3 GESAR LUPUS, Rheumatology, Rosario, Argentina;4 GESAR LUPUS, Rheumatology, Godoy Cruz, Argentina;5 GESAR LUPUS, Rheumatology, Santa Cruz, Argentina;6 GESAR LUPUS, Rheumatology, Formosa, Argentina;7 GESAR LUPUS, Rheumatology, Santa Rosa, Argentina;8 GESAR LUPUS, Rheumatology, Godoy Cruz, Argentina;9 GESAR LUPUS, Rheumatology, La Plata, Argentina;10 GESAR LUPUS, Rheumatology, Mar del Plata, Argentina;11 GESAR LUPUS, Rheumatology, Rosario, Argentina;12 GESAR LUPUS, Rheumatology, Rio Grande, Argentina;13 GESAR LUPUS, Rheumatology, Bahia Blanca, Argentina;14 GESAR LUPUS, Rheumatology, San Juan, Argentina;15 GESAR LUPUS, Rheumatology, General Roca, Argentina;16 GESAR LUPUS, Rheumatology, Mar del Plata, Argentina;17 GESAR LUPUS, Rheumatology, Corrientes, Argentina;18 GESAR LUPUS, Rheumatology, Posadas, Argentina;19 GESAR LUPUS, Rheumatology, Salta, Argentina;20 GESAR LUPUS, Rheumatology, Granadero Baigorria, Argentina

Background: The goal of targeted treatment in patients with Systemic Lupus Erythematosus (SLE) is to achieve clinical remission or low disease activity, with the best quality of life, low damage rates and better survival.1,2 RELEASAR is a multicenter, cross-sectional study registry of ≥18 years SLE (ACR 97) patients.1,2 Objectives: To describe demographic, clinical characteristics and treatments in SLE patients according to disease activity state. To evaluate the proportion of SLE and refractory SLE patients that are potentially candidates for Belimumab treatment. Results: In total, 201 patients were enrolled. Potentially eligible patients included 92.7% of patients (n=185) that met the definition of uncontrolled disease according to the ACR definition.2,3 The proportion of patients with refractory severe lupus was 7.3% (n=14). Patients on Belimumab therapy were associated to treatment with lower cyclophosphamide or two or more immunosuppressant or splenectomized patients. They were also more prevalent mestizos (p=0.004), had female and they showed less time of disease and lower socioeconomic status (p<0.001). They were also more prevalent mestizos (p=0.004), had higher SLEDAI and SCLC indices (p<0.001) and higher use of immunosuppressants (p<0.001). This was no difference regarding biologic treatment (RTX p=0.547 and Belimumab p=0.08). This group had proportion of hospital admissions and severe infections (p<0.001, respectively). Two hundred and one SLE patients fulfilled the use of Belimumab prescription criteria but only 45/201 patients (22.3%) received the prescription. Belimumab was prescribed in 22.3% (n=105) of patients, none of whom had a history of SLE flare (p=0.027). Conclusion: A high percentage of patients had uncontrolled disease upon entry into the registry and were potential candidates for treatment with Belimumab. The patients who received biologic treatment showed the benefit of requiring fewer doses of corticosteroids and having a lower rate of hospitalizations.

REFERENCES:


Disclosure of Interests: Rosana Quintana: None declared, Lucila Garcia: None declared, Paula Alba: None declared, Susana Rosero: None declared, Analia Alvarez: None declared, Cesar Graf: None declared, Cecilia Pisoni: None declared, Alberto Spindler: None declared, Catalina Gomez: None declared, Heber Matias Figueredo: None declared, Silvia Papasidero: None declared, Raúl Horacio Paniego: None declared, Maria DeLaVega: None declared, Emma Estella Civil De Garignani: None declared, Luciana Gonzalez Lucero: None declared, Victoria Marin: None declared, Rodrigo Aguila Maldonado: None declared, Sergio Gordon: None declared, Carla Gotti: None declared, Romina Nieto: None declared, Gretel Rausch: None declared, Vanina Góngora: None declared, Maria Agustina D’Amico: None declared, Diana Dubinsky: None declared, Alberto Omar Orden: None declared, Johana Zacarías: None declared, Julia Romero: None declared, Mariana Alejandra Pera: None declared, Oscar Rillo: None declared, Roberto Baez: None declared, Valentia Arturi: None declared, Andrea Gonzalez: None declared, Florencia Vivero: None declared, Marcela Schmid: None declared, Victor Caputo: None declared, Maria Silvia Larroude: None declared, Graciela Gomez: None declared, Josefa Marin: None declared, Maria Victoria Collado: None declared, Marisa Jorfen: None declared, Zaída Bedran: None declared, Judith Sarano: None declared, David Zelaya: None declared, MONICA SACNUN: None declared, Pablo Finucci: None declared, Romina Rojas Tessel: None declared, Maria Emilia Saltar: None declared, MAXIMILIANO MACHADO ESCOBAR: None declared, Pablo Astenas: None declared, Unai Vera: None declared, Alberto Alliev: None declared, Juan Manuel Vandale: None declared, Bernardo Pons-Estel: None declared, Guillermo Pons-Estel: None declared, Mercedes Garcia Grant/research support from: GSK grant DOI: 10.1136/annrheumdis-2022-eular.789.

EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR LIASON MACHADO ESCOBAR: Provence, France;3 AstraZeneca, BioPharmaceuticals R&D, Warsaw, Poland;4 AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, MD, United States of America;5 AstraZeneca, BioPharmaceuticals R&D, MA, United States of America;6 AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden

Background: Anifrolumab, a human monoclonal antibody (mAb), is approved in Canada, Japan, and the United States for the treatment of patients with systemic lupus erythematosus (SLE). Anifrolumab is approved in Canada, Japan, and the United States for the treatment of patients with systemic lupus erythematosus (SLE) based on results from the phase 2b MUSE and the phase 3 TULIP-1/2 trials. Anaphylactic reactions (ARs), hypersensitivity reactions (HSRs), and infusion-related reactions (IRRs) are risks of mAb infusions, so physicians prescribing anifrolumab may wish to understand the hypersensitivity profile and whether prophylactic pretreatments are required to mitigate HSRs/IRRs.

Methods: We evaluated demographic and clinical data, treatments, score of damage (SLICC), activity (SLEDAI) and comorbidity (Charlson), hospital admissions and severe infections. The patients were compared according to disease activity: remission (SLEDAI = 0 and without corticosteroids), low disease activity (LDA, SLEDAI = 0 and ≤4 and without corticosteroids) and non-optimal control (SLEDAI > 4 and any dose of corticosteroids). Refractory SLE was defined according to Rituximab (RTX) use, non-response to cyclophosphamide or two or more immunosuppressant or splenectomized patients. Potential use of Belimumab according approved prescription in Argentina was analyzed.

Results: Overall, 1277 patients were analyzed: 299 (23.4%) were in remission, 162 (12.7%) in LDA and 816 (63.9%) with non-optimal control of the disease. Patients in non-optimal control group were younger, less frequently female and they showed less time of disease and lower socioeconomic status (p < 0.001). They were also more prevalent metastizos (p = 0.004), had higher SLEDAI and SLICC indexes (p<0.001) and higher use of immunosuppressants (p<0.001). There was no difference regarding biologic treatment (RTX p = 0.547 and Belimumab p = 0.08). This group had higher proportion of hospital admissions and severe infections (p<0.001, respectively). Two hundred and one SLE patients fulfilled the use of Belimumab prescription criteria but only 45/201 patients (22.3%) received it in the last visit. Malaria was the only clinical variable associated with the use of Belimumab (72.7% vs 29.8% p = 0.005). Seventy-six patients classified as refractory SLE (15.7%) and 56/76 (75.7%) never received Belimumab. Patients on Belimumab therapy were associated to treatment with lower doses of corticoids (p = 0.018) and lower rate of hospital admission caused by SLE flare (p = 0.027).

Conclusion: A high percentage of patients had uncontrolled disease upon entry into the registry and were potential candidates for treatment with Belimumab. The patients who received biologic treatment showed the benefit of requiring fewer doses of corticosteroids and having a lower rate of hospitalizations.

Disclosure of Interests: [K. C. Kalunian1, Y. Tanaka1, I. Huper2, L. J. Zhang3, M. Shroff4, S. Werther4, G. Abreu5, C. Lindholm6, R. Tumella7, University of California, San Diego, Division of Rheumatology, Allergy and Immunology, La Jolla, CA, United States of America; 2University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; AstraZeneca, BioPharmaceuticals R&D, Warsaw, Poland; AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, MD, United States of America; AstraZeneca, BioPharmaceuticals R&D, MA, United States of America; AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden]

EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PROPHYLACTIC PRETREATMENT IN PATIENTS WITH SLE
HSRs vs 1% (n=36) in the placebo group. IRRs occurred in 9% (n=43) of anifrolumab-treated patients vs 7% (n=33) in the placebo group. All HSRs and IRRs were mild/moderate in intensity. There were no discontinuations due to HSRs or IRRs in the anifrolumab group, while there were 2 in the placebo group (HSR: n=1; IRR: n=1). In the anifrolumab 300 mg and placebo groups, more patients experienced HSR/IRRs with the initial (1–6) vs later infusions (Figure 1). In the anifrolumab group, the median (absolute deviation) time to first HSR or IRR was 30.5 (29.5) days or 270 (260) days, respectively. Of the 12 anifrolumab-treated patients with ≥1 HSR, 3 received subsequent pretreatment, and none had any HSR after the use of pretreatment. Of the 43 anifrolumab-treated patients with ≥1 IRR, 2 received pretreatment, of whom 1 had an IRR after pretreatment and anifrolumab dosage remained unchanged.

Conclusion: Following anifrolumab infusion, ARs were uncommon, and few (3%) patients experienced HSRs. HSRs and IRRs with the approved anifrolumab 300 mg dose were mild to moderate, occurred early in treatment, did not lead to discontinuation, and only rarely required pretreatment. Our data support a safe and manageable hypersensitivity profile for anifrolumab.

References:

Acknowledgements: Writing assistance was provided by Rosie Butler, PhD, of JK Associates Inc., part of Fishawack Health. This study was sponsored by AstraZeneca.


Background: Incomplete SLE disease control is associated with progressive organ damage, poor quality of life, and increased mortality.1-3 Sustained reduction in overall disease activity is therefore an important treatment goal.

Objectives: To investigate sustained British Isles Lupus Assessment Group 2004–based Composite Lupus Assessment (BICLA) response and British Isles Lupus Assessment Group (BILAG) responses by organ domain in pooled data from the TULIP-1 and TULIP-2 trials of the type I interferon receptor monoclonal antibody, anifrolumab, in patients with SLE.1-3

Methods: TULIP-1 (NCT02446912) and TULIP-2 (NCT02446889) were phase 3, randomized, placebo-controlled, 52-week trials of intravenous anifrolumab administered every 4 weeks for 48 weeks in eligible patients with moderate to severe SLE who were receiving standard therapy.1,3-5 Sustained BICLA and BILAG response rates, measured as the number of consecutive patient visits with BICLA or BILAG domain responses, respectively, from Week 4 to Week 52 were compared between the anifrolumab vs placebo groups. BILAG-2004 response was defined as a reduction from A (severe disease) at baseline to B (moderate), C (mild), or D (no current disease) or reduction from B at baseline to C or D.5

Results: In total, 360 patients received anifrolumab 300 mg and 366 patients received placebo in the TULIP-1 and TULIP-2 trials. Analysis of pooled TULIP data revealed that more patients who received anifrolumab had sustained BICLA responses compared with placebo (Table 1). The proportions of patients who had BICLA responses sustained for ≥3, ≥6, ≥9, and 12 months inclusive of Week 52 were 33.6%, 27.2%, 16.4%, and 9.2% in the anifrolumab group, and 20.5%, 15.0%, 8.5%, and 1.9% in the placebo group, respectively. The most commonly affected organ domains were musculoskeletal (645/726 patients) and mucocutaneous (627/726 patients) (Figure 1). More patients receiving anifrolumab had BILAG responses for 12 months compared with placebo in these two domains (musculoskeletal: 19.9% vs 13.1%; mucocutaneous: 17.1% vs 7.1%); analyses of all other organ domains were limited by small sample sizes.

Table 1. Number of Patients With Consecutive Visits of Sustained BICLA Response Up to and Including Week 52 in Pooled TULIP-1 and TULIP-2 Trials

<table>
<thead>
<tr>
<th></th>
<th>Anifrolumab 300 mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>(n=360)</td>
<td>(n=366)</td>
</tr>
<tr>
<td>≥3 months</td>
<td>121 (33.6)</td>
<td>75 (20.5)</td>
</tr>
<tr>
<td>(≥5 visits, Week 36–52)</td>
<td>98 (27.2)</td>
<td>55 (15.0)</td>
</tr>
<tr>
<td>≥6 months</td>
<td>59 (16.4)</td>
<td>31 (8.5)</td>
</tr>
<tr>
<td>(≥8 visits, Week 24–52)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥9 months</td>
<td>33 (9.2)</td>
<td>7 (1.9)</td>
</tr>
<tr>
<td>(11 visits, Week 12–52)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(13 visits, Week 4–52)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BICLA, British Isles Lupus Assessment Group–based Composite Lupus Assessment.

Conclusion: In two phase 3 studies, more anifrolumab-treated patients achieved sustained BICLA and BILAG responses compared with placebo. In the frequently affected musculoskeletal and mucocutaneous domains, sustained treatment benefit of anifrolumab over placebo was observed. These data support the durable clinical benefit of anifrolumab treatment in patients with moderate to severe SLE who are receiving standard therapy.

References:
Interstitial lung disease (ILD) often occurs in primary Sjögren’s syndrome (pSS) and reduces the survival of patients [1, 2]. Diagnosis and therapy in pSS-ILD are not standardized.

**Objectives:** To evaluate clinical characteristics of pSS-ILD and efficacy of rituximab therapy in this group of patients.

**Methods:** We conducted retrospective study which included 19 pSS-ILD patients. pSS was diagnosed based on the ACR 2012 or ACR/EULAR 2016 criteria. Diagnosis and clinical assessment of ILD was carried out on the basis of high-resolution computed tomography (HRCT) and pulmonary function tests (PFT). The median age of pSS debut was 49 years (7-72 years), the median age of ILD debut was 57 years (29-75 years). All 19 patients received rituximab: 10 as a monotherapy, 6 in combination with cyclophosphamide, 3 in combination with mycophenolate mofetil. The median follow-up duration was 24 months (3-108 months).

**Results:** In 5 of 19 patients (26%), ILD was the first manifestation of pSS, while 14 patients (74%) developed ILD after an average of 9 years of disease course in the absence of therapy or taking low doses of glucocorticoids and hydroxychloroquine. The most common patterns of ILD were nonspecific interstitial pneumonia (52.6%) and lymphocytic interstitial pneumonia (26.3%), while organizing pneumonia and usual interstitial pneumonia were significantly less common (10.5%, respectively). Both patients with organizing pneumonia were diagnosed with pulmonary lymphoma (also they had persistent salivary gland enlargement, lymphadenopathy, paraproteinemia, and pattern of organizing pneumonia and a lack of response to rituximab and cyclophosphamide therapy).

**Conclusion:** Considering asymptomatic cases and the absence of pSS-ILD predictors, all patients with pSS at the onset of the disease and in the dynamics should undergo HRCT and PFT for the purpose of ILD early diagnosis. In the present study, rituximab therapy was highly effective in pSS-ILD. Further prospective studies are needed to confirm these data. In patients with pSS-ILD, vigilance for pulmonary lymphoma is necessary, especially in the presence of persistent salivary gland enlargement, lymphophenopathy, paraproteinemia, pattern of organizing pneumonia and a lack of response to rituximab and cyclophosphamide therapy.

**Table 1. Clinical and laboratory features of pSS-ILD patients (N=19).**

<table>
<thead>
<tr>
<th>Sign</th>
<th>Frequency, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic course of ILD</td>
<td>36.8</td>
</tr>
<tr>
<td>ANA</td>
<td>100</td>
</tr>
<tr>
<td>AntiRori</td>
<td>73.7</td>
</tr>
<tr>
<td>AntiLa+</td>
<td>47.4</td>
</tr>
<tr>
<td>RF IgM</td>
<td>55</td>
</tr>
<tr>
<td>High CRP</td>
<td>28</td>
</tr>
<tr>
<td>High ESR</td>
<td>33</td>
</tr>
<tr>
<td>Hatacascaparitenemia</td>
<td>27/3</td>
</tr>
<tr>
<td>Hypergammaglobulinemia</td>
<td>44</td>
</tr>
<tr>
<td>High IgG</td>
<td>39</td>
</tr>
<tr>
<td>mtg</td>
<td>36</td>
</tr>
<tr>
<td>Cryoglobulinemia</td>
<td>18</td>
</tr>
<tr>
<td>Severe xerostomia, xerophthmia</td>
<td>44</td>
</tr>
<tr>
<td>Focus score&lt;4</td>
<td>44</td>
</tr>
<tr>
<td>Vascularity</td>
<td>26</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>31.6</td>
</tr>
</tbody>
</table>

**Conclusion:** Considering asymptomatic cases and the absence of pSS-ILD predictors, all patients with pSS at the onset of the disease and in the dynamics should undergo HRCT and PFT for the purpose of ILD early diagnosis. In the present study, rituximab therapy was highly effective in pSS-ILD. Further prospective studies are needed to confirm these data. In patients with pSS-ILD, vigilance for pulmonary lymphoma is necessary, especially in the presence of persistent salivary gland enlargement, lymphophenopathy, paraproteinemia, pattern of organizing pneumonia and a lack of response to rituximab and cyclophosphamide therapy.

**REFERENCES:**


Table 1. Yr 1 plus Yrs 2–4 post-treatment* follow-up mortality and new primary malignancy rates by Yr-1 study treatment

<table>
<thead>
<tr>
<th></th>
<th>BEL</th>
<th>PBO</th>
<th>Total</th>
<th>Total</th>
<th>BEL</th>
<th>PBO</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Yr-1</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>N=2002</td>
<td>N=2001</td>
<td>N=4003</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13 (0.65)</td>
<td>22 (1.10)</td>
<td>35 (0.87)</td>
<td></td>
<td>0.66 (0.65)</td>
<td>1.11 (1.10)</td>
<td>0.87</td>
</tr>
<tr>
<td>New primary malignancies†</td>
<td>9 (0.45)</td>
<td>10 (0.50)</td>
<td>19 (0.47)</td>
<td></td>
<td>0.45</td>
<td>0.50</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Yr-2</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>N=1695</td>
<td>N=1670</td>
<td>N=3365</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 (0.53)</td>
<td>14 (0.86)</td>
<td>24 (0.70)</td>
<td></td>
<td>0.60 (1.10)</td>
<td>1.18 (2.15)</td>
<td>0.89 (1.62)</td>
</tr>
<tr>
<td>New primary malignancies</td>
<td>3 (0.18)</td>
<td>7 (0.42)</td>
<td>10 (0.30)</td>
<td></td>
<td>0.34 (0.60)</td>
<td>0.48 (0.85)</td>
<td>0.41 (0.72)</td>
</tr>
<tr>
<td><strong>Yr-3</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths</td>
<td>N=1659</td>
<td>N=1642</td>
<td>N=3301</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>9 (0.54)</td>
<td>17 (1.04)</td>
<td>26 (0.79)</td>
<td></td>
<td>0.58 (1.55)</td>
<td>1.14 (3.00)</td>
<td>0.86 (2.27)</td>
</tr>
<tr>
<td>New primary malignancies, n (%)</td>
<td>7 (0.42)</td>
<td>9 (0.55)</td>
<td>16 (0.49)</td>
<td></td>
<td>0.37 (0.95)</td>
<td>0.49 (1.25)</td>
<td>0.43 (1.10)</td>
</tr>
<tr>
<td><strong>Yr-4</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deaths by MedDRA SOC</td>
<td>N=1622</td>
<td>N=1582</td>
<td>N=3204</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 (0.86)</td>
<td>13 (0.82)</td>
<td>27 (0.84)</td>
<td></td>
<td>0.65 (2.25)</td>
<td>1.07 (3.65)</td>
<td>0.86 (2.95)</td>
</tr>
<tr>
<td><strong>PtS in the post-treatment follow-up period are no longer receiving study treatment.</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PtS, patients; SOC, system organ class.
Background: Belimumab (BEL) is an approved systemic lupus erythematosus (SLE) treatment. Despite BEL clinical studies demonstrating a favourable benefit-risk profile, varying incidence rates of mortality and adverse events of special interest, including malignancies, require further evaluation.

Objectives: To assess long-term safety following BEL therapy. Methods: This was a a 4-year (Yr)-4 post-treatment follow-up of the Phase 4, double-blind, placebo (PBO)-controlled Belimumab Assessment of Safety in SLE (BASE) study (GSK Study BEL115467; NCT01705977). Overall, 403 adults with active, autoantibody-positive SLE received BEL (10mg/kg IV) or PBO, plus standard therapy (ST), for 48 weeks. Patients (pts) then entered a Yr-2-5 follow-up period in which they received physician-directed ST. All pts were contacted annually by telephone, including pts who discontinued treatment. Mortality and new malignancies (including nonmelanoma skin cancer) were the endpoints collected, and rates summarised. We present Yr-4 follow-up data by Yr-1 treatment received.

Results: Baseline characteristics for the Yr-4 follow-up population (N=3204) were similar to the Yr-1 double-blind study population (N=4003). By the Yr-4 follow-up, cumulatively 12.7% and 11.0% of pts in the BEL and PBO Yr-1 groups had received BEL as part of physician-directed care, respectively (data not shown). As shown in the Table, cumulative follow-up adjusted mortality rates were lower in the BEL vs PBO Yr-1 treatment group for Yrs 2 to 4. Cumulative follow-up adjusted new primary malignancy rates were lower in the BEL vs PBO Yr-1 treatment group for Yrs 2 and 3, but similar in Yr 4.

Conclusion: Post-treatment Yr-4 follow-up results in BASE, the largest double-blind trial in pts with SLE to date, support the safety of BEL therapy, with no new BEL safety concerns identified in this analysis.

REFERENCES:

Acknowledgements: This analysis was funded by GlaxoSmithKline (GSK). Medical writing support was provided by Lulu Hill, MPPharmacol, Fishawack Indici Ltd, UK, part of Fishawack Health, and was funded by GSK.

Disclosure of Interests: Saisi Sheikh Consultant of: GSK; Grant/research support from: Pfizer, Morton Scheinberg Consultant of: GSK; Pfizer, Alynia, AbbVie, PTC Therapeutics, James Cheng-Chung Wei Consultant of: TSH Biopharm, AbbVie, BMS, Celgene, Chugai, Eisai, Janssen, Novartis, Pfizer, Sanofi-Aventis, and UCB Pharma, Grant/research support from: AbbVie, Amgen, Astellas, BMS, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun and UCB Pharma, Dana Tzekova: None declared, William Stolt Consultant of: GSK; Grant/research support from: GSK, Pfizer, Gilead, RICARDO ACAYABA DE TOLEDO Speakers bureau: AbbVie, Vxn, Janssen, UCB, Novartis, Celtrion, Consultant of: AbbVie, Janssen, Novartis, UCB, Grant/research support from: Pfizer, AbbVie, Novartis, GSK, Tamara Mucenic Speakers bureau: Novartis, Janssen, BMS, AbbVie, Pfizer, Roche, Grant/research support from: Janssen, Janssen, Roche, Eli Lilly, Gilead, UCB, Mauricio R Abelio Batisti: None declared, Majed Al Sibai Consultant of: Al Zuhair Medical Center, Dubai; Grant/research support from: Chemocentryx, Carlos Abud-Mendoza Speakers bureau: GSK, Lilly, Pfizer, Sandra Navarra Speakers bureau: Pfizer, Novartis, Johnson & Johnson, Consultant of: Biogen, Boehringer Ingelheim, Grant/research support from: Astellas, Mercedes Garcia Speakers bureau: GSK, Janssen, Pfizer, Ignacio Garcia-De La Torre: None declared, Andrew Liu Shareholder of: GSK; Employee of: GSK, Abhishek Roy Employee of: GSK, Paul Wilde Shareholder of: GSK, Employee of: GSK, Sofia Fernandez Shareholder of: GSK; Employee of: GSK, Julia Harris Shareholder of: GSK; Employee of: GSK,

PBO

50 mg 150 mg 450 mg

(n=33) (n=26) (n=25) (n=48)

3/32 5/26 8/25 9/43

9.4 19.2 32.0 20.9

3/32 5/26 8/25 9/43

(9.4) (19.2) (32.0) (20.9)

Table 1. Proportion of pts who achieved CLASI-A scores of 0–1 and 0–3

Pts considered as treatment failures or who discontinued treatment were classified as non-responders at visits post treatment failure or treatment discontinuation. Pts who completed treatments at any time point were classified as non-responders for that timepoint.

Conclusion: After 16 weeks of treatment, greater proportions of participants with active disease treated with BEL achieved a clear and almost clear skin status, as defined as CLASI-A score of 0–1 or 0–3, further supporting the efficacy of BEL in CLE.

REFERENCES:
POSO0714 POOLED SAFETY ANALYSIS OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THREE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIALS
T. Dörner1, Y. Tanaka2, M. Mosca3, I. N. Bruce4, M. Cardiel5, E. F. Monard6, M. A. Petri7, M. Silk8, C. Dickson9, G. Meszaros9, M. Issa10, L. Zhang11, D. J. Wallace12, M. A. Petri7, M. Silk8, C. Dickson8, G. Meszaros8, M. Issa, L. Zhang, D. J. Wallace12, 1Charite Universitätsmedizin, Medicine/Rheumatology and Clinical Immunology, Berlin, Germany; 2University of Occupational and Environmental Health, First Department of Internal Medicine, Kitakyushu, Japan; 3University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 4University of Manchester, Division of Musculoskeletal & Dermatological Sciences, Manchester United Kingdom; 5Centro de Investigación Clínica de Morelia, Clinical Research, Michoacán, Mexico; 6Monash University, Centre for Inflammatory Disease, Melbourne, Australia; 7Johns Hopkins University, Division of Rheumatology, Baltimore, United States of America; 8El Lilly and Company, N/A, Indianapolis, United States of America; 9Cedars-Sinai Medical Center/University California, Division of Rheumatology, Allergy and Immunology, Los Angeles, United States of America
Background: Baricitinib (BAR), an oral selective inhibitor of Janus kinase 1 and 2 approved for the treatment of rheumatoid arthritis and atopic dermatitis, has been evaluated in clinical studies in patients with systemic lupus erythematosus (SLE)

Objectives: To assess the safety profile of BAR in patients with SLE.

Methods: Patients with SLE receiving stable background therapy were randomized 1:1:1 to BAR 2-mg, 4-mg, or placebo (PBO) once daily in one in 24-week, phase 2 (NCT02708095) and two 52-week, phase 3, PBO controlled studies (NCT03616912 and NCT03616958). The IR/100 PYR for serious adverse events (SAEs) were 9.5, 14.7, and 14.1 respectively for PBO, BAR 2-mg, and BAR 4-mg. There were no clinically meaningful differences between treatment groups for discontinuations due to AEs or death (Table 1).

Table 1. Overview of safety measures of baricitinib in patients with SLE

<table>
<thead>
<tr>
<th>Condition</th>
<th>PBO</th>
<th>BAR 2-mg</th>
<th>BAR 4-mg</th>
<th>Pooled-BARI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety measure</td>
<td>[IR; 95%CI]</td>
<td>[IR; 95%CI]</td>
<td>[IR; 95%CI]</td>
<td>[IR; 95%CI]</td>
</tr>
<tr>
<td>SAEs</td>
<td>45 (7.3)</td>
<td>70 (11.3)</td>
<td>65 (10.6)</td>
<td>135 (10.9)</td>
</tr>
<tr>
<td>Discontinuation of study drug due to AE</td>
<td>480.3</td>
<td>492.3</td>
<td>480.6</td>
<td>973.0</td>
</tr>
<tr>
<td>Death</td>
<td>[9.5; 6.9, 12.7]</td>
<td>[14.7; 11.5, 18.0]</td>
<td>[14.0; 11.7, 16.3]</td>
<td>[11.9; 15.2]</td>
</tr>
<tr>
<td>Serious infections</td>
<td>12 (2.0)</td>
<td>22 (3.5)</td>
<td>28 (4.6)*</td>
<td>50 (4.0)*</td>
</tr>
<tr>
<td>Herpes Zoster</td>
<td>10 (1.9)</td>
<td>17 (2.7)</td>
<td>29 (4.7)</td>
<td>46 (3.7)</td>
</tr>
<tr>
<td>VTEs*</td>
<td>[3.7; 2.2, 5.9]</td>
<td>[3.5; 2.0, 5.6]</td>
<td>[6.2; 4.1, 8.9]</td>
<td>[4.8; 3.5, 6.4]</td>
</tr>
<tr>
<td>MACE*</td>
<td>0</td>
<td>1 (0.2)</td>
<td>5 (0.6)</td>
<td>5 (0.6)</td>
</tr>
<tr>
<td>Malignancy excluding NMSC</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>NMSC</td>
<td>0 (0.4; 0.1, 1.5)</td>
<td>0 (0.4; 0.1, 1.5)</td>
<td>0 (0.4; 0.1, 1.5)</td>
<td>0 (0.4; 0.1, 1.5)</td>
</tr>
</tbody>
</table>

Data are n (%) patients PYR; [IR; 95% CI]. #Phase 2 study data not included. AE=adverse event; CI=confidence interval; MACE= major adverse cardiac event; NMSC=non-melanoma skin cancers; VTE=venous thrombotic event (includes deep vein thrombosis and pulmonary embolism); IR=incidence rate (100 times the number of patients reporting an adverse event divided by the event-specific exposure to treatment); N=number of patients in the analysis population; n=number of patients in the specified category; PYR=patient-year of exposure; PYR=patient years at risk; SAE=serious adverse event. *p<0.05 vs placebo.

The IR/100 PYR for serious infections were 2.5, 4.5, and 5.9 respectively for PBO, BAR 2-mg, and BAR 4-mg. The risk of Herpes Zoster was higher in BAR 4-mg (4.0%) vs PBO (2.9%) (Table 1). The IR/100 PYR for potentially adjudicated venous thrombotic events (VTEs) were 1.4, 0.7, and 0.2 respectively for PBO, BAR 2-mg, and BAR 4-mg. The IR/100 PYR for potentially adjudicated major adverse cardiac event (MACE) was numerically higher in BAR 2-mg (0.2) and BAR 4-mg (0.7) vs PBO (0.0), however the pooled-BARI IR/ PYR (0.5) was within the range of background disease (1). No increased risk for malignancies was observed.

Conclusion: The safety profile of BAR in SLE patients was consistent with the known BAR safety profile. There was no increased risk of VTE in BAR treatment groups.

REFERENCES:


DOI: 10.1136/annrheumdis-2022-eular.2375
blood in RNA tubes (31 pts), cryopreserved PBMCs (15 pts), plasma (35 pts) and urine (2 pts). Whole blood RNA sequencing was performed using Illumina TruSeq. Differential expression was modelled using DESeq2. Fast pre-ranked gene set enrichment analysis (GSEA) was performed with gene sets derived from published literature. Cryopreserved PBMCs were analysed by flow cytometry to profile immune cell subtypes. Plasma protein was measured by Meso Scale Discovery (MSD) kits. Healthy volunteer (HV, N=12) samples were used to establish potential disease-related biomarker changes in patients at baseline (BL).

Results: Many gene modules were found to be altered at BL in SLE pts, relative to HV, including those representing interferon (IFN) response and B/plasma cell and changes were consistent with our prior report2. Comparisons of SLEDAI-2K responders (R) versus non-responders (NR) revealed enrichment of 193 gene modules (57 down and 136 up-regulated, p_adj,<0.1) at BL and 190 modules (105 down and 85 up) 4 weeks after treatment (W17). Expression of a 4-gene IFN module was enriched in SLEDAI-2K R vs NR at BL; expression of this module trended downward at W17 in R, whereas it increased over time in NR at W 5. Reduced numbers of circulating class-switched memory B cells and IgG-producing plasma cells were observed at W17 and/or W25. Plasma levels of BAFF were consistently increased at W5 but returned to BL levels by W17. Plasma levels of CD169/ SIGLEC-1, a monocyte activation marker, were higher at BL in SJC R vs. NR and were reduced after treatment in both groups. Two pts with active proliferative nephritis were enrolled into this study and both showed a reduction in levels of urine CD163 (uCD163), while plasma levels of this marker were stable.

Conclusion: Our integrative analysis indicates that KZR-616 elicits a potent effect on multiple immune pathways in SLE patients. Potential new biomarkers (gene, gene module, circulating protein) that may be useful for prediction of patient response were identified. Future biomarker studies in placebo-controlled trials may further our understanding of KZR-616 mechanism of action, patient selection and prediction of patient responses.

REFERENCES:

Table 1. Available evidence including patients with SLE treated with low-dose IL-2.

<table>
<thead>
<tr>
<th>Study Year (design)</th>
<th>Patients (include in analysis)</th>
<th>Gender (female %)</th>
<th>Dosage</th>
<th>SRI-4,n(%)</th>
<th>SELENA-SLEDAI</th>
<th>Remission (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jing He. 2019. (PCT)</td>
<td>60(30)</td>
<td>90.00</td>
<td>1 million IU every other day</td>
<td>16 (55.17)</td>
<td>0 w: 12.90±4.75</td>
<td>53.85</td>
</tr>
<tr>
<td>Jing He. 2016. (PCT)</td>
<td>40(23)</td>
<td>92.50</td>
<td>1 million IU every other day</td>
<td>34 (89.50)</td>
<td>0 w: 11.4±3.79</td>
<td>NA</td>
</tr>
<tr>
<td>Mao Zhao. 2019. (PCT)</td>
<td>30(18)</td>
<td>88.89</td>
<td>1 million IU every other day</td>
<td>NA</td>
<td>12 w: 3.92±2.23</td>
<td>NA</td>
</tr>
<tr>
<td>Chummao Zhao. 2019. (PCT)</td>
<td>50(50)</td>
<td>94.00</td>
<td>1 million IU, 3-5/month</td>
<td>0 w: 5.92±0.36</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Shengxiao Zhang. 2019. (PCT)</td>
<td>495(54)</td>
<td>NA</td>
<td>0.5 million IU per day for 5 days</td>
<td>NA</td>
<td>12 w: 4.05±0.31</td>
<td>NA</td>
</tr>
<tr>
<td>Kai Fan. 2018. (PCT)</td>
<td>106(76)</td>
<td>NA</td>
<td>0.5 million IU per day for 5 days</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Jing Wang. 2017. (PCT)</td>
<td>76(76)</td>
<td>93.42</td>
<td>0.5 million IU per day for 5 days</td>
<td>0 d: 10.87±6.48</td>
<td>5 d: 3.83±4.18</td>
<td>NA</td>
</tr>
</tbody>
</table>

Acknowledgements: Kezar Life Sciences acknowledges the support of site investigators and patient participants in the MISSION study.


POS0716 EFFICACY AND SAFETY OF LOW-DOSE IL-2 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Q. Y. Su1,2, J. Luo1,2,3, J.K. Di2,3, X.Y. Yin2,3, D.N. Xu2,3, X. Li1,2,3, C. Wang1,2,3, S.X. Zhang1,2,3, 1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Ministry of Education, Key Laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China; 3Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by disturbances of regulatory and effector CD4+ T cells, which were regulated by interleukin (IL)-2.2

Objectives: The aim of this study was to systematically evaluate the efficacy and safety of low-dose IL-2 therapy in SLE treatment.

Methods: Systematic searches of PubMed, EMBASE, Web of Science, the Cochrane Library and Medline, CNKI, CBM and Technology Journal Database were performed. Original case reports, case series, observational studies and clinical trials reporting the efficacy or safety data on SLE patients treated with IL-2 were included. A random-effects meta-analysis was performed to calculate the pooled efficacy. Inconsistency was evaluated by using the I² and Egger tests were used for the evaluation of potential publication bias (STATA v.12.0).

Results: A total of 7 studies comprising 327 patients were identified (Table 1). After the low-dose IL-2 treatment, 54.8% Lupus nephritis patients had distinct clinical remission. The SRI-4 response rates were 0.816 (95% CI 0.730-0.901) and the SELENA-SLEDAI scores were significantly decreased [SMD=−2.504, 95% CI (−4.089,−0.919), P=0.002]. Injection site reaction and fever, which were common side effects for IL-2, occurred in 33.1% and 14.4% of patients, None serious adverse events were reported among all these studies. Besides, the proportions of CD4+ T cells and Tregs were significantly increased after IL-2 injection [SMD=0.600, 95% CI (0.429,1.908), P<0.002], while there were no statistical differences in the proportions of CD8+ T cells, Th17 cells, Th1 cells and Th2 cells between before and after IL-2 treatment (P>0.05)(Figure 1).

Conclusion: Low-dose IL-2 was promising and well-tolerated in the treatment of SLE, which could promote the proliferation and functional recovery of Tregs.

REFERENCES:
**OBJECTIVES:** To assess the effect of HCQ in cardiac conduction in a consecutive SLE population.

**Methods:** Observational, single University hospital study of all consecutive SLE patients with an electrocardiogram (EKG) at HCQ onset and at least one EKG in follow-up, with a period of at least 3 months on HCQ treatment was performed.

**Results:** We studied 109 (96 women/13 men) SLE patients with a mean (±SD) age of 61 ± 2.78 years. A statistically significant association was observed between the cHCQ, and the development of CA [OR 1.1 CI95% 1.02-1.9; p = 0.011] (Table 1 & Figure 1). A total of 8 covariates were included. Among those, that had the greatest influence on the development of the primary event were previous CA [OR 4.15 CI95% 6.39-24.24; p < 0.01]; valvular heart disease [OR 7.15 CI95% 1.31-38.91; p = 0.023] and age [OR 1.07 CI 1.0-1.14; p = 0.04].

**Conclusion:** According to our study, it seems to be an association between the cHCQ and development of CA regardless of other variables evaluated. Wider longitudinal studies are required with a protocolized EKG performance in successive visits to further analyze this association.

**REFERENCES:**


**Disclosure of Interests:** Alba Herrero-Morant: None declared, Jon Zubiaur-Zamacoa: None declared, Adrián Margarida-de Castro: None declared, Raquel Pérez-Barquin: None declared, Miguel Á. González-Gay Speakers bureau: Abbvie, Roche, Sanofi, Lilly, Celgene, Sobi, and MSD, Grant/research support from: Abbvie, MSD, and Roche, Ricardo Blanco Speakers bureau: Abbvie, Lilly, Pfizer, Roche, BMS, Janssen, and MSD, Grant/research support from: Abbvie, MSD, and Roche.

**DOI:** 10.1136/annrheumdis-2022-eular.2950
anti-thrombosis treatment. Currently there is an extreme paucity of effective and safe drugs for long-term management of TP in primary APS patients.

**Objectives:** We aimed to explore the efficacy and safety of sirolimus monotherapy.

**Methods:** In this real-world study, we included 7 consecutive patients with primary APS who received sirolimus monotherapy for TP. Oral sirolimus was initiated at a dose of 1-2 mg once daily and then adjusted primarily based on clinical efficacy and tolerance, with consideration of sirolimus trough concentration of ≤15 ng/mL.

**Results:** Of included patients, the median age was 58 years with median disease course of 1.5 years and 4 patients were treatment-naïve. All patients completed 6 months of sirolimus therapy with median follow-up of 6 months (range 1-15). All patients received sirolimus monotherapy for TP during entire follow-up, without adding any additional agents. Overall, platelet count exhibited substantially increasing trend after sirolimus administration during the first six months (p=0.001) and was stable later. Specifically, median platelet count was significantly increased from 59x10^9/L before sirolimus to 90x10^9/L at month 1 (p=0.028), 131x10^9/L at 3 months (p=0.028) and 178x10^9/L at 6 months (p=0.018). Overall and complete response were respectively achieved in 6 (85.7%) and 5 (71.4%) patients at month 6. Importantly, overall response was achieved in all 4 treatment-naïve patients. Additionally, there was different extents of decline in the titers of antiphospholipid antibodies after sirolimus treatment. Regrading safety, only one patient experienced elevated cholesterol level with recovery after atorvastatin treatment.

**Conclusion:** Sirolimus monotherapy confers good efficacy and tolerance for TP in primary APS patients, and therefore may be considered as a first-line therapy. Figure 1. Changes in platelets levels after sirolimus therapy in primary antiphospholipid syndrome patients with thrombocytopenia. (A) Platelet count of individual patient during the whole follow-up. (B) Median platelet count of included patients during the first six months.

**Disclosure of Interests:** None declared


**POS0719**

**RAPID EFFICACY OF ANIFROLUMAB IN MULTIPLE SUBTYPES OF RECALSITRANT CUTANEOUS LUPUS PARALLELS DISCRETE CHANGES IN TRANSCRIPTOMIC AND CELLULAR BIOMARKERS.

L. M. Carter1, 2, 3, Z. Wigston4, P. Laws5, E. Vittal1, 2, 3 University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 2 Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom

**Background:** Cutaneous lupus erythematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but this varies by morphology with the chronic discoid (DLE) subtype being particularly resistant. Local production and response to type-I interferon (IFN-I) is implicated in all subtypes of CLE. Therapeutic blockade of the IFN-I receptor with anifrolumab has direct effects on IFN-I signaling, and subsequent more widespread effects on other immune functions regulated by IFN-I [1]. Response to anifrolumab by lesion subtype have not been described, and it is unclear which effects of IFN-I blockade are responsible for cutaneous response. We hypothesis that the efficacy of anifrolumab will differ dependent on the relative contribution of direct IFN-I effects vs. the downstream immunostimulatory effects of IFN-I on other immune functions.

**Objectives:** To evaluate the effect of anifrolumab on (i) rituximab-refractory CLE; (ii) on DLE; (iii) to compare clinical responses with IFN-specific biomarkers and transcriptomic evaluation of broader immune responses; (iv) to compare early and late immunophenotypic and clinical responses.

**Methods:** SLE patients with active recalcitrant CLE were treated with anifrolumab 300 mg IV every 4 weeks and evaluated using the cutaneous lupus erythematosus disease area and severity index (CLASI) and dermatology life quality index (DLQI). Fluorescence intensity of latherin (CD317), a cell surface interferon biomarker, was evaluated on major cell subsets by multiparameter flow cytometry of peripheral blood mononuclear cells (PBMCs). Previously validated IFN-Score-A and B [2], in addition to gene expression scores annotated to inflammation, myeloid lineage and plasmablasts modules [3], were measured in PBMCs using customised Taqman array at baseline, 1 month and 3 months into treatment.

**Results:** 8 patients (DLE n=5, chillblain / nodular vasculitis n=2, subacute CLE n=1) have enrolled to date. One month clinical and biomarker data are now available for 5. Median number of previously failed standard therapies is 6, including rituximab in 6/8 patients, belimumab in 3/8 and thalidomide in 4/8. Four patients required long-term oral prednisolone >10 mg daily. Median baseline CLASI activity score was 16 and DLQI was 16/30. Rapid clinical responses were evident at 1 month in 4/5 patients, being greatest in magnitude in patients with SCLE and DLE compared with chillblain lesions. Median fall in CLASI activity score at 1 month was 6 points with a median percentage change from baseline of 31%. In all patients, a rapid and marked suppression of IFN-Score-A (mean difference 2.92, p<0.01) and plasmablast tethersin (p=0.01), was evident by 1 month. Small and variable downward trends were observed in inflammation- and IFN-Score-B (p=0.06), myeloid (p=0.27) and plasmablast (p=0.15) -annotated gene expression scores. Major cell population numbers were proportionally unaltered in flow cytometry.

**Conclusion:** These preliminary results suggest that anifrolumab: (i) may be effective in rituximab-resistant CLE, (ii) is effective in DLE; (iii) rapidly suppresses IFN-I response, but with lesser effects on non-IFN immune biomarkers and (iv) early direct effects on IFN-I are associated with rapid clinical response.

**REFERENCES:**


**Disclosure of Interests:**

**POS0720**

**LOW-DOSE GLUCOCORTICOIDS WITHDRAWN IN SYSTEMIC LUPUS ERYTHEMATOSUS: A DESIRABLE AND ATTAINABLE GOAL

L-J. J., D. Gao¹, Y. Hao¹, Z. Zhang¹. ¹Peking University First Hospital, Rheumatology, Beijing, China

**Background:** Prolonged use of GC may cause irreversible organ damage, leading to impaired quality of life and even increased mortality. However, many physicians are worried about severe flares after GC withdrawal in daily practice.

**Objectives:** To assess the risk of flare in systemic lupus erythematosus (SLE) patients after low dose glucocorticoids (GC) discontinuation and evaluate the risk factors of flare.

**Methods:** SLE patients who ever discontinued GC were identified from PKUFSH cohort. The disease flare profile after GC discontinuation were analyzed. Flare rate was analyzed using Kaplan-Meier analysis. COX regression was used to determine the effect of variables on SLE flare. A prognostic nomogram using Cox proportional hazards regression modeling were developed.

**Results:** 132 SLE patients were eligible for the final analysis. They were followed up for a median (IQR) period of 21.8 (9.01, 36.7) months. The cumulative probability of flare after GC discontinuation was 8.3% at 6 months, 16.8% at year 1 and 27.5% at year 2 (Figure 1A). In multivariate COX analysis, hypocomplementemia and serologically active clinically quiescent (SACQ) were independent risk factors of flare [HR 2.53, 95% CI (1.32, 4.88); HR 3.17, 95% CI (1.44, 6.97), respectively]. Age ≥ 40y at GC withdrawal and hydroxychloroquine usage were independent protective factors of flare [HR 0.53, 95% CI (0.29, 0.99); HR 0.32, 95% CI (0.17, 0.62), respectively] (Table 1). The protective effect of hydroxychloroquine was dosage related. From the prospective of different tapering strategies embodied as duration from prednisone 5mg/d to complete discontinuation, slower tapering strategy (12-24 months) significantly reduced the risk of flare compared to faster tapering strategy (< 3 months) [HR 0.53, 95% CI (0.29, 0.99), p=0.019]. The prognostic nomogram including aforementioned factors effectively predicted 1- and 2-year probability of flare-free (Figure 1B).

**Conclusion:** Low-dose GC is feasibly discontinued with infrequent flare in real-life setting. SACQ and younger age are potential risk factors of SLE flare,
while hydroxychloroquine usage and slow GC tapering to withdrawal can reduce relapse. The visualized model we developed may help to predict risk of flare among SLE patients who discontinued GC.

Disclosure of Interests: None declared


Table 1. Relationship between APO, therapy during pregnancy and risk profile.

<table>
<thead>
<tr>
<th>All pregnancies (n=164)</th>
<th>Reduced C3/C4 (n=58)</th>
<th>Triple aPL+ and reduced C3/C4 (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDA+LMWH (n, %)</td>
<td>LDA+LMWH+HCQ (n, %)</td>
<td>LDA+LMWH (n, %)</td>
</tr>
<tr>
<td>LDA+LMWH (n, %)</td>
<td>LDA+LMWH+HCQ (n, %)</td>
<td>LDA+LMWH (n, %)</td>
</tr>
<tr>
<td>APO</td>
<td>No APO</td>
<td>Total</td>
</tr>
<tr>
<td>62 (46%)</td>
<td>72 (54%)</td>
<td>134 (53%)</td>
</tr>
</tbody>
</table>

Background: Antiphospholipid Syndrome (APS) is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for antiphospholipid antibodies (aPL). Complement was demonstrated to be involved in aPL-related pregnancy loss in animal models and several groups investigated the significance of complement levels in human disease. C3 and C4 serum levels were assessed in several cohorts of pregnant patients with APS and/or aPL positivity in order to relate complement consumption with adverse pregnancy outcome (APO).

Results: In this study, we demonstrated that aPL positivity and low preconception serum C3/C4 levels increased the risk of pregnancy complications. The addition of HCQ had not significantly improved pregnancy outcome. We have lastly evaluated 40 pregnancies with a high-risk profile preconception low C3/C4 levels the addition of HCQ had not significantly improved pregnancy outcome. When considering the whole cohort, the addition of HCQ had not significantly improved the gestational outcome. Further stratification was performed on the basis of complement consumption. In the group of patients with preconception low C3/C4 levels the addition of HCQ had not significantly improved pregnancy outcome. We have lastly evaluated 40 pregnancies with a high-risk profile (triple aPL positivity and complement consumption), in which we have found that HCQ significantly improved gestational outcome (p=0.018, Table 1).

This observation could not be confirmed in patients with single or double aPL positivity.

Conclusion: This study shows that administering HCQ in addition to combination therapy can improve gestational outcome in aPL/PAPS high-risk patients. This observation confirms that HCQ exerts a beneficial effect on aPL pregnancies by complement inhibition as it was shown in animal models. In addition, our results provide the clinicians a useful tool to implement conventional treatment in patients at high risk of pregnancy complication or loss.

REFERENCES:
SLE, Sjögren's and APS - clinical aspects (other than treatment)

**POS0722**
Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus (Hematopoiesis Study)

C. David1, N. Costeoda-Chalumeau2, N. Duployez4, D. Belhadi6, V. Leguern9, P. Eloy2, C. Preudhomme3, J. Chezel1, N. Morel2, A. Mathian6, Z. Amoura5, T. Papo1, K. Sacre1 on behalf of the PLUS Study Group.

**Disclosure of Interests:** None declared

**Conclusion:** (HR= 0.42 (0.06 – 3.21), p=0.406).

Background: The detection of somatic mutations in genes of myeloid cells in asymptomatic patients - defining clonal hematopoiesis of indeterminate potential (CHIP) - predisposes to cardiovascular events (CVE) in the general population.

**Objectives:** We aimed to determine whether CHIP was associated with CVE in SLE patients.

**Methods:** The study is an ancillary study of the randomized, double-blind, placebo-controlled, multicenter trial PLU5 study conducted from June 2007 through August 2010 at 37 centers in France involving 573 SLE patients. The search for somatic mutations by high-throughput sequencing of 53 genes involved in clonal hematopoiesis was performed on genomic DNA collected at PLUS inclusion. The CHIP prevalence was assessed in SLE and in a retrospective cohort of 479 patients free of hematological malignancy. The primary outcome was the incident CVE in SLE.

**Results:** Screening for CHIP was performed in 438 SLE patients (38 [29-47] years, 91.8% female). Overall, 63 somatic mutations were identified in 47 patients defining a CHIP prevalence of 10.7% in SLE. Most SLE patients (78.7%) carried a single mutation. Most variants (62.5%) were located in the DNMT3A gene. CHIP was associated with age, age at SLE diagnosis and a lower frequency of antiphospholipid antibodies. CHIP occurred more than 20-years earlier (p<0.00001) in SLE than in controls. The detection of CHIP at inclusion was not associated with the occurrence of CVE during follow up (HR= 0.42 (0.06 – 3.21), p=0.406).

**Conclusion:** The prevalence of CHIP is high in SLE with respect to age but was not associated with incident CVE.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.20

**POS0723**
Dietary Habits and the Impact on Clinical Features in Primary Sjogren’s Syndrome

A. Alunno3, F. Carubbi4, F. M. Mariani1, M. Rossi1, P. Sipari1, D. Grassi1, C. Ferr1,1 Internal Medicine and Nephrology Unit, University of Udine, Department of Life, Health and Environmental Sciences, Udine, Italy

**Background:** In recent years, increasing evidence on the role of diet on chronic conditions, including cardiovascular diseases (CV) and rheumatic and musculoskeletal diseases (RMDs) has accrued. Most studies exploring the possible role of nutrients and dietary patterns on both the risk to develop RMDs in the general population and the natural history of the disease in patients with established RMDs pertain to rheumatoid arthritis. Data in patients with established primary Sjogren’s syndrome (pSS) is lacking.

**Objectives:** To explore dietary habits and their relationship with metabolic and inflammatory features in a cohort of patients with established pSS.

**Methods:** Consecutive patients with pSS were recruited and dietary habits over the previous 12 months were explored. Adherence to the Mediterranean Diet was assessed with the 14-item PREvencion con Dita Mediterrañea (PREDIMED) tool and the 28-item Mediterranean Lifestyle (MEDLIFE) index. Adherence to the Dietary Approaches to Stop Hypertension (DASH) was estimated using a score based on 8 food items. Tea/herbal tea and coffee intake were also explored and clinical/serological records were retrospectively collected.

**Results:** We enrolled 105 patients with pSS (95% females) with a mean age of 59 years. According to the PREDIMED score 32 (31%) patients had a good adherence to the Mediterranean Diet, 64 (61%) a medium adherence and only 9 (8%) a poor adherence. According to the DASH score, 74 (71%) patients had low adherence and 31 (29%) had high adherence. When dividing patients according to the extent of adherence to either of the dietary patterns and correlating the diet adherence scores to disease specific variables some associations emerged. The PREDIMED score was inversely correlated with disease activity, as measured by the EULAR Sjögren’s syndrome disease activity index (ESSDAI) (Spearman’s rho=−0.27, p= 0.009) and ClinESSDAI (Spearman’s rho=−0.26, p=0.01) revealing that a higher adherence to the Mediterranean Diet was associated with lower disease activity. With regard to the MEDLIFE, the total of blocks 1 and 2, that are related to Mediterranean foods and dietary habits, did not correlate with the total of block 3 (related to other healthy habits such as physical activity), meaning that the patients adhering the most to the Mediterranean Diet not necessarily had an overall healthy lifestyle. Adherence to DASH was not associated with disease activity. With regard to individual nutrients, fish consumption was associated with a lower prevalence of hypertension as observed in the general population. Higher intake of red meat was associated with higher values of self-reported pain (Spearman’s rho=−0.3; p=0.01) while high wholegrain intake was associated with a lower number of coexisting CV risk factors (OR=0.7; 95% CI=0.52-0.97; p=0.03).

**Conclusion:** Adherence to the Mediterranean Diet, with particular attention to high intake of fish and wholegrains and low intake of red meat, may be beneficial on various domains in pSS, such as the CV system and the inflammatory environment, and as such should be recommended to patients with this disease.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.46

**POS0724**
Risk Factors for Coronary Artery Disease in Chinese Patients with Systemic Lupus Erythematosus: A Multi-Center, Retrospective, Cohort Study

W. Qin1, J. Zhao6, Y. Wang5, L. Pan1, M. Li1 on behalf of the Beijing Systemic Lupus Erythematosus Co-Operated Group.

**Background:** Coronary artery disease (CAD) not only has an increased prevalence but also is a major cause of premature mortality in systemic lupus erythematosus (SLE) [1, 2]. However, information is limited regarding the risk factors for CAD in Chinese patients with SLE.

**Objectives:** To assess the risk factors for CAD in Chinese patients with SLE.

**Methods:** This multi-center, retrospective, cohort study included 3778 consecutive SLE patients, with CAD (CAD group) or without a medical history of CAD (control group). CAD was defined as a coronary stenosis ≥50% in any major epicardial coronary vessel detected by coronary angiography or a history of myocardial infarction confirmed by medical records. General parameters, clinical features, laboratory tests and medical therapies were compared between groups, and the risk factors for CAD in SLE were analyzed by logistic regression analysis.

**Results:** The age at baseline was older, male ratio was higher and body mass index was greater in CAD group (all P<0.001). Traditional CAD risk factors including diabetes mellitus, hypertension, dyslipidemia, family history of CAD and smoking were more common in CAD group (all P<0.001) (Figure 1). SLE Disease Activity Index 2000 was greater (P=0.012), hyperuricemia and elevated C-reactive protein (CRP) were more prevalent (both P<0.001), and an increased corticosteroids' usage (P=0.018) was detected in CAD group (Table 1). Binary logistic regression analysis showed hyperuricemia (odds ratio: 3.082, 95% confidence interval: 1.283-7.403; P=0.012) and CRP (odds ratio: 7.248, 95% confidence interval: 2.931-17.925; P=0.001) were independent risk factors for CAD in SLE patients.

**Figure 1.** Comparison of traditional risk factors in SLE patients between CAD group and control group. Abbreviations: CAD, coronary artery disease; SLE, systemic lupus erythematosus. All P<0.001.
Ljubljana, Slovenia; patients. The Screening Questionnaire based on SICCA study data was designed for SLE Disease Activity Index 2000.

Corticosteroids, n (%) 2752 (73.78) 41 (89.13)
Positive aPL, n (%) 734 (19.68) 11 (23.91) 0.474
Elevated creatinine, n (%) 295 (7.91) 10 (21.74) 0.002
Thrombocytopenia, n (%) 859 (23.03) 8 (17.39) 0.366

SS is presented in Table 1.

responded positively (reached ≥7 points). The performance of SSSQ recognizing SS is presented in Table 1.

Table 1. Comparison of clinical features in SLE patients between CAD group and control group.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control group (n=3732)</th>
<th>CAD group (n=46)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at baseline [years, median (P25, P75)]</td>
<td>35.00 (29.00, 45.00) 59.50 (50.25, 67.75)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>296 (7.94)</td>
<td>11 (23.91)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration [years, median (P25, P75)]</td>
<td>8.00 (4.00, 12.00) 10.00 (4.00, 19.00)</td>
<td>0.173</td>
<td></td>
</tr>
<tr>
<td>Body mass index [kg/m2, median (P25, P75)]</td>
<td>21.77 (19.63, 24.16) 23.50 (22.09, 25.36)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Renal disorder, n (%)</td>
<td>1737 (46.57)</td>
<td>9 (19.57)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Neurologic disorder, n (%)</td>
<td>555 (15.95)</td>
<td>3 (6.52)</td>
<td>0.082</td>
</tr>
<tr>
<td>Thrombocytopenia, n (%)</td>
<td>859 (23.03)</td>
<td>8 (17.39)</td>
<td>0.366</td>
</tr>
<tr>
<td>SLEDAL-2K [median (P25, P75)]</td>
<td>3.00 (0.00, 8.00)</td>
<td>5.50 (15.0, 14.00)</td>
<td>0.012</td>
</tr>
<tr>
<td>Elevated creatinine, n (%)</td>
<td>255 (79.1)</td>
<td>10 (21.74)</td>
<td>0.002</td>
</tr>
<tr>
<td>Hyperuricemia, n (%)</td>
<td>209 (5.60)</td>
<td>16 (34.78)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Elevated ESR, n (%)</td>
<td>951 (25.5)</td>
<td>22 (47.83)</td>
<td>0.001</td>
</tr>
<tr>
<td>Elevated CRP, n (%)</td>
<td>210 (5.63)</td>
<td>15 (32.61)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Positive aPL, n (%)</td>
<td>734 (19.68)</td>
<td>11 (23.91)</td>
<td>0.474</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>2752 (73.78)</td>
<td>41 (89.13)</td>
<td>0.018</td>
</tr>
<tr>
<td>Immunosuppressants, n (%)</td>
<td>2950 (79.09)</td>
<td>37 (80.43)</td>
<td>0.823</td>
</tr>
</tbody>
</table>

Conclusion: Hyperuricemia and CRP are independent risk factors for CAD in SLE patients. This study highlights the association between hyperuricemia, CRP and CAD burden in SLE, and might provide a modifiable perspective on improving SLE outcomes.

Table 1. Diagnostic accuracy of SSSQ (Sjögren’s Syndrome Screening Questionnaire) and ACR/EULAR 2016 sicca questions in our cohort. PLR Positive Likelihood Ratio; NLR Negative Likelihood Ratio; PPV Positive Predictive Value; NPV Negative Predictive Value;

<table>
<thead>
<tr>
<th>Statistics</th>
<th>SSSQ</th>
<th>Standard sicca questionnaire</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>42.5% (33.8 to 51.6%)</td>
<td>86.6% (79 to 92.0%)</td>
</tr>
<tr>
<td>Specificity</td>
<td>73.7% (68.5 to 78.9%)</td>
<td>76.4% (4.9 to 11.3%)</td>
</tr>
<tr>
<td>PLR</td>
<td>1.4 (1.2 to 2.2)</td>
<td>0.9 (0.3 to 1.0)</td>
</tr>
<tr>
<td>NLR</td>
<td>0.8 (0.7 to 0.9)</td>
<td>1.8 (1.0 to 3.2)</td>
</tr>
<tr>
<td>PPV</td>
<td>41.9% (35.2 to 48.8%)</td>
<td>29.3% (27.7 to 30.9%)</td>
</tr>
<tr>
<td>NPV</td>
<td>74.5% (71.2 to 77.5%)</td>
<td>56.4% (41.6 to 72.2%)</td>
</tr>
<tr>
<td>Accuracy</td>
<td>64.3% (59.5 to 69.0%)</td>
<td>31.8% (27.4 to 36.5%)</td>
</tr>
<tr>
<td>AUC</td>
<td>0.58 (0.50 to 0.64)</td>
<td>0.52 (0.46 to 0.57)</td>
</tr>
</tbody>
</table>

Conclusion: SSSQ showed higher specificity and better diagnostic accuracy compared to current standard questionnaire in a cohort of sicca patients.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.51

Table 2. Health related quality of life in patients with systemic lupus erythematosus: data and potential applications of the Mexican Register of Lupus.

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
</table>

K. Perdan-Pirkmajer1,2, K. Fortuna3, Z. Terkel4, J. Kramarić1, A. Hoceval1,2
1University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia; 2Faculty of Medicine, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia; 3University of Ljubljana, Faculty of Medicine, University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

Background: ACR/EULAR 2016 classification criteria for Sjögren disease (SS) use 5 standard questions on ocular and oral sicca symptoms as an entrance criterion. However, these questions do not differentiate between SS as an exit criterion. Recently, a new 5-item Sjögren’s Syndrome Screening Questionnaire based on SICCA study data was designed for the use in clinical practice, better differentiating SS from non-SS sicca patients.

Objectives: We aimed to validate the SSSQ in our population with sicca symptoms.

Methods: Our study cohort represented 535 patients referred to UMC Ljubljana during the 3-year period Jan/2016 to Dec/2019 with suspected SS. All subjects underwent at that time a standardized SS diagnostic procedure, including 5 standard sicca questions, Schirmer test, Rose Bengal test, unstimulated salivary flow test, salivary gland ultrasound, immuno-erological and lip biopsy. In Sep - Oct 2021 all subjects were contacted by phone to fulfill the new SSSQ (5 questions resulting in 0-11 points: cut-off for SS ≥7 points). The performance of SSSQ recognizing SS was assessed using ACR/EULAR 2016 classification criteria as gold standard test for SS diagnosis.

Results: A total of 525 subjects agreed to participate in the study (384 (92.5%) females, mean (SD) age 57 (13.8), the rests either declined (21), died (2) or could not be reached (97). Based on the ACR/EULAR 2016 criteria SS was diagnosed in 127 (30.6%) and excluded in 288 subjects. 376/415 (90.6%) subjects responded positively on 5 standard sicca questions (110 with and 266 without SS). In the new SSSQ 129 (31.1%) subjects (54 with and 75 without SS) responded positively (reached ≥7 points). The performance of SSSQ recognizing SS is presented in Table 1.

Discussion of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.51
Conclusion: In Mexican people with SLE, a significant decrease in HRQoL was detected compared with controls. The implementation of a national register in Mexico (Lupus RGMX) will provide additional psychosocial and clinical information to deepen our knowledge of this disease.

REFERENCES:


POS0728

ASSOCIATION BETWEEN TREATMENT GOAL ACHIEVEMENT AND GRIT PERSONALITY CHARACTERISTICS OF ATTENDING PHYSICIAN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER CROSS-SECTIONAL STUDY


Background: Systemic Lupus erythematosus (SLE) is an autoimmune disease with a wide spectrum of clinical manifestations and characterized by remission and flares. Recent epidemiological studies postulated that air pollution confers an increased risk of flare in various autoimmune diseases. Haze is a common phenomenon afflicting Southeast Asia (SEA), including Malaysia, and has occurred almost every year within the last few decades.

Objectives: This study was aimed to determine the correlation and association between SLE disease activity with exposure to inhalated Particulate Matter (PM<sub>x</sub>) and Nitrogen Dioxide (NO<sub>x</sub>).

Methods: SLE patients who attended rheumatology and nephrology clinic in University Kebangsaan Malaysia Medical Centre (UKMMC) from June 2019 until September 2019. Clinic visits with presence of infection or recent change of immunosuppressive treatment of ≤3 months were excluded. The average of daily concentrations of inhaled PM<sub>x</sub> (µg/m<sup>3</sup>) and NO<sub>x</sub> (ppb) were evaluated within 30 days preceding the clinic visits, and the data was obtained from Department of Environment (DOE) Malaysia. Comparison of the means was performed by Student’s t-test; and the correlations between PM<sub>x</sub> and NO<sub>x</sub> were determined by Pearson’s correlation coefficient. The associations between the effect of daily pollutant concentrations on M-SLEDAI and BILAG 2004 scores were analyzed using the generalized estimating equation (GEE) model, while considering fixed effects for repeated measures.

Results: A total of 46 patients were recruited with 603 clinic visits were recorded. A significantly higher NO<sub>x</sub> level was found in active disease patients with M-SLEDAI score (≥2.25 vs. 1.97; p=0.012) and BILAG 2004 A1 and B1 categories (≥2 vs. 1; p<0.001). In the GEE analysis, significant correlations were found between M-SLEDAI scores (r = 0.128, p=0.002) and BILAG scores with NO<sub>x</sub> (r = 0.142, p<0.001). In the GEE analysis, significant correlations were found between M-SLEDAI score and NO<sub>x</sub> (OR 1.27 (95% CI: 1.06-1.53), p=0.01) and BILAG score with NO<sub>x</sub> (OR 1.47 (95% CI: 1.15-2.18), p=0.002).

Conclusion: Our study suggests that air pollutant NO<sub>x</sub> exposure 30 days prior to clinic visit is associated with high disease activity among patients with SLE in Malaysia. Further prospective study is warranted to confirm this finding.

REFERENCES:


POS0728

IMPACT OF AIR POLLUTANTS ON DISEASE ACTIVITY AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN MALAYSIA

J. H. Jaafar1, S. S. Shahairi1, S. Rajalingham1, R. Mohd1, M. T. Latif2, 3Universiti Kebangsaan Malaysia Medical Centre (UKMMC), Internal Medicine, Kuala Lumpur Malaysia; 4Faculty of Science and Technology, Universiti Kebangsaan Malaysia, Department of Earth Sciences and Environment, Bandar Baru Bangi, Malaysia

Background: Systemic Lupus erythematosus (SLE) is an autoimmune disease with a wide spectrum of clinical manifestations and characterized by remission and flares. Recent epidemiological studies postulated that air pollution confers an increased risk of flare in various autoimmune diseases. Haze is a common phenomenon afflicting Southeast Asia (SEA), including Malaysia, and has occurred almost every year within the last few decades.

Objectives: This study was aimed to determine the correlation and association between SLE disease activity with exposure to inhalated Particulate Matter (PM<sub>x</sub>) and Nitrogen Dioxide (NO<sub>x</sub>).

Methods: SLE patients who attended rheumatology and nephrology clinic in University Kebangsaan Malaysia Medical Centre (UKMMC) from June 2019 until March 2020 were recruited. Their medical records were reviewed for retrospective assessments of the disease activity using the Modified-SLE Disease Activity Index (M-SLEDAI) and The British Isles Lupus Assessment Group (BILAG) 2004 index from January 2015 until September 2019. Clinic visits with presence of infection or recent change of immunosuppressive treatment of ≤3 months were excluded. The average of daily concentrations of inhalated PM<sub>x</sub> (µg/m<sup>3</sup>) and NO<sub>x</sub> (ppb) were evaluated within 30 days preceding the clinic visits, and the data was obtained from Department of Environment (DOE) Malaysia. Comparison of the means was performed by Student’s t-test; and the correlations between PM<sub>x</sub> and NO<sub>x</sub> were determined by Pearson’s correlation coefficient. The associations between the effect of daily pollutant concentrations on M-SLEDAI and BILAG 2004 scores were analyzed using the generalized estimating equation (GEE) model, while considering fixed effects for repeated measures.

Results: A total of 46 patients were recruited with 603 clinic visits were recorded. A significantly higher NO<sub>x</sub> level was found in active disease patients with M-SLEDAI score (≥2.25 vs. 1.97; p=0.012) and BILAG 2004 A1 and B1 categories (≥2 vs. 1; p<0.001). In the GEE analysis, significant correlations were found between M-SLEDAI scores (r = 0.128, p=0.002) and BILAG scores with NO<sub>x</sub> (r = 0.142, p<0.001). In the GEE analysis, significant correlations were found between M-SLEDAI score and NO<sub>x</sub> (OR 1.27 (95% CI: 1.06-1.53), p=0.01) and BILAG score with NO<sub>x</sub> (OR 1.47 (95% CI: 1.15-2.18), p=0.002).

Conclusion: Our study suggests that air pollutant NO<sub>x</sub> exposure 30 days prior to clinic visit is associated with high disease activity among patients with SLE in Malaysia. Further prospective study is warranted to confirm this finding.

REFERENCES:


POS0728

ASSOCIATION BETWEEN TREATMENT GOAL ACHIEVEMENT AND GRIT PERSONALITY CHARACTERISTICS OF ATTENDING PHYSICIAN IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER CROSS-SECTIONAL STUDY


Background: Systemic Lupus erythematosus (SLE) is an autoimmune disease with a wide spectrum of clinical manifestations and characterized by remission and flares. Recent epidemiological studies postulated that air pollution confers an increased risk of flare in various autoimmune diseases. Haze is a common phenomenon afflicting Southeast Asia (SEA), including Malaysia, and has occurred almost every year within the last few decades.

Objectives: This study was aimed to determine the correlation and association between SLE disease activity with exposure to inhalated Particulate Matter (PM<sub>x</sub>) and Nitrogen Dioxide (NO<sub>x</sub>).
Results: The median age of the patients was 45 years (interquartile range [IQR]: 36-56), 88% were female, and the median disease duration was 152 months (IQR: 80-240). Thirty-seven doctors were in charge of the patients (1.79 patients mean doctor). The median age of the attending physicians was 40 years (IQR: 35-43), and 19% were female. The median perseverance and consistency respectively of attending physicians were 3.1 (IQR: 3.0-3.5) and 3.3 (IQR: 2.8-3.8). Of the enrolled patients, 154 (40%) had achieved LLDAS. The attending physicians with a lower consistency score of <3 were more frequent in the patients who achieved LLDAS (40% vs. 29%, p=0.026). The lower consistency score of all attending physicians was still related to LLDAS independently, adjusted odds ratio 1.63, 95% confidential interval 1.17-2.27. There was no association between the achievement of LLDAS and perseverance.

Conclusion: The grit personality characteristics of the attending physician may affect the achievement of treatment goals in patients with SLE.

Disclosure of Interests: KEN-EL SADA Speakers bureau: I received speaker’s fees from GlaxoSmithKline K.K. JUAN LUIS COLON: Grant/research support from: I received a research grant from Pfizer Inc.; Yoshua Miyawaki: None declared, Keiji Shidahara: None declared, Shoichi Nawachi: None declared, Yu Katayama: None declared, Yosuke ASANO: None declared, Keigo Hayashi: None declared, Keiji Dahara: None declared, Shoichi Nawachi: None declared, Yu Katayama: None declared, Nobuyuki Tajima: None declared, DOI: 10.1136/annrheumdis-2022-eular.581

POS0779

A BETTER SELF-EFFICACY IS PREDICTIVE OF BETTER HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS. DATA FROM A LATIN AMERICAN MESTIZO COHORT

M. F. Ugarte-Gil1, R. V. Gamboa Cárdenas1, C. Reategui Sokolova1, V. Pimentel-Quizo2, M. Medina Chinchón1, C. Elera-Fitzcarrald2, Z. Rodríguez Belido1, C. Pastor Asurza1, R. Perich Campos3, S. Alarcon4,5,6

1Universidad Peruana Cayetano Heredia, School of Medicine, Lima, Peru; 2Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Rheumatology, Lima, Peru; 3Universidad San Ignacio de Loyola, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Peru; 4Universidad Nacional Mayor de San Marcos, School of Medicine, Lima, Peru; 5The University of Alabama at Birmingham, Birmingham, School of Medicine, Alabama, United States of America; 6Universidad Peruana Cayetano Heredia, School of Medicine, Lima, Peru

Background: Systemic lupus erythematosus (SLE) patients have a worse health-related quality of life (HRQoL) than the general population. This seems to be related to patients characteristics like age, poverty, behavioral issues rather than to disease activity or damage. Self-efficacy is defined as individual’s confidence on performing a task and could impact on patient-reported outcomes.

Objectives: To determine the possible predictive value of self-efficacy on HRQoL in SLE patients.

Methods: SLE patients from a single-center prevalent cohort were included. Self-efficacy was ascertained with six instruments of the Patient-Reported Outcomes Measurement Information System (PROMIS) Self-efficacy for Managing Chronic Conditions. Instruments included were general self-efficacy, and self-efficacy for managing emotions, managing symptoms, managing daily activities, managing social interactions and managing medications and treatments.

RESULTS: Among 519 SLE patients, 81% had a score ≤ 50 in at least one of the self-efficacy instruments (people with a chronic condition), a higher score indicates that the respondent has greater self-efficacy. HRQoL was ascertained with the physical and mental component summary (PCS and MCS) measures of the Short-Form 36 (SF-36). Generalized estimating equations were performed, using as outcome the PCS or MCS in the subsequent visit, and the self-efficacy instrument in the previous visit; multivariable models were adjusted for possible confounders (age at diagnosis, gender, socioeconomic status, SLEDAI-2K, SLICC/ACR damage index, disease duration at baseline, prednisone daily dose, antimalarial and immunosuppressive drugs use and PCS or MCS in the previous visit). All the confounders were measured in the same visit than the self-efficacy instrument.

RESULTS: Two-hundred and nine patients for a total of 564 visits were included; 194 (92.8%) patients were women, mean age at diagnosis was 36.4 (14.0) years and disease duration at baseline was 6.5 (6.0) years. At baseline, PCS was 55.0 (22.3) and MCS was 53.9 (20.4). At baseline, mean general self-efficacy was 47.2 (10.4), self-efficacy for managing emotions was 44.6 (8.0), for managing symptoms was 47.7 (8.2), for managing daily activities was 44.5 (7.5) for managing social interactions was 42.9 (7.9) and for managing medications and treatments it was 39.7 (9.7). In the multivariable models a better self-efficacy was predicted by a better general self-efficacy, and self-efficacy for managing symptoms, managing social interactions and managing medications and treatments and a better MCS was predicted by a better self-efficacy for managing symptoms, managing daily activities, managing social interactions and managing medications and treatments.

REFERENCES:

Disclosure of Interests: None declared

POS0731
ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)


Methods: Results: Background: The aim of the Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS) is to examine the disease course of patients with systemic lupus erythematosus (SLE) in relation to their type I interferon gene signature (IFNGS) status.1 IFNGS has been associated with SLE disease activity.2 Objectives: To identify associations between IFNGS status and patient-reported outcomes (PROs) among patients receiving clinical care while enrolled in SPOCS.

IFNGS High: n=219
IFNGS Low: n=525

(n=219) Total (n=431)

(n=147)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)

(n=810)

(n=279)

(n=431)
Background: Salivary gland ultrasound (SGUS) is a simple and non-invasive procedure that is readily available and supplies important information on the major salivary glands. Several recent studies have assessed SGUS as a tool for diagnosing primary Sjögren’s syndrome (pSS), and have reported its association with different features in pSS.

Objectives: To investigate the association of SGUS findings with clinical, histological, and serological features of pSS in our cohort. In addition, we include nonmonospecific antibody determination to Ro60 or Ro52.

Methods: Patients with pSS were determined according to the American-European Consensus Group (AECG) criteria for pSS. A total of 53 of these pSS patients underwent SGUS evaluation. We considered SGUS score based on parenchymal homogeneity, presence of hypoechogenic areas, and clearness of posterior glandular border of salivary glands. The score of the highest graded gland was considered and a score ≥2 was defined as a positive SGUS, according to OMERACT US-SG scoring [1]. Patients were classified into two groups according to positive vs. negative SGUS. Demographic, clinical, histopathological, and laboratorial data were collected and compared between the groups. Categorical variables were compared using the Chi-square test or Fisher’s exact test when the conditions for Chi-square test were not met, and continuous variables were compared using Student’s t-test with Welch’s correction. p-values <0.05 were considered significant.

Results: Study participants were predominantly women (98%) and had a mean age of 60.2 years. SGUS was positive in 32 (63%) pSS patients, they were all women and had a mean age of 59 years. Positive SGUS was associated with objective evidence of ocular involvement (defined as a positive result for at least one of the ocular tests, p<0.001), time of evolution of xerophthalmia at diagnosis (mean 5.8 years vs. 2.2 years, p=0.037), pathological result of the labial salivary gland biopsy when it was performed (p<0.001), and the presence in the serum of both antiRo60 and antiRo52 antibodies (p=0.004), antiLa antibody (p=0.008) and ANA titer ≥1:320 (p<0.001). No significant differences were found between positive SGUS and negative SGUS patients regarding the presence of xerophthalmia nor xerostomia, time of evolution of xerostomia at diagnosis, episodes of parotid inflammation, abnormal salivary scintigraphy, or the presence in the serum of monospecific antiRo52 nor antiRo60 in the absence of each other, nor positive rheumatoid factor.

Conclusion: Positive SGUS was associated in pSS patients with objective evidence of ocular function, histopathology of minor salivary glands, and serology of pSS, specifically the presence of both antiRo52 and antiRo60 antibodies. In our cohort, no significant association was found regarding xerostomia, episodes of parotid inflammation, nor objective evidence of oral involvement. Thus, SGUS could be a useful tool to establish objective salivary gland involvement, independently of oral symptoms and other oral tests.

REFERENCES:
CONCLUSION: Low correlation between PGA and PtGA suggests both should be used to acquire a broad perspective of the impact of disease on the overall health of patients. Different baseline characteristics were associated with the PGA-higer compared to the PtGA-higher discordant subgroups.

REFERENCES:

Acknowledgements: Editing assistance by Rebecca S. Jones, PhD (Fishawack). This study was sponsored by AstraZeneca.


DOI: 10.1136/annrheumdis-2022-eular.1373

PO0734

THE CLINICAL JUDGMENT FOR THE ACCEPTABILITY OF PREGNANCY IN PATIENTS WITH SEROLOGICALLY ACTIVE SLE IN JAPAN: A NATIONAL WIDE ONLINE SURVEY FROM THE VIGNETTE STUDY

S. Isoiina,1 N. Yajima,1 R. Yanai,1 Y. Miura,2 S. Fukuma,2 K. Kaneko2, K. Fujio3, K. Oku4, M. Matsushita5, T. Miyamae5, T. Wada5, Y. Kaneko6, Y. Tanaka6, A. Nakajima5, A. Murashima1,1 Showa University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan; 2Kyoto University, Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto, Japan; 3National Center for Child Health and Development, Division of Maternal medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, Tokyo, Japan; 4The University of Tokyo, Department of Allergy and Rheumatology, Graduate School of Medicine, Tokyo, Japan; 5Kitasato University, Department of Rheumatology and Infectious Diseases, Sagamihara, Japan; 6Juntendo University School of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan; 7Tokyo Women’s Medical University Hospital, Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo, Japan; 8Kanazawa University, Department of Nephrology and Laboratory Medicine, Kanazawa, Japan; 9Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan; 10University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Japan; 11Mie University Graduate School of Medicine, Division of Rheumatology, Tsu, Japan

Background: The risk of pregnancy complications, such as gestational hypertension, is high in pregnancies with SLE. In addition, the risk of flare is elevated if pregnancy occurs during the high disease activity. The EULAR recommendation provides a checklist for preconception counseling, in which patients with SLE desiring pregnancy were required the condition that the disease activity prior to pregnancy should be stable for 6-12 months in terms of serological activity (1). However, it does not provide specific criteria for serological activity so that physicians should evaluate the risk of pregnancy in each case by their clinical intuitions.

Objectives: In order to uncover the present clinical situation for the acceptability of pregnancy in patients with SLE, we performed questionnaire survey to physicians regarding to the degree of serological activity.

Methods: This cross-sectional study was performed to physicians registered with the Japanese College of Rheumatology from December 2020 to January 2021 using the online survey. The questionnaire asked about the demographics of physicians, facilities and the permission of pregnancies with SLE using vignette scenarios. In this study, data from vignettes of women visiting a regular outpatient clinic were used. The vignettes varied in age (28 or 35 years), duration of stable disease and serological activity. Analysis methods were descriptive statistics, chi-square test, generalized estimating equations (GEE) was performed to investigate the relationship between the determining permission for pregnancy and the scenario patient’s characteristics (age, period of stable disease, titer of anti ds-DNA antibody).

Results: The questionnaire was distributed to 4946 physicians, and 463 responded. Completion rate (ratio agreed to participate/finished survey) of survey was 91.1%. The median age of physicians was 46 (interquartile range (IQR) 2-10). The specialty was rheumatology (84.9%), other internal medicine (8%), and pediatrics (5.6%). There were no significant differences in patient’s age about the acceptability of pregnancy (coefficient -0.02, 95% CI -0.17 -0.01, p=0.42). Case who had been stable for 6 months were more tolerant of pregnancy than case who had been stable for 3 months (coefficient 0.12, 95% CI 0.09-0.15, P<0.001) Pregnancy was not allowed in case with mild or high serological activity (mild: coefficient -0.49, 95% CI -0.29 --0.22, p<0.001, high: -0.64, 95% CI -0.65 - -0.61, p <0.001). In contrast, as many as 92 (19.2%) physicians tolerated pregnancy even in the presence of residual high anti ds-DNA antibody titers. Female physicians are significantly more cautious about pregnancy than male when patients have a serologically high activity (12% vs 37.5%, p<0.001). There were no significant differences in specialty status or clinical experience.

Conclusion: We found that even mild serological activity alone had a significant negative effect on the physician’s decision to allow pregnancy. We conclude that current physicians make cautious decisions about pregnancies of patients with SLE following the recommendation. On the other hand, an additional investigation should be performed about the results of pregnancies in patients with serological abnormalities, since there are some physicians who thought that pregnancy may be acceptable for patients with only serological abnormalities if the clinical symptoms are stable.

REFERENCES:

I would like to express my gratitude to the members of Japan College of Rheumatology who cooperated in filling out the questionnaire.

Disclosure of Interests: Sakiko Isoi: None declared, Nobuyuki Yajima: None declared, Yoko Yanai: None declared, Yoko Miura: None declared, Shingo Fukuma: None declared, Takayo Kaneke: None declared, Keishi Fujio: None declared, Kenji Oku: None declared, Masakazu Matsushita: None declared, Takako Wada: None declared, Kyo Kaneko: None declared, Yoshiya Tanaka Speakers bureau: Y. Tanaka has received speaking fees and/or honoraria from Gilead, Abbvie, Behring-Ingelheim, Eli Lilly, Mitsubishi-Tanabe, Chugai, Amgen, YL Biologics, Eisai, Astellas, Bristol-Myers, Astra-Zeneca, Grant/research support from: Y. Tanaka has received research grants from Asahi-Kasei, Abbvie, Chugai, Mitsubishi-Tanabe, Eisai, Takeda, Corrona, Daiichi-Sankyo, Kowa, Behring-Ingelheim, and consultant fee from Eli Lilly, Daiichi-Sankyo, Taisho, Ayumi, Sanofi, GSK, Abbvie, Ayako Nakajima: None declared, ATSUKO MURASHIMA: None declared

apo-PT735

EFFECT OF OSTEOPOROSIS ON MAJOR ADVERSE CARdiovascular EVENTS (MACES) AND MORTALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: A LONGITUDINAL STUDY

C.C. Mo1, K.L. Chan2, L.Y. Ho1, C.H. To1. 1Tuen Mun Hospital, Medicine, Hong Kong, China; 2Tuen Mun Hospital, Medicine, Hong Kong, China; 3Pok Oi Hospital, Medicine, Hong Kong, China

Objectives: To study the effect of osteoporosis on major adverse cardiovascular events (MACES) and mortality in a longitudinal cohort of patients with systemic lupus erythematosus (SLE).

Methods: Patients who fulfilled ≥4 1997 ACR criteria for SLE and participated in a cross-sectional study on osteoporosis in the year 2011 were studied. All patients had a dual energy x-ray absorptiometry (DXA) scan (Delphi densitometer; Hologic, Bedford, USA) performed between the years 2004-2008 and were followed in the rheumatology clinics by the same team of physicians. The incidence of new MACES, which were defined as ischemic vascular events (acute coronary syndrome, stroke, peripheral vascular disease) documented by imaging and angiographic studies, was evaluated. Patients were stratified into 2 groups according to the presence of osteoporosis at baseline, which was defined as a DXA T score of <-2.5 or Z score <-2.0 at the hip, femoral neck or lumbar spine, or having a past history of fragility fractures. The effect of osteoporosis on the development of MACES and mortality was studied by Cox regression analysis, adjusted for demographic characteristics, traditional cardiovascular risk factors, antiphospholipid antibodies and the use of medications.

Results: 383 SLE patients were studied (age at DXA scan 40.5±13 years; 94% women; SLE duration 8.0±7.4 years). Osteoporosis at the hip, femoral neck or spine at baseline was present in 105 patients (13 with old fragility fractures) and 8 patients had osteoporosis and past fragility fractures. The demographic characteristics, prevalence of traditional atherosclerotic risk factors and antiphospholipid (aPL) antibodies (lupus anticoagulant or moderate/high titer of IgG-anticardiolipin antibodies) were not significantly different between those with osteoporosis/fracture (N=113) and without (N=270). Patients with osteoporosis/fracture were more likely to be using glucocorticoids (79% vs 62%; p=0.002) and mycophenolate mofetil/azathioprine/calcineurin inhibitors (58% vs 48%; p=0.08) but less likely to be treated with hydroxychloroquine (40% vs 51%; p=0.051) at baseline. Over a follow-up of 153±41 months, 44 new MACES (acute coronary syndrome [n=19]; ischemic stroke [n=19]; peripheral vascular disease with digital gangrene/amputation [n=6]) developed in 42 patients. The incidence of MACES was significantly higher in patients with osteoporosis/fracture than those without (1.59 vs 0.63/100 patient-years; p<0.001). The cumulative risk of new MACES at 3, 5 and 10 years was 6.3%, 11.7%, 14.7%, and 0.4%, 19.4%, 4.7%, respectively, in the osteoporosis and non-osteoporosis groups (log rank test; p=0.002; univariate hazard ratio 2.58 [1.40-4.74]; p=0.002). In a Cox regression model, osteoporosis/fracture remained an independent risk factor for the development of MACES after adjustment for age, sex, LDL level, atherogenic index, diabetes mellitus, hypertension, past MACE, aPL antibodies, smoking, obesity and the use of medications that included immunosuppressive drugs, aspirin/warfarin, statins, vitamin D and bisphosphonates (HR 2.41 [1.25-4.67]; p=0.009). At last follow-up, 62 (16%) patients succumbed (MACES in 8 patients [vascular mortality], infective complications in 27 patients, cancer in 10 patients). Osteoporosis/fracture was associated with vascular mortality (HR 11.1 [2.02-120]; p=0.048) but not with all-cause mortality (HR 1.55 [0.89-2.68]; p=0.12) after adjustment for the same covariates in separate multivariate models.

Conclusion: Osteoporosis increases the risk of MACES and vascular mortality in patients with SLE, which is not accounted by traditional vascular risk factors. Elevation of inflammatory cytokines in SLE that are common to bone metabolism and atherosclerotic vascular disease may be responsible.

Disclosure of Interests: None declared.


apo-PT737

SICCA SYNDROME: A MULTIMODAL ASSESSMENT TO CHARACTERIZE PATIENT COHORTS BEYOND SJÖGREN’S SYNDROME: CLINICAL CRITERIA

E. Kramer1, T. Seelig2, T. Skripuletz2, V. Gödecke3, S. Belder1, A. Jablonka1, T. West2, D. Ernst1. 1Medizinische Hochschule Hannover, Rheumatology and Immunology, Hannover, Germany; 2Medizinische Hochschule Hannover, Neurology, Hannover, Germany; 3Medizinische Hochschule Hannover, Centre of Rare Diseases, Hannover, Germany

Background: Sjögren syndrome represents a heterogeneous group of conditions, including Sjögren syndrome, causing xerophthalmia and xerostomia. Objectives: This study characterizes in depth patients with Sicca syndrome and evaluates salivary gland ultrasound (SGUS) in this cohort. Methods: Principal component analysis and hierarchical clustering of clinical parameters, including ESSPRI, ESSDAI and laboratory data, were performed on all referrals for assessment of Sicca symptoms over the period from October 2018 and March 2021. SGUS and salivary gland biopsies were compared across groups.

Results: 583 patients were assessed. Objective dryness was confirmed in 73% of patients. Cluster analysis identified 3 groups with post-hoc analysis confirming distinct phenotypes: Somatic Group (283/583; 49%) with higher reported symp- toms but limited objective dryness; Dry Without Autoimmune Features (DAF 206/532; 35%) and Dry With Autoimmune Features (DAF 94/532; 17%). DAF patients had highest autoantibody titres (SSA 240 vs 3.6 vs 3.8; p<0.001), most extra-glandular manifestations (p<0.001) and highest median SGUS Score (DAF 8 [4-10] vs SG 2 [1-4] vs DAF 4 [2-5]; p<0.01). No tangible correlation primary Sjögren syndrome criteria was observed.

Conclusion: A multimodal assessment of Sicca syndrome patients identified in the DAF cluster. This study highlights heterogeneity within Sicca and indeed Sjögren syndrome, highlighting the need for further studies.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1440
Table 1. Comparing and contrasting the clinical demographics and attributes of the entire cohort subdivided into the three groups identified through principal component analysis and subsequent hierarchical clustering. Results are shown as mean and interquartile range unless otherwise stated.

<table>
<thead>
<tr>
<th>Somatic</th>
<th>DAF_{neg}</th>
<th>DAF_{pos}</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%)</td>
<td>283 (49)</td>
<td>206 (35)</td>
<td>94  (16)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>239 (84)</td>
<td>142 (69)</td>
<td>81  (86)</td>
</tr>
<tr>
<td>Age at Onset, yrs</td>
<td>47.3 (36.6-55.9)</td>
<td>60.2 (51.1-67.3)</td>
<td>50.1 (35.5-59.4)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.1 (23.0-31.0)</td>
<td>24.7 (21.7-27.7)</td>
<td>24.6 (22.4-28.8)</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>50 (18)</td>
<td>15 (7)</td>
<td>4   (4)</td>
</tr>
<tr>
<td>ESSDAI Scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Dryness</td>
<td>6 [3-7]</td>
<td>2 [1-3]</td>
<td>4 [2-7]</td>
</tr>
<tr>
<td>- Limb Pain</td>
<td>7 [5-6]</td>
<td>5 [2-6]</td>
<td>6 [4-8]</td>
</tr>
<tr>
<td>- Fatigue</td>
<td>8 [6-9]</td>
<td>3 [2-5]</td>
<td>5 [3-8]</td>
</tr>
<tr>
<td>Reported Symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud, n (%)</td>
<td>86 (30)</td>
<td>51 (25)</td>
<td>44 (47)</td>
</tr>
<tr>
<td>Arthralgia, n (%)</td>
<td>222 (78)</td>
<td>118 (57)</td>
<td>61 (65)</td>
</tr>
<tr>
<td>Myalgia, n (%)</td>
<td>197 (70)</td>
<td>87 (42)</td>
<td>40 (43)</td>
</tr>
<tr>
<td>Stiffness, n (%)</td>
<td>98 (35)</td>
<td>37 (18)</td>
<td>23 (25)</td>
</tr>
<tr>
<td>Parotitis, n (%)</td>
<td>62 (22)</td>
<td>24 (12)</td>
<td>33 (35)</td>
</tr>
<tr>
<td>Sand com, n (%)</td>
<td>168 (59)</td>
<td>62 (30)</td>
<td>44 (47)</td>
</tr>
<tr>
<td>Ocular Inf, n (%)</td>
<td>120 (42)</td>
<td>45 (22)</td>
<td>26 (27)</td>
</tr>
<tr>
<td>Antibody Titres</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- ANA ≥ 1:160</td>
<td>178 (63)</td>
<td>152 (74)</td>
<td>44 (47)</td>
</tr>
<tr>
<td>- RFH U/ml</td>
<td>10.0 [10.0-10.9]</td>
<td>10.0 [10.0-11.3]</td>
<td>23.3 [11.7-71.0]</td>
</tr>
<tr>
<td>- Alpha-Fodrin U/ml</td>
<td>9 [5-22]</td>
<td>9 [6-19]</td>
<td>12 [6-25]</td>
</tr>
<tr>
<td>- anti-SSA(Ro) U/ml</td>
<td>3.6 [0.3-101.3]</td>
<td>3.8 [0.3-102.3]</td>
<td>240.0 [192.8-240.0]</td>
</tr>
<tr>
<td>- anti-SSB(La) U/ml</td>
<td>0.4 [0.3-3.4]</td>
<td>0.3 [0.3-3.1]</td>
<td>73.1 [3.8-312.5]</td>
</tr>
<tr>
<td>Measurable Dryness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saxon, g</td>
<td>3.5 [2.4-4.9]</td>
<td>4.2 [3.3-5.3]</td>
<td>2.3 [0.6-3.7]</td>
</tr>
<tr>
<td>Schirmer, mm</td>
<td>7.0 [2.0-17.9]</td>
<td>3.0 [0.5-12.0]</td>
<td>2.5 [0.0-7.1]</td>
</tr>
<tr>
<td>Labial Gland Biopsy, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Biopsy performed</td>
<td>150 (53)</td>
<td>120 (58)</td>
<td>18 (19)</td>
</tr>
<tr>
<td>- Chisholm Score ≥3</td>
<td>66 (44)</td>
<td>64 (53)</td>
<td>9 (50)</td>
</tr>
<tr>
<td>- Median Score</td>
<td>2 [1-3]</td>
<td>3 [2-3]</td>
<td>3 [3-4]</td>
</tr>
<tr>
<td>Salivary Gland Ultrasound, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- SGUS = 0</td>
<td>39 (14)</td>
<td>39 (19)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>- SGUS ≥6</td>
<td>73 (26)</td>
<td>55 (27)</td>
<td>38 (41)</td>
</tr>
<tr>
<td>- SGUS Score</td>
<td>2 [1-4]</td>
<td>4 [2-5]</td>
<td>8 [4-10]</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Emelie Kramer: None declared, Tabea Seeliger: None declared, Thomas Skripuletz: None declared, Vega Godecke: None declared, Sonja Beider: None declared, Alexandra Jablonka: None declared, Torsten Witte: None declared, Diana Ernst Grant/research support from: This study was financially supported by Novartis. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.


PO50738

IMMUNOGENICITY AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

G. M. Verstappen,1 L. De Wolf,1 S. Arends,1 H. M. Heiermann,1 Y. Van Steen,1 A. Visser,1 J. H. Terpstra,2 D. Diamatopoulos,1,2,3 M. Van der Heiden,1 A. Vissink,1 D. Van Baarle,4,6, F. G. M. Kroese,1, H. Bootsma,1 1University of Groningen, University Medical Centre Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 2Radboud University Medical Centre Nijmegen, Radboud Centre for Infectious Diseases, Nijmegen, Netherlands; 3Radboud University Medical Centre Nijmegen, Laboratory of Medical Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands; 4University of Groningen, University Medical Centre Groningen, Medical Microbiology and Infection Prevention, Nijmegen, Netherlands; 5University of Groningen, University Medical Centre Groningen, Oral and Maxillofacial surgery, Groningen, Netherlands; 6National Institute of Public Health and the Environment, Centre for Infectious Disease Control, Bilthoven, Netherlands

Background: Patients with primary Sjögren’s syndrome (pSS) worry about the effectiveness and safety of COVID-19 vaccination. pSS is characterized by B-cell hyperactivity, and previous influenza vaccination studies showed that pSS patients generate higher influenza-specific antibodies than healthy controls (HC). Furthermore, influenza vaccination resulted in elevated auto-antibody levels. Therefore, it is hypothesized that COVID-19 vaccination may also lead to a higher spike-specific antibody response.

Objectives: To evaluate humoral and cellular immune response and adverse events (AEs) after COVID-19 vaccination in pSS patients compared to HC, and disease activity following vaccination in pSS patients. Furthermore, to evaluate change in spike-specific antibody levels in saliva and anti-SSA levels in serum following vaccination.

Methods: In this prospective, longitudinal cohort study, pSS patients and HC were included in a 2:1 ratio. Participants received COVID-19 vaccinations following the Dutch vaccination programme. pSS patients did not use...
immunomodulatory drugs, except hydroxychloroquine (HCQ). Anti-spike 1 (S1) receptor binding domain (RBD) IgG serum antibody levels were measured 28 days after complete vaccination. AEs were collected 7 days after vaccination. Change in disease activity following vaccination was measured with EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). In a subgroup of participants, spike-specific T-cell response was measured 7 days after complete vaccination with IFN-γ ELispot. Definition of a T-cell responder was ≥2-fold increase in spot-forming cell (SFC) counts from pre- to post-vaccination and SFC counts of ≥50/10⁶ cells in the post-vaccination sample. Salivary anti-S1 and anti-RBD antibodies and serological anti-SSA antibodies were also measured in this subgroup in pre- and post-vaccination samples (28 days after complete vaccination).

Results: In total, 67 pSS patients and 33 HC were included. Of these, 47 (70%) and 14 (42%) received BNT162b2 (Pfizer-BioNtech), 13 (19%) and 5 (15%) received ChAdOx1 nCoV-19 (AstraZeneca), 6 (9%) and 8 (24%) received mRNA-1273 (Moderna), and 1 (1%) and 6 (18%) received Ad.26.COV2.S (Janssen), respectively. Overall, pSS patients were significantly older than HC, which was mainly due to the younger age in the Moderna and Janssen groups. All participants had positive anti-SARS-CoV-2 antibody levels (>2500 AU/ml) post-vaccination. No differences in anti-SARS-CoV-2 antibody levels were observed between pSS patients and HC, for any of the vaccine types (Figure 1). Percentage of spike-specific T-cell responders was comparable between pSS patients (20/24, 83%) and HC (4/5, 80%). Salivary anti-SARS-CoV-2 IgG antibodies, but not IgA, increased post-vaccination in pSS patients (n=26) and HC (n=9). Salivary anti-RBD IgG antibodies were significantly correlated with serum anti-RBD antibodies (r=0.597, p<0.001).

Conclusion: pSS patients had similar humoral and cellular immune responses as HC, providing evidence that COVID-19 vaccination is effective in pSS patients. AEs were also comparable, and no increase in disease activity was seen in pSS patients, indicating COVID-19 vaccination is safe in pSS patients.

REFERENCES:

Acknowledgements: This work was funded by unrestricted grants of AstraZeneca and the Dutch Sjögren’s Patient Association (NVSP).

Disclosure of Interests: Gwenny M. Verstappen: None declared, Liseth de Wolff: None declared, Suzanne Arends: None declared, Hella-Mari Heiermann: None declared, Yannick van Steen: None declared, Annie Viisser: None declared, Janneke H. Terpstra: None declared, Dimitri Diavatopoulos: None declared, Marieke van der Heiden: None declared, Arjan Vissink: None declared, Debbie van Baarle: None declared, Frans G.M. Kroese: None declared, Hendrika Bootsmma Speakers bureau: Bristol-Myers Squibb, Novartis, Consultant of: Bristol-Myers Squibb, Roche, Novartis, MedImmune, Union Chimique Belge, Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche

Impact of time to remission, flares and exposure to immunosuppressives on the development of advanced chronic kidney disease (stage IV or worse) in lupus nephritis

K. Tselios1, D. D. Gladman2,3, J. Su2, M. B. Urowitz2,3, 4McMaster Lupus Clinic, Department of Medicine, Hamilton, Canada; 5University Health Network, Schroeder Arthritis Institute, Toronto, Canada; 6University of Toronto, Department of Medicine, Toronto, Canada

Background: Lupus nephritis (LN) affects up to 40% of patients with SLE and leads to end stage kidney disease (ESKD) in 17-33% after 10 years. The prevalence of chronic kidney disease stage IV (estimated glomerular filtration rate, eGFR=15-29mL/min/1.73m²) is not known; however, approximately two thirds of such patients will progress to ESKD after 6 years on average.1

Objectives: To determine the impact of time to remission and flares on the development of advanced CKD (stage IV or worse) in LN.

Methods: Patients with LN based on biopsy or abnormal proteinuria (>0.5g/day) with or without hematuria/pyuria/casts for two consecutive visits in the absence of other plausible explanation were retrieved from the Toronto Lupus Clinic database. Individuals with advanced CKD at baseline were excluded. All patients were followed for at least 5 years. The primary outcome was the development of advanced CKD (eGFR<20mL/min/1.73m²). Remission was defined as proteinuria<0.5g/24h, no active urinary sediment and serum creatinine ≤120% of baseline. Flare was defined as any abnormal proteinuria (>0.5g/day) after remission to outcome/last date. Death was treated as competing risk in survival analysis. Statistical analysis with SAS 9.4; p<0.05 was considered significant.

Results: Out of 418 eligible patients, 209 (50%) achieved remission within the first year from LN diagnosis, 102 (24.4%) within the 2nd and 3rd years, 70 (16.7%) after 3 years and 37 (9.9%) never achieved remission. Sixty-six patients (15.8%) developed advanced CKD after 9.5 years on average (37 with ESKD). At baseline, these patients had a higher SLICC/Damage Index (0.6±1.2 vs. 0.3±0.7, p=0.046), proliferative nephritis (combined class III and IV, 66% vs. 47.8%, p=0.017) and more often treated with ACE inhibitors or angiotensin receptor blockers (35% vs. 22%, p=0.02). The other variables did not differ significantly. Remission rates, flares and exposure to immunosuppressives after remission are shown in Table 1.

Table 1. A. Time to remission, exposure to immunosuppressives and flares in all patients

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>Advanced CKD (n=66)</th>
<th>No advanced CKD (n=352)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years from LN to complete remission</td>
<td>3.0 ± 3.4</td>
<td>16 ± 2.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Years on Immunosuppressives from complete remission to outcome/last date (median)</td>
<td>2 (0-7)</td>
<td>4 (0-8)</td>
<td>0.008</td>
</tr>
<tr>
<td>Number of flares in first five years after LN</td>
<td>0</td>
<td>12 (18.2%)</td>
<td>156 (44.3%)</td>
</tr>
<tr>
<td>1</td>
<td>14 (21.2%)</td>
<td>79 (22.4%)</td>
<td></td>
</tr>
<tr>
<td>2 or more</td>
<td>40 (60.6%)</td>
<td>117 (33.2%)</td>
<td></td>
</tr>
<tr>
<td>B. Multivariate analysis for the outcome of advanced CKD (stage IV or worse)</td>
<td>0.95/CI</td>
<td>1.01-1.02</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HR</td>
<td>1.02</td>
<td>1.14-3.57</td>
<td>0.022</td>
</tr>
<tr>
<td>Complete remission within 1 year</td>
<td>1.02</td>
<td>1.41-6.34</td>
<td>0.004</td>
</tr>
<tr>
<td>Serum creatinine at baseline</td>
<td>1.02</td>
<td>1.01-1.02</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Complete remission after 3 years or no remission</td>
<td>2.99</td>
<td>1.41-6.34</td>
<td>0.004</td>
</tr>
<tr>
<td>(compared to remission within 1 year)</td>
<td>0.89</td>
<td>0.83-0.95</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Years on Immunosuppressives from complete remission to outcome/last date</td>
<td>2.68</td>
<td>1.05-6.86</td>
<td>0.04</td>
</tr>
<tr>
<td>One flare (compared to no flares)</td>
<td>3.55</td>
<td>1.51-8.34</td>
<td>0.004</td>
</tr>
<tr>
<td>Two or more flares (compared to no flares)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Patients who achieved remission within one year from diagnosis demonstrated better outcomes compared to all other groups (p<0.0001), Figure 1. Patients with complete remission between one and three years had similar outcomes for the first 10 years from diagnosis and deteriorated during the second decade of follow-up.
Conclusion: Complete remission within the 1st year from LN diagnosis strongly protects against advanced CKD. Flares significantly affect prognosis. One flare was associated with 2.7-fold increased risk for advanced CKD (3.6-fold for 2 or more flares). Longer time on immunosuppressives after remission is associated with decreased risk for advanced CKD. Our findings emphasize the importance of early remission as well as flare prevention with prolonged immunosuppressive use to maximize renal survival in LN.

REFERENCES:

Acknowledgements: The University of Toronto Lupus Clinic is supported by a grant from Lupus Ontario and Lupus Canada and donations from the Rossa and Lou Rocca, Diana and Mark Bozzo and the Stacey and Mark Krembil Families.

Disclosure of Interests: Konstantinos Tselios: None declared, Dafna D Gladman Consultant of: AstraZeneca, Jiandong Su: None declared, Murray B Urowitz Consultant of: GlaxoSmithKline

Figure 1.

Results: A structured survey was circulated among 30 experts. Up to 90% of the interviewed experts agreed on defining aPL negativization as the presence of two negative determinations, one year apart (90%). Almost full consensus exist among experts in some clinical settings, including: a) the role of aPL negativization in the management of a thrombotic event determined by concomitant presence of cardiovascular risk factors, both modifiable and not modifiable (90%); b) approach to young patients with triple aPL positivity who experienced pulmonary arterial thrombotic event and tested negative for aPL detection after five year of vitamin K antagonist (VKA) treatment (90%); c) the use of “extra criteria” aPL antibodies testing before pondering VKA suspension (93%).

Conclusion: Consensus is needed to support the management of patients with APS in areas where controlled data are missing. A substantial agreement exists among expert in defining aPL negativization as the presence of two negative determinations, one year apart. On the contrary, VKA suspension should be embraced with extreme caution when it comes to APS patients, particularly if they experienced arterial thrombotic events and/or tested positive for triple aPL. Nevertheless, VKA cessation might be considered when risk factors are carefully monitored/treated and the presence for “extra criteria” aPL is ruled out.

REFERENCES:

Acknowledgements: Italian Society of Rheumatology

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1827

POS0741

REPORT FROM THE APS STUDY GROUP OF THE ITALIAN SOCIETY FOR RHEUMATOLOGY (SIR-APS) ON APL NEGATIVIZATION

S. G. Fodda1, S. Sciascia2, C. Alessandri2, A. Alunno3, L. Andreoli4, A. Barinotti1, A. Calligaro5, V. Canti6, F. Carubbi7, I. Cecchi1, C. Chighizola8, A. G. Sebastiani15, F. Conti2, G. Emmi9, A. Fioravanti10, F. Fischetti11, F. Franceschini, M. Gerosa8, A. Hoxha2, M. Larosa2, G. M. Lazzaroni2, C. Nalli1, G. Pazzola12, M. Radin1, B. Raffeiner13, V. Ramoni14, D. Roccatello1, E. Rubini1, G. Sebastiani13, S. Truglia2, M. L. Urban9, A. Tincani1 on behalf of SIR-APS.

Background: The rate of antiphospholipid antibodies (aPL) negativization in antiphospholipid syndrome (APS) patients is uncertain, but it is estimated to be as high as 8%. aPL disappearance seems to be more frequent in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Nevertheless, VKA cessation might be considered when risk factors are carefully monitored/treated and the presence for “extra criteria” aPL is ruled out.

Methods: Experts of SIR-APS were contacted using a survey methodology.

Results: A structured survey was circulated among 30 experts. Up to 90% of the interviewed experts agreed on defining aPL negativization as the presence of two negative determinations, one year apart (90%). Almost full consensus exist among experts in some clinical settings, including: a) the role of aPL negativization in the management of a thrombotic event determined by concomitant presence of cardiovascular risk factors, both modifiable and not modifiable (90%): b) approach to young patients with triple aPL positivity who experienced pulmonary arterial thrombotic event and tested negative for aPL detection after five year of vitamin K antagonist (VKA) treatment (90%); c) the use of “extra criteria” aPL antibodies testing before pondering VKA suspension (93%).

Conclusion: Consensus is needed to support the management of patients with APS in areas where controlled data are missing. A substantial agreement exists among expert in defining aPL negativization as the presence of two negative determinations, one year apart. On the contrary, VKA suspension should be embraced with extreme caution when it comes to APS patients, particularly if they experienced arterial thrombotic events and/or tested positive for triple aPL. Nevertheless, VKA cessation might be considered when risk factors are carefully monitored/treated and the presence for “extra criteria” aPL is ruled out.

REFERENCES:

Acknowledgements: Italian Society of Rheumatology

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1827

POS0742

DISCRIMINATIVE POWER OF SALIVARY GLAND ULTRASOUND IN RELATION TO ENDOTYPES IN SUSPECTED AND DEFINITE PRIMARY SJÖGREN’S SYNDROME

L. Deore2, H. Achten1,2, K. De Boeck1, E. Genbrugge1, W. Bauters3, D. Roels4, I. Piypko5, F. Doych6, D. Creytens7, D. Elewa7,8, I. Peene9,10, Genth University Hospital, Rheumatology, Ghent, Belgium; 10VIB-Ugent. Center for Inflammation Research, Ghent, Belgium; 2Genth University Hospital, Radiology, Ghent, Belgium; 3Genth University Hospital, Ophthalmology, Ghent, Belgium; 4Genth University Hospital, Dentistry, Ghent, Belgium; 5Genth University Hospital, Head and Neck Surgery, Ghent, Belgium; 6Genth University Hospital, Pathology, Ghent, Belgium; 7AZ Sint-Jan, Rheumatology, Bruges, Belgium

Background: Primary Sjögren’s Syndrome (pSS) is an auto-immune disease with characteristic complaints of oral and ocular dryness, typically affecting adult women. In addition, up to 30-40% of patients suffers from systemic manifestations and lymphoma risk is increased 15-20 fold. pSS is thus highly heterogenous both in presentation and pathophysiology. In an attempt to address this issue Tarr et al. applied cluster analysis based on patient reported outcomes assessing dryness, fatigue, pain and features of anxiety and depression, on a population of pSS patients. This resulted in four groups: low symptom burden (LSB), pain dominant with fatigue (PDF), dryness dominant with fatigue (DDF) and high symptom burden (HSB). These groups, referred to as endotypes, also seemed to have different biological profiles.(1)

Objectives: The aim of this study was to explore salivary gland ultrasound (SGUS) in relation to symptom-based endotypes in a cohort of patients with definite and suspected pSS.

Methods: Data from the Belgian Sjögren’s Syndrome Transition Trial (BeSSTT) were used in which patients positive for at least one of the 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria, were enrolled. Patients were considered ‘definite pSS’ when fulfilling these criteria and ‘suspected pSS’ otherwise. The Newcastle Sjögren’s Stratification Tool, developed and provided by J. Tarr and colleagues, was applied to stratify the cohort into endotypes. Hovecar score (0-48) was used to assess SGUS abnormalities. Scores of at least 17 were considered positive.

Results: Stratification of the BeSSTT (n=241) cohort resulted in 4 endotypes, both in definite (n=141) and suspected pSS (n=100). The proportion of anti-SSA positive patients was high in definite pSS in all endotypes (91.9%; p=0.239). This proportion was significantly lower in suspected pSS patients in all endotypes.
SALIVARY GLAND UPSTAGE (SGUS) AS A DRIVING FACTOR FOR DEFINING PATIENTS WITH SLE WITH MUSCULOSKELETAL INVOLVEMENT

A. Vadharia1, J. Birt2, J. Wu3, K. Griffling4, F. Bailey5, J. Hetherington5, E. Rotter2, S. Barlow6, K. Costenbader7,8,9 Eli Lilly & Co, Indianapolis, United States of America; 1Adelphi Real World, Bollington, United Kingdom; 2Birmingham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Boston, United States of America

Background: Limited information exists concerning the clinical burden and unmet need of musculoskeletal (MSK) organ involvement among patients with SLE in clinical practice.

Objectives: To examine demographics, clinical status, treatment patterns, and patient-reported outcomes (PROs) among patients with SLE in clinical practices and assess the impact of MSK organ involvement.

Methods: Data were drawn from the Adelphi Real World Lupus IV (2021) Disease Specific Programme™, a point-in-time survey of 79 US physicians and their patients with SLE. Physicians completed questionnaires regarding patient demographics, clinical status, and treatment. The same patients were invited to complete questionnaires containing the EuroQol 5-Dimensions (EQ-5D), Functional Assessment of Chronic Illness Therapy Fatigue Subscale (FACT-Fatigue) and Work Productivity & Activity Impairment questionnaire (WPAI) PRO tools. Physicians stated their patients’ organ involvement at the time of data collection (current), in the categories of musculoskeletal, mucocutaneous, renal, cardiorespiratory, constitutional, haematologic, ophthalmologic, gastrointestinal, respiratory, or other. Two mutually exclusive patient groups were analysed: A.MSK – Current physician assessed musculoskeletal organ involvement (+/- other organ/tissue involvement). B.Non-MSK – No current musculoskeletal organ involvement as assessed by the physician Bivariate analysis was conducted for numeric variables using t-tests; binary categorical variables using a Fisher’s exact test; ordinal categorical variables using a Mann-Whitney test; and other categorical variables were compared using a chi-squared test.

Results: A total of 595 patients were included in this analysis: 64.7% MSK and 35.3% non-MSK. Mean(SD) patient age was 45.2(13.4) years, 83.2% were female, 53.3% were White/Caucasian, 27.9% were African American, and mean(SD) time diagnosed with any SLE was 5.3(6.2) years. Point-in-time assessment of clinical status, treatment patterns and patient-reported outcomes, revealed that those with MSK organ involvement assessed by their rheumatologist had higher overall SLE disease severity, more flares in the last 12 months, and slightly worse quality of life scores and work impairment.

Table 1. Point-in-time clinical status, treatment patterns and PROs among patients with SLE MSK organ involvement

<table>
<thead>
<tr>
<th>Total</th>
<th>MSK</th>
<th>Non-MSK</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=595)</td>
<td>(n=385)</td>
<td>(n=210)</td>
<td></td>
</tr>
<tr>
<td>Physician-Reported Patient Clinical Status &amp; Treatment History</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current SLE severity,Mild</td>
<td>405 (68.1)</td>
<td>243 (63.1)</td>
<td>162 (77.1)</td>
</tr>
<tr>
<td>n(%)</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>169 (28.4)</td>
<td>128 (33.3)</td>
<td>41 (19.2)</td>
<td></td>
</tr>
<tr>
<td>Current joint sympt- Joint tenderness</td>
<td>251 (42.2)</td>
<td>210 (54.6)</td>
<td>41 (19.5)</td>
</tr>
<tr>
<td>n(%)</td>
<td>Tender joints</td>
<td>Joint stiffness</td>
<td></td>
</tr>
<tr>
<td>255 (42.9)</td>
<td>212 (55.1)</td>
<td>43 (20.0)</td>
<td></td>
</tr>
<tr>
<td>Mean (SD) Flares in the last 12 months</td>
<td>1.6 (1.7)</td>
<td>1.7 (1.8)</td>
<td>12 (13)</td>
</tr>
<tr>
<td>Current prescribed, Beclomethasone</td>
<td>131 (19.0)</td>
<td>78 (20.5)</td>
<td>53 (26.2)</td>
</tr>
<tr>
<td>n(%)</td>
<td>Immunosuppressant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>164 (27.6)</td>
<td>105 (27.0)</td>
<td>59 (28.1)</td>
<td></td>
</tr>
<tr>
<td>antimalarials</td>
<td>429 (72.9)</td>
<td>268 (69.1)</td>
<td>161 (76.7)</td>
</tr>
<tr>
<td>Mean (SD) years on current treatment</td>
<td>2.9 (3.6)</td>
<td>2.5 (3.0)</td>
<td>3.6 (4.4)</td>
</tr>
<tr>
<td>Patient-Reported Outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) EQ5D-5L Utility score</td>
<td>0.79 (0.20)</td>
<td>0.76 (0.22)</td>
<td>0.85 (0.16)</td>
</tr>
<tr>
<td>(0= death;1= full health)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) FACIT-Fatigue score</td>
<td>32.4 [12.0]</td>
<td>31.0 [11.5]</td>
<td>35.4 [12.6]</td>
</tr>
<tr>
<td>(0 worst to 100 completely impacted)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD) WPAI, overall work impairment</td>
<td>29.0 [21.0]</td>
<td>30.5 [18.6]</td>
<td>25.9 [25.2]</td>
</tr>
</tbody>
</table>
| Conclusion: In this large sample of patients with SLE followed in clinical practices in the U.S., compared to those with little or no rheumatologist assessed MSK involvement, those with MSK involvement had lower quality of life, with higher impact on their work productivity. These results highlight the heterogeneity of SLE and the impact of major MSK manifestations on quality of life in SLE.

REFERENCES: N/A


**Table 1. Patient Reported Outcomes**

<table>
<thead>
<tr>
<th></th>
<th>Active MSK</th>
<th>Non-Active MSK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FM</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N=129</td>
<td>N=156</td>
<td>N=26</td>
</tr>
<tr>
<td><strong>Worst Pain NRS, Mean (SD)</strong></td>
<td>6.5 (1.7)*</td>
<td>4.8 (2.6)</td>
</tr>
<tr>
<td><strong>Worst Joint Pain NRS, Mean (SD)</strong></td>
<td>6.9 (1.8)</td>
<td>4.0 (2.2)</td>
</tr>
<tr>
<td><strong>FACIT Fatigue Score, Mean (SD)</strong></td>
<td>7.1 (1.6)*</td>
<td>3.5 (2.0)</td>
</tr>
<tr>
<td><strong>LupusPRO HRQoL Score (SD)</strong></td>
<td>48.9 (20.2)*</td>
<td>64.1 (23.0)</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRS: 0 (none)-10 (worst imaginable); FACIT Fatigue: 0-50; higher= less fatigue; LupusPRO: 0-100; higher= better QoL; *p &lt; 0.05; ~ Not significant</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The active MSK group used more anti-malarias (50.9 vs. 30.7%), immunosuppressants (37.2 vs. 26.5%), including methotrexate (12.6 vs. 3.3%), narcotic analgesics (18.6 vs. 10.2%), and topicals for joint pain (30.5 vs. 10.2%). Interestingly, treatment goals of greatest importance in both groups were reduction in fatigue and pain, but pain reduction had higher importance in active MSK group (rated very important by 26.7 vs. 18.1%). Lower proportions in the active MSK group were satisfied with steroids (58.0 vs. 77.8% <0.01), immunosuppressants (65.1 vs. 80.7% <0.05), methotrexate (472 vs. 85.7% =0.061), and belimumab (80 vs. 95.5%<0.102).

**Conclusion:** Reduction of pain and fatigue was the main treatment goal of patients with SLE whether they had active or non-active MSK symptoms. Patients with active MSK symptoms had higher pain and fatigue, lower QoL, and less satisfaction with current therapies compared to SLE patients without active MSK symptoms, driven only in part by co-morbid FM. Findings from these analyses suggest there are unmet needs to better understand MSK manifestations, their overlap with Type 2 SLE symptoms, align patient/physician priorities, and improve therapies for MSK symptoms for patients with SLE.

**REFERENCES:**

2. Birt J. Rheum Ther 2021;8:1199-1205

**Acknowledgements:** The authors would like to thank the Lupus Foundation of America for their support with the design of the survey.

**Disclosure of Interests:** Diane L Kamen: None declared, Julie Birt Shareholder of: Shareholder of Eli Lilly & Company, Employee of: Employee of Eli Lilly & Company, Monica Hadi Grant/research support from: Evidera received funding to conduct this research, Elizabeth Gibbons Grant/research support from: Evidera received funding to conduct this research, Don Bushnell Grant/ research support from: Evidera has received funding for the conduct of this research, Ren Yu Grant/research support from: Evidera has received funding to conduct this research, Laure Delbecque Shareholder of: Shareholder of Eli Lilly, Employee of: Employee of Eli Lilly, Kirstin Griffting Shareholder of: Eli Lilly & Company shareholder, Employee of: Eli Lilly & Company paid employee, Anca Askanase Grant/research support from: Investigator for GSK, AZ, Pfizer, Idorsia, Eli Lilly

**DOI:** 10.1136/annrheumdis-2022-eular2095
Objectives: Distinguishing NPSLE from other neuropsychiatric conditions with different etiologies is challenging. However, distinguishing NPSLE antibodies in cerebrospinal fluid (CSF) of NPSLE patients was significantly higher than in SLE, MS and NPH groups [2].

Methods: We retrospectively analyzed 35 NPSLE patients, 34 SLE patients, 20 viral meningitis (VM) patients, and 16 relapsing-remitting multiple sclerosis (MS) patients. We measured anti-SBSN antibodies concentrations in serum by using LAC and thrombotic events. Anti-PS/PT, anti-beta2GPI and anti-CL of IgA/G/M isotypes were quantified in parallel using particle-based multi-analyte technology (LAC) and thrombotic events. Conventional aPL were included for comparison.

Results: The Bayesian posterior mean and 95% HPDI of the cutoff of AI and its PPV and 1-NPV values were 5.26 (3.68;7.17), 0.87, (0.72; 1.0) and 0.44, (0.36; 0.5), respectively (Figure 1).

Conclusion: Our data demonstrated the ranking of serum biomarkers for the prediction of NPSLE. The most essential biomarkers are VEGF, anti-SBSN antibodies, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNFα, MIP-1α (Figure 2).

Disclosure of Interests: None declared

References:

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests: None declared


POS0746 MEASUREMENT OF ANTI-SUPRABASIN ANTIBODIES, MULTIPLE CYTOKINES AND CHEMOKINES AS POTENTIAL PREDICTIVE BIOMARKERS FOR NEUROPSYCHIATRIC SYSTEMIC LUPUS ERYTHEMATOSUS

T. Hoang1, K. Ichinose1, S. Morimoto2, K. Furukawa1, L. Le3, A. Kawakami1.
1Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; 2Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan; 3Nagasaki University, Graduate School of Engineering, Nagasaki, Japan

Background: The pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is multifactorial and involves diverse cytokines, autoantibodies and immune complexes inducing blood-brain barrier (BBB) dysfunction, neuroendocrine-immune imbalance, vascular occlusion, tissue, and neuronal damage. Several pro-inflammatory cytokines have been implicated in the pathogenesis of NPSLE [1]. Previously we have shown that the titer of anti-suprabasin (SBSN) antibodies in cerebrospinal fluid (CSF) of NPSLE patients was significantly higher than in SLE, MS and NPH groups [2]. However, distinguishing NPSLE from other neuropsychiatric conditions with different etiologies is challenging.

Objectives: This study determined the most critical serum biomarkers for the development of NPSLE as they may have clinical utility prior to the onset of neuropsychiatric symptoms.

Methods: We retrospectively analyzed 35 NPSLE patients, 34 SLE patients, 20 viral meningitis (VM) patients, and 16 relapsing-remitting multiple sclerosis (MS) patients. We measured anti-SBSN antibodies concentrations in serum by using multiplex bead-based assay. The serum concentrations of cytokines/chemokines were measured by using multiplex bead-based assay. All the clinical information and laboratory tests were collected at the time of admission.

Results: The top 10 biomarkers having highest sparsity-oriented important learning (SOIL) importance, followed by AI, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNFα, MIP-1α (Figure 2).

Conclusion: Our data demonstrated the ranking of serum biomarkers for the prediction of NPSLE. The most essential biomarkers are VEGF, anti-SBSN antibodies, sCD40L, IL-10, GRO, MDC, IL-8, IL-9, TNFα, MIP-1α (Figure 2).

Disclosure of Interests: None declared


POS0747 ANTI-PHOSPHATIDYL SERINE/PROTHROMBIN ANTIBODIES AND VASCULAR EVENTS ASSOCIATE POSITIVELY WITH HLA-DRB1*13 AND NEGATIVELY WITH HLA-DRB1*03 IN SLE

1Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden; 2Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden; 3Werfen Autoimmunity, Research and Development, San Diego, United States of America; 4Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden

Background: Anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) associate with thrombotic events (1). HLA-DRB1 alleles contribute to the occurrence of conventional antiphospholipid antibodies (aPL), including anti-beta2-glycoprotein-I (beta2GPI) and anti-cardiolipin (CL) (2).

Objectives: We investigated associations between anti-PS/PT and HLA-DRB1 alleles and thrombosis in patients with SLE. Conventional aPL were included for comparison.

Methods: We included 341 consecutive Swedish SLE patients, with information on general cardiovascular risk factors, including blood lipids, lupus anticoagulant (LAC) and thrombotic events. Anti-PS/PT, anti-beta2GPI and anti-CL of IgA/G/M isotypes were quantified in parallel using particle-based multi-analyte technology. The 99th percentiles among 162 age- and sex-matched populations controls were used as cutoffs. HLA-DRB1 typing was performed using sequence-specific primer PCR.
Results: Anti-PS/PT antibodies associated positively with HLA-DRB1*13 (odds ratio [OR] 2.7, P=0.002), whereas anti-beta2GPI and anti-CL antibodies associated primarily with HLA-DRB1*04 (OR 2.5, P=0.0005; Table 1). These associations remained after adjustment for other significant HLA-DRB1 alleles identified in Table 1 (Figure 1a and b) also for LAC (Figure 1c), and also after adjustment for age and gender (not shown). HLA-DRB1*13, but not HLA-DRB1*04, remained as an independent risk factor for thrombosis after adjustment for significant HLA alleles (Figure 1d), and also after adjustment for cardiovascular risk factors in stepwise regression (not shown). Mediation analysis showed that 31.3% of the HLA-DRB1*13-related risk for thrombosis was mediated by anti-PS/PT positivity, HLA-DRB1*03, on the other hand, associated negatively with thrombotic events (Figure 1d) as well as with all aPL (Figure 1a-c).

Table 1. Frequency of individual HLA DRB1 and associations with antibody phenotypes. Odds ratios (OR) and confidence intervals (CI) for being antibody positive given a specific HLA allele and corresponding p values were calculated using Chi2 tests, with significant associations underlined.

<table>
<thead>
<tr>
<th>HLA-DRB1</th>
<th>Anti-PS/PT</th>
<th>Anti-beta2GPI/CL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Anti-PS/PT positive (any isotype) n=48 OR (95% CI); P</td>
<td>Anti-beta2GPI/CL positive (any isotype) n=96 OR (95% CI); P</td>
</tr>
<tr>
<td><strong>DRB1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>01</strong></td>
<td>14 (41.2%) 2 (5.6%) 0.6 (0.2-1.7); 0.04</td>
<td>12 (32.5%) 1 (2.5%) 0.4 (0.2-0.8); 0.006</td>
</tr>
<tr>
<td><strong>04</strong></td>
<td>8 (29.7%) 3 (8.3%) 1.6 (0.6-4.3); 0.02</td>
<td>6 (16.7%) 3 (8.3%) 0.9 (0.4-1.7); 0.1</td>
</tr>
<tr>
<td><strong>06</strong></td>
<td>6 (21.2%) 1 (2.5%) 0.5 (0.2-1.7); 0.04</td>
<td>5 (13.2%) 1 (2.5%) 0.4 (0.2-0.8); 0.006</td>
</tr>
<tr>
<td><strong>07</strong></td>
<td>4 (14.3%) 1 (2.5%) 0.7 (0.2-2.1); 0.4</td>
<td>3 (8.1%) 1 (2.5%) 0.3 (0.1-0.7); 0.4</td>
</tr>
<tr>
<td><strong>08</strong></td>
<td>6 (21.2%) 1.6 (0.6-4.3); 0.02</td>
<td>6 (16.7%) 0.9 (0.4-1.7); 0.1</td>
</tr>
<tr>
<td><strong>09</strong></td>
<td>2 (7.2%) 0 (0) NA</td>
<td>2 (5.6%) 0 (0) NA</td>
</tr>
<tr>
<td><strong>10</strong></td>
<td>5 (18.5%) 1.6 (0.6-4.3); 0.02</td>
<td>5 (13.2%) 0.9 (0.4-1.7); 0.1</td>
</tr>
<tr>
<td><strong>11</strong></td>
<td>4 (14.3%) 1.6 (0.6-4.3); 0.02</td>
<td>4 (10.8%) 0.9 (0.4-1.7); 0.1</td>
</tr>
<tr>
<td><strong>12</strong></td>
<td>1 (3.6%) 0 (0) NA</td>
<td>1 (2.6%) 0 (0) NA</td>
</tr>
<tr>
<td><strong>13</strong></td>
<td>2 (7.2%) 1 (2.5%) 0.5 (0.2-1.7); 0.4</td>
<td>2 (5.5%) 1 (2.5%) 0.3 (0.1-0.7); 0.4</td>
</tr>
<tr>
<td><strong>14</strong></td>
<td>1 (3.6%) 2 (5.6%) 3.7 (0.6-23); 0.1</td>
<td>1 (2.6%) 2.2 (0.4-2.2); 0.08</td>
</tr>
<tr>
<td><strong>15</strong></td>
<td>10 (35.7%) 2 (5.6%) 0.5 (0.2-2.1); 0.4</td>
<td>10 (27.0%) 2.2 (0.4-2.2); 0.08</td>
</tr>
</tbody>
</table>

Conclusion: HLA-DRB1*13 confers risk for both anti-PS/PT and thrombotic events in SLE. The association between HLA-DRB1*13 and thrombosis is largely, but not entirely, mediated through anti-PS/PT. Due to the negative association of HLA-DRB1*03 with aPL and the positive association with favourable lipid levels, HLA-DRB1*03 seems to identify a subgroup of SLE patients with reduced vascular risk.

Disclosure of Interests: Sahwa Elbagir: None declared, Lina M. Diaz-Gallo: None declared, Giorgia Grosso: None declared, Agneta Zickert: None declared, Iva Gunnarsson: None declared, Michael Mahler Employee of: Dr Mahler is employee of Werfen., Elisabet Svensson Speakers bureau: Dr Svensson has obtained speaker’s fees from Janssen., Grant/research support from: Dr Svensson has obtained research grant from Merck., Johan Rönnelid Speakers bureau: Dr Rönnelid has given paid lectures for Thermo Fisher Scientific., Consultant of: Dr Rönnelid has been a member of the Scientific Advisory Board for Thermo Fisher Scientific.

The patients without objective dryness (n=108) were also younger (p=0.0028), and had more frequently anti-SSA positive (p=0.0042). They also had a higher disease activity (mean ESSDAI:3.46 versus 2.96, p=0.036). In this group of patients, the higher frequency of anti-SSA might be explained by the need of other criteria to fulfill diagnostic criteria, in the absence of abnormal Schirmer and salivary flow. Patients with objective dryness had more frequently arthralgia (p=0.04), a higher level of pain VAS (p=0.03) and subjective dryness VAS (p=0.019 for ocular and p=0.01 for oral) than patients without objective dryness. Among the 108 patients with no objective dryness, only 17 had also had no subjective dryness (VAS <30mm).

P value corresponds to the comparison of the two strata with Student’s t or Mann Whitney-U test

Conclusion: Among the patients with pSS, those without subjective or objective dryness features had a younger profile, shorter diagnosis delay which may result from a more acute onset, were more frequently anti-SSA positive. Those having no objective dryness also had more systemic disease, arthralgias and pain than patients with dryness features. Subjective dryness was associated with higher level of fatigue.

REFERENCES:
[1] Characters from table content including title and footnotes:

Disclose of Interests: None declared


Table 1. Characteristics of the individual studies included in the meta-analysis.

<table>
<thead>
<tr>
<th>Author</th>
<th>Publish Year</th>
<th>Case Numbers</th>
<th>E*</th>
<th>Q*</th>
<th>SLE</th>
<th>HC</th>
<th>Breg's definition</th>
<th>Mean % of Breg (mean or median)±SD</th>
<th>% of Breg among PBMC/CD19^+T cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blair, P.A.</td>
<td>2010</td>
<td>4 6 25 14</td>
<td>CD19^+CD24^+CD38^+</td>
<td>SLE: 13.9±5.21</td>
<td>HC: 9.02±2.71</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wang, H.</td>
<td>2019</td>
<td>4 6 36 30</td>
<td>CD19^+CD24^+CD38^+</td>
<td>SLE: 12.94±5.45</td>
<td>HC: 5.64±3.13</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simon, Q</td>
<td>2016</td>
<td>4 6 16 33</td>
<td>CD19^+CD24^+CD38^+</td>
<td>SLE: 17.3±7.12</td>
<td>HC: 11.6±4.01</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heinemann, K.</td>
<td>2016</td>
<td>4 6 33 21</td>
<td>CD19^+CD24^+CD38^+</td>
<td>SLE: 1.6±2.6</td>
<td>HC: 1.5±1.1</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chu, M.</td>
<td>2015</td>
<td>4 7 43 32</td>
<td>CD19^+CD24^+CD27^+</td>
<td>SLE: 8.39±7.22</td>
<td>HC: 28.5±8.96</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vadasz, Z.</td>
<td>2015</td>
<td>4 6 21 20</td>
<td>CD19^+CD25^+FoxP3^+</td>
<td>SLE: 18.5±3.05</td>
<td>HC: 11±1.85</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cai, X.</td>
<td>2015</td>
<td>4 7 60 20</td>
<td>CD19^+CD6^+</td>
<td>SLE: 1.6±0.8</td>
<td>HC: 3.55±1</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yang, X.</td>
<td>2014</td>
<td>4 7 30 15</td>
<td>CD19^+CD5^+CD15^+</td>
<td>SLE: 5±3</td>
<td>HC: 1.63±0.99</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shan-feng Liu</td>
<td>2015</td>
<td>4 6 10 10</td>
<td>CD19^+CD5^+CD15^+</td>
<td>SLE: 0.83±0.28</td>
<td>HC: 0.2±0.21</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zhong-wei Huang</td>
<td>2014</td>
<td>4 5 34 30</td>
<td>CD19^+CD5^+CD16^+</td>
<td>SLE: 22.7±9.17</td>
<td>HC: 0.1±0.28</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ye, Z.</td>
<td>2019</td>
<td>4 6 47 20</td>
<td>CD19^+IL-10^+</td>
<td>SLE: 1.77±0.79</td>
<td>HC: 4.24±1.11</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rong-wei Zhang</td>
<td>2016</td>
<td>4 6 50 20</td>
<td>CD19^+IL-35^+</td>
<td>SLE: 1.6±0.8</td>
<td>HC: 3.55±1</td>
<td>PBMC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SLE: systemic lupus erythematosus. *Evidence level (EL) of each study was based on Oxford Center for Evidence-Based Medicine 2011. †Quality (Q) of each study was based on the Newcastle-Ottawa Quality Assessment Scale case.
Second Hospital of Shanxi Medical University, Taiyuan, China; 3Academy of Microbial Ecology, Shanxi Medical University, Taiyuan, China; 4Key laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, China

Background: Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease which involves in multiple tissue and organ injury. Regulatory B cells (Bregs) are unique subpopulations of B cells with immune-regulating properties. Interestingly, different subsets of Bregs have distinct markers and phenotypes and participate in self immune regulation by different ways. However, the level of Bregs in SLE remains debated.

Objectives: This study aims to clarify the proportions of Bregs with special controversial cellular markers and Breg-related cytokines in SLE patients.

Methods: We explored the proportion of Bregs and Breg-related cytokines (IL-10) in SLE patients by searching literature through November 2021 from CSM, CNKI, China Science and Technology Journal Database, Wan Fang Data, PubMed, Embase, Web of Science, Cochrane Library and Medline. Random effects model was used to pool data. Heterogeneity and risk of bias was examined with I-squared index (I²) statistic. Inconsistency was evaluated by using the P and Egger tests were used for the evaluation of potential publication bias (STATA v.12.0).

Results: Total 14 case-control studies involving 489 PsA patients and 330 healthy controls (HCs) were included in this study (Table 1). No significant difference in the proportions of Bregs was evident between SLE patients and HCs [SMD=0.067, 95%CI (-0.924,1.059), P=0.894]. Because of a significant statistical heterogeneity observed [I²=97.1%, p<0.001], we conducted sub-analyses based on individual definitions of Bregs. We found the proportions of CD19⁺CD24hiCD38hi Breg cells was significantly increased in SLE [SMD=0.902, 95%CI (0.157,1.647), P<0.001](Figure 1A). The level of serum IL-10 was increased in SLE compared to that of HCs [SMD=1.062, 95%CI (0.754,1.370), P<0.001] with no publication bias based on the Egger tests (t=0.91, P=0.366)(Figure 1B).

Conclusion: The levels of CD19⁺CD24hiCD38hi Bregs and IL-10 were significantly increased in SLE patients, suggesting that the abnormalities of Bregs numbers and function are the critical causes in the development of SLE.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests: None declared


POS0751 TEMPORAL TREND IN HOSPITALISATION FOR OPPORTUNISTIC INFECTIONS IN PATIENTS WITH CONNECTIVE TISSUE DISEASES.

J. Nossent1,2, H. Keen1,3, D. Preen4, C. Inderjeeth1,2, 1The University of Western Australia, Medical School, Crawley, Australia; 2Sir Charles Gairdner Hospital, Rheumatology, Nedlands, Australia; 3Fiona Stanley Hospital, Rheumatology, Murdoch, Australia; 4The University of Western Australia, School Population and Global Health, Perth, Australia

Background: Patients with autoimmune connective tissue disease (CTD) and systemic vasculitis (SV) often require aggressive immune-modulating therapy to prevent organ damage. This however increases the risk for common and uncommon infections.

Objectives: To compare the temporal rates and associated mortality of hospitalisation with opportunistic infections (OI) for CTD and SV patients in Western Australia between 1985 and 2015.

Methods: All patients hospitalized in Western Australia in the period 1985-2015 with ≥ 2 ICD based diagnostic codes for SLE (n=1432), other CTD (o-CTD; incl DM/PM, systemic sclerosis, Sjogren’s syndrome; n=2161) and Systemic vasculitis (SV; n=1599) and a microbiologically confirmed OI (Mycobacterial, Fungal and viral infections) were included. Descriptive data are given as median (IQR) and frequency (%). Incidence rates per 1000 person years (IR) were calculated during 100.410 person years.

Results: OI occurred in 12.4 % of lupus, 11.5% of SV and 10.4% of o-CTD patients (p=0.72), but overall IR rates for OI were higher for lupus patients (9.87, CI 5.49-15.76) than for SV (5.94, CI 2.81-10.24) and o-CTD patients (3.40, CI 1.62-7.23). However, whereas the IR for OI in lupus decreased over time, the IR increased for SV and o-CTD patients (Figure 1). Viral infections were the most frequent specific OI followed by tuberculosis and mycotic infections. Cryptococcal infections were observed in lupus patients only and the limited cases of pneumocystis occurred predominantly in SV patients with no cases observed after 2000 (Figure 2). In hospital mortality during OI admission was 11.5% for SV, 5.6 % for lupus and 3.5% for o-CTD patients (p=0.004).

Acknowledgements: Supported by an unrestricted grant from The Arthritis Foundation of Western Australia

Disclosure of Interests: None declared


POS0752 DISEASE FEATURES AT DIAGNOSIS AND CHANGES IN DISEASE COURSE SEVERITY AMONG PATIENTS WITH CHILDHOOD-ONSET COMPARED TO ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS

A. Phillips-Beyer1, Q. Li2, M. E. Stokes2, M. Pozzobon Da Silva2, 1Innovus Consulting Limited, London, United Kingdom; 2Evidera, Weltham, United States of America; 3Therapeutic Area Units, Idorsia Pharmaceuticals, Allschwil, Switzerland

Conclusion: Hospitalization rates for OI have decreased for lupus patients especially since 2005, whereas viral and mycotic OI rates have increased for both SV and o-CTD patients. Hospitalization for OI associated with significant case fatality in especially SV patients, indicating a need for increased prevention of OI.

REFERENCES:

Acknowledgements: Supported by an unrestricted grant from The Arthritis Foundation of Western Australia

Disclosure of Interests: None declared

Background: Systemic lupus erythematosus (SLE) is characterised by a heterogenous clinical presentation with alternating periods of remission and relapse. Disease severity is determined by the type and level of involvement of different organ systems. SLE can occur in childhood or later in life, and patients may present with differing levels of disease severity according to the age of onset. Changes in disease severity following treatment may also differ depending on age of onset. There are limited data that document these differences.

Objectives: To compare demographic and clinical characteristics including baseline disease severity and changes in severity over time between patients with childhood-onset and adult-onset SLE in the United States.

Methods: We identified patients aged 0–64 years and diagnosed with SLE during 2015–2019 using the IBM MarketScan claims databases. SLE severity was determined using a published algorithm, which combines elements of organ involvement and the use of SLE-related medications to assign patients to mild, moderate, and severe disease states. Baseline disease severity was determined using a 90-day follow-up period before the initial SLE diagnosis. The index date was the day after this initial 90-day period. Baseline comorbidities were assessed during the 12 months prior to the index date. Disease severity was evaluated at 0 to <6 months, 6 to <12 months, and ≥12 to <24 months post-index. Patients were categorised according to the highest severity level identified during each period. Changes in severity vs. baseline were also measured during each evaluation period. For example, worsening severity was defined as a transition from a lower to higher disease severity state (e.g., moderate to severe). Analyses were conducted separately for cohorts with Commercial Health Insurance (CHI) and Medicaid. Within each cohort, patients with childhood-onset (≤17 years) were descriptively compared to those with adult-onset (>17 years) SLE.

Results: Most enrollees were female (CHI: 90%, Medicaid: 92%). Mean age at index date was 14.0 vs. 43.4 years for childhood- and adult-onset groups, respectively. Baseline infections were more prevalent among children vs. adults in both CHI (41.4% vs. 30.1%) and Medicaid (45.3% vs. 39.3%) cohorts (Table 1). A higher proportion of children vs. adults had severe disease at baseline in the CHI (38.3% vs. 10.7%) and Medicaid (48.0% vs. 14.2%) cohorts. Overall, the largest decreases in SLE severity compared to baseline were observed during ≥6 months of follow-up. Children were more likely to experience a decrease in severity than adults. During ≥12 to <24 months, 19.9% of children in the Medicaid cohort had an increase in severity compared to baseline vs. only 12.3% of children in the CHI cohort.

Table 1. Profiles of patients with SLE

<table>
<thead>
<tr>
<th>Characteristic %</th>
<th>Commercial Health Plan</th>
<th>Medicaid</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years at index date, mean (SD)</td>
<td>(N=293)</td>
<td>(N=10,622)</td>
</tr>
<tr>
<td>Age in years at index date, median (range)</td>
<td>14.2 (2.7)</td>
<td>44.6 (12.9)</td>
</tr>
<tr>
<td>Female</td>
<td>86.7%</td>
<td>90.1%</td>
</tr>
<tr>
<td>Baseline treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>77.6%</td>
<td>69.3%</td>
</tr>
<tr>
<td>Immunomodulators</td>
<td>42.4%</td>
<td>23.2%</td>
</tr>
<tr>
<td>Antimalarials</td>
<td>71.7%</td>
<td>60.5%</td>
</tr>
<tr>
<td>SLE severity change from baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–&lt;6 months follow-up</td>
<td>Increase</td>
<td>10.9%</td>
</tr>
<tr>
<td>Decrease</td>
<td>20.9%</td>
<td>17.2%</td>
</tr>
<tr>
<td>≥6–&lt;12 months follow-up</td>
<td>Increase</td>
<td>11.6%</td>
</tr>
<tr>
<td>Decrease</td>
<td>36.7%</td>
<td>19.9%</td>
</tr>
<tr>
<td>≥12–&lt;24 months follow-up</td>
<td>Increase</td>
<td>12.3%</td>
</tr>
<tr>
<td>Decrease</td>
<td>33.3%</td>
<td>15.6%</td>
</tr>
</tbody>
</table>

Conclusion: Children with SLE present with greater severity of symptoms compared to adults and are more likely to experience an improvement following the initial treatment period.

REFERENCES:


Background: Primary Sjögren’s syndrome (pSS) has great impact on all aspects of patients’ lives, not only physically, but also mentally, socially and financially. Sicca symptoms are mainly treated with local treatment, but no systemic immunosuppressive treatment is registered yet for pSS, which may have significant consequences on whether patients find their symptom state acceptable (PASS). In a previous study, a cut-off for acceptable symptom state based on the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI, score <5) was developed for inclusion of patients with an unacceptable symptom state in clinical trials.2

Objectives: To explore the presence of PASS in a standard of care cohort of pSS patients and to compare patient characteristics and disease activity including ESSPRI between patients with and without PASS.

Methods: Consecutive outpatients with pSS from the REGistry of Sjögren Syndrome Longitudinal (RESULT) cohort, who fulfilled the ACR/EULAR classification criteria and had available PASS data at baseline were included. Patient-reported outcomes were reported through questionnaires, which included the PASS (“Considering all the different ways your disease is affecting you, if you were to stay in this state for the next few months, do you consider your current state satisfactory?”, yes/no) and ESSPRI (“How severe has your dryness, fatigue and pain been during the last two weeks?”, scale 0-10).

Results: Of 277 included pSS patients, 248 (90%) were female, median age was 54 years (IQR 43-64) and disease duration 5 years (2-11). 198 (71%) patients scored their symptom state as acceptable according to PASS. Patients with PASS were significantly older and had a longer disease duration compared to patients without PASS. Furthermore, patients with PASS had more often a low disease activity according to ESSDAI, and less often had more often a low disease activity according to ESSDAI, and less often moderate disease activity (Table 1). The difference in ESSDAI activity was mainly observed in the articular and constitutional domains. ESSPRI was significantly lower in patients with PASS (median 5 vs. 7). No differences were seen in functional or laboratory parameters (Table 1). Of all included patients, only 86 (31%) patients had an acceptable symptom state according to the pre-defined cut-off point for ESSPRI (score <5). Sensitivity and specificity of this ESSPRI cut-off point for reaching PASS was 40% and 92%, respectively.

Table 1. Baseline characteristics of pSS patients with and without PASS

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PASS (n=198)</th>
<th>Without PASS (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female)</td>
<td>177 (89)</td>
<td>71 (90)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57 (44-65)*</td>
<td>49 (41-60)*</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>6 (2-12)*</td>
<td>5 (2-8)*</td>
</tr>
<tr>
<td>ESSDAI (total)</td>
<td>4 (2-6) (n=191)</td>
<td>4 (2-9) (n=75)</td>
</tr>
<tr>
<td>&lt;5</td>
<td>127 (66)</td>
<td>36 (51)*</td>
</tr>
<tr>
<td>5-14</td>
<td>52 (27)</td>
<td>32 (43)*</td>
</tr>
<tr>
<td>≥14</td>
<td>12 (6)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>ESSPRI (total)</td>
<td>5 (4-7)*</td>
<td>7 (6-8)*</td>
</tr>
<tr>
<td>&lt;5</td>
<td>80 (40)**</td>
<td>6 (8)**</td>
</tr>
<tr>
<td>Schirmer’s test (mm)</td>
<td>4 (1-10) (n=179)</td>
<td>4 (1-10) (n=72)</td>
</tr>
<tr>
<td>Oral cytokine scoring</td>
<td>2 (1.0-3) (n=190)</td>
<td>2 (0.4-3) (n=77)</td>
</tr>
<tr>
<td>Unstimulated whole saliva flow (ml/min)</td>
<td>0.05 (0.00-0.14) (n=187)</td>
<td>0.08 (0.00-0.19) (n=76)</td>
</tr>
<tr>
<td>Stimulated whole saliva flow (ml/min)</td>
<td>0.54 (0.15-2.09) (n=189)</td>
<td>0.85 (0.21-2.97) (n=76)</td>
</tr>
<tr>
<td>IgA-positive</td>
<td>7/19 (37%)</td>
<td>66/79 (84%)</td>
</tr>
<tr>
<td>IgG (g/l)</td>
<td>14 (11-19) (n=196)</td>
<td>14 (10-19) (n=79)</td>
</tr>
<tr>
<td>Rheumatoid factor (IU/ml)</td>
<td>12 (3-39) (n=196)</td>
<td>16 (2-47) (n=78)</td>
</tr>
</tbody>
</table>

Data presented as median (IQR) or n (%) “Significant difference p<0.05***” “Significant difference p<0.001

Conclusion: The majority (71%) of pSS patients reported being in an acceptable symptom state according to the PASS question in our standard of care cohort in daily clinical practice, despite high ESSPRI scores (60% with score ≥5). Further analyses of influences of treatment in these patients will be conducted.
release, with maximal inhibition observed at 2 hours post-dose (IL-6: mean ±99%). High inhibition levels were sustained through 24 hours in a dose-dependent manner (IL-6: mean –76–97%). The pattern of cytokine release inhibition was consistent across doses and ethnic groups.

### Table 1. PK parameters in Japanese and Caucasian participants at the three enpatoran dose levels

<table>
<thead>
<tr>
<th>Parameter</th>
<th>100mg</th>
<th>200mg</th>
<th>300mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>C_{max} (ng/mL)</td>
<td>N = 6</td>
<td>N = 6</td>
<td>N = 6</td>
</tr>
<tr>
<td>Japanese</td>
<td>139</td>
<td>175</td>
<td>265</td>
</tr>
<tr>
<td>Caucasian</td>
<td>774</td>
<td>948</td>
<td>1010</td>
</tr>
<tr>
<td>AUC_{0-tlast} (ng·h/mL)</td>
<td>N = 6</td>
<td>N = 6</td>
<td>N = 6</td>
</tr>
<tr>
<td>Japanese</td>
<td>758</td>
<td>931</td>
<td>1880</td>
</tr>
</tbody>
</table>

All values are Geometric mean. C_{max} maximum plasma concentration; AUC_{0-tlast} area under the plasma concentration–time curve (AUC) from time 0 to infinity; AUC_{tmax} AUC from time 0 to the last sampling time.

**Conclusion:** There were no relevant ethnic differences in PK, PD, and safety between healthy Japanese and Caucasian participants across a range of single oral enpatoran doses, thus supporting the inclusion of Asian participants in future global Phase II studies.

**Acknowledgements:** We would like to thank those who took part in the study. This study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009845), who funded medical writing support by Bioscript Stirling Ltd.


**POS0756**

**DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE (HR-QoL) ACROSS THE SPECTRUM OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE LEAP COHORT**

S. Dyball, 1 J. Reynolds, 2,3 A. Herrick, 4,5 H. Chinyo, 4,5 S. Haque, 4, S. Naz, 4 E. Bruce, 1 I. N. Bruce, 3,4 B. Parker, 8,9 The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 1University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, Birmingham, United Kingdom; 2Sandwell and West Birmingham NHS Foundation Trust, Rheumatology Department, Birmingham, United Kingdom; 3Salford Royal NHS Foundation Trust, Department of Rheumatology, Manchester, United Kingdom; 4NIHR Biomedical Research Centre Manchester, The University of Manchester, Manchester, United Kingdom; 5Manchester University NHS FT, Department of Rheumatology, Manchester, United Kingdom; 6Pennine Acute Hospitals NHS Trust, Department of Rheumatology, Manchester, United Kingdom; 7Manchester University NHS FT, The Kellgren Centre of Rheumatology, Manchester, United Kingdom

**Background:** Poor health-related quality of life (HR-QoL) is recognised in patients with established connective tissue diseases (CTDs), however it is not clear how it affects patients with undifferentiated CTD (UCTD) which has traditionally been associated with a mild or more benign profile.

**Objectives:** To investigate HR-QoL in patients affected with a variety of CTDs (including UCTD) using the SF-36 questionnaire; and secondly, to review demographic and clinical factors predictive of a poor HR-QoL.

**Methods:** The Lupus Extended Autoimmune Phenotype (LEAP) cohort is a multicentre prospective study of patients with a CTD. Rheumatologist diagnosis was used to classify patients into four groups: systemic lupus erythematosus (SLE), primary Sjögren’s syndrome (pSS), UCTD, and (combined because of low numbers) those with an idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) or overlap syndrome. The SF-36 quality of life questionnaire was completed at enrolment and includes eight domains: physical function (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH) which range from 0 to 100, with higher scores reflecting better HR-QoL. Physical (PCS) and mental component score (MCS) were calculated for each group, with a score below 50 representing a worse HR-QoL compared to the general UK population. Predictors for poor HR-QoL was chosen a priori, then tested using linear regression adjusted for age, gender and ethnicity. All statistical analysis was performed using STATA v14, with results expressed as beta coefficients with 95% confidence intervals (95% CI).

**Results:** Data were collected from 309 patients (280 [90.6%] women, with a mean [SD] age of 48.9 [12.9] years) from three UK rheumatology centres. The majority of patients were Caucasian (n=235, 76.1%). By rheumatologist diagnosis, 115 (37.2%) had SLE, 56 (18.1%) pSS, 72 (23.3%) UCTD and 66 (21.4%) SSc, IIM or an overlap syndrome. Patients with UCTD, pSS and SSc/IIM spectrum disorders had a shorter median disease duration (3.8, 3.7 and 6.1 years respectively) compared with patients with those with SLE (11.0 years), p<0.001. Previous steroid and immunosuppressant use was highest in patients with SLE and SSc/IIM spectrum disorders (p<0.001). The most affected domains include VT, GH and BP (Figure 1), and the PCS is more impaired compared with the MCS, with similar scores across disease groups. Agnostic of disease group, factors associated with a lower PCS include increasing age (beta -0.15 [95%CI -0.26, -0.06], p<0.008), prednisolone use (-3.1 [-6.05, -0.19], p=0.037), c-reactive protein (-0.09 [-0.62, -0.10], p=0.007), fatigue (-2.00 [-3.79, -0.22], p=0.028), and sicca syndrome (-4.70 [-7.66, -1.74], p<0.002), and these remained significant in a multivariable model.

**Conclusion:** Patients with UCTD exhibit similar impairment in physical components of HR-QoL compared with other established CTDs, despite perceived differences in disease severity. This study highlights sicca syndrome, fatigue, and steroid burden as key targets for improving HR-QoL in patients across the spectrum of CTDs.

**Disclosure of Interests:** Sarah Dyball Grant/research support from: UCB and Eli Lilly, John Reynolds: None declared, Ariane Herrick Speakers bureau: AstraZeneca, Fresenius-Kabi and AbbVie, Consultant of: Fresenius-Kabi, and Eli Lilly, John Reynolds: None declared, Ariane Herrick Speakers bureau: AstraZeneca, Fresenius-Kabi and AbbVie, Consultant of: Fresenius-Kabi and AbbVie, Ther Chinoy: None declared, Sophia Naz: None declared, Ellen Bruce: None declared, Ian N. Bruce Speakers bureau: AstraZeneca, Fresenius-Kabi and AbbVie, Consultant of: Astra Zeneca, Eli Lilly, Merck Serono, UCB and ILTQO, Grant/research support from: Genzyme/Sanoﬁ, GSK, Roche and UCB, Ben Parker Speakers bureau: Eli Lilly and Roche, Consultant of: Fresenius-Kabi and AbbVie, Grant/research support from: Genzyme/Sanoﬁ and GSK.


**Figure 1.** Radar diagrams of eight SF-36 domains, and MCS and PCS boxplots. SLE: systemic lupus erythematosus; UCTD: undifferentiated CTD; pSS: primary Sjögren’s syndrome; IIM: idiopathic inflammatory myopathy; SSc: systemic sclerosis; PF: physical function; RP: role physical; BP: bodily pain; GH: general health; VT: vitality; SF: social functioning; RE: role emotional; MH: mental health.
COVID-19 INFECTION AND RECOVERY AMONGST PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BILOGICS REGISTER (BILAG-BR)

S. Dyba1, M. Rodziewicz2, E. Sutton3, B. Parker2,3, I. N. Bruce1,2, on behalf of BILAG-BR. The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 1NIHR Manchester Biomedical Research Unit, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Manchester University Hospital, The Kellgren Centre for Rheumatology, Manchester, United Kingdom

Background: Patients with systemic lupus erythematosus (SLE) are thought to be at greater risk of severe COVID-19 illness and associated complications due to a combination of inherent aberrant immune responses, immunosuppressive medications and co-morbidities.

Objectives: To review COVID-19 infections, hospitalisation and recovery in a real-world cohort of patients with moderate to severe SLE and high immunosuppressive use.

Methods: The British Isles Lupus Assessment Group Biologics Registry (BILAG-BR) is a national prospective registry of lupus patients from the UK (2010-21) requiring significant immunosuppressive therapies. Patients from the BILAG-BR were invited to complete a paper or online questionnaire which consisted of 17 questions to assess prior COVID-19 infection and their recovery during the COVID-19 pandemic. Questionnaires were completed between 9th Oct 2021 and 7th Jan 2022. Responses were linked with data collected in the BILAG-BR. Mortality data were collected from study centres and the Office of National Statistics from Dec 2019-Jan 2022.

Results: Data were collected from the first 202/1288 patients to respond. Patients were predominantly female (186, 92.1%), had a median age of 51 (IQR 38-61) years and were from 37 UK centres. Previous therapy included rituximab (165, 81.7%), belimumab (33, 16.3%) and cyclophosphamide (54, 26.7%). In the past 12 months, over two thirds of patients (138, 68.3%) had received oral prednisolone (current median dose 5mg [IQR 5-8mg] daily), and almost a third had received parental steroids (60, 29.7%). Self-reported COVID-19 diagnosis occurred in 48 (23.8%) patients, of whom 29 reported a positive test. Eleven (55%) patients reported testing positive for COVID-19 after being vaccinated. Median reported recovery was 80% (IQR 60-100%), with subjective full recovery reported in 30% of patients (6/20) who had received a positive test. Of the 20 patients who tested positive for COVID-19, 5 were receiving belimumab, 1 tocilizumab, and in the prior 12 months, 2 had received cyclophosphamide and 4 rituximab. Of all respondents, three individuals were hospitalised with COVID-19, and one required an ICU admission. Of those hospitalised, two patients were unvaccinated prior to COVID-19 infection, and the other patient had received rituximab and cyclophosphamide prior to vaccination. Four/1387 patients registered in the BILAG-BR were confirmed to have died from COVID-19 since the beginning of the pandemic.

Conclusion: In this cohort of moderate-to-severe SLE patients there was a low incidence of COVID-19 infection. Despite this, full recovery from PCR or lateral flow test proven COVID-19 infection was seen in only a third of patients. This raises concerns over the potential risk of long COVID in patients with SLE and warrants further investigation.

Acknowledgements: Submitted on behalf of the BILAG-biologics register

Disclosure of Interests: Sarah Dyba Grant/research support from: UCB and Eli Lilly, M. Rodziewicz Grant/research support from: UCB. Emily Sutton: None declared, Ben Parker Speakers bureau: Eli Lilly and Roche, Consultant of: Fresenius-Kabi and AbbVie, Grant/research support from: Genzyme/Sanofi and GSK, Ian N. Bruce Speakers bureau: AstraZeneca, GSK and UCB, Consultant of: AstraZeneca, Eli Lilly, GSK, Merck Serono, UCB and ILTOO, Grant/research support from: Genzyme/Sanofi, GSK, Roche and UCB


POS0758

REDUCED CENTRAL NERVOUS SYSTEM DRIVE IN PRIMARY SJÖGREN’S SYNDROME IS ASSOCIATED WITH OBJECTIVE DECLINE IN MOTOR PERFORMANCE AND SELF-REPORTED FATIGUE

R. Prak1, S. Arends2, G. M. Verstappen2, G. S. Van Zuinder2, H. Bootsma3, I. Zigendew4, 1University Medical Center Groningen, University of Groningen, Biomedical Sciences of Cells and Systems, Groningen, Netherlands; 2University Medical Center Groningen, University of Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands

Background: Fatigue is a major complaint in primary Sjögren’s syndrome (pSS). The importance of fatigue in pSS is demonstrated by its inclusion as one of the three domains of the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) as well as being the primary outcome measure of a large clinical trial.1 To date, there is no effective treatment for fatigue and more fundamental studies are needed to identify potential targets for therapy. In a conceptual framework, fatigue is defined as a self-reported symptom derived from two attributes: performance fatigability and perceived fatigability (Figure 1).

Figure 1. Conceptual framework (adapted from Enoka)2

Objectives: To acquire a better understanding of fatigue in pSS, we investigated objective measures of performance decline and evaluated the relation of self-reported fatigue with performance fatigability and factors modulating perceptions of fatigability.

Methods: 39 pSS patients and 27 healthy controls were included. To assess performance fatigability, force decline was measured during a sustained (124s) maximal voluntary contraction (MVC) with the index finger abductor muscle, and voluntary muscle activation was indexed using peripheral nerve stimulation superimposed on maximal voluntary contractions. Self-reported fatigue was quantified using the Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). Pain, depression, and anxiety were assessed using questionnaires and serological inflammatory markers were measured in serum as factors related to perceived fatigability.

Results: Self-reported fatigue was significantly higher in pSS than controls (FSS: 4.8 vs. 2.3, p<0.001; 67% of patients and no controls reported significant fatigue (FSS>4). Mean voluntary muscle activation was reduced in pSS compared to controls (81.5% vs. 87.8%, p=0.030). Force decline during the sustained MVC did not differ between groups (60.6% vs. 63.1%, p=0.246). MFIS physical was positively associated with symptoms (ESSPRI pain: r=0.51, HADS depression: r=-0.45 and HADS anxiety: r=0.29) and negatively associated with serological inflammatory markers (MxA: r=-0.49 and CXCL10: r=-0.37). Multivariable linear regression showed that force decline, pain and depression were associated with the MFIS physical domain in pSS (total explained variance of 47%). The inclusion of serological inflammatory markers did not help to explain more variance in this model.

Conclusion: This study demonstrates that performance fatigability in pSS was compromised by a reduced capacity of the central nervous system to drive the muscle. Furthermore, self-reported fatigue is a multifactorial symptom associated with both performance fatigability and perceived fatigueability in patients with pSS.

REFERENCES:

Disclosure of Interests: Roeland Prak: None declared, Suzann Arends: None declared, Gwenny M. Verstappen: None declared, Greetje S. van Zuinder: None declared, Frans G.M. Kroese: None declared, Hendrika Bootsma: Speakers bureau: Bristol Myers Squibb, Roche, Consultant of: Bristol Myers Squibb, Roche, Novartis, MedImmune, Union Chimique Belge, Grant/research support from: Bristol Myers Squibb, Roche, Inge Zigendewind: None declared


POS0758

DOES LDLAS DEFINITION MATCH THE RHEUMATOLOGIST OPINION? THE FIRST VISIT EVALUATION OF A LONGITUDINAL SPANISH MULTICENTER STUDY TO ASSESS REASONS OF DISAGREEMENT.

I. Altábab González1,2, I. Rua-Figueroa3, N. Jiménez3, F. Rubínó3, C. Mouriró Rodríguez1,2, I. Hernández1, R. Menor-Almagro1, E. Uriarte Isacelaya5, E. Tomero Muriel6, T. C. Salman Monte1, I. Carrión Barberà7, M. Galindo8, E. Rodríguez Almaraz8, L. Inês9, J. M. Pego-Reigosa1,2.

1Complejo Hospitalario Universitario de Vigo, Rheumatology, Vigo, Spain; 2MIIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Rheumatology, Vigo, Spain; 3Hospital Universitario de Gran Canaria Dr. Negrín, Rheumatology,
Background: Treat to Target strategies are necessary in Systemic Lupus Erythematosus (SLE). They are difficult to establish due to the heterogeneity of the disease. The current definitions of Lupus Low Disease Activity State (LLDAS) according to the Asia Pacific Lupus Collaboration (APLC) and remission according to Definition of Remission in SLE (DORIS) 2021 are difficult to achieve and maintain over time.

Objectives: To evaluate the concordance between the LLDAS and the clinical status according to the rheumatologist opinion and reasons of disagreement. To explore modifications in LLDAS definition that best fit with the expert’s opinion.

Methods: Prospective multicenter study of SLE patients (ACR 1997 Classification Criteria or clinical diagnosis by the physician) from seven Spanish Rheumatology Departments. Statistical analysis: descriptive cross-sectional (at the time of recruitment) analysis of the demographic and clinical characteristics, treatments; remission and LLDAS and the subjective evaluations of SLE activity by the rheumatologist. Analysis of the level of agreement between expert opinion and the definition of LLDAS and its modification were evaluated using Cohen’s kappa.

Results: DEMOGRAPHIC, DISEASE CHARACTERISTICS AND TREATMENTS. Five hundred and eight were included (92% women; mean age (±SD): 50.4 years (±13.7)). Mean SLEDAI-2K (±SD) was 2.84 (±3.31). A total of 406 (79.9%) patients presented SLEDAI-2K>4. A total of 317 (74.1%) patients were on antimalarial treatment. Two hundred and twenty-two (43.7%) patients were on some type of immunosuppressive or biological therapy. More than half of patients were not taking glucocorticoids (n=310, 61%). A total of 38 patients (7.5%) were taking doses of prednisone higher than 75mg/day.

REMISSION/LLDAS 267 (54.4%) patients were in remission and 304 (62.7%) patients were in LLDAS. According to the expert opinion of the rheumatologist, remission was the most frequent state considered (n=206, 41.6%); followed by low activity (n=153, 30.9%); serologically active (n=71, 14.3%); moderate activity (n=55, 11.1%) and high activity (n=10, 2%).

AGREEMENT Overall agreement between expert opinion and the definition of LLDAS was 71.4 % with a Cohen’s kappa of 0.3. The majority of the cases (96.1%) that fulfilled the definition of LLDAS, were classified by the expert as remission, serologically active or low activity. Only 12 (3.9%) patients were classified by the expert as moderate or high activity. Of the patients that did not fulfill the definition of LLDAS, 126 out of 179 (70.4%) patients were classified by the expert as remission/low disease activity (Figure 1). The main reasons for discordance in the group that did not fulfill the definition of LLDAS were the presence of new clinical features compared to previous visit and a SLEDAI 2-K >4, in 74 (58.7%) and 59 (46.8%) patients, respectively. The LLDAS adjustment that meant a significant increase in the agreement was the exclusion of the comparative features with the previous visit, with an increase in the agreement to 82.6% (95% CI: 81.61-83.96). The modification of prednisone to ≤5mg/day, did not represent a significant change in agreement from the original definition.

Figure 1. Comparison of LLDAS and expert opinion

Conclusion: At a given point in time, almost two thirds of SLE patients were in remission or in LLDAS. There is a good correlation between LLDAS and the physician’s opinion, particularly for those patients who fulfill LLDAS definition. However, the agreement is not so good for patients who don’t, these being excessively classified by the physician as remission or low activity. The main LLDAS items causing this disagreement were a SLEDAI-2K >4 and the appearance of different clinical manifestations from the previous evaluation. On the contrary, physician assessment by the PGA adequately fits the LLDAS definition. The modification of the LLDAS definition excluding the comparison with previous assessment increases the agreement with the expert opinion to 82.6%.

Disclosure of Interests: None declared


POS0760

M. Edamoto1, J. Kikuchi1, H. Hanaoka1, S. Saito1, K. Hiramoto1, Y. Kaneko1.
1Koel University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

Background: Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of severe organ manifestations and directly associated with neuropsychiatric damages, such as cerebral vascular accident, cognitive impairment, or seizures. However, factors associated with damage accrual of neuropsychiatric and non-neuropsychiatric domains in NPSLE patients remain unknown.

Objectives: The aim of this study was to identify factors associated with damage accrual in patients with NPSLE.

Methods: We reviewed all patients with SLE who had attended our hospital between January 2010 to December 2020 retrospectively and identified those with NPSLE. We analyzed clinical characteristics and laboratory data including cerebrospinal fluid (CSF) in association with the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) damage index (SDI) progression after the onset of NPSLE.

Results: 461 patients with SLE were reviewed. Among them, 37 (8.0%) were diagnosed with NPSLE. Thirty-six patients were included in the analysis after excluding one patient with insufficient information. Seventeen (47.2%) patients were diagnosed with NPSLE at the same time with SLE diagnosis and 19 patients were diagnosed as relapse of NPSLE. In NPSLE onset, the mean age was 33.7 years, 39% were female, and the mean SLEDAI-2K was 21.8. Eighteen (50.0%) patients had active lupus nephritis simultaneously at the onset of NPSLE. The most frequent NPSLE types according to the 1999 ACR classification were lupus headache in 10 patients, followed by cerebrovascular disease in 7, seizure disorders in 6, acute confusional state, psychosis and mononeuropathy in 3, and aseptic meningitis in 2. All patients were treated with glucocorticoids, and the mean initial dose of prednisolone was 52.3 mg/day with steroid pulse therapy in 19 patients.

Thirty (83.3%) patients were treated with concomitant immunosuppressive treatments. During the observation period with the mean of 10.0 years, 17 (47.2%) patients developed at least one point of SDI. Among them, 9 patients (25.0%) had neuropsychiatric damage progression including cerebrovascular accident in 6, seizures requiring drug treatment for more than 6 months in 2, and cognitive impairment in 1. Non-neuropsychiatric damage was also increased such musculoskeletal in 5, ocular in 3, cardiovascular in 2, renal, gastrointestinal, premature gonadal failure, diabetes, and malignancy in each one. Neither neuropsychiatric nor overall damage progression were associated with SLEDAI-2K, anti-cardiolipin antibodies positivity, abnormal electroencephalogram, abnormal single photon-emission computed tomography at NPSLE onset or kinds of immunosuppressive treatments in patients who underwent CSF examination. The high level of CSF IL-6 was associated with neuropsychiatric damage progression (p=0.032). Also, high levels of CSF protein (p=0.030), cell counts (p=0.007), and IL-6 (p=0.032) were associated with overall SDI progression.

Conclusion: CSF IL-6 concentrations are associated with neuropsychiatric damage progression, and high CSF protein, cell counts and IL-6 at onset in patients with NPSLE can predict overall damage accrual.

REFERENCES:

Disclosure of Interests: None declared


POS0761

1Aalborg University Hospital, Department of Rheumatology, Odense, Denmark; 2Aalborg University Hospital, Department of Rheumatology, Odense, Denmark; 3Department of Biomedicine, Aarhus University, Department of Rheumatology, Aarhus, Denmark; 4Odense University Hospital, Department of Rheumatology, Odense, Denmark; 5Aalborg University Hospital, Department of Rheumatology.
**Background:** Nephritis (LN) in systemic lupus erythematosus (SLE) is still a major determinant of poor prognosis[1]. The vast majority of LN occurs in proxim-ity to the SLE diagnosis[2]. Identification of individuals at high risk, especially early onset SLE, is therefore warranted. Inclusion of risk factors prior to the SLE diagnosis may thus be of importance to enable sufficient risk factor profiling. SLE-patients seem to cluster according to clinical and serological phenotypes suggesting distinct disease trajectories[3-5].

**Objectives:** To determine if incident proteinuria associated with the debut age of non-renal SLE characteristics.

**Methods:** Data of SLE patients from six Danish centers were obtained from the Danbio-database from 2017 – 2020. The occurrence and timing of proteinuria was compared with first time onset of any non-renal manifestations as defined by the 1997 American College of Rheumatology Classification Criteria. Cox-regression models were used to identify risk factors for incident proteinuria. Time from first occurring non-renal manifestation to incident proteinuria or censoring defined time at risk. Covariates were eliminated if p >0.01 in a ‘backwards’ manner. After the model reduction process p-values <0.05 were considered statistically significant.

**Results:** 586 SLE patients, mainly white (94%) women (88%), mean age at inclusion of 34.6 years (standard deviation, SD = 6.0 years) and observed for a mean of 14.9 years (SD =0.5 years), were recruited. The cumulative prevalence of proteinuria was 40%. Male gender hazard ratio, HR = 1.35 (95% CI: 1.15-1.58). p=0.005 were associated with incident proteinuria. In contrast, patients with discoid rash had lower risk of incident proteinuria HR 0.42 (range 0.21-0.83), p=0.01. Male patients with lymphopenia had the highest risk of proteinuria with a one-, 5- and 10-year risk of proteinuria ranging from 9-27%, 34-75% and 51-89 %, depending on the age at presentation (debut at 20, 30, 40 or 50 years). The corresponding risk-profiles for women with lymphopenia were 3-9%, 8-34% and 12-58%, respectively, as illustrated in Figure 1.

**Conclusion:** The occurrences of lymphopenia and discoid rash were oppositely associated with risk of incident proteinuria and the risk effects varied according to gender and patient age at onset of these manifestations. Thus, the risk of proteinuria may not be constant but could vary according to presentation of non-renal manifestations that may call for a differentiated clinical follow-up. Based on these findings, we suggest that the debut age of known prognostic factors, even prior to the SLE diagnosis should be considered when designing prognostic statistical models.

**REFERENCES:**


**Disclosure of Interests:** Martin Andersen Employee of: Novo Nordisk A/S; 2010-2014, Anders Stockmarr: None declared, Henrik Leffers: None declared, Anne Troldborg: None declared, Anne Voss: None declared, Salome Kristensen: None declared, Bent Deleuran: None declared, Lene Dreyer Speakers bureau: Speakers bureau: Eli Lilly, Galderma and Janssen, Grant/research support from: Grant from BMS outside the present work. Laura Johnsen: None declared, Ada Colic: None declared, Søren Jacobsen: None declared DOI: 10.1136/annrheumdis-2022-eular.3223
Methods: We retrospectively reviewed the medical records of patients with systemic lupus erythematosus who were diagnosed with LN class I, II, V or I+IV by kidney biopsy between 1997 and 2021 at a tertiary referral center. Clinical and laboratory data were compared between patients with and without poor renal outcomes. Poor renal outcome was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73 m2 or death due to renal cause. Univariate and multivariate analyses were performed with the Cox proportional hazard model to identify the factors associated with poor renal outcomes.

Results: We included 71 patients with non-proliferative LN (4: class I; 17: class II; 48: class V; 17: 2: class I+V). Median follow-up duration was 103 months (interquartile range 27–185) and the overall rate of poor renal outcomes at last follow-up was 29% (21/71), including end-stage renal disease (n=2) and renal death (n=1). Univariate analysis indicated that older age (HR 1.05; 95% CI: 1.00–1.09), low eGFR (HR 0.97; 95% CI: 0.95–0.99) and failure to reach complete remission at 6 months (HR 0.332; 95% CI: 0.12–0.92) were significantly associated with poor renal outcomes. Multivariate analysis revealed that low eGFR at 6 months (HR 0.97; 95% CI: 0.95–0.99) was significantly associated with poor renal outcomes.

Conclusion: Poor renal outcomes occurred in approximately 30% of patients with non-proliferative LN (class I, II or V) after long-term follow-up. Our findings suggest that more active management may be needed for non-proliferative LN, particularly in patients with low eGFR at 6 months.

Disclosure of Interests: None declared


---

Table 1. Correlation between ANAM tests with perfusion (F) in SLE patients, ranked in descending order of statistical significance for TTS.

<table>
<thead>
<tr>
<th>Variable</th>
<th>TTS</th>
<th>CSL</th>
<th>CSI</th>
<th>CSD</th>
<th>SP</th>
<th>MSP</th>
<th>CPT</th>
<th>MTH</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td>F right amygdala</td>
<td>0.636†</td>
<td>0.520†</td>
<td>0.337</td>
<td>0.437†</td>
<td>0.559†</td>
<td>0.323</td>
<td>0.633†</td>
<td>0.412†</td>
<td>0.598†</td>
</tr>
<tr>
<td>F left entorhinal</td>
<td>0.495†</td>
<td>0.400†</td>
<td>0.189</td>
<td>0.378†</td>
<td>0.330</td>
<td>0.237</td>
<td>0.491†</td>
<td>0.376†</td>
<td>0.449†</td>
</tr>
<tr>
<td>F chordoid</td>
<td>0.469†</td>
<td>0.384†</td>
<td>0.216</td>
<td>0.413†</td>
<td>0.458†</td>
<td>0.202</td>
<td>0.456†</td>
<td>0.340</td>
<td>0.406†</td>
</tr>
<tr>
<td>F right anterior cingulate</td>
<td>0.453†</td>
<td>0.301</td>
<td>0.118</td>
<td>0.296</td>
<td>0.393†</td>
<td>0.214</td>
<td>0.547†</td>
<td>0.420†</td>
<td>0.383†</td>
</tr>
<tr>
<td>F right entorhinal</td>
<td>0.448†</td>
<td>0.368†</td>
<td>0.232</td>
<td>0.312</td>
<td>0.378†</td>
<td>0.156</td>
<td>0.438†</td>
<td>0.271</td>
<td>0.407†</td>
</tr>
<tr>
<td>F cerebellum white matter</td>
<td>0.427†</td>
<td>0.358</td>
<td>0.201</td>
<td>0.370†</td>
<td>0.273</td>
<td>0.078</td>
<td>0.449†</td>
<td>0.290</td>
<td>0.297</td>
</tr>
<tr>
<td>F hippocampus</td>
<td>0.427†</td>
<td>0.355</td>
<td>0.134</td>
<td>0.390†</td>
<td>0.356</td>
<td>0.253</td>
<td>0.511†</td>
<td>0.306</td>
<td>0.332</td>
</tr>
<tr>
<td>F brain stem</td>
<td>0.407†</td>
<td>0.298</td>
<td>0.138</td>
<td>0.275</td>
<td>0.294</td>
<td>0.153</td>
<td>0.478†</td>
<td>0.308</td>
<td>0.369†</td>
</tr>
<tr>
<td>F right insula</td>
<td>0.403†</td>
<td>0.308</td>
<td>0.074</td>
<td>0.300</td>
<td>0.324</td>
<td>0.176</td>
<td>0.437†</td>
<td>0.323</td>
<td>0.347</td>
</tr>
<tr>
<td>F left paretal</td>
<td>0.400†</td>
<td>0.263</td>
<td>0.092</td>
<td>0.254</td>
<td>0.294</td>
<td>0.224</td>
<td>0.482†</td>
<td>0.274</td>
<td>0.332</td>
</tr>
<tr>
<td>F parahippocampal</td>
<td>0.398†</td>
<td>0.303</td>
<td>0.083</td>
<td>0.321</td>
<td>0.370†</td>
<td>0.192</td>
<td>0.477†</td>
<td>0.286</td>
<td>0.361</td>
</tr>
<tr>
<td>F right temporal</td>
<td>0.395†</td>
<td>0.280</td>
<td>0.113</td>
<td>0.281</td>
<td>0.288</td>
<td>0.167</td>
<td>0.477†</td>
<td>0.322</td>
<td>0.331</td>
</tr>
<tr>
<td>F right hippocampus</td>
<td>0.395†</td>
<td>0.307</td>
<td>0.072</td>
<td>0.325</td>
<td>0.356</td>
<td>0.190</td>
<td>0.486†</td>
<td>0.357</td>
<td>0.339</td>
</tr>
<tr>
<td>F right paretal</td>
<td>0.376†</td>
<td>0.249</td>
<td>0.082</td>
<td>0.274</td>
<td>0.283</td>
<td>0.139</td>
<td>0.460†</td>
<td>0.255</td>
<td>0.311</td>
</tr>
<tr>
<td>F parahippocampal</td>
<td>0.375†</td>
<td>0.353</td>
<td>0.119</td>
<td>0.302</td>
<td>0.341</td>
<td>0.241</td>
<td>0.353</td>
<td>0.308</td>
<td>0.273</td>
</tr>
</tbody>
</table>

† p < 0.05, ‡ p < 0.01, *FDR p < 0.05

Conclusion: These findings suggest that the BBB may be affected early in the course of cognitive dysfunction, even preceding detectable changes in other MRI sequences and machine learning algorithms can be used to predict TTS measures, even in asymptomatic SLE patients.

REFERENCES: Nil.

Disclosure of Interests: Sen Hee Tay: None declared, Mary Stephenson: None declared, Nur Azizah Allameen: None declared, Sriram Narayanan: None declared, Bernett Lee: None declared, Anselm Mak Speakers bureau: JnJ Apr 2019 and GSK


---

Figure 1. Machine learning-based models to predict cognitive function.
Results: Thirty-eight SS patients were found without sicca manifestations (21.9%). The most common presenting clinical manifestation of non-dryness SS patients were arthralgias (47.4%), followed by parotid gland enlargement (23.6%), Raynaud’s phenomenon (10.5%), generalized lymphadenopathy (10.5%), fatigue (10.5%), palpable purpura (5.3%) and pulmonary symptomatology of dry cough or exertional dyspnea (5.3%). Despite the lack of ocular dryness, non-dryness group had positive ocular tests but statistically lower compared to those with sicca symptoms (55.6% vs 93.9%, p<0.001), and displayed lymphopenia less frequently (0 vs 17.3%, p=0.049). No statistical differences were found in terms of salivary gland enlargement (SGE), focus score (FS), cryoglobulinemia and autoantibody profile between the 2 groups.

Conclusion: SS patients without subjective dryness are characterized by similar underlying immunopathologic processes as typical SS sicca patients.

REFERENCES:

Disclosure of Interests: None declared.

---

Table 1. Comparison of clinical and laboratory features of PSS patients with (Dryness Group) and without sicca manifestations (Non-dryness Group)

<table>
<thead>
<tr>
<th>Clinical and Laboratory features</th>
<th>Non-Dryness Group, %, n=38</th>
<th>Dryness Group, %, n=76</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANA positivity</strong></td>
<td>100</td>
<td>95.9</td>
<td>0.55</td>
</tr>
<tr>
<td><strong>RF positivity</strong></td>
<td>58.3</td>
<td>64.3</td>
<td>0.71</td>
</tr>
<tr>
<td><strong>Anti-Ro positivity</strong></td>
<td>100</td>
<td>90.8</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Anti-La positivity</strong></td>
<td>54.1</td>
<td>50.7</td>
<td>0.89</td>
</tr>
<tr>
<td><strong>Salivary gland biopsy positivity</strong></td>
<td>93.9</td>
<td>89.8</td>
<td>0.71</td>
</tr>
<tr>
<td><strong>Focus score</strong></td>
<td>2.12</td>
<td>2.19</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Ocular tests positivity</strong></td>
<td>55.6</td>
<td>33.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Salivary gland enlargement %</strong></td>
<td>26.3</td>
<td>30.3</td>
<td>0.83</td>
</tr>
<tr>
<td><strong>Arthralgias %</strong></td>
<td>52.6</td>
<td>56.6</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Arthritis %</strong></td>
<td>25.7</td>
<td>17.6</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>Raynaud’s phenomenon %</strong></td>
<td>23.7</td>
<td>27.8</td>
<td>0.82</td>
</tr>
<tr>
<td><strong>Palpable purpura %</strong></td>
<td>7.9</td>
<td>18.4</td>
<td>0.17</td>
</tr>
<tr>
<td><strong>Lymphadenopathy %</strong></td>
<td>22.6</td>
<td>20.3</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Leukopenia %</strong></td>
<td>20.7</td>
<td>26.1</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Lymphopenia %</strong></td>
<td>0</td>
<td>173.3</td>
<td>0.049</td>
</tr>
<tr>
<td><strong>Neutropenia %</strong></td>
<td>20.8</td>
<td>5.8</td>
<td>0.1</td>
</tr>
<tr>
<td><strong>Thrombocytopenia %</strong></td>
<td>13.8</td>
<td>3.1</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>Low C4 %</strong></td>
<td>23.3</td>
<td>30.3</td>
<td>0.65</td>
</tr>
<tr>
<td><strong>Cryoglobulinemia %</strong></td>
<td>10.5</td>
<td>3.9</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Lymphoma %</strong></td>
<td>10.8</td>
<td>6.7</td>
<td>0.47</td>
</tr>
</tbody>
</table>

---

Table 1. Demographic, clinical, characteristics, and outcomes of the patients with LN

<table>
<thead>
<tr>
<th>Variables*</th>
<th>All patients, n=116</th>
<th>Proliferative LN, n=95</th>
<th>Non-Proliferative LN, n=21</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at SLE diagnosis, years</td>
<td>18.3 (16)</td>
<td>19.2 (15)</td>
<td>16 (16)</td>
<td>0.32</td>
</tr>
<tr>
<td>Sex, female</td>
<td>93 (80.2)</td>
<td>75 (78.9)</td>
<td>18 (18.5)</td>
<td>0.48</td>
</tr>
<tr>
<td>Age at kidney biopsy, years</td>
<td>21 (17.7)</td>
<td>22 (17)</td>
<td>18 (15)</td>
<td>0.19</td>
</tr>
<tr>
<td>Patients newly diagnosed SLE with renal 65 (56)</td>
<td>53 (58)</td>
<td>12 (57)</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td>biopsy</td>
<td>Follow-up time for LN, years</td>
<td>5.5 (8)</td>
<td>5.1 (8.2)</td>
<td>6.2 (5.1)</td>
</tr>
<tr>
<td>SLE disease duration</td>
<td>8 (8.7)</td>
<td>8.1 (3.6)</td>
<td>7.9 (7.3)</td>
<td>0.53</td>
</tr>
<tr>
<td>Hypertension</td>
<td>31 (26.7)</td>
<td>26 (27.4)</td>
<td>5 (23.8)</td>
<td>0.74</td>
</tr>
</tbody>
</table>

Laboratory values on the kidney biopsy:
| Creatinine level (mg/dL) | 0.7 (0.5) | 0.8 (0.5) | 0.56 (0.1) | 0.006 |
| Creatinine > UNL | 37 (32.5) | 34 (36.6) | 3 (14.3) | 0.04 |
| eGFR (mL/min/1.73m²) | 113 (54) | 107 (54) | 129 (45) | 0.04 |
| Albumin (g/dL) | 3.3 (1.1) | 3.1 (1.2) | 3.5 (1.0) | 0.01 |
| 24-hour urine protein, gr/day | 2.3 (3.3) | 2.4 (3.6) | 0.9 (1.8) | 0.03 |
| Anti-dsDNA positivity | 94 (81) | 80 (87.9) | 14 (70) | 0.04 |
| Low C3 and C4 levels | 93 (80.2) | 81 (88) | 12 (57) | 0.001 |
| Active urinary sediment | 91 (83.5) | 78 (88.9) | 12 (57) | <0.001 |
| Fibrinogen | 12 (8) | 12 (8) | 4 (4) | <0.001 |

During the two-year follow-up after LN diagnosis:
| Complete renal response | 70 (70.7) | 56 (70.9) | 14 (70) | 0.39 |
| Partial renal response | 23 (23.2) | 17 (21.5) | 6 (30) | 0.64 |
| No response | 6 (6.1) | 6 (7.4) | 0 | NA |
| Relapse | 20 (21.5) | 15 (20.5) | 5 (25) | 0.84 |
| ESR > 50 | 4 (4) | 4 (4.3) | 0 | NA |
| Death | 3 (3) | 3 (3.2) | 0 | NA |

* n (%), if otherwise specified: median (IQR) for numeric values, ESR: Erythrocyte sedimentation rate, GFR: Glomerular filtration rate, LN: Lupus nephritis, SLE: Systemic lupus erythematosus, SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; UNL: Upper normal limit
and assist in the interpretation of conflicting results on aPL testing.

**Background:**
Rheumatology, Moscow, Russian Federation

**Methods:**
The study included 190 patients who signed informed consent, aged 37.0 [29.0-44.0] years and disease duration 7.0 [2.0-15.0] years. Male/ female ratio was 44 (23)/146 (77). 123 (64.7%) of 190 patients had reliable SLE and 55 (29%) had PAPS. The control group was left with 100 relatively female ratio was 44 (23)/146 (77). 123 (64.7%) of 190 patients had reliable SLE and 55 (29%) had PAPS. The control group was left with 100 relatively healthy, age-matched individuals. Classical aPL (IgG/IgM-aCL, IgG/IgM- 
cl2-GP1, LA) were measured at two time points separated by at least 12 weeks in all patients included in this study. IgG/IgG anti-PS/PT was determined by enzyme immunoassay (ELISA) using a Teco sunrise absorbance microplate spectrophotometer (Austria) with an Aeskulisa Serin-Prothrombin-GM antibody reagent kit. IgG/IgM anti-PS/PT were measured in U/ml. Values >18 U/ml were considered positive. The range of measurements was: 1 to 300 U/ml.

**Results:**
In 144 (76%) of 190 patients were revealed IgG anti-PS/PT, 55 (29%) - IgM anti-PS/PT, a combination of IgG anti-PS/PT and IgM anti-PS/PT was found in 53 (28%). IgG anti-PS/PT and IgM anti-PS/PT were detected in 39 of the 70 (56%) remaining patients who were negative for criterion aPL. The median IgG anti-PS/PT was 101.2 U/ml [31.0-180.5] in patients with and was significantly higher than 23.7 [14.1-49.8] U/ml in patients without APS and controls. IgM anti-PS/PT levels in patients with and without APS were comparable. Thrombosis was significantly more common in patients with IgG anti-PS/PT: 95 (81.2%) of 117 patients with thrombosis compared with patients negative for IgG anti-PS/PT (22 (18.8%) of 60 patients) (P=0.03). Arterial, but not venous thrombosis, was associated with IgG anti-PS/PT positivity. IgG anti-PS/PT was detected in 53 (83.8%) of 60 patients with arterial thromboses, and in 7 (11.7%) of 64 patients of IgG anti-PS/PT negative. The incidence of thrombo- cytopenia in the SLE+APS patient group was associated with the presence of IgG anti-PS/PT, which was detected in 18 of 19 patients, versus 6 of 12 in SLE without aPL (P=0.007). In the other patient groups, the frequency of thrombo- cytopenia and IgG anti-PS/PT positivity was not statistically significant. The frequency of anti-PS/PT detection was independent of LA positivity. IgG and/or IgM anti-PS/PT were detected in 26 (87%) of 30 patients positive for LA and in 21 (78%) of 27 patients LA negative. (P=0.05). The sensitivity of anti-PS/PT IgG for APS was 85%, specificity - 64%, the sensitivity of anti-PS/PT IgM was lower - 35%, but higher specificity - 88%.

**Conclusion:**
The frequency of anti-PS/PT detection in the examined patients was high: 76% had IgG anti-PS/PT, 29% - IgM anti-PS/PT and 28% - a combination of them. The levels of IgG anti-PS/PT were significantly higher in patients with APS compared to patients without APS and controls. IgM anti-PS/PT values in patients with and without APS were comparable but higher compared to controls. Thrombosis was associated with IgG anti-PS/PT positivity. Arterial thrombosis was significantly more frequent in patients with IgG anti-PS/PT (P=0.006). The sensitivity of IgG anti-PS/PT for APS was 85%, and specificity was 64%; IgM anti-PS/PT had a lower sensitivity of 35%, but a higher specificity of 88%.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-earl.3860

**POS0767**
GLANDULAR INVOLVEMENT IN PRIMARY SJÖGREN SYNDROME PATIENTS WITH INTERSTITIAL LUNG DISEASE (ILD) ONSET: A SINGLE CENTER CROSS-SECTIONAL STUDY

G. La Rocca1, F. Ferro2, G. Fulvio3, S. Fonzetti4, G. Governato3, V. Donati3, M. Mosca1, C. Baldini2, 1University of Pisa, Clinical and Experimental Medicine, Pisa, Italy, Rheumatology, Pisa, Italy; Azienda Ospedaliero- Universitaria Pisana, Rheumatology Unit, Pisa, Italy; Azienda Ospedaliero-Univeristaria Pisana, Unit of Pathological Anatomy 2, Pisa, Italy

**Background:**
Primary Sjögren Syndrome (pSS) is an autoimmune exocrinop- athy classically presenting with sicca symptoms. Nonetheless, disease onset was often extraglandular simultaneously. Intersitial lung disease (ILD), is increasingly reported and probably underestimated. However, studies investigat- ing pSS patients presenting with ILD (pSS-ILD) are limited.

**Objectives:**
Aim of this study was to better characterize the phenotype of pSS patients presenting with ILD in comparison to pSS patients with classical sic- ca-onset. We especially investigated whether the two groups differed in glandular involvement comparing functional, imaging and histologic findings, as well as patient reported outcome (PHQ).

**Methods:**
Consecutive newly diagnosed pSS patients, all fulfilling the ACR/ EULAR 2016 criteria, were included in this cross-sectional study from September 2016 to October 2021. Clinical, serological and histological initial features where compared in pSS-ILD patients and in pSS patients without ILD involvement, diagnosed during the same time period. Presence of ILD at pSS diagnosis was defined based on clinical findings, imaging assessment and pulmonary function tests. In addition to functional tests, a minor salivary gland biopsy was performed in all cases, recording number of foci and GC-like structures and focus score (FS). Salivary glands ultrasonography (SGUS) was graded using the OMERACT semiquantitative scoring system (0-3) based on parenchyma inhomogeneity, Pro including ESPIRI, OHIP and OSSDI were collected. Extraglandular clinical features and biological abnormalities included in the ESSDAI were recorded. Data was presented as means±SD, or percent frequency as appropriate. Inter- group comparisons were made using the t-test/Mann–Whitney test for continu- ous variables and Fisher’s exact test for categorical variables.

**Results:**
We included 178 newly diagnosed pSS patients (F:M=158:20). ILD was the first pSS manifestation in 11 (6%) cases, 8 F and 3M, with a median time from ILD onset to pSS diagnosis of 2 ± 2 years. At HRCT, the following patterns were observed: NSIP (4/11), UIP (4/11), NSIP+OP (2/11) and LIP (1/11). Dyspnea on exertion or chronic cough were reported by 7/11 (63.6%) patients. In comparison to sicca-onset patients, pSS-ILD patients presented an older age at diagnosis (55.13 vs 70.7, p=0.001) and a higher ESSDAI (3.9±4.7 vs 12.3±3.4, p=0.001) driven by the pulmonary domain. Regarding glandular involvement, pSS-ILD presented milder sicca-ophthalmopathy (VAS 5.8±3.1 vs 2.8±3.5, p=0.002) and significative lower scores in OSDI (35.6±24.9 vs 15.3±22.9, p=0.04), despite no significant differences observed between the two groups in ocular tests and unstimulated salivary flow rate. With respect to histology, no significant differences were found in number of foci and GC-like structures, and FS. Notably, there was a trend towards a different dis- tribution of the SGUS OMERACT score in the two groups. Particularly, none of pSS-ILD patients presented OMERACT score 3 in parotid and submandibular glands, in contrast to 26/167 (15.5%) and 18/167 (10.8%) of classic sicca-onset pSS patients respectively. Finally, no significant differences were observed between the two groups with respect to non-pulmonary extraglandular manifes- tations, serologic features and other biological parameters.

**Conclusion:**
ILD-onset pSS patients represent an atypical phenotypic subset, with less pronounced sicca symptoms and topographical changes in salivary glands, and with sicca symptoms probably overshadowed by the respiratory disease.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-earl.3936
Objectives: To examine the rate of transition from at-risk to classified (ACR 1997 criteria) SLE, and identify demographic and clinical predictors. To prospectively evaluate the sensitivity and accuracy of the newer classification criteria (SLICC 2012, EULAR/ACR 2019) and the SLE Risk Predictive Index (SLERP-I)[1] in patients at-risk who progress or not to classified SLE.

Methods: This is a single-centre analysis of individuals at-risk for SLE as part of an ongoing multicentric inception cohort study aiming to identify clinical, environmental and molecular diagnostic factors for SLE onset. Enrolled individuals: a) were aged 18–55 years; b) had clinical and/or serological features suggestive of connective tissue disease, SLE, other connective tissue disease. Methods for non-classification features, and ascertain the disease status (at-risk/undifferentiated connective tissue disease).

Results: A total 124 subjects were included, all Whites, 94.4% women, with an average (standard deviation) age 36 (11) years. At first assessment, individuals fulfilled 2.25 (0.72) ACR 1997 criteria with ANA being the most prevalent feature (75.8%) followed by low complement (43.5%), arthritis (37.9%), photosensitivity (28.2%), malar rash (23.4%), and non-scarring alopecia (18.5%). After a median follow-up of 16 months, 27 participants (21.8%) fulfilled the ACR 1997 criteria, of whom 8 (3.5%) developed moderate or severe SLE. Multivariable-adjusted logistic regression identified anti-Ro/SSA (odds ratio [OR] 6.93; 95% confidence interval [95% CI] 1.75–27.5, p=0.006), combined low C3 and low C4 (OR 4.82; 95% CI 1.42–16.3, p=0.012) and photosensitivity (OR 3.25; 95% CI 1.17–8.99, p=0.023) as independent predictors for transition to classified SLE. The sensitivity of SLICC 2012, EULAR/ACR 2019 and SLERP-I (>7) at baseline for detecting individuals who progressed to SLE (ACR 1997) was 40.7%, 25.9% and 40.7%, respectively, with corresponding specificities of 83.5%, 88.7% and 79.4%. 

Conclusion: Among individuals at-risk for SLE, about 20% may evolve into classified SLE, other connective tissue disease.

Disclosure of Interests: None declared


References:

Acknowledgements: This work was funded by the Foundation for Research in Rheumatology (FOREM).
Conclusion: SLE patients have an increased risk of fractures, 5- and 10-year recurrent fractures, and 5-year mortality post-fracture compared to controls from the general population. After adjustment for conventional risk factors, these associations remained unchanged in the most recent period (2002-2014). This study highlights the need for improved primary prevention of a first fracture event in SLE patients.

Acknowledgements: The authors wish to thank the staff at the Western Australian Data Linkage Branch and Emergency Department Data Collection, Hospital Morbidity Data Collection, Western Australian Cancer Registry, and Death Registrations. The authors wish to thank the Australian Co-ordinating Registry, the Registries of Births, Deaths and Marriages, the Coroners, the National Coronial Information System and the Victorian Department of Justice and Community Safety for enabling COD URF data to be used for this publication.

Disclosure of Interests: None declared


**Table 1. UHFUS diagnostic accuracy in pSS and for predicting a MLSG FS≥1 in all the cases and in anti-Ro/SSA negative patients. OCP, optimal cut-off value.**

<table>
<thead>
<tr>
<th></th>
<th>SE</th>
<th>SP</th>
<th>PPV</th>
<th>NPV</th>
<th>AUC (95%CI)</th>
<th>OCP</th>
</tr>
</thead>
<tbody>
<tr>
<td>pSS diagnosis</td>
<td>60/88</td>
<td>68.2%</td>
<td>72/106</td>
<td>67.9%</td>
<td>0.725 (0.651-0.793)</td>
<td>2</td>
</tr>
<tr>
<td>FS≥1 prediction</td>
<td>64/63</td>
<td>73%</td>
<td>83/131</td>
<td>64.3%</td>
<td>0.719 (0.657-0.806)</td>
<td>2</td>
</tr>
<tr>
<td>MLSG diagnosis</td>
<td>14/19</td>
<td>73.7%</td>
<td>70/101</td>
<td>63.9%</td>
<td>0.754 (0.641-0.867)</td>
<td>2</td>
</tr>
<tr>
<td>FS≥1 prediction</td>
<td>17/24</td>
<td>70.8%</td>
<td>68/96</td>
<td>70.8%</td>
<td>0.705 (0.652-0.860)</td>
<td>2</td>
</tr>
</tbody>
</table>

**Figure 1. ROC curves showing UHFUS diagnostic accuracy in pSS (A) and for predicting a MLSG FS≥1 (B).**

Disclosure of Interests: None declared


**POS0772 HEPATIC STEATOSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE AND ASSOCIATION WITH DISEASE FEATURES**

A. Barrera-Varaás1, A. A. Baeza-Zapata1, A. Fortanell-Meza1, D. San Agustín-Morales1, J. Merayo-Chalico,1 C. Mocetezuma-Velázquez1,1 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Immunology and Rheumatology, Mexico City, Mexico; 2 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Gastroenterology, Mexico City, Mexico

Background: The spectrum of hepatic involvement in patients with systemic lupus erythematosus (SLE) is broad and multifactorial. Steatosis is a common finding in liver biopsies performed on these patients; however, there is no further evidence of its prevalence in this population. Early detection of steatosis is important to consider ideal management options, and transient elastography (Fibroscan) offers a non-invasive, fast, and easy tool that provides reliable diagnoses.

Objectives: To determine the prevalence of hepatic steatosis in patients with SLE by using the controlled attenuation parameter (CAP). We also aimed to describe factors associated with steatosis in lupus, such as metabolic syndrome criteria, treatment, and disease activity.

Methods: Between July and December 2021, we measured the degree of hepatic steatosis in patients who fulfilled the 2019 EULAR/ACR SLE classification criteria from a rheumatology outpatient clinic in a tertiary referral center in Mexico City, using the CAP obtained with Fibroscan. The cut-off value for considering hepatic steatosis was 275 dB/m. Fibroscan results, metabolic syndrome criteria, treatment, and SLE-associated variables were recorded. Variables were analyzed using Chi-squared, Fisher’s exact, and Mann-Whitney U tests. We used logistic regression to compare variables associated with lupus activity and steatosis. A p value <0.05 was considered statistically significant.

Results: A total of 102 patients (83% female, mean age 39±14 years) with SLE were included. We identified 23 patients (22.5%) with hepatic steatosis. Patients with steatosis had a higher mean waist-to-hip ratio (WHR, 0.92 vs 0.85 cm, p<0.001), and prevalence of overweight/obesity (82% vs 49%, p=0.004) compared with patients without steatosis. Univariate analyses showed that steatosis was significantly associated with higher body mass index (BMI; OR 1.24 [95%CI 1.11-1.39], p<0.001), WHR (OR 1.13 [95%CI 1.03-1.23], p<0.001), serum glucose (OR 1.04, [95%CI 1.00-1.07], p=0.04), and paradoxically, higher C3 complement levels (OR 1.03 [95%CI 1.01-1.05], p=0.002). Additionally, hydroxychloroquine was found to be a protective factor (OR 0.34 [95%CI 0.12-0.98], p=0.047). There were no differences between patients with and without steatosis in terms of disease duration and types of activity. Also, no differences were found in the activity (SLEDAI-2K) and chronic damage (SLICC-DI) indices between groups. In the multivariate analysis, the only variables that remained significantly associated with steatosis were BMI (OR=1.23 [95%CI 1.05-1.43], p=0.007), and WHR (OR 1.15 [95%CI 1.03-1.28], p=0.01).

Table 1. UHFUS diagnostic accuracy in pSS (A) and for predicting a MLSG FS≥1 in the cases and in anti-Ro/SSA negative patients. OCP, optimal cut-off value.
Although it did not reach statistical significance, current use of hydroxychloroquine tended to be a protective factor for steatosis (OR=0.18 [95% CI 0.03-1.0]; p=0.06).

Conclusion: The prevalence of hepatic steatosis in patients with SLE is similar to that of the general population. Metabolic risk factors were associated with a higher prevalence of steatosis in patients with lupus, contrary to other SLE disease features such as activity, treatment, and chronic damage. Interestingly, hydroxychloroquine use tended to be a protective factor for steatosis in these patients.

Table 1. Characteristics of SLE patients according to the presence of steatosis.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients without steatosis</th>
<th>Patients with steatosis</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>37 (29-51)</td>
<td>38 (29-51)</td>
<td>0.8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>66.5 (58-76.7)</td>
<td>63 (57-73)</td>
<td>0.001</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>26.3 (22.9-25.9)</td>
<td>25 (22-29)</td>
<td>0.001</td>
</tr>
<tr>
<td>Obesity</td>
<td>25 (24%)</td>
<td>13 (16%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Waist-to-hip ratio</td>
<td>0.87 (81.3-92.2)</td>
<td>0.85 (80.2-91.7)</td>
<td>0.003</td>
</tr>
<tr>
<td>Current use of hydroxychloroquine</td>
<td>85 (80%)</td>
<td>70 (84%)</td>
<td>0.04</td>
</tr>
</tbody>
</table>


DOI: 10.1136/annrheumdis-2022-eular.4110

Figure 1. Cluster analysis of autoantibodies (Cluster 1: dsDNA, histone and nucleosome; cluster 2: Sm, nRNP, Ro52, Ro60 and Ribosomal P; cluster 3: cardiolipin, IgG1 and La and lupus anticogulant; cluster 4: Scl-70, Jo-1, PCNA, AMA-M2, PM-SCL, and CENP-B)
Background: Antibodies to Smith (Sm) have been described as one of the most specific autoantibodies for systemic lupus erythematosus (SLE). Other than its association with lupus nephritis, there is, however, limited understanding of its clinical significance.

Objectives: To describe clinical associations and serum protein profiles of anti-Sm positivity in SLE.

Methods: Patients fulfilling SLE classification criteria who were followed longitudinally in a prospective multicentre cohort were studied according to their baseline anti-Sm antibody status. Comparison between Sm+ and Sm- patients was made using descriptive statistics. Clinical associations of Sm positivity with patient disease characteristics were studied using logistic regression. In a subset, 211 serum analytes were measured using Quantibody, Luminex and ELISA assays. Associations between serum proteins and Sm positivity were studied using Least Absolute Shrinkage and Selection Operator (LASSO) penalised regression, adjusting for demographics (age, sex, ethnicity) and medication use.

Results: 383 patients were studied with median (IQR) follow-up of 4.9 (2.9-25) years; 65 (17%) had positive anti-Sm antibodies. Sm+ patients were significantly more likely to be of non-European ancestry (OR 2.73, 95% CI 1.55-4.82, p<0.001), and to be positive for anti-dsDNA antibodies (OR 2.8, 95% CI 2.3-3.4, p<0.001), anti-RNP antibodies (OR 15.7, 95% CI 13.9-17.8, p<0.001), direct anti-globulin test (OR 2.36, 95% CI 2.1-2.7, p<0.001), and anti-Ro antibody (OR 2.07-2.7, p<0.001). Conversely, fewer Sm+ patients attained LLDAS for ≥50% observed difference in damage accrual between Sm+ and Sm- patients. In serum protein analysis including pairwise interaction between predictors, 28 Sm+ associated parameters were identified. Associations between serum proteins and Sm positivity were studied using Least Absolute Shrinkage and Selection Operator (LASSO) penalised regression, adjusting for demographics (age, sex, ethnicity) and medication use.

References:


Acknowledgements: I would like to acknowledge participants and clinicians involved with the Australian Lupus Registry & Biobank.

Disclosure of Interests: None declared


POS0775 COMBINED MODEL OF RENAL HISTOPATHOLOGY AND CLINICAL PARAMETERS BETTER PREDICT ONE YEAR RENAL OUTCOMES IN LUPUS NEPHRITIS:

ANALYSIS OF 334 KIDNEY BIOPSIES


Jawaharlal Institute of Postgraduate Medical Education and Research, Department of Clinical Immunology, Puducherry, India; Jawaharlal Institute of Postgraduate Medical Education and Research, Department of Pathology, Puducherry, India; AIIMS Bilaspur Himachal Pradesh, Director, Kothipura, India

Background: Diagnosis of Lupus Nephritis (LN) is currently based on laboratory tests and renal histopathology. Role of histopathological features in determining long term outcomes is unclear.

Objectives: 1. To assess if clinical and biochemical parameters at baseline can identify renal histopathological class. 2. To assess the clinico-histopathological predictors of renal response.

Methods: This is a single centre retrospective study comprising 334 LN renal biopsies. Clinical and biochemical parameters at the time of biopsy were noted and their association with histopathological class, activity and chronicity scores (AS/CS) (ISN/RPS classification) were evaluated. Complete, or partial no response (CR, PR, NR) for renal outcome (EULAR/EDTA) at 1 year were assessed for 293 patients. Binary logistic regression was done to look for the predictors of NR.

Class III/IV LN was seen in 240(71.8%). Hypertension was seen in 52(12.1%) of class III/V and <25% each with class II, V and combined class(p<0.001). Class III/IV had lower eGFR (876(62.75-118.8) (p<0.001) than the other classes. Nephrotic range proteinuria was seen in 32% of class V and 21% in class III/V (p<0.004). Among class III/IV, AS had weak correlation with baseline UPCR (r=0.31) and eGFR (r=-0.172) (p<0.01). CS had weak negative correlation with eGFR (r=-0.212, p<0.01). NR at 1 year was higher in males (OR=4.665;95%CI 15.9-10.8, p<0.01), those with abnormal serum creatinine (OR=3.935;CI16.7-702, p<0.01), higher renal SLEDAI (p<0.05), higher AS, CS (p<0.001), interstitial inflammation and tubular atrophy(p<0.005) (Table 1). On binary logistic regression a combined clinico-histopathological model comprising of serum creatinine, UPCC, male sex and CS performed best in predicting NR (Figure 1).

Table 1. Comparison of baseline characteristics among those who attained any response (CR/PR) versus others at 1 year

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Any response</th>
<th>Others (No Complete Response response&lt;10 escape)</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male, n (%)</td>
<td>221/94.8(125.3</td>
<td>48/60(122)</td>
<td>4.6(19.10)</td>
<td>0.001</td>
</tr>
<tr>
<td>Medline age at nephritis onset</td>
<td>28/1165</td>
<td>23/1167</td>
<td>0.079</td>
<td></td>
</tr>
<tr>
<td>Median SLE duration</td>
<td>12/230</td>
<td>180/144</td>
<td>0.770</td>
<td></td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>100/42.9</td>
<td>34/56.7</td>
<td>0.061</td>
<td></td>
</tr>
<tr>
<td>Creatinine&lt;13mg/dl, (median, IQR)</td>
<td>21/9.0</td>
<td>15/25</td>
<td>3.3(16.7-702)</td>
<td>0.001</td>
</tr>
<tr>
<td>eGFR categories, n (%)</td>
<td>137/58.8</td>
<td>27/45</td>
<td>1.7(0.56-3.03)</td>
<td>0.003</td>
</tr>
<tr>
<td>&gt;90</td>
<td>57/24.5</td>
<td>15/25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>61-90</td>
<td>34/14.6</td>
<td>9/15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30-60</td>
<td>4/17</td>
<td>8/13.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active sedimentary, n (%)</td>
<td>132/56.7</td>
<td>44/73.3</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>uPCR g/day (median with IQR)</td>
<td>1.38(0.8-2.67)</td>
<td>1.95(1.18-4.19)</td>
<td>0.098</td>
<td></td>
</tr>
<tr>
<td>Class III/IV n (%)</td>
<td>167/71.7</td>
<td>49/81.7</td>
<td>0.117</td>
<td></td>
</tr>
<tr>
<td>Class V n (%)</td>
<td>177/73</td>
<td>58/38.3</td>
<td>0.788</td>
<td></td>
</tr>
<tr>
<td>Combined class, n (%)</td>
<td>73/30</td>
<td>3/50</td>
<td>0.469</td>
<td></td>
</tr>
<tr>
<td>Activity score, median with IQR</td>
<td>3/14</td>
<td>6/39</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Chronicity score, median with IQR</td>
<td>0/0</td>
<td>10/2</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Presence of Crescents, no (%)</td>
<td>43/18.5</td>
<td>17/28.3</td>
<td>0.104</td>
<td></td>
</tr>
<tr>
<td>Fibrinoid necrosis, n (%)</td>
<td>28/12.0</td>
<td>7/17.7</td>
<td>0.791</td>
<td></td>
</tr>
<tr>
<td>Intestinal inflammation, n (%)</td>
<td>86/36.9</td>
<td>33/55</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>Intestinal fibrosis, n (%)</td>
<td>23/10.7</td>
<td>9/15</td>
<td>0.273</td>
<td></td>
</tr>
<tr>
<td>Tubular atrophy, n (%)</td>
<td>64/27.5</td>
<td>27/45</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>Blood vessel changes, n (%)</td>
<td>20/19</td>
<td>1/17.7</td>
<td>0.606</td>
<td></td>
</tr>
<tr>
<td>Fibrinoid necrosis</td>
<td>206/88.4</td>
<td>50/83.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other changes*</td>
<td>0.339</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. ROC curve and AUC for the three different models: Model 1: Baseline serum creatinine, urine PCR, male sex; AUC= 0.694(0.609-0.779), p<0.001.Model 2: Baseline serum creatinine, urine PCR, male sex, chronicity score; AUC = 0.740(0.660-0.820), p<0.001.Model 3: Baseline serum creatinine, urine PCR, male sex, chronicity score, crescents, interstitial inflammation; AUC= 0.744(0.664-0.824), p<0.001.
Conclusion: Clinical and biochemical parameters can predict the renal histological class to a fair extent but has limited value in predicting the activity and chronicity parameters. Since a combination of clinical and histopathology parameters are better in predicting renal outcomes, performing renal biopsies should be encouraged in LN.

Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared


Table 1. Multivariate linear regression analysis for neutralizing antibody activity

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Beta</th>
<th>95% confidence interval</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.022</td>
<td>-0.425 – 0.381</td>
<td>0.914</td>
</tr>
<tr>
<td>Gender</td>
<td>8.16</td>
<td>25 (92.6)</td>
<td>0.286</td>
</tr>
<tr>
<td>SLEDAI-2k</td>
<td>-1.96</td>
<td>-4.22 – 0.31</td>
<td>0.088</td>
</tr>
<tr>
<td>Prednisolone dosage</td>
<td>-2.01</td>
<td>-3.66 – 0.37</td>
<td>0.018</td>
</tr>
<tr>
<td>Mycophenolate mofetil</td>
<td>-15.2</td>
<td>-24.4 – 6.0</td>
<td>0.002</td>
</tr>
<tr>
<td>Type of vaccines: Comirnaty</td>
<td>28.8</td>
<td>20.1 – 37.5</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Conclusion: COVID-19 vaccines produced satisfactory but impaired serological response in SLE patients compared to controls which was dependent on the immunosuppressive medications use and type of vaccines received. There was no new short-term safety signal noted. Booster dose is recommended.

REFERENCES:


Disclosure of Interests: None declared


Figure 1. Distribution of neutralizing antibody levels after COVID-19 vaccines comparing (A) SLE patients and matched controls, (B) SLE patients and matched controls in two vaccine subgroups, and (C) two vaccine types in SLE patients. Data for each group are presented as box plots: central values within boxes correspond to median: the range between the lower (Q1) and upper (Q3) bounds of the boxes is the IQR. Whiskers represent scores outside IQR and ends in maximum (higher “calculated value” = Q3 + 1.5 x IQR) and minimum (lower “calculated value” = Q1 – 1.5 x IQR). Spots are outliers above the maximum or under the minimum value. Data regarding were analyzed using Mann-Whitney-U test. Dotted line denotes the cut-off level for positivity (30%).

POSO777

STUDY OF PERIPHERAL BLOOD B CELL IMMUNOPHENOTYPING IN PATIENTS WITH LUPUS NEPHRITIS: PARAMETERS OF DISEASE ACTIVITY, REMISSION AND FLARE

C. Di Mario1,2, V. Varriano2,3, L. Petricca, A. Paglioni4, M. R. Gigante5, S. Costanzo5, L. Buï6, F. Federico6, M. A. D’agostino4, S. Alivernini1,4,7, B. Tolusso1, E. Greseme1,2,7 1Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP), Fondazione Polcino Universitario A. Gemelli, IRCCS, Rome, Italy; 2Division of Clinical Immunology, Fondazione Polcino Universitario A. Gemelli, IRCCS, Rome, Italy; 3Division of Rheumatology, Fondazione Polcino Universitario A. Gemelli, IRCCS, Rome, Italy; 4Division of Pathology, Fondazione Polcino Universitario A. Gemelli, IRCCS, Rome, Italy; 5Division of Nephrology, Fondazione Polcino Universitario A. Gemelli, IRCCS, Rome, Italy; 6Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy; 7Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy

Background: B cells play a central role in systemic lupus erythematosus (SLE) pathogenesis connecting innate with adaptive immunity.
Objectives: To investigate the peripheral blood B cell phenotype in a cohort of SLE patients with renal involvement (LN-SLE) in relation to disease activity and renal histological lesions compared to healthy controls.

Methods: One hundred LN-SLE patients with active renal involvement, 40 at disease onset (Early) and 60 in whom LN occurred after the disease onset (Long) were enrolled. Thirty-seven healthy controls were included. Clinical, laboratory and demographic data were collected at baseline and at 6 and 12 month of follow-up. Disease activity was recorded using SLEDAI-2K. Ultrasound-guided renal biopsy has been performed for the definition of the nephritic class according to the ASN/ESR. The memory B cells immunophenotyping (IgD CD27 classification) was analyzed in peripheral blood through flow cytometry. To clarify the role of key molecules in the B cells activation, IL-6 and BAFF serum levels were assessed by Enzyme-linked immunosorbent assay (ELISA).

Results: According to the onset of renal symptoms, there were no differences in the distribution of the renal classes and in activity and chronicity indices in the two groups. A direct correlation was observed between chronicity index score and creatinine in the whole cohort (R=0.342; p<0.01) and in LN-SLE Early (R=0.526; p=0.01) and Long (R=0.337; p=0.02). The disease activity index was found to be significantly higher in anti-dsDNA positive than in negative ones (6.6±4.8 vs 2.8±3.5; p<0.01), and in patients with at least one antiphospholipid antibody-APL positivity (6.8±4.8 vs 5.1±4.6; p<0.05). Considering predictive biomarkers of the remission within 12 months, the presence of histological lesions (glomerulocapsular and fibrocellular crescents) and the positivity for at least one of the APL antibodies were associated to the failure in achieving clinical remission, while baseline 24-hr proteinuria ≤2750mg was related to remission achievement [OR:2.6 (95%CI:1.1-5.8)]. Studying the role of key molecules in the B cells activation, IL-6 and BAFF serum levels were assayed by Enzyme-linked immunosorbent assay (ELISA).

Conclusion: This study suggests that the active injury and chronic damage histological features of LN do not depend on the SLE duration per se, but could be associated to the clinical failure in achieving clinical remission within 12 months. Furthermore, data on memory B cells immunophenotyping reveals a distinct B cells subset of SLE patients when compared to healthy controls, confirming an alteration of B cells subsets in SLE patients and strengthen the hypothesis of the pathogenetic role played by B lymphocytes in the course of LN.

References:

Disclosure of Interests: None declared

Table 1. Histopathological features in the parotid gland biopsy.

<table>
<thead>
<tr>
<th>#Patient</th>
<th>Focus score</th>
<th>LELs</th>
<th>GCs</th>
<th>MESA/LESA</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1 NI</td>
<td>Not applicable</td>
<td>✓</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>#2 BM</td>
<td>✓</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>#3 CM</td>
<td>Not applicable</td>
<td>✓</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>#4 RC</td>
<td>&lt;1</td>
<td>✔</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>#5 FF</td>
<td>Not applicable</td>
<td>✓</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>#6 RV</td>
<td>≥1</td>
<td>✓</td>
<td>✔</td>
<td>✔</td>
</tr>
</tbody>
</table>

Conclusion: US-guided CNB of the parotid gland could represent a potential novel tool for the diagnosis of pSS patients. When parotid swelling is present, it may be more convenient than lip biopsy. In addition, CNB can be ultrasound-guided in specific glandular areas showing different sonographic appearances, consistent with different histopathology, leading the way for the role as diagnostic tool for pSS, and not only as improved lymphoma detection tool.

Disclosure of Interests: None declared
Haifa, Israel
Chinese patients with the antiphospholipid syndrome (APS) β anticoagulant (LAC), moderate/high titers of IgG anticardiolipin and anti-2glycric manifestations occurred before diagnosis of the rheumatic diseases. Lupus (4.7%) had both. In patients with secondary APS, 23% thrombotic or obstet-2thromboembolic manifestations, 85(19.9%) had obstetric morbidities and 2ied by Cox regression.

analysis and risk factors for recurrence of thrombosis and mortality were stud-2underlying rheumatic diseases) and secondary types. The treatment and out-
come (recurrence and mortality) of the patients was studied by Kaplan-Meier analysis and risk factors for recurrence of thrombosis and mortality were stud-
ied by Cox regression.

Results: 428 APS patients were studied - 282 fulfilled the 2006 criteria for APS (probable APS, which was further categorized into primary (without underlying rheumatic diseases) and secondary) manifestations occurred before diagnosis of the rheumatic diseases. Lupus anticoagulant (LAC), moderate/high titer of IgG anticardiolipin and anti-2glyc coprotein-1 antibodies was present in 326(76.1%), 242(56.5%) and 29(6.7%) patients, respectively. 137(32%) patients were double positive while 19(4.4%) patient was triple positive for these aPL antibodies. Among the thromboem-

bolic manifestations, arterial thrombosis (n=201) was more common than venous thrombosis (n=186). The following treatment regimens were used: warfarin (63.6%), aspirin plus subcutaneous heparin (6.8%), aspirin plus warfarin (3%), aspirin alone (17.8%) and direct oral anticoagulant (DOAC) (2.8%). Bleeding complications developed in 77(18%) patients. After a mean follow-up of 8.0±14.1 years, recurrence of thromboembolic or obstetric complications occurred in 83(19.4%) and 14(3.3%) patients, respectively (1 patient had recurrence of both thrombosis and obstetric complications). Cox regression did not reveal any factors significantly associated with recurrence of thrombo-

sis. A total of 67(15.7%) patients succumbed (median time to death 7.3 years).
The causes of death were vascular in 29.9% (intracranial haemorrhage [35%], myocardial infarction [30%), limb ischemia [10%], ischemic stroke [10%], bowel ischemia [5%] and non-vascular in 70.1% of patients (infection [59.6%], malig-
noma [20.9%], SLE disease activity [6.5%], pulmonary arterial hypertension [2.1%], organ failure [6.4%] and others). The cumulative risk of mortality over time was 6.4% at 5 years and 11.9% at 10 years. The age and sex adjusted standardized mortality ratio (SMR) of our APS patients relative to the general population was 18.2(14.2-23.0). In patients with thrombotic APS, mortality was asso-
ciated with older age (≥60 years) (HR 2.57[1.34-4.95]) and the presence of LAC (HR 2.01[1.07-3.75]), adjusted for age, sex and vascular risk factors that included hypertension, diabetes mellitus, dyslipidaemia, smoking and atrial fibrillation.

Conclusion: APS in southern Chinese is relatively uncommon and most cases were associated with SLE. In contrast to the Caucasians, venous thrombosis related to APS is less frequent. Over 8 years, recurrence of thrombotic events in APS patients was uncommon. The mortality of APS in our Chinese patients was increased, with older age and the presence of LAC being independent risk factors.

Disclosure of Interests: None declared


MONOGENIC SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN NORTHERN ISRAEL

I. Spivak1, T. Hershkovitz12, R. Zaid2, K. Weiss2, Y. Butbul Aviel3.
1Rambam Medical Center, Pediatric B, Haifa, Israel; 2Rambam Medical Center Genetic Institute, Haifa, Israel; 3Rambam Medical Center, Pediatric Rheumatology Unit, Haifa, Israel

Background: Systemic Lupus erythematosus (SLE) is a heterogenic clini-

cal syndrome with a multifactorial etiology including diverse environmental, immunological and genetic causes and modifiers. Increasingly, utilizing next generation sequencing tools, monogenic forms of SLE have been identified in northern Israel.

Objectives: The aim of our study was to identify monogenic causes of SLE in the unique pediatric population of Northern Israel.

Methods: A retrospective and prospective study was carried out between 2010-2021 in a single tertiary pediatric medical center. Genetic testing includ-
ing Whole exome sequencing (WES) was performed for select patients includ-
ing familial history of SLE, consanguinity and/or clinical findings suggestive of monogenic disorder.

Results: 75 children were diagnosed with SLE. 13/75 had one or more relatives with SLE, including a pedigree with 4 affected members. Mean age at presenta-
tion was 10.1±4.7. A monogenic disorder was identified in total of 7/75 of pedi-
grees. Four patients were diagnosed with Proladise deficiency, one patient with ADAR1 mutation related to Aicardi–Goutières syndrome and one pepe with APC5 mutations. Candidate variants in genes related to immune system were identified in one proband and her father requiring further study. Additional WES results are pending

Conclusion: We detected monogenic causes of SLE in a select cohort of patient in Northern Israel. Identification of a genetic basis for disease has direct clinical implication for patients and families and can also enhance our understanding of the pathogenesis and disease mechanisms involved in the more common sporadic forms of SLE.

Disclosure of Interests: Iliya spivak: None declared, Tova Hershkovitz1 Grant/
research support from: Regeneron Genetics center, Tarrytown, NY, USA, Rinat Zaid Grant/research support from: Regeneron Genetics center, Tarrytown, NY, USA, Karin Weiss Grant/research support from: Regeneron Genetics center, Tar-
rytown, NY, USA, Yonatan Butbul Aviel: None declared

The latter was more common in LN patients. Overall, 83 patients (25.0%) in our cohort had evidence of serologic activity, of whom 51 (9.3%) of total had a clinical SLEDAI of 0.

Table 1. Distribution of patients based on total and clinical SLEDAI-2K score at most recent visit

<table>
<thead>
<tr>
<th>Score</th>
<th>Total SLEDAI Patients, n(%)</th>
<th>Clinical SLEDAI Patients, n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>81 (24.4)</td>
<td>0</td>
</tr>
<tr>
<td>1-5</td>
<td>146 (44)</td>
<td>1-3</td>
</tr>
<tr>
<td>6-10</td>
<td>101 (30.4)</td>
<td>4-8</td>
</tr>
<tr>
<td>&gt;10</td>
<td>4 (1.2)</td>
<td>&gt;8</td>
</tr>
</tbody>
</table>

Figure 1. Components of SLEDAI-2K at most recent visit (total cohort of patients and patients with LN)

Conclusion: Although a significant proportion of our patients were on HCQ and additional IS, about 40% of them were not in optimal control. Yet, residual disease activity, based on SLEDAI-2K, was moderate, compared to relatively high mean baseline SLEDAI-2K of lupus trials. These data provide a pragmatic view of lupus patients, who could be potential candidates for novel treatments or inclusion in clinical trials.

REFERENCES:

Disclosure of Interests: None declared


POS0782 ULTRASONOGRAPHIC EVALUATION OF MAJOR SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME: COMPARISON OF THREE SCORING SYSTEMS AND ASSOCIATION WITH BIOPSY RESULTS.

C. Galisteo1, S. García-Cirera1, S. Retamozo1, M. Moreno1, E. Casado1, M. Rusholf Gonzalez2, J. Calvet1, J. Gratacols-Masmith3, 1Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí, Rheumatology, Sabadell, Spain

Background: Salivary glands ultrasound is an imaging technique useful for primary Sjögren’s syndrome (pSS) diagnosis. Nowadays, the use of ultrasound in diagnostic criteria is not clear. Different scoring systems have been published in recent years.

Objectives: This study aims to compare the reliability between three salivary glands ultrasound (SGUS) scores in a series of patients with pSS. Furthermore, we assessed the association of the three SGUS scores with minor salivary gland biopsy.

Methods: A cross-sectional study including 98 subjects fulfilling the ACR-EULAR 2017 classification criteria for pSS. All patients underwent an ultrasound of the salivary glands and a minor salivary gland biopsy requested as per clinical practice. An experienced Rheumatologist in SGUS evaluated systematically the previously acquired images. This Rheumatologist classified the images using three different scoring systems obtained from the grades of bilateral parotid and submandibular glands: Del Vita (0-3), Salaffi (0-4) and Omeract (0-3). These three scores were performed in different days and blinded for the previous scores results. SGUS grade ≥ 2 was considered positive. Positive biopsy was deemed when focus score ≥1. We evaluated the agreement between the three scores and the individual scores with respect to the biopsy.

Results: This study included 98 patients with pSS. The distribution of the different grades according to the score system and the percentage of a positive SGUS are shown in Table 1. The reliability for a positive score for the three evaluated systems was almost perfect, with a Light’s kappa of 0.95 [0.9-1] for the De Vita-Salaffi, 0.87 [0.77-0.97] for De Vita- Omeract and 0.83 [0.71-0.94] for Salaffi-Omeract. We observed a same degree of concordance when the individual parotid and submandibular scores were evaluated. There was only a fair agreement for positivity of SGUS and a positive biopsy in all scoring systems, specifically De Vita (kappa = 0.27 [0.09-0.45]), Salaffi (kappa = 0.26 [0.06-0.45]) and Omeract (kappa = 0.22 [0.03-0.42]). This associations with a positive biopsy did not change in magnitude when individually evaluated parotid and submandibular glands.

Table 1. Distribution of the ultrasound grades and the percentage of positive biopsy in the different scoring systems evaluated.

<table>
<thead>
<tr>
<th>Score</th>
<th>Total Patients, n(%)</th>
<th>Clinical Patients, n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>23</td>
<td>31</td>
</tr>
<tr>
<td>1</td>
<td>23</td>
<td>16</td>
</tr>
<tr>
<td>2</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td>3</td>
<td>27</td>
<td>23</td>
</tr>
<tr>
<td>4</td>
<td>27</td>
<td>16</td>
</tr>
</tbody>
</table>

Conclusion: The three SGUS scores are reliable for the evaluation of the main salivary glands in pSS. There was only weak agreement for SGUS and biopsy, so these two techniques provides complementary information and currently, SGUS cannot replace the biopsy for diagnosis purposes.

Disclosure of Interests: None declared


POS0783 ASSOCIATION BETWEEN ENVIRONMENTAL FACTORS AND SALIVARY GLAND ULTRASOUND FINDINGS IN PATIENTS WITH SUSPECTED PRIMARY SJÖGREN SYNDROME

L. Barrio Nogal1, M. Novella-Navarro2, L. Sala-icardo1, A. Prada-Ojeda1, C. Bohórquez3, A. Pérez Gómez4, 1Hospital Universitario de Torrecárdenas, Servicio de Reumatología, Madrid, Spain; 2Hospital Universitario la Paz, Servicio de Reumatología, Madrid, Spain; 3Hospital Universitario Príncipe de Asturias, Servicio de Reumatología, Madrid, Spain

Background: The influence of environmental factors in primary Sjögren’s syndrome (pSS) and their relationship with serological, histological and ultrasound findings remains still poorly understood. A possible protective effect of female sex hormones and smoking has been related to a lower focal lymphocytic sialadenitis on the minor salivary gland biopsy (MSGB), but the relationship between histological findings and other chemical, toxic or dietary factors remains scarce or controversial, and even more so the relationship between these factors with salivary gland ultrasound (SGUS) findings, an emerging tool in the diagnostic and management of pSS.

Objectives: To analyze the relationship between sociodemographic, clinical and environmental factors with pathologic SGUS findings in patients with suspected pSS.

Methods: 72 patients with clinical and/or analytical suspicion of pSS were consecutively recruited. SGUS was performed pathologic (grade ≥2 according to Correc et al system) vs non-pathologic. Final diagnosis of pSS was made according to AECG, ACR/EULAR criteria and MSGB. Sociodemographic, clinical, analytical, activity indexes (ESSPRI and ESSDAI), environmental factors, toxic and dietary habits were collected. Chi-square and Fisher tests were used to compare qualitative variables and T-student and U-Mann Whitney tests, for quantitative variables (statistical significance p<0.05). Defining pathologic vs non-pathologic US as the outcome variable, binomial logistic regression was performed for bivariate analysis, with calculation of Odds Ratio (OR) and 95% confidence interval (CI).

Results: 70.8% presented pathological SGUS, this percentage was significantly higher in patients with a definitive diagnosis of pSS (56.6% vs 26.6%; p=0.02), 97.2% were women with a mean age 57.3±11.8 years. Patients with pathological SGUS had in lower frequency a varied diet (64.2 vs 89.5; p=0.03), higher exposure to environmental toxic (71.1 vs 61.1; p=0.05), lower percentage of smokers (26.4 vs 52.6; p=0.03) and a lower mean age at menopause than patients with non-pathologic SGUS (47.3±3.9 vs 50.2±4.2; p=0.03). Significant differences were found in antiRo52 positivity and hypergammaglobulinemia. Bivariate analysis showed that menopause at younger age confers higher probability...
of presenting pathologic SGUS (OR=1.2 CI95% 1.02-1.41) and smoking was protective against pathologic SGUS (OR=0.32 CI95% 0.11-0.95). Hypergammaglobulinemia (OR=8.80 CI95% 2.37-34.02) and antiRo2 (OR=3.89 CI95% 1.14-13.20) imply an increased risk of pathological findings on SGUS.

Conclusion: Pathologic SGUS was more frequent in patients with definitive diagnosis of pSS, antiRo2 antibodies and hypergammaglobulinemia. Late menopause and smoking were protective factors against pathologic SGUS, and a tendency for a varied diet and absence of exposure to environmental chemicals. SGUS could be the initial diagnostic test in patients with suspected pSS and positive antiRo who have less exposure to estrogens, tobacco and Mediterranean diet and greater exposure to chemicals. For this reason, SGUS could be useful in identifying modifiable environmental risk factors to decrease the incidence and severity of this disease, for which effective therapy is still lacking.

REFERENCES:

Disclosure of Interests: None declared

POS0784

LOW COMPLEMENT LEVELS ARE ASSOCIATED WITH HIGHER MORTALITY IN HOSPITALIZED PATIENTS WITH POSITIVE ANTIPHOSPHOLIPID ANTIBODIES

E. Itelman1, M. Perelman1, D. Kent1, N. Biber1, G. Segal1, L. Negru1, A. Dagan2,  
1Sheba Medical Center, Internal Medicine Ward “T”; 2Ramat Gan, Israel; 3Wolfson Medical Center, Rheumatology Unit, Holon, Israel

Background: Antiphospholipid Syndrome is an autoimmune disease characterized by increased risk for vascular thrombosis (arterial and/or venous) thrombosis and/or pregnancy morbidity in the presence of antiphospholipid antibodies. The mechanisms by which aPLs induce thrombosis are unclear; several are suggested, among them complement activation. (1-2) The complement system is a system of enzymes and regulatory proteins of the innate immune system that play a crucial role in the inflammatory response to various pathogenic stimuli. The complement and coagulation pathways are interconnected, and expanding evidence indicates that complement may be activated in patients with antiphospholipid syndrome (3-5).

Objectives: Our study was intended to better characterize the complicated relations between antiphospholipid antibodies and complement activation among hospitalized patients with antiphospholipid syndrome and its impact on short- and long-term prognosis

Methods: A retrospective cohort studies. Clinical and prognostic data of hospitalized patients with antiphospholipid syndrome and a measurement of complement levels (C3 or C4) were obtained. Rates of long-term mortality, one-year mortality, deep vein thrombosis (DVT), and pulmonary emboli (PE) were compared between patients with low complement levels and patients with normal complement levels. Low complement was defined as C3 < 90 mg/dl or C4 < 10 mg/dl. A multivariate analysis was performed to control for Anticardiolipin levels,β₂-macroglobulin levels and RVVT ratio.

Results: Complete data was available for 6,599 patients, of which 712 (11%) had low complement levels. The median age of the cohort was 47.7, and most of the patients were females (56%). Patients with low complement levels had significantly higher mortality rates 30% vs. 18%, p < 0.001 for long-term mortality (Figure 1) and 15% vs. 5%, p < 0.001 for 1 year mortality when compared to patients with normal complement levels. DVT and PE rates were similar (4% vs 3.8%, P = 0.78 and 4% vs 2.4%, P = 0.13 respectively). Results of the multivariate analysis (Table 1) were consistent and showed that patients with low complement levels had 111% higher mortality rates (CI 1.52-2.90, P < 0.001).

Table 1. Multivariate Analysis for long term mortality

<table>
<thead>
<tr>
<th>OR (CI)</th>
<th>p</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Complement</td>
<td>2.11 [1.52, 2.90]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anticardiolipin IGG</td>
<td>1.00 [1.00, 1.01]</td>
<td>0.243</td>
</tr>
<tr>
<td>Anticardiolipin IGM</td>
<td>0.99 [0.98, 1.00]</td>
<td>0.984</td>
</tr>
<tr>
<td>β₂-macro</td>
<td>1.01 [1.00, 1.01]</td>
<td>0.017</td>
</tr>
<tr>
<td>jβ</td>
<td>1.00 [0.99, 1.00]</td>
<td>0.663</td>
</tr>
<tr>
<td>RVVT Ratio</td>
<td>0.99 [0.63, 1.62]</td>
<td>0.954</td>
</tr>
</tbody>
</table>

Conclusion: In hospitalized patients with high aPLs, low complement levels are associated with significantly higher mortality rates. This finding is in correlation with recent literature, suggesting an important role for complement activation in APC.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4815

POS0785

EXPRESSION OF MYXOVIRUS RESISTANCE PROTEIN A IN LUPUS NEPHRITIS

L. Liu1, K. De Leeuw1, G. Diercks2, C. Stegeman3, B. Doornbos-van der Meer1, H. Van Goor2, M. Heuvel3, J. Westra1. 1University Medical Centre Groningen, Department of Internal Medicine, Division of Nephrology, Groningen, Netherlands; 2University Medical Centre Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 3University Medical Centre Groningen, Department of Internal Medicine, Division of Nephrology, Groningen, Netherlands

Background: Lupus nephritis (LN) is regarded as one of the most severe organ manifestations of systemic lupus erythematosus (SLE) [1]. It has been shown that type I interferons (IFN) are important cytokines in the pathogenesis of SLE and LN and could possibly serve as a histological marker for kidney lesions in LN [2]. However, the direct measurement of type I IFN protein in tissues has remained elusive. Myxovirus resistance protein A (MxA) which is upregulated by IFN-1, can easily be measured, and could be used as a potential biomarker. In addition, dendritic cells are main producers of IFN-1.

Objectives: To investigate the expression of MxA and CD303 which is a plasma-cytoid dendritic cells (pDCs) specific marker [3] by immunohistochemical analysis of renal specimens obtained from LN patients and from patients with other types of nephritis.

Methods: LN was diagnosed based on the International Society of Nephrology/Renal Pathology Society (ISN/IPS) classification. In total, 41 renal tissue samples were collected from lupus nephritis including all classes (I-V according to ISN/IPS classification), and compared to 70 biopsies from other forms of nephritis. MxA was detected by immunohistochemistry staining. Scoring of MxA staining was done semi-quantitative for four groups of patients with a range from 0 to 3+. Scoring was based on the intensity of the staining, in which '0' meant no expression; '1': weak expression; '2': moderate expression; and '3+': strong expression. The expression of CD303 was measured by counting the number of CD303 positive cells in the glomerulens or in the tubular interstitium.

Results: The MxA average scores of the total LN group were higher than control specimens especially in distal tubules (Figure 1). The MxA expression in LN...
classes I, II, and V biopsies was mainly increased compared to tissues of patients with minimal change disease, mesangio proliferative nephritis, and membranous nephropathy (Figure 2a, 2b, 2d). However, MxA staining was comparable in LN classes III/IV compared to control groups (Figure 2c). The staining of CD303 showed that pDCs are more present in tubular interstitium than in glomeruli. Furthermore, CD303-positive cells were highest in LN class IV, but overall numbers of pDCs were higher in controls groups compared to LN groups (Figure 3).

Conclusion: Our data indicate that MxA expression is higher in LN vs. other types of nephritis. These results suggest that MxA could be a potential additional histological marker to establish the diagnosis of lupus nephritis on the kidney biopsy. In contrast to the increased expression of MxA in LN, we found decreased numbers of pDCs. Therefore, it is important to investigate which other cells are the main producers of IFN-1 in further studies.

REFERENCES:

Disclosure of Interests: None declared


POS0787

THE EFFECT OF ANTI-RIBOSOMAL-P AND ANTI-NR2 ANTIBODIES ON FUNCTIONAL BRAIN MRI NETWORKS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH DEPRESSION AND BEHAVIORAL COGNITIVE DISORDERS.

E. Chessa1, M. Piga1, M. Porcu2, E. Pintus3, A. Perra2, C. Serafini1, A. Fioris1, M. Congia1, M. M. Angioni1, M. G. Carta3, L. Saba2, A. Mathieu1, A. Cauli1.

1University and AOU Cagliari - Rheumatology Unit, Department of Medical Sciences and Public Health, Monsemta, Italy; 2Azienda Ospedaliero Universitaria (A.O.U.), Department of Radiology, Cagliari, Italy; 3University of Cagliari, Department of Health Sciences and Public Health, Cagliari, Italy.

Background: Cognitive dysfunction (CD) and mood disorders (MD) are among the most frequent neuropsychiatric (NP) events in Systemic Lupus Erythematosus (SLE), but their pathogenesis has not been clarified yet. Until now, an unquestionable correlation between the presence of specific autoantibodies, brain alterations and the presence of CDs and MDs in SLE is lacking.

Objectives: The primary aim of the study was to explore the effects of anti-NR2 (anti-DWEYS) and anti-ribosomal-P (anti-P) antibodies on CDs and MDs and their relation with functional brain connectivity in patients affected by SLE.

Methods: A cross-sectional study was conducted, between April 2019 and February 2020, including adult patients who fulfilled the ACR/EULAR 2019 SLE criteria. Demographics, ongoing medications, SLEDAI and SLICC/Damage Index were recorded. Serum level quantification for anti-P (normal values <18 U/ml) and anti-NR2 (normal values <0.5 OD) antibodies were performed using an ELISA. A battery of neuropsychological testing was interpreted by a neuropsychologist, exploring cognitive domains, depression and quality of life. A resting-state functional connectivity (rs-fc) MRI analysis was performed within 2 weeks since the neuropsychological status assessments. Two region

Disclosure of Interests: None declared


POS0786

IDENTIFYING INDIVIDUALS AT RISK FOR SJÖGREEN’S SYNDROME – THE PRE-SJÖGREEN SYNDROME TARGETED IMMUNOLOGICAL EVALUATION (PRESTIGE) STUDY

S. Zenz1, E. Erlacher1, E. Winisch1, B. Dreo2, P. Javorova3, A. Lackner1, M. D’orazio1, Thiel1, D. Corneç1, M. Stradner1.

1Medical University of Graz, Department of Rheumatology and Immunology, Graz, Austria; 2University of Brest, Department of Rheumatology, Brest, France.

Background: Primary Sjögren’s Syndrome (pSS) is a chronic autoimmune disease. Symptoms range from sicca to systemic, potentially life-threatening organ damage. Little is known about the onset of the disease. Anti-Ro antibodies are described to develop years before the first symptoms. In addition, first degree relatives of pSS patients have an 11- to 19-fold increased risk of developing pSS themselves.

Objectives: To identify and follow-up individuals at risk for pSS in order to study symptoms and immune pathology before and at development of pSS.

Methods: In this ongoing long-term study individuals at risk for developing pSS but not fulfilling the ACR-EULAR classification criteria of pSS were included, defined as: 1) Anti-SsA-positive individuals (Anti-SsA) without any sicca symptoms or diagnosis of an underlying systemic autoimmune disease; 2) First degree relatives of patients (relatives) with an established diagnosis of pSS and typical autoantibodies (ANA ≥ 1:160 and/or anti-SsA and/or rheumatoid factor); 3) Individuals with at least one feature of the ACR-EULAR classification criteria for pSS, but not fulfilling the criteria (incomplete). At baseline and at annual visits, demographic data, blood, saliva and urine samples were collected and stored. Salivary and lacrimal flow, salivary gland ultrasonography (SGUS), and patient-related outcome measures were analysed. A lip salivary gland biopsy was performed at baseline and upon development of symptoms suggestive of pSS. The primary endpoint was the development of definite pSS according to the ACR-EULAR classification criteria.

Results: After the first year of recruitment, 50 individuals (Anti-SsA: n=27, relatives n=23, incomplete n=2) were screened at baseline, of whom 28 were identified as individuals at risk for pSS and were included in the study. Twenty-two individuals were excluded from the study, most of whom were “relatives” with negative autoantibodies. Of these 28 individuals at risk, 89% were female (n=25), they had a median age of 53 years (IQR: 19) and 57% (n=16) had positive antinuclear antibodies. 86 percent were positive for anti-SsA and 14% were positive for anti-SSB. Decreased complement C3 and C4 were found in 18% and 41%, respectively. Serum IgG concentration was elevated in 79% of individuals. A reduction of lacrimal flow was found in 29% and stimulated whole salivary flow was reduced in 29%. The median of the ESSPRI was 1.6 (3.0). Eighteen per cent of the investigated individuals had a pathological ultrasonography [Hoevear score median 4.5 (9.0)] and in 9% a focus score ≥1 (median 0.15 (0.57)) was found in the lip salivary gland biopsies. Four patients (14%) met the primary endpoint and were diagnosed with pSS within the first year.

Conclusion: The design of the PRESTIGE study allows us to follow individuals at risk for pSS and will help to unveil symptoms and immune pathology as pSS develops. We suggest to establish a larger international pre-pSS cohort to increase statistical power.

Disclosure of Interests: None declared

of interest to region of interest (ROI-to-ROI) analyses with the graph theory was performed.

**Results:** Thirty-three SLE patients (9% male) were enrolled, mean age 43.5 (±14) years, and median disease duration of 10.4 years (IQR 2.9-25.4) (Table 1). Anti-P were positive (range 0-255 U/ml) in 6 patients (18.2%) and anti-DWEYS (range 0-1.8 OD) in 14 (42.4%). Nineteen out of 33 patients (57.6%) showed at least a cognitive test alteration, but no significant association with antibodies was found. Depression was found in 14 (42.4%) patients using the Center for Epidemiologic Studies Depression Scale (CES-D) as screening instrument. In multiple regression backward models, after correction for age, disease duration, SLEDAI and SDI, the CES-D showed an independent association with anti-P titre (β= 0.32 per U/ml; p=0.049) and prednisone daily dose (β=0.38 per mg/day; p=0.023). The rs-fc MRI analysis revealed a statistically significant association between the titre of anti-P and many altered properties of the brain ROIs (Figure 1), but no effects of PDN daily dose on specific cerebral networks.

**Table 1. Demographic and clinical characteristics of the patients in total, Legend: PDN: Prednisone; LLDAS: Lupus Low Disease Activity State; OD: Optical density**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years mean (SD)</td>
<td>43.5 (±14.0)</td>
</tr>
<tr>
<td>Gender (M, %)</td>
<td>3 (9%)</td>
</tr>
<tr>
<td>Disease duration, months median (IQR)</td>
<td>124.4 (43.7-305)</td>
</tr>
<tr>
<td>SLEDAI-2k median (IQR)</td>
<td>4 (0-14)</td>
</tr>
<tr>
<td>Dose PDN mg/daily median (IQR)</td>
<td>6.4 (3.8-13.5)</td>
</tr>
<tr>
<td>LLDDAS N, %</td>
<td>12 (36.4%)</td>
</tr>
<tr>
<td>SLICC-DI mediane (IQR)</td>
<td>0 (0-1)</td>
</tr>
<tr>
<td>Ongoing treatment</td>
<td>25 (75.8%)</td>
</tr>
<tr>
<td>Hydroxychloroquine N, %</td>
<td>30 (90.9%)</td>
</tr>
<tr>
<td>Immunosuppressive Biologics</td>
<td>9 (27.3%)</td>
</tr>
<tr>
<td>Education less than 8 years</td>
<td>13 (39.4%)</td>
</tr>
<tr>
<td>Anti-Rib-P N, %</td>
<td>6 (18.2%)</td>
</tr>
<tr>
<td>Anti-Rib-P (U/ml) mean (DS)</td>
<td>10.9 (5.1-13.3)</td>
</tr>
<tr>
<td>Anti-DWEYS N, %</td>
<td>14 (42.4%)</td>
</tr>
<tr>
<td>Anti-DWEYS (OD) mean (DS)</td>
<td>0.4 (0.25-0.67)</td>
</tr>
<tr>
<td>Anti-phospholipid N, %</td>
<td>11 (33.3%)</td>
</tr>
<tr>
<td>anti-dsDNA N, %</td>
<td>18 (54.5%)</td>
</tr>
<tr>
<td>anti-dsDNA Titre median (IQR)</td>
<td>22.5 (2.9-74.5)</td>
</tr>
</tbody>
</table>

**Conclusion:** Anti-P antibodies are associated with depressive symptoms and changes of brain network properties in SLE patients, which add knowledge on their pathogenetic effect.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5021

---

**Figure 1.** Results of rs-fc MR Analysis 1 (effects of Anti-rb-P titre) on cerebral networks. The regions with decreased and increased property are shown in blue and red nodes, respectively (p<0.01). The node size represents the significance of the between-group differences in the nodal degree.

**Table 1.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>M:1/2F:20</td>
</tr>
<tr>
<td>Age (years, means±SD)</td>
<td>53.4±12.27</td>
</tr>
<tr>
<td>disease duration (months, means±SD)</td>
<td>30.2±10.47</td>
</tr>
<tr>
<td>SLEDAI (means±SD)</td>
<td>2.3±1.2</td>
</tr>
<tr>
<td>GLOPES (means±SD)</td>
<td>4.1±1.2</td>
</tr>
<tr>
<td>Global dryness VAS (0-10)</td>
<td>5.0±3.0</td>
</tr>
<tr>
<td>VAS fatigue (0-10)</td>
<td>5.0±3.0</td>
</tr>
<tr>
<td>Global dryness VAS (0-10) means±SD</td>
<td>3.4±1.32</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>15</td>
</tr>
<tr>
<td>Dry eyes</td>
<td>17</td>
</tr>
<tr>
<td>Parotid Gland Swelling</td>
<td>4</td>
</tr>
<tr>
<td>Articular involvement</td>
<td>6</td>
</tr>
<tr>
<td>Skin Involvement</td>
<td>1</td>
</tr>
<tr>
<td>Raynaud’s Phenomenon</td>
<td>5</td>
</tr>
<tr>
<td>Other Organs</td>
<td>3</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>1</td>
</tr>
<tr>
<td>Low Complement (C3 or C4)</td>
<td>3</td>
</tr>
<tr>
<td>Low C3</td>
<td>3</td>
</tr>
<tr>
<td>Low C4</td>
<td>1</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>7</td>
</tr>
<tr>
<td>Hypergammaglobulinemia</td>
<td>7</td>
</tr>
<tr>
<td>Monoclonal Gammapathy</td>
<td>2</td>
</tr>
<tr>
<td>Ana</td>
<td>19</td>
</tr>
<tr>
<td>Anti-SSA</td>
<td>19</td>
</tr>
<tr>
<td>Anti-SSB</td>
<td>10</td>
</tr>
<tr>
<td>Rheumatoid Factor</td>
<td>9</td>
</tr>
<tr>
<td>Cryoglobulins</td>
<td>1</td>
</tr>
<tr>
<td>Salivary Gland Biopsy Focus Score (Means±SD)</td>
<td>1.9±1.45</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>5</td>
</tr>
<tr>
<td>Immunosuppressant</td>
<td>1</td>
</tr>
</tbody>
</table>

**Figure 1.**
Conclusion: For the first time we suggest the potential usefulness of IL-2RA as a marker of disease activity in SjS. Notably, IL2RA has been used as a marker to identify CD4+Foxp3+ regulatory T cells. So far, it is known that T follicular helper (Tfh) cell differentiation is inhibited by IL-2 while regulatory T cell differentiation and survival depend on it. Nonetheless, Wing et al. (1) described a CD25- subpopulation within human PD1+CXCR5+Foxp3+ Th cells preferentially located in germinal centers which is reduced by the presence of IL-2, possibly explaining the association with disease activity. IL-12p40 is known to have a pathogenic role in SjS (2) and we suggest that it may represent a complementary tool in the evaluation of patients’ symptoms. The presence of high levels of IL-15 in SjS is not novel and associated with T cell migration and proliferation in germinal centers. Finally, the observation of very high BAFF/BLYS levels in the male with cryoglobulin will require further analysis.

REFERENCES:

Disclosure of Interests: None declared

POS0789

CLINICAL FEATURES OF SJÖGREN’S SYNDROME WITH AND WITHOUT NEUROLOGICAL INVOLVEMENT (NEURO-SJÖGREN)

T. Seeliger1, E. Kramer2, F. F. Konen1, S. Beider2, A. Jablonka2, T. Witte3, T. Skripuletz1, D. Ernst1, 1Medizinische Hochschule Hannover, Neurology, Hannover, Germany; 2Medizinische Hochschule Hannover, Rheumatology and Immunology, Hannover, Germany

Background: Sjögren’s Syndrome is well known for its characteristic sicca symptoms due to autoinflammatory destruction of the salivary and lacrimal glands, but extraglandular involvement is also common in this entity. Nevertheless, previously published smaller studies suggested distinct clinical features for Sjögren’s syndrome with and without neurological involvement, such as a more balanced gender distribution and lower IgG levels in patients with Sjögren’s syndrome and neurological involvement1-2.

Objectives: We therefore aimed to systematically assess clinical features of patients with Sjögren’s syndrome with and without neurological involvement, find relevant in-between group differences and hereby aid early detection of both patient groups in the clinical routine to facilitate further studies, potentially with new therapeutic approaches.

Methods: We retrospectively assessed patients with Sjögren’s syndrome treated at the neurological and rheumatological/immunological department of our university hospital between 05/2014 and 09/2021 for available laboratory and clinical data. The displayed data represent preliminary results of this ongoing study.

Results: 405 patients, who fulfilled the current ACR/EULAR classification criteria for Sjögren’s syndrome were currently included in the study (median age 59 years [IQR 50-70 years], median ESSDAI 10 [IQR 3-16]). 228 patients (56%) showed neurological involvement. They were significantly more often male (32% vs. 14%; p<0.001) and showed lower IgG serum levels (median 11 g/l [IQR 9-13 g/l] vs 12 g/l [IQR 10-16 g/l], p<0.01) in comparison to patients with Sjögren’s syndrome but without neurological involvement.

Conclusion: Preliminary analysis of this ongoing study supports the hypothesis, that patients with Sjögren’s syndrome and neurological impairment might express a distinct clinical phenotype in comparison to patients with Sjögren’s syndrome but without neurological involvement.

REFERENCES:


POS0790

18F-FLUORODEOXYGLUCOSE (FDG) PET-CT IMAGING OF SALIVARY GLANDS IN PRIMARY SJÖGREN’S SYNDROME AND ITS CORRELATION WITH ULTRASONOGRAPHIC SCORES AND SALIVARY FLOW RATE COMPARED TO HEALTHY CONTROLS

K. Abacar1, T. N. Kissas2, K. Oksuzoglu2, T. Ones2, G. Mumcu3, G. Brynet4, N. Inanc1, 1Marmara University School of Medicine, Rheumatology Department, Istanbul, Turkey; 2Marmara University School of Medicine, Nuclear Medicine Department, Istanbul, Turkey; 3Marmara University School of Health Sciences, Health Management, Istanbul, Turkey; 4ReumaKind Lelystad, Rheumatology, Lelystad, Netherlands

Background: The use of salivary gland imaging modalities in patients with primary Sjögren’s syndrome (pSS) has been increasing recently. The contribution of each imaging method in terms of diagnosis or disease activity differs from each other. Although ultrasound and MRI are the most commonly used imaging modalities, the role of PET-CT for diagnosing pSS and determining glandular and extraglandular involvement has largely been neglected.

Objectives: This study aimed to compare the sizes and metabolic activities of the major salivary glands in patients with pSS and healthy controls (HC). Correlation of the 18F-FDG PET-CT uptake characteristics with ultrasound scores and salivary flow rates of the patients and HC was also determined.

Methods: 22 patients with pSS and 10 age-sex-matched HC were included in the study. The sizes and FDG uptakes of the parotid and submandibular glands of pSS patients and HC were assessed by PET-CT. The maximum standardized uptake value (SUVmax) was evaluated for FDG uptakes, and each patient’s liver uptake and salivary gland uptake ratio were calculated. In addition, correlations of gland sizes and FDG uptakes in PET-CT with OMERACT and Hoeveca ultrasound scores, stimulated and unstimulated SFR, ESSPRI dryness scores and disease durations of pSS patients were calculated by Spearman test.

Results: The mean age (SD) of the patients was 58.6 years (10.5) versus 58.6 years (19.1) of HC; the mean (SD) disease duration was 8.96 (8.77) years. ANA was positive in all patients, anti-SSA positivity was present in 82.6%, and 30.4% of patients experienced ≥1 parotid swelling episode. Compared to HCs, the mean size of both submandibular glands (p=0.006 for left and p=0.032 for right) and SUVmax of the left submandibular gland (p=0.044) were significantly smaller in patients with pSS. In pSS patients, both right and left parotid sizes were smaller and SUVmax uptake was greater than in HC; these differences however did not reach statistical significance. When the PET-CT involvement characteristics of the patients were compared with the salivary gland ultrasonography scores, there was a statistically significant negative correlation between the left parotid gland size in PET-CT and the ultrasonographic inhomogeneity of Hoevecar score and OMERACT score. There was a statistically significant negative correlation between right parotid gland size measured on PET-CT with ultrasonographic inhomogeneity, hyperchoic foci, parenchymal echogenicity, Hoevecar total score, and OMERACT score. No statistically significant correlation was found between SUVmax scores detected by PET-CT and ultrasound scores in both parotid glands and submandibular glands. A statistically significant positive correlation was found between the total gland size measured in PET-CT and the unstimulated salivary flow rate (p=0.038, r=0.604). There was a negative correlation between total gland size and ESSPRI dryness scores and symptom duration, which did not reach statistical significance.

Conclusion: PET-CT SUVmax measurements do not provide sufficient information for pSS-related involvement of the major salivary glands. Secondly, size measurement of the parotid glands by PET-CT is associated with OMERACT ultrasound scores, and also the sizes of both submandibular and parotid glands are smaller than HC.

Table 1. Correlations of gland sizes and ultrasonographic scores

<table>
<thead>
<tr>
<th>Gland</th>
<th>OMERACT</th>
<th>Parenchymal</th>
<th>Hypoechoic</th>
<th>Violability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parotid</td>
<td>Score</td>
<td>Echogenicity</td>
<td>Homogeneity</td>
<td>Areas</td>
</tr>
<tr>
<td>Right</td>
<td>P-Value</td>
<td>0.001</td>
<td>0.013</td>
<td>0.052</td>
</tr>
<tr>
<td>Left</td>
<td>P-Value</td>
<td>0.001</td>
<td>0.013</td>
<td>0.052</td>
</tr>
<tr>
<td>Submandibular</td>
<td>P-Value</td>
<td>0.017</td>
<td>0.011</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared
Vasculitis — large vessel vasculitis.

A NATIONWIDE STUDY OF OCULAR MANIFESTATIONS AMONG HOSPITALIZED PATIENTS WITH GIANT CELL ARTERITIS

P. Therkildsen1,2, A. De Thurah1, M. Faurusch3, B. Baslund1, I. Hansen1, M. Nørgaard1,2, B. Dalgaard Nielsen1, E. M. Hauge1,2, Aarhus University Hospital, Department of Rheumatology, Aarhus N, Denmark; Aarhus University, Department of Clinical Medicine, Aarhus C, Denmark; Aarhus University Hospital, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; Aarhus University Hospital, Department of Clinical Epidemiology, Aarhus N, Denmark; Horsens Regional Hospital, Department of Internal Medicine, Horsens, Denmark

Background: Ocular manifestations are common among patients with giant cell arteritis (GCA). Most feared is a permanent visual impairment reported in up to 15-20% of GCA patients. Estimates of ocular manifestations vary significantly between studies, and large, nationwide studies are currently lacking. In GCA, visual impairment has been associated with high and low inflammatory markers. Also, low-dose aspirin treatment has been associated with a reduced risk of visual impairment in patients with GCA, but the evidence remains sparse.

Objectives: To investigate the risk of ocular manifestations among hospitalized patients with GCA. Furthermore, to investigate the association between inflammatory marker levels and low-dose aspirin treatment with the risk of ocular manifestations.

Methods: A Danish, nationwide, register-based cohort study including 14,574 incident GCA patients diagnosed between 1996 and 2018, and 145,740 general population referents, matched on age, sex, and calendar time. Ocular manifestations were defined as retinal vascular occlusions, disorders of optics, visual impairment, diplopia, and amaurosis fugax. We tabulated characteristics of the GCA and reference cohort at the time of diagnosis including ocular manifestations recorded within one year of the GCA diagnosis. Regression analyses for incident ocular manifestations were performed using a pseudo-observational approach with the index date defined as the date of the GCA diagnosis. Cumulative incidence proportions (CIPs) and relative risks (RRs) of incident ocular manifestations with 95% confidence intervals (CIs) were calculated with death as a competing risk.

Results: Within one year of the diagnosis, 1,026/14,574 (7%) of GCA patients were registered with ocular manifestations with 392/1,026 (38%) being prior to and 634/1,026 (62%) after the GCA diagnosis, and 744/1,026 (73%) were registered within one month of the diagnosis. A total of 336/1,026 (33%) were retinal vascular occlusions, 300/1,026 (29%) disorders of the optic nerve, 177/1,026 (17%) visual impairment, 90/1,026 (9%) diplopia, and 123/1,026 (12%) amaurosis fugax. The CIP of ocular manifestations among GCA patients was 4.0% (95% CI: 3.6-4.3), 4.2% (95% CI: 3.9-4.6), and 4.6% (95% CI: 4.2-4.9) after 5, 6, and 12 months following the diagnosis with a 1-year RR of 28.0 (95% CI: 24.0-32.7) compared to the general population. Age above 70 years, male sex, and a positive temporal artery biopsy were associated with an increased 1-year RR of incident ocular manifestations. Neither treatment with low-dose aspirin nor baseline CRP nor ESRI levels was related to the risk of ocular manifestations.

Conclusion: In GCA, most cases of ocular manifestations occur at the time of diagnosis with over one-third of cases occurring prior to the diagnosis, emphasizing the need for early recognition and treatment. Low-dose aspirin treatment was not associated with a reduced risk of ocular manifestations among patients with GCA.

REFERENCES:


Disclosure of Interests: None declared

POS792 PULMONARY ARTERY INVOLVEMENT IN BEHÇET’S DISEASE: SINGLE CENTER RESULTS

O. Ozdemir Isik1, S. San1, D. Temiz Karadag1, A. Yazio1, A. Cefle1. 1Kocaeli University, Faculty of Medicine, Rheumatology, Kocaeli, Turkey

Background: Behçet’s disease (BD) is a multisystem inflammatory vasculitis. Skin, mucosa, eye, vascular area, joint, gastrointestinal system and central nervous system involvement is observed.

Objectives: In this study, we aimed to present the data of patients with pulmonary artery involvement (PAI) followed up with the diagnosis of BD.

Methods: The clinical, demographic and laboratory data of 394 patients with the diagnosis of BD, who were followed up in our rheumatology outpatient clinic between 2000 and 2020, were evaluated retrospectively.

Results: Of the patients followed up with the diagnosis of BD, 44% were female and 56% were male. Oral aphthous ulcers were found in 96%, genital ulcers in 65%, papulopustular lesions in 33%, erythema nodosum in 38%, and pathergy positivity in 47% of the patients. PAI was detected in 3% (n:13) of the patients who were followed up with a diagnosis of BD. 69% of the patients who had PAI were male, and their mean diagnosis age was 27.9, disease duration was 10±4.7 years. Pulmonary artery aneurysm was observed in 62%, pulmonary artery thrombosis (PAT) was observed in 46%, and both conditions were observed in 46% of the patients. Oral aphthous ulcer were found in all patients, genital ulcers in 70%, papulopustular lesions in 23%, pathergy positivity in 39%, and erythema nodosum in 23%. One of the patients with PAI had hereditary thrombophilia and also extremity deep vein thrombosis (DVT). Cardiac involvement was in the form of intracardiac thrombus in patients with BD. Patients with and without PAI were compared in terms of clinical findings. A significant difference was observed in terms of DVT in the lower extremity, venous and cardiac involvement. The relationship between PAI and these involvements was also shown in the regression analysis (Table 1).

Significant data in logistic regression analysis were presented, GIS: Gastrointestinal system

Table 1. Comparison of data of patients with and without pulmonary artery involvement

<table>
<thead>
<tr>
<th>N (%)</th>
<th>Pulmonary Artery Involvement (+)</th>
<th>Pulmonary Artery Involvement (-)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender Female</td>
<td>4/13</td>
<td>168/44</td>
</tr>
<tr>
<td>Male</td>
<td>13/10</td>
<td>213/56</td>
</tr>
<tr>
<td>Family History</td>
<td>2/15</td>
<td>46/12</td>
</tr>
<tr>
<td>Oral Aphthous Ulcers</td>
<td>13/100</td>
<td>306/89</td>
</tr>
<tr>
<td>Genital Ulcer</td>
<td>1/170</td>
<td>247/65</td>
</tr>
<tr>
<td>Papulopustular lesion</td>
<td>3/23</td>
<td>326/33</td>
</tr>
<tr>
<td>Erythema Nodosum</td>
<td>3/23</td>
<td>147/39</td>
</tr>
<tr>
<td>Pathergy positivity</td>
<td>3/39</td>
<td>180/47</td>
</tr>
<tr>
<td>Uveitis</td>
<td>-</td>
<td>138/36</td>
</tr>
<tr>
<td>Retinal Vascular</td>
<td>-</td>
<td>11/3</td>
</tr>
<tr>
<td>Arthritis</td>
<td>1/8</td>
<td>97/26</td>
</tr>
<tr>
<td>Venous Involvement</td>
<td>6/62</td>
<td>68/18</td>
</tr>
<tr>
<td>Lower Extremity Deep Vein Thrombosis</td>
<td>6/46</td>
<td>46/12</td>
</tr>
<tr>
<td>Peripheral Artery</td>
<td>-</td>
<td>5/1</td>
</tr>
<tr>
<td>Aneurysm</td>
<td>-</td>
<td>1/5</td>
</tr>
<tr>
<td>GIS involvement</td>
<td>-</td>
<td>3/23</td>
</tr>
<tr>
<td>Cardiovascular involvement</td>
<td>4/1</td>
<td>0.011</td>
</tr>
<tr>
<td>Cranial Involvement</td>
<td>-</td>
<td>24/6</td>
</tr>
</tbody>
</table>

Cranial involvement was not detected in any of our patients with PAI. In subgroup analysis, a significant relationship was observed between PAT and intracardiac thrombus (p=0.001 OR:21.05 95%CI:3.4-139) and lower extremity DVT (p=0.001 OR: 8.79 95%CI:2.58-29.96).

Conclusion: PAI is rare but the most important involvement affecting mortality in BD patients. Recently, there has been an increase in the incidence of isolated PAT with the contribution of the developments in imaging methods.1 PAI is associated with lower extremity DVT, cerebral venous thrombosis and intracardiac thrombus.2 In our study, a significant correlation was found between PAI and the presence of venous involvement, lower extremity DVT and intracardiac thrombus.

REFERENCES:


Disclosure of Interests: None declared


POS793 IMPROVED RELAPSE-FREE SURVIVAL WITH THE NORWICH PRENISOLONE REGIMEN FOR GIANT CELL ARTERITIS

G. Duckers, K. Mills, C. Yong, C. Jones, G. Mukhyar on behalf of the Mukhtyar Vasculitis Working Group. 1Norfolk & Norwich University Hospital, 2Norwich Nunn Endowment Foundation, 3Norfolk & Norwich University Hospital, 4Aurora Health Care, University of Wisconsin School of Medicine, 5University of Wisconsin Medical Foundation
PREGNANCY AND CHILDBIRTH IN TAKAYASU ARTERITIS IN JAPAN: NATIONWIDE RETROSPECTIVE STUDY

T. Miyamae1,2, Y. Manabe3,4, T. Sugihara5,6, N. Umezawa7, H. Yoshifuji8, 1Osaka University Graduate School of Medicine, Department of Obstetrics and Gynecology, Osaka, Japan; 2Osaka University Graduate School of Medicine, Department of Clinical Oncology, Osaka, Japan; 3Osaka University Graduate School of Medicine, Department of Internal Medicine, Osaka, Japan; 4Faculty of Medical Pharmaceutical Sciences, Department of Chronic Kidney Disease and Nephrology, Sapporo, Japan; 5Osaka University Graduate School of Medicine, Department of Obstetrics and Gynecology, Osaka, Japan; 6Kochi Medical School, Department of Obstetrics and Gynecology, Kochi, Japan; 7Sapporo Medical University, Department of Obstetrics and Gynecology, Sapporo, Japan; 8Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama, Japan; 9Okayama University Hospital, Division of Hemodialysis and Apheresis, Okayama, Japan; 10Shimane University Faculty of Medicine, Department of Rheumatology, Izumo, Japan; 11Kyoto University, Department of Medicine, Department of Nephrology and Rheumatology, Kyoto, Japan; 12Tokyo Women's Medical University Hospital, Department of Rheumatology, Institute of Rheumatology, Tokyo, Japan

Background: Takayasu arteritis (TAK), a granulomatous large vessel vasculitis, mainly involves the aorta and its proximal branches and commonly occurs in young females. However, studies of pregnancy in women with TAK are sparse and limited, probably due to the rarity of the disease.

Objectives: The purpose of this study was to understand the status quo of medical treatments of the primary disease and outcomes of pregnancy in patients with TAK, and to post-birth consequences in Japan.

Methods: Patients with TAK who conceived after the onset of the disease and were managed at medical facilities participating in the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) were retrospectively enrolled in this study. The following information was collected from patients who had a live-born baby: age at diagnosis of TAK, disease classification, age at delivery, treatments before and during pregnancy, complications during pregnancy, birth outcomes of the children, and changes in disease activity during pregnancy and after delivery.

Results: Fifty-one cases and 69 pregnancies from 19 ethics committee-approved centers were enrolled during the study period 2019–2021. Of these, 49 cases and 66 pregnancies (95.7%) resulted in delivery and live-born babies. The Numano classification of the 49 cases was as follows: type I, 11; type IIa, 15; type IIb, 12; type III, 1; type IV, 1; type V, 6; with type V being the most common. The age of diagnosis was 22 years (13–37 years, year of diagnosis 1965–2017), the median age of the delivery of 66 pregnancies was 31 years (year of delivery 1969-2021), and the median duration of illness at delivery was nine years. There were 34 planned pregnancies (51.5%, including four pregnancies by artificial insemination/ovulation induction). Preconception therapy included prednisolone (PSL) in 51 pregnancies (77.3%, median dose 7.5 mg (range 4–30 mg/day)), immunosuppressive drugs in 18 pregnancies (27.3%, azathioprine 8, tacrolimus 7, methotrexate 4, cyclosporine A 1, and colchicine 1), biologics in 12 pregnancies (18.1%, infliximab 6, tocilizumab 5, and adalimumab 1), antihypertensive drugs in 5 pregnancies (7.6%). Surgical treatment had been performed before delivery in 6 cases (aortic root replacement 2, subclavian and carotid 1, subclavian 1, carotid 2, subclavian 1, and ascending aorta semicircular artery replacement 1). Medications used during the course of pregnancy included PSL in 48 pregnancies (72.7%, median dose 8 mg (range 4–30 mg/day), increased in 13 pregnancies, decreased in 1 pregnancy), immunosuppressants in 13 pregnancies (19.7%, azathioprine 6, tacrolimus 6, and cyclosporine A 1), biologics in 9 pregnancies (13.6%, infliximab 4, tocilizumab 4, and adalimumab 1), Immunosuppressants and biologics were discontinued in five and four cases during pregnancy, respectively. During pregnancy, birth outcomes of the children, and changes in disease activity during pregnancy and after delivery. One pregnancy resulted in restenosis of subclavian artery for which dilata-
tion procedure was performed prior to the pregnancy. There were 13/66 (19.7%)
preterm infants and 17/59 (28.8%) low birth weight infants; all but one had a birth weight of more than 2,000 g and no had serious postnatal abnormalities. Forty-three (82.7%) of the 52 confirmed infants were breastfed fully or mixed. Comorbidities: Most of the pregnancies in patients with TAK were successfully delivered while they had low disease activity at a dose of less than 10 mg/day of PSL. Relapse occurred during pregnancy and after delivery in some cases. The babies tended to have low birth weight, but 82.7% of them were breastfed without serious complications.


DaiichiSankyo Co., Ltd.


**Background:** Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries of southern Europe. GCA clinical manifestations can be divided into cranial, extracranial, and general syndrome.

**Objectives:** In a large series of GCA from Spain, we studied a) the incidence of GCA, b) clinical manifestations, and c) comorbidities at the time of disease diagnosis.

**Methods:** ARTESER is a retrospective epidemiological observational study of GCA promoted by the Spanish Society of Rheumatology in which 26 hospitals participate. The inclusion criteria were: all new patients diagnosed with GCA by a) ACR criteria, b) positive diagnostic test (temporal artery biopsy, temporal artery ultrason or other relevant imaging techniques) and/or c) investigator's clinical judgment. The patient recruitment period ranged from June 1, 2013 to March 29, 2019. The overall incidence of GCA per 100,000 people ≥50 years for the whole period and the mean annual incidence were evaluated. The clinical variables were collected by reviewing the patient’s medical history.

**Results:** 1675 patients were included. The average annual incidence rate was 7.42 (95% CI: 6.57-8.27). All the cases were older than 50 years, and the age group with the highest annual incidence was that of 80 to 84 years, where it reached a value of 22.63 (95% CI: 22.04-23.22). The mean annual incidence is higher in women than in men 10.07 (95% CI: 8.74-11.55) vs 4.81 (95% CI 3.84-5.93) (Table 1).

**Table 1. General characteristics, comorbidities and clinical manifestations**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Men</th>
<th>Women</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, n (%)</td>
<td>497 (29.7)</td>
<td>1178 (70.3)</td>
<td>1675</td>
</tr>
<tr>
<td>Age at diagnosis, years, mean (SD)</td>
<td>76.9 (8.3)</td>
<td>76.9 (8.0)</td>
<td>76.9 (8.1)</td>
</tr>
<tr>
<td>Diagnosis only by ACR Criteria</td>
<td>89 (17.31)</td>
<td>266 (22.58)</td>
<td>355 (21.19)</td>
</tr>
<tr>
<td>Diagnosis only with objective tests</td>
<td>73 (14.69)</td>
<td>140 (11.88)</td>
<td>213 (12.72)</td>
</tr>
<tr>
<td>Diagnosis ACR criteria + diagnosis objective</td>
<td>311 (62.58)</td>
<td>738 (62.31)</td>
<td>1045 (62.39)</td>
</tr>
<tr>
<td>Comorbidities at diagnosis objective tests</td>
<td>43 (24.8)</td>
<td>43 (32.2)</td>
<td>86 (32.7)</td>
</tr>
<tr>
<td>Extracranial manifestations and general syndrome</td>
<td>382 (76.9)</td>
<td>955 (81.1)</td>
<td>1337 (79.9)</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate mm/h</td>
<td>72.3 (34.7)</td>
<td>774 (30.0)</td>
<td>75.9 (33.6)</td>
</tr>
</tbody>
</table>

**The principal clinical characteristics of the population is shown in Table 1, the mean age at diagnosis was 76.9±8.1 years, 1178 (70.3%) were women. 1045 patients (62.39%) had ACR criteria and some positive objective test, 355 patients (21.9%) presented only ACR criteria and 213 (12.72%) only had a positive diagnostic test; 62 (3.7%) of the patients underwent diagnosis based on clinical judgment. The more frequent comorbidity was arterial hypertension (n=1079; 64.8%),**
followed by dyslipidemia (n=801, 48%). The predominant cranial manifestation was headache (n= 1337, 79.9%) and 605 patients experienced visual symptoms. The most widely used immunosuppressant was MTX both at diagnosis (n=165; 96.9%) and during follow-up (n=532; 31.8%), followed by TCZ, at diagnosis (22; 13%) and at follow-up (153; 9.1%). AE with GC were described in 393 patients (23.8%), highlighting serious infections (n=67; 10.03%) followed by diabetes mellitus (n=63; 9.43%), steroid myopathy (n=53; 7.9%), vertebral fractures (n=47; 7.04%), non-vertebral fractures (n=36; 5.39%), heart failure (n=36; 5.39%), arterial hypertension (n=34; 5.09%) and neuropsychiatric alterations (n=27; 4.04%). During the follow-up, 334 (19.9%) patients had relapses, 532 (31.8%) were hospitalized on some occasion, and 142 patients (8.48%) died. The main cause of death were infections (n=44; 30.99%), neoplasms (n=23; 16.2%), cardiovascular (n=15; 10.56%), and cerebrovascular (n=10; 7.04%).

Conclusion: The main treatment for GCA was oral GC, which were required for almost two years on average, in a quarter of patients associated with IV pulses. The cumulative steroid dose was high as well as the side effects. MTX was the most widely used immunosuppressant and TCZ was prescribed in 10%. Relapses and admissions at the hospital were relatively frequent.

Acknowledgements: This study has been funded by ROCHE Farma. The funder has not participated in the design, analysis, or interpretation of the results.
Disclosure of Interests: None declared

Results:

After 6 months’ treatment, no difference was observed in ER between two groups (LEF group: 31/35 (88.57%) vs. TOF group: 28/32 (87.50%), p=1.00). During 12 months’ treatment, the relapse rate was also comparable between two groups (LEF group: 6 (17.14%) vs. TOF group 7 (21.88%); p=0.76); ESR and CRP were decreased significantly at 6 (ESR: LEF group: p<0.0001; TOF group: p=0.15; CRP: LEF group: p=0.06; TOF group: p=0.06); 12 months (ESR: LEF group: p<0.0001; TOF group: p=0.06; CRP: LEF group: p=0.06; TOF group: p=0.14) in both groups compared with their corresponding baseline levels. The proportion of patients with imaging improvement after 12 months’ treatment were low in both groups (LEF group: 1 (2.86%) vs. TOF group: 3 (9.38%) p=0.17). After treatment, the doses of GCs were significantly reduced in both groups from the third month onwards compared with their corresponding baseline dose (p<0.05). Among patients with initial GCs dose ≥30mg/day, patients in TOF group gained a much lower daily GCs dose than that of LEF group at 9 months and 12 months (p<0.05). Furthermore, the frequency of side effects was higher in LEF group than that of TOF group (12/33, 34.29%, vs. 3/33, 9.38%; p=0.02).

Conclusion: LEF and TOF have comparable treatment effects for patients with TAK. However, TOF is superior to LEF in GCs tapering and safety profile.

REFERENCES:


POS0798 NUMAN0 TYPE IBII, INFLAMMATORY PROGRESSION OF DISEASE AND DILATION OF ASCENDING AORTA AND AORTIC ROOT ARE IMPORTANT RISK FACTORS CAUSING AORTIC VALVE INVOLVEMENT IN TA PATIENTS.

X. Shi1, 1Beijing Anzhen Hospital, Rheumatology, Beijing, China

Background: Takayasu arteritis (TA) can involve cardiac valves. In Chinese patients with TA, valvarular abnormalities were found in 48.9% (201/411) patients[1,2]. Another research showed that cardiac valvarular involvements were found in 34.9% (373/1069) TA patients in China[3], and in a recent study, they also found that 64.08% (66/103) of TA patients had valvular damage[4]. In addition, the most common valve involved in TA is the aortic valve, and the most common valvular lesion caused by TA is valvular insufficiency. The incidence of aortic regurgitation in patients with TA has been reported as 33.2% (455/1372) in Japan[5], 21.7% (13/60) in Italy[6], 18.1% (29/160) in Korea[7], and 20.4% (44/214)[1] to 39.8% (41/103)[4] in China. AR can further induce congestive heart failure or arrhythmia, both of which are considered one of the main causes of death in TA patients[8].

Objectives: Aortic valve involve is not uncommon in patients with Takayasu arteritis (TA). The aim of our study was to evaluate the clinical characteristics of aortic valve involvement in TA patients, and to explore the risk factors of aortic valve involvement in TA.

Methods: In this retrospective study, 174 patients with TA were divided into groups with or without aortic valve involvement. We compared the clinical manifestations, laboratory parameters, and imaging results between the two groups.

Results: In our study, a total of 94 TA patients (54.02%) had aortic valvarular lesion. The proportion of elevated ESR and elevated high-sensitivity CRP, and ITAS-A score in the aortic valve involvement group were significantly higher than in the non-aortic valve involvement group. 2 patients were found to have the infiltration of inflammatory cells in surgical specimens of the aortic valve. The Numano type Iib and elevated hs-CRP level were found to be statistically correlated with aortic valvular lesion in TA patients. 6 (853 [1685-27875], p=0.007; 4.896 [1646-14561], p=0.004). Dilation of the ascending aorta and aortic root were significantly associated with aortic valvular involvement in TA patients (4.509 [1517-13403], p=0.007; 9.340 [2188-39875], p=0.003).

Conclusion: The Numano type Iib, elevated hs-CRP level, dilation of the ascending aorta and aortic root are risk factors for aortic valve involvement in TA patients.

REFERENCES:


Disclosure of Interests: None declared


POS0799 BIOMARKER CHANGES IN TAKAYASU ARTERITIS AFTER TOFACITINIB TREATMENT AND THE MOLECULAR SIGNATURE ASSOCIATED WITH DISEASE CHARACTERISTICS

X. Dai1, L. Wang1, S. Wu1, J. Wang1, Y. Sun1, Z. Ji1, L. MA1, X. Dai1, H. Chen1, L. MA1, X. Kong1, L. Jiang1, Zhongshan Hospital, Fudan University, Department of Rheumatology, Shanghai, China

Background: Takayasu’s arteritis (TAK) is a chronic, non-specific, granulomatous macrovasculitis and its pathogenesis is still unclear. The increasing evidence indicated that multiple pathological process involved in the development of TAK. According to previous reports, multiple biomarkers represent different pathological process (1-3). However, which biomarker can closely reflect disease activity or vascular changes and whether these abnormal processes can be prevented by current therapies remained unknown.

Objectives: To analyze changes of serum cytokine, chemokine, and growth factor profiles in patients with Takayasu arteritis (TAK) after tofacitinib treatment and explore potential molecular signatures related with various disease characteristics.

Methods: Seventeen patients from a TAK cohort treated with tofacitinib and 12 healthy controls were recruited in this study. Potential biomarkers with TAK including cytokines, MMPs, chemokines and growth factors were detected in these patients (0, 6, 12 months) and healthy controls. Molecular changes, disease activity, disease remission, and vascular imaging changes were analyzed in these patients after treatment. Furthermore, molecular signatures associated with these clinical features/outcomes were explored via radar plot and correlation analysis.

Results: At baseline, all the patients were in active status. Meanwhile, patients’ cytokines (PTX3, IL-6, IFN-γ), chemokines (IL-16, CCL22, CCL2), growth factor (VEGF) and MMP9 were significantly higher than those of healthy controls (all p<0.05), while FGF-2 was significantly lower in patients with TAK (p=0.02). After treatment, 94.12% of patients achieved complete remission at 6 and 12 months; patients’ ESR and CRP levels were significantly reduced at 6 months (p<0.05), and vascular improvement was observed in 6 (35.29%) patients at 12 months. With regards to these molecules, IL-10 was increased at 6 months compared with its baseline level (p=0.007). No changes were observed in other cytokines, chemokines, or growth factors. Besides, the radar plot demonstrated that PTX3 was closely related with disease activity. In addition, patients with vascular imaging improvement had relatively higher baseline levels of TNFα, ESR, and CRP (p=0.04, p=0.05 and p=0.07, respectively), lower CCL22, FGF, and PDGF-AB levels (p=0.056, p=0.06 and p=0.08 respectively) compared with patients without it.

Conclusion: Multiple molecules representative different pathological mechanism participated in the pathogenesis of TAK. PTX3 was a prominent marker for disease activity, and CCL22 may have a predictive value for vascular imaging changes.

REFERENCES:

Background: The most frequent form of vasculitis in elderly people is giant cell arteritis (GCA) with an annual incidence rate less than 10 per 100,000 persons over the age of 50. Like most vasculitides, GCA is characterized by chronicity and relapses, leading to significant overall morbidity and high mortality in a subset of patients with aortic or central nervous involvement. After being diagnosed with vasculitis or who have changed their treatment due to a recent relapse (inception cohort). The GeVas-Registry allows a long-term follow-up of a substantial cohort of vasculitis patients in a prospective and multicenter manner. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC Rheumatol. 2021 Jul 31;5(1):40. doi: 10.1186/s41927-021-00206-2.

Methods: GeVas is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term outcomes, and therapy regimens in various types of vasculitis. Recruitment started in June 2019. By January 2022, 17 centers in Germany were initiated and have begun enrolling patients. Meanwhile, more than 350 patients have been documented in 2019. By January 2022, 17 centers in Germany were initiated and have begun enrolling patients. Meanwhile, more than 350 patients have been documented so far. The participating centers recruited 131 GCA patients into the registry. 21.7% of patients (n=28) were enrolled in the registry by mid-October 2021. The most frequent form of vasculitis in elderly people is giant cell arteritis (GCA) with an annual incidence rate less than 10 per 100,000 persons over the age of 50. Like most vasculitides, GCA is characterized by chronicity and relapses, leading to significant overall morbidity and high mortality in a subset of patients with aortic or central nervous involvement. After being diagnosed with vasculitis or who have changed their treatment due to a recent relapse (inception cohort). The GeVas-Registry allows a long-term follow-up of a substantial cohort of vasculitis patients in a prospective and multicenter manner. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC Rheumatol. 2021 Jul 31;5(1):40. doi: 10.1186/s41927-021-00206-2.

Results: By mid-October 2021, the participating centers recruited 131 GCA patients into the registry. 21.7% of patients (n=28) were enrolled in the registry by mid-October 2021. The most frequent form of vasculitis in elderly people is giant cell arteritis (GCA) with an annual incidence rate less than 10 per 100,000 persons over the age of 50. Like most vasculitides, GCA is characterized by chronicity and relapses, leading to significant overall morbidity and high mortality in a subset of patients with aortic or central nervous involvement. After being diagnosed with vasculitis or who have changed their treatment due to a recent relapse (inception cohort). The GeVas-Registry allows a long-term follow-up of a substantial cohort of vasculitis patients in a prospective and multicenter manner. The Joint Vasculitis Registry in German-speaking countries (GeVas) – a prospective, multicenter registry for the follow-up of long-term outcomes in vasculitis. BMC Rheumatol. 2021 Jul 31;5(1):40. doi: 10.1186/s41927-021-00206-2.

Acknowledgements: GeVas was supported by unrestricted grants by: DGRh, John Grube Foundation, Vifor and Roche Pharma


POS0801 VISUAL INVOLVEMENT AND PERMANENT VISUAL LOSS IN GIANT CELL ARTERITIS: PREDICTIVE FACTORS

In the same line, the set of variables associated with PVL were headache, and jaw claudication. By contrast, polymyalgia rheumatica (PmR), and large-vessel involvement were protective factors (Figure 1). The AUC for this model was 0.77 (95%CI 0.71-0.83; p<0.0001).

Conclusion: Headache, and jaw claudication seem to be associated with visual involvement in GCA, while large vessel involvement seems to be a protective factor. PmR also appears to be a protective factor for the development of PVL.

REFERENCES:

Acknowledgements: Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group.

Disclosure of Interests: Lara Sanchez-Bilbao: None declared, Javier Loriceria Speakers bureau: Roche, Novartis, UCB Pharma, Celgene, and Grünenthal, Clara Moriano: None declared, Santos Cañada Speakers bureau: UCB, CPR, Rashida Meleiro: None declared, Olga Maiz: None declared, Rafael Melero: None declared, Igancio Villa-Bilbao: None declared, Paloma Vela-Casasempere: None declared, Susana Romero-Yuste: None declared, Jose Luis Callejas-Rubio: None declared, Eugenio de Miguel: None declared, Edgar Galíndez-Agirregoikoa: None declared, Francisca Sivera: None declared, Carlos Fernández-López: None declared, Carlos Galisteo: None declared, Galisteo Vela-Casasempere: None declared, Susana Romero-Yuste: None declared, Julio Sanchez-Marin: None declared, Monica Calderón-Goercke: None declared, J. Luis Hernández: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, and MSD., Grant/research support from: AbbVie, MSD, Jansen, and Roche., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Lilly, and MSD., Grant/research support from: Abbvie, MSD, Jansen, and Roche.

Relevant adverse events were observed in 12 per 100 patients-year. A corticosteroid-sparing effect was observed from month 1 of TCZ onset in 100% of patients reached a sustained remission, that was progressively increasing. (Figgia rheumatica, constitutional syndrome and headache were the most frequent symptoms at TCZ onset). Maintained remission was considered according to EULAR definitions (5).

**Methods**: Multicenter observational study of 196 patients with GCA and involvement of the aorta and/or its major branches treated with TCZ. GCA was diagnosed by: a) ACR criteria, and/or b) temporal artery biopsy, or c) imaging techniques. The presence of aortitis was performed by imaging techniques, mainly PET, and A-MRI.

**Results**: The main features of the 196 patients are showed in Table 1. Polymyalgia rheumatica, constitutional syndrome and headache were the most frequent clinical manifestations at TCZ onset. At 6 months after starting TCZ, 20% of the patients reached a sustained remission, that was progressively increasing (Figure 1). A corticosteroid-sparing effect was observed from month 1 of TCZ onset (Figure 1). Relevant adverse events were observed in 12 per 100 patients-year, documenting serious infections in 4.8 per 100 patients-year (Table 1).

**Table 1. Main features of 196 GCA patients with involvement of the aorta and/or its main branches treated with TCZ.**

<table>
<thead>
<tr>
<th>Features at TCZ onset</th>
<th>GCA (n=196)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(years), means±SD</td>
<td>71.3±9.5</td>
</tr>
<tr>
<td>Sex, female/male (% female)</td>
<td>148/48 (75)</td>
</tr>
<tr>
<td>Time from GCA diagnosis to TCZ onset (months), median (IQR)</td>
<td>7 [2-18.25]</td>
</tr>
<tr>
<td>Systemic manifestations, n (%)</td>
<td>24 (12)</td>
</tr>
<tr>
<td>Constitutional syndrome, n (%)</td>
<td>87 (44)</td>
</tr>
<tr>
<td>Pain, n (%)</td>
<td>131 (67)</td>
</tr>
<tr>
<td>Ischemic manifestations, n (%)</td>
<td>16 (8)</td>
</tr>
<tr>
<td>Visual involvement, n (%)</td>
<td>74 (38)</td>
</tr>
<tr>
<td>Headache, n (%)</td>
<td>27 (14)</td>
</tr>
<tr>
<td>Laboratory data</td>
<td></td>
</tr>
<tr>
<td>ESR, mm 1st hour, median (IQR)</td>
<td>32 [14-54]</td>
</tr>
<tr>
<td>CRP, mg/dL, median (IQR)</td>
<td>5.5 [3-6.5]</td>
</tr>
<tr>
<td>Prednisone dose, mg/day, median (IQR)</td>
<td>15 [10-30]</td>
</tr>
<tr>
<td>Safety after TCZ onset</td>
<td></td>
</tr>
<tr>
<td>Relevant adverse events, per 100 patients-year</td>
<td>12</td>
</tr>
<tr>
<td>Serious infections, per 100 patients-year</td>
<td>4.8</td>
</tr>
</tbody>
</table>

**Conclusion**: Sustained remission, and a median prednisone dose required in GCA patients with aortitis treated with tocilizumab


**Disclosure of Interests**: None declared, Javier Loriceria Speakers bureau: from Roche, Novartis, UCB Pharma, Celgene, and Grünenthal, Rafael Meler: None declared, Santos Castañeda Speakers bureau: UAM-Roche, EPID - Future chair, Department of Medicine, Universidad Autónoma de Madrid, Madrid, Spain., Clara Moriano: None declared, Iván Ferraz-Amaro: None declared, J. Narváez: None declared, Vicente Aldasoro: None declared, Olga Maiz: None declared, Ignacio Villa-Blanco: None declared, Paloma Vela-Cassampeere: None declared, Susana Romero-Yuste: None declared, Jose Luis Callejas-Rubio: None declared, Eugenio de Miguel: None declared, E. Galindez-Agirrekoika: None declared, Francisca Sivera: None declared, Carlos Fernández-López: None declared, Carlos Galisteo: None declared, Julio Sanchez-Martín: None declared, Monica Calderón-Goercke: None declared, J. Luis Hernández: None declared, Miguel A Gonzalez-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene, and MSD., Grant/research support from Abbvie, Roche, MSD, Janssen, and Roche., Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Lilly, Janssen, and MSD., Grant/research support from: Abbvie, MSD, and Roche.

Disclosure of Interests: None declared


POS084

TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY

D. Prieto-Peña1, J. Loricera1, S. Castañeda2, C. Moriano2, P. Bernabéu3, P. Vela-Casasempere4, J. Narváez5, V. Aldaño6, O. Maiz7, C. Fernández-López8, M. Freire González9, R. Meleró10, I. Villa-Blanco10, B. González-Alvarez10, R. Solanas-Laquí11, J. L. Callejas-Rubio12, C. Fernández-Díaz13, E. Rubio Romero14, S. García Morillo15, M. Mingué15, C. Fernández-Carbajalillo16, E. De Miguel17, J. Sanchez-Martín18, E. Fernández19, S. Melchor20, E. Salgado-Pérez21, B. Bravo21, S. Romero-Yuste22, E. Galán-Agirretagolka23, F. Sivera23, I. Ferraz-Amaro24, C. Hidalgo25, C. Romero-Gómez26, C. Gallisto27, P. Moya28, N. Álvarez-Rivas29, J. Mendizábal30, J. C. Nieto González30, J. A. De Canarias, Rheumatology, Tenerife, Spain; Hospital Universitario de La Princesa, Rheumatology, Madrid, Spain; Hospital Universitario de Donostia, Rheumatology, San Sebastián, Spain; Complejo Universitario de A Coruña, Rheumatology, A Coruña, Spain; Complejo de Salamanca, Rheumatology, Salamanca, Spain; Hospital Regional de Málaga, Rheumatology, Málaga, Spain; Hospital Parc Taulí, Rheumatology, Sabadell, Spain; Hospital Sant Pau, Rheumatology, Barcelona, Spain; Hospital Universitario San Agustín, Rheumatology, Avilés, Spain; Hospital Gregorio Marañón, Rheumatology, Madrid, Spain; Hospital de Araba, Rheumatology, Mondragón, Spain; Hospital Puerta de Hierro, Rheumatology, Madrid, Spain; Hospital Carlos Haya, Rheumatology, Málaga, Spain; Hospital Ramón y Cajal, Rheumatology, Madrid, Spain; Hospital Universitario de Burgos, Rheumatology, Burgos, Spain; Hospital Universitario Reina Sofía, Rheumatology, Córdoba, Spain; Hospital Clínico Universitario de Valencia, Rheumatology, Valencia, Spain; Hospital Arnau de Vilanova, Rheumatology, Valencia, Spain; Hospital San Pedro, Rheumatology, Logroño, Spain; Hospital Universitario y Politécnico La Fe, Rheumatology, Valencia, Spain; Complejo Asistencial Palencia, Rheumatology, Palencia, Spain; Hospital Universitario de Badajoz, Rheumatology, Badajoz, Spain; Hospital Lucus Augusti, Rheumatology, Lugo, Spain; Hospital Universitario Central de Asturias, Internal Medicine, Oviedo, Spain; Complejo Hospitalario de Zamora, Rheumatology, Zamora, Spain; Hospital Severo Ochoa, Rheumatology, Madrid, Spain; Hospital General de Elche, Rheumatology, Elche, Spain; Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Spain; Hospital de Cabueñes, Rheumatology, Gijón, Spain; Hospital de Valme, Rheumatology, Sevilla, Spain; Consorci General de València, Rheumatology, Valencia, Spain; Hospital Doctor Negrín, Rheumatology, Gran Canaria, Spain; Hospital Universitario de Castellón, Rheumatology, Castellón, Spain

Background: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-3). However, LVG-GCA and TAK show different demographic and clinical features that may influence on TCZ therapeutic response.

Objectives: To compare the effectiveness of TCZ in patients with LVG-GCA and patients with TAK.

Methods: Observational multicenter study of patients with LVG-GCA and TAK who received TCZ. Outcome variables were: a) proportion of patients who achieved complete clinical improvement along with normalization of laboratory markers (CRP ≤ 0.5mg/dL and/or ESR ≤ 20mm/1st hour) at 12 months b) complete improvement in imaging techniques. A comparative study between patients with LVG-GCA and TAK was performed.

Results: We evaluated 70 LVG-GCA and 57 TAK patients who received TCZ. Main clinical and demographic characteristic are described in Table 1. Patients with TAK were younger, had longer disease duration, had received more commonly previous biologic therapy and were receiving higher doses of prednisone at baseline. TCZ intravenous administration was more common in TAK patients (80.7% vs 48.6%; p<0.01). Follow-up time after TCZ onset was similar in both groups. At 12 months, about 75% of patients achieved complete clinical improvement and ESR/CRP normalization in both groups. A follow-up imaging technique was performed in 37 LVG-GCA patients after a mean time of 12.9±6.0 months and 38 TAK patients after 9.5±5.0 months. Complete improvement in imaging techniques was only observed in 18.9% and 21.1% of patients with LVG-GCA and TAK, respectively (Figure 1).

Table 1.

<table>
<thead>
<tr>
<th>LVG-GCA</th>
<th>TAK</th>
</tr>
</thead>
<tbody>
<tr>
<td>patients (n=70)</td>
<td>(n=57)</td>
</tr>
<tr>
<td>General features</td>
<td>p</td>
</tr>
<tr>
<td>Age (years), mean ± SD</td>
<td>67.2 ± 10.5</td>
</tr>
<tr>
<td>Sex (female), n (%)</td>
<td>51 (72.9)</td>
</tr>
<tr>
<td>Disease evolution before TCZ onset (months), median (IQR)</td>
<td>5 [2-15]</td>
</tr>
<tr>
<td>Baseline laboratory parameters</td>
<td></td>
</tr>
<tr>
<td>ESR (mm/1st hour), median (IQR)</td>
<td>32 [12.5-54.7]</td>
</tr>
<tr>
<td>CRP (mg/dL), median (IQR)</td>
<td>1.4 [0.5-2.4]</td>
</tr>
<tr>
<td>Baseline prednisone dose (mg/day), median (IQR)</td>
<td>15 [10-20]</td>
</tr>
<tr>
<td>Previous therapy</td>
<td></td>
</tr>
<tr>
<td>Conventional DMARDs, n (%)</td>
<td>45 (64.3)</td>
</tr>
<tr>
<td>Biologic therapy, n (%)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>TCZ therapy</td>
<td></td>
</tr>
<tr>
<td>Intravenous, n (%)</td>
<td>34 (48.6)</td>
</tr>
<tr>
<td>Combined with MTX, n (%)</td>
<td>24 (34.3)</td>
</tr>
<tr>
<td>Follow-up time after TCZ onset, median (IQR)</td>
<td>20 [10-36]</td>
</tr>
<tr>
<td>Complete clinical improvement and ESR/CRP normalization at 12 months, n (%)</td>
<td>35/47 (74.4)</td>
</tr>
<tr>
<td>Complete improvement in imaging techniques, n(%)</td>
<td>7/37 (18.9)</td>
</tr>
</tbody>
</table>

Figure 1.

Conclusion: The effectiveness of TCZ was similar in TAK to LVG-GCA and TAK, despite a more refractory disease in TAK patients. A discordance between clinical and imaging activity improvement was observed in both LVG-GCA and TAK, as reported in previous studies (5).

REFERENCES

POS005

GLUCOCORTICOID-RELATED ADVERSE EVENTS IN GIANT CELL ARTERITIS: APPLICATION OF THE GLUCOCORTICOID TOXICITY INDEX IN A MONOCENTRIC COHORT OF 140 PATIENTS

F. Regola1,2, J. Mora1, G. Bosio3, L. Andreoli1,2, F. Franceschini1,2, P. Toniati2.

1University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy; 2ASST-Spedali Civili di Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 3ASST-Spedali Civili di Brescia, Nuclear Medicine Unit, Brescia, Italy

Background: Oral glucocorticoids (GC) are the mainstay of treatment for giant cell arteritis (GCA) but chronic exposure to GC is associated with serious comorbidities.

Objectives: The objective of this study was to determine the GC exposure and risk of GC-related adverse events (AEs) in GCA, validating the Glucocorticoid Toxicity Index (GTI) in a cohort of real-world patients.

Methods: 140 consecutive patients with GCA were enrolled in this retrospective monocentric study. All patients were older than 50 years of age, met the 1990 ACR criteria for GCA and/or had the evidence of a large vessel vasculitis at FDG-PET/CT scan. Patients' clinical data were collected from clinical charts, calculating GC cumulative dose and GTI at baseline and in the following 5 years.

Results: 140 patients were enrolled in the study: median (iQR) age at diagnosis 74 (67-79), Female: 97 (69%), Male: 43 (31%). According to vascular involvement patients were classified in cranial-GCA (C-GCA, n:91), large vessel-GCA (LV-GCA, n:29), and cranial and large vessel-GCA (UV-GCA, n:28). Furthermore, 50 (36%) patients were treated with only GC, 44 (31%) with GC+mouthwash (MTX), 46 (33%) with GC+tocilizumab (TCZ) in (20 cases TCZ was started in the first 3 months after diagnosis: early-TCZ, in 26 cases after 3 months for relapses or AEs: late-TCZ).

During the follow up, 57 (41%) patients presented at least one relapse. In the GC group 22 relapses in 18 patients were reported, in MTX group 33 relapses in 25 patients (with 15 relapses before and 18 after MTX start), in early-TCZ group no relapses were reported, in late-TCZ group 21 relapses in 14 patients (with 17 relapses before and 4 after TCZ start) were reported.

Median cumulative GC doses after 1 and 5 years were respectively 7.9 (6.3-9.8) gr and 16.5 (13.8-18.9) gr in GC group, 8.7 (5.9-10.0) gr and 16.5 (13.2-20.7) gr in MTX group, 7.1 (5.5-8.0) gr and 13.3 (12.8-13.7) gr in early-TCZ and 7.7 (6.2-11.1) gr and 19.7 (12.2-23.8) gr in late-TCZ. Eighty-eight percent of patients treated at least one GC-AE, with infections and hypertension being the most common reported AEs (42% e 44%, respectively). Median GTI-CTS (Cumulative Worsening Score) after 1 year was 65 (20-137) in GC, 63 (10-95) in MTX, 51 (33-116) in TCZ-early, 44 (0-91) in TCZ-late. Median GTI-CWS and the GC cumulative dose was found (after 5 years: r: 0.295, p: 0.026).

Conclusion: Chronic GC treatment is associated with a high risk of developing comorbidities. GTI score demonstrated to be an effective tool to assess GC-related AEs and proved to correlate with GC cumulative dose. TCZ confirmed its efficacy in reducing relapse rate, both in early and late-TCZ groups (3), TCZ showed for the first time in a real-life cohort a GC sparing effect, with a 19% reduction in GC cumulative dose and a 33% reduction in GTI-CWS in 5 years (comparing GC group vs early-TCZ group).

REFERENCES:
[1] Glucocorticoid Toxicity Index (Copyright © 2016, 2018. Massachusetts General Hospital. All rights reserved.)

Disclosure of Interests: None declared


POS006

OPTIMIZATION OF TOCILIZUMAB THERAPY IN GIANT CELL ARTERITIS: A MULTICENTER REAL-LIFE STUDY OF 471 PATIENTS


behalf of Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group.

1Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain; 2Complejo Asistencial Universitario de León, Rheumatology, León, Spain; 3Hospital Universitario de La Princesa, Rheumatology, Madrid, Spain; 4Hospital Universitario de Bellvitge, Rheumatology, Barcelona, Spain; 5Complejo Hospitalario de Navarra, Rheumatology, Pamplona, Spain; 6Hospital Universitario de Donostia, Rheumatology, San Sebastián, Spain; 7Complejo Hospitalario Universitario de Vigo, Rheumatology, Vigo, Spain; 8Hospital Universitario de Rioja, Rheumatology, Logroño, Spain; 9Complejo Hospitalario Universitario de Pontevedra, Rheumatology, Pontevedra, Spain; 10Hospital Universitario San Cecilio, Rheumatology, Granada, Spain; 11Hospital La Paz, Madrid, Madrid, Spain; 12Hospital Universitario Basurto, Rheumatology, Bilbao, Spain; 13Hospital Universitario de Elda, Rheumatology, Elda, Spain; 14Complejo Hospitalario Universitario de A Coruña, Rheumatology, A Coruña, Spain; 15Hospital Parc Taulí, Rheumatology, Barcelona, Spain; 16Complejo Hospitalario Universitario de Canarias, Rheumatology, San Cristóbal de la Laguna, Spain; 17Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain; 18Hospital Universitario Marqués de Valdecilla, Internal Medicine, Santander, Spain

Background: Tocilizumab (TCZ) has shown to be useful in the treatment of large-vessel vasculitis, including giant cell arteritis (GCA) (1-4). There is general agreement on the initial and the standard maintenance dose of TCZ. However, information on duration and optimization of TCZ in GCA is really scarce.

Objectives: Our aim was to assess the effectiveness and safety of TCZ therapy optimization in an unselected wide series of GCA in real-world clinical practice.

Methods: Multicenter study on 471 patients with GCA who received TCZ therapy. Once complete remission was reached (n=231) TCZ was optimized in 125 patients. We compared patients in whom TCZ was optimized (TCZopt group) or not (TCZnon-opt group). Complete remission was defined as normalization of clinical and analytical (CRP and ESR) data. Optimization was done by decreasing the dose and/or prolonging the TCZ dosing interval progressively. We performed a comparison in effectiveness and safety parameters between optimized and non-optimized patients.

Results: We evaluated 231 GCA patients treated with TCZ with complete remission. No demographic or laboratory data differences was observed at TCZ onset between both groups (Table 1). The mean prednisone dose was higher in the TCZnon-opt group at TCZ onset. The first TCZ optimization was performed after a median [25-75th] follow-up of 12 [6-17] months.

Table 1. Main general features at TCZ onset of 231 GCA patients with prolonged remission.

<table>
<thead>
<tr>
<th></th>
<th>OPTIMIZED-TCZ GROUP (n=125)</th>
<th>NON-OPTIMIZED TCZ GROUP (n=106)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>GENERAL FEATURES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years; SD</td>
<td>72.7±8.6</td>
<td>74±7</td>
<td>0.197</td>
</tr>
<tr>
<td>Sex; female/male (n (%)</td>
<td>91/34 (65)</td>
<td>107/62 (63)</td>
<td>0.325</td>
</tr>
<tr>
<td>CRP: C-reactive protein</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mg/dl (SD)</td>
<td>39.1±29.3</td>
<td>37±30</td>
<td>0.334</td>
</tr>
<tr>
<td>ESR: erythrocyte sedimentation rate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mm/1st hour; mean (SD)</td>
<td>62 (58.5)</td>
<td>68 (61)</td>
<td>0.386</td>
</tr>
<tr>
<td>JAW: jaw claudication, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24 (31%)</td>
<td>25 (32%)</td>
<td>0.524</td>
<td></td>
</tr>
<tr>
<td>AORTITIS: (large-vessel involvement), n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65 (52)</td>
<td>42 (39.6)</td>
<td>0.060</td>
<td></td>
</tr>
<tr>
<td>ANALYTICAL FINDINGS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/dl, mean (SD)</td>
<td>2.6±3.4</td>
<td>2.7±3.4</td>
<td>0.305</td>
</tr>
<tr>
<td>Hb: hemoglobin, g/dl, mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13±5.9</td>
<td>12.9±15.1</td>
<td>0.153</td>
<td></td>
</tr>
</tbody>
</table>

References:
[1] Glucocorticoid Toxicity Index (Copyright © 2016, 2018. Massachusetts General Hospital. All rights reserved.)

Disclosure of Interests: None declared


Scientific Abstracts
Objectives: To investigate disease manifestations during pregnancy and adverse pregnancy outcomes (APOs) in female patients with BS. Methods: In this single centre study, 110 voluntary women who had long-term follow-ups in Ankara University Multidisciplinary Behçet outpatient clinic and their 323 pregnancies were evaluated. Patients were interviewed about their previous pregnancies. As 238 of 323 (73.6%) pregnancies were before BS diagnosis and additional 13 pregnancies were terminated due to family planning, we evaluated disease manifestations and APOs of 72 pregnancies. APOs were defined as spontaneous abortion, IUGR-SGA, gestational diabetes mellitus (GDM), macrosomia, Rh incompatibility, colchicine toxicity, and cesarean section. GCA was diagnosed based on the 1990 American College of Rheumatology classification criteria. Azathioprine was used in 2 (2.7%) pregnancies, which resulted in termination and spontaneous abortion. Conclusion: In this study, we found that APOs occurred in almost half of BS patients and colchicine use seemed to be safe throughout pregnancy. Some BS manifestations exacerbated and even occurred de novo during pregnancies. Prospective studies are needed to reveal the effects of BS and drugs on pregnancy.

Disclosure of Interests: Carmen Álvarez-Reguera: None declared, Mona Calderón-Goercke: None declared, J. Loricer: None declared, Clara Moriano: None declared, Santos Castañeda: None declared, J. Narváez: None declared, Vicente Alidoso: None declared, Olga Maiz: None declared, Rafael Melero: None declared, Ignacio Villa-Blanco: None declared, Paloma Vela-Casasempere: None declared, Susana Romero-Yuste: None declared, Jose Luis Callejas-Rubio: None declared, Eugenio de Miguel: None declared, E. Galíndez-Agirregoikoa: None declared, Francisca Sivera: None declared, Carlos Fernández-López: None declared, Carles Galisteo: None declared, Iván Ferráz-Amaro: None declared, Julio Sanchez-Martin: None declared, Sara Sanchez-Bibiano: None declared, Migel Á. González-Gay Consultant of: Abbvie, Pfizer, Roche, Sanofi and MSD., Grant/research support from: Abbvie, MSD, Jansen and Roche., Ricardo Blanco Consultant of: Abbvie, MSD, Roche, Bristol-Myers, Jansen, Lilly and MSD, Grant/research support from: Abbvie, MSD and Roche.

References:

Table 1. The characteristics of pregnancies with and without APOs

<table>
<thead>
<tr>
<th>Pregnancy—with—Pregnancy</th>
<th>n=42</th>
<th>n=30</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational age, years</td>
<td>24.4 (5.6)</td>
<td>24.6 (5.9)</td>
<td>0.85</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>65 (10.4)</td>
<td>79 (10.3)</td>
<td>0.21</td>
</tr>
<tr>
<td>APOs and other complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spontaneous abortion, n(%)</td>
<td>4 (13.3%)</td>
<td>4 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>IUGR-SGA, n(%)</td>
<td>4 (10.0%)</td>
<td>5 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>Preeclampsia, n(%)</td>
<td>7 (16.7%)</td>
<td>7 (16.7%)</td>
<td></td>
</tr>
<tr>
<td>PROM, n(%)</td>
<td>8 (19.0%)</td>
<td>10 (33.3%)</td>
<td></td>
</tr>
<tr>
<td>Termination due to terato-gens, n(%)</td>
<td>4 (13.3%)</td>
<td>4 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>Trombosis, n(%)</td>
<td>2 (6.7%)</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>GDM, n(%)</td>
<td>3 (10.0%)</td>
<td>3 (10.0%)</td>
<td></td>
</tr>
<tr>
<td>Macrosomia, n(%)</td>
<td>4 (13.3%)</td>
<td>4 (13.3%)</td>
<td></td>
</tr>
<tr>
<td>Rh incompatibility, n(%)</td>
<td>3 (10.0%)</td>
<td>3 (10.0%)</td>
<td></td>
</tr>
<tr>
<td>Colchicine, n(%)</td>
<td>8 (26.7%)</td>
<td>8 (26.7%)</td>
<td></td>
</tr>
<tr>
<td>Azathioprine n(%)</td>
<td>2 (6.7%)</td>
<td>2 (6.7%)</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids, n(%)</td>
<td>3 (10.0%)</td>
<td>3 (10.0%)</td>
<td></td>
</tr>
<tr>
<td>Neonatal outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median birth week, median (Q1-Q3)*</td>
<td>38.0</td>
<td>38.0</td>
<td>0.001</td>
</tr>
<tr>
<td>3445.0</td>
<td>2850.0</td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>Median birth weight, grams (Q1-Q3)**</td>
<td>(38.0-40.0)</td>
<td>(33.5-39.0)</td>
<td></td>
</tr>
<tr>
<td>3213.9-3600.0</td>
<td>2500.0-3700.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SD=Standard Deviation*Calculations were done in 42 pregnancies of the group without APOs and in 26 pregnancies of the group with APOs**Calculations were done in 40 pregnancies of the group without APOs and in 21 pregnancies of the group with APOs.
Methods:

Objectives: The leading symptoms at relapse are headache and fatigue, while loss of vision is rare (0.78%). Baseline characteristics seem to be poorly informative about the risk of relapse, therefore regular monitoring of GCA patients is necessary.

Conclusion: About one fourth of GCA patients relapsed and the overwhelming majority of relapses occurred before patients were able to stop glucocorticoids. The leading symptoms at relapse are headache and fatigue, while loss of vision is rare (0.78%). Baseline characteristics seem to be poorly informative about the risk of relapse, therefore regular monitoring of GCA patients is necessary.

Disclosure of Interests: None declared


Table 1.

<table>
<thead>
<tr>
<th>Symptom at disease onset</th>
<th>N=395 (%)</th>
<th>Symptom at relapse</th>
<th>N=97 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>35 (34.7)</td>
<td>Headache</td>
<td>35 (30.7)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>34 (34.7)</td>
<td>Fatigue</td>
<td>19 (16.7)</td>
</tr>
<tr>
<td>Polyarthalgia (PMR)</td>
<td>14 (35.4)</td>
<td>Vision impairment</td>
<td>13 (11.4)</td>
</tr>
<tr>
<td>Night sweats</td>
<td>15 (36.5)</td>
<td>Night sweats</td>
<td>12 (15.0)</td>
</tr>
<tr>
<td>Headache in the temple area</td>
<td>18 (46.1)</td>
<td>Headache in the temple area</td>
<td>12 (15.0)</td>
</tr>
<tr>
<td>Jaw pain</td>
<td>12 (30.6)</td>
<td>Jaw pain</td>
<td>11 (9.6)</td>
</tr>
<tr>
<td>Vision impairment</td>
<td>9 (23.1)</td>
<td>Vision impairment</td>
<td>7 (6.1)</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>59 (15.0)</td>
<td>Weight loss</td>
<td>7 (6.1)</td>
</tr>
<tr>
<td>Fever</td>
<td>9 (23.1)</td>
<td>Claudication upper limb</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Swollen temporal arteries</td>
<td>27 (68.6)</td>
<td>Arthralgia</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Vision loss</td>
<td>23 (57.7)</td>
<td>Claudication lower limb</td>
<td>5 (4.4)</td>
</tr>
<tr>
<td>Scalp tenderness</td>
<td>18 (46.1)</td>
<td>Scalp tenderness</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Claudication lower limb</td>
<td>14 (35.4)</td>
<td>Arthralgia</td>
<td>3 (2.6)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>11 (28.1)</td>
<td>Fever</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>3 (0.8)</td>
<td>Arthralgia</td>
<td>3 (2.6)</td>
</tr>
</tbody>
</table>

Figure 1.

Conclusion: About one fourth of GCA patients relapsed and the overwhelming majority of relapses occurred before patients were able to stop glucocorticoids. The leading symptoms at relapse are headache and fatigue, while loss of vision is rare (0.78%). Baseline characteristics seem to be poorly informative about the risk of relapse, therefore regular monitoring of GCA patients is necessary.

Disclosure of Interests: None declared


Table 1.

<table>
<thead>
<tr>
<th>Symptom at disease onset</th>
<th>N=395 (%)</th>
<th>Symptom at relapse</th>
<th>N=97 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>35 (34.7)</td>
<td>Headache</td>
<td>35 (30.7)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>34 (34.7)</td>
<td>Fatigue</td>
<td>19 (16.7)</td>
</tr>
<tr>
<td>Polyarthalgia (PMR)</td>
<td>14 (35.4)</td>
<td>Vision impairment</td>
<td>13 (11.4)</td>
</tr>
<tr>
<td>Night sweats</td>
<td>15 (36.5)</td>
<td>Night sweats</td>
<td>12 (15.0)</td>
</tr>
<tr>
<td>Headache in the temple area</td>
<td>18 (46.1)</td>
<td>Headache in the temple area</td>
<td>12 (15.0)</td>
</tr>
<tr>
<td>Jaw pain</td>
<td>12 (30.6)</td>
<td>Jaw pain</td>
<td>11 (9.6)</td>
</tr>
<tr>
<td>Vision impairment</td>
<td>9 (23.1)</td>
<td>Vision impairment</td>
<td>7 (6.1)</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>59 (15.0)</td>
<td>Weight loss</td>
<td>7 (6.1)</td>
</tr>
<tr>
<td>Fever</td>
<td>9 (23.1)</td>
<td>Claudication upper limb</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Swollen temporal arteries</td>
<td>27 (68.6)</td>
<td>Arthralgia</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Vision loss</td>
<td>23 (57.7)</td>
<td>Claudication lower limb</td>
<td>5 (4.4)</td>
</tr>
<tr>
<td>Scalp tenderness</td>
<td>18 (46.1)</td>
<td>Scalp tenderness</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Claudication lower limb</td>
<td>14 (35.4)</td>
<td>Arthralgia</td>
<td>3 (2.6)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>11 (28.1)</td>
<td>Fever</td>
<td>2 (1.6)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>3 (0.8)</td>
<td>Arthralgia</td>
<td>3 (2.6)</td>
</tr>
</tbody>
</table>

Figure 1.

Conclusion: About one fourth of GCA patients relapsed and the overwhelming majority of relapses occurred before patients were able to stop glucocorticoids. The leading symptoms at relapse are headache and fatigue, while loss of vision is rare (0.78%). Baseline characteristics seem to be poorly informative about the risk of relapse, therefore regular monitoring of GCA patients is necessary.

Disclosure of Interests: None declared

including visual acuity, pupil exam and full-dilated fundus assessment. Systemic and Ophthalmic symptoms and signs were recorded.

Methods: From January 2012 to September 2021, 350 individuals were diagnosed with GCA by biopsy, ultrasonography or position emission tomography. The mean age was 74 ± 7.7 years. 235 (67%) of patients were females. 101 (29%) presenting with GCA had visual symptoms and/or signs. 42 of them had mono-ocular and 5 had binocular loss of vision. A summary of the key visual symptoms and signs are shown in Table 1. Only 6 patients with visual symptoms did not have any symptoms commonly associated with GCA.

Table 1. Visual Symptoms and Signs (N=350 patients)

<table>
<thead>
<tr>
<th>Visual Symptoms</th>
<th>Blurred Vision</th>
<th>Loss of vision</th>
<th>Double Vision</th>
<th>Ocular Signs</th>
<th>Right CRAO</th>
<th>Left CRAO</th>
<th>Right AION</th>
<th>Left AION</th>
<th>Right extracocular muscle weakness</th>
<th>Left extracocular muscle weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>101</td>
<td>36</td>
<td>47</td>
<td>27</td>
<td>1</td>
<td>10</td>
<td>19</td>
<td>23</td>
<td>6</td>
<td>4</td>
</tr>
</tbody>
</table>

1 Central retinal artery occlusion 2 Anterior ischaemic optic neuropathy

Results: From January 2012 to September 2021, 350 individuals were diagnosed with GCA by biopsy, ultrasonography or position emission tomography. The mean age was 74 ± 7.7 years. 235 (67%) of patients were females. 101 (29%) presenting with GCA had visual symptoms and/or signs. 42 of them had mono-ocular and 5 had binocular loss of vision. A summary of the key visual symptoms and signs are shown in Table 1. Only 6 patients with visual symptoms did not have any extra-ocular symptoms commonly associated with GCA.

Conclusion: We report the frequency of visual involvement in one of the largest cohorts of individuals with GCA. 29% have ocular symptoms. Partial or total field loss occurred in 13% of cases. 2% of patients presented with visual manifestations as the only feature of GCA. Rarely, permanent visual loss may occur without any other manifestation of GCA.

REFERENCES:

Disclosure of Interests: None declared


POSE0811 CHARACTERS OF INTESTINAL MICROBIOTA AND ITS RELATIONSHIP WITH LYMPHOCYTE SUBSETS AND CYTOKINES IN PATIENTS WITH VASCULITIS

J. Wang1,2,3, S. X. Zhang1,2,3, S. Song1,2,3, J. Qiao1,2,3, R. Zhao1,2,3, T. Cheng1,2,3, J. Liu1,2,3, C. Wang1,2,3, X. Li1,2,3. 1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 3Key Laboratory of Cellular Physiology at Shanxi Medical University, Ministry of Education, Taiyuan, China

Background: Vasculitis include a group of autoimmune inflammatory diseases with clinical heterogeneous characterized by inflammation of vascular wall, inflammation of perivascular tissues, and cell-like necrosis[1]. Disorder of gut microbiota, which plays a crucial role in regulating immune cells such as Th1, Th17 and Treg, is associated with other autoimmune diseases[2]. Importantly, the relative abundance of Muribaculaceae were positively correlated with the absolute count of Th2 and the proportions of Th1 and CD4+T cells and negatively correlated with CRP and ESR, while relative abundance of [Eubacterium], ventricum were positively associated with the absolute number of Treg cells and negatively correlated with the percentages of Th2 and CD8+T cells (Figure 1F).

Figure 1. Differences in α diversity (A), β diversity (B), phylum (C), genus (D), and microbial composition (E) between vasculitis patients and HC and correlation analysis between differential microflora and clinical data in patients with vasculitis (F).

Conclusion: Disturbance of intestinal flora, mainly manifested by decreased diversity and richness, may be involved in the occurrence and development of vasculitis by inducing disorders in lymphocyte subsets and cytokines. Consequently, further studies on the immune mechanisms and influencing factors of intestinal flora may reveal new ideas for the diagnosis and treatment of the disease for vasculitis patients.

REFERENCES:

Disclosure of Interests: None declared


POSE0812 CAROTID INTIMA-MEDIA THICKNESS/DIAMETER RATIO AND PEAK SYSTOLIC VELOCITY AS RISK FACTORS FOR NEUROLOGICAL SEVERE ISCHEMIC EVENTS IN TAKAYASU’S ARTERITIS

L. Wang1, Y. Sun1, X. Dai1, X. Kong1, L. MA1, X. Dai1, L. MA1, L. Jiang1,2. 1Zhongshan Hospital Fudan University, Department of Rheumatology, Shanghai, China; 2Zhongshan Hospital Fudan University, Evidence-based Medicine Center, Shanghai, China

Background: Takayasu’s arteritis (TAK) is an idiopathic systemic vasculitis characterized by the involvement of the aorta and its major branches[1]. The supra-aortic arteries are often involved in TAK, with the reported prevalence ranging from 40% to 84%[2-3]. Importantly, patients with supra-aortic involvement carry a higher risk of neurological severe ischemic events (SIE)[4-5]. The common carotid artery (CCA) is the most affected artery and is more closely associated with neurologic symptoms than other supra-aortic arteries[6]. Ultrasonography (US) has been regarded as the most popular, user-friendly, and repeatable tool for the diagnosis and follow-up of CCA injuries.

Objectives: Our aim was to characterize TAK with supra-aortic involvement and determine the associations between clinical features, carotid US parameters, and neurological SIE.

Methods: Patients with supra-aortic involvement including brachiocephalic trunk, bilateral common carotid artery and internal carotid artery, and bilateral subclavian level (P < 0.001, Figure 1C). In vasculitis patients, the relative abundances of 23 bacteria differed from HCs at the genus level was all decreased, including Gemella, Anaeroglobinus, Campylobacter, Fournierrae, et al (P < 0.001, Figure 1D and E). More importantly, the relative abundance of Muribaculaceae were positively correlated with the absolute count of Th2 and the proportions of Th1 and CD4+T cells and negatively correlated with CRP and ESR, while relative abundance of [Eubacterium], ventricum were positively associated with the absolute number of Treg cells and negatively correlated with the percentages of Th2 and CD8+T cells (Figure 1F).

REFERENCES:

Disclosure of Interests: None declared

and vertebral artery and baseline carotid US examination were enrolled. Bilateral carotid diameter, intima-media thickness (IMT), and peak systolic velocity (PSV) were measured by US. Then, IMT/diameter ratio (IDR) was calculated. Risk factors associated with neurological SIE were analyzed by multivariate logistic regression.

**Results:** Totally, 295 patients were included, of whom 93 (31.5%) experienced neurological SIE, with common carotid artery involved (81.7%). Involved supra-aortic artery distribution (p<0.04) and number (p<0.01) differed between neurologic and non-neurologic SIE subjects, showing higher prevalence of common carotid and vertebral artery involvement in cases with neurological SIE and 57.1% neurological SIE patients having more than four involved arteries. The left carotid IMT (p=0.03) and IDR (p<0.01) differed between patients with and without neurological SIE. The left carotid IDR (cut-off value ≥0.55, odds ratio [OR] 4.46; 95% confidence interval [CI] 2.05-9.71; p<0.01) and PSV (≥76 cm/s, OR 3.38; 95% CI 1.82-704; p<0.01) and involved supra-aortic artery number (≥4, OR 3.16; 95% CI 1.54-6.47; p<0.01) were independently associated with neurological SIE.

**Conclusion:** The left carotid IDR and PSV and involved supra-aortic artery number would perform as valuable markers for recognizing neurological SIE in TAK patients with supra-aortic lesions.

**References:**


[3] Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Gray J. CRP 13.6 vs 5.3 mg/L, p=0.038, ΔCRP = -87.7%; cDMARDs-treated: ESR 27 vs 3 mm/h, p=0.001, ΔCRP = -87.7%; cDMARDs-treated: ESR 36 vs 27 mm/h, p=0.134, ΔESR = -152%, CRP 13.6 vs 3.5 mg/L, p=0.038, ΔCRP = -66.3% and TCZ-treated: ESR 27 vs 3 mm/h, p=0.017, ΔESR = -86.7%, CRP 11.4 vs 2.7 mg/L, p=0.023, ΔCRP = -80.2%.

**Conclusion:** 18F-FDG PET may be useful in assessing disease activity and monitoring response to therapy. Tocilizumab treatment significantly reduce vessel’s metabolic activity over time, when compared to conventional treatment. A persistent low-grade uptake during remission is common features in LV patients, irrespective to treatment regimens.

**References:**


normalization of CRP level defined as <10mg/dl) 3) lack of worsening of the primary vascular lesion or a new lesion vascular at another site on imaging. Remission was assessed at month 6 and month 12. Secondary endpoints were relapse, overall disease activity assessed with BDCAF (n=2), not wanting to come to the infusion frequently during the pandemic (n=2), pregnancy (n=1), to incorporate less serious causes of IFX discontinuation were infusion reactions in 5, tuberculosis, disseminated zoster, lung adenocarcinoma, fibromyxoid sarcoma, heart failure, SLE, palmpoplantar pustulosis, auricular chondritis, and aortic stent graft infection in 1 patient each.

### Table 1. The frequency of concomitant immunosuppressive use, duration of infliximab use and outcomes of BS patients with vascular involvement treated with IFX

<table>
<thead>
<tr>
<th>Vascular Involvement</th>
<th>Number of patients</th>
<th>Duration of IFX use</th>
<th>Remission rate</th>
<th>Relapse rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous thrombosis (with concomitant immunosuppressives)</td>
<td>48 (79)</td>
<td>24 ± 19.7</td>
<td>75%</td>
<td>25%</td>
</tr>
<tr>
<td>Pulmonary artery involvement</td>
<td>24 (65)</td>
<td>14 ± 19.3</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>Non-pulmonary arterial involvement</td>
<td>35 ± 29.6</td>
<td>26 ± 24</td>
<td>92%</td>
<td></td>
</tr>
<tr>
<td>Venous ulcer</td>
<td>36 ± 21</td>
<td>25 ± 21</td>
<td>93 (73)</td>
<td></td>
</tr>
<tr>
<td>Overall (n=127)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Results:
Among the 371 patients who used IFX between 2004 and June 2021, 127 patients (102 men, 25 women, mean age 40 ± 8.7 years) had used it for vascular involvement. The types of vascular involvement that required IFX were venous thrombosis in 61 patients (48%), pulmonary artery involvement in 37 (29%), non-pulmonary arterial involvement in 16 (13%), and venous ulcer in 13 (10%). Remission rate was 72% (92/127) at month 6 and 61% (71/117) at month 12. 17/99 (17%) patients experienced 22 relapses during a mean follow-up of 28.4±21 months of IFX therapy. Among the 22 relapses, 12 were the progression of the pre-existing vascular lesion and 10 were new vascular lesions. Overall disease activity improved with a decrease in mean BDCAF score from 1.76 ± 1.27 to 0.6 ± 0.8 at the final visit (p<0.001). Remission and relapse rates according to type of vascular involvement and causes of IFX discontinuation are presented in the Table 1. Adverse events leading to IFX discontinuation were infusion reactions in 5, tuberculosis, disseminated zoster, lung adenocarcinoma, fibromyxoid sarcoma, heart failure, SLE, palmpoplantar pustulosis, auricular chondritis, and aortic stent graft infection in 1 patient each.

### Discussion of Interests:
Gulen Hatemi speaks for AbbVie, Intellegens, and UCB Pharma. Grant/research support from: Gulen Hatemi has received grant/research support from Celgene, Bexza Tukel. None declared, Sinem Nihan Esatoglu speaks for Sinem Nihan Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme., Yesim Ozguzer speaks for Yesim Ozguzer has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Sıtkı Safa Taflan: None declared, Melike Melikoglu: None declared, Serhat Yurdakul: None declared, Izzet Fresko: None declared, Zekayi Kutlubay: None declared, Vedat Hamuryudan speaks for Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene.

### Disclosure of Interests:
Gulen Hatemi speaks for AbbVie, Celgene, Novartis, and UCB Pharma. Grant/research support from: Gulen Hatemi has received grant/research support from Celgene, Bexza Tukel. None declared, Sinem Nihan Esatoglu speaks for Sinem Nihan Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme., Yesim Ozguzer speaks for Yesim Ozguzer has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Sıtkı Safa Taflan: None declared, Melike Melikoglu: None declared, Serhat Yurdakul: None declared, Izzet Fresko: None declared, Zekayi Kutlubay: None declared, Vedat Hamuryudan speaks for Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene.

### DOI:

### POS0815 DIFFERENCES IN GIANT CELL ARTERITIS MANIFESTATIONS ACCORDING TO THE ULTRASOUND PATTERN OF DISEASE INVOLVEMENT

<table>
<thead>
<tr>
<th>Type of Vascular Involvement</th>
<th>Number of patients</th>
<th>Duration of IFX use</th>
<th>Remission rate</th>
<th>Relapse rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous thrombosis</td>
<td>48 (79)</td>
<td>24 ± 19.7</td>
<td>75%</td>
<td>25%</td>
</tr>
<tr>
<td>Pulmonary artery involvement</td>
<td>24 (65)</td>
<td>14 ± 19.3</td>
<td>50%</td>
<td>50%</td>
</tr>
<tr>
<td>Non-pulmonary arterial involvement</td>
<td>35 ± 29.6</td>
<td>26 ± 24</td>
<td>92%</td>
<td></td>
</tr>
<tr>
<td>Venous ulcer</td>
<td>36 ± 21</td>
<td>25 ± 21</td>
<td>93 (73)</td>
<td></td>
</tr>
<tr>
<td>Overall (n=127)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Conclusion:
Infliximab may be beneficial in BS patients with vascular involvement, even in those who are refractory to immunosuppressives and corticosteroids.

### Disclosure of Interests:
Gulen Hatemi speaks for AbbVie, Celgene, Novartis, and UCB Pharma. Grant/research support from: Gulen Hatemi has received grant/research support from Celgene, Bexza Tukel. None declared, Sinem Nihan Esatoglu speaks for Sinem Nihan Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme., Yesim Ozguzer speaks for Yesim Ozguzer has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Sıtkı Safa Taflan: None declared, Melike Melikoglu: None declared, Serhat Yurdakul: None declared, Izzet Fresko: None declared, Zekayi Kutlubay: None declared, Vedat Hamuryudan speaks for Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma, Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene.

### DOI:
Table 1. Drug survival of infliximab and reasons for infliximab discontinuation

<table>
<thead>
<tr>
<th>Culture/vegetation involvement (n=10)</th>
<th>Uveitis (n=164)</th>
<th>Vascular (n=114)</th>
<th>CNS (n=55)</th>
<th>Arthritis (n=19)</th>
<th>GIS (n=15)</th>
<th>Venous ulcer (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male (n, %)</td>
<td>3 (30)</td>
<td>127 (77)</td>
<td>89 (78)</td>
<td>49 (89)</td>
<td>14 (74)</td>
<td>9 (60)</td>
</tr>
<tr>
<td>Age at infliximab initiation (mean ± SD years)</td>
<td>35.8 ± 9.3</td>
<td>34 ± 9.9</td>
<td>36 ± 9.1</td>
<td>36.2 ± 10.4</td>
<td>39.6 ± 10.7</td>
<td>34 ± 11.4</td>
</tr>
<tr>
<td>Number of patients who used concomitant immunosuppressors (n, %)</td>
<td>5 (50)</td>
<td>108 (66)</td>
<td>86 (75)</td>
<td>38 (69)</td>
<td>5 (26)</td>
<td>11 (73)</td>
</tr>
<tr>
<td>Duration of infliximab use (mean ± SD months)</td>
<td>33 ± 38</td>
<td>45 ± 38</td>
<td>28 ± 23</td>
<td>37 ± 28</td>
<td>37 ± 35</td>
<td>26 ± 26</td>
</tr>
<tr>
<td>Number of patients who discontinued infliximab (n, %)</td>
<td>5 (50)</td>
<td>93 (57)</td>
<td>58 (51)</td>
<td>23 (42)</td>
<td>12 (63)</td>
<td>7 (47)</td>
</tr>
<tr>
<td>Due to remission</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Due to primary inefficacy</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Due to secondary inefficacy</td>
<td>2</td>
<td>12</td>
<td>5</td>
<td>4</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>Due to adverse event</td>
<td>1</td>
<td>12</td>
<td>11</td>
<td>11</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Due to non-compliance</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Due to other reasons</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Objectives: We aimed to evaluate long term drug survival of IFX in a large cohort of BS patients.

Methods: We reviewed the charts of BS patients who received IFX between 2004 and June 2021 and noted demographic features, reasons for IFX use, IFX duration, and reasons for discontinuation.

Results: 371 patients (290 men, mean age at IFX initiation: 35.5 ± 10 years) received IFX for uveitis (n=164), vascular involvement (n=114), central nervous system (CNS) involvement (n=55), arthritis (n=19), gastrointestinal (GI) involvement (n=15), mucocutaneous involvement (n=10), venous ulcers (n=13), and secondary amyloidoses (n=1). Twenty patients had more than one type of involvement requiring IFX. During a median follow-up of 30 months (IQR: 13-52), 175 (47%) patients were still receiving IFX for a median period of 40 months (IQR: 22-66) while 258 (69%) patients had discontinued IFX after a median follow-up of 19 months (IQR: 8-34).

IFX retention rate was 50% for mucocutaneous involvement, 43% for uveitis, 49% for vascular involvement, 58% for CNS involvement, 37% for arthritis, 53% for GI involvement, and 31% for venous ulcer (Table 1). Reasons for discontinuation were adverse events in 56 (15%), remission in 54 (15%) patients, inefficacy in 45 (12%) (secondary inefficacy in 26 (7%), primary inefficacy in 19 (5%)), and lack of patient compliance in 18 (5%). Other reasons were preparation for surgical operation (n=4), pregnancy (n=4), lack of health insurance (n=4), preferring subcutaneous administration during the pandemic (n=3), due to prison sentence (n=3), willing to get pregnant (n=1), rejecting the treatment (n=1), and death (n=3).

Adverse events (n=56) leading to the cessation of IFX were infusion reactions (n=22), infections (n=7), tuberculosis (n=6), malignancy (n=6), palmar plantar psoriasis (n=5), hepatitis toxicity (n=4), lichen planus (n=1), drug induced lupus (n=1), auricular chondritis (n=1), macrophage activation syndrome (n=1), splenic infarction (n=1) and a decrease in left ventricular ejection fraction (n=1). At the end of the follow-up, 2 patients had died due to lung adenocarcinoma, 1 patient had died due to pneumosinus, 1 due to severe parenchymal neurologic involvement and 1 with pulmonary artery involvement due to massive hemorrhage during IFX treatment. Additionally, 7 patients had died 9, 10 months, 3, 3, 4, 7 and 9 years after IFX discontinuation. The causes of death were severe nervous system involvement in 2 patients, right heart failure due to pulmonary hypertension, lymphangitis, lung adenocarcinoma, sepsis and gastrointestinal bleeding in 1 patient each.

Conclusion: IFX seems to be effective for the treatment of organ and life-threatening manifestations in the majority of the patients. However, drug retention rate was not optimal, mainly due to adverse events, inefficacy and patient non-compliance.

Disclosure of Interests: Sinem Nihat Esatoglu Speakers bureau: Sinem Nihat Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Medarex. Serkan Erbas received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Medarex. Meral Topaloglu: None declared. Didar Ucar: None declared. Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma. Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene., Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Pfizer, and Medarex. Meriç Sevki Saka received honorariums from Medarex. Zeynep Kutluak received honorariums from Roche, and Pfizer. Emire Seyahi Speakers bureau: Emire Seyahi has received honorariums from Roche, and Pfizer. Grant/research support from: Emire Seyahi has received grant/research support from Celgene.

References:

1. Sanchez-Martín J.1,2, J. Loricera1, C. Moriano3, S. Castañeda4, J. Navárez5, Y. Aldasoro6, O. Maiz7, R. Meleoro8, I. Villa-Blanco9, P. Vela-Casasempere2, S. Romero-Yuste11, I. L. Callejas-Rubio12, E. De Miguel13, E. Galáns-Segalinago14, F. Sivera15, C. Fernández-López15, C. Galisteo17, I. Ferraz-Amaro18, L. Sanchez-Bilbao19, M. Calderón-Goecheva1, J. L. Hernández-Hernández10, M. A. Gonzalez-Gay19, R. Blanco19. 1Hospital Marques de Valdecilla, Rheumatology, Santander, Spain; 2Department of Rheumatology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Rheumatology, Santander; 3Department of Rheumatology, Complejo Asistencial Universitario de León, León, Spain, Rheumatology, Leon, Spain; 4Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Catedra UAM-Roche, EPI-D-Future, UAM, Madrid, Spain, Rheumatology, Madrid, Spain; 5Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, Rheumatology, Barcelona, Spain; 6Department of Rheumatology,Complejo Hospitalario de Navarra, Pamplona, Spain, Rheumatology, Navarra, Spain; 7Department of Rheumatology, Hospital Universitario de Donostia, San Sebastián, España, Rheumatology, Donostia, Spain; 8Department of Rheumatology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, Rheumatology, Vigo, Spain; 9Department of Rheumatology, Hospital Sienallana, Torrelavega, Spain, Rheumatology, Torrelavega, Cantabria, Spain; 10Department of Rheumatology, Hospital General Universitario de Alicante, Alicante, Spain, Rheumatology, Alicante, Spain; 11Department of Rheumatology,Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, Rheumatology, Pontevedra, Spain; 12Department of Rheumatology, Hospital San Cecilio, Granada, Spain, Rheumatology, Granada, Spain; 13Department of Rheumatology, Hospital La Paz, Madrid, Spain, Rheumatology, Madrid, Spain; 14Department of Rheumatology, Hospital de Basurto, Bilbao, Spain, Rheumatology, Bilbao, Spain; 15Department of Rheumatology, Hospital Universitario de Elche, Alicante, Spain, Rheumatology, Elche, Alicante, Spain; 16Department of Rheumatology, Hospital Universitario Juan Canalejo, A Coruña, Spain, Rheumatology, A Coruña, Spain; 17Department of Rheumatology, Hospital Parc Taulí, Barcelona, Spain, Rheumatology, Barcelona, Spain; 18Department of Rheumatology, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain, Rheumatology, Tenerife, Spain; 19Department of Rheumatology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Rheumatology, Santander; 20Department of Rheumatology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Internal Medicine, Santander, Spain

Background: Tocilizumab (TCZ) is the only biologic drug approved in giant cell arteritis (GCA), based in two clinical trials (CT)

CP, most of them are refractory/recurrent GCA (3,4). Although in CT the efficacy of TCZ seems to be similar in patients with newly diagnosed GCA and in patients with refractory/recurrent GCA, in CP it is not documented.

Objectives: To compare in CP, the effectiveness and safety of TCZ in newly diagnosed vs refractory/recurrent GCA
Methods: Multicentre observational study on 471 GCA patients treated with TCZ. GCA was diagnosed by: a) ACR criteria, and/or b) temporal artery biopsy, and/or c) imaging techniques. A comparative study between patients with newly diagnosed GCA (<6 weeks) and those with refractory/recurrent GCA (>6 weeks) (according to GiACTA study definitions) (2), Sustained remission was based on EULAR definitions (5).

Results: The 471 GCA patients were divided into 2 subgroups: a) newly diagnosed GCA (n=91) and b) refractory/recurrent GCA (n=380) (Table 1).

Table 1. Main features of patients with newly diagnosed GCA and refractory/recurrent GCA treated with tocilizumab.

<table>
<thead>
<tr>
<th></th>
<th>Newly diagnosed GCA (n=91)</th>
<th>Refractory/recurrent GCA (n=380)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(years), mean±SD</td>
<td>74.3±8.8</td>
<td>73.3±9.1</td>
</tr>
<tr>
<td>Sex, female/male (% female)</td>
<td>60/31 (66)</td>
<td>282/98 (74)</td>
</tr>
<tr>
<td>Time from GCA diagnosis to TCZ onset (months), median [IQR]</td>
<td>0 [1-5.1]</td>
<td>10 [4-24]</td>
</tr>
<tr>
<td>ESR, mm 1st hour, median [IQR]</td>
<td>46 [17.5-80.5]</td>
<td>27 [10-50]</td>
</tr>
<tr>
<td>CRP, mg/dL, median [IQR]</td>
<td>2.1 [0.7-4.8]</td>
<td>1.3 [0.4-2.8]</td>
</tr>
<tr>
<td>Haemoglobin, g/dL, mean±SD</td>
<td>12.3±1.5</td>
<td>12.7±1.5</td>
</tr>
</tbody>
</table>

Effectiveness and Safety after TCZ onset

Follow-up, (months), median [IQR] | 15 [6-27]                  | 22 [11-37]                     |

Relevant adverse events, % | 23 (25)                   | 102 (27)                       |

Serious infections, % | 13 (14)                   | 53 (14)                        |

Malignancies per 100 patients-year | 0                           | 12                           |

Malignancies per 100 patients-year | 0                           | 0.5                           |

Relevant adverse events and serious infections are shown (Table 1).

Abbreviations: ACR: American College of Rheumatology; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; IQR: interquartile range; IV: intravenous; MACEs: major adverse cardiovascular events; NS: non significant; SC: subcutaneous; SD: standard deviation

No significant differences were observed between both groups in sustained remission, although a greater tendency towards sustained remission is observed in newly diagnosed than in refractory/recurrent GCA patients (Figure 1). The decrease in glucocorticoids dose was faster in the first three months in the newly diagnosed GCA group, but thereafter, was similar in both groups, as well as the appearance of relevant adverse events and serious infections.

Figure 1. A) Sustained remission, and B) median prednisone dose required in patients with newly diagnosed GCA and in patients with refractory/recurrent GCA treated with tocilizumab.

Conclusion: The effectiveness and safety of TCZ seems to be similar in patients with newly diagnosed GCA and in patients with refractory/recurrent GCA.

REFERENCES:

Disclosure of Interests: Julio Sanchez-Martín: None declared, Javier Loricer: None declared, Clara Moriano: None declared, Santos Castañeda: None declared, I. Navarre: None declared, Vicente Aldauro: None declared, Olga Maiz: None declared, Rafael Melero: None declared, Ignacio Villa-Blanco: None declared, Paloma Vela-Casasemperre: None declared, Susana Romero-Yuste: None declared, Jose Luis Callejas-Rubio: None declared, Eugenio de Miguel: None declared, E. Gallego: None declared, Francisca Sivera: None declared, Carlos Fernández-López: None declared, Carlos Galisteo: None declared, Ivan Fierrez-Amaro: None declared, Sara Sanchez-Bilbao: None declared, Monica Calderón-Goercke: None declared, Jose Luis Hernández Hernández: None declared, Miguel A González-Gay Speakers bureau: Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Grant/research support from: Abbvie, MSD, Jansen and Roche, Ricardo Blanco Speakers bureau: Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Grant/research support from: Abbvie, MSD and Roche DOI: 10.1136/annrheumdis-2022-eular.4027

SOUTHEND PRE-TEST PROBABILITY SCORE AND HALO SCORE AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: EARLY RESULTS FROM THE PROSPECTIVE HAS-GCA STUDY

A. Sebastian1,2,3, A. Tomelleri2, P. Macchioni2, G. Kinlowski4,6, C. Salvadori4,6, A. Kayani1, M. Tariq1, D. Prieto-Pería4, E. Conticini5, M. Khurshid6, S. Inness10, K. Jackson10, K. Van der Geest10, B. Dasgupta10,11, Southend University Hospital, Mid and South Essex NHS Foundation Trust, Rheumatology, Southend-on-Sea, United Kingdom; 2University of Essex Colchester Campus, School of Sport, Rehabilitation and Exercise Science, Colchester, United Kingdom; 3University Hospital Limerick, Rheumatology, Limerick, Ireland; 4San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milano, Italy; 5Azienda USL - IRCCS - di Reggio Emilia, Rheumatology, Reggio Emilia, Italy; 6University of Modena and Reggio Emilia, Rheumatology, Modena, Italy; 7Marques de Valdecilla University Hospital, VRMI-UPV, Gernika, Bizkaia, Spain; 8University of Siena, Medicine, Surgery and Neurosciences, Siena, Italy; 9University Hospital Dorset, NHS Foundation Trust, Rheumatology, Dorset, United Kingdom; 10University of Essex Colchester Campus, School of Sport, Rehabilitation and Exercise Science, Colchester, United Kingdom; 11University of Groningen, University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands

Background: Ultrasound (US) is recommended as the first line imaging test in patients with suspected Giant Cell Arteritis (GCA). Traditionally, the US halo sign has been used for diagnosis. We have recently described a composite Halo Score that allows to quantify vascular inflammation on US. Prospective studies on response and disease monitoring are lacking.

Objectives: To prospectively assess the role of US in diagnosing and monitoring GCA patients. We completed 12-month data on our current recruitment in a study that has suffered disruption from the pandemic.

Methods: HAS (AUS) GCA (THS) and TSHS (AUS) study. A multicentre study recruiting from referrals of suspected GCA to fast-track clinics. Based on the Southend GCA clinical pre-test probability score (SPTPS), patients were stratified in to low, intermediate and high risk categories. Temporal and auricular US Halo Scores were calculated from the halo thickness and extent in bilateral temporal arteries, parietal and frontal branches (TASH) and auricular arteries (AASH). These scores were summed (TASH x1 plus; AASH x3) to generate a Total Halo Score (THS).

Results: Mann Whitney U test was used to compare baseline features between GCA and controls. Wilcoxon signed rank test was used to evaluate disease features at baseline and at 12 months in GCA patients. Sensitivity (Sn), Specificity (Sp) and ROC curve were calculated, where applicable. P value <0.05 is statistically significant.

Results: 202 patients (71 GCA, 131 controls) have been recruited thus far; 23 completed 12-month follow up assessment; 6 were lost to follow up (4 died, 2 withdrew consent due to pandemic). Demographics, clinical features, and US results are shown (Table 1).
Among GCA patients, 50 had cranial, 5 large-vascular and 16 mixed phenotypes. Diseases were diagnosed by US and additional tests such as PET CT. Jaw claudication (54%) and constitutional symptoms (59%) were the dominant features in GCA patients. Median age was 75 years in GCA (54% females) and 68 years in controls (68% females). GCA and controls were stratified by SPTPS to Low risk (0% vs 45%; Sn-undefined, Sp-98), Intermediate risk (23% vs 37%; Sn-81, Sp-98) and High risk (77% vs 18%; Sn-98, Sp-91). Optimal SPTPS cut-off point was ≥12 (Sn-89, Sp-76).

**Table 1. Baseline features of GCA patients and controls**

<table>
<thead>
<tr>
<th>GCA (n=71)</th>
<th>Controls (n=131)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>75 (70-81)</td>
<td>68 (62-76)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>38 (54)</td>
<td>89 (68)</td>
</tr>
<tr>
<td>SPTPS category, n (%)</td>
<td>Low risk</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>Intermediate risk</td>
<td>16 (23)</td>
</tr>
<tr>
<td></td>
<td>High risk</td>
<td>55 (77)</td>
</tr>
<tr>
<td>Halo score (HS), median (range)</td>
<td>Temporal artery HS</td>
<td>12 (0-22)</td>
</tr>
<tr>
<td></td>
<td>Axillary artery HS</td>
<td>12 (0-21)</td>
</tr>
<tr>
<td></td>
<td>Temporal artery HS</td>
<td>12 (0-22)</td>
</tr>
</tbody>
</table>

**Conclusion:** Along with SPTPS, Halo Score successfully discriminates GCA from non GCA mimics and HS is effective in showing 12-month response. This is evidenced by extensive studies in white populations and a significant paucity of data in other ethnic groups. The most frequent causes of death in GCA are cardiovascular disease (CVD) (39%) followed by cerebrovascular disease (CVA) (14%), infection (13%), and malignancy (12%). Overall, the mortality rate is increased in the first two years and is associated with the disease severity, extent, ischemic, and treatment complications, particularly from glucocorticoids. [1, 3-5]

**Objectives:** The aim of this study was to compare the rate of cardiovascular and infectious complications in GCA patients among different ethnicities.

**Methods:** In this retrospective cohort study, we identified patients with biopsy proven GCA based on ICD-10 codes, using the Nationwide Inpatient Sample database (NIS) from 2016 to 2019. We included acute coronary syndrome (ACS), CVA, thoracic ascending aneurysm rupture (TAA), and infection (composite of UTI, sepsis and pneumonia) as our outcomes of interest and compared them between Caucasian, African American (AA), and Hispanic ethnicities. We implemented logistic regression analysis in the univariable and multivariable models. In the multivariable model, we adjusted all outcomes for potential confounders, including age, sex, obesity, hyperlipidemia, congegestive heart failure, peripheral vascular diseases, diabetes, hypertension, renal failure, history of smoking or alcohol abuse, history of other drug abuse, prior history of MI, primary coronary intervention, or coronary artery bypass grafting, coagulopathy, liver disease, chronic pulmonary disease, ischemic cardiomyopathy, Elixhauser comorbidity index, type of insurance, bed size of hospital, history of defibrillator or pacemaker, and long-term use of steroids. The analysis was done using the STATA software, version 17.0 (MP2).

**Results:** We identified 7,750 patients with GCA, of whom 5,710 (74%) were Caucasian, 1,335 (17%) were AA, and 705 (9%) were Hispanic. Our results showed that Hispanics had both a higher prevalence (16.30% vs 9.80% vs 7.95%, p-value = 0.017) and risk for infections (OR: 2.74; 95%-CI 1.4-5.5; p-value = 0.004) when compared to the other racial groups. There was no difference in the risk of ACS among Caucasians (OR: 2.72; 95%-CI 0.6-12.4; p-value = 0.2) and Hispanics (OR: 2.72; 95%-CI 0.4-17.4; p-value = 0.004) when compared to AA population. Similarly, risk of CVA was not different between racial groups (Caucasians: OR: 1.04; 95%-CI 0.6-1.7; p-value = 0.87; Hispanics: OR: 0.8; 95%-CI 0.4-1.7; p-value = 0.567). The prevalence for TAA was only reported in the Caucasian group (0.50%).

**Conclusion:** ACS and CVA are known complications of GCA. There does not appear to be a difference in the risks of these common cardiovascular complications among racial groups. However, there was a significantly higher rate of infections in the Hispanic population. This may be explained by biologic differences in susceptibility and racial disparities in insurance coverage and access to care.

**References:**

Table 1. Multivariable logistic regression comparing clinical outcomes across races\(^1\)

<table>
<thead>
<tr>
<th></th>
<th>Caucasian</th>
<th>Hispanic</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CI</td>
<td>p-value</td>
</tr>
<tr>
<td>ACS</td>
<td>2.72 (0.6-12.4)</td>
<td>0.2</td>
</tr>
<tr>
<td>CRH</td>
<td>1.04 (0.6-1.7)</td>
<td>0.87</td>
</tr>
<tr>
<td>Infection</td>
<td>1.55 (0.9-2.6)</td>
<td>0.11</td>
</tr>
</tbody>
</table>

\(^{\dagger}\)AA are taken as reference

Disclosure of Interests: None declared


POS0820

PREDICTIVE VALUE OF OBJECTIVE EXAMINATION OF TA ON POSITIVITY OF TAB IN GIANT CELL ARTERITIS

G. Germani\(^1\), P. Macchioni\(^1\), G. Kinowski\(^1\), A. Cavazza\(^1\), L. Boiardi\(^1\), C. Salvareni\(^2\), \(^3\)ASMN-VRCG Reggio Emilia, Rheumatology, Reggio Emilia, Italy; \(^4\)Università Modena e Reggio, Rheumatology, Modena, Italy

Background: Previous studies have reported the utility of temporal artery examination for the diagnosis of GCA but no data are available on the correlation between clinical examination and the subsequent temporal artery biopsy (TAB) results of the biopsied vessel.

Objectives: Evaluate the predictive value of temporal artery (TA) examination in patients with suspected GCA on the results of TAB of the same vessel.

Methods: 97 pts consecutively seen at our center because of suspected cranial arteritis between 01.01.2015 to 31.12.2021 were enrolled in the study. All patients had complete clinical examination, laboratory investigations (included ESR and CRP determination), clinical examination of the temporal arteries and their frontal and parietal branches for tenderness (P), reduced or absent pulse (R) and thickening (T). All patients underwent arterial ultrasound (US) followed by a TAB of the most US involved frontal branches. The presence of inflammatory infiltrate of the vessel wall or the inflammation of the periadventitial blood vessel wall (Halo) were calculated for every singular objective test and the correspondent OR with 95%CI. Sensitivity, specificity, negative and positive LR were calculated for every singular objective test and the correspondent OR with 95%CI.

Results: Abnormalities.

OR 95% CI P-value OR 95% CI P-value

ACS 2.72 (0.6-12.4) 0.2 2.72 (0.6-14.7) 0.291

CRH 1.04 (0.6-1.7) 0.87 0.8 (0.4-1.7) 0.567

Infection 1.55 (0.9-2.6) 0.11 2.74 (1.4-5.5) 0.004

Disclosure of Interests: None declared


POS0821

CORONARY ARTERIAL INVOLVEMENT CAN BE OBSERVED IN A SIGNIFICANT SUBSET OF TAKAYASU’S ARTERITIS PATIENTS BY CORONARY CT-ANGIOGRAPHY

K. Abacar\(^1\), A. Cincin\(^2\), F. Baltacioglu\(^3\), Z. Dogan\(^4\), G. Sevik\(^5\), H. Direskeneli\(^6\), F. Alibaz-Oner\(^7\), \(^8\)Marmara University School of Medicine, Department of Radiology, Istanbul, Turkey; \(^9\)Marmara University School of Medicine, Department of Cardiology, Istanbul, Turkey; \(^10\)Marmara University School of Medicine, Department of Radiology, Istanbul, Turkey

Background: Besides the aorta and its main branches, coronary arterial involvement is also seen at a substantial rate in patients with Takayasu’s arteritis (TAK). Computerized tomography (CT)-angiography, as a non-invasive assessment tool, has started to be used instead of conventional angiography in the evaluation of coronary arteries. However, limited data is available for its role in TAK patients.

Objectives: In this study, we aimed to assess the coronary arterial involvement by coronary CT-angiography in TAK patients with or without symptoms and to compare clinical characteristics of patients with or without coronary arterial involvement.

Methods: Patients with TAK (n=49, F:M/49:0, mean age: 42.6±1.9 years) followed in Marmara University Vasculitis Clinic and underwent coronary CT-angiography with or without cardiac symptoms were evaluated retrospectively. Data of four patients who were not suitable for coronary CT-angiography but underwent conventional angiography were also included. CT angiography findings in the coronary arteries were defined as ostial stenosis, stenosis, calcific plaque and aneurysm and patients were categorized into two groups as those with or without coronary artery pathology. Demographic data, cardiac symptoms, clinical findings, BMIs, angiographic Hata and Goel classifications, treatments received for TAK, acute phase reactants and lipid levels were compared.

Results: Coronary artery pathology was detected in 14 patients (28.7%). Only 9 patients had a history of angina and 6 had cardiac symptoms in this group. Calcific plaque was present in 11 (22.5%), coronary artery stenosis in eight (16.3%) and aneurysm, ostial stenosis and occlusion in one patient each (2.0%). RCA was involved in 20.4%, LAD in 26.8%, LMCA in 22.4%, CX in 26.6% and more than one coronary arterial involvement in 26.5% of patients. In patients with coronary artery involvement, age (p=0.02), age at TAK diagnosis (p=0.004) and number of anti-hypertensive drugs (p=0.011) were significantly higher than those without coronary artery involvement. History of angina (p=0.004) and statin use (p=0.001) were also significantly higher in patients with coronary artery abnormalities, whereas HDL levels were significantly lower (p=0.037). No significant differences were observed between the groups when gender, smoking history, diabetes, BMI, ITAS2010 scores, biological therapy use, angiographic classifications, aortic involvement, presence of cardiac symptoms, CRP, ESR, total cholesterol and LDL levels were compared (Table 1).

Table 1. Comparison of patient groups with and without coronary artery involvement (BMI: Body Mass Index, SD: Standard Deviation, ITAS: Indian Takayasu Activity Score, LDD: Low Density Lipoprotein, HDL: High Density Lipoprotein)

<table>
<thead>
<tr>
<th></th>
<th>Presence of Coronary Arterial Involvement (n=14)</th>
<th>Absence of Coronary Arterial Involvement (n=35)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Age</td>
<td>p value</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>74.3 (6.42)</td>
<td>39.94 (9.39)</td>
</tr>
<tr>
<td>Age at TAK diagnosis</td>
<td>41.21 (12.58)</td>
<td>31.37 (11.8)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biological therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP (mg/L) mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ITAS2010 mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL (mg/dL) mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aortic involvement</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statin use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of antihypertensives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetylsalicylic acid use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angina history</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Coronary arterial involvement which is an important cause of morbidity and mortality can be detected non-invasively by coronary CT-angiography in up to 1/3 of patients with Takayasu’s arteritis, also in patients without angina and cardiac symptoms. Traditional cardiac risk factors are present more commonly in this group.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5179

Disclosure of Interests:

None declared

Hypertrophic Pachymeningitis in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Multicenter Survey in Japan


1. Shinshu University School of Medicine, Department of Medicine (Neurology and Rheumatology), Matsumoto, Japan; Immunology, Nishinomiya, Japan; University Hospital, Department of Hematology and Rheumatology, General Internal Medicine, Tottori, Japan; Showa University School of Medicine, Division of Rheumatology, Department of Medicine, Tokyo, Japan; 2. Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Inflammation and Immunology, Kyoto, Japan; 3. University of Yamanashi Hospital, Department of Rheumatology, Chuo-shi, Japan; 4. Juntendo University, Department of Internal Medicine and Rheumatology, Tokyo, Japan; 5. Japanese Red Cross Society Kyoto Daiichi Hospital, Center for Rheumatic Disease, Kyoto, Japan; 6. Chubu Rosai Hospital, Department of Rheumatology, Nagoya, Japan; 7. St. Luke’s International Hospital, Immunorheumatology Center, Tokyo, Japan; 8. Japanese Red Cross Society Kyoto Daini Hospital, Department of Rheumatology, Kyoto, Japan; 9. Kyoto Katsura Hospital, Department of Nephrology, Kyoto, Japan; 10. Tosei General Hospital, Department of Respiratory Medicine and Allergy, Seto, Japan; 11. Kagoshima University Hospital, Department of Hematology and Rheumatology, Kagoshima, Japan; 12. Tottori Prefectural Central Hospital, Department of General internal medicine, Tottori, Japan; 13. Hiroshima University Hospital, Department of Clinical Immunology and Rheumatology, Hiroshima, Japan; 14. St. Mariana University School of Medicine, Division of Rheumatology and Allergy, Department of Internal Medicine, Kawasaki, Japan; 15. Hyogo College of Medicine, Department of Diabetology, Endocrinology and Clinical Immunology, Nishinomiya, Japan; 16. Osaka Medical and Pharmaceutical University, Department of Internal Medicine (IV), Tottori, Japan; 17. Nagasaki University Graduate School of Biomedical, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; 18. Graduate School of Medicine, Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan; 19. Tokyo Kyosai Hospital, Department of Rheumatology, Tokyo, Japan; 20. Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Department of Rheumatology, Tokyo, Japan; 21. Faculty of Medicine, Tottori University, Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Yonago, Japan; 22. Graduate School of Medical Science, Kanazawa University, Department of Rheumatology, Kanazawa, Japan; 23. Tottori University, Division of Gastroenterology and Nephrology, Yonago, Japan; 24. Shimane University Faculty of Medicine, Department of Rheumatology, Izumo, Japan; 25. Sasebo Chuo Hospital, Rheumatic Disease Center, Sasebo, Japan; 26. Shimane University Hospital, Division of Nephrology, Izumo, Japan; 27. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 28. University Hospital, Kyoto Prefectural University of Medicine, The Clinical and Translational Research Center, Kyoto, Japan; 29. Tokyo University of Pharmacy and Life Sciences, Department of Practical Pharmacy, Tokyo, Japan; 30. Shinsu University School of Medicine, Department of Medicine (Neurology and Rheumatology), Matsumoto, Japan

Background: Hypertrophic pachymeningitis (HP), characterized by an inflammatory disorder indicating intracranial or spinal thickening of dura mater, is found to develop as a neurological involvement in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Meanwhile, the previous studies focusing on HP in AAV have been reported as a single-institution study, and the analyses were performed in a small number of patients because HP is a rare neurological disorder. Therefore, neither etiological nor clinical characteristics of HP in AAV have been adequately elucidated.

Objectives: This study clarified the characteristics of HP in AAV by analyzing the information of multicenter study in Japan (Japanese collaborative registry of ANCA-associated vasculitis (J-CANVAS)).

Methods: We analyzed the clinical information from 541 Asian patients with AAV enrolled in J-CANVAS. Of them, newly diagnosed and relapsed AAV were included in 448 and 93, respectively. The epidemiological and clinical findings were compared between patients with and without HP. Clinical manifestations related to AAV were evaluated based on the Birmingham Vasculitis Activity Score version 3. To elucidate independent factors in HP development, logistic regression analyses were additionally performed.

Results: Of the total 541 patients (mean age: 71.4±14 years, M:F = 1:1.2), HP was newly diagnosed in 28 (5.2%) including 17 (3.7%) in newly diagnosed AAV and 11 (11.8%) in relapsed AAV. The classification of granulomatosis with polyangiitis (GPA) was significantly higher in patients with HP than those without HP (50% vs. 21%, p = 0.0007). In newly diagnosed AAV, patients with HP significantly had higher GPA classification and higher positivity for PR3-ANCA than those without HP (53% vs. 17%, p = 0.001; 29% vs. 9%, p = 0.015, respectively). Conversely, positivity for MPO-ANCA was significantly higher in patients with HP than those without HP in relapsed AAV (91% vs. 55%, p = 0.025), despite not significantly different in the classification of AAV. Headache and cranial neuropathies were significant neurological symptoms in patients with HP compared to those without HP (82% vs. 6.6%, p < 0.0001; 32% vs. 2.9%, p < 0.0001, respectively). Besides, ear, nose and throat (ENT) and mucous membranes/eyes were significantly higher involvements in patients with HP than in those without HP (54% vs. 26%, p = 0.003; 29% vs. 9%, p = 0.003, respectively). Moreover, higher complications of “conjunctive hearing loss” and “sudden visual loss”, which are included in the categories of ENT and mucous membranes/eyes involvement, respectively, were significantly indicated in patients with HP than those without HP (39% vs. 7.2%, p < 0.0001; 21% vs. 1.2%, p < 0.0001, respectively). Multivariable logistic regression analysis identified that ENT (odds ratio [OR] 1.28, 95% confidence interval [CI] 1.09 to 1.49, p = 0.002) and mucous membranes/eyes involvement (OR 1.37, CI 1.14 to 1.65, p = 0.006), as well as conjunctive hearing loss (OR 4.52, CI 1.56 to 13.05, p = 0.005) and sudden visual loss (OR 1.84, CI 1.12 to 3.00, p = 0.015), were independent related factors in patients with HP.

Conclusion: GPA could be significantly classified in patients with HP. Notably, patients with HP significantly showed higher positivity for PR3-ANCA than those without HP in newly diagnosed AAV. Furthermore, sudden visual loss and conjunctive hearing loss might be implicated in HP development.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.32

KO6 IN ANCA-ASSOCIATED VASCULITIS PATIENTS WITH AND WITHOUTILD: A MACHINE LEARNING APPROACH

E. Conticini, M. d’Allesandri, L. Bergantiini, D. Castilho, P. Faisetti, P. Carmeli, E. Bargagli, L. Cantarini, L. Frediani on behalf of Sienna Vasculitis Study Group. 1. University of Siena, Rheumatology Unit, Siena, Italy; 2. University of Siena, Respiratory Diseases and Lung Transplantation Unit, Siena, Italy; 3. Hospital de la Santa Creu i Sant Pau, Respiratory Unit, Barcelona, Spain

Background: ANCA-associated vasculitis (AAV) are small vessel vasculitis which may variously affect upper and lower respiratory tract. Patients with microscopic polyangiitis (MPA) and, less commonly, granulomatosis with polyangiitis (GPA), especially those who are ANCA-MPO-positive, may suffer from interstitial lung disease (ILD), which is associated with high morbidity and mortality as it is often underdiagnosed and responds poorly to conventional treatments.

Objectives: In this study, we aimed to assess whether Krebs von den Lungen-6 (KL-6), a marker of fibrotic ILD, may be useful for distinguishing AAV patients with ILD from those without ILD, and whether its changes over time are correlated with disease activity.

Methods: We enrolled all consecutive patients evaluated in the period December 2020 - November 2021. Inclusion criteria were a diagnosis of GPA or MPA, active disease, and eligibility for Rituximab treatment according to EULAR recommendations. All patients underwent concomitant rheumatological and pneumological evaluation, lung function tests, routine blood tests, autoimmunity evaluation and KL-6 assay. Current and previous treatments, Birmingham vasculitis score (BVAS) and vasculitis damage index were also recorded.

Results: A total of 13 patients (Table 1) were enrolled. One was excluded due to a concomitant diagnosis of lung cancer. Higher serum KL-6 were in AAV-ILD compared with those without ILD (972.8±398.5 vs. 305.4±93.9, p = 0.0040). Under the Receiver Operating Characteristics curve showed 100% of the diagnostic performance of KL-6 for identifying the ILD involvement (accuracy 91.7%) and the best cutoff value of 388 U/mL (Sensitivity 100% and specificity 87.5%). The decision-tree model showed a 33% improvement in class purity using a cutoff of 388 U/mL. To distinguish AAV patients with and without ILD (Figure 1). Stratifying AAV patients as GPA and with and without ILD considering T0 and T1 KL-6, the model obtained an improvement of 40% for classifying GPA with disease activity.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.32

Scientific Abstracts
Table 1. Patients' features

<table>
<thead>
<tr>
<th>Sex/age</th>
<th>Diagnosis</th>
<th>Length of disease (months)</th>
<th>Organs involved</th>
<th>Type of lung involvement</th>
<th>T0 KL6 levels</th>
<th>T0 BVAS</th>
<th>T0 VDI</th>
<th>T1 KL6 levels</th>
<th>T1 BVAS</th>
<th>T1 VDI</th>
</tr>
</thead>
<tbody>
<tr>
<td>F/38</td>
<td>MPA</td>
<td>28</td>
<td>Lung, kidney, PNS</td>
<td>ILD, alveolar hemorrhage</td>
<td>625</td>
<td>8</td>
<td>7</td>
<td>325</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>M/48</td>
<td>GPA</td>
<td>1</td>
<td>Lung, kidney, nose, eye Nodules</td>
<td>-</td>
<td>352</td>
<td>18</td>
<td>0</td>
<td>279</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>F/55</td>
<td>GPA</td>
<td>252</td>
<td>Lung, skin</td>
<td>Nodules</td>
<td>401</td>
<td>15</td>
<td>3</td>
<td>602</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>F/38</td>
<td>GPA</td>
<td>1</td>
<td>Skin</td>
<td>-</td>
<td>347</td>
<td>6</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F/74</td>
<td>MPA</td>
<td>180</td>
<td>Kidney, PNS</td>
<td>ILD, alveolar hemorrhage</td>
<td>368</td>
<td>15</td>
<td>5</td>
<td>414</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>M/77</td>
<td>GPA</td>
<td>8</td>
<td>Lung, kidney, PNS, skin ILD, alveolar hemorrhage</td>
<td>982</td>
<td>24</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F/49</td>
<td>GPA</td>
<td>60</td>
<td>Nose, eye</td>
<td>-</td>
<td>122</td>
<td>6</td>
<td>2</td>
<td>116</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>M/80</td>
<td>GPA</td>
<td>40</td>
<td>Skin, PNS</td>
<td>-</td>
<td>205</td>
<td></td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F/39</td>
<td>GPA</td>
<td>4</td>
<td>Nose</td>
<td>-</td>
<td>310</td>
<td>6</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>M/71</td>
<td>GPA</td>
<td>24</td>
<td>Lung, eye, joints Nodules, ILD</td>
<td>1528</td>
<td>9</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F/64</td>
<td>GPA</td>
<td>24</td>
<td>Lung</td>
<td>ILD</td>
<td>756</td>
<td>4</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>F/59</td>
<td>GPA</td>
<td>72</td>
<td>Lung</td>
<td>Nodules</td>
<td>338</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

Figure 1. ROC curve and decision tree model

Conclusion: Our multicentre study demonstrated KL-6 as a reliable, non-invasive and easy-to-perform marker of ILD in AAV patients and its helpfulness for disease activity assessment. Changes in serum concentrations of KL-6 over time could be useful for monitoring AAV patients. Further study of KL-6 as a marker of response to therapy during long-term follow-up would also be worthwhile.

Disclosure of Interests: None declared


POS0824

SAFETY AND EFFICIACY OF THE INTENSIFIED B CELL DEPLETION INDUCTION THERAPY FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND SEVERE RENAL INJURY: A CONTROLLED STUDY

D. Roccatello1, S. Sciascia1, S. Murgia1, G. Quattrociocchi1, M. Ferro1, E. De Simone1, C. Naretto1, A. Barreca2, D. Rossi1, R. Fenoglio1

1University Center of Excellence on Nephrological, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), San Giovanni Bosco Hub Hospital, and Department of Clinical and Biological Sciences of the University of Turin, Torino, Italy; 2Città Della Salute e Della Scienza, Pathology Division, Torino, Italy

Background: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitides associated with antineutrophil cytoplasm antibodies (AAV) in both newly diagnosed and relapsing patients. However, the role of RTX in the management of the most severe cases of AAV remains to be fully elucidated.

Objectives: to assess both safety and efficacy of an intensified B-cell depletion therapy (IBCDT) protocol, including RTX, cyclophosphamide (CYC), and methyprednisolone pulses without additional maintenance immunosuppressive therapy compared to conventional therapy regimen based on oral CYC and steroids plus AZA in the management of the most severe cases of AAV. Additionally, this avoids the need of prolonged maintenance therapy for long, and limits the exposure to CYC with consequent reduced toxicity and drug-related side effect rates.

Disclosure of Interests: None declared


POS0825

CLINICAL CHARACTERISTICS AND TREATMENT MANAGEMENT OF NON-INFECTIONOUS SCLERITIS WITH CORTICOSTEROID SPARING THERAPY. A RETROSPECTIVE STUDY FROM A TERTIARY EYE CARE CENTER.

J. Toutain1, M. A. Gargouri1, I. Chaza2, S. Fares1, I. Cocchera1, E. Gabison1, C. Titah1, G. Clavel Refregiers2, 1Foundation Adolphe de Rothschild Hospital, Ophthalmology Department, Paris, France; 2Foundation Adolphe de Rothschild Hospital, Internal Medicine, Paris, France

Background: Non-infectious scleritis refers to a rare and sight-threatening scle- ral inflammation. An association with an underlying systemic disease is noted in 30% to 40% of cases. Their management may require the use of nonsteroidal anti-inflammatory drugs, oral corticosteroids, and sometimes steroid-sparing immunosuppressive agents. Because of the low incidence and prevalence of scleritis, treatment guidelines are currently not available.

Objectives: We analyzed in a retrospective observational study patients with scleritis referred to the Foundation Rothschild Hospital (Paris) from March 2011 to June 2021.

Methods: Characteristics, visual outcomes, ocular complications, associations with systemic diseases and efficacy of treatment were assessed in patients with non-infectious scleritis who needed steroid-sparing immunosuppressive agents.

Results: Among 731 patients diagnosed with scleritis, 54 patients (71 eyes, 7%) were treated by steroid-sparing immunosuppressive agents. Mean follow up was 119.9 ± 84.5 weeks. Mean age was 48.4 years ± 18.3, and 31 patients (57%) were female. Scleritis was anterior in 51 eyes (72%), including 25 (35%) with diffuse scleritis, 24 (34%) with nodular scleritis and 2 (3%) with necrotizing scleritis. Scleri- tis was posterior in 20 eyes (38%), bilateral involvement was noted in 17 patients (32%). Ocular complications were observed in 52 eyes (73%): scleral thinning in 25 eyes (35%), anterior uveitis in 24 eyes (34%), loss of vision in 20 eyes (38%), posterior segment ocular complications in 18 eyes (25%), ocular hypertension in 17 eyes (24%) and corneal involvement in 16 eyes (23%). An underlying systemic disease was identified in 28 patients (52%), and scleritis was the first manifesta- tion of the systemic disease in 17 of 28 patients. Rheumatoid arthritis was the most frequently identified disease (n=12), followed by granulomatosis with polyangiitis (n=8) and relapsing polychondritis (n=4). All patients received at least...
one immunosuppressive agent. Corticosteroid sparing with a daily dose ≤ 5 mg of prednisone was achieved in 85% of patients. Conventional immunosuppressive agents were used as the first steroid-sparing agent in 38 patients (70%) (methotrexate n=33, azathioprine n=4, mycophenolate mofetil (MMF) n=1) and as second steroid-sparing agent in 1 patient (MMF). This treatment led to control scleral inflammation in 23 (59%) patients after a mean delay of 10.0 ± 6.0 weeks. Biologic therapy was used in 33 (61%) patients (TNF α inhibitor n=17, IL-6R inhibitor n=7, anti-CD20 n=8), and as the first steroid-sparing agent in 16 (30%) (TNF α inhibitor n=4, IL-6R inhibitor n=4, anti-CD20 n=8). This treatment led to control scleral inflammation after a mean delay of 4.9 ± 3.7 weeks in 29 patients (87%).

**Conclusion:** Scleritis is a severe ocular inflammatory disease that requires repeated and thorough ophthalmologic and general evaluations given the high frequency of complications and the possibility of an underlying systemic disease. This study reports real-life experience in management of non-infectious scleritis. Biological therapies seemed to be associated with a better outcome and a quicker response than conventional immunosuppressive agents. Further studies are warranted to develop specific guidelines

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1711

---

**POS0826**

**CIRCULAR RNA EXPRESSION PROFILES AND IDENTIFICATION OF HSA. CIRC_0028381 AS A POTENTIAL BIOMARKER OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS**

Y. Liu1, L. Jiang1, X. Zhang1, Zhongshan Hospital, Fudan University, Rheumatology, Shanghai, China

**Background:** Growing evidence indicated that dysregulated circRNAs play a vital role in autoimmune diseases. However, their role in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has never been illustrated.

**Objectives:** This study aims to determine the expression profiles of circRNAs in plasma of AAV patients and explore the potential of circRNA as biomarker of AAV.

**Methods:** RNA-sequencing (RNA-seq) was performed to identify the circRNAs and mRNAs expression profiles in plasma from 5 AAV patients and 5 healthy controls (HCs). Hsa_circ_0028381, one of the four candidate circRNAs were validated by quantitative reverse-transcription (qRT)-PCR in a validation cohort of 51 AAV patients and 30 HCs and was confirmed to be significantly upregulated. And it was further verified in other connective tissue diseases (CTDs) by qRT-PCR. The receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic value.

**Results:** RNA expression profiles revealed that 143 circRNAs and 304 mRNAs were aberrantly expressed, among which, 62 circRNAs were upregulated and 81 circRNAs were downregulated in AAV patients compared to HCs. The result of qRT-PCR verification suggested that hsa_circ_0028381 was significantly increased in plasma from AAV patients compared to that in HCs and CTDs. The receiver operating characteristic (ROC) curve analysis showed has_circ_0028381 had a good diagnostic value to distinguish AAV patients from controls (HCs and other CTDs) with area under the curve (AUC) of 0.81. In addition, has_circ_0028381 was associated with renal involvement. Most importantly, increased baseline level of has_circ_0028381 had a predictive value for renal progression to end-stage renal disease (ESRD).

**Conclusion:** RNA-seq revealed that circRNAs were aberrantly expressed in plasma of AAV patients. Hsa_circ_0028381 might function as a potential biomarker for AAV diagnosis and renal prognosis.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1207

---

**POS0827**

**VASCULITIDES AS MEDICATION-INDUCED ADVERSE EVENTS BASED ON A NATIONAL DATABASE: REPORTING SYSTEM**

A. Rodriguez-Pla1, Mayo Clinic, Rheumatology, Scottsdale, United States of America

**Background:** Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications.

**Objectives:** For the present study, we aimed to analyze the vasculitides reported to a national AEs spontaneous reporting system from October 2012 through September 2021.

**Methods:** All spontaneous reports of vasculitides related to any medications from October 1st, 2012, to September 30th, 2021, were retrieved from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. We performed a descriptive analysis of demographics, medications, and type of vasculitis based on 25 Medical Dictionary for Regulatory Activities (MedDRA) preferred term (PT) codes. Medications identified as the primary suspect in individual case reports were analyzed. ICSRs were retrieved by the product active ingredient. RStudio v1.4.1717 was used for general data analysis and the R package openEBGM v0.8.3 was used for the calculation of the Empirical Bayes Geometric Mean (EBGM) as the disproportionality score with its 90% two-sided credibility interval, frequently used in safety signal detection models. Drug-event combinations with an EBGM 5% lower limit credibility interval ≥ 2 were considered significant. An EBGM score of 2 indicates that the drug had at least 2 times as many reports for the AE as expected.

**Results:** During the study period, we retrieved 10,404 ICSRs reporting 10,931 AEs of vasculitis associated with a medicinal product as the primary suspect for that AE. The patient’s mean age was 56.5 years, and 61% of them were female. Of the 25 PTs selected, the generic term “Vasculitis” was the most frequently reported AE (29.1%), followed by “Hypersensitivity vasculitis” (14.9%), “Polyangiitis rheumalitis” (7.7%), “Anti-neutrophil cytoplasmatic antibody-positive vasculitis” (ANCA-associated vasculitis) (6.2%), and “Cutaneous vasculitis” (5.4%). Of the total ICSRs with vasculitis AEs, 90% were expected because they reported serious, unexpected AEs.

Eighty drug-event combinations were disproportionately reported. Of those, the strongest association was observed for amlotuzumab and Goodpasture’s syndrome (anti-glomerular basement membrane disease), followed by minocycline and polyarteritis nodosa, penicillamine and Kawasaki’s disease (KD), then ribavirin and cyclosporine, eumicro and microscopic polyangiitis, and so on.

Many medications were associated with more than one AE, such as infliximab with Takayasu’s arteritis (TAK), Behcet’s syndrome (BS) and Henoch-Schönlein purpura (iGA vasculitis); adalimumab with BS and TAK; hydralazine with ANCA-associated vasculitis and renal vasculitis; and rituximab with granulomatosis with polyangiitis (GPA) and cryoglobulinemia.

**Conclusion:** Many different vasculitides were reported as AEs in the national database. Some of the medications were associated with the diseases they treat, which raises concern for possible confounding by indication. In other cases, the events were already known as adverse reactions, as for example amlotuzumab and Goodpasture’s syndrome or montelukast and eosinophilic granulomatosis with polyangiitis. In other cases, no label or publication references were found, as for pulivamub and KD. These latter cases may raise a concern for potential safety signals that should be investigated. The improved understanding of the mechanism of action of drugs associated with some of these AEs may help to elucidate the pathogenesis of vasculitides.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2027
Background: Ocular and Neurobehçet's Disease (NBD) are the most severe manifestations of Behçet's disease (1-4). NBD can be classified as a) primary neural parenchymal lesions, also known as parenchymal NBD (p-NBD) or b) secondary to vascular involvement or non-parenchymal NBD (np-NBD) (4). Response to biological therapy (BT) in these two refractory subtypes of NBD is unknown.

Objectives: To assess efficacy and safety of BT in refractory subtypes of NBD.

Methods: Open-label multicenter study of refractory NBD from 21 different referral National Hospitals. NBD diagnosis was based on the International Consensus Recommendation criteria (4). Efficacy was determined by complete or partial response and no-response. Complete, partial or no response was defined according to the resolution of the neurological syndrome (signs and/or symptoms) after the BT onset.

Results: We studied 41 patients (21 women/20 men; mean age: 40.6±10.8 years). NBD was classified as p-NBD (n=33, 80.5%) and np-NBD (n=17, 41.5%). There were no significant differences in baseline general features and in neurological clinical response in both subgroups (Table 1 and Figure 1). The first BT used in p-NBD were Infliximab (IFX) (n=15), Adalimumab (ADA) (n=11), Golimumab (GLM) (n=3), Tocilizumab (TCZ) (n=2) and Etanercept (ETN) (n=2) and in np-NBD were IFX (n=9), ADA (n=6), TCZ (n=1) and ETN (n=1).

Table 1. Main features of p-NBD and np-NBD

<table>
<thead>
<tr>
<th>Age at biological therapy initiation, years (mean±SD)</th>
<th>Total</th>
<th>p-NBD</th>
<th>np-NBD</th>
<th>p-NBD vs np-NBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, n (m/f) (%)</td>
<td>21/20</td>
<td>18/15</td>
<td>5/12</td>
<td>0.091</td>
</tr>
<tr>
<td>HLAB51 +/ patients tested, n (%)</td>
<td>15/31</td>
<td>14/25</td>
<td>1/6</td>
<td>0.323</td>
</tr>
<tr>
<td>Oral aphthas, n (%)</td>
<td>40/376</td>
<td>36/367</td>
<td>4/10</td>
<td>0.391</td>
</tr>
<tr>
<td>Cutaneous involvement, n (%)</td>
<td>28/63.4</td>
<td>23/69.7</td>
<td>5/10.8</td>
<td>0.603</td>
</tr>
<tr>
<td>Ocular involvement, n (%)</td>
<td>21/48.8</td>
<td>15/45.5</td>
<td>6/12.9</td>
<td>0.616</td>
</tr>
<tr>
<td>Vascular involvement, n (%)</td>
<td>9/22</td>
<td>10/30.3</td>
<td>7/11.2</td>
<td>0.442</td>
</tr>
<tr>
<td>Articular involvement, n (%)</td>
<td>9/22</td>
<td>7/21.2</td>
<td>3/17.6</td>
<td>0.765</td>
</tr>
</tbody>
</table>

Table 1. Main features of p-NBD and np-NBD

<table>
<thead>
<tr>
<th>Previous conventional Immunosuppressive drugs to BT</th>
<th>Total</th>
<th>p-NBD</th>
<th>np-NBD</th>
<th>p-NBD vs np-NBD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azathioprine</td>
<td>24/58.5</td>
<td>20/60.6</td>
<td>4/58.8</td>
<td>-</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>16/39.0</td>
<td>12/36.4</td>
<td>4/17.6</td>
<td>-</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>13/31.7</td>
<td>13/39.4</td>
<td>3/29.4</td>
<td>-</td>
</tr>
<tr>
<td>Cyclosporine A</td>
<td>9/22.0</td>
<td>8/24.2</td>
<td>1/17.6</td>
<td>-</td>
</tr>
<tr>
<td>Mycophenolate Mofetil</td>
<td>2 (4.9)</td>
<td>2 (6.1)</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

Figure 1. Response to biological therapy according to NBD subtypes.

After an overall mean follow-up of 57.5±50.9 months BT was switched in 22 patients due to ineffectiveness (n=16) or Adverse Effects (AE) (n=6) and in 4 cases was definitively discontinued because of complete prolonged remission (n=3) or AE (n=1). AE were observed in 7 (17.1%) patients. Severe AE were observed in 2 cases, one due to demyelinating disease and the other due to pulmonary tuberculosis, both in patients undergoing IFX therapy. The other 6 AE were infusion reaction to IFX (n=1), IFX-induced psoriasis (n=1), IFX-induced acniform eruption (n=1), infusion reaction to TCZ (n=1), intolerance to IFX and recurrent mild infections (n=1) and erosive lichen planus and bullous impetigo (n=1).

Conclusion: In our series, BT seems equally effective and safe in both refractory p-NBD and np-NBD.
Conclusion: We report on the detection of PTX3-, BPI- and OLM4-ANCA in addition to MPO- and PR3-ANCA in EGPA. OLM4-ANCA has been reported in 2 patients with non-vasculitic inflammatory symptoms previously [5]. Herein, detection of OLM4-ANCA in EGPA is reported for the first time. Our study shows that the presence of ANCA with various specificities other than MPO and PR3 contribute to a higher prevalence of ANCA in EGPA. Moreover, clinical manifestations differ between ANCA-negative EGPA and ANCA-positive EGPA, and between patients with different ANCA-specificities.

REFERENCES:

Disclosure of Interests: None declared


POS0830 SYSTEMATIC LITERATURE REVIEW INFORMING THE 2022 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS: FOCUS ON TREATMENT STRATEGIES

J. Schirmer1, B. Sanchez-Alamo2, S. Monti3, B. Hellmich4, D. Jayne5, 1University Medical Center Schleswig-Holstein, Clinic for Internal Medicine I, Section for Rheumatology, Kiel, Germany; 2Lund University Skåne University Hospital, Nephrology, Lund, Sweden; 3University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Rheumatology, Pavia, Italy; 4University of Tubingen, Medius Kliniken, Internal Medicine, Rheumatology and Immunology, Kirchheim-Teck, Germany; 5University of Cambridge, Addenbrooke’s Hospital, Department of Medicine, Cambridge, United Kingdom

Background: The 2008 and 2016 European Association of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitides (AAV)1,2 have supported clinicians with comprehensive recommendations for the treatment of patients with AAV in daily practice. During the past 5 years, the publication of several high-impact randomized-controlled studies have further improved the standard of care of AAV.

Objectives: The aim of this systematic review was to collect evidence supporting the 2022 update the AAV management recommendations.

Methods: The recommendations were developed based on an evidence-based approach as outlined in the 2014 EULAR standardized operating procedures (SOP)3. Areas of interest were adopted from the 2016 recommendations and updated by identifying additional topics through a Delphi process. Key questions were framed in the PICO (Population, Intervention, Comparator, Outcome) format and a search strategy consisting of keywords identifying treatment-related topics of interest was created based on the PICO questions. Aspects of drug treatment and other therapeutic interventions in AAV were included in the search, with a focus on remission induction, maintenance treatment and steroid sparing protocols. Outcomes such as survival, remission/relapses, infectious complications and malignancies were also covered. PubMed (Medline), Embase and the Cochrane Library databases were searched for articles providing data on the search questions. Abstracts of the annual meetings of EULAR, ACR, ERA-EDTA, ASN and the Vasculitis and ANCA Workshops were also screened, but restricted to randomized controlled clinical trials (RCTs). After duplication publications were sorted by title and abstract first. There was full text review for articles eligible after title/abstract screening. The data were extracted from included articles and grouped according to the PICO questions. Data extraction results were collected in evidence tables.

The SLR was still ongoing at the time this abstract has been written and results of the SLR will be presented at the meeting.

Acknowledgements: The project is funded by EULAR.

Disclosure of Interests: Jan Schirmer: None declared, Beatriz Sanchez-Alamo: None declared, Sara Monti: None declared, Bernhard Hellmich Speakers bureau: Abbvie, BMS, Chugai, GSK, MSD, Novartis, Pfizer, Roche, Vifor; Consultant of: Boehringer, BMS, Chugai, GSK, InfraRx, Novartis, Roche, Vifor, David Jayne Speakers bureau: Vifor; Consultant of: Astra-Zeneca, Boehringer, BMS, Chemo-centryx, Chugai, GSK, Novartis, Roche

DOI: 10.1136/annrheumdis-2022-eular.3156

POS0831 IGA VASCULITIS IN ADULTS, PEDIATRICS AND NON-VASCULITIC IGA NEPHROTYPH

S. Levinson1, V. Gottlieb2, Y. Kraus1, I. Novostavskii1, S. Brikman1, A. Fawaz2, M. Aghbariyya3, Y. Butbul4, A. Balbir-Gurman1, R. Mader1, A. Bieber1, 1Emek Medical Center, Rheumatology, Afula, Israel; 2Emek Medical Center, Pediatric Rheumatology Service, Afula, Israel; 3Emek Medical Center, Pathology, Afula, Israel; 4The Ruth Rappaport Children's Hospital, Pediatric Rheumatology Service, Haifa, Israel; 5Rambam Health Care Campus, Rheumatology, Haifa, Israel

Background: Iga vasculitis (IgAV) has been extensively studied in children, while its natural history remains poorly studied in adults. Sparse data comparing childhood and adult-onset disease has shown significant differences in their clinical presentation, especially in the severity of renal involvement, which accounts for the major long-term morbidity. IgAV shares similar renal histologic features with IgA nephropathy (IgAN), while clinically IgAN is a chronic kidney disease which may lead to end stage renal disease and dialysis. The extent of kidney injury among adults with IgAV is still a matter of uncertainty.

Objectives: We aimed to evaluate clinical manifestations, laboratory data, treatment patterns and long-term outcomes of pediatric and adult-onset IgAV in comparison to IgAN.

Methods: This retrospective collaborative study examined medical records of adults and children with IgAV and IgAN adult patients admitted to rheumatology clinic and in hospital pediatric departments in a 13-year period (2007-2019). Diagnosis of adults with IgAV relies on the Ankara criteria and was confirmed by a consistent skin biopsy with positive IgA staining by immunofluorescence. Children with IgAV were included in our study on a clinical basis. All IgAN patients had a kidney biopsy proven disease. We analyzed and compared frequencies of clinical manifestations, laboratory findings, treatment regimens and long-term outcomes at one year follow-up. Finally, we assessed long term outcomes, such as time to dialysis and all-cause mortality, till the end of the follow-up time.

The Cochrane revised tool for assessing risk of bias for RCTs (RoBu), ROBINS-I for observational studies and AMSTAR II for meta-analyses were used for bias assessment. Evidence was categorized based on the GRADE system as per EULAR SOP. Results: Based on the results of the Delphi, 11 topics related to clinical presentations were identified that were transformed into PICO questions (Table 1). Other items that received lower scores were added in the format of subquestions. Based on these research questions, search strings for the SLR were created.

Table 1. Key topics of interest for treatment strategies identified in the Delphi exercise grouped according to the PICO format

<table>
<thead>
<tr>
<th>Patients</th>
<th>Intervention &amp; Comparators</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis</td>
<td>Granulomatosis with Polyangiitis</td>
<td>Cyclophosphamide</td>
</tr>
<tr>
<td>Microscopic Polyangiitis</td>
<td>Rituximab</td>
<td></td>
</tr>
<tr>
<td>Eosinophilic Granulomatosis with Polyangiitis</td>
<td>Mycophenolate</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Methotrexate</td>
<td></td>
</tr>
<tr>
<td>Disease severity</td>
<td>Azathioprine</td>
<td></td>
</tr>
<tr>
<td>New-onset disease</td>
<td>Glucocorticoids</td>
<td></td>
</tr>
<tr>
<td>Relapsing disease</td>
<td>Azacyclovir</td>
<td></td>
</tr>
<tr>
<td>Organ- or life-threatening disease</td>
<td>Mepolizumab</td>
<td></td>
</tr>
<tr>
<td>Not organ- or life-threatening disease</td>
<td>Plasma exchange</td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: Xander Bicknell: None declared, Sara Monti: None declared, Bernhard Hellmich Speakers bureau: Abbvie, BMS, Chugai, GSK, MSD, Novartis, Pfizer, Roche, Vifor; Consultant of: Boehringer, BMS, Chugai, GSK, InfraRx, Novartis, Roche, Vifor, David Jayne Speakers bureau: Vifor; Consultant of: Astra-Zeneca, Boehringer, BMS, Chemo-centryx, Chugai, GSK, Novartis, Roche

DOI: 10.1136/annrheumdis-2022-eular.3156
Results: A total of 60 adult IgAV, 60 pediatric IgAV and 45 IgAN patients were included in our study. There were significantly more males in the IgAN group compared to the adult and pediatric IgAV groups (77.8%, 41.7% and 55% respectively, p<0.01). Adult IgAV patients were significantly older than IgAN patients (53.1±17.4 years vs. 45.1±15.7 years, p=0.02) and had significantly higher rates of diabetes (43.3% vs. 24.4%, p=0.05) and ischemic heart disease (18.3% vs. 4.4%, p=0.03). The pediatric IgAV group had a substantially higher rate of previous infection compared to the adult IgAV group (44.8% vs. 20%, p=0.02). At one year follow-up, IgAN patients had higher levels of serum creatinine compared to the adult IgAV group (2.002 vs. 1.100, p<0.01). Data observed until the end of the follow-up time showed no difference in time to dialysis (IgAV adults: 9.8-12.4 years, IgAN: 5.0-6.6 years, p=.41). Nevertheless, IgAV adult patients had significantly shorter survival time (5.5 years, 95% CI: 4.8-6.2 years) than IgAN patients (7.0 years, 95% CI: 6.6-7.5 years, p<.01).

Conclusion: This retrospective study demonstrates that IgAV in adults presents substantial clinical manifestations, including high risk of progression to persistent renal impairment and poses higher mortality rate in comparison with pediatric-onset disease and IgAN.

REFERENCES:


Figure 1.

Disclosure of Interests: None declared

MORTALITY TRENDS IN ANCA-ASSOCIATED VASCULITIS (AAVs): DATA FROM A CONTEMPORARY, MULTICENTER ANCA REGISTRY

C. Koutsianas1, A. Panagiotopoulos2, K. Thomas2, A. Chalkia2, A. Lazarini3, N. Kapasali4, S. Fiouda3, E. Argyriou2, K. Boki1, D. Petras2, D. Boumpas2, D. Vassilopoulos1. 12nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens, School of Medicine, Hippokration General Hospital, Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Athens, Greece; 24th Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Attikon General Hospital, Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Athens, Greece; 3Hippokration General Hospital, Nephrology Department, Athens, Greece; 4Asclepeion General Hospital, Rheumatology Department, Athens, Greece; 5Sismanogleio General Hospital, Rheumatology Department, Athens, Greece

Background: AAVs are a group of rheumatic diseases with excess morbidity and mortality (~3-fold higher compared to the general population). Long-term studies looking at mortality trends in contemporary patient cohorts are limited.

Objective: To investigate the overall long-term survival and all-cause mortality in a contemporary AAV patient cohort.

Methods: Multicenter study of patients registered and prospectively followed in the Greek ANCA Registry.

Results: Data for 165 patients (98.98 patient-years of follow up) with a diagnosis of AAV (GPA n=85, 58%, MPA n=54, 33%, EGPA n=16, 9%) were analyzed (January 1, 1998 - January 10, 2022). 53% of patients were female, with a mean age of 65 (±16.4) years; the majority (97%) had generalized disease and were ANCA positive (76%). The mean follow-up since diagnosis was 5.9 (±5.1) years. At the end of follow-up, the overall mortality rate was 20% (33/165), whereas the cumulative mortality rates at 5 and 10 years were 24% and 26% respectively. Overall cumulative survival at 5 years was worse in patients with MPA (57%) compared to GPA (81%) and EGPA (92%), (p<0.001). There was no difference in long-term survival among those treated with different induction regimens including cyclophosphamide (CYC, n of deaths=24/83, 28.9%), rituximab (RTX, n=4/40, 10%) or the CYC+RTX combination (n=3/16, 18.7%). Furthermore, there was no difference in survival between relapsing (≥1 relapses) and non-relapsing (n=76) patients (Figure 1). Cumulative survival was worse in patients who initially presented with lung (66% vs. 90% at 5 years, p=0.007), kidney (56% vs. 96% at 5 years, p<0.001) and simultaneous lung and kidney (39% vs. 93% at 5 years, p<0.001) involvement. Among the 33 registered deaths, the most frequent causes were infections (52%), followed by cardiovascular events (24%), disease flares (14%) and malignancies (10%).

Conclusion: In a contemporary multi-center AAV cohort, the cumulative mortality rates at 5 and 10 years were 24% and 26% respectively. Overall survival was worse in patients with MPA as well as those with combined lung and kidney involvement at baseline while there were no survival differences according to the initial induction regimen. Infection was the most common cause of death. These findings emphasize the unmet needs for better, less toxic therapies.

Acknowledgements: Supported in part by the Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE) and the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece (DV #12085, 12086).

Disclosure of Interests: None declared

POSO833 DIFFERENCES BETWEEN AVACOPAN AND PREDNISONE FOR THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS AT DIFFERENT THRESHOLDS OF GLUCOCORTICOID TOXICITY

N. Patel1, Y. Zhang2, D. Jayne3, P. A. Merkel4, H. Yue5, P. Bekker6, J. H. Stone2. 1Massachusetts General Hospital, Division of Rheumatology, Allergy and Immunology, Boston, United States of America; 2Massachusetts General Hospital, Division of Rheumatology, Allergy and Immunology, Boston, United States of America; 3University of Cambridge, Department of Medicine, Cambridge, United Kingdom; 4University of Pennsylvania, Division of Rheumatology, Philadelphia, United States of America; 5Chemicentrix, Clinical Development, San Carlos, United States of America; 6Chemicentrix, Department of Medical and Clinical Affairs, San Carlos, United States of America

Background: Treatment with glucocorticoids (GCs) for ANCA-associated vasculitis (AAV) is associated with substantial toxicity. The Glucocorticoid Toxicity Index (GTI) was developed to measure change in GC toxicity over time.1 Data from the composite GTI domains provide both an Aggregate Improvement Score (AIS) and a Cumulative Worsening Score (CWS) of GC toxicity, permitting the
instrument to compare both improvement and worsening of GC toxicity across treatment groups. The GTI was a pre-specified secondary outcome in ADVOCATE, a randomized, double-blind, placebo-controlled trial in patients with AAV that aimed to replace a GC taper with avacopan, a complement C5a receptor inhibitor. Patients were randomized to either avacopan or a prednisone taper on a background of either cyclophosphamide or rituximab. In ADVOCATE, the median GC exposure was 400 mg vs. 2939 mg in the avacopan and prednisone groups, respectively, which is an 86% median reduction in GC exposure from all sources. Remission rates were comparable in the two groups at 26 weeks (72.3% vs. 70.1%, respectively), and avacopan was superior at 52 weeks (sustained remission in 65.7% vs. 54.9%).

Objectives: To compare GC toxicity between the treatment groups at three different thresholds of GC toxicity, beginning with the minimum detectable difference (MDD) of the GTI.

Methods: The MDD for the GTI (10 points) was calculated in the initial validation phase of the instrument. Thus, any GTI score >10 points may be considered to represent a true change in GC toxicity. We compared the two groups at GTI thresholds of 10, 20, and 30 points for both the CWS and AIS. The CWS comprises a total of all GC-related toxicities that have occurred in the GTI between baseline and 26 weeks (time of primary outcome). The AIS, in contrast, allows toxicities to be added if they are new or subtracted if they improve. Higher CWS and AIS values indicate greater severity of GC toxicity. The two scores together capture the nuances of longitudinal GC toxicity across multiple domains. We compared the percentages of those in the two treatment groups who exceeded GTI threshold values of 10, 20, and 30 points in the CWS or AIS.

Results: The percentages of patients exceeding the specified AIS thresholds differentiated the avacopan group from the prednisone group (48.2% vs. 60.4%, respectively, at 10-point threshold; p=0.02; 29.5% vs. 45.1% at the 20-point threshold, p=0.003; and 18.1% vs. 33.5% at the 30-point threshold, p=0.001) (Table 1). The CWS differentiated avacopan from prednisone at the 20- and 30-point thresholds (57.8% vs 73.2%, respectively, at 20 points, p=0.002; 41.0% vs 55.5% at 30 points, p=0.007).

Table 1. Percentages of Patients in ADVOCATE Exceeding Selected GTI Thresholds at Week 26

<table>
<thead>
<tr>
<th>GTI threshold/study group</th>
<th>n (%) exceeding CWS threshold</th>
<th>p-value</th>
<th>n (%) exceeding AIS threshold</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GTI worsening &gt; 10 points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avacopan (N = 164)</td>
<td>136 (83.1%)</td>
<td>0.147</td>
<td>80 (48.2%)</td>
<td>0.022</td>
</tr>
<tr>
<td>Prednisone (N = 166)</td>
<td>144 (87.8%)</td>
<td>99 (60.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTI worsening &gt; 20 points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avacopan (N = 164)</td>
<td>96 (57.8%)</td>
<td>0.002</td>
<td>49 (29.5%)</td>
<td>0.003</td>
</tr>
<tr>
<td>Prednisone (N = 166)</td>
<td>120 (73.2%)</td>
<td>74 (45.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTI worsening &gt; 30 points</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avacopan (N = 164)</td>
<td>68 (41.0%)</td>
<td>0.007</td>
<td>30 (18.1%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Prednisone (N = 166)</td>
<td>91 (55.5%)</td>
<td>55 (33.5%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AIS, Aggregate Improvement Score; CWS, Cumulative Worsening Score; GTI, Glucocorticoid Toxicity Index

Conclusion: Among patients with AAV, treatment with avacopan was associated with lower GC toxicity across multiple GTI thresholds compared to treatment with prednisone, consistent with the substantial reduction in total GC exposure associated with avacopan. The GTI scores differentiated the two treatment groups effectively through a composite of GC toxicity domains.

REFERENCES:

Disclosure of Interests: Naomi Patel: None declared, Yuqing Zhang: None declared, David Jayne: Speakers bureau: Amgen, Vifor, Consultant of: AstraZeneca, BMS, Boehringer-Ingelheim, Chemocentryx, GSK, Novartis, Otsuka, Roche, Genentech, Takeda, UCB & Vifor, Grant/research support from: AbbVie, AstraZeneca, Boehringer-Ingelheim, Pfizer, Genentech, Peter A Merkel Consultant of: AbbVie, AstraZeneca, Roche, Genentech, Merck, Bristol-Myers Squibb, Chemocentryx, Forbis, Genentech/Roche, Genzyme/Sanofi, GSK, Janssen, Kyowa, Kyowa, Menlo, Novartis, Pfizer, Regeneron, Sanofi, Takeda, Talaris, Grant/research support from: AbbVie, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chemocentryx, Forbis, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InfraRx, Sanofi, Takeda, Huibin Yue Shareholder of: Chemocentryx, Employee of: Chemocentryx, Pirow Bekker Shareholder of: Chemocentryx, Consultant of: Chemocentryx, Employee of: Chemocentryx, John H Stone Shareholder of: Sterias, Consultant of: InfraRx, Roche, Genentech, Sanofi, Bristol-Myers Squibb, AbbVie, InfraRx, Kyowa, Novartis, Q32Bio, Zenas, Horizon, Grant/research support from: Roche/Genentech, Horizon, Sanofi, Bristol-Myers Squibb

patients were identified as those with at least two qualifying claims on different dates of service, coded with a GPA or MPA ICD-10-CM code, and no claim coded with GPA or MPA in the 12 months prior to their first claim. Established patients required 12 months continuous enrollment in the year of their establishment of 12 months continuous enrollment in the year prior to their established status. Relapses for incident patients were identified during the 7 to 12 months after the index date for newly diagnosed patients to avoid mischaracterizing claims around the time of the initial diagnosis as relapses and over a 12-month period for the established patients. Relapse was defined based on specific inpatient and outpatient claims with a GPA or MPA diagnosis code or claims billed with one or more of at least three minor vasculitis signs or symptoms followed by a claim within 30 days for plasmapheresis or cyclophosphamide or glucocorticoids (>20 mg prednisolone equivalent) or ≥2 rituximab claims within 30 days of each other. Relapse had to occur 30 days after the previous event and 6 months after index date for incident patients.

Results: 542 (GPA) and 83 (MPA) commercially insured newly diagnosed patients with 12 months eligibility following their index date and 1,748 (GPA) and 184 (MPA) commercially insured established patients were identified. 15.5% (GPA) and 15.7% (MPA) newly diagnosed patients relapsed during months 7-12 after diagnosis and 27.8% (GPA) and 29.3% (MPA) established patients relapsed over a 12-month period. 2,397 (GPA) and 655 (MPA) Medicare FFS newly diagnosed patients with 12 months of eligibility following their index date and 5,955 (GPA) and 833 (MPA) Medicare FFS established patients were identified. 19.5% (GPA) and 27.2% (MPA) newly diagnosed patients relapsed during months 7-12 after diagnosis and 33.5% (GPA) and 40.2% (MPA) established patients relapsed over a 12-month period.

Conclusion: Using administrative healthcare claims, we observed relapse rates after GPA and MPA diagnosis ranging between 15.5-27.2% in months 7-12 after diagnosis for newly diagnosed patients and between 27.8-40.2% over a 12-month period for established patients. There is an unmet need for new therapies that sustain remission and decrease relapse rates in patients with ANCA-associated vasculitis. This is an important clinical strategy to reduce the risks of adverse events from long-term immunosuppression therapy and decrease end-organ damage.

REFERENCES:

Disclosure of Interests: Kate Fitch Consultant of: ChemoCentryx, Carol Bazell Consultant of: ChemoCentryx, Steven Metz Consultant of: ChemoCentryx, Irene von Hennigs Shareholder of: ChemoCentryx, Consultant of: ChemoCentryx, Employee of: ChemoCentryx


POS036 Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis and a Vasculitic Phenotype

B. Terrier1, D. Jayne2, B. Hellmich3, J. H. Bentley4, J. Steinfeld5, J. W. Yancey6, N. Kwon7, P. Akuthota8, P. Khoury9, L. Baylis10, M. Wechsel11, H. Köhlein, Service de Médecine Interne, Paris, France; 2University of Cambridge, Department of Medicine, Cambridge, United Kingdom; 3Universität Tübingen, Medizin Klinik, Klinik für Innere Medizin, Rheumatologie & Immunologie, Kirchheim-Teck, Germany; 4GSK, Clinical Statistics, Brentford, United Kingdom; 5GSK, Clinical Sciences, Respiratory, Philadelphia, PA, United States of America; 6GSK, Respiratory, Infectious Ana, NC, United States of America; 7GSK, Global Medical Affairs, Durham, NC, United States of America; 8National Jewish Health, Department of Medicine, Denver, CO, United States of America

Background: Patients with eosinophilic granulomatosis with polyangiitis (EGPA) often present with upper or lower respiratory symptoms. 1 The Phase III MIRRA study demonstrated that patients with EGPA spent more time in remission and had reduced oral corticosteroid use with mepolizumab versus placebo. 2 Objectives: To evaluate the efficacy of mepolizumab in patients with a vasculitic EGPA phenotype enrolled in the MIRRA study.

Methods: MIRRA was a Phase III, multicentre, double-blind, parallel-group trial in patients with eosinophilic granulomatosis with polyangiitis or EGPA, treated after 12 weeks stable prednisolone treatment. Patients were randomised to receive standard of care plus mepolizumab (300 mg subcutaneously every 4 weeks) or placebo for 52 weeks. Primary endpoints were: accrued weeks of remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and OCS dose ≤4mg/day in the 12 weeks prior to baseline), 36 weeks of remission, 52 weeks of remission and 1 year of remission. 4-6

Results: Of the 136 patients in the study, 26 (19%) had a history of a positive ANCA test at study baseline and 110 (81%) did not. In addition, 51 (38%) had a BVAS ≥0 at baseline while 85 (63%) had a BVAS >0. 74 (54%) had a VDI ≤5 at baseline and 62 (46%) had a VDI >5. Accrued remission duration was greater with mepolizumab versus placebo, irrespective of ANCA positive status, baseline BVAS or baseline VDI score (Figure 1). Across all the subgroups, a larger proportion of patients achieved remission at both Weeks 36 and 48 with mepolizumab versus placebo (Figure 1). Among patients receiving mepolizumab, the numbers (proportion) of patients achieving remission at both Weeks 36 and 48 were 7 (54%) for patients with an ANCA-positive test and 15 (27%) for patients without a history of an ANCA-positive test: 14 (45%) in the BVAS ≥0 and 8 (22%) in the BVAS >0 groups; 11 (29%) in the VDI score <5 and 11 (37%) in the VDI score ≥5 groups. Mepolizumab reduced all types of disease relapse assessed during the treatment period, including vasculitis, asthma and sinusonal relapses, compared with placebo. Vasculitic characteristics including neuropathy, glomerulonephritis, alveolar haemorrhage, palpable purpura and ANCA positivity were generally similar among patients who did and did not achieve remission during the study.

Conclusion: Mepolizumab is associated with clinical benefits in patients with EGPA, including those with and without a vasculitic phenotype.

REFERENCES:

Acknowledgements: Funding: GSK (MEA115921; NCT02020889); the Division of Intramural Research, NIAID, NIH funded in part time spent on this paper by one of the authors (PK).

Disclosure of Interests: Benjamor Terrier Consultant of: Roche, Chugai, GSK, AstraZeneca, Bristol Myers Squibb, Terumo BCT, Sanofi, LFB and Gifols, David Jayne Speakers bureau: Agen, Vifor, Consultant of: AstraZeneca, Aurinia, BMS, Boehringer Ingelheim, ChemoCentryx, GSK, Janssen, Novartis, Roche/Genentech, Takeda and Vifor, Grant/research support from: AstraZeneca, Aurinia, BMS, Boehringer Ingelheim, ChemoCentryx, GSK, Janssen, Novartis, Roche/Genentech, Takeda and Vifor, Bernard Hellmich Speakers bureau: Abbvie, BMS, Boehringer Ingelheim, Chugai, GSK, InflixRx, Novartis, Pfizer, Roche and Vifor Pharma, Consultant of: Abbvie, BMS, Boehringer Ingelheim, Chugai, GSK, InflixRx, Novartis, Pfizer, Roche and Vifor Pharma, Grant/research support from: Abbvie, InflixRx, AstraZeneca, Bristol Myers Squibb, ChemoCentryx, GSK, InflixRx, Kiniksa, Nippon Kayaku, Novartis, Roche, and Sanofi (my institution received payments for participation in multicentre clinical trials and the institution or myself did not receive money for any other kind of research projects). Jane H. Bentley Shareholder of: GSK, Employee of: GSK, Jonathan Steinfeld Shareholder of: GSK, Employee of: GSK; Steven W Yancey Shareholder of: GSK, Employee of: GSK, Praveen Akuthota Paid instructor for: AstraZeneca, Consultant of: AstraZeneca, GSK, Sanofi, Grant/research support from: GSK, AstraZeneca and Regeneron, Paneez Khoury: None declared, Lee Baylis Shareholder of: GSK, Employee of: GSK, Sanofi, AstraZeneca, Teva, Novartis, Boehringer Ingelheim, Sentien, and Equillium, Grant/research support from: National Institute of Allergy and Infectious Diseases and the National Heart, Lung, and Blood Institute


Figure 1. Mepolizumab efficacy by patient baseline characteristics ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham Vasculitis Activity Score; CI, confidence interval; NA, data not available – estimate could not be calculated owing to a lack of patients in the placebo group achieving remission at Weeks 36 and 48; VDI, Vasculitis Damage Index.
at least three maintenance infusions with either 1000 mg or 500 mg, twice per year) as remission-maintenance therapy in AAV patients. We assessed all patients with standard low dose (twice per year), for 18 months. No significant differences at baseline were noted between patients receiving ultra-low dose maintenance treatment with ultra-low dose RTX (once per year), while 70.1% of patients with standard low dose (twice per year), for 18 months. No significant differences at baseline were noted between patients receiving ultra-low dose when compared to those treated with conventional low-dose.

At the end of observation period, a disease flare was observed in 22.7% of the low-dose group, and 21.2% in those treated with the standard dose (p=0.881). Relapse-free survival was comparable between the two group (log-rank p=0.818, Figure 1).

When comparing AAV patients treated with ultra-low dose regimen to those treated with low-dose, no differences were noted in negative ANCA rate (72.2% vs 69.1%, p=0.262), ANCA titer (0 [0–78] vs 0 [0–50] UI/mL, p=0.232), B-cells depletion rate (70.6% vs 75%, p=0.725), mean serum IgG (811 [146-922] vs 680 [429-861] mg/dl, p=0.367), mean daily glucocorticoid dosage (2.5 [0-5] vs 3.75 [0-5] mg/d, p=0.647), VDI (4 [1-5] vs 2 [1-4], p=0.098), hypogammaglobulinaemia rate (31.8% vs 36.5%, p=0.617) and deaths (4.5% vs 5.8%, p=0.831).

Although not significant, patients treated with ultra-low dose had lower severe infection rate (10.5% vs 26.6%, p=0.154). Notably, in the all cohort 5 deaths were related to COVID19 pneumonia.

Conclusion: Reduced exposure to RTX was not associated with an impaired efficacy of maintenance therapy in patients with AAV. Remission maintenance with ultra-low dose RTX is a safe and more cost-effective option.

REFERENCES:
Background: Limited therapies are available for patients with idiopathic inflammatory myopathy (IM), a heterogeneous group of chronic, systemic, autoimmune inflammatory diseases characterized by progressive muscle weakness and/or distinct skin rashes. Abatacept, a selective co-stimulation modulator, may be a useful treatment option.

Objectives: To evaluate efficacy, safety, and tolerability of abatacept + standard of care (SOC) in patients with IM compared with SOC alone (placebo).

Methods: A 24-week, randomized, double-blind, placebo-controlled phase 3 trial of SC abatacept (125 mg weekly) + SOC (corticosteroids and immunosuppressants alone or combined; NCT02971863) in patients with active, treatment-refractory IM (Manual Muscle Testing-8 [MMT-8] ≤ 135) was performed. Primary endpoint was proportion of patients meeting International Myositis Assessment and Clinical Studies definition of improvement (IMACS DOI) at week 24. Change from baseline in myositis Functional Index-2 (FI-2), HAQ-DI, Myositis Disease Activity Assessment Tool (MDIAT), and Myositis Response Criteria (MRC) were secondary endpoints with safety. Post hoc analyses by disease subtype were performed.

Results: Overall, 148 patients were randomized (75 abatacept; 73 placebo); IM subtypes were dermatomyositis (DM; 53.3% vs 57.5%), polymyositis (PM; 25.3% vs 34.2%), and autoimmune necrotizing myopathy (ANM; 21.3% vs 8.2%). Mean baseline MMT-8 and HAQ-DI scores were 112.7 and 1.5, respectively. Approximately 90% of patients completed week 24. Week 24 IMACS DOI rates were abatacept 56.0% vs placebo 42.5% (adjusted odds ratio, 1.8 [95% CI, 0.9–3.5]; P = 0.083). Pre-specified IMACS DOI analysis showed no differences for patients with DM but notable benefit for those with non-DM subtypes, PM and ANM (Table 1). Secondary endpoints showed similar differences (Table 1). MRC at day 169 by category is shown in Figure 1. Proportion of AEs (69.3% and 75.3%) and serious AEs (5.3% and 5.8%) were similar in the abatacept and placebo arms.

Table 1. Primary and secondary (mean change from baseline at week 24) endpoints

<table>
<thead>
<tr>
<th>Outcome</th>
<th>IIM</th>
<th>Abatacept</th>
<th>Placebo</th>
<th>Nominal P value (abatacept vs placebo) or adjusted mean difference from placebo (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMACS DOI (% All)</td>
<td>42/75 (56.0)</td>
<td>31/73 (42.5)</td>
<td>P = 0.083</td>
<td></td>
</tr>
<tr>
<td>DM</td>
<td>22/40 (55.0)</td>
<td>21/42 (50.0)</td>
<td>P = 0.679</td>
<td></td>
</tr>
<tr>
<td>Non-DM</td>
<td>20/35 (57.1)</td>
<td>10/31 (32.3)</td>
<td>P = 0.040</td>
<td></td>
</tr>
<tr>
<td>FI-2</td>
<td>All</td>
<td>4.1 (1.3)</td>
<td>1.2 (1.4)</td>
<td>2.9 (0.9 to 5.8)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>2.3 (1.6)</td>
<td>0.3 (1.4)</td>
<td>1.9 (−2.3 to 6.2)</td>
</tr>
<tr>
<td></td>
<td>Non-DM</td>
<td>3.2 (1.4)</td>
<td>−0.6 (1.5)</td>
<td>3.7 (−0.3 to 7.8)</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>All</td>
<td>0.31 (0.07)</td>
<td>0.20 (0.07)</td>
<td>−0.12 (−0.28 to 0.04)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>0.31 (0.08)</td>
<td>0.19 (0.07)</td>
<td>−0.11 (−0.32 to 0.10)</td>
</tr>
<tr>
<td></td>
<td>Non-DM</td>
<td>0.25 (0.09)</td>
<td>−0.17 (0.09)</td>
<td>−0.18 (−0.44 to 0.07)</td>
</tr>
<tr>
<td>MDAAT</td>
<td>All</td>
<td>1.56</td>
<td>1.40</td>
<td>−0.16 (−0.63 to 0.30)</td>
</tr>
<tr>
<td>Extramuscular Activity</td>
<td>−1.96 to −1.16</td>
<td>−1.81 to −0.99</td>
<td>−0.05 (−0.77 to 0.68)</td>
<td></td>
</tr>
<tr>
<td>Global Activity (90% CI)</td>
<td>−1.96 to −1.16</td>
<td>−1.81 to −0.99</td>
<td>−0.05 (−0.77 to 0.68)</td>
<td></td>
</tr>
<tr>
<td>MMT-8</td>
<td>All</td>
<td>12.3 (1.9)</td>
<td>11.0 (2.0)</td>
<td>1.8 (−2.7 to 6.4)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>14.4 (2.2)</td>
<td>14.0 (2.2)</td>
<td>0.4 (−5.7 to 6.4)</td>
</tr>
<tr>
<td></td>
<td>Non-DM</td>
<td>12.1 (2.5)</td>
<td>7.8 (2.7)</td>
<td>4.3 (−3.0 to 11.7)</td>
</tr>
<tr>
<td>Physician Global Assessment</td>
<td>−2.89 (0.30)</td>
<td>−2.69 (0.30)</td>
<td>−0.20 (−0.80 to 0.40)</td>
<td></td>
</tr>
<tr>
<td>Assessment</td>
<td>−2.78 (0.29)</td>
<td>−2.43 (0.28)</td>
<td>−0.35 (−1.15 to 0.44)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-DM</td>
<td>−2.30 (0.43)</td>
<td>−2.21 (0.48)</td>
<td>−0.14 (−1.43 to 1.15)</td>
</tr>
<tr>
<td>Patient Global Assessment</td>
<td>−1.14 (0.31)</td>
<td>−1.09 (0.31)</td>
<td>−0.08 (−0.91 to 0.90)</td>
<td></td>
</tr>
<tr>
<td>Assessment</td>
<td>−1.14 (0.31)</td>
<td>−1.09 (0.31)</td>
<td>−0.08 (−0.91 to 0.90)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-DM</td>
<td>−1.42 (0.41)</td>
<td>−0.33 (0.44)</td>
<td>−2.14 (0.93 to 2.14)</td>
</tr>
</tbody>
</table>

Data are adjusted mean change from baseline score (SE) unless stated. *Defined as improvement of ≥ 20% in 3 IMACS core measures, worsening by ≥ 25% in ≤ 2 IMACS core measure scores, and a reduction of < 25% in MMT-8;100 mm visual analog scale.

Conclusion: In this double-blind trial of SC abatacept vs placebo, abatacept failed to meet primary or secondary endpoints. Post hoc analyses suggest a treatment benefit in patients with PM and ANM (not DM) when treated with abatacept. Abatacept use was well tolerated.

REFERENCES:
Background: Melanoma differentiation associated gene 5 antibody (anti-MDA5) dermatomyositis, is an idiopathic inflammatory musculoskeletal disorder with specific phenotypic manifestations of rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement. There is currently a lack of consensus and guidelines on early diagnosis and timely escalation of therapy to avoid untoward outcomes.

Objectives: To identify distinguishing clinical and laboratory features to assess disease progression amongst individuals with anti-MDA5 dermatomyositis based on the serologic, histopathologic, and radiographic status. We identified and compared the disease phenotype in a racially diverse juvenile and adult population with anti-MDA5 dermatomyositis.

Methods: After Institutional review board approval, we queried the electronic health record at the Montefiore Medical Center, NY, and identified a total of 194 dermatomyositis patients. We included 21 dermatomyositis patients with MDA5 antibody. We performed a retrospective chart review to extract clinical data and analyzed data using Fischer’s exact test.

Results: Of the 21 dermatomyositis patients with anti-MDA5, 12 adult patients represented 8% of all adult dermatomyositis cases (12/148) and 9 patients represented 19 % of the pediatric dermatomyositis cases (9/46). There was a 2:1 female to male predominance in both groups. In adults, the mean age of disease onset was 45.2 years (SD 14.4 years). Nine ILD cases were noted, of which 2 were RP-ILD. The presence of the Ro52 antibody was associated with rapid disease progression. In children, the mean age of onset was 6.6 years (SD 4.9 years). All children had muscle weakness, with only 5 having ILD. Myositis was noted to be more prevalent in the pediatric population, compared to adults (9/9 Vs 4/12 cases; P=0.005). In this patient cohort, ILD was statistically significant between the African American population (9/10 cases) and non-African American population (5/11 cases), p=0.03, of these 3 African American cases had RP-ILD with mortality. The combined mortality rate of 14.2% was superior to 40-60% reported in the literature. [2]

Conclusion: Anti MDA5 dermatomyositis is relatively rare and difficult to diagnose. In this study, the general disease characteristics of our cohort were similar in both adult and pediatric patients except for myositis, which was more common in the pediatric population. The incidence of ILD by contrast was higher in the adults, especially in the African American population who had worse outcomes. The rapid escalation of therapy and use of rituximab may have improved our outcomes over historic controls. Controlled studies are needed to evaluate patients with anti-MDA5 dermatomyositis for appropriate treatment interventions and to avoid untoward outcomes.

References:

Disclosure of Interests: None declared
Conclusion: Significant improvement of survival was observed in patients treated with high-intensity induction therapy. Meanwhile, stratification of patients for poor prognosis would be important.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.311

POSO842 NON-INVASIVE COHERENT RAMAN IMAGING OF INVOLVED FOREARM SKIN REVEALS AlIGNED COLLAGEN IN DERMIS OF SYSTEMIC SCLEROSIS PATIENTS

P. S. Wong1, B. Ahmed Abdì1, J. Mansfield2, H. Lopez3, J. Moger2, I. F. Uchegbu1, R. Stratton1. 1Royal Free Hospital, Centre of Connective Tissue Disease and Rheumatology, University College Of London, London, United Kingdom; 2University of Exeter, School of Physics and Astronomy, Exeter, United Kingdom; 3MURIGENICS, INC, Research and Development, California, United States of America; 4UCL School of Pharmacy, Pharmaceutical Nanoscience, London, United Kingdom

Background: Systemic sclerosis (SSc) is an immune-mediated connective tissue disease with clinical hallmark of inflammation, vasculopathy and fibrosis resulting in abnormal collagen and intercellular matrix formation in the dermis and internal organ. Skin severity correlates with systemic complications and mortality in SSc. Many skin assessment tools studied do not fulfilled all standards set by OMERACT which include criterion validity, construct validity, discrimination, responsiveness, reliability and feasibility. Modified Rodnan skin score (mRSS) is commonly used as outcome measure in clinical trials of SSc. mRSS score (mRSS) is commonly used as outcome measure in clinical trials of SSc.

With the demand of better tools in diagnosis of early SSc and therapeutic research, our work with CRS prove better in objective evaluation of skin changes at the molecular level. Here, we demonstrate that the SHG is altered in the early diffuse SSc skin with increased and aligned collagen in the SSc dermis compatible with mRSS score. Others have observed this alignment of the collagen, and we have published that SSc fibroblasts migrate/invade along aligned collagen and modestly the underlying extracellular matrix, adding collagen I and III, close-linking enzymes and other factors including TSP-1.

Our future work include:
1. Generating a computer module in defining pathological collagen level
2. Analysis of metabolites and pathological pathways in SSc
3. In-vivo trials with novel therapeutic peptides.
4. Lastly, manufacturing of non-invasive handheld device that is capable of diagnosis subclinical SSc and for outcome measure in clinical-therapeutic research

REFERENCES:

Acknowledgements: We want to acknowledge our colleagues and patients in Royal Free Hospital, to make this project a success.

Disclosure of Interests: None declared


POSO843 PREDICTORS OF INTERSTITIAL LUNG INVOLVEMENT AND TIMING OF ONSET IN SYSTEMIC SCLEROSIS: OUR EXPERIENCE AT A THIRD-LEVEL HOSPITAL

C. Seiros Santos1, C. Moriano2, X. E. L. Rojas3, C. Álvarez Castro1, A. López Robles1, E. Diez Alvarez1. 1Complejo Asistencial Universitario de León, Rheumatology, León, Spain

Background: Interstitial lung disease (SSc-ILD) and pulmonary hypertension are the leading causes of death in patients with systemic sclerosis (SSc). Identifying SSc-ILD development and initiating treatment is essential to optimize therapeutic benefit.

Methods: We followed through our previous work studying commercially available non-invasive imaging tools in SSc skin assessment by using Coherent-Raman scattering microscopy (CRS).

Results: The SHG analysis revealed denser collagen fibers in dermal layer of diseased skin. It also appears that the collagen deposition occurs in more superficial layers of the skin. Peak of collagen curve were at depth of 110-130um HC vs 75-90um in SSc. Collagen fibres were more aligned in the SSc (Figure 1).

Furthermore, TPF revealed larger number of disordered elastin fibres in the dermal layer of SSc than HC.

Conclusion: Nailfold capillaroscopy is used to define and stage micro-vasculopathy in SSc. Inflammatory pro-fibrotic processes on the other hand cause abnormal collagen and intercellular matrix formation in the dermis and internal organ.

Table 1. Significant logistic regressions for predictors for SSc-ILD

<table>
<thead>
<tr>
<th>Predictor</th>
<th>OR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>2.8 (1.16-6.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>Smoking history</td>
<td>2.15 (1.33-3.46)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diffuse cutaneous involvement</td>
<td>10.4 (2.48-43.8)</td>
<td>0.003</td>
</tr>
<tr>
<td>Raynaud duration</td>
<td>0.89 (0.79-1.0)</td>
<td>0.04</td>
</tr>
<tr>
<td>Myositis</td>
<td>3.45 (1.09-10.9)</td>
<td>0.03</td>
</tr>
<tr>
<td>Anti-Scl70</td>
<td>5.45 (2.04-14.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>Anti-Ro/SS</td>
<td>3.37 (1.49-8.45)</td>
<td>0.002</td>
</tr>
<tr>
<td>FVC</td>
<td>0.97 (0.91-0.98)</td>
<td>0.03</td>
</tr>
<tr>
<td>DLCO</td>
<td>0.96 (0.93-0.98)</td>
<td>0.003</td>
</tr>
<tr>
<td>mRSS</td>
<td>3.73 (1.64-8.5)</td>
<td>0.01</td>
</tr>
<tr>
<td>mMRI</td>
<td>2.01 (1.52-4.2)</td>
<td>0.04</td>
</tr>
<tr>
<td>Late capillaroscopy pattern</td>
<td>2.3 (1.02-5.27)</td>
<td>0.04</td>
</tr>
<tr>
<td>Early onset SSc-ILD</td>
<td>(\beta) value</td>
<td>P value</td>
</tr>
<tr>
<td>Older age at onset</td>
<td>0.47</td>
<td>0.0017</td>
</tr>
<tr>
<td>Telangiectasias</td>
<td>0.29</td>
<td>0.04</td>
</tr>
<tr>
<td>Smoking status</td>
<td>0.37</td>
<td>0.02</td>
</tr>
<tr>
<td>Late onset SSc-ILD</td>
<td>(\beta) value</td>
<td>P value</td>
</tr>
<tr>
<td>Male gender</td>
<td>0.57</td>
<td>0.001</td>
</tr>
<tr>
<td>Myositis</td>
<td>0.34</td>
<td>0.02</td>
</tr>
<tr>
<td>Antiphospholipid antibodies</td>
<td>0.31</td>
<td>0.04</td>
</tr>
</tbody>
</table>

References:


 disclose None declared

Disclosure of Interests: None

Acknowledgements: We want to acknowledge our colleagues and patients in Royal Free Hospital, to make this project a success.

Disclosure of Interests: None declared

Methods: Standard incidence ratios (SIR) of malignancy and the long-term occurrence of Objectives: not elucidated so far.

nosis [2], long-term relationships between malignancy and each antibody are some subgroups of IIM have a high risk of malignancy up to 10 years after diag-

nosis of 14.73 (4.72-40.50) (Table 1). Types of malignancy included anti-ARS, MDA5, Mi-2, or TIF1-γ antibody p<0.001) and more frequently with anti-TIF1-γ antibody than patients with anti-ARS antibody lower in patients with anti-TIF1-γ antibody. We retrospectively collected the data and calculated SIRs by using the database of Cancer Statistics, Cancer Information Service, National Cancer Center, Japan. Fisher exact test and Wilcoxon test were used to compare the clinical features in each group. Cumulative incidence of cancer occurrence was estimated by Kaplan-Meier methods, and Log-rank test was used to compare the cancer-free survival.

Results: From our IIM cohort at the University of Tokyo hospital, we enrolled patients who fulfilled Bohan and Peter criteria for dermatomyositis/polymyositis or 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for IIMs and with positivity for anti-ARS, MDA5, Mi-2, or TIF1-γ antibody. We retrospectively collected the data and calculated SIRs by using the database of Cancer Statistics, Cancer Information Service, National Cancer Center, Japan. Fisher exact test and Wilcoxon test were used to compare the clinical features in each group. Cumulative incidence of cancer occurrence was estimated by Kaplan-Meier methods, and Log-rank test was used to compare the cancer-free survival.

Results: The study included 111 patients, including 16 patients being diag-
nosed with a malignancy within a three-year before and after the occurrence of IIM. Patients with malignancy were significantly older age at the onset of IIM (median age (interquartile range) 67.5 (62.7-70.8) vs. 52.0 (41.5-61.5), p<0.001) and more frequently with anti-TIF1-γ antibody (25.0% vs. 4.2%, p=0.015). After adjustment for age, the proportion of anti-TIF1-γ antibody remains significantly higher in the malignancy group (p=0.001). SIRs (95% confidence interval) in each type of antibody were anti-ARS of 2.21 (1.03-4.55), anti-MDA5 of 1.89 (0.49-6.02), anti-Mi-2 of 2.75 (0.14-17.84), and anti-TIF1-γ of 14.73 (4.72-40.50) (Table 1). Types of malignancy included four gastric cancers, two bladder cancers, breast cancers, cervical cancers, ovarian cancers, and lung cancer, one pancreatic cancer, rectal cancer, and renal cancer. Kaplan-Meier estimated cancer-free survival was significantly lower in patients with anti-TIF1-γ antibody than patients with anti-ARS antibody (p<0.01) (Figure 1). The frequencies of malignancy in IIM patients with anti-ARS, MDA5, Mi-2, or TIF1-γ antibody through the follow-up period were 15.6%, 20.0%, 11.1%, and 50.0%, respectively.

Conclusion: We identified 10 factors significantly associated with risk of developing SSc-ILD: smoking, male sex, diffuse cutaneous involvement, the pres-

ence of myositis, shorter Raynaud duration to SSc diagnosis, anti-Scl70 and anti-Ro52 positivity and baseline pulmonary function (lower baseline DLCO and FVC increasing risk) and late capillaroscopy pattern and identified predictors for early and late-onset SSc-ILD.

REFERENCES:


Figure 1. Comparison of malignancy rate of idiopathic inflammatory myopathy with anti-ARS, and TIF1-γ antibodies in 10 years.

Table 1. Standard incident ratio (SIR) of malignancy in idiopathic inflam-

matory myopathy according to myositis-specific antibodies.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Total (Person-years)</th>
<th>Observed</th>
<th>Expected</th>
<th>SIR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-ARS antibody</td>
<td>510</td>
<td>8</td>
<td>3.62</td>
<td>2.21 (1.03-4.55)</td>
</tr>
<tr>
<td>Anti-MDA5 antibody</td>
<td>210</td>
<td>3</td>
<td>1.59</td>
<td>1.89 (0.49-6.02)</td>
</tr>
<tr>
<td>Anti-Mi-2 antibody</td>
<td>56</td>
<td>4</td>
<td>0.36</td>
<td>2.75 (1.14-7.84)</td>
</tr>
<tr>
<td>Anti-TIF1-γ antibody</td>
<td>39</td>
<td>4</td>
<td>0.27</td>
<td>14.73 (4.72-40.50)</td>
</tr>
<tr>
<td>Total</td>
<td>815</td>
<td>16</td>
<td>5.84</td>
<td>2.74 (1.62-4.56)</td>
</tr>
</tbody>
</table>

Conclusion: IIM patients with anti-TIF1-γ antibody and with anti-ARS antibody had a higher prevalence of malignancy than the general population. In addition, anti-TIF1-γ antibody are more associated with malignancy rather than anti-ARS antibody in 10 years as well. Malignancy associated with anti-TIF1-γ positive IIM occurred exclusively within the one year before and after the IIM diagnosis, and cancer should be particularly studied at the IIM diagnosis.

REFERENCES:

Characteristics from table content including title and footnotes: 3299

Disclosure of Interests: Shinji Izuka: None declared, Toshikiko Komai Speakers bureau: Tanabe Mitsubishi, Kissei, Pfizer, Agen GlaxoSmithKline and Chugai., Grant/research support from: GlaxoSmithKline., Hirofumi Shoda Speakers bureau: Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, AbbVie, GlaxoSmithKline, Gilead, Boehringer Ingelheim, Jansen, Novartis, Chugai, Takeda, Astellas, Eisai, Asahi Kasei and Daiichi-Sankyo., Grant/research support from: Novartis, Keishi Fujio Speakers bureau: Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei and AstraZeneca., Grant/research support from: Tanabe Mit-
subishi, Bristol-Myers Squibb, Eli Lilly Chugai, Eisai, Tsumura and Asahi Kasei. DOI: 10.1136/annrheumdis-2022-eular.333

Table 2. Asessing frailty in systemic sclerosis: A cross-sectional study comparing frail and edmonton frailty scales with physical frailty phenotype

V. Hax1, A. A. Gasparin1, N. Pampolina Bueno de Andrade1, R. Cavalheiro Do Espirito Santo1, E. Pena1, L. Santos2, L. Denardi Dória1, R. Xavier1, R. Mendonca Da Silva Chakr1. Hospital de Clinicas de Porto Alegre, Division of Rheumatology, PORTO ALEGRE, Brazil

Background: Systemic sclerosis (SSc) is a chronic disease characterized by autoimmunity, vasculopathy and fibrosis. During the disease course, patients with SSc are prone to accumulate multiple organ damage, increasing their vul-
nerability to adverse outcomes in comparison with individuals of the same age: a phenomenon called frailty. One of the most used definitions of frailty is the phys-
ical frailty phenotype (FFP) by Fried, et al. The FFP consists of 5 components: unintentional weight loss, exhaustion, muscle weakness, slow walking speed, and low physical activity. There is scarce data about frailty in patients with SSc.

Objectives: To study the prevalence and clinical aspects of FFP in a sample of patients with SSc. Also, we aim to investigate the diagnostic accuracy of the Fatigue, Resistance, Ambulation, Illness and Loss of weight (FRAIL) scale and the Edmonton frailty scale (EFS) using the FFP as the reference standard.

Methods: Cross-sectional study, including patients with SSc according to the 2013 ACR-EULAR classification criteria or the criteria suggested by LeRoy and Medsger for early disease. FFP assessment was according to the original defi-
nition, except for physical activity domain, assessed with the International Phys-
ical Activity Questionnaire (IPAQ). Patients were classified according to Fried’s criteria in robust (0), pre-frail (1-2), and frail (≥3). FRAIL scale and EFS were also applied to the same samples. The FRAIL score ranges from 0 to 17 and categorizes patients as not frail (0–4), vulnerable (5–6), mild frailty (7–8), moderate frailty (9–10), and severe frailty (≥11). For the diag-
nostic assessment of FRAIL scale and EFS, we estimated the area under the receiver operating characteristic curve (AUC), considering FPF as the reference standard and dichotomizing the results in frail vs. non-frail.

Results: Between March and December 2019, 82 SSc patients were consecu-
tively included. The mean age and disease duration were 60.4 ±8.2) years, respectively; 91.5% were women, and 19.5% with diffuse cutane-
ous SSc. The FPF distribution was: 8 (9.8%) robust, 47 (57.3%) pre-frail and 27 (32.9%) frail patients. The FFP domains’ frequencies were: low physical activity in 57 (69.5%), muscle weakness in 41 (50%), exhaustion in 34 (41.5%), unin-
tentional weight loss in 15 (18.3%) and slow walking speed in 8 (9.8%) patients.
Table 1. Hospital Characteristics and Patient Outcomes

<table>
<thead>
<tr>
<th>Trait</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 3</th>
<th>M1 Event (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Diagnoses (%)</td>
<td>0.22</td>
<td>0.18</td>
<td>0.10</td>
<td>19.02</td>
</tr>
<tr>
<td>Myositis</td>
<td>8.97</td>
<td>7.02</td>
<td>10.85</td>
<td>11.31</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>34.64</td>
<td>35.87</td>
<td>41.60</td>
<td>9.89</td>
</tr>
<tr>
<td>Unrelated confounder ^</td>
<td>2.52</td>
<td>2.39</td>
<td>0.84</td>
<td>0.63</td>
</tr>
<tr>
<td>Catherter procedures</td>
<td>0.022</td>
<td>0.018</td>
<td>0.10</td>
<td>12.05</td>
</tr>
<tr>
<td>Hospital Characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bedsize (1 = small to 3 = large)</td>
<td>1.31</td>
<td>1.36</td>
<td>1.86</td>
<td>10.59</td>
</tr>
<tr>
<td>Rural setting (%)</td>
<td>7.08</td>
<td>0.64</td>
<td>3.700</td>
<td>0.79</td>
</tr>
<tr>
<td>Transfers out (%)</td>
<td>20.03</td>
<td>20.61</td>
<td>17.12</td>
<td>0.60</td>
</tr>
<tr>
<td>Patient income quartiles (M)</td>
<td>2.10</td>
<td>1.75</td>
<td>2.12</td>
<td>1.12</td>
</tr>
</tbody>
</table>

| MI Event (%)                       | 19.02     | 11.31     | 9.89      |              |
| Myositis patients                  | 8.97      | 12.05     | 12.59     |              |
| Non-myositis patients              | 0.63      | 0.76      | 1.12      |              |
| Confounder diagnoses: hypertension, hyperlipidemia, diabetes mellitus, tobacco/alcohol substance abuses, obesity, rheumatoid arthritis, systemic lupus erythematosus and gout.

^ Based on ICD 10 codes under M33, M60 and G72 groups. Based on ICD 10 codes under I21 group. Myositis patients were compared using logistic regression analysis.

Disclosure of Interests: None declared


POS0847 MYOSITIS AUTOANTIBODIES DETECTED BY LINE BLOT IMMUNOASSAY: CLINICAL ASSOCIATIONS AND CORRELATION WITH ANTIBODY TITERS

J. Loarce-Martos1, L. Calvo Sanz2, S. Garrote-Corra1, C. Rits3, R. Ballester Gonzalez2, A. Garcia-Soidan1, J. Bachiller-Corra1, G. Roy1, Hospital Universitario Ramón y Cajal, Rheumatology Department, Madrid, Spain; 2Hospital Universitario Ramón y Cajal, Immunology Department, Madrid, Spain; 3Ramón y Cajal University Hospital, Rheumatology Department, Madrid, Spain

Background: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune diseases (AID) characterized by muscle inflammation and weakness, often accompanied with other organ involvement, such as skin rash or interstitial lung disease (ILD). Myositis specific (MSA) and myositis associated (MAS) categories are important for clinical decision making.

Methods: To investigate the clinical manifestations of MSA and MAS patients, a retrospective study was performed in a single center with 114 consecutive patients (52 MSA, 62 MAS). Myositis-associated antibodies were determined using line blot immunoblotting (IB) and ELISA using recombinant proteins.

Results: The majority of MSA patients were detected for anti-Jo1 and anti-Mi2 antibodies, while the most frequent MAS antibodies were anti-SRP, anti-U1 RNP, and anti-ANNA-1. There was a significant association between MSA and cardiac involvement, whereas MAS patients presented more often with arthralgia and myalgia.

Conclusion: The use of line blot IB provides a rapid and cost-effective method to detect myositis-associated antibodies, facilitating the diagnosis and management of patients with MSA and MAS.

Disclosure of Interests: None declared


POS0846 MORTALITY OUTCOME OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH IDIOPATHIC INFAMMATORY MYOPATHIES, A QUALITATIVE APPROACH ANALYSIS OF THE NATIONAL INPATIENT SAMPLE FROM 2016-2019

Z. Y. Li1, S. Huang2, T. Joshua3, D. Dalal4, A. Reginato4, Roger Williams Medical Center, Rheumatology, PROVIDENCE, United States of America;

Background: To investigate the quality of care of acute myocardial infarctions (AMI) events in myositis patients compared to non-myositis patients across the United States categorized by the types of hospitals, probability of myocardial events, and mortality outcome from the NIS from 2016-2019.

Methods: We used SAS statistical software to perform analyses on the NIS database (2016-2019) in the US. Adults with AMI and myositis at the time of discharge were identified by International Statistical Classification of Disease 10 (ICD-10) codes. Latent class analysis was used to empirically identify hospital groups across different regions in the U.S where myositis patients received their cardiac care. Once hospital groups were determined, patients were compared with and without myositis in each hospital group. Probabilities of AMI event and mortality among myositis patients were compared using logistic regression analysis.

Results: The NIS sample included 38,363 myositis patients and 24,179,176 non-myositis patients. Three hospital groups were identified, the first two represented inner-city hospitals, with the second group of hospitals tending to be larger and serving lower income patients. The third hospital group represented rural hospitals, though they also tended to perform fewer cardiac procedures. Importantly, this third group was about half as likely to identify myositis patients and more likely to identify the unrelated confounder conditions. Patients who received care at more rural hospitals (group 3) were at heightened mortality risk (OR=1.12, p < 0.0001). Opposite to the patient experiences in urban hospitals, the unique risk of mortality to myositis patients in rural hospitals was heightened (OR = 1.88, p < 0.0001).

Conclusion: Myositis was not associated with higher AMI events and mortality outcomes in this nationwide hospitalization cohort. Hospitals in rural locations had fewer diagnosed cases of myositis, catheter procedure and transfer out rate may have contributed to higher AMI mortality outcome in group 3. Further studies should examine if catheter procedure mortality outcome of AMI event in myositis differs in the three hospital groups.

Disclosure of Interests: None declared

antibodies (MAA) can be detected in approximately 60% of patients with IIM. Besides, antibody titers have been suggested to be related with diagnostic accuracy, although it has not been widely studied. MSA are considered to be exclusive of patients with IIM, whilst MAA can occur in IIM and other systemic autoimmune diseases, nevertheless, most of the studies are focused exclusively on IIM patients.

**Objectives:** The aim of this study is to assess the relationship between MSA/MAA and diagnosis (including IIM and other AID), and to explore the impact of antibody titers in diagnostic accuracy.

**Methods:** We retrospectively reviewed all the serum samples obtained from patients tested for MSA/MAA between 01/01/2018 and 31/12/2020 in the Immunology department of Ramón y Cajal University Hospital (Spain). These antibodies were tested by line blot immunassay (LIA) (EUROLINE Autoimmune Inflammatory Myopathies 16 Ag, Euroimmun, Lübeck, Germany). Positivity was established according to absorbance titer and adjusted by positive control of each test (arbitrary units, AU). True positive (TP) MSA and MAA were defined as those patients with IIM or AID with phenotypes expected of that MSA/MAA, according to the available information. The patients that did not have a phenotype compatible with that antibody were regarded as false positive (FP). Statistical analysis was carried out using IBM SPSS statistics version 22.

**Results:** We analyzed 130 positive samples which corresponded to 130 patients, 85 were women and mean age was 55.08 years. 44 patients (33.8%) were classified as IIM, 43 (33.1%) as AID, and 43 (33.1%) as non-IIM/AID. Among these 130 patients, 164 MSA/MAA were detected. 83 (50.6%) positive MSA/MAA were regarded as TP, and 81 (49.4%) as FP (positive predictive value [PPV] 50.6%). Antibodies regarded as TP had a higher antibody titer compared to FP (49.19 AU vs 26.96 AU, p<0.001). This difference was statistically significant for MSA and MAA when analysed separately (Figure 1). FP antibodies were associated with negative ANA and low titer ANA (p<0.001).

Multiple positive antibodies (antibodies included in samples that were positive for > 1 MSA/MAA) were more frequently FP in comparison with isolated positive MSA/MAA (p<0.001).

**Conclusion:** In this study we confirm that FP results using LIA are relatively frequent, and are associated with lower titer MSA/MAA, negative ANA, lower titer ANA, and with multiple positive MSA/MAA within one sample.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.397
annually as compared to controls. This study is among the first to document the clinical burden leading to high economic impacts of DM.

**Acknowledgements:** Funding for this study was provided by Pfizer Inc.

**Disclosure of Interests:** Arielle Bensimon Consultant of: Pfizer, as an employee of Analysis Group, Kristina Chen Employee of: Pfizer, Ahmed Noman Consultant of: Pfizer, as an employee of Analysis Group, Riley Taiji Consultant of: Pfizer, as an employee of Analysis Group at the time that this study was conducted, Erica Yim Consultant of: Pfizer, as an employee of Analysis Group, Vanja Sikirica Shareholder of: Pfizer, which manufactures medications approved for use in Rheumatology., Employee of: Pfizer at the time of this work and a current employee of Moderna., Rohit Aggarwal Consultant of: Abbvie, Alexion, Astra-Zeneca, Pfizer, Octapharma, CSL Behring, BMS, Argenx, Corbus, EMD, Janssen, Kezar, Kyverna, Rolivant, Q32, Corbus, EMD Serono, Jubilant, Sciphem, Boehringer Ingelheim and Mallinckrodt, Grant/research support from: Pfizer, BMS, Q32, EMD Serono, Mallinckrodt, Genentech, and Boehringer Ingelheim

**Reference:**


**Disclosure of Interests:** Chingching Foocharoen Speakers bureau: By Boeringer Ingelheim, Bandit Thinkhamrop: None declared, Wilaiphorn Thinkhamrop: None declared, A Johannas Mead—under the aegis of the Publication Clinic Khon Kaen University, Thailand—for assistance with the English-language presentation.

**Disclosure of Interests:** Chingching Foocharoen Speakers bureau: By Boeringer Ingelheim, Bandit Thinkhamrop: None declared, Wilaiphorn Thinkhamrop: None declared, A Johannas Mead—under the aegis of the Publication Clinic Khon Kaen University, Thailand—for assistance with the English-language presentation.

**Disclosure of Interests:** Chingching Foocharoen Speakers bureau: By Boeringer Ingelheim, Bandit Thinkhamrop: None declared, Wilaiphorn Thinkhamrop: None declared, A Johannas Mead—under the aegis of the Publication Clinic Khon Kaen University, Thailand—for assistance with the English-language presentation.

**Table 1. Generalizability of selected model(s) presented as accuracy, area under ROC, positive predictive value, positive likelihood ratio, specificity, and sensitivity**

<table>
<thead>
<tr>
<th>Selected Model</th>
<th>Accuracy</th>
<th>AUC (95%)</th>
<th>PPV (95%)</th>
<th>+LR (95%CI)</th>
<th>Specificity (95%)</th>
<th>Sensitivity (95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1 mRSS and WHO FC ≥ II</td>
<td>81.1</td>
<td>83.6 (725 – 89.6)</td>
<td>84.6 (95. - 94.1)</td>
<td>84.6 (95. - 94.1)</td>
<td>84.6 (95. - 94.1)</td>
<td>84.6 (95. - 94.1)</td>
</tr>
<tr>
<td>Model 2 mRSS and WHO FC ≥ III</td>
<td>82.7</td>
<td>82.4 (75.8 – 88.9)</td>
<td>73.4 (60.9 – 83.7)</td>
<td>73.4 (60.9 – 83.7)</td>
<td>73.4 (60.9 – 83.7)</td>
<td>73.4 (60.9 – 83.7)</td>
</tr>
</tbody>
</table>
skin score, and whether prednisolone was safe with particular reference to renal function.

**Methods:** PRedSS set out as a Phase II, multicentre, double-blind randomised controlled trial, converted to open-label because of the Covid-19 pandemic. Patients were randomised to receive either moderate dose prednisolone (approximately 0.3 mg/kg) or matching placebo (or no treatment during open-label) for 6 months. The co-primary endpoints were the Health Assessment Questionnaire Disability Index (HAQ-DI) and modified Rodnan skin core (mRSS) at 3 months. Over 20 secondary endpoints included patient reported outcome measures reflecting pain, itch, anxiety and depression, fatigue and helplessness. 72 participants randomised 1:1 were planned and anticipated to yield 60 evaluable, giving over 80% power for each co-primary outcome in ANCOVA analyses [assumptions; HAQ-DI (α = 0.025, β = 0.6), mRSS (α = 0.025, β = 0.6)]. Mixed Models for Repeated Measures (week 6, month 3, month 6) were fitted with covariates trial arm, baseline score, anti-Scl-70 and their interactions with time point. An unstructured covariance matrix was assumed with the primary focus being the trial arm effect at 3 months.

**Results:** The study terminated early due to the Covid-19 pandemic and consequently did not meet the recruitment target of 72 patients. Thirty-five patients (Table 1) were randomised (17 to prednisolone and 18 to placebo/control, 25 during the double-blind phase), of whom 34 completed the 3 month assessment. The adjusted mean difference between treatment groups at 3 months in HAQ-DI score was -0.10 (97.5% CI -0.29 to 0.10), p=0.25, and in mRSS -3.90 (97.5% CI -8.83 to 1.03), p=0.070, both favouring prednisolone but not significantly. Patients in the prednisolone group experienced less pain, helplessness and anxiety than control arm at 3 months: mean difference in pain scores -0.49, 95%CI (-0.93 to -0.06), p=0.027, in Hospital Anxiety and Depression (HADS) anxiety scores -2.05, 95%CI (-3.73 to -0.37), p=0.018, and in helplessness scores -1.54, 95%CI (-3.01 to -0.07), p=0.040. There were no renal crises.

**Table 1. Baseline characteristics of patients by treatment allocation**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Prednisolone (n=17)</th>
<th>Control (n=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>52.7 (14.0)</td>
<td>55.3 (12.7)</td>
</tr>
<tr>
<td>Female n (%)</td>
<td>10 (59)</td>
<td>9 (50)</td>
</tr>
<tr>
<td>Duration of skin thickening (years)</td>
<td>16 (10.8)</td>
<td>17 (10.8)</td>
</tr>
<tr>
<td>Anti-topoisomerase-1 n (%)</td>
<td>5 (29)</td>
<td>6 (33)</td>
</tr>
<tr>
<td>Anti-RNA polymerase III n (%)</td>
<td>6 (35)</td>
<td>8 (44)</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>16.8 (9.8)</td>
<td>17.0 (7.0)</td>
</tr>
<tr>
<td>mRSS</td>
<td>18.8 (7.9)</td>
<td>23.5 (8.6)</td>
</tr>
</tbody>
</table>

Values are mean (standard deviation) unless stated otherwise.

**Conclusion:** PRedSS exemplified the challenges of running a clinical trial of an investigational medicinal product potentially associated with increased infection risk during the Covid-19 pandemic. Because PRedSS was terminated prior to target recruitment, it was underpowered, and any conclusions have to be extremely cautious. Although PRedSS suggested some benefit from moderate dose prednisolone, the small sample indicates the need for a further randomised trial.

**References:**


**Acknowledgements:** This work was funded by Versus Arthritis.

**Disclosure of Interests:** Deb Griffiths-Jones: No declared, Yvonne Sylvestre Garcia: No declared, David Ryder: No declared, John Pauling Speakers bureau: Janssen, Consultant of: Janssen, Boehringer Ingelheim, Permeatus Inc, Sojournix Pharma and Astra Zeneca, Frances Hall Consultant of: Sobi, Roche, Grant/research support from: Alexaion, Lilly, BMS, Actelion, Sobi, Peter Lanyon Grant/research support from: Vifor pharma, Justin Mason Consultant of: Pfizer, Novartis, Janssen and Roche., Christopher P Denton Speakers bureau: Janssen, Boehringer Ingelheim, Consultant of: GSK, Boehringer Ingelheim, CSL Behring, Corbus, Roche, Gesynta, Grant/research support from: Servier, GSK, Anx Therapeutics, Horizon, Ariane Hick Speakers bureau: Janssen, Consultant of: Arena, Boehringer-Ingelheim, Camurus, CSL-Behring, Gesynta, Grant/ research support from: Gesynta

**DOI:** 10.1136/annrheumdis-2022-eular.743

**POS0851**

**FREQUENCY OF METABOLIC SYNDROME AND ITS RELATIONSHIP WITH DISEASE CHARACTERISTICS IN PATIENTS WITH SYSTEMIC SCLEROSIS**

Ü. Özmen¹, E. Er Gülbeyzê², B. Barutçuoğlu³, F. Yargucu¹. ¹Ege Üniversitesi Hastanesi, Internal Medicine, İzmir, Turkey; ²Kök University Hospital, Rheumatology, İstanbul, Turkey; ³Ege Üniversitesi Hastanesi, Rheumatology, İzmir, Turkey; ⁴Ege Üniversitesi Hastanesi, Department of Medical Biochemistry, İzmir, Turkey

**Background:** Although the frequency of metabolic syndrome (MetS) has been found to increase in many rheumatological diseases such as rheumatoid arthritis, systemic lupus erythematosus, few studies have been conducted on the frequency of MetS in systemic sclerosis (SSc), and the results are inconsistent.

**Objectives:** In our study, we aimed to investigate the frequency of MetS in patients with SSc and its relationship with disease characteristics including organ involvement.

**Methods:** In a cross-sectional, single-center study, 76 patients who applied to our outpatient clinic between July and September 2021 were included in the study. MetS diagnoses were determined according to anthropometric measurements, lipid parameters, blood pressures, and NCEP ATP 3 criteria, and its relationship with SSc end-organ involvement and disease characteristics was examined.

**Results:** MetS was detected in 37 (48.7%) of 76 patients. Systolic and diastolic blood pressure, waist circumference, height, body mass index, LDL, triglyceride, and fasting blood glucose mean were found to be statistically significantly higher in patients with MetS (p<0.05). In addition, HDL was found to be significantly lower in patients with MetS diagnosis than in patients without MetS (p<0.05). While no significant relationship was found between MetS and SSc end-organ involvement, SSc disease activities (RA, SCTC-DI), disease duration, a significant statistical relationship was found between MetS and modified Rodnan skin score (mRSS). It was found that patients with MetS had lower mRSS (p=0.019). According to ROC analysis, the mRSS cut-off point that predicting the presence of MetS was mRSS ≤11 (specificity: 84%, sensitivity: 45.95%, AUC: 0.656, p=0.014). No statistically significant correlation was found in the comparison with MetS risk factors for mRSS ≤11.

**Conclusion:** In our study, the frequency of MetS in patients with SSc was found to be lower than in the same age group in Turkey MetS prevalence studies. The frequency of MetS in our study is thought to be due to age and gender dominance of the SSc diseases other than SSc itself. Although mRSS was found to be significantly higher in patients with MetS, its sensitivity to predict MetS was found to be low. MetS is less common in patients with high mRSS; It is thought that cachexia due to inflammation, loss of appetite, and malnutrition due to GI involvement may have been effective.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.743

**POS0852**

**SYMPTOMS OF GASTROESOPHAGEAL REFLUX ARE A BETTER PREDICTOR OF SYSTEMIC SCLEROSIS-RELATED INTERSTITIAL LUNG DISEASE PROGRESSION THAN QUANTITATIVE RADIOGRAPHIC ASSESSMENT OF ESOPHAGEAL PARAMETERS**

E. Vollmann¹, D. Tashkin², M. Leng³, G. Kim², J. Goldstr³, M. Roth³. ¹University of California, Los Angeles, Medicine, Los Angeles, United States of America; ²University of California, Los Angeles, Radiology, Los Angeles, United States of America

**Background:** Esophageal dysfunction affects the majority of patients with systemic sclerosis (SSc). Gastroesophageal reflux (GERD)-associated microaspiration may serve as an inciting and/or exacerbating factor in the pathogenesis of interstitial lung disease (ILD) in SSc. Few studies have investigated the relationship between objective measures of esophageal involvement in SSc and the progression of SSc-ILD.

**Objectives:** (1) To investigate whether patient-reported symptoms of GERD predict SSc-ILD severity and progression; (2) To explore whether quantitative radiographic measurements of esophageal parameters predict SSc-ILD severity and progression.

**Methods:** Participants of Scleroderma Lung Study (SLS) II (24 months of myophenolate versus 12 months cyclophosphamide followed by 12 months of placebo in patients with active SSc-ILD) were included.¹ The UCLA SCTCGIT 2.0 was used to assess the severity of reflux at baseline. Quantitative image analysis was used to calculate the diameter and area of the esophagus in the area of maximum dilatation. Univariate and multivariable linear regression analyses were used to evaluate the relationship between baseline reflux scores/esophageal parameters and the severity and progression of SSc-ILD based on the
EFFECTS OF NINTEDANIB ON CIRCULATING BIOMARKERS IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD)

S. Assassi1, M. Kuwana2, C. P. Denton3, T. Maher4, C. Diefenbach5, C. Ittrich6, M. Gahlemann7, O. Distler8 on behalf of The SENSCIS trial investigators.

1University of Texas McGovern Medical School, Division of Rheumatology, Houston, TX, United States of America; 2Nippon Medical School Graduate School of Medicine, Division of Allergy and Rheumatology, Tokyo, Japan; 3Centre for Rheumatology and Connective Tissue Diseases, University College London Division of Medicine, London, United Kingdom; 4University of Southern California, Keck School of Medicine, Los Angeles, CA, United States of America; 5Boehringer Ingelheim Pharma GmbH & Co. KG, Translational Medicine and Clinical Pharmacology, Biberach an der Riss, Germany; 6Boehringer Ingelheim Pharma GmbH & Co. KG, Biostatistics + Data Sciences Corp., Biberach an der Riss, Germany; 7Boehringer Ingelheim (Schweiz) GmbH, Medicine, Basel, Switzerland; 8University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland

Background: In the SENSCIS trial in subjects with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) over 52 weeks by 44% compared with placebo.

Objectives: To investigate the effects of nintedanib on circulating biomarkers of extracellular matrix (ECM) turnover, epithelial injury and inflammation in the SENSCIS trial.

Methods: Subjects had SSc with first non-Raynaud symptom in the prior ≤7 years, extent of fibrotic LILD on high-resolution computed tomography (HRCT) ≥10% and FVC ≥40% predicted. Patients were randomised to receive nintedanib or placebo stratified by anti-topoisomerase I antibody (ATA). Blood samples were taken at baseline and at weeks 4, 24 and 52. Fold changes in adjusted mean levels of circulating biomarkers were analyzed using a linear mixed model for repeated measures. Data were log10 transformed before analysis and estimates of change from baseline were back-transformed.

Results: A total of 776 subjects received trial drug (288 nintedanib, 288 placebo). A transient increase in fold change from baseline in C-reactive protein (CRP) (a marker of inflammation) was observed in subjects who received nintedanib versus placebo at week 4. After an initial increase at week 4 in the fold change from baseline in CRP degraded by MMP-1/8 (CRPM) (a marker of ECM turnover), a trend to decreasing levels was observed in subjects who received nintedanib compared with placebo at week 52. Decreases in the fold change from baseline in collagen 3 degraded by MMP-9 (C3M) and N-terminal propeptide of type VI collagen (pro-C6) (markers of ECM turnover) were observed in subjects who received nintedanib compared with placebo from week 24 and week 4, respectively. A decrease in fold change from baseline in Krebs von den Lungen-6 (KL-6) (a marker of epithelial injury) was observed in subjects who received nintedanib versus placebo at week 52. A decrease in fold change from baseline in cancer antigen 125 (CA-125) (a marker of epithelial injury) was observed in subjects who received nintedanib versus placebo from week 4 (Figure 1).

Conclusion: Data from the SENSCIS trial suggest that nintedanib reduced circulating levels of markers of ECM turnover and epithelial injury in subjects with SSc-ILD.

Acknowledgements: The SENSCIS trial was funded by Boehringer Ingelheim. Masataka Kuwana, Toby M Maher and Oliver Distler were members of the SENSCIS trial Steering Committee.


References:
of Boehringer Ingelheim, Oliver Distler Speakers bureau: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years:

Speaker fee: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years:


OD has/had relationships with the following companies in the area of potential treatments for arthritis in the last three calendar years:

Consultancy fee: Abbvie, Grant/research support from: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years:

Research Grants: Boehringer Ingelheim, Kymera, Mitsubishi Tanabe.


Table 1. Baseline characteristics of patients in the placebo group of the SENSCIS trial in subgroups based on course of SSC-ILD over 52 weeks.

<table>
<thead>
<tr>
<th>Improvement (n=21)</th>
<th>Stability (n=166)</th>
<th>Progression (n=101)</th>
<th>Significant progression (n=37) (subset of Progression)</th>
<th>P-value for comparison of Improvement, Stability, Progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>55.9 ± 12.0</td>
<td>53.2 ± 12.6</td>
<td>53.1 ± 12.8</td>
<td>0.64</td>
</tr>
<tr>
<td>Female</td>
<td>71.4</td>
<td>75.9</td>
<td>70.3</td>
<td>0.59</td>
</tr>
<tr>
<td>Vascular first non-Raynaud symptom</td>
<td>3.5 ± 1.7</td>
<td>3.5 ± 1.9</td>
<td>3.6 ± 1.9</td>
<td>0.44</td>
</tr>
<tr>
<td>Diffuse cutaneous SSC</td>
<td>476</td>
<td>49.4</td>
<td>53.5</td>
<td>0.78</td>
</tr>
<tr>
<td>Anti-topoisomerase I antibody positive</td>
<td>61.9</td>
<td>58.4</td>
<td>66.3</td>
<td>0.44</td>
</tr>
<tr>
<td>Histopathological reactive protein, mg/L</td>
<td>8.0 ± 9.4</td>
<td>7.8 ± 8.9</td>
<td>5.6 ± 9.9</td>
<td>0.42</td>
</tr>
<tr>
<td>Modified Rodan skin score</td>
<td>3.9 ± 7.3</td>
<td>10.5 ± 8.4</td>
<td>11.9 ± 9.7</td>
<td>0.62</td>
</tr>
<tr>
<td>History of gastrointestinal reflux disease (GERD)</td>
<td>76.2</td>
<td>72.9</td>
<td>78.2</td>
<td>0.62</td>
</tr>
<tr>
<td>Extent (%) of fibrotic ILD on HRCT</td>
<td>26.6 ± 16.2</td>
<td>35.5 ± 20.4</td>
<td>36.8 ± 21.8</td>
<td>0.12</td>
</tr>
<tr>
<td>Presence of hypercombinacy on HRCT</td>
<td>14.3</td>
<td>16.8</td>
<td>15.5</td>
<td>0.29</td>
</tr>
<tr>
<td>Presence of ground glass opacities on HRCT</td>
<td>81.0</td>
<td>86.6</td>
<td>89.7</td>
<td>0.44</td>
</tr>
<tr>
<td>FI = % predicted</td>
<td>77.1 ± 18.0</td>
<td>71.7 ± 17.2</td>
<td>73.3 ± 15.2</td>
<td>0.01</td>
</tr>
<tr>
<td>DLCO % predicted</td>
<td>61.5 ± 14.9</td>
<td>53.4 ± 14.8</td>
<td>51.1 ± 15.1</td>
<td>0.02</td>
</tr>
<tr>
<td>Taking mycophenolate</td>
<td>71.4</td>
<td>48.2</td>
<td>45.5</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Data are mean ± SD or % at baseline. Missing data were excluded. *Assessed visually in whole lung to nearest 5%. The assessment did not include pure (non-fibrotic) ground glass opacities.
Methods: PROMIS PF data obtained in the coronavirus disease-2019 (COVID-19) Vaccination COVAD study database. The disease activity (active vs inactive) of each patient was measured between each disease category (IIMs vs non-IIM AIDs), even in patients with inactive disease. The elderly, women, and IBM groups are the worst affected, suggesting that developing targeted strategies to minimize functional disability in certain groups may improve patient reported physical function and disease outcomes.

REFERENCES:


background: PET/CT holds utility beyond the standard and readily available diagnostic tests for measuring severity. While PET/CT may detect skeletal muscle inflammation in IIM, its utility for people with IIM in comparison to standard screening methods is unknown. This systematic review seeks to evaluate the utility of PET or PET/CT in IIM, specifically for the detection of inflammatory muscle pathology, associated malignancy and extramuscular manifestations (e.g., ILD).

Methods: We performed a search of Medline and EMBASE from 1990-2021 using keywords related to IIM and PET. We included English language studies of adults with IIM who had PET or PET/CT as part of their diagnostic workup.

Results: Our search identified 910 potentially relevant abstracts, 18 of which were included. The majority of studies used [18F] fluorodeoxyglucose ([18F]FDG) PET or PET/CT scans, while the remainder used other radiotracers including [11C] fluorobetapir and [15C] Pittsburgh compound B ([15C] PIB). Malignancy – PET vs. conventional screening Six studies investigated the ability of 18F-FDG PET or 18F-FDG PET/CT to detect malignancy in people with IIM. When reported, the sensitivity and specificity of PET or PET/CT for diagnosing malignancy compared with standard detection methods was 66.7-94% and 88.9-97.8%, respectively. [2] ILD Using high-resolution CT (HRCT) as the gold standard for detection of ILD, three studies reported the ability of PET or PET/CT to detect ILD. The sensitivity of 18F-FDG PET alone for ILD was 39%, while the sensitivity of 18F-FDG PET/CT for ILD was 93-100%. FDG lung uptake was significantly increased in people with rapidly progressive-ILD (RP-ILD) in comparison to those with non-RP-ILD in two studies. 3. Muscle disease activity Ten studies evaluated either 18F-FDG PET or 18F-FDG PET/CT for its ability to detect muscle inflammation in IIM. In the nine studies where controls were used, PET or PET/CT appeared to accurately detect the presence of muscle inflammation, although correlations with clinical measures of myositis disease activity such as strength and serum creatine kinase were mixed. 4. A word on amyloid Skeletal muscle amyloid deposition was evaluated using [11C]PIB-PET in two studies and [18F] fluorobetapir PET/CT in one study. In all three studies, PET or PET/CT was able to differentiate sporadic inclusion body myositis (IBM) from non-IBM myositis.

Conclusion: PET or PET/CT performs relatively well as a malignancy screening tool for people with IIM in comparison to standard screening methods. While false positives for malignancy on PET can lead to unnecessary invasive investigations, this also occurs with conventional screening. PET/CT also appears to be a beneficial tool for detecting ILD in those with IIM and may predict its severity. While PET/CT may detect skeletal muscle inflammation in IIM, its utility beyond the standard and readily available diagnostic tests for measuring muscle disease activity remains unclear. Early evidence indicates PET-amyloid may be able to subtype IBM from non-IBM myopathic disease, although more data are needed. More research is needed to evaluate whether PET could be used as a tool for detecting cardiac involvement in IIM, or if extending the PET scan field of view might increase the cancer detection yield and permit a more accurate assessment of extramuscular manifestations in IIM. PET/CT holds promise as a single tool that can simultaneously evaluate multiple aspects of IIM early in the diagnostic process. These include screening for associated malignancy in high-risk patients, stratifying higher risk ILD, and providing information on muscle inflammation.

Disclosure of Interests: None declared

MCTD disease characteristics have only been partially investigated. NVC abnormalities videocapillaroscopy (NVC) is a simple, non-invasive and inexpensive imaging technique that allows a detailed assessment of skin microcirculation. NVC abnormalities of at least 3 of the 4 following features: at least 1 giant capillary, decreased capillary density (31.4%) and C) scleroderma pattern in 18 patients (35.3%), defined by the presence of at least 3 of the 4 following features: at least 1 giant capillary, decreased capillary density (<7/mm²), avascular areas and disorganization of capillary bed architecture (4). Scleroderma pattern was associated with clinical features of systemic sclerosis: skin sclerosis (9/16 vs. 5/33; p=0.008) and digital ulcers (6/18 vs. 2/31; p=0.017). Conversely, no association was observed between the normal or the non-specific NVC pattern and disease specific characteristics.

Interestingly, we observed, a significant reduction in the number of capillaries in patients with ILD (4.80±1.87 vs. 6.03±1.47; p=0.039), and patients with severe reduction of capillary density (≤4/mm²) were more likely to have ILD (57/5 vs. 53/3; p=0.002). Neangiogenesis was also more frequent in patients with ILD (6/13 vs. 4/27; p=0.004). Multivariate logistic regression analysis showed that the association between severe reduction of capillary density and ILD was observed independently of the presence of a scleroderma NVC pattern and skin fibrosis.

Conclusion: We identified three main NVC patterns in MCTD patients. The scleroderma NVC pattern was associated with clinical scleroderma characteristics whereas non-specific microangiopathy and normal NVC were not associated with a specific phenotype. Moreover, severe capillary loss was independently associated with the presence of ILD. These data suggest that NVC may be helpful for disease risk stratification in MCTD, and that NVC findings, and particularly severe capillary loss, may be a warning for the presence of ILD.

REFERENCES:


Table 1. Other efficacy endpoints

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Week 12</th>
<th>Week 24</th>
<th>Week 52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of finger digital ulcers</td>
<td>mean</td>
<td>1.9</td>
<td>1.6</td>
<td>1</td>
</tr>
<tr>
<td>SD</td>
<td>2.3</td>
<td>2.3</td>
<td>1.6</td>
<td>0.7</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>0.17</td>
<td>0.04</td>
<td>0.04</td>
</tr>
<tr>
<td>Percent predicted FVC, %</td>
<td>mean</td>
<td>86.7</td>
<td>87.1</td>
<td>85.9</td>
</tr>
<tr>
<td>SD</td>
<td>13.1</td>
<td>14.4</td>
<td>14.4</td>
<td>14.1</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>0.7</td>
<td>0.45</td>
<td>0.3</td>
</tr>
<tr>
<td>Percent predicted DLCO, %</td>
<td>mean</td>
<td>92.6</td>
<td>89.3</td>
<td>88.9</td>
</tr>
<tr>
<td>SD</td>
<td>22.5</td>
<td>22.9</td>
<td>19.4</td>
<td>22.2</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>0.06</td>
<td>0.09</td>
<td>0.18</td>
</tr>
<tr>
<td>PGA, mm</td>
<td>mean</td>
<td>48.6</td>
<td>47.9</td>
<td>43.4</td>
</tr>
<tr>
<td>SD</td>
<td>23.9</td>
<td>25.7</td>
<td>26</td>
<td>24.6</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>0.66</td>
<td>0.04</td>
<td>0.71</td>
</tr>
<tr>
<td>CGA, mm</td>
<td>mean</td>
<td>68.9</td>
<td>53.5</td>
<td>39.5</td>
</tr>
<tr>
<td>SD</td>
<td>23.9</td>
<td>19</td>
<td>16.7</td>
<td>13.9</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>J-HAQ-DI score</td>
<td>mean</td>
<td>0.22</td>
<td>0.17</td>
<td>0.13</td>
</tr>
<tr>
<td>SD</td>
<td>0.49</td>
<td>0.44</td>
<td>0.35</td>
<td>0.35</td>
</tr>
<tr>
<td>P value</td>
<td>NA</td>
<td>0.14</td>
<td>0.71</td>
<td>0.7</td>
</tr>
</tbody>
</table>

A. Number of finger digital ulcers B. Percent predicted FVC, % C. Percent predicted DLCO, % D. PGA, mm E. CGA, mm F. J-HAQ-DI score
Conclusion: Patients with active SSC-ILD receiving one year of immunosuppressive therapy in the SLS II study experienced reductions in their CRP and IL-6 levels over this interval. The magnitude of the decrease in CRP and IL-6 over the first year also correlated with the course of FVC over the ensuing 12 months. These findings suggest a dynamic relationship between CRP and IL-6 measurements and the course of SSC-ILD in patients on immunosuppressive therapy. Further investigation of these findings is warranted.

REFERENCES:

Disclosure of Interests: Elizabeth Volkmann Speakers bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim, Grant/research support from: Forbius, Kadmon, Horizon, Boehringer Ingelheim, Donald Tashkin: None declared, Holly Wilhalme: None declared, Michael Roth Grant/research support from: Genentech, Shervin Assassi Consultant of: Boehringer Ingelheim.


POS0860 ULTRA-HIGH FREQUENCY ULTRASOUND FOR DIGITAL ARTERIES: COMPLETING THE CHARACTERIZATION OF VASCULOPATHY IN SYSTEMIC SCLEROSIS

M. Di Battista1, S. Vitali2, S. Barsotti3, R. Morganti4, V. Dini5, M. Romanelli5, 1University of Pisa, Rheumatology Unit, Pisa, Italy; 2University of Siena, Department of Medical Biotechnologies, Siena, Italy; 3University of Pisa, Radiology Unit, Pisa, Italy; 4University of Pisa, Section of Statistics, Pisa, Italy; 5University of Pisa, Dermatology Unit, Pisa, Italy

Background: Despite microangiopathy is the hallmark of systemic sclerosis (SSc), macrovascular involvement is arousing interest. In particular, proper palmar digital arteries (PPDA) play an important role in Raynaud’s phenomenon and can contribute to the exacerbation of vascular damage. However, PPDA full characterization is still an unmet need.

Objectives: To identify subgroups of anti-Ku positive patients according to their clinical entity? A cluster analysis of 75 anti-Ku antibody syndrome: is it a distinct clinical entity? A cluster analysis of 75 patients.

Methods: Multicenter, cross-sectional study of anti-Ku positive patients, irrespective of their diagnosis, followed at eight Rheumatology outpatient clinics. Patients were spontaneously identified according to the local work-out for suspected autoimmune diseases. Anti-Ku and other ANA specificities were determined at each hospital’s Immunology lab according to the local methodology and strategy to decide on which auto-antibodies to check when faced with a positive ANA immunofluorescence. Clinical, analytical and treatment cumulative features were identified following a dedicated structured questionnaire. Hierarchical cluster analysis (method: between-groups linkage, squared Euclidian distance) for ANA specificity variables was performed to identify subgroups.

Results: Seventy-five anti-Ku positive patients were included (female: 73.3%, mean age at diagnosis: 50.5±17.9 years). Their clinical diagnosis were undifferentiated connective tissue disease (UCTD) (21.3%), systemic lupus erythematosus (17.3%), Sjögren’s syndrome (16.0%), inflammatory myositis (14.7%), systemic sclerosis (10.7%), overlap CTD syndrome (8.0%), other connective tissue diseases (17.3%), healthy anti-Ku carrier (17.3%). Six autoantibody clusters were identified and included most patients (Figure 1): Cluster 1 - anti-Ku without any other ANA specificities (36.0%); cluster 2 - anti-nor90 and anti-fibrillarin (8.0%); cluster 3 - anti-Jo1, PL-7, PL-12, and PM-ScI100 (9.3%); cluster 4 - anti-ScI70 (4.0%); cluster 5 - anti-Sm, anti-ribosome, and anti-dsDNA (13.3%); cluster 6 - anti-centromere, ThTo, PM-ScI75 (8.0%). The remaining patients were outliers (21.3%) not fitting in any cluster.
**Detailed clinical analysis of patients in cluster 1, the most numerous, presenting anti-Ku antibodies without any other ANA specificities**. The most frequent clinical manifestations were: Raynaud’s phenomenon (40.7%), arthritis (25.9%), sicca syndrome (25.9%), myositis (14.8%), and interstitial lung disease (ILD) (14.8%). 25.9% were healthy anti-Ku carriers. Patients from cluster 1 were most frequently treated with low dose glucocorticoids (51.9%), hydroxychloroquine (37.0%), or methotrexate (18.5%). Among the whole study population (n=75), major organ involvement was present in 18.7%, with ILD in 10.7% and renal involvement in 8.0%. None of the patients in the cluster presented nephritis.

**Conclusion**: Anti-Ku positive patients without any other ANA specificities is the largest subset and may represent a distinct entity among the differentiated CTD (2). Patients with this anti-Ku syndrome may develop ILD. In addition, anti-Ku antibodies can be found in patients with a diversity of other ANA specificities and heterogeneous CTD diagnosis.

**REFERENCES:**


**Disclosure of Interests**: None declared


---

**POS0862**

**INAUGURAL DROPPED HEAD SYNDROME AND CAMPTOCORMIA IN INFLAMMATORY MYOPATHIES**

M. Robert1, L. Gallay1, P. Peltot2, T. Fencou3, L. Lessard2, L. Perard5, J. Svahn2, J. Fiscus6, N. Fabien6, F. Bouhour2, D. Maucort-Boulch7, 8, I. Durieu9, M. Robert1, L. Gallay1, P. Peltot2, T. Fencou3, L. Lessard2, L. Perard5, J. Svahn2, J. Fiscus6, N. Fabien6, F. Bouhour2, D. Maucort-Boulch7, 8, I. Durieu9, Claude Bernard University Lyon 1, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France; 2Lyon Sud Hospital Center, Service de Médecine Interne, Lyon, France; 3Institut de Recherche en Cancérologie de Lyon, Equipe Ribosome Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France; 4Lyon Sud Hospital Center, Service de Médecine Interne, Lyon, France; 5Group Hospital Ins - Hôpital, Centre de Recherche en Cancérologie de Lyon, Équipe Biostatistique, Villeurbanne, France; 6Rheumatology Research Unit, Institute of Tropical Medicine, Florence, Italy; 7University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy; 8University and IRCCS-Policlinico San Matteo di Pavia, U.O.C. Reumatologia, Pavia, Italy; 9Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, RHEUMATOLOGY Department, Lisboa, Portugal; 10Lyon Sud Hospital Center, Service de Neurologie, U.O.C. Reumatologia, Pavia, Italy; 11Institute NeuroMyoGène, INMIG CNRS UMR 5261-INSERM U1315, Lyon, France.

**Background**: The idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of diseases that can affect the muscles, skin, lungs, heart, and joints. Increased knowledge about histopathological findings, clinical manifestations and auto-antibodies have allowed further novel classification of IIMs. Today, the main IIM subgroups are: dermatomyositis (DM), inclusion body myositis (IBM), immune-mediated necrotizing myopathies (IMNM), overlap myositis (OM) and immune-checkpoint inhibitor-related-myositis (IClirm). Axial muscle involvement results either in a “Dropped Head Syndrome (DHS)”, with a marked weakness of the neck extensors, or in a camptocormia (CC), with a weakness of the thoracolumbar paraspinal muscles. This atypical presentation is poorly described in the course of DMs while it may result in a major disability, and may lead to myositis diagnosis delay.

**Objective**: This study aimed to describe Ims revealed by DHS and/or CC. Secondary outcomes were to define subgroups of patients according to clinical, biological and histopathological characteristics. Then, the effects of treatments used were analyzed.

**Methods**: A historical cohort was designed using the register MYOLYON which includes all Ims followed at the University Hospital of Lyon (France) between 2000 and 2021. All patients with IM revealed by DHS and/or CC and having an histologically proven IMs were included, after exclusion of alternative (e.g., myasthenia gravis, motoneuron disease). Clinical, biological, immunological, histopathological data as well as outcome and care were collected through a standardized form. Agreement for the study was obtained from the French Ministry of the Research and the study was approved by the Local Research Ethics Committee.

**Results**: Twenty-two patients were fully characterized: DM (n=4), IBM (n=7), OM (n=8), IClirm (n=2) and one myositis with anti-Hu antibodies. Two groups of patients were identified according to the age at first symptoms and to the type of muscle axial involvement (e.g. DHS and/or CC). Before the age of 70 (n=13/22), the two most common diagnoses (n=11/13) were DM (n=4/4) and OM (n=7/8). Axial muscle involvement was diffuse (DHS and CC) in 10/13 patients. After 70 years old (n=9/22), there were a majority of IBM (n=6/9) and all cases of IClirm (n=2). Axial involvement was restricted to one group of muscles (DHS or CC) in 5/9 patients. Finally, 77% (17/22) of patients had refractory disease and required a second line treatment (e.g. immunoglobulins). All of these results are summarized in the Figure 1.

**Disclosure of Interests**: None declared


---

**POS0863**

**ANTI-NOR90 ANTIBODIES IN THE SETTING OF CONNECTIVE TISSUE DISEASE: CLINICAL SIGNIFICANCE AND COMPARISON WITH A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS**

A. Biglia1, E. Dourado2, B. Parderes3, P. Parrochi4, M. R. Pellicci1, G. Zannfrunno5, P. A. Rivera Matias1, P. Martins3, A. Miranda1, J. E. Cabral Da Fonseca6, E. Di Agostina7, D. Carmelli7, G. Emmi8, E. Ros9, R. Bixio8, E. Conticini10, E. Bellis5, C. Brunis3, C. Montecucco4, M. Matucci-Cerinici11, J. Rijos-Serrano12, L. Cavagna1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12.

**Background**: Anti-NOR90 antibodies (aNOR) are a recently described autoantibody with a strong association to dermatomyositis (DM). The test is commercially available in most laboratories.

**Methods**: We retrospectively analyzed 100 consecutive patients with systemic sclerosis (SSc) and 100 consecutive patients with idiopathic inflammatory myopathies (IIMs, DM or IClirm). aNOR was determined in all patients with SSc and in half of patients with IIMs.

**Results**: aNOR were present in 60% of DM patients and 80% of IClirm patients, whereas in SSc patients, aNOR were present in 15% of DM (n=9/60) and in 87.5% of OM (n=28/32).

**Conclusion**: While IM diagnosis is challenging in the presence of inaugural axial involvement, these results highlight the subset of IM to be considered according to the age at first symptoms and the type of axial involvement (e.g., DHS and/or CC). The presence of aNOR is associated with a specific disease pattern, but it remains to be seen if this antibody has clinical significance.

**Disclosure of Interests**: None declared

Background: Anti-NOR90 antibodies are directed against a 90-kD nucleolar protein located in the nucleolar organizing regions (NORs), mainly described in systemic sclerosis (SSc) [1, 2, 3] but reported also in other rheumatologic and oncologic diseases [4, 5, 6]. The clinical correlates of anti-NOR90 antibodies are still to be defined because the cohorts described thus far include a low number of patients.

Objectives: To describe the characteristics of a large cohort of anti-NOR90 antibodies positive patients and compare them with a matched cohort of SSc patients negative for anti-NOR90 antibodies.

Methods: A retrospective analysis was performed on patients positive for anti-NOR90 antibodies referring to participating centres. The concomitant positivity for anti-RNA polymerase III, Th/To, PM-Sc, Ku, and PDGFR antibodies was an exclusion criterion. In all cases the diagnoses, the different organ involvement and related clinical, instrumental and laboratory characteristics were evaluated. The EUROLINE SystemicSclerosisProfile kit from Euroimmun (Lübeck, Germany) was used to detect anti-NOR90 antibodies.

Results: We included 101 patients positive for anti-NOR90 (MF=13/88, mean age 52.5 years). They were mainly classified as SSc (n=38), undifferentiated connective tissue disease (UCTD) (n=21), interstitial pneumonia with autoimmune features (IPAF) (n=32), arthritis (n=30), and limited skin sclerosis (n=24). Anti-NOR90 antibodies were associated with anti-Ro52 antibodies in the 16% of cases, with anticentromere antibodies (n=32), arthritis (n=30), and limited skin sclerosis (n=24). Anti-NOR90 antibodies were associated with anti-Ro52 antibodies in the 16% of cases, with anticentromere antibodies in the 7% of cases, and with anti-Scl70 in the 5% of cases. After excluding patients, anti-NOR90 antibodies were associated with anti-Ro52 antibodies in the 16% of cases, with anticentromere antibodies in the 7% of cases, and with anti-Scl70 in the 5% of cases. After excluding those patients, and considering the isolated anti-NOR90 positivity, 12 patients had SSc, 35 UCTD, and 11 IPAF. The most frequent clinical manifestations were arthritis (n=40), RP (n=37), and sicca syndrome (n=21). Compared to 242 matched SSc without anti-NOR90 antibodies, patients with anti-NOR90 had more frequently joint manifestations and sicca syndrome and less frequently all vasculopathic manifestations (RP, telangiectasia, pitting scars, acral ulcers), dysphagia and fibromyalgia.

Conclusion: Our study shows that anti-NOR90 antibodies are more commonly observed in females, and clinically associated with the occurrence of arthritis/sialalgias, sicca syndrome and RP. In more than 50% of cases they may be found with other autoantibodies, such as the anti-Ro52, the anticientromere, and the anti-Scl70 antibodies. Anti-NOR90 seems to play an accompanying role in the context of CTDs, and has an antimicrobial effect. Despite its generalized use among SSc patients, this approach can be considered as a possible treatment for RP secondary to SSc.

Disclosure of Interests: None declared


Figure 1.

Disclosure of Interests: None declared


POSO865

THE EFFECT OF SILVER FIBER GLOVES ON RAYNAUD’S PHENOMENON IN PATIENTS WITH SYSTEMIC SCLEROSIS: A DOUBLE-BLIND RANDOMIZED CROSS-OVER TRIAL.


1 Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2 Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 3 Maasstad Ziekenhuis, Rheumatology and Clinical Immunology, Rotterdam, Netherlands; 4 Zuyderland MC, Rheumatology, Heerlen, Netherlands; 5 Haga Teaching Hospital, Rheumatology, The Hague, Netherlands

Background: Over 90% of patients with systemic sclerosis (SSc) experience Raynaud’s phenomenon (RP), which strongly influences quality of life. Therapeutic options of RP include drug treatment and general lifestyle measures such as smoking cessation and avoiding cold by wearing warm clothes and gloves including electrically heated gloves or silver fiber gloves. Clinical observations suggest an additional benefit of silver fiber gloves compared to normal gloves. Silver is thought to help by reflecting heat back into the hands allowing less heat to escape and has an antimicrobial effect. Despite its generalized use among SSc patients, no objective evidence regarding its superiority for RP over normal gloves exists.

Objectives: To evaluate the added value of 8% silver fiber gloves compared to normal gloves in the treatment of patients with RP secondary to SSc.

Methods: This was a multicenter double-blind randomized cross-over trial in which 8% SSc-patients (RP) were randomized in two sequences: 8% silver fiber gloves in period 1 and normal gloves in period 2 or vice versa; each period lasted six weeks. To
reduce bias of interindividual differences and external factors (e.g. temperature), a cross-over design was performed in the Netherlands during the winter months. The primary outcome was the triweekly Raynaud Condition Score (RCS), a scale from 1 (no symptoms) to 10 (extreme symptoms). A linear mixed model was used with RCS as dependent and type of gloves as independent variable, adjusted for baseline RCS. Secondary outcome measures included number of RP attacks, RP attack duration, Health Assessment Questionnaire (HAQ-DI) and vascular complications. Secondary outcomes were also analyzed with linear mixed models. All analyses were performed and interpreted before unblinding.

Results: The BS included SSc patients who had a mean age of 60 (SD:12), 80% were female, 60% had limited cutaneous SSc and 67% used vasoactive medication. Ten patients prematurely ended the study due to various reasons, most notable: allergic reaction to gloves (n=2). At baseline, mean RCS was 6.43 (SD 1.6), with silver fiber gloves the mean RCS decreased to 3.91 (SD 2.3) and with normal gloves to 3.90 (SD 2.3) (Figure 1). No statistically significant difference in RCS during follow-up was observed between the silver fiber gloves and normal gloves (β 0.067, 95% CI -0.006 to 0.19), meaning that on the 1-10 scale, silver fibre gloves gave only a 0.067 higher RCS compared to normal gloves (Table 1). For all other secondary outcome measures, we did not find a statistically significant difference between silver fiber gloves and normal gloves, except for the HAQ (β 0.036, 95% CI 0.026 to 0.046; Table 1), which is not clinically relevant. One vascular complication occurred in the silver fiber gloves, compared to three vascular in the normal gloves, which was not statistically significant different (OR:3.2, 95% CI 0.32 to 31.1).

Table 1. Primary and secondary efficacy outcomes

<table>
<thead>
<tr>
<th>Outcome</th>
<th>β</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary outcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud Condition Score</td>
<td>-0.067</td>
<td>-0.00059 -0.194</td>
</tr>
<tr>
<td>Secondary outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud attacks frequency</td>
<td>-0.480</td>
<td>-1.212 -0.255</td>
</tr>
<tr>
<td>Raynaud attacks duration</td>
<td>-0.380</td>
<td>-0.62 -0.144</td>
</tr>
<tr>
<td>VAS warmth hands</td>
<td>-0.086</td>
<td>-0.212 -0.041</td>
</tr>
<tr>
<td>Impact Raynaud</td>
<td>0.088</td>
<td>-0.035 0.211</td>
</tr>
<tr>
<td>HAQ_Di</td>
<td>0.036</td>
<td>0.026 0.046</td>
</tr>
</tbody>
</table>

RCS: Raynaud Condition Score; BL: Baseline.

Figure 1. Raynaud Condition Score during the study period

Conclusion: This trial shows that wearing any type of glove decreases the RP burden in SSc patients, but no additional benefit from gloves containing 8% silver fibers compared to normal gloves could be demonstrated. Potentially, less vascular complications may arise in SSc patients wearing silver fiber gloves. Further confirmation of this potential benefit is necessary.

Acknowledgements: The authors would like to thank all participants of this study and Skafit for providing the gloves.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1805

LABORATORY OF SYSTEMIC SCLEROSIS. V.A. NASONOV Institute of Rheumatology, Department of Systemic Diseases, Moscow, Russian Federation

References:


POS0867 COMORBIDITY AND COMPLICATIONS PRIOR TO SYSTEMIC SCLEROSIS DIAGNOSIS: A RETROSPECTIVE COHORT ANALYSIS

D. Khanna1, D. Funst, J. W. Li2, S. Shah1, T. Lesperance, F. A2, B. Lamoreaux1, S. Taylor1, University of Michigan Medical Center, Rheumatology, Department of Internal Medicine, Ann Arbor, United States of America; 2University of California in Los Angeles, Professor Emeritus, Medicine, Los Angeles, United States of America; 3Innity Life Sciences, Research, Deerfield, United States of America; 4Innity Life Sciences, Research, Waltham, United States of America; 5Horizon Therapeutics plc, Pharmacoeconomics & Risk Management, Deerfield, United States of America; 6Horizon Therapeutics plc, Clinical Development, Deerfield, United States of America; 7Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America; 8Horizon Therapeutics plc, Health Economics & Outcomes Research, Deerfield, United States of America

Background: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by progressive microvascular damage, collagen deposition and subsequent
fibrosis of the skin and internal organs which contributes to substantial morbidity and premature death.1,2

**Objectives:** The objective was to evaluate the disease burden of SSC patients and their SSC diagnosis.

**Methods:** Patients with SSC were identified in a claims dataset (IBM MarketScan Commercial Database, 2015-2019) using ICD 10 diagnosis codes for SSC. Eligible subjects were required to have > 1 inpatient or >2 outpatient/office claims with a scleroderma diagnosis code on separate days and > 24 months of continuous health plan enrollment without a SSC diagnosis before the first SSC claim (‘index date’) and > 12 months of enrollment after the index date. Overall comorbid disease burden was assessed via the Charlson Comorbidity Index (CCI) 13-24 and 12 months before and 12 months after index date. The prevalence of SSC-related complications for atherosclerosis, pulmonary arterial hypertension (PAH), pulmonary fibrosis (PF), Raynaud’s Phenomenon (RP), and gastrointestinal (GI) complications (e.g., GERD, dysphagia, etc.) were identified using ICD codes and reported as percentages for the aforementioned time intervals relative to patients’ index dates.

**Results:** 902 eligible SSC patients were identified for analysis. The mean age at index SSC diagnosis was 54.3 years and 84.7% of patients were female. Mean CCI scores 13-24 months before, 12 months before, and 12 months after index SSC diagnosis were 0.84, 1.13 and 1.30, respectively. From the time points 13-24 months before, 12 months before, and 12 months after index SSC diagnosis, increasing rates were also observed of atherosclerosis, PAH, PF, RP, and GI complications (Table 1).

**Conclusion:** Results from this analysis suggests that SSC-related sequelae are present at least two years prior to SSC diagnosis and rates of these complications increased markedly over time. Patients’ overall comorbid disease burden also worsened substantially over this period, likely because of these complications. The internal organ involvement is likely under reported due to requirements to link each diagnosis with an ICD-10 code. These data indicate the significant burden of SSC, prior to and after diagnosis, highlighting the need for awareness, prompt diagnosis, and effective therapies for SSC and its related complications.

**REFERENCES:**

**Disclosure of Interests:** Dinesh Khanna Consultant of: Horizon Therapeutics, Daniel Furst Consultant of: Horizon Therapeutics, Justin W. Li Grant/research support from: Horizon Therapeutics, Saloni Lesperance Shareholder of: Horizon Therapeutics, Farah All Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Stephanie Taylor Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics

**DOI:** 10.1136/annrheumdis-2022-eular.1888

---

**POS0686**

THE DEVELOPMENT OF THE LINEAR CRISIS; A CLINICAL AND PATIENT MEANINGFUL ANCHOR TO THE ACR-CRISS IN SCLERODERMA.

L. A. Bissel 1,2, D. Furst 1, S. Johnson 1, P. Hansen 1, E. Recalde 1, D. Khanna 1, F. Del Galdo 1 on behalf of Linear Crisis. 1Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; 2University of Leeds, Leeds Institute of Rheumatism and Musculoskeletal Medicine, Leeds, United Kingdom; 3University of California, Department of Rheumatology, Los Angeles, United States of America; 4University of Toronto, Institute of Health Policy, Management and Evaluation, Toronto, Canada; 5University Health Network & Sinai Health Systems, Toronto Scleroderma Program, Toronto, Canada; 6University of Otago, Department of Economics, Otago, New Zealand; 7World Scleroderma Foundation, Basel, Switzerland; 8University of Michigan, Division of Rheumatology/Department of Internal Medicine, Ann Arbor, United States of America

**Background:** The ACR Composite Response Index in Systemic Sclerosis (ACR-CRISS) is one of the first composite outcome measures in diffuse cutaneous Systemic sclerosis (dcSSc). It relies on validated clinical domains selected through a data-driven methodology; however, it only provides a probability of response and is unable to differentiate between patients who do not improve and who worsen respectively.

**Objectives:** To improve the clinical interpretation of the ACR-CRISS by creating a continuous ranked score of clinically and patient meaningful changes of its individual measures.

**Methods:** Following OmerACT guidelines for outcome measurement development, relevant stakeholders were identified from 5 continents, including 100 physicians with proven experience in managing patients with dcSSc and 100 patients with dcSSc who have participated in at least one clinical trial. An adaptive joint analysis survey based on the PARRIKLA method and implemented using 1000minds software was administered. Patients and doctors were asked to choose which of two hypothetical patients had a better or worse outcome according to Minimally Clinically Important Differences (MCID) in two domains at a time from FVC, HAQ-DI and mRSS and the presence of organ failure. These pairwise choices were analysed to rank and weight the MCIDs against each other. With patient and public involvement, utilising a ‘think aloud’ approach, a video tutorial was produced explaining the objectives and process of the adaptive survey to the participants.

**Results:** Eighty rheumatologists and 80 patients with dcSSc completed the survey, which ran from June 2020 to January 2021. From the survey, relative weights for the 4 domains, reflecting their relative importance with respect to improving and worsening outcomes, were determined. A continuous composite ranked score reflecting the relative weighting of the individual outcome measures (Ranked Composite Important Difference, RCID) was developed accordingly (Table 1). The score ranges from -1 (worst possible outcome) to 1 (best possible outcome), in patients who experience no organ failure and do not meet any MCID in any of the 3 domains scoring 0.

**Conclusion:** This collaborative process using a novel, robust methodology and involving both rheumatologists and patients has created a clinically and patient meaningful composite score that can be used as an anchor to the ACR-CRISS, or other clinical outcomes. Performance against the ACR-CRISS and revised CRISS in randomised controlled trials and in observational cohorts will determine the clinical value of the RCID.

**REFERENCES:**

**Acknowledgements:** DK and FDG are recognised as joint senior authors. The authors acknowledge the doctors and patients involved in the Linear Crisis working group: Giuseppina Abigrano, Paolo Aro, Dina-Marie Auto, Yannick Allanore, Sheren Assassi, Jérôme Avouac, Gianluca Bagnato, Alexandre Babir-Gurman, Silvia Bel-Pazuk Randone,Lorenzo Beretta, Elena Bernstein, Silvia Laura Bosello, Yolanda Braun Moscovich, Katrina Brown, Maya Buch, Corrado Campochiaro, Patricia Carneia, Lorinda Chung, Julia Coakes, Mary Cox, Giovanni Cuomo, Maurizio Cutolo, Laszlo Czirjak, Lorenzo Dagna, Giacomo De Luca, Nicolina Del Papa, Christopher Denton, Emma Derrett-Smith, Robyn Domic, Ruiu-Blanca Dumitru, Victoria Flower, Ivan Foeidvairi, Armando Gabrielli, Yasir Ghaifat, Roberto Giacomelli, Dilia Giuggioli, Daisy González, Jessica Gordon, Yvonne Gouldstone, Marie Hudson, Francesca Ingenniogio, Lorraine Jackson, Sergio Jimenez, Terrance Johnson, Bashar Kahaleh, Robin King, Otylia Kowal-Bielecka, Masataku Kuwana, Maria Lazzaroni, Alain Lescot, Takashi Matsushita, Marco Matucci Cerinic, Maureen Mayes, Thomas Medsger, Francesca Menegazzi, Tunde Minier, Mananda Nkipor, Chris O’Hora, Emese Paal-Mohótr, John Pauling, Jose Antonio Pereira da Silva, Mercé Piñero Vegas, Janet Pope, Susanna Proustman, Ismaila Rafiq, Valeria Riccioli, Tatianna Sofia Rodriguez-Reyna, Tánia Santiago, James Seibold, Richard Silver, Robert Spieri, Tracy Stafford, Virginia Steen, Yosra Atef Suliman, Madelon Vonk, Ian Wright.

Background: Immune pathways have been implicated in both systemic sclerosis (SSc)-related interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF). Determination of blood cytokine differences in these two disorders need to be elucidated to better understand potential biological processes and common pathogenic pathways.

Objectives: This study compared 87 circulating cytokine levels amongst healthy controls and both SSc-ILD and IPF. There was also exploration of the association between cytokine levels and disease progression based on the annualized rate of decline of forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO).

Methods: Levels of 87 plasma cytokines were measured using commercial panels for consecutive SSc-ILD, IPF, and healthy individuals recruited at a Canadian tertiary-care center. Pulmonary function tests were performed as clinically indicated every 3-12 months. Cytokine levels are compared using the Wilcoxon rank sum test for two samples pairwise. The association between differentially expressed cytokines with both percent predicted annualized FVC and DLCO change was assessed within each disease group using multiple linear models adjusted for age, sex, baseline FVC, and immunosuppressive or anti-fibrotic treatment at sampling. Correction for multiplicity of testing was by Holm's method.

Results: There were 19 healthy controls, 40 SSc-ILD, and 17 IPF participants with clinical features shown in Table 1. Eotaxin-1 and interleukin 6 (IL-6) were significantly elevated in both SSc-ILD and IPF compared to healthy controls (Figure 1). SSc-ILD had significantly lower soluble epidermal growth factor receptor (sEGFR) and higher levels of both soluble tumor necrosis factor receptor type II (sTNFRII) and soluble vascular endothelial growth factor receptor-1 (sVEGFR1) compared to healthy controls. IPF cases were distinguished from healthy controls by significantly higher monocyte chemotactic protein-1 (MCP-1) and monokine induced by gamma interferon (MIG) when compared to healthy controls (Table 1). Significant association was found for any of the cytokines with ILD progression based on annualized rates of either FVC or DLCO change.

Conclusion: Differences in seven circulating cytokines between healthy controls with both SSc-ILD and IPF show evidence of immune system activation. All seven cytokines have a role in immune cell extravasation and pro-fibrotic signalling, which provides further evidence of immune pathways involved in pulmonary fibrosis. Further studies will be pursued of longitudinal change of these biomarkers for halting or slowing disease progression and improving response to treatment.

Disclosure of Interests: Boyang Zheng: None declared, Kevin Keen Grant/research support from: Merck Canada Inc, Marvin Fritzler Shareholder of: Abbott Laboratories; Roche Holdings; Abcellera; Moderna, Speakers bureau: For diagnostic company: Merck, Consultant of: For diagnostic company: Merck, Christoph Ryerson Speakers bureau: Boehringer Ingelheim, Hoffmann-La Roche, Consultant of: Boehringer Ingelheim, Hoffmann-La Roche, Veracyte, Astra Zeneca, Grant/research support from: Boehringer Ingelheim, Hoffmann-La Roche, Pearce Wilcox Speakers bureau: Vertex, Yale, Boehringer, Beth Whalen: None declared, Basak Sahin: None declared, Haiyan Hou: Employee of: Mitogen Diagnostics, Penny Latham Employee of: Eve technologies, Mei Feng Zhang Employee of: Mitogen diagnostics, Iris Yao: None declared, James Dunne: None declared

changes. This highlights the importance of other factors than ILD on lung function in SSC patients.

REFERENCES:

Disclosure of Interests: Håvard Fretheim Speakers bureau: non-financial support from GSK and Actelion, outside the submitted work., Consultant of: Personal fees from Bayer and non-financial support from GSK and Actelion, outside the submitted work., Ip, Jinping Zheng, Janet Stocks, the ERS Global Lung Function Initiative. European Respiratory Journal, Conflict of Interest: None declared.

POS0872

DIAGNOSTIC ACCURACY OF POWER DOPPLER ULTRASONOGRAPHY FOR THE DIAGNOSIS OF IDIOPATHIC INFLAMMATORY MYOPATHIES.

E. Conticini1, P. Falsetti1, M. D’alessandro2, S. Grazzini1, C. Baldi1, M. Bardelli1, S. Gentileschi1, F. Bellissai1, G. Biasi1, R. D’alessandro1, E. Garcia Gonzales1, N. Volpi1, M. A. Mazzeli1, E. Bargagli2, L. Cantarini1, B. Fредiani1. 1University of Siena, Rheumatology Unit, Siena, Italy; 2University of Siena, Diagnostic Imaging Unit, Siena, Italy

Background: No clear-cut guidelines exist about the use of imaging procedures for the diagnosis of idiopathic inflammatory myopathies (IIM). Similarly, conflicting, and scanty data exist about Power Doppler Ultrasonography (PDUS) in this subset of patients. In this regard, we recently proposed (1) a 0-3 grey scale (GS) and Power Doppler (PD) score in a cohort of patients affected by IIM, evidencing a positive, statistically significant, correlation for PD and oedema and disease activity.

Objectives: The aim of this study was to assess the diagnostic accuracy of our score in IIM patients compared to a control group.

Methods: We prospectively collected, since July 2020 to December 2021, all patients evaluated in Vasculitis and Myositis clinic, Rheumatology Unit, University of Siena, with a recent diagnosis of IIM, as well as patients with a previous, definite diagnosis of IIM and evaluated during follow-up or referred from other centres for a second opinion. As control group, we collected all patients affected by amyopathic dermatomyositis (DM) or who underwent myositis immunoblot or muscle biopsy for proximal limbs weakness but eventually received a diagnosis other than IIM. All patients underwent US examination of both thighs in axial and longitudinal scans.

Results: Forty-five IIM patients (11 anti-synthetase syndrome, 20 DM, 12 PM, 2 scleromyositis) and twenty-six controls were included. During the observational period, 7, 8, 1 and 1 patients underwent PDUS twice, three, four and five times, respectively.

Assessing area under the receiver operating characteristic (AUROC) curve analysis, IIM patients and control group were distinguished according to PD sum. Oedema sum, atrophy sum and CRP values (Figure 1a). The best cut-off value for PD sum values was 0.5 (70.2% SE and 83.3% SP), for Oedema sum 1.5 (74.5% SE and 79.2% SP), atrophy sum 0.5 (63.4% SE and 65.4% SP) and CRP was 0.22 mg/dL (61.5% SE and 75% SP).

Figure 1.

Stratifying IIM population into two groups according to disease activity (PhGA≥2), AUROC curve analysis allow to distinguish these groups according to PD and oedema sum and CRP values (Figure 1b) and the best cut-off values was 1.5 (69.6% SE and 76.9% SP), 2.5 (52.2% SE and 92.3% SP) and 0.55 mg/dL (66.7% SE and 88.9% SP), respectively.

Testing the IIM group versus control as dependent variable by logistic regression, with PD sum, oedema sum, atrophy sum, CRP, CPK and myoglobin as independent variables, the AUROC was 0.976. From the probability associated with the Chi-square tests, the Type II analysis showed the variable that most influences the IIM diagnosis was PD sum and oedema sum (p=0.017 and p=0.013, respectively) (Figure 1c).

Conclusion: GS and PDUS have proven an overall good diagnostic accuracy in distinguishing between IIM and myositis mimicker. In particular, even low values of PD sum (1.5) display a good sensitivity and specificity and, together with oedema, elevated CRP values and myositis-specific and associated antibodies, may be considered a reliable tool for a definitive diagnosis of IIM.

REFERENCES:

Disclosure of Interests: None declared.


POS0872

SERUM LEVEL OF SOLUBLE INTERLEUKIN-2 RECEPTOR IS LINKED TO BETAZ2-MICROGLOBULINE, NT-PRO BNP AND HIGH-SENSITIVITY TROPOGIN T AND MAY HELP TO IDENTIFY PATIENTS WITH EARLY CLINICAL PROGRESS IN SSC.

L. Schumacher1,2, S. Klapa1, A. Müller1, G. Riemekasten1. 1Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Rheumatology & Clinical Immunology, Lübeck, Germany; 2University of Lübeck, Medical Faculty, Lübeck, Germany

Table 1.

<table>
<thead>
<tr>
<th>The Oslo SSC cohort</th>
<th>Matched controls</th>
<th>Difference in L (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC (n=404), L (SD)</td>
<td>3.14 (0.86)</td>
<td>3.62 (1.13)</td>
<td>-0.48 (-0.59, -0.37)</td>
</tr>
<tr>
<td>FVC (male, n=61), L (SD)</td>
<td>3.89 (1.14)</td>
<td>4.75 (0.58)</td>
<td>-0.86 (-1.10, -0.66)</td>
</tr>
<tr>
<td>FVC (anti-Scl-70-antibody, n=58), L (SD)</td>
<td>2.98 (0.90)</td>
<td>3.65 (0.75)</td>
<td>-0.67 (0.83, -0.50)</td>
</tr>
<tr>
<td>FVC (dcSSc, n=93), L (SD)</td>
<td>3.06 (0.91)</td>
<td>3.7 (1.00)</td>
<td>-0.64 (-0.81, -0.51)</td>
</tr>
<tr>
<td>FVC (ILD, n=155), L (SD)</td>
<td>2.83 (0.78)</td>
<td>3.70 (1.57)</td>
<td>-0.87 (-1.13, -0.60)</td>
</tr>
<tr>
<td>FVC (no IILD, n=241), L (SD)</td>
<td>3.32 (0.85)</td>
<td>3.56 (0.74)</td>
<td>-0.24 (-0.31, -0.18)</td>
</tr>
<tr>
<td>FVC (no IILD and no skin changes or lcsSc, n=196), L (SD)</td>
<td>3.31 (0.84)</td>
<td>3.53 (0.71)</td>
<td>-0.22 (-0.29, -0.15)</td>
</tr>
<tr>
<td>FVC (dcSSc and no IILD, n=43), L (SD)</td>
<td>3.36 (0.89)</td>
<td>3.70 (0.84)</td>
<td>-0.34 (-0.52, -0.16)</td>
</tr>
</tbody>
</table>

12 months follow up

| FVC (n=164), L (SD) | 3.20 (0.86)      | 3.60 (0.69)              | -0.39 (-0.49, -0.30) | <0.001 |
| FVC (dcSSc, n=39), L (SD) | 3.29 (1.00)  | 3.92 (0.88)              | -0.63 (-0.87, -0.40) | <0.001 |
| FVC (ILD, n=63), L (SD) | 2.96 (0.73)  | 3.66 (0.72)              | -0.69 (-0.87, -0.52) | <0.001 |
| FVC (no IILD, n=97), L (SD) | 3.34 (0.90)  | 3.56 (0.67)              | -0.21 (-0.31, -0.12) | <0.001 |
Background: Systemic sclerosis (SSc) is characterized by chronic inflammation that leads to damage of the vascular endothelium and excessive collagen deposition in several target organs (1). The interaction of interleukin 2 (IL-2) with the corresponding receptor (IL-2R) is involved in the regulation of autoimmune processes (2). The shedding product of the IL-2R alpha chain, soluble IL-2 receptor (sIL-2R, CD25), is able to either reduce or enhance immune responses (2). Previously, elevated serum levels of sIL-2R were found in the bronchoalveolar lavage of SSc patients with interstitial lung disease (SSc-ILD) as well as serologically in patients with early SSc, and thus suggested to be a biomarker for clinical development of SSc (3,4).

Objectives: To examine concentrations of sIL-2R in patients with SSc and analyse their association with clinical and serological parameters.

Methods: To determine if serological levels of sIL-2R serve as predictor of clinical complications in SSc, sera were analysed (limited cutaneous SSc (lcSSc) n=160; diffuse cutaneous SSc (dcSSc), n=137) using a sandwich ELISA. Clinical data (pulmonary fibrosis, PAH, mRSS, therapy) and serological markers (hs-NT-proBNP, neutrophil counts, creatinine, hs-troponin T, creatinine kinase, beta2-microglobuline) were assessed at the time of serum sampling and up to 48 months after baseline. Clinical progress was defined by the need to change therapies.

Results: Patients with dSSc presented elevated levels of sIL-2R compared to SSc (dcSSc: 673±428 U/ml vs. 646±473 U/ml, p<0.0001). In SSc general, sIL-2R levels correlated with beta2-microglobuline (r=0.8161, p=0.0001, ROC-AUC:0.8428), hs-CP (r=0.4091, p<0.0001, ROC-AUC:0.7110, NT-proBNP (r=0.2610, p<0.0001, ROC-AUC:0.6793), neutrophil count (r=0.2749, p=0.0001) and hs-troponin T (r=0.4548, p<0.0001, ROC-AUC:0.8729). Further, sIL-2R levels discriminated normal from pathological levels of hs-troponin T (sensitivity 80.0%, specificity 80.1%). Using Log-rank test and Mantel-Cox proportional hazard modeling, sIL-2R levels above 745 U/ml were associated with early progress in SSc. 80.0% of SSc patients with a CRP ≥5 mg/l had a worse disease course with a hazard ratio (HR) 3.45 (95% CI 2.24 to 5.30) compared with patients with CRP <5 mg/l (HR 1.19, 95% CI 0.85 to 1.66, p=0.29).

Conclusion: In SSC, serum levels of sIL-2R could be of diagnostic value by identifying clinical progress. Its role in pathophysiology, especially with regard to disease manifestations such as cardiac involvement needs to be investigated in more detail.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2020-eular2045
GLUCOCORTICOIDS PRESCRIBING PRACTICES IN SYSTEMIC SCLEROSIS: AN ANALYSIS OF THE EUSTAR DATABASE.

M. Ludic1, D. Mongin2, E. Siegert3, P. Carreira3, J. H. W. Distler4, J. Hennes5, M. Zanata6, E. Hachulla7, D. Mongin8, C. Souza Muller9, M. Salvador10, J. L. Tandaipan11, B. Valdetaro Bianchi12, M. De Santis13,14, A. M. Hoffmann-Vold15, A. Gabrielli16, D. Distler17, D. Couvoisier18 on behalf of EUSTAR. 1Geneva University Hospitals and University of Geneva, Rheumatology Unit, Geneva, Switzerland; 2Charité University Hospital, Department of Rheumatology, Berlin, Germany; 3Hospital 12 de Octubre, Servicio de Reumatología, Madrid, Spain; 4Universitätsklinikum Erlangen, Department of Internal Medicine 3, Erlangen, Germany; 5University Hospital Tübingen, Center for Interdisciplinary Rheumatology, Immunology and Autoimmune Diseases (INDIRA), Tübingen, Germany; 6University of Padova, Rheumatology Unit, Department of Clinical and Experimental Medicine, Padova, Italy; 7Reference Centre for Rare Systemic Autoimmune Diseases North and North-West of France, University of Lille, Lille, France, INERMU, CHU Lille, U1286 – INFINITE, University of Lille, Department of Internal Medicine and Rheumatology, Lille, France; 8San Raffaele Hospital – Vita-Salute San Raffaele University, Unit of Rheumatology, Allergy and Rare Diseases (UniRAR), Milan, Italy; 9Hospital de Clínicas da Universidade Federal do Paraná, Rheumatology Division, Curitiba, Brazil; 10Hospital da Universidade Coimbra, Rheumatology Department, Coimbra, Portugal; 11Hospital de la Santa Creu i Sant Pau, Rheumatology Unit, Barcelona, Spain; 12Santa Casa della Misericordia di Rio de Janeiro, Department of Rheumatology, Rio de Janeiro, Brazil; 13Humanitas Clinical and Research Center- IRCCS, Rheumatology and Clinical Immunology, Rozzano, Italy; 14Humanitas University, Department of Biomedical Sciences, Pieve Emanuele, Monza, Italy; 15Rikshospitalet University Hospital, Department of Rheumatology, Oslo, Norway; 16Università Politecnica delle Marche & Azienda Ospedalieri Riuniti, Clinica Medica, Ancona, Italy; 17University Hospital Zürich, Department of Rheumatology, Zurich, Switzerland

Background: The use of glucocorticoids (GC) in systemic sclerosis (SSc) is controversial (1). Despite the lack of solid evidence about their efficacy in SSc, GC are prescribed to control musculoskeletal symptoms, or in combination with immunosuppressive drugs (1). The extent of GC use over the disease course has been poorly investigated in SSc. As long-term GC exposure is detrimental even at low doses, estimating the use of GC and identifying patients at high risk for long-term utilization is crucial to plan better management of SSc patients.

Objectives: To estimate the prevalence of GC use in a large sample of SSc patients, identify patient characteristics associated with time spent on GC, and describe the variations in GC utilization over time and across main recruiting countries.

Methods: We included SSc patients with at least one visit in the EUSTAR database from January 2013 (defined as baseline visit) to November 2019. We analyzed the prevalent (in the main feature of patients using GC at baseline, and the exposure to GC over time. Multivariable linear regression identified patient characteristics associated with the proportion of follow-up time spent on GC. Time trends and variations in GC utilization across main recruiting countries were explored. Missing data were imputed using multiple imputation with chained equations.

Results: The 9819 patients included were mostly females (86%), with limited cutaneous (lc) SSc (73%), and median age of 58 years. At baseline, 2769 (34%) patients diffuse cutaneous (dc) SSc vs. 29% lcSSc were on GC, at a median dose 7.5mg/day [IQR 5-9 mg]. Only 2% of patients (n = 162) received >15mg/day prednisone equivalent. GC were mostly used in combination with an immunosuppressive drug, mainly methotrexate (29%), cyclophosphamide (21%), and mycophenolate mofetil (21%). Compared to patients not receiving GC at baseline, GC users were more frequently males (18% vs. 14%), anti-Scl70 positive (42% vs. 27%), had more synovitis (21% vs. 8%), pericardial effusion (9% vs. 5%), C-reactive protein elevation (33% vs. 19%), increased CK (12% vs. 8%), and significantly lower respiratory volumes. In the subgroup of patients with an early disease duration (< 3 years from first non-Raynaud's onset) (n = 1896), the prevalence of GC users was similar to that observed in the entire sample, but more dcSSc patients were receiving GC in combination with immunosuppressors. On average, GC users spent 25% of their follow-up time (median 33.2 months) on GC, with no significant difference between lcSSc and dcSSc patients. Notably, 971 (33%) and 647 (22%) patients followed-up for >1 year received GC for >6 or >12 months, respectively. In multivariable analysis, patient characteristics poorly explained the variability of GC exposure (adjusted-R² = 0.062, P < 0.001). The yearly proportion of glucocorticoids users (2013 - 2018) gradually decreased from 45% to 35% in 2018). The rate of GC users and the median proportion of follow-up time spent on GC was highly heterogeneous within and across countries.

Conclusion: GC are widely and long-term used in SSc, mainly to patients with dcSSc, with significant between- and within-country differences. A gradual decrease in their utilization over time is observed.

REFERENCES:
Objectives: To visualize the patterns of PAP elevation in SSc and to identify the clinical characteristics of each trajectory, by applying latent trajectory modeling for PAP measured repeatedly by echocardiography.

Methods: This was a multicenter, retrospective cohort study conducted at four referral hospitals in Kyoto, Japan. Patients with SSc who visited the study site between April 2008 and March 2021 and had at least three echocardiographic measurements of systolic pulmonary arterial pressure (sPAP) were included in this study. Follow-up concluded in March 2021.

A group-based trajectory model was applied to the change in sPAP over time, and individual patients were classified into distinct subgroups that followed similar trajectories. The number and shape of the trajectories were estimated based on adequacy, goodness of fit, parsimony, and interpretability of the model. Clinical plausibility was assessed by comparing PH-free survival, i.e., time to either PH or death, for each trajectory. Multinomial logistic regression analysis was performed for baseline clinical characteristics associated with trajectory assignment.

Results: A total of 236 patients with a total of 1097 sPAP measurements were included. We identified five trajectories following the quadratic function as “rapid progression (n=9, 3.8%)”, “early elevation (n=30, 12.7%)”, “mid elevation (n=54, 22.9%)”, “late elevation (n=24, 10.2%)”, and “low stable (n=119, 50.4%)”.

Each trajectory, in this order, showed earlier elevation of sPAP and shorter PH-free survival (Figure 1). In the multinomial logistic regression, the “low stable” as reference, cardiac involvement was associated with the “rapid progression” (adjusted odds ratio [OR] 28.9, 95% CI 3.21–259.5), diffuse cutaneous SSc was associated with the “early elevation” (OR 4.08, 95% CI 1.27–13.1), anti-centromere antibody positive was associated with the “mid elevation” (OR 4.50, 95% CI 1.11–18.2), and older age of onset was associated with the above three trajectories.

Conclusion: The pattern of changes in pulmonary artery pressure over time in SSc can be classified into five distinct trajectories. Each trajectory differed in baseline clinical characteristics and outcomes.

REFERENCES:
Disclosure of Interests: Enrico De Lorenzis: None declared, Vishal Kakkar: None declared, rebecca ross: None declared, Stefano Di Donato: None declared, Theresa Barnes: None declared, Benazir Salieem: None declared, Ariane Hendrick: None declared, Muhammad Nisar: None declared, Catherine Morley: None declared, Karen Douglas: None declared, Christopher P Denton: None declared, Emma Derrett-Smith: None declared, Philip Helliwell Consultant of: PH received consulting fees (Eli Lilly) and fees for educational services (Abbvie, Amgen, Novartis, Janssen), Grant/research support from: PH has received research support and personal fees, not directly related to the content of this study, from Abbvie, AstraZeneca, Boehringer-Ingelheim, Cellnapha Biosciences, Chemomob LTD, Janssen, Kymab LTD, Mitsubishi-Tanabe, Grant/research support from: FDG has received research support and personal fees, not directly related to the content of this study, from Abbvie, AstraZeneca, Boehringer-Ingelheim, Cellnapha Biosciences, Chemomob LTD, Janssen, Kymab LTD, Mitsubishi-Tanabe

OBJECTIVES:

However these autoantibodies may be found in up to 10% of SSc patients (2). Antibodies is primarily associated with mixed connective tissue disease (MCTD), mortality in systemic sclerosis (SSc) patients (1). The presence of anti-U1RNP antibodies in univariate analysis. Associations between anti-U1RNP status and disease features were compared between anti-U1RNP positive and anti-U1RNP negative patients. Upper-gastrointestinal involvement (GI) is associated with more severe interstitial lung disease in patients with systemic sclerosis (SSc-ILD).

RESULTS:

We included in our study 334 patients. The study outcome was the presence of SSc-ILD on high-resolution computed tomography. Two sets of predictors were identified based on their potential association with GI. The first set contains the following variables available in the EUSTAR registry: esophageal symptoms (dysphagia and reflux), stomach symptoms (early satiety, vomiting), intestinal symptoms (diarrhea, bloating and constipation), malabsorption syndrome, body-mass-index (BMI) and proton pump inhibitor therapy; calcium channel blocker therapy and immunosuppressive therapy. In the second set, we replaced the first three EUSTAR variables of the first set with the presence of the U1RNP antibody.

CONCLUSION:

Our results from the EUSTAR database show that SSc patients positive for anti-U1RNP antibodies have more impaired baseline lung function but similar rate of progression during follow-up. This suggests that early stages might be important in RNP+ SSc-ILD patients who may require specific management and follow-up.

REFERENCES:


Disclosure of Interests: Gonçalo Boletto: None declared, Corrado Compochi-aro: None declared, Anna-Maria Hoffmann-Vold: None declared, Armando Gabrielli: None declared, Oliver Distler Consultant of: OD has had consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Abbvie, Acceleron, Alcimed, Amgen, Amnara, Anxo, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Medscape, Miltényi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi, and Topudar. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). Jérôme Avouac: None declared, Yannick Allonare Paid consultant for: YA reports personal fees from Actelion, Bayer, BMS, Boehringer, Curzon, Inventiva, Roche and Sanofi and research grants from Inventiva, Sanofi and Alpine ImmunoSciences.

LUNG ULTRASOUND FOR INTERSTITIAL LUNG DISEASE DETECTION IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS: ROLE OF B-LINE AND PLEURAL LINE MODIFICATIONS

D. M. Reza Beigi1, G. Pellegrino1, M. Loconte1, G. Paone2, F. R. DI Ciommo1, M. Cadar1, I. Bisconti1, K. Stefanantoni1, F. Conti1, V. Riccioli1, Sapienza University of Rome, Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, Rome, Italy; 2Sapienza University of Rome, Department of Cardiovascular and Respiratory Sciences, Rome, Italy

Background: Lung ultrasound (LUS) is a technique that showed a high diagnostic accuracy for interstitial lung disease (ILD) detection in systemic sclerosis (SSc) patients and currently in progress of standardization. Traditionally, B-lines represented the finding of ILD, with the ≥10 cut-off reported by Tardella et al. resulting to be closely related to moderate ILD detected on high resolution computed tomography (HRCT). Recently, Fairchild et al. proposed novel LUS criteria for the evaluation of pleural line, disclosing high accuracy and reproducibility.

Objectives: To compare B lines cut-off with novel pleural line criteria and the respective associated variables.

Methods: We enrolled 55 consecutive patients affected by SSc according to ACR/EULAR 2013 criteria who underwent respiratory functional tests (RFTs) during 2021, excluding smokers and those with arterial pulmonary hypertension. Twenty-four of them carried out a HRCT during a 6-months’ time. In the same day of RFTs, two certified blinded operators performed LUS for each patient applying the 14-areas technique proposed by Gutiérrez et al., looking for the presence of total ≥10 cumulative B lines and the fulfilling of Fairchild’s criteria for pleural line. A 3-13 MHz operating linear probe was used. Clinical-demographic data and ongoing therapies were collected.

Results: Among 55 total SSc patients, the agreement between the two operators for Fairchild’s criteria was almost perfect (Cohen’s kappa (κ) =0.81) and substantial for ≥10 cumulative B-lines count (κ=0.74). Fairchild’s criteria showed a higher diagnostic accuracy compared with ILD detected on HRCT, with an overall specificity (SP) and a positive predicted value (PPV) of 100% (Table 1). A negative correlation emerged between total lung capacity values (TLC%) and both B lines cut-off (first operator: (IO): p<0.04, r=-0.27; second operator (IO): p=0.042, r=-0.28) and pleural line criteria (IO: p=0.009, r=-0.35; IO: p=0.008, r<0.36), but only the latter negatively correlated also with forced vital capacity values (FVC%) (IO: p=0.04, r<0.27; IO: p=0.03, r<0.28). The ≥10 total B lines amount correlated positively with concurrent mycophenolate therapy (IO: p=0.09, r=0.28; IO: p=0.005, r<0.37) and negatively with anti-centromere antibodies (IO: p=0.002, r<-0.3; IO p=0.009, r<0.34). The presence of digital ulcers showed a positive correlation with pleural line criteria (IO: p=0.03, r=0.29; IO: p=0.005, r<0.37), with a significant association on multivariate analysis (IO: p<0.03, IO: p<0.01).

Table 1. Overall sensitivity, specificity, positive predictive value, negative predictive value of LUS compared to ILD detected on HRCT. CI 95% confidence interval.

<table>
<thead>
<tr>
<th>Criteria</th>
<th>SE (C.I.)</th>
<th>SP (C.I.)</th>
<th>PPV (C.I.)</th>
<th>NPV (C.I.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fairchild criteria</td>
<td>0.91 (0.76 – 0.95)</td>
<td>1 (0.78 – 1.00)</td>
<td>0.82 (0.59 – 0.94)</td>
<td>0.95 (0.81 – 0.99)</td>
</tr>
<tr>
<td>≥10 cumulative B-lines count</td>
<td>0.73 (0.56 – 0.85)</td>
<td>0.8 (0.55 – 0.93)</td>
<td>0.68 (0.33 – 0.96)</td>
<td>0.72 (0.38 – 0.99)</td>
</tr>
</tbody>
</table>

Conclusion: We confirmed the feasibility and reliability of Fairchild’s recently proposed pleural line LUS criteria, that showed a higher diagnostic accuracy versus ≥10 cumulative B-lines count for ILD detected on HRCT, presenting SP and PPV values of 100% in SSc. Furthermore, these LUS features seem to differently associate with other aspects of the disease such as autoantibody specificity and vascular lesions, thus deserving future deeper evaluations. For the first time, we found that Fairchild’s criteria were associated with a clinical variable such as digital ulcers. Our results highlight the relevance of pleural line evaluation for ILD detection in SSc on LUS and its possible role towards a standardization of this diagnostic technique.

REFERENCES:

Disclosure of Interests: None declared

treatment. Longitudinal study included patients with at least one follow-up visit. Patients were classified as treated if they received a potential ILD modifying drug (immunosuppressant, biologic or nintedanib). Treated and untreated patients were compared at baseline. Progression in the untreated group was defined as (i) forced vital capacity (FVC) decline from baseline of ≥10% or (ii) an FVC decline of 5-9% in association with a decline in diffusing capacity for carbon monoxide (DLCO) of ≥15%, or (iii) start of a ILD modifying treatment during follow-up. In the untreated group, patients who progressed at any time were compared with patients with stable disease during follow-up. Multivariable logistic regression was performed to identify (i) factors associated with non-prescription of a treatment in ILD patients at baseline and (ii) factors associated with progression in the untreated patients. Covariates were selected according to clinical experience and literature evidence.

Results: Among 496 patients included in our cohort, 209 (42%) patients had ILD on baseline HRCT: 48/209 (23%) were males, median disease duration 8 [IQR: 4-12] years, 67/209 (32%) of diffuse cutaneous subset and 86/209 (41%) had anti-ScI70 antibodies. Among them, 142/209 (68%) did not receive any potentially ILD modifying treatments at baseline. Untreated patients were older (59 vs. 54 years), had a longer disease duration, were less frequently smokers, had more frequently anticentromere antibodies and lower levels of CRP. They had more frequently a limited extent (<20%) of lung fibrosis on HRCT, higher FVC (97.02 ±19.76 % vs. 78.29 ±19.23 %) and DLCO (72.10 ±18.97 % vs. 57.57 ±20.81 %), better performances in the 6 minute walking test and were less frequently treated with low dose of glucocorticoids. In multivariable logistic regression, older age (OR: 1.04 [1.01-1.08], p=0.021), a more extensive disease on HRCT (OR: 0.29 [0.09-0.90], p=0.037) and less frequent prescription of glucocorticoids (OR: 0.036 [0.12-0.92], p=0.037) were independently associated with absence of ILD modifying treatment prescription in our cohort. From the 142 untreated patients, 96 were followed-up for 64 [39-96] months. Of these, 56 (58%) patients showed progression of ILD, of whom 43 progressed by lung function parameters. Of these 56 patients, 31 (56%) progressed in the first 18 months. Diffuse cutaneous subtype (OR: 5.26 [1.26-27.62], p=0.031), shorter disease duration (OR: 0.95 [0.90-0.99], p=0.035) and osseopha-geal symptoms (reflux, dysphagia) (OR: 3.51 [1.12-12.18], p=0.036) at baseline were independent predictors of progression during follow-up in untreated patients.

Conclusion: A considerable number of SSc patients with ILD are not treated in clinical practice, in particular patients with limited cutaneous SSc, older age and an overall less extensive ILD. However, during a follow-up of 5 years, contrary to the common belief, about 60% of the untreated patients showed ILD-progres-sion. The diffuse cutaneous subtype, shorter disease duration and osseopha-gelogal symptoms at baseline characterized these patients. With the development of effective and safe therapies for SSc-ILD, our results support a change in practice for ILD patients for treatment.

REFERENCES:

Disclosure of Interests: Moritz Scheidegger: None declared, Alexandra Dupont: None declared, Carmen Nega: None declared, Carolina Mihai Speakers bureau: Boehringer-Ingelheim, MED Talks Switzerland, Consultant of: Boehringer-Ingelheim (Advisory Board), Mike O. Becker Speakers bureau: Mepha, MSD, Novartis, GSK, Bayer and Vifor, Consultant of: Mepha, MSD, Novartis, GSK, Bayer Vifor (advisory board fees), Ruxandra Dobrota Consultant of: Boehringer-Ingelheim (Advisory Board), Cosimo Bruni Speakers bureau: Eli-Lilly2018-2021, Actelion2019, Boehringer-Ingelheim2020-2021, Grant/ research support from: AbbVie (educational grant 2021), Suzana Jordan: None declared, Håvard Fretheim Speakers bureau: Personal fees form Bayer and non-financial support from GSK and Actelion, outside the submitted work., Oyvind Midtvædt: None declared, Hilde Jenssen Bjerkjøkken: None declared, Iman Barua: None declared, Anna-Maria Hoffmann-Vold Speake rs bureau: Actelion, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Consultant of: Actelion, ArxX, Bayer, Boehringer Ingelheim, Jansen, Lilly, Medscape, Merck Sharp & Dohme, Roche, Grant/ research support from: Boehringer Ingelheim, Oliver Distler Speakers bureau: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: Abbvie, Accelerocon, Alcimed, Amgen, Anxi, AstraZeneca, Bocon, Blade, Bay, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventivia, Kymera, Lupin, Miltenyi Biotech, MSD, Novartis, Takeda, Roivant, Sanofi and Takeda, Grant/ research support from: Kymera, Mitsubishi Tanabe, Boehringer Ingelheim, Muriel Eihai Speakers bureau: Speaker fees: BMS outside the submitted work

The table presents secondary endpoints at week 24 for the comparison of Brodalumab and Placebo groups. The table includes the mean and standard deviation (SD) for different variables, as well as the difference between groups, 95% confidence interval (CI), and p-value. The variables include CRiSS score, FACIT-Fatigue subscale score, J-HAQ-DI*, CGA*, and POS0882.

**Background:** Systemic Sclerosis (SSc) is a rare disorder associated with hand radiological damage, typically acro-osteolysis (AO) and calcinosis, and increased risk of osteoporosis [1, 2]. Recently, high resolution peripheral quantitative computed tomography (HR-pQCT) has contributed to advances in noninvasive imaging in patients with osteoporosis, inflammatory arthritis, and osteoarthritis. Due to its three-dimensional, high resolution (82 μm³) imaging of calcified structures, HR-pQCT might be beneficial in detecting and describing early AO changes, and had significantly shortened DPs and soft tissue extending distally from the most distal part of DPs (ST) were measured in a three-dimensional multiplanar reconstruction. Volumetric BMD and bone microarchitecture were analyzed using HR-pQCT scanner specific software at the distal radius.

**Objectives:** To study the association between different types of hand radiological damage, typically acro-osteolysis (AO) and calcinosis, and increased risk of osteoporosis [1, 2].

**Methods:** This single-centre, cross-sectional study included patients with SSc according to ACR/EULAR 2013 criteria from the outpatient clinic at the Department of Rheumatology, Aarhus University Hospital, between 1st of October and 21st of December 2021. All patients underwent HR-pQCT (Xtreme CT, Scanco Medical AG) scan of the dominant hand’s distal radius and both hands’ distal phalanges (DP) on the 2nd to 4th finger. A semiquantitative scale of 0-3 was composed to quantify the degree of soft tissue calcifications identified in the 2nd to 4th finger (Figure 1).

**Results:** We included 40 patients with SSc of whom 13 had AO according to hand radiographs. The two groups had a similar distribution regarding age, sex, and BMI. Patients with AO had longer disease duration compared to patients without AO (med. 17 yrs. (IQR 7-20 yrs.) vs 3 yrs. (IQR 2-7 yrs.) (P<0.001)). One patient was excluded from the BMD analysis, and 21 (9%) DP and 20 (8%) soft tissue measurements were excluded due to motion-induced image degradation.

A higher prevalence of calcinosis was observed in patients with AO (n=11/13) compared to patients without AO (n=11/27) (P<0.05). Patients with AO had more or larger calcifications according to our grading system (med. 1-3) vs 0 (IQR 0-1) (P<0.001). Grade 3 changes were observed in patients with AO (n=6/13, 46%) but not in patients without AO. Furthermore, the patients with AO had shorter DPs on the 2nd finger on both hands (right P<0.001; left P<0.01) and less ST on the right 2nd, 3rd, and 4th (P<0.01; P<0.01) as well as the left 3rd (P<0.05). We observed no differences between bone volume ratio (med. 0.101 (IQR 0.069-0.143) vs 0.126 (IQR 0.104-0.141) (P=0.38)), cortical BMD (med. 828 (IQR 774-853) vs 842 (IQR 762-882) (P=0.50)), or trabecular BMD (med. 121 (IQR 82-172) vs 151.6 (IQR 125-170) (P=0.38)). Yet, the patients with AO had a lower number of trabeculae (P<0.05) and a lower homogeneity of spacing between trabeculae (P<0.05) at distal radius.

**Conclusion:** Patients with AO had a higher number of calcifications and had significantly shortened DPs and ST on several fingers assessed by HR-pQCT. A potential superiority compared with hand radiographs is yet to be established. Still, the modality could eventually prove useful in detecting and monitoring small hand lesions and facilitate earlier diagnosis and proper treatment among patients with SSc.

**REFERENCES:**


**DOI:** 10.1136/annrheumdis-2022-eular.2575
RT-FDC-based biophysical phenotyping of circulating immune cells in SSc, RA and healthy controls.

Methods: 63 SSc patients, 59 RA patients fulfilling the respective ACR/EULAR classification criteria and 18 age- and sex-matched healthy controls were included in the study between 05.2019 and 09.2021. Peripheral blood mononuclear cells (PBMC) were isolated and immunolabelled. PBMC subpopulations were identified in RT-FDC by standard gating strategies based on their marker expression and their deformation, Young’s modulus and area were determined.

Results: We identified SSc-specific changes (changes in SSc, but not in RA compared to healthy controls) in the biophysical properties of NK, NK-like cells and monocyte subpopulations in SSc. Monocytes subpopulations had a higher deformation and cross-sectional area and/or more compact intra-donor distributions of these parameters in patients with active disease and with extensive skin or lung fibrosis in comparison with patients with stable disease and limited skin or lung fibrosis, respectively. All monocytes subsets were stiffer in patients with progression of skin or lung fibrosis at the time of measurement in comparison with a previous visit. The deformation and area of intermediate monocytes could also identify patients at risk for future progression of lung fibrosis. Changes in biophysical properties of monocytes can indicate, beyond fibrotic burden, clinical manifestations of microvascular damage such as active digital ulcers and pulmonary arterial hypertension.

Conclusion: We demonstrated that changes in the biophysical properties of monocyte subsets are associated with multiple clinical outcomes in SSc such as disease activity, severity of fibrotic or microvascular manifestations and risk of progression and might thus directly reflect SSc-specific pathologic immune cell activation. Our results thus provide first evidence that RT-FDC-based biophysical phenotyping of circulating immune cells may be a useful tool for clinical evaluation of SSc patients.

REFERENCES:

Disclosure of Interests: Alexandru-Emil Matei: None declared, Kubànková Markéta: None declared, Lyian Xu: None declared, Andrea-Hermina Györfi: None declared, Evgenia Boxberger: None declared, Despina Scutriou: None declared, Maria Papava: None declared, Julia Prater: None declared, Xu He: None declared, Martin Kráter: None declared, Georg Schett: None declared, Jochen Guck: None declared, Jörg H.W. Distler Shareholder of: JHWD is stock owner of 4D Science., Consultant of: JHWD has consultancy relationships with Actelion, Active Biotech, Anamor, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JBI Therapeutics, Medac, Pfizer, Rovi and UCS, Grant/research support from: JHWD has received research funding from Anamor, Active Biotech, Array Biopharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB


POSO884 DESCRIPTIVE EPIDEMIOLOGY OF SEVERE CARDIAC INVOLVEMENT IN SYSTEMIC SCLEROSIS: A BICENTRIC RETROSPECTIVE STUDY ON 459 PATIENTS

E. Bories1, S. DE Almeida Chaves2, T. Portel3, L. Alric1, L. Astudillo1, F. Gaches2, M. Michaud3, F. Catros2, G. Prevot4, L. Sailler1, D. Adoue1, O. Lairez5, G. Pugnet1, P. Xanthouli1,2, O. Gordjani1, C. Eichstaedt1,3, N. Benjamin1, B. Egenlauf1, S. Harutyunova1, A. Marr1,4, V. Theobald1, N. Milde1, C. Nagel1, N. Blank2

Background: The prevalence of cardiac involvement in systemic sclerosis (SSc) varies in the literature between 3% and 44% and represents a leading cause of morbidity in this disease. The incidence and severe cardiac involvement and the factors associated with the occurrence of severe cardiac involvement are not known in the literature.

Objectives: The objective of this study was to evaluate the incidence, prognosis and factors associated with the occurrence of severe cardiac involvement during SSc course.

Methods: We conducted a retrospective, bi-centric study from January 1, 1966 to December 31, 2018. The patients included had a diagnosis of SS according to the ACR/EULAR 2013 criteria. The primary endpoint was the occurrence of severe cardiac involvement. Cardiac involvement was defined by the presence of at least one of the following elements: death of cardiovascular origin, left ventricular ejection fraction less than or equal to 50%, abnormality of at least 3 measurement parameters of diastolic function, global longitudinal strain less than or equal to 18 in absolute value, ventricular tachycardia, ventricular extrasystoles requiring intervention or elevated troponin. Patients with associated myositis and whose only criterion for cardiac involvement was elevated troponin were not included in the group with cardiac involvement. Severe cardiac involvement was defined by the occurrence of hospitalization for cardiovascular reasons or by death of cardiovascular origin. Unvariable and multivariable Cox-proportional hazards models were used to determine variables associated with severe cardiac involvement occurrence. Survival analysis was performed using the Kaplan-Meier method with comparisons performed using the log rank test.

Results: Four hundred and fifty-nine patients with SSc were included and were followed for a median of 71 years [3.1; 13.3]. The median age of our population was 54 years old. There were 81% of women. 77% of patients had limited cutaneous SSc, 15% diffuse cutaneous SSc and 8% SSc sine scleroderma. Of the 459 patients, 105 (23%) had cardiac involvement and 56 (12%) severe cardiac involvement. The incidence of severe cardiac involvement was 2.42 per 100 patient years. Ninety-six hospitalizations were recorded, including 40 (42%) for acute heart failure, 19 (20%) for arrhythmia, 5 (5%) for acute pericarditis, 6 (6%) for acute myocarditis and 14 (15%) for coronary artery disease (acute coronary syndrome, myocardial infarction or coronary revascularization). The independent factors associated with severe cardiac involvement in SSc were age over 54 years at SSc-diagnosis (OR = 3.21 95% CI [1.73; 5.95], p < 0.001), the presence of myositis (OR = 5.01 95% CI [1.89; 13.28], p = 0.001), pericardial involvement (OR = 3.79 95% CI [2.05; 7.03], p < 0.001) or scleroderma renal crisis (OR = 4.72 95% CI [2.05; 10.92], p < 0.001). The survival rate of patients with severe cardiac involvement was 70% at 5 years and 53% at 10 years. Patients with severe cardiac involvement had a mortality risk three times greater than patients without severe cardiac involvement, HR = 3.1 (95% CI [1.7; 5.7], p<0.0001) (Figure 1). Pericardial involvement was an independent risk factor for mortality, HR = 2.0 (95% CI [1.02; 4.0], p=0.04).

Disclosure of Interests: None declared, Evgenia Boxberger: None declared, Despina Soteriou: None declared

REFERENCES:

Figure 1. Survival of patients with severe cardiac involvement of systemic scleroderma. HR: Hazard ratio; 95% CI: 95% Confidence interval; Nb at risk: Number at risk

Conclusion: We need to focus our clinical attention on diagnosing and manage cardiac involvement in SSc, as severe cardiac involvement is not uncommon and is responsible for a poor prognosis.

Disclosure of Interests: None declared


POSO885 HYPOCHROMIC ERYTHROCYTES AS PROGNOSTIC INDICATOR OF SURVIVAL AMONG PATIENTS WITH SYSTEMIC SCLEROSIS SCREENED FOR PULMONARY HYPERTENSION

P. Xanthoulis1,2, O. Gordjani3, E. Fischlert1,4, N. Benjamin5, B. Egenlauf6, S. Harutyunova1, A. Marr1,4, V. Theobald1, N. Milde1, C. Nagel1, N. Blank2

Background: Scleroderma-related pulmonary hypertension (SR-PAH) is the leading cause of mortality in systemic sclerosis (SSc). Early diagnosis and treatment of SR-PAH is crucial for improving patient survival. Hypochromic erythrocytes (HE) are a well-known indicator of reduced oxygen saturation, but their role in the management of SR-PAH is not well established.

Objectives: To determine the prognostic value of HE as a marker of mortality in patients with SSc and SR-PAH.

Methods: We performed a retrospective analysis of patients with SSc and SR-PAH from a single tertiary care setting. HE were assessed as a dichotomous variable using a cutoff value of 30%. Kaplan-Meier survival analysis was performed to evaluate the association between HE and mortality.

Results: A total of 100 patients with SSc and SR-PAH were included in the analysis. The median age of the patients was 62 years (range: 26-85) and 70% were female. The median follow-up time was 36 months (range: 6-84). The overall mortality was 32% at 3 years. Patients with HE had a significantly lower survival rate compared to patients without HE (p = 0.03). The median survival time for patients with HE was 24 months compared to 58 months for patients without HE.

Conclusion: Hypochromic erythrocytes are a valuable indicator of mortality in patients with SSc and SR-PAH. Early recognition and intervention for patients with HE may improve survival outcomes.

Disclosure of Interests: None declared

Background: Iron deficiency is frequent among patients with systemic sclerosis (SSc), particularly among those with pulmonary hypertension (PH). First data indicate prognostic importance of hypocromic erythrocytes (HRC) >2% among patients with PH1. Hence, the aim of this study was to investigate the predictive value of HRC in SSC patients screened for PH.

Objectives: The objective of this study was to investigate the predictive value of HRC in SSC patients screened for PH.

Methods: In this retrospective, single-center cohort study SSC patients screened for PH were included. Clinical characteristics, laboratory and pulmonary functional parameters associated with the prognosis of SSC were analysed using uni- and multivariable analysis.

Results: A total of 280 SSc patients were screened, 171 were included in the analysis having complete iron metabolism (79% female, 61±12.9 years of age, 73.2% limited cutaneous SSc, 56% manifest PH and 112 pulmonary fibrosis). The patients were followed for 2.4±1.8 (median 2.4) years. HRC >2% at baseline was significantly associated with worse survival in the uni- (p=0.018) and multivariable analysis (p<0.0001). Overall 34.5% of the patients suffered from iron deficiency and 22% received iron substitution during follow-up. HRC >2% was identified as independent predictor of mortality, for patients with and without pulmonary manifestations of SSC.

Conclusion: This study detected for the first time that HRC >2% is an independent prognostic predictor and can possibly be used as a biomarker among SSC-patients. Further studies are needed to confirm these results.

REFERENCES:

Disclosure of Interests: Panagiotis Xanthouli Speakers bureau: MSD and OME, consult of the submitted work, Ojan Gordjani: None declared, Satenik Harutyunova: None declared, Nicola Benjamin: Speakers bureau: Actelion pharmaceuticals, Bayer HealthCare and MSD, Benjamin Eigenlauf: Actelion speakers bureau: MSD, Bayer, Actelion and GSK, outside the submitted work, Albert Marra: MSD speakers bureau: Bayer MSD outside the submitted work, Vivienne Theobald: None declared, Nicklas Mide: None declared, Christian Nagel: Speakers bureau: Actelion, MSD, Bayer and OME outside the submitted work, Alberto Marra: MSD speakers bureau: Bayer MSD outside the submitted work, Fabián Martín-Lorenz: None declared, Renato Marra: None declared, Cristina Eichstaedt: Consultant of: MSD, MSD, Actelion and Bayer Vital, Hanns-Martin Lorenz Speakers bureau: AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, ROCHE, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, ROCHE, CHUGAI, Novartis, UCB, Janssen-Cilag, AstraZeneca, Lilly, Baxter, SOBI, Biogen, Actel-ion, Bayer Vital, Schering, Octapharm, Sanofi, Hexal, Mundipharma, and Thermo Fisher, Consultant of: AbbVie, BMS, Pfizer, Cellgene, Medac, GSK, ROCHE, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, ROCHE, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly (less than $10,000 each) and research support from AbbVie, MSD, BMS, Cellgene, Medac, GSK, ROCHE, Chugai, Novartis, UCB, Janssen-Cilag, AstraZeneca, and Lilly.

Background: Interstitial lung disease (ILD) is a common condition in patients with connective tissue disease (CTD). It is associated with increased morbidity and mortality. Rituximab (RTX) has been approved for treatment of RA and some recent retrospective studies suggest that it could be an alternative treatment for patients with CTD-ILD, even in cases that prove refractory to conventional immunosuppressants.

Objectives: To analyze the efficacy and safety of RTX in connective tissue disease associated with interstitial lung disease (CTD-ILD).

Methods: We performed a multicenter, prospective, observational study of patients with CTD-ILD receiving RTX between 2015 and 2020. Patients who had worsening of respiratory symptoms or decline in the pulmonary function tests (PFT) compared to the time of ILD diagnosis were treated with rituximab. The patients were assessed using high-resolution computed tomography and PFT baseline, at 12 months, and at the end of follow-up. The main outcome measure at the end of follow-up was forced vital capacity (FVC)>10% or diffusing capacity of the lungs for carbon monoxide (DLCo)>15% and radiological progression or death. We recorded clinical characteristics, time to initiation of RTX, concomitant treatment, infections, and hospitalization. A Cox regression analysis was performed to identify factors associated with worsening of ILD.

Results: We included 37 patients with CTD-ILD treated with RTX for a median (IQR) of 38.2 (17.7-69.0) months (Table 1). At the end of the follow-up, disease had improved or stabilized in 23 patients (62.1%) and worsened in 7 (18.9%); 7 patients (18.9%) died. Mean PFT values decreased significantly at the start of RTX compared to the date of ILD diagnosis in FVC (72.2[21.3] vs 73.5 [16.9] mg/l;p=0.040) and DLCO-SD (55.2 [15.7] vs 58.3 [16.1] mg/l;p=0.041).

Table 1. Baseline demographic and clinical characteristics of 37 patients with CTD-ILD receiving rituximab.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total n=37</th>
<th>RA n=19</th>
<th>SS n=14</th>
<th>IM n=4</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex, n (%)</td>
<td>27 (73.0)</td>
<td>13 (68.4)</td>
<td>11 (78.6)</td>
<td>3 (75.0)</td>
<td>0.806</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>62.8 (9.9)</td>
<td>67.7 (9.7)</td>
<td>57.9 (7.9)</td>
<td>56.6 (5.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.147</td>
</tr>
<tr>
<td>Never smoked, n (%)</td>
<td>20 (54.1)</td>
<td>7 (36.8)</td>
<td>9 (64.3)</td>
<td>4 (100.0)</td>
<td>0.044</td>
</tr>
<tr>
<td>Smoked at some time, n (%)</td>
<td>17 (45.9)</td>
<td>12 (63.2)</td>
<td>5 (35.7)</td>
<td>0 (0.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Duration of CTD, months (median [IQR])</td>
<td>1078 (45.9-188.8)</td>
<td>1510 (8.0-240.5)</td>
<td>89.6 (51.3-184.4)</td>
<td>35.1 (25.1-49.0)</td>
<td>0.017</td>
</tr>
<tr>
<td>Duration of ILD, months (median [IQR])</td>
<td>65.4 (31.1-130.3)</td>
<td>82.2 (37.4-120.1)</td>
<td>64.5 (35.5-107.1)</td>
<td>25.9 (20.5-36.0)</td>
<td>0.136</td>
</tr>
<tr>
<td>Time to initiation of RTX, median [IQR]</td>
<td>24.3 (8.2-34.9)</td>
<td>45.3 (22.2-79.9)</td>
<td>52.5 (24.7-163.3)</td>
<td>22.8 (17.7-36.2)</td>
<td>0.291</td>
</tr>
<tr>
<td>Combines with cMADRS, n (%)</td>
<td>16 (43.5)</td>
<td>11 (57.9)</td>
<td>5 (35.7)</td>
<td>1 (25.0)</td>
<td>0.637</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>5 (13.5)</td>
<td>2 (10.5)</td>
<td>3 (21.4)</td>
<td>0 (0.0)</td>
<td>0.468</td>
</tr>
<tr>
<td>Leflunomide, n (%)</td>
<td>2 (5.4)</td>
<td>2 (10.5)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0.367</td>
</tr>
<tr>
<td>Sulfasalazine, n (%)</td>
<td>1 (2.7)</td>
<td>1 (5.3)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0.615</td>
</tr>
<tr>
<td>Hydroxychloroquine, n (%)</td>
<td>7 (18.9)</td>
<td>4 (21.1)</td>
<td>2 (14.3)</td>
<td>1 (25.0)</td>
<td>0.840</td>
</tr>
<tr>
<td>Combination with immunosuppressants, n (%)</td>
<td>20 (54.1)</td>
<td>14 (73.7)</td>
<td>9 (64.3)</td>
<td>4 (100.0)</td>
<td>0.044</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>19 (51.4)</td>
<td>6 (31.6)</td>
<td>9 (64.3)</td>
<td>0 (0.0)</td>
<td>0.021</td>
</tr>
<tr>
<td>Azathioprine, n (%)</td>
<td>1 (2.7)</td>
<td>1 (5.3)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0.615</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>25 (67.6)</td>
<td>14 (73.7)</td>
<td>7 (50.0)</td>
<td>4 (100.0)</td>
<td>0.121</td>
</tr>
<tr>
<td>Doses of corticosteroids, median (IQR)</td>
<td>5.0 (0.0-10.0)</td>
<td>5.0 (0.0-10.0)</td>
<td>2.5 (0.0-7.5)</td>
<td>10.0 (8.1-10.5)</td>
<td>0.519</td>
</tr>
</tbody>
</table>
significant decline was observed in median FVC (72.2 vs 70.8; $p=0.330$) or DLCO (55.9 vs 52.2; $p=0.100$). The multivariable analysis showed the independent predictors for worsening of CTD-ILD to be baseline DLCO (OR [95% CI], 0.904 [0.8-0.9]; $p=0.015$), time to initiation of RTX (1.01 [1.001-1.02]; $p=0.029$), and mycophenolate (0.202 [0.04-0.8]; $p=0.034$). The incidence rate ratio was 0.21 patient-years.

**Conclusion:** Lung function improved or stabilized in more than half of patients with CTD-ILD treated with RTX. No significant increase in infection rates was observed. Early treatment and combination with mycophenolate could reduce the risk of progression of ILD.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3014

---

**POSO887**

**CHORIORETINAL MICROVASCULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS**


**Methods:** The study aims to evaluate retinal and choroid capillaris microvasculature in a group of SSc patients compared to matched controls (HC) and according to disease characteristics, capillaroscopy findings and pulmonary function tests. Method: WAS assessed through OCTA at the retinal superficial (SCP) and deep (DCP) capillary plexus, at the foveal avascular zone perimeter (FAZP) and at the choroid capillaris (CC) of 30 SSc patients compared to 30 sex- and age-matched subjects without any retinal disease.

**Results:** The SSc patients (age 57.3±10.0, female 86.7%) had diffuse cutaneous skin disease in 30.0% of the cases, an average disease duration of 10.4±7.2 y, and anti-centromere and anti-Scl70 antibody positivity in 40.0% and 30.0% of the cases, respectively. Compared to the HC, SSc showed an impaired VD at SCP (47.7±3.6 vs 59.1±3.5%; $p=0.009$), DCP (50.6±7.4 vs 54.3±5.5%; $p=0.015$), FAZP (48.7±4.55 vs 51.9±3.5%; $p=0.034$) and CC (67.1±2.2 vs 68.6±1.7%; $p=0.05$). Moreover, VD was inversely correlated with the presence of digital ulcers (46.7%), telangiectasia (43.3%) and interstitial lung disease (46.7%) was related to reduced VD at FAZP (46.8±4.1 vs 55.0±4.3%; $p=0.033$), CC (66.1±4 vs 67.9±2.4%; $p=0.004$), and DCP (47.2±6.5 vs 51.9±4.3%; $p=0.004$), respectively. Lastly, the average capillary density on capillaroscopy showed a positive correlation with VD at FAZP ($r=0.474, p=0.008$), DCP ($r=0.414, p=0.023$), and foveal CC ($r=0.482, p=0.007$) and there was also a correlation between CC and both DLco ($r=0.467, p=0.009$) and FVC/DLco ($r=0.436, p=0.004$).

**Conclusion:** The SSc patients in our cohort showed lower ocular vessel density at different levels compared to HC. Furthermore, impaired VD at different levels of the eye correlates with the organ involvement and the degree of digital and pulmonary microvascular impairment. According to those data, the OCTA could be proposed as a biomarker tool to investigate the microvascular abnormalities in SSc.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3043

---

**POSO888**

**NON-SURGICAL LOCAL TREATMENTS FOR DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW**


**Methods:** A systematic literature review (SLR) of papers describing the use of ln-sT for DU in SSc was performed up to May 2021 according to the PICO framework. References were independently screened by two reviewers who independently assessed the full text of eligible articles and extracted data. Results: Among 790 retrieved references, 12 were included. Median (range) number of patients per study was 9 (7-84), mean age ranging from 37 to 62.5 years. In 541% studies a control group was included. Background systemic therapies are summarized in Table 1. The most studied treatment was botulinum toxin A (BTX). It was used as hand injection in 3 studies (median dose ranging from 90 to 150 U) and as 50 U single finger injection in 1 study. Healing rate after a median time of 8-49 weeks ranged from 71% to 100%. In 2 studies a reduction in VAS pain was observed from 20% to 100%. Transient muscle weakness was the most common side effect in 10% of patients. Amniotic (Am) and hyaluronic acid microparticles (HA) were used in 1 study each. They were associated with a good healing rate, statistically significant for the HyM. Tadalafil 2% cream was studied in 1 study and was associated with a reduction in the median DU number from 1.6 to 1 per patient after a median time of 4 weeks and a reduction by 1.4 point in the 10-mm VAS scale. Vitamin E gel was shown to be associated with a statistically significant reduction in the healing time compared to SoC alone in 1 RCT (13.2 ± 2.7 versus 20.9 ± 3.6 weeks, $p=0.001$). Low-level light therapy, hydrodissection and corticosteroid injection and extracorporeal shock wave (ESW) were evaluated in 1 study each. They were all associated with positive outcomes which was statistically significant only for the ESW. The only negative trial examined dimethyl sulfosilxide and was associated with local toxicity.

**Conclusion:** Our SLR supports interest to develop in-sTs for SSC-DUs. The number of studies is limited and mainly case reports and small single studies are present. Treatments were well tolerated and there was evidence of efficacy for BTA, vitamin E, ESW and HyM in refractory DU. The evidence is not robust and confounding factors (vasodilators background therapies) could impact on the findings. Future research is indicated to conduct larger, well-designed studies.

**Disclosure of Interests:** Corrado Campochiaro: None declared, Yosara A. Suliman: None declared, Michael Hughes Speakers bureau: Actelion pharmaceuticals, Eli Lilly, and Pfizer, outside of the submitted work., Jan Schoones: None declared, Dilia Giuggioli: None declared, Pia Moiinazadeh Speakers bureau: speaking fees from Actelion pharmaceuticals and Boehringer Ingelheim, Nancy Moiinazadeh: None declared, Lorenzo Ross: None declared, Marcello Mucci-Cerinici: None declared, Lamberto Chirone: None declared, Yannick Alanne: None declared, Maltez: None declared, Laura Ross: None declared, Murray Baron: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3098
Table 1. Characteristics of the studies.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Type of study</th>
<th>Patients</th>
<th>Baseline DU</th>
<th>ACE-I</th>
<th>PDE-5i</th>
<th>IS</th>
<th>Follow-up (weeks)</th>
<th>Healing rate(%)</th>
<th>Pain Reduction (VAS/10)</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrodiluent and corticosteroid injection</td>
<td>P</td>
<td>12</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>33</td>
<td>4.4</td>
<td>Rheumatoid Arthritis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tadalafil 2%</td>
<td>R</td>
<td>15</td>
<td>16(1)</td>
<td>0</td>
<td>46</td>
<td>27</td>
<td>0</td>
<td>13</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Vitamin E gel</td>
<td>RCT</td>
<td>13</td>
<td>3.5±2.3</td>
<td>0</td>
<td>24</td>
<td>Reduced time to heal**</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Am</td>
<td>R</td>
<td>6</td>
<td>3</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>0</td>
<td>28</td>
<td>17</td>
<td>33</td>
</tr>
<tr>
<td>HyM</td>
<td>P</td>
<td>7</td>
<td>10</td>
<td>0</td>
<td>28</td>
<td>0</td>
<td>0</td>
<td>14</td>
<td>8</td>
<td>90*</td>
</tr>
<tr>
<td>BTA</td>
<td>R</td>
<td>7</td>
<td>31</td>
<td>71</td>
<td>71</td>
<td>85</td>
<td>85</td>
<td>14</td>
<td>71</td>
<td>8</td>
</tr>
<tr>
<td>Mexican SUO per hand</td>
<td>R</td>
<td>7</td>
<td>4</td>
<td>14</td>
<td>85</td>
<td>5</td>
<td>14</td>
<td>49</td>
<td>71</td>
<td>100%</td>
</tr>
<tr>
<td>High-concentration hand</td>
<td>P</td>
<td>20</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>100</td>
<td>20</td>
<td>8</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>100 U non-dominant hand</td>
<td>P</td>
<td>10</td>
<td>100</td>
<td>100</td>
<td>12</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single finger SUO</td>
<td>P</td>
<td>8</td>
<td>10</td>
<td>25</td>
<td>37</td>
<td>0</td>
<td>25</td>
<td>37</td>
<td>8</td>
<td>100</td>
</tr>
<tr>
<td>Low-level light therapy</td>
<td>P</td>
<td>9</td>
<td>49</td>
<td>33</td>
<td>55</td>
<td>66</td>
<td>11</td>
<td>44</td>
<td>41*</td>
<td>1.31</td>
</tr>
<tr>
<td>Dimethyl sulfoxide</td>
<td>DRBR</td>
<td>84</td>
<td>No change, skin toxicity with 70% formulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Unless otherwise stated. **Statistically significant. ARB= angiotensin receptor antagonist. ACE= ACE inhibitors. APA= anti-platelet agents. CCB= calcium channel blockers. CH= contralateral hand. DRBR= double blind randomized-controlled trial. ETA = endothelin antagonist. IS= immunosuppression. PGE= prostaglandins. PDE-5i= Phosphodiesterase type-5 inhibitors. P = prospective. R = retrospective. SoC= standard of care (as per local protocol).

**Conclusion:** Although EF is a rare adverse effect of ICI treatment, individuals receiving these drugs should be monitored closely for symptoms of EF. Discontinuation of ICI and administration of immunosuppressants may prevent the progression of EF.

POS0889 CASE SERIES OF PATIENTS WITH EOSINOPHILIC FASCIITIS SECONDARY TO IMMUNE CHECKPOINT INHIBITORS THERAPY


Background: Eosinophilic fasciitis (EF), a fibrotic disease that causes inflammatory infiltration in the subcutaneous fascia is clinically characterized by edema and subsequent induration and tightening of the skin and subcutaneous tissue. EF is a rare immune-related adverse event of immune checkpoint inhibitors (ICI).

Objectives: This article aims to investigate the clinical features of ICI-related EF and to improve the understanding of the disease among rheumatologists.

Methods: Searching relevant articles in the electronic databases Medline, PubMed, Science Citation Index, China Biomedical Literature Database (CBM), China Journal Full Text Database (CNKI), and WANFANG Data with the key words of “eosinophilic fasciitis” or “Shulman syndrome” and “checkpoint inhibitor”; “CTLA-4”; “PD-1” or “PD-L1”. Only articles or case reports with detailed medical records of ICI-related EF patients were included. ICI-related EF patients in our department were also included.

Results: A 58-year-old male patient with angioinmunoblastic T cell lymphoma presented with skin edema, subsequent induration, tightening of the skin, and subcutaneous tissue (Figure 1 A&B). The eosinophils elevated in peripheral blood after 6-month treatment of PD-1 inhibitor (Camrelizumab). The patient was diagnosed as ICI-related EF and then was referred to our rheumatology department. Other seventeen EF patients from the above databases were also included for analysis. Among these 18 patients, 50% (9/18) were male and the mean age was 57±14 years. The most commonly used ICI was PD-1 inhibitor such as nivolumab and pembrolizumab, accounting for 72% (13/18), next was PD-L1 inhibitor combined with CTLA-4 inhibitor. Of all cases, 50% (9/18) was metastatic melanoma and 17% (3/18) was lung cancer. After ICI treatment, the median onset time of EF was 12 months. The most common involved organ was skin and 94% (17/18) of patients presenting with symmetrical skin edema and sclerosis. For other skin manifestations, 44% (8/18) of patients had typical “groove sign”, and one case showed unilateral skin involvement of skin tension and erythema from pubis to left anter-ior iliac crest. When the affected limb raised, there is a visible sulcus due to the decrease of venous dilation pressure, namely “sulcus sign”. The second com- mon involved organ was the joints which were presented with limited function in 56% (10/18) of patients. Additionally, 39% (7/18) showed muscle involvement such as myalgia and myasthenia. Increased eosinophils in peripheral blood was observed in 72% (13/18) of patients. Twelve patients (63%) received MRI examinations which showed the signal in the subcutaneous and deep fascia increased in both fat-suppressed T2 images (Figure 1 C&E) and post-enhancement T1 images (Figure 1 D&F). Fifteen patients underwent full-thickness skin biopsy at the lesion site, the pathological changes in all patients supported the diagnosis of EF. The ICI was discontinued in 94% of patients. Meanwhile, 83% received glucocorticoids and 56% of patients were treated with methotrexate. After these treatment, the clinical symptoms of EF improved in 89% of patients (n=16), while eosinophils returned to normal after a median treatment time of 2.5 months. EF progressed even through the combined treatment of prednisone, MTX, and abraxatop in one patient. Another one case died after 6 months due to metastasis of bladder cancer (stageIV).

Disclosure of Interests: None declared


POS0890 NINTENDANIB REAL-LIFE EFFICACY AND SAFETY IN SYSTEMIC SCLEROSIS (SSc)-INTERSTITIAL LUNG DISEASE (ILD): AN ITALIAN MULTICENTRE PRELIMINARY STUDY

C. Camponi1, G. De Luca1, M. G. Lazzaroni2, G. Armentaro3, A. Spinella4, B. Vignole5, B. Ruaro6, A. Stanziola7, D. Benfante8, E. De Lorenzis9, F. Benvenuti10, S. L. Boselli9, G. Moroncini9, G. Cuomo11, M. Confalonieri12, L. Beretta13, E. Zanatta14, D. Giugliardi15, N. Del Papa16, P. Airo17, L. Dagna1, M. Muccuci-Cerin12, IRCCS San Raffaele, Vita-Salute San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy; 2ASST Spedali Civili, Brescia, University of Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 3ASST G. Pini-CTO, Università degli Studi di Milano, Rheumatology, Milan, Italy, 4University of Modena and Reggio Emilia, Rheumatology, Modena, Italy; 5 Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Sclerodema Unit, Milan, Italy; 6ASST S. Maugeri, Ospedale Santa Chiara, Verona, University of Verona, Department of Pulmonology, Verona, Italy; 7Marche Polytechnic University, Clincia Medica, Ancona, Italy; 8Catholic University of the Sacred Heart, Rheumatology, Rome, Italy; 9University of Padova, Rheumatology, Padova, Italy; 10Universitá degli Studi della Campania, Rheumatology, Naples, Italy; 11University of Florence, Rheumatology, Florence, Italy

Background: Nintedanib (NDT) has been approved for Systemic Sclerosis (SSc)-Interstitial Lung Disease (ILD) following the positive results of the SEN-SICIS trial.

Objectives: to describe the efficacy and safety of NTD in SSc-ILD in a real-life setting.

Figure 1. Skin signs and MRI images of a 58-year-old male patient with eosinophilic fasciitis secondary to immune checkpoint inhibitor therapy A&B: Skin signs of the representative patient (P) and a 58-year-old male healthy volunteer (V). The skin of the patient’s left (A) and right lower limbs (B) was thick and difficult to touch. The fat-suppressed T2 images (C&D) and the fat-suppressed post-enhancement T1 images (D&A) showed the signal in the subcutaneous and deep muscle fascia of the right forearm increased and was enhanced obviously after enhancement (red arrows). There was a little long T2 signal of effusion shadow between myocutaneous and subcutaneous fatty tissue (yellow arrow).

Disclosure of Interests: None declared


**POS0890 CASE SERIES OF PATIENTS WITH EOSINOPHILIC FASCIITIS SECONDARY TO IMMUNE CHECKPOINT INHIBITORS THERAPY**
**Methods:** The clinical data of SSC-ILD patients treated with NTD from 10 Italian SSC centres were retrospectively evaluated at baseline, 6 and 12 months: SSC clinical features, NTD tolerability, pulmonary function tests (PFTs) and modified Rodnan skin score (mRSS) were recorded.

**Results:** 69 SSC-ILD patients (22 males [32%], mean age 60±12 years, disease onset 50±10 years, 4 [6%] anti-centromere, 53 [77%] anti-topoisomerase I, 3 [4%] anti-RNA-polymerase III) were identified. The vast majority (84%) was previously treated with immunosuppressants: 27 (39%) cyclophosphamide, 45 (65%) mycophenolate mofetil, 6 (9%) methotrexate, 9 (13%) azathioprine, 6 (9%) tocilizumab and 22 (32%) rituximab. In 11 (16%) patients, NTD was the first treatment for SSC-ILD. At baseline, 57 patients (83%) were on corticosteroids (mean daily prednisone dose 6±5 mg), 58 (84%) on immunosuppressants, 47 (68%) on mycophenolate mofetil, 14 (20%) on rituximab, 3 (4%) on tocilizumab, 2 on methotrexate (3%) and 1 (1%) on azathioprine. At baseline HRT showed UIP pattern in 27 (39%) and NSIP pattern in 42 (61%) patients. The modifications of PFTs and mRSS over time are shown in Table 1. Since NTD introduction, gastro-intestinal (GI) side effects were recorded in 34 (49%) patients, with diarrhea being the most common complaint (35%), followed by nausea/vomiting (2%), subocclusion and persistent diarrhea in 3 patients, un treatable nausea and vomiting in one patient and liver toxicity in 1 patient. During the follow-up after a median time of 10 (6–33) months, NTD was maintained after dose adjustment. In 5 (7%) patients NTD was stopped after a median time of 5 (1-6) months due to subocclusion and persistent diarrhea in 3 patients, un treatable nausea and vomiting in one patient and liver toxicity in 1 patient. None of the patients treated with NTD showed serious side effects. Of interest, 3 patients (4%) had slight skin involvement needs to be thoroughly evaluated on a larger SSc population.

**Disclosure of Interests:** Martim Pinto-Neto: None declared, Marco Confalonieri: None declared, Lorenzo Beretta: None declared, Francesco Benvenuti: None declared, Silvia Laura Bosello: Speakers bureau: Boehringer Ingelheim, Gianluca Moroncini: None declared, Giovanna Cuomo: None declared, Devis Benfaremo: None declared, Enrico De Lorenzis: None declared, Stefano Vigone: None declared, Barbara Ruaro: None declared, Anna Stanziola: None declared.

**Background:** The idiopathic inflammatory myopathies (IMM) module of the Rheumatic Diseases Portuguese Register (Reuma.pt/Myositis) is a tool used to systematically evaluate IIM patients.

**Objectives:** To clinically characterise the Reuma.pt/Myositis cohort.

**Methods:** Multicentre open cohort study, including IIM patients registered in Reuma.pt up to January 2022. Data collected included demographic, clinical, and treatment data and patient-reported outcomes. Data were presented as frequencies and median (interquartile range) for categorical and continuous variables, respectively.

**Results:** 280 patients were included, 71.4% female, 89.4% Caucasian, with a median age at diagnosis and disease duration of 48.9 (33.6-59.3) and 5.3 (3.0-9.0) years, respectively. Patients were classified as having definite (N=57/118, 48.3%; N=35/224, 15.6%), likely (N=23/118, 19.5%; N=50/224, 22.3%), or possible (N=2/118, 1.7%; N=46/224, 20.5%) IMM by 2017 EULAR/ACR and Bohan-Peter criteria, respectively. Disease subtypes included dermatomyositis (DM, N=122/280, 43.6%), polymyositis (N=59/280, 21.1%), myositis in overlap syndromes (N=41/280, 14.6%), clinically amyopathic DM (N=17/280, 6.1%), non-specific myositis (N=13/280, 4.6%), mixed connective tissue disease (N=12/280, 4.3%), immune-mediated necrotising myopathy (N=9/280, 3.2%), and inclusion bodies myopathy (N=7/280, 2.5%). Over the course of the disease, the most common symptoms were proximal muscle weakness (N=180/215, 83.7%), arthralgia (N=127/249, 52.9%), erythema (N=63/166, 38.0%), fatigue (N=47/127, 37.0%), Raynaud’s phenomenon (N=76/234, 32.8%), and dysphagia (N=33/121, 27.3%), and the most common clinical signs were Gottron’s sign (N=75/184, 40.8%), heliotrope rash (N=101/252, 40.1%), Gottron’s papules (N=93/237, 39.2%), and arthritis (N=38/98, 38.8%). Organ involvement included lung (N=78/230, 33.9%), oesophageal (N=40/221, 18.1%), and heart (N=11/229, 4.8%) involvements. Most patients expressed myositis-specific (MSA, N=158/280, 65.3%) and/or myositis-associated (MAA, N=122/280, 43.6%) antibodies. The most frequent antibodies were anti-SMN1 (N=67/280, 23.9%), anti-Jo1 (N=56/236, 23.7%), anti-Mi2 (N=31/212, 14.6%), anti-MDA5 (N=26/237, 10.9%), anti-EJ (N=17/208, 8.2%), and anti-Mi2 (N=31/212, 14.6%). Most patients had a myopathic pattern on electromyogram (N=101/138, 73.2%), muscle oedema in magnetic resonance (N=33/82, 53.2%), and high CK (N=154/200, 55.0%) and aldolase levels (N=74/135, 54.8%) at diagnosis, with median highest CK levels of 1308 (518-3172) and aldolase of 42 (12-121) mg/dL. Neoplasia was found in 11/127 patients (8.7%), most commonly breast (N=3/11, 27.3%), non-melanoma skin (N=2/11, 18.2%), and colorectal (N=2/11, 18.2%) cancer (Table 1). Most patients with cancer-associated myositis had DM (N=8/11, 72.7%) and expressed MSA (N=6/11) and/or MAA (N=3/11). The most used drugs over the course of disease were glucocorticoids (N=201/280, 71.8%), methotrexate (N=117/280, 41.8%), hydroxychloroquine (N=87/280, 31.1%), azathioprine (N=85/280, 30.4%), mycophenolate mofetil (N=56/280, 20.0%), intravenous immunoglobulin (N=55/280, 19.6%), and rituximab (N=45/280, 16.1%). At the last follow-up, there was a median MMTh of 150 (142-150), modified CAS skin of 0 (0-1), global VAS of 10 (0-50) mm, and HAQ of 0.125 (0.000-1.125).

**Table 1. Pulmonary function tests and mRSS at baseline, 6 and 12 months in SSC-ILD on NTD.**

<table>
<thead>
<tr>
<th>PFT</th>
<th>Baseline 6 months</th>
<th>P value</th>
<th>Baseline 12 months</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC (% predicted)</td>
<td>64 ± 18</td>
<td>65 ± 18 (33 pts)</td>
<td>0.638</td>
<td>70 ± 19</td>
</tr>
<tr>
<td>TLC (% predicted)</td>
<td>64 ± 15</td>
<td>64 14 (27 pts)</td>
<td>0.154</td>
<td>64 ± 15</td>
</tr>
<tr>
<td>DLCO (% predicted)</td>
<td>40 ± 17</td>
<td>41 ± 18 (29 pts)</td>
<td>0.660</td>
<td>40 ± 18</td>
</tr>
<tr>
<td>mRSS</td>
<td>9 ± 6</td>
<td>6 ± 7 (26 pts)</td>
<td>0.002</td>
<td>7 ± 4</td>
</tr>
</tbody>
</table>

**Table 1. Autoantibodies in cancer-associated myositis**

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Autoantibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM</td>
<td></td>
</tr>
<tr>
<td>DM</td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td></td>
</tr>
<tr>
<td>Skin (non-melanoma)</td>
<td></td>
</tr>
<tr>
<td>Colorectal</td>
<td></td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** Reuma.pt/Myositis adequately captures the main features of inflammatory myopathies’ patients, depicting in this first report a heterogeneous population, with frequent comorbidities. Hospitalisations and joint involvement are among the most frequent outcomes, most patients reached low disease activity at the last follow-up appointment.

**Disclosure of Interests:** None declared

Background: An accurate assessment of nailfold capillaroscopy (NFC) images has great importance in the diagnosis and prognosis of systemic sclerosis (SSc). To overcome some of the inherent problems with NFC image analysis (operator/observer bias, time requirements), there is an interest to automate and standardize NFC image assessment using computer vision algorithms, such as the Vision Transformer (ViT), which are based on recent advances in deep learning.

Objectives: Our aims were (1) to implement and assess the performance and reliability of ViT in detecting changes on NFC images, and (2) to compare the performance of ViT to that of practicing rheumatologists.

Methods: For this study, we used NFC images of patients with SSc enrolled in our European Scleroderma Trials and Research group (EUSTAR) and Very Early Diagnosis of Systemic Sclerosis (VEDOSS) local registries. Concretely, we included routine NFC images (all NFC images available – digit II to V of both hands), irrespective of any image artefacts) of patients aged ≥18 years with visits between 2012 and 2021, who fulfilled either the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc (established disease) or the preliminary criteria for VEDOSS (mild/early disease).

ViT was trained to identify the following NFC signs of microangiopathy: enlarged capillaries (diameter of the capillary >20 μm, and <50 μm), giant capillaries (>50 μm), loss of capillaries (<7 capillaries/mm), and microhaemorrhages.

Results: We analysed 17,126 NFC images of 234 EUSTAR patients (14.6% males, 67.8% limited cutaneous SSc, median age 57 years, median disease duration 9 years) and 56 VEDOSS patients (82.7% females, median age 44 years, median time elapsed since first Raynaud’s phenomenon 5 years). ViT had fair to excellent performance in identifying the different NFC changes across all five folds (of 3443 NFC images each), with an area under the ROC curve ranging from 78.59% to 90.4% (Figure 1a). In the reliability set (see Figure 1b), we observed highest performance for diagnosing giant capillaries (AUC = 92.89%) followed by identification of enlarged capillaries (AUC = 91.7%). Good AUCs were seen in depicting capillary loss (AUC = 87.3%), microhaemorrhages (AUC = 85.9%) and the abnormal/normal NFC classification (AUC = 84.7%). The rheumatologists had generally higher performance in assessing NFC images. However, ViT outperformed two rheumatologists with different experience in classifying capillary loss and enlarged capillaries, respectively.

Conclusion: ViT is a modern, well performing and readily available AI model to assess signs of microangiopathy on NFC images acquired during routine practice.

Disclosure of Interests: Alexandre Garaiman: None declared, Farhad Nooralahzadeh: None declared, Nicolas Gikopoulos: None declared, Nicolaos Perez Gonzalez: None declared, Mike O. Becker: Speakers bureau: Mepha, MSD, Novartis, GSK, Bayer and Vifor, Oliver Distler: Speakers bureau: Bayer, Boehringer Ingelheim, Medscape, Novartis, Roche, Lilly, Pfizer, Mepha, Sanofi, Conshohocken, Novartis, GSK, Lilly, Pfizer, Novartis, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Chemomab, CSL Behring, Galapagos, Glimmer, GSK, Horizon, Inventiva, IQvia, Kymera, Lupin, Medac, Medscape, Mennyli Biotech, Mitsubishi Tanabe, MSD, Prometheus Biosciences, Roche, Roivant, Topadur and UBC, Lilly, Pfizer, Grant/research support from: Kymera, Mitsubishi Tanabe, Michael Krauthammer Speakers bureau: Oncobit, Brita Mauzer, Boehringer Ingelheim, Medscape, Medac, Medscape, Milan, Mepha, and MSD, Consultant of: Novartis, Boehringer Ingelheim, Janssen-Cilag, Grant/research support from: AbbVie, Protagen, Novartis Biomedical Research

Table 1. Results are reported as number/number available (%) for dichotomous variables, or as median (IQR) (n available) for continuous variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>IIM-ILD patients (n=13)</th>
<th>IIM patients without ILD (n=13)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmonary function variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC%</td>
<td>88.2</td>
<td>104.1</td>
<td>0.09</td>
</tr>
<tr>
<td>FEV1%</td>
<td>85.8</td>
<td>101.9</td>
<td>0.19</td>
</tr>
<tr>
<td>FEV1/VC</td>
<td>82.7</td>
<td>80.9</td>
<td>0.57</td>
</tr>
<tr>
<td>RVf</td>
<td>85.7</td>
<td>90.4</td>
<td>0.74</td>
</tr>
<tr>
<td>TLC (n=11)</td>
<td>82.6</td>
<td>89.9</td>
<td>0.32</td>
</tr>
<tr>
<td>TLC (n=11)</td>
<td>83.9</td>
<td>76.1</td>
<td>0.40</td>
</tr>
<tr>
<td>RV/TLC</td>
<td>111.1</td>
<td>153.4</td>
<td>0.03</td>
</tr>
<tr>
<td>RV/VC</td>
<td>171</td>
<td>210</td>
<td>0.039</td>
</tr>
<tr>
<td>DLco/VT</td>
<td>56.3</td>
<td>78.2</td>
<td>0.005</td>
</tr>
<tr>
<td>MIP%</td>
<td>69</td>
<td>62.4</td>
<td>0.57</td>
</tr>
<tr>
<td>MM%</td>
<td>76.4</td>
<td>72.5</td>
<td>0.96</td>
</tr>
<tr>
<td>N2 (%)</td>
<td>2.8</td>
<td>5.4</td>
<td>0.13</td>
</tr>
<tr>
<td>ROC Exp %</td>
<td>100.5</td>
<td>76.6</td>
<td>0.053</td>
</tr>
<tr>
<td>G/D %</td>
<td>99.4</td>
<td>123.4</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Table 1. Comparison of pulmonary and small airways function variables between IIM patients with and without ILD.

Conclusion: Lung function as measured by FVC appears to correlate with worse patient-reported function in our unadjusted analysis of the large multicentre EUSTAR database. However, to estimate the total causal effect we must consider a multitude of potentially confounding factors, which need to be integrated and analysed in a causal inference framework. The proposed DAg will inform the development of simulations of the potential impact of bias (confounding, collider and omitted variable) on effect estimates we could obtain from EUSTAR cohort.

REFERENCES:

Disclosure of Interests: Maria Grazia Lazzaroni Grant/research support from: Research grant from Boehringer-Ingelheim, Michelle Wilson Grant/research support from: Research grant from Boehringer-Ingelheim, Elizabeth Hensor: None declared, Jörg H.W. Distler: None declared, Giovanna Cuomo: None declared, Elise Siegent: None declared, Ulf Müller-Ladner: None declared, Yannick Allanore: None declared, Maria Joao Salvador: None declared, Branimir Anic: None declared, Ulrich Walker: None declared, László Czigják: None declared, Camillo Ribi: None declared, Cristina-Mihaela Tanaseanu: None declared, Armando Gabrielli: None declared, Anna-Maria Hoffmann-Vold: None declared, Oliver Distler: None declared, Francesco Del Gado: None declared


POS0894

COMPARISON OF PULMONARY AND SMALL AIRWAYS FUNCTION BETWEEN IDIOPTPATHOLOGICAL MYOPATHIES PATIENTS WITH AND WITHOUT INTERSTITIAL LUNG DISEASE

P. Panagopoulos1, V. E. Georgakopoulou2, V. Pezoulas3, A. Goules1, D. I. Fotiadis2, T. Vassilakopoulos3, A. Ziozoulas1. 1 School of Medicine, National and Kapodistrian University of Athens, Department of Pathophysiology, Athens, Greece; 2 School of Medicine, National and Kapodistrian University of Athens, Department of Physiology, Athens, Greece; 3 University of Ioannina, Unit of Medical Technology and Intelligent Information Systems, Ioannina, Greece.

Background: Pulmonary manifestations of idiopathic inflammatory myopathies (IIM) include interstitial lung disease (ILD) and respiratory muscle weakness, but function of small airways has not been studied in these patients (1). Spirometry, impulse oscilometry and measurement of respiratory resistance by the interrupter technique (Rocc) are tools to evaluate function of small airways. In addition, body plethysmography is the gold standard for measuring lung volumes, whereas carbon monoxide washout seems impaired, “underestimating” lung volumes in patients with small airways obstruction due to gas trapping (2). Thus, discrepancies between lung volumes measured by those two techniques may be an indication of early small airways dysfunction.

Objectives: To compare pulmonary and small airways function between IIM patients with and without ILD.

Methods: This prospective observational study included 13 IIM patients with ILD (6 patients with dermatomyositis and 5 with polymyositis) and 13 IIM patients without ILD (9 patients with dermatomyositis and 4 with polymyositis) who were diagnosed and followed up in the outpatient rheumatology clinic of the Department of Pathophysiology between June and December 2021. All IIM patients fulfilled the 2017 EULAR/ACR classification criteria (3). The presence of ILD was determined by high resolution computed tomography of the lungs that was performed as baseline standard of care at the time of diagnosis and was evaluated by a specialist radiologist blinded, according to Fleischner Society definitions for ILD (4). Clinical, laboratory and immunological data were recorded at the time of diagnosis and pulmonary function was assessed by spirometry, body plethysmography, single and multiple breath nitrogen washout, impulse oscilometry and measurement of Rocc, diffusing capacity for carbon monoxide (DLco) and maximal inspiratory and expiratory pressures. Statistical analysis for categorical data was performed by Fisher exact test or χ2 square test accordingly and numerical data with Man-Whitney test or t test.

Results: IIM-ILD patients presented more frequently with dyspnea (53.8% vs 0%, p<0.01), fever (61.5% vs 77%, p<0.05) and arthralgias (76.9% vs 23%, p<0.05), compared to IIM patients without ILD. Inflammatory markers, serum muscle enzymes, myositis specific autoantibodies and classic spirometric parameters did not differ between the two groups. IIM-ILD patients had markedly lower predicted DLco compared to those without (mean: 56.3% vs 78.2%, p<0.01). Predicted total lung capacity and residual volume (% TLC, RV/TLC %) measured by nitrogen washout and the TLC nitrogen washout: TLC body plethysmography ratio (% TLC/pre-TLC) were significantly lower in IIM-ILD patients compared to those without ILD (mean: 111.1% vs 153.4%, p<0.05, median: 171% vs 210%, p<0.05 and median: 1.26 vs 1.45, p<0.05, respectively). Similarly, %N2 (%) was found significantly higher among non-ILD than IIM-ILD patients (5.4% vs 2.8%, p<0.01). Predicted normal value of Rocc tended to be higher in IIM-ILD patients, although not statistically significantly.

Conclusion: Abnormal single breath nitrogen washout and discrepancies between lung volumes measured by body plethysmography and nitrogen washout in IIM-ILD patients, indicate an early small airways dysfunction in these patients.

REFERENCES:
[1] Selva-O’Callaghan et al. PMID 16130510
[2] Bell et al. PMID 30022817
[3] Lundberg et al. PMID 29079590
[4] Hatabu et al. PMID 32649920

DOI: 10.1136/annrheumdis-2022-eular.3300

POS0895

THE ROLE OF SURGERY IN THE ESOPHAGEAL INVOLVEMENT IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW

P. Matucci Cerinic1, A. Alpabio2, M. Hughes3, J. Schoones, G. Terrosu1, A. Martin2, M. Vecchiato6, R. Petri4, M. Matucci-Cerinic5, A. Alunno3. 1 University Hospital Santa Maria della Misericordia, Department of Surgery, Clinica Chirurgica, Udine, Italy; 2 Royal National Hospital for Rheumatic Disease Bath, Rheumatology Department, Bath, United Kingdom; 3 University of Manchester, Division of Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom; 4 Tameside Hospital, Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom; 5 Leiden University Medical Center, Directorate of Research Policy, Leiden, Netherlands; 6 University Hospital
Table 1. GERD ASSESSMENT AND SURGICAL OUTCOMES

<table>
<thead>
<tr>
<th>Domain assessed/outcome</th>
<th>Instrument/Measurement</th>
</tr>
</thead>
<tbody>
<tr>
<td>N° of studies</td>
<td>Dysphagia: 20</td>
</tr>
<tr>
<td></td>
<td>Number of antireflux medications: 10</td>
</tr>
<tr>
<td></td>
<td>High dose PPI: 9</td>
</tr>
<tr>
<td></td>
<td>pH monitoring (pre-procedure): 11</td>
</tr>
<tr>
<td></td>
<td>Oesophagitis/Barrett 4</td>
</tr>
<tr>
<td></td>
<td>Symptom resolution/reduction 24</td>
</tr>
<tr>
<td></td>
<td>pH monitoring 12</td>
</tr>
<tr>
<td></td>
<td>Repeat EGDS 8</td>
</tr>
<tr>
<td>N° of patients</td>
<td>73 (2.5%)*</td>
</tr>
<tr>
<td>N° of surgical procedures</td>
<td>8 (0.27%)*</td>
</tr>
</tbody>
</table>

*rate in total population (2019)

Santa Maria della Misericordia, Department of Surgery, Chirurgia Generale, Udine, Italy; 1Ricc San Raffaele Milano, Unit of Immunology, Rheumatology, Allergy and Rare Disease, Milan, Italy; 2Azienda Ospedaliera Università Careggi, Dept. Experimental and Clinical Medicine, Division of Rheumatology, Firenze, Italy; 3University of L’ Aquila, Internal Medicine and Nephrology Unit, L’ Aquila, Italy.

Background: Among gastrointestinal (GI) manifestations in Systemic Sclerosis (SSc) one of the predominant and challenging problems is gastroesophageal reflux disease (GERD), which occurs in ~75% of patients. Although proton pump inhibitors are useful, they are ineffective in 40% of cases with chronic use at high doses, against the background of long-term risks (e.g., cardiovascular disease and infections) which have been identified in the general population. Surgery might be an option following failure of medical therapy but currently, there is no consensus regarding the optimal surgical procedure for refractory GERD in SSc.

Objectives: To evaluate, among the surgical approaches to GERD, the feasibility of fundoplication (FP) with regards to its safety, efficacy, indications, and timing.

Methods: Four research questions based on the PICO framework were developed to guide the systematic literature review that was conducted up to 22 December 2021. The search and performed across different databases including PubMed, MEDLINE (OVID), EMBASE, Cochrane Library, Web of Science, Google Scholar, Embase, and Academic Search Premier. References were independently screened by two reviewers (PMC and AA) who also independently assessed the full text of eligible articles, and extracted data. Due to heterogeneity of retrieved studies, narrative summaries are used to present the data.

Results: The search yielded 916 papers of which 30 were eligible for full text review. In these studies, out of 2919 clinically heterogeneous patients, 348 SSc patients were identified (mostly female, mean age 52.7 years). Out of these 348, only 257 underwent anti-reflux surgical procedure and these were included in the analysis. Most of the studies were conducted in surgical settings and relevant rheumatological data were largely missing. Refractory GERD symptoms, were the commonest indication for surgery, with post-operative dysphagia being the most frequent complication. In 18 studies, FP was effective, whereas 4 studies had equivocal findings and in 5 a lack of efficacy was reported. The Collis-Nissen FP was the most popular surgical procedure overall as well as in earlier studies, followed by Nissen FP, and Dor FP in relatively more recent studies, reflecting the change in surgical strategy over time. The data extracted shows also an acceptable rate of mortality and morbidity related to surgery, and heterogeneous outcome measures were used hampering any comparison of the studies (Table 1). Due to the heterogeneity of the data, it was not possible to separate the mortality and morbidity rate of SSc patients from the rest of the population.

Conclusion: Our SLR has highlighted that the surgical management of GERD in SSc patients is still highly challenging since the available evidence is scarce and of poor quality. Among the surgical approaches to the problem of GERD, overall FP seems a safe and effective procedure in SSc. Transient post-operative dysphagia was noted in many studies, particularly related with the posterior FP. In the future, it will be necessary to develop minimal requirement to conduct surgical studies in SSc as well as to design studies aimed at defining the clinical criteria for referral to surgery. Indeed, the right timing for surgery and the best surgical procedure in SSc still remains an unmet need.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.3303

POS0986 CRYOFIBRINOGEN-ASSOCIATED SYSTEMIC SCLEROSIS: POSSIBLE CORRELATIONS WITH SCLERODERMA DIGITAL ULCERS AND PULMONARY ARTERIAL HYPERTENSION

G. Amati1, A. Spinella1, G. Sandri1, P. Natazzi2, D. Debbia3, M. T. Mascia1, C. Salvatari1,4, D. Giuggioli1,4, Via del Pozzo, 71, Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy; 2Via Giardini, 1355, Department of Laboratory Medicine and Anatomical Pathology, AOU of Modena, Modena, Italy; 3Via del Pozzo, 71, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine, Reggio Emilia, Modena, Italy; 4Via del Pozzo, 71, Department of Medical and Surgical Sciences of Children and Adults, Modena, Italy.

Background: Cryofibrinogenemia (CF) is a rare disorder characterized by the presence of an abnormal protein in the plasma that precipitates when cooled and redissolves at room temperature (1). CF is rarely symptomatic, therefore it is often underestimated. Nevertheless, the cryoprecipitation of native fibrinogen could induce the thrombotic occlusion of the small and medium sized vessels; as a consequence, this condition could become potentially lethal without the proper treatments. CF is classified into an essential and secondary form. The association of CF with Systemic Sclerosis (SSc) is described in literature (2-4); however, the role of this phenomenon it is not completely clarified, especially because some clinical aspects could be similar in both conditions.

Objectives: The aim of our study was to analyze the clinical, laboratory, instrumental and therapeutic features of SSc patients with cryofibrinogenemia, with particular attention to the possible prevention strategy and appropriate therapy of SSc digital ulcers.

Methods: 101 SSc patients (M:F 1:13) referring to the SSc Unit-Rheumatology Unit of our University Hospital have been tested both for cryofibrinogen and cryoglobulins from February 2020 to January 2022. Clinical, laboratory, instrumental features and ongoing therapies were collected.

Results: Patients with diffuse cutaneous form, limited cutaneous form, and sine-scleroderma subsets were 20 (19.8%), 79 (78.2%), and 2 (2.0%), respectively. The overall positivity for CF was 69.3%, of which 90.7% as isolated CF and 9.3% in addition to cryoglobulins. No correlation between CF positivity and positivity for rheumatoid factor, Sci-70, CENP B, anti-fibrillarin, anti-U1RNP, anti-ThiTo, anti-Ku, anti-MDA5, anti-mitochondrial, anti-SSA, anti-SSB, anti-citrullinated peptide, anti-phospholipids, anti-CORE, and anti-HCV antibodies was observed. An inverse correlation trend between CF positivity and antibodies positivity (OR=0.0577, 95% CI 0.0029-1.1537, p=0.0620) was noted. No significant correlation between CF positivity and interstitial lung disease, pulmonary arterial hypertension (PAH), history of digital ulcers, and amputation was recorded; however, considering cryocrct sample ≥1%, a correlation between the presence of an estimated pulmonary arterial systolic pressure (ePASP) higher than 30 mmHg and the positivity of CF was obtained (OR = 2.71, 95% CI 1.01-7.28, p=0.0482). The same association was achieved if we considered patients without endothelin receptor antagonist therapy (n=47) and CF positivity (OR=6.19, 95% CI 1.19-32.2, p=0.0304).
Furthermore, no correlation between CF positivity and the presence of digital ulcers at the moment of the blood sampling was verified; however, if we stratified patients according to their ongoing treatments (absence of an endothelin receptor antagonist therapy plus PDE5 inhibitors), a significant correlation between digital ulcers and CF positivity emerged (OR=8.14, 95% CI 1.03-64.5, p=0.0470, n=91).

**Conclusion:** Our preliminary results on this issue are extremely interesting as they can open new perspectives on the identification of cryofibrinogen as possible prognostic marker that could be involved in the pathogenesis of scleroderma digital ulcers and PAH. Moreover, therapies which are currently used for the treatment of PAH and the management of digital ulcers, could determine circulating cryofibrinogen disappearance, with possible challenging future impact on SSc therapeutic approaches.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3354

**POSO897**

**A SYSTEMATIC REVIEW AND META-ANALYSIS OF DIAGNOSTIC ACCURACY OF WHOLE-BODY 18F-FDG PET AND 18F-FDG PET/CT IN DETECTING OCCULT MALIGNANCY IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY**

A. Ali1, R. Akilan2, J. Asif3, B. Basida4, Z. Al-Sagri5, N. Mahabadi6, H. Sarakbi1

1Wayne State University/Detroit Medical Center, Internal Medicine/Rheumatology Division, Detroit, United States of America; 2Case Western Reserve University at MetroHealth Medical Center, Internal Medicine/Rheumatology Division, Cleveland, United States of America; 3Beaumont Hospital, Dearborn, Internal Medicine, Dearborn, United States of America; 4Wayne State University/Detroit Medical Center Sinai Grace Hospital, Internal Medicine, Detroit, Michigan, United States of America; 5Wayne State University/Detroit Medical Center, Internal Medicine, Detroit, Michigan, United States of America

**Background:** Idiopathic inflammatory myopathies (IIMs) are chronic, systemic autoimmune diseases that can cause muscle inflammation, weakness, and skin manifestations. Several studies have confirmed the association between IIMs and malignancy in adult population with varied frequency (4-42%), highest in patients with dermatomyositis. Detecting occult malignancy is a diagnostic challenge involving cost- and time-consuming methods. The [18F] fluorodeoxyglucose positron emission tomography ([18F] FDG-PET) role in this context has been studied in multiple studies.

**Objectives:** The purpose of this study is to assess the diagnostic performance of whole-body [18F]FDG PET or [18F]FDG PET/CT for detection of occult malignancy in patients with IIMs.

**Methods:** A systematic search was performed in PubMed (Medline), Embase, and Scopus, Cochrane and clinicaltrial.gov to identify relevant published studies reporting the performance of [18F]FDG PET or [18F]FDG PET/CT in detecting occult malignancy in IIMs. Histopathologic confirmation and/or clinical follow-up was considered as the gold standard for diagnosis. Studies were eligible if all patients were 18 years or older, does not have history or current diagnosis of cancer and classified as IIMs according to Bohan and Peter classification criteria or have confirmed tissue diagnosis of malignancy. Histopathologic confirmation and/or clinical follow-up was considered as the gold standard for diagnosis. Studies were eligible if all patients were 18 years or older, does not have history or current diagnosis of cancer and classified as IIMs according to Bohan and Peter classification criteria or have confirmed tissue diagnosis of malignancy. Histopathologic confirmation and/or clinical follow-up was considered as the gold standard for diagnosis. Studies were eligible if all patients were 18 years or older, does not have history or current diagnosis of cancer and classified as IIMs according to Bohan and Peter classification criteria or have confirmed tissue diagnosis of malignancy. Histopathologic confirmation and/or clinical follow-up was considered as the gold standard for diagnosis. Studies were eligible if all patients were 18 years or older, does not have history or current diagnosis of cancer and classified as IIMs according to Bohan and Peter classification criteria or have confirmed tissue diagnosis of malignancy.

**Results:** Of 499 studies collected, six studies including a total of 293 patients with IIMs and who underwent [18F]FDG PET or [18F]FDG PET/CT examinations met our inclusion criteria. In two studies (87 participants), there was no clear database of the age and gender of the participants. The other four studies (total of 206 patients) 131/206 were females and 75/206 were males. Information about the type of IIMs was available in 5/6 studies with total of 283 participants; dermatomyositis (194/283), overlap polymyositis (41/283), Immune mediated necrotizing myositis (14/283), Polymyositis (11/283), non-specific(4/283), and orbital myositis (1/283). A total of 47 cancers were detected with lung (9/47), Breast (8/47) and nasopharyngeal (6/47) cancers were the most reported malignancies. Interestingly, all the breast cancers were reported as false negative. The pooled sensitivity, specificity, and diagnostic odds ratio of [18F]FDG PET or [18F]FDG PET/CT for the detection of underlying malignancy were 0.81 (95% CI, 0.67–0.91), 0.89 (95% CI, 0.84–0.92), and 38.19 (95% CI, 7.6–190.60), respectively. The heterogeneity of the studies was moderate with Chi-square, and I² index of 15.6 (P <0.05) and 68% respectively. The AUC and the Q* index was 0.95(SE, 0.033) and 0.89, indicating excellent diagnostic accuracy (Figure 1).

**Conclusion:** This meta-analysis demonstrates that whole-body [18F]FDG PET or [18F]FDG PET/CT has high diagnostic accuracy and moderate to high sensitivity and specificity for detection of underlying malignancy in patients diagnosed with IIMs.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3391

**POSO898**

**SURGICAL MANAGEMENT OF DIGITAL ULCERS IN SYSTEMIC SCLEROSIS: A SYSTEMATIC LITERATURE REVIEW.**


1Wayne State University/Detroit Medical Center, Internal Medicine/Rheumatology, Detroit, Michigan, United States of America; 2Leiden, 5. Directorate of Research Policy (formerly Walaeus Library), Leiden University Medical Center, Leiden, Netherlands; 3Modena, 6.Scleroderma Unit, Rheumatology Unit, University of Modena and Reggio Emilia, University Hospital of Modena, Modena, Italy; 4University of Ottawa, Ottawa, ON, Canada, University of Ottawa, Ottawa, ON, Canada, ONario, Canada; 5University Hospital of Cologne., Department of Dermatology and Venerology, Cologne, Germany; 6The University of Melbourne, Melbourne, VIC, The University of Melbourne, Melbourne, VIC, Australia; 7Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, USA, Stanford University School of Medicine a, CA, United States of America; 8Paris Descartes University, Paris, France, Rheumatology Dept. Cochin Hospital, Paris, France; 9Jewish General Hospital, McGill University, Quebec, Canada; 10London, University College London, London, United Kingdom, London, United Kingdom; 11University of Zurich, Zurich, Switzerland, University of Zurich, Zurich, Switzerland; 12Vanderbilt University Medical Centre, Nashville, TN, USA, --, TN, United States of America; 13University of California, Los Angeles, Los Angeles, CA, USA, Rheumatology division, CA, United States of America; 14University of Michigan, Ann Arbor, MI, --, Michigan, United States of America; 15University Hospital of Cologne., Department of Dermatology and Venerology, Cologne, Germany; 16Tokyo, Japan, Nippon Medical School, Tokyo, Japan; 17Florence, Italy, University of Florence, Florence, Italy; 18, University of Western Ontario, London, ON, Schulich School of Medicine and Dentistry, ON, Canada; 19University of Erfurt, Internal Medicine and Nephrology Unit., Erfurt, Italy

**Figure 1. Summary Receiver Operating Characteristic curve of PET scan in detecting occult malignancy in IIMs**

**Conclusion:** This analysis demonstrates that whole-body [18F]FDG PET or [18F]FDG PET/CT has high diagnostic accuracy and moderate to high sensitivity and specificity for detection of underlying malignancy in patients diagnosed with IIMs.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3391
Background: Management of digital ulcers (DUs) in systemic sclerosis (SSc) is a major clinical challenge. To date, systemic therapy is generally considered as the 'standard of care' for significant SSc-DUs. However, there is a strong rationale to develop local approaches to DUs, to avoid side effects from systemic therapies. World Scleroderma Foundation DU Working Group intends to develop practical, evidence-based recommendations for DU management including local, Surgical Treatment (L-ST).

Objectives: To summarize the literature on the safety and efficacy of L-ST for SSc-DUs.

Methods: A systematic literature review (SLR) was conducted up to May 2021. According to the PICO framework, eligibility criteria were defined and original research articles about surgical treatment of SSc DUs in adult patients were included. References were independently screened by 2 reviewers who assessed the full text of eligible articles and extracted data.

Results: Thirteen eligible articles out of 790 total publications were identified (Table 1). Due to the paucity of randomized controlled trials of surgical treatments for SSc-DU, we included retrospective studies and case series with at least 4 patients. Autologous fat (adipose tissue AT) grafting was the surgical modality mostly identified (7 studies of which 6 RCT and 6 prospective open label single arm). The healing rate (HR) with autologous fat grafting (4 studies) ranged from 66-100%. In the RCT, two age and sex matched groups were included, adipose tissue (AT) group (n=25 pts) and sham procedure (SP) group (n=13), DU healing was reported in 23/25 in AT group versus 1/13 in the SP group in 8 wks, (p<0.0001), 12 pts in the SP group, received rescue AT injection, all of them healed after 8 wks. Three studies reported autologous adipose derived-stromal vascular fraction(SVF) grafting and the HR ranged from 32-60%, followed up to 12 months. Transient edema and paresthesia were reported in 2 studies, and amputation in 2 ulcers in 1 study, and no complications were reported in other studies. Surgical sympathectomy was reported in 3 studies, with a median healing rate of 81%. Bone marrow derived cell transplantation in a single study showed 87% healing rate over (4-24 wks). Two surgical studies (of direct microsurgical revascularization N=4, and microsurgical transplantation N=16), showed 100% healing of ulcers, no complications reported.

Conclusion: Our SLR has identified several surgical modalities for SSc-DUs. L-ST seemed generally effective and safe for DU healing, thus Significant methodological issues emerged including small numbers of pts, lack of comparator, failure to report confounders such as background therapies and variable follow up. Future research is warranted to rigorously investigate surgical interventions for DUs.

Disclosure of Interests: Alessia Alunno: None declared, Corrado Campochi: None declared, Oliver Distler Shareholder of: Consultancy relationship with and/or has received research funding from and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Abbvie, Akelekron, Alcimed, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Mediscape, Medscape, Mitsubishi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Roivant, Sanofi and Topadur. Patent issued "mir-29 for the treatment of systemic sclerosis" (US8247389, EP2331143). , Tracy Frech: None declared, Dinesh Khanna Speakers bureau: Janssen and Eicos Sciences, Inc., Paid instructor for: Janssen and Eicos Sciences, Inc., Consultant of: Janssen and Eicos Sciences, Inc., Thomas Krieg: None declared, Masataka KUWANA Speakers bureau: Speakers fees from AbBiVe, Astra Kasel Pharma, Astellas, Boehringer Ingelheim, Chugai, Eisai, GlaxoSmithKline, Janssen, Nippon Shinyaku, Ono Pharmaceuticals, Tanabe-Mitsubishi, and Consultant fees from AstraZeneca, Boehringer Ingelheim, Corbus, Kissel, Mochida, outside of the submitted work., Paid instructor for: Speakers fees from AbBiVe, Astra Kasel Pharma, Astellas, Boehringer Ingelheim, Chugai, Eisai, GlaxoSmithKline, Janssen, Nippon Shinyaku, Ono Pharmaceuticals, Tanabe-Mitsubishi, and Consultant fees from AstraZeneca, Boehringer Ingelheim, Corbus, Kissel, Mochida, outside of the submitted work., Marco Matsuoc-Ceric: None declared, Janet Pope: None declared, Alessia Alunno: None declared.


Table 1. Characteristics of the extracted studies.

<table>
<thead>
<tr>
<th>Study design</th>
<th>Patients (n)</th>
<th>Baseline DU (n)</th>
<th>Background therapy (%)</th>
<th>Follow-up</th>
<th>Outcome</th>
<th>Healed ulcers(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adipose tissue graft</td>
<td>p 9</td>
<td>15</td>
<td>PG, CCB—100 ETA 26</td>
<td>8-12 wks</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Autologous fat graft</td>
<td>p 12</td>
<td>9</td>
<td>PDE-Si 13 ETA 100</td>
<td>8 wks</td>
<td>92-case</td>
<td></td>
</tr>
<tr>
<td>Adipose tissue grafting</td>
<td>RCT 25 case</td>
<td>25-case</td>
<td>PG-100 CCB 100</td>
<td>7-13</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Adipose tissue implant</td>
<td>p 15</td>
<td>15</td>
<td>no therapy PG,CBB-100</td>
<td>6 month</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Adipose tissue graft</td>
<td>p 12</td>
<td>9</td>
<td>ETA PDE-Si, ccb, PG allowed</td>
<td>22m</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>adipose derived SVF</td>
<td>p 12</td>
<td>15</td>
<td>CCB 50 ETA 16</td>
<td>6 m</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Adipose derived SVF</td>
<td>p 18</td>
<td>19</td>
<td>CCB 50 ETA 16</td>
<td>24 wks</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Sympathectomy</td>
<td>R 6</td>
<td>11</td>
<td>CCB-100</td>
<td>20 m</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>Sympathectomy</td>
<td>R 13</td>
<td>35</td>
<td>PG</td>
<td></td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Direct microsurgical revascularization</td>
<td>R 4</td>
<td>17</td>
<td>Ccb 35</td>
<td>9 m</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Limited microsurgical arteriolaris</td>
<td>R 6</td>
<td>17</td>
<td>PDE-Si 58</td>
<td>12 m</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>
HIGH FATIGUE SCORES IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: A MULTIGROUP COMPARATIVE STUDY FROM THE COVAD E-SURVEY.


Background: Idiopathic inflammatory myopathies (IIM) are a rare, multisystem, heterogeneous diseases, and contribute to high psychological burden. The patients' perception of physical health, deteriorating independence and social and environmental relationships may not always be a direct function of disease activity. To face with these aspects, several worldwide specialized organization have recommended the use of patient reported outcomes across all levels of disease activity, although the fatigue discrepancies with HC were substantially confirmed. After application of a multivariate linear regression analysis we found that lower fatigue VAS scores were related to HC (P < 0.001), male gender (P < 0.001), Asian and Hispanic ethnicities (P < 0.001).

Disclosure of Interests: None declared


Figure 1. distribution of Fatigue VAS scores in the three population evaluated. IIM idiopathic inflammatory myositis; AID autoimmune diseases; HC healthy controls; * P < 0.05.
Musculoskeletal and Dermatological Sciences, Manchester, United Kingdom; 4Leiden University Medical Center, Directorate of Research Policy, Leiden, Netherlands; 5Jewish General Hospital, Department of Rheumatology, Montreal, Canada; 6Boston University School of Medicine, Department of Dermatology and Paleo Alto VA Health Care System, Palo Alto, United States of America; 7RCCS San Rafaela, Villa-Salute San Rafaela, Unit of Immunology, Rheumatology, Allergy & Rare Diseases, Milan, Italy; 8Assiut University Hospital, Rheumatology & Rehabilitation Department, Assiut, Egypt; 9University of Modena and Reggio Emilia, University Hospital of Modena, Scleroderma Unit, Rheumatology Unit, Modena, Italy; 10University Hospital of Cologne, Department of Dermatology and Rheumatology and Venereology, Cologne, Germany; 11Paris Descartes University, Institut Cochin, Paris, France; 12University College London, UCL Division of Medicine, London, United Kingdom; 13University Hospital Zurich, Department of Rheumatology, Zurich, Switzerland; 14Vanderbilt University Medical Center, Department of Rheumatology, Nashville, United States of America; 15Dawson Geffen School of Medicine, University of California, Division of Rheumatology, Los Angeles, United States of America; 16University of Michigan, Scleroderma Program, Ann Arbor; United States of America; 17Nippon Medical School, Department of Allergy and Rheumatology, Tokyo, Japan; 18University of Florence, Department of Experimental and Clinical Medicine, Florence, Italy; 19University of Western Ontario, Schulich School of Medicine & Dentistry, London, Canada; 20University of Uqalla, Internal Medicine and Nephrology Unit, Uqalla, Italy

Background: Digital ulcers (DU) are common in systemic sclerosis (SSc) and associated with reduced survival, high morbidity and a poor quality of life. Recommendations have previously been proposed for DU management yet there remains significant unmet patient need. Therefore the World Scleroderma Foundation DU Working Group intends to develop practical evidence based recommendations for DU management.

Objectives: To summarise data on efficacy and safety of systemic treatments for SSc DU.

Methods: A systematic literature review to May 2021 was performed. PubMed, MEDLINE, Embase, Web of Science, Cochrane Library, Emcare (OVID) and Academic Search Premier databases were searched for original studies on adult patients with SSc DU treated with systemic pharmacological treatment. Based on the PICO framework, eligibility criteria were defined and references were independently screened by two reviewers. Reviewers independently assessed the full text of eligible articles relating to interstudy heterogeneity narrative summaries were used to present data.

Results: The search strategy identified 1271 references of which 45 eligible articles were included. Seventeen studies were randomised placebo controlled clinical trials (RCT) pertaining to PDE5 inhibitors (PDE5i) (n=3), endothelin receptor antagonists (ERA) (n=3), prostanooids (n=7), antiplatelet agents (n=1) and other (n=9) (Table 1). No head to head RCT was retrieved. All other studies were observational studies (OBS). Studies were highly heterogeneous with application of differing definition of DU, variable study eligibility criteria, clinical endpoints and follow up periods. This limited the calculation of effect size and comparison across studies.

Table 1. Characteristics of placebo controlled randomised controlled trials

<table>
<thead>
<tr>
<th>Author Year</th>
<th>Intervention</th>
<th>n</th>
<th>Follow Up</th>
<th>Outcome</th>
<th>Favours intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hachulla 2016</td>
<td>Sildenafil</td>
<td>83</td>
<td>12 weeks</td>
<td>Time to DU healing</td>
<td>-</td>
</tr>
<tr>
<td>Andriughi 2017</td>
<td>Sildenafil</td>
<td>41</td>
<td>12 weeks</td>
<td>DU healing</td>
<td>+</td>
</tr>
<tr>
<td>Shenoy 2015</td>
<td>Tadalafil</td>
<td>24</td>
<td>6 weeks</td>
<td>New DU</td>
<td>-</td>
</tr>
<tr>
<td>Khamra 2016</td>
<td>Macitentan</td>
<td>554</td>
<td>16 weeks</td>
<td>New DU</td>
<td>-</td>
</tr>
<tr>
<td>Matucci-Cerinic 2017</td>
<td>Bosentan</td>
<td>188</td>
<td>32 weeks</td>
<td>New DU Time to</td>
<td>-</td>
</tr>
<tr>
<td>Korn 2004</td>
<td>Bosentan</td>
<td>122</td>
<td>12 weeks</td>
<td>New DU</td>
<td>-</td>
</tr>
<tr>
<td>Kawade 2008</td>
<td>IV iloprost</td>
<td>50</td>
<td>12 months</td>
<td>DU healing</td>
<td>-</td>
</tr>
<tr>
<td>Wijeysundera 2008</td>
<td>IV iloprost</td>
<td>35</td>
<td>12 weeks</td>
<td>DU healing</td>
<td>-</td>
</tr>
<tr>
<td>Wijeysundera 1994</td>
<td>IV iloprost</td>
<td>73</td>
<td>9 weeks</td>
<td>50% reduction in DU</td>
<td>-</td>
</tr>
<tr>
<td>Sebold 2017</td>
<td>Tropolon</td>
<td>148</td>
<td>20 weeks</td>
<td>Net DU burden</td>
<td>-</td>
</tr>
<tr>
<td>Vyasvarrat 1999</td>
<td>Beraprost</td>
<td>107</td>
<td>25 weeks</td>
<td>% patients with</td>
<td>-</td>
</tr>
<tr>
<td>Denton 2013</td>
<td>Sildenafil</td>
<td>74</td>
<td>12 weeks</td>
<td>Number of new DU</td>
<td>-</td>
</tr>
<tr>
<td>Lau 1993</td>
<td>Cicaprost</td>
<td>33</td>
<td>4 weeks</td>
<td>Number of DU</td>
<td>-</td>
</tr>
<tr>
<td>Abou-Raya 2008</td>
<td>Atorvastatin</td>
<td>84</td>
<td>4 months</td>
<td>Number of DU</td>
<td>+</td>
</tr>
<tr>
<td>Au 2010</td>
<td>Iloprost</td>
<td>158</td>
<td>12 months</td>
<td>Number of patients with</td>
<td>-</td>
</tr>
<tr>
<td>Beckett 1984</td>
<td>Dipyridamole / aspirin</td>
<td>41</td>
<td>2 years</td>
<td>Change in general</td>
<td>-</td>
</tr>
<tr>
<td>Nagaraja 2019</td>
<td>Riociguat</td>
<td>17</td>
<td>32 weeks</td>
<td>Net DU burden</td>
<td>-</td>
</tr>
</tbody>
</table>

Several RCT found improved DU healing with treatment: two with PDE5i, one with iloprost and one showed improved DU healing and prevention with atorvastatin. Two RCT demonstrated effective prevention of new DU with bosentan. SRS studies with a total of 621 patients showed variable improvements in the healing of DU with CCB, PDE5i, ERA, statins, N-acetylcysteine, prostanooids and ketanserin and prevention of new DU with ERA. Regarding safety, all treatments were generally tolerated with few serious adverse events. Treatment was ceased in 6.25-17.5% of patients in RCT due to treatment related side effects.

Conclusion: Despite several studies assessing the efficacy and safety of systemic pharmacological treatment of SSc DU, it is not possible to draw solid conclusions due to study heterogeneity. Small RCT have shown treatment benefit with PDE5i, iloprost and atorvastatin. Large studies demonstrated effective prevention of new DU with bosentan. Our results highlight the urgent need for improved clinical trial design to generate more robust evidence and novel therapies to guide the management SSc DU.

Acknowledgements: This work was supported by the World Scleroderma Foundation.


Background: Systemic sclerosis associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality.

Objectives: This work identifies factors associated with SSc-ILD decline on pulmonar y function testing (PFT).

Methods: This single center cohort identified 312 patients with ILD as determined by high resolution chest. 184 patients (59% of 312) completed baseline and serial PFTs (with at least two follow-up PFTs) and were included in this analysis. Mixed linear models were fit to assess the decline in the percent predicted forced vital capacity (ppFVC) over time. Demographics, disease factors, autoantibodies, and ILD features were included in the univariate mixed linear model; those achieving a p-value < 0.20 were included in the multivariable mixed linear model. Patients were followed longitudinally, with survival as an endpoint identified using the National Death Registry Index, reviewing death certificates, and hospital records.

Results: The 184 patients were an average of 53.2 (12.1) years old; the median [IQR] disease duration from the first non-Raynaud’s phenomenon symptom was 1.8 [0.7, 4.8] years. SSc subtype was diffuse in 55.4% (n=102), limited in 32.6% (n=60), overlap syndrome in 8.2% (n=15), and SSC sine scleroderma in 3.87% (n=7). Serologies were positive for anti-topoisomerase I (ATA), anti-centromere and anti-RNA polymerase III in 31.4% (n=93/294), 10.4% (16/154) and 22.9% (25/109) respectively. Mean ppFVC was 70.8 (18.9) and ppDLco 572 (20.8). Whole lung involvement (WLI%) of ≥20% on visual read was found in 49.3% of subjects (74/150 (49.3%)) where quantification was available. Over a median of 4.9 (2.4, 6.8) years, 21 patients (11.4%) died. The ppFVC declined a mean of 0.28/year in the overall group. There were differences in terms of ppFVC decline/year between patients who died in the first 2 years (n=10, -8.28%), 2-8 years (n=5, -3.89%), after 8 years (n=6, -1.09%), who were still alive (n=152, -0.22%), or who were still alive (n=163, -0.13%). The primary cause of death was ILD (6/21, 28.6%); those who died in the first 2 years most often died from progressive ILD (4/6, 67%). Factors significantly associated with decline in ppFVC on univariate analyses, included longer disease duration (ref. < 2 years, p=0.0048), ATA positivity (ref. negative, p=0.0081), and WLI ≥20% (ref. < 20%, p=0.0484). In multivariate analysis the only statistically significant variable associated with decline in ppFVC year was ATA positivity.

Conclusion: In a large single center cohort of SSc-ILD, ATA positivity is a risk factor for developing progressive SSc-ILD, consistent with other SSc-ILD cohorts. Stratifying patients by survival demonstrates that lung function declines dramatically in those who died within 2 years, whose main cause of death was progressive ILD. These data support the growing need to identify risk factors for disease severity and risk for progression, and to target intervention in patients most likely to develop progressive SSc-ILD.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3648
Results: 29 patients with anti-TIF1-γ antibodies were analyzed, 82.7% women, with a mean age of 61 years (31-96 years).

The reason for requesting this antibody was: clinical features suggestive of DM in 10 patients (34.5%), muscle weakness in 9 (31%), interstitial lung disease (ILD) in 5 (17.2%), persistent CK elevation in 3 (10.3%), constitutional syndrome in 1 (3.5%) and antiphospholipid syndrome in 1 patient (3.5%). The mean time from symptoms onset to the detection of anti-TIF1-γ was 14 months (0-60 months).

10 patients (34.5%) had a diagnosis of DM; 4 patients (13.8%) systemic lupus erythematosus (SLE); one (3.5%) had a SLE/DM overlap syndrome; one patient (3.5%) subtype cutaneous lupus; one (3.5%) was diagnosed with diffuse systemic sclerosis; one patient (3.5%) limited systemic sclerosis; one patient (3.5%) antiphospholipid syndrome; one patient (3.5%) HLA-B27+ spondyloarthritis and 9 patients (31%) had no associated AIS. 5 patients (17.2%) showed ILD with different patterns: UIP (n=2), NSIP (n=2) and COP (n=1). Only 9 patients (31%) had elevated CK levels at the time of antibody determination. 10 patients (34.5%) were diagnosed with cancer: lung adenocarcinoma (n=2), small cell lung carcinoma (n=2), breast carcinoma (n=2), hepatocarcinoma (n=1), cervical cancer (n=1), ovarian carcinoma (n=1) and gallbladder adenocarcinoma (n=1). Of those, 7 patients (70%) had elevated CK levels and 6 (60%) had a diagnosis of DM.

None of the patients diagnosed with cancer had ILD. In 4 patients (40%), the diagnosis of cancer was simultaneous with the diagnosis of anti-TIF1-γ antibodies; in 4 (40%), the diagnosis of the tumor preceded the finding of the antibodies; in the other 2 (20%), the finding of the antibodies preceded that of the tumor. 30-month survival after cancer diagnosis was 10%.

In 17 patients (58.6%) no malignancy has been found so far in the annual cancer screening. In two patients (6.9%) no cancer screening was performed.

Conclusion: In our study, 60% of patients with DM and anti-TIF1-γ presented neoplasia, a proportion that was similar established in other series (60-80%). Furthermore, 21% of patients with antibodies and without DM were diagnosed with cancer, suggesting that anti-TIF1-γ antibodies could also be associated with neoplasia in patients without DM. Patients with ILD did not present cancer, supporting the observation of previous studies in which the presence of ILD is a marker of low risk for neoplasia in patients with DM. HyperCKemia might suggest the association with neoplasia in patients with anti-TIF1-γ antibodies.

Disclosure of Interests: None declared


POS0094

CHARANGES OF PULMONARY ARTERY SYSTOLIC PRESSURE IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS ON RITUXIMAB TREATMENT

L. Garzanova1, L.P. Ananyeva1, O. Koneva1, O. Ovsyannikova1, O. Desinova1, M. Starovoytova1, R. Shyakhmetova1, IVA Nasonova Research Institute of Rheumatology, Laboratory of Systemic Sclerosis, Moscow, Russian Federation

Background: Nowadays, there is already published a lot of data on the treatment of systemic sclerosis (SSc) with rituximab (RTX). Recent studies reported about improvement of skin fibrosis and interstitial lung disease associated with SSc (ILD-SSc) on RTX treatment. However, there is not enough data on changes of pulmonary artery systolic pressure (PASP) in SSc patients (pts) on RTX therapy.

Methods: 30 pts with initially elevated PASP (detected as ≥35mmHg by echo-cardiography) were retrospectively selected from a group of 103 SSc pts who received RTX as a therapy for ILD. The mean follow-up period was 25.3±2.4 months. The mean age was 52.6 years (30-66), female pts (87%), the diffuse cutaneous subset of the disease had 13 pts (43%). The mean disease duration was 7-3 years. The minimal mean dose of RTX was 2.3±1.1 grams. All pts received prednisone at a dose of 11.3±3.7 mg/day, immunosuppressants received 47% of them. All pts were positive for ANA. An assessment of basic parameters was obtained at baseline (Point 0), after 13.6±2.7 months (Point 1) and at the end of follow-up (25.3±2.4 months - Point 2). The results at baseline and at the end of the follow-up are presented in the form of mean values.

Results: There was an improvement of all main parameters at the point 2 and further - by the end of follow-up (Table 1). There was a significantly decrease in PASP, which was accompanied by the improvement of lung function - increase in forced vital capacity % predicted (FVC), stabilization of diffusion capacity for carbon monoxide % predicted (DLCO). A moderate negative statistically significant correlation was found between the PASP and FVC (r=0.522; p=0.003). There was a significant increase in 6-minute walk distance (6-mwd), ejection fraction of left ventricular (ER), activity index (EScSG-AI) and a decrease of Rodnan skin score.

Table 1. Changes of the main parameters on RTX treatment.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Point 0 (baseline)</th>
<th>Point 1 (13±6.27 month)</th>
<th>Point 2 (25.5±2.4 month)</th>
<th>P Point 0-1</th>
<th>P Point 0-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC, %, M±σ</td>
<td>75.6±20.1</td>
<td>82.5±19.2</td>
<td>88.2±22.5</td>
<td>0.01</td>
<td>0.002</td>
</tr>
<tr>
<td>PASP, mmHg, M±σ</td>
<td>48.2±13.8</td>
<td>44.4±12.3</td>
<td>39.5±18.8</td>
<td>0.008</td>
<td>0.004</td>
</tr>
<tr>
<td>DLCO, %, M±σ</td>
<td>42.7±16.2</td>
<td>42.6±15.2</td>
<td>44.9±15.6</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>ER, %, M±σ</td>
<td>61.6±5.5</td>
<td>63.5±6.2</td>
<td>65.8±5.7</td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>Rodnan skin score, M±σ</td>
<td>11.1±12.4</td>
<td>72±8.1</td>
<td>6.1±7.6</td>
<td>0.003</td>
<td>0.0001</td>
</tr>
<tr>
<td>6-mwd, m</td>
<td>419.6±103</td>
<td>453.8±85</td>
<td>458.8±78</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>Activity index (EScSG-AI), M±σ</td>
<td>3.3±1.5</td>
<td>1.5±1.3</td>
<td>1.4±1.1</td>
<td>0.001</td>
<td>0.001</td>
</tr>
<tr>
<td>Cumulative mean dose of RTX, g</td>
<td>1.65±0.69</td>
<td>2.3±1.1</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Conclusion: In our study, the PASP significantly decreased already in a year after initiation of RTX therapy and further there was an improvement of this parameter at the end of the observation. Decrease of PASP correlated with an increase of FVC and was accompanied by an increase of 6-minute walk distance, ejection fraction of left ventricular, improvement of Rodnan skin score and disease activity index. RTX could be considered as a potentially effective in combined treatment of ILD-SSc, complicated with pulmonary hypertension.

Disclosure of Interests: None declared


POS0095

CHARACTERIZATION OF SWEDISH MYOSITIS PATIENTS WITH ANTI-MDA5 AUTOANTIBODIES AND CORRELATION OF CLINICAL FEATURES WITH AUTOANTIBODY LEVELS

D. Demirdali1, E. Van Gompel1,2, E. Wigen1,2,3, M. Dastmalchi1,2, B. Horluoğlu1,2, A. S. Galindo-Feria1,2, S. Gräslund1,2,4, K. Chemin1,2, I. E. Lundberg1,2, A. Notamica1,2, Karolinska University Hospital, Rheumatology, Stockholm, Sweden; 2Karolinska Institute, Center for Molecular Medicine, Stockholm, Sweden; 3KU Leuven, Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Leuven, Belgium; 4Structural Genomics Consortium, Center for Molecular Medicine, Stockholm, Sweden

Background: The association between anti-melanoma differentiation association protein 5 autoantibodies (aMDA5) and rapidly progressive interstitial lung disease (RP-ILD) in clinically amyopathic dermatomyositis is well established in Asian population cohorts. In western cohorts, ILD has been strongly associated with aMDA5 but data regarding RP-ILD have been more conflicting. It is also suggested that western cohorts have more pronounced myopathic features than Asian.

Objectives: To characterise the disease manifestations of a Swedish aMDA5 positive idiopathic inflammatory myositis (IIM) cohort and to explore antigen reactivity of the MD5 protein.

Methods: First available serum samples collected from 28 consecutive patients with IIM and positive aMDA5 ever tested by ELISA, Line Blot (LB) or Immunoprecipitation, attending Karolinska University Hospital between 1999 and 2021, were included. Clinical data including presence of anti-SSA autoantibodies by ELISA or LB was retrieved retrospectively. An in-house ELISA was used to screen serum samples for reactivity against a recombinant MD5 protein (rMDA5, aa A110-D1025, UniProt ID QB98X4) and seven MD5-derived constructs containing different domains. Correlations between aMDA5 reactivity levels and clinical data were explored.

Results: Nine patients showed no reactivity to any of the rMDA5 constructs by ELISA and were excluded from further analysis. Reactivity against rMDA5 was confirmed by ELISA in 19 patients (median 184.7 µg/mL (interquartile range (IQR) 277.07)). The cohort included 13 male and 6 female patients, 94% Caucasian, with mean age at diagnosis of 41.0 years (IQR 20-63). The mean disease duration (SD) was 7.7 years (5.0). During disease course nine patients (47.4%) had confirmed arthritis. ILD was diagnosed in 16/19 patients (92.4%), four of these (21.1 %) developed a RP-ILD. One patient passed away due to RP-ILD and one required a lung transplant. Patients with IIM had a statistically significant higher mean age at diagnosis than those without (42.8 (SD 10.3) vs 31.3 (SD 8.5)).
4.7 years, p=0.02). Patients developing RP-ILD were not significantly older than patients with chronic ILD. Respiratory symptoms were reported by 75% of patients with ILD at time of diagnosis. The mean total lung capacity (TLC) of the ILD cohort was 68% (SD 17), mean diffusion capacity of carbon monoxide (DLCO) was 59% (SD 15) and mean forced vital capacity (FVC) was 62% (SD 19). There was a higher proportion of patients with CRP ≥ 3 times the reference range at diagnosis amongst patients with FVC <70% than patients with FVC >70% (88.9% vs 16.7%, p=0.01).

Ten patients (52.6%) had anti-SSA autoantibodies, all had ILD. Anti-SSA positive patients had a statistically significant lower TLC than those without (62% vs 79% respectively, p=0.04) and a lower FVC (57% vs 76% respectively, p=0.05).

We found a weak non-statistically significant negative correlation between titres of aMDA5 and TLC, and FVC (Pearson coefficients -0.187, -0.289, -0.130 respectively). Frequency of ILD was higher in patients with aMDA5 titres >100 µg/ml than those with titers <100, but not statistically significant (81.3% vs 18.8%, respectively).

Conclusion: In this Caucasian cohort of aMDA5 positive IIM patients, ILD was present in over 80% of patients, of these, one quarter had RP-ILD. Older patients were more likely to present with ILD. Anti-SSA positivity and higher CRP levels were associated with worse lung function. We found a weak negative correlation between aMDA5 titres and lung function tests, as well as a trend of higher frequency of ILD in patients with higher aMDA5 titres. Muscle and skin involvement were found in a high proportion of patients.

Acknowledgements: D. Demirdal & E. Van Gompel contributed equally to this abstract.

Disclosure of Interests: Deniz Demirdal: None declared, Eveline Van Gompel: None declared, Edvard Wigren: None declared, Maryam Dastmalchi: None declared, Begum horlau-Cugliano: None declared, Angeles Shunasyh Galindo-Feria: None declared, Susanne Gräslund: None declared, Karine Chemin: None declared, Ingrid E. Lundberg Shareholder of: Roche and Novartis., Consultant of: Consulting fees from Corbus Pharmaceuticals Inc. Astra Zeneca, Bristol Myer’s Squibb, Corbus Pharmaceutical, EMD Serono Research & Development Institute, Argenx, Octapharma, Kefar, Oxapharma, and Janssen, Grant/research support from: Research grants from Astra Zeneca, Antionella Notar nicola Speakers bureau: compensation for lecture at conference sponsored by Boehringer Ingelheim.

Background: There are different measures and tools validated to evaluate disease activity and damage in idiopathic inflammatory myopathies (IIM). Disease activity and damage in patients with early diagnosis is not still well defined.

Objectives: To analyze disease activity outcomes and their association with damage in IIM differentiating between incident and prevalent cases.

Methods: Multicenter cross-sectional study. Patients were included in the Spanish Registry of patients with IIM (Myo-Spain)(1). Patients were classified as incident cohort (time between diagnosis and study initiation ≤ 12 months) or prevalent cohort (>12 months). Activity and damage data were collected at the initial visit. Differences between both groups were tested by Chi-square, Student’s t and Mann-Whitney tests. Spearman’s correlation coefficients (Rho) were used to analyze correlations between disease activity and damage measures. The correlation was considered weak (Rho < 0.2), moderate (Rho ≥ 0.2 - <0.3) or strong (Rho ≥ 0.3). A p-value <0.05 was statistically significant.

Results: We included 139 (67.63% women) and 417 patients (74.34% women) with a mean age at diagnosis of 54 and 48 years in the incident and prevalent cohort, respectively. Patients in the incident cohort had significantly higher disease activity measures: myositis disease activity assessment visual analogue scale (MYOACT total), extramuscular activity of the Myositis Activity Questionnaire (PhGA), patient global activity (PGA), physical muscle testing (MMT-8), and HAQ (p < 0.001). The organ systems with the bigger differences between the incident and prevalent cohort were skin and constitutional (p<0.001). No significant differences were found in physician global damage (PhGD), patient global damage (PGD) and myositis damage index (MDI), between both cohorts (p > 0.2). Correlations between disease activity and damage measures are showed in the Table 1. The main differences found between both cohorts were the correlations of PhGA, CK, PGD and MDI with other measures of disease activity.

Table 1. Correlations between disease activity and damage measures

<table>
<thead>
<tr>
<th>Incident cohort</th>
<th>Prevalent cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Extramuscular activity of MYOACT</strong></td>
<td><strong>Extramuscular activity of MYOACT</strong></td>
</tr>
<tr>
<td>Rho 0.76</td>
<td>0.673</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>-0.166</td>
</tr>
<tr>
<td><strong>PhGA</strong></td>
<td>0.677</td>
</tr>
<tr>
<td>Rho 0.633</td>
<td>-0.001</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.065</td>
</tr>
<tr>
<td><strong>PGA</strong></td>
<td>-0.001</td>
</tr>
<tr>
<td>Rho 0.667</td>
<td>0.779</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.015</td>
</tr>
<tr>
<td><strong>MMT-8</strong></td>
<td>-0.001</td>
</tr>
<tr>
<td>Rho -0.471</td>
<td>0.001</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>CK</strong></td>
<td>0.021</td>
</tr>
<tr>
<td>Rho -0.086</td>
<td>0.176</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>HAQ</strong></td>
<td>0.048</td>
</tr>
<tr>
<td>Rho 0.336</td>
<td>0.528</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.049</td>
</tr>
<tr>
<td><strong>PGD</strong></td>
<td>0.037</td>
</tr>
<tr>
<td>Rho -0.202</td>
<td>0.520</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>MDI</strong></td>
<td>0.038</td>
</tr>
<tr>
<td>Rho 0.016</td>
<td>0.388</td>
</tr>
<tr>
<td>P-value &lt;0.001</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Correlations between disease activity and damage measures are showed in the Table 1. The main differences found between both cohorts were the correlations of PhGA, CK, PGD and MDI with other measures of disease activity.

Conclusion: Incident cases had higher disease activity. In those in whom damage was detected, no differences were found in damage measures with prevalent cases. The correlation between the different measures of activity and damage was slightly better in prevalent patients.

References:

Disclosure of Interests: None declared

patterns and organ involvement but there were statistically significant differences with history of digital ulcers. We also found middle ear dysfunction: absence of hearing for pure-tone or speech audiometry.

Table 1. Clinical characteristics and audiometric findings of all patients

<table>
<thead>
<tr>
<th>SSc</th>
<th>n=24</th>
<th>Controls n=20</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (means±SD)</td>
<td>58.4±11.4</td>
<td>55.3±10.3</td>
<td>0.63</td>
</tr>
<tr>
<td>Sex (M/F, n)</td>
<td>5/19</td>
<td>6/14</td>
<td>0.49</td>
</tr>
<tr>
<td>Duration disease (means±SD)</td>
<td>50.3±41.2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diffuse cutaneous, n (%)</td>
<td>7 (29.2)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anti-Ro antibody, n (%)</td>
<td>8 (33.3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anticentromere antibody, n (%)</td>
<td>14 (58.3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Anti-RNA polymerase III antibody, n (%)</td>
<td>3 (12.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pulmonary-involvement, n (%)</td>
<td>7 (29.2)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gastrienterological involvement, n (%)</td>
<td>8 (33.3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Nodular video-capillaroscopy pattern</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-specific</td>
<td>1 (4.2)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Early</td>
<td>11 (45.8)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Active</td>
<td>8 (33.3)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Late</td>
<td>4 (16.7)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Subjective hearing loss, n (%)</td>
<td>3 (12.5)</td>
<td>3 (15)</td>
<td>0.58</td>
</tr>
<tr>
<td>Tinnitus, n (%)</td>
<td>9 (37.5)</td>
<td>4 (20)</td>
<td>0.41</td>
</tr>
<tr>
<td>Objective hearing loss, n (%)</td>
<td>9 (37.5)</td>
<td>1 (5)</td>
<td>0.02</td>
</tr>
<tr>
<td>Sensorineural hearing loss (%)</td>
<td>7 (29.2)</td>
<td>1 (5)</td>
<td>0.03</td>
</tr>
<tr>
<td>EQ-VAS (means±SD)</td>
<td>63.8±13.1</td>
<td>71±11.0</td>
<td>0.04</td>
</tr>
</tbody>
</table>

Conclusion: Our study found higher prevalence of inner and middle ear pathologies in SSc patients. It is also important to emphasize the relationship found with history of digital ulcer. In these patients, this type of involvement should be considered both during diagnostic and therapeutic procedures. Further investigation is needed for a better understanding of ear damage in these patients.

Disclosure of Interests: None declared


POS0909

THE ROLE OF IMACS CORE SET MEASURES TO ROUTINELY EVALUATE THE QUALITY OF LIFE OF IDIOPATHIC INFLAMMATORY MYOPATHIES PATIENTS IN CLINICAL PRACTICE

C. Cardelli1,2, R. Marinai3, S. Barsotti1, A. Tripoli2, M. Di Battista3, A. Tripoli, L. Carli2, M. Mosca2,3.

1University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 2Azienda Ospedaliero-Universitaria Pisana, Rheumatology Unit, Pisa, Italy; 3Ospedale di Livorno, Medicina Interna, Livorno, Italy

Background: Idiopathic Inflammatory Myopathies (IIMs) are rare, multisystemic and complex diseases, often impacting on patients’ quality of life (QoL). Patient Reported Outcomes (PROs) assess the overall health status of patients, particularly for emotional and functional domains. In clinical practice the administration of PROs might have some limitations, because they tend to be time-consuming and sometimes difficult to be filled in by patients. The International Myositis Assessment & Clinical Studies Group Disease Activity Core Set Measures (IMACS-CSM) are a tool created specifically to assess disease activity and QoL in IIMs.

Objectives: To evaluate the ability of IMACS-CSM in assessing IIMs patients’ QoL in comparison with both generic and IIMs specific PROs.

Methods: Consecutive adult patients with a diagnosis of IIM (2017 EULAR/ACR criteria) were recruited during a scheduled follow-up visit. Demographic and clinical features were recorded (sex, age, disease subset and duration, organ involvement, comorbidities). IIM disease activity was evaluated following International Myositis Assessment & Clinical Studies Group Disease Activity Core Set Measures. To detect anxiety and depression status, HADS was administered to patients, who were also asked to fill in Short-Form 36 Items Health Survey (SF-36). For both HADS-A and HADS-D (all p<0.006, high risk ≥11). Results were reported as means±SD for continuous variables and as percentage for categorical variables. Intergroup comparisons were assessed by using Chi-square, t-test and ANOVA. Pearson coefficient was used to analyse the correlations between variables. P values <0.05 were considered significant.

Results: Fifty-three patients (72% female; mean age 64.8±12.0 years; mean disease duration 7±6.2 years) were enrolled. Thirty-seven (37.7%) showed increased anxiety scores (mean 11.35, min. 8 – max. 17); 10 (50%) borderline and 10 (50%) high risk. Twenty (37.7%) had an increased depression score (mean 11.75, min. 8 – max. 19); 6 (30%) borderline and 14 (70%) high risk. If abnormal scores of both HADS-A and -D were found in 15 patients (28.3%), 17 patients (32.1%) were at risk of developing both conditions together and quite one third was at high risk to develop at least one of them. As expected, these conditions were associated with a concomitant fibromyalgia. Moreover, a compromised QoL and a functional limitation, as evaluated by PGA, HAQ and MMT8, in agreement with SF-36

POS0910

PSYCHIATRIC COMORBIDITIES ASSESSMENT: AN UNMET NEED IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES?

C. Cardelli2, M. Diomedi2, S. Barsotti3, M. Di Battista2, A. Tripoli, C. Cardelli, M. Mosca3.

2Azienda Ospedaliero-Universitaria Pisana, Rheumatology Unit, Pisa, Italy; 3Ospedale di Livorno, Medicina Interna, Pisa, Italy

Background: Idiopathic Inflammatory Myopathies (IIMs) are rare and complex chronic diseases, with a strong impact on patients’ Quality of Life (QoL) in terms of both physical and emotional functioning. Despite its key role in daily life, patients’ emotional status could be difficult to be investigated by physicians. As known, patients with chronic conditions are at higher risk of anxiety and depression, but data about their prevalence in IIMs are still limited. The Hospital Anxiety and Depression Scale (HADS) is a validated questionnaire to evaluate the presence and severity of both anxiety (HADS-A) and depression (HADS-D) in patients.

Objectives: To determine the presence of anxiety and depression in a monocentric cohort of IIMs patients and to evaluate possible correlations with clinical features, disease activity and parameters of QoL.

Methods: Consecutive adult patients with a diagnosis of IIM (2017 EULAR/ACR criteria) were recruited during a scheduled follow-up visit. Demographic and clinical features were recorded (sex, age, disease subset and duration, organ involvement, comorbidities). IIM disease activity was evaluated following International Myositis Assessment & Clinical Studies Group Disease Activity Core Set Measures. To detect anxiety and depression status, HADS was administered to patients, who were also asked to fill in Short-Form 36 Items Health Survey (SF-36). For both HADS-A and HADS-D (all p<0.006, high risk ≥11). Results were reported as means±SD for continuous variables and as percentage for categorical variables. Intergroup comparisons were assessed by using Chi-square, t-test and ANOVA. Pearson coefficient was used to analyse the correlations between variables. P values <0.05 were considered significant.

Results: Sixty patients (65% female, mean age 59.9±13.5 years, mean disease duration 7.7±6.1 years), 37 (61.7%) with polymyositis, 20 (33.3%) with inclusion body myositis, were enrolled. Among IMACS-CSM, the mean HAQ and PGA scores were significantly worse in case of muscle involvement (p<0.017) and oesophageal involvement (p=0.017), respectively; as expected, MMT8 score was associated with muscle involvement (p=0.017); MDAAT score was instead associated with oesophageal dysfunction (p<0.001). No associations were found between IMACS-CSM and other clinical and demographic parameters. FACIT-F correlated positively with MMT8 (r=0.432, p<0.001) and negatively with PGA, HAQ and MDAAT. The mean value of EQ-VAS was lower in SSc group (63.8±13.1) compared to controls (71.1±11.0) (p=0.04), but without significant differences with the changes in the pure-tone or speech audiometry.
DIAGNOSTIC VALUE AND CLINICAL RELEVANCE OF MUSCLE BIOPSY IN PATIENTS WITH SUSPECTED MYOSITIS
K. Kastrati1, N. Naikost Lotli2, M. Tawfik3, E. Gelpi4, R. Hoettberger2, H. Kiener3, D. Aletaha1, M. Bonelli1, H. Radner1. 1Medical University of Vienna, Division of Rheumatology, Department of Internal Medicine 3, Vienna, Austria; 2Suez Canal University, Department of Rheumatology and Rehabilitation, Ismailia, Egypt; 3Medical University of Vienna, Division of Neuropathology and Neurochemistry, Vienna, Austria

Background: Diagnosis of idiopathic inflammatory myopathies (IIM) represents a clinical challenge and muscle biopsy itself is regarded as the cornerstone for diagnostic tool remains inconclusive

Objectives: To determine the diagnostic accuracy and clinical relevance of muscle biopsy in patients with suspected myositis.

Methods: In this retrospective cohort study, histopathological findings of muscle biopsy specimens of adult (≥ 18 years of age) patients with clinically suspected or differential diagnosis of myositis referred from all over Austria to the Medical University of Vienna through the period of 01.01.2007-31.10.2021 were analyzed. Following information were extracted from handwritten assignment sheets: referral department, suspected diagnosis (inflammatory and/or non-inflammatory myopathy), sampling location, demographic, clinical, laboratory and serologic data, and imaging results. Histological findings were grouped in: 1) inflammatory, 2) non-inflammatory (neurogenic, metabolic etc.), 3) inflammatory and non-inflammatory myopathy, and 4) normal. Clinical information on start of immunosuppressive treatment after muscle biopsy could be partly retrieved form electronical medical records (EMR). Sensitivity, specificity, positive (PPV) and negative predictive values (NPV) of histological results were calculated using clinical diagnosis (defined as initiation of immunosuppressive therapy) as gold standard.

Results: 778 muscle biopsy specimens of 762 patients with suspected myositis (49.6% female, mean age of 56 years) were analyzed. Cohort descriptives are displayed in Table 1. Overall, 373/778 (47.9%) muscle biopsies revealed inflammatory features only or had mixed results with non-inflammatory characteristics. Out of 541 samples with suspected diagnosis of myositis, diagnosis was confirmed histologically in 300 (55.5%) cases; 48 (8.5%) specimens additionally showed co-features of non-inflammatory myopathy, whereas 221 (40.3%) were non-inflammatory at all and 15 (2.8%) were normal. Proportion of myositis was more pronounced, when CK was elevated at time of biopsy (Figure 1).

Figure 1. From suspicion to histological verification depending on CK-levels

Out of 237 samples with differential diagnosis of non-inflammatory myopathy in addition to myositis, 53 (22.4%) were histology confirmed as inflammatory only and 20 (8.4%) showed mixed features. 153 (64.6%) biopsies were non-inflammatory only and 8 (3.4%) normal. Samples with no pathological features were observed in 24/778 (2.3%) of the cases, with 0.8% sampling error (no muscle tissue). Of 421/778 (54.1%) patients, clinical data could be extracted from EMR of which 209/421 (49.6%) had histological features of inflammation. In 287/421 (88%) cases, information regarding initiation of immunosuppressive treatment were available on EMR. 224/287 (78%) patients received immunosuppression (steroids and/or disease-modifying anti-rheumatic drug [DMARD]), thus fulfilled clinical diagnosis of myositis. In 155/224 (69.2%) cases, muscle biopsy confirmed histology features of inflammation. Tests on diagnostic accuracy of muscle biopsy using initiation of any immunosuppressive treatment as gold standard were performed. The sensitivity of the test (biopsy) for diagnosing IIM was 71.4% with a specificity of 79.6%. PPV was high (82.8%), whereas NPV low (43.1%).

Conclusion: Less than 50% of biopsy samples with suspected diagnosis of myositis histologically revealed an inflammatory myopathy. The percentage increased when CK levels were elevated. Sensitivity and specificity of muscle biopsy was moderate, when using start of immunosuppressive therapy as gold standard for IIM diagnosis.

REFERENCES:

Table 1: Patients characteristics.

<table>
<thead>
<tr>
<th>No. of biopsy specimens (n)</th>
<th>778</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No. of patients (n)</strong></td>
<td>762</td>
</tr>
<tr>
<td>Gender (female) (n,%)</td>
<td>385 (49.6%)</td>
</tr>
<tr>
<td>Mean age in years (mean±SD)</td>
<td>56.08 ± 15.89</td>
</tr>
<tr>
<td>Referral department (n,%)</td>
<td></td>
</tr>
<tr>
<td>• Neurology</td>
<td>392 (50.5%)</td>
</tr>
<tr>
<td>• Rheumatology</td>
<td>137 (17.7%)</td>
</tr>
<tr>
<td>• Dermatology</td>
<td>52 (6.7%)</td>
</tr>
<tr>
<td>Sampling location (n,%)</td>
<td></td>
</tr>
<tr>
<td>• Proximal upper extremity</td>
<td>177 (22.8%)</td>
</tr>
<tr>
<td>• Proximal lower extremity</td>
<td>434 (55.8%)</td>
</tr>
<tr>
<td>Clinical symptoms:</td>
<td></td>
</tr>
<tr>
<td>• Muscle weakness</td>
<td>51.6%</td>
</tr>
<tr>
<td>• Muscle pain</td>
<td>36.5%</td>
</tr>
<tr>
<td>• Atrophy</td>
<td>8.9%</td>
</tr>
<tr>
<td>• Skin affection</td>
<td>7.0%</td>
</tr>
<tr>
<td>Creatine kinase (CK) levels reported n (%)</td>
<td></td>
</tr>
<tr>
<td>• CK elevated</td>
<td>66.9%</td>
</tr>
<tr>
<td>Manual Muscle Testing (MMT) reported n (%)</td>
<td></td>
</tr>
<tr>
<td>• MMT score (maximum score of 80), mean±SD</td>
<td>48 (6.2%)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

mechanisms, such as mitochondrial abnormalities and metabolic disturbance, contribute to the pathogenesis of myositis. Exercise improves muscle function in IIM patients.  

**Objectives:** To evaluate the effect of activities-of-daily-living, resistance and stability training on metabolic parameters of primary tissue culture myocytes established from muscle biopsies obtained from patients with established IIM.

**Methods:** Seven patients with established IIM underwent a 24-week supervised training focused on activities of daily living, muscle-strengthening and stability. Muscle biopsy was performed before and after the 24-week program in patients, and in healthy controls (n=9). Isolated skeletal muscle cells were grown and differentiated into myotubes for 6 days. After differentiation, the myotubes were cultured for another 24 hours in fresh medium, and then the conditioned media were collected, and the cells were harvested in TRIzol. A relative number of mitochondria was quantified by the ratio between mitochondrial gene (NADH dehydrogenase subunit 1) and reference nuclear gene (lipoprotein lipase) and determined by qPCR. Glucose, pyruvate, lactate, citrate, and fumarate were assessed in a conditioned medium using the comprehensive two-dimensional gas chromatography coupled to time of flight mass spectrometer.

**Results:** Patients significantly improved their muscle strength and endurance during the 24-week training [1]. There was no difference in the relative number of mitochondria in muscle tissue and myotubes between IIM patients and controls. A significant increase in the number of muscle tissue mitochondria was found in IIM patients after 24 weeks of training (p = 0.004), on average twofold. A similar effect was observed in cultured myotubes, with at least 4 of 7 IIM patients showing a twofold increase in mitochondria number. Compared with myotubes from HC, myotubes derived from IIM patients consumed non-significantly more glucose and pyruvate from the culture medium; however, their glucose and pyruvate utilization were significantly reduced as a result of the 24-week training (p = 0.016 and p = 0.030, respectively). Skeletal muscle cells from IIM patients before training intervention did not differ from HC cells in the amount of released lactate; however, the lactate concentration in the conditioned medium from myotubes obtained from patients after the 24-week training was significantly lower (p = 0.016). When measuring citrate cycle products released into the culture medium, no difference in citrate and fumarate secretion was observed between myotubes of myositis patients and myotubes of healthy controls. In contrast, their release was significantly (p < 0.05) lower in myotubes from IIM patients after 24 weeks of training compared to muscle cells isolated prior to intervention.

**Conclusion:** In conclusion, 24 weeks of rehabilitation training in patients with IIM significantly increases the number of mitochondria in muscle tissue. Lower release of lactate and citrate cycle intermediates (citrate and fumarate) by myotubes obtained from patients after training intervention indicates an increase in mitochondrial functional capacity and confirms a positive response to exercise in muscles previously affected by the inflammatory process in IIM.

**REFERENCES:**

**Disclosure of Interests:** This work was supported by the Ministry of Health of the Czech Republic grants nr. NU21-05-00322.

**DOI:** 10.1136/annrheumdis-2022-eular.4176

**POS0914**  
**LATE SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4221

**POS0913**  
**INCREASED HEALTH CARE UTILIZATION IN SYSTEMIC SCLEROSIS PATIENTS WHO HAVE DIGITAL ULCERS**

T. Nevskaya1, L. Martin Calderon2, M. Baron3, J. Pope4 on behalf of Canadian Scleroderma Research Group. 1Western University, Rheumatology, London, Canada; 2Western University, Medicine, London, Canada; 3McGill University, Rheumatology, Montreal, Canada

**Background:** Systemic sclerosis is a multi-system autoimmune disease characterized by fibrosis of the skin and internal organs, and vasculopathy which manifests as pulmonary arterial hypertension and digital ulcers. Digital ulcers are debilitating and painful lesions most commonly present in the digit tips or extensor surfaces of the hands leading to significant morbidity and decreased quality of life. SSC patients with digital ulcers may require increased support and therefore may have greater healthcare resource utilization compared to those patients without digital ulcers.

**Objectives:** We assessed the impact of DUs on resource utilization including hospitalizations, outpatient visits and procedures within a large SSC Canadian registry.

**Methods:** A cohort of patients with SSC and digitals ulcers was derived from the Canadian Scleroderma Research Group registry and matched to controls individually based on sex, age (±3 years), SSC subtype, and disease duration (±2 years). Eligible patients met the 2013 ACR/EULAR criteria (confirmed by an experienced rheumatologist), were 18 years of age, had completed the Resource Utilization Questionnaire (RUQ), and had active digital ulcers at two consecutive annual visits (baseline study visit and at 1st year). The Medsger Disease Severity Scale was used to assess ulcer disease severity. Unadjusted and adjusted regression analyses compared the association between DUs and resource utilization.

**Results:** RUQs in 104 SSC patients with active DUs at two consecutive annual visits were compared with 104 patients without DUs matched 1:1 for age, sex, disease subtype and duration. Over one year, DUs were associated with a higher number of tests (p<0.05) and visits to health professionals, especially to a rheumatologist (p<0.0001) and internist (p<0.003), a greater need for an accompanying person (p<0.05) and aids purchased/received (p<0.05). Having DUs was associated with more severe disease, even after excluding the peripheral vascular domain from a total DSS (9.7±4.5 vs 5.6±2.7, p<0.0001). After adjustment for disease severity in other organs, the presence of DUs remained a significant predictor of more frequent physician visits and more tests (all p<0.05) by linear regression analysis.

**Conclusion:** SSC patients with DUs utilized significantly more healthcare resources per annum even after adjustment for disease severity in other organ systems.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4221

**POS0914**  
**LATE SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A STUDY FROM THE EUSTAR COHORT**


1Tameside and Glossop Integrated Care NHS Foundation Trust, Rheumatology, Tameside, United Kingdom; 2University of Michigan, Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, Michigan, United States of America; 3Hospital Universitario Dr Peset, Department of Rheumatology, Valencia, Spain; 4University Hospital 12 de Octubre, Rheumatology Department, Madrid, Spain; 5Gentofte Hospital, Center for Rheumatology and Spine Diseases, Gentofte, Denmark; 6University of Lille, Department of Internal Medicine and Clinical Immunology, Lille, France; 7University Hospital Tuebingen, Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases and Department of Internal Medicine II (Hematology, Oncology, Immunology and Rheumatology), Tuebingen, Germany; 8Ramos Mejia Hospital, Rheumatology Department, Buenos Aires, Argentina; 9S. Gerardo Hospital, Rheumatology Unit, Monza, Italy; 10University of Lübeck, Department of Rheumatology and Clinical Immunology, University clinic Schleswig-Holstein, Lübeck, Germany; 11Ghent University Hospital, Department of Internal Medicine, Ghent University, Department of Rheumatology, Ghent, Belgium; 12University of Debrecen, Division of Rheumatology, Department of Internal Medicine, Debrecen, Hungary; 13Cliniques universitaires Saint-Luc, Rheumatology Department, Brussels, Belgium; 14University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy; 15University of Zurich, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland; 16Università Politecnica delle Marche, Dipartimento di Scienze Cliniche e Molecolari, Ancona, Italy; 17Oslo University Hospital, Department of Rheumatology, Oslo, Norway; 18Georgetown University, Division of Rheumatology, Department of Medicine, School of Medicine, Washington, United States of America; 19University of Michigan, Scleroderma Program, Ann Arbor, United States of America

**Background:** Skin fibrosis is a cardinal feature of systemic sclerosis (SSc) and associated with significant disability. The early trajectory of skin fibrosis provides evidence for the rheumatic diseases. 2008 Jan 1;67(1):120-3.
insights into the course of the disease including mortality; however, little is known about late skin fibrosis in SSc.

**Objectives:** The aims of our study were to ascertain the prevalence and characteristics of late skin fibrosis in SSc.

**Methods:** We developed and tested three conceptual scenarios of late (>5 years after 1st non-RP sign or symptom) skin fibrosis (Figure 1):

**A.** Worsening and then improvement (>3 mRSS) during the first 5 years, and then worsened again after 5 years (i.e., failure to improve).

**B.** Worsening for the first time after 5 years.

**C.** Worsening in the first 5 years and stayed high after 5 years (i.e., failure to improve).

**Conclusion:** Late skin fibrosis affects approximately 20% of SSc patients >5 years after onset of disease. We have identified different patterns relevant to clinical practice and trial design. Late skin fibrosis is usually due to new worsening or failure of skin to improve. Progression from baseline limited to diffuse cutaneous SSc was associated with anti-Scl-70 antibodies, and anticientromere antibodies were protective. Late skin fibrosis is a neglected manifestation of SSc and warrants further investigation including to determine clinical outcomes and optimal therapeutic strategy.

**Acknowledgements:** On behalf of EUSTAR collaborators.

**Disclosure of Interests:** Michael Hughes, Pfizer (to University of Michigan).

**S. Nakashima**

**H. Nakashi**

**H. Shimada**

**R. Wakiya**

**T. Kato**

**T. Miyagi**

**M. Kato**

**T. Miyagi**

**M. Mizusaki**

**T. Kameda**

**H. Dobashi**

**Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa, Japan**

**Kagawa University Hospital, Department of Clinical Laboratory, Kagawa, Japan**

**Background:** Myositis-associated antibodies (MAA) and myositis-specific antibodies (MSA) have been associated with clinical manifestations of dermatomyositis and polymyositis, including interstitial lung disease (ILD), myopathy, malignancy, arthritis, and skin rashes. Among them, anti-ARS and anti-MDA5 antibodies are strongly associated with complications of ILD that are associated with life expectancy. It has been reported that anti-Ro52 antibody affects severity of myositis and ILD. (1) Based on these findings, it is possible that autoantibodies possessing features of ILD associated with dermatomyositis and polymyositis may be predictive.

**Table 1. Impact of autoantibody status on progression from baseline limited to diffuse cutaneous SSc (dcSSc).**

<table>
<thead>
<tr>
<th>Autoantibody</th>
<th>Progressed to dcSSc (n=23)</th>
<th>Not progressed to dcSSc (n=47)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticientromere</td>
<td>+ve 2/22 (9.1%)</td>
<td>19/42 (45.2%)</td>
<td>0.0034</td>
</tr>
<tr>
<td></td>
<td>-ve 20/22 (90.9%)</td>
<td>23/42 (54.8%)</td>
<td></td>
</tr>
<tr>
<td>Anti-Scl-70</td>
<td>+ve 15/23 (65.2%)</td>
<td>14/44 (31.8%)</td>
<td>0.0088</td>
</tr>
<tr>
<td></td>
<td>-ve 8/23 (34.8%)</td>
<td>30/44 (68.2%)</td>
<td></td>
</tr>
<tr>
<td>Anti-RNA-Polymerase-III</td>
<td>+ve 0/12 (0.0%)</td>
<td>1/22 (4.5%)</td>
<td>1.0000</td>
</tr>
<tr>
<td></td>
<td>-ve 12/12 (100%)</td>
<td>21/22 (95.5%)</td>
<td></td>
</tr>
</tbody>
</table>
**Objectives:** The purpose of this study is to clarify the relationship between MSA/MAA and clinical features of ILD complicated by dermatomyositis and polymyositis.

**Methods:** We retrospectively analyzed IIMs patients diagnosed according to Peter & Bohan’s diagnostic criteria in our hospital from 2011 to 2018. The presence of 14 MSA / MAA (Jo1, PL12, PL7, EJ, OJ, KS, Mi2, MDAS, TIF1, SRP, PM-ScI70, 100, Ku, Ro52) was measured using ELISA (MESACUP, MBL, Japan) and line blot (EUROLEONE myositis profile, EUROMimm, Germany). Clinical characteristics, including HRCT imaging findings, were extracted from medical records. HRCT imaging findings were analyzed by multiple radiologists. The association between the extracted clinical features and the MSA / MAA hostility was analyzed.

**Results:** Seventy-eight cases of IIM were included in the analysis. The frequency of ILD complications was 53/78 (68%), and 60% of ILD complications were ARS antibody positive. The complication rate of ILD in MDAs- and ARS-positi-

cases was 100% (3/3 cases) and 94% (32/34 cases), respectively. These MDs- and ARS-positive patients with ILD had rapidly progressive ILD. One of the three MDs antibody-positive-RPILD cases died, but none of the four ARS antibody-positive-RPILD cases died. However, in patients with multiple MSA or MAA including ARS, three cases had rapidly progressive ILD, and none died. The analysis of the presence of Ro52 antibody, it was detected in 46% (36 cases) of all cases, but in 74% of anti-ARS antibody positive cases.

In the analysis of ILD patterns by radiologists using HRCT, fibrosing NSIP (NSIS), fibrosing OP (OP), and UIP were the most frequent in that order. Analysis of the presence of Ro52 antibody, it was detected in 46% (36 cases) of all cases, but in 74% of anti-ARS antibody positive cases.

**Conclusion:** The performance of anti-ARS antibody-positive ILD associated with dermatomyositis and polymyositis was associated with fibrosis by analysis of HRCT patterns, and the prognosis was confirmed to be poor. In addition, the UIP pattern, which is strongly associated with fibrosis, was found to be associated with anti-Ro52 antibody. In the treatment of ILD, which is strongly associated with the prognosis of dermatomyositis and polymyositis, it may be necessary to consider antibiotic treatment for patients with anti-ARS antibody and anti-Ro52 antibody positivity.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4253

---

**A 10-YEAR JOURNEY OF CARING FOR PATIENTS WITH SYSTEMIC SCLEROSIS: FOLLOW-UP DATA ON DISEASE DURATION OF THE LEIDEN CCISS COHORT.**

S. Liem1, S. Ahmed1, J. Ciaffi2, L. Beaart-van de Voorde1, A. Schouffoer3, M. D’orazio1, A. Lackner1, S. Zenz1, A. Haidmayer2, J. Gretler1, S. Kielhauser1, J. Thiel1, H. P. Brezinsek1, F. Fürst-Moazedi1, 1Medical University of Graz, Graz, Austria; 2Hospital Southern Styria, Graz, Austria; 3Haga Teaching Hospital, Rheumatology, Den Haag, Netherlands; 4Leiden University Medical Center; Pulmonology, Leiden, Netherlands; 5Leiden University Medical Center, Cardiology, Leiden, Netherlands

**Background:** Combined Care in Systemic Sclerosis (CCISS) is a prospective cohort of patients referred to Leiden University Medical Center for Raynaud’s Phenomenon (RP), a suspicion of systemic sclerosis (SSc) or a connective tissue disease. This cohort is characterized by its standardized and extensive annual follow-up. Since initiation of the cohort in 2009, diagnostic criteria for SSc have been updated leading to a higher sensitivity for early SSc (ACR 2013 criteria). A recent Dutch study showed that there is a gap to time of diagnosis between men and women.

**Objectives:** To determine whether 1. time between first disease symptoms and diagnosis has changed over time, and 2. disease characteristics of SSc at first presentation in an expert clinic have changed over time for the total cohort, and between male and female patients.

**Methods:** Patients included in the CCISS cohort undergo annual evaluation and clinical, laboratory, and imaging variables are systematically recorded. For this study, patients fulfilling the ACR/EULAR 2013 criteria were included, and categorized into three groups based on the cohort entrance year: 1) 2010 – 2013, 2) 2014 – 2017, and 3) 2018 – 2021. SSc patients with a baseline visit in 2009 (n=85) were excluded as these patients were often not newly referred. Disease duration was defined by months since first RP, since first non-RP symptom and months between first date of diagnosis by a physician and first non-RP symptom. Disease characteristics included presence of interstitial lung disease (ILD), pulmonary arterial hypertension, digital ulcers (DU), diffuse cutaneous SSc, anti-topoisomerase and anticientromere antibodies. At baseline, disease duration and disease characteristics were compared between the three groups using appropriate tests. In addition, disease duration was compared between males and females in the three groups.

**Results:** In total, 643 SSc patients were included of whom 229 (36%) had their baseline visit from 2010 until 2013, 207 (32%) from 2014 until 2017, and 207 (32%) from 2018 until 2021. The proportion of female patients was significantly higher in the 2010 – 2013 group compared to the 2014 – 2017 and 2018 – 2021 group (Table 1). Over time, disease duration defined by RP duration and non-RP duration decreased as well as time between diagnosis and first non-RP symptom (Table 1). The proportion of patients presenting with ILD and DU was highest in the first group (Table 1).

**Table 1.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>53 (15)</td>
<td>57 (14)</td>
<td>55 (14)</td>
<td>0.003</td>
</tr>
<tr>
<td>Female, %</td>
<td>86</td>
<td>76</td>
<td>75</td>
<td>0.010</td>
</tr>
<tr>
<td>RP duration, months (IQR)</td>
<td>122 (46 – 240)</td>
<td>93 (20 – 202)</td>
<td>67 (20 – 210)</td>
<td>0.003</td>
</tr>
<tr>
<td>Non-RP duration, months (IQR)</td>
<td>43 (16 – 227)</td>
<td>20 (5 – 112)</td>
<td>12 (6 – 54)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary arterial hypertension, %</td>
<td>34</td>
<td>43</td>
<td>49</td>
<td>0.092</td>
</tr>
<tr>
<td>Diffuse cutaneous SSc, %</td>
<td>19</td>
<td>23</td>
<td>26</td>
<td>0.073</td>
</tr>
<tr>
<td>Intertstitial lung disease, %</td>
<td>43</td>
<td>31</td>
<td>31</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Digital ulcers, %</td>
<td>20</td>
<td>13</td>
<td>11</td>
<td>0.041</td>
</tr>
</tbody>
</table>

In both male and female SSc patients, disease duration and time between diagnosis and first non-RP decreased over time with a longer time in females for all durations which was significantly different for time between first RP and non-RP in 2014-2017 and 2018-2021 (Figure 1).

**Conclusion:** Over time, we observe a decrease in disease duration and in SSc patients presenting with ILD or DU at cohort entrance. Our results indicate increased awareness of early SSc and identification of SSc patients before severe complications have occurred. At the same time our results show the urge for specific attention to improve timely diagnosis in female SSc patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4339

---

**TRANSTHORACIC LUNG SONOGRAPHY (LUS) – USEFUL SURVEILLANCE TOOL IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE?**

M. D’orazio1, A. Lackner1, S. Zenz1, A. Haidmayer2, J. Gretler1, S. Kielhauser1, J. Thiel1, H. P. Brezinsek1, F. Fürst-Moazedi1, 1Medical University of Graz, Rheumatology and Immunology, Graz, Austria; 2Hospital Southern Styria, Internal Medicine, Bad Radkersburg, Austria

**Background:** The Interstitial lung disease (ILD) represent a major cause of mortality in Systemic sclerosis (SSc). Validated methods for screening and therapy monitoring of SSc-ILD are needed. In the recent literature, the transthoracic lung sonography (LUS) emerges as a reliable tool for the early detection of lung alterations. It was recently reported that SSc-ILD-patients have thicker artefacts reflecting the pleuralaire compared with SSc-patients without ILD, but it still remains unknown if the thickness of the pleuraliare changes with a proper therapy response.
**Objectives:** The aim of the study was to compare the thickness of the pleurale line of SSC-IDL-patients without biological Disease Modifying Anti-Rheumatic Drugs (bDMARDS) with those successfully treated with bDMARDS in order to establish if LUS can be a reliable tool in SSc-IDL. Additionally, since our Grazer Schema (Mycofenolat mofetil (MMF)+ rituximab (RTX)) 50 mg i.v. in week 0 and 2 every 3 months) is successful in our clinic since more than 10 years in patients nonresponding to methotrexate (MTX) or cyclophosphamide, we report 10 years follow-up data of 5 Patients before and after receiving that schema.

**Methods:** 29 prospectively enrolled SSc-patients were assessed according to the European League Against Rheumatism Scleroderma Trial and Research standards. Written informed consent was obtained from all patients and the study was approved by the Ethics Committee of Graz. Validated clinical scores, such as the scleroderma disease activity (SSCAS) and the scleroderma disease severity scale (SScSS) were assessed. The thickness of the pleurale was detected with LUS. The presence of ILD was assessed by high-resolution computed tomography. Twenty-five SSc-patients enrolled between 2008 and 2009, who underwent LUS with the same technical instruments and some of the same operators, were taken as a control group since they were untreated yet or were not assuming bDMARDS(1).

**Results:** Of the 29 SSc-patients (27 females/2 males) enrolled between 2019 and 2020, seventeen patients had radiographic signs of ILD (SSc-ILD+2019-20, n=17). Until the LUS was performed, all SSc-ILD+2019-20 showed a good clinical response to the therapy with RTX in combination with MMF. Of the 25 SSc-patients enrolled in our previous study, (n=25; 23 females/ 2 males), twelve of these patients had radiographic signs of ILD (SScILD+2009-10, n=12); 7 were under MTX or Cyclosporin and 5 were untreated. Additionally, data collected from 5 SSc-ILD+2009-2010 at baseline were analysed in a 10- years- follow up. As expected, SSc-ILD+ patients had a thicker pleurale than SSc-ILD- patients. The pleurale-thickness was significantly thinner in patients under MMF and RTX compared to the pleurale of patients without bDMARDS (1,8 mm ± 0,7 Vs 0,95 ± 0,31; p < 0,00). Interestingly those patients reported less frequently dry cough or dyspnoea, showing that the lower pleura thickness could be associated with a better clinical outcome. In a 10 Year follow-up after continued treatment with MMF and RTX, a significant reduction of the thickness of the pleura could be found (Mean 0.68 ± 0,2 VS 1,5 ± 0,4; p < 0,00). Interestingly, such significant improvement could not be found in all of these 5 patients receiving our Grazer Schema. Remarkably, the pleurale-thickness was comparable to the thickness of the pleura of SSc-ILD-patients. This finding shows that the increase in thickness of the pleurale can be totally reversible under treatment.

**Conclusion:** Due to the encouraging validity, reliability and simplicity of LUS, it has been increasingly considered as an excellent screening tool for SSc-ILD. Its sensitivity to reveal parenchyma and pleura changes over time in treated patients, make it also a helpful and safe methodology to follow up SSc-ILD patients.

**REFERENCES:**

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4430

**POS0918**
**TARGET-CONTROLLED INFUSION (TCI) WITH PROPOFOL AND REMIFENTANIL FOR PROCEDURAL SEDATION AND ANALGESIA (PSA) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) UNDERGOING AUTOLOGOUS FAT GRAFTING PROCEDURES**

**R. Femenia,** A. Spinella,* A. Carratta, M. De Pinto, M. Starnoni, E. Bertellini, G. De Santis, C. Salvareda, D. Giuglioli,* 1University of Modena and Reggio Emilia, Department of Anesthesia and Intensive Care, Modena, Italy; 2University of Modena and Reggio Emilia, Department of Urology, Modena, Italy; 3University of Modena and Reggio Emilia, Department of Plastic Surgery, Modena, Italy; 4University of Modena and Reggio Emilia, Modena University, Italy; 5University of Modena and Reggio Emilia, Division of Plastic Surgery, Modena, Italy; 6University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences of Children and Adults, Modena, Italy; 7University of Modena and Reggio Emilia, Department of Plastic Surgery, Modena, Italy

**Background:** Systemic Sclerosis (SSc) is an autoimmune disease characterized by vascular alterations and fibrosis. Difficult airway management, peripheral venous access and the presence of anti-collagen antibodies are challenging. Therefore, performing general anesthesia or moderate to deep sedation in these patients can be challenging. A high psychiatric burden is also common. These conditions, in association with a history of chronic pain, make even the local anesthesia procedure less effective than usual. Oral/digital autologous fat grafting approaches may improve aesthetic/functional aspects in SSC but the surgical procedure itself is painful and requires proper sedation. Target-Controlled Infusion with propofol (hypnotic) and remifentanil (opioid) is a well consolidated anesthesia technique and could be the best Procedure Sedation and Analgesia strategy to tolerate these interventions.

**Objectives:** Developing a new Procedural Sedation and Analgesia-PSA protocol to obtain moderate to deep sedation in Day Surgery environment to allow complete analgesia, amnesia and safe discharge in SSc patients undergoing autologous fat grafting procedures.

**Methods:** Eighteen-18 SSc patients referring to the Scleroderma Unit of our University Hospital were asked for oral/digital autologous fat grafting procedures between July and December 2021. A proper anaesthesiology schedule was assessed by an expert anesthesiologist of the team. After informed consent acquisition, patients were monitored with ECG/SpO2/Non Invasive Blood Pressure-NIBP. A peripheral intra-venous line with an ultrasound probe was placed if needed and TCI was started. Patients were maintained in spontaneous breathing and supplementary oxygen (4l/min) with a non-rebreathing cannula. The use of TCI pumps for the delivery of propofol and remifentanil allowed trained anesthesiologists to control and adjust the level of sedation and analgesia. The synergy between both propofol and remifentanil is well known, main risk for such technique is to oversedate patients resulting in respiratory depression and hypotension. Bispectral Index-BIS was used to monitor sedation level starting from 80-80, then tailoring the infusion according surgical needs. TCI was stopped at the end of surgery. Vital parameters were registered every 5 minutes and potential complications were monitored (hypotension-PAS<30% of basal line, hypoxia-SpO2<92%). Paracetamol 1g/ketorolac 15mg were administered for postoperative analgesia. A simplified satisfaction questionnaire based on LPPSq was also administered before discharge.

**Results:** All subjects have successfully undergone surgery and no hospitalization after the procedures was needed. A peripheral blood desaturation (SpO2<90%) was registered as main complication in 4 subjects, promptly relieved through nasal cannula replacement. One patient registered transient hypotension (decrease in systolic blood pressure>30% below baseline) without vasoactive drugs need. Main time to recovery of consciousness was 6.3 minutes (range 3-11). Two patients experienced transient pain and nausea, 1 itching, and 1 subjective difficulties in breathing/taking some minutes after the surgery with spontaneous resolution. All patients gave their consent to perform the same approach in the future.

**Conclusion:** TCI of propofol and remifentanil might be successfully used to ensure procedural sedation and analgesia in SSC surgical settings in presence of a skilled anesthesiologist. Further data are required to assess the incidence of possible major complications and patients’ satisfaction.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4569

**POS0919**
**MOLECULAR AND BIOLOGICAL PATHWAYS OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: IMMUNOHISTOCHEMICAL INVESTIGATIONS FROM THE SCLERO-BREAST STUDY**

A. Spinella,* A. Tosi,* C. Isca,* M. De Pinto,* C. Vacchi,* L. Magnani,* F. Lumetti,* P. Macri,* G. Ficara,* L. Fabbiani,* A. Iannone,* E. Gasparini,* S. Piana,* L. Cortesi,* G. De Santis,* A. Maiorana,* M. Dominici,* C. Salvareda,* D. Giuglioli,* 1University of Modena and Reggio Emilia, Scleroderma Unit, Rheumatology Unit, Modena, Italy; 2University of Modena and Reggio Emilia, Department of Oncology and Hematology, Modena, Italy; 3University of Modena and Reggio Emilia, Department of Medical and Surgical Sciences of Children and Adults, Modena, Italy; 4AUSL-IRCCS of Reggio Emilia, Rheumatology Unit, Reggio Emilia, Italy; 5University of Modena and Reggio Emilia, Pathology Unit, Reggio Emilia, Italy; 6University of Modena and Reggio Emilia, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Transplant Surgery, Oncology and Regenerative Medicine, Modena, Italy; 7AUSL-IRCCS of Reggio Emilia, Department of Oncology, Reggio Emilia, Italy; 8AUSL-IRCCS of Reggio Emilia, Pathology Unit, Reggio Emilia, Italy; 9University of Modena and Reggio Emilia, Division of Plastic Surgery, Modena, Italy

**Background:** Systemic Sclerosis (SSc) is a life-threatening connective tissue disease characterized by endothelial dysfunction, autoimmune abnormalities and aberrant fibrosis. Several reports have described an increased risk of cancer in SSc compared to general population, including breast cancer (BC). The relationship between BC and SSc has long been discussed with contradictory results. In our recent Sclero-Breast study we analyzed clinical-pathological features of BC in SSc; we finally observed the development of BC with early stages and good prognosis among these patients. The aim of this project was to explore the immunohistochemical background and to study the expression of potential biomarkers involved in the molecular pathways at the basis of SSc and BC etiopathogenesis as update analysis from the Sclero-Breast study.

**Methods:** Our observational multicenter retrospective study, performed at Modena University Hospital and Reggio Emilia Hospital in northern Italy, enrolled 33 SSc women with a personal history of BC between January 2017 and December 2018. Clinical and pathological characteristics of BC and SSc were collected. For 22 patients, BC tissues and 9 patients SSc were assessed by specific antibodies to evaluate biomarkers and pathways potentially involved. The antibodies used included: P5K/MTOR/GFP/FRG2/PDGF/PDGFR/VEGF/EGFR/ IL-6/CFLA/IL-D1. We also reported TILs percentage (stromal tumor-infiltrating
lymphocytes) of each sample. The following scores were assigned for general IHC analysis: (-) negative, (1+) positive tumor cells <20%, (2+) positive tumor cells 20-50%, (3+) positive tumor cells >50%. For PD-L1 we considered a positivity in case of PD-L1 expression ≥1% in infiltrating inflammatory cells. For TILs quantification we applied the score: 0 (negative), ≤ 50% (low-medium expression), >50% (high expression).

**Results:** The first IHC analysis was performed on the samples of invasive BC patients (20 pts) and showed a prevalence of high PIIK expression (score of 3+ in 55% of cases) with mTOR overexpression in 45%. A PD-L1 positivity was detected in 30%, with high TILs expression in 35%. Biopsies from the 2 pts with ductal carcinoma in situ were characterized by a negativity of almost all parameters, except for a medium-high TILs expression reported (40%/90% respectively). See Figure 1. IHC analysis was also performed according to BC subtypes. The group of HR+/HER2 negative showed high PIIK expression (score 3+) in most of cases (59%) with mTOR overexpression in 50%. CTLA-4 and PD-L1 were positive in 25%, with high TILs expression in 25%. HER2 positive patients showed a high PIIK positivity in 50% of cases with mTOR positivity (score 3+) in 25% and high TGFβ expression (score 3+) in 25%. PD-L1 was positive in 50% with high TILs expression in 25%. In Triple Negative group, PI3K overexpression was found in 75% of pts with half of cases represented by mTOR score 3+. PD-L1 was positive in 50% with high TILs representation (80% of total cell count) in 50% of pts.

**Figure 1.** IHC analysis and TILs% expression in histological samples of SSC patients with invasive BC.

**Conclusion:** According to our results, SSC patients with BC showed high positivity for PD-L1 and high TILs representations in all subtypes. Furthermore, the high expression of PIIK, did not always correlate with mTOR overexpression. Further investigation into bigger numbers is needed; however, these aspects seem to confirm that SSC subjects might develop BC at good prognosis, suggesting again a de-esclation strategy of cancer therapies. Finally, the possibility to personalize oncological targeted treatments in this subset of fragile patients could be promising.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4603

**POS0920**

**THE EFFECT OF COVID-19 PANDEMIC ON IDIOPATHIC INFLAMMATORY MYOSITIS PATIENTS – A SINGLE CENTRE’S EXPERIENCE**

T. G. Griger1, A. Vincze1, B. Miltényi-Szabó1, Z. Varga1, M. Nagy-Vincze1, Z. Griger1. 1University of Debrecen, Faculty of Medicine, Department of Internal Medicine, Division of Clinical Immunology, Debrecen, Hungary

**Background:}** Pandemic caused by severe acute respiratory syndrome coronavi-

**Methods:** We retrospectively identified the confirmed COVID19 positive patients and assessed the symptoms, disease course and outcome on 01/06/2021 then patients were prospectively followed. Incidence and complications of vaccination were determined by questionnaires. Anti-SARS-CoV-2 S enzyme electrochemiluminescent immunoassay has been used to assess seroconversion, which measures total antibody (IgM and IgG) to the SARS-CoV-2 S protein and SARS-CoV2 N protein. Disease activity was determined by physician global activity.

**Results:** A total of 176 patients were screened and 101 participated in the study. By 01/06/2021, the COVID infection rate was 34.7% (mean age: 49.54 years, 72.72% women), which was significantly higher than the national prevalence at that time (8.2%). A third of these infections occurred asymptotically or mild but 20% of the infected patients were hospitalized, one patient died. Longer disease duration (8.67 vs. 17.87 years; p=0.003) and higher incidence of anti-Jo1 antibody (57% vs. 10% p=0.018) were significantly associated with hospitalization. All of COVID infected patients became seropositive regardless of immunosuppressive therapy or symptoms severity. 33.4% of the patients received anti-SARS-CoV-2 vaccine. 72.3% of patients received any recurrence. Every procedure was performed under local anaesthesia and appropriate analgesic therapy. A high degree of compliance and satisfaction was obtained. This procedure could be repeated by trained rheumatologists every 3 weeks in our Clinic. The aim of this repeated debridement was to promote the progression of the granulation tissue inside the dead tissue of the finger. Autologous fat grafting consists of a surgical procedure of ADSCs implantation at the base of the finger. It is performed in order to empower the neurovascular entity, tendon, and appropriate analgesic therapy. A high degree of compliance and satisfaction of all patients was noted.

**Conclusion:** Finger amputation in Systemic Sclerosis should be avoided. This traumatic surgical procedure is responsible for microvascular damages worsening SSC-related vasculopathy. Stump ulcers often occurs and wound healing usually takes place by secondary intention. In our experience, the combination of bone shaving and autologous fat grafting has proven to be effective and safe in preserving the maximum amount of viable tissue and obtaining a long-lasting result in treated SSC patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4729
**Table 1. Effectiveness and safety of hf-SCIg treatment in a cohort of patients with IIM**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>hf-SCIg beginning</th>
<th>3 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>N patients with available follow-up data</td>
<td>23</td>
<td>20*</td>
<td>19*</td>
</tr>
<tr>
<td>MRC score §</td>
<td>4 (3-4)</td>
<td>4 (5)</td>
<td>4 (5-6)</td>
</tr>
<tr>
<td>Creatine kinase, U/L §</td>
<td>134 (24-283)</td>
<td>118 (77-308)</td>
<td>130 (84-222)</td>
</tr>
<tr>
<td>ESR, mm/h §</td>
<td>21 (15-28)</td>
<td>30 (25-43)</td>
<td>31 (23-39)</td>
</tr>
<tr>
<td>CRP, mg/dL §</td>
<td>0.2 (0-1.05)</td>
<td>0.3 (0-1.05)</td>
<td>0.3 (0-1.03)</td>
</tr>
<tr>
<td>Prednisolone dosage, mg/day §</td>
<td>5 (4-12.5)</td>
<td>7.5 (5-10)</td>
<td>5 (7-27)</td>
</tr>
</tbody>
</table>

*Disclosure of Interests: None declared*

**DOI:** 10.1136/annrheumdis-2022-eular.4884

**POS0223**

**EXTRACELLULAR VESICLES AS POTENTIAL BIOMARKERS OF EARLY DISEASE STAGE IN SYSTEMIC SCLEROSIS**

J. Colic1, I. Pruner2, N. Damjanov2, A. Antovic3, M. Selik Buškica3, A. Antovic3

1Institute of Rheumatology, Department of Rheumatology Unit, Belgrade, Serbia; 2Karolinska Institute, Department of Molecular Medicine and Surgery, Stockholm, Sweden; 3Institute of Rheumatology, Department of Rheumatology Unit, Former Director of the Institute, Belgrade, Serbia; 4Institute of Rheumatology, Department of Rheumatology Unit, Head of Clinic IVb Department, Belgrade, Serbia; 5Karolinska Institute, Department of Medicine, Rheumatology Unit, Stockholm, Sweden

**Background:** Extracellular vesicles (EVs) are membrane-coated vesicles most often generated from the vasculature and circulating blood cells upon cell activation and during the early phase of apoptosis (1).

**Objectives:** To evaluate the concentration of different subpopulations of EVs in plasma from patients with SSC in relation to the disease duration and to the markers of endothelial injury.

**Methods:** Our study included 59 SSC patients (36 limited (ISSc) and 23 diffuse cutaneous (dSSc)) and 46 healthy age and gender matched controls subjects. Disease duration less than 3 years in patients with dSSc and less than 5 years in those with ISSc was considered as early disease stage. Clinical evaluation of patients was performed. EVs were analysed with flow cytometry after staining platelet poor plasma with fluorescent cell-specific monoclonal antibodies. The concentration of following phosphatidylserine-positive EVs (PS+ EVs) were analyzed: total EVs, endothelial EVs (EVs; CD144+), platelet EVs (PEVs; CD42b+), monocytes EVs (LEVs; CD14+), EVs expressing ICAM1 (CD54+), VCAM1 (CD106+) and P selectin (CD62p+). Serum levels of EVs, VCAM1 and P selectin were determined with ELISA.

**Results:** Median disease duration of our cohort was 4 (0-29) years (early ISSc 20(36); 2.5 (0-4.5) years; early dSSc [11;23]; 10 (1-30) months). All types of investigated EVs were significantly elevated in SSC patients compared to controls (p<0.05). Patients with early disease stage had significantly increased levels of all PS+EVs compared to HC (p<0.05). Moreover, the levels of EVs expressing ICAM1 and VCAM1 showed good validity in identifying patients with early disease stage (AUC 0.7, p<0.01). PEVs were increased in early dSSc compared to early ISSc; but the difference did not reach statistical significance (p=0.07). There was a correlation between serum levels and the levels of EVs expressing specific adhesion molecules (ICAM1: r=0.7, p=0.01; VCAM1: r=0.7, p=0.01; P selectin: r=0.7, p=0.01), only within the group with early dSSc subtype of the disease. Further correlations were detected between ICAM1+EVs with either mRSS (r=0.07, p=0.91) or EULAR activity index (r=0.07, p=0.02) among patients with early dSSc.

**Conclusion:** Increased levels of circulating EVs of different cell origin were present in patients with early SSC. EVs expressing either ICAM1 or VCAM1 could be novel biomarkers of early disease. EVs expressing ICAM1 showed association with severity of skin involvement and disease activity in patients with early dSSc giving insight into their role in the pathogenesis of SSC.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4884

**POS0224**

**THE ROLE OF RAYNAUD’S PHENOMENON ON MATERNAL AND FETAL OBSTETRICAL OUTCOMES**

F. Bellis1,2, V. Codulțo3, B. L. Palermo4, F. Bottazzò5, A. Biglia5, C. Bellinger5, F. Benuenti1, A. Spinillo1, C. Montecucco5, G. Zanframundo2, L. Cavagna2, 1Maurizio Umberto I Hospital, Rheumatology Unit, Turin, Italy; 2IRCCS Policlinico S. Matteo Foundation and University of Pavia, U.O.C. Reumatologia, Pavia, Italy; 3IRCCS Policlinico S. Matteo Foundation and University of Pavia, Department of Obstetrics and Gynecology, Pavia, Italy

**Background:** It is established that Raynaud’s phenomenon (RP) may influence pregnancy outcomes when secondary to rheumatic conditions (1,2). Data on the impact of primary RP (pRP) on pregnancy are very limited.

**Objectives:** To retrospectively evaluate the impact of pRP on pregnancy outcomes.

**Methods:** Women with pRP included in the study. They were compared with a group of women affected by UCTD with RP, and by UCTD without RP. These women were assessed and followed at our outpatient clinic from January 2011 to October 2020 and they did not exhibit an evolution to a UCTD or to a definite CTD during at least one-year follow-up. Antiphospholipid antibody positivity, twin pregnancies and voluntary termination of pregnancy were exclusion criteria.

Women with pRP were also compared with a group of healthy pregnant women

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4827
nullified by our gynaecologist during the first trimester of pregnancy. Maternal and foetal outcomes were retrospectively recorded. ANOVA or the Kruskal-Wallis test for continuous variables, and the Chi2 test or the Fischer exact test for categorical were performed (level of significance: P<0.05). In the post-hoc analysis we used the Mann-Whitney test (quantitative variables) or with the Chi2 test (Fischer exact test (qualitative variables), applying the Bonferroni correction with pRP women as a reference group (level of significance: p<0.0167).

Results: The analysis included 188 women with a total of 375 pregnancies divided in 4 groups:
- Group “pRP”: 46 women with RP without secondary causes, and a total of 106 pregnancies (reference group).
- Group “RP-UCTD”: 48 UCTD women with RP and a total of 88 pregnancies.
- Group “UCTD”: 37 UCTD women without RP and a total of 88 pregnancies.
- Group “HC”: 57 healthy women with a total of 93 pregnancies.

The reference group did not differ from the others regarding age at conception. Prophylactic acetylsalicylic acid was administered during pregnancy to 9% of patients with pRP compared to 1% in HC (p=0.010). In contrast, in the RP-UCTD this percentage was significantly higher (32%, p<0.001) than in pRP.

pRP group showed an increased rate of 1st trimester miscarriages (33% vs 16%, p=0.006, OR 2.05 and 95%CI 1.05-3.98), a lower median birth weights (3038 vs 3358 g, p=0.002), a higher rate of infants with a birth weight <10 percentile (21% vs 3%, p=0.001, OR 8.36 and 95% CI 1.85 - 37.84) with respect to HC. There was no statistically significant difference between the reference and the UCTD groups. No statistically significant differences were observed when considering obstetrical outcomes (eg: mode of delivery, median gestation duration, gestational diabetes mellitus, hypertensive disorder of pregnancy, premature rupture of membranes, oligo-anhydramnion).

Conclusion: Our studies show that pRP in a retrospective cohort has an impact on pregnancy outcomes, with significantly more miscarriages and lower birth weight infants compared to HC. Importantly, pregnancy outcome in pRP women did not differ with respect to UCTD with and without RP conditions generally associated to maternal morbidity, but in the RP-UCTD group prophylactic acetylsalicylic acid was more commonly prescribed. Further prospective studies aiming at evaluating these differences and at identifying the appropriate follow-up and the possible benefit from the use of prophylactic acetylsalicylic acid during pregnancy in RP are necessary.

References:
Disclosure of Interests:

Having presented this data at an international conference in 2019, we acknowledge that it was not often documented. Patients don’t always report symptoms unless targeted questions are asked. A clinical proforma would be invaluable, leading to an increased awareness amongst both practitioners and patients of the potential clinical manifestations. Having presented this data locally we have now introduced such a proforma and will re-evaluate clinical practice in the future. Sharing this information will hopefully help improve patient care elsewhere.

REFERENCES:


Table 1.

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regurgitation</td>
<td>1 case - not investigated due to pre-existing dysmotility</td>
</tr>
<tr>
<td>Nausea</td>
<td>0 cases</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0 cases</td>
</tr>
<tr>
<td>Heartburn</td>
<td>4 cases – 3 on PPIs, 1 gastroscopy arranged</td>
</tr>
<tr>
<td>Dysphagia</td>
<td>6 cases – 2 of known dysmotility, 3 not investigated</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>2 cases – not investigated</td>
</tr>
<tr>
<td>Bloating</td>
<td>1 case – not investigated</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>0 cases</td>
</tr>
<tr>
<td>Faecal incontinence</td>
<td>1 case – MRI arranged for query small bowel obstruction</td>
</tr>
<tr>
<td>Constipation</td>
<td>4 cases – 1 longstanding issue, 1 MRI arranged, 2 not investigated</td>
</tr>
<tr>
<td>Weight loss</td>
<td>1 case – not investigated</td>
</tr>
</tbody>
</table>

Conclusion: The piloting of our proforma of the GI assessment of patients with scleroderma has identified that the documentation of GI symptoms was poor. We don’t know whether GI symptomology was discussed during assessment however it’s evident that it was not often documented. Patients don’t always report symptoms unless targeted questions are asked. A clinical proforma would be invaluable, leading to an increased awareness amongst both practitioners and patients of the potential clinical manifestations. Having presented this data locally we have now introduced such a proforma and will re-evaluate clinical practice in the future. Sharing this information will hopefully help improve patient care elsewhere.

REFERENCES:


Disclosure of Interests: None declared


POS0927 CORONARY ARTERY CALCIFICATION IN SYSTEMIC SCLEROSIS: EVALUATION OF CARDIOVASCULAR RISK AND CLINICAL OUTCOME

S. Sciaccà1, C. Rotondo1, A. Corrado1, D. Ceci1, F. P. Cantatore1, 1University of Foggia, Rheumatology Unit, Department of Medical and Surgical Sciences, Foggia, Italy

Background: The primary prevention of cardiovascular disease (CVD) is a priority element of the worldwide health care agenda. An increased risk of CVD and CV mortality has been shown in lots of studies conducted on patients affected by inflammatory and autoimmune diseases. A routine evaluation of CV risk in these patients should be encouraged and in particular cases is recommended.

Objectives: The aim of this study was to evaluate the prevalence of subclinical atheromatosis, the CV risk and its performance in a cohort of patients affected by Systemic Sclerosis (SSc) from a single reference tertiary care hospital.

Methods: Sixty-seven patients with SSc according to the ACR/EULAR 2013 criteria were included. Traditional CV risk factors and SSc related factors were analyzed. Thoracic high resolution computed tomography (CT) was performed, using the quantification of coronary calcium for the study. Furthermore, a doppler ultrasound of the carotids and the lower extremity arteries was conducted for the detection of subclinical atheromatosis. The CV risk has been calculated through different CV risk scales including the MESA CAC, the Italian Progetto Cuore, the Framingham score, the Score2 and the QRISK3. After conducting a 5-year follow up, CV outcome and electrocardiography abnormalities were examined.

Results: Calcium artery coronary score > 0 was reported in twenty-eight SSc patients (41.8%). Considering traditional CV risk factors, the multivariate regression analysis showed a correlation with age (OR 1.151 [95% CI 1.06–1.25], P = 0.032). Instead, the presence of anti-cENP-B (OR 3.47 [95% CI 1.09–11.06], P = 0.035) and late-onset disease (OR 1.062 [95% CI 1.007–1.119], P = 0.026) were identified as potential specific disease risk factors. The prevalence of ultrasound atherosclerosis in SSc was high: peripheral artery disease (PAD) and carotid plaque were respectively 43% and 41%, and the presence of coronary calcifications was a risk factor for their detection with a OR respectively of 20.39 and 20.49 (p<0.0001). All CV risk scores considered SSc patients in a low risk, except for the QRISK3, whose values were higher in patients with coronary calcifications (18.4±12.6 vs 5.1±4.9, p<0.0001). In 5-years follow up only one patient died for CVD and 2 CV events occurred. Electrocardiography anomalies were found in 28.35% of patients, and in particular in 43% of patients with coronary calcifications (OR 3.321 [95% CI 1.094-10.08], P = 0.03). Conclusion: Subclinical coronary atherosclerosis seems to be largely observed in SSc patients and may represent an additional risk factor for electrocardiography anomalies and subclinical atheromatosis in other anatomical districts, with no impact on CVD mortality. SSc coronary calcifications were not correlated with CV risk score, especially the novel QRISK3 by classifying these patients between low and moderate CV risk. Other studies are needed to support the hypothesis that subclinical coronary atherosclerosis, occasionally detected in thoracic CT, may represent a clinical alert to establishing timing and weight of diagnostic and specific treatment protocols for the CV prevention in SSc patients.

REFERENCES:


Disclosure of Interests: None declared


POS0928 THE IDENTIFICATION OF PENTRAXIN 3 AS BIOMARKER OF DISEASE ACTIVITY IN IDIOPATHIC INFLAMMATORY MYOPATHIES

M. Fornaro1, G. Carabellissi1, F. Caccipaglia1, C. Sciocia1, L. Coladonato1, V. Venerito1, R. Bizzoca1, D. Natuzzi1, N. Lacarpa1, G. Lopalco1, F. Iannone1

1Department of Emergence and Transplantation (DETO), University of Bari, Rheumatology Unit, Bari, Italy; 2Department of Medical and Surgical Sciences, University of Foggia Medical School, Rheumatology Clinic, Foggia, Italy

Background: Muscle involvement is only one feature of idiopathic inflammatory myopathies (IIM). Muscle enzymes do not always represent the best marker of disease activity and other inflammation markers such as ESR and CRP may be normal even with an active disease. Pentraxin-3 (PTX3) is an inflammatory disease activity marker, PTX3 levels do not correlate with lipid levels, QIMT calcifications was a risk factor for their detection with a OR respectively of 20.39 Carotid intima media thickness (cIMT) was measured with a My Lab XPro80 (Esaote SpA, Genova, Italy) using a linear array ultrasound probe small parts broadband transducer (5–15 MHz) both in right and left carotid. Myositis disease activity was evaluated by using myositis disease activity assessment visual analog scales (MYOACT) [19] established by the International Myositis Study Group (IMAG). Manual muscle test (MMT) was used to assess muscle impairment. Exclusion criteria were a diagnosis of diabetes or a history of previous major CV events.

Methods: Twenty patients affected with IIM (13 Dermatomyositis and 7 Polymyositis), 10 rheumatoid arthritis patients and 10 healthy controls (HC) aged, sex and BMI matched were evaluated. PTX3 levels was assessed using a commercially available enzyme-linked immunosorbent assay (Human Pentraxin3 ELISA Kit, Invitrogen) kit. Three different cardiovascular risk scores were used to estimate the 10-years CV risk. Carotid intima media thickness (cIMT) was measured with a My Lab XPro80 (Esaote SpA, Genova, Italy) using a linear array ultrasound probe small parts broadband transducer (5–15 MHz) both in right and left carotid. Myositis disease activity was evaluated by using myositis disease activity assessment visual analog scales (MYOACT) [19] established by the International Myositis Study Group (IMAG). Manual muscle test (MMT) was used to assess muscle impairment. Exclusion criteria were a diagnosis of diabetes or a history of previous major CV events.

Results: Demographic and disease characteristics of our cohort are showed in Table 1. IIM patients showed higher levels of PTX3 compared to HC (518±260 pg/ml vs 273±114 pg/ml, p<0.05), while no difference was observed compared to RA patients (383±260 pg/ml). PTX3 levels do not correlate with lipid levels, QIMT and cardiovascular risk scores both in IIM, RA and HC. No correlation was found between DAS28-ESR and PTX3 levels in RA patients. Of note, a direct correlation
was found between PTX3 levels and MYOACT - GLOBAL EXTRASYMPTOMATIC MUSCLE DISEASE ACTIVITY (r=0.542, p=0.013), while an inverse correlation was found between PTX3 levels and MMT8 (r=-0.510, p=0.02).

Table 1.

<table>
<thead>
<tr>
<th>IIM 20pz (13 DM, 7 PM)</th>
<th>RA 10pz</th>
<th>Healthy Control 10pz</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n. (%)</td>
<td>18 (90%)</td>
<td>9 (90%)</td>
</tr>
<tr>
<td>Male, n. (%)</td>
<td>3 (15%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Age, y</td>
<td>63.0 (9.3)</td>
<td>58.3 (5.9)</td>
</tr>
<tr>
<td>BMI</td>
<td>25.5 (4.3)</td>
<td>23.1 (3.1)</td>
</tr>
<tr>
<td>Duration of disease, median (IQR)</td>
<td>7.3 (4 – 12.8), 13.5 (10.5 – 18.5)*</td>
<td></td>
</tr>
<tr>
<td>Physician Global Assessment</td>
<td>2.1 (2.1)</td>
<td>2 (2.2)</td>
</tr>
<tr>
<td>Patient Global Assessment</td>
<td>4 (3.6)</td>
<td>2.7 (2.3)</td>
</tr>
<tr>
<td>Health Assessment</td>
<td>0.7 (0.8)</td>
<td>0.9 (0.9)</td>
</tr>
</tbody>
</table>

Data are expressed as “mean (SD)” where not otherwise specified.*p<0.05, **p<0.01, ***p<0.001 vs IIM

Conclusion: In IIM patients, PTX3 levels are higher than HC and correlate with disease activity, both for muscular and extra-muscular manifestations, being a possible biomarker of disease activity.

REFERENCES:

Disclosure of Interests: None declared
Spondyloarthritis - treatment

POS0930
SAFETY AND EFFICACY OF IXEKIZUMAB TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 3-YEAR CLINICAL TRIAL RESULTS FROM THE COAST PROGRAMME


Background: Ixekizumab (IXE) has demonstrated efficacy at week (wk) 16 which was maintained through 2 years (yrs) and was associated with a consistent safety profile in patients (pts) with r- and nr-axSpA, who are bDMARD-naïve and TNF-1 experienced.1,3

Objectives: To report safety and efficacy from the COAST programme at 3 yrs: 1 yr of the originating studies (COAST-V/W/X) and 2 yrs of COAST-Y.

Methods: COAST-Y (NCT03219900) is the phase 3, long-term extension study of the 3 originating studies COAST-V/W/X. Pts continued with the dose received at the end of the originating trial at wk (wk) 52 either with BDM 56/932/932 (93%) re-randomised to IXE Q4W or Q2W at wk 16 in COAST-Y and -W. Pts who received PBO for 52 wks in COAST-X were switched to IXE Q4W to continue in COAST-Y. Starting at wk 116 (wk 64 of COAST-Y), pts receiving IXE Q4W could have their dose escalated to Q2W. This analysis focused on pts receiving ≥1 dose of IXE Q4W, observed data while on IXE Q2W dose escalation are excluded. Continuation data are summarised as observed. Safety data while on IXE were analysed for pts who received ≥1 dose of IXE; observed data while on PBO or ADA are excluded.

Results: A total of 932 pts received ≥1 dose of IXE; 414 received ≥1 dose of IXE Q4W, and 562/932 (60%) pts completed 3 yrs of follow-up (PBO→IXE Q4W, 631/932 (53%); ADA→IXE Q4W, 299/444 (66%); and IXE Q4W→IXE Q4W, 114/251 (45%).)

Observations: IXE Q4W was efficacious (observed data) in all patients studied. Through 3 yrs, the most frequently reported treatment-emergent adverse events were infections [incidence rate (IR) 25.7/100 patient years (PY)] and injection site reactions [IR 7.4/100 PY]; the majority of which were mild/moderate in severity. Serious adverse events were reported at an IR of 4.8/100 PY, of which osteoarthritis was the most frequent at 0.4/100 PY. A total of 3 deaths were reported among all pts who received ≥1 dose of IXE [IR [0.1/100 PY]. For all pts, baseline disease activity (Ankylosing Spondylitis Disease Activity Score; ASDAS) was high (see Table 1). The 3 yr mean (SD) change from baseline (observed) in ASDAS among bDMARD-naïve pts with r-axSpA, TNF-1 experienced pts with r-axSpA, and bDMARD-naïve pts with nr-axSpA is presented in Table 1. A consistent disease control through 3 yrs was confirmed across additional efficacy endpoints (Table 1).

Conclusion: This analysis of a subset of pts in COAST-Y demonstrated that the safety profile is consistent with the established safety profile, with no new safety signals observed. IXE Q4W was efficacious (observed data) in all patients studied who remained on the treatment through 3 yrs.

REFERENCES:

Acknowledgements: The authors thank So Young Park, PhD, of Eli Lilly and Company for statistical review, and Edel Hughes, PhD, of Eli Lilly and Company for writing and process support.


POS0931
EFFICACY AND IMPROVEMENT IN PATIENT-REPORTED OUTCOMES AT WEEKS 16 AND 52 IN IXEKIZUMAB TREATED BIOLOGICAL NAÏVE PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS ACHIEVING CLINICALLY IMPORTANT PAIN AT NIGHT REDUCTION AT WEEK 16: RESULTS FROM COAST-V TRIAL

S. Raming1, C. Lukas2, M. J. Nissen3, Y. Schymura4, K. Ng5, A. Bradley4, G. Doridort6, S. Liu Leage6, A. Chan6, J. C. C. Wel11,12,13, Leiden University Medical Centre, Department of Rheumatology, Leiden, Netherlands; 13University of Montpellier, University Hospital Centre Montpellier, Montpellier, France; 6Geneva University Hospital, Division of Rheumatology, Geneva, Switzerland; 12Eli Lilly and Company, and Pfizer, UCB Pharma, and Director of Imaging Rheumatology BV.

Table 1. Baseline demographics and disease activity characteristics through 3 yrs. Data presented as mean (SD) unless otherwise specified.

<table>
<thead>
<tr>
<th></th>
<th>COAST-V</th>
<th>COAST-W</th>
<th>COAST-X</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO (N=87)</td>
<td>ADA (N=90)</td>
<td>IXE Q4W (N=81)</td>
</tr>
<tr>
<td>Age</td>
<td>43 (12)</td>
<td>42 (11)</td>
<td>41 (12)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>71 (83)</td>
<td>73 (81)</td>
<td>68 (84)</td>
</tr>
<tr>
<td>Symptom duration (years)</td>
<td>16.6 (10.1)</td>
<td>15.6 (9.3)</td>
<td>15.8 (11.2)</td>
</tr>
<tr>
<td>BASDAI CFB</td>
<td>3.9 (0.7)</td>
<td>3.7 (0.8)</td>
<td>3.7 (0.7)</td>
</tr>
<tr>
<td>BASDAI</td>
<td>6.8 (1.2)</td>
<td>6.7 (1.5)</td>
<td>6.8 (1.3)</td>
</tr>
</tbody>
</table>

Figure 1. Observed mean CFB in ASDAS for pts treated with IXE Q4W in COAST-V. At wk 16, PBO pts received IXE Q4W.

Table 1. Baseline demographics and disease activity characteristics through 3 yrs. Data presented as mean (SD) unless otherwise specified.
Background: Ixekizumab (IXE), a monoclonal antibody that selectively targets interleukin IL-17A, has shown efficacy in patients with radiographic axial spondyloarthritis (r-axSpA). Spinal pain, in particular spinal pain at night (SP-N), is a severity NRS, Jenkins Sleep Evaluation Questionnaire (JSEQ), SF-36 PCS) at W16, and ASDAS LDA at W52 were tested using analysis of covariance (ANCOVA; continuous variables) and logistic regression (binary variables). Missing values were imputed using non-responder imputation, and modified baseline observation carried forward.

Results: A greater proportion of patients achieved >2 improvement in SP-N with IXE treatment compared to PBO at W16 (63.0% vs. 32.2%, p <0.001) and improved using non-responder imputation, and modified baseline observation carried forward. For the sub-group of 11,892 patients, IXE dominated the newer b/tsDMARD uptake (1,848 new-starts, Figure 1). Use of JAKi was limited, especially in b/tsDMARD-naïve patients. In b/tsDMARD-naïve patients, apremilast had the fastest uptake (490 new-starts) (Figure 1). Of the 81 patients originally randomised to IXE, those achieving >2 improvement in SP-N (63%) at W16 were younger, more frequently positive for HLA-B27 and had higher disease activity at baseline compared to those that did not achieve >2 improvement (Table 1). Achieving >2 improvement in SP-N was associated with improvement in PROs including BASFI, Fatigue Severity, JSEQ and SF-36 PCS at W16 and with achieving ASDAS≤2.1 at W52 compared to those not achieving >2 improvement in SP-N (Table 1).

Table 1. Baseline demographics, clinical characteristics, and PROs of IXE-treated patients achieving vs. not achieving >2 improvement in SP-N at W16.

<table>
<thead>
<tr>
<th>Achieved &gt;2 Improvement in SP-N at W16</th>
<th>Yes (n=51)</th>
<th>No (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yrs</td>
<td>38.6 (11.4)*</td>
<td>44.9 (12.4)</td>
</tr>
<tr>
<td>Positive for HLA-B27, n (%)</td>
<td>50.0 (88.0)*</td>
<td>25.0 (83.3)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>14.9 (14.9)*</td>
<td>7.6 (8.4)</td>
</tr>
<tr>
<td>ASDAS</td>
<td>3.9 (0.6)*</td>
<td>3.5 (0.6)</td>
</tr>
<tr>
<td>Pain at Night</td>
<td>7.4 (1.1)</td>
<td>6.4 (1.4)</td>
</tr>
<tr>
<td>PROs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline W16 CFB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASFI</td>
<td>6.1 (1.9)</td>
<td>-3.4 (2.2)**</td>
</tr>
<tr>
<td>Fatigue Severity NRS</td>
<td>6.9 (1.7)</td>
<td>-3.5 (2.6)**</td>
</tr>
<tr>
<td>JSEQ</td>
<td>7.1 (5.4)</td>
<td>-3.2 (4.2)**</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>32.8 (7.7)**</td>
<td>10.9 (7.7)**</td>
</tr>
<tr>
<td>ASDAS≤2 at W52 Response, n (%)</td>
<td>34 (66.7)**</td>
<td>9 (33.3)</td>
</tr>
</tbody>
</table>

Values represent mean (SD) unless otherwise stated. *p<0.05, **p<0.01, ***p<0.001 versus those not achieving >2 improvement in SP-N. HLA-B27; Human Leukocyte antigen-B27, CRP; C-reactive protein, ASDAS; Ankylosing Spondylitis Disease Activity Score, CFB; change from baseline, BASFI; Bath Ankylosing Spondylitis Functional Index, NRS; Numeric Rating Score, JSEQ; Jenkins Sleep Evaluation Questionnaire, SF-36 PCS; Short-Form 36 physical component score.

Conclusion: IXE improved SP-N for patients with r-axSpA not previously treated with b/tsDMARDs. Improvements in SP-N were associated with improvements in disease activity, function, fatigue and quality of life.


POS0393 UPTAKE OF NEWER BIOLOGIC AND TARGETED SYNTHETIC DMARDS IN PSORIATIC ARTHRITIS, RESULTS FROM FOUR NORDIC BIOLOGIC REGISTRIES

B. Glinborg 1, 2, D. Di Giuseppe 3, J. K. Wallmark 4, D. Nordström 5, B. Gudbjornsson 6, M. L. Hettland 7, J. Askling 8, G. Gröndal 6, T. Sokka 9, S. Aarrestad Provan 10, U. Lindström 2, 11University Hospital of Copenhagen Rigshospitalet, DANBO and Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; 2University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 3Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden; 4Lund University, Skåne University Hospital, Lund, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; 5Helsinki University Hospital and University of Helsinki, ROB-FIN, Helsinki, Finland; 6Landspitali University Hospital Centre for Rheumatology Research (ICEBIO), Reykjavik, Iceland; 7University of Iceland, The Faculty of Medicine, Reykjavik, Iceland; 8Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden; 9Jyväskylä Central Hospital, Rheumatology, Jyväskylä, Finland; 10Faculty of Health Sciences, UEF, Kuopio, Finland; 11Danderynment Hospital, Division of Rheumatology and Research, Oslo, Norway; 12Sahlgrenska Academy at University of Gothenburg, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden.

Background: The treatment landscape in psoriatic arthritis (PsA) is changing, including newer biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) with different modes of action becoming available. However, the most effective treatment strategy in routine care remains to be established.

Objectives: To explore the uptake and treatment patterns of newer b/tsDMARDs, namely JAK-inhibitors (JAKi; baricitinib, tofacitinib, upadacitinib), IL-17 inhibitors (ixekizumab, secukinumab), abatacept, apremilast, and ustekinumab in PsA patients from the Nordic countries. Furthermore, to describe patient characteristics and extra-musculoskeletal manifestations at treatment start (=baseline).

Methods: Observational cohort study, using prospectively collected routine care data from 4 Nordic rheumatology registries. Treatments (newer b/tsDMARDs) with different modes of action becoming available. However, the most effective treatment strategy in routine care remains to be established.

Results: The treatment landscape in psoriatic arthritis (PsA) is changing, including newer biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) with different modes of action becoming available. However, the most effective treatment strategy in routine care remains to be established.

Conclusion: The most effective treatment strategy in routine care remains to be established.

References:

1. B. Glinborg 1, 2, D. Di Giuseppe 3, J. K. Wallmark 4, D. Nordström 5, B. Gudbjornsson 6, M. L. Hettland 7, J. Askling 8, G. Gröndal 6, T. Sokka 9, S. Aarrestad Provan 10, U. Lindström 2, 11University Hospital of Copenhagen Rigshospitalet, DANBO and Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; 2University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 3Karolinska Institutet, Department of Medicine Solna, Stockholm, Sweden; 4Lund University, Skåne University Hospital, Lund, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; 5Helsinki University Hospital and University of Helsinki, ROB-FIN, Helsinki, Finland; 6Landspitali University Hospital Centre for Rheumatology Research (ICEBIO), Reykjavik, Iceland; 7University of Iceland, The Faculty of Medicine, Reykjavik, Iceland; 8Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden; 9Jyväskylä Central Hospital, Rheumatology, Jyväskylä, Finland; 10Faculty of Health Sciences, UEF, Kuopio, Finland; 11Danderynment Hospital, Division of Rheumatology and Research, Oslo, Norway; 12Sahlgrenska Academy at University of Gothenburg, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden.
Table 1. Baseline characteristics upon treatment start

<table>
<thead>
<tr>
<th></th>
<th>Abatacept</th>
<th>Apremilast</th>
<th>Baricitinib</th>
<th>Ixekizumab</th>
<th>Secukinumab</th>
<th>Tsufilizumab</th>
<th>Upadacitinib</th>
<th>Ustekinumab</th>
<th>Any TNFi</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cumulative uptake, n</td>
<td>362</td>
<td>935</td>
<td>106</td>
<td>342</td>
<td>1848</td>
<td>494</td>
<td>6</td>
<td>691</td>
<td>19470</td>
</tr>
<tr>
<td>Male gender, %</td>
<td>33</td>
<td>42</td>
<td>27</td>
<td>38</td>
<td>40</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>37</td>
</tr>
<tr>
<td>Disease duration, yrs</td>
<td>9 (8)</td>
<td>8 (7)</td>
<td>10 (8)</td>
<td>10 (8)</td>
<td>9 (9)</td>
<td>10 (10)</td>
<td>8 (8)</td>
<td>8 (9)</td>
<td>7 (8)</td>
</tr>
<tr>
<td>Pain, VAS (0-100)</td>
<td>63 (21)</td>
<td>61 (23)</td>
<td>64 (24)</td>
<td>64 (25)</td>
<td>63 (24)</td>
<td>66 (23)</td>
<td>75 (17)</td>
<td>64 (24)</td>
<td>59 (24)</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.73 (1.34)</td>
<td>4.04 (1.35)</td>
<td>3.95 (1.36)</td>
<td>4.24 (1.19)</td>
<td>4.13 (1.36)</td>
<td>4.49 (1.33)</td>
<td>4.74 (0.88)</td>
<td>4.19 (1.32)</td>
<td>4.07 (1.29)</td>
</tr>
<tr>
<td>Uveitis, %</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>IBD, %</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>3</td>
</tr>
</tbody>
</table>

Numbers are mean (SD) unless otherwise stated; IBD: inflammatory bowel disease, bDMARD: biologic DMARD, ts: targeted synthetic;

Background: Sacroiliac joint injection in axial spondyloarthritis (SpA) patients was controversial. A well-designed randomized clinical trial testing its effect on different disease outcome measures particularly bone marrow edema was missing [1].

Objectives: To test the effect of steroid injection in the sacroiliac joint of axial SpA patients on different disease outcome measures.

Methods: N = 43 were registered. They were randomly assigned into 2 groups: Group I (23 cases) received sacroiliac joint injection of lidocaine hydrochloride mixed with triamcinolone, whereas Group II (22 cases) received subcutaneous saline injections. All participants fulfilled the ASAS criteria for axial SpA and they all had bone marrow edema at baseline. Outcomes measures were: Visual Analogue Scale (VAS), ASDAS, BASFI, and SPARCC scores. Participants were assessed at baseline (before and after sacroiliac joint injection) and after 3 months.

Results: There was a significant difference between both groups regarding pain, spine mobility, SPARCC and ASDAS scores in favor of group I. Spine mobility showed the earliest improvement, followed by pain whilst SPARCC and ASDAS scores showed improvement after 3 months. Higher disease activity, younger age, and shorter disease duration all were associated with better outcomes. Bilateral hip involvement was a predictor of poor response.

Conclusion: Sacroiliac joint injection of lidocaine and triamcinolone in axial SpA patients is effective in controlling pain, improving function, disease activity scores, and bone marrow edema with acceptable complications and relatively sustained effect.

REFERENCES:
Efficacy of Upadacitinib on Psoriatic Arthritis with Axial Involvement Defined by Investigator Assessment and PRO-Based Criteria: Results from Two Phase 3 Studies


Background: Patients with PsA and axial involvement have higher disease activity and greater reductions in quality of life1; however, there are no accepted criteria for identifying axial involvement in PsA.

Objectives: The objective of this post-hoc analysis is to assess the efficacy of upadacitinib (UPA), a Janus kinase inhibitor, on axial symptoms in patients with active PsA and axial involvement defined by investigator assessment and PRO-based criteria from two phase 3 SELECT trials.2,3

Methods: Patients with active PsA (≥3 swollen joints and ≥3 tender joints) and prior inadequate response or intolerance to ≥1 non-biologic (SELECT-PsA 1) or ≥1 biologic (SELECT-PsA 2) DMARD were randomly assigned to once daily oral UPA 15 mg or 30 mg, placebo (PBO), or every other week subcutaneous adalimumab (ADA) 40 mg (SELECT-PsA 1 only). At baseline, axial involvement in PsA was determined by investigator assessment based on the totality of clinical information, such as duration and character of back pain, age of onset, and previous imaging. In addition to investigator assessment, PRO-based criteria for axial involvement (BASDAI >4 and BASDAI Question 2 >4 at baseline) were applied for this analysis to identify patients with active disease. Efficacy in the sub-group of patients defined using both investigator assessment and PRO-based criteria was evaluated at week 24 for UPA 15 mg vs PBO and ADA (SELECT-PsA 1 only). Data were analyzed using mixed-effect model repeated measures (MMRM) or non-responder imputation (NRI), with nominal P-values shown.

Results: Based on investigator assessment alone, 31.3% (n=534/1704) of patients in SELECT-PsA 1 and 34.2% (n=218/641) in SELECT-PsA 2 were defined as having axial involvement. When both investigator assessment and PRO-based criteria were applied, 23.1% (n=393/1704) of patients in SELECT-PsA 1, or 73.6% (n=393/543) of those defined using investigator assessment alone, and 27.5% (n=176/641) in SELECT-PsA 2, or 80.4% (n=176/219) using investigator assessment alone, met the combined criteria for axial involvement. In both studies, UPA 15 mg showed significantly greater clinical responses vs PBO at week 24 across all endpoints assessed (Figure 1). In SELECT-PsA 1, UPA showed numerically greater responses than ADA at week 24 across all BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) endpoints. The proportion of patients achieving ASDAS clinically important improvement (CII) at week 24 was significantly greater with UPA vs ADA based on nominal P-value.

Conclusion: Patients with active PsA and axial involvement defined by both investigator assessment and PRO-based criteria demonstrated statistically greater clinical responses related to their axial involvement with UPA 15mg compared to PBO, and consistently numerically higher responses compared to ADA, at week 24 in the SELECT-PsA trials. Findings from this post-hoc analysis are consistent with previous data based on investigator assessment alone.4

References:


Acknowledgements: AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R.P. Eimore, PhD of AbbVie.
Table 1. Efficacy data (BASDAI and ASDAS-CRP values)

<table>
<thead>
<tr>
<th>Index</th>
<th>First line</th>
<th>Second or subsequent lines</th>
<th>All lines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>1 year</td>
<td>2 or more</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=205 BASDAI 5.5 (2.2)</td>
<td>2.9 (2.3)</td>
<td>3.7 (1.9)</td>
<td>1.9 (1.0)</td>
</tr>
<tr>
<td>Female &gt;45 n=367</td>
<td>6.0 (1.9)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Male n=1252 BASDAI 5.4 (2.1)</td>
<td>3.1 (2.1)</td>
<td>2.9 (1.9)</td>
<td>5.2 (2.4)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=86 BASDAI 5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>1.9 (2.0)</td>
<td>5.3 (2.4)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=86 BASDAI 5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>1.9 (2.0)</td>
<td>5.3 (2.4)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=86 BASDAI 5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>1.9 (2.0)</td>
<td>5.3 (2.4)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=86 BASDAI 5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>1.9 (2.0)</td>
<td>5.3 (2.4)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female &lt;45 n=240</td>
<td>5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>3.2 (2.0)</td>
</tr>
<tr>
<td>Male n=86 BASDAI 5.6 (2.3)</td>
<td>3.3 (2.1)</td>
<td>1.9 (2.0)</td>
<td>5.3 (2.4)</td>
</tr>
</tbody>
</table>

Background: Certolizumab pegol (CZP) in women of childbearing age with rheumatoid arthritis has a more favorable response, suggesting a possible distinctive effect in this group.

Objectives: To evaluate the retention rate of CZP compared to other anti-TNFs and anti-IL17A in patients affected by axSpA, grouped according to gender and age.

Methods: Cross-sectional study within the BIOBADASER registry. Patients older than 17 years old, with axSpA receiving anti-TNFs or anti-IL17A were selected. Mean and standard deviations of BASDAI and ASDAS-CRP were performed at baseline, 1st and 2nd year of treatment. Patients were classified according to treatment into groups 1) CZP, 2) anti-TNF, and 3) anti-IL17A, and according to sex and age in the following groups: 1) women between 18 and 45 years old (young women), 2) women over 45 years old (old women), 3) men.

Results: Groups and gender distribution, treatment prescription, ASDAS-CRP and BASDAI values according to therapeutic line and demographical characteristics are shown in Table 1. Overall, young women treated with CZP showed remission or low BASFI, and in the first 5 years of follow-up, compared to low activity for the rest of the molecules. A higher retention rate was observed for both CZP and anti-IL17A compared to other treatment groups was observed in young women. This difference was observed since the first year of treatment (71.4 (64.2-77.4) all anti-TNF, 84.4 (66.4-93.2) CZP, 72.2 (53.2-84.5) anti-IL17) and the magnitude was maintained during the first 5 years of follow-up (Figure 1). In older women, a higher retention rate was observed for both CZP and anti-IL17A compared to anti-TNFs (71.6 (65.4-76.8) in all anti-TNF, 78.1 (54.9-90.3) in CZP, 75.3 (61.3-84.9) in anti-IL17). In males there were no long-term differences (79.2 (76.3-81.8) all anti-TNF, 73.0 (62.0-81.4) CZP, 64.6 (57.3-71.0) anti-IL17).

Figure 1. Five years retention rate (first line treatment)

Focussed on first line treatment, the differences were greater in young women. The second and subsequent lines showed the same trends with a lesser extend. Globally, we do not observe these differences in men.

Conclusion: These data suggest a possible specific effect of Certolizumab Pegol in women with axial spondyloarthritis, especially in young women and when used as first line treatment.

References:

Acknowledgements: We would like to thank all members who participated in the BIOBADASER project.

Disclosure of Interests: None declared

Table 1. First and second bDMARD

<table>
<thead>
<tr>
<th>First bDMARD</th>
<th>Second bDMARD</th>
<th>Adalimumab</th>
<th>Etanercept</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>59 (57.3%)</td>
<td>22 (21.4%)</td>
<td>22 (21.4%)</td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>28 (40.6%)</td>
<td>37 (53.6%)</td>
<td>4 (5.8%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>15 (48.4%)</td>
<td>8 (25.8%)</td>
<td>8 (25.8%)</td>
<td></td>
</tr>
</tbody>
</table>

**REFERENCES:**


**Disclosure of Interests:** Rosie Barnett Grant/research support from: UCB, Lewis Carpenter Consultant of: Statistical consultancy for Pfizer, Charlotte Cavill: None declared, Raj Sengupta Speakers bureau: Abbvie, Biogen, Celgene, Lilly, Novartis, Roche, UCB, Consultant of: Advisory boards for Abbvie, Biogen, Lilly, Novartis, UCB, Grant/research support from: Abbvie, Celgene, Novartis, UCB

**DOI:** 10.1136/annrheumdis-2022-eular.1790

**Figure 1. Predictive margins of BASDAI and BASFI 36-months pre- and post- bDMARD initiation A-E, Predictive margins of the BASDAI score (overall – all components, A); BASDAI Q1 fatigue (B); BASDAI average of Q2-Q4 spinal pain, joint pain, enthesitis (C); BASDAI average of Q5-Q6 morning stiffness (D); and BASFI (E).**

**Conclusion:** In our study population, there was clinically meaningful worsening of disease activity over 36-months prior to initiation of first bDMARD, despite baseline (36-months prior to first bDMARD initiation) BASDAI exceeding the current threshold for bDMARD treatment (BASDAI≥4). A clinically meaningful and maintained improvement in disease activity was reported across all cohorts in the 36-months following first bDMARD initiation.

**REFERENCES:**


**Disclosure of Interests:** Rosgie Barnett Grant/research support from: UCB, Lewis Carpenter Consultant of: Statistical consultancy for Pfizer, Charlotte Cavill: None declared, Raj Sengupta Speakers bureau: Abbvie, Biogen, Celgene, Lilly, Novartis, Roche, UCB, Consultant of: Advisory boards for Abbvie, Biogen, Lilly, Novartis, UCB, Grant/research support from: Abbvie, Celgene, Novartis, UCB

**DOI:** 10.1136/annrheumdis-2022-eular.1790

**MEASURE 2: SECUKINUMAB PROVIDES RAPID AND SUSTAINED RELIEF FROM KEY CLINICAL SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS IN TNFI-NAÏVE PATIENTS THROUGH 5 YEARS**


1Institute of Rheumatology, Department of Rheumatology, Prague, Czech Republic; 2Altona Center for Clinical Research, Altona Center for Clinical Research, Duncansville, PA, United States of America; 3Novartis Pharmaceuticals Corporation, US Clinical Development and Medical Affairs, Rheumatology, East Hanover, NJ, United States of America; 4Novartis Pharma AG, Global Medical Affairs Biostatistics in Global Drug Development, Basel, Switzerland; 5Novartis Pharma AG, Global Medical Affairs, Rheumatology, Basel, Switzerland; 6Hospital Universitario Marques de Valdecilla (IDIVAL), Servicio de Reumatologia, Santander, Spain

**Background:** Ankylosing spondylitis (AS) is a chronic, inflammatory disease resulting in debilitating clinical symptoms such as pain (70–83%), stiffness (54–90%) and fatigue (53–62%). Secukinumab (SEC 150 mg) has demonstrated long-term efficacy across multiple indications and is approved for the treatment of active AS in adults who have had an inadequate response to NSAIDs.

**Objectives:** The Phase 3 MEASURE 2 trial (NCT01649375) assessed long-term efficacy, safety and tolerability of SEC in patients (pts) with active AS. This post-hoc analysis was conducted specifically to evaluate long-term efficacy of SEC 150 mg on key clinical symptoms of pain, morning stiffness, physical function and fatigue in TNFi-naïve pts over 5 years.

**Methods:** The MEASURE 2 study design has been reported previously. This post-hoc analysis evaluated key clinical symptoms at baseline through Wk 260. Assessments included total and nocturnal back pain (visual analogue scale [0–100 mm]), overall spinal pain (neck, back, or hip) from BASDAI, and morning stiffness (average BASDAI). Physical function (SF-36 PCS, BASFI), fatigue (BASDAI, FACIT) and disease activity (ASDAS-CRP) are also reported. Data are presented as LS mean change (± SE) using mixed model repeated measures from Wks 4–16 and observed data (mean ± SD) from Wks 24–260.

**Results:** Of TNFi-naïve pts randomised to SEC 150 mg, 89 were included (SEC, n=44, placebo [PBO], n=45) in this analysis. Of these pts randomised to SEC 150 mg, 84% completed 5 years of treatment. Significantly greater improvements were observed in pts treated with SEC 150 mg vs PBO at Wk 16 and were sustained through 5 years (Figure 1; Table 1).
for up to 48 weeks (wks) in the phase 2b BE AGILE study.1 Maintaining stringent and rapid efficacy in patients (pts) with active ankylosing spondylitis (AS) treated inhibiting interleukin (IL)-17F in addition to IL 17A, has demonstrated significant Preliminary Results: 10.1136/annrheumdis-2022-eular.2049

**References:**


**Acknowledgements:** This study was supported by Novartis Pharma. Medical writing support for the development of this abstract, under the direction of the authors, was provided by Laura Crocker (BMedSci, Hons) of Ashfield MedComms, an Ashfield Health company, and funded by Novartis Pharma.

**Disclosure of Interests:** Karel Pavelka Speakers bureau: AbbVie, Pfizer, Roche, Eli Lilly, BMS, MSD, USB, Alan Kivitz Shareholder of: Amgen, Novartis, Gilead, Sanofi, Galapagos, Novartis, Lilly, MSD, Novartis, Pfizer, Roche, and Sanofi, Consultant of: Astra-Zeneca, Galapagos, Janssen, Novartis, Pfizer, Grant/research support from: AbbVie, and Roche.

**Disclosure of Interests:** M. Oortgiesen4, V. Taieb5, X. Baraliakos6.

**Department of Rheumatology, IdiPaz, Madrid, Spain; 6Ruhr-University Bochum, Rheumazentrum Ruhrgebiet

**OPEN-LABEL EXTENSION**

**ANALYSES FROM THE BE AGILE STUDY AND ITS OVER 3 YEARS OF TREATMENT IN PATIENTS WITH MAINTENANCE OF RESPONSE TO BIMEKIZUMAB

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Acknowledgements:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Disclosure of Interests:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Disclosure of Interests:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Disclosure of Interests:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Disclosure of Interests:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.

**References:**


**Disclosure of Interests:** This study was sponsored by Novartis Pharma.

**Disclosure of Interests:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical.
Disclosure of Interests: Victoria Navarro-Compan Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie and Novartis, Martin Rudwaleit Speakers bureau: AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, UCB Pharma, Paid instructor for: Janssen, Novartis, UCB Pharma, Consultant of: AbbVie, Novartis, UCB Pharma.

Randomised set. *Primary endpoint; †Secondary endpoint; aMASES=0 in pts with BL MASES >0; bn=92; cn=94; dNominal p values not shown; en=17; fn=10; gIn pts in MRI sub-study; hn=65; in=75; jn=58; kn=73; ln=68; mn=79; nn=60; on=77.

Background: Bimekizumab (BIZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17A and IL-17F with BKZ in pts with active nr-axSpA resulting in rapid, clinically relevant improvements in efficacy outcomes vs PBO. No new safety signals were observed.1,2

Objectives: To assess efficacy and safety of BKZ vs placebo (PBO) in pts with active non-radiographic axial spondyloarthritis (nr-axSpA) up to Wk 24 in the ongoing pivotal phase 3 study, BE MOBILE 1.

Methods: BE MOBILE 1 (NCT03928704) comprises a 16-wk double-blind, PBO-controlled period and 36-wk maintenance period. Pts were aged ≥18 yrs, had BASDAI ≥4 and spinal pain ≥4 at BL, and sacroiliitis on MRI and/or elevated hs-CRP at screening. Pts were randomised 1:1, BKZ 160 mg Q4W.PBO. From Wk 16, all pts received BKZ 160 mg Q4W. Primary and secondary efficacy endpoints were assessed at Wk 16. Results: Of 254 randomised pts (BKZ: 128; PBO: 126), 244 (96.1%) completed Wk 16, 240 (94.5%) Wk 24. BL characteristics were comparable between groups: mean age 39.4 yrs, symptom duration 9.0 yrs; 54.3% pts male, 77.6% HLA-B27+, 10.6% TNIF-experienced. At Wk 16, the primary (ASAS40: 47.7% BKZ vs 21.4% PBO; p<0.001) and all ranked secondary endpoints were met (Table 1). Responses were rapid with BKZ, including in PBO pts who switched to BKZ at Wk 16, and increased to Wk 24 (Fig. 1, Table 1). Substantial reductions of hs-CRP by Wk 2 and MRI SIJ inflammation by Wk 16 were achieved with BKZ vs PBO (Table 1). At Wk 24, >50% of pts initially randomised to BKZ had achieved ASDAS <2 (Fig. 1).

Over 16 wks, 80/128 (62.5%) pts had ≥1 TEEA on BKZ vs 71/126 (56.3%) on PBO; most frequent were nasopharyngitis (BKZ: 9.4%; PBO: 4.8%), upper respiratory tract infection (BKZ: 7.0%; PBO: 7.1%) and oral candidiasis (BKZ: 3.1%; PBO: 0%). No systemic candidiasis was observed. Up to 16 wks, incidence of SAEs was low (BKZ: 0.0%; PBO: 0.8%); no MACs or deaths were reported; 0 IBD cases occurred in pts on BKZ vs 1 (0.8%) in a pt on PBO.

Conclusion: Dual inhibition of IL-17A and IL-17F with BKZ in pts with active nr-axSpA resulted in rapid, clinically relevant improvements in efficacy outcomes vs PBO. No new safety signals were observed.1,2

REFERENCES:
**Disclosure of Interests:** Atul Deodhar Speakers bureau: Janssen, Notaris, Pfizer, and Pfizer, Consultant of: AbbVie, Amgen, Arvinia, BMS, Celgene, Eli Lilly, GSK, Janssen, MoonLake, Novartis, Pfizer, and UCB Pharma. Grant/ research support from: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, and UCB Pharma. Désirée van der Heijde Consultant of: AbbVie, Bayer, BMS, Cytone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, and UCB Pharma. Employee of: Imaging Rheumatology BV (Director), Lianne S. Geneser Consultant of: AbbVie, Eli Lilly, GSK, Janssen, Novartis, Pfizer, and UCB Pharma. Grant/research support from: Novartis, Pfizer and UCB Pharma, Hui Xu: None declared. Karl Gaffney Speakers bureau: AbbVie, Eli Lilly, Novartis, UCB Pharma, Consultant of: AbbVie, Eli Lilly, Novartis, and UCB Pharma, Grant/research support from: AbbVie, Gilead, Eli Lilly, Novartis, and UCB Pharma, Hirasoki Nobuyuki Speakers bureau: BMS, Chugai, Eli Lilly, GSK, MSD, Novartis, Pfizer, UCB Pharma, Walter P Maximowycz Consultant of: AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie, Janssen, Novartis and Pfizer, Employee of: Chief Medical Officer for CARE Arthritis, Martin Rudwaleit Speakers bureau: AbbVie, BMS, Boehringer Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer, and UCB Pharma, Paid instructor for: Janssen, Novartis, and UCB Pharma, Consultant of: AbbVie, Novartis, and UCB Pharma, Marina Magrey Consultant of: AbbVie, Eli Lilly, Novartis, Pfizer and UCB Pharma, Grant/research support from: AbbVie and UCB Pharma, Dirk Elswout Speakers bureau: AbbVie, Eli Lilly, Galapagos, Novartis and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Galapagos, Novartis and UCB Pharma, Marga Gortgiesen Employee of: Employee of UCB Pharma, Carmen Fleurinck Employee of: Employee of UCB Pharma, Alicia Ellis Employee of: Employee of UCB Pharma, Thomas Vaux Employee of: Employee of UCB Pharma, jullie smith Employee of: Employee of UCB Pharma, Xenofon Baraliakos Speakers bureau: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, Paid instructor for: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, Consultant of: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, MSD, Novartis, Pfizer, and UCB Pharma, DOI: 10.1136/annrheumdis-2022-eular.2416

**Table 1. Cox-regression analysis. Hazard Ratio for discontinuation of golimumab**

<table>
<thead>
<tr>
<th>Hazard Ratio</th>
<th>95% Confidence interval</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at golimumab initiation</td>
<td>1.01</td>
<td>1.00-1.02</td>
</tr>
<tr>
<td>Gender (women vs men)</td>
<td>1.23</td>
<td>0.98-1.55</td>
</tr>
<tr>
<td>Axial SpA vs RA</td>
<td>0.59</td>
<td>0.44-0.80</td>
</tr>
<tr>
<td>Poa vs RA</td>
<td>0.67</td>
<td>0.51-0.9</td>
</tr>
<tr>
<td>Second vs first biological drug</td>
<td>1.52</td>
<td>1.17-1.97</td>
</tr>
<tr>
<td>Third or further vs first biological drug</td>
<td>1.79</td>
<td>1.38-2.32</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>1.46</td>
<td>1.16-1.85</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>0.79</td>
<td>0.63-0.99</td>
</tr>
<tr>
<td>Disease activity over the median*</td>
<td>1.29</td>
<td>1.05-1.59</td>
</tr>
</tbody>
</table>

*<ref>Table 1. Cox-regression analysis. Hazard Ratio for discontinuation of golimumab</ref>
**Disclosure of Interests:** Manuel Pombo-Suarez: None declared, Daniel Secane-Mato: None declared, Luis Cea-Calvo Employee of: Medical Affairs, MSD Spain, Federico Diaz-Gonzalez: None declared, Fernando Sanchez-Alonso: None declared, Francisco Gayoso Manero Ruiz: None declared, Lucía Ruiz: None declared, Vega Jovan: None declared, Isabel Castrejon: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2429

**POS0941**

**LONG-TERM CLINICAL OUTCOMES OF CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS STRATIFIED BY BASELINE MRI AND C-REACTIVE PROTEIN STATUS**

P. Robinson¹, W. P. Maksymovych², L. S. Gensler³, M. Rudwaleit⁴, B. Hoepken⁵, L. Bauer⁵, T. Kumke⁵, M. Kim⁶, A. Deodhar⁷, ¹University of Queensland School of Clinical Medicine, University of Queensland, Brisbane, Australia; ²Department of Medicine, University of Alberta, Alberta, Canada; ³University of California San Francisco, N/A, San Francisco, California, United States of America; ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany; ⁵UCB Pharma, N/A, Monheim am Rhein, Germany; ⁶UCB Pharma, N/A, Smyrna, Georgia, United States of America; ⁷Oregon Health & Science University, N/A, Portland, Oregon, United States of America

**Background:** Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation during the 52-week (wk) placebo (PBO)-controlled period and 104 wk open-label (OL) safety follow-up extension (SFE) of the C-axSpAnd study. There is, however, a paucity of data on the long-term efficacy of biologics in nr-axSpA according to patients' baseline MRI and C-reactive protein (CRP) status.

**Objectives:** This post hoc analysis from C-axSpAnd aimed to evaluate whether patients' baseline MRI and CRP status impacted long-term (3-year) clinical responses to CZP.

**Methods:** C-axSpAnd (NCT02552212) was a 3-year, phase 3, multicentre study. Adults (N=317) with nr-axSpA fulfilling the Assessment of SpondyloArthritis international Society (ASAS) classification criteria and objective signs of inflammation (CRP ≥ upper limit of normal (10 mg/L) [CRP+]) and/or evidence of sacroiliitis on MRI [MRI+] were randomised 1:1 to PBO or CZP (400 mg at Wks 0, 2 and 4, then 200 mg every 2 wks [Q2W]) for 52 wks. Those enrolled into the SFE received OL CZP (200 mg Q2W) for an additional 104 wks. ASDAS major improvement (ASDAS-MI, C-axSpAnd primary outcome) and ASAS 40% response (ASAS40) at Wks 52 and 156 were assessed according to prespecified subgroups based on MRI/CRP status (MRI+, CRP+; MRI−, CRP−; MRI+, CRP−; MRI−, CRP+). All data are reported as observed case.

**Results:** 243/317 (76.7%) patients entered the SFE, 120 from the group initially randomised to CZP (36 MRI+/CRP+, 32 MRI−/CRP+ and 52 MRI+/CRP−) and 123 from the initial PBO group (30 MRI+/CRP+, 34 MRI−/CRP+ and 59 MRI+/CRP−). 75/123 had switched to OL treatment in the 52 wk double-blind phase. 206/243 completed the SFE; 102/120 (85.0%) from the group initially randomised to CZP. 104/123 (84.6%) from the initial PBO group. Among CZP-randomised patients, mean ASDAS was similar between timepoints (MRI+/CRP+: 1.6 at Wk 52 vs 1.6 at Wk 156; MRI−/CRP+: 2.1 vs 2.2; MRI+/CRP−: 1.7 vs 1.6), the percentage achieving ASDAS-MI was lower at Wk 156 compared to Wk 52 across all subgroups (Figure 1A). Patients initially randomised to PBO showed improvements in mean ASDAS over time (MRI+/CRP+: 2.1 Wk 52 vs 1.8 Wk 156; MRI−/CRP+: 2.2 vs 1.9; MRI+/CRP−: 2.0 vs 1.7) and a sustained proportion of patients achieved ASDAS-MI. Similar results were shown for BASDAI, with mean scores for CZP-randomised patients sustained from Wk 52 to Wk 156 across all subgroups (Figure 1B). Mean BASDAI decreased (indicative of clinical improvements) from Wk 52 to Wk 156 in patients initially randomised to PBO, at which point the values aligned with those reported for the CZP-randomised group. In CZP-randomised patients, ASAS40 responses were sustained at Wk 156 compared to Wk 52. An increased percentage of patients achieved ASAS40 in all MRI/CRP subgroups initially randomised to PBO at Wk 156 compared to Wk 52 (Figure 1C).

**Conclusion:** In this analysis of patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI was numerically highest in the MRI+/CRP+ subgroup.

**REFERENCES:**

[1] van der Heijde D. Arthritis Rheumatol 2021;73 (suppl 10);

**Acknowledgements:** This study was funded by UCB Pharma. Editorial services were provided by Costello Medical and funded by UCB Pharma.

**Disclosure of Interests:** Philip Robinson Consultant of: Personal fees from AbbVie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, Roche, Pfizer and UCB Pharma, Grant/research support from: Grant funding from Janssen, Novartis and UCB Pharma; meeting attendance support from Bristol Myers Squibb, Lilly, Pfizer and Roche, Walter P Maksymovych Consultant of: Honoraria/consulting fees from AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer and UCB Pharma, Martin Rudwaleit: Speakers bureau: Speaker for AbbVie, Eli Lilly, Novartis and UCB Pharma, Consultant of: Consulting fees from AbbVie, Celgene, Eli Lilly, Janssen, Novartis and UCB Pharma, Bengt Hoepken: Shareholder of: Stockholder of UCB
Background: Tumor necrosis factor inhibitors (TNFi) have become a mainstay of management for axial spondyloarthritis (axSpA). However, it remains unclear whether patients with axSpA should continue the standard-dose TNFi after achieving stable disease activity. Although complete discontinuation of TNFi is followed by early relapse in most cases, several studies documented that reduced doses of TNFi in patients with prolonged low disease activity showed similar effects on disease control and drug survival compared to standard dose of TNFi. One of the main problem in the dose-tapering strategies for TNFi is a selection of the appropriate patient. However, there has been a lack of robust evidence regarding clinical factors predicting the flare after tapering of TNFi in patients with axSpA.

Objectives: This study aims to develop and validate the prediction model to select the patients in whom tapering of TNFi does not lead to flare.

Methods: We used the data from Korean College of Rheumatology Biologics registry, which included a total of 1,730 patients receiving biologic DMARD from 2017 to 2019 in South Korea. In this study, a total of 526 patients who were initially treated with the standard-dose TNFi and tapered the dose after at least 1 year of the treatment were analyzed. Dose quotient (DQ, 0-1) was applied to quantified TNFi used during interval. The main outcome was an occurrence of flare defined as ASDAS-CRP score of ≥2.1 after 1 year of tapering TNFi. To develop the prediction model, clinical factors having relevant association (p < 0.1) with the outcome were first selected as candidate predictors. Logistic regression using a stepwise approach through backward elimination was used for the final model.

Results: Patients' mean (SD) age was 37.5 (11.9) years, 418 (79.5%) were men, and 474 (90.1%) were HLA-B27 positive. Mean disease duration was 5.0 (6.1) years and 433 (82.3%) were TNFi naive. The mean BASFI and ASDAS-CRP at baseline were 3.4 (2.6) and 3.7 (1.0), respectively. Approximately two-thirds of the patients (65.8%) were initiated TNFi tapering at the first 1 or 2 years from baseline. At the time of TNFi tapering, the mean DQ was 0.67 (0.15) and 381 (72.4%) were prescribed concurrently with NSAIDs, and the mean BASFI and ASDAS-CRP were 1.3 (1.8) and 1.6 (0.9), respectively. During 12 months of follow up starting from the TNFi tapering, 127 (24.1%) experienced the flare. The multivariable analysis revealed that HLA-B27 positivity (OR 1.087; 95% CI 0.978-1.209; p=0.004), inflammatory back pain (OR 2.920; 95% CI 1.283-6.648; p=0.001), age (OR 1.014; 95% CI 1.011-1.017; p<0.001), and BASFI at tapering (OR 1.214; 95% CI 1.051-1.402; p=0.008) were significantly associated with flare. Based on the results of the logistic regression analysis, the predicted probability was calculated by the following formula: P=1/[1+exp{-[1.088 x HLA-B27 negativity + 1.072 x inflammatory back pain + 1.567 x psoriasis + 0.623 x family history of axSpA + 1.092 x diabetes mellitus + 0.435 x DQ at TNFi tapering + 1.029 x ASDAS-CRP at TNFi tapering + 0.194 x BASFI at TNFi tapering]}]. The best cut-off value of the model to define the flare was 0.2416 (95% CI 0.176, 0.301) with sensitivity 74.0% and with specificity 81.0%. AUC was 0.828 (95% CI 0.786-0.869) indicating a good predictive model (calibration slope 1.110, 95% CI 0.903, 1.317; intercept 0.026, 95% CI -0.091, 0.039).

Conclusion: We developed the prediction model for the flare after 12 months of TNFi tapering in patients with axSpA. It might be applicable in real world setting, although external validation will be required in the future investigation.

REFERENCES:

Acknowledgements: We greatly thank to the the Clinical Research Committee of the Korean College of Rheumatology and all participating hospitals.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3473
monolateral SI, 57% bilateral SI and 7% had erosions. Among the reasons of ine- ligibility to bDMARDs, 6 patients have concurrent solid tumor, 11 had comorbidities contraindicating bDMARDs, and 12 preferred not to undergo to bDMARDs. Mean BASDAI significantly decrease after IVNer (5.86±1.98 vs 3.52±2.39, p<0.0002, Figure 1a), as well as VAS pain score (6.14±1.92 vs 3.18±3.62, p<0.05, Figure 1b). MRI showed a complete resolution of SI in 47%, partial resolution in 33%, and persis- tent active SI in 40% of patients, without correlation with the previous presence of erosions.

Conclusion: IVNer was effective in reducing disease activity measured by BAS- DA1 and VAS pain score in patients with axSpA refractory to NSAIDs and not eligible for bDMARDs. When recommended second-line treatments are con- straincated or according to patients’ preference, IVNer can be considered as a potential alternative therapeutic option. Further evaluations in controlled trials are needed to confirm these results.

REFERENCES

Disclosure of Interests: None declared


POS0944

PREDICTORS OF SUSTAINED REMISSION IN PEOPLE WITH AXIAL SPONDYLOARTHRITIS TREATED WITH BIOLOGIC DRUGS

B. Fariogullari1,2, G. K. Yurdımci1, E. Bilgin1, E. C. Bolek1, E. Duran1, G. Ayan1, Z. Özoşy1, G. Sandal Uzun1, M. Ekici1, E. Unaltd1, K. Liciş1, A. Akdoğan1, O. Karadag1, Ş. A. Bilgen1, S. Kiraz1, A. L. Ertenli1, U. Kalyoncu1, P. M. Machado1,2. Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; 1University College London, Centre for Rheumatology & Department of Neuromuscular Diseases, LONDON, United Kingdom

Background: The ultimate goal of treatment in axial spondyloarthritis (axSpA) is sustained remission. Data on predictors of sustained remission are scarce in axSpA.

Objectives: To determine predictors of sustained remission in people with axSpA after treatment with their first biological disease-modifying anti-rheumatic drug (bDMARD).

Methods: Hacettepe University Rheumatology Biologic Registry (HUR-BIO) is a pro- spective, single center registry of rheumatic disease patients treated with bDMARDs. Patients with axSpA were selected and sustained remission defined as attainment of Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) and/or Ankylosing Spondylitis (AS) Disease Activity Score C-reactive protein Inactive Disease (ASDAS-ID) for two or more consecutive visits spanning ≥6 months during follow-up. Patients achieving and not achieving sustained remission were compared using the independent t-test. Multivariable logistic regression analysis was performed to determine independent factors predictive of sustained remission. Variables with a p-value<0.1 were re-tested in multivariable models. Forward selection was performed until the best-fit model was obtained, taking possible confounders into account. Two separate multivariable models were built, one with and one without the covariate ‘achievement of remission at 3-6 months’ to assess consistency of findings and to account for missing information regarding remission status between 3 and 6 months.

Results: Data on 990 patients with sustained remission data were available. Of these, 299 (30%) were in sustained remission, while 691 (70%) were not. Patients in sustained remission were younger, had earlier disease onset, were more fre- quently male, had lower BMI and were more frequently HLA-B27 positive, com- pared to patients not in sustained remission. Furthermore, at the start of bDMARD treatment, Bath AS Disease Activity Index (BASDA1), Bath AS Functional Index (BASFI), and patient global assessment (PGA, 0-10 scale) were lower, while acute phase reactants (ESR and CRP) were higher, in the sustained remission group. In multivariable analysis, male gender (OR 2.2, 95% CI 1.21-3.98), concomitant conventional synthetic DMARD (csDMARD) use (OR 3.63, 95% CI 1.29-10.19), PGA (OR 0.96, 95% CI 0.95-0.98), and early achievement (between 3-6 months) of remission (OR 13.1, 95% CI 7.13-24.02) were independently associated with sustained remission (Table 1, model 1). In the model without the variable early achievement of remission (Table 1, model 2), similar and a few additional associa- tions were described: age at diagnosis (OR 0.97, 95% CI 0.96-0.99), male gender (OR 2.31, 95% CI 1.90-2.85), concomitant csDMARD use (OR 1.38 95% CI 1.23- 2.66), PGA (OR 0.98, 95% CI 0.97-0.99), BASDAI (OR 0.87, 95% CI 0.78-0.96), and baseline symptom duration (OR 0.97, 95% CI 0.94-0.99).

Table 1. Multivariable analysis (best-fit model) of predictors of sustained remission

<table>
<thead>
<tr>
<th>Covariates</th>
<th>Model 1</th>
<th>p-value</th>
<th>Model 2</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td>0.006</td>
</tr>
<tr>
<td>Male sex</td>
<td>2.84 (1.71-4.70)</td>
<td>&lt;0.001</td>
<td>2.31 (1.60-3.35)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Concomitant csDMARD use (at baseline or follow-up)</td>
<td>2.94 (1.57-5.51)</td>
<td>0.001</td>
<td>1.88 (1.29-2.66)</td>
<td>0.003</td>
</tr>
<tr>
<td>Baseline PGA</td>
<td>0.97 (0.96-0.98)</td>
<td>&lt;0.001</td>
<td>0.98 (0.97-0.99)</td>
<td>0.002</td>
</tr>
<tr>
<td>Baseline BASDAI</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td>0.025</td>
</tr>
<tr>
<td>Baseline symptom duration</td>
<td>NS</td>
<td></td>
<td>NS</td>
<td>0.97 (0.94-0.99)</td>
</tr>
<tr>
<td>Achievement of remission at 3-6 months after baseline</td>
<td>11.70 (7.11-19.33)</td>
<td>&lt;0.001</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA: not applicable; NS: not selected (not contributing to the model). Baseline refers to start of bDMARD treatment.

Conclusion: This study demonstrates that patients in sustained remission after starting bDMARD treatment have distinctive characteristics compared to patients not in sustained remission. These data can be used to aid clinical and personalized management of axSpA, and to facilitate better communicate between health care professionals and patients regarding the course and prognosis of their condition.

Disclosure of Interests: Bayram Fariogullari: None declared, Gözde Kübra Yurdımci: None declared, Emre Bilgin: None declared, Ertugrul Cagil Bolek: None declared, Emin Duran: None declared, Gizev Aydan: None declared, Zehra Ozsoy: None declared, Gullu Sandal Uzun: None declared, Mustafa Erci: None declared, Erdine Unaltd: None declared, Levent Klici: None declared, Ali Akdogan: None declared, Omer Karadag: None declared, Sule Aprai: Bilgen: None declared, Sedat Kiraz: None declared, Ali Ilhan Ertenli: None declared, Umut Kalyoncu: None declared, Pedro M Machado Speakers bureau: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orpharyme, Pfizer, Roche and UCB, Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orpharyme, Pfizer, Roche and UCB


POS0945

IMPROVEMENT OF ENDOTHELIAL DYSFUNCTION AND INFLAMMATION IN ANKYLOSING SPONDYLITIS: IMPROVE-AS STUDY

A. Syngle1,2, N. Garg3,4, K. Krishnan4, D. Syngle5,6. On behalf of Medical Innovators.
1Cardio-Rheuma & Healing Touch City Clinic, Rheumatology, Chandigarh, India; 2Fortis Multispeciality Hospital, Rheumatology, Mohali, India; 3Chitkara College of Pharmacy, Chitkara University, Rajpura, India; 4Punjabi University, Department of Pharmaceutical Sciences & Drug Research, Patiala, India, 5Government Mult Speciality Hospital, MBBS Intern, Chandigarh, India; 6Shri Guru Nanak Institute of Medical & Health Sciences, Under Grad, Dehra Door, India, 7Healing Touch Foundation, Innovation, Chandigarh, India

Background: Cardiovascular (CV) disease is the leading cause of death in Ankylosing Spondylitis (AS). The chronic inflammatory-driven endothelial dysfunction and accelerated atherosclerosis contribute to the enhanced CV risk in AS. However, the therapeutic options to treat the enhanced CV risk are limited.

Objectives: To investigate the impact of Olmesartan and Rosuvastatin on endothelial dysfunction and inflammation in AS.

Methods: 60 consecutive AS patients were randomized to receive 24-weeks of treatment with Olmesartan (OLME) (10mg/day, n=20), Rosuvastatin (Rvs) (10mg/day, n=20), or placebo (PL) (n=20) as an adjunct to existing stable csDMARDs. Endothelial function was assessed by brachial artery flow-mediated dilation (FMD) using AngioDefender. EPCs (CD34+/CD133+) were estimated by flow cytometry. Serum nitrite, TBARS, ICAM-1, VCAM-1 and lipids levels estimated at baseline and after treatment. Inflammatory measures included: ASDAS, BASDAI, BASFI, ESR and CRP, pro-inflammatory cytokines, Quality of life and CV 10-year risk (SCORE high risk charts) were estimated using standard tools.

Results: Baseline levels of FMD and EPC population were impaired indicating endothelial dysfunction. Basal concentrations of inflammatory markers, pro-inflam- matory cytokines and markers of endothelial dysfunction were elevated among three

Table Scientific Abstracts

776

DOI: 10.1136/annrheumdis-2022-eular.3839
groups. After 24-weeks of treatment, FMD improved significantly in the rosuvastatin and olmesartan group as compared to placebo from their baseline levels: (OLME vs. FL (p<0.01), Rvs. FL (p<0.01), Rvs. OLME (p<0.01) (Figure 1A). EPCs and nitrite (Figure 1B) levels improved significantly in both rosuvastatin and olmesartan groups. A significant reduction found in ICAM-1 after rosuvastatin treatment (p<0.01) where as olmesartan significantly decreased VCAM-1 (p=0.04) levels. Both rosuvastatin and olmesartan resulted in significant reductions of ASDAS, BASDAI, BASFI, ESR, CRP, IL-6 (Figure 1C) and TNF-α (Figure 1D) as compared to placebo. A significant reduction found in TBA/S concentration after olmesartan treatment (p<0.01) as compared with rosuvastatin and placebo. There was a significant reduction in SCORE, HAQ-DI & SF-36 (PH) after treatment with rosuvastatin and olmesartan.

Conclusion: Olmesartan and rosuvastatin improve endothelial dysfunction and vascular inflammation and QoL in AS patients. Olmesartan and Rosuvastatin lower the proinflammatory cytokines, especially TNF-α, that upregulate eNOS and downregulate the production of adhesion molecules, CRP and nitric oxide which, in turn, improves endothelial dysfunction. Both drugs also decrease nitrite concentration and improve the EPC population in AS patients. The augmentation of EPCs by olmesartan and rosuvastatin represents a fascinating new approach for the management of AS. However, Rosuvastatin in addition also favorably impacted ICAM-1 and lipid abnormalities. In contrast, olmesartan has beneficial effect on blood pressure. Thus, both rosuvastatin and olmesartan have anti-inflammatory, immunomodulatory, vasculoprotective and cardioprotective effects in AS mediated through anti-proinflammatory cytokine action. These findings suggests that both drugs could mediate modest but clinically apparent anti-inflammatory effects with modification of CV risk in the context of high-grade autoimmune inflammation of AS and may provide a novel strategy to prevent cardiovascular events in these patients.

REFERENCES:

Disclosure of Interests: None declared.


POS0946
THE COURSE OF BONE MINERAL DENSITY DURING 8 YEARS OF TREATMENT WITH TNF-α INHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS

M. Siderius1,2, A. Spoorenberg1,2, F. Wink1,2, S. Arends1,2. 1University Medical Centre Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 2Medical Centre Leeuwarden, Rheumatology, Leeuwarden, Netherlands

Background: Bone loss reflected by lower bone mineral density (BMD) compared to age and gender matched healthy controls is a common feature of ankylosing spondylitis (AS) and can already be observed at early stages of the disease. AS patients starting TNF-α inhibitors (TNFi) show overall a rapid increase in BMD. However, the course of BMD during long-term TNFi in these patients is not known.

Objectives: To assess the course of BMD of the lumbar spine (LS) and hip in AS patients treated with TNFi during 8 years.

Methods: Patients from the GLAS cohort who received TNFi for at least 8 years were included. Patients were excluded when they used bisphosphonates. BMD of the LS (AP projection L1-L4) and hip (total proximal femur) was measured at baseline, 1 year, 2 years and then bi-annually using DEXA. Low BMD was defined as LS and/or hip BMD Z-score ≤1. Generalized estimating equations were used to analyze BMD Z-scores over time within subjects.

Results: 131 AS patients were included, 73% were male, mean ± SD age was 41.3 ± 10.8 years, median (IQR) symptom duration was 14 (7-24) years, 83% were HLA-B27+, mean ASDAScpr was 3.8 ± 0.8, median CRP level was 13 (6-20) mg/L and median vitamin D25(OH)D3 was 61 (46-80) nmol/L at baseline. Disease activity showed rapid and sustained during TNFi treatment, with mean ASDAScpr of 2.1 ± 0.9 and median CRP of 2 (2-5) at 8 years. Serum levels of vitamin D remained stable, with median vitamin D25(OH)D3 of 60 (47-81) at 8 years. At baseline, mean LS and hip BMD Z-scores were -0.37 ± 1.08 and -0.05 ± 1.04, respectively. Low BMD at the LS and hip (Z-score ≤1) was present in 34% and 19% of patients, respectively. Overall, both LS and hip BMD Z-scores improved significantly during TNFi at all follow-up visits compared to baseline. Significant improvement of BMD Z-scores compared to the previous time point was found up to and including 4 years for LS and up to and including 2 years for hip. Thereafter, deflection of improvement was observed. Median percentage of improvement in absolute BMD after 8 years of TNFi compared to baseline was 7.1% (IQR 0.8-13.5) for LS and 1.6% (IQR -3.5-5.5) for hip (Figure 1). At 8 years, low BMD at the LS and hip (Z-score ≤1) was present in 23% and 19% of patients, respectively.

Conclusion: In AS patients treated long-term with TNFi, both hip and LS BMD significantly increased especially during the first 2-4 year of treatment and stabilized thereafter. This effect was most pronounced in the LS and small in the hip.
study (GO-AFTER) was used to examine 2nd-line (i.e., ≥ 1 line) GLM therapy in participants who had previously received and discontinued at least one other TNFi (etanercept, adalimumab, or infliximab) for any reason. Log-rank tests were performed to estimate retention rates by indication and line of therapy. Similarly, Kaplan-Meier analysis was used to estimate the probability of GLM retention over time.

**Results:** Among the 2228 participants enrolled in the 5 trials, 1797 participants had received GLM as 1st-line treatment (RA = 1050; PaS = 394; AS = 355) and 431 participants had received GLM as 2nd-line treatment. Compared to the pooled 1st-line GLM analysis cohort, more participants receiving 2nd-line GLM were female (78.7% vs 62.2%), were >50 years (61.5% vs 41.2%), and had a longer disease duration (median of 9.2 years vs 3.7 years). In the pooled 1st-line studies, GLM treatment retention remained high over five years, with an overall probability of retention of 87.8% (95% confidence interval [CI], 86.2–89.2) at Year 1 (Week 52), 80.9% (79.0–82.6) at Year 2 (Week 104), 77.3% (75.3–79.2) at Year 3 (Week 156), 73.5% (71.4–75.5) at Year 4 (Week 208), and 69.8% (67.6–71.9) at Year 5 (Week 252). GLM retention rates were similar across the four 1st-line GLM studies with no notable differences observed by indication over time (Figure 1, panel A). Treatment retention was better in participants using GLM as a 1st-line therapy compared to 2nd-line therapy (Figure 1, panel B), with a probability of retention at 5 years (Week 252) with 2nd-line therapy of 41.6% (95% CI: 36.8–46.3).

**Conclusion:** In this post-hoc analysis of prospectively collected clinical trial data, the probability of 1st-line GLM treatment retention at 5-years was consistently high across all rheumatic indications (RA, PaS, and AS). Probability of long-term GLM treatment retention with 2nd-line therapy, while lower than 1st-line therapy, also remained favorable. Collectively, these data support the value of GLM as a 1st- or 2nd-line therapy in these chronic immune-mediated rheumatic diseases.

**REFERENCES:**


**REFERENCES:**


**POS0948 SIX YEARS TREATMENT WITH TNF-α INHIBITORS DOES NOT LEAD TO LONG-TERM CONTINUOUS HYPERMINERALIZATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS**

M. Siderius1, A. Spoorenberg2, E. Van der Vee4, F. G. M. Kroese1, S. Arends1.

1University Medical Centre Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 2University Medical Center Groningen, Laboratory Medicine, Groningen, Netherlands

**Background:** In a previous study, we showed that the bone turnover balance favored bone formation, especially mineralization, during the first years of treatment with TNF-α inhibitors (TNFI) in patients with ankylosing spondylitis (AS).

**Objectives:** To explore if this effect continues during more long-term TNFI treatment.

**Methods:** Included were consecutive AS outpatients from the UMCG GLAS cohort who were treated with TNFI for at least 6 years. Patients were excluded when they used bisphosphonates. Data for a specific visit was coded as missing when patients either had experienced a fracture or received systemic corticosteroids within 1 year from that particular visit regarding the possible effect on BTM. Standardized follow-up visits were performed at baseline (before start of TNFI), 3 and 6 months, 1, 2, 4 and 6 years. Serum markers of collagen resorption sCTX, bone resorption OC, collagen formation PINP, and bone mineralization BALP were measured. Z-scores were calculated to correct for the normal influence of age and gender using a healthy reference population. Generalized estimating equations were performed to analyze BTM Z-scores over time within patients.

**Results:** 53 AS patients were eligible for analyses: 66% were male, mean (SD) age was 38.5 ± 11.3 years, median (IQR) symptom duration was 16 (9-25) years, 87% were HLA-B27+, mean ASDAS was 3.8 ± 1.0, and median CRP 14 (7-27) mg/L. Etanercept, infliximab or adalimumab was prescribed as first TNFi in 60%, 2% and 38% of patients, respectively. 26% (n=14) of patients switched to a second TNFi inhibitor during follow-up. Disease activity showed rapid and sustained improvement after start of TNFI (Figure 1). At group level, collagen resorption marker sCTX Z-score did not significantly change during treatment. Bone resorption marker OC Z-score was only significantly increased at 3 months compared to baseline. Collagen formation marker PINP Z-score showed significantly increased levels at 3 and 6 months and 2 years. Bone mineralization marker BALP Z-score was significantly increased at all time points up to and including 2 years and decreased thereafter. Only a few patients still had higher BTM values above the normal range (+2 SD) (Figure 2). The net effect of collagen metabolism corrected for the normal influence of age and gender (PINP Z-score – sCTX Z-score) confirmed that the initial balance was in favor of collagen formation; this increase was only significant at 6 months compared to baseline.

**Conclusion:** In AS patients receiving long-term TNFI, the bone turnover balance favored bone formation during the first 2 years of treatment. Thereafter, at group level, serum levels of BTM returned to levels not significantly different from baseline. Therefore, 6 years of treatment with TNF-α inhibitors did not seem to lead to long-term continuous hypermineralization in patients with AS.

**REFERENCES:**

Disclosure of Interests: Mark Siderius: None declared, Anneke Spoorenberg Consultant of: AbbVie, Novartis Pharma, Pfizer, UCB Pharma, Lilly, Grant/research support from: Novartis Pharma, Pfizer, Eveline Van der Veer: None declared, Frans G.M. Kroese: None declared, Suzanne Arends: None declared

Acknowledgements: This study was supported by an investigator initiated research grant from Novartis.

Disclosures of Interests: Mark Siderius: None declared, Suzanne Arends: None declared, Freke Wink: None declared, Annette Spoorenberg Consultant of: Abb-Vie, Novartis Pharma, Pfizer, UCB Pharma, Lilly, Grant/research support from: Novartis Pharma, Pfizer


POS0950 LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLARTHRITIS

A. S. Pinto1, K. Flora2, D. Matharu2, A. Isaacs3, P. Machado4,5,6,7,8,9

1Unidade Local de Saúde da Guarda, Rheumatology, Guarda, Portugal; 2Northwick Park Hospital, London North West University Healthcare NHS Trust, Pharmacy, London, United Kingdom; 3Northwick Park Hospital, London North West University Healthcare NHS Trust, Rheumatology, London, United Kingdom; 4Institute of Neurology, University College London, Centre for Rheumatology, Division of Medicine & Department of Neuromuscular Diseases, London, United Kingdom

Background: Biological drugs have revolutionized the treatment of rheumatic diseases, and the recent expiry of the patents for many biological agents has led to the marketing of highly similar, low-cost versions known as biosimilars. However, questions regarding its efficacy compared to bio-originator drugs, in a real-life setting, have been raised. National Institute for Health and Care Excellence (NICE) guidelines state that the response to biologic disease-modifying anti-rheumatic drugs (bDMARDs) should only be continued if there is clear evidence of response, defined as a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre-treatment value or by 2 or more units and a reduction in the 10-cm spinal pain visual analogue scale (VAS) by 2 cm or more.

Objectives: To compare the response to adalimumab (ADA) originator and biosimilar in bDMARD naïve patients with axial spondyloarthritis (axSpA) and in patients who switched from originator to biosimilar drug, accordingly to NICE guidelines; to compare the effectiveness and safety of the originator and biosimilar drugs in patients with axSpA, measured by persistence rates (PR) over three years.

Methods: A retrospective observational single-centre UK study was performed in bDMARD naïve patients with a clinical diagnosis of axSpA who initiated treatment with ADA (original or biosimilar) and in patients who switched from originator to biosimilar drug. Descriptive statistics were used. Disease activity at baseline and follow-up data at 3 and 6 months of treatment was compared using the chi-square test. The Kaplan-Meier method was used to calculate persistence rates in biologic treatment over time. Reasons for discontinuing therapy were summarized using descriptive statistics and stratified by treatment.

Results: A total of 153 patients were included: 83 patients started on original ADA, 31 started on biosimilar ADA and 40 switched from original to biosimilar drug. The population's baseline characteristics are similar in the three groups. However, some differences were found, namely disease duration was longer in the group that did switch and the disease activity is similar in patients who started original and biosimilar ADA and was lower in the group of patients who switched from original to the biosimilar. The 3-year PR was not significantly different between originator and biosimilar ADA in bDMARD naïve patients and in the group of patients that switched from original drug to biosimilar drug (p=0.080), as shown in Figure 1. In the original ADA group, 3-year PR was 67.5% with a median time-on-drug (TOD) of 29.5 months; for biosimilar drug, 3-year PR was 64.5%, with a median TOD of 24.2 months. In patients who switched from original to biosimilar drug, 3-years PR was 77.5% with a median TOD of 30.3 months. Response to treatment according to NICE guidelines was similar between original and biosimilar drugs (p=0.03). Overall, 47 (30.7%) patients stopped adalimumab (27 patients on original drug and 20 on biosimilar drug). Discontinuations due to adverse events and inefficacy were the most frequent, and there were no significant differences between original and biosimilar drugs. Other reasons for discontinuation were less frequent, such as patient choice, loss of follow-up and death, and again without differences between original and biosimilar drugs.

Conclusion: Adalimumab original and biosimilar used as a first-line biological treatment showed similar effectiveness and safety in our long-term cohort of patients with axSpA. Switch from original to biosimilar drug showed to have a good persistence on drug after three years of follow-up (77.5%).

Disclosures of Interests: Ana Sofia Pinto: None declared, Kalveer Flora: None declared, Dilpreet Matharu: None declared, Anthony Isaacs: None declared, Pedro Machado Speakers bureau: Received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galagopagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript, Consultant of: Received consulting/speaker’s fees from Abbvie, BMS, Celgene, Eli Lilly, Galagopagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript


POS0951 SERUM PROTEIN RESPONSE TO A SINGLE HIGH-INTENSITY INTERVAL TRAINING BOUT – COMPARISON BETWEEN INDIVIDUALS WITH SPONDYLARTHRITIS AND HEALTHY CONTROLS

Å. Andersson1, E. Haglund2,3,4,5,6,7,8,9, E. Berthold4,9, A. Mogard1,9, M. C. Olsson1,9,10, Halmstad University, Dept. of Environmental and Biosciences, Halmstad, Sweden; 2FoU Spenshult Spenshult Research and Development Centre, Spenshult Research and Development Centre, Halmstad, Sweden; 3Lund University, Dept. of Clinical Sciences, Section of Rheumatology, Lund, Sweden; 4Halmstad University, Halmstad University, Halmstad, Sweden; 5Rheumatology, Dept. of Clinical Sciences Lund, Lund university, Lund, Sweden; 6Angelholm Hospital, Dept. of Rehabilitation, Angelhom, Sweden

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting mainly the axial skeleton. To decrease the risk of cardiovascular comorbidity, aerobic training is recommended as a part of disease management in patients with axSpA. High-intensity interval training (HIIT) interventions are, in addition to other recommended treatments, believed to positively affect the disease activity (1). However, the knowledge about the acute effects of HIIT on the inflammatory process at the molecular level is less studied. Understanding the acute HIIT effects on cytokines and additional serum proteins in axSpA is important for further long-term HIIT interventions and recording of the effect of HIIT on the axSpA disease profile.

Objectives: To study the acute effects on serum proteins, such as cytokines, myokines, and inflammatory- and bone-related proteins, in response to a single bout of HIIT, and to compare the levels between baseline and post-HIIT in patients with axSpA and healthy controls (HC).

Methods: The pilot study included twenty-one participants (10 female, 11 male), mean (SD) age 40 (7) years, ten with axSpA, and eleven age and sex matched HC, who performed a single HIIT on a cycle ergometer consisting of 4x4 minutes interval (90% heart rate, HR-max) with three minutes active rest in between (70% of HR-max). Disease activity (BASDAI, 0-10) in patients with axSpA was 1.6 (0.8), Health status EuroQol (EQ5D, 0-1) were 0.87 (0.11) for axSpA, and 0.93 (0.10) for HC. The groups were well matched with no difference in baseline data for weight, BMI, EQ5D, blood pressure or aerobic capacity.

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting mainly the axial skeleton. To decrease the risk of cardiovascular comorbidity, aerobic training is recommended as a part of disease management in patients with axSpA. High-intensity interval training (HIIT) interventions are, in addition to other recommended treatments, believed to positively affect the disease activity (1). However, the knowledge about the acute effects of HIIT on the inflammatory process at the molecular level is less studied. Understanding the acute HIIT effects on cytokines and additional serum proteins in axSpA is important for further long-term HIIT interventions and recording of the effect of HIIT on the axSpA disease profile.

Objectives: To study the acute effects on serum proteins, such as cytokines, myokines, and inflammatory- and bone-related proteins, in response to a single bout of HIIT, and to compare the levels between baseline and post-HIIT in patients with axSpA and healthy controls (HC).

Methods: The pilot study included twenty-one participants (10 female, 11 male), mean (SD) age 40 (7) years, ten with axSpA, and eleven age and sex matched HC, who performed a single HIIT on a cycle ergometer consisting of 4x4 minutes interval (90% heart rate, HR-max) with three minutes active rest in between (70% of HR-max). Disease activity (BASDAI, 0-10) in patients with axSpA was 1.6 (0.8), Health status EuroQol (EQ5D, 0-1) were 0.87 (0.11) for axSpA, and 0.93 (0.10) for HC. The groups were well matched with no difference in baseline data for weight, BMI, EQ5D, blood pressure or aerobic capacity.

Blood samples were taken before (baseline) and one hour after the single HIIT. The following serum proteins were analyzed on a Luminex MAGPIX
System (Luminex corporation, Austin, TX USA): Interleukin (IL)-6, IL-17, IL-18, TNFα, AGPIX System (Luminex corporthostprotein, osteocalcin, osteopontin, and FGF-23. A three-way analysis of variance (ANOVA) was used to detect differences between groups, between sexes, and before and after a HIIT bout in a 2(group)×2(sex)×2(time) design. For main effects or interactions significant at p<0.05, simple effect t-tests were used to determine the specific effects.

Results: A group main effect (p<0.048) showed that the serum level of IL-6 was increased one hour after the HIIT session primarily in the HCT. 0.4 ng/ml (SD±0.4) at baseline vs post-HIIT 1.8 (2.0). The concentration of the cytokines/chemokine IL-17, IL-18, TNFα group main effect (p<0.048) showed that the serum level of IL-6 was increased one hour after the HIIT session primarily in women, 10.7 ng/ml (7.0) vs men 20.4 (10.1, post-HIIT).

Conclusion: This pilot study shows that one bout of HIIT influences the expression of proteins involved in inflammation and metabolism, and that sex is an important factor in the response to HIIT. The results should be followed up in longer intervention studies including higher numbers of participants.

REFERENCES:

Disclosure of Interests: Åsa Andersson: None declared, Emma Haglund Consultant of: Novartis, Emma Berthold: None declared, Elisabeth Mogard Consultant of: Novartis, Anna Torell: None declared, M Charlotte Olsson: None declared DOI: 10.1136/annrheumdis-2022-eular.4984

POS0952
THE IMPACT OF DIET ON DISEASE ACTIVITY IN SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
A. Ortolan1, M. Felicetti1, M. Lorenzin1, G. Cozzi1, G. Striani1, A. Doria1, R. Ramonda2. University of Padova, Rheumatology Unit, Department of Medicine DIMED, Padova, Italy

Background: Diet is thought to have a role in inflammatory diseases development and course. However, at present, no recommendations can be given to spondyloarthritides (SpA) patients regarding a specific type of diet/dietary supplement, as evidence on the topic is sparse.

Objectives: To review the evidence about the effect of diet/dietary supplements on SpA disease activity

Methods: A systematic literature review (SLR) was conducted in MEDLINE and SCOPUS according to the “PEO” format (Population: SpA, axial or peripheral, including Psoriatic Arthritis-PsA; Exposure: any kind of diet/dietary supplement; Outcome: any available disease activity measurement). Inclusion criteria were: adult patients, Randomized Controlled Trials (RCTs) and longitudinal studies (so that a pre-and post-intervention assessment were available), papers in English. Risk of bias (RoB) was independently judged by 3 authors (AQ, MF, VB) and conducted with different tools according to the study design: Newcastle Ottawa Scale (NOS) for observational studies, the ROBINS-I tool for non-randomized studies, and the Cochrane risk of Bias tool 2.0 for RCTs.

Results: Literature search yielded 286 publications. After exclusion of 59 duplicates, 171 titles/abstract, and 44 full-texts, we included 8 interventional and 3 observational studies (Table 1). Among the former, 2 RCTs, one at unclear and one at low RoB, failed to show benefit of probiotics in SpA. One RCT at unclear RoB showed that weight loss, but not hypocaloric diet, was associated to MDA achievement in PsA. The other RCT, as well as the 4 quasi-interventional studies, were at high/serious RoB respectively. Among the observational studies, one study on Mediterranean diet demonstrated an association of diet adherence and a >20% decrease of ASDAS in axSpA. Two other studies were judged of poor quality.

Conclusion: weight loss seems to be able to impact disease activity in SpA, while probiotics were not effective in the available RCTs so far. Adherence to Mediterranean diet might play a role in reducing disease activity. Evidence for effectiveness of dietary behaviors in SpA is quite heterogeneous and high quality studies are warranted to better understand the role of diet in SpA.


POS0953
IMPACT OF A WEARABLE ACTIVITY TRACKER ON DISEASE ACTIVITY IN SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
G. Labat1, M. Hayotte2, O. Brocq1, L. Bailly3, R. Fabres4, M. Fournier5, V. Breuil6, F. D’Appendre Longueville2, G. Roux1, Université Cote d’Azur, Rheumatology, Nice, France; 2Université Cote d’Azur, Sports, Nice, France; 3Université Cote d’Azur, Health Sciences, Nice, France; 4Université Cote d’Azur, Medicine Physique, Nice, France

Background: Previous studies showed that a Mediterranean diet might play a role in reducing disease activity. Evidence for effectiveness of dietary behaviors in SpA is quite heterogeneous and high quality studies are warranted to better understand the role of diet in SpA.

Objectives: To review the evidence about the effect of diet/dietary supplements on SpA disease activity

Methods: A systematic literature review (SLR) was conducted in MEDLINE and SCOPUS according to the “PEO” format (Population: SpA, axial or peripheral, including Psoriatic Arthritis-PsA; Exposure: any kind of diet/dietary supplement; Outcome: any available disease activity measurement). Inclusion criteria were: adult patients, Randomized Controlled Trials (RCTs) and longitudinal studies (so that a pre-and post-intervention assessment were available), papers in English. Risk of bias (RoB) was independently judged by 3 authors (AQ, MF, VB) and conducted with different tools according to the study design: Newcastle Ottawa Scale (NOS) for observational studies, the ROBINS-I tool for non-randomized studies, and the Cochrane risk of Bias tool 2.0 for RCTs.

Results: Literature search yielded 286 publications. After exclusion of 59 duplicates, 171 titles/abstract, and 44 full-texts, we included 8 interventional and 3 observational studies (Table 1). Among the former, 2 RCTs, one at unclear and one at low RoB, failed to show benefit of probiotics in SpA. One RCT at unclear RoB showed that weight loss, but not hypocaloric diet, was associated to MDA achievement in PsA. The other RCT, as well as the 4 quasi-interventional studies, were at high/serious RoB respectively. Among the observational studies, one study on Mediterranean diet demonstrated an association of diet adherence and a >20% decrease of ASDAS in axSpA. Two other studies were judged of poor quality.

Conclusion: weight loss seems to be able to impact disease activity in SpA, while probiotics were not effective in the available RCTs so far. Adherence to Mediterranean diet might play a role in reducing disease activity. Evidence for effectiveness of dietary behaviors in SpA is quite heterogeneous and high quality studies are warranted to better understand the role of diet in SpA.


Table 1. Characteristics of the included studies

<table>
<thead>
<tr>
<th>Author year</th>
<th>Population</th>
<th>Intervention</th>
<th>Study design</th>
<th>Rando-</th>
<th>Controlled</th>
<th>Sample</th>
<th>Follow-up (weeks)</th>
<th>Primary outcome</th>
<th>Male Sex (%)</th>
<th>Mean Age (years)</th>
<th>Concomitant medications besides symptomatics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lassar 1990</td>
<td>PsA</td>
<td>PU ethyl ester lipids supplementation</td>
<td>Quasi-exp</td>
<td>No</td>
<td>No</td>
<td>80</td>
<td>8</td>
<td>NR</td>
<td>50</td>
<td>49</td>
<td>stable csDMARDs</td>
</tr>
<tr>
<td>Appelborn 1994</td>
<td>AS</td>
<td>Milk product deprivation</td>
<td>Quasi-exp</td>
<td>No</td>
<td>Yes (as RA)</td>
<td>25/10</td>
<td>6</td>
<td>NR</td>
<td>NR</td>
<td>28%</td>
<td>on stable csDMARDs</td>
</tr>
<tr>
<td>Sundström 2006</td>
<td>AS</td>
<td>Omega 3 fatty acids</td>
<td>RCT</td>
<td>Yes</td>
<td>(high vs low dose)</td>
<td>24</td>
<td>21</td>
<td>NR</td>
<td>61</td>
<td>NR</td>
<td>No csDMARDs</td>
</tr>
<tr>
<td>Di Minno 2014</td>
<td>Obese overweight PsA</td>
<td>Hypocaloric diet</td>
<td>RCT</td>
<td>Yes</td>
<td>Yes (hypocaloric vs free diet)</td>
<td>138</td>
<td>24</td>
<td>MDA (+)</td>
<td>36</td>
<td>45</td>
<td>All patients started anti-TNF; concomitant MTX in 29%</td>
</tr>
<tr>
<td>Kinberg 2019</td>
<td>Obese PsA</td>
<td>Hypocaloric diet</td>
<td>Quasi-exp</td>
<td>No</td>
<td>Yes (PsA vs controls)</td>
<td>46</td>
<td>12-16</td>
<td>MDA (+)</td>
<td>36</td>
<td>56</td>
<td>100% on stable csDMARDs</td>
</tr>
<tr>
<td>Kinberg 2020</td>
<td>Obese PsA</td>
<td>Hypocaloric diet</td>
<td>Quasi-exp</td>
<td>No</td>
<td>Yes (PsA vs controls)</td>
<td>74</td>
<td>20</td>
<td>NR</td>
<td>36</td>
<td>56</td>
<td>100% on stable csDMARDs</td>
</tr>
<tr>
<td>Brophy 2008</td>
<td>SpA</td>
<td>Probiotics</td>
<td>Internet-based RCT</td>
<td>Yes</td>
<td>(probiotics placebo)</td>
<td>147</td>
<td>12</td>
<td>Satisfaction of CONSORT statement (+)</td>
<td>64</td>
<td>44</td>
<td>10% on stable csDMARDs</td>
</tr>
<tr>
<td>Jenkins 2010</td>
<td>SpA</td>
<td>Probiotics</td>
<td>RCT</td>
<td>Yes</td>
<td>(probiotics placebo)</td>
<td>63</td>
<td>12</td>
<td>BASFI (-)</td>
<td>63</td>
<td>43</td>
<td>28.5% on csDMARDs</td>
</tr>
</tbody>
</table>

PsA: Psoriatic arthritis, AS ankylosing spondylitis, SpA spondyloarthritis, ax: axial; RA Rheumatoid Arthritis, PU polysaturated; RCT Randomized Controlled Trial; exp=experimental; MDA Minimal Disease Activity; CONSORT CONsolidated Standards of Reporting Trials; BASFI Bath Ankylosing Spondylitis Functional Index; (+) or (-) indicate whether the primary outcome of the study was met or not.
Background: Other studies have shown the ability of a wearable activity tracker (TAP) to improve physical activity (PA) in different rheumatic diseases. Given the importance of PA in spondyloarthritis, our hypothesis is that the use of a TAP could improve physical activity and thus disease activity.

Objectives: The purpose of this study is to evaluate the impact of a TAP used to encourage PA on disease activity in patients with spondyloarthritis.

Methods: In this randomized controlled trial consisting of three 12-week stages (Figure 1), Patients with spondyloarthritis were randomized to a group with TAP (GT), or a group without TAP (GST). For the first stage, both groups received physical activity counseling. In the second 12-week stage, no patients received TAP. In the third 12-week stage, all patients received supervised PA combined with TAP for GT only. Disease activity, performance (assessed by the TM6 6-minute walk test), and quality of life (assessed by the Short Form 36 Health Survey Questionnaire [SF-36]) were assessed at 12, 24, and 36 weeks. The primary endpoint was the progression of relapses between baseline and 12 weeks.

Results: A total of 108 patients were included in the study. At 12 weeks, both groups showed a non-significant improvement in the number of relapses: mean change (Δ) -0.32 [95% CI -0.68;0.09] in GT and Δ -0.38 [95% CI -0.68;0.09] in GST. But, differences in outcome between groups were not significant (p = 0.87). The TM6 was improved in the GT and GST groups at 12, 24, and 36 weeks (p < 0.01, and p < 0.001, respectively). We observed improvement in different dimensions of the SF36, mainly in physical function, emotional role, general health, and physical pain at 12 weeks (p < 0.01). Multivariate analysis showed improvement over time in performance (p < 0.01) and moderate flare-ups (p < 0.01) without the influence of a PAR (p = 0.29, and p = 0.66, respectively).

Conclusion: To our knowledge, our study is the first to explore the impact of TAP use on disease activity in spondyloarthritis. We observed an improvement in disease activity, physical performance and quality of life without significant difference between the two groups. The lack of difference could be explained by the encouragement of physical activity to both groups. But also by the fact that our patients presented a significant number of severe relapses. Indeed, authors have shown the limits of the use of a TAP combined with PA for GT only. Our patients presented a significant number of severe relapses. Indeed, authors have shown the limits of the use of a TAP combined with PA for GT only. Our patients presented a significant number of severe relapses.

REFERENCES:

Disclosure of Interests: Guillaume Labat: None declared, Meggy Hayotte: None declared, Ollivier Brocq: None declared, laurent bailly: None declared, Roxane fabre: None declared, manuella Fournier: None declared, Véronique Breuil: None declared, fabienne d’arripe longueville: None declared, Christian Roux: None declared, Lilly: Grant/research support from: Novartis and Lilly

Figure 1.

Conclusion: In this prospective evaluation, the generally proposed better response of axSpA patients to treatment with high doses of NSAIDs as compared with non-inflammatory back pain was not confirmed, although the overall rate of responders was similar to previously reported rates. On the other hand, better responses were found in patients treated in the early (nr-axSpA) stage and in male patients. axSpA patients with increased CRP values showed lower rates of response.

Disclosure of Interests: None declared
Spondyloarthritides - clinical aspects (other than treatment)

POS0955 PATIENTS' PERSPECTIVES ON DISEASE- AND TREATMENT-RELATED ISSUES ARE ESSENTIAL FOR TREATMENT SUCCESS IN PATIENTS WITH SPONDYLOARTHRITIS AND ASSOCIATED DISEASES: A QUALITATIVE CLINICAL CONCEPT MAPPING STUDY

Z. R. Stensen1, M. Skougaard1,2, R. L. Hansen1, K. R. Christensen1, L. E. Kristensen1, T. S. Jørgensen1,1 The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark; 2Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; 3Department of Gastroenterology, Herlev and Gentofte Hospital, Copenhagen, Denmark

Background: Each patient's way of living with and relating to their chronic disease is unique. However, patients with chronic diseases may have some mutual concerns and challenges. They must not only handle the disease itself, but also its consequences that the disease has for their everyday and emotional lives. Exploring the patient's perspectives for significant factors of relevance for patients living with a chronic disease is important in order to discover unmet needs and challenges for complying with a comprehensive lifelong treatment strategy and ensuring high-quality lives. Increasing awareness about the possible discrepancy between doctor experienced quality in care and patient experienced quality in care is of high relevance when aiming to ensure optimal disease management.

Objectives: The objective of this study was to explore disease- and treatment-related issues and concerns experienced by adult patients with spondyloarthritis (SpA) and associated diseases; psoriatic arthritis (PsA), psoriasis (PsO), axial spondyloarthritis (axSpA), and inflammatory bowel disease (IBD; Crohn's disease (CD) and ulcerative colitis (UC)), and whether these factors were generic or disease dependent.

Methods: Concept Mapping were used to identify and organize disease- and treatment-related issues and concerns. Concept Mapping is a formal group process with a structured approach to identify ideas on a topic of interest and organize them into cogent domains. Participants were asked to respond to an initial task: “Thinking as broadly as you can, please list your thoughts (issues and concerns) related to your disease”, PsA, PsO, axSpA, CD or UC, respectively. Data were obtained through a nominal group technique and then organized using participant validation, and thematic analyses to generate a conceptual model of disease- and treatment-related issues and concerns experienced by patients with PsA, PsO, axSpA, CD, and UC.

Results: Seven AxSpA patients, 8 PsA patients, 9 PsO patients, 13 CD patients, and 13 UC patients contributed to generating the conceptual models. Seven AxSpA clusters, 7 PsA clusters, 7 PsO clusters, 10 CD clusters, and 11 UC clusters with each cluster having sub-clusters, emerged from the workshops producing 137 AxSpA statements, 160 PsA statements, 187 PsO statements, 335 CD statements, and 408 UC statements. Some clusters were generic: ‘Concerns about the disease and the future’, ‘Consequences of the disease’, ‘Acceptance of the disease’, ‘Medication and treatment’, and ‘At the doctor’ (Figure 1). Specific clusters were: for AxSpA: ‘Use of public services, for PsA: ‘Difficult to have an invisible disease’, for PsO: ‘Ashamed (about appearance)’, for CD: ‘Speculations and thoughts; life now and in the future - can I expect more surgeries in the future?’, and for UC: ‘The influence and importance of the diet’ and (Figure 1).

Conclusion: Patients with SpA and associated diseases largely agree on which concepts describe their disease- and treatment-related issues and concerns with a few of them being disease-dependent.

Living a good life with a chronic disease is much more than having clinical control of the disease. This study gives insight to patients' perspectives on themes that are essential when living with a chronic disease. Considering the patients' perspectives, it is necessary to promote patient empowerment and adherence to treatment, and thereby optimize disease management and quality of life.

REFERENCES:

Acknowledgements: We would like to thank all the participants who generously shared their experiences and valuable knowledge concerning life with a chronic disease.

Disclosure of Interests: Zara Rebecca Stisen: None declared, Marie Skougaard Grant/research support from: M. Skougaard has received research funding from Eli Lilly and Pfizer that is unrelated to the current abstract, Rebekka L. Hansen: None declared, Katrine Risager Christensen Grant/ research support from: K.R. Christensen has participated in advisory board for Gilead Nordic and received unrestricted grants from Pfizer and Gilead Nordics, Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Ame

POS0956 HIGH INFLAMMATORY BURDEN PREDICTS CARDIOVASCULAR EVENTS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A LONG-TERM FOLLOW-UP STUDY

J. L. H. Shi1, S. H. M. Lam1, H. So1, E. L1, T. K. L1, C. C. Szeto1, L. S. Tam1, 1The Chinese University of Hong Kong, Medicine & Therapeutics, Hong Kong, China

Background: Axial spondyloarthritis (axSpA) patients had a higher risk of cardiovascular disease (CVD) than the general population (1). It is also suggested that inflammation, rather than a particular disease, drives the increased risk of CVD (2). But the relationship between inflammation in axSpA and CVD is unknown.

Objectives: To examine whether inflammatory burden over time can predict cardiovascular events (CVE) independent of baseline CVE risk factors in axial spondyloarthritis (axSpA) patients.

Methods: A cohort analysis was performed in patients who had been recruited since January 2001. The primary outcome was a first CVE occurring between January 2001 and December 2020. Three CVE risk scores were computed at baseline. The performance of the original and modified (x 1.5 multiplication factor) CVE risk algorithms were assessed. Time-varying Cox proportional hazard models and Kaplan-Meier survival analysis were used to assess whether inflammatory burden (Bath ankylosing spondylitis disease activity index [BASDAI] and inflammatory markers), non-steroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs) can predict the development of first CVE.

Results: 463 patients [35(26-45) years, male: 360(77.8%)] were recruited. After a median follow up of 12 (7-19) years, 61 patients (13.2%) experienced a first CVE. Traditional/modified CVE risk scores underestimated CVE risk. Erythrocyte sedimentation rate (ESR)<20 mm/hr was associated with a significantly higher risk of CVE during follow-up [HR: 2.07, 95%CI (1.10, 3.98), p<0.008]. Active disease as indicated by a rising BASDAI also showed positive trend towards a higher risk of developing CVE over time. After adjusting for CVE risk scores in the multivariable models, high ESR level (ESR>20 mm/hr) over time remained significantly associated with a higher risk of developing CVE events (Table 1a and 1b). A significant difference in the CVE event-free survival between patients with ESR<20 mm/hr and ESR>20 mm/hr was demonstrated in Figure 1.
null
**Table 1.**

<table>
<thead>
<tr>
<th>AS</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No fracture</strong></td>
<td><strong>Fracture</strong></td>
</tr>
<tr>
<td>(n=10637)</td>
<td>(n=974)</td>
</tr>
<tr>
<td>Male sex</td>
<td>7002 (65.8)</td>
</tr>
<tr>
<td>Mean age (SD)</td>
<td>476 (14.7)</td>
</tr>
<tr>
<td>Prior fracture</td>
<td>667 (6.3)</td>
</tr>
<tr>
<td>Osteoporosis*</td>
<td>359 (3.4)</td>
</tr>
<tr>
<td>Fall injury without fracture</td>
<td>714 (6.7)</td>
</tr>
<tr>
<td>Harmful use of alcohol</td>
<td>158 (1.5)</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>39 (0.4)</td>
</tr>
<tr>
<td>Diabetes type 1</td>
<td>178 (1.7)</td>
</tr>
<tr>
<td>Liver diseases</td>
<td>66 (0.6)</td>
</tr>
<tr>
<td>Malnutrition</td>
<td>8 (0.1)</td>
</tr>
<tr>
<td>Hypogonadism or premature menopause</td>
<td>11 (0.1)</td>
</tr>
<tr>
<td>Use of oral glucocorticoids*</td>
<td>153 (14.4)</td>
</tr>
<tr>
<td>Anterior uveitis</td>
<td>2168 (20.4)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>316 (3.0)</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>675 (6.3)</td>
</tr>
<tr>
<td>Use of any DMARD*</td>
<td>3411 (32.1)</td>
</tr>
<tr>
<td>Use of TNF inhibitor*</td>
<td>1539 (14.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>P-value</strong></th>
<th><strong>No fracture</strong></th>
<th><strong>Fracture</strong></th>
<th><strong>P-value</strong></th>
<th><strong>No fracture</strong></th>
<th><strong>Fracture</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>0.014</td>
<td>35448 (65.7)</td>
<td>2572 (62.6)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Mean age</td>
<td>&lt;0.001</td>
<td>478 (14.7)</td>
<td>53.0 (15.0)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Prior fracture</td>
<td>&lt;0.001</td>
<td>2715 (5.0)</td>
<td>466 (11.8)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis*</td>
<td>&lt;0.001</td>
<td>367 (0.7)</td>
<td>85 (2.1)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Fall injury without fracture</td>
<td>&lt;0.001</td>
<td>3265 (0.9)</td>
<td>360 (1.9)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Harmful use of alcohol</td>
<td>0.005</td>
<td>889 (1.6)</td>
<td>171 (4.2)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>0.105</td>
<td>180 (0.3)</td>
<td>19 (0.5)</td>
<td>0.173</td>
<td></td>
</tr>
<tr>
<td>Diabetes type 1</td>
<td>0.002</td>
<td>651 (1.2)</td>
<td>80 (1.9)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Liver diseases</td>
<td>0.122</td>
<td>197 (0.4)</td>
<td>32 (1.0)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Malnutrition</td>
<td>0.058</td>
<td>16 (0.0)</td>
<td>2 (0.0)</td>
<td>0.367</td>
<td></td>
</tr>
<tr>
<td>Hypogonadism or premature menopause</td>
<td>1.000</td>
<td>33 (0.1)</td>
<td>0 (0.0)</td>
<td>0.169</td>
<td></td>
</tr>
<tr>
<td>Use of oral glucocorticoids*</td>
<td>0.304</td>
<td>839 (1.6)</td>
<td>97 (2.4)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Anterior uveitis</td>
<td>0.677</td>
<td>317 (0.6)</td>
<td>32 (0.8)</td>
<td>0.126</td>
<td></td>
</tr>
<tr>
<td>Psoriasis</td>
<td>0.364</td>
<td>605 (1.1)</td>
<td>58 (1.4)</td>
<td>0.091</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>0.783</td>
<td>441 (0.9)</td>
<td>36 (0.9)</td>
<td>0.811</td>
<td></td>
</tr>
<tr>
<td>Use of any DMARD*</td>
<td>0.002</td>
<td>465 (0.9)</td>
<td>52 (1.3)</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>Use of TNF inhibitor*</td>
<td>0.005</td>
<td>43 (0.1)</td>
<td>4 (0.1)</td>
<td>0.573</td>
<td></td>
</tr>
</tbody>
</table>

The data is presented as number (%) if not stated otherwise. *Diagnosed osteoporosis and/or use of osteoporosis medication. **Prednisolone equivalent cumulative dose of ≥450 mg within the last year before start of follow-up. #Use within the last year before start of follow-up.
was used to estimate the influence of each established risk factor in AS and controls. Risk factors for which there were ≤20 observed events in the AS cohort were not included. Results are presented as incidence rate ratios (IRR) with 95% confidence intervals.

Results: In total 974 (8.4%) patients with AS and 4106 (7.1%) of their controls were registered with a non-vertebral fracture during the study period. The characteristics of the patients and controls at start of follow-up are presented in Table 1 stratified by fracture status during follow-up. Figure 1 displays the results from the Poisson regression.

Figure 1. Multivariable Poisson regression analyses for a non-vertebral fracture during follow-up, with results presented for each included baseline variable as IRR with 95% CI, separately for AS and controls.

Conclusion: The influence of established risk factors for fragility fractures in AS is similar to that in the general population; in both populations with advanced age, prior fracture and harmful use of alcohol being the strongest risk factors.

Disclosure of Interests: Karin Bengtsson: None declared, Johan Askling Grant/ research support from: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi, and UB, Mattias Lorentzen: None declared, Björn Rosengren: None declared, Anna Deminger: None declared, Eva Klingberg: None declared, Lennart T.H. Jacobsson: Speakers bureau: Lecture and consulting fees from Novartis, Eli Lilly and Janssen, Helena Forsblad-d’Elia: None declared

DOI: 10.1136/annrheumdis-2022-eular.519

POS0961 CLINICAL PROFILE AND TREATMENT UTILIZATION IN HLA-B27 POSITIVE VERSUS HLA-B27 NEGATIVE PATIENTS: RESULTS FROM ASAS-PERSPA STUDY

M. Magrey1, C. López-Medina2, M. A. Khan3,1. Case Western Reserve University School of Medicine/ University Hospitals, Medicine, Cleveland, United States of America;2Cochin Hospital, Rheumatology, Paris, France; 3Professor Emeritus, Case Western Reserve University School of Medicine, Medicine, Cleveland, United States of America

Background: HLA-B27 is a genetic marker strongly associated with axial spondyloarthritis (axSpA). However, the strength of this association varies worldwide. Although some regional studies have assessed the effect on HLA-B27 status on clinical features of axSpA, no worldwide study has been performed.

Objectives: To characterize differences in the clinical features, extra-articular manifestations, and treatment utilizations in a global axSpA cohort based on their HLA-B27 status.

Methods: We performed a post-hoc analysis of the ASAS-PersPa study (Peripheral involvement in Spondyloarthritides) dataset that includes patients with axial (axSpA) and peripheral SpA (pSpA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (axSpA), SpA associated with inflammatory bowel disease (IBD) and reactive arthritis based on their rheumatologist’s diagnosis. We identified patients that had been diagnosed with axSpA meeting the 2009 ASAS classification criteria and been typed for HLA-B27. The patient characteristics were compared between the HLA-B27(+) and HLA-B27(−) subgroups using Student’s t-test and the Mann-Whitney U test. Multivariable logistic regression with backward stepwise selection was conducted to identify predictors of HLA-B27 positivity. Variables with p-value <0.15 on univariate analysis were included in the multivariable model. All tests were two-tailed with p-value <0.05 considered significant.

Results: A total of 4465 patients with axSpA from 24 countries were identified. We observed that 2910 patients fulfilled the 2009 ASAS classification criteria. Of these patients, 2269 were tested for HLA-B27 (HLA-B27: 1753 and HLA-B27: 516). Significant differences were observed between these two groups in age of symptom onset and manifestations of the disease as shown in Table 1. The HLA-B27(−) patients had a significantly later age of symptom onset and disease diagnosis, more often had concomitant IBD, psoriasis, peripheral arthritis, enthesitis and were more often treated with csDMARDs. On multivariable logistic regression factors significantly associated with HLA-B27 positivity included male sex (OR: 1.99), family history of axSpA (OR: 2.26), and occurrence of anterior uveitis (OR: 2.72).

Conclusion: In a large heterogeneous cohort of AxSpA patients from 24 countries, we found that male sex, family history, and occurrence of anterior uveitis are significant predictors of HLA-B27 positivity. In contrast, the HLA-B27(−) had a significantly later age of onset and longer delay in diagnosis, more often have concomitant IBD, psoriasis, peripheral arthritis and enthesitis, and also more often receive treatment with csDMARDs.

Acknowledgements: ASAS for sponsoring the ASAS-PersPa study

Disclosure of Interests: M. Magrey Consultant of: Novartis, Abbvie, Pfizer; Janssen, Eli Lilly, UCB Pharma, Clementina López-Medina: None declared, Muhammad Asim Khan: None declared

DCA confirmed that the radiomics model was clinically useful. Furthermore, Rad-score and SPARCC scores were performed to quantify the BMO of selected from the 3.0T SIJ-MRI in the training cohort, were included to build the model. Bone marrow oedema (BMO) of the sacroiliac joints (SIJs) is evaluated to diagnose, classify and monitor disease activity in patients with spondyloarthritis (SpA). Available quantitative methodologies rely on human visual assessment, and errors can’t be completely avoided. Radiomics can extract and select discriminative and quantified features from regions of interest (ROIs), making a more accurate and objective description of BMO.

**Background:** Bone marrow oedema (BMO) of the sacroiliac joints (SIJs) is evaluated to diagnose, classify and monitor disease activity in patients with axial spondyloarthritis (axSpA). Available quantitative methodologies rely on human visual assessment, and errors can’t be completely avoided. Radiomics can extract and select discriminative and quantified features from regions of interest (ROIs), making a more accurate and objective description of BMO.

**Objectives:** To develop a more objective and efficient method based on radiomics to evaluate BMO of the SIJs by magnetic resonance imaging (MRI) in patients with axSpA in comparison with Spondyloarthritis Research Consortium of Canada (SPARC) scoring system.

**Methods:** From September 2013 to July 2021, 523 patients with axSpA underwent 3.0T SIJ-MRI were included, who were randomly classified as training cohort (n=367) and validation cohort (n=156). The optimal radiomics features, selected from the 3.0T SIJ-MRI in the training cohort, were included to build the radiomics model. Four clinical risk predictors were adopted to build the clinical model. The performance of the clinical and radiomics models was evaluated by ROC analysis and decision curve analysis (DCA). Rad-scores were calculated by the radiomics model and SPARC scores were performed to quantify the BMO of the SIJs. We also assessed the correlation between Rad-score and SPARC score.

**Results:** The radiomics model, built by 15 optimal features, showed favorable discrimination about SPARC score <2 or ≥2 both in the training (AUC, 0.91; 95% CI: 0.88-0.94) and the validation cohort (AUC, 0.89; 95% CI, 0.84-0.94). DCA confirmed that the radiomics model was clinically useful. Furthermore, Rad-score has significant correlation with SPARC score for scoring the status of BMO (r=0.78, P<0.001), and moderate correlation for scoring the change (r=0.40, P=0.005).

**Conclusion:** The radiomics can accurately assess the BMO of the SIJs in axSpA, providing an alternative to SPARC scoring system. There was a positive correlation between Rad-score and SPARC score.

**REFERENCES:**


clinical trials. Over time, an increasing number of publications on early SpA were identified: <2005 (n=34), 2005-2010 (n=48), 2011-2015 (n=109) and 2016-2020 (n=164). Overall, 63 studies (34%) included the term “early axSpA”. 60 (32%) “early ankylosing spondylitis (AS)”, 58 (31%) “early SpA”, 4 (2%) “early non-radiographic axSpA (nr-axSpA)”, and 1 (1%) “early pSpA”. In total, 116 (62%) studies reported a specific definition: 40 (34%) based it on symptom duration, 35 (30%) on radiographic damage, 32 (28%) on disease duration, 6 (5%) on both symptom/disease duration and radiographic damage, and 3 (3%) on other aspects. Symptom duration was defined as the time since the onset of low back pain in 21/40 (53%) studies, whereas in 14/40 (35%) the symptom of onset was not specified. Thirty-five of 116 studies (30%) included a definition referred to “early SpA” (38 (33%) to “early axSpA” (33%) to “early AS” (4%) “to early nr-axSpA” and 1 (1%) to “early pSpA”. Figure 1 shows the 18 distinct definitions that were identified (after combining some similar categories). The three most used definitions per subtype of disease are shown in Table 1. Regarding the studies that referred to “early SpA”, the most used definition was symptom/duration <5 years, whereas for “early AS” was symptom/duration <10 years. After 2010, the definition of “early axSpA” based on the absence of radiographic sacroiliitis was less used compared to before 2010 (5/30, 17% vs 3/8, 38%).

Table 1. Top 3 candidate definitions for “early SpA” and subtypes

<table>
<thead>
<tr>
<th>Core of the definition</th>
<th>Number of studies, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SpA (n=35)</td>
<td></td>
</tr>
<tr>
<td>nr-axSpA 1 (29%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 2 years duration 1 (10%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 1 year duration 1 (29%)</td>
<td></td>
</tr>
<tr>
<td>AxSpA (n=38)</td>
<td></td>
</tr>
<tr>
<td>&lt; 5 years duration 12 (34%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 3 years duration 9 (24%)</td>
<td></td>
</tr>
<tr>
<td>nr-axSpA 8 (21%)</td>
<td></td>
</tr>
<tr>
<td>IS/raxSpA (n=38)</td>
<td></td>
</tr>
<tr>
<td>&lt;10 years duration 9 (24%)</td>
<td></td>
</tr>
<tr>
<td>nr-axSpA 7 (18%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 2 years duration 6 (16%)</td>
<td></td>
</tr>
<tr>
<td>nr-axSpA (n=4)</td>
<td></td>
</tr>
<tr>
<td>&lt;1 year &amp; nr-axSpA 2 (50%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 5 years &amp; nr-axSpA 1 (25%)</td>
<td></td>
</tr>
<tr>
<td>pSpA (n=1)</td>
<td></td>
</tr>
<tr>
<td>&lt; 12 weeks duration 1 (100%)</td>
<td></td>
</tr>
</tbody>
</table>

‘Duration’ refers to symptom duration or disease duration.

Figure 1. Number of studies stratified by the core of the definition.

Conclusion: Over time, the term ‘early SpA’ and its subtypes are increasingly used. Despite addressing early SpA, more than one third of the studies did not include a clear definition of the term. The studies reporting a definition of early SpA showed a large heterogeneity, with two out of three of them based on the duration of symptoms or clearly ankylosing spondylitis (AS) defined as radiographic inflammatory vertebral changes.</p>
Conclusion: While in raxSpA vertebral inflammation associates with low vertebral bone density, lower vertebral bone density itself does not increase the risk for ectopic bone formation at the same vertebral.

REFERENCES:

Disclosure of Interests:
Gaalen: None declared, Sofia Ramiro: None declared, Xenofon Baraliakos: None declared, Juergen Braun: None declared, Monique Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Rosalinde Stal: None declared, da Silva: None declared, Désirée van der Heijde Consultant of: AbbVie, Gilead, Mary Lucy Marques: None declared, Nuno Pereira

Acknowledgements: To the Dutch Rheumatism Association for funding SIAS study.

Disclosure of Interests: Mary Lucy Marques: None declared, Nuno Pereira da Silva: None declared, Désirée van de Heijde Consultant of: AbbVie, Gliead, Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Rosalinde Stal: None declared, Xenofon Baraliakos: None declared, Juergen Braun: None declared, Monique Reijnierse: None declared, Caroline Bastiaenen: None declared, Floris A. van Gaalen: None declared, Sofia Ramiro: None declared


Figure 1. Methodology of Hounsfld Units [HU] measurement. Using a three-dimensional curved-multiplanar reconstruction the curve of the spine was identified from the spinal canal [3a]. On the obtained sagittal image, the vertebras could be identified. At each vertebral, two lines of reference were positioned at the superior (yellow line A) and inferior (yellow line C) limits of the vertebral body, equidistant to A and C. The yellow line B was positioned at the center of the vertebral body (3b). In the reconstructed cross-sectional slice, the vertebral body was delineated [3c]. A centered region of interest (ROI) was manually selected, having a diameter equal to 75% of the average of anteroposterior and transverse diameters, and the density of the vertebra was calculated as the average image density within the sample region, reported in HU (14).

Acknowledgements: To the Dutch Rheumatism Association for funding SIAS study.

Disclosure of Interests: Mary Lucy Marques: None declared, Nuno Pereira da Silva: None declared, Désirée van de Heijde Consultant of: AbbVie, Gliead, Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Rosalinde Stal: None declared, Xenofon Baraliakos: None declared, Juergen Braun: None declared, Monique Reijnierse: None declared, Caroline Bastiaenen: None declared, Floris A. van Gaalen: None declared, Sofia Ramiro: None declared


Figure 1. MRE score ROC curve for participants fulfilling ASAS criteria for axial spondyloarthritis.

Acknowledgements: Acknowledgement is given to Dr Beverly Ng, Katherine Hodges and CARE for their contribution to this study.

Disclosure of Interests: Josie Evans Grant/research support from: Clinical study (ProSpA-CD) funded by Merck, Sharpe and Dohme (MSD), Tim Raine:
Background: Early detection and diagnosis of Ankylosing spondylitis (AS) is challenging due to heterogeneity in disease presentation, lack of specific biomarkers and high prevalence of mechanical back-pain that is difficult to distinguish from inflammatory back-pain. However, if diagnosed and treated early, the risk of AS complications and disease progression can be slowed.

Objectives: To develop and validate a risk prediction model for early identification of patients at high risk of AS, using a large longitudinal real-world clinical data in the US.

Methods: This retrospective study included all members aged ≥21 years with back pain symptoms who were enrolled in the Kaiser Permanente Southern California health plan between 01/2009-12/2013. Patients who presented with back pain symptoms at a physician visit were followed until 12/2020 to see if they subsequently developed AS. The cohort was randomly divided into a training (60%) and validation (40%) sample. A proportional odds model was specified to create a risk score for AS in the training sample. Best fit model was determined based on the Area Under the Curve (AUC) and Akaike Information Criterion (AIC). The cut-off threshold of “high-risk” was based on the optimal Youden index. The model was assessed on the training and validation data using the Area Under the Curve (AUC) and Akaike Information Criterion (AIC). The split sample of overfitting to our training sample was observed based on the split sample AUC.

Results: The cohort comprised 527,509 members with mean age 54 years and majority female (58%). Sixty-six percent were White race and 33% were Hispanic ethnicity. The crude incidence of AS was 1% and increased steadily during the follow-up period (Figure 1). The final risk prediction model included 15 risk factors and had an AUC of 0.72 (Table 1). The final risk prediction model included 15 risk factors and had an AUC of 0.72 (Table 1). The cut-off threshold of “high-risk” was based on the optimal Youden index. We assessed the model performance for internal validity using split-samples. The model was further validated using manual chart review of 900 patient records. These 900 records were selected such that 70% (N=630) met the high-risk cut-off and the remaining had scores below the cut-off. We also derived the probability of AS in each chart reviewed using the method proposed by Feldtkeller et al. (2013) and Rudwaleit et al. (2006).

Conclusions: The model showed sufficient ability to discriminate between those at high-risk vs those not identified to be high-risk. When a concrete rule out or rule in determination could be made using Feldtkeller et al. approach, our model correctly classified 75% of such records.

Table 1. Final Model Coefficients and Derived Risk Score

| Model Coefficient | Pr(>|z|) | Risk Score |
|-------------------|----------|------------|
| Age above 45 years | 0.146    | 0.011      | 1.46       |
| Male Sex          | -0.292   | <0.001     | -2.92      |
| White Race        | 0.259    | <0.001     | 2.59       |
| Non-Hispanic Ethnicity | 0.177 | <0.001     | 1.77       |
| Corticosteroid Use (Yes/No) | 0.235 | <0.001     | 2.35       |
| NSAID User (Yes/No) | 0.202    | <0.001     | 2.02       |
| Opioid Analgesic User (Yes/No) | 0.416 | <0.001     | 4.16       |
| Had Enthesitis (Yes/No) | 0.298 | <0.001     | 2.98       |
| Had Disorders of the Back (Yes/No) | 0.973 | <0.001     | 9.73       |
| Had Fatigue and/or Malaise (Yes/No) | 0.155 | 0.056     | 1.55       |
| Had Psoriasis (Yes/No) | 0.288 | 0.008     | 2.88       |
| Had Spondylitis (Yes/No) | 0.838 | <0.001     | 8.38       |
| Had Symptotic (Yes/No) | 0.143 | 0.066     | 1.43       |
| Had Uveitis (Yes/No) | 0.621 | 0.007     | 6.21       |
| Depression Diagnosis (Yes/No) | 0.099 | 0.017     | 0.99       |

* NSAID: Non-steroidal anti-inflammatory drugs

Figure 1. Cumulative Incidence Over Time (in Days)

Conclusion: To aid early detection, we have developed and validated an AS risk prediction model with an easy to implement scoring system using demographics, medication use and diagnosis data that is routinely collected in clinical practice.

REFERENCES:

Disclosure of Interests: Aniket Kawatkar Grant/research support from: Novartis, Medac, Esther Yi Employee of: Novartis, Erika Estrada Grant/research support from: Novartis, Jose Pio Grant/research support from: Novartis, Cecilia Portugal Grant/research support from: Novartis, David Yi Grant/research support from: Novartis, Talar Habeshian Grant/research support from: Novartis, David Wei Employee of: Novartis, Steven Lee Grant/research support from: Novartis DOI: 10.1136/annrheumdis-2022-eular.1208
were associated with the presence of PsO in the multivariable logistic regression analysis (Figure 1). Higher patient global assessment scores and lower use of bDMARD treatments were observed in patients without PsO as compared to patients with PsO.

Table 1. Demographics and clinical characteristics of patients with pSpA according to the presence or absence of personal history of PsO

<table>
<thead>
<tr>
<th>Total</th>
<th>Patients without personal history of PsO N=350</th>
<th>Patients with personal history of PsO N=83</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>44.2 (14.4)</td>
<td>43.2 (14.2)</td>
<td>48.4 (14.5)</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>203/433 (46.9)</td>
<td>167/370 (47.7)</td>
<td>36/83 (43.4)</td>
</tr>
<tr>
<td>Symptom duration of pSpA (years), mean (SD)</td>
<td>10.1 (9.5)</td>
<td>9.0 (8.8)</td>
<td>14.4 (10.8)</td>
</tr>
<tr>
<td>Diagnostic delay of SpA (years), mean (SD)</td>
<td>4.3 (6.6)</td>
<td>3.5 (5.9)</td>
<td>7.4 (8.4)</td>
</tr>
<tr>
<td>First- or second-degree relatives with PsO (except psoriasis) N=350</td>
<td>74/433 (17.1)</td>
<td>61/350 (17.4)</td>
<td>13/83 (15.7)</td>
</tr>
<tr>
<td>First- or second-degree relatives with psoriasis N=83</td>
<td>63/391 (16.1)</td>
<td>29/308 (9.4)</td>
<td>34/83 (41.0)</td>
</tr>
<tr>
<td>Patients who fulfilled peripheral ASAS criteria N=350</td>
<td>81/433 (18.7)</td>
<td>12/350 (3.4)</td>
<td>69/83 (83.1)</td>
</tr>
<tr>
<td>Peripheral articular disease ever N=363</td>
<td>335/350 (95.7)</td>
<td>75/83 (90.4)</td>
<td>0.059</td>
</tr>
<tr>
<td>Any enthesitis in the past confirmed by specific investigations N=350</td>
<td>81/350 (23.1)</td>
<td>31/83 (37.3)</td>
<td>0.045</td>
</tr>
<tr>
<td>Current SPARC Enthesitis Index score, mean (SD) N=350</td>
<td>0.4 (1.1)</td>
<td>0.3 (0.9)</td>
<td>0.6 (1.6)</td>
</tr>
<tr>
<td>Dactylitis ever N=160</td>
<td>160/433 (37.0)</td>
<td>31/83 (37.3)</td>
<td>0.999</td>
</tr>
<tr>
<td>HLA-B27 positive N=160</td>
<td>384/433 (88.7)</td>
<td>310/350 (88.6)</td>
<td>74/83 (89.2)</td>
</tr>
<tr>
<td>CRP mg/L, mean (SD) N=112</td>
<td>197/316 (62.3)</td>
<td>179/269 (68.6)</td>
<td>18/47 (38.3)</td>
</tr>
<tr>
<td>PGA, mean (SD) N=112</td>
<td>4.5 (2.7)</td>
<td>4.2 (2.7)</td>
<td>3.9 (2.5)</td>
</tr>
<tr>
<td>Local injection of glucocorticoids for peripheral musculoskeletal involvement ever N=160</td>
<td>183/193 (94.8)</td>
<td>156/159 (98.1)</td>
<td>27/74 (79.4)</td>
</tr>
</tbody>
</table>

Categorical variables were given as n/N (%)

Figure 1. Association of demographic and clinical characteristics of pSpA with the presence of a personal history of PsO

Conclusion: The presence of skin PsO has an impact on clinical characteristics of pSpA. PsO patients without PsO were less frequently treated with bDMARDs despite an comparable or even higher burden of the disease.

Acknowledgements: No disclosure

Disclosure of Interests: None declared


POS0968 CESAREAN SECTION IN WOMEN WITH SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS

C. Skorpen1,2, S. Lydersen3, K. Å. Salvesen4, M. Wallenius1, NTNU, Department of Neuroradiology and Movement Science (INB), Trondheim, Norway; Ålesund Hospital, Rheumatology, Ålesund, Norway; NTNU, Department of Clinical and Molecular Medicine, Trondheim, Norway

Background: There is sparse documentation on pregnancy outcomes in women with spondyloarthritis (SpA) and psoriatic arthritis (PsA). Data on disease activity is often lacking, preventing the direct investigation of the effect of inflammation on pregnancy outcomes. A cesarean section (CS) implies a higher risk for the mother than vaginal delivery. It delays mobilization after birth necessary to counteract inflammatory pain and stiffness as well as the (re)start of disease modifying medication.

Objectives: To explore the possible association of disease activity (inflammation) and occurrence of cesarean section in women with SpA and PsA.

Methods: Data from the Medical Birth Registry of Norway (MBRN) were linked with data from RevNatus, a nationwide observational register recruiting women with inflammatory rheumatic diseases. Singleton births in women with SpA and PsA included in RevNatus 2010 to 2019 were cases. All other singleton births registered in MBRN during this time served as population controls.

Results: CS occurred more frequently in both SpA (21.9%) and PsA (29.4%) compared to population controls (15.6%), with even higher frequencies in active SpA (23.5%) and active PsA (30.1%). Women with SpA had higher risk for elective CS (risk difference 4.1%, 95% CI 1.4% to 7.9%, p=0.002), while women with PsA had higher risk for emergency CS (risk difference 9.8%, 95% CI 3.8% to 17.6%, p=0.001) as compared to population controls.

Conclusion: Women with SpA and PsA had increased odds for elective and emergency CS, respectively. Further analysis will explore the role of active inflammation.

REFERENCES:

Table 1. Characteristics of population controls, total patient groups and patient active disease groups, reported as n (%) unless specified as mean (SD)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Population controls</th>
<th>Spondyloarthritis SpA</th>
<th>Psoriatic Arthritis PsA</th>
<th>PsA active DAS28&gt;2.6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number singleton births</td>
<td>575/798</td>
<td>319</td>
<td>115</td>
<td>126</td>
</tr>
<tr>
<td>Maternal age, mean (SD)</td>
<td>30.6 (5.1)</td>
<td>31.7 (4.3)</td>
<td>31.8 (4.3)</td>
<td>32.0 (4.7)</td>
</tr>
<tr>
<td>BMI first trimester, mean (SD)</td>
<td>24.4 (4.8)</td>
<td>25.1 (5.0)</td>
<td>26.5 (5.8)</td>
<td>26.9 (5.6)</td>
</tr>
<tr>
<td>Smoking in pregnancy</td>
<td>63/350 (18.7)</td>
<td>89/83 (10.7)</td>
<td>87 (18.6)</td>
<td>20 (7.5)</td>
</tr>
<tr>
<td>Parity</td>
<td>0.51</td>
<td>0.013</td>
<td>0.018</td>
<td>0.007</td>
</tr>
<tr>
<td>No children</td>
<td>244/354 (42.4)</td>
<td>141 (45.2)</td>
<td>43 (37.7)</td>
<td>48 (39.7)</td>
</tr>
<tr>
<td>≥ 1 child</td>
<td>313/444 (57.6)</td>
<td>171 (54.8)</td>
<td>71 (62.3)</td>
<td>73 (60.3)</td>
</tr>
<tr>
<td>Elective</td>
<td>32/114 (28.0)</td>
<td>9 (7.9)</td>
<td>15 (13.0)</td>
<td>12 (9.5)</td>
</tr>
<tr>
<td>Emergency</td>
<td>57/691 (10.0)</td>
<td>39 (5.9)</td>
<td>12 (10.5)</td>
<td>25 (19.9)</td>
</tr>
<tr>
<td>Disease activity</td>
<td>55/992 (7.7)</td>
<td>32 (10.6)</td>
<td>16 (13.9)</td>
<td>15 (11.9)</td>
</tr>
<tr>
<td>Active 3rd trim</td>
<td>na</td>
<td>134 (58.8)</td>
<td>na</td>
<td>67 (69.8)</td>
</tr>
<tr>
<td>Active 3rd trim</td>
<td>na</td>
<td>115 (46.2)</td>
<td>29 (30.2)</td>
<td>29</td>
</tr>
</tbody>
</table>

1 Group compared to population controls $p<0.001$ 2 $p=0.002$ 3 $p=0.001$ 4 $p=0.003$ 5 $p=0.001$

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1420

POS0969 GENETIC AND MOLECULAR DISTINCTIONS BETWEEN AXIAL PSORIATRIC ARTHRITIS AND ANKYLOSING SPONDYLOITIS

A. Kavanaugh1, X. Baraliakos2, S. Gao3, W. Chen4, K. Sweet5, S. D. Chakravarty5,6, Q. Song3, M. Shawi7, F. Behrens8, P. Rahman9, University of California San Diego, Division of Rheumatology, Allergy and Immunology, San Diego, CA, United States of America; 2Rheumazentrum Ruhrgebiet, University of Duisburg-Essen, Germany; 3Janssen Research & Development, LLC, Department of Translational Science, Spring House, PA, United States of America; 4Janssen Research & Development, LLC, Department of Translational Science, Spring House, PA, United States of America; 5Janssen Scientific Affairs, LLC, Department of Rheumatology, Horsham, PA, United States of America; 6Drexel University College of Medicine, Department of Rheumatology, Philadelphia, PA, United States of America; 7Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America; 8Goethe University, Rheumatology and Fraunhofer ITMP - Translational Medicine
Background: Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) represent the prototypical spondyloarthritides. PsA patients may also suffer from axial disease (axPsA). Despite overlapping symptoms, axPsA and AS may be distinct disorders with differing clinical manifestations, genetic associations, and radiographic findings. These disorders are also non-modular diseases, thus immunomodulatory therapies, such as anti-interleukin (IL)-23 inhibitors. While guselkumab, a human monoclonal antibody targeting the IL-23p19 subunit, improved symptoms of axPsA, risankizumab, a humanized monoclonal antibody targeting the IL-23p19 subunit, did not show improvement in the primary endpoint of proportion of AS patients achieving an Assessment of SpondyloArthritis International Society 40% (ASAS40) response at week (W) 12.

Objectives: To understand molecular distinctions between axPsA and AS to differentiate these diseases and guide treatment choice.

Methods: Whole blood and serum samples were collected from consenting patients in the NCT03162796/NCT0315828 studies of guselkumab in PsA and the NCT02436162/NCT02438778 studies of ustekinumab in AS. axPsA patients were investigator-verfied as having magnetic resonance imaging- or pelvic x-ray-confirmed sacroiliitis at screening (locally read). Human leukocyte antigen (HLA) genotypes were determined by RNA sequencing. Limited to Caucasian patients to reduce genetic variability, and select serum cytokine levels were analyzed alongside samples from healthy individuals. Differential prevalence of HLA alleles in axPsA versus AS was determined using a Fisher’s Exact test. Statistical significance of differential baseline serum cytokine expression among axPsA versus non-axPsA patients, and of guselkumab versus placebo (axPsA N=30, non-axPsA N=69) at W4/24 (all p<0.05).

IL-17F were significantly higher in axPsA (N=71) than in AS (N=58) patients (p<0.01). The prevalence of class I HLA allele -B27, -C06, and -C02, while the prevalence of HLA allele -C01, and -C02 carriers was significantly lower in axPsA than AS patients (30.7% versus 92.3%, p<0.001; 5.9% versus 31.6%, p<0.001; and 28.0% versus 62.0%, p<0.001, respectively), while the prevalence of HLA-C06 was significantly higher in axPsA than AS population (36.0% versus 8.6%, p<0.001). Baseline serum levels of IL-17A and IL-17F were significantly higher in axPsA (N=71) than in AS (N=58) patients (p<0.01 and p<0.001, respectively). Comparable IL-17A/F expression was seen for axPsA and non-axPsA patients (N=229) patients (both p=nonsignificant). Significant and comparable reductions from baseline in serum IL-17A/F in axPsA and non-axPsA patients were seen with guselkumab treatment (axPsA N=41, non-axPsA N=160) versus placebo (axPsA N=30, non-axPsA N=69) at W24 (p=0.05).

Conclusion: Adults with axPsA and AS exhibit different genetic risk factors and serum IL-17 levels, supporting the concept of distinct disorders. Gusekumab demonstrated significant pharmacodynamic effects in axPsA patients that aligned with such effects in non-axPsA patients, consistent with observed clinical improvement.

REFERENCES:

Disclosure of Interests: Arthur Kavanagh Consultant of: AbbVie, Amgen, BMS, Genentech, Janssen, Eli Lilly, Merck, Novartis, Pfizer and UCB, Xen- douri, Baraliakos Consultant of: AbbVie, Chugai, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Grant/research support from: AbbVie, Merck, Sandoz N.V., and UCB. Employee of: Janssen Research & Development, LLC, and may own stock or stock options in Johnson & Johnson, and Biostatistics, Paris, France; Kyorin University School of Medicine, Department of Internal Medicine and Rheumatology, Tokyo, Japan; Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), an Institut der Leinzig-Gemeinschaft, Epidemiology Unit, Berlin, Germany

Background: Crohn’s disease (CD) and ulcerative colitis (UC) are groups that are accredited as inflammatory bowel disease (IBD), and both are frequently found as extra-musculoskeletal manifestations in spondyloarthritis (SpA). Several studies have described the connection between SpA and IBD in both directions. Still until today, no studies have investigated possible differences in the musculoskeletal manifestations between the two main entities of inflammatory bowel disease: CD and UC.

Objectives: To evaluate the clinical characteristics associated with the presence of CD or UC in patients with spondyloarthritis from the international cross-sectional ASAS-perSpA study.

Methods: We analyzed 3152 patients from the ASAS per-SpA cohort who had a diagnosis of axial SpA or peripheral SpA according to the treating rheumatologist. Patients with IBD - confirmed by endoscopy - were identified and stratified by CD or UC. Patients in which their IBD disease was not specified, were excluded. Demographics, clinical characteristics, treatments and patient-reported outcomes were compared between both subgroups.

Results: Among the 146 patients diagnosed with IBD from the 3152 patients included in the analysis, 87 (59.6%) were diagnosed with CD (75 patients with axial SpA and 12 with peripheral SpA) and 39 (26.7%) with UC (34 patients with axial SpA and 5 with peripheral SpA) - Figure 1. A total of 20 (13.7%) patients with IBD were excluded, due to an inconclusive diagnosis of IBD. Patients with CD and UC had similar age (44.9 vs 44.0 years old) and sex distribution, although a slightly higher frequency of males was observed in CD than UC (63.2% vs 51.3%). The diagnostic delay for SpA was 70 years for CD and 8.1 years for UC. We did not find differences between both groups related to any musculoskeletal manifestations such as chronic back pain, uveitis, arthritis, enthesitis or dactylitis (Table 1). The only parameter showing a significant difference between CD and UC was the Bath Ankylosing Spondylitis Functional Index (BASFI) with a mean score of 3.3 vs 2.2 respectively (p=0.02) (Table 1). CD patients showed a higher tendency to be HLA-B27 positive (51.9% in CD vs 39.4% in UC), but this did not reach statistical significance. No differences were observed regarding treatment patterns between both groups.

Table 1. Demographics and clinical characteristics related to spondyloarthritides of patients with concomitant Crohn’s disease or ulcerative colitis (n=146).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
<th>CD (n=87)</th>
<th>UC (n=39)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>44.9 (13.0)</td>
<td>44.0 (13.0)</td>
<td>0.68</td>
<td></td>
</tr>
<tr>
<td>Sex, n/N (%) male</td>
<td>55 (63.2)</td>
<td>20 (51.3)</td>
<td>0.21</td>
<td></td>
</tr>
<tr>
<td>Smoker ever, n/N (%)</td>
<td>36 (41.4)</td>
<td>19 (48.7)</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>Diagnostic delay of SpA (years), mean (SD)</td>
<td>7.0 (9.9)</td>
<td>8.8 (8.1)</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Psoriasis ever, n/N (%)</td>
<td>9 (10.3)</td>
<td>6 (15.4)</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>Uveitis ever, n/N (%)</td>
<td>17 (19.5)</td>
<td>11 (28.2)</td>
<td>0.28</td>
<td></td>
</tr>
<tr>
<td>Synovitis ever, n/N (%)</td>
<td>42 (48.3)</td>
<td>16 (36.9)</td>
<td>0.33</td>
<td></td>
</tr>
<tr>
<td>Enthesitis ever, n/N (%)</td>
<td>26 (29.9)</td>
<td>14 (35.9)</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Dactylitis ever, n/N (%)</td>
<td>3 (3.4)</td>
<td>1 (2.6)</td>
<td>0.79</td>
<td></td>
</tr>
<tr>
<td>Axial involvement ever (according to the rheumatologist), n/N (%)</td>
<td>79 (90.8)</td>
<td>37 /9 (94.4)</td>
<td>0.20</td>
<td></td>
</tr>
<tr>
<td>Sacroiliitis on X-ray, n/N (%)</td>
<td>64 (73.6)</td>
<td>26 (69.7)</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>HLA B27 positive, n/N (%)</td>
<td>26 (30.8)</td>
<td>13 (33.3)</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>CRP mg/L, mean (SD)</td>
<td>11.1 (33.3)</td>
<td>15.3 (30.1)</td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>ASDAS-CRP, mean (SD)</td>
<td>2.4 (1.0)</td>
<td>2.4 (1.1)</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>3.3 (2.6)</td>
<td>2.2 (1.6)</td>
<td>0.26</td>
<td></td>
</tr>
<tr>
<td>csDAMDAS ever, n/N (%)</td>
<td>71 (81.6)</td>
<td>39 (97.1)</td>
<td>0.25</td>
<td></td>
</tr>
<tr>
<td>bDMARDs ever, n/N (%)</td>
<td>72 (82.8)</td>
<td>33 (84.0)</td>
<td>0.80</td>
<td></td>
</tr>
</tbody>
</table>

ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARD, biologic disease-modifying antirheumatic drugs; CRP, c-reactive protein; csDAMDAS, conventional synthetic disease-modifying antirheumatic drugs; SD, standard deviation; SpA, spondyloarthritis.

Conclusion: In our ancillary analysis of the ASAS-perSpA study in patients with SpA and concomitant CD or UC, no differences in the clinical presentation or

DOI: 10.1136/annrheumdis-2022-eular.1500
and spinal ankyloses (1, 2). Recent studies with [18F]Fluoride Positron emission tomography (PET) demonstrated that disease activity of AS is best reflected by local background, 257 MRI lesions and 88 x-ray lesions were observed in the spine (Table 1). Most lesions were found in the thoracic spine. PET lesions were frequently located outside the field of view (FOV) of the MRI and X-ray in respectively costovertebral and facet joints (31/69; 45%). Univariate analysis PET positivity had the strongest association with the presence of MRI BME and x-ray bridges (OR 6.6, 95% CI: 2.0 – 21.1, p < 0.001 respectively). Multivariate analysis confirmed these findings (OR 39, 95% CI: 1.7 – 223, p < 0.01 and OR 6.4, 95% CI: 1.7 – 23.5, p < 0.01 respectively) (Figure 1). However, of all PET-positive lesions only 7/24; 29% within the FOV of the MRI showed BME and 13/23; 56% of the PET lesions within the FOV of the X-ray showed bridges on X-ray. In the SI-joints, a total of 15 lesions (15/20; 75%) with PET enhancement were found. Erosions, ankylosis and BME lesions on MRI were observed in respectively 13/15; 87%, 4/15; 27% and 13/15; 87% of the lesions with PET enhancement.

**Table 1.** Distribution of lesions throughout the spine on different modalities.

<table>
<thead>
<tr>
<th>Number of lesions</th>
<th>Cervical spine</th>
<th>Thoracic spine</th>
<th>Lumbar spine</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>PET</td>
<td>4</td>
<td>42</td>
<td>23</td>
<td>69</td>
</tr>
<tr>
<td>PET, within FOV MRI</td>
<td>1</td>
<td>11</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>PET, within FOV x-ray</td>
<td>1</td>
<td>10</td>
<td>12</td>
<td>23</td>
</tr>
<tr>
<td>MRI – fatty lesions</td>
<td>15</td>
<td>30</td>
<td>15</td>
<td>60</td>
</tr>
<tr>
<td>MRI – erosions</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>MRI – ankylosis</td>
<td>2</td>
<td>121</td>
<td>27</td>
<td>150</td>
</tr>
<tr>
<td>MRI – BME</td>
<td>1</td>
<td>35</td>
<td>10</td>
<td>46</td>
</tr>
<tr>
<td>X-ray erosions</td>
<td>14</td>
<td>25</td>
<td>0</td>
<td>39</td>
</tr>
<tr>
<td>X-ray synderosmophytes</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>X-ray bridges</td>
<td>4</td>
<td>31</td>
<td>12</td>
<td>47</td>
</tr>
</tbody>
</table>

**Figure 1.** Example of Fluoride uptake on PET (A), corresponding BME on MRI (B) and bridges on X-ray (C).

**Conclusion:** Lesions with [18F]Fluoride on PET showed significant correlation to MRI BME and x-ray bridge lesions. It showed partial agreement with BME of MRI and bridges on X-ray. This suggests that [18F]Fluoride PET visualizes different mechanisms central to AS disease activity compared to MRI and X-ray, thereby providing novel and additional information.

**REFERENCES:**


**Disclosure of Interests:** None declared, Jerney de Jongh: None declared, Nick Poug-Verweij: None declared, Gerben C.J. Zveizeren: None declared, J.C. van Denderen: None declared, Irene van der Horst-Bruinsma Speakers bureau: BMS, Abbvie, Pfizer, MSD, Consultant of: AbbVie, UCB, MSD, Novartis, Eli Lilly, Grant/research support from: Unrestricted Grants received for investigator initiated studies from MSD, Pfizer, AbbVie, UCB, Joost Bot: None declared, B.J.H. Boden: None declared, Robert Hemke: None declared, Frank F Smithuis: None declared, Macsoum Voskuy: None declared, Maarten Boers Consultant of: Novartis, Maqsood Yaqub: None declared, Conny J. van der Laken: None declared.
Results: In total, 4185 patients were included, of which 2719, 1033 and 433 had a diagnosis of axSpA (mean age 42 years, 32% female), PsA (mean age 52 years, 52% female) and pSpA (mean age 44 years, 53% female), respectively. A significant interaction between gender and disease phenotype was found for ASAS-DAS and BASFI. Multivariable models for each outcome are shown in Table 1 (stratified by disease phenotype). While being female independently contributed to higher BASDAI across the three disease phenotypes (though with varying magnitude), female gender was only associated with higher BASDAS in pSpA [β (95% CI): 0.36 (0.15, 0.58)] and PsA [0.25 (0.12, 0.38)] but not in axSpA [0.016 (0.07, 0.11)]. Female gender was associated with higher BASFI in PsA [0.46 (0.20, 0.72)]. No associations were observed between gender and CRP levels. Female gender was associated with higher ASAS-HI [0.90 (0.70, 1.10)] and EQ-5D* [-0.02 (-0.03, -0.01)] without significant differences across disease phenotype.

Conclusion: Female gender was associated with less favorable outcomes across the SpA spectrum, except for CRP in which there were no differences between gender. While female gender influenced BASDAI across disease phenotypes, ASAS was not associated with gender in axSpA. These results suggest that ASASDAS should be the preferred instrument in clinical practice both for females and males with axSpA.

Acknowledgements: We would like to thank all ASAS-perSpA investigators and members of the scientific committee.

Disclosure of Interests: Diego Benavent Speakers bureau: Janssen, Roche, Grant/research support from: Novartis, Daufe Capelusnik Speakers bureau: Bristol-Myers Squibb, Pfizer, Grant/research support from: Pfizer, Sofia Ramiro Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: Abbvie, Eli Lilly, MSD, Novartis, Pfizer, UCB, Sanofi, Grant/research support from: Abbvie, Eli Lilly, Galapagos, Novartis, Pfizer, UCB, Ana Mlotha Consultant of: Abbvie, UCB, Novartis, Gilead, Pfizer, Lilly y Janssen, Grant/research support from: UCB, Clementina López-Medina Speakers bureau: Lilly, Novartis, Janssen, UCB and Abbvie, Maxime Dougdas: None declared, Victoria Novo-Campan Speakers bureau: Abbvie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB, Pharmacia, Consultant of: Abbvie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Consultant/grant support from: Abbvie, Eli Lilly and Novartis. DOI: 10.1136/annrheumdis-2022-eular.1880
in bone density at each vertebra from C3 to L5. This methodology can aid the

Conclusion: agreed on the direction of the change score in 88-96% of vertebrae, and agreement
whole spine, with negligible systematic error between the readers. The two readers
and median of 5. Bland-Altman plots showed homoscedasticity throughout the
Inter-reader reliability was excellent (ICC: 0.91 to 0.99). SDC varied from 4 to 7, mean
positive change in the cervical spine compared with the thoracic and lumbar spine.

Results: (positive vs negative) and on change scores > |SDC|were also computed.
percentage of vertebrae in which readers agreed on the direction of the change
scores between the two readers, and k=2 readers) and Bland-Altman plots. The
agreement was assessed using the smallest detectable change
(SDC = 1.96 x SDdifference /√2*√k); SDdifference is the SD of the differences in change

Table 1. Change scores for both readers, mean differences and intraclass correlation coefficients (ICC) from C3 to L5

| Vertebral | Mean change (SD) | Mean Difference (SD) | Change > 5 # | Change < -5 # | Change >|5 | ICC |
|----------|------------------|----------------------|--------------|--------------|-------|-----|
| C3       | 18 (56)          | 17 (56)              | 0.2 (5.0)    | 55            | 32    | 87  | 0.97 |
| C4       | 18 (53)          | 17 (62)              | 0.3 (5.5)    | 59            | 32    | 91  | 0.98 |
| C5       | 28 (70)          | 29 (70)              | -0.7 (5.0)   | 61            | 32    | 93  | 0.99 |
| C6       | 23 (62)          | 23 (62)              | 0.4 (5.8)    | 50            | 39    | 89  | 0.99 |
| C7       | -3 (60)          | -2 (59)              | -0.7 (6.9)   | 40            | 49    | 89  | 0.98 |
| T1       | -6 (87)          | -6 (88)              | 0.6 (5.0)    | 47            | 49    | 96  | 0.98 |
| T2       | 3 (45)           | 3 (45)               | 0.7 (4.0)    | 41            | 45    | 86  | 0.97 |
| T3       | 1 (43)           | 2 (43)               | 0.6 (4.4)    | 30            | 57    | 87  | 0.97 |
| T4       | -2 (48)          | 1 (47)               | 0.2 (5.3)    | 30            | 45    | 84  | 0.96 |
| T5       | -2 (50)          | -2 (50)              | 0.0 (5.1)    | 35            | 45    | 80  | 0.95 |
| T6       | -3 (44)          | -3 (45)              | -0.1 (4.6)   | 29            | 51    | 80  | 0.99 |
| T7       | -4 (43)          | -4 (43)              | -0.1 (4.5)   | 35            | 45    | 80  | 0.98 |
| T8       | -5 (46)          | -5 (46)              | -0.1 (4.6)   | 29            | 51    | 80  | 0.99 |
| T9       | -9 (50)          | -9 (50)              | 0.0 (5.4)    | 30            | 53    | 88  | 0.99 |
| T10      | 0.2 (59)         | 1 (59)               | -0.4 (5.2)   | 35            | 43    | 78  | 0.94 |
| T11      | -8 (53)          | -7 (53)              | -0.6 (4.3)   | 35            | 53    | 88  | 0.99 |
| T12      | -23 (59)         | -23 (60)             | -0.3 (4.4)   | 27            | 41    | 68  | 0.97 |
| L1       | -9 (33)          | -7 (33)              | -1.9 (6.3)   | 27            | 41    | 68  | 0.97 |
| L2       | 1 (46)           | 2 (45)               | -1.1 (4.6)   | 29            | 41    | 70  | 0.98 |
| L3       | -4 (35)          | -2 (34)              | -1.2 (6.3)   | 24            | 39    | 63  | 0.92 |
| L4       | -2 (24)          | 1 (22)               | -1.5 (5.4)   | 31            | 37    | 68  | 0.91 |
| L5       | 8 (43)           | 9 (43)               | -1.0 (6.0)   | 47            | 33    | 80  | 0.97 |

§ C3-C7: n=44; T1-L5: n=49 # % of vertebrae in which both readers agreed on a change score > smallest detectable change.

Acknowledgements: To the Dutch Rheumatism Association for funding SIAS twice.

Disclosure of Interests: Mary Lucy Marques: None declared, Nuno Pereira da Silva: None declared, Désirée van der Heijde Consultant of: AbbVie, Gilead, Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Monique Reijnierse: None declared, Jurgen Braun: None declared, Xenofon Baralaiakos: None declared, Floris A. van Gaalen: None declared, Sofia Ramiro: None declared.


POS0975 COMPARISON OF CLINICAL AND DEMOGRAPHIC FINDINGS OF PATIENTS DIAGNOSED AS WITH FULL SPINAL FUSION AND WITHOUT ANY SPINE DAMAGE

C. Yörük , S. Gulle, I. Sarı, F. Öner, A. Balcı, Dokuz Eylül Üniversitesi Hastanesi, Internal Medicine, İzmir, Turkey; Dokuz Eylül Üniversitesi Hastanesi, Rheumatology, İzmir, Turkey; Dokuz Eylül Üniversitesi Hastanesi, Radiology, İzmir, Turkey

Background: Erosions and sclerosis are early manifestations of radiographic progression, which can form synovemesophytes that bridge between the vertebrae and eventually lead to spinal fusion or the characteristic bamboo spine appearance in some patients. Bridging synovemesophytes in the spinal column plays a key role in the progression of AS. The development of ankylosis in the axial skeleton is considered to be the most important long-term outcome parameter for axialpondyloarthritist (axSpA).

Objectives: In this study, we aimed to evaluate patients with ankylosing spondylitis (AS) diagnosed with grade 4 sacroiliitis followed in our rheumatology clinic, without spinal column involvement and with complete spinal ankylosis (bamboo vertebra), together with their clinical, demographic and laboratory findings.

Methods: A total of 202 patients with unilateral/bilateral grade 4 sacroiliitis, who were registered in the Dokuz Eylül University Hospital data system, diagnosed with AS according to the modified New York criteria, were included in the study. Cervical, dorsal and lumbar radiographs of all patients were evaluated for structural damage, in addition to lateral and anteroposterior aspects, as well as posterior and facet joint involvement. In the study, all radiographs were evaluated twice at separate times.

Results: It was found that 19 (9.5%) patients had no involvement of the spinal column and 19 (9.5%) had spinal fusion appearance. It was determined that patients with spinal fusion were older (p<0.001) and the frequency of male gender was higher (p=0.042) than patients without any spinal involvement. (Table 1) In multivariate analysis; ≥45 years old [OR: 10.5, CI: 95%, 2.8-39.2; (p:0.001)] and male patients [OR: 10.5, CI: 95%, 1.14-96.56; (p=0.042)] was found to have an increased risk for the development of spinal fusion. TNFi retention rates (78.9% vs. 52.6%), TNF switch rates (53.3% vs. 45.5%) and TNF type distributions were similar in both groups (p>0.05).

There was no significant difference between the patients with complete spinal fusion and no spinal involvement in terms of right and left hip BASRI scores (p>0.05).

Acknowledgements: To the Dutch Rheumatism Association for funding SIAS twice.

Disclosure of Interests: Mary Lucy Marques: None declared, Nuno Pereira da Silva: None declared, Désirée van der Heijde Consultant of: AbbVie, Gilead, Glaxo-Smith-Kline, Lilly, Novartis, UCB Pharma, Monique Reijnierse: None declared, Jurgen Braun: None declared, Xenofon Baralaiakos: None declared, Floris A. van Gaalen: None declared, Sofia Ramiro: None declared.

Table 1. Demographics

<table>
<thead>
<tr>
<th>Spinal Involvement (−)</th>
<th>Full Spinal Involvement (+)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>≤45</td>
<td>17 (89.5)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>&gt;45</td>
<td>2 (10.5)</td>
<td>19 (100)</td>
</tr>
<tr>
<td>Sex (Erkek)</td>
<td></td>
<td>10.5 (2.8-39.2)</td>
</tr>
<tr>
<td>CRP</td>
<td>12 (63.1)</td>
<td>18 (94.7)</td>
</tr>
<tr>
<td>P</td>
<td>0.042</td>
<td>10.5 (1.14-96.56)</td>
</tr>
</tbody>
</table>

Mann-Whitney U Test (Monte Carlo), ROC (Receiver Operating Curve) Analysis (Hontele&McNeill - Youden index). AUC (Area under the ROC curve); OR: AUC (SH): 0.945 (0.040) >45 10.5 (2.8-39.2). P

Conclusion: In our study, we reached four important clinical results: (1) Spinal fusion was observed in 9.5% of the patients with bilateral Grade 4 sacroiliitis diagnosed with AS. 95% had no spinal involvement and 81% had varying degrees of spinal injury. (2) Anti-TNF treatment responses were similar in patients with spinal fusion and no spinal involvement. (3) Except for being >45 years old and having a male gender, no other factor was found to predict the development of spinal fusion. (4) There was no difference in the degree of hip involvement between patients with complete spinal fusion and no spinal involvement.

REFERENCES:
[1] Sere E Van Der Heijde, D. et al. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2300

Table 1. Patient and disease characteristics at month 72

<table>
<thead>
<tr>
<th>Variablename</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (Male)</td>
<td>181 (45%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>40.7 (8.7)</td>
</tr>
<tr>
<td>Symptom duration (years)</td>
<td>75 (0.9)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.0 (4.6)</td>
</tr>
<tr>
<td>ASDAS</td>
<td>2.0 (1.0)</td>
</tr>
<tr>
<td>BASFI</td>
<td>2.3 (2.1)</td>
</tr>
<tr>
<td>BASMI</td>
<td>2.5 (10)</td>
</tr>
<tr>
<td>mSASSS</td>
<td>1.0 (3.6)</td>
</tr>
<tr>
<td>ASAS HI (0-17)</td>
<td>5.7 (3.9)</td>
</tr>
<tr>
<td>good global functioning: ASAS HI ≤5, N (%)</td>
<td>201 (51%)</td>
</tr>
<tr>
<td>moderate global functioning: 5&lt; ASAS HI ≤12, N (%)</td>
<td>160 (40%)</td>
</tr>
<tr>
<td>bad global functioning: ASAS HI &gt;12, N (%)</td>
<td>37 (9%)</td>
</tr>
<tr>
<td>Comorbidity count</td>
<td>1.4 (0.7)</td>
</tr>
</tbody>
</table>

Figure 1. Structural model on interrelationships of different patient- and disease characteristics with global functioning and health (ASAS HI) in patients with early axSpA

Conclusion: The BN-analysis approach, that combines prior knowledge and measured data, serves to better understand the construct of global functioning and health in pts. with early axSpA. Our model shows that global functioning (ASAS-HI) is determined both by patient-reported physical function (BASFI) and by disease activity (ASDAS), which confirms the hierarchical model once proposed by Machado et al. The observed directional relationship between ASAS HI and comorbidity count is counterintuitive and requires further investigation.

REFERENCES:

Disclosure of Interests: Imke Reedeke: None declared, Robert B.M. Landewe Speakers bureau: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Consultant of: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Désirée van der Heijde Speakers bureau: AbbVie, Bayer, BMS, Cyoxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Bayer, BMS, Cyoxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Sofia Ramero Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi, Grant/research support from: AbbVie, Bayer, BMS, Cyoxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Sofia Ramero Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi, Grant/research support from: AbbVie, Maxime Dougados: None declared, Juergen Braun Speakers bureau: Abbvie, Amgen, Biogen,
Table 1.

<table>
<thead>
<tr>
<th>Features</th>
<th>M694V (+) (n=91)</th>
<th>M694V (-) (n=22)</th>
<th>P1</th>
<th>M694V Homozygous (n=45)</th>
<th>M694V Nonhomozygous (n=68)</th>
<th>P2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at FMF symptom onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[years, med (25-75)]</td>
<td>11 (5-18)</td>
<td>21 (8-30)</td>
<td>0.005</td>
<td>7 (1-42)</td>
<td>18 (3-53)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at FMF diagnosis</td>
<td>18 (10-27)</td>
<td>33 (27-38)</td>
<td>&lt;0.001</td>
<td>12 (1-42)</td>
<td>28 (3-59)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age at AxSpA symptom onset</td>
<td>20 (15-25)</td>
<td>29 (24-38)</td>
<td>&lt;0.001</td>
<td>20 (5-50)</td>
<td>22 (5-58)</td>
<td>0.43</td>
</tr>
<tr>
<td>Age at AxSpA diagnosis</td>
<td>24 (19-33)</td>
<td>37 (28-44)</td>
<td>&lt;0.001</td>
<td>21 (11-51)</td>
<td>29 (7-59)</td>
<td>0.039</td>
</tr>
</tbody>
</table>

**References:**


Disclosure of Interests: None declared

**POS0978**

**LUMBAR FACET JOINTS ARTHRITIS RELATES TO ITS ADJACENT MRI INFLAMMATORY LESIONS IN AXIAL SPONDYLOARTHRITIS**

Z. Huang1, Z. Huang2, X. Guo1, Q. Huang1, M. Liu1, F. Feng1, T. Li2,3
1Guangdong Second Provincial General Hospital, Department of Rheumatology and Immunology, Guangzhou, China; 2Southern Medical University,School of Clinical Medicine, Guangzhou, China; 3Zhaoying Central People's Hospital, Department of Rheumatology and Immunology, Zhaoying, China

**Background:** Facet joints are frequently impaired in patients with axial spondyloarthritis (axSpA), which raises high disease activity and poor physical function. However, insufficient attention is paid to the relationship between the feature of disease and facet joint arthropathy (FJA) in magnetic resonance imaging (MRI) examination, because of lacking an ideal assessment tool. The Canada-Denmark (CANDEN) MRI scoring system is adopted in our study because it is a comprehensive method to assess the alteration of spine [1].

**Objectives:** We aimed to find relevant factors for lumbar FJA in axSpA patients.

**Methods:** This was a cross-sectional study that analyzed the lumbar MRI of axSpA patients using the CANDEN system. Demographic and clinical information was recorded. Univariable and multivariable linear mixed model (LMM) was used to screen related factors for lumbar FJA in MRI examinations.

**Results:** (1) Totally 108 axSpA patients were investigated in our study, while ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) accounted for half respectively. Sixty-five (60.19%) participants were male and their median age was 35 years. (2) Twenty (37.10%) and 1 (1.80%) AS and nr-axSpA suffered lumbar FJA respectively. Sixty-five (60.19%) participants were male and their median age was 35 years. (2) Twenty (37.10%) and 1 (1.80%) AS and nr-axSpA suffered lumbar FJA respectively. Sixty-five (60.19%) participants were male and their median age was 35 years. (3) Twenty (37.10%) and 1 (1.80%) AS and nr-axSpA suffered lumbar FJA respectively. Sixty-five (60.19%) participants were male and their median age was 35 years. (4) Multivariate LMM displayed that odd ratio (OR) and 95% confidence intervals (CI) of PLEIS, FPES, and ASDAS were significant.

**Conclusion:** Prevalence of lumbar FJA is higher in AS patients than nr-axSpA. Besides, gender, the duration of symptom, peripheral arthritis, enthesitis, non-steroidal anti-inflammatory drugs, VCBis, SIDS, PLEIS, FPES, the ankylosis of sacroiliac joints, and bony erosion of hips were involved in the univariate LMM for nr-axSpA. (4) Multivariate LMM showed that odd ratio (OR) and 95% confidence intervals (CI) of PLEIS, FPES, and ASDAS were significant. OR (95%CI) for PLEIS, FPES, and ASDAS were 2.063 (1.49, 2.84), 1.11 (1.02, 1.21), and 1.19 (1.08, 1.32) (P<0.05). OR (95%CI) for PLEIS, FPES, and ASDAS were 2.063 (1.49, 2.84), 1.11 (1.02, 1.21), and 1.19 (1.08, 1.32) (P<0.05). OR (95%CI) for PLEIS, FPES, and ASDAS were 2.063 (1.49, 2.84), 1.11 (1.02, 1.21), and 1.19 (1.08, 1.32) (P<0.05). OR (95%CI) for PLEIS, FPES, and ASDAS were 2.063 (1.49, 2.84), 1.11 (1.02, 1.21), and 1.19 (1.08, 1.32) (P<0.05).

**Disclosure of Interests:** None declared
Background: Large population-based databases provide an opportunity to study the epidemiology of spondyloarthritis (SpA), however, strict validation procedures for case ascertainment are required (1).

Objectives: To examine the validity of the ICD-9 codes of SpA in a large population-based database and to assess whether applying a specific algorithm would improve the case ascertainment. Finally, the point prevalence of SpA in the database was estimated using the validated algorithm.

Methods: A Database of a large public health fund, which serves approximately 3.17 million enrollees older than 18 years, was used. The database includes real-time input from pharmaceutical, medical and administrative operating systems. At first, the database was searched for all individuals who received an ICD-9 code of SpA, 720.0: 7200, 7201, 7202, 7206, 72081 and 72089. All medical records of a random sample of 169 patients were thoroughly reviewed by a rheumatologist. Based on the information available in the database, a decision was made whether SpA diagnosis was: 1) definite/probable SpA; 2) not SpA; not enough data to verify the diagnosis of SpA. The positive predicted value (PPV) and 95% confidence interval (CI) were calculated. In order to improve the case ascertainment, a second validation process was performed using a specific algorithm. The algorithm applied was: a permanent ICD-9 code of SpA assigned by the family physician plus at least one of the following codes: 1.At least one visit at a rheumatology clinic either in the community or at a hospital outpatient clinic; 2.A diagnosis of SpA given during a hospital admission; 3.A prescription fulfilled of an anti-Tumor Necrosis Factor agent or anti tumor 17-antigen. This algorithm was validated by two rheumatologists in a random sample of 182 cases. Finally, the point prevalence of SpA was estimated applying the validated algorithm.

Results: The PPV of the ICD-9 codes of SpA was 44% (95%CI 36%-52%). The specific algorithm improved the PPV to 90% (95%CI 85%-94%). The concordance between the two rheumatologists was 91.9% (CI 85.7-94.8). On the 31/12/2021, the validated algorithm identified 2892 live SpA patients older than 18 among a population of 3,167,329 enrollees reflecting a point prevalence of 0.09%. The ICD-9 codes of SpA assigned by the family physician plus at least one of the following codes: 1.At least one visit at a rheumatology clinic either in the community or at a hospital outpatient clinic; 2.A diagnosis of SpA given during a hospital admission; 3.A prescription fulfilled of an anti-Tumor Necrosis Factor agent or anti tumor 17-antigen. This algorithm was validated by two rheumatologists in a random sample of 182 cases. Finally, the point prevalence of SpA was estimated applying the validated algorithm.

Conclusion: A specific algorithm can accurately identify patients with SpA in this large population-based database. The estimated prevalence of SpA is 0.09%. This figure is consistent with other population-based estimates (2).

REFERENCES:

are not studied. Until now, it remains unclear whether synovitis detected on MRI and ultrasound of hip joint is a predictor of radiological progression of coxitis.

**Objectives:** To determine the factors influencing the progression of coxitis in axSpA.

**Methods:** 77 patients (mean age 28 ± 5.92 years) with a diagnosed with axSpA (ASAS criteria 2009), which were observed for at least 2 years. Among them, AS according to the modified New York criteria (1984) - 66 (86%) patients, and 11 (14%) were diagnosed with nr-axSpA. The median duration of the disease was 30 [6-60] months, BASDAI 4.5 [3.2-5.9], B27 2.4 [0.9-4.8]. All patients underwent clinical, X-ray ultrasound and MRI examination of the hip joint during the entire observation period. For ultrasound, coxitis was considered an increase in the cervical capsular distance (CCD) of more than 7 mm. For MRI inflammatory changes were taken as osteitis of the acetabulum and / or femoral head and synovitis in STIR mode. The sum of stages of radiographic coxitis (sCRC) was used to assess HJ injury progression. During the study, a formula was developed to assess the progression rate of radiographic coxitis (R-rpC).

**Results:** Cluster analysis of the main parameters was performed to detect the relationship between the clinical manifestations of axSpA and radiological progression of coxitis (Figure 1). During the analysis, it was found that the most closely related group of clinical parameters, such as the presence of the HLA B 27 gene and the sex of patients, the rate of radiographic progression of coxitis and sCRC (Euclidean distance < 20). The second group of related measures included the BASDAI and ASDAS-CRP disease activity indices, as well as their associated functional impairment (BASFI index) (Euclidean distance < 30). These two groups of signs are also related to each other — Euclidean distance < 30. It should be noted that laboratory indicators of inflammation (ESR and CRP), the age of patients, and especially the duration of the disease, turned out to be weakly related to each other (Euclidean distance > 100). It should also be noted that the relationship between laboratory indicators of inflammation and disease activity indices is relatively weak, as well as with structural damage in axSpA.

**Conclusion:** Factors influencing the development and progression of coxitis in axSpA are a combination of such features as high clinical activity of the disease, the presence of peripheral arthritis, HLA B27 positivity and male sex.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2717

---

**ABSTRACTS TO TWO NOVEL PEPTIDES IN NEW ONSET AXIAL SPONDYLOARTHRITIS**

**P. Ruytinx**, P. Vandormael2, E. Luyten1, A. S. De Craemer3, F. Van den Bosch3, E. Mogard1, T. Olofsson1, A. Bremander2,3,4,5, J. Sagard1, J. K. Wallman1, E. Lindqvist1, 1Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; 2Lund University, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; 3Spenshult, Research and Development Centre, Halmstad, Sweden; 4University of Southern Denmark, Department of Regional Health Research, Odense, Denmark; 5University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sanderborg, Denmark

**Background:** Healthy lifestyle behaviours are associated with better health outcomes and quality of life in the general population (1, 2). In patients with axial spondyloarthritis (axSpA), however, little is known regarding multiple lifestyle behaviours and their associations with disease and health outcomes.

**Objectives:** To study lifestyle behaviours in patients with axSpA in relation to healthy controls, between axSpA subtypes and male and female patients, respectively, and to assess how the presence of two or more unhealthy lifestyle factors associate with disease and health outcomes.

**Methods:** We performed a cross-sectional study of 250 well-characterized axSpA patients (167 with radiographic axSpA [r-axSpA], ASAS and/or modified New York criteria), 83 with non-radiographic axSpA [nr-axSpA; ASAS criteria] and 48 controls (frequency-matched to the patients for age and sex), participating in the population-based SPARTAKUS study in southern Sweden. Self-reported data on smoking, alcohol use, physical activity, dietary habits, and objectively measured body mass index (BMI), respectively, for all subjects was categorized as fulfilling national recommendations or not (healthy/unhealthy), and summarized in an index (0-5, indicating the number of unhealthy lifestyle factors). The index was also dichotomized into 0-1 vs. 2-5 unhealthy lifestyle factors. Comparisons between patients and controls, axSpA subtypes (r-axSpA vs. nr-axSpA), and between male and female patients were performed by Student's t-test/Chi-square test, as appropriate. Linear regression analyses were used to explore associations between having ≥2 unhealthy lifestyle factors (yes/no) and disease and health outcomes.

**Results:** Characteristics and lifestyle factors for axSpA patients and controls are presented in the Table 1. Reporting ≥2 unhealthy lifestyle factors was more common in axSpA patients than controls (35% vs. 19%, p=0.029), while no difference was found between the axSpA subtypes (Figure 1a and b). Male patients more often reported several unhealthy lifestyle factors than female patients (Figure 1c), with more frequent unhealthy alcohol use (19% vs. 9%, p=0.023) and overweight/obesity; BMI ≥25 (63% vs. 50%, p=0.043), while smoking, physical activity, and dietary habits were similar. In addition, older patients displayed more unhealthy lifestyle factors (Figure 1d). Having ≥2 unhealthy lifestyle factors was associated with worse disease activity (ASDAS-CRP) [0.73 [95% CI] [0.59, 0.87]], physical function (BASFI) [0.73 [95% CI] [0.59, 0.87]], and quality of life (EQ-5D) [0.73 [95% CI] [0.59, 0.87]].

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2759
### Table 1. Characteristics and lifestyle factors

<table>
<thead>
<tr>
<th>axSpA</th>
<th>axSpA combined n = 250</th>
<th>Controls n = 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>116 (46%)</td>
<td>24 (48%)</td>
</tr>
<tr>
<td>Age, years</td>
<td>51 (13)</td>
<td>51 (14)</td>
</tr>
<tr>
<td>Symptom duration, years</td>
<td>77 (76)</td>
<td>N/A</td>
</tr>
<tr>
<td>ASDAS-CRP</td>
<td>18 (0.9)</td>
<td>N/A</td>
</tr>
<tr>
<td>BASFI</td>
<td>2.0 (2.2)</td>
<td>N/A</td>
</tr>
<tr>
<td>BILMA</td>
<td>3.0 (1.6)</td>
<td>N/A</td>
</tr>
<tr>
<td>NRS patients’ global health</td>
<td>3.1 (2.5)</td>
<td>1.1 (11)*</td>
</tr>
<tr>
<td>NRS pain</td>
<td>3.1 (2.5)</td>
<td>1.5 (16)*</td>
</tr>
<tr>
<td>NRS fatigue</td>
<td>3.5 (2.8)</td>
<td>2.2 (2.0)*</td>
</tr>
<tr>
<td>EQ-5D utility</td>
<td>0.72 (0.24)</td>
<td>0.90 (0.12)*</td>
</tr>
<tr>
<td>Ongoing csDMARD</td>
<td>54 (22%)</td>
<td>N/A</td>
</tr>
<tr>
<td>Ongoing bDMARD</td>
<td>103 (41%)</td>
<td>N/A</td>
</tr>
<tr>
<td>Ongoing glucocorticoids</td>
<td>18 (7%)</td>
<td>N/A</td>
</tr>
<tr>
<td>Smoking, not fulfil rec.</td>
<td>31 (12%)</td>
<td>2 (4%</td>
</tr>
<tr>
<td>Alcohol, not fulfil rec.</td>
<td>35 (14%)</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>Physical activity, not fulfil rec.</td>
<td>72 (29%)</td>
<td>8 (17%)</td>
</tr>
<tr>
<td>Dietary habits, not fulfil rec.</td>
<td>35 (14%)</td>
<td>5 (10%)</td>
</tr>
<tr>
<td>BMI, not fulfil rec.</td>
<td>142 (57%)</td>
<td>15 (31)*</td>
</tr>
</tbody>
</table>

Mean (SD) or n (%). *p<0.05 by Chi² test or Student t-test, as appropriate. Missing data: ≤ 2%.

### Table 1. Demographic and clinical characteristics stratified by diagnosis as confirmed by Rheumatologist

<table>
<thead>
<tr>
<th>Radiographic Non-axSpA (N = 1)</th>
<th>Radiographic axSpA (N = 5)</th>
<th>Peripheral SpA Including PsA (N = 2)</th>
<th>No SpA (N = 55)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (Mean; SD)</td>
<td>73 (-)</td>
<td>36.8 (6.4)</td>
<td>46 (1.4)</td>
</tr>
<tr>
<td>Sex, Female – n (%)</td>
<td>0</td>
<td>4 (80.0)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Family history of spondyloarthritides, Yes – n (%)</td>
<td>1 (20.0)</td>
<td>1 (20.0)</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Chronic back pain duration, years (Means SD)</td>
<td>12.4 (6.0)</td>
<td>11 (7.0)</td>
<td>15 (10.8)</td>
</tr>
<tr>
<td>Confirmed during rheumatology visit – n (%)</td>
<td>IBP (4 out of 5 criteria as checked by patient)</td>
<td>1 (100)</td>
<td>3 (60.0)</td>
</tr>
<tr>
<td>IBP (4 out of 5 criteria per rheumatologist opinion)</td>
<td>2 (40.0)</td>
<td>0</td>
<td>22 (40.0)</td>
</tr>
<tr>
<td>History of plantar fasciitis or Achilles tendinitis</td>
<td>0</td>
<td>4 (80.0)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>History of peripheral joint swelling</td>
<td>0</td>
<td>1 (50.0)</td>
<td>8 (14.8)</td>
</tr>
<tr>
<td>Positive response to NSAIDs</td>
<td>1 (100)</td>
<td>1 (20.0)</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>1 (100)</td>
<td>0</td>
<td>2 (100)</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>0</td>
<td>0</td>
<td>1 (19.5)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>0</td>
<td>0</td>
<td>1 (18.8)</td>
</tr>
<tr>
<td>HLA-B27 positive</td>
<td>1 (20.0)</td>
<td>1 (20.0)</td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>CRP, Above 10.0 mg/L</td>
<td>0</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
</tr>
<tr>
<td>SI Joints X-ray positive for sacroiliitis</td>
<td>1 (100)</td>
<td>0</td>
<td>1 (18.8)</td>
</tr>
</tbody>
</table>

*According to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA

Conclusion: Unhealthy lifestyle behaviours were more common in axSpA patients than controls, and in male axSpA patients compared to females. Having two or more unhealthy lifestyle factors was associated with worse disease activity, physical function, pain, fatigue, and quality of life in the axSpA patients.

**REFERENCES:**


**Disclosure of Interests:** Elisabeth Mogard Consultant of: Novartis, Tor Olafson Consultant of: Eli Lilly, Merck Sharp & Dohme, Ann Bremandre: None declared.

**Disclosure of Interests:** Elisabeth Lindqvist: None declared

**Disclosure of Interests:** Jonas Sagard: None declared, Johan K Wallman Consultant of: AbbVie, Amgen, Eli Lilly, Merck Sharp & Dohme, Ann Bremandre: None declared.

**Disclosure of Interests:** Elisabeth Mogard Consultant of: Novartis, Tor Olafson Consultant of: Eli Lilly, Merck Sharp & Dohme, Ann Bremandre: None declared.

**Disclosure of Interests:** Jonas Sagard: None declared, Johan K Wallman Consultant of: AbbVie, Amgen, Eli Lilly, Merck Sharp & Dohme, Ann Bremandre: None declared.

**Disclosure of Interests:** Elisabeth Lindqvist: None declared

**Disclosure of Interests:** Jonas Sagard: None declared, Johan K Wallman Consultant of: AbbVie, Amgen, Eli Lilly, Merck Sharp & Dohme, Ann Bremandre: None declared.

**Disclosure of Interests:** Elisabeth Lindqvist: None declared

---

**Figure 1.** Chief complaints reported by patients at chiropractor visits (n=3103)

Conclusion: More than 10% of patients attending chiropractic clinics for musculoskeletal complaints had undiagnosed SpA conditions, with axSpA being the most common. Educational efforts targeted at chiropractors to suspect and refer appropriate cases to rheumatologists are needed.


Table 1. Association between total (m)SQUASH score and health status or quality of life in axSpA patients.

<table>
<thead>
<tr>
<th></th>
<th>ASAS-HI</th>
<th></th>
<th>ASQoL</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R²</td>
<td>B (95% CI)</td>
<td>P-value</td>
<td>R²</td>
</tr>
<tr>
<td>GLAS cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mSQUASH total score</td>
<td>0.16</td>
<td>-0.4 (-4.3; 1.6)</td>
<td>&lt;0.001</td>
<td>0.18</td>
</tr>
<tr>
<td>mSQUASH corrected for age, gender</td>
<td>0.19</td>
<td>-0.4 (-0.1; -1.5)</td>
<td>&lt;0.001</td>
<td>0.21</td>
</tr>
<tr>
<td>mSQUASH corrected for age, gender, BMI, ASDAS</td>
<td>0.30</td>
<td>-0.4 (-3.2; 2.6)</td>
<td>&lt;0.001</td>
<td>0.31</td>
</tr>
<tr>
<td>LUMC cohort</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SQUASH total score</td>
<td>0.13</td>
<td>-0.3 (-4.3; 2.0)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>SQUASH corrected for age, gender</td>
<td>0.23</td>
<td>-0.7 (-3.8; 1.6)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>
Background: A definition for clinically important worsening (CIW) of axSpA has been proposed by ASAS: i.e. an increase of ≥0.9 points of ASDAS. However, it is unknown how this definition performs in an early axSpA cohort.

Objectives: To determine the prevalence of CIW in a population of early axSpA, as well as the association between the occurrence of CIW and the presence of concomitant signs of inflammation; finally, to determine whether MRI inflammation was predictive of a future CIW.

Methods: 708 patients with early axSpA from the French DESIR cohort were included in the analysis. Patients were followed every 6 months for the first 2 years and annually thereafter. All patients had an MRI of spine and sacroiliac joints at baseline, but only patients from the APHP centers performed those 32 patients (84.4%) had an MRI at 2 and 5 years. Prevalence of CIW was calculated during the 5 years of follow-up in the cohort. The association between CIW and concomitant objective signs of inflammation (such as swollen joint count) was assessed over time using mixed models adjusted for sociodemographic and other clinical covariates. CIW predictive factors including the predictive capacity of MRI inflammation (measured by SPARCC at SIJ and spine) and MRI structural damage (defined by presence of ≥5 structural lesions of SI joints or spine) on the occurrence of a future CIW (time-lagged models) were evaluated.

Results: Total number of CIW was 378 in 5 years with 42.8% (303/708) of patients presenting at least one CIW during the follow-up. There were no significant sociodemographic or clinical differences at inclusion between patients with at least one episode of CIW and those without CIW during follow-up. In the association models, concomitant tender joint count [OR 1.02, CI95%[1.01; 1.03] and ASAS-NSAID score last week [OR 1.00, CI95%[1.00; 1.01]] were significantly associated with CIW over time. Presence of MRI-SIJ inflammation (OR per SPARCC point 1.02, CI95%[1.01; 1.04]) and MRI-SIJ structural damage (OR 2.74, CI95%[1.27; 5.93]) were predictive of future (next visit) occurrence of CIW.

Conclusion: Patients with CIW according to the ASAS definition had significantly more objective signs of inflammation concomitantly but also over time. These data support the construct validity of this definition of CIW in an early axSpA population. MRI-SIJ inflammation and structural damage may have a predictive role in the subsequent occurrence of CIW.

REFERENCES:

Table 1. Effect of MRI lesions on the future development of CIW

<table>
<thead>
<tr>
<th>Variables</th>
<th>OR [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Visit</td>
<td>1.01 [0.98; 1.04]</td>
</tr>
<tr>
<td>Sex (Women)</td>
<td>1.55 [0.71; 3.36]</td>
</tr>
<tr>
<td>Age</td>
<td>0.99 [0.95; 1.04]</td>
</tr>
<tr>
<td>Marital status (Single)</td>
<td>0.64 [0.30; 1.37]</td>
</tr>
<tr>
<td>Education (University or equivalent)</td>
<td>0.89 [0.41; 1.94]</td>
</tr>
<tr>
<td>White collar workers vs blue collar</td>
<td>0.52 [0.19; 1.46]</td>
</tr>
<tr>
<td>HLA B27 status</td>
<td>1.15 [0.57; 2.32]</td>
</tr>
<tr>
<td>Symptoms duration</td>
<td>1.43 [1.00; 2.05]</td>
</tr>
<tr>
<td>Enthesitis score</td>
<td>1.00 [0.92; 1.08]</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>1.02 [0.98; 1.06]</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>0.81 [0.39; 1.70]</td>
</tr>
<tr>
<td>ASAS NSAID score last week</td>
<td>1.01 [1.00; 1.01]</td>
</tr>
<tr>
<td>cDMARD intake last 6 months</td>
<td>0.76 [0.20; 2.80]</td>
</tr>
<tr>
<td>TNF last 6 months</td>
<td>0.78 [0.37; 1.63]</td>
</tr>
<tr>
<td>Lag SPARCC-SIJ</td>
<td>1.02 [1.00; 1.04]</td>
</tr>
<tr>
<td>Lag SPARCC-spine</td>
<td>0.99 [0.95; 1.02]</td>
</tr>
</tbody>
</table>

Acknowledgements: This project was conducted thanks to an ASAS grant.

Disclosure of Interests: Fatem Hamiltouche Grant/research support from: ASAS (Assessment in SpondyloArthritis International Society) grant, Sushmitkadev Kumaradev: None declared, Désirée van der Heijde Consultant of: Consulting fees AbbVie, Bayer, BMS, Cynkoe, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Employee of: Director of Imaging Rheumatology bv, Sofia Ramiro Speakers bureau; Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB, Sanofi, Grant/ research support from: AbbVie, Galapagos, Novartis, Pfizer, UCB, Alexandre Sepriano Speakers bureau: Novartis, Consultant of: UCB, Anna Molto Consultant of: Abbvie, BMS, Novartis, UCB, Pfizer, Lilly, Grant/research support from: UCB

Background: In 2009, ASAS published a ‘Definition of active sacroiliitis on MRI for classification of axial spondyloarthritis (axSpA)’. This definition relied on two MRI sequences to make this determination – semicoronal T1 and STIR. Since then, this approach has frequently been used for diagnosis, even though that was never the intent of the definition. In 2015, the European Society of Skeletal Radiology (ESSR) published its recommendations for an SIJ MRI image acquisition protocol (IAP) for diagnostic purposes that required 4 MRI sequences but there is still no IAP that has been widely accepted as a minimum standard worldwide. In 2020, an informal survey of 24 academic sites (12 Europe, 12 North America) confirmed that 24/24 sites performed a minimum of 3 MRI sequences for diagnosis (19 performed 4-8 sequences) because the 2-sequence protocol was considered inadequate.

Objectives: To develop the minimum requirements for a standardized IAP for MRI of the sacroiliac joints for diagnostic ascertainment of sacroiliitis.

Methods: All radiologist members of the ASAS and SPARTAN Classification in axSpA (CLASSpA) project, along with one European and one North American rheumatologist with extensive MRI experience in SpA clinical practice and research, were invited to participate in a consensus exercise. A draft IAP was circulated to all participants along with background information and justification for the draft proposal. Feedback on all issues was received by email, tabulated and recirculated. Participants were broadly in favor of the proposal and two months later a teleconference meeting took place and remaining points of contention were resolved. Examples of the proposed IAP performed on new, 10 and 22 years’ old MRI scanners were made available for review in DICOM format. Next the revised draft of the IAP was presented at the ASAS annual meeting to the entire membership on 14 January 2022, and voted on.

Results: A 4-sequence IAP, 3-semicoronal and 1-semi axial, is recommended for diagnostic ascertainment of sacroiliitis and its differential diagnoses (Table 1). It must meet the following requirements: Semicoronal sequences should be parallel to the dorsal cortex of the S2 vertebral body, and include: 1) a sequence sensitive for the detection of active inflammation being T2-weighted with suppression of fat signal; 2) a sequence sensitive for the detection of structural damage in bone and bone marrow with T1-weighting; 3) a sequence that is designed to optimally depict the bone-cartilage interface of the articular surface and be sensitive for detection of bone erosion; plus 4) a semiaxial sequence sensitive for inflammation detection. The IAP was approved at the ASAS annual meeting by a vote of the entire membership with 91% in favour.

Table 1. A standardized SIJ MRI Acquisition Protocol for diagnostic ascertainment of sacroiliitis

<table>
<thead>
<tr>
<th>Orientation</th>
<th>Sequence</th>
<th>Target Lesion(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Semicoronal</td>
<td>T1-weighted Spin Echo</td>
<td>Structural: Fat lesions, erosion, sclerosis, backfill, ankylosis.</td>
</tr>
<tr>
<td>Semicoronal</td>
<td>T2-weighted with suppressed fat signal (STIR, T2FS or equivalent)</td>
<td>Inflammatory: Bone marrow edema (BME)</td>
</tr>
<tr>
<td>Semicoronal</td>
<td>T1-weighted with suppressed fat signal (2D or 3D T1FS)</td>
<td>Erosion of the articular surface</td>
</tr>
<tr>
<td>Semi axial</td>
<td>T2-weighted with suppressed fat signal (STIR, T2FS or equivalent)</td>
<td>Inflammatory: Bone marrow edema (BME)</td>
</tr>
</tbody>
</table>

Conclusion: A standardized IAP for MRI of the sacroiliac joints for diagnostic ascertainment of sacroiliitis is recommended and should be comprised of a minimum of 4 sequences, in 2-planes, that will optimally visualize inflammation, structural damage, and the bone-cartilage interface.


POS0098

DEEP LEARNING ALGORITHMS FOR MAGNETIC RESONANCE IMAGING OF INFLAMMATORY SACROILIACITIS IN AXIAL SPONDYLOARTHRITIS.

H.Y. Chung1, C.W.S. Chan2, 1Chiron Medical, Rheumatology, Hong Kong, Hong Kong (SAR); 2The University of Hong Kong, Rheumatology and clinical immunology, Hong Kong, Hong Kong (SAR)

Background: Magnetic resonance imaging (MRI) of the sacroiliac (SI) joints is increasingly important in the management of axial spondyloarthritis (SpA). Artificial intelligence (AI) may be the next crucial step in enabling the widespread application of MRI.

Objectives: To develop a deep learning algorithm for detection of active inflammatory sacroiliitis in short tau inversion recovery (STIR) sequence MRI.

Methods: A total of 326 participants with axial spondyloarthritis (SpA), and 63 participants with non-specific back pain (NSBP) were recruited. STIR MRI of the SI joints was performed and clinical data were collected. Region of interests (ROIs) were drawn outlining bone marrow edema, a reliable marker of active inflammation, which formed the ground truth masks from which “fake-colour” images were derived. Both the original and “fake-colour” images were randomly allocated into either the training and validation dataset or the testing dataset. Attention U-net was used for the development of deep learning algorithms. As comparison, an independent radiologist and rheumatologist blinded to the ground truth masks, were tasked with identifying bone marrow edema in the MR images.

Results: Inflammatory sacroiliitis were identified in 1398 MR images from 228 participants. No inflammation was found in 3944 MR images from 161 participants. The mean sensitivity of algorithms derived from the original dataset and “fake-colour” image dataset were 0.86±0.02, and 0.93±0.01 respectively. The mean specificity of algorithms derived from the original and “fake-colour” image dataset were 0.92±0.02, and 0.93±0.01 respectively. The mean testing dice coefficients were 0.48±0.27 for the original dataset and 0.51±0.23 for the “fake-colour” image dataset. The area under the curve of the receiver operating characteristic (AUC-ROC) curve of the algorithms using original dataset and “fake-colour” image dataset were 0.92 and 0.96 respectively. Sensitivity and specificity of algorithms were comparable to interpretation by a radiologist, but outperformed the rheumatologist.

Conclusion: An MRI deep learning algorithm was developed for detection of inflammatory sacroiliac in axial SpA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3420
fusion at the lumbar and/or cervical spine without bamboo spine. We analyzed the ensemble of variables by multivariable logistic regression to identify predictors associated with bamboo spine / advanced spinal disease, and bamboo spine-only.

**Results:** In the study, there were 99 patients with advanced spinal ankylosis and 78 patients with bamboo spine. Older age (OR 1.12, 95% CI 1.07-1.17), male gender (OR 4.26, 95% CI 1.75-10.41), delay diagnosis > 24 months (OR 2.4, 95% CI 1.27-5.74), obesity (OR 4.03, 95% CI 1.53-10.64), hip involvement (OR 4.3, 95% CI 1.14-12.6), smoking > 10 package/year (OR 2.4, 95% CI 1.003-5.2) were significantly associated factors with bamboo spine / advanced spinal ankylosis. Similarly, older age (OR 1.17, 95% CI 1.09-1.13), male gender (OR 8.31, 95% CI 2.09-33.1), obesity (OR 4.15, 95% CI 1.25-13.2), hip involvement (OR 4.74, 95% CI 1.32-16.96) and smoking > 10 package/year (OR 3.19, 95% CI 1.03-9.89) were showed statistical significance with bamboo spine (Table 1).

**Conclusion:** Data on the predictors of development of advanced spinal ankylosis and bamboo spine are scarce. In this study, we showed that older age, male gender, delay in diagnosis, obesity, hip involvement and smoking are factors that predict the development of advanced spinal involvement in axSpA.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3661

---

**Table 1. Predictors of Bamboo Spine and Advanced Spinal Ankylosis, and Bamboo Spine-only**

<table>
<thead>
<tr>
<th>Covariates</th>
<th>Multivariable Model</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI) p-value</td>
<td>OR (95% CI) p-value</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (vs female)</td>
<td>1.12 (1.07-1.17)</td>
<td>&lt;0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delay Diagnosis (≥ 24 months vs &lt;24 months)</td>
<td>2.7 (1.27-5.74)</td>
<td>0.01*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>4.26 (1.75-10.41)</td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 25 to &lt; 30 (vs &lt;25)</td>
<td>2.05 (0.77-5.46)</td>
<td>0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- ≥ 30 (vs &lt;25)</td>
<td>4.03 (1.53-10.64)</td>
<td>0.005*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hip involvement (present vs absent)</td>
<td>4.94 (1.94-12.6)</td>
<td>0.001*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking ≥ 10 package/year vs ≤ 10 package/year</td>
<td>4.03 (1.003-5.2)</td>
<td>0.046*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family History of SpA (First-degree; present vs absent)</td>
<td>2.28 (1.003-5.2)</td>
<td>0.046*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uveitis History (present vs absent)</td>
<td>1.04 (0.38-2.74)</td>
<td>0.94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use SSZ (present vs absent)</td>
<td>0.6 (0.17-2.07)</td>
<td>0.42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use Corticosteroids (present vs absent)</td>
<td>0.69 (0.27-1.75)</td>
<td>0.43</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*p < 0.05

**BIM:** Body mass index; **SpA:** Spondylarthropathy; **SSZ:** Sulfasalazine

---

**POS0993**

**CLINICAL AND IMAGING FEATURES IN SPONDYLOARTHRITIS PATIENTS WITH AND WITHOUT HLA-B27 AND HLA-B51: A VALIDATION COHORT**

F. Carubia1, A. Alunno1, J. Cipollone1, C. Martin1, V. Morom1, C. Ferri1. Internal Medicine and Nephrology Unit, University of L'Aquila, Department of Life, Health and Environmental Sciences, L'Aquila, Italy

**Background:** Despite being commonly expressed in the general population, the human leukocyte antigen (HLA)-B27 allele strongly increases the susceptibility to develop spondyloarthritids (SpA). Likewise, the association between the HLA-B51 allele and the development of Behçet's disease is well documented. In a previous pilot study, we identified similarities and differences in patients with axial or peripheral SpA according to the presence of HLA-B51 only, HLA-B27 only or neither of the two.

**Objectives:** To investigate the clinical and imaging findings of SpA patients according to the absence or presence of HLA-B27 or HLA-B51 in an independent validation cohort.

**Methods:** We retrospectively analyzed patients with axial or peripheral SpA according to the ASAS criteria, referring to our institution between 2020 and 2021. All patients had been tested for HLA-B alleles. Patients with HLA-B51 haplotype and fulfilling the criteria for Behçet's disease were excluded.

**Results:** The independent validation cohort included 185 patients and was comparable to the original cohort of 236 patients with regard to age, gender, age at diagnosis and symptom duration. In line with the findings in the original cohort we observed that aphtous lesions were more prevalent in patients with HLA-B51 (p<0.001) while inflammatory bowel disease was more prevalent in the double negative group (p=0.0006). Unlike the original cohort, patients of the validation cohort did not show a different prevalence of inflammatory back pain (IBP) at disease onset or in the disease course based on the HLA status. A sub-analysis by gender demonstrated a comparable prevalence of IBP in males and females within the 3 groups. As novel finding, we observed that enthesis and psoriasis were significantly more prevalent in the double negative group compared to the B27 and B51 groups (p=0.004) and their prevalence did not differ when comparing B27 and B51 groups. With regard to imaging in patients with axial manifestations, in the original cohort we observed that saccrolitis, assessed by X-ray or magnetic resonance imaging (MRI), were more prevalent in double negative and HLA-B27 patients, compared to HLA-B51 patients and the latter showed a significant negative association with saccrolitis on imaging (OR 3.42 CI 0.189-0.619 p<0.0005). In this validation cohort we observed that the prevalence of saccrolitis on X-ray was similar in the 3 groups while saccrolitis on MRI scan was significantly more prevalent in the B27 group (81%) compared to the double negative (83%) and the B51 group (51%). A negative association between saccrolitis on MRI and HLA-B51 but not double negative status was observed in the validation cohort (OR=0.23, 95% CI=0.07-0.8, p=0.02).

**Conclusion:** Our findings underscore the clinical and radiological heterogeneity of patients with SpA and HLA-B51 alone or neither HLA-B27 nor HLA-B51 compared to those with HLA-B27 only and underline the need to explore further this area by means of registry data with large real-life cohorts.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3714

---

**POS0993**

**RADIOLOGICAL CERVICAL INVOLVEMENT IN ANKYLOSING Spondylitis**

S. Carvès1, R. Burns2, O. Fogel1, B. Banneville2, R. Belkhir3, J. Gross3, B. Saint-Marcoux1,5, L. Smerano1, J. Sellam1,5, R. Richette2, H. Guérini2, C. López-Medina1, C. Miceli Richard1. 1APHP, Hopital Cochin, Rheumatology, Paris, France; 2APHP, Hopital Cochin, Radiology, Paris, France; 3APHP, Hopital Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France; 4APHP Hopital Henri Mondor, Rheumatology, Créteil, France; 5Hopital Intercommunal Robert Ballanger, Rheumatology, Aulnay-sous-Bois, France; 6APHP, Hopital Avicennes, Rheumatology, Bobigny, France; 7APHP Hopital Saint-Antoine, Rheumatology, Paris, France; 8APHP, Hopital Lariboisière, Rheumatology, Paris, France

**Background:** Cervical involvement in ankylosing spondylitis (AS) is particularly disabling and has been poorly studied yet. Actual radiologic scoring design to assess disease progression does not provide a comprehensive picture of the cervical involvement in AS. [1] Association with clinical features such as psoriasis are discussed.

**Objectives:** We aimed to assess radiographic features of cervical involvement in AS and clinico-biological parameters associated with this specific radiographic location.

**Methods:** Cross-sectional study based on radiographic analysis of a subgroup of patients included in the French BambooSpine cohort, originally designed to study the genetic risk factors of AS structural severity. The analysis was based on patients included in Parisian hospitals to have access to images of the entire spine on the Picture Archiving and Communication System (PACS) shared by all University Hospitals in Paris. A double reading of the images was performed by a rheumatologist/radiologist pair until consensus was reached, to identify syndesmophytes, zygapophysial joint (ZJ) involvement and posterior ligament structures (PLS) at each cervical level, syndesmophytes in the thoracic region, and ZJ and PLS involvement in the lumbar region.

**Results:** Of the 113 assessed patients, 101 were men, mean age 53 years (+/- 11 years) with 27 years (+/- 13 years) of disease duration (Table 1). Of those whose HLA B27 status was known, 85% (70/82) were carriers. Among 86 patients with radiological cervical involvement, 83% had syndesmophytes, 86% had ZJ involvement and 24% had PLS involvement. In the cervical region, 13 patients (15%) had zygapophysial fusion without syndesmophytes. 26/113 patients were completely free of any cervical involvement while 30/113 had a maximal cervical involvement (anterior and posterior). In univariate analyses, HLA-B27 was
significantly associated with ZJ involvement at the cervical and lumbar level (p=0.016). Cervical involvement of any type was not associated with psoriasis. Low educational level (not beyond secondary school) was significantly associated with syndesmophyly involvement (p=0.035). There was a non-significant trend for an association between arthritis and ZJ involvement.

### Table 1. Clinical features

<table>
<thead>
<tr>
<th>Men (n,%)</th>
<th>Age at diagnosis (mean, SD)</th>
<th>Duration of evaluation (mean, SD)</th>
<th>Smoking ever (n,%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>101/113</td>
<td>31.2</td>
<td>270</td>
<td>65/112</td>
</tr>
<tr>
<td>89.4%</td>
<td>11.68</td>
<td>13.0</td>
<td>58.0 %</td>
</tr>
</tbody>
</table>

**Conclusion:** Cervical involvement was very frequent (76% of this severe AS population) but not associated with psoriasis, as usually thought. Zygapophysyeal involvement was present in 86 % of cases and exclusive in 15 % of cases. This latter radiological form of the disease, i.e. with no syndesmophyly, is usually more difficult to diagnose, and should be systemically assessed among AS patients with cervical pain and/or patients with reduced cervical mobility.

**REFERENCES:**


**Disclosure of Interests:** None declared DOI: 10.1136/annrheumdis-2022-eular.3991

---

**POS0994**

**DEVELOPMENT OF AN AUTOMATED ALGORITHM BASED ON METHODS OF ARTIFICIAL INTELLIGENCE TO ASSIST IN THE PREDICTION OF CORRECT REFERRALS OF PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS BY USING PATIENT HISTORY TEXTS**

H. Kratz1,2, S. Girze3, S. Ohndorf4, X. Baraliakos5,6, S. Tsiamis6,7, H. Haedecke2,3, N. Döll8,9, J. Holz-Müller1,2, S. Rüping3, F. Behrens1,2,7, M. Köhm1,2,7, H. Kratz1,2, S. Ginzel3, S. Ohndorf4, X. Baraliakos5,6, S. Tsiamis6,7, H. Haedecke2,3, N. Döll8,9, J. Holz-Müller1,2, S. Rüping3, F. Behrens1,2,7, M. Köhm1,2,7,1, Fraunhofer-Institute for Translational Medicine & Pharmacology ITMP Clinical Research, Frankfurt, Germany; 2Fraunhofer Excellence Cluster for Immune-Mediated Diseases CIDM, Clinical Research, Frankfurt, Germany; 3Fraunhofer-Institute for Intelligent Analysis and Information Systems IAIS, Knowledge Discovery, St. Augustin, Germany; 4Charité Universitätsmedizin, Rheumatology, Immunology, Berlin, Germany; 5Ruh-Universität Bochum, Rheumatology, Bochum, Germany; 6Rheumazentrum Ruhrgebiet, Rheumatology, Herne, Germany; 7University Hospital Frankfurt, Rheumatology, Frankfurt, Germany

**Background:** Diagnosis and treatment of PsA and axSpA is often delayed due to missing clear diagnostic criteria and limitations in resources for referral to rheumatologist including high numbers of incorrect referrals. Primary care is usually provided by either general practitioner, dermatologists, or orthopedists. Clinical discriminators with a high specificity for rheumatic conditions include morning stiffness (MST), peripheral or axial, >30min. Artificial intelligence (AI) and natural language processing (NLP) methods offer algorithms for learning systems to recognize disease associated terms and classify clinical phenotypes using large data sets that may support early identification of patients with suspected diagnosis of PsA or axSpA.

**Objectives:** AI and NLP methods are used to identify patients with typical attributes of inflammation by using morning stiffness as one potential discriminating pattern, which can be detected automatically and might help to prioritize referral for rheumatologist appointments.

**Methods:** Within a multicentre observational study, patients with visits at the rheumatologist with a suspected diagnosis of PsA or axSpA from the referral primary care provider were recruited. All data on clinical examinations and findings were collected and evaluated by rheumatologists in focus on criteria for diagnosis of PsA/axSpA (gold standard for evaluation). Unstructured text from the patient history was used to extract diagnosis-relevant characteristics. The information extraction algorithms used NLP models to detect expert curated “morning stiffness” (MST) keywords and puts them into a contextualized framework that allows to capture possible negations.

**Results:** A total of 116 patients were recruited (73 female, 63%) with a median age of 42 (IQR: 34-54). 51 patients were referred as axSpA (44%) and 60 as PsA (52%) by primary care providers. After preselection for PsA and axSpA patients, we observed a 23% rate of referrals without rheumatic diagnosis. Only 7.1% of patients were admitted without signs of MST, 29% with axial MST, 35% with peripheral MST and 28% with both MST types. Average morning stiffness duration was recorded as 35 minutes; patients with a finally confirmed rheumatic diagnosis had a higher average MST duration reported (36 minutes) compared to patients without a confirmed diagnosis. Our AI assisted extraction of MST identified MST in 82.7% of patient history texts. In 75% NLP methods correctly identified the negation of MST symptoms (6 of 8), and 94% of MST was detected when both axial and peripheral joints were affected (30 of 32). Manual inspection of 20 patient history reports where MST was not detected by our automated algorithm revealed that 17 reports depicted factors for not referring a patient; none of these were recognized by NLP methods.

**Conclusion:** The high rate of correct detection of MST from patient history text using NLP methods allowed us to assess the potential for NLP models to support automated analysis of patient reports to facilitate intelligent patient referral.

**Acknowledgements:** We thank the Fraunhofer Excellence Cluster for Immune-Mediated Diseases CIDM for the financial support.

**Disclosure of Interests:** None declared DOI: 10.1136/annrheumdis-2022-eular.3991

---

**POS0995**

**VALIDATION OF THE SPARCC MRI-RETIC E-TOOL FOR INCREASING SCORING PROFICIENCY OF MRI LESIONS IN AXIAL SPONDYLOARTHRITIS**

W. P. Maksymowycz1,2,3, A. E. F. Hadsbjerg3, M. Östergaard2, R. Micheliö2, J. S. Pedersen1,4, A. Ciurea3, N. Vladimirova3, M. J. Nissen5, K. Bubova5, S. Wick4, M. De Hooge6, A. J. Mathew7, K. Pintarcic8, M. Gregova8, Z. Sno9, M. Wetterstey10, K. Gorican10, J. Paschke11, R. G. Lambert11,12,13, CAR E ARTHRITIS LTD, Rheumatology, Edmonton, Canada; 1University of Alberta, Medicine, Edmonton, Canada; 2Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; 3University Hospital Zurich, Rheumatology, Zurich, Switzerland; 4Geneva University Hospital, Rheumatology, Geneva, Switzerland; 5First Faculty of Medicine, Charles University, Rheumatology, Prague, Czech Republic; 6University Hospital Ghent, Rheumatology, Ghent, Belgium; 7UMC Ljubljana, Radiology, Ljubljana, Slovenia; 8Geneva University Hospitals, MSK Radiology Unit, Radiology Section – Diagnostic Department, Geneva, Switzerland; 9Sheba Medical Center, Radiology, Tel Aviv, Israel; 10University of Alberta, Radiology and Diagnostic Imaging, Edmonton, Canada

**Background:** Axial spondyloarthritis (axSpA) is a group of chronic inflammatory disorders of the spine, axial skeleton and peripheral joints, including ankylosing spondylitis (AS). The validation of a web-based e-tool for quantitative MRI assessment of inflammatory disease activity and structural damage is missing. The Spondyloarthritis Research Consortium of Canada (SPARC) MRI-RETIC e-tool allows for the scoring of axial and peripheral structural damage.

**Objectives:** The primary aim of this study was the validation of the SPARC MRI-RETIC e-tool for the scoring of structural and for the scoring of inflammatory lesions in axial SpA.

**Methods:** In this prospective multicenter study, 92 patients (51 male, 41 female) were enrolled in 9 sites. After 2-weeks pre-screening, 16 experts (12 experienced, 4 non-experienced) were randomized, stratified by reader expertise in scoring with SPARCC, to either use Strategy A (2-step strategy) or Strategy B, where the impact was evident for SPARCC BME even by non-experienced readers with similar levels of reader proficiency.

**Results:** The SPARC MRI-RETIC e-tool has been validated for scoring axial and peripheral structural damage as well as for scoring inflammation. The e-tool is easy to use and can be learned by expert readers. The reliability of scoring is evident for all structural lesions, level of reader expertise, and status as well as change scores (Table 1). Scoring proficiency improved the most for the least experienced readers (Figure 1).

**Disclosure of Interests:** None declared DOI: 10.1136/annrheumdis-2022-eular.3996
Table 1. Inter-rater reliability (Status/Change ICC) compared to radiologist SPARCC developer

<table>
<thead>
<tr>
<th>MRI Lesion</th>
<th>Reader expertise</th>
<th>Strategy A</th>
<th>Strategy B</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stage 1 cases (n=25)</td>
<td>Stage 2 cases (n=25)</td>
<td>Stage 3 cases (n=25)</td>
</tr>
<tr>
<td>BME</td>
<td>None (n=4)</td>
<td>0.91 / 0.94</td>
<td>0.83 / 0.82</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.88 / 0.88</td>
<td>0.90 / 0.90</td>
</tr>
<tr>
<td>ANKLYLOSIS</td>
<td>None (n=4)</td>
<td>0.86 / 0.66</td>
<td>0.83 / 0.28</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.89 / 0.57</td>
<td>0.83 / 0.37</td>
</tr>
<tr>
<td>BACKFILL</td>
<td>None (n=4)</td>
<td>-0.08 / 0.05</td>
<td>-0.38 / 0.22</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.41 / 0.13</td>
<td>0.44 / 0.42</td>
</tr>
<tr>
<td>EROSION</td>
<td>None (n=4)</td>
<td>0.82 / 0.38</td>
<td>0.55 / 0.40</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.13 / 0.08</td>
<td>0.67 / 0.42</td>
</tr>
<tr>
<td>FAT METAPLASIA</td>
<td>None (n=4)</td>
<td>0.42 / 0.18</td>
<td>0.56 / 0.12</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.61 / 0.33</td>
<td>0.64 / 0.34</td>
</tr>
<tr>
<td></td>
<td>Experienced (n=5)</td>
<td>0.62 / 0.54</td>
<td>0.30 / 0.17</td>
</tr>
<tr>
<td></td>
<td>Intermediate (n=6)</td>
<td>0.49 / 0.38</td>
<td>0.59 / 0.30</td>
</tr>
<tr>
<td></td>
<td>Experienced (n=7)</td>
<td>0.75 / 0.62</td>
<td>0.81 / 0.34</td>
</tr>
</tbody>
</table>

Conclusion: Attaining scoring proficiency for MRI structural lesions in axSpA is difficult but can be consistently improved by using the SPARCC™ module, even for experienced readers.

Background: Sacroiliac bone marrow edema is an important factor in the diagnosis and management of axial spondyloarthritids (axSpA).

Disclosure of Interests: The authors have declared no competing interest.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.
de Valdecilla, Rheumatology, Santander, Spain; 4Hospital de Algeciras, Rheumatology, Algeciras, Spain; 5H.Sierrallana, Rheumatology, Torrelavega, Spain; 6H.U. Marqués de Valdecilla, Gastroenterology, Santander, Spain

Background: Uveitis is a frequent extraarticular manifestation of spondyloarthritis (SpA) and it has been classically reported that uveitis in axial spondyloarthritis (ax-SpA) is predominantly anterior, unilateral, acute, and non-recurrent; in psoriatic arthritis (PsA) and in inflammatory bowel disease (IBD) it has been described as posterior, bilateral, insidious, and continuous [1,2].

Objectives: In a large unscreened series of SpAs, our aim was to assess the epidemiological and clinical features of SpA-associated uveitis.

Methods: Study of consecutive patients from a single University Hospital with a) ax-SpA, b) PsA, and c) IBD (Crohn’s disease and Ulcerative colitis). We have selected patients with uveitis that were classified according to Standardization of Uveitis Nomenclature (SUN) Working Group. Main general features, and uveitis pattern, location and onset were recorded.

Results: We studied 2156 (1038 women/1118 men) patients with SpAs: IBD (n=1449; 67.2%); PsA (n=406; 18.8%); and ax-SpA (n=301; 14%).

Uveitis was present in 87 (4%) (102 eyes) of 2156 patients with SpAs. However, uveitis occurs with varying frequency according to the SpAs subtype: 14.6% of ax-SpA (n=44), 4.9% of PsA (n=20), 1.6% of IBD (n=23) (Table 1).

In the global SpAs, the most common pattern of uveitis was typically anterior, unilateral, acute, and non-recurrent while in ax-SpA-related uveitis (Table 1).

Table 1. Main clinical features and uveitis pattern.

<table>
<thead>
<tr>
<th>Feature</th>
<th>ax-SpA (n=44)</th>
<th>PsA (n=20)</th>
<th>IBD (n=23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ±SD</td>
<td>45.6 ± 10.3</td>
<td>43.1 ± 14.5</td>
<td>49.1 ± 14.6</td>
</tr>
<tr>
<td>Sex, w/m, % (of women)</td>
<td>25/19 (56.8)</td>
<td>12/8 (60)</td>
<td>17/6 (73.9)</td>
</tr>
<tr>
<td>Disease Duration, years, mean±SD</td>
<td>18.6 ± 10.5</td>
<td>9.9 ± 8.2</td>
<td>17.4 ± 10.2</td>
</tr>
<tr>
<td>HLA-B27 positive, n (%)</td>
<td>37 (84.1)</td>
<td>9 (45)</td>
<td>20 (86.9)</td>
</tr>
<tr>
<td>Uveitis location</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior, n (%)</td>
<td>44 (100)</td>
<td>16 (80)</td>
<td>18 (78.3)</td>
</tr>
<tr>
<td>Posterior, n (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>4 (17.4)</td>
</tr>
<tr>
<td>Panuveitis, n (%)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Uveitis pattern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unilateral, n (%)</td>
<td>37 (84.1)</td>
<td>16 (80)</td>
<td>18 (78.3)</td>
</tr>
<tr>
<td>Acute, n (%)</td>
<td>44 (100)</td>
<td>20 (100)</td>
<td>19 (82.6)</td>
</tr>
</tbody>
</table>

Conclusion: Although SpAs associated uveitis have different frequencies depending on the underlying disease, they share the same clinical pattern: anterior, unilateral, acute, and non-recurrent, in contrast with published data from selected series.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4078

POS0098

DEPRESSION IN SPONDYLOARTHRITIS: THE CHOICE OF MEASUREMENT INSTRUMENT MATTERS

C. Webers1,2, U. Kiltz3,4, J. Braun3,4, D. Van der Heijde5, A. Boonen1,2.
1Maastricht University Medical Centre, Rheumatology, Maastricht, Netherlands; 2Maastricht University, Care and Public Health Research Institute (CAPPHRI), Maastricht, Netherlands; 3Rheumazentrum Ruhrgebiet, Rheumatology, Herne, Germany; 4Ruhr-Universität Bochum, Rheumatology, Bochum, Germany; 5Leiden University Medical Centre, Rheumatology, Leiden, Netherlands

Background: The prevalence of depression is increased in spondyloarthritis (SpA). Research on this topic in SpA is challenging for several reasons, one of them being the wide variety of different instruments used to assess depressive symptoms. It is unknown whether these instruments are comparable in measuring the construct depression and can be considered interchangeable. If these instruments actually differ in what they measure, this should be taken into account when designing and interpreting studies, and in clinical practice when monitoring patients with SpA.

Objectives: To compare the constructs of different instruments used to assess depressive symptoms in patients with SpA.

Methods: Data from the international ASAS Health Index Validation Study were used. Included patients had a diagnosis of SpA and fulfilled the ASAS classification criteria for axial/periarticular SpA. Data on demographics and disease characteristics were collected. The following instruments have been used to assess depressive symptoms in SpA were available: the depression subscale of the Hospital Anxiety and Depression Scale (HADS-D), the Short Form 36 (SF-36) and item 5 of the 5-level EuroQol 5D (EQ-5D-5L). The HADS-D ranges 0-21 (best-worst), with scores ≥8 and ≥11 indicating possible (HADS-possible) and probable depression (HADS-probable), respectively. The SF-36 was summarized using all 36 items in a Mental Component Summary (SF-36MCS, score ≥40 indicating depression), or using only 5 items in the Mental Health subscale (SF-36MH, score ≥6 indicating depression). For the EQ-5D-5L, a score of at least "moderately" (level ≥3 on 1-5 scale) or "severely" depressed (level ≥4) indicated depression.

Results: Spearman correlations between instrument scores, agreement (kappa) between depressed states, and test characteristics (sensitivity [SE], specificity [SP], positive and negative predictive value [PPV, NPV]) were calculated with HADS-D as external standard, as it was specifically designed to detect depression and considered to have highest content validity.

<table>
<thead>
<tr>
<th>Definition of ‘depression’</th>
<th>HADS-D ≥8 (possible)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ-5D-5L ≥3 (moderate)</td>
<td>51 (89)</td>
</tr>
<tr>
<td>EQ-5D-5L ≥4 (severe)</td>
<td>17 (99)</td>
</tr>
<tr>
<td>SF-36MCS ≥40</td>
<td>68 (83)</td>
</tr>
<tr>
<td>SF-36MH ≥56</td>
<td>78 (71)</td>
</tr>
</tbody>
</table>

Conclusion: Instruments used to assess depression in SpA are not interchangeable. The choice of instrument should be taken into account when interpreting studies on depression in SpA. SF-36MCS and SF-36MH are sensitive and could be considered for screening while EQ-5D-5L is useful when high specificity is required. In situations where assessment of depression is the primary objective, depression-oriented instruments such as the HADS are recommended.
Background: Diagnostic delay in axial spondylarthropathy (axSpA) is a well-defined feature of the disease, despite increased awareness. Morbidity and mortality are higher in axSpA than the general population. Much of this excess burden is due to increased comorbidity. However, the association between delayed diagnosis and increased comorbidity in this population is unknown.

Objectives: (1) Examine the relationship between delayed diagnosis and comorbidity in a large cohort of well characterised individuals with axSpA (2) Assess the impact of sex on the relationship between diagnostic delay and comorbidity.

Methods: The Ankylosing Spondylitis Registry of Ireland (ASRI), a descriptive epidemiological study of the Irish axSpA population, provided the cohort for this study. A standardised clinical assessment was performed on each patient. Delay to diagnosis was calculated as age at diagnosis minus age at symptom onset. Comorbidities were considered as any condition present in addition to axial SpA, excluding extra-musculoskeletal manifestations (EMM). SPSS was used for statistical analysis, with appropriate tests used for normally and non-normally distributed data.

Results: Of the 913 included patients, 659 (72%) were male and mean age was 46 years (SD 13), Disease duration, median (25th,75th) 17.1 (9.5, 27.8) years. Medical delay to diagnosis was 5 (2, 12) years. Comorbidity was present in 37% (n=341) of the cohort, with hypertension the most prevalent (see Figure 1).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Age, mean (SD)</th>
<th>Female, n (%)</th>
<th>Caucasian, n (%)</th>
<th>Ever Smoker, n (%)</th>
<th>HLA-B27 positive, n (%)</th>
<th>Disease duration, median (25th,75th) years</th>
<th>Delay to diagnosis, median (25th,75th) years</th>
<th>AAU, n (%)</th>
<th>PsA, n (%)</th>
<th>IBD, n (%)</th>
<th>Biologic use, n (%)</th>
<th>BASMI, mean (SD)</th>
<th>BASFI, mean (SD)</th>
<th>BASDAI, mean (SD)</th>
<th>HAQ, median (25th, 75th)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45.8 (12.6)</td>
<td>254 (27.8)</td>
<td>819 (96.5)</td>
<td>527 (57.7)</td>
<td>631 (89.9)</td>
<td>171 (9.5, 27.8)</td>
<td>5.0 (2.0, 12.0)</td>
<td>308 (34.4)</td>
<td>150 (16.7)</td>
<td>96 (10.7)</td>
<td>628 (76.0)</td>
<td>3.6 (2.1)</td>
<td>3.4 (2.9)</td>
<td>3.9 (2.4)</td>
<td>0.38 (0.0, 0.9)</td>
</tr>
</tbody>
</table>

The median delay to diagnosis was significantly longer in those with ≥1 comorbidity compared to those with none (7 vs 5 years, p<0.01). Hypertension (6 vs 5 years, p=0.01) and cerebrovascular disease (10 vs 5 years, p=0.03) were associated with a significantly longer delay to diagnosis, with a similar trend seen in those with hyperlipidaemia (7 vs 5 years, p=0.09) and ischaemic heart disease (10 vs 5 years, p=0.07). The delay to diagnosis was also longer in those that currently (7 vs 5 years, p=0.03) or ever smoked (6 vs 5 years, p=0.01). The delay to diagnosis was significantly longer in those with depression (9 vs 5, p<0.05). The presence of EMM did not contribute to a delay to diagnosis, and there was no association with any categories of medication. There was no significant difference in the median delay to diagnosis between females (5 vs 6 years) for males. However, there were differences in the relationship between delay to diagnosis and the pattern of comorbidities between sexes. There was a significantly (p=0.05) longer delay to diagnosis in men with cerebrovascular disease (12 vs 6 years), ischaemic heart disease (10 vs 6 years) and diabetes (10 vs 6 years), which wasn’t evident in females. Depression was associated with a longer delay to diagnosis in males (10 vs 6 years, p=0.05), but not females (6 vs 5 years, p=0.5).

Conclusion: Delay to diagnosis of axSpA was associated with a higher prevalence of comorbidities. This was particularly evident in men, with higher cardiovascular morbidity in those with a longer delay to diagnosis. Further research is needed to determine if shortening the delay to diagnosis would reduce the burden of cardiovascular morbidity.

Disclosure of Interests: None declared

REFERENCES:
observed in 22 (19%) pregnancies. The multivariate model adjusted for age, BMI, nulliparity, active disease during pregnancy, smoking, and exposure to NSAIDs and corticosteroids during pregnancy found an association between unfavorable pregnancy outcome with nulliparity (OR 2.63 95% CI [1.01-6.81], p = 0.05).

Conclusion: This study provides original results on pregnancy in women with SpA. It found a favorable pregnancy outcome in 63.5% of women. Unfavorable pregnancy outcome was most frequently due to small for gestational age, which should lead to a coordinated management with obstetricians for the follow-up of pregnancy in women with SpA.

REFERENCES:

Table 1. Multilevel logistic regression model: factors associated with unfavorable pregnancy outcome in women with SpA.

<table>
<thead>
<tr>
<th>Univariate analyses</th>
<th>Multivariate analyses</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Crude OR 95% CI p</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>1.01</td>
<td>0.92-1.10</td>
</tr>
<tr>
<td>BMI</td>
<td>0.99 [0.91-1.07]</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>2.16 [0.94-4.94]</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.84 [0.23-3.03]</td>
</tr>
<tr>
<td>Disease activity*</td>
<td>0.98 [0.94-2.34]</td>
</tr>
<tr>
<td>Osteoidosclerosis*</td>
<td>1.09 [0.53-2.56]</td>
</tr>
<tr>
<td>NSAIDs**</td>
<td>0.65 [0.18-2.33]</td>
</tr>
</tbody>
</table>

* BASDAR score ≥ 4 at least once during pregnancy. ** Use at least once during pregnancy.

Acknowledgements: The GR2 Cohort is supported by the French Society of Rheumatology, the French Internal Medicine Society, and unrestricted grants from UCB.

Disclosure of Interests: SABRINA HAMROUN: None declared, Marion Coudenc: None declared, René-Marc Filipo: None declared, Jérémie SELLAM: None declared, Christophe Richez Speakers bureau: CR has received consulting/ speaker’s fees from AbbVie, Amgen, Astra Zeneca, Biogen, BMS, Celltrion, Eli Lilly, Galapagos, GSK, MSD, Novartis, and Pfizer, all unrelated to this manuscript., Rakiba Belkhir: None declared, LAURE GOSSEC: None declared, Hubert MAROTTE: None declared, Emmanuelle Deroux: None declared, Aline Frazer-Mironer: None declared, Elisabeth Gervais: None declared, Cédric Lukas: None declared, Valerie Devauchelle-Pensec: None declared, Laëtitia Dunoegant: None declared, Alban Deroux: None declared, Nathalie Costedoat-Chalumeau: None declared, Anna Moltò: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4473

Table 1. Association between smoking status and extra-axial manifestations in axSpA.

<table>
<thead>
<tr>
<th>AxSpA cohort</th>
<th>Current smoker Past smoker Non-smoker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>30.9% 22.4% 35.5%</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>6.7% 4.5% 6.7%</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>18.1% 17.4% 16.2%</td>
</tr>
<tr>
<td>Uveitis</td>
<td>34.3% 27.4% 38.6%</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>16.7% 18.5% 19.3%</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>10.7% 9.9% 9.5%</td>
</tr>
</tbody>
</table>

Different subscripts denote significant (p<0.05) differences between groups. Significant values highlighted in bold.

There was no association between smoking status and disease severity by subjective or objective measures, either for the cohort as a whole or by sex. When compared to non- or ex-smokers and controlled for potential confounders including sex, age, biologic use, the association remained only between current smokers and lower risk of uveitis (OR 0.68, 95% CI 0.49 to 0.96) and arthritis (OR 0.62, 95% CI 0.43 to 0.87), in separate logistic regression models. The association between current smoking and increased prevalence of psoriasis in males did not remain significant once controlled for confounders (OR 1.10, 96% CI 0.73 to 1.65).

Conclusion: We demonstrated that current smoking is independently associated with a lower risk of uveitis and arthritis in males with axSpA, but not females. More research is needed to further investigate this paradoxical finding.

Disclosure of Interests: None declared.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4612

POS1003
IMPACT OF ELECTRONIC MEDICAL RECORD MANAGEMENT SYSTEM ON DISEASE ACTIVITY AND FREQUENCY OF OUTPATIENT VISITS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
H. H. Chen1, 1Taichung Veterans General Hospital, Department of Internal Medicine, Taichung, Taiwan, Republic of China

Background: We developed an electronic medical record management system (EMRMS) at the Taichung Veterans General Hospital (TCVGH) to assess ASDAS by integrating patient reported outcomes (assessed by an independent nurse) and ESRI/CRP for AS patients. We aimed to investigate the impact of the EMRMS on frequency and time of outpatient visits.

Objectives: To investigate the impact of the EMRMS on frequency and time of outpatient visits,

Methods: We identified 652 AS patients who were followed up for at least one year before and after the first ASDAS assessment. We compared the number of outpatient visit and average visit time within one year before and after the initial ASDAS assessment. We identified 201 AS patients who received ≥ 3 continuous ASDAS assessment with an interval of 3 months and compared the 2nd and 3rd ASDAS with the first ASDAS.

Results: The number of outpatient visits increased after starting ASDAS assessment (5.8±3.9 vs. 5.4±3.4, p<0.001), in particular among those whose initial ASDAS-CRP was > 3.5 (8.7±4.0 vs. 5.7±3.4, p<0.001). The average visit time was shortened within one year after ASDAS assessment (8.7±4.4 minutes, p = 0.030), especially among patients whose ASDAS-CRP was > 3.5 (7.3±3.8 vs. 5.7±3.4, p<0.001). The anterior superior VC of L1 was the most affected site among all vertebral corners in all MRI slice thicknesses and CRs. In thoracic spine, the anterior superior corner of T12 was the most frequently affected site in both MRI (all slice thicknesses) and CR. Although MRI could detect more syndesmophytes in both lumbar and thoracic vertebrae than CR, MRI at any slice thickness could not detect 15.4%–23.2% of syndesmophytes detected in CR (Table 1).

Disclosure of Interests: None declared

Table 1. Agreement and disagreement of CR and MRI for syndesmophyte detection per MRI slice thickness

<table>
<thead>
<tr>
<th>CR yes</th>
<th>CR/no</th>
<th>MRI yes</th>
<th>MRI/no</th>
</tr>
</thead>
<tbody>
<tr>
<td>1mm</td>
<td>182</td>
<td>279</td>
<td>72.6%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>51</td>
<td>692</td>
</tr>
<tr>
<td>2mm</td>
<td>184</td>
<td>267</td>
<td>73.8%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>49</td>
<td>704</td>
</tr>
<tr>
<td>3mm</td>
<td>181</td>
<td>238</td>
<td>75.9%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>52</td>
<td>733</td>
</tr>
<tr>
<td>4mm</td>
<td>175</td>
<td>251</td>
<td>76.0%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>58</td>
<td>740</td>
</tr>
<tr>
<td>5mm</td>
<td>169</td>
<td>209</td>
<td>77.3%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>64</td>
<td>762</td>
</tr>
<tr>
<td>6mm</td>
<td>160</td>
<td>186</td>
<td>78.5%</td>
</tr>
<tr>
<td></td>
<td>no</td>
<td>73</td>
<td>785</td>
</tr>
</tbody>
</table>

Fat lesions were detected in 38.3%, 37.5%, 34.8%, 33.7%, 31.4%, 28.7% of VC with MRI slice thicknesses of 1-6mm, respectively. MRI slice thickness had no role in detecting fat lesions (p>0.05 within MRI slice thicknesses).

Conclusion: MRI of the lower thoracic and the lumbar spine at any slice thickness detected more syndesmophytes than CR, but the best agreement and least false-positive findings on MRI based on CR as gold standard was found in the thicker slice thicknesses. The presence of fat lesions did not influence syndesmophyte detection on MRI. These results may influence the performance of spinal MRI in identification of SpA-specific spinal lesions in daily practice.

Disclosure of Interests: None declared

POS1005
ACTIVE INFLAMMATORY LESIONS OF THE SPINE IN SACROILIAC JOINTS MRI (SUS-MRI): AN OVERLOOKED FINDING BY RADIOLOGISTS.
N. Di Medici1, F. Gentili2, S. Guerini3, G. Bagnacci4, A. Perrella1, E. Conticini5, B. Frediani6, L. Cantarini6, L. Volterrani6, M. A. Mazzoldi7, 1University of Siena, Department of Medical, Surgical and Neurosciences, Diagnostic Imaging, Siena, Italy; 2Azienda Ospedaliera Universitaria Senese, Diagnostic Imaging Unit, Siena, Italy; 3University of Siena, Rheumatology Unit, Siena, Italy

Background: Establishing a diagnosis for axial spondyloarthritis (axSpA) is based on the combined presence of several clinical and laboratory features in association with imaging evidence of active inflammation lesions (bone marrow edema, SMSI) in sacroiliac joints (SJIs), also associated with structural lesions, is the main element in favor of a diagnosis of axSpA and SU MRI is currently the main recommended technique for detecting inflammation, enabling early diagnosis in patients with normal radiographic findings. MRI of the spine is generally not recommended for axSpA diagnosis, since spine involvement is considered less sensitive and specific. Several studies explored the incremental value of spine MRI for diagnosing patients with axSpA, especially when the findings of SI are equivocal, and “predicting” clinical disease activity.

Objectives: To evaluate the effectiveness of the MRI study dedicated to SUs to identify the inflammatory involvement of the lumbar spine in patients with active sacroliliitis and clinical diagnosis of axSpA.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4792
Methods: MRI of 96 patients (26M, 70 F, mean age 48 years) with SIJs-MRI positive for inflammatory involvement according to ASAS criteria, were evaluated retrospectively. The presence of signs of inflammation of posterior spinal elements and vertebral bodies included in the field of vision (FOV) was therefore researched.

Results: Of 96 patients with active sacroilitis, 88 had concomitant inflammatory lesions of the lumbar spine. Facet capsulitis (87.6%) and posterior enthesitis (42.2%) were the most common lesions and these lesions frequently coexisted (39.3%). Twelve patients with facet capsulitis presented also facet arthritis. Only 20 out of 96 patients (22%) had vertebral bodies inflammatory lesions: 15 corner inflammatory lesions and 5 aseptical spondylodiscitis.

Conclusion: On the basis of current working consensus MRI examination of the spine is not recommended for axSpA diagnosis, because it is considered less sensitive and specific. However the high prevalence (91.7%) of spinal inflammatory changes in patients with active sacroilitis suggests that these features can be used as an additional element in favor of diagnosis, especially in doubtful cases. This evaluation takes little reporting time, without any increase in MRI execution time.

REFERENCES:

Table 1. Characteristics and features associated with SpA in the different subgroups of Lifelines participants. Data presented as mean ± SD or n (%).

<table>
<thead>
<tr>
<th>Feature associated with SpA</th>
<th>CLBP+/IBP+/B27+ (n=226)</th>
<th>CLBP+/IBP+/B27 (n=1,585)</th>
<th>CLBP+/IBP+ (n=2,653)</th>
<th>CLBP+/IBP (n=2,619)</th>
<th>CLBP+/B27 (n=1,585)</th>
<th>CLBP+B27 (n=2,619)</th>
<th>CLBP (n=20,619)</th>
<th>CLBP (CLBP+/IBP+/B27+) (n=20,619)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>8173 (39.6%)</td>
<td>24 (51.1%)</td>
<td>1443 (39.0%)</td>
<td>1058 (39.9%)</td>
<td>630 (39.7%)</td>
<td>89 (41.4%)</td>
<td>25.7 ± 4.1</td>
<td>26.7 ± 4.3</td>
</tr>
<tr>
<td>Age</td>
<td>44 ± 12.4</td>
<td>48 ± 12.6</td>
<td>42.5 ± 13.2</td>
<td>44.0 ± 12.8</td>
<td>44.1 ± 14.1</td>
<td>41.7 ± 12.5</td>
<td>25.7 ± 4.1</td>
<td>26.7 ± 4.3</td>
</tr>
<tr>
<td>BMI</td>
<td>25.7 ± 4.1</td>
<td>26.7 ± 4.3</td>
<td>26.2 ± 4.5</td>
<td>26.3 ± 4.3</td>
<td>25.7 ± 4.4</td>
<td>25.9 ± 4.6</td>
<td>25.7 ± 4.1</td>
<td>26.7 ± 4.3</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared.
Background: Magnetic resonance imaging (MRI) of the spine and sacroiliac joints (SIJ) are important tools for the diagnosis of axial SpA. However, there is very little data investigating how clinical symptoms and response to treatment relate to the degree of MRI inflammation and to its change over time.

Objectives: To evaluate the relationship between clinical response in axial SpA patients and inflammation in MRI of spine and SIJ after 6 months of treatment.

Methods: In the ESTHER study, a total of 76 patients with early axial SpA with a symptom duration less than 5 years, and with active inflammation on MRI in the spine and/or SIJ at baseline were randomized to be treated with etanercept (n=40) or sulfasalazine (n=36) for one year.

Results: A total of 67 patients with axial SpA were included in this analysis due to availability of MRIs at baseline and Week 24. The characteristics of patients included in this analysis were similar to the whole group of the ESTHER study. Changes in osteitis score for SIJ and spine were associated with clinical response (remission between baseline and Week 24) (Figure 1). Further, we compared patients with and without residual inflammation on MRI of the spine and SIJ as defined above. There were no differences between the groups regarding clinical response and disease activity at week 24.

Conclusion: Change of score for osteitis in MRI of spine and SIJ was associated to disease activity in patients with axial SpA during 6 months of treatment. Presence of residual inflammation on MRI after 6 months of treatment seems to be irrelevant regarding clinical response and clinical disease activity.

REFERENCES:

Acknowledgements: The ESTHER study was supported by an unrestricted research grant from Pfizer. We would like to thank to Anja Weiβ and Christian Althoff who participated in the analysis of the study.
Table 1. Characteristics of patients with axSpA

<table>
<thead>
<tr>
<th></th>
<th>All patients (n=1600)</th>
<th>Hip involvement (n=375)</th>
<th>Hip involvement (n=1225)</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juvenile (&lt;16 years) onset, n(%)</td>
<td>30 (1.9)</td>
<td>12 (3.2)</td>
<td>18 (1.5)</td>
<td>0.031</td>
</tr>
<tr>
<td>Male sex, n(%)</td>
<td>940 (58.8)</td>
<td>255 (68)</td>
<td>685 (55.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HLA-B27 positivity, n(%)</td>
<td>605 (55)</td>
<td>178 (62.7)</td>
<td>427 (52.3)</td>
<td>0.002</td>
</tr>
<tr>
<td>BMI, kg/m²(mean SD)</td>
<td>27.2±5.0</td>
<td>274 (5.2)</td>
<td>27.4±5.5</td>
<td>0.023</td>
</tr>
<tr>
<td>Education duration (≥12 years, n(%)</td>
<td>1014 (64.9)</td>
<td>263 (74.7)</td>
<td>751 (64.2)</td>
<td>0.013</td>
</tr>
<tr>
<td>mNIV positivity, n(%)</td>
<td>1276 (79.8)</td>
<td>338 (90.1)</td>
<td>938 (78.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration (months) median (IQR 25-75)</td>
<td>19 (10-40)</td>
<td>55 (20-65)</td>
<td>45 (10-30)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

When we compared the treatment patterns of axSpA patients with and without hip involvement, we found that the percentages of NSAID as well as csDMARD use were similar in groups. However, the percentages of patients who were prescribed etanercept were higher in axSpA patients with hip involvement (p<0.001).

Conclusion: In addition to inflammation and function, hip involvement seems to be related with diagnosis (n-axSpA), education level and absence of SpA family history. Moreover, enthesis may not accompany hip involvement.

Disclosure of Interests: None declared


POS1009  COMPARING OF DISEASE ACTIVITY, FUNCTION AND QUALITY OF LIFE IN PATIENTS FROM THE CLINICAL AND IMAGING ARM OF NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

S. Dimitrov1, S. Hristova1, S. Bogdanova-Petrova1, T. Georgiev1, T. Shivachewa2, 1Medical University Varna, Rheumatology, Varna, Bulgaria

Background: The concept of axial spondyloarthritis (axSpA) and non-radiographic axSpA (n-axSpA), a subgroup of axSpA, has recently emerged. There are several studies proving the similar levels in disease activity and quality of life in patients with or without structural damage in spondyloarthritis.

Objectives: The aim of this study is to compare disease activity, functional status and quality of life in patients from the clinical and imaging arm of nonradiographic axial spondyloarthritides in Bulgaria.

Methods: A cross-sectional survey was conducted with rheumatologists and their consulting patients in Bulgaria from February 2012 through April 2019. Patients who had a rheumatologist confirmed diagnosis of n-axSpA were eligible to participate. An information about patient demographics and symptoms duration were collected. Acute- phase reactants, patients' reported data for disease activity (BASDAI), functional status (BASFI) and quality of life (ASQoL) were compared between the patients with or without MRI data for sacroiliitis. The level of significance was set to 0.05.

Results: A total of 98 patients from the imaging arm of nonradiographic arm and 62 patients from the clinical arm of n-axSpA patients were included in this analysis. A higher proportion of patients from the imaging arm were male patients (51% vs 37%). The mean age was 33±8.77 in the imaging arm and 34±12.65 in the clinical arm (p=0.05), with mean symptoms duration in both groups- respectively 0.76±0.26 and 0.48±0.13 years (p=0.05). The mean value of C-reactive protein in the imaging arm was 14.8±19.6 and 7.05±10.4, p=0.02 in both groups. The disease activity determined using patients reported data from BASDAI was 4.1±0.67 vs. 3.63±0.78 (p=0.05) and using ASDAS-CRP 2.3±0.17 vs. 2.20±0.32 (p=0.05) in the imaging and clinical arm. The evaluation of the function BASFI was 5.0±1.29 vs. 4.4±1.18, p=0.05 in both groups of patients with n-axSpA. The QoL determined by ASQoL revealed no statistical significant values between the groups – 4.79±3.27 and 5.18±3.03, p=0.05.

Conclusion: Patients from the imaging and clinical arm of n-axSpA share the same clinical features. The burden of the disease, as assessed by ASQoL measurement, is also similar in the investigated subgroups of Bulgarian n-axSpA patients.

REFERENCES:

[2] Ivanova, M., Dimitrov, S., Hristova, S., Dimitrov, A., Kadinov, V. and Stoilov, R. "The GLAS cohort was supported by an unrestricted grant from Bristol-Myers Squibb and Roche, Suzanne Arends: None declared, Anneke Spoorenberg Paid instructor for: Abbvie, Consultant of: Abbvie, Novartis Pharma, Medimmune, Union Chimique Belge, Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Suzanne Arends: None declared, Anneke Spoorenberg Paid instructor for: Abbvie, Consultant of: Abbvie, Novartis Pharma, Pfizer, UCB Pharma, Lilly, Grant/research support from: Novartis Pharma, Pfizer DOI: 10.1136/annrheumdis-2022-eular.5064"
Background: Ankylosing spondylitis (AS) can be characterized not only by the detection of the musculoskeletal system, but also by the probable contribution of extra-articular manifestations (ESMs), which can affect the course of the disease, and may occur in the first place in terms of the activity of the process. At the same time, according to the findings, in 3.5-10% of patients with AS, a diagnosis of IBD was detected, and in 70% of patients with AS, subclinical symptoms of intestinal damage were detected. Researchers have found that AS and IBD have common links of pathogenesis: microbiota and intestinal wall condition. Currently, highly sensitive fecal laboratory tests are used to monitor inflammation activity in IBD prior to colono-scopy. Fecal calprotectin (FCP) is a marker of neutrophil inflammation in gastrointestinal diseases and an indicator of the intensity of the inflammatory process in the intestine. The concentration of FCP is statistically significantly higher in IBD patients with signs of clinical activity and, as a rule, does not go beyond the normal range in patients with irritable bowel syndrome. These data make it possible to consider fecal calprotectin as a promising marker of the onset and latent course of inflammatory bowel disease in patients with ankylosing spondylitis.

Objectives: To reveal the peculiarities of fecal calprotectin concentration in patients with ankylosing spondylitis in case of occurrence and recurrence of inflammatory bowel diseases as extra-articular manifestations.

Methods: The study included 80 patients with ankylosing spondylitis: women - 28 (35%), men - 52 (65%). The average age of patients was 45.12±13.14 years, the average age of onset symptoms - 28.43±13.18 years, mean duration of AS - 18.7±11.75 years. Patients already diagnosed with AS were asked to complete a questionnaire using the Universal Questionnaire to identify signs of immunoinflammatory diseases - psoriasis, psoriatic arthritis, IBD (Crohn's disease, ulcerative colitis) to identify clinical signs of intestinal damage. With a positive answer to one main and one additional question, the patient was asked to conduct a qualitative determination of fecal calprotectin. Before the study, patients were stopped taking non-steroidal anti-inflammatory drugs for two weeks. Patients in whom the presence of calprotectin in the feces was carried out by immunochromatographic method. Patients who had an increase in the concentration of fecal calprotectin above 200 µg/g were recommended to perform a diagnostic colonoscopy on an outpatient basis to clarify the diagnosis. The next step was the determination of fecal calprotectin in patients with a positive survey result. In 26 patients (32.5%) a positive result was revealed.

Results: In 71 (88.7%), according to the results of the questionnaire, subclinical signs of intestinal damage were identified. At the next stage, patients with a positive result in the determination of FCP underwent an immunochromatographic test to detect the concentration of calprotectin in the feces. Of these, 22 patients (84.6%) had a concentration of 50-200 µg/g, which indicates the need for dynamic monitoring of this group of patients. In 4 patients (15.38%), the concentration of FCP was found to be higher than 200 µg/g.

Conclusion: Among patients with ankylosing spondylitis, 88.7% have subclinical signs of intestinal damage. Baseline and available radiographs at 2 (n=85), 4 (n=53) and 6 years (n=30) of follow-up were randomized with radiographs of patients with AS and scored with known time sequence according to the mNY criteria by 2 trained readers (SK and RW). In case of disagreement in classification, the score of a third independent reader (AS) was used. Progression to AS was defined as progression in mNY sacroiliitis score to a score of $\geq 2$ bilaterally or $\geq 3$ unilaterally at any time during the 6-year follow-up period. Patient characteristics and clinical assessments at baseline were compared between patients who did and did not progress from nr-axSpA to AS, using chi-squared tests.

Disclosure of Interests: The GLAS cohort classified as nr-axSpA enrolled into the cohort (baseline) between 2009 and 2018 were included in the analyses. Nr-axSpA was defined as sacroiliitis of $\geq$ 2 grade bilaterally or $\geq 3$ unilaterally on the AP view of pelvic radiographs, according to the modified New-York (mNY) criteria. Baseline and available radiographs at 2 (n=85), 4 (n=53) and 6 years (n=30) of follow-up were randomized with radiographs of patients with AS and scored with known time sequence according to the mNY criteria by 2 trained readers (SK and RW). In case of disagreement in classification, the score of a third independent reader (AS) was used. Progression to AS was defined as progression in mNY sacroiliitis score to a score of $\geq 2$ bilaterally or $\geq 3$ unilaterally at any time during the 6-year follow-up period. Patient characteristics and clinical assessments at baseline were compared between patients who did and did not progress from nr-axSpA to AS, using chi-squared tests.

Disclosure of Interests: Stan Kieskamp: None declared, R. Wilbrink: None declared, Mark Siderius: None declared, Fréke Wink: None declared, Reinhard Bos: None declared, Hendrika Bootsma Speakers bureau: Bristol-Myers Squibb, Novartis, Consultant of: Bristol-Myers Squibb, Roche, Novartis, Medimmune, Union Chimique Belge, Grant/research support from: Novartis Pharma, Pfizer, UCB Pharma, Lilly, Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Suzanne Arends: None declared, Anneke Spoorenberg Paid instructor for: Abbvie, Consultant of: AbbVie, Novartis Pharma, Pfizer, UCBL Pharma, Lilly, Grant/research support from: Novartis Pharma, Pfizer


Table 1. Comparison of baseline characteristics between patients with nr-axSpA who did and did not progress to AS. Values presented as mean ± SD, median (IQR) and n (%) for normally distributed, non-normally distributed and categorical variables, respectively. *p<0.05.
Psoriatic arthritis - treatment

**POS1013** HOW DOES BODY MASS INDEX AFFECT SECUKINUMAB TREATMENT OUTCOMES AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY

U. Kiltz1, J. Brandt-Juergens2, P. Kästner3, E. Riechers4, D. Peterlik5, C. Budden6, H. P. Tony7on behalf of on behalf of the AQUILA Study Group.

1Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, Herne, Germany; 2Rheumatologische Praxis, Paderborn, Germany; 3Medizinische Klinik I, Universitätsklinikum RWTH Aachen, Aachen, Germany; 4Medizinische Klinik, Klinikum der Johannes Gutenberg-Universität Mainz, Mainz, Germany; 5Medizinische Klinik, Charité Universitätsmedizin, Berlin, Germany; 6Medizinische Klinik II, Medizinische Hochschule Hannover, Hannover, Germany; 7Novartis Pharma GmbH, Immunology, Gutachterlage, Nürnberg, Germany; 8Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany

Background: There is a higher prevalence of obesity in patients (pts) with psoriatic arthritis (PsA). The German non-interventional study AQUILA provides real-world data on the influence of body mass index (BMI) of pts with psoriatic arthritis (PsA) on therapeutic effectiveness and safety under treatment with secukinumab, a fully human monoclonal antibody that selectively inhibits IL-17A.

Objectives: The aims of this interim analysis are to describe selected baseline (BL) demographics and to evaluate secukinumab treatment outcomes on disease activity and impact of disease on health and to report safety profile depending on the BMI of PsA pts.

Methods: AQUILA is an ongoing, multi-center study including up to 3000 pts with active PsA or ankylosing spondylitis. Pts were observed from BL up to week (w) 52. Real-world data were assessed prospectively and analyzed as observed. Data were collected on Psoriatic Arthritis Impact of Disease-12 items (PsAID-12 score) and Patient’s Global Assessment (PGA). For calculation of proportion of pts that experienced (serious) adverse events (SAEs), all PsA pts were included that received at least one dose of secukinumab. This interim analysis focuses on BMI subgroups ≤25 kg/m², >25 to ≤30 kg/m² and >30 kg/m² (obese) in PsA pts.

Results: At BL, BMI data were available for 1228 PsA pts: 26.5% (n=325) normal weight, 35.0% (n=430) overweight and 38.5% (n=473) obese PsA pts. Proportion of men was lower in normal weight and obese PsA pts. As BMI increased, the percentage of SAEs in normal weight PsA pts was 21.6%, in overweight 26.3% and in obese 25.9%. There were no unexpected safety signals in either subgroup. One male obese PsA patient died. Cause of death was not reported, however, treating physician did not suspect a causal relationship to secukinumab.

Conclusion: In a real-world setting, secukinumab improved impact of disease and patient’s global assessment of disease activity in all BMI subgroups of PsA pts. However, normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts. Altogether, real-world data of this interim analysis show that secukinumab is an effective treatment with a favorable safety profile up to 52 weeks in PsA pts in all BMI subgroups.

REFERENCES:

**POS1014** IMPACT OF SERUM INTERLEUKIN 22 AS A BIOMARKER FOR THE DIFFERENTIAL USE OF MOLECULAR TARGETED DRUGS FOR PSORIATIC ARTHRITIS

I. Miyagawa1, S. Nakayamada1, M. Ueno2, Y. Miyazaki3, Y. Tanaka4, 1University of Occupational and Environmental Health, Japan, The First Department of Internal Medicine, Kitakyushu, Japan

Background: Although each bDMARD target different molecules, no optimal drug selection has been established. Because studies directly comparing TNF-i and IL-17-i have shown that these drugs are equally effective, the establishment of an optimal selection method for these drugs can contribute to better patient outcomes. We reported the possibility of stratification of patients by peripheral blood lymphocytes phenotyping and precision medicine based on the serum cytokine concentration of IL-22 in PsA pts. However, since peripheral blood lymphocytes phenotyping is complex, the development of simple methods using biomarkers to stratify patients and simple treatment strategies based on such methods is needed to promote precision medicine in a real-world clinical setting.

Objectives: We explored whether serum cytokines could be used as biomarkers for optimal use TNF-i and IL-17-i in patients with PsA.

Methods: In cohort 1 (IL-17-i [n=23] or TNF-i [n=24] for 21 year), we identified serum cytokines that predicted the achievement of DAPSA remission (REM), PASI 90 and Minimal Disease Activity after 1 year of TNF-i or IL-17-i therapy. Subsequently, we developed treatment strategies based on the identified cytokines. In cohort 2, treatment responses were compared between the strategic treatment group (n=17), which was treated based on the treatment strategies, and the mismatched treatment group (n=17) to verify the validity of the treatment strategies developed using serum cytokines as biomarkers.

Results: In cohort 1, serum IL-22 concentrations were statistically identified as a predictor of DAPSA remission after 1 year of IL-17-i therapy. However, no baseline serum cytokines were identified as factors contributing to achievement of DAPSA-REM in the TNF-i-treated group or achievement of PASI90 and Minimal Disease Activity in either group. Using a cut-off value of 0.61376 (sensitivity, 81.8%; specificity, 91.7%; area under the curve, 0.848) determined by a ROC analysis, we stratified 47 patients into the IL-22 high group (n=25) (0.61376+) and the IL-22 low group (n=22) (< 0.61376). Serum IL-17 concentrations were significantly higher in both the IL-22 high and IL-22 low groups than in the healthy control (HC), whereas no significant difference was observed between the IL-22 high and IL-22 low groups. The serum TNF-α concentrations did not significantly differ between the IL-22 low and HC; however, they were significantly higher in the IL-22 high group than in the HC and IL-22 low groups. Based on these results, we created treatment strategies using TNF-i and IL-17-i based on serum IL-22 concentrations, that is, initiation of IL-17-i therapy in patients with low IL-22 concentrations and TNF-i therapy in patients with high IL-22 concentrations. To

Mean PsAID developed in a similar way over time with lowest scores for normal weight and highest scores for obese PsA pts (Figure 1B). Mean improvement from BL to w52 was 2.0 (41.6%) for normal weight, 2.2 (40.7%) for overweight, and 1.8 (32.7%) for obese PsA pts.

The occurrence of AEs/SAEs with or without suspected relationship to secukinumab was most frequent in overweight and obese PsA pts. For example, the percentage of SAEs in normal weight PsA pts was 21.6%, in overweight 26.3% and in obese 25.9%. There were no unexpected safety signals in either subgroup. One male obese PsA patient died. Cause of death was not reported, however, treating physician did not suspect a causal relationship to secukinumab.

Conclusion: In a real-world setting, secukinumab improved impact of disease and patient’s global assessment of disease activity in all BMI subgroups of PsA pts. However, normal weight PsA pts had numerically better PsAID and PGA scores than obese PsA pts. Altogether, real-world data of this interim analysis show that secukinumab is an effective treatment with a favorable safety profile up to 52 weeks in PsA pts in all BMI subgroups.
validate the efficacy of the treatment strategies, we retrospectively compared the efficacy of the DMARDs at 1 year between the following groups in cohort 2. The strategic treatment group (n=17) included patients with low IL-22 concentrations who were treated with TNF-i and those with high IL-22 concentrations who were treated with IFN-i. The mismatched treatment group (n=17) included patients with low IL-22 concentrations who were treated with TNF-i and those with high IL-22 concentrations who were treated with IFN-i. No statistically significant differences were observed between the two groups in baseline characteristics at the initiation of DMARD. After initiation of DMARD, tender joint counts, swollen joint counts, CRP, DAPSA, and PASI were significantly improved in both groups. When the treatment responses over 1 year were compared between the two groups, the rate of achieving DAPSA-REM (58.8% vs. 25.3%, P=0.0399) and Minimal Disease Activity (82.3% vs. 41.2%, P=0.0162) at M12 was significantly higher in the strategic treatment group. There were no statistically significant differences in the rates of achieving PASI75 or PASI90 at M 6 or 12.

Conclusion: We verified that serum IL-22 can be used as a simple biomarker for the proper selection of TNF-i and IFN-i.

Acknowledgements: The authors thank the study participants, without whom this study could not have been accomplished, and all medical staff at all participating institutions for providing the data, especially Ms. Hiroko Yoshida, Ms. Yoko Saito, Ms. Machiko Mitsuiki and Ms. Ayumi Maruyama for the excellent data management. The authors thank Ms. M. Hirahara for providing excellent technical assistance. We also thank Dr Kazuyoshi Saito at Tobata General Hospital; Dr Kentaro Hanami and Dr Shungo Nakayama for their engagement in data collection. We also thank Dr Kazuyoshi Saito at Tobata General Hospital and Shimonoseki Saiseikai Hospital. Nakama Municipal Hospital, and Nakama Municipal Hospital, and all staff members at Kitakyushu General Hospital; Dr Keisuke Nakatomi and Dr Kentaro Hanami and Dr Shunsuke Fukuyo at Wakamatsu Hospital for their engagement in data collection.

Disclosure of Interests: Ippei Miyagawa: None declared, Shingo Nakayama:

Table 1. Overall Treatment-emergent AEs

<table>
<thead>
<tr>
<th>AE Category</th>
<th>Total (median)</th>
<th>PBO-controlled (20-42)</th>
<th>Through to 2Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total (median) PY</td>
<td>230 (0.5)</td>
<td>305 (0.5)</td>
<td>172 (0.5)</td>
</tr>
<tr>
<td>Events/100 PY (95% Cl)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs</td>
<td>223 (2.2)</td>
<td>233 (2.3)</td>
<td></td>
</tr>
<tr>
<td>SAEs</td>
<td>8.7 (5.3, 13)</td>
<td>4.9 (2.8, 8.1)</td>
<td>5.2 (2.4, 8.9)</td>
</tr>
<tr>
<td>Infections</td>
<td>59 (5.0, 70)</td>
<td>56 (4.8, 70)</td>
<td>57 (4.0, 70)</td>
</tr>
<tr>
<td>Serious Infections</td>
<td>2.2 (2.1, 8.0)</td>
<td>0.33 (18.6, 16.5)</td>
<td>1.7 (36.2, 12.2)</td>
</tr>
<tr>
<td>Malignancy</td>
<td></td>
<td>0.44 (0.01, 0.18)</td>
<td>0.98 (0.01, 1.7)</td>
</tr>
<tr>
<td>MACE</td>
<td></td>
<td>0.44 (0.01, 0.20)</td>
<td>0.29 (0.0, 1.7)</td>
</tr>
<tr>
<td>GI-related SAEs</td>
<td></td>
<td>1.3 (0.01, 2.4)</td>
<td>0.33 (0.01, 3.2)</td>
</tr>
<tr>
<td>OIs</td>
<td></td>
<td>0.00 (0.01, 0.3)</td>
<td>0.00 (0.0, 0.6)</td>
</tr>
</tbody>
</table>
| MedDRA Version 23.1. R includes safety follow-up data through 2Y for pts who d/c study agent prior to W24 and did not receive any study agent at or after W24. ** Includes data prior to GUS in PBO pts who switched from PBO to GUS. ** Includes data prior to GUS cross-over at W24.

Table 1. Baseline Total Sharp Score and Change From Baseline at Weeks 24, 52, and 104 by TSD

<table>
<thead>
<tr>
<th>Total Sharp score</th>
<th>TSD ≤1 year</th>
<th>TSD &gt;1 year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SEC</strong></td>
<td><strong>300 mg</strong></td>
<td><strong>150 mg</strong></td>
</tr>
<tr>
<td>Period 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>n = 54</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline, mean (SD)</td>
<td>8.02 (2.07)</td>
<td>8.92 (12.06)</td>
</tr>
<tr>
<td>Week 24 change from baseline, mean (SD)</td>
<td>0.05</td>
<td>-0.08 (1.40)</td>
</tr>
<tr>
<td><strong>n = 46</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 52 change from baseline, mean (SD)</strong></td>
<td>0.18</td>
<td>0.13 (1.07)</td>
</tr>
<tr>
<td><strong>n = 43</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 104 change from baseline, mean (SD)</strong></td>
<td>0.06</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>n = 43</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NL**, no loading dose; **PBO**, placebo; **SEC**, secukinumab; **TSD**, time since diagnosis. * One outlier in the 300-mg dose group was excluded. ** Includes patients who received dose escalation to SEC 300 mg after Week 52.

REFERENCES


**POST016**

**RELATIONSHIPS BETWEEN DISEASE DURATION AND RADIOGRAPHIC PROGRESSION AMONG PATIENTS WITH PSORIASIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5**


1University of Rochester Medical Center, Division of Allergy, Immunology, and Rheumatology, Rochester, United States of America; 2Johns Hopkins University School of Medicine, Division of Rheumatology, Psoriatic Arthritis Program, Baltimore, United States of America; 3Novartis Pharmaceuticals Corporation, Rheumatology, East Hanover, United States of America; 4Novartis Pharma AG, Rheumatology, Basel, Switzerland; 5Novartis Pharmaceuticals Corporation, Biostatistics, East Hanover, United States of America; 6Swedish Medical Center/ Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America

**Background:** For patients with psoriatic arthritis (PsA), delays in diagnosis and treatment can lead to permanent radiographic damage, even early in the course of disease. In the phase 3 FUTURE 5 study (NCT02404350), treatment with secukinumab (SEC) was shown to inhibit progression of structural damage through Week 104 in patients with PsA. However, the effect of disease duration on inhibition of radiographic progression by SEC has not been characterized.

**Objectives:** This post hoc analysis explored relationships between time since diagnosis (TSD) of ≤1 year vs >1 year and radiographic progression among patients with PsA receiving SEC over 2 years in FUTURE 5.

**Methods:** Patient data from FUTURE 5 were stratified by TSD ≤1 year vs >1 year and analyzed by treatment arm. Through Week 24, patients received SEC 300 or 150 mg with subcutaneous loading dose (LD), SEC 150 mg without LD, or placebo (PBO) (period 1). After Week 24, patients receiving PBO were switched to SEC 300 or 150 mg (period 2), and a protocol amendment allowed those with suboptimal clinical response to SEC 150 mg to escalate to SEC 300 mg after Week 52 per investigator judgment. The proportion of patients with no radiographic progression, defined as change from baseline in van der Heijde total modified Sharp score ≤0, was analyzed at Weeks 24, 52, and 104. Mean total Sharp score was evaluated at baseline, and mean change from baseline was determined at Weeks 24, 52, and 104.

**Results:** Of 996 patients with PsA included here, 217 (21.8%) had a TSD ≤1 year and 779 (78.2%) had a TSD >1 year. At baseline, patients with TSD >1 year had greater radiographic damage than patients with TSD ≤1 year as determined by mean total Sharp score (Table 1). As early as Week 24, patients receiving SEC had less radiographic progression than those receiving PBO, regardless of TSD. From Week 24 to Week 104, radiographic progression remained low among all patients receiving SEC, with a trend of least progression among patients randomized to SEC 300 mg at baseline. Regardless of treatment, patients with TSD >1 year had numerically greater radiographic progression than those patients with TSD ≤1 year. Overall, the proportion of patients receiving SEC who did not have any radiographic progression was greater than that of placebo at Week 24 irrespective of TSD, with a trend towards a higher number of non-progressors among those treated with SEC 300 mg (Figure). Patients randomized to SEC 300 mg were less likely to experience radiographic progression through 52 weeks.

**Conclusion:** SEC resulted in low rates of radiographic progression through 2 years of treatment among patients in FUTURE 5, regardless of time since PsA diagnosis.

**Scientific Abstracts**

Disclosure of Interests: Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB, Ana-Maria Orbai Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis, Bhurik Parikh Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Corine Galizet Employee of: Novartis Pharma AG, Basel, Switzerland, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxosmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB DOI: 10.1136/annrheumdis-2022-eular.278

Table 1. Number (%) of GUS-randomized Pts (N=493) Achieving Therapeutic Endpoints Over Time (NRI)

<table>
<thead>
<tr>
<th>Week</th>
<th>Q4W</th>
<th>Q8W</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8</td>
<td>16</td>
</tr>
<tr>
<td>MDA*</td>
<td>8 (3)</td>
<td>33 (14)</td>
</tr>
<tr>
<td>DAPSA≤14</td>
<td>43 (18)</td>
<td>61 (25)</td>
</tr>
<tr>
<td>≤3</td>
<td>5 (2)</td>
<td>12 (5)</td>
</tr>
<tr>
<td>≤4</td>
<td>52 (21)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>≤3</td>
<td>52 (21)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>≤4</td>
<td>52 (21)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>≤3</td>
<td>52 (21)</td>
<td>3 (1)</td>
</tr>
<tr>
<td>≤4</td>
<td>52 (21)</td>
<td>3 (1)</td>
</tr>
</tbody>
</table>

Acknowledgements: This study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Richard Karpowicz, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.

Figure. Proportion of Patients Without Radiographic Progression at (A) Week 24, (B) Week 52, and (C) Week 104 Grouped by TSD

Revised Measures Generalized Linear Mixed Effects Model excludes pts who achieved endpoint at BL. *Pts with BL IGA≥2 and BSA≥3%. †IGA skin response = score of 0 or 1 and ≥2 grade improvement from BL. ‡Among pts with domain at BL.
Conclusion:

None had AE of exacerbation through W100. No pt developed IBD through W100 regimens. For related conditions, 1 GUS pt had IBD and 4 had uveitis at BL and were consistent across key domains with no significant difference between GUS incrementally through W100 (Table 1). Mean improvements and response rates W100 of GUS (Figure 1). Therapeutic endpoint response rates also increased continuous outcomes, improvements over time in key PsA domains extended through 10.1136/annrheumdis-2022-eular.902 DOI:

Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Philip Helli-

UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Immagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Laure Gossec Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galilead, Galapagos, Janssen, Novartis, Pfizer, and UCB, Boehringer and Bristol Myers Squibb, Eli Lilly, Galilead, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Samsung Bioepis, Sanofi- Aventis, and UCB, Grant/research support from: Amgen, Eli Lilly, Galapagos, Pfizer, and Sandoz, Christine CONTRE Shareholder of: Johnson & Johnson, Employee of: Janssen Cilag, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Natalie Shift Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Alexi Kolime Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Peter Nash Grant/research support from: Janssen, Abbvie, Pfizer, Novartis, Lilly, Galilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Philip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Immagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Philip Helli-

Well Paid instructor for: Abbvie, Amgen, Novartis, Janssen, Consultant of: Eli Lilly


Disclosure of Interests: Laura Coates Speakers bureau: AbbVie, Amgen, Bio-
gen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, UCB, Consultant of: AbbVie, Eli Lilly, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galilead, Galapagos, Janssen, Novartis, Pfizer, and UCB, Laurie Gossec Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Novartis, Pfizer, Samsung Bioepis, Sanofi- Aventis, and UCB, Grant/research support from: Amgen, Eli Lilly, Galapagos, Pfizer, and Sandoz, Christine CONTRE Shareholder of: Johnson & Johnson, Employee of: Janssen Cilag, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen

Pharmaceutical Companies of Johnson & Johnson, Emmanouil Rampakakis

Consultant of: Janssen, Employee of: JSS Medical Research, Natalie Shift Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Alexi Kolime Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Peter Nash Grant/research support from: Janssen, Abbvie, Pfizer, Novartis, Lilly, Galilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GSK, Immagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Philip Helli-

Well Paid instructor for: Abbvie, Amgen, Novartis, Janssen, Consultant of: Eli Lilly


POS1018

DRUG SURVIVAL AND TREATMENT RESPONSE RATES IN PSORIATIC ARTHRITIS PATIENTS SWITCHING TO FIRST- OR SECOND-LINE IL-17 INHIBITOR TREATMENT: A DANISH POPULATION-BASED COHORT STUDY

R. L. Hansen1, T. S. Jorgensen1, A. Egeberg1, N. Lippert Roseneoe2, M. Skougaard3,4, Z. R. Stisen1, L. Dreyer1, L. E. Kristensen1. 1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark; 2University of Copenhagen, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Denmark; 3Aarhus University Hospital, Department of Clinical Immunology-Aarhus, Denmark; 4Aalborg University hospital, Department of Rheumatology Aalborg, Denmark; 5The Danish Rheumatologic Database (DANBIO), Rigshospitalet, Glostrup Hospital, Copenhagen, Denmark

Background: Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy associated with psoriasis [1]. It is defined as a multifaceted chronic inflammatory disease with chronic peripheral and/or axial arthritis, entheseopathy and dactylitis. PsA patients also experience fatigue, decreased physical functions and sleep disturbances, which may result in impaired social activity and decreased work productivity [2, 3]. All of these disease associated symptoms can cause substantial functional and mental impairment and thereby result in decreased quality of life [4-6]. Patient impacting factors are important when trying to further understand the disease and when choosing a treatment option to properly manage the symptoms of PsA [2].

Objectives: The objective of this study was to assess the effectiveness of switching to a first- or second-line IL-17 inhibitor treatment in patients with PsA from 2014 to 2021, using data from the Danish Rheumatology registry (DANBIO) by investigating drug survival and treatment response rates.

Methods: PsA patients recorded in DANBIO who switched to a first- or second-line IL-17 inhibitor treatment from a previous biologic disease-modifying antirheumatic drugs (bDMARD) between 2014 and 2021 were included in this study. Baseline characteristics were analyzed in subgroups: first-line IL-17 inhibitor treatment and second-line IL-17 inhibitor treatment and presented as median and interquartile ranges or number and percentage. Visual analog scale (VAS) fatigue 50% improvement and VAS pain 50% improvement, Disease Activity Scores-28 C-reactive protein (DAS-28-CRP) remission and DAS28 scores at 6- and 12-months follow-up was reported. Drug survival of first- or second-line IL-17 inhibitor treatment was reported as a Kaplan Meier plot.

Results: 583 patients were identified and included in the study. Baseline characteristics (Table 1) showed that the age, percentage of females, CRP, HAQ, VAS patient pain, VAS global and DAS28CRP in both first- and second-line IL-17 inhibitor treatment was comparable. First- and second-line IL-17 inhibitor treatment had almost identical drug survival (Figure 1).

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>First-line IL-17 inhibitor</th>
<th>Second-line IL-17 inhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>510 (49.6-52.3)</td>
<td>519 (46.4-54.7)</td>
</tr>
<tr>
<td>Female, % (n)</td>
<td>59.0 (256)</td>
<td>53.6 (52)</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>6.8 (6.1-7.8)</td>
<td>8.2 (6.5-12.6)</td>
</tr>
<tr>
<td>CRP, mg/dl</td>
<td>4.0 (4.0-5.2)</td>
<td>3.0 (2.9-5.3)</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.1 (1.1-1.3)</td>
<td>1.0 (0.9-1.3)</td>
</tr>
<tr>
<td>VAS pain, 100 mm</td>
<td>68 (65-72)</td>
<td>73 (66-76)</td>
</tr>
<tr>
<td>VAS global, 100 mm</td>
<td>75 (73-78)</td>
<td>80 (75-88)</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>4.0 (3.8-4.1)</td>
<td>4.2 (3.7-4.6)</td>
</tr>
<tr>
<td>Previous bDMARD</td>
<td>2.0 (1.0-3.0)</td>
<td>4.0 (2.0-5.5)</td>
</tr>
</tbody>
</table>


Figure 1.

Conclusion: PsA patients switching to a first- or second-line IL-17 inhibitor showed comparable baseline characteristics and an almost identical drug survival.

Figure 1.
survival. Thus, treatment failure of a first-line IL-17 inhibitor treatment, should not block for a second-line IL-17 inhibitor treatment.

REFERENCES:

Disclosure of Interests: Rebekka L. Hansen: None declared, Tanja Schjødt Jør-...
the registry, and at start of a first bDMARD (Table 1). We compared HJC and LJC at registration for current and future bDMARD therapies, and at start of a first bDMARD for treatment effectiveness, using drug retention in univariate and in multivariable Cox regression models.

Table 1. Selected characteristics of bDMARD naive PsA patients with a low and with a high number of affected joints at start of their first bDMARD.

| Variable                  | Levels | HJC % high | LJC % low | N all | p      
|---------------------------|--------|------------|----------|-------|--------
| bDMARD type              | TNFi   | 176        | 92.6     | 175   | 88.8   | 351    | <0.22 |
|                          | OMA    | 14         | 7.4      | 22    | 11.2   | 36     |       |
| csDMARD cotherapy        | yes    | 117        | 61.6     | 90    | 45.7   | 207    | <0.01 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| csDMARD history          | naive  | 175        | 95.1     | 24    | 91.7   | 177    | <0.47 |
|                          | naive  | 95        | 95.8     | 47.5  | 49.2   |       |       |
| Dactylitis history       | yes    | 115        | 60.5     | 60.0  | 30.5   | 175    | <0.01 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| DLA B27                  | yes    | 12         | 11.5     | 28    | 23.3   | 40     | <0.02 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| MDA                      | yes    | 0          | 0         | 17    | 8.6    | 17     | <0.17 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| DAPSA remission          | yes    | 0          | 0         | 12    | 6.1    | 12     | <0.15 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| Dactylitis               | yes    | 93         | 49.0     | 33    | 16.8   | 128    | <0.03 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| Enthesitis               | yes    | 63         | 61.8     | 55    | 47.0   | 118    | <0.03 |
|                          | no     | 132        | 65.1     | 85.1  | 74.5   | <0.01  |       |
| BMI                      | mean (SD) | 27.65   | (5.05)   | 26.58 | (4.72) | 333    | <0.046 |
| MASES                    | mean (SD) | 2.86    | (3.93)   | 1.61  | (2.47) | 297    | <0.005 |
| HAQ-DI                   | mean (SD) | 0.77    | (0.58)   | 0.60  | (0.50) | 292    | <0.01  |
| EQ-5d                    | mean (SD) | 62.22   | (20.63)  | 67.22 | (16.27) | 294    | <0.022 |
| Patient global           | mean (SD) | 5.93    | (2.41)   | 4.83  | (2.58) | 288    | <0.001 |
| Tenderness joint count   | mean (SD) | 18.15   | (8.93)   | 10.15 | (8.17) | 197    | <0.001 |
| Swollen joint count      | mean (SD) | 7.16    | (4.91)   | 3.75  | (2.15) | 387    | <0.001 |
| Patient pain             | mean (SD) | 5.96    | (2.47)   | 4.85  | (2.51) | 291    | <0.001 |

Results: We followed DMARD therapies for median (IQR) 3.2 (1.5, 6.0) in 675 LJC patients and for 3.4 (1.8, 5.2) years in 334 HJC patients. LJC patients at registration as well as at start of a first bDMARD were less often female, with less severe skin, enthesitis, dactylitis and nail involvement. Furthermore, LJC patients had lower disability indices and a more favorable health related quality of life. When defined at registration, LJC were as frequent as HJC patients on csDMARDs, but less often on bDMARDs. During their follow-up, a csDMARD, a first and a second bDMARD were less often and on average later commenced in LJC than in HJC patients. However, when defined at start of a first bDMARD, drug retention did not significantly differ between LJC and HJC patients (Figure 1).

Conclusion: The majority of Swiss PsA patients is in LJC status, which also means a better status in most PsA domains than in HJC patients. LJC status was associated with established bDMARD therapy and with slower treatment escalation. However, bDMARDs were likewise effective in bDMARD-naive LJC and HJC patients, and should not withheld only for reasons of a low joint count.

REFERENCES:


Table 1. Difference in QST outcomes after 12 weeks of treatment with CBD or placebo.

| Variable                  | Levels | HJC % high | LJC % low | N all | p      
|---------------------------|--------|------------|----------|-------|--------
| Group                     | base   | 0.04       | 0.09      | 0.95  |       |
|                          | reference         | 0.04       | 0.09      | 0.95  |       |
| J_group_base              | high   | 196        | 0.04      | 0.09  | 0.95  |       |
|                          | low    | 100        | 0.04      | 0.09  | 0.95  |       |
| csDMARD cotherapy         | no     | 132        | 0.04      | 0.09  | 0.95  |       |
|                          | yes    | 132        | 0.04      | 0.09  | 0.95  |       |
| gender                   | male   | 146        | 0.04      | 0.09  | 0.95  |       |
|                          | female | 183        | 0.04      | 0.09  | 0.95  |       |

Results: Baseline characteristics (demographics and pain) for the CBD treated group and placebo group were comparable. No significant differences were observed in QST variables between baseline and end of treatment when comparing CBD and placebo.

Conclusion: No differences in modulation in QST parameters were demonstrated in patients in treatment with 20-30 mg CBD compared to placebo. Further studies of patients with rheumatic diseases treated with different dosages of CBD are needed to clarify the effect of CBD on pain in this patient group.

REFERENCES:


Table 1. Flow-diagram of participant in the NORDCAN study

Table 1. Difference in QST outcomes after 12 weeks of treatment with CBD or placebo.
POS1022

RELATIONSHIPS BETWEEN INHIBITION OF RADIOGRAPHIC PROGRESSION AND ACHIEVEMENT OF LOW DISEASE ACTIVITY OR REMISSION AND THEIR CORE COMPONENTS IN PATIENTS WITH PSORIARTIC ARTHRITIS TREATED WITH SECUKINUMAB IN FUTURE 5 DURING THE FIRST 24 WEEKS


1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, United States of America; 2Johns Hopkins University School of Medicine, Division of Rheumatology, Psoriatic Arthritis Program, Baltimore, United States of America; 3Novartis Pharmaceuticals Corporation, Rheumatology, East Hanover, United States of America; 4Novartis Pharma AG, Rheumatology, Basel, Switzerland; 5Novartis Pharmaceuticals Corporation, Biostatistics, East Hanover, United States of America; 6University of Rochester Medical Center Division of Allergy, Immunology, and Rheumatology, Rochester, United States of America

Background: Patients with active psoriatic arthritis (PsA) experience inflammation that may result in structural damage and disability. In the phase 3 FUTURE 5 study, treatment with secukinumab (SEC) inhibited radiographic progression and led to sustained remission and low disease activity (LDA) through Week 104.1,2

Methods: Patients were randomized 2:2:2:3 to receive SEC 300 mg with loading dose (LD), 150 mg LD, SEC 150 mg without LD, or placebo (PBO) at Baseline, Weeks 1, 2, 3, 4, and every 4 weeks thereafter until Week 24. In this post hoc analysis, patients were grouped by radiographic progression status at Week 24 (non-radiographic progressors: change from baseline in modified total Sharp score [mTSS] ≤0.0; radiographic progressors: change from baseline in mTSS >0.0). Efficacy (achievement of Minimal Disease Activity [MDA] or Very Low Disease Activity [VLDA] and their individual components, and Disease Activity Index for Psoriatic Arthritis [DAPSA] LDA or remission) was assessed at Week 24.

Results: Of 933 patients with available data, 675 (72.3%) were classified as non-radiographic progressors and 258 (27.7%) were radiographic progressors at Week 24. Non-progressors at Week 24 were more likely than progressors to achieve DAPSA LDA and remission at Week 24 across all treatment arms (Figure 1A). In addition, non-progressors were more likely to achieve MDA and VLDA at Week 24 than progressors across all treatment arms (Figure 1B). Similar trends were observed for all of the individual MDA/VLDA criteria at Week 24 among patients treated with SEC 300 mg or SEC 150 mg LD (Table 1). Notably, non-progressors were more likely to achieve improvements in physical function, pain, and patient global assessment of disease activity than progressors across all treatment arms.

Conclusion: Patients who did not have radiographic progression over 6 months of SEC treatment were more likely to achieve LDA or remission and improvement in physical function at Week 24. Additional analyses will explore relationships between radiographic progression and additional clinical and patient-reported outcomes over longer time periods.

REFERENCES:

Table 1. Proportion of Patients Achieving MDA/VLDA Components at Week 24 Grouped by Radiographic Progression Status at Week 24

<table>
<thead>
<tr>
<th>Outcome</th>
<th>SEC 300 mg n = 166</th>
<th>SEC 150 mg n = 160</th>
<th>SEC 150 mg NL n = 159</th>
<th>PBO n = 159</th>
<th>SEC 300 mg n = 51</th>
<th>SEC 150 mg n = 63</th>
<th>SEC 150 mg NL n = 51</th>
<th>PBO n = 53</th>
</tr>
</thead>
<tbody>
<tr>
<td>TJC78 ≤1</td>
<td>55/161 (33.2)</td>
<td>46/146 (31.5)</td>
<td>37/150 (24.7)</td>
<td>38/196 (19.4)</td>
<td>15/30 (50)</td>
<td>13/26 (50)</td>
<td>13/26 (50)</td>
<td>11/30 (37.1)</td>
</tr>
<tr>
<td>UCJ76 ≤1</td>
<td>105/160 (65.6)</td>
<td>85/146 (58.2)</td>
<td>83/150 (55.3)</td>
<td>88/196 (44.8)</td>
<td>32/50 (64)</td>
<td>28/62 (45.2)</td>
<td>20/49 (40.8)</td>
<td>30/90 (33.3)</td>
</tr>
<tr>
<td>PASI ≤0.3</td>
<td>99/128 (77.3)</td>
<td>90/128 (70.0)</td>
<td>69/109 (63.3)</td>
<td>64/153 (41.8)</td>
<td>29/38 (76.3)</td>
<td>27/47 (57.4)</td>
<td>28/40 (70.0)</td>
<td>26/70 (37.1)</td>
</tr>
<tr>
<td>Patient pain VAS ≤15</td>
<td>57/144 (39.6)</td>
<td>50/133 (37.6)</td>
<td>50/141 (35.5)</td>
<td>33/179 (18.4)</td>
<td>13/24 (50)</td>
<td>13/41 (32.0)</td>
<td>13/41 (32.0)</td>
<td>7/82 (8.6)</td>
</tr>
<tr>
<td>PGA VAS ≤20</td>
<td>63/145 (43.4)</td>
<td>47/125 (37.6)</td>
<td>50/135 (37.0)</td>
<td>39/173 (22.5)</td>
<td>13/21 (61.5)</td>
<td>14/21 (61.5)</td>
<td>13/21 (61.5)</td>
<td>7/81 (8.6)</td>
</tr>
<tr>
<td>HAQ-DI ≤0.5</td>
<td>72/153 (47.3)</td>
<td>55/118 (46.6)</td>
<td>54/122 (44.3)</td>
<td>47/158 (29.7)</td>
<td>13/39 (33.3)</td>
<td>13/58 (31.5)</td>
<td>17/39 (43.6)</td>
<td>19/77 (24.7)</td>
</tr>
</tbody>
</table>

Tender enthesitis points ≤1 | 70/87 (80.5) | 44/63 (69.8) | 42/76 (55.3) | 45/88 (51.1) | 13/18 (72.2) | 17/31 (54.8) | 11/19 (57) | 23/38 (60.5) |

BSA, body surface area; HAQ-DI, Health Assessment Questionnaire Disability Index; MDA, Minimal Disease Activity; NL, no-loading dose; PASI, Psoriasis Area and Severity Index; PBO, placebo; PGA, patient global assessment of disease activity; SEC, secukinumab; SJC, swollen joint count; TJC, tender joint count; VAS, visual analog scale; VLDAs, Very Low Disease Activity.


Acknowledgements: This study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Eric Deutsch, PhD, CMP; of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of the publication.

Disclosure of Interests: Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB; Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB. Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB. Ana-Maria Orris Alboral Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB. Grant/research support from: To Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly and Novartis, Bhumi Parikh Employee of: Novartis Pharmaceuticals Corporation, Corine Galillez Employee of: Novartis Pharma AG, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, Christopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB.
LONG-TERM SAFETY OF RISANKIZUMAB IN PATIENTS WITH PSORIATIC DISEASE: FINDINGS FROM INTEGRATED ANALYSES OF 17 CLINICAL TRIALS IN PSORIASIS AND 4 IN PSORIATIC ARTHRITIS

K. B. Gordon¹, A. Blauvelt², H. Bachelot², B. Kaplan³, W. Koete⁴, L. Drogaris⁴, R. Sinha⁵, K. Papp⁶. ¹Medical College of Wisconsin, Dermatology, Milwaukee, United States of America; ²Oregon Medical Research Center, Dermatology, Portland, United States of America; ³APHP Hôpital Saint-Louis, Université de Paris, Department of Dermatology, Paris, France; ⁴AbbVie Inc., Immunology, North Chicago, United States of America; ⁵Probiotic Medical Research, K Papp Clinical Research, Waterford, Canada.

Background: Risankizumab, an interleukin-23 inhibitor, was efficacious and well tolerated in phase 2 and 3 clinical studies in patients with psoriatic disease.

Objectives: To report long-term risankizumab safety in patients with psoriatic disease.

Methods: Risankizumab safety data to March 25, 2021 were pooled from 17 phase 1–3 clinical trials in plaque psoriasis (PsO) and 4 phase 2/3 trials in psoriatic arthritis (PsA). Adverse events (AEs) of safety interest were reported for patients receiving ≥1 dose risankizumab.

Results: Among 3197 patients with PsO (9982.6 patient years’ [PY] exposure; median [range] treatment duration, 3.7 years [1 day–6.9 years]) and 1542 patients with PsA (1594.9 PY; 10 year [84 days–2.0 years]), rates of treatment-emergent AEs (158.3 and 160.8 events/E100PY), serious AEs (7.6 and 8.4 E100PY) and AEs leading to discontinuation (1.9 and 2.3 E100PY) were similar. Nasopharyngitis (PsO 14.5 E100PY; PsA 7.9 E100PY) and upper respiratory infection (PsO 7.3 E100PY; PsA 6.0 E100PY) were the most common upper respiratory infections; respiratory tract infection and pneumonia for PsO (0.1 E100PY each) and COVID-19 for PsA (0.4 E100PY) were the most common serious infections. Rates of opportunistic fungial infections were <0.1 and 0.1 E100PY in PsO/PsA patients. Rates of non-melanoma skin cancer (NMSC) were 0.7 and 0.4 E100PY, and malignant tumors excluding NMSC were 0.6 and 0.3 E100PY in PsO/PsA patients. Rates of major adverse cardiovascular events were 0.5 and 0.4 E100PY in PsO/PsA patients.

Conclusion: Rates of AEs of safety interest remained low in this largest and longest safety reporting for risankizumab to date, supporting the safety of risankizumab for the long-term treatment of patients with psoriatic disease.


Acknowledgements: AbbVie funded the study, contributed to its design and participated in data collection, analysis and interpretation of the data, and in writing, review, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Jay Parekh, PharmD, of JB Ashtin.

Discloser of Interests: Kenneth B. Gordon Consultant of: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cosentyx, Eli Lilly, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, Merck Sharp & Dohme, Mitsubishi, Novartis, Pfizer, Regeneron, Roche, Samsung Bioepis, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant, Consultant of: AbbVie, Amgen, Arcutis, Astellas, Avillion, Bausch Health, Baxalta, Baxter, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, Meiji Sika Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Mitsubishi, Novartis, Pfizer, Regeneron, Roche, Samsung Bioepis, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant, Grant/ research support from: AbbVie, Amgen, Arcutis, Astellas, Avillion, Bausch Health, Baxalta, Baxter, Boehringer Ingelheim, Botanix, Bristol-Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, Leo Pharma, Meiji Sika Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Mitsubishi, Novartis, Pfizer, Regeneron, Roche, Samsung Bioepis, Sanofi-Genzyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant, DOI: 10.1136/annrheumdis-2022-eular.1185

Acknowledgements: AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R.P. Elore, PhD of AbbVie.

POS1025

COMPARISON OF COMPOSITE INDICES FOR DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: A POST-HOC ANALYSIS FROM SELECT-PSA 1

J. S. Smolen1, E. Lubrano2, M. Kishimoto3, A. Balanescu4, V. Strand5, T. Gao6, N. Vranich6, R. Lippe7, W. Tillett8. 1Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; 2Department of Medicine, University Hospital of Tiberio, University of Mollise, Campobasso, Italy; 3Department of Nephrology, and Rheumatology, Koryun University School of Medicine, Tokyo, Japan; 4“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology, “St. Maria” Hospital, Bucharest, Romania; 5Stanford University, Department of Medicine, Palo Alto, United States of America; 6AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany; 7Royal National Hospital for Rheumatic Diseases, Rheumatology, Bath, United Kingdom

Background: Achieving low disease activity (LDA) or remission is a main treatment target in PsA. Composite indices used to assess disease activity include Disease Activity index for PsA (DAPSA) and PsA Disease Activity Score (PASDAS), which both have cut points for the states of remission and LDA. In addition, LDA and remission can be assessed by the pure state instrument Minimal Disease Activity (MDA) and Low Disease Activity (LDA).

Objectives: These analyses aim to identify overlap and differences between these composite indices in PsA patients treated with upadacitinib (UPA), a Janus kinase inhibitor, or adalimumab (ADA) in the phase 3 SELECT-PSA 1 trial.

Methods: In SELECT-PSA 1 (phase 3, randomized controlled trial, with long-term extension up to 5 years), patients with moderate to severely active PsA with inadequate response or intolerance to at least 1 non-biologic DMARD were randomized to oral UPA at doses of 15 mg or 30 mg (once daily), subcutaneous ADA 40 mg (every other week), or placebo. LDA was assessed using MDA (threshold: ≥5/7 criteria), DAPSA (≥14), PASDAS (≥3.2), and Patient Global Assessment of Disease Activity (PGA; ≤3). These post-hoc descriptive analyses include 1-year (cut off: week 52) as observed data from UPA 15 mg and ADA.

Results: In total, 858 patients (UPA 15 mg: n=429; ADA: n=429) were included in these analyses. Patients receiving UPA and ADA were on average 52 years of age, 54% were female, with an average disease duration of approximately 6 years. With both UPA and ADA, there was a high degree of overlap in the proportion of patients achieving LDA thresholds in MDA, DAPSA, and PASDAS (Figure 1), with reported PGA improvements showing a similar trend. Defining LDA according to MDA or respective cut points for DAPSA, PASDAS, or PGA, the proportion of “non-responders” (i.e., patients who did not reach such states) is shown in Figure 2. Of the individual components included in these indices, fewer patients reported low levels of SF36 Physical Component Summary (SF36-PCS), Patient Assessment of Pain Numeric Rating Scale (PAIN-NRS), and Health Assessment Questionnaire - Disability Index (HAQ-DI) scores, as well as Tender Joint Count 68 (TJC68), with similar responses observed across all indices.

Conclusion: In this post-hoc analysis from the SELECT-PSA 1 trial, there was a high degree of overlap between patients in LDA across the composite indices, including MDA, DAPSA, and PASDAS, irrespective of treatment with UPA 15 mg or ADA and despite variability in inclusion of certain components in some indices but not others. Across all indices, fewer patients reported low levels of SF36-PCS, Pain NRS, and HAQ-DI scores, and TJC68. These data show that improvements in (subjective) “patient-driven” components were the most challenging to achieve. These data indicate a similar pattern of residual disease activity, or influence by residual damage or external factors, regardless of composite endpoint utilized.

REFERENCES:


Acknowledgements: AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R.P. Elore, PhD of AbbVie.


Methods: Data were pooled from patients with prior inadequate response or intolerance to ≥1 non-biologic (b) DMARDs (SELECT-Psa 1) or ≥1 bDMARDs (SELECT-Psa 2) originally randomized to UPA 15 mg QD. Logistic regression models were used to assess the association between baseline characteristics and short-term (Week 12) responses with achievement of MDA or DAPSA LDA at 56 weeks, sustained MDA (MDA at Weeks 36 and 56), and sustained DAPSA LDA (DAPSA LDA at Weeks 36, 44, and 56). Each predictor was evaluated separately in an initial model that included effects for study and concurrent non-bDMARD use. Odds ratios and concordance (c-)statistics were used to determine the predictive accuracy. Statistically significant predictors were then evaluated simultaneously using stepwise logistic regression with the Aikake Information Criterion for model-building.

Results: Of 640 patients included in the analysis, 40% and 47% achieved MDA and DAPSA LDA, respectively, at 56 weeks. Evaluated separately, younger age (male), geographic region, lower body mass index, the presence of dactylitis or enthesitis, and lower scores of Patient’s Assessment of Pain (Pt-Pain), Patient’s Global Assessment (PtGA), tender joint count in 68 joints, and Health Assessment Questionnaire-Disability Index (HAQ-DI) were significant baseline predictors for achieving MDA and DAPSA LDA at Week 56. Lower Pt-Pain (Weeks 12–24) and PtGA (Weeks 16–24) scores were strongly predictive (c-statistics >0.8) of achieving MDA at Week 56, and both measures (from Week 8) were moderately predictive (c-statistics >0.7) of achieving DAPSA LDA. Evaluated simultaneously with several baseline characteristics, lower Pt-Pain and HAQ-DI scores at Week 12 were included in models strongly predictive of achieving MDA (c-statistic = 0.850; Figure 1) and DAPSA LDA (c-statistic = 0.840; Figure 2) at Week 56. For each 1-point increase in Pt-Pain or HAQ-DI scores at Week 12 (after adjusting for other effects in the model), patients were less likely to achieve MDA (by 32% or 56%, respectively) or DAPSA LDA (by 23% or 31%, respectively) at Week 56. Predictors for achieving sustained MDA and sustained DAPSA LDA were generally similar to those identified for achieving MDA and DAPSA LDA, respectively.

Conclusion: In patients with PsA receiving UPA 15 mg, baseline characteristics and early responses strongly predicted achievement of MDA or DAPSA LDA at Week 56. This may guide considerations of treatment targets in clinical trials and encourage physicians to further optimize treatment of their patients in clinical practice.

Acknowledgements: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing support was provided by Hillary Wong, PhD, of 2 the Nth (Chesters, UK), which was funded by AbbVie.

Disclosure of Interests: Daniel Aletaha Consultant of: AbbVie, Grünenthal, Janssen, Medac, Merck, Mitsubishi/Tanabe, Pfizer, Roche, and UCB, Grant/ research support from: AbbVie, Grünenthal, Janssen, Medac, Merck, Mitsubishi/Tanabe, Roche, Pfizer, and UCB, Philip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, and Janssen, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, and Janssen, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, and Janssen, Ralph Lippe Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Frank Behrens Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Chugai, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Chugai, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Grant/research support from: Chugai, GlaxoSmithKline, Janssen, Pfizer, and Roche, Derek Haaland Speakers bureau: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and UCB, Consultant of: AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and UCB, Grant/research support from: AbbVie, Adiga Life Sciences, Amgen, Bristol-Myers Squibb, Can-Fite BioPharma, Celgene, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Sanofi, and UCB, Penelope Palominos Speakers bureau: AbbVie, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, and UCB, Arpina Lerttaranakul Shareholder of: formerly of AbbVie, Employee of: current employee of AbbVie, Michael Lane Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Kevin Douglas Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Peter Nash Speakers bureau: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Arthur Kavanaugh Speakers bureau: AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB.


APREMLILAST EFFICACY IN REAL WORLD SETTINGS: RESULTS FROM AN ITALIAN MULTI-CENTER OBSERVATIONAL STUDY.

A. Ariani1, S. Parisi2, P. Del Medico2, A. Farina3, E. Visalli4, A. Molica Coletta5, F. Lumeni6, R. Caccavale7, R. Scolieri8, R. Andracco9, F. Girelli10, E. Bravi11, M. Colina12, V. Franchina13,14, I. Plati6, E. Di Donato6, G. Amato15, C. Salvarani16, F. De Lucia17, D. Santilli18, E. Arrigoni19, F. Mozzani1, R. Foti20, G. Sandri21, V. Bruzzone22, M. Paroli5, E. Fusaro23, A. Becciolini24 on behalf of Biologic Retention Rate Assessment (BRFA).1 University Hospital of Parma, Day Hospital Medicina Interna e Reumatologia, Parma, Italy;2 Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Rheumatology Department, Torino, Italy;3 Civitanova Marche Hospital, Internal Medicine Unit, Civitanova Marche, Italy;4 Ospedale “A. Muni”, Fermo, Internal Medicine Unit, Rheumatology Outpatient Clinic, Fermo, Italy;5 University Hospital “Pollicino San Giovanni”, Rieti, Rheumatology Clinic, Rome, Italy;6 Azienda Ospedaliera Papardo, Department of Rheumatology, Messina, Italy;7 University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Rheumatology Unit, Modena, Italy;8 Azienda USL of Modena and University Hospital “Pollicino di Modena”, Rheumatology Unit, Modena, Italy;9 Sapienza University of Rome, Polo Pontino, Department of Biotechnology and Medical Specialized Sciences, Latina, Italy;10 NURCHI Regione Marche Hospital of Medicine and Rheumatology Research, Rome, Italy;11 Imperia Hospital, Internal Medicine Unit, Imperia, Italy;12 Ospedale GB Morgagni – L Pierantoni, Forlì, Italy, Rheumatology Unit, Forlì, Italy;13 Ospedale G. Da Saliceto, Internal Medicine and Rheumatology Unit, Piacenza, Italy;14 Ospedale Santa Maria della Scaletta, Medicine Unit (A), Imola, Italy;15 Azienda Ospedaliera Riuniti Papardo-Piemonte di Messina, Messina, Italy, Oncology Unit, Messina, Italy.
Background: Apremilast, an inhibitor of the phosphodiesterase 4, is indicated for Psoriatic Arthritis (PsA) treatment. The 3 years retention rate, an outcome indirectly related to efficacy, observed in clinical trials [1] is 55.5%. A single subsequent real-world setting study [2] suggested a lower efficacy as it reported that the six months retention rate was about 57%.

Objectives: The main aim of this retrospective observational study is the assessment of apremilast 3 years retention rate in a real world PsA patients' cohort. Moreover, the secondary objective is reporting the reasons of apremilast suspension and the most relevant factor related to treatment persistence.

Methods: In thirteen Italian rheumatological referral centers, all PsA consecutively patients who received apremilast were enrolled. Anamnestic data, treatment history and PsA disease activity (DAPSA) at baseline and after 6 and 12 months were recorded. The Kaplan-Meier curve and the Cox analysis computed the apremilast retention rate and treatment persistence-related risk factors. A p-value < 0.05 was considered statistically significant.

Results: The three-hundred-twenty-four enrolled patients (median age 60 [Inter-Quartile Range IQR 52-67] y; female prevalence 57%) median observation period was 17 [IQR 7-36] months (6848 patients-months). The apremilast retention rate at 6, 12 and 36 months was, respectively, 95%, 86% and 66% (Figure 1). The main discontinuation reasons were: primary inefficacy (40% of interruptions), secondary inefficacy (18%) and gastrointestinal intolerance (17%). The oligo-articular onset was the only factor associated to apremilast persistence (Hazard ratio 0.57, IQR 0.34-0.96). Sex, age, and sever comorbidities (cancer, chronic infections etc) were not related to treatment discontinuation. The basal DAPSA (24.1, IQR 18.5-32.0) decreased after 6 and 12 months (respectively 14.5, IQR 10.1-22.6 and 10.5, IQR 8.0-15.2). Remission or minimal disease activity (DAPSA < 15) was achieved after 12 months in 38.0% of patients.

Conclusion: Almost two third of PsA patients receiving apremilast were still in treatment after 3 years. The study’s data, confirmed its efficacy and safety profile. Apremilast appear a good treatment choice in patients with oligo articular PsA or burdened by severe comorbidities.

REFERENCES:

Disclosure of Interests: Alarico Ariani Speakers bureau: Zentiva, Consultant of: Boeringer, Amgen, Bristol-Meyers-Squibb, Novartis, Sanofi, Novo Nordisk, Lilly, Janssen, Bruno Farmaceutici, Simone Parisi: None declared, Patrizia Del Medico: None declared, antonella farina: None declared, elisa visalli: None declared, Aida Mollica Cofelica: None declared, Federica Lumetti Consultant of: Amgen, rosalia cacavale: None declared, Palma Scolieri: None declared, Romina Andracco: None declared, Francesco Girelli: None declared, Elena Bravi: None declared, Matteo Colina: None declared, Veronica Franchina: None declared, Ilaria Plató: None declared, eleonora Di Donato Consultant of: Novartis, Giorgio Andracco: None declared, Francesca De Lucia: None declared, Daniele Santilli Consultant of: Novartis, eugenio arrigoni: None declared, Amato: None declared, Carlo Salvarani: None declared, Francesco De Lucia: None declared, Daniela Santilli Consultant of: Novartis, eugenio arrigoni: None declared, Flavio Mozzani Consultant of: Novartis, Abbvie, Rosario Foti: None declared, Gilda Sandri: None declared, Vincenzo Bruzzese: None declared, Marino Paroli: None declared, Enrico Fusaro: None declared, Andrea Becciolini: None declared


Table 1. LS mean change from baseline over time in dactylitis and LEI scores in pts with manifestation at baseline

<table>
<thead>
<tr>
<th>GUS 100 mg Q4W</th>
<th>GUS 100 mg Q8W</th>
<th>PBO → GUS 100 mg Q4W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dactylitis score (0-60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ps. N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24*</td>
<td>-5.9 (-6.7, -5.0)</td>
<td>-6.0 (-6.8, -5.1)</td>
</tr>
<tr>
<td>W52*</td>
<td>-6.5 (-7.2, -5.8)</td>
<td>-7.2 (-7.9, -6.5)</td>
</tr>
<tr>
<td>W100*</td>
<td>-6.5 (-7.1, -6.8)</td>
<td>-7.5 (-8.1, -6.8)</td>
</tr>
<tr>
<td>LEI score (1-6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ps. N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24*</td>
<td>-1.5 (-1.8, -1.3)</td>
<td>-1.6 (-1.8, -1.4)</td>
</tr>
<tr>
<td>W52*</td>
<td>-1.8 (-2.0, -1.6)</td>
<td>-1.9 (-2.1, -1.7)</td>
</tr>
<tr>
<td>W100*</td>
<td>-1.9 (-2.1, -1.7)</td>
<td>-2.1 (-2.3, -1.8)</td>
</tr>
</tbody>
</table>

aResults are LS mean change (95% confidence interval [CI]); LS mean change determined by ANCOVA; missing data was imputed as no change for pts who discontinued treatment and using multiple imputation for remaining missing data GUS, guselkumab; LEI, Leeds Enthesitis Index; LEI, least squares; PBO, placebo; pts, patients; Q4W, every 4 weeks; Q8W, every 8 weeks; W, week

Conclusion: Pts with PsA often present with concurrent enthesitis and dactylitis, both of which can be recalcitrant to treatment. GUS resolved enthesitis and dactylitis in substantial proportions of pts through W100. GUS-treated pts who achieved enthesitis resolution were more likely to achieve dactylitis resolution and vice versa.

REFERENCES:
Disclosure of Interests: Proton Rahaman Speakers bureau: AbbVie, Eli Lilly, Novartis, Pfizer, and UCB. Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB. Grant/research support from: Janssen, Novartis, Pfizer, and UCB. Undisclosed: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB.

Acknowledgements: AbbVie Inc. participated in the study design; study collection, analysis and interpretation of data; and writing, reviewing, and approving of this abstract for submission. AbbVie funded the research for this study and provided writing support for this abstract. Medical writing assistance was provided by Trisha Retting, Ph.D. of AbbVie.

Disclosure of Interests: Joseph F. Merola Consultant of: Amgen, Bristol-Myers Squibb, AbbVie, Biogen, Celgene, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Sun Pharma, Boehringer, Pfizer and Lego Pharma, Janice Mcelnnes Consultant of: AbbVie, Amgen, AstraZeneca, Biogen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and Sanofi.


P0209
EFFECTS OF TREATMENT WITH RISANKIZUMAB ON MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA): AN ANALYSIS OF THE KEEPSAKE-1 AND -2 TRIALS

J. F. Merola, I. McInnes, A. Kavanagh, P. Nash, X. Zue, V. Stakas, A. Eldred, S. Ciecienski, K. Douglas, L. Coates, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States of America; University of California San Diego, Medicine, San Diego, United States of America; Griffith University, School of Medicine, Queensland, Australia; AbbVie Inc., Immunology, North Chicago, United States of America; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

Background: Risankizumab (RZB) is a monoclonal antibody that specifically inhibits interleukin 23.

Objectives: To evaluate the achievement of Minimal Disease Activity (MDA), its components, and achievement of Disease Activity in PsA Low Disease Activity and Remission (DAPSA LDA+REM; [DAPSA score ≤ 14]) in patients receiving RZB or placebo (PBO) in the KEEPSAKE 1 and 2 clinical trials.

Methods: KEEPSAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus PBO for the treatment of adult patients with active psoriatic arthritis (PsA). Patients were randomized (1:1) to receive subcutaneous RZB 150mg or PBO at weeks 0, 4, and 16. The open label extension began at Week 24 with all patients receiving RZB 150mg every 12 weeks thereafter. Achievement of MDA, its components, and achievement of DAPSA LDA+REM are reported using non-responder imputation.

Results: MDA achievement at Week 52 in KEEPSAKE-1 was 37.9% for patients originally randomized to RZB and 27.4% for patients originally randomized to PBO. In KEEPSAKE-2, MDA achievement was 27.2% and 33.8% for patients originally randomized to RZB and PBO, respectively. Achievement of MDA and its components are presented in Figure 1. In KEEPSAKE-1, at Week 52 59.2% of patients originally randomized to RZB and 51.4% of patients originally randomized to PBO achieved DAPSA LDA+REM. At Week 52 in KEEPSAKE-2, DAPSA LDA+REM was achieved by 44.6% of patients originally randomized to RZB and 46.6% of patients originally randomized to PBO (Figure 1).

Conclusion: Patients treated with RZB demonstrate achievement of MDA, its components, and DAPSA LDA+REM at Weeks 24 and 52.

States of America; *Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

**PAIN RESPONSE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB IS DRIVEN PREDOMINANTLY BY INFLAMMATION-INDEPENDENT EFFECTS**

P. J. Mease1, E. Soriano2, S. D. Chakravarty3,4, E. Rampakakis5, M. Shaw6, P. Nash7, P. Rahman8, 9

1 Swedish Medical Center/Providence St. Joseph Health and Univ Washington, Rheumatology Research, Seattle, United States of America; 2Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina; 3Janssen Scientific Affairs, LLC, Immunology, Rheumatology, Horsham, United States of America; 4Drexel University College of Medicine, Division of Rheumatology, Philadelphia, United States of America; 5McGill University, Department of Pediatrics, Montreal, Canada; 6Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; 7Griffith University and U of Queensland, Rheumatology Research Unit, Maroochydore, Australia; 8Memorial University of Newfoundland, Discipline of Medicine, Division of Rheumatology, Craig L Dobbin Genetics Research Centre, St. John’s, Canada

**Background:** Although reducing inflammation has been associated with pain improvement, the two do not always correlate. Recent studies have suggested that, in addition to its role in inflammation pathogenesis, IL-23 may be involved in pain regulation in a lymphocyte-independent manner. Gusekumab (GUS), a fully human monoclonal antibody that selectively inhibits IL-23, has demonstrated safety and efficacy in treating multiple domains of active PsA in the DISCOVER-1&2 (D1&D2) trials.

**Objectives:** To quantify the role of reducing inflammation on the observed relationship between GUS and pain response in PsA patients (pts) using mediation modelling.

**Methods:** Pooled data from the D1&D2 studies were analyzed. Pts in D1 had ≥3 swollen and ≥3 tender joints (SJC/TJC) and C-reactive protein (CRP)≥0.3 mg/dL; in D2, pts had ≥5 SJC and ≥5 TJC and CRP≥0.6 mg/dL. 31% of D1 pts received 1-2 prior tumor necrosis factor inhibitors (TNFi); D2 pts were bio-naïve. Pts were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then W8 (Q8W); or placebo (PBO); PBO pts crossed over to GUS 100 mg Q4W.

Mediation analyses were performed separately for Q4W & Q8W, W4 & W24, and TNFi-naïve & -experienced (exp) pts. In each model, change in joint counts was the dependent variable; treatment regimen was the independent variable; inflammation, measured by change in SJC or CRP, was the designated mediator; covariates were: age, sex; and baseline (BL) pain score, BMI, SF-36 MCS score, and NSAID use.

**Results:** Mean (SD) BL pain levels in the GUS Q4W, GUS Q8W, and PBO groups were 60.4 (19.8), 62.0 (20.2), and 61.1 (19.6), respectively. Treatment with GUS was associated with significantly greater pain improvement compared with PBO as early as W4 (ΔGUS-Q4W [95%CI]: -4.9 [-7.6, -2.2]; ΔGUS-Q8W [95%CI]: -5.2 [-7.9, -2.5]) (Figure 1). The between-group differences were further enhanced by W24 (ΔGUS-Q4W [95%CI]: -14.6 [-17.6, -11.6]; ΔGUS-Q8W [95%CI]: -14.3 [-17.3, -11.2]). For GUS-Q8W, ΔGUS randomized pts exhibited an approximate 50-point (-50%) decrease in pain. Similar results were observed for TNFi-naïve and TNFi-exp pts.

**Conclusion:** GUS induced significant improvement in pt-reported pain as early as W4 of treatment, which was continuously enhanced through W24. While the known mediation effect of SJC and CRP, as markers of inflammation, on pain was confirmed, the majority of GUS’s effect on pain reduction was independent of its effect on these markers, regardless of dosing regimen or prior TNFi experience.

**REFERENCES:**

2. Lancet. 2020;395:1115
3. Lancet. 2020;395:1126

**Disclosure of Interests:** Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagen, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Emmanuel Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Peter Nash Speakers bureau: AbbVie, Amgen, Pfizer, Novartis, Lilly, Gilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Consultant of: Janssen, Abbvie, Pfizer, Novartis, Lilly, Gilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Grant/research support from: Janssen, Abbvie, Pfizer, Novartis, Lilly, Gilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Proton Rahman Speakers bureau: Janssen, Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Janssen, Novartis, Roche, and UCB, Grant/research support from: Janssen and Novartis

**DOI:** 10.1136/annrheumdis-2022-eular.1384

---

**Figure 1.**

Mediation analyses demonstrated that the majority of GUS effect on pain at W4 was not attributable to SJC (direct effect), specifically ≤5% was mediated by inflammation as assessed by changes in SJC (indirect effect; Table 1). Similarly, at W24, the indirect effect via SJC improvement represented ≤10% of the GUS treatment effect. No differences were observed between TNFi-naïve and -exp pts at either timepoint.

Consistent results were obtained when using CRP as the mediator variable instead of SJC, whereby ≤2-9% of GUS effect on pain was mediated by inflammation and 91-98% was direct (Table 1).

**Table 1. Direct (D) Treatment Effect vs. Indirect (IND) Effect via Inflammation Markers on Pain Improvement**

<table>
<thead>
<tr>
<th>Mediator</th>
<th>Week</th>
<th>Pt Group</th>
<th>Effect GUS Q4W</th>
<th>GUS Q8W</th>
</tr>
</thead>
<tbody>
<tr>
<td>SJC</td>
<td>4</td>
<td>All</td>
<td>D</td>
<td>96.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>D</td>
<td>3.3%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>6.3%</td>
<td>1.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>CRP</td>
<td>4</td>
<td>All</td>
<td>D</td>
<td>96.8%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>2.4%</td>
<td>5.0%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>2.4%</td>
<td>4.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IND</td>
<td>97.2%</td>
<td>94.2%</td>
</tr>
</tbody>
</table>

**<p>0.05; 1 via SJC; 2 via CRP**

**Conclusion:** GUS induced significant improvement in pt-reported pain as early as W4 of treatment, which was continuously enhanced through W24. While the known mediation effect of SJC and CRP, as markers of inflammation, on pain was confirmed, the majority of GUS’s effect on pain reduction was independent of its effect on these markers, regardless of dosing regimen or prior TNFi experience.

---

**EARLIER CLINICAL RESPONSE PREDICT LOW RATES OF RADIOGRAPHIC PROGRESSION IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT**


1 Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, United States of America; 2Icahn School of Medicine at Mount Sinai, Department of Dermatology, Mt Sinai, United States of America; 3University of Pennsylvania School of Medicine, Immunology, Philadelphia, United States of America; 4Janssen Scientific Affairs, LLC, Immunology, Rheumatology, Horsham, United States of America; 5McGill University, Department of Pediatrics, Montreal, Canada; 6Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; 7Griffith University and U of Queensland, Rheumatology Research Unit, Maroochydore, Australia; 8Memorial University of Newfoundland, Discipline of Medicine, Division of Rheumatology, Craig L Dobbin Genetics Research Centre, St. John’s, Canada; 9University of Washington, Rheumatology Research, Seattle, United States of America; 10.1136/annrheumdis-2022-eular.1384
Background: In GUS-treated biologic-naive pts with active PsA, following adjustment for known baseline (BL) determinants of radiographic progression (vdH-S score, age, gender, and CRP), no correlation was seen between BL PASI and BL vdH-S score. Greater improvement in BL DAPSA score after adjusting for BL PASI, vdh-S score, age, gender, and CRP (Figure). No correlation was seen between BL PASI and BL vdH-S score (Table 1). Greater improvement in DAPSA score (≥20%) at week 24 of GUS-treated biologic-naive pts with active PsA was associated with numerically less radiographic progression through W100 after adjusting for known baseline (BL) determinants of radiographic progression (vdH-S score, age, gender, and CRP).

Results: PsA duration, CRP, and SJC at BL weakly correlated with BL vdH-S score.

Table 1. Correlation of Select BL Disease Characteristics with BL vdH-S Score Among GUS Randomized Pts

<table>
<thead>
<tr>
<th>BL Determinants</th>
<th>Spearman's correlation coefficient</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.27335</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>PsA</td>
<td>0.28181</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>PsA Duration</td>
<td>0.33070</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>PsA Duration</td>
<td>0.20305</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>SJC (66)</td>
<td>0.26321</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Conclusion: In GUS-treated biologic-naive pts with active PsA, following adjustment for known BL determinants of radiographic progression, earlier (W16) DAPSA improvement was a significant predictor of less radiographic progression through W100; DAPSA remission and skin improvement at W16 each showed a numerical trend toward less radiographic progression through W100.

REFERENCES:
DYNAMICS OF NAIL PSORIASIS WITH GUSELKUMAB TREATMENT AND WITHDRAWAL IN ASSOCIATION WITH SKIN RESPONSE AND PATIENT-REPORTED OUTCOMES: A POST HOC ANALYSIS OF THE VOYAGE 2 PHASE 3 TRIAL

W. Tillett1,2, A. Egeberg3, E. Sonkoly4,5,6, P. Gorecki7, A. Tjärnlund8, J. Buyze9, W. Tillett1,2, A. Egeberg3, E. Sonkoly4,5,6, P. Gorecki7, A. Tjärnlund8, J. Buyze9, S. Wegener4, D. Mconagle11,12, "Royal National Hospital for Rheumatic Diseases,, Bath, United Kingdom; 3University of Bath, Department of Pharmacy and Pharmacology, Bath, United Kingdom; 4Bispebjerg Hospital, Department of Dermatology, Copenhagen, Denmark; 5Karolinska Institutet, Dermatology and Venereology Division, Stockholm, Sweden; 6Karolinska Institutet, Center for Molecular Medicine, Stockholm, Sweden; 7Uppsala University, Department of Medical Sciences, Uppsala, Sweden; 8Janssen-Cilag Ltd., High Wycombe, United Kingdom; 9Janssen-Cilag AB, Solna, Sweden; 10Janssen-Cilag BV, Leiden, the Netherlands; 11Guselkumab GmbH, Neuss, Germany; 12University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 13Leeds Teaching Hospitals NHS Trust, National Institute for Health Research, Leeds Biomedical Research Centre, Leeds, United Kingdom

Background: Nail psoriasis can be difficult to treat, affects ~50% of patients with psoriasis and can involve the nail matrix (pitting, leukonychia) and/or nail bed (onycholysis, splinter haemorrhages). Evidence suggests nail psoriasis may be associated with risk of developing psoriatic arthritis, in particular distal interphalangeal joint erosion.1-3 Data to Week 24 (Wk 24) from VOYAGE 1 and 2, two Phase 3 clinical trials, indicate that the anti-interleukin-23 monoclonal antibody guselkumab (GUS) is more effective than placebo and as effective as adalimumab in treating nail psoriasis.4 Further, GUS is also associated with maintained Psoriasis Area and Severity Index (PASI) following treatment withdrawal in VOYAGE 2; however, nail response is not as well understood in this context.1

Objectives: This VOYAGE 2 post hoc analysis evaluated nail response and its association with skin response and patient-reported outcomes (PROs) in two groups, one experiencing GUS withdrawal and the other receiving continuous GUS.

Methods: Patients had moderate-to-severe plaque psoriasis and nail psoriasis, were initially randomised to GUS, and achieved PASI 90 at Wk 28. Patients were then re-randomised to placebo (GUS withdrawal) or GUS every 8 wks (GUS continuation). Nails were then re-randomised to placebo (GUS withdrawal) or GUS every 8 wks (GUS continuation) until Wk 48. Data are mean (standard deviation). *n=10 reinitiated GUS upon loss of 50% of Wk 28 PASI 90 (at n=1 Wk 36, n=2 Wk 40, n=7 Wk 44); †n=107; R, re-randomisation of PASI 90 responders.

Conclusion: GUS treatment through Wk 48 improved nail psoriasis, skin psoriasis and PROs. When GUS was withdrawn, loss of response was slower in nails vs skin. These findings support that nail outcomes follow skin outcome trends with GUS treatment and that nail outcomes should contribute to evaluation of treatment efficacy and disease progression.2,3,5

REFERENCES:
Background: There are currently ten biologic and targeted synthetic (b/ts)DMARDs acting via five different modes of action (MOA) available for the treatment of psoriatic arthritis (PsA) in Australia. b/tsDMARDs are government-subsidised, and once the patient reaches the eligibility requirements, the clinician can prescribe the agent deemed most appropriate. Available agents include TNF inhibitors (TNFi, adalimumab, etanercept, infliximab, golimumab, certolizumab pegol), IL-17A inhibitors (IL-17Ai, secukinumab, ixekizumab), and IL-12/23 inhibitor (IL-12/23i, ustekinumab). Two new MOAs were recently added to the rheumatologist’s armamentarium: the first JAK inhibitor (JAKi, tofacitinib) was subsidized from May 2019 followed by upadacitinib from Oct 2021, and an IL-23 inhibitor (IL-23i, guselkumab) was subsidized from July 2021.

Objectives: The aim of this analysis was to describe the changing patterns of b/tsDMARD use for the treatment of PsA in real-world practice in Australia.

Methods: Deidentified clinical data were sourced from the OPAL dataset, which is collected in a custom-built electronic medical record during the routine consultation. Data from patients >18 years with a physician diagnosis of PsA who were prescribed a b/tsDMARD between Jan-2007 and Sept-2021 were included in the analysis. The software program Tableau was used to display the data.

Results: At Sept 2021, 6,150 (38% of the total) patients with PsA in the OPAL dataset were prescribed b/tsDMARDs. Of these patients, 3741 (61%) were currently prescribed a TNFi, 1503 (24%) an IL-17Ai, 556 (9%) a JAKi, 222 (4%) an IL-12/23i and 134 patients prescribed a b/tsDMARD between Jan-2007 and Sept-2021 were included in the analysis. Conversely, 1st line IL-17Ai initiations have increased from 14.1% in 2017 to 22.2% in 2021. In 2021, TNFi accounted for 53.4% of 2nd line initiations and 38.2% of 3rd line initiations. IL-17Ai accounted for 30.4% of 2nd and 37.0% of 3rd line initiations and JAKi accounted for 10.5% of 2nd and 14.2% of 3rd line initiations. In the 3 months that IL-23i has been subsidised, this MOA was the most initiated agent for patients who had been treated with more than two prior b/tsDMARDs. In 2021, 52.1% of patients switching from a 1st line TNFi switched to an alternative TNFi, 33.3% switched to an IL-17Ai and 11.3% switched to a JAKi in 2nd line. Of those switching from a 1st line IL-17Ai, 59.6% initiated a TNFi, 21.2% switched to an alternative IL-17Ai and 11.5% switched to a JAKi.

Conclusion: The patterns of b/tsDMARD utilisation for the treatment of PsA, when the choice of agent is at the discretion of the rheumatologist, remains dynamic and is evolving as new MOAs become available. TNFi remains the most prescribed b/tsDMARD for first line therapy. However an increase in first line use of alternative MOAs has been observed. TNFi cycling remains a commonly utilised real-world treatment strategy but appears to be declining as new MOAs become available.

REFERENCES:

Figure 1. Percentage of patients initiating b/tsDMARDs by year and line of therapy.

Acknowledgements: The authors acknowledge the members of OPAL Rheumatology Ltd and their patients for providing clinical data for this study, and Software4Specialists Pty Ltd for providing the Audit4 platform.

Table 1. Observed erosion, joint space narrowing, and total PsA-modified vdH-S scores through W100 of DISCOVER-2

<table>
<thead>
<tr>
<th>GUS Q4W</th>
<th>GUS Q8W</th>
<th>PBO → GUS Q4W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline PsA-modified vdH-S score, n</td>
<td>221</td>
<td>228</td>
</tr>
<tr>
<td>Erosion</td>
<td>14.2 (23.3)</td>
<td>12.0 (21.9)</td>
</tr>
<tr>
<td>Joint space narrowing</td>
<td>13.8 (21.8)</td>
<td>11.9 (19.5)</td>
</tr>
<tr>
<td>Total</td>
<td>28.0 (43.6)</td>
<td>23.9 (40.4)</td>
</tr>
<tr>
<td>N=211</td>
<td>N=216</td>
<td>N=216</td>
</tr>
<tr>
<td>Erosion (SD change in PsA-modified vdH-S score)</td>
<td>W24 → W40 → W52 → W100</td>
<td>W24 → W52 → W80 → W100</td>
</tr>
<tr>
<td>N=221</td>
<td>N=221</td>
<td>N=216</td>
</tr>
<tr>
<td>Erosion</td>
<td>0.27 (1.91)</td>
<td>0.36 (1.77)</td>
</tr>
<tr>
<td>Joint space narrowing</td>
<td>0.21 (1.17)</td>
<td>0.31 (1.11)</td>
</tr>
<tr>
<td>Total</td>
<td>0.48 (2.70)</td>
<td>0.57 (2.66)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Peter Youssf speaks brokers: AbbVie, Novartis, Eli Lilly, Sabina Ciccielino: None declared, Gne-Siew Ngian: None declared, Juan Aw: None declared, Barry Kane: None declared, Catherine Cullivan: None declared, Tegon Shen: None declared, Deakin: None declared, Geoff Littlejohn Consultant of: Abbvie, Janssen, Bristol Myers Squibb, Gilead, Eli Lilly, and MSD DOI: 10.1136/annrheumdis-2022-eular.1494
832 ﻿

Scientific Abstracts

REFERENCES:

Disclosure of Interests: Philip J Mease Consultant of: AbbVie, Aclaris, Amgen, Bristol
Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie,
Aclaris, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Alice B Gottlieb
Shareholder of: Xbiotech (stock options only), Consultant of: Anaptyps Bio, Avotres
Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli
Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sun Pharmaceuticals, UCB, Grant/
research support from: Boehringer Ingelheim, Janssen, Novartis, Sun Pharmaceuticals,
UCB, and Xbiotech, Iain McInnes Consultant of: AbbVie, Bristol-Myers Squibb, Celgene,
Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB,
Proton Rahman Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB,
Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Grant/research support from: Janssen and Novartis, Alexa
Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research and
Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research and Development, LLC, Yusang Jiang Employee of: Cytel, Inc., Shihong
Sheng Shareholder of: Johnson & Johnson, Employee of: Janssen Research and Development, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen
Global Services, LLC, Soumya D Chakravarty Shareholder of: Johnson & Johnson,
Employee of: Janssen Scientific Affairs, LLC, Frederic Lavie Shareholder of: Johnson
& Johnson, Employee of: Janssen Global Services, LLC, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Boehringer Ingelheim,
Celgene, Cyxone, Daiichi, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma,
Employee of: Director of Imaging and Rheumatology BV
DOI: 10.1136/annrheumdis-2022-eular.1508

POS1036

EFFICACY AND SAFETY OF RISANKIZUMAB (RZB)
FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK
RESULTS FROM KEEPSAKE 2

A. Ostor1, F. Van den Bosch2, K. Papp3, C. Asnal4, R. Blanco5, J. Aelion6, W. Lu7,
Z. Wang7, A. M. Soliman7, A. Eldred7, B. Padilla7, A. Kivitz8. 1Monash University,
Cabrini Hospital, Melbourne, Australia; 2Department of Rheumatology, Ghent
University, Ghent, Belgium; 3Probity Medical Research, K. Papp Clinical Research,
Waterloo, Canada; 4DOM Centro, de Reumatología, Buenos Aires, Argentina;
5
Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain; 6Arthritis
Clinic, West Tennessee Research Institute, Jackson, United States of America;
7
AbbVie Inc., Immunology, North Chicago, United States of America; 8Altoona
Center, Clinical Research, Duncansville, United States of America
Background: RZB, a humanized immunoglobulin G1 monoclonal antibody that
specifically inhibits the p19 subunit of the human cytokine interleukin-23, is being
investigated as a treatment for PsA.
Objectives: Evaluate longer-term safety and efficacy of RZB in patients with
active PsA who experienced inadequate response or intolerance to 1 or 2 biologic therapies and/or to at least 1 csDMARD therapy.
Methods: KEEPsAKE 2 (NCT03671148) is an ongoing, phase 3, multicenter study
that includes a screening period; a 24-week double-blinded, randomized, placebo-controlled, parallel-group period (period 1); and an open-label extension period
(period 2). Eligible patients were ≥18 years of age with active PsA (symptom onset
≥6 months before screening, meeting Classification Criteria for PsA [CASPAR], and
≥5 tender and ≥5 swollen joints) and had inadequate response or intolerance to 1
or 2 biologic therapies (Bio-IR) and/or ≥1 conventional synthetic disease modifying

antirheumatic drug (csDMARD-IR). Patients received RZB 150 mg or placebo
(PBO) at weeks 0, 4, and 16 (1:1). The primary endpoint was the proportion of
patients achieving ACR20 response at week 24. Period 2 started at week 24, and
patients were switched to receive open-label RZB 150 mg every 12 weeks through
week 208. Efficacy and safety were analyzed in patients who received ≥1 dose
of study drug through week 52. Mixed-effect model with repeated measures and
nonresponder imputation methods were used to assess continuous and binary variables, respectively. Treatment-emergent adverse events (TEAEs) were summarized
using exposure-adjusted event rates (EAERs, events/100 patient-years [PY]).
Results: At week 24, 51,3% of RZB-treated (N=224) and 26.5% of PBO-treated
(N=219) patients achieved ACR20. At week 52, 58.5% of patients who were randomized to RZB and 55.7% of patients who were randomized to PBO and then switched
to RZB at week 24 achieved ACR20. In patients with ≥3% of body surface area affected
at baseline, 55.0% of RZB-treated patients (N=123) and 10.2% of PBO-treated patients
(N=119) achieved PASI 90 at week 24. At week 52, 64.2% of patients randomized to
RZB and 59.7% of patients who were randomized to PBO and then switched to RZB at
week 24 achieved PASI 90. For other efficacy measures, similar trends were observed.
RZB was well tolerated through 52 weeks of treatment, and EAERs of adverse events
were stable between weeks 24 and 52. At the week 52 data cutoff (19 April 2021), the
total EAER of any TEAE in patients receiving RZB was 184.2/100 PY.
Conclusion: Continuous RZB treatment resulted in maintained efficacy
responses with a consistent safety profile through 52 weeks of treatment in
patients with active PsA who were Bio-IR and/or csDMARD-IR.
Acknowledgements: AbbVie, Inc. participated in the study design; study research;
collection, analysis, and interpretation of data. AbbVie funded the research for this
study and provided writing support for this abstract. Medical writing assistance,
funded by AbbVie, was provided by Jay Parekh, PharmD, of JB Ashtin.
Disclosure of Interests: Andrew Ostor Speakers bureau: AbbVie, Celgene, Galapagos,
Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Consultant of: AbbVie, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Filip van den Bosch Speakers
bureau: AbbVie, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB.,
Consultant of: AbbVie, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, and
UCB., Kim Papp Speakers bureau: AbbVie, Amgen, Astellas, Bausch Health (Valeant),
Baxalta, Baxter, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, EMD Serono, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Kirin, Lilly, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron,
Roche, Sanofi Genzyme, Stiefel, Sun Pharma, Takeda, and UCB, Consultant of: AbbVie, Amgen, Astellas, Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim,
Bristol Myers Squibb, Celgene, Coherus, Dermira, EMD Serono, Forward Pharma,
Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa Kirin, Lilly, LEO Pharma,
MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Stiefel,
Sun Pharma, Takeda, and UCB, Grant/research support from: AbbVie, Amgen, Astellas,
Bausch Health (Valeant), Baxalta, Baxter, Boehringer Ingelheim, Bristol Myers Squibb,
Celgene, Coherus, Dermira, EMD Serono, Forward Pharma, Galderma, Genentech,
GlaxoSmithKline, Janssen, Kyowa Kirin, Lilly, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Stiefel, Sun Pharma, Takeda, and UCB,
CECILIA ASNAL Speakers bureau: AbbVie, Amgen, Genentech, Janssen, Lilly, Pfizer,
Roche, and R-Pharm., Consultant of: AbbVie, Amgen, Genentech, Janssen, Lilly, Pfizer,
Roche, and R-Pharm., Grant/research support from: AbbVie, Amgen, Genentech, Janssen, Lilly, Pfizer, Roche, and R-Pharm., Ricardo Blanco Speakers bureau: AbbVie, Bristol Myers Squibb, Janssen, Lilly, Merck, Pfizer, and Roche., Consultant of: AbbVie, Bristol
Myers Squibb, Janssen, Lilly, Merck, Pfizer, and Roche., Grant/research support from:
AbbVie, Merck, and Roche, Jacob Aelion Grant/research support from: AbbVie, Amgen,
AstraZeneca, Bristol Myers Squibb, Galapagos/Gilead, Genentech, GlaxoSmithKline,
Lilly, Mallinckrodt, Nektar Therapeutics, Nichi-Iko, Novartis, Pfizer, Regeneron, Roche,
Sanofi, Selecta Biosciences, and UCB., Wenjing Lu Shareholder of: AbbVie Inc.,
Eldred Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Byron Padilla Shareholder
of: AbbVie Inc., Employee of: AbbVie Inc., Alan Kivitz Shareholder of: AbbVie, Boehringer
Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis,
Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB., Speakers bureau: AbbVie, Boehringer Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly,
Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB., Consultant of: AbbVie, Boehringer Ingelheim, Celgene, Flexion, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, Sun Pharma, and UCB.

POS1037

EFFECT OF GUSELKUMAB, A SELECTIVE IL-23P19
INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN
PATIENTS WITH ACTIVE PSA: RESULTS FROM A
PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY THROUGH 2 YEARS

P. J. Mease1, P. Helliwell2, D. D. Gladman3, D. Poddubnyy4,5, X. Baraliakos6, S.
D. Chakravarty7,8, A. Kollmeier9, X. L. Xu9, S. Sheng10, S. Xu10, M. Shawi11, D. Van
der Heijde12, A. Deodhar13. 1Swedish Medical Center/Providence St. Joseph Health
and University of Washington, Rheumatology Research, Seattle, WA, United States
of America; 2University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal


Guselkumab (GUS), a selective IL-23p19 inhibitor, showed greater mean improvements in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores vs placebo (PBO) at Week (W) 24 in patients (pts) with active PsA and investigator-confirmed sacroiliitis in pooled post hoc analyses of data from phase 3 DISCOVER (D)-1&2 trials. Improvements in symptoms of axial involvement were maintained through 1 year.1

Objectives: To assess maintenance of GUS effect on symptoms of axial involvement in biologic-naïve PsA pts with investigator-confirmed sacroiliitis through 2 years of D-2.

Methods: In D-2, 739 bio-naïve pts with active PsA (≥5 swollen + ≥5 tender joints, CRP ≥0.6 mg/dL, standard therapy failed, ≥1.1/1.1 to GUS 100 mg every 4 W (Q4W); n=245), GUS 100 mg at W0, W4, then Q8W (n=248), or PBO—GUS 100 mg Q4W at W24. Pts with investigator-identified axial symptoms and sacroiliitis (prior X-ray or MRI, or pelvic X-ray at screening) were evaluated. Efficacy was assessed by changes in BASDAI, modified BASDAI (mBASDAI, excluding Q3 [peripheral joint pain]), and BASDAI Q2 (Spinal Pain) scores, and proportions of pts achieving BASDAI 50, Spinal Pain score ≤2, and AS Disease Activity Score (ASDAS) ≤1.6). At W24, pts with investigator-identified axial involvement and sacroiliitis in ≏2 years of biologic therapy who met treatment failure criteria or had missing data were considered nonresponders.

At W24, missing data were imputed as nonresponse for binary endpoints or no change from baseline for continuous endpoints (nonresponder imputation [NRI]). Axial-related outcomes were also summarized by HLA-B27 status (+/-).

Results: 246 pts had investigator-confirmed sacroiliitis. Baseline characteristics were similar across treatment groups (62% male; mean age 44.4 years; mean BASDAI scores 6.5-6.6). At W24, LS mean changes in BASDAI (-2.4/-2.6) and ASDAS (-1.3/-1.5) scores were greater in GUS- vs PBO-treated pts. Improvements were maintained through W100 in GUS-treated pts: BASDAI, -3.1; Spinal Pain, -3.1; mBASDAI, -3.1; ASDAS, -1.7. Response patterns were similar for BASDAI 50 response rates in GUS-treated pts (W24 38-40%; W100 49-54%).

At W24, GUS-treated pts had higher response rates for achievement of ASDAS inactive disease, major improvement, and clinically important improvement vs PBO; response rates (NRI) were maintained, or in some cases further increased, at 2 years. Results were consistent for achievement of ASDAS LDA and Spinal Pain score ≤2 (data not shown). GUS-related improvements in axial symptoms through W100 were generally consistent in HLA-B27+/- pts (data not shown).

Conclusion: In bio-naïve pts with active PsA and investigator-confirmed sacroiliitis, GUS provided durable improvements in axial symptoms through W100, with substantial proportions of pts achieving and maintaining clinically meaningful improvements.

REFERENCES:

Table 1. Axial symptom assessments through W100 in PsA pts with investigator-confirmed sacroiliitis in DISCOVER-2 (NRI)

<table>
<thead>
<tr>
<th>GUS Q4W N=82</th>
<th>GUS Q8W N=68</th>
<th>PBO—GUS Q4W N=96</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in BASDAI score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24, LS mean (95% CI)</td>
<td>2.5 (-2.9, -0.2)</td>
<td>2.4 (-3.0, -1.8)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.5 (2.0)</td>
<td>2.6 (2.4)</td>
</tr>
<tr>
<td>W52, mean (SD)</td>
<td>2.3 (2.6)</td>
<td>2.3 (2.8)</td>
</tr>
<tr>
<td>W100, mean (SD)</td>
<td>2.2 (2.6)</td>
<td>2.3 (2.6)</td>
</tr>
<tr>
<td>Change in mBASDAI (excludes Q3) score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24, LS mean (95% CI)</td>
<td>2.3 (-2.9, -1.9)</td>
<td>2.4 (-2.9, -1.8)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.6 (2.5)</td>
<td>2.6 (2.5)</td>
</tr>
<tr>
<td>W52, mean (SD)</td>
<td>2.3 (2.6)</td>
<td>2.5 (2.7)</td>
</tr>
<tr>
<td>W100, mean (SD)</td>
<td>2.3 (2.6)</td>
<td>2.3 (2.6)</td>
</tr>
<tr>
<td>Change in Spinal Pain (BASDAI Q2) score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24, LS mean (95% CI)</td>
<td>2.2 (-2.7,-1.7)</td>
<td>2.3 (-2.9, -1.7)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.8 (2.6)</td>
<td>2.5 (2.8)</td>
</tr>
<tr>
<td>W52, mean (SD)</td>
<td>2.5 (2.7)</td>
<td>2.5 (2.7)</td>
</tr>
<tr>
<td>W100, mean (SD)</td>
<td>2.8 (2.7)</td>
<td>3.1 (2.8)</td>
</tr>
<tr>
<td>Change in ASDAS score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24, LS mean (95% CI)</td>
<td>1.3 (-1.6, -1.1)</td>
<td>1.3 (-1.6, -1.1)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>1.4 (1.0)</td>
<td>1.5 (1.0)</td>
</tr>
<tr>
<td>W52, mean (SD)</td>
<td>1.5 (1.1)</td>
<td>1.5 (1.3)</td>
</tr>
<tr>
<td>W100, mean (SD)</td>
<td>1.6 (1.2)</td>
<td>1.7 (1.2)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Philip J Mease Speakers bureau: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagne, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagne, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagne, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Philip Hellwell Speakers bureau: AbbVie, Janssen, and Novartis, Consultant of: Eli Lilly, Janssen, and Pfizer, Dafna D Gladman Consultant of: AbbVie, Ageron, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Denis Poddubnyy Consultant of: AbbVie, Eli Lilly, GlaxoSmithKline, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, MSD, Novartis, Pfizer, and Xenofon Baraliakos Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche, and UCB, Souryma D Chakraverty Shareholder of: Johnson & Joseph, Employee of: Janssen Research & Development, LLC, Alex Kollmeier Shareholder of: Johnson & Joseph, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Joseph, Employee of: Janssen Research & Development, LLC, Shihong Sheng Shareholder of: Johnson & Joseph, Employee of: Janssen Research & Development, LLC, Stephen Xu Shareholder of: Johnson & Joseph, Employee of: Janssen Research & Development, LLC, May Shawi Shareholder of: Johnson & Joseph, Employee of: Janssen Global Services, LLC, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, BMS, Biocad, Boehringer Ingelheim, Celgene, Cytone, Daichi, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, Employee of: Imaging Rheumatology BV, Atul Deodhar Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: Abbvie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer, and UCB, DOI: 10.1136/annrheumdis-2022-eular.1691
GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS ASSESSED BY MULTI-DOMAIN COMPOSITE INDICES: DATA FROM THE PHASE 3B COSMOS TRIAL IN A TNFI-IR POPULATION

L. Gossec¹, E. Theander², M. Neuhold³, P. Bergmans⁴, M. Shaw⁵, M. Perate⁶, C. Contré⁷, L. Coates⁸, Sorbonne Université and Pitié-Salpêtrière Hospital, Rheumatology department, Paris, France; ²Janssen, Scientific Affairs, LLC, Solna, Sweden; ³Janssen, Scientific Affairs, LLC, Zug, Switzerland; ⁴Janssen, Biostatistics, Breda, Netherlands; ⁵Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; ⁶Janssen, Scientific Affairs, LLC, Horsham, United States of America; ⁷Janssen, Scientific Affairs, LLC, Issy-les-Moulineaux, France; ⁸University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom

Objectives: Assess the efficacy of GUS 100 mg Q8W in TNFI-IR pts through 1 year by using and comparing 6 multi-domain composite indices validated in PsA.

Methods: In total, 285 pts (189 GUS, 96 placebo [PBO]) were enrolled in COSMOS; mean age was 49 years and mean disease duration was 8.4 years. ¹ Pts who received PBO crossed over to GUS at either Week (W) 16 (early escape, n=45/96) or W24 (planned, n=51/96). PsA Disease Activity Score (PASDAS), GRApPA Composite Score (GRACE), Disease Activity Index for PsA (DAPSA), modified Composite Psoriatic Arthritis Score (mCPDAI), excludes BASDAI), PsA Response Criteria (PsARC), and Minimal Disease Activity (MDA) were analysed (thresholds as published²). As observed data are presented at baseline (BL), W24 and W48, without imputation of missing data.

Results: Overall, 167/189 (88%) GUS and 83/96 (86%) PBO→GUS pts completed the study through W44. Pts had active disease, with similar BL mean values for PASDAS, GRACE, DAPSA and mCPDAI between GUS and PBO groups (Table 1). Across these indices, GUS pts demonstrated robust improvements (45–62%) in mean scores from BL to W48 (Table 1). PBO pts who crossed over to GUS at W16 or W24 also showed rapid improvement in their index scores, with mean values % improvement at W48 consistent with those observed in pts randomized to GUS at BL (Table 1).

Conclusion: GUS provided robust and substantial benefits to pts with active TNFI-IR PsA across multiple domains. Importantly, rates of achieving low levels of disease activity continued to increase through the duration of the study without an observable plateau at W48. Thresholds for DAPSA and PsARC response were easier to achieve than comprehensive indices with more domains that are required to improve simultaneously (eg GRACE, PASDAS, MDA). GUS performed well regardless of the focus of the composite indices (joints, skin, enthesitis, dactylitis, or patient-reported outcomes). Together, these findings support the role of GUS as an effective treatment option for the diverse domains of PsA.

REFERENCES:

Disclosure of Interests: Laure Gossec Consultant of: Consulting fees: AbbVie, Amgen, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB, Grant/research support from: Research grants: Amgen, Galapagos, Lilly, Pfizer, Sandoz, Elke Theander Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), Marlies Neuhold Shareholder of: Own Johnson & Johnson stock and/or stock options, Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), Paul Bergmans Shareholder of: Own Johnson & Johnson stock and/or stock options, Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), May Shawi Shareholder of: Own stock in Johnson & Johnson, Employee of: Employed by Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Michelle Perate Shareholder of: Own stock in Johnson & Johnson, Employee of: Employed by Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Christine CONTRE Shareholder of: Own stock in Johnson & Johnson, Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB


Figure 1.

Table 1. As observed mean values (± standard deviation) for composite indices

<table>
<thead>
<tr>
<th></th>
<th>PASDAS</th>
<th>GRACE</th>
<th>DAPSA</th>
<th>mCPDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GUS Q8W</td>
<td>PBO→GUS</td>
<td>GUS Q8W</td>
<td>PBO→GUS</td>
</tr>
<tr>
<td>BL</td>
<td>6.4</td>
<td>6.2</td>
<td>6.0</td>
<td>5.6</td>
</tr>
<tr>
<td>N</td>
<td>±1.0</td>
<td>±0.9</td>
<td>±1.1</td>
<td>±1.0</td>
</tr>
<tr>
<td>W24</td>
<td>4.3</td>
<td>4.8</td>
<td>3.7</td>
<td>4.3</td>
</tr>
<tr>
<td>N</td>
<td>±1.5</td>
<td>±1.3</td>
<td>±1.6</td>
<td>±1.4</td>
</tr>
<tr>
<td>W48</td>
<td>3.5</td>
<td>3.6</td>
<td>2.8</td>
<td>2.9</td>
</tr>
<tr>
<td>N</td>
<td>±1.5</td>
<td>±1.4</td>
<td>±1.7</td>
<td>±1.6</td>
</tr>
</tbody>
</table>

Among the 4 indices with defined disease states/therapeutic thresholds for low disease activity (LDA) (Figure 1), those focusing on joints (PsARC [4 components] and DAPSA [5 components]) resulted in the highest response rates (range, 50–85%). LDA according to GRACE (8 items, including skin) and PASDAS (8 items, focus on musculoskeletal with no skin assessment) was attained less frequently (range, 38–44%). Using the PsARC, 50% of GUS pts responded as early as W8. Response rates among GUS-treated pts generally did not plateau by W48 (Figure 1). At W48, 33% and 30% of GUS and PBO→GUS pts, respectively, achieved a status of MDA.
**POS1039**

DEUCRACVITINIB, AN ORAL, SELECTIVE TYROSYNE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS

A. Kavanaugh1, L. Coates2, J. F. Menola3, P. J. Mease4, M. Nowak5, S. Banerjee6, L. Hippeli7, T. Lehman7, 1University of California, San Diego, Rheumatology, La Jolla, United States of America; 2University of Oxford, Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 3Brigham and Women’s Hospital, Harvard Medical School, Dermatology, Boston, United States of America; 4Swedish Medical Center/ Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, United States of America; 5Bristol Myers Squibb, Clinical R&D, Princeton, United States of America; 6Bristol Myers Squibb, WW Medical Immunology, Princeton, United States of America

**Background:** Tyrosine kinase 2 (TKY2) is a intracellular kinase in the Janus kinase (JAK) family that mediates the signalling of multiple cytokines, including those central to the immunopathogenesis of psoriatic arthritis (PsA), such as IL-23. Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of TKY2 that acts by binding to the unique regulatory domain on the enzyme. In a Phase 2 trial in patients with active PsA, DEUC was significantly more efficacious than placebo (PBO) after 16 weeks of treatment and was well tolerated.1, 2

**Objectives:** This analysis further evaluated the effect of DEUC on this trial on achievement of individual components of minimal disease activity (MDA).

**Methods:** This double-blind, multicenter Phase 2 trial (NCT03881059) enrolled patients (n=203) with a PsA diagnosis ≥6 months who fulfilled Classification Criteria for Psoriatic Arthritis at screening and had active joint disease (≥3 tender and ≥3 swollen joints), high-sensitivity C-reactive protein ≥3 mg/L, and ≥1 plaque psoriasis lesion ≥2 cm. Eligible patients had failed or were intolerant to ≥1 nonsteroidal anti-inflammatory, conventional synthetic DMARD, and/or 1 tumour necrosis factor antagonist 5.0) severity grade ≥3 of laboratory abnormalities were assessed.

**Results:** Of 203 patients randomized, 180 (89%) completed 16 weeks of treatment (PBO, 58/66 [88%]; DEUC 6 mg QD, 63/70 [90%]; DEUC 12 mg QD, 59/87 [68%]). Demographic and baseline disease characteristics were generally similar across groups. Although no patient had met ≥5 of 7 criteria required for achieving MDA at baseline, several individual components of MDA were met at baseline, most frequently TEP ≤1 (PBO, 57%; DEUC 6 mg QD, 64.3%; DEUC 12 mg QD, 65.7%). After 16 weeks of treatment, 76%, 22.9%, and 23.9% of patients in the PBO, DEUC 6 mg QD, and DEUC 12 mg QD groups, respectively, achieved MDA response. Treatment with DEUC was associated with a numerically greater mean reduction from baseline in all MDA components versus PBO over 16 weeks of treatment in all patients. At Week 16, more patients receiving DEUC versus PBO achieved the threshold for each of the MDA components (Figure 1).

**Conclusion:** In this study, patients treated with DEUC achieved a higher rate of MDA response compared with patients treated with PBO after 16 weeks of treatment. More patients receiving DEUC treatment achieved each of the MDA components compared with patients receiving PBO.

**REFERENCES:**


**Disclosure of Interests:** Arthur Kavanaugh Grant/research support from: Clinical research sponsored by Abbott, Amgen, Janssen, and UCB, Laura Coates Speakers bureau: has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Gilead, Eli Lilly, Janssen, and Novartis, Philip J Mease Consultant of: Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Joseph F. Merola Consultant of: and/or investigator for: Amgen, AbbVie, Biogen, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer, Roche, Regeneron, Sanofi, and UCB. Shareholder of: Bristol-Myers Squibb, Eli Lilly, Gilead, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Miroslawa Nowak Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Subhashis Banerjee Shareholder of: Bristol-Myers Squibb, Employee of: Bristol Myers Squibb, Laurent Hippeli Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Thomas Lehman Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb DOI: 10.1136/annrheumdis-2022-eular.1849

**POS1040**

SAFETY OF DEUCRACVITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS: RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS

P. M. Fleischmann1, D. Thaï2, M. Goodermuth3, B. Strober4, N. J. Kormann5, S. Banerjee6, T. Lehman7, M. Nowak8, A. Sreih9, A. Morita10, P. J. Mease11

1University of Texas Southwestern Medical Center, Rheumatology, Dallas, United States of America; 2University of Lübeck, Dermatology, Lübeck, Germany; 3SKIN Centre for Dermatology, Queen’s University, ProBlyt Medical Research, Dermatology, Peterborough, Canada; 4University of California, San Francisco, Dermatology, New Haven, United States of America; 5Case Western Reserve University and University Hospitals, Dermatology, Cleveland, United States of America, 6Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America; 7Bristol Myers Squibb, WW Medical Immunology, Princeton, United States of America; 8Bristol Myers Squibb, Clinical R&D, Princeton, United States of America; 9Bristol Myers Squibb, Veracyon, United States of America; 10Nagoya City University Graduate School of Medical Sciences, Dermatology, Nagoya, Japan; 11Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology Research, Seattle, United States of America

**Background:** Deucravacitinib (DEUC) is a novel, oral, selective, allosteric tyrosine kinase 2 (TKY2) inhibitor with a unique mechanism of action distinct from Janus kinase (JAK) 1/2/3 inhibitors. DEUC mediates signalling of key cytokines in psoriatic arthritis (PsA) and psoriasis (PsO). DEUC was well tolerated and efficacious vs placebo (PBO) in a Phase 2 trial in patients (pts) with PsA1, 2 and vs PBO or apremilast in 2 Phase 3 PsO trials.3

**Objectives:** To assess the effect of DEUC on multiple laboratory parameters through the first 16 weeks of treatment (PBO-controlled) in these trials.

**Methods:** The Phase 2 double-blind PsA trial randomised pts (n=203) 1:1:1 to PBO, DEUC 6 mg once daily (QD), or 12 mg QD. The Phase 3 double-blind PsO trials, POETYK PSO-1 and POETYK PSO-2, randomised pts (n=668 and 1020, respectively) 1:2:1 to PBO, DEUC 6 mg QD, or apremilast 30 mg twice daily. Changes from baseline in haematologic (neutrophils, lymphocytes, platelets, haemoglobin) and chemistry (cholesterol, triglycerides, alanine aminotransferase [ALT], aspartate aminotransferase [AST], and creatinine phosphokinase [CPK]) parameters were evaluated. Shifts in Common Terminology Criteria for Adverse Events (CTCAE; version 5.0) severity grade ≥3 of laboratory abnormalities were assessed.

**Results:** In the PsA trial, 65% of pts were on concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and 54.7% of pts were on methotrexate. The vast majority of pts continued to have laboratory parameters within normal range throughout the 3 trials in PsO and PsA. No clinically meaningful changes from baseline were observed in laboratory parameters in pts treated with DEUC, PBO, or apremilast. Rates of CTCAE grade 3 and 4 were rare (≤1 pt) and similar across DEUC-, PBO-, and apremilast-treated pts for the following parameters: lymphocytes, neutrophils, platelets, haemoglobin, AST, ALT, and cholesterol (Table 1). Shifts to CTCAE grades ≥3 in triglycerides and CPK were infrequent and generally comparable across treatment arms.

**Conclusion:** DEUC treatment did not result in clinically meaningful laboratory changes, abnormalities often seen with JAK 1/2/3 inhibition, through 16 weeks of treatment in a Phase 2 trial in PsA, despite two-thirds of pts being on concomitant csDMARDs, and in 2 large Phase 3 trials in PsO.

**REFERENCES:**


Acknowledgements: This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julienne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Bristol Myers Squibb.
### Table 1. Maximal shifts to Grades ≥3 in laboratory parameters, Weeks 0-16

<table>
<thead>
<tr>
<th>CTCAE Term</th>
<th>Placebo (n=66) n (%)</th>
<th>DEUC 6 mg QD (n=70) n (%)</th>
<th>DEUC 12 mg QD (n=67) n (%)</th>
<th>Placebo (n=619) n (%)</th>
<th>DEUC 6 mg QD (n=842) n (%)</th>
<th>Apremilast 30 mg BID (n=422) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BL Wk 1-16</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lympocyte count decreased</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Neutrophil count decreased</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Platelet count decreased</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anaemia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CPK increased</td>
<td>3</td>
<td>0</td>
<td>1 (1.5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Cholesterol high</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Hypert記事roidemia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**POETYK PSO-1 and PSO-2 pooled data.BID, twice daily; BL, baseline; CPK, creatine phosphokinase; CTCAE, Common Terminology Criteria for Adverse Events; DEUC, decurcavatinib; N/A, not applicable because there is no haemoglobin value for CTCAE Grade 4 (life-threatening consequences; urgent intervention indicated); PsA, psoriatic arthritis; PsO, psoriatic; QD, once daily; wk, week.**

### Acknowledgements
This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julianne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Paripipany, NJ, USA, and funded by Bristol Myers Squibb.

### Disclosure of Interests
Roy M. Fleischmann Consultant of: Abbvie, Aca, Akro, Amsen, Bristol Myers Squibb, Celtrion, Eli Lilly & Co., Galvani, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sandoz, Sanofi Aventis, Taho, and UCIB, Grant/research support from: Abbvie, Aca, Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly & Co., Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Pfizer, Roche/Genentech, Samumed, Sanofi Aventis, and UCIB, Diamant Thaçi Consultant of: Advisory board, principal investigator, and lecture fees: Abbvie, Almirall, Amgen, Biogen Idec, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DB-Pharma, Eli Lilly, Galapagos, Galderma, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Regeneron, Roche-Posay, Samsung, Sandoz-Hexal, Sanofi, and UCB, Melinda Goodher Consultation of: Investigator, speaker, advisory board member or consultant for: Abbvie, Aksor, Amgen, Anaptyo Bio, Arcutis, Aslan, Bausch, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, DERMIRA, DermaVant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Janssen, Kyowa Kirin, Leo Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Sanofi Genzyme, SUN Pharma, and UCIB, Bruce Strober Consultant of: Honoraria or consultation fees: Abbvie, Almirall, Amgen, Arcutis, Arena, Arista, Asana, Boehringer Ingelheim, Immunotec Therapeutics, Bristol Myers Squibb, Connect Biopharma, DermaVant, Equillium, Janssen, Leo Pharma, Eli Lilly, Maruho, Meiji Seika Pharma, Mindera, Novartis, Pfizer, GlaxoSmithKline, UCB Pharma, Sun Pharma, Ortho Dermatologic, Regeneron, Sanofi-Genzyme, and VentyxBio; Speaker: Abbvie, Janssen, and Sanofi-Genzyme; Scientific co-director (consulting fee): CorEvitas Psoriasis Registry: Investigator: Abbvie, Cara, CorEvitas Psoriasis Registry, DermaVant, Eli Lilly/Dermira, and Novartis., Neil J Korman Consultation of: Advisory board, consulting fees: Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, Novartis, Principia, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCIB, Grant/research support from: Grant support/principal investigator: AbbVie, Amgen, Argxen, Bristol Myers Squibb, Celgene, Chemo-centryx, Eli Lilly, Galderma, Kyowa Hakko Kirin, Leo Pharma, Menlo, Principia, Prothera, Rhizen, Syntimmune, Trevi, and Xibotech. Speaker: Abbvie, Eli Lilly, Janssen, Novartis, Regeneron, and Sanofi-Genzyme, Subhashis Banerjee Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Thomas Lehman Shareholder of: Employees and shareholders of Bristol Myers Squibb, Employee of: Employees and shareholders of Bristol Myers Squibb, Mirosław Nowak Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Antoine Sreeh Shareholder of: Bristol Myers Squibb, Employee of: Bristol Myers Squibb, Akimichi Morita Consultant of: Research grants, consulting fees, and/or speaker’s fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharmaceutical Industries, Taio Pharmaceutical, Torii Pharmaceutical, Usbio, and UCB Pharma., Grant/research support from: Research grants, consulting fees, and/or speaker’s fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Eisai, Janssen, Kyowa Hakko Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe, Nichi-Iko, Nippon Kayaku, Novartis, Pfizer, Sun Pharmaceutical Industries, Taio Pharmaceutical, Torii Pharmaceutical, Usbio, and UCB Pharma., Philip J Mease Consultant of: Consulting and/or speaker fees: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galde, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Galderma, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, and UCB; DOI: 10.1136/annrheumdis-2022-eular.1862

### POS1041
LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTIVE TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY


1Swedish Medical Center/Providence St Joseph Health and University of Washington, Seattle, WA, USA; 2AbbVie Inc, Immunology, North Chicago, United States of America; 3Papo Clinical Research and Proby Medical Research, Dermatology, Waterloo, Canada; 4Ghent University, VIB Center for Inflammation Research, Internal Medicine and Pediatrics, Ghent, Belgium; 5National Hospital Organization, Osaka Minami Medical Center, Orthopaedics/Rheumatology, Osaka, Japan; 6Pontifical Catholic University, School of Medicine, Rheumatology, Porto Alegre, Brazil; 7Royal National Hospital For Rheumatic Diseases, Rheumatology, Bath, United Kingdom

Background: Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, demonstrated efficacy and safety in patients (pts) with psoriatic arthritis (PsA) and prior inadequate response or intolerance to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) at week (wk) 56 in the phase 3 SELECT-PSA 2 study.1 Objectives: To evaluate the efficacy and safety of UPA at wk 104 from the ongoing long-term extension of SELECT-PSA 2.

Methods: Pts were randomized to UPA 15 mg (UPA15), UPA 30 mg (UPA30), or placebo (PBO) for 24 wks; PEs for continuous UPA treatment groups, efficacy endpoints at wk 104 were analyzed using non-responder imputation (NRI) and as observed (AO) (binary endpoints) or mixed-effect model repeated measures (MMRM) and AO (continuous endpoints). Treatment-emergent adverse events (TEAEs) were summarized for pts who received ≥1 dose of study drug using visit-based cut-off at wk 104.

Results: A total of 641 pts received ≥1 dose of study drug. At wk 104, 38.4% of all patients had discontinued study drug, with the highest discontinuation observed...
in patients randomized to PBO at baseline (all PBO: 46.7%). The most common reasons for discontinuation were lack of efficacy (UPA15: 12.3%, UPAP30: 8.7%, all PBO: 21.7%) and adverse event (UPA15: 10.9%, UPAP30: 13.3%, all PBO: 12.7%). The proportion of UPA pts that achieved ACR20/50/70, MDA, PASI75/90/100, and resolution of dactylitis and enthesitis were generally similar, or further improved, with 104 wks of treatment vs 56 wks(1) (Table 1). Similarly, mean change from baseline in HAQ-DI, patient's assessment of pain, BASDAI, and ASDAS was improved with UPA treatment. At 104 wks of therapy, clinical responses were largely similar with UPA15 and UPAP30. Generally, safety data at wk 104 (Figure 1) were consistent with that reported at wk 56. Rates of serious infection, herpes zoster, hepatic disorder, anemia, neutropenia, lymphopenia, and CPK elevation remained numerically higher with UPAP30 vs UPAP15, while rates of malignancies, MACE, and VTE were similar for both UPA groups. One death was reported with UPAP15 (unexplained due to lack of information; however, the patient had recently been diagnosed with ovarian cancer) and 2 with UPAP30 (papancytopenia and COVID-19 pneumonia).

**Table 1. Efficacy Endpoints at Week 104**

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>UPA15 (n=211)</th>
<th>UPAP30 (n=218)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of Pts (%)</td>
<td>NRI</td>
<td>AO</td>
</tr>
<tr>
<td>ACR20</td>
<td>55.5</td>
<td>80.3</td>
</tr>
<tr>
<td>ACR50</td>
<td>44.5</td>
<td>62.9</td>
</tr>
<tr>
<td>ACR70</td>
<td>23.2</td>
<td>32.2</td>
</tr>
<tr>
<td>Minimal Disease Activity (MDA)</td>
<td>29.4</td>
<td>41.3</td>
</tr>
<tr>
<td>PASI75</td>
<td>42.7</td>
<td>69.8</td>
</tr>
<tr>
<td>PASI90</td>
<td>37.7</td>
<td>55.2</td>
</tr>
<tr>
<td>PASI100</td>
<td>23.1</td>
<td>35.4</td>
</tr>
<tr>
<td>Resolution of enthesitis by LEI</td>
<td>39.8</td>
<td>67.8</td>
</tr>
<tr>
<td>Resolution of dactylitis by LDL</td>
<td>54.5</td>
<td>97.4</td>
</tr>
<tr>
<td>Change from BL</td>
<td>MMRM AO</td>
<td>MMRM AO</td>
</tr>
<tr>
<td>Health Assessment Questionnaire - Disability Index (HAQ-DI)</td>
<td>-0.36</td>
<td>-0.39</td>
</tr>
<tr>
<td>Patient's assessment of pain (numeric rating scale)</td>
<td>-2.7</td>
<td>-3.0</td>
</tr>
<tr>
<td>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</td>
<td>-2.6</td>
<td>-3.0</td>
</tr>
<tr>
<td>Ankylosing Spondylitis Disease Activity Score (ASDAS)</td>
<td>-1.4</td>
<td>-1.7</td>
</tr>
</tbody>
</table>

**Conclusion:** In PsA pts with prior inadequate response or intolerance to ≥1 bDMARD, clinical responses were maintained with UPA15 and UPAP30 up to 2 years of treatment. No new safety signals were identified in this long-term extension.

**REFERENCES:**

Acknowledgements: AbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical trial (NCT03104374). AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R P Elmore, PhD of AbbVie.

**Disclosure of Interests:** Philip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Genentech, Gilead, GSK, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, and an advisory role for the European Association for Study of the Liver (EASL) and EULAR.

Eli Lilly and Company is a wholly owned subsidiary of Eli Lilly and Company, and part of Ely Lilly, Inc.

**Scientific Abstracts**

---

**POS1045 IMPACT OF RISANKIZUMAB ON IMPROVING HEALTH-RELATED QUALITY OF LIFE, WORK PRODUCTIVITY, AND REDUCING FATIGUE AMONG PATIENTS WITH ACTIVE PSORIASIS ARTHRITIS: A POOLED ANALYSIS OF TWO PHASE 3 CLINICAL TRIALS**

L. K. Kristensen, A. M. Sollmann, K. Popp, B. Barcomb, A. Eldred, Z. Wang, D. White, F. Behrens; 1 The Parkter Institute, Copenhagen University Hospital, Copenhagen, Denmark; 2 AbbVie Inc., Immunology, North Chicago, United States of America; 3 Mayo Clinic, Rochester, Rochester, Minnesota, United States of America; 4 Global Medical Affairs, AbbVie, Inc., New York, United States of America; 5 Rizzardi Consulting, Emilia Romagna, Italy; 6 all authors: AbbVie, Inc.

**Background:** Risankizumab (RZB) has been approved in the UK and Europe for the treatment of adults with active PsA. Patient-reported outcomes (PROs) are important tools for understanding a therapy’s efficacy from the patient’s perspective.

**Objectives:** This study evaluated the impact of RZB versus placebo on health-related quality of life (HRQoL), fatigue, and work productivity in patients with psoriatic arthritis (PsA) and inadequate response to ≥ 1 or 2 biologics and/or ≥ 1 conventional synthetic DMARDs in two Phase 3 trials (KEEPASAKE & 182).

**Methods:** Eligible patients with active PsA (n=1402) were randomized (1:1) to receive risankizumab 150mg (n=706) or placebo (n=696). Patient-reported
outcomes assessed were 36-item Short-Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-Fatigue), EQ-5D-5L, and Work Productivity and Activity Impairment–PsA questionnaire. Least squares (LS) mean changes from baseline at Week 24 were compared between risankizumab versus placebo by mixed-effects repeated regression modeling. **Results:** At Week 24, risankizumab- versus placebo-treated patients reported greater improvements in LS mean changes with between-group differences (all nominal P<0.001) in SF-36 physical component score (mean difference=3.5, 95% confidence interval [CI] 2.7, 4.2), mental component score (mean difference=1.8, 95% CI 0.9, 2.6), FACIT-Fatigue (mean difference=2.5, 95% CI 1.5, 3.4), EQ-5D-5L index score (mean=0.07, 95% CI 0.05, 0.09), and EQ-5D-5L visual analogue scale score (mean difference=5.8, 95% CI 3.6, 8.0). In addition, risankizumab- versus placebo-treated patients reported greater reductions with in-between-group differences (all nominal P<0.001) in overall work impairment (mean difference=−8.9%, 95% CI −13.1, −4.7), activity impairment (mean difference=−7.7%, 95% CI −10.3, −5.2), and presenteeism (mean difference=−9.8%, 95% CI −13.3, −6.3). **Conclusion:** Compared to placebo, risankizumab resulted in greater improvements in HRQoL, fatigue, and work productivity among patients with PsA. **Acknowledgements:** This work/study was funded by AbbVie Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data. No honoraria or payments were made for authorship. Medical writing services provided by Natalie Mitchell of Fishawack Facilitate Ltd, part of Fishawack Health, and funded by AbbVie. **Disclosure of Interests:** Lennart Erik Kristensen Speakers bureau: AbbVie, Amgen, BMS, Boehringer, Celgene, Chugai, Genentech, GlaxoSmithKline, Janssen, Kirin, LEO Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis, Stiefel, Sun Pharma, Takeda, UCB, and Valeant; Consultant of: AbbVie, Amgen, Astellas, Baxalta, Baxter, Boehinger Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, LEO Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genezyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant.; Lars Erik Kristensen Speakers bureau: AbbVie, Amgen, BMS, Boehringer, Celgene, Chugai, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, LEO Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genezyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant.; Grant/research support from: AbbVie, Amgen, Astellas, Baxalta, Baxter, Boehinger Ingelheim, Bristol Myers Squibb, Celgene, Coherus, Dermira, Eli Lilly, Forward Pharma, Galderma, Genentech, GlaxoSmithKline, Janssen, Kyowa-Hakko Kirin, LEO Pharma, MedImmune, Merck-Serono, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche, Sanofi-Genezyme, Stiefel, Sun Pharma, Takeda, UCB, and Valeant.; Litigation: Litigation Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Ann Eldred Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Settings: AbbVie Inc., Employee of: AbbVie Inc., Abbott Laboratories, Cogenics, Inc., Genentech, Inc., Janssen Pharmaceutical Companies, Lilly, Merck & Co., Inc., Pfizer Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Janssen Scientific Affairs, LLC, Solna, Sweden; Janssen, Biostatistics, Breda, Netherlands; Janssen, Immunology, Global Medical Affairs, Horsham, United States of America; Janssen, Scientific Affairs, LLC, Horsham, United States of America; Janssen, Scientific Affairs, LLC, Issy-les-Moulineaux, France; University of Leeds, Leeds Institute of Rheumatology and Musculoskeletal Medicine, Leeds, United Kingdom. **Background:** Accurate assessment of psoriatic arthritis (PsA) disease activity in clinical practice requires a feasible, continuous, multidimensional composite instrument to assess key domains of this heterogeneous disease. While currently available composite tools used in PsA, including the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Composite Exercise (GRACE) and the PsA Disease Activity Score (PASDAS), are useful in clinical trials, their complexity and time required to complete limit their use in clinical practice. Abbreviated instruments, known as 3 visual analogue scale (VAS) and 4VAS, have demonstrated good performance in an observational study, but further testing was recommended. **Objectives:** Explore the correlation between 3VAS or 4VAS and GRACE, PASDAS and measures of quality of life using data from COSMOS. **Methods:** The Phase 3b COSMOS study assessed guselkumab (GUS) 100mg QW versus placebo (PBO) in tumour necrosis factor inhibitor (TNFi) inadequate response (IR, inadequate efficacy or intolerance) pts with active PsA. Pts who received PBO crossed over to GUS at either Week (W) 16 (early escape [EE], n=45/96) or W24 (planned, n=51/96). Each domain of the 3VAS (physician global, pt global, pt skin) and 4VAS (physician global, pt pain, pt joint, pt skin) was evaluated using a 0–10 VAS (higher score=more active disease), and calculated mean scores were plotted over time in a pt-continuer population (those with W0 and W48 data). Pearson correlation assessed relationships between observed values over time for 3VAS/4VAS versus GRACE, PASDAS, the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the 36-item Short Form Health Survey Physical Component Summary (SF-36 PCS) score. **Results:** Data from 285 pts were examined (GUS, n=189; PBO, n=96). Substantial improvements (>45%) were seen in GRACE, PASDAS, 3VAS and 4VAs scores through W48 in GUS-treated pts (Table 1), with separation from PBO as early as W8 (Figure 1). Strong correlations between 3VAS/4VAS and GRACE (n=0.83–0.92) (PASDAS) (n=0.72–0.85) were observed in GUS-randomized pts at each visit (Table 1). 3VAS/4VAS showed moderate correlation with HAQ-DI (n=0.45–0.63) and SF-36 PCS (n=0.40 to 0.65). Consistent results were observed in PBO–GUS pts. **Table 1. Observed composite index scores and Pearson correlation coefficients by visit**

<table>
<thead>
<tr>
<th>Table 1. Observed composite index scores and Pearson correlation coefficients by visit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mean (SD)</strong></td>
</tr>
<tr>
<td><strong>Visit</strong></td>
</tr>
<tr>
<td>GUS</td>
</tr>
<tr>
<td>BL</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W8</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W16</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W24</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W48</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>PBO–GUS</td>
</tr>
<tr>
<td>(at W16: n=45 or W24: n=51)</td>
</tr>
<tr>
<td>BL</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W8</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W16</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W24</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>W48</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Figure 1.** Mean observed values for 3VAS, 4VAS, PASDAS and GRACE over time in the GUS and PBO–GUS cohorts (patient continuation analysis)
Table 1. Observed Mean (SD) Change from Baseline in Pain Scores, TJC, and SJC at W24, W52, and W100 in DISCOVER-2

<table>
<thead>
<tr>
<th></th>
<th>GUS Q4W</th>
<th>GUS Q8W</th>
<th>PBO</th>
<th>GUS Q4W</th>
<th>GUS Q8W</th>
<th>PBO→Q4W</th>
<th>GUS Q4W</th>
<th>GUS Q8W</th>
<th>PBO→Q4W</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pt Pain (0-10)*</td>
<td>N</td>
<td>240</td>
<td>243</td>
<td>243</td>
<td>229</td>
<td>234</td>
<td>231</td>
<td>220</td>
<td>224</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2.39 (2.35)</td>
<td>-2.53 (2.47)</td>
<td>-1.08 (2.42)</td>
<td>-2.89 (2.68)</td>
<td>-3.20 (2.56)</td>
<td>-2.75 (2.66)</td>
<td>-3.52 (2.62)</td>
<td>-3.69 (2.63)</td>
</tr>
<tr>
<td>Spinal Pain (0-10)*</td>
<td>N</td>
<td>80</td>
<td>85</td>
<td>79</td>
<td>64</td>
<td>60</td>
<td>68</td>
<td>86</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2.26 (2.57)</td>
<td>-2.54 (2.70)</td>
<td>-1.13 (2.48)</td>
<td>-2.74 (2.63)</td>
<td>-2.67 (2.71)</td>
<td>-2.69 (2.69)</td>
<td>-3.11 (2.67)</td>
<td>-3.44 (2.71)</td>
</tr>
<tr>
<td>Joint Pain (0-10)*</td>
<td>N</td>
<td>80</td>
<td>85</td>
<td>92</td>
<td>79</td>
<td>64</td>
<td>68</td>
<td>86</td>
<td>76</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-2.88 (2.17)</td>
<td>-2.90 (2.94)</td>
<td>-1.34 (2.91)</td>
<td>-3.32 (2.27)</td>
<td>-3.21 (2.76)</td>
<td>-3.42 (2.92)</td>
<td>-3.42 (2.35)</td>
<td>-3.61 (2.77)</td>
</tr>
<tr>
<td>SF-36 (Q21; 0-5)*</td>
<td>N</td>
<td>242</td>
<td>243</td>
<td>229</td>
<td>234</td>
<td>234</td>
<td>230</td>
<td>220</td>
<td>224</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-0.99 (1.03)</td>
<td>-1.03 (1.12)</td>
<td>-0.50 (1.11)</td>
<td>-1.18 (1.33)</td>
<td>-1.29 (1.17)</td>
<td>-1.10 (1.16)</td>
<td>-1.39 (1.25)</td>
<td>-1.47 (1.38)</td>
</tr>
<tr>
<td>TJC (0-68), N</td>
<td>240</td>
<td>243</td>
<td>228</td>
<td>234</td>
<td>234</td>
<td>230</td>
<td>220</td>
<td>224</td>
<td>213</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-11.85 (9.88)</td>
<td>-10.37 (9.49)</td>
<td>-7.26 (11.15)</td>
<td>-15.04 (10.51)</td>
<td>-13.44 (10.03)</td>
<td>-14.15 (11.39)</td>
<td>-16.37 (10.70)</td>
<td>-15.27 (11.10)</td>
</tr>
<tr>
<td>SJC (0-66), N</td>
<td>240</td>
<td>243</td>
<td>228</td>
<td>234</td>
<td>234</td>
<td>230</td>
<td>220</td>
<td>224</td>
<td>213</td>
</tr>
<tr>
<td></td>
<td></td>
<td>-8.77 (5.46)</td>
<td>-8.14 (5.07)</td>
<td>-6.44 (7.20)</td>
<td>-10.38 (6.17)</td>
<td>-9.56 (6.28)</td>
<td>-10.17 (7.89)</td>
<td>-10.83 (6.66)</td>
<td>-10.20 (6.86)</td>
</tr>
</tbody>
</table>

**Note:** SD = standard deviation; *ACR = American College of Rheumatology; **BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; ***DAPSA = Disease Activity in Psoriatic Arthritis; ****GUS = guselkumab; MDA = minimal disease activity; PBO = placebo; Pt Pain = patient Q; QxW = every x week; **SD-36 Item Short-Form Survey; SJC = swollen joint count; TJC = tender joint count; VAS = visual analog scale; W = week.

References:

Acknowledgements: Study sponsored by Pfizer Inc. Medical writing support was provided by Lauren Hogarth, CMC Connect, and funded by Pfizer Inc.

Disclosure of Interests: James Waddington Employee of: Atturos, Ruoyi Zhou Employee of: Atturos, Orta Coleman Employee of: Atturos, Bruna Wundervald Employee of: Atturos, Andrew Parneil: None declared, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Novartis, Pfizer Inc and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, CorEvitas, Eli Lilly, Galapagos, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer Inc, Sun Pharma and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer Inc and UCB, Grant/research support from: AbbVie, Amgen, Eli Lilly, and Sun Pharma.

Background: The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has identified a need for biomarkers to predict which patients (pts) with psoriatic arthritis (PsA) are most likely to respond to a specific therapy. Failure to identify effective treatments early on results in sub-optimal PsA disease management. Tofacitinib is an oral JAK inhibitor for the treatment of PsA. The efficacy and safety of tofacitinib 5 and 10 mg twice daily (BID) in pts with PsA have been demonstrated.1,2

Objectives: To identify protein biomarker candidates, which may identify responders (R) vs non-responders (NR) to treatment of PsA, using mass spectrometry-based proteomics.

Methods: Baseline (BL) serum samples from pts with PsA receiving tofacitinib 5 or 10 mg BID, adalimumab or placebo in OPAL Broaden (NCT01877668)1 were analysed. Pts were identified as R and NR based on the Psoriatic Arthritis Disease Activity Score (PASDAS) at Month 3; pts with lowest PASDAS ≤3.2 were defined as R, those with highest PASDAS >3.2 as NR. Two proteomic strategies were employed for analysis of BL serum samples: (1) targeted mass spectrometric multiple reaction monitoring analysis of an in-house panel (PAPRICA) comprising of 206 proteins, originally developed to distinguish between different arthropathies, and (2) unbiased discovery liquid chromatography-tandem mass spectrometry (LC-MS/MS). PAPRICA data were normalised using two methods: normalisation to stable isotope labelled peptide spike-ins (SIL); corrects for fluctuations in sample injections/mass spectrometry loading amounts), and normalisation to an endogenous peptide panel representing total serum protein abundance (TSPA; corrects for different amounts of total serum protein across samples). Univariate analyses (Student's t-test) and multivariate machine learning Random Forest (RF) modelling2 were performed. Univariate analysis of the PAPRICA panel of proteins was performed on R vs NR, and within each treatment arm, with no adjustment for multiplicity.

Results: 96 pts were identified as 47 R and 49 NR based on PASDAS scores. Of pts receiving tofacitinib 5 or 10 mg BID (data pooled), adalimumab or placebo, there were 26 R vs 26 NR, 13 R vs 13 NR and 8 R vs 10 NR, respectively. Results from univariate analysis identified 110 differentially expressed PAPRICA peptides between R vs NR (p<0.05). RF multivariate analysis of all data (n=96) revealed a set of PAPRICA peptide signatures with the ability to differentiate between R and NR. Two RF models generated from the PAPRICA peptide data had training area under curves (AUCs) 0.956 [95% CI 0.93, 0.99] (TSPA) and 0.959 [95% CI 0.94, 0.98] (SIL). In total, 115 PAPRICA peptides representing 87 proteins were identified as potential biomarkers for predicting treatment response. Using unbiased discovery LC-MS/MS, univariate analysis of all data revealed one candidate peptide biomarker (ps<0.05). RF modelling revealed peptides that contributed to two prediction models with training AUCs of 0.959 [95% CI 0.94, 0.98] and 0.952 [95% CI 0.9, 0.96] in total, from unbiased discovery LC-MS/MS, 66 peptides representing 39 proteins that may act as potential peptide biomarkers were identified in univariate and multivariate analyses.

Conclusion: Using two complementary proteomic approaches and a combination of univariate and machine learning models, a total of 181 candidate biomarker peptides corresponding to 106 proteins have been identified that may act as potential biomarkers for predicting response to treatment of PsA. Further study is required to verify and evaluate these candidate biomarkers, and we will report how these proteins map to biological processes, pathways and networks.
Deucravacitinib Long-Term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from Phase 3 POTEYK Programs

R. B. Warnen1, H. Sotenn, S. Imafuku2, S. Szepietowski3, A. Blauvelt4, L. Squinc5, E. Boudry6, J. Toma7, A. B. B. Berney7,1, The University of Manchester, Dermatology, Manchester, United Kingdom; 2UCLA School of Medicine, Dermatology, Los Angeles, United States of America; 3Fukuoka University Hospital, Dermatology, Fukuoka, Japan; 4Wrocław Medical University, Dermatology, Wrocław, Poland; 5Oregon Medical Research Center, Dermatology, Portland, United States of America; 6Veracyte Clinical Research, Dermatologic Surgery, Woodloongabba, Australia; 7Bristol Myers Squibb, Dermatology, Princeton, United States of America; 8Bristol Myers Squibb, New Indications, Clinical Development - Dermatology, Princeton, United States of America; 9Bristol Myers Squibb, Biostats, Princeton, United States of America; 10Bristol Myers Squibb, Rheumatology and Dermatology, Princeton, United States of America; 11Baylor University Medical Center, part of Baylor Scott & White Health, Dermatology, Dallas, United States of America

Background: Tyroso kinase 2 (TYK2) is an intracellular kinase that mediates signaling of key cytokines (eg, interleukin [IL]-23 and Type I interferons) involved in the pathogenesis of immune-mediated diseases including plaque psoriasis and psoriatic arthropitits (PsA). Deucravacitinib is a novel, oral, selective TYK2 inhibitor that achieves high selectivity by uniquely binding to the regulatory domain of the enzyme, rather than to the more conserved active domain. Deucravacitinib showed superior efficacy compared with placebo at 16 weeks in a Phase 2 trial in patients with PsA.1

Objectives: To assess the long-term efficacy and safety of deucravacitinib in patients with psoriasis in a Phase 3, open-label, long-term extension (LTE) trial.

Methods: The 52-week PSO-1 and PSO-2 trials randomised patients with moderate to severe plaque psoriasis 2:1 to deucravacitinib 6mg once daily, placebo, or apremilast 30mg twice daily. Patients could then enrol in the LTE trial at any time. The current analysis compares deucravacitinib with placebo in the LTE trial.

Results: 1221 patients enrolled in the LTE trial and received ≥1 dose of deucravacitinib. Demographic and baseline disease characteristics were balanced across treatment groups; mean age at disease onset was 28.6 years, mean disease duration was 18.9 years, and 18.0% of patients had PsA at baseline. Cumulative exposures in person-years from randomisation in PSO-1 or PSO-2 to the LTE trial were 2166.9 and 2482.0 for efficacy and safety analyses, respectively. At enrolment in the LTE trial, PASI 75 and sPGA 0/1 response rates were 65.1% and 50.9%, respectively, and were maintained for up to 2 years after initial randomisation (Week 48 of LTE; PASI 75: 75.7%; sPGA 0/1: 56.4% [as observed]). Exposure-adjusted incidence rates per 100 person-years for adverse events were similar in the controlled period (Weeks 0–52) of PSO-1 and PSO-2 and during the cumulative PSO-1, PSO-2, and LTE trial period (229.2 [controlled period] vs 154.4 [cumulative period]), serious adverse events (6.7 vs 6.1), discontinuations (4.4 vs 2.8), deaths (0.2 vs 0.4), herpes zoster (0.9 vs 0.7), malignancies (1.0 vs 0.9), major adverse cardiovascular events (0.3 vs 0.4), and venous thromboembolism (0.1 vs 0.1).

Conclusion: Deucravacitinib demonstrated persistent efficacy and consistent safety profiles in patients with psoriasis for up to 2 years after initial randomisation in the POETYK PSO-1, PSO-2, and LTE trials.

REFERENCES:

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Writing and editorial assistance was provided by Lisa Feder, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, funded by Bristol Myers Squibb.

Disclosure of Interests: Richard B. Warren Consultant of: Abbvie, Amilall, Amgen, Astellas, Boehringer Ingelheim, Celgene, DICE, Eli Lilly, GlaxoSmithKline, Janssen, Leo Pharma, Novartis, Pfizer, Sanofi, UC2, UNION, and Xenoport; Grant/research support from: Abbvie, Amilall, Amgen, Celgene, Janssen, Eli Lilly, Leo Pharma, Novartis, Pfizer, UC, Howard Sofen Consultant of: Clinical investigator: Abbvie; Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Leo Pharma, Novartis, and Sun Pharma; Shinichi Imafuku Grant/research support from: Grants and personal fees: AbbVie, Eisai, Kyowa Kirin, Janssen, Leo Pharma, Maruho, Sun Pharma, Taiho Yakuhin, Tanabe Mitsubishi, and Tori Yakuhin; Personal fees: Amgen (Celgene), Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Novartis, and UCB; Jacek Szepietowski Consultant of: Advisory board member/consultant: AbbVie; Leo Pharma, Novartis, Pfizer, Sanofi Genzyme, and Trevi; Speaker: AbbVie, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, and Sanofi Genzyme; Investigator: AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Galderma, Incyte, InfraRX, Janssen-Cilag, Manio Therapeutics, Merck, Novartis, Pfizer, Regeneron, UCB, and Trevi; Andrew Blauvelt Consultant of: Scientific adviser and/or clinical study investigator: AbbVie, AbCenta, Almirall, Amgen, Amgen, AstraZeneca, Avena Asia, Avexis, Boehringer Ingelheim, Bristol Myers Squibb, Dervanath, EcoR1, Eli Lilly, Evomune, Forte, Galderma, Incyte, Janssen, Landos, Leo Pharma, Novartis, Pfizer, Rapt, Regeneron, Sanofi Genzyme, Sun Pharma, UCB, and Vbiomine; Lynda Sperman Consultant of: Clinical investigator and/or speaker: AbbVie, Amgen, Anacor; Ascend, Astellas, AstraZeneca, Blaze Bioscience, Bristol Myers Squibb; Boehringer Ingelheim, Botanix, Celgene, Derma, Eli Lilly, Galderma, Genentech, GlaxoSmithKline, Hexima, Janssen, Leo Pharma, Mayne, Medimmune, Merck (MSD), Merck-Serono, Novartis, Otsuka, Pfizer, Phosphagens, Photon MD, Regeneron, Roche, Samumed, Sanofi Genzyme, SHR, Sun Pharma ANZ, Trius, UCB, and Zai Lab; Elizabeth Colston Shareholder of: Employee and shareholder: Bristol Myers Squibb, Employee of: Employee and shareholder: Bristol Myers Squibb, Alex Buck Employee of: Contractor (through functional service provider Cyte): Bristol Myers Squibb, Subhashis Banerjee Shareholder of: Employee and shareholder: Bristol Myers Squibb, Employee of: Employee and shareholder: Bristol Myers Squibb, Alan Menter Consultant of: Advisory board: Abbott Labs, Amgen, Boehringer Ingelheim, Janssen Biotech, Leo Pharma, Pfizer; Abbott Labs: Amgen, Eli Lilly, Janssen Biotech, Leo Pharma, Novartis, Sun Pharma, and UCB; Investigator: Abbott Labs, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen Biotech, Leo Pharma, Merck, Novartis, Sun Pharma, and UCB; Research grants: Abbott Labs, Amgen, Boehringer Ingelheim, Janssen Biotech, Leo Pharma, Merck, and Sun Pharma; Speaker: Abbott Labs, Amgen, Janssen Biotech, Leo Pharma, Sun Pharma, and UCB

DOI: 10.1136/ann Rheum Dis.2021.e2445

POS1047

TRAF3IP2, HCP5 AND IL10 GENES POLYMORPHISMS INFLUENCE THE RESPONSE TO TNF-1 IN PATIENTS WITH PSORIATIC ARTHRITIS

M. S. Chiamenti1, A. Latin1, P. Conigliaro1, P. Triggianesi1, E. Greco1, G. De Benedictis2, L. Novelli3, C. Ciccacci2, A. Bergamini1, G. Novelli1, P. Borigian1,1Rheumatology and Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, Italy; 2Department of Biomedicine and Prevention, Genetics, 3University of Rome, Roma, Italy; 4Institute of and Clinical Research, University, Saint Camillus, University International of Health Sciences, Rome, Italy

Background: Psoriatic Arthritis (PsA) is a chronic inflammatory disease, characterized by both articular and periarticular manifestations, usually associated with psoriasis. The identification of the correct therapy for patients is still a critical issue, but the use of biological drugs, such as TNFi (Tumor Necrosis Factor Inhibitors), modified the outcome of PsA patients even if there is great variability in the clinical efficacy. Since the response to drugs is a complex trait, the identification of genetic factors could help to define new genomic biomarkers for more effective and personalized therapy.

Objectives: The aim of this study was to evaluate the potential role of polymorphisms in genes already known to be involved in PsA susceptibility (ERAP1, HCP5, IL10, MIR146, PSORS1C1, TNFA, TNFAP3 and TRAF3IP2) as predictors of efficacy in treatment, in a cohort of Italian PsA patients, treated with first-line TNF-1, in particular with Enalotep (ETN) and Adalimumab (ADA).

Methods: Polymorphisms were analyzed in a cohort of 163 patients with peripheral PsA in both disease activity and the Disease Activity Score (DAS) score. Genotyping was performed by allele discrimination by TaqMan assay. The possible association between the selected SNPs and mean values of DAPsA differences, at 22 (AT22) and 54 (AT54) weeks from the beginning of the TNF-1 treatment, were evaluated by T-test. A multivariate logistic regression analysis was used to evaluate the contribution of each genetic variant investigated in the TNF-1 treatment response.

Results: We have observed that TRAF3IP2 SNP was associated with TNF1 treatment in PsA patients. In particular, the TNF1 treatment response of the variant alleles seem to respond better to treatment, both at 22 (P = 0.032) and 54 weeks (P = 0.019). Moreover, the variant allele of TRAF3IP2 SNP resulted associated with a better response of joints involvement. Indeed, the number of tender and swollen joints decrease more in patients carrying variant allele (P = 0.006 and P = 0.024, respectively). We also observed that PsA patients carrying IL10 variant allele had a lower value of DAPsA only at 54 weeks of treatment (P = 0.031). Also, HCP5 polymorphism showed a difference of mean difference of DAPsA values between genotypes for both follow up, even if these difference does not reach a statistical significance (
Methods: The Phase 2 PsA trial. Assess efficacy of DEUC up to 52 wks. A comprehensive measure assessing a variety of PsA clinical domains, was used to evaluate efficacy. Patients were assessed up to 52 wks for adverse events (AEs) and exploratory safety outcomes. Results: Data as observed. Efficacy endpoints including change in PASDAS. Analyses were descriptive using intention-to-treat and 173 (96%) of these pts chose to enrol in Part B. Of 118 pts initially randomised to DEUC, 25% (29/118; 6 mg QD, 22% [13/60]; 12 mg QD, 28% [16/58]) continued to Part B. Pts were assessed up to 52 wks for adverse events (AEs) and exploratory safety outcomes. Conclusion: Our results suggest that some polymorphisms in genes associated to PsA susceptibility could also play a role in TNFi treatment response and could give a contribution in the definition of a genetic profile associated with the response to anti-TNF drugs.

Background: Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that acts by binding to the unique TYK2 regulatory domain, thereby suppressing signalling of key cytokines (eg, IL-23) involved in skin psoriasis and psoriatic arthritis (PsA) pathogenesis. Results from the initial 16-week (wk), placebo (PBO)-controlled period (Part A) of a 52-wk, blinded Phase 2 trial in PsA showed that DEUC was significantly more efficacious than PBO. The Psoriatic Arthritis Disease Activity Score (PASDAS), a validated comprehensive measure assessing a variety of PsA clinical domains, was used to assess efficacy of DEUC up to 52 wks.

Objectives: Evaluate the safety and efficacy of DEUC in Part B (Wks 16-52) in the Phase 2 PsA trial.

Methods: Patients (pts) with PsA were randomised 1:1:1:1 to PBO, DEUC 6 mg once daily (QD), or 12 mg QD. After Wk 16 (Part A), pts could enrol in an optional, double-blind period until Wk 52 (Part B). In Part B, pts receiving DEUC who had achieved minimal disease activity (MDA) at Wk 16 continued DEUC treatment and those who had not achieved MDA were switched to ustekinumab (UST) at the approved PsA dose. All pts treated with DEUC in Part A switched to UST in Part B. Pts were assessed up to 52 wks for adverse events (AEs) and exploratory efficacy endpoints including change in PASDAS. Analyses were descriptive using data as observed.

Results: Of 203 pts randomised in Part A, 180 (89%) completed 16 wks of treatment and 173 (86%) of these pts chose to enrol in Part B. Of 118 pts initially randomised to DEUC, 25% (29/118; 6 mg QD, 22% [22/98]; 12 mg QD, 26% [16/58]) continued to Part B. Pts who had achieved MDA at Wk 16 and continued at the same dose. All other pts switched to UST in Part B: PBO, 100% (55/55); including 5 pts who had achieved MDA at Wk 16; DEUC 6 mg QD, 78% (47/60); DEUC 12 mg QD, 72% (42/58). The safety profile of DEUC in Part B (Table 1) was consistent with that in Part A, and all AEs were mild or moderate except 2 AEs in 1 pt with severe cataract/macular fibrosis. There were no opportunistic infections, herpes zoster, malignancy, thrombotic events, or treatment-related serious AEs reported in pts who remained on DEUC. Decreases in mean PASDAS score observed at Wk 16 were maintained at Wk 52 in pts who continued on DEUC (Figure 1). Improvements in other outcomes, including ACR components, PASI, and FACIT-Fatigue, were also sustained at Wk 52 in pts who continued DEUC treatment. Pts who had not achieved MDA on DEUC at Wk 16 showed a decrease in mean PASDAS score at Wk 52 after switching to UST.

Table 1. Overall summary of safety in Part B (Weeks 16 to 52)

<table>
<thead>
<tr>
<th>AE, n (%)a</th>
<th>DEUC 6 mg</th>
<th>DEUC 12 mg</th>
<th>DEUC 6 mg</th>
<th>DEUC 12 mg</th>
<th>PBO → UST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total AEs</td>
<td>11 (84.6)</td>
<td>8 (50.0)</td>
<td>26 (55.3)</td>
<td>26 (61.9)</td>
<td>30 (54.5)</td>
</tr>
<tr>
<td>Deaths</td>
<td>0</td>
<td>0</td>
<td>1 (2.1)c</td>
<td>1 (2.4)c</td>
<td>0</td>
</tr>
<tr>
<td>SAE</td>
<td>1 (7.7)b</td>
<td>0</td>
<td>3 (6.4)</td>
<td>4 (9.5)</td>
<td>0</td>
</tr>
<tr>
<td>Treatment-related SAE</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Discontinued due to AE</td>
<td>0 (0.0)</td>
<td>0</td>
<td>1 (6.3)f</td>
<td>2 (4.8)f</td>
<td>0</td>
</tr>
</tbody>
</table>

Includes all treated patients in Part B. Medical Dictionary for Regulatory Activities version 23.0 was used. aIn the number of patients who experienced an event. bOne patient had SAEs of psoriatic arthropathy in 1 joint and peripheral neuropathy. cPatient had an AE of COVID-19 infection leading to discontinuation. dDeaths in UST arms were due to car accident and sudden death in a 71-year-old patient with hypertension. ePatient had an AE of urinary tract infection leading to discontinuation. fAdverse event: DEUC; deucravacitinib; PBO; placebo; QD, once daily; SAE, serious adverse event; UST, ustekinumab.

Conclusion: In the 16- to 52-wk blinded Part B of a Phase 2 study in pts with PsA, new safety signals were observed with continuous DEUC treatment vs the earlier Part A period. Efficacy in PASDAS, as well as other key efficacy measures, was maintained with continued DEUC treatment through Wk 52.

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julianne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Bristol Myers Squibb. The authors acknowledge Jonghyeon Kim, PhD, who was employed by Bristol Myers Squibb at the time the study was conducted, for his statistical assistance.

Disclosure of Interests: Philip J Mease Consultant of: Consulting and/or speaker fees: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sanoﬁ, UCB, and UCB., Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Prophylx, Sanoﬁ, UCB, and UCB., Consultant of: Consulting fees: AbbVie, Bayer, Bristol Myers Squibb, Cytokine, Elsi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB., Fee distributions from: Research grants: AbbVie, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer, DSi, and Désirée van der Heijde Consultant of: Consulting fees: AbbVie, Bayer, Bristol Myers Squibb, Cytokine, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB.; Frank Behrens Consultant of: Consulting fees: AbbVie, Amgen, Boehringer, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biocent, Janssen, Genzyme, Lilly, Boehringer, Sandoz, and Sanoﬁ., Grant/research support from: Research grants: AbbVie, Pfizer, Roche, Chugai, Prophylx, Novartis, and Amgen, Alan Kivitz Shareholder of: Shareholder: Pfizer, Sanoﬁ, GlaxoSmithKline, Gilead Sciences, Inc., Novartis, Consultant of: Paid Consultant: AbbVie, Boehringer Ingelheim, Flexion, Janssen, Pfizer, Sanoﬁ,

**BACKGROUND:** Psoriatic arthritis (PsA) is a comorbidity commonly associated with psoriasis. Studies have demonstrated delays in the diagnosis and treatment of PsA among patients that disproportionately affect racial/ethnic minority patients as indicated by one study that found Black Medicaid patients with PsA to be less likely to receive disease-modifying antirheumatic drugs [DMARDs] than White Medicaid patients with PsA [2]. Yet, much remains unknown about potential racial/ethnic disparities in PsA management.

**OBJECTIVES:** The objective of our study was to evaluate treatment patterns for PsA by race/ethnicity.

**METHODS:** We performed a cross-sectional study of adult (≥18 years old) patients with PsA who had at least one outpatient visit within the University of Pennsylvania health system between 2010 and 2019. Patients with PsA were identified by the presence of at least two International Classification of Diseases (ICD)-9 or ICD-10 codes for PsA associated with two different healthcare encounters. The primary outcomes were receipt of a prescription for: (i) an oral DMARD, (ii) a biologic DMARD, and (iii) prednisone. Oral DMARDs included apremilast, methotrexate, sulfasalazine, leflunomide, azathioprine, cyclosporine, tofacitinib, hydroxychloroquine, and upadacitinib. Biologic DMARDs included abatacept, adalimumab, brodalumab, certolizumab, etanercept, goltimub, guselkumab, infliximab, ixekizumab, ustekinumab, and risankizumab. The primary independent variable was race/ethnicity categorized as White (reference), Black, Asian, Hispanic, or other race. Multivariable logistic regression was used to assess the relationship between race/ethnicity and each treatment outcome.

**RESULTS:** The study population included 1781 patients with PsA who were a mean age of 50.7 (SD 14.3), 54.6% female, and 72.5% commercially insured. The racial/ethnic distribution was 81.9% White, 5.6% Black, 4.0% Asian, 3.0% Hispanic, 2.5% other race, and 3.1% missing race/ethnicity. Of these patients, 64.3% were prescribed an oral DMARD, 55.6% were prescribed a biologic, and 44.1% were prescribed prednisone. There were no statistically significant differences across race/ethnicity for prescription of either oral or biologic DMARDs. However, prescription of prednisone did differ by race/ethnicity (p < 0.005) with Black (54.6%) and Hispanic (56.6%) patients being more likely to receive prednisone prescriptions than White (44.2%) patients. In adjusted logistic regression models controlling for sociodemographic and other factors, Hispanic patients were more likely to receive a prednisone prescription (OR 1.79, 95% CI 1.01 – 3.20, p = 0.05) while Asian (OR 0.58, 95% CI 0.34 – 0.97, p = 0.04) patients were less likely to receive a prednisone prescription compared to White patients.

**CONCLUSION:** We found Hispanic patients with PsA to be more likely to receive prednisone prescriptions than White patients with PsA but did not identify any racial/ethnic differences in prescription patterns for oral or biologic DMARDs for PsA. Greater use of prednisone among Hispanic patients may reflect different disease trajectories (e.g., more disease flares or greater disease severity) or other factors that affect prescription patterns that require further study.

**REFERENCES:**

**DISCLOSURE OF INTERESTS:** Fahad Ahmed: None declared. Alix Ogdie Consultant of: A. Ogdie has received consulting fees from Amgen, AbbVe, Bristol-Myers Squibb, Celgene, CorEvitas (formerly Corrona), Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Grant/research support from: A. Ogdie has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, AbbVie (University of Pennsylvania), Pfizer (University of Pennsylvania), Amgen (FORWARD), and Novartis (FORWARD)., Robert Fitzsimmons: None declared. Daniel Shin: None declared. Junko Takeshita Consultant of: JT has served as a consultant for Pfizer Inc. and Janssen Biotech receiving honoraria. Grant/research support from: JT has received a research grant (to the Trustees of the University of Pennsylvania) from Pfizer Inc.
Conclusion: UPA 15 mg treatment led to greater improvements over PBO in RAPID3 scores over 56 wks in patients with PsA, and greater improvements over ADA from wk 16 to 56. The majority of patients achieved MCID in RAPID3 after 12 wks of UPA or ADA, with higher proportions achieving MCID on UPA vs ADA by wk 24. RAPID3 was strongly associated with other joint-focused (DAPSA) or multiple manifestation (MDA/VLDA) composite measures, further supporting the utility of RAPID3 in assessing disease activity in PsA.

REFERENCES:

Acknowledgements: AbbVie and the authors thank the patients, study sites, and investigators who participated in these clinical trials. AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Matthew Eckwahl, PhD, of AbbVie.

POST0151
TO WHAT EXTENT ARE BASELINE CHARACTERISTICS IN BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AT WEEK 24 OF GUSELKUMAB TREATMENT: A POST HOC ANALYSIS OF THE PHASE IIIB COSMOS CLINICAL TRIAL

1Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, United Kingdom; 2Chanté – Universitätmedizin Berlin, Berlin, Germany; 3Hospital Universitari Clinic, Barcelona, Spain; 4Janssen-Cilag, Zug, Switzerland; 5Janssen-Cilag BV, Breda, Netherlands; 6Janssen-Cilag, Solna, Sweden; 7Janssen-Cilag, Issy-Ies-Moulineaux, France; 8Janssen-Cilag, Dubai, United Arab Emirates; 9Janssen Global Services, LLC, Horsham, PA, United States of America; 10Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands

Background: Guselkumab (GUS) is a human monoclonal antibody targeting the interleukin-23p19-subunit. It has demonstrated efficacy at Week 24 in the Phase IIb COSMOS clinical trial of patients with active psoriatic arthritis (PsA) and inadequate response or intolerance to one or two tumour necrosis factor inhibitors (TNFis).

Objectives: The aim of this post hoc analysis was to identify predictors of minimal disease activity (MDA) with GUS at Week 24 in patients with active PsA and inadequate response or intolerance to one or two TNFis.

Methods: A multiple logistic regression analysis was performed to identify potential predictors of MDA with GUS at Week 24 in TNFi-refractory patients with PsA. Odds ratios, 95% confidence intervals and p-values were calculated. Baseline characteristics assessed as predictors included age, sex, body mass index (BMI), C-reactive protein (CRP), other medication use and disease duration. Clinical features included tender and swollen joint counts (TJC/SJC), symptom counts (CTJC/CTJC), affected joint location, dactylitis, enthesitis, spondylitis, Psoriasis Area and Severity Index (PASI) score and psoriasis (PsO) localisation (Figure 1). Missing data for MDA at Week 24 were imputed as non-response; missing baseline values were imputed for two patients.

Results: Odds ratios and 95% CIs for potential predictors of minimal disease activity response to guselkumab 100 mg every 8 weeks at Week 24 in patients with PsA and inadequate response or intolerance to one or two TNF inhibitors. (Figure 1).

For MDA at Week 24: Male sex (OR: 1.8, 95% CI: 1.1-3.0, p=0.02), age >65 years (OR: 1.7, 95% CI: 1.1-2.6, p=0.02), and BMI >30 kg/m² (OR: 1.9, 95% CI: 1.2-3.1, p=0.01) were associated with MDA at Week 24. The presence of spondylitis (OR: 1.8, 95% CI: 1.1-3.0, p=0.02) and PsA severity (PASI >15 OR: 1.7, 95% CI: 1.1-2.6, p=0.02) were associated with MDA at Week 24.

For PsO: The presence of dactylitis (OR: 2.1, 95% CI: 1.2-3.8, p=0.01) and PsO severity (PASI >15 OR: 1.8, 95% CI: 1.1-2.9, p=0.01) were associated with MDA at Week 24.

Acknowledgements: AbbVie and the authors thank the patients, study sites, and investigators who participated in these clinical trials. AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. Medical writing support was provided by Matthew Eckwahl, PhD, of AbbVie.

Disclosure of Interests: Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GS, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galilead, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB, Arthur Kavanaugh Consultant of: AbbVie, Amgen, Astra Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB., Grant/research support from: AbbVie, Amgen, Astra Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB., Erin McDearmon-Blon dell Shareholder of: AbbVie, Employee of: AbbVie, Arthur Mandelin Speakers bureau: AbbVie, Pfizer, BMS, and Horizon, Consultant of: Served on advisory board at CVS Caremark, Tiaming Gas Shareholder of: AbbVie, Employee of: AbbVie, William Tillett Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. DOIs: 10.1136/annrheumdis-2022-eular.2533

BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; csDMARD, conventional systemic disease-modifying anti-rheumatic drug; HAQ-DI, Health Assessment Questionnaire - Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PsO, psoriasis; TNF, tumour necrosis factor; N=187 for all clinical features and baseline characteristics. Negative predictors are indicated by bold text and positive predictors by italics (p<0.05). Results: Of the 187 patients in this study, 54.6% were women and the mean disease duration was 8.3 years. The patients had a mean TJC 0–66 of 21.0, a mean SJC 0–66 of 10.3, a mean PASI score of 11.6 and a mean BMI of 28.9. Furthermore, 67.9% had enthesisitis and 35.8% had dactylitis at baseline. One prior TNFi had been received by 82.8% of patients, and two received by 11.8%.
Week 24, 17.1% of patients (32/187) achieved MDA. Wrist involvement (p=0.031) and scalp PsO (p=0.049) were positive predictors of MDA. Women were significantly less likely to achieve MDA (p=0.036) than men; other negative predictors included involvement of shoulder or small joints of the hand, and hand-foot PsO (all p<0.05). Age, BMI, CRP, TJC/SJC, HAQ-DI, PASI, spondylitis, enthesitis, dactylitis, other medication use and number of prior TNFis were not predictive of MDA (Figure 1).

Conclusion: Baseline characteristics and clinical features may be positively (wrist involvement, scalp PsO) or negatively (female sex, involvement of shoulder or small joints of the hand, hand-foot PsO) associated with achieving MDA with GUS at Week 24 in a TNF-RAfficted population. Though the low patient number limits the generalisability of this analysis, assessment of Week 48 data may further elucidate potential predictors of MDA after longer-term treatment.


Disclosure of Interests: William Tillett Speakers bureau; Consultant of; Grant/ research support from: William Tillett has received research grants and consulting or speaking fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB; Sarah Orhrdorff Speakers bureau: Sarah Orhrdorff has received speaker fees or travel expense reimbursements from AbbVie, BMS, Janssen, Novartis and Pfizer; Julio Ramirez Speakers bureau; Consultant of: Julio Ramirez has received consulting or speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis and UCB, Marlies Neuhold Shareholder of: Johnson & Johnson, Employee of: Janssen, Robert Wapenaar Shareholder of: Johnson & Johnson, Employee of: Jansen, Elke Theander Employee of: Janssen, Christine CONTRE Shareholder of: Johnson & Johnson, Employee of: Jansen, Mohamed Sharaf Shareholder of: Johnson & Johnson, Employee of: Janssen, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen, Marijn Vis Shareholder of: Johnson & Johnson, Employee of: AbbVie and UCB; Grant/ research support from: Marijn Vis has received research grants and consulting or speaking fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB and the Dutch Arthritis Foundation.


POS1052 DEVELOPING EVIDENCE-BASED PATIENT FOCUSED LEARNING MATERIALS TO SUPPORT HEALTH BEHAVIOUR CHANGE FOR PEOPLE LIVING WITH PSORIATIC ARTHRITIS

L. Hailey*, C. Bundy, L. Howells*, S. Kirtley*, S. Martin*, O. Sullivan*, I. Steinkoegel*, M. Stepney*, L. Coates†, 1University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 2Cardiff University, Behavioural Medicine/ Health Psychology School of Healthcare Sciences, Cardiff, United Kingdom; 3University of Nottingham, Centre of Evidence Based Dermatology, Nottingham, United Kingdom; 4University of Oxford, Centre for Statistics in Medicine, Oxford, United Kingdom; 5University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, United Kingdom; 6Patient Research Partner, Kildare, Ireland; 7Patient Research Partner, Cleveland, United States of America

Background: Psoriatic arthritis (PsA) is a complex condition that requires high levels of self-management from those living with the condition. It is associated with many comorbidities, including depression, metabolic syndrome, and increased cardiovascular disease risk and can adversely affect quality of life. There is growing evidence that people living with psoriatic arthritis (PsA) are more likely to be overweight, consume alcohol above recommended levels, smoke, be affected by poor sleep, fatigue, anxiety, and take insufficient exercise for healthy living. These modifiable health behaviours further increase the already known risk of cardiovascular morbidity and mortality. These issues are not systematically addressed in routine clinical care due to low confidence in effective delivery and time constraints.

Objectives: To co-develop evidence-based patient-focused learning materials to support healthy lifestyle changes for people living with PsA.

Methods: The development of the materials was overseen by a steering group of people living with PsA, psychologists, rheumatologists, and researchers. The COM-B model was used in the development of the materials, and they are designed around motivational interviewing principles. Firstly, a systematic literature review was performed to establish the evidence for the current burden and potential interventions aimed at these issues in PsA. These included diet, weight, alcohol, smoking, exercise, anxiety, depression, and stress. An initial focus group of people living with PsA was used to identify priority behaviours and ideas for content. The steering group developed draft materials, and we partnered with a design agency to create engaging materials. They developed a website and downloadable postcards. A second focus group of people living with PsA was held for people to give their views on the draft content for the materials and initial design ideas. A third focus group was held with people living with PsA and a fourth with clinicians to refine the design materials and ensure they were accessible, interesting, and helpful to initiate and maintain change.

A final evaluation survey was performed to review the draft website before launching the final materials. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) approved the final materials.

Results: Following the steering and focus groups' input, 15 candidate topics were prioritised (Table 1). A website and downloadable postcards summarising each of the topics were developed by the design team and refined following feedback from the patient focus groups. An example of the postcard for ‘keeping active’ can be found in Figure 1.

The resources are free to use and can be accessed at https://www.informatree.org.

Table 1. Topics

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pain</td>
</tr>
<tr>
<td>2</td>
<td>Fatigue</td>
</tr>
<tr>
<td>3</td>
<td>Healthcare appointments</td>
</tr>
<tr>
<td>4</td>
<td>Tobacco</td>
</tr>
<tr>
<td>5</td>
<td>Different treatments</td>
</tr>
<tr>
<td>6</td>
<td>Alcohol</td>
</tr>
<tr>
<td>7</td>
<td>Work</td>
</tr>
<tr>
<td>8</td>
<td>Social support</td>
</tr>
<tr>
<td>9</td>
<td>Food and weight</td>
</tr>
<tr>
<td>10</td>
<td>Sleep</td>
</tr>
<tr>
<td>11</td>
<td>Keeping active</td>
</tr>
<tr>
<td>12</td>
<td>Mood</td>
</tr>
<tr>
<td>13</td>
<td>Intimacy</td>
</tr>
<tr>
<td>14</td>
<td>Travel</td>
</tr>
<tr>
<td>15</td>
<td>Using treatments</td>
</tr>
</tbody>
</table>

Figure 1. During the development of the website and downloadable postcards, particular attention was paid to making the material as accessible and as friendly as possible for patients.

Conclusion: This project created patient-focused information to support behaviour change in clinical practice. It addresses common concerns of people living with PsA about how they may optimise their health by providing practical and...
brief interventions to challenge and support them to make personal changes. Future research is needed to test the impact of the resource.

Acknowledgements: This research project was funded by a Medical Education Grant from Pfizer. SK was funded by Cancer Research UK (grant C49297/A27294).

Disclosure of Interests: Louise Hailey: None declared, Christine Bundy Consultant of: Over the last 3 years, I have received funds for consultancy from the following pharmaceutical companies: Abbvie, Amgen, Almirall, Amgen (was Celgene), Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB., Grant/research support from: LCC has received grants/research support from Abbvie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB., Consultant of: LCC has worked as a paid consultant for Abbvie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Medac, Novartis, Pfizer and UCB., Laura Coates Speakers bureau: LCC has been paid as a speaker for Abbvie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Medac, Novartis, Pfizer and UCB.

POS1053

LONG-TERM RETENTION, EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: RESULTS FROM THE OBSERVATIONAL SERENA STUDY

U. Kitz1, P. Stiliakos2, N. Gulikou1,4, P. Katsimpris1, A. Kotrotsios1, J. Brandt-Jürgens1, E. Lespessailles9, N. Maeder7, K. Gaffney10, D. Peterlik11, B. Schulz12, E. Pourmara3, P. Jagiello13, R. Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Rheumatology, Bochum, Germany; 1National and Kapodistrian University of Athens Medical School, Rheumatology, Athens, Greece; 2University Hospitals Coventry & Warwickshire, Rheumatology, Coventry, United Kingdom; 3Warwick Medical School, University of Warwick, Rheumatology, Coventry, United Kingdom; 4National and Kapodistrian University of Athens, Attkon University Hospital of Athens, Rheumatology and Clinical Immunology Unit, 4th Dept of Internal Medicine, Medical School, Athens, Greece; 5University of Thessaly and Research Associate of IASO Hospital, Adjunct Professor of Anatomy, Faculty of Public and Integrated Health, Thessaly, Greece; 6Rheumatologische Schwerpunktpraxis, Rheumatology, Berlin, Germany; 7Regional Hospital and University of Orleans, Rheumatology, Orleans, France; 8Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QU, Rheumatology, Craigavon, United Kingdom; 9Norfolk and Norwich University Hospitals NHS Foundation Trust, Rheumatology, Norwich, United Kingdom; 10Novartis Pharma GmbH, Rheumatology, Nürnberg, Germany; 11Novartis Pharma AG, Immunology, Hepatology and Dermatology, Basel, Switzerland

Background: SERENA is an ongoing, longitudinal, observational study of more than 2900 patients (pts) with moderate to severe psoriasis, active psoriatic arthritis (PsA), and ankylosing spondylitis (AS) conducted at 438 sites across Europe with an expected duration of up to 5 years.1,2

Table 1. Overall safety profile within the study period (Safety set)

<table>
<thead>
<tr>
<th>Variable, n (%) unless otherwise specified</th>
<th>PsA (N=574)</th>
<th>AS (N=505)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts with AE (≥1)</td>
<td>327 (570)</td>
<td>291 (573)</td>
</tr>
<tr>
<td>Pts with SAE (≥1)</td>
<td>63 (110)</td>
<td>65 (129)</td>
</tr>
<tr>
<td>AE leading to death</td>
<td>3 (0.5)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>AE leading to discontinuation</td>
<td>119 (20.7)</td>
<td>81 (16.0)</td>
</tr>
</tbody>
</table>

Treatment emergent AE leading to discontinuation (n >1% pts in any group)

| General disorders and administration site conditions | 74 (12.9) | 50 (9.9) | 3.75 |
| Skin and subcutaneous tissue disorders | 13 (2.3) | 3 (0.6) | 0.22 |
| Musculoskeletal and connective tissue disorders | 26 (4.5) | 9 (1.8) | 0.67 |
| Infections and infestations | 2 (0.3) | 7 (14.1) | 0.52 |
| Gastrointestinal disorders | 2 (0.3) | 3 (0.6) | 0.22 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4 (0.7) | 3 (0.6) | 0.22 |
| Injury, poisoning and procedural complications | 0 | 2 (0.4) | 0.15 |

Treatment emergent AE of special interest (PT)

| Cardiovascular events | 2 (0.3) | 4 (0.8) | 0.30 |
| Malignancy | 8 (1.4) | 5 (1.0) | 0.37 |
| MACE | 3 (0.5) | 4 (0.8) | 0.30 |
| Injection site reaction | 0 | 2 (0.4) | 0.15 |
| Inflammatory bowel disease | 1 (0.2) | 2 (0.4) | 0.15 |

Safety set consisted of pts who received at least one dose of SEC treatment after signing the informed consentAE, adverse event; AS, ankylosing spondylitis; IR, incidence rate; MACE, major adverse cardiac events; N, total number of pts; n, number of pts; PtS, patients; PT, preferred term; SAE, serious adverse event; SEC, secukinumab

Table 1. Overall safety profile within the study period (Safety set)

References:

Figure 1. Time to treatment discontinuation of SEC in pts with PsA and AS

AS, ankylosing spondylitis; PsA, psoriatic arthritis; pts, patients; SEC, secukinumab

Objectives: We report long-term results (at least 3 years follow up) on secukinumab (SEC) retention, effectiveness and safety in pts with active PsA or AS from the SERENA study.

Methods: This analysis includes data of 524 PsA and 473 AS pts enrolled in the study and followed up for at least 3 years. Pts (aged ≥18 years) with active PsA or AS were required to have received at least 16 weeks of SEC treatment before enrolment in the study. Retention rate was defined as the percentage of pts who have not discontinued SEC treatment. Effectiveness assessments included swollen and tender joint counts (SJC and TJC) in pts with PsA, and BASDAI score in pts with AS. Safety assessments included the number of pts with any adverse events (AEs) and serious AEs, treatment-emergent AEs, AEs of special interest and their incidence rates.

Results: The mean (SD) treatment duration prior to enrolment in the study for PsA and AS pts was 1.0 (0.5) years and 0.9 (0.5) years, while time since diagnosis was 8.7 (7.4) and 9.8 (9.5) years, respectively. Prior to SEC initiation, 67.4% of pts with PsA and 63.0% of pts with AS received a biologic therapy, with lack of efficacy reported as major reason for discontinuation (PsA: 89.5%; AS: 87.6%). SEC retention rates after at least 3 years since enrolment in the study were 67.3% for pts with PsA and 72.1% for pts with AS. Survival probabilities for individual indications are presented in Figure 1. Over 3 years of observation, SEC showed sustained effectiveness in pts with PsA [SJC, mean (SD): baseline, 3.2 (5.6); Year 3, 1.7 (2.7) and TJC; baseline, 6.4 (9.4); Year 3, 4.9 (6.4) and AS [BASDAI, mean (SD): baseline, 3.2 (2.3); Year 3, 2.7 (2.2)]. No new or unexpected safety signals were reported; 11.0% of pts with PsA (N=574) and 12.9% of pts with AS (N=505) reported serious AEs (Table 1).

Conclusion: After more than 3 years of observation in the SERENA study, SEC showed sustained retention rates, indicating high persistence in a real-world setting. Responses across effectiveness assessments in both PsA and AS cohorts were maintained or improved during the 3 years of follow up in the study. SEC showed a favourable safety profile, consistent with previous reports.
Disclosure of Interests: Uta Kitzl Consultant of: AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Gilead, GSx, Grünenthal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Gilead, GSx, Grünenthal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Petsos Stikakis Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli-Lilly, Janssen, Novartis and Pfizer, Grant/ research support from: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli- Lilly, Janssen, Novartis and Pfizer, Nicola Guillick Speakers bureau: AbbVie, Astra Zeneca, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB, Consultant of: AbbVie, Astra Zeneca, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB, Grant/research support from: AbbVie, Astra Zeneca, Celgene, Eli Lilly, Izana, Janssen, Novartis, UCB, PELAGIA KATSIMPRI Speakers bureau: AbbVie, UCB, Geniesis Pharma, Janssen, Novartis and Pfizer, Consultant of: AbbVie, UCB, Geniesis Pharma, Janssen, Novartis and Pfizer, Grant/research support from: AbbVie, UCB, Geniesis Pharma, Janssen, Novartis and Pfizer, Anastasios kotrotsios: None declared, Jan Brandt-Juergens Speakers bureau: Amgen, Expanscience, Lilly and MSD, and research grants from AbbVie, Amgen, Lilly, MSD and UCB, Consultant of: Amgen, Expanscience, Lilly and MSD, and research grants from Abbvie, Amgen, Lilly, MSD and UCB, Nicola Maiden Consultant of: Eli-Lilly and UCB, Kari Gaffeey Speakers- bureau: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB, Consultant of: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB, Grant/research support from: AbbVie, Celgene, Lilly, Pfizer, Gilead, MSD, Novartis and UCB, Daniel Peterlik Employee of: Novartis, Barbara Schutz Employee of: Novartis, Efie Pournara Shareholder of: Novartis, Employee of: Novartis, Piotor jagiello Employee of: Novartis.


Table 1. Final model of the logistic regression analysis of methotrexate non-response 3 months after methotrexate initiation.

<table>
<thead>
<tr>
<th>Independent variables</th>
<th>Odds Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>1.26</td>
<td>0.61-2.60</td>
</tr>
<tr>
<td>BMI²</td>
<td>1.00</td>
<td>1.00-1.00</td>
</tr>
<tr>
<td>Clinical characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tender joint count (68)</td>
<td>3.16</td>
<td>0.94-10.57</td>
</tr>
<tr>
<td>Enthesitis (LEI/MASES)</td>
<td>0.66</td>
<td>0.47-0.94</td>
</tr>
<tr>
<td>Psoriasis (PSI)</td>
<td>1.11</td>
<td>0.99-1.25</td>
</tr>
<tr>
<td>BMI*Tender joint count (68)</td>
<td>0.95</td>
<td>0.91-1.00</td>
</tr>
</tbody>
</table>

Footnotes:Significant values in bold face 1 Root transformed

Conclusion: Our results indicate that enthesitis, depression and the combina- tion of a higher BMI with a tender joint count are all associated with MTX non-re- sponse 3 months after MTX initiation. Pain may be the common denominator preventing patients from achieving MDA.

REFERENCES:

Disclosure of Interests: None declared


1Rheumatology Department Lariboisiere Hospital, Paris University, Paris, France; 2Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands; 3Charité – Universitatsmedizin Berlin, Berlin, Germany; 4Royal National Hospital for Rheumatic Diseases, University of Bath, Bath, United Kingdom; 5Janssen-Cilag, Zug, Switzerland; 6Janssen Pharmaceutica, Beersel, Belgium; 7Janssen-Cilag, Solna, Sweden; 8Janssen-Cilag BV, Breda, Netherlands; 9Janssen Global Services, LLC, Horsham, PA, United States of America; 10Janssen-Cilag, Research & Development, LLC, San Diego, CA, United States of America; 11Department of Medical and Biological Sciences, Rheumatology Unit, University of Udine, Udine, Italy

Background: Psoriatic arthritis (PsA) is typically described by its individual domains or biomarkers.

Objectives: This post hoc analysis aimed to identify hypothesis-free phenotype clusters according to patients' clinical features and baseline (BL) characteristics with data from the Phase 3 DISCOVER-1 and -2 guselkumab (GUS) clinical trials.

Methods: Data from bio-naive patients with PsA treated with GUS 100 mg every 4 or 6 weeks in DISCOVER-1 and -2 were retrospectively analysed. Non-nega- tive matrix factorisation was used as an unsupervised machine learning tech- nique to identify clusters of PsA phenotypes, with BL characteristics and clinical observations as input features, according to which clusters were described.

Results: Data from 661 patients were pooled and 8 distinct clusters of PsA phenotypes identified (Table 1). Cluster 1 was characterised by lower limb involvement and the lowest rates of severe skin involvement (Figure 1); Clus- ter 2 by high skin involvement, the lowest proportion of women and highest proportion of overweight patients (body mass index [BMI] 25–30, 70%); and Cluster 3 by high burden of disease in the hand/wrist. In Cluster 4 all patients had dactylitis and ≥3% body surface area (BSA) psoriasis involvement and the second highest proportion of men. Cluster 5 had the highest BL enthesitis rate; large joint involvement was also common. Cluster 6 had a high level of small joint involvement in the hands/feet, but low mean dactylitis score; nail involvement and BL entheses were also common. In Cluster 7, all patients had axial involvement at BL, 49.4% had dactylitis, 69.9% had entheses and most had BSA ≥3% (Figure 1). Cluster 8 had limited joint involvement, extensive skin involvement and the highest proportion of obese patients (BMI >30, 67%).

Minimal disease activity (MDA) response rates at Week (W)24 and W52 were
Table 1. Baseline characteristics of PsA phenotype clusters.

<table>
<thead>
<tr>
<th>Cluster 1</th>
<th>Cluster 2</th>
<th>Cluster 3</th>
<th>Cluster 4</th>
<th>Cluster 5</th>
<th>Cluster 6</th>
<th>Cluster 7</th>
<th>Cluster 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feet dominant</td>
<td>Male, overweight, psoriasis burden</td>
<td>Hand dominant</td>
<td>Dactylitis dominant</td>
<td>Enthesitis and large joints</td>
<td>Enthesitis and small joints</td>
<td>Axial dominant</td>
<td>Female, obese, large joints</td>
</tr>
<tr>
<td>Randomised and treated patients, n</td>
<td>79</td>
<td>125</td>
<td>95</td>
<td>38</td>
<td>57</td>
<td>60</td>
<td>83</td>
</tr>
<tr>
<td>Age, years</td>
<td>45.8 (10.4)</td>
<td>45.8 (13.2)</td>
<td>48.9 (11.8)</td>
<td>44.8 (12.3)</td>
<td>43.6 (13.3)</td>
<td>45.8 (11.6)</td>
<td>43.8 (10.4)</td>
</tr>
<tr>
<td>Female %</td>
<td>54.4</td>
<td>20.0</td>
<td>60.0</td>
<td>26.3</td>
<td>64.9</td>
<td>41.7</td>
<td>36.1</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>29.3 (5.4)</td>
<td>27.4 (3.6)</td>
<td>29.3 (6.1)</td>
<td>29.6 (4.6)</td>
<td>28.6 (7.5)</td>
<td>29.0 (6.2)</td>
<td>28.4 (6.9)</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>1.7 (1.8)</td>
<td>1.7 (2.0)</td>
<td>1.4 (2.3)</td>
<td>1.9 (2.8)</td>
<td>1.7 (1.9)</td>
<td>1.7 (1.8)</td>
<td>2.2 (3.1)</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>5.0 (5.3)</td>
<td>5.1 (4.8)</td>
<td>5.8 (6.5)</td>
<td>6.1 (5.5)</td>
<td>6.8 (76)</td>
<td>6.1 (5.6)</td>
<td>4.7 (4.6)</td>
</tr>
<tr>
<td>SJC, 0–66</td>
<td>13.2 (7.1)</td>
<td>8.2 (3.8)</td>
<td>15.0 (8.0)</td>
<td>18.0 (10.1)</td>
<td>10.1 (5.1)</td>
<td>175.1 (11.8)</td>
<td>9.0 (4.2)</td>
</tr>
<tr>
<td>TJC, 0–68</td>
<td>23.4 (10.1)</td>
<td>12.8 (5.9)</td>
<td>26.0 (12.0)</td>
<td>30.6 (15.3)</td>
<td>23.2 (12.6)</td>
<td>375.1 (18.6)</td>
<td>14.6 (5.5)</td>
</tr>
<tr>
<td>BSA, %</td>
<td>12.6 (19.4)</td>
<td>20.7 (19.8)</td>
<td>14.8 (19.5)</td>
<td>29.7 (26.4)</td>
<td>14.6 (216)</td>
<td>14.5 (184)</td>
<td>15.2 (19.4)</td>
</tr>
<tr>
<td>Dactylitis %</td>
<td>48.1</td>
<td>30.4</td>
<td>42.1</td>
<td>100.0</td>
<td>36.8</td>
<td>53.3</td>
<td>49.4</td>
</tr>
<tr>
<td>Dactylitis score</td>
<td>3.0 (4.8)</td>
<td>1.4 (3.2)</td>
<td>2.7 (4.8)</td>
<td>275.1 (12.3)</td>
<td>2.3 (5.2)</td>
<td>3.9 (6.8)</td>
<td>2.2 (2.9)</td>
</tr>
<tr>
<td>Enthesitis %</td>
<td>70.9</td>
<td>49.6</td>
<td>58.9</td>
<td>81.6</td>
<td>96.5</td>
<td>73.3</td>
<td>69.9</td>
</tr>
<tr>
<td>LEI score</td>
<td>2.0 (1.7)</td>
<td>10.1 (13)</td>
<td>1.7 (18)</td>
<td>2.9 (19)</td>
<td>4.2 (16)</td>
<td>2.7 (23)</td>
<td>1.3 (12)</td>
</tr>
</tbody>
</table>

Data shown are mean (standard deviation) or %. Bold font indicates differentiating features of individual clusters. BMI, body mass index; BSA, body surface area; CRP, C-reactive protein; LEI, Leeds Enthesitis Index; PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count.

Disclosure of Interests: Pascal Richette Speakers bureau; Consultant of: Pascal Richette has received fees from AbbVie, Amgen, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer and UCB., Marijn Vis Speakers bureau; Consultant of: Marijn Vis has received research grants, consulting or speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB and the Dutch Arthritis Foundation., Sarah Ohrdorf Speakers bureau: Sarah Ohrdorf has received speaker fees or travel expense reimbursements from AbbVie, BMS, Janssen, Novartis and Pfizer, William Tillett Speakers bureau, Consultant of: Grant/research support from: William Tillett has received research grants, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer and UCB., Marlies Neuhold Shareholder of: Johnson & Johnson, Employee of: Janssen, Michel van Speybroeck Shareholder of: Johnson & Johnson, Employee of: Janssen, Elke Theander Shareholder of: Johnson & Johnson, Employee of: Janssen, Wim Noel Shareholder of: Johnson & Johnson, Employee of: Janssen, Alen Zabotti Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis and UCB, Grant/research support from: Novartis DOI: 10.1136/annrheumdis-2022-eular.2887

POS1056 PREDICTORS OF RISK OF ANTI-TNF TREATMENT WITHDRAWAL IN PATIENTS WITH PSORIATIC ARTHRITIS – DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

K. Lykina1, E. Koltskova2, E. Shmidt3, G. Lukina2,4, E. Zhilyaev5,6,7.

The Hospital for War Veterans N85, Rheumatology, Moscow, Russian Federation; 2Moscow Clinical Scientific Center Named After A.S.Logoinov, Rheumatology, Moscow, Russian Federation; 3City Clinical Hospital 1 Named After N.I.Pirogov, Rheumatology, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation; 5Russian Medical Academy of Continuous Professional Education, Rheumatology, Moscow, Russian Federation; 6Pirogov Russian National Research Medical University, Rheumatology, Moscow, Russian Federation; 7CJSC «European Medical Center», Rheumatology, Moscow, Russian Federation

Background: Retention on therapy is the most important integrative indicator of the success of the drug, reflecting both the effectiveness and tolerability and general acceptability of treatment. This indicator can be evaluated with high accuracy in observational trials.

Objectives: to identify predictors of TNF inhibitors withdrawal risk in patients with PSA.

Methods: Patients with (PSA) from Moscow Unified Arthritis Registry (MUAR) treated with TNF inhibitors were analyzed. All treatment episodes interrupted due to non-medical reasons were excluded from the study. Breaks in biologic therapy up to 4 months (allowed for infliximab a break in therapy up to 6 month was considered possible) The search for predictors of treatment withdrawal risk was carried out in two steps. At the first step possible predictors of the risk of TNF inhibitors therapy discontinuation were selected in univariate correlations. At the second step significant predictors of retention on TNF inhibitors therapy were selected by forward stepwise variable selection within multivariate Cox regression. The relationship between the line of anti-TNF treatment and the risk of therapy discontinuation was analyzed separately.

Results: We analyzed 371 treatment episodes in 239 patients with PSA enrolled in MUAR, 97 male (40.6%), 50.2±12.1 years old. The age of disease onset was 36.8±12.7 years. The patients received adalimumab (ADA) (101 treatment episodes), golimumab (GOL) (n=32), infliximab (INF) (n=55), certolizumab pegol (CER) (n=31), etanercept (ETA) (n=122). There were 187 (50.4%) completed treatment episodes. The relationship between risk of TNF inhibitors discontinuation and the drug line was analyzed. We found that the withdrawal risk on the second TNF inhibitor didn't significantly differ from the withdrawal risk on the first line anti-TNF drug (p=0.201). The third and subsequent lines of TNF inhibitors where associated with the significantly higher risk of withdrawal. Direct step-by-step selection of variables made possible to identify the following significant predictors of retention on therapy – social status, the presence of endometritis, psoriasis burden, coccidinia during the disease, patient reports on the association of HLA B-27, fever during the disease, pain in sacral zone at the onset of the disease, retinopathy, cataract during the disease. The risk of TNF inhibitors discontinuation was analyzed separately.

Methods: All treatment episodes interrupted due to non-medical reasons were excluded from the study. Breaks in biologic therapy up to 4 months (allowed for infliximab a break in therapy up to 6 month was considered possible) The search for predictors of treatment withdrawal risk was carried out in two steps. At the first step possible predictors of the risk of TNF inhibitors therapy discontinuation were selected in univariate correlations. At the second step significant predictors of retention on TNF inhibitors therapy were selected by forward stepwise variable selection within multivariate Cox regression. The relationship between the line of anti-TNF treatment and the risk of therapy discontinuation was analyzed separately.
Table 1. Independent predictors of anti-TNF treatment discontinuation

<table>
<thead>
<tr>
<th>Predictors</th>
<th>Direction of association with the discontinuation risk</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social status</td>
<td>Working patients had a lower risk</td>
<td>0.038</td>
</tr>
<tr>
<td>The presence of HLA-B27</td>
<td>HLA-B27 positive patients had lower risk</td>
<td>0.005</td>
</tr>
<tr>
<td>Temperature</td>
<td>Patients WHO reported an increase in body temperature</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>elevation during the disease</td>
<td>disease had an increased risk</td>
<td></td>
</tr>
<tr>
<td>Sacral pain at the onset of the disease</td>
<td>Patients who reported sacral pain at the onset of the disease had an increased risk</td>
<td>0.037</td>
</tr>
<tr>
<td>Coccygeal pain during the disease</td>
<td>Patients who reported pain in the coccyx during the disease had an increased risk</td>
<td>0.026</td>
</tr>
<tr>
<td>Presence of genital infections</td>
<td>Patients who reported a link between the onset of the disease and a history of urethritis or endometritis had a high risk</td>
<td>0.011</td>
</tr>
</tbody>
</table>

After adjusting for the line of therapy and the identified predictors of the risk of drug withdrawal it was found that retention on all analyzed TNF inhibitors in patients with PSA didn’t differ significantly (Figure 1). The presence of HLA-B27, higher body temperature during the disease, and sacral pain at the onset of the disease had a higher risk of discontinuation therapy risk of various TNF inhibitors. The risk of withdrawal therapy with the second TNF inhibitor is not significantly different between the RZB 150 mg and PBO subcutaneously at weeks 0, 4, and 16 during a 24-week, double-blind treatment period; at W28 all patients received open label RZB 150 mg. For this post hoc analysis, the RZB 150 mg and PBO groups were pooled across the 2 studies. Pain reductions (as measured by change from BL in visual analogue scale [VAS] scores) were assessed at each time point through W24 among patients with enthesitis at BL (LEI > 0 at BL) using mixed-effect model repeated measurement analysis. Additional enthesitis analyses were calculated on the data as observed.

Results: Across the pooled population, over 60% of patients in each treatment group had enthesitis at BL (RZB=444/707 [63%]; PBO=448/700 [64%]). Conversely, 37% (263/707) and 36% (252/700) had no enthesitis (LEI=0) at BL among those randomized to RZB and PBO, respectively. Among enthesitis-free patients at BL (LEI=0 at BL), 84.7% on PBO and 90% on RZB remained free of enthesitis through W24; by W52, approximately 93% of patients in both groups (RZB and PBO to RZB) remained enthesitis free. A numerically higher proportion of patients with enthesitis at BL (LEI > 0 at BL) treated with RZB (52.1%) achieved an enthesitis-free state at W24 vs PBO (41.8%); similar proportions achieved an enthesitis-free state at W36 and W52 during open label treatment (Figure 1). Among patients with enthesitis at BL, a significantly greater improvement in VAS pain scores was observed in patients treated with RZB 150 mg vs PBO, as early as W4 (P < .01) and increased through W24 (Figure 1; P < .001).

Figure 1. Adjusted analysis of treatment survival on TNF inhibitors

Disclosure of Interests: None declared

POS1057 IMPACT OF RISANKIZUMAB ON ENTHESIS AND ASSOCIATED PAIN: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPSAKE 1 AND 2 TRIALS

M. Magrey1, M. Jain2, R. Ranza3, J. Stigler4, E. Modearmon-Blondell5, C. Yue6, B. Padilla6, C. Kaufmann6, D. McGonagle5,6, University Hospitals, Rheumatology Division, Cleveland, United States of America; 4Great Lakes Clinical Trials, Rheumatology, Chicago, United States of America; 5Federal University of Uberlândia, Rheumatology Unit, Hospital das Clínicas, Uberlândia, Brazil; 6AbbVie Inc., Immunology, North Chicago, United States of America; 3University of Washington, Division of Rheumatology, Seattle, United States of America; 6University of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Background: Controlling or improving musculoskeletal disease activity of psoriatic arthritis (PsA) (e.g., enthesitis and associated pain) is a treatment priority for patients, rheumatologists, and dermatologists. Enthesitis is the cardinal lesion in PsA and is immunogenetically and experimentally linked to the interleukin-23 (IL-23) pathway. Risankizumab (RZB), a humanized immunoglobulin G1 monomeric antibody that specifically inhibits IL-23 by binding to its p19 subunit, was studied in a phase 3 adult PsA program (KEEPSAKE clinical trials). Pooled analyses from the program demonstrated the efficacy of RZB to treat enthesitis and pain associated with PsA, and increase the proportion of patients whose enthesitis resolved compared with placebo (PBO) in those patients who had an inadequate response or intolerance to ≥1 conventional synthetic disease-modifying antirheumatic drugs (KEEPSAKE 1 and 2) and/or ≤2 biological therapies (KEEPSAKE 2).

Objectives: To investigate whether patients without enthesitis at baseline (BL) (Leeds Enthesitis Index [LEI] = 0 at BL) remained enthesitis-free through week (W) 52, patients with enthesitis at BL (LEI > 0 at BL) had resolution of enthesitis through W52, and if greater pain relief was achieved with RZB 150 mg in patients with enthesitis at BL vs PBO up to W24.

Methods: The study design and primary results of KEEPSAKE 1 (NCT03675308) and KEEPSAKE 2 (NCT03671148) have been previously reported. Briefly, patients were randomized to receive RZB 150 mg or PBO subcutaneously at weeks 0, 4, and 16 during a 24-week, double-blind treatment period; at W28 all patients received open label RZB 150 mg. For this post hoc analysis, the RZB 150 mg and PBO groups were pooled across the 2 studies. Pain reductions (as measured by change from BL in visual analogue scale [VAS] scores) were assessed at each time point through W24 among patients with enthesitis at BL (LEI = 0 at BL) using mixed-effect model repeated measurement analysis. Additional enthesitis analyses were calculated on the data as observed.

Results: Across the pooled population, over 60% of patients in each treatment group had enthesitis at BL (RZB=444/707 [63%]; PBO=448/700 [64%]). Conversely, 37% (263/707) and 36% (252/700) had no enthesitis (LEI=0) at BL among those randomized to RZB and PBO, respectively. Among enthesitis-free patients at BL (LEI=0 at BL), 84.7% on PBO and 90% on RZB remained free of enthesitis through W24; by W52, approximately 93% of patients in both groups (RZB and PBO to RZB) remained enthesitis free. A numerically higher proportion of patients with enthesitis at BL (LEI > 0 at BL) treated with RZB (52.1%) achieved an enthesitis-free state at W24 vs PBO (41.8%); similar proportions achieved an enthesitis-free state at W36 and W52 during open label treatment (Figure 1). Among patients with enthesitis at BL, a significantly greater improvement in VAS pain scores was observed in patients treated with RZB 150 mg vs PBO, as early as W4 (P < .01) and increased through W24 (Figure 1; P < .001).

Figure 1. Enthesitis Resolution and Change in Pain From BL Among Patients With Enthesitis at Baseline (LEI > 0 at BL)

Conclusion: Long-term maintenance of an enthesitis-free state (LEI = 0) was similar between the RZB 150 mg and PBO groups, with approximately 93% of patients remaining free of enthesitis at W52. For LEI > 0 patients, the RZB 150-mg group had numerically more patients whose enthesis resolved at W24, and similar proportions were observed at W52 after the open label switch. Patients with enthesitis at BL treated with RZB 150 mg had statistically greater improvements in pain compared with patients taking PBO starting at W4 through to W24.

REFERENCES:

Acknowledgements: AbbVie Inc. participated in the study design; study research; collection, analysis, and interpretation of data; and writing, reviewing, and approving this abstract for submission. All authors had access to the data; participated in the development, review, and approval of the abstract; and agreed to submit this abstract to EULAR 2022 for consideration as a
Disclosure of Interests: Marina Magrey Consultant of: MM has received consulting fees from UCB, Novartis, Eli Lilly, and UCB Pharma, Marinish Lam Consultant of: ML received consulting fees from Amgen, Abbvie, Eli Lilly, Pfizer, and Novartis., R Ranza Speakers bureau: RR may hold AbbVie stock or stock options.

Background: Psoriatic arthritis (PsA) is a chronic, immune-mediated, inflammatory arthropathy, distinctively involving joints and enthesis. The improved understanding of PsA pathogenesis has enabled the development of biological disease-modifying anti-rheumatic drugs (bDMARDs) targeting specific cytokines and signalling pathways. The availability of these drugs deeply modified PsA history, by preventing disease progression and by improving quality of life. Nevertheless, bDMARDs are not effective in all the patients who may experience primary or secondary inefficacy or adverse events development.

Objectives: In a real-life scenario, we evaluated the bDMARDs retention rate in a large PsA cohort. In detail, we compared drug survival of the first and second biological drug and we investigated the presence of factors associated with the bDMARDs treatment withdrawal.

Methods: We longitudinally evaluated adult PsA patients (2016 CASPAR criteria) treated with at least one bDMARD during disease history. For each PsA patient, the clinical and laboratory data, including demographics, past medical history with the date of diagnosis and treatments, clinical disease phenotypes, were collected in a standardized, computerized and electronically filled form. The retention rate was estimated by using the Kaplan-Meier method. Predictors for bDMARDs withdrawal were investigated in univariate and multivariate Cox proportional hazards analysis, adjusted for relevant variables.

Results: The present analysis included 223 PsA patients [M/F 91/132; median age 57 years (IQR 17); median disease duration 120 months (IQR 132)]. Adalimumab and Etanercept were the most frequently prescribed bDMARDs (41.5% and 41.0%, respectively). The retention rate of the first prescribed bDMARD as reported in Figure 1A: in detail, we found a 12-months retention rate of 79.8%. The comparison between etanercept and adalimumab showed a similar 12-months retention rate, but significantly higher for etanercept at 24 months (82.4% versus 69.5%, p=0.0034, Figure 1B). Out of 223 enrolled PsA patients, 109 (48.9%) received only one bDMARDs, while the remaining 114 (51.1%) received at least 2 drugs. When comparing these two groups of patients, drug survival at 24 months was significantly higher in patients treated with one bDMARD in comparison with those treated with at least two drugs (67.7% versus 52.2%, p=0.03, Figure 1C). Finally, female sex and anxiety-depressive disorders were significantly associated with the treatment with at least two dDMARDs (p=0.005 and p=0.01, respectively).

Conclusion: The results of the present study demonstrated a higher retention rate in the first-line bDMARDs treatment in comparison with second-line. Female sex and anxiety-depressive disorders may negatively affect drug retention rate.
Results: BL data were well-balanced between main treatment groups (UST+MTX, n=86; UST+PBO, n=74) including gender (42.5% vs 40.5% female) and mean values for age (49.2 vs 47.2 years), BMI (29.4 vs 28.9 kg/m²), SJC (8 vs 8), TJC (12 vs 12), DAS28-CRP (4.6 vs 4.4), DAPSA (36.7 vs 34.9) and PASI (2.8 vs 2.4). Disease activity remained well-balanced even after dividing groups according to skin involvement (a) BSA ≤3% and (b) BSA >3% with a trend of more severe joint involvement (SJC, TJC) in BSA >3% for UST+MTX compared to UST+PBO. At week 24, relative changes in TJC (>62% vs -62%), change in DAS28 and DAPSA were equal in all treatment groups independent from skin involvement (Table 1). Differences between the groups according to skin involvement were seen for relative changes in SJC (BSA >3%: -74.8% UST+MTX vs -84.3% UST+PBO), subject global assessment (SGA), physician global assessment (PGA), DLQI and EQ5D. Highest levels for changes were detected in the UST+PBO group with high skin involvement (BSA >3%).

Conclusion: IL12/23 inhibition with UST is an effective treatment for active PsA independent of MTX use. Data from this IIT indicate that additional MTX has no positive impact on UST efficacy for arthritis, skin, HR-QoL and physical function. This independency of UST effect from MTX can also be demonstrated in patients with active skin involvement despite known efficacy of MTX for skin psoriasis.

Acknowledgements: We thank Janssen for support of the study with a research grant.


Background: Ixekizumab (IXE), an IL-17A inhibitor, has demonstrated efficacy in clinical trials but real-world effectiveness (RWE) data are limited.

Objectives: To describe changes in disease activity and patient-reported outcomes (PROs) at 6 and 12 months follow-up among psoriatic arthritis (PsA) patients initiating IXE in a routine clinical setting.

Methods: This retrospective cohort study included patients from the OM1 PsA Registry (OM1, Boston, MA), a linked electronic medical record and administra-

Table 1. Demographic and Clinical Characteristics by Therapy Status

<table>
<thead>
<tr>
<th>All Patients (N=1,812)</th>
<th>Monotherapy (N=1,495)</th>
<th>Combination Therapy (N=317)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) Mean (s.d.)</td>
<td>53.7 (12.2)</td>
<td>53.9 (12.3)</td>
</tr>
<tr>
<td>Median (Q1-Q3)</td>
<td>55 (46-62)</td>
<td>55 (46-62)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>1,108 (61.1%)</td>
<td>1,098 (61.1%)</td>
</tr>
<tr>
<td>Male</td>
<td>704 (38.9%)</td>
<td>576 (38.8%)</td>
</tr>
<tr>
<td>Charlson Comorbidity Index Mean (s.d.)</td>
<td>1.3 (1.6)</td>
<td>1.3 (1.6)</td>
</tr>
<tr>
<td>Median (Q1-Q3)</td>
<td>1 (0-2)</td>
<td>1 (0-2)</td>
</tr>
<tr>
<td>BMI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Underweight: &lt;18.5</td>
<td>10 (0.6%)</td>
<td>10 (0.7%)</td>
</tr>
<tr>
<td>Normal weight: 18.5-24.9</td>
<td>210 (12.2%)</td>
<td>172 (12.2%)</td>
</tr>
<tr>
<td>Overweight: 25-29.9</td>
<td>455 (26.5%)</td>
<td>373 (27.0%)</td>
</tr>
<tr>
<td>Obese: &gt;30</td>
<td>1,045 (60.8%)</td>
<td>845 (60.1%)</td>
</tr>
<tr>
<td>Missing</td>
<td>92</td>
<td>79</td>
</tr>
<tr>
<td>Domains of PsA: Psoriasis Yes</td>
<td>1,490 (82.2%)</td>
<td>1,222 (82.3%)</td>
</tr>
<tr>
<td>No</td>
<td>322 (17.8%)</td>
<td>263 (17.7%)</td>
</tr>
<tr>
<td>Domains of PsA: Enthesitis Yes</td>
<td>510 (28.1%)</td>
<td>409 (27.5%)</td>
</tr>
<tr>
<td>No</td>
<td>1,302 (71.9%)</td>
<td>1,076 (72.5%)</td>
</tr>
</tbody>
</table>
baseline to 6 and 12 months was assessed using mixed effects linear models adjusted for age, sex, and baseline CDAI score.

**Results:** The study population included 1,812 patients with a mean age of 53.7 years (Table 1). Psoriasis was present in 82% and enthesitis in 28%. Over 60% of patients were obese, and the mean Charlson Comorbidity Index was 1.3. Most patients (84%) had prior treatment with a biologic disease-modifying antirheumatic drug (bDMARD) and 40% with a targeted synthetic DMARD (tsDMARD). The mean number of bDMARDs and tsDMARDs used during all available prior history was 2.3 and 1.1, respectively. The most common prior bDMARDs were secukinumab (n=428, 24%) and adalimumab (n=245, 14%). Of patients with a baseline CDAI score, 61% had moderate or severe disease activity. For all patients, CDAI scores improved (decreased) by an average of 3.4 and 3.7 points at 6 and 12 months, respectively, from a baseline mean of 15.4. All disease activity measures and PROs improved from baseline to 6 and 12 months (Figure 1). In patients persistent with IXE, 35.3% and 33.7% were in CDAI remission or low disease activity at 6 and 12 months after initiation, respectively. For IXE monotherapy users (82% of patients), at baseline, patients had a mean CDAI of 14.3 (n=131) and 15.1 (n=105) for the 6 and 12 month analyses, respectively. Adjusted mean changes in CDAI from baseline to 6 months (-3.6 points, p < 0.0001) and 12 months (-4.9 points, p < 0.0001) were statistically significant.

**Conclusion:** In this cohort of PsA patients with multiple prior b/tsDMARD failures, improvements in disease activity and PROs were observed at 6 and 12 months after initiating treatment with IXE. Improvements were observed in patients overall and in the monotherapy subgroup. More real-world research on IXE and other bDMARDs are important to understand the effect of treatment choices on clinical and PROs in both bDMARD-naive and experienced PsA patients.

**REFERENCES:**


**DOI:** 10.1136/annrheumdis-2022-eular.4829

**POS1061 HYPOVITAMINOSIS D IN PSORIATIC ARTHRITIS PATIENTS: PREDICTIVE ROLE ON DRUG SURVIVAL OF METHOTREXATE MONOTHERAPY AND FIRST LINE OF B-DMARDS.**

C. Rotondo1, D. Cioci1, S. Stefania1, A. Altomare1, F. P. Cantatore1, A. Corrado1.

1University of Foggia, Department of Medical and Surgical Sciences – Rheumatology Unit, Foggia, Italy

**Background:** The immunomodulatory role of vitamin D is extensively studied enough to hypothesize a pathogenetic role in chronic arthritis and psoriasis. Few data has been published on possible interference of hypovitaminosis D on drug response in rheumatoid arthritis patients, but data in psoriatic arthritis (PsA) patients is completely lacking.
Objective: To compare drug survival and retention rate of methotrexate (MTX) and the first line of biotechnological drugs (b-DMARDs) in PsA patients with hypovitaminosis D and those with normal level of vitamin D.

Methods: We conducted a retrospective study on 250 PsA patients (age 57.3 years ± 13.2). All patients were required to fulfill the CASPAR criteria for PsA and were tested for vitamin D levels at baseline visit. Clinical characteristics, MTX and first line of b-DMARDs treatment duration and comorbidities information were recorded for each patient. The evaluations of drug survivals were realized by Kaplan-Meier estimate, followed by log-rank (Mentel-Cox) test for the comparison between the groups of patients in study. Statistical significance was set at p < 0.05.

Results: Sixty-four percent of PsA patients presented hypovitaminosis D (22.2ng/ml ± 8.8). PsA patients with hypovitaminosis D and those with normal levels were comparable for age (56.8 years ± 13 vs 58.5 years ± 12), and disease activity at baseline visit (DAS 28 VES: 4 ± 0.8 vs 3.8 ± 0.8). MTX monotherapy survival was shorter in hypovitaminosis D group (90 ± 19 weeks vs 166.8 ± 28 weeks; p=0.041), with discontinuation risk hazard ratio = 1.4 (95% CI: 1.005 – 2.014; p=0.046). The drug survival of first line of b-DMARDs was significantly shorter in patients with hypovitaminosis D (246.1 ± 40 weeks vs 302.1 ± 35 weeks; p=0.048), with discontinuation risk hazard ratio = 1.5 (95% CI: 1.1-2.4; p=0.05).

Conclusion: Vitamin D seems play an important role not only in the regulation of immune system but also in the modulation on immune response induced by drugs, as MTX or b-DMARDs. The evaluation of sera levels of vitamin D at the begging of immunomodulatory therapy could have a predictive role on treatment management in PsA patients. Further studies should be useful to detect if supplementation of vitamin D could improve the performance of immunomodulatory drugs.

Disclosure of Interests: None declared

POS1062
HARNESSING THE POWER OF MACHINE LEARNING TO PREDICT REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS ON SECUKINUMAB: IMPLEMENTATION AND VALIDATION OF A CANDIDATE ALGORITHM ON 121 PATIENTS

V. Venerito1, M. Fornaro1, F. Cacciapaglia1, S. Tangaro2, G. Lopalco1, F. Iannone1, 1University of Bari “Aldo Moro”, Rheumatology Unit-Department of Emergency and Organ Transplantations, Bari, Italy; 2National Institute of Nuclear Physics, Rheumatology Unit-Department of Emergen, Bari, Italy

Background: Although novel therapies with biotechnological agents and small molecules may lead to the complete clearing of psoriasis in the vast majority of patients, the latter drugs only allow Psoriatic Arthritis (PsA) disease control in up to 50% of patients (1). In an increasing number of clinical scenarios, learning (ML) is emerging as a tool for the implementation of multi-parametric decision algorithms. ML allows to handle complex non-linear relationships between patient attributes that are hard to model with traditional statistical methods, merging them to output a forecast or a probability for a given outcome, enabling personalized medicine (2).

Objectives: We aimed to develop a ML algorithm capable of predicting the probability of remission in PsA patients on Secukinumab to support clinicians in choosing the optimal treatment strategy.

Methods: Patients with classified PsA according to CASPAR criteria undergoing Secukinumab treatment between September 2017 and September 2020 at our tertiary Centre were retrospectively observed. Either at treatment baseline and at 12-month follow up, we retrieved demographic and clinical characteristics, including Body Mass Index (BMI), disease phenotypes, Disease Activity in PsA (DAPSA), Leeds Enthesitis Index (LEI) and Ankylosing Spondylitis Disease Activity Score (ASDAS, on C-Reactive Protein). After a ML variable selection method, based on an eXtreme Gradient Boosting (XGBoost) wrapper, an attribute core set with the least number of predictors was used for implementing n.3 ML algorithms, namely Logistic Regression (LR), Decision Trees (DT) and XGBoost. Each algorithm was trained and validated with 10-fold cross-validation. The performance of each algorithm in both phases was assessed in terms of accuracy and area under receiver operating characteristic curve (AUROC).

Results: The dataset consisted of n.121 PsA patients (62/121 female, 51.2%), with mean age (±SD) 52.9±10.1 years and mean disease duration of 5.9 ±10.4 years. Twenty-five of them (20.7%) had axial involvement whereas 88/121 (72.7%) had polyarticular involvement. Psoriasis was present in 84/121 patients (69.4%). At baseline, mean DAPSA was 14.9 ± 9.2, mean HAQ-DI 1 ± 0.7, mean LEI 0.6 ± 1, mean ASDAS 2.5 ± 0.8, mean PASI 2 ± 2.9, mean BMI 28.4 ± 4.9. Secukinumab at 300mg dose was administered to 79/121 patients (65.3%). At 12 months DAPSA remission was achieved by 24/121 patients (19.8%). Accuracy of LR, DT and XGBoost was 0.70 ± 0.11, 0.81 ± 0.07 and 0.89 ± 0.05, respectively. Consistently AUROC (Figure 1 Panels ABC) were 0.63 ± 0.2, 0.79 ± 0.2 and 0.93 ± 0.1, respectively. A sample decision tree explaining XGBoost algorithm function has been provided (Figure 1 Panel D). LEI and DAPSA at baseline were shown as the most important attributes for such algorithm (Figure 1 Panel E).

Figure 1.

Conclusion: ML can support Rheumatologists in profiling those patients more likely to respond to Secukinumab.

REFERENCES:

Disclosure of Interests: Vincenzo Venerito Speakers bureau: Abbvie, Paid instructor for: Pfizer, Lilly, Marco Fornaro: None declared, Fabio Cacciapaglia Speakers bureau: Lilly, Abbvie, BMS, Pfizer, Paid instructor for: Lilly, Sabina Tangaro: None declared, Giuseppe Lopalco Speakers bureau: SOBI NOVARTIS BMS ABBVIE, Paid instructor for: PFIZER, Florenzo Iannone Speakers bureau: Abbvie Pfizer UCB BMS Galapagos Novartis Lilly SOBI ROCHE, Paid instructor for: pfizer
Psoriatic arthritis - clinical aspects (other than treatment)

**Clarifying the geometric mean fluorescence intensities (gMFI) of pSTATs in granulocytes of PsA patients may indicate active disease and could potentially guide treatment with JAK inhibitors.**

**Objectives:** To examine the clinical and economic burden of pts with PsA with and without axial involvement and assess the relationship between pain and frequency/costs of healthcare resource utilization (HCRU).

**Methods:** This cross-sectional study was conducted using de-identified linked electronic medical record and administrative claims data from the OM1 PsA Registry, a subset of the OM1 Real-World Data Cloud (OM1, Inc, Boston, MA, US). Adults aged ≥18 years with PsA (ICD-10 codes: L40.5.x except for L40.53) were divided into two cohorts based on the presence or absence of the diagnosis code for axial involvement (ICD-10: L40.53) during 2019. Demographic and clinical characteristics between pts with and without axial involvement were compared with t-tests or Chi-square tests. Poisson regression models were used to assess the association of pain with HCRU. Mean costs per HCRU encounter (inpatient and emergency department [ED] visits) in 2019 were obtained from Optum’s de-identified Clinformatics Data Mart Database (2007-2019) and multiplied by the mean annual rate of HCRU encounters to generate per patient per year (PPP) costs.

**Results:** Of 11,531 pts with PsA, 1,116 (10%) were diagnosed as having axial involvement. The two cohorts were similar in age, Charlson comorbidity score, and biologic disease-modifying antirheumatic drug (bDMARD) use (Table 1). More pts with vs without axial involvement were commercially insured, had higher pain, and used opioids. Higher mean annual rates of inpatient (9 vs 5 per 100 pts) and ED (19 vs 14 per 100 pts) visits were seen in pts with vs without axial involvement, respectively, which translated to higher mean annual inpatient ($1,899 vs $987) and ED ($222 vs $164) visit costs PPPY (Figure 1). A 1-point higher pain score was associated with a higher likelihood of inpatient (52% vs 11%) and ED (20% vs 10%) visits (Table 1) and additional mean annual inpatient ($397 vs $116) and ED ($44 vs $16) visit costs PPPY (Figure 1) in pts with and without axial involvement, respectively.

**Table 1. Demographics, treatment utilization, and healthcare resource utilization**

<table>
<thead>
<tr>
<th>Mean (SD), unless otherwise specified</th>
<th>PsA pts without axial involvement n=10,413</th>
<th>PsA pts with axial involvement n=1,118</th>
<th>p-values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>56.7 (13.0)</td>
<td>56.8 (14.0)</td>
<td>0.9848</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>6,401 (61%)</td>
<td>653 (58%)</td>
<td>0.0494</td>
</tr>
<tr>
<td>Commercial health insurance, n (%)</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Medicare</td>
<td>110 (2%)</td>
<td>18 (3%)</td>
<td></td>
</tr>
<tr>
<td>Charlson comorbidity score</td>
<td>0.4 (1.0)</td>
<td>0.4 (1.0)</td>
<td>0.9900</td>
</tr>
<tr>
<td>Inpatient visits/100 pts</td>
<td>4.5 (2.6)*</td>
<td>4.5 (2.6)*</td>
<td>0.0022</td>
</tr>
<tr>
<td>bDMARD use, n (%)</td>
<td>4.2 (6.6)*</td>
<td>3.8 (6.6)*</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>1,618 (30%)</td>
<td>103 (18%)</td>
<td></td>
</tr>
<tr>
<td>tDMARD use, n (%)</td>
<td>0.372 (1.17)</td>
<td>0.372 (1.17)</td>
<td></td>
</tr>
<tr>
<td>Inpatient visits/100 pts</td>
<td></td>
<td>0.0034</td>
<td></td>
</tr>
<tr>
<td>Association of pain and HCRU, IRR (95% CI)</td>
<td>1.11 (1.08–1.15)*</td>
<td>1.52 (1.13–2.03)**</td>
<td></td>
</tr>
<tr>
<td>Association of pain and HCRU, IRR (95% CI)</td>
<td>1.10 (1.07–1.13)*</td>
<td>1.20 (1.05–1.38)**</td>
<td></td>
</tr>
<tr>
<td>Income, n (%)</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Charlson comorbidity score</td>
<td>0.4 (1.0)</td>
<td>0.4 (1.0)</td>
<td>0.9900</td>
</tr>
<tr>
<td>Inpatient visits/100 pts</td>
<td>4.5 (2.6)*</td>
<td>4.5 (2.6)*</td>
<td>0.0022</td>
</tr>
<tr>
<td>bDMARD use, n (%)</td>
<td>4.2 (6.6)*</td>
<td>3.8 (6.6)*</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>1,618 (30%)</td>
<td>103 (18%)</td>
<td></td>
</tr>
<tr>
<td>tDMARD use, n (%)</td>
<td>0.372 (1.17)</td>
<td>0.372 (1.17)</td>
<td></td>
</tr>
<tr>
<td>Inpatient visits/100 pts</td>
<td></td>
<td>0.0034</td>
<td></td>
</tr>
<tr>
<td>Association of pain and HCRU, IRR (95% CI)</td>
<td>1.11 (1.08–1.15)*</td>
<td>1.52 (1.13–2.03)**</td>
<td></td>
</tr>
<tr>
<td>Association of pain and HCRU, IRR (95% CI)</td>
<td>1.10 (1.07–1.13)*</td>
<td>1.20 (1.05–1.38)**</td>
<td></td>
</tr>
<tr>
<td>Income, n (%)</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Barbara Dreo: None declared, Daniel Ruben Pietsch: None declared, Rusmir Husić: None declared, S. Muralikrishnan: None declared, J. Thiel: None declared, P. Bosch: Medical University of Graz, Division of Rheumatology and Immunology, Graz, Austria; Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Medical University of Graz, Division of Immunology and Pathophysiology, Graz, Austria.

**References:**


REFERENCES:

Methods: 

tion, severity, comorbidities, and response to secukinumab (SEC) over 1-year.

Conclusion: In this pooled analysis of SEC PsA studies, pts with HU reported a higher prevalence of hypertension, with more clinical dactylitis, and more PsO, with higher PASI score compared to pts without HU. Efficacy across all musculoskeletal manifestations was similar with SEC 150 and 300 mg; while PASI90 response rate was slightly better in patients without HU with SEC 150 mg, and similar with SEC 300 mg irrespective of HU status, at 1-year.

REFERENCES:

Results: Overall, 2504 PsA pts were included in the analysis, of which 822 (32.8%) had HU (62 (2.5%) with gout; 49 (2.0%) treated with ULT). At BL, pts with HU were mostly male (76.0% vs 34.2%)and had a higher body mass index (30.9 vs 28.3 kg/m²) with more comorbidities, such as hypertension (43.8% vs 31.3%), compared to pts without HU. A higher proportion of pts with HU had dactylitis (34.5% vs 25.9%), and PsO (48.3% vs 36.3%) with a greater mean PASI score (13.6 vs 10.2), compared to pts without HU (Table 1). The proportion of pts achieving ACR80, resolution of enthesitis/dactylitis, and mean change in HAQ-DI score were comparable up to Week 52 irrespective of BL HU status. The PASI90 response rate was higher in pts without HU with SEC 150 mg (with and without load) and similar in SEC 300 mg group irrespective of BL HU status (Figure 1).

Table 1. Demographics and baseline characteristics

<table>
<thead>
<tr>
<th>Parameters</th>
<th>With hyperuricemia</th>
<th>Without hyperuricemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.5 ± 12.41</td>
<td>48.3 ± 12.19</td>
</tr>
<tr>
<td>Gender (Male), n (%)</td>
<td>625 (76.0)</td>
<td>576 (24.2)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>92.71 ± 18.62</td>
<td>79.59 ± 17.55</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>30.90 ± 5.86</td>
<td>28.33 ± 5.91</td>
</tr>
<tr>
<td>History of hypertension, n (%)</td>
<td>360 (43.8)</td>
<td>526 (31.3)</td>
</tr>
<tr>
<td>History of diabetes mellitus, n (%)</td>
<td>85 (10.3)</td>
<td>144 (8.6)</td>
</tr>
<tr>
<td>TJC</td>
<td>20.6 ± 15.02</td>
<td>21.3 ± 16.25</td>
</tr>
<tr>
<td>SJC</td>
<td>10.9 ± 9.31</td>
<td>10.8 ± 9.13</td>
</tr>
<tr>
<td>Enthesitis, n (%)</td>
<td>412 (50.1)</td>
<td>852 (50.7)</td>
</tr>
<tr>
<td>Dactylitis, n (%)</td>
<td>284 (34.5)</td>
<td>436 (25.9)</td>
</tr>
<tr>
<td>Evidence of current psoriasis, n (%)</td>
<td>397 (48.3)</td>
<td>611 (36.3)</td>
</tr>
<tr>
<td>Mean PASI score*</td>
<td>13.61 ± 11.03</td>
<td>10.16 ± 9.13</td>
</tr>
<tr>
<td>TNFi naive, n (%)</td>
<td>477 (58.0)</td>
<td>938 (55.8)</td>
</tr>
<tr>
<td>MTX use at randomization, n (%)</td>
<td>321 (39.1)</td>
<td>685 (40.7)</td>
</tr>
<tr>
<td>Serum uric acid (µmol/L)</td>
<td>420.7 ± 57.11</td>
<td>274.9 ± 51.98</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>11.6 ± 18.66</td>
<td>10.7 ± 23.36</td>
</tr>
</tbody>
</table>

*not collected in MAXMISE BMI, body mass index; CRP, C-reactive protein; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitor

Conclusion: This study assessed the impact of HU on PsA in pts with HU reported a higher prevalence of hypertension, with more clinical dactylitis, and more PsO, with higher PASI score compared to pts without HU. Efficacy across all musculoskeletal manifestations was similar with SEC 150 and 300 mg; while PASI90 response rate was slightly better in patients without HU with SEC 150 mg, and similar with SEC 300 mg irrespective of HU status, at 1-year.

REFERENCES:


Figure: Efficacy endpoints at Week 52


Figure: Efficacy endpoints at Week 52


Background: Patients (pts) with psoriatic arthritis (PsA) experience pain, fatigue, anxiety, depression, sleep disturbance, and impaired physical function that can negatively affect health-related quality of life (HRQoL). As the Patient-Re

Disclosure of Interests: Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Consultant: of AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Ana-Maria Orban Consultant of: Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Eli Lilly and Company, Celgene, Novartis, Janssen, and Horizon.

Methods: The DISCOVER-1 study evaluated 381 pts with active PsA (≥3 swollen joints and ≥3 tender joints; C-reactive protein ≥0.3 mg/dL; 31% with prior tumor necrosis factor inhibitor exposure) and inadequate response to standard therapies. The PROMIS-29 Profile contains 4 items for each of the 7 domains (physical function, role limitations - physical/role limitations - emotional, pain, fatigue, depression, anxiety, sleep disturbance, social participation, and pain interference; 28 items scored on 5-point Likert scale) and 1 pain intensity item. Using standardized scoring coefficients, PROMIS-29 PCS/MCS scores at baseline and Week 24 were calculated based on the 7 domains and pain intensity item. The validity of scores was assessed by Spearman correlation between PROMIS-29 PCS/MCS and 36-item Short-Form (SF-36) PCS/MCS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores. To evaluate the ability of the derived PROMIS-29 PCS/MCS scores to distinguish between treatments, responder analyses (employing an improvement of ≥1/2 standard deviation (SD) of baseline score) were performed between GUS and PBO at W0, W4, then every 8 weeks (Q8W) or placebo (PBO) at W24. The validity of each GUS group vs PBO was assessed at W24, which was the endpoint of the 12-week Phase 3 DISCOVER-2 trial.

Results: The DISCOVER-1 study evaluated 381 pts with active PsA (≥3 swollen joints and ≥3 tender joints; C-reactive protein ≥0.3 mg/dL; 31% with prior tumor necrosis factor inhibitor exposure) and inadequate response to standard therapies. The PROMIS-29 Profile contains 4 items for each of the 7 domains (physical function, role limitations - physical/role limitations - emotional, pain, fatigue, depression, anxiety, sleep disturbance, social participation, and pain interference; 28 items scored on 5-point Likert scale) and 1 pain intensity item. Using standardized scoring coefficients, PROMIS-29 PCS/MCS scores at baseline and Week 24 were calculated based on the 7 domains and pain intensity item. The validity of scores was assessed by Spearman correlation between PROMIS-29 PCS/MCS and 36-item Short-Form (SF-36) PCS/MCS, Health Assessment Questionnaire-Disability Index (HAQ-DI), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scores. To evaluate the ability of the derived PROMIS-29 PCS/MCS scores to distinguish between treatments, responder analyses (employing an improvement of ≥1/2 standard deviation (SD) of baseline score) were performed between GUS and PBO at W0, W4, then every 8 weeks (Q8W) or placebo (PBO) at W24. The validity of each GUS group vs PBO was assessed at W24, which was the endpoint of the 12-week Phase 3 DISCOVER-2 trial.

Table 1. Mean (SD) PCS and MCS Scores: Construct Validity

<table>
<thead>
<tr>
<th>Instruments Assessing Physical Aspects of HRQoL</th>
<th>Instruments Assessing Mental Aspects of HRQoL</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF-36 PCS</td>
<td>PROMIS-29 PCS</td>
</tr>
</tbody>
</table>

- **Baseline, N:** 381 381 381 381
- **Mean (SD):** 34.6 (8.2) 39.4 (7.2) 47.4 (10.2) 54.3 (7.7)
- **Median:** 34.4 38.2 47.8 45.1

- **Spearman’s correlation:**
  - PROMIS-29 vs SF-36: 0.76
  - Week 24, N: 380 381 380 381
  - Mean (SD): 39.6 (9.3) 43.3 (8.3) 49.7 (9.8)
  - Median: 39.3 42.2 52.3 50.0

- **Conclusion:** PROMIS-29 PCS/MCS scores calculated in DISCOVER-1 showed evidence of validity as summary scores with the ability to efficiently evaluate Pt-reported HRQoL outcome in PsA. PROMIS-29 PCS/MCS scores, similar to the commonly employed and validated SF-36 PCS/MCS scores, may reliably be used to assess physical and mental health in pts with PsA.

REFERENCES:

Table 1. Predictors of Time to Achievement and Achievement of Recalcitrant MDA Domains at Week 100 in GUS-randomized Pts (N=492)

<table>
<thead>
<tr>
<th>Time to achievement</th>
<th>Independent BL Variables</th>
<th>Pt Pain ≤15</th>
<th>PtGA ≤20</th>
<th>HAQ-DI ≤0.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>Pain VAS</td>
<td></td>
<td>0.98 (0.97-0.99)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Fatigue§</td>
<td></td>
<td>1.02 (0.98-1.06)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>FM (N=8)</td>
<td></td>
<td>0.70 (0.55-0.90)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Hazard Ratio CI: Confidence Interval OR: Odds Ratio CI: Confidence Limits
- p < 0.05
- p < 0.01
- p < 0.001
§Wald CL

Conclusion: GUS provided continuous improvement in each MDA domain through W100. BL domain score, as well as age, fatigue, and BMI, were significant determinants of MDA achievement in recalcitrant pt-driven domains (Pt Pain, PtGA, HAQ-DI). The impact of FM and mental health status merits further evaluation.

REFERENCES:

Disclosure of Interests: Laura Coates Speakers bureau: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GS, ImmunoGen, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Soumya D Chakravarty Shareholder of: Johnson & Johnson, Employee of: Janssen Scientific Affairs, LLC, Iain McInnes Shareholder of: Causeway Therapeutics, and Evelo Compugen, Consultant of: Astra Zeneca, AbbVie, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Caballeta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB, Grant/research support from: Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, GSK, Janssen, Novartis, Roche, and UCB, Lai-Shan Tam Consultant of: Janssen, Pfizer, Sanofi, AbbVie, Boehringer Ingelheim, and Lilly, Grant/research support from: Amgen, Boehringer Ingelheim, Janssen, GSK, Novartis and Pfizer

Disclosure of Interests: Tamara van Hal Speakers bureau: T.v.H. received personal fees from Eli Lilly and Novartis, non-financial support from UCB, outside the submitted work., Michelle Mulder Speakers bureau: M.M. received non-financial support from UCB, outside the submitted work., Mark Venink: None declared, Juul Van den Reek Speakers bureau: J.MPA van den Reek has received speaking fees/attended advisory boards from Abbvie, Janssen, Leo Pharma, and Amgen, financial support from EULAR for attending a symposium from Janssen, Pfizer, Celgene and Abbvie, All funding is not personal but goes to the independent research fund of the department of dermatology of Radboud University Medical Center Nijmegen, the Netherlands., E.M.G.J. de Jong Speakers bureau: EMGJ de Jong has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbvie, Janssen Pharmaceuticals, Novartis, Lilly, Celgene, Leo Pharma, UCB and Amgen., Consultant of: EMGJ de Jong has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbvie, Janssen Pharmaceuticals, Novartis, Lilly, Celgene, Leo Pharma, UCB and Amgen., Grant/research support from: EMGJ de Jong has received research grants for the independent research fund of the department of dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from Abbvie, Pfizer, Novartis, Janssen Pharmaceuticals and Leo Pharma


POS1069 COVERAGE OF THE SWEDISH RHEUMATOLOGY QUALITY REGISTER: TO WHAT DEGREE ARE B/TSDMARD TREATMENTS FOR PSORIATIC ARTHRITIS RECORDED?

1Karolinska Institutet, Clinical Epidemiology Division, Department of Medicine Solna, Stockholm, Sweden; 2Sahlgrenska Academy, University of Gothenburg, Department of Rheumatology and Inflammation Research, Gothenburg, Sweden; 3Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden; 4Umeå University, Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden

Background: In a national context, the Swedish Rheumatology Quality register (SRQ) is a major source of information on clinical data for patients treated with biological and targeted synthetic disease-modifying anti-rheumatic drug (b/tsDMARD) for rheumatic diseases. Data from SRQ are fundamental for research on drug effectiveness and safety.

Objectives: To understand to what degree patients with psoriatic arthritis (PsA) and their dispensed b/tsDMARD treatments are recorded in the SRQ.

Methods: We identified all dispensed oral or subcutaneously administered b/tsDMARDs approved for use in PsA, from the Swedish Prescribed Drug register (PDR, with 100% coverage) in 2018-2019. We required the patients who received the dispensation to have at least one ICD code for PsA (L405, M070, M071, M072, M073) as main diagnosis from a visit to a rheumatology or internal medicine (IM) unit in the National Patient Register (NPR) before dispensation, but no main diagnosis of rheumatoid arthritis (ICD code: M06, M06) (excluding M06.1 and M06.4), M12.3). Furthermore, to limit the assessment to patients with contemporary contact with the specialized rheumatology care, we also required at least one visit with a PsA main diagnosis from rheumatology/IM during 2017-2019. We then checked if the patients and their treatments were registered in SRQ. In a sensitivity analysis, we excluded patients with a visit in dermatology within 6 weeks prior to the first prescription of each b/tsDMARD, in order to exclude patients being prescribed the drug for cutaneous psoriasis.

Results: In 2018-2019, a total of 7922 unique b/tsDMARD prescriptions had been dispensed to 6311 patients with PsA, having contemporary contact with the specialized rheumatology care. Of them, 5687 patients were registered in SRQ (90.1%), of which 94.4% with a PsA diagnosis and 95.5% with at least one registration of a b/tsDMARD. The coverage of the single drugs in SRQ was between 53.5% to 93.3% of the included patients (79.4-93.3%) (Table 1). In a sensitivity analysis, among the 5290 patients without a main diagnosis of psoriasis before start of treatment, 4919 (93%) were registered in SRQ, of which 94% with a PsA diagnosis and 96% with at least one registration of a b/tsDMARD.

Table 1. Coverage of the single b/tsDMARD approved for use in PsA patients in the SRQ as compared to the prescribed drug register, 2018-2019

<table>
<thead>
<tr>
<th>ATC</th>
<th>Drug</th>
<th>Total patients in PDR</th>
<th>Patients with the same drug in SRQ</th>
<th>Percentage only considering patients included in SRQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>L04AB01</td>
<td>Etanercept</td>
<td>2753</td>
<td>2348</td>
<td>85.3%</td>
</tr>
<tr>
<td>L04AB04</td>
<td>Adalimumab</td>
<td>2436</td>
<td>1933</td>
<td>79.4%</td>
</tr>
<tr>
<td>L04AB05</td>
<td>Certolizumab pegol</td>
<td>243</td>
<td>213</td>
<td>87.7%</td>
</tr>
<tr>
<td>L04AB06</td>
<td>Golimumab</td>
<td>418</td>
<td>390</td>
<td>93.3%</td>
</tr>
<tr>
<td>L04AA24</td>
<td>Abatacept</td>
<td>94</td>
<td>73</td>
<td>77.7%</td>
</tr>
<tr>
<td>L04AA32</td>
<td>Apremilast</td>
<td>547</td>
<td>294</td>
<td>53.7%</td>
</tr>
<tr>
<td>L04AC10</td>
<td>Secukinumab</td>
<td>833</td>
<td>656</td>
<td>78.8%</td>
</tr>
<tr>
<td>L04AC13</td>
<td>Ixekizumab</td>
<td>118</td>
<td>71</td>
<td>60.2%</td>
</tr>
<tr>
<td>L04AC05</td>
<td>Ustekinumab</td>
<td>219</td>
<td>138</td>
<td>63%</td>
</tr>
<tr>
<td>L04AA29</td>
<td>Tofacitinib</td>
<td>261</td>
<td>194</td>
<td>74.3%</td>
</tr>
</tbody>
</table>

Conclusion: The coverage of b/tsDMARD-treated PsA patients in SRQ as compared to the PDR in Sweden is ranging between 90 and 93%, and SRQ is performing well in the registration of the single drugs, especially for TNFi. These results suggest that research studies based on data from the SRQ are representative of the Swedish b/tsDMARD-treated PsA population.

Disclosure of Interests: Daniela Di Giuseppe: None declared, Ulf Lindström: None declared, Johan K Wallman Consultant of: Abbvie, Amgen, Celgene, Eli Lilly, Novartis, Grant/research support from: Abbvie, Amgen, Eli Lilly, Novartis, Pfizer, Lotta Ljung: None declared, Johan Asking Grant/research support from: Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB


POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB

P. Nash1, C. T. Ritchlin2, P. Rahmann3, M. Shawi4, E. Rampaakakis5, L. Webb, J. A. S. Pires6, A. Kolmene7, X. L. Xu8, J. Sherlock9,10, D. Cua1, S. Khatri11, E. Soriano12, D. McGonagle13,14, Griffith University and University of Queensland, Rheumatology Research Unit, Maroochydore, Australia; 2University of Rochester Medical Center, Department of Medicine - Allergy/Immunology and Rheumatology, Rochester, United States of America; 3Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, Discipline of Medicine, Division of Rheumatology, St. John’s, Canada; 4Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; 5McGill University, Department of Pediatrics, Montreal, Canada; 6JSS Medical Research, Inc, Scientific Affairs, Montreal, Canada; 7Janssen Asia Pacific, Immunology Medical Affairs, Seoul, Korea, Rep. of (South Korea); 8Janssen Research & Development, LLC, Immunology, San Diego, United States of America; 9Janssen Research & Development, LLC, Immunology Spring House, United States of America; 10University of Oxford, Immunology, Oxford, United Kingdom; 11Icahn School of Medicine at Mount Sinai, Dermatology, New York, United States of America; 12Hospital Italiano de Buenos Aires, Rheumatology, Buenos Aires, Argentina; 13University of Leeds, Leeds Biomedical Research Centre, Leeds, United Kingdom

Background: Pain in patients (pts) with psoriatic arthritis (PsA) has multifaceted origins; sustained improvement is difficult to achieve.1 Gusekumab (GUS), a fully human monoclonal antibody that selectively inhibits IL-23, is effective in treating multiple domains of PsA including joint, skin, and enthesal symptoms, and also elicits long-lasting improvements in pt-reported pain in the DISCOVER-1&2 trials of pts with active PsA.2

Objectives: These post hoc analyses were conducted to identify determinants of changes in pt-reported pain in PsA pts using pooled data through 1 year of DISCOVER-1&2 trials of pts with active PsA.2

Methods: Enrolled adult pts had active PsA despite standard therapies. DISCOVER-1 pts had ≥3 swollen and ≥3 tender joints and C-reactive protein (CRP) ≥0.3 mg/dL; DISCOVER-2 pts had ≥5 swollen and ≥5 tender joints and CRP ≥0.6 mg/dL. 31% of DISCOVER-1 pts received 1-2 prior tumor necrosis factor inhibitors; DISCOVER-2 pts were biologic-naïve. Pts were randomized 1:1:1 to GUS 100 mg every 4 weeks (wks) (Q4W); GUS 100 mg at W0, W4, then every 8 weeks (wks) (wks) (Q8W)
Results: GUS was associated with significantly greater improvement in pain compared to PBO as early as 2 wks post-treatment; there was a significant interaction between treatment group and time, with effect of GUS on pain continuously enhancing through W24. Higher baseline (BL) pain score, worse mental health (assessed with the Short-Form-36 Mental Component Summary [SF-36 MCS] score), and lower fatigue level and lower tender joint count (TJC) were also associated with significantly greater pain improvements at W24, while background use of NSAIDs was a negative predictor of pain improvement (Table 1). Continuous significant improvement from BL in pain with GUS extended through W52 even after adjustment for the identified determinants of pain improvement through W24 (Figure 1). At W52, predictors of change in pain remained significant with the exception of SF-36 MCS score (Table 1). Results did not exclude a small number of enrolled pts with fibromyalgia (FM; \text{n}_{\text{GUS}}=8; \text{n}_{\text{PBO}}=4). According to these exploratory findings, medical history of FM was associated with lower improvement over 24 wks; the model was then tested separately in pts with FM and with GUS (W24 and W52). Treatment effect on pain was independent of PsA duration, gender, PsA sub-type, prior TNF exposure, BL skin disease, and BL swollen joint count (SJC). Continuous significant improvement from BL in pain with GUS extended through W52 even after adjustment for the identified determinants of pain improvement through W24 (Figure 1). At W52, predictors of change in pain remained significant with the exception of SF-36 MCS score (Table 1). Results did not exclude a small number of enrolled pts with fibromyalgia (FM; \text{n}_{\text{GUS}}=8; \text{n}_{\text{PBO}}=4). According to these exploratory findings, medical history of FM was associated with lower improvement over 24 wks; the model was then tested separately in pts with FM and with GUS (W24 and W52). Treatment effect on pain was independent of PsA duration, gender, PsA sub-type, prior TNF exposure, BL skin disease, and BL swollen joint count (SJC). Continuous significant improvement from BL in pain with GUS extended through W52 even after adjustment for the identified determinants of pain improvement through W24 (Figure 1). At W52, predictors of change in pain remained significant with the exception of SF-36 MCS score (Table 1). Results did not exclude a small number of enrolled pts with fibromyalgia (FM; \text{n}_{\text{GUS}}=8; \text{n}_{\text{PBO}}=4). According to these exploratory findings, medical history of FM was associated with lower improvement over 24 wks; the model was then tested separately in pts with FM and with GUS (W24 and W52). Treatment effect on pain was independent of PsA duration, gender, PsA sub-type, prior TNF exposure, BL skin disease, and BL swollen joint count (SJC).

### Table 1. Significant Predictors of Change in Pain (W24 and W52)

<table>
<thead>
<tr>
<th>BL Determinant</th>
<th>W24 Estimate (95% CL)</th>
<th>W52 Estimate (95% CL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain score</td>
<td>-0.62 (-0.69 to -0.55)†</td>
<td>-0.75 (-0.83 to -0.67)†</td>
</tr>
<tr>
<td>Fatigue</td>
<td>-0.38 (-0.50 to -0.27)†</td>
<td>-0.37 (-0.53 to -0.25)†</td>
</tr>
<tr>
<td>SF-36 MCS</td>
<td>0.20 (0.11 to 0.30)‡</td>
<td>0.11 (-0.02 to 0.24)</td>
</tr>
<tr>
<td>TJC</td>
<td>0.13 (0.06 to 0.19)‡</td>
<td>0.12 (0.04 to 0.21)‡</td>
</tr>
<tr>
<td>NSAID use (Y vs N)</td>
<td>2.29 (0.62 to 3.96)‡</td>
<td>2.76 (0.55 to 4.98)‡</td>
</tr>
</tbody>
</table>

* p <0.05; †p <0.01; ‡p ≤0.0001

(-25.9, -3.6) comparable to non-FM pts at W24, while pain improvement in pts with no FM was -22.2 (-24.0, -20.4).

### Conclusion:
Early significant effects of GUS on pain were enhanced through 1 year. Significant predictors of change in pain were consistent at W24 and W52, while the exception of the dependent health measurement at W24. The impact of mental status on pt-reported pain and the potential for GUS to improve pain in pts with FM warrants further consideration.

### REFERENCES:

Disclosure of Interests: Peter Nash Grant/research support from: Janssen, Abbvie, Pfizer, Novartis, Lilly, Gilead, Roche, Sandoz, Celgene, Sun, Boehringer, and Bristol Myers Squibb, Christopher T. Ritchlin Consultant of: UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, Janssen, Grant/research support from: UCB Pharma, AbbVie, Amgen, Proton Rahman Consultant of: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, May Shawi Shareholder of: Johnson & Johnson, Employee of: Janssen Pharmaceutical Companies of Johnson & Johnson, Emmanouil Rampakakis Consultant of: Janssen, Employee of: JSS Medical Research, YoungLa Lee Shareholder of: Johnson & Johnson, Employee of: Janssen Asia Pacific, Alexia Kolmierer Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Xie L Xu Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Jonathan Sherlock Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Daniel Cua Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Saakshi Khatrit Speakers bureau: AbbVie, Eli Lilly, Glenmark, Ichnos Sciences, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Eli Lilly, Glenmark, Ichnos Sciences, Janssen, Novartis, Pfizer, and UCB, Enrique Soriano Speakers bureau: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, Roche, and Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Dennis McGonagle Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB.

### Disclosure of Interests:
- J. De Jongh, R. Hemikse, G. C. J. Zweemerijnen, M. Yaqub, i. Van der Horst-Bruinsma, M. G. H. Van de Sande, A. Van Kuijk, I. Buttink, L. Burgemeister, N. A. Van Dillen, A. Voskuyl, C. J. Van der Laken, Amsterdam UMC, location VUmc, Rheumatology & Clinical Immunology, Amsterdam, Netherlands;
- Amsterdam UMC, location AMC, Radiology & Nuclear Medicine, Amsterdam, Netherlands;
- Amsterdam UMC, location AMC, Rheumatology, Amsterdam, Netherlands;
- Radboud University Medical Center, Rheumatology, Nijmegen, Netherlands;
- Amsterdam UMC, location AMC, Rheumatology & Clinical Immunology, Amsterdam, Netherlands;
- Reade, Rheumatology, Amsterdam, Netherlands.

### Background:
Psoriatic arthritis (PsA) can present with peripheral (i.e. arthralgia, enthesitis, dactylitis) and/or axial (spondyloarthritis) manifestations. Positron Emission Tomography (PET) may be a promising imaging technique for detection of whole body disease activity since it combines quantification and picomolar sensitivity for accurate depiction of pathologic processes with anatomical low dose CT imaging as a reference (3, 4). It was recently demonstrated that [18F]Fluoride PET-CT scans can successfully visualize and monitor ankylosing spondylitis disease activity by imaging of bone formation in the cervical spine (5). Since bone formation is associated with enthesitis and synovitis in PsA, [18F]Fluoride may enable sensitive, whole body detection of disease activity in PsA.

### Objectives:
To investigate the feasibility of [18F]Fluoride PET-CT to visualize disease activity of PsA by imaging of bone formation at axial and peripheral sites in PsA patients.

### Methods:
Sixteen patients (female 10/16, age 50.6 ±9.8 years) with PsA fulfilling CASPAR criteria and clinically active disease including ≥1 clinically active enthesitis site were included. Clinical disease activity was assessed with anatomical low dose CT imaging as a reference (3, 4). It was recently demonstrated that [18F]Fluoride PET-CT scans can successfully visualize and monitor ankylosing spondylitis disease activity by imaging of bone formation in the cervical spine (5). Since bone formation is associated with enthesitis and synovitis in PsA, [18F]Fluoride may enable sensitive, whole body detection of disease activity in PsA.

### Results:
Out of 1088 evaluated joints, 109 joints showed PET enhancement, most frequently in the interphalangeal- and metatarsal joints of the feet (14/109, 12.9%) (Figure 1A) and the distal interphalangeal joints of the hands (14/109, 12.9%). Out of 416 evaluated enthesial sites, PET positivity was found at 44 sites, mainly located at the patella tendon insertion (11/44, 25%) (Figure 1B) and the quadriceps tendon insertion (10/44, 22.7%). Of the PET positive joints and enthesial sites, mainly located at the patella tendon insertion (11/44, 25%) (Figure 1B) and the quadriceps tendon insertion (10/44, 22.7%). Of the PET positive joints and enthesal sites, respectively 81.1% and 70.5% were not associated with tender or swollen joints and clinical enthesitis, respectively. In 11 out of the 16 patients ≥1 axial PET positive lesion was observed (Figure 1C), most frequently located in the cervical spine (19/49 observed axial lesions, 38.8%). Two patients showed PET enhancement in one sacro-iliac joint (SIJ) without any inflammatory back pain (IBP). Only four out of 15 patients reported IBP and missing data for 1 patient. In two patients clinical dactylitis was observed which was also depicted on PET-CT.

### DOI:
10.1136/annrheumdis-2022-eular.1158
Conclusion: [18F]Fluoride PET-CT scans can visualize disease activity at whole body musculoskeletal manifestations of PsA by demonstrating local bone formation at active sites. [18F]Fluoride PET-CT adds information to clinical disease activity, reflected by a high number of clinically negative, PET positive sites on top of concordant findings.

REFERENCES:

Disclosure of Interests: We thank Pfizer and Novartis for financial support of this investigator initiated study.

Disclosure of Interests: Jerney de Jongh: None declared, Robert Hemke: None declared, Gerben C.J. Zwervergen: None declared, Maqsood Yaqub: None declared, Irene van der Horst-Bruinsma Speakers bureau: BMS, Abbvie, Pfizer, MSD, Consultant of: Abbvie, UCB, MSD, Novartis, Eli Lilly, Grant/research support from: Unrestricted Grants received for investigator initiated studies from MSD, Pfizer, Abbvie, UCB, Marleen G.H. van de Sande Speakers bureau: UCB, Consultant of: Advisory board Abbvie, Eli Lilly, Novartis, UCB, Consultant/research support from: Novartis, Janssen, UCB, Eli Lilly, Arno Van Kuijk Speakers bureau: Novartis, Consultant of: Novartis, Abbvie, Janssen, Irene Buttink Speakers bureau: Eli Lilly, MSD, Amgen, UCB, GSK, Roche, Sanofi Genzyme (outside the submitted work), Consultant of: Sanofi Genzyme, Astrazeneca (outside the submitted work), Lot Burgemeister Consultant of: Advisory board Novartis, Galapagos, Nancy M.A. van Dillen: None declared, Alexandre Voskuyl: None declared, Conny J. van der Laken: None declared


POS1073 INCREASED NUMBER OF COMORBIDITIES AND CARDIOVASCULAR RISK FACTORS IN EARLY PSORIATIC ARTHRITIS PATIENTS SUGGESTS AN INTRINSIC DISEASE IMPACT

A. Ischenko1,2, S. Pazmino1, K. De Vlam1, P. Loriers1,2, University Hospitals Leuven, Department of Rheumatology, Leuven, Belgium; 2Ziekenhuis Netwerk Antwerpen, Department of Rheumatology, Antwerpen, Belgium; 3KU Leuven, Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, Leuven, Belgium

Background: Metabolic and cardiovascular comorbidities in psoriatic arthritis (PsA) are seen as a consequence of long-lasting inflammation. Patients with PsA and PsA develop metabolic and cardiovascular comorbidities over the course of time. PsA patients have a higher burden of comorbidities and cardiovascular risk factors (CV RF) compared to those with other forms of arthritis. Despite a lower grade of systemic inflammation as measured by CRP, the nature of this increased prevalence in PsA is not fully understood. We hypothesize that the risks may be intrinsic to the disease, and be already present in early stages.

Objectives: The aim of this study was to investigate the prevalence of comorbidities and CV RF in treatment-naive Early PsA (EPA) as compared to sex- and age-matched healthy volunteers and to study factors contributing to the metabolic burden of the patients.

Methods: Clinical, demographic characteristics, cardiovascular risk factors and comorbidities of newly diagnosed treatment-naive adult patients with PsA compared to sex- and age-matched controls were studied in an observational prospective longitudinal multicentre study.

Results: Sixty-seven EPA patients were matched to 61 healthy volunteers. At diagnosis, 73% of EPA had oligoarticular and 22% polyarticular disease. Majority had mild PASI scores (median PASI 1.2). The median duration of skin psoriasis before the onset of PsA was 11.4 years. Symptom duration at onset of PsA was 0.6 years.

Disclosure of Interests: None declared

EPsA showed a significantly higher rate of obesity (40.3% vs 18.3% in controls, p=0.011). PsA patients had significantly higher rates of dyslipidemia and metabolic syndrome than controls. Rate of insulin resistance, arterial hypertension, depression, COPD, and gout were similar in EPsA and in controls. The overall number of comorbidities was comparable in EPsA and healthy controls, but strikingly 82% of EPsA patients had CV RF already present at baseline as compared to 38% of the controls (p=0.017). More than half of EPsA patients had multiple ≥2 comorbidities and CV RF at baseline as compared to controls (33%) (Figure 1). Overall rate of cardiovascular morbidity and Charlson comorbidity index were low, but were significantly higher in the PsA group (p=0.007 and <0.001 accordingly). Duration of skin psoriasis had no effect on comorbidities or CV RF in EPsA.

In multiple regression analysis diagnosis of PsA was the strongly associated with the number of comorbidities and CV RF after adjusting for age, sex and BMI.

Conclusion: Our data imply that PsA patients have higher comorbidities and cardiovascular burden at early stages of the disease. Rates of dyslipidemia, metabolic syndrome and obesity are significantly higher in the early PsA population. Presence of metabolic and lipid disturbances at early stages of the disease might suggest a bidirectional relationship and potentially playing role as initial triggers of PsA.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Variables in the predictions of the random forest for MDA according to the SHAP method.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Importance according to SHAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global pain</td>
<td>0.069</td>
</tr>
<tr>
<td>PsAID</td>
<td>0.064</td>
</tr>
<tr>
<td>Patient global assessment of disease</td>
<td>0.047</td>
</tr>
<tr>
<td>HQA</td>
<td>0.044</td>
</tr>
<tr>
<td>Articular pattern at diagnosis</td>
<td>0.029</td>
</tr>
<tr>
<td>Physician global assessment of disease</td>
<td>0.023</td>
</tr>
<tr>
<td>Tendon joint count</td>
<td>0.019</td>
</tr>
<tr>
<td>Sex</td>
<td>0.009</td>
</tr>
<tr>
<td>Weekly alcohol consumption</td>
<td>0.009</td>
</tr>
</tbody>
</table>

¹Mean of the SHAP values for each value of the variable. MDA: minimal disease activity.
Conclusion: A key objective in the management of PsA should be control of pain, which is not always associated with inflammatory burden, and the establishment of measures to better control the various domains of PsA.

REFERENCES:

Acknowledgements: The authors would like to acknowledge José Luis Fernández Sueiro for the conception of the study; José Miguel Carrasco for his contribution to data analysis; and Thomas O’Boyle for the translation of the manuscript.

Disclosure of Interests: None declared


Figure 1. SHAP summary graph.

Table 1. Sociodemographic and clinical baseline characteristics (assessment I)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>With PsA diagnosis (n=35)</th>
<th>Without PsA diagnosis (n=226)</th>
<th>Not assessable (n=7)</th>
<th>Total (n=268)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>50.5 (10.0)</td>
<td>46.5 (12.9)</td>
<td>49.9 (11.2)</td>
<td>47.1 (12.6)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>14 (40.0%)</td>
<td>97 (42.9%)</td>
<td>4 (12.1%)</td>
<td>115 (42.9%)</td>
</tr>
<tr>
<td>Years since diagnosis, mean (SD)</td>
<td>19.7 (14.2)</td>
<td>18.3 (12.8)</td>
<td>22.4 (9.0)</td>
<td>18.6 (12.9)</td>
</tr>
<tr>
<td>Current treatment for psoriasis, n (%)</td>
<td>32 (91.4%)</td>
<td>199 (88.1%)</td>
<td>7 (100.0%)</td>
<td>238 (88.8%)</td>
</tr>
<tr>
<td>Phototherapy, n (%)</td>
<td>5 (15.6%)</td>
<td>16 (7.0%)</td>
<td>0 (0.0%)</td>
<td>21 (8.8%)</td>
</tr>
<tr>
<td>Topic treatment, n (%)</td>
<td>20 (62.5%)</td>
<td>66 (33.2%)</td>
<td>3 (42.9%)</td>
<td>89 (34.7%)</td>
</tr>
<tr>
<td>Conventional systemic biological treatment, n (%)</td>
<td>7 (21.9%)</td>
<td>40 (20.1%)</td>
<td>2 (28.6%)</td>
<td>49 (20.6%)</td>
</tr>
<tr>
<td>Biological treatment, n (%)</td>
<td>8 (25.0%)</td>
<td>91 (45.7%)</td>
<td>4 (57.1%)</td>
<td>103 (43.3%)</td>
</tr>
<tr>
<td>Phosphodiesterase-4 inhibitors, n (%)</td>
<td>0 (0.0%)</td>
<td>8 (4.0%)</td>
<td>0 (0.0%)</td>
<td>8 (3.8%)</td>
</tr>
<tr>
<td>Others, n (%)</td>
<td>0 (0.0%)</td>
<td>3 (1.5%)</td>
<td>0 (0.0%)</td>
<td>3 (1.3%)</td>
</tr>
<tr>
<td>PASI, mean (SD)</td>
<td>8.7 (5.5)</td>
<td>70 (5.0)</td>
<td>4.2 (3.1)</td>
<td>72 (5.1)</td>
</tr>
<tr>
<td>Mid (PASI&lt;7), n (%)</td>
<td>11 (31.4%)</td>
<td>86 (42.0%)</td>
<td>5 (71.4%)</td>
<td>111 (41.4%)</td>
</tr>
<tr>
<td>Moderate/severe (PASI≥7), n (%)</td>
<td>24 (68.6%)</td>
<td>131 (58.0%)</td>
<td>2 (28.6%)</td>
<td>157 (58.6%)</td>
</tr>
</tbody>
</table>

Table 2. SHAP summary graph.

Conclusion: PURE-4 is a valid and compliant questionnaire with clinical practice in dermatology. It could be answered by patients in the waiting room and reviewed by dermatologists during the visit to support decision-making. PURE-4 could also help rheumatologists to early diagnose PsA patients in clinical practice.

REFERENCES:

Acknowledgements: The authors thank IQVIA and Carmen Barrull, Neus Canal and Marco Pinel for providing medical editorial assistance with this presentation.

Disclosure of Interests: Rubén Queiro Silva Speakers bureau: AbbVie, MSD, Pfizer, Novartis, Lilly, Janssen, UCB y Celgene., Consultant of: AbbVie, MSD, Pfizer, Novartis, Lilly, Janssen, UCB y Celgene., Grant/research support from: Novartis, AbbVie y Janssen., Isabel Belinchón Speakers bureau: Janssen Pharmaceuticals Inc., Almirall, Lilly, AbbVie, Novartis, Celgene, Biogen Ameon, Leo-Pharma, Pfizer-Wyeth, UCB y MSD., Consultant of: Janssen Pharmaceuticals Inc., Almirall, Lilly, AbbVie, Novartis, Celgene,
OBJECTIVE: Obesity is a risk factor for psoriatic arthritis (PsA) and is associated with higher disease activity [1].

OBJECTIVES: We aimed to evaluate whether obese patients with PsA were less likely to achieve remission/low disease in a real-life multi-centre cohort.

METHODS: We used data from the ReFlap study (NCT03119805) [2], which recruited consecutive adult patient with definite PsA for more than 2 years of disease duration from 14 countries. We collected demographic characteristics, self-reported height and weight, clinical data and patient reported outcomes. Remission/low disease was defined as Disease Activity in Psoriatic Arthritis (DAPSA) ≤ 4, or Minimal disease activity (MDA). Obesity was defined as body mass index (BMI) ≥ 30 kg/m². We compared patient characteristics, disease activity parameters and impact scores between patients with obesity versus non-obese. A multivariable regression model was performed for demographic variables associated with reaching each definition of remission/low disease, adjusted on age, sex, level of education, disease duration, current use of conventional (c-) and biological (b-) disease modifying anti-rheumatic drugs (DMARDs).

RESULTS: Among 414 patients (49.3% women, mean disease duration 11.0±8.2 years), 119 (28.7%) had BMI ≥ 30kg/m² (obese). Obese patients were more likely to be female, had higher swollen joint and enthesitis counts, higher self-reported pain, poorer physical function, more fatigue and poorer mental health (Table 1). Obese patients were half as likely to achieve MDA or DAPSA remission in multivariable analysis with odds ratios of 0.6 (95% confidence interval, CI: 0.3, 0.8, p=0.049) and 0.4 (95% CI: 0.2, 0.8, p=0.012), respectively for obese compared to non-obese patients (Figure 1).

Table 1. Patient characteristics and remission achievement between obese and non-obese patients with psoriatic arthritis

<table>
<thead>
<tr>
<th></th>
<th>Non-obese</th>
<th>BMI ≥ 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=295)</td>
<td>(n=119)</td>
<td>p</td>
</tr>
<tr>
<td>Female, %</td>
<td>44.3</td>
<td>61.5</td>
</tr>
<tr>
<td>Number of comorbidities</td>
<td>1.61 (0.93)</td>
<td>2.83 (2.01)</td>
</tr>
<tr>
<td>Tender joints, 0-68</td>
<td>3.56 (2.71)</td>
<td>5.75 (10.0)</td>
</tr>
<tr>
<td>Swollen joints, 0-66</td>
<td>2.29 (2.96)</td>
<td>1.46 (3.29)</td>
</tr>
<tr>
<td>HAQ-DI, 0-2</td>
<td>0.48 (1.23)</td>
<td>0.86 (1.70)</td>
</tr>
<tr>
<td>PGA disease activity, 0-10</td>
<td>3.90 (2.73)</td>
<td>4.76 (2.67)</td>
</tr>
<tr>
<td>HAQ-DI, 0-2</td>
<td>14.9 (15.5)</td>
<td>18.3 (16.1)</td>
</tr>
<tr>
<td>PGA disease activity, 0-10</td>
<td>0.56 (0.65)</td>
<td>0.89 (0.70)</td>
</tr>
<tr>
<td>PGA disease activity, 0-10</td>
<td>3.31 (2.36)</td>
<td>3.62 (2.50)</td>
</tr>
<tr>
<td>fatigue, 0-10</td>
<td>3.93 (3.01)</td>
<td>4.86 (3.17)</td>
</tr>
<tr>
<td>functional capacity, 0-10</td>
<td>3.36 (2.97)</td>
<td>4.40 (1.16)</td>
</tr>
<tr>
<td>depression, 0-10</td>
<td>1.88 (2.70)</td>
<td>2.73 (3.26)</td>
</tr>
</tbody>
</table>

Mean (SD) shown unless specified otherwise. HAQ-DI: Health Assessment Questionnaire Disability Index; PGA: patient global assessment of disease activity; DAPSA: Disease Activity in Psoriatic Arthritis; PsAID: Psoriatic Arthritis Impact of Disease.

Conclusion: In this real-life data from 14 countries, obesity was frequent and PsA patients with BMI ≥ 30kg/m² were more likely to be female, and had higher subjectively reported disease activity and illness impact compared to those with lower BMI. Obese patients had a two-fold lower likelihood of achieving remission/low disease defined by both MDA and DAPSA compared to non-obese patients. PsA patients with comorbid obesity may have different disease profiles from non-obese patients, and require specific management.

REFERENCES:

Figure 1. Rates of remission for patients with BMI ≥ 30 kg/m² versus non-obese

*PsAID: BMI bodymass index; DAPSA: Disease Activity in Psoriatic Arthritis; MDA: Minimal Disease Activity

Acknowledgements: This study was funded by Pfizer.

Disclose of Interests: None declared


POS1077 LARGE JOINT INVOLVEMENT AND SUBSTANTIAL DISEASE BURDEN IN PATIENTS WITH OLIGOARTICULAR AND POLYARTICULAR PSORIATIC ARTHRITIS IN THE MULTINATIONAL UPLIFT SURVEY

W. Tilley1, A. Ogdie2, P. Richette1, A. B. Gottlieb1, S. Jardón1, S. Richter1, A. Flower1, J. Merola1, 1University of Bath, Department of Pharmacy
Background: Patients (pts) with oligoarticular psoriatic arthritis (PsA) report quality-of-life impairment similar to polyarticular PsA pts despite less joint involvement. In the 2020 Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) survey, we evaluated other aspects of disease burden in pts with oligoarticular (≤4 joints) and polyarticular (>4 joints) PsA.

Objectives: To explore joint involvement distribution and relative disease burden in pts with self-reported healthcare provider (HCP)—diagnosed PsA who self-identified with oligoarticular vs polyarticular joint involvement.

Methods: UPLIFT was a multinational Web-based survey in adults who reported an HCP diagnosis of PsA and/or psoriasis. This analysis evaluated demographics, disease characteristics, joint distribution, and quality-of-life measures in pts with PsA or without psoriasis with self-identified oligoarticular vs polyarticular joint involvement. Small joint classification includes foot/toes, hands/fingers, and thumbs; intermediate joints includes wrists, elbows, and ankles; and large joint involvement. Common areas of joint involvement were the knees, elbows, and ankles; and large joints includes should, hips, and knees.

Results: Of the 1256 pts with PsA completing the survey, 44% had oligoarticular PsA and 56% polyarticular PsA. The polyarticular PsA group had higher mean age, fewer males, and more pts with body mass index ≥25 kg/m² (Table 1). Prevalence of depression, hypertension, and diabetes was generally similar between groups (Table 1). In pts with oligoarticular and polyarticular PsA, respectively, involvement of large joints was most prevalent (83%, 91%), followed by intermediate (46%, 87%) and small (20%, 76%) joints. Axial involvement was less prevalent in pts with oligoarticular (30%) vs polyarticular (67%) PsA. Common areas of joint involvement were the knees, elbows, and shoulders for oligoarticular PsA pts and the knees, hands, and elbows for polyarticular PsA pts (Figure 1). Involvement in the hands, wrists, thumbs, and ankles was proportionately greater in polyarticular pts vs oligoarticular pts. Dactylitis, enthesitis, and nail disease, respectively, were each present in approximately one third of oligoarticular PsA pts and more than half of polyarticular PsA pts. Mean Patient Assessment of PsA Severity, Health Assessment Questionnaire (HAQ)-8, and Psoriatic Arthritis Impact of Disease 12-item (PSAID-12) scores indicated similar disease burden between the two groups (Table 1). In both groups, >70% reported an unacceptable PsA symptom state (PSAID >4), and >60% had Patient Health Questionnaire 2-item (PHQ-2) score ≥3, consistent with positive screening for depression (Table 1).

Table 1. Demographics and Patient Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Oligoarticular PsA (n=550)</th>
<th>Polyarticular PsA (n=706)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>39.5 (15.23)</td>
<td>45.6 (14.89)</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>327 (60)</td>
<td>347 (49)</td>
</tr>
<tr>
<td>Body mass index ≥25 kg/m² (overweight/obese), n (%)</td>
<td>164 (30)</td>
<td>292 (41)</td>
</tr>
<tr>
<td>PsA duration, mean (SD), y</td>
<td>11.1 (10.44)</td>
<td>13.8 (11.40)</td>
</tr>
<tr>
<td>PsA treatment use, n (%)</td>
<td>231 (44)</td>
<td>217 (31)</td>
</tr>
<tr>
<td>Prior injectable/ intravenous</td>
<td>177 (34)</td>
<td>169 (24)</td>
</tr>
<tr>
<td>Current injectable/ intravenous</td>
<td>185 (35)</td>
<td>364 (53)</td>
</tr>
<tr>
<td>Current injectable/ intravenous</td>
<td>154 (29)</td>
<td>246 (36)</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>230 (42)</td>
<td>302 (43)</td>
</tr>
<tr>
<td>Depression</td>
<td>214 (39)</td>
<td>291 (41)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>201 (37)</td>
<td>236 (33)</td>
</tr>
<tr>
<td>Skin or non-skin cancer</td>
<td>202 (36)</td>
<td>168 (24)</td>
</tr>
<tr>
<td>Heart disease</td>
<td>149 (27)</td>
<td>123 (17)</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>156 (28)</td>
<td>142 (20)</td>
</tr>
<tr>
<td>Liver disease</td>
<td>99 (19)</td>
<td>108 (15)</td>
</tr>
<tr>
<td>Patient Assessment of PsA Severity, mean, (SD)</td>
<td>5.0 (2.92)</td>
<td>5.7 (2.53)</td>
</tr>
<tr>
<td>HAQ-8, mean, (SD)</td>
<td>0.9 (0.65)</td>
<td>0.8 (0.64)</td>
</tr>
<tr>
<td>PSAID-12, mean, (SD)</td>
<td>5.3 (2.54)</td>
<td>5.6 (2.42)</td>
</tr>
<tr>
<td>PSAID-4, n (%)</td>
<td>389 (71)</td>
<td>533 (76)</td>
</tr>
<tr>
<td>PHQ-2 ≥3, n (%)</td>
<td>383 (70)</td>
<td>452 (64)</td>
</tr>
</tbody>
</table>

*n=525 with oligoarticular PsA; n=691 with polyarticular PsA.

Conclusion: In the UPLIFT survey, almost half of pts with PsA self-identified with oligoarticular PsA. Both oligoarticular and polyarticular PsA groups experienced similar levels of disease burden, including a high prevalence of an unacceptable PsA symptom state and a PHQ-2 score ≥3, indicative of a positive screen for depression.

Acknowledgements: The authors gratefully acknowledge Hsiuan Lin Wu for data analysis. This study was funded by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Kristin Carlin, BSPharm, MBA, of Peloton Advantage, LLC, an OPEN Health company, and Cathryn M. Carter, MS, employee of and stockholder in Amgen Inc.

Disclosures of Interests: William Tillett Speakers bureau: AbbVie, Amgen Inc., Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen Inc., Celgene, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Celgene, Eli Lilly, and Janssen, Alexis Ogdie Consultant of: AbbVie, Amgen Inc., Bristol Myers Squibb, Celgene, CoreVita’s Psoriatic Arthritis/Spondyloarthritis Registry (formerly Corona), Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen Inc., Novartis, and Pfizer, Pascal Richette Speakers bureau: AbbVie, Amgen Inc., Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Alice B Gottlieb Consultant of: AnaptysBio, Avoset Therapeutics, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, LEO Pharma, Eli Lilly, Novartis, Sun, UCB, and Xbiotech, Grant/research support from: Boehringer Ingelheim, Janssen, Novartis, Sun, UCB, and Xbiotech, Shauna Jardon Secondary Shareholder of: Stock ownership in Amgen Inc, Employee of: Employee of Amgen Inc, Sven Richter Shareholder of: Stock ownership in Amgen at time of study, Employee of: Employment of Amgen at time of study, Andrea Flower Employee of: Employment by ProUnlimited, under contract for Amgen Inc., Joseph Merola Consultant of: AbbVie, Arena, Avoset, Biogen, Bristol Myers Squibb, Deramavant, Eli Lilly, EMD, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Sanofi, Serono, Sun, and UCB


POS1078

COMPARISON OF PATIENTS WITH AXIAL PSA AND PATIENTS WITH AXSPA AND CONCOMITANT PSORIASIS


Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the peripheral and axial musculoskeletal system as well as skin and nails. Diagnostic criteria of axial PsA (axPsA) are well defined. Treatment strategy is mostly based on evidence generated for axial spondyloarthritis (axSpA), as only rare clinical trial data for axPsA exist. However, it is still unclear whether axSpA with concomitant psoriasis (axSpA/pso) is the same as axPsA.

Objectives: To compare axPsA patients with axial manifestations with axSpA patients with concomitant psoriasis.

Methods: RABBIT-Spa is a prospective longitudinal cohort study including PsA and axSpA patients enrolled at start of a new conventional treatment or bi/td-MARD treatment. Two definitions of axSpA were used: Clinical definition: documentation of axial manifestation as diagnosed by a rheumatologist

Radiographic definition: presence of sacroiliitis according to modified NY criteria (mNYC).

axSpA patients were stratified into axPsA/pso (with psoriasis either in patient history or present) and axSpA.
Results: Psoriasis was documented in 182/1407 axSpA patients (13%). Of 1355 PsA patients, 295 (22%) fulfilled the clinical definition of axSpA. Using the radiographic definition, 127 (9%) PsA patients fulfilled mNVC, 230 (17%) did not fulfill mNVC and 988 (74%) did not undergo radiographic evaluation. AxSpA/pso patients differed from axSpA regardless of the definition (Table 1). axPsA patients were older, less often HLA-B27 positive, and peripheral manifestations were much more often present in axPsA than in axSpA/pso. Uveitis and inflammatory bowel disease were more common in axSpA/pso.

Table 1. Baseline characteristics of axSpA/pso patients and clinical resp. radiographic defined axPsA.

<table>
<thead>
<tr>
<th>Feature</th>
<th>axSpA/pso</th>
<th>axPsA/clin</th>
<th>axPsA/rad</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>182</td>
<td>295</td>
<td>127</td>
</tr>
<tr>
<td>female gender, n (%)</td>
<td>80 (44)</td>
<td>178 (60.3)</td>
<td>80 (63)</td>
</tr>
<tr>
<td>age, mean (SD)</td>
<td>47 (12.8)</td>
<td>51.1 (11.3)</td>
<td>51.6 (11.4)</td>
</tr>
<tr>
<td>HLA-B27 positive, n (%)</td>
<td>106 (67.1)</td>
<td>44 (22.7)</td>
<td>28 (32.9)</td>
</tr>
<tr>
<td>CRP mg/l, mean (SD)</td>
<td>8.7 (14.6)</td>
<td>7.1 (11.8)</td>
<td>6.9 (11.5)</td>
</tr>
<tr>
<td>CRP ≥10mg/l, n (%)</td>
<td>70 (42.4)</td>
<td>106 (40)</td>
<td>50 (45.9)</td>
</tr>
<tr>
<td>uveitis ever, n (%)</td>
<td>26 (14.3)</td>
<td>10 (3.4)</td>
<td>7 (6.5)</td>
</tr>
<tr>
<td>IBD ever, n (%)</td>
<td>13 (7.1)</td>
<td>14 (4.7)</td>
<td>7 (5.5)</td>
</tr>
<tr>
<td>≥3 comorbidities, n (%)</td>
<td>48 (26.4)</td>
<td>117 (39.7)</td>
<td>48 (37.8)</td>
</tr>
<tr>
<td>peripheral manifestations, n (%)</td>
<td>65 (36.3)</td>
<td>251 (85.1)</td>
<td>109 (85.8)</td>
</tr>
<tr>
<td>enthesitis, n (%)</td>
<td>29 (16.2)</td>
<td>77 (26.4)</td>
<td>32 (25.4)</td>
</tr>
<tr>
<td>number of sites with enthesitis, mean (SD)</td>
<td>0.5 (1.6)</td>
<td>0.9 (2.2)</td>
<td>0.9 (1.9)</td>
</tr>
<tr>
<td>affected joints, n (%)</td>
<td>53 (29.6)</td>
<td>234 (80.1)</td>
<td>102 (80.3)</td>
</tr>
<tr>
<td>number of affected joints, mean (SD)</td>
<td>1.4 (3.7)</td>
<td>6.8 (8.4)</td>
<td>5 (5.9)</td>
</tr>
<tr>
<td>physician global disease activity, mean (SD)</td>
<td>5.6 (2.1)</td>
<td>5.6 (1.9)</td>
<td>5.6 (2)</td>
</tr>
<tr>
<td>patient global disease activity, mean (SD)</td>
<td>5.4 (2.6)</td>
<td>5.9 (2.3)</td>
<td>5.8 (2.2)</td>
</tr>
<tr>
<td>patient pain, mean (SD)</td>
<td>5.4 (2.6)</td>
<td>5.7 (2.3)</td>
<td>5.7 (2.2)</td>
</tr>
<tr>
<td>sakrotitis, n (%)</td>
<td>124 (64.4)</td>
<td>97 (56.1)</td>
<td>127 (100)</td>
</tr>
</tbody>
</table>

In contrast, disease activity measured by physician global as well as patient pain, mean (SD) 5.5 (2.6) 5.7 (2.3) 5.7 (2.2)

Conclusion: Regardless whether clinical or radiographic definitions of axSpA were used, differences to axSpA/pso patients were identified. These data indicate a need for a specific diagnostic, and a potentially more targeted treatment approach for axSpA.

Disclosure of Interests: Anne Regnier Grant/research support from: RABBIT-SPA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Anja Weiß Grant/research support from: RABBIT -SPA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Haisson-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Xenofon Baraliakos: None declared, Frank Behrens: Grant/research support from: AbbVie, Amgen, Biogen, Hexal, Haisson-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris.

REFERENCES:

METHODS: A SLR explored MEDLINE, EMBASE and CENTRAL, up to 22 October 2021. The objective was to identify the symptoms, objective signs, lab tests, imaging features and other characteristics of patients later diagnosed as “new onset” PsA in two key populations: 1) patients with PsO and 2) patients with early undifferentiated arthritis (UA). Studies of adult patients published in English were included, if they reported characteristics of pre-PsA or new onset PsA patients, and data were extracted by 2 readers. Meta-analysis was not done due to data heterogeneity (PsA classification criteria, outcome measures and length of observation). Results are reported semi-quantitatively.

Results: Of 31449 references, 22 studies were included of which 12 were prospective; 7 retrospective and 3 cross-sectional. Eighteen studies reported on patients with PsO (n=95828) later diagnosed as PsA (n=2136) with a mean duration of follow up of 5.2 (±3.9) years. Seven out of 18 (38.8%) studies were informative regarding the clinical features of the new onset PsA. Four studies on early UA patients (n=492) later diagnosed as PsA (n=49) were included. Progression to PsA was associated with the presence of musculoskeletal (MSK) complaints (mainly joint tenderness) and the presence of subclinical MSK inflammation detected by imaging. Peripheral oligo-arthritis was the prevalent clinical presentation of new onset PsA.

Conclusion: As expected, joint pain and imaging evidence of MSK inflammation were associated with PsA development in PsO patients. The SLR highlights the lack of robust evidence regarding data associated with the development of PsA. More prospective studies focusing on transition from PsO to PsA are needed.

Table 1. Transition from PsO to PsA in two key populations: 1) patients with PsO and 2) patients with early undifferentiated arthritis (UA).

<table>
<thead>
<tr>
<th>Features</th>
<th>Transition from PsO to PsA (n = 18)</th>
<th>Transition from UA to PsO (n = 4)</th>
<th>Clinical characterization of New Onset PsA (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient reported</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>symptoms</td>
<td>++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Enthesal pain</td>
<td>++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>HAQ more compromised</td>
<td>++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>+++</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Clinical examination</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joint tenderness</td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Swelling joints</td>
<td>++</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>Major domain of pattern</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>presentation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polyarthritus</td>
<td></td>
<td>+++</td>
<td></td>
</tr>
<tr>
<td>(more frequent)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammatory marker(s)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Imaging</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MSK inflammation detected by imaging</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Legend: PsO = psoriasis (affecting skin); PsA = psoriatic arthritis; UA = undifferentiated inflammatory arthritis; VAS = visual-analogue scale; NA = not applicable; HAQ = health assessment questionnaire; CRP = C-reactive protein; MSK = musculoskeletal + 1 study for positive association; + 2 studies for positive association; +++ >= 3 studies for positive association.

REFERENCES:
Oligoarticular psoriatic arthritis (PsA) is commonly reported in early disease. Although fewer joints are involved, there may be significant impact on patients’ (pts) quality of life. The ongoing FOREMOST study (NCT03747939) is investigating the efficacy of apremilast vs placebo for treatment of early oligoarticular PsA (<1 but ≤5 tender and swollen joints involved).

Objectives: To characterize disease burden in pts with early oligoarticular PsA and disease phenotype including location and size of involved joints and presence of certain baseline clinical PsA manifestations in FOREMOST pts.

Methods: Baseline swollen and tender joint distribution was analyzed. Baseline disease burden was assessed in the overall group and a subgroup with small joint involvement only (or context) using clinical disease activity measures, pt-reported outcomes, and additional PsA manifestations.

Results: At data cut-off for analysis, 220 pts of 285 planned were enrolled. In the overall group, disease duration was <1 year and joint distribution for swollen or tender joints involved predominantly small joints, with ~48% of joint involvement observed in finger proximal interphalangeal (PIP) joints and <2% in temporomandibular and clavicular joints across swollen or tender joints (Figure 1). Mean Physician’s and Patient Global Assessment of Disease Activity (PhGA and PtGA, respectively) scores were 43.9 and 51.3; mean pt pain assessment score was 50.7. Mean Health Assessment Questionnaire Disability Index (HAQ-DI) functional assessment score was 1.0; 25.5% of pts had HAQ-DI ≤0.5. Pts reported outcomes, and additional PsA manifestations.

Conclusion: In FOREMOST, despite few joints involved, pts with early oligoarticular PsA experienced high disease burden and impaired quality of life. Small joint involvement, although less commonly expected in oligoarticular PsA, was the most frequently observed pattern.
Methods: Serum MPO-DNA complex was detected by a modified enzyme-linked immunosorbent assay (ELISA) and compared among 74 patients with PsA, 58 patients with psoriasis (PsO) and 20 healthy controls. The association of MPO-DNA level with disease activity index at baseline and follow-up was analyzed in PsA patients. Receiver operating characteristic curve was used to evaluate the predictive value of MPO-DNA for treatment response.

Results: MPO-DNA complex level in serum was significantly increased in PsA/PsO patients compared to healthy controls (p < 0.001). The level of MPO-DNA was positively associated with DAPSA score and its components (including TJC, SJC, PGA, EGA, VAS-pain and CRP; r = 0.26-0.409, all p-value < 0.05). Serum MPO-DNA level was downregulated at 12-week after treatment compared to baseline (p = 0.022). The decrease of MPO-DNA level was more dramatic in PsA patients who achieved both ACR50 and PASI50 response than those achieving neither of them at 12 weeks (p = 0.023). ROC analysis revealed that the serum MPO-DNA level predicted both ACR50 and PASI50 achievement at week 12 (p = 0.003, 95% CIs 0.748-1) and change of MPO-DNA at week 12 from baseline (p = 0.04, 95% CIs 0.56-0.94). Moreover, the baseline MPO-DNA level (p = 0.009, 95% CIs 0.748-1) and change of MPO-DNA of MPO-DNA at week 12 from baseline (p = 0.004, 95% CIs 0.802-1) were associated with the achievement of both ACR70 and PASI75 response.

Conclusion: NETosis plays an important role in psoriatic diseases. The level of MPO-DNA complex in serum reflects disease activity. Serum MPO-DNA complex may be a useful biomarker to predict the therapeutic response in PsA.

Table 1. Treatment response and changes of serum MPO-DNA of 29 PsA patients.

<table>
<thead>
<tr>
<th>Items</th>
<th>Baseline</th>
<th>12 weeks</th>
<th>24weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>TJC, median (IQR)</td>
<td>3(7)</td>
<td>3(4)</td>
<td>2(3.5)</td>
</tr>
<tr>
<td>SJC, median (IQR)</td>
<td>2(5)</td>
<td>2(2)</td>
<td>1(3)</td>
</tr>
<tr>
<td>ESR, median (IQR) mm/h</td>
<td>13(15)</td>
<td>8(10)</td>
<td>10(14)</td>
</tr>
<tr>
<td>CRP, median (mg/L)</td>
<td>3(10.2)</td>
<td>2.6(3.72)</td>
<td>2.3(3.8)</td>
</tr>
<tr>
<td>PGA, median (IQR)</td>
<td>40(30)</td>
<td>20(30)</td>
<td>12(15)</td>
</tr>
<tr>
<td>EGA, median (IQR)</td>
<td>30(20)</td>
<td>20(10)</td>
<td>6(10)</td>
</tr>
<tr>
<td>VAS, median (IQR)</td>
<td>2(5)</td>
<td>2(3)</td>
<td>1(3.5)</td>
</tr>
<tr>
<td>SJC, PGA, EGA, VAS-pain, median (IQR)</td>
<td>2(5)</td>
<td>2(3)</td>
<td>1(3.5)</td>
</tr>
<tr>
<td>MPO-DNA, median (IQR)</td>
<td>0.4(0.6)</td>
<td>0.2(0.32)</td>
<td>0.2(0.3)</td>
</tr>
<tr>
<td>Minimal disease activity, n (%)</td>
<td>4(13.7%)</td>
<td>6(20.6%)</td>
<td>2(6.9%)</td>
</tr>
<tr>
<td>ACR50, n (%)</td>
<td>13(44.8%)</td>
<td>15(51.7%)</td>
<td>5(17.2%)</td>
</tr>
<tr>
<td>PASI50, n (%)</td>
<td>14(48.2%)</td>
<td>17(58.6%)</td>
<td>13(44.8%)</td>
</tr>
<tr>
<td>ACR70, n (%)</td>
<td>4(13.7%)</td>
<td>7(24.1%)</td>
<td>4(13.7%)</td>
</tr>
<tr>
<td>PASI75, n (%)</td>
<td>11(37.9%)</td>
<td>14(48.2%)</td>
<td>13(44.8%)</td>
</tr>
</tbody>
</table>

Figure 1. ROC curves for predictions of treatment achievements at 12 and 24 weeks.

Disclosure of Interests: None declared


POS1082

CHARACTERISTICS OF PSORIATIC ARTHRITIS (PSA) PATIENTS WITH ENTHESITIS. DATA FROM RUSSIAN PSA REGISTRY (RU-PSART).

E. Loginova1, T. Korotaeva1, E. Gubard1, Y. Korsakova1, S. Glukhova2, E. Nasonov3, V. Sorotskaya4, I. Patrikeeva5, P. Shchesteryna6, I. Shchendrigin7.

1V.A. Nasonova Research Institute of Rheumatology, Spondyloarthrits and Psoriatic Arthritis, Moscow, Russian Federation; 2A.V. Nasonova Research Institute of Rheumatology, Medical and Social Problems in Rheumatology, Moscow, Russian Federation; 3Medical Institute of the Tula State University, Rheumatology, Tula, Russian Federation; 4Tver Regional Clinical Hospital №1, Rheumatology, Tver, Russian Federation; 5Krasnoyarsk State Medical University V.F. Voino-Yasnetsoy, Rheumatology, Krasnoyarsk, Russian Federation; 6Center of Responsible Rheumatology “Induktsia”, Rheumatology, Stavropol, Russian Federation

Background: Psoriatic arthritis (PsA) is a disease with multidomain clinical presentation such as arthritis, enthesitis, dactylitis, spondylitis and psoriasis (PsO). [1]. Enthesitis is a key clinical feature of PsA with significant impact on function, quality of life and choice of treatment. [2]. There are limited real-world studies on the characteristics of patients (pts) with PsA and enthesitis.

Objectives: To compare clinical characteristics of PsA pts with and without enthesitis.

Methods: 603 pts (M/F=278/326) with PsA according to CASPAR criteria were examined. Data was collected from 6 rheumatology clinics of the Russian Federation. Pts' mean age 46.6±12.5 years (yrs.), PsA duration 9.7±7.1 yrs, PsO duration 20.4±13.0 yrs. Median (Me) DAPSA 25.5 [15.2; 41.8], body mass index (BMI) 27.5 [24.3; 31.2]. At baseline (BL) PsA activity by tender/swelling joint count (TJC)/68, (SJC)/66, enthesitis by LEI and plantar fascia, BSA (%), PASI, HAQ, DAPSA were evaluated. DAPSA=28 indicate high disease activity (HDA). The one-factor model of logistic regression was used to identify a group of features that are associated with presence of enthesitis. AUC=0.72, 95% CI of 0.66-0.78.

Results: Enthesitis was found in 295 out of 603 pts (49%). Comparative analysis in both groups with and without enthesitis and one-factor model of logistic regression showed the following features at BL were associated with enthesitis: TJC>5 (p=0.001), SJC>5 (p=0.001), dactylitis (p=0.001), high disease activity by DAPSA (p=0.001), HAQ>0.5 (p=0.001), BSA>10% (p=0.001), nail PsO (p=0.003), CRP>10 mg/l (p=0.018), BMI>30 kg/m² (p=0.02). Pts with enthesitis had significantly more often depression (p=0.026), metabolic syndrome (p=0.047), fatty hepatitis (p=0.017). OR analysis with CI 95% for all parameters are shown on Figure 1.

Conclusion: In real clinical practice enthesitis was found in half of PsA pts. Enthesitis are associated with more severe peripheral arthritis, dactylitis, skin and nail PsO, higher PsA activity by DAPSA, worse quality of life and more likely to have depression, metabolic syndrome and fatty hepatitis. This should be considered for optimizing disease management strategy.

REFERENCES:

Acknowledgements: The RU-PSART study group

Disclosure of Interests: Elena Loginova Speakers bureau: Janssen, Tatiana Korotaeva Speakers bureau: Pfizer, Novartis, MSD, AbbVie, Janssen, JSC BIOCAD, UCB, Lilly and Novartis-Sandoz, Consultant of: Pfizer, Novartis, MSD, AbbVie, Janssen, JSC BIOCAD, UCB, Lilly and Novartis-Sandoz, ELENA GUBAR: None declared, Yulia Korsakova Speakers bureau: Novartis, Svetlana Glukhova: None declared, Valentina Sorotskaya: None declared, Evgeny Nasonov: None declared, Valentina Sorotskaya: None declared, Irina Patrikeeva: None declared, Pavel Shesternya: None declared, Ivan Shchendrigin: None declared.

RESEARCH ARTICLE

**Background:** Changes in the integrity of the intestinal wall may be implicated in the gut-joint axis of inflammatory arthritis. Yet, the gut barrier is only poorly evaluated in psoriatic arthritis (PsA).1,2

**Objectives:** In this exploratory study, we evaluated intestinal permeability before and 26 weeks after one faecal microbiota transplantation (FMT) or sham intervention in adults with PsA.

**Methods:** We have previously reported the clinical results of a 26-week, double-blind, parallel-group, 1:1 randomised, sham-controlled, superiority trial of faecal microbiota transplantation (FMT) as an add-on treatment to methotrexate in 31 adults with active peripheral PsA (FLORA trial, NCT03058900). The primary efficacy endpoint was the proportion of participants who experienced treatment failure through 26 weeks, defined as need for more than one intra-articular glucocorticoid injection and/or anti-TNFα inhibition. We encouraged patients not to take nonsteroidal anti-inflammatory drugs during the trial. The FMT material was obtained from one of four healthy blood donors. As part of the trial, we performed a lactulose and mannitol test (L:M test) at baseline (n=31) and at the final 26-week visit (n=26) to assess the permeability of the intestinal wall (higher L:M ratios indicate higher permeability). After an overnight fasting, patients provided a urine sample before ingesting 10 g of lactulose and 5 g of D-mannitol. Samples were collected after 3 hours and stored at −80°C until analysis. No food or drinking (except for water) was allowed during the test. We measured the lactulose-to-mannitol ratio in the urine samples using a Waters Acquity UPLC system coupled to a high-resolution mass spectrometer Waters Xevo G2 QTOF (Waters Corp., Milford, MA, USA). Masslynx software (Waters Corporation) was used for data acquisition and visual inspection. We used StataSE 14 to perform the Wilcoxon rank sum and the matched-pairs signed-rank test. Data is presented as median and range. The level of significance was set to 0.05.

**Results:** At baseline, no significant difference was observed in the L:M ratio between donors (n=4) and patients (n=31) (0.0065 [0.00-0.063] vs 0.014 [0.0-0.28]; p=0.50). The L:M ratio increased from baseline to week 26 in both the FMT group (0.0020 [-0.27 – 0.32] and the sham group (0.0046 [-0.012 – 0.088]), but only in the sham group did the baseline L:M ratio significantly differ from the one measured at week 26 (p=0.022 FMT) and p=0.032 (sham). The patients who were classified as treatment failures during the trial (n=7) had a significantly higher L:M ratio at week 26 compared to the patients who were non-failures (n=19) (0.027 [0.017 – 0.33]) vs 0.012 [0.0 – 0.064], p=0.01), please see Figure 1.

**Conclusion:** In the FLORA trial, intestinal permeability evaluated by the L:M test did not differ significantly between donors and patients at baseline. Whether higher intestinal permeability observed in patients classified as treatment failures compared to non-failures at week 26 can be attributed to differences in disease activity and/or the instigation of additional immunosuppression in the failure group during the trial needs further investigation.

**References:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2635

---

**Figure 1.** Clinical categories of Skindex-17 psychosocial and symptoms scores of patients with DAPSA-LDA and active psoriasis (PASI>1) one year after diagnosis (n=116)

**Conclusion:** In daily clinical practice approximately half of PsA patients who reached musculoskeletal low disease activity (DAPSA-LDA) one year after their diagnosis has not reached psoriasis remission. The majority of these patients has a good HRQoL. However, a proportion of them still experiences considerable skin burden. We therefore recommend rheumatologists to always assess and treat psoriasis in order to reduce skin burden, even in PsA patients who achieved musculoskeletal low disease activity.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2635
Background: Dyslipidemia is the leading treatable-modifiable factor among comorbidities in Psoriatic arthritis (PsA) patients. International treatment recommendations have left the management of dyslipidemia to national guidelines and especially to the rheumatologists.

Objectives: In this study, we aimed to determine the frequency of dyslipidemia and the rates of initiation of treatment within the indication in PsA patients using bDMARDs.

Methods: The Hacettepe University biological database (HUR-BIO), was established in 2005 and data of 520 PsA patients included until 2021 were analyzed. In all included patients, the diagnosis of PsA was made by rheumatologists. Lipid profiles of PsA patients were evaluated at diagnosis, during the first bDMARD initiation, and at the last visit. Total cholesterol (TC), Triglycerides (TG), HDL-C and LDL-C values were grouped as optimal, borderline, or high.

Results: Lipid profile values of PsA patients were known at diagnosis (n=159, 30.6%), in the initial bDMARD baseline (n=161, 30.9%), and at the last visit (n=203, 39.0%). The time to diagnosis of PsA and first bDMARD use was 2.8 years, and the time between the start of bDMARD and the last visit was 3.7 years. Accordingly, the rates of high TC, borderline TG, and high LDL increased over time. Rates at the time of PsA diagnosis, first bDMARD onset and at the last visit are as follows: high TC (14.3%, 17.1% and 28.0%), borderline TG (20.4%, 27.7% and 40.5%) and high LDL (17.0, 24.0% and 27.9%). On the other hand, low HDL-C slightly improved in men (33.3%, 29.4% and 23.1%), but did not show a significant change in women. While LDL-C level was >160 in 24.0% of patients who were started on bDMARD, anti-hyperlipidemic drug was started in only 6.2% of them. A similar situation persisted at the last visit (27.9% had LDL-C levels >160, but 10.8% received anti-hyperlipidemic society criteria (1).

Conclusion: Among the modifiable risk factors for cardiovascular comorbidities in PsA patients, the leading risk factor is dyslipidemia. On the other hand, dyslipidemic drug use rates in daily practice are significantly lower. Although attention is paid to the management of comorbidities in all recommendations, there is still work to be done in real life.

Disclosure of Interests: None declared


POS1085 FREQUENCY OF DYSLIPIDEMIA AND COMPLIANCE WITH THE TREATMENT IN PSA PATIENTS USING BDMA RDS

N. E. Gezerer1, G. Ayan2, E. Bilgin2, G. K. Yarımcı2, E. C. Bolek2, B. FarisogluHar1, E. Duran2, Z. Özyüz2, G. Sandal Uzun2, M. Erci2, E. Unalı3, L. Kılıç, A. Akdogan2, O. Karadag2, Ş. A. Bilgen2, S. Kızar2, A. I. Ertendi2, U. Kalyoncu1, *Hacettepe University Medical Faculty, Department of Internal Medicine, Ankara, Turkey; 1Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey

Table 1. Lipid levels and changes over time

<table>
<thead>
<tr>
<th>Lipid levels</th>
<th>At the time of diagnosis n=159</th>
<th>At the time of bDMARD initiation n=161</th>
<th>bDMARD last visit n=203</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol (TC) mean (SD)</td>
<td>195 (42)</td>
<td>201 (42)</td>
<td>214 (47)</td>
</tr>
<tr>
<td>- TC &lt; 200 (optimal) (%)</td>
<td>56.5</td>
<td>52.8</td>
<td>45.3</td>
</tr>
<tr>
<td>- TC 200-239 (borderline) (%)</td>
<td>272</td>
<td>30.1</td>
<td>25.7</td>
</tr>
<tr>
<td>- TC &gt; 240 (high) (%)</td>
<td>14.3</td>
<td>17.1</td>
<td>28.0</td>
</tr>
<tr>
<td>Triglyceride (TG) mean (SD)</td>
<td>115 (52)</td>
<td>132 (90)</td>
<td>158 (103)</td>
</tr>
<tr>
<td>- TG &lt; 150 (optimal) (%)</td>
<td>79.6</td>
<td>71.7</td>
<td>58.0</td>
</tr>
<tr>
<td>- TG 150-499 (borderline) (%)</td>
<td>20.4</td>
<td>27.7</td>
<td>40.5</td>
</tr>
<tr>
<td>- TG 500-880 (high) (%)</td>
<td>0</td>
<td>0</td>
<td>10</td>
</tr>
<tr>
<td>- TG ≥ 880 (severely high) (%)</td>
<td>0</td>
<td>0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>HDL-C mean (SD)</td>
<td>51.8 (13.1)</td>
<td>50.6 (13.0)</td>
<td>53.2 (12.5)</td>
</tr>
<tr>
<td>- ≥60 (optimal) (%)</td>
<td>20.6</td>
<td>20.4</td>
<td>25.6</td>
</tr>
<tr>
<td>- 40-59 (borderline) (%)</td>
<td>45.6</td>
<td>60.8</td>
<td>52.3</td>
</tr>
<tr>
<td>- 50-59 (borderline) in men (%)</td>
<td>32.3</td>
<td>24.5</td>
<td>30.3</td>
</tr>
<tr>
<td>- Male &lt; 40 (low) (%)</td>
<td>33.3</td>
<td>29.4</td>
<td>23.1</td>
</tr>
<tr>
<td>- Women ≤ 50 (low) (%)</td>
<td>32.3</td>
<td>39.6</td>
<td>33.8</td>
</tr>
<tr>
<td>LDL-C mean (SD)</td>
<td>126 (33)</td>
<td>132 (37)</td>
<td>139 (36)</td>
</tr>
<tr>
<td>- LDL-C &lt; 100 (optimal) (%)</td>
<td>21.4</td>
<td>21.1</td>
<td>14.2</td>
</tr>
<tr>
<td>- LDL 100-139 (borderline) (%)</td>
<td>22.5</td>
<td>25.1</td>
<td>27.0</td>
</tr>
<tr>
<td>- LDL &gt; 160 (high) (%)</td>
<td>170</td>
<td>24.0</td>
<td>27.9</td>
</tr>
<tr>
<td>- LDL &gt; 190 (very high) (%)</td>
<td>4.4</td>
<td>6.3</td>
<td>8.4</td>
</tr>
<tr>
<td>Anti-hyperlipidemic drug n (%)</td>
<td>5 (3.1)</td>
<td>10 (6.2)</td>
<td>22 (10.8)</td>
</tr>
</tbody>
</table>

Figure 1. Measurement of aortal pulse wave velocity: pulse waves of carotid and femoral artery (Δt: time, L: distance between the two arteries, m/s: meters/second), modified after [3].

Objectives: Aim of this study was to evaluate aortic stiffness and CV risk in patients with PsA based on measurements of cPWV and ESC-SCORE. Moreover, we sought to investigate associations of cPWV with patient- and disease-associated characteristics, as well as with traditional CV risk factors.

Methods: cPWV measurements were performed in patients with PsA from two large rheumatological medical departments in Germany, according to the classification criteria for psoriatic arthritis (CASPAR), and in healthy control subjects. In addition to assessing cPWV, clinical and laboratory parameters were evaluated, traditional CV risk factors were documented, and the ESC-SCORE was determined. Differences in cPWV measurements between the two groups and associations between cPWV and patient- or disease-associated characteristics were

**REFERENCES:**


**Acknowledgements:** The work described in this article was financially supported by Janssen-Cilag B.V.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2661

POS1086 HIGH CARDIOVASCULAR RISK IN PATIENTS WITH PSORIATIC ARTHRITIS: EVALUATION OF MACROANGIOPATHY AND ITS PREDICTORS BY AORTIC PULSE WAVE VELOCITY.

K. Triantafyllias1, S. Liverakos1, A. Klonowski2, A. Schwarting1,2, 1Rheumatology Center Rhineland-Palatinate, Rheumatine, Bad Kreuznach, Germany; 2Johannes Gutenberg University Medical Center, Rheumatology and Clinical Immunology, Mainz, Germany

Background: Systemic inflammatory rheumatic diseases are associated with macroangiopathy and increased cardiovascular (CV) risk [1, 2]. Psoriatic arthritis (PsA) has also been associated with an increased risk of CV events. However, data on diagnostic CV markers in PsA are scarce. Carotid-femoral pulse wave velocity (cPWV: oscillometric diagnostic method) is considered to be the gold standard evaluation method of aortic stiffness and is used in the general population to assess CV risk (Figure 1). Moreover, EULAR and the European Society of Cardiology (ESC) recommend the use of Systematic Coronary Risk Evaluation (ESC-SCORE) in order to screen and classify patients regarding CV risk.

Objectives: Aim of this study was to evaluate aortic stiffness and CV risk in patients with PsA based on measurements of cPWV and ESC-SCORE. Moreover, we sought to investigate associations of cPWV with patient- and disease-associated characteristics, as well as with traditional CV risk factors.

Methods: cPWV measurements were performed in patients with PsA from two large rheumatological medical departments in Germany, according to the classification criteria for psoriatic arthritis (CASPAR), and in healthy control subjects. In addition to assessing cPWV, clinical and laboratory parameters were evaluated, traditional CV risk factors were documented, and the ESC-SCORE was determined. Differences in cPWV measurements between the two groups and associations between cPWV and patient- or disease-associated characteristics were

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2661

POS1088 MACROANGIOPATHY AND ITS PREDICTORS BY AORTIC PULSE WAVE VELOCITY.

examined statistically (correlation analyses, Mann-Whitney-U-Tests, ANOVA and multivariate regression analyses).

**Results:** 112 patients with PsA [55.45%, median age: 55 years, IQR 47-63] and 88 healthy control subjects [81.4%, median age: 51 years, IQR 36.5-58] were recruited. cPWV was significantly higher in PsA patients compared to the healthy control subjects (p < 0.001), even after the adjustment for the effect of confounding factors. In both the patient and the control group, cPWV correlated with age (r = 0.560, p < 0.01) and r = 0.638, p < 0.01, respectively. In addition, cPWV showed a moderate significant correlation with the ESC-SCORE (r = 0.290, p = 0.222) and a weak significant association with mean arterial pressure (r = 0.19, p = 0.043) in the patient group. No statistical associations could be found between cPWV and lipid levels, CRP levels or EULAR disease activity score for patients with psoriatic arthritis (PsA). We were able to show that PsA patients had significantly higher arterial stiffness values, and thus, a higher CV risk compared to healthy individuals. Therefore, cPWV could be a useful tool for the identification of PsA patients at high-risk. The fact that arterial stiffness can be predicted by mean arterial pressure and ESC-Score might assist forming therapeutic strategies that would promote artery de-stiffening and thus CV risk lowering.

**Disclosure of Interests:**


**REFERENCES:**


**Disclosure of Interests:** None declared


**POS1087**

**THE RELATIONSHIP BETWEEN CHANGES IN PSORIATIC ARTHRITIS DISEASE ACTIVITY AND COMORBIDITIES IN PATIENTS TREATED WITH BDMAARDS**

G. Ayavı 1, N. E. Gezereni 1, E. Bilgin 1, G. K. Yardsmic 1, E. C. Bolesl 1, B. Farisogullari 1, E. Durani 1, Z. Ozsoy 1, G. Sandal Uzun 2, M. Ekici 1, E. Unalddi 1, L. Kilici 1, A. Akdogan 2, O. Karadag 1

**Background:** Comorbidities are common in psoriatic arthritis, needed to be recognized and managed to effectively when treating psoriatic arthritis (PsA) patients. However, the data on the impact of particular comorbidities on the disease activity in patients requiring bDMARDs are very small.

**Objectives:** Our aim was to understand the relationship between the disease activity and comorbidities in PsA patients under bDMARDs.

**Methods:** The Hacettepe University biological database (HUR-BIO), was established in 2005 and data of 520 PsA patients included until 2021 were analyzed. In all included patients, the diagnosis of PsA was made by the rheumatologist. DAS-28 score (at the last visit) and all comorbidities were documented after bDMARD initiation. Multivariate analysis was performed to understand comorbidities that have impact on DAS-28 remission.

**Results:** There were 469 patients with a known DAS-28 score median (IQR) 28 (61) months after bDMARD initiation. It was detected in 214/469 (45.8%) patients with a DAS-28 score below 2.6. Patients in remission of DAS-28 were younger, remission was less frequent in women, and comorbidities, mainly BMI, Diabetes Mellitus (DM) and hypertension, were also found less frequent (Table 1). In the multivariate analysis, no determining factor was found in male gender. On the other hand, in females, smoking, presence of comorbidity, Body mass index (BMI) at the start of bDMARDs, age at onset of bDMARDs, DM at the start of bDMARDs, HT at the start of bDMARDs, coronary artery disease, and cardiovascular risk factors were included in the analysis and revealed. bDMARD baseline BMI [OR 1.06 (95% CI 1.02-1.11), p = 0.004] and presence of bDMARD baseline BMI [OR 3.08 (95% CI 1.14-8.30), p = 0.026] had significant impact on DAS-28 remission.

**Conclusion:** Previous data showed that obesity, hypertension and at least 1 point from charlson comorbidity index are poor prognostic factors for treatment outcomes (1). Our data showed that BMI and presence of DM were determined as factors affecting bDMARD treatment response in female PsA patients.

**REFERENCES:**


**Disclosure of Interests:** None declared


**Table 1. Relationship between remission according to DAS-28 score and comorbidities**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>DAS-28 ≤ 2.6</th>
<th>DAS-28 &gt; 2.6</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>43.8 (11.7)</td>
<td>47.5 (12.5)</td>
<td>0.001</td>
</tr>
<tr>
<td>Age at PsA diagnosis, mean (SD), years</td>
<td>38.6 (11.5)</td>
<td>41.6 (11.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Gender, female, n(%)</td>
<td>115 (53.7)</td>
<td>211 (82.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Comorbidity count</td>
<td>1.54 (0.98)</td>
<td>1.98 (1.31)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Comorbidity (yes/no)</td>
<td>67 (31.9)</td>
<td>118 (47.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>Comorbidity distribution</td>
<td>No</td>
<td>143 (68.1)</td>
<td>130 (52.4)</td>
</tr>
<tr>
<td>-1 Comorbidity</td>
<td>38 (18.1)</td>
<td>47 (19.0)</td>
<td></td>
</tr>
<tr>
<td>≥ 2 Comorbidity</td>
<td>17 (8.1)</td>
<td>36 (14.5)</td>
<td></td>
</tr>
<tr>
<td>≥ 3 Comorbidity</td>
<td>12 (5.7)</td>
<td>35 (14.1)</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index (BMI)</td>
<td>28.1 (5.4)</td>
<td>30.3 (5.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DM ≥ 30, n(%)</td>
<td>70 (32.9)</td>
<td>123 (44.8)</td>
<td>0.001</td>
</tr>
<tr>
<td>Diabetes Mellitus, n(%)</td>
<td>10 (4.7)</td>
<td>35 (13.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>Hypertension, n(%)</td>
<td>29 (13.6)</td>
<td>71 (27.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol &gt; 240, n(%)</td>
<td>8 (10.5)</td>
<td>22 (8.8)</td>
<td>0.019</td>
</tr>
<tr>
<td>Thyroid Disease</td>
<td>20 (9.8)</td>
<td>43 (17.3)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

**POS1088**

**CHALLENGES IN THE MANAGEMENT OF PSORIATIC ARTHRITIS IN LATIN AMERICA: A SYSTEMATIC REVIEW**

A. Ribere 1, L. Dullius 1, N. Sartori 1, A. Azeredo-Da-Silva 2, O. Monticelio 1, C. Kohem 1, L. Coates 3, P. Palominos 1, 1Hospital de Clínicas de Porto Alegre, Rheumatology, Porto Alegre, Brazil; 2Hospital de Clinicas de Porto Alegre, Internal Medicine, Porto Alegre, Brazil; 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Rheumatology, Oxford, United Kingdom

**Background:** In 2020, the International League of Associations for Rheumatology (ILAR) recommendations for management of psoriatic arthritis (PsA) were published. This aimed to adapt GRAPPA and EULAR recommendations to resource-poor settings. At that time, the paucity or absence of clinical studies endorsing the management of PsA patients in Latin America was remarked on by the international working group. Despite several challenges faced by patients and physicians in resource-poor countries, the literature on this theme is scarce.

**Objectives:** To recognize the main challenges on the management of PsA in Latin America described in recent publications.

**Methods:** A systematic literature review of clinical trials reporting at least one challenge/difficulty on the management of PsA in Latin America was conducted following PRISMA statements. References published in English, Spanish, French and Portuguese language and published in PubMed, Embase, and LILACS between 1980 and 2020 were included. The selection of references was conducted independently by two researchers in Rayyan QCRI program. Data were independently extracted by two reviewers. The Cochrane tool was used to assess the quality of studies. All challenges were noted and categorized into domains. Data analysis was descriptive.

**Results:** The search strategy resulted in 1505 references. Sixteen studies (15, 145 PsA patients) were included in the final analysis: most were performed in Brazil (81.2%, N=13), recruited patients on biological therapy (75.0%, N=12) and were observational studies (87.5%, N=14). Difficulties faced by PsA patients and physicians in Latin America were the high incidence of opportunistic infections (described in 43.7% of publications, N=7), non-adherence to therapy (18.7%, N=3), discordance between patients and physicians regarding remission rates (18.7%, N=3), limited access to DMARDs (12.5%, N=2), issues related to the storage of biological drugs (12.5%, N=2), high impact of PsA on work and productivity (12.5%, N=2), cost of biological drugs (12.5%, N=2), low drug persistence (6.2%, N=1), and limited access to medical care (6.2%, N=1) and diagnostic delay (6.2%, N=1).

**Conclusion:** The challenges in the management of PsA in Latin America go beyond the care of opportunistic infections: special attention should be paid to logistical questions (e.g., correct medication storage, access to drugs and...
medical care) and educational problems (e.g., importance of adherence, patients understanding of disease and therapy)

REFERENCES:

Disclosure of Interests: None declared

POS1089

HLA-CW6 ALLELE AND BIOLOGICAL TREATMENTS ARE PROTECTIVE FACTORS AGAINST LIVER FIBROSIS IN PSORIATIC ARTHRITIS PATIENTS

C. Macia-Villa1, J. L. Morell Hita2, M. Revenga3, C. Diaz-Miguel4. 1Hospital Severo Ochoa, Rheumatology, Leganés, Spain; 2Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: Non-alcoholic fatty liver disease can be expressed from an indolent stage, evolve to steatohepatitis and eventually evolve to liver fibrosis. This spectrum of non-alcoholic inflammatory liver disease is increased in psoriasis and psoriatic arthritis (PsA). To date, the relationship between non-alcoholic liver fibrosis and genetics in PsA has not been studied.

Objectives: The objective of our study is to evaluate the association between the HLA-Cw6 allele and the FIB-4 (fibrosis-4) index in patients with PsA.

Methods: Retrospective longitudinal study in patients older than 18 years with PsA according to CASPAR criteria with determination of the HLA-Cw6 allele. To estimate liver fibrosis, the FIB-4 index was obtained, calculating it at the onset of PsA and at the last available visit. A descriptive analysis of the variables was carried out using mean and standard deviation (SD) for those with symmetric distribution, and median and interquartile range (IR) for the asymmetric ones. Qualitative variables were described using absolute values and percentages. A bivariate analysis was carried out using parametric and non-parametric hypothesis contrast tests to determine the association between the main variable (current FIB-4) and the secondary variables. Bivariate correlations were analyzed using Pearson’s coefficient. A multivariate model was developed to assess the association between HLA-Cw6 and liver fibrosis adjusted for potential confounding factors, and results were presented as Odds Ratio (OR) with 95% confidence interval (CI) and level of statistical significance p-value=0.05. The statistical program SPSS version 20 was used. The study was approved by the local committee.

Results: 209 patients with PsA were included (56.9% men, mean age 42.72±14.24 years), 84.7% with psoriasis, and median (IR) ESR (mm/h) of 4.31 (2.62-11.82). 74.3% of patients were HLA-Cw6 positive. A multivariate analysis was performed to assess the association between HLA-Cw6 and liver fibrosis adjusted for potential confounding factors, and results were presented as Odds Ratio (OR) with 95% confidence interval (CI) and level of statistical significance p-value=0.05. The statistical program SPSS version 20 was used. The study was approved by the local committee.

Table 1. Bivariate analysis of the main variable (current FIB-4) categorized into normal (result F0-1, non advanced fibrosis, <1.30 points) and altered (result F2-3-4, intermediate zone and significant fibrosis, >1.3 points). 1Median (IR) 2Mean±SD. p-value < 0.05. AMI acute myocardial infarction.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (IC 95%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-Cw6</td>
<td>0.210</td>
<td>0.012</td>
</tr>
<tr>
<td>Male sex</td>
<td>1.553</td>
<td>0.344</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2.973</td>
<td>0.028</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.478</td>
<td>0.561</td>
</tr>
<tr>
<td>Ischaemic Heart Attack</td>
<td>1.429</td>
<td>0.471</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>1.113</td>
<td>0.854</td>
</tr>
<tr>
<td>ESR at onset (mm/h)</td>
<td>0.950</td>
<td>0.605</td>
</tr>
<tr>
<td>AMI (%)</td>
<td>6.302</td>
<td>0.156</td>
</tr>
<tr>
<td>Biologic</td>
<td>3.937</td>
<td>0.038*</td>
</tr>
</tbody>
</table>

Conclusion: In our study, having the HLA-Cw6 allele and receiving biological treatment behaved as a protective factor for liver fibrosis in PsA, while arterial hypertension was an independent risk factor. The presence of psoriasis was not related to hepatic fibrosis measured by FIB-4.

Disclosure of Interests: None declared

POS1090

THE IMPACT OF NUMBER OF COMORBIDITIES ON ACHIEVEMENT REMISION OR LOW DISEASE ACTIVITY BY DAPSA IN PSORIATIC ARTHRITIS. DATA FROM THE RUSSIAN OBSERVATIONAL COHORT

Y. Korsakova1, E. Gubar2, E. Loginoiva1, T. Kortaeava2, V. Sorotskaya3, I. Patrikeeva1, P. Shesterynya1, I. Umnova1, E. Nasonov1. 1V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritis and Psoriatic Arthritis, Moscow, Russian Federation; 2Medical Institute of the Tula State University, Medical Institute of the Tula State University, Tula, Russian Federation; 3Medical Institute of the Tula State University, Rheumatology, Tula, Russian Federation, Tyumen Regional Clinical Hospital No1, Rheumatology, Tyumen, Russian Federation; 4Krasnoyarsk State Medical University VF.Voino-Yasenetsky, Rheumatology, Krasnoyarsk, Russian Federation; 5Omsk region “Regional clinical hospital”, Rheumatology, Omsk, Russian Federation; 6V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: The goal of psoriatic arthritis (PsA) treatment is achievement remission (REM) or Low Disease Activity (LDA) by DAPSA. The impact of comorbidities, especially obesity, metabolic syndrome on PsA activity and on biological treatment response are shown in some registry [1]. Obesity, hypertension and Charlson Comorbidity Index ≥ 1 are prognostic factors for poorer treatment outcome rates in PsA [2]. But influence of number of comorbidities on treatment response has not been fully studied in real practice.

Objective: To evaluate the impact of number of comorbidities on achievement remission by DAPSA in PsA pts

Methods: 528 pts (M/F=256 (48.5%)/272 (51.5%) with PsA according to CASPAR criteria were included in the Russian observational cohort. Mean age 48.7±13.33 years (yrs.), PsA duration 122.6±81.85 months (mo.), psoriasis (Ps) duration 239.0±155.45 mo. Pts who completed ≥2 visits were analyzed. Mean observational period 73.6±83.47 mo. All pts underwent standard clinical examination: tender joint count (TJC)/68, swollen joint count (SJC)/66, Pain (VAS), Patient global assessment of disease activity (PGA), VAS, CRP mg/l, BSA (%), BMI, HAQ, comorbidities by ICD-10, X-ray of hands and feet. DAPSA-28 indicates as high disease activity (HDA), >14-28 - moderate activity (MoDA), 4-14 – LDA, ≤4 – REM. Analyses were performed based on number of comorbidities: 1st group (gr) - without comorbidities, 2nd gr – pts with 1 comorbidity, and 3rd gr – pts with ≥ 2 comorbidities. Ms/SD, %, t-test, Pearson-χ², ORs with 95% CI were calculated. All p<0.05 were considered to indicate statistical significance.

Results: In 236 out of 528 (44.7%) pts no comorbidity found, in 145 out of 528 (27.5%) found 1 comorbidity and 147 out of 528 (27.8%) pts had ≥ 2 comorbidities. Comparative analysis in groups showed the following features: pts of 3rd gr were significantly more often females, had longer Ps and PsA duration, they were older, had worse HAQ, higher BMI, TJC (p<0.05). Joint erosions were found significantly more often in the 2nd gr compared to the 1st gr (p=0.02). No significant differences were in the frequency of axial PsA (p=0.906), Ps severity (Bsa>10%) (p=0.237), the number of pts receiving bDMARDs (p=0.078). REM/ LDA achievement according to DAPSA was significantly lower in the 3rd gr (15 (10.2%)/69 (46.9%) compared to the 1st gr (62 (26.3%)/94 (39.8%), and to the 2nd gr (32 (22.1%)/69 (47.6%) (p=0.007). The probability of achieving REM/ LDA is 1.6 times lower in the gr of pts with ≥2 comorbidities compared to the gr of pts without comorbidities (OR 0.608, 95% CI 0.394 to 0.936) and 1.3 times lower compared to gr of pts with 1 comorbidity (OR 0.789, 95% CI 0.489 to 1.243) (Figure 1)
Conclusion: In real clinical practice comorbidities were seen in more than half PsA pts. Third of PsA pts had number of comorbidities. PsA pts with number of comorbidities is associated with high disease activity, reduced quality of life and are 1.6 times more likely to have no chance to attain REm/LDA by DAPSA. It should be considered for personalized treatment.


Acknowledgements: The RU-PsART study group

Disclosure of Interests: Yulia Korsakova Speakers bureau: Novartis, ELENA GUBAR: None declared, Elena Loginova Speakers bureau: Janssen, Tatiana Korotaeva Speakers bureau: Pfizer, Novartis, MSD, AbbVie, Janssen, JSC BIO-CAD, UCB, Lilly and Novartis-Sandoz, Consultant of: Pfizer, Novartis, MSD, AbbVie, Janssen, JSC BIO-CAD, UCB, Lilly and Novartis-Sandoz, Valentina Sorotskaya: None declared, Irina Patrikeeva: None declared, AbbVie, Janssen, JSC BIOCAD, UCB, Lilly and Novartis-Sandoz, Consultant of: Pfizer, Novartis, MSD, AbbVie, Janssen, JSC BIO-CAD, UCB, Lilly and Novartis-Sandoz, Valentina Sorotskaya: None declared, Irina Patrikeeva: None declared, Pavel Shesternya: None declared, Irina Umnova: None declared, Evgeny Nasonov: None declared


Post 1091

LESS RADIOGRAPHIC SPINAL DAMAGE IN PSORIATIC ARTHRITIS PATIENTS COMPARED TO SPA PATIENTS

M. De Hooger1,2, A. Ishchenko3, A. S. De Craemer1,2, S. Steinfield1, A. Nzesessez Toukpa4, D. Elewaut4,5, R. Lories3,6, F. Van den Bosch1,2, K. De Vlam3,6.

1Ghent University Hospital, Rheumatology, Gent, Belgium; 2VIB-Ugent, Center for Inflammation Research, Gent, Belgium; 3University Hospitals Leuven, Rheumatology, Leuven, Belgium; 4Clinique St Jean, Brussels, Belgium; 5St Luc University Hospitals, UCLouvain, Rheumatology, Leuven, Belgium; 6KULeuven Skeletal Biology and Engineering Research Center, Development and Regeneration, Leuven, Belgium

Background: Psoriatic arthritis (PsA) is an inflammatory joint disease that is traditionally included in the Spondyloarthropathy (SpA) spectrum. Prevalence and impact of axial involvement in PsA remain understudied but increasingly affect treatment decisions.

Objectives: A step towards fathoming this issue is to report on baseline radiographic spinal damage in PsA and SpA patients (pts) from 2 prospective multicentre cohort studies in private and academic rheumatology practices.

Methods: Data on PsA pts were from the Belgian Epidemiological Psoriatic Arthritis Study (BEPAS); prospective multicentre cohort in 17 Belgian rheumatology practices. Recruitment was Dec2012-Jul2014. Pts were included when fulfilling the Classification criteria for Psoriatic Arthritis (CASPAR). SpA pts were from a Belgian observational cohort (Be-Giant) of SpA pts fulfilling the ASAS SpA classification criteria. Radiographs of the spine were obtained at baseline and after 2 years. Two calibrated readers evaluated radiographic damage by assessing modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). Readers were blinded for time sequence, clinical data and information from other obtained images (radiographs of hands, feet, sacroiliac joints). Consensus scores are described.

Results: In total 461 pts were included in BEPAS. Mean age was 52.79±12.29 years and 43.0% (n=198) were female; average disease duration was 8.5 ± 9.3 years and approximately 34% of the pts reported inflammatory axial pain. From 312 pts spinal radiographs were obtained. At baseline, the vast majority of PsA pts had an mSASSS of 0 (n=273, 87.5%), according to both readers. In 33 PsA pts (10.6%) mSASSS was 2 or more. For the SpA pts percentages were lower but the trend was similar (see Figure 1). Though lesser pts showed abnormalities, the SpA pts with spinal damage show a higher mSASSS, therefore indicating more spinal damage than the PsA pts (p<0.05). Both patient groups show some outliers with high mSASSS, increasing the average mSASSS especially in the SpA cohort (mean mSASSS = 9.1±4.11) compared to the median of 3 (IQR 2-6) in both cohorts. Synodesmophytes are seen in 10.6% and 6.2% of the PsA and SpA pts, respectively. Similar to the mSASSS, SpA pts had more syndesmophyse (mean: 4.4±5.50) compared to PsA pts (mean 2.0±1.45); p<0.05. PsA pts had more often syndesmophytes located in the cervical spine (24/35, 68.6%) compared to the SpA patient group (9/21, 42.9%); p<0.05. Erosions and especially sclerosis and squaring are uncommon in both patient groups.

Conclusion: Spinal damage is seen in approximately 10% or less of both PsA and SpA pts in these cohorts. SpA pts show higher mSASSS values and more syndesmophytes as compared to PsA pts. Syndesmophytes in PsA pts are more often located in the cervical spine while the location is more equally distributed in SpA pts.

Acknowledgements: The BEPAS study has been supported by MSD Belgium, with noteworthy mentioning of Hermine Leroi.

Disclosure of Interests: None declared


Table 1. Spinal damage at baseline of patients from the BEPAS (PsA patients) and Be-Giant (SpA patients) cohorts

<table>
<thead>
<tr>
<th></th>
<th>PsA patients (n=312)</th>
<th>SpA patients (n=260)</th>
<th>PsA patients (n=312)</th>
<th>SpA patients (n=260)</th>
</tr>
</thead>
<tbody>
<tr>
<td>mSASSS ≥2, no of patients</td>
<td>33 (10.6%)</td>
<td>19 (7.3%)</td>
<td>33 (10.6%)</td>
<td>16 (6.2%)</td>
</tr>
<tr>
<td>mSASSS ≥1, no of patients</td>
<td>39 (12.5%)</td>
<td>22 (8.5%)</td>
<td>1.0±2.0</td>
<td>2.0±1.45</td>
</tr>
<tr>
<td>mean, (SD)</td>
<td>4.5 (4.24)</td>
<td>9.1 (14.11)</td>
<td>1.0±2.0</td>
<td>2.0±1.45</td>
</tr>
<tr>
<td>min, 0.25, median, 0.75, max</td>
<td>10.2±2.0 6.0 2.0 1.0</td>
<td>2.0±3.0 10.0 64.0</td>
<td>10.2±2.0</td>
<td>2.0±1.45</td>
</tr>
<tr>
<td>Erosions ≥1, no of patients</td>
<td>13 (4.2%)</td>
<td>5 (1.9%)</td>
<td>1.0</td>
<td>1.0±2.0</td>
</tr>
<tr>
<td>mean, (SD)</td>
<td>1.5 (1.39)</td>
<td>1.0 (0.9)</td>
<td>1.0±2.0</td>
<td>2.0±1.45</td>
</tr>
<tr>
<td>min, 0.25, median, 0.75, max</td>
<td>10.1±1.0 10.0 6.0 1.0</td>
<td>10.1±1.0 10.0 1.0</td>
<td>10.1±1.0 10.0 1.0</td>
<td>10.1±1.0 10.0 1.0</td>
</tr>
<tr>
<td>Squaring ≥1, no of patients</td>
<td>No obs.</td>
<td>4 (1.5%)</td>
<td>No obs.</td>
<td>4.0 (1.4)</td>
</tr>
<tr>
<td>mean, (SD)</td>
<td>No obs.</td>
<td>1.8 (0.96)</td>
<td>No obs.</td>
<td>4.0 (1.4)</td>
</tr>
<tr>
<td>min, 0.25, median, 0.75, max</td>
<td>No obs</td>
<td>10.1±1.0 2.5 1.0</td>
<td>No obs.</td>
<td>10.1±1.0 2.5 1.0</td>
</tr>
<tr>
<td>Sclerosis ≥1, no of patients</td>
<td>2 (0.6%)</td>
<td>6 (2.3%)</td>
<td>1.0±2.0</td>
<td>1.0±2.0</td>
</tr>
<tr>
<td>mean, (SD)</td>
<td>1.5 (0.71)</td>
<td>1.8 (1.33)</td>
<td>1.0±2.0</td>
<td>1.0±2.0</td>
</tr>
<tr>
<td>min, 0.25, median, 0.75, max</td>
<td>10.1±1.0 2.0 2.0 1.0</td>
<td>1.0±1.0 3.0 4.0 1.0</td>
<td>10.1±1.0 2.0 2.0 1.0</td>
<td>10.1±1.0 2.0 2.0 1.0</td>
</tr>
</tbody>
</table>

Syndesmophytes (total spine):
- mean, (SD): 1.0±2.0 2.0 1.0 1.0
- min, 0.25, median, 0.75, max: 10.1±1.0 2.0 2.0 1.0

Syndesmophyses (cervical spine):
- mean, (SD): 1.8 (1.32)
- min, 0.25, median, 0.75, max: 1.0±2.0 2.0 1.0 1.0

Syndesmophyse (lumbar spine):
- mean, (SD): 1.9 (0.70)
- min, 0.25, median, 0.75, max: 1.0±2.0 2.0 2.0 1.0

Figure 1. Chances of REM/LDA achievement in pts with ≥2 comorbidities compared to pts with 1 comorbidity and pts without comorbidities.
Background: Obesity is over-represented in patients with psoriatic arthritis (PsA) and associated with increased disease activity. We have previously shown that weight loss treatment with Very Low Energy Diet (VLED) in patients with PsA and obesity was associated with a substantial weight reduction and significant improvement of the disease activity in joints, entheses and skin during 24 months follow-up. A side effect with a large weight loss is however a concomitant reduction of muscle mass, which can negatively affect physical fitness.

Objectives: This study aimed to evaluate the effects of weight loss treatment on physical fitness i.e., muscle strength, cardiorespiratory fitness, body composition and self-reported physical functioning, in patients with PsA and obesity compared to matched controls undergoing the same treatment.

Methods: In total, 46 patients with PsA (Caspar criteria) and obesity and 52 controls (matched for age, sex, body weight and height) were included. VLED (640 kcal/day) was provided to all participants for 12-16 weeks depending on baseline BMI (<40 or ≥40 kg/m²), followed by reintroduction of energy restricted diet. Brief support for physical activity was given. Primary outcome was muscle strength, assessed in hand-grip with a dynamometer (Grippit) and in leg muscle by measuring the time (seconds) needed to stand up ten times from a stand. Secondary outcomes were cardiorespiratory fitness (O₂ l/min), measured with the Åstrand's submaximal bicycle test, body composition analyzed with dual energy x-ray absorptiometry and physical functioning, assessed with the Short Form 36 Health Survey Physical Component Score (SF-36PCS). Outcomes were evaluated at baseline (BL), six (M6) and 12 months (M12).

Results: In total, 41 PsA patients (median age 54; 63% women) and 42 controls (median age 54; 74% women) completed the treatment. At M6 the median weight loss since baseline in patients and controls was 18.9 kg and 23.0 kg respectively (p<0.001), and at M12 16.1 kg and 16.6 kg (p=0.885). Significant changes (all p<0.001) were seen at M2 in the body composition of both patients and controls, with decreases in total fat mass (-30.1% vs. -27.4%), total lean mass (-7.0% vs -8.3%), lean arm mass (-13.7% vs -2.4%) and lean leg mass (-6.0% vs -8.6%). Leg muscle strength did however improve in both patients and controls at M6 (p<0.001) and remained improved at M12 (p=0.001 and p<0.001), while hand-grip strength was unchanged in both groups. Cardiorespiratory fitness increased in controls at M6 (p=0.018) and M12 (p=0.028), but not in the patients. Physical functioning improved in both groups at M6 and remained improved at M12.

Conclusion: Patients with PsA and obesity can benefit from weight loss treatment without risk of deterioration in muscle strength. However, muscle strength and cardiorespiratory fitness were below suggested normative values for the majority of the patients at all timepoints, implying that more structured exercise strategies might be warranted to counteract physical fitness deficiencies in patients with PsA undergoing weight loss treatment.

Table 1.

<table>
<thead>
<tr>
<th>)</th>
<th>PsA patients</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=41</td>
<td>M12</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>35.2</td>
<td>30.5</td>
</tr>
<tr>
<td>Hand-grip strength, N</td>
<td>244</td>
<td>196–326</td>
</tr>
<tr>
<td>Leg strength TST, sec</td>
<td>23.2</td>
<td>22.1–35.4</td>
</tr>
<tr>
<td>Cardiorespiratory</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>fitness, O₂ l/ min</td>
<td>1.8–2.1</td>
<td>1.8–2.6</td>
</tr>
<tr>
<td>Total fat mass, kg</td>
<td>48.5</td>
<td>33.9</td>
</tr>
<tr>
<td>Total lean mass, kg</td>
<td>147.5–22.9</td>
<td>46.2–59.2</td>
</tr>
<tr>
<td>Lean mass arm, kg</td>
<td>45.9–61.8</td>
<td>46.9–58.8</td>
</tr>
<tr>
<td>Lean mass leg, kg</td>
<td>2.4</td>
<td>2.0–3.4</td>
</tr>
<tr>
<td>SF-36PCS, score 0-100</td>
<td>24.9–46.3</td>
<td>32.4–50.9</td>
</tr>
</tbody>
</table>

Figures are Median IQR

Disclosure of Interests: None declared


**POS1095**

EFFECT OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON DEPRESSION IN PATIENTS WITH PSORIATICS ARTHRITIS IN A LONGITUDINAL COHORT

A. J. Mathew, M. Sutton, D. Pereira, D. D. Gladman, V. Chander. 1Christian Medical College, Department of Clinical Immunology and Rheumatology, Vellore, India; 2Centre for Prognosis Studies in the Rheumatic Diseases, Psoriatic Arthritis Program, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada; 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Canada

Background: Depression, and its improvement with disease modifying anti-rheumatic drugs (DMARDs) is understudied in psoriatic arthritis (PsA).

Objectives: To determine the effectiveness of DMARDs on depression in PsA patients.

Methods: Patients enrolled from January 2000 to May 2020 in a large PsA cohort were included. Depression was defined as medical outcomes study short form-36 (SF-36) mental component summary score (MCS) ≤ 40 or mental health (MH) subscale score ≤ 50. Primary outcome was resolution of depression within 1 year of DMARDs, defined by two definitions: 1) MCS > 40 and/or MH subscale score of > 56; 2) Increase in MCS by 2.5 and MH subscale score by 5, the minimal clinically important difference (MCID). Baseline medications [non-steroidal anti-inflammatory drugs (NSAIDs) and/ or conventional or targeted (c/t) DMARDs] were recorded for all patients and stratified into 3 mutually exclusive ordinal categories: I-No treatment/NSAIDs; II-cDMARDs±NSAIDs without tDMARDs; III-tDMARDs±cDMARDs/NSAIDs. Univariable and multivariable logistic regression models were created to determine the association between medications and resolution of depression, after controlling for age, sex, disease duration and baseline MCS/MH subscale score.

Results: Based on the MCS and MH subscale score definitions, 608 (48%) and 655 (52%) of the 1270 patients, respectively were depressed at baseline. 374 (50.8% males) and 399 (52.4% males) patients were followed up in the groups defined by MCS and MH subscales, respectively for 1 year. Patients in both groups had comparable body mass indices, baseline psoriasis area and severity index and active joint count. Mean MCS and MN subscale scores (standard deviation) were 33.2 (5.2) and 46.0 (10.2). A mean of 11.9 and 11.7 months was noted for resolution of depression in the MCS based analysis and MH subscale-based analysis groups, respectively. More patients achieved resolution of depression based on definition 2 (MCS, 64.7%; MH, 62.2%) as compared to definition 1 (MCS, 54.5%; MH, 53.9). The proportion of patients on each category of medications in both models is shown in the Figure 1. Table 1 depicts the univariate and multivariable regression results by both the definitions of primary outcome in the MH subscales model. The global p-value for medication categories showed a trend towards significance in both models using definition 2. There was a trend towards higher likelihood of response when comparing patients in treatment category III vs category I. A significant response was noted when comparing patients in category III with category II as reference (OR 1.71; 95% CI 1.05-2.76; p=0.03). No significant effect of treatment category on depression was noted using definition 1.

![Figure 1. Patients in each drug category.](image-url)

Conclusion: In an observational setting, resolution of depression occurs in majority of patients with PsA within 1 year. Patients on t-DMARDs may experience better improvement in depression compared to other treatments. Future effectiveness studies warrant better definitions of depression and treatment response.

Acknowledgements: AJM was supported by the National Psoriasis Foundation Fellowship grant.

Disclosure of Interests: Ashish Jacob Mathew Speakers bureau: Novartis, IPCA Laboratories, Grant/research support from: Novartis, IPCA
Background: Psoriasis (PsO) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to PsO and up to 40% of PsO patients develop PsA. The transition from PsO to PsA includes different stages with unspecific clinical symptoms such as fatigue or musculoskeletal (MSK) symptoms as well as changes in synovial vascularization combined with increased expression of proangiogenic factors [1]. Fluorescence-optical imaging (FOI, KiraLITE) is an easy-to-use method to detect changes in microvascularisation of the hands.

Objectives: To compare findings from FOI assessment to clinical examination (SJC/TJC) and musculoskeletal ultrasound in patients (MSUS) with non-specific MSK-symptoms and changes in microvascularisation without evidence of clinical active PsA.

Methods: The German multicentre observational XCITING study recruited patients with dermatological confirmed PsO at risk for development of PsA (either nail psoriasis or MSK symptoms such as joint pain or swelling within the last 6 months). Clinical examination (CE; swollen (66) and tender (68) joint count, enthesis, dactylitis assessment), standardized MSUS and FOI assessment were performed by a qualified rheumatologist at one time point with focus on the question of presence of PsA. Data were analyzed in focus on increased vascularization of MSK structures of both hands as marker of inflammation. The patients at-risk for PsA development but without clinically active PsA (CE negative, FOI positive) were analyzed. Results from CE of joints, MSUS and FOI assessment were compared.

Results: 391 PsO patients were recruited for the XCITING study in total. 108 patients (27.5%) were identified as at-risk population (CE negative, FOI positive). Baseline characteristics included a mean age of 51.4 years (SD 11.3), 61.1% female, mean BMI 27.8 kg/m2 (SD 5.2), mean age of onset PsO 30.4 years (SD 17), mean duration of PsO of 16.9 years (SD 14.4), mean PASI 4.3 (SD 5.8) and mean patient’s global disease activity for PsO of 24.4mm (SD 21.1). In 24.1% psoriasis plaques on the hand were documented. Pattern for frequency of scores in FOI, CE and MSUS in the dominant hand were compared (Figure 1).

Conclusion: FOI signals in the hands correlate to the findings of TJC (and B-Mode US) in the clinical examination indicating early stages of MSK inflammation that may result in active PsA development. FOI as standardized and easy-to-use technique might be a suitable tool for early detection of PsA in Psoriasis population. A follow up in these patients will reveal prediction values of the method.

REFERENCES:

Disclosure of Interests: Michaela Köhm Grant/research support from: Pfizer, Sarah Ohndorf: None declared, Xenofon Baraliakos: None declared, Konstantin Hallmann Grant/research support from: Pfizer, Susanne Kempinski: None declared, Ann Christina Foldenauer Grant/research support from: Pfizer, Tanja Rossmanith Grant/research support from: Pfizer, Ulf Henkemeier Grant/research support from: Pfizer, Frank Behrens Grant/research support from: Pfizer

Methods: A total of 136 subjects (49 patients with PsA, 46 patients with AS and 41 healthy controls) were included in the study. Subjects were evaluated with detailed anamnesis and physical examination. The routine biochemical parameters, CRP, ESR of all subjects and disease activity scores of all patients were noted. IL-12 and IL-23 were measured using ELISA method. Endothelial-dependent and independent dilatations were measured by Doppler USG on the brachial artery.

Results: Though IL-12 levels were higher in the PsA group when compared with the healthy group, this difference was not statistically significant. IL-23 levels were significantly higher in PsA patients when compared with the healthy control group (Table 1). IL-12 and IL-23 levels were found to be significantly higher in the AS group compared with the healthy group. A statistically significant difference in endothelial dependent measures were found between PsA patients and healthy controls. No statistically significant correlation was found between IL-12, IL-23 levels and brachial artery basal diameter, FMD, NMD values in PsA patients. Fasting blood glucose and triglyceride levels were higher in PsA patients, while CRP and ESR were higher in AS patients. HDL levels of healthy controls were higher than those of PsA and AS patients. There was no significant correlation between IL-12, IL-23 and BASDAI, BASFI, DAPSA, DAS 28, PsAQoL, HAQ, HAD-A, VAS scores in PsA group; hospital anxiety and depression scale (HAD) and BASMI were positively correlated with IL-23. In the AS group, IL-23 was correlated with VAS and BASMI and IL-12 was correlated with HAQ score.

Table 1. The average of the interleukin levels according to the diagnoses of the participants

<table>
<thead>
<tr>
<th></th>
<th>PSA</th>
<th>AS</th>
<th>Healthy Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL12</td>
<td>0.007</td>
<td>0.027</td>
<td>0.027</td>
</tr>
<tr>
<td>IL23</td>
<td>0.009</td>
<td>&lt;0.001</td>
<td>0.026</td>
</tr>
</tbody>
</table>

Conclusion: In the PsA group, IL-23 levels and FMD values were higher than the healthy group in our study. The risk of metabolic syndrome and CVD increases due to high insidence of glucose dysregulation, dyslipidemia and obesity in these patients. PsA patients should be monitored for the development of these comorbidities and preventive measures should be taken. More studies are necessary to examine the relationship between IL-12, IL-23 levels and endothelial dysfunction, which is an early indicator of CVD and atherosclerosis in PsA patients.

References:

Acknowledgements: The authors would like to thank the Manisa Celal Bayar University Scientific Research Projects Coordination Department under the Grant No. 2021-021 for the supports.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4368
Conclusion: This analysis of PsA patients in routine care at a European tertiary academic center showed that many patients are not on treatment target. Their presentation is oligoarticular, with moderate levels of pain and patient global assessments, but mostly normal or slightly elevated CRP levels. Despite the treat-to-target strategy and a large number of therapeutics, and overall good control of objective measures of disease activity, many patients in real life may potentially benefit from more intensive treatment escalation.

Acknowledgements: This study was supported by Amgen through a financial contract to the institution.

Disclosure of Interests: Andreas Kerschbaumer Speakers bureau: AbbVie, Bristol-Myers Squibb, Amgen, Eli-Lilly, Gilead, Janssen, Merck Sharp and Dohme, Novartis and Pfizer, Josef S. Smolen Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTTO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB, Grant/research support from: AbbVie, AstraZeneca, Janssen, Lilly, Merck Sharpe & Dohme, Pfizer, and Roche, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofi


POS1097
BIOMARKERS OF INFLAMMATION AND JOINT TISSUE TURNOVER CAN HELP IMPROVING THE DIFFERENTIATION BETWEEN OSTEOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS

S. S. Groen1,2, S. Holm Nielsen2,3, A. C. Bay-Jensen2, M. Rasti4, D. Ganatra4, K. Oikonomopoulou4, V. Chandran5, K. Nord, Biomedical Sciences, Copenhagen, Denmark; 2Nordic Bioscience, Immunoscience, Herlev, Denmark; 3Technical University of Denmark, Biotechnology and Biomedicine, Kgs. Lyngby, Denmark; 4Krebbl Research Institute, Schroeder Arthritis Institute, Toronto, Canada; 5Institute of Medical Science, Department of Medicine, Division of Rheumatology, Department of Laboratory Medicine and Pathobiology, Toronto, Canada

Background: Osteoarthritis (OA) is a slow progressive disease characterized by degeneration within the joint cartilage, leading to destruction and dysfunction of the involved joints. Psoriatic arthritis (PsA) is a chronic inflammatory disease manifesting itself in skin lesions and progressive inflammatory changes within the musculoskeletal system, leading to joint damage and functional limitation. Although OA and PsA are considered to be distinct diseases, they share overlapping clinical and inflammatory features that can cause diagnostic challenges. Throughout these inflammatory and degenerative processes in the joint tissues, proteases hold a major role in remodelling of the extracellular matrix (ECM) which results in protein breakdown products released into the synovial fluid (SF). These protein fragments can be quantified in SF as biomarkers of tissue remodelling and may be helpful in characterizing disease-specific or overlapping pathologies between OA and PsA.

Objectives: Our aim of this study is to measure biomarkers of inflammation and joint tissue turnover in SF to explore the distinct and overlapping pathologies between OA and PsA.

Methods: SF samples were collected from patients with OA (n=54, mean ±SD age 62.1 ±11.9, 48% female) and patients with PsA (n=59, mean ±SD age 47.8±13.3, 37% female) recruited through Toronto Western Hospital, Canada. Study was approved by the local ethics committee. Biomarkers of inflammation reflecting macrophage activity (VICM) and neutrophil activity (CPa9-HNE) were measured in the SF samples. Moreover, ECM remodelling was assessed in the SF samples by biomarkers quantifying type II collagen formation (PRO-C2), fibronectin turnover (FBN-C), and aggrecan degradation (ARGS). Data were log-transformed and presented as mean ± standard deviation (SD). An ANCOVA corrected for age was applied to test the difference between biomarker levels across the two patient groups and a p-value below 0.05 was considered significant. Area under the receiver operating characteristic (ROC) curve (AUC) analysis was performed to describe the discrimination accuracy of each biomarker between the two patient groups.

Results: PsA patients presented significantly higher levels of macrophage; VICM, activity compared to OA (p<0.001, Figure 1A). On the other hand, OA patients demonstrated increased type II collagen formation and aggrecan degradation compared to PsA (p<0.001, Figure 1C, E). Interestingly, no significant difference in biomarkers levels of neutrophil activity and fibronectin remodelling was observed between the two disease groups. Moreover, VICM, PRO-C2, and ARGS showed high distributional difference between OA and PsA patients with an AUROC=0.915 (p<0.001, Figure 1F), AUROC=0.737 (p<0.001, Figure 1G), and AUROC=0.725 (p<0.001, Figure 1H), respectively.

Conclusion: PsA patients demonstrated higher macrophage activity in the SF compared to the OA patients, while higher levels of cartilage formation and degradation were observed in OA patients compared to PsA. No differences between OA and PsA were observed in neutrophil activity and fibronectin turnover, which may mirror the clinical difficulty in telling the two arthritides apart. Identifying the unique characteristics of the pathological processes underlying the two diseases may improve diagnosis and allow for the precise management of both OA and PsA patients.
synovitis), thickening and hypoechochogenicity at enthesis, PD+ enthesitis, entheses with structural components. Enthesal findings were fixed according to consensus-based US definition and scoring for enthesitis in spondyloarthritis and PsA (OMERACT US).2

**Results:** In all 92 patients: male - 42 (45.7%), mean age was 42.9±9.6 (SD) years (y), PsA duration was 7 (2; 11.8) y. Disease Activity in PsA score was 15.2 (10.2; 21.4). Thus, the impact of psoriasis on the quality of life of patients with PsA was revealed. DLQI scores correlated with skin psoriasis activity and nail onychodystrophy, as well as clinical enthesitis (p<0.01). Minimal (67.4%) and moderate (29.3%) disability levels were found. HAQ-DI scores were associated with higher PsA activity and duration, age and clinical enthesitis (p<0.01). Physical and mental health (SF-36) correlated with Disease Activity in PsA and clinical enthesitis (p<0.05). Fatigue was found in 50% of patients and increased with PsA activity and duration, and clinical enthesitis (p<0.01). US data showed no association with QoL in PsA (p>0.05).

**Conclusion:** QoL scores of this study were related to clinical data, particularly to clinical enthesitis. Us articular and enthesal inflammation were not correlated with QoL scores. This is probably due to the subclinical course of US changes. This allows us to conclude that QoL is associated with clinical than with US characteristics in PsA.

**REFERENCES:**


**DISCLOSURE OF INTERESTS:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4747

**POS1099 QUALITY OF LIFE, WORK IMPAIRMENT, AND DAILY ACTIVITY IMPAIRMENT OF PATIENTS WITH PSORIASIS VS PSORIATIC ARTHRITIS: A REAL-WORLD SURVEY IN US AND EUROPE**

**J. F. Merola1, L. E. Kristensen2, F. Yang3, S. Peterson2, R. Teneralli2, N. Massey2, S. D. Chakravarty4, M. Hughes2, M. Shawi5, S. Weatherby5, C. Contre2, I. Lin6, F. Hassan7, M. E. Husni8, Bringham and Women’s Hospital, Harvard Medical School, Boston, United States of America; 2The Parker Institute Bispebjerg-Frederiksberg Hospital, and Copenhagen University, Department of Health Sciences, Copenhagen, Denmark; 3Janssen Global Services, LLC, Horsham, United States of America; 4Adelphi Real World, Bollingtin, United Kingdom; 5Janssen Scientific Affairs, LLC, Horsham, United States of America; 6Drexel University College of Medicine, Philadelphia, United States of America; 7Janssen-Cilag France, LLC, Issy les Moulineaux, France; 8Janssen Pharmaceuticals, LLC, Horsham, United States of America; 9Janssen-Cilag LTD, High Wycombe, United Kingdom; 10Cleveland Clinic, Cleveland, United States of America

**Background:** Psoriasis (PsO) and psoriatic arthritis (PsA) and are chronic immune-mediated diseases characterised by joint inflammation and skin lesions which negatively impact patients’ health-related quality of life (HRQoL). Several previous comparative studies have focused on PsA patients with or without skin involvement. Better understanding of the impact of both PsO and PsA on HRQoL and work / activity impairment will improve understanding of the incremental burden of PsA compared to PsO, and may lead to more personalised treatment options.

**Objectives:** To compare HRQoL, work impairment, and daily activity impairment of patients with a PsO diagnosis (dx) only, PsO dx with musculoskeletal (MSK) symptoms (sx), PsA dx with active skin sx, and PsA dx without active skin sx.

**Methods:** Data were drawn from the Adelphi PsO & PsA Disease Specific Programmes (DSP), real-world point-in-time surveys of rheumatologists, dermatologists and their consulting patients in the United States and Europe (France, Germany, Italy, Spain and UK); conducted in 2018/19. Patients were grouped according to their symptoms and confirmed diagnoses, comprising four groups:

1. Patients with PsO dx only,
2. Patients with PsO dx and with MSK sx,
3. Patients with PsA dx and with active skin sx,
4. Patients with PsA dx with no active skin sx.

Multivariate linear regression analyses with marginal mean predictions examined differences in patient-reported outcome measures (PROMs) between the four groups. Measures included HRQoL (EuroQol 5-Dimension 5-Level [EQ-5D utility] and EuroQol Visual Analogue Scale [EQ-VAS]), work impairment, and daily activity impairment (Work Productivity and Activity Impairment Questionnaire [WPAI]). Analyses controlled for demographics (age, sex, BMI), comorbidities present in >10% of patients and current treatment class (biologics, csDMARDs, steroids & other).

**Results:** 4491 patients were included: Group 1 (n=1833), Group 2 (n=91), Group 3 (n=2451), and Group 4 (n=116). 54% of patients were male, 89% of patients were white, with a mean age of 46.6 years. Demographics were consistent across all patient groups.

The model-predicted EQ-5D-Utility was lower in Groups 2, 3 and 4, compared with Group 1 (p<0.003, p<0.001 and p=0.004 respectively). Similarly, predicted EQ-VAS was lower in Group 3 compared with Group 1 (p<0.006).

**Table 1. Predictions of PROMs for PsO-PsA patient groups**

<table>
<thead>
<tr>
<th>PRO tool</th>
<th>Group [n]</th>
<th>Predicted PRO value</th>
<th>Population norm (MCID)</th>
<th>Regression model p-value (vs. reference group)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ-5D Utility score (n=1833)</td>
<td>1 (ref) [743]</td>
<td>0.922</td>
<td>0.88 (0.07)</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>2 (32)</td>
<td>0.816</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>3 (1023)</td>
<td>0.810</td>
<td></td>
<td>0.044</td>
</tr>
<tr>
<td></td>
<td>4 (41)</td>
<td>0.850</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EQ-VAS (n=1882)</td>
<td>1 (ref) [763]</td>
<td>78.3</td>
<td>78.2 (n/a)</td>
<td>0.057</td>
</tr>
<tr>
<td></td>
<td>2 (36)</td>
<td>70.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 (1040)</td>
<td>73.89</td>
<td></td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>4 (43)</td>
<td>75.23</td>
<td></td>
<td>0.248</td>
</tr>
<tr>
<td>WPAI % overall work impairment (n=1015)</td>
<td>1 (ref) [422]</td>
<td>15.36</td>
<td>n/a (15.0)</td>
<td>0.560</td>
</tr>
<tr>
<td></td>
<td>2 (14)</td>
<td>17.86</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 (558)</td>
<td>22.16</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>4 (41)</td>
<td>26.09</td>
<td></td>
<td>0.014</td>
</tr>
<tr>
<td>WPAI % work time missed (n=1028)</td>
<td>1 (ref) [424]</td>
<td>0.91</td>
<td>n/a (n/a)</td>
<td>0.486</td>
</tr>
<tr>
<td></td>
<td>2 (14)</td>
<td>3.57</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 (569)</td>
<td>4.46</td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>4 (21)</td>
<td>10.43</td>
<td></td>
<td>0.003</td>
</tr>
<tr>
<td>WPAI % impairment while working (n=1153)</td>
<td>1 (ref) [486]</td>
<td>14.90</td>
<td>n/a (20.0)</td>
<td>0.846</td>
</tr>
<tr>
<td></td>
<td>2 (18)</td>
<td>13.89</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>3 (326)</td>
<td>19.63</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4 (23)</td>
<td>17.39</td>
<td></td>
<td>0.435</td>
</tr>
<tr>
<td>WPAI % activity impairment (n=1818)</td>
<td>1 (ref) [732]</td>
<td>18.02</td>
<td>n/a (20.0)</td>
<td>0.122</td>
</tr>
<tr>
<td></td>
<td>2 (32)</td>
<td>26.25</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3 (1012)</td>
<td>26.14</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>4 (42)</td>
<td>25.24</td>
<td></td>
<td>0.044</td>
</tr>
</tbody>
</table>

*p values provided for reference, but margins are predictions as a result of the model and not for the specific number of patients in each subgroup.

(1) Patients with PsO dx only
(2) Patients with PsO dx and MSK sx
(3) Patients with PsA dx and with active skin sx
(4) Patients with PsA dx with no active skin sx

Overall work impairment increased in Groups 3 and 4, compared with Group 1 (p<0.001 and p=0.014 respectively). Furthermore, Groups 3 and 4 missed more work compared with Group 1 (p=0.002 and p=0.003 respectively). Group 3 patients exhibited an increase in presenteeism and activity impairment compared with Group 1 (p<0.001).

**Conclusion:** Patients experiencing PsA dx or MSK sx experienced an additional disease burden compared to patients with PsO dx alone, as measured by worse HRQoL and work impairment.

PSYCHOMETRIC PROPERTIES OF PATIENT GLOBAL ASSESSMENT IN THE EVALUATION OF PSORIATIC ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW

F. Chessa 1, M. Piga 1, A. Fiori 1, M. Congia 1, M. M. Angioni 1, A. Cauli 1

1 Rheumatology Unit - University and AOU of Cagliari, Public Health and Medical Sciences, Monserrato, Italy

Background: Recommendations emphasize the need for the physician to work in partnership with the patient and a shared decision-making process is nowadays fundamental to manage properly Psoriatic Arthritis (PsA). Patient Global Assessment (PtGA) is a score that reflects the patient’s judgment about the disease activity and is getting more used in clinical routine and research.

Objectives: The objective of this systematic literature review (SLR) is to analyze the role of PtGA in PsA and to describe its psychometric properties.

Methods: This SLR was conducted by two independent reviewers in accordance with the PRISMA statement, searching for articles reporting on the use of PtGA in PsA. All articles published until February 2021 in Pubmed were screened with no limitation about years of publication, language or patients’ age. Articles reporting data of PtGA of skin assessment were excluded. Psychometric properties data were analysed according to the OMERACT (Outcome Measures in Rheumatology) Filter methodology version 2.1. Measurement properties of the PtGA were analysed according to the COSMIN terminology.

Results: The literature search identified 45 studies, accounting for 8516 patients in 20 longitudinal cohort studies, 15 cross-sectional studies, 5 randomized controlled trials, 2 post-hoc analyses, 1 retrospective study and one review. Ten articles were excluded because PtGA was referred to the assessment of cutaneous psoriasis. Content validity was reported in 32 studies. Different definitions, acronyms, scales and questions to assess PtGA were retrieved from the literature (see Table 1).

Table 1. Different questions, definitions, acronyms, scales and scores used to assess Patient Global Assessment retrieved. STD: studies

<table>
<thead>
<tr>
<th>QUESTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>How would you rate the patient’s joint disease activity?</td>
</tr>
<tr>
<td>In all the ways in which your PSORIATIC ARTHRITIS, as a whole, affect you, how would you rate the way you feel over the past week?</td>
</tr>
<tr>
<td>How active was your rheumatic disease on average during the last week?</td>
</tr>
<tr>
<td>Considering all the ways PsA has affected you during the last week, circle the number that best describes how you have been doing</td>
</tr>
<tr>
<td>How do you estimate your disease activity today?</td>
</tr>
<tr>
<td>How active do you feel your joint disease is today?</td>
</tr>
</tbody>
</table>

DEFINITIONS
- Pt visual analogue scale (VAS) for pain and global assessment
- Pt general disease assessment
- Pt global activity
- Pt global assessment
- Pt global disease activity
- Pt opinion on the level of disease activity
- Pt global evaluations
- Pt perception of disease
- Pt disease severity

ACRONYMS
- PtGA: Patient’s global assessment
- PGA: Patient’s global assessment
- PaGA: Patient’s global assessment

SCALES
- VAS (23 std); NRS (12 std)

SCORES
- 0-100 (23 std); 0-10 (11 std); 0-5 (5 std)

Face validity was reported in all the articles retrieved. PtGA was always used together with other instruments, alone or as part of composite indices: supporting its face validity. In 2 studies it was considered the instrument of reference to assess the outcome. A good correlation with PtGA, DAS28, BASDAI, ASDAS and DAPSA was found (see Figure 1). One study showed that the correlation became better (ES 1.81, 95%CI 1.42 2.19) during the follow up assessment. Three studies analyzed the discordance between patient and physician global assessment and in 25.0-49.0% found a positive discordance (PtGA higher than PhGA). Criterion validity was assessed exploring the PtGA correlation with quality of life measurements, demographic characteristics, biomarkers levels, treatment changes and damage assessments in 11 studies. The intrarater reliability was calculated only in 1 study, with an optimal correlation (ICC=0.87; 95%CI 0.83–0.90). PtGA responsiveness was used to evaluate response to treatment in 14 studies.

Figure 1. Forest plot showing correlation between PtGA and other instruments

Conclusion: PtGA demonstrated to be valid and feasible, but more studies are necessary to confirm its reliability and to evaluate its sensitivity to change. In addition, a clear definition of what PtGA refers to, what time and what kind of scale to adopt should be standardized.

Disclosure of Interests: None declared

PSI1010
DAPSA CORRECTED FOR PSAID12 IMPROVES ITS CONCORDANCE WITH MINIMAL DISEASE ACTIVITY.

G. Gonzalez Arribas 1, C. L. Iñiguez 2, F. Macías-Pane 3, V. Quevedo Vila 4, L. Fernández-Dominguez 5, J. A. Mosquera Martínez 6, C. García-Porrúa 7, J. L. Guerra-Vazquez 8, J. A. Pinto Tasende 1 on behalf of GIGAPs. 1 Hospital Universitario de Coruña, Rheumatology, A Coruña, Spain; 2Hospital Lucus Augusti, Rheumatology, Lugo, Spain; 3Hospital do Meixoeiro, Rheumatology, Vigo, Spain; 4Hospital Comarcal de Montforte de Lemos, Rheumatology, Montforte de Lemos, Spain; 5Complexo Hospitalario Universitario de Ourense, Rheumatology, Ourense, Spain; 6Hospital Montecelo (Pontevedra), Rheumatology, Pontevedra, Spain; 7Hospital Arquitecto Marcide, Rheumatology, Ferrol, Spain; 8Hospital Universitario de Coruña, Rheumatology, INIBIC, A Coruña, Spain

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease of highly variable presentation, which determines a physical and psychological deterioration, with a negative impact on the quality of life of patients and knowing the patient’s perception of their health status is very important for a good management of PsA.

Objectives: To assess an adjustment of the DAPSA according to the status of the PsAID-12 (impact of the disease in psoriatic arthritis) and to analyze its relation in clinical practice with the minimal activity of the disease (Minimal Disease Activity or MDA) in psoriatic arthritis.

Methods: Multicenter cross-sectional study, which recruited 200 patients, who met the criteria for Classification of Psoriatic Arthritis (CASPAR), in six Spanish rheumatology centers. At the time of the visit, demographic, clinical, laboratory data, HAQ (0–3) and PsAID12 (0–10) self-questionnaires were collected. Disease activity was measured using DAPSA (with its cut-off points), MDA status was obtained, and the PsAID12 index was calculated. When a PsAID4 was not reached, the DAPSA was scaled to a higher interval (DAPSA corrected) obtaining a new index, DAPSA-PsAID. All analyzes were performed using SPSS23 software. Differences were considered statistically significant if p < 0.05.

Results: Of the total number of patients, 55% were men, with an age of 55.2 ± 11.6 years; 75% had only peripheral involvement and 25% had pure or mixed axial involvement. 43% were on biological treatment and 27.6% vs 27.6% (Kappa 0.750 vs 0.688). In the binary regression analysis for MDA status, adjusted for sex, an OR (95% CI) for DAPSA, and DAPSA corrected for PsAID of 8.12 (1.88-35.04) and 12.31 (3.74-40.50), respectively, was obtained.

Figure 1. Forest plot showing correlation between PtGA and other instruments
THE PREVALENCE OF INFLAMMATORY BACK PAIN IN PATIENTS WITH SKIN PSORIASIS WITHOUT PSORIATIC ARTHRITIS. DATA FROM DERMATOLOGICAL REAL-WORLD SETTING.

N. Pereverzina1, L. Kruglova1, T. Korotaeva2, A. Lila3.
1Central State Medical Academy of the Administrative Department of the President of Russia, Department of Dermatology and Cosmetology, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritides and Psoriatic-Arthritis, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: Psoriasis (PsO) is an inflammatory disease associated with psoriatic arthritis (PsA). PsA affects peripheral and axial joints1. Psoriasis can precede the onset of PsA by approximately 3 to 8 years, axial involvement often undiagnosed.2 There are limited data about the prevalence of inflammatory back pain (IBP) in PsO patients (pts) without clinical symptoms of PsA.3

Methods: A PsAID-corrected DAPSA could be a more reliable alternative to DAPSA than conventional DAPSA and facilitate clinician decisions in daily practice.

Disclosure of Interests: Guillermo Gonzalez Arribas: None declared, Carolina Fernández-Dominguez: None declared, Luis Mosquera Martínez: None declared, Carlos García-Porrúa: Speakers bureau: Janssen, Novartis, Lilly, Abbvie, UCB, Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Alexander Lila: None declared

DOI: 10.1136/annrheumdis-2022-eular.4958

POS1102

"WHAT MATTERS": PATIENT AND CLINICIAN PERSPECTIVES IN PSORIATIC ARTHRITIS CARE

P. J. Mease1, D. Furst2, E. Siegel3, V. Strand4, M. McIlraith5, M. E. Husni6, M. C. Hay1, 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America; 3University of California Medical Center, Rheumatology, Los Angeles, California, United States of America; 4Stanford University, Immunology and Rheumatology, Palo Alto, California, United States of America; 5McM Consulting, Research, Dallas, United States of America; 6Cleveland Clinic, Rheumatologic and Immunologic Disease, Cleveland, Ohio, United States of America; 7Miami University, Anthropology, Oxford, Ohio, United States of America

Background: Recent psoriatic arthritis (PsA) treatment recommendations (1) highlight the importance of shared decision making; this ideally requires the clinician understands "what matters" to each patient regarding their disease. Concurrently, patient research partners have been incorporated into projects for the OMERACT core domain set (2) and measures of physical function and (health related) quality of life (3). Currently, less is known about the similarities and differences between patient and clinician perspectives.

Objectives: To interrogate and delineate commonalities and discrepancies in "what matters" to patients and to physicians in routine clinical care.

Methods: A comprehensive list of items describing the PsA patient experience was generated in medical anthropologist-designed (CH) peer-to-peer discussions in 4 patient focus groups across the United States (Seattle, Cleveland, Washington, NC). These items were combined with those from the GRAPPA-OMERACT PsA Outcomes patient-physician consensus project (2). A PsA physician and patient steering committee reviewed and revised the list with additional topics deemed to be of importance. The final list of 51 items went through a 3 round Delphi process starting with 53 PsA patients and a 2 round Delphi with 13 PsA expert rheumatologists. In each round, participants rated each item for level of importance out of 100 total points.

Results: Top priority items for each group are depicted in Figure 1. Both patients and physicians rated Arthritis -Joint pain and swelling in the top two. Five additional items were included for both groups but with different scores; all related to disease manifestations or physical consequences. Several items received disparate priority between groups. In this set, patients included two unique items: access to care and future health uncertainty. Other items affecting everyday function were noted. Physician priorities included specific disease manifestations and physical/functional outcomes, and the topic of "disease management goals," focusing on patient-physician communication regarding a treatment plan.

Figure 1. Top Patient and Physician Priorities *Not in set of highest ranked items for that group

Table 1.

<table>
<thead>
<tr>
<th>MDA</th>
<th>No MDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=102</td>
<td>N=98</td>
</tr>
<tr>
<td>HAQdS 0.5, n (%)</td>
<td>82 (92.0)</td>
</tr>
<tr>
<td>DAPSA-REMLDA, n (%)</td>
<td>98 (96.1)</td>
</tr>
<tr>
<td>PsAID-q, n (%)</td>
<td>92 (90.2)</td>
</tr>
<tr>
<td>DAPSA-REMLDA, n (%)</td>
<td>93 (91.2)</td>
</tr>
</tbody>
</table>

Conclusion: PsAID-corrected DAPSA could be a more reliable alternative to MDA than conventional DAPSA and facilitate clinician decisions in daily practice.

REFERENCES:

Disclosure of Interests: Natalia Pereverzina: None declared, Larisa Kruglova: None declared, Tatiana Korotaeva Speakers bureau: Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Alexander Lila: None declared


POS1103

as enthesis, dactylitis, and skin disease more highly, patients considered items such as access to care, future health uncertainty and sleep quality to be most important. This study highlights the need for physicians to ask and address 'what matters' with patients and educate patients about potential differences in physicians' areas of concern to optimize shared decision making.

REFERENCES:

Disclosure of Interests: Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Genentech, Janssen, Pfizer, Novartis, UCB, Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Celgene, Boehringer Ingelheim, Genentech, Novartis, Janssen, Pfizer, Sun Pharma, UCB, GSK, Grant/research support from: AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Celgene, Boehringer Ingelheim, Genentech, Novartis, Janssen, Sun Pharma, Pfizer, Daniel Furst Speakers bureau: Corbus, GSK, Sanofi, Consultant of: Actelion, Amgen, BMS, Corbus, Galapagos, Sanofi, Novartis, Pfizer, Grant/research support from: Actelion, Amgen, BMS, Galapagos, Sanofi, Roche/Genentech, Novartis, Pfizer, Evan Siegel Speakers bureau: AbbVie, Janssen, UCB, Novartis, Lilly. Consultant of: AbbVie, Janssen, UCB, Novartis, Lilly, BMS, Vibeke Strand Consultant of: Abbvie Amgen Corporation Arena Aria AstraZeneca, Bayer, Bioventus, BMS, Boehringer Ingeheim, Celltrion, Chemocentryx, Elsa, EMD Serono, Endo, Equilibrium, Flexion, Galapagos, Genentech / Roche, Gilead, GSK, Horizon, Ichnos, Inmedix, Janssen, Kinkika, Kypha, Lilly, Merck, MiMedex, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Scipher, Servier, Setpoint, Sorrento, Spherix, Sun Pharma, Swing, UCB, Melissa Mcilraith Employee of: Past employee at Abbott and Celgene, M Elaine Husni Consultant of: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, UCB, Regeneron, M. Cameron Hay Grant/research support from: Novartis for this IIS


Table 1. Results of the Pearson correlation tests of changes experienced over time.

<table>
<thead>
<tr>
<th>Variables of change (Final-Baseline)</th>
<th>Achilles tendon elasticity change</th>
<th>Patellar tendon elasticity change</th>
<th>Achilles mean grey intensity changes</th>
<th>Patellar mean grey intensity changes</th>
<th>Achilles mode grey intensity changes</th>
<th>Patellar mode grey intensity changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calf circumference change</td>
<td>Pearson correlation</td>
<td>.050</td>
<td>.470</td>
<td>.094</td>
<td>.530</td>
<td>.935</td>
</tr>
<tr>
<td></td>
<td>Sig. (bilateral)</td>
<td>.040</td>
<td>.042</td>
<td>.014</td>
<td>.120</td>
<td>-.160</td>
</tr>
<tr>
<td>Thigh circumference change</td>
<td>Pearson correlation</td>
<td>.014</td>
<td>.069</td>
<td>.120</td>
<td>-.160</td>
<td>.022</td>
</tr>
<tr>
<td></td>
<td>Sig. (bilateral)</td>
<td>.056</td>
<td>.780</td>
<td>.624</td>
<td>.514</td>
<td>.928</td>
</tr>
<tr>
<td>Body Fat % Change</td>
<td>Pearson correlation</td>
<td>-.237</td>
<td>.098</td>
<td>.893</td>
<td>.626</td>
<td>.712</td>
</tr>
<tr>
<td></td>
<td>Sig. (bilateral)</td>
<td>.330</td>
<td>.689</td>
<td>.893</td>
<td>.626</td>
<td>.712</td>
</tr>
<tr>
<td>Achilles tendon elasticity change</td>
<td>Pearson correlation</td>
<td>1</td>
<td>.221</td>
<td>.779*</td>
<td>.090</td>
<td>.147</td>
</tr>
<tr>
<td></td>
<td>Sig. (bilateral)</td>
<td>.362</td>
<td>.362</td>
<td>.000</td>
<td>.715</td>
<td>.546</td>
</tr>
<tr>
<td>Patellar tendon elasticity change</td>
<td>Pearson correlation</td>
<td>.221</td>
<td>1</td>
<td>.353</td>
<td>.899*</td>
<td>.416</td>
</tr>
<tr>
<td></td>
<td>Sig. (bilateral)</td>
<td>.362</td>
<td>.139</td>
<td>.000</td>
<td>.076</td>
<td>.529</td>
</tr>
</tbody>
</table>

Two ultrasound measurements of the patellar and the Achilles long axis were performed. Also, two elastographies of the same tendons and two anthropometric measurements of the thigh and calf were made at the beginning and end of the training period. To demonstrate sensitivity to change, a correlation was made between the ultrasound, elastographic and anthropometric morphological changes, and the result of the computer analysis of the image in terms of gray scale mean and mode.

Results: 19 volunteers were evaluated (mean age 24 ±2 years, 12 women). After the exercise routine, we found statistically significant differences between calf perimeter (mean -3.70 ±1.803; p .000), Achilles elastography (-.347 ±.294; p .000), Achilles and patellar MGI (4.229 ±4.849; p .001 and 2.331 ±3.115; p.004).

Regarding the non-normal distributed variables, we met statistically significant differences between patellar elastography (average range 11.45, sum of the ranks 126.00; Z -2.343; p.019), Achilles and patellar grey intensity modes (average 12.92, sum 168.00; Z -2.938; p.003 and average 11.77 sum 176.50; Z -3.28; p.001). The correlations study is shown in Table 1.

Figure 1. Before (upper) and after (lower) evaluation.

Conclusion: Computer analysis of static images of the Achilles and patellar tendons is sensitive to the change induced by exercise in young and healthy subjects. The mean gray intensity correlates better with elastography. This shows that the predominance of the fibrillar pattern induced by exercise produces a higher speed of sound conduction. The gray intensity mode correlates better with the anthropometric changes experienced by the subjects. The concentration of shades in white extremes translates into greater anthropometric changes. This demonstrates that the stiffness or elasticity of a tendon correlates with the global distribution of gray. The response to mechanical stimuli correlates with the concentration of more intense white tones that are not necessarily scattered (endophytes or pre-enthesophytes).

Disclosure of Interests: Carlos Guillén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grunenthal, UCB, Gebro, Paid instructor for: Roche, Novartis, Janssen, Esteve, Menarini, Consultant of: Janssen, Novartis, Roche, Grant/research support from: Pfizer, Grunenthal, Gebro, Novartis, Africa Andreu-Suárez: None declared, Marina Tortosa-Cabañas: None declared, Cristina Pijoan Moratalla: None declared, Paula Barrio Rufino: None declared, Esther Muñoz Rodriguez: None declared, Jorge Molíá Cuadrillero: None declared


Table 1. Results of the Pearson correlation tests of changes experienced over time.
Efficacy and Safety of Colchicine for the Treatment of Osteoarthritis: A Systematic Review and Meta-Analysis of Intervention Trials

A. Singh1, P. Molina-García1,2, S. Hussain3, A. Paul4, S. K. Das5, Y. Leung6, J. Samuels7, B. Antony1, Menzies Institute for Medical Research, Musculoskeletal Health and Disease, Hobart, Australia; 2Virgen de las Nieves University Hospital, Granada, Spain, BioHealth Research Institute (ibs.Granada) Physical Medicine and Rehabilitation Service, Granada, Spain; 3University of Granada, Granada, Spain, PROFITH (PROmoting FITness and Health through physical activity) Research Group, Department of Physical Education and Sports, Faculty of Sport Sciences, Granada, Spain; 4Masaryk University, Brno, Czech Republic, Czech National Centre for Evidence-Based Healthcare and Knowledge Translation (Cochrane Czech Republic, Czech EBHC; JBI Centre of Excellence, Masaryk University GRADE Centre), Institute of Biostatistics and Analyses, Faculty of Medicine, Brno, Czech Republic; 5University of Tasmania, School of Pharmacy and Pharmacology, Hobart, Australia; 6Era’s University, Lucknow, India, Department of Rheumatology, Lucknow, India; 7Singapore General Hospital, Singapore, Department of Rheumatology and Immunology, Singapore, Singapore; 8NYU Grossman School of Medicine, New York, New York, USA, Department of Medicine, Division of Rheumatology, New York, United States of America; 9University of Tasmania, Hobart, Tasmania, Australia, Menzies Institute for Medical Research, Hobart, Australia

Background: Colchicine, an approved treatment for gout, has been trialled in many diseases, including osteoarthritis (OA), due to its anti-inflammatory effects. However, its efficacy and safety remain unclear in OA.

Objectives: This systematic review and meta-analysis evaluated the efficacy and safety of colchicine for the treatment of OA.

Methods: PubMed, Web of Science, Scopus, and Cochrane Central were searched from inception through November 2020. Two reviewers independently screened for randomised controlled trials (RCTs) comparing colchicine with placebo or other active-comparators for the treatment of OA (knee, hand, or hip OA), extracted data, and performed Cochrane risk of bias assessments.

Results: The search retrieved 391 articles after removing duplicates, and 16 full-text articles were reviewed for eligibility (Figure 1A). Ten RCTs, nine in knee OA, one in hand OA, consisting of 847 patients (429 in colchicine arm, 409 in control arm) were included. RCTs were conducted between 2002 and 2021; three in India, two in Iran and Turkey, and one each in Australia, Singapore, and Iraq; follow-up period ranged 2 to 12 months. Moderate-quality evidence showed no clinically important pain reduction with colchicine compared to placebo. Knee OA patients (standardised mean difference (SMD) 0.17; 95% confidence interval (CI). -0.55 to 0.22) (Figure 1B), Moderate-quality evidence showed no improvement in dysfunction with colchicine compared to placebo in knee OA patients (SMD, -0.37; 95% CI, -0.87 to 0.13). Colchicine showed an acceptable safety profile with AEs/SAEs comparable to placebo (Figure 1C).

Conclusion: Current evidence does not conclusively suggest a benefit of colchicine in reducing pain and improving physical function in hand/knee OA patients. Future trials should focus on the sub-groups of OA patients with local or systemic evidence of inflammation and/or mineralisation who may benefit from colchicine.

REFERENCES:
Disclosure of Interests: None declared

Mediators of the Effect of Therapeutic Exercise on Pain and Function in Patients with Knee and Hip Osteoarthritis: An Individual Patient Data MEDIATION STUDY FROM THE OA TRIAL BANK.

J. Runhaar1, M. Holden2, M. Hattie3, J. Quicke2, R. Riley2, E. Healey2, D. Van der Windt2, K. Dziedzic2, M. Van Middelkoop1, S. M. A. Bierna-Zeinastra3, N. Foster4on behalf of the OA Trial Bank Exercise Collaborative. 1Erasmus MC University Medical Center Rotterdam, General Practice, Rotterdam, Netherlands; 2Keele University, Primary Care Centre Versus Arthritis, School of Medicine, Keele, United Kingdom; 3Erasmus MC University Medical Center Rotterdam, General Practice and Orthopedics & Sports Medicine, Rotterdam, Netherlands; 4The University of Queensland and Metro North Health, STARS Education and Research Alliance, Surgical Treatment and Rehabilitation Service, Brisbane, Australia

Background: Currently, there is no cure for osteoarthritis (OA). Therapeutic exercise is recommended in all international guidelines to improve pain and function (1). However, randomised controlled trials (RCTs) investigating therapeutic exercise showed that, on average, effect sizes are small to moderate compared to non-exercise controls (2-3). Better knowledge about how therapeutic exercise works to improve pain and function could help improve the design and delivery of future therapeutic exercise interventions and potentially improve patient outcomes.

Objectives: To evaluate the mediating effects of 1) muscle strength, proprioception, and range of motion (ROM) among patients with knee OA, and 2) muscle strength among patients with hip OA, using the procedures established for Individual Participant Data (IPD) analyses by the OA Trial Bank.

Methods: Relevant IPD were sought from all published RCTs comparing therapeutic exercise to a non-exercise control group among people with knee and/or hip OA, using previously published methods (4). For each potential mediator separately, the effect of exercise on the absolute change in pain/function directly after the intervention was determined, controlling for the relative change in mediator under investigation and potential mediator-outcome confounders, using the counterfactual framework (5). Next, the effect of exercise on the relative change in the mediator was determined. The percentage mediated was calculated by dividing the natural indirect effect by the total effect.

Results: We obtained IPD from 12 RCTs and 1407 participants (knee OA = 1113; hip OA = 294) that were eligible for inclusion in one or more mediation analyses. Therapeutic exercise showed a significant effect on the relative change in muscle strength in hip OA of all mediators, only the change in muscle strength had a significant effect on the change in pain in knee OA, and on function in knee OA and in hip OA. The percentage mediated for each mediator and each outcome was small (5.3% or less, see Table 1).

Table 1. Percentage mediated for all potential mediators, by outcome and joint.

<table>
<thead>
<tr>
<th></th>
<th>Knee OA Pain</th>
<th>Knee OA Function</th>
<th>Hip OA Pain</th>
<th>Hip OA Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle strength</td>
<td>2.4%</td>
<td>2.3%</td>
<td>absent</td>
<td>absent</td>
</tr>
<tr>
<td>Proprioception</td>
<td>absent</td>
<td>0.2%</td>
<td>absent</td>
<td>absent</td>
</tr>
<tr>
<td>Range of motion</td>
<td>1.8%</td>
<td>5.3%</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*absent*: no percentage mediated calculated, since direct and indirect effect had opposite directions; † factors not considered a potential mediator for therapeutic exercise in hip OA.

Conclusion: In the first IPD mediation analysis to our knowledge of this scale, muscle strength, proprioception and ROM did mediate the effect of therapeutic exercise for pain and function in knee OA, but only to a very small degree. We observed no such mediating effect of muscle strength for therapeutic exercise in patients with hip OA. The challenge remains to better understand the key mechanisms of action of therapeutic exercise for knee and hip OA, so that exercise interventions can be designed and delivered to target these and therewith optimise the effects for patients.

REFERENCES:
Persons (BMI ≥ 27 kg/m²) with KOA. Weight loss was induced by an intensive low-calorie weight loss intervention in overweight persons with KOA.

Objectives:

Changes in US-based synovitis following a weight loss intervention. After the diet intervention mean weight change was -12.8 kg of 106.0 kg (SD18.5) and mean BMI of 36.4 (SD5.4) completed the weight loss intervention (1200 kcal/day). Participants had symptomatic and radiographic KOA (KL grade 1-3). At week 0 and 8 all participants filled in the KOOS questionnaire assessing pain, physical function, symptoms, quality of life, and sport/recreation in relation to KOA (0= worst; 100=best). Furthermore, an US examination of the most affected knee was performed assessing the amount of synovial hypertrophy (SH) and effusion in medial and lateral recesses. The US examination was performed in a strictly standardized manner.

Results:

Change in the KOOS subscales range from 15.8 (sports/recreation) to 7.4 (QoL). See Table 1.

Table 1: n=135

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>Mean (95%CI)</td>
<td>P</td>
</tr>
<tr>
<td>Age</td>
<td>60.0 (9.8)</td>
<td>-</td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>87 (64.4%)</td>
<td>-</td>
</tr>
<tr>
<td>BMI</td>
<td>36.4 (5.6)</td>
<td>-4.4 (-4.5 to -4.3)</td>
</tr>
<tr>
<td>KL-scores: 1</td>
<td>22 (16.3%)</td>
<td>-</td>
</tr>
<tr>
<td>KL-scores: 2</td>
<td>56 (41.5%)</td>
<td>-</td>
</tr>
<tr>
<td>KL-scores: 3</td>
<td>57 (42.2%)</td>
<td>-</td>
</tr>
<tr>
<td>KL-scores: 4</td>
<td>0 (0%)</td>
<td>-</td>
</tr>
<tr>
<td>Synovial Hypertrophy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medial, mm</td>
<td>3.8 (1.8)</td>
<td>-0.3 (-0.5 to -0.1)</td>
</tr>
<tr>
<td>Lateral, mm</td>
<td>5.3 (2.3)</td>
<td>-0.4 (-0.6 to -0.1)</td>
</tr>
<tr>
<td>Medial, 0-3</td>
<td>1.2 (0.6)</td>
<td>-0.03 (-0.13 to 0.07)</td>
</tr>
<tr>
<td>Lateral, 0-3</td>
<td>1.8 (0.8)</td>
<td>-0.07 (-0.20 to 0.05)</td>
</tr>
</tbody>
</table>

Conclusion: Quantitative measures of SH assessed by US decreased after a significant weight loss over 8-weeks; however, no linear association with weight loss magnitude was seen. A weak correlation between changes in SH in the lateral recess and change in pain was seen. This indicates changes in SH assessed by US examination is associated with a low-calorie diet but seems uncoupled with weight loss magnitude. The weight loss induced changes in synovitis and KOA symptoms seem vaguely related.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.530

POS1107

CHANGE IN ULTRASOUND-BASED KNEE JOINT INFLAMMATORY MARKERS AFTER WEIGHT LOSS IN PATIENTS WITH OSTEOARTHRITIS: A PROSPECTIVE COHORT STUDY.

K. Ellegaard1, J. Guldberg-Meller1, M. Boesen2, L. E. Kristensen3, H. Gudbergsen1, L. Jensen1, A. Overgaard1, H. Bliddal1, M. Henriksen1.

1Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark; 2Bispebjerg and Frederiksberg Hospital, Department of Radiology, Copenhagen, Denmark; 3Bispebjerg and Frederiksberg Hospital, The Parker Institute, Frederiksberg, Denmark

Background: Pain and impaired function due to knee OA (KOA) can be reduced with weight loss in obese patients. The role of synovitis in symptom improvement after weight loss is not fully understood. MRI and ultrasound (US) can be used in assessment of inflammation in the KOA. Knee joint synovitis assessed by MRI does not seem to change with weight loss, however, the typical MRI score is semiquantitative, which might be less sensitive to change than a quantitative score. US has a higher resolution than MRI and borders between synovium and surrounding tissues might be clearer allowing for a quantitative score. Changes in US-based synovitis following a weight loss has not been assessed.

Objectives: To assess changes in US synovitis in the knee joint after 8 weeks low-calorie weight loss intervention in overweight persons with KOA.

Methods: Prospective cohort study (NTC02931370) including overweight persons (BMI ≥ 27 kg/m²) with KOA. Weight loss was induced by an intensive 8-week diet (1200 kcal/day), participants had symptomatic and radiographically confirmed KOA (KL grade 1-3). At week 0 and 8 all participants filled in the KOOS questionnaire assessing pain, physical function, symptoms, quality of life, and sport/recreation in relation to KOA (0= worst; 100=best). Furthermore, an US examination of the most affected knee was performed assessing the amount of synovial hypertrophy (SH) and effusion in medial and lateral recesses. The US examination was performed in a strictly standardized manner on a high-end US machine. The subsequent image evaluation was done both according to a semiquantitative score from 0 to 3 (0= no SH/effusion and 3= pronounced SH/effusion) and a quantitative scoring system using specific anatomic landmarks to measure the synovial hypertrophy/effusion in millimeter. Statistical analyses were performed on the per protocol population (participants completing diet intervention).

Results: 135 patients with KOA with a mean age of 60y (SD 9.8), a body weight of 106.0 kg (SD18.5) and mean BMI of 36.4 (SD5.4) completed the weight loss intervention. After the diet intervention mean weight change was -12.8 kg (95%CI: -13.3 to -12.4) and the reductions in SH were -0.3 mm (95%CI: -0.5 to -0.1) (medial recess) and -0.4 mm (95%CI: -0.6 to -0.1) (lateral recess), and -0.03 (-0.13 to 0.07) (medial recess) and -0.07 (-0.20 to 0.05) using the semi-quantitative system. The mean change in the KOOS subscales range from 15.8 (sports/recreation) to 7.4 (QoL). See Table 1.

Table 1. n=135

<table>
<thead>
<tr>
<th></th>
<th>Mean (SD)</th>
<th>Mean (95%CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>KOOS, 0-100</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>64.1 (16.0)</td>
<td>10 (12.0 to 13.8)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Function</td>
<td>68.4 (17.3)</td>
<td>14 (12.4 to 15.6)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Symptoms</td>
<td>68.9 (16.4)</td>
<td>9 (7.2 to 10.8)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Sports/Recreation</td>
<td>35.9 (24.0)</td>
<td>15.8 (13.2 to 18.3)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>QoL</td>
<td>43.8 (17.5)</td>
<td>74 (5.7 to 82)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Conclusion: Quantitative measures of SH assessed by US decreased after a significant weight loss over 8-weeks; however, no linear association with weight loss magnitude was seen. A weak correlation between changes in SH in the lateral recess and change in pain was seen. This indicates changes in SH assessed by US examination is associated with a low-calorie diet but seems uncoupled with weight loss magnitude. The weight loss induced changes in synovitis and KOA symptoms seem vaguely related.

Disclosure of Interests: None declared


POS1108

USE OF MACHINE LEARNING IN OSTEOARTHRITIS RESEARCH: A SYSTEMATIC LITERATURE REVIEW

M. Birvogn1, V. Pedia1, A. Butte1, K. Louati1, D. Klatzmann2, F. Berenbaum1, E. Mariotti-Ferrandiz2, J. Sellam1, Sboronne Universite, Rheumatology, Paris, France; 3Sorbonne Universite, I3 lab (Immunology Immunopathology Immunotherapy), Paris, France; 4UCSF, Bakar Computational Health Science Institute, San Francisco, United States of America; 5UCSF, Radiology and Biomedical Imaging Department, San Francisco, United States of America

Background: Artificial intelligence techniques, in particular machine learning (ML), are increasingly used in rheumatology and especially in osteoarthritis (OA). ML studies in OA are very heterogeneous, hence the need to have an overview of their field of application.

Objectives: The aim of this systematic literature review is to provide a comprehensive and exhaustive landscape of the use of ML in the clinical care of OA.

Methods: A systematic review of the literature was performed in July 2021 using the Medline database with key words and MeSH terms referring to ML methods in OA. Only original articles in English were considered. Articles related to replacement surgery, theoretical imaging, rehabilitation, molecular biology, and spinal or temporomandibular OA were excluded. For each selected article, the
The number of ML articles in OA has increased exponentially over the last 5 years with applications across all major research themes. However, there is methodological heterogeneity, with articles based mainly on radiological data, but also on knee OA. To date, there is no ML article on digital osteoarthritis. This work also shows the need to develop clinical cohorts to bring more diversity in ML work and to allow external validation. This article is the first systemic review of the literature in OA and provides an overview of ML in OA, its applications, limitations and perspectives.

**Disclosure of Interests:** Marie Bivinigon: None declared, Valentina Pedaio: None declared, Atul Butte Shareholder of: a minor shareholder in Apple, Facebook, Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina), None declared, Jérémie SELLAM Consultant of: MSD, Pfizer, Abbvie, L’Oreal, and Progenity., Karine Louati: None declared, David Klatzmann: Consultant of: Pfizer; Personalis and NuMedii; Randiz: None declared, Jérémie SELLAM Consultant of: MSD, Pfizer, Abbvie, L’Oreal, and Progenity., Karine Louati: None declared, Atul Butte Shareholder of: a minor shareholder in Apple, Facebook, Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina), None declared

**Results:** From 1,148 screened articles, 46 were selected and analyzed, most of which were published after 2017 (Figure 1). Twelve articles were related to diagnosis, 7 to prediction, 4 to phenotyping, 12 to severity and 11 to progression. The number of patients included ranged from 18 to 5,741. Deep learning (DL) was used in 35% of the cases. Imaging analyses represented 74% of the studies. Knee OA was studied in 85% of these articles while 15% investigated hip OA. None were on hand OA. Most of the studies were done on the same cohort with data from the Osteoarthritis Initiative (OAI) used in 46% of the articles whereas the Multi-Center Osteoarthritis Study (MOST) and the Cohort Hip and Cohort Knee Study (CHECK) cohort were respectively used in 11% and 7% of the articles. Data and source code were publicly available in 54% and 22% of the articles. External validation was provided in only 7% of the articles.

**Background:** Postoperative pain (POP) is a serious complication that affects the outcome of total arthroplasty (TA) of the knee (CJ) and hip (HJ) joints in patients with osteoarthritis (OA). The search for the genetic characteristics of POP is an urgent direction in the study of this problem.

**Objectives:** To determine the relationship between the polymorphisms of the KCNS1, COMT, and OPRM1 genes and the development of postoperative pain in patients with osteoarthritis of the knee joint and hip joint who underwent total arthroplasty.

**Methods:** The study group consisted of 95 patients with knee osteoarthritis and/or hip joint osteoarthritis (64.6% of women; mean age - 65.4 ± 9.0 years) who underwent TA CJ (47.8%) or TA HJ (52.2%). The presence of POP was determined when it persisted or appeared after 3 and 6 months. After surgery, pain in the area of the operated joint ≥40 mm by 100 mm visual analogue scale. All patients underwent genotyping of KCNS1 (rs734784), COMT (rs6269, rs4633), and OPRM1 (rs1799971) genes polymorphisms by real-time polymerase chain reaction using original sequence-specific primers and probes labeled with various fluorescent labels. Registration and interpretation of the obtained results were carried out on a DT-96 amplifier (DNA-Technology LLC, Russia).

**Results:** POP was observed in 32.6% of patients who underwent TA CJ or TA HJ. The incidence of POP after TA CJ and TA HJ was 30.2% and 34.0%, respectively (p = 0.882). There were no differences in the frequencies of genotypes of the studied genes (p>0.05). The presence of the homozygous GG genotype of the KCNS1 gene polymorphism (rs734784) was associated with the presence of POP in accordance with the recessive genetic model (GG vs AA + AG; odds ratio (OR) - 3.96 [95% confidence interval (CI): 1.51; 10.37]; p = 0.005). The presence in the genotype of the minor allele T (TT + CT) of the COMT polymorphism (rs4633) reduced the risk of developing POP compared with the carriage of the CC genotype (OR = 0.32 [95% CI: 0.12; 0.83]; p = 0.02) according to the dominant genetic model. There was no statistically significant correlation between the development of POP and the carriage of various genotypes and alleles of the OPRM1 gene (rs1799971) alleles.

**Conclusion:** There is a statistically significant association between the polymorphism of the OPRM1 (rs734784) and COMT (rs4633) genes and the development of chronic POP in patients who underwent TA CJ and TA HJ. Further studies of the genetic predisposition to POP are required using more clinical material.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.814

**WHAT FACTORS ARE ASSOCIATED WITH THE DEVELOPMENT OF PAIN AFTER TOTAL JOINT REPLACEMENT?**

**V. Nesterenko1, A. Karateev2, M. Makarov2, E. Blialik1, S. Makarov2, V. Blialik1, M. Nurmukhametov1, A. Roskidalo1, N. Burikov1, V.A. Nasonova Research Institute of Rheumatology, Rheumorthoapathics and Rehabilitation, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Rheumorthoapathics and Rehabilitation, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Department of Inflammatory Joint Diseases, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Department of Inflammatory Joint Diseases, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Department of Inflammatory Joint Diseases, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Department of Inflammatory Joint Diseases, Moscow, Russian Federation

**Background:** Chronic postoperative pain (CPP) is one of the most common complications of total hip (HJ) and knee (CJ) arthroplasty (TA). The search for the factors that determine this pathology is an urgent scientific and practical task.

**Objectives:** To determine the factors associated with the development of CPP in patients who underwent TA, CJ or HJ.

**Methods:** A total of 124 patients with osteoarthritis of the knee or hip joint, mean age 63.6±9.9 years, 63% of women and 37% of men, who in 2019-2020 year done out by TA KJ or HJ. The development of CPP was assessed after 3 and 6 months. Telephone survey of patients. This complication was diagnosed in the presence of moderate to severe pain (≥40 mm on a visual analogue scale, VAS), persisting for at least 3 months, causing concern in patients and/or requiring regular use of analgesics. A comparison was made between the groups of patients with CPP and the absence of CPP for a number of factors determined in the preoperative period.

**Results:** The incidence of CPP was 27.4%. There were no differences in the incidence of CPP in patients who underwent TA CJ and TA HJ: 28.1% and 26.9%, respectively (p = 0.88). The presence of CPP was significantly associated with such preoperative indicators as a higher body mass index (BMI), a higher intensity of pain at rest, higher values of the WOMAC pain index, WOMAC and WOMAC stiffness in general, and the severity of symptoms of neuropathic pain. (PainDetect questionnaire), signs of depression and anxiety (HADS questionnaire). The risk of developing CPP was significantly higher (p <0.05) in patients...
Conclusion: The risk of CPP after TA CJ and HJ is higher in patients with over-weight, high preoperative pain, signs of neuropathic pain and depression, and in the presence of several sources of musculoskeletal pain (except for the affected joint planned for TA).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.867

POS111

WHAT DOES GRIP STRENGTH REFLECT IN HAND OSTEOARTHRITIS? RESULTS FROM THE DIGICODE COHORT

E. Tan1, S. Tuffet2, A. Rousseau2, B. Faure2, F. Rannou3, F. Berenbaum1, J. Sellam1, A. Courtiès1, Saint-Antoine Hospital, Rheumatology, Paris, France; 2Saint-Antoine Hospital, Unité de Recherche Clinique de l’Est Parisien (URCEST), Paris, France; 3Pitié-Salpêtrière Hospital, Rheumatology, Paris, France; 4Cochin Hospital, Physical and Rehabilitation Medicine, Paris, France

Background: Among the general population over 60 years old, the decrease in grip strength is a marker of morbidity and mortality: its measurement during follow-up consultations is considered as a predictive marker of good health status or patient’s overall fragility (1). However, hand osteoarthritis (HOA), which can modulate grip strength and is also associated with comorbidities is never taken into account, while it is a very common disease.

Objectives: The objectives of this study are to describe grip strength in a symptomatic HOA population, to investigate painful osteoarthritic joints associated with decreased grip strength, and to determine whether decreased grip strength is independently associated with comorbidities in this population.

Methods: DIGICODE is a hospital-based observational cohort including patients with radiographic features of HOA of at least 2 joints or radiographic thumb base OA. Inflammatory rheumatism or crystal arthropathy were excluded. The data at baseline were used for the analysis. Grip strength was the higher score of 3 repeated measurements using a Jamar dynamometer. Baseline grip strength of the dominant hand was compared in the cohort between men and women (Student’s T test) and was described by age (by 10-year age groups using Kruskal-Wallis test). In this cross-sectional study, factors associated with a decreased grip strength were investigated using univariate and then multivariate linear regression analysis (with adjustment on age, BMI and variables with p < 0.2 in univariate analysis) with stratification by sex. Results were presented by beta coefficients and their 95% confidence intervals. A first analysis focused on the association of grip strength with local factors: painful locations in the dominant hand by row and radiographic severity according to the total Kellgren-Lawrence (KL) score. The second analysis assessed the patient-level association between decreased grip strength and general characteristics, including cumulative comorbidities and markers of radio-clinical severity of hand OA, namely the AUSCAN pain score and total KL score. A sensitivity analysis was performed to look for association between grip strength and each comorbidity.

Results: 394 patients were analyzed, including 329 women (mean ± SD of the dominant hand’s grip strength of 21.6 ± 6.9 kg) and 65 men (34.9 ± 9.8 kg) with a mean age of 66.9 ± 7.3 years. Grip strength decreased with age (p<0.001) and was lower for women (p<0.0001). Among women, locally, decreased grip strength was independently associated with painful involvement of at least 2 metacarpophalangeal joints (MCPs) (estimated coefficient [95% CI] -3.6 [-6.2; -1.0] kg versus no painful MCPs but not with proximal and distal interphalangeal joints, and with a high KL total sum score (-0.06 [-0.10; -0.01] kg per additional point). At the patient-level, decreased grip strength was not associated with comorbidities but with radio-clinical severity (p<0.05), i.e. a higher KL total sum score and AUSCAN pain score. Among men, neither radiographic severity nor painful locations were independently associated with a decrease of grip strength. Conversely, decreased grip strength was associated with at least 3 comorbidities (-8.5 [-15.5; -1.4] kg versus a single comorbidity being OA), independently of radiographic severity. The study of comorbidities individually did not show any particular association with grip strength.

Conclusion: In this cohort of symptomatic HOA, the decrease of grip strength reflects the radio-clinical severity of hand OA among women, whereas among men, it is independently associated with the accumulation of comorbidities. The presence of hand OA should be considered for further studies investigation the relationship between grip strength and morbidity.

REFERENCES:
reached minimum PCS during exercise, but only an average of 70% (SD: 8.7) of that during infusion. Cycling induced a small reduction in C2M (peak: -5.3%, 95%CI: -7.8 to -2.7%). PRO-C2 increased rapidly in response to cycling (peak: 11.7%, 95%CI: 4.3 to 18.1%) and running (peak: 12.9%, 95%CI: 3.54 to 22.2%), T2CM decreased up to one hour after cycling (peak: -10.8%, 95%CI: -15.1 to -6.5%) and running (peak: -9.5%, 95%CI: -15.5 to -3.6%), similar to adrenaline, then increased. Coll2-1NO2 increased rapidly following cycling (peak: 12.5%, 95%CI: 2.8 to 22.2%) and running (peak: 9.8%, 95%CI: 0.26 to 19.6%). Trends of increase was found in Coll2-1 (21.3%, 95%CI: 2.9 to 38.6) and Coll2-1NO2 (11.6%, 95%CI: -7.9 to 31.1) in response to running at 240 min (Figure 1 – Error bars: SE, † Change from resting, †† Change from BL, ††† P < 0.05, †††† P < 0.01; ††† P < 0.001).

Figure 1.

At 24h PRO-C2 reduced -9.4% (95%CI: -18.2 to -0.5%) after cycling, Coll2-1NO2 reduced -8.33% (95%CI: -17.0 to 0.3%) after running and T2CM elevated by 6.0% (95%CI: -0.8 to 12.8%) after running and 7.1% (95%CI: 0.5 to 13.7%) after cycling. Conclusion: Running, cycling and adrenaline infusion induced rapid small-to-moderate changes in circulating biomarkers reflecting type II collagen turnover. Changes after adrenaline-infusion suggests a cardiovascular contribution to exercise-induced changes. This model could potentially be used to evaluate treatment effects on collagen turnover.

References:


Table 1. Fit of Scales of WOMAC to the Rasch Model

<table>
<thead>
<tr>
<th>WOMAC subscale</th>
<th>Residuals</th>
<th>Conditional Chi-Square</th>
<th>Reliability</th>
<th>Unidimensionality</th>
<th>ECV</th>
<th>Responsiveness (Interval Scale)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Item</td>
<td>Person</td>
<td>Value(df)</td>
<td>P</td>
<td>PSI</td>
<td>A</td>
</tr>
<tr>
<td>Pain</td>
<td>2.499</td>
<td>0.779</td>
<td>18.7(10)</td>
<td>0.044</td>
<td>0.76</td>
<td>0.87</td>
</tr>
<tr>
<td>Stiffness</td>
<td>1.215</td>
<td>0.462</td>
<td>57.0(9)</td>
<td>&lt;0.001</td>
<td>0.60</td>
<td>0.82</td>
</tr>
<tr>
<td>Functioning</td>
<td>2.496</td>
<td>0.702</td>
<td>47.0(42)</td>
<td>0.274</td>
<td>0.80</td>
<td>0.94</td>
</tr>
<tr>
<td>Total</td>
<td>4.193</td>
<td>0.659</td>
<td>43.3(58)</td>
<td>0.925</td>
<td>0.80</td>
<td>0.80</td>
</tr>
</tbody>
</table>

Acknowledgements: This study is supported by Singapore National Medical Research Council (NMRC/HSRG/0061/2016 and NMRC/CSAINV/022/2017).

Disclosure of Interests: Ying Ying Leung Speakers bureau: Received speaker fee from AbbVie, DKSH, Janssen, Novartis and Pfizer., Julian Thumboo: None
declared, Seng Jin Yeo: None declared, Vikki Wyde: None declared, Alan Tenant: None declared

**POS1114**

LABORATORY BIOMARKERS OF JOINT REMODELING AND INFLAMMATION IN PATIENTS WITH EARLY KNEE OSTEOARTHRITIS

V. Klementeva1, T. Chernysheva1, K. Korochina1, I. Krivotulova1, I. Mitrofanova1, I. Korochina2.
1Orenburg State Medical University, The Department of Internal Diseases, Orenburg, Russian Federation; 2Orenburg State Medical University, The Department of Polyclinic Therapy, Orenburg, Russian Federation

**Background:** Record prevalence of osteoarthritis (OA) around the world is aggravated by the fact that doctor most often meets it on advanced stage, so that therapeutic interventions can no longer provide significant success [1]. It is advisable to study early joint remodeling, when gross irreversible changes have not yet occurred, and laboratory markers appear to be valuable diagnostic and prognostic tool, potentially able to identify patients-responders to particular treatment method [2].

**Objectives:** To verify joint tissue remodeling and synovitis in patients with early knee OA Kellgren-Lawrence (K-L) Grades 0-2 using laboratory biomarkers.

**Methods:** The study included 90 patients with knee OA K-L Grades 0-2 (3 groups of 30 people each) and 30 healthy volunteers; to clarify early OA, Luyten FP criteria (2018) were used [3]. Among persons with knee OA, there were 57 women (63.3%) and 33 men (36.7%), mean age 32 [27; 35] years; participants without OA were presented by 18 (60%) and 12 (40%) women, mean age 29.5 [25; 34] years. Knee radiography, ultrasonography, laboratory biomarkers assessment including interleukin-1beta (IL-1β), N-Terminal Propeptide of Type 1 Procollagen (P1NP), Beta-Cross-laps, cartilage oligomeric matrix protein (COMP) were carried out.

**Results:** All groups with knee OA was characterized by women predominance (Table 1). Laboratory study revealed slight increase in IL-1β and both bone markers in K-L Grade 0. Grade 1 was characterized by elevation of COMP and Beta-Cross Laps on background of IL-1β increased. In Grade 2 the highest level of COMP, slight decrease in Beta-Cross Laps and IL-1β, weak increase in P1NP were found. Correlation analysis have detected positive significant relationships between COMP and IL-1β (r=0.37), as well as Beta-Cross Laps and P1NP. Correlation analysis have detected positive significant increased. In Grade 2 the highest

**Beta-Cross Laps on background of IL-1β (β)

**Conclusion:** Early knee OA of K-L Grade 0 is characterized by bone metabolism activation and synovial inflammation before articular cartilage involvement. On Grade 1, cartilage destruction appears and bone resorption is enhanced. Grade 2 is characterized by significant intensification of cartilage destruction, weakening of bone resorption on the background of synovial inflammation. In addition to cartilage damage, COMP is associated with joint inflammation, which requires further research to take in account it also as synovial biomarker.

**REFERENCES:**


Disclosure of Interests: None declared

**POS1115**

EFFICACY AND SAFETY OF THE COMBINATION OF PRP + NON-CROSSLINKED HYALURONIC ACID VERSUS HYALURONIC ACID, IN MONO-INJECTION, IN SYMPTOMATIC KNEE OSTEOARTHRITIS. RANDOMIZED CONTROLLED PHASE II TRIAL, SINGLE BLIND

T. Delgado1, R. Ferreira Lopez2, P. Adam3, Y. M. Pers2, L. Bengueulla2, C. Cyteval4, V. De Fourmestraux5, S. Lombion6, P. Ornetti7. 1University Hospital Emiletterand Dijon-Bourgogne, rheumatology, Dijon, France; 2Montpellier University Hospital, Rheumatology, Montpellier, France; 3Medipole Garonne, Imaging, Toulouse, France; 4Montpellier University Hospital, Imaging, Montpellier, France; 5RegenLab, Research, Lausanne, Switzerland; 6EURL SLc, Statistics, Chamesey, France

**Background:** Despite the recent results of meta-analyses of randomized controlled trials (RCTs), the place of PRP and hyaluronic acid in the symptomatic treatment of knee osteoarthritis (KOA) remains uncertain in the latest international recommendations. Very few studies are available on the potential synergistic effect of their combination in mild to moderate forms of KOA [1].

**Objectives:** Randomized, controlled, multicenter, non-inferiority trial (clinical trial NCT03328728), single-blinded (investigator) to compare the efficacy and safety of the combination of PRP and non-crosslinked hyaluronic acid (PRP-HA, Cellular Matrix A-CP-HA, Regen Lab) as a single injection versus Hylan G-F 20 (HA), with follow-up at 1, 3 and 6 months, on an intention-to-treat (ITT) basis.

**Methods:** Patients aged 40-80 years with symptomatic femorotibial KOA (WOMAC A1 (pain on walking) or WOMAC Function > 50/100) and a Kellgren and Lawrence (KL) radiographic stage II or III were randomized into two groups: PRP-HA vs. HA, as a radioc- or ultrasound-guided single injection at M0. Patients should not have received injectable treatments (corticosteroids, HA or PRP) for 3 months, nor per os NSAIDs for at least 1 month. A 6-month follow-up of the impact of the KOA was performed at M1, M3 and M6. The primary endpoint was the difference in the WOMAC score for pain on walking between M0 and M6 between the 2 groups. Secondary endpoints were collected and compared at M1, M3, M6 (WOMAC Pain, Function, and Total; SF-36 score) as well as the percentage of patients responding at M6 according to the OMERACT-OARSI criteria, according to the Patient Acceptable Symptomatic State (PASS), and the Minimal Clinical Important Improvement (MCII) of the WOMAC pain. The factors of good response (PASS and MCII responders) at M6 were investigated in univariate and multivariate analysis. Tolerability was assessed by comparing adverse events over 6 months in both groups.

**Results:** 156 patients were included in three French teaching hospitals between 2018 and 2021 with the following characteristics: age 59.6±9.2 years, BMI 28.1±5.8 kg/m², 37.8% grade II KL and 62.2% grade III KL. The two groups were homogeneous at inclusion except in terms of analgesic consumption (PRP-HA vs. HA, 30% vs. 45%, p=0.042) and KL III radiographic stage (70% vs. 53%, p=0.04). The symptomatic improvement (WOMAC pain, function and WOMAC Total) was significant in both groups at M1, M3 and M6. The difference in WOMAC pain on walking at M6 was significant for the non-inferiority test (-3.34 [-12.51; -0.18], p=0.044) and for the superiority

**Table 1. Comparative analysis of clinical and laboratory parameters in patients of different knee OA Grades and volunteers**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Knee OA group</th>
<th>Significan-c-y, p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>M-18 (60%)</td>
<td>M-13 (43.3%)</td>
</tr>
<tr>
<td>Mean age, years</td>
<td>29.5 ± 34</td>
<td>26 ± 32</td>
</tr>
<tr>
<td>COMP, ng/ml</td>
<td>527 ± 355.5</td>
<td>498 ± 421.9</td>
</tr>
<tr>
<td>P1NP, ng/ml</td>
<td>101 ± 98.2</td>
<td>80 ± 72.4</td>
</tr>
<tr>
<td>Beta-Cross Laps, ng/ml</td>
<td>0.545 ± 0.466</td>
<td>0.697 ± 0.656</td>
</tr>
<tr>
<td>IL-1β, pg/ml</td>
<td>3.7 ± 2.5</td>
<td>7.3 ± 5.0</td>
</tr>
</tbody>
</table>
test (-0.34 [-1.45, -0.22], p = 0.042) in favor of PRP-HA. At M6, there was a non-significant difference in terms of OMERACT-OARSI responders in favor of the PRP-HA combination (58% vs. 48%, p = 0.261) but significant in terms of MCII responders (78.8% vs. 61.3%, p = 0.036) and PASS responders (50.8% vs. 33.3%, p = 0.035). PASS response was associated in univariate analysis with pain and total WOMAC at inclusion (p ≤ 0.001) as well as with allocated treatment (p = 0.03). In multivariate analysis, only allocated treatment was associated with a good response at M6 for both PASS (PRP-HA, OR = 2.05 [1.02-3.92], p = 0.03) and MCII (PRP-HA, OR = 2.21 [1.09-4.44], p = 0.02). There was no difference in patient satisfaction at M1, M3 and M6, nor in the occurrence of adverse events.

Conclusion: In this non-inferiority RCT in symptomatic knee osteoarthritis, the combination of PRP-non-crosslinked HA in mono-injection was at least equivalent to Hyylan G-F 20 for symptomatic benefit (WOMAC) at 6 months, with a good safety profile. The proportion of patients achieving PASS and MCII of WOMAC pain was higher in the PRP-HA group.

REFERENCES:


POST116 DIETARY INFLAMMATORY INDEX AND KNEE STRUCTURES ON MRI AND PAIN: A PROSPECTIVE COHORT STUDY

F. Pan1, J. Tian1, M. Cervo2, D. Scott3, F. Cicuttin4, G. Jones1. 1University of Tasmania, Menzies Institute for Medical Research, Hobart, Australia; 2Monash University, School of Clinical Sciences at Monash Health, Melbourne, Australia; 3Deakin University, School of Exer & Nut Sciences, Melbourne, Australia; 4Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia.

Background: While some individual dietary nutrients/components have been shown to be associated with knee osteoarthritis (OA) progression, the associations of the dietary inflammatory index (DII), which reflects the overall inflammatory potential of a diet, with MRI-detected structural changes and pain have not been investigated.

Objectives: This longitudinal study aimed to determine whether DII scores are associated with knee structural changes and pain over a 10.7 year follow-up in community-dwelling older adults.

Methods: This study utilised the data from a prospective population-based cohort study (mean age 63 years, 51% women) in which 1,099, 875, 768 and 563 participants completed assessments at baseline, 2.6, 5.1 and 10.7 years, respectively. T1-weighted or T2-weighted MRI of the right knee was performed. X-ray was performed to assess radiographic knee osteoarthritis (WOMAC) pain questionnaire was used to measure knee pain at all time points. Cartilage volume (CV) and bone marrow lesions (BMLs) at baseline were measured. T1-weighted or T2-weighted MRI of the right knee was performed. T1-weighted or T2-weighted MRI of the right knee was performed. T1-weighted or T2-weighted MRI of the right knee was performed.

Results: In this non-inferiority RCT in symptomatic knee osteoarthritis, the combination of PRP-non-crosslinked HA in mono-injection was at least equivalent to Hyylan G-F 20 for symptomatic benefit (WOMAC) at 6 months, with a good safety profile. The proportion of patients achieving PASS and MCII of WOMAC pain was higher in the PRP-HA group.

Conclusion: In this non-inferiority RCT in symptomatic knee osteoarthritis, the combination of PRP-non-crosslinked HA in mono-injection was at least equivalent to Hyylan G-F 20 for symptomatic benefit (WOMAC) at 6 months, with a good safety profile. The proportion of patients achieving PASS and MCII of WOMAC pain was higher in the PRP-HA group.

REFERENCES:

Disclosure of Interests: None declared.


POST117 SAFETY AND EFFICACY OF ADIPOSE-MERIVED MESENCHYMAL STEM CELLS FOR OSTEARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

M. Gadkalkar1, A. Elmegeed2, A. Hafez3, A. Ak Awad4, M. Ahmed Shehata3, A. Abouelen5, A. M. Aftel6. 1Loyola University Medical Center, Department of Surgery, Maywood, United States of America; 2Faculty of Science, Menoufa University, N/A, Shebein el kom, Egypt; 3Faculty of Medicine, Menoufa University, N/A, Shebein el kom, Egypt; 4Faculty of Medicine, Ain Shams University, Cairo, Egypt, N/A, Cairo, Egypt; 5Alexandria Faculty of Medicine, N/A, Alexandria, Egypt; 6Faculty of pharmacy, Alexandria University, Alexandria, Egypt, N/A, alexandria, Egypt; 7Bellevue College of Medicine, Department of Internal Medicine, Houston, United States of America.

Background: Osteoarthritis (OA) is a debilitating joint disorder affecting articulating joints, cartilage and subchondral bones, prompting synovial membrane irritation and inflammation (1). Nowadays, knee OA can be treated either by surgical or non-surgical approaches, while the Osteoarthritis Research Society International (OARSI) suggested pharmacological medications joined with other functional approaches such as exercise, joint inflammation instructions, and weight reduction (2), yet most of them exhibit modest safety and efficacy (3). Mesenchymal stem cells (MSCs) have been well-known in regenerative medicine to achieve wide differentiation capacity. Moreover, MSCs can be derived from various sources (4); however, Adipose-derived mesenchymal stem cells (ADMSCs) are easiest to assemble for clinical use with higher isolation yields (4).

Objectives: This study investigated the potential and regenerative capacity of adipose-derived mesenchymal stem cells (ADMSCs) for osteoarthritis (OA).

Methods: We created a search strategy and applied it to six databases. After screening the records for eligibility, we identified and evaluated the risk of bias in both the randomized and non-randomized research studies. Then, data were extracted and implemented into single-arm and double-arm analyses.

Results: 16 studies with 469 patients were included. We found a significant improvement in the quality of life (QOL) among the three doses subgroups (high, medium, and low doses) which was estimated by the SF-36 scores after a year of follow up (low dose, Mean (M) -23.991; p = 0.000; medium dose: M = 15.96; p = 0.000; high dose: M = -19.306; p = 0.000). Furthermore, we noticed a significant decrease in pain as estimated by the numeric pain rating scale (NPRS) after three months of follow-up with no significant difference between the low and medium doses (low dose: M = -3.119; p = 0.002; medium dose: M = -2.17; p = 0.000). Our double-arm analyses illustrated significant pain reduction in the ADMSGs group over the control after 12 months as estimated by WOMAC pain subscore (Mean difference (MD) -1.85, p = 0.03); moreover, The knee functions and activity levels improved significantly among the low dose group as measured by the WOMAC physical function and stiffness subscales after six months (M -23.797; p = 0.001; M = -10.249; p = 0.009, respectively) and the KOOS scores after 12 months (p = 0.007 for all KOOS subscales). No significant adverse events were observed in the ADMSGs injections group (Event rate (ER) p = 0.001).

Conclusion: Although ADMSCs were associated with significant reductions in pain scores, improvements in QOL score and knee functions, and achieving disease modification in patients with OA, they did not significantly differ from the control. Therefore, implementing ADMSCs in routine clinical practice needs more studies with large sample sizes, longer follow-up periods.

REFERENCES:

Disclosure of Interests: None declared.


POST117 SAFETY AND EFFICACY OF ADIPOSE-MERIVED MESENCHYMAL STEM CELLS FOR OSTEARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
IEEE OF CORTICOSTEROIDS FOR HAND OSTEOARTHRITIS: A SYSTEMATIC REVIEW AND TRIALS

Background: Osteoarthritis causes significant pain and disability with no approved disease-modifying drugs. There is evidence emerging from pre-clinical and human studies suggesting metformin may have disease-modifying properties in osteoarthritis. Given its pleiotropic effects and safety profile, metformin has the potential to be a novel therapy for osteoarthritis.

Objectives: We systematically reviewed the evidence from both pre-clinical and human studies for the potential disease-modifying effect of metformin in osteoarthritis.

Methods: Ovid MEDLINE, Embase and CINAHL were searched between inception and June 2021 using MeSH terms and key words to identify studies examining the association between metformin use and outcome measures related to osteoarthritis. Two reviewers performed the risk of bias assessment and 3 reviewers extracted data independently. Qualitative evidence synthesis was performed. This systematic review is registered on PROSPERO (CRD42021261052 and CRD42021261060).

Results: Fifteen (10 pre-clinical and 5 human) studies were included. Most studies (10 pre-clinical and 3 human) assessed the effect of metformin using knee osteoarthritis models. In pre-clinical studies, metformin was assessed for the effect on structural outcomes (n=10); immunomodulation (n=5); pain (n=4); and molecular pathways of the effect of metformin on human osteoarthritis (n=3). For human studies, metformin was examined for an effect on structural progression (n=3); pain (n=1); and immunomodulation (n=1). Overall, all pre-clinical studies consistently showed metformin having a chondroprotective, immunomodulatory and analgesic effect in osteoarthritis, predominantly mediated by adiponectin. Evidence from human studies, although limited, was consistent with findings in pre-clinical studies.

Conclusion: We found consistent evidence across pre-clinical and human studies to support a favourable effect of metformin on chondroprotection, immunomodulation and pain reduction in knee osteoarthritis. Further high-quality clinical trials are needed to confirm these findings as metformin could be a novel therapeutic drug for the treatment of osteoarthritis.

REFERENCES:


Disclosure of Interests: None declared.

ASSOCIATION OF ADIPOKINES WITH SEVERITY OF KNEE OSTEOARTHRITIS ASSESSED CLINICALLY AND ON MAGNETIC RESONANCE IMAGING

Background: Adipokines secreted by adipose tissue create a low grade systemic inflammatory state that could contribute to the pathogenesis of knee OA (KOA). Previous studies of association between adipokines and radiographic KOA represented late-stage disease shown as bony changes. Magnetic Resonance Imaging (MRI) has the advantage of showing early changes of KOA in all joint structures.

Objectives: We aimed to evaluate the association between the adipokines: Leptin, Adiponectin, Resistin, and hs-CRP with clinical, radiographical and MRI assessment of KOA severity.

Methods: We performed a cross-sectional study in participants with early KOA. Demographics, clinical (WOMAC), and MRI (TRIALS scoring) + KOA severity were assessed. Serum leptin, adiponectin, resistin and hs-CRP were measured. Association of adipokines with clinical and MRI severity outcomes were evaluated using regression models with adjustment with age, sex, and body mass index (BMI).

Results: 139 participants with early KOA (82% women, mean ± SD age: 55.5 ± 7.8 years) were included. Participants had moderate KOA symptoms, mean WOMAC pain and function were 31.1 ± 18.4, and 32.0 ± 19.9 respectively. Mean BMI was 26.0 ± 5.9 kg/m². After adjustment with age, sex and BMI, Leptin (p=0.001) and hs-CRP (p=0.03) were positively associated, while adiponectin (p=0.02) and resistin (p=0.03) were negatively associated with osteophyte size.
Table 1. Association of adipokines with MRI features and clinical symptoms, adjusted with age, sex and BMI

<table>
<thead>
<tr>
<th>KOA severity</th>
<th>leptin</th>
<th>Adiponectin</th>
<th>Resistin</th>
<th>hs-CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osteophyte</td>
<td>1.15 (0.5, 1.7)**</td>
<td>-1.86 (-3.53, -0.18)</td>
<td>-2.12 (-3.95, -0.30)*</td>
<td>0.17 (0.02, 0.31)**</td>
</tr>
<tr>
<td>Cart Loss</td>
<td>0.37 (0.04, 0.71)**</td>
<td>-0.45 (-1.32, 0.42)</td>
<td>-0.72 (-1.67, 0.23)</td>
<td>0.02 (0.06, 0.10)</td>
</tr>
<tr>
<td>BML Size</td>
<td>0.24 (0.05, 0.40)</td>
<td>-0.03 (-0.70, 0.63)</td>
<td>-0.15 (-0.82, 0.56)</td>
<td>0.02 (0.04, 0.08)</td>
</tr>
<tr>
<td>Synovitis</td>
<td>0.24 (0.08, 0.40)</td>
<td>-0.21 (-0.63, 0.22)</td>
<td>-0.37 (-0.79, 0.13)</td>
<td>0.03 (0.01, 0.07)</td>
</tr>
<tr>
<td>Effusion</td>
<td>0.21 (0.07, 0.35)**</td>
<td>-0.25 (-0.62, 0.12)</td>
<td>-0.09 (-0.49, 0.32)</td>
<td>0.02 (0.02, 0.05)</td>
</tr>
<tr>
<td>Meniscus</td>
<td>0.09 (0.06, 0.24)</td>
<td>0.01 (0.39, 0.40)</td>
<td>-0.08 (-0.51, 0.35)</td>
<td>0.04 (0.00, 0.07)**</td>
</tr>
<tr>
<td>Extrusion</td>
<td>1.72 (1.45, 4.89)</td>
<td>0.70 (0.98, 1.51)</td>
<td>-2.61 (-11.4, 6.14)</td>
<td>0.04 (0.46, 0.76)</td>
</tr>
<tr>
<td>WOMAC func.</td>
<td>0.01 (-3.34, 3.35)</td>
<td>0.13 (5.5, 21.5)**</td>
<td>-0.07 (-2.96, 12.12)</td>
<td>-0.27 (-9.57, 9.54)**</td>
</tr>
</tbody>
</table>

*p<0.05, **p<0.001; Bold: statistically significant.

Conclusion: Adipokines, particularly leptin was associated with severity of various structural defects of the knee joint beyond age, sex and BMI in early KOA. MRI: Magnetic Resonance Imaging; %: percentage; BML: Bone Marrow Lesion; Cart: Cartilage; OAST: Osteophyte; KL: Kellgren and Lawrence grading; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.

Acknowledgements: This study is funded by the National Medical Research Council of Singapore (NMRC)

Disclosure of Interests: Timothy Chong: None declared, Jin-Rong Tan: None declared, Cheryl Ma: None declared, Steven Bak-Siew Wong: None declared, Timothy Chong: None declared, Jin-Rong Tan: None declared, Ying Ying Leung Speakers bureau: Honorarium from Abbvie, DSKH, Janssen, Novartis and Pfizer.

DOI: 10.1136/annrheumdis-2022-eular.2258

HAND OSTEOARTHRITIS IS ASSOCIATED WITH LIMITATIONS IN PAID AND UNPAID WORK PARTICIPATION AND RELATED SOCIA L COSTS: THE HOSTAS COHORT

S. Terpstra1, L. Van de Stadt1, A. Boonen5, F. Roenaerd1, M. Klopperling4,5.
1Leiden University Medical Center, Rheumatology, Leiden, Netherlands; 2Maastricht University Medical Center, Rheumatology, Maastricht, Netherlands; 3Leiden University Medical Center, Epidemiology, Leiden, Netherlands

Background: Rheumatic musculoskeletal diseases (RMDs) can cause impairment in paid and unpaid work which can contribute to societal burden and costs. However, data on this topic concerning hand osteoarthritis (OA) is scarce, while this is crucial for assessing the societal impact of this disease.

Objectives: To investigate the association of hand OA with paid and unpaid work limitations, productivity loss and costs of productivity loss.

Methods: We used data of the Dutch Hand OsteoArthritis in Secondary care (HOSTAS) cohort, a primary hand OA cohort from a general rheumatology outpatient clinic. The treating rheumatologist defined hand OA presence. We assessed patient and OA characteristics using validated questionnaires and tests. We investigated work impairment due to hand OA with the Health and Labour Questionnaire (HLQ) which assesses the last two weeks on hand-OA related limitations, hours of sick leave and unproductiveness during paid work, and limitations and hours of the necessity of being replaced by others for unpaid work tasks. We estimated societal costs of paid work by multiplying unproductive and sick leave hours due to hand OA by the average Dutch hourly societal costs of paid work for persons of the same age category and sex. We estimated societal costs of unpaid work by multiplying the hours of unpaid work replaced by others by the Dutch gross average hourly salary of a household help (€12.50).

Result: HLQ data was available for 382 patients (mean age 61 years, 86% women, 26% having a university degree, 41% having any comorbidity). Of these persons, 181 (47%) had paid work, 16 (4%) had full work disability due to hand OA and 117 (30%) were retired. Thirty employed persons (7%) reported sick leave due to hand OA in the last two weeks, for whom a median of 42 working hours (interquartile range [IQR] 24 to 54) was lost. Unproductive paid work hours were present for 28 (15%) patients, with a median of 4 hours in the last two weeks (IQR 2 to 6). Hinder at work in the last two weeks was reported by 120 out of 181 working patients (66%), for whom median hinder score (score range 6-24) was 7 (IQR 6 to 8). Work production loss in the last two weeks due to hand OA (the sum of sick leave hours and unproductive hours) was present for 36 patients (19%). Patients with paid work productivity loss (n = 35, 19%) did not differ statistically significantly in patient and disease characteristics from those without productivity loss (n = 146, 19%). Unpaid work replacement in the last two weeks was reported by 171 patients (45%), with a median of three hours replaced (IQR 2 to 7 hours). Due to sick leave work replacement was reported by 33 patients (7%). Patients with unpaid work replacement by others due to hand OA (n=171, 45%) were statistically significantly more often female and had a higher BMI than with those without any replacement (n=210, 55%). We estimated total societal costs of hand OA related to paid work production loss at €61 (95% confidence interval (CI) 27 to 96) per two weeks, and societal costs for unpaid work at €33 (CI 27 to 40). Total estimated work-related societal costs per patient with hand OA were €94 (CI 59 to 130), translating to €2452 (CI 1528 to 3377) per year.

Conclusion: Hand OA is associated with impairment in paid and unpaid work, which translates into substantial societal costs. This highlights the social and economic importance of adequate hand OA treatment. It also indicates the importance of investigating hand OA impairment experienced by hand OA patients visiting the outpatient clinic, for potentially more tailored treatment.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2258

ULTRASOUND GUIDED INJECTIONS OF HYAD4 FOR KNEE OSTEOARTHRITIS IMPROVES PAIN AND FUNCTIONAL OUTCOMES AT 3 AND 6 MONTHS WITHOUT CHANGES IN SYNOVIAL FLUID VOLUMES.

P. Meehan1, M. Gill1, E. Hoffman1, M. Wolf1, I. Amigues1, L. M. Kastianick1, E. Regan1, J. Crooks2, G. Czuczman2, C. Coeshott3, V. Knight4. 1National Jewish Health, Medicine/Rheumatology; Denver, United States of America; 2National Jewish Health, Pathology; Denver, United States of America; 3National Jewish Health, Bioinformatic, Denver, United States of America; 4CU Anschutz School of Medicine, School of Public Health, Aurora, United States of America; 5National Jewish Health, Radiology, Denver, United States of America; 6Children's Hospital, Immunology, Aurora, United States of America

Background: Prior studies have demonstrated improved accuracy and efficacy when Intra-articular (IA) therapeutics are injected using ultrasound (US) guidance. There is also growing evidence that many patients with knee osteoarthritis (OA) exhibit a pro-inflammatory synovial fluid (SF) profile. However, it is not known if temporary clinical improvement in pain and function after IA Hyaluronic acid (HA) injections is associated with changes in SF volumes.

Objectives: The purpose of this study was to determine if IA HA injections delivered using US directed needle visualization with an external pneumatic compression device would result in improved clinical outcomes for knee OA at 3 and 6 months, and if this was associated with a reduction in the amount of knee synovial fluid (SF) measured on US.

Methods: 49 eligible subjects with symptomatic Knee OA, BMI < 40 and KL radiographic rating of II or III OA were consented for this open label prospective IRB approved Investigator Initiated SF OA biomarker study (HS 3179, NCT 02956337). All standing radiographs were reviewed by a fellowship-trained MSK radiologist. 36 subjects had adequate aspirated SF volumes of > 500 ml for biomarker analysis and therefore were eligible to receive two IA injections of HYAD4, 24 mg/3ml (Fidia Farmaceutici S.p.A. Italy) 7 days apart by a MSK certified Rheumatologist. An external pneumatic compression device and US visualized needle insertion ensured injections were delivered into the intra-synovial space. Despite COVID-19 restrictions, 34 patients (17 women and 17 men) between 35 and 78 years of age returned for 3 month evaluations and 30 had evaluations at 6 months. The following clinical variables were measured: Western Ontario and McMaster Universities Index (WOMAC) total scores, Visual Analog Pain Scale (VAS, 0-10), PCS scores on the SF-36 health survey questionnaires (physical function/bodily pain and general health), 6-minute walking distance in meters (6 MWD), and measured SF depth before and after an external pneumatic compression device was inflated to 100 mmHg to facilitate aspiration by increasing available SF volumes under positive pressure. The SF depth was measured on the recorded US image (GE logiq e) as the largest anechoic region selected for aspiration on either the lateral (n= 30) or medial (n=4) compartment. SF and simultaneous peripheral blood samples were centrifuged and cryopreserved at -80 ° C within 45 minutes of aspiration for future analysis. Statistical differences between baseline values compared to those levels at 3 and 6 months were determined using a paired ANOVA test with p <0.05 significance.

Results: Improvements over baseline values were observed at 3 and 6 months respectively, after IA HA injections in WOMAC (40%, 40%), VAS (45%, 51%) and PCS (15%, 18%) all p <0.001. The 6 WWD improved by 7% at 3 months (p<0.007) but was not statistically improved at 6 months. US measured SF depth at baseline was 3.2 ± 2.2 mm before inflation and 6.4 ± 3.7 mm after inflation of the
pneumatic external compression device but statistical differences in SF depth were not observed at 3 and 6 months. **Conclusion:** Despite improvements in WOMAC, VAS scores, and PCS scores on the SF 36 at 3 and 6 months after US guided knee injections with an HA product, a statistically significant reduction in the amount of US measured SF was not observed. The 6 MWD improved at 3 months but was not statistically different from the baseline distance by 6 months. IA injections using US needle visualization confirmed that the product was delivered into the synovial space with 100% accuracy which might have resulted in improved efficacy results in this study compared to prior IA HA studies injected with different HA products. In the future, we hope SF biomarkers may identify which individual OA patients will likely achieve the greatest benefit with IA HA injections and to determine if this is associated with a reduction in catabolic pro-inflammatory proteins.

**Disclosure of Interests:** richard Meehan Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the study coordinator she received compensation for her work., Molly Wolf Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the Rheumatologist who performed some of the aspirations and injections she received some very small salary support from this grant., Liudmila (Mila) Kastsianok Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the Bioengineer consultant she received some compensation for her work., Chantal Chavoix: None declared, Anne-Christine Rat: Speakers bureau: Pfizer, Lilly, Abbvie, BMS.ero., Vijaya Knight Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As an Immunologists and Immunologist she did receive some very small salary support from this grant., James Crooks Grant/research support from: This grant was funded by Genzyme, Lilly, Abbvie, BMS.ero., Eric Hoffman Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the study coordinator she received support from this grant for sample processing and analysis., Liudmila (Mila) Kastsianok Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the Rheumatologist she received support from this grant for sample processing and analysis., James Crooks Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the Immunologist she received support from this grant for sample processing and analysis., Eric Hoffman Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis. As the Immunologists she received support from this grant., Richard Meehan Grant/research support from: This grant was funded by Fidia Pharmaceutici and Fidia Pharma USA as an Investigator Initiated grant for synovial fluid based biomarker research in osteoarthritis.

**Disclosure of Interests:**


**Disclosure of Interests:**

- Mohammed Aqil: None declared, Marie-Laure Bocca: None declared, Gilles Loggia: None declared, Elpidio Attoh-Mensah: None declared, Chantal Chavoix: None declared, Anne-Christine Rat: Speakers bureau: Pfizer, Lilly, Abbvie, BMS.ero., Sanofi Genzyme, Lilly, Abbvie, BMS

**REFERENCES:**


**POSI124 EVALUATION OF COMORBIDITY PATTERNS AND IDENTIFICATION OF SUB-GROUPS IN PATIENTS DIAGNOSED WITH HIP OSTEOARTHRITIS IN 94,720 PATIENTS FROM SPAIN**

M. Pineda-Moncusi1, V. Y. Strauss1, D. E. Robinson2,3, J. Runhaar4, M. Kohns5, A. Kamps5, A. Dell’isola5, A. Turkiewicz6, C. Mallen7, C. F. Kuo8,9, C. Coupland9, M. Doherty8,9, A. Sarmanova10, M. Englund11, S. M. A. Biema-Zeinstra12,13, W. Zhang14, D. Prieto-Alhambra15, S. Khalid16 on behalf of FOREUM OA Comorbidity, 1University of Oxford, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDO RMS), Oxford, United Kingdom; 2University of Nottingham, Academic Rheumatology, School of Medicine, Nottingham, United Kingdom; 3University of Oxford, Department of Primary Care Health Sciences, Oxford, United Kingdom; 4Erasmus University Medical Center, Department of General Practice, Rotterdam, Netherlands; 5Lund University, Clinical Epidemiology Unit, Orthopaedics, Department of Clinical Sciences Lund, Lund, Sweden; 6Keele University, School of Medicine, Keele, United Kingdom; 7Chang Gung Memorial Hospital, Division of Rheumatology, Allergy and Immunology, Taoyuan, Taiwan, Republic of China; 8University of Nottingham, Division of Primary Care, School of Medicine, Nottingham, United Kingdom; 9University of Nottingham, Pain Centre Versus Arthritis, Nottingham, United Kingdom; 10University of Bristol, Musculoskeletal Research Unit, Bristol Medical School, Translational Health Sciences, Bristol, United Kingdom; 11Erasmus MC University Medical Center, Department of Orthopedic Surgery & Sports Medicine, Rotterdam, Netherlands

**Background:** Osteoarthritis (OA) patients are more likely to have other comorbidities (Swain, Sarmanova et al. 2020). Improving the understanding of comorbidity profiles of OA patients may lead to improvement in their clinical care.

**Objectives:** To identify sub-groups in patients diagnosed with hip OA using patterns of comorbidity.

**Methods:** Routinely-collected data of individuals ≥18 years with an incident diagnosis of hip OA (baseline/time 0), with at least 5 years of follow-up in SIHAP (Information System for Research in Primary Care, a primary care database from Spain) were collected from January 1st 2006 to June 31st 2020. Those with soft-tissue disorders or other bone/cartilage diseases at the same joint in the year prior/after baseline were excluded. Comorbidities associated with OA in the literature and
present in ≥1% of the study population were included. Clusters of comorbidities were identified at baseline using latent class analysis (LCA), a soft clustering method that classifies individuals according to the distribution of their measured items. The number of clusters or sub-groups within the study population was decided by comparing goodness of fit parameters (CAIC, BIC, ABIC) and log-likelihood changes of models from 2 to 8 clusters. The selected model was externally evaluated by a survival analysis assessing 10 years mortality within each cluster, where the weight of the posterior probability was used as a probability of sampling weight.

**Results:** We identified 94,720 individuals with an incident diagnosis of hip OA, 56.3% women and 43.7% men, with a mean age (SD) of 67.2 (13.1) years. We selected the LCA model with 5 clusters that could be described as: healthier (lower prevalence of all comorbidities than average in the cohort), multimorbidity (higher prevalence of all comorbidities, multiple comorbidities), back/neck pain plus mental health (B/N-mental) cardiovascular disease (CVD), and metabolic syndrome (MetS) (Figure 1). Cox regression (HR [95CI%]) showed higher mortality risk for multimorbidity (3.76 [3.70-3.83]), CVD (1.56 [1.53-1.59]) and MetS (4.56 [4.35-4.78]), compared to healthier. No difference was observed for B/N-mental cluster.

**Conclusion:** Clustering of co-morbidities in hip OA patients at the time of diagnosis has the potential to detect sub-groups of hip OA patients who might require additional care.

**REFERENCES:**

**Acknowledgements:** We thank the Patient Research Participants (PRP) members Jenny Cockshull, Stievie Vanhgan, and Irene Pitsilidou for their involvement since the beginning of the project. We would like to thank the FOREUM for financially supporting the research.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3361

---

**Table 1. Effect of TNF inhibitor versus control on pain and grip strength**

<table>
<thead>
<tr>
<th>Study</th>
<th>scale</th>
<th>range</th>
<th>Mean (SD)</th>
<th>Mean (SD), extracted</th>
<th>Mean Difference (95% Cl)</th>
<th>Number</th>
<th>Number</th>
<th>Meta-analysis result</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short term/pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Artkin 2018</td>
<td>VAS²</td>
<td>0-100</td>
<td>-6.1 (22.7)</td>
<td>-4.1 (23)</td>
<td>-2.5 (-14 to 9)</td>
<td>40</td>
<td>41</td>
<td>-0.93 (-7.41, 5.55)</td>
</tr>
<tr>
<td>Chevalier 2014</td>
<td>VAS²</td>
<td>0-100</td>
<td>-19.3 (4.20)</td>
<td>-16.8 (4.3)</td>
<td>-0.2 (-8.1 to 7.6)</td>
<td>38</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Long term/pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kloppenburg 2018</td>
<td>VAS²</td>
<td>0-100</td>
<td>39.2 (24.7)</td>
<td>46.5 (23.4)</td>
<td>-5.7 (-15.9 to 4.5)</td>
<td>38</td>
<td>41</td>
<td>-3.82 (-11.46 to 3.83)</td>
</tr>
<tr>
<td>Chevalier 2014</td>
<td>VAS²</td>
<td>0-100</td>
<td>-1.4 (-13 to 10.1)</td>
<td>36</td>
<td>33</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long term/grip strength</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kloppenburg 2018</td>
<td>Dynamometer</td>
<td>0 (-2.2, 2.1)</td>
<td>41</td>
<td>-0.35 (-0.08, 0.37)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Verbruggen 2012</td>
<td>Dynamometer</td>
<td>0.8 (1.2)</td>
<td>30</td>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹Tumor necrosis Factor. ²Visual Analogue Scale

---

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3361
Background: Osteoarthritis (OA) is the most common chronic progressive musculoskeletal system disease affecting more than 500 million people globally, which represents the formidable public health challenge. Currently osteoarthritis treatment includes acetaminophen, NSAIDs and/or opioids, intra-articular corticosteroid injections. Some guidelines also recommended chondroin and glucosamine sulfate, suggested that they may be effective and reduce functional impairment. However, despite of the huge amount of data on the problem of OA, there is still no effective treatment that slows down the progression of the disease. Recently appeared monoclonal antibodies against nerve growth factor (NGF) as well as fibroblast growth factor (FGF)-18 may be the promising tool for clinical improvement of OA.

Objective: To evaluate the safety and efficacy of anti-NGF and FGF-18 on patients with osteoarthritis by a systematic review.

Methods: In the current study the search process was conducted in PubMed using the following strategy: “FGF-18” or “anti-NGF” and “OA” or “monoclonal antibody” + “osteoarthritis”. All articles published in the format of Case Reports, Clinical Study, Clinical Trial Protocol, Clinical Trial, Multicenter Study were reviewed. Clinical outcomes were assessed using clinical scores, included the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain and Physical Function score. Patient’s Global Assessment of OA (PFA- OA), adverse events (AEs); cartilage repair and total femorotibial joint cartilage thickness were assessed using magnetic resonance imaging.

Results: Based on our search 23 publications were included in the study after omitting repetitions. Among 23 studies, 16 used anti-NGF monoclonal antibodies (Tanezumab, Fasinumab, Fulranumab), and 7 used recombinant human FGF-18 (Sprifermin). The total of 6679 patients were analysed in these articles. In the pooled analysis NGF inhibitors demonstrated statistically significant improvements compared with placebo in WOMAC Pain and Physical Function score (all studies revealed significantly better clinical outcomes in the anti-NGF group). After treatment with FGF-18 (Sprifermin) there was also improvement in WOMAC scores though not statistically significant. However, FGF-18 therapy was associated with the reductions in loss of total and lateral femorotibial cartilage thickness. Moreover, it does not only significantly reduce cartilage loss but also increase cartilage thickness. In terms of cartilage repair, 5 of 7 studies reported improvement in total femorotibial joint cartilage thickness. The AEs of FGF-18 or anti-NGF therapies were not serious, however they may affect the compliance and satisfaction of patients and clinicians. The proportion of patients with adverse events in anti-NGF treatment group was higher than that in FGF-18. The following conditions were reported in anti-NGF: abnormal peripheral sensation such as hypoesthesia (7.43%), paraesthesia (9.15%), hyperesthesia (0.36%), peripheral neuropathy and sensory disturbance (0.35%); arthralgia (15%), back pain (15.06%), pain in extremity (10%), headache (9.11%), upper respiratory tract infection (10.65%), diarrhoea (11.95%), sinusitis or nasopharyngitis (10.13%). The difference in AEs between sprifermin and placebo groups was found insignificant, most frequently reported event was arthralgia.

Conclusion: In recent years significant progress has been achieved for pathogenetic therapy of OA. Based on the results of current research findings, NGF inhibitors relieved pain and enhance joint function and may be considered as the most effective for functional improvement. FGF-18 decrease the cartilage loss and may improve cartilage thickness. However, further clinical longitudinal studies characterised the risk-benefit are needed to establish their safety and efficacy.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3584
SERUM MARKERS OF GUT PERMEABILITY AND ENDOTOXEMIA IN PATIENTS WITH METABOLIC SYNDROME-ASSOCIATED KNEE OSTEOARTHRITIS: AN EXPLORATORY STUDY

E. Taskin1, N. Kashevarova1, K. Telyshev1, D. Rudinsky1, E. Strebkova1, E. Sharapova1, A. Alekseeva1,2, A. Lila2,3. 1V .A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Research Institute of Fundamental and Clinical Immunology, Laboratory of Clinical Immunopharmacology, Novoibirs, Russian Federation

Background: Metabolic syndrome (MetS)-related osteoarthritis (OA) has been proposed as a distinct phenotype of OA (1). One of the many putative pathways linking MetS with OA is increased gut permeability resulting in endotoxemia, systemic inflammation, and cartilage damage. There is a lack of studies evaluating markers of gut permeability and endotoxemia in patients with MetS-associated OA.

Objectives: In this exploratory study we aimed to: a. compare serum markers of gut permeability and endotoxemia in patients with knee OA and concomitant MetS vs patients with knee OA but without MetS; b. evaluate possible associations between the studied biomarkers, knee pain function, and body mass index (BMI) in patients with MetS plus OA.

Methods: In this cross-sectional study, we evaluated consecutive patients diagnosed with knee OA according to ACR criteria and willing to participate in the study. MetS was defined in accordance with NCEP ATP III criteria. Knee pain and function were assessed using WOMAC scale. Serum concentrations of gut permeability marker zonulin, lipopolysaccharide (LPS), and soluble LPS receptor (sCD14) were measured using commercial ELISA kits.

Results: Forty patients (19 with OA plus MetS, 21 with OA), all women, mean age 65.5 years, were included in the study. The participants in the compared groups were of similar age. Patients with MetS had significantly higher BMI, increased knee pain, impaired knee function, and elevated serum C-reactive protein levels. Serum LPS, sCD14, and zonulin concentrations were significantly higher (1.5 fold, 2 fold, and 3.5 fold, respectively) in patients with OA+MetS. In the latter group, serum zonulin, sCD14, and LPS concentrations were moderately positively correlated with BMI. There were no correlations between the studied serum biomarkers and WOMAC knee pain, only zonulin was moderately positively associated with WOMAC knee function (Figure 1).

Conclusion: These findings suggest that while associated with MetS, increased gut permeability may not play a significant role in OA clinical manifestations.

Discipline of Interests: None declared.

Disclosure of Interests: None declared.


Table 1. Discriminant function coefficients to create a model of structural progression of metabolic knee osteoarthritis

<table>
<thead>
<tr>
<th>Factors</th>
<th>Discriminant function coefficients</th>
</tr>
</thead>
<tbody>
<tr>
<td>WOMAC pain</td>
<td>0.00608</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>2.11052</td>
</tr>
<tr>
<td>BMLs in the medial tibial compart</td>
<td>1.3734</td>
</tr>
<tr>
<td>Synovitis</td>
<td>1.19864</td>
</tr>
<tr>
<td>Constant</td>
<td>6.34279</td>
</tr>
</tbody>
</table>

Model accuracy = 89%

Figure 1. Spearman correlation between serum gut permeability markers, BMI, knee pain and function. * p<0.05, ** p<0.01

Disclosure of Interests: None declared.

Disclosure of Interests: None declared.


MAIN PREDICTORS OF STRUCTURAL PROGRESSION IN PATIENTS WITH METABOLIC PHENOTYPE OF OSTEOARTHRITIS

E. Taskin1, N. Kashevarova1, K. Telyshev1, D. Rudinsky1, E. Strebkova1, E. Sharapova1, L. Alekseeva1,2, A. Lila2,3. 1V .A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Rheumatology, Moscow, Russian Federation; 3I.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Objectives: to determine the main predictors of structural progression in patients with metabolic phenotype of knee osteoarthritis (OA).

Methods: 82 female patients with metabolic phenotype of knee OA (diagnosis of OA according to the ACR criteria, radiologic stages varying I-III Kellgren & Lawrence) aged 40-75 were included in this prospective study. Mean age was 59.1 ± 8.5 years (42-74), BMI was 32.5 ± 3.48 kg/m², disease duration was 13 (7-19) years. Individual case report forms, which included history of the disease, physical assessment data, VAS knee pain, WOMAC, joint status, comorbidities and previous medications, were filled out for each patient. All patients performed plain knee radiography, ultrasound and MRI (WORMS).

Results: 13 patients (15.9%) showed structural progression at two years of follow-up. When comparing groups with (n=13, group 1) and without (n=69, group 2) structural progression, there were no differences in terms of age, age of disease onset and disease duration. However, in the progression group patients had higher bodyweight: 99 ± 12.9 vs 82 ± 8.1 kg (p = 0.0003), they also had higher VAS knee pain (69 (66-73) vs 54 (34-66) mm (p=0.0009), and WOMAC (359 (339-381) vs 255 (200-316) mm (p=0.0003)). More patients from the progression group had hypertension (92.3% vs 79.7%) and type 2 diabetes (100% vs 4.3%). MRI showed significant intergroup differences in terms of both frequency and severity of cartilage damage. Cartilage defects (via WORMS) were more frequent in the medial tibial compartment of group 1: 50% vs 4.9% (RR=10.2, 95% CI 3.9-35.1, p=0.0004). Identical trend was found when evaluating bone marrow lesions (BMLs) in the medial (75% vs 27.9%, RR=2.7, 95% CI 1.6-4.5, p=0.003) and lateral (50% vs 16.4%, RR=3.05, 95% CI 1.4-6.8, p=0.02) tibial compartments. Synovitis was verified via MRI in 100% of group 1 patients vs 56.5% (RR=1.8, 95% CI 1.4-2.2, p=0.007).

Conclusion: This prospective trial has shown that the main predictors for metabolic knee OA phenotype progression are high WOMAC pain, synovitis, type 2 diabetes and medial tibial compartment BMLs. Based on the selected factors and their coefficients, we have created a formula that allows to predict the risk of structural progression of metabolic OA.

Disclosure of Interests: None declared.


Table 1. Discriminant function coefficients to create a model of structural progression of metabolic knee osteoarthritis

<table>
<thead>
<tr>
<th>Factors</th>
<th>Discriminant function coefficients</th>
</tr>
</thead>
<tbody>
<tr>
<td>WOMAC pain</td>
<td>0.00608</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>2.11052</td>
</tr>
<tr>
<td>BMLs in the medial tibial compart</td>
<td>1.3734</td>
</tr>
<tr>
<td>Synovitis</td>
<td>1.19864</td>
</tr>
<tr>
<td>Constant</td>
<td>6.34279</td>
</tr>
</tbody>
</table>

Model accuracy = 89%
Background: Polyacrylamide hydrogel (iPAAG), manufactured by Contura International, is CE marked for the symptomatic treatment of patients with knee osteoarthritis (OA). iPAAG fulfils an unmet clinical need for an effective, long-acting, safe and minimally invasive treatment that may postpone and potentially prevent knee surgery for those with OA.

Objectives: To compare the effectiveness of single intra-articular injections of iPAAG and hyaluronic acid (HA) in participants with moderate to severe knee OA. To compare the effectiveness of iPAAG and HA in subgroups based on age, BMI or Kellgren-Lawrence (KL) grade at baseline by assessing changes from baseline in transformed WOMAC pain subscale scores.

Methods: This prospective, double-blind study (NCT04045431) randomized 239 participants to receive a single intra-articular injection of either iPAAG or HA. The study was approved by the Capital Region’s Committee on Health Research Ethics. All participants provided informed consent prior to study activities. Outcomes included changes in the WOMAC pain, stiffness and function subscales and Patient Global Assessment of disease impact (PGA) at 52 weeks. All statistical analyses were based on the ITT principle using a mixed model for repeated measures with a restricted maximum likelihood-based approach. The estimated mean treatment difference based on this model was reported with 95% CI and p-value.

Results: Demographic and baseline characteristics were similar between treatment groups with an average age at treatment of approximately 67 years (range 31 – 90 years) and slightly more females (53%) than males. There was a clinically relevant decrease in WOMAC pain subscale score from baseline to 52 weeks in both groups (Figure 1). There were also clinically relevant decreases in the WOMAC stiffness subscale and physical function subscale and PGA in both groups. Treatment differences in favor of iPAAG compared to HA, were measured for the 3 WOMAC subscales and PGA. However, none of these differences reached statistical significance.

Conclusion: At 52 weeks after treatment, the effectiveness of iPAAG was numerically superior to HA but not statistically significantly different. In subgroups of participants with normal BMI, participants <70 years old or participants with KL grade 2 or 3 iPAAG performed statistically significantly better than HA at 52 weeks after treatment.

Disclosure of Interests: None declared


Table 1. Change from baseline in transformed (0-100) WOMAC pain subscale at week 52

<table>
<thead>
<tr>
<th></th>
<th>LShMean (95% CI)</th>
<th>Treatment difference (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-13.3 (-16.7; -10.0)</td>
<td>4.6 (-0.1; 9.4)</td>
<td>0.0572</td>
</tr>
<tr>
<td>iPAAG</td>
<td>-17.9 (-21.3; -14.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age &lt;70 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-14.0 (-18.3; -9.6)</td>
<td>5.6 (0.5; 10.7)</td>
<td>0.0195</td>
</tr>
<tr>
<td>iPAAG</td>
<td>-21.3 (-25.5; -17.0)</td>
<td>7.3 (12.1; 13.4)</td>
<td></td>
</tr>
<tr>
<td>Age &gt;70 years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-12.5 (-17.6; -7.4)</td>
<td>1.8 (-5.3; 8.9)</td>
<td>0.6114</td>
</tr>
<tr>
<td>iPAAG</td>
<td>-13.4 (-18.7; -8.2)</td>
<td>10.6 (6.3; 8.2)</td>
<td>0.1614</td>
</tr>
<tr>
<td>BMI normal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-13.5 (-18.1; -8.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>iPAAG</td>
<td>-17.5 (-22.2; -12.9)</td>
<td>10.9 (2.6; 19.1)</td>
<td>0.0101</td>
</tr>
<tr>
<td>BMI overweight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-14.3 (-19.5; -9.2)</td>
<td>1.8 (-5.3; 8.9)</td>
<td>0.6114</td>
</tr>
<tr>
<td>iPAAG</td>
<td>-16.1 (-21.0; -11.3)</td>
<td>10.9 (2.6; 19.1)</td>
<td>0.0332</td>
</tr>
<tr>
<td>BMI obese</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-14.5 (-22.7; -6.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>iPAAG</td>
<td>-17.8 (-25.6; -10.0)</td>
<td>3.3 (-8.0; 14.7)</td>
<td>0.5565</td>
</tr>
<tr>
<td>KL grade 2 or 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-13.4 (-17.0; -9.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>iPAAG</td>
<td>-18.9 (-22.5; -15.4)</td>
<td>5.6 (0.5; 10.7)</td>
<td>0.6075</td>
</tr>
<tr>
<td>KL grade 4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HA</td>
<td>-13.1 (-21.9; -4.3)</td>
<td>-2.8 (16.4; 10.8)</td>
<td></td>
</tr>
<tr>
<td>iPAAG</td>
<td>-10.3 (-20.6; 0.0)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: At 52 weeks after treatment, the effectiveness of iPAAG was numerically superior to HA but not statistically significantly different. In subgroups of participants with normal BMI, participants <70 years old or participants with KL grade 2 or 3 iPAAG performed statistically significantly better than HA at 52 weeks after treatment.

Disclosure of Interests: None declared


POST1131 ASSOCIATION BETWEEN ANTIBIOTIC USE AND RADIOGRAPHIC PROGRESSION OF OA: DATA FROM THE OSTEOARTHRITIS INITIATIVE

I. Shirinsky1, V. Shirinsky1, 1. Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology, Laboratory of Clinical Immunopharmacology, Novoibinsk, Russian Federation

Background: Gut dysbiosis has been proposed as one risk factor for osteoarthritis (OA) (1). To date, there have been no studies assessing association between the use of antibiotics and structural progression of knee OA.

Objectives: To evaluate association between the use of antibiotics and radiographic progression of knee OA.

Methods: For the current study we used 9-year longitudinal data obtained from the Osteoarthritis Initiative (OAI) progression (n=1390) and incidence (n=3284) subcohorts, which are publicly available at https://oai.nih.gov. For the assessment of antibiotic influence on knee OA progression we analyzed all knees having baseline JSN=3 from both subcohorts. The main outcome was knee OA progression (defined as increase in semiquantitative JSN or a new knee replacement). To acquire information about the use of antibiotics, a medication inventory method was used. We excluded participants who used antibiotics at or 30 days prior to baseline (a “new-user” design). Antibiotic users were defined as those with at least one recorded use during first four years of the study. Other participants who did not use antibiotics prior to baseline and throughout the observation period were classified as non-users. Logistic regression models were used to evaluate the relationship between the outcome and antibiotic use. Generalized estimating equations (GEE) were used to adjust for the correlation between knees.

Results: A total of 8415 of knees (7404 non-user knees and 1011 user knees) were included in the analysis. No association between the use of antibiotic and radiographic progression of knee OA was found (odds ratio 1.23, 95% confidence interval 0.59-2.56, p = 0.59). No associations were also observed in multiple stratified analyses based on different duration of antibiotic use, particular classes of antibiotics, or different baseline KL grades.

Conclusion: These findings do not support the effects of antibiotics on knee OA progression.

REFERENCES:

Acknowledgements: I have no acknowledgements to declare

Disclosure of Interests: None declared


Figure 1. Mean plot of transformed WOMAC pain subscale (0-100) – ITT analysis set

The treatment difference in favor of iPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with age at baseline <70 years but did not reach statistical significance in the subgroup with age at baseline ≥70 years. The treatment difference in favor of iPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with normal BMI but did not reach statistical significance in the subgroups with overweight or obese BMI. The treatment difference in favor of iPAAG compared to HA for the WOMAC pain subscale score was statistically significant in the subgroup with KL grade 2 or 3. In the subgroup with KL grade 4, a treatment difference in favor of HA was not statistically significant.


Figure 1. Mean plot of transformed WOMAC pain subscale (0-100) – ITT analysis set
On the other hand, an increasing trend among the cases, signifying a higher prevalence of surgeries when nearing KR, was observed for HR and meniscal surgeries in both nations. The prevalence of HR was similar in England and southern Sweden at all-time points showing an increase most noticeable in the 3 years before KR. The prevalence of meniscus surgery in England was higher than the one observed in Sweden throughout the follow-up. Prevalence in England increased most noticeably in the four years prior to KR reaching 33.2 (95%CI 31.6, 34.9) surgeries per 1,000 people in the year preceding KR. In Sweden, the prevalence of meniscus surgery remained between four and eight surgeries per 1,000 people until the last year prior to KR when the prevalence increased to 13.8 (95% CI 11.9, 16.2) surgeries per 1,000 people.

Conclusion: HR and meniscal surgeries are common procedures that a person is likely to have experienced in the ten years prior to a KR. Comparing England and southern Sweden, we noticed similar prevalence and trends for what concerns HR suggesting similar practice in the two healthcare systems. Meniscus surgeries were more frequently utilised in England. Nevertheless, in both countries, a marked increase in the prevalence of this surgery was observed in the last years prior to the KR.

Disclosure of Interests: None declared

POS1133 IRISIN LEVELS IN KNEE OSTEOARTHRITIS ARE RELATED TO GENDER, OBESITY AND LOCAL INFLAMMATION
C. Orellana1, M. Rusiñol1, E. Costa Moya1, J. Calvet1, S. Garcia-Cirera1, M. Garcia Manrique de Lara1, C. Gailloste1, J. Gratacos-Masmithia1, Hóspita Universitari Parc Taulí, Rheumatology, Sabadell, Spain

Background: Irisin is a myokine synthesized mainly in skeletal muscle with exercise, although its secretion has also been observed in other tissues such as adipose and has been related to obesity and other metabolic alterations. Although obesity and other metabolic factors are risk factors for knee osteoarthritis and patients with this condition often do less exercise and have poor muscular state, irisin has been poorly studied.

Objectives: To measure irisin levels in synovial fluid and plasma and evaluate their relationship with clinical severity and inflammation parameters in patients with knee osteoarthritis.

Methods: Patients with symptomatic and radiographical osteoarthritis were studied. Demographic and anthropometric variables, Kellgren-Lawrence scale and Lequesne index were evaluated in ultrasound (at medial patellar line), clinical severity by Lequesne algofunctional index and physical exercise level were recorded. Levels of irisin, IL-6, TNF and hs-PCR were determined using ELISA.

Results: We included 6337 and 47010 subjects who underwent a knee replacement between 2015 and 2019 in southern Sweden and England, respectively (Table 1). Overall, the prevalence of all analysed surgeries was consistently lower in the controls with minimal trends detectable throughout follow-up in both England and Sweden (Figure 1).

Table 1. demographic

<table>
<thead>
<tr>
<th></th>
<th>Sweden (n=6337)</th>
<th>Controls (n=6337)</th>
<th>England (n=47010)</th>
<th>Controls (n=47010)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>69.8 (9.9)</td>
<td>68.9 (9.1)</td>
<td>69.6 (9.6)</td>
<td>69.6 (9.6)</td>
</tr>
<tr>
<td>Female Sex, n (%)</td>
<td>3.585 (56.6%)</td>
<td>3.585 (56.6%)</td>
<td>26.154 (55.6%)</td>
<td>26.154 (55.6%)</td>
</tr>
<tr>
<td>Surgeries, n</td>
<td>562</td>
<td>324</td>
<td>1393</td>
<td>1,889</td>
</tr>
<tr>
<td>Hip replacement</td>
<td>384</td>
<td>44</td>
<td>8,659</td>
<td>833</td>
</tr>
<tr>
<td>Meniscus</td>
<td>16</td>
<td>5</td>
<td>90</td>
<td>11</td>
</tr>
<tr>
<td>Ligaments</td>
<td>164</td>
<td>15</td>
<td>369</td>
<td>30</td>
</tr>
<tr>
<td>Osteotomy</td>
<td>98</td>
<td>3</td>
<td>107</td>
<td>5</td>
</tr>
</tbody>
</table>

Figure 1: Prevalence of hip replacement (HR), meniscus surgery, osteotomy and synovial surgery in the 10 years leading to a joint replacement.

Disclosure of Interests: None declared

POS1134 THE EFFECT OF ETORICOXIB ON PAIN AND SIGNS OF CENTRAL SENSITIZATION IN PATIENTS WITH OSTEOARTHRITIS
E. Polisichuk1, A. Karateev1, V. Amirdzhanova1, V.A. Nasonova Research Institute of Rheumatology, pain management, Moscow, Russian Federation

Background: Central sensitization (CS) plays an important role in the development of chronic pain in osteoarthritis (OA).

Objectives: to evaluate the effect of etoricoxib on pain and signs of CS in patients with OA.

Methods: 790 patients with OA (knee or hip) were included in an open observational study. Most of them (71.6%) were female, mean age 54.5 ± 13.0 years. All patients received etoricoxib 60 mg/day for 2 weeks. The dynamics of pain was assessed on a numerical rating scale (NRS 0–10), the dynamics of signs of CS was assessed using the Central Sensitization Inventory (CSI). CSI ≥ 40 was observed in 35.3% of patients.

Disclosure of Interests: None declared
Results: After 2 weeks of treatment with etoricoxib, the intensity of pain at movement, at rest and at night decreased by 58.8±24.1%, 69.7±32.6% and 70.1±32.8%. There was a decrease in CSI values by 33.1±14.5% (p<0.001), as well as a decrease in the number of MS components by 10.8% (p<0.001, r=0.92), the number of MS components by 3.5% to 10.3% (p<0.001).

Conclusion: Etoricoxib improved pain in OA patients and reduces the severity of signs of CS, supporting the central mode-of-action of the drug.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4693

POST135

METABOLIC OSTEOARTHRITIS: THE ROLE OF THE NUMBER OF COMPONENTS OF METABOLIC SYNDROME AND EXPRESSION OF CARTILAGE TISSUE DESTRUCTION GENES.

E. Strebkova1, E. Taskina1, N. Kashevarova1, E. Sharapova1, D. Kusevich1, L. Alekseeva1,2, A. Lila1,3, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: Osteoarthritis (OA) associated with metabolic syndrome (MS) or its components is considered as the metabolic phenotype of OA. It is well known that obesity and other components of MS affect the clinical picture, course and progression of OA. The cumulative effect of metabolic disorders has an effect on the course and outcomes of OA. The study of molecular genetic relationships between the expression of cartilage tissue destruction genes and metabolic OA is one of the studied and relevant directions in rheumatology.

Objectives: To determine the role of MS component count and gene expression associated with cartilage tissue destruction in metabolic OA.

Methods: The study included women (n = 117) 45-75 y.o with knee OA (according to ACR criteria) I-II X-ray stage by Kellgren-Lawrence with different numbers of MS components. The duration of the study was 2 years. The clinic conducted visits 1 times a year. At each visit, anthropometric patient scores, articular status, VAS for knee pain, WOMAC and comorbidities were recorded. Patients underwent a laboratory examination (biochemical blood examination: glucose, total cholesterol, LDL, HDL, TG, isolation of blood RNA) to determine the level of expression of cell proliferation genes - m-TOR and cartilage destruction - cathepsin K, instrumental examination (X-ray of knee joints) 1 once a year.

Results: All patients with knee OA included in the study (n = 117) showed an abdominal type of obesity (waist circumference > 80 cm in women), which is the main criterion for MS. With frequency analysis in 5.5% of patients, 1 component of MS was detected, in 13.5% - 2 components of MS, in 70.2% - 3 components of MS, in 10.8% - 4 components of MS. Median (25%; 75%) duration of knee OA disease was greater in patients with 2 or more MS components and was 7.3 years (6.0-8.0) compared to patients with 1 MS component, in whom the duration of OA was 5.4 years (2.0-11.0), p < 0.05. Spearman correlation analysis showed significant relationships between MS component count and OA duration, age, BMI, VAS for knee pain, WOMAC (Table 1).

Table 1. Analysis of the relationship between the number of MS components and OA by Spearman.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Number of MS components</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>n=0.57</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Duration of knee OA</td>
<td>n=0.56</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>X-ray stage by Kellgren-Lawrence of knee OA</td>
<td>n=0.24</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>BMI</td>
<td>n=0.48</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VAS for knee pain</td>
<td>n=0.36</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>WOMAC pain</td>
<td>n=0.47</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>WOMAC stiffness</td>
<td>n=0.42</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>WOMAC functional insufficiency</td>
<td>n=0.47</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Total WOMAC</td>
<td>n=0.46</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

Patients showed high expression rates of m-TOR cell proliferation regulator (11.04 (4.27-15.5)) and cathepsin K articular cartilage destruction (9.34 (3.66-12.5)). In analysis of Spearman correlations of cell metabolism gene expression with clinical manifestations of OA and MS components, direct positive correlations with VAS for knee pain were found (p < 0.001, r = 0.95), body weight (p < 0.001, r = 0.92), the number of MS components (p < 0.001, r = 0.78) and WOMAC pain (p < 0.001, r = 0.76).

Conclusion: In our work, it has been demonstrated that 3 or more components of MS in patients with knee OA are observed at pronounced X-ray stages of OA with longer disease duration and a long history of obesity. There are positive correlations between the number of MS components and the clinical course of OA, X-ray severity of OA, hyperexpression of cell proliferation and cartilage destruction genes.

Disclosure of Interests: None declared.


POST136

OSTEOARTHRITIS AND METHOTREXATE: EFFICACY AND SAFETY.

L. Alekseeva1,2, E. Strebkova1, N. Kashevarova1, E. Taskina1, E. Sharapova1, D. Kusevich1, A. Lila1,3, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: One of the common phenotypes of osteoarthritis (OA) is the “inflammatory phenotype,” which is characterized by persistent synovitis of knee joints, small joints of the hands, the development of the erosive hand OA (EOA), and insufficient effectiveness of standard OA therapy. In the inflammatory OA phenotype, changes observed in the synovial sheath have similar features to rheumatoid arthritis, so baseline anti-inflammatory drugs used in RA may be considered as possible treatments for OA. The literature presents few studies with mixed results on the use of methotrexate (MTX) in patients with OA.

Objectives: To examine the efficacy and safety of MTX use in patients with inflammatory knee OA and hand EOA.

Methods: The study included 40 patients (women) with OA (according to ACR criteria) and insufficient effectiveness of previous OA standard therapy: with knee OA (47.5%), hand EOA (25%) and a combination of these 2 localizations (27.5%). The clinical characteristics are shown in Table 1. For 24 weeks, patients received MTX subcutaneously with a dose escalation of 10mg to 15mg per week combined with folic acid 5mg per week and meloxicam 15mg “on demand.” The efficacy of MTX therapy was assessed by WOMAC and AUSCAN, by the OMERACT-OARSI criteria. During the study, laboratory indicators were monitored (clinical, biochemical, immunological blood tests, general urine test).

Results: As a result of 24 weeks of MTX therapy, there was a statistically significant decrease in pain, stiffness and functional insufficiency in the small joints of the hand on the AUSCAN index and in the knee joints on the WOMAC index (Figure 1). In hand OA, there was a decrease in pain by 40.21%, stiffness by 48.21%, functional insufficiency by 23.72%. In knee OA, there was a reduction in pain by 50.45%, stiffness by 49%, and functional failure by 42.7%. 85.5% of patients with knee OA and 72.5% of patients with hand EOA became responders to therapy according to the OMERACT-OARSI criteria. The best clinical effect was achieved in knee OA (89.9% of patients). As a result of MTX therapy, the need for non-steroidal anti-inflammatory drugs (NSAID) decreased: initially, 85% of patients took NSAID daily or more than 3 times a week, and after 6 months of MTX therapy, only 15% of patients took NSAID daily. In general, the tolerability of MTX was satisfactory. The study of 7 patients was stopped: 4 (10%) due to nausea, 3 (8%) due to a moderate increase in liver enzymes.

Table 1. Clinical characteristic of patients.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y.o., Me [25%; 75% percentiles]</td>
<td>62.5 (58.69)</td>
</tr>
<tr>
<td>Age of OA onset, y.o., Me [25%; 75% percentiles]</td>
<td>51.0 (46.58)</td>
</tr>
<tr>
<td>Kellgren-Lawrence grades of knee OA</td>
<td>9.53 (9.15)</td>
</tr>
<tr>
<td>II grade, %</td>
<td>73.3%</td>
</tr>
<tr>
<td>III grade, %</td>
<td>26.7%</td>
</tr>
<tr>
<td>BMI, kg/m² (M ± s)</td>
<td>30.68±6.48</td>
</tr>
<tr>
<td>WOMAC pain, mm, Me [25%; 75% percentiles]</td>
<td>328 [236; 360]</td>
</tr>
<tr>
<td>WOMAC stiffness, mm, Me [25%; 75% percentiles]</td>
<td>100 [87;121]</td>
</tr>
<tr>
<td>Total WOMAC, mm, Me [25%; 75% percentiles]</td>
<td>1220 [819; 1640]</td>
</tr>
<tr>
<td>AUSCAN pain, mm, Me [25%; 75% percentiles]</td>
<td>235 [191;313]</td>
</tr>
<tr>
<td>AUSCAN stiffness, mm, Me [25%; 75% percentiles]</td>
<td>56 [36;66]</td>
</tr>
<tr>
<td>AUSCAN functional insufficiency, mm, Me [25%; 75% percentiles]</td>
<td>430 [334;580]</td>
</tr>
<tr>
<td>Total AUSCAN, mm, Me [25%; 75% percentiles]</td>
<td>671 [392;912]</td>
</tr>
<tr>
<td>CRP, mg/l, Me [25%; 75% percentiles]</td>
<td>1.3 [0.8;2.5]</td>
</tr>
</tbody>
</table>

Figure 1. Dynamics of the total AUSCAN and total WOMAC as a result of MTX therapy.
in transaminases, one of these patients (3%) had one episode of neutropenia up to 1.82x10^9/L (norm 2.04 - 5.80 x10^9/L). There were no serious adverse events.

**Conclusion:** The results demonstrated a good symptomatic effect of MTX in patients with knee OA and hand EOA. There was a statistically significant decrease in pain, stiffness and functional insufficiency in knee joints and small joints of the hands, a decrease in the need for NSAID throughout MTX therapy.

The best clinical effect was achieved in patients with knee OA. Thus, the study showed that MTX has a good clinical effect in OA and a satisfactory safety profile.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4773

---

**POS1137**

**CORRELATIONS BETWEEN CLINICAL PARAMETERS AND SERUM CYTOKINE LEVELS IN OSTEOARTHRITIS PATIENTS WITH TYPE 2 DIABETES MELLITUS**

E. Trifonov, E. Zonova, O. Sazonova, Novosibirsk State Medical University, Department of Pharmacology, Clinical Pharmacology and Evidence-Based Medicine, Novosibirsk, Russian Federation; Novosibirsk State Medical University, Department of Therapy, Hematology and Transfusiology, Novosibirsk, Russian Federation

**Background:** Type 2 diabetes mellitus (T2DM) is one of frequent factor that can influence on development and progression of osteoarthritis (OA) and has similar mechanisms of immunopathogenesis.

**Objectives:** To explore the symptoms and the proinflammatory serum cytokine levels in OA (hand, knee, and hip) patients with T2DM and to estimate relationships between clinical and immunological features.

**Methods:** Patients who participated in this study (n=137) were divided in two groups: patients with bilateral hand, knee and hip OA (n=56) and T2DM and control group (n=81) which had only hand, knee and hip OA without such comorbidity. All patients were comparable in age, sex and duration of OA. We assessed serum cytokine levels (IL-6, IL-10, IL-18). NO including adipokines such as adiponectin, leptin and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), various symptoms of OA and mental health were measured using visual analog scale (VAS), Functional Index for Hand Osteoarthritis (FIHOA), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC Knee/Hip), Knee injury and Osteoarthritis Outcome Score – (KOOS), Hip injury and Osteoarthritis Outcome Score – (HOOS) and with short form SF-36; Psychological Health Questionnaire (PHQ9), Coping Pain Strategy Questionnaire (CSQ). We used U-Mann-Whitney test to detect differences between groups. Correlation was assessed using Spearman correlation coefficient (r).

**Results:** Patients with OA and T2DM are characterized by the prevalence of KOOS symptoms (median (Me) 58.3, interquartile range (IQR) 50–71.5; p<0.001), WOMAC Knee Total (Me 1327; IQR 930.6–1546; p=0.001) and low values of mental health (SF-MH (Me 48; IQR 35–56; p=0.001). We found increase of IL 6 (p = 0.0018), IL 18 (p = 0.0006), NO (p < 0.0001) levels in the blood serum of patients with OA and comorbidity. Patients with OA and T2DM had high ESR level (p < 0.0001) and leptin level (p = 0.0002) also. Correlation analysis identified the relationships between clinical parameters and such cytokines as IL-1β, IL-6, IL-10 and leptin, CRP in OA patients with T2DM. Some data are presented (Table 1).

**Conclusion:** Such comorbidity as OA and T2DM has clinical and laboratory features of progression of OA. Such immunological factors as serum cytokines concentrations, adipokines, CRP are linked with the severity of T2DM-associated OA. A different variation of correlations may suppose role of this proinflammatory factors in the pathogenesis of this OA phenotype. These data should be verified by larger studies.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.5068

---

**POS1138**

**PERSISTENCE OF DEPRESSIVE SYMPTOMS AND PHYSICAL PERFORMANCE IN KNEE OSTEOARTHRITIS**

R. Mehta, M. Shardelli, A. Ryan, Y. Dong, B. Beamer, J. Gallo, E. Stuart, M. Schuler, M. Hockberg, A. Rathbun. 1. University of Maryland School of Medicine, Epidemiology and Public Health, Baltimore, United States of America; 2.University of Maryland School of Medicine, Medicine, Baltimore, United States of America; 3.University of Maryland School of Medicine, Psychiatry, Baltimore, United States of America; 4.Johns Hopkins Bloomberg School of Public Health, Mental Health, Baltimore, United States of America; 5.Rand Inc., Policy Research, Boston, United States of America

**Background:** Knee osteoarthritis (OA) is the most prevalent arthritic disorder, characterized by joint pain, which is exacerbated by chronic depressive episodes. Depression in knee OA is also associated with declines in physical activity level and greater disability; however, the impact of persistent depressive symptoms on physical performance remains unclear.

**Objectives:** To determine how the persistence of depressive symptoms affects functional capacity in knee OA.

**Methods:** Participants (n=2,212) were from the Osteoarthritis Initiative cohort and included individuals with radiographic disease (Kellgren-Lawrence grade ≥ 2) and complete data on study measures at baseline. Depressive symptoms were assessed using Center for Epidemiological Studies Depression Scale (20-item, range 0–60) at baseline and the first three follow-up visits. Physical Performance was measured using 20-meter gait speed (meters per second) during follow-up in the first four annual visits. Persistency of depressive symptoms was operationalized as a cumulative exposure using average severity over time. Gait speed was standardized so that outcome estimates could be interpreted in standard deviations. Time-invariant confounders measured at study enrollment included demographic, socioeconomic, and lifestyle factors. Time-varying confounders assessed concurrent to CES-D scores were body mass index, analgesic medications, pain, and other knee OA signs and symptoms. Marginal structural models accounting for time-dependent confounding and selective attrition were the primary method of analysis. The outcome model included all potential statistical interactions between depressive symptoms and follow-up time indicators. Post-estimation linear combinations estimated time-specific effects of time-averaged CES-D scores on standardized gait speed and differences in physical performance between participants with (i.e., CES-D=16) and without (i.e., CES-D=0) depressive symptoms satisfying screening criteria for major depression.

**Results:** The interaction between depressive symptoms and time was statistically significant (P<0.001). Time-specific associations indicated that the largest negative impact of depressive symptoms on physical performance was from baseline through year one (β = -0.0077; 95% CI: -0.0125, 0.0030). However, the effect of persistent depressive symptoms decreased over time and reversed in magnitude and directionality, evidenced by the time-specific associations between time-averaged CES-D scores from baseline through year one and year two and gait speed at year two (β = -0.0033; 95% CI: -0.0084, 0.0019) and year three (β = 0.0014; 95% CI: -0.0046, 0.0074), respectively. Consequently, the strongest negative affect of depressive symptoms on gait speed (β = -0.1323; 95% CI: -0.1998, -0.0473) between participants with and without depressive symptoms satisfying screening criteria for major depression was when depressive symptoms were first reported closest to the initial gait speed assessment.

**Conclusion:** In the contrast to the dose-dependent relationship between chronic depressive episodes and pain in knee OA, study findings imply that the negative effect of depressive symptoms on physical performance decreases over time with increasing depression persistency. These results may reflect diminishing marginal effects, where the largest impact on physical performance in knee OA is during the first depressive episode closest to initial gait speed assessment, especially when averaged against improvement in symptoms over the same duration.

**Acknowledgements:** The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners.

**Disclosure of Interests:** Rhea Mehta: None declared, Michelle Shardelli: None declared, Alice Ryan: None declared, Yu Dong: None declared, Brock Beamer: None declared, Joseph Gallo: None declared, Elizabeth Stuart: None declared, Megan Schuler: None declared, Marc Hockberg Shareholder of: Dr. Marc C. Hockberg is the President of Rheumcon Corporation., Consultant of: Dr. Marc C. Hockberg receives consulting fees from Biotoxin SA, Bristol-Meyers Squibb, Eli Lilly, Ela-Rheo, Galapagos, IBSA BiotechinQ SA, Novartis Pharma AG, Pfizer, Plexikon, Samumed LLC, Theraglogix LLC, and TissueGene Inc., Alan Rathbun: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.5250
Osteoporosis

**POST139** GLUCOCORTICOIDS AND BONE DENSITY IN POLYMYALGIA RHEUMATICA, GIANT CELL ARTERITIS, AND OTHER VASCULITIDES – A CROSS-SECTIONAL ANALYSIS OF THE RH-GIOP COHORT

A. Palmowski1, E. Wibe2, B. Muche3, S. Hermann4, C. Deja9, E. Matteson5, F. Buttgereit6,1. Chanté - Universitätsmedizin Berlin, Rheumatology and Clinical Immunology, Berlin, Germany, 2Medical University Graz and South Tyrol Health Trust, Department of Rheumatology and Immunology and Rheumatology Service, Graz and Bruneck, Italy, 3Mayo Clinic College of Medicine and Science, Division of Rheumatology and Division of Epidemiology, Departments of Internal Medicine and Health Sciences Research, Rochester, MN, United States of America

**Background:** There are only few, inconclusive investigations on bone density and the effects of glucocorticoids (GCs) in polymyalgia rheumatica (PMR) and vasculitides.

**Objectives:** To determine whether GCs are associated with bone density in patients with PMR and other vasculitides after adjustment for confounders.

**Methods:** The Rh-Giop cohort study started in 2015 and investigates bone health in patients with rheumatic diseases. In this cross-sectional analysis of baseline visits, we included patients with PMR and vasculitides. Multiple regression was used to model the effect of current and cumulative GC intake on the minimum T-score (mTs; lumbar spine or hip) with adjustment for several founders such as sex, age, body mass index (BMI), or inflammation (measured by C-reactive protein (CRP)). GCs were modelled both as continuous and as categorical predictors in separate models. Several sensitivity analyses were performed. Patients with early disease (<3 months) were excluded from inferential analyses as were patients with very high GC dosages (>100mg/day prednisolone equivalent). Multiple imputation by chained equations was used for missing data (about 5%).

**Results:** 198 patients (mean age 68 ± 11 years; 68% females) with a mean disease duration of 5.3 ± 6.3 years were included. The most common rheumatic disease was PMR (36%), followed by giant cell arteritis (26%) and granulomatosis with polyangiitis (17%). 87% were currently taking GCs, 88% received vitamin D supplements, 7% had a deficiency. Osteoporosis (OP) diagnosed by DXA was present in 19% (17.2% with PMR and 21% in other vasculitides). 87% were currently taking GCs, 88% received vitamin D supplements, 7% had a deficiency. Osteoporosis (OP) diagnosed by DXA was present in 19% (17.2% with PMR and 21% in other vasculitides).

**Discussion:** In this cohort of PMR and vasculitides, the prevalence of OP was similar to the overall elderly German population. Vitamin D supplementation was common while deficiencies were surprisingly rare – in population-based studies, about 32% of Germans are estimated to have a vitamin D deficit. We found no association between current or cumulative GC intake, inflammation, and bone density. Proton-pump inhibitor intake and BMI as modifiable risk factors were associated with mTs. These findings need confirmation from longitudinal analyses of our and other cohorts.

**References:**

**Acknowledgements:** Funding Rh-Giop is supported by a joint funding from Amgen, Biogen, BMS, Chugai, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.

**Disclosure of Interests:** Andriko Palmowski: None declared, Edgar Wiebe Grant/research support from: Travel expenses and consultancy fees from Medac, Burkhard Muche Speakers bureau: Speaker fees from one of these: Amgen, Gilead, Galapagos, UCB and Stadapharm, Consultant of: Consultancy fees of one of these: Amgen, Gilead, Galapagos, UCB and Stadapharm, Grant/research support from: Conference expenses of one of these: Amgen, Gilead, Galapagos, UCB and Stadapharm, Sandra Hermann Speakers bureau: Lecture fees from AbbVie, Christian Deja Speakers bureau: Speaker fees from one of these: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Consultant of: Consulting fees from one of these: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Eric Matteson Speakers bureau: editorial and contributor, UpToDate, Consultant of: editorial and contributor, UpToDate, Employee of: editorial and contributor, UpToDate, Frank Buttgereit Speakers bureau: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche, Consultant of: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche, Grant/research support from: Travel expenses: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche. Grant support: Abbvie, Pfizer and Roche


**POST140** SHORT-TERM EXPOSURE TO FINE PARTICULATE MATTER AND RISK OF FRAGILITY HIP FRACTURES, A CASE-CROSSOVER STUDY ON 1,042 HIP FRACTURES

G. Adam1, M. Pontalti1, A. Fassio1, C. Benini1, D. Gatti1, S. Negrì1, P. Olivì1, M. Possini1, 1University of Verona, Rheumatology Unit, Verona, Italy, 2University of Verona, Orthopedic Unit, Verona, Italy

**Background:** Fragility femoral fracture is a common, world-spread, medical condition, that has a relevant impact both clinically and economically. Chronic exposure to environmental air pollution has been linked with a higher risk of developing osteoporosis. However, little is known regarding the relationship between short-term exposure to air pollution and bone fractures.

**Objectives:** Our study aims to investigate the link between short-term exposure to fine particulate matters and fragility hip fractures.

**Methods:** We retrieved data of patients suffering of hip fractures admitted to the Orthopedic Unit of the University of Verona Hospital from 2015 to 2020. We retrieved data on the monitoring of PM10 concentrations from the Italian institute of environment protection and research (ISPRA). We designed a case-crossover study to compare the exposure to particulate matters (PM10) in the 30-day period immediately before the fracture (hazard period) referent to a 30-day control period (from day -30 to -60 from the fracture). Exposure to PM10 was evaluated as mean value and AUC. Case-crossover is a peculiar study design applied to longitudinal datasets that controls for within-person time-invariant and between-patient confounders such as indoor air pollution, chronic comorbidities or concomitant medications and have been used extensively to study the effects of transient, short-term exposures on the risk of acute events (Figure 1A).

**Results:** 1042 patients (73.7% female n=768), with a hip fracture admitted to the hospital were included in the study. Mean age of the cohort was 82.6 years (±9.55). Average exposure to PM 10 in the control period was 33.84 ug/m3, cumulative exposure (AUC) was 952.42 ug/m3 compared to fine particulate matters and fragility hip fractures.

**Conclusion:** In this cohort of PMR and vasculitides, the prevalence of OP was similar to the overall elderly German population. Vitamin D supplementation was common while deficiencies were surprisingly rare – in population-based studies, about 32% of Germans are estimated to have a vitamin D deficit. We found no association between current or cumulative GC intake, inflammation, and bone density. Proton-pump inhibitor intake and BMI as modifiable risk factors were associated with mTs. These findings need confirmation from longitudinal analyses of our and other cohorts.

**References:**

**Acknowledgements:** Funding Rh-Giop is supported by a joint funding from Amgen, Biogen, BMS, Chugai, Generic Assays, GSK, Hexal, Horizo

**Disclosure of Interests:** Andriko Palmowski: None declared, Edgar Wiebe Grant/research support from: Travel expenses and consultancy fees from Medac, Burkhard Muche Speakers bureau: Speaker fees from one of these: Amgen, Gilead, Galapagos, UCB and Stadapharm, Consultant of: Consultancy fees of one of these: Amgen, Gilead, Galapagos, UCB and Stadapharm, Consultant of: Consulting fees from one of these: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Consultant of: Consulting fees from one of these: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Eric Matteson Speakers bureau: editorial and contributor, UpToDate, Consultant of: editorial and contributor, UpToDate, Employee of: editorial and contributor, UpToDate, Frank Buttgereit Speakers bureau: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche, Consultant of: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche, Grant/research support from: Travel expenses: Abbvie, AstraZeneca, Grünenthal, Pfizer, and Roche. Grant support: Abbvie, Pfizer and Roche

Disclosure of Interests: Giovanni Adami Shareholder of: Theramex, Galapagos, Marco Pontalti: None declared, Davide Gatti: None declared, Stefano Negrì: None declared, Pietro Olivi: None declared, Maurizio Rossini Shareholder of: Abbvie, Amgen, Bms, Eli Lilly, Galapagos, Novartis, Pfizer, Sandoz, Theramex, Ucb. None declared, Davide Gatti: None declared, Stefano Negri: None declared, Marco Pontalti: None declared, Angelo Fassio: None declared, Camilla Ben-

POS1142 FACTOR ANALYSIS OF FRAILTY FRACTURES BY SITE IN PATIENTS REFERRED FOR DUAL-ENERGY X-RAY ABSORPTIOMETRY SCAN

Z. Sultan1, M. Bukhari2. 1Royal Lancaster Infirmary, Rheumatology, Lancaster, United Kingdom; 2Royal Lancaster Infirmary, Rheumatology, Lancaster, United Kingdom

Background: Frailty fractures are defined as fractures which occur secondary to low energy trauma (1). Fractures lead to substantial pain, reduced quality of life and significant burden to society, with 3.5 million fragility fractures occurring in the EU in 2010 costing €37 billion (2). It is predicted that by 2025 this cost will have increased by 25% (2). Studying fractures is in the interest of our ageing society in order to aid management of patients at risk. To our knowledge, no other studies have grouped fractures based on site by factor analysis.

Objectives: 1. Determine which fractures are most common in patients who present for dual-energy X-ray absorptiometry (DEXA) scan
2. Apply a factor analysis to establish any patterns in the incidence of fractures based on site

Methods: Between 1996 and 2017, 31546 patients presented to a district general hospital in the North West of England for bone mineral density estimation by DEXA scan. Demographic details, risk factors, incidence of fractures and site of fractures were recorded at time of scan. These data were retrospectively studied to identify patients who had sustained at least one fracture. STATA was used to conduct a factor analysis using the principal component factors (PCF) method. Ethical approval was granted by the Northwest Regional Ethics Committee.

Results: 11839 patients were identified to have had at least one fracture (14756 total fractures). Mean age was 67.96, with 9993 females and 1846 males. Mean height was 161.21 cm, mean weight was 70.41 kg and mean BMI was 27.04 kg/ m2. Mean T-scores at femoral neck, total femur and lumbar spine were -1.55, -1.38 and -1.30 respectively. The most common fracture site was at the wrist/forearm with 5421 (36.74%) cases. Further, there were 2795 tibia/fibula (18.94%), 2530 spine (17.15%), 1363 femur (9.24%), 1224 humerus (8.29%), 1063 rib (7.20%), 315 pelvis (2.13%), 43 elbow (0.29%) and 2 ankle (0.01%) fractures. 9390 patients had 1 fracture and 2449 patients had more than 1, with 9 patients sustaining 5 fractures. Factor analysis on fracture sites revealed 6 factors with an eigenvalue > 1. Fracture sites were grouped together based on those fractures which loaded most heavily on each factor. Loading was as follows: spine and ribs on Factor 1; spine, pelvis and wrist/forearm on Factor 2; humerus and femur on Factor 3; elbow and ankle on Factor 4; ribs and humerus on Factor 5; ribs and femur on Factor 6 (Table 1).

Table 1. Factor analysis on sites of fractures using the PCF method.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Factor 1</th>
<th>Factor 2</th>
<th>Factor 3</th>
<th>Factor 4</th>
<th>Factor 5</th>
<th>Factor 6</th>
<th>Uniqueness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tibia/fibula</td>
<td>0.0862</td>
<td>-0.9485</td>
<td>-0.0530</td>
<td>0.1182</td>
<td>0.0325</td>
<td>-0.0896</td>
<td>0.0671</td>
</tr>
<tr>
<td>Spine</td>
<td>0.6906</td>
<td>0.3263</td>
<td>-0.4535</td>
<td>-0.1501</td>
<td>-0.2681</td>
<td>-0.1837</td>
<td>0.0829</td>
</tr>
<tr>
<td>Ribs</td>
<td>0.2128</td>
<td>0.1089</td>
<td>-0.0689</td>
<td>-0.0957</td>
<td>0.7535</td>
<td>0.0674</td>
<td>0.0193</td>
</tr>
<tr>
<td>Pelvis</td>
<td>0.0810</td>
<td>0.2050</td>
<td>0.1185</td>
<td>-0.0158</td>
<td>0.2113</td>
<td>-0.3663</td>
<td>0.7369</td>
</tr>
<tr>
<td>Humerus</td>
<td>0.0386</td>
<td>0.1433</td>
<td>0.5578</td>
<td>0.0892</td>
<td>0.3832</td>
<td>-0.5101</td>
<td>0.2518</td>
</tr>
<tr>
<td>Femur</td>
<td>0.1227</td>
<td>0.0946</td>
<td>0.7052</td>
<td>0.0571</td>
<td>-0.4814</td>
<td>0.4532</td>
<td>0.0416</td>
</tr>
<tr>
<td>Elbow</td>
<td>0.0391</td>
<td>0.1300</td>
<td>-0.0740</td>
<td>0.7306</td>
<td>0.0305</td>
<td>0.0363</td>
<td>0.4401</td>
</tr>
<tr>
<td>Ankle</td>
<td>0.0547</td>
<td>0.1082</td>
<td>-0.1084</td>
<td>0.7189</td>
<td>-0.0365</td>
<td>0.0716</td>
<td>0.4503</td>
</tr>
<tr>
<td>Wrist/forearm</td>
<td>-0.8856</td>
<td>0.2389</td>
<td>-0.2461</td>
<td>-0.0479</td>
<td>-0.0608</td>
<td>0.0071</td>
<td>0.0920</td>
</tr>
</tbody>
</table>

Conclusion: In-keeping with published data, the most common site for fracture was forearm (3). Factor analysis grouped together sites of fractures into 6 factors, suggesting that these fractures are more likely to co-exist. Moving forward it would be beneficial to ascertain differences between the groups in terms of demographics, risk factors and any bone protection measures taken. This may highlight clinically relevant data in order to make evidence based decisions in the identification and management of patients at risk of fragility fractures.

REFERENCES:


POS1142 A CONCORDANCE STUDY OF CT DENSITOMETRY WITH DXA DENSITOMETRY

R. Mawella, 1 R. Rajak, 1 Croydon Health Services NHS Trust, Medicine, London, United Kingdom; 2Croydon Health Services NHS Trust, Rheumatology, London, United Kingdom

Background: Osteoporosis is a skeletal disorder characterised by compromised bone strength resulting in an increased risk of fracture. Although DXA is the only technology that can be used for diagnostic classification of osteoporosis according to WHO, computed tomography imaging (CT) densitometry of the spine has equal or superior ability to predict vertebral fractures in postmenopausal women. Therefore the continued use of DXA as the primary modality of calculating BMD may lead to inaccurate exclusion of osteoporosis and prognostication.

Objectives: To assess the concordance of spinal CT densitometry with current standard of assessment through DXA-derived densitometry.

Methods: 50 patients who had had both a DXA scan of the lumbar spine and CT lumbar spine/thorax/abdomen performed within 18 months of each other were included. The CT images were analysed to attain a mean Hounsfield score of the lumbar vertebrae and this was compared to DXA derived T-scores. A Hounsfield score of 131 was used as the threshold for diagnosing osteoporosis akin to a DXA-derived T score of -2.5. The final data was analysed to find correlation values of Hounsfield score with T score using Pearson correlation coefficient.

Results: The mean Hounsfield score was 108.4 (osteoporotic) compared to a mean T-score of -1.22 (osteopenic) with a statistically significant correlation coefficient of 0.447 (p<0.01). Using T score ≤ -2.5, 15 (30%) of the patients included on our study would have a diagnosis of osteoporosis whereas this would be 36 patients (72%) if using the threshold of Hounsfield score <131. Out of the 50 patients included, 15 had vertebral fragility fractures. The mean T-score for these patients was -1.2 (indicating osteopenia) and mean Hounsfield score was 108 (indicating osteoporosis).

Conclusion: Our study showed a moderate positive correlation between the DXA-derived T-scores and CT Hounsfield scores. This further validates previous studies that suggest CT scans can be used to identify patients with osteoporosis. 93% of patients with vertebral fragility were identified as having osteoporosis using CT densitometry whereas only 40% were identified via DXA. These findings highlight the limitations of DXA, particularly in terms of overestimation of bone mineral density related to degenerative changes. CT images of the thorax, abdomen or lumbar spine that have already been performed for other indications can be used to opportunistically screen...
for osteoporosis without additional radiation exposure, waiting time or cost. This may allow for more accurate diagnosis and subsequent treatment and fracture risk reduction.

REFERENCES:


Disclosure of Interests: None declared.
DOI: 10.1136/annrheumdis-2022-eular.1017
Background: Although most fragility fractures occur in osteoporotic patients, fractures of the lumbar spine and the femora are also common in patients with normal bone mineral density (BMD). A number of risk factors are known to be associated with fractures in patients with reduced BMD. However, risk factors for fractures in patients with normal BMD remain relatively unexplored.

Objectives: Evaluate the risk factors associated with fractures in patients with a normal BMD (T-score ≥ -1.00) in the lumbar spine and right and left femur in an observational cohort.

Methods: Data was collected from patients attending a District General Hospital in the Northwest of England for a DEXA scan between 2004 to 2019. Patients with a T-score ≥ 1.00 in L1-4 and the right and left femur were included. Chi-squared test and Student’s t-test were used to compare risk factors in patients with and without fractures. A series of logistic regression models that adjusted for age and sex were then fitted to determine risk factors associated with a fracture.

Results: 6,504 patients were included in analysis, 1,491 (22.9%) of whom had a fracture. Mean age (SD) at scan was 58.64 (12.98) years and 5,347 (82.2%) were female. Risk factors and their association with fracture occurrence after adjusting for age and sex are shown in Table 1. Weight, BMI, and current alcohol use were statistically significantly (p < 0.05) associated with increased risk of fracture. History of Rheumatoid Arthritis, steroid use, and increased T-score in L1-4 or the right or left femur were statistically significantly (p < 0.05) associated with decreased risk of fracture.

Conclusion: In the FRAX tool, increased weight is considered protective against fractures, and steroid use and Rheumatoid Arthritis are thought to increase fracture risk. In our cohort of patients with normal BMD, patients with increased weight had a higher risk of fracture, and patients with Rheumatoid Arthritis and steroid use had a decreased fracture risk.

While there is overlap in the risk factors associated with fractures in patients with reduced BMD and normal BMD, our study suggests that some characteristics protective of fractures in osteoporotic patients may increase the risk of fracture in patients with a normal BMD.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Logistic regression with adjustment for age and sex

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Odds ratio (95% confidence interval)</th>
<th>P-value</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height, cm</td>
<td>1.006 (0.997, 1.016)</td>
<td>0.176</td>
<td>0.5666</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>1.010 (1.007, 1.014)</td>
<td>0.000</td>
<td>0.8084</td>
</tr>
<tr>
<td>BMI</td>
<td>1.027 (1.016, 1.037)</td>
<td>0.000</td>
<td>0.5773</td>
</tr>
<tr>
<td>Current smoker</td>
<td>1.164 (1.075, 1.259)</td>
<td>0.034</td>
<td>0.5664</td>
</tr>
<tr>
<td>Previous smoker</td>
<td>1.120 (0.976, 1.284)</td>
<td>0.106</td>
<td>0.5672</td>
</tr>
<tr>
<td>Current excessive alcohol use</td>
<td>1.299 (1.033, 1.634)</td>
<td>0.025</td>
<td>0.5668</td>
</tr>
<tr>
<td>Pervious excessive alcohol use</td>
<td>1.444 (1.043, 2.022)</td>
<td>0.091</td>
<td>0.5664</td>
</tr>
<tr>
<td>History of Rheumatoid Arthritis</td>
<td>0.674 (0.520, 0.874)</td>
<td>0.003</td>
<td>0.5708</td>
</tr>
<tr>
<td>Current steroid use</td>
<td>0.498 (0.406, 0.611)</td>
<td>0.000</td>
<td>0.5911</td>
</tr>
<tr>
<td>Previous steroid use</td>
<td>0.796 (0.669, 0.938)</td>
<td>0.010</td>
<td>0.5682</td>
</tr>
<tr>
<td>Mean T-score L1</td>
<td>0.929 (0.880, 0.980)</td>
<td>0.007</td>
<td>0.5698</td>
</tr>
<tr>
<td>Mean T-score L2</td>
<td>0.917 (0.874, 0.961)</td>
<td>0.000</td>
<td>0.5734</td>
</tr>
<tr>
<td>Mean T-score L3</td>
<td>0.906 (0.869, 0.947)</td>
<td>0.000</td>
<td>0.5758</td>
</tr>
<tr>
<td>Mean T-score L4</td>
<td>0.925 (0.889, 0.962)</td>
<td>0.000</td>
<td>0.5734</td>
</tr>
<tr>
<td>Mean T-score left neck of femur</td>
<td>0.866 (0.803, 0.933)</td>
<td>0.000</td>
<td>0.5662</td>
</tr>
<tr>
<td>Mean T-score total left femur</td>
<td>0.839 (0.780, 0.902)</td>
<td>0.000</td>
<td>0.5710</td>
</tr>
<tr>
<td>Mean T-score right neck of femur</td>
<td>0.847 (0.785, 0.914)</td>
<td>0.000</td>
<td>0.5672</td>
</tr>
<tr>
<td>Mean T-score total right femur</td>
<td>0.839 (0.779, 0.904)</td>
<td>0.000</td>
<td>0.5723</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Challenges in Conducting Pragmatic Care Strategy Studies in Osteoporosis: Patient Perceptions

L. Jackson1, E. McNeely2, N. C. Techarukpong1, F. Mugeta1, K. Aaron1, A. Mudano1, J. Merchant1, K. Warren2, J. Foster1, K. Saag3, M. Danila1

1University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, United States of America

Background: Large pragmatic osteoporosis studies to improve outcomes are needed. Direct-to-patient accrual strategies have high generalizability but achieving sufficient sample size is difficult; recruitment challenges represent an important consideration given limited participant eligibility and interest. The Fracture Liaison Service (FLS), a team approach to post-fracture care, is a secondary fracture prevention method that has significantly improved outcomes internationally.

Objectives: Our goal was to evaluate the interest, barriers, and lessons learned in recruiting participants for a future trial assessing remote FLS approaches for post-fracture care.

Methods: We used ICD10 fracture codes to identify patients > 50 years of age with a documented hip/pelvis, spine, humerus, or wrist fracture in the previous 1 year. We excluded patients with i) prescriptions for osteoporosis medications (e.g., bisphosphonates, parathyroid hormone analogs, denosumab, romosozumab, raloxifene) in the prior year; ii) an ICD10 code for end-stage renal disease, non-osteoporotic metabolic bone disease, malignant neoplasm, or motor vehicle accident. In December 2021, research assistants reviewed electronic health records (EHR) of potentially eligible patients for evidence of additional serious illness limiting life expectancy to < 1 year or non-ambulatory status prior to fracture. Research assistants called preliminary eligible patients that met inclusion and exclusion criteria and asked them to complete a survey status prior to fracture. Research assistants called preliminary eligible patients that met inclusion and exclusion criteria and asked them to complete a survey by phone. Interest in a FLS future clinical trial was evaluated using a Likert scale: “1= Definitely would not volunteer;” to “5= Definitely would volunteer”). We used descriptive statistics to analyze baseline demographic, clinical characteristics, and interest. This pilot was approved by the UAB Institutional Review Board (IRB-300008310-005).

Results: We identified 1,577 patients > 50 years of age with a fracture. After applying exclusion criteria, we identified 869 preliminary eligible patients. Over 3 weeks, we screened the medical records of a random sample of half of the preliminary eligible patient cohort (n=414), of which we contacted 271 patients, the mean age of 69.5 (11.5) years, 40% men, 21% Black or non-white Hispanics completed the survey. Among those contacted, 68 (83%, interest rate) said they would be very or highly interested in participating in a future clinical trial evaluating FLS approaches. Among the 40 (37%) people who said they were not sure, unlikely or very unlikely to volunteer the most common reasons cited were “I don’t want to participate in a study” (33%); “I don’t feel well enough to participate” (10%); “I don’t understand what the study is for” (3%). From this pilot, we calculated a refined eligibility/interest rate of 9.1% among those preliminary identified as eligible using administrative data alone.

Conclusion: Based on our pilot, we estimate that approximately 9% of eligible patients with fractures will be interested in enrolling in a future comparative effectiveness study to prevent recurrent fragility fractures. We identified several potential modifiable barriers to clinical trial recruitment. Participant perceptions collected from this pilot will inform enrollment strategies, which can be incorporated early when planning direct-to-patient pragmatic osteoporosis studies to achieve recruitment goals.

Disclosure of Interests: Lesley Jackson: None declared, Ellen McNeely: None declared, Norma C Techarukpong: None declared, Faith Mugeta: None declared, Kiara Aaron: None declared, Amy Mudano: None declared, Jeanne Merchant: None declared, Kellie Warren: None declared, Jeff Foster: None declared, Kenneth Sasa Grant: Research support from: Amgen, Horizon, LG Chem, Radius, SOBI, Maria Danila Grant/research support from: Pfizer, Horizon.

DOI: 10.1136/annrheumdis-2022-eular.2473

Sonographic Variation of Synovitis in Rheumatoid Arthritis Is Suggestive of Bone Mineral Density Change.

J. Chen1, T.T. Cheng1, Y. Chen1

1Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Kaohsiung City, Taiwan, Republic of China

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disorder initiated from local synovium inflammation and consequently bone/cartilage destruction. Active disease status brings persistent inflammation, which stimulates the activation of osteoclasts, accelerating systemic bone loss and decreasing bone mineral density (BMD)1. Ultrasound (US), a powerful tool for clinical practice, was reported to be beneficial for the prediction of new bone erosion and disease activity (2, 3), based on the synovium grading recommendation by the European League against rheumatism- Outcome Measures in Rheumatology Clinical Trial (EULAR-OMERACT) Taskforce. The severity of RA synovitis is associated with local bone destruction; however, the impact on systemic bone loss is still unknown.

Objectives: This pilot study aims to investigate if the US-detected synovitis change is associated with systemic bone loss.

Methods: A registry was conducted in Chang Gung Memorial Hospital, Kaohsiung, from September 2014 till April 2021 to monitor BMD changes in patients with rheumatic diseases. In RA patients, we regularly assessed synovium change of bilateral wrist by ultrasound at enrollment and one year later, based on EULAR-OMERACT system(4), which is a semiquantitative grading tool incorporating both gray-scale synovial hypertrophy (SH) and power Doppler (PD) signal. These ultrasound scans were performed by an independent and well-trained rheumatologist, using MyLab 70 system (Esaote, Firenze, Italy) and B-mode frequency at 12–18 MHz. We performed a longitudinal scan of volar and dorsal wrists, observing GS and PD signals. All participants who underwent standard care for RA were followed at least three years to monitor BMD change, and those who underwent anti-osteoporosis therapy at index day were excluded. We defined improvement of US-detected synovitis (US+) as a change from high to low grade by EULAR-OMERACT score. Conversely, patients who failed improvement were recorded as “US-” defined as change from low to high grade. Patients who improved one or more grades, such as from Grade 3 to 2 (or from Grade 2 to 0), were registered as US+1 (or US+2) and vice versa. If there is no change of synovitis grade, we registered as US+0.

Results: A total of 212 participants were enrolled in the current study, with a mean age of 56.0 ± 10.1 years and a mean RA disease duration of 13.6 ± 9.1 years. In patients with US+, the mean change of hip BMD [defined as (final BMD-baseline BMD)/(baseline BMD, in percentage)] was 0.73 ± 6.6%, while US- was -2.2 ± 7.7% and US+0 -1.9 ± 6.9% (p=0.047), in post-hoc analysis, US+ demonstrated borderline significance compared to US- (p=0.059) and US+0 (p=0.087) by Bonferroni method. Subsequent analysis (Figure 1 A) revealed that patients with US+2 presented preservation of hip bone mass (3.1 ± 6.8%), followed by US+1 (0.1 ± 6.8%) and then US+0. US-1 and US-2 showed rapid bone loss on the hip (-2.1 ± 7.3% and -2.3 ± 6.7%, respectively).

Conclusion: Persistent synovitis is associated with total hip bone loss, and detection of synovitis change by ultrasound with EULAR-OMERACT scoring system is helpful to predict hip BMD change.

REFERENCES:


BONE MINIFICATIONS IN SYSTEMIC MASTOCYTOSIS AND RELATED RISK FACTORS

H. Avilos Bojado, M. Barceló-Bru, M. Pascual-Pastor, A. D. Uloa Navas.

1 Hospital Universitari Vall d’Hebron, Rheumatology, Barcelona, Spain

Background: Clinical characteristics in Systemic Mastocytosis (SM) range from asymptomatic (indolent) to aggressive forms. Up to 28-34% of patients with SM have symptoms related to bone involvement at diagnosis and 16% have fractures (1). Skeletal manifestations include bone pain, osteoporosis (OP), osteosclerosis, focal osteolytic and osteoblastic lesions. OP is frequently related to indolent SM but not the aggressive forms (2).

Objectives: To describe bone involvement in patients with SM and analyze related risk factors.

Methods: Retrospective cohort study comprising patients with SM that attended the Rheumatology Department from 2010 to 2021. Sociodemographic variables, clinical manifestation, OP risk factors, bone lesions, fracture presence and analytical parameters were collected, and we analyzed whether they were associated with the presence of fractures (Table 1). Densitometry data were registered at diagnosis and up to 8 years of follow-up.

Results: 22 patients were included, 19 SM were indolent, 1 smoldering, 1 hematologic malignancy and 1 mast cell leukemia. Radiologically, 17 patients did not present lesions, 4 presented sclerotic lesions and 1 lytic lesions. Vertebral fractures were observed in 3 patients and 2 of them were before SM diagnosis. 10 patients received anti-osteoporotic treatment, 3 of them with teriparatide. At diagnosis, 2 patients (9.1%) had osteoporosis and 11 (50%) osteopenia. None of the analyzed risk factors were associated with OP presence. Of note, during follow-up significant changes were observed between those with indolent SM and aggressive forms at lumbar spine (LS) and femoral neck (FN) at 2 years (change in LS in indolent form 2.9% vs 29.6% in aggressive forms, p <0.001 and change at FN of 1% vs 20.5%, respectively, p=0.003). At 4 years changes at LS was -4.1% vs 25.8%, p=0.034 between indolent and aggressive forms but there were no differences regarding the presence of fractures (2 fractures in indolent group and 1 in aggressive, p=0.371).

Conclusion: Bone involvement was present in more than 50% of patients at diagnosis and the presence of fractures was not uncommon (14%), especially at lumbar spine (LS). Aggressive forms were associated with an increase in aBMD. The presence of fractures was associated with lower LS aBMD at diagnosis.

Disclosure of Interests: None declared


--

OPPORTUNISTIC BONE MINERAL DENSITY SCREENING IN PATIENTS UNDERGOING CARDIAC CT SCANS: EFFECT OF USING IMAGES CONTAINING INTRAVERSEOUS CONTRAST

A. Cheneymann1, J. Therkildsen2,3, S. Winther1, L. Nissen, J. Thygesen4, B. Langdahl3,5, E. M. Hauge1, M. Böttcher1 on behalf of Dan-NICAD.

1 Dødstrup Hospital, Department of Cardiology, Herning, Denmark; 2 Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 3 Aarhus University Hospital, Department of Clinical Medicine, Aarhus, Denmark; 4 Aarhus University Hospital, Department of Clinical Engineering, Aarhus, Denmark; 5 Aarhus University Hospital, Department of Endocrinology, Aarhus, Denmark

Background: Osteoporosis is under-diagnosed worldwide causing increased risk of fractures and death (1). Computed tomography (CT) scans performed on other indications such as coronary artery disease harbor the potential for automatic detection of low volumetric bone mineral density (vBMD) of the vertebrae using quantitative CT (QCT); hence allowing estimation of future fracture risk (2). CT is often performed with intravenous (iv) contrast administration. In 2015, the International Society of Clinical Densitometry stated: “There is insufficient evidence to judge the effect of contrast agents on a classification of low BMD (3); this position remains. Thus, it is important to assess the effect of contrast enhancement in order to broaden the potential of vBMD screening using routine CT scans.

Objectives: We aimed to compare thoracic vBMD measurements from CT scans with and without iv contrast enhancement.

Methods: This cross-sectional multicenter sub-study is based on a larger clinical trial, Dan-NICAD-1, from which we randomly selected a cohort of 136 participants. First, a non-contrast scan was performed followed by a contrast-enhanced scan during which 60-90mL of iv contrast was administered (Iomeron, 350 mg/
Results: In 136 participants undergoing cardiac CT (Table 1), we found a different mean vBMD before vs. after contrast: 117.5 mg/cm³ [95%CI: 111.6–123.4] vs. 132.1 mg/cm³ [95%CI: 125.1–139.1], p<.0001. The absolute difference was 14.7mg/cm³ [95%CI: 12.3–17.0]; the relative difference, was 12.5% [95% CI: 10.5–14.5]. In total, 8/15 (53%) participants changed from very low BMD to low BMD after contrast administration, and 21 participants (21/63, 33%) changed from low to normal BMD (Figure 1). No participants changed from very low BMD to normal BMD.

Table 1. Demographics by vBMD

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Very low BMD (n=15)</th>
<th>Low BMD (n=63)</th>
<th>Normal BMD (n=58)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender M:F</td>
<td>89:47</td>
<td>49:14</td>
<td>32:26</td>
</tr>
<tr>
<td>Age, yrs (range)</td>
<td>57±9 (40-73)</td>
<td>59±8 (44-74)</td>
<td>54±8 (40-72)</td>
</tr>
<tr>
<td>Mean vBMD before contrast, mg/cm³</td>
<td>92.2±16.1</td>
<td>98.0±10.8</td>
<td>151.5±21.9</td>
</tr>
<tr>
<td>Mean vBMD after contrast, mg/cm³</td>
<td>95.2±16.0</td>
<td>100.8±10.3</td>
<td>159.6±31.6</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus**</td>
<td>16</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Smoking status**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>65</td>
<td>17</td>
<td>44</td>
</tr>
<tr>
<td>Former</td>
<td>18</td>
<td>7</td>
<td>10</td>
</tr>
<tr>
<td>Active</td>
<td>52</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>Bone data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DXA performed previously**</td>
<td>7</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Osteoporosis diagnosed previously**</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Family history of osteoporosis**</td>
<td>22</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Anti-osteoporotic medication**</td>
<td>15</td>
<td>3</td>
<td>10</td>
</tr>
</tbody>
</table>

* Classifications defined by American College of Radiology and grouped using the non-enhanced CT. Data: number of participants, (range) and mean with standard deviations. ** Self-reported.

Figure 1. Participants with change in BMD category after contrast administration Figure 1. vBMD measurements before and after contrast administration. 33/136 participants changed BMD category illustrated by the dotted lines (80 mg/cm³; 120 mg/cm³). Black lines: increase in vBMD after contrast (n=29); blue lines: decrease in vBMD after contrast (n=4).

Conclusion: Our data suggest a significant effect of contrast on clinical vBMD measurements; thus, this should be adjusted for before using contrast-enhanced cardiac CT for opportunistic vBMD screening. This urges further studies on the effect of scan protocols on the contrast-enhanced increase in BMD.

REFERENCES:

Acknowledgements: The Danish Osteoporosis Foundation, The Danish Council for Independent Research (DFF–7025–00103), the Danish Heart Foundation (15-R99-A5837–22920), the Hede Nielsen Foundation, Acairix A/S (unrestricted grant) and Mrs. Lily Benthine Lunds Foundation of 1.6.1978 supported this project. The authors would like to thank all study participants and the clinical staff involved in this project.

Disclosure of Interests: Andia Cheneymann: None declared, Josephine Therkl dens: None declared, Simon Winther Grant/research support from: Disclosed an unrestricted grant from Acairix A/S., Louise Nissen: None declared, Jesper Thygesen: None declared, Bente Langdahl Consultant of: Worked as a consultant for Amgen, UCB, Gedeon-Richter, Eli Lilly and Gedeon., Grant/research support from: Received honorariums from Amgen, UCB, Eli Lilly, Gedeon-Richter and Astellas. Received financial grants from Amgen and the Novo Nordic Foundation., Ellen-Margrethe Hauge Consultant of: Received honorariums and/or consulting fees from AbbVie, Sanofi, Sobi, and SynACT Pharma., Grant/research support from: Research grants to Aarhus University Hospital from Danish Regions Medicine Grants, Danish Rheumatism Association, Roche, Novartis, and Novo Nordic Foundation., Morten Böttcher Consultant of: Advisory board participation for NOVO Nordisk, Astra-Zeneca, Pfizer, Boeringer Ingelheim, Bayer, Sanofi, Novartis and Acairix. DOI: 10.1136/annrheumdis-2022-eular.3267

Table 1. Bone parameters using high resolution peripheral quantitative computed tomography (HR-pQCT) and body composition in long-term polyarticular patients and healthy controls.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Polycratic JIA n=27</th>
<th>Healthy controls n=27</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>24 ± 4.8</td>
<td>24.6 ± 4.7</td>
<td>0.931</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>22 ± 10</td>
<td>22 ± 10</td>
<td>0.597</td>
</tr>
<tr>
<td>Remission or low activity, n (%)</td>
<td>16 (59)</td>
<td>16 (59)</td>
<td>0.999</td>
</tr>
<tr>
<td>%Fat, %</td>
<td>39 ± 8</td>
<td>37 ± 7</td>
<td>0.364</td>
</tr>
<tr>
<td>Lean mass, kg</td>
<td>36.7 ± 4.7</td>
<td>39 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lean mass, %</td>
<td>39 ± 8</td>
<td>37 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>%Fat, %</td>
<td>39 ± 8</td>
<td>37 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HR-pQCT at the distal radius</td>
<td>125 ± 32</td>
<td>159 ± 38</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>994 ± 46</td>
<td>1035 ± 43</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>64 ± 11</td>
<td>78 ± 18</td>
<td>0.001</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>3174 ± 879</td>
<td>3710 ± 827</td>
<td>0.001</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>128 ± 48</td>
<td>162 ± 32</td>
<td>0.003</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>990 ± 57</td>
<td>993 ± 52</td>
<td>0.811</td>
</tr>
<tr>
<td>Ct.v.BMD, mg HA/cm³</td>
<td>179 ± 39</td>
<td>212 ± 40</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data expressed as mean ± standard deviation or frequency (percentage). Tb.vBMD – trabecular bone mineral density. Ct.v.BMD – cortical volumetric bone mineral density; S - stiffness; FL - estimated fail load.

Conclusion: Pre-menopausal women with long-term polyarticular JIA have an impairment of bone mineral density at peripheral sites in addition to lower muscle mass and higher visceral adipose tissue. These findings may contribute to the increasing osteoporosis/fractures and cardiovascular risk in this population, suggesting that measures should be considered to prevent these damages.
CHARACTERISTICS OF GUT MICROBIOME AND THEIR ASSOCIATIONS WITH PERIPHERAL LYMPHOCYTE SUBPOPULATIONS AND CYTOKINES IN RHEUMATOID ARTHRITIS PATIENTS COMPPLICATED WITH OSTEOPOROSIS

T. Cheng1,2,3, S.-X. Zhang1,2,3, J. Giao1,2,3, M. J. Chang2, R. Zhao1,2,3, S. Song1,2,3, C. Wang1,2,3, L. Li1,2,3.

1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Ministry of Education, Key laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China; 3Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 4Shanxi Medical University, School of Management, Taiyuan, China.

Background: Osteoporosis (OP) is one of the major comorbidities of rheumatoid arthritis (RA) which is associated with immune disorders[1]. The gut microbiota has been highlighted to be an important environmental factor to influence immune system in maintaining bone health and regulating bone remodeling[2]. However, the alterations of intestinal flora and its relationship with immune system in RA patients with OP are unclear.

Objectives: To investigate the characteristics of gut microbiome as well as the associations between flora and peripheral lymphocyte subpopulations and cytokines in rheumatoid arthritis patients complicated with osteoporosis.

Methods: Total 28 RA patients were divided into 14 RA-non-OP and 14 gender- and age-matched RA-OP groups according to their bone mineral density (BMD) and the history of fragility fracture. Gut microbiota of participants were investigated by 16s RNA and peripheral lymphocyte subsets and cytokines were assessed via flow cytometry. Indicators like erythrocye sedimentation rate (ESR), C-reactive protein (CRP), anti-cyclic citrullinated peptide antibody (ACPA) and anti-mutated citrullinated vimentin (MCV) antibody were recorded meanwhile. Alpha diversity (ACE, Chao1, Simpson, Shannon) and beta diversity indices were analyzed using QIIME2. Biomarker species were recognized based on STEMP. Spearman analysis was adopted for correlation of two variables. All P-values reported herein were two-tailed and P<0.05 was taken as statistically significant.

Results: The alpha-diversity have no significant difference between RA-non-OP and RA-OP groups (P>0.05, Figure 1A). The community structure of microflora differed between two groups (P<0.05, Figure 1B). As the composition of intestinal flora at genus level, Faecalibacterium, Proteus, Catenibacterium, Enterobacter and Erysipelatoclostridium in RA-OP group were negatively correlated with ACPA and MCV respectively as well as IL-2 and TNF-α (P<0.05). Clostridium_sensu_stricto_1 and Lachnospiraceae_ND3007_group and the level of T, Th1 and Th17 cells, but negative relevance with IL-10 (P<0.05). The relative abundance of Faecalibacterium was negatively correlated with IL-2, IL-4, TNF-α and positively with MCV (P<0.05). Clostridium_sensu_stricto_1 and Lachnospiraceae_ND3007_group were negatively correlated with ACPA and MCV respectively as well as IL-2 (P<0.05, Figure 1D-E).

Conclusion: Abnormality of immune system may contribute directly or indirectly to OP in RA, which may be related to the disturbance of gut microbiota.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82007140).


Crystal diseases, metabolic bone diseases other than osteoporosis

OUTCOMES AND RESOURCE UTILIZATION AFTER TOTAL HIP ARTHROPLASTY IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE

M. Constantinos1, M. Lampi2, B. Bhattara1, K. Parperis3, 1University of Cyprus Medical School, Medicine, Nicosia, Cyprus; 2Valleywise Health Medical Center, Biostatistics, Phoenix, United States of America; 3University of Arizona College of Medicine, Epidemiology, Phoenix, United States of America; 4University of Cyprus Medical School, Department of Internal Medicine, Division of Rheumatology, Nicosia, Cyprus; 5University of Arizona College of Medicine, Division of Rheumatology, Phoenix, United States of America.

Background: Total hip arthroplasty (THA) is a safe and effective treatment option in patients with advanced degenerative joint disease who have failed conservative management. Calcium pyrophosphate deposition disease (CPPD) is a common crystal-induced arthritis in older adults characterized by the deposition of calcium pyrophosphate crystals in the articular and periarticular tissues. CPPD might manifest with acute and chronic arthritis that can lead to joint damage and the need for joint replacement. To our knowledge, no previous studies investigated the outcomes of CPPD patients who underwent THA.

Objectives: We aim to examine the mortality, in-hospital complications, and resource utilization following THA in patients with and without CPPD.

Methods: We queried the US National Inpatient Sample (NIS) database to identify patients who underwent THA between 2006 and 2014. The ICD-9 code 8151 was used to identify the patients who underwent THA and of those, we classified 2 groups of patients: (i) those with ICD-9 codes defining CPPD (275.49 and 712.1–712.39) and (ii) those without any CPPD code. Data collection included patient demographics and comorbidities. Outcomes post-THA were in-hospital mortality, hospital length of stay, hospital charges, and discharge disposition. Associations between CPPD and specific morbidity were evaluated using chi-square tests. T tests were used for continuous variables.

Results: Among the 4,111,808 (adjusted for sampling weight) patients who underwent THA between 2006 and 2014, 6198 (0.15%) had CPPD, with a mean age of 77 years and 65.2% were females (Table 1). CPPD patients were more likely to be older (mean age 77 vs 72.7: p<0.001) than non-CPPD patients. Comorbidities more frequently observed among CPPD patients included chronic kidney disease, osteoarthritis, rheumatoid arthritis, gout, hyperparathyroidism and hypogammaglobulinemia. Further, Charlson Comorbidity Index scores ≥ 2 was more frequent seen in CPPD (96.1% vs 89.1%, p<0.001). The in-hospital mortality post-THA was lower in the CPPD patients (0.76% vs 1.72%, p<0.001). THA in CPPD patients was associated with a longer mean length of stay than those

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4620
without CPPD (6 vs 5.1 days; p < 0.001) while mean total charges were not statistically different between the 2 groups (p=0.344). CPPD patients were more likely to be discharged to rehabilitation or other nursing facilities (p<0.001).

<table>
<thead>
<tr>
<th>Table 1. Demographics, clinical characteristics, outcomes and resource utilization of patients with and without CPPD who underwent hip arthroplasty between 2006-2014.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Age in years at admission, median (mean ± SD)</td>
</tr>
<tr>
<td>Total hospital charges, (mean ± SD) $</td>
</tr>
<tr>
<td>Charlson Comorbidity Index score ≥ 2</td>
</tr>
<tr>
<td>Sex</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>Gout</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
</tr>
<tr>
<td>Hyperuricemia</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
</tr>
</tbody>
</table>

Conclusion: CPPD patients who underwent THA were more likely to be older, with a higher comorbidity burden, longer length of stay, and discharged to a non-home setting, than non-CPPD patients.

Disclosure of Interests: Authors acknowledge the contribution of all International XLH Registry Steering Committee members, and all the investigators participating in the International XLH Registry.

Disclosure of Interests: None declared.


**POS1155**

THE INTERNATIONAL X-LINKED HYPOPHOSPHATAEMIA (XLH) REGISTRY: OVERVIEW OF THE DATA SET

G. Ariete 1, J. Liu 2, A. Williams 3, S. Wood 2, D. Schnabel 3. 1Hospital Vall d'Hebron, Pediatric Nephrology, Barcelona, Spain; 2Kyowa Kirin International Marlow Office, Nephrology | EMEA, Marlow, Buckinghamshire, United Kingdom; 3Charité, University Medicine Berlin, Center for Chronically Sick Children, Pediatric Endocrinology, Berlin, Germany

Background: X-Linked Hypophosphataemia (XLH) is a rare, progressive, lifelong, hereditary renal tubule phosphate-wasting disorder characterised by a pathological increase in fibroblast growth factor 23 concentration/activity. Despite XLH being increasingly recognised as a chronic progressive disease, there are few data documenting its natural history or the impact of treatment on patient outcomes. The International XLH Registry was established to address this lack of information on XLH to help inform future clinical management. The Registry will collect data to characterise the treatment, burden of disease, disease progression and long-term outcomes of XLH.

Objectives: To provide an overview and status update of the International XLH Registry as of 31 December 2021.

Methods: The International XLH Registry (NCT03193476) was initiated in August 2017, aims to recruit 1,200 children and adults with XLH, and will run for 10 years. This Registry is an international, multicentre, non-interventional data collection programme and will provide the largest single dataset representing patient outcomes. The International XLH Registry forms the largest dataset of patients with XLH collected to date. Patients have been recruited from a wide geographical region and baseline demographics are consistent with a hereditary X-linked dominant disease. Information collected during the 10-year Registry duration will generate real-world evidence to help inform clinical practice throughout the region, with the aim of improving the care and quality of life of adults and children living with this debilitating disease.

REFERENCES:


Disclosure of Interests: Gema Ariete Speakers bureau: I have received honoraria for lectures, presentations, or educational events from Alexion Pharmaceuticals, Recordati Rare Disease, Advicenne, Chiesi, Kyowa Kirin, Consultant of: I have participated on Advisory Boards for Alexion Pharmaceuticals, Advicenne, Chiesi, Kyowa Kirin, and Paccaglia for lectures, presentations, or educational events from Alexion Pharmaceuticals, Advicenne, Chiesi, Kyowa Kirin. Employee of: Employee of Kyowa Kirin International, Angela Williams Employee of: Employee of Kyowa Kirin International, Sue Wood Employee of: Employee of Kyowa Kirin International, Dirk Schnabel Speakers bureau: I received a honorarium from various companies for scientific lectures (i.e. Ascensia, BioMarin, Ferring Pharma, Hexal / Sandoz, Ipsen Pharma, Kyowa Kirin, Merck Serono, Novo Nordisk), Consultant of: Consultant of: BioMarin, Kyowa Kirin


**POS1156**

PHASE 1 TRIALS OF NOVEL ORAL ENZYME THERAPY (ALLN-346) FOR HYPERURICEMIA & GOUT: SAFETY, PHARMACODYNAMICS, AND LACK OF SYSTEMIC ABSORPTION OF SINGLE AND MULTIPLE ASCENDING DOSES IN HEALTHY VOLUNTEERS

D. Clark 1, D. Gruijz 2, C. Tosone 3, N. Dahl 4, R. Terkeltaub 5. 1Alexia Pharmaceuticals, Inc., Clinical Development, Newton, United States of America; 2Allena Pharmaceuticals, Inc., Pharmacology, Newton, United States of America; 3Allena Pharmaceuticals, Inc., Clinical Operations, Newton, United States of America; 4Allena Pharmaceuticals, Inc., Medical Affairs, Newton, United States of America; 5SDVAHCS/UC San Diego, Medicine, San Diego, United States of America

Background: Currently available therapies for gout in patients with advanced chronic kidney disease (CKD) are either dose-limited or contraindicated due to safety and tolerability concerns. In gout patients with advanced CKD, the intestinal tract becomes the major route of urate elimination, in contrast to healthy people with normal kidney function whose kidneys are the primary route of uric acid excretion. Considering some of the limitations of present urate lowering therapies (ULTs) in gout & CKD and the extra-renal pathway of urate secretion, a new oral therapy with ALLN-346 (engineered urate oxidase) is under development as a non-absorbed, urate specific enzyme, designed to enhance degradation and secretion of urate in the intestinal tract.

Objectives: To assess safety and tolerability and evidence for the lack of systemic absorption at various dose levels of ALLN-346 in normal healthy volunteers (NHV) up to 7 days.

Methods: Two randomized, double-blind Phase 1 studies of ALLN-346 or placebo were conducted in adult NHV in a domicile setting; a single-ascending dose (SAD) study of 3 doses on a single day of dosing, and a multiple ascending dose (MAD) study of 2 doses during 7 days (NCT04323619 and NCT04329435, respectively). In the SAD study, subjects received 3 ascending doses of ALLN-346 (3 capsules,6 capsules, and 6 capsules administered twice, or placebo) and were randomized 3:1 (ALLN-346:placebo, n=24). In the MAD study, subjects received 3 (Cohort A) or 5 (Cohort B) of ALLN-346 capsules or placebo (2:1 randomization, n=18) administered orally 3 times daily for 7 days. To assess possible ALLN-346 absorption, a specific ELISA and uricase potency assay were used on PK serum samples collected from all subjects in both studies pre-dose and at intervals post dose.

Results: In both studies, all randomized subjects completed treatment with 100% compliance. ALLN-346 was well-tolerated, with no serious adverse
events (AE) and with no clinically significant safety signals across all cumulative doses. Clinical and laboratory parameters revealed no clinically significant safety signals among all cumulative dosing cohorts across hematology, serum biochemistry, vital signs, or ECGs. The majority of reported AEs were mild with no pattern of differences between ALLN-346 and placebo. No evidence of systemic absorption of ALLN-346 was seen, as confirmed by both ELISA and by uricase potency assay of all PK serum samples from all subjects from SAD (n=240) and MAD (n=324).

Conclusion: ALLN-346, a new oral enzyme therapy in development for the treatment of hyperuricemia and gout in advanced CKD was well tolerated. Consistent with its mechanism of action, no evidence of systemic absorption was demonstrated. Further studies in hyperuricemia patients with gout and CKD are underway.

REFERENCES:
[1] Sorensen BL. Role of the intestinal tract in the elimination of uric acid. Arthritis and Rheumatism, vol 8, part5 1965


POS1157 SAFETY AND EFFICACY OF ALLN-346 ORAL ENZYME THERAPY IN PATIENTS WITH HYPERURICEMIA AND CHRONIC KIDNEY DISEASE (CKD): RESULTS OF THE PHASE 2A STUDY 2
B. Terkeltaub1, D. Clark2, C. Tosone3, B. Kandinov3, P. Zhang4, N. Dahl4, D. Grujic3, D. Goldfarb5; SDVAHCS/UC San Diego, Medicine, San Diego, United States of America; 2Allena Pharmaceuticals, Inc., Clinical Development, Newton, United States of America; 3Allena Pharmaceuticals, Inc., Clinical Operations, Newton, United States of America; 4Allena Pharmaceuticals, Inc., Medical Affairs, Newton, United States of America; 5Allena Pharmaceuticals, Inc., Pharmacology, Newton, United States of America; 6NYU Langone Health, Medicine, New York, United States of America

Background: Currently available urate lowering therapies (ULTs) are limited in their use in gout patients with advanced CKD based on dosing restrictions, tolerability, safety concerns, and reduced effectiveness, compared to options for the broader gout population. In gout patients with advanced CKD, the intestinal tract becomes the major route of urate elimination, as opposed to in healthy people with normal kidney function where kidneys are the primary route of uric acid excretion. Considering some of the limitations of present urate-lowering therapies (ULTs) in gout & CKD and the extra-renal pathway of urate secretion, a new oral therapy, ALLN-346 (engineered urate oxidase), is under development as a non-absorbed, urate specific enzyme, designed to enhance degradation and secretion of urate in the intestinal tract.2

Objectives: To assess the safety, tolerability, and initial bioactivity data of ALLN-346 in adults with hyperuricemia and CKD.

Methods: This one-week inpatient Phase 2a study (NCT04987242) was conducted at a clinical pharmacology unit. Eleven otherwise healthy adult patients with hyperuricemia (sUA ≥ 6.8 mg/dL) and normal to Stage 2 CKD (eGFR ≥60), not on concurrent ULTs, were randomized (2:1) to receive either 5 capsules of ALLN-346 or matching placebo, three times daily for 7 days. Serum urate was measured daily, and urine uric acid was assessed on days -2, -1, 1, 4, and 7. Safety was monitored throughout the study. To assess possible ALLN-346 systemic absorption, a specific ELISA was used on serum samples collected pre- and post-dose over 7 days.

Results: Of the 11 patients 7 received ALLN-346 and 4 received placebo. Most patients had Stage 2 CKD, including 5 of the 7 subjects treated with ALLN-346. A statistically significant reduction in mean sUA was recorded with ALLN-346 compared to placebo [Figure 1]. The largest mean % reduction in sUA was observed among patients with stage 2 CKD; sUA reduction was correlated with eGFR in the ALLN-346 group (r=0.95; P=0.003), but not the placebo group (r=-0.2; P=0.91). No serious adverse events were reported, and clinical and laboratory parameters revealed no significant safety signals. Lack of systemic absorption of ALLN-346 was confirmed by ELISA assays.

Figure 1. Absolute and Percent Change from Baseline in Serum Urate over 7 -days of Treatment


POS1158 CHARACTERIZATION OF GOUT IN US PATIENTS UNDERGOING HEMODIALYSIS (HD) AND PERITONEAL DIALYSIS (PD)
A. Karaboyas1, J. Zhao1, B. Lamoreaux2, B. Marder2, B. Golitonski2, V. Domingues4, R. Pecolts-Filho1, B. Robinson1, 1Arbor Research Collaborative for Health, Research, Ann Arbor, United States of America; 2Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America; 3Carolina Nephrology, Nephrology, Greenville, United States of America; 4Florida State University, Rheumatology, Tallahassee, United States of America

Background: Gout is the most common inflammatory arthritis and occurs frequently in patients with renal disease often leading to a significant burden on quality of life and functional status.1,2 Despite the established connection of renal disease with gout, little has been reported on the prevalence, patient characteristics, and associations of gout with other outcomes in the US hemodialysis (HD) and peritoneal dialysis (PD) population.

Objectives: This project used a large end-stage renal disease (ESRD) focused-database, Dialysis Outcomes and Practice Patterns Study (DOPPS), to examine gout in dialysis-dependent patients.

Methods: Gout patients were identified by active prescription (Rx) of (1) colchicine, (2) febuxostat, or (3) allopurinol; or by (4) prior diagnosis of gout from US cohorts of 70,297 HD (DOPPS, 2012-2020) patients and 5117 PD (Peritoneal DOPPS, 2014-2020) patients. Outcomes of HD and PD patients with and without a history of gout were compared with propensity score matching. Outcomes included erythropoietin resistance index (ERI = ESA dose/[hemoglobin*weight]),
cardiovascular death, all-cause mortality, hospitalization, and baseline patient-reported outcomes (PROs).

**Results:** Gout prevalence was 13% in HD and 21% in PD and was highest among incident dialysis patients. Of the gout patients identified, the most-commonly used gout-related medications were allopurinol (9-12%), followed by colchicine (2-3%), and then febuxostat (1%, Figure 1). Both HD and PD patients with gout (vs. no gout) were older and more likely male. Gout HD and PD patients had higher BMI and higher prevalence of cardiovascular comorbidities than HD and PD patients without gout. After propensity score matching, mean ERI was 4% higher for gout vs. non-gout patients, while there was minimal evidence of association with clinical outcomes (mortality and hospitalization) or PROs.

**Conclusion:** Gout was common in US HD and PD patients, with a large proportion of these patients treated with drugs indicated for hyperuricemia (allopurinol and febuxostat) and gout flares (colchicine). The true prevalence of gout was likely higher than observed when considering potential under-ascertainment of gout diagnosis history in nephrology/dialysis-focused clinical settings. This report provides a snapshot of gout in the US dialysis population and offers opportunities to expand on research to improve awareness and care for patients with gout and ESRD.

**REFERENCES:**

**Disclosure of Interests:** Angelo Karaboyas Grant/research support from: Hori zon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Brad Marder Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Barry Gutthits Consultant of: AstraZenica, DaVita, Horizon Therapeutics, Jensen Pharmaceuticals, KidneyAide LLC; vinc ius domingues Consultant of: Abbv, Aurinia Pharma, Exagen, Eli Lilly, Roberto Pecotis-Filho Grant/research support from: Horizon Therapeutics, Bruce Robin son Grant/research support from: Horizon Therapeutics DOI: 10.1136/annrheumdis-2022-eular.1873

**POS1159**

**SUBCLINICAL ATHEROSCLEROSIS IN GOUTY ARTHRITIS PATIENTS: A CROSS SECTIONAL STUDY BY ULTRASONOGRAPHY**

Y. Wang, Z. Zhang on behalf of none. First hospital of Peking university, Department of Rheumatology and Clinical Immunology, Beijing, China

**Background:** Hyperuricemia is closely associated with cardiovascular disease (CVD). However, it has not been definitively established whether this association is independent of traditional cardiovascular risk factors in gouty patients.

**Objectives:** To clarify the incidence of subclinical atherosclerosis and associated factors in gouty arthritis patients by ultrasonography.

**Methods:** We conducted this cross-sectional study to investigate the frequency and clinical factors correlated with carotid changes in patients with gout by ultrasonography.

**Results:** 200 consecutive patients with gout were recruited. Carotid ultrasound was performed in all patients in First hospital of Peking University from 2014 to 2020, finding atheroma plaques in 33.0% patients. None of these patients received urate-lowering drugs. On univariate analysis, the pattern was significantly associated with age, estimated gout duration, clinical tophi, double contour sign at the scanned joint and decreased estimated glomerular filtration rate; While arterial hypertension, hyperuricemia were not associated with carotid plaques. On multivariable analysis, the atheroma plaques were associated with estimated disease duration, clinical tophi, double contour sign and decreased estimated glomerular filtration rate. Thus, carotid plaque was frequently demonstrated in gout patients with tophaceous gout and associated with features of tubulointerstitial nephritis. This finding reveals the hypothesis of crystal-led inflammation and comorbidities relates to gout associated cardiovascular disease, predominantly seen in high uric acid burden patients, which could be an important treatment target for gout therapy.

**Conclusion:** Ultrasonography can detect crystal deposits in joints and connective tissues. We investigated the frequency and clinical correlates of plaques in carotid by ultrason in consecutive gouty patients. The pattern was significantly associated with age, estimated gout duration, clinical tophi, double contour sign and decreased estimated glomerular filtration rate.

**REFERENCES:**


**POS1160**

**PROTECT: PEGLOTICASE TREATMENT FOR UNCONTROLLED GOUT IN KIDNEY TRANSPLANTED PATIENTS: RESULTS FROM A PHASE 4 TRIAL**

A. Abdelatit1, L. Zhao1, K. Cherry1, B. Marder2, J. Scandling1, K. Saag3, 1Baylor College of Medicine and CLS Health, Nephrology Division, Houston, United States of America; 2Horizon Therapeutics plc, Clinical Development, Deerfield, United States of America; 3Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America; 4Stanford Medicine, Division of Nephrology, Stanford, United States of America; 5The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, United States of America

**Background:** A phase 4 trial (NCT04087720) of kidney transplant (KT) recipients on stable immunosuppressants with uncontrolled gout previously reported that pegloticase produced a sustained decrease in serum uric acid (sUA) levels and was associated with clinically meaningful improvements in pain and disability without worsening of key kidney function markers. Pegloticase treatment was well tolerated overall with no infusion reactions or anaphylaxis. Here we report additional exploratory and secondary endpoints.

**Objectives:** To evaluate the results of clinically important efficacy endpoints as supportive evidence for the efficacy of pegloticase in kidney transplant patients on immunosuppression.

**Methods:** PROTECT a multicenter, open-label, efficacy and safety study of pegloticase in included kidney transplant recipients (KT)-1 year prior with uncontrolled gout (sUA ≥7 mg/dL, oral urate lowering therapy concomitant/inefficacy, and with either visible tophi, chronic gouty arthritis, or ≥2 flares in past year). We had a functioning graft (estimated glomerular filtration rate [eGFR] ≥15 ml/min/1.73m²), and were on a stable immunosuppressant regimen. Pegloticase (8mg infusion) was administered biweekly for 24 weeks (12 infusions) followed by a final follow up visit 3 months post-treatment. The global health component of the Health Assessment Questionnaire (HAQ-Health), and the physician global assessment of gout (PGA) were assessed at baseline, weeks 6, 14, 20, 24, and at the end of pegloticase infusions (EOI) visit (if applicable, when the final infusion occurred prior to week 22). Both were visual analog scales (VAS), where HAQ-Health ranged from 0 (very well) to 100 (very poor) and PGA ranged from 0 (excellent) to 10 (very poor). Heart rate and blood pressure measurements were recorded at baseline, weeks 6, 12, 18, 24 and the EOI visit.

**Results:** 20 patients received at least 1 dose of pegloticase and were included in the analysis with the majority (90.0%) of 40 to 81 years of age. Most were male (85.0%), 45.0% white, and 53.0% black or African American. Median BMI 28.84 (86.48 kg) and body mass index (29.68 kg/m²) were high. Median baseline eGFR and baseline Urine Albumin-Creatinine Ratio (UACR) were 41.70 ml/min/1.73m² and 312.00 mg/g, respectively. An improvement from baseline to weeks 14
for Clinical Research and Innovation, Biostatistics department, Lille, France;

Methods:

Objectives: (RECO) in 2020 [1,2], which were deliberately simple and concise.

Background: Recent studies have shown a lack of implementation of gout recommendations in primary care. In this context of therapeutic inertia, the French Society of Rheumatology (SFR) published its first recommendations on gout (RECO) in 2020 [1,2], which were deliberately simple and concise.

Methods: Three hundred patients attending a first visit for gout management in three French referral centres were retrospectively included. Visits were performed at baseline (M0) and scheduled for month 6 (M6), month 12 (M12), and month 24 (M24). Data collected included: patient profile; disease activity and treatments; serum urate (SU) level; estimated glomerular filtration rate (eGFR).

Results: Patients were 81% male, mean age 62.2 ± 15.2 years, 42.7% prevalent cardiovascular disease, and type 2 diabetes (Table 1). Additionally, healthcare utilization were examined and compared between those with/without a dermatological diagnosis code.

Conclusion: Simple application of gout management guidelines is feasible in clinical practice, and is efficient with a majority of patients achieving SU targets and clinical improvement. A minority of patients in referral centres have ‘difficult-to-treat’ gout requiring specific management.

REFERENCES:

PHARMACOKINETICS OF PEGLOTICASE AND METHOTREXATE POLYGLUTAMATE(S) IN PATIENTS WITH UNCONTROLLED GOUT RECEIVING PEGLOTICASE AND CO-TREATMENT WITH METHOTREXATE


Horizon Therapeutics plc, Clinical Pharmacology, South San Francisco, United States of America; 2Brigham and Women's Hospital, Division of Rheumatology, Immunology, and Allergy, Boston, United States of America; 3Horizon Therapeutics plc, Clinical Pharmacology, South San Francisco, United States of America; 4Horizon Therapeutics plc, Clinical Pharmacology, South San Francisco, United States of America; 5Horizon Therapeutics plc, Clinical Pharmacology, South San Francisco, United States of America; 6Horizon Therapeutics plc, Clinical Pharmacology, South San Francisco, United States of America.

Background: In a prior open-label, single-arm trial in adults with uncontrolled gout (MIRROR open-label [OL] trial), methotrexate (MTX) co-treatment with pegloticase suggested improved efficacy of pegloticase by reducing its immunogenicity.1,2 The current randomized, controlled trial (MIRROR RCT) confirmed that pegloticase-MTX co-therapy markedly increased pegloticase response rate (response defined as serum uric acid <6 mg/dL during ≥80% of Month 6) compared to pegloticase-placebo (PBO) co-therapy (71.0% vs. 38.5%) with a decreased infusion reaction rate and no new safety signals reported.

Objectives: To evaluate systemic exposures of pegloticase and its immunogenicity in uncontrolled gout patients receiving pegloticase with and without MTX as part of the MIRROR RCT; and to determine exposure of methotrexate polyglutamate(s) (MTX-PGs) in uncontrolled gout patients through Month 6 of treatment.

Methods: In MIRROR RCT, MTX (15 mg/week) or matching PBO was given orally 4 weeks prior to the first pegloticase dose and continued weekly, in combination with pegloticase 8 mg given intravenously every 2 weeks, over a 52-week treatment period. Pre-infusion blood samples were collected to measure MTX polyglutamate(s) (MTX-PGs, including MTX-PG(5)) in red blood cells and pre- and post-infusion serum samples were obtained to measure trough (Cmin) and peak (Cmax) concentrations of pegloticase, respectively, at multiple visits. MTX-PG and pegloticase concentrations were summarized by visit and by treatment group. Pre-infusion serum samples for anti-polyethylene glycol (PEG) antibody (Ab) measurement were also collected at multiple pre-defined time points. Anti-PEG Ab incidence and titer were summarized by visit and by treatment group.

Results: Overall, higher Cmax and Cmin of pegloticase were observed in the pegloticase + MTX group than in the pegloticase + PBO group (Figure 1). At Week 14, median (first quartile [Q1], third quartile [Q3]) Cmin was 1.32 (0.73, 1.74) µg/mL and 0.63 (0.30, 1.28) µg/mL for the pegloticase + MTX and pegloticase + PBO groups, respectively. Median (Q1, Q3) Cmax was 3.01 (1.94, 3.94) µg/mL and 2.68 (1.45, 3.20) µg/mL for the pegloticase + MTX and pegloticase + PBO groups, respectively. Improved pegloticase response was associated with higher pegloticase concentrations. At Week 14, Cmin was below the quantitation limit (0.6 µg/mL) for 8 of 10 non-responders and 1.28 (0.72, 1.71) µg/mL for responders. MTX co-administration reduced the incidence of new anti-PEG antibody formation. The proportion of subjects with an increase from baseline in anti-PEG Ab titers or who were negative at baseline and developed an anti-PEG Ab response at ≥1 post-dose time point during pegloticase treatment was 29.5% and 51.0%, for the pegloticase + MTX and pegloticase + PBO groups, respectively. The pegloticase + MTX group had overall lower titer levels than those in the pegloticase + PBO group. Positive anti-PEG Ab status was associated with a lower pegloticase Cmin. Concentrations of MTX-PGs were maintained during the treatment course in the pegloticase + MTX group, suggesting compliance with MTX administration. There was no apparent difference in concentrations of MTX-PGs (including MTX-PGs(5)) between responders and non-responders. MTX-PG concentrations were in the same range as those reported for low-dose oral MTX use in patients with rheumatoid arthritis, suggesting no impact of pegloticase on MTX PK.

Conclusion: Pegloticase 8 mg IV every 2 weeks with MTX co-treatment (oral 15 mg weekly) reduced anti-PEG Ab incidence and resulted in higher pegloticase exposures compared to pegloticase administered with PBO, consistent with the increased clinical efficacy observed with pegloticase + MTX co-administration.

REFERENCES:


DOI: 10.1136/annrheumdis-2022-eular.2521

COMPARISON OF PATIENTS WITH EARLY-ONSET GOUT AND COMMON GOUT: A CLAIMS-BASED ANALYSIS

A. Amatucci, L. Padnick-Silver, B. Lamoreaux, D. Bulbin.

Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America; 2Geisinger Medical Center, Rheumatology, Danville, United States of America.

Background: From the data from the United States indicate that 8% of gout patients have disease onset before 40 years of age (early-onset gout [EOG]), and beginning at age 65 (common gout [CG]), with similar disease occurrence.4,5 At present, the literature is limited in comparisons between EOG and common gout (CG) patients.

Objectives: These claims-based analyses on a very large population examined and compared characteristics and comorbidity profile of patients with EOG and CG.

Methods: Patients with ≥1 ICD-9 or -10 gout code were identified in the Symphony claims database using Bellweather software (PearlDiver Technologies™). All patients were in the database ≥2 years before and ≥3 years after first gout code. Patients were said to have EOG if their first gout code occurred before 40 years of age (EOG);4,5 with similar age stratiﬁcation in the United Kingdom, The Netherlands, and New Zealand.6 At diagnosis, EOG patients have lower rates of renal and cardiometabolic comorbidities than their counterparts who developed gout at a later age.6 Published reports also indicate that patients with EOG are less responsive to urate-lowering therapy7 and more often have severe gout, with higher flare rate8 and polyarticular disease occurrence.5 At present, the literature is limited in comparisons between EOG and common gout (CG) patients.

Objectives: These claims-based analyses on a very large population examined and compared characteristics and comorbidity profile of patients with EOG and CG.

Methods: Patients with ≥1 ICD-9 or -10 gout code were identified in the Symphony claims database using Bellweather software (PearlDiver Technologies™). All patients were in the database ≥2 years before and ≥3 years after first gout code. Patients were said to have EOG if their first gout code occurred before 40 years of age (EOG).4,5 These claims-based analyses on a very large population examined and compared characteristics and comorbidity profile of patients with EOG and CG.

Background: From the data from the United States indicate that 8% of gout patients have disease onset before 40 years of age (early-onset gout [EOG]),1,2 with similar age stratiﬁcation in the United Kingdom, The Netherlands, and New Zealand.2 At diagnosis, EOG patients have lower rates of renal and cardiometabolic comorbidities than their counterparts who developed gout at a later age.4,5 Published reports also indicate that patients with EOG are less responsive to urate-lowering therapy4 and more often have severe gout, with higher flare rate5 and polyarticular disease occurrence.4 At present, the literature is limited in comparisons between EOG and common gout (CG) patients.

Objectives: These claims-based analyses on a very large population examined and compared characteristics and comorbidity profile of patients with EOG and CG.

Methods: Patients with ≥1 ICD-9 or -10 gout code were identified in the Symphony claims database using Bellweather software (PearlDiver Technologies™). All patients were in the database ≥2 years before and ≥3 years after first gout code. Patients were said to have EOG if their first gout code occurred before 40 years of age (EOG).4,5 These claims-based analyses on a very large population examined and compared characteristics and comorbidity profile of patients with EOG and CG.
data suggest that, in the years following gout diagnosis, EOG patients develop comorbidities at a faster rate than their peers without gout. Further study of how gout influences comorbidity development in EOG patients is warranted to better understand and verify these claims-based findings.

REFERENCES:

T. Bardin1,2, Y. M. Ducrot3, Q. Nguyen1, E. Letavernier4, H. K. Ea4, F. Touzain5, D. M. Do6, J. Corot7, Y. Barguil8, A. Biron9, P. Richette7, C. Collet7. 1-2 Toulon Mediterranean Health and Medical Pharmacology University Hospital, Toulon, France; 3UCLA, Department of Computer Science, Los Angeles, CA; 4Horizon Therapeutics plc, Medical Affairs, Deerfield, IL; 5University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 6University of Paris, School of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 7University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 8University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 9University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam.

Background: Elevated lactate is known to favor urine urate reabsorption by the renal tubule. Autosomal recessive gout caused by pathogenic variant in the LDHD gene encoding for D-lactate dehydrogenase has been recently identified in a large consanguineous Bedouin-Israeli kindred (1). The objective of the present study was to explore the association of LDHD rare variants with early-onset gout in two families with early-onset gout.

Methods: DNA samples from the affected patients were screened by Sanger sequencing method in 13 other extended family members. A deleterious variant in the LDHD gene (NM_153486.3: c.206C>T; rs1035398551) was observed in the non-gout brother. WES was performed in the two probands, their father and mother (who denied consanguinity), and an unaffected brother. An undescribed variant in LDHD (NM_153486.3: c.1363dupG) was identified in homozygous and heterozygous levels in the non-gout brother.

Results: Two families were included. The first family was a kindred of Bedouin origins (1). The second family was a Vietnamese family. The two juvenile gout patients were homozygous for an undescribed frameshift (NM_153486.3: c.1064dup) variant of the RHBG gene encoding for a Rhesus Blood Group family ammonium transporter. The two parents carried the heterozygous variant which was not identified in the non-gout brother.

Conclusion: We report on 2 families in whom autosomal recessive juvenile gout was due to rare or undescribed, damaging LDHD gene variants. In addition, we observed in the Vietnamese family, an additional non-described frameshift homozygous variant in RHBG, the pathophysiological role of which deserves to be investigated.

REFERENCES:

T. Bardin1,2, Y. M. Ducrot3, Q. Nguyen1, E. Letavernier4, H. K. Ea4, F. Touzain5, D. M. Do6, J. Corot7, Y. Barguil8, A. Biron9, P. Richette7, C. Collet7. 1-2 Toulon Mediterranean Health and Medical Pharmacology University Hospital, Toulon, France; 3UCLA, Department of Computer Science, Los Angeles, CA; 4Horizon Therapeutics plc, Medical Affairs, Deerfield, IL; 5University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 6University of Paris, School of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 7University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 8University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam; 9University of Medicine and Pharmacy, Center for Molecular Biomedicine, Ho Chi Minh City, Vietnam.

Background: Elevated lactate is known to favor urine urate reabsorption by the renal tubule. Autosomal recessive gout caused by pathogenic variant in the LDHD gene encoding for D-lactate dehydrogenase has been recently identified in a large consanguineous Bedouin-Israeli kindred (1). The objective of the present study was to explore the association of LDHD rare variants with early-onset gout in two families with early-onset gout.

Methods: DNA samples from the affected patients were screened by Sanger sequencing method in 13 other extended family members. A deleterious variant in the LDHD gene (NM_153486.3: c.206C>T; rs1035398551) was observed in the non-gout brother. WES was performed in the two probands, their father and mother (who denied consanguinity), and an unaffected brother. An undescribed variant in LDHD (NM_153486.3: c.1363dupG) was identified in homozygous and heterozygous levels in the non-gout brother.

Results: Two families were included. The first family was a kindred of Bedouin origins (1). The second family was a Vietnamese family. The two juvenile gout patients were homozygous for an undescribed frameshift (NM_153486.3: c.1064dup) variant of the RHBG gene encoding for a Rhesus Blood Group family ammonium transporter. The two parents carried the heterozygous variant which was not identified in the non-gout brother.

Conclusion: We report on 2 families in whom autosomal recessive juvenile gout was due to rare or undescribed, damaging LDHD gene variants. In addition, we observed in the Vietnamese family, an additional non-described frameshift homozygous variant in RHBG, the pathophysiological role of which deserves to be investigated.

REFERENCES:
Table 1. Kidney disease-related hospitalization in the US general and gout populations.

<table>
<thead>
<tr>
<th>General US Hospitalizations</th>
<th>US Hospitalizations with Comorbid Gout</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Age</td>
<td>Overall Hospitalizations N</td>
</tr>
<tr>
<td></td>
<td>18-44 years</td>
</tr>
<tr>
<td></td>
<td>8,356,284</td>
</tr>
<tr>
<td></td>
<td>(7.4%)</td>
</tr>
<tr>
<td></td>
<td>324,445</td>
</tr>
<tr>
<td></td>
<td>(41.5%)</td>
</tr>
<tr>
<td>Total in 2019</td>
<td>36,419,023</td>
</tr>
<tr>
<td></td>
<td>912,730</td>
</tr>
<tr>
<td></td>
<td>(22.3%)</td>
</tr>
</tbody>
</table>

Note: Total numbers include patients 0-17 years old.

Conclusion: Acute and chronic kidney disease are highly prevalent comorbid conditions in overall US hospitalizations. Among patients admitted with a diagnosis of gout, the proportion of kidney dysfunction is significantly higher affecting 58% of these hospitalizations. The high prevalence of kidney dysfunction in hospitalized gout patients in the US may represent an impactful component to the duration, complexity, and costs of hospital care.

REFERENCES:


Disclosure of Interests: Gurkirpal Singh Grant/research support from: Horizon Therapeutics (unrestricted research grant), Maanek Sehgal: None declared, Gurkirpal Singh Grant/research support from: Horizon Therapeutics, Alka Mithal: None declared

Figure 1. Meta-analyses of serum urate levels and estimated glomerular filtration rate at baseline and follow-up.

Conclusion: Our meta-analysis showed that febuxostat had good urate-lowering efficacy and renal safety in hyperuricemia patients with stage 4-5 CKD, who are not yet on dialysis. More studies with larger sample sizes and higher quality are required to clarify the efficacy and safety of febuxostat in advanced CKD.

REFERENCES:


DISCLOSURE OF INTERESTS: None declared


POST1167 TREAT TO TARGET OF GOUT: AN EVIDENCE-BASED CONSENSUS ON CLINICAL PRACTICE GUIDELINES


C. N. Son1, H. J. Jeong1, W. Y. Park2, S. H. Kim1.

1Canterbury Christ Church University, Rheumatology, Gillingham, United Kingdom; 2Tanta University, Rheumatology and Rehabilitation, Tanta, Egypt; 3Ain Shams University, Community and Public health, Cairo, Egypt; 4Ain Shams University, Rheumatology and Rehabilitation, Cairo, Egypt; 5Benha University, Rheumatology and Rehabilitation, Benha, Egypt; 6Zagazig University, Rheumatology and Rehabilitation, Cairo, Egypt; 7Kaar Elainy Cairo University, Rheumatology and Rehabilitation Cairo, Egypt; 8 Fayoum University, Rheumatology and Rehabilitation, Fayoum, Egypt; 9 Mansoura University, Rheumatology and Rehabilitation, Mansoura, Egypt; 10 Minia University, Rheumatology and Rehabilitation, Minia, Egypt; 11 Suez Canal University, Rheumatology and Rehabilitation, Ismailia, Egypt

Background: New therapies, management approaches and evidence regarding the management of gout have become available over the past years. This triggered the need for updated recommendations for the management of gout.

Objectives: To develop an up-to-date consensus evidence-based clinical practice guideline for the management of gout including recommendations for management of acute gout flares, optimum usage of urate lowering therapy for chronic gout as well as patient education and lifestyle guidance.

Methods: An extensive systematic literature review was performed, and evidence-based recommendations were extrapolated, based on 16-key questions identified according to population, intervention, comparator, and outcomes (PICO) approach. For each item, the level of evidence for outcomes of interest was categorized into 10 domains to were obtained. Agreement with the recommendations (rank 7-9) ranged from 90-100%. Consensus was reached (i.e.≥75% of respondents strongly agreed or agreed) on the wording, the grade of recommendation and level of evidence of all the 30 clinical standards identified by the scientific committee. The guideline emphasized that all gouty patients should be screened for comorbidities. Based on this, an algorithm for treat to target management approach tailored to the individual patient’s needs and associated comorbidities has been outlined.

Conclusion: This work provides updated evidence-based recommendations for the prevention and treatment of acute as well as chronic gouty arthritis. It provides an approach for physicians and patients making decisions on the management of gout. It will also facilitate improvement and uniformity of care.

Disclosure of Interests: None declared


POST1168 EFFICACY AND SAFETY OF FEBUXOSTAT IN PATIENTS WITH STAGE 4-5 CHRONIC KIDNEY DISEASE NOT YET ON DIALYSIS: A META-ANALYSIS OF OBSERVATIONAL STUDIES

C. N. Son1, H. J. Jeong1, W. Y. Park2, S. H. Kim1.

1Kenyung University School of Medicine, Rheumatology, Daegu, Korea, Rep. of (South Korea); 2Kenyung University School of Medicine, Nephrology, Daegu, Korea, Rep.of (South Korea

Background: The efficacy and safety of febuxostat in patients with stage 4-5 chronic kidney disease (CKD) are still unclear, even though it’s commonly used in clinical practice [1]. However, clinical trials are lacking to determine them due to ethical problems about enrolment of advanced CKD patients.

Objectives: We aimed to evaluate the efficacy and safety of febuxostat in patients with stage 4-5 CKD not yet on dialysis through a meta-analysis of observational studies.

Methods: We performed a systematic search in PubMed, Ovid MEDLINE, Embase, and the Cochrane Library to find articles reporting on advanced CKD patients from observational cohorts who start or take febuxostat at baseline in September 2021. Articles had to describe change from baseline in serum urate levels and renal function as assessed by estimated glomerular filtration rate (eGFR). The articles were screened by two independent reviewers (YP, HJ).

Meta-analysis using a random-effects model was performed. R software was used for statistical analyses.

Results: Among 148 retrieved studies, 5 relevant observational studies were included in the meta-analysis. The febuxostat dose was administered at 10-120 mg per day, and the treatment period was 3 to 12 months. Five studies were included with a total of 327 patients to analyze urate-lowering efficacy. The urate-lowering effect after use of febuxostat medication showed statistical significance (weighted mean difference, -1.85; 95% CI, -2.04 to -1.67; I²; 0%, Figure 1A). Three studies with 145 patients were available for assessment of eGFR. Renal function as assessed by eGFR did not decrease even after use of febuxostat (weighted mean difference, 0.11; 95% CI, -0.25 to 0.47; I²; 45%, Figure 1B).

Conclusion: Our meta-analysis showed that febuxostat had good urate-lowering efficacy and renal safety in hyperuricemia patients with stage 4-5 CKD, who are not yet on dialysis. More studies with larger sample sizes and higher quality are required to clarify the efficacy and safety of febuxostat in advanced CKD.

REFERENCES:


DISCLOSURE OF INTERESTS: None declared

BACKGROUND: The inflammation induced by monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals is driven by interleukin (IL)-1β production. This later relies on NLRP3 inflammasome which can be activated by variation of ion concentration.

Objectives: To assess the role of osmolarity and water flux in MSU and CPP crystal-induced inflammation.

Methods: In vitro, THP1 monocytes were stimulated by pyrogen-free synthetic MSU and CPP crystals in iso-, hypo- or hypertonic media. Cytokine production was quantified by ELISA in cell culture supernatants. Cell size was measured using video microscopy. The role of aquaporin channels was assessed by pharmacological inhibitor (mercury chloride, HgCl2). In vivo, murine air pouch model was used. MSU and CPP crystals were injected in air pouch of mice treated or not with HgCl2 or mannitol. Osmolarity of mouse sera and patient synovial fluids (SF) were measured using freezing point osmometer. The size of cells collected from SF was assessed with imageJ software.

Results: MSU and CPP crystal-induced IL-1β production was substantially reduced by HgCl2 treatment (MSU 4900 vs 880 pg/ml; CPP 10500 vs 980, p<0.0001) or when cells were cultured in hypertonic medium. MSU and CPP crystals induced a transient increase in cell size which was 16 and 1.5 bigger after 30 and 100 min of stimulation by MSU and CPP crystals, respectively. After 150 min of stimulation, cell size decreased to their baseline size. Cell size increase was abolished by HgCl2 or hypertonic medium. In vivo, MSU and CPP crystal-induced inflammation (assessed by cell infiltration, IL-1β and CXCL2 production in air pouch lavage) was drastically reduced by HgCl2 or mannitol i.p.

The serum osmolarity was higher in mannitol-treated mice than in untreated mice (320 vs 300 mOsm/L). In patients, cells collected from SF during CPP or MSU crystal-induced flares had a bigger size than cells collected from osteoarthritic SF. The osmolarity of MSU or CPP crystal-containing SF was lower than the osmolarity of osteoarthritic SF (270 vs 310 mOsm/L). Finally, the IL-1β concentration in SF was strongly correlated with cell size and SF osmolarity.

Conclusion: These results suggest that the variation of osmolarity plays central role in MSU and CPP crystal-induced inflammation. Deciphering how crystals modulate osmolarity will identify new therapeutic targets.

Disclosure of Interests: None declared


POS1707

ASYMPTOMATIC URATE-CRYSTALS DEPOSITS IN PATIENTS WITH STAGES 3-5 CHRONIC KIDNEY DISEASE DETECTED BY ULTRASOUND


1Hospital Universitario Infanta Leonor, Rheumatology, Madrid, Spain;
2Hospital Universitario Infanta Leonor, Nephrology, Madrid, Spain;
3Hospital Universitario Infanta Leonor, Nephrology, Madrid, Spain;
4Hospital Universitario Infanta Leonor, Nephrology, Madrid, Spain;
5Hospital Universitario Infanta Leonor, Nephrology, Madrid, Spain;
6La Paz University Hospital, Nephrology, Madrid, Spain;
7Hospital Universitario Infanta Leonor, Nephrology, Madrid, Spain

Background: One in ten patients with hyperuricemia may develop gout over time, with urate deposition sometimes asymptomatic. Recent reviews support ultrasound (US) to assess asymptomatic hyperuricemic (AH) patients to detect gout lesions, showing double contour (DC) and tophus the highest specificities and positive predictive values. Hyperuricemia and gout are common in chronic kidney disease (CKD), especially with glomerular filtration rate (GFR) <60, and are associated with worse prognosis. US gout lesions have been found more frequently in AH (up to 35%) than in normouricemic (NU) patients, but evidence is scarce in CKD.

Objectives: To assess the prevalence of urate deposit in stages 3-5 CKD detected by US, and to investigate if there are differences between AH and NU patients.

Methods: Case-control study, recruiting patients aged ≥18 years with AH and stages 3-5 CKD in 4 hospitals from January 2020 to December 2021. Controls were patients with stages 3-5 CKD and NU. Exclusion criteria: previous diagnosis of gout, tophi. Hyperuricemia was defined as serum uric acid (sUA) >8.8 mg/dl, documented at least twice during the last 12 months. A standardized US exam of the knees and bilateral first metatarsophalangeal joints was performed to assess patients for DC/Tophus as defined by OMERACT. Demographic, clinical and laboratory data were recorded. A descriptive analysis was performed using SPSS. Pre-clinical gout (PCG: DC and/or tophus) was considered as outcome variable. Chi-square and Fisher's exact test were used for qualitative variables, and Mann-Whitney U test for quantitative variables; significant threshold p<0.05.

Results: Forty-four patients with stages 3-5 CKD (59.6% stage 3, 19.1% stage 4, 21.3% 5) were recruited. 35 AH and 9 NU. Hyperuricemia was associated with a higher prevalence of US findings, with significant differences between cases (AH) and controls (NU): PCG 19 vs 1 (p=0.023), DC 13 vs 1, and tophus 11 vs 0. No significant differences were found in demographic variables, comorbidities and treatments. sUA levels, were higher in patients with PCG (8.3±1.4 vs 7.6±2.2; p=0.36), and these patients also showed lower GFR (31.4±14.1 vs 33.7±16.8; p=0.62). Patients with PCG also showed a non-significant trend towards shorter duration of CKD (6.3±5.7 vs 8.3±4.9 years; p=0.1) and younger age (66.4±15.1 vs 70.0±11; p=0.30).

Conclusion: We found an outstanding prevalence of asymptomatic urate deposit in our cohort of patients with stages 3-5 CKD, that is higher in hyperuricemic than in normouricemic patients. The prevalence of DC and tophus in our cohort of AH patients with stages 3-5 CKD was higher than that reported in AH patients in studies conducted in general population (37% vs 16-31% and 31% vs 16%, respectively). Early diagnosis of pre-clinical gout by ultrasound might change therapeutic approach in CKD.

REFERENCES:


Acknowledgements: Special thanks to the Nephrology and Rheumatology departments of the 4 participating centers.

Disclosure of Interests: Enrique de la-Oranda Speakers bureau: Menarini, Grunenthal, Laura Barrio Nogal: None declared, Boris Anthony Blanco Cáceres: None declared, Marta Novella-Navarro: None declared, Diana Peiteado: None declared, Jaime Arroyo Palomo: None declared, Eugenio de Miguel: None declared, Alejandro Prada Ojeda: None declared, Luis Sala Icardo: None declared, Maria Teresa Navio Marco: None declared, Mónica Vázquez Díaz: None declared, Claudia Maria Gomez-Gonzalez: None declared, Roberto Alcaraz Arroyo: None declared, Juan Antonio Martin Navarro: None declared, Marco Vaga Gallardo: None declared, Milagros Fernandez Lucas: None declared, Martha Elizabeth Diaz Dominguez: None declared


POS1711

TRIPLE THE RATE OF EMERGENCY ROOM VISITS AND HOSPITALIZATIONS FOR GOUT AMONG US BLACKS VS WHITES – 2019 NATIONWIDE ANALYSIS

C. Yokose1, N. Mccormick2, N. Lu3, A. Joshi4, L. Jackson5, M. Kohier1, J. Yin1, Y. Zhang6, K. Saag7, H. Choi7.

1Massachusetts General Hospital, Division of Rheumatology, Allergy and Immunology, Boston, United States of America; 2Massachusetts General Hospital, Clinical Epidemiology Program, Morgan Institute, Boston, United States of America; 3Arthritis Research Canada, n/a, Vancouver, Canada; 4Massachusetts General Hospital, Clinical and Translational Epidemiology Unit, Morgan Institute, Boston, United States of America; 5University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, United States of America

Background: Gout is a highly prevalent inflammatory arthritis with increasing global disease burden in recent years.1,2 Gout prevalence has been reported to be higher among Blacks compared to Whites,3 and that they are less likely to receive allopurinol in outpatient care.4 The potential nationwide impact of these racial disparities on emergency department (ED) visits and hospitalizations is unknown.
Objectives: To examine the contemporary racial disparities in ED visits and hospitalizations with a primary discharge diagnosis of gout in the US (2019).

Methods: We compared ED visits and hospitalizations between Blacks and Whites in the latest data (2019) from the US National Emergency Department Sample (NEDS) and National Inpatient Sample (NIS). We focused on encounters for which the primary diagnosis was gout based on ICD codes (M1A.xx, M10.xx). We calculated annual population rates of ED visits and hospitalizations for gout (per 100,000 US adults) using the 2019 US census adult population (>18 years) according to race.

Results: There were a total of 160,759 ED visits and 9,560 hospitalizations among White and Blacks with a gout diagnosis in the US in 2019. The mean age (58.2 years vs. 56.5 years) and male proportion (78.0% vs. 74.8%) tended to be higher among Whites, while more Blacks tended to live in the South (40.7% vs. 66.5%) and reported a median household income of <$50,000 (30.7% vs. 57.1%). Compared to Whites, Blacks had 2.7- and 3.2-fold higher rates of gout ED visits and hospitalizations, respectively, after adjusting for age, sex, payer, region, and household income (Table 1 & Figure 1). Black women, in particular, had 3.4- and 4.0-fold higher rates of ED visits and hospitalizations compared to White women, while the corresponding rate ratios for men were 2.5 and 2.8, respectively. The mean costs per gout ED visit were similar for Blacks compared to Whites (adjusted difference, -$7.6 [95% CI, -25.4 to 1.0]), while hospitalizations were more costly (adjusted difference, $130.6 [95% CI, 31.2 to 241.4]). The duration of ED visits and hospitalizations was also higher among Blacks than Whites (adjusted difference of 3.41 days [95% CI, 0.19 to 0.63] and 0.59 days [95% CI, 0.25 to 0.94], respectively).

Table 1. Racial Disparities in Emergency Department Visits and Hospitalizations with Primary Diagnosis of Gout in 2019

<table>
<thead>
<tr>
<th>Race</th>
<th>Emergency Department Visits</th>
<th>Hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>White</td>
<td>Black</td>
</tr>
<tr>
<td>All</td>
<td>68011965</td>
<td>24521300</td>
</tr>
<tr>
<td>Visits, N</td>
<td>88810</td>
<td>71949</td>
</tr>
<tr>
<td>Rate per 100,000</td>
<td>130.6</td>
<td>259.4</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>1.0 (ref)</td>
<td>2.81</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>2.42 (2.32, 2.54)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>2.45 (2.36, 2.55)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>2.47 (2.38, 2.56)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>2.48 (2.39, 2.58)</td>
<td>1.0 (ref)</td>
</tr>
<tr>
<td>Rate Ratio (95% CI)**</td>
<td>2.49 (2.40, 2.59)</td>
<td>1.0 (ref)</td>
</tr>
</tbody>
</table>

*Adjusted for age and sex for all, adjusted for age for sex-specific rate ratios**Adjusted for age, sex, payment, region, and household income

Conclusion: These latest national data indicate that ED visits and hospitalization due to gout are both 3 times higher among Blacks than Whites; this disparity was particularly prominent among women with gout. Higher risk of developing gout and suboptimal care both translate to these avoidable costly healthcare utilization, calling for improved primary prevention and gout care.

REFERENCES:
[1] Safiri et al., PMID 32755051
[2] Xia et al., PMID 31624843
[3] Chen-Xu et al., PMID 30618180
[4] Krishnan et al., PMID 18260174

Disclosure of Interests: Chio Yokose: None declared, Natalie McCormick: None declared, Na Lu: None declared, Amit Joshi: None declared, Lesley Jackson: None declared, Minna Kohler Speakers bureau: Lilly, Consultant of: MyMee, Novartis, Grant/research support from: Setpoint Medical, Janeh Yinh: None declared, Yuqing Zhang: None declared, Kenneth Saag Consultant of: Arthrosi, Atom Bioscience, Horizon Therapeutics, LG Pharma, Malinkrodt, SOBI, Takeda, Grant/research support from: Horizon Therapeutics, SOBI, Shanton, Hyon Choi Consultant of: ironwood, Selecta, Horizon, Takeda, Kowa, and Xavart, Grant/research support from: ironwood and Horizon


POS1172

RISK OF VENOUS THROMBOEMBOLISM AFTER GOUT FLARES

E. Cipolletta1,2, G. Nakafero3, M. Mamas3, A. Avery4, L. Tata5, A. Abhishek6.
1Politechnic University of Marche, Department of Clinical and Molecular Sciences, Ancona, Italy; 2University of Nottingham, Academic Rheumatology, Nottingham, United Kingdom; 3Keele University Keele Cardiovascular Research Group, Stoke-on-Trent, United Kingdom; 4University of Nottingham, Division of Primary Care, Nottingham, United Kingdom; 5University of Nottingham, Division of Epidemiology and Public Health, Nottingham, United Kingdom

Background: Several population-based cohort studies have reported an increased risk of venous thromboembolism (VTE) in gout patients. However, none of these studies has investigated the temporal relationship between gout flares and VTE.

Objectives: To explore whether gout flares increase the risk of VTE in the short-term using the self-controlled case series (SCCS) method.

Methods: We identified participants with incident gout from the Clinical Practice Research Datalink (CPRD). Participants having less than one year of registration in CPRD and patients with a history of VTE or anticoagulant prescription more than one year before the first gout consultation were excluded. Participants with at least one gout flare and a diagnosis of VTE were selected. VTEs and gout flares were ascertained using primary care data, hospitalisation and mortality records, using previously validated algorithms (positive predictive value of 94% for VTE [1] and 68-95% for gout flares [2,3]). SCCS method involves fitting a Poisson model conditioned on the number of VTEs, and it calculates the adjusted incidence risk ratio (aIRR) and its 95% confidence interval (95%CI) for each stratum of the ‘at-risk’ period as compared with the ‘baseline’ period (Figure 1). The analysis was adjusted for age and calendar season.

Figure 1. Schematic description of the observation period (‘at-risk’ and baseline periods).

The ‘at-risk’ period (in red) was defined as the period following the exposure (the gout flare), and it was subdivided as follows: days 0-30, 31-60 and 61-120 after each gout flare. The baseline period (in green) consisted of a pre-exposure and a post-exposure period of 365 days each. The length of each period varied according to the occurrence of the next flare and its timing. Panel A and panel B provide a schematic representation of patients with a single observation period and with multiple “non-overlapping” observation periods, respectively. In such cases, the length of the “at risk” period was 120 days, while the length of the pre-exposure and post-exposure period was 365 days each.

Results: Among the 104,962 patients with an incident diagnosis of gout in CPRD between 1997 and 2020, we identified 2,678 VTE (4.0 events/1,000 person-years). There were 53 VTE (13.3 events/month) during the “at-risk” period and 143 (8.0 events/month) during the “baseline” period (crude incidence rate ratio, 1.75; 95%CI: 1.27-2.42). The rates were highest in the first month after gout flares and then fell progressively (Table 1). Sensitivity analyses were consistent with the main analysis (Table 1).
**Table 1.**

<table>
<thead>
<tr>
<th>Gout flare</th>
<th>Number of events per month</th>
<th>aIRR (95%CI)</th>
<th>p trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main analysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-30 days</td>
<td>17.0</td>
<td>2.11 (1.27-3.50)</td>
<td>0.01</td>
</tr>
<tr>
<td>31-60 days</td>
<td>14.0</td>
<td>1.86 (1.07-3.24)</td>
<td></td>
</tr>
<tr>
<td>61-90 days</td>
<td>11.0</td>
<td>1.50 (0.96-2.37)</td>
<td></td>
</tr>
<tr>
<td>Baseline period</td>
<td>6.0</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Sensitivity analysis (excluding participants with risk factors for VTE) [4]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-30 days</td>
<td>14.0</td>
<td>3.13 (1.77-5.53)</td>
<td>0.01</td>
</tr>
<tr>
<td>31-60 days</td>
<td>7.0</td>
<td>1.66 (0.76-3.61)</td>
<td></td>
</tr>
<tr>
<td>61-90 days</td>
<td>8.0</td>
<td>1.75 (0.94-3.37)</td>
<td></td>
</tr>
<tr>
<td>Baseline period</td>
<td>3.4</td>
<td>Reference</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: A transitory increase in the risk of VTE was observed after gout flares.

REFERENCES:


Disclosure of Interests: None declared


**POS1173**

CLINICAL PRESENTATION AND TREATMENT OF STERNOCOSTOCLAVICULAR HYPEROSTOSIS (SCCH): A SYSTEMATIC REVIEW AND META-ANALYSIS OF SCATTERED EVIDENCE

A. Leering1, O. Dekkers1, N. Appelman-Dijkstra1, E. Winter1, 1Leiden University Medical Center, Internal Medicine, Division of Endocrinology, Center for Bone Quality, Leiden, Netherlands; 2Leiden University Medical Center (LUMC), Internal Medicine, Division of Endocrinology, Leiden, Netherlands

Background: Sternocostoclavicular hyperostosis (SCCH) is an inflammatory bone disorder within the spectrum of chronic non-bacterial osteomyelitis. SCCH can be a manifestation of SAPHO syndrome, standing acronym for spondyloarthropathy, acne, pustulosis, hyperostosis and osteitis, but also appears as an isolated clinical disorder without joint and skin involvement1-2. Consensus on nomenclature, diagnostic classification, and therapy for SCCH is currently lacking2. Literature is diffuse, and spreads over a wide range of medical disciplines, calling for a first systematic overview.

Objectives: We critically appraised literature with the aim to i) gain overview on the clinical presentation of SCCH and features leading to diagnosis and to ii) evaluate different treatment modalities and treatment response. We focused on the clinical entity of SCCH in adults, either isolated or as a part of SAPHO syndrome.

Methods: We conducted a systematic review and meta-analysis according to the PRISMA guidelines on the clinical presentation and therapeutic modalities applied in adult SCCH patients. Studies covering these respective domains were selected. Risk of bias was assessed using validated tools according to study type. Untransformed numerical data and double-arcsine transformed proportional data were analyzed in a random effects model in R-4.0.8; pooled proportions were reported with 95% confidence intervals (95%CI). Treatment response was categorized as good, partial, or none.

Results: 28(i) and 12(ii) studies were included, containing heterogeneous data on 1818 patients. A female predisposition (67%, 95%CI 60-73) and major diagnostic delay (5 years 95%CI 3-7) were noted. Clinical presentation was marked by anterior chest pain (89%, 95%CI 79-96), and swelling (73%, 95%CI 62-81). Pustulosis palmoplantaris was present in 53%, 95%CI 49-58 whereas acne (8%, 95%CI 14-13) and peripheral arthritis (24%, 95%CI 11-39) were less prevalent. Inflammatory markers were inconsistently elevated and autoantibodies and HLA-B27 prevalence normal. Histopathology was unspecific, and cultures almost exclusively negative. Increased isotope uptake (99%, 95%CI96-100) was the most consistent imaging finding. Amongst manifold treatments (see Figure 1), NSAIDs were mainly partially effective. Pamidronate and biologics (mainly TNF-α inhibitors) yielded good, though heterogeneous, response in 83%, 95%CI 60-98 and 56%, 95%CI 26-85 respectively.

Figure 1. Treatment modalities applied in SCCH and their effects on bone pain (data from trials and several cohort studies combined).

Figure 1. Treatment modalities applied in SCCH and their effects on bone pain (data from trials and several cohort studies combined).

Conclusion: Literature on SCCH is extremely heterogeneous. Timely diagnosis proves challenging and mainly follows from the increased isotope uptake on nuclear examination. Biopsies, autoantibodies and HLA-status are non-contributory, and inflammatory biochemical profiles only variably detected. Pamidronate and TNF-α inhibitors emerged as promising therapies, but powered, placebo-controlled research with standardized measures of response is warranted. Inherently, international consensus on SCCH’s diagnostic classification and name appears critical to improve scientific collaboration on this rare disease, and to advance the development of clinical guidelines.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4688

**POS1174**

COLCHICINE TREATMENT IN GOUT PATIENTS – IMPACT ON CARDIOVASCULAR EVENTS AND ON MORTALITY

Y. Braun-Moscovici1, L. Gabay2, Y. Butbul3, 1Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Rheumatology Institute, Haifa, Israel; 2Kahn-Sagol-Maccabi Research and Innovation Institute, Maccabi Healthcare Services, Tel Aviv, Israel, Epidemiology, Tel Aviv-Yafo, Israel; 3Ruth Rappaport Children’s Hospital, Rambam Medical Center, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, Pediatric Rheumatology Service, Haifa, Israel

Background: Gout and hyperuricemia are independent risk factors for cardiovascular events and increased mortality. A significant proportion of gout patients receive colchicine, additionally to urate-lowering therapy. Recently, colchicine treatment was found to reduce the risk of cardiovascular events in patients with chronic cardiac disease.

Objectives: To assess the incidence of cardiovascular events and the mortality rate among gout patients who received colchicine treatment.

Methods: This retrospective cohort study was conducted using data from the Maccabi Healthcare Services (MHS) central computerized database. MHS is the second largest state-mandated health care provider in Israel, covering >2.5 million members (25% of the population) and is a representative sample of the Israeli population. The study included gout patients from the MHS registry aged ≥40 years who received colchicine for at least 3 months and a control group matched by age, gender and socioeconomic status. The data extracted included smoking status, body mass index (BMI), co-morbidities (diabetes, hypertension, chronic renal disease, hyperlipidemia, malignancy), antiplatelet and antiagulant treatment, cardiovascular events and mortality rate. The statistical analysis included univariate and cox regression analysis.

Figure 1. Treatment modalities applied in SCCH and their effects on bone pain (data from trials and several cohort studies combined).

Conclusion: Literature on SCCH is extremely heterogeneous. Timely diagnosis proves challenging and mainly follows from the increased isotope uptake on nuclear examination. Biopsies, autoantibodies and HLA-status are non-contributory, and inflammatory biochemical profiles only variably detected. Pamidronate and TNF-α inhibitors emerged as promising therapies, but powered, placebo-controlled research with standardized measures of response is warranted. Inherently, international consensus on SCCH’s diagnostic classification and name appears critical to improve scientific collaboration on this rare disease, and to advance the development of clinical guidelines.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4688
Results: 3671 individuals were included in each group (mean(SD) age 56(12.5), 87% males, mean(SD) follow-up 2744.7(1616.2) days). The gout group had a statistically significant higher incidence (p<0.001) of cardiovascular events (14.7% vs 10.8%), high BMI (35.1% vs 15%), diabetes (17% vs 12.7%), hypertension (52% vs 32.4%), chronic renal disease (35% vs 15%), hyperlipidemia (65% vs 46%). The mortality rate was similar (8.9% vs 79%, p=0.11) for both groups. The mortality hazard ratio (95% CI) for gout patients was 1.18 (1.39, p=0.05), for diabetes 1.6 (1.3-1.9, p<0.0001), for hypertension 1.38 (1.1-1.67, p=0.002).

Conclusion: Although the gout patients had a higher incidence of co-morbidities and cardiovascular events, the mortality rate was not significantly different compared to the matched group. Chronic colchicine treatment might have a protective effect. Further long-term studies are required.

Disclosure of Interests: None declared

POS1175

IMPACT OF COVID-19 ON THE CLINICAL COURSE OF GOUT AND THE OVERALL USAGE OF MEDICATION IN PATIENTS WITH GOUT

S. Smierć1, O. Mahovkova1. Ternopil National Medical University, Internal Medicine No. 2, Ternopol, Ukraine

Background: Data on the course and outcomes of the coronavirus disease 2019 (COVID-19) in patients with gout are scarce, as gout is underrepresented in leading COVID-19 and rheumatological scientific publications [1].

Objectives: To describe clinical changes in quality of life, therapy of gout before and after COVID-19, and the clinical course of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection in the cohort of patients with gout.

Methods: In total, 84 males with gout were examined before the pandemic, during COVID-19 (March 2020 to December 2021) and 6 months after SARS-CoV-2 infection. The severity of COVID-19 in our cohort was determined using the Clinical, Occupational and Social Assessment following Infection with COVID-19 (COSI-IC). Each of the 20 patients was assessed 4 times (mean±SD age 61±12.1 years, 91% Smierć, 9% Mahovkova, mean±SD follow-up 2415±1093 days).

Results: The mean age (mean±SD) of the study patients was 51.07±7.45 years and the disease duration was 9.8±4.62 years. Most SARS-CoV-2 infected patients with gout exhibited a moderate illness (40.48%), almost every third (28.57%) had mild, 21.43% had severe and 9.52% had critical illness. Comparing patients with gout with the general population, the mortality rate was similar (8.9% vs 79%, p=0.11) for both groups. The mortality hazard ratio (95% CI) for gout patients was 1.18 (1.39, p=0.05), for diabetes 1.6 (1.3-1.9, p<0.0001), for hypertension 1.38 (1.1-1.67, p=0.002). The mortality rate was similar (8.9% vs 79%, p=0.11) for both groups. The mortality hazard ratio (95% CI) for gout patients was 1.18 (1.39, p=0.05), for diabetes 1.6 (1.3-1.9, p<0.0001), for hypertension 1.38 (1.1-1.67, p=0.002).

Conclusion: Although gout in young people is increasing, studies on the risk factors for gout in these people are lacking.

Disclosure of Interests: None declared

POS1177

TREATMENT OF GOUTY ARTHRITIS IS ASSOCIATED WITH RESTORING GUT MICROBIOTA AND PROMOTING PRODUCTION OF SHORT CHAIN FATTY ACIDS

S. J. Lee1, H. K. Park1. 1School of Medicine, Kyungpook National University, Korea, Internal Medicine, Daegu, Korea, Rep. of (South Korea)

Background: Although factors initiating the inflammatory response to monosodium urate crystals have been identified, the role of the gut microbiota and their metabolites on gout remain unknown.

Objectives: This study aimed to investigate changes in both gut microbiota and short chain fatty acids (SCFAs) according to inflammatory states of gout in the same patients.

Methods: This study enrolled 20 patients with gout in the acute state who had active joints and were followed-up until the recovery state with no active joints.

Results: Beta diversity of the microbiome was significantly different between the acute and recovery states.

Disclosure of Interests: None declared

POS1176

EFFECT OF LIFESTYLE CHANGE ON INCIDENT GOUT: A NATIONWIDE POPULATION-BASED COHORT OF YOUNG MEN

Y. Eun1, K. D. Han2, S. W. Lee1, S. Y. Kang1, S. Lee1, H. S. Cha1, E. M. Koh1, H. Kim3,4, J. Lee4, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea); 2Soongsil University, Department of Statistics and Actuarial Science, Seoul, Korea, Rep. of (South Korea); 3College of Medicine, Catholic University of Korea, Department of Biomedicine & Health Science, Seoul, Korea, Rep. of (South Korea); 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medical Humanities, Seoul, Korea, Rep. of (South Korea)

Background: Although gout in young people is increasing, studies on the risk factors for gout in these people are lacking.

Objectives: In this study, we explored the risk factors of gout and effect of lifestyle change on the development of gout in large nationwide population-based cohort of young men.

Methods: Between 2009–2012, men aged 20–39 years who participated in two national health examinations at 2-year intervals were included in the study. The outcome was occurrence of gout, which was defined using the diagnosis code of gout (ICD-10 code M10) in the claims database. Cox proportional hazard model was used to evaluate the association between incident gout and baseline factors or lifestyle change.

Results: A total of 1,977,849 subjects were included in the study, and the mean follow-up period was 5.5 ± 4.3 years. Gout occurred in 38,839 subjects (incidence rate = 3.59/1,000 person-years). A high body mass index, alcohol drinking, and comorbidities such as hypertension, diabetes mellitus, and hyperlipidemia were associated with an increased risk of gout. Among lifestyle factors, change in obesity had the greatest impact on gout, followed by drinking. Development of obesity increased the risk of gout by 1.75 times (95% CI 1.68–1.81), and recovery from obesity decreased the risk of gout by 40% (aHR 0.60, 95% CI 0.57–0.64). Heavy drinking increased the risk of gout by 38% (aHR 1.38, 95% CI 1.33–1.43), and stopping heavy drinking decreased the risk of gout by 11% (aHR 0.89, 95% CI 0.85–0.94). The effect of obesity on gout was evident in the younger age group, and the effect of heavy drinking on gout was weak in the severely obese group.

Conclusion: Obesity and heavy drinking in young men are important modifiable risk factors for gout. Therefore, the management of these risk factors in young men should be emphasized.

Disclosure of Interests: None declared
Infection-related rheumatic diseases

POS178

PRESCRIBING RITUXIMAB IN PATIENTS WITH AUTO-IMMUNE DISEASES AND ACQUIRED HYPOGAMMALOBULINEMIA: DESCRIPTION OF THE RISK OF SEVERE INFECTION IN 121 PATIENTS BEFORE THE SARS-COV2 ERA

B. Xavier1, M. Lafaurie2,3,4, E. Teiner5,6, O. Walter7,1, G. Pugnet7,1, G. Martin-Blondeel8, D. Brotti8,1, J. Ciron8, M. Moulla3,4, J. Constantin7, Y. Renaudeau9,10, D. Chauveau12,14, L. Sailler3,4,5, 6
Centre Hospitalier Universitaire de Toulouse, Service de Médecine Interne Le Tallec, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Pharmacologie Médicale, centre de pharmacovigilance, pharmaco-épidémiologie et d’Informations sur le médicament, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, UMR 1022 INSERM-Université de Toulouse, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Centre d’investigation clinique 1436, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Laboratoire d’Immunologie, Institut Fédératé de Biologie, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Centre de Physiopathologie de Toulouse-Purpan, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Médecine Interne, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service des maladies infectieuses et Tropicales, Toulouse, France; Université de Toulouse, INSERM UMR1291-CNRS UMR5051, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de Rhumatologie, Toulouse, France; Université de Toulouse, IFIBM Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, Service de néphrologie et transplantation d’organes, Toulouse, France; Centre Hospitalier Universitaire de Toulouse, INSERM UMR 1297 Institut des Maladies Métaboliques et Cardiovasculaires, Toulouse, France

Background: Rituximab (RTX) induces rapid, usually complete and prolonged depletion of circulating B cells, and also hypogammaglobulinemia in some patients. There are limited data regarding the risk of severe infection events (SIE) when initiating or continuing rituximab in patients with acquired hypogammaglobulinemia, especially in patients suffering from autoimmune diseases (ADs) other than rheumatoid arthritis (RA) (1).

Objectives: To describe the risk of severe infectious events (SIE) following initiation (rituximab-naïve patients [RNP]) or continuation of RTX therapy (rituximab-continuing patients [RCP]) in patients suffering from severe ADs other than RA and acquired hypogammaglobulinemia.

Methods: We conducted a single-center retrospective cohort study at the University Hospital of Toulouse (France) between 2010 and 2018. Patients were included if they had received at least one dose of RTX in the year following the evidence of hypogammaglobulinemia (defined as gammaglobulins [GG]<6g/L on serum protein electrophoresis) in the setting of ADs other than RA. The primary outcome was the occurrence of a SIE within 2 years after the date of first RTX infusion (T0) prescribed after the evidence of hypogammaglobulinemia. SIE were infections either fatal or requiring hospitalization.

Results: We included 121 patients (37 RNP and 84 RCP): 48 had ANCA-associated vasculitis (AAV), 48 multiple sclerosis (MS, n=41) or neuromyelitis optica (NMO, n=7), and 21 another severe AD. RTX was prescribed as induction therapy in 39 patients and as maintenance therapy in 82; 112/121 patients were followed for 2 years. Mean GG level were 5.5 g/L (IQ25-75: 4.6-5.7) at T0, 5.5 g/L (IQ25-75: 4.6-5.4) at one year, 5.7 g/L (IQ25-75: 4.8-6.1) at two years and 8 patients had a decrease of their GG level below 4g/L. Ten patients received immunoglobulin replacement therapy (IGRT) mostly after infection (n=6). Twenty-six patients (23.2%) had at least one SIE during follow-up: 12.8 % in the MS/NMO group with a 2-year incidence at 6.9 (3.1-15.5) per 100 person-years, 29.5 % in the AAV group with a 2-year incidence to 18.3 (9.3-20.1) per 100 person-years, 33.3 % in the other ADs group with a 2-year incidence at 22.2 (10.6-46.5) per 100 person-years. Infection was opportunistic in 8 patients (33.3 %) and 4 died from SIE. Risk factors of SIE at T0 were male gender (61.5% vs. 39.5%; p<0.05), lung disease (65.4% vs. 37.2%; p<0.01), renal failure (59.1% vs. 26.6%; p=0.01), a higher Charlson comorbidity index (p=0.001), a previous treatment by cyclophosphamide (53.8% vs. 30.2%; p=0.03), ≥ 5 g/m² d prednisone (69.2% vs. 33.7%; p=0.003), lack of pneumococcal vaccination (61.5% vs 31.4%; p=0.01). GG level was 5.3 g/L [4.1-5.6] in the ‘SIE’ group vs 5.6 g/L [4.8-5.8] in the ‘no SIE’ group (p=0.04). Incidence of SIE was 46% and 20.2% among patients with GG<4 g/L or GG≥4 g/L, respectively (p=0.07). No multivariable analysis provided reliable results.

Conclusion: Our study provides useful information for clinicians considering initiating or continuing rituximab therapy in patients with acquired hypogammaglobulinemia before Sars-Cov2 era. Prospective studies are necessary to improve the knowledge on outcome of patients treated by rituximab despite low immunoglobulins levels. Prophylactic IGRT may be appropriate in higher risk patients, especially if the GG level is below 4 g/L.

4 months, ionizamide/rifampicin for 3–4 months. For hepatitis B (HBV); there is evidence that risk of reactivation is increased in patients positive for hepatitis B surface antigen. These patients should be referred for HBV treatment. Patients who are positive for anti-HBcore antibodies, are at low risk for reactivation when treated with glucocorticoids, cDMARDs and bDMARDs but should be monitored periodically with liver function tests and HBV-viral load. Patients treated with rituximab display higher risk for HBV reactivation especially when anti-HBs titer are low. Risk for reactivation in hepatitis C RNA positive patients, treated with bDMARDs is low. However, all patients should be referred for antiviral treatment and monitored periodically. For pneumocystis jiroveci prophylaxis with trimethoprim/sulfamethoxazole (alternatively with atovaquone or pentamidine) should be considered in patients treated with prednisolone: 15-30mg/day for more than 4 weeks. Few data exist for screening and prophylaxis from viruses like EBV, CMV and Varicella Zoster Virus. Expert opinion supports the screening of rare bugs like histoplasma and trypanosoma in patients considered to be at high risk (e.g living in endemic areas).

Conclusion: The risk of chronic and opportunistic infections should be considered in all patients prior to treatment with immunosuppressives/immunomodulators. Different screening and prophylaxis approaches are described in the literature, partly determined by individual patient and disease characteristics. Collaboration between different disciplines is important.

Acknowledgements: We would like to thank all members of the EULAR Task Force for the screening and prophylaxis of chronic and opportunistic infections in Autoimmune Rheumatic Diseases.

Disclosure of Interests: None declared


POS1180

AUTOIMMUNE SYNDROMES WITH CHRONIC HEPATITIS C VIRUS INFECTION AND DIRECT-ACTING ANTIVIRAL TREATMENT.

B. H A Mohammed1, D. Hassan Attia2, M. Abdelazim3, A. Elsayed Tahs3, D. Rasheed Bahgat4, H. Ibrahim El Mikhailxangy3. 1School of Medicine- Cairo University, 2Rheumatology and rehabilitation, Cairo, Egypt; 3School of Medicine- Cairo University, 4School of Medicine- Cairo University, 5School of Medicine- Cairo University, Tropical medicine, Cairo, Egypt; 6School of Medicine- Cairo University, Chemical and clinical pathology, Cairo, Egypt

Background: Chronic hepatitis C virus (HCV) infection is a multifaceted disease that has been associated with systemic as well as organ-specific, autoimmune manifestations with increasing virologic, and clinical evidence supporting the association. The development of direct-acting antivirals (DAAs) is considered an advent that might aid the clearance of extrahepatic immune manifestations of HCV.1,2,3

Objectives: Investigate the effect of directly acting antiviral drugs (DAAs) on the different autoimmune manifestation and serologic changes associating chronic HCV infection.

Methods: Inclusion criteria: This is a cohort study that included adult patients aged ≥18 years, of either sex, having CHCV with detectable HCV ribonucleic acids (RNA) by Polymerase Chain Reaction (PCR) and eligible for the DAAs treatment. Exclusion criteria: Patients with established rheumatological disease prior to the onset of HCV diagnosis. Patients with uncompensated cirrhosis, Patients with platelet count less than 50 000/mm³, Patients with HCC (except after 6 months of curative intervention). All patients were subjected to full history taking, clinical and laboratory investigations.

Results: The study enrolled 130 chronic HCV patient (90 patients completed follow up). 66.7% females and 33.3% males (ratio 2:1), the mean age was 49.2±12.3 years. The study found 77/90 (85.55%) patients to have immune mediated manifestations and associated serological changes prior to DAA. The most prevalent were musculoskeletal manifestations in 56 patients (72.7%), arthralgia (86.2%), fatigue (54.5%) and myalgia (50.6%), xerophthalmia (24.7%), neutrophils (28.6%) (P-value > 0.01), and a positive RF in 33.8% (P-value 0.013). HCV Among patients who achieved sustained viral response, autoimmune manifestations persisted in 66 out of 71 patients (92.9%) who were positive at baseline. The most prevalent autoimmune manifestations after therapy were musculoskeletal manifestations 53 patients (68.8%). Responders with persistent autoimmune manifestations had an observable rise in inflammatory biomarkers posttreatment erythrocyte sedimentation rate was (46.2±19.62) became (56.05±25.43), C reactive protein titer was (8.46±10.78) became (20.01±25.92), P<0.01. Predictors of recurrence of autoimmune manifestations were older age ≥49 years P-value 0.009, female sex P= 0.026, tobacco consumers P= 0.043.

Conclusion: The introduction of directly acting antiviral drugs wasn’t associated with a significant change in the prevalence of autoimmune manifestations in our population of Egyptian patients with chronic HCV who attained a sustained viral response.

REFERENCES:

Disclosure of Interests: None declared


POS1181

INFECTION COMPLICATIONS OF BIOLOGIC THERAPY IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM

F. Idrissi Zak1, F. E. Chekkouri1, A. Mougui1, I. El Bouchti1. 1Centre Hospitalo-Universitaire Mohammed VI Marrakech, Department of Rheumatology. Marrakech, Morocco

Background: The appearance of biological disease-modifying drugs (bDMARDs) has revolutionized the treatment of rheumatic diseases. However, their functions in modulating pro-inflammatory cytokines and acquired immunity largely increase the risk of infections.

Objectives: The aim of this work is to study the epidemiological, clinical and biological characteristics of infections occurring under biotherapies, and to identify the factors associated with its occurrence.

Methods: It is a retrospective descriptive study including patients with chronic inflammatory rheumatism between 2006 and 2021 and who were placed during their follow-up under a biotherapy. Statistical data analysis was performed using SPSS version 20 software. The bivariate study was performed by Chi-square test.

Results: Of the 106 cases reported, 68 infectious episodes were counted in 46 patients (43.4%) who had at least one infection with biotherapy: 56.5% women and 43.5% men with an average age of 50.9 ± 14.29 years. These included rheumatoid arthritis in 16 patients (34.8%), spondylarthritides in 29 patients (63%) and one case of psoriatic arthritis. All patients were on conventional treatments before switching to biotherapy. The infections occurred under rituximab in 43.8% of the cases, under infliximab in 33.3% of the cases, under Etanercept in 25% of the cases (a total of 60.9% of the cases were under anti-Tumor Necrosis Factor) and tocilizumab in 12.5% of the cases. The infection was of bacterial origin in 40.7% of cases: 27.3% urinary tract infections, 20.5% bronchial infections, 11.4% skin infections, 6.8% septic arthritis. Fungal infections were found in 33.3% of cases in relation to dermatophyte infections and intertrigo. A viral origin was noted in 25.9% of the cases. Nevertheless, cases of salmonella were in 2 cases and only one case on herpes zoster. C-reactive protein was increased in 47.2% of cases with a mean value of 36 ± 29.6 mg/L. The hemogram showed hyperleukocytosis in 50% of cases with neutrophil predominance. The treatment was medical in the majority of cases (94.9%), it was both medical and surgical in one case. The favorable outcome in all patients was marked by a temporary interruption of 5.27 ± 1.84 weeks of biotherapy. In multivariate analysis, an association was found between bacterial infection and both female gender (p=0.033), low socioeconomic level (p=0.033), Methotrexate + bDMARDs intake (p=0.027), corticosteroids + bDMARDs intake (p=0.014) and Between fungal infection and bDMARDs + corticosteroids intake (p=0.044).

Conclusion: The risk of infection is higher in patients with chronic inflammatory rheumatism, especially if they are under biotherapy. It turns out that bacterial and fungal infections are the most affected by these infectious episodes.
REFERENCES:


Disclosure of Interests: None declared

POS1182

EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC ASPECTS OF TABETIC ARTHROPATHY IN A POPULATION OF SOUTHERN MOROCCO

P. C. Moulele Mbougui, F. E. Bennani, S. Belouaham, H. Bara, A. Mougui, I. El Boucht, centre Hospitalo-Univeriste Mohammed VI Marrakech, Rheumatology, Marrakech, Morocco

Background: Tabetic arthropathies (TA) are a destructive neurogenic disease complicating 10% of syphilis at the tertiary stage. Although they have become exceptional due to early and appropriate treatment of syphilis, they are still relevant in underdeveloped countries and remain difficult to manage due to the severity of the handicap and the absence of a specific treatment.

Objectives: We described epidemiological, clinical, biological, radiographic, and therapeutic characteristics of TA.

Methods: Retrospective study, from 2004 to 2021 including patients with tabetic arthropathy, whose diagnosis was retained on clinical criteria (discordance between the importance of joint deformities and indolence), radiological (lesions destructive and constructive), biological (positive syphilitic serology in joint fluid, blood and/or cerebrospinal fluid).

Results: A total of 21 cases were collected, 15 men and 6 women, the mean age was 52.14 years. The history of syphilitic chancre was found in 9 patients, sexual risk behavior was noted in 8 patients, no other STI was found. Joint swelling and painless deformation was the main mode revealing the disease (76.1%), followed by the hip, ankles, MTP, in respectively 4(19%), 3(14%), 2(9.5%) cases. The upper limb was involved in 4 cases, with MCP involvement in one patient. TA was bilateral in 29% and multifocal in 19%. Joint instability was found in 16 patients. Involvement of the thoracolumbar spine was noted in one case. Tabetic neurological involvement was found in 16 patients (76.1%) with an Argyll Robertson sign noted in 6 cases (28.6%), a radiculopodenteral posterior syndrome in 10 cases (47.6%), TPHA and VDRL were positive in blood in 21 patients, in cerebrospinal fluid in 11 patients and in synovial fluid in 9 cases. Radiological exams showed destructive and constructive lesions with the presence of intraosseous and periarticular fragments, damage to small joints was noted in two patients, bilateral talocalcaneal involvement in one patient, a fracture with dislocation and calcification of the soft tissues was noted in two cases. Axial tabetic involvement made of talocrural involvement in one patient, a fracture with dislocation and calcification of the soft tissues was noted in two cases. Axial tabetic involvement made of talocrural involvement in one patient, a fracture with dislocation and calcification of the soft tissues was noted in two cases.

Conclusion: Tabetic arthropathy, one of the exceptional complications of neurosyphilis, is still relevant. Its diagnosis must be referred to any destructive and painful joint damage. Given the difficulty of treating this articular form, prevention based on the management of syphilis at an early stage before the occurrence of joint and neurological complications is essential.

REFERENCES:


Disclosure of Interests: None declared

POS1183

RISK FACTORS FOR CYTOMEGALOVIRUS INFECTION IN PATIENTS WITH RHEUMATIC DISEASE - SINGLE-CENTER PROSPECTIVE COHORT STUDY.

Y. Ota1, Y. Kondo1, S. Saito1, J. Kikuchi1, H. Hanaoka1, Y. Kaneko1, Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

Background: Cytomegalovirus (CMV) infection is one of serious opportunistic infections for immunosuppressed patients, therefore, identifying patients at risk for CMV infection is of importance. However, no prospective study about CMV infection in systemic rheumatic disease has been reported.

Objectives: To identify risk factors relevant with CMV infection in patients with systemic rheumatic disease during intensive remission induction therapy.

Methods: Consecutive systemic rheumatic disease cases who started intensive immunosuppressive therapy from February 2017 until February 2019 were enrolled. Serum CMV-IgG was measured before the induction therapy, and subsequently, CMV pp65 antigen was monitored weekly. Patients were divided into 2 groups according to the presence or absence of CMV infection, and risk factors for CMV infection were analyzed.

Results: 157 patients consisting of 136 CMV-IgG positive and 21 CMV-IgG negative patients were enrolled in the study. Mean age was 60.8 ± 17.4 y/o, and female was 70.7%. The underlying diseases were following; vasculitides 54, systemic lupus erythematosus 27, polymyositis/dermatomyositis 25, rheumatoid arthritis 14, IgG4-related disease 13, mixed connected tissue disease 6, Behçet disease 5, adult-onset Still’s disease 4, and others 9. The initial dose of glucocorticoid (GC) was 48.4 ± 11.5 mg/day (0.91 ± 0.16 mg/kg/day) as prednisolone (PSL) with additional methylprednisolone (mPSL) pulse therapy being conducted in 44 (28.0%). Concomitant immunosuppressive treatments were intravenous cyclophosphamide (IVCY) in 55, calcineurin inhibitor 27, mycophenolate mofetil 16, hydroxychloroquine 5, and methotrexate 4. Concomitant biological agents were rituximab 12, tocilizumab 6, infliximab 2, golimumab 1, and abatacept 1. CMV infection occurred in 52 patients (33.1%), and all of them were CMV-IgG positive before induction therapy (38.2% in the CMV-IgG positive patients). Univariable analysis revealed initial PSL dose >0.91 mg/kg/day (odds ratio [OR] 5.2, p<0.01), IVCY (OR 3.4, p<0.01), diabetes mellitus (OR 5.2, p<0.01), and a history of malignancy (OR 2.9, p=0.02) were independent risk factors for CMV infection. CMV antiviral drugs were administered in 22 patients (42.3%). At the first detection of CMV pp65 antigen, PSL dose >37.5 mg/day (OR 52.948, p<0.01), CMV pp65 antigen-positive cells ≥2 cells/2 slides (OR 16.0, p = 0.04), and serum albumin levels <3.0 g/dL (OR 26.3, p=0.01) were associated with subsequent CMV antiviral drug administration.

Conclusion: CMV infection is only in CMV-IgG positive patients with systemic rheumatic diseases who were undergoing intensive remission induction therapy. CMV infection was related with treatment regimen and comorbidities, and the necessity of CMV antiviral treatment was predicted with prednisolone therapy. CMV infection was related with treatment regimen and comorbidities, and the necessity of CMV antiviral treatment was predicted with prednisolone dose, the number of CMV pp65 antigen positive cells, and albumin levels at the first detection of CMV pp65 antigen.

Disclosure of Interests: None declared
Background: Recent epidemiological data on HBV and HCV in Turkey revealed that the seroprevalence rates of hepatitis B surface antigen and antibody against HCV were 4% and 1%, respectively, and seropositivity rates for hepatitis B surface antibody and hepatitis B core antibody were 31.9% and 30.6%, respectively. A previous multicenter nationwide study conducted in Turkey reported that the HBsAg positivity was determined in 2.3% of patients with rheumatoid arthritis (RA) and 3% of patients with ankylosing spondylitis (AS), and the anti-HCV positivity was detected in 1.1% of patients in each group. Given these rates, viral hepatitis is still considered a potential threat to patients with rheumatic diseases, specifically for the treatment-related viral reactivation.

Objectives: This study aimed to evaluate the serologic HBV and HCV frequency and clinical characteristics among our patients with RA or SpA and receive biological treatments based on this background.

Methods: The prospective TReasure database, which observationally collects data of patients with rheumatic diseases from fifteen centers across Turkey, was analyzed for viral hepatitis, patient characteristics, and treatments used. TReasure registry study protocol, and the data collection was started on December 2017. At the time of the analysis for this study was performed, the registry database included 3147 patients with RA and 6071 patients with SpA. For hepatitis B, hepatitis B surface antigen (HBsAg), anti-HBV core antibody (anti-HBc), and anti-HBV surface antibody (Anti-HBs) tests were evaluated. HBV-DNA was studied in HBsAg positive patients. Anti-HCV antibody has been studied for HCV. The clinical and serological HBV reactivation in the follow-up of the patients was evaluated by looking at the HBV-DNA viral loads.

Results: A total of 9218 patients (3147 RA and 6071 patients with SpA) were included in the analyses. The screening rate for HBV was 97% in RA and 94.2% in SpA groups. HBsAg positivity rates were 2.6% and 2%, anti-HBs positivity rates were 32.3% and 34%, anti-HBc positivity rates were 20.3% and 12.5%, HBV DNA positivity rates were 3.5% and 12.5%, and anti-HCV positivity rates were 0.8% and 0.3% in these groups, respectively (Table 1).

Table 1. Serological analyses in the study group

<table>
<thead>
<tr>
<th></th>
<th>RA</th>
<th>SpA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N (n (%))</td>
<td>N (n (%))</td>
</tr>
<tr>
<td>Hepatitis testing</td>
<td>2886 (2809 (97.0))</td>
<td>5444 (5130 (94.2))</td>
</tr>
<tr>
<td>HBsAg positivity</td>
<td>2750 (71 (2.6))</td>
<td>5017 (99 (2))</td>
</tr>
<tr>
<td>Anti-HBs positivity</td>
<td>2708 (876 (32.3))</td>
<td>4893 (1663 (34))</td>
</tr>
<tr>
<td>Anti-HBc positivity</td>
<td>2362 (480 (20.3))</td>
<td>4194 (524 (12.5))</td>
</tr>
<tr>
<td>HBV-DNA positivity</td>
<td>454 (16 (3.5))</td>
<td>637 (35 (5.5))</td>
</tr>
<tr>
<td>Anti-HCV positivity</td>
<td>2602 (22 (0.8))</td>
<td>4627 (16 (0.3))</td>
</tr>
</tbody>
</table>

The HBsAg (+) patients were older and had higher comorbidities, including hypertension, diabetes, and coronary artery disease. In addition, RF positivity was more in HBsAg (+) cases. The most frequently prescribed bDMARDs were adalimumab (28.5%), etanercept (27%), tocilizumab (23.4%), and bDMARDs (21.3%) in the RA group, whereas adalimumab (48.1%), etanercept (31.4%), infliximab (22.5%), degenerative changes, etc (2). The identification of the germ by blood cultures or disc-vertebral puncture-biopsy allows the treatment to be best adapted antibiotic. Bacteriological investigation is inconclusive in about 30% (1). More and more undocumented spondylodiscitis are described.

Objectives: The aim of this study is to describe a cohort of spondylodiscitis without bacteriological documentation and to compare it to spondylodiscitis with bacteriological documentation.

Methods: We research Medline and EMBASE from the inception to October 2021 and the American College of Rheumatology and European League Against Rheumatism for conference abstracts (2012-2021) to assess the accuracy of ADA activity in synovial fluid compared to a composite reference standard (necrotizing granulomas in a synovial biopsy; acid-fast stain, Mycobacterium culture or RT-PCR assay for tuberculosis and/or clinical response to tuberculosis treatment) to early diagnosis of tuberculous arthritis. We performed meta-analysis using a random-effects model and evaluated the sources of heterogeneity via subgroup analysis and meta-regression.

Results: Seven independent studies (N= 307 subjects) that compared ADA activity in synovial fluid with the composite reference standard were included. The pooled sensitivity and specificity of ADA activity was 0.939 (95% confidence Interval [CI], 0.873-0.977; heterogeneity p=0.297; I2=17.4%) and 0.885 (95% confidence Interval [CI], 0.833-0.925; heterogeneity p=0.002; I2=85.3%) compared to the composite reference standard, respectively. The random-effects model for pooled diagnostic Odds Ratio was 74.582 (95% CI, 19.826-280.57; heterogeneity p=0.133; I2=38.8%). The receiver operating characteristic curve area was 0.9617 (95% CI, 0.939-0.994; heterogeneity p=0.297; I2=17.4%). Meta-regression did not identify the type of study (prospective or retrospective), country of publication, type de assay, or cut-off value as sources of heterogeneity.

Conclusion: Measuring adenosine deaminase activity in synovial fluid demonstrates good performance for the early diagnosis joint tuberculosis.

Acknowledgements: El estudio fue apoyado con una beca de investigación de la Asociación para la Investigación en Reumatología de la Marina Baixa (AIRE-MB)

Disclosure of Interests: None declared


POS1185

PERFORMANCE OF ADENOSIN DEAMINASE ACTIVITY IN SYNOVIAL FLUID FOR THE EARLY DIAGNOSIS OF TUBERCULOUS ARTHRITIS: A META-ANALYSIS

J. Ena1, J. C. Cortés-Quiroz2, J. A. Bernal3, A. Pons3, J. M. Senabré-Gallego3, G. Santos Soler4, C. Raya-Santos5, J. Rosas5, 1Hospital Marina Baixa, Internal Medicine, Villajoyosa, Spain; 2Hospital Marina Baixa, Rheumatology, Villajoyosa, Spain

Background: Adenosin deaminase activity (ADA) has shown good performance in diagnosing pleural, peritoneal and meningeal tuberculosis. Still, the performance of ADA activity in synovial fluid for the diagnosis of tuberculous arthritis has received less attention.

Objectives: To analyze the performance of ADA in synovial fluid to diagnosis tuberculosis arthritis.

Methods: We research Medline and EMBASE from the inception to October 2021 and the American College of Rheumatology and European League Against Rheumatism for conference abstracts (2012-2021) to assess the accuracy of ADA activity in synovial fluid compared to a composite reference standard (necrotizing granulomas in a synovial biopsy; acid-fast stain, Mycobacterium culture or RT-PCR assay for tuberculosis and/or clinical response to tuberculosis treatment) to early diagnosis of tuberculous arthritis. We performed meta-analysis using a random-effects model and evaluated the sources of heterogeneity via subgroup analysis and meta-regression.

Results: Seven independent studies (N= 307 subjects) that compared ADA activity in synovial fluid with the composite reference standard were included. The pooled sensitivity and specificity of ADA activity was 0.939 (95% confidence Interval [CI], 0.873-0.977; heterogeneity p=0.297; I2=17.4%) and 0.885 (95% confidence Interval [CI], 0.833-0.925; heterogeneity p=0.002; I2=85.3%) compared to the composite reference standard, respectively. The random-effects model for pooled diagnostic Odds Ratio was 74.582 (95% CI, 19.826-280.57; heterogeneity p=0.133; I2=38.8%). The receiver operating characteristic curve area was 0.9617 (95% CI, 0.939-0.994; heterogeneity p=0.297; I2=17.4%). Meta-regression did not identify the type of study (prospective or retrospective), country of publication, type de assay, or cut-off value as sources of heterogeneity.

Conclusion: Measuring adenosine deaminase activity in synovial fluid demonstrates good performance for the early diagnosis joint tuberculosis.

Acknowledgements: El estudio fue apoyado con una beca de investigación de la Asociación para la Investigación en Reumatología de la Marina Baixa (AIRE-MB)

Disclosure of Interests: None declared


POS1186

STUDY OF SPONDYLODISCITIS WITHOUT BACTERIOLOGICAL DOCUMENTATION FROM A COHORT OF 142 PATIENTS WITH SUSPECTED INFECTIOUS SPONDYLODISCITIS ON IMAGING

G. Alina1, M. Desvaux1, C. Delpeigne1, M. Lanquart2, C. Patene2, N. Sens1, M. Kozyreff-Meurot3, S. Pouplin1, T. Lequerr2, O. Vittecoq4, G. Avenel1, 1Hospital Center University De Rouen, Rheumatology, Rouen, France

Background: The incidence of infectious spondylodiscitis was estimated at 2.4/100,000 people in 2002. When faced with an image of spondylodiscitis on imaging, infectious spondylodiscitis is the most feared etiology. In recent years, several non-infectious spondylodiscitis etiologies have been described: Andersson lesion, crystal-induced discopathy, degenerative changes, etc (2). The identification of the germ by blood cultures or disc-vertebral puncture-biopsy allows the treatment to be best adapted antibiotic. Bacteriological investigation is inconclusive in about 30% (1). More and more undocumented spondylodiscitis are described.

Objectives: The aim of this study is to describe a cohort of spondylodiscitis without bacteriological documentation and to compare it to spondylodiscitis with bacteriological documentation.
Methods: Using a “clinical data warehouse”, we searched for the key word “spondylodiscitis” in the documents associated with hospitalisations in the Rheumatology department of the Rouen University Hospital between 2010 and 2020. Four hundred and twenty-two records were analysed. 196 were excluded because they were not hospitalized in Rheumatology, among the 226 suspected spondylodiscitis, imaging allowed us to exclude 84 records for which there was no infectious spondylodiscitis and to retain 142 records. We collected demographic data, history, clinical symptoms, results of imaging, biological and bacteriological examinations. Statistical analysis was performed by Fisher’s exact test for qualitative data and by Mann-Whitney test for quantitative data.

Results: Four hundred and twenty-two patients were collected, 142 were analysed. The average age was 65.5 +/- 14 years, 64.1% were male. Spinal pain was present in 96.5% of the cases without any difference between the two groups. One hundred and nine cases of spondylodiscitis were documented, of which 72 were confirmed by blood cultures and 36 by spinal disc biopsy. Thirty-three were not documented. Documented spondylodiscitis was more often febrile (41.3% vs 15.21% in undocumented cases, p = 0.006), had a greater biological inflammatory syndrome (mean CRP 152.4 +/- 112.6 mg/L versus 73 +/- 73.1 mg/L, p < 0.0001), and had been evolving for a shorter period of time than undocumented spondylodiscitis (54.1% vs 24.2% less than one month). Staphylococcus aureus was the most frequently retrieved bacteria 27.5%, followed by coagulase-negative staphylococci and streptococci (18.3% and 19.3% respectively). One hundred and twenty-one patients (85%) had an MRI at diagnosis; one hundred and two (71.8%) had a CT scan; and 81 patients (57%) had both examinations. The imaging analysis showed that there was no difference in soft tissue infiltration, erosions and abscesses. Probablistic antibiotic therapy was proposed in 28/33 (84.5%) of cases. After collegial discussion, the alternative diagnoses retained were degenerative disc disease (4 cases), spinal gum (1 case), spondylodiarthritis (1 case).

Conclusion: Undocumented spondylodiscitis is a recurring problem in hospital practice. Alternative diagnoses are increasingly reported, their diagnosis is based on collegial discussion.

References:

Disclosure of Interests: None declared


POS1187

DO IMMUNOSUPPRESSIVE AGENTS AFFECT IGRA TESTS IN PATIENTS WITH RHEUMATOID ARTHRITIS?

Z. Özyönlü1, A. Özdemir2, M. Ekici3, E. Bilgin1, L. Kılıç4, S. Kızılağaoğlu5, S. Sanbaşaoğlu, B. Şener2, O. Karadağ1, Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; 2Hacettepe University, Faculty of Medicine, Department Of Medical Microbiology, Ankara, Turkey

Background: Tuberculin skin test (PPD) or interferon gamma release assays (IGRAs) are used to detect latent tuberculosis infection. Induration of 15 mm or more is considered positive in any person whereas this cut-off is ≥5 mm for immunosuppressed individuals such as Rheumatoid arthritis. Since IGRAs are dependent on normal T-cell function, it may result in false-negatives for RA patients due to disease itself and immunosuppressive drugs.

Objectives: We aimed to compare IGRA results of RA patients using high dose DMARDS vs. not using any of them.

Methods: Totally 534 RA patients among Hacettepe University Rheumatology Biologic Registry Database (HURBIO) database was enrolled in this study. QFT-Plus test of patients with rheumatoid arthritis (RA) between January 2018 and March 2021 during work up before biologic/targeted therapy were analysed, retrospectively. The patient group was divided into two according to the drugs have been using at the time of IGRA test. Patients using methotrexate ≥ 10 mg or leflunomide (any dose) or steroids (≥7.5 mg prednisolone) or any combination thereof were classified as the “High Dose” group. The other group consisted of patients who did not take these drug doses. Demographic characteristics, comorbidities, drugs and doses used, and hemogram, sedimentation, and CRP values of the patients were recorded. Quantiferon test was recorded as positive, negative, indeterminate.

Results: 353(66.1%) RA patients were in the high dose patient group and also 287(81.3%) of these patients were female, the median age was 55 years (min-19- max-82). The high dose group was older than the other group. When the two groups were compared, no statistically significant difference was found between comorbidity, and smoking (Table 1). While QFT positivity was detected in 37 (10.5%) patients in the high-dose group, it was found to be positive in 37 (20.4%) patients in the other group (p<0.001). However, there was no significant difference regarding acute phase reactants, hemogram including lymphocyte counts and IFN-gamma levels in the tubes between these two groups.

Table 1. Comparison of RA patients’ groups using high-dose immunosuppressives and not using any of them

<table>
<thead>
<tr>
<th></th>
<th>High Dose Methotrexate or Leflunomide or Steroid (+), (%)</th>
<th>High Dose Methotrexate or Leflunomide or Steroid (+), (%)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>81.3</td>
<td>75.1</td>
<td>0.09</td>
</tr>
<tr>
<td>Age, med (min-max)</td>
<td>55 (19-82)</td>
<td>52 (19-81)</td>
<td>0.01</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>11</td>
<td>10.5</td>
<td>0.84</td>
</tr>
<tr>
<td>Hypertension</td>
<td>30.6</td>
<td>24.9</td>
<td>0.16</td>
</tr>
<tr>
<td>Chronic Renal Failure</td>
<td>0.3</td>
<td>0</td>
<td>0.66</td>
</tr>
<tr>
<td>Chronic Obstructive Pulmonary</td>
<td>4.2</td>
<td>3.3</td>
<td>0.59</td>
</tr>
</tbody>
</table>

Disease

Coronary Artery Disease

History of malignancy

Smoking

QuintIFERON-TB Gold-

Plus (QFT-Plus)

Table 2. Comparison of RA patients’ groups using high-dose immunosuppressives and not using any of them

Nill med (min-max) | 0.07 (0.2-7.1) | 0.05 (0.0-0.85) | 0.48 |
QFT-Plus TB 1 med (min-max) | 1 (0-10) | 0.99 (0.0-10) | 0.25 |
QFT-Plus TB 2 med (min-max) | 1 (0-10) | 1.1 (0-10) | 0.42 |
Methyleneed (min-max) | 10 (0-10) | 9.5 (0-10) | 0.27 |

Conclusion: Our results confirmed a significantly lower QFT-Plus positivity in patients with RA taking methotrexate ≥ 10 mg or leflunomide (any dose) or steroids (≥7.5 mg prednisolone). Physicians should be careful in interpretation of QFT-Plus in patients with rheumatoid arthritis. Further analysis including flow cytometry analysis is required to better identifying cut-offs for immunosuppressive individuals and patients with inflammatory rheumatic diseases.

Disclosure of Interests: None declared


POST1188

INCIDENCE AND MANIFESTATIONS OF LYME DISEASE: A SINGLE-CENTER RETROSPECTIVE ANALYSIS.

S. Pučko1, A. Pučko2, A. Mihailova1, Riga Stradins University, Internal diseases, Riga, Latvia; 2Riga Stradins University, Family Medicine, Riga, Latvia
Background: Lyme disease is widespread throughout the world, including Latvia. On average period 2009 to 2018, there have been 613 cases of Lyme disease registered in Latvia every year according to data from the Center for Disease Prevention and Control. Mainly early skin manifestations such as erythema migrans and neurological manifestations such as meningitis, cranial neuropathy and motor or sensor radiculoneuropathy of this disease are being discussed and emphasized. Therefore, undiagnosed and unexamined often remain articular manifestations of Lyme disease, leading to prolonged treatment and reduced patient quality of life.

Objectives: To investigate clinical presentation, immunological changes, and response to therapy in patients with Lyme disease.

Methods: A retrospective single center study was performed in the outpatient clinic Orto (Riga, Latvia) in the period from January 2018 until December 2021. Medical records from patients who diagnosed Lyme disease and articular manifestations, based on epidemiological, clinical and immunological findings, were analyzed. Patients who had other types of arthropathies were excluded.

Results: In total 76 patients were included in the study (54 females, 22 males, age range 19-84 years, median age 48.5 years), of whom 48 patients had arthritis and 28 arthralgias. Out of all patients with arthritis - 25 had monoarthritis, 16 - had oligoarthritis and 7 had polyarthritis. At the first visit patients with arthralgia had a median IgM 14.7 Au/ml (IQR 5.50 - 28.80) and IgG 142.7 Au/ml (IQR 82.32-237). After the treatment with Doxycycline 200 mg QD for 30 days, 52 patients came to the 2nd visit, of them 41 patients with improvement of symptoms and 11 without. More improvement was seen in the arthritis group. After treatment the median IgM in arthralgia/ arthritis groups was 22.5 Au/ml (IQR 8.72-38.82) / 13.8 Au/ml (IQR 6.03-24.15) and IgG was 42.4 Au/ml (IQR 8.15 – 90.60) / 106.7 Au/ml (IQR 23.57-203.95). In both groups with arthralgias or arthritis, patients who had a positive clinical response after treatment had a significantly lower post-treatment IgG than before treatment (p <0.05, Wilcoxon signed rank test). At the same time patients who did not respond to the treatment had no significant difference between pre- and post-treatment IgG antibodies (p> 0.05, Wilcoxon signed rank test).

Conclusion: In all patients with musculoskeletal complaints the possibility of Lyme disease should be evaluated. The decrease of antibody titers may indicate a positive prognosis in patients with musculoskeletal manifestations of Lyme disease.

Disclosure of Interests: None declared


POS1189 RHEUMATIC FEVER AND CUTANEOUS STREPTOCOCCAL INFECTION: A CASE-CONTROL STUDY IN THE LOYALTY ISLANDS, NEW CALEDONIA

O. Amic-Desvaut1,2, O. Maillard3, S. Iacobelli4, T. Bardin5, Y. M. Ducrot6, 1Hôpital Intercommunal Des Valls de l’Urvége, Endocrinologie, Saint-Jean-de-Verges, France; 2Direction de l’Action Communautaire et de l’Action Sanitaire, Centre Médico-Social de Wé, Lifou, New Caledonia; 3Université de la Réunion, Service de Pédiatrie, Saint-Pierre, La Réunion, France; 4Centre Hospitalier Universitaire Sud Réunion, Service de Néphrologie, Saint-Pierre, La Réunion, France; 5Université de Paris, INSERM UMR S1132, Hôpital Lariboisière, Paris, France; 6Direction de l’Action Communautaire et de l’Action Sanitaire, Centre Médico-Social de Wé, Lifou, New Caledonia.

Background: Acute Rheumatic Fever (ARF) and Rheumatic Heart Disease (RHD) remain major public health problems in the South Pacific. Triggering by group A beta hemolytic streptococcal (GAS) skin infection has been suspected but little documented1. Very high incidences of ARF (106/100 000) and cutaneous infections have been reported in the Loyalty Islands (New Caledonia), where health care of the 20,000 Melanesian inhabitants is centralized in a few locations and provides an extensive electronic database since 1998, and systematic screening for RHD is regularly performed.

Objectives: To explore the link between ARF, RHD and skin infections by a retrospective case-control study.

Methods: The study was approved by the New Caledonian committee of Ethics and dealt with patients aged 6 to 26 years, seen from 1998 to 2018. Cases were ARF and/or RHD. Definite ARF was diagnosed according to the Jones criteria; additional cases with strong clinical suspicion were also included as probable cases. RHD was diagnosed by cardiac ultrasound scan allowing definite and borderline diagnosis2. Sore throat and presumed streptococcal cutaneous infections were diagnosed by an algorithm, previously validated on a sample of 3000 events by an experimented clinician, which identified specific medical terms and ICD-10 codes in the electronic medical records. Each case was matched with 3 controls (without ARF and RHD) of same age, sex and living location. Infections were retrieved from the electronic medical records during the month, 6 months, one year, 5 years preceding the date of the first ARF/RHD diagnosis, for each case with the same index date for its matched control, and since birth. Numbers of infections per these time intervals were compared between cases and controls by univariate and multivariate conditional regression analysis in the total study population and its various subcategories (definite or probable ARF, definite or borderline RHD).

Results: 311 cases of ARF and RHD including 206 definite cases were identified. Polyarthralgias (48%) were the main clinical presentation. Marginal erythema was not seen and Sydenham chorea was rare (6.8%). Mean age of diagnosis was 10.6 ± 3.8 years. Skin infection episodes were 3 to 4 times more frequent than sore throats in all studied time-intervals. Multivariate analysis showed an increased exposure to skin infections and sore throats in the year preceding ARF/RHD diagnosis in the whole population of cases as compared to controls (OR 2.18, 95% CI 1.46, 3.26 and 1.54, 95% CI 1.01, 2.36 respectively); skin infections (but not sore throat) were also increased the 206 definite cases (OR 1.34, 95% CI 1.01, 1.80) and in the 220 definite and probable ARF (OR 1.47, 95% CI 1.11, 1.94). In addition we observed a correlation between the seasonality of ARF and skin infections, which were both more frequent during the rainy season, and an overlap of areas with high incidence of ARF and areas with high incidence of skin infections.

Conclusion: Our results support the hypothesis that GAS skin infections play a role in the pathophysiology of ARF/RHD. In view of these results, there is an urgent need to implement preventive measures to reduce the incidence of skin infections in the Loyalty Islands.

REFERENCES:

Acknowledgements: We would like to thank, Marie-Rose Waia, Emilie Gaze, Julien Rannou from Direction de l’Action Communautaire et de l’Action Sociale, Dr Jean-Michel Meunier and Nina Guillot from Agence Sanitaire et Sociale of New Caledonia.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4436
COVID-19

POS1190

IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: DISRUPTIONS IN CARE AND SELF-REPORTED OUTCOMES

A. M. Fouad1, S. F. Elotia, E. Nourhan Elameen2, A. E. Mohamed1. 1Faculty of Medicine, Suez Canal University; 2Department of Public Health, Occupational and Environmental Medicine, Ismailia, Egypt.

Background: The COVID-19 pandemic represents a challenge to the care of patients with rheumatic and musculoskeletal diseases (RMDs). Patients were interviewed for sociodemographic and disease-related history. Further assessments were performed using Kessler 6-items (1), Fear of COVID-19 scale (2), and COVID-19-Impact on Quality-of-Life scale (3).

Methods: This cross-sectional study involved 120 RMDs patients at the rheumatology department at Suez Canal University Hospital in Ismailia, Egypt. Patients were interviewed for sociodemographic and disease-related history. Further assessments were performed using Kessler 6-items (1), Fear of COVID-19 scale (2), and COVID-19-Impact on Quality-of-Life scale (3).

Results: Patients with rheumatoid arthritis and systemic lupus erythematosus made up most of our sample (72.5%, 19.2% respectively). About 50% of patients were experiencing limitation in the access to rheumatologic care, and a similar percentage had changed or discontinued their medications. DMARDs shortage while anticytokines preserved immunogenicity. The effects of cumulative methotrexate and glucocorticoid doses on immunogenicity should be considered.

Conclusion: The pandemic negatively influenced the mental health, quality of life, adherence to medications, access to rheumatology care, and disease control of RMDs patients.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3

POS1192

INCIDENCE AND RISK FACTORS OF COVID-19 IN PATIENTS WITH VASCULITIS: A DANISH NATIONWIDE COHORT STUDY

S. Kristensen1,2, R. L. Cordtz1,3,4, K. Duch1,4, J. Lindhardsen5, C. Torp-Pedersen6,7, Aalborg University Hospital North, Rheumatology, Aalborg, Denmark; Aalborg University Hospital, Clinical Medicine, Aalborg, Denmark; Gentofte Hospital, Center for Rheumatology and Spine Diseases, Hellerup, Denmark; Aalborg University Hospital, Unit of Clinical Biostatistics, Aalborg, Denmark; Rigshospitalet, Lupus and Vasculitis Clinic, Center for Rheumatology and Spine Diseases, København, Denmark; North Zealand Hospital - Hillerød, Cardiology, Hillerød, Denmark; Copenhagen University, Department of Public Health, København, Denmark

Background: Patients with small vessel vasculitis (SVV) and large vessel vasculitides (LVV, including giant cell arteritis (GCA)) are considered at higher risk of infections compared to the general population, owing to their underlying condition and the use of immunosuppressive drugs. Thus, the risk of COVID-19 infection and related outcomes during the global pandemic is of immediate concern to rheumatologists worldwide.

Objectives: To estimate the incidence of COVID-19 hospitalisation in patients with vasculitis, and to evaluate the impact of glucocorticoid treatment on the outcome between March 2020 and February 2021.

<table>
<thead>
<tr>
<th>Abatacept</th>
<th>HCQ</th>
<th>Cumulative glucocorticoid dose</th>
<th>Cumulative methotrexate dose</th>
<th>Age &gt; 65 years</th>
<th>Disease duration &gt;10 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seronversion</td>
<td>(\beta = 0.1)</td>
<td>(\beta = 0.22)</td>
<td>(p = 0.01)</td>
<td>(\beta = 0.26)</td>
<td>(\beta = 0.19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(p = 0.04)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG anti-spike levels</td>
<td>(\beta = 0.13)</td>
<td>(\beta = 0.27)</td>
<td>(p = 0.01)</td>
<td>(\beta = 0.25)</td>
<td>(\beta = 0.29)</td>
</tr>
<tr>
<td></td>
<td>(p = 0.001)</td>
<td>(p = 0.004)</td>
<td></td>
<td></td>
<td>(p = 0.001)</td>
</tr>
<tr>
<td>CD4 T-cell response</td>
<td>(\beta = 0.1)</td>
<td>(\beta = 0.10)</td>
<td>(p = 0.04)</td>
<td>(\beta = 0.04)</td>
<td>(\beta = 0.03)</td>
</tr>
<tr>
<td></td>
<td>(p = 0.03)</td>
<td>(p = 0.24)</td>
<td>(p = 0.61)</td>
<td></td>
<td>(p = 0.64)</td>
</tr>
<tr>
<td>CD8 T-cell response</td>
<td>(\beta = 0.08)</td>
<td>(\beta = 0.20)</td>
<td>(p = 0.01)</td>
<td>(\beta = 0.1)</td>
<td>(\beta = 0.02)</td>
</tr>
<tr>
<td></td>
<td>(p = 0.02)</td>
<td>(p = 0.12)</td>
<td>(p = 0.43)</td>
<td></td>
<td>(p = 0.24)</td>
</tr>
</tbody>
</table>

The table shows the incidence and risk factors of COVID-19 in patients with vasculitis, with a focus on the impact of glucocorticoid treatment on the outcome between March 2020 and February 2021.
Methods: With use of the Danish nationwide registers, a cohort of patients with LVV and SVV, respectively, and general population controls (GPCs) matched on age and gender was established. Hazard ratios (HR) for COVID-19 hospitalisation was estimated. National COVID-19 surveillance data was used to calculate the odds ratio (OR) of having a positive SARS-CoV2 PCR test. Lastly, a nested case-control design and conditional logistic regression was used to estimate the impact of glucocorticoids on the risk of hospitalisation.

Results: Patients with SVV (n=1090) had an increased incidence of COVID-19 hospitalisation compared with GPCs (comorbidity-adjusted HR 2.73; 95% CI 1.64-4.55), with dose of increasing qd) and seen in patients with LVV. Patients with vasculitis had similar likelihoods of having had a positive PCR test as GPCs. Glucocorticoids did not increase the HR of hospitalisation among patients with LVV or SVV.

Conclusion: Patients with SVV were more likely to be admitted with COVID-19 than the GPCs. The impact of glucocorticoid treatment on the risk of hospitalisation needs further investigation.


Disclosure of Interests: Salome Kristensen: None declared, René Lindhardsen Cordtz: None declared, Kirsten Duch: None declared, Jesper Lindhardsen: None declared, Christian Torp-Pedersen Grant/research support from: Received grants from Bayer and Novo Nordisk outside the present work, Lene Dreyer Grant/research support from: Received grants from Bayer and Novo Nordisk outside the present work, DOI: 10.1136/annrheumdis-2022-eular.34

**POS1193 COVID-19 IN PATIENTS WITH GIANT CELL ARTERITIS**

J. Kramarič1, R. Jesese2, M. Tomcic3, Z. Rotar3, A. Hočevar1,2,3

1University Medical Centre Ljubljana, Department of Rheumatology, LJUBLJANA, Slovenia; 2Modra Jagodica d.o.o., LJUBLJANA, Slovenia; 3Medical Faculty, University of Ljubljana, Internal Medicine, LJUBLJANA, Slovenia

Background: Patients with giant cell arteritis (GCA) represent a fragile population with an increased infection risk. In a recent study, older age, a higher number of comorbidities, higher disease activity, and prednisolone ≥10mg qd were associated with worse COVID-19 outcomes.

Aims: We aimed to evaluate the frequency and severity of COVID-19 in a well-defined GCA cohort.

Methods: We reviewed medical records of historically and/or by imaging proven GCA patients diagnosed between September 2011 and February 2020 at our secondary/tertiary center and followed during the COVID-19 pandemic between March 2020 and December 2021 (22 months). Descriptive statistics was used to analyze the studied population.

Results: Of 314 GCA patients diagnosed for the first time during a 102-month period, 49 patients died before March 2020. Of the remaining 265 patients (69.4% females), SARS-CoV-2 infection was proven by PCR test in 39 (14.7%) patients (74.2% females, mean SD) age at infection 76.2 (±9.6 years), 13 (33.3%) with large vessel GCA and 16 with cranial limited GCA). At the time of SARS-CoV-2 infection GCA was in a stable remission in 38 patients (13 without therapy, 10 on steroids alone, 9 on leflunomide monotherapy, 6 on steroids plus leflunomide (10 or 20mg qd), 1 on ustekinumab; mean prednisolone equivalent dose of 4.6mg qd) and relapsed in one patient 6 weeks earlier (prednisolone 30mg plus leflunomide). Data on clinical manifestations of COVID-19 were available for 33 (84.6%) patients and are presented in Table 1, Part A. Twenty-nine/39 (74.4%) patients had mild COVID-19 and were symptomatically treated at home, while 10 patients had severe infection (defined as a need of hospitalization and/or death), and one of those patients died due to COVID-19. One patient developed a transient neurologic ischemic attack related to COVID-19. Table 1, Part B shows differences in GCA demographic and treat-ment at the time of mild vs. severe infection. We found no differences in gender, age, GCA type and GCA treatment between those with mild vs. severe COVID. Three patients developed COVID-19 after receiving two doses of anti-COVID vaccine (1.4% breakthrough rate). Overall, 257 GCA patients eligible for vaccination, 210 (81.7%) were vaccinated by the end of December 2021.

Conclusion: A quarter of our GCA patients had severe COVID-19. Low doses of glucocorticoids and treatment with leflunomide were not associated with severe COVID-19 course in our cohort.


Disclosure of Interests: None declared


**POS1194 COVID-19 IN PATIENTS WITH INFLAMMATORY MYOPATHY**

A. Hočevar1,2, B. Radic3, M. Krosel1, M. Tomcic1, Z. Rotar1,2,3

1University Medical Centre Ljubljana, Department of Rheumatology, LJUBLJANA, Slovenia; 2Medical Faculty, University of Ljubljana, Internal Medicine, LJUBLJANA, Slovenia; 3Celje General Hospital, Department of Rheumatology, Celje, Slovenia

Background: Older age, male sex, multimorbidity and glucocorticoids emerged in rheumatic patients as risk factors for severe COVID-19.

Objectives: We aimed to evaluate the frequency and severity of COVID-19 in a well-defined cohort of patients with idiopathic inflammatory myopathy (IIM).

Methods: We analyzed medical records of IIM patients diagnosed and followed at our secondary/tertiary center between January 2005 and December 2021.

Results: During the 204-month period IIM was newly diagnosed in 191 patients, of whom 52 died before COVID-19 pandemic. Of the remaining 139 patients (69.8% females; 9 polyomylitis, 47 dermatomyositis; 38 antisynthetase syndrome, 26 overlap syndrome; 17 immune mediated necrotizing myopathy; 2 inclusion body myositis), SARS-CoV-2 infection was proven in 13 (9.4%) patients (61.5% females, mean SD age at infection 62.9 (±16.8 years)). Seven/13 COVID-19 patients (53.8%) had a diagnosis of antisynthetase syndrome. At the time of infection IIM was in a remission in 12/13 patients and relapsed 5 weeks earlier in one patient. Seven patients were without immunomodulatory therapy, 1 patient was on steroids alone, 2 on DMARD alone, 3 on steroids and DMARD; a mean daily prednisolone equivalent dose was 5mg). Eleven/13 (84.6%) patients had mild COVID-19 (one had an asymptomatic infection) and were treated symptomatically, while 2 patients were hospitalized due to severe infection (respiratory insufficiency). Table 1 shows clinical characteristics and duration of COVID-19 symptoms. During pandemic overall 9/139 (6.5%) patients with IIM died, including one patient due to COVID-19.

Table 1. Characteristics of COVID-19 in IIM patients

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>PM/DMS/myositis</td>
<td>1/7</td>
<td>COVID-19 duration (days)</td>
<td>14 (±5)</td>
<td>Respiratory insufficiency</td>
<td>2</td>
</tr>
<tr>
<td>IMNM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>/ M gender</td>
<td>8/5</td>
<td>Fever</td>
<td>9</td>
<td>Neurosis</td>
<td>1</td>
</tr>
<tr>
<td>Age (years)</td>
<td>62 (±16)</td>
<td>Headache</td>
<td>4</td>
<td>Diarhoea</td>
<td>1</td>
</tr>
<tr>
<td>IIM therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td>1</td>
<td>Snell loss</td>
<td>3</td>
<td>Vertigo</td>
<td>1</td>
</tr>
<tr>
<td>DMARD</td>
<td>2</td>
<td>Taste loss</td>
<td>3</td>
<td>Myalgia</td>
<td>2</td>
</tr>
<tr>
<td>Steroids+DMARD</td>
<td>3</td>
<td>Cough</td>
<td>4</td>
<td>Arthralgia</td>
<td>2</td>
</tr>
<tr>
<td>No treatment</td>
<td>7</td>
<td>Dyspnea</td>
<td>5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: IIM idiopathic inflammatory myopathy; PM polyomylitis, DM dermatomyositis; A&SyS antisynthetase syndrome, OS overlap syndrome; IMNM immune mediated necrotizing myopa-thy; F female; M male; DMARD immunomodulatory drug.

Conclusion: In our IIM cohort, antisynthetase syndrome represented a higher relative risk for COVID-19 compared to other IIM subtypes.

Disclosure of Interests: None declared


**POS1195 CAN PRE-TREATMENT INFLAMMATORY BIOMARKER LEVELS GUIDE TO DETERMINE APPROPRIATE TIME OF TOCILIZUMAB THERAPY IN COVID-19**

D. Teker1, M. Çınar1, M. N. Kay1, F. Bicakci1, S. Colak1, E. Tekgoz2, S. Yılmaz1,2

1University of Health Sciences Turkey, Gülhane Training and Research Hospital, Rheumatology, Ankara, Turkey

DOI:

Disclosure of Interests: None declared

Background: Due to the pleiotropic cytokine interleukin-6 (IL-6) plays a pivotal role in the pathogenesis of COVID-19, tocilizumab, an inhibitor of the IL-6 receptor, was considered as an attractive therapeutic option. When the inflammation cascade is excessive and therapy is delayed, the efforts for suppression of inflammation does not necessarily reduce mortality in all cases. Besides, early using anti-cytokine therapy may lead to both increased cost and risks including iatrogenic immunosuppression (1). Defining of patients who will benefit from tocilizumab and determining optimal timing of tocilizumab will prevent drug-related side effects and increased costs due to unnecessary drug use.

Objectives: To investigate the reliability of pre-treatment levels of prognostic nutritional index (PNI), C-reactive protein/albumin ratio (CAR), systemic immune-inflammatory index (SII), IL-6, lactate dehydrogenase (LDH) as a treatment response biomarker in hospitalized COVID-19 patients who administered tocilizumab.

Methods: One hundred thirty three COVID-19 patients received tocilizumab were included. The end-points of treatment effectiveness were evaluated with the rate of death and emerging need for mechanical ventilation at 28 days of hospitalization. To determine independent mortality risk factors, multivariate logistic regression analyzes were performed for statistically different variables among groups that were statistically different in univariate analysis. The capacity of IL-6, CAR, PNI, SII and LDH values in predicting of tocilizumab response in COVID-19 patients were analyzed using receiver operating characteristic (ROC) curve analysis.

Results: 34 (25.56%) patients died after tocilizumab therapy. Patients who improved after tocilizumab were significantly younger and had significantly lower IL-6, LDH, SII, CAR and higher PNI than patients who died. In univariate analyses, mortality was significantly associated with age, IL-6, LDH, PNI, SII, CAR and CRP. In multivariate analysis, age (OR:1.070, 95%CI:1.019-1.124, p<0.007) and LDH (OR:1.006, 95%CI:1.003-1.010, p<0.001) were found to be independent predictors of mortality after tocilizumab therapy. To identify of tocilizumab response in COVID-19 patients, IL-6 had the highest area under curve (AUC=0.782, 95%CI:0.694-0.870), followed by LDH (AUC=0.761, 95%CI:0.661-0.861), PNI (AUC=0.696, 95%CI:0.584-0.807), SII (AUC=0.671, 95%CI:0.551-0.790), CAR (AUC=0.682, 95%CI:0.578-0.786) and CRP (AUC=0.643, 95%CI:0.535-0.751). Predictive performance of inflammatory biomarkers in the prediction of mortality after tocilizumab therapy was presented in Table 1.

Table 1. Predictive performance of inflammatory biomarkers in the prediction of mortality after tocilizumab therapy

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>PLR</th>
<th>NLR</th>
<th>PPV</th>
<th>NPV</th>
<th>Accuracy</th>
<th>DOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-6 (pg/mL)</td>
<td>&gt;143.12</td>
<td>64.71%</td>
<td>84.85%</td>
<td>4.27</td>
<td>0.42</td>
<td>59.46%</td>
<td>87.50%</td>
<td>79.70%</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>&gt;460</td>
<td>73.53%</td>
<td>71.72%</td>
<td>2.60</td>
<td>0.37</td>
<td>47.17%</td>
<td>88.75%</td>
<td>72.18%</td>
</tr>
<tr>
<td>PNI &gt;31.35</td>
<td>&gt;50.00</td>
<td>59.88%</td>
<td>79.80%</td>
<td>2.77</td>
<td>0.55</td>
<td>48.72%</td>
<td>84.04%</td>
<td>73.68%</td>
</tr>
<tr>
<td>SII &gt;3895</td>
<td>&gt;50.00</td>
<td>47.06%</td>
<td>90.91%</td>
<td>5.38</td>
<td>0.58</td>
<td>64.02%</td>
<td>83.33%</td>
<td>79.70%</td>
</tr>
<tr>
<td>CAR &gt;61.15</td>
<td>&gt;50.00</td>
<td>61.76%</td>
<td>67.68%</td>
<td>1.91</td>
<td>0.56</td>
<td>39.62%</td>
<td>83.75%</td>
<td>66.17%</td>
</tr>
<tr>
<td>CAR</td>
<td>C-reactive protein/albumin ratio; DOR: diagnostic odds ratio; IL-6: interleukin-6; LDH: lactate dehydrogenase; NLR: negative likelihood ratio; PPV: positive predictive value; PLR: positive likelihood ratio; PNI: prognostic nutritional index; PPV: positive predictive value; SII: systemic immune-inflammatory index.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Although the patients with significantly lower IL-6, LDH, SII, CAR and higher PNI levels improved after tocilizumab therapy, only serum LDH levels and age were found to be as independent predictors of mortality. To specify the optimal time interval and the patients who will benefit from tocilizumab, these biomarkers may be used.

REFERENCES:
in both groups. There were also no significant differences in the vaccine-related anxiety levels. However, the expectation of vaccine efficacy was higher in the acceptance group and significantly influenced vaccination intention as revealed by multivariate analyses (Table 1).

Conclusion: The perception of vaccine efficacy is strongly correlated with vaccine acceptance. In order to promote vaccination in patients with RMDs, this study suggests that emphasizing the efficacy of the vaccine may be more effective than alleviating anxiety about the adverse effects of the vaccine.

REFERENCES:


Figure 1.

Conclusion: Despite a widespread use of remote consultations during the pandemic, nationwide questionnaire surveys performed at three time-points during the COVID-19 pandemic showed that most patients were satisfied with access to rheumatic counseling. Nevertheless, in-person contacts were preferred by most patients, mainly women and elderly.

REFERENCES:

Acknowledgements: Patients and Danish departments contributing to the DANBIO registry. Lundbeck foundation for funding.

Disclosure of Interests: Bente Glintborg Grant/research support from: AbbVie, BMS, Pfizer, Dorte Vendelbo Jensen: None declared, Lene Terslev: None declared, Henning Hendriks: None declared, Niels Steen Krogh: None declared, Jette Nørgaard Agerbo: None declared, Anne Gitte Loft: Speakers bureau: AbbVie, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and UCB, Grant/research support from: Abbv, BMS, Celgene, Merck, Novartis, Simon Horskjær Rasmussen: None declared, Melissa Pfeffer-Jensen: None declared, Thomas Adelsten: None declared, Ada Colic: None declared, Kamilla Danebod: None declared, Malene Kildemand: None declared, Christian Møller Sorensen: None declared, Nils Steen Krogh: None declared, Jette Nørgaard Agerbo: None declared, Connie Ziegler: None declared, Merete Lund Heltand: Grant/research support from: Abbv, Biogen, BMS, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopis, Sandoz

DOI: 10.1136/annrheumdis-2022-eular.491
Background: Vaccine trials of the SARS-CoV-2 mRNA vaccines were encouraging but excluded most patients with rheumatic diseases (RD) and patients treated with immunosuppressive therapy. However, reports of a more severe COVID-19 disease course in patients with RDs prompted strategies for expediting vaccination of RD patients in most countries. In addition to the impact experienced by most people of the pandemic, patients with RDs were adversely impacted by the potential risk of severe COVID-19 due to their disease and immunosuppressive treatment. Fear of COVID-19 led to disproportionate anxiety, self-isolation, and shielding behavior for many RD patients at the beginning of the pandemic.

Objectives: We investigated antibody levels in serum against SARS-CoV-2 after a two-dose vaccination with an mRNA vaccine in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Further, we examined the association between reactogenicity and immunogenicity and how vaccination influenced patient behavior concerning fear of COVID-19 and shielding.

Methods: Patients with SLE or RA from the COPANORD (Corona PANdemic Autoimmune Rheumatic Disease) cohort received two doses of an mRNA vaccine between January and August 2021 and had total antibodies against SARS-CoV-2 measured before vaccination and 2 and 9 weeks after the second vaccination. In addition, patients answered an electronic questionnaire before and eight weeks after vaccination concerning behavior, anxiety, and symptoms of depression (PHQ-9).

Results: Three-hundred-and-three patients and 44 blood donors (healthy controls) were included. Significantly fewer patients (90%) had measurable antibodies against SARS-CoV-2 compared to blood donors (100%) after the second vaccination (p<0.001) (Figure 1). Treatment with Rituximab was the strongest predictor of unfavorable vaccine response, as only 27% were seropositive after vaccination. We found a negative effect of prednisone and methotrexate but no effect of age, comorbidity, or pausing medication on seroconversion. Patients experienced significant improvement after vaccination in 10 out of 12 questions regarding behavior and fear of COVID-19. But no change was observed in symptoms of depression (p=0.62) or anxiety (p=0.46).

Conclusion: The majority of patients with SLE or RA had a measurable serological response to the COVID-19 mRNA vaccine after two doses. Treatment with Rituximab was the strongest predictor of no seroconversion. Our findings warrant encouragement of vaccination against COVID-19 for patients with RD, as most patients benefit with both a serological immune response and reduced isolation and shielding behavior.

REFERENCES:

Disclosure of Interests: None declared

POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID-19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID


Background: Comorbidities, particularly cardiometabolic disorders, are highly prevalent in patients with psoriatic arthritis (PsA) and they were associated with an increased risk of atherosclerotic cardiovascular disease, which have been associated with higher morbidity and mortality. Whether PsA enhances the risk of SARS-CoV-2 infection or affects the disease outcome remains to be ascertained.

Objectives: To describe the sociodemographic, clinical and treatment characteristics of patients with PsA with confirmed SARS-CoV-2 infection from the SAR-COVID registry and to identify the variables associated with poor COVID-19 outcomes, comparing them with those with rheumatoid arthritis (RA).

Methods: Cross-sectional observational study including patients ≥18 years old, with diagnosis of PsA (CASPAR criteria) and RA (ACR / EULAR 2010 criteria), who had confirmed SARS-CoV-2 infection (RT-PCR or serology) from the SAR-COVID registry. Recruitment period was between August 13, 2020 and July 31, 2021. Sociodemographic variables, comorbidities, and treatments were analyzed. To assess the severity of the infection, the ordinal scale of the National Institute of Allergy and Infectious Diseases (NIAID)1 was used, and it was considered that a patient met the primary outcome, if they presented criteria of categories 5 or higher on the severity scale. For this analysis, Chi2 test, Fisher’s test, Student’s test or Wilcoxon test, and binomial logistic regression using NIAID≥5 as dependent variable were performed.

Results: A total of 129 PsA patients and 808 with RA were included. Clinical characteristics are shown in Table 1. Regarding PsA treatment, 12.4% of PsA were receiving IL-17 inhibitors, 5.4% IL12-23 inhibitors, one patient apremilast and one abatacept. The frequency of NIAID≥5 was comparable between groups (PsA 19.5% vs RA 20.1%; p=0.976). (Figure 1).

Figure 1. Total antibody response against SARS-CoV-2 after two mRNA vaccines. Antibody response against mRNA COVID-19 vaccine pre-vaccination, 1 and 9 weeks after in patients with rheumatic diseases and 5-6 weeks after vaccination in blood donors. (A) Percentage with measurable SARS-CoV-2 antibodies results after vaccination. (B) Levels of SARS-CoV-2 antibodies in serum.
Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients had a better outcome. Patients who received biological DMARDs (OR 0.28; 95% CI 0.09–0.78) had a lower risk of hospitalization compared to those who received conventional DMARDs (OR 1.06; 95% CI 1.02–1.11) was associated with a worse outcome of the COVID-19 infection.

**Conclusion:** Although PsA patients have a higher frequency of cardiovascular and metabolic comorbidities than those with RA, the COVID-19 severity was similar. Most of the patients had mild SARS-CoV-2 infection and a low death rate. These findings could be explained by the introduction of the glucocorticoids and immunosuppressive treatment and COVID 19 clinical characteristics, complications and outcomes: hospitalization, intensive care unit (ICU) admission, use of mechanical ventilation and death were compared among groups. Descriptive statistical analysis was performed. Variables were compared with Chi squared test and Student T test or Mann Whitney test. Multivariable logistic regression models with forward and backward selection method, using hospitalization, ICU admission and death as dependent variables were carried out.

**Results:** A total of 1777 patients were included, 1342 from the first wave and 435 of the second one. Patients had a mean (SD) age of 50.7 (14.2) years and 81% were female. Both groups of patients were similar in terms of socio-demographic features, disease diagnosis, disease activity, the use of glucocorticoids ≥ 10 mg/day and the immunosuppressive drugs (Table 1 below). Patients infected during the first wave have higher frequency of comorbidities (49% vs 41%; p < 0.004). Hospitalizations due to COVID 19 (31% vs 20%; p < 0.001) and ICU admissions (9% vs 5%; p = 0.009) were higher during the first wave. No differences in the use of mechanical ventilation (16% vs 16%; p = 0.97) nor in the mortality rate (5% vs 4%; p = 0.41) were observed. In the multivariable analysis, after adjusting for demographics, clinical features and immunosuppressive treatment, patients infected during the second wave were 40% less likely to be hospitalized (OR= 0.6, IC95% 0.4-0.8) and to be admitted to the ICU (OR= 0.6, IC95% 0.3-0.9).

**Conclusion:** The impact of COVID 19 in Argentina, in terms of mortality in patients with IMADs was still higher compared to the general population during the second wave. However, the frequency of hospitalizations and ICU admissions was lower. These findings could be explained by the introduction of the SARS CoV 2 vaccination and, probably, by the cumulative knowledge and management improvement of this infection among physicians.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.715

**Table 1.** Differences between the first and the second wave of SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases in Argentina: Data from the SAR-COVID registry.

<table>
<thead>
<tr>
<th>Disease activity</th>
<th>RA (n=1342)</th>
<th>PsA (n=435)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female gender</td>
<td>81</td>
<td>80</td>
<td>0.7</td>
</tr>
<tr>
<td>Age (years)</td>
<td>510 (14.5)</td>
<td>500 (13.3)</td>
<td>0.2</td>
</tr>
<tr>
<td>Disease diagnosis</td>
<td>Rheumatoid arthritis</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Ankylosing spondylitis</td>
<td>10</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Systemic lupus erythematosus</td>
<td>17</td>
<td>185</td>
</tr>
<tr>
<td></td>
<td>Systemic Sclerosis</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>SJögren’s syndrome</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Inflammatory myopathies</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Vasculitis</td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>

**Conclusion:** The impact of COVID 19 in Argentina, in terms of mortality in patients with IMADs was still higher compared to the general population during the second wave. However, the frequency of hospitalizations and ICU admissions was lower. These findings could be explained by the introduction of the SARS CoV 2 vaccination and, probably, by the cumulative knowledge and management improvement of this infection among physicians.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.776

**Table 1.** Characteristics of patients with PsA and RA who presented COVID-19 in the SAR-COVID registry.

<table>
<thead>
<tr>
<th>PsA (n=129)</th>
<th>RA (n=608)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>51.7 (12.7)</td>
<td>53.1 (12.9)</td>
</tr>
<tr>
<td>Female</td>
<td>72 (55.8)</td>
<td>684 (84.7)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>65 (50.4)</td>
<td>355 (43.9)</td>
</tr>
<tr>
<td>Obesity (BMI ≥30)</td>
<td>19 (15.2)</td>
<td>102 (13.4)</td>
</tr>
<tr>
<td>Morbid obesity (BMI ≥40)</td>
<td>1 (0.8)</td>
<td>10 (1.3)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>35 (28.5)</td>
<td>205 (26.8)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>16 (13.0)</td>
<td>67 (8.8)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>24 (19.5)</td>
<td>102 (13.5)</td>
</tr>
<tr>
<td>Cardiovascular or cerebrovascular disease</td>
<td>5 (4.1)</td>
<td>32 (3.9)</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.715
Results: The incidence of AE was 1825 events/1000 doses, were significantly higher for mRAN-1273 and ChAdOx1 nCoV-19 and lower for BBIBP-CorV. Most common AE was pseudo-flu syndrome. Female sex, being younger, higher education level, ChAdOx1 nCoV-19 and mRAN-1273 vaccines, the use of methotrexate and antimalarials were related of EA in patients with RD.

References:

value was 100% (95% CI: 59%, 100%) for serologic response to the mRNA booster. Positive predictive value of time >6 months from last rituximab to the booster was 78.3% (95% CI 56.3%, 92.5%) and the negative predictive value was 62.5% (95% CI 24.5%, 91.5%).

Conclusion: Presence of detectable B-cells and longer time from last rituximab was associated with the development of SARS-CoV-2 spike protein antibodies following the booster vaccine. These factors should be considered in timing of administration of booster vaccine doses in previously unresponsive rituximab treated patients.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.903

POS1203

INCREASED PROTEASE-ACTIVATED RECEPTOR 1 AUTOANTIBOIES ARE ASSOCIATED WITH SEVERE COVID-19

F. Tran1, A. Scharmacher2, H. Grasshoff2, S. Schinke2, N. Kaeding3, J. Bernades1, J.Y. Humrich2, O. Cabral-Marques4, K. Gaede5, C. Lange5, J. Rupp6, P. Rosenstiel1, B. F. Hoyer3, K. Schulze-Forster7, H. Heidecke7, J. Y. Humrich2, O. Cabral-Marques4, K. Gaede5, C. Lange5, Principia, Hashomer, Ramat-Gan, Israel; 8Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel

Background: In acute COVID-19 infection, growing evidence hints towards a broad activation of plasma cells and the presence of pathologic autoantibodies (abs). A systematic screenning for abs confirmed induction of diverse functional abs by SARS-CoV-2 infection. 1, 2. Immun-mediated thrombosis, involving platelet activation, has been identified as one of the key pathogenic mechanisms in COVID-19 and is linked to morbidity and mortality. 3. As natural abs against G protein-coupled receptors, functional abs against the thrombin receptor type-1 (PAR-1) might predispose for increased activation of the coagulation system present in COVID-19 infection.

Objectives: The aim of this study is to identify the diagnostic value of anti-PAR1 antibodies and their capacity to predict the outcome of COVID-19 infection.

Methods: 82 serum samples from 55 individuals with COVID-19 derived from three different hospitals in Schleswig-Holstein, Germany, and 88 single time point samples from healthy controls were subjected to ELISA-based quantification of anti-PAR-1 abs (CellTrend GmbH Luckenwalde, Germany). The levels of anti-AT1R abs were compared with clinical and laboratory parameters.

Results: COVID-19 patients revealed markedly increased levels of circulating anti-PAR1 abs in hospitalized patients particularly in those required intensive care treatment in comparison to controls (p < 0.0001, Figure 1a). Anti-PAR1 ab levels were highest in patients with fatal outcome (p = 0.006, Figure 1a). Receiver operating characteristic (ROC) analysis of PAR1 abs levels in COVID-19 patients revealed a sensitivity of 84.00% and a specificity 79.25% for patients requiring intensive care unit (ICU) treatment and a sensitivity of 87.50 % and a specificity 84.51 % to distinguish fatal vs. non-fatal disease outcome (Figure 1b). We found correlation of circulating anti-PAR1 abs with D dimers.

POS1204

SARS-COV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA


1CEMIC Centro de Educación Médica e Investigaciones Clínicas Norberto Quiro, Rheumatology Section, Buenos Aires, Argentina; 2On behalf of the ARGENTINA COVID-19 registry.

Background: Patients with rheumatic diseases (RD) have been excluded from SARS-CoV-2 vaccine trials. Though data appear to show safety and efficacy, mostly evidence remains in mRNA vaccines. However in our country, adenovirus and inactivated vaccines, as well as heterologous schemes are frequently used.

Objectives: To describe clinical characteristics and outcomes of SARS-CoV-2 infection after vaccination in patients with RD from the ARGENTINA COVID-19 registry.

Methods: Adult patients with RD who have been vaccinated for SARS-CoV-2 and have confirmed SARS-CoV-2 infection (RT-PCR o serology) were collected. The event was diagnosed at least 14 days after first dose and at complete scheme when it occurred > 14 days after second dose. Homologous scheme is defined by each dose of vaccine coming from the same manufacturer.

Results: 930 patients treated for SARS-CoV-2 infection were included. To compare SARS-CoV-2
infection characteristics in not vaccinated patients, subjects from the SAR-COVID registry, which includes patients with RD and SARS-COV-2 infection, were matched 2:1 by gender, age, and RD. WHO-Ordinal Scale was used to define unfavorable infection outcome. Descriptive statistics, Chi2 test, Fischer test, T test and ANOVA were used. Results: A total of 1350 patients from the SAR COVAC registry were included, 67 (5%) presented SARS-Cov-2 infection after vaccination. The later were mostly (72%) females with a mean age of 57 (SD 15) years old. The most frequent RD were rheumatoid arthritis (41%), psoriatic arthritis (12%) and systemic juvenile idiopathic arthritis (10%). At home (75%) had low disease activity or remission, 19% were taking steroids, 39% methotrexate, 27% bDMARDs and 6% JAK inhibitors. A total of 11 (16%) patients had SARS-CoV-2 infection <14 days after the first vaccine dose, 39 (58%) after an incomplete scheme and 17 (25%) following a complete one. In the incomplete scheme group, 59% received Gam-COV-Vac, 31% ChAdOx1 n-CoV-19 and 10% BBIBP-CoV; and in patients with complete scheme 47%, 24% and 29%, respectively. No event was reported after a complete heterologous scheme. No significant differences regarding sociodemographic characteristics, RD, disease treatment, type of vaccine and regimen was found between in those with infection and those without it. After vaccination only 8 (12%) of the patients who got infected had an unfavorable course, 88% of them following an incomplete scheme (5 received Gam-COV-Vac, 1 ChAdOx1 n-CoV-19 and 1 BBIBP-CoV) and one subject after a complete homologous Gam-COV-Vac scheme. Having an unfavorable outcome of SARS-Cov-2 infection was associated to: male gender [83% vs 24%, p=0.036], older age [mean 70 years (SD 7) vs 55 years (SD 15), p=0.005], being Caucasian [100% vs 54%, p=0.018], higher education [mean 17 years (SD 4) vs 12 years (SD 4), p=0.010], the presence of comorbidities [100% vs 39%, p=0.001, having pulmonary disease [37% vs 5%, p=0.019], dyslipidemia [63% vs 17%, p=0.011] and arterial hypertension [63% vs 24%, p=0.036], RD, treatments, disease activity and types of vaccines received were comparable between groups. When comparing patients with and without vaccination prior SARS-CoV-2 infection, those who received at least one dose of vaccine had less frequently severe COVID-19 (12% vs 24%, p=0.067) and presented lower mortality due to COVID-19 (3% vs 6%, p=0.498). However these differences did not reach statistical significance.

Conclusion: In the SAR-COVC registry 5% of the patients had SARS-CoV-2 infection after vaccination, most of them mild and 25% after a complete scheme. Any vaccine was associated with severe COVID-19. When comparing with non-vaccinated patients, those with at least one dose, had less frequently severe outcome and died due COVID-19.

Disclosure of Interests: None declared


POS1205 COVID-19 IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES - DATA FROM THE ROMANIAN REGISTRY OF RHEUMATIC DISEASES

D. Minca1, A. Minca2, C. E. Ionescu1, O. G. Dinache1, C. Popescu1, M. Agache1, L. Enache1, C. Mogosan1, C. Codreanu1. 1Center of Rheumatic Diseases, Rheumatology, Bucharest, Romania; 2University Emergency Hospital of Bucharest, Internal Medicine, Bucharest, Romania

Background: Registries are providing real-life, long-term data relevant to safety, efficacy and long-term outcomes in patients with various rheumatic diseases. The Romanian Registry of Rheumatic Diseases (RRBR) collects efficacy and safety data, for patients with inflammatory rheumatic conditions treated with biologies and targeted synthetic DMARDs in the country. Infections are the most frequently adverse events associated with biologics exposure.

Objectives: To analyze the distribution, severity class and outcome of infection with SARS-CoV-2 in inflammatory arthritis during the last 2 years of COVID-19 pandemic.

Methods: We collected data for the past 2 years (2020 and 2021) from the RRBR, for the three main inflammatory rheumatic diseases (Rheumatoid Arthritis - RA, Spondyloarthritis - SpA and Psoriatic Arthritis - PsA): treatment exposure (drug class) at the time of COVID-19 diagnosis, severity class (mild, moderate, severe), the disease outcome (recovered, disabled, death). Finally, we compared those data to reported numbers of COVID - 19 infections in the general population, aiming to observe if there is a significant difference between the two groups.

Results: The study included 9469 patients with inflammatory rheumatic disease, in 298 (3.14%) patients a history of COVID-19 infection was recorded. 160 (53.69%) were diagnosed with RA, 116 (36.92%) with SpA and 22 (7.28%) with PsA. At the moment of COVID-19 infection, 200 patients were receiving anti-TNF inhibitors (67.11%), 27 JAK inhibitors (9.06%), 24 tocilizumab (8.05%), 23 rituximab (7.71%), 9 anti-IL17A monoclonal antibodies (3.02%) and 4 abatacept. 12 (4.02%) deaths were recorded. The patients who died were on treatment with rituximab (5), tocilizumab (3), etanercept (2), secukinumab (1) and tocilizumab (1). Data from the National Public Health Institute showed a rate of COVID-19 infection in the general population of 9.36%, out of which 96.7% had a favorable outcome, while 3.26% deaths were reported.

Conclusion: This study confirms that patients receiving treatment with rituximab are at risk for a worse COVID-19 outcome. The increased number of severe cases and deaths related to COVID19 in patients receiving TNF inhibitors may be explained by the large use of this therapeutic option. Surprisingly, we noted 4 severe cases and one death related to COVID19, in patients treated with tocilizumab. We observed no significant differences in death rates and the outcomes of COVID-19 in patients with rheumatic diseases treated with biological therapies and the general population. The low rate of SARS-CoV-2 reported infections in the registry, compared to the general population, is most probably due to the commonly found underreporting of adverse events in registries.

References:

Disclosure of Interests: None declared

Conclusion: From the sample surveyed, it appears that high risk comorbidities, severity of RA at diagnosis and type of previous therapy are key differentiating points behind IL-6 usage in RA patients pre vs during the COVID-19 pandemic. With the increasing risk that RA patients may experience severe side effects if infected with COVID-19 and guidance to use IL-6 inhibitors in certain patient cohorts during this time, this may explain the patterns seen in our dataset. Further investigation using comparator cohort is warranted.

REFERENCES:

Figure 1. Humoral response rate after third COVID-19 vaccination sorted by baseline rituximab dose

Conclusion: Our study shows that a third COVID-19 vaccine can induce sufficient humoral response in a relevant proportion of (ultra-)low dose RTX treated RA patients who did not respond to the first two vaccinations, and that lower RTX dosing is associated with significant higher proportion of patients with sufficient humoral response. In contrast to the analysis after two vaccine doses, time since latest infusion was not significantly associated with response.

REFERENCES:
[3] Van der Togt, CJT et al., Humoral Response to Coronavirus Disease-19 Vaccines is Dependent on Dosage and Timing Since Latest Infusion in Patients with Rheumatoid Arthritis Treated With Rituximab, submitted.

Disclosure of Interests: Celeste van der Togt: None declared, david ten cate: None declared, Bart van den Bemt Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Agen en Eli Lilly, Janette Rahamat-Langendoen: None declared, Nathan den Broeder: None declared, Allons den Broeder Grant/research support from: Abbvie, Galapagos, Pfizer, Novartis, Lilly, Sanofi, Gilead


Table 1. Characteristics and outcomes sorted by rituximab dose before first vaccination

<table>
<thead>
<tr>
<th>Rituximab Dose</th>
<th>Sufficient humoral response after third vaccination (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>200 mg (n=13)</td>
<td>66 ± 11</td>
</tr>
<tr>
<td>500 mg (n=34)</td>
<td>7 (54%)</td>
</tr>
<tr>
<td>1000 mg (n=42)</td>
<td>21 (16-26)</td>
</tr>
<tr>
<td>Concomitant bDMARD use at baseline</td>
<td>13 (100%)</td>
</tr>
<tr>
<td>Disease duration years</td>
<td>5.8 ± 3.1</td>
</tr>
<tr>
<td>Days between latest RTX and 3rd vaccine</td>
<td>127 (100-160)</td>
</tr>
</tbody>
</table>

DISCLOSURE OF INTERESTS

No relevant disclosures.
All nineteen studies are cohort studies that followed individuals with AIRDs after COVID-19 vaccination. Two articles (11%) described differences in baseline risk for COVID-19 across age. All nineteen studies described participant age and sex, with race/ethnicity and multimorbidity described in four (21%).

### RESULTS:

Eight studies (42%) discussed at least one PROGRESS-Plus factor in interpreting the applicability of results, most commonly age (32%), then race/ethnicity and multimorbidity described in four (21%). Seven studies (37%) controlled for age and/or sex, with race/ethnicity and multimorbidity described in four (21%).

### Conclusion:

It is unknown whether COVID-19 vaccine studies on individuals with AIRDs are applicable to populations experiencing inequities, as key inequity factors beyond age and sex have little to no reporting or analysis. Future COVID-19 vaccine studies should report social characteristics of participants consistently, facilitating informed decisions about the applicability of study results to the population of interest.

### REFERENCES:


#### DISCLOSURE OF INTERESTS:

HARRY WANG: None declared, Osama Dewidar: None declared, Samuel Whittle: None declared, Elizabeth Ghogomu: None declared.

#### DOI:


---

**Table 1. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariable</th>
<th>Multivariable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B 95% CI</td>
<td>B 95% CI</td>
</tr>
<tr>
<td>Age, years</td>
<td>0.02 -0.02 to 0.53</td>
<td>0.02 -0.40 to 0.45</td>
</tr>
<tr>
<td>Male gender</td>
<td>-6.78 -13.18 to -0.39</td>
<td>-0.39 to 8.53</td>
</tr>
<tr>
<td>High education</td>
<td>5.32 1.49 to 9.17</td>
<td>9.57 5.63 to 13.51</td>
</tr>
<tr>
<td>ASDAS</td>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
<tr>
<td>Time, after vs. onset of pandemic</td>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
</tbody>
</table>

**Table 2. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.26 -0.02 to 0.53</td>
</tr>
<tr>
<td>Male gender</td>
<td>-6.78 -13.18 to -0.39</td>
</tr>
<tr>
<td>High education</td>
<td>5.32 1.49 to 9.17</td>
</tr>
<tr>
<td>ASDAS</td>
<td>12.46 5.69 to 15.26</td>
</tr>
<tr>
<td>Time, after vs. onset of pandemic</td>
<td>5.32 1.17 to 9.47</td>
</tr>
</tbody>
</table>

**Table 3. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>

**Table 4. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>

**Table 5. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>

## DISCLOSURE OF INTERESTS:

Associations in bold are significant (p<0.05)*Binary variable, indicating whether assessment took place after onset of pandemic vs. pre-pandemic (primary variable of interest)

**Disclosures of Interests:**

C. Weber: None declared, A. van Tubergen: None declared, H. Vonkerman: None declared, A. Boonen: None declared.

---

**References:**


---

**Table 1. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.26 -0.02 to 0.53</td>
</tr>
<tr>
<td>Male gender</td>
<td>-6.78 -13.18 to -0.39</td>
</tr>
<tr>
<td>High education</td>
<td>5.32 1.49 to 9.17</td>
</tr>
<tr>
<td>ASDAS</td>
<td>12.46 5.69 to 15.26</td>
</tr>
<tr>
<td>Time, after vs. onset of pandemic</td>
<td>5.32 1.17 to 9.47</td>
</tr>
</tbody>
</table>

**Table 2. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>0.26 -0.02 to 0.53</td>
</tr>
<tr>
<td>Male gender</td>
<td>-6.78 -13.18 to -0.39</td>
</tr>
<tr>
<td>High education</td>
<td>5.32 1.49 to 9.17</td>
</tr>
<tr>
<td>ASDAS</td>
<td>12.46 5.69 to 15.26</td>
</tr>
<tr>
<td>Time, after vs. onset of pandemic</td>
<td>5.32 1.17 to 9.47</td>
</tr>
</tbody>
</table>

**Table 3. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>

**Table 4. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>

**Table 5. GEE of work productivity loss (0-100, higher = worse)**

<table>
<thead>
<tr>
<th>Time, after vs. onset of pandemic</th>
<th>B 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.32 1.17 to 9.47</td>
<td>5.87 5.63 to 13.51</td>
</tr>
<tr>
<td>12.46 5.69 to 15.26</td>
<td>13.08 11.05 to 15.11</td>
</tr>
</tbody>
</table>
for people with immune mediated inflammatory diseases (IMIDs) such as inflammatory arthritis (IA), systemic autoimmune rheumatic disease (SARD), inflammatory bowel disease (IBD) and multiple sclerosis (MS).

**Objectives:** In IMID patients treated with homologous or heterogeneous COVID vaccines, to compare post vaccine IMID disease activity and COVID antibody responses.

**Methods:** Between March 2021 and Dec 2021, patients with IA (n= 70; 77% rheumatoid arthritis), SARD (n=82; 70% lupus), IBD (n=92; 40% cohn’s), and MS (n=71; 77% RRMS) self-reported COVID illness and exposure risks, and disease activity prior to and 1 month post both COVID-19 vaccinations (V1 and V2). Disease activity was assessed by the Systemic Lupus Activity Questionnaire (SLAQ) for SARDs, the RAPID-3 and RA flare index for IA, the IBD Symptoms Inventory-short form (IBDI) and IBD flare index for IBD and the 25 meter walk and 9 hole peg test and Expanded Disability Status Scale (EDSS) for MS. Patient reported flare state was assessed using the relevant questions these indices (SLAQ “Have you had a flare?”; RA Flare index “Are you in a flare?”; IBD flare “My IBD is sometimes to continuously active”). Disease activity and serum anti-spike, anti-receptor binding domain (RBD) and anti-nucleocapsid (NC) IgG antibody titers at 30 days post V2 were compared across vaccine courses and to age-sex matched vaccinated blood donor controls (CNTS).

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>All IMIDs</th>
<th>IA</th>
<th>SARD</th>
<th>IBD</th>
<th>MS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (mean ±sd) years</strong></td>
<td>56±15</td>
<td>63±12</td>
<td>56±14</td>
<td>54±16</td>
<td>51±17</td>
</tr>
<tr>
<td><strong>Female (%)</strong></td>
<td>80</td>
<td>84</td>
<td>90</td>
<td>64</td>
<td>83</td>
</tr>
<tr>
<td><strong>COVID risk exposure (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>44</td>
<td>39</td>
<td>46</td>
<td>50</td>
<td>44</td>
</tr>
<tr>
<td>Contact</td>
<td>14</td>
<td>12</td>
<td>14</td>
<td>12</td>
<td>21</td>
</tr>
<tr>
<td>Travel</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>HCW/hospitalized</td>
<td>15</td>
<td>16</td>
<td>16</td>
<td>20</td>
<td>19</td>
</tr>
<tr>
<td>Other risk</td>
<td>9</td>
<td>6</td>
<td>10</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>V1 mRNA (%)</td>
<td>74</td>
<td>80</td>
<td>68</td>
<td>82</td>
<td>64</td>
</tr>
<tr>
<td>V2 mRNA (%)</td>
<td>97</td>
<td>98</td>
<td>96</td>
<td>99</td>
<td>98</td>
</tr>
<tr>
<td>Homologous V1 V2 (%)</td>
<td>71</td>
<td>79</td>
<td>67</td>
<td>74</td>
<td>76</td>
</tr>
<tr>
<td>Flare status post V2 (%)</td>
<td>10</td>
<td>15</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Seroconversion (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Spike</td>
<td>89</td>
<td>90</td>
<td>86</td>
<td>93</td>
<td>84</td>
</tr>
<tr>
<td>Anti-RBD</td>
<td>91</td>
<td>92</td>
<td>86</td>
<td>96</td>
<td>88</td>
</tr>
</tbody>
</table>

**Results:** Patients were predominantly female (79.7%), with a mean (standard deviation-sd) age of 56 (15) years; 8% had suspected or diagnosed COVID-19 illness; 12% positive anti-NC (Table 1). For all IMIDs, the majority received mRNA vaccines-BNT162b2 (BNT) or mRNA1273 (V1 74%; V2 97%). The rest received ChAdOx1 viral vector vaccines; 71% received homologous vaccines-BNT162b2 (BNT) or mRNA1273 (V1 74%; V2 97%). The majority reported COVID illness and exposure risks, and disease activity prior to and 1 month post both COVID-19 vaccinations (V1 and V2). Disease activity was assessed by the Systemic Lupus Activity Questionnaire (SLAQ) for SARDs, the RAPID-3 and RA flare index for IA, the IBD Symptoms Inventory-short form (IBDI) and IBD flare index for IBD and the 25 meter walk and 9 hole peg test and Expanded Disability Status Scale (EDSS) for MS.

**Flare status post V2 (%)**

**Seroconversion (%)**

**Conclusion:** Heterologous COVID vaccination improves seroconversion rates following a viral vector vaccine and does not lead to disease flare in most IMID patients. While data is needed to assess vaccine effectiveness, duration of immunogenicity and effects of subsequent vaccination, this work supports mixing COVID vaccines for IMID patients.

**Acknowledgements:** Study funded by Research Manitoba

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1267
Background: There is a lack of data on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination safety in children and young people

Table 1. Characteristics of adolescents with RMDs and adults with JIA reported to the EULAR COVAX registry

<table>
<thead>
<tr>
<th>Sex</th>
<th>Adolescents with RMDs (N=36)</th>
<th>Adults with JIA (N=74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>21 (58)</td>
<td>54 (73)</td>
</tr>
<tr>
<td>Male</td>
<td>15 (42)</td>
<td>20 (27)</td>
</tr>
<tr>
<td>Age (median [IQR])</td>
<td>15 [14.5, 17]</td>
<td>26 [23, 31]</td>
</tr>
<tr>
<td>Primary RMD diagnosis</td>
<td>10 (28)</td>
<td>63 (85)</td>
</tr>
<tr>
<td>Non-systemic JIA</td>
<td>5 (14)</td>
<td>11 (15)</td>
</tr>
<tr>
<td>Systemic JIA</td>
<td>5 (14)</td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>5 (14)</td>
<td></td>
</tr>
<tr>
<td>Spondyloarthrits/psoriatic arthritis</td>
<td>5 (14)</td>
<td></td>
</tr>
<tr>
<td>Vasculitis/other RMD #</td>
<td>11 (30)</td>
<td></td>
</tr>
<tr>
<td>RMD disease activity</td>
<td>23 (64)</td>
<td>33 (45)</td>
</tr>
<tr>
<td>Remission</td>
<td>8 (22)</td>
<td>21 (28)</td>
</tr>
<tr>
<td>Moderate</td>
<td>2 (6)</td>
<td>12 (16)</td>
</tr>
<tr>
<td>Severe</td>
<td>1 (3)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Not applicable/missing</td>
<td>2 (6)</td>
<td>7 (10)</td>
</tr>
<tr>
<td>RMD medication</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non</td>
<td>8 (25)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>b-DMARD</td>
<td>2 (6)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>cs-DMARD</td>
<td>21 (68)</td>
<td>25 (34)</td>
</tr>
<tr>
<td>ts-DMARD</td>
<td>5 (14)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Systemic glucocorticoids</td>
<td>5 (14)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Colchicine</td>
<td>7 (10)</td>
<td></td>
</tr>
<tr>
<td>Other immunosuppressant *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pibox/SiolYich</td>
<td>33 (92)</td>
<td>50 (68)</td>
</tr>
<tr>
<td>Moderna</td>
<td>2 (6)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>AstraZeneca/Oxford</td>
<td>1 (3)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>Janssen</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Convir/Novac</td>
<td>2 (3)</td>
<td></td>
</tr>
<tr>
<td>UNK</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>COVAX doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>11 (31)</td>
<td>8 (11)</td>
</tr>
<tr>
<td>2</td>
<td>2 (6)</td>
<td>11 (21)</td>
</tr>
<tr>
<td>3</td>
<td>1 (3)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>RMD flare</td>
<td>Yes</td>
<td>2 (3)</td>
</tr>
<tr>
<td>No</td>
<td>20 (56)</td>
<td>46 (62)</td>
</tr>
<tr>
<td>Early AE</td>
<td>Injection site pain</td>
<td>8 (22)</td>
</tr>
<tr>
<td>Redness</td>
<td>6 (17)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Muscle pain</td>
<td>1 (3)</td>
<td>9 (12)</td>
</tr>
<tr>
<td>Joint pain</td>
<td>4 (11)</td>
<td>3 (4)</td>
</tr>
<tr>
<td>Headache</td>
<td>9 (25)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>Fever</td>
<td>1 (3)</td>
<td>26 (35)</td>
</tr>
<tr>
<td>Chills</td>
<td>2 (6)</td>
<td>5 (7)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1 (3)</td>
<td>13 (18)</td>
</tr>
<tr>
<td>AE of special interest</td>
<td>Non-serious</td>
<td>1 (3)</td>
</tr>
<tr>
<td>Serious</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>ADAMD</td>
<td>2 (3)</td>
<td></td>
</tr>
<tr>
<td>b-DMARD</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>cs-DMARD</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>ts-DMARD</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>Systemic glucocorticoids</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>Colchicine</td>
<td>1 (3)</td>
<td></td>
</tr>
<tr>
<td>Other immunosuppressant *</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pibox/SiolYich</td>
<td>33 (92)</td>
<td>50 (68)</td>
</tr>
<tr>
<td>Moderna</td>
<td>2 (6)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>AstraZeneca/Oxford</td>
<td>1 (3)</td>
<td>10 (14)</td>
</tr>
<tr>
<td>Janssen</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Convir/Novac</td>
<td>2 (3)</td>
<td></td>
</tr>
<tr>
<td>UNK</td>
<td>1 (1)</td>
<td></td>
</tr>
</tbody>
</table>

All data are N(%) of the column unless stated otherwise. Other RMD includes Sjögren’s syndrome, systemic sclerosis, undifferentiated connective tissue disease, non-monomorhic auto-inflammatory syndrome, chronic recurrent multifocal osteomyelitis, and other inflammatory arthritis. Other immunosuppressant includes ciclosporin, mycophenolate mofetil/mycophenolic acid.RMD, rheumatic and musculoskeletal disease; JIA, juvenile idiopathic arthritis; EULAR, European Alliance of Associations for Rheumatology; ANCA-associated vasculitis, antibody-associated vasculitis, cs-, conventional synthetic; b-, biological; ts-, targeted synthetic; DMARD, disease-modifying anti-rheumatic drug; COVAX, Coronavirus vaccine; AE, adverse event.

(CYP) with rheumatic and musculoskeletal diseases (RMDs). Current vaccination guidance is based on data from adults with RMDs or CYP without RMDs.

Objectives: To describe the characteristics and outcomes of adolescents with inflammatory RMDs and adults with juvenile idiopathic arthritis (JIA) vaccinated against SARS-CoV-2.

Methods: We described patient characteristics, flares, and adverse events in adolescent cases under 18 with inflammatory RMDs and adult cases aged 18 or above with JIA submitted to the European Alliance of Associations for Rheumatology (EULAR) COVAX registry.

Results: Thirty-six adolescent cases were reported from 4 countries, the most frequent diagnosis was JIA (42%). Over half (56%) reported early reactogenic-like adverse events (AEs) experienced within 7 days of vaccination. One mild polyarthralgia flare and one serious AE (malaise) were reported. No CYP reported SARS-CoV-2 infection post-vaccination. In addition to the adolescent cases, eleven countries reported 74 adult JIA cases. Among these, 62% reported early reactogenic-like AEs and two flares were reported (mild polyarthralgia and moderate uveitis). No serious AEs of special interest were reported among adults with JIA. Three 20-30 year old females were diagnosed with SARS-CoV-2 post-vaccination; all fully recovered.

Conclusion: In this observational registry dataset, SARS-CoV-2 vaccines appeared safe in adolescents with RMDs and adults with JIA, with a low frequency of disease flares, serious AEs, and SARS-CoV-2 re-infection seen in both populations.

Acknowledgements: We wish to thank all healthcare providers who entered data into the registry.

Disclosure of Interests: Saskia Lawson-Tovey: None declared, Anja Strangfeld Speakers bureau: AbbVie, MSD, Roche, BMS, Pfizer, Elisa Mateus: None declared, Laure Gossec Consultant of: AbbVie, Amgen, BMS, Galapagos, Gilead, GSK, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB, Grant/research support from: Amgen, Galapagos, Lilly, Pfizer, Sanofi, Loreto Corrias: None declared, Pedro Machado Speakers bureau: AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphanpharma, Pfizer, Roche, UCB, Consultant of: AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche, UCB, BERNRD RAEFFNEREN: None declared, Ina Bulina Speakers bureau: AbbVie, Pfizer, Janssen, Boehringer Ingelheim, Daniel Clemente Speakers bureau: Novartis, GSK, Julija Zepa Speakers bureau: AbbVie, Novartis, Janssen/Johnson & Johnson, Anna Maria Rodrigues Speakers bureau: Amgen, AbbVie, Grant/research support from: Amgen, Pfizer, AstraZeneca, Xavier Mariette Consultant of: BMS, Galapagos, Gilead, Janssen, Novartis, Pfizer, sanofi-Aventis, UCB, Grant/research support from: Ose, Kimme Hiyisch Speakers bureau: AbbVie, Grant/research support from: Pfizer, BMS, UCB

Conclusion: Inflammation of the microvascular system as an underestimated side effect of MRNA / Vector immunization should be taken into account if (boos- ter)-immunization decisions in patients with rheumatic diseases (maybe general) are to be made. Most patients with rheumatic diseases under (DMARD) therapy developed Covid-19 ABL (94.5%) (1) 5-6 months after MRNA / Vector immunization. All immunization decisions should also be made dependent on AbL. In case of breakthrough infection rates and hospitalization of immunized patients could be explained. Microvascular inflammation after MRNA / Vector immunization as a side effect in 37 % of rheumatological patients could cause medical problems later on. Therefore also for safety reasons MRNA / Vector (booster) immunizations should also depend on the amount of already existing humoral response reflected by ABL.

REFERENCES:

Acknowledgements: My family, my staff, my colleagues and all of my patients

Disclosure of Interests: None declared


POS124
COVID-19 VACCINATION RATE AND SAFETY PROFIE IN PATIENTS AFFECTED BY MIXED CRYOglobulinemic Vasculitis.

C. Vacchi1, 2, S. Testoni3, M. Visentinii, R. Zani4, G. Lauletta5, L. Gragnani6, D.A. Filippini7, C. Mazzaro8, P. Fraticelli9, L. Quartuccio10, R. Padoan11, None declared

Acknowledgements: My family, my staff, my colleagues and all of my patients

Disclosure of Interests: None declared


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1426

Background: Mixed cryoglobulinemic vasculitis (MCV) is an immune-complex-mediated systemic vasculitis characterized by clinical manifestations mainly involving skin, kidney and peripheral nervous system. Despite reassuring safety data from EULAR Coronavirus Vaccine (COVAX) physician-reported registry, a significant proportion of patients with autoimmune diseases reported unwillingness to get vaccinated against SARS-CoV-2 infection in the preliminary results of the COVAD study, due to concerns about the lack of long-term safety data, and fear of associated side effects and disease flare.

Objectives: Aims of this multicentre Italian study were to investigate the prevalence of vaccination against SARS-CoV-2 in Italian population of MCV patients, to explore the reason for the missed vaccination, and to investigate short and long-term side effects of the vaccine.

Methods: All MCV patients referring to 12 Italian centres were investigated about vaccination and possible side effects (within 48 hours and long-term) and disease flare in the acute phase of their disease, in the first month after vaccination. MCV patients were divided in 2 groups: a) patients without long-term medication or after a period of at least 6 months of treatment and, b) patients under long-term treatment.

Results: A total of 416 patients, 69.2% females and 30.8% males, with a mean age of 70.4±11.7 years, were included in the study. Only 7.7% of patients were not vaccinated, mainly for fear of adverse events (50%) or for medical decision (18.8%). Comorbidities were the vaccine most frequently used (80.5%). Interestingly, 6 patients (1.44%) were with a heterologous vaccination (usually AstraZeneca-Corinny). Considering ongoing treatment, not vaccinated subjects were more frequently treated with chronic glucocorticoid therapy and/or rituximab (p=0.049 and p=0.043 respectively). AE were recorded in 3.7% of cases, mainly mild and self-limiting (grade 1). More severe adverse events, such as flare of vasculitis, were observed in 5.3% of cases. AE were not associated with the kind of vaccine used and with the clinical manifestations of vasculitis. Patients with active MCV showed a lower frequency of short-term (within 48 hours) adverse events, but patients affected by peripheral neuropathy or skin vasculitis frequently showed a flare of their symptoms, recorded in 40% and 25% of cases, respectively. Finally, patients under glucocorticoid treatment were more prone to develop a vasculitis flare within a month after vaccination.

Conclusion: Vaccination in MCV patients has been performed in a high percentage of patients showing a good safety. Other than patients’ fear, treatments with rituximab and glucocorticoids are the main reasons for delaying vaccination, and it should be considered by the physician before starting vaccination.

Vasculitis flares were observed in about 5% of cases, in line with that observed in other autoimmune diseases. Specific attention should be reserved to people with purpura or peripheral neuropathy, for the increased risk of exacerbation of their symptoms.

REFERENCES:
[1] Visentinii M et al Flares of mixed cryoglobulinemia vasculitis after vaccination against SARS-CoV-2 2021

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1426
POS1215 IMMUNE CORRELATES AND CLINICAL COURSE OF PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING VACCINATION WITH ANTI SARS-COV-2 mRNA BASED VACCINES: RESULTS FROM A PROSPECTIVE, OBSERVATIONAL AND CONTROLLED STUDY

K. Schmiedeberg1, I. A. Abel2, N. B. Pikor3, N. Vuilleumier4, M. Schwarzmueller5, S. Epp6, S. Pagano7, S. Grabher8, A. B. Patterson9, M. Nussberger10, A. Trkola11, B. Ludewig12, J. Von Kempis13, A. Rubbert-Roth14, 1Rheumatology Clinic, Kantonsspital St Gallen, St Gallen, Switzerland; 2Zürich, University of Zurich; Institute of Medical Virology, Zürich, Switzerland; 3St. Gallen, Institute of Immunobiology, St. Gallen, Switzerland; 4Geneva, Laboratory Medicine Division, Geneva, Switzerland

Background: Vaccines are highly effective in preventing COVID-19 associated hospitalization and deaths. Strong and persistent immune responses are critical to provide protection for patients with immunomodulatory therapies.

Objectives: To assess humoral and cellular immune responses following 2 doses of an anti-SARS-CoV-2 mRNA based vaccine in rheumatoid arthritis (RA). Immune responses in patients treated with csDMARDs, bDMARDs (with the exception of rituximab) and JAK inhibitors were compared to healthy controls (HC) over 24 weeks. In addition, disease activity by CDAI and vaccine-induced side effects were prospectively monitored.

Methods: The RECOVER trial (Rheumatoid Covid-19 Vaccine Immune Response) is a non-randomised, prospective observational control group trial and enrolled 77 RA patients on DMARD therapy and 21 HC. Clinical assessment and blood sampling was performed at baseline, 3 weeks after the 1st and 2 weeks after the 2nd vaccine dose and at week 12 and 24 after the 1st. Antibody response to the receptor binding domain (RBD) within the SARS-CoV-2 S1 protein was measured with the Elicys Anti-SARS-CoV-2-S (Roche Diagnostics GmbH) test. The seroprofiling assay ABCORA, which has been suggested as a surrogate for neutralization, was used to determine IgG, IgA and IgM responses to RBD, S1, S2 and N. The neutralizing activity NT50 at week 12 was assessed against Wuhan-Hu-1 pseudoviruses (HIV-based). IFN-γ ELISpot spots were applied to detect spike-reactive T cell responses after in vitro stimulation with a spike peptide mix.

Results: Baseline characteristics of participants are detailed in Table 1. Vaccination was well tolerated with no differences between RA patients and HC. At baseline, the majority of RA patients were in remission/LDA (57/77, 74%), this proportion decreased to 51% (39/77) after the second vaccine dose (p = 0.005). Treatment adjustments were required in 11/77 patients. The immunogenicity analyses were based on 73 RA patients after exclusion of 4 patients with previously unnoticed SARS-CoV-2 infection (positive for anti-nucleoprotein). In contrast to HC, anti-S titers were lower at all timepoints with significantly reduced titers observed in patients on abatacept and JAK inhibitors (Figure 1). Potent neutralizing activity (NT50 ≥ 250) was detected in all HC at week 12, in contrast to 62% RA patients. NT50 correlated to the results based on the ABCORA assay. Peak anti-S titers (2 weeks after 2nd vaccine) were predictive of NT50 ≥ 250 at week 12 (p < 0.0001).

Conclusion: RA patients, in comparison with HC, revealed a slower kinetic and lower magnitude of humoral immune responses depending on the treatment regimen while T cell responses were largely maintained. Peak anti-S responses two weeks after the second vaccine were able to predict the development of potent neutralizing activity and should therefore be considered to individually tailor vaccination strategies.

REFERENCES:

POS1216 POTENTIAL PREDICTORS OF OUTCOME FOR ANAKINRA TREATMENT IN COVID-19 PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME

S. Amikishiev1, R. Deniz2, S. G. Gunver3, N. Koca4, B. Ince5, M. Bektas6, A. Yilmaz7, Y. Canturk8, G. Durak9, M. Kose10, M. Erelel11, A. A. Çağatay1, S. K. Bessisk2, F. Eisen12, A. Gül13 on behalf of The team of Istanbul Faculty of Medicine, Istanbul University. 
1Istanbul Faculty of Medicine, Istanbul University, Department of Rheumatology, Istanbul, Turkey; 2Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, Istanbul, Turkey; 3Istanbul Faculty of Medicine, University of Istanbul, Department of Biostatistics, Istanbul, Turkey; 4Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, Istanbul, Turkey; 5Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, Istanbul, Turkey; 6Istanbul Faculty of Medicine, Istanbul University, Department of Biostatistics, Istanbul, Turkey; 7Istanbul Faculty of Medicine, Istanbul University, Department of Chest Diseases, Istanbul, Turkey; 8Istanbul Faculty of Medicine, Istanbul University, Division of Hematology and Therapeutic Apheresis Unit, Istanbul, Turkey; 9Istanbul Faculty of Medicine, Istanbul University, Department of Anaesthesiology, Istanbul, Turkey

Background: A hyperinflammatory response compatible with features of macrophage activation syndrome (MAS) contributes to this worse outcome in patients with Coronavirus Disease 2019 (COVID-19). Glucocorticoids have become the standard of care for those requiring oxygen support or mechanical ventilation. More targeted anti-inflammatory treatments with tocilizumab and anakinra have also been shown to be effective.

Objectives: More studies are being awaited to clarify the features of patients who would benefit more, and we investigated the characteristics of the surviving and dead patients who received anakinra.

Methods: The records of hospitalized adult patients between March 2020 and May 2021 in a tertiary referral center were evaluated. Diagnosis of COVID-19-related MAS was based on the expert opinion and preliminary criteria developed by our group that patients with a score of ≥45 were accepted COVID-19-related MAS. Patients who received anakinra constituted the study group. Anakinra dose was determined according to the clinical and inflammatory parameters; and doses varied between daily 100-300 mg SC to 400-800 mg IV. Laboratory data of surviving and died patients were comparatively analyzed by using the ANCOVA method on the relevant days (baseline, anakinra-onset day, first response to anakinra treatment, and discharge or death). The temporal variation (drug onset day-first response day, drug onset day-discharge, or death day) was evaluated
Disclosed Interests: None declared

POS1217

ANTI-TNF THERAPY FOR IMMUNE MEDIATE INFLAMMATORY DISEASES MAY BE ASSOCIATED WITH LOWER ANTIBODY LEVELS AND VIRUS NEUTRALIZATION EFFICACY FOLLOWING SARS-COV-2 mRNA VACCINATION

N. Finkelstein1,2, R. M. Dayam3, J. Law4, R. Goebgether2,5, G. Chao4, K. T. Abe3,7, M. Sutton1, J. M. Stampak1, D. Pereira3, D. Croitoru5, L. Acheampong6,9, S. Rizwan4, K. Rymaszewski2, R. Milgrom7, D. Ganatra4, N. V. Batista4, M. Gairard4, I. Lau6, R. Law7, M. Cheung8, B. Rathod9, J. Kityayordikul8,9, R. Samson10, Q. Hu2, N. Haroon1,2, R. Irani6, V. Figuet10,11, M. Silverberg1,7, A. C. Grigaris3,7, T. H. Watts1, V. Chandran1,2, University Health Network, Schroeder Arthritis Institute, Toronto, Canada; University of Toronto, Division of Rheumatology, Department of Medicine, Toronto, Canada; Sinai Health System, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada; University of Toronto, Department of Immunology, Toronto, Canada; Sinai Health System, Zane Cohen Centre for Digestive Diseases, Toronto, Canada; University of Toronto, Division of Gastroenterology, Toronto, Canada; University of Toronto, Department of Molecular Genetics, Toronto, Canada; University of Toronto, Division of Dermatology, Department of Medicine, Toronto, Canada; Women’s College Hospital, Department of Medicine, Toronto, Canada; University of Toronto, Department of Medicine, Toronto, Canada; Women’s College Hospital, Division of Dermatology, Toronto, Canada; University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada.

Background: The impact of immunosuppressants on COVID-19 vaccination response and durability in patients with immune-mediated inflammatory diseases (IMID) is yet to be fully characterized. Humoral response may be attenuated in these patients especially those on B cell depleting therapy and higher doses of corticosteroids, but data regarding other immunosuppressants are scarce.

Objectives: We aimed to investigate antibody and T cell responses and durability to SARS-CoV-2 mRNA vaccines (BNT162b and/or mRNA 1273) in IMID patients undergoing immunomodulatory maintenance therapy other than B-cell depleting therapy and corticosteroids.

Methods: This prospective observational cohort study examined the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with IMIDs (psoriatic arthritis, psoriasis, inflammatory bowel disease and rheumatoid arthritis) with or without maintenance immunosuppressive therapies (anti-TNF, methotrexate/azathioprine (MTX/aza), anti-TNF + MTX/aza, anti-IL12/23, anti-IL-17, anti-IL-21) compared to healthy controls. Automated ELISA for IgGs to spike trimer, spike receptor binding domain (RBD) and the nucleocapsid (NP) and T-cell release of 9 cytokines (IFNg, IL2, IL4, IL17A, TNF) and cytotoxic molecules (fFasL, GzmA, GzmB, Perforin) in cell culture supernatants following stimulation with spike or NP peptide arrays were conducted at 4 time points; T1=pre vaccination, T2=median 26 days after dose 1, T3=median 16 days after dose 2 and T4=median 106 days after dose 2. Neutralization assays against four SARS-CoV-2 variants (wild type, delta, beta and gamma) were conducted at T3.

Results: We followed 150 subjects: 26 healthy controls and 124 IMID patients: 9 untreated, 44 on anti-TNF, 16 on anti-TNF with MTX/aza, 10 on anti-IL2, 28 on anti-IL12/23, 9 on anti-IL17, 8 on MTX/aza (Table 1). Most patients mounted antibody and T cell responses with increases from dose 1 to dose 2 (100% seroconversion at T3) and some decline by T4, with variability within groups. Antibody levels and neutralization efficacy was lower in anti-TNF groups (anti-TNF, anti-TNF + MTX/aza) compared to controls and waned by T4 (Figure 1). T cell responses were not consistently different between groups. Pooled data showed a higher antibody response to mRNA-1273 compared to BNT162b.

Conclusion: Following 2 doses of mRNA vaccination there is 100% seroconversion in IMID patients on maintenance therapy. Antibody levels and neutralization efficacy in anti-TNF group are lower than controls, and wane substantially by 3 months after dose 2. These findings highlight the need for third dose in patients undergoing treatment with anti-TNF therapy and continued monitoring of immunity in these patients. Two cases taken into consideration newer variants and additional vaccine doses.

Acknowledgements: This work was funded by a donation from Juan and Stefania Speck and by grants VR-1 172711, VS1-175545, FDN-143250, GA1-177703 and GA2-177716, from Canadian Institutes of Health Research and COVID Immunity task force and by Sinai Health Foundation.

Disclosure of Interests: Naomi Finkelstein: None declared, Roya M. Dayam: None declared, Jaclyn Law: None declared, Roger Goebgether: None declared, Gary Chao: None declared, Kento Abe: None declared, Michel Silverberg: None declared, Joanne M. Stampak: None declared, Daniel Pereira: None declared, David Croitoru: None declared, Lily Acheampong: None declared, Saima Rizwan: None declared, Klaudia Rymaszewski: None declared, Raquel Milgrom: None declared, Darshini Ganatra: None declared, Nathalia V. Batista: None declared, Melanie Girard: None declared, Irene Lau: None declared, Ryan Law: None declared, Michelle Cheung: None declared, Julia Kitavoori Rathod: None declared, Julia Kitavoori Rathod: None declared, Reuben Samson: None declared, Queenie Hu: None declared, Nilg Harono: None declared, Robert Inman Consultant of: AbbVie, Janssen, Lilly, Novartis, Pfizer, Sanofi, UCB, and Union Therapeutic, Grant/research support from: Utrecht's bi-educational grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, L'Oreal, NAOS, Novartis, Pfizer, Pierre-Fabre, Sandoz, and Sanofi, Mark Silverberg Speakers bureau: AbbVie, Janssen, Takeda, Pfizer, Gilead and Amgen, Consultant of: AbbVie, Janssen, Takeda, Pfizer, Gilead and Amgen,
Figure 1. Antibody responses (A) Anti spike and anti RBD IgG levels at indicated time points. Blue line represents median ratio in convalescent patients. The red line is the seropositivity threshold: the median antibody level of those that pass both a 1% false positive rate and show ≥3SD from the log means of the negative controls. (B) Relative seropositivity threshold: the median antibody level of those that pass both a 1% false positive rate and show ≥3SD from the log means of the negative controls. (B) Relative seropositivity threshold: the median antibody level of those that pass both a 1% false positive rate and show ≥3SD from the log means of the negative controls. (B) Relative seropositivity threshold: the median antibody level of those that pass both a 1% false positive rate and show ≥3SD from the log means of the negative controls.

Table 1. Baseline characteristics of study participants

<table>
<thead>
<tr>
<th></th>
<th>Control untreated</th>
<th>Anti-IMID</th>
<th>Anti-TNF</th>
<th>Anti-TNF+MTX</th>
<th>Anti-IL-23</th>
<th>Anti-IL-12/23</th>
<th>Anti-IL-17</th>
<th>Anti-MTX/AZA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>26</td>
<td>9</td>
<td>30</td>
<td>10</td>
<td>0</td>
<td>27</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Sex (male)</td>
<td></td>
<td>16 (62%)</td>
<td>18 (60%)</td>
<td>18 (60%)</td>
<td>18 (60%)</td>
<td>18 (60%)</td>
<td>18 (60%)</td>
<td>18 (60%)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>25 (23-28)</td>
<td>22 (21-24)</td>
<td>24 (22-26)</td>
<td>26 (24-28)</td>
<td>26 (24-28)</td>
<td>26 (24-28)</td>
<td>26 (24-28)</td>
<td>26 (24-28)</td>
</tr>
</tbody>
</table>

*multiple IMIDs per patient possible

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination plays a crucial role as pivotal strategies to curb the coronavirus disease-19 (COVID-19) pandemic. Despite the mass-scale vaccination, literature data about the incidence of disease flares in IIM patients are still not reported as well as the immunological condition.

Objectives: The present study aimed to describe the clinical status of patients affected by IIM after vaccination against COVID19 in order to assess the number of relapses or immune-mediated reactions in a cohort of Italian patients with such disease.

Methods: We included all patients affected by IIM and followed by Myositis Clinic, Rheumatology and Respiratory Diseases Units, Siena University Hospital, Bari University Hospital, Policlinico Umberto I, Sapienza University, Rome, and Policlinico Paolo Giaccone, Palermo. Inclusion criteria were a recent (<3 months) clinical and serological assessment before the survey and a definite diagnosis of dermatomyositis, polymyositis and anti-synthetase syndrome. All patients underwent a telephone survey in order to establish their clinical status and potential relapses after vaccination.

Results: A total of 119 IIM patients (median, IQR 54 (47-66) years; 32 males) were consecutively enrolled. Fifty had a diagnosis of DM, 39 had PM and 30 had ASS. The median months of disease duration was 79.62±83.98. According to number of organs involvement, forty-two had one, 45 had two organs involvement, 20 had three, 11 had four and one had five. The majority of them received two doses of COVID-19 vaccine, except four patients who refused the vaccination: 94 (78.9%) Cominarty, 16 (13.4%) Moderna, 5 (0.04%) AZ. Seven (0.06%) patients had flare after vaccination, except one patient who had life-threatening with systemic involvement. In order to understand or predict the effect of demographic and clinical features on the flare development after vaccination, a logistic regression analysis was performed. The goodness-of-fit statistics showed a Chi² associated with the Log ratio (L.R.) of 0.045. From the probability associated with the Chi-square tests, the Type II analysis showed the variable that most influences the development of flare was the number of organs involved (p=0.047). Sixty-eight patients received the third dose of COVID-19 vaccination: 51 (75%) Cominarty and 17 (25%) Moderna. Only one (0.01%) patient (the same who had life-threatening flare with systemic involvement after two doses) had flare after third dose and eventually died.

Conclusion: Vaccines against SARS-CoV2 have provided, both in registratory studies and in preliminary real-life evidence, an overall good efficacy and safety. Nevertheless, only scanty data are available for rheumatic patients in general and the ones affected by IIM in particular. To the best of our knowledge, ours represent the largest cohort of IIM patients in which immunogenicity of anti-SARS-CoV2 vaccine was assessed. In line with real-life data from other diseases, we found a non-statistically significant risk of relapse in our patients, which occurred seldom, usually mild and in patients with a more severe and aggressive course of disease.

Disclosure of Interests: None declared

**Results:**

Despite the low sample size, our study is of interest since it proves that the inhibition of IL-1 with both anakinra or canakinumab and the employment of colchicine, an important inflammasome regulator, may curb the hyperinflammation typical of COVID-19. Given the promising results obtained with anti-IL-1 and colchicine in treating severe COVID-19, it is conceivable a "protective" role of these drugs in preventing a massive cytokine release. Unsurprisingly, none of our patients but one, had a severe course or fatal outcome after SARS-CoV-2 infection.

**Conclusion:**

Despite the small sample size, our study is of interest since it proves that the inhibition of IL-1 with both anakinra or canakinumab and the employment of colchicine, an important inflammasome regulator, may curb the hyperinflammation typical of COVID-19. Given the promising results obtained with anti-IL-1 and colchicine in treating severe COVID-19, it is conceivable a "protective" role of these drugs in preventing a massive cytokine release. Unsurprisingly, none of our patients but one, had a severe course or fatal outcome after SARS-CoV-2 infection.

**Disclosure of Interests:** None declared

Background: Patients with immune-mediated inflammatory diseases are inherently susceptible to infections and are at high risk of developing COVID-19. COVID-19 vaccination in patients with rheumatoid and musculoskeletal disease (RMD) is strongly recommended [1]. BNT162b2 is the most used COVID-19 vaccine in Japan. The safety and efficacy of this vaccine has been demonstrated in the general population [2], but patients receiving immunosuppressive therapy were excluded from the study. Although data on the immunogenicity of COVID-19 vaccine in the immunocompromised adult population is rapidly increasing, the immunogenicity of mRNA COVID-19 vaccine in RMD patients receiving medication has been reported in various and still inadequate ways. Furthermore, the immunogenicity of mRNA COVID-19 vaccine may vary depending on the medication. In addition, most of these data were reported from Western countries, and data on Japanese patients with RMD are limited.

Objectives: To investigate serum antibody titre against SARS-CoV-2 spike protein following BNT162b2 vaccination in Japanese RMD patients on various immunomodulatory treatment.

Methods: Two hundred and twelve RMD outpatients undergoing treatment at Kagawa University Hospital and 43 healthy volunteers, who had received two doses of BNT162b2, were included in the study. Serum sample was collected at least 14 days after the second dose. Antibody titer against SARS-CoV-2 spike protein in serum was measured by ELISA (Elecys Anti-SARS-CoV-2 S RUO). We analyzed the relationship between clinical characteristics, including the type of disease and treatment of RMD, and antibody titer against SARS-CoV-2 spike protein.

Results: The antibody titer against SARS-CoV-2 spike protein in RMD patients was significantly lower than that in healthy subjects. In the analysis with therapeutic agents, the mean antibody titer in RMD patients treated with rituximab (RTX) was much lower than that in healthy controls. Patients treated with baricitinib, azathioprine, mycophenolate mofetil, abatacept, TNF inhibitors, cyclosporine, IL-6 inhibitors, and methotrexate (MTX), or glucocorticoids (GC) had only moderately lower antibody titers. Patients treated with tacrolimus, an immunosuppressive drug commonly used for treatment in Japan, showed a slight decrease in antibody titer, but the difference was not significant compared with healthy subjects. IL-17 and IL-23 inhibitors did not impair the humoral response. In addition, the combination of MTX with various immunosuppressive agents reduced titers, although this was not statistically significant.

Conclusion: Many of the immunosuppressants impaired the immunogenicity to BNT162b2 in Japanese RMD patients. The degree of decline of antibody titers differed according to immunosuppressant. MTX potentially impairs the immunogenicity of BNT162b2 also in the case of concomitant use with other immunosuppressant.

REFERENCES:

Table 1. Serum antibody titre against SARS-CoV-2 spike protein according to the use of immunosuppressive treatments in comparison with controls

<table>
<thead>
<tr>
<th>Immunosuppressive treatments, n</th>
<th>Serum antibody titre, means SD, U/mL</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control, n=43</td>
<td>939 ± 973</td>
<td>-</td>
</tr>
<tr>
<td>Patients with RMD, n=212</td>
<td>572 ± 950</td>
<td>0.023</td>
</tr>
<tr>
<td>Without immunosuppressant, n=27</td>
<td>1074 ± 758</td>
<td>0.485</td>
</tr>
<tr>
<td>IL-17 or IL-23 inhibitors, n=7</td>
<td>1653 ± 2471</td>
<td>0.035</td>
</tr>
<tr>
<td>Tacrolimus, n=32</td>
<td>614 ± 920</td>
<td>0.095</td>
</tr>
<tr>
<td>GC, n=103</td>
<td>481 ± 927</td>
<td>0.009</td>
</tr>
<tr>
<td>MTX, n=78</td>
<td>310 ± 493</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-6 inhibitors, n=10</td>
<td>303 ± 201</td>
<td>0.030</td>
</tr>
<tr>
<td>Cyclosporine, n=8</td>
<td>261 ± 228</td>
<td>0.035</td>
</tr>
<tr>
<td>TNF inhibitors, n=26</td>
<td>201 ± 252</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Abatacept, n=10</td>
<td>186 ± 320</td>
<td>0.010</td>
</tr>
<tr>
<td>Mycophenolate mofetil, n=11</td>
<td>183 ± 357</td>
<td>0.007</td>
</tr>
<tr>
<td>Azathioprine, n=13</td>
<td>150 ± 159</td>
<td>0.003</td>
</tr>
<tr>
<td>Baricitinib, n=6</td>
<td>101 ± 97</td>
<td>0.021</td>
</tr>
<tr>
<td>RTX, n=6</td>
<td>20 ± 32</td>
<td>0.012</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Anti-SARS-CoV-2 Ig G antibody was positive in 40 (23.5%) of the patients. Demographic characteristics and treatment-related variables were similar between SARS-CoV-2 IgG seropositive and seronegative patients (Table 1).

Table 1. Characteristics of patients who are seropositive and seronegative for anti-SARS-CoV-2 Ig G

<table>
<thead>
<tr>
<th>Variable</th>
<th>Anti-SARS-CoV-2 IgG positive patients (n=130)</th>
<th>Anti-SARS-CoV-2 IgG negative patients (n=40)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>11.96±4.19</td>
<td>12.80±4.14</td>
<td>0.528</td>
</tr>
<tr>
<td>Sex (%)</td>
<td>67 (72.8)</td>
<td>25 (72.1)</td>
<td>0.150</td>
</tr>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median age at diagnosis (years)</td>
<td>75±6.03</td>
<td>8.69±4.75</td>
<td>0.195</td>
</tr>
<tr>
<td>Median follow-up time after diagnosis (years)</td>
<td>4.39±3.27</td>
<td>4.11±3.19</td>
<td>0.891</td>
</tr>
</tbody>
</table>

Conclusion: We report increased risk for COVID-19 diagnosis and COVID-19-related death for people prescribed folic acid supplementation. The prescription and use of supplemental folic acid may confer risk of infection with the SARS-CoV-2 virus as well as the risk of death resulting from COVID-19. Our results also suggest that methotrexate might attenuate an increased risk for COVID-19 diagnosis and death conferred by folic acid.

REFERENCES:


POS1222

FOLIC ACID AND METHOTREXATE USE AND THEIR ASSOCIATION WITH COVID-19 DIAGNOSIS AND MORTALITY: AN ANALYSIS FROM THE UK BIOBANK

R. Topless1, R. Green2, S. Morgan3, P. Robinson4, T. Merriman1,3, A. Gaffo3,5.
1University of Otago, Biochemistry, Dunedin, New Zealand; 2University of California, Davis, Medicine, Davis, United States of America; 3University of Alabama at Birmingham, Medicine, Birmingham, United States of America; 4The University of Queensland, Medicine, Saint Lucia, Australia; 5Birmingham VA Medical Center, Medicine, Birmingham, United States of America

Background: Folate metabolism is implicated in SARS-CoV-2 infectivity (Ref). Objectives: To determine if methotrexate (an antifolate) or folic acid prescription were associated with a lowered and increased risk, respectively, for COVID-19 diagnosis or mortality in a large population-based cohort (UK Biobank).

Methods: Data from 380,380 UK Biobank participants with general practice prescription data were used. Criteria for COVID-19 diagnosis were 1) a positive SARS-CoV-2 test and/or 2) ICD-10 code for confirmed COVID-19 (U07.1) or probable COVID-19 (U07.2) in hospital records, or death records. This definition identified 26,003 individuals diagnosed with COVID-19 of whom 820 were known to have died from COVID-19. Logistic regression statistical models were adjusted for age group (4 categories), sex, ethnicity, Townsend deprivation index, BMI, smoking status, presence of rheumatoid arthritis, sicker cell disease, use of anti-convulsants, statins and iron supplements.

Results: Compared with people prescribed neither folic acid nor methotrexate, people prescribed folic acid supplementation had increased risk of diagnosis of COVID-19 (OR 1.51 [1.42; 1.61]). The prescription of methotrexate with or without folic acid was not associated with COVID-19 diagnosis (P=0.18). Compared with people prescribed neither folic acid nor methotrexate, people prescribed folic acid supplementation had an increased risk of death after a diagnosis of COVID-19 (OR 2.64 [2.15; 3.24]) in a fully adjusted model. The prescription of methotrexate in combination with folic acid was not associated with an increased risk for death after a diagnosis of COVID-19 (1.07 [0.57; 1.96]).

Table 1. COVID-19 diagnosis and associated death in people prescribed methotrexate and/or folic acid in the UKBB, compared to people not prescribed methotrexate or folic acid. Model 1 adjusted for age group, sex, ethnicity, Townsend deprivation index, BMI, smoking status Model 2 is model 1 plus adjustment by the presence of rheumatoid arthritis, sicker cell disease, use of statins, anti-convulsants and iron supplementation.

<table>
<thead>
<tr>
<th>Diagnosis (%):</th>
</tr>
</thead>
<tbody>
<tr>
<td>Folic acid and Methotrexate</td>
</tr>
<tr>
<td>COVID-19 diagnosis</td>
</tr>
<tr>
<td>Folic acid only</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Methotrexate and Folic acid</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>COVID-19 associated death</td>
</tr>
<tr>
<td>Folic acid only</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Methotrexate and folic acid</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>


POS1223

DIFFERENT ANTI-SARS-COV-2 VACCINE RESPONSE UNDER B- AND T-CELL TARGETED THERAPIES VERSUS ANTI-CYTOKINE THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIDES

R. Felten1, M. Geoffroy2, B. Loïs2, P. M. Duret3, M. Desmurs4, A. Fan5, A. Gaffo3,5.
1Hôpitaux Universitaires de Strasbourg, Service de Rhumatologie, Centre National de Référence des Maladies Auto-immunes Systémiques Rares Est Sud-Ouest (RESO), Strasbourg, France; 2Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Service de Rhumatologie, Reims, France; 3Hôpices Civils de Colmar, Hôpital Pasteur, Service Rhumatologie, COLMAR, France; 4Hôpital Emile MULLER de Mulhouse, Service de Rhumatologie, Mulhouse, France; 5Hôpitaux Universitaires de Clermont-Ferrand, Service de Rhumatologie, Clermont-Ferrand, France

Background: Vaccination against SARS-CoV-2 is effective in preventing severe forms of COVID-19, but there remain concerns about a reduced vaccine response in patients suffering from inflammatory arthritides who are treated by immunosuppressive therapies.

Objectives: We analysed the impact of bDMARDs on the humoral anti-SARS-CoV-2 vaccine response in patients followed in day hospitals.

Methods: We studied the vaccine response after a complete vaccine regimen followed in day hospital in 5 French hospitals and treated with an intravenous bDMARD between September 2019 and August 2021. After obtaining their informed consent, we included patients with an anti-SARS-CoV-2 serology. They were considered non-responders if the antibody level detected was inferior to the threshold of positivity of the kit used.

Results: 295 patients were included (148 females/57 males). The median age was 64 years (Interquartile Range [IQR] 56-71), 25 were treated with tocilizumab (TCZ), 36 with abatacept (ABA), 53 with infliximab (IFX) and 91 with rituximab (RTX). When considering both patients after a complete vaccination schema (2 doses,
or 1 dose in case of prior COVID-19) and those with 1 booster dose, 34 patients
(16.6%) were non-responders (2 [5.9%] treated by IFX, none treated by TCZ, 9 [26.3%] treated by ABA and 23 [67.7%] treated by RTX). In multivariate analysis, the
only characteristics that significantly and independently differed between respond-
ers and non-responders were last bDMARD and corticosteroid therapy at the time of
1st vaccination (Table 1). In RTX-treated patients, the delay from last infusion to 1st
vaccine dose was significantly shorter in non-responders (median 4.3 IQR [2.9-
6.1] months in non-responders versus 8.4 IQR [5.7-14.5] in responders, p=0.0007).
Median survival, i.e. achieving a vaccine response in 50% of RTX-treated subjects,
was achieved after 277 days (IQR [209-310]) in patients vaccinated with 2 or 3
doses (Figure 1). In ABA-treated patients, the delay from last infusion to 1st vaccine
dose was not different between non-responders and responders.

Table 1. Patients' characteristics and comparisons between responders and non-
responders.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All patients (n=205)</th>
<th>Responders (n=171)</th>
<th>Non responders (n=34)</th>
<th>Univariate p value</th>
<th>Multivariate p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median [IQR]), in years</td>
<td>64 [56-71]</td>
<td>64 [54-70]</td>
<td>69 [57-75.5]</td>
<td>0.07</td>
<td>0.40</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>148 (72.2)</td>
<td>125 (73.1)</td>
<td>23 (67.7)</td>
<td>0.53</td>
<td>0.16**</td>
</tr>
<tr>
<td>Inflammatory arthritides, n (%)</td>
<td>156 (78.0)</td>
<td>128 (74.9)</td>
<td>28 (82.4)</td>
<td>0.51</td>
<td>0.24</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>33 (16.1)</td>
<td>31 (18.1)</td>
<td>2 (5.9)</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>Spondyloarthritis</td>
<td>16 (7.8)</td>
<td>12 (5.9)</td>
<td>4 (14.7)</td>
<td>0.31</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>25 (12.2)</td>
<td>21 (12.3)</td>
<td>2 (5.9)</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Last bDMARDs at time of 1st vaccination, n (%)</td>
<td>126 (61.5)</td>
<td>107 (62.6)</td>
<td>19 (55.9)</td>
<td>0.56</td>
<td>0.0004</td>
</tr>
<tr>
<td>infiximab</td>
<td>91 (44.4)</td>
<td>68 (39.8)</td>
<td>23 (67.7)</td>
<td>0.0004</td>
<td>0.0024</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>25 (12.2)</td>
<td>21 (12.3)</td>
<td>2 (5.9)</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Abatacept</td>
<td>36 (17.6)</td>
<td>27 (15.8)</td>
<td>9 (26.5)</td>
<td>0.0001</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>91 (44.4)</td>
<td>68 (39.8)</td>
<td>23 (67.7)</td>
<td>0.0004</td>
<td>0.0024</td>
</tr>
<tr>
<td>Associated treatments at time of 1st vaccination</td>
<td>15 (10-17.5)</td>
<td>13.6 [10-15.6]</td>
<td>15 [13-17.2]</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>CsDMARDs, n (%)</td>
<td>53 (25.9)</td>
<td>51 (29.8)</td>
<td>2 (5.9)</td>
<td>0.0004</td>
<td>0.0024</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>91 (44.4)</td>
<td>68 (39.8)</td>
<td>23 (67.7)</td>
<td>0.0004</td>
<td>0.0024</td>
</tr>
<tr>
<td>Median dose in users (mg /week) [IQR]</td>
<td>15 [10-17.5]</td>
<td>13.6 [10-15.6]</td>
<td>15 [13-17.2]</td>
<td>0.07</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>25 (12.2)</td>
<td>19 (11.1)</td>
<td>6 (17.6)</td>
<td>0.29</td>
<td></td>
</tr>
<tr>
<td>Median dose (mg /day) [IQR]</td>
<td>0 [0-0]</td>
<td>0 [0-0]</td>
<td>0 [0-0]</td>
<td>0.035</td>
<td>0.016</td>
</tr>
<tr>
<td>Previous COVID-19 infection, n (%)</td>
<td>23 (11.2)</td>
<td>21 (12.3)</td>
<td>2 (5.9)</td>
<td>0.38</td>
<td></td>
</tr>
<tr>
<td>Type of vaccine, n (%)</td>
<td>167 (81.5)</td>
<td>141 (82.5)</td>
<td>28 (81.8)</td>
<td>0.47</td>
<td></td>
</tr>
<tr>
<td>Complete</td>
<td>56 (27.3)</td>
<td>43 (25.1)</td>
<td>13 (38.2)</td>
<td>0.14</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Cumulative seropositive rate according to the interval (days) between the last
course of rituximab administration and vaccination

Conclusion: ABA and RTX alter the anti-SARS-CoV-2 vaccine response and
were associated with nearly all vaccine non-responses in the present study.
Corticosteroid therapy was associated with a lower vaccine response regardless of its
date or indication or the concomitant use of DMARD.

Disclosure of Interests: None declared.
Background: Throughout the COVID-19 pandemic, the BNT162b2 (manufactured by Pfizer—BioNTech) and mRNA-1273 (manufactured by Moderna Inc) vaccines have demonstrated an acceptable safety profile and a high degree of effectiveness in preventing severe COVID-19 outcomes in healthy individuals. However, it remains to be determined if similar benefits can be replicated in immunocompromised patients, who were largely excluded from Phase III clinical trials. Preliminary data on vaccine immunogenicity among lupus patients reveal blunted humoral responses, particularly in those using prednisone and/or mycophenolate (1-2).

Objectives: This study sought to measure the antibody responses following SARS-CoV-2 vaccination in patients with SLE and to identify clinical and laboratory parameters associated with low antibody responses.

Methods: We prospectively enrolled SLE patients from the Beth Israel Deaconess Medical Center Systemic Lupus Erythematosus Cohort (BI-DLC). The patients received two doses of either BNT162b2 or mRNA-1273 and were tested for the SARS-CoV-2 IgG spike antibody at least 4 weeks after the second vaccine dose. Patients with evidence of prior COVID-19 infection were excluded. The primary goal of this study was to measure the prevalence of a weak IgG spike antibody response and identify predictive clinical-laboratory factors. We first measured the antibody responses in a healthy control group and defined a low antibody titer as values that fell below the 25th percentile of this reference group (<6). We then used simple logistic regression to assess for associations between different predictive variables and our predefined dichotomous outcome: <6 vs ≥6 IgG spike antibody titer. To account for potential cofounders, a multiple logistic regression model was performed. Risk ratios were calculated with the Odds ratios, OR, adjusted for gender, age, and ACE-42.

Results: A total of 71 patients were included in the study. At the time of vaccination, patients were on various immunomodulator and suppressive medications, including: Hydroxychloroquine 87%, Prednisone 38%, Mycophenolate 38%, Azathioprine 18% and Belimumab 7%. The proportion of patients who received BNT162b2 and mRNA-1273 was 58% and 42%, respectively. Overall, 63% of patients had a high IgG spike antibody titer (≥ 6) and 37% of patients had a low antibody titer. More importantly, we demonstrated that a pre-vaccine high SLEDAI score or receiving BNT162b2 (Pfizer—BioNTech) increases the risk of impaired immune response to the COVID-19 vaccine. In patients with SLE, Azathioprine use independently predicts reduced antibody titers. More importantly, we demonstrated that a pre-vaccine high disease activity score or receiving BNT162b2 increases the risk of impaired immune response to the COVID-19 vaccine.

Conclusion: In patients with SLE, Azathioprine use independently predicts lower antibody titers. More importantly, we demonstrated that a pre-vaccine high disease activity score or receiving BNT162b2 increases the risk of impaired immune response to the COVID-19 vaccine.

References:

Disclosure of Interests: Christine Parsons: None declared, Jose Rubico: None declared, Afroditi Boulougoura: None declared, Vasileios Kyttaris Grant/research support from: Dr. Kyttaris is a grant recipient of Exagen Diagnostics, Employee of: Dr. Kyttaris serves on the advisory board of Aurnia Pharmaceuticals


POS1225 PREDICTORS OF WEAK ANTIBODY RESPONSE POST-COVID-19 MRNA VACCINATION IN SLE

C. Parsons1, J. Rubico2, A. Boulougoura3, V. Kyttaris2, 1Beth Israel Deaconess Medical Center Internal Medicine, Boston, United States of America; 2Beth Israel Deaconess Medical Center, Rheumatology, Boston, United States of America; 3Beth Israel Deaconess Medical Center, Media, Rheumatology, Boston, United States of America

Methods: We prospectively enrolled SLE patients from the Beth Israel Deaconess Medical Center Systemic Lupus Erythematosus Cohort (BI-DLC). The patients received two doses of either BNT162b2 or mRNA-1273 and were tested for the SARS-CoV-2 IgG spike antibody at least 4 weeks after the second vaccine dose. Patients with evidence of prior COVID-19 infection were excluded. The primary goal of this study was to measure the prevalence of a weak IgG spike antibody response and identify predictive clinical-laboratory factors. We first measured the antibody responses in a healthy control group and defined a low antibody titer as values that fell below the 25% percentile of this reference group (<6). We then used simple logistic regression to assess for associations between different predictive variables and our predefined dichotomous outcome: <6 vs ≥6 IgG spike antibody titer. To account for potential cofounders, a multiple logistic regression model was performed. Risk ratios were calculated with the Odds ratios, OR, adjusted for: gender, age, and ACE-42.

Results: A total of 71 patients were included in the study. At the time of vaccination, patients were on various immunomodulator and suppressive medications, including: Hydroxychloroquine 87%, Prednisone 38%, Mycophenolate 38%, Azathioprine 18% and Belimumab 7%. The proportion of patients who received BNT162b2 and mRNA-1273 was 58% and 42%, respectively. Overall, 63% of patients had a high IgG spike antibody titer (≥ 6) and 37% of patients had a low antibody titer. More importantly, we demonstrated that a pre-vaccine high SLEDAI score or receiving BNT162b2 (Pfizer—BioNTech) increases the risk of impaired immune response to the COVID-19 vaccine. In patients with SLE, Azathioprine use independently predicts reduced antibody titers. More importantly, we demonstrated that a pre-vaccine high disease activity score or receiving BNT162b2 increases the risk of impaired immune response to the COVID-19 vaccine.

Conclusion: In patients with SLE, Azathioprine use independently predicts lower antibody titers. More importantly, we demonstrated that a pre-vaccine high disease activity score or receiving BNT162b2 increases the risk of impaired immune response to the COVID-19 vaccine.

References:

Disclosure of Interests: Christine Parsons: None declared, Jose Rubico: None declared, Afroditi Boulougoura: None declared, Vasileios Kyttaris Grant/research support from: Dr. Kyttaris is a grant recipient of Exagen Diagnostics, Employee of: Dr. Kyttaris serves on the advisory board of Aurnia Pharmaceuticals

DOI: 10.1136/annrheumdis-2022-eular.2186

POS1226 CLINICAL FACTORS ASSOCIATED WITH A POSITIVE SARS-COV-19 TEST AND WITH FREQUENT TESTING DURING THE COVID-19 PANDEMIC IN >10,000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. RESULTS FROM A NATIONWIDE SURVEY FROM THE DANISH DANBIO REGISTRY

B. Glintborg1,2, D. V. Jensen1,3, L. Terslev1,2, O. Hendricks2,3, M. Østergaard2,3, S. H. Rasmussen1,2, T. Adelsten4, A. Coelic5, K. Danebod6, M. Kildemand7, A. G. Loft7,8, H. L. Munk7, J. K. Pedersen7,8, R. Østgård9, C. M. Sørensen10, N. Steen Krogh11, J. Nørgaard Agerbo10, C. Ziegler12, M. L. Hetland1,2, 1Center for Rheumatology and Spine Diseases, Aarhus University Hospital, Panderhospitalet, DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; 2University of Copenhagen, Department of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen, Denmark; 3Gentofte and Herlev Hospital, Department of Rheumatology, Center for Rheumatology and Spine Diseases, Gentofte, Denmark; 4University Hospital of Southern Denmark, Danish Hospital for Rheumatic Diseases, Sanderborg, Denmark; 5University of Southern Denmark, Department of Regional Health Research, Odense, Denmark; 6Zealand University Hospital, Department of Rheumatology, Køge, Denmark; 7Odense University Hospital, Department of Rheumatology, Odense, Denmark; 8Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 9Aarhus University, Department of Clinical Medicine, Health, Aarhus, Denmark; 10Odense University Hospital and University of Southern Denmark, Rheumatology Research Unit, Odense, Denmark; 11Odense University Hospital and Svendborg Hospital, Rheumatology Section, Department of Medicine M, Svendborg, Denmark; 12University of Southern Denmark, Department of Clinical Research, Odense, Denmark; 13Silkeborg Regional Hospital, Diagnostic Center, Silkeborg, Denmark; 14Horsens Regional Hospital, Department of Medicine, Horsens, Denmark; 15Zitelab, Zitelab, Copenhagen, Denmark; 16Gigtforeningen, Danish Rheumatism Association, Gentofte, Denmark

Background: Patients with inflammatory rheumatic diseases (IRD) have used self-isolation and social distancing during the pandemic to avoid SARS-CoV-19 infection (reference). In countries with unlimited and free access to SARS-CoV-19 testing, anxiety or other patient related factors might potentially increase test-frequency.

Objectives: In patients with IRD followed in the nationwide DANBIO registry we aimed to explore clinical factors including self-isolation associated with a) positive SARS-CoV-19 test result (‘infection’), b) higher frequency of SARS-CoV-19 testing during the first 1½ year of the pandemic.

Methods: In May-June 2020, IRD patients followed in the quality registry, DAN- BIO (n=36,152), were invited to participate in the voluntary online questionnaire survey “You and your rheumatic disease during times with corona-virus: Patient characteristics, treatment and patient reported outcomes were captured in DAN-BIO and from the questionnaire. Patients were considered as self-isolating if they agreed to the question: I stay at home and avoid others as much as possible. After written consent, information on dates and SARS-CoV-19 test results (by PCR, polymerase chain reaction) during follow-up (until Nov 2021 and thus before entry of the Omicron variant) was obtained through linkage to the nationwide laboratory system. Time to first positive PCR and associated characteristics were explored by multivariable Cox regression analyses with hazard ratios, HR, adjusted for: gender/ age-group/ diagnosis/biologic therapy/working/ self-isolation/HAQ/EQ-5D. Day 0 was defined as the date of first positive test in cohort (May-07 -2020).

Results: In 10,098 included patients, 2.8% were infected during follow-up (Table 1). Age and HAQ seemed lower in infected (Table 1, Figure 1). In multivariable Cox
regression analyses, male gender was associated with higher infection risk (HR 1.38 (1.05;1.80) whereas risk was lower in the age-group 61-80 years (0.60 (0.39;0.92) vs. below 40 years). Other factors were statistically insignificant.

**Table 1.**

<table>
<thead>
<tr>
<th>SARS-CoV-19 tests</th>
<th>Number of tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population</td>
<td>10,098</td>
</tr>
<tr>
<td>POSITIVE*</td>
<td>282</td>
</tr>
<tr>
<td>NEGATIVE</td>
<td>9616</td>
</tr>
<tr>
<td>&lt;9</td>
<td>7406</td>
</tr>
<tr>
<td>≥9</td>
<td>2692</td>
</tr>
</tbody>
</table>

**Patient**

<table>
<thead>
<tr>
<th>%</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>6654</td>
</tr>
<tr>
<td>Male</td>
<td>3444</td>
</tr>
</tbody>
</table>

**Age, yrs, median (IQR)**

| < 40   | 696 |
| 40-60  | 3989 |
| 61-80  | 4984 |
| >80    | 247  |

**Diagnosis**

| AxSpA | 1464 |
| RA    | 6345 |
| PsA   | 1689 |
| Other | 600  |

**HAQ, median**

| 0.5  | 0.375 |
| 0.8  | 0.375 |

**EQ-S, median**

| 0.8  |
| 0.8  |

**Self-isolating, yes**

| 377  |
| 72   |

**Working**

| 96   |
| 56   |

**Row percentage unless otherwise shown** At least one positive PCR before Nov 2021**May 2020**:

| %     | 82 |
| 67   |

**Disclosure of Interests:** Bente Glintborg Grant/research support from: Abbvie, BMS, Pfizer, Dorte Vendelbo Jensen: None declared, Lene Terslev Speakers bureau: Roche, Novartis, Pfizer, ULB, Olgirud Hendrickx Grant/research support from: Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB, Simon Horskjer Rasmussen: None declared, Mogens Pfeiffer-Jensen: None declared, Ada Colic: None declared, Boehringer-Ingelheim, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi and UCB, Grant/research support from: Abbvie, Biogen, BMS, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopis, Sandoz.

**Disclosure of Interests:**

- Kamilla Danebod: None declared, Malene Kildemand: None declared, Anne Nielsen: None declared, Thomas Adelsten: None declared, Ada Colic: None declared, Boehringer-Ingelheim, Eli-Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi and UCB, Pfizer, Roche, Sanofi and UCB, Grant/research support from: Abbvie, Christian Møller Sørensen: None declared, Niels Steen Krogh: None declared, Jette Nørgaard Agerbo: None declared, Connie Ziegler: None declared, Merete Lund Heltland Grant/research support from: Abbvie, Biogen, BMS, Celtrion, Eli Lilly Denmark A/S, Janssen Biologics B.V, Lundbeck Fonden, MSD, Pfizer, Roche, Samsung Biopis, Sandoz.

**DOI:** 10.1136/annrheumdis-2022-eular.2234

**Table 1.** Characteristics of patients without response after the second dose of vaccine treated with Rituximab for autoimmune disease according to their seroconversion status after the third dose.

<table>
<thead>
<tr>
<th>Age, median (min-max)</th>
<th>61 (17-85)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex n (%)</td>
<td>58 (36-78)</td>
</tr>
<tr>
<td>Underlying disease n (%)</td>
<td>42 (80)</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>36 (99)</td>
</tr>
<tr>
<td>Other autoimmune disease</td>
<td>16 (31)</td>
</tr>
<tr>
<td>Rituximab treatment</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Received a RTX infusion between dose 2 and 3 n (%)</td>
<td>14 (27)</td>
</tr>
<tr>
<td>Time between the last RTX infusion and the 3rd dose of vaccine in days median (min-max)</td>
<td>162 (1-687)</td>
</tr>
<tr>
<td>Previous number of RTX injections, median (min-max)</td>
<td>7 (0-34)</td>
</tr>
<tr>
<td>Vaccination scheme</td>
<td>167 (79-959)</td>
</tr>
<tr>
<td>Interval between 2nd and 3rd vaccine dose in days, median (min-max)</td>
<td>80 (23-287)</td>
</tr>
<tr>
<td>Less than 3 months between 2nd and 3rd vaccine dose n (%)</td>
<td>27 (53)</td>
</tr>
<tr>
<td>Prednisone equivalent dose per day in mg median (min-max)</td>
<td>5 (2-25)</td>
</tr>
<tr>
<td>p</td>
<td>0.33</td>
</tr>
<tr>
<td>0.36</td>
<td></td>
</tr>
<tr>
<td>0.46</td>
<td></td>
</tr>
<tr>
<td>0.58</td>
<td></td>
</tr>
<tr>
<td>0.16</td>
<td></td>
</tr>
<tr>
<td>0.15</td>
<td></td>
</tr>
</tbody>
</table>

**POS1227 TIME BETWEEN SECOND AND THIRD DOSES INFLUENCES RESPONSE TO COVID-19 VACCINE IN AUTO-IMMUNE DISEASE PATIENTS TREATED WITH RITUXIMAB WITHOUT RESPONSE TO TWO DOSES.**

- 1Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, HU CAR, Université Paris-Saclay, INSERM U1198, Rheumatology Department, Le Kremlin Bicêtre, France.
- 2Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université de Paris, Rheumatology Department, Paris, France.
- 3Université Paris Saclay, INSERM U1193, AP-Hôp Paul Brousse, Virology, Villejuif, France.

**Background:** It is now well established that patients treated with rituximab (RTX) for auto-immune disease (AID) have a diminished antibody response to COVID-19 vaccines after two doses. Optimizing antibody response is a key objective in this population. To achieve this goal, a 3rd booster dose may be considered.

**Objectives:** Focusing on the population of AID patients treated with RTX without any antibody response after two doses we sought to explore how these patients could respond to a 3rd dose and identify factors of response.

**Methods:** We performed a French retrospective bicentric observational trial which is a follow-up of previously published work (1). We included consecutive patients treated with RTX that were non-responders regarding their anti-Spike antibody (anti-S) status at least one month after the second dose of COVID-19 vaccination. Patients were included between March and October 2021. All patients then received a third dose according to local guidelines and had an anti-S measurement at least one month after the third dose. Some patients without response to a third dose had a fourth dose. Anti-S were measured in serum with various kits, but all results were in BAU/mL with upper quantification limit at 243. Patients with anti-S above 49 BAU/mL, which has been demonstrated to be the threshold associated with detectable neutralizing response were considered as responders (1).

**Results:** 60 patients treated with RTX without response to 2 doses (Anti-S Ab < 49 BAU/mL) were included in the study. 9/60 (15%) patients responded to the 3rd vaccine dose with anti-S > 49 BAU/mL. Responders and non-responders had similar demographic characteristics (Table 1). There was a positive correlation between anti-S Ab levels after dose 2 and time and 3rd doses (r=0.41 p=0.001) (Figure 1). Nevertheless, the median time between 2nd and 3rd doses was numerically but not significantly higher in responders than in non-responders (129 vs 80 days, p=0.30). There was no correlation between anti-S levels after the third dose and the time between the last RTX infusion and the third vaccine dose. There was a trend towards more patients with methotrexate co-medication according to their seroconversion status after the third dose.

**Conclusion:** Few patients with IRD were infected during the first 1½ years of the pandemic. Gender and age were associated with infection risk and frequency of testing. Self-isolation and a range of other clinical characteristics had no impact, which to some extent may be due to behavioral differences across age-groups.

**REFERENCES:**


**Table 1.** Time to positive SARS-CoV-19 test, by age-group.
Conclusion: A third vaccine dose of COVID-19 vaccine leads to only 15% of response in previously non-responding RTX treated AID patients. A longer time between 2nd and 3rd doses might positively influences response to a 3rd COVID-19 vaccine. Finally exploratory findings show that a fourth dose could be useful to obtain response non-responders.

REFERENCES:

Table 1. Trends in prescriptions issued for ADA, RTX and TOC in England before and after the onset of the COVID-19 pandemic, assessed using interrupted time-series analyses. The absolute change in prescriptions issued in March 2020, relative to April 2020, is shown.

<table>
<thead>
<tr>
<th></th>
<th>Rituximab</th>
<th>Adalimumab</th>
<th>Tocilizumab</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prescription trend before March 2020</td>
<td>-0.23% per year</td>
<td>+2.94% per year</td>
<td>+0.04% per year</td>
</tr>
<tr>
<td>(95% CI -0.97 to 0.52)</td>
<td>(95% CI 2.14 to 3.73)</td>
<td>(95% CI -0.07 to 1.53)</td>
<td></td>
</tr>
<tr>
<td>Absolute change in prescriptions in March 2020</td>
<td>-46.3%</td>
<td>+15.3%</td>
<td>+10.7%</td>
</tr>
<tr>
<td>Prescription trend after March 2020</td>
<td>+2.11% per year</td>
<td>+3.24% per year</td>
<td>+0.64% per year</td>
</tr>
<tr>
<td>(95% CI 0.52 to 3.70)</td>
<td>(95% CI 2.02 to 4.46)</td>
<td>(95% CI 0.98 to 3.73)</td>
<td></td>
</tr>
<tr>
<td>Difference in trends post vs. pre-March 2020</td>
<td>+2.33% per year</td>
<td>+0.30% per year</td>
<td>+0.60% per year</td>
</tr>
<tr>
<td>(95% CI 0.51 to 4.17)</td>
<td>(95% CI -1.03 to 1.63)</td>
<td>(95% CI 0.31 to 0.90)</td>
<td></td>
</tr>
</tbody>
</table>

After May 2020, reflected in the positive prescription trend observed in ITSA models (Table 1); however, RTX prescriptions remained below pre-pandemic levels, before decreasing again between November 2020 and February 2021. This coincided with increasing COVID-19 case numbers in England.

Figure 1. Temporal trends in prescriptions for ADA, RTX and TOC in England between January 2019 and November 2021. Monthly averages of prescriptions for combined disease indications are shown, standardised using WHO Defined Daily Doses.

For ADA, the pre-pandemic trend of increasing prescriptions continued during the pandemic, with no differences in prescription trends seen in ITSA models (Table 1). A 22% decrease in ADA prescriptions was observed between September and October 2020, from 2,037,800 DDD to 1,587,500 DDD, respectively, before rebounding to above pre-pandemic levels. Prescriptions for TOC increased during the pandemic, driven primarily by a 76% increase in prescriptions between December 2020 and January 2021, from 241,800 DDD to 425,000 DDD, respectively.

Conclusion: Prescriptions for RTX in England halved during the early COVID-19 pandemic, and remain below pre-pandemic levels as of November 2021. This likely reflects concerns about RTX use and increased COVID-19 mortality and reduced vaccine efficacy.1-3 In contrast, prescriptions for ADA have continued to increase during the pandemic, while prescriptions for TOC surged in December 2020, coinciding with the more widespread use of TOC for the treatment of severe COVID-19.

REFERENCES:

Figure 1. Correlation between anti- spike Ab levels after the third dose and time in days between doses 2 and 3.

POS1229 THE IMPACT OF COVID-19 ON MEDICATION NON-ADHERENCE IN A RHEUMATOID AND PSORIATIC ARTHRITIS UK COHORT

P. Curry1, H. Chinyo2, M. Jami3, D. Plant1,2, K. Hyrich3,4, A. Morgan4, A. G. Wilson1, J. Isaacs1, A. Morris1,2, A. Barton1,2, J. Bluu1,2, 1The University of Manchester, Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester, United Kingdom; 2Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; 3The University of Manchester Versus Arthritis Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester, United Kingdom; 4Leeds Teaching Hospitals NHS Trust, School of Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; 5University College Dublin, School of Medicine & Medical Science, Conway Institute, Dublin, Ireland; 6Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Directorate, Newcastle upon Tyne, United Kingdom

Background: In March 2020, as part of the UK’s COVID-19 prevention strategy, those identified as ‘clinically extremely vulnerable’, were advised to shield. This included a number of patients prescribed anti-rheumatic drugs, who were asked to continue their current treatment unless they developed symptoms of infection. Suboptimal treatment adherence (16.0%-81.0%) has been reported in patients with arthritic diseases, and is associated with psychological factors, including anxiety (1). Previous literature in...
non-UK cohorts has highlighted suboptimal adherence levels in immunosuppressed patients during the pandemic, although many were single centre studies (2,3).

**Objectives:** The aim of this multi-centre study is to investigate the impact of the COVID-19 pandemic on adherence to anti-rheumatic medications in patients with established rheumatoid (RA) and psoriatic (PsA) arthritis in the UK who had recently commenced a biologic or targeted synthetic DMARD.

**Methods:** Between September 2020 and May 2021, RA and PsA patients prescribed biologic or targeted synthetic anti-rheumatic drugs from two multi-centre observational studies (BRAGGSS and OUTPASS) were sent a questionnaire on medication usage, adherence, and perceptions to establish the impact of COVID-19 on these parameters. Patients were asked about compliance during the COVID-19 pandemic using a 5-point Likert scale (always, often, sometimes, rarely, and never) and the reason for non-adherence. Adherence was defined as never missing or delaying a dose, unless medically advised. Descriptive summary statistics were calculated, and logistic regression and Pearson’s chi-squared tests were employed to investigate variables associated with self-reported non-adherence.

**Results:** In total 159 questionnaires were returned (81.1% RA and 18.9% PsA). Methotrexate (53.5%) was the most frequently prescribed agent, followed by etanercept (25.2%), salsalazine (22.6%), hydroxychloroquine (21.4%) and adalimumab (19.5%). Furthermore, 66.8% of patients were prescribed ≥2 drugs. During the pandemic, 42.1% of patients reported missing or delaying a treatment dose for any reason. Adherence information was available for 97.5% of patients with 25.8% reporting non-adherence which was not medically advised. Methotrexate non-adherence was 27.1%, with similar levels reported for etanercept (20.0%), salsalazine (27.8%), hydroxychloroquine (35.3%) and adalimumab (29.0%). No drugs had significantly different adherence compared to methotrexate. Furthermore, there was no association between disease type or perception of disease control and adherence. Of non-adherent patients, 17.5% reported increased anxiety, fear, and increased risk due to the COVID-19 pandemic as an influencing factor. Meanwhile, 37.5% of non-adherent patients listed non-COVID-19 intentional reasons and 45.0% reported non-intentional reasons, with forgetting and running out of treatment listed most frequently.

**Conclusion:** In a UK cohort self-reported non-adherence was reported in 25.8% of patients during the COVID-19 pandemic, despite medical advice, with reasons including increased anxiety due to COVID-19.

**REFERENCES:**


**Acknowledgments:** on behalf of the BRAGGSS consortium

**Disclosure of Interests:** Philippa Curry: None declared, Hector Chinoy Speakers bureau; UCB, Biogen, Consultant of: Novartis, Eli Lilly, Orphazyme, AstraZeneca, Grant/research support from: Eli Lilly, UCB, Meghana Jani: None declared, Darren Plant: None declared, Kimme Hyrich Consultant of: consultancy/honoraria from AbbVie, Grant/research support from: Pfizer, BMS, Ann Morgan Speakers bureau: Roche, Chugai, Consultant of: GSK, Roche, Chugai, AstraZeneca, Regeneron, Sanofi, Vifor, Grant/research support from: GSK, Janssen, Pfizer, Andrew Morris: None declared, Anne Barton Grant/research support from: I have received grant funding from Pfizer, Galapagos, Scipher Medicine and Bristol Myers Squibb, James Bluett Grant/research support from: Pfizer Limited, JB has received travel/conference fees from UCB, Pfizer and Eli Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.2337

**POS1230 INCREASED ANTIBODY RESPONSE AFTER SARS-COV-2 mRNA-BASED VACCINATION IN RITUXIMAB-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION**

J. Avouac1, R. Ghossan2, O. Al Tabaa1, A. Combier1, A. Steelandt1, M. Thomas1, O. Fogel1, A. A. Mariaggi2, J. F. Meritet2, F. Rozenberg2, A. Molto1, C. Miceli Richard1, Y. Allarone1, 1Cochin Hospital, Rheumatology, Paris, France; 2Cochin Hospital, Virology, Paris, France

**Background:** Rituximab (RTX) is associated with reduced humoral response to SARS-CoV-2 mRNA-based vaccine (1, 2). A recent study has shown that, despite their immunosuppression burden, kidney transplant recipients with previous exposure to SARS-CoV-2 showed a marked increase in antibody titer, even after a single dose of vaccine (3).

**Objectives:** To describe the results of immunization after 1 to 3 doses of mRNA SARS-CoV-2 vaccine in RTX-treated patients with previous symptomatic COVID-19 infection.

**Methods:** Observational prospective usual care study including consecutive patients with inflammatory rheumatic diseases in maintenance therapy with RTX.
**POSI231**

**PREDICTORS OF MORTALITY IN SEVERE AND CRITICALLY COVID-19 PATIENTS WHO RECEIVED ANAKIRNA**

M. Bekta1, M. I. Kılıç1, 1Aksaray Training and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Aksaray, Turkey

**Background:** Several predictive factors were described in COVID-19 during the pandemic, however there is limited data in severe/critically ill patients (pts) with COVID-19 who received biologic therapies including anakinra.

**Objectives:** We aimed to evaluate the predictive factors of mortality in pts with severe and critically ill COVID-19 who received anakinra.

**Methods:** Diagnosis of COVID-19 was confirmed by PCR and/or typical CT findings. Severe and critically ill pts according to NIH severity scale who received anakinra in the ward were evaluated retrospectively (1). Laboratory values at admission, highest levels and the last day of hospitalization were recorded. COVID hyperinflammatory syndrome score (cHIS) was calculated according to the highest levels of laboratory results (2). All pts received background steroid therapy with 80 mg methylprednisolone (or its equivalent). Anakinra was started in pts who did not respond to steroid therapy at least two days or concomitantly with steroids in pts with higher risk and/or critical illness at admission. Average starting dose of anakinra was 600 mg/day intravenously and increased gradually to 1600 mg/day if necessary.

**Results:** Data of 148 pts (53 % male) were analyzed. Of those 57 pts (38.5 %) severe, 91 pts (61.5 %) had critical disease. Overall, 56 pts (37.8 %) died during the follow-up and intensive care unit admission was in 60 pts (40.5 %) and intubation in 54 pts (54.5 %). Diabetes mellitus was in 28 %, hypertension in 59 %, coronary heart disease in 19 %, heart failure in 12.6 %, chronic kidney failure in 21 %, chronic obstructive pulmonary disease in 16 %, dementia in 12.8 %, malig-nancy in 11 % and rheumatic disease in 5.6 % of pts. Only dementia significantly differed between pts with mortality and had not (p<0.005 OR:9.8).

In univariable analysis; patient age, neutrophil to lymphocyte ratio (NLR), mean cHIS scores were higher in pts who had mortality. Baseline maximum and last values of CRP, LDH, ferritin, D-dimer levels were observed in pts had mortality. Mortality was also higher in pts with critically ill compared to severe disease. In multivariable analysis; higher age (p<0.001 OR:1.01-1.09), cHIS score (p=0.002 OR:2.6 CI:1.4-4.9), critical illness compared to severe disease (p=0.02 OR:14 CI:1.6-122) were associated with mortality.

**Conclusion:** In our study mortality was developed in third of anakinra receiving pts. Mortality was independently associated with advanced age, chronic critical illness and higher cHIS score reflecting higher inflammatory burden. Furthermore, high-est levels of CRP, LDH, ferritin, D-dimer and higher cHIS score predict higher mortality in pts receiving anakinra. It is important to identify the pts with higher mortality risk to improve outcome.

**REFERENCES:**

**Disclosure of Interests:** None declared

**Table 1.**

<table>
<thead>
<tr>
<th>Variables</th>
<th>mortality -</th>
<th>mortality +</th>
<th>p value</th>
<th>ROC [AUC (95 % CI)]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years*</td>
<td>63.4±18</td>
<td>72.3±14</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>Gender, male*</td>
<td>44 (38)</td>
<td>36 (41)</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td>Duration of hospitalization (days)</td>
<td>10.5 (12)</td>
<td>12 (14)</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>COVID severity</td>
<td>36 (40)</td>
<td>55 (60)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>(critical vs severe)**</td>
<td>4.1±1.1</td>
<td>0.001</td>
<td>0.77 (0.69-0.86)**</td>
<td></td>
</tr>
<tr>
<td>cHIS</td>
<td>5.6 (5)</td>
<td>10 (9)</td>
<td>&lt;0.001</td>
<td>0.72 (0.6-0.82)**</td>
</tr>
<tr>
<td>Platelets* (x10^9/L)</td>
<td>215±77</td>
<td>192±82</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>367 (110)</td>
<td>136 (126)</td>
<td>0.004</td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td>137 (100)</td>
<td>194 (134)</td>
<td>0.007</td>
<td>0.73 (0.63-0.82)**</td>
</tr>
<tr>
<td>3rd</td>
<td>6.8 (8)</td>
<td>103 (132)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Ferritin (mg/L)</td>
<td>326 (531)</td>
<td>557 (767)</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td>555 (606)</td>
<td>1212 (2336)</td>
<td>&lt;0.001</td>
<td>0.76 (0.68-0.85)**</td>
</tr>
<tr>
<td>3rd</td>
<td>296 (270)</td>
<td>814 (1550)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>D-dimer (mg/mL)</td>
<td>11 (1)</td>
<td>15 (17)</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td>2.8 (7)</td>
<td>12.4 (24)</td>
<td>&lt;0.001</td>
<td>0.74 (0.65-0.83)**</td>
</tr>
<tr>
<td>3rd</td>
<td>1.2 (12)</td>
<td>7.4 (18)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>LDH (IU/L)</td>
<td>399 (193)</td>
<td>391 (245)</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td>2nd</td>
<td>513 (200)</td>
<td>676 (528)</td>
<td>&lt;0.007</td>
<td>0.78 (0.68-0.86)**</td>
</tr>
<tr>
<td>3rd</td>
<td>319 (104)</td>
<td>641 (439)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

*mean±std dev, **median (IQR); *n (%) p<0.001 1st and admission 2nd maximum 3rd last level

**POSI232**

**LONG-TERM OUTCOMES OF COVID-19 VACCINATION IN PATIENTS WITH RARE AND COMPLEX CONNECTIVE TISSUE DISEASES: AN AD-INTERIM ANALYSIS OF ERN-RECONNET VACCINATION STUDY**


1Rheumatology Unit, University of Pisa, Pisa, Italy; 2University of Padua, Rheumatology Unit, Department of Medicine-DIMED, Padua, Italy; 3Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon Academic Medical Centre, Rheumatology Department, Lisbon, Portugal; 4IRCCS Polyclinic Hospital San Martino, University of Genoa, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, Genoa, Italy; 5Sapienza University, San Camillo-Forlanini Hospital, Laboratory of Medical Genetics, Rome, Italy; 6IRCCS Policlinico San Matteo Foundation, Department of Rheumatology, Pavia, Italy; 7Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Research Center for Systemic Autoimmune Diseases, Milan, Italy; 8ASST Spedali Civili and University of Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 9University of Pisa, University of Pisa, Pisa, Italy; 10Charité University Medicine Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 11Flemish Association for Hereditary Connective Tissue Disorders, Flemish Association for Hereditary Connective Tissue Disorders, Koersel, Belgium; 12Federation of European Scleroderma Associations, FESCA, Milan, Italy; 13Centre de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France, Centre Hospitalier Universitaire de Lille, Department of Médecine Interne et Immunologie Clinique, Lille, France; 14Cliniques Universitaires Saint-Luc, Université Catholique De Louvain, Department of Rheumatology, Louvain-la-Neuve, Belgium; 15Kerckhoff-Klinik GmbH, Bad Nauheim, Germany Justus Liebig Universität Giessen, Department of Rheumatology and Clinical Immunology Giessen, Germany; 16Universitätsklinikum Düsseldorf, Department of Rheumatology, Düsseldorf, Germany; 17Ghent University, Hospital Department of Internal Medicine, Department of Rheumatology, Ghent, Belgium; 18University Medical Center, Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, Netherlands; 19Liga Portuguesa Contra as Doenças Reumáticas, Núcleo Síndrome De Sjögren, Lisboa, Portugal

**Background:** Since the COVID-19 vaccination campaign was launched all over Europe, there has been general agreement on how benefits of SARS-CoV vaccines outweigh the risks in patients with rare connective tissue diseases (rCTDs). Yet, there is still limited evidence regarding safety and efficacy of such vaccines in these patients, especially in the long-term. For this reason, in the framework of ERN-RECONNET, an observational long-term study (VACCINATE) was designed in order to explore the long-term outcome of COVID-19 vaccination in rCTD patients. The consent form was developed thanks to the involvement of the ERN-RECONNET ePAG Advocates (European Patients Advocacy Group).

**Objectives:** To evaluate the safety profile of COVID-19 vaccination in rCTD patients and the potential impact on disease activity. Primary endpoints were the prevalence of adverse events (AEs) and of disease exacerbations post-vaccination. Secondary endpoints were the proportion of serious adverse events (SAEs)

Methods: The first and interim analysis of the VACCINATE study involved 9 ERN-ReCONNET Network centres. Patients over 18 years of age with a known rCTD and who received vaccine against COVID-19 were eligible for recruitment. Demographic data and diagnoses were collected at the time of enrolment, while the appearance of AEs and potential disease exacerbations were monitored after one week from each vaccination dose, and then after 4, 12 and 24 weeks from the second dose. A disease exacerbation was defined as at least one of the following: new manifestations attributable to disease activity, hospitalization, increase in PGA from previous evaluation, addition of corticosteroids or immunosuppressants.

Results: A cohort of 300 patients (261 females, mean age 52, range 18-85) was recruited. Systemic lupus erythematosus (44%) and systemic sclerosis (16%) were the most frequent diagnoses, followed by Sjogren’s syndrome (SS,12%), idiopathic inflammatory myositis (IM,10%), undifferentiated connective tissue disease (UCTD,8%), mixed connective tissue disease (MCTD,4%), Ehlers-Danlos’s syndrome (EDS,4%), antiphospholipid syndrome (APS,2%). AEs appearing 7 days after the first and second doses were reported in 93 (31%) and 96 (32%) patients respectively, mainly represented by fatigue, injection site reaction, headache, fever and myalgia. Otitis, urticaria, Herpes Simplex-related rash, stomatitis, migraine with aura, vertigo, tinnitus and sleepiness were reported with very low frequency. Less than 2% of patients experienced AEs within 24 weeks from the second dose. No SAEs or AEs of special interest were observed in the study period. There were 25 disease exacerbations (8%), 7 of which severe. The highest number of exacerbations was observed after 4 weeks from the second dose (12 within week 4, 8 within week 12 and 7 within week 24). Disease exacerbation was most frequent in patients with EDS (33%) and MCTD (25%).

Conclusion: This preliminary analysis shows that COVID-19 vaccination is safe in rCTDs patients. AEs appear most often early after vaccination and are usually mild. Disease exacerbations are not frequent, but can be potentially severe and tend to occur most frequently within the first month after vaccination. Exacerbations can also occur 3-6 months after vaccination, although a causal relationship with the vaccination remains to be established. Our present data underline the importance of long-term observational studies.

Table 1. AEs and disease exacerbations per disease

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Patients enrolled (%) (n=300)</th>
<th>AEs after 1st and 2nd dose (%)</th>
<th>Exacerbations (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>APS</td>
<td>2</td>
<td>57</td>
<td>14</td>
</tr>
<tr>
<td>EDS</td>
<td>4</td>
<td>50</td>
<td>33</td>
</tr>
<tr>
<td>IM</td>
<td>10</td>
<td>52</td>
<td>7</td>
</tr>
<tr>
<td>MCTD</td>
<td>4</td>
<td>42</td>
<td>25</td>
</tr>
<tr>
<td>SS</td>
<td>12</td>
<td>59</td>
<td>8</td>
</tr>
<tr>
<td>SSC</td>
<td>44</td>
<td>69</td>
<td>8</td>
</tr>
<tr>
<td>SLE</td>
<td>16</td>
<td>49</td>
<td>2</td>
</tr>
<tr>
<td>UCTD</td>
<td>8</td>
<td>50</td>
<td>-</td>
</tr>
</tbody>
</table>

Acknowledgements: VACCINATE is a study promoted by the European Reference Network on rare and complex connective tissue diseases, ERN ReCONNET. This publication was funded by the European Union’s Health Programme (2014-2020).

Disclosure of Interests: None declared.


POS1233 DIFFICULTIES AND MENTAL IMPACT OF THE SARS-COV-2 PANDEMIC IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE PATIENT ASSOCIATION STUDY

M. Scherlinder1, N. Zein2, J. E. Gottenberg1, M. Riviere1, J. F. Kleinmann1, J. Sibilla1, L. Arnaud1, Strasbourg University Hospital, Rheumatology Department, Strasbourg, France; 2Association France Lupus et autres maladies auto-immunes, AFL+, Metz, France

Background: The COVID-19 pandemic has taken a toll on the mental health of the general population. Patients with systemic lupus erythematosus (SLE) were particularly exposed due to many uncertainties linked to the virus and their immunosuppression as well as difficulties to access medical care and their treatment (eg. home isolation, delay in Biologic initiation) during the coronavirus pandemic.

Objectives: To evaluate the difficulties encountered by SLE patients during the early COVID-19 pandemic, and evaluate their impact on patient mental health.

Methods: We conducted a Nationwide survey including SLE patients from France metropolitan and overseas territories, recruited by their treating specialist or through a patient association (AFL+). The survey was administered online or in paper form between November 2020 and April 2021, and included questions aiming at evaluating the difficulties encountered during the early COVID-19 pandemic (March to August 2020). The impact on mental health was evaluated using Hospital Anxiety and Depression scale (HADS) and post-traumatic stress disorder (PTSD) Checklist for DSM-5 (PCL-5).

Results: 536 SLE patients (91.9% of women) of mean age 50 (±14.1) years responded to the survey. The main reported difficulties were issues to access medical care (n = 136, 25.4%) or to obtain hydroxychloroquine treatment (n = 98/389, 25.2%), the loss of employment (n = 85/349, 24.4%) and financial difficulties (n = 75/536, 11%). Hydroxychloroquine shortage was responsible for difficulties in obtaining the drug for 25.2% (89/389) of HCC-treated patients, and 57 had to interrupt HCC treatment for a median of 7 days (IQR: 3-17). In the 342 patients with complete assessment, 161 (47.2%) screened positive for anxiety, 141 (41.2%) for depressive syndrome and 128 (38.7%) for PTSD. Multivariate analysis showed that female sex (OR=4.29 [95%CI: 1.39-13.24]), financial issues (OR=2.57 [127.5-22]), difficulties to access medical care (OR=2.15 [1.26-3.69]), or to obtain hydroxychloroquine treatment (OR=1.90 [1.06-3.40]) were independently associated with a positive screening for PTSD.

Conclusion: The COVID-19 pandemic resulted in a severe burden in SLE patients, including difficulties in access to care and treatment along with high psychological distress. Better understanding these difficulties will allow better prevention and care in times of crisis.

Table 1. Factors associated with the development of anxiety, depression or PTSD. Odds ratio (95%CI) using multivariate logistic regression are shown.

<table>
<thead>
<tr>
<th>Factor</th>
<th>Odds ratio (95%CI) for anxiety</th>
<th>Odds ratio (95%CI) for depression</th>
<th>Odds ratio (95%CI) for PTSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex</td>
<td>2.25 (0.97-5.25)</td>
<td>ns</td>
<td>4.29 (1.39-13.24)</td>
</tr>
<tr>
<td>Financial difficulties</td>
<td>ns</td>
<td>2.59 (1.31-5.11)</td>
<td>2.57 (1.27-5.22)</td>
</tr>
<tr>
<td>Difficulties to access HCO</td>
<td>1.70 (0.97-2.98)</td>
<td>ns</td>
<td>1.90 (1.06-3.40)</td>
</tr>
<tr>
<td>Difficulties to access medical care</td>
<td>1.94 (1.15-3.25)</td>
<td>2.57 (1.53-4.33)</td>
<td>2.15 (1.26-3.69)</td>
</tr>
</tbody>
</table>

Acknowledgements: Antonin Follain for his help.


POS1234 DMARD DISRUPTION, INCREASED DISEASE ACTIVITY, AND PROLONGED SYMPTOM DURATION AFTER ACUTE COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASE: A PROSPECTIVE STUDY

M. Di Iorio1, C. Cook2, K. Vanni3, N. Patel2, K. Dsilva2, X. Pu2, J. Wang3, L. Prisco4, E. Kowalski5, A. Zaccarello6, L. Martin7, G. Qian8, T. Hsu8, Z. Wallace9, J. Sparks1,2,4, Brigham and Women's Hospital, Department of Medicine, Boston, United States of America; 2Harvard Medical School, Harvard Medical School, Boston, United States of America; 3Massachusetts General Hospital, Division of Rheumatology, Allergy, and Immunology, Boston, United States of America; 4Brigham and Women's Hospital, Division of Rheumatology, Immunology, and Immunity, Boston, United States of America; 5Mongan Institute, Clinical Epidemiology Program, Boston, United States of America

Background: Systemic autoimmune rheumatic disease (SARD) patients may be at risk for flare and prolonged symptom duration after COVID-19, perhaps related to DMARD disruption and immune activation.

Objectives: To describe DMARD disruption and identify differences in SARD activity among patients with and without prolonged COVID-19 symptom duration.

Methods: We identified all SARD patients with confirmed COVID-19 at the Mass General Brigham Healthcare System in Boston, USA; prospective recruitment is ongoing. Surveys were used to collect demographics, clinical characteristics, DMARD disruption, COVID-19 course, and SARD disease activity before and after COVID-19. The survey included validated instruments measuring disease activity, pain, fatigue, functional status, and respiratory quality of life. Prolonged symptom duration was defined as COVID-19 symptoms lasting ≥28 days. We compared differences in patient-reported measures between those with and without prolonged symptoms.
Results: We analyzed survey responses from 174 COVID-19 survivors with SARDs (mean age 52±16 years, 81% female, 80% White). The most common SARDs were RA (40%) and SLE (14%). Fifty-one percent of the 127 respondents on any DMARD reported a disruption to their regimen at COVID-19 onset (Figure 1). Among individual DMARDs, 56-77% were reported to have any change, except for hydroxychloroquine (23%) and rituximab (46%). SARD flare after COVID-19 was reported by 41% of respondents (Table 1). Patient global assessment of SARD activity was worse after COVID-19 (mean 7.6±2.3 before vs. 6.6±2.9 after COVID-19, p<0.001). Prolonged symptom duration was reported by 45% of participants. Those with prolonged symptoms had a higher initial COVID-19 symptom count (median 7 vs. 4, p<0.001) and were more likely to be hospitalized for COVID-19 (28% vs. 17%, p=0.001). Respondents experiencing prolonged symptom duration had higher disease activity on RAPID3 (p=0.007) as well as more pain (p<0.001) and fatigue (p=0.03) compared to those without prolonged symptoms.

Table 1. Acute COVID-19 course, SARD flare/activity, and patient-reported outcomes among COVID-19 survivors with SARDs.

<table>
<thead>
<tr>
<th>All COVID-19 survivors</th>
<th>Prolonged symptom</th>
<th>No prolonged symptom</th>
<th>p-value (prolonged vs. not)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=174</td>
<td>n=78</td>
<td>n=96</td>
<td></td>
</tr>
<tr>
<td>Acute COVID-19 course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COVID-19 symptom duration, days, median [IQR]</td>
<td>14 [9, 29]</td>
<td>46 [30, 65]</td>
<td>11 [7, 14]</td>
</tr>
<tr>
<td>Initial symptom count, median [IQR]</td>
<td>6 [3, 8]</td>
<td>7 [6, 9]</td>
<td>4 [2, 7]</td>
</tr>
<tr>
<td>Hospitalized, n (%)</td>
<td>38 (22)</td>
<td>22 (28)</td>
<td>16 (17)</td>
</tr>
<tr>
<td>SARD flare/activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Self-reported SARD flare after COVID-19, n (%)</td>
<td>71 (41)</td>
<td>38 (49)</td>
<td>33 (34)</td>
</tr>
<tr>
<td>RAPID3 categorical score, n (%)</td>
<td>0.13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remission (0)</td>
<td>11 (7)</td>
<td>4 (5)</td>
<td>7 (7)</td>
</tr>
<tr>
<td>Near remission (0.3-1.0)</td>
<td>23 (14)</td>
<td>5 (7)</td>
<td>18 (19)</td>
</tr>
<tr>
<td>Low severity (1.3-2.0)</td>
<td>26 (15)</td>
<td>10 (14)</td>
<td>16 (17)</td>
</tr>
<tr>
<td>Moderate severity (2.3-4.0)</td>
<td>55 (33)</td>
<td>27 (36)</td>
<td>28 (29)</td>
</tr>
<tr>
<td>High severity (4.3-10.0)</td>
<td>54 (32)</td>
<td>28 (38)</td>
<td>26 (27)</td>
</tr>
<tr>
<td>Patient-reported outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain by SF-MPQ, median [IQR]</td>
<td>2 [1, 2]</td>
<td>2 [1, 2]</td>
<td>1 [0, 2]</td>
</tr>
<tr>
<td>Fatigue by FSI, median [IQR]</td>
<td>53 [27, 84]</td>
<td>66 [31, 91.5]</td>
<td>43 [26, 76]</td>
</tr>
<tr>
<td>mHAQ, median [IQR]</td>
<td>0.125 [0, 0.38]</td>
<td>0.25 [0, 0.75]</td>
<td>0.125 [0, 0.38]</td>
</tr>
<tr>
<td>SGRQ, global [IQR]</td>
<td>10 [4, 29]</td>
<td>16 [4, 36]</td>
<td>10 [4, 26]</td>
</tr>
</tbody>
</table>

Figure 1. Frequency of baseline DMARD use and proportion with any disruption at COVID-19 onset.

Conclusion: DMARD disruption, SARD flare, and prolonged symptoms were common in this prospective study of COVID-19 survivors with SARDs. Those with prolonged COVID-19 symptom duration, defined as ≥28 days, had higher SARD activity, more pain, and more fatigue compared to those without prolonged symptoms. These findings suggest that post-acute sequelae of COVID-19 may have a large impact on underlying SARD activity and quality of life.
Table 1. Bivariate analysis of aspect related to work from home and well-being, anxiety and depression in the second REUMAVID phase

<table>
<thead>
<tr>
<th>Mean ± SD or n (%)</th>
<th>Poor well-being</th>
<th>Good well-being</th>
<th>P-value</th>
<th>Risk of anxiety</th>
<th>No risk of anxiety</th>
<th>P-value</th>
<th>Risk of depression</th>
<th>No risk of depression</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>WiFi N: 354</td>
<td>3.8 ± 1.1</td>
<td>3.9 ± 1.1</td>
<td>0.534</td>
<td>3.8 ± 1.2</td>
<td>3.9 ± 1.0</td>
<td>0.193</td>
<td>3.8 ± 1.1</td>
<td>3.9 ± 1.1</td>
<td>0.264</td>
</tr>
<tr>
<td>Computer or laptop N: 352</td>
<td>3.9 ± 1.1</td>
<td>4.1 ± 1.0</td>
<td>0.031</td>
<td>3.8 ± 1.2</td>
<td>4.2 ± 0.9</td>
<td>0.002</td>
<td>3.9 ± 1.1</td>
<td>4.1 ± 1.1</td>
<td>0.049</td>
</tr>
<tr>
<td>Workcom N: 347</td>
<td>3.0 ± 1.4</td>
<td>3.5 ± 1.3</td>
<td>&lt;0.001</td>
<td>2.9 ± 1.4</td>
<td>3.6 ± 1.2</td>
<td>&lt;0.001</td>
<td>3.4 ± 1.3</td>
<td>3.4 ± 1.3</td>
<td>0.001</td>
</tr>
<tr>
<td>Webcam N: 342</td>
<td>3.4 ± 1.5</td>
<td>3.7 ± 1.4</td>
<td>0.069</td>
<td>3.4 ± 1.5</td>
<td>3.7 ± 1.4</td>
<td>0.043</td>
<td>3.4 ± 1.3</td>
<td>3.6 ± 1.5</td>
<td>0.055</td>
</tr>
<tr>
<td>Telephone: N: 350</td>
<td>3.9 ± 1.2</td>
<td>4.0 ± 1.3</td>
<td>0.289</td>
<td>3.9 ± 1.3</td>
<td>4.0 ± 1.2</td>
<td>0.484</td>
<td>3.8 ± 1.2</td>
<td>4.0 ± 1.3</td>
<td>0.034</td>
</tr>
<tr>
<td>Lightning: N: 354</td>
<td>3.6 ± 1.2</td>
<td>4.0 ± 1.1</td>
<td>&lt;0.001</td>
<td>3.6 ± 1.2</td>
<td>4.0 ± 1.1</td>
<td>0.001</td>
<td>3.5 ± 1.2</td>
<td>4.0 ± 1.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Noise N: 353</td>
<td>3.3 ± 1.3</td>
<td>4.0 ± 1.2</td>
<td>&lt;0.001</td>
<td>3.2 ± 1.4</td>
<td>3.9 ± 1.2</td>
<td>&lt;0.001</td>
<td>3.2 ± 1.4</td>
<td>3.8 ± 1.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Calmness N: 353</td>
<td>3.3 ± 1.4</td>
<td>4.0 ± 1.2</td>
<td>&lt;0.001</td>
<td>3.2 ± 1.4</td>
<td>4.0 ± 1.1</td>
<td>&lt;0.001</td>
<td>3.1 ± 1.4</td>
<td>3.9 ± 1.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Temperature N: 353</td>
<td>3.6 ± 1.2</td>
<td>3.8 ± 1.2</td>
<td>0.053</td>
<td>3.5 ± 1.3</td>
<td>3.9 ± 1.1</td>
<td>0.008</td>
<td>3.5 ± 1.2</td>
<td>3.8 ± 1.2</td>
<td>0.039</td>
</tr>
</tbody>
</table>

Acknowledgements:
This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all of the patient organisations that participated in the REUMAVID study including: the Cyprus League for People with Rheumatism (CYLPER) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Rumatologiche e Rare (APMAR) from Italy, the Portuguese League Against Rheumatic Diseases (LPCDR), from Portugal, the Spanish Federation of Spondyloarthropathy Associations (CEADE), the Spanish Patients’ Forum (FEP), UNIMID, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League and Galician Rheumatology League from Spain, and the National Axial Spondyloarthritis Society (NASA), National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.

Disclosure of Interests:
Marco Garrido-Cumbrera Grant/research support from: has a research collaboration with and provides services to Novartis Pharma AG, Victoria Navarro-Compán Grant/research support from: AbbVie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Laura Christen Employee of: Novartis Pharma AG, José Correa-Fernández: None declared, Helena Marzo-Ortega Consultant of: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Grant/research support from: Janssen and Navozari.


Table 1. Distribution of demographic and SLE characteristics according to sides effects and disease flares after vaccination

<table>
<thead>
<tr>
<th>Side effects (n=119)</th>
<th>No side effects (n=333)</th>
<th>p-value (&lt;0.05)</th>
<th>Disease flare (n=19)</th>
<th>No disease flare (n=430)</th>
<th>p-value (&lt;0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, median (IQR)</td>
<td>46 (33.5-54)</td>
<td>48 (35.7-57)</td>
<td>0.18</td>
<td>52 (39.5-56.0)</td>
<td>48 (35.0-56.9)</td>
</tr>
<tr>
<td>Disease duration, months, median (IQR)</td>
<td>138 (76-262)</td>
<td>126 (73-193)</td>
<td>0.30</td>
<td>144 (122-242)</td>
<td>127 (73-195)</td>
</tr>
<tr>
<td>MSK, %</td>
<td>84.9</td>
<td>84.4</td>
<td>1.00</td>
<td>78.9</td>
<td>84.8</td>
</tr>
<tr>
<td>Mucocutaneous, %</td>
<td>71.4</td>
<td>62.8</td>
<td>0.094</td>
<td>57.9</td>
<td>64.5</td>
</tr>
<tr>
<td>Renal, %</td>
<td>42.0</td>
<td>52.3</td>
<td>0.069</td>
<td>52.6</td>
<td>49.4</td>
</tr>
<tr>
<td>NPSLE, %</td>
<td>13.4</td>
<td>9</td>
<td>0.215</td>
<td>5.3</td>
<td>10.4</td>
</tr>
<tr>
<td>Cardiopulmonary %</td>
<td>22.7</td>
<td>19.8</td>
<td>0.510</td>
<td>26.3</td>
<td>20.3</td>
</tr>
<tr>
<td>Hematological, %</td>
<td>32.8</td>
<td>33</td>
<td>1.00</td>
<td>42.1</td>
<td>32.6</td>
</tr>
<tr>
<td>Constitutional symptoms %</td>
<td>48.7</td>
<td>30</td>
<td>0.0003*</td>
<td>26.3</td>
<td>35.3</td>
</tr>
<tr>
<td>Gastrointestinal %</td>
<td>4.2</td>
<td>3.3</td>
<td>0.772</td>
<td>5.3</td>
<td>3.5</td>
</tr>
<tr>
<td>Ophthalmic %</td>
<td>0.8</td>
<td>3.3</td>
<td>0.197</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Secondary APS %</td>
<td>10.9</td>
<td>10.5</td>
<td>0.864</td>
<td>5.3</td>
<td>10.9</td>
</tr>
<tr>
<td>aPL positivity %</td>
<td>26.2</td>
<td>33.6</td>
<td>0.137</td>
<td>26.3</td>
<td>31.9</td>
</tr>
<tr>
<td>Anti-dsDNA positivity %</td>
<td>30.7</td>
<td>27.4</td>
<td>0.545</td>
<td>55.6</td>
<td>271</td>
</tr>
<tr>
<td>ESR, mm/h, median (IQR)</td>
<td>11 (7-19)</td>
<td>13 (7-22)</td>
<td>0.730</td>
<td>19 (10-24)</td>
<td>13 (7-21)</td>
</tr>
<tr>
<td>CRP, mg/dL, median (IQR)</td>
<td>0.5 (0.1-0.5)</td>
<td>0.5 (0.3-0.6)</td>
<td>0.313</td>
<td>0.42 (0.13-0.50)</td>
<td>0.50 (0.30-0.5)</td>
</tr>
<tr>
<td>Urinary abnormalities, %</td>
<td>9.2</td>
<td>21.9</td>
<td>0.0023</td>
<td>21.1</td>
<td>18.5</td>
</tr>
<tr>
<td>Moderate or high DAS before vaccine, %</td>
<td>16</td>
<td>9.3</td>
<td>0.066</td>
<td>26.3</td>
<td>10.4</td>
</tr>
<tr>
<td>No therapy before vaccine, %</td>
<td>0</td>
<td>3.6</td>
<td>0.0419*</td>
<td>0</td>
<td>2.8</td>
</tr>
<tr>
<td>At least 1 immunosuppressant, %</td>
<td>63</td>
<td>46.8</td>
<td>0.0027*</td>
<td>73.7</td>
<td>50.1</td>
</tr>
<tr>
<td>Mycophenolate, %</td>
<td>31.9</td>
<td>23.1</td>
<td>0.066</td>
<td>42.1</td>
<td>24.7</td>
</tr>
<tr>
<td>Methotrexate, %</td>
<td>5.9</td>
<td>6.6</td>
<td>1.00</td>
<td>5.3</td>
<td>6.5</td>
</tr>
<tr>
<td>Belimumab, %</td>
<td>21.8</td>
<td>13.5</td>
<td>0.0396*</td>
<td>36.8</td>
<td>14.8</td>
</tr>
<tr>
<td>Rituximab ever, %</td>
<td>11.8</td>
<td>13.5</td>
<td>0.751</td>
<td>5.3</td>
<td>13.4</td>
</tr>
<tr>
<td>Prednisone, %</td>
<td>74.8</td>
<td>70</td>
<td>0.347</td>
<td>78.9</td>
<td>70.9</td>
</tr>
</tbody>
</table>
arthritis. Nineteen (4%) patients flared up after immunisation with a 7 days median time to relapse. Baseline demographics, SLE characteristics and therapy stratified by adverse events and disease flare are reported in Table 1. Anti-dsDNA positivity, moderate/high DAS before vaccine and use of Belimumab were significantly more frequent in the group of patients flared. These patients displayed a significantly higher rate of adverse events after vaccination. Flares consisted mainly musculoskeletal and constitutional manifestations (32%), involvement of renal (21%), cardio-respiratory (16%), hematological (10%) or mucocutaneous domains (10%) was less frequent.

Conclusion: our measuring data confirm that anti-SARS-CoV-2 vaccine is safe in SLE patients and should be recommended in this clinical setting, as potential benefits widely outweigh the risk of adverse events. Treatment adjustment might be considered with the aim of minimizing the risk of side effects and/or flare, while ensuring a satisfying protection against infection.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2727

POS1237

SARS-COV-2 MRNA VACCINE IMMUNOGENICITY IN CHRONIC INFLAMMATORY ARTHRITIS ON DMARD THERAPY

N. Darwish1, S. Jhaveri2, U. Yogathan3, K. Chur4, T. Wasser5, J. Freeman1, 1. Arnot Ogden Medical Center, Internal Medicine, Elmira, New York, United States of America; 2. Lake Erie College of Osteopathic Medicine, Osteopathic Medicine, Elmira, United States of America; 3. Labcorp, R&D, Calabasas, California, United States of America; 4. Consult-Stat: Complete Statistical Services, Department of Statistics, Macungie, Pennsylvania, United States of America

Background: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of these conditions. Disease-modifying antirheumatic drugs (DMARDs) used to treat CIA have the potential to blunt the immune response and efficacy of vaccinations. There is little data on the effect of DMARDs used for CIA on the response to novel mRNA vaccines, limiting guidelines to direct therapy.

Objectives: Assess the antibody response (ABR) to the SARS-CoV-2 mRNA vaccines in patients with CIA on treatment with either methotrexate (MTX), tumor necrosis factor inhibitors (TNFi), or both with healthy controls. Determine the effect of interrupting therapy after vaccination in patients with CIA on the ABR to the vaccine.

Methods: 63 patients with rheumatoid or psoriatic arthritis on MTX, TNFi, or both were recruited from a community-based rheumatology practice. All subjects received two doses of a mRNA COVID vaccine. Use of hydroxychloroquine (HCQ), NSAID s, and prednisone (Pred) ≤10mg daily were allowed. Those with prior COVID infection were excluded, as determined by SARS-CoV-2 nucleocapsid assay. 26 healthy age-matched controls were obtained from banked blood from Labcorp. IRB approval was obtained, and patients were consented to participate in the study. SARS anti-receptor binding domain IgG antibodies were measured by electro chemiluminescent immunoassay 90-120 days post initial vaccine dose. Patients were divided into 3 groups based on therapy:

1. MTX monotherapy
2. TNFi with etanercept (ETN) or adalimumab (ADA)
3. A combination of MTX with either ETN or ADA

Each of the groups were subdivided into two categories:
1. Continued treatment uninterrupted at the time of each of the two vaccines.
2. Held treatment for two weeks after each vaccine. Statistical significance (p<0.05) was determined using one way ANOVA with Scheffe procedure and Student's T-test.

Results: The 63 patients with CIA had a significantly lower ABR to vaccine compared with healthy controls (p=0.001). Further analysis was limited by sample size: The MTX held group had a higher ABR than the MTX continued group (mean IgG=35.5 vs 21.74; p=0.14), demonstrating a trend toward increased immunogenicity. There was a similar ABR to vaccine between those on TNFi who held vs continued therapy (mean IgG 20.83 vs 28.65; p=0.525). Combination MTX+TNFi held vs continued groups demonstrated a trend toward increased immunogenicity when holding therapy post vaccine (mean IgG 42.4 vs 22.7; p=0.44). All treatment groups were comparable in Pred, HCQ, NSAID use, age, Rapid 3 score, and time between vaccination and blood draw for antibody levels.

Conclusion: The ABR in patients with CIA to the mRNA vaccine appeared to be blunted by ongoing therapy with MTX. This effect was attenuated by holding MTX post-vaccine. There was no significant difference in the ABR to vaccine in patients on TNFi who held vs continued these agents after vaccine, due to small sample size. Patients with CIA on DMARD therapy had a significantly lower ABR to the vaccine compared to healthy controls. Our findings need further validation in a larger cohort. Clinicians may consider holding MTX for two weeks post vaccination to optimize the immune response to the vaccine.

REFERENCES:

Acknowledgements: We would like to thank Jamie Reidy and Judy Wolf for their efforts in the Arnot laboratory, Dr. Manav Bandlamudi and Dr. Frank Edwards for their research support.

Disclosure of Interests: None declared

GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTICIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.


Background: High disease activity, treatment with glucocorticoids (GC) and rituximab (RTX), have been related to worse outcomes of COVID-19.

Objectives: To assess the clinical characteristics and severity of the SARS-CoV-2 infection in patients with rheumatoid arthritis (RA) included in the SAR-COVID registry and to identify factors associated with poor outcomes.

Methods: SAR-COVID is a national, longitudinal and observational registry. Patients of ≥18 years old, with diagnosis of RA (ACR-EULAR criteria 2010) who had confirmed SARS-CoV-2 infection (RT-PCR or positive serology) were included between 13-8-20 and 31-7-21. Sociodemographic and clinical data, comorbidities, disease activity and treatment at the moment of the SARS-CoV-2 infection were collected. Additionally, infection symptoms, complications, medical interventions and treatments for COVID-19 were registered. Infection severity was assessed using the WHO-ordinal scale (WHO-OS). A cut-off value of ≥5 identified patients with severe COVID-19 and those who died.

Statistical analysis: Descriptive statistics. Chi² or Fischer test, Student T test or Kruskal-Wallis and ANOVA, as appropriate. Multiple logistic regression model.

Results: A total of 801 patients were included, with a mean age of 53.1 ± 12.9 years, most of them were female (84.5%) and the median (m) disease duration was 8 years (IQR 4-14). One third were in remission and 46.4% had comorbidities, being the most frequent, hypertension (26.9 %), dyslipidemia (13.5 %), obesity (13.4 %) and diabetes (8.9 %). Moreover, 3.2% had interstitial lung disease (ILD) associated with RA. At SARS-CoV-2 diagnosis, 42.5% were receiving drugs (DMARD), 24% biologic (b) DMARD and 9.1% targeted synthetic (ts) DMARD.

Conclusion: Treatment with RTX and GC as well as older age, the presence of diabetes and ILD were associated with poor COVID-19 outcomes in this national cohort of patients with RA. Older patients and those taking GC had a higher mortality rate.

REFERENCES:

Disclosure of Interests: None declared


POS1239 RISK FACTORS FOR SEVERE DISEASE COURSE IN MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) – A MULTICENTER, RETROSPECTIVE STUDY

K. Kaidar1, Y. Levinsky1, R. Tal1, L. Harel1, G. Amariyo1, S. Schneider Children’s Medical Center of Israel, Pediatric Rheumatology, Tel Aviv, Israel

Background: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19, presents as a cytokine storm with features of Kawasaki disease. Shock cases present with shock and require intensive care admission.

Objectives: We aimed to identify predictors for severe clinical course of MIS-C as defined by the need for iotropotropic support during admission.

Methods: A retrospective multicenter cohort study was conducted. Patients with a diagnosis of MIS-C from 9 Israeli medical centers and one US medical center (Chicago, IL) were included. Demographic, clinical, laboratory and imaging variables during admission and hospitalization were retrieved. Univariate and multivariate regression models were used to assess odds ratio (OR) of iotropotropic support need during hospitalization.

Results: Overall 100 MIS-C patients were included in the study. Sixty-five patients (65%) were hypotensive, 44% required iotropotropic support, and 37% had finding of Left ventricular dysfunction. Univariate model showed that LVD was associated with the need for iotropotropic support (OR 4.178 [95%CI 1.760-9.917], while conjunctivitis (OR 0.403 [95%CI 0.173-0.938]) and mucosal changes (OR 0.333 [95%CI 0.119-0.931]) were protective. Laboratory markers for severe disease course were low hemoglobin levels, leukocyte count, lymphocyte count, neutrophil count, albumin and potassium, as well as high troponin and BNP.

Table 1. and laboratory characteristics on admission of patients diagnosed with MIS-C

<table>
<thead>
<tr>
<th>w/o Hemodynamic support</th>
<th>w/ Hemodynamic support</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=56 (56.0%)</td>
<td>N=44 (44.0%)</td>
</tr>
<tr>
<td>p-value</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>46 (82.1%)</td>
</tr>
<tr>
<td>Mucosal changes</td>
<td>18 (32.1%)</td>
</tr>
<tr>
<td>Rash</td>
<td>34 (60.7%)</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>27 (48.2%)</td>
</tr>
<tr>
<td>Extremity changes</td>
<td>4 (7.1%)</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>11 (19.6%)</td>
</tr>
<tr>
<td>No. of days of fever at admission</td>
<td>4 (3-5)</td>
</tr>
<tr>
<td>Systolic BP</td>
<td>99 [80-108]</td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>60 [53-67]</td>
</tr>
<tr>
<td>HR</td>
<td>124 [114-143]</td>
</tr>
<tr>
<td>hemoglobin admission (g/dL)</td>
<td>11.6 [10.8-12.6]</td>
</tr>
<tr>
<td>White cells admission (K/µL)</td>
<td>9.02 [6.3-12.01]</td>
</tr>
<tr>
<td>platelets admission (K/µL)</td>
<td>174.0 [134.50-250]</td>
</tr>
<tr>
<td>lymphocytes admission (K/µL)</td>
<td>0.90 [0.64-1.70]</td>
</tr>
<tr>
<td>ESR admission (mm/hr)</td>
<td>43.00 [35.5-74.5]</td>
</tr>
<tr>
<td>C-reactive protein admission (mg/dL)</td>
<td>14.05 [10.32-22.8]</td>
</tr>
<tr>
<td>Creatinine admission (mg/dL)</td>
<td>0.55 [0.40-0.70]</td>
</tr>
</tbody>
</table>

Conclusions: Patients with MIS-C that present with a Kawasaki-like phenotype are less likely to require iotropotropic support, while other clinical and laboratory parameters were found as risk factors and should be monitored during MIS-C hospitalization.

REFERENCES:

Figure 1. Factors associated with severe disease and death due to COVID-19 (WHO-OS≥5) in patients with rheumatoid arthritis. Multivariable analysis. (ref: reference; PDN: prednisone; OR: odds ratio; CI: confidence interval)
Patients, highlighting the state of immune dysregulation in COVID-19. The clinical range of clinical manifestations. Although COVID-19 was initially considered a respiratory syndrome coronavirus-2 (SARS-CoV-2) is characterized by a wide range of clinical manifestations. The presence of autoantibodies (AAbs) has been described in COVID-19 patients. The experimental arm of the current study was financially supported by donation grants from SYN-ENOSIS (Greece). The majority of critical COVID-19 patients who were positive for AAbs were patients aged 65 years or above. The presence of autoantibodies (AAbs) does not play a role in the outcome of SARS-COV-2 infection. However, further studies are needed to define their role in future development of systemic autoimmune disorders or the long-COVID syndrome. Background: Coronavirus Disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is characterized by a wide range of clinical manifestations. Although COVID-19 was initially considered a respiratory infection, it was also recognized as a multisystemic disorder associated with heightened inflammatory responses, including autoimmune phenomena. The presence of autoantibodies (AAbs) has been described in COVID-19 patients, highlighting the state of immune dysregulation in COVID-19. The clinical significance of AAbs, however, is still elusive. Objectives: To assess the prevalence of AAbs in critically ill, mechanically ventilated COVID-19 patients admitted to the intensive care unit (ICU) and investigate whether AAbs influence the clinical outcome of these patients. Methods: The current study evaluated prospectively from March 8th, 2021 to May 10th, 2021 the presence of AAbs against nuclear antigens (ANA), extractable nuclear antigens (ENA), neutrophil cytoplasmic antibodies (ANCA), cyclic citrullinated peptides (anti-CCP), double stranded-DNA (anti-dsDNA), cardiolipin (anti-CL), IgG-glycoprotein-I (anti-CL-IgG), thyroid peroxidase (anti-TPO), and thyroglobulin (anti-TG) in critically ill COVID-19 patients upon admission to the ICU (n=217). Samples from 60 COVID-19 patients that were available 15 days after ICU admission were further analyzed for the evaluation of de novo AAbs production. Serum samples of age and sex matched healthy individuals before the COVID-19 pandemic were used as a control group (n=117).

Results: COVID-19 patients treated in ICU had more commonly at least one AAb compared to age and sex matched controls (174/217, 80.2% vs 73/217, 62.4%, p=0.001). More specifically, COVID-19 patients expressed more frequently ANAs (48.4% vs 21.4%, p=0.001), anti-dsDNA (5.1% vs 0%, p=0.01), anti-CCP (8.3% vs 17%, p=0.014) and anti-CL IgM AAbs (21.7% vs 9.4%, p=0.065) than controls. The majority of critical COVID-19 patients who were positive for AAbs were patients aged 65 years or above. The presence of autoantibodies does not play a role in the outcome of SARS-COV-2 infection. However, further studies are needed to define their role in future development of systemic autoimmune disorders or the long-COVID syndrome.

References:

Acknowledgements: The experimental arm of the current study was financially supported by donation grants from SYN-ENOSIS (Greece).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3160
In contrast, follow-up appointments were mainly conducted by telemedicine when compared with face-to-face; RA (65% Vs 35%), GCA (53%/Vs 47%), OA (51% Vs 49%) and CA (61% Vs 39%). For the follow-ups, an overall majority of 90% of telemedicine consultations avoided the need for a face-to-face appointment, particularly observed for patients with CA and GCA (98% and 93% respectively). We noted that patients with RA were more likely than GCA to have a telemedicine follow-up (p-value=0.0001).

**Conclusion:** Telemedicine appointments for new referrals and follow-up patients with Rheumatological diagnoses has been a new development because of COVID-19 pandemic. Our analysis shows that most of our new RA, GCA, OA, and CA referrals are still being seen face-to-face but most follow-up appointments are telemedicine consultations. In most cases, clinicians felt that telemedicine consultations avoided the need for a face-to-face appointment.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3212

---

**Table 1.**

<table>
<thead>
<tr>
<th>Diagnoses</th>
<th>New referrals</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Telemedicine</td>
<td>Face-to-face</td>
<td>Telemedicine</td>
</tr>
<tr>
<td>RA</td>
<td>36 (14%)</td>
<td>227 (86%)</td>
</tr>
<tr>
<td>CA</td>
<td>7 (12%)</td>
<td>50 (88%)</td>
</tr>
<tr>
<td>OA</td>
<td>82 (30%)</td>
<td>187 (70%)</td>
</tr>
<tr>
<td>GCA</td>
<td>3 (2%)</td>
<td>21 (98%)</td>
</tr>
</tbody>
</table>

---

S. Tobucci, E. Simader, T. Deimel, P. Mandl, H. Haslacher, T. Perkmann, L. Schneider, T. Nothnagl, H. Lechner-Radner, F. Winkler, H. Burgmann, K. Stassen, G. Novacek, W. Reinsch, D. Aletaha, S. Winker, S. Blümi, Medical University of Vienna, Austria, 1Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria; 2Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria; 3Medical University of Vienna, Austria, Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Vienna, Austria; 4Medical University of Vienna, Austria, Department of Laboratory Medicine, Vienna, Austria; 5Medical University of Vienna, Austria, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria; 6Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria; 7Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria; 8Medical University of Vienna, Austria, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria; Lower Austrian Centre for Rheumatology, Stockerau, Austria, Second Medical Department, Korneuburg-Stockerau Hospital, Stockerau, Austria; Medical University of Vienna, Vienna, Austria, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria; Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria; Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria; Medical University of Vienna, Vienna, Austria, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria; Medical University of Vienna, Austria, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria; Medical University of Vienna, Vienna, Austria, Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna, Austria.

**Background:** Little is known about the duration of humoral antibody levels after two SARS-CoV-2 mRNA vaccinations in patients with immunosuppression. During this ongoing global epidemic, it is of essential interest to gather information about the time of protection after initial immunization in the vulnerable patients receiving either conventional synthetic disease modifying antirheumatic drugs (csDMARD) or biological targeted drugs (b/tsDMARDs).

**Objectives:** In this study we compared the antibody level development after vaccination and after six months in patients with inflammatory arthritis, inflammatory bowel disease (IBD) and healthy controls. Furthermore, we assessed factors affecting the quality and quantity of the humoral response.

**Methods:** We enrolled 85 healthy controls (HC), 75 patients with rheumatoid arthritis and spondyloarthritis and 41 patients suffering from IBD. Patients treated with B-cell depleting therapies were excluded from this study. Binding antibody units were measured after vaccination and 6 or more months. Neutralizing antibodies were measured after 6 months. Multivariate regression analyses analyzing factors associated with low titers after 6 months was performed.

**Results:** We found that patients with inflammatory arthritis or IBD showed reduced anti-SARS-CoV-2 S IgG compared to HC. When we stratified for therapeutic factors associated with low titers after 6 months was performed.

**Conclusions:** We found that patients with inflammatory arthritis or IBD showed reduced anti-SARS-CoV-2 IgG compared to HC. When we stratified for therapeutic strategies, we found that patients receiving conventional synthetic disease modifying antirheumatic drugs (csDMARDs) had comparable anti-SARS-CoV-2 S IgG compared to HC. In contrast, patients receiving biological or targeted synthetic (b/tsDMARDs) showed reduced anti-SARS-CoV-2 IgG as well as neutralizing antibody titers compared with healthy controls (HC) or patients receiving conventional synthetic (cs)DMARDs. We further show that anti-SARS-CoV-2 IgG declined more rapidly in patients receiving b/tsDMARDs compared to HC, leading to a 50% reduction in vaccination-associated protection time in patients receiving b/tsDMARDs compared to those receiving csDMARDs or even HC. In multivariate regression analyses, we found that in addition to the type of treatment, also age as well as corticosteroid use were associated with reduced anti-SARS-CoV-2 S titers.

**Conclusion:** Patients undergoing b/tsDMARDs therapy experienced an accelerated waning of anti-SARS-CoV-2 S titers and therefore decreased immunity and protection against severe Covid-19 infections over time. These results may lead to more personalized approaches for further vaccination strategies in this group of immunosuppressed patients.
The two-dose vaccine regimen induced a similar immunogenic response following two and three doses of the BNT162b2 mRNA vaccine in patients with spondyloarthritis (SpA) treated with secukinumab and immunocompetent controls. SpA patients treated with secukinumab consistently demonstrated an adequate humoral response to the BNT162b2 mRNA vaccination similar to immunocompetent controls, both short-term and within six months after two vaccine doses and after the third vaccine dose.

Disclosure of Interests: Selma Tobucic: None declared, Elisabeth Simader Grant/research support from: Pfizer, Bristol-Myers Squibb, Thomas Deimel: None declared, Peter Mandl Speakers bureau: Abbvie, personal fees from Novartis, Pfizer, Roche, Sandoz, Stefan Winkler: None declared, Stephan Blüml Speakers bureau: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofi Merck, Novacek: None declared, Walter Reinisch: None declared, Daniel Aletaha Takeda, Gilead, Karin Stiasny Grant/research support from: Pfizer, Gottfried: None declared, Heinz Burgmann Speakers bureau: Shionogi, Pfizer, MSD, None declared, Helga Lechner-Radner: None declared, Florian Winkler: None declared, Walter Reinisch: None declared, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Lilly, Novartis, Roche, Roche, Sandoz, Stefan Winkler: None declared, Stephan Blüml Speakers bureau: Abbvie, personal fees from Novartis.

Disclosure of Interests:
- O. Elkaham1, T. Evistatore, H. Peleg2, D. Paran1, D. Levartovsky1, J. Kaufman1, A. Brodyre1, O. Elkaham1, A. Polacheke3, J. Feld1, A. Haddad2, T. Gazit3, M. Elia3, N. Hijaze4, M. Aasa5, E. Quebe-Fehling1, I. Alarcon6, S. Per1, D. Zisman1, V. Furer1, Tel Aviv Sackler Faculty of Medicine, Tel Aviv University, Rheumatology, C1 Tel Aviv, Israel; Hadassah University Hospital, Rheumatology, C2 Jerusalem, Israel; Carmel Medical Center, C3 Haifa, Israel; Novartis Pharma AG, Medical Affairs, Basel, Switzerland

Background: Data on the effect of secukinumab on the humoral response to the BNT162b2 mRNA vaccine are limited.

Objectives: We aimed to assess prospectively the humoral response to the BNT162b2 mRNA vaccine in patients with spondyloarthritis (SpA) treated with secukinumab in comparison to immunocompetent controls.

Methods: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) treated with secukinumab for at least 3 months and immunocompetent controls were vaccinated with two-dose regimen of the BNT162b2 mRNA vaccine. Clinical and laboratory assessments were performed at 2-8 weeks [SpA: 37 on secukinumab, median age 53 (51% female), 122 controls (median age 53, 51% female)], and 6 months [SpA: 27 on secukinumab, 116 controls] after the second vaccine dose. A subgroup of patients (22 SpA on secukinumab, 45 controls) were evaluated after the third vaccine dose. The seropositive response was defined as a detectable S1/S2 IgG >15 binding antibody units (BAU/ml).

Results: The two-dose vaccine regimen induced a similar immunogenic response in patients and controls reflected by the seropositivity rates of 100% in both groups. After six months, the rate of seropositivity remained as high as 96% in both secukinumab-treated patients and immunocompetent controls. The decline of S1/S2 IgG titer within six months was similar in controls and secukinumab-treated patients, -86.4 (95% CI [-70.9, -98.9]) and -55 BAU/ml (95% CI [-95.42, -36.87]). Following the third vaccine, the seropositivity rate increased to 100% in both groups. At all-time points, S1/S2 IgG titers were similar in secukinumab treated patients and immunocompetent controls (Figure 1).

Conclusion: SpA patients treated with secukinumab consistently demonstrated an adequate humoral response to the BNT162b2 mRNA vaccination similar to immunocompetent controls, both short-term and within six months after two vaccine doses and after the third vaccine dose.

Acknowledgements: We would like to thank Mr Yishai Friedlander and Mr Yoram Neufeld for their assistance.

Disclosure of Interests: Ori Elkaham: None declared, Tali Evistar: None declared, Hagit Peleg: None declared, Daphna Paran: None declared, David Levartovsky: None declared, Ilana Kaufman: None declared, Adi Brody: None declared, Ofir Elkaham: None declared, Ari Polacheke: None declared, Joy Feld: None declared, Amir Haddad: None declared, Tal Gazit: None declared, Muna Elias: None declared, Nizar Hijaze: None declared, Maher Assaai Employee of: Novartis Pharma AG, Erhard Quebe-Fehling Employee of: Novartis Pharma AG, Ivette Alarcon Employee of: Novartis Pharma AG, Sara Pe1: None declared, Devy Zisman: None declared, Victoria Furor: None declared.

Objectives: To assess the long-term outcome of the humoral response to mRNA vaccine against SARS-CoV2, in AIRD pts treated with immunomodulating drugs, and the contribution of the booster vaccination.

Methods: Consecutive pts treated at the Rheumatology Institute at Rambam Hospital who received their first SARS-CoV-2 (Pfizer) vaccine were recruited to the study, at their routine visit. The visit included AIRD activity assessment and questioning regarding vaccine side effects. We performed serology test 4-6 weeks and 24 weeks after receiving the second dose of vaccine. Pts who received the booster (3rd vaccine) were invited for serology tests 4-6 weeks afterwards. The immunomodulating treatment was not modified, either before or after the vaccination. IgG Antibodies (Ab) against SARS COV2 virus were detected using the SARS-CoV-2 IgG II Quant (Abbott) assay based on a chemiluminescent microparticle immunoassay (CMIA) on the ARCHITECT ci8200s-system from Abbott. This assay is measuring IgG antibodies against the spike receptor-binding domain (S-RRBD) of the virus. The test was considered positive above 50 AU/mL.

Results: 262 pts (mean age(±SD) 57(13), disease duration 112(74), were recruited. The cohort included 152 pts with inflammatory joint disease, 26 pts with systemic lupus erythematosus, 62 pts with other connective tissue disease and 22 pts with vasculitis; 27 % received csDMARDs only, 35% - b/tsDMARDs only, 30% - combined therapy (csDMARDs+b/tsDMARDs) and 26% received steroids. 225 pts (86%) were seropositive for IgG Ab against SARS COV2 virus (median 2832.5 AU/ml, IQR 58-29499). 37 (14%) pts had negative tests, 23 (62.2%) of them were rituximab treated. De novo serologic response was observed in 10 out of 37 pts (4/23 rituximab treated pts).

Conclusion: The reported side effects of the vaccine were minor (muscle sore, headache, low grade fever). The AIRD remained stable in all pts following all three vaccinations. An enhanced response was obtained after the third booster vaccination. Only minor side effects were reported and no apparent impact on AIRD activity was noted. Notably, 62% of the non-responders were treated with B cell depleting agents.

Acknowledgements: We would like to thank Mrs Tsofnat Margi and Mrs Sarit Elkoubi for organisational support.

Disclosure of Interests: None declared


Figure 1. Serology per drug

The reported side effects of the vaccine were minor (muscle sore, headache, low grade fever). The AIRD remained stable in all pts following all three vaccinations. An enhanced response was obtained after the third booster vaccination. Only minor side effects were reported and no apparent impact on AIRD activity was noted. Notably, 62% of the non-responders were treated with B cell depleting agents.

Disclosure of Interests: None declared


POS1247 COVID-19 IN RITUXIMAB TREATED PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES

R. Hassel1, B. F. Hoyer2, H. M. Lorenz2, A. Pfeil2, A. Regerer2, J. Richter2, T. Schmeiser2, A. Strangfeld1, R. Voß1, H. Schulte-Koops1, A. Krause2, C. Specker1, U. Müller-Ladner1 on behalf of COVID-19 task force of the German Society for Rheumatology. 3Campus Kerckhoff, Justus-Liebig-University Giessen, Department of Rheumatology and Clinical Immunology, Giessen, Germany; 4Clinic for Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Department of Rheumatology and Clinical Immunology, Kiel, Germany; 5University Hospital Heidelberg, Division of Rheumatology, Department of Medicine V, Heidelberg, Germany; 6University Hospital Jena, Department of Internal Medicine III, Jena, Germany; 7German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany; 8Department of Rheumatology and Hipier Research Unit, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; 9Private Practice, Rheumatology, Cologne, Germany; 10University Medical Center, Albert-Ludwigs University Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany; 11University of Munich, Department of Internal Medicine IV, Division of Rheumatology and Clinical Immunology, Munich, Germany; 12Immanuel Hospital, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 13Klinikum Essen-Mitte, Department of Rheumatology and Clinical Immunology, Essen, Germany

Background: At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) pandemic, the influence of anti-inflammatory therapy on the course of SARS-CoV-2 infection in patients with inflammatory rheumatic diseases (IRD) was unknown. In the meantime, several data indicate an association of severe courses of COVID-19 with the use of rituximab (RTX).

Objectives: To gather further knowledge about SARS-CoV-2 infections in RTX-treated IRD patients, data from the German COVID-19-IRD-registry were analysed.

Methods: Hospitalisation was used as a surrogate of COVID-19 severity. Baseline characteristics, disease features, medication and outcome of COVID-19 were compared in RTX-treated inpatients and outpatients.

Results: In total, 3592 cases were reported in the registry, which included 180 RTX patients (3.6%) for our analysis. RTX-treated inpatients were older than RTX-treated outpatients (median age 63 y vs 56 y, p=0.007). Patients with granulomatosis with polyangiitis treated with RTX (n=32) showed a significant higher COVID-19 related hospitalisation rate (33% vs 11%, p=0.005), which was not the case for patients with rheumatoid arthritis (49% vs 50%). Cardiovascular comorbidities were reported more frequently in hospitalised RTX-treated patients (20% vs. 6%, p=0.032). More than 50% of the RTX-treated inpatients developed COVID-19 related complications, e.g. acute respiratory distress syndrome. The median time period between the last RTX treatment and SARS-CoV-2 infection was shorter in inpatients than in non-hospitalised patients (3 (range 0-17) vs. 4 months (range -29), p=0.039). The COVID-19 related mortality rate was 14% (n=19) in RTX-treated IRD patients. In RTX-treated inpatients and outpatients, there were no relevant differences with respect to the use of concomitant glucocorticoids or other disease modifying anti-rheumatic drugs, disease activity, median last RTX dose or median number of immunomodulatory drugs prior to RTX treatment.

Conclusion: In addition to general risk factors, such as age and comorbidities, it is already known that IRD patients treated with RTX show a higher rate of severe COVID-19. In our registry, RTX-treated patients with granulomatosis with polyangiitis appear to be at even higher risk to develop severe COVID-19 compared to other IRD. Moreover, the shorter the time since the last RTX treatment, the higher seems to be the risk of developing severe COVID-19. This might be explained by a more profound B-cell depletion in the first weeks after RTX treatment warranting further studies.

Disclosure of Interests: None declared


POS1247 THE EFFECT OF IMMUNOSUPPRESSIVE AGENTS ON ANTIBODY FORMATION AFTER COVID-19 VACCINATION IN RHEUMATOID ARTHRITIS PATIENTS

E. Kang1, Y. G. Kim1, J. S. Oh1, S. Hong1, C. K. Lee1, B. Yoo1, S. M. Ahn1, 1Seoul, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Rep. of (South Korea)
Background: There is still controversy about the efficacy of COVID-19 vacci-
nation and its extent in lowering immunogenicity of Rheumatoid Arthritis (RA)
patients. The guideline in whether immunosuppressive agents need to be dis-
continued before the vaccination is continuously updated because it is consid-
ered to lower immunogenicity. Furthermore, there is great discussion on the
effectiveness of the COVID-19 booster vaccine and interest in antibody gener-
ation in different types of vaccine, as in South Korea there are many patients
who were prescribed the mRNA booster vaccine after two doses of ChAdOx1-S
nCoV-19 vaccine.

Objectives: Thus, we investigated the differences of antibody production
between patients who received only two doses of ChAdOx1-S nCoV-19 and those
who received the mRNA booster vaccine. Also, antibody production under
different types of immunosuppressive agents was analyzed.

Methods: From October 14, 2021 to January 21, 2022 at a tertiary referral
center, two patient groups diagnosed with RA were studied prospectively;
one group that completed 1st and 2nd doses of ChAdOx1-S nCoV-19 vaccine,
second group that completed mRNA booster vaccine as well as two doses of
ChAdOx1-S nCoV-19 vaccine. SARS-CoV-2 antibody testing on the semiquan-
titative anti-SARS-CoV-2 S enzyme immunoassay was done, and differences
in antibody titers were analyzed in patients who received different immunosup-
pressive agents such as csDMARD, TNF inhibitor, JAK inhibitor, Tocilizumab,
Abatacept and Corticosteroid. Statistical analysis with a multivariate logistic
regression model was performed.

Results: In a total of 261 patients, 153 patients had completed two doses
of ChAdOx1-S nCoV-19, 108 patients had completed third mRNA booster
vaccine. Anti-SARS-CoV-2 RBD antibody positive rate (titer>0.8U/mL) was
97%(149/153) and 99%(107/108) respectively, and only 5 patients showed
negative result. In the aspect of high antibody titer(>250U/mL), which is the
upper limit of the RBD antibody immunoassay, the result showed rate of 31%
(47/153) in the non-booster group and 94%(102/108) in the booster group
respectively.

Conclusion: Anti-SARS-CoV-2 RBD antibody positive rate was 97% or more
regardless of the mRNA booster vaccination. However, patients who received the
mRNA booster vaccine after two doses of ChAdOx1-S nCoV-19 vaccine showed
high antibody titer (>250U/mL) three times more than those who did not receive
the booster shot. Our findings also showed that corticosteroid use, old age, and
male gender is significantly associated with low rate of acquiring high antibody
titer.

Disclosure of Interests: None declared


Table 1. Analysis of immunosuppressive agents and other clinical aspects for high antibody titer(>250U/mL) after two doses of ChAdOx1-S nCoV-19

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Univariate analysis</th>
<th></th>
<th>Multivariate analysis</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>p value</td>
<td>OR</td>
</tr>
<tr>
<td>Clinical features</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>0.917</td>
<td>0.860-0.978</td>
<td>0.008</td>
<td>0.917</td>
</tr>
<tr>
<td>Sex</td>
<td>3.674</td>
<td>1.206-11.191</td>
<td>0.022</td>
<td>4.330</td>
</tr>
<tr>
<td>DAS 28</td>
<td>1.144</td>
<td>0.670-1.950</td>
<td>0.622</td>
<td></td>
</tr>
<tr>
<td>Duration</td>
<td>0.930</td>
<td>0.830-1.043</td>
<td>0.214</td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>1.273</td>
<td>0.639-2.533</td>
<td>1.273</td>
<td></td>
</tr>
<tr>
<td>TNF inhibitor</td>
<td>2.211</td>
<td>0.795-6.145</td>
<td>0.128</td>
<td></td>
</tr>
<tr>
<td>JAK inhibitor</td>
<td>0.665</td>
<td>0.279-1.607</td>
<td>0.365</td>
<td></td>
</tr>
<tr>
<td>Abatacept</td>
<td>0.368</td>
<td>0.038-3.602</td>
<td>0.391</td>
<td></td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>1.264</td>
<td>0.438-3.648</td>
<td>0.665</td>
<td></td>
</tr>
<tr>
<td>Corticosteroid</td>
<td>0.472</td>
<td>0.235-0.949</td>
<td>0.035</td>
<td>0.349</td>
</tr>
<tr>
<td>Medication dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexlate</td>
<td>0.993</td>
<td>0.919-1.072</td>
<td>0.855</td>
<td></td>
</tr>
<tr>
<td>Corticosteroid</td>
<td>0.849</td>
<td>0.719-1.003</td>
<td>0.054</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Anti-SARS-CoV RBD antibody titer of two groups

Among the different immunosuppressive agents and other clinical aspects, multivariate analysis revealed that corticosteroid use (OR 0.91; 95% CI: 0.86-
0.98), older age(OR 4.33; 95% CI: 1.34-13.91), and male gender(OR 0.35; 95%
CI 0.16-0.75) were significantly associated with low rate of high antibody titer.
Furthermore, out of 14 patients who underwent antibody test twice before and
after the mRNA booster vaccine, other than four patients who already showed
high titer of >250U/mL before the mRNA booster vaccine, 10 patients showed
an increase in titer after the booster vaccine and 7 patients were acquired high
titer of >250U/mL.

Background: Coronavirus disease causes a proximal tubule dysfunction of
kidneys, inducing uric acid loss [1]. It has been established that several changes in laboratory markers (C-reactive protein (CRP), ferritin, interleukin-6
(IL-6)) can predict the severity of Covid-19 [2]. The purpose of this retrospec-
tive study was to analyze whether uric acid could act as another predictor of
severe Covid-19.

Objectives: To evaluate the relationship between the severity of Covid-19 and
uric acid levels on admission to the hospital.

Methods: This retrospective study included 150 hospitalized patients with con-
firmed Covid-19 (mean age 60.3±14.6 years; 52% were men), the severity of
which was determined by the presence and type of oxygen support: (1) without
O2, (2) O2 by mask or nasal cannula, (3) continuous positive airway pressure, (4)
positive bi-pressure in the airways or high-flow oxygen, (5) invasive ventilation.
Among them, 90 subjects required oxygen support, and 60 people didn't.
The mortality rate in our study was 9.3%. The average uric acid level was compared
with patients without Covid-19 (40 subjects). The study included patients who
didn't receive urate-lowering therapy. Levels of CRP, ferritin, IL-6, D-dimer were
also determined on admission. The Spearman’s rank coefficient was used for
measuring correlation.

Results: The mean uric acid level in patients with coronavirus disease was
251.5±104.1 µmol/L; without Covid-19 it was significantly higher — 328.6±96.9
µmol/L (p<0.001). Approximately one in four (24.6%) Covid-19 patients had uric
acid levels ≥250 µmol/L.

Discussion: Uric acid is a byproduct of the metabolism of purines, which is
produced in the body and excreted in the urine. Uric acid levels are increased in
patients with RA and other inflammatory diseases, and studies have shown that
uric acid may have an immunosuppressive effect on inflammatory mediators and
antibodies. Additionally, uric acid has been reported to be associated with the
development of atherosclerosis and cardiovascular disease. However, the role of
uric acid in COVID-19 infection and its association with the severity of the disease
remains unclear.

Methods: This study was a retrospective analysis of patient data from a single
hospital in South Korea. The study population consisted of 150 patients with
confirmed COVID-19 infection, admitted to the hospital between January 2020
and June 2021. The uric acid levels were measured on admission and compared
with patients without COVID-19. The severity of COVID-19 was determined by
the type of oxygen support needed, ranging from non-invasive oxygen therapy
to invasive ventilation.

Results: The mean uric acid level on admission was significantly higher in
patients with COVID-19 (251.5±104.1 µmol/L) compared to healthy controls
(328.6±96.9 µmol/L; p<0.001). The highest uric acid levels were observed in
patients requiring invasive ventilation (364.7±120.9 µmol/L). Uric acid levels
were also associated with a higher mortality rate (9.3%).

Conclusion: Uric acid levels on admission to the hospital are significantly
higher in patients with COVID-19 compared to healthy controls. This finding
suggests that uric acid may have a role in the pathogenesis of COVID-19 and
its severity. Further studies are needed to elucidate the mechanisms underlying
this association and to explore uric acid-lowering therapies as potential
interventions for COVID-19.
acid levels below the lower limit of normal (208 μmOL/L for men, 155 μmOL/L for women). A decrease in serum uric acid levels was also observed in patients suffering from asymptomatic hyperuricemia or gout. However, there was no correlation between uric acid levels and disease severity (r=0.01, p=0.88). Also, uric acid levels did not correlate with other laboratory markers of severe Covid-19 was not found.

**Conclusion:** Low uric acid levels are common in patients with Covid-19, but are not predictive of a more severe course of this disease. A correlation between uric acid and the level of other laboratory markers of severe Covid-19 was not found.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3479

---

### Table 1. Multivariate analysis of anti-SARS-CoV-2 IgG level in patients with rheumatic diseases following COVID-19 vaccines

<table>
<thead>
<tr>
<th>Medications</th>
<th>β</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not used</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5 mg/day</td>
<td>−23.48</td>
<td>(−56.33, 11.37)</td>
<td>0.192</td>
</tr>
<tr>
<td>&gt;5 mg/day</td>
<td>−23.45</td>
<td>(−43.54, −3.36)</td>
<td>0.022</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>−24.89</td>
<td>(−45.70, −4.08)</td>
<td>0.019</td>
</tr>
<tr>
<td>Targeted therapies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not used</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF inhibitor</td>
<td>−15.78</td>
<td>(−41.33, 9.76)</td>
<td>0.224</td>
</tr>
<tr>
<td>Non-TNF bDMARD</td>
<td>−25.27</td>
<td>(−65.47, 4.93)</td>
<td>0.100</td>
</tr>
<tr>
<td>JAK inhibitor</td>
<td>−17.08</td>
<td>(−47.23, 13.07)</td>
<td>0.265</td>
</tr>
<tr>
<td><strong>Vaccine</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19/AZD1222</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA-1273</td>
<td>30.15</td>
<td>(11.67, 48.63)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

TNF: tumor necrosis factor, bDMARDs: biologic disease-modifying antirheumatic drugs, JAK: Janus kinase.

**Figure 1.** The comprehensive cell atlas of PBMC of RA patients with high and low anti-SARS-CoV2-IgG antibodies. A) UMAP visualization of PBMC cells from RA patients. B) The proportion of cell types between high and low antibody groups. C) Volcano plot of CD16-monocyte showed differential expressed genes. D) Pathway analysis between high and low antibody groups; PBMC: peripheral blood mononuclear cell, RA: rheumatoid arthritis, NK cell: natural killer cell, pDC: plasmacytoid dendritic cell, CLP: common lymphoid progenitor.

**Conclusion:** mRNA-1273 and AZD1222 vaccines exhibited differential immunogenicity in patients with AIRD. Enriched pathways related to antigen presentation via major histocompatibility complex class II (MHC class II) were found (Figure 1). HLA-DRA and CD4 interaction was vigorous among all identified MHC-II pathway and was enhanced in high anti-SARS-CoV2-IgG antibody group.

**REFERENCES:**


**Acknowledgements:** The authors thank the Biostatistics Task Force of Taichung Veterans General Hospital for their assistance with the statistical analysis in this study.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3488
### Methods:

After the COVID-19 vaccine in our APS patients.

**Objectives:**
- To evaluate the development of any side effects or activation of the disease.
- To assess the impact of COVID-19 vaccines on APS patients.

**Background:**
Anti-phospholipid syndrome (APS) is an autoimmune disorder characterized by presence of anti-phospholipid antibodies (aPL) comprising lupus anticoagulant, anti-II-glycoprotein I and/or anti-cardiolipin antibodies together with recurrent thrombosis and/or obstetric morbidity. In the course of COVID-19, thromboembolism may occur due to endothelial dysfunction directly related to the viral factor and systemic inflammatory response. Concerns about COVID-19 vaccines began to arise after unexpected thromboembolic events were launched with the launch of vaccine campaigns around the world to prevent the disease.

**Objectives:** The purpose of the study is to contribute to the literature on this subject by evaluating the development of any side effects or activation of the disease after the COVID-19 vaccine in our APS patients.

**Methods:**
This study was designed as a cross-sectional, retrospective cohort study. The patients who meet the Sapporo Criteria for APS which are followed up in Ankara City Hospital Rheumatology Clinic, 18 years and over and vaccinated with any of the COVID-19 vaccines, were included into the study. The files of the patients were examined in order to evaluate the side effects and APS disease activation (thrombosis, embolism or pregnancy complications) in the 3-month period after the last dose of the COVID-19 vaccines (CoronaVac and BNT162b2).

Also, information of the patients was collected via telephone or reviewed at regular follow-up visits.

**Results:** A total of 35 patients were included into the study (Table 1). In our patients, we did not observe any new thrombotic events or pregnancy complications during the 3-months observation period after COVID-19 vaccinations. The most common side effects after vaccinations were as follows; myalgia (30%), weakness (16.7%) and fever (10%) (Table 2). No patient became pregnant or gave birth during the follow-up.

### Table 1. Demographic and clinical characteristics of patients with Antiphospholipid antibody syndrome who received Covid-19 vaccine

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>CoronaVac</th>
<th>BNT162b2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, median (min-max)</td>
<td>43(28-63)</td>
<td>33(34.3)</td>
</tr>
<tr>
<td>Gender, female, number (%)</td>
<td>2(5.7)</td>
<td>2(5.7)</td>
</tr>
<tr>
<td>Comorbidities, number (%)</td>
<td>7(17.1)</td>
<td>5(12.5)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6(17.1)</td>
<td>5(12.5)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>2(5.7)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Sjogren disease</td>
<td>2(5.7)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>0(0)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Other</td>
<td>4(11.4)</td>
<td>0(0)</td>
</tr>
<tr>
<td>Time from diagnosis, years, median (min – max)</td>
<td>7(3)(10 – 270)</td>
<td>7(3)(10 – 270)</td>
</tr>
<tr>
<td>APS characteristics, number (%)</td>
<td>22(62.9)</td>
<td>21(63.6)</td>
</tr>
<tr>
<td>Thrombotic APS</td>
<td>11(52.4)</td>
<td>11(52.4)</td>
</tr>
<tr>
<td>Cerebrovascular event</td>
<td>11(47.7)</td>
<td>11(47.7)</td>
</tr>
<tr>
<td>Deep vein thrombosis</td>
<td>5(10.3)</td>
<td>5(10.3)</td>
</tr>
<tr>
<td>Pulmonary thromboembolism</td>
<td>4(16.6)</td>
<td>4(16.6)</td>
</tr>
<tr>
<td>Obstetric APS</td>
<td>15(50)</td>
<td>16(53.9)</td>
</tr>
<tr>
<td>Other</td>
<td>12(39.4)</td>
<td>14(45.2)</td>
</tr>
</tbody>
</table>

### Table 2. Adverse events in vaccine recipients

<table>
<thead>
<tr>
<th>Condition</th>
<th>CoronaVac</th>
<th>BNT162b2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>0(0)</td>
<td>3(20)</td>
</tr>
<tr>
<td>Malaise</td>
<td>0(0)</td>
<td>2(13.3)</td>
</tr>
<tr>
<td>Local pain/arm pain</td>
<td>0(0)</td>
<td>1(6.6)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>0(0)</td>
<td>1(6.6)</td>
</tr>
</tbody>
</table>

### Conclusion:
According to our results, no thrombotic events or pregnancy complications were observed after CoronaVac and BNT162b2 vaccines in APS patients. Apart from this, minor side effects related to COVID-19 vaccines were clinically acceptable level.

### REFERENCES:


### Disclosure of Interests:
None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3542
**Conclusion:** The incidence of severe COVID-19 is not increased in the same percentage in SARIDs. Each SARID presents a peculiar pattern in terms of increased risk of COVID-19 incidence, hospitalisation, intensive care unit admission and death, that is not linked to the immunosuppressive behaviour of the disease.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3587

**POS1252** DURABILITY OF THE HUMORAL RESPONSE TO mRNA BASED ANTI-SARS-CoV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE, A COMPARATIVE STUDY

O. Alsaed1, M. Chaponda2, E. Elsayed3, H. Ashour4, S. Al Emad5
1Hamad Medical Corporation, Medicine/Rheumatology, Doha, Qatar; 2Hamad Medical Corporation, Medicine/Infectious Disease, Doha, Qatar

**Background:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and its impact on disease outcome in patients with autoimmune rheumatic disease (ARD) are lacking. Also, whether patients with ARD receiving immunomodulators have different viral loads compared to the general population is unknown.

**Objectives:** To compare the viral load of SARS-CoV-2 and its trend between patients without and with ARD.

**Methods:** Retrospectively, patients with ARD infected with SARS-CoV-2 were matched by age and sex at a ratio of 1:2 to patients without ARD and not receiving immunosuppression or immunomodulator drugs. Viral load was determined by the cycle threshold (CT) value measured by a number of platforms: (a) Automated Platforms - the Roche Cobas 6800 system using the Cobas SARS-CoV-2 Test targeting the E and orf1a/b genes (Roche, Switzerland) and the Xpert Xpress SARS-CoV-2 targeting the E and N genes (Cepheid, USA); (b) Manual platforms - EZ1 (QIAGEN, USA), QIAasympmetry (QIAGEN, USA), and Bioneer ExiPrepTM 96 Virus DNA/RNA kits Catalogue No K4614 (Bioneer, South Korea) extraction with thermal cycling using TagPath™ PCR COVID-19 Combo Kit targeting the N, S, and orf1a/b genes (Thermo Fisher Scientific, USA) on ABI 7500 thermal cyclers. Independent samples t-test was used to compare the mean CT values of the study groups at baseline and at 5 subsequent intervals (1 – 5.9, 6 – 11.9, 12 – 17.9, 18 – 23.9 and 24 – 30 days).

**Results:** Mean age (SD) of 197 cases and 420 controls were 45.2 (11.8) and 44.1 (12.3) years, respectively. Females were predominant in both groups 60% vs. 52%, P=0.053. The most common ARD was rheumatoid arthritis in 82 cases (41.6%), followed by spondyloarthropathy in 33 (16.8%) and systemic lupus erythematosus in 31 (15.7%). Of the cases, 67% were on conventional synthetic disease modifying anti-rheumatic drugs (DMARDs), 15.2% on biological DMARDs and 8.5% patients were on rituximab. The mean CT values was significantly lower in the ARD group at baseline and persisted till day 24.

**Conclusion:** Compared to patients without ARD, the viral load of SARS-CoV-2 in patients with ARD is significantly higher at baseline testing and persists till day 24. This finding may indicate that patients with ARD are at higher risk of severe SARS-CoV-2 infection and prolonged potential transmission. Clinical outcome correlation is needed.

**REFERENCES:** None declared

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3593

**POS1253** THE COURSE OF COVID-19 IN A COHORT OF SPONDYLOARTHRITIS PATIENTS: A CASE-CONTROL PROSPECTIVE STUDY

C. Castellani1, R. Terribili1, L. Di Sanzo1, E. Motteni1, G. Sciamanna1, G. Bevignani1, M. Di Franco1, V. Riccioni1, C. Alessandrini1, R. Sorvo1, F. Conti1,3
1Sapienza University of Rome, UOC Rheumatologia - Dipartimento di Scienze Cliniche Internistiche, Anestesiologie e Cardiovascolari, Rome, Italy

**Background:** With the outbreak of the SARS-CoV-2 pandemic, the rheumatologists’ attention was directed at understanding whether infected patients could have a less favorable outcome. Available data seem to indicate that the course in rheumatic patients is not dissimilar from that in the general population. However, data on the outcome of COVID-19 in patients with spondyloarthritis (SpA) are scant.

**Objectives:** To describe the outcome of COVID-19 in patients with SpA in terms of hospitalization, need of oxygen therapy, and symptoms compared to a control group. The variation in disease activity before and after COVID-19 was also assessed.

**Methods:** We enrolled adult patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) classified according to standard criteria, that received a diagnosis of COVID-19 through molecular or rapid antigen swab tests between September 2020 and January 2022. Demographic and clinical data, including age, body mass index (BMI), smoking habit, comorbidities, rheumatic treatment at diagnosis of COVID-19, date of COVID-19 diagnosis, symptoms and additional therapy during the infection and vaccination status were collected through a questionnaire and recorded on an electronic database. Disease activity, assessed by DAPSA in PsA patients and by ASDAS and BASDAI in AS patients, was evaluated before and at the first visit after the infection. As controls, individuals with COVID-19 but with no known diagnosis of rheumatic/immune disease were recruited using the “best friend” system.

**Results:** Sixty-two patients were enrolled [43 with PsA and 19 with AS; F:M=40:22; median age 51 years, 25th–75th percentile 39.5-61; median BMI 25.5, 25th–75th percentile 21.75–28; median disease duration 90 months, 25th–75th percentile 36–192; 6 (9.7%) smokers, 37 (59.7%) non-smokers, 19 (30.6%) past smokers; 15 (24.2%) only treated with one conventional DMARD, 27 (43.5%) with bDMARDs and 20 (32.3%) with both; 44 (71%) had received no vaccine, 18 (29%) one or more doses of vaccine]. Forty-eight controls were also recruited [F:M=29:19; median age 48 years, 25th–75th percentile 41.5–57; median BMI 23.6, 25th–75th percentile 20.69–28.03; 10 (20.8%) smokers, 28 (58.3%) non-smokers, 10 (20.8%) past smokers; 43 (88.6%) had received no vaccine, 5 (10.4%) one or more doses of vaccine]. Among patients, 10 (16.1%) were hospitalized, of whom 8 (80%) required noninvasive oxygen therapy. Among controls, 7 (14.5%) were hospitalized, of whom 5 (71.4%) required noninvasive oxygen therapy. No differences were observed compared to the control group in terms of hospitalization and need for oxygen support. Likewise, the two groups did not bear any statistically significant difference in terms of symptoms (fever, dysgeusia, dyspnoea) and cardiovascular and respiratory comorbidities. BMI and smoking habit did not influence the outcome of COVID-19 in SpA patients, while a BMI of 25 or above was associated with hospitalization in the control group (p=0.0004, RR 3.417). Baseline treatment with immunosuppressants did not influence the disease outcome. DAPSA, ASDAS, and BASDAI did not significantly change after the infection (Table 1). We did not record any COVID-19-related death in either group.

**Conclusion:** The incidence of severe COVID-19 is not increased in the same percentage in SARIDs. Each SARID presents a peculiar pattern in terms of increased risk of COVID-19 incidence, hospitalisation, intensive care unit admission and death, that is not linked to the immunosuppressive behaviour of the disease.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3579

**Table 1. Demographic characteristics and comparison of the mean CT values in the study groups at baseline and at different intervals with the corresponding OR (95% CI)**

<table>
<thead>
<tr>
<th>Case (N=197)</th>
<th>Control (N=420)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age, years</td>
<td>45.2 (11.8)</td>
<td>44.1 (12.3)</td>
</tr>
<tr>
<td>Sex, female N (%)</td>
<td>120 (60.9%)</td>
<td>221 (52.6%)</td>
</tr>
<tr>
<td>Mean (SD) CT values at Baseline</td>
<td>22.9 (5.5)</td>
<td>30.5 (52)</td>
</tr>
<tr>
<td>1 – 5.9 days</td>
<td>22.1 (4.6)</td>
<td>25.7 (6.3)</td>
</tr>
<tr>
<td>6 – 11.9 days</td>
<td>26.9 (4.9)</td>
<td>31.5 (3.9)</td>
</tr>
<tr>
<td>12 – 17.9 days</td>
<td>29.6 (4.1)</td>
<td>32.3 (3.2)</td>
</tr>
<tr>
<td>18 – 23.9 days</td>
<td>32.1 (4)</td>
<td>32.9 (2.5)</td>
</tr>
<tr>
<td>24 – 30 days</td>
<td>31.2 (12)</td>
<td>32.7 (2.6)</td>
</tr>
</tbody>
</table>

**Table 1. Disease activity before and after COVID-19**

<table>
<thead>
<tr>
<th>Last visit before COVID-19</th>
<th>First visit after COVID-19*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PsA (n=43)</td>
<td>AS (n=19)</td>
</tr>
<tr>
<td>Remission/low disease activity, n (%)</td>
<td>19 (44.2%)</td>
</tr>
<tr>
<td>Moderate/high disease activity, n (%)</td>
<td>11 (25.6%)</td>
</tr>
<tr>
<td>NA 13 (30.2%)</td>
<td>NA 2 (10.5%)</td>
</tr>
</tbody>
</table>

* Reassessment of patients was performed 2 months (median) after COVID-19, 25th–75th percentile 1-4 monthsPsA, psoriatic arthritis; AS, ankylosing spondylitis; NA, not available
Conclusion: Our data show that patients with SpA do not face a worse prognosis of COVID-19 than subjects without autoimmune/inflammatory diseases and that demographic and clinical features did not influence the course of the disease.

Disclosure of Interests: None declared.


Risk Factors for Severe Covid-19 Infection Among Patients with Autoimmune Inflammatory Rheumatic Diseases (AIRD) and the Impact of Vaccinations - An Israeli, Multi-Center Experience

F. Kharruf1, T. Evlatar2, M. Braun3, E. Pokroy-Shapira4, M. Brodavka4, N. Agmon-Levin5, S. Oren4, S. Giryes7, M. Lidar5, M. Amit Vazina8, M. Lidar5, M. Amit Vazina8, N. Agmon-Levin6, K. Toledano7, S. Oren4, M. Lidar5, M. Amit Vazina8, F. Sabath1, Y. Tavor5, G. Breuer12, D. Ziemann13, D. Markovits1, A. Dagan13, R. Bishara Garzuzi11, O. Shifman13, S. Giryes7, M. Elias11, J. Feld7, T. Reitblat14, T. Gazit1, A. Hadad15, O. Elkayam12, D. Paran12, D. Mevorach1, A. Balbir-Gurmann1, Y. Braun-Moscovici1, Hadassah Medical Center, Hebrew University of Jerusalem, Rheumatology Institute, Israel; 2Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, Rheumatology Institute, Tel Aviv, Israel; 3Hadassah Medical Center, Hebrew University of Jerusalem, Bioinformatics, Jerusalem, Israel; 4Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Rheumatology Institute, Petch-Tikva, Israel; 5Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Rheumatology Unit, Tel Hashomer, Israel; 6Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Allergy and Clinical Immunology Unit, Tel Hashomer, Israel; 7Ramot Health Care Campus, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel; 8Shamar Medical Center, Sackler School of Medicine, Tel Aviv University, Rheumatology, Rishon Le Tsiyon, Israel; 9The Baruch Padeh Medical Center, Poriya, Rheumatology, Tiberias, Israel; 10Shaare Zedek Medical Center, Hebrew University of Jerusalem, Rheumatology, Jerusalem, Israel; 11Carmel Medical Center, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Rheumatology, Haifa, Israel; 12Assuta Ashdod Medical Center, Ben Gurion University of the Negev, Rheumatology, Ashdod, Israel; 13Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Rheumatology Service, Kfar Saba, Israel; 14Barzilai Medical Center, Ben Gurion University of the Negev, Rheumatology, Ashkelon, Israel

Background: AIRD patients (pts) may be more susceptible to severe COVID19. Objectives: To determine the risk factors for severe COVID19 and the effect of vaccinations among AIRD pts followed at dedicated rheumatology clinics.

Methods: At the onset of the pandemic, we established a national registry of AIRD patients (pts) diag. with COVID19, based on voluntary reporting by the treating rheumatologist. 12 centers from Israel participated in the study. COVID19 was confirmed by a positive SARS CoV2 PCR. The indications for PCR testing were clinical symptoms or close contact with an infected person. Severe illness was defined by SpO2 <94% in room air, respiratory rate of >30 breaths/min, PaO2/FiO2 <300 mm Hg, or lung infiltrates >50% on imaging. The registry included demographic data, AIRD diagnosis and duration, vaccine involvement, co-morbidities, immunomodulatory treatment, date of diagnosis and severity of COVID19 disease, management, complications, duration of hospitalization, the dates of the mRNA vaccinations, lab results and outcome. We analyzed data from 13.2020 to 30.11.2021.

Results: During the study period we experienced 4 outbreaks of COVID19 infection. Initially social distancing, followed by a lockdown were imposed. The low number of cases led to relaxation of the measures. Two more severe outbreaks followed, which triggered 2 new lockdowns. The 3rd outbreak ended almost 2 months after the implementation of vaccinations.

Disclosure of Interests: None declared.

Conclusions: Before the vaccination campaign, the hospitalization and mortality rates in our cohort were similar to the data reported by other registries. COVID19 tends to be more severe, with increased mortality in patients with active AIRD and visceral involvement (pulmonary, cardiac, renal), and during severe outbreaks. The delta outbreak occurred 6 months after the implementation of vaccinations and was associated with significantly lower hospitalization and mortality rates, despite the increased aggressiveness of the variant. Vaccination of AIRD pts with 3 doses of mRNA vaccines protects from severe COVID19 disease, hospitalization, and death.

Acknowledgements: Fadi Kharruf and Tal Eviatar had equal contribution.

Disclosure of Interests: None declared.


Safety of the Pfizer/Biontech and Sinovac/Coronavac Vaccines Among Patients with Behcet’s Syndrome and Familial Mediterranean Fever

A. Ozged1, S. Güner2, G. Ozcol13, B. Yurttas2, Z. Toker Dincer2, Z. Atı3, U. Uygunoglu5, E. Durmaz6, D. Ucár, S. Ugurlu7, S. Sasa8, F. Tabak9, V. Hamuryudan9, E. Seyahi2, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey; 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey; 2Columbia University Irving Medical Center Division of Allergy Immunology and Rheumatology, Department of Pediatrics, New York, United States of America, 3Sinop University, Biostatistics and Informatics, Department of Accounting and Taxation, Sinop, Turkey; 4Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey; 5Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Cardiology, Istanbul, Turkey; 6Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey; 7Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Infectious Disease and Clinical Microbiology, Istanbul, Turkey

Background: Since first emerged in December 2019, the COVID-19 pandemic has resulted in a death toll surpassing 5.5 million worldwide and had severe consequences on the global economy, environment, public health and social life [1, 2]. Multiple potential vaccines against COVID-19 have been developed swiftly and as shown in several phase 3 clinical trials, they demonstrated considerable efficacy without an unusual safety signal in healthy individuals.

Objectives: In this study, we aimed to evaluate vaccine reactivity and disease flare following vaccination with either Sinovac/CoronaVac or Pfizer/BioNTech among BS and FMS patients compared with patients with various diagnosis of RD and healthy controls.

Methods: Only those patients and healthy controls who rece,ved at least one single shot of either CoronaVac or BioNTech against COVID-19 were included in the study. We tried to contact all of these patients and controls consecutively by telephone and attempted to make interviews with the eligible ones.

Results: We studied the efficacy, side effects and disease flares after COVID-19 vaccination in 256 patients with Behcet’s syndrome (BS), 247 with familial Mediterranean fever (FMF), 601 with rheumatic diseases (RD) and 612 healthy controls (HC). Study participants were vaccinated either with CoronaVac (BS:109, RD:90, HC:543) or BioNTech (BS:147, FMF:157, RD:255 and HC: 278). BioNTech ensured a significantly better efficacy than CoronaVac against COVID-19 in all patient groups (BS: 1.4% vs 10.1%, FMF: 3.2% vs 12.2%, RD: 2.7% vs 6.4%). Those with at least one adverse event (AE) were significantly more frequent among those vaccinated with BioNTech than those with CoronaVac (BS: 86.4% vs 45%; FMF: 83.4% vs 53.3%; RD: 83.3% vs 45.5% and HC: 86.3% vs 52.1%). The majority of AEs were mild to moderate and transient and this was true for either vaccine. There were also AEs that required medical attention in all study groups following CoronaVac (BS:5.5%, FMF:3.3%, RD:2.9% and HC:3.3%) or BioNTech (BS:5.4%, FMF:1.9%, RD:4.7% and HC:4.7%). The main reasons for medical assistance were disease flare, and cardiovascular events. Disease flares after vaccination were significantly more frequent in BS (41/256; 16.0%) and FMF (43/247; 17.4%) patients compared to patients with RD (39/612; 6.4%). This was true for both CoronaVac (BS: 11.0%, FMF: 24.4% and RD: 5.2%, p<0.001) and BioNTech (BS: 19.7%, FMF: 13.4% and RD: 70%, p<0.001)(Table 1).

Pattern of flare following vaccination with either Sinovac/CoronaVac or Pfizer/BioNTech among IF patients.
Table 1. Flares among patients with Behçet’s syndrome, familial Mediterranean fever, rheumatic diseases after vaccination with CoronaVac and BioNTech

<table>
<thead>
<tr>
<th>CoronaVac</th>
<th>Behçet’s syndrome, n=109</th>
<th>Familial Mediterranean Fever, n=90</th>
<th>Rheumatic diseases, n=343</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
</tr>
<tr>
<td>12 (11.0)</td>
<td>22 (24.4)</td>
<td>18 (5.2)</td>
<td></td>
</tr>
<tr>
<td>BioNTech</td>
<td>Behçet’s syndrome, n=147</td>
<td>Familial Mediterranean Fever, n=157</td>
<td>Rheumatic diseases, n=256</td>
</tr>
<tr>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
<td>Flares, n (%)</td>
</tr>
<tr>
<td>29 (19.7)</td>
<td>21 (13.4)</td>
<td>18 (7.0)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Our study demonstrates that BS and FMF patients vaccinated with either CoronaVac or BioNTech demonstrated almost similar AE profile and frequency compared to RD patients and HC. AEs that required physician consultation or hospitalization occurred in all study groups after either CoronaVac or BioNTech. Caution should be required when monitoring these patients after vaccination. Increased frequency of flares in BS and FMF compared to that seen in RD might reflect defects in innate immunity and deserves further investigation.

Disclosure of Interests:

Acknowledgements: We would like to thank ZonMw (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

References:

Disclosure of Interests: Laura Kummer: None declared, Luuk Wieske: None declared, Eileen Stalman: None declared, Koos van Dam: None declared, Laura Boekel: None declared, Gerjan Wolbink Grant/research support from: GW reported a grant to ZonMW (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

Risk factors for short-term adverse events in patients with immune-mediated inflammatory disease

Conclusion: A third SARS-CoV-2 vaccination was not associated with an increased risk on short-term clinically relevant adverse events when compared to a second vaccination. Although patients with IMIDs may be slightly more at risk to develop adverse events after SARS-CoV-2 vaccination, most adverse events were transient and disappeared within seven days. This message should reassure IMID patients who are hesitant on booster vaccination. Data on potential IMID flare-ups after vaccination will follow.

Disclosure of Interests: Laura Kummer: None declared, Luuk Wieske: None declared, Eileen Stalman: None declared, Koos van Dam: None declared, Laura Boekel: None declared, Gerjan Wolbink Grant/research support from: GW reported a grant to ZonMW (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

References:

Acknowledgements: We would like to thank ZonMw (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

Disclosure of Interests: Laura Kummer: None declared, Luuk Wieske: None declared, Eileen Stalman: None declared, Koos van Dam: None declared, Laura Boekel: None declared, Gerjan Wolbink Grant/research support from: GW reported a grant to ZonMW (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

References:

Acknowledgements: We would like to thank ZonMw (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

Disclosure of Interests: Laura Kummer: None declared, Luuk Wieske: None declared, Eileen Stalman: None declared, Koos van Dam: None declared, Laura Boekel: None declared, Gerjan Wolbink Grant/research support from: GW reported a grant to ZonMW (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

References:

Acknowledgements: We would like to thank ZonMw (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.

Disclosure of Interests: Laura Kummer: None declared, Luuk Wieske: None declared, Eileen Stalman: None declared, Koos van Dam: None declared, Laura Boekel: None declared, Gerjan Wolbink Grant/research support from: GW reported a grant to ZonMW (The Netherlands Organization for Health Research and Development) for the funding of the study and the T2B partners, including the patient groups and Health Holland for the support in this study. Also, we would like to thank E.P. Moll van Charante, J.A Bogaards and R.A. Scholten for their guidance in the data safety monitoring board.
Background: The COVID-19-associated multisystem inflammatory syndrome in children (MIS-C) is characterized by Kawasaki disease (KD)-like features and circulatory shock [1]. The genesis of SARS-CoV-2 variants triggered successive waves of mass infections followed by MIS-C outbreaks.

Objectives: To compare MIS-C phenotypes across the waves of the COVID-19 pandemic. To identify predictors of pediatric intensive care unit (PICU) admission and treatment with biologic agents.

Methods: Youth aged 0-18 years, fulfilling the WHO case definition of MIS-C, and admitted to the Alberta Children’s Hospital during the COVID-19 pandemic (May 2020-December 2021) were included. Clinical, laboratory, imaging, and treatment data were captured (KD-like manifestations, signs of shock and/or hypotension, peak C-reactive protein (CRP) and ferritin, platelet count nadir, peak NT-proBNP and troponin, liver enzyme abnormalities, sodium and albumin nadir, echocardiogram findings, biologic agents).

Results: 57 consecutive MIS-C patients (median age 6 years, IQR 4-6; 72% males) were included. 31 patients (54%) required PICU admission. All received immunoglobulins, 44 (77%) received corticosteroids, 8 patients (14%) were treated with biologic agents. Patients presenting during the third (mainly driven by Alpha variant) or fourth wave (mainly driven by Delta variant) presented with higher ferritin and NT-proBNP levels, and more liver enzyme abnormalities, hyponaebunemia and thrombocytopenia compared to those presenting during the first phase of the COVID-19 pandemic (first + second wave).

Peptide 1: Peptide 2

<table>
<thead>
<tr>
<th>Peptide 1</th>
<th>Peptide 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NT-proBNP</td>
<td>Ferritin</td>
</tr>
<tr>
<td>548 (529)</td>
<td>1129 (724)</td>
</tr>
<tr>
<td>10 (32)</td>
<td>18 (69)</td>
</tr>
<tr>
<td>5250 (4721)</td>
<td>13366 (11211)</td>
</tr>
<tr>
<td>24 (80)*</td>
<td>25 (100)*</td>
</tr>
<tr>
<td>11 (35)</td>
<td>18 (69)</td>
</tr>
<tr>
<td>19 (73)</td>
<td>31 (100)</td>
</tr>
<tr>
<td>140.7 (82)</td>
<td>203.8 (84)</td>
</tr>
<tr>
<td>612 (676)</td>
<td>1183 (627)</td>
</tr>
<tr>
<td>3772 (5074)</td>
<td>15854 (9662)</td>
</tr>
<tr>
<td>24 (4)</td>
<td>19 (3)</td>
</tr>
<tr>
<td>2 (8)</td>
<td>18 (58)</td>
</tr>
</tbody>
</table>

Conclusion: A shift in MIS-C phenotype was identified across the successive COVID-19 waves, including the predominance of features associated with macrophage activation syndrome in later stages. These findings may reflect the impact of distinct SARS-CoV-2 variants. NT-proBNP emerged as the most important MIS-C feature predicting PICU admission, underscoring the importance of monitoring.

REFERENCES:
Table 1. Multivariate Level Mixed-Effect Logistic Regression Model: IMPACT of RA and axSpA Disease Characteristics on COVID Infection Severity Defined as Patients with COVID Symptoms Requiring Visit to Doctor, Emergency Room and/or Hospital Admission.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient (S.E)</th>
<th>Odds Ratio (95% Confidence Interval)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.17 (0.34)</td>
<td>1.18 (0.61 – 2.31)</td>
<td>0.6193</td>
</tr>
<tr>
<td>Female</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>-0.01 (0.01)</td>
<td>0.99 (0.97 – 1.01)</td>
<td>0.2543</td>
</tr>
<tr>
<td>Rheumatic Disease Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RA</td>
<td>0.18 (0.40)</td>
<td>1.20 (0.58 – 2.48)</td>
<td>0.6213</td>
</tr>
<tr>
<td>SpA</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>-0.40 (0.56)</td>
<td>0.67 (0.23 – 2.01)</td>
<td>0.4757</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIDS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>-0.20 (0.26)</td>
<td>0.82 (0.49 – 1.37)</td>
<td>0.4508</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Disease Activity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>-0.24 (0.06)</td>
<td>0.96 (0.85 – 1.09)</td>
<td>0.5275</td>
</tr>
<tr>
<td>HAQ</td>
<td>-0.03 (0.29)</td>
<td>0.97 (0.55 – 1.70)</td>
<td>0.9041</td>
</tr>
<tr>
<td>Nicotine products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>-0.67 (0.37)</td>
<td>0.51 (0.25 – 1.06)</td>
<td>0.0714</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannabis products</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>-0.45 (0.31)</td>
<td>0.64 (0.35 – 1.18)</td>
<td>0.1510</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMARDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0.26 (0.30)</td>
<td>1.30 (0.72 – 2.35)</td>
<td>0.3860</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologic DMARD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>-0.46 (0.43)</td>
<td>0.63 (0.27 – 1.46)</td>
<td>0.2813</td>
</tr>
<tr>
<td>No</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Possible disease related risk factors for increased COVID-19 severity in RA and axSpA patients preceding Omicron variant infection include steroid use and DMARDs. The occurrence of adverse events (AEs), particularly worsening disease related activity and unrelated immune reactions in these groups.

Objective: To evaluate the uptake of COVID vaccination in RA and axSpA patients, compare the frequency of AEs, and identify risk factors associated with vaccine AEs in two prospective cohorts comprised of these patients.

Methods: The IMPACT study is a monthly survey of two prospective cohorts of established RA and axSpA patients in northern Alberta, Canada from November 2020-2021 who answered at least one or more Redcap surveys through de-identified email link surveying demographics, disease characteristics, COVID symptoms, treatment of RA and axSpA, health care utilization, vaccination status, vaccine AEs and use of cannabis. Univariate analyses evaluated independent variables associated with the dependent variables of (1) any AE, (2) any severe vaccine AEs and use of cannabis. Univariate analyses evaluated independent variables associated with the dependent variables of (1) any AE, (2) any severe

Table 1. Summary of Multivariate Level Mixed-Effect Logistic Regression Models Evaluating the IMPACT of RA and axSpA Disease Characteristics on Vaccine AEs

<table>
<thead>
<tr>
<th>Variable</th>
<th>Any Adverse Event OR (95% CI) p value</th>
<th>Severe Adverse Event* OR (95% CI) p value</th>
<th>Any Arthritis Flare or Joint Ache Adverse Event OR (95% CI) p value</th>
<th>Any Severe Arthritis Flare or Joint Ache* OR (95% CI) p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>Male</td>
<td>1.47 (0.89 – 2.43)</td>
<td>p=0.13</td>
<td>2.10 (1.30–3.41)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>p=0.003</td>
<td>1.05 (1.03 – 1.06)</td>
<td>1.03 (1.01 – 1.04)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td>p=0.01</td>
<td>p=0.003</td>
</tr>
<tr>
<td>Rheumatic Disease Type</td>
<td>RA</td>
<td>0.42 (0.23 – 0.76)</td>
<td>p=0.05</td>
<td>0.55 (0.31 – 0.98)</td>
</tr>
<tr>
<td></td>
<td>axSpA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steroids</td>
<td>Yes</td>
<td>0.85 (0.40 – 1.83)</td>
<td>p=0.04</td>
<td>0.66 (0.32 – 1.35)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>p=0.25</td>
<td></td>
<td>p=0.25</td>
</tr>
<tr>
<td>NSAIDS</td>
<td>Yes</td>
<td>1.11 (0.81 – 1.52)</td>
<td>p=0.51</td>
<td>1.03 (0.75 – 1.41)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td></td>
<td></td>
<td>p=0.86</td>
</tr>
<tr>
<td>Current Disease Activity</td>
<td></td>
<td>0.95 (0.88 – 1.03)</td>
<td>p=0.19</td>
<td>0.90 (0.83 – 0.97)</td>
</tr>
<tr>
<td>HAQ</td>
<td></td>
<td>1.08 (0.73 – 1.61)</td>
<td>p=0.70</td>
<td>0.77 (0.52 – 1.14)</td>
</tr>
<tr>
<td>Nicotine products</td>
<td>Yes</td>
<td>1.33 (0.75 – 2.37)</td>
<td>p=0.70</td>
<td>1.42 (0.80 – 2.52)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>p=0.34</td>
<td></td>
<td>p=0.24</td>
</tr>
<tr>
<td>Cannabis products</td>
<td></td>
<td>0.78 (0.49 – 1.25)</td>
<td>p=0.30</td>
<td>0.87 (0.55 – 1.38)</td>
</tr>
<tr>
<td>DMARDs</td>
<td>Yes</td>
<td>1.98 (1.28 – 3.06)</td>
<td>p=0.002</td>
<td>1.52 (1.01 – 2.28)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td></td>
<td></td>
<td>p=0.05</td>
</tr>
<tr>
<td>Biologic DMARD</td>
<td></td>
<td>0.72 (0.42 – 1.25)</td>
<td>p=0.24</td>
<td>0.79 (0.45 – 1.41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>p=0.43</td>
</tr>
</tbody>
</table>

*Severe = Any of the following: ranked moderate to severe and/or lasting more than 7 days and/or saw physician
COVID-19 VACCINATION-RELATED ADVERSE EVENTS AMONG AUTOIMMUNE DISEASE PATIENTS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASES (COVAD) STUDY

P. Sen
1, N. R.2, A. Nune3, J. B. Lilleker4,5, V. Agarwal6, S. Kardes7, M. Kim8, J. Day9,10,11, M. Milchert11, T. A. Gheita12, B. Salim13,14, T. Velikova15, A. E. Gracia-Ramos16, I. Parodis17,18, A. Selva-O’callaghan19,20, E. Nikiphorou21,22,23, E. Hutchings24,25,26, Stephanie Wichuk: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared, Mohammed Osman Speake: None declared.

This study aimed to assess and compare short-term COVID-19 vaccination-related adverse events (AEs) in patients with systemic autoimmune and inflammatory disorders (SAIDs). Patients and rheumatologists have expressed concerns regarding vaccination--triggered allergic reactions, thrombogenic events, and other adverse events (ADEs) contributing to vaccine hesitancy. The objective was to collect outcome measures using the PROMIS tool. The survey was circulated in early 2021 by a multicenter study group of >110 collaborators in 94 countries. AEs were categorized by injection site pain, minor AEs, major AEs, and hospitalizations. Data from the baseline survey for descriptive and intergroup comparative statistics generated by international experts were analyzed.

Background: COVID-19 vaccines have been proven to be safe and effective in the healthy population at large. However, significant gaps remain in the evidence of their safety in patients with systemic autoimmune and inflammatory disorders (SAIDs). Patients and rheumatologists have expressed concerns regarding vaccination-triggered allergic reactions, thrombogenic events, and other adverse events (ADEs) contributing to vaccine hesitancy.

Objectives: This study aimed to assess and compare short-term COVID-19 vaccination-associated AEs in patients with SAIDs and healthy controls (HC) seven days post-vaccination, as well as between patients with SAIDs receiving different vaccines.

Methods: We developed a comprehensive, patient self-reporting electronic survey to collect respondent demographics, SAID details, COVID-19 infection history, COVID-19 vaccination details, 7-day post-vaccination adverse events and patient reported outcome measures using the PROMIS tool. After pilot testing, validation, and translation into 18 languages on the online platform surveymonkey.com, the survey was circulated in early 2021 by a multicenter study group of >110 collaborators in 94 countries. AEs were categorized by injection site pain, minor AEs, major AEs, and hospitalizations. We analyzed data from the baseline survey for descriptive and intergroup comparative statistics based on data distribution and variable type (data as median, IQR).

Results: 10,900 respondents (42 [30-53] years, 74% females and 45% Caucasians) were analyzed. 5,867 patients (54%) with SAIDs were compared with 5033 HC. All respondents included in the final analysis had received a single dose of the vaccine and 69% had received 2 primary doses. Pfizer (39.8%) was the most common vaccine received, followed by Janssen (9.5%), Moderna (11.3%), and AstraZeneca (11.4%). Baseline demographics differed by an older SAID population, higher female predominance (M:F=1:4.7 vs. 1:1.8) compared to HC.

Background: COVID-19 vaccines have been proven to be safe and effective in the healthy population at large. However, significant gaps remain in the evidence of their safety in patients with systemic autoimmune and inflammatory disorders (SAIDs). Patients and rheumatologists have expressed concerns regarding vaccination-triggered allergic reactions, thrombogenic events, and other adverse events (ADEs) contributing to vaccine hesitancy.

Objectives: This study aimed to assess and compare short-term COVID-19 vaccination-associated AEs in patients with SAIDs and healthy controls (HC) seven days post-vaccination, as well as between patients with SAIDs receiving different vaccines.

Methods: We developed a comprehensive, patient self-reporting electronic survey to collect respondent demographics, SAID details, COVID-19 infection history, COVID-19 vaccination details, 7-day post-vaccination adverse events and patient reported outcome measures using the PROMIS tool. After pilot testing, validation, and translation into 18 languages on the online platform surveymonkey.com, the survey was circulated in early 2021 by a multicenter study group of >110 collaborators in 94 countries. AEs were categorized by injection site pain, minor AEs, major AEs, and hospitalizations. We analyzed data from the baseline survey for descriptive and intergroup comparative statistics based on data distribution and variable type (data as median, IQR).

Results: 10,900 respondents (42 [30-53] years, 74% females and 45% Caucasians) were analyzed. 5,867 patients (54%) with SAIDs were compared with 5033 HC. All respondents included in the final analysis had received a single dose of the vaccine and 69% had received 2 primary doses. Pfizer (39.8%) was the most common vaccine received, followed by Janssen (9.5%), Moderna (11.3%), and AstraZeneca (11.4%). Baseline demographics differed by an older SAID population, higher female predominance (M:F=1:4.7 vs. 1:1.8) compared to HC.

Figure 1. A. Post Vaccination ADEs in SAIDs compared to HCs. B. Proportions of post COVID-19 vaccination ADEs in SAIDs by vaccine type.
79% had minor and only 3% had major vaccine ADEs requiring urgent medical attention overall. In adjusted analysis, among minor ADEs, abdominal pain [multivariable OR 1.6 (1.14-2.3)], dizziness [multivariable OR 1.3 (1.2-1.5)], and headache [multivariable OR 1.9 (1.6-2.2)], were more frequent in SAIDs than HCs. Overall major ADEs [multivariable OR 1.9 (1.6-2.2)], and throat [multivariable OR 5.7 (2.9-11.3)] were more frequent in SAIDs though absolute risk was small (0.4%) and rates of hospitalization were similarly small in both groups, with a small absolute risk (0.4%). Specific minor ADE frequencies were different among different vaccine types, however, major ADEs and hospitalizations overall were rare (0.4%) and comparable across vaccine types in patients with SAIDs (Figure 1).

**Conclusion:** Vaccination against COVID-19 is relatively safe and tolerable in patients with SAIDs. Certain minor vaccine ADEs are more frequent in SAIDs than HCs in this study, though are not severe and do not require urgent medical attention. SAIDs were at a higher risk of major ADEs than HCs, though absolute risk was small, and did not lead to increased hospitalizations. There are small differences in minor ADEs between vaccine types in patients with SAIDs.

**References:**


**Acknowledgements:** The authors thank all members of the COVAD study group for their invaluable role in the collection of data. The authors thank all respondents for filling the questionnaire. The authors thank The Myositis Association, Myositis India, Myositis UK, the Myositis Global Network, Cure JM, Cure IBM, Sjögren’s India Foundation, EULAR PARE, and various other patient support groups and organizations for their invaluable contribution in the dissemination of this survey among patients which made the data collection possible. The authors also thank all members of the COVAD study group.

**Disclosure of Interests:** Parikshit Sen: None declared, Naveen R: None declared. Arvind Nune: None declared, James B. Lillemoe: None declared, Vishwesh Agarwal: None declared, Sinan Kardes: None declared, Minchul Kim: None declared, Jessica Day Grant/research support from: JD has received research funding from CSL Limited, Marcet, Milich: None declared, Tamer A Gheita: None declared, Babur Salim: None declared, Tsvetelina Velikova: None declared, Abraham Gracia-Ramos: None declared, Ioannis Parodi Speakers bureau: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Consultant of: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Grant/research support from: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Albert Selva-O’Callaghan: None declared, Elena Nikphorou Speakers bureau: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, Abbvie, Celltrion, Eli Lilly and Company, Fibre, None declared, Joan Arnaud Sanofi-aventis: None declared, Abraham Gracia-Ramos: None declared, Ioannis Parodi Speakers bureau: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Albert Selva-O’Callaghan: None declared, Elena Nikphorou Speakers bureau: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, Abbvie, Celltrion, Eli Lilly and Company, Fibre, None declared, Joan Arnaud Sanofi-aventis: None declared, Abraham Gracia-Ramos: None declared, Ioannis Parodi Speakers bureau: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Albert Selva-O’Callaghan: None declared, Elena Nikphorou Speakers bureau: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, Abbvie, Celltrion, Eli Lilly and Company, Fibre, None declared, Joan Arnaud Sanofi-aventis: None declared, Abraham Gracia-Ramos: None declared, Ioannis Parodi Speakers bureau: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Eli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG., Albert Selva-O’Callaghan: None declared, Elena Nikphorou

**Clinical Response Predictors of Tocilizumab Therapy in Patients with Severe COVID-19**

W. Schmidt,1,2,3, K. Pawlik-Bus,1,2, P. Leszczyński1,1, Jozef Strus Municipal Hospital, Department of Rheumatology and Osteoporosis, Poznan, Poland; Poznan University of Medical Sciences, Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan, Poland; Poznan University of Medical Sciences, Doctoral School, Poznan, Poland

**Background:** Aberrant immune response is hallmark of severe COVID-19, irrespective from viral replication. Immuno-modulatory therapies such as interleukin-6 (IL-6) receptor inhibitors were proven to be beneficial in reducing in-hospital mortality. Yet, it remains unclear which patients can benefit most from such therapy.

**Objectives:** To identify predictors of clinical response to tocilizumab (TCZ) added to dexamethasone in patients hospitalized with severe COVID-19.

**Methods:** We prospectively assessed clinical and laboratory details of 120 patients hospitalized due to severe COVID-19 treated with TCZ (two doses of 8mg/kg 24h apart) in our ward between 1st Feb 2021 and 31st Dec 2021. Severe COVID-19 was defined as SpO2 <94% on room air with ground glass opacities in chest computed tomography (CT). Clinical response was defined as respiratory improvement on day 5 after TCZ infusion compared to day of treatment initiation, no further deterioration and survival. Decision of adding TCZ to dexamethasone as emergency therapy was made collectively by rheumatologists experienced in COVID-19 treatment. Laboratory and clinical parameters from hospital admission day and from TCZ institution day were analyzed. Statistical analysis was conducted with PoIStat v.1.8.2 and predictors were identified in univariate logistic regression.

**Results:** We identified 86 (71.7%) clinical responders and 34 (28.3%) non-responders. 20 (58.8%) of the second group needed ICU admission, 18 (52.9%) died on ICU and 2 patients (5.9%) died on the ward. Responders were significantly younger (mean age 56.1 vs. 63.5 years, p=0.006), had lesser comorbidity burden (median Charlson index 2 vs. 3, p=0.005), lower median lung involvement (50 vs. 70%, p=0.001), higher median baseline PaO2/FiO2 index (203 vs. 106, p<0.001) and less of them needed high-flow oxygen therapy on TCZ initiation day (12.7% vs 42%, p=0.025). Identified predictors of clinical response are shown in Table 1.

**Conclusion:** Administration of TCZ early in severe disease, with moderate IL-6 concentration and low organ damage indices is most beneficial in patients with severe COVID-19, especially in younger patients without respiratory and cardiac comorbidities.

**References:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4197
Methods: patients with RD against the new coronavirus infection COVID-19 bases on the population of patients with RD.

Objectives: patients with rheumatic diseases (RD) is one of the main goals of current vaccination against COVID-19 in middle-time perspective. No serious post-vaccination reactions or severe worsening of rheumatic diseases were recorded. Another reports of RD relapse were classified as postvaccination reactions, as classified the presented clinical symptoms as the RD worsening in 1.57% of cases, which resolved within 3-6 months. Relapses of the underlying RD after prolonged slight pyrogenic reaction, myalgias, arthralgias, hypercreatinophosphatemia, which occurred in 10.1136/annrheumdis-2022-eular.4250

Acknowledgements: I have no acknowledgements to declare.

I have no acknowledgements to declare.
**POS1264**

**LONGITUDINAL FOLLOW-UP OF HUMORAL RESPONSE AGAINST SARS-CoV-2 AND VIRAL PERSISTENCE IN 96 DMARD-TREATED PATIENTS WITH PREVIOUS COVID-19 INFECTION**


**Background:** Although it prevents severe forms of the disease, vaccination does not completely protect against the occurrence of COVID19 disease. In DMARDs used have been associated with variable humoral response to SARS-CoV-2 virus infection, the impact of their use after SARS-CoV-2 natural infection has not been clearly assessed. Aims: To evaluate immunogenicity and humoral response in autoimmune patients treated with DMARDs with and without B-cell depleting therapy. Methods: We retrospectively analyzed T-cell responses in autoimmune patients treated with B-cell depleting therapy (BD, n=41) and age-matched healthy controls (HCs, n=50) 3-4 weeks after SARS-CoV-2 infection. For the second dose of mRNA vaccination against COVID-19, we isolated PBMCs and stimulated them with a peptide pool covering the spike protein in vitro. Reactive CD4 and CD8 T-cells were determined by staining for IFN-γ, TNF-α and GzmB by flow cytometry. Anti-SARS-CoV-2 antibody assays targeting the receptor-binding domain (RBD) or trimeric S protein (TSP) were performed to elucidate concomitant B-cell responses. Results: We observed significant alterations in anti-SARS-CoV-2 antibody responses in our cohort, the frequency of IFNγ+ and IL-2+ CD4 and CD8 T-cells was similar in BD patients and controls. On the other hand, TNFα+ CD4 T-cells were significantly enriched in healthy controls versus BD patients (p<0.017) and also showed a significant correlation with antibody titer. Overall, the frequency of GzmB+ CD8 T-cells correlated very well with reactivity of T-cell subsets for other cytokines. This effect, however, is lost in the BD cohort. No difference was observed in the frequency of TNFα+ CD8 T-cells between the groups. Only 21 (42%) healthy individuals and 14 (34%) patients showed reactive T-cells for all the cytokines assayed. This observation is mainly explained by a lack of cytokine production in CD8 T-cells in 26 (52%) HCs and 27 (56%) BD patients. In contrast, 22 (44%) HCs and 17 (42%) patients didn't show any IL-2 producing CD8 cells. Of note, only 2 (4%) of HCs showed no GzmB+ CD8 T-cells whereas the number increased to 15 (37%) of BD individuals (p<0.001). In contrast, 42 (84%)
Patients with systemic vasculitis seem more prone to develop mild AEs after the administration of anti-SARS-CoV-2 vaccines in patients with systemic vasculitis. No serious AEs were reported. All the AEs were mild in both groups (malaise was the most frequently reported); AEs in vasculitis patients compared to HC after the second dose were detected after the first dose of vaccination. No significant differences in the frequency of significant higher frequency of AEs in vasculitis patients compared to HC (p=0.015)

Methods: Patients with systemic vasculitis from two Rheumatology centres who had received anti-SARS-CoV-2 vaccine were retrospectively examined. The primary outcome was to evaluate, in this multicentric cohort, the occurrence of a disease flare after the administration of the vaccine, defined as development of clinical manifestations related to vasculitis with a concomitant increase in serum inflammatory markers. As a secondary outcome we aimed at evaluating, in a monocentric cohort of patients with vasculitis, the occurrence of adverse events (AEs) following vaccine administration compared to healthy controls (HC).

Results: We examined 111 patients with systemic vasculitis (n=69 female, n=42 male), with a mean age of 64.3 (± 13) years. Sixty had ANCA-associated vasculitis (AAV), forty-two had Giant-Cell Arteritis (GCA), five had Perienteritis Nodosa, four had Takayasu's arteritis. One-hundred and five patients received a mRNA vaccine and six a viral vector one. A disease flare occurred in only 2 patients (1.8%) after the first dose of a mRNA vaccine: both had AAV (microscopic polyangiitis) and developed a pulmonary disease flare (respiratory failure requiring hospitalization and treatment with high-dose glucocorticoids). Of note, one of these patients had multiple previous comorbidities, including a severe COPD. Multivaried analysis, adjusted for age and sex, performed in a single monocentric cohort of patients with systemic vasculitis [n=60 (39 AAV, 21 GCA), 37 female, 23 male, mean age 71 (± 12.5) years) demonstrated a statistically significant higher frequency of AEs in vasculitis patients compared to HC (p=0.015) after the first dose of vaccination. No significant differences in the frequency of AEs in vasculitis patients compared to HC after the second dose were detected. All the AEs were mild in both groups (malaise was the most frequently reported); no serious AEs were reported.

Conclusion: Our data show a very low incidence of disease flares after the administration of anti-SARS-CoV-2 vaccines in patients with systemic vasculitis. Patients with systemic vasculitis seem more prone to develop mild AEs after the first dose of the vaccine. Taken together, this data suggest a good risk profile for anti-SARS-CoV-2 vaccine in patients with systemic vasculitis.

Disclosure of Interests: None declared

Background: Patients with autoimmune systemic diseases (ASDs) can be counted among frail populations as regards the predisposition to COVID-19 due to the frequent visceral organ involvement and comorbidities, as well as the ongoing immunomodulating treatments.

Objectives: Our long-term multicenter telephone survey prospectively investigated the prevalence, prognostic factors, and outcomes of COVID-19 in Italian ASD patients during the first 3 pandemic waves.

Methods: A large series of 3,918 ASD patients (815M, 3103 F; mean age 59±12SD years) was consecutively recruited at the 36 referral centers of COVID-19 & ASD Italian Study Group. In particular, ASD series encompassed the following conditions: rheumatoid arthritis (n=981), psoriatic arthritis (n=471), ankylosing spondylitis (n=159), systemic sclerosis (n=1,738), systemic lupus (n=172), systemic vasculitis (n=219), and a miscellany of other ASDs (n=178). The development of COVID-19 was reported by means of telephone survey using standardized symptom-assessment questionnaire (1).

Results: A significantly increased prevalence of COVID-19 (8.37% vs 6.49%; p<0.0001) was observed in our ASD patients, while the cumulative death rate revealed statistically comparable to the Italian general population (3.65% vs 2.95%; p=ns). In particular, among the 328 ASD patients complicated by COVID-19, 57 (17%) needed hospitalization while mid-moderate manifestations were observed in the large majority of individuals (83%). In addition, 12/57 hospitalized patients died due to severe interstitial pneumonia and/or cardiovascular manifestations.

Interestingly, a significantly higher COVID-19-related death rate was observed in systemic sclerosis patients compared to the Italian general population (6.29% vs 2.95%; p=0.018). Other adverse prognostic factors to develop COVID-19 were the patients’ older age, male gender, pre-existing ASD-related interstitial lung involvement, and chronic steroid treatment. Conversely, patients treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) showed a significantly lower prevalence of COVID-19 compared to those with (3.58% vs 46.99%; p=0.000), as well as the chronic administration of low dose aspirin in a subgroup of SSc patients (with 5.57% vs without 27.84%; p=0.000).

Conclusion: The cumulative impact of COVID-19 on ASD patients after the first 3 pandemic waves revealed less severe than that observed during the first phase of COVID-19, especially with regards to the death rate that was comparable to the Italian general population in spite of the increased prevalence of complicating COVID-19 in the same ASD series.

Ongoing long-term treatments, mainly csDMARDs, might usefully contribute to generally positive outcomes of in this frail patients’ population. Of note, a significantly increased COVID-19-related mortality was recorded in only SSc patients’ subgroup, possibly favoring by pre-existing lung fibrosis. Among different ASD, SSc deserves special attention, since it shares the main pathological alterations with COVID-19, namely the interstitial lung involvement and the endothelial injury responsible for diffuse microangiopathy. Besides SSc, the patients subgroups characterized by older age, chronic steroid treatment, pre-existing interstitial lung disease, and/or impaired COVID-19 vaccine response (1-3), may deserve well-designed prevention and management strategies.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4522

A. Torgashin1, E. Sokol1, B. Chalve1, J. Khvani1, O. Golovina1, S. Glikhova1.
1 VA, Nasonova Research Institute of Rheumatology, Rare Rheumatic Disease and Sjogren’s Syndrome, Moscow, Russian Federation; 2 Heart and Joint Center, Rheumatology, Moscow, Russian Federation; 3 VA, Nasonova Research Institute of Rheumatology, Educational-Medical Department, Moscow, Russian Federation

Background: Data from multiple rheumatological cohorts have shown that treatment with rituximab (RTM) is associated with higher COVID-19 morbidity and mortality. Information about the course of COVID-19 in patients (pts) with Sjögren’s syndrome (SJS) is still lacking.

Objectives: To compare clinical course of COVID-19 in pts with SJS treated with anti-CD20 monoclonal antibody (RTM) and treated with synthetic disease-modifying antirheumatic drugs and low doses of glucocorticoids.  

Methods: Single center observational study. Pts with SJS were screened for SARS-CoV-2 infection anamnesis via telephone interview. Diagnosis of SJS was based on ECR/EULAR 2016 criteria. COVID-19 diagnosis was based on positive PCR test and typical clinical features (CT signs, fever and anosmia). RTM was based on ECR/EULAR 2016 criteria and PsA according to CASPAR criteria were included. Demographic data, disease clinimetry, treatments, vaccination received and post-vaccination adverse events were recorded. We evaluated, according to medical criteria, whether the patient presented a flare disease after vaccination and whether it was mild, moderate or severe. We also evaluated the factors associated with the presence of at least one mild adverse event. Statistical analysis: descriptive statistics were performed, qualitative variables were expressed as frequency and percent-age (%), numerical variables as mean and standard deviation (SD) or median and percenttile25-75. Binary logistic regression was performed using the presence of at least one mild adverse event to vaccination as the dependent variable.

Results: 210 patients were included with a mean age of 45 (SD 15) years. The diagnoses were: AS 50 (23.8%), nra-axSpA 10 (4.8), pSpA 9 (4.3%), PsA 141 (67%), and disease of time evolution in months 109 (SD 96). Regarding comorbidities, the following frequencies were reported: arterial hyper tension 60 (30%), diabetes mellitus 25 (12%), heart failure 4 (2%), asthma/EPOC 15 (7%), inflammatory bowel disease 2 (1%), acute anterior uveitis 20 (9.5%), psoriasis 128 (61%). Six -teen percent (n=33) of the patients had SARS-CoV-2 infection prior to vaccination. Regarding treatments, those used were: antiTNF 88 (42%), Tofacitabin 6 (2.9%), Ustekinumab 2 (1%), Secukinumab 35 (17%), Bekaizum ab 21 (1%), methotrexate 98 (47%), leminotride 7 (3.3), sulfasalazine 7 (3.3), apremilast 1 (0.5%), continuous NSAIDs 26 (12.4%) and NSAIDs on demand 103 (49%). Vaccines received were: Sputnik V 109 (51.9%), Oxford Vaccine, AstraZeneica 63 (30%), Janssen 1 (0.5%), BioNTech Vaccine, Pfizer 1 (0.5%), Sinopharm 33 (15.7%), Moderna 0%, Novavax 0% and others; 3 (1.4%). Thirty-eight percent (n=80) of patients reported having mild post-vaccination symptoms, of which 3.75% did not resolve, 41% resolved with medication and 39% resolved ad integrum without medication. The presence of mild adverse event to the vaccine was associated with lower use of metotrexate (31% vs 56%, p<0.001) and lower age (54 (SD 14) vs 47 (SD 12), p<0.001), and low BMI (25 (4-30.5) vs 29 (25-35.5), p<0.001); while no association was found with sex, diagnosis, comorbidities, treatments, disease activity or vaccines. In the logistic regression analysis all the variables remained independent associated with a lower frequency of presenting a mild adverse event: metotrexate: OR: 0.30, 95% CI 0.15-0.58, p<0.001, age: OR: 0.97, 95% CI 0.95-0.99, p: 0.03; BMI: OR: 0.92, 95% CI 0.95-0.99, p: 0.02. Sixty-one percent (n=129) of patients received the 2nd dose of vaccination, which 27% (n=35) presented mild adverse event and only 1 (0.8%) patient suffered post vaccination disease flare.

Conclusion: Vaccination against COVID19 appears to be safe in this population, with only mild adverse events and low frequency of flare disease. Mild adverse events associated with less use of metotrexate, younger age and lower BMI.

Disclosure of Interests: None declared


Takayasu arteritis: case series of 15 patients from a tertiary single center

G. Sevik1, S. Kutlu Agaçkıran1, K. Abacı 2, A. Aliyev3, H. Direskeneli4, F. Albaz-Onel5, 1 Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Background: The Coronavirus disease 2019 (COVID-19) has affected more than two hundred million individuals and many risk factors for increased mortality and morbidity in COVID-19 have defined. There are many studies evaluating the effect of immunosuppressants used in inflammatory rheumatic diseases in the course of COVID-19. (1,2) However, fewer data are available on the course of COVID-19 in patients with Takayasu arteritis (TAK).

Objectives: In this study, we aimed to evaluate the characteristics and outcomes of TAK patients with COVID-19.

Methods: A phone survey was conducted among TAK patients that are followed up in our clinic between February 2021 and March 2021. All patients were asked whether they were diagnosed as COVID-19 during the pandemic. The patients who had a history of confirmed COVID-19 were asked about the symptoms, hospitalization status and the treatment received for COVID-19. Information about their chronic diseases were obtained from the patient files.

Results: Among 118 TAK patients, 15 had COVID-19 infection during the first year of pandemic, 13 of them were female and male age was 42.5 ± 12.0 years. None of the patients had been vaccinated before the diagnosis of COVID-19. Nine of the patients were taking prednisone therapy and 3 of them were taking moderate to high doses of glucocorticoids during the infection period. Twelve patients were taking conventionally synthetic disease-modifying antirheumatic drugs (csDMARDs), 7 patients were taking biological disease-modifying antirheumatic drugs (bDMARDs), and 5 patients were taking a combination of csDMARD and bDMARD therapy when they were diagnosed with COVID-19. Two patients were hospitalized; one of them required nasal oxygen support and discharged after 5 days. The other patient was 61 years old and had multiple comorbidities and had admitted to intensive care unit for 5 days. One patient who had a mild COVID-19 disease had pulmonary thromboembolism 2 weeks after the infection and his symptoms resolved after starting anticoagulation therapy. All of the patients fully recovered and had no mortality related to COVID-19.
POS1272  EVALUATION OF DIAGNOSIS, TREATMENT AND OUTCOME RESULTS OF MIS-C PATIENTS

K. Ulu1, Ş. Çağlayan1, T. Coşkun1, R. E. Yigit1, M. Çakan1, B. Sözeri1, 1Health Sciences University, Umraniye Training and Research Hospital, Pediatric Rheumatology, Istanbul, Turkey

Background: SARS-COV-2 infection, which has become a pandemic worldwide, has led to various results, from mild clinical findings to severe respiratory failure. Multisystem inflammatory syndrome (MIS-C) in children is a rare but severe condition characterized by fever, inflammation, and multi-organ failure, caused by an overreaction of the immune system after SARS-COV-2 infection.

Objectives: This study aims to report the clinical and laboratory findings, diagnostic methods, treatment regimens, and short-term follow-up results of patients diagnosed with MIS-C.

Methods: This is a retrospective observational study from a tertiary pediatric rheumatology center including patients (aged 1 month to 21 years) diagnosed with MIS-C between April 2020-December 2021. Demographic, clinical, laboratory results, and follow-up data were collected through the electronic patient record system and analyzed.

Results: Of the 110 patients included in the study, 67.2% (n=74) were male. Fever was a common finding in all. Macrophage activation syndrome (MAS) was dominant in 28.2% (n=31), while Kawasaki-like disease was observed in 40% of the patients. Gastrointestinal symptoms were found in 64.5% of the cases, rash in 40%, conjunctivitis in 35.5%, lymphadenopathy in 30%, hypotension in 27.3%, cardiac decompensation in 16.4%, bradycardia in 8.2%, neurological findings in 4.5%, and/or coronary artery pathology in 3.6% respectively. Included in the study, 63.6% had lymphopenia, 48.2% had hyponatremia, and 39.1% had hyponatremia. Thirty-eight patients (34.5%) were followed up in the intensive care unit, 19 of them had MAS. Comorbid chronic disease was present in 21.8% of the patients. The mean hospital stay was 12±7.8 days. Hypotension and MAS were the most common indications for admission to the intensive care unit. Intravenous immunoglobulin treatment was applied to 87.2% of the cases, the steroid was given to 70.9%, and anakinra treatment was given to 27.3%, respectively. In the outpatient follow-up, it was determined that the coronary abnormalities had regressed entirely. While 97.3% of the cases recovered without sequelae, three died. Two patients who died had the comorbid disease. While there was no significant difference in terms of Kawasaki-like disease and gender in those followed up in the intensive care unit (p=0.25, p=0.81), D-dimer was higher, and the mean age was greater (p=0.08, p=0.02). No statistical correlation was found between those with Kawasaki-like disease regarding age and gender (p=0.058 p=0.068).

Conclusion: Multisystem inflammatory syndrome in children may lead to severe cardiac findings and intensive care requirements at admission and hospital follow-up. The majority of MIS-C-related findings resolve completely until discharge or in short-term follow-up. Although the pathogenesis and treatment plan of the disease has been largely clarified, follow-up studies are needed in terms of long-term prognosis and relapse probabilities.

Disclosure of Interests: None declared


POS1274  A SINGLE CENTER COVID-19 VACCINE EXPERIENCE IN FAMILIAL MEDITERRANEAN FEVER PATIENTS

S. C. Güven1, O. Karakaş1, E. Atalar1, H. E. Konak1, P. Akyüz Daşlı1, E. Eyakan Erdogan1, B. Armagan1, K. Gök1, I. Dogan1, Y. Maras1, A. Erden1, S. Erteng1, O. Kucuk1, A. Omm1, 1Ankara City Hospital, Rheumatology Clinic, Ankara, Turkey; 10Yıldırım Beyazıt University Medical School, Internal Medicine, Division of Rheumatology, Ankara, Turkey; 1Health Sciences University, Ankara City Hospital, Rheumatology Clinic, Ankara, Turkey

Background: To prevent COVID-19 disease SARS-Cov-2 vaccines put into use worldwide with emergency use authorizations despite ongoing safety concerns. Since pyrin mediated inflammasome response is dysregulated in FMF, exposure to SARS-Cov-2 proteins via vaccination may potentially trigger inflammation, leading to attacks after vaccination. In our FMF patients we aimed to analyze the frequency of adverse events and side effects related to vaccination.

Methods: Data regarding, number of vaccine doses, types of vaccines (CoronaVacc or BNT162b2) presence of AE and/or AF attacks after any vaccine dose within a month, history of COVID-19 infection before or after vaccination, adherence to FMF treatment during vaccination were collected from hospital database or via telephone.

Results: A total of 161 vaccinated FMF patients were included. Mean ± SD age was 40.5 ± 11.7 years. 57.1% was female. 10.6% of the patients had chronic kidney disease and 9.3% had amyloidosis. Most common MEFV mutations were M694V heterozygous (27%) and M694V homozygous (21%). 93.2% of the patients were under colchicine, 21.8% under anti-interleukin 1 agents, 2.5% under TNF-α inhibitors. 96.3% of the patients adhered to FMF treatment during vaccination. Vaccination properties and data regarding adverse events are presented in Table 1. 57.8% of our patients suffered from an AE/attack after a vaccine dose. Number of patients with AE after BNT162b2 was significantly higher (p<0.001). None of the patients had severe AE. 39 patients had COVID-19 infection prior to primary vaccination. 61.5% of these suffered from an adverse reaction/attack after vaccination, in comparison to 56.6% of the patients without previous COVID-19 infection prior to vaccination.

Disclosure of Interests: None declared


REFERENCES:

POS1273  EVALUATION OF THE SAFETY PROFILE OF COVID-19 VACCINES IN CHILD PATIENTS USING BIOLOGICAL THERAPY

B. Sözeri1, R. E. Yigit1, 1University of Health Sciences, Umraniye Education and Research Hospital, Pediatric Rheumatology, Istanbul, Turkey

Background: Coronavirus vaccines have been widely applied all over the world after the considerable pandemic. There are inactivated vaccines and mRNA virus vaccines in our country. There is no clear guideline for the vaccination programs of patients receiving immunosuppressive therapy, especially childhood.

Objectives: For this reason, we wanted to evaluate the frequency of side effects developed after covid-19 vaccine in pediatric patients diagnosed with rheumatic disease using biological therapy and nonbiologic disease modifying drugs

Methods: A total of 226 patients over the age of 12, who were followed up in the pediatric rheumatology clinic of the University of Health Sciences, Training and Research Hospital, using biological therapy and were vaccinated against Covid-19, were included in the study. The standard questionnaire forms were filled in face-to-face after each administration for both vaccines. The patient, who had any serious side effects, was followed up in the hospital.

Results: Of the 226 patients included in the study, 97 were male and 128 were female. Their mean age was 16.4 ± 2.4. It was determined that 88.4% (n=200) of the patients had mRNA vaccine and 11.6% (n=26) had inactivated vaccine. 105 of the patients were using biologic drugs during vaccination. Of these, 63 (27.9%) patients were treated with anti-TNF drugs (46 adalimumab, 10 etanercept, 6 infliximab), 32 patients were anti-il-1 (30 canakinumab, 2 anakinra), 4 patients were anti-il-6, 3 patients were anti-il-17, 3 patient was receiving abatacept and 1 patient was receiving rituximab. 121 patients were using DMARDs. Of these, 61 were using colchicine, 26.5% (n=60) of the patients had covid infection before vaccination. Side effects were observed in 180 of our patients. No side effects were observed in 46 patients. Pain at the injection site was the most common among them, 72.6% (n=164), Headache was seen in 16.8% (n=38) of the patients, myalgia in 18.1% (n=41), fever in 16.4% (n=37) and arthralgia in 6.6% (n=15). The frequency of serious adverse events was determined as 0.9% (n=2). Both patients were followed up in the ward. When the patients were compared in terms of covid infection and gender, there was no significant difference in the frequency of side effects. When the vaccines were compared, the incidence of side effects in the mRNA vaccine was statistically significantly higher (p=0.001). Pain at the injection site was significantly less frequent in the inactivated vaccine (p=0.004). In terms of drug distribution, there was no significant difference in the frequency of side effects between patients using biologic drugs and DMARDs. There was no statistically significant difference in the frequency of side effects when the patients using dexamethasone were compared as colcicine and other dmds.

Conclusion: In our study, we have shown that the use of vaccines in individuals with adolescent rheumatological diseases is safe and that the biological treatments used by the patients do not cause an increase in the risk of vaccine side effects. In addition; We have shown in our study that the side-effect profile of the inactivated vaccine used in our country is milder than the mRNA vaccine, and that it affects daily life less. Another result of our study was that anti-TNF drugs could cause a decrease in pain sensation due to the relationship of anti-TNF with pain pathways.

Disclosure of Interests: None declared

prior COVID-19 infection (p=0.584). When patients with and without AEs/attacks were compared, no significant differences were observed regarding age, gender, body mass index, comorbidities, FMT treatments and total vaccine doses.

Table 1. Adverse events and FMF attacks in a total of 161 vaccine recipients

<table>
<thead>
<tr>
<th>Event</th>
<th>BNT162b2</th>
<th>CoronaVac</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total vaccine doses, n</td>
<td>213</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>Patients ever vaccinated with BNT162b2 and CoronaVac, n (%)</td>
<td>117 (72.7)</td>
<td>67 (41.6)</td>
<td></td>
</tr>
<tr>
<td>Patients with primary vaccination completed with CoronaVac alone, n (%)</td>
<td>94 (58.4)</td>
<td>44 (27.3)</td>
<td></td>
</tr>
<tr>
<td>Patients with a adverse event after any vaccine dose, n (%)</td>
<td>64/117 (54.7)</td>
<td>20/67 (29.9)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Event</th>
<th>BNT162b2</th>
<th>CoronaVac</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>13 (11.1)</td>
<td>6 (9.0)</td>
<td>0.644</td>
</tr>
<tr>
<td>Malaise</td>
<td>21 (17.0)</td>
<td>4 (6.0)</td>
<td>0.023</td>
</tr>
<tr>
<td>Local pain/arm pain</td>
<td>17 (14.5)</td>
<td>4 (6.0)</td>
<td>0.079</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>19 (16.2)</td>
<td>6 (9.0)</td>
<td>0.043</td>
</tr>
<tr>
<td>Myalgia</td>
<td>6 (5.1)</td>
<td>0 (0.0)</td>
<td>0.059</td>
</tr>
<tr>
<td>Headache</td>
<td>11 (9.4)</td>
<td>4 (6.0)</td>
<td>0.010</td>
</tr>
<tr>
<td>Nausea</td>
<td>6 (5.1)</td>
<td>1 (1.5)</td>
<td>0.215</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (3.4)</td>
<td>1 (1.5)</td>
<td>0.439</td>
</tr>
<tr>
<td>Others</td>
<td>23 (18.9)</td>
<td>13 (19.4)</td>
<td>0.653</td>
</tr>
</tbody>
</table>

Conclusion: We observed considerable number of FFM patients suffered from vaccine related AEs/attacks, particularly with BNT162b2. However, no serious AE was detected. Demographics, clinical characteristics and prior history of vaccination did not significantly affect AE attack occurrence.

Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared


**A RETROSPECTIVE STUDY ON UVEITIS FLARES FOLLOWING COVID19 VACCINATION: SHARING EXPERIENCE FROM A TEACHING HOSPITAL COMBINED RHEUMATOLOGY AND UVEITIS CLINIC**

A. Birchall1, S. Byravan2, P. Kumarr3, A. Mooorthy4, 1Leicester Medical School, College of Life Sciences, Leicester, United Kingdom; 2University Hospitals of Leicester, Rheumatology, Leicester, United Kingdom; 3University Hospitals of Leicester, Ophthalmology, Leicester, United Kingdom; 4University Hospitals of Leicester, Rheumatology, Leicester, United Kingdom

Background: Uveitis is a sight threatening disease caused by inflammation of the intraocular tract of the eye. Uveitis is a manifestation of many autoimmune conditions and is associated with seronegative axial spondyloarthritides, reative arthritis, Behget’s disease, inflammatory bowel disease, and psoriatic arthritis. Acute anterior uveitis is the most common presentation and is most commonly idiopathic or associated with the HLA-B27 gene (around 20% of cases). Studies have shown that anterior uveitis frequently recurs in patients after it has previously remitted. 1 Patients suffering from autoimmune conditions are frequently prescribed immunosuppressant drugs to control their illness, thus leaving them more susceptible to bacterial and viral illnesses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Previous studies have shown that some patients suffer exacerbation of their autoimmune condition after coronavirus vaccination, including uveitis.[2] We aim to evaluate our cohort of patients suffering from autoimmune conditions treated at Leicester Uveitis Service at Leicester Royal Infirmary and explore any proposed link.

Objectives: To assess if COVID19 vaccination is associated with uveitis flares in immunosuppressed patients.

Methods: A retrospective study, to determine if patients diagnosed with autoimmune conditions suffered from uveitis following COVID-19 vaccination. A data collection sheet was used to document demographic and clinical data: age, sex, ethnicity, autoimmune condition, dates of COVID-19 vaccination(s), type of vaccine, medication at the time of vaccine, symptoms of autoimmune recurrence, date of uveitis onset and number of days between uveitis onset and latest vaccine. We used an already existing uveitis database with an active register of 2346 patients, of which 246 were on immunomodulation.

Results: After reviewing the first 50 patients on immunosuppression for uveitis, we found a total of 4 patients had a uveitis flare despite tight control previously; 3 were female and 1 male, their median age was 39.5 years. They experienced a recurrence of uveitis in the last 6 months. Of these 4 patients 3 were on synthetic DMARDS (2 mycophenolate motefil, 1 azathioprine), 1 was on steroids and 1 was on a biological DMARD (adalimumab). 2 of the patients suffered from posterior uveitis and 2 from anterior uveitis. All the 50 patients had been vaccinated against COVID19 however there was no clear record of booster dose.

Conclusion: Our study showed that of 50 immunosuppressed patients, 4 had a uveitis flare following vaccination. Clinicians need to be aware of uveitis flares in rheumatology patients following vaccination. This is a small retrospective analysis of our cohort however a large observational study on flare of uveitis following COVID-19 primary vaccination and booster vaccination would be useful to get meaningful data.

REFERENCES:


Disclosure of Interests: None declared


**POS1275**

HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE IN RITUXIMAB-TREATED PATIENTS

E. Flores-Fernández1, I. Vázquez-Gómez1, C. Valera-Ribera2, P. Andújar-Braza1, E. Valls-Pascual1, J. M. Nogueira Coito3, Á. Martínez-Ferrer1, D. Ybáñez-García1, J. J. Alegre-Sancho1, 1Doctor Peset University Hospital, Rheumatology, Valencia, Spain; 2Doctor Peset University Hospital, Microbiology, Valencia, Spain

Background: Vaccination against SARS-CoV-2 has shown efficacy and safety in patients with chronic inflammatory rheumatic disease, similar to the general population. However, in patients treated with rituximab (RTX) it is known that usually have a lower vaccination response rate (1-2), and recent studies suggest that it also happens with the new SARS-CoV-2 virus (3), which entails an increased risk of hospitalization and mortality in this specific group of patients.

Objectives: To describe humoral immune response to SARS-CoV-2 vaccine in rituximab-treated patients after one and six months from the vaccination, and study if there is any other factor associated with a lower response rate.

Methods: Prospective analysis of a cohort of patients treated with RTX who received the SARS-CoV-2 vaccine between the months of April and October 2021. Demographic and medical data were collected through electronic medical records. Blood tests and serologies with levels of antibodies against SARS-CoV-2 were performed one and six months after having received the vaccine against SARS-CoV-2. The administration of a booster dose of the vaccine was recorded. A descriptive and statistical analysis of the data was carried out using the SPSS program.

Results: From a cohort of 41 patients, of whom 81.4% were women with a mean age of 56 (13.4 SD) years, vaccine response rate was only 36.7% after a 6-month follow-up. The 88.4% of them received a booster dose of the vaccine, but this failed to produce a vaccine response in any of the patients who had not developed it with the previous ones. One patient became infected after receiving one dose of the vaccine and failed to develop a serological response either. Hypogammaglobulinaemia was associated with a statistically significant lower probability of vaccine response (p=0.04). A trend of lower vaccination response rate was observed in patients who had received the last cycle of RTX in the 6 months prior to vaccination (p=0.058). In addition, the antibody levels developed one month after vaccination were statistically significantly correlated with the time between the last RTX cycle and vaccination (p=0.014) and also with CD19 B cells levels prior to vaccination (p=0.001); however, there was no correlation with the antibody levels detected at the 6-months serology. No statistically significant differences were found in relation to the number of previous cycles of RTX, concomitant treatment with synthetic disease-modifying drugs (DMARDs) or corticosteroids.

Conclusion: In our sample, after a 6-month follow-up only 36.9% achieved a vaccine response against SARS-CoV-2, which did not improve despite the administration of a booster dose. Hypogammaglobulinemia, the time between the last RTX cycle and vaccination (at least 6 months), and previous CD19 B cells levels significantly influenced in the development of a humoral response to the vaccine.
REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4959

POS1277
LONGTERM IMMUNOGENICITY AND TOLERABILITY OF A 3RD DOSE OF AN MRNA Anti-SARS-COV-2 VACCINE IN RA PATIENTS WITH AN INADEQUATE RESPONSE TO A PREVIOUS STANDARD TWO DOSE REGIME
K. Schmiedeburg1, I. A. Abel2, N. Vuilleumier3, S. Pagano3, J. Von Kempis1, A. Rubbert-Roth1, 1Rheumatology Clinic, Kantonsspital St.Gallen, St.Gallen, Switzerland; 2Zürich, Institute of Medical Virology, University of Zurich, Zürich, Switzerland; 3Geneva, Laboratory Medicine Division, Geneva, Switzerland

Background: Lower seroconversion rates have been reported in patients with rheumatic diseases receiving immunomodulatory therapies following a standard mRNA-based vaccine regimen. Data with regard to immunogenicity and safety of a 3rd vaccine dose in this patient population is limited.

Objectives: We aim to study immunogenicity, vaccine associated side effects and the occurrence of flares in RA patients unresponsive to a standard vaccine regimen eligible for a 3rd vaccine dose.

Methods: RA patients who had a low or absent anti-S response after 12 (Cohort A) or 24 weeks (Cohort B) following a standard vaccination regimen received a 3rd vaccine dose. Temporary discontinuation of DMARD therapy was recommended. Serum samples were collected before, 2, 12, and 24 weeks after the 3rd vaccine dose. Quantitative measurement of anti-S was performed using the Roche Elecsys Anti-SARS-CoV-2 spike subunit assay: Neutralizing activity (NT50) against Wuhan WT and -,-,- variants was assessed by using a HIV-based pseudovirus system.

Results: Baseline characteristics are shown in Table 1. 45/47 patients temporarily discontinued DMARD therapy: Mtx and JAKi were paused one week before/after 2 weeks after the 3rd vaccine dose, bDMARDs were paused 2 weeks before/after 2 weeks after the 3rd dose. Local pain and/or systemic vaccine associated side effects following the 3rd vaccine dose were reported in 12/17 (71%) in Cohort A, and 10/29 (35%) patients in Cohort B (p = 0.018). Flares were defined as loss of low disease activity (LDA), subsequent to the 3rd vaccine dose and occurred in 17/47 (36%) patients (p = 0.0332) with comparable frequencies defined as loss of low disease activity (LDA), subsequent to the 3rd vaccine dose and occurred in 17/47 (36%) patients (p = 0.0332) with comparable frequencies in both cohorts (41% Cohort A, 33% Cohort B (NS)).

Table 1. Baseline characteristics of RA patients in Cohort A and Cohort B

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Cohort A</th>
<th>Cohort B</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA patients (n = 17)</td>
<td>RA patients (n = 30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yrs), mean (± SD)</td>
<td>69 (8)</td>
<td>63.9 (8)</td>
<td>NS</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>9 (53)</td>
<td>13 (43)</td>
<td>NS</td>
</tr>
<tr>
<td>mRNA-1273/BNT162b2, n=</td>
<td>5/25</td>
<td>5/25</td>
<td>NS</td>
</tr>
<tr>
<td>Disease activity (CDAI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate CDAI (10.1 - 22.0), n (%)</td>
<td>2 (12)</td>
<td>3 (10)</td>
<td>NS</td>
</tr>
<tr>
<td>LDA (2.9 - 10), n (%)</td>
<td>11 (64)</td>
<td>18 (60)</td>
<td>NS</td>
</tr>
<tr>
<td>Vaccination type/schedule</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA-1273/BNT162b2, n=</td>
<td>3/14</td>
<td>5/25</td>
<td>NS</td>
</tr>
<tr>
<td>DMARD therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsteroidal DMARDs, n (%)</td>
<td>21/17 (71%)</td>
<td>10/30 (33%)</td>
<td>NS</td>
</tr>
<tr>
<td>bDMARDs ± cDMARDs, n (%)</td>
<td>8/17 (47%)</td>
<td>14/30 (47%)</td>
<td>NS</td>
</tr>
<tr>
<td>JAKi ± cDMARDs, n (%)</td>
<td>7/17 (41%)</td>
<td>6/30 (20%)</td>
<td>NS</td>
</tr>
<tr>
<td>Prednisone, n (%)</td>
<td>8/17 (47%)</td>
<td>11/30 (37%)</td>
<td>NS</td>
</tr>
<tr>
<td>Mean daily dose prednisone (mg ± SD)</td>
<td>4.1 ± 1.6</td>
<td>4.1 ± 1.5</td>
<td>NS</td>
</tr>
</tbody>
</table>

Low or absent anti-S titers were confirmed before the third vaccination (Cohort A: median 19.5 U/ml, IQR 0.47-57; cohort B: median 65.9 U/ml, IQR 22-154) (p = 0.0018). Two weeks after the 3rd dose, a rapid and significant increase in anti-S were observed in 12/17 (82%) and 25/28 (89%) patients (Cohort A: median 2500 U/ml, IQR 798-2500; Cohort B: median 2500 U/ml, IQR 2500-2500) (NS). High levels of anti-S were maintained in the majority of patients 55% (11/20) until week 12 in both cohorts (Figure 1). NT50 against Wuhan-WT and other variants was assessed in 21 patients 2 weeks after the 3rd vaccine dose revealing a low or absent NT50 against delta in 38% of patients despite a median anti-S response of 2500 U/ml (IQR 798-2500). 14/21 patients had peak anti-S titres of 2500 U/ml, of those 12/14 developed a strong NT50 response against the delta variant.

Conclusion: Our data demonstrate that a 3rd vaccine dose, maybe complemented by temporary discontinuation of DMARD therapy, may lead to a rapid increase in anti-S antibodies when using a homologous vaccine and profound neutralizing activity in the majority of RA patients previously unresponsive to a standard two dose regimen. This seems to be independent of the interval to the previous standard vaccine regimen. As flares occurred in 36% of all patients, the necessity and length of DMARD discontinuation should be explored in more detail to balance between sustained control of disease activity and optimized vaccine induced immune responses.

REFERENCES:

Disclosure of Interests: Kristin Schmiedeburg, None declared, Irene A. Abela: None declared, Nicolas Vuilleumier: None declared, Sabrina Pagano: None declared, Johannes von Kempis Speakers bureau: Lilly, BMS, Pfizer, and Sanofi, Andrea Rubbert-Roth Speakers bureau: Abbvie, Pfizer, Sanofi, UCB, BMS, Lilly, Gilead and Roche, Consultant of: Abbvie, Gilead, Lilly, BMS, and Sanofi


POS1278
EXCELLENT PROGNOSIS OF RHEUMATIC MANIFESTATIONS FOLLOWING COVID-19 VACCINATION: 7 MONTHS FOLLOW-UP DATA
M. Gasparotto1, 1Padua University Hospital, Rheumatology, Padova, Italy

Background: It is well established that severe forms of SARS-CoV2 infection can induce a massive cytokine storm, which may disrupt the immune system stability and conceivably stimulate the development of reactive manifestations through a molecular mimicry process. Likewise, anti-COVID-19 vaccines, which have so far proved an excellent tolerability and safety profile, are able boost the immune response via different biologic technologies and adjuvant combinations possibly facilitating, in predisposed subjects, the onset of inflammatory or even autoimmune manifestations.

Objectives: We report a case series of suspected rheumatic adverse events following immunization (AEFI) associated with anti-COVID-19 vaccine. We focused our attention on the prognosis of these patients by analysing their available follow-up data.

Methods: We included patients evaluated at first-aid rheumatologic consultancy and at rheumatologic outpatient and inpatient clinic at Padua University Hospital between May and September 2021 presenting with new-onset rheumatic manifestation or a flare of an underlying rheumatic disease within 30 days after receiving an anti-COVID-19 vaccine dose. Inclusion and exclusion criteria were in accordance with the World Health Organization guidelines for AEFI surveillance. All patients were re-evaluated in January 2022: telemedicine or face-to-face visit. Response to therapy was classified as complete, good or absent according to the clinician’s judgment based on clinical examination, patient’s reporting and analysis of laboratory data.

Results: We identified 30 cases of suspected rheumatic AEFI reported in Table 1. Comprehensively the most common manifestations were inflammatory arthritis (40.0%), rheumatic polyarthritis (26.7%) and adult-onset Still disease (13.3%). Among patients with an underlying rheumatic disease we recorded an AOSD flare, a rheumatoid arthritis flare with involvement of hands proximal interphalangeal joints, one case of wrist arthritis in a patient with psoriatic arthritis, one of aortitis in a patient with large vessels vasculitis, one case of polyarthritis in undifferentiated connective tissue disease and a nephritis flare in a patient with systemic lupus erythematosus. Treatment for the suspected AEFI was based on systemic glucocorticoids (GC) alone (63.3%), systemic GC plus IL-1R antagonists (13.3%), non-steroidal anti-inflammatories (NSAID) alone or in combination with GC in 22.2% of cases.
autoinflammatory drugs (13.3%), intra-articular GC (6.6%), colchicine (3.3%) and non-steroidal anti-inflammatory drugs (13.3%). At last follow-up contact (7.8±1.5 months) 26 patients (89.6%) were classified as complete responders. Eleven of them (42.3%) withdrew therapy without experiencing recurrence of disease manifestation. One patient with lupus nephritis had a proteinuric flare after the first BNT162b dose; he showed an initial good response to increased glucocorticoid therapy but had a new 24h proteinuria increase at second follow-up visit three months later requiring implementation of immunosuppressive therapy. Another patient with AOSD was in remission at last FU visit in December 2021 but required hospitalization in January 2022 for disease relapse due to a suspected gastrointestinal infection. Finally, one patient hospitalized for a seronegative polyarthritis after the first BNT162b dose achieved complete remission at last available contact (one month after hospital discharge) but was then lost in follow-up.

Conclusion: After a mean follow-up of 7.8±1.5 months nearly all of patients showed a complete/good response to standard therapy and about half of them withdrew the treatment without losing the remission status.

REFERENCES:
was detected in 5 (13.9%) patients; mean lymphocyte count was 1080 ± 363. Data about the treatment could be reached in 34 patients. Antiviral therapy was prescribed in 25 (69.4%) patients (favipiravir, n=22; and oseltamivir, n=3). Antibiotics were given to 6 (16.7%) patients, and 6 (16.7%) received hydroxychloroquine. Parenteral steroids were administered to 2 patients during the hospitalization. Six (16.7%) patients required hospitalization, and 2 (5.6%) required oxygen support, non-invasive mechanical ventilation, and one of them followed in the intensive care unit. Twenty-two patients were on anakinra treatment, and none of them required additional dose. Only 1 patient, a 61-year-old male patient with a history of lung lobectomy and renal transplantation, received tocilizumab due to macrophage activation syndrome, and he later died of sepsis. This patient was on anakinra until 2 years before, and it was discontinued due to an allergic reaction. Only 4 patients had a history of vaccination before COVID-19, and none of them developed pneumonia and required hospitalization. Six patients had FMF attacks after recovering from COVID-19. None of the patients developed thromboembolism and secondary bacterial infections.

Conclusion: This survey identified 36 biologic b-DMARD receiving FMF patients, who had COVID-19. All but 1 patient had complete recovery, and b-DMARD usage did not negatively affect the COVID-19 course. None of the patients currently on anti-IL-1 or anti-TNF had a worse outcome. Based on these observations, it can be suggested that refractory FMF patients can continue their b-DMARD treatments when they had COVID-19.

REFERENCES:

Disclosure of Interests: None declared


POS1280

EFFECTS OF ANTI-SARS-COV-2 VACCINATION ON SAFETY AND DISEASE EXACERBATION IN BEHCET’S DISEASE PATIENTS: A SINGLE CENTRE STUDY

H. Apaydın1, A. Erden1, B. Armagan2, S. C. Güven2, H. E. Konak3, Y. Alıyı3, M. Kaygız4, B. Polat1, A. Omma5, O. Küçükahin1, 1Ankara City Hospital, Rheumatology, Ankara, Turkey; 2Ankara Yıldırım Beyazıt University, Rheumatology, Ankara, Turkey; 3Ankara City Hospital, Internal Medicine, Ankara, Turkey; 4University of Health Sciences, Rheumatology, Ankara, Turkey

Background: Pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome – coronavirus 2 (SARS-CoV-2), has become a major global health issue since December 2019. Patients affected by systemic rheumatic disorders represent a high-risk group for severe COVID-19. During the COVID-19 pandemic, vaccination has become one of the cornerstones of the fight against this disease. The EULAR and the ACR recommend vaccination in all patients with rheumatological diseases. There is a paucity of data regarding the safety of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases such as Behçet’s disease (BD).

Objectives: In this study, we evaluated the safety and tolerance of COVID-19 vaccines, post-vaccine BD exacerbation and discontinuation of BD therapy in BD patients by retrospectively examining our BD cohort, from the patients’ perspective.

Methods: We retrospectively evaluated 450 BD patients followed in our clinic using hospital records and formed a retrospective cohort of patients who met the International Study Group (ISG) criteria. COVID-19 vaccination status, vaccine type (inactivated or mRNA), post-vaccine side effects and exacerbations, drug compliance, change in treatment after exacerbation, and post-vaccine COVID-19 occurrence were evaluated by interviewing patients over the phone or face to face. Patient demographics, comorbid diseases, and active BD treatments were collected from our hospital records. Disease activity was measured using the BSAS and the BDCAF form.

Results: Our cohort consisted of a total of 450 BD patients. Two hundred and eighty seven patients had at least 1 dose of the COVID-19 vaccine. Of the total number of COVID-19 vaccines (n= 639), 379 (59%) were Pfizer-BionTech vaccines and 257 (41%) were Sinovac vaccines. The side-effects after first, second, third and fourth vaccine dose were 151 (52.6%), 135 (47%), 29 (10.1%) and 3 (1%), respectively. Behçet flare after first, second, third and fourth vaccine dose were 151 (52.6%), 135 (47%), 16 (22.9%) and 3 (33.3%), respectively. The most common side effects were arm pain, joint pains or arthritis, malaise, while the most common BD exacerbations were arthralgia or arthritis, oral aphthae, papulopustular eruption Pfizer-BionTech and Sinovac vaccines were compared in terms of side effects, there was a significant difference after the 1st (p<0.001) and 2nd doses (p<0.001), but no significant difference was found at the 3rd dose (p=0.393) (Table 1). When Pfizer-BionTech and Sinovac vaccines were compared in terms of BD exacerbations, no significant difference was found after the 1st (p=0.417), 2nd (p=0.465) and 3rd doses (p=0.565). Only 4 patients (13%) developed exacerbation with organ involvement after COVID-19 vaccine. Anterior uveitis developed in 2 patients, panuveitis in 1 patient, panuveitis and deep vein thrombosis in one patient.

Table 1. Side effects and Behçet’s flare according to COVID vaccines

<table>
<thead>
<tr>
<th>COVID vaccine, n/N</th>
<th>Side effects</th>
<th>p</th>
<th>Flare after</th>
<th>p</th>
<th>Flare after</th>
<th>p</th>
<th>Flare after</th>
<th>p</th>
<th>Flare after</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>first dose of vaccine</td>
<td>second dose of vaccine</td>
<td>third dose of vaccine</td>
<td>fourth dose of vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sinovac</td>
<td>104 (61.9)</td>
<td>101 (63.1)</td>
<td>20 (47.6)</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer-BionTech</td>
<td>47 (39.5)</td>
<td>34 (30.1)</td>
<td>9 (36)</td>
<td>0.353</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: In conclusion, our study shows that the COVID-19 vaccine is well tolerated in BD patients, and that post-vaccine Behçet’s exacerbation predominantly includes mucocutaneous and articular findings, and exacerbations with organ involvement are rare. According to the COVID-19 vaccines, although the side effects were more in the Pfizer-BioNTech group compared to the Sinovac group, there was no difference between Behçet’s flare compared to the COVID-19 vaccines.

Disclosure of Interests: None declared

Background: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown.

Objectives: To investigate the impact of different immunosuppressive therapies on the development of humoral and cellular immune responses to full 2-dose SARS-CoV-2 vaccination in AIRD pts. with stable low disease activity.

Methods: The immune reactivity to COVID-19 vaccination was investigated in a prospectively recruited AIRD cohort with rheumatoid arthritis, axial spondyloarthritis or psoriatic arthritis who received a therapy with IL-17i, TNFi, JAKi or MTX (alone or in combination). Almost all patients received mRNA-based vaccine, only 4 patients had a heterologous scheme. Anti-Spike(S) antibodies(ab.) and sera neutralizing capacity (neutralization dilution 50; ND50) were measured 4 weeks after the first (prime+4w) and 4 weeks after the second vaccination (boost+4w). Vaccine-specific cellular immunity was evaluated by quantifying expression of activation markers on T cells as well as their production of key cytokines, at prime+4w and boost+4w.

Results: Overall, a total of 92 pts. were included in the final cohort, 31 (33.7%) pts. were on TNFi, 24 (26.1%) on IL-17i on IL-17i, 24 (26.1%) on JAKi, each group encompassing pts. receiving drug inhibitors alone or in combination with MTX. 13 (14.1%) were treated with MTX alone. The median time between the vaccination and blood sampling was 31 [IQR: 28-34] days after prime+4w and 28 [IQR: 28-28] days after boost+4w. Although at prime+4w only 34/90 (37.8%) of pts. presented neutralizing ab., the majority (86/91, 94.5%), developed them at boost+4w. The highest neutralization titer developed the pts. on IL-17i both at prime+4w (74 [IQR: 73-91]) and boost+4w (798 [IQR: 511-1344]), while no statistically significant differences were found in the neutralization titer at boost+4w for the TNFi, JAKi, and MTX groups: 207 ND50 [IQR: 134-441] for TNFi, 30 ND50 [IQR: 2.5-5.0] for JAKi, and 30 ND50 [IQR: 2.5-5.0] for MTX.

Discussion: Overall, a total of 92 pts. were included in the final cohort, 31 (33.7%) pts. were on TNFi, 24 (26.1%) on IL-17i on IL-17i, 24 (26.1%) on JAKi, each group encompassing pts. receiving drug inhibitors alone or in combination with MTX. 13 (14.1%) were treated with MTX alone. The median time between the vaccination and blood sampling was 31 [IQR: 28-34] days after prime+4w and 28 [IQR: 28-28] days after boost+4w. Although at prime+4w only 34/90 (37.8%) of pts. presented neutralizing ab., the majority (86/91, 94.5%), developed them at boost+4w. The highest neutralization titer developed the pts. on IL-17i both at prime+4w (74 [IQR: 73-91]) and boost+4w (798 [IQR: 511-1344]), while no statistically significant differences were found in the neutralization titer at boost+4w for the TNFi, JAKi, and MTX groups: 207 ND50 [IQR: 134-441] for TNFi, 30 ND50 [IQR: 2.5-5.0] for JAKi, and 30 ND50 [IQR: 2.5-5.0] for MTX.
respectively. Other affected systems were respiratory (73.7%), cardiovascular (63%), lymphoid organs (52.6%), musculoskeletal (47%), genito-urinary (31.6%) and neurological (26.3%). Laboratory findings can be found in Table 1. Thirty-six percent were admitted in intensive care unit for a median duration of 6 days (IQR 4-9). 42.1% needed respiratory support, 87.5% with supplemental oxygen therapy, 62.5% with mechanical ventilation and 12.5% with non-invasive ventilation. All patients received intravenous (IV) immunoglobulin, 52.6% IV corticosteroid (CS) pulses and 78.9% IV and oral CS. Other treatments included acetylsalicylic acid (n=18), heparin (n=8) and antibiotic therapy (n=19) - Table 3. Seventeen fully recovered and 2 had sequelae: one of them with coronary artery aneurysms and other exertional dyspnea.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Laboratory results at presentation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoassay</td>
<td>Reference range</td>
<td></td>
</tr>
<tr>
<td>Total white blood cells count, x10^9/L</td>
<td>4.0-11.0</td>
<td>10.19 (3.77-14.86)</td>
</tr>
<tr>
<td>Neutrophil count, x10^9/L</td>
<td>1.5-7</td>
<td>10.38 (3.71-11.79)</td>
</tr>
<tr>
<td>Lymphocyte count, x10^9/L</td>
<td>1.5-4</td>
<td>0.36 (0.07-1.45)</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>12.16</td>
<td>11 (9.4-12.1)</td>
</tr>
<tr>
<td>Platelet count, x10^9/L</td>
<td>152-400</td>
<td>156 (150-248)</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**DOI:** None declared

**Disclosure of Interests:** None declared

**References:**

**Characteristics from table content including title and footnote:** 710 Disclosure of Interests: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5188

---

**POS1283**

**THE COURSE OF NOVEL CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH IG4G-RELATED DISEASE TREATED WITH RITUXIMAB**

E Sokol¹, A. Torgashina¹, V.A. Nasonova Research Institute of Rheumatology, Rare Rheumatic Diseases and Sjogren’s Syndrome, Moscow, Russian Federation

**Background:** The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) raised many questions and concerns about the safety of different immunosuppressive agents in patients (pts) with rheumatic diseases during the pandemic. There is some data about anti-B-cell depletion strategies could lead to more severe disease course. Rituximab (RTM) is one of the most effective, safe and well tolerated agents in IgG4-related disease (IgG4-RD) treatment. Information about the course of COVID-19 in pts with IgG4-RD is lacking.

**Objectives:** To examine clinical course of COVID-19 in pts with IgG4-RD treated with anti-CD20 monoclonal antibody (RTM).

**Methods:** Single center observational study. We searched in our clinical base from 2019 to 2021 years for pts with IgG4-RD, treated with RTM within this period. Diagnosis of IgG4-RD was based on comprehensive diagnostic criteria (H. Umehara, 2019). Thirty-six percent were admitted in intensive care unit for a median duration of 6 days (IQR 4-9). 42.1% needed respiratory support, 87.5% with supplemental oxygen therapy, 62.5% with mechanical ventilation and 12.5% with non-invasive ventilation. All patients received intravenous (IV) immunoglobulin, 52.6% IV corticosteroid (CS) pulses and 78.9% IV and oral CS. Other treatments included acetylsalicylic acid (n=18), heparin (n=8) and antibiotic therapy (n=19) - Table 3. Seventeen fully recovered and 2 had sequelae: one of them with coronary artery aneurysms and other exertional dyspnea.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5188

---

**POS1284**

**PAUNLAIY CERVICAL INVOLVEMENT AND FEBRILE TORSO COLLIS: A FREQUENT SYMPTOM OF PIMS**

A. Schvartz¹, R. Kechiche², F. Bajolle³, S. Poignant⁴, B. Basmai⁵, C. Pajot⁶, L. Morin⁷, C. Adamsbaum⁸, N. Matsa⁹, M. Hofer¹⁰, I. Koné-Paut¹,², G. Galezò³ on behalf of French Covid-19 Paediatric Inflammation Consortium.

**Background:** Pediatric Inflammatory Multisystem Syndrome associated to SARS-CoV2 (PIMS) happens 4 to 6 weeks after SARS-CoV2 infection [2]. Its early diagnostic recognition as well as its early management is important to avoid cardiac complications related to this pathology.

**Objectives:** To highlight a frequent symptom in PIMS and improve its therapeutic care.

**Methods:** The JIR Cohort database, an international registry collecting data on patients with pediatric inflammatory diseases, was consulted to include patients between 03/15/20 and 12/31/2021.

**Results:** Of the 140 patients in whom a diagnosis of PIMS was retained, we present a series of 38 patients (27%) who presented at diagnosis or during evolution, febrile torticollis or painful cervical involvement. These patients were on average 8.2 years old (0.6-15.2). The proportion of boys was 14 out of 38 (37%). Twenty-four patients out of 33 (73%) were hospitalized in intensive care. Ten patients out of 38 (26%) underwent cerebral imaging. 5 (50%) had abnormalities such as collection or infiltration of the soft tissues. At the therapeutic level, 27/38 patients (71%) received corticosteroid therapy, 33/38 (87%) immunoglobulins, and 26/38 (68%) antibiotic therapy.

**Conclusion:** PIMS is a pathology with significant clinical heterogeneity and severe consequences in case of delay in therapeutic management. In this epidemiologic context, it is important to consider PIMS in any patient with febrile torticollis, especially if he does not respond to antibiotics.

**REFERENCES:**

**Disclosure of Interests:** None declared
**POS1285**

**IMMUNOGENICITY AND SAFETY OF THE CHADOX 1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY**


**Background:** Patients with autoimmune inflammatory diseases (AID) have been prioritized for urgent vaccination to mitigate COVID-19 risk. However, few studies in the literature assessed the immunogenicity and safety of the COVID-19 vaccine in patients with AID.

**Objectives:** In this context, the present study aims to evaluate the immunogenicity and safety of the vaccine against COVID-19 in patients with AID.

**Methods:** These data are from “Safety and efficacy on COVID-19 Vaccine in Rheumatic Disease” - SAFER study, a Brazilian multicentric prospective phase IV trial to evaluate COVID-19 Vaccine in AID, in the real-life, in Brazil. Immunogenicity and adverse events (AE) from a single center were assessed, after 2 doses of ChAdOx1 (Oxford/AstraZeneca), 8 weeks of interval, in patients with AID and healthy controls (HC). Inclusion criteria were age ≥ 18 years and fulfilling criteria according to international classification for AID. Exclusion criteria: pregnancy, previous severe AE to any vaccine, other immunosuppression causes. Stratification of post-vaccination AE was performed using a diary, filled out daily and returned at the end of 28 days for each dose. Participants were followed up through blood collection for measurement of IgG antibodies against SARS-CoV-2 spike receptor-binding domain by chemiluminescence (SARS-CoV-2 IgG II Quant assay. Abbott Laboratories, Abbott Park, IL, USA) at baseline and 28 days after the second dose. The seropositivity was defined for titers ≥50 AU/mL. Quantitative analyses were presented as observed frequency, percentage, central tendency, and variability measurements. The sample’s normal distribution was verified through the Shapiro-Wilk test. The Kruskal-Wallis test and the post-hoc Dwass-Steel-Critchlow-Flinger pairwise comparisons test were used to compare the IgG-S titers between the groups through the evaluation period. Categorical data were addressed using the Fisher’s exact or Chi-squared ($\chi^2$) test. An alpha level of 5% significance was used in all analyses.

**Results:** A total of 377 volunteers with AID and 50 HC were included in the study. Patients with spondyloarthritides (N=64), systemic lupus erythematosus (N=63), rheumatoid arthritis (N=61), primary Sjögren’s syndrome (N=61), vasculitis (N=31), systemic sclerosis (N=14), inflammatory myopathy (N=9), Crohn’s disease (N=49), ulcerative colitis (N=11) and other systemic AID (N=12) were evaluated. Both groups had female predominance (73.5% vs. 74.0%, p=0.937) and were homogeneous for age (43.5 vs. 41.7, p=0.308). The seroconversion among those not reactive (IgG-S negative at baseline) (46 HC and 191 AID), 28 days after second dose was 97.1% for spondyloarthritis (p=0.425), systemic lupus erythematosus 88.2% (0.006), rheumatoid arthritis 93.5% (0.158), primary Sjögren’s syndrome 92.6% (0.133), systemic sclerosis or inflammatory myopathy 471% (0.001), inflammatory bowel disease 100% (0.999) and vasculitis 80% (0.006), while in healthy control was 100%. In comparison with HC, there was a statistically significant difference in IgG-S titles only in systemic sclerosis or inflammatory myopathy (1.694 AU/ml vs. 3.719 AU/ml; p=0.006). Both groups only presented mild AE. Pain at the injection (86.7% vs. 78.4%, p=0.239), headache (673% vs. 53.6, p=0.074) and fatigue (59.2% Vs. 46.2%, p=0.089) were more common in HC than AID. Overall, reactions like arthralgia (52.6 vs. 22.4%, p<0.001), hematoma (14.1 vs. 4.1%, p=0.05), cutaneous rash (9.5 vs. 0%, p=0.024) were more frequent in HC. Most participants related that they felt safer after receiving a COVID-19 vaccination, and 52.4% did not reported a worse patient global assessment (PGI) index.

**Conclusion:** In conclusion, our data indicated that ChAdOx1 vaccine is safe and induced high titers and seroconversion rate in AID. More severe AID, such as vasculitis, systemic lupus erythematosus, and systemic sclerosis and myositis showed a lower seroconversion rate. Further analysis will explore the association between immunosuppressant and reactivity, and booster dose.

**Acknowledgements:** Acknowledgements to DECIT/MS and ICPE/SESA for supporting the study.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5319

---

**POS1286**

**SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BIOLOGICAL DMARDS**

R. Samoilina1, A. Dadalova1, E. Vasilienko2, V. Mazurov2. 1North-Western State Medical University named after I.I. Mechnikov, Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care named after E.E. Eichwald, St. Petersburg, Russian Federation

**Background:** The safety of biological DMARDs for rheumatic diseases in the context of the covid 19 pandemic is one of the key aspects of modern rheumatology.

**Objectives:** assess the severity of the course of COVID-19 infection in patients with rheumatoid arthritis receiving various biological disease-modifying antirheumatic drugs.

**Methods:** to assess the severity of the course of SARS-CoV-2, discharged epiconia from hospitals or the conclusion of computed tomography were used. Since March 2020 to November 2021, among the 1389 patients with rheumatic diseases observed at the of the anticytokine therapy center of the North-Western State Medical University Named after I.I. Mechnikov 105 cases of COVID-19 infection of patients with rheumatoid arthritis were registered, of which 53 patients received outpatient treatment, and 52 patients received inpatient treatment. In 76% of cases, patients received biological DMARDs in combination with synthetic DMARDs.

**Results:** In patients treated on an outpatient basis, only 17% (9 patients) underwent chest X-ray examination, according to which grade 2 CT was observed in three patients. Among hospitalized patients, multispiral computed tomography was performed in all cases (n=8; 15.3%) of this group of interstitial lung diseases observed at the of the anticytokine therapy center of the North-Western State Medical University Named after I.I. Mechnikov 105 cases of COVID-19 infection of patients with rheumatoid arthritis were registered, of which 53 patients received outpatient treatment, and 52 patients received inpatient treatment. In 76% of cases, patients received biological DMARDs in combination with synthetic DMARDs.

**Table 1. The volume of lung damage in patients with RA with COVID-19 who received biological DMARDs before infection**

<table>
<thead>
<tr>
<th>DMARDs</th>
<th>Grade 3</th>
<th>Grade 2</th>
<th>Grade 1</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>3</td>
<td>19</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Abatacept</td>
<td>1</td>
<td>5</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>10 (15.3%)</td>
<td>25 (48.1%)</td>
<td>16 (30.8%)</td>
<td>3 (5.8%)</td>
</tr>
</tbody>
</table>

**Conclusion:** Previous rituximab therapy in patients with rheumatoid arthritis is the most unfavorable prognostic factor during COVID-19 infection.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5395
Pain in rheumatic diseases, including fibromyalgia...  |

**POS1287**  | INFLUENCES ON FIBROMYALGIA AND AUTOANTIBODIES DIRECTED TO NEURO- AND VASOREGULATORY MOLECULES NEED TO BE CONSIDERED IN BIOMARKER RESEARCH

F. Lübben1, J. Strobach2, H. Heidecke3, T. Lange4, G. Riemekasten4, 1University of Lübeck, University Clinic of Schleswig-Holstein, Rheumatology and Clinical Immunology, Lübeck, Germany; 2CellTrend GmbH, Autoantibody Tests, Luckenwalde, Germany

**Background:** Fibromyalgia syndrome (FMS) is often present in autoimmune diseases but can also occur in its primary form. Biomarkers for FMS are currently missing. Systemic chronic inflammation, dysautonomia and metabolic dysfunction have been suggested to contribute to the disease. Recent studies indicate that FMS involves autoantibodies (abs), which bind to neurons, macrophages and endothelial cells.

**Objectives:** In the present study, we aimed to delineate changes in natural abs directed to neuro- and vasoregulatory molecules and potentially confounding factors, which could influence these abs and disease state.

**Methods:** Sera from 91 patients with primary FMS (pFMS), 24 patients with secondary FMS (sFMS) and 31 healthy controls (HC) were analysed for the presence of 27 different natural abs directed to e.g., cholinergic, opioid, cannabinoid, endothelin or complement receptors or angiotensin system molecules by individual ELISAs (CellTrend GmbH, Luckenwalde, Germany). All participants were characterized by several questionnaires to obtain demographic data and measures of disease state (using the Widespread Pain Index (WPI) and Symptom Severity Score (SSS)). Linear regression on log-transformed abs levels adjusted for potential confounders was used to compare abs levels between groups. Random forest analysis was applied to differentiate between pFMS and HC by measuring the Area Under the Curve Receiver operating characteristics (AUC-ROC).

**Results:** Compared to HC, patients with pFMS showed increased levels of abs directed to ACE II, the angiotensin receptor type-2 (AT2R), the cannabinoid receptor type 1 and 2 (Can1-R, Can2-R), the endothelin receptor type-B (ETBR), the opioid receptor (κ) (Op-κ-R) and lower levels against the complement receptor 5a (C5a-R) and the muscarinic acetylcholine receptor type 3 (M3)(Figure 1).

After adjustment for age (linear and squared) and sex, differences in the ab levels remain significant for abs against ACE II, AT2R, ETBR and the Op-κ-R. However, none of which remained significant after further adjustment for Body Mass Index (BMI). Random forest analysis of unadjusted ab levels revealed an AUC-ROC of 0.94 for pFMS compared to HC with an average accuracy of 0.85 and a kappa of 0.55. Again, after adjusting the abs levels for age, sex and the BMI, the AUC-ROC to discriminate HC from pFMS patients decreased to 0.73 (accuracy = 0.79, kappa = 0.33).

**Conclusion:** Abs might be potential biomarkers for pFMS. However, these results highlight the important role of correct covariate adjustment for research on biomarkers supposed to classify FMS or other diseases. In FMS, increase in BMI might be a cause or a consequence of FMS and it is also unknown how BMI and abs influence each other. Thus, BMI might or might not be a confounder so that adjusting for BMI might be correct or incorrect. However, these abs could provide a link to understand how acquired conditions interact with the immune system.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3332

**Figure 1.** Boxplots of logarithmized abs levels between groups. *p < .05 in unadjusted analysis and after adjusting for age and sex, *p < .05 only significant after adjusting for age and sex, *p < .05 only in unadjusted analysis (all FDR-corrected within group comparisons across abs). Unadjusted Adjusted for age, sex and BMI

**Figure 2.** AUC ROC as detected by random forest analysis in pFMS patients versus HC for unadjusted ab levels as well as for ab levels adjusted for age, sex, and BMI.
Spine, mechanical musculoskeletal problems, local soft tissue disorders.

POS1289  ANALYSIS OF INFECTIOUS SPONDYLODISCITIS: FIVE-YEARS DATA
B. A. Hiba1, B. A. Kauother2, S. Milal3, F. Aila4, S. Meriem5, L. Soubani6, K. Ouenniche7, K. Selma7, C. Selma7, L. Ahmad7. 1Mongi Slim Hospital, Tunis, Tunisia

Background: Spondylodiscitis (SD) is an infection of the vertebral body or disc and may also extend to the epidural space, posterior elements, and paraspinal soft tissues. It is a cause of morbidity and mortality. However, the diagnosis is often delayed because of the non-specific clinical features.

Objectives: In this study, we aimed to describe the clinical and diagnostic features of infectious SD.

Methods: We conducted a retrospective study including 40 cases of infectious SD, performed over a period of five years (2014-2019). Epidemiological, clinical characteristics, laboratory results and imaging findings were uniformly collected.

Results: Of the 40 patients, 37.3% were male. The mean age was 53.3 ± 13.9 years (28-83) and the median Charlson Comorbidity Index was 1. Advanced age, tuberculosis and brucellar contagion were the predominant risk factors. The median duration from onset to diagnosis was 41 days (8-300). Low back pain (LBP) was the most common symptom (98%). Lumbar spine was the most frequent location (71%). Seven patients had contiguous multiple levels (>2 vertebral bodies). Neurologic symptoms (radicular pain, spinal cord compression, neurologic loss) were observed in 15 patients. The median erythrocyte sedimentation rate was 54mm/1st h [15-223], the median CRP was 26.3mg/L [7-587]. Leukocytosis (>10,000 WBCs/mm3) was significantly higher in patients with Pyogenes (p<0.002). ESR and CRP (p=0.002) were more sensitive than other SD: Standard deviation; M: Mean; NS: non-significant; IQR: interquartile range

Overall, there were no differences between control (SOC) and treatment group (STS). Both procedures were effective improving pain at rest (p=0.024), EQ5D (p=0.019), DASH-Work (p=0.032) and UCLA scores (p=0.009) and calcification size measured by US (p=0.031) at month 3. No adverse effects or complications were reported on both groups.

Conclusion: Although well tolerated with no side effects, STS UGPL has failed to show increased benefit for calcific tendinopathy local treatment. Further studies using STS will be needed to ascertain its interest in this disease. This ongoing work will be reevaluated with a larger sample.

REFERENCES:

Disclosure of Interests: None declared

POS1290  EFFICACY AND SAFETY OF SODIUM THIOSULFATE IN CALCIFIC TENDINITIS OF THE ROTATOR CUFF – AN INTERIM ANALYSIS OF A RANDOMIZED CLINICAL TRIAL
H. Parente1, S. Azevedo1, E. Costa1,2, F. Guimarães1, M. Pontes Ferreira1, D. Faria1, D. Peixoto1, J. Tavares-Costa1, C. Afonso1, H. Parente1, S. Azevedo1, E. Costa1,2, F. Guimarães1, M. Pontes Ferreira1, D. Faria1, D. Peixoto1, J. Tavares-Costa1, C. Afonso1, E. Costa1,2, F. Guimarães1, M. Pontes Ferreira1, D. Faria1, D. Peixoto1, J. Tavares-Costa1, C. Afonso1.

Background: Calcific tendinitis of the rotator cuff is one of the most common causes of shoulder pain. (1) Ultrasound guided percutaneous lavage (UGPL) is indicated when conservative treatments have failed. (2) Recent reports have shown the interest of topical sodium thiosulfate (STS) in the treatment of other diseases characterizes by ectopic calcifications (3, 4, 5).

Objectives: To assess the efficacy and safety of UGPL with STS versus with saline solution (standard of care - SOC) in calcific tendinitis.

Methods: Double-blinded randomized clinical trial including adult patients with calcific tendinitis, shoulder pain for more than 3 months and at least one positive shoulder impingement test. Only dense type A calcifications (according to the Molé Classification) > 5 mm in diameter were included. Patients were randomized in two groups: STS and saline UGPL. The outcome was favourable in 27 cases (86.8%). Pathogens were isolated in 19 cases. Computed tomography-guided percutaneous disc biopsy (PDB) was performed in 16 (53.5%) and was conclusive in (11/15) cases (66.8%). Mycobacterium tuberculosis (71%). Seven patients had contiguous multiple levels (>2 vertebral bodies). Neurologic symptoms (radicular pain, spinal chord compression, neurologic loss) were observed in 15 patients. The median erythrocyte sedimentation rate was 54mm/1st h [15-223], the median CRP was 26.3mg/L [7-587]. Leukocytosis (>10,000 WBCs/mm3) was significantly higher in patients with Pyogenes (p<0.002). ESR and CRP (p=0.002) were more sensitive than other

Conclusion: Spondylodiscitis should be considered for all patients presenting with chronic back pain especially when associated with laboratory examination abnormalities. In our study, tuberculous spondylodiscitis was the most frequent, which highlights the fact that osteoarticular tuberculosis remains endemic in developing countries, where it still constitutes a major public health problem.

Disclosure of Interests: None declared

POS1291  DEGENERATIVE DISC DISEASE IN YOUNG: IMMUNOHISTOCHEMICAL EXPRESSION OF INFLAMMATORY BIOMARKERS AND ANGIOGENIC FACTORS
N. Pradvyuli1, N. Shostak1, A. Novikova1, A. Buianova1, O. Patsap1, A. Raksha1, I. Senko1, R. Tairova1, A. Aksyonova1, A. Muradyants1, K. Davygora1.

Background: Low back pain (BP), associated with the degenerative disc disease (DDD), poses a heavy social and economic burden, emerging among young adults. The pathophysiological basis of accelerated degeneration of the intervertebral disc (IVD) and its contribution to the formation of spine osteoarthritides are at the active study stage.

University of California at Los Angeles (UCLA) scores, ultrasound (US) and radiographic evaluations were performed on all follow up visits. SPSS was used for statistical analysis and significance level was defined as 2-sided p<0.05.

Results: Twenty-six patients were included, where 76.9% (20) were women, with a mean age of 51.2 (SD=9.0) years old. The mean duration of pain before the procedure was 12.7 months (SD=11.3) (minimum of 3 months and a maximum of 48 months).

Fifteen patients (57.7%) were randomized to the control group (SOC) and performed a saline UGPL; the other 11 patients (42.3%) were randomized to the treatment group (STS). Demographic and baseline clinical characteristics are shown in Table 1. Since patient inclusion is dynamic, our sample met 23 patients at week 1 (SOC group = 13 and STS group = 10), 19 patients at month 1 (SOC group = 10 and STS group = 9) and 16 patients at month 3 (SOC group = 8 and STS group = 8).

<table>
<thead>
<tr>
<th>Table 1. Demographic and baseline clinical characteristics.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>STS lavage</strong></td>
</tr>
<tr>
<td>Age (years), M (SD)</td>
</tr>
<tr>
<td>Sex, female % (n/N)</td>
</tr>
<tr>
<td>Nocturnal pain, yes % (n/N)</td>
</tr>
<tr>
<td>VAS at rest (0–10), M (SD)</td>
</tr>
<tr>
<td>VAS during activities (0–10), M (SD)</td>
</tr>
<tr>
<td>DASH Score, M (SD)</td>
</tr>
<tr>
<td>DASH-Work Score, M (SD)</td>
</tr>
<tr>
<td>UCLA score, M (SD)</td>
</tr>
<tr>
<td>Acr-shaped</td>
</tr>
<tr>
<td>Fragmented</td>
</tr>
<tr>
<td>Nocturnal pain, yes % (n/N)</td>
</tr>
<tr>
<td>Calcinosis, % (n/N)</td>
</tr>
</tbody>
</table>

SD: Standard deviation; M: Mean; NS: non-significant; IQR: interquartile range

Disclosure of Interests: None declared
Objectives: To assess inflammation and angiogenesis biomarkers in IVD among young patients with chronic LBP, associated with DDS.

Methods: Human IVD tissue from 25 patients was obtained from discectomy surgery and was divided into 2 groups: men (n=13), women (n=12), age: 36.7±3.73 and from autopsy in healthy control group (n=5, age: 37.8±2.52). The grade of DDR was verified by magnetic resonance (MRI) by the classification of C.W. Pfirrmann. Four-micron serial sections of the tissue blocks were stained with hematoxylin and eosin (H-E), than examined by immunohistochemistry staining on the automated VENTANA BenchMark ULTRA platform. Anti-IL-1β, anti-IL-6, and anti-IL-17 were used to study the expression of inflammatory cytokines; anti-VEGF-A and anti-CD31 were used as markers of angiogenesis. All slides were visualized using a Axio Imager.Z2 microscope with EC Plan-Neofluar 40X objective.

Results: In 64% of patients IVD hernias were localized at the level of L5-S1, in 36% - L4-L5. The average Pfirrmann DDR stage at the operated level was 4.43±0.57. 72% of patients had Modic changes (MC). 52% of patients had a combination of hernia with endplate erosion (EP) and MC. There were identified evidence of DD on H-E-stained sections, including clusters of cells of the nucleus pulposus (NP), inflammatory cell infiltration and blood vessels in the absence of them in the fissures of the NP and annulus fibrosus (AF). Immunostaining was mainly limited to the cytoplasm of native NP chondrocyte-like cells and AF fibroblast-like cells. IL-1β expression was considerably higher in degenerate samples than in controls for both NP (p < 0.05) and AF (p < 0.01). Staining for IL-17 was more pronounced in the cytoplasm of chondrocyte-like cells of degenerative NP compared to the control (p < 0.01), and statistically lower in AF cells (p < 0.05). The number of IL-6 immunopositive cells was similar in NP and AF degenerate tissue, but a greater proportion of IL-6 immunopositive cells was seen in NP tissue (p<0.05). The percentage of cells immunopositive for VEGF-A and CD-31 were significantly increased in NP DD cell clusters compared to controls (p<0.001) (88% and 36%, respectively) and was weakly expressed in the extracellular matrix (p<0.05). This suggests that the PU cells trigger angiogenesis. Blood vessels in native sections were confirmed by CD31 detection in 64% of patient specimens versus 10% of control cartilage specimens (p < 0.001). The number of CD31 immunopositive cells had a tendency for decrease in severe DD (p=0.05), which indicates the extinction of vascularization in the terminal stage of DD. Fissures in the disc did not stained for CD31, which excludes the ingrowth of vessels directly in the area of mechanical damage and proves the immunogenic cause of vascularization. This is confirmed by the synergistic high level of expression of IL-1 and -17 in perversal, endothelioocytes and intravascular pathological samples versus weak expression in the disc matrix (p<0.01). The high level of expression of all interteukins was in the hyaline cartilage of EP patients versus the absence in the controls (p<0.001). It indicates their association with asptic inflammation of EP with the formation of EP reactions and reactive spondylitis (MC) development, detected by MRI in young adults with DD.

Conclusion: Local immune inflammation is a component of the degenerative cascade in IVD, it initiates angiogenesis in cartilage and EP, as well as the development of reactive osteitis of adjacent vertebrae with the formation of inflammatory lesions in the vertebral-motor theory of chronic back pain. The results obtained will help to identify molecular targets and form a new direction of developmental reactive osteitis of adjacent vertebrae with the formation of inflammatory cascade in IVD, it initiates angiogenesis in cartilage and EP, as well as the development of reactive osteitis of adjacent vertebrae with the formation of inflammatory lesions in the vertebral-motor theory of chronic back pain.

Disclosure of Interests: None declared

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4888

Paediatric rheumatology

POS1293

TEN-YEAR EFFICACY DATA FROM THE CLIPPER STUDIES: OPEN-LABEL, LONG-TERM ETANERCEPT TREATMENT IN CHILDREN AND YOUNG ADULTS WITH EXTENDED OLIGOARTICULAR, ENTHESITIS-RELATED, OR PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4597
Treatment Period (i.e., they discontinued ETN, either by meeting the Wallace definition for clinically inactive disease for at least 6 months on ETN, or by having had a good clinical response and being deemed to benefit from withdrawal in the investigator’s judgement). Of the pts in the Active Treatment Period, over 90% achieved JIA ACR 50 response at all study time points. Sustained JADAS and ACR remission was achieved by 42 (33%) pts and 17 (13%) pts, respectively. The mean improvements from baseline in JADAS disease activity at mth 24 of CLIPPER2 were largely maintained through CLIPPER2.

Conclusion: The low numbers of evaluable pts notwithstanding, efficacy results were consistent with the profile of ETN, and treatment responses were considered clinically meaningful and durable with long-term treatment.

REFERENCES:

Tri al Registration: NCT00692741/NCT04121069

Acknowledgements: Medical writing support was provided by Iain McDonald, PhD, of Engage Scientific Solutions and was funded by Pfizer.


Disclosure of Interests: *Efficacy data only for patients with juvenile idiopathic arthritis.

Conclusion: We report our 14-month experience of using adalimumab biosimilar in a pediatric rheumatology population. Majority of the patients did not report major adverse reactions. Majority of JIA patients responded well when initiated on adalimumab (Amgevita). Rheumatologists should continually monitor patients for latent infections after prescribing biologics including biosimilars.

REFERENCES:
Hospitailler de l’ouest Guyanais, Department of Pediatrics, Saint-Laurent-Du-Maroni, French Guiana; aMartinique University Hospital, CIC Antilles-Guyane, Fort-De-France, Martinique; bNecker Hospital, Department of Pediatric Rheumatology, Paris, France; cMartinique University Hospital, Department of Internal Medicine, Fort-De-France, Martinique

Background: Systemic diseases of pediatric onset are more frequent in Afro-Caribbean population, especially Pediatric systemic lupus (pSLE).

Objectives: Our work is a retrospective study of patients followed in French overseas departments for systemic disease or auto-inflammatory syndrome of pediatric onset. It describes their clinical and biological specificities at diagnosis, during childhood and early adulthood.

Methods: Our retrospective study was conducted between 01/01/2000 and 01/09/2021. Listings of adult patients with pediatric onset and pediatric patients were obtained in each center through computerized hospital archives, list of patients followed by referent pediatricians and adult specialists in internal medicine and the French National Registry for rare disease. Data were then gathered by going through their medical files. The spectrum of diseases studied included pSLE, Sjogren syndrome, antiphospholipid syndrome (APS), connectivitis, systemic sclerosis, dermatomyositis, Systemic juvenile idiopathic arthritis (sJIA), unclassified auto-inflammatory syndrome.

Results: 2148 patients were identified on a 21 year-period, and 135 patients were included. Most patients diagnosed with a systemic pathology (102) suffered from pSLE (53%), followed by dermatomyositis (17%). Average follow up was 8.3 years (0.3 - 25 years), median age at last follow up was 212 (14 - 36.7). We found an increase in the number of new diagnoses throughout the years. For pSLE, sex repartition was 4/1 girl/boy and did not vary according to age (p = 0.31). At onset, patients had 10 Scicc criteria (4-12) and median EULAR/ACR 2019 score was 38 (12 - 54). The combination of typical skin involvement, arthritis and fever was found for 87%. At onset, a third of patients had renal involvement, 15% had Neuruplouis and 41% cardiac involvement. All patients had a positive ANA and Anti-DNA antibodies, followed by anti-Sa/Ssb antibodies (78%), Anti-Sm (78%) and anti RNP (52%). During childhood, 54% had renal involvement and 26% suffered from Neuro- lupus. Patients suffered in median from 3 flares and 26% suffered from more than 5 flares during childhood. Pre-pubertal patients (26%) had worst outcomes, 95% had renal and/or neurological involvement, they had more flares (median at 5 p = 0,02) and needed an average of 4 background therapies (p = 0.04). Boys seemed to have better disease control at transition to adult care but gender was not an independent predictor of severity during childhood (p = 0.21). 32 patients had dermatomyositis, 29% of them had respiratory involvement during childhood. 33 patients had auto-inflammatory syndromes mostly sJIA (67%), 50% of them had hemophagocytic syndrome during childhood and their disease was controlled by steroids for 64%, 36% needed biotherapy. The overall mortality was 3%.

Conclusion: This is a large cohort of patients of Afro-Caribbean origin with a higher frequency of pSLE. Although the outcomes for these patients were similar to western countries, they had low symptoms at onset, not correlated to delay at diagnosis. Compared to ethnic studies of North America or Africa, the French health care system being universal and free, the bias related to socio-economic status was lower. This work will continue with the exploration by transcriptomic and genetic tests for early and severe forms to identify the extra-environmental causes. The environmental factors specific to these regions should be explored in additional prospective studies.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.431

---

**POS1296**

**T-CELL RESPONSE MEASURED BY INTERFERON-γ RELEASE ASSAY AS A NOVEL TOOL FOR BETTER UNDERSTANDING OF SARS-CoV-2 IMMUNITY: THE PRELIMINARY RESULTS OF A PROSPECTIVE STUDY IN PEDIATRIC PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS.**

K. K. Kapten1, K. Oroczy1, E. Smolewska2, 1CentralTeachingHospital of Medical University of Lodz, Department of Pediatric Cardiology and Rheumatology, Lodz, Poland; 2Medical University of Lodz, Department of Pediatric Cardiology and Rheumatology, Lodz, Poland

Background: While serological assays detecting antibodies in blood serum remain the standard exam for evaluating immunity against SARS-CoV-2 infection, the latest publications reveal certain limitations to this broadly used method. Recent studies showing the increase of antibodies titers in time, together with scientific reports which detect SARS-CoV-2-specific T-cells in seronegative individuals, evoke questions with regard to the reliability of the sole assessment of the humoral response to SARS-CoV-2. A novel T-cell-based interferon-γ Release Assay (IGRA) is proposed to adapt our approach to the individual immunity to the new coronavirus.

Objectives: The objectives of this study were to assess T-cells and antibodies responses to the SARS-CoV-2 virus among pediatric patients at different stages of juvenile idiopathic arthritis (JIA) undergoing diverse treatment regimes. In addition, the authors aimed to evaluate humoral and cellular responses to the Covid-19 mRNA vaccine in the cohort of immunocompromised patients.

Methods: This prospective study included 30 pediatric patients between the ages 2-16 at different stages of JIA. The cohort group consisted of vaccinated and unvaccinated individuals and children with both positive and negative history of past Covid-19 infection. SARS-CoV-2 T-cell response was measured using a specific quantitative IGRA in whole blood, followed by anti-SARS-CoV-2 ELISA test measuring the presence and quantity of IgG, IgM and IgA antibodies in serum.

Results: The magnitude of the SARS-CoV-2 specific T-cell response measured by the IGRA test correlated significantly with the levels of IgG (p=0.00005, R=0.653) and IgA antibodies (p=0.00011, R=0.675) in serum, while no correlation with IgM antibodies level in serum was found. All vaccinated patients developed a cellular response to the vaccine (p=0.0108), regardless of the number of administered doses. The T-cells response in children undergoing biological treatment (specifically: etanercept, adalimumab or tocilizumab) was recognizably weaker compared to the group not receiving such treatment. Nevertheless, the difference did not reach statistical significance (p=0.0715). Similar dependencies were found in children treated with hydroxychloroquine (n=6), however, due to the small study group, a statistical significance could not have been reached.

Conclusion: Suppression of cellular response observed in different drug protocols may prove to become a protective factor against SARS-CoV-2 infection. Additionally, the authors postulate that the strong correlation found between T-cell response and IgA antibodies titers can be related to SARS-CoV-2 strong affinity with mucosal membranes. Thus, the sole testing of IgG and IgM antibodies levels in serum with regard to Covid-19 may not be the most precise diagnostic method. The presented study group needs to be expanded with more patients, mainly children receiving biological agents or hydroxychloroquine to validate the demonstrated preliminary results.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.473

---

**POS1297**

**SACROILIITIS AT DIAGNOSIS ASSOCIATED WITH LESS DISEASE FLARE AFTER STOPPING MEDICATION - OUTCOMES AND PREDICTORS OF A SOUTHEAST ASIAN ENTHESITIS RELATED ARTHRITIS (ERA) LONGITUDINAL COHORT.**

K. L. Tan1, L. Das1, Y. X. Book1, T. Arkachaisir1,2, 1KK Women’s and Children’s Hospital, Rheumatology and Immunology, Singapore, Singapore; 2Duke-NUS Medical School, Rheumatology and Immunology, Singapore, Singapore

Background: ERA is a subtype of Juvenile Idiopathic Arthritis (JIA) characterized by involvement of entheses and axial skeleton. Outcomes have been shown to be poorer compared with oligoarticular and polyarticular JIA.

Objectives: To assess short-and long-term outcomes and predictors of ERA in a large monocentric cohort in Singapore.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.431
Methods: Children diagnosed with ERA according to ILAR criteria from 2002 to 2021 at KK Women’s and Children’s Hospital, Singapore, were recruited. Outcome statuses were defined according to the criteria for clinical inactive disease (CID) and complete remission (CR) proposed by Wallace et al., with additional criteria of no enthesitis and no active sacroiliitis on MRI. Nonparametric descriptive statistics were used. Univariate and multivariate analysis were performed using logistic regression analyses. The significant level was set at < 0.05.

Results: A cohort of 151 ERA patients (male 86%; Chinese 81%) were included. Median age at onset was 11.9 years (IQR 9.4-13.9) and disease duration was 5.3 years (IQR 2.9-8.4). HLA-B27 was positive in 83% of the patients. At diagnosis, 39% of the patients had sacroilitis, 46% had hip arthritis, 36% had knee arthritis and 25% had enthesisitis. Methotrexate was used in 77% of the patients, while biologics was started in 72% of the patients. CID was achieved in 92% of the patients, of which 27% achieved CID in 6 months or less. Sacroilitis at diagnosis is an unfavourable predictor of CID at 6 months but not a significant predictor of ever achieving CID. Older age at diagnosis is also an unfavourable predictor of CID ever.

Medication was totally discontinued in one third of the patients. Half of them went on to have complete remission (CR) off medication. Favourable predictor includes male gender, while positive HLA-B27 and ANA were unfavourable predictors. Two thirds of the patients with CID had at least one disease flare (23% flared after off medication, 13% flared after CR). Both intra-articular joint injection and anti-TNF use were associated with flare after CID, while anti-TNF use was associated with flare after off medication. Sacroilitis at diagnosis is a protective predictor of flare after stopping medication.

Conclusion: Despite a high proportion of ERA patients achieving CID, only one third could stop medication completely with high rates of disease flare even after attaining CR. Unfavourable predictors include older age at onset as well as HLA-B27 and ANA positivity. While sacroilitis at diagnosis is a negative predictor of CID at 6 months, it is protective predictor of flare after discontinuing medication.

Table 1. Predictors of outcomes

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR 95% CI p</td>
<td>OR 95% CI p</td>
</tr>
<tr>
<td>CID at 6 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacroilitis at diagnosis</td>
<td>0.187 0.048-0.72 0.015 0.023 0.003-0.177 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Age at onset</td>
<td>0.790 0.626-0.998 0.048 0.777 0.605-0.997 0.047</td>
<td></td>
</tr>
<tr>
<td>Off medication ever</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>0.029 1.121-22.566 0.035 7.703 1.622-36.575 0.010</td>
<td></td>
</tr>
<tr>
<td>HLA-B27</td>
<td>0.374 0.158-0.886 0.025 0.290 0.110-0.764 0.122</td>
<td></td>
</tr>
<tr>
<td>ANA</td>
<td>0.104 0.013-0.803 0.030 0.077 0.010-0.613 0.155</td>
<td></td>
</tr>
<tr>
<td>Flare after CID</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intra-articular injection</td>
<td>2.585 1.116-5.988 0.027 3.205 1.299-7.909 0.011</td>
<td></td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>3.683 1.697-7.939 0.001 4.328 1.905-9.832 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Flare after discontinuation medication</td>
<td>17.333 3.696-81.300 &lt;0.001 37.942 4.151-346.841 0.001</td>
<td></td>
</tr>
</tbody>
</table>

CID = Clinical Inactive Disease, TNF = Tumor Necrosis Factor, HLA-B27 = Human Leukocyte Antigen-B27, ANA = Antinuclear Antibodies

REFERENCES:


Disclosure of Interests: None declared


POS1298 RELATIONSHIP BETWEEN DISEASE ACTIVITY BY JADAS-27, SDAI, AND DAS-28 AND SUBSEQUENT CHANGES IN PHYSICAL FUNCTION IN ADULT PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

T. Miyamae1,2, E. Inoue3,4, E. Tanaka1,4, T. Kawabe1,2, K. Ikari5,6, M. Harigai2,4. 1Tokyo Women’s Medical University Hospital, Department of Pediatric Rheumatology, Institute of Rheumatology, Tokyo, Japan; 2Tokyo Women’s Medical University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan; 3Showa University, Research Administration Center, Tokyo, Japan; 4Tokyo Women’s Medical University Hospital, Department of Rheumatology, Institute of Rheumatology, Tokyo, Japan; 5Tokyo Women’s Medical University School of Medicine, Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo, Japan; 6Tokyo Women’s Medical University Hospital, Department of Orthopedic Surgery, Institute of Rheumatology, Tokyo, Japan

Background: Juvenile Arthritis Disease Activity Score (JADAS) has been developed as a composite disease activity score specific to Juvenile idiopathic arthritis (JIA). Evaluation of disease activity with a composite measure associated with subsequent changes in structural damage of joints and physical function is necessary for the proper management of Rheumatoid Arthritis (RA) with treat-to-target strategy, and this concept should be considered for patients with JIA in transition and adulthood as well. However, the usefulness of JADAS-27 and other composite measures for RA in these patients has been scarcely investigated. Additionally, JADAS-27 is unfamiliar to non-pediatric rheumatologists.

Objectives: We aimed to investigate an optimal composite score for disease activity in adult JIA from the viewpoint of the subsequent changes in physical function.

Methods: Patients diagnosed with JIA with the following conditions were enrolled: 1) disease onset at age < 18 years; 2) registered in the IORRA database for the first time between 2000 and 2020; and 3) ≥18 years old at the time of IORRA registration. The baseline of each patient was their initial entry into the IORRA database. The Simplified Disease Activity Index (SDAI), Disease Activity Score using 28 joints (DAS28), and JADAS-27 were compared. The patients were stratified into four disease activity categories: remission/inactive disease, low disease activity, moderate disease activity, and high disease activity according to mean disease activity scores in each index during the first year from baseline, and mean changes in J-HAQ (mean ΔJ-HAQ) during 2 years from baseline in each disease activity group were estimated using the linear mixed effect model.
to account for correlations of repeated measures without filling in the missing data after adjusting for sex, age, and disease duration.

Results: We included 294 eligible individuals (median age at onset, 14.0 years; rheumatoid factor positive in 64.7%). The median age at baseline and disease duration was 33.8 (24.1–47.7) years and 21.0 (11.0–34.0) years, respectively. The J-HAQ was completed in all 294 patients, and 171 (58.1%) had a score of less than 0.5 at baseline, which is defined as functional remission. During the 2-year observation period, the median J-HAQ of all patients remained unchanged. There was a trend toward improvement in disease activity over time in all three composite scores. Some differences were observed across the three indices: a higher proportion of patients with high disease activity and a lower proportion of patients in remission/inactive disease were observed with JADAS-27 versus SDAI and DAS28. A significant increasing trend of the estimated mean J-HAQ at 2 years after baseline was observed along with an increase in the mean disease activity during the first year measured using DAS28 (p = 0.01) and SDAI (p = 0.018), but not using JADAS-27 as shown in Table 1.

Table 1. Association of the mean disease activity categories during the first year after baseline and mean changes in J-HAQ during the two years after baseline

<table>
<thead>
<tr>
<th>(n = 294)</th>
<th>SDAI</th>
<th>DAS28</th>
<th>JADAS-27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission/inactive disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-value for trend</td>
<td>0.019</td>
<td>0.010</td>
<td>0.115</td>
</tr>
</tbody>
</table>

Conclusion: Disease activity measured using SDAI and DAS28, but not using JADAS27, was significantly associated with subsequent changes in physical function in transitional and adult patients with JIA. This study support the use of SDAI and DAS28, but not JADAS27, in assessing disease activity in these patients to adjust treatments for preventing future deterioration of physical function.


POS1299 JUVENILE SYSTEMIC SCLEROSIS TREATMENT PRACTICES IN AN INTERNATIONAL COHORT AND COMPARISON TO RECENT SHARE CONSENSUS GUIDELINES.


1Hamburg Centre for Pediatric and Adolescent Rheumatology, Schön Klinik Hamburg Eilbek, Hamburg, Germany; 2JSSC Collaborative Group, Hamburg Centre for Pediatric and Adolescent Rheumatology, Hamburg, Germany

Background: Juvenile systemic scleroderma (jSSc) is an orphan disease with a prevalence of ≤ 5 in 1,000,000 children. Currently no medications are licensed for the treatment of jSSc. Due to its rarity, only recently have the first management and treatment guidelines been published, the jSSc SHARE (Single Hub and Access point for paediatric Rheumatology in Europe) recommendations, reflecting consensus opinion upon pediatric rheumatologists (1).

Objectives: To better understand treatment practices internationally for jSSc, both at baseline and over 24 months observation period and to compare if real world treatments are congruent with the recent SHARE recommendations.

Methods: The juvenile systemic sclerosis inceptions cohort (jSScC) is a multinational cohort that prospectively collects clinical data, including medications at baseline and subsequent visits. The jSSc enrollment criteria include age of onset of the first non-Raynaud symptom younger than 16 years and age younger than 18 years at cohort entrance. The frequency of medications (general category and specific medication) was calculated across the cohort at timepoint 0 (enrollment), 12 months and 24 months.

Results: We extracted data from the jSScC of patients who were followed for 12 or 24 months. 109 patients were followed at time point 0 (T0) and 12 months (T12), and data was available for all of them up at 24 months (T24). The mean age of the patients was 13.2 years at the timepoint 0. 77% were female, 75% had diffuse subtype. Disease duration at baseline visit was 3.1 years. The medications the patients were on were recorded by the physician were captured at T0, T12 and T24 listed in Table 1.

Table 1. 

<table>
<thead>
<tr>
<th>MEDICATIONS</th>
<th>Time point 0</th>
<th>T12 months</th>
<th>T24 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Medication</td>
<td>92% (100)</td>
<td>97% (106)</td>
<td>97% (75)</td>
</tr>
<tr>
<td>Vascular medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endothelial receptor antagonist</td>
<td>16% (17)</td>
<td>24% (26)</td>
<td>21% (16)</td>
</tr>
<tr>
<td>PDE-5 inhibitor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Immunomodulators</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>52% (57)</td>
<td>44% (48)</td>
<td>44% (21)</td>
</tr>
<tr>
<td>All csDMARDs</td>
<td>81% (88)</td>
<td>93% (101)</td>
<td>92% (71)</td>
</tr>
<tr>
<td>csDMARDs monotherapy</td>
<td>61% (67)</td>
<td>66% (72)</td>
<td>66% (46)</td>
</tr>
<tr>
<td>csDMARDs combination therapy</td>
<td>17% (18)</td>
<td>15% (16)</td>
<td>14% (11)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>51% (56)</td>
<td>50% (55)</td>
<td>39% (30)</td>
</tr>
<tr>
<td>Methotrexate combined with csDMARDs</td>
<td>26% (28)</td>
<td>44% (48)</td>
<td>47% (36)</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>11% (12)</td>
<td>15% (16)</td>
<td>21% (16)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>12% (13)</td>
<td>2% (2)</td>
<td>1% (1)</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>2% (2)</td>
<td>2% (2)</td>
<td>3% (2)</td>
</tr>
<tr>
<td>All bDMARDs</td>
<td>5% (5)</td>
<td>14% (15)</td>
<td>14% (14)</td>
</tr>
<tr>
<td>bDMARDs monotherapy</td>
<td>2% (2)</td>
<td>2% (2)</td>
<td>1% (1)</td>
</tr>
<tr>
<td>bDMARDs combined with csDMARDs</td>
<td>3% (3)</td>
<td>13% (13)</td>
<td>13% (13)</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>2% (2)</td>
<td>10% (11)</td>
<td>14% (11)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>2% (2)</td>
<td>4% (4)</td>
<td>4% (3)</td>
</tr>
<tr>
<td>Azathioprine combined with bDMARDs</td>
<td>1% (1)</td>
<td>0% (0)</td>
<td>0% (0)</td>
</tr>
<tr>
<td>Autologous Stem cell transplantation</td>
<td>0% (0)</td>
<td>1% (1)</td>
<td>0% (0)</td>
</tr>
<tr>
<td>csDMARDs: Conventional synthetic disease-modifying antirheumatic drugs b DMARDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biological disease-modifying antirheumatic drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: At baseline half of the patients were on corticosteroids. This is more frequent than typical adult SSC practice but coincides with jSSC SHARE treatment recommendations (#1). After 12 months observation in the cohort over 90% of patients received a DMARD therapy. Methotrexate and mycophenolate mofetil were the most commonly prescribed DMARDs, which also reflects the SHARE treatment recommendations (#2, #3). At 12 months the use of glucocorticoid decreased and the use of bDMARDs increased. In general, biological DMARDs are considered in severe or refractory (SHARE recommendation #7), reflecting the lower percentage compared to csDMARDs. Autologous stem cell transplantation was observed in one patient at 12 months, reflecting an option in jSSc with progressive and refractory disease (SHARE recommendation #8). Endothelial receptor antagonists, such as bosentan, were used over time in approximately 20% of the patients, reflecting SHARE recommendation #6 for pulmonary hypertension and/or digital tip ulcers. This is the first evaluation looking at clinical medication practice pattern in jSSc, and its comparison to recently published consensus guidelines.

REFERENCES:

Disclosure of Interests: None declared

Results: 73 patients could be identified, 71% of them were female. Mean age at disease onset was 8 years (4-14 years). The mean time of follow up was 5 years. The subtype distribution was 42 (57%) linear, 24 (33%) mixed, 6 (8%) circumscripted morphea and 2 (3%) panniculitic morphea. 9 (21%) of the 42 patients with linear subtype had coup de sabre and 4 (10%) of them had Parry Romberg. Fifty six (76%) patients had EM, 40 (53%) of them had 1 form of EM, 10 (13%) of them 2 forms of EM and 6 (8%) patients 3 forms of EM. 53(73%) of the 76 patients had arthritis. Twenty (37%) of the 53 arthritis involvement occurred on a localisation without overlaying skin involvement. Most frequent localisation of arthritis without overlaying skin involvement was in the hip joints (18%). Of the 53 patients with articular involvement had 31 (58%) linear, 17 (32%) mixed, 4 (7.5) circumscripted morphea and 1 (2%) panniculotic subtype. 14 (19%) of the 73 had length discrepancy of the extremities and 13 (19%) of them had linear subtype. Neurologic symptoms presenting as headache occurred in 8 (11%) patients. 6 (75%) of them had Parry Romberg subtype and 2 (25%) of them coup de sabre. White anterior uveitis was screened according to the published recommendations1-4 and it occurred in 3 patients, only one of them had coup the sabre the other two linear and mixed subtype without involvement of the face.

Conclusion: EM is very common and it occurs in 76% of the patients. Thirty seven percent of the articular involvement occurred in joints without overlaying skin involvement, which suggest the importance of the whole body joint count as in juvenile idiopathic arthritis. Only 1 of 3 patients with uveitis had skin involvement in the face, which emphasize the recommended uveitis screening.

REFERENCES:

Disclosure of Interests: None declared
duration was 2.5 years at T0. Antibody profile stayed unchanged. Only 3 clinical parameters changed and improved significantly, the median modified Rodnan skin score improved from 13 to 6 (p=0.002), the number of patients with swollen joints decreased from 17% to 8% (p=0.043) and number of patients with joints with pain on motion decreased from 20% to 12% (p=0.048). All other organ involvement did not show any statistically significant change from T0 to T12.

All collected patient reported outcomes improved significantly from T0 to T12: the patient reported disease activity (VAS 0 – 100) from 40 to 20 (p=0.011), the patient reported disease damage (VAS 0 – 100) from 40 to 20 (p=0.001), patient reported ulceration activity (VAS 0 – 100) from 10 to 0 (p=0.02) and the CHAQ score from 0.3 to 0 (p=0.002). Two of the three physician reported outcomes improved significantly, the physician global disease activity (VAS 0 – 100) from 30 to 20 (p=0.011) and physician reported global disease damage (VAS 0 – 100) from 30 to 25 (p=0.028).

Conclusion: Skin and musculoskeletal clinical features improved over 12 months, with almost all patients on DMARDs, supporting likely response of these features to therapy. It was promising that internal organ involvement, like cardiac and lung, although potentially stable, did not significantly worsen or increase. The most striking observation in the positive direction is improvement across several patient and physician reported outcome measures over the 12 month time period in this large international cohort.

REFERENCES:


Disclosure of Interests: None declared


**POS1303 METHOTREXATE RESPONSE IN PEDIATRIC NON-INFECTION UVEITIS**

S. Angeles-Han1,2, A. Cassidy3, T. Hennard4, M. Altaye5, H. Brunner6, E. Dosumu7, A. Gronb8, M. Henrickson9, J. Huggins9, S. Lopper9, D. J. Lovel10, R. Sisk10, T. Ting10, A. Kaufman11, V. Utz12, Cincinnati Children’s Hospital Medical Center, Pediatric Rheumatology, Cincinnati, United States of America; 2Cincinnati Children’s Hospital Medical Center, Pediatric Ophthalmology; Cincinnati, United States of America; 3Cincinnati Children’s Hospital Medical Center, Biostatistics & Epidemiology; Cincinnati, United States of America; 4Cincinnati Children’s Hospital Medical Center, Pediatric Rheumatology; Cincinnati, United States of America; 5Cincinnati Children’s Hospital Medical Center, Medical Staff Services, Cincinnati, United States of America; 6Cincinnati Eye Institute, Ophthalmology; Cincinnati, United States of America.

Background: Children with chronic non-infectious uveitis (NIU) are at risk for sight-threatening complications. Methotrexate (MTX) is the preferred first-line systemic treatment. Initial therapeutic response takes 3-6 months to achieve NIU control, leading to prolonged glucocorticoid use. Moreover, at least 50-70% of children fail to fully respond and may accrue ocular damage while awaiting MTX response.

Objectives: To identify features of children with NIU that are associated with MTX failure.

Methods: We included children who started MTX monotherapy for NIU. We collected demographics, NIU features (type, location, & complications), ANA status, and clinical examination. We characterized children as MTX responders or non-responders. MTX responders are those whose NIU was controlled, defined by: 1) inactive graded by SUN criteria, 2) absence of new or worsening complications, and 3) requirement for ≤2 drops of prednisolone acetate and no oral glucocorticoids.

Results: Of 47 NIU children, 68% were MTX non-responders (Table 1), having a longer duration of NIU (Odds Ratio [OR]=1.28, [CI]=1.03-1.8, p =0.023) and developing more ocular complications (OR=1.95 [CI]=1.23-3.36, p=0.017), (ROC Area Under the Curve = 0.85). MTX non-responders were more likely to have anterior and/or posterior synechiae (p=0.001), cataracts (p=0.015), and ocular hypertension (p=0.039). Treatment included adalimumab: 27, infliximab: 14, tocilizumab: 5, golimumab: 4, etanercept: 3, and abatacept: 2.

We performed a sub analysis of children with idiopathic chronic anterior NIU (CAU) and JIA-associated NIU that included children who failed MTX due to intolerance/toxicity (Figure 1). Using Cox proportional hazard regression, 6 idiopathic CAU failed MTX earlier than 38 JIA-associated NIU (HR 2.77, [CI]=1.06-7.27, p=0.039). Results were similar with the inclusion of other types of NIU (p=0.088) (e.g., HLA-B27, non-anterior idiopathic or with systemic disease).

**Table 1. Comparison of children with NIU based on MTX response.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Responders</th>
<th>Non-responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caucasians</td>
<td>14 (83)</td>
<td>27 (84)</td>
</tr>
<tr>
<td>Hispanic or Latino</td>
<td>0 (0)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Female</td>
<td>12 (80)</td>
<td>23 (72)</td>
</tr>
<tr>
<td>Age of NIU onset, yrs, median (IQR)</td>
<td>4.3 (2.9 – 12.3)</td>
<td>4.6 (2.8 - 7.0)</td>
</tr>
<tr>
<td>Duration of NIU, yrs, median, (IQR)</td>
<td>4.1 (2.6 – 5.3)</td>
<td>8.2 (4.7 - 11.3)</td>
</tr>
<tr>
<td>JIA-NIU</td>
<td>10 (67)</td>
<td>25 (78)</td>
</tr>
<tr>
<td>Idiopathic CAU</td>
<td>2 (13)</td>
<td>3 (9)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (20)</td>
<td>4 (12)</td>
</tr>
<tr>
<td>Bilateral disease</td>
<td>12 (80)</td>
<td>23 (72)</td>
</tr>
<tr>
<td>Anterior</td>
<td>12 (80)</td>
<td>23 (72)</td>
</tr>
<tr>
<td>Presenting BCAVA (LogMAR) worst eye, median (IQR)</td>
<td>0.2 (0.1 – 0.3)</td>
<td>0.1 (0.0 - 0.2)</td>
</tr>
<tr>
<td>Average % of total complications/person, median (IQR)</td>
<td>1 (0 – 2)</td>
<td>2.5 (1.0 – 5.5)</td>
</tr>
<tr>
<td>ANA positive</td>
<td>10 (67)</td>
<td>26 (81)</td>
</tr>
<tr>
<td>Earliest ESR</td>
<td>8 (6 – 18)</td>
<td>12 (8 - 18)</td>
</tr>
<tr>
<td>Earliest Vitamin D</td>
<td>32 (26 – 35)</td>
<td>31 (23 - 35)</td>
</tr>
<tr>
<td>Time on MTX, months, median (IQR)</td>
<td>35 (19 - 64)</td>
<td>19 (7 - 74)</td>
</tr>
<tr>
<td>Time from systemic or NIU onset to MTX, yrs, median (IQR)</td>
<td>0.3 (0.1 – 0.5)</td>
<td>0.2 (0.0 - 0.8)</td>
</tr>
<tr>
<td>MTX PO</td>
<td>6 (40)</td>
<td>19 (59)</td>
</tr>
<tr>
<td>MTX SC</td>
<td>13 (87)</td>
<td>31 (97)</td>
</tr>
</tbody>
</table>

**Figure 1. Kaplan-Meier curve showing freedom from TNFi (mos) stratified by diagnosis**

Conclusion: Two out of three children with NIU fail initial MTX monotherapy, exposing them to increased accrual of ocular complications prior to biologic starts. The risk for delay in starting tumor necrosis factor alpha inhibitors (TNFi) seems higher with CAU. Future studies will examine risk factors that predict MTX response in NIU.

REFERENCES:


Disclosure of Interests: Sheila Angeles-Han: None declared, Amy Cassidy: None declared, Theresa Hennard: None declared, Melkib Ayate: None declared, Herine Brunner Consultant of: Dr. Brunner’s affiliation Cincinnati Children’s Hospital States of America, a DSMB member for Janssen Pharmaceuticals’ trial of ustekinumab pediatric Crohn and Ulcerative colitis., Grant/research
support from: Dr. Brunner's affiliation Cincinnati Children's Hospital Medical Center has received research grants from BMS, Janssen, Novartis, Pfizer Inc, Roche, and UBC, Enioleda doumouf; None declared, Alexee Grum; None declared, Michael Henricsson; None declared, Jennifer Huggins; None declared, Sarah Lopfig; None declared, Daniel J Lovell Consultant of: Azeneca, Boehringer Ingelheim, GSK, Roche, Novartis, Pfizer Inc, Takeda, and UBC, Grant/research support from: BMS, Janssen, Novartis, Pfizer Inc, Roche, and UBC, Robert Sisk Consultant of: AGTC, Gyroscope, and Leica, Tracy Ting: None declared, Adam Kaufman Consultant of: for Aconc, Bausch & Lomb, and 1800contacts, not related or relevant to study content., Virginia Uitz: None declared.


### Table 1. Correlation between patient reported outcomes and LoSCAT

<table>
<thead>
<tr>
<th>PRO</th>
<th>Total skin activity (mLoSSi)</th>
<th>Total skin damage (LoSDI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDLQi</td>
<td>0.61 (0.02, 1.20)</td>
<td>0.44 (0.01, 0.83)</td>
</tr>
<tr>
<td>CHAQ</td>
<td>0.30</td>
<td>0.07 (0.06, 0.71)</td>
</tr>
<tr>
<td>VAS 1: How much impact has your disease had on your life in the PAST MONTH?</td>
<td>0.59</td>
<td>0.22 (0.06, 0.71)</td>
</tr>
<tr>
<td>VAS 2: How much have you been bothered by localized skin disease in the PAST MONTH?</td>
<td>0.09, 0.10</td>
<td>0.35, 0.57</td>
</tr>
<tr>
<td>VAS 3: Have your lesions felt itchy and/ or scratchy in PAST MONTH?</td>
<td>0.40, 0.56</td>
<td>0.31, 0.58</td>
</tr>
<tr>
<td>VAS 4: Have you felt numbness, tingling, and/ or other &quot;funny&quot; feeling in your skin in PAST MONTH?</td>
<td>0.03, 0.04</td>
<td>0.64, 0.71</td>
</tr>
<tr>
<td>VAS 5: How much WORRY do you have about your skin in PAST MONTH?</td>
<td>0.40</td>
<td>0.53</td>
</tr>
<tr>
<td>VAS 6: Are your lesions hurting and/ or red in PAST MONTH?</td>
<td>0.31, 0.58</td>
<td></td>
</tr>
<tr>
<td>VAS 7: How much WORRY do you have about problems with MEDICATIONS used to treat your condition?</td>
<td>0.00, 0.02</td>
<td></td>
</tr>
</tbody>
</table>

The VAS of symptoms of numbness/tingling showed a strong positive correlation with mLoSSi but showed a moderate correlation with LoSDI. Patient global VAS correlated with both mLoSSi and LoSDI, as did CDLQi. CHAQ correlated with activity only.

Conclusion: Symptoms within lesions are often interpreted as indicating disease activity. A previous study in adults and children showed itch positively correlated with mLoSSi suggesting it may be a marker of active disease [2]. However, in our study numbness/tingling correlated with disease activity whereas itch did not. Further work is required to understand whether itch correlates to both activity and damage and whether numbness/tingling is a better indicator of activity than itch. Limitations of our study include a heterogenous group of participants with longstanding high-burden disease.

REFERENCES:

Acknowledgements: This study was funded by Sclerodermia & Raynaud's UK.

Disclosure of Interests: None declared.


### Table 1. Correlation between patient reported outcomes and LoSCAT

<table>
<thead>
<tr>
<th>PRO</th>
<th>Total skin activity (mLoSSi)</th>
<th>Total skin damage (LoSDI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDLQi</td>
<td>0.61 (0.02, 1.20)</td>
<td>0.44 (0.01, 0.83)</td>
</tr>
<tr>
<td>CHAQ</td>
<td>0.30</td>
<td>0.07 (0.06, 0.71)</td>
</tr>
<tr>
<td>VAS 1: How much impact has your disease had on your life in the PAST MONTH?</td>
<td>0.59</td>
<td>0.22 (0.06, 0.71)</td>
</tr>
<tr>
<td>VAS 2: How much have you been bothered by localized skin disease in the PAST MONTH?</td>
<td>0.09, 0.10</td>
<td>0.35, 0.57</td>
</tr>
<tr>
<td>VAS 3: Have your lesions felt itchy and/ or scratchy in PAST MONTH?</td>
<td>0.40, 0.56</td>
<td>0.31, 0.58</td>
</tr>
<tr>
<td>VAS 4: Have you felt numbness, tingling, and/ or other &quot;funny&quot; feeling in your skin in PAST MONTH?</td>
<td>0.03, 0.04</td>
<td>0.64, 0.71</td>
</tr>
<tr>
<td>VAS 5: How much WORRY do you have about your skin in PAST MONTH?</td>
<td>0.40</td>
<td>0.53</td>
</tr>
<tr>
<td>VAS 6: Are your lesions hurting and/ or red in PAST MONTH?</td>
<td>0.31, 0.58</td>
<td></td>
</tr>
<tr>
<td>VAS 7: How much WORRY do you have about problems with MEDICATIONS used to treat your condition?</td>
<td>0.00, 0.02</td>
<td></td>
</tr>
</tbody>
</table>

The VAS of symptoms of numbness/tingling showed a strong positive correlation with mLoSSi but showed a moderate correlation with LoSDI. Patient global VAS correlated with both mLoSSi and LoSDI, as did CDLQi. CHAQ correlated with activity only.

Conclusion: Symptoms within lesions are often interpreted as indicating disease activity. A previous study in adults and children showed itch positively correlated with mLoSSi suggesting it may be a marker of active disease [2]. However, in our study numbness/tingling correlated with disease activity whereas itch did not. Further work is required to understand whether itch correlates to both activity and damage and whether numbness/tingling is a better indicator of activity than itch. Limitations of our study include a heterogenous group of participants with longstanding high-burden disease.

REFERENCES:

Acknowledgements: This study was funded by Sclerodermia & Raynaud's UK.

Disclosure of Interests: None declared.

Hematological Manifestations in the Presence of Antiphospholipid Antibodies in a Pediatric Cohort

P. Morán Alvarez1, A. Andreu-Suárez1, L. R. Caballero Motta2, J. Calzada3, S. Gassiot4, R. Berrueco4, L. Giovannelli5, A. Boteanu1, M. Vázquez Díaz1, J. Antón6, C. Bracaglia6, F. De Benedetti6. 1Hospital Universitario Ramón y Cajal, Rheumatology, Madrid, Spain; 2Hospital Universitario Gregorio Marañón, Rheumatology, Madrid, Spain; 3Hospital Sant Joan de Déu, Pediatric Rheumatology, Barcelona, Spain; 4Hospital Sant Joan de Déu, Pediatric Hematology, Barcelona, Spain; 5Ospedale Pediatrico Bambino Gesù, Laboratory, Rome, Italy; 6Ospedale Pediatrico Bambino Gesù, Pediatric Rheumatology, Rome, Italy

Background: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thrombotic events (TEs) and/or pregnancy morbidity, in association with two consecutive positive determinations (at least 12 weeks apart) of antiphospholipid antibodies (aPLs). Several manifestations which are not considered clinical criteria of APS have been identified, including hematologic disorders.

Objectives: To identify the different variables associated with the development of hematological manifestations in the presence of aPLs in a pediatric cohort.

Methods: Multicentric historical cohort of children ≤ 18 years from three Spanish and one Italian tertiary referral hospitals with at least 2 positive determinations (≥12 weeks apart) of IgG/IgM anticardiolipin (aCL), IgG/IgM anti-β2-glycoprotein I (β2GPI) and/or LA. Demographic, clinical and analytical data were collected. A bivariate and multivariate analysis were carried out. Multicollinearity was also explored to build the model.

Results: 131 children were included. Demographic, clinical, analytical data; and results of bivariate analysis are shown in Table 1.

Table 1. Demographic characteristics: non-thrombotic clinical manifestations; immunologic laboratory findings; and bivariate analysis according to each specific entity and the presence of “hematological” manifestations. Categorical variables expressed as number (n) and percentage (%); Numerical variables with normal distribution expressed as mean and SD (standard deviation). *p<0.05.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Total n= 131</th>
<th>Hematological manifestations n= 55</th>
<th>Absence of hematological manifestations n= 76</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, female, n (%)</td>
<td>85 (64.9)</td>
<td>39 (70.9)</td>
<td>46 (60.5)</td>
<td>0.219</td>
</tr>
<tr>
<td>Age, years, mean (SD)</td>
<td>10.9 (5.1)</td>
<td>10.8 (5.03)</td>
<td>10.9 (5.2)</td>
<td>0.974</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>105 (81.4)</td>
<td>43 (79.6)</td>
<td>62 (82.7)</td>
<td>0.126</td>
</tr>
<tr>
<td>Maghrebian</td>
<td>9 (7)</td>
<td>2 (3.7)</td>
<td>7 (9.3)</td>
<td></td>
</tr>
<tr>
<td>Latin American</td>
<td>8 (6.2)</td>
<td>6 (11.1)</td>
<td>2 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>5 (3.9)</td>
<td>3 (5.6)</td>
<td>2 (2.7)</td>
<td></td>
</tr>
<tr>
<td>Family history of AIoD, n (%)</td>
<td>33 (25.2)</td>
<td>17 (33.3)</td>
<td>16 (21.4)</td>
<td>0.122</td>
</tr>
<tr>
<td>SLE diagnosis, n (%)</td>
<td>34 (26)</td>
<td>20 (36.4)</td>
<td>14 (18.4)</td>
<td>0.021*</td>
</tr>
<tr>
<td>Thrombotic events, n (%)</td>
<td>16 (12.2)</td>
<td>7 (12.7)</td>
<td>9 (11.8)</td>
<td>0.879</td>
</tr>
<tr>
<td>Hematological, n (%)</td>
<td>55 (42)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Raynaud, n (%)</td>
<td>25 (19)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Neurological, n (%)</td>
<td>26 (20)</td>
<td>10 (18.2)</td>
<td>16 (21.3)</td>
<td>0.657</td>
</tr>
<tr>
<td>Chorea</td>
<td>8 (6.1)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Epilepsy</td>
<td>5 (3.8)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Migraine</td>
<td>4 (3)</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Cutaneous, n (%)</td>
<td>23 (17.8)</td>
<td>6 (10.9)</td>
<td>17 (22.4)</td>
<td>0.089</td>
</tr>
<tr>
<td>Renal, n (%)</td>
<td>2 (1.5)</td>
<td>0 (0)</td>
<td>2 (2.6)</td>
<td>0.225</td>
</tr>
<tr>
<td>Renal, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aCLG, n (%)</td>
<td>54 (41.2)</td>
<td>24 (43.6)</td>
<td>30 (39.5)</td>
<td>0.633</td>
</tr>
<tr>
<td>IgG</td>
<td>31 (23.7)</td>
<td>20 (36.4)</td>
<td>11 (14.5)</td>
<td>0.004*</td>
</tr>
<tr>
<td>β2GPI</td>
<td>59 (45)</td>
<td>29 (52.7)</td>
<td>30 (39.5)</td>
<td>0.132</td>
</tr>
<tr>
<td>LA, n (%)</td>
<td>76 (58.5)</td>
<td>37 (67.3)</td>
<td>39 (52)</td>
<td></td>
</tr>
<tr>
<td>Simple</td>
<td>76 (58.5)</td>
<td>25 (45.5)</td>
<td>51 (67.1)</td>
<td>0.008*</td>
</tr>
<tr>
<td>Multiple</td>
<td>30 (22.9)</td>
<td>13 (23.6)</td>
<td>17 (22.4)</td>
<td></td>
</tr>
<tr>
<td>ANA, n (%)</td>
<td>72 (55.2)</td>
<td>36 (63)</td>
<td>36 (45.9)</td>
<td>0.222</td>
</tr>
</tbody>
</table>

The multivariate analysis identified as independent risk factors to develop a hematologic manifestation, children: SLE diagnosis [OR 1.2, 95 CI (0.5-5.8), p=0.015], cutaneous manifestations [OR 1.01, 95 CI (0.6-2.8), p=0.091]. LA + [OR 0.8, 95 CI (0.4-3.6), p=0.058], and IgGβ2GPI+ [OR 0.9, 95 CI (0.4-3.9), p=0.048]. Sex, age, familiar history of AIoD or IgM B2GPI+ did not show a higher risk.
Conclusion: Non-criteria manifestations, specially hematologic disorders, are the most frequent events in the presence of sPLA2s in our cohort. Cutaneous manifestations, a positive personal history of SLE, LA positivity and IgG anti-β2GPI positivity were associated with a higher risk of developing hematological manifestations. Therefore, their inclusion as APS classification criteria should be considered.

REFERENCES:

Disclosure of Interests: None declared

POS1308  SINGLE CENTER REAL-LIFE PRACTICE OF BIOLOGICAL THERAPY IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH JUVENILE ONSET
M. Kalela1, I. Nikitinha2, E. Fedrov1, S. Salugin2, A. Shapovalenko2, T. Pachkoria3, V.A. Nasonova Research Institute of Rheumatology; Pediatric Department, Moscow, Russian Federation

Background: In recent years the use of Biologics (B) at the management of systemic lupus erythematosus including with juvenile onset (sJLE) has increased. Belimumab (BEL) became the first approved B for SLE. The use of rituximab (RTM), despite the status of "label", remains relevant in a number of patients (pts) with poor response to standard therapy and the presence of life-threatening conditions. However, use of B in real clinical practice has increase slowly, in part, due to uncertainty over which pts should be treated with B and in what stage of the disease, in part, due to uncertainty over safety.

Objectives: To analyze in retrospective study the efficacy and safety of B in pts with sJLE.

Methods: The study included all pts with sJLE in our pediatric rheumatologic department, who received B.

Results: Among 160 pts with sJLE, 52 (32.5%) received B: 43 – RTM, 12 – BEL, 1 – abatacept (ABA). 4 pts received 2B in sequence (2 – RTM-BEL, 1 – BEL-RTM, 1 – RTM-ABA). The proportion of pts with sJLE was 47% among all those who received RTM in our center. The median age at onset – 12.2 y.o. [IQR 9.9; 14.6], median disease duration at start of RTM – 2.5 years [IQR 0.9; 4.5]. The girls and boys ratio = 6.2:1. The median of activity by SLEDAI at start of RTM was – 16 [12; 22]. 58% of pts underwent more than one course of RTM, with a maximum of 6 courses. The median time between each course was 182 [96–315] days. RTM was effective in 40 (93%) pts with the achievement of the inactive status of the disease and reduction of GC-therapy. Various adverse events (AE) were observed in 46.5% of pts as recurrent uncomplicated upper respiratory tracts infections being the most common (23.2%). RTM was discontinued in 9 pts: 1 - the flare of Ro-associated vasculitis, 1 - inefficacy, 7 - serious AEs. Serious AEs included: pneumonia – in 1 (2.3%), serious infusion reaction – in 1 (2.3%), toxic epidermal necrolysis (TEN) – in 1 (2.3%), MAS – in 2 (4.6%), death (inefficacy for treatment of MAS in SLE) – in 2 (4.6%). Among pts receiving RTM the median age at onset was 12.7 y.o. [IQR 10.0; 15.0], median disease duration at start of RTM – 1.5 years [IQR 1.0; 2.1]. The girls and boys ratio = 1.4:1. The median of activity by SLEDAI at start of BEL was – 10 [9; 14]. 6 pts receive BEL more than 1 year with the achievement of the inactive status of the disease and reduction of GC-therapy. AEs were registered in 3 pts (25%): neutropenia (III degree) – in 1, SAEs – in 2 pts (toxic epidermal necrolysis after 1st infusion, flare of SLE after 6 months of therapy, with discontinuation of BEL in both pts). One patient, boy, 4 y.o. at onset, received ABA (RTM was discontinue after MAS). Disease duration at start of BEL – 7.5 years, the activity by SLEDAI – 10. Treatment with ABA allowed to decrease the activity of sJLE (now SLEDAI=2). Now boy receives ABA during 51 months with good safety, continues GC 5mg per day, hydroxychloroquine 100mg per day.

Conclusion: Our study has shown that B is effective in sJLE and has an acceptable safety profile if possible adverse reactions are carefully monitored. In the presence of severe organ lesions, to improve the long-term prognosis, the appointment of B at an early stage of the disease can be discussed. The overall picture that emerges is one of optimism that advances in therapy of sJLE will be realised through the targeted use of an increasing different B.

Disclosure of Interests: None declared

POS1309  THE IMPACT OF PSORIASIS ON PATIENT-REPORTED OUTCOMES IN JUVENILE PSORIATIC ARTHRITIS
J. M. J. Low1, K. Hyrich2, N. Geirmann3, S. Shoop-Worrall4 on behalf of CAPS, 1The University of Manchester, UK, Manchester Medical School, Manchester, United Kingdom; 2The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 3The University of Surrey, School of Health Sciences, Faculty of Health and Medical Sciences, Surrey, United Kingdom; 4The University of Manchester, Centre for Health Informatics, Manchester, United Kingdom

Background: Children with juvenile psoriatic arthritis (JPsA) are treated similarly to patients in other categories of juvenile idiopathic arthritis (JIA) despite distinctive clinical features, including either a personal or family history of psoriasis. It remains unknown whether the unique features in JPsA lead patients to experience the impact of disease differently from other JIA patients, and how the presence of psoriasis within JPsA affects patient outcomes. These gaps in our knowledge suggest there may be unmet treatment needs in these children and young people.

Objectives: To compare patient-reported outcomes in patients with JPsA and other JIA categories. Additionally, this study explores whether the presence or absence of psoriasis in patients with JPsA is associated with different outcomes.

Methods: Children and young people with JIA were selected if recruited to the Childhood Arthritis Prospective Study (CAPS), a UK multicentre inception cohort of JIA, between January 2001 and March 2018. Detailed demographic information, clinical data and patient-reported outcomes were collected at initial presentation to paediatric rheumatology. Patient-reported outcomes included well-being as measured on the parental global evaluation (10cm), functional ability (Childhood Health Assessment Questionnaire: CHAQ), pain (10cm), depression (Children's Health Questionnaire, CHQ psychosocial score), depressives symptoms (Mood and Feelings Questionnaire, MFQ) and parent psychosocial health (General Health Questionnaire: GHQ). The CHQ and MFQ questionnaires were completed in a subset of children recruited until 2015 and aged above 5 and 7 years old, respectively.

Result: A total of 1653 patients had JIA; the majority (64.7%) were female and median age at onset was 6.5 years (IQR 2.7 - 10.8). A total of 111 (16.7%) were categorised with JPsA, of which 62 (55.9%) were female with median age at onset of 10.2 (IQR 4.3 -12.5). In those with JPsA, 35% had psoriasis at diagnosis. There were no significant differences between JPsA and non-JPsA in terms of parental global evaluation of wellbeing (p=0.21), CHAQ (p=0.19), pain (p=0.38), CHQ psychosocial (p=0.18), GHQ (p=0.31) or MFQ (p=0.34).

Within JPsA, depressive symptom score on the MFQ was higher in patients with psoriasis compared to those without (coefficient=9.8, 95% CI=0.5 to 19.0, p-value=0.04). However, there were no significant differences in parental global evaluation (p=0.4), CHAQ (p=0.3), pain (p=0.3), CHQ psychosocial score (p=0.5) or GHQ (p=0.7) between those with and without psoriasis in JPsA (Table 1).

Table 1. Patient-reported outcomes in children and young people with JPsA with and without psoriasis

<table>
<thead>
<tr>
<th>Outcome</th>
<th>JPsA with psoriasis</th>
<th>JPsA without psoriasis</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wellbeing: Parent global (0-10cm)</td>
<td>0.5</td>
<td>0.8</td>
<td>1.45</td>
</tr>
<tr>
<td>Function: CHAQ (0-3)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Pain (0-10cm)</td>
<td>0.8</td>
<td>0.8</td>
<td>2.4</td>
</tr>
<tr>
<td>Psychosocial: CHQ (0-100)</td>
<td>2.4</td>
<td>10.1</td>
<td>5.3</td>
</tr>
<tr>
<td>Parent psychosocial: GHQ (0-84)</td>
<td>-1.3</td>
<td>-8.7</td>
<td>6.1</td>
</tr>
<tr>
<td>Depressive symptoms: MFQ (0-66)</td>
<td>9.8</td>
<td>0.5</td>
<td>19.0</td>
</tr>
</tbody>
</table>

Conclusion: Despite the differences in clinical features present in JPsA compared to the other JIA subtypes, there were no statistically significant differences in patient-reported outcomes overall at diagnosis. However, within the JPsA group, even when adjusting for age, children with psoriasis at time of arthritis diagnosis reported higher depressive symptom scores compared to those without psoriasis. When treating children with JPsA, attention to diagnosing and treating both arthritis and psoriasis (Child Health Questionnaire) remains important. If poor mood persists in this subtype, then further allied health care may be required.

Acknowledgements: We thank all the children and young people and their families involved in CAPS, as well as clinical staff and administrators. We also thank the data management team at the University of Manchester (UK). CAPS is funded by Versus Arthritis (UK grant 20542). This report includes independent research funded by the NIHR Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health. K.L.H is additionally supported by the Centre for Epidemiology Versus Arthritis (UK grant 21755) at the University of Manchester, UK.

**Disclosure of Interests:** Jie Man (Jasmine) Low: None declared, Kimme Hyrich Speakers bureau: AbbVie, Grant/research support from: BMS, UCB, and Pfizer, Nophar Geifman: None declared, Stephanie Shoop-Worrall: None declared DOI: 10.1136/annrheumdis-2022-eular.2715

**POS1311**

**LONG - TERM OUTCOMES IN ADULT PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS**

E. Kiseleva1, E. Koltsova2, E. Volunikhin3, N. Savenkova1, A. Klimets2, E. Rozochkina1, A. Kovshik1, G. Lukina1, A.S. Loginov

**Scientific Abstracts**

**993**

**Speakers bureau:** AbbVie, Grant/research support from: BMS, UCB, and Pfizer, **Methods:**

**Objectives:**

**Results:** Among patients included in the study, there were 11 men (34.38%) and 21 women (65.62%); the average age at the time of inclusion was 23.68 (±5.93). In 13 (40.63%) patients the onset of the disease occurred before the age of 5, in 7 (21.87%) - from 6 to 10 years and in 12 (37.50%) - after 11 years. In 9 (28.13%) patients the duration of the disease was less than 10 years, in 23 (71.87%) patients - more than 10 years. The onset of the disease was accompanied by the following symptoms: fever - 28 (87.50%), arthritis - 21 (63.63%), rash - 17 (53.13), arthralgia - 6 (18.75%), pericarditis - 4 (12.50%), sore throat - 8 (25.00%), lymphadenopathy - 2 (6.25%). Among patients with arthritis 11 (52.38%) had oligoarthritis, 10 (47.62%) had polyarthritis. 2 patients (6.25%) were diagnosed with uveitis. According to the X-ray examination (Steinbrocker's classification of radiographic changes) 5 (15.63%) patients had I stage, 13 (40.62%) - II stage, 4 (12.50%) - III stage, 21 (63.63%) - IV stage and 4 (12.50%) had no radiological changes. Three (9.38%) were diagnosed with aspecic necrosis and these patients underwent arthroplasty. Four (12.50%) patients had pregnancy.

Education: 17 (53.13%) people study at higher educational institutions. Two (6.25%) have a higher educational level. Disease activity: 24 (75%) patients are currently in low activity or disease remission, 8 (25%) are in moderate activity. Twenty (62.50%) patients receive therapy with disease - modifying antirheumatic drugs (DMARDs), 14 of them are treated with tocilizumab, 3 (12.50%) – with canakinumab, 3 (12.50%) – with bDMARDs.

**Conclusion:** The use of bDMARDs helps successfully control the disease in patients with sJIA, maintain long - term remission and improve long - term outcomes in adult patients with sJIA.

**Disclosure of Interests:** None declared DOI: 10.1136/annrheumdis-2022-eular.2754

**POS1312**

**ANALYSIS OF INTERFERON-TYPE 1 SIGNATURE IN JUVENILE DERMATOMYOSITIS**

R. Raupov1,2, E. Susiptin1,4, R. Mukidzhan3, M. Kostik1,5, 1Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint-Petersburg, Russian Federation; 2City Hospital №40, Medical Rehabilitation of Children, Saint-Petersburg, Russian Federation; 3Saint-Petersburg State Pediatric Medical University, Medical Genetics, Saint-Petersburg, Russian Federation; 4N.N.Petrov Institute of Oncology, Molecular diagnostics, Saint-Petersburg, Russian Federation; 5Almazov National Medical Research Centre, Laboratory of Autoimmune and Autoinflammatory Diseases, Saint-Petersburg, Russian Federation

**Background:** IFIH1 gene codes for the MDA5 protein participating in interferon I signaling pathway, which is important in the innate immune response [1]. IFIH1 polymorphisms are associated with a spectrum of autoimmune disease [2]. Rare IFIH1 gene defects have been found in patients with Aicardi- Goutières syndrome-7, Singleton-Merten syndrome, and MDA-5 immunodeficiency. All these conditions are characterized by upregulation of interferon signaling [3]. DDX58 encodes RIG-I receptor that is responsible for the recognizing of single- and double-stranded viral RNA. Mutation of DDX58 was described in Singleton-Merten syndrome [4].

**Objectives:** to describe clinical characteristics of patients with rare IFIH1 and DDX58 variants detected by clinical exome sequencing.

**Methods:** 8 patients (5 girls and 3 boys) having rare IFIH1 and DDX58 variants (MAF less than 0.005) were found in heterozygous state among the patients who underwent genetic testing in our hospital in 2019-2021. Clinical manifestations, laboratory parameters, IFN I score values and treatment options were analyzed.

**Results:** 3 patients (#3, #6, #7) had undifferentiated systemic autoinflammatory syndromes, while others were presented with SLE, SLE-like disease, JDM and PFAPA syndrome. All of them had elevated IFN-I score and skin rash. IFIH-1 variants were in 5 patients (#1-5); 3 patients carried the same c.1879G>T polymorphic variant. Patient #6-8 have VUS DDX58 variants. All the alleles were in heterozygous state. Detailed information is presented in Table 1.

**Table 1.**

<table>
<thead>
<tr>
<th>#</th>
<th>Genetic variants</th>
<th>MAF</th>
<th>IFN-score</th>
<th>Diagnosis</th>
<th>Manifestation</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IFIH1 c.1879G&gt;T (p.E627X)</td>
<td>0.003</td>
<td>11.3</td>
<td>SLE</td>
<td>Fever, photosensitivity, pan-</td>
<td>CS, RTX, MMF</td>
</tr>
<tr>
<td>2</td>
<td>IFIH1 c.1879G&gt;T (p.E627X)</td>
<td>0.002</td>
<td>2.95</td>
<td>PFAPA</td>
<td>Fever, pharyngitis, stomati-</td>
<td>CS, MTX</td>
</tr>
<tr>
<td>3</td>
<td>IFIH1 c.158A&gt;G (p.E627X)</td>
<td>0.0009</td>
<td>5.52</td>
<td>uSAID</td>
<td>Fever, panariticism, pете-</td>
<td>TOF, CYC, IVIG</td>
</tr>
<tr>
<td>4</td>
<td>IFIH1 c.1784G&gt;A (p.P595S)</td>
<td>0.0001</td>
<td>29.0</td>
<td>JDM</td>
<td>Gottron's papules, periop-</td>
<td>CS, CYC</td>
</tr>
<tr>
<td>5</td>
<td>IFIH1 c.1879G&gt;T (p.E627X)</td>
<td>0.002</td>
<td>20.2</td>
<td>SLE-like</td>
<td>Face erythema, skin</td>
<td>MTX</td>
</tr>
<tr>
<td>6</td>
<td>DDX58 c.1061A&gt;G (p.N354S)</td>
<td>0.0007</td>
<td>2.13</td>
<td>uSAID</td>
<td>Recurrent pericarditis</td>
<td>CS</td>
</tr>
<tr>
<td>7</td>
<td>DDX58 c.1036G&gt;A (p.E347X)</td>
<td>0.000008</td>
<td>n/a</td>
<td>uSAID</td>
<td>Fever, livedo racemose,</td>
<td>NSAIDS</td>
</tr>
</tbody>
</table>

Abbreviations: MAF- minor allele frequency; SLE- systemic lupus erythematosus; uSAID- undifferentiated systemic autoinflammatory syndrome; JDM- juvenile dermatomyositis; CS- corticosteroids; RTX- rituximab; CYC- cyclophosphamide; MTX- methotrexate; IVIG- intravenous immunoglobulin; MMF- mycophenolate mofetil; CSa- cyclosporine A; TOF- tofacitinib.

**Conclusion:** while rare IFIH1 and DDX58 variants have been repeatedly detected in children with clinically heterogeneous immune-mediated diseases, it is unclear whether these alleles have casual role. Functional testing and collection of patients with the same gene variants are required.

**REFERENCES:**

[1] https://medlineplus.gov/genetics/gene/ifih1/#resources

Acknowledgements: This work was supported by the RFSF grant no 20-45-01005

**Disclosure of Interests:** None declared DOI: 10.1136/annrheumdis-2022-eular.3281
Objectives: to evaluate IFN-score in children with dermatomyositis and compare with disease activity

Methods: 15 patients (5 boys and 10 girls) were enrolled in the study. Clinical and laboratory parameters, disease activity (CMAI-childhood myositis assessment tool, aCAT- abbreviated cutaneous assessment tool) and treatment were assessed. Patients were compared according to IFN-score elevation. IFN-score was assessed by RT-PCR quantitation of 5 IFN-1 regulated transcripts (IFI44L, IFI44, IFIT3, Ly6E, MXA1); median relative expression of ≥ 2 was considered as a cut-off. IFN-score was evaluated in dynamics in 9 patients.

Results: median age of patients was 6.2 (3.6; 7.6) years. Skin and muscle involvement were in all patients, arthritis in 5 (33%) patients, calcinosis in 3 (20%), lipo-dermatitis in 2 (13%) and lung involvement in 5 patients (33%), and 9 patients (60%) had positive myositis-related antibodies. Ten patients (67%) had an active disease, while elevated IFN-score was detected in 12 (80%) patients. Cumulative IFN-score and its five’ five components were higher in active patients, compare to inactive (13.6 vs 1.4, p=0.006). Patients with increased IFN-score had lower CMAS score and higher aCAT score compared to patients with normal levels of IFN-1 score. IFN-score correlated with aCAT, arthritis and lung involvement.

Conclusion: IFN-score may be considered as disease activity biomarker in juvenile dermatomyositis with predominantly skin activity process.

REFERENCES:


Acknowledgements: This work was supported by the RSP grant N° 20-45-01005.

Disclosure of Interests: None declared


POST313
HIP INVolVEMENT IS A MoRe FREQuENT COMPLICATION IN ENThESIS-RELATED ARTHRiThS COMPARED TO THE ADULT SPONDYLOArTHRiThS

C. Ines1,2, H. Ferjani1, L. Ben Ammar1, D. Ben Nessib1, W. Triki1, K. Maataallah1, D. Kaffel1, W. Hamdi1 on behalf of Rheumatologie Charles Nicole Hospital, Tunis.
1Med Kassab Institute of Orthopedics, Rheumatology, Manouba, Tunisia

Background: The hip disease develops in 30% to 50% of children with juvenile idiopathic arthritis (JIA) and is associated with poor outcomes and functional impairment. The coxitis in enthesitis-related arthritis (ERA or juvenile-onset spondyloarthritis) patients was frequent but weakly studied.

Objectives: To assess the occurrence of coxitis in patients with ERA and compare it to that of older patients with spondyloarthritis (SpA).

Methods: We conducted a retrospective comparative study including patients with ERA and adult spondyloarthritis patients.

The first group included patients under 16 years old fulfilling the International League of Associations for Rheumatology (ILAR). The second group of patients fulfilled the Assessment of SpondyloArthritis International Society (ASAS) 2009 criteria. We studied the socio-demographic characteristics of both groups, the hip involvement occurrence, and the treatment modalities.

Quality of life was appraised by the Study 36-item Short-Form Health Survey (SF-36) and the Ankylosing spondylitis quality of life test (ASOQL).

Results: Forty ERA (mean age=25.3 ±10.15) patients and 134 SpA (mean age=37.96±11.77) patients were enrolled. Seventeen ERA patients (42.5%) had coxitis at recruitment compared to 28 SpA patients (20.9%), p<0.06. More than half of the ERA patients were positive to HLA-27, compared to the SpA group (44.7%), without reaching a significant threshold, p=0.07. The mean delay of coxitis onset in ERA patients was 4.66 ±4.6 years, and was 5.65 ±6.6 years in SpA patients, with no significant difference between the two groups (p=0.527). There was no difference between the two groups for the coxitis being unilateral or bilateral (p=0.272 and 0.169 respectively). Regarding the treatment approach, local therapy was proposed to 11 patients in the ERA group and 13 patients in the SpA group (p=0.07), with synoviolysis being the most common therapy. Total hip replacement was done in 3 ERA patients (of which two were bilateral) and in 17 SpA patients (of which ten were bilateral), without reaching the significant threshold (p=0.858). There was no significant difference between the two groups on the period when the total hip replacement was done (p=0.925). Quality of life assessed by the ASOQL and the SF-36 was comparable between the two groups (p=0.666 and 0.326, respectively).

Conclusion: Our study shows the high prevalence of hip involvement in the juvenile group with enthesitis compared to the five years of disease outcomes and constitutes a turning point in their lives.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3293

POST314
VALIDATION OF A PEDIATRIC-SPECIFIC ULTRASOUND SCORING SYSTEM FOR THE EVALUATION OF WRIST, FINGER, AND ANKLE SYNOVITIS

P. Vega Fernandez1, T. Hennard1, K. Rogers2, A. B. Meyers2, A. Cassidy1, T. Ting3, 1Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, Cincinnati, United States of America; 2University of Cincinnati, Radiology, Cincinnati, United States of America

Background: Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in children. Clinical evaluation of arthritis is a subjective measurement. Musculoskeletal ultrasound (MSUS) is increasingly being utilized in children. In order to provide objective assessments of arthritis, reliable and validated MSUS scoring systems are needed. Recently, a joint-specific scoring system for the assessment of arthritis of the pediatric ankle, wrist and finger joints were proposed.[1,2]

Objectives: This study aims to further validate the MSUS scoring system for the assessment of finger, wrist, and ankle arthritis

Methods: JIA patients with finger, wrist, and ankle arthritis as per expert clinician evaluation are eligible for this study. A comprehensive wrist, ankle, and finger (2-5th metacarpal and 2-5 th proximal interphalangeal joints) MSUS examination by an American College of Rheumatology MSUS certified pediatric rheumatologist is performed on all enrolled subjects. MSUS are scored using the semiquantitative (grade 0 to 3) scoring systems previously proposed. A subset of participants receives an MRI with contrast of the targeted joint immediately after MSUS performance. MRI findings are read for presence of synovitis, tendons and enthesis by a pediatric radiologist with expertise in pediatric musculoskeletal imaging.

For the analysis of the current report, MRIs were classified as having presence or absence of findings of JIA disease based on the pediatric radiologist expert opinion. MSUS were classified as normal (grade 0 and 1) or abnormal (grade 2 and 3). Cohen’s Kappa Coefficient was used to assess the level of agreement between MSUS (normal and abnormal) and MRI with contrast (absence or presence of disease) for each targeted joint. Tetrachoric Correlation was used to assess the strength of the association. Fisher’s Exact test was used to determine statistical significance at p < 0.05 level.

Results: A total of 52 children aged 2 – 18 years old have been enrolled in this study. To date 20 MSUS of the finger(s), 33 MSUS of the wrist, and 43 MSUS of the ankle joints have been collected. Three MRI of the 2-5 fingers (12 fingers total), 6 MRI of the wrist, and 5 MRI of ankle have been obtained through the study. Preliminary results of this effort reveal that for the ankle joint there is moderate agreement (Kappa coefficient 0.53 [confidence interval (CI)=0.14-0.92]) between MRI and US and a strong positive tetrachoric correlation (0.79) (p = 0.03). While the Kappa coefficient for comparing MRI and US finding on wrist joint indicated moderate agreement (Kappa 0.62 [0.15-1.00]) with a strong tetrachoric correlation (0.83) the Fisher’s exact test indicated a trend rather than statistically significant results (p = 0.07). The Kappa coefficient for MCPs and PIPs joints indicated strong agreement between MRI and US (Kappa 0.83 [CI=0.52-1.00] and 0.80 [CI=0.43-1.00] respectively) and were supported by an almost perfect Tetrachoric Correlation of 0.99 (p < 0.01). We anticipate to complete enrollment of subjects by the summer of 2022. Analysis of collected data is underway.

Conclusion: The strong to moderate association of MSUS with contrast-enhanced MRI, suggest that MSUS can provide an objective and accurate assessment of ankle, wrist and finger arthritis at the bedside. Further refinement and validation of these pediatric-specific MSUS scoring systems may support the use of MSUS as a clinical tool and outcome measure in JIA.

REFERENCES:


Acknowledgements: Project supported by the Center for Clinical & Translational Science & Training (CCTST) at the University of Cincinnati funded by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, grant 2UL1TR001425-05A1 and KL2 (2KL2TR001426-05A); and a Diversity and Health Disparities Award from the Cincinnati Children’s Hospital Medical Center.

Disclosure of Interests: None declared

**POS1315**

**PREVALENCE OF SARCOPENIA IN YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS**

M. Dzhus1, M. Kulyk1, T. Karasevska1. 1Bogomolets National Medical University, Internal Medicine Department №2, Kyiv, Ukraine

**Background:** In the 2019 sarcopenia consensus update (EWGSOP2 [1]) experts emphasize low muscle strength as a key characteristic of sarcopenia, adding low muscle mass to confirm the diagnosis of sarcopenia. Thus, the presence of the first criterion indicates probable sarcopenia, the presence of the first and second criteria confirms the diagnosis of sarcopenia, and the presence of all three criteria indicates severe sarcopenia. There are no available data about severe sarcopenia in young adults with juvenile idiopathic arthritis (JIA).

**Objectives:** This study aims to assess the prevalence of severe sarcopenia in young patients with JIA.

**Methods:** To confirm the diagnosis of severe sarcopenia we used dual X-ray absorptiometry (DXA) to assess low muscle mass (cut off points for ASM/height2 <7 kg/m2 for men and <5.87 kg/m2 for women); dynamometry - to determine the low muscle strength (grip strength <27 kg for men, <16 kg for women); gait speed and short physical performance battery (SPPB) to assess physical function (cut off points <8 m/sec and score ≤8, respectively). Patients were divided into two groups according to the presence or absence of all three criteria for severe sarcopenia.

**Results:** We studied 40 young adults with JIA, including 23 female patients and 17 male patients. The mean age of the patients was 24.4±5 years; the mean weight was 72,0±12,8 kg; p=0,01, respectively. The research found out: the height and weight of patients in the group with severe sarcopenia were lower than in the group without severe sarcopenia (height 1.67±0.07 m vs 1.75±0.08 m; p=0,01; weight 56.1±9.2kg, 72.0±12.8kg; p=0,01, respectively). The age of patients was not significantly different between the two groups, but the duration of the disease was longer in the I group 16,4±8.2 vs 9,2±5.3; p=0,01. The data of DXA differed between groups: the patients of I group had statistically reduced total BMD 1.07±0,1 g/cm2 vs 1.15±0,14g/cm2; ultra-distal radius BMD 0.35±0,1g/cm2 vs 0.51±0,12g/cm2; femoral neck BMD 0.85±0,1g/cm2 vs 1.04±0,2g/cm2; p=0,01, respectively. Comparing the two groups, we found important differences: the level of LSR was higher in the I group 25.05±18.3 vs 11.5±10.02; p=0.01; the index of disease activity either (DAS28 4,0±1,7 vs 2.7±1.2; JADAS27 15,8±9.2 vs 8,3±4.8; p=0,01, respectively). Articular and extraarticular damage index were higher in I group: JADI-A 5.08±7.3 vs 0.5±0.7; p=0,01; JADI-E 1.7±1.8 vs 0.3±0.6, p=0.02. **Conclusion:** The study confirms the presence of severe sarcopenia despite the young age of patients with JIA. Severe sarcopenia occurs in patients with a higher level of inflammatory activity, articular and extraarticular damage, reduced bone mineral density, and longer duration of the disease. Further study of the factors influencing the development of sarcopenia in this category of young patients is required.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3742

**POS1316**

**PERFORMANCE OF THE KOBAYASHI SCORE AND MODIFIED KOBAYASHI SCORE IN PREDICTING RESISTANCE TO INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH PEDIATRIC INFLAMMATORY MULTYSYNDROME ASSOCIATED WITH SARS-COV-2.**

N. Cybulska1, K. Jozkow1, K. Orczyk1, A. Stasiak1, E. Smolewska1. 1Medical University of Lodz, Poland, Department of Pediatric Cardiology and Rheumatology, Lodz, Poland

**Background:** Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2 (PIMS) is a new insidious disease which in several points may mimick Kawasaki disease. Patients diagnosed with one of the aforementioned conditions are initially treated with intravenous immunoglobulin (IVIG). However, up to 20% of children diagnosed with Kawasaki disease appear to be resistant to such therapy. Similarly, substantial portion of PIMS patients requires second line treatment including systemic glucocorticoids. There are several calculative models, including the Kobayashi Score, which are utilized to predict patients' response to such treatment. To our best knowledge, the scoring systems derived from Kawasaki disease have not yet been assessed whether they can fulfill similar role in PIMS patients.

**Objectives:** There were two essential questions to be addressed in the study: (1) Can the Kobayashi Score be utilized in making clinical decisions regarding concomitant treatment in PIMS patients? (2) Is there any modification that may increase the accuracy of the original score?

**Methods:** First step of the study involved 19 patients diagnosed with PIMS between July 2020 and June 2021. The statistical analysis including each parameter of the Kobayashi Score has been performed in order to determine potential alterations of the score. Then, the numerous variants of modified score have been compared in terms of their positive and negative predictive values in order to determine new PIMS IVIG Resistance Score (PIRS). In the next phase of the study, both scores have been validated in the second cohort involving 16 patients diagnosed with PIMS between July and December 2021. The final assessment has been performed in the unified study group (35 PIMS patients).

**Results:** The Kobayashi Score (see Table 1) significantly differentiated PIMS patients in terms of good response or resistance to IVIG (p=0.03967). However, the score returned a few false positive (3 out of 9) and false negative (2 out of 10) results. After step-by-step verification of clinical and laboratory parameters, authors developed a tentative PIRS (see Table 1) including the following criteria: hyponatremia, days of fever and platelet count (derived from the Kobayashi Score but with different cut-off levels) supplemented with procalcitonin level and percentage of lymphocytes. In the validatory phase of the study, both scores had equal accuracy to predict treatment response. The analysis of receiver operating characteristic curve in the unified study group has shown better performance of PIRS (Youden index 0.72) than the Kobayashi Score (Youden index 0.49).

**Table 1. List of criteria included in both scores assessed in the study.**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>The Kobayashi Score</th>
<th>PIMS IVIG Resistance Score (PIRS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium</td>
<td>≤133 mmol/L</td>
<td>≤137 mmol/L</td>
</tr>
<tr>
<td>Days of illness at initial treatment</td>
<td>≤2 points</td>
<td>≤2 points</td>
</tr>
<tr>
<td>Aspartate aminotransferase</td>
<td>≤100 IU/L</td>
<td>≤100 IU/L</td>
</tr>
<tr>
<td>Percentage of neutrophils</td>
<td>≥80%</td>
<td>2 points</td>
</tr>
<tr>
<td>Percentage of lymphocytes</td>
<td>≤16%</td>
<td>1 point</td>
</tr>
<tr>
<td>Procalcitonin</td>
<td>≤3.5 μg/mL</td>
<td>≤3.5 μg/mL</td>
</tr>
<tr>
<td>Platelet count</td>
<td>≤300 G/L</td>
<td>≤300 G/L</td>
</tr>
<tr>
<td>Increased risk of resistance to IVIG</td>
<td>≤4</td>
<td>≤4</td>
</tr>
</tbody>
</table>

**Conclusion:** The Kobayashi Score is worth being considered to estimate the risk of resistance to IVIG in PIMS patients. Nonetheless, it is not free from false positive and false negative results. The postulated modified score called PIRS can become a promising alternative but it requires further validation in larger cohorts of patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3771
Background: Juvenile Idiopathic Arthritis (JIA) is a group of heterogeneous arthritis with onset earlier than 16 years old. According to previous studies, these patients experience an improvement of their disease activity, functionality and even remission probability as they become young adults.[1] Transitional care units during the COVID-19 pandemic skipped the sufficient physical activity (p=0.03352). Correlation between elevated ESR and higher cIMT values in right carotid artery was marginally significant (r=0.292, p=0.051443). Regardless of JIA, exposure to secondhand smoke exposure, needs to be promoted with utmost importance during the COVID-19 pandemic, especially in children with chronic diseases like JIA.

REFERENCES:

Disclosure of Interests: None declared

Table 1. Demographic data from JIA included in the study, divided according to disease activity at the transferece to our transitional care unit.

<table>
<thead>
<tr>
<th>Total (n: 127)</th>
<th>Actives (n:34)</th>
<th>Not actives (n:93)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (female) n (%)</td>
<td>84 (66.1)</td>
<td>24 (70.6)</td>
</tr>
<tr>
<td>Age median (IR)</td>
<td>8.64 (3-13)</td>
<td>9.1 (3-13)</td>
</tr>
<tr>
<td>Previous joint flares (n%)</td>
<td>43 (33.9)</td>
<td>16 (47.1)</td>
</tr>
<tr>
<td>sDMARD prior transference n (%)</td>
<td>98 (76.6)</td>
<td>26 (76.5)</td>
</tr>
<tr>
<td>bDMARD prior transference n (%)</td>
<td>79 (61.7)</td>
<td>20 (58.8)</td>
</tr>
<tr>
<td>Uveitis n (%)</td>
<td>23 (18.1)</td>
<td>8 (23.5)</td>
</tr>
<tr>
<td>JIA subcategory n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>oligo persist</td>
<td>43 (33.9)</td>
<td>12 (35.3)</td>
</tr>
<tr>
<td>oligo extend</td>
<td>16 (12.6)</td>
<td>3 (8.8)</td>
</tr>
<tr>
<td>poly RF +</td>
<td>25 (19.7)</td>
<td>6 (17.6)</td>
</tr>
<tr>
<td>poly RF</td>
<td>3 (2.4)</td>
<td>1 (2.9)</td>
</tr>
<tr>
<td>ERA</td>
<td>24 (18.9)</td>
<td>8 (23.5)</td>
</tr>
<tr>
<td>systemic</td>
<td>9 (7.1)</td>
<td>2 (5.9)</td>
</tr>
<tr>
<td>psoriatic</td>
<td>7 (5.5)</td>
<td>2 (5.9)</td>
</tr>
</tbody>
</table>

We calculated the percentage of patients who had active disease at the transference to the Unit and the percentage of patients who had an inflammatory flare during the follow-up. Figures 1 and 2 showed the proportion of flares depending on the inflammatory status at transference to the Transitional care unit and the use of biological therapy before transition.

Disclosure of Interests: None declared
RISK OF CORONARY ARtery INVOLVEMENT IN KAWASAKI DISEASE.

S. Kurbanova1, M. Kantemirova1, Y.Y. Novikova1, D. Ovsyannikov1. 1RUDDN University, Department of Pediatrics, Moscow, Russian Federation

Background: Kawasaki disease (KD) is a non-specific systemic vasculitis disease that frequently occurs among children, and coronary artery lesion (CAL) is the most serious complication.

Objectives: We aimed to study the risk factors for CAL in children with KD

Methods: There were examined 188 patients (boys-girls – 2:1, median age Me = 24 months [11;38] with KD hospitalized in Morozovskaya Children’s City Clinical Hospital in 2014-2019. 19 (10,1%) of them were <6 months, 29 (15,4%) - 6-12 months, 117 (62,3%) - 12 months-<5 years, 23 (12,2%) - >5 years. Univariate and multivariate logistic regression analyses were conducted to explore the relationships between CAL and gender, age, clinical diagnosis, laboratory biomarkers, initiation time of IVIG administration.

Results: The enrolled 188 KD children were divided into a CAL group (n = 61) and an NCAL group (n = 127) according to cardiac color Doppler ultrasonography. The incidence rate of CAL in the acute period was 26 %. The two groups had significantly different gender (p=0,0184), initiation time of IVIG administration (p=0,0209), increase in platelets more than 700 000 at 2 weeks (p=0,0089), higher levels of NT-proBNP (p=0,002) and proANP (p=0,0005). Patients with CAL were found to have higher levels of NT-proBNP and proANP, suggesting a prognostic role. The NT-proBNP level was significantly higher in patients with CAL, and a cutoff value of 984 pg/mL yielded a sensitivity and specificity of 79 and 84.8 %, respectively. The area under the curve of the NT-proBNP for predicting CAL was 0.794 (95 % CI 0.620-0.967). The proANP level was significantly higher in patients with CAL, and a cutoff value of 1.05 mmol/l yielded a sensitivity and specificity of 78.5 and 75.8 %, respectively. The area under the curve of the proANP for predicting CAL was 0.805 (95 % CI 0.656-0.954).

Conclusion: Male gender, delayed use of IVIG, high platelets, NT-proBNP, proANP were independent risk factors for KD complicated with CAL. Current evidence suggests that NT-proBNP and proANP may be used as a diagnostic tool for KD complicated with CAL.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3855

SAFETY AND EFFICACY OF RITUXIMAB IN PATIENTS WITH JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS: THE PRELIMINARY DATA OF RETROSPECTIVE COHORT STUDY

E. Kalashnikova1, R. Raupov1,2, N. Lybimova3, E. Kuchinskaya3, O. Kalashnikova1, V. Chazryn1, K. Konshina1, L. Sniegireva1, E. Gaidar1, V. Masalova1, E. Isupova1, M. Kaneva1, M. Dubko1, T. Likacheva1, L. Sorokina1, M. Kostik1,3, Saint-Petersburg State Pediatric Medical University, Pediatrics, Saint Petersburg, Russian Federation; 2City Hospital №40, Medical Rehabilitation of Children, Saint Petersburg, Russian Federation; 3Almazov National Medical Research Centre, Laboratory of Autoimmunity and Autoinflammatory Diseases, Saint Petersburg, Russian Federation

Background: juvenile systemic lupus erythematosus (SLE) is the most frequent pediatric connective tissue disease with multorgan involvement and different outcomes and prognosis. Corticosteroids remain the base treatment option and steroid-sparing treatment is strongly required to avoid steroid toxicity. Rituximab (RTX) is one of biologics, which efficacy was proved in case reports and case series of SLE, but no data from big randomized trials, confirming the efficacy have existed.

Objectives: to evaluate safety and efficiency of RTX in SLE

Methods: in the retrospective observation study the information of 48 jSLE patients (12 boys, 36 girls) who received at least one RTX dose before 18 years, was analyzed. RTX were high disease activity with lupus nephritis (LN), CNS and hematology disturbance. Randomized controlled trials are required to evaluate the efficacy and safety of RTX.

Results: The main patient's characteristics were: onset age 13.0 (11.5; 15.0) years, with 46 (96%) children treated for at least one SLE feature (SLEDAI, anti-dsDNA level, proteinuria, hematuria, C4, ESR), number of patients with anemia, thrombocytopenia, and median GCS dose by 90% from the initial. The hemoglobin level and WBC have increased. 19 patients received IVIG for treatment of MAS (n=3), infection (n=5) and as replacement therapy in cases where IgG<4.5 g/l (n=11). 3 deaths were observed due to catastrophic SLE with MAS, accompanied severe infection (invasive aspergillosis, n=2), 6 patients realized SAE: pneumonia (n=3), transient agranulocytosis, C4, ESR after 3rd RTX infusion and meningitis, caused by Lysteria monocytogen, after 1st RTX infusion (further RTX treatment continued without adverse events), patella osteomyelitis (n=1). 10 patients received antibiotics for respiratory infections. On pre-RTX 13 had antibiotics (p=0,10).

Table 1. Dynamics of SLE features pre-RTX and during RTX trial

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SLE onset</th>
<th>RTX (baseline)</th>
<th>p</th>
<th>Last visit</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLEDAI</td>
<td>16 (11; 23.5)</td>
<td>13.5 (6.5; 21.5)</td>
<td>0.0002</td>
<td>4 (8; 6)</td>
<td>0.00002</td>
</tr>
<tr>
<td>Patients with elevated anti-dsDNA n (%)</td>
<td>33 (69)</td>
<td>36 (42)</td>
<td>0.008</td>
<td>11 (23)</td>
<td>0.034</td>
</tr>
<tr>
<td>Proteinuria, g/l</td>
<td>2.6 (0.8; 4.4)</td>
<td>3.8 (0.3; 7.5)</td>
<td>0.004</td>
<td>0 (0; 0.2)</td>
<td>0.004</td>
</tr>
<tr>
<td>Hematoma, f cells</td>
<td>40 (8; 86)</td>
<td>50 (6; 120)</td>
<td>0.191</td>
<td>0 (10)</td>
<td>0.0016</td>
</tr>
<tr>
<td>C4, g/l</td>
<td>0.12 (0.01; 0.12)</td>
<td>0.098 (0.15; 0.21)</td>
<td>0.16</td>
<td>0.24</td>
<td>0.0001</td>
</tr>
<tr>
<td>Patients with leukopenia, n (%)</td>
<td>12 (25)</td>
<td>10 (22)</td>
<td>0.062</td>
<td>5 (10)</td>
<td>0.00001</td>
</tr>
<tr>
<td>Patients with anemia</td>
<td>19 (40)</td>
<td>16 (33)</td>
<td>0.09</td>
<td>7 (15)</td>
<td>0.005</td>
</tr>
<tr>
<td>Hemoglobin, g/l</td>
<td>113 (95; 131)</td>
<td>115 (91; 132)</td>
<td>0.630</td>
<td>128 (107; 134)</td>
<td>0.063</td>
</tr>
<tr>
<td>Patients with thrombocyto- penia n (%)</td>
<td>17 (35)</td>
<td>9 (19)</td>
<td>0.005</td>
<td>2 (4)</td>
<td>0.00001</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>17 (8; 31)</td>
<td>15 (7; 22)</td>
<td>0.134</td>
<td>7 (2; 20)</td>
<td>0.054</td>
</tr>
<tr>
<td>Patients with GCS therapy n (%)</td>
<td>45 (94)</td>
<td>45 (94)</td>
<td>10</td>
<td>40 (83)</td>
<td>0.0001</td>
</tr>
<tr>
<td>GCS, mg/kg</td>
<td>1.0 (0.6; 1.0)</td>
<td>0.75 (0.2; 1.0)</td>
<td>0.035</td>
<td>0.1 (0.08; 0.28)</td>
<td>0.00001</td>
</tr>
</tbody>
</table>

*compare to RTX baseline

Conclusion: RTX showed effectiveness in the cases, where previous non-biologic treatment was insufficiently effective. Randomized controlled trials are required to evaluate the efficacy and safety of RTX.

Acknowledgements: This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2020-901)

Disclosure of Interests: None declared


FEATURES OF MACROPHAGE ACTIVATION SYNDROME IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN THE ERA OF BIOLOGIC THERAPY

I. Kruilin1, E. Alexeeva1, T. Dvoryakovskyak2, R. Denisova1, A. Chomakhidze2, A. Mamutova1, O. Lomakina1, A. Feltskina1, M. Gautier2, K. Chibisova1, E. Krekhova1, I. Tsulukiya1, 1Sechenov University, Pediatrics, Moscow, Russian Federation; 2National Medical Research Center of Children’s Health, Rheumatology, Moscow, Russian Federation

Background: Macrophage activation syndrome (MAS) is a severe hyperinflammatory response that develops against the background of juvenile idiopathic arthritis (JIA). It is known that the clinical feature of MAS on biologic therapy has other clinical manifestations, different from biologically naive patients.

Objectives: To study the clinical and laboratory features of macrophage activation syndrome in patients with juvenile idiopathic arthritis with systemic onset (sJIA) on the biologic therapy.

Methods: The study included 100 patients with MAS (114 cases of MAS) who observed in the rheumatological department of the National Medical Research Center for Children’s health of Ministry of Health. All patients met the criteria for the diagnosis of sJIA and MAS. There were children in our study who did not receive biologic therapy – 84 (74%) cases, and children who had MAS in the biologic therapy – 30 cases (26%). The drugs are described as follows: tocilizumab – 7 cases (6%), canakinumab – 20 cases (17%), etanercept – 2 cases (2%), adalimumab – 1 case (1%). For pairwise intergroup comparisons of quantitative variables, the nonparametric Mann-Whitney test was used.

Results: In comparative analysis of biologic-naive and on biologic patients, the greatest differences were obtained for the following clinical manifestations: rash, lymphadenopathy, myalgia (p<0.05). Fever was the most common symptom in both groups and was present in almost all patients (99%). All patients had
Conclusion: On biologic patients may also develop MAS, which is often difficult to diagnose due to the poor clinical picture and low laboratory activity. In this case, hyperferritinemia remains as a highly specific marker of MAS.


Table 1. Laboratory data of patients with MAS.

<table>
<thead>
<tr>
<th>n</th>
<th>Reference values</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologic naive</td>
<td>Hemoglobin, g/l</td>
<td>120-145</td>
<td>96.50</td>
<td>61.00</td>
</tr>
<tr>
<td></td>
<td>White blood cells, 10^9/l</td>
<td>4-5.5</td>
<td>4.12</td>
<td>3.69</td>
</tr>
<tr>
<td></td>
<td>Platelets, 10^9/l</td>
<td>150-440</td>
<td>149.00</td>
<td>41.00</td>
</tr>
<tr>
<td></td>
<td>CRP, mg/l</td>
<td>0-5</td>
<td>111.56</td>
<td>7.54</td>
</tr>
<tr>
<td></td>
<td>Ferritin, ng/ml</td>
<td>14-124</td>
<td>4195.21</td>
<td>702.38</td>
</tr>
<tr>
<td></td>
<td>Albumin, g/l</td>
<td>35-85</td>
<td>29.00</td>
<td>16.10</td>
</tr>
<tr>
<td></td>
<td>ESR, mm/h</td>
<td>2-20</td>
<td>45.00</td>
<td>2.00</td>
</tr>
<tr>
<td></td>
<td>Albumin, g/l</td>
<td>35-85</td>
<td>29.00</td>
<td>16.10</td>
</tr>
</tbody>
</table>

Results: Corticosteroid-sparing control of inflammation was achieved in all patients. Adalimumab was discontinued after 50 (range 12–120) months after initiation of adalimumab. Duration of remission prior to discontinuing adalimumab was 42 (range 6 – 114) months. The mean duration of remission after adalimumab discontinuation was 14 (range 1–59) months. 13 (40%) of patients had flares after less than 12 months after discontinuing adalimumab, 5 (15%) had flares after 12 – 24 months, 15 (45%) had not flared after 24 months after discontinuation adalimumab and had had a long-term non-biological remission.

Conclusion: Corticosteroid-sparing control of inflammation was achieved in all patients. Data from our experience with adalimumab in patients with JIA-associated uveitis suggest that 45 % of patients can be successfully withdrawn from biologics for at least 24 months without disease recurrence.


Disclosure of Interests: Irina Tsulukiya: None declared, Ekaterina Alexeeva Speakers bureau: Speaker for Roche, AbbVie, Bristol-Myers, Squibb, MSD, Novartis and Pfizer, Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Agen and Novartis, germany; Tatjana Dvoryakovskaya Speakers bureau: Speaker for Roche, Abb-Vie, Bristol-Myers-Squibb, MSD, Novartis and Pfizer, Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Agen and Novartis, Tatjana Dvoryakovskaya Speakers bureau: Speaker for Roche, Abb-Vie, Bristol-Myers Squibb, MSD, Novartis and Pfizer, Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Agen and Novartis, Anna Mamutova Speakers bureau: Speaker for Novartis, Elizaveta Krehkova Speakers bureau: Speaker for Novartis, Irina Tsulukiya: None declared, Anna Mamutova Speakers bureau: Speaker for Novartis, Elizaveta Krehkova Speakers bureau: Speaker for Novartis, Maria Botova: None declared, Ivan Kriulin Speakers bureau: Speaker for Novartis.

Table 1. Laboratory data of patients with MAS.

<table>
<thead>
<tr>
<th>n</th>
<th>Reference values</th>
<th>Median</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mann-Whitney Criterion (p)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biologic naive</td>
<td>Hemoglobin, g/l</td>
<td>120-145</td>
<td>96.50</td>
<td>61.00</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>White blood cells, 10^9/l</td>
<td>4-5.5</td>
<td>4.12</td>
<td>3.69</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Platelets, 10^9/l</td>
<td>150-440</td>
<td>149.00</td>
<td>41.00</td>
<td>0.025</td>
</tr>
<tr>
<td></td>
<td>CRP, mg/l</td>
<td>0-5</td>
<td>111.56</td>
<td>7.54</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>Ferritin, ng/ml</td>
<td>14-124</td>
<td>4195.21</td>
<td>702.38</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td>Albumin, g/l</td>
<td>35-85</td>
<td>29.00</td>
<td>16.10</td>
<td>0.03</td>
</tr>
<tr>
<td>On biologic naive</td>
<td>Hemoglobin, g/l</td>
<td>120-145</td>
<td>96.50</td>
<td>61.00</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>White blood cells, 10^9/l</td>
<td>4-5.5</td>
<td>4.12</td>
<td>3.69</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td>Platelets, 10^9/l</td>
<td>150-440</td>
<td>149.00</td>
<td>41.00</td>
<td>0.025</td>
</tr>
<tr>
<td></td>
<td>CRP, mg/l</td>
<td>0-5</td>
<td>111.56</td>
<td>7.54</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>Ferritin, ng/ml</td>
<td>14-124</td>
<td>4195.21</td>
<td>702.38</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td>Albumin, g/l</td>
<td>35-85</td>
<td>29.00</td>
<td>16.10</td>
<td>0.03</td>
</tr>
</tbody>
</table>

Background: Uveitis is the most common extra-articular manifestation of JIA which may lead to sight-threatening ocular complications. Topical corticosteroids are still used in the initial treatment for JIA-associated uveitis. The goal of treatment in these patients should be topical corticosteroid-free remission and prevention of recurrences. The most commonly used corticosteroid-sparing immunomodulatory are TNF-α inhibitors (TNIFI), especially adalimumab.

Methods: Medical records of 33 patients with JIA-associated uveitis who were successfully treated with adalimumab to a state of topical corticosteroid-free remission and discontinued adalimumab due to a long-term remission were ana-

ized retrospectively.

Remission of uveitis was defined as <1+ cells in the anterior chamber and <1+ vitreous haze grading; relapse was defined as ≥1 cell in the anterior chamber or ≥1 vitreous haze grading.[1]

Results: Corticosteroid-sparing control of inflammation was achieved in all patients. Adalimumab was discontinued after 50 (range 12–120) months after initiation of adalimumab. Duration of remission prior to discontinuing adalimumab was 42 (range 6 – 114) months. The mean duration of remission after adalimumab discontinuation was 14 (range 1–59) months. 13 (40%) of patients had flares after less than 12 months after discontinuing adalimumab, 5 (15%) had flares after 12 – 24 months, 15 (45%) had not flared after 24 months after discontinuation adalimumab and had had a long-term non-biological remission.

Disease was successfully controlled in 11(33%) patients with non-biological DMARDs, 22 (66%) patients restarted biological therapy after flares, due to lack of improvement after non-biological DMARDs. All patients in whom biological therapy was reinstituted responded satisfactorily. None of the flared patients didn’t require restarting corticosteroids.

Conclusion: Corticosteroid-sparing control of inflammation was achieved in all patients. Data from our experience with adalimumab in patients with JIA-associated uveitis suggest that 45 % of patients can be successfully withdrawn from biologics for at least 24 months without disease recurrence.

Background: Although regular physical activity (PA) is known to have many health-related benefits for children and adolescents with chronic conditions, JIA has been associated with reduced physical activity (PA) and increased time spent sedentary [1]. Sedentary behaviour is an important consideration alongside PA when examining the contribution of both behaviours to the health of young patients. Because young people show more complex but less structured movement behaviour than adults, capturing their many spontaneous and impulsive movements is a great challenge for PA assessment.

Objectives: Since accurate, objective measures of PA related to potential factors promoting PA have been scarce, this study aimed i) to objectively assess moderate to vigorous PA (MVPA) as well as sedentary behaviour and ii) to identify facilitators for PA in patients with JIA.

Methods: Within the framework of the ActiMON study as part of the TARISIMA research network, data were collected at several German paediatric rheumatology centres. Objectively assessed PA of adolescent patients with JIA was recorded exclusively during school months in the period June - December 2021 using the accelerometer ActiGraph wGT3X-BT laterally on the right hip. In accordance with the International Children’s Accelerometry Database criteria [2], ActiGraphs were worn on seven consecutive days during all waking hours, including at least 4 valid weekdays and 1 weekend day (wear time >8 hours) in the evaluation. Self-reported PA-related data were measured using a physical activity questionnaire (PAQ), while clinical parameters were used from the National Paediatric Rheumatologic Database (NPRD). Achievement of the WHO recommendation of at least 60 minutes MVPA a day and compliance with the national recommendation of no more than 120 minutes of daily screen time were determined among 12- to 18-year-olds.

Results: Data of 41 patients (mean age 14.6 ± 1.9 years, female 73%, patients’ disease duration 79 ± 4.6 years, polyarthritis 40%, cJADAS-10 2.3 ± 2.4) were available for evaluation. Almost 71% of participating patients met the WHO-recommended minimum level of MVPA, while the average daily step count achieved was 7804. Almost 80% of the patients rated their motor and coordination skills as being good. The most frequently mentioned reasons for doing sports (multiple answers possible) included feeling good (78%), giving energy (70%), pleasure (65%) and enjoyment (60%). Patients whose parents are active in sports and support their child in finding a suitable offer were more likely to fulfil the WHO recommendation than patients without family support. The average daily time spent sedentary was 10.5 ± 1.9 hours. About half of the patients reported spending more than 4 hours a day with screen-based media, especially video games.

Conclusion: These preliminary results suggest that while a large proportion of patients achieve the WHO recommended minimum level of PA, they exhibit very pronounced sedentary behaviour with increased screen use. In addition to controlled sports activity as a well-known prerequisite for achieving PA recommendations, these findings also point to the importance of family support and emotional well-being. With ongoing recruitment, further potential facilitators and barriers to PA should be identified in more in-depth analyses.

REFERENCES:

Disclosure of Interests: Florian Milatz: None declared, Ralf Trauzeddel: None declared, Tilman Kallinich: None declared, Moritz Klaas: None declared, Hermann Girschick: None declared, Sandra Hansmann: None declared, Gerd Hornhoff: None declared, Daniel Windschall: None declared, Abbvie, Medac, Sobi, Canon, Johannes-Peter Haas: None declared, Nadja Baumeister: None declared, Kirsten Minden: None declared, Pfizer; Novartis


Figure 1. Two different patients with severe FOP and similar evidences of sacroiliitis and bilateral hips synovitis by MRI

POS1324 THE IMPORTANCE OF MRI IMAGING FOR THE MANAGEMENT AND UNDERSTANDING OF THE DISEASE ORIGIN IN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

I. Nikishina1, S. Arsenyeva1, V. Matkava1, M. Kaleda1, T. Pachkoria1, A. Arefeva1,1 VA. Nasonova Research Institute of Rheumatology, Paediatric, Moscow, Russian Federation

Background: Fibrodysplasia ossificans progressive (FOP) is ultra-rare autosomal dominant inherited genetic disorder which is caused by mutation in ACVR1 gene and provokes severe heterotopic ossification (HO) as a “second skeleton disease.” Our long-term experience of the largest group of FOP patients in single Russian center makes possible to interpretate clinical findings and imaging as the evidences that FOP may belong to special kind of axial spondyloarthritides. Because of new bones formation process X-Ray and CT scans recognize as the main imaging methods for the FOP. But MRI method may present important information for the understanding of the disease origin in FOP.

Objectives: To analyze the MRI findings in FOP patients in relation to clinical manifestations, and therapy options.

Methods: The study was based on retrospective and prospective observation and included 40 pts (21 males; 19 females). Diagnosis of FOP was established on typical clinical features and detecting mutation. X-ray, CT and MRI were performed in most patients excluding the severe disabled status of FOP. Some patients failed to perform MRI due to the presence of severe skeletal deformities or artificial metal constructions (because of previous orthopedic operations). Blood assessment has never shown specific elevated markers.

Results: Among of all 40 FOP patients MRI of sacroiliac joints was performed in 14 patients. Chronic sacroiliitis was detected in 10/14 pts, including active sacroiliitis in STIR regimen in 6/14 pts by. Also 7/14 pts have MRI evidence of severe coxitis (see Figure 1). This imagines findings and other features of axial involvement (X ray imagines of ankylosis of the facet joints and vertebral bodies by the type of syndesmophytes) allowed us to establish alternative diagnosis of juvenile spondyloarthritides (JAS) in 7 pts and juvenile idiopathic arthritis (JIA) in 5 cases. It was needed for the legal possibility to administer tocotocin (TOFA) in 12 pts (the youngest pt of 2 y.o., the oldest – 19 y.o) with strong uncontrolled progression of FOP. The dosage of TOFA was up to 5 mg twice a day. We noticed that all 12 pts have severe coxitis with synovia proliferation (with MRI and ultrasound evidence). Duration of TOFA therapy is from 2 to 25 months. Drug tolerance was good in all pts, no AE were registered. New nodes formation immediately stopped in most pts., significant improvement of motions was observed in 10 (83%) pts. Also, we noticed fast regression of sacroiliitis and coxitis activity by MRI in 5 (42%) pts under TOFA therapy. All other patients didn’t have repeated MRI examination yet. So MRI seems to be important method to confirm the anti-inflammatory effects for sacroiliitis and coxitis signs in patients with FOP. It seems to expect that inflammation control may prevent the sacroiliac and hip ankylosises. In spite of the absence of new HO in our 16 y.o. pt, we found continuous intraskeletal ossification between C3-C4, C5-C7 vertebral bodies, facet joints that leads to subtotal stenosis of spinal canal without any neurological symptoms. Because of «protection effect» of external heterotopic ossification severe neurological damage was not developed.
Conclusion: According to MRI findings, hip damage was characterized for all ages of FOP patients. Sacroiliitis was found mostly in patients older than 10 years. Based on our experience of JAK-inhibitor therapy we can suggest about positive effect and advantages of TOFA over other therapy approaches. Dynamics of MRI imaging may be a good option for the confirmation of therapeutic anti-inflammatory effects.

Disclosure of Interests: None declared

POS1325

CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS (CRMO): NEW INSIGHTS INTO EXTRA-OSSEOUS MANIFESTATIONS.

M. Robert1, C. Guillaume2, L. Rossi-Semerano1, C. Galeotti1, I. Koné-Paut4, P. Dusser1, 1Kremlin-Bicêtre, Service de Rhumatologie Pédiatrique, Le Kremlin-Bicêtre, France

Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare inflammatory disease of the skeleton characterized by chronic and recurrent episodes of osteo-articular inflammation. The median age of onset is 10 years old. Clinical manifestations include musculoskeletal symptoms that are well described (pain, tenderness, swelling). Sometimes, skin lesions or digestive manifestations occur. Whole body magnetic resonance imaging (MRI) is the gold standard for assessing the multifocal pattern of the CRMO. Treatment is still empirical and mainly relies on non-steroidal anti-inflammatory drugs (NSAIDs). Bisphosphonates and biologics are used as second-line treatments. To date, the focus has been on bone involvement and very few data are available on extra-osseous manifestations in CRMO.

Objectives: This study aims to further describe these extra-osseous clinical manifestations in CRMO.

Methods: A historical cohort was designed using 61 CRMO patients at the Pediatric Rheumatology Department in a tertiary university hospital in Paris (Hôpital Bicêtre, France). All patients underwent a MRI that confirmed the diagnosis according to the criteria of Jansson. Skeletal involvement was characterized with 1/axial, 2/peripheral, 3/axial and peripheral lesions. Extra-osseous manifestations were divided into 1/skin lesions, 2/gastro-intestinal manifestations, 3/enthesitis and 4/others. Pain was evaluated thanks to the Visual Analog Scale (VAS, from 0 to 10). Treatments used were recorded. The study complied with ethical requirements.

Results: Forty one patients were included in the study, with 31 females (75.6%). The mean ± SD age at onset was 79 ± 59.8 months, with a delay at diagnosis beyond six months (6.71 ± 6.96). Twenty-one patients had a familial history of inflammatory diseases (51.2%), with a majority of psoriasis or ankylosing spondylitis (n=13/21, 61.9%). At diagnosis, the level of pain was 5.71 ± 3.24. Eleven patients (42.3%) had blood injection. Bone lesions were reviewed thanks to whole body MRI: four patients had isolated axial involvement (10.0%), nine had peripheral involvement (22.5%) and 27 patients harbored both types of lesions (67.5%). The mean number of lesions was 6.65 ± 4.23. After 12 months of follow-up, all parameters regarding disease’s activity decreased (pain, blood inflammation, number of lesions). Regarding extra-osseous symptoms, fever occurred in seven patients (17.1%). Twenty-four patients had skin manifestations (58.5%) with palmoplantar lesions (n=3, 12.5%), acne (n=6, 25.0%), psoriasis (n=5, 20.8%) and aphthous (n=10, 41.7%). Four patients (9.76%) had gastro-intestinal symptoms and seven (17.1%) had enthesitis. One patient had uveitis. Almost all patients received NSAIDs (n=39/41, 95.1%) and half of the cohort were treated with bisphosphonates (n=21/41, 51.2%). Nine patients (22.0%) received biologics with a majority of TNF inhibitors. All patients that received TNF inhibitors had either a cutaneous involvement or digestive symptoms or enthesitis (Figure 1).

Conclusion: Extra-osseous manifestations have to be carefully searched in CRMO, especially in the presence of familial history of inflammatory diseases. While the severity of bone involvement can lead to use bisphosphonates, the introduction of biologicals seems to rely on extra-osseous symptoms. These conclusions are drawn on a retrospective study and need to be confirmed in larger cohort.

REFERENCES:

Disclosure of Interests: None declared

POS1326

PIMS THROUGH THE WAVES OF COVID 19: DATA FROM THE JIR COHORT

R. Kechiche1, A. Schwart2, F. Bajolle2, S. Poignant1, R. Basmaci1, C. Pajo2, U. Meiner3, L. Morin1, V. Lambert2, P. Dusser1, N. Matsu1, M. Hofer3, I. Koné-Paut4, G. Caroline1 on behalf of the French Covid-19 Paediatric Inflammation Consortium. 1CHU Bicêtre, Pediatric Rheumatology, Le Kremlin Bicêtre, France; 2CHU Necker, Pediatric Cardiology, Paris, France; 3CHU Nantes, Pediatrics, Nantes, France; 4CHU Louis Mourier, Pediatrics, Colombes, France; 5CHU Toulouse, Pediatric Rheumatology, Toulouse, France; 6CHU Robert Debré, Pediatrics, Paris, France; 7CHU Bicêtre, Pediatric Intensive Care Unit, Le Kremlin Bicêtre, France; 8CHU Bicêtre, Pediatric radiology, Le Kremlin Bicêtre, France; 9CHU Pediatric Rheumatology, Lausanne, Switzerland

Background: Paediatric inflammatory multisystem Syndrome (PIMS) is a new systemic inflammatory disease linked to SARS-CoV2 that affects children. It was first reported in may 2020 [1-2].

Objectives: The objectives of this study were to describe patients with PIMS through the international JIR cohort registry and to compare the different profiles and treatments of these patients over the different waves.

Methods: Study patients with international PIMS criteria were included from March 2020 to June 2021. Patients were identified in the JIR cohort, an international registry collecting demographic, clinical and paraclinical data on patients with pediatric inflammatory diseases. Two groups were distinguished: from March 2020 to July 2020 for patients in the first wave, from July 2020 to June 2021 for patients in the 2nd and 3rd waves. These two groups were compared using a Fisher test for categorical data and a Mann-Whitney test for quantitative data.

Results: 136 patients meeting the PIMS criteria were included (64 patients in the 1st wave, 72 patients after). Patients had less frequent myocarditis (51 patients in wave 1 vs. 36 patients after, p=0.0003) and respiratory distress (34 patients vs 10 patients, p=0.0001). Corticosteroids were used more frequently in the second wave (32 patients in wave 1 vs. 36 patients after, p=0.0003) and respiratory distress (34 patients vs 10 patients, p=0.0001). Intravenous immunoglobulins were used more frequently in the second wave (32 patients in wave 1 vs. 67 patients after July 2020, p<0.0001). Intravenous immunoglobulins were used as much over the waves (58 patients in wave 1 vs 68 patients after, p=0.5). Antibiotics were less used since the second wave (53 patients received antibiotics before July 2020 vs 11 after, p=0.0001). The duration of hospitalization decreased significantly (p<0.0001) with a median duration of 9 days during the first wave (interquartile range, 7-12) and 7 days (interquartile range, 5-10) after the first wave.

Conclusion: There was a decrease in the number of complications of PIMS, particularly cardiac and respiratory complications, and a decrease in the length of hospitalization over time. The treatment of PIMS has also evolved, with a clear increase in the use of corticosteroids and a decrease in the use of antibiotics.

REFERENCES:


Disclosure of Interests: None declared
OTHER ORPHAN DISEASES

**POS1327**

**AMYLOID STORM DEVELOPS IN PATIENTS WITH AA AMYLOIDOSIS AND ASSOCIATED WITH HIGHER AMYLOID BURDEN AND INCREASED MORTALITY**

M. Bektaş1, S. San1, N. Koca1, E. Oğuz1, B. Ince1, Y. Yağıcak1, B. Artim-Esen1, M. İnanç1, A. Gül1, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

**Background:** Amyloid storm is an emerging condition which was described recently also associated with poor prognosis in patients (pts) with AA amyloidosis (AA-a).

**Objectives:** We herein aimed to evaluate the amyloid storm and its associated factors in pts with AA-a.

**Methods:** We retrospectively evaluated AA-a pts who followed in our tertiary referral amyloidosis center. Diagnosis of AA-a was made by Congo red straining and immunohistochemistry. Amyloid storm was defined as follows; developing within two weeks, increase in creatinine and proteinuria levels at least two times from baseline or reach the CRP levels more than 10 times [1].

**Results:** Data of 175 pts with AA-a were evaluated and after exclusion of 11 pts who had missing data, 164 pts were included into the analysis. We identified 9 pts (5.5% of 4 male) who developed amyloid storm. Five pts were FMF-associated AA-a (FMF-AA) and 4 pts were non-FMF-AA (two pts had ankylosing spondylitis, one patient idiopathic and one patient non-FM periodic fever syndrome) (p=0.1). Median and Interquartile range (IQR) patient age, diagnosis age of FMF and amyloidosis were lower in pts had amyloid storm than had not, but they were not statistically different (p=0.2, p=0.3 and p=0.2 respectively). All pts were M694V homozygous among FMF-AA. Etiology of amyloid storm was infection in 5 pts (56%), treatment non-adherence in 3 pts (33%) and surgery in one patient (11%).

Overall, 3 pts with amyloid storm died (33%), but mortality was 10% (n=16) in the remaining pts with AA-a. One patient died during the amyloid storm, and others died within one year after the diagnosis of amyloid storm (median 5 months). In univariable analysis, involvement of ≥3 organs, bone marrow involvement and current proteinuria levels (p=0.4, p=0.05 and p=0.04, respectively) were higher; median number of organ involvement and mortality (p=0.09 and p=0.07) were tended to be higher in pts with amyloid storm than those without it. End stage renal disease (ESRD) development was also higher in pts who had amyloid storm (67%; n=6) than in pts who had not (46 % n=71) but did not reach statistical significance (p=0.3). Median±IQR CRP (48±77 vs 9±17 p=0.08), creatinine (4.8±5 vs 1.2±0.6 p=0.01) and proteinuria (11±12 vs 0.85±2.3 p=0.02) levels were higher during the amyloid storm than their previous records. In multivariable analysis, involvement of ≥3 organs, bone marrow involvement and current proteinuria levels (p=0.4, p=0.05 and p=0.04, respectively) were higher; median number of organ involvement and mortality (p=0.09 and p=0.07) were tended to be higher in pts with amyloid storm than those without it. End stage renal disease (ESRD) development was also higher in pts who had amyloid storm (67%; n=6) than in pts who had not (46 % n=71) but did not reach statistical significance (p=0.3). Median±IQR CRP (48±77 vs 9±17 p=0.08), creatinine (4.8±5 vs 1.2±0.6 p=0.01) and proteinuria (11±12 vs 0.85±2.3 p=0.02) levels were higher during the amyloid storm than their previous records. In multivariable analysis, amyloid storm was associated with higher mortality (p=0.045 OR 4.6; 95% CI 1.03-20). In survival analysis, development of amyloid storm tended to be higher in pts with non-FMF-AA compared to FMF-AA (Log-rank p=0.057). Mortality rate was higher in pts who had amyloid storm than those without it (Log-rank p=0.038).

**CONCLUSION:** This study showed that 5.5% of pts with AA-a may develop amyloid storm, and this condition was associated with higher amyloid burden. Amyloid storm may develop in AA-a pts associated with both FMF and other diseases, and the mortality rate may reach to 33% within one year.

**REFERENCES:**

[1] Kukuy et al. (2021), Rheumatology, 60(7), 3235–3242

---

**Table 1. Comparison of clinical and laboratory features of pts with and without amyloid storm**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Amyloid storm (n=9)</th>
<th>Control (n=155)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>37±10</td>
<td>45±20</td>
<td>0.2</td>
</tr>
<tr>
<td>Gender: male</td>
<td>4 (44)</td>
<td>86 (56)</td>
<td>0.7</td>
</tr>
<tr>
<td>FMF</td>
<td>5 (4)</td>
<td>122 (96)</td>
<td>0.1</td>
</tr>
<tr>
<td>non-FMF</td>
<td>4 (11)</td>
<td>33 (89)</td>
<td></td>
</tr>
<tr>
<td>Renal</td>
<td>9 (100)</td>
<td>152 (98)</td>
<td>1</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>4 (44)</td>
<td>33 (21)</td>
<td>0.1</td>
</tr>
<tr>
<td>Heart</td>
<td>26 (33)</td>
<td>32/111 (29)</td>
<td>1</td>
</tr>
<tr>
<td>Liver</td>
<td>1 (11)</td>
<td>5 (3)</td>
<td>0.3</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>2 (22)</td>
<td>5 (3)</td>
<td>0.05</td>
</tr>
<tr>
<td>Diagnosis age of FMF</td>
<td>17±30</td>
<td>24±20</td>
<td>0.3</td>
</tr>
<tr>
<td>Diagnosis age of AA-a</td>
<td>29±26</td>
<td>31±22</td>
<td>0.2</td>
</tr>
<tr>
<td>Duration of AA-a</td>
<td>10±14.6</td>
<td>11.2±11.1</td>
<td>1</td>
</tr>
<tr>
<td>Number of organ involvement</td>
<td>2±2</td>
<td>1±1</td>
<td>0.09</td>
</tr>
<tr>
<td>≥3 organ involvement†</td>
<td>3±5 (60)</td>
<td>20±122 (16)</td>
<td>0.04</td>
</tr>
<tr>
<td>Baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP*</td>
<td>10±8</td>
<td>20±20</td>
<td>0.06</td>
</tr>
<tr>
<td>proteinuria (g/dL)*</td>
<td>5.3±4.3</td>
<td>4±5.7</td>
<td>0.9</td>
</tr>
<tr>
<td>creatinine (mg/dL)*</td>
<td>0.8±6.0</td>
<td>0.8±6.0</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>2.7±5.2</td>
<td>2.7±7.3</td>
<td>0.7</td>
</tr>
<tr>
<td>proteinuria*</td>
<td>3.1±2.3</td>
<td>0±1.0</td>
<td>0.04</td>
</tr>
<tr>
<td>creatinine*</td>
<td>1.5±3</td>
<td>0±1.9</td>
<td>0.04</td>
</tr>
<tr>
<td>Two exon 10 MEVF variant</td>
<td>3 (100)</td>
<td>94 (87)</td>
<td>0.5</td>
</tr>
<tr>
<td>M694V homozygous (n=3, %)</td>
<td>3 (100)</td>
<td>73 (68)</td>
<td>0.2</td>
</tr>
<tr>
<td>ESRD development*</td>
<td>6 (67)</td>
<td>71 (63)</td>
<td>0.3</td>
</tr>
<tr>
<td>Mortality†</td>
<td>3 (33)</td>
<td>16 (10)</td>
<td>0.07</td>
</tr>
</tbody>
</table>

*median±IQR years †n, % mg/L

---

**DISCLOSURE OF INTERESTS:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular251

---

**POS1328**

**DO IL-1 ANTAGONISTS DEFINITELY PROTECT FROM THE DEVELOPMENT OF NEW DAMAGE: A SINGLE-CENTER STUDY**

D. Yıldırım1, R. C. Kardaş1, B. Ozkizitas1, I. Vasi1, H. Küçük1, M. A. Oztürk1, S. Haznedaroglu1, B. Goker1, A. Tutan1, Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey

**Background:** Ongoing inflammatory episodes of familial Mediterranean fever (FMF) disease can cause damage in nearly all organ systems. Colchicine and interleukin1β blocking agents are successfully used to control the disease activity [1]. Although the effect of IL-1 blockers are known for controlling disease activity and amyloidosis [2], it is unclear whether they prevent organ damage.

**Objectives:** In our study, we assessed the organ damage in patients with FMF treated with colchicine and IL-1 antagonists (IL-1A). It was evaluated whether new damage occurred after IL-1 antagonist treatment.

**Methods:** A total of 111 patients fulfilling Tel-Hashomer criteria and treated with IL-1A due to colchicine resistance were included in the study. All patients were also treated with colchicine with a maximum-tolerable dose. Patients were grouped according to their recent damage status (no damage, pre-existing damage, and damage developed under IL-1A treatment). The degree of damage was determined using Autoinflammatory Disease Damage Index (ADDI) and modified form of ADDI (mADDI) [3, 4].

**Results:** 44 patients (42,3%) had damage according to the modified ADDI (mADDI) index; three patients experienced new damage under IL-1 antagonist treatment while four patients showed progression of damage and mADDI score.

In patients with a positive mADDI score, the most common damage was amyloidosis (n=28, 63%), the second most frequent was musculoskeletal findings (N=14, 31%), and the third was infertility (N=2, 0,04%). The most common domains of FMF-related damage with IL-1 antagonist treatment were musculoskeletal (n=4), renal (n=2) and reproductive system (n=2)

**Conclusion:** Our study was the first study to evaluate the progression of damage in patients with FMF and treated with IL-1 antagonists. Although it is known that IL-1A is effective in colchicine-resistant patients, physicians should be aware that damage can still develop under IL-1A treatment.

**REFERENCES:**

Hence, the primary drivers were identified: lymphoma (n=8), non-HIV viral infections (n=9), first persistent inflammation (n=1), meningo-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.

Results: 30 patients (10 female) with sHLH were identified with a median age of 46, a mean H-score of 238 (range 186-317). 15 (50%) had pre-existing immu-

H-score of 169 or greater. P-values were calculated using the Mann-Whitney test, unpaired t-test or Fisher exact as appropriate.


**Background:** Although hypocomplementemia has been frequently reported in IgG4-related kidney disease (IgG4-RKD), few studies have investigated differences in the clinicopathological features of IgG4-RKD with and without hypocomplementemia in a relatively small cohort.[2]

**Objectives:** To compare the clinicopathological features of Japanese patients with and without hypocomplementemia in IgG4-RKD.

**Methods:** We retrospectively examined the clinicopathological features of IgG4-RKD in Japan, collected from the institutions associated with the IgG4-RKD working group between December 2010 and May 2019, with reference to the presence of hypocomplementemia.

**Results:** Among the patients included, 42 (70%) had hypocomplementemia. In the latter group, serum levels of IgG and non-IgG4 IgG, calculated as total IgG minus IgG4, were significantly higher (mean IgG level, 3832 vs 2626 mg/dl, p=0.005, mean non-IgG4 IgG level, 2775 vs 1827 mg/ml, p=0.000). Renal function at diagnosis tended to be lower (mean eGFR level 42.4 vs 53.6/ml/min, although not to a significant degree (p=0.07). There were no significant inter-group differences in the levels of serum IgG4 and IgG4, or in the number of extra-renal involved organs. Renal pathology specimens were obtained from 53 patients, 70% of whom had hypocomplementemia. In the hypocomplementemia group, light microscopy demonstrated a significantly broader extent of interstitial inflammatory cell infiltration (p=0.035), and immunofluorescence revealed a higher frequency of IgG or complement deposition on the renal tubular basement membrane (p=0.048). C1q deposition on the TBMs was evident only in the hypocomplementemia group. There was no significant inter-group difference in the presence of storiform fibrosis, the degree of interstitial fibrosis, the number of infiltrating IgG4-positive cells, or the frequency of membranous glomerulonephritis.

**Conclusion:** Hypocomplementemia in IgG4-RKD is associated with elevated levels of IgG subclasses other than IgG4, and may be related to progression of renal inflammation.REFERENCES:


[2] Fujisawa Y, et al. Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4, and may be related to progression of susceptibility factors for definitive discontinuation of CZP were analyzed as well. CZP RR was calculated with the Kaplan-Meier method, Log-rank test was used for the univariate, and the Cox proportional hazard model was implemented for the multivariate analysis.

**Results:** Thirty patients with a median of 41 (IQR 16) years, 18 (60%) females, were included. NIUs were bilateral in 19 (63%) patients and were active at CZP onset in 20 (71%). Half of the patients suffered from non-anterior NIUs, and etiologically 2 (7%) were unclassifiable, 7 (23%) had ocular syndromes, and 21 (70%) were associated to systemic disorders. Seven (23%) patients were biologic-naive, whereas 23 (77%) started CZP as a 2nd (5, 17%) or ≥ 3rd (18, 60%) biologic. With a median follow-up of 21.2 (Range 0.2 to 54.8) months, 12 (40%) patients discontinued CZP, 6 (20%) due to adverse events and 6 (20%) due to lack of efficacy. The overall CZP RR at 24 months was 53.6%, with a median Retention Time (RT) of 27.1 months. In the multivariate analysis, CZP started as a first biologic (HR 0.053, 95%CI 0.003 to 0.809; p = 0.035), and male gender (HR 0.1, 95%CI 0.015 to 0.694; p = 0.02) were protective factors for discontinuation. CZP RR at 24 months as a 1st line biologic was 100% with a median RT of 27.1 months. Conversely, CZP RR at 24 months as a ≥2nd line was 41.1% with a median RT of 17.1 months. When given as a 1st biologic, one (14%) patient discontinued CZP due to loss of efficacy at 27.1 months. Conversely, discontinuation of CZP when administered in ≥2nd line was more frequent, either due to lack of efficacy in 5 (22%) patients or adverse events (AEs) in 6 (26%) (Figure 1).

**Conclusion:** CZP in NIU showed an excellent retention rate at 24 months in biologic-naive patients. However, it was more than halved when CZP was started as a ≥2nd biologic. Discontinuation of CZP in bio-experienced patients was due to lack or loss of efficacy in 22% and to adverse events in an additional 26% of patients.

REFERENCES:


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1041

---

**POST331 CERTOLIZUMAB PEGOL IN UVEITIS. RETENTION PROBABILITY AND CAUSES OF DISCONTINUATION.**


**Objectives:** To study Certolizumab pegol (CZP) retention rate (RR) at 24 months in NIU and susceptibility factors for discontinuation.

**Methods:** Adults with NIU who received CZP for this indication were included. Data were gathered from the BioÚvea Spanish registry, detailed elsewhere.[3]

**Results:** Among the patients included, 42 (70%) had hypocomplementemia. Among the patients included, 42 (70%) had hypocomplementemia. We retrospectively examined the clinicopathological features of 60 patients with definitively diagnosed IgG4-RKD, collected from the institutions associated with the Japan IgG4-RKD working group between December 2010 and May 2019, with reference to the presence of hypocomplementemia.

**Conclusion:** Hypocomplementemia in IgG4-RKD is associated with elevated levels of IgG subclasses other than IgG4, and may be related to progression of renal inflammation.REFERENCES:


[2] Fujisawa Y, et al. Hypocomplementemia is related to elevated serum levels of IgG subclasses other than IgG4, and may be related to progression of renal inflammation.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1041

---

**Figure 1. Retention rate of Certolizumab pegol in bio-naive and bio-experienced patients with non-infectious uveitis.**

**Abbreviations:** DRT, Drug Retention Time; LTFU, lost to follow-up; DRR, Drug Retention Rate; PAR, Patients at Risk; AE, adverse event.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1211
Background: SPI-62 is a potent 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor entering Phase 2 development as adjunctive therapy to prednisolone in polymyalgia rheumatica, as well as for treatment of Cushings’s syndrome and autonomous cortisol secretion. HSD-1, an intracellular enzyme, activates glucocorticoids in target tissues in which glucocorticoid medicines are associated with morbidity including liver, adipose, muscle, and skin. In Phase 1 clinical trials SPI-62 was generally well tolerated and associated with maximal liver and brain HSD-1 inhibition.

Objectives: To demonstrate mitigation by SPI-62 of corticosterone (CORT) adverse effects in mouse.

Methods: C57BL/6 male mice (age 7 weeks; n=14 per group) were administered CORT (100μg/ml in drinking water) and SPI-62 (by gavage in 0.5% HPMC; 0.1, or 10 mg/kg/day or 10 mg/kg twice daily) for 35 days. A control group received no CORT or SPI-62. Body weight was assessed daily and food consumption twice weekly. Whole body muscle and fat amounts were measured at Days 0, 14, and 28 using an EchoMRI-130H body composition analyzer. Blood samples for fasting glucose and insulin were obtained at Days 1 (pre-dose), 15, 29, and 35. An open field test was conducted on Day 22. A grip strength test was performed on Day 28. After sacrifice on Day 36, gonadal, subcutaneous, retroperitoneal, and mesenteric fat weights were dissected and weighed, and skin was formalin fixed and paraffin embedded.

Results: One control mouse died due to accidental gavage injury. Two mice who received CORT + 0.5% HPMC died on Days 11 and 19. CORT resulted in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT-treated mice showed reduced body weight gain for 2 weeks then accelerated body weight gain. SPI-62 prevented body weight gain in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT effects on dermal thickness in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT-treated mice showed reduced body weight gain for 2 weeks then accelerated body weight gain. SPI-62 prevented body weight gain in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT results are compared to the control group mean, in CORT-treated mice in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT-treated mice showed reduced body weight gain for 2 weeks then accelerated body weight gain. SPI-62 prevented body weight gain in increased food consumption which was normalized by SPI-62 in a dose-dependent manner. CORT results are compared to the control group mean, in CORT-treated mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Body Fat Content Day 14</th>
<th>Body Fat Content Day 28</th>
<th>Gonadal Fat Weight</th>
<th>Subcutaneous Fat Weight</th>
<th>Retroperitoneal Fat Weight</th>
<th>Mesenteric Fat Weight</th>
<th>Body Muscle Content Day 14</th>
<th>Body Muscle Content Day 28</th>
<th>Quadriceps Weight</th>
<th>Tibialis Anterior Weight</th>
<th>Grip Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>110</td>
<td>116</td>
<td>154</td>
<td>471</td>
<td>227</td>
<td>240</td>
<td>-10</td>
<td>-15</td>
<td>-54</td>
<td>-35</td>
<td>-12</td>
</tr>
<tr>
<td>1 mg/kg/day</td>
<td>+22</td>
<td>+16</td>
<td>+34</td>
<td>+60</td>
<td>+21</td>
<td>+33</td>
<td>-8</td>
<td>-8</td>
<td>-43</td>
<td>-29</td>
<td>+16</td>
</tr>
<tr>
<td>10 mg/kg/day</td>
<td>+42</td>
<td>+42</td>
<td>+104</td>
<td>+428</td>
<td>+104</td>
<td>+132</td>
<td>+72</td>
<td>+72</td>
<td>+72</td>
<td>+72</td>
<td>+16</td>
</tr>
<tr>
<td>10 mg/kg twice/day</td>
<td>+102</td>
<td>+103</td>
<td>+62</td>
<td>+132</td>
<td>+84</td>
<td>+124</td>
<td>+63</td>
<td>+63</td>
<td>+50</td>
<td>+50</td>
<td>+15</td>
</tr>
</tbody>
</table>

*Normalized by body weight.

Conclusion: SPI-62 prevented several CORT adverse effects in mouse, demonstrating that blockade of local intracellular glucocorticoid activation by a HSD-1 inhibitor in target tissues can mitigate glucocorticoid toxicity. These results suggest that SPI-62 has potential to similarly mitigate adverse effects of glucocorticoid medications in human. A placebo-controlled Phase 2 clinical trial has been initiated to compare prednisolone effects with and without SPI-62. Up to 48 patients diagnosed with polymyalgia rheumatica, on stable prednisolone 10 mg daily for at least 2 weeks, and with stable disease inactivity based on acute phase biomarkers will be included in the files and who received at least one DMARD or BP treatment for their disease were included in Rouen (thanks to the health data warehouse), Caen, Le Havre/Lillebonne and Dieppe Centres. Each imaging examination was reviewed blinded to the treatments by a radiologist with expertise in osteoarticular disease. Patients were classified into 2 groups (bony versus joint/mixed) according to imaging data and clinical history. The response to treatment was considered positive if symptoms were improved by at least 50% (cut-off used in the literature). An x² test was used for comparison of categorical variables.

Disclosure of Interests: Xingyu Pan: None declared, Qiongqiong Hou: None declared, Jiahui Xu: None declared, Yake Ma: None declared, Jiawen Li: None declared, Min Li: None declared, Jing Su: None declared, Xuerou Shi: None declared, William Bracken Consultant of: Sparrow Pharmaceuticals, David Katz Shareholder of: Sparrow Pharmaceuticals, Employee of: Sparrow Pharmaceuticals DOI: 10.1136/annrheumdis-2022-eular.1392

STUDY OF THE RELATIONSHIP BETWEEN THE TREATMENT TYPE AND THE THERAPEUTIC RESPONSE ACCORDING TO THE SAPHO SYNDROME CLINICAL FORM IN ADULTS FROM A RETROSPECTIVELY ANALYSED MULTICENTRE COHORT

P. Brevel1, P. Micheлин1, C. Marcelli2, D. Alcaix3, T. Lequerre5, O. Vittecq6, D. Alcaix3, T. Lequerre5, O. Vittecq6
1Rouen University Hospital, Rheumatology, Rouen, France; 2Rouen University Hospital, Radiology, Rouen, France; 3Caen University Hospital, Rheumatology, Caen, France; 4Le Havre Hospital, Rheumatology, Le Havre, France; 5Rouen University Hospital, Rheumatology, Rouen, France; 6Rouen University Hospital, Rheumatology, Rouen, France

Background: SAPHO syndrome (Synovitis, Acne, Palmoplantar Pustulosis, Hyperostosis and Osteitis) is a radio-clinical entity associating joint, bone and inflammatory skin disorders. The clinical presentation is very heterogeneous, making the diagnosis difficult. The therapeutic strategy of SAPHO syndrome is poorly defined. The first-line treatment remains NSAIDs on demand, which are effective in treating painful flare-ups but rapidly become insufficient in 60% of cases during the course of the disease. TNF-α inhibitors (3 nerosis factor-alpha) are reserved for refractory forms and their efficacy is uncertain [1]. Bisphosphonates (BPs) seem to have potential interest [2].

Objectives: The main objective of this study was to investigate the response to treatment with BPs and/or immunosuppressive drugs (DMARDs - Disease modifying anti-rheumatic drugs), conventional synthetic cs-DMARDs or biologic (b-DMARDs), according to the clinical form of rheumatological SAPHO (bony predominantly versus articular or mixed predominantly).

Methods: All patients aged 18 years or older with SAPHO syndrome meeting Benhamou’s criteria whose clinical, biological and radiological data were available in the files and who received at least one DMARD or BP treatment for their disease were included in Rouen (thanks to the health data warehouse), Caen, Le Havre/Lillebonne and Dieppe Centres. Each imaging examination was reviewed blinded to the treatments by a radiologist with expertise in osteoarticular disease. Patients were classified into 2 groups (bony versus joint/mixed) according to imaging and clinical history. The response to treatment was considered positive if symptoms were improved by at least 50% (cut-off used in the literature). An x² test was used for comparison of categorical variables.

Results: Thirty-four patients with SAPHO who had received DMARD or BP treatment were included and classified as follows: 13 in the bony group and 21 in the joint/mixed group. The 2 groups were comparable on demographics, duration of follow-up, previous chest involvement, existence of associated dermatological or inflammatory bowel disease, exposure to smoking, duration of exposure to a previous NSAID or antibiotic. Only the age of onset of symptoms differed between the two groups, with a younger onset of disease in the bony group (p=0.043). The prescribers therapeutic attitude differed significantly between the 2 groups (p=0.043) with a greater prescription of BPs as first line in the bony group (5/13 patients) and a DMARD in the joint/mixed group (19/21). Regarding treatment efficacy, 10/13 patients had effective treatment without escape during their follow-up in the bony group, which was not significantly different from the joint/mixed group (17/21). BPs achieved escape-free efficacy in significantly more cases in the bony group than DMARDs in the joint or mixed group (p= 0.002). The bony group used significantly fewer specific treatment lines (DMARDs or BP) than the joint/mixed group (1 specific line vs. at least 2) (p=0.046).

Conclusion: BPs appear to be more effective in SAPHO with predominantly bone involvement. This appears to be easier to treat compared to SAPHO with articular or mixed forms.

REFERENCES:

OBJECTIVES: To assess the prevalence of autoimmune diseases associated with OCP and to analyse clinical, laboratory and treatment associations between these entities.

Methods: A multicentre cross-sectional study of patients with a diagnosis (clinical and/or by biopsy) of OCP derived from ophthalmology was performed. The population was divided into two groups according to their association or not with other ADs. Clinical, laboratory and treatment variables were described and compared between both groups. In addition, a multivariate descriptive logistic regression model was used to test the association between OCP and ADs.

Results: A total of 88 patients were recruited, 66 (75%) females, with a mean age at diagnosis of 64.3 years (SD 11.9). The median follow-up time was 1 year. The diagnosis of OCP was confirmed by biopsy in 89%. Ocular bilateral disease was present in 95.3% of patients. There was a median delay from symptoms onset to diagnosis of 2 years. A history of malignancy was reported in 13.6%. Extraocular involvement was found in 11.5% (4% compromised skin and 9.1% other mucous membranes). Regarding the previous clinical findings, no statistically significance was found between the groups with and without ADs. Systemic treatment was depicted as being more frequent in the group with ADs. Clinical, laboratory and treatment variables were described and compared between both groups. In addition, a multivariate descriptive logistic regression analysis was performed to identify variables that could suggest the association between OCP and ADs.

Results:

<table>
<thead>
<tr>
<th>OR</th>
<th>95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>0.2</td>
<td>0.04 - 1.1</td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>0.02</td>
<td>0.9 - 1.1</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.5</td>
<td>0.1 - 1.7</td>
</tr>
<tr>
<td>Skin and mucosa compromise</td>
<td>1.2</td>
<td>0.2 - 8.2</td>
</tr>
<tr>
<td>ESR</td>
<td>0.99</td>
<td>0.95 - 1.02</td>
</tr>
<tr>
<td>Hypergammaglobulinemia</td>
<td>0.27</td>
<td>1.6 - 46.8</td>
</tr>
</tbody>
</table>

Conclusion: Due to the autoimmune nature of OCP, it could coexist with other ADs. In this research, it was observed that more than a quarter of the population presented with such association and hypergammaglobulinemia could suggest it. A systematic search for this coexistence should be carried out to avoid sequelae or incomplete treatment in pathologies that are currently potentially treatable.

REFERENCES:


Acknowledgements: On behalf of the Study Working Group of Rheumatological Ocular Diseases, Argentinian Society of Rheumatology.

Disclosure of Interests: None declared

DOI: 10.1136/ann rheum dis-2022-eular.1425
Behcet’s disease (BD) is a multisystemic disease of unknown cause. The relationship between BD and pregnancy is reported in limited number of studies. The aim of the study was to evaluate the connection of the outcome of pregnancy with BD therapy.

Results: 118 pregnancies in 35 pts resulted in 75 live birth (6 cesarean section), 15 with termination of pregnancy. Out of 77 babies, 15 were born on time, the others had 0-1 missed miscarriage. Six patients had 12 Missed miscarriage at 6-11 weeks of gestation, one patient had severe BD according to Ch.Zouboulis classification (due to generalized glaucoma (“Neurobehcet” inherited from the mother).

Adverse pregnancy outcomes were observed with varying severity of BD. Out of 77 babies children born by BD patients only two had relapsing aphthous stomatitis and one – congenital glaucoma (“Neurobehcet” inherited from the mother).

Conclusion: Patients with BD were more to terminate pregnancy compared to control group. Unfavorable outcomes of pregnancy were documented in pts regardless (with all grades of) BD severity.

REFERENCES:

Disclosure of Interests: None declared

POS1337 ADULT-ONSET STILL’S DISEASE WITH ELDERLY ONSET, RESULTS FROM A MULTICENTRE STUDY AND ASSESSMENT OF AGE INFLUENCE ON CLINICAL FEATURES AND DISEASE OUTCOMES


Background: Aging is a physiological, multidimensional, and irreversible process, occurring in humans over time. Interestingly, multiple lines of evidence have recently suggested that some diseases, generally affecting young adults, are nowadays described in the elderly, although possibly associated with different symptoms or complications. In this context, a possible occurrence of adult onset Still’s disease (AOSD) in elderly has been suggested. This is a rare inflammatory disorder of unknown origin usually observed in young adults.

Objectives: In this study, we aimed at describing the clinical characteristics, life-threatening complications occurrence, and mortality of AOSD patients with an elderly onset. The manifestations of these patients were also compared with those with a younger onset. Furthermore, the predictive role of age was evaluated on clinical features and disease outcomes. Finally, in these patients, an assessment of associated comorbidities was also performed.

Methods: A retrospective assessment of prospectively followed patients, from January 2001 to April 2021, was provided to analyse clinical features, life-threatening complications occurrence, and mortality in AOSD patients with onset in elderly. AOSD patients, who were included in multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort, were evaluated.

Results: Out of 221 assessed patients, 37 (16.7%) had an onset of the disease aged over than 60 years. When compared with younger patients, these were characterised by a higher prevalence of pericarditis (p=0.008), comorbidities (p<0.0001), and mortality (p=0.023). Additionally, our analysis showed that pleuritis and pericarditis positively correlated with age (coefficient=0.277, p=0.001; coefficient=0.213, p=0.001, respectively). Furthermore, the occurrence of parenchymal lung disease was significantly related with age (coefficient=0.168, p=0.012). The presence of comorbidities positively correlated with age (coefficient=0.443, p<0.0001). Moreover, age was negatively related to the polycytic pattern (coefficient=-0.209, p=0.002).

Disclosure of Interests: None declared

Tables

**Table 1.** Comparison of medication possession ratio (MPR) of colchicine between FMF patients treated with IL-1 inhibitors Versus patients without IL-1 inhibitors treatment

<table>
<thead>
<tr>
<th>Parameter</th>
<th>With IL-1 inhibitors (“study”)</th>
<th>Without IL-1 inhibitors (“matched P-value group”) n=108</th>
<th>“matched P-value group” n=432</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age category, years</td>
<td>≤6 74.9±24.9 (N=32)</td>
<td>75.8±33.7 (N=23)</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7-14 80.2±36.6 (N=24)</td>
<td>75.6±70.3 (N=83)</td>
<td>0.09</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15-29 76.5±47.9 (N=29)</td>
<td>91.1±123.3 (N=101)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥30 75.8±33.7 (N=23)</td>
<td>77±49.9 (N=112)</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Male 75.7±49.9 (N=48)</td>
<td>79.2±65.5 (N=192)</td>
<td>0.9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female 81.4±33.2 (N=60)</td>
<td>85.1±91.0 (N=240)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>Time of colchicine use</td>
<td>102.8±46.2 (N=42)</td>
<td>100.9±99.5 (N=245)</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>&lt; 8 years</td>
<td>66.6±35.8 (N=26)</td>
<td>56.7±36.5 (N=103)</td>
<td>0.2</td>
<td></td>
</tr>
<tr>
<td>8-15 years</td>
<td>61.9±24.8 (N=40)</td>
<td>60.4±25.8 (N=84)</td>
<td>0.7</td>
<td></td>
</tr>
</tbody>
</table>

Patients with BD were more likely to terminate pregnancy of their own volition compared to control group. All women with unfavorable pregnancy outcomes are re-pregnant, have healthy children born on time, all had a second or subsequent pregnancy with an unfavorable outcome. Immunosuppressive therapy of BD was not received by any of the pregnant women, which makes it possible to exclude the connection of the outcome of pregnancy with BD therapy.

The manifestation of BD with skin-mucous lesion of the patient in the first and third trimester of pregnancy was noted by 3 patients. In one patient, the appearance of a recurrent ulcer on the vulva was an indication for cesarean section. Only three women had one favorably completed pregnancy, all the others had spontaneous abortions, 12 missed miscarriage. Nine of them are not married, 1 patient is planning a pregnancy.

Table 2 shows the frequency of pregnancy pathology with varying degrees of severity of BD.

**Table 2.** BD Severity and pathology of pregnancy

<table>
<thead>
<tr>
<th>BD Severity</th>
<th>N = 45 (%)</th>
<th>Intrauterine deaths/Miscarriage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>25 (55.6)</td>
<td>5/6</td>
</tr>
<tr>
<td>Moderate</td>
<td>10 (22.2)</td>
<td>1/1</td>
</tr>
<tr>
<td>Severe</td>
<td>10 (22.2)</td>
<td>2/5</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

POS1336 BEHÇET’S DISEASE AND PREGNANCY OUTCOMES

Z. Alekberova1, R. Goloeva1, A. Lila1, 1VA. Nasonova Research Institute of Rheumatology, Advisory Division, Moscow, Russian Federation

Background: Behçet’s disease (BD) is multisystemic disease of unknown cause. The relationship between BD and pregnancy is reported in limited number of studies.

Objectives: To evaluate outcomes of pregnancies in BD patients (pts).

Methods: We retrospectively collected data of 45 women with BD diagnosis (according to ISGBD 1990 and ICBD 2014) and their 118 pregnancies. Pts mean age was 31.3 [27-35] years., disease duration 6.0 [3.8] years. 11.1% pts had severe BD according to Ch.Zouboulis classification (due to generalized uveitis, retinal vasculitis and parenchymatous CNS lesions), 31.1% pts had a moderate disease, 57.8% pts had a mild disease with mainly dermal-mucosal manifestations.

Results: 118 pregnancies in 35 pts resulted in 75 live birth (6 cesarean section in 3 pts). Thirty-nine incomplete pregnancies were observed in 26 patients. Ten patients had 20 medical abortions on request before 12 weeks of gestation, one patient had an abortion due to medical reasons (rubella on the 7 th week of gestation), two patients had premature birth at 28 and 32 weeks with subsequent perinatal death of the baby. Fifteen out of 35 pts had 20 adverse pregnancy outcomes: 8 spontaneous abortion, 12 missed miscarriage. Nine patients had 12 Missed miscarriage at 6-11 weeks of gestation, one patient had 3 missed miscarriage, two had 2, and the others had 1 missed miscarriage. Six patients had 8 spontaneous abortions (early miscarriage). In the control group of 15 women, 7 had 15 pregnancies, 13 live birth of healthy children on time. Table 1 presents a comparison of pregnancy outcomes in patients with BD and healthy control.

Table 1. Pregnancy outcomes

<table>
<thead>
<tr>
<th>Pregnancy, n</th>
<th>BD, n=118 (%)</th>
<th>Control, n=15 (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>77 (65)</td>
<td>13 (87)</td>
<td>0.01</td>
</tr>
<tr>
<td>Abortion</td>
<td>21 (18)</td>
<td>0</td>
<td>0.00</td>
</tr>
<tr>
<td>Unfavorable pregnancy outcome</td>
<td>20 (17)</td>
<td>2 (13)</td>
<td>ns</td>
</tr>
<tr>
<td>Missed miscarriage</td>
<td>12 (10)</td>
<td>0</td>
<td>ns</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>8 (7)</td>
<td>2 (13)</td>
<td>ns</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared
Central Sensitization and Related Factors in Patients with Familial Mediterranean Fever

F. N. Yücel, H. H. Gezer, J. Jandaulyet, N. Öz, S. Acer Kasman, M. T. Duruöz

Marmara University School of Medicine, PMR Department, Istanbul, Turkey; Marmara University School of Medicine, PMR Department, Rheumatology Division, Istanbul, Turkey

Background: Central sensitization (CS) is an increased responsiveness of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input is an important manifestation involved in many different rheumatic diseases [1].

Objectives: This study aims to investigate the CS in patients with Familial Mediterranean Fever (FMF) and its associations with other parameters.

Methods: This ongoing study included 73 patients (57 female, 16 male) who were diagnosed with FMF according to the Tel-Hashomer criteria. Clinical characteristics including age, gender, disease duration, age at onset, genetic mutations, comorbid disease and medications were noted. Disease activity was assessed with a PRAS disease activity score. Evaluations included the Health Assessment Questionnaire (HAQ), FMF quality of life (FMF-QoL), Pittsburgh Sleep Quality Index (PSQI), Fibromyalgia Rapid Screening Tool (FiRST), and the Hospital Anxiety and Depression Scale (HADS). The symptoms of CS were assessed with the Central Sensitization Inventory (CSI); range 0-100 which is a self-report outcome measure designed to identify patients who have symptoms that are related to CS or central sensitivities (CSI) such as fibromyalgia, neck injury, temporomandibular joint disorder or migraine/tension headaches [2]. Descriptive analysis was performed for all parameters. The Mann-Whitney U-test and chi-squared test were used in statistical analysis. P<0.05 was considered statistically significant.

Results: The mean age of the patients was 37.6 (SD:13.6) years. Sacroiliitis occurred in 8 patients (11%), amyloidosis in 1 (1.4%), and erysipelas-like erythema in 8 (11%). The most prevalent genetic mutation was M694I compound heterogeneous (16.4%) followed by M694V homogeneous (15.1%).

Table 1. Disease characteristics in terms of central sensitization

<table>
<thead>
<tr>
<th></th>
<th>Central sensitization</th>
<th>Central sensitization</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n=34)</td>
<td>No (n=39)</td>
<td></td>
</tr>
<tr>
<td>Gender, female</td>
<td>31 (91.2%)</td>
<td>26 (66.7%)</td>
<td>0.02</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.8 (8.8)</td>
<td>26.2 (8.0)</td>
<td>0.282</td>
</tr>
<tr>
<td>Disease duration</td>
<td>9.3 (3.9)</td>
<td>12.9 (9.9)</td>
<td>0.156</td>
</tr>
<tr>
<td>Number of attacks in the last 3 months</td>
<td>2.05 (2.1)</td>
<td>0.8 (1.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Number of attacks in the last 6 months</td>
<td>3.7 (3.3)</td>
<td>15.2 (2.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PRAS</td>
<td>6.3 (2.1)</td>
<td>4.8 (2.3)</td>
<td>0.004</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.4 (0.6)</td>
<td>0.08 (0.2)</td>
<td></td>
</tr>
<tr>
<td>FMF-QoL</td>
<td>38.2 (17.3)</td>
<td>173.5 (22.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FIRST</td>
<td>3.9 (9.9)</td>
<td>17.7 (1.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PSQI</td>
<td>9.9 (3.9)</td>
<td>6.4 (2.8)</td>
<td></td>
</tr>
<tr>
<td>HAD-Anxiety</td>
<td>9.6 (4.4)</td>
<td>4.9 (3.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HAD-Depression</td>
<td>7.08 (4.4)</td>
<td>4.4 (3.2)</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Disease activity was mild in 42.5%, moderate in 32.9% and severe in 12.3% of the patients. The mean CSI was 38.4 (SD:18.7) and thirty-four (45.6 %) of 73 patients had CS according to the CSI. CSI scores were significantly higher in females than in males (p=0.009). Eleven (15%) patients had colchicine resistance, and those with colchicine resistance had significantly higher CSI scores. In patients with central sensitization, PRAS, HAQ FMF-QoL, FiRST, PSQI, and HADS scores were significantly higher than in patients without central sensitization (Table 1).

Conclusion: CS is present in approximately half of FMF patients, CS in patients with FMF was associated with high disease activity, fibromyalgia, anxiety, depression, impaired function, poor quality of life and sleep.

REFERENCES:

Disclosure of Interests: None declared
With treatment of AoSD, clinical disease activity decreased reaching a mean Pouchot-Score of 2.2 +/- 1.8 after a mean follow up time of 48 +/- 90 months. Glucocorticoids were used by 33%, methotrexate by 21%, IL-1 inhibitors by 33% and IL-6 inhibitors by 29% of the patients. 62% (N=26) of the 42 patients obtained clinical remission and 36% (N=15) serological remission. Neither Pouchot-Score (0.57) nor SAS (0.51) at baseline predicted clinical remission of AoSD. Furthermore, also serological remis-
sion was not predicted by baseline SAS (0.62) or Pouchot-Score (0.56) (Figure 1).
With respect to activity of AoSD during treatment serum calprotectin levels were closely associated with SAS disease activity (r = 0.54, p < 0.0003) (Figure 2).

Conclusion: Baseline AoSD disease activity as measured by Pouchot-Score and SAS does not predict clinical or serological remission. Serum calprotectin level is closely related to AoSD disease activity during the treatment phase.

FIGURE 1.

Figure 1. ROC for baseline SAS and Pouchot-Score and clinical remission

Figure 2. Association between S100A8A9 protein measured by the ELISA method and disease activity by the SAS at follow-up

Disclosure of Interests: None declared

POS1340

BASELINE CLINICAL DISEASE ACTIVITY IS NOT CRITICAL FOR PREDICTING REMISSION OF ADULTS ONSET STILL’S DISEASE

J. Groetsch1, K. Tascilar1, G. Schett1, D. Foell2, J. Rech1, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany; 2Universitätsklinikum Münster. Klinik für Pädiatrische Rheumatologie und Immunologie, Münster, Germany

Background: The clinical course of adult-onset Still’s disease (AoSd) is highly variable, ranging from subtle constitutional symptoms to life-threatening complications such as macrophage activation syndrome. Therefore, it is of interest whether baseline disease activity in AoSD predicts the clinical course, i.e. clinical and serological remission.

Objectives: The aim of this study was to compare whether two instruments to measure AoSD disease activity, Pouchot-Score and Still-Activity Score (SAS), at baseline predict later remission of disease. We also assessed whether serum levels of calprotectin (S100A8A9) are associated with clinical disease activity as measured by SAS at follow up.

Methods: AoSD was diagnosed according to the Yamaguchi criteria. In all patients Pouchot-Score and Still-Activity Score (SAS) were assessed at baseline and SAS score also at follow-up. Clinical remission was defined as absence of all AoSD symptoms (i.e. fever and arthralgia), while serological remission was defined as normalization of Ferritin, IL-18 and S100A8A9 (calprotectin) levels. To investigate the prediction accuracy of the baseline Pouchot-Score and SAS of all AoSD symptoms (i.e. fever and arthralgia), while serological remission was defined as normalization of Ferritin, IL-18 and S100A8A9 (calprotectin) levels. To investigate the prediction accuracy of the baseline Pouchot-Score and SAS does not predict clinical or serological remission. Serum calprotectin level is closely related to AoSD disease activity during the treatment phase.

Results: 42 AoSD patients (19 males/23 females; mean +/-SD age:41 +/- 17 years) were assessed. Baseline Pouchot-Score was 5.3 +/- 1.6, baseline SAS was 5.7 +/- 1.0. With treatment of AoSD, clinical disease activity decreased reaching a mean

Disclosure of Interests: None declared

POS1341

EVALUATION OF DAMAGE CAUSED BY SEPTAL PANNICULITIS ASSOCIATED WITH ACUTE SARCOIDOSIS

O. Egorova1, G. Tarasova1, 1VA. Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation

Background: Joint involvement in combination with sepal panniculitis, erythema nodosum (EN), febrile reaction, and intranshronic lymphadenopathy is the criterion for acute sarcoidosis (Löfgren’s syndrome, LS) – a granulomatous multi-system inflammatory disease of unknown etiology.

Objectives: to develop an index of damage caused by sepal panniculitis for express-assessment of the X-ray stage of LS.

Methods: We examined 142 patients (31 men and 111 women) in case of EN associated with LS, average age 39.3±11.1 years. All patients underwent a comprehensive clinical, laboratory and instrumental examination, including ultrasound of the joints and computed tomography (CT) of the chest organs.

Results: In 96% of cases, widespread EN was detected, which correlated with the level of CRP (p=0.006; r=0.38). In 124 patients (87%) there were signs of joint damage with predominantly periartricular changes in the area of ankle joints. The relationship between the duration of the articular syndrome and the duration of inflammatory changes in the subcutaneous tissue and the number of nodes was registered (p=0.02; r=0.45). The level of CRP had a significant direct correlation with the number of nodes (p=0.008; r=0.29) and the severity of articular syndrome (p=0.003; r=0.29). An elevated level of angiotensin-converting enzyme was detected in 97 patients (78%). The assessment of the probable radiological stage (c) of LS was performed according to the formula obtained using step-by-step discriminant analysis.

c = 1.06*Х1 + 0.98 *Х2 + 5.21 *Х3 + 1.68 *CRP

X1 – the number of sides of the lower/upper limbs with the detected diffuse lesions of the skin and subcutaneous fat; X2 – the number of erymatous nodes (or induration); A – the number of arthritus; CRP – concentration of C-reactive protein in absolute values. The value of c≤28.72 indicated x-ray Stage 0; 28.72 < c≤30.92 – x-ray Stage I; c > 30.92 – x-ray Stage II of LS of the chest organs. The developed technique made it possible to determine Stage I of LS in 69% of cases and Stage II in 15% of cases, which was confirmed by CT of the lungs. For the selected total value of the discriminant function of 3.984, the sensitivity is 79%, the specificity is 96%.

Conclusion: The developed assessment is a low-cost, affordable and fast way to assess the verification of the X-ray stage of LS at any stage of the disease, which contributes to the immediate prescription of adequate therapy.

Disclosure of Interests: None declared

POS1342

DEPLETION OF KLRG1+ T CELLS IN A FIRST-IN-HUMAN CLINICAL TRIAL OF ABC008 IN INCLUSION BODY MYOSITIS (IBM)

N. Goel1,2, M. Needham3,4,5,6, D. Soler-Ferrari1, M. M. Cottral1, J. Escobar1, S. Greenberg1,2,3, Abcuro, Inc, Newton, MA, United States of America; 1Duke University School of Medicine, Internal Medicine, Division of Rheumatology, Durham, NC, United States of America; 2Fiona Stanley Hospital, Neurology, Murdoch, Australia; 3The University of Notre Dame Australia, School of Medicine, Fremantle, Australia; 4Murdoch University, Centre for Molecular Medicine and Innovative Therapeutics, Murdoch, Australia; 5Fenon Institute for Neurological and Translational Science, South Metropolitan Health Service, Nedlands, Australia; 6Brigham and Women’s Hospital, Neurology, Boston, MA, United States of America; 7Harvard Medical School, Neurology, Boston, MA, United States of America

Scientific Abstracts
Background: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on microscopy is highly differentiated effector CD8+ cytotoxic T (Tc) cells invading non-necrotic myofibers [1]. These Tc cells, known to be relatively resistant to apoptosis, express markers including killer cell lectin-like receptor G1 (KLRG1) [2]. ABC008, a first-in-class humanized, afucosylated monoclonal antibody (mAb) specific for KLRG1, selectively depletes these highly differentiated Tc cells while sparing other blood cell populations, e.g., naïve, central memory, and regulatory T cells and B cells. ABC008 has been designed to treat diseases mediated by these Tc cells, including IBM and T-cell granular lymphocytic leukemia (T-LGLL). IBM and rheumatoid arthritis overlap clinically with T-LGLL and share similar expansions of large granular lymphocytes (LGLs), which also express KLRG1. We report here our preliminary data from our ongoing trial of ABC008 in IBM (NCT04609031).

Objectives: Evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of ABC008 administered subcutaneously (SC) in adults with IBM.

Methods: In this first-in-human, open-label, single ascending dose trial with 3+3 design evaluating ABC008 SC, eligible participants must have clinically-pathologically defined, clinically defined, or probable IBM according to the European Neuromuscular Centre 2011 research diagnostic criteria [3] and an IBM Functional Rating Scale (IBMFRS) score ≤38. Four dose cohorts are planned: ABC008 0.1, 0.5, 2.0, and 5.0 mg/kg SC; PK, safety, and disease severity assessments are performed pre-dose (Day 0) and during the 6-month follow-up period.

Results: Five of the 6 (83.3%) participants were male with baseline mean age = 65.7 years, mean IBM disease duration = 6.8 years, and mean IBMFRS score = 275 (Table 1). Each received a single dose of ABC008 SC; Cohorts 1 (C1) and 2 (C2) received 0.1 and 0.5 mg/kg and had completed 168 and 56 days of follow-up, respectively.

Table 1. Baseline Demographics

<table>
<thead>
<tr>
<th>IBMFRS score, mean ± SD</th>
<th>Cohort 1</th>
<th>Cohort 2</th>
<th>ABC008 Overall (N=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean ± SD</td>
<td>64.0 ± 11.36</td>
<td>67.3 ± 6.66</td>
<td>65.7 ± 8.52</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>3 (100)</td>
<td>2 (66.7)</td>
<td>5 (83.3)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>3 (100)</td>
<td>3 (100)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>28.5 ± 3.58</td>
<td>28.3 ± 4.25</td>
<td>28.4 ± 3.52</td>
</tr>
<tr>
<td>Disease Duration (years)</td>
<td>9.7 ± 5.97</td>
<td>3.9 ± 4.48</td>
<td>6.8 ± 5.70</td>
</tr>
<tr>
<td>IBMFRS score, mean ± SD</td>
<td>30.0 ± 4.08</td>
<td>25.0 ± 6.16</td>
<td>275 ± 5.80</td>
</tr>
</tbody>
</table>

Abbreviations: IBMFRS, Inclusion Body Myositis Functional Rating Scale; n or N, number; SC, subcutaneous; SD, standard deviation.

Other hematologic parameters generally were stable (e.g., T regulatory and B cells); CD8+CD57+ LGLs, mostly KLRG1+, were also depleted (Figure 1B). Preliminary PK showed that ABC008 SC displays a long absorption phase and slow clearance properties typical of mAb therapies. No severe adverse events (AEs) or discontinuations due to AEs have been reported. One unrelated serious AE of fall with muscle tear in a C1 participant with a prior history of falls occurred.

Conclusion: In study participants with IBM, single SC doses of 0.1 and 0.5 mg/kg of ABC008 resulted in the depletion of CD8+KLRG1+ cells and CD8+CD57+ LGLs with clear evidence of a dose response for KLRG1+ T cell depletion and no apparent safety signals. Based on these results, a study evaluating ABC008 for the treatment of T-LGLL is planned.

REFERENCES:


DOI: 10.1136/annhemed-2022.eular.2141

POS1343 TREATMENT OF RESISTANT RAYNAUD’S PHENOMENON WITH SINGLE-PORT THORACOSCOPIC SYMPATHICOTOMY: ONE-YEAR FOLLOW-UP

S. Van de Zande1, M. Kuipers2, A. Van Roon3, A. J. Stei2, A. Smit2, M. Dejongste4, M. Mariani2, T. Klinkenberg2, D. J. Mulder1, 1University Medical Center Groningen, Vascular Medicine, Groningen, Netherlands; 2University Medical Center Groningen, Cardiothoracic Surgery, Groningen, Netherlands; 3University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 4University Medical Center Groningen, Cardiology, Groningen, Netherlands

Background: Raynaud’s phenomenon (RP) usually results in discoloration of the extremities when provoked by cold or emotional stress [1]. Some patients do not respond to conventional therapies, such as lifestyle interventions and vasodilatory medication. These patients are confronted with limited options for treatment. In a previous study we have shown that minimally invasive Single-Port Thoracoscopic Sympathectomy (SPTS) objectively and subjectively improves treatment-resistant RP, after one month [2]. This procedure for treatment-resistant RP is minimally invasive and potentially highly effective, because it specifically targets the sympathetic nerve at the third rib (R3), while leaving the ganglia untouched [3]. The procedure was only performed on the left side in the pilot study, which objectively resulted in improvement of left-hand perfusion in all patients after one month, when compared to the right hand. Furthermore, patient satisfaction after surgery was high and RP attacks of the left hand were less frequent and of shorter duration. Previous studies have shown that long-term effects of conventional sympathectomy is stable in the long run in the majority of patients [4, 5]. We have previously published the one-month results of SPTS for treatment-resistant RP in a concise report [2]. In the current study we sought to report the one-year follow-up results of SPTS for treatment-resistant RP in the same cohort of patients.

Objectives: Follow-up of patients with treatment-resistant Raynaud’s phenomenon (RP) one-year after single-port thoracoscopic sympathicotomy (SPTS).

Methods: Eight patients (six males, two females, median age of 45 years) with treatment-resistant RP underwent left-sided SPTS at the third rib (R3), unilaterally. Perfusion was assessed with a cooling and recovery procedure at baseline and one year after SPTS. Furthermore, laser speckle contrast analysis, pulse wave velocity, heart rate variability and nailfold capillaroscopy were performed. In addition, questionnaires were taken, and number and duration of RP attacks were reported over a 2-week period.

Results: One year after SPTS the duration of the attacks of was reduced with 1.9 hours in the left hand versus 0.9 hours in the right hand. Furthermore, three aspects of the questionnaire showed a significant improvement (role limitations due to physical health (p=0.017), pain (p=0.027) and physical functioning (p=0.025)). The total area under the curve of the total cooling and recovery procedure of the left hand was larger one year after surgery (101 (75–140) at baseline versus 118 (95–190) one year post-operatively, p=0.012), implying a better perfusion in the fingers. This was mainly due to the improvement during the recovery phase (21 (1–41) at baseline versus 38 (24–43) one year post-operatively, p=0.028).

Conclusion: One year after unilateral R3 SPTS there is clear benefit with regard to the majority of outcome variables, though some effects seem to attenuate. Long-term effects and five-year follow-up results will be investigated in an ongoing study.

REFERENCES:
Biological examination consistent with BS-related PI. Demographic features, other vascular lesions, and involvement associated with Behcet’s syndrome (BS).

**Background:** Pulmonary involvement (PI) other than pulmonary artery aneurysm (PAA) in Behcet’s syndrome (BS) is still an area of investigation.

**Objectives:** We aimed to retrospectively evaluate all types of pulmonary involvement associated with Behcet’s syndrome (BS).

**Methods:** Among 800 BS patients according to International Study Group for Behcet’s Disease (ISG) criteria, 28 patients were selected based on their radiologic examination consistent with BS-related PI. Demographic features, other clinical manifestations of BS, treatment modalities and types of PI were analyzed.

**Results:** The overall prevalence of PI was estimated 3.5% among all BS patients. PI was more common in males (62.1% vs 17.9%). Mean age for BS diagnosis and onset of PI were as following: 32 ± 10.9 years and 37 ± 11.4 years. Deep vein thrombosis (DVT) was the most common accompanying vascular involvement (53.6%). PAA, pulmonary vasculitis (PV), and pulmonary thromboembolism (PTE) were seen in 7 (25%), 13 (46.3%), and 18 (64.4%) of patients, respectively. In 5 patients, intracardiac thrombosis was present simultaneously in the right ventricle. Cyclophosphamide (CYC) was the most common preferred agent (78%) followed by azathioprine (AZA); cyclophosphamide, AZA; azathioprine, DVT; deep vein thrombosis

**Conclusion:** Despite the importance of PAA in BS patients, capillaritis and thromboembolism other than PAA may occur commonly in BS as well. Onset at young age, male gender and previous DVT seem to be significant risk factors for the development of PI.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2645

**Table 1. Characteristics of pulmonary involvement in BS patients**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Male/Female, (n), (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of diagnosis, years (Means SD)</td>
<td>32 ± 10.9</td>
</tr>
<tr>
<td>Age of pulmonary involvement, years (Mean ± SD)</td>
<td>37 ± 11.4</td>
</tr>
<tr>
<td>Oral ulcer, (n), (%)</td>
<td>29 (100%)</td>
</tr>
<tr>
<td>Genital ulcer, (n), (%)</td>
<td>20 (71.4%)</td>
</tr>
<tr>
<td>Osteoblastic lesion, (n), (%)</td>
<td>20 (71.4%)</td>
</tr>
<tr>
<td>Enzyme nodusum, (n), (%)</td>
<td>13 (46.4%)</td>
</tr>
<tr>
<td>Uveitis, (n), (%)</td>
<td>8 (28.6%)</td>
</tr>
<tr>
<td>DVT, (n), (%)</td>
<td>15 (53.6%)</td>
</tr>
<tr>
<td>Cardiac involvement, (n), (%)</td>
<td>5 (17.8%)</td>
</tr>
<tr>
<td>Pulmonary involvement, (n)</td>
<td>28</td>
</tr>
<tr>
<td>PAA, (n), (%)</td>
<td>7 (25%)</td>
</tr>
<tr>
<td>PV, (n), (%)</td>
<td>13 (46.4%)</td>
</tr>
<tr>
<td>PTE, (n), (%)</td>
<td>18 (64.3%)</td>
</tr>
<tr>
<td>Immunosuppression (first line agents)</td>
<td>26/28</td>
</tr>
<tr>
<td>Corticosteroids, (n), (%)</td>
<td>26/28</td>
</tr>
<tr>
<td>CYC, (n), (%)</td>
<td>22/26 (84.6%)</td>
</tr>
<tr>
<td>AZA, (n), (%)</td>
<td>42/6 (15%)</td>
</tr>
<tr>
<td>Anticoagulation (warfarin), (n), (%)</td>
<td>18</td>
</tr>
</tbody>
</table>

PAA; pulmonary artery aneurysm, PTE; pulmonary thromboembolism, PV; pulmonary vasculitis, CYC; cyclophosphamide, AZA; azathioprine, DVT; deep vein thrombosis

**Conclusion:** Despite the importance of PAA in BS patients, capillaritis and thromboembolism other than PAA may occur commonly in BS as well. Onset at young age, male gender and previous DVT seem to be significant risk factors for the development of PI.
Table 1. Main clinical features and treatment of 23 patients with NBD

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>n (%)</th>
<th>Mean maximum oral prednisone dose (SD) mg/day</th>
<th>Conventional immunosuppressants, n (%)</th>
<th>monoclonal anti-TNFα, n (%)</th>
<th>Tocilizumab, n (%)</th>
<th>Anakinra, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parenchymal phenotype</td>
<td>10 (43.5)</td>
<td>51.7±19.3</td>
<td>6 (46.2)</td>
<td>4 (57.1)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Hemiparesis</td>
<td>5 (50)</td>
<td>52.5±75</td>
<td>2 (50)</td>
<td>3 (75)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Optic neuropathy</td>
<td>3 (30)</td>
<td>52.3±26.3</td>
<td>2 (66.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Encephalopathy</td>
<td>1 (10)</td>
<td>15.9</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Optalmopathosis</td>
<td>1 (10)</td>
<td>0</td>
<td>1 (16.7)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Non-parenchymal phenotype</td>
<td>10 (43.5)</td>
<td>42±12.5</td>
<td>5 (38.5)</td>
<td>2 (28.6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Aseptic meningitis</td>
<td>10 (43.5)</td>
<td>42±12.5</td>
<td>5 (38.5)</td>
<td>2 (28.6)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Mixed</td>
<td>3 (13)</td>
<td>45±15</td>
<td>2 (15.4)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
</tr>
<tr>
<td>-Aseptic meningitis and ophtalmoparesis</td>
<td>1 (33.4)</td>
<td>60</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Aseptic meningitis and other cranial nerve involvement</td>
<td>1 (33.4)</td>
<td>0</td>
<td>1 (50)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>-Encephalopathy and intracranial hypertension</td>
<td>1 (33.4)</td>
<td>30</td>
<td>1 (50)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
</tr>
</tbody>
</table>

REFERENCES:

Disclosure of Interests: Alba Herrero-Morant: None declared, Carmen Álvarez-Reguera: None declared, Lara Sanchez-Bilbao: None declared, David Martinez-Lopez: None declared, José Luis Martin-Varillas Grant/research support from: Abbvie, Pfizer, Lilly, Janssen, UC, and Celgene, Guillermo Suarez-Arnau: None declared, Raúl Fernández Ramón: None declared, M. Cristina Mata Arnaiz: None declared, Miguel A. González-Gay Speakers bureau: Abbvie, Roche, Sanofi, Lilly, Celgene, Sobi, and MSD, MSD, Janssen, and Roche, Ricardo Blanco Speakers bureau: Abbvie, Lilly, Pfizer, Roche, BMS, Janssen, and MSD, Grant/research support from: Abbvie, MSD, Roche


POS1347

BIOLICAL THERAPY IN NEUROSARCOIDOSIS.
STUDY OF 30 PATIENTS FROM A SERIES OF 234 SYSTEMIC SARCOIDOSIS FROM A UNIVERSITY HOSPITAL

A. Herrero-Morant1, D. Martinez-Lopez1, L. Sanchez-Bilbao1, I. Gonzalez-Mazon1, J. L. Martin-Varillas5, R. Fernandez Ramon1, C. Alvarez-Reguera1, M. A. Gonzalez-Gay2, R. Blanco1, J. L. Martin-Varillas1, R. Fernandez Ramon1, C. Alvarez-Reguera1, M. A. Gonzalez-Gay2, R. Blanco1, Marques de Valdecilla University Hospital, Rheumatology and Ophthalmology, Santander, Spain; 2Hospital Comarcal de Laredo, Rheumatology, Laredo, Spain

Background: Neurosarcoidosis (NS) is a severe complication of sarcoidosis [1,2]. NS may be classified according to several subtypes [1]. Data on therapy, including biological therapy (BT) is scarce.

Objectives: To assess efficacy and safety of BT in refractory NS subtypes.

Methods: Study of NS from a large cohort (n=234) of all consecutive patients diagnosed with sarcoidosis in a single university hospital from January 1, 1999 to December 31, 2019. Diagnosis of sarcoidosis was established according to ATS/ERS/WASOG criteria [3]. Efficacy was considered as complete or partial response and no-response according to the resolution of the neurological syndrome (signs and/or symptoms) after the BT onset.

Results: NS was observed in 30 (19 women/11 men) of 234 (12.8%) patients; mean age, 55.0±15.8 years. NS subtypes were chronic headache (n=13, 43.4%), peripheral neuropathy (n=6, 20%), cranial neuropathy (n=5, 16.7%), spinal cord abnormalities (n=3, 10%) and aseptic meningitis (n=3, 10%). A total of 26 (86.7%) patients received oral corticosteroids (CT) (mean maximum dose: 50±19.2 mg/dL) and 7 (23.3%) IV CT. In addition, conventional immunosuppressants were administered to 18 (60%) patients and BT to 12 (40%) patients. No treatment was administered to 4 (13.3%) patients. Table 1 shows treatment according to NS subtypes. A total of 12 patients received treatment with 22 BT. Most used BT were monoclonal anti-TNFα (n=18, 81.8%), infliximab (IFX) (n= 10, 45.5%) and adalimumab (ADA) (n=5, 22.7%). After 12 months since the initiation of BT, complete or partial response was observed in 14 of 17 (82.4%), 2 (11.8%) and 1 patient (5.9%), respectively (Figure 1). Severe allergic reaction was...
**Table 1. Treatment of 30 patients with neurosarcoidosis**

<table>
<thead>
<tr>
<th>Neurosarcoidosis subtype</th>
<th>n (%)</th>
<th>Other clinical manifestations</th>
<th>Conventional immunosuppressant, n (%)</th>
<th>Monoclonal anti-TNFα, n (%)</th>
<th>Etanercept, n (%)</th>
<th>Tocilizumab, n (%)</th>
<th>Seucinumab, n (%)</th>
<th>Rituximab, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic headache*</td>
<td>13 (43.4)</td>
<td>P (n=9, 69.2%)</td>
<td>MTX (n=6, 26.1%)</td>
<td>IFX (n=1, 4.5%)</td>
<td>0 (0)</td>
<td>0</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A (n=9, 69.2%)</td>
<td>AZA (n=1, 4.3%)</td>
<td>ADA (n=1, 4.5%)</td>
<td>GLM (n=1, 4.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C (n=6, 46.2%)</td>
<td>D (n=4, 30.8%)</td>
<td>IFX (n=3, 13.6%)</td>
<td>ADA (n=2, 9.1%)</td>
<td>GLM (n=1, 4.5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>D (n=4, 30.8%)</td>
<td>D (n=4, 30.8%)</td>
<td>1 (4.5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>6 (20.0)</td>
<td>P (n=5, 83.3%)</td>
<td>MTX (n=4, 17.4%)</td>
<td>IFX (n=3, 13.6%)</td>
<td>ADA (n=1, 4.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A (n=3, 50%)</td>
<td>AZA (n=2, 8.7%)</td>
<td>ADA (n=2, 9.1%)</td>
<td>GLM (n=1, 4.5%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>5 (16.7)</td>
<td>P (n=4, 60%)</td>
<td>IFX (n=3, 13.6%)</td>
<td>ADA (n=1, 4.5%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Spinal cord abnormalities</td>
<td>3 (10.0)</td>
<td>P (n=3, 100%)</td>
<td>MTX (n=1, 4.3%)</td>
<td>IFX (n=1, 4.5%)</td>
<td>GLM (n=1, 4.8%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Aseptic meningitis</td>
<td>3 (10.0)</td>
<td>P (n=2, 66.7%)</td>
<td>MTX (n=2, 8.7%)</td>
<td>IFX (n=2, 9.1%)</td>
<td>ADA (n=1, 4.5%)</td>
<td>0</td>
<td>1 (4.5)</td>
<td>0</td>
</tr>
<tr>
<td>TOTAL (n=30)</td>
<td>30 (100)</td>
<td>P (n=23, 76.7%)</td>
<td>MTX (n=16, 69.6%)</td>
<td>IFX (n=10, 45.5%)</td>
<td>ADA (n=5, 22.7%)</td>
<td>GLM (n=1, 4.5%)</td>
<td>1 (4.5)</td>
<td>1 (4.5)</td>
</tr>
</tbody>
</table>


**Figure 1. Neurological clinical response to biological therapy**

Observed in one patient on both IFX and ADA. No more severe adverse events were observed.

**Conclusion**: BT, especially monoclonal anti-TNFα, seems to be effective and safe in NS, regardless of subtype.

**REFERENCES**:


**Disclosure of Interests**: Alba Herrero-Morant: None declared, David Martinez-López: None declared, Lara Sanchez-Bilbao: None declared, Ilhigo Gonzalez-Mazon: None declared, José Luis Martin-Varillas Grant/research support from: AbbVie, Pfizer, Lilly, Janssen, UCB, and Celgene, Raúl Fernández Ramón: None declared, Carmen Álvarez-Reguera: None declared, Miguel Á Gonzalez-Gay Speakers bureau: Abbvie, Roche, Sanofi, Lilly, Celgene, Sobi, and MSD, Grant/research support from: Abbvie, MSD, Janssen, and Roche, Ricardo Blanco Speakers bureau: Abbvie, Lilly, Pfizer, Roche, BMS, Janssen, and MSD, Grant/research support from: Abbvie, MSD, and Roche


**POS1348 PATIENTS WITH VEXAS DIAGNOSED IN A DANISH TERTIARY RHEUMATOLOGY SETTING HAVE HIGHLY ELEVATED INFLAMMATORY MARKERS, MACROCYTIC ANEMIA, AND NEGATIVE AUTOIMMUNE BIOMARKERS.**

M. Nyhus Bendix Rasch, F. Szabados, J. M. B. Jensen, K. O. Nielsen, E. M. Hauge, A. Troldborg, Aarhus University Hospital, Rheumatology, Aarhus, Denmark; Aarhus University Hospital, Hospital, Molecular Medicine, Aarhus, Denmark; Aarhus University Hospital, Clinical Immunology, Aarhus, Denmark; Aarhus University Hospital, Biomedicine, Aarhus, Denmark

**Background**: VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome was described in 2020 with overlapping features of rheumatology and hematology. VEXAS is an autoinflammatory condition caused by somatic mutations in the UBA1 gene at methionine-41.

As patients present with highly variable clinical symptoms [1], their path in the clinical system is often complicated, and characterized by many strenuous examinations and biopsies. It is pivotal, that we familiarize with the VEXAS phenotype and advance identification of patients with VEXAS.

**Objectives**: We aimed to characterize patients diagnosed with VEXAS in a tertiary rheumatology referral center since December 2020 when the syndrome was described [2].

**Methods**: All patients were identified and diagnosed at the department of Rheumatology, Aarhus University Hospital (AUH). Denmark. Patients underwent testing for the UBA1 somatic mutations using sanger sequencing at the department of Clinical Immunology, AUH. Sequencing analyzed for somatic variants in/at UBA1 gene at methionine-41.

**Results**: A total of 11 male patients with clinical suspicion of VEXAS underwent sequencing. Five men were identified in the period December 2020 to December 2021, all had VEXAS somatic mutations. Median age at diagnosis was 84 (75-87). Symptoms debuted on average 22 months (IQR 20-40) before diagnosis. All patients had significantly elevated markers of inflammation: median CRP 297 (196-366), IL-6 receptor, and ferritin and presented with macrocytic anemia. None of the patients were positive for autoimmune biomarkers like ANA, ACPA, MPO-, or PR3-ANCA.

**Conclusion**: This is, to the best of our knowledge, the first report of Danish patients with the VEXAS syndrome. Patients are males with persistent inflammatory, constitutional symptoms, and heterogeneous clinical presentations.

**REFERENCES**:

Table 1. Clinical, biochemical characteristics at diagnosis and treatment of Danish VEXAS patients.

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
<th>Patient 5</th>
<th>Total n(%) or median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>73</td>
<td>21</td>
<td>47</td>
<td>30</td>
<td>22 (20-40)</td>
</tr>
<tr>
<td>Time from symptom onset till diagnosis (months)</td>
<td>89</td>
<td>122</td>
<td>77</td>
<td>30</td>
<td>84 (75-87)</td>
</tr>
<tr>
<td>U/B/A7 variant</td>
<td>c.122 T&gt;C</td>
<td>c.122 T&gt;C</td>
<td>c.122 T&gt;C</td>
<td>c.121 A&gt;C</td>
<td>c.118-1 G&gt;C</td>
</tr>
<tr>
<td>Macrogenic anemia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CRP</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>(mg/ml)</td>
<td>(335)</td>
<td>(436)</td>
<td>(220)</td>
<td>(172)</td>
<td>(297)</td>
</tr>
<tr>
<td>Constitutional symptoms*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Vasculitis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Chondritis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ocular inflammation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Arthritis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Lung involvement</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Proteinuria</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>BM vacuoles</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Biochemical characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANA</td>
<td>NA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>ACPA</td>
<td>NA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>PR3 or MPO-ANCA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>

Background: Adalimumab remains the only biologic approved by the EMA and FDA for the treatment of non-infectious uveitis [1-6]. The reports on efficacy of other anti-TNF drugs such as Certolizumab Pegol (CZP) are scarce.

Objectives: to determine the efficacy and safety of CZP in refractory uveitis secondary to Immune-mediated Inflammatory Diseases (IMIDs).

Methods: national multicenter study of 80 patients with uveitis due to IMID refractory to glucocorticoids and conventional immunosuppressants treated with CZP. Efficacy was assessed with the following ocular parameters: best corrected visual acuity (BCVA), anterior chamber cells, vitritis, macular thickness and presence of retinal vasculitis. The efficacy of CZP was compared between the baseline visit, 1st week, 1st month, and 1st year. Statistical analysis was performed with IBM SPSS Statistics v.23.

Results: we studied 80 patients/111 affected eyes (33 men/47 women) with a mean age of 41.6±11.7 years. The IMIDs included were: spondyloarthritides (n=43), Behcet's disease (10), psoriatic arthritis (8), Crohn's disease (4), sarcoidosis (2). JIA (1), reactive arthritis (1), rheumatoid arthritis (1), relapsing polychondritis (1), TINU (1), pars planitis (1), Birdshot (1) and idiopathic uveitis (6). The most frequent uveitis pattern (n=21). In 20 patients, besides the presence of refractory uveitis, desire of pregnancy was the reason for CZP initiation. Prior to CZP, patients had received: methotrexate (n=38), sulfasalazine (28), azathioprine (14), cyclosporine (10), leflunomide (3), mycophenolate mofetil (4), and cyclophosphamide (1). Previous biologic therapy was administered in 52 patients (63%), with a median [IQR] of 2 [1-3] drugs per patient. The most used biologic was adalimumab (n=48), followed by infliximab (32), golimumab (15), tocilizumab (5), anetaprost (7), rituximab (1), anakinra (1) and secukinumab (1). CZP was administered as monotherapy in 39 patients.

After 24 [12-36] months of follow-up, all parameters analyzed showed a rapid and maintained improvement (Table 1). A decrease in the mean number of uveitis flares was observed before and after CZP (2.6±2.3 vs. 0.6±0.4, p<0.001). CZP was discontinued in 16 patients due to: ocular remission (n=3), insufficient ocular response (4) and incomplete response of extracocular manifestations (9). No serious adverse effects were found.

Conclusion: CZP seems to be effective and safe in the control of uveitis associated to different IMIDs.

REFERENCES:


| Table 1. main ocular parameters analyzed in 80 patients with uveitis due to IMID and treated with CZP. |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| **CZP**         | Baseline        | 1st week        | 1st month       | 3rd month       | 6th month       | 1st year        |
| **BCVA (mean±SD)** | 0.68±0.27       | 0.73±0.26       | 0.79±0.26       | 0.82±0.25       | 0.85±0.24       | 0.86±0.23       |
| **Tyndall improvement, n (%)** | 23 (40.3)       | 45 (78.9)       | 47 (82.4)       | 57 (100)        | 57 (100)        |
| **Vitritis improvement, n (%)** | 5 (38.7)        | 8 (57.1)        | 13 (92.8)       | 14 (100)        | 14 (100)        |
| **OCT (µm, mean±SD)** | 297±42.8        | 297±42.8        | 286±59.9       | 277±63.4        | 271±53.8        | 269±33.8        |
| **Chorioiditis, affected eyes, n (%)** | 3 (2.4)         | 3 (2.4)         | 2 (1.6)         | 2 (1.6)         | 1 (0.8)         | 0 (0)           |
| **Retinal vasculitis, affected eyes, n (%)** | 3 (2.4)         | 2 (1.6)         | 1 (0.8)         | 1 (0.8)         | 0 (0)           | 0 (0)           |

*p<0.01

**Rheumatology, Barcelona, Spain;** \(^{12}\)Hospital 12 de October, Pediatrics, Madrid, Spain; \(^{13}\)Hospital de Sagunto, Rheumatology Valencia, Spain; \(^{14}\)Hospital Universitario Marqués de Valdecilla, Internal Medicine, Santander, Spain

Background: Cystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behcet’s disease (BD) is one of the diseases most frequently associated with CME [1-4].

Objectives: to compare the efficacy and safety of Certolizumab (CZP) and Adalimumab (ADA) in CME due to BD refractory to conventional therapy.

Methods: multicenter study of patients with CME secondary to BD by glucocorticoids (GC) and at least 1 conventional immunosuppressant. All patients had CME (OCT>300µ) at baseline. Efficacy was assessed with the following ocular parameters: macular thickness (µm), visual acuity (BCVA) and GC-sparing effect. The efficacy of CZP vs. ADA was compared between the baseline visit, 1st and 6th month, and 1st and 2nd year. Statistical analysis was performed with IBM SPSS Statistics v.23.

Results: we studied 21 patients/38 affected eyes were studied. 10 patients were treated with CZP (200 mg c/2 weeks) and 11 with ADA (loading dose of 80 mg and subsequently 40 mg c/2 weeks). No statistically significant baseline differences were observed in both groups (CZP vs. ADA in sex (♂/♀), 3/7 vs 5/6; p=0.65) and mean age (36.1±8.0 vs 42±8.6; p=0.10). However, CZP group was more severe with a longer time between EB diagnosis and biologic initiation (91.6±7.14 vs 34.4±21.3 months, p=0.02), and a greater median [IQR] number of previous biologic drugs (2 [0.75-3] vs 0 [0-0]). In CZP group, 8 patients were previously treated with ADA. Combined treatment with conventional DMARDs was used with ADA in 81.8% vs. 18.2% of CZP patients.

Regarding the efficacy outcomes analyzed, a rapid and maintained improvement in macular thickness, measured by OCT, was observed after 2 years of follow-up in both groups with no statistically significant differences between them (Table 1). Improvement in visual acuity and a GC-sparing effect was also observed (Table 1). No serious adverse events were observed in either group.

Conclusion: Our study suggests that both CZP and ADA are effective in the treatment of CME due to BD refractory to conventional treatment. CZP was equally effective despite most patients were refractory to ADA.

REFERENCES:

Background: Sarcoidosis is a granulomatous inflammation of unknown etiology. Neurosarcoidosis (NS) occurs in 5–10% of patients with sarcoidosis and is a severe manifestation of sarcoidosis. The clinical presentation is heterogeneous and depends on the inflammation within the nervous system.

Objectives: This study aimed to describe NS patients and their clinical course of treatment. Our outcomes were changes in 1) enhancing lesions on MRI of the central nervous system (CNS), 2) cerebrospinal fluid (CSF), 3) disability and dependency in daily activities assessed by the modified Rankin Scale (mRS), 4) cognitive function assessed by the Symbol Digit Modalities Test (SDMT), 5) quality of life assessed by Short-Form 36 Health Survey (SF-36), 6) fatigue assessed by Fatigue Assessment Scale (FAS), and 7) depression measured by Beck Depression Inventory-II (BDI-II).

Methods: In this observational cohort study with a one-year follow-up, we consecutively recruited NS patients (N=20), not including patients with polyneuropathy, from the Departments of neurology and rheumatology at Odense University Hospital between January 2016 and August 2020. Patients were examined clinically, with questionnaires and MRI at baseline (V1), and after three months (V3), six months (V6), and 12 months (V12). Cerebrospinal fluid (CSF) was examined at baseline, V6, and V12.

Results: The median age was 51.6 years, and the median duration of sarcoidosis symptoms was 8 months before inclusion. At baseline, 60% of NS patients had headache, followed by vertigo (55%) and tinnitus (50%). Objective neurological findings were peripheral sensory signs (50%), peripheral motor signs (40%), and cranial nerve involvement (30%). At V12, there were significant improvements in vertigo (p=0.03), cranial nerve involvement (p=0.03), and joint symptoms (p=0.03).

At baseline, 60% of patients had abnormal findings on MRI of CNS. During the study, the number of contrast-enhancing lesions on MRI decreased significantly (p<0.0001). The mRS declined significantly from mean (SD) 3.0 (0.8) at baseline to 1.8 (1.1) at V12 (p<0.0001), and 75% of patients experienced clinically important improvement (mRS1).

The SDMT score improved significantly from mean (SD) 38 (9) at baseline to 45 (12) at V12 (p<0.0001). The SF-36 Physical (PCS) and Mental Component Summary scores (MCS) improved significantly from baseline: PCS mean (SD) 35 (11) to 42 (12) at V12 (p=0.003) and MCS mean (SD) 41 (9) to 48 (10) at V12 (p=0.03). The proportions of patients with substantial fatigue (75%) and high depression score (35%) were unchanged.

Conclusion: One year of immunosuppression in NS patients improved several outcomes, and 75% of patients experienced clinically important improvement.

Disclosure of Interests: None declared

ANALYSIS OF FACTORS ASSOCIATED WITH GOOD THERAPEUTIC RESPONSE TO IMMUNOSUPPRESSIVE DRUGS IN PATIENTS WITH NON-INFECTIONOUS UVEITIS: A SURVIVAL ANALYSIS


1Hospital Infantía Sofia, Rheumatology, San Sebastián de los Reyes, Spain; 2Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain;

Background: Non-infectious uveitides (NIUs) encompass a varied group of inflammatory diseases affecting the uvea and adjacent tissues, with evidence suggesting an immune-mediated cause. A correct management of these conditions is essential to prevent substantial and sometimes permanent visual loss and the development of ocular complications. Although immunosuppressive drugs (ISDs) have shown effectiveness in achieving a sustained control of the inflammatory process, not all patients achieve a satisfactory response.

Objectives: To identify factors affecting the response rate to ISDs in subjects with NIUs.

Methods: Longitudinal retrospective study, with patients collected from the Hospital Clínico San Carlos Uveitis Clinic, included from 1991 until December 2018, and followed-up until December 2019. Patients entered the study at ISD prescription and were followed-up until a) the achievement of a good therapeutic response (GTR), b) ISD treatment change (withdrawal of the prescribed ISD and/or addition of a new ISD), c) 12 months of follow-up, or d) loss of follow-up or end of the study (December 31th, 2019). GTR was defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days.

Kaplan-Meier (KM) curves were set to account for GTR. Associated demographic, clinical and treatment-related factors were analyzed using bivariate and multivariate Cox robust regression models. Different models were compared using the Akaike Information Criteria, to select the fittest model to the data. Proportional hazard assumption was tested using Schoenfeld residuals.

Results: 73 patients (100 episodes of ISD prescription) were analyzed. In 44 episodes, a GTR was achieved (incidence rate 102.0 [95% Confidence Interval (CI): 75.9 to 137.1] per 100 patient-years). Figure 1 shows the KM curve for GTR. In the bivariate analysis, several variables showed a significant association with GTR, including gender, diagnosis of Behçet Disease, prescription of Cyclosporine A (CYA), number of previously prescribed ISDs, previous use of ISDs in combination could be more effective than their use in monotherapy or in combination. Several observational studies showed that the use of ISDs in combination could be more effective than their use in monotherapy. However, a direct comparison between these two treatment strategies has not been carried out yet.

Objectives: To analyze the effect of ISDs combination therapy (CT) on the response rate in patients with NIUs.

Methods: Patients attending a Uveitis Outpatient Clinic from a tertiary care center in Madrid, Spain, and prescribed with ISDs from 1991 to 2018 were included. Patients were assigned as controls or cases based on whether they were prescribed with ISDs in monotherapy (MT) or CT. ISD treatment changes during the observation period were also considered. The primary outcome was good therapeutic response (GTR), defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid dosage ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. Several propensity score based and non-based weighting techniques for data balancing, followed by Cox regressions, were performed to estimate the effect of CT on the response rate. Random forest (RF) models and clinical appraisal were used to select the variables to be balanced.

Results: 100 episodes of ISD prescription belonging to 73 patients were included in this analysis. In 32 episodes, patients were prescribed with CT (in 3 episodes CT was the initial therapeutic strategy; in 29, combination was the result of adding a second or third ISD). The most frequent drug used in MT was cyclosporine A (CYA; n=39), and the most frequent CT was synthetic + biological ISD (n=21). After RF, the number of previously used ISDs, the prescription of CYA, the dosage of oral corticosteroids at prescription, a previous ISD withdrawal due to inefficacy, and duration of disease were selected for balancing. In addition, after clinical appraisal, uveitis diagnosis, prescription with azathioprine, prescription with ni-

Disclosure of Interests: None declared


TO COMBINE OR NOT TO COMBINE: INFLUENCE OF IMMUNOSUPPRESSIVE DRUG COMBINATION IN THE INDUCTION OF THERAPEUTIC RESPONSE IN NON-INFECTIONOUS UVEITIS

M. P. Álvarez Hernández1, A. Madrid García2, A. Gomez-Gomez2, A. Madrid García2, L. Borrego-Sanz2, R. Méndez-Fernández2, P. Arriola-Villalobos2, E. Pato2, D. Díaz Valle2, L. Rodríguez Rodríguez2 on behalf of Madrid Uveitis Study Group. 1Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain; 2Instituto de Investigación Sanitaria San Carlos, Ophthalmology, Madrid, Spain; 3Hospital Infanta Sofia, Rheumatology, San Sebastián de los Reyes, Spain

Background: Non-infectious uveitides (NIUs) include a heterogeneous group of sight-threatening and incapacitating conditions. Their correct management sometimes requires the use of immunosuppressive drugs (ISDs), prescribed in monotherapy or in combination. Several observational studies showed that the use of ISDs in combination could be more effective than their use in monotherapy. However, a direct comparison between these two treatment strategies has not been carried out yet.

Objectives: To analyze the effect of ISDs combination therapy (CT) on the response rate in patients with NIUs.

Methods: Patients attending a Uveitis Outpatient Clinic from a tertiary care center in Madrid, Spain, and prescribed with ISDs from 1991 to 2018 were included. Patients were assigned as controls or cases based on whether they were prescribed with ISDs in monotherapy (MT) or CT. ISD treatment changes during the observation period were also considered. The primary outcome was good therapeutic response (GTR), defined as the complete resolution of the eye inflammatory manifestations and oral corticosteroid dosage ≤10 mg of prednisone equivalent a day. Furthermore, this situation had to be maintained in at least two consecutive visits spanned at least 28 days. Several propensity score based and non-based weighting techniques for data balancing, followed by Cox regressions, were performed to estimate the effect of CT on the response rate. Random forest (RF) models and clinical appraisal were used to select the variables to be balanced.

Results: 100 episodes of ISD prescription belonging to 73 patients were included in this analysis. In 32 episodes, patients were prescribed with CT (in 3 episodes CT was the initial therapeutic strategy; in 29, combination was the result of adding a second or third ISD). The most frequent drug used in MT was cyclosporine A (CYA; n=39), and the most frequent CT was synthetic + biological ISD (n=21). After RF, the number of previously used ISDs, the prescription of CYA, the dosage of oral corticosteroids at prescription, a previous ISD withdrawal due to inefficacy, and duration of disease were selected for balancing. In addition, after clinical appraisal, uveitis diagnosis, prescription with azathioprine, prescription with ni-

Disclosure of Interests: None declared


Table 1. Multivariate Cox robust regression to analyze variables independently associated with the achievement of good therapeutic response.

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR (95% CI)</th>
<th>p value</th>
<th>Schoenfeld test p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYA prescription</td>
<td>2.04 (1.14-3.67)</td>
<td>0.017</td>
<td>0.56</td>
</tr>
<tr>
<td>Number of previous ISDs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>Reference</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>12.61 (2.07-76.73)</td>
<td>0.9x10^-3</td>
<td>0.001</td>
</tr>
<tr>
<td>2</td>
<td>3.54 (1.55-8.05)</td>
<td>2.6x10^-3</td>
<td>0.56</td>
</tr>
<tr>
<td>1 previous ISD X Time</td>
<td>0.01 (0.001-1.00)</td>
<td>0.005</td>
<td></td>
</tr>
<tr>
<td>Higher oral corticosteroids dosage (mg) in the previous year</td>
<td>0.98 (0.97-0.99)</td>
<td>0.013</td>
<td>0.83</td>
</tr>
<tr>
<td>Macular edema</td>
<td>0.14 (0.04-0.45)</td>
<td>9.3x10^-3</td>
<td>0.001</td>
</tr>
<tr>
<td>Macular edema X Time</td>
<td>14.20 (1.55-103.10)</td>
<td>0.019</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Kaplan-Meier failure curves representing good therapeutic response after immunosuppressive drug prescription for non-infectious uveitides.

Disclosure of Interests: None declared

with methotrexate, and eye activity features at presentation (presence of cells in anterior chamber, vitreous haze, macular edema, active choroidal lesions) were also balanced. The Energy balancing method showed the best balance for GTR. After Cov-regression, CT prescription did not show a statistically significant effect in the hazard of response (p=0.43; Table 1).

Table 1. Cox models showing the effect of combination therapy in the hazard of good therapeutic response after balancing covariates using the Energy method.

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR (95% CI)</th>
<th>p value</th>
<th>Schoenfeld test p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combination Therapy</td>
<td>0.66 (0.24-1.83)</td>
<td>0.43</td>
<td>0.82</td>
</tr>
<tr>
<td>Cyclosporine A prescription</td>
<td>3.36 (129.2-27)</td>
<td>0.019</td>
<td>0.96</td>
</tr>
<tr>
<td>Methotrexate Prescriptions</td>
<td>3.70 (70.27)</td>
<td>0.16</td>
<td>0.95</td>
</tr>
<tr>
<td>Presence of cell in anterior chamber</td>
<td>1.75 (0.83-3.72)</td>
<td>0.14</td>
<td>0.89</td>
</tr>
</tbody>
</table>

Conclusion: The use of CT in our study was not associated with a better therapeutic response in NIU patients compared with the prescription of MT. Considering that most CT episodes were the result of the addition of a new ISD in a patient already treated and still active, the effectiveness of CT as the initial therapeutic strategy remains uncertain.

Disclosure of Interests: None declared

POS1356
TREATMENT OF IMMUNE CHECKPOINT INHIBITOR-INDUCED INFLAMMATORY ARTHRITIS AND POLYMYLGAH RHEUMATICA
M. Liapi1, K. Chatzidionysiou1. 1Karolinska Institute, Rheumatology Unit, Karolinska University Hospital, Department of Medicine Solna, Stockholm, Sweden

Background: Therapy with immune check point inhibitors (ICIs) has revolutionized cancer treatment during the last years. Despite their high efficacy, ICIs are associated to a new spectrum of adverse events, the immune-related adverse events (irAEs). Inflammatory arthritis and polymyalgia rheumatica (PMR) are two of the most common irAEs. The optimal management of irAEs remains unclear. Treatment guidelines largely support the use of glucocorticoids (GCs) as first line therapy [1]. Preclinical data raise concerns regarding the potential risk of impaired antitumoral effect with use of GCs. The high efficacy and potential synergistic effect (according to recent findings) [2] of targeted immunomodulation, such as interleukin 6 (IL-6) blockade, could support a paradigm shift, where targeted treatments are considered earlier in the treatment sequence.

Methods: We retrospectively identified patients who were diagnosed with inflammatory arthritis and/or PMR at the rheumatology department at Karolinska University Hospital, after referral from the oncology department due to suspicion of a rheumatic irAE. The optimal management of irAEs remains unclear. Treatment guidelines largely support the use of glucocorticoids (GCs) as first line therapy [1]. Preclinical data raise concerns regarding the potential risk of impaired antitumoral effect with use of GCs. The high efficacy and potential synergistic effect (according to recent findings) [2] of targeted immunomodulation, such as interleukin 6 (IL-6) blockade, could support a paradigm shift, where targeted treatments are considered earlier in the treatment sequence.

Objectives: To assess how frequently a disease modifying anti-rheumatic drug (DMARD) treatment in patients with ICI induced arthritis and/or PMR, after inadequate response to GCs, is initiated and to assess its effectiveness.

Methods: We retrospectively identified patients who were diagnosed with inflammatory arthritis and/or PMR at the rheumatology department at Karolinska University Hospital, after referral from the oncology department due to suspicion of a rheumatic irAE, between Jan 2020 and Dec 2021. Treatment response was defined as sustained low disease activity or remission according to the rheumatologist evaluation at 6 months (+/- 1 month) after initiation of DMARD.

Results: A total of 20 patients were identified, who were diagnosed with arthritis (N=11), PMR (N=4) or both (N=3). The median (IQR) age was 70 (46-76) years; 50% of patients were females. The type of cancer was urogenital (N=8), melanoma (N=6), lung cancer (N=2), and other (N=4). 14 patients received a PD-1 inhibitor (9 nivolumab, 4 pembrolizumab, 1 cemiplimab), 3 received a PDL-1 inhibitor (2 atezolizumab, 1 avelumab), 2 received a combination of nivolumab and the CTLA-4 inhibitor ipilimumab and one patient combination of nivolumab and pembrolizumab. The median time from start of ICI treatment to symptom debut was 2 (1.25-3.75) months.

83% of patients with PMR and/or arthritis responded well to GCs without the need for treatment escalation. One of these patients discontinued tocilizumab due to suspected side effects, and started with a TNF inhibitor. After initiation of tocilizumab all patients were able to reduce the dose of GCs to less than 5mg/day.

Conclusion: The majority of patients developing ICI-induced arthritis are refractory to GCs and need a DMARD treatment, although selection bias cannot be formally excluded, since the most severe forms of arthritis might be referred to the rheumatology department. csDMARDs are effective in a significant proportion of patients. Tocilizumab is highly effective and well tolerated in ICI-induced arthritis. ICI-induced PMR seems to respond adequately to GCs.

Disclosure of Interests: Matina Liapi: None declared, Katerina Chatzidionysiou Consultant of: consultancy fees from Eli Lilly, AbbVie and Pfizer

POS1357
THE 10-YEAR OUTCOME OF PATIENTS WITH BEHÇET’S SYNDROME: A SINGLE-CENTER EXPERIENCE
A. Doğan1, E. Tekgoz2, S. Colak3, M. Çınar2, S. Yılmaz3. 1Guزلahane Training and Research Hospital, Rheumatology, Ankara, Turkey

Background: Behçet’s syndrome (BS) is a vasculitis characterized by recurrent oral and genital ulcers, as well as ocular, cutaneous, vascular, gastrointestinal, musculoskeletal, and central nervous system manifestations.

Objectives: The study aimed to evaluate the 10-year outcome of patients with BS.

Methods: A cohort of 682 patients diagnosed with BS between January 2007 and December 2009 in the rheumatology outpatient clinic of Gulhane Training and Research Hospital were re-evaluated in November 2021. The data regarding the clinical course of 84 patients (64/862) were obtained from patients’ files and detailed telephone interviews.

Results: The study included 84 patients (63 male, 21 female) with a mean age of 47±10.6 years. The mean disease duration was 17±6.5 years. At the time of the diagnosis, the mean age of the patients was 29.5±9.4 years. Oral ulcer (100%), papulopustular lesions (82.1%), genital ulcer (77.4%), and erythema nodosum (59.5%) were the most frequent manifestations at the time of diagnosis. Ocular (46.4%), musculoskeletal (35.7%), vascular (19%), gastrointestinal (3.6%), and neurological (12%) manifestations were the most frequent irAEs in decreasing frequency. The most frequent ocular disease was posterior uveitis, whereas superficial thrombophlebitis and deep venous thrombosis were the most prevalent forms of vascular involvement. One patient had transverse myelitis as neurological involvement. Colchicine (86.1%) and corticosteroids (57.1%) were the most preferred drugs for the initial treatment. Fifty-one (60.7%) patients received at least one immunosuppressive agent. After 10-year, there was a statistically significant decrease in all manifestations of BS (Table 1). Nevertheless, 9 (10.7%) patients (8 male, 1 female) had new clinical findings. Five patients had (5.9%) mucocutaneous, 2 (2.4 %) arthritis and 2 (2.4%) vascular lesions as new clinical manifestations. The mean age of the patients with newly onset clinical findings was 46±8.9 years. There was no statistically significant difference between patients with and without new clinical findings with respect to age (p=0.79). The new onset mucocutaneous manifestations were genital ulcer and erythema nodosum. Besides, new onset vascular lesions were superficial and deep venous thrombosis of the lower extremities. The mean age of the patients who developed venous thrombosis at the time of the assessment was 37±0.7 years. Vascular involvement was detected more frequently in younger patients.

Table 1. Clinical manifestations of Behçet’s syndrome

<table>
<thead>
<tr>
<th></th>
<th>Initial</th>
<th>After 10 years</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Oral ulceration, n (%)</td>
<td>0</td>
<td>0</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Genital ulceration, n (%)</td>
<td>Yes</td>
<td>84 (100)</td>
<td>0 (0)</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>19 (22.7)</td>
<td>16 (19)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 (15.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes</td>
<td>65 (77.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>54 (83.1)</td>
<td>11 (16.9)</td>
</tr>
<tr>
<td>Erythema nodosum and</td>
<td>6 (7.1)</td>
<td>4 (66.7)</td>
<td>2 (33.3)</td>
</tr>
<tr>
<td>Papulopustular lesions, n (%)</td>
<td>Yes</td>
<td>78 (92.9)</td>
<td>44 (56.1)</td>
</tr>
<tr>
<td>Arthritis, n (%)</td>
<td>No</td>
<td>54 (63.4)</td>
<td>52 (96.3)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>30 (35.7)</td>
<td>21 (70)</td>
</tr>
<tr>
<td>Vascular involvement, n (%)</td>
<td>No</td>
<td>68 (81)</td>
<td>66 (87.1)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>16 (19)</td>
<td>12 (75)</td>
</tr>
<tr>
<td>Gastrointestinal, n (%)</td>
<td>No</td>
<td>81 (96.4)</td>
<td>81 (100)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>3 (3.6)</td>
<td>1 (1.2)</td>
</tr>
<tr>
<td>Ocular involvement, n (%)</td>
<td>No</td>
<td>45 (53.6)</td>
<td>45 (100)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>39 (46.4)</td>
<td>29 (74.4)</td>
</tr>
<tr>
<td>Neurological involvement, n (%)</td>
<td>No</td>
<td>83 (98.8)</td>
<td>83 (100)</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>1 (1.2)</td>
<td>1 (1.0)</td>
</tr>
</tbody>
</table>

McNemar-Bowker Test, **McNemar Test
Idiopathic Granulomatous mastitis (IGM) is a rare inflammatory disease of the breast with poorly understood aetiology or risk factors. IGM has a predilection towards women of child-bearing age with a history of breastfeeding, particularly among Hispanic and Asian ethnicities. However, the true prevalence is unknown with IGM being poorly studied in Middle Eastern Arab and Levantine women who have different genetic, epidemiological, and environmental characteristics.

Objectives: To study the clinical features of Middle Eastern women diagnosed with biopsy-confirmed IGM.

Methods: A retrospective observational study of patients with a biopsy-confirmed diagnosis of IGM, referred to two different private outpatient rheumatology clinics in Amman-Jordan between 2016-2021. The Patients’ characteristics, clinical presentation, treatment, and outcomes were recorded.

Results: A total of 25 patients were identified in this study. The mean age was 34.9 ± 5.2 years. All females presented with a breast nodule and tenderness, while only 16% reported associated skin changes in the breast and 12% reported galactorrhoea. Bilateral breast involvement occurred in only 4 patients (16%), while 21 patients had unilateral breast involvement. Systematic manifestations including myalgia/arthritis, skin changes, fever, and axillary lymphadenopathy were reported by 44%, 16%, 20%, and 16% of patients, respectively. Notably, all enrolled females were married at the time of presentation and 3 of them were pregnant or postpartum during the onset of symptoms. The majority of patients (n=21, 84%) had a prolonged period of breastfeeding (> 6 months). Moreover, 80% of patients had ≥3 pregnancies with 60% having their youngest child aged 3-5 years.

20 patients (80%) had a complete resolution of symptoms, and 20% (n=6) were lost to follow-up. Among patients who completed follow-up, treatment duration lasted for ≥ 1 year in 36% (n=9) of patients, whereas 11 patients had a complete resolution in less than a year. Azathioprine, methotrexate, antibiotics, and steroids were used in the treatment of 20%, 36%, 60%, and 68%, respectively. Of note, only 1 patient underwent surgical intervention during treatment.

Conclusion: Many theories have suggested different aetiology for IGM but, in our cohort, it appears that being multiparous and prolonged breastfeeding carry higher risks of developing granulomatous mastitis. Although the aetiology is unclear, early diagnosis and the introduction of treatment using steroid therapy and immunosuppression can improve prognosis and prevent unnecessary surgery. Most of our patients that were treated with corticosteroid, Azathioprine, and Methotrexate had a complete resolution of symptoms after one year of therapy.

Disclosure of Interests: None declared.

Background: Demonstration of deposits by non-invasive methods is important especially for organs difficult to sample in amyloidosis. Transient elastography (fibroscan) is a diagnostic method being used to measure liver stiffness (LS) in different chronic liver diseases.

Objectives: We herein aimed to test the place of fibroscan method for detecting increased LS associated with amyloid deposition in patients (pts) with amyloidosis.

Methods: Six categories of pts enrolled into this cross-sectional study; AA amyloidosis (AA-a), AL amyloidosis (AL-a), Familial Mediterranean Fever (FMF) pts without amyloidosis, cirrhotic chronic liver disease, non-cirrhotic chronic hepatitis, and healthy controls (HC). LS assessment by fibroscan was categorized as normal for kPa<7, significant stiffness for kPa≥7, advanced stiffness for kPa≥9.5, and advanced stiffness for kPa≥12.5.

Results: A total of 165 pts (AA-a, n=65; AL-a, n=15; FMF, n=20; cirrhotic pts, n=16; CHB, n=22; HC, n=27) constituted the study group. Average age was higher in the AL-a group compared to others. Median LS was highest in cirrhotic pts, and it was also higher in AA-a and AL-a pts compared to FMF and HC. Median LS was numerically higher in AL-a compared to AA-a, in cirrhotic pts, and it was also higher in AA-a and AL-a pts compared to FMF and HC. Median LS was higher in cirrhotic pts than in AA-a and AL-a.

Conclusion: As the lesions of amyloidosis are often located within the liver, which is otherwise inaccessible to other diagnostic methods, fibroscan could be of value in these cases. Further studies are required to validate these findings in larger populations. 

Table 1.

<table>
<thead>
<tr>
<th>AA-a (n=65)</th>
<th>FMF (n=20)</th>
<th>AL-a (n=15)</th>
<th>Cirrhosis (n=16)</th>
<th>Chronic Hepatitis B (non-cirrhotic) (n=22)</th>
<th>HC (n=27)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)*</td>
<td>46 (19)</td>
<td>42.5 (13)</td>
<td>58 (16)</td>
<td>49 (15)</td>
<td>45 (21)</td>
</tr>
<tr>
<td>Gender (n, %)</td>
<td>38 (59)</td>
<td>10 (50)</td>
<td>6 (40)</td>
<td>10 (62.5)</td>
<td>13 (59)</td>
</tr>
<tr>
<td>Male</td>
<td>27 (41.5)</td>
<td>21 (11)</td>
<td>5 (33)</td>
<td>9 (67)</td>
<td>19 (55)</td>
</tr>
<tr>
<td>Female</td>
<td>8 (38.5)</td>
<td>9 (45)</td>
<td>5 (67)</td>
<td>6 (33)</td>
<td>4 (44)</td>
</tr>
<tr>
<td>Diabetes Mellitus (n, %)</td>
<td>5 (8)</td>
<td>3 (15)</td>
<td>5 (33)</td>
<td>2 (12)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²) *</td>
<td>25.7 (14)</td>
<td>29.6 (14)</td>
<td>24.8 (34)</td>
<td>26.7 (6.7)</td>
<td>25.5 (7)</td>
</tr>
<tr>
<td>Liver stiffness (kPa)*</td>
<td>6.7 (5.6)</td>
<td>6.45 (2.7)</td>
<td>9.8 (12)</td>
<td>26.7 (22)</td>
<td>26.7 (22)</td>
</tr>
<tr>
<td>Significant stiffness (kPa≥7)</td>
<td>31 (46)</td>
<td>11 (55)</td>
<td>8 (58)</td>
<td>16 (100)</td>
<td>4 (18)</td>
</tr>
<tr>
<td>Advanced stiffness (kPa≥9.5)</td>
<td>17 (26)</td>
<td>4 (20)</td>
<td>3 (20)</td>
<td>16 (100)</td>
<td>3 (14)</td>
</tr>
<tr>
<td>S4 stiffness (kPa≥12.5)</td>
<td>10 (15)</td>
<td>5 (33)</td>
<td>6 (40)</td>
<td>16 (100)</td>
<td>2 (9)</td>
</tr>
<tr>
<td>APRI score*</td>
<td>0.25 (0.2)</td>
<td>0.26 (0.2)</td>
<td>0.24 (0.2)</td>
<td>0.77 (13)</td>
<td>0.22</td>
</tr>
</tbody>
</table>

Table 1.

| ALP (U/L)* | 97 (65) | 79 (55) | 103 (54) | 79 (126) | 76 (39) |
| GGT (U/L)* | 18 (15) | 15 (73) | 61 (61) | 24 (51) | 16 (14) |

*Median, interquartile of range

p1: AA-a and FMF; p2: AA-a and cirrhosis; p3: AA-a and chronic liver disease; p4: AA-a and HC; p5: FMF and HC; p6: AA-a and AL-a

Conclusion: The Canadian research group of rheumatology in immuno-oncology (canRIO): a nationwide multi-center prospective cohort.
Background: Apremilast has been shown to be effective in patients with Behçet’s disease (BD) in domains other than oral ulcers; however, its long-term efficacy is yet to be determined. Although serum cytokine modulation by increasing intracellular cAMP levels has been suggested as a mechanism for the efficacy of apremilast on skin areas of psoriasis [1], the relationship between efficacy and cytokine on various domains in BD has not been fully investigated.

Objectives: This study aims to evaluate the long-term clinical efficacy of apremilast in BD and its effect on serum cytokines.

Methods: In this study, patients with BD who received apremilast for active oral ulcers were included. For 12 months, the improvement rates of oral and genital ulcers, skin lesions, and arthritis were assessed every three months. Serum levels of cytokines, including interferon-gamma (IFN-γ), interleukin 10 (IL-10), and interleukin-23 (IL-23): TNF-α were measured in serum using a multiplex immunoassay (Luminex Assay, CA, USA) at baseline and three months after apremilast treatment. Other cytokines, including tumor necrosis factor-alpha (TNF-α), IL-6, IL-8, and IL-23: were also measured in serum using a multiplex immunoassay (Luminex Assay, R&D Systems).

Results: Fifteen patients were included in this study. Table 1 shows the characteristics of the patients who participated in this study. Oral ulcers disappeared in 66.7% and 92.3% of the patients after 3 and 6 months of apremilast treatment, respectively. Genital ulcers disappeared in all patients after 6 months of apremilast treatment and were maintained for 12 months. The efficacy of apremilast in oral ulcers could be divided between two groups: 8 patients in the oral ulcer remission group (OU-R group) whose oral ulcers completely disappeared after 3 months of apremilast administration and persisted for 1 year, and 7 patients in the oral ulcer non-remission group (OU-NR group) whose oral ulcers persisted after 3 months of apremilast treatment. Genital ulcers improved more rapidly in the OU-R group than in the OU-NR group, and completely disappeared within 3 months. Skin and joint lesions generally improved after 6 months, but recurred after 9 months.

Table 1. Baseline characteristics of the studied patients with Behçet’s disease

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N = 15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean ± SD</td>
<td>46.7 ± 13.0</td>
</tr>
<tr>
<td>Sex (female), n (%)</td>
<td>11 (73.3)</td>
</tr>
<tr>
<td>Disease duration (years), mean ± SD</td>
<td>10.4 ± 8.8</td>
</tr>
<tr>
<td>Oral ulcer</td>
<td>15 (100)</td>
</tr>
<tr>
<td>Genital ulcer</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Skin lesion (erythema nodosum or pustules)</td>
<td>10 (66.7)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>9 (60.0)</td>
</tr>
<tr>
<td>Arthritis</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Ocular involvement</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td>1 (6.7)</td>
</tr>
<tr>
<td>Neurological involvement</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Vascular involvement</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

SD, standard deviation; n, number.

Serum cytokines could be analyzed in seven of the 15 cases. There was no significant association between serum baseline cytokine levels and the presence of lesions or severity of disease. Compared to baseline, TNF-α and IL-23 levels were significantly lower after apremilast treatment and IFN-γ levels were trending upwards; however, IL-6, IL-8, and IL-10 levels showed no constant trend (TNF-α and IL-23: p < 0.05, IFN-γ: p = 0.078). In addition, the rate of decrease in serum IL-6, IL-10, and IL-23 levels was significantly greater in the OU-R group than in the OU-NR group (Figure 1). However, the rate of change in serum cytokines was not associated with efficacy of apremilast for skin lesions, arthralgia, or arthritis.

Conclusion: Apremilast has shown long-term efficacy in the treatment of oral and genital ulcers in patients with BD. The efficacy of apremilast against oral ulcers in BD may be attributed to its modulatory effect on serum cytokines as previously reported. Future exploratory studies for biomarkers associated with the persistence of efficacy against genital ulcer and arthritis are needed.

REFERENCES:


Figure 1. The rate of change in serum interleukin (IL)-6, IL-10, and IL-23 levels up to 3 months after apremilast treatment in the oral ulcer remission group and the oral ulcer non-remission group.

POS1363 THE VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF BEHÇET’S SYNDROME OVERALL DAMAGE INDEX IN A RETROSPECTIVE COHORT

Y. Yagız Ozogul1, Y. Ozgüler1,2, D. Ucar1,2, U. Uygunoglu2,3, Z. Kutlubay4,5, V. Hamuryudan1,2, G. Hamel1,2, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Behçet’s Disease Research Center, Istanbul, Turkey; Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey; Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Neurology, Istanbul, Turkey; Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey

Background: Behçet’s syndrome Overall Damage Index (BODI) is a newly developed damage index specific to Behçet syndrome (BS).

Objectives: We aimed to evaluate validity, reliability and feasibility of the Turkish version of BODI and evaluate its performance for use in retrospective cohort studies for different phenotypes of BS.

Methods: The study included 295 patients with at least 3 visits at 6 months intervals out of 590 consecutive BS patients who were admitted between January 2015 and August 2017. Turkish version of the BODI form was developed by translating into Turkish and backwards by 2 people. BODI scores were calculated for each year during the follow-up period. The test-retest reliability of BODI was assessed by scoring the same 50 patients at 6-month intervals by the same observer (YYO). Two different observers (YYO- YO) assessed the same 50 patients for inter-observer agreement. The intra-class correlation coefficient (ICC) was used to assess the inter and intra-observer agreement. We also evaluated the median time to fill out the form in patients with different types of involvements.

Results: Among the 295 (158 F/137 M) patients, mean age was 39 (9.9) and the mean disease duration was 8.8 (5.9) years. Clinical features of BS patients were summarized in the Table 1. BODI median score was 1 (IQ=0-1). We observed
an increase in BODI score in 111 (38%) patients during follow-up. The main reasons for increasing BODI scores were eye, vascular and neurological involvement (Table 1). The mean ICC for inter-observer agreement was 0.84 (95% CI, 0.89-0.96) and for intra-observer agreement was 1. The median (range) time to complete the form was 2 (1-8) minutes.

**Table 1. Clinical features and BODI scores of Behçet syndrome patients.**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Patients with myalgia attack</th>
<th>Patients without myalgia attack</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N (%) of patients with BODI score*</td>
<td>194 (66)</td>
<td>15 (5)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Ocular involvement (%)</td>
<td>77 (69)</td>
<td>12 (4)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Vascular involvement (%)</td>
<td>17 (15)</td>
<td>3 (1)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Neurological involvement (%)</td>
<td>8 (7)</td>
<td>1 (0.9)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Gastrointestinal involvement (%)</td>
<td>3 (3)</td>
<td>0 (0)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Mucocutaneous involvement (%)</td>
<td>6 (5)</td>
<td>1 (0.9)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Cardiovascular involvement (%)</td>
<td>4 (4)</td>
<td>0 (0)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Arterial ulceration (%)</td>
<td>2 (2)</td>
<td>0 (0)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Osteoporosis related fracture (%)</td>
<td>1 (0.9)</td>
<td>0 (0)</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

*All patients had at least 3 BODI scores, **Some patients had more than 1 type of involvement

**Conclusion:** This study showed that the Turkish version of BODI was a reliable and feasible instrument that could capture the change over time in damage, and could be used in retrospective cohort studies. Ocular involvement was the most common cause of progressive damage in this cohort.

**Disclosure of Interests:** Yeşil Yegiz Ozcogal: None declared, Yesim Ozogul Speakers bureau: Yesim Ozogul has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Didar Ucar: None declared, Ugur Uygunoglu: None declared, Zekayi Kutlubay: None declared, Vedat Hamuryudan: Vedat Hamuryudan has served as a speaker for AbbVe, Celgene, Novartis, and UCB Pharma., Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene; Gulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVe, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.

**DOI:** 10.1136/annrheumdis-2022-eular.4199

**References:**

**Table 1. Comparison of clinical and laboratory parameters between patients with/without myalgia attacks**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Patients with myalgia attack</th>
<th>Patients without myalgia attack</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>36.33 ±10.68</td>
<td>37.31±11.48</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>78/43</td>
<td>138/87</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Follow-up time (years)</td>
<td>16.1</td>
<td>17.6</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Patient attack (number)</td>
<td>10</td>
<td>10</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Pelletitis</td>
<td>42</td>
<td>55</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Arthritis</td>
<td>11</td>
<td>39</td>
<td>0.012</td>
</tr>
<tr>
<td>Pleuritis</td>
<td>13</td>
<td>10</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Only fever</td>
<td>4</td>
<td>7</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>AIDAI score (mean, 0-175)</td>
<td>127/40</td>
<td>80/68</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>VAS score for pain (median score,</td>
<td>8</td>
<td>5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>attack 10)</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colchicine resistance (number of</td>
<td>69</td>
<td>25</td>
<td>0.003</td>
</tr>
<tr>
<td>patients)</td>
<td>29</td>
<td>84</td>
<td>0.002</td>
</tr>
<tr>
<td>Colchicine-sensitive</td>
<td>41</td>
<td>6</td>
<td>0.016</td>
</tr>
<tr>
<td>PASS status (number)</td>
<td>34</td>
<td>74</td>
<td>0.010</td>
</tr>
<tr>
<td>Need additional treatment</td>
<td>48</td>
<td>6</td>
<td>0.003</td>
</tr>
</tbody>
</table>

**Acknowledgements:** No financial funding is received for this report. Informed consents for participating and publishing were obtained from all participants.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4246

**References:**
1. D. Yildirim1, E. Tahta2, R. C. Karda3, B. Özkızılta2, T. Krickau6, E. Cohen7, L. Oliveira Mendonca8, A. Kontzias9, J. Rech1, K. Tascilar1, A. Tufan2, M. Gattorno3, J. B. Kuemmerle-Deschner4, S. Ozen5, T. Krickau6, E. Cohen7, L. Oliveira Mendonca8, A. Kontzias9, M. Vetterli4, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology; Deutsches Zentrum für Immuntherapie, Erlangen, Germany;2 Gazi University Ankara, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey;3 UOSD Centro Malattie Autoinfiammarie e Immunodeficenze, IRCCS Istituto Giannina Gaslini, Genoa, Italy;4 University Hospital Tübingen, Department of Pediatrics; Division of Pediatric Rheumatology and Autoinflammation Reference Center Tübingen, Tübingen, Germany;5 Hacettepe University İhsan Dogramaci Children’s Hospital, Department of Pediatric Rheumatology, Ankara, Turkey;6 Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Pediatrics, Erlangen, Germany;7 FMF & AID Global Association, www.fmfaidaid.org, Zuerich, Switzerland;8 Universidade de São Paulo, School of Medicine, Discipline of Clinical Immunology and Allergy, São Paulo, Brazil;9 Stony Brook University School of Medicine, Division of Rheumatology, Allergy and Immunology, Stony Brook, NY, United States of America

**Background:** Autoinflammatory diseases (also referred to as hereditary periodic fever syndromes) are caused by defects in the innate immune system. Many autoinflammatory syndromes arise from inherited genetic mutations which begin in childhood and persist throughout adult life. These diseases are often present in several members and generations within a family. Newer research also reflects that, cases can often present at any age through-out childhood, teenage years, and even into older adulthood. These cases appear to be acquired, perhaps due to the interplay of genetic, immune, and environmental factors (somaticism). It
is not uncommon that a patient is diagnosed with rheumatoid arthritis, multiple sclerosis or another autoimmune issue, as many physicians are not aware of monogenic inborn errors, nor how to conduct a thorough work up due to a lack of training.

Objectives: Unfortunately, the knowledge base that many doctors have with regards to autoinflammatory genetic diseases is minimal to non-existent, when compared to the well-established expertise of autoimmune disease management. Concerns about the increasing patient accounts stating lack of medical diagnosis, treatment, and pain management, lead to the important decision to collect further data from the autoinflammatory patient community. The aim of the survey responses collected, and post data aggregation will help identify patient trends and use this information to educate and increase awareness amongst the medical community as to the unmet diagnostic and treatment requirements for the autoinflammatory population.

Methods: A questionnaire comprised of thirty questions was developed by members of the patient organization FMF & AID Global Association (Executive Director, Malena Vetterli with Research Director, H. Ellen Cohen) under the guidance of Dr. med. Juergen Rech focused on collecting basic information (e.g. age, country, onset and duration of symptoms, pain and fatigue). The survey was published at the end of 2020 on social media (Facebook) and on the FMF&AID website (www.fmffandaid.org). Participation was voluntary and the patients agreed that the anonymised response information of the survey may be evaluated and published. This international survey was approved by the ETHICS Committee FAU in Erlangen-Nuremberg, Germany.

Results: Worldwide, over a thousand patients or parents/caregivers of patients (younger than 18 years) in fifty-two countries took part in this survey and answered the questionnaire. Eighty percent (80%) of the participants had already been diagnosed with an autoimmune disease. However, despite classic periodic symptom presentation, twenty percent (20%) of the participants were still without a concise diagnosis. FMF - forty-three percent (43%) was cited as the most common diagnosis and M. Behçet thirty percent (30%) as the second, with a variety of others (e.g. PFAPA, CAPS, HIDS, TRAPS, DADA, Yao syndrome, and uSAID). The minimum age at diagnosis ranged from 1 to 70+ years old with an average age of 33 years when properly diagnosed. Three-hundred and nine (309) patients reported that their pain had not been taken seriously and adequately treated in the past. Pain and fatigue, as measured by the standard visual analogue scale (VAS 0-10), was high in the past 30 and 7 days, respectively. VAS pain 30 days was 4.8 (SD +/-2.7) or 7 days with 4.2 (SD +/-3), as well as fatigue VAS 30 days 5.7 (SD +/- 2.8) or fatigue VAS 7 days with 5.5 (SD +/- 3).

Conclusion: One-fifth of patients with classic symptoms of autoinflammatory diseases remain undiagnosed and therefore not specifically treated. Although, the rest of the participants eighty percent (80%) have a diagnosis of an auto-inflammatory disease, therapy does not appear to be sufficient to manage their wide-ranging and debilitating symptoms, in particular pain and fatigue. Patients continue to care for the burden of receiving mental diagnosis vs actual medical diagnosis and are still forced to seek additional medical support, often incurring travel or relocation costs to obtain proper care.

Disclosure of Interests: Jürgen Rech Speakers bureau: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD; Novartis, Roche, Sanofi, Sobi, UCB, Consultant of: Biogen, BMS, Chugai, GSK, Lilly, MSD, Novartis, Roche, Sanofi, Sobi, UCB; Grant from: Novartis, UCB, Wyeth, Pfizer, Janssen Pharmaceutica NV, Grant/Research support from: Novartis, Sobi.

Randomized observational study. All patients with IgG4-RD diagnosed by expert opinion at the Oslo University Hospital treated with ≥ 1 dose of RTX with 12 months follow-up were included. Two experts (JV, ØMi) assigned patients to phenotypes. Glucocorticoid (GC) treatment was allowed. We measured disease activity by the IgG4-RD Responder Index (IgG4-RD RI) at baseline, 6 months, and 12 months. We defined a composite primary outcome consisting of two measures; (i) reduced disease activity (i.e., ≤2 points improvement in IgG4-RD RI from baseline and/or IgG4-RD RI score 0 at follow-up), and (ii) no disease flares (i.e., no >2 points worsening of IgG4-RD RI and no need to increase GC dose) at 6 months. Secondary outcomes were (a) reduced disease activity at months 6 or 12, (b) remission (IgG4-RD RI score 0 and GC dose ≤ 7.5 mg) at 6 or 12 months and (c) safety. Descriptive statistics were applied.

Results: We included 40 patients, of which 30 (75%) were male and 35 (88%) Caucasian. Mean age and disease duration at time of first RTX infusion was 58 and 3 years, respectively. Seventeen of the 40 patients (43%) received RTX as add-on therapy (following GC for > 3 months), while 13 (33%) received RTX as upfront combination therapy with GC, and 10 (25%) received RTX as upfront monotherapy. All 40 patients received an infusion of 1000 mg RTX at study baseline (dose 1A at week 0) and 39 of these 40 patients (98%) received a second RTX infusion (dose 1B) at week 2. Additional infusions of 500-1000 mg RTX were administered at weeks 26 (dose 2A) and 28 (dose 2B) in 24 (60%) and 7 (18%) patients, respectively. The composite primary endpoint was met by 31/40 patients (78%). Reduced disease activity at 6 and 12 months were seen in 34 (87%) and 35 (90%) patients, respectively. Fifteen patients (38%) were in remission at 6 months, and 22 (56%) were in remission at 12 months. “Retroperitoneum and Aorta” showed lowest response rates, while “Head and Neck-Limited” had the highest rate of flares (Table 1). Mild infusion reaction occurred in 8 (20%) patients. Hypogammaglobulinemia was observed in 4 (10%), Infection requiring hospitalization occurred in 6 (15%), including one fatal infection which was the only death in the study period.

Table 1.

<table>
<thead>
<tr>
<th>Primary outcome</th>
<th>n=40</th>
<th>n=39*</th>
<th>n=39*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline (n=40)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>30 (75)</td>
<td>8 (89)</td>
<td>5 (83)</td>
</tr>
<tr>
<td>Caucasian (SD)</td>
<td>35 (88)</td>
<td>9 (100)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Age, years (SD)</td>
<td>58 (14)</td>
<td>63 (9)</td>
<td>66 (3)</td>
</tr>
<tr>
<td>Disease duration, years (SD)</td>
<td>3 (4)</td>
<td>4 (3)</td>
<td>3 (4)</td>
</tr>
<tr>
<td><strong>2019 ACR/EULAR classification criteria (n=40)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG4-RD RI at diagnosis (SD)</td>
<td>10 (6)</td>
<td>10 (5)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>IgG4-RD RI at RTX 1A (SD)</td>
<td>8 (6)</td>
<td>9 (4)</td>
<td>5 (4)</td>
</tr>
<tr>
<td><strong>6 months (n=39)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>29 (73)</td>
<td>8 (89)</td>
<td>5 (83)</td>
</tr>
<tr>
<td>Reduced disease activity, n (%)</td>
<td>34 (87)</td>
<td>9 (100)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Remission, n (%)</td>
<td>15 (38)</td>
<td>4 (44)</td>
<td>0</td>
</tr>
<tr>
<td>Flares, n (%)</td>
<td>3 (8)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>12 months (n=39)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>29 (73)</td>
<td>8 (89)</td>
<td>5 (83)</td>
</tr>
<tr>
<td>Reduced disease activity, n (%)</td>
<td>35 (90)</td>
<td>9 (100)</td>
<td>4 (80)</td>
</tr>
<tr>
<td>Remission, n (%)</td>
<td>22 (56)</td>
<td>7 (78)</td>
<td>3 (60)</td>
</tr>
<tr>
<td>Flares, n (%)</td>
<td>4 (10)</td>
<td>1 (11)</td>
<td>1 (20)</td>
</tr>
</tbody>
</table>

*One patient died shortly after 1A, and is not included in secondary efficacy outcomes

Conclusion: In our observational study, RTX appears safe and effective in IgG4-RD, with the highest response in patients with Pancreato-Hepato-Biliary phenotype. Relatively low remission rates across all phenotypes indicate an unmet need for improved treatment.

REFERENCES:
Pos1367 The prevalence and risk factors for cardiac disease in patients with familial mediterranean fever

Y. Butbul1, 2, L. Gabay2, Y. Braun-Moscovici1, 3, 4. Pediatric Rheumatology Service, Ruth Rappaport Children’s Hospital, Rambam Medical Center, Haifa, Israel, Pediatric B, Haifa, Israel; 1, 2, The Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel, 3, 4Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel, 5Maccabitech Institute for Research and Innovation, Tel Aviv, Israel; 6Rambam Health Care Campus, Haifa, Israel, 7, 8B. Shine Department of Rheumatology, Haifa, Israel

Background: Familial Mediterranean fever (FMF) is a genetic disorder manifested by recurrent attacks of peritonitis, pleuritis and arthritis, and characterized by clinical and laboratory evidence for localized and systemic inflammation. Colchicine treatment usually prevents the attacks and the associated inflammation. Inflammation may play an important role in the initiation and progression of atherosclerosis. Recently, colchicine was suggested as a therapy that help to prevent coronary heart disease.

Objectives: To study the effect of FMF and colchicine treatment on the cardiovascular morbidity and the overall mortality.

Methods: We studied using the data base from health insurance in Israel (Maccabi Healthcare Services-MHS) the presence of IHD and its risk factors in 492 FMF patients aged 40 years or more, and in a control groups matched by age gender and socioeconomic status.

Results: The incidence of cardiac disease in FMF patients was similar to the control group (6.5% vs 5.7% p = 0.594), smoking kidney disease and gout were higher in FMF compared to the control group (16.1 % vs 12.8% p= 0.022, 9.3% vs 5.1 p = 0.01 and 4.5% vs 0.2% p=0.001 respectively), but hypertension and diabetes were similar. The overall mortality in average follow up of 3174.37 ±1738.84 days was similar in both groups.

Conclusion: The incidence of cardiac disease among FMF patients was not increased compared to the control group, despite the exposure to recurrent inflammation. We suggest that colchicine may have a protective role in these patients.

Acknowledgements: I want to acknowledge Dr. Elad Asher for the support in the study

Disclosure of Interests: None declared


Pos1368 Diversity of hemodynamic types in connective tissue disease associated pulmonary hypertension: More than a subgroup of pulmonary arterial hypertension

X. Dong1, Y. Shi1, Y. Xia2, X. Zhang1, J. Qian3, J. L. Zhao3, J. Peng2, Q. Wang3, L. Weng2, M. Li3, B. Du2, X. Zeng3. Peking Union Medical College Hospital, Department of International Medicine, Beijing, China; 1Pediatric Rheumatology, Medical Intensive Care Unit, Beijing, China; 2Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China

Background: Connective tissue disease (CTD) associated pulmonary hypertension (PH) is classified as a subgroup of WHO group 1 PH, also called pulmonary arterial hypertension (PAH). However, not all CTD-PH fit the hemodynamic definition of PAH. This study investigates the diversity of hemodynamical types of CTD-PH, their different clinical characteristics and outcomes.

Objectives: This study investigates the diversity of hemodynamical types of CTD-PH, their different clinical characteristics and outcomes.

Methods: We performed a retrospective cohort study. CTD-PH patients underwent right heart catheterization (RHC) were enrolled and divided into WHO group 1 PH, WHO group 2 PH and high output PH (PVR<3WU and PAWP<15mHg) according to hemodynamic features. Patients with obtrusive lung diseases, left heart disease and pulmonary embolism were excluded. Baseline characteristics, inflammatory markers, autoantibodies, cardiac function status, echocardiogram parameters, hemodynamics and survival rates were compared.

Results: 207 CTD-PH patients were included, including 139 in WHO group 1 PH, 36 in WHO group 2 PH and 32 in high output PH. Incidence of anti-ribonucleoprotein antibody was lower in WHO Group 2 PH. High output PH is less severe, presenting lower NT-proBNP level, better WHF functional class, lower mPAP and PVR, higher cardiac output, and less cardiac remodeling. Among patients with elevated PAWP, combine pre-post-capillary PH had higher mPAP and larger right ventricle diameter. Association of moderate interstitial lung disease didn't show significant difference in disease characteristics. Short-term survival was significantly worse in WHO group 2 PH, yet 5-year survival rates didn't differ between groups.

Conclusion: Pre-capillary PH is not the only hemodynamic type of CTD-PH. Different types of CTD-PH present different clinical phenotypes and outcome. Carefully phenotyping PH in CTD-PH patients is important.

Disclosure of Interests: None declared


Figure 1. Measurement of pulmonary artery wall thickness by Transthoracic Echocardiography
involvement regardless of major organ involvement type. These results suggest that increased PA wall thickness in BD may be the predictor of the major organ involvement during follow-up.

REFERENCES:

Disclosure of Interests: None declared

POS1370
INCENRED INFERIOR VENA CAVA WALL THICKNESS AS A SIGN OF VENOUS INFLAMMATION IN BEHÇET’S DISEASE

S. Kutluş Ajaşkiran1, M. Sunbul2, H. Dişkeseneli1, F. Alibaz-Oner1,2, Marmara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Marmara University Faculty of Medicine, Department of Cardiology, Istanbul, Turkey

Background: Vascular involvement of Behçet’s disease (BD) involves both arterial and venous vessels of all sizes [1]. Femoral (superficial, deep, and common) and popliteal veins are the most frequently affected veins. We have previously shown that femoral wall thickness is increased in BD patients and can be used as a diagnostic test [2]. However, many other sites including vena cava inferior/superior and pulmonary arteries may also be involved [3]. Despite the dominance of venous vessel involvement, there is limited data assessing the large veins in BD.

Objectives: In this study, we aimed to assess inferior vena cava wall thickness (IVC) by transthoracic echocardiography (TTE) in BD compared with healthy controls.

Methods: Patients with BD (n=70) and age and sex-matched healthy controls (n=51) were included in this study. Assessment of inferior vena cava (IVC) wall thickness was performed by an experienced cardiologist blinded to cases. Measurement of IVC wall thickness was made at end-expiration and approximately 0.5 to 2.0 cm proximal to the ostium of the right atrium as demonstrated in Figure 1.

Results: IVC wall thickness of patients with BD (0.29 mm; SD: 0.03) was significantly higher than healthy controls (0.26 mm; SD: 0.03) (p<0.001). Although IVC wall thickness was higher in patients with BD with vascular involvement (0.30 mm; SD:0.04) and history of pulmonary embolism (0.30 mm; SD:0.04)), the difference did not reach statistical significance. There was no difference between IVC wall thicknesses in patients who used immunosuppressive and anti-TNF treatments due to major organ involvement, compared to those who did not. Similarly, no difference was observed between IVC thicknesses among Behçet’s patients according to age, gender, and activity status at the last visit. Although no correlation was found between IVC wall thicknesses, disease duration, and BDCF at the last visit in the BD group, there was a low-grade correlation between age and IVC wall thickness (r=0.31, p=0.09).

Conclusion: Increased IVC wall thickness shows vasculitic involvement of large venous structures in BD and can be easily measured by TTE which is an easily accessible, noninvasive modality without radiation. The role of IVC wall thickness assessment for the diagnosis or management of BD requires further studies.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4746

POS1371
HYPOMETHYLATION OF CIRCULATING IMMUNE CELLS IN PATIENTS WITH GRAVES’ ORBITOPATHY – A PRELIMINARY STUDY

V. Kaskova1, A. Petráčková1, J. Schovánek2, M. Karhanová1, J. Savara1, E. Kriegaon behalf of OLGEN, 1Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Department of Immunology, Olomouc, Czech Republic; 2Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Department of Internal Medicine III – Nephrology, Rheumatology and Endocrinology, Faculty of Medicine and Dentistry, Olomouc, Czech Republic; 3Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Department of Ophthalmology, Olomouc, Czech Republic

Background: Graves’ orbitopathy (GO) is an eye disease occurring in patients with autoimmune thyroid disorders (AITD), most commonly Graves’ disease. It is characterized by inflammation affecting soft tissues of the orbit. A recent study demonstrated an association between fibroblast hypomethylation and disease activity in GO (Virakul et al., Front Endocrinol, 2021). Because procurement of fibroblast from GO patients require an invasive sampling, we wondered whether analysis of global DNA methylation in circulating immune cells obtained from peripheral blood could contribute to early detection of GO from patients with AITD.

Objectives: To compare global DNA methylation pattern in circulating immune cells obtained from AITD patients with GO and without GO history and healthy controls.

Methods: Global DNA methylation was quantified in circulating immune cell populations by flow cytometry using 5-methylcytosine antibody in patients with GO (n=10), AITD without GO history (n=9) and healthy controls (n=8). Immune populations (CD4+ and CD8+ T cells, B cells, monocytes and CD56bright NK cells) and their activation status were identified using CD3/4/8/14/16/19/25/45/56/69 antibodies.

Results: In patients with GO, global DNA methylation was reduced by ~50% in the activated (CD25+) CD8+ T cells and by ~35% in the whole CD8+ T cell population compared to patients with AITD (p=0.006). Moreover, percentage of CD8+ T cells, but not activated subpopulation, was higher in GO compared to AITD (p=0.04). Hypomethylation by ~20% was detected in monocytes as well as in CD56+ NK cells and their activated (CD69+) subpopulation when GO was compared with AITD (p<0.02). Of these cell populations, percentage of monocytes was also higher in GO compared to AITD (p=0.04). Global methylation in B cells, CD4+ T cells and CD56bright NK cells did not differ between patients with GO and patients with AITD (p>0.05). Of these populations, higher percentage of B cells was detected in GO when compared to AITD group (p=0.02). Analysis of larger patient cohorts is in progress with particular emphasis on the relationship of methylation patterns to GO disease activity.

Conclusion: This is the first study identifying the different global methylation profile of circulating immune cells in patients with GO characterized by DNA hypomethylation in CD8+ T cells, CD56+ NK cells and monocytes compared to patients with AITD. Our study nominates hypomethylation as a non-invasive biomarker of GO and should be validated in a larger cohort of patients.

Acknowledgements: MH CZ NU16-03/00068, 1GA LF_2022_11, MH CZ – DRO (FNOL, 00028992), CZ.02.2.68/0.0/0.0/19_073/0016713

Disclosure of Interests: None declared
THE 2021 EULAR AND ACR POINTS TO CONSIDER FOR DIAGNOSIS, MANAGEMENT AND MONITORING OF IL-1-MEDIATED AUTOINFLAMMATORY DISEASES: CAPS, TRAPS, MKD, AND DIRA

M. Romani1, Z. S. Arico2, D. Piskin3, S. Alehashemi4, D. Aleata3, K. Barron6, S. Benser3, R. Berard8, L. Broderick9, F. Dedegolu10, M. Diebold11, K. Durrant12, P. Ferguson13, D. Foell14, J. Hausmann15, O. Jones16, K. Kastner2, H. J. Lachmann18, R. Laxer19, D. Rivera20, N. Ruperto21, A. Simon22, M. Twilt23, J. Frenkel24, H. Hoffman9, A. De Jesus4, J. Kuenemierdescher27, S. Ozer28, M. Gattorno31, R. Goldbach-Mansky32, E. Demirkaya on behalf of EULAR/ACR IL1 mediated group. 1Schulich School of Medicine & Dentistry, University of Western Ontario, Department of Pediatrics, Division of Pediatric Rheumatology, Behcet and Autoinflammatory Disease Center, London, Canada; 2Sanilufra Training and Research Hospital, Department of Pediatric Rheumatology, Sanilufra, Turkey; 3Schulich School of Medicine & Dentistry; University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada; 4NIH, Translational Autoinflammatory Diseases Section (TADS), Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, NIH, Bethesda, United States of America; 5Medical University Vienna, Division of Rheumatology, Vienna, Austria; 6NIH, Division of Intramural Research, National Institute of Allergy and Immunology, Bethesda, United States of America; 7Alberta Children’s Hospital, Cumming School of Medicine, University of Calgary, Alberta, Canada, Rheumatology Department of Pediatrics, Calgary, Canada; 8Schulich School of Medicine & Dentistry, University of Western Ontario, Department of Pediatrics, Division of Pediatric Rheumatology, London, Canada; 9University of California and Rady Children’s Hospital, Division of Pediatric Allergy, Immunology, and Rheumatology, San Diego, United States of America; 10Division of Immunology, Rheumatology Program, Boston Children’s Hospital, Department of Pediatrics, Harvard Medical School, Boston, Canada; 11Schulich School of Medicine & Dentistry; University of Western Ontario, Paediatric Rheumatology, London, Canada; 12Autoinflammatory Alliance, San Francisco, CA, Kaiser Foundation Hospital-Inpatient Pediatriocs, San Francisco, CA, USA, San Francisco, United States of America; 13University of Iowa, Department of Pediatrics, Division of Pediatric Rheumatology, Iowa City, United States of America; 14University of Muenster, Department of Pediatric Rheumatology and Immunology, Muenster, Germany; 15Boston Children’s Hospital, Division of Immunology, Program in Rheumatology, Boston, United States of America; 16Walter Reed National Military Medical Center (WRNMMC), Department of Pediatrics, Bethesda, Canada; 17NIH, Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch, National Human Genome Research Institute, Bethesda, United States of America; 18University College London, National Amyloidosis Centre, Royal Free Hospital and Division of Medicine, London, United Kingdom; 19The Hospital for Sick Children, University of Toronto, Division of Rheumatology, Toronto, Canada; 20Autoinflammatory Alliance, San Francisco, CA, Autoinflammatory Alliance, San Francisco, United States of America; 21IRCCS Istituto Giannina Gaslini, USOIS Centro Tnfal, Genova, Italy; 22Hadzbud University Medical Centre, Department of General Internal Medicine, Nijmegen, Netherlands; 23Alberta Children’s Hospital, University of Calgary, Department of Pediatrics, Calgary, Canada; 24Wilhelmina Kinderziekenhuis, Department of Pediatrics, Utrecht, Netherlands; 25University Hospital Tubingen, Division of Pediatric Rheumatology and Autoinflammation Reference Center Tubingen, Department of Pediatrics, Tubingen, Germany; 26Hacettepe University, Ankara, Department of Pediatric Rheumatology, Ankara, Turkey; 27IRCCS G. Gaslini, Center for Autoinflammatory Diseases and Clinical Immunology, Genova, Italy; 28Schulich School of Medicine & Dentistry, University of Western Ontario, Department of Paediatrics, Division of Paediatric Rheumatology, Behcet and Autoinflammatory Disease Center and Department of Epidemiology and Biostatistics, London, Canada

Background: The Interleukin-1 (IL-1) mediated systemic autoinflammatory diseases (SAIDs), including the cryopyrin-associated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), and deficiency of the IL-1 receptor antagonist (DIRA) belong to a group of rare immunoregulatory diseases that primarily present in early childhood with variable multorgan involvement. When untreated, patients with severe clinical phenotypes have a poor prognosis, and diagnosis and management of these patients can be challenging. However, recently approved treatments targeting the pro-inflammatory cytokine IL-1 have been life-changing and have significantly improved patient outcomes.

Objectives: We aimed to establish evidence-based recommendations on diagnosis, treatment, and monitoring to standardize the management of these patients.

Methods: A multinational, multidisciplinary task force consisting of physician experts including rheumatologists, patients or caregivers, and allied health care professionals was established. Evidence synthesis including systematic literature reviews and expert consensus (Delphi process) was conducted. Consensus methodology was utilized to formulate and vote on statements to guide optimal patient care.

Results: The task force devised five overarching principles, 14 statements related to diagnosis, 10 on therapy, and 9 focused on long-term monitoring that were evidence and/or consensus-based for patients with IL-1 mediated diseases. An outline was developed for disease-specific monitoring of inflammation-induced organ damage progression and reported therapies of CAPS, TRAPS, MKD, and DIRA, and inform the various stakeholders about optimized patient care to improve disease outcomes.

References:

Disclosure of Interests: micol romanov: None declared, Zehra Serap Aric: None declared, David Piskin: None declared, Sara Alehashemi: None declared, Daniel Aleata Shaha speakers bureau: Lilly, Merck, Pfizer, Roche, Sandoz, Consultant of: Abbvie, Amgen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofi, Karyl Barron: None declared, Susa Benser: None declared, Roberta Berard Consultant of: Sandoz and Roche, Lori Broderick Grant/research support from: Novartis and Regeneron, Fatma Dedegoul Consultant of: Novartis, Michelle Diebold: None declared, Karen Durrant: None declared, Polly Ferguson Consultant of: Novartis, Grant/research support from: NIH, CARRA, Inc, Dirk Foell Speakers bureau: Novartis, Peer Voice and SoBi, Consultant of: Boehringer Ingelheim, Chugai Roche, Merck, Novartis, SoBi, Grant/research support from: Novartis and SoBi, Jonathan Hausmann Consultant of: Novartis, Biogen and Pfizer, Grant/research support from: CARRA, SoBi, Olcay Jones: None declared, Daniel Kastner: None declared, Helen J. Lachmann: None declared, Ronald Laxer Consultant of: SoBi, Novartis, Sanofi, Dorelia Rivera: None declared, Nicolina Ruperto Speakers bureau: Eli-Lilly, GSK, Pfizer SoBi and UCB, Consultant of: Abylynx, Amgen, Astrazeneca-Medimmune, Auriya, Bauer, Bristol Myers and Squib, Cambridge Healthcare research, Celgene, Domain therapeutic, Eli-Lilly, EMD Serono, GSK, Ixonsia, Janssen, Novartis, SoBi, Pfizer and UCB, Anna Simon: None declared, Marina Twilt: None declared, Joost Frenkel: None declared, Hal Hoffman Consultant of: Novartis, Regeneron, SoBi, Aclaris, Grant/research support from: Bristol-Meyer-Squib, Jecure, Takeda and Zomagen, Adriana de Jesus: None declared, Jasmin Kuenemierdescher-Deschner Speakers bureau: Novartis and SoBi, Consultant of: Novartis and SoBi, Grant/research support from: Novartis and SoBi, Sez錮 Oz錦 閔kak Consultant of: Novartis and SoBi, Marco Gattorno Speakers bureau: Novartis and SoBi, Grant/research support from: Novartis, Raphaella goldbach-mansky; None declared, Erkan Demirkaya Grant/research support from: SoBi


THE DIAGNOSTIC ROLE OF PATHERYTEST IN PATIENTS WITH BEHÇET’S DISEASE FROM WESTERN EUROPE

A. Vitale1, V. Berlingerio2, J. Sota3, S. Barneschi4, M. Mourabiri5, C. Fabiani6, S. Gentilestchi7, V. Caggiano8, G. M. Tos1, B. Friediani9, L. Cantarini10 on behalf of Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease Clinics. 1Viale Mario Bracci, Department of Medical Sciences, Surgery and Neurosciences, Siena, Italy

Background: pathergy is the term used to describe the hyper-reactivity of the skin in response to a minimal trauma, as the consequence of an exacerbated response of the innate immune system [1]. Pathergy test has a central role for the diagnosis of Behçet’s disease (BD), especially in doubtful and atypical cases. However, while its incidence has been decreasing over the past few decades, there are significant variations in the frequency of pathergy among different geographical contexts [2]. These aspects affect the diagnostic role of pathergy test for patients with suspected BD.

Objectives: to evaluate the frequency and features of positive pathergy test (PPT) in Italy, its role in the diagnosis of BD, and any association with other BD-related manifestations.
Methods: 29 BD patients, 15 patients with spondyloarthrits (SpA) and 19 healthy controls (HCs) underwent two types of pathergy test, which were performed on the hairless part of the volar forearm ipsilaterally: intradermal injection of 0.5 ml normal saline and intra-dermally needle soaked with fresh self-saliva. Both prick were done with a monouse 25 gauge hypodermic needle inserted with a vertical approach at a depth of 5 mm into the skin. The needle was withdrawn with a twisting movement. Skin reactions were observed 48 hours after prick. The results of pathergy tests were statistically analysed in the light of demographic, clinical, and therapeutic features of subjects enrolled. The BD activity at the time of the pathergy test was assessed with the Behçet’s Disease Current Activity Form (BDCF) [3].

Results: pathergy test performed with saline solution resulted always negative in all groups. Skin prick test using self-saliva resulted in the occurrence of a papule in 2 (6.9%) BD patients and in 1 (6.7%) patient with SpA. A ≥15 mm erythematous area surrounding the needle prick site was observed in 12 (41.4%) BD patients, in 4 (26.7%) patients with SpA (including the patient with the papule), and in 1 (5.8%) HCs (p=0.022). The frequency of skin erythema was significantly higher among BD patients compared to HCs (p=0.015); no statistically significant differences were observed between BD and SpA patients (p=0.53) as well as between SpA patients and HC (p=0.21).

The occurrence of skin erythema was not associated with any of the BD-related clinical manifestations. No statistically significant differences were observed between BD patients with positive and negative pathergy test according to sex (p=0.873); HLA-B51 positivity (p-value=0.461); age at the pathergy test (p=0.929); and disease duration at the pathergy test (p=0.487). The mean BDCF was 1.33±0.65 among patients with PPT and 0.82±0.72 among patients with negative pathergy test (p=0.092).

Conclusion: this study confirms the lower frequency of PPT in Western European BD patients if considering the development of a papule or a pustule in the site of pathergy test. Conversely, the onset of a ≥15 mm erythematous area surrounding the prick site could be sufficient to unveil the hyper-reactivity of the innate immune system in BD patients from Western Europe. Pathergy test is not pathognomonic of BD, as its positivity can be also observed in other innate immune system disorders, as observed for SpA patients.

REFERENCES:

Disclosure of Interests: None declared
Disclosure of Interests: J. B. Kuevermeier-Deschner Consultant of: Novartis, AbbVie, Sobí, Grant/research support from: Novartis, AbbVie, Sobí, Jörg Hennes Consultant of: Novartis, AbbVie, Sobí, Roche, Janssen, Boehringer-Ingelheim, Grant/research support from: Novartis, Roche, Tilmann Kallinich Consultant of: Novartis, Tilmann Kallinich Consultant of: Sobí, Roche, Grant/ research support from: Novartis, Prasad Oommen Consultant of: Novartis, AbbVie, Sobi, Grant/research support from: Novartis, Jürgen Rech Speakers bureau: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Grant/research support from: AbbVie, Bayer, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Ales Janda: None declared, Ivan Foeildvari Consultant of: Novartis, Hexai, Medac, Pfizer, Catharina Schuetz: None declared, Frank Dressler Consultant of: AbbVie, Mylan, Novartis, Pfizer, Grant/research support from: Novartis, Michael Borte Grant/research support from: Pfizer, Schier, Markus Hufnagel Consultant of: Novartis and SOBI, Florian Meiers Speakers bureau: Novartis, Michael Fiene: None declared, Julia Weber-Arden Employee of: Novartis, Norbert Blank Consultant of: Novartis, Sobi, Lilly, AbbVie, BMS, MSD, Actelion, UCB, Boehringer-Ingelheim, Roche, Grant/research support from: Novartis, Sobí DOI: 10.1136/annrheumdis-2022-eular.4903

POS1375 THE EVALUATION OF OBESITY IN ADULT-ONSET STILL’S DISEASE. DATA FROM A MULTICENTRE COHORT.

I. Di Cola1, C. Di Muzio1, F. Sensini1, R. Giacomelli1, P. Cipriani2, P. Ruscitti1 on behalf of AOSD GIRRCS Study Group. 1University of Uqiala, Department of Biotechnological and Applied Clinical Sciences, Uquila, Italy; 2University of Rome Campus Biomedico, Department of Medicine, Rome, Italy

Background: Over the last few decades, obesity has become an increasing public health problem worldwide [1]. This is a complex disease characterised by an abnormal or excessive fat accumulation which is usually assessed by body mass index (BMI). A value of BMI over 30 identifies the threshold to define the obesity. High BMI is common feature among patients with rheumatic disease and it is associated with higher disease activity and disability [2]. Thus, the presence of obesity may be considered as a negative prognostic factor in these patients. Against this background in rheumatic disorders, the prevalence of obesity in adult-onset Still’s disease (AOSD) has not been entirely clarified so far. Similarly, the impact of being obese on disease features and outcomes has not been fully elucidated in these patients. AOSD is a rare inflammatory disease usually characterised by fever, arthritis, and evanescent skin rash associated with a typical hyperferritinaemia [3].

Objectives: In this study, we aimed at evaluating the prevalence of obesity in patients with AOSD. Furthermore, we descriptively assessed the clinical characteristics of these patients. We also described the occurrence of life-threatening complications, the disease courses, and the rate of mortality of obese patients with AOSD than non-obese ones.

Methods: A retrospective assessment of prospectively followed patients, from January 2001 to April 2021, was provided to analyse clinical features of patients with AOSD characterised by a BMI ≥30. AOSD patients were evaluated among those included in the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRFRC) cohort. This is a large cohort of patients with AOSD comprising almost 200 patients [4]. The presence of obesity was evaluated at the time of diagnosis of the disease. In this evaluation, only patients with available data about BMI were included.

Results: In this assessment, 139 patients, who had BMI registered in our database, were evaluated. Out of those, 26 (18.7%) had a BMI ≥30 and were defined as having obesity. These patients had a mean age of 39.3±13.6 years and were 46.2% male. Concerning main clinical features, obese patients with AOSD were characterised by fever (96.2%), skin rash (84.6%), arthralgia (76.9%), myalgia (65.4%), and arthritis (61.5%). An explorative comparison between obese and non-obese patients.

Conclusion: Clinical features of obese patients with AOSD were described in our multicentre cohort. Almost 20% of patients with AOSD were obese at the time of diagnosis of the disease. These patients were characterised by a lower prevalence of novartis, pericarditis and pleuritis, and by higher values of CRP. However, obesity did not appear to influence the main disease features and outcomes in AOSD, although further studies are needed to fully elucidate this issue.

REFERENCES:

Disclosures of Interests: None declared


POS1376 LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH HIDS (HYPER-IgD SYNDROME) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY

P. Oommen1, T. Kallinich2, J. Rech3, N. Blank4, J. Weber-Arden5, J. B. Kuevermeier-Deschner1, Heinrich-Heine-University Düsseldorf, Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Division of Pediatric Rheumatology, Duesseldorf, Germany; 2Charité University Medicine Berlin, Department of Pediatrics, Division of Pulmonology, Immunology and Critical Care Medicine, Berlin, Germany; 3Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätlinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology Erlangen, Germany; 4University Hospital Heidelberg, Rheumatology, Heidelberg, Germany; 5Novartis Pharma GmbH, IHD, Nuernberg, Germany; 6University Hospital Tuebingen, Department of Pediatrics, Division of Pediatric Rheumatology, Tuebingen, Germany

Background: Hyper-IgD syndrome/mevalonate kinase deficiency (HIDS/MKD) is a rare autoinflammatory condition caused by a defect in the gene coding for mevalonate kinase. This periodic fever syndrome is characterized by severe systemic and organ inflammation. Treatment with intravenous [+] inhibitor canakinumab (CAN), approved and applied for treatment of HIDS/MKD patients since 2017 [1], resulted in rapid remission of symptoms and normalization of laboratory parameters in most patients in clinical trials [2] as well as in real-life.

Objectives: To explore the long-term efficacy and safety of CAN under routine clinical practice conditions in pediatric (age ≥2 years) and adult HIDS/MKD patients.

Methods: RELIANCE is a prospective, non-interventional, multi-center, observational study based in Germany with a 3-year follow-up period. Patients with clinically confirmed diagnoses of TRAPS, CAPS, FMF or HIDS/MKD who routinely receive CAN are enrolled in order to evaluate efficacy and safety of CAN under standard clinical practice conditions at baseline and at 12, 18, and 24 months.

Results: The present interim analysis shows baseline data of 8 HIDS/MKD patients enrolled by December 2021 as well as preliminary 18-month data. Of these patients, 5 (63%) were females and median age at baseline was 8 years (2–39 years). The median duration of prior CAN treatment at baseline was 1.5 years (0–5 years). Standard, low, and high dose CAN treatment was evenly distributed at every interval.

Table 1. Baseline characteristics and interim analysis data of patients with HIDS.

<table>
<thead>
<tr>
<th>Baseline</th>
<th>6 months</th>
<th>12 months</th>
<th>18 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N=8)</td>
<td>(N=7)</td>
<td>(N=6)</td>
<td>(N=4)</td>
</tr>
<tr>
<td>Number (%) of patients in disease remission (physician assessment)</td>
<td>37/50</td>
<td>37/50</td>
<td>37/38</td>
</tr>
<tr>
<td>Physician assessment of disease activity, percentage of absent/mild/moderate/severe rating</td>
<td>7/35</td>
<td>7/35</td>
<td>7/35</td>
</tr>
<tr>
<td>Patient’s assessment of current disease activity, 0–10, median (min; max)</td>
<td>0 (0; 7)</td>
<td>0 (0; 7)</td>
<td>0 (0; 7)</td>
</tr>
<tr>
<td>Patient’s assessment of current fatigue, 0–10, median (min; max)</td>
<td>2.5 (0; 7)</td>
<td>2.5 (0; 7)</td>
<td>2.5 (0; 7)</td>
</tr>
<tr>
<td>Number (%) of patients without improvement of social life by the disease</td>
<td>3/5 (60%)</td>
<td>3/5 (60%)</td>
<td>3/5 (60%)</td>
</tr>
<tr>
<td>Number (%) of patients with days absent from work/school during last 6 months</td>
<td>0 (0; 7)</td>
<td>0 (0; 7)</td>
<td>0 (0; 7)</td>
</tr>
<tr>
<td>CRP, median (mg/dl)</td>
<td>0.2</td>
<td>0.2</td>
<td>0.2</td>
</tr>
<tr>
<td>SAA, median (mg/dl)</td>
<td>0.6</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>ESR, median (mm/h)</td>
<td>10.0</td>
<td>10.0</td>
<td>10.0</td>
</tr>
</tbody>
</table>

CRP, c-reactive protein; SAA, serum amyloid A; ESR, erythrocyte sedimentation rate
Preliminary results indicate stable remission and disease control by physicians’ and patients’ assessment as well as laboratory parameters (Table 1). In total, 4 patients were affected by adverse drug reactions, however, none of these events was classified as serious.

**Conclusion:** Baseline characteristics and preliminary data of HIDS/MKD patients from the RELIANCE study indicate good clinical and laboratory disease control and no unexpected safety concerns at the 18 months interim analysis.

**REFERENCES:**

[1] Ilarisa, INN-canakinumab (euroopa.eu)


**Disclosure of Interests:** Prasad Oommen Grant/research support from: Novartis, Tillmann Kallinich Consultant of: Sobi, Novartis, Roche, Grant/research support from: Novartis, Jurgen Rech Speakers bureau: Abbvie, Biogen, BMS, Chugai, GSK, Janssen, Lilly, MSD; Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Consultant of: Abbvie, Biogen, BMS, Chugai, GSK, Janssen, Lilly, MSD, Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Grant/research support from: Novartis, Sobi, Lilly, Pfizer, Abbvie, BMS, MSD, Actelion, UCB, Boehhringer-Ingelheim, Roche, Grant/research support from: Novartis, Sobi, Julia Weber-Anden Employee of: Novartis, J. B. Kummer-Le-Deschner Consultant of: Novartis, AbbVie, Sobi, Grant/research support from: Novartis, AbibVie, Sobi.

**DOI:** 10.1136/annrheumdis-2022-eular.5063

**POS1377**

**LUNG INVOLVEMENT IN VEXAS SYNDROME**

M. Casal Moura1, M. Baqi1, X. Tandon2, M. Samec1, K. Reichard1, A. Mangaonkar1, R. Go3, K. J. Warrington3, M. Patnaik4, M. Koster3, J. H. Ryu1.

1Mayo Clinic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, United States of America; 2Mayo Clinic, Radiology, Rochester, United States of America; 3Mayo Clinic, Division of Rheumatology, Department of Medicine, Rochester, United States of America; 4Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, United States of America; 5Mayo Clinic, Division of Hematology, Department of Medicine, Rochester, United States of America

**Background:** Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently identified disorder caused by somatic mutations in the UBA1 gene of myeloid cells. Various manifestations of pulmonary involvement have been reported, but a detailed description of lung involvement and radiologic findings is lacking.

**Objectives:** To describe lung involvement in VEXAS syndrome.

**Methods:** A retrospective cohort study was conducted of all patients identified at the Mayo Clinic with VEXAS syndrome since October 2020. Clinical records and chest high resolution computed tomography (HRCT) scans were reviewed.

**Results:** Our cohort comprised 22 white men with a median age of 69 years (IQR 62-74, range 57-84). Hematologic disorders including multiple myeloma, myelodysplastic syndrome and pancytopenia were present in 10 patients (45%), rheumatologic diseases including granulomatosis with polyangiitis, IgG4-related disease, polyarteritis nodosa, relapsing polychondritis, and rheumatoid arthritis were found in 10 patients (45%), and 4 patients had dermatologic presentations including Sweet syndrome, Schnitzler-like syndrome or drug rash with eosinophilia skin syndrome (DRESS). VEXAS syndrome-related features included fever (18, 82%), skin lesions (20, 91%), lung infiltrates (12, 55%), chondritis (10, 45%), venous thromboembolism (10, 45%), myalgias or arthritis (40%). In our study, the male/female ratio was found to be 45%, and 21 (95%), respectively, and were documented prior to VEXAS diagnosis. Most of the patients were non-smokers (14, 64%) and obstructive sleep apnea (OSA) was present in 11 patients (50%). Seven patients (32%) used non-invasive ventilation, 6 used C-PAP, and 1 used Bi-PAP. Bronchoalveolar lavage (BAL) was available in 4 patients, and the findings were compatible with neutrophilic alveolitis in 3. Two patients had lung biopsies (2 transbronchial and 1 surgical) that showed ATTr amyloidosis and organizing pneumonia with lymphoid interstitial pneumonia, respectively. Pulmonary function tests were available in 9 (41%) patients and showed normal results in 5; 3 patients had isolated reduction in DLCO and 1 with mild restriction. On chest HRCT, 16 patients (73%) had parenchymal changes including ground-glass opacities in 9, septal thickening in 4, and nodules in 3; pleural effusions were present in 3 patients, air-trapping in 3 patients and tracheomalacia in 1 patient. Follow-up chest HRCT was available for 8 patients (36%), the ground-glass opacities resolved in 5 patients, 3 patients manifested new or increased ground-glass opacities, and 1 patient had increased interlobular septal thickening. After 1 year of follow-up, 4 patients (17%) had died; 3 due to pneumonia (2 COVID-19, 1 bacterial) and 1 due to heart failure. VEXAS flares occurred in 18 patients (82%), the maximum number of relapses was 7, and they were mainly managed with GC and with changes in the immunosuppressive regimen.

**Conclusion:** Pulmonary involvement was documented by chest HRCT in most patients with VEXAS syndrome. Respiratory symptoms occurred over one half of patients and about 20% had PFT abnormalities. The pulmonary manifestations of VEXAS are nonspecific and characterized predominantly by inflammatory parenchymal involvement.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5232

**POS1378**

**ARTHRITIS IN PATIENTS WITH FAMILY MEDITERRANEAN FEVER**

S. Yenigü1, A. Y. Ayla1, S. N. Baspinar1, M. B. Yuzbasıoglu2, A. Alkan1, I. Duruçoğan1, M. Kirman1, B. C. Poal1, S. Ergün1, H. Ozdogan2, S. Uğurlu1, S. Cerrahpasa Medical Faculty, Internal Medicine, Istanbul, Turkey; 2Cerrahpasa Medical Faculty, Internal Medicine, Division of Rheumatology, Istanbul, Turkey

**Background:** Familial Mediterranean fever (FMF) is an inherited autoinflammatory disease characterized by recurrent episodes of fever and serositis. Arthritis is one of the most common attack manifestations. Arthritis in FMF is usually in the form of acute mono- or oligoarthritis of the large joints of the lower extremities. While acute attacks of arthritis usually heal without causing permanent deformity, the severe, long-lasting form of chronic arthritis can last for months or even years and result in permanent deformity.

**Objectives:** In this study, we described the characteristics of joint involvement in FMF in a single cohort.

**Methods:** The medical records of patients with joint involvement from our cohort of 2350 patients who were diagnosed with familial Mediterranean fever were retrospectively scanned through the files and hospital database. The prevalence, demographic information, genetic test results, clinical features, features of joint involvement, treatments and responses, acute phase values in the attack and remission periods, and family history of patients with joint involvement were recorded.

**Results:** 953 patients (n=953) from a total of 2350 patients had arthropagia or arthritis (40%). In our study, the male/female ratio was found to be 1028:1022.

**Table 1. Concomitant diseases of our FMF cohort**

<table>
<thead>
<tr>
<th>Concomitant Diseases (n=376)</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spondyloarthrites</td>
<td>8%</td>
</tr>
<tr>
<td>Bellharts Syndrome</td>
<td>1%</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>2%</td>
</tr>
<tr>
<td>Acute Rheumatic Fever</td>
<td>0%</td>
</tr>
<tr>
<td>Systemic Lupus Erythematosus</td>
<td>0%</td>
</tr>
<tr>
<td>Inflammatory Bowel Disease</td>
<td>2%</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>0%</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>1%</td>
</tr>
<tr>
<td>Coronary Artery Disease</td>
<td>0%</td>
</tr>
<tr>
<td>Diabetes Melitus</td>
<td>0%</td>
</tr>
<tr>
<td>Chronic Kidney Disease</td>
<td>0%</td>
</tr>
<tr>
<td>Apathy</td>
<td>2%</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>0%</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5232
0.49 (male n=316, female n=637). The number of patients who underwent genetic testing was 787 (82%), and 702 (89%) of these patients had mutations in the MEFV gene. The most common pathogenic mutation is the M694V mutation with a rate of 43%. Concomitant diseases and their frequencies are shown in Table 1, the most common accompanying disease was spondylarthritis at a rate of 27%. Arthritis was present in the first attack in 55% (n=531), while arthritis was found in the ongoing attacks in 45%. The duration of the attack was between 24-96 hours in 77% (n=837) of the patients, and the duration was longer than 96 hours in 23% (n=116).

The most common finding accompanying the attacks was exercise-related leg pain. Family history was present in 61% (n=580). 73% of the patients (n=696) were involved in the ankle and 51% were involved in the knee (n=492). The incidence of sacroiliitis was 14% (n=142). As for the number of joints, 91% of the patients had mono- and oligoarthritis. Asymmetric involvement was detected in 77% of the patients. Red arthritis was present in 73% of our study group. HLA-B27 was examined in 185 patients, 24 of them were positive (12%). It was found that 43% of the patients had treatment changes due to arthritis. Colchicine dose increases and changes were performed in 32% of these patients. NSAIDs were started in 21%, corticosteroids in 15%, DMARDs in 12%, anti-TNF in 10%, and anti-IL-1 in 8%. The mean dose of colchicine was as 1.56 ± 0.5 mg. Unresponsiveness to colchicine was found in 21% (n=122).

Conclusion: FMF diagnosis should definitely be considered in people with red mono-oligoarthritis in the large joints of the lower extremities. One of the most important features of joint involvement in FMF patients is the short duration of arthritis. The accompanying effort-related leg pain is an important symptom that should suggest FMF. In patients with a diagnosis of FMF and arthritis, the required colchicine dose in the treatment and the rate of colchicine unresponsiveness are higher than in other attack types. The incidence of sacroiliitis and spondyloarthropathy increases in patients with FMF, and joint involvement features are similar. FMF should be considered in the differential diagnosis of patients with inflammatory low back pain.

Disclosure of Interests: None declared


Figure 1.
Background: The presence of anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF) are prognostic for erosive severity by radiography in patients with rheumatoid arthritis (RA) [1]. However, others have shown that RF mainly acts as an enhancer for ACPAs mediated bone loss [2]. High-resolution rheumatoid factor (RF) are prognostic for erosive severity by radiography in patients with RA.

Methods: Patients with RA and disease duration ≥ 5 years had their second and third MCP joints imaged by HR-pQCT. RF status were acquired. From the Danish Clinical Quality Program – The Danish Rheumatologic Database (DANBIO) [3], the average 28-joint Disease Activity Score (DAS28-CRP) and Health Assessment Questionnaire (HAQ) from five years before inclusion were extracted. Statistical significance was investigated by HR-pQCT according to the presence of autoantibodies. The hypothesis is that the presence of RF and especially ACPA is associated with erosive damage in two metacarpophalangeal (MCP) joints assessed by HR-pQCT; this has previously been shown using 44 joints assessment of both hands and feet by conventional radiography.

Results: A total number of 353 patients with RA were included in this study. 203 was RF+/ACPA+ positive, 52 was RF-/ACPA+ positive, 24 were RF+/ACPA- patients, RF-/ACPA- patients, and autoantibodies negative patients. Analysis of variance was used to investigate the difference between the groups for age and sex. Cuzick’s Rank-sum test for trend of ordered groups was used to test for trend for disease duration, 5-year average HAQ, 5-year average DAS28, number of erosions, total erosive volume, and average erosion volume.

Conclusions: In the current study, HR-pQCT scanning of only two MCP joints supports previous findings by radiography of both hands and feet, showing the accumulated erosive burden is higher in patients double-positive for RF and ACPA.
Methods: The rheumatological clinical practice in Italy, and 2) to gauge expert's attitudes on the assessment of rheumatic patients in the Italian clinical setting. This survey aimed: 1) to obtain an overview on the usage of capillaroscopy in the diagnosis of Raynaud's phenomenon (Rp) [2]. Despite growing interest in the use of capillaroscopy as part of the clinical routine in the screening of Rp and as part of the annual checkup of CTDs. Critical issues remain the lack of a specific program and network with the general practitioners. To have a wider vision on this topic, our survey could be further extended to other European countries.

References:

This study has received a grant from the Catalan Rheumatology Society (2019) for the implementation of a virtual annual meeting the same year. Nowadays capillaroscopy is a well-established, non-invasive technique with useful clinical applications in the assessment of microcirculation in rheumatic diseases in Italy are not available. The Rheumatology (SIR) endorsed the Italian study group (SG) on capillaroscopy (CAPSIR) that first convened at the University of Genova—IRCCS San Martino Polyclinic Hospital, Department of Internal Medicine, Research Laboratories and Academic Medicine, Division of Rheumatology, Genova, Italy; 7Università Sapienza, Dipartimento di Scienze Cliniche, Internistiche, Anestesiochirurgiche e Cardiovascolari, Roma, Italy.

Background: In May 2020, the executive committee of the Italian Society of Rheumatology (SIR) endorsed the Italian study group (SG) on capillaroscopy and microcirculation in rheumatic diseases (CAPSIR) that first convened at the annual meeting the same year. Nowadays capillaroscopy is a well-established, non-invasive technique with useful clinical applications in the assessment of connective tissue diseases (CTDs) [1] and mandatory for the differential diagnosis of Raynaud’s phenomenon (Rp) [2]. Despite growing interest in the use of this imaging technique in clinical and research settings, data on its current usage to assess microcirculation in rheumatic diseases in Italy are not available.

Objectives: To obtain an insight into the current utilization of capillaroscopy in the assessment of rheumatic patients in the Italian clinical setting. This survey aimed: 1) to obtain an overview on the usage of capillaroscopy in rheumatological clinical practice in Italy, and 2) to gauge expert's attitudes on the assessment of rheumatic patients in the Italian clinical setting. This survey aimed: 1) to obtain an overview on the usage of capillaroscopy in the diagnosis of Raynaud’s phenomenon (Rp) [2]. Despite growing interest in the use of capillaroscopy as part of the clinical routine in the screening of Rp and as part of the annual checkup of CTDs. Critical issues remain the lack of a specific program and network with the general practitioners. To have a wider vision on this topic, our survey could be further extended to other European countries.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.626

Table 1. Demographic and clinical characteristics of the study sample.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>382</td>
</tr>
<tr>
<td>Female (%)</td>
<td>218 (57%)</td>
</tr>
<tr>
<td>Age at diagnosis in years [IQR]</td>
<td>70.0 [63-78]</td>
</tr>
<tr>
<td>Follow-up in months [IQR]</td>
<td>34.0 [21-49]</td>
</tr>
<tr>
<td>Diagnosed in rheumatology (%)</td>
<td>299 (79%)</td>
</tr>
<tr>
<td>Treated in rheumatology (%)</td>
<td>276 (72%)</td>
</tr>
<tr>
<td>N. of visits [IQR]</td>
<td>6.5 [3–12.0]</td>
</tr>
<tr>
<td>Diagnosis changed during follow-up (%)</td>
<td>125 (32.7%)</td>
</tr>
</tbody>
</table>

Limitations: All patients with a new primary diagnosis of PMR (International Classification of Diseases – 10th revision [ICD-10] code M35.3) on at least one (in-outpatient) visit during years 2016–2019 were identified from the hospital discharge register of Turku University hospital in Finland. We did a chart review of the patient charts including the full clinical follow-up period (median 34 months).

We studied how often the primary diagnosis of PMR changed after further diagnostic evaluation or during follow-up.
Results: In 125 (32.7%) of the 382 patients, the initial diagnosis of PMR changed during further diagnostic evaluation or follow-up. Most common diagnoses initially misdiagnosed as PMR were inflammatory arthritides 36.0% (45/125), degenerative or stress-related musculoskeletal disorder 12.8% (16/125), infection 9.6% (12/125), malignancy 9.6% (12/125), giant cell vasculitis 6.4% (8/125) and other vasculitis 6.4% (8/125) (Table 1). Diagnosis changed in 19% (39/207) of patients fulfilling the 2012 ACR/EULAR PMR classification criteria and in 49% (86/175) of patients who did not.

Conclusion: In a university hospital setting, a third of initial diagnoses of PMR were changed during further evaluation and follow-up. Our findings highlight that thorough consideration of differential diagnosis is always essential when diagnosing PMR. Especially in patients with atypical presentation, there is a substantial risk for misdiagnosis.

Disclosure of Interests: Johanna Paltta: None declared, Saara Suuronen: None declared, Laura Pirilä Consultant of: Has received consulting fees from Novartis, UCSF, Pfizer, Lilly, Roche, Sanofi, Abbvie, Bristol-Myers-Squibb, Jansen-Cilag, Celgene and MSD, all unrelated to this work, Antti Palomäki Speakers bureau: Has received a lecture fee from Pfizer and Sanofi, all unrelated to this work, Consultant of: Has received consulting fees from Pfizer, Amgen and Abbvie, all unrelated to this work


POS1384

NON-INVASIVE IN VIVO METABOLIC PROFILING OF INFLAMMATION IN JOINTS AND ENTHESES BY OPTOACOUSTIC IMAGING

K. Tascilar1,2, F. Fagni1,2, A. Kleyer1,2, S. Bayat1,2, R. Heidemann1,2, G. Krönke1,2, D. Bohr1,2, A. Ramming1,2, F. Hartmann1,2, D. Kliet1,2, A. Federle1,2, A. Regensburger1,2, A. L. Wagner1,2, F. Knelling1,2, M. F. Neurath1,2, G. Schett1,2, M. Waldner1,2, D. Simon1,2, F. Steiger1,2, K. Tascilar1,2, F. Fagni1,2, A. Kleyer1,2, S. Bayat1,2, R. Heidemann1,2, G. Krönke1,2, D. Bohr1,2, A. Ramming1,2, F. Hartmann1,2, D. Kliet1,2, A. Federle1,2, A. Regensburger1,2, A. L. Wagner1,2, F. Knelling1,2, M. F. Neurath1,2, G. Schett1,2, M. Waldner1,2, D. Simon1,2, F. Steiger1,2

Background: An in-depth metabolic characterization of joints and entheses at the tissue level can help in the early diagnosis and treatment selection for patients with inflammatory arthritis [1]. However, current knowledge about the metabolic profiles of synovitis and enthesitis is limited. Multispectral optoacoustic tomography (MSOT), a novel metabolic imaging technology, could be used to undertake metabolic profiling of joints and entheses non-invasively using near-infrared multispectral laser to stimulate tissues and detect the emitted acoustic energy, enabling quantification of tissue components in vivo based on differential absorbance at multiple wavelengths [2, 3].

Objectives: To explore the metabolic characteristics of arthritis and enthesitis using MSOT.

Methods: We performed a cross sectional study on healthy controls (HC) and patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) (Table 1). Participants underwent clinical, ultrasound (US), and MSOT examination of metacarpophalangeal joints, wrists, entheses of lateral epicondyles, patellar, quadriceps and Achilles tendons. MSOT-derived hemoglobin, oxygen saturation, collagen and lipid levels were measured. We calculated scaled mean differences (SDM) between affected and unaffected joints and entheses as defined by clinical examination of US using linear mixed effects models.

Results: We obtained 1535 MSOT and 982 US scans from 87 participants (36 HC, 34 PsA, 17 RA). Enthoseal tenderness was not associated with metabolic changes, whereas US enthesitis was associated with increased total hemoglobin, oxygen saturation and collagen content. In contrast, clinical and US arthritis showed increased hemoglobin levels but reduced oxygen saturation and reduced collagen content. Synovial hyperpufency was associated with increased lipid content in the joints (Figure 1).

Conclusion: MSOT allows a non-invasive characterization of metabolic changes in arthritis and enthesitis. These findings can be interpreted as a reflection of increased synovial cellularity, collagen degradation, and metabolic demand in synovitis, and of an increased tissue apposition and vascularization in enthesitis. Our results support that synovitis and enthesitis do not only differ at the clinical and anatomical-functional level, but also exhibit divergent metabolic changes.

REFERENCES:

POS1385

INTERNATIONAL CONSENSUS FOR ULTRASOUND DEFINITIONS OF TENOSYNOVITIS IN JUVENILE IDIOPATHIC ARTHRITIS: RESULTS OF A DELPHI PROCESS

P. Collado1, S. Lanni2, O. De Lucia3, P. Balint4, S. Guillaume5, C. Hernandez-Diaz6, N. M. K. Sande7, S. Magni-Manzon8, C. Malatsia9, V. Martire10, L. Rossi-Semerano11, J. Roth12, T. Ting12, P. Vega Fernandez12, D. Windschall13, M. A. D’agostino14, E. Naredo15 on behalf of Pediatric Tenosynovitis Task Force of the OMERACT Ultrasound Working Group, 1Hospital Universitario Severo Ochoa, Rheumatology, Madrid, Spain; 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Paediatric Rheumatology, Milan,
Background: Musculoskeletal ultrasonography (US) is a suitable tool for the clinical assessment in juvenile idiopathic arthritis (JIA). Recently US definitions for normal components of pediatric joints and synovitis have been developed by the OMERACT US working group. Currently this group is working on development and validation of US definition for tenosynovitis as it is also an essential prerequisite for the reliable use of this technology in the pediatric age group.

Objectives: To produce consensus-based definitions for US tenosynovitis in JIA through a Delphi process.

Methods: We undertook a Delphi process on US-defined tenosynovitis in children that consisted of two steps. As a prior systematic literature review showed that US anatomy of the tendons is similar to adults, a Delphi questionnaire was written based on the consensual definitions developed for and used in adults with rheumatoid arthritis [1, 2]. The Delphi questionnaire was sent to rheumatologists and pediatricians who perform pediatric US examination, asking them to rate their level of agreement with each statement of US-defined tenosynovitis. Group agreement was considered if ≥80% of responders scored an item as 3 or 4 in the second step; validations were performed on 88 standardized US images displaying various degrees of tenosynovitis obtained from JIA patients at various ages. Tendons often involved in JIA were selected (foot and ankle tendons, hand and wrist tendons, bicep tendon.). US images of both normal and tenosynovitis elementary lesions were collected by the 18 experts participating in the OMERACT US task force on pediatric tenosynovitis. An agreement ≥70% was considered mandatory for accepting the definition as applicable in the rated image.

Results: The response rate was 75% (28 out of 37) from the first Delphi questionnaire. Strong group agreement (≥86%) was obtained for the US definitions tested. The response rate was 88.9% (16 out of 18) from the Web-exercise after four rounds. The final definitions were validated on still images for all tendons, tested. The response rate was 88.9% (16 out of 18) from the Web-exercise after four rounds. The final definitions were validated on still images for all tendons, tested. The response rate was 88.9% (16 out of 18) from the Web-exercise after four rounds. The final definitions were validated on still images for all tendons, tested.

Conclusion: US anatomies of the tendons are similar to adults, US definitions of tenosynovitis and its elementary components were successfully developed through a Delphi process.

REFERENCES:

[2] Taylor RP, Linderhof MA. FCγ-receptor-mediated trophic effects are involved in the response to RTX therapy [2]. In this study, the risk of IRRs to RTX tend to increase when the plasma level of MPO-DNA complexes is low. Further research is needed to clarify the impact of activated neutrophils on RTX therapy.

REFERENCEs:

[2] Taylor RP, Linderhof MA. FCγ-receptor-mediated trophic effects are involved in the response to RTX therapy [2]. In this study, the risk of IRRs to RTX tend to increase when the plasma level of MPO-DNA complexes is low. Further research is needed to clarify the impact of activated neutrophils on RTX therapy.

Disclosure of Interests: None declared


POS1386

THE OCCURRENCE OF INFUSION-RELATED REACTIONS TO RITUXIMAB IS ASSOCIATED WITH LOW PLASMA LEVELS OF MYELOPEROXIDASE-DNA COMPLEXES.

C. H. Lu1, T. J. Lee1, C. L. Yu1, S. C. Hsieh1. 1National Taiwan University, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taipei, Taiwan, Republic of China; 2National Taiwan University, Graduate Institute of Clinical Medicine, College of Medicine, Taipei, Taiwan, Republic of China

Background: Rituximab (RTX), a chimeric anti-CD20 antibody, is used in the treatment of rheumatic diseases. Infusion-related reactions (IRRs) are the most common adverse event, and premedication may reduce the incidence [1]. To date, there is still no effective predictor for the occurrence of IRRs.

Objectives: To identify factors predicting the occurrence of IRRs during the first course of RTX therapy in patients with rheumatic diseases.

Methods: We prospectively enrolled 29 patients with rheumatic diseases underwent the first course of RTX infusion, which consisted of two 500-mg intravenous infusions separated by about 2 weeks. Each patient received 100 mg intravenous methylprednisolone 60 minutes prior to each RTX infusion. Complete blood counts and C-reactive protein tests were performed before each infusion. The plasma levels of IL-1α, IL-6, IL-8, TNF-α, B-cell activating factor (BAFF) and plasma levels of myeloperoxidase (MPO)-DNA complexes were measured. All-grade IRRs occurring within 24 hours after infusions were recorded. Mann-Whitney U test was conducted to analyze factors associated with IRRs.

Results: The demographics and characteristics of the patients are shown in Table 1. Two patients reported IRRs in the first infusion, and three patients had IRRs in the second infusion of the first course. Among the five IRRs, four were skin rashes and one was headache. No serious events were found. A significant association between the low levels of MPO-DNA complexes and IRRs in the second infusion was noted ($p = 0.011$). The low plasma levels of MPO-DNA complexes also tended to be associated with the occurrence of IRR in the first infusion. The IRRs were not significantly correlate with absolute neutrophil counts, absolute lymphocyte counts, and the plasma levels of IL-1α, IL-6, IL-8, TNF-α, and BAFF.

Table 1. The characteristics of the patients received the first course of RTX treatment ($n = 29$).

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Gender, female (%)</th>
<th>Diagnosis</th>
<th>Anti-CD20 treatment (n = 29).</th>
</tr>
</thead>
<tbody>
<tr>
<td>44.9 (38.4 to 50.9)</td>
<td>26 (89.7)</td>
<td>Rheumatoid arthritis, n (%)</td>
<td>1 (3.4)</td>
</tr>
<tr>
<td>Others, n (%)</td>
<td>5 (17.2)</td>
<td>MPO-DNA complexes levels</td>
<td>11% (3% to 53%)</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>8.3 (6.9 to 11.2)</td>
<td>15% (3% to 32%)</td>
<td></td>
</tr>
<tr>
<td>IL-8 (pg/mL)</td>
<td>14.4 (12.6 to 15.9)</td>
<td>12.1 (8.5 to 13.8)</td>
<td></td>
</tr>
<tr>
<td>TNF-α (pg/mL)</td>
<td>8.9 (6.9 to 12.7)</td>
<td>8.1 (6.1 to 11.2)</td>
<td></td>
</tr>
<tr>
<td>BAFF (pg/mL)</td>
<td>151.1 (123.7 to 231.9)</td>
<td>276.8 (203.3 to 331.2)</td>
<td></td>
</tr>
<tr>
<td>Absolute neutrophil count (µL)</td>
<td>4380 (3411 to 5890)</td>
<td>4360 (3286 to 8195)</td>
<td></td>
</tr>
<tr>
<td>Absolute lymphocyte count (µL)</td>
<td>1518 (1198 to 1799)</td>
<td>1214 (864 to 1465)</td>
<td></td>
</tr>
<tr>
<td>C-reactive protein (mg/dL)</td>
<td>0.03 (0.01 to 0.10)</td>
<td>0.04 (0.02 to 0.21)</td>
<td></td>
</tr>
</tbody>
</table>

Footnotes: Data are presented in median and interquartile range. *Other diagnoses include systemic sclerosis, dermatomyositis, vasculitis, pemphigus, myasthenia gravis. Data are presented in ratio to positive control.

Conclusion: Plasma MPO-DNA complexes represent neutrophil extracellular traps released by activated neutrophils. Neutrophils could be involved in the response to RTX therapy [2]. In this study, the risk of IRRs to RTX tend to increase when the plasma level of MPO-DNA complexes is low. Further research is needed to clarify the impact of activated neutrophils on RTX therapy.

REFERENCES:

[2] Taylor RP, Linderhof MA. FCγ-receptor-mediated trophic effects are involved in the response to RTX therapy [2]. In this study, the risk of IRRs to RTX tend to increase when the plasma level of MPO-DNA complexes is low. Further research is needed to clarify the impact of activated neutrophils on RTX therapy.

Disclosure of Interests: None declared


POS1387

ULTRASOUND FINDINGS OF JOINTS AND ENTHESES FOLLOWING ONE HOUR OF AGE AND GENDER ADJUSTED WEIGHT TRAINING.

J. K. Schreiner1, F. Recker1, D. Scheich2, P. Karakostas3, J. Zib1, C. Behning4, P. Preus5, P. Brossart1, V. Schäfer1. 1University Hospital Bonn, Clinic of Internal Medicine III, Department of Oncology; 2Haematology, Rheumatology and Clinical Immunology, Bonn, Germany; 3University Hospital Bonn, Department of Obstetrics and Prenatal Medicine, Bonn, Germany; 4Porz am Rhein Hospital, Germany;

Background: It is well known that physical activity and weight training have a positive impact on body composition and bone metabolism. However, it is not clear whether the one-hour weight training has a significant effect on joint and enthesis ultrasound findings, which could provide insights into the potential impact of weight training on joint health.

Objectives: To investigate the effects of one-hour weight training on joint and enthesis ultrasound findings in children.

Methods: A total of 30 children aged 9-12 years were randomly assigned to a weight training group (n=15) or a control group (n=15). Both groups performed a one-hour weight training session. The ultrasound images of the knee joints and enthesis were evaluated before and after the weight training. The ultrasound parameters included joint thickness, enthesis thickness, and synovitis score.

Results: The mean joint thickness decreased by 10% in the weight training group compared to the control group (p<0.05). The enthesis thickness remained unchanged in both groups. The synovitis score showed a non-significant decrease in the weight training group (p=0.08).

Conclusion: One-hour weight training has a positive effect on joint thickness but not on enthesis thickness and synovitis score in children. This study suggests that weight training may have potential benefits for joint health.

Disclosure of Interests: None declared


Scientific Abstracts

1033
Department of Rheumatology, Cologne, Germany; 
University Hospital Bonn, Department of Dermatology and Allergy, Bonn, Germany; 
University Hospital Bonn, Institute for Medical Biometry, Informatics and Epidemiology, Bonn, Germany; 
University Bonn, University Sports Division, Bonn, Germany

Background: Joint effusion and enthesis are common ultrasound findings in rheumatologic diseases such as rheumatoid arthritis or spondyloarthritides. Physically active individuals and athletes were also found to exhibit structural and vascular changes in their entheses, as well as joint effusion through different imaging approaches [1, 2].

Objectives: The aim of this study was to evaluate the development of joint and entheseal ultrasound findings in large and medium joints of young healthy individuals after one hour of standardized weight training.

Methods: A total of three musculoskeletal ultrasound examinations were performed in healthy individuals under the age of 30 years. The first examination was carried out before the individuals conducted one hour of standardized weight training, the second examination 24 hours later and the third examination 48 hours later. The examination comprised shoulder, elbow, wrist, hip, knee, and ankle joints, as well as associated entheseal sites. Poisson mixed effects models were applied to analyse the development of the ultrasound findings within 48 hours after the weight training.

Results: Fifty-one healthy individuals with a mean age of 23.7 years (± 5.6, range: 19-30) (52.9% female) were enrolled in this study. Fourteen participants (27.5%) presented with at least one abnormal enthesis at baseline, increasing to 24 (47.1%) after 24 hours and to 29 (56.9%) 48 hours after the weight training. Hyperperfusion was the only entheseal pathology detected by ultrasound after the training.

The number of individuals with at least one joint effusion increased from 37 (72.6%) at baseline to 45 (88.2%) after 24 hours and to 48 (94.1%) 48 hours after the weight training. The Poisson mixed effects models showed a significant increase of the number of joints with effusion and entheses with pathologies with time after the weight training (p<0.001, Exp(b)=1.63 and p<0.001, Exp(b)=1.58).

Conclusion: Prevalence of joint effusion in large and medium joints as well as the prevalence of entheseal pathology increase significantly within 48 hours after one hour of weight training. As a result, the individual’s physical activity should be considered when performing a musculoskeletal ultrasound examination.

Disclosure of Interests: None declared


C. Mazeda1, S. P. Silva1, R. Monteiro2, R. Aguiar1, A. Barcelos1, 1Centro Hospitalar Baixo Vouga, Rheumatology, Centro Académico Clínico Egas Moniz, Aveiro, Portugal; 2Centro Hospitalar Baixo Vouga, Clinical Pathology, Aveiro, Portugal

Background: Anti-Ro/SSA antibodies are directed against different proteins of intracellular small ribonucleic acid (RNA)-protein complexes, Ro60 (60kDa) and Ro52 (52kDa) and are the most frequently detected autoantibodies in patients’ sera. The clinical associations with antibodies to the Ro60 protein is well documented and includes systemic lupus erythematosus (SLE) and Sjögren syndrome (SS). [1] The presence of anti-Ro52 antibodies has been reported in a large variety of diseases, such as neoplastic diseases or viral infections [1, 2].

Objectives: The aim of this study was to analyze the clinical relevance and the disease phenotype of patients with anti-Ro52 and/or anti-Ro60 autoantibodies in a single portuguese tertehospital.

Methods: Retrospective and descriptive study included all patients screened for anti-nuclear antibodies (ANA) in the database of the immunology laboratory of our Hospital between 2017 and 2021. Only adult patients (≥ 18-years-old) with positive anti-Ro52 and/or Ro60 were included in the study and divided into three groups: group 1 – Ro52+/Ro60−; group 2 – Ro52+/Ro60+; and group 3 – Ro52−/Ro60+. The presence of ANA was tested by indirect immunofluorescence (threshold of positivity established at titer 1/160) and further screened for anti-extractable nuclear antigen (ENA) antibodies. Socio-demographic and clinical data were collected. Descriptive analysis was performed, p-values<0.05 was statistically significant.

Results: Among 1210 patients, 277 were positive for the antibody anti-Ro52 and/or Ro60. Most of the patients included were women (79.8%) with a mean age of 58.8±16.12. Immune-mediated rheumatologic diseases were diagnosed in 173 (62.5%) patients, while 104 (37.5%) had non-rheumatologic disease. About 38.6% were exclusively anti-Ro52 positive, 30.3% of patients were anti-Ro60 positive alone and 31% tested positive for both. The clinical data of the patients in these three groups is represented in Table 1. In each of the three groups, the most frequent pattern was nuclear fine speckled (AC-4). In group 2, SS was the most frequent diagnosis (46.5%), followed by SLE (19.6%). Regarding ANA titers, a higher amount was observed in this group (p<0.05). The most frequently associated autoantibodies were anti-La (15.1%). In group 3, the diagnosis of SS was the most frequent (23.8%) followed by undifferentiated connective tissue disease (16.7%). Lupus anticoagulant (7.1%) and anti-RNP (6.0%) were more represented in this group. Finally, in group 1, non-rheumatologic disease was the most represented group of disease. In the case of SLE and systemic sclerosis, there were no statistically significant differences between the three groups and the different types of organ involvement. In SS, sicca symptoms were more prevalent in group 2, with statistically significant differences between the groups (p=0.027).

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 Ro52+/Ro60-</th>
<th>Group 2 Ro52+/Ro60+</th>
<th>Group 3 Ro52−/Ro60+</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune-mediated rheumatologic diseases (n)</td>
<td>51</td>
<td>69</td>
<td>53</td>
<td>0.004</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>10</td>
<td>16</td>
<td>7</td>
<td>0.396</td>
</tr>
<tr>
<td>Sjögren syndrome</td>
<td>21</td>
<td>40</td>
<td>20</td>
<td>0.050</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>0.216</td>
</tr>
<tr>
<td>Inflammatory myositis</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>0.024</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>9</td>
<td>2</td>
<td>7</td>
<td>0.020</td>
</tr>
<tr>
<td>Undifferentiated connective tissue disease</td>
<td>4</td>
<td>9</td>
<td>14</td>
<td>0.025</td>
</tr>
<tr>
<td>Other diseases</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0.824</td>
</tr>
<tr>
<td>Non-rheumatologic disease</td>
<td>56</td>
<td>17</td>
<td>31</td>
<td>0.369</td>
</tr>
<tr>
<td>Infections</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0.978</td>
</tr>
<tr>
<td>Neoplasms</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>0.319</td>
</tr>
<tr>
<td>Liver cirrhosis</td>
<td>6</td>
<td>2</td>
<td>8</td>
<td>0.178</td>
</tr>
<tr>
<td>Intestinal lung disease</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0.637</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0.736</td>
</tr>
<tr>
<td>Unclassified</td>
<td>36</td>
<td>13</td>
<td>17</td>
<td>0.444</td>
</tr>
</tbody>
</table>

Conclusion: In line with published studies, our work demonstrated that, among the sera tested, autoreactivity to anti-Ro52 alone was the most often observed and in most patients the presence of this antibody alone was not associated with immune-mediated rheumatologic disease, but mainly with malignancies. We also identified the clinical phenotype of patients with positive anti-Ro52 and/or anti-Ro60. Thus, we reinforce the importance of specific detection such as Ro-52 or Ro60 as they present individual diagnostic utility.

REFERENCES:

Disclosure of Interests: None declared


K. Triantafyllias1, K. Altamimi2, A. Schwarting1,2, 1Rheumatology Center Rhineland-Palatinate, Rheumatology, Bad Kreuznach, Germany; 2Johannes Gutenberg University Medical Center, Rheumatology and Clinical Immunology, Mainz, Germany

Background: Optical spectral transmission (OST) is a modern diagnostic modality able to assess the blood-specific absorption of light transmitted through a tissue, promising quantification of inflammation in the finger and wrist joints of...
patients with rheumatoid arthritis (RA) (HandScan -Demcon/Hemics, The Netherlands). Early data on OST revealed both correlations with clinical and arthrosonomic activity markers of RA, as well as a high diagnostic value during disease follow-up [1-3]. However, in a previous work we could detect and describe several OST confounding factors that complicate the establishment of universal cut-off values [2].

**Objectives:** Aim of this study was to examine and suggest OST-cut-off values after adjusting for the effect of statistically identified confounding factors. Moreover, we sought to describe a clinical model that would represent the probability of a positive RA diagnosis on the basis of OST values and presence of confounders in every individual patient.

**Methods:** Newly diagnosed RA patients (ACR-EULAR Classification Criteria 2010) were examined by OST and compared with healthy controls. Moreover, RA patients underwent clinical (tender & swollen joint counts, DAS28) and laboratory (inflammation markers) examinations. To identify factors that could have a confounding effect on OST, we performed logistic multivariate regression analyses, taking into account patient-associated characteristics such as age, gender, BMI, hand size, nicotine use. After identifying confounders, we determined OST cut-offs for different patient categories. In addition, we calculated the probability of the presence of an RA-diagnosis, based on the measured OST value and the presence of the identified influencing factors. Finally, we examined correlations of OST with clinical and laboratory RA activity parameters.

**Results:** 74 early RA patients [64%]; median age 59 years (53-70, IQR); median DAS28 4.58 (3.5-5.3, IQR)] and 101 controls [80%; median age 45 years (35-56, IQR)] were recruited. Male gender and advanced age were statistically identified as OST influencing factors. Receiver operating characteristics (patients vs. controls) revealed an OST cut-off of 11.2 (sensitivity 85%, specificity 72%) for female and an OST cut-off of 16.07 (sensitivity 75.7%, specificity 72.7%) for male patients. Two models were shown to be statistically appropriate for calculating the probability of the presence of RA based on the measured OST values and confounders: one model with included age for females and one model with included age and smoking status for males (Table 1). OST showed statistically significant moderate correlations with DAS28 (r=0.42, p<0.001), swollen joint count (r=0.437, p<0.001), VAS (r=0.355, p=0.002) and a weak significant correlation with CRP (r=0.23, p=0.045).

**Table 1. Statistical models for calculating the probability of the presence of rheumatoid arthritis based on measured OST values and OST confounding factors.**

<table>
<thead>
<tr>
<th>Statistical model</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>( P(\text{RA}) )</td>
<td>( \frac{e^{(-7.85+0.057x_1)+0.347x_2}}{1+e^{(-7.85+0.057x_1)+0.347x_2}} )</td>
<td>( \frac{e^{(-7.561+0.109x_1)+0.113x_2)+0.253x_3}}{1+e^{(-7.561+0.109x_1)+0.113x_2)+0.253x_3}} )</td>
</tr>
</tbody>
</table>

OST: optical spectral transmission; P(\text{RA}): probability of RA diagnosis X1 for age, X2 for OST; X3 for nicotine use

**Conclusion:** The establishment of OST cut-off values adjusted for confounding factors and the suggested statistical models could contribute to an increase of the diagnostic value of HandScan and assist clinicians during patient screening. To our knowledge, this is the first report in the literature on the specific topic. Further patient recruitment and research regarding additional confounders are currently taking place with the aim of improving the diagnostic capabilities of this new and promising diagnostic technology.

**REFERENCES:**

**Disclosure of Interests:** None declared

Conclusion: In RA patients in strict clinical remission, PD assessment at baseline but not clinical joint count could help identify patients who will relapse after the cessation of a bDMARD. Due to insufficient recruitment and limited power of the included study, however, no definitive conclusion can be made.

REFERENCES:

Acknowledgements: This study was funded by a grant of the Austrian Research Fund (KLI14-B30).

Disclosure of Interests: Christian Dejaco Speakers bureau: Pfizer, Abbott, MSD, Roche, BMS, UCB, Consultant of: Pfizer, AbbVie, MSD, Roche, BMS, UCB, Grant/research support from: Pfizer, Irina Gessl: None declared, Rusmir B, Consultant of: Pfizer, AbbVie, MSD, Roche, BMS, UCB, Consultant of: Pfizer, AbbVie, MSD, Roche, UCB, Consultant of: Pfizer, AbbVie, MSD, Roche, BMS, UCB, Consultant of: Pfizer, AbbVie, MSD, Roche, UCB, Consultant of: Pfizer, AbbVie.

REFERENCES:

Disclosure of Interests: None declared.


POS1391

DEEP LEARNING-BASED PANNUS LOCALIZATION SOFTWARE IN THE HANDS OF INFLAMMATORY ARTHRITIS USING TIME-INTENSITY CURVE (TIC) SHAPE CLASSIFICATION ON DYNAMIC MRI DATASET

W Fang1, Y An2, H Sugimori3, S Ichii4, T Kamishima1. 1Faculty of Health Sciences, Hokkaido University, Sapporo, Japan; 2Graduate School of Health Sciences, Hokkaido University, Sapporo, Japan; 3AIC, Yaezu Clinic, Tokyo, Japan

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with significant functional impairment and disability, linked to inflammatory and structural articular and peri-articular damage [1]. Synovitis is a characteristic feature of RA, and is considered an important factor in disease activity and the best predictive marker of joint damage [2]. Therefore, accurate quantification of synovitis can play an important role in clinical evaluation and treatment serving as a biomarker. Pixel-by-pixel time-intensity curve (TIC) shape analysis is a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) technique to help visualize differently shaped TICs [3]. Pixels having TIC shape type 4, which is characterized as early enhancement followed by washout phase, were regarded as synovitis pixel [4]. A deep residual network called ResNet50 model, a convolutional neural network (CNN) that is 50 layers deep, might effectively classify TIC shapes.

Objectives: This study aimed to develop software that can automatically demonstrate the distribution of enhancing synovial pannus of patients with inflammatory arthritis on DCE-MRI.

Methods: Modified ResNet50 was used on MATLAB. Two investigators drew regions of interest (ROIs) of muscle, bone, and synovitis under expert guidance and obtained TICs for each tissue on DCE-MRI of ten rheumatoid patients. Through cross-validation and batch evaluation, we verified the confusion matrices for the performance of the classifier. Then we identified the pixels of enhancing synovial pannus by image classification from the obtained pixel-by-pixel TIC shape and displayed them in color. The software performance was evaluated using a visual assessment on seven hand joints of one patient.

Results: 150 ROIs for muscles, 150 ROIs for bones, and 59 ROIs for synovitis on DCE-MRI of the hand joints were drawn in ten patients and obtained 4049, 3825, and 1041 TIC shape images, respectively. The classifier’s accuracy, precision, sensitivity, and specificity were 99.6%, 99.3%, 98.4%, and 99.7%, respectively. Out of seven joints, four were assessed as good, two as fair, and one as fail.

Figure 1. Software performance on contrast enhanced dynamic MRI of the wrist

Conclusion: Our classifier showed high accuracy, precision, sensitivity, and specificity. And through the comparison between manual outlining and the result of software, our software had relatively good performance. This automatic software developed using deep learning with CNN might accurately display the enhancing synovial pannus in RA.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2196

POS1392

TISSUE DOPPLEROGRAPHY AS A DIAGNOSTIC TOOL FOR MYOCARDIAL DYSFUNCTION IN PATIENTS WITH RHEUMATIC DISEASES

L Feiskhovitch1. 1Kazan State Medical University, Department of Hospital Therapy, Kazan, Russian Federation

Background: Pathology of the cardiovascular system has a significant impact on the mortality rate in the population of patients with rheumatic diseases, including rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Involvement of the cardiovascular system determines the course and prognosis of many rheumatic diseases. In the general population, left ventricular diastolic dysfunction is an independent predictor of mortality and symptomatic chronic heart failure. However, routine screening for diastolic dysfunction is rarely performed in patients with RA and AS, especially in those who do not have clinical symptoms.

Objectives: To identify early preclinical signs of myocardial dysfunction in patients with RA and AS.

Methods: 142 people with verified rheumatic diseases were examined. All patients were divided into 2 groups. The first group consisted of patients with RA - 95 pts (average age 46.5±11.1 years). The second group consisted of patients with AS, 47 pts (average age 42.3±10.3 years). The control group included 70 healthy individuals (average age 43.7±12.1 years). All patients underwent standard laboratory and instrumental diagnostic tests, which included joint radiography...
Background: Intestinal lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment represents still the major cause of death. It may be established within the first 4 years of SSc and frequently is subclinical [1].

To evaluate the presence of ILD, there are different available tools in addition to the clinical evaluation including respiratory functional tests (RFT) and imaging methods, especially HRCT which remain the mainstay for the diagnosis of SSc-ILD.

It has been recently proposed that pulmonary ultrasound (US) may have a potential role for the assessment of ILD in patients with SSc [2, 3]. Despite the growing body of evidence, there are no established data regarding its potential role in both detecting ILD in subclinical stages and on the follow-up of SSc patients.

Objectives: To investigate the validity of US in detecting subclinical ILD in SSc and to determine its potential in the follow-up of these patients.

Methods: 133 patients without respiratory symptoms and 133 healthy controls were included. Borg scale dyspnea index, Rodnan skin score (RSS) and pulmonary auscultation were performed. X-ray and respiratory function tests (RFT) were performed the same day. An expert rheumatologist blinded to clinical assessment performed the US. To determine the concurrent validity high-resolution CT (HRCT) scans was performed. HRCT findings were scored according to Warrick score whereas US findings were classified according the previously proposed scale. An inter-observer reliability was performed. A follow-up including US, RFT and Borg scale was done every 3 months for 12 months.

Results: A total of 54 of 133 SSc patients (40.6%) showed US signs of ILD in contrast to healthy controls (4.8%) (p=0.0001). The clinical and laboratory variables associated with ILD were anti-centromere antibodies (p=0.005) and RSS (p=0.005). A positive correlation was demonstrated between the US and HRCT findings (p<0.001). Sensitivity and specificity of US in detecting ILD was 91.2% and 88.6% respectively. A good inter-observer reliability was also observed (k = 0.72).

In the follow-up, a total of 30 patients (22.6%) that demonstrated US signs of ILD at baseline showed US worsening. Nine patients (30%) developed symptoms of ILD.

Conclusion: US is valid to detect subclinical ILD in SSc. Our results showed a high prevalence of this complication. Despite encouraging data, it seems still controversial its role in monitoring the ILD progression in SSc.
REFERENCES:


Disclosure of Interests: None declared


POSI395

NEUROFILAMENT LIGHT CHAIN, AN EARLY BIOMARKER FOR POLYNEUROPATHY IN HEREDITARY ATTR AMYLOIDOSIS.

A. F. Brunger1, M. Berends2, J. Bijzet3, P. Van der Zwaag4, B. J. Kroesen5, C. Teunissen5, S. In ’t Veld5, G. Drost6, F. Lange6, R. Gans2, B. Hazenberg1, H. A. Nienhuis1 on behalf of Amyloidosis Center of Expertise, University Medical Center Groningen. 1University Medical Center Groningen, Rheumatology & Clinical Immunology, Groningen, Netherlands; 2University Medical Center Groningen, Internal Medicine, Groningen, Netherlands; 3University Medical Center Groningen, Medical Genetics, Groningen, Netherlands; 4University Medical Center Groningen, Laboratory Medicine, Groningen, Netherlands; 5Amsterdam UMC, Locatie VUmc, Clinical Chemistry, Amsterdam, Netherlands; 6University Medical Center Groningen, Neurology, Groningen, Netherlands

Background: Serum neurofilament light chain (sNfL) is a sensitive marker for polyneuropathy (PNP) in hereditary transthyretin-related (ATTRv) amyloidosis patients and correlates with the severity of polyneuropathy [1-4]. We hypothesized that sNfL may diagnose neuronal damage in patients with hATTR amyloidosis before the onset of symptoms and before PNP can be detected by electromyography (EMG) examination.

Objectives: To establish the course of sNfL in three different groups: 1. persistently asymptomatic variant carriers (with and without detected amyloid), 2. ATTRv amyloidosis patients with PNP on treatment, 3. variant carriers who develop PNP.

Methods: sNfL levels were assessed longitudinally in asymptomatic variant carriers (with and without detectable amyloid), ATTRv amyloidosis patients with PNP on treatment (either a transthyretin (TTR) stabilizer or patisiran, an RNA interference therapeutic), and variant carriers who developed PNP. sNfL was established by EMG examination. The single-molecule array (Simoa) assay was used to assess sNfL levels.

Results: sNfL levels significantly increased over 1 year in 20 persistently asymptomatic carriers (p<0.001), with the strongest increase in variant carriers (n=8) with detectable amyloid in the subcutaneous abdominal fat tissue. In 21 symptomatic ATTRv amyloidosis patient with PNP on treatment with a TTR stabilizer, sNfL levels remained stable over 1 year. In 24 patients treated with patisiran, sNfL levels significantly decreased after 1 year of treatment (p<0.01). In 8 out of 9 variant carriers who developed PNP a rise in the sNfL level could be observed before the onset of symptoms and establishment of PNP by EMG examination (Figure 1).

Conclusion: sNfL is a marker for early neuronal damage since a rise in sNfL levels occurs before abnormalities can be detected by EMG examination. Our data support the use of sNfL in monitoring disease progression, screening asymptomatic variant carriers and monitoring of treatment effect.

REFERENCES:


Disclosure of Interests: Anne Floor Brunger: None declared, Milou Berends: None declared, Johan Bijzet: None declared, Paul van der Zwaag: None declared, Bart-Jan Kroesen: None declared, Charlotte Teunissen: None declared, Spiros in’t Veld: None declared, Gea Drost: None declared, Fiete Lange: None declared, Reinold Gans: None declared, Bouke Hazenberg Consultant of: Alnylam and Pfizer, Hans L.A. Nienhuis Consultant of: Alnylam and Pfizer


POSI396

PSORIASIS, WITHOUT RHEUMATOLOGICAL MANIFESTATIONS, IS ASSOCIATED WITH STRUCTURAL CHANGES OF THE SACROILIAC JOINT, A CONTROLLED STUDY USING CT SCAN

T. Leriche1, O. Fakh1, F. Aubin2, M. Chouk3, C. Prat1, 2, D. Wendling1, 4, F. Verhoeven3, 1, CHU Besançon, Rheumatology, Besançon, France; 1CHU Besançon, Dermatology, Besançon, France; 2Université de Franche Comté, EA 4267 PEPITE, Besançon, France; 3Université de Franche Comté, EA 4266 EPILAB, Besançon, France

Background: Plaque Psoriasis (PsO) is an inflammatory disorder that could be associated with rheumatological manifestations defining Psoriatic arthritis. Moreover, recent studies showed that the presence of plaque psoriasis is associated with more structural damage in axial Spondyloarthritids [1]. To our knowledge, no study has specifically evaluated the extent of structural lesions of the sacroiliac joints (SIJs) on computed tomography (CT) in patients with PsO, without rheumatological manifestations, compared with healthy controls.

Objectives: To describe SJ CT characteristics in patients with PsO and compare them with those of age- and sex-matched controls.

Methods: An observational, retrospective study was performed using medical records from Besançon University Hospital’s rheumatology and dermatology departments, which were screened to identify patients with PsO, diagnosed by a dermatologist. A search was then carried out for patients in the hospitals’ imaging archiving system to identify those who had undergone a CT which included the SIJs in their entirety. Non-inclusion criteria were the existence of pelvic bone lesions and a history of pelvic radiotherapy. Each patient was then matched with a control of the same age and sex, recruited through the hospital’s imaging archiving system.

For each individual, CT was interpreted by two independent readers using a quantitative method to assess structural damage. Specifically, structural damage was assessed using the Chi-2 test. For this study, we also observed the existence of intra-articular gas and diffuse idiopathic skeletal hyperostosis (DISH) lesions for each region. Quantitative variables were compared using Student’s t-test. Qualitative variables were compared using the Chi-2 test.

Results: 60 patients and 457 controls were included. Mean (SD) age was 52.2 ± 17.7 in the PsO group and 53.6 ± 16.7 in the control group. 31% (52%) were male in PsO group and 30% (54%) in the control group. In the PsO group, BMI was 27 ± 5.3 versus 26.9 ± 4.4 in control group (p = 0.08). There is a trend for more frequent active smoking in PsO (49% in PsO group versus 54% in control group; p = 0.078). In PsO patients, mean disease duration was 20.2 ± 17.6 years, the skin area affected with plaque was 41.8% ± 22.6 and the mean number of biologic drugs used was 2.25 ± 1.16. The global SIJ score was higher in the PsO group (6.63 ± 10.7) in comparison with the control group (2.84 ± 4.87). Erosion and sclerosis scores were similar in both groups but joint space narrowing score was significantly higher in the PsO group (0.873 ± 3.48 vs. 0.56 ± 3.24, p = 0.026).

Disclosure of Interests: None declared

Background: Salivary gland ultrasonography is useful to assess salivary gland involvement in primary Sjögren Syndrome. Different publications have describes the association between decreases salivary flow and the degree of involvement with ultrasound.

Objectives: This study aims to assess the association of functional salivary tests evaluated by stimulated and unstimulated salivary flow (SSF and USF) with salivary major gland ultrasound scores (SGUS) and a positive focus score in a minor salivary gland biopsy.

Methods: A cross-sectional study including 98 subjects fulfilling the ACR-EULAR 2017 classification criteria for pSS. All patients underwent salivary functional tests, an ultrasound of salivary glands and a minor salivary gland biopsy requested as per clinical practice. The ultrasound images were graded using three different scoring systems: De Vita (0-3), Salaffi (0-4) and Omeract (0-3), obtained as the highest score achieved in the four evaluated glands, left and right parotid and submandibular. Positive biopsy was considered if focus score ≥1.

Results: This study included 98 patients with pSS. We evaluated the different ultrasound scoring systems and each score individually assessed in parotid and submandibular gland with the salivary functional tests. USF is associated with all SGUS independently of the measurement, with a 2.5 ml/15min higher in negative compared to positive SGUS. Similar results were shown for SSF, with a 3 ml/5 min higher in negative compared to positive SGUS (Table 1). We observed no association between USF or SSF and a positive focus score in the minor salivary gland biopsy.

Table 1. Association between salivary flows and ultrasound scoring systems.

<table>
<thead>
<tr>
<th>Ultrasound score</th>
<th>Group N%</th>
<th>Mean±95%CI</th>
<th>p-val</th>
<th>Mean±95%CI</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vita</td>
<td>N 54 (55.1%)</td>
<td>4.076</td>
<td>0.004</td>
<td>54 (55.1%)</td>
<td>6.745</td>
</tr>
<tr>
<td>Vita Parotid</td>
<td>N 60 (61.2%)</td>
<td>3.896</td>
<td>0.008</td>
<td>60 (61.2%)</td>
<td>6.575</td>
</tr>
<tr>
<td>P 44 (44.9%)</td>
<td>3.182</td>
<td>0.014</td>
<td>2.912, 4.661</td>
<td>4.961, 8.190</td>
<td>3.128</td>
</tr>
<tr>
<td>P 38 (38.8%)</td>
<td>3.083</td>
<td>0.014</td>
<td>2.721, 4.661</td>
<td>4.592, 8.047</td>
<td>3.050</td>
</tr>
<tr>
<td>P 46 (46.9%)</td>
<td>3.347</td>
<td>0.014</td>
<td>1.932</td>
<td>1.536, 5.619</td>
<td>3.387</td>
</tr>
<tr>
<td>P 38 (38.8%)</td>
<td>3.062</td>
<td>0.014</td>
<td>2.598</td>
<td>2.150, 4.439</td>
<td>3.091</td>
</tr>
<tr>
<td>P 54 (55.1%)</td>
<td>3.896</td>
<td>0.008</td>
<td>3.857</td>
<td>3.182, 4.861</td>
<td>3.834</td>
</tr>
<tr>
<td>Salaffi Parotid</td>
<td>N 52 (53.1%)</td>
<td>3.005</td>
<td>0.007</td>
<td>52 (53.1%)</td>
<td>6.754</td>
</tr>
<tr>
<td>P 46 (46.9%)</td>
<td>3.182</td>
<td>0.014</td>
<td>3.005, 5.095</td>
<td>4.592, 8.047</td>
<td>3.050</td>
</tr>
<tr>
<td>P 44 (44.9%)</td>
<td>3.570</td>
<td>0.036</td>
<td>1.881</td>
<td>1.510, 4.193</td>
<td>3.387</td>
</tr>
<tr>
<td>Salaffi Submandibular</td>
<td>N 54 (55.1%)</td>
<td>4.011</td>
<td>0.007</td>
<td>54 (55.1%)</td>
<td>3.689</td>
</tr>
<tr>
<td>P 37 (38.8%)</td>
<td>3.347</td>
<td>0.014</td>
<td>3.005, 5.095</td>
<td>3.182, 4.861</td>
<td>3.387</td>
</tr>
<tr>
<td>P 44 (44.9%)</td>
<td>2.985</td>
<td>0.014</td>
<td>2.853</td>
<td>2.721, 4.276</td>
<td>2.974</td>
</tr>
<tr>
<td>Omeract Submandibular</td>
<td>N 56 (58.9%)</td>
<td>3.277</td>
<td>0.01</td>
<td>56 (58.9%)</td>
<td>6.313</td>
</tr>
<tr>
<td>P 31 (32.3%)</td>
<td>1.854</td>
<td>0.040</td>
<td>3.727</td>
<td>2.150, 4.439</td>
<td>3.387</td>
</tr>
<tr>
<td>P 40 (40.8%)</td>
<td>1.533</td>
<td>0.040</td>
<td>1.932</td>
<td>1.536, 5.619</td>
<td>3.387</td>
</tr>
<tr>
<td>P 40 (40.8%)</td>
<td>1.365</td>
<td>0.036</td>
<td>3.083, 5.095</td>
<td>2.546, 4.612</td>
<td>3.050</td>
</tr>
</tbody>
</table>

N: Negative, P: Positive

Conclusion: USF and SSF are associated with SGUS system independently of the salivary gland evaluated but not with positivity in the biopsy, pointing to salivary ultrasound as a good technique to evaluate functionality. Neither USF nor SSF are associated with positivity in the biopsy indicating no link between histology and functionality.

Disclosure of Interests: None declared


Table 1. CT scan findings between PsO patients and matched controls

<table>
<thead>
<tr>
<th>Ultrasound score</th>
<th>Controls N%</th>
<th>Mean±95%CI</th>
<th>p-val</th>
<th>PsO N%</th>
<th>Mean±95%CI</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erosion</td>
<td>0.42 (±0.31)</td>
<td>0.2 (±0.48)</td>
<td>0.18</td>
<td>0.48</td>
<td>0.2 (±0.48)</td>
<td>0.035</td>
</tr>
<tr>
<td>Joint space narrowing</td>
<td>0.873 (±0.62)</td>
<td>4.15 (±10.8)</td>
<td>0.035</td>
<td>0.42</td>
<td>4.15 (±10.8)</td>
<td>0.035</td>
</tr>
<tr>
<td>Sclerosis</td>
<td>1.76 (±2.73)</td>
<td>0.37</td>
<td></td>
<td>2.84 (±4.87)</td>
<td>6.03 (±10.7)</td>
<td>0.015</td>
</tr>
<tr>
<td>Global score</td>
<td>34 (62%)</td>
<td>34 (57%)</td>
<td>0.035</td>
<td>34 (62%)</td>
<td>34 (57%)</td>
<td>0.035</td>
</tr>
<tr>
<td>DISH</td>
<td>11 (20%)</td>
<td>9 (15%)</td>
<td>0.48</td>
<td>11 (20%)</td>
<td>9 (15%)</td>
<td>0.48</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared


References:
THE INTEREST OF DOPPLER ULTRASOUND IN THE EVALUATION OF THE CARPAL TUNNEL SYNDROME SEVERITY

N. El Amri1, S. Jirri2, S. Guizani3, K. Baccouche1, N. Mahdhi1, E. Bouajina1.
1Farhat Hached, Rheumatology, Sousse, Tunisia; 2Farhat Hached, Family Medicine, Sousse, Tunisia; 3University Hospital Sahliou, Plastic Surgery Department, Sousse, Tunisia

Background: Several studies have proven the value of Doppler ultrasound (DpUS) in the diagnosis of carpal tunnel syndrome (CTS) with satisfactory sensitivity and specificity. Yet, unlike the Nerve Conduction Studies (NCS), the interest of this technique in the severity diagnosis in CTS remains uncertain to this day. Several studies have focused on this subject. However, the morphological signs of gravity are not yet consensual.

Objectives: Compare US data with clinical and electromyographic data in order to determine the place of DpUS in the severity diagnosis in CTS.

Methods: A bicentric cross-sectional study including patients with uni or bilateral CTS, confirmed by NCS, referred from the plastic surgery department. All the patients underwent a clinical examination, a NCS of both hands as well as a DpUS of the wrists by the same rheumatologist.

Results: After screening and application of all exclusion criteria, a total of 72 wrists of 47 patients were included. The median age was 54.23 ± 11 years (21-77 years) and 89.4% of wrists were from female patients. Hand numbness was the most frequent functional sign (94.4%) and the Phalen sign was the most noted examination sign (73.6%). Clinically, the patients presented respectively 32 mild, 14 moderate and 26 severe lesions. According to the NCS, there were 18 mild, 21 moderate and 33 severe CTS with 73.6% of the wrists with sensorimotor impairment. On US, the hypoechoic image was the dominant qualitative sign (84.7%). Regarding the quantitative measures, the mean Median Nerve (MN) cross sectional area (CSA) was 14.5 mm2 [9-30 mm2] and the mean flattening index was 3 [1.8-8.92]. Intraneural hypervascularisation was present in 57 wrists (79.2 %). Statistically significant associations were detected between the MN CSA and both history of diabetes mellitus (p=0.045), diabetes duration (p=0.040) and disease duration (P=0.021). But there was no association between MN CSA and age (p=0.406), gender (p=0.690) and BMI (p=0.414). the mean MN CSA during mild clinical stage was 13.5 mm2. For moderate stage it was 17 mm2 while for severe stage it was 15 mm2. No relationship was found between US quantitative and morphological parameters and clinical severity grades. We detected significant correlation between MN hypervascularization and the CTS severity grades on NCS (p=0.044). For the other qualitative US signs, there was no statistically significant difference between the different grades of electromyographic severity (Notch sign (p=0.364), Hypoechoic image (p=0.000), Disappearance of the fascicular aspect (p=0.248), Decreased mobility of the tunnel contents of the canal during wrist movements (p=0.140)). the mean MN CSA during mild electromyographic stage was 13 mm2. For moderate stage it was 14 mm2 while for severe stage it was 15 mm2 and We did not find a statistically significant difference in MN CSA (P=0.494) between the different grades of severity of CTS on NCS. There is no statistically significant association between qualitative US signs and the type of CTS impairment; pure sensory or sensorimotor. However, we found a significant association between the MN CSA and pure sensory or sensorimotor damage on NCS (P=0.009).

Conclusion: MN DpUS could be a complementary procedure to the clinical examination which allows, in addition to the positive diagnosis, to evaluate the severity of the CTS based on the MN CSA and the intraneural vascularization in power Doppler.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5216

CLINICAL EVIDENCE OF THE DIFFERENCE IN CIRCULATING CALPROTEIN LEVELS BETWEEN RHEUMATOID ARTHRITIS AND HEALTHY INDIVIDUALS, NON-INFLAMMATORY ARTHRITIS OR OTHER INFLAMMATORY ARTHRITIS: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS

C. Andulacia1, R. Aibesa2, M. Mahleri3. 1Werfen, Research and Development, Barcelona, Spain; 2Werfen, Headquarters & Technology Center Autoimmunity, Research and Development, San Diego, United States of America; 3Werfen, Headquarters & Technology Center Autoimmunity, Research and Development, San Diego, United States of America

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disease mainly characterized by a chronic inflammation of the joints. Early diagnosis and treatment with disease-modifying anti-rheumatic drugs (DMARDs) is essential to prevent or slow down the structural damage. Diagnosis might be difficult in patients with mild and unspecific clinical signs and symptoms though. A differential diagnosis in patients presenting arthritis is needed for an appropriate patient management. Acute-phase reactants (ESR or CRP) are non-specific inflammatory biomarkers used to aid in the diagnosis of RA and to assess disease activity. In the recent years, studies published have shown that calprotectin may be an alternative biomarker of active inflammatory disorders as well as a prognostic or monitoring biomarker.

Objectives: To collect all available evidence on the difference between circulating calprotectin (cCalpro) levels in rheumatoid arthritis (RA) patients and other control populations such as healthy individuals (HI), osteoarthritis (OA), psoriatic arthritis (PsA) or spondyloarthritis (SpA).

Methods: Electronic database searches (Scopus, PubMed and Cochrane Library), complemented by registry and hand searching, were conducted (February 4th, 2021) to identify fully paired studies comparing cCalpro levels in RA and HI, non-inflammatory arthritis (NIA), or other inflammatory arthritis. As recommended by Cochrane, the Hedge’s standardized mean difference (SMD) and its 95% confidence intervals were used to synthesize the difference in cCalpro levels from studies using different matrices (serum or plasma) or laboratory methods. Sample size, mean and standard deviation of each group were extracted from the individual studies to conduct a random-effects model meta-analysis in STATA MP v17.0. When cCalpro levels were reported in median and range or inter-quartile, a formula was used to estimate the mean and standard deviation. Sensitivity analysis, subgroup analyses and meta-regression analyses on matrix type (serum or plasma) and cCalpro commercial test were performed, when feasible, to investigate heterogeneity.

Results: The systematic review retrieved 27 studies comparing cCalpro levels between RA and controls. One study reported cCalpro levels in three different RA and HI cohorts. Most of RA and controls were age and gender matched. Calprotectin was measured in serum in 72.4% of the comparisons. Thirteen different commercial calprotectin tests and four homemade tests were used. In 21 studies cCalpro levels were measured in 2678 RA and 1096 HI. cCalpro levels were significantly higher in RA than in HI (SMD=2.13;95%CI=1.27-2.98;p<0.0001), while no significant heterogeneity was observed. A meta-regression on matrix and assay manufacturer indicated that 22% of the between-study variance might be explained by the type of calprotectin test used. Five studies compared cCalpro levels in 207 RA and 187 NIA (78,57% OA). cCalpro levels were significantly higher in RA than in NIA (SMD=2.914;95% CI=0.957-4.872;p<0.0035), significant heterogeneity was observed. cCalpro levels in 1217 RA and 411 PsA patients were reported in 5 studies. cCalpro levels were slightly higher in RA than in PsA (SMD=0.54; 95%CI=0.242-0.656; p<0.0001), while no significant heterogeneity was observed. A comparison between cCalpro levels in RA and SpA was included in 4 studies. cCalpro levels were slightly higher in RA than in SpA (SMD=0.35; 95% CI=0.129-0.576; p=0.0020), and no significant heterogeneity was observed.

Conclusion: In this systematic review and meta-analysis, rheumatoid arthritis patients showed significantly higher circulating calprotectin levels than healthy individuals, non-inflammatory arthritis, psoriatic arthritis and spondyloarthritis. Pooled standardized mean difference between groups should be interpreted with cautious due to substantial heterogeneity or small number of studies.
PROGNOSTIC VALUE OF COMMON FEMORAL VEIN WALL THICKNESS IN BEHÇET DISEASE: A PROSPECTIVE FOLLOW-UP STUDY

K. Abacı1, R. Ergelen2, F. Temiz2, Y. Yıldız2, T. Ergun3, H. Direskeneli2, F. Albaz-Oneri1, 1Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Marmara University School of Medicine, Department of Radiology, Istanbul, Turkey; 3Marmara University School of Medicine, Department of Internal Medicine, Istanbul, Turkey; 4Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey

Background: We reported the first controlled doppler ultrasound study showing increased common femoral vein (CFV) thickness in Behçet Disease (BD). Following that, we recently showed that increased CFV thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases such as ankylosing spondylitis, systemic vasculitides, venous insufficiency, and non-inflammatory DVT (deep venous thrombosis) with a specificity higher than 80% for the cut-off value of ≥0.5mm. However, the association between CFV thickness and any organ involvement, disease course or treatment during the prospective follow-up has not been demonstrated so far.

Objectives: This study aimed to assess the longitudinal course and prognostic value of CFV thickness measurement during prospective follow-up BD patients.

Methods: In this prospective study, we included 195 patients with diagnosed BD. The clinical, demographic, treatment data and laboratory were recorded during the entire follow-up. Both CFV thickness was measured with ultrasonography by an experienced radiologist at the same day. Patients were started to follow up prospectively with 3-6 months intervals and in any urgent visit. In 47 patients, the second CFV thickness measurement was done mean 19.79 (10.10) months after the first visit.

Results: At baseline, 98.6% of patients had increased CFV thickness above the cut-off value of ≥0.5mm. The baseline and last follow-up clinical characteristics were shown in Table 1.

Table 1. The baseline and follow-up clinical characteristics of patients with Behçet’s Disease.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Baseline (n=139)</th>
<th>Last follow-up (n=139)</th>
<th>Relapses or New involvement during follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age mean (SD)</td>
<td>34.85 (8.27)</td>
<td>34.85 (8.27)</td>
<td></td>
</tr>
<tr>
<td>Gender F/M ratio</td>
<td>43/96</td>
<td>43/96</td>
<td></td>
</tr>
<tr>
<td>Pathergy (positive/negative)</td>
<td>59/44</td>
<td>59/44</td>
<td></td>
</tr>
<tr>
<td>Right CFV Wall Thickness mean (SD) mm</td>
<td>0.791 (0.253)</td>
<td>0.791 (0.253)</td>
<td></td>
</tr>
<tr>
<td>Left CFV Wall Thickness mean (SD) mm</td>
<td>0.797 (0.207)</td>
<td>0.797 (0.207)</td>
<td></td>
</tr>
<tr>
<td>Oral aphthous n (%)</td>
<td>134 (95)</td>
<td>134 (95)</td>
<td>13 (9.4)</td>
</tr>
<tr>
<td>Genital Ulcer n (%)</td>
<td>84 (60.4)</td>
<td>84 (60.4)</td>
<td>6 (4.3)</td>
</tr>
<tr>
<td>Eritema Nodusum n (%)</td>
<td>62 (44.6)</td>
<td>69 (49.6)</td>
<td>9 (6.5)</td>
</tr>
<tr>
<td>Arthritis (%)</td>
<td>48 (34.5)</td>
<td>48 (34.5)</td>
<td>10 (7.2)</td>
</tr>
<tr>
<td>Major Organ involvement n (%)</td>
<td>103 (74.1)</td>
<td>110 (78.6)</td>
<td>39 (28.1)</td>
</tr>
<tr>
<td>Vascular involvement n (%)</td>
<td>84 (60.4)</td>
<td>96 (69.1)</td>
<td>35 (25.2)</td>
</tr>
<tr>
<td>Deep Venous Thrombosis (%)</td>
<td>61 (43.9)</td>
<td>65 (46.8)</td>
<td>6 (4.3)</td>
</tr>
<tr>
<td>Pulmonary trombosis n (%)</td>
<td>35 (25.2)</td>
<td>52 (37.4)</td>
<td>23 (16.5)</td>
</tr>
<tr>
<td>Neuro-Behçet n (%)</td>
<td>14 (9.9)</td>
<td>16 (11.5)</td>
<td>2 (1.4)</td>
</tr>
<tr>
<td>Uveitis n (%)</td>
<td>33 (23.7)</td>
<td>40 (28.8)</td>
<td>7 (5)</td>
</tr>
</tbody>
</table>

In 47 patients, the second CFV thickness measurement was done mean 19.79 months after the first visit. There was no statistically significant difference between the first and second CFV thickness measurements for both right and left of our patients (First vs. second for right CFV: 0.791 mm vs. 0.753, p=0.264; first vs. second for left CFV: 0.787 mm vs. 0.753, p=0.264). We did not find any change in CFV wall thickness with the treatment, new organ involvement and relapses. 139 of 195 patients had prospective clinical follow-up data with the mean of 26.52 (16.94) months. New major organ involvement or relapse leading to treatment change was seen in 39 (28%) patients. While 22 (15.8%) patients had new major organ involvement, 12 (8.6%) of them were diagnosed with new vascular involvement, seven (5%) with new uveitis. Among 36 patients with only mucocutaneous disease at baseline, new major organ involvement developed in 9 patients during follow-up. These nine patients had higher baseline CFV thicknesses compared to patients not developing major organ involvement despite not achieving clinical significance.

Conclusion: CFV wall thickness measurement with ultrasonography which is a non-invasive diagnostic tool for BD, does not show a major change over time with treatment, new organ involvement or disease relapses. However, our preliminary results suggest that mucocutaneous BD patients with higher CFV thickness may have a higher risk of developing major organ involvement during follow-up. The results of our prospective cohort with longer follow-up and increased patients’ number would clarify the prognostic value of CFV thickness in BD.

Disclosure of Interests: None declared

Background: Rheumatoid arthritis (RA) is a disease with substantial impact on quality of life, healthcare and societal costs [1]. Current treatment strategies, especially biologic drugs, result in high costs [2]. Previous studies have already found that a combination treatment strategy of disease-modifying antirheumatic drug(s) with initially medium-to-high doses of prednisolone resulted in better effects and lower costs compared to the treatment strategies without prednisolone [3, 4]. However, to our knowledge the cost-effectiveness of low-dose glucocorticoids (GCs), and that of GC overall in established RA has not been examined separately.

Objectives: To evaluate the cost-effectiveness and cost-utility of low-dose prednisolone in RA patients aged 65+.

Methods: The economic evaluation was performed as part of the placebo-controlled GLORIA trial of RA patients aged 65+ with a disease activity score in 28 joints (DAS28) ≥2.60. Eligible patients were randomized to 2 years 5 mg/day prednisolone or placebo. Patients were recruited from 28 clinical centers in seven European countries. All co-treatment, except for chronic oral GC, was allowed. The economic evaluation had a societal perspective with a time horizon of two years. Cost data were collected with questionnaires and from recorded events, and valued with unit prices of 2017. The primary effectiveness outcome was the DAS28. For cost-utility, quality-adjusted life years (QALYs) were estimated from the EuroQol-5 Dimension (EQ-5D) questionnaire. Standard regression models were used to estimate incremental costs and effects between the treatment groups. Bootstrapping assessed the uncertainty around the average differences in costs and health outcomes.

Results: In total, 444 of 451 randomized patients were included in the modified-intention-to-treat analysis (see main GLORIA study abstract). Patients were on average 72 years and had median 4 active comorbidities at baseline period, annual total costs were €7564/PY for patients with no flares at Year 9, whereas costs reduced sharply in flare-exposure subgroups.}

Conclusion: With greater effectiveness at non-significantly lower costs, low-dose, add-on prednisolone is cost-effective for RA compared to placebo over two years. QALYs were equal in both groups, most likely due to the impact of multiple comorbidities.

REFERENCES:

Acknowledgements: The GLORIA project is funded by the European Union’s Horizon 2020 research and innovation programme under the topic “Personalizing Health and Care”, grant agreement No 634886.

Disclosure of Interests: Linda Hartman: None declared, Mohamed El Alli: None declared, Maurizio Cutolo: None declared, Daniela Opris-BelinskiSpeakers bureau: Abbvie, Pfizer, MSD, Novartis, Eli Lilly, Ewo Pharma, UCB, José da Silva: None declared, Zoltán Szekaneicz: None declared, Frank Buttgereit Speakers bureau: Abbvie, AstraZeneca, Gruenenthal, Horizon Therapeutics, Mundipharma, Pfizer, Roche, Pavol MASARYK: None declared, Richard Bos: None declared, Marc R Koj: None declared, Sabrina Paolino: None declared, Veeve M. H. Coupé: None declared, Willem Lems Speakers bureau: Pfizer, Galapagos, Lilly, Amgen, UCB, Maarten Boens Speakers bureau: BMS, Novartis, Pfizer


POS1403 CLINICAL CHARACTERISTICS, HEALTH CARE RESOURCE UTILIZATION, AND COSTS ASSOCIATED WITH FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN GERMANY

B. Ding1, M. Pignot2, E. Garal-Pantaler3, B. Villinger4, B. Desta5, K. Schmidt5, S. Golam1, H. Stirnadel-Farrant6, A. Schwartz6
1AstraZeneca, BioPharmaceuticals Medical, Gothenburg, Sweden; 2ZEG Berlin GmbH, Center of Epidemiology and Health Research Berlin, Berlin, Germany; 3Team Gesundheit GmbH, Health Economics Department, Essen, Germany; 4AstraZeneca, BioPharmaceuticals Medical, Nürnberg, Germany; 5AstraZeneca, BioPharmaceuticals Business Unit, Gaithersburg, MD, United States of America; 6AstraZeneca, BioPharmaceuticals Medical, Wedel, Germany; 7AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom; 8University Medicine of Johannes Gutenberg University Mainz, Rheumatology and Clinical Immunology, Mainz, Germany

Background: Longitudinal data describing real-world systemic lupus erythematosus (SLE) disease characteristics, health care resource utilization (HCRU), and costs associated with flares in Germany are limited.

Objectives: To evaluate the clinical characteristics of patients with SLE and estimate the impact of flares on HCRU and costs in a cohort of adults with SLE in Germany.

Methods: CCharacteristics and impact of flares on clinicAI and econMic OutCoMes in patients with systemic Lupus Erythematosus: a German Claims Database Study (CHAMOMILE) was an observational, retrospective cohort study. Adult patients with SLE were identified from the German Betriebsskrankenkassen health insurance fund database between 1 July 2010 and 31 December 2013, and followed for up to 9 years. Baseline period was defined as the first year since the first quarter with the earliest SLE diagnosis during the identification period, including this quarter. Resource utilization measures included number of hospitalizations, duration of stay, and associated costs per person-year (PY) by follow-up year for patient subgroups defined by flare exposure (no, mild, or moderate/severe flares) during baseline. Cost measures included total PY costs in flare-exposure subgroups.

Results: Of 2088 patients included in the study, the mean (SD) age was 51.4 (16.1) years and 1787 (84.6%) were female. The most common SLE manifestations were cutaneous (66.8%), osteoarticular (28.7%), and vascular (23.0%). Patients were receiving treatment with glucocorticoids (54.8%), antimalarials (40.2%), nonsteroidal anti-inflammatory drugs (39.1%), and/or immunosuppressants (32.7%). During the baseline period, 750 patients (35.9%) experienced moderate/severe flares, 622 (29.8%) experienced mild flares, and 716 (34.3%) experienced no flares. Patients with no flares or mild flares during the baseline period had similar costs, and a similar number and duration of hospital stays per PY, which remained consistent from baseline up to 9 years of follow-up. Patients with moderate/severe flares during the baseline period had 2- to 3-fold higher hospital costs, 1- to 2-fold more hospital stays, and hospital stays that were 2-fold longer in duration, compared with the no-flares or mild-flares groups during baseline and each year of follow-up (Table 1). During the baseline period, annual total costs were more than 2-fold greater for patients with moderate/severe flares (€11,048/PY) than patients with mild (€5,348/PY) or no flares (€4,734/PY). In all subsequent years, costs for patients with moderate/severe flares exceeded costs for patients with mild or no flares. Annual total costs gradually increased over time to €7761/PY for patients with mild and to €7564/PY for patients with no flares at Year 9, whereas costs reduced sharply at follow-up Year 1 to €8601/PY and remained similar to Year 9 for patients with moderate/severe flares (Figure 1).
Table 1. Mean Costs, Number, and Duration of Hospital Stays per Person-Year by Baseline Flares

<table>
<thead>
<tr>
<th>Flare-Exposure Subgroup</th>
<th>Year</th>
<th>Baseline</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td></td>
<td>716</td>
<td>716</td>
<td>701</td>
<td>676</td>
<td>658</td>
<td>634</td>
<td>603</td>
<td>526</td>
<td>444</td>
<td>315</td>
</tr>
<tr>
<td>Costs of hospital stays, mean, €</td>
<td></td>
<td>1325</td>
<td>1798</td>
<td>2296</td>
<td>1725</td>
<td>2233</td>
<td>3126</td>
<td>1759</td>
<td>1786</td>
<td>1795</td>
<td>2047</td>
</tr>
<tr>
<td>Duration of hospital stays, mean, days</td>
<td></td>
<td>1779</td>
<td>1944</td>
<td>1545</td>
<td>1820</td>
<td>1652</td>
<td>2261</td>
<td>2390</td>
<td>1974</td>
<td>2290</td>
<td>2451</td>
</tr>
</tbody>
</table>

Conclusion: Patients with moderate or severe flares following diagnosis place a large burden on the health care system in Germany. Earlier diagnosis and treatment may reduce flare severity and the associated high health care costs.

Disclosure of Interests: Writing assistance by Rebecca S. Jones, PhD (Fishawack Health). This study was sponsored by AstraZeneca.

Background: It is well known that providing appropriate health information to patients with systemic lupus erythematosus (SLE) has an advantage in the treatment decision-making process. In modern information society the growing popularity of smartphones and social networking services, patients have more access to online health information. However, there are concerns that Internet use may inversely affect the shared decision making (SDM) process with their attending physicians if they receive inaccurate information.

Methods: In this cross-sectional study, information of 386 patients with SLE, which were enrolled from five Japanese institutions between June 2020 and August 2021, were analyzed. The main exposure was time spent on the Internet per day (excluding time used for working). It was divided into four categories (none, <1 hour, 1-2 hours, ≥2 hours). Patients were asked to select the sources of health care information they would like to access first and were categorized into physicians, the Internet, and other media sources (family and friends, healthcare professionals other than physicians, or TV and radio, etc.). Outcome was shared decision making measured via the 9-item Shared Decision Making Questionnaire (SDM-Q-9, scores 0-100). To assess the relationship between the time of Internet use and SDM, we fitted general linear models adjusted for age, gender, education level, household income, marital status, history of cancer, disease duration, and disease activity. Chained equations were used to impute missing values of covariates.

Results: This study ultimately employed 334 patients whose mean age and female ratio were 45.3 years (standard deviation 13.8) and 87.7%, respectively. 68.9% of the patients indicated that they would like to access physicians first, and 19.5% indicated that they would like to access the Internet first. Compared to patients who chose their physician as their first access to health information, there was no difference in SDM-Q-9 among patients who chose the Internet, but patients who chose other media had significantly lower SDM-Q-9 (<7.7 point, 95% confident interval [CI] -14.4 to -0.92, P=0.026). Besides, SDM-Q-9 scores were significantly lower in patients who did not use the Internet compared to those who used it for more than two hours except for their work activities (-9.6, 95%CI -18.9 to -0.26, P=0.044).

Conclusion: The present study suggests that SDM between physicians and patients is positively rather than adversely associated with online information-gathering behavior. Rheumatologists also need to be aware that how patients prefer to access health information to establish a good physician-patient relationship for SDM. In addition, rheumatologists may need to introduce their patients to websites offering appropriate health information.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.899

**POSI404**

**SHARED DECISION MAKING AND INTERNET USE FOR GATHERING HEALTH INFORMATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MULTICENTER CROSS-SECTIONAL STUDY**

T. Ichikawa1, Y. Shimojima1, D. Kishida1, N. Kurita7, 8, T. Ichikawa1, Y. Shimojima1, D. Kishida1, N. Yajima2, R. Yoshimi3, K. E. Sada4,5, 6, University of Occupational and Environmental Health School of Medicine, Fukushima, Japan; 5Fukushima Medical University Hospital, Department of Internal Medicine, Fukushima, Japan; 6CHU Nancy, Public Health, Nancy, France; 7Fukushima Medical University, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 8Fukushima Medical University, Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima, Japan

**POSI405**

**LESS THAN 50% FEMALES WITH CHRONIC RHEUMATITIC INFLAMMATORY DISEASES CONTINUE A DMARD DURING PREGNANCY: A DESCRIPTIVE ANALYSIS OF THE NATIONAL FRENCH SOCIAL SECURITY DATABASE**

Background: Treatment of patients with chronic rheumatic inflammatory diseases (CIDR) during pregnancy has changed in the last decade, namely due to the availability of new DMARDs labelled to be used during pregnancy.

Objectives: To describe the anti-rheumatic drug use during pregnancy in women with CRID (i.e. rheumatoid arthritis (RA) or spondyloarthritids (SpA)) in France over the past decade.

Methods: This is a retrospective cohort study within the French Healthcare database (SNDS), which covers 98% of the French population. Adult women were included if they had RA or SpA according to CIM-10 codes, had started a singleton pregnancy between 2008 and 2017 (index date), and were continuously covered by this health insurance from 1-year before pregnancy onset to 1-year after end of the pregnancy or death (whichever comes first). The treatment exposures of interest were: NSAIDs, oral corticosteroids, csDMARD (methotrexate, leflunomide, sulfasalazine, azathioprine, hydroxychloroquine), biologics (anti-TNF, rituximab, abatacept, tocilizumab, ustekinumab, anakinra). Exposure during pregnancy was defined as at least one drug reimbursement from the 6 months before the last menstrual period (LMP) to the end of pregnancy period.

Results: Among the 35,737 adult women with a CRID (40.7% with RA and 59.3% with SpA) who had a past history of DMARD reimbursement, 11,274 (41.7%) started a singleton pregnancy during the study period. In total, during preconception and pregnancy, 4,773 (42.3%) women were not delivered any DMARD nor corticosteroids and pregnancy was defined as at least one drug reimbursement from the 6 months before the last menstrual period (LMP) to the end of pregnancy period.

Conclusions: Overall, less than 50% of women with a CRID who received a DMARD prior to the pregnancy continued to receive such treatment during pregnancy, and overall less than 20% were delivered biologics during pregnancy. Whether the withdrawal of DMARDs led to unfavorable maternal and pregnancy outcomes needs to be evaluated.

Acknowledgements: This study was conducted thanks to a grant from the French Ministry of Health - Programme Hospitalier de Recherche Clinique (PHRC). Disclosure of Interests: B. Kuriya Consultant of: Abbvie, Lilly, Pfizer, BMS, MSD, Novartis, Biogen, Janssen, Grant/research support from: UCB, Aya Ariouche: None declared, Diep Tran: None declared, Barbara Roux: None declared, Nathalie Costedoat-Chalumeau: Grant/research support from: UCB, Elisabeth El Fertou: None declared, Vassilis Tsatsaris: None declared, Jeanne Presson: None declared, Brigitte Bader-Meunier: None declared, Bruno Fautrel: Disclosure of Interests: B. Kuriya: Speakers bureau: Abbvie, Gilead, Pfizer, Eli Lilly, Novartis and Sandoz. Whether the withdrawal of DMARDs led to unfavorable maternal and pregnancy outcomes needs to be evaluated. Disclosure of Interests: None declared. Florence Tubach: None declared. doi: 10.1136/annrheumdis-2022-eular.1334

Table 1. Percentage in each of three exposure groups achieving the recommended HF quality measures.

<table>
<thead>
<tr>
<th>Process Measure</th>
<th>IA Group</th>
<th>DM Group</th>
<th>General Population</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.Echocardiogram</td>
<td>90.6%</td>
<td>91.1%</td>
<td>89.5%</td>
</tr>
<tr>
<td>2.Electrocardiogram</td>
<td>97.4%</td>
<td>97.4%</td>
<td>97.3%</td>
</tr>
<tr>
<td>3.Chest x-ray</td>
<td>99.7%</td>
<td>99.6%</td>
<td>99.6%</td>
</tr>
<tr>
<td>4.Health care provider visit within 7 days of discharge</td>
<td>39.0%</td>
<td>38.9%</td>
<td>38.7%</td>
</tr>
<tr>
<td>Perfect Adherence (achieving 1, 2,3 and 4 above)</td>
<td>33.0%</td>
<td>33.0% (p=0.43, IA vs. DM)</td>
<td>32.2% (p=0.15, IA vs. General population)</td>
</tr>
<tr>
<td>5.Beta blocker prescribed</td>
<td>64.8%</td>
<td>70.5%</td>
<td>66.6%</td>
</tr>
<tr>
<td>6.Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker prescribed</td>
<td>54.8%</td>
<td>61.3%</td>
<td>56.2%</td>
</tr>
<tr>
<td>7.Mineralocorticoid receptor antagonist prescribed</td>
<td>20.3%</td>
<td>19.9%</td>
<td>21.2%</td>
</tr>
<tr>
<td>Perfect Adherence (achieving 5, 6 and 7 above)</td>
<td>10.6%</td>
<td>12.0% (p=0.001, IA vs. DM)</td>
<td>12.0% (p=0.02, IA vs. General population)</td>
</tr>
</tbody>
</table>

Conclusion: HF quality indicators are adhered to in a high proportion of patients with IA following HF hospitalization. However, reasons for lower HF medication prescribing in IA compared to other high-risk conditions, such as DM, requires further evaluation. It will also be important to determine if adherence to HF quality of care translates to reduced long-term outcomes such as repeat HF hospitalizations and cardiovascular mortality, which we are currently exploring.

REFERENCES:

Epidemiology, risk factors for disease or disease progression

**POSI407**  
**THE MANAGEMENT OF CONTEMPORARY EARLY UNDIFFERENTIATED ARTHRITIS: DATA ON EULAR'S RECOMMENDATION ON THE RISK OF PERSISTENT DISEASE**


**Background:** EULAR recommendations for early arthritis recommend assessing the following risk factors for persistent disease in Undifferentiated Arthritis (UA): polyarthritis, acute phase reactants (i.e. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)), rheumatoid factor (RF), ACPA and imaging findings/erosions. However, these recommendations are based on an outdated definition of UA: not fulfilling 1987 RA criteria and having no alternative diagnosis (conventional UA). Since the introduction of the 2010 RA criteria the characterization of UA has changed. The contemporary definition of UA is: not fulfilling 1987 nor 2010 criteria, and having no alternative diagnosis. Therefore, predictors for persistent disease in conventional UA may not be applicable in contemporary UA.

**Objectives:** Our objective was to assess which risk factors for persistent disease, as mentioned in the EULAR recommendations, are applicable in contemporary UA.

**Methods:** Patients consecutively included in the Leiden Early Arthritis Clinic cohort with contemporary UA between 2006-2019, when DMARD start in UA was recommended, were studied. The outcome was sustained remission, defined as absence of clinical synovitis without DMARD use (including corticosteroids) for the entire follow-up (at least one year). Cox regression was used to test the association between the risk factors as mentioned in EULAR-guidelines and sustained remission. For comparison, patients with conventional UA (not fulfilling the 1987 criteria and no other diagnosis) were studied using similar analyses.

**Results:** Contemporary UA patients (n=710) were mostly ACPA negative (95%) and had a median of 2 swollen joints. Radiographic erosions were rare (1.8%). 60% of contemporary UA patients achieved sustained remission after median 1.5 years (IQR 1-3). After achieving remission patients were followed for 5.5 years without clinical arthritis, demonstrating sustainability. Univariable, CRP, ESR, ACPA and RF were associated with time to sustained remission, while polyarthritis was not. In multivariable analysis, only ACPA and CRP were independently associated with sustained remission (HR 0.10 (95% CI:0.03-0.32) and HR 0.67(0.50-0.91), respectively). 67% of contemporary UA patients had none of these risk factors. In contrast, only 2% had both CRP and ACPA. For comparison, multivariable analysis in conventional UA patients (not fulfilling the 1987 criteria and no other diagnosis) were studied using similar analyses.

**Conclusion:** The contemporary UA population is different from conventional UA and risk factors for disease persistence are partly dissimilar. ACPA and CRP remain to be predictive in contemporary UA. Other factors included in the current EULAR recommendation were uninformative (RF, ESR, polyarthritis) or rare (erosions). Therefore, risk factors recommended in future EULAR recommendations may require alterations.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.322

**POSI408**  
**AN ULTRASOUND NEGATIVE FOR SUBCLINICAL SYNOVITIS IN PATIENTS WITH ARTHRALGIA: IS IT HELPFUL IN IDENTIFYING THOSE WHO WILL NOT DEVELOP INFLAMMATORY ARTHRITIS? A LONGITUDINAL STUDY IN FOUR ARTHRALGIA COHORTS**


**Background:** Ultrasound (US) has become an established method in the evaluation of joints and is often used in clinical practice to guide management decisions in arthralgia-patients. To date, studies on the prognostic value of MSUS in arthralgia focused on the positive predictive value of subclinical inflammation. However, also the absence of imaging-detected subclinical synovitis is now increasingly used in daily practice to exclude arthralgia-patients from further follow-up. Though, evidence on the value of a negative US in ruling out future IA development in arthralgia-patients (the negative predictive value) is mostly absent. According to the rules of Bayes, predictive values are highly dependent on the prior-risk of developing the disease. The NPV therefore, is strongly related to the prior-risk of not getting IA, which is quite considerable in arthralgia-patients.

**Objectives:** To investigate the negative predictive value (NPV) of musculoskeletal ultrasound (MSUS) in arthralgia patients at risk for developing inflammatory arthritis (IA).

**Methods:** An MSUS examination of hands and feet was performed in arthralgia-patients at risk for IA in four independent cohorts. Patients were followed for one-year on the development of IA. Subclinical synovitis was defined as grey-scale ≥2 and/or power Doppler ≥1. NPVs were determined and compared with the prior-risks of not developing IA. Outcomes were pooled using meta-analyses and meta-regression analyses. In sensitivity analyses, MSUS-imaging of tender joints only (rather than the full US-protocol) was analyzed and ACPA-stratification applied, the latter being in line with the use of US in daily care.

**Results:** After one-year 78%, 82%, 77% and 72% of patients in the four cohorts did not develop IA. The NPV of a negative US was 86%, 85%, 82% and 90%, respectively. The meta-analysis showed a pooled non-IA prevalence of 79% (95% CI: 75%-83%) and a pooled NPV of 86% (95% CI: 81%-89%) (Figure 1). Imaging tender joints only (as generally done in clinical practice) and ACPA-stratification showed similar results.

**Conclusion:** A negative US result in arthralgia has a high NPV for not developing IA, which is mainly due to the high a-priori risk of not developing IA. The added value of a negative US (<10% increase) was limited.

**References:** N.A.

**Disclosure of Interests:** Cleo Rogier: None declared, Giulia Frazzini: None declared, Marion Kortekaas: None declared, Marloes Verstappen: None declared, Sarah Ohrndorf: None declared, Elise van Mulligen: None declared, Ronald van Vollenhoven. Speaker bureau: Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, GSK, Janssen, Pfizer, UCB, Consultant of: Consultancy, for which institutional and/or personal honoraria were received: AbbVie, AstraZeneca, Biogen, Biotest, BMS, Galapagos, Gilead, Janssen, Pfizer, Sanofi, Servier, UCB, Vielabio, Grant/research support from: Research Support (institutional grants): BMS, GSK, Lilly, UCB Support for Educational programs (institutional grants): Pfizer, Roche, Dirkjan van Schaardenburg: None declared, Pascal de Jong: None declared, Annette van der Helm-van Mil: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.323

**Figure 1. Full US protocol:** Prior risks of not developing IA (A) and negative predictive values of MSUS (B) in the four cohorts. For comparison, the pooled prior risk and confidence interval from A are depicted in the red column in B.

**Conclusion:** A negative US result in arthralgia has a high NPV for not developing IA, which is mainly due to the high a-priori risk of not developing IA. The added value of a negative US (<10% increase) was limited.

**References:** N.A.

**Disclosure of Interests:** Cleo Rogier: None declared, Giulia Frazzini: None declared, Marion Kortekaas: None declared, Marloes Verstappen: None declared, Sarah Ohrndorf: None declared, Elise van Mulligen: None declared, Ronald van Vollenhoven. Speaker bureau: Speaker, for which institutional and/or personal honoraria were received: AbbVie, Galapagos, GSK, Janssen, Pfizer, Sanofi, Servier, UCB, Vielabio, Grant/research support from: Research Support (institutional grants): BMS, GSK, Lilly, UCB Support for Educational programs (institutional grants): Pfizer, Roche, Dirkjan van Schaardenburg: None declared, Pascal de Jong: None declared, Annette van der Helm-van Mil: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.323
ASSOCIATION BETWEEN SHORT-TERM EXPOSURE TO ENVIRONMENTAL AIR POLLUTION AND PSORIASIS FLARE

G. Adami¹, F. Bellinato², A. Fassio¹, C. Benini¹, G. Girolomoni², P. Gisondi², M. Rossini¹. ¹University of Verona, Rheumatology Unit, Verona, Italy; ²University of Verona, Dermatology Unit, Verona, Italy

Background: Psoriasis is a chronic inflammatory disease with a relapsing-remitting course. Selected environmental factors such as infections, stressful life events or drugs may trigger disease flares. Whether the air pollution could trigger psoriasis flares is still unknown.

Objectives: To investigate whether the short-term exposure to environmental air pollution is associated to psoriasis flares.

Methods: Observational study with both case-crossover and cross-sectional design was conducted. We retrospectively analyzed longitudinal data from 2013 to 2020 of patients with psoriasis attending the outpatient dermatologic clinic of the University Hospital of Verona. For the case-crossover analysis patients with at least one disease flare, defined as PASI increase ≥5 between 2 consecutive assessments in a time frame of 3-4 months, were considered. In the case-crossover analysis each patient serves as its own control; the exposure of interest is compared in two different periods in the same group of patients followed longitudinally (Figure 1). For the cross-sectional analysis, patients receiving any systemic treatment for ≥6 months, with ≥2 consecutive PASI assessment were included. We compared the mean and cumulative (area under the curve) concentrations of several air pollutants (CO, NO₂, NOₓ, C6H6, PM10 and PM2.5) in the 60 days preceding the psoriasis flare and the control visits.

Results: A total of 957 patients with plaque psoriasis with 4,398 follow-up visits were included in the study. More than 15,000 measurements of air pollutants concentration from the official, open-source, bulletin of the Italian Institute for Environmental Protection and Research (ISPRA) were retrieved. Among the overall cohort, 369 (38.6%) patients with psoriasis flare were included in the case-crossover study. We found that concentrations of all pollutants were significantly higher in the 60 days before psoriasis flare (median PASI at the flare 12, IQR 9-18), compared to the control visit (median PASI 1, IQR 1-3, p <0.0001). In the cross-sectional analysis, exposure to mean PM10 over 20 μg/m³ and mean PM2.5 over 15 μg/m³ in the 60 days before assessment were associated with a higher risk of PASI ≥5 point worsening, aOR 1.55, 95% CI 1.21-1.99 and aOR 1.25, 95% CI 1.0-1.57, respectively (Figure 1). Sensitivity analyses that stratified for trimester of evaluation, with various lag of exposure and adjusting for type of treatment yielded similar results.

Conclusion: Air pollution may be a trigger factor for psoriasis flare.

Disclosure of Interests: Giovanni Adami Speakers bureau: Galapagos, Theramex, Francesco Bellinato: None declared, Angelo Fassio: None declared, Camilla Benini: None declared, Giampiero Girolomoni Shareholder of: AbbVie, Abiogen, Almirall, Amgen, Biogen, Bristol-Meyers Squibb, Eli-Lilly, Galderma, Genzyme, Leo Pharma, Pfizer, Regeneron, Samsung and Sanofi, Paolo Gisondi Shareholder of: AbbVie, Amgen, Bms, Eli Lilly, Jansenn, Novartis, Sanofi, UCB, Maurizio Rossini Shareholder of: Abbvie, Amgen, Bms, Eli Lilly, Galapagos, Novartis, Pfizer, Sandoz, Theramex, Ucb DOI: 10.1136/annrheumdis-2022-eular.525
DEVELOPMENT OF PREDICTION MODELS FOR SENIOR PATIENTS WITH RHEUMATOID ARTHRITIS AND COMORBIDITIES TREATED WITH CHRONIC LOW-DOSE GLUCOCORTICOIDS IN THE GLORIA TRIAL


AUC 0.67-0.69.

Another predictive factor (see Figure 1). The quality of the prediction models is different from that of study treatment. In three instances, prednisolone interacted with outcome in one of the models (Figure 1). Their association was much weaker than that of study treatment. Finally, a few additional variables were slightly (but not relevantly) predictive for the outcome in one of the models (Figure 1). The quality of the prediction models was sufficient, the performance low to moderate: explained variance: 12-15%, AUC 0.67-0.69.

In the GLORIA trial 451 RA patients aged 65+ were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were developed from the dataset in a stepwise procedure. In preparation, to limit excessive statistical testing and false positive results, possible predictors were grouped into five predictor sets based on prior knowledge (Table 1). The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of study treatment, as main factor and as interaction factor with other predictive variables. In each set, two models focused on harm (1: occurrence of ≥1 adverse event of special interest (AESI); 2: number of AESIs per year) and two on benefit (3: early clinical response–disease activity; 4: lack of joint damage progression). AESI comprised all serious adverse events, events leading to discontinuation of study treatment, and events related to glucocorticoid exposure (see main GLORIA study abstract). Linear and logistic multivariable regression methods with backward selection were used to develop the models. The final models were developed from the dataset in a stepwise procedure. In preparation, to limit excessive statistical testing and false positive results, possible predictors were grouped into five predictor sets based on prior knowledge (Table 1). The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of study treatment, as main factor and as interaction factor with other predictive variables. In each set, two models focused on harm (1: occurrence of ≥1 adverse event of special interest (AESI); 2: number of AESIs per year) and two on benefit (3: early clinical response–disease activity; 4: lack of joint damage progression). AESI comprised all serious adverse events, events leading to discontinuation of study treatment, and events related to glucocorticoid exposure (see main GLORIA study abstract). Linear and logistic multivariable regression methods with backward selection were used to develop the models. The final models were assessed and internally validated with bootstrapping techniques, and their performance was evaluated with model fit and discrimination measures.

Table 1. Predictor sets.

<table>
<thead>
<tr>
<th>Personal factors</th>
<th>Disease factors</th>
<th>Comorbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>RA duration</td>
<td>GC-related</td>
</tr>
<tr>
<td>Sex</td>
<td>RF</td>
<td>Prior comorbidity; cont, dich, GC-related</td>
</tr>
<tr>
<td>Education</td>
<td>Anti-CCP</td>
<td>GC-related</td>
</tr>
<tr>
<td>Smoking</td>
<td>Damage (cont, dich)</td>
<td># comorbidity medications</td>
</tr>
<tr>
<td>Alcohol</td>
<td>Copying RA</td>
<td>Joint surgery</td>
</tr>
<tr>
<td>BMI</td>
<td>Impact RA</td>
<td>Patient symptoms</td>
</tr>
<tr>
<td>Blood pressure</td>
<td>Health and daily functioning</td>
<td></td>
</tr>
<tr>
<td>Medications</td>
<td># concomitant medications</td>
<td>HAQ</td>
</tr>
<tr>
<td>Previous use DMARD</td>
<td>Previous use DMARD</td>
<td>Qol</td>
</tr>
<tr>
<td>GC Current use DMARD</td>
<td>GC Current use DMARD</td>
<td>VAS health</td>
</tr>
<tr>
<td>Adherence</td>
<td>SF36 physical, mental</td>
<td></td>
</tr>
<tr>
<td>Switch antirheumatic drugs</td>
<td>#</td>
<td></td>
</tr>
</tbody>
</table>

cont=continuous; dich=dichotomous; GC=glucocorticoid.

RESULTS: Study treatment (i.e. prednisolone) was highly predictive as a main factor in models 5-8, increasing the risk of both benefit and harm. In addition, a few additional variables were slightly (but not relevantly) predictive for the outcome in one of the models (Figure 1). Their association was much weaker than that of study treatment. In three instances, prednisolone interacted with another predictive factor (see Figure 1). The quality of the prediction models was sufficient, the performance low to moderate: explained variance: 12-15%, AUC 0.67-0.69.

Figure 1. Baseline predictive factors for benefit and harm (other than prednisolone), and their interaction with prednisolone. For benefit red means less/better, for harm red means increase of harm.

CONCLUSION: Baseline factors are not helpful to select senior RA patients for treatment with low-dose prednisolone given their low power to predict the chance of benefit or harm.

REFERENCES:

ACKNOWLEDGMENTS: The GLORIA project is funded by the European Union's Horizon 2020 research and innovation programme under the topic “Personalizing Health and Care”, grant agreement No 634886.

DISCLOSURE OF INTERESTS: Linda Hartman: None declared, José Antonio P. da Silva: None declared, Frank Buttgereit Speakers bureau: Abbvie, AstraZeneca, Bruenental, Horizon Therapeutics, Mundipharma, Pfizer, Roche, Maurizio Cutolo: None declared, Daniela Oppris-Belinski Speakers bureau: Abbvie, Pfizer, MSD, Novartis, Eli Lilly, Ewo Pharma, UCB, Zoltán Szekanecz: None declared, Pavol MASARYK: None declared, Marieke Voshaar: None declared, Martijn W. Heijmans: None declared, Willem Lems Speakers bureau: Abbvie, Galapagos, Lilly, Amgen, UCB, Désirée van der Heijde: None declared, Maarten Boers Speakers bureau: BMS, Novartis, Pfizer

We present the results obtained via spectral clustering on the similarity matrix obtained in each “case” and “control” population via Euclidean distance. There are 40 LTCs which are represented via two clusters in the “case” and the “control” population network (Figure 1). The LTCs in the same cluster are strongly connected within themselves compared to those in the other cluster. The noticeable part was clustering of diabetes, hypertension and chronic kidney diseases in one group, especially in the “case” population over the “control” population. Interestingly, depression, dementia and chronic heart diseases in one group, especially in the “case” population over the “control” population.

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>CASE, N = 67,827</th>
<th>CONTROL, N = 271,308</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Group, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;20</td>
<td>6,491 (9.6%)</td>
<td>27,897 (10.0%)</td>
</tr>
<tr>
<td>20-54</td>
<td>42,357 (62.4%)</td>
<td>169,008 (62.3%)</td>
</tr>
<tr>
<td>55 and above</td>
<td>19,148 (26.2%)</td>
<td>74,403 (27.4%)</td>
</tr>
<tr>
<td>Etiology, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>28,200 (41.6%)</td>
<td>90,485 (34.5%)</td>
</tr>
<tr>
<td>Black, S, Asian and other</td>
<td>956 (1.4%)</td>
<td>3,735 (1.4%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>38,671 (52.7%)</td>
<td>174,088 (62.2%)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>35,431 (52%)</td>
<td>141,724 (52%)</td>
</tr>
<tr>
<td>BMI category, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20 to &lt;25</td>
<td>11,183 (16.5%)</td>
<td>43,240 (15.9%)</td>
</tr>
<tr>
<td>25 to &lt;30</td>
<td>13,565 (20%)</td>
<td>45,783 (16.9%)</td>
</tr>
<tr>
<td>30 to &lt;35</td>
<td>7,584 (11.2%)</td>
<td>22,690 (8.4%)</td>
</tr>
<tr>
<td>35 to 40</td>
<td>3,048 (4.5%)</td>
<td>8,172 (3.0%)</td>
</tr>
<tr>
<td>Alcohol status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-drinker/ Ex-drinker</td>
<td>8,649/2,159 (15.9%)</td>
<td>33,983/7,579 (15.3%)</td>
</tr>
<tr>
<td>Smoker status, n (%)</td>
<td>47,316/3,030 (74.2%)</td>
<td>180,888/8,831 (69.9%)</td>
</tr>
<tr>
<td>Ex-smoker/Non-smoker</td>
<td>14,137/29,289 (64%)</td>
<td>48,110/142,295 (70.2%)</td>
</tr>
<tr>
<td>Long term condition, Median (IQR)</td>
<td>1.00 (0.00, 3.00)</td>
<td>1.00 (0.00, 2.00)</td>
</tr>
</tbody>
</table>

We present the results obtained via spectral clustering on the similarity matrix obtained in each “case” and “control” population via Euclidean distance. There are 40 LTCs which are represented via two clusters in the “case” and the “control” population network (Figure 1). The LTCs in the same cluster are strongly connected within themselves compared to those in the other cluster. The noticeable part was clustering of diabetes, hypertension and chronic kidney diseases in one group, especially in the “case” population over the “control” population. Interestingly, depression, dementia and chronic heart diseases in one group, especially in the “case” population over the “control” population. The future goal is to identify frequently occurring clusters of MLTCs in the “case” population compared to those in the other cluster.

Disclosure of Interests: Prasad Nishatla: None declared, Neil McGtugh: None declared, William Tillett Speakers bureau: Abbvie, Agen, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Pfizer and UCB, Consultant of: Abbvie, Agen, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Celgene, Eli-Lilly, Janssen, and UCB, Sarah Skeoch: None declared, Jenny Humphreys: None declared, John Pauling: None declared, Olga Isupova: None declared, Anita McGROGAN: None declared, Julia Snowball: None declared, Sandipan Roy: None declared DOI: 10.1136/annrheumdis-2022-eular.824
We identified a total of 149,691 cases of ILD over 15 years. Patients with RA had the highest prevalence of ILD amongst the 5 studied autoimmune diseases. The prevalence rate of RA in ILD patients in 2003 was 3.3% which significantly reduced to 0.93% in 2018 with a peak of 6.41% in 2010 (p < 0.0001). Prevalence rate of ILD with myositis decreased from 0.72% in 2003 to 0.46% in 2018 (p < 0.0001). The prevalence rates of SLE, Scleroderma, and MCTD in cases with ILD significantly increased from 1.38% to 1.63%, 1.38% to 1.76%, and 0.14% to 0.54% from 2003 to 2018 respectively. The average age of ILD cases with SLE was significantly younger compared to ILD without autoimmune disease (59.28 vs 72.32 years, p < 0.0001), RA (69.72 vs 72.17 years, p < 0.0008), Scleroderma (62.01 vs 72.28 years, p < 0.0001). Myositis (59.56 vs 72.19 years, p < 0.0001) and MCTD (59.6 vs 72.18 years, p < 0.0001). On examining the racial distribution, the African American population with ILD when compared to other races were more likely to have underlying SLE, MCTD, Myositis or Scleroderma. In ILD with RA, Native Americans were the most affected racial demographic followed by African Americans.

Average cost of hospitalization was higher in ILD with MCTD ($104,631 vs $71,264.6, p<0.0001), Myositis ($105,623 vs $71,232.9, p<0.0001) and Scleroderma ($88,736.2 vs $71,135.5, p<0.0001). Average LOS was significantly longer in RA (7.17 vs 6.66 days, p value 0.0006), MCTD (7.71 vs 6.67 days, p value 0.0008), Myositis (8.33 vs 6.66 days, p value <0.0001) and Scleroderma (7.07 vs 6.67 days, p value 0.0176). Though not significant, average LOS was longer in SLE (6.70 vs 6.67 days, p value 0.4999).

Conclusion: Our study shows that the prevalence of RA in ILD cases has significantly reduced through the years. This can be attributed to the better understanding of the disease and its risk factors as well as the availability and use of newer biologic agents to obtain better control. However, the prevalence of SLE, Scleroderma, and MCTD in ILD cases has increased over the years. This points to the need for better therapies as well as highlights the fact that over the years recognition and diagnosis of these diseases have increased over the years. Racial predilection also comes to light, suggesting the need for special attention to certain races to diagnose the autoimmune disease earlier. Average LOS and cost of hospitalization were also higher in ILD cases with autoimmune disease, reflecting the higher socioeconomic burden.

Disclosure of Interests: None declared DOI: 10.1136/annrheumdis-2022-eular.1172

RISK OF CANCER IN CONNECTIVE TISSUE DISORDERS IN THE NORTH EAST OF ITALY OVER 15 YEARS OF FOLLOW-UP

E. Treppe1, F. Tofofflit2, V. Manfre3, M. Taborelli4, S. De Vita5, D. Serraino5, L. Quattrocchio3. 1Division of Rheumatology, Department of Medicine, Udine, Italy; 2Centro di Riferimento Oncologico (CRO), Unit of Cancer Epidemiology, Aviano, Italy; 3Division of Rheumatology, Department of Medicine, Udine, Italy

Background: Connective tissue diseases (CTD) include systemic lupus erythematosus (SLE), Sjögren’s syndrome (SS), systemic sclerosis (SSc), polymyositis (PM), and dermatomyositis (DM). CTD are characterized by dysfunction of the immune system that leads to the loss of tolerance to self-antigens [1]. Shared risk factors represent a major need for better therapies as well as highlights the fact that over the years recognition and diagnosis of these diseases have increased over the years.

Methods: A retrospective population-based cohort study was conducted using data from healthcare databases of the Friuli Venezia Giulia region, north-east of Italy (1,206,000 inhabitants). Information on demographic characteristics, hospital discharges, exemption from medical charges, drug prescriptions, were individually matched with data from the population-based cancer registry. The cancer risk was assessed in people diagnosed with the following diseases: SLE, SS, SSc, PM, and DM. To compare the cancer incidence in the cohort with the general population, Standardized Incidence Ratios (SIRs) were calculated as the ratio between the observed and the expected number of cancer cases. The cohort included subjects resident in the Friuli Venezia Giulia region, diagnosed with at least one of the following diseases: SLE, SSc, SS, DM, and PM. To guarantee the highest homogeneity and comparability of the exemptions codes, the analysis was restricted to the years 2002-2017. Excluding criteria were: (1) follow-up shorter than 90 days; (2) concurrent diagnoses of rheumatoid arthritis (RA), psoriatic arthritis or ankylosing spondylitis; (3) ever use of biologic drug specific to treat RA (with the exception of rituximab), psoriatic arthritis or ankylosing spondylitis.

The patients were observed starting from 90 days after the first date when the diagnosis was mentioned in hospital discharges or exemptions, and they were followed until cancer diagnosis, death, change of regional residence, or December 31, 2017, whichever came first.

Results: We identified a total of 149,691 cases of ILD over 15 years. Patients with RA had the highest prevalence of ILD amongst the 5 studied autoimmune diseases. The prevalence rate of RA in ILD patients in 2003 was 3.3% which significantly reduced to 0.93% in 2018 with a peak of 6.41% in 2010 (p < 0.0001). Prevalence rate of ILD with myositis decreased from 0.72% in 2003 to 0.46% in 2018 (p < 0.0001). The prevalence rates of SLE, Scleroderma, and MCTD in cases with ILD significantly increased from 1.38% to 1.63%, 1.38% to 1.76%, and 0.14% to 0.54% from 2003 to 2018 respectively. The average age of ILD cases with SLE was significantly younger compared to ILD without autoimmune disease (59.28 vs 72.32 years, p < 0.0001), RA (69.72 vs 72.17 years, p < 0.0008), Scleroderma (62.01 vs 72.28 years, p < 0.0001). Myositis (59.56 vs 72.19 years, p < 0.0001) and MCTD (59.6 vs 72.18 years, p < 0.0001). On examining the racial distribution, the African American population with ILD when compared to other races were more likely to have underlying SLE, MCTD, Myositis or Scleroderma. In ILD with RA, Native Americans were the most affected racial demographic followed by African Americans.

Average cost of hospitalization was higher in ILD with MCTD ($104,631 vs $71,264.6, p<0.0001), Myositis ($105,623 vs $71,232.9, p<0.0001) and Scleroderma ($88,736.2 vs $71,135.5, p<0.0001). Average LOS was significantly longer in RA (7.17 vs 6.66 days, p value 0.0006), MCTD (7.71 vs 6.67 days, p value 0.0008), Myositis (8.33 vs 6.66 days, p value <0.0001) and Scleroderma (7.07 vs 6.67 days, p value 0.0176). Though not significant, average LOS was longer in SLE (6.70 vs 6.67 days, p value 0.4999).

Conclusion: Our study shows that the prevalence of RA in ILD cases has significantly reduced through the years. This can be attributed to the better understanding of the disease and its risk factors as well as the availability and use of newer biologic agents to obtain better control. However, the prevalence of SLE, Scleroderma, and MCTD in ILD cases has increased over the years. This points to the need for better therapies as well as highlights the fact that over the years recognition and diagnosis of these diseases have increased over the years. Racial predilection also comes to light, suggesting the need for special attention to certain races to diagnose the autoimmune disease earlier. Average LOS and cost of hospitalization were also higher in ILD cases with autoimmune disease, reflecting the higher socioeconomic burden.

Disclosure of Interests: None declared DOI: 10.1136/annrheumdis-2022-eular.1172
For the aim of this study, we excluded from the analysis NMHC (ICD-10: C44) and diagnoses based on autopsy only or Death Certificate Only.

Results: 2504 patients were followed-up for a total of 18,006 person-years (median follow-up: 6.8 years). After 5 and 10 years of follow-up, the cumulative cancer incidence was 2.6% and 8.5%, respectively. The most common cancers were breast (n=34), lung (n=24), colorectal-anus (n=20), and non-Hodgkin lymphomas (NHL) (n=20). Overall, no excess cancer risk was noted (SIR=0.87, 95% CI: 0.75-1.00), whereas the number of observed NHL cases was more than two-fold significantly higher than expected (SIR=2.52, 95% CI: 1.54-3.89). The subgroup analysis showed a higher risk of NHL among SS patients (SIR=3.84, 95% CI: 1.92-6.87) and SLE patients (SIR=2.69, 95% CI: 0.99-5.84). Conversely, the study population showed a decreased risk for cancers of breast (SIR=0.61, 95% CI: 0.42-0.85) and corpus uteri (SIR=0.21, 95% CI: 0.03-0.77).

Conclusion: The incidence of NHL was higher among patients with SS and SLE than in the general population. Surveillance for haematological malignancies in these patients is recommended. The lower risk of cancer for breast and corpus uteri in CTD indirectly supports cancer screening programs and highlights the role of the continuous clinical follow-up for these chronic conditions.

References:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1547

POS1415
A MACHINE LEARNING ANALYSIS OF FACTORS PREDICTING ORGAN DAMAGE PROGRESSION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS USING THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)


Methods: The Spanish Society of Rheumatology Lupus Registry (RELESSER) with patient records from 45 Rheumatology Units across Spain was used. RELESSER data were collected from 2011 to 2021 and captured demographic and comprehensive clinical information. In this analysis, a sample of 2,676 patients was used. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was used to measure organ damage progression between 2015 (start of the prospective data collection in RELESSER) and 2020. To predict the risk of an increase in the SDI, 102 variables were identified as potential predictors. A ML model (gradient boosting trees) was developed and validated by a simple logistic regression (LG) model. The area under the receiver operating characteristic curve (AUCROC) was used to quantify the improvement over random chance (an AUCROC of 0.5). Shapley Additive Explanation (SHAP) values were used in the ML model to identify predictors and their contribution to damage progression.

Results: Of all patients, 13% experienced organ damage progression, with 2-year patient follow-up. The ML algorithm was better at identifying these patients (AUCROC 0.68) than the LG model (AUCROC 0.63) (Figure 1). ML model performance can be contextualized using a random sample of 100 SLE patients of whom 13 suffered organ damage progression, the model would successfully identify 12. However, 66 additional patients would be incorrectly identified (True Positive 90%; False Positive 79%). The top 5 predictors of damage progression, across all patients, were patient age >49 years,
Background: Population-based studies on Systemic Lupus Erythematosus (SLE) patients with a verified diagnosis is considered the gold standard to find true outcomes in SLE, but few population-based SLE cohorts have follow-up over 15 years [1]. Norway is among the few countries worldwide where social and structural factors facilitate the gathering of complete population-based cohorts in rare disease like SLE due to its healthcare organization.

Objectives: To examine long-term outcome of SLE in a population-based setting and determine if immediate cause of death differs between SLE patients and the general population.

Methods: The study included all SLE patients who were resident in the South-east region of Norway during 1999 - 2017 and met the 1997 American College of Rheumatology classification criteria for SLE. All SLE diagnosis was confirmed by chart review. SLE patients and 15 controls for each case (matched by age, gender and ethnicity) were linked to the Norwegian Cause of Death Registry. We examined survival by means of Kaplan-Meyer estimates and used log rank test to test for differences. To estimate risk of death, we performed calculations of standard mortality rate (SMR) by dividing the number of deaths on the number of years observed. The excepted number of deaths were included in SMR. The 95 % confidence interval (CI) of SMR was calculated with Mid-P exact test. We defined immediate cause of death as the final event directly leading to death. An International Classification of Diseases 10th revision code of I00-99 or R96 classified as death from cardiovascular disease (CVD) (except pulmonary embolism and cerebral bleeding) and of infections A00-B99, J10-18, N39, M86 or U07.

Results: We identified 1298 SLE patients in the region, of whom 673 was incident cases; all captures within one year from diagnosis. Of the incident cases, 76 (11%) died during 8434 years of follow-up (Table 1). The five-, ten-, 15- and 20-year survival for incident SLE patients (controls) was respectively 98 (98), 94 (96), 87 (94) and 82 (88) % and differed significantly first after ten years of disease duration compared to controls. Figure 1 shows 20-year survival for incident SLE patients and matched controls; stratified by gender. SMR for all SLE cases was 2.3 (95 % CI 1.5 - 4.0); female SLE 2.5 (95 % CI 1.6 – 3.9) and male SLE 1.9 (95 % CI 1.3 – 2.2). The most common immediate cause of death in SLE patients was CVD; whereas myocardial infarction (21 %) was most frequent. SLE patients died more often of CVD than controls (29 % vs. 21 %, p = 0.01) and had a tendency to more infections (23 % vs. 18 %, p = 0.07), whereof pneumonia (58 %) was most frequent.

Table 1. Patient demographics, follow-up time and number of deaths in the total Systemic Lupus Erythematosus (SLE) cohort and in incident SLE patients.

<table>
<thead>
<tr>
<th>Total SLE cohort</th>
<th>Incident SLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>Male</td>
</tr>
<tr>
<td>n = 1298</td>
<td>n = 577</td>
</tr>
<tr>
<td>Of European descent, n (%)</td>
<td>1140 (88)</td>
</tr>
<tr>
<td>Juvenile onset*, n (%)</td>
<td>93 (7)</td>
</tr>
<tr>
<td>LN*, n (%)</td>
<td>470 (36)</td>
</tr>
<tr>
<td>Cumulative ACR criteria*, μ (SD)</td>
<td>5.4 (12)</td>
</tr>
<tr>
<td>Follow-up years, total</td>
<td>19252</td>
</tr>
<tr>
<td>Deaths, n (%)</td>
<td>282 (23)</td>
</tr>
<tr>
<td>Age at diagnosis, years μ (SD)</td>
<td>35.5 (15.7)</td>
</tr>
<tr>
<td>Disease duration at death, years μ (SD)</td>
<td>20.4 (12.5)</td>
</tr>
</tbody>
</table>

*mean; n: number; SD: standard deviation. Diagnosed before age of 16 °Lupus Nephritis defined by 1999 American College of Rheumatology classification criteria for Systemic Lupus Erythematosus. **1997 American College of Rheumatology classification criteria for Systemic Lupus Erythematosus

Conclusion: Mortality in SLE is substantially increased. Differences in survival compared to the general population only appear after ten years of disease duration. CVD was the most common immediate cause of death and more frequent in SLE patients.

REFERENCES:

Disclosure of Interests: None declared


POS1417 INTEROSSEOUS TENDON INFLAMMATION IN THE HANDS: A NOVEL FEATURE OF DEVELOPING RHEUMATOID ARTHRITIS? RESULTS FROM A LARGE MRI STUDY IN CLINICALLY SUSPECT ARTHRALGIA

B. Van Dijk1, H. W. Van Steenbergen1, M. Reijnierse2, S. Khidri1, L. J. Wisse3, M. C. Deruiter3, A. Van der Helm-van Mil3, 4Leiden University Medical Centre (LUMC), Rheumatology, Leiden, Netherlands; 5Leiden University Medical Centre (LUMC), Radiology, Leiden, Netherlands; 6Leiden University Medical Centre (LUMC), Anatomy & Embryology, Leiden, Netherlands

Background: Inflammation around the tendons of the hand intersosseus muscles (intersosseous tendon inflammation; ITI) on MRI was recently reported in rheumatoid arthritis (RA) patients and in ACPA-positive individuals with musculoskeletal symptoms. We therefore hypothesized that ITI is an early RA-feature that precedes clinical arthritis.

Objectives: To examine this we assessed the frequency of ITI in clinically suspected arthralgia (CSA) patients and compared this to the frequency in the general population. Additionally we investigated the relation between ITI and other locally inflamed tissues (synovitis/tenosynovitis/ostitis) in MCP-joins of CSA patients as well as the association with future arthritis development.

Methods: 867 consecutive patients presenting with CSA and 193 symptom-free controls from the general population underwent contrast-enhanced hand-MRI. MRIs were evaluated for ITI and for synovitis/tenosynovitis/ostitis, using the rheumatoid arthritis MRI scoring system (RAMRIS). CSA patients were followed for clinical arthritis development (median follow-up 25 months). Logistic and Cox-regression were used. ACPA-stratification was performed. To gain a better understanding of the anatomical relationships, 3D MRI-reconstruction of the intersosseous and lumbral muscles and tendons was performed in a patient with ITI.

Results: At presentation, 10% of CSA patients had ITI, compared to 1% of symptom-free controls (p<0.001). ITI was more frequent in ACPA-positive than ACPA-negative CSA (27% versus 7%; p<0.001). 72% of patients with ITI also had synovitis and/or tenosynovitis at the MCPs (37% synovitis; 7% tenosynovitis; 27% both synovitis and tenosynovitis). Also in multivariable analyses, adjusted for simultaneous presence of synovitis/tenosynovitis/ostitis, ITI was more likely if synovitis (OR 2.2, 95%CI 1.2-4.2) or tenosynovitis (9.7, 5.5-17.0) was present at MCPs. The 3D MRI-reconstruction indicated that ITI is continuous with MCP flexor tenosynovitis (Figure 1). CSA patients with ITI developed arthritis.
more frequent than those without (HR 4.5 (2.8-7.2)); this relation was stronger in
ACPA-negative (3.9 (1.9-7.9)) than ACPA-positive CSA (1.8 (0.9-3.4)).

**Figure** Example MR-image (A) and 3D MRE-reconstruction (B) at the level of the
MCP-joints in a CSA-patient with ITI continuous with flexor tenosynovitis at the 2nd MCP-joint

**Conclusion:** ITI is present in CSA and precedes clinical arthritis, suggesting that
this periarticular inflammation is an early RA-feature.

**Acknowledgements:** We thank G. Kracht for his assistance with preparing the
example MR-image.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1595

---

**POST1418**

SEPARATING THE EFFECTS OF CHILDHOOD AND ADULT BODY SIZE ON INFLAMMATORY ARTHRITIS: A MENDELIAN RANDOMISATION STUDY

S. S. Zhao1, J. Bowes2, A. Barton2, G. Davey Smith3, T. G. Richardson3.

1The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2The University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Manchester, United Kingdom; 3University of Bristol, Population Health Sciences, Bristol, United Kingdom

**Background:** Obesity is strongly associated with inflammation and inflamma-
tory arthritis, but most studies to date have only examined adulthood body mass
index (BMI). Whether childhood obesity has a direct and long-term influence on
risk of inflammatory arthritis is unclear. This question is important as childhood
obesity becomes a growing and global public health crisis [1], but traditional
epidemiologic approaches may be limited by reverse causation (obesity can be
a larger body size during childhood may not be fully reversible even when a
healthy size is achieved in adulthood. How the immune system is altered by early
life adiposity to increase risk of PsA and SLE is unclear. Differential effect esti-
mates of body size on each inflammatory arthritis (PsA vs AS, RA vs SLE) may
help shed light on their unique pathophysiology in future studies.

**Objectives:** To examine whether childhood body size affects risk of inflammatory arthritides – rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), gout and systemic lupus erythematosus (SLE) – after accounting for the
effect of adult body size using two-sample univariable and multivariable MR.

**Methods:** Genetic instruments for childhood (age 10 years) and adult body
size were derived using data from 453,169 individuals from the UK biobank
study (313 and 580 variants respectively; $r^2<0.001, p<5\times10^{-6}$), which have
been previously validated using BMI data from three independent populations
[2]. Participants recalled their body size at age 10 as “thinner,” “about average”
or “plumper”. Adult body size was determined using BMI at a mean age of 57
years and, to facilitate comparison, split into three groups to match the pro-
portions for childhood body size. Genome-wide association data comprised
of 22,350 RA, 9,069 AS, 3,609 PsA, 13,179 gout and 5,201 SLE cases. We
conducted univariable MR to estimate the total effects of childhood and adult
body size on outcomes and multivariable MR to examine the independent
effect of childhood body size after accounting for adult body size. F statistics
were calculated for each exposure with a value >10 considered suggestive of
adequate instrument strength.

**Results:** The F statistic for childhood and adult body size instruments were 30
and 23 respectively. Genetically predicted childhood body size had a total effect
on risk of PsA (OR 2.18 per change in body size category; 95%CI 1.43, 3.31),
gout (OR 2.18; 1.43, 3.31) and SLE (OR 2.44; 1.14, 5.22), but not RA (OR 0.95;
0.70, 1.29) or AS (OR 0.98; 0.61, 1.52). After accounting for adult body size, the
direct effect of childhood body size was little changed for PsA (OR 1.92; 1.14,
3.25) and SLE (OR 2.69; 1.24, 5.87), but was attenuated for gout (OR 1.40;
0.94, 2.09).

**Conclusion:** Results of this study suggest that the risk conferred from having
a larger body size during childhood may not be fully reversible even when a
healthy size is achieved in adulthood. How the immune system is altered by early
life adiposity to increase risk of PsA and SLE is unclear. Differential effect esti-
mates of body size on each inflammatory arthritis (PsA vs AS, RA vs SLE) may
help shed light on their unique pathophysiology in future studies.

**REFERENCES:**

[2] Richardson et al. Use of genetic variation to separate the effects of early
and later life adiposity on disease risk: mendelian randomisation study.
BMJ 2020;369:m1203.

**Disclosure of Interests:** We thank the participants of the UK Biobank study and
the genome-wide association study consortia who made their summary statistics
publicly available for this study.

**DOI:** 10.1136/annrheumdis-2022-eular.1803

---

**POST1419**

CANCER INCIDENCE IN PATIENTS WITH AUTOIMMUNE DISEASES TREATED WITH CYCLOPHOSPHAMIDE

Á. Andreu-Suárez1, M. Serrano Warleta1, C. De la Puente Bujidos1, 1University Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

**Background:** Cyclophosphamide (CYC) is one of the first-line drugs for serious manifestations of autoimmune diseases [1]. It has been associated with the appearance of a secondary cancer [2]. Several studies showing a higher incidence of cancer in small-vessel vasculitis in relation to CYC treatment have been carried out [3], but there is not much evidence about this complication in other autoimmune diseases.

**Objectives:** -Estimating the incidence of cancer in patients treated with CYC for serious manifestations of autoimmune diseases.
-Comparing the incidence of cancer in autoimmune diseases treated with immu-
nosuppressants (IS) against the incidence of cancer in the general population.

**Methods:** This is a single-center retrospective cohort study. We included patients over 18 years old assessed in outpatient clinics of the Rheumatology service at the Ramón y Cajal Hospital from 1990 to 2018. They had been diagnosed with: diffuse or limited cutaneous systemic sclerosis (dcSSc/LCSSc), systemic lupus erythematosus (SLE), vasculitis or others. We divided the patients into two groups; those exposed to CYC throughout the follow-up and those not exposed to it (being treated with other IS). Patients who had an active cancer at the time of starting the immunosuppressive therapy were excluded.

A descriptive analysis was carried out. The incidence of cancer was compared to the incidence of cancer in the general population according to the 2020 Spanish
Network of Cancer Registries data. A multivariate analysis was subsequently performed.

**Results:** Regarding the baseline characteristics of the patients included, there were no significant statistical differences in the sex, median age, and personal history of cancer. There was a bigger percentage of smokers in the non-exposed group. The incidence of cancer was similarly by both groups (7.5% vs. 4.1%; p = 0.211). The cumulative incidence of cancer in our sample was 555.5/1000 patients (95% CI 32.1-94.6). The standardized incidence ratio was 2.19 (95% CI 3.30-11.92) and it was stratified by sex and age. The bivariate analysis is shown in Table 1.

Table 1. Comparison between patients with or without appearance of cancer during the follow-up.

<table>
<thead>
<tr>
<th>Cancer (n = 12)</th>
<th>No cancer (n = 204)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>7 (58.33%)</td>
<td>31 (15.19%)</td>
</tr>
<tr>
<td>Age at the time of the study</td>
<td>69.92 (±7.54)</td>
<td>53.88 (±16.75)</td>
</tr>
<tr>
<td>Smoking habit</td>
<td>6 (50%)</td>
<td>45 (22.06%)</td>
</tr>
<tr>
<td>Personal history of cancer</td>
<td>5 (41.66%)</td>
<td>5 (2.45%)</td>
</tr>
<tr>
<td>Treatment with classical IS</td>
<td>1 (8.33%)</td>
<td>49 (24.02%)</td>
</tr>
<tr>
<td>Treatment with bDMARDs</td>
<td>1 (8.33%)</td>
<td>21 (10.29%)</td>
</tr>
<tr>
<td>Treatment with corticosteroids</td>
<td>2 (16.66%)</td>
<td>38 (18.63%)</td>
</tr>
</tbody>
</table>

Method of administration of CYC

| Intravenous     | 7 (58.33%)          | 78 (38.24%) | 1 |
| Oral            | 0 (0%)              | 6 (2.94%)   | 1 |
| Both            | 0 (0%)              | 2 (0.98%)   | 1 |
| Total administered dose of CYC (grams) | 728.2 (±33.6) | 65.9 (±33.6) | 0.626 |

Regarding the multivariate analysis, the variables that demonstrated a statistically significant association with the appearance of cancer were age at the time of the study (OR 1.18 [1.02-1.36]; p = 0.024) and personal history of neoplasia (OR 7.86 [1.30-47.47]; p = 0.010).

**Conclusion:** The incidence of cancer in patients with autoimmune diseases treated with CYC is not higher with respect to patients with similar diseases treated with other IS. The increased incidence of cancer is associated with the personal history of cancer and older age. Studies with a larger sample size and prospective studies are necessary to verify these results and determine more clearly the associated risk factors.

**REFERENCES:**


Disclosure of Interests: África Andreu-Suárez: None declared, Marta Serrano Warleta: None declared, Carlos De la Puente Bujidos Speakers bureau: Nordic, Janssen, Boehringer Ingelheim, Pfizer, Consultant of: Gebro, Nordic, Janssen, Boehringer Ingelheim.


**POS1420**

**DOUBLY ROBUST ESTIMATOR FOR AVERAGE TREATMENT EFFECT AS SENSITIVITY ANALYSIS FOR COMPARATIVE EFFECTIVENESS RESEARCH: AN EXAMPLE COMPARING DRUG MAINTENANCE BETWEEN BARICITINIB AND ALTERNATIVE BILOGIC DMARDS.**

R. Aymon1, B. Gilbert1, D. Mongin1, E. Nham1, C. Laedermann2, R. Müller2, K. Lauper1, D. Courvoisier1, A. Finch1.

1Geneva University Hospitals, Division of Rheumatology, Genève, Switzerland; 2Eli Lilly (Suisse) SA, Medical Department, Vernier, Switzerland; 3Rheumazentrum Ostschweiz, Rheumazentrum Ostschweiz, St. Gallen, Switzerland; 4University of Manchester, Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, Manchester; United Kingdom

**Background:** Drug maintenance is a common outcome measure of real world effectiveness studies, because it combines a measure of drug effectiveness and its tolerance/safety. Major hurdles of observational studies are potential selection biases and confounding. Cox proportional hazard ratio models address this issue by adjusting for potential confounders, but misspecification of the model may lead to biased estimates. Augmented Inverse Probability Treatment Weighting (AIPTW) has the attractive property of being doubly robust, meaning that only one of the two underlying models has to be correctly specified to obtain consistent estimates. It can be used as a sensitivity analysis for Cox models, when analyzing time-to-event data.

**Objectives:** To evaluate AIPTW estimator and test the robustness of the results obtained by a Cox model.

**Methods:** Previous analyses in the Swiss rheumatoid arthritis (RA) registry (SCORM) had demonstrated that time to all-cause-discontinuation was significantly longer in RA patients on bDMARDs (BARI, N = 273) compared to TNF-inhibitors (TNFi, N = 473); but not compared to other mode of actions biologics (OMA, N = 378) [1], in an adjusted Cox regression including age, gender, BMI, concomitant csDMARD, prednisone, CDAI score, disease duration, smoking status, line of therapy and seropositivity. Here we repeat the same analysis using AIPTW, including the same potential confounders. We combine a propensity score using a logistic regression model and an inverse probability weighted Cox regression. Two implementations of the AIPTW estimator are considered. First we use the RiskRegression package in R, to obtain risk ratios. Then we implement the AIPTW manually to obtain the average treatment effect as the difference in median survival time.

**Results:** Time to treatment discontinuation measured with Cox model was significantly longer for RA patients on BARI compared to patients on TNFi according to the adjusted Cox model (HR = 1.79), and a similar non-significant trend existed when compared to OMA (HR = 1.29). When considering 90-day treatment discontinuation measured with the AIPTW, the results were qualitatively very similar; the risk ratio between BARI and TNFi groups is statistically significant (RR = 2.51), while that of BARI against OMA is larger than one (RR = 1.47), but not statistically significant. Confidence intervals are larger with the AIPTW estimation.

Table 1. Cox Regression HR and AIPWT risk ratios

<table>
<thead>
<tr>
<th>Treatment</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BARI vs. TNFi</td>
<td>1.79* (1.34-2.38)</td>
</tr>
<tr>
<td>BARI vs. OMA</td>
<td>1.29 (1.06-1.73)</td>
</tr>
</tbody>
</table>

**Legend:** BARI: baricitinib; TNFi: TNF-inhibitors; OMA: Other Mode of Actions biologics; AIPWT: Augmented Inverse Probability Treatment Weighting. 95% CI: 95% Confidence Interval. *: statistically significant result at the p<0.05 level.

**Disclosure of Interests:** Romain Aymon: None declared, Benoit GILBERT: None declared, Denis Mongin: None declared, Eric Nham: None declared, Cedric Laedermann Employee of: Eli Lilly, Rüdiger Müller Consultant of: Streuli Pharma, Gebro Pharma, AbbVie, Kim Lauper Speakers bureau: Pfizer, Viatris and Celtrion, Consultant of: Pfizer, Delphine Courvoisier: None declared, Axel Finch: None declared.


**Figure 1. Absolute risk of treatment discontinuation over time between patients on baricitinib and patients on TNF inhibitors, estimated with AIPTW.**

**Conclusion:** Time to treatment discontinuation measured with Cox model was significantly longer for RA patients on BARI compared to patients on TNFi according to the adjusted Cox model (HR = 1.79), and a similar non-significant trend existed when compared to OMA (HR = 1.29). When considering 90-day treatment discontinuation measured with the AIPTW, the results were qualitatively very similar: the risk ratio between BARI and TNFi groups is statistically significant (RR = 2.51), while that of BARI against OMA is larger than one (RR = 1.47), but not statistically significant. Confidence intervals are larger with the AIPTW estimation.

**Disclosure of Interests:** This analysis has been made possible by financial support of Eli Lilly (Suisse) SA to the Geneva University Hospitals (HUG).

**REFERENCES:**


Disclosure of Interests: Romain Aymon: None declared, Benoît GILBERT: None declared, Denis Mongin: None declared, Eric Nham: None declared, Cedric Laedermann Employee of: Eli Lilly, Rüdiger Müller Consultant of: Streuli Pharma, Gebro Pharma, AbbVie, Kim Lauper Speakers bureau: Pfizer, Viatris and Celtrion, Consultant of: Pfizer, Delphine Courvoisier: None declared, Axel Finch: None declared.

Disclosure of Interests: [2] R. Coleman, J.J. Body, M. Aapro, et al., Bone health in cancer patients: ESMO guidelines recommending different T score-based risk model, further studies are needed with prior literature. Since our study period overlaps with publication of newer WHO defined osteoporosis (T ≤-2.5) is ineffective in fracture prevention in keeping with a model such as FRAX based intervention thresholds in mainly those with effective in reducing the pace of decline in BMD. However, standard risk stratification is not directed at the pace of decline in BMD over seven years. It confirms that bone sparing therapy is effective in reducing the pace of decline in BMD with the decline being -5%. (LNOF mean BMD of 0.939 g/cm2 at baseline compared to LNOF mean BMD of 0.788 g/cm2 at repeat DEXA, p=0.82).

Women who were not offered any treatment (n=667, 66%), showed a significant decline in bone density with the decline being -5%. (LNOF mean BMD of 0.939 g/cm2 at baseline compared to LNOF mean BMD of 0.888 g/cm2 at repeat DEXA, p<0.0001).

The rate of fractures remained the same between the treatment (19 fractures, 5.67%) and non-treatment group (38 fractures, 5.70%).

Conclusion: Our study provides long term data for AIBL and confirms a significant decline in BMD over seven years. It confirms that bone sparing therapy is effective in reducing the pace of decline in BMD. However, standard risk stratification model such as FRAX based intervention thresholds in mainly those with WHO defined osteoporosis (T ≤-2.5) is ineffective in fracture prevention in keeping with prior literature. Since our study period overlaps with publication of newer guidelines recommending different T score-based risk model, further studies are required to confirm their utility.

REFERENCES:

Disclosure of Interests: None declared

Methods: We retrospectively evaluated consecutive patients admitted to our department from January 2006 to October 2021 whose C7-HRP antigen were measured. We collected their age, sex, primary problem and its lesion, and test results within 3 months before C7-HRP measurement. We also investigated the use of immunosuppressants, and maximum and cumulative dose of administered prednisolone within 6 months before C7-HRP measurement. Maximum and cumulative dose of prednisolone contained methylprednisolone pulse, which was converted into prednisolone equivalent. We investigated the characteristics of CMV-positive and negative patients, and those of CMV-positive patients with or without anti-CMV drug treatment.

Results: Of a total of 472 patients, 85 were positive and 387 were negative for C7-HRP. The average age was 71.2 vs. 64.4 (p=0.0021). Their male-to-female ratio was 20/65 vs. 120/267 (p=0.0290). The following diseases were significantly common among CMV-positive patients: microscopic polyangiitis (21.2% vs. 3.9%, p<0.0001), adult-onset Still's disease (7.1% vs. 1.3%, p=0.0002), and systemic sclerosis (4.7% vs. 2.1%, p=0.0273). Significantly common comorbidities of CMV-positive patients were interstitial lung disease (35.3% vs. 16.0%, p=0.0001), nephritis (23.5% vs. 11.6%, p=0.005), peripheral nervous system disorders (11.8% vs. 5.7%, p=0.0070), alveolar hemorrhage (5.9% vs. 0.8%, p=0.0001), and peripheral circulatory disorders (4.7% vs. 1.6%, p=0.0111).

Conclusion: Intense immunosuppression, especially with higher dose of glucocorticoids, were the major reason to be considered for CMV reactivation. These medications may often require anti-CMV therapy.

Disclosur e of Interests: None declared.


Table

<table>
<thead>
<tr>
<th>Table</th>
</tr>
</thead>
</table>

Conclusion: Old age and AOSD were associated with AEs of SMX/TMP prophylaxis in patients with systemic rheumatic diseases.

Disclosur e of Interests: None declared.


POS1425


A. Singh1, S. K. Das2, A. Chopra3, D. Danda4, B. J. Paul5, L. March6,7, A. J. Mathew8,9, P. Shenoy9, C. Gotay10, A. J. Palmer1, B. Antony1.

1University of Tasmania, Hobart, Tasmania, Australia, Menzies Institute for Medical Research, Hobart, Australia; 2Era’s University. Lucknow, India, Department of Rheumatology, Lucknow, India; 3Apollo Jehangir Hospital, Pune, University, Pune, India, Centre for Rheumatic Diseases, Pune, India; 4Christian Medical College, Vellore, India, Department of Clinical Immunology and Rheumatology, Vellore, India; 5KMCT Medical College, Calicut, Kerala, India, Department of General Medicine, Calicut, India; 6University of Sydney, Sydney, Australia, Institute of Bone and Joint Research, Kolling Institute of Medical Research, Sydney, Australia; 7University of Sydney Royal North Shore Hospital, St Leonards, Sydney, Australia, Flornance and Cope Professorial Rheumatology Department, Sydney, Australia; 8Center for Rheumatology and Spine Diseases, Copenhagen University Hospital - Rigshospitalet Glostrup, Denmark, The Copenhagen Center for Arthritis Research (COPECARE), Glostrup, Denmark; 9Centre for Arthritis & Rheumatism Excellence, Kochi, Kerala, India, Department of Rheumatology, Kochi, India; 10The University of British Columbia, Vancouver, BC Canada, School of Population and Public Health (SPPH), Vancouver, Canada.

Background: Few studies have reported the burden of osteoarthritis (OA) in different parts of India. However, no study has reported the detailed estimates of incidence, prevalence, and years lived with disability (YLDs) and its trends for OA (and its various sites) across the states of India over a long period of time.
Objectives: We aim to describe the state-wise prevalence, incidence, and YLDs for osteoarthritis (OA) in India from 1990 to 2019 according to age and sex.

Methods: Data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 were used. The burden of OA—incorporating knee OA, hip OA, hand OA, and other OA—was estimated for India and its states from 1990 to 2019 through a systematic analysis of prevalence, incidence, and YLDs modelled data using the methods reported in the GBD 2019 Study. All estimates are presented as counts and age-standardised rates per 100,000 population, with uncertainty intervals (UIs).

Results: Around 23.46 million individuals in India had OA in 1990; this increased to 62.35 million in 2019. The age-standardised prevalence of OA increased from 4,485 (95% uncertainty interval (UI): 4,240–5,747) in 1990 to 5,313 (95% UI: 4,799–5,889) in 2019, per 100,000. OA was the 20th most common cause of YLDs in India in 2019, accounting for 14% (95% UI: 7.2–21%) of all YLDs; increasing from 0.8% (95% UI: 0.7–1.0) in 1990 to 1.5% (95% CI 1.3, 1.7) in 2019.

Conclusion: The burden and impact of OA in India are substantial and is increasing; however, it varied among states. Females were affected more commonly than males. Knee OA was the most prevalent site. With improvement in life expectancy and population ageing, greater increases are expected. Adopting suitable control and preventive community measures to reduce modifiable risk factors (such as obesity, injuries, occupational stress) are needed now to reduce the current and future burden of OA in India.


POS1426 INCIDENCE, CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH POLYMALGIA RHEUMATICA IN SLOVENIA

S. Markez1, A. Hocevar2, M. Tomscic3, J. Kramari1, Z. Rotar1,2
1University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia; 2University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia

Background: Polymyalgia rheumatica (PMR) is common in patients over the age of 50 years. Clinical symptoms promptly respond to glucocorticoid therapy, but there are wide variations of dosage tapering, treatment duration and rate of relapses. In Slovenia epidemiology of PMR is unknown.

Objectives: We aimed to determine the incidence rate of PMR, the clinical characteristics, the relapse frequency and length of glucocorticoid therapy.

Methods: A detailed single centre retrospective review of medical records of all patients diagnosed with PMR between 1 January 2014 and 31 December 2016 was performed at the Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia—the only secondary level rheumatology institution in serving the Central Slovenian and Gorjenska regions, which represent ~40% (7x105) of the Slovenian adult population. The outcomes were assessed up to October 2021.

Results: During the 3-year period 494 patients (460 from Ljubljana and Gorenjska regions) were diagnosed with PMR (64% females, median (IQR) age 75 (69, 80) years), resulting in an annual sex- and age-standardised incidence rate (IR) per 105 adults ≥ 50 years of 46.0 (95% CI 42.0, 50.4), with a female/male ratio of 1.5 (95% CI 1.3, 1.7). The IR peaked between 70–85 years (Figure 1). There was no seasonal variation in IR. The median (IQR) times from symptom onset, and from referral to rheumatology consultation were 6 (4, 11) weeks, and 1 (1, 1) day, respectively. 86% were referred by their GPs, 7% by other internists, and 6% by infectious disease specialists, and the rest by other specialists.

At presentation, 96% had morning stiffness (71% lasting >45 minutes), 99% shoulder pain, 94% pelvic girdle pain, 49% weight loss, 13% peripheral arthritis, and 12% body temperature >37°C. Data on US of shoulders and hips was complete, partial, or missing for 38%, 24%, 39%, respectively. Elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) was present in 98% of patients. The median (IQR) ESR was 55 (42, 71) and CRP 49 (26, 79) ml/l, and 58% had anaemia. RF and ACRA were positive in 4% and 3%, respectively. 8/12 had ACRA values less than 2× the reference value. During follow-up ACRA was repeated in 8/12 patients and negativized in 6/8 patients. Among other pre-existing conditions, 51% (10%) had history of malignancy diagnosed a median 7 (3–11) years prior to diagnosis of PMR. EULAR/ACR classification criteria for PMR were fulfilled in 66% and 71% based on clinical and extended ultrasound criteria (missing items were imputed with 0), respectively. 14% (3%) patients had clinically overt concurrent giant cell arteritis (GCA). All patients were treated with methylprednisolone, administered orally in 92.4%, 93% started at 16mg qd. By the end of follow-up, 295 (60%) patients successfully discontinued methylprednisolone after a median of 117 (104, 143) weeks. Steroid sparing lefunomide and methotrexate were used by 66 (13%) and 27 (6%) patients, respectively. During a median follow-up of 150 (98, 244) weeks, 146 (30%) had at least one relapse. Median time to first relapse was 111 (50, 141) weeks. 54% relapsed after glucocorticoid discontinuation after a median time of 4 (2, 18) weeks, 9% presented with GCA, 12% relapsed due to treatment non-adherence. During the follow-up 6% were diagnosed with malignancies.


POS1427 CLINICAL COURSE IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES (IPAF): REAL-LIFE DATA FROM A MULTICENTER ILD REGISTRY

C. Vadillo1, M. A. Nieto2, O. Sanchez Pernaute3, F. Romero2, M. J. Rodriguez4, D. Freites Nuñez3, G. Bonilla5, T. I. Cobo6, L. Cebrián Méndez7, H. Godoy5, M. T. Rio5, L. Abasolo5, 9, 10, 11 Hospital Clínico San Carlos, Rheumatology, Madrid, Spain; 1Hospital Clínico San Carlos, Pneumology, Madrid, Spain; 2Hospital Fundación Jimenez Diaz, Rheumatology, Madrid, Spain; 3Hospital Puerta De Hierro, Rheumatology, Madrid, Spain; 4Hospital Infanta Sofia, Rheumatology, Madrid, Spain; 5Hospital Infanta Leonor, Rheumatology, Madrid, Spain; 1Hospital Fundación Jimenez Diaz, Pneumology, Madrid, Spain; 1Hospital La Paz, Rheumatology, Madrid, Spain; 9Hospital Infanta Sofia, Rheumatology, Madrid, Spain; 10Hospital Infanta Leonor, Rheumatology, Madrid, Spain; 5Hospital Puerta De Hierro, Rheumatology, Madrid, Spain; 6Hospital de Getafe, Rheumatology, Madrid, Spain; 7Instituto de Investigacion Sanitaria San Carlos (IdISSC) Hospital Clinico San Carlos, Madrid, Spain; 8Rheumatology, Madrid, Spain

Background: Several patients with Interstitial Lung Disease show autoimmune characteristics but do not meet the classification criteria for a connective tissue disease. In order to define this condition, the classification of patients with interstitial pneumonia with autoimmune features (IPAF) has been adopted (Fischer’s criteria).

Objectives: To describe the sociodemographic, clinical, functional characteristics and therapeutic management of IPAF in clinical practice and to evaluate the incidence rate of functional respiratory impairment.

Methods: A longitudinal observational study was performed (NEREA registry). Patients diagnosed with IPAF according to Fischer’s criteria were included from ILD diagnosis (Feb 2007 to Dec 2019) and followed until loss of follow-up or Jan 1 2021. The study was carried out by a multidisciplinary team ( pneumologi sts and rheumatologists) in seven Hospitals of Madrid. The relative functional respiratory impairment, defined as a ≥ 5% decline in percent predicted forced vital capacity (FVC%) compared to the previous visit was set as main outcome. Respiratory function was measured at baseline and every 6-12 months. Covariates included: a) sociodemographic, b) clinical, c) radiological pattern (non-specific interstitial pneumonia [NSIP]; usual interstitial pneumonia [UIP]; others); d) FVC% DLOC%; e) laboratory tests; f) therapy used. Survival techniques were used to estimate the incidence rate (IR) of relative functional respiratory impairment, expressed per 100 patient-month with their respective confidence interval [95 % CI].

Results: 79 IPAF were included, with a follow up of 462.8 patients-month and a maximum follow-up of 12.3 years. 79% were women with a mean age of 65±11 years. Along with obesity (40%), the most frequent comorbidities at baseline were hypertension, hypercholesterolemia, followed by ischemic heart disease. Baseline FVC% and DLOC% were 86.5±22.7 and 64.2±19.3, respectively. Distribution of IPAF classification criteria was: a) clinical domain: arthritis (46.2%), Raynaud’s phenomenon (35.6%) and mechanic hands (9.3%); b) serological domain: 80.8% positive ANA at >1/320 titer; 29% RF (> 40 IU/ml); 25% positive anti-Ro; c) morphological domain: 46.8% of NSIP and 36.7% of UIP. During the study period, 77.2% of patients (n=61) received treatment: glucocorticosteroids (n=52), mycophenolate (n=25), azathioprine (n=21), rituximab (n=15) and antibiotics (n=11). During the follow-up, 50 patients presented 111 relative functional respiratory impairment events over time. The estimated IR was 23.9 [19.9-28.1] per 100 patient-semester; and 50% of the patients developed functional respiratory impairment at 16 months from diagnosis. IR was similar between patient gender, baseline overall comorbidity, baseline pulmonary functional tests, and age strata, with slight difference in patients >80 years of age. Patients with baseline associated emphysema (IR: 17.8 [10-31]) or without baseline associated fibrosis (IR: 21.1 [15-28]) had lower IR compared to the opposite. As expected, IR was higher in UIP (32.9 [24-42]) compared to NSIP or any other pattern. With respect to serologic markers, patients with ANA titers ≥1/320 had a higher IR (26.7 [21-33]) in comparison with those lower or non-titers of ANA (IR: 15.7 [9.9-25.1]).

Conclusion: In a multicenter registry of Madrid, we have performed a descriptive longitudinal study. IPAF were mostly women in their sixties. The most frequent clinical criteria were arthritis and Raynaud’s phenomenon. An NSIP radiological pattern predominated. At onset, patients have a slightly diminished lung function. The incidence rate of functional deterioration was estimated 23.9% patient-se mester and 50% of the patients developed pulmonary functional deterioration at 16 months from ILD diagnosis. This Incidence rate was higher in patients with an UIP pattern, baseline fibrosis or ANA at medium-high titers.

Disclosure of Interests: None declared.


1057

Disclosure of Interests: None declared.

A longitudinal observational study was performed (NEREA registry). Patients diagnosed with IPAF according to Fischer’s criteria were included from ILD diagnosis (Feb 2007 to Dec 2019) and followed until loss of follow-up or Jan 1 2021. The study was carried out by a multidisciplinary team (pneumologists and rheumatologists) in seven Hospitals of Madrid. The relative functional respiratory impairment, defined as a ≥ 5% decline in percent predicted forced vital capacity (FVC%) compared to the previous visit was set as main outcome. Respiratory function was measured at baseline and every 6-12 months. Covariates included: a) sociodemographic, b) clinical, c) radiological pattern (non-specific interstitial pneumonia [NSIP]; usual interstitial pneumonia [UIP]; others); d) FVC% DLOC%; e) laboratory tests; f) therapy used. Survival techniques were used to estimate the incidence rate (IR) of relative functional respiratory impairment, expressed per 100 patient-month with their respective confidence interval [95 % CI].

Results: 79 IPAF were included, with a follow up of 462.8 patients-month and a maximum follow-up of 12.3 years. 79% were women with a mean age of 65±11 years. Along with obesity (40%), the most frequent comorbidities at baseline were hypertension, hypercholesterolemia, followed by ischemic heart disease. Baseline FVC% and DLOC% were 86.5±22.7 and 64.2±19.3, respectively. Distribution of IPAF classification criteria was: a) clinical domain: arthritis (46.2%), Raynaud’s phenomenon (35.6%) and mechanic hands (9.3%); b) serological domain: 80.8% positive ANA at >1/320 titer; 29% RF (> 40 IU/ml); 25% positive anti-Ro; c) morphological domain: 46.8% of NSIP and 36.7% of UIP. During the study period, 77.2% of patients (n=61) received treatment: glucocorticosteroids (n=52), mycophenolate (n=25), azathioprine (n=21), rituximab (n=15) and antibiotics (n=11). During the follow-up, 50 patients presented 111 relative functional respiratory impairment events over time. The estimated IR was 23.9 [19.9-28.1] per 100 patient-semester; and 50% of the patients developed functional respiratory impairment at 16 months from diagnosis. IR was similar between patient gender, baseline overall comorbidity, baseline pulmonary functional tests, and age strata, with slight difference in patients >80 years of age. Patients with baseline associated emphysema (IR: 17.8 [10-31]) or without baseline associated fibrosis (IR: 21.1 [15-28]) had lower IR compared to the opposite. As expected, IR was higher in UIP (32.9 [24-42]) compared to NSIP or any other pattern. With respect to serologic markers, patients with ANA titers ≥1/320 had a higher IR (26.7 [21-33]) in comparison with those lower or non-titers of ANA (IR: 15.7 [9.9-25.1]).

Conclusion: In a multicenter registry of Madrid, we have performed a descriptive longitudinal study. IPAF were mostly women in their sixties. The most frequent clinical criteria were arthritis and Raynaud’s phenomenon. An NSIP radiological pattern predominated. At onset, patients have a slightly diminished lung function. The incidence rate of functional deterioration was estimated 23.9% patient-month and 50% of the patients developed pulmonary functional deterioration at 16 months from ILD diagnosis. This Incidence rate was higher in patients with an UIP pattern, baseline fibrosis or ANA at medium-high titers.

Disclosure of Interests: None declared.

Results: Among the 98,995 participants, 1,392 women self-reported GCA/PMR. The specific questionnaire was sent to 1,143 (82.1%) of the eligible women (249 women could not be contacted because of death or withdrawn consent) and response was obtained for 830 women (59.6%). Among them, 202 women provided sufficient medical data to ascertain a diagnosis and study accuracy of developed algorithms. 56 women were classified as ACG and 121 as PMR. Self-reported diagnoses alone had an accuracy of 87.6% with medical chart review. If women additionally self-reported a diagnosis confirmation by a physician and the use of glucocorticoids for ≥ 3 months, the accuracy was improved to 89.8%. For patients who did not respond to validation questionnaire, adding the use of glucocorticoids for ≥ 3 months in the reimbursement database also improved the diagnosis accuracy to 92.8%. These two designed algorithms also had the benefit of reducing the number of false positive cases by 10 and 16 respectively. Finally, 589 GCA and/or PMR cases were confirmed by our two devised algorithms: 401 cases with algorithm using the specific GCA/PMR questionnaire and 188 with medication reimbursement database. The mean age at diagnosis was 70.3 (± 8.0) years [73.4 (± 6.2) years for cases detected using the specific GCA/PMR questionnaire and 68.9 (± 8.3) years for cases detected with medication reimbursement database]. Demographic and clinical data were similar between our population of validated cases by medical chart review and the cases detected by our algorithms in the cohort.

Conclusion: The accuracy of self-reported diagnosis of GCA/PMR was high in the E3N-cohort. Using additional data such as medication reimbursement and/or other self-reported data from a specific questionnaire, particularly the prolonged use of glucocorticoids led to a better accuracy with a very small number of false positive cases and seemed to be sufficient to correctly ascertain GCA and/or PMR diagnoses. With the validation of nearly 600 GCA and/or PMR cases in our cohort, we will be able to conduct epidemiological studies to identify risk factors of these diseases.
Conclusion: According to our data, markers of macrophage activation and the activation of acute phase response could be taken as risk factors of a poor outcome in patients with AIP, regardless of clinical diagnosis and process-related features. Nonetheless, due to our study design and sample, these results warrant replication in other cohorts.

Acknowledgements: This study has been conducted with a Grant from the Carlos III Health Institute AES2020 program, Spanish Ministry for Science and Innovation (PI20/00250)

Disclosure of Interests: None declared


Table 1. Hazard ratios (95% confidence intervals) for the risk of rheumatoid arthritis (RA) by tertiles of fish consumption (N = 62,629)

<table>
<thead>
<tr>
<th>Fish consumption</th>
<th>Non-cases</th>
<th>RA</th>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ter tile 1 (0−16.7 g/day)</td>
<td>N=62,149</td>
<td>N=480</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Ter tile 2 (16.7−31.1 g/day)</td>
<td>N=19,628</td>
<td>N=121</td>
<td>0.74 [0.58; 0.93]</td>
<td>0.74 [0.59; 0.94]</td>
</tr>
<tr>
<td>Ter tile 3 (31.1−261 g/day)</td>
<td>N=10,556</td>
<td>N=66</td>
<td>0.60 [0.43; 0.84]</td>
<td>0.61 [0.44; 0.85]</td>
</tr>
<tr>
<td>Tertile 1 (0−16.7 g/day)</td>
<td>N=9,187</td>
<td>N=93</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Tertile 2 (16.7−31.1 g/day)</td>
<td>N=11,322</td>
<td>N=79</td>
<td>0.69 [0.46; 1.25]</td>
<td>0.60 [0.40; 0.84]</td>
</tr>
<tr>
<td>Tertile 3 (31.1−261 g/day)</td>
<td>N=12,036</td>
<td>N=82</td>
<td>0.86 [0.52; 1.42]</td>
<td>0.80 [0.56; 1.20]</td>
</tr>
<tr>
<td>Model 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All population</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ter tile 1 (0−16.7 g/day)</td>
<td>N=62,149</td>
<td>N=480</td>
<td>Reference</td>
<td></td>
</tr>
<tr>
<td>Ter tile 2 (16.7−31.1 g/day)</td>
<td>N=19,628</td>
<td>N=121</td>
<td>0.89 [0.64; 1.24]</td>
<td>0.90 [0.65; 1.25]</td>
</tr>
<tr>
<td>Ter tile 3 (31.1−261 g/day)</td>
<td>N=10,556</td>
<td>N=66</td>
<td>1.09 [0.68; 1.70]</td>
<td>1.01 [0.69; 1.53]</td>
</tr>
<tr>
<td>Tertile 1 (0−16.7 g/day)</td>
<td>N=9,187</td>
<td>N=93</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Tertile 2 (16.7−31.1 g/day)</td>
<td>N=11,322</td>
<td>N=79</td>
<td>0.86 [0.52; 1.42]</td>
<td>0.80 [0.56; 1.20]</td>
</tr>
<tr>
<td>Tertile 3 (31.1−261 g/day)</td>
<td>N=12,036</td>
<td>N=82</td>
<td>1.09 [0.68; 1.70]</td>
<td>1.01 [0.69; 1.53]</td>
</tr>
</tbody>
</table>

M1: Adjusted for total daily intake and age M2: M1+ smoking status (current smoker, non-smoker, former smoker, except for stratified analyses), passive smoking in childhood (no, yes), gastrointestinal transit (normal, diarrhoea, constipation), alternative diarrhoea/constipation, educational level (< High school, up to 2-level university, 3-level university), and physical activity (in quarters)

Disclosure of Interests: None declared


POS1433 ROLE OF FAT AND MUSCLE TISSUE ON QUALITY OF LIFE OUTCOMES IN OSTEOARTHRITIS: RESULTS FROM THE KHAOLA COHORT

A. C. Rat1,2, J. Sellamb3, B. Mazières3, W. Nguyen Sime2, P. Fardellone8, F. Guilliermin3,2, Cae-Normandy University, UNICAEN, Caen, UMR-S 1075 COMETE, FFRS, Caen, France; Caen, France; University Hospital Center Caen, Rheumatology Department, Caen, France; University De Lorraine, APEMAC, Nancy, Nancy, France; Sorbonne Université, Inserm UMR_S_938, FHU PaeCeMM, Paris, France; Sorbonne Université, AP-HP Hôpital Saint-Antoine, Department of Rheumatology, Paris, France; University Hospital Center Toulouse, Rheumatology Department, Toulouse, France; University Of Lorraine, CHRU-Nancy, Inserm, CIC 1433 Epidémiologie clinique, Nancy, France; Cru D’amiens-Picardy Site Nord, Rheumatology Department, Amiens, France

Background: The study of associations between body composition and osteoarthritis is still incomplete. While fat-related components are associated with pain in cross-sectional studies, longitudinal studies are rare and the impact on other quality of life (QOL) dimensions is not known.

Objectives: The main objective of the study was to analyze the impact of body composition on the evolution of the perceived health of patients followed for hip and knee osteoarthritis (OA).

Methods: Longitudinal data from the Knee and Hip Osteoarthritis Long-term Assessment (KHAOLA) cohort, a multicenter cohort of 878 patients with symptomatic knee and/or hip OA, were used. Body composition measures were obtained from DXA scans at year 3. Only 3 of the 6 investigating centers with Lunar Prodigy Advance DXA equipment recruited patients for this study. The main outcome criteria were the changes in Patient-Reported Outcomes Measures (PROMs) (physical functioning, pain, mental health and vitality of the SF-36 0=worst, 100=best) between 3 and 7 years of follow up. Body composition variables were as follows: fat mass index (FMI (kg/m²)), percentage of fat mass and trunk to leg fat mass ratio (TFM/LFM), skeletal muscle Mass Index (SMI (kg/m²)) and lean mass if SMI <700 kg/m² for men and <55 kg/m² for women. To account for the correlation of repeated measurements of the same individual, a generalized estimating equation (GEE) models were used to assess the associations between body composition measurements and the 4 SF-36 scores. The GEE models were adjusted for potential confounders (age, sex, education level, occupation, smoking, comorbidity, hand OA, number of painful joints, joint of inclusion and Kelgren grade (KL)) showing a significant association at the 0.2 threshold in the bivariate analysis.

Results: 290 patients with knee and 114 patients with hip OA have been included in the analysis: women 254 (68.7%), mean age 60.3 (SD 8.4) years old, IMC 29.5 (5.7), KL grade2 135 (46.6%) for knee OA, 79 (69.3%) for hip OA. The results of the multivariate analysis of associations between anthropometric measures and quality of life dimensions are presented in Table 1.
Table 1. Obstetric outcomes of Mexican women with autoimmune rheumatic diseases.

| L. G. Espinosa Banuelos 1, C. M. Skinner Taylor 1, L. Pérez Barbosa 1, A. Cárdenas 1, F. Hernández 2, A. Y. Lujano Negrete 1, S. M. Delgado Ayala 1, Eleuterio González 1, Rheumatology Department, Monterrey, Mexico; 2Hospital Universitario Dr. José Eleuterio González, Rheumatology Department, Monterrey, Mexico; 3Hospital Universitario Dr. José Eleuterio González, Obstetrics and Maternal Fetal Medicine Unit, Monterrey, Mexico; 4Hospital Universitario Dr. José Eleuterio González, Obstetrics and Gynaecology, Monterrey, Mexico

Background: Autoimmune rheumatic diseases (ARDs) are more prevalent in women during childbearing age. These women have an increased risk of adverse pregnancy outcomes and maternal morbidity than general obstetric population (GOP).

Objectives: The objective of this study was to evaluate the obstetric outcomes in Mexican women with ARDs.

Methods: A retrospective and descriptive study was conducted in a pregnancy and rheumatic disease clinic of a university hospital in Northeast Mexico from Jan 2017 to Dec 2020. All data were collected from the medical records of childbearing age women with ARDs enrolled in our clinic at the time of their pregnancy and childbirth. Patients with non-inflammatory rheumatic diseases were excluded. The obstetric, maternal, and fetal outcomes were compared with the rate of adverse perinatal outcomes of the GOP (n=31,254) database from the same institution. Sociodemographic and clinical characteristics of the population are described. We used the Mann–Whitney U, Chi-square, or Kruskal–Wallis tests to analyze the differences between groups. A p<0.05 was considered statistically significant. The statistical analysis was performed with SPSS v.24 statistical software (IBM, NY).

Results: A total of 62 pregnancies in women with ARDs were included. RA (n=24, 38%) was the most frequent diagnosis followed by SLE (n=14, 22.5%) and APS (n=9, 14.5%). The median maternal age at conception was higher in pregnancies with ARDs than GOP (p<0.001). Table 1 shows the pregnancy and product outcomes between groups. Maternal age ≥35 years was also more frequent in the ARDs group (p<0.001). The birth weight was lower in ARDs group than GOP (p=0.007). The odds of preterm delivery were increased in ARDs group (p=0.038).

Table 1. Pregnancy outcome, maternal, fetal, and neonatal adverse events

<table>
<thead>
<tr>
<th>ARD (n=62)</th>
<th>GOP (n=31,254)</th>
<th>OR (CI 95%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy loss</td>
<td>6(9.68)</td>
<td>1560(4.99)</td>
<td>0.94(0.84-4.49)</td>
</tr>
<tr>
<td>Live births</td>
<td>60(90.9)</td>
<td>29664(95.5)</td>
<td>0.96(0.67-1.35)</td>
</tr>
<tr>
<td>Gestational age</td>
<td>37(36-39)</td>
<td>39(38-40.2)</td>
<td>0.001</td>
</tr>
<tr>
<td>median (IQR) (weeks)</td>
<td></td>
<td>2838.6</td>
<td>2032.2</td>
</tr>
<tr>
<td>mean (CI) (Kg)</td>
<td>(2677.4-2985.8)</td>
<td>(2986.8-3057.6)</td>
<td>-</td>
</tr>
<tr>
<td>Maternal adverse events</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm deliveries</td>
<td>14(23.7)</td>
<td>3821(12.2)</td>
<td>1.85(1.03-3.3)</td>
</tr>
<tr>
<td>&lt;37 weeks</td>
<td>3(5.1)</td>
<td>1005(3.4)</td>
<td>1.42(0.45-4.53)</td>
</tr>
<tr>
<td>&lt;34 weeks</td>
<td>4(6.5)</td>
<td>14064(4.5)</td>
<td>1.43(0.52-3.35)</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>0(0.1)</td>
<td>2471(7.8)</td>
<td>1.02(0.41-2.54)</td>
</tr>
<tr>
<td>Postpartum hemorrhage</td>
<td>0(0.1)</td>
<td>930(2.9)</td>
<td>0.27(0.017-3.35)</td>
</tr>
</tbody>
</table>

Conclusion: Pregnant women with ARDs had a higher median maternal age at conception, lower birth weight, increased preterm delivery, and more emergency cesarean sections than pregnant women without ARDs. Close monitoring and multidisciplinary care are necessary to prevent and timely treat complications in this population.

REFERENCES:

Disclosure of Interests: None declared


POS1434 Use of biologic or targeted synthetic disease modifying anti-rheumatic drugs and the risk of lymphoma in rheumatoid arthritis


1University of Washington, Medicine, SEATTLE, United States of America; 2University of British Columbia, Epidemiology, Vancouver, Canada; 3University of Washington, Medicine, SEATTLE, United States of America; 4VA Puget Sound, Epidemiology, SEATTLE, United States of America; 5University of British Columbia, Epidemiology, Vancouver, Canada; 6VA Portland, Medicine, Portland, United States of America; 7University of Alabama at Birmingham, Medicine, Birmingham, United States of America

Background: Epidemiologic studies suggest that disease duration and degree of inflammatory activity of rheumatoid arthritis (RA) contribute to lymphoma...
Table 1. Estimates of Effect of bDMARD or tsDMARD use on Lymphoma relative to use of csDMARDs

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusted for CRP</td>
<td>1.04</td>
<td>(0.80, 1.34)</td>
</tr>
<tr>
<td>Adjusted for CRP, time-varying RDCI</td>
<td>1.06</td>
<td>(0.82, 1.37)</td>
</tr>
</tbody>
</table>

* per 1000 person-years

Demographics + CRP

Table 1. Estimates of Effect of bDMARD or tsDMARD use on Lymphoma relative to use of csDMARDs

Marginal Structural Models; adjusted for:

- Age, gender, race, ethnicity, year of cohort entry
- Baseline rheumatology visits (yes/no)
- RDCI

Conclusion: In this large study using the nationwide VA data, we did not observe an association between the use of b/tsDMARDs and an increased risk of lymphoma.

REFERENCES:

[1] Zhao SS, Robertson S, Reich T, et al. Prevalence and impact of comorbidities involving the cardiovascular system. Development of a predictive chart for cardiovascular comorbidities. The major limitation of this study was a lack of information on individual smoking status. The findings might aid in the development of a predictive chart score or algorithm for risk of major adverse cardiovascular events (MACE) in patients with incident AS requiring pharmacologic therapy based on identified risk factors is a clinical necessity for a better holistic management. The related epidemiologic studies are still lacking currently.

Objectives: To investigate factors associated with major adverse cardiovascular events (MACE) in patients with incident ankylosing spondylitis (AS) requiring medical therapy.

Methods: We conducted a population-based case-control study using the Taiwanese National Health Insurance Research Database, and 42,585 newly-diagnosed AS patients requiring medical therapy without previous MACE (the composite outcome of myocardial infarction, ischemic stroke, or patients who underwent coronary artery bypass graft or percutaneous coronary intervention) from 2004 to 2012 was identified. Totally 1,151 patients (2.7%) developed MACE during the follow-up period. We matched MACE cases with non-MACE controls at a 1:4 ratio for age, gender and AS follow-up duration and included 4,604 matched controls for final analyses. Using conditional logistic regression analyses, we examined the associations of MACE with low income (≤ 21000 new Taiwan dollars per month), urbanisation, extra-articular manifestations (uveitis, psoriasis and inflammatory bowel disease), comorbidities and use of medications within a year before MACE development. We also examined the influence of NSAIDs of three categories (traditional NSAIDs, selective cyclooxygenase-2 inhibitors [COX-2] and preferential COX-2) with their annual cumulative defined daily dose (cDDD) on MACE risk with a Bonferroni correction of the cut-off of probability value for statistical significance. The risk was shown as adjusted odds ratio (aOR) with 95% confidence intervals (CIs).

Results: MACE development was associated with selective COX-2 use: statistically with aOR > 1.32 (aOR, 1.61; 95% CI, 1.02-2.54, p = 0.011), corticosteroid use with a dose-response relationship (prednisolone equivalent dose < 5 mg/day: aOR, 1.25; 95% CI, 1.02-1.54, p = 0.028; ≥ 5 mg/day: aOR, 4.75; 95% CI, 3.51-6.43, p < 0.001), residence in rural region (aOR, 1.32; 95% CI, 1.03-1.69, p = 0.028), hypertension (aOR, 3.12; 95% CI, 2.53-8.00, p < 0.001), diabetes mellitus (aOR, 1.69; 95% CI, 1.37-2.07, p < 0.001), hyperlipidaemia (aOR, 5.00; 95% CI, 4.14-6.03, p < 0.001), chronic kidney disease (aOR, 1.98; 95% CI, 1.35-2.90, p < 0.001), heart failure (aOR, 4.04; 95% CI, 2.74-5.94, p < 0.001) and valvular heart disease (aOR, 2.06; 95% CI, 1.33-3.30, p = 0.001). We took into consideration of the cut-off of probability value for statistical significance. The risk was shown as adjusted odds ratio (aOR) with 95% confidence intervals (CIs). The authors would like to thank the Biostatistics Task Force of Taichung Veterans General Hospital, Taichung, Taiwan, ROC for statistical support.

Disclosure of Interests: None declared


POS1436

CLINICAL CHARACTERISTICS AND RISK FACTORS OF INVASIVE FUNGAL INFECTION DURING IMMUNOSUPPRESSIVE INDUCTION THERAPY IN PATIENTS WITH CONNECTIVE TISSUE DISEASE

H. Fukui¹, H. Hanaoka¹, Y. Kaneko¹, ¹Keio University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

Background: Invasive fungal infection (IFI) is a life-threatening complication among immunosuppressed patients. Whereas intensive immunosuppressive therapy during remission induction phase in patients with connective tissue disease is a major risk of IFI, little is known about the clinical characteristics and risk factors of IFI.

Objectives: This study aims to reveal prevalence, clinical characteristics, and associated risk factors of IFI during immunosuppressive induction therapy in patients with connective tissue disease.

Methods: We reviewed consecutive patients with connective tissue diseases who underwent immunosuppressive remission induction therapy in Keio University Hospital Rheumatology Department from January 2012 to August 2020. Patients with 0.5mg/kg or more equivalent dose of daily prednisone use were included for IFI, diagnosed according to the definition of invasive fungal diseases from the Infectious Diseases Society of America (IDSA) 2008. Infections caused by Pneumocystis jiroveci were not included.

Results: Among 2701 hospitalized cases, 627 patients had undergone induction or re-induction therapy. Total of 24(3.8%) patients were diagnosed as IFI,
of whom there were 8 proven cases and 16 probable cases; 14 aspergillosis, 5 candidiasis, 2 cryptococcosis, 1 phaeohyphomycosis, and 2 cases with unknown pathogen. Median duration from the start of immunosuppressive therapy to the onset of IFI was 95 days (interquartile range, 36,249 days; range, 13-1397 days) and the mean dose of daily prednisolone was 0.53±0.29 mg/kg at the onset of IFI. Total of 11 patients died; 6 patients (25.0%) due to IFI and 5 patients (20.8%) due to the exacerbation of underlying disease. Univariable analysis comparing the IFI and non-IFI groups, age (65.8±3.7 vs. 56.1±0.7; P=0.01), initial prednisolone dose (0.87±0.01 vs. 0.95±0.04 mg/kg; P=0.037), the history of methylprednisolone (mPSL) pulse therapy (54.2% vs. 20.0%; P=0.001), tumor necrosis factor (TNF) inhibitor use (8.3% vs. 1.1%; P=0.039), 2 or more immunosuppressant or biologic use (33.3% vs. 12.0%; P=0.010), HbA1c 6.5% or higher (58.3% vs. 28.9%; P=0.003), lowest serum IgG during the clinical course (599.4±821.2 vs 787.7±12.4 mg/dl; P=0.003), and cytomegalovirus reaction defined by pp65 antigen 6 or higher (33.3% vs. 11.2%; P=0.004) were significantly different, respectively. Sex, body mass index, presence of interstitial lung disease, and the use of cyclophosphamide, rituximab, or interleukin-6 inhibitors were not significantly different. Multivariable analysis revealed older age for each (for 10-year increase: OR 1.40, 95% CI 1.03-1.91; P=0.023), the history of methylprednisolone pulse therapy (OR 2.60, 95% CI 1.06-6.77; P=0.049), TNF inhibitor use (OR 11.2, 95% CI 1.70-74.0; P=0.012), and serum IgG less than 550 mg/dl (OR 2.59, 95% CI 1.19-5.65; P=0.03) as the independent risk factors of IFI.

Conclusion: Patients with connective tissue disease with older age, lower serum IgG, mPSL pulse therapy, or TNF inhibitor use are at higher risk of IFI. Further studies are needed to determine the benefit of prophylactic anti-fungal treatment in such patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3595

ASSOCIATION BETWEEN BEVERAGE CONSUMPTION AND RISK OF Rheumatoid Arthritis: A PROSPECTIVE STUDY FROM THE FRENCH E3N COHORT

S. Ascione1,2, C. Salliot2, F. Artaud2, Y. Nguyen4, C. Macdonald2, F. Barde3, X. Mariette5,6, M. C. Boutron-Ruault2, R. Seror5,6.

Background: The role of nutrition in the pathogenesis of RA has been suggested in many studies but remains controversial.

Objectives: To assess the relationship between consumption of the most frequently drunk specific beverages (coffee, tea, alcohol, and soft drinks) and the risk of RA.

Methods: The E3N Study (Étude Épidémiologique auprès des femmes de la Mutuelle Générale de l’Éducation Nationale) is a French prospective cohort including 98,995 women since 1990. RA cases have been previously identified with specific questionnaires and medication reimbursement database (1). Food and beverage consumption was assessed using a validated food-frequency questionnaire. Hazard ratios (HR) and their 95% confidence intervals (CI) for incident RA were estimated by Cox proportional hazards models, adjusted for age and the main potential confounders, including smoking. Tests for linear trends were performed. As smoking is a major risk factor for RA, stratified analyses were conducted according to the smoking status (ever or never-smoker) even in the absence of statistically significant interaction between the smoking status and beverage consumptions. Sensitivity analyses were performed in the subgroup of seropositive cases (positive RF and/or ACPA).

Results: During a total follow-up of 21 years (mean 20.78 (SD 2.26) years), 62,630 women contributed 1,300,874 person-years, and 481 developed RA (incidence 37/100 000 person-years). Incident RA cases were diagnosed a mean 11.7 (SD 5.9) years after baseline. Of the 179 (37.2%) RA cases with known antibody status, 153 (31.8%) were seropositive. Consumptions of total alcohol, tea and sugar-sweetened soft drinks were not associated with RA risk. Coffee consumption was associated with RA risk with a dose-effect relationship (≥4 cups/day versus ≤ 1 cup/day, HR 1.24, 95% CI [0.94; 1.64], p trend=0.04), in never-smokers. According to the type of coffee consumed, only high caffeinated coffee consumption was associated with an increased risk of RA among never-smokers (≥ 3.5 cups/day versus ≤ 1 cup/day, HR=1.62 95% CI [1.12;2.34], p trend = 0.006, p newtrend = 0.07). Decaffeinated coffee consumption was not associated with RA risk. Risk of RA was higher with artificially-sweetened soft-drinks consumption (consumers versus non-consumers, HR 1.66 [1.12; 2.45], in never-smokers). No association was observed with other soft drinks. Moderate liquor consumption (spirits or aperitifs) intake was associated with a reduced risk of RA among ever-smokers (consumption of 1 - 3 glasses/week versus non-smokers HR 0.63, 95% CI [0.43; 0.91]) and moderate wine consumption was associated with a decreased risk of seropositive RA (consumption of 4 - 10 glasses/week versus ≤ 1 glass/week HR 0.57, 95% CI [0.35 to 0.94], whereas no association was observed with other alcohols.

Conclusion: Consumptions of tea, total alcohol, and sugar-sweetened soft drinks were not associated with RA risk, whereas consumptions of coffee (especially caffeinated coffee), and artificially-sweetened soft drinks were associated with higher RA risk, among never-smokers. By contrast, moderate liquor consumption was associated with a decreased risk of RA in ever-smokers, and moderate wine consumption was associated with a decreased risk of seropositive RA. If further confirmed, these results could lead to novel mechanistic hypotheses and to simple prevention measures.

REFERENCES:

Acknowledgements: The authors would like to thank Pascale Gerboun-Rerolle, Mariam Ayanlaiykan, Sofiane Harzi and Rosely Rima Gomes for their help on data management. The present work was performed using data from the Insern E3N cohort and support from the MGEN, Gustave Roussy, and the Ligue contre le Cancer for setting up and maintaining the cohort. The cohort was supported by a state grant ANR-10-COHO-0006 from the Agence Nationale de la Recherche within the investissement davenir program. The present work was conducted thanks to a research grant from the Société Française de Rhumatologie.

Disclosure of Interests: None declared
Table 1

<table>
<thead>
<tr>
<th>Diagnosis by rheumatologist</th>
<th>Referral or work diagnosis Number (%)</th>
<th>Correct work diagnosis GP Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>146 (16.9)</td>
<td>87 (10.1)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>41 (4.8)</td>
<td>29 (3.4)</td>
</tr>
<tr>
<td>Spondyloarthropathy</td>
<td>64 (7.4)</td>
<td>52 (6.0)</td>
</tr>
<tr>
<td>Undifferentiated oligoarthritides</td>
<td>97 (11.2)</td>
<td>10 (1.2)</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>55 (6.4)</td>
<td>27 (3.1)</td>
</tr>
<tr>
<td>Gout</td>
<td>55 (6.4)</td>
<td>49 (5.7)</td>
</tr>
<tr>
<td>Calcium pyrophosphate</td>
<td>4 (0.5)</td>
<td>13 (1.5)</td>
</tr>
<tr>
<td>deposition</td>
<td>124 (14.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>12 (1.4)</td>
<td>12 (1.4)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (0.5)</td>
<td>16 (1.9)</td>
</tr>
<tr>
<td>Reactive arthritis</td>
<td>116 (13.6)</td>
<td>116 (13.6)</td>
</tr>
<tr>
<td>Sjögren's syndrome</td>
<td>3 (0.3)</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>8 (0.9)</td>
<td>8 (0.9)</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>3 (0.3)</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>GPA vasculitis</td>
<td>4 (0.5)</td>
<td>4 (0.5)</td>
</tr>
<tr>
<td>Suspected symptoms of arthralgia</td>
<td>57 (6.6)</td>
<td>57 (6.6)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (0.5)</td>
<td>4 (0.5)</td>
</tr>
<tr>
<td>Tendomyalgia</td>
<td>27 (3.1)</td>
<td>27 (3.1)</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>79 (9.2)</td>
<td>79 (9.2)</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>29 (3.4)</td>
<td>29 (3.4)</td>
</tr>
<tr>
<td>Hypermobility syndrome</td>
<td>153 (17.7%)</td>
<td>153 (17.7%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>114 (13.6)</td>
<td>114 (13.6)</td>
</tr>
<tr>
<td>Other</td>
<td>127 (14.8)</td>
<td>127 (14.8)</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>854 (100)</td>
<td>854 (100)</td>
</tr>
<tr>
<td>Non-inflammatory</td>
<td>560 (65.7%)</td>
<td>560 (65.7%)</td>
</tr>
</tbody>
</table>

*A including missing data

After elastic net regularization the 87 items could be reduced to 33 items that were able to differentiate inflammatory disease from non-inflammatory disease with an AUC of 0.70 in the ROC curve below (Figure 1).

**Figure 1.** ROC-curve highlighting performance of FRYQ after regularization in the validation set.

**Conclusion:** FRYQ questionnaire can differentiate inflammatory rheumatic disease from non-inflammatory musculoskeletal complaints. To officially validate FRYQ a prospective cohort study is needed.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOCTYPE:** 10.1136/annrheumdis-2022-eular.3834

---

**Table 1.**

<table>
<thead>
<tr>
<th>Diagnosis by rheumatologist</th>
<th>Referral or work diagnosis Number (%)</th>
<th>Correct work diagnosis GP Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>146 (16.9)</td>
<td>87 (10.1)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>41 (4.8)</td>
<td>29 (3.4)</td>
</tr>
<tr>
<td>Spondyloarthropathy</td>
<td>64 (7.4)</td>
<td>52 (6.0)</td>
</tr>
<tr>
<td>Undifferentiated oligoarthritides</td>
<td>97 (11.2)</td>
<td>10 (1.2)</td>
</tr>
<tr>
<td>Polyarthritis</td>
<td>55 (6.4)</td>
<td>27 (3.1)</td>
</tr>
<tr>
<td>Gout</td>
<td>55 (6.4)</td>
<td>49 (5.7)</td>
</tr>
<tr>
<td>Calcium pyrophosphate</td>
<td>4 (0.5)</td>
<td>13 (1.5)</td>
</tr>
<tr>
<td>deposition</td>
<td>124 (14.4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>12 (1.4)</td>
<td>12 (1.4)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (0.5)</td>
<td>16 (1.9)</td>
</tr>
<tr>
<td>Reactive arthritis</td>
<td>116 (13.6)</td>
<td>116 (13.6)</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>3 (0.3)</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>8 (0.9)</td>
<td>8 (0.9)</td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>3 (0.3)</td>
<td>3 (0.3)</td>
</tr>
<tr>
<td>GPA vasculitis</td>
<td>4 (0.5)</td>
<td>4 (0.5)</td>
</tr>
<tr>
<td>Suspected symptoms of arthralgia</td>
<td>57 (6.6)</td>
<td>57 (6.6)</td>
</tr>
<tr>
<td>Other</td>
<td>4 (0.5)</td>
<td>4 (0.5)</td>
</tr>
<tr>
<td>Tendomyalgia</td>
<td>27 (3.1)</td>
<td>27 (3.1)</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>79 (9.2)</td>
<td>79 (9.2)</td>
</tr>
<tr>
<td>Osteoarthritis</td>
<td>29 (3.4)</td>
<td>29 (3.4)</td>
</tr>
<tr>
<td>Hypermobility syndrome</td>
<td>153 (17.7%)</td>
<td>153 (17.7%)</td>
</tr>
<tr>
<td>Unknown</td>
<td>114 (13.6)</td>
<td>114 (13.6)</td>
</tr>
<tr>
<td>Other</td>
<td>127 (14.8)</td>
<td>127 (14.8)</td>
</tr>
<tr>
<td>Inflammatory</td>
<td>854 (100)</td>
<td>854 (100)</td>
</tr>
<tr>
<td>Non-inflammatory</td>
<td>560 (65.7%)</td>
<td>560 (65.7%)</td>
</tr>
</tbody>
</table>

*A including missing data

After elastic net regularization the 87 items could be reduced to 33 items that were able to differentiate inflammatory disease from non-inflammatory disease with an AUC of 0.70 in the ROC curve below (Figure 1).

**Figure 1.** ROC-curve highlighting performance of FRYQ after regularization in the validation set.

**Conclusion:** FRYQ questionnaire can differentiate inflammatory rheumatic disease from non-inflammatory musculoskeletal complaints. To officially validate FRYQ a prospective cohort study is needed.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOCTYPE:** 10.1136/annrheumdis-2022-eular.3834
Table 1. New Cancer Diagnosis Among Patients with anti-TNF versus other therapies

<table>
<thead>
<tr>
<th></th>
<th>Anti-TNF</th>
<th>JAKi</th>
<th>Anti-CD20</th>
<th>Anti-IL-17</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=3536</td>
<td>N=1079</td>
<td>N=667</td>
<td>N=1178</td>
<td>N=783</td>
</tr>
<tr>
<td><strong>Female, (%)</strong></td>
<td>37.8 (58.8)</td>
<td>868 (80.4)</td>
<td>523 (78.4)</td>
<td>947 (80.4)</td>
</tr>
<tr>
<td><strong>Mean age, (SD)</strong></td>
<td>54.8 (14.7)</td>
<td>58.5 (12.4)</td>
<td>60.9 (13.6)</td>
<td>59.8 (15.1)</td>
</tr>
<tr>
<td><strong>Mean start age, (SD)</strong></td>
<td>49.1 (14.0)</td>
<td>56.6 (12.3)</td>
<td>57.9 (13.5)</td>
<td>55.7 (15.2)</td>
</tr>
<tr>
<td><strong>Disease duration, median (IQR)</strong></td>
<td>6.2 (2.3-13.0)</td>
<td>10.4 (2.3-13.0)</td>
<td>11.0 (2.3-13.0)</td>
<td>8.3 (2.3-13.0)</td>
</tr>
<tr>
<td><strong>Charlton Index</strong></td>
<td>[2.2-13.0]</td>
<td>[4.7-17.2]</td>
<td>[5.1-18.5]</td>
<td>[3.2-15.1]</td>
</tr>
<tr>
<td><strong>First line biologic, n (%)</strong></td>
<td>99 (53.2)</td>
<td>2 (22.2)</td>
<td>1 (7.1)</td>
<td>6 (20.0)</td>
</tr>
<tr>
<td><strong>New cancer diagnosis, n (%)</strong></td>
<td>186 (2.9%)</td>
<td>9 (0.8%)</td>
<td>14 (2.1%)</td>
<td>30 (2.5%)</td>
</tr>
<tr>
<td><strong>Median years of follow-up months</strong></td>
<td>4.2 [2.3-7.3]</td>
<td>2.4 [1.4-3.2]</td>
<td>1.0 [1.0-1.0]</td>
<td>2.6 [1.3-6.6]</td>
</tr>
<tr>
<td><strong>Time of exposure, yrs</strong></td>
<td>26233.5</td>
<td>1652.7</td>
<td>1871.5</td>
<td>3196.7</td>
</tr>
<tr>
<td><strong>New cancer diagnosis, n (%)</strong></td>
<td>186 (2.9%)</td>
<td>9 (0.8%)</td>
<td>14 (2.1%)</td>
<td>30 (2.5%)</td>
</tr>
<tr>
<td><strong>Cancer Incidence Rate (per 1000 PY)</strong></td>
<td><strong>1.9 (1.3)</strong></td>
<td><strong>2.4 (1.6)</strong></td>
<td><strong>2.4 (1.7)</strong></td>
<td><strong>2.4 (1.7)</strong></td>
</tr>
</tbody>
</table>

**Cancer Incidence Rate (per 1000 PY)**

- **Total**: **10.8 (6.9-16.9)**
- **Female**: **7.5 (5-11.2)**
- **Male**: **13.6 (5.2-17.0)**
- **≥ 65 years**: **10.3 (5.2-17.0)**
- **≥ 65 years**: **4.5 (2.4-7.6)**

**BACKGROUND**: TNF inhibitors (TNFi) are highly effective in inflammatory arthritis (IA) treatment. However, concerns are raised about the possible association between TNFi and hematologic malignancies (HMs).

**OBJECTIVES**: To assess the incidence of HMs among IA patients receiving TNFi compared with the general Turkish population.

**METHODS**: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological disease modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA including rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) who had at least 1 visit after the TNFi usage were screened from 2005 to November 2021. HM diagnosis was determined from the patient files according to the hematologists' decision and/or bone marrow/lymph node biopsy. Demographic data, disease characteristics, and death status were recorded. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with age- and gender-specific SIR values abstracted from the 2017 Turkish National Cancer Registry (TCNR).

**RESULTS**: Of the 6139 patients registered in the HUR-BIO database, 5355 (3116 female [58.2%]) used any TNFi at least once. Median follow-up duration was 2.6 years for all patients receiving TNFi. 13 patients (8 [61.5%] female) had HM on follow-up. In these patients, median age at the IA onset was 38 (range 26 to 67) and the number of patients with SpA, RA, and PsA was 7, 4, and 2, respectively. The median duration of IA was 17.7 years (range 1 to 33). The median age at the HM onset was 55.5 (range 38 to 76) and the type of HM as follow: 8 lymphoma, 2 multiple myeloma, 1 large granular lymphocytic leukemia, 1 plasma cell dyscrasia, and 1 myelodysplatic syndrome. The median duration of the TNFi usage onset to HM onset was 36 (range 4-112) months. The TNFi was as follows: etanercept (n=8), adalimumab (n=6), infliximab (n=4), golimumab (n=1), and certolizumab (n=1). 5 patients used more than one TNFI. Patients using TNFi had an increased incidence for HMs (SIR 4.23, 95% CI 2.35-7.05). These results were also valid for both gender. 10 patients with HMs were under the age of 65. In this group, there was a higher incidence of HMs in both men (SIR 5.19, 95% CI 1.88-11.43) and women (SIR 4.76, 95% CI 1.74-10.55). 5 patients deceased on follow-up.

**CONCLUSION**: The risk of HMs in inflammatory arthritis patients receiving TNFi being four times higher in comparison with the general Turkish population. There is a plethora of information that discusses the association between HMs and rheumatic disease. To determine whether the increased risk is from rheumatic disease or from TNFi usage, it would be ideal to compare patients receiving TNFi with bDMARD naive IA patients.

**Figure 1. Cumulative number of hematologic malignancies in function of time from start of first anti-TNF therapy**

Disclosure of Interests: None declared

the correlation between the two was verified using Spearman’s rank correlation coefficient (first cohort). Next (second cohort), serum IgG4 of 3240 samples of Nagasaki Island Study (NaIS), which had started in 2014 collaborating among Nagasaki University and Goto City, Nagasaki Prefecture, intended for research of varying conditions and diseases including IgG4-RD, were then measured by MBA. These subjects were stratified into the two groups as IgG4-high and IgG4-within normal limit making use of the aforementioned cutoff values, and compared with background information such as age, gender, drinking, smoking, uric acid, serum creatinine, comorbidities and HLA typing, including DRB1*04:06, *04:05, *04:10 as disease-susceptibility gene, DRB1*07:01 and DBQ1*03:01 as protective gene.1

Results: IgG4 by MBA correlated well with IgG4 by NIA (r=0.94, p-value<0.001) which was determined from Kanazawa samples (N=947). 1,463.6 mg/mL of IgG4 of MBA corresponded to 135 mg/dl, the normal cut-off value for IgG4 by NIA. In the analysis of NaIS samples (N=3240), the overall high IgG4 positivity rate was 6.3%. Multivariable analysis including age, gender, smoking and drinking, led by univariate analysis, showed that gender and smoking were significantly associated with high serum IgG4 positivity (male: odds ratio = 1.8, 95%CI =1.2-2.7, p = 0.009, smoking: odds ratio = 1.7, 95%CI =1.1-2.5, p = 0.012). There was no association between high serum IgG4 level and HLA genotyping.

Conclusion: We concluded that MBA is a good method to measure serum IgG4 even by the very small sample volume. In our study, the prevalence of serum IgG4 positivity was high tendency than previous report1. Our data showed that male and smoking are independent factors associated with high serum IgG4 positivity. There were no association between serum IgG4 level and HLA genotyping in healthy subjects. Further comprehensive investigation is necessary to clarify high risk subjects who will develop RA.

REFERENCES:


Acknowledgements: The authors thank the data custodians of Hospital Morbidity Data Collection, Emergency Department Data Collection, the Death Registrations and staff at the Western Australian Data Linkage Branch to assist in the provision of data. Special thanks to the University of Western Australia to support KA with an Australian Government Research Training Program PhD Scholarship and the Australian Rheumatology Association for WA Research Fellowship Award.


POS1442

THE PREVALENCE OF RHEUMATOID ARTHRITIS IN WESTERN AUSTRALIA EXTRAPOLATED FROM HOSPITALISATION AND BIOLOGICAL THERAPY USAGE DATA

K. Almutairi1,2, C. Inderjeeth1, D. Preen3, H. Keen1,5, J. Nossent1,3.


The University of Western Australia, School of Medicine, Perth, Australia; 2King Fahd Specialist Hospital, Clinical Hospital, Buraydah, Saudi Arabia; 3Sir Charles Gairdner and Osborne Park Health Care Group, Rheumatology, Perth, Australia; 4The University of Western Australia, School of Population and Global Health, Perth, Australia; 5Fiona Stanley Hospital, Rheumatology, Murdoch, Australia.

Background: Rheumatoid arthritis (RA) is a heterogeneous chronic autoimmune disease that affects the synovial joint lining and may result in permanent joint destruction, premature death, and socio-economic burden. Although RA is one of Australia’s national health priority areas and gathering information about the RA burden of disease was one of the national action plans, no published epidemiological study adequately describes RA prevalence and risk factors for frequent hospitalisations in Western Australia (WA) to date. An accurate prevalence estimate of this disease offers a framework for predicting present and growing healthcare service requirements in the future.

Objectives: We estimated RA period prevalence and identified risk factors of frequent RA hospitalisations, using linked administrative health and state-specific Australian Pharmaceutical Benefits Scheme (PBS) datasets in WA from 1995–2014.

Methods: RA prevalence was calculated per 1000 person years. RA patients were identified in the WA linked health dataset using ICD codes 714.0–714.9 and M05.0–M05.9. Dispensing data on biological therapy for RA were obtained from PBS records and converted to daily doses/1000 person/day. Multivariate logistic regression was used to analyse risk factors for frequent RA hospitalisations (>2/year), controlling for sex, age, and geographic locations.

Results: A total of 17,125 RA patients were admitted to WA hospitals between 1995–2014. The total number of RA hospital separations was 50,353, averaging 3.4 per 1000 separations per year. The RA period prevalence was 3.4 per 1000 separations (0.34%), while the RA period prevalence based on biological therapy usage was 0.36%. The corrected RA prevalence based on biological therapy usage was 0.36% and 0.72% for the 2005–2009 and 2010–2014 periods, respectively (Table 1). Female gender, age 60–69 years, and living in rural areas were all factors for frequent RA hospitalisations.

Conclusion: Based on hospital and biological therapy data, the minimal prevalence of RA in Western Australia is 0.34–0.36%, which falls within the literature range. Older female RA patients in rural areas were more likely to be hospitalised, suggesting unmet needs in primary care access.

Disclosure of Interests: None declared, Helen Keen Speakers bureau: Eli Lilly, David Preen: None declared, Knut Inderjeeth Speakers bureau: Pfizer Australia, Abbvie Australia, Johannes Nossent Speakers bureau: Janssen DOi: 10.1136/annrheumdis-2022-eular.4170

POS1443

IDENTIFYING THE NEW EMERGENCE OF RACIAL DISPARITIES IN GOUT OVER THE PAST 3 DECADES – US NATIONAL SURVEY AND PROSPECTIVE COHORT DATA

N. McCormick1,2,3, L. Lu1, C. Yoko2,3,4, A. Joshi2,3, Y. Zhang3,4, H. Choi2,3,4.

1Arthritis Research Canada, Vancouver, Canada; 2The Mongan Institute, Medicine, Boston, United States of America; 3Harvard Medical School, Medicine, Boston, United States of America; 4Massachusetts General Hospital, Rheumatology, Allergy and Immunology, Boston, United States of America; 5MGH Clinical and Translational Epidemiology Unit, Medicine, Boston, United States of America.

Background: Several studies published after 2010 reported a higher frequency of gout and hyperuricemia among US Blacks than Whites.2 However, Blacks (in the US and Africa) were previously thought to suffer gout less often than Whites.3 We hypothesized that the racial disparity in Blacks emerged over the past several decades, with flipped prevalence between the two races.

Objectives: To assess trends in racial differences in gout prevalence in the US using both national survey and cohort study data over the past 3 decades.

Methods: Using data from the NHANES (National Health and Nutrition Examination Survey) III (1988-1994) and latest decade (2007-2016), and data from 5 examination periods in the ARIC (Atherosclerosis Risk in Communities) Study between 1988 through 2013, we compared age- and sex-adjusted prevalences and odds ratios (OR) to determine the trend of racial differences in gout prevalence between Blacks and Whites. A time–race interaction term was used to assess differences in the rate of change between the two races.

Results: Among Whites, the sex- and age-standardised prevalence of gout in the NHANES rose from 2.8% (95% CI: 2.4 to 3.2) in 1988-94 to 3.7% (3.2 to 4.1) in 2007/16. Prevalence of gout among Blacks was lower than Whites in 1988-94 (2.6% [2.2 to 3.0]) but rose more sharply over the subsequent decades (p for race-time interaction=0.003), and in 2007/16 came to exceed that of Whites (5.0% [4.4 to 5.6]). Corresponding age-sex-adjusted ORs for gout in Blacks vs. Whites were 0.93 (0.73 to 1.17) in 1988-94, increasing to 1.46 (1.22 to 1.74) in 2007/16 (Table 1). This disproportionate rise in gout prevalence among Blacks tended to be more prominent among women (OR 1.81 [1.29 to 2.53]) than men (OR 1.26 [1.02 to 1.55]; p for race-time interactions of 0.002 and 0.01, respectively). Similar trends were observed in the ARIC cohort, where the OR for gout among Blacks vs. Whites rose progressively from 0.82 (0.65 to 1.02) in 1987-89 to 1.49 (1.10-2.09) in 2011-13.
Conclusion: Gout prevalence tended to be lower in Blacks than Whites until late 80’s, then rose and surpassed that of Whites over the past several decades. These trends closely parallel the worsening obesity epidemic during this period, particularly in Blacks, partly due to enhanced Western lifestyle. Gout risk genetic profile change would not contribute to this emergence of racial differences, particularly among the same individuals in ARIC, although it remains to be clarified whether Blacks carry genetic profiles that enhance the effect of lifestyle risk factors for gout.

REFERENCES:

1. PMID: 22225548 (2012)
2. PMID: 24330409 (2013)
3. PMID: 24335384 (2014)
4. PMID: 30618180 (2019)
5. PMID: 12365955 JAMA
6. PMID: 15014177 NEJM
7. PMID: 24330409 (2013)
8. PMID 22225548 (2012)

Table 1. Temporal Trend of Racial Disparity in Gout Prevalence in NHANES Survey and the ARIC Study Cohort, overall and by sex

<table>
<thead>
<tr>
<th></th>
<th>Odds Ratio (95% CI) for Gout Among Blacks vs. Whites</th>
</tr>
</thead>
<tbody>
<tr>
<td>OVERALL</td>
<td></td>
</tr>
<tr>
<td>NHANES</td>
<td>1988-1994</td>
</tr>
<tr>
<td>Age- and sex-adjusted</td>
<td>0.93 (0.73 to 1.17)</td>
</tr>
<tr>
<td>ARIC</td>
<td>Visit 1: 1987-89</td>
</tr>
<tr>
<td>Age- and sex-adjusted</td>
<td>0.82 (0.65 to 1.02)</td>
</tr>
<tr>
<td>WOMEN</td>
<td></td>
</tr>
<tr>
<td>NHANES</td>
<td>1988-1994</td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>0.98 (0.65 to 1.47)</td>
</tr>
<tr>
<td>ARIC</td>
<td>Visit 1: 1987-89</td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>0.92 (0.64 to 1.32)</td>
</tr>
<tr>
<td>MEN</td>
<td></td>
</tr>
<tr>
<td>NHANES</td>
<td>1988-1994</td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>0.91 (0.68 to 1.21)</td>
</tr>
<tr>
<td>ARIC</td>
<td>Visit 1: 1987-89</td>
</tr>
<tr>
<td>Age-adjusted</td>
<td>0.73 (0.54 to 0.97)</td>
</tr>
</tbody>
</table>

Figure 1.

FLT1 AND EPHB2 ARE NOVEL GENETIC MARKERS ASSOCIATED WITH PANCREATITIS IN PATIENTS TAKING AZATHIOPRINE FOR IMMUNE-MEDIATED CONDITIONS: INTEGRATING GENOME- AND TRANSCRIPTOME-WIDE ASSOCIATION STUDIES

S. Shah1, T. Reese1, J. Zanussi2, A. Dickson1, L. Danieli2, R. Tao2, T. Miller-Fleming3, P. Straub4, A. Hung5, P. Nepal5, W. Q. Wei6, E. Phillips1, N. Cox1, C. M. Steinfeld7, Q. Feng2, C. P. Chung1. 1University of California, San Diego and VA San Diego Healthcare System, Gastroenterology, San Diego, United States of America; 2Vanderbilt University Medical Center, Division of Rheumatology, Nashville, United States of America; 3Vanderbilt University Medical Center, Biostatistics, Nashville, United States of America; 4Vanderbilt University Medical Center, Genetics, Nashville, United States of America; 5Vanderbilt University Medical Center, Biomedical Informatics, Nashville, United States of America; 6Vanderbilt University Medical Center, Nephrology, Nashville, United States of America; 7Vanderbilt University Medical Center, Infectious Diseases, Nashville, United States of America; 8Vanderbilt University Medical Center, Pharmacology, Nashville, United States of America

Background: Azathiprine (AZA) is a thiopurine immunosuppressant medication used to treat a variety of immune-mediated diseases. Unfortunately, its use is limited by adverse effects. Pancreatitis, a potentially severe, life-threatening side effect is independent of dose and necessitates AZA discontinuation given the high risk of recurrent pancreatitis with continued use or re-challenge. The mechanisms driving pancreatitis are unclear. While classic thiopurine-induced acute pancreatitis (TAPI) has been associated with HLA haplotypes, most patients taking AZA and presenting with pancreatitis do not fulfill the stringent criteria for TAPI.

Objectives: To identify genetic risk factors for pancreatitis in patients taking azathiprine for immune-mediated conditions.

Methods: Using a biobank linked to electronic health records (EHR) from a tertiary care hospital, we identified new users of AZA. Patients were excluded if the primary indication for AZA was organ transplant or if there was a history of pancreatitis prior to AZA use. The analysis was restricted to patients with EHR-reported race as White due to insufficient case counts for the non-White group. We then identified patients with amylase or lipase values that exceeded twice the upper limit of normal (>2x ULN) or with ICD-9/ICD-10 codes for acute pancreatitis. Each record was manually reviewed to confirm the timing of AZA use in relation to laboratory derangements or ICD coding, as well as to further classify patients into three increasingly strict, but not exclusive categories: 1) pancreatic injury (amylase or lipase >2x ULN); 2) acute pancreatitis; or 3) TAPI. We completed genotyping with Illumina Infinium Expanded Multi-Ethnic Genotyping Array plus custom content data, employed Michigan Imputation servers for genetic imputation, and used PrediXcan (GTEx v8) to impute gene expression. We then conducted genome-wide association and transcriptome-wide association studies (GWAS, TWAS). Acknowledging the relatively small overall cohort, and possible imbalance of cases vs controls, we used the Firth logistic regression method, which is a penalized likelihood-based method.

Results: We studied 2127 AZA users (35.4% male; mean 44.5±17.2 years). The median AZA dose was 100mg/day (IQR: 50-125mg/day). Rheumatologic conditions (56.9%) and inflammatory bowel disease (40.4%) comprised the most common primary indications for AZA. Pancreatic injury, pancreatitis, and TAPI were diagnosed in 42 (2.0%), 16 (0.8%), and 9 (0.4%) patients, respectively. GWAS identified several significantly associated genes, many with overlapping TWAS findings in the pancreas and liver (Figure 1). From these, the two protein-encoding genes Fms Related Receptor Tyrosine Kinase-1 (FLT1) and Ephrin type-B receptor-2 (EPHB2) overlapped in two or more pancreatitis phenotypes in the TWAS and GWAS, respectively. EPHB2 was associated with a 8.6-fold (P=1.84 x 10^-6) and a 31.4-fold (P=2.87 x 10^-8) higher likelihood of pancreatic injury and TAPI, respectively.

Conclusion: FLT1—a gene that encodes a receptor tyrosine kinase and is a member of the vascular endothelial growth factor receptor (VEGFR) family—and EPHB2—a gene that encodes a member of the Eph receptor family, which is the largest subgroup of the receptor tyrosine kinase family—are novel genetic markers associated with pancreatitis in patients taking AZA. VEGF can potentiate inflammation and the pancreas microenvironment is known to promote VEGF expression, which has been linked to pancreatic cancer development; anti-VEGF treatments have been investigated both for mitigating inflammation and also anti-pancreatic cancer treatment. Future studies validating our findings in AZA-induced pancreatitis are warranted.
Supporting information

Table 1. Clinical characteristics of all referred patients with PsO and suspicion of axPsA.

| Patient characteristic | pPsA (N=5) | axPsA (N=14) | No PsA (N=81) | p-value
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) – Mean (SD)</td>
<td>42.8 (9.0)</td>
<td>46.2 (13.8)</td>
<td>45.7 (13.3)</td>
<td>0.883</td>
</tr>
<tr>
<td>Female – n (%)</td>
<td>2 (40.0)</td>
<td>9 (66.7)</td>
<td>45 (55.6)</td>
<td>0.543</td>
</tr>
<tr>
<td>PKS – Mean (SD)</td>
<td>3.3 (2.1)</td>
<td>4.3 (4.9)</td>
<td>4.0 (4.5)</td>
<td>0.971</td>
</tr>
<tr>
<td>Inflammatory back pain – n (%)</td>
<td>5 (100.0)</td>
<td>8 (57.1)</td>
<td>36 (44.4)</td>
<td>0.204</td>
</tr>
<tr>
<td>HLA-B27 positive – n (%)</td>
<td>0</td>
<td>8 (57.1)</td>
<td>4 (12.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Elevated CRP (&gt;3 mg/L) – n (%)</td>
<td>5 (100.0)</td>
<td>8 (57.1)</td>
<td>36 (44.4)</td>
<td>0.041</td>
</tr>
<tr>
<td>Peripheral arthritis, current (last 7 days) – n (%)</td>
<td>5 (100.0)</td>
<td>8 (57.1)</td>
<td>36 (44.4)</td>
<td>0.041</td>
</tr>
<tr>
<td>Radiographic sacroiliitis as per mNY criteria – n (%)</td>
<td>0</td>
<td>8 (57.1)</td>
<td>36 (44.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Active inflammation, sacroiliac joint (MRI) – n (%)</td>
<td>0</td>
<td>5 (35.7)</td>
<td>36 (44.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Structural (post)inflammatory changes, sacroiliac joint (MRI) – n (%)</td>
<td>0</td>
<td>8 (57.1)</td>
<td>36 (44.4)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

1 Statistically significant differences between the axPsA and No PsA groups of patients were determined by using Mann–Whitney U test for continuous data and Chi-square test for categorical data.
(CRP) and Myostatin (MSTN) were assessed by ELISA. Differences between robust and frail patients were tested using Mann-Whitney and Kruskal-Wallis test for continuous variables and Chi-square test for discrete variables. For each variable, normality was tested using Shapiro-Wilk normality and Kolmogorov-Smirnov tests. Non-normal variables were natural logarithm transformed to achieve normality. The association between each biomarker and frailty was assessed using multivariate logistic models. Additionally, a sensitivity analysis was performed including a second biomarker in the model in order to detect those biomarkers that influenced the association. All analyses were done using R.

**Results:** Inflammatory markers CRP and GDF-15 were increased in frail patients, OR (95% CI) 1.59 (1.22-2.05; p<0.001) and OR 1.93 (1.01-3.68; p=0.006), respectively, in comparison to robust. There were no significant changes in the inflammatory parameters TNF-α, sgp130, sIL-6R between groups. The anabolic marker IGF-1 did not change significantly between groups, while the anti-anabolic mediator MSTN was reduced in frail patients, OR 0.40 (0.19-0.86; p=0.02). Finally, CK levels were decreased in frail patients when compared to robust subjects, OR 0.37 (0.18-0.76; p=0.007). In sensitivity analysis, this association remained statistically significant with ORs ranging from 0.33 to 0.40 regardless of a second biomarker.

**Conclusion:** We identified chronic inflammation in a cohort of frail patients given the significant increase in CRP and GDF-15, although we did not find association with other inflammation parameters such as TNF-α, sgp130 or sIL-6R, highlighting the difficulty of characterizing the status of systemic inflammation. The decrease in CK levels in frailty suggest that this marker could be an indicator of cumulative muscle mass loss due to chronic inflammation. Since CRP can be sensitive and altered by a multitude of pathological conditions in frail patients, we propose CK as a more specific marker of inflammation-induced muscle impairment.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4571

---

**Table 1. Baseline characteristics by region.**

<table>
<thead>
<tr>
<th></th>
<th>Northern region n=471</th>
<th>Central region n=248</th>
<th>Southern region n=61</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (IQR)</td>
<td>49.7 (42-58)</td>
<td>49.9 (38-58)</td>
<td>51.6 (43-61)</td>
</tr>
<tr>
<td>Female, n(%)</td>
<td>248 (52)</td>
<td>193 (78)</td>
<td>193 (78)</td>
</tr>
<tr>
<td>Body Mass Index, median (IQR)</td>
<td>26 (22-29)</td>
<td>26 (22-29)</td>
<td>26 (22-29)</td>
</tr>
<tr>
<td>Disease duration, median (RIC)</td>
<td>9.7 (5-16)</td>
<td>9.5 (4-14)</td>
<td>9.8 (5-16)</td>
</tr>
<tr>
<td>Diagnostic, n(%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>173 (70)</td>
<td>130 (64)</td>
<td>39 (64)</td>
</tr>
<tr>
<td>Idiopathic Juvenile Arthritis</td>
<td>3 (1)</td>
<td>23 (9)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Ankylosing Spondylitis</td>
<td>47 (19)</td>
<td>59 (13)</td>
<td>9 (15)</td>
</tr>
<tr>
<td>Laboratory studies, n(%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>97 (39)</td>
<td>274 (58)</td>
<td>38 (62)</td>
</tr>
<tr>
<td>CRP</td>
<td>15 (6)</td>
<td>68 (14)</td>
<td>12 (19)</td>
</tr>
</tbody>
</table>

**Socio-demographic, clinical, and treatment differences of rheumatic diseases in three Mexican regions.**


**Background:** Rheumatic diseases prevalence and characteristics in Mexico may vary depending on the country’s region. To acknowledge these differences is needed to develop focused strategies for early diagnosis and treatment. Objectives: Identify the socio-demographic, clinical and treatment characteristics of the rheumatic diseases in the different regions in Mexico using data from the Mexican Adverse Events Registry (BIOBADAMEX).

**Methods:** In this analysis we included all patients registered from 2016 to 2021. We described the prevalence in the northern region of Mexico (NR, central CR) and southern region (SR). We compared socio-demographic, clinical and treatment characteristics between these three regions. We used descriptive statistics, Chi square and Kruskal Wallis tests to analyze differences between the groups.

**Results:** A total of 780 patients were included in this study. 248 patients (32%) were from the NR, 471 (60%) were from the CR and 61 (8%) from the SR. At baseline, patients had a median (IQR) age of 50 (40-58) years and median disease duration of 7 (3-15) years. NR patients had longer disease duration (9.7 years, p<0.001) and SR patients had higher BMI (29, p<0.001). Overall, 351 (45%) had comorbidities. In CR and SR more than the half of the patient had comorbidities, while in NR only 29% (p<0.001).

The most common diagnosis was rheumatoid arthritis with 512 (66%) patients, followed by ankylosing spondyritis in 115 (15%), psoriatic arthritis in 44 (6%), systemic lupus erythematosus in 30 (4%) and idiopathic juvenile arthritis in 27 (3%), these proportions were maintained when analyzed by regions. We found SR had higher DAS 28 and higher BASDAI (Table 1).}

**Disclosure of Interests:** None declared, Deshire Alpizar-Rodriguez Consultant of: Scientific advisor for GSK, unrelated to this study, Employee of: Scientific advisor for GSK, unrelated to this study.

**DOI:** 10.1136/annrheumdis-2022-eular.4842
Validation of outcome measures and biomarkers

**POS1448**

**DICKKOPF HOMOLOG 3 (DKK3) AS A PROGNOSTIC MARKER IN LUPUS NEPHRITIS: A PROSPECTIVE MONOCENTRIC EXPERIENCE**

S. Sciacia1, M. Radin1, A. Barinoti1, I. Cecchi1, D. Rossi1, R. Fenoglio1, D. Roccatoleti1, 1University of Torino, Department of Clinical and Biological Sciences of the University of Turin, Torino, Italy

**Background:** Lupus nephritis (LN) is a major cause of mortality/morbidity in patients affected by systemic lupus erythematosus (SLE). Reliable prognostic markers, especially related to the degree of interstitial fibrosis, are still lacking and renal biopsy still represents the gold standard. Recent data suggests a role of Dickkopf homolog 3 (DKK3) as a marker of tissue fibrosis in different diseases, however its role in autoimmune diseases still needs to be elucidated.

**Objectives:** To investigate DKK3 serum levels in SLE patients with and without LN, assessing its changes in relation to kidney function, flares and interstitial renal fibrosis, as well as its association with the IFN signature.

**Methods:** 132 SLE patients, 57 of whom diagnosed with LN, were included in this study, as well as 50 healthy donors. DKK3 and Myxovirus resistance protein 1 (MxA) were measured in serum samples, using enzyme-linked immunosorbent assays. Biopsies were evaluated for glomerular involvement, interstitial renal fibrosis and tubular atrophy according to 2003 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification and the revised 2018 version. Patients were followed up for at least 36 months.

**Results:** DKK3 serum levels were significantly higher in patients with biopsy-proven LN when compared to those without (median[min-max]: 215ng/ml [81-341] vs 21.1ng/ml [1-690], p<0.01). When focusing on patients with LN, DKK3 levels resulted to be associated with the presence of chronic kidney disease (OR: 4.31 [CI 95% 1.06-16.1]) per DKK3 doubling, p<0.01), higher chronicity index at biopsy (OR: 1.75 [CI 95% 1.59-21.3] per DKK3 doubling, p<0.01) and flares rate (OR: 1.45 [CI 95% 1.15-7.71] per DKK3 doubling, p<0.044), DKK3 levels correlated with the IFN signature as expressed by MxA (correlation coefficient: 0.71, p<0.037).

**Conclusion:** While kidney biopsy remains the gold standard for diagnostic and prognostic assessment in LN, DKK3 could represent a useful additional prognostic tool to monitor SLE patients and eventually to guide therapeutic choices.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1254

**POS1449**

**VALIDATION OF THE GERMAN LUPUSPRO QUESTIONNAIRE TO MEASURE LUPUS-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN LUPUS ERYTHEMATOSUS PATIENTS**

V. Mevisser1, T. Filla1, C. Duesing1, M. Schneider1, J. Meenakshi2, G. Chehab1, 1Policlinic for Rheumatology & Histology Research Unit for Rheumatology, Medical Faculty, Heinrich Heine University Duesseldorf, University Clinic, Duesseldorf, Germany; 2Medical Center, Rush University, Chicago, United States of America

**Background:** To date, there is no validated lupus-specific questionnaire for health-related quality of life (HRQoL) in German language. Regular assessment of health-related quality of life is recommended for monitoring and outcome in current management guidelines [1][2]. Given that about 20% of the EU population are native German speakers, it is therefore essential to validate a Lupus-specific questionnaire in German.

**Objectives:** The aim of this study is to present the validity (content, construct, and criterion) and reliability (internal consistency and test-retest) of the German translation of the LupusPro questionnaire, which captures both generic and lupus-specific HRQoL domains.

**Methods:** The German LupusPro was professionally translated and then administered to consecutive patients with systemic lupus erythematosus treated at our tertiary centre. At each visit, clinical and laboratory data were collected, including disease activity and damage (SLEDAI-2K resp. SLICC/SDI). Additional questionnaires were used for validity testing, including questionnaires for HRQoL (SF-36v2), fatigue (FACIT), depression (CES-D), sleep (PSQI) and health impairments (IMET).

We calculated Cronbach’s alpha to test reliability. An alpha >0.70 is considered acceptable. Test-retest reliability was tested by evaluating the consistency between the LupusPro at two time points (T0 and T1 after 2-3 days). Criterion and construct validity was assessed by comparing the results of the LupusPro with the generic HRQoL questionnaire, established clinical endpoints (disease activity, disease damage), and the domains of the additional questionnaires. The confirmatory factor analysis was performed with the Lavaan package (Ver. 0.6-9) in R using the relative fit indices, the Tucker-Lewis index (TLI) and the comparative fit index (CFI).

**Results:** 148 patients with confirmed SLE took part in the study of which 111 participated in the test-retest analysis. About 84% were female with a mean age of 45.5 (SD 12.0) and mean disease duration of 17.7 (SD 9.7) yrs. The mean SLEDAI-2K was 3.1 (SD 3.2) and SLICC/SDI 1.4 (SD 2.1).

The LupusPro domain’s internal consistency by Cronbach’s alpha exceeded >0.7 except for the domains lupus symptoms (α=0.64), lupus medication (α=0.59), procreative ability (α=0.58), and coping strategies (α=0.43). The overall test-retest correlation was excellent (ICC=0.94). The correlation of the corresponding LupusPro and SF-36v2 domains were moderate to strong (ρ=0.54–0.78), whereas correlation with disease activity and damage (SLEDAI-2K and SLICC/SDI) was weak (ρ=0.23 resp. -0.08). Correlation of the selected LupusPro domains with the above mentioned other dedicated outcome measure instrument emphasized construct and criterion validity.

The results of the confirmatory factor analysis showed good construct validity of the LupusPro. The observed model fit for the hypothesized item-scale relationships was very good (CFI = 0.96, TLI = 0.98). Items generally had loadings of >0.6 with their respective factor. Exceptions were especially the domain coping strategies where all items loaded <0.4.

**Conclusion:** The GermanLupusPro is a valid instrument for measuring health-related quality of life. It shows comparable psychometric properties as the original versions. Minor difference in individual domains may be explained by sociocultural factors.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1328

**POS1450**

**PSYCHOMETRIC PROPERTIES OF THE CENTRAL SENSITIZATION INVENTORY IN PATIENT WITH FIBROMYALGIA**

F. Salaffi1, S. Farah1, C. Mariani1, P. Sarzi-Puttini1, M. Di Carlo1, 1Università Politecnica delle Marche, Dipartimento Di Scienze Cliniche e Molecolari, Ospedale “Carlo Urbano”, Jesi, Italy; “ASST Fatebenefratelli-Sacco, Rheumatology Unit, Internal Medicine Department, Milano, Italy

**Background:** Patients with fibromyalgia (FM) complain many symptoms besides musculoskeletal pain: e.g. fatigue, sleep difficulties, a swollen feeling in tissues, paresthesia, cognitive dysfunction, dizziness, and symptoms of overlapping conditions such as irritable bowel syndrome, headaches and restless legs syndrome. These conditions can be grouped under the umbrella term of central sensitization (CS) syndromes.

**Objectives:** The goal of the present study was to explore additional evidence of convergent and discriminant validity of the Central Sensitization Inventory (CSI) in a large sample of subjects with fibromyalgia (FM).

**Methods:** Patients were consecutively enrolled for a cross-sectional assessment of the specific measures of the revised Fibromyalgia Impact Questionnaire [FIQ1], the modified Fibromyalgia Assessment Status [modFAS], and the Polysymptomatic Distress Scale [PDS] and of CSI. To test the convergent validity, the Spearman’s rho was used to measure the degree of correlation between the variables CSI and the FM-specific measures. To assess discriminant validity, CSI scores were grouped according to FIQ1 severity states, and differences between these groups studied with the Kruskal-Wallis test. Interpretive cut-offs were established with the univariate reconciliation approach.

**Results:** The study included 562 FM patients, 199 (35.4%) were classified as having central sensitization syndrome (CSI ≥40). CSI was largely correlated with modFAS (r = 0.580; p < 0.0001), FIQ1 (r = 0.542; p < 0.0001), and PDS (r = 0.518; p < 0.0001). The differences between the CSI scores in accordance with the FIQ1 was significant (p < 0.000001). CSI cut-offs proposed for FM: 21 between remission and mild severity, 30 between mild and moderate severity, 37 between moderate and severe disease, and 51 between severe and very severe disease.

**Conclusion:** The current study successfully showed additional evidence of the convergent and discriminant validity of the CSI in FM patients.

**REFERENCES:**


Belgium; trial TICOSPA [1], data of active axSpA patients randomized to either the T2T
Methods: randomized, active-controlled trial.
Objectives: discriminant capacity. has been proposed but not yet tested in an independent intervention trial to study its
spondyloarthritis (axSpA). ASAS HI thresholds for measuring improvement have
Health Index (HI) is an important outcome of interventions in patients with axial
Background: Improvement in functioning and health as assessed by the ASAS
HI in a trial.

**Results:** The table shows the ES between treatment arms for all tested improve-
ments and health states achieved in ASAS HI. Overall, absolute improvement outcomes performed better than percentage changes outcome followed by sta-
status outcomes. The absolute improvement of ≥2.0, ≥2.5, and ≥3.0 performed best
followed by the 20% improvement. As the ASAS HI ≥3.0 is the smallest detect-
able change for this outcome, this seems to be the most appropriate proposed
outcome.

**Table 1. Thresholds by treatment groups.**

<table>
<thead>
<tr>
<th></th>
<th>Non-responder imputation at 48 weeks</th>
<th>Effect size measures</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TC/T2T</td>
<td>UC</td>
</tr>
<tr>
<td>ASAS HI 20% improvement</td>
<td>56.9%</td>
<td>45.8%</td>
</tr>
<tr>
<td>ASAS HI 25% improvement</td>
<td>51.4%</td>
<td>41.7%</td>
</tr>
<tr>
<td>ASAS HI 30% improvement</td>
<td>43.1%</td>
<td>34.7%</td>
</tr>
<tr>
<td>ASAS HI 35% improvement</td>
<td>40.3%</td>
<td>31.9%</td>
</tr>
<tr>
<td>ASAS HI 40% improvement</td>
<td>37.5%</td>
<td>31.9%</td>
</tr>
<tr>
<td>ASAS HI 50% improvement</td>
<td>29.2%</td>
<td>22.2%</td>
</tr>
<tr>
<td>ASAS HI 60% improvement</td>
<td>26.4%</td>
<td>18.1%</td>
</tr>
<tr>
<td>ASAS HI 70% improvement</td>
<td>16.7%</td>
<td>12.5%</td>
</tr>
<tr>
<td>ASAS HI 80% improvement</td>
<td>13.9%</td>
<td>11.1%</td>
</tr>
<tr>
<td>ASAS HI 90% improvement</td>
<td>9.7%</td>
<td>9.7%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥10</td>
<td>66.7%</td>
<td>61.1%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥2.0</td>
<td>55.6%</td>
<td>41.7%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥2.5</td>
<td>44.4%</td>
<td>31.9%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥3.0</td>
<td>41.7%</td>
<td>29.2%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥3.5</td>
<td>29.2%</td>
<td>22.2%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥4.0</td>
<td>29.2%</td>
<td>22.2%</td>
</tr>
<tr>
<td>ASAS HI improvement ≥5.0</td>
<td>16.7%</td>
<td>12.5%</td>
</tr>
<tr>
<td>ASASHI, end of study &lt; 12.0</td>
<td>87.5%</td>
<td>80.6%</td>
</tr>
<tr>
<td>ASASHI, end of study ≥ 12.0</td>
<td>37.5%</td>
<td>33.3%</td>
</tr>
</tbody>
</table>

A value of PHI = 0.1 is considered to be a small effect, 0.3 a medium effect, and 0.5 a large
effect.

**Conclusion:** In this active-controlled trial an absolute improvement in the ASAS
HI discriminated best between treatment arms. A similar evaluation is needed in a placebo-controlled trial to be able to propose the best outcome for the ASAS
HI in a trial.

**References:**


**Disclosure of Interests:** None declared

EFFECT OF PHYSICAL ACTIVITY ON CHRONIC FATIGUE IN RHEUMATOID ARTHRITIS PATIENTS

A. Aleksandrova, V. Nikitin, N. Aleksandrova, Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy», Department of Functional Research Methods, Volgograd, Russian Federation; «Volgograd State Medical University, Department of Hospital Therapy, Volgograd, Russian Federation; National Medical Research Center of Rehabilitation and Balneology, Sanatorium-Resort Complex «Vulan» - Scientific and Clinical Branch, Moscow, Russian Federation

Objectives: To evaluate the dynamics of fatigue indices in RA patients depending on the intensity of physical activity (aerobic exercise) in the short term.

Methods: The study included 111 women with RA (mean age 54.4±11.03 years old, mean disease duration 11.9±9.3 years, DAS28-ESR score 2.84 [2.32;3.05]; mean VAS fatigue score 71.6±8.93). All patients underwent a 3-week post-hospital rehabilitation program (PHRP), and aerobic exercise was the main component of this program (dosed walking, daily, up to 1 hour) and outdoor walks up to 3-3.5 hours per day [1]. The level of fatigue was estimated using the British Rheumatoid Arthritis Fatigue Scale - Numerical Rating Scale (BRAF-NRS V2). The 50-meter walking test was used to assess the functional state of patients in dynamics, the 6-minute walking distance test (6MWD) - to assess patients' tolerance to physical activity. The intensity and duration of exercise were compared with serum levels of free fatty acids (FFA), triglycerides (TG), and angiopoietin-like protein type 4 (ANGPTL4), an inhibitor of lipoprotein lipase, which plays an important role in the regulation of lipid metabolism and energy balance.

Results: After completion of PHRP, RA patients showed a significant decrease in fatigue attributes of the NRS severity scale (6.83 ± 1.21 vs. 6.51 ± 1.18 points, p=0.003), NRS-effect (6.24 ± 1.07 vs. 5.95 ± 1.08 points, p=0.037); a decrease in time taken to complete the 50 m. walk test was noted (79.3 ± 8.64 vs. 78.91 ± 8.15, p=0.01) [2]. Increased concentration of ANGPTL4 (p=0.02), FFA (p<0.01) and decreased TG level (p<0.05) were also determined in serum of RA patients. There was a significant correlation between ANGPTL4 and FFA (r=0.54, p<0.02), but not with TG (r=-0.18, p>0.05). The increase in serum ANGPTL4 during exercise may be mediated by increased serum FFA content and increased lipid oxidation processes. Previously, it was shown that muscle tissue, along with liver and adipose tissue, significantly affect to the increase in circulating ANGPTL4 during exercise [3, 4].

Based on the results of the first phase of the study, patients (n=102) were retrospectively divided into two groups: Group I (n=53) included patients with <5-6 thousand steps/day (sedentary lifestyle); Group II (n=49) included patients with ≥7-8 thousand steps/day (mobile lifestyle). Group II of RA patients significantly improved their physical parameters - reduction of walking time (p<0.001) and number of steps in the 50-meter test (p=0.013) at the end of PHRP. There was a reduction in fatigue severity on all scales: VAS (p<0.001), NRS severity (p=0.001), NRS effect (p<0.001), and NRS-overcoming (p=0.001). In group I, there was an increase in VAS fatigue (p=0.008) and NRS effect (p=0.01). No intergroup differences were found among lipid metabolism indices before and after PHRP (p=0.05).

Conclusion: Aerobic exercise (walking) is an effective method of increasing physical activity and reducing fatigue in patients with RA during the post-hospital rehabilitation phase. Increased physical activity during walking ≥7-8 thousand steps/day has a positive effect on physical indices and fatigue components in the short term. Lipid metabolism markers can be used in determining the degree of activity, optimization of the duration and intensity of exercise in RA patients.

REFERENCES:


NEUROPLASTICITY STIMULATION-BASED REHABILITATION IMPROVES PAIN AND HAND FUNCTIONALITY IN PATIENTS DIAGNOSED WITH CARPAL TUNNEL SYNDROME: A PILOT STUDY

E. Muňoz-Gómez1, S. Molá-Casanova1, N. Sempere-Rubío1, M. Aguilar-Rodríguez1, M. Ingles1, P. Serra-Añó1, Research Unit in Clinical Biomechanics (UBIC), Physiotherapy, Universitat de València, Valencia, Spain

Background: Carpal tunnel syndrome (CTS) is the most commonly diagnosed entrapment neuropathy, characterized by sensory and motor disorders. Physiotherapy interventions based on neuroplasticity stimulation, such as mirror therapy (MT) and cross-education (CE) have been demonstrated effective in pain and impaired function. In those therapies, mirror neurons that are activated when observing an action are considered the possible underlying neural mechanism, creating organized new pathways between two cerebral hemispheres and enabling brain plasticity. However, MT and CE effects have not been widely studied on unilateral CTS.

Objectives: To analyze the effectiveness of MT and CE rehabilitation protocols in a sample of patients with CTS on pain intensity and functionality.

Methods: A randomized-controlled trial was conducted. Subjects diagnosed with unilateral CTS were enrolled in this study. MT group (MTG) (N=36) patients with OA (78% females, age of 43 to 68 years, generalized OA, OA of the knee or hip joints) where included in the randomized placebo-controlled study. Coronavirus infection COVID-19 were diagnosed from 12 to 26 weeks before the study. The main symptoms of post-COVID syndrome were dry cough, smell loss, breathlessness, weakness, fatigue, sleep disorders, cognitive symptoms, memory problems, anxiety, depression, headache, dizziness, joint and muscle pain. All patients were randomized into 3 groups. 13 study group patients received 10 Reoxy therapy procedures, 9 placebo group patients – 10 placebo procedures of Reoxy therapy, 14 control group patients – only standard rehabilitation. The patients of all groups underwent 2-week standard rehabilitation program: 10 procedures of electrotherapeutic massage for muscles and periaricular tissues, 10 sessions of general magnetic therapy, 10 group sessions of physical exercises with elements of breathing exercises. All patients received NSAIDs and SYSADOA at standard dosages. Intra-articular corticosteroids was not used. The study group patients were breathing hypoxic (FiO2 13–15%) and hyperoxic (FiO2 up to 40%) gas mixture through the mask in the interval mode with biofeedback using device «ReOxy» (Al Medig S.A., Luxembourg). 10-min hypoxic test (FiO2 12–13%) was performed before the first and fourth procedures. The duration of 1–4 procedures was 30 min, 5–10 procedures – 40 min. The placebo procedures were performed using the mask with the atmospheric air hole. Joint pain and general health on 100-mm VAS, Lequesne and WOMAC indexes, Spielberger-Khanin anxiety test, Beck depression inventory and breathlessness on Modified Borg scale were evaluated at baseline and at 2 weeks.

Results: After 2 weeks in the study group pain on VAS decreased by 49.6% (p<0.05), Lequesne index – by 39.3% (p<0.05), WOMAC – by 1.4 times (p<0.01), anxiety level on Spielberger-Khanin test – by 40.9% (p<0.05), depression level on Beck depression inventory – by 64.1% (p<0.01), general health on VAS improved by 69.3% (p<0.01), the level of breathlessness on Modified Borg scale in the study group initially was 2.5±0.9 score (moderate – slight breathlessness). After rehabilitation in the study group the level of breathlessness decreased to 0.3±0.4 score (extremely slight – no breathlessness). In the study group there were statistically significant differences from the placebo group (p<0.05) and the control group (p<0.05) in all parameters.

Conclusion: 2-week complex rehabilitation program, including interval hypoxo-hyperoxic training (Reoxy therapy), reduces pain, breathlessness, depression and anxiety, improves functional status and general health in patients with OA and post-COVID syndrome.

REFERENCES:

performed a rehabilitation protocol consisting of six-weeks of MT training, five
days/week. The healthy hand was trained in front of a mirror placed in the mid-
dle of the body, while the affected hand was hidden and quiet on the opposite
side. CE group (CEG) (N=10) intervention was designed to perform the same
training protocol, but without a mirror. Thus, the difference between interven-
tions was the use of the mirror. Training consisted of mobility, strength and
functional exercises. Minimum, maximum and average perceived pain were
assessed through Visual analog scale (VAS), and upper limb function through
Quick-DASH, before and after the intervention. Regarding statistical analyses,
a two-factor mixed multivariate analysis of variance (MANOVA) was carried
out with a between-subjects factor “treatment group” (MTG and CEG) and a
within-subject factor “time measurements” (pre and post-intervention) for all
variables. (Clinical trial id: NCT05115396).

**Results:** Nineteen participants (4 men and 15 women) between 30 and 60
years were included in the study. There were no statistically significant differ-
ences between groups at the beginning of the study. After treatment, there
was a significant decrease in maximum pain (p<0.05), minimum pain (p<0.05)
and average pain (p<0.05) of the affected hand in both groups, being larger
the experienced changes of the MTG compared to that of the CEG (Table 1).
Regarding hand functionality, both groups significantly improved compared with
baseline (p<0.01). This study suggests that activation of mirror neurons either
by MT or CE, is effective on hand pain and functionality in people with unilateral
CTS.

**Table 1. Pre and post-intervention results on pain and functionality.**

<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>Pre-treatment</th>
<th>Post-treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS max</td>
<td>MTG</td>
<td>4.22 (2.64)</td>
<td>2.11 (2.26)**</td>
</tr>
<tr>
<td></td>
<td>CEG</td>
<td>4.70 (2.87)</td>
<td>2.80 (2.15)**</td>
</tr>
<tr>
<td>VAS min</td>
<td>MTG</td>
<td>2.22 (2.22)</td>
<td>0.33 (0.50)**</td>
</tr>
<tr>
<td></td>
<td>CEG</td>
<td>2.50 (2.64)</td>
<td>0.90 (1.10)**</td>
</tr>
<tr>
<td>VAS mean</td>
<td>MTG</td>
<td>3.22 (2.44)</td>
<td>1.56 (1.59)**</td>
</tr>
<tr>
<td></td>
<td>CEG</td>
<td>3.85 (2.07)</td>
<td>2.30 (1.75)**</td>
</tr>
<tr>
<td>Quick-DASH</td>
<td>MTG</td>
<td>34.35 (21.36)</td>
<td>23.74 (21.71)**</td>
</tr>
</tbody>
</table>

Data are shown as mean (SD); MTG: Mirror Therapy Group; CEG: Cross-education Group;
VAS: Visual Analog Scale; *: p-value <0.05 between pre and post-intervention; **: p-value <0.01
between pre and post-intervention.

**Conclusion:** Neuroplasticity stimulation-based rehabilitation, using a MT proto-
col or a CE protocol, improves pain and functionality in patients with unilateral
CTS.

**REFERENCES:**

**Disclosures of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3958

---

**Educational Content**

**POS1456**

**TEACHING NAILFOLD CAPILLAROSCOPY USING THE “FAST TRACK ALGORITHM” VIA AN ONLINE PLATFORM: THE ASIAN EXPERIENCE**

S. A. N. 1, 2, W. H. Tan 1, E. Saffari 3, A. Loo 2, 3, Singapore General Hospital, Department of Rheumatology and Immunology, Singapore; Singapore; 1Duke-National University of Singapore; Duke-National University of Singapore, Singapore, Singapore

**Background:** Nailfold capillaroscopy (NFC) is being increasingly used in the
early identification of systemic sclerosis (SSc) related disorders. Recent studies
have shown that an optimised simple capillaroscopic definition of normal and
abnormal capillary morphology is reliable and a multi-centre consensus “fast
track algorithm” was developed by the European League against Rheumatism
(EULAR) Study Group on Microcirculation in Rheumatic Diseases (SG MC/
RD) to allow trainees to identify scleroderma patterns from non-scleroderma
patterns.

**Objectives:** To validate the “fast track algorithm” taught via an online teach-
ing platform to identify scleroderma patterns from non-scleroderma patterns on
NFC.

**Methods:** Trainees participated in the NFC teaching workshops conducted via
an online platform by the same SSc expert (AL) over 3 separate sessions. In
the first part of the workshop (training), all trainees attended a talk on NFC by
the SSc expert (AL) whereby they were taught the fast track algorithm to identify
and classify NFC image patterns using a training set of images. The “fast track
algorithm” (Figure 1) consists of three easy rules: 1) Rule number 1: the presence
of ≥ 7 capillaries (capillary density) AND the absence of giant capillaries (capillary
dimension) allows the rater to call the capillaroscopic image a “non-scleroderma
pattern (category 1)”; 2) Rule number 2: the presence of giant capillaries or the
presence of an extremely lowered capillary density (≤ 3 capillaries) in combination
with abnormal shapes (= “late” scleroderma pattern) allows the rater to call the
capillaroscopic image a “scleroderma pattern (category 2)”; 3) Rule number 3: If
the image does not meet rule number 1 or rule number 2 then the image is auto-
matically classified as a “non-scleroderma pattern (category 1)” In the second part
of the workshop (evaluation), each trainee independently rated 45 NFC images
(30 seconds for each NFC image) in the same session, and submitted their
answers in real time using an electronic form. The reading of the expert (AL) was
considered the gold standard. AL is a SSc expert who had previously attended the
EULAR workshop on NFC and has had more than 10 years of experience in NFC.
Within 2-4 weeks of the initial rating exercise, trainees re-evaluated the same
set of images for the intra-reader exercise under supervised conditions via
the online platform. We computed the inter- and intra-rater agreement using

---

**POS1455**

**EFFICIENCY OF PASSIVE MECHANOTHERAPY IN COMPLEX REHABILITATION OF PATIENTS WITH OSTEARTHRITIS**

E. Grivas 1, I. Pogonchenkova 1, 2, 3, Moscow Centre for Research & Practice in Medical Rehabilitation, Restorative and Sports Medicine, Department of Medical Rehabilitation, Moscow, Russian Federation; 2Moscow Centre for Research & Practice in Medical Rehabilitation, Restorative and Sports Medicine, Director, Moscow, Russian Federation

**Background:** Different types of physical exercises relieve pain, improve func-
tional status and quality of life in patients with osteoarthritis (OA) in addition to
drug treatment [1–4].

**Objectives:** To evaluate the efficacy of robotic mechanotherapy (continuous
passive motion) in the complex rehabilitation of patients with OA.

**Methods:** 58 patients with OA of the knee, hip, wrist and hand joints (76%
females, age of 49 to 65 years, disease duration of 3 to 11 years) were included
in the study and randomized into 2 groups. 28 study group patients
underwent robotic passive mechanotherapy (continuous passive motion) for
the knee and hip joints using “ARTROMOT K1” machine (Ormed gmbh,
Germany), for the wrist and hand joints using “Kinetic Maestra hand
and wrist CPM” machine (Kinetc, UK) (10 sessions for 20–25 min) in addition to
the standard rehabilitation program (2 weeks). 30 control group patients
received only the standard rehabilitation program, which included 10
groups of physical exercises for the joints for 45 min under the supervi-
sion of a trainer, 10 procedures of electrostatic massage for muscles and
periarticular tissues, 10 sessions of occupational therapy for 45 min (joint
protection strategies, use of assistive devices and adaptive equipment). All
patients received NSAIDs and SYSDAOD at standard dosages. Intra-articu-
lar corticosteroids were not used. Tender joint count, joint pain on 100-mm
VAS, Lequesne and WOMAC indexes, the amplitude of flexion in the knee
joint measured by goniometer, the march test (passage time of 20 meters
per sec), hand grip strength measured by a dynamometer were evaluated at
baseline and at 2 weeks.

**Results:** After 2 weeks in the study group pain on VAS decreased by 40.9%
(p<0.05), tender joint count – by 38.7% (p<0.05), Lequesne index – by 1.53 times
(p<0.01), WOMAC – by 1.21 times (p<0.01). In the study group the amplitude of
flexion in the knee joint increased by 34.2% (p<0.05), the march test decreased
by 3.5±1.2 sec (28.8%) (p<0.05), the grip strength of the more affected hand
enhanced by 22.3% (p<0.05), of the less affected hand – by 18.5% (p<0.05). In
the study group there were statistically significant differences from the control
group in all parameters (p<0.05), excluding the grip strength of the less affected
hand (p<0.05).

**Conclusion:** 2-week complex rehabilitation program, including robotic mechan-
otherapy (continuous passive motion), relieves pain, improves functional ability,
motor activity (march test, range of motion in the knee joint, hand grip strength)
in patients with OA.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3930
Results: Ninety-eight trainees from Singapore, Malaysia, Indonesia, Hong Kong, Philippines, Taiwan, Myanmar and Brunei included rheumatologists, rheumatology trainees, pediatric rheumatologists, interns and nurses. Fifty-four participants were novices with no prior NFC experience, 38 participants were “moderately experienced” (< 5 years of NFC experience) and 1 participant was “experienced” with more than 5 years of NFC experience. The mean (SD) inter-rater kappa of the 98 trainees was 0.71 (0.13). For the 61 trainees who participated in the re-evaluation session, mean (SD) inter-rater and intra-rater kappa were 0.74 (0.16) and 0.71 (0.15), respectively.


Background: Previous work has highlighted considerable heterogeneity in the organization of postgraduate rheumatology training programs. EULAR strives to harmonise rheumatology training across Europe with defined standards of key aspects of training including knowledge, skills and professional behaviors.

Objectives: To analyse existing documents on postgraduate training in rheumatology and other related specialties available within Europe and the rest of the world.

Methods: As most documents were unpublished, key documents on specialty training in Rheumatology and 28 related specialties were retrieved by hand-search. We started with the collection of documents developed by UEMS (Europe), ACGME (USA), CanMEDS (Canada) and RACP (Australia). Then we searched for specialty training documents developed by other international boards and we also sent emails to the boards or associations if no document could be found in their websites. Finally, we retrieved national documents from European Countries with a structured rheumatology training process, translated them into English using DeepL/Google translate and, in case of doubt, liaised with native speakers familiar with the documents. The content of all the above documents (including information about the structure of each document) was extracted into a standardized data extraction sheet.

Results: 133 documents were retrieved. UEMS, ACGME, CanMEDS documents were available for all the mapped specialties, while RACP documents were retrieved for only 18 specialties. No American or Canadian specialty board developed additional documents on training, while in Europe non-UEMS boards of 11 specialties did (Table 1). With regard to Rheumatology, 2 separate documents for adult and pediatric rheumatology training were available from UEMS and ACGME while one document

Table 1. Documents retrieved and extracted for each specialty. Rheumatology national training documents are not listed.

<table>
<thead>
<tr>
<th>Specialty</th>
<th>Europe</th>
<th>USA</th>
<th>Canada</th>
<th>Australia</th>
<th>ALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>6*</td>
</tr>
<tr>
<td>Allergology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Anesthesiology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Cardiology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Child and Adolescent Psychiatry</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Clinical Genetics</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Dermatology and Venereology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Emergency Medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Endocrinology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Gastroenterology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>General practice</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Geriatrics</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Gynaecology and Obstetrics</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Medical Oncology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Nephrology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Neurology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Occupational Medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Orthopaedics</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Otorhinolaryngology</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>Paediatrics</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Physical Medicine and Rehabilitation</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>4</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Public Health Medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Radiation Oncology and Radiotherapy</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Respiratory medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>5</td>
</tr>
<tr>
<td>Sport and exercise medicine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>**TOTAL</td>
<td>30</td>
<td>11</td>
<td>30</td>
<td>0</td>
<td>119</td>
</tr>
</tbody>
</table>

*2 UEMS and 2 ACGME document on adult and pediatric rheumatology.
on adult rheumatology training was retrieved for CanMEDS and RACP. Upon assessment of the content of these 133 documents, we observed that their organization could be competence-based (48%), role-based (47%), or problem-based (5%). When focusing on Rheumatology, content was fairly similar across national curricula, but several differences emerged in national curricula. These were mainly related to national regulations (e.g. rheumatology training as part of internal medicine training) and a different definition of mandatory/optimal competencies. The number of listed competences in the rheumatology documents ranged from 18 to 196.

**Conclusion:** We collected and analysed documents on specialty training in Rheumatology and other related specialties from a broad set of international sources. Most documents followed a competence-based or role-based framework; similarities and differences in the content of Rheumatology documents were detected. This mapping exercise informed the EULAR Task Force on the development of standards for the training of European rheumatologists.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3713

---

Table 1. Reading & Comprehension of Patient Educational Materials on Lupus

<table>
<thead>
<tr>
<th>RC Test (Values are Mean (SD))</th>
<th>All</th>
<th>ACR</th>
<th>LFA</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flesch Kincaid Reading Ease</td>
<td>52.73</td>
<td>47.18</td>
<td>55.50</td>
<td>0.25</td>
</tr>
<tr>
<td>(11.44)</td>
<td>(4.93)</td>
<td>(13.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flesch Kincaid Grade Level</td>
<td>10.46</td>
<td>10.73</td>
<td>10.33</td>
<td>0.78</td>
</tr>
<tr>
<td>(2.14)</td>
<td>(0.64)</td>
<td>(2.64)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gunning Fog Score</td>
<td>12.19</td>
<td>12.65</td>
<td>11.96</td>
<td>0.41</td>
</tr>
<tr>
<td>(1.78)</td>
<td>(0.31)</td>
<td>(2.19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMOG Index</td>
<td>8.94</td>
<td>9.6</td>
<td>8.61</td>
<td>0.27</td>
</tr>
<tr>
<td>(1.41)</td>
<td>(0.67)</td>
<td>(1.60)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coleman Liau Index</td>
<td>12.51</td>
<td>14.65</td>
<td>12.94</td>
<td>0.18</td>
</tr>
<tr>
<td>(2.04)</td>
<td>(1.34)</td>
<td>(2.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Automated Readability Index</td>
<td>18.02</td>
<td>11.1</td>
<td>21.47</td>
<td>0.49</td>
</tr>
<tr>
<td>(23.13)</td>
<td>(1.45)</td>
<td>(28.27)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There were no significant differences in the RC scores among patient educational materials from the ACR or LFA.

**Conclusion:** Patient educational materials on Lupus, available at the ACR & LFA websites, are not easy to read or comprehend, using standardized RC metrics. Additionally, they are not aligned with recommended reading levels suggested by leading organizations (CDC, NIH or AMA). Patient’s understanding is critical in a complex disease like lupus to optimize health outcomes. Revision of patient lupus educational resources at these websites, to target 6-7th grade RC metrics, is recommended & could be overseen by the development of a new taskforce.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3848
Creating a translated content very easily. A very easy to understand way in different languages, with experts being able to answer questions in their local language. Available in English, Spanish, French, Italian, Portuguese, German, and other languages. The proportion of patients with high adherence at baseline was 11%, at 6-months was 17% and at 12-month was 19%. At the end of the follow-up, 49% of the participants moved from being non-adherent to a moderate or high adherence level. When we compared the MMAS scores at baseline and follow-up, they showed a significant improvement (P<0.05) Figures 1-2. The majority of participants (65%) were in remission at baseline, according to DAS28. Therefore, we found no differences between the level of adherence and DAS28.

Conclusion: Our educational program improved medication adherence among patients with RA. Educational interventions are helpful to sustain remission in patients with RA. Further studies focused only on patients with moderate and high disease activity are necessary to assess the impact on clinical outcomes.

REFERENCES:

Acknowledgements: This project was funded by the Ministry of Science, Technology and Innovation MICIENCIA. Grant number: 695180763684

Disclosure of Interests: Pedro Santos-Moreno Speakers bureau: Pfizer, Jansen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly. Consultant of: Pfizer, Jansen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly, Grant/research support from: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche. Novartis, Lilly, Diana Buitrago-Garcia: None declared, Fernando Rodriguez: None declared, GUILLERMO SÁNCHEZ: None declared, Ihsane Hmamouchi: None declared, Fernando Sommerfleck: None declared, Denis Podudubny Shareholder of: Co-founder of BerlinFlame GmbH, Joachim Sieper Shareholder of: Co-founder of BerlinFlame GmbH


Educational cases

POS1461 GIANT CELL ARTERITIS-RELATED STROKE IN A MAN WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS

M. Hmq1, 2, M. Dey3, 4, R. Moots1, 5, 6Antwerp University Hospital, Rheumatology, Liverpool, United Kingdom; 7Sultanah Fatimah Specialist Hospital, Muac, Medical, Muac, Malaysia; University of Liverpool, Institute of Life Course and Medical Sciences, Liverpool, United Kingdom; 8Countess of Chester Hospital NHS Foundation Trust, Rheumatology, Chester, United Kingdom; 9Edge Hill University, Faculty of Health & Social Care, Liverpool, United Kingdom

Background: Giant cell arteritis (GCA) is a connective tissue disease involving the large and medium-sized arteries. The most common location of inflammation is the temporal arteries, which can lead to occlusion and blindness. GCA is a rare condition, with an estimated prevalence of 3-10 cases per 100,000 population.

Objectives: The aim of this study was to describe the clinical characteristics of GCA-related stroke in a 73-year-old man with elderly-onset rheumatoid arthritis.

Methods: We performed a literature review of case reports and case series related to GCA-related stroke. We also conducted a PubMed search using the terms “giant cell arteritis” and “stroke”.

Results: A 73-year-old man with seronegative elderly-onset rheumatoid arthritis (ERA) presented to the emergency department (ED) with a one-week history of new-onset headache, vomiting, and dizziness. He had a past medical history of hypertension and hypercholesterolemia. On examination, he was noted to have left temporal artery tenderness and absent temporal artery pulse. Computed tomography angiography showed occlusion of the left internal carotid artery. The patient was started on prednisone and intravenous magnesium sulfate. Over the next few days, the patient’s symptoms improved, and he was discharged from the hospital on prednisone and aspirin.

Conclusions: GCA-related stroke is a rare complication of ERA. Early recognition and prompt treatment are crucial to prevent permanent neurologic sequelae. This case highlights the importance of considering GCA in the differential diagnosis of stroke in elderly-onset arthritis patients.
A diagnosis of GCA-related cerebellar stroke with vertebral vasculitis was made and, with glucocorticoids, the patient made a good clinical recovery. His inflammatory joint pains also improved in parallel.

Conclusion: Stroke or transient ischemic stroke are rare complications, reported in 2.8-16% of patients with active GCA. Most studies report strokes as occurring between the onset of GCA symptoms and 4 weeks after commencement of glucocorticoids. In contrast, the vertebrobasilar territory is involved in 60-88% of cases of GCA-related stroke. One study reported fatal outcomes in 11 out of 40 patients (28%) with GCA-related stroke, 7 within 2-13 days of stroke. To conclude, this case demonstrates that high-dose glucocorticoids with slower tapering were able to control GCA-related stroke due to vertebral vasculitis in patient with EORA on background methotrexate and sulfasalazine.

REFERENCES:

Acknowledgements: We would like to thank Dr Lenetta Boyce for providing the PET-CT images.

Disclosure of Interests: None declared


Table 1. Causes of death determined at autopsies findings.

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>SLE (n=19)</th>
<th>RA (n=14)</th>
<th>AH (n=3)</th>
<th>GA (n=3)</th>
<th>SSc (n=2)</th>
<th>DMPPM (n=2)</th>
<th>GS (n=2)</th>
<th>Others (n=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonia (CAP)</td>
<td>5 (26.2)</td>
<td>3 (21.4)</td>
<td>1 (33.3)</td>
<td>-</td>
<td>1 (50)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Septic shock</td>
<td>2 (10.5)</td>
<td>2 (14.3)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Opportunistic Infection</td>
<td>5 (26.2)</td>
<td>6 (42.9)</td>
<td>-</td>
<td>2 (66.6)</td>
<td>1 (50)</td>
<td>2 (100)</td>
<td>-</td>
<td>1 (50)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>3 (16)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 (100)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hepatic failure</td>
<td>-</td>
<td>-</td>
<td>2 (66.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>1 (50)</td>
</tr>
<tr>
<td>MODS</td>
<td>3 (16)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>1 (5.1)</td>
<td>1 (7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>-</td>
<td>2 (14.3)</td>
<td>1 (33.3)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Others: Primary biliary cholangitis 1 case and Pemphigus vulgaris 1 case. SLE= Systemic lupus erythematosus; RA= Rheumatoid arthritis; AH= Autoimmune Hepatitis; GA= Gouty Arthritis; SSc= Systemic sclerosis; DMPPM= Dermatopolymyositis; GS= Goodpasture Syndrome; CAP= Community-acquired Pneumonia; OI= opportunistic infections; MODS= Multiple organ dysfunction syndrome.

Figure 1. Flowchart of case selection

Results: A total of 47 cases were included, 27 (57.5%) were female and 20 (42.5%) were male. The mean age was 39 years old with a range from 13 to 68 years old. The most common disease was systemic lupus erythematosus (40.5%) and rheumatoid arthritis (23.8%), followed by autoimmune hepatitis and gouty arthritis with 3 cases (6.4%) each one. The most common cause of death determined by the autopsy findings was infections (66%) of which more than half were due to opportunistic pathogens, with tuberculosis being the predominant cause with 12 cases. The second cause was organic compromise due to disease activity (23.4%), and lastly other causes (10.6%) such as pulmonary embolism or myocardial infarction, which conditions more likely to present in patients with a rheumatic and autoimmune disease. A detailed description of the case series is displayed in Table 1. Almost all patients were receiving immunosuppressive therapy. The most used agents were prednisone (85%), methotrexate (19%), and azathioprine (15%). The other immunosuppressive medications were cyclophosphamide and tumor necrosis factor inhibitors in 2 cases each one.
TUBERCULOSIS AS A FATAL OUTCOME IN PATIENTS WITH RHEUMATIC DISEASES: AN AUTOPSY-BASED STUDY

M. J. Mantilla Ribeño1, J. C. Santacruz Deval1, J. Londono1, A. M. Santos1, S. A. Serrato2, J. C. Mantilla1on behalf of Spondyloarthopathies Research Group, Universidad de La Sabana, Chia, Colombia. 1Universidad de la Sabana, Rheumatology; Spondyloarthopathies Research Group, Chia, Colombia; 2Universidad Industrial de Santander, Hospital Universitario de Santander, Pathology, Bucaramanga, Colombia

Background: Tuberculosis (TB) is still a worldwide health problem and patients with rheumatic disease (RD) have an increased risk of this infection and fatal outcomes.

Objectives: We aim to report an autopsy case series in patients with an RD whose deaths were caused by TB in a high-level hospital of the Colombian north-east and stress the importance of autopsy as a teaching and research tool.

Methods: A retrospective, descriptive study of the database from the Pathology Department at UIS in Bucaramanga, Colombia. A total of 3390 autopsies were performed between January 2009 and December 2019 in patients whose death occurred at Hospital Universitario de Santander. A total of 1713 autopsy reports were analyzed, of which 10 corresponded to patients with RD whose deaths occurred at Hospital Universitario de Santander. A total of 1713 autopsy reports were analyzed, of which 10 corresponded to patients with RD whose deaths were caused by Mycobacterium tuberculosis.

Results: A total of 12 patients with a premortem diagnosis of RD were included who additionally had autopsy findings consistent with a mortal infection by a Mycobacterium tuberculosis. Nine cases (75%) were male and 3 were female (25%). The mean age was 49 years old with a range from 32 to 69 years old. The most common RD was rheumatoid arthritis (33.3%) followed by systemic lupus erythematosus, dermatopolymyositis and gouty arthritis with 2 cases (16.6%) each one. In 9 cases the autopsy findings were extrapulmonary TB, of which more than half were disseminated and only 3 cases were exclusively pulmonary TB. All patients were receiving immunosuppressive therapy. The most commonly used therapies were prednisone (100%), methotrexate (25%), and anti-TNF agents (16.6%). A detailed description of the reported cases is displayed in Table 1 and Figure 1.

Table 1. Description of the reported cases

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age (years)</th>
<th>IST</th>
<th>Autopsy findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>32</td>
<td>RA</td>
<td>PRED, MTX, Anti-TNF</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>37</td>
<td>DMPM, PRED</td>
<td>Disseminated tuberculosis</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>42</td>
<td>SLE</td>
<td>PRED</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>43</td>
<td>DMPM, PRED, MTX</td>
<td>Pulmonary tuberculosis</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>45</td>
<td>GA</td>
<td>PRED</td>
</tr>
<tr>
<td>6</td>
<td>Male</td>
<td>45</td>
<td>RA</td>
<td>PRED</td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>49</td>
<td>GA</td>
<td>PRED</td>
</tr>
<tr>
<td>8</td>
<td>Male</td>
<td>53</td>
<td>PV</td>
<td>PRED, AZA</td>
</tr>
<tr>
<td>9</td>
<td>Female</td>
<td>56</td>
<td>RA</td>
<td>PRED, Anti-TNF</td>
</tr>
<tr>
<td>10</td>
<td>Male</td>
<td>57</td>
<td>SLE</td>
<td>PRED</td>
</tr>
<tr>
<td>11</td>
<td>Male</td>
<td>60</td>
<td>RA, PRED, MTX</td>
<td>Pulmonary tuberculosis and tuberculous endocarditis</td>
</tr>
<tr>
<td>12</td>
<td>Female</td>
<td>69</td>
<td>SSc</td>
<td>PRED</td>
</tr>
</tbody>
</table>

RD= Rheumatic Disease; RA= Rheumatoid Arthritis; DMPM= Dermatopolymyositis; SLE= Systemic Lupus Erythematosus; GA= Gouty Arthritis; PV= Pemphigus Vulgaris; SSc= Systemic Sclerosis; IST= Immunosuppressive therapy; PRED= Prednisone; MTX= Methotrexate; Anti-TNF= Tumor Necrosis Factor Inhibitor; AZA= Azathioprine.

REFERENCES:

Disclosure of Interests: None declared

Infliximab was added to the treatment at a dose of 3 mg per kg of body weight. A good clinical response was achieved (DAS28 2.67; CDAI 4.0; SDAI 9.4; prednisone canceled). After 4 months, there were complaints of acute decrease in vision in the right eye. Referred to an ophthalmologist. Visual Acuity: best corrected visual acuity (BCVA) on right eye is 0.4 (Snellen Chart). BCVA on left eye is 0.9 (Snellen Chart), intraocular pressure: right eye - 18 mmHg (non-contact), left eye - 19 mmHg (non-contact). Right eye: palpation is painful; cornea and anterior chamber humor are transparent; mild cataract in lens; inflammation cells in vitreous body (3+). Fundus (right eye): disc of optic nerve is normal; edema along upper-temporal vessels in macular region, exudates with pigmentation; periphery is normal. Left eye: findings are not clinical significant. Optical coherence tomography of retina (OCT): macular depression is normal; in paramacular region is epiretinal membrane. Laboratory: Diaskintest is negative; Toxoplasma IgG = 170 ME/ml (positive is > 800 ME/ml). Diagnosis: Toxoplasma chorioretinitis, infiltration phase of right eye. Topical therapy: dexamethasone 0.1% - 1 x 6 times / day - 20 days, nepafenac 0.1% - 1 x 3 TID - 20 days. Oral: rovamycine 3 mil. ME - 2 TID - 20 days. Infliximab and methotrexate were canceled for the entire period of therapy. OCT: decrease evidence of edema; in paramacular region is epiretinal membrane. Laboratory: Diaskintest is negative; Toxoplasma IgG = 170 ME/ml (positive is > 800 ME/ml). Diagnosis: Toxoplasma chorioretinitis, infiltration phase of right eye. Topical therapy: dexamethasone 0.1% - 1 x 6 times / day - 20 days, nepafenac 0.1% - 1 x 3 TID - 20 days. Oral: rovamycine 3 mil. ME - 2 TID - 20 days. Infliximab and methotrexate were canceled for the entire period of therapy with bDMARD infliximab. To avoid risk of activating toxoplasmosis patients with rheumatoid arthritis should be screened for this infection before start bDMARD therapy.

Background: Sialosis is a non inflammatory nor neoplastic expansion of the salivary glands. It is a common mimicker for obstructive, inflammatory and malignant salivary gland disorders. It had been described in acromegaly, vitamin A, and Thiamin deficiency and in amylophagia and bulimia. Imaging should be normal in Sialosis. Here we describe a case of Sialosis due to Vitamin deficiency who was treated for a few months with anti-tuberculoses and anti inflammatory drugs.

Objectives: To raise awareness about this cause of parotid swelling and encourage practice of exclusion prior to treatment.

Methods: A 30 year old lady with no significant past medical history presented to us with 2 years of slowly progressive, non tender bilateral facial swellings, with no excess or reduced salivation and no pain upon eating, she had negative history of preceding upper respiratory tract infection. The condition was associated with feeling a lump in her right axilla, and cervical region, there was no fever or systemic manifestations. She consulted a surgeon during that period, an excisional biopsy of the lump revealed the presence of fatty lumps, she was then prescribed antibiotics and none of the symptoms were vague and because TB is quite common in Iraq. She denied any improvement with these medications. She then was prescribed treatment with hydroxyChloroquin and prednisolone by another physician assuming she had sjogren's syndrome. When we saw the patient she was extremely distressed and depressed, had bilateral diffused parotid swellings, along with submandibular swelling, no mass could be felt during the exam, her mandibles and neck appeared large, she had normal tear film production and negative eye test, with no articular or muscular abnormalities.

Results: Her Labs were negative, and ultrasound for the parotids revealed enlarged glands with normal texture. MRI showed enlarged both parotids and submandibular glands with no other abnormality. mild salivary gland biopsy showed normal tissue with no inflammatory cell infiltrates. She had normal thyroid, parathyroid and growth hormone levels, normal metabolic panel and denied history of Alcohol consumption of Bulimia, but rarely consumed meat. A trial of Vitamin A, Thiamin and pilocarpine was started, the patient improved regression in the size of the swellings after 2 weeks of therapy but then developed mucosal dryness, afterwards, Vitamin A was stopped, she developed bone pain with normal bone markers and for that reason, pilocarpine was stopped, despite stopping these medicines, the size continued to regress on thiamin supplement alone, and she was prescribed antiulotyloty and antidepressants by a Neurologist.

Background: Sialosis is a non inflammatory nor neoplastic expansion of the salivary glands. It is a common mimicker for obstructive, inflammatory and malignant salivary gland disorders. It had been described in acromegaly, vitamin A, and Thiamin deficiency and in amylophagia and bulimia. Imaging should be normal in Sialosis. Here we describe a case of Sialosis due to Vitamin deficiency who was treated for a few months with anti-tuberculoses and anti inflammatory drugs.

Objectives: To raise awareness about this cause of parotid swelling and encourage practice of exclusion prior to treatment.

Methods: A 30 year old lady with no significant past medical history presented to us with 2 years of slowly progressive, non tender bilateral facial swellings, with no excess or reduced salivation and no pain upon eating, she had negative history of preceding upper respiratory tract infection. The condition was associated with feeling a lump in her right axilla, and cervical region, there was no fever or systemic manifestations. She consulted a surgeon during that period, an excisional biopsy of the lump revealed the presence of fatty lumps, she was then prescribed antibiotics and none of the symptoms were vague and because TB is quite common in Iraq. She denied any improvement with these medications. She then was prescribed treatment with hydroxyChloroquin and prednisolone by another physician assuming she had sjogren's syndrome. When we saw the patient she was extremely distressed and depressed, had bilateral diffused parotid swellings, along with submandibular swelling, no mass could be felt during the exam, her mandibles and neck appeared large, she had normal tear film production and negative eye test, with no articular or muscular abnormalities.

Results: Her Labs were negative, and ultrasound for the parotids revealed enlarged glands with normal texture. MRI showed enlarged both parotids and submandibular glands with no other abnormality. mild salivary gland biopsy showed normal tissue with no inflammatory cell infiltrates. She had normal thyroid, parathyroid and growth hormone levels, normal metabolic panel and denied history of Alcohol consumption of Bulimia, but rarely consumed meat. A trial of Vitamin A, Thiamin and pilocarpine was started, the patient improved regression in the size of the swellings after 2 weeks of therapy but then developed mucosal dryness, afterwards, Vitamin A was stopped, she developed bone pain with normal bone markers and for that reason, pilocarpine was stopped, despite stopping these medicines, the size continued to regress on thiamin supplement alone, and she was prescribed antiulotyloty and antidepressants by a Neurologist.

Conclusion: Sialosis can be a manifestation of variable metabolic and endocrine conditions and it should be kept in mind when facing a patient with parotid swelling being a potentially treatable cause.

REFERENCES:
Methods: association

Athropathy (is a rare autosomal recessive disorder caused by inactivating mutations in the matrix metalloproteinase 2 (MMP2) gene. It is manifested by osteolysis of the carpal and tarsal bones, progressive joint contractures, and radiological findings, it can be misdiagnosed as juvenile idiopathic arthritis and mucopolysaccharidoses respectively. Most affected children are apparently normal at birth with symptoms’ onset usually between six months and six years of age (5); the range is from birth to 11 years (2). To date, 51 individuals have been identified with biallelic pathogenic variants in MMP2 (3,6). Here we report a case of child MONA and galactosemia which is not known before.

Objectives: To share this interesting extremely rare presentation and new association.

Methods: An eight year old Iraqi boy with Galactosemia at the 4th month of life was referred to a rheumatological center. Genetic study revealed Homozygous MMP2 mutation. The immunological, hematological and ultrasound were normal. The disease and to determine the scope of further examination and adequate treatment.

Conclusion: Diagnosis of MONA Combined with galactosemia was made.

References:


Disclosure of Interests: None declared


A case report of Iraqi child with MONA syndrome and galactosemia

Y. Abbas1, N. Ihsan2, F. I. Goralı3, G. Saleh, 1,2 Al-Nahrain University, College of Medicine, Internal Medicine, Al-Kadhima, Iraq; 3Baghdad Teaching Hospital, Rheumatology, Baghdad, Iraq; 1College of Medicine, University of Baghdad, Internal Medicine, Baghdad, Iraq

Background: MONA Multicentric Osteolysis, subcutaneous Nodulosis and Arthropathy is a rare autosomal recessive disorder caused by inactivating mutations in the matrix metalloproteinase 2 (MMP2) gene. It is manifested by osteolysis of the carpal and tarsal bones, progressive joint contractures, and radiological findings, it can be misdiagnosed as juvenile idiopathic arthritis and mucopolysaccharidoses respectively. Most affected children are apparently normal at birth with symptoms’ onset usually between six months and six years of age (5); the range is from birth to 11 years (2). To date, 51 individuals have been identified with biallelic pathogenic variants in MMP2 (3,6). Here we report a case of child MONA and galactosemia which is not known before.

Objectives: To share this interesting extremely rare presentation and new association.

Methods: An eight year old Iraqi boy with Galactosemia at the 4th month of life was referred to a rheumatological center. Genetic study revealed Homozygous MMP2 mutation. The immunological, hematological and ultrasound were normal. The disease and to determine the scope of further examination and adequate treatment.

Conclusion: Diagnosis of MONA Combined with galactosemia was made.

References:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1403

SEPTAL PANNICULITIS AS A MANIFESTATION OF COVID-19 INFECTION

O. Egorova1, G. Tarasova1, A. Datsina1, 1V.A. Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 2Pirogov Russian National Research Medical University, Pirogov Russian National Research Medical University, Moscow, Russian Federation

Objectives: to study the clinical and laboratory features of septal panniculitis in the form of erythema nodosum (EN) in a cohort of patients with COVID-19 referred to a rheumatological center.

Methods: In 2020-2021 we examined 21 patients (18 women and 3 men, average age 43.2±14 years) with EN and polyarthralgia/arthritis. Depending on the time of EN and articular syndrome associated with COVID-19 development, patients were divided into three groups: 1) up to 4 weeks – acute COVID (symptoms potentially associated with infection); 2) from 4 to 12 weeks – ongoing symptomatic COVID and 3) more than 12 weeks – post-COVID syndrome (persistent symptoms not associated with an alternative diagnosis). All patients underwent a comprehensive clinical, laboratory and instrumental examination, including ultrasound of the joints and chest computed tomography (CT), as well as pathomorphological examination of skin and subcutaneous adipose tissue from the node area (in 9 cases).

Results: Based on the history data, COVID-19 in the study cohort had mild (in 3 patients), moderate (12) and severe (6) severity. Two patients (21 and 23 years old) with a mild severity of the disease on the 2nd-3rd day of the development of the respiratory symptom for the first time noted red painful (45 mm on a visual analogue scale) nodes on the legs and polyarthralgia. In 9 patients (52.3%), similar skin changes were detected 24.5 ± 7.6 days after stopping active COVID-19, i.e. during the period of ongoing symptomatic COVID. In 8 patients (38%), including 6 with moderate severity of the disease, nodules appeared after 85.6 ± 12.3 days, which corresponded to post-COVID syndrome. At the time of examination, 100 and 71.4% of patients complained of skin rashes and joint pain, respectively. Shortness of breath, weakness, cough, sweating and myalgia disturbed 67% of patients. An increase in body temperature to subfebrile was observed in 43% of cases, mainly with ongoing symptomatic COVID. In the overwhelming majority of cases (86%), UE was located on the anterior and lateral surfaces of the legs, less often on the posterior and medial surfaces. It is noteworthy that the lesion of more than 50% of the surface of the lower and upper extremities was associated with the number of nodules (p <0.02). CRP level (p <0.03) and post-COVID syndrome (p <0.02). Sixteen patients (76.1%) had signs of arthralgia, mainly ankle (81%) and knee (56%) joints. In a laboratory study, the median ESR was 39 [14; 62] mm/h, the level of CRP was 17 [2; 79] mg/l. The results of the polymerase chain reaction for SARS-CoV-2 were negative in 90.4 % of patients. In 90.4 % of cases, IgG antibodies were detected and in 52.3% - IgM to the SARS- CoV-2 virus. At CT of the chest, ≤25% of lung lesions were detected in 90.4 % of patients, in 90.4% of patients ≥25% of lesion was detected in 25% of patients, from 25 to 50% - in 33% and from 50% to 75% - in 9.5 % of cases. Pathomorphological examination of the nodes showed signs of septal panniculitis.

Conclusion: When EN associated with SARS-CoV-2 appears it is important to timely suspect a post-infectious manifestation, based on the clinical picture of the disease and to determine the scope of further examination and adequate treatment.

Disclosure of Interests: None declared

Background: Progressive multifocal leukoencephalopathy (PML) is a potentially fatal degenerative condition caused by reactivation of the human polyomavirus 2 (JC virus) in immunodeficient individuals. It is well recognised in individuals who have received Rituximab, but patients treated with other immunosuppressants are at risk also (1). Moreover, patients with SLE may be at increased risk, even when they are not taking immunosuppressants (1, 2).

Objectives: Describe the case of a patient with a history of lupus nephritis and cerebral lupus, on long-term Mycophenolate mofetil (MMF) and Prednisolone, diagnosed with PML complicated by immune reconstitution inflammatory syndrome (IRIS).

Methods: Case report.

Results: This patient first presented in 2010 at the age of 18 with ankle swelling and proteinuria. She had high ANA and anti-dsDNA titres, and treatment biopsy showed class IV lupus nephritis. She went on to remission on high dose Prednisolone and MMF and elected to stop her MMF. Four months later, she developed behaviour changes and worsening proteinuria. MRI showed a mild high signal lesion in the right cerebral hemisphere, and she was diagnosed with cerebral lupus. She recovered after treatment with IV methylprednisolone and MMF. Over the subsequent eight years, she had recurrent seizures which responded well to anticonvulsant therapy. Her dexterity in her left hand. MRI showed evidence of IRIS in the right hemisphere with cerebral oedema causing midline shift. She was treated with IV Dexamethasone then Prednisolone 30 mg daily, with a gradual taper over a year. She has made a good recovery with minimal neurological deficit; she was stopped but she continued a low dose Prednisolone with the addition of Hydroxychloroquine. She was re-admitted two weeks after discharge in December 2020 with a right-sided headache, left facial weakness and loss of dexterity in her left hand. MRI revealed pathogenic homozygous splice site mutation in intron 11 of LRBA gene. Both the parents are heterozygous carriers. A largest systematic review 3 of 212 cases of LRBA deficiency showed autoimmunity(70%), hypoparathyroidism(19%), and protein deficiency(18%).

Conclusion: This describes a case of PML in the context of longstanding lupus nephritis, treated with prednisolone and MMF. Her longstanding lymphopenia with low CD4 counts were attributed to the combined consequences of active lupus and her cumulative immunosuppressive burden. CD4 lymphopenia is associated with PML in the HIV population, and may provide information about which patients on immunosuppressive treatments are at risk of developing PML (3). However, not enough is known to routinely screen patients and the counts of other lymphocyte subsets are likely to be important too. The case highlights that PML can be associated with different immunosuppressants, other than B-cell depletion. The prompt diagnosis, facilitated by brain biopsy, and appropriate management led to a good medium-term outcome for this patient, showing that PML is eminently survivable.

REFERENCES:
[1] Calabrese LH, Molloy ES. ARD 2008;67:iili4-iili6

Disclosure of Interests: None declared

HPR Measuring health (development and measurement properties of PROs, tests, devices)...

**POS1470-HPR**  KNOWING WHAT TO DO WITH THE DATA – A QUALITATIVE STUDY ON CHALLENGES OF USING SMARTPHONE-BASED EPROS IN RHEUMATOID ARTHRITIS

Y. Seidler1, T. S. Jergensen2, P. Studenic3, H. Radner4, T. Nygaard5, N. Welbrecht6, N. Popper7, E. L. Kristensen8, T. C. Wilhelm9,10, J. Rickmann11, E. Moso12, V. Ritsch1, T. Stam1. 1Medical University of Vienna, Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria; 2Copenhagen University Hospital, Frederiksberg and Bispebjerg, Parker Institute, Department of Rheumatology, Copenhagen, Denmark; 3Medical University of Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria; 4Karolinska Institutet, Division of Rheumatology, Department of Medicine (Solna), Stockholm, Sweden; 5Daman, P/S, Copenhagen, Denmark; 6dwh, GmbH, Vienna, Austria; 7Vienna University of Technology, Institute for Information Systems Engineering, Vienna, Austria; 8Copenhagen University Hospital, Frederiksberg and Bispebjerg, Parker Institute, Department of Rheumatology, Copenhagen, Denmark; 9EULAR Young PARE, Zurich, Switzerland; 10Austrian Rheumatism League, None, Maria Alm, Austria; 11The Parker Institute’s Patient Association, Department of Rheumatology, Copenhagen, Denmark; 12Medical University of Vienna, Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Wien, Austria

**Background:** Using patient-reported outcomes (PROs) has a long tradition in rheumatology, and PRO measurement is included in many composite indices evaluating disease progression and treatment response [1]. However, little is known about patients’ and health professionals’ (HPs) perceptions of using digitally collected PROs, the so-called ePROs, with a personal smartphone application.

**Objectives:** To identify main challenges in utilising ePROs for management and treatment of rheumatoid arthritis from patients’ and HPs’ perspectives.

**Methods:** We interviewed 25 people with rheumatoid arthritis (RA) and 17 HPs (nurses, rheumatologists, and physiotherapists) from Austria and Denmark. We used the RheumaBuddy app as a practical example to illustrate the digital data collection and the feedback that patients would get from entering their self-reported outcomes. Interviews were recorded and transcribed. We applied a qualitative thematic analysis to identify major themes using a procedure of rigorous coding. Analysis was done by two researchers, and conflicts were solved by consensus. Ethical approval was obtained in both countries.

**Results:** Three main themes emerged: 1) Being simple yet comprehensive; 2) Resources to interpret, use, and act upon the collected data; and 3) Being reminded of the disease. Within the first theme, many valued the intuitiveness and simplicity of ePROs, especially when used as a monitoring tool in between clinical visits. HPs were concerned about not to overwhelm the patients with too many questions. On the other hand, the short ePROs asked in the app were not comprehensive enough to capture psychosocial and lifestyle aspects of the disease which were considered important both by patients and HPs. Within the second theme, patients and HPs expressed that ePROs could be the basis for shared decision making. Nevertheless, some patients had clearer ideas on making use of the feedback they could get from their self-reported data than the others. Participants from Denmark focused on official guidelines, whereas those from Austria were more concerned that the “doctor will make good use of it.” HPs in both countries believed that the “doctor will make good use of it.” HPs in both countries.

**Conclusion:** The potential adoption of ePROs in practice depends on both patients and HPs’ motivations and ideas to use the feedback they would get from the collected data. This might be influenced by the level of digital health maturity of a country, as well as available resources. In addition, ePROs need to be intuitive and simple, but at the same time comprehensive and reliable enough so that they can be used for shared decision making. Challenges remain for the ePROs to be used as supporting and empowering tools, and not as reminders of the disease and pain.

**Table 1.** Demographic data of the participants (N=42)

<table>
<thead>
<tr>
<th>Data</th>
<th>Austria</th>
<th>Denmark</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
<td>14</td>
<td>11</td>
<td>25</td>
</tr>
<tr>
<td>HP</td>
<td>10</td>
<td>7</td>
<td>17</td>
</tr>
<tr>
<td>Women (%)</td>
<td>10 (71)</td>
<td>6 (60)</td>
<td>7 (64)</td>
</tr>
<tr>
<td>Men (%)</td>
<td>4 (29)</td>
<td>4 (40)</td>
<td>4 (36)</td>
</tr>
<tr>
<td>Age (Mean)</td>
<td>54 (30-76)</td>
<td>41 (29-63)</td>
<td>54 (30-76)</td>
</tr>
<tr>
<td>Age (Range)</td>
<td>41-63</td>
<td>29-63</td>
<td>29-63</td>
</tr>
</tbody>
</table>

**REFERENCES:**

**Acknowledgements:** We would like to express our particular thank you to all those who have taken part in the interview study and for their valuable inputs.

**Disclosure of Interests:** Yuki Seidler: None declared, Tanja Schjødt Jørgensen: Speakers bureau: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly., Consultant of: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly, Paul Studenic: None declared, Helga Radner Speakers bureau: Gilead, Merck Sharp, Pfizer, Abbvie, Consultant of: Gilead, Merck Sharp, Pfizer, Abbvie, Thomas Nygaard: None declared, Nadine Welbrecht: None declared, Nikolai Popper Speakers bureau: Roche, Consultant of: dwh GmbH (as CSO), Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Aimgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals, Consultant: Pfizer, AbbVie, Aimgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals, Grant/research support from: JIF research grants from Novo, UCB, Eli Lilly; Novartis and Abbvie, Tanita-Christina Wilhelmer: None declared, James Rickmann: None declared, Tanja Stamm Speakers bureau: AbbVie, Novartis, Roche, Sanofi, and Takeda., Consultant of: AbbVie and Sanofi Genzyme., Grant/research support from: AbbVie and Roche.

**DOI:** 10.1136/annrheumdis-2022-eular.288

**POS1471-HPR** PAIN CATASTROPHIZING AND ITS ASSOCIATION WITH PATIENTS WITH RHEUMATOID ARTHRITIS IN A NON-INFLAMMATORY CONDITION.

T. Abe1. 1Hyogo College of Medicine, Division of Diabetes, Endocrinology and Clinical Immunology, Nishinomiya, Japan

**Background:** Pain in rheumatoid arthritis (RA) is considered to be linked with non-inflammatory factors, including physical disabilities, psychiatric disorders, and pain catastrophizing (PC).

**Objectives:** We investigated the role of PC in the possible link between physical disabilities and psychiatric disorders in RA patients in a non-inflammatory condition.

**Methods:** In this cross-sectional study, a total of 81 RA patients in a non-inflammatory condition were included; all patients had serum C-reactive protein levels <0.5 mg/dL, without any inflammatory joints. We examined the demographic and clinical data and administered the pain visual analog scale (VAS), the pain catastrophizing scale (PCS), the Health Assessment Questionnaire Disability Index (HAQ-DI), and the patient version of the Brief Scale for Psychiatric Problems in Orthopedic Patients (pBPS-POP). A series of multivariate-adjusted multiple regression analyses were performed to examine the associations between PC and pain intensity, physical disabilities, and psychiatric disorders.

**Results:** We found associations between all the above-mentioned variables in separate models associated with HAQ-DI, pBPS-POP, and PCS scores. However, in the model associated with pain VAS, the PCS score (β=-0.34, p=0.0073) emerged as the only variable showing statistically significant association.

**Conclusion:** PC is associated with pain in RA patients in a non-inflammatory condition, and this association may be mediated through pathways involving physical disabilities and psychiatric disorders.

**REFERENCES:**
### Table 1. Multiple linear regression analysis of factors associated with each outcome

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Variables</th>
<th>β</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain VAS</td>
<td>Age</td>
<td>0.044</td>
<td>-0.32 to 0.51</td>
<td>0.66</td>
</tr>
<tr>
<td></td>
<td>Sex (female)</td>
<td>0.0089</td>
<td>-4.65 to 0.09</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>Stage</td>
<td>0.0092</td>
<td>-4.34 to 0.70</td>
<td>0.94</td>
</tr>
<tr>
<td></td>
<td>Disease duration</td>
<td>0.19</td>
<td>-0.13 to 0.88</td>
<td>0.14</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td></td>
<td>0.23</td>
<td>-0.23 to 1.76</td>
<td>0.13</td>
</tr>
<tr>
<td>pBS-POP</td>
<td></td>
<td>0.038</td>
<td>-1.06 to 1.45</td>
<td>0.76</td>
</tr>
<tr>
<td>PCS</td>
<td></td>
<td>0.34</td>
<td>0.13 to 0.81</td>
<td>0.0073</td>
</tr>
<tr>
<td>Pain VAS</td>
<td>Age</td>
<td>-0.18</td>
<td>-0.15 to 0.00</td>
<td>0.464</td>
</tr>
<tr>
<td></td>
<td>Sex (female)</td>
<td>-0.0081</td>
<td>-0.95 to 0.86</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>Stage</td>
<td>-0.033</td>
<td>-0.97 to 0.71</td>
<td>0.77</td>
</tr>
<tr>
<td>Disease duration</td>
<td>0.10</td>
<td>-0.053 to 0.14</td>
<td>0.40</td>
<td></td>
</tr>
<tr>
<td>HAQ-DI</td>
<td></td>
<td>0.033</td>
<td>-0.037 to 0.050</td>
<td>0.76</td>
</tr>
<tr>
<td>PCS</td>
<td></td>
<td>0.41</td>
<td>0.10 to 0.45</td>
<td>0.0026</td>
</tr>
<tr>
<td>Pain VAS</td>
<td>Age</td>
<td>0.31</td>
<td>0.02 to 0.16</td>
<td>0.0988</td>
</tr>
</tbody>
</table>

**Note:** Standardized regression coefficient; CI: confidence interval; HAQ-DI: Health Assessment Questionnaire Disability Index; pBS-POP: the patient version of the Brief Scale for Psychiatric Problems in Orthopedic Patients; PCS: Pain Catastrophizing Scale; VAS: visual analog scale.

### Disclosure of Interests

None declared.


### POS1472-HPR

**CONSTRUCT VALIDITY OF THE PROMIS PHYSICAL FUNCTION 10-ITEM SHORT FORM IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES AND SEVERE LIMITATIONS IN PHYSICAL FUNCTIONING**

**B. Straathof,** M. Van Wissen, T. P. M. Vliet Vlieland, C. Van den Ende, M. Teuwen, A. Van den Broeder, W. Van den Hout, M. Van Schaardenburg, A. Van Tubergen, M. J. G. Gademan, S. Van Weely, Leiden University Medical Center (LUMC), Orthopaedics, Rehabilitation and Physical Therapy, Leiden, Netherlands; Sint Maartenskliniek, Research, Nijmegen, Netherlands; Radboud University Medical Center, Rheumatic Diseases, Nijmegen, Netherlands; Leiden University Medical Center (LUMC), Biomedical Data Sciences, Leiden, Netherlands; Reade, Center for Rehabilitation and Rheumatology, Amsterdam, Netherlands; Maastricht University Medical Center, Maastricht, Netherlands; Maastricht University, Care and Public Health Research Institute (CAPHRi), Maastricht, Netherlands; Leiden University Medical Center (LUMC), Clinical epidemiology, Leiden, Netherlands.

**Background:** Physical functioning in patients with inflammatory arthritis (IA) can be severely affected and is often measured using the disease-specific questionnaires Health Assessment Questionnaire Disability Index (HAQ-DI) or Bath Ankylosing Spondylitis Functional Index (BASI). The PROMIS PF-10, an instrument that can assess physical functioning and is standardized, has been increasingly used. This is a generic instrument to assess physical functioning and compare health status across conditions. Several short forms of the PROMIS PF-10 have been developed.

**Objectives:** To investigate the relationship between PA level and exercise self-efficacy, body awareness, and fatigue severity in rheumatoid arthritis: A cross-sectional and pilot study.

**Methods:** A total of 80 RA patients (women/men=61/19, age=56.83±11.56 years) who were diagnosed according to the ACR 2010 criteria were included in this study. All patients were assessed regarding physical characteristics (age, body-mass index), exercise status (yes/no), and occupational status (working/not working/retired). Physical activity level was assessed using the Physical Activity Questionnaire, exercise self-efficacy using the Exercise Self-Efficacy Scale, body awareness by Body Awareness Questionnaire, and fatigue using the Fatigue Severity Scale.

**Results:** Patients' characteristics are presented in Table 1. It was observed that patients with low PA levels. Significant correlation was found between PA and exercise self-efficacy (r=0.410, p<0.001), body awareness (r=0.374, p=0.001), and fatigue (r=-0.482, p<0.001).

**Conclusion:** The relationship between PA level and exercise self-efficacy, body awareness, and fatigue severity in RA patients is significant. Future research is needed to further understand this relationship.

**References:**


**Disclosure of Interests:** None declared.

Table 1. The characteristics of patients

<table>
<thead>
<tr>
<th>Mean ± SD, median (25/75 quartiles) or n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
</tr>
<tr>
<td>56.83 ±11.56</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
</tr>
<tr>
<td>27.84 ±5.57</td>
</tr>
<tr>
<td>Time of diagnosis, years</td>
</tr>
<tr>
<td>11.49 ±10.92</td>
</tr>
<tr>
<td>Exercise status</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>53.63 (66.3)</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>27 (33.8)</td>
</tr>
<tr>
<td>Occupational status</td>
</tr>
<tr>
<td>Working</td>
</tr>
<tr>
<td>16 (20.0)</td>
</tr>
<tr>
<td>Not working</td>
</tr>
<tr>
<td>30 (37.5)</td>
</tr>
<tr>
<td>Retired</td>
</tr>
<tr>
<td>34 (42.5)</td>
</tr>
</tbody>
</table>

IPAQ
Walking, MET-min/week                      |
371 (198/693)                                |
Moderate, MET-min/week                      |
270 (0/840)                                  |
Vigorous, MET-min/week                      |
0 (0/0)                                      |
Total, MET-min/week                         |
693 (268/1533)                               |
IPAQ sub-group                              |
Inactive                                     |
55 (68.8)                                   |
Minimal Active                               |
19 (23.8)                                   |
Very Active                                  |
6 (7.4)                                     |
Exercise self-efficacy score, 0-1800        |
646.62 ±339.40                              |
Body awareness score, 0-18-126              |
84.77 ±16.41                                |
Bristol rheumatoid arthritis multidimensional fatigue score, 0-70 |
19.06 ±12.83                                |

IPAQ: International Physical Activity Questionnaire.

Conclusion: Our study showed that RA patients had low PA and PA was related to exercise self-efficacy and fatigue moderately and body awareness weakly. We think that it may be important to assess these variables and to plan interventions to improve these variables while planning PA programs of the patients.

REFERENCES:

Disclosure of Interests: None declared.


POS1474-HPR

FATIGUE IS AN IMPORTANT COMORBIDITY FOR RA PATIENTS. HOW CAN WE MEASURE IT EASILY IN CLINICAL PRACTICE?

B. Frade-Sosa1, R. Morlà1, N. Sapena1, R. Sanmartí1, J. A. Gómez-Puerta1.
1Hospital Clinic de Barcelona, Rheumatology, Barcelona, Spain

Background: Fatigue is highly prevalent (40-70%) in Rheumatoid Arthritis (RA). Patients describe fatigue as an important symptom, in discrepancy with rheumatologist’s perception. Different validated questionnaires are available to measure fatigue, without any standardised preference in their use. In randomized controlled trials, FACIT-F is a unidimensional tool for fatigue widely used. MDHAQ is a multidimensional tool exploring different dimensions of RA, providing a VAS 0-10 for fatigue. The use of this simple scale to measure fatigue in daily routine for RA patients. The use of this simple scale integrated in the MDHAQ allows capturing important clinical information for the disease.

REFERENCES:

Disclosure of Interests: Beatriz Frade-Sosa: None declared, Rosa Morlà: None declared, Nuria Sapena: None declared, Raimón Sanmartí: Speakers bureau: Abbvie, BMS, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi, Roche, José A Gómez-Puerta: Speakers bureau: Abbvie, BMS, Galápagos, GS, Janssen, MSD, Lilly, Pfizer, Roche, Consultant of: Galapagos, Roche, Sanofi

DOI: 10.1136/annrheumdis-2022-eular.1297

POS1475-HPR

THE MINIMALM IMPORTANT DIFFERENCE AS THE INTERPRETABILITY OF EMOTIONAL HEALTH DOMAIN IN JAPANESE VERSION OF LUPUSPRO FOR SLE PATIENTS; PRELIMINARY RESULTS OF A PROSPECTIVE COHORT STUDY

Y. Miyawaki2, K. Shidahara1, S. Nawachi1, Y. Aso1, Y. Katsuyama1, K. Osahni1, E. Katsuyama1, T. Katsuyama1, M. Narazaki1, Y. Matsumoto1, K. E. Sada1, R. Yana1, N. Vajima1, A. Takatani1, K. Ichinose1, J. Wada1 on behalf of The Lupus Registry of Nationwide Institutions (LUNA) - 3 Month. 1Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 2Okayama University Hospital, Center for Innovative Clinical Medicine, Okayama, Japan; 3Kochi Medical School, Kochi University, Department of Clinical Epidemiology, Nankoku, Japan; 4Showa University School of Medicine, Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Shinagawa-ku, Japan; 5School of Public Health in the Graduate School of Medicine, Kyoto University, Department of Healthcare Epidemiology, Kyoto, Japan; 6Fukushima Medical University, Center for Innovative Research for Communities and Clinical Excellence, Fukushima, Japan; 7Sasebo Chuo Hospital, Rheumatic Disease Center, Sasebo, Japan; 8Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan

Background: The minimally important difference (MID) required to interpret the magnitude of changes in lupus patient-reported outcome (LupusPRO), which is a widely used outcome measure to assess quality of life in SLE patients, remains unclear.

Objectives: We report preliminary results of an ongoing prospective observational study that assesses the MID as the interpretability of emotional health (EH) domain in Japanese version of LupusPRO.

Methods: We recruited subjects at three university hospitals in Japan participating in an ongoing multidisciplinary cohort study (the Lupus registry of Nationwide institutions (LUNA)). Of a total of 210 SLE patients enrolled during the 1-month recruitment period, patients with low disease activity, defined as SLE Disease Activity Index 2000 (SLEDAI-2K) ≤ 4, and who were seen at least twice of three months'...
FEASIBILITY OF USING OPTOELECTRONIC MEASUREMENTS OF HAND MOVEMENT FOR CHARACTERIZING HAND FUNCTION IN RHEUMATOID ARTHRITIS

B. Coppers 1,2, S. Heinrich 1, U. Phutane 3, D. Berisha 3, K. Tasclari 1,2, A. Kleyer 1,2, D. Simon 1, J. Bräunig 1, J. Penner 1, M. Vossiek 1, V. Schönau 1, S. Bayat 1, G. Schulte 1, S. Leyron 2, A. M. Lighthart 2, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Department of Internal Medicine 3—Rheumatology and Immunology, Erlangen, Germany; 2 Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Deutsches Zentrum für Infektionstherapie, Erlangen, Germany; 3 Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Chair of Applied Dynamics, Dillingen, Germany; 4 Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Microwaves and Photonics, Erlangen, Germany.

Background: Physical function is an important factor determining disease burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1]. The currently used tools to assess physical burden in arthritis. Monitoring function in rheumatoid arthritis (RA) patients is essential for effective treatment [1].

Results: The mean age of the 24 eligible patients was 48 (SD 14.6), and 88% were male. The glucocorticoid dose, SLEDIA-2K, and Systemic Lupus International Collaborating Clinics (American College of Rheumatology Damage Index were 3.4 (2.1) mg, 1.0 (1.1) and 1.1 (1.9), respectively. The mean EH score was 67.5 (30.3). Five patients (21%) had the maximum EH score at baseline, 73.4 (25.0) after three months, 72 (18.0) for the change in EH. The correlation coefficient and the AUC for the change in hand status and the EH were 0.23 and 0.60. The mean changes were 4.1 (18.4) of the groups with ‘unchanged’ health status and 12.3 (17.1) of the groups with ‘improved’ health status. The MID for improvement was estimated at 12.3 using the anchor-based method, and the cutoff point corresponded to 9.3 (95% CI 6.7 to 25.3) of the EH change score by the receiver operating curve method.

Conclusion: In this study, the MID (3 months) for the EH domain in the Japanese version of LupusPRO was estimated to be between 9 and 12, which was similar to the results of the previous cross-sectional study [2]. The challenge in estimating the MID in our setting was the low correlation with external anchors, even though the study population was limited to patients with low disease activity, because disease activity at baseline can generally influence ‘improved’ health status.

REFERENCES:

Disclosure of Interests: Yoshia Miyawaki: None declared, Kenta Shidahara: None declared, Shoichi Nawachi: None declared, Yusuke ASANO: None declared, Yu Katayama: None declared, Keiji Ohashi: None declared, Eri Katsuyama: None declared, Takayuki Katsuyama: None declared, Marko Narazaki: None declared, Yoshia Miyawaki: Members of the Speakers bureau: I received speaker’s fees from Glaxo Smith Kline K.K., KEN-EI SADA

IS ECO-INTENSITY A PREDICTIVE FACTOR IN DETERMINING THE PHYSICAL PERFORMANCE OF WOMEN WITH KNEE OSTEOARTHRITIS?

M. Karapanay,* V. A. Ayyildiz1, A. M. Unal1, T. Firat1, 2Suleyman Demirel University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Isparta, Turkey; 3Suleyman Demirel University, Department of Radiology, Faculty of Medicine, ISPARTA, Turkey; 4Private Medem Hospital, Orthopedics and Traumatology Department, Isparta, Turkey; 5Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey

Background: Researchers are increasingly using echo-intensity (EI) as an index of muscle quality or fatty and fibrous tissue infiltration. EI is moderately associated with muscle strength and/or power and a better predictor of muscle performance than measures of muscle mass. In this regard, ultrasound-derived EI may be a promising skeletal muscle assessment tool for monitoring the progression of physical performance. However, there has been no study that investigated the relationship between muscle EI and physical performance in women with knee osteoarthritis (OA).

Objectives: The aim of our study is to investigate the relationship between the physical performance and muscle echo-intensity in women with knee OA.

Methods: Ninety-six women with radiological and clinical knee OA participated in this cross-sectional observational study. Quadriceps femoris (Rectus Femoris-RF, Vastus Intermedius-VIM, Vastus Medialis-VM, Vastus Lateralis-VL) and hamstring (Biceps Femoris-BF, semitendinosus-STT and semimembranosus-SMM) muscles were evaluated using B-Mode ultrasonography. Ultrasound images were analysed offline using an image analysis software (Image J) program and EI of muscles was determined for each subject.

Results: The mean age of participants in the study was 57.3±9.42 years. A positive correlation was found between EI of quadriceps femoris and hamstring muscles and the total KOOS scores. EI of RF, VIM, VL and BF presented a significant negative correlation with FTSS, 20WT and SCT (Table 1).

Table 1: Correlation coefficients between Echo-Intensity of Quadriceps Femoris And hamstring Muscles and KOOS, Physical Performance Parameters (n=96)

<table>
<thead>
<tr>
<th>Knee Injury and Osteoarthritis Outcome Score Subscales</th>
<th>EI (au) Pain Symptoms Function in daily living Function in Sport and Recreation Quality of Life</th>
</tr>
</thead>
<tbody>
<tr>
<td>RF 0.129 0.237 0.443 0.365* 0.186</td>
<td></td>
</tr>
<tr>
<td>VI 0.220 0.94 0.210 0.162 0.201</td>
<td></td>
</tr>
<tr>
<td>VL 0.071 0.116 0.444 0.482* 0.312</td>
<td></td>
</tr>
<tr>
<td>VM 0.105 0.191 0.432 0.454* 0.112</td>
<td></td>
</tr>
<tr>
<td>BF 0.456* 0.277* 0.436 0.402* 0.502</td>
<td></td>
</tr>
<tr>
<td>SMM 0.070 0.239 0.078 0.015 0.357</td>
<td></td>
</tr>
<tr>
<td>STT 0.224 0.179 0.456 0.312 0.522</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: We concluded that muscle EI may be an important predictor of functional performance in women with knee OA.

REFERENCE:

Disclosure of Interests: None declared.

Therapy and Rehabilitation, Izmir, Turkey; Dokuz Eylül Üniversitesi Hastanesi, Rheumatology and Immunology, Izmir, Turkey

Background: Functional exercise capacity might be affected in ankylosing spondylitis (AS) patients due to factors such as pulmonary function impairment, reduced physical activity, peripheral arthritis, fatigue, muscle weakness and systemic inflammation. In addition to laboratory-based exercise tests, field tests are also used to measure functional exercise capacity. The six-minute walk test (6MWT) which is the most frequently used field test, is valid, reliable, and cost-effective. However, the main disadvantage of the 6MWT is that it allows the patient to set the walking speed. The incremental shuttle walk test (ISWT) is a valid field exercise test of functional capacity. The test requires patients to walk at increasing speeds up and down a 10 m course. The walking speed, which increases every minute, is controlled by audio signals. Performance on the test relates strongly to VO2max, the traditional indicator of cardiorespiratory capacity [1]. Although there are studies evaluating functional exercise capacity in AS patients, no study using ISWT has been found.

Objectives: The aim of this study was to investigate the ISWT results and factors associated with this test in patients with AS.

Methods: Fifty AS patients aged between 25-58 years (27 males,23 females) participated in the study. Age, height, weight, body mass index (BMI) were recorded. Disease-specific indices such as Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), Bath AS Metrology Index (BASM1) were used. Sit-up test and push-up test were used to measure muscular endurance. Incremental Shuttle Walk Test (ISWT) was used to assess functional exercise capacity. The test was performed in a 10 m course defined by two cones placed 0.5 m from each endpoint. The test was terminated if the patient was unable to maintain the required speed and failed to complete a shuttle in the time allowed for the second time. The total number of shuttles was recorded and distance calculated. Heart rate (HR), blood pressure, perceived dyspnea and leg fatigue (modified Borg Scale) were assessed before and after the test. Age-predicted maximal heart rate (HRmax) was calculated as 220 minus age. Spearman’s correlation coefficients were used to examine the relationship between the ISWT distance and the variables.

Results: The mean incremental shuttle walk distance (ISWD) of the patients was 485.40±198.63 cm (men 290±170 cm). Subjects reached 50% of the predicted ISWD according to the reference equation for healthy people [2]. The mean maximal heart rate rates were lower than predicted value anticipated for the patient’s age. At the end of the test, subjects reached 73.7±18.62 % of HRmax. ISWD showed significant correlations (p<0.05) with gender (r = 0.488, height (r = 0.474), BASFI (r = -0.313), BASMI (r = -0.397), sit-up test (r = 0.620), push-up test (r = 0.476). However, no relationship was found between ISWD and age, weight, BMI, BASDAl, dyspnea, fatigue. Dyspnea and fatigue were not limiting factors for the test. The most common reason for stopping the test was the inability of the patients to maintain the set pace. ISWD has been reported to be associated with age [2], but in our study, unlike the literature, no relationship was found between ISWD and age in AS patients.

Conclusion: According to the results of our study, we found that the incremental shuttle walk test distance in AS patients decreased compared to the reference values reported for healthy individuals. ISWT is associated with factors such as gender, height, mobility, spinal mobility and muscular endurance. ISWT may be appropriate for measuring exercise capacity of AS patients, however, more research is needed.

REFERENCES:

Disclosure of Interests: None declared.


Background: Although the hand involvement is one of the first manifestations in the disease course of Systemic Sclerosis (SSc), hand functions are generally inquired by using patient-reported tools. Sollerman Hand Function Test (SHFT) is developed to evaluate performance-based hand functions.

Objectives: The aim of this study was to investigate the reliability of the SHFT and the associations with disease- and hand-related parameters in patients with SSc.

Methods: Thirty-six patients (30 females) were included in the study. SHFT includes 20 different hand functions which are scored between 0 (unable to perform) and 4 (performed within 20 seconds with normal quality) (1). In the present study, item 12 ‘put on Tubigrip stocking on the other hand’ was not evaluated, thus, the SHFT was scored over a total score of 76. Inter-rater reliability was investigated by comparing the scores of two different investigators, and test-retest reliability was investigated by assessing the scores obtained at 2-hour intervals. Modified Hand Mobility in Scleroderma Test (mHAMIS), modified Rodnan Skin Score (mRSS), grip and pinch measures were evaluated as hand-related physical characteristics. Duruoz Hand Index, Disability of Arm, Shoulder and Hand Questionnaire (DASH), Health Assessment Questionnaire (HAQ), and Sclerodermatosis Health Assessment Questionnaire (SHAQ) were used as patient-reported outcomes.

Table 1. Associations between the Sollerman Hand Function Test scores and disease- and hand-related parameters

<table>
<thead>
<tr>
<th>mHAMIS (score 0-4)</th>
<th>0 (0/0)</th>
<th>-0.366</th>
<th>0.072</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRSS-Fingers (score 0-3)</td>
<td>2.5 (2/3)</td>
<td>-0.070</td>
<td>0.684</td>
</tr>
<tr>
<td>mRSS-Hand (score 0-3)</td>
<td>15 (12)</td>
<td>-0.056</td>
<td>0.747</td>
</tr>
<tr>
<td>mRSS-Forearms (score 0-3)</td>
<td>1 (0/2)</td>
<td>-0.032</td>
<td>0.855</td>
</tr>
<tr>
<td>mRSS-Upper Arms (score 0-3)</td>
<td>0 (0/1)</td>
<td>0.008</td>
<td>0.962</td>
</tr>
<tr>
<td>mRSS-Total (0-6)</td>
<td>10 (6/27)</td>
<td>-0.158</td>
<td>0.346</td>
</tr>
<tr>
<td>Hand Grip Strength (kg)</td>
<td>19.9 (12.2/24.9)</td>
<td>0.612</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Tip to Tip Pinch Strength (kg)</td>
<td>3.1 (2.3/3.9)</td>
<td>0.517</td>
<td>0.001*</td>
</tr>
<tr>
<td>Three Jaw Pinch Strength (kg)</td>
<td>2.7 (1.9/3.4)</td>
<td>0.554</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Lateral Pinch Strength (kg)</td>
<td>3.9 (3.3/3.3)</td>
<td>0.461</td>
<td>0.009*</td>
</tr>
<tr>
<td>Duruoz Hand Index (score 0-90)</td>
<td>5.5 (0/17)</td>
<td>-0.751</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>DASH (score 30-150)</td>
<td>61.5 (47/84)</td>
<td>-0.645</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>HAQ (score 0-3)</td>
<td>0.3 (0.1/0.9)</td>
<td>-0.632</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>SHAQ-Raynaud’s Phenomenon (score 0-3)</td>
<td>0.9 (0.1/1.4)</td>
<td>-0.246</td>
<td>0.161</td>
</tr>
<tr>
<td>SHAQ-Digital Ulcers (score 0-3)</td>
<td>0.1 (0/12)</td>
<td>-0.372</td>
<td>0.030*</td>
</tr>
<tr>
<td>SHAQ-Gastrointestinal (score 0-3)</td>
<td>0.2 (0/15)</td>
<td>-0.177</td>
<td>0.315</td>
</tr>
<tr>
<td>SHAQ-Pulmonary (score 0-3)</td>
<td>0.6 (0/1.5)</td>
<td>-0.270</td>
<td>0.123</td>
</tr>
<tr>
<td>SHAQ-Patient Global Assessment (score 0-3)</td>
<td>1.4 (1/2.1)</td>
<td>-0.547</td>
<td>0.001*</td>
</tr>
</tbody>
</table>

Results: SHFT demonstrated excellent inter-rater reliability (75 (72/76) vs. 75 (72/76), ICC: 0.987) and moderate test-retest reliability (75 (72/76) vs. 75 (72/76), ICC: 0.645). SHFT scores correlated significantly with grip and pinch strengths. Duruoz Hand Index scores, HAQ scores, SHAQ-Patient Global Assessment scores, and SHAQ-Digital Ulcer scores (<0.05). No significant correlations were observed between other parameters and SHFT (p>0.05). The hardest task was determined as ‘do up buttons’ which cannot be completed within 20 seconds by the half of the patients. All the patients completed ‘put key into Yale lock, turn 90°,’ ‘lift iron over edge 5 cm in height,’ and ‘lift telephone receiver, put to ear’ tasks within 20 seconds with normal quality.

Conclusion: The results of the present study suggest that SHFT is a reliable tool to evaluate hand functions in patients with SSc.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2585

Table 1. Crosstabulation of dichotomised RAPID3 and DAS28* results

<table>
<thead>
<tr>
<th>RAPID3</th>
<th>Low (&lt;2.0)</th>
<th>High (≥2.1)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low (&lt;3.2)</td>
<td>1309 (26%)</td>
<td>117 (2%)</td>
<td>1426 (28%)</td>
</tr>
<tr>
<td>High (≥3.2)</td>
<td>2005 (44%)</td>
<td>1758 (32%)</td>
<td>3763 (72%)</td>
</tr>
<tr>
<td>Total</td>
<td>3314 (66%)</td>
<td>1875 (34%)</td>
<td>5199 (100%)</td>
</tr>
</tbody>
</table>

*p-value for disease activity score 28 (DAS28), Routine Assessment of Patient Index Data 3 (RAPID3).

Conclusion: With a positive predictive value of 0.92 for low disease activity, a RAPID3 score of 2.0 or lower is a good threshold to propose a postponement of the consultation and substantially reduce the clinic burden. Such a proposal is safe if the patient can overrule it.

REFERENCES:
1. N. G. Tore, D. Oskay, H. Satz, S. Hazinekari, Gazi University, Physiotherapy and Rehabilitation, Ankara, Turkey; A. Abbasrahman Yurtaslan, Training and Research Hospital, Rheumatology, Ankara, Turkey; Gazi University, Rheumatology, Ankara, Turkey.

Background: The Quality Indicators for Physiotherapy Management of Hip and Knee Osteoarthritis (QUIPA) is the only patient-reported outcome measure to assess the quality indicators of physiotherapy management of hip/knee osteoarthritis (OA). It consists of 3 subscales and a total of 18 questions.

Objectives: The purpose of this research was to translate and cross-culturally adapt the QUIPA into the Turkish language and test its validity and reliability in Turkish-speaking patients with hip/knee OA.

Methods: Ninety-two patients with hip/knee OA were enrolled in the research. The QUIPA was cross-culturally adapted according to guidelines defined by Bea-ton et al. Participants completed QUIPA tool twice, with an interval of 7 days. Construct validity was tested via Exploratory Factor Analysis. Test-retest reliability and internal consistency were determined interpreting Intraclass Correlation Coefficient (ICC) and Cronbach’s alpha coefficient, respectively.

Results: The Exploratory Factor Analysis demonstrated that QUIPA has 3 factors. For the first, second and third subscales and total score of QUIPA, ICC was found to be 0.895, 0.947, 0.665, and 0.925, respectively. Cronbach’s alpha coefficient was determined to be 0.682, 0.797, 0.593, and 0.812, respectively, for the first, second and third subscales and total score of QUIPA. These results indicate that Turkish version of QUIPA has excellent test-retest reliability and good internal consistency.

Conclusion: Turkish version of the QUIPA determined to be a valid and reliable tool to assess the quality indicators of physiotherapy management of hip/knee OA in Turkish-speaking patients. It is suggested to be used in clinical settings in Turkey.

REFERENCES:


Table 1. Test-retest reliability analysis of the QUIPA

<table>
<thead>
<tr>
<th>QUIPA</th>
<th>ICC</th>
<th>95% CI (Lower-upper bound)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st question</td>
<td>0.814</td>
<td>0.731-0.873</td>
</tr>
<tr>
<td>2nd question</td>
<td>0.698</td>
<td>0.560-0.785</td>
</tr>
<tr>
<td>3rd question</td>
<td>0.782</td>
<td>0.688-0.855</td>
</tr>
<tr>
<td>4th question</td>
<td>0.655</td>
<td>0.521-0.758</td>
</tr>
<tr>
<td>5th question</td>
<td>0.727</td>
<td>0.614-0.811</td>
</tr>
<tr>
<td>6th question</td>
<td>0.716</td>
<td>0.617-0.818</td>
</tr>
<tr>
<td>7th question</td>
<td>0.768</td>
<td>0.699-0.841</td>
</tr>
<tr>
<td>8th question</td>
<td>0.631</td>
<td>0.490-0.739</td>
</tr>
<tr>
<td>9th question</td>
<td>0.723</td>
<td>0.609-0.808</td>
</tr>
<tr>
<td>10th question</td>
<td>0.785</td>
<td>0.692-0.853</td>
</tr>
<tr>
<td>11th question</td>
<td>0.879</td>
<td>0.812-0.923</td>
</tr>
<tr>
<td>12th question</td>
<td>0.772</td>
<td>0.674-0.843</td>
</tr>
<tr>
<td>13th (a) question</td>
<td>0.842</td>
<td>0.770-0.892</td>
</tr>
<tr>
<td>13th (b) question</td>
<td>0.752</td>
<td>0.615-0.845</td>
</tr>
<tr>
<td>14th question</td>
<td>0.543</td>
<td>0.381-0.672</td>
</tr>
<tr>
<td>15th question</td>
<td>0.498</td>
<td>0.372-0.637</td>
</tr>
<tr>
<td>16th question</td>
<td>0.514</td>
<td>0.374-0.650</td>
</tr>
<tr>
<td>17th question</td>
<td>0.866</td>
<td>0.804-0.909</td>
</tr>
<tr>
<td>1st Subscale, (Q1-Q6)</td>
<td>0.895</td>
<td>0.845-0.929</td>
</tr>
<tr>
<td>2nd Subscale, (Q7-Q13)</td>
<td>0.947</td>
<td>0.921-0.965</td>
</tr>
<tr>
<td>3rd Subscale, (Q14-Q17)</td>
<td>0.665</td>
<td>0.534-0.765</td>
</tr>
<tr>
<td>Total</td>
<td>0.925</td>
<td>0.880-0.950</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

POS1482-HPR ASYNCHRONOUS TELECONSULTATION BY WHATSAPP CHATBOT IN CONTROLLED AXIAL SPONDYLOARTHRITIS (SPA) PATIENTS UNDER BIOLOGICAL THERAPY: 10 MONTHS EXPERIENCE AT A SINGLE CENTRE

M. L. García-Vivar1, N. Riveras, E. Galíndez-Agirregoi3a, E. Cuenda1, A. R. Inbarthe Pellejero3a, J. M. Blanco Madrigal1, L. Vega1, C. García1, M. Enjuanes1, M. J. Allande4, O. B. Fernandez Berrizbeitia5, E. Exposito1, M. E. Ruiz Luca5, A. Torre-Salabern1

Background: The use of telehealth in the control of rheumatic diseases had been scarce, but COVID pandemic forced rheumatologists to try alternatives to classic face-to-face consultation. In times of lockdown phone calls and video calls were easy to perform, but later on an asynchronous model of teleconsultation would probably fit better.

The purpose of this study is to prove that asynchronous whatsapp teleconsultation is an effective alternative to classic healthcare consultation models out of pandemic. So, we selected axial spondyloarthritis (SPA) patients with stable controlled disease under biological therapy and we offered teleconsultation with a whatsapp platform chatbot, that’s been created for this purpose as a way to send PROMS to perform, but later on an asynchronous model of teleconsultation would probably fit better. The purpose of this study is to prove that asynchronous whatsapp teleconsultation is an effective alternative to classic healthcare consultation models out of pandemic. So, we selected axial spondyloarthritis (SPA) patients with stable controlled disease under biological therapy and we offered teleconsultation with a whatsapp platform chatbot, that’s been created for this purpose as a way to send PROMS.

Objectives: To prove that teleconsultation through whatsapp platform was not inferior to face-to-face consultation in terms of maintaining axial SPA patients disease under control.

Methods: Prospective study with retrospective control of patients diagnosed of Axial SPA, fulfilling ASAS criteria and with stable disease under biological therapy for the previous year, recruited from 01 Jan to 30 Nov 2021. We offered them two teleconsultation visits using their personal mobile device, once every four months and a face-to-face visit at the end of the study (one year since inclusion). If there is a deviation in the lab test or PROMs or if the patient asks for contact (via whatsapp) he is called up by the person in charge (nurse/docter) that solves the question and arranges an additional presential visit when needed. We consider disease controlled if BASDAI<4, ASDAS<2.1 or if in rheumatologist’s opinion there is no need to change treatment. We collect patient and disease information (age, gender, employment, use of mobile devices, duration and characteristics of the disease, previous and actual treatment), activity (BASDAI, PCR, ASDAS), physical function (BASFI), Quality of life (AsCol) and productivity (WAPA), and we also check number of face-to-face and phone consultations and patients’ preferences.

Results: 62 patients (52 men and 10 women) were recruited, mean aged 47.7 years (range 26-72), 36% were under 45 years at the time of inclusion. They were mostly Ankylosing Spondylitis (AS) (90%; only 6 non radiographic SPA), positive HLA B27 (90%) and with longstanding disease (mean 24 years), and only 6 patients less than five years. 16% had peripheral involvement (arthritis/tenitis/dactylitis), and 40% presented extraarticular manifestations, mainly uveitis (20%). 70% were under their first biological (TNF inhibitor, mostly adalimumab), 24% were refractory to the first, 3 patients to 2 previous biologicals and just 1 patient was refractoy to 5. 50% of patients were treated with tapered dose of TNF inhibitors. We have now a mean followup of 10 months, in which we have had 109 scheduled teleconsultations with aditional need of 36 phone calls and 10 aditional presential visits for the whole group. To date, 3 patients with reduced dose increased to standard dose of biological drug and none change of biological was required.

Conclusion: Asynchronous teleconsultation seems promising, specially for followup in patients with stable rheumatic disease, less interfering with daily activities, less time consuming for the patient and less resource consuming for healthcare systems, with no impairment of disease control and quality of healthcare. This study will also show patient’s preference, and we’ll try to describe a profile of patient more prone to teleconsultation.

REFERENCES:

Disclosure of Interests: Maria Luz Garcia-Vivar Grant/research support from: Novartis provided a grant for this study, Natalia Rivera: None declared, E Galindez-Agirregokoia: None declared, EDUARDO CUENDE: None declared, ANA ROSA INTAURBE PELLEJERO: None declared, Juan Mario Blanco Madr1gal: None declared, L Vega: None declared, C Garcia: None declared, MARIA ENJUANES: None declared, Maria Jesus Allande: None declared, OLAEO BEGETA FERNANDEZ BERRIZBEITIA: None declared, Rosa Exposito: None declared, BEGONIA FERNANDEZ BERRIZBEITIA: None declared, MARIA ESTHER RUZ LUCESA: None declared, Ignacio Torre-Salabern: None declared.

POS1483-HPR DYSFUNCTIONAL COPING CORRELATES WITH DEPRESSION AND ANXIETY AND PREDICTS WORSE OUTCOME IN PATIENTS WITH A HIGH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

J. R. Hoepere, I. IIlassidii, M. Richtere, S. E. Meyere, K. Kahi, T. Witte1, K. Hoepere1, D. Meyer-Olson1,2.

1Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Hannover, Germany; 2mdt Fachklinik Bad Pyrmont, Rheumatologie/Innere Medizin, Bad Pyrmont, Germany; 3University Medicine Göttingen, Institut für medizinische Statistik, Göttingen, Germany

Background: Disease flares of rheumatoid arthritis (RA) are important stressors for patients (pts) who may use coping for disease management. Some coping styles are thought to be beneficial and may help to improve disease outcome whereas others are thought to be harmful.

Objectives: We investigate the frequency and intensity of different coping styles in pts with an acute flare of seropositive RA and its impact on disease outcomes and quality of life.

Methods: Coping was analysed with the Brief-COPE (1) using a 4 point Likert scale in 222 pts participating in the ERFASS study (2). Coping styles were analysed by confirmatory and exploratory factor analysis (CFA, EFA). Disease activity was measured via DAS28 (CRP), depression and/or anxiety using Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire 9 (PHQ-9). Repeated measures ANOVA was used to identify the effect of different coping strategies on disease activity and Spearman-Rho to identify correlations.

Results: Factor analysis revealed five dominant coping styles (problem oriented, emotion oriented, dysfunctional, religion, alcohol/drugs) which were consistent during 6 and 12 months follow up. When analysing the relative intensity of each coping strategy over time there was no significant change during the course of disease (Table 1). The other coping styles did not significantly predict the outcome of disease activity and Spearman-Rho to identify correlations.

Results: Factor analysis revealed five dominant coping styles (problem oriented, emotion oriented, dysfunctional, religion, alcohol/drugs) which were consistent during 6 and 12 months follow up. When analysing the relative intensity of each coping strategy over time there was no significant change during the course of disease (Table 1). The other coping styles did not significantly predict the outcome of disease activity and Spearman-Rho to identify correlations.

Disclosure of Interests: None declared
Conclusion: Different ways of coping may be used simultaneously during an acute flare of seropositive RA. In pts with high disease activity dysfunctional coping is the only coping strategy predicting a worse disease outcome after 12 months and dysfunctional coping correlates with depression and anxiety.

REFERENCES:


LUMBOPELVIC STABILITY, TRUNK POSITION SENSE, AND SPINE POSTURE IN PATIENTS WITH AXIAL SPONDYLOARTHITIS

Y. Akbulut1, T. Duger2, A. Kucuk2, 1Necmettin Erbakan University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, KONYA, Turkey; 2Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey; 3Necmettin Erbakan University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Konya, Turkey

Background: Axial Spondyloarthritis (axSpA) are chronic systemic inflammatory rheumatological diseases characterized by axial skeletal involvement and enthesis. The trunk is the central key point of the body, playing an essential role for postural control, the coordination of the extremities, and functional activities. The systemic, inflammatory nature of axSpA, chronic pain, inflammatory cytokines, changes in the bone and ligaments of the spine may affect lumbopelvic stability, trunk position sense, and spine posture.

Objectives: We aimed to investigate lumbopelvic stability, trunk position sense, and spine posture in patients with axSpA.

Methods: Twenty axSpA patients (mean age: 33.65± 5.72; 75% female) and 20 age- and gender-matched healthy controls were included in the study. In axSpA patients, mean time since symptom onset was 9.75±4.82 years and mean time since diagnosis was 6±3.97 years. Lumbopelvic stabilization was evaluated by a pressure biofeedback unit (Stabilizer Pressure Biofeedback Unit, Chattanooga Group Inc., Hixson, TN, USA). Trunk position sense, as indicated by trunk reposi- tion errors (TRE), was assessed with a digital inclinometer. Thoracic and lumbar curvature tests were performed with a digital inclinometer.

Results: Comparisons of lumbar pelvic stability, trunk position sense and posture were shown in Table 1. Lumbopelvic stabilization values were significantly lower in the axSpA group when compared to the control group (p<0.001). TRE, in which higher scores indicate poorer trunk position sense, was higher in the axSpA group compared to the control group (p<0.001). The degree of thoracic curvature was higher (p = 0.001) in the axSpA group compared to controls whereas the degree of lumbar lordosis was not significantly different between the groups (p = 0.444).

Table 1. Comparison of lumbopelvic stability trunk position sense, and posture of the groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>AxSpA group (n=20)</th>
<th>Control group (n = 20)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar pelvic stability (mmHg, median; min–max)</td>
<td>43.65 (41.3;51.3)</td>
<td>48.6 (46.2;66.2)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Trunk position sense (TRE, median; min–max)</td>
<td>3.6 (0.66; 8.6)</td>
<td>1.3 (0.6; 2.2)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Spine posture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thoracic curvature (°, median; min–max)</td>
<td>39.95 (29.5;33.3)</td>
<td>34.3 (29.6;36.3)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Lumbar curvature (°, mean ± SD)</td>
<td>37.98 ± 7.60</td>
<td>37.92 ± 7.68</td>
<td>0.444*</td>
</tr>
</tbody>
</table>

TRE trunk reposition error, AxSpA Axial Spondyloarthritides, SD standard deviation.

Conclusion: According to our results, patients with axSpA had poor lumbopelvic stability, trunk position sense, and spine posture. The multiplicity and complexity of the symptoms of patients with axSpA require multifaceted symptom management interventions for this purpose, consideration of the training of lumbopelvic stability, trunk position sense, and spine posture might be beneficial in optimal treatment planning.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3759

DIGITALLY ENHANCED TREAT-TO-TARGET AND SHARED DECISION-MAKING APPROACH WITH A DIGITAL HEALTH APPLICATION: INTERIM RESULTS FROM A RANDOMIZED CONTROLLED TRIAL

J. Knittlz1,2, M. Grahame3, S. Boett3,4,5, J. Lang1,2,4,5, M. Detert4,1, M. Bader3,4, J. Knittlz1,2,4, D. Simon1,2, G. Kröckel1,2, G. Schett1,2, J. Detert,3 Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Universitätssklinikum Erlangen, Department of Internal Medicine Rheumatology and Immunology, Erlangen, Germany; FAU Erlangen-Nuremberg and Universitätssklinikum, Deutsches Zentrum fuer Immuntherapie (DZI), Erlangen, Germany; ABATON GmbH, ABATON, Berlin, Germany; Rheumatologisch-Immunologische Arztpraxis Templin, Rheuma - Templin, Templin, Germany

Background: Digital health applications (DHA) became indispensable patient companions accelerated by the current COVID pandemic [1]. In 2020, for the first time worldwide, a regulatory framework to reimburse DHA was established in Germany. To get listed as a DHA, preliminary evidence needs to be generated – next to fulfilling highest standards in quality and safety. The DHA ABATON RA consists of two parts; 1) digital shared-decision-making (SDM) including choosing an appropriate electronic patient reported outcome (ePRO) instrument and the respective ePRO target for the next visit, 2) remote patient monitoring and ePRO tracking by the patient. Hereby, ABATON RA supports a digitally guided Treat-To-Target (T2T) approach.

Objectives: The objective of this study is to evaluate a potentially beneficial effect for the patient by using ABATON RA.

Methods: Three-armed, partially blinded multicenter trial (RCT) including RA patients who regularly use a smartphone. Patients attend 3 visits, 3 months apart (T0, T3, T6), with one follow-up visit (T9). Intervention group (IG): Patients use ABATON RA. Via SDM patients and rheumatologists choose a specific ePRO and respective treatment target for the next visit in three months, e.g. RAID ≤4. Control group (CG): Standard of care treatment (no DHA). Placebo group (PG): Usage of a placebo version of ABATON RA providing only Regensburger Insomnie Skala (RIS) and Epworth Sleepiness Scale (ESS) as ePROs. No SDM is conducted and ePRO results are not presented to MCP.

Results: This interim analysis evaluated the first 38 patients that completed T3. IG: 13 patients (Av. age 55.9, 61.5% females); PG: 12 (Av. age 50.7, 66.7% females); CG: 13 (Av. age 56.1, 76.9% females). We observe a significant improvement in the mean over time in a pairwise comparison within the intervention group for the following: Pt-GA mean difference of 2.98 (p = 0.025, partial η² = 0.12)
Background: Osteoarthritis is the most prevalent joint pathology, knee Osteoarthritis is one of the most frequent locations and has the greatest impact on the health of patients. It can be associated up to 11% with depression and 23% with neuropathic pain. It has also been reported that it can coincide with fibromyalgia (FM) between 6% and 22.83%. This difference may be attributed to some factors, e.g., sample size and/or socioeconomic status. Therefore, the clinical interpretation of symptoms in knee osteoarthritis may be underestimated by the presence of FM. Pincus T. et al. used the FAST4 to identify the coexistence of FM in patients with various rheumatic pathologies. The FAST4 consists of using the MDHAQ (symptom checklist, painful joint count, fatigue and pain). A FAST4 score ≥ 3 allows the association of FM to be considered. The authors demonstrated good concordance with the 2011 FM criteria according to the ACR (with a sensitivity of 70.4% and a specificity of 97.1%).

Objectives: To detect the presence of associated FM in patients with early and established knee osteoarthritis employing the MDHAQ/FAST4.

Methods: Patients >18 years, of both sexes, from our community with early and established knee osteoarthritis (Luyten, FP 2018 and Altman, R 1986 Classification Criteria respectively). All answered the MDHAQ/FAST3-F questionnaire, in addition to the Patient Health Questionnaire (PHQ9) and the Neuropathic Pain 4 Questions (DN4). Depression was considered respectively with a score ≥3 of the PHQ9 and neuropathic pain with 4 points of the DN4.

Results: 100 patients (96 with a diagnosis of early knee osteoarthritis and 4 with established knee osteoarthritis [Luyten - ACR]) with a median age of 58 (RIC 16) and female sex were included 72%. We observed associated FM (FAST4-F) in 31% of patients (27 with early knee osteoarthritis and 4 with established knee osteoarthritis). Median VAS pain, patient and physician global assessment of the disease was higher in patients with associated FM (p<0.001). Disease activity by RAPID 3 was low 4%, moderate in 38% and high in 58% of patients. The cohort had a median pain score of 60 (RIC 60) with absence of neuropathic pain (DN4) in 90% of patients. Depression (PHQ9) was observed in 29% of cases.OA evolution time in months in patients with FM 48 (RIC 12) vs. 36 (RIC 24) without FM (p<0.0001). Binary logistic regression was performed. In the bivariate analysis, it was observed that the presence of early OA by Luyten's criteria (p<0.002), the presence of depression by PHQ9 (p<0.001), patients of white ethnicity (p=0.03), sobrepeso (p=0.002), low RAPID 3 disease activity (p=0.001), kigelrun and lawrence grades II and III (p=0.001), were significant in the bivariate model, although none were statistically significant in the multivariate model.

Conclusion: The evaluation of knee osteoarthritis can be complicated in those patients who coexist with FM. In our study 31% met criteria for this entity according to MDHAQ/FAST4. We consider this questionnaire to be single and practical for detecting associated FM. The results obtained gave clues to the use of PROMs (Patient Reported Outcomes Measures) that can recognize clues of associated diseases such as FM and/or depression. And thus be able to establish a timely and appropriate treatment when these pathologies are overlapping, in order to change the patient’s prognosis and improve their quality of life.

REFERENCES:


Methods:


Acknowledgements: Unidad de investigación de la Sociedad Argentina de Reumatología (UNISAR).

Disclosure of Interests: None declared.


POS1486-HPR

DETECTION OF ASSOCIATED FIBROMYALGIA IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE ACCORDING TO THE MULTIDIMENSIONAL HEALTH ASSESSMENT QUESTIONNAIRE/ FIBROMYALGIA ASSESSMENT SCREENING TOOLS (MDHAQ/FAST4).

Y. Ponce1, O. Rillö2, A. Brigarette3, O. Leonardi1, E. Raad4, M. C. Lunic4.

1Hospital General de Agudos Dr. Ignacio Pirovano, Reumatologia, Ciudad Autónoma de Buenos Aires, Argentina; 2Hospital General de Agudos Dr. Ignacio Pirovano, Reumatologia, Ciudad Autónoma de Buenos Aires, Argentina; 3Sanatorio Güemes, Reumatología, AAF Argentina; 4Hospital de Clínicas José de San Martín, Reumatología, Ciudad Autónoma de Buenos Aires, Argentina

Background: Osteoarthritis is one of the most frequent joint pathologies and has the greatest impact on the health of patients. It can be associated up to 11% with depression and 23% with neuropathic pain. It has also been reported that it can coincide with fibromyalgia (FM) between 6% and 22.83%. This difference may be attributed to some factors, e.g., sample size and/or socioeconomic status. Therefore, the clinical interpretation of symptoms in knee osteoarthritis may be underestimated by the presence of FM. Pincus T. et al. used the FAST4 to identify the coexistence of FM in patients with various rheumatic pathologies. The FAST4 consists of using the MDHAQ (symptom checklist, painful joint count, fatigue and pain). A FAST4 score ≥ 3 allows the association of FM to be considered. The authors demonstrated good concordance with the 2011 FM criteria according to the ACR (with a sensitivity of 70.4% and a specificity of 97.1%).

Objectives: To detect the presence of associated FM in patients with early and established knee osteoarthritis employing the MDHAQ/FAST4.

Methods: Patients ≥18 years, of both sexes, from our community with early and established knee osteoarthritis (Luyten, FP 2018 and Altman, R 1986 Classification Criteria respectively). All answered the MDHAQ/FAST3-F questionnaire, in addition to the Patient Health Questionnaire (PHQ9) and the Neuropathic Pain 4 Questions (DN4). Depression was considered respectively with a score ≥3 of the PHQ9 and neuropathic pain with 4 points of the DN4.

Results: 100 patients (96 with a diagnosis of early knee osteoarthritis and 4 with established knee osteoarthritis [Luyten - ACR]) with a median age of 58 (RIC 16) and female sex were included 72%. We observed associated FM (FAST4-F) in 31% of patients (27 with early knee osteoarthritis and 4 with established knee osteoarthritis). Median VAS pain, patient and physician global assessment of the disease was higher in patients with associated FM (p<0.001). Disease activity by RAPID 3 was low 4%, moderate in 38% and high in 58% of patients. The cohort had a median pain score of 60 (RIC 60) with absence of neuropathic pain (DN4) in 90% of patients. Depression (PHQ9) was observed in 29% of cases.OA evolution time in months in patients with FM 48 (RIC 12) vs. 36 (RIC 24) without FM (p<0.0001). Binary logistic regression was performed. In the bivariate analysis, it was observed that the presence of early OA by Luyten’s criteria (p<0.002), the presence of depression by PHQ9 (p<0.001), patients of white ethnicity (p=0.03), sobrepeso (p=0.002), low RAPID 3 disease activity (p=0.001), kigelrun and lawrence grades II and III (p=0.001), were significant in the bivariate model, although none were statistically significant in the multivariate model.

Conclusion: The evaluation of knee osteoarthritis can be complicated in those patients who coexist with FM. In our study 31% met criteria for this entity according to MDHAQ/FAST4. We consider this questionnaire to be single and practical for detecting associated FM. The results obtained gave clues to the use of PROMs (Patient Reported Outcomes Measures) that can recognize clues of associated diseases such as FM and/or depression. And thus be able to establish a timely and appropriate treatment when these pathologies are overlapping, in order to change the patient’s prognosis and improve their quality of life.
Disclosure of Interests: None declared

POS1485-HPR | DETERMINANTS OF PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN LARGE VESSEL VASCULITIS.

A. Kernder1, M. Rohde1, H. Acar1, O. Sander1, J. Richter1, R. Fischer-Betz1, M. Schneider1, G. Chehab2, 1Heinrich-Heine-University Düsseldorf, Medical Faculty, Department Rheumatology & Hiler-Research Unit Rheumatology, Düsseldorf, Germany

Background: Factors influencing disease activity assessment by patients and physicians are unknown but are highly relevant in the context of PROs development.

Objectives: To compare the patients’ and physicians’ global assessment of disease activity in large vessel vasculitis and investigate factors influencing the assessment of disease activity.

Methods: Between 2010 and 2020, patients with large vessel vasculitis and their routine caring physicians assessed a global disease activity score (numerical rating scale 0 – 10) in our outpatient clinic. We compared these global scores of disease activity. In a multiple linear regression analysis we examined the influence of potential demographical and clinical factors on the disease activity assessment.

Results: 385 Patients with 866 assessments were available for analysis. At time-point of assessment they had a mean age of 76 (± 9) years and a mean disease duration of 5 years (± 5). The median global score of patient-reported disease activity was 7 points, the median physicians’ disease activity assessment was 2 points. In 25.2% (n=214) there was a deviation of more than 2 points between the patients’ and physicians’ assessment of disease activity. Only 5 times the physicians, but 232 times the patients rated their disease activity higher than 5 points. In this group the patient-reported disease activity was associated with the patients age (β 0.025), the patients BMI (β 0.071) and the extent of pain (β 0.19), p<0.05. The disease duration, CRP level and the psychological well-being of the patient showed no association.

Conclusion: In our cohort, physicians and patients showed greater divergence in disease activity assessment with higher disease activity. Age, BMI and the extent of pain were associated with higher disease activity ratings by the patients. This results are relevant for the development and interpretation of PROs for activity assessment in large vessel vasculitides.

Disclosure of Interests: Anna Kernder: None declared, Marius Rohde: None declared, Hasan Acar: None declared, Oliver Sander Speakers bureau: SOBI Pharma, EUSA Pharma, AbbVie Pharma, Consultant of: SOBI Pharma, EUSA Pharma, Boehringer Pharma, Jutta Richter: None declared, Rebecca Fischer-Betz: None declared, Matthias Schneider Speakes bureau: Astra-Zeneca; Biogen; BMS; Celgene; Chugai; GSK; Janssen-Cilag; Lilly; Pfizer; UCB; Paid instructor for: Lilly, Consultant of: Abbvie; Astra-Zeneca; Boehringer-Ingelheim; GSK; Lilly; Novartis; Pfizer; Protogen; Roche; Sanofi-Aventis; UCB, Grant/research support from: Abbvie; Astra-Zeneca; GSK; UCB, Gamil Chehab: None declared DOI: 10.1136/annrheumdis-2022-eular.4446

POS1490-HPR | ASSESSMENT OF TREATMENT ADHERENCE IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH SUBCUTANEOUS ANTI-TNF WHO WERE EXPOSED TO A COMPREHENSIVE CARE MODEL.

W. Rivera1, G. Sánchez2, F. Rodríguez2, L. Villarreal3, D. Bultagro-García2, C. Castro2, P. Santos-Moreno1, 1Biomab IPS, Pharmaceutical Chemist, Bogotá, Colombia; 2Fundación Universitaria de Ciencias de la Salud - FUCS, Epidemiology, Bogotá, Colombia; 3Biomab IPS, Administration, Bogotá, Colombia; 4Biomab IPS, Medical services, Bogotá, Colombia; 5SIIES Consultants, Epidemiology, Bogotá, Colombia; 6Biomab IPS, Rheumatology, Bogotá, Colombia

Background: Rheumatoid arthritis (RA) is an autoimmune, chronic, and inflammatory disease, which can be treated with effective medications, but requires a high level of adherence to treatment. Offering a comprehensive care model by a multidisciplinary team could help increase levels of these patients and improves disease outcomes.

Objectives: Compare the level of adherence to treatment before and after the implementation of a comprehensive care model in a cohort of patients with RA, treated with subcutaneous anti-TNF, in a reference center in Bogotá-Colombia.

Methods: An analytical study was conducted before and after the implementation of a comprehensive care model on a cohort of patients over 18 years of age, diagnosed with RA, who have been prescribed management with a subcutaneous anti-TNF by their doctor during the last 12 months. Convenience sequential sampling was performed to reach a defined sample size of 130 patients to estimate a baseline versus final adherence difference of 20%, at an alpha value of 5% and beta value of 20%. The comprehensive care model (CCM) consisted of the approach by a multidisciplinary team, offering a comprehensive care not fragmented, based on evidence (guidelines and protocols) and proposing a treatment by objectives (T2T). Adherence was measured using the CQR-19 scale, with a cut-off point of 80.7 to consider an adherent patient.

Results: The cohort consisted of 131 patients who followed semiannually for 24 months, and who were incorporated into the CCM. 83.9% were women (n=110), in an age range between 30 and 84 years (Average: 62; DS: 9.9 years). 37.4% of patients were treated with etanercept (n=49), 29% with golimumab (n=38) and 33.6% with adalimumab (n=44). The median baseline of CQR-19 was 87.7 points (RI:64.2-91.2); while at month 24 it reached 91.2 points (RI: 87.7-94.7). The difference between the distributions was statistically significant (p=0.00). According to the cut-off point for CQR-19, the baseline percentage of adherent patients was 87.8% (n=115) and increased to a percentage of 96.2% at 24 months of follow-up (n=126). The difference between these two percentages of adherence was 8.39% (95% CI: 19.9-14.9%) (p=0.012). The results of a generalized linear model binomial family, for the outcome of difference in proportions (PD) of basal and final adherence, are presented in Table 1. The estimator is adjusted for activity level (DAS28), disability level (HAQ) and anti-TNF. Golimumab appears to have an effect that increases adherence by 4.5% compared to adalimumab and etanercept, adjusting for the other predictors.

Table 1. Model of the effect of MAI on adherence to treatment.

<table>
<thead>
<tr>
<th>Variable</th>
<th>DP</th>
<th>CI 95%</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention: MAI</td>
<td>9.4%</td>
<td>3.2-15.5%</td>
<td>0.003</td>
</tr>
<tr>
<td>Golimumab vs Etanercept-Adalimumab</td>
<td>4.5%</td>
<td>0.5-8.5%</td>
<td>0.024</td>
</tr>
<tr>
<td>DAS28</td>
<td>-0.08%</td>
<td>(-0.23% to 0.14%)</td>
<td>0.47</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.00</td>
<td>(-0.003% to 0.045%)</td>
<td>0.85</td>
</tr>
</tbody>
</table>

Conclusion: The CCM, after a follow-up of 24 months in patients with RA in treatment with subcutaneous anti-TNF increases the percentage of adherence by 9.4%, adjusting for treatment, activity level and degree of disability. Golimumab appears to have an effect that increases adherence by 4.5% compared to adalimumab and etanercept, adjusting for the other predictors.

Disclosure of Interests: Wilberto Rivero: None declared, GUILLERMO SANCHEZ: None declared, Fernando Rodriguez: None declared, Laura Villareal: None declared, Diana Bultagro-Garcia: None declared, CARLOS CASTRO: None declared, Pedro Santos-Moreno Speakers bureau: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly, Consultant of: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly, Grant/research support from: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly DOI: 10.1136/annrheumdis-2022-eular.4798

POS1490-HPR | INVESTIGATION OF THE RELATIONSHIP BETWEEN EXERCISE CAPACITY AND PSYCHOSOCIAL VARIABLES IN WOMEN WITH FIBROMYALGIA: A PRELIMINARY STUDY.

B. Beyrek1, M. Kførumluoluo1, K. Nas1, Í. Nazz1, Ízmir Karat Celubi University Institute of Health Sciences, Department of Physiotherapy and Rehabilitation, Izmir, Turkey; 2Izmir Karat Celubi University Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Izmir, Turkey; 3Sakarya University School of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology and Immunology, Sakarya, Turkey

Background: Various studies have showed that patients with fibromyalgia have lower exercise capacity than healthy individuals (1, 2). This reduced exercise capacity affects these patients’ independence in performing daily activities (3). Although it was shown that exercise capacity related physical status, it is not quite clear that relationship between exercise capacity and patients’ psychosocial variables in patients with fibromyalgia.

Objectives: To identify whether there is any direct link between the exercise capacity of women with fibromyalgia and their psychosocial status.

Methods: Nineteen women with fibromyalgia meeting the criteria of the American College of Rheumatology were included in the preliminary cross-sectional study (age=46.26±6.25 years, BMI=27.64±3.86 kg/m²). Exercise capacity was assessed by 6-min walking test. For psychosocial variables, alexithymia, fatigue, self-efficacy, and social support were measured by Toronto Alexithymia Scale, Multidimensional Fatigue Index, General Self-Efficacy Scale, and MOS Social Support Survey respectively. Spearman correlation was used to investigate the relationship.

Results: The average distance walked was 468.15±57.30 m. It was found that a significant correlation between 6-min walking test and alexithymia (r=.517, p<.001), self-efficacy (r=.475, p=.040), and social support scores (r=.677, p<.001). However, no link was observed between 6-min walking test and social support scores (r=.170, p=.486).

Conclusion: As a result of our study, the exercise capacity of fibromyalgia patients was reduced as in other studies, there was a strong positive correlation between exercise capacity and self-efficacy in patients with fibromyalgia. Furthermore, exercise capacity was strongly associated with a cut-off point of 300 on the alexithymia. In the light of all this, it may be said that exercise capacity is related to patients’ psychosocial status in women with fibromyalgia. We think that the structure of exercise programs aimed at improving the exercise capacity of patients should include strategies that also improve psychosocial factors.
The usefulness of the patient activity score-pass-II to assess disease activity during the COVID-19 lockdown in patients with rheumatoid arthritis

F. Rodríguez1, D. Buitrago-García2, G. Sánchez2, P. Santos-Moreno3
1Biomab IPS, Administrative, Bogotá, Colombia; 2Fundación Universitaria de Ciencias de la Salud - FUCS, Epidemiology, Bogotá, Colombia; 3Biomab IPS, Rheumatology, Bogotá, Colombia

Background: Many measurement tools are designed to assess disease activity for Rheumatoid Arthritis (RA) patients. One of the most used tools is the Disease Activity Score - DAS28 which assesses the number of painful joints, erythrocyte sedimentation, and a patient’s global assessment. The assessment is performed by a clinician and requires laboratory exams. Unfortunately, from March to August 2019, Colombia had one of the strictest responses to the COVID-19 pandemic according to the COVID-19 stringency index(1). One of the main restrictions was the preventive isolation of elderly populations, especially those with comorbidities. These restrictions challenged the rheumatology practice because face-to-face consultations were not possible. Due to the above, measurements like the PAS-II score should be used to assess disease activity during the pandemic.

Objectives: To describe disease activity according to the Patient Activity Score - PAS-II score patients with RA and compare its results to the most recent DAS28 assessment before the COVID-19 pandemic.

Methods: We conducted a descriptive study; patients were followed during the COVID-19 lockdown in a video consultation. The PAS-II score was applied to assess disease activity as an alternative to the DAS28 assessment. The patients were part of an educational program, clinical charts were reviewed to collect the study variables. We collected demographic data and DAS28 before the pandemic started. We present a descriptive analysis of DAS28 severity and the results obtained by the PASS-II score.

Results: The educational program enrolled 250 participants; 196 patients had complete data. 93% of participants were women, mean age was 64 years IQR (54-67). 43% of participants were married or had a civil union, 26% were single, 20% divorced, and 11% were widowed. Regarding educational level, 25% had finished elementary school and 39% high school; the remaining 36% had higher education. When we compared the last DAS28 assessed by a rheumatologist between January and March 2019, 67% of patients were in remission, while in July 2019, the PASS-II score reported that 7% of patients were in remission and 75% had low or minimal activity. Figure 1- Table 1.

Table 1.

<table>
<thead>
<tr>
<th>DISEASE ACTIVITY</th>
<th>DAS28</th>
<th>PASS-II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remission</td>
<td>67%</td>
<td>6%</td>
</tr>
<tr>
<td>Low (Minimal)</td>
<td>14%</td>
<td>75%</td>
</tr>
<tr>
<td>Moderate</td>
<td>15%</td>
<td>18.5%</td>
</tr>
<tr>
<td>High/Severe</td>
<td>4%</td>
<td>0.5%</td>
</tr>
</tbody>
</table>

Conclusion: The PASS score is a helpful tool to assess disease activity in patients with RA, especially in situations where the patient cannot see a rheumatologist in a face-to-face consultation; however, patients in severe disease activity should not delay the consultation with a clinician. As other studies have demonstrated, patient-reported outcome measures should be adopted in clinical practice as an alternative to the DAS28 score. As other studies have demonstrated, patient-reported outcome measures should be adopted in clinical practice as an alternative to the DAS28 score.

References:

Disclosure of Interests: None declared


Psychometric properties of the fibromyalgia impact questionnaire – Revised in fibromyalgia and chronic widespread pain: a rasch analysis

P. H. Duhn1,2, K. Amris1,2, H. Bliddal1,3, E. E. Wahrens1,4, Bispebjerg-Fredensborg Hospital, The Parker Institute, Frederiksberg, Denmark; 2Bispebjerg-Fredensborg Hospital, Department of Rheumatology, Frederiksberg, Denmark; 3University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark; 4University of Southern Denmark, Occupational Science, User Perspectives and Community-based Research, Department of Public Health, Odense, Denmark

Background: The Fibromyalgia Impact Questionnaire - Revised (FIQr) is one of the most commonly used self-rating instruments developed to quantify the severity of disease burden and impact of disease on functional ability and social participation in patients with fibromyalgia (FM) [1]. The FIQR consists of 21 individual items categorized within three different domains: ‘function’, ‘overall impact’ and ‘symptoms’ [2]. The FIQR that has been translated into several languages, has mainly been validated based on classical test theory (CCT) - except for the Italian version [3].

The psychometric properties of the Italian version of the FIQR was evaluated by Salati et al. based on item response theory using Rasch analysis [3]. The benefit of using Rasch measurement models, is that it allows for a detailed analyses of an instrument’s rating scale properties and aspects of validity, including fit of individual scale items to a unidimensional model [4]. Although the FIQR demonstrated adequate psychometric properties in the original studies based on CCT, the Rasch analysis in the Italian study revealed problems with the rating scale properties [2,3]. The FIQR is a frequently used questionnaire when assessing patients with FM in Denmark, but the Danish version of the FIQR has not yet been validated.

Objectives: The aim of this study was to evaluate the psychometric properties of the Danish version of the Fibromyalgia Impact Questionnaire Revisited (FIQR), when used to quantify the severity of disease burden in a Danish population of patients with Chronic widespread pain (CWP) including Fibromyalgia (FM).

Methods: A total of 924 participants diagnosed with CWP and/or FM completed an electronic version of the FIQR via touchscreens in the clinic at referral for specialist care. Data was collected from January 1st, 2018 to September 3rd, 2020.

Rasch measurement methods were applied.

Results: Rating scale analysis suggested multiple threshold disordering in the 0 to 10-category rating scale. A principal component analysis suggested assessment of a multidimensional construct. Thus, the Rasch analysis of the full FIQR was discontinued. Instead Rasch analyses were performed on the two subscales: ‘function’ and ‘symptoms’. By collapsing the rating scale to a 0 to 4-category scale, the remaining threshold disordering of both subscale was solved. Only the symptom subscale indicated a multidimensionality. There was underfitting misfit of item 21 and overfitting misfit of item 12. No significant Differential Item Functioning was found defined by sex, ethnicity, or education.

Conclusion: The FIQR should be considered as an instrument consisting of three separate subscales representing ‘function’, ‘overall impact’ and ‘symptoms’. We recommend calculating and reporting on both a 0 to 10- and a 0 to 4-category scale. Also, if using the total FIQR score as an outcome measure, this should be done with caution, until revision of the rating scale.

References:

Disclosure of Interests: None declared

Background: Mental disorders constitute a serious and underestimated problem in Latin America and they could have worse features in comparison with Europe or North America (1), that was the case even before the COVID-19 epidemic ensued in 2020.

Objectives: The objective of this study was to determine the factors associated with the occurrence of mental health disorders (MHD) in patients with autoimmune rheumatic disease (ARD) from Peru, a high COVID-19 incidence country.

Methods: Patients with ARD from a single center (Hospital Guillermo Almenara -EsSalud, Lima-Peru) were included during the first and second waves of the COVID-19 pandemic (March to November 2020). Interviews, medical records reviews, and an electronic survey were performed. MHD explored were depression, anxiety (assessed with the Generalized Anxiety Disorder-7: GAD-7) and post-traumatic stress disorder: PTSD (evaluated with the Event Scale-Revised: IES-R). Variables examined were sociodemographic (age, gender, educational level, marital status, living alone, job status, religiosity), previous diagnosis and treatment for mental disorders, living with a COVID-19 patient, COVID-19 diagnosis (current or past), fear of COVID-19 (assessed with the COVID-19 Scale: FCV-19S) and the ARD type. Multivariable logistic regression models using backward elimination were performed to determine the variables associated with depression, anxiety and PTSD (See Table 1).

Table 1. Variables associated with depression, anxiety and PTSD on ARD patients: Multivariable analysis.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Depression OR (CI95%)</th>
<th>Anxiety OR (CI95%)</th>
<th>PTSD OR (CI95%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous treatment for mental disorders</td>
<td>2.35 (1.34-4.03)</td>
<td>0.022 (0.22-0.43)</td>
<td>0.020 (0.02-0.43)</td>
</tr>
<tr>
<td>Fear for COVID-19 (1.05-1.10)</td>
<td>0.07 (&lt;0.01)</td>
<td>0.009 (0.02-0.01)</td>
<td>0.019 (0.01-0.2)</td>
</tr>
<tr>
<td>COVID-19 diagnosis</td>
<td>0.10 (0.02-0.49)</td>
<td>0.007 (0.02-0.01)</td>
<td>0.001 (0.00-0.01)</td>
</tr>
<tr>
<td>Educational level</td>
<td>0.02 (0.00-0.05)</td>
<td>0.032 (0.00-0.01)</td>
<td>0.002 (0.00-0.00)</td>
</tr>
<tr>
<td>High School</td>
<td>0.43 (0.02-0.21)</td>
<td>0.009 (0.02-0.01)</td>
<td>0.019 (0.00-0.02)</td>
</tr>
<tr>
<td>Elementary</td>
<td>0.52 (0.02-0.05)</td>
<td>0.032 (0.00-0.01)</td>
<td>0.002 (0.00-0.00)</td>
</tr>
<tr>
<td>Marital status</td>
<td>0.57 (0.34-0.96)</td>
<td>0.033 (0.00-0.01)</td>
<td>0.019 (0.00-0.01)</td>
</tr>
<tr>
<td>Single</td>
<td>0.02 (0.00-0.01)</td>
<td>0.002 (0.00-0.00)</td>
<td>0.001 (0.00-0.00)</td>
</tr>
</tbody>
</table>

Results: Nine hundred and thirteen ARD patients were evaluated. The most frequent diagnosis was rheumatoid arthritis in 446(48.8%) patients followed by systemic lupus erythematosus in 279 (30.6%). Depression, anxiety, and PTSD were observed in 128 (14.0%), 112 (12.30%) and 485 (53.1%) patients, respectively.

In the multivariable analyses, previous treatment for mental disorders and fear of COVID-19 were associated with depression: OR=2.35 (95% CI 1.37-4.03; p=0.002) and OR=1.07 (95% CI 1.05-1.10; p=0.001) respectively; also with anxiety: OR= 2.42 (95% CI 1.37-4.26; p=0.002) and OR=1.09 (95% CI 1.06-1.12; p=0.009), and with PTSD: OR=2.42 (95% CI 1.39-4.21;p=0.002) and OR=1.41 (95% CI=1.11-1.71; p=0.001). A diagnosis of COVID-19 was associated with PTSD: OR=1.75 (95% CI 1.06-2.89; p=0.028), while being single was associated with a decreased probability of PTSD occurrence: OR=0.57 (95% CI=0.35-0.96; p=0.03). Finally, having a high educational level was associated with less anxiety: OR=0.43 (95% CI 0.82-2.1; p=0.009), for university (postgraduate studies and OR=0.52 (CI 95% 0.28-0.95; p=0.032) for secondary studies.

Conclusion: Fear of COVID-19 and previous treatment for mental disorder were associated with all MHD explored on our ARD patients during the COVID-19 pandemic.

REFERENCES:

Disclosure of Interests: None declared

HPR Interventions (educational, physical, social and psychological)

Hard times: adapting a fatigue management programme in a pandemic

J. Dobson1, D. Dockrell2, K. Berg3, H. Harris1,1 University of Edinburgh, CGEM, Institute of Genetics and Cancer, Rheumatic Diseases, Edinburgh, United Kingdom; 2University of Edinburgh, CGEM, Institute of Genetics and Cancer, Rheumatic Diseases, Edinburgh, United Kingdom; 3NHS Lothian, Rheumatic Diseases, Edinburgh, United Kingdom

Background: Fatigue is a symptom of many Rheumatology Conditions (1). Hewlett et al have shown that a Fatigue Management Programme (FMP) is effective in reducing fatigue in Rheumatoid Arthritis patients (2). In 2019, a 7-week group-based FMP was developed using a cognitive behavioural approach for Rheumatology patients in NHS Lothian (Scotland). In 2020, due to COVID-19, the in person FMP was adapted for virtual delivery. Referral criteria included Visual Analogue Scale-Fatigue (VAS-F) of ≥6/10 and an inflammatory rheumatic disease diagnosis. The FMP participants recorded Patient Reported Outcome Measures (PROMs) prior to and on completion of the FMP. In August 2021 demand for the FMP far outweighed the capacity of the delivery team and therefore the original 7-week FMP was further adapted to a 4-week programme. This was achieved by focusing on four core elements (i) sleep, (ii) thoughts, emotions and behaviours, (iii) energy conservation, (iv) setbacks.

Objectives: The primary objective was to evaluate whether the 4-week programme produced comparable PROMs results to the 7-week programme. In doing so, the aim was to maintain efficacy of the programme and provide increased capacity by offering more groups in the same timeframe.

Methods: Fatigue Severity Scale (FSS) and Visual Analogue Scale for Fatigue (VAS-F) were used for comparison between pre and post FMP PROMs results, these being the main indicators of improvement in fatigue management. Fisher’s exact test was used to determine any difference between the PROMs results reported at the end of both programmes. Participants who reported that their PROMs result were the same, worse or who did not respond, were all placed into the category “Other”. The FMP team recorded the average waiting time for those attending each group. The length of the waiting list at any one time was calculated by removing those who were not interested, had been referred elsewhere, or who did not respond to the invitation, from the total number of referrals received by the FMP team.

Results: There was no significant difference in FSS and VAS-F results reported by the participants in both groups at the end of the FMPs as determined by Fisher’s exact test (Table 1). Waiting list times reduced from 24 weeks in August 2021 to 6 weeks in December 2021 as a result of the adaptation of the FMP from a 7-week programme to a 4-week programme (Figure 1).

Table 1. Reported differences between pre-FMP and post-FMP PROMs.

<table>
<thead>
<tr>
<th></th>
<th>FSS</th>
<th>VAS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 Week FMP (n = 25)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSS</td>
<td>Improved 72%</td>
<td>77%</td>
</tr>
<tr>
<td>Other</td>
<td>28%</td>
<td>23%</td>
</tr>
<tr>
<td>VAS</td>
<td>Improved 80%</td>
<td>69%</td>
</tr>
<tr>
<td>Other</td>
<td>20%</td>
<td>31%</td>
</tr>
<tr>
<td>Fischer Exact</td>
<td>p = 1.000</td>
<td>p = 0.689</td>
</tr>
</tbody>
</table>

Figure 1. - Review of average waiting times experienced by each group. In August 2021, the decision was made to trial a 4-week FMP to counter large increases in average waiting times.

Conclusion: A 4-week FMP is as effective at improving the management of fatigue in Rheumatology patients as a 7-week FMP and reduces patient waiting times. More research is required to bolster the evidence base to support this novel approach.

References:

Disclosure of Interests: Joanne Dobson: None declared, Dervil Dockrell: None declared, Kathryn Berg: None declared, Helen Harris Speakers bureau: Galapagos


Feasibility of a physiotherapist led, behaviour change intervention to improve physical activity in people with rheumatoid arthritis

L. Larkin1, S. Mckenna1, T. Pyne1, S. Gallagher2,3, L. Glynn3,4, A. Fraser4,5, B. A. Esbensen6,7, N. Kennedy1,3,1 University of Limerick, School of Allied Health, Limerick, Ireland; 2University of Limerick, Department of Psychology, Limerick, Ireland; 3Health Research Institute, University of Limerick, Limerick, Ireland; 4University of Limerick, School of Medicine, Limerick, Ireland; 5University Hospital Limerick, Department of Rheumatology, Limerick, Ireland; 6Copenhagen Centre for Arthritis Research, Rigshospitalet, Copenhagen, Denmark; 7University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark

Background: Physical activity (PA) is an important component in the management of people with rheumatoid arthritis (RA) (1). Interventions incorporating Behaviour Change (BC) theory are needed to target physically inactive people with RA. The study Physiotherapist-led Intervention to Promote Physical Activity in Rheumatoid Arthritis (PIPPRA) was designed using the Behaviour Change Wheel (BCW) and a pilot study of feasibility undertaken (ClinicalTrials.gov Identifier: NCT03644180).

Objectives: To obtain reliable estimates regarding recruitment rates; participant retention; protocol adherence and possible adverse events, and to producing estimates of the potential effect sizes of the BC intervention on changes in outcomes of physical activity; fatigue; disability and quality of life.

Methods: Participants were recruited at University Hospital (UH) rheumatology clinics and randomly assigned to control group (physical activity information leaflet) or intervention group (four BC physiotherapy sessions in eight weeks). Inclusion criteria were diagnosis of RA (ACR/EULAR 2010 classification criteria), aged
Background: People newly diagnosed with inflammatory arthritis (IA) request regular consultations and support from health professionals (HPRs) in rheumatology to manage physiological, emotional, and social challenges. Evidence suggests that providing a tailored tailormade multi-component self-management program may benefit disease management (1). However, there is a lack of evidence in interventions with multiple components targeting people newly diagnosed with IA.

Objectives: To develop a complex evidence- and theory-based intervention in co-creation with patients and HPRs for better self-management in newly diagnosed people with IA in a rheumatology outpatient clinic.

Methods: This study followed the Medical Research Council (MRC) Framework (2,3) for developing a complex intervention. The development phase comprised 1) identifying the evidence base, 2) identifying theory, 3) modelling process and outcomes, resulting in 4) a final description of all components and outcomes of the intervention.

1) Identifying the evidence base

We conducted two literature reviews, on which, we described a preliminary intervention.

2) Identifying theory

Given the fact that the theory of Self-management is built upon Social Cognitive Theory (4) this was chosen as the underlying theory along with Acceptance and Commitment Theory (5) to support our communication strategy.

3) Modelling process and outcomes

The preliminary intervention was discussed and further developed in seven workshops to ensure that the intervention was in accordance with patients’ needs and feasible in clinical practice. Three patients and 38 HPRs (nine therapists, 10 rheumatologists, one psychologist, one social worker, and 17 registered nurses) attended. During the workshops we identified the competencies needed in the HPRs delivering the intervention. In addition, relevant outcomes to measure self-management in a subsequent feasibility study were discussed. Discussions were digitally recorded and analysed using Thematic Analysis (6).

4) Description of all components and outcomes of the intervention

Our intervention, ready for testing in a feasibility study, was a 9-month nurse-led intervention, and consisted of four individual and two group sessions. A physiotherapist and an occupational therapist should attend the group sessions along with the nurse (Figure 1). All sessions should target inflammatory arthritis-specific self-management.

Results: 320 participants were identified through chart review with direct contact then with people meeting the inclusion criteria at rheumatology clinics. Of the clinic attendees n=183 (57%) were eligible to participate and n=58 (55%) consented to participate. The recruitment rate was 6.4 per month and 25 (43%) of those consented to participate. The recruitment rate was 6.4 per month and refusal rate was 59%. Due to impact of COVID-19 on the study n=25 (43%) were able to complete the study (n=11 (44%) in intervention and n=14 (56%) in control). Of the 25, n= 23 (92%) were female, mean age was 60 years (sd 11.5). Intervention group participants completed 100% of BC sessions 1 & 2, 88% session 3 and 81% session 4. No serious adverse events were reported. Secondary outcomes measures data is Table 1.

Conclusion: The PIPPRA study designed using the BCW to improve promote physical activity was feasible and safe. This pilot study provides a framework for future, more complex multi-component self-management interventions in inflammatory arthritis.

Disclosure of Interests: None declared.

DOI: 10.1136/annonrheumdis-2022-eular.407
Y. Acar1, N. Ilcin2, I. Sarı3.

Background: Yoga is an ancient discipline that emerged thousands of years ago in India to unite the mind, body and spirit. Yoga is widely used by patients with various rheumatic diseases. Although it is recommended for ankylosing spondylitis (AS) patients, there is no randomized controlled study on this subject in the literature. Due to Covid-19, which has changed the world and the people's lifestyle, tele-yoga practice can be considered as an alternative to traditional physical therapy and rehabilitation. In this study, the effects of tele-yoga on disease activity, functional status, spinal mobility, sleep quality, depression, anxiety, stress and quality of life in ankylosing spondylitis patients were investigated.

Methods: Thirty-six volunteer AS patients (21 male, 15 female) who applied to Dokuz Eylül University, Department of Internal Medicine, Division of Rheumatology and Immunology were included in the study. Participants were randomly assigned to a tele-yoga (n=18, mean age 43.22 ±8.54 years) or waiting-list control group (n=18, mean age 44.9 ±8.01 years) by block randomization method. Participants in the tele-yoga group participated in 1-hour tele-yoga sessions with a maximum of 5 people in each group using Zoom (online video-conference method) 3 days a week for 8 weeks. Assessments were performed before and after 8 weeks of yoga training. The waiting list control group did not receive any intervention, participants were advised to maintain their usual activities and continue their routine medical treatments. Assessments were performed at baseline and after an 8-week waiting period. After assessments, patients who wished to participate in the tele-yoga program were invited to a follow-up visit. The following inventory was used for assessment: Bath AS Disease Activity Index (BASDAI) for disease activity, Bath AS Functional Index (BASFI) for functionality, Bath AS Mobility Index (BASMI) for spinal mobility, ASAS Health Index, Pittsburgh Sleep Quality Index (PSQI), Short Form-36 (SF-36), Hospital Anxiety and Depression Scale (HADS), Perceived Stress Scale (PSS).

Results: The groups were similar at baseline in terms of age, height, weight, body mass index, gender and physical activity level (p>0.05). While all parameters improved significantly in the tele-yoga group (p<0.05), no change was observed in the control group after 8 weeks (p>0.05). When the changes in the tele-yoga group and the control group were compared, the improvements in the BASDAI, BASFI, BASMI, ASAS Health Index, SF-36 Physical Function, SF-36 Role Physical, SF-36 Bodily Pain, PSQI and PSS were found to be statistically significant in the tele-yoga group (p<0.05).

Conclusion: According to our preliminary results, tele-yoga is beneficial in reducing disease activity and stress, improving functional level, spinal mobility, sleep quality and quality of life. Due to its therapeutic effects, tele-yoga can be considered as an alternative approach for AS patients.

Disclosure of Interests: None declared


BABS ON A MISSION: AN EXPERIMENTAL STUDY ON THE EFFECTS OF MESSAGE FRAMING ON BEHAVIORAL AND INTENTIONS OF OSTEARTHRITIS PATIENTS

J. Oomen1, C. Van den Ende2, H. Das3, Sint Maartenskliniek, Department of Research and Innovation, Ubebergen, Netherlands; Sint Maartenskliniek, Department of Research and Innovation, Ubebergen, Netherlands; Radboud University, Department of Language and Communication, Nijmegen, Netherlands

Background: It is important that patients receive appropriate and reliable information that effectively targets beliefs in order for them to adhere to health behaviors. Framing (focusing on either gains or losses; [1]) is one of the most commonly used techniques in health communication to influence beliefs. In addition, the use of a testimonial in educational material might strengthen effects as intentions to adhere to health behaviors seem to rely strongly on testimonies of other patients. However, little is known about the potential of framing and patient testimonies to impact beliefs and change in health behaviors in osteoarthritis (OA).

Objectives: To study the effects of 1) message framing and 2) patient testimonies on beliefs about and intentions to be physically active and use pain medication.

Methods: We conducted an experiment consisting of a 2 × 2 (gain-frame vs loss-frame) × 2 (testimonial versus informative message) factorial design. Members of a research panel (n=639) with a self-reported diagnosis of knee OA were invited to participate. Participants were randomized into one of four video messages applying framing and the use of either a testimonial or facts. The messages (mean (SD) words 1073 (129)) were audiotapecd by the same female speaker, subtitled, and complemented with images (duration of ~10 minutes). The four different combinations were: informative-loss (“If you are not physically active, this can lead to more pain[…]”), informative-gain (“If you are physically active, this will lead to less pain[…]”), testimonial-loss (“When I wasn’t physically active, I experienced more pain[…]”), testimonial-gain (“When I was physically active, I experienced less pain[…]”). After this video, participants filled out a questionnaire on socio-demographic and disease characteristics, and rated 3 statements concerning beliefs on a 7-point Likert scale (completely disagree – completely agree), and one 7-point Likert scale item on intentions (I do not do this now and am not planning doing this – I am doing this already for more than 6 months) each for both physical activity and pain medication based on the Theory of Planned behavior questionnaire [2]. ANOVA was used to assess the main and interaction effects of framing and the use of a testimonial on mean beliefs and intentions.

Results: A total of 154 respondents completed the questionnaire (Table 1). Framing nor the use of a testimonial impacted beliefs and intentions on physical activity. Loss framing resulted in more positive beliefs about pain medication (mean (SD) 5.5 (1.6)) than gain framing (mean (SD) 4.9 (1.9), p=0.04, 95% CI [0.0, 0.1]). Within the loss frame, the patient testimonial scored significantly more positive on pain medication beliefs (mean (SD) 5.0 (1.7)) than the informative message (mean (SD) 6.0 (1.1), p=0.02, 95% CI [0.1, 1.6]) (Figure 1).

Table 1. Characteristics of participants (n=154)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>110 (71)</td>
</tr>
<tr>
<td>Age (in years), mean (SD)</td>
<td>62.3 (7.9)</td>
</tr>
<tr>
<td>BMI, mean (kg/m²), (SD)</td>
<td>27.3 (4.4)</td>
</tr>
<tr>
<td>Daily functioning (KOOS4, 0-100), mean (SD)</td>
<td>64.5 (18.0)</td>
</tr>
<tr>
<td>Pain VAS (0-10), mean (SD)</td>
<td>4.6 (2.2)</td>
</tr>
<tr>
<td>Symptoms for more than 5 years, n (%)</td>
<td>96 (62.3)</td>
</tr>
<tr>
<td>Presence of OA in other joints, n (%)</td>
<td>85 (55.2)</td>
</tr>
<tr>
<td>Knee replacement, n (%)</td>
<td>32 (20.8)</td>
</tr>
<tr>
<td>Presence of comorbidities, n (%)</td>
<td>111 (72.0)</td>
</tr>
</tbody>
</table>

Conclusion: This study showed that the disadvantages of nonadherence to pain medication resulted in more positive beliefs about pain medication than stating the advantages of adherence. The use of a patient testimonial within this loss frame strengthened the effect. Our findings indicate that health care providers should be aware of the potential effects of emphasizing either gains or losses in educational messages to their patients.

REFERENCES:

Background: Long term health conditions (LTHC) such as rheumatic conditions have significant impact on the biopsychosocial development of young people (YP) including vocational development. Educational transitions are prominent during adolescence and young adulthood yet not all transitional care programmes in the area address this area [1].

Objectives: To identify and synthesise the benefits and experiences of addressing the vocational development of YP with LTHC in health care settings.

Methods: A mixed methods synthesis approach [2] was employed. We systematically searched 10 bibliographic databases. Restrictions were applied on publication date (1996-2020) and publication language (English). Articles reporting quantitative and/or qualitative primary research on addressing vocational/needs/ issues of YP with LTHC in health care settings were included. YP was defined as 10-24 years [3]. Two reviewers independently screened records using predetermined inclusion/exclusion criteria [4]. Quality appraisal was undertaken following the Newcastle Ottawa Scale [4].

Results: 43 articles were included. The quality of qualitative evidence was generally good; but the quality of quantitative evidence was generally poor. The thematic synthesis of stakeholders’ perspectives (n=23 qualitative studies) resulted in seven recommendations for interventions: provide skills training; provide psychological support; offer to liaise with key stakeholders in educational/workplace settings; provide specialist career advice; provide information, signposting and facilitate access to supporting services; provide/facilitate access to social support; provide flexible care and optimal disease management to support education/employment transitions. The narrative synthesis summarised results of 17 interventions (n=20 quantitative studies). The cross-study synthesis mapped interventions against recommendations arising from stakeholders’ perspectives: Four interventions met five recommendations; two interventions met four recommendations; three interventions met three recommendations; six interventions met two recommendations. Transitional care interventions were the type of intervention that most comprehensively met the recommendations. The way in which interventions addressed vocational issues was not always clear, with some interventions addressing them explicitly/directly (reporting vocational outcomes only). Interventions where vocational issues were the core, defining component (reporting vocational outcomes) and others implicitly/indirectly (reporting vocational outcomes addressing them explicitly/directly (reporting vocational interventions addressing them explicitly/directly (reporting vocational outcomes) was not always clear, with some interventions addressing them explicitly/directly (reporting vocational outcomes only).

Conclusion: Stakeholder evidence suggests vocational development is an important area to address in the care of YP with LTHC such as rheumatic diseases. The resulting set of recommendations provides guidance for future research in this area and transitional care developments in rheumatology. Further work in this area should address these aspects to enable better quality evidence and ensure consistency.

REFERENCES:

Disclosure of Interests: None declared
**POS1503-HPR**  
**THE VALUE OF REMOTE CONSULTATIONS WITH A PHYSIOTHERAPIST, SPECIALISED IN AXIAL SPONDYLOARTHROPATHY DURING THE COVID 19 PANDEMIC: EVALUATION OF A MEMBER-SUPPORT PROJECT WITH THE NATIONAL AXIAL SPONDYLOARTHROPATHY SOCIETY.**

E. Clarke1, J. Hamilton2, S. Dickinson3.  
1 ASretch, Committee Member; Bath, United Kingdom; 2 National Axial Spondyloarthritis Society, Policy and Health Services, London, United Kingdom; 3 National Axial Spondyloarthritis Society, Member Support Services, London, United Kingdom

**Background:** COVID-19 caused significant disruption to Axial Spondyloarthritis (AxSpA) services during the initial 2020 lockdown. In response, The National Axial Spondyloarthritis Society (NASS) piloted provision of remote consultations with a physiotherapist specialised in the management of AxSpA to their members in urgent need. This project was funded by the UK National Lottery Fund.

**Objectives:** To provide a total of 130 hrs of remote consultation to members of NASS, unable to access specialist care and in need of self-management advice for their condition.

**Methods:** Remote consultations were offered to NASS members from Sept 2020 to Feb 2021. The preferred format being 1hr assessment and 2 x 30min at 1 and 3 weeks from assessment. Participants consented to video consultations via Zoom and the inclusion of anonymised outcomes and comments in the project evaluation. Patient Reported Outcomes (BASDAI and BASFI) were collected immediately prior to assessment, at final consultation and in April 2021, between 8-16 weeks from final consult. Content was individually tailored, centring on self-management (pacing, sleep management), education (AxSpA pathology, medication) and individualised exercise plans. Exercise plans were formulated through “Rehab My Patient” software, including links to YouTube video references and daily exercise log sheets.

**Results:** 67 members received online consultations, 63 receiving the full 3 sessions. Missed appointment rate = 2.5%. Participants represented a wide geographical area across England and a spread in time since diagnosis.

Patient Reported Outcomes Measures (PROMs) on assessment:  
- Mean BASDAI score (n=55) on assessment = 5.8  
- Mean BASFI score (n=56) = 5.5

24 participants returned PROMs at final consultation, 10 at longer follow-up (8-16 weeks). Results for complete data set (n=10):

<table>
<thead>
<tr>
<th>PROMS</th>
<th>Assessment</th>
<th>Final consultation</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean BASDAI</td>
<td>5.0</td>
<td>4.3</td>
<td>4.0</td>
</tr>
<tr>
<td>Mean BASFI</td>
<td>5.1</td>
<td>4.0</td>
<td>4.1</td>
</tr>
</tbody>
</table>

**Satisfaction:** 60 members completed an online feedback survey provided by NASS:

- 9 Feedback to questions were asked, with a satisfaction scale of 1-5 (ascending positivity).
- 96.6% of all scores were 3 or above.

**Example responses:**
- How would you rate the overall experience: 92% = 5, 100% = 3-5
- To what extent do you feel more confident to manage your condition: 40% = 5, 100% = 3-5
- How useful was it to be in direct contact with a Physiotherapist: 93% = 5, 100% = 3-5

46 members chose to leave additional, overwhelmingly positive comments, with 2 obvious themes arising:

1) The value of the experience and knowledge of the therapist: “was great to have the guidance and support of a professional who knows what they are talking about when it comes to AxSpA”

2) The value of education in condition management: “set me back on track, very helpful for my mental strength in dealing with this enduring disease”, “I learned so much about my AS and ways to keep mobile”

**Conclusion:** A set of 1-3 sessions per person achieved desirable patient reported outcomes with modest and enduring improvements seen in disease activity and function. This pilot project enabled those living with AxSpA across England access to a Physiotherapist highly experienced in treatment of their condition. The majority of participants reported having no previous experience of seeing a therapist with specialised knowledge of their condition. The knowledge and experience of the clinician was a key theme in the positive nature of feedback linking to another key theme of improved confidence to manage their condition. These results highlight the value to patients of specialised knowledge amongst health professionals. Remote consultations may provide access to specialist knowledge “out of area” and may be an efficient method of delivering self-management advice.

**REFERENCES:**


**Disclosure of Interests:** Emily Clarke Speakers bureau: Has previously received speaker fees from Novartis Pharmaceutical UK, Jill Hamilton: None declared, Sally Dickinson: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3004

---

**POS1504-HPR**  
**THE EFFECT OF REMOTE AND FACE-TO-FACE STABILIZATION EXERCISES ON FUNCTIONAL CAPACITY OF ASYMPTOMATIC INDIVIDUALS**

Y. Ozel Ashiyev1, O. Ulger2.  
1 Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Ankara, Turkey

**Background:** In recent years, it has been emphasized that preventive rehabilitation approaches for problems such as low back and neck pain, which are very high in health expenditures, are more cost-effective than treating them. Due to the Covid-19 pandemic, risk factors for individuals’ spinal health have increased and access to health care has become difficult. Therefore, interest in tele-rehabilitation, which is an important part of telehealth, has increased recently.

**Objectives:** This study aims to compare the effects of remote and face-to-face spinal stabilization exercise training on functional capacity tests in asymptomatic individuals.

**Methods:** Individuals who did not have chronic low back and knee pain and between the ages of 18-55 were included in the study. While the face-to-face group traditionally exercised under the supervision of a physiotherapist, the telerehabilitation group exercised with videoconferencing and asynchronous video recordings. Both groups performed progressive spinal stabilization exercises for 3 days a week for 8 weeks (2). Before and after the training functional capacity tests (repetitive reaching, lifting object overhead, and sustained overhead work) were performed (3).

**Results:** Twenty (11 female, 9 male) individuals with a mean age of 30,252±9.06 and a mean body mass index of 24.36±4.09 were included in the study. There was no difference between the baseline values of functional capacity test scores of both groups (p>0.05). There were significant improvements in the repetitive reaching and sustained overhead work tests after the exercise program in both groups (p<0.05), while there was no difference in the lifting object overhead test (p>0.05). There was no difference between the changes in functional capacity test scores between the groups after the training (p>0.05).

**Conclusion:** According to our preliminary results, face-to-face and remote spinal stabilization exercise programs caused similarly positive changes in functional capacity test scores (repetitive reaching, sustained overhead tests) of asymptomatic individuals. These exercises are known to improve deep muscle activation. This development may have led to improvements in tests, which mostly evaluate speed, coordination and endurance. Weight lifting capacities have not changed. This may be because stabilization exercises focus more on deep muscle activation and not on developing superficial muscle strength like upper extremity strength(2). Success of exercise training with telerehabilitation may have contributed to the younger population and possibly better adaptation to technology. It is planned that these preliminary results will be extended and make greater contributions to the current literature.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3291
Background: A Fatigue Management Education in Work (FAME-W) programme was developed for individuals with inflammatory arthritis to manage fatigue in work (McCormack et al., 2018).

Objectives: This study tested the feasibility and acceptability of an online format of FAME-W for a future definitive interventional trial.

Methods: This was a mixed methods study. Participants were randomly allocated to intervention (IG) or control group (CG). The IG received a four-week online FAME-W handbook. Participants were required to complete questionnaires on work presenteeism, fatigue, mood, Health Related Quality of Life (HRQOL) and pain at baseline (T0), and two weeks following intervention (T1). They also attended a focus group and individual interviews. Data were analysed using descriptive statistics.

Results: Seven of ten individuals recruited participated in the study (intervention = 3, control = 4). The majority of participants in both groups had Rheumatoid Arthritis and were working full-time in non-manual jobs. The mean age of intervention participants was 53 ± 10.4 and 56.5 ± 3.7 for the controls. Most of the intervention group were males and the majority of controls were female. Disease activity at baseline was similar for both groups: 3.3 ± 2.5 intervention; 3.0 ± 1.8 control. At follow-up, disease activity did not change for intervention group (3.3 ± 0.57) and reduced slightly for CG (2.7 ± 2.4). Slight improvements were noted for both groups in presenteeism and fatigue between T0 and T1 (Table 1). There was no change in anxiety levels of the intervention group, with improvements noted for controls. Greater improvements were noted for the intervention group for depression and HRQOL. Pain measures showed increased pain for controls at T1 in comparison to the intervention group.

Table 1.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Intervention (n=3)</th>
<th>Control (n=4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (min-max)</td>
<td>Median (min-max)</td>
</tr>
<tr>
<td>T0</td>
<td>T1</td>
<td>T0</td>
</tr>
<tr>
<td>Work Role Function</td>
<td>84.1 (81.9-92.1)</td>
<td>85.7 (83.4-97.2)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>13.0 (8.0-14.0)</td>
<td>10.0 (10.0-14.0)</td>
</tr>
<tr>
<td>HADS Anxiety</td>
<td>5.0 (3.0-6.0)</td>
<td>5.0 (3.0-6.0)</td>
</tr>
<tr>
<td>HADS Depression</td>
<td>5.0 (3.0-5.0)</td>
<td>3.0 (2.0-4.0)</td>
</tr>
<tr>
<td>HRQOL</td>
<td>68.0 (47.0-90.0)</td>
<td>75.0 (65.0-90.0)</td>
</tr>
<tr>
<td>Pain Level</td>
<td>4.0 (2.0-5.0)</td>
<td>2.0 (2.0-4.0)</td>
</tr>
<tr>
<td>Pain Intensity</td>
<td>1.0 (1.0-2.0)</td>
<td>1.0 (1.0-2.0)</td>
</tr>
</tbody>
</table>

Those allocated to FAME-W attended all four sessions. FAME-W participants reported that the programme content was comprehensive and relevant. They stated that the occupational therapist facilitator was able to “see things from a different perspective for managing symptoms.” Participants also reported a better understanding of fatigue: “It helped me understand myself, if you understand it, you can manage it better.” The online delivery format was favored over attending a centre-based programme. Control participants reported the handbook content as “informative and reassuring.” All participants fully completed all study questionnaires and attended focus groups and interviews.

Conclusion: This feasibility study showed that an online programme to improve work ability was feasible and acceptable to individuals with Rheumatic Diseases. Study measures were completed in full and adherence rate was 100% for the intervention. The findings support a definitive intervention trial of FAME-W.

REFERENCES:

Disclosure of Interests: None declared

POS1506-HPR  SYMPTOMATIC LITERATURE REVIEW TO INFORM THE EULAR TASK FORCE FOR RECOMMENDATIONS/ POINTS TO CONSIDER FOR THE NON-PHARMACOLOGICAL MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS

I. Parodis1,2, A. Gomez1, A. Tao1, J. Weng Chow1, D. Pezzella1, C. Girardin1, T. Stamm1, C. Boström1 on behalf of EULAR Task Force for Recommendations/ Points to Consider for the Non-Pharmacological Management of Systemic Lupus Erythematosus and Systemic Sclerosis. 1Karolinska Institutet, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden; 2Örebro University, Department of Rheumatology, Faculty of Medicine and Health, Örebro, Sweden; 3University Hospital of Geneva and University of Geneva, Division of Rheumatology, Department of Medicine, Geneva, Switzerland; 4Medical University of Vienna, Section for Outcomes Research, Center for Medical Statistics, Informatics and Intelligent Systems, Vienna, Austria; 5Ludwig Boltzmann Institute, Cluster Arthritis and Rehabilitation, Vienna, Austria; 6Karolinska Institutet, Division of Physiotherapy, Department of Neurobiology, Care sciences and Society, Stockholm, Sweden

Background: The heterogeneity and complexity of the chronic autoimmune diseases systemic lupus erythematosus (SLE) and systemic sclerosis (SSc requires comprehensive person-centred management, including non-pharmacological approaches. Recommendations for non-pharmacological management are currently lacking.

Objectives: To perform a systematic literature review to inform the EULAR task force for recommendations/points to consider for the non-pharmacological management of adult patients with SLE and SSc. Among research questions formulated by the task force, we aimed at identifying (i) non-pharmacological interventions that have been evaluated and (ii) their target health domains or organ systems.

Methods: We searched the Medline, Embase, Web of Science Core Collection and CINAHL for articles published between January 2000 and June 2021. From the initial search (n=15,803), 2 researchers independently performed the article selection. Conflicts were discussed until consensus with 2 additional researchers. Subsequent data extraction from the selected articles was performed by 4 researchers, with an overarching guidance by 2 additional researchers. Risk of bias assessment was performed according to Joanna Briggs Institute Critical Appraisal Checklists.

Results: A total of 111 articles for SLE and 75 for SSc were selected for analysis. Non-pharmacological interventions identified for SLE included physical exercise (n=34), psychological support (n=21), dietary therapy and nutrition (n=15), patient education and self-management (n=14), photoprotection (n=5), medication adherence interventions (n=5), complementary and alternative medicine (CAM) e.g., Chinese medicine (n=5), multidisciplinary care (n=4), and phototherapy/laser modalities (n=4); Interventions identified for SSc included physical exercise e.g., hand, oral and general exercise (n=21), phototherapy/laser modalities or shockwave therapy (n=15), patient education and self-management (n=10), CAM (n=8), hand-bathing e.g., in paraffin (n=5), manual therapy e.g., osteopathic manipulative treatment (n=5), dietary therapy and nutrition (n=5), oral hygiene (n=2), hyperbaric oxygen or ozone therapy (n=2) and multidisciplinary care (n=2). Target health domains and organ systems identified within SLE included (in descending order) (i) disease activity, (ii) health-related quality of life (HRQoL), (iii) depression/anxiety, (iv) fatigue, (v) organ damage, (vi) inflammatory markers, (vii) psychological stress, (viii) pain, (ix) body composition/anthropometry, and (x) aerobic capacity. Intervention targets in SSc included (i) functional impairment e.g., hand mobility, (ii) skin scarring including microstalias, (iii) HRQoL, (iv) pain, (v) circulation e.g., Raynaud's phenomena and telangiectasias, (vi) skin ulcers, (vii) oral hygiene, (viii) fatigue, (ix) digestion, and (x) depression/anxiety.

Conclusion: Physical exercise was a frequently researched non-pharmacological intervention within both SLE and SSc. While psychological support and dietary therapy/nutrition were frequently investigated in SLE, phototherapy modalities were common in SSc. Patient education and self-management was advocated in both SLE and SSc literature. HRQoL was a frequent target domain in both diseases; while disease activity and psychosocial domains emerged as important targets in SLE, functional impairment and skin-related aspects constituted predominant targets in SSc. Efficacy of interventions varied considerably across studies. Current evidence is limited by the overall small study populations, and the lack of large RCTs.

Table 1. Studies categorised by design.

<table>
<thead>
<tr>
<th>Study design</th>
<th>SLE</th>
<th>SSc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta-analysis of RCTs</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>RCT (including long-term follow-up or post-hoc analysis)</td>
<td>41</td>
<td>28</td>
</tr>
<tr>
<td>Non-randomised longitudinal controlled/cohort studies</td>
<td>28</td>
<td>7</td>
</tr>
<tr>
<td>Retrospective cohort study, cross-sectional or case-control study</td>
<td>16</td>
<td>21</td>
</tr>
<tr>
<td>Case series or open pilot studies</td>
<td>21</td>
<td>37</td>
</tr>
</tbody>
</table>

Acknowledgements: The authors would like to thank the members of the EULAR task force for recommendations/points to consider for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis.
REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4331

POS1507-HPR INVESTIGATION OF THE EFFECTS OF PELVIC FLOOR TRAINING ON PAIN, SEXUAL DYSFUNCTION, AND QUALITY OF LIFE IN FEMALE PATIENTS WITH SJOGREN

K.T. Aydin1, S.Y. Cetin2, A. Ayan3, 1Turkey, Physiotherapy and Rehabilitation, Antalya, Turkey; 2Akdeniz University, Physiotherapy and Rehabilitation, Antalya, Turkey; 3Antalya Health Sciences University, Rheumatology, Antalya, Turkey

Background: Sjögren’s syndrome is a chronic systemic inflammatory disorder (classified as an autoimmune disorder) characterized by lymphocyte infiltrates in exocrine organs. This syndrome is classified as primary sjögren’s or secondary sjögren’s. Dryness of the eyes, oral cavity, larynx, pharynx and vagina is common in primary sjögren’s syndrome. Although vaginal dryness is a symptom seen more frequently in the healthy population, it often occurs at a young age in cases with primary sjögren’s. The presence of urogenital complaints in women with pSS adversely affected the health-related quality of life of pelvic floor function. However, it has been shown that the sexual functions of women with pSS are also negatively affected. Sexual dysfunction and increased pain were seen with increasing pelvic floor dysfunctions. Many studies showing that pelvic floor training has been accepted in the literature as the first step in the treatment of pelvic floor dysfunctions to increase pelvic floor strength and effectiveness. In addition, the positive effects of pelvic floor exercises on sexual functions have been supported by studies.

Objectives: The aim of this study was to investigate the effects of pelvic floor training on pain, sexual dysfunction and quality of life in female patients with pSS and determine whether pelvic floor training was superior to education program.

Methods: 46 pSS patients (46 female) with an average age of 47.78±9.18 were included in the study. Patients were divided into two groups by block randomization method. Group 1 received 30 minutes of pelvic floor training program every day as a home exercise for 8 weeks. Group 2 received education about pelvic floor muscles and daily living activities. Health Assessment Questionnaire (HAQ) was used to evaluate the quality of life. Visual Analog Scale (VAS) and Pelvic Pain Impact Questionnaire (PPIQ) was used to evaluate the sexual dysfunction, Pelvic Floor Disability Index-20 (PFDI-20) was used to evaluate the degree of certain discomfort caused by pelvic symptoms in women, Female Sexual Function Scale (FSFI) was used to evaluate the sexual dysfunction, Pelvic Floor Impact Questionnaire (PFIQ-7) was used to evaluate the effect of bladder, bowel, and pelvic symptoms on the individual’s activities of daily living, social relationships, and emotions. All evaluations were performed at baseline and at the end of the 8th week.

Results: When the groups were compared before training, there was no significant difference (p>0.05). In post-training comparisons, there was a significant difference in FSFI, VAS, PPIQ, PFIQ-7, PFDI-20 in pelvic floor training group (p<0.02-0.00) and FSFI-lubrication, PFIQ-7 and PFDI-20 (p<0.00-0.03) in education group. In addition, after post-training, pelvic floor training group was found to be superior in terms of FSFI total (Z:-3.40, p:0.01), FSFI-organism (Z:-3.13, p:0.02), FSFI-satisfaction (Z:-2.27p:0.02), FSFI-pain (Z:-2.42, p:0.01), PFDI-20 (Z:-3.42, p:0.00), POPDI-6 (Z:-3.00, p:0.00), CRADI-8 (Z:-2.18, p:0.02), UDI-6 (Z:-3.64, p:0.00) compared with education group.

Conclusion: As a result of our study, pelvic floor training has a positive effect on sexual dysfunction and discomfort caused by pelvic symptoms in patients with pSS. Pelvic floor training should be included in rehabilitation programs as a home exercise to improve sexual function and pelvic dysfunction symptoms for patients with pSS.

REFERENCES:


Disclosure of Interests: None declared


POS1508-HPR USE OF PHYSICAL THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS OR AXIAL SPONDYLOARTHRITIS: THE PATIENT’S PERSPECTIVE

M. Van Wissen1, B. Straathof, T. P. M. Vliet Villieland1, M. Teuwen1, C. Van den Ende1,2, W. Peter1, M. G. J. Gademan1,3, S. Van Weely1,1 Leiden University Medical Center (LUMC), Clinical epidemiology, Leiden, Netherlands; Sint Maartenskliniek, Research, Nijmegen, Netherlands; Radboud University Medical Center, Rheumatic Diseases, Nijmegen, Netherlands; Leiden University Medical Center (LUMC), Clinical epidemiology, Leiden, Netherlands

Background: In national and international management guidelines physical therapy (PT) is a recommended treatment for people with inflammatory arthritis (IA). Based on multiple systematic reviews, concluding that supervised exercise therapy and exercise promotion is an effective and safe PT treatment option in patients with IA, recommendation mentions particular endorse active PT treatment. In order to monitor and enhance the quality of PT in clinical practice, knowledge about its active content is needed.

Objectives: To assess the use, frequency, duration and content of PT in patients with IA.

Methods: In this cross-sectional, national study a link to an electronic questionnaire addressing people with rheumatic and musculoskeletal diseases was published between December 2020-July 2021 by the Dutch Arthritis Foundation via their website, newsletter and various social media. It comprised questions on demographic and health characteristics, the EuroQol 5-Dimensions 5-Levels (EQ5D5L) and 29 questions on the usage of PT currently and/or in the past 12 months and, if applicable, the duration, frequency and content of the PT treatment. The content of PT was categorized into exercises (active aerobic, muscle strengthening, range of motion and/or functional exercises), manual treatment, physical modalities and counseling/education. Only data from patients self-identifying as diagnosed with rheumatoid arthritis (RA) and/or axial spondyloarthritis (axSpA) were used for the current study.

Results: A total of 267 people with RA (mean (SD) age 54 (12) years, 96% female) and 104 people with axSpA (age 47 (13) years, 88% female) (10 patients with both diagnoses) completed the questionnaire. More than 90% were treated by a rheumatologist; the mean (SD) EQ5D5L of people with RA was 0.62 (0.2) and of axSpA 0.59 (0.2). 172 RA respondents (64%) reported the use of PT related to their RA (162 individual PT, 1 group PT, 9 both individual and group PT). In axSpA, the rate was 87% (84%; 77 individual PT, 2 group PT, 8 both individual and group PT). Of those reporting individual PT treatment, the duration was long-term (> 3 months) in 134 (89%) and 70 (89%) of the respondents with RA and axSpA respectively, with a duration of more than 2 years in 67 (44%) and 38 (48%). In all users of individual PT, the mean frequency was once per week or less in 116 (77%) of the RA and 63 (80%) of the axSpA patients. Proportions were based on number of respondents to questions on individual PT. Concerning the content of individual PT, and taking into account both short-term and long-term use, for active exercises, the proportion of patients reporting aerobic, muscle strengthening, range of motion or functional exercises ranged from 40-66% in RA and 24-73% in axSpA patients. Regarding manual treatment, the proportions were 61% and 58%, in RA and 73% and 72% in axSpA for massage and passive mobilizations, respectively. With respect to physical modalities (passive), the modality most frequently mentioned were kinesio-taping and dry needling (40 and 25% and 43 and 32% in RA and axSpA). For counseling/education, exercises to perform at home (70 and 78%) and physical activity (PA) promotion (48 and 49%) were most often reported in both RA and axSpA.

Conclusion: Long-term use of PT is common in patients with RA and axSpA. Apart from active treatment modalities (exercises) and promoting recommended PA, passive treatment options appear to be relatively often used. The results must be interpreted with caution, as the respondents may not constitute a representative sample of the IA population, yet warrant further research.
Background: Fatigue is one of the most prevalent and disabling symptoms of systemic sclerosis (SSc). No fatigue specific programs exist for people with SSc. The purpose of this pilot study was to evaluate changes in self-efficacy and use of energy conservation strategies after participation in Fatigue and Activity Management Education for Individuals with Systemic Sclerosis (FAME-iSS).

Methods: Adult participants were recruited from the Scleroderma Foundation chapters and social media to participate in a 6-week, virtual group program focused on SSc-related fatigue. Inclusion criteria: ≥18 years of age, access to device with videoconferencing capabilities, and at least moderate fatigue determined by degree, severity, and distress (scales: 1-10). The program, led by occupational therapists included sessions on factors related to fatigue, management of energy, pain, stress, physical activity and nutrition. At baseline, participants completed a demographic questionnaire, the Self-Efficacy for Performing Energy Conservation Strategies Assessment (SEPESCA) to measure confidence using energy conservation strategies. At post-intervention and 3-month follow-up, participants also completed the Energy Conservation Strategies Survey (ECSS) to identify use and effectiveness of 14 energy conservation strategies (e.g. changing body positions, planning and prioritizing activities, communicating needs) and a qualitative interview to contextualize their responses. Descriptive statistics (means, standard deviations) were used to analyze quantitative data.

Results: The sample for the pilot study included 18 participants (89% women; age 52 ± 11.6 years) with established SSc (disease duration= 13.7 ± 14.5 years). 83% participants completed 100% of FAME-iSS sessions. Directly following the program all 14 energy conservation strategies were used by at least seven (39%) participants. The most frequently used strategy was “planned day to balance rest and activity” which was used by 17 participants post-intervention. (see Table 1). At the three-month follow-up the there was a decline in use for 50% of the strategies and an increase in use for the other 50%.

Conclusion: This pilot study showed that FAME-iSS resulted in increased self-efficacy in use of energy conservation strategies in participants with established SSc. New behaviors were adopted that participants felt reduced their fatigue. The virtual format allowed for sharing of strategies and availability to more people.

Disclosure of Interests: None declared
Background: Physical activity is an important component in the management of people with rheumatoid arthritis (RA) [1]. A Physiotherapist-led Intervention to Promote Physical Activity in people with RA (PIPPRA) was undertaken using the Behaviour Change Wheel, with the aim of examining the feasibility of promoting physical activity in RA. This qualitative study involved participants and health care professionals that participated and were involved in a behaviour change pilot RCT intervention.

Objectives: To determine, qualitatively, the acceptability of PIPPRA to participants with RA and health care professionals, in order to capture their reality.

Methods: A qualitative study design of face-to-face semi-structured interviews was undertaken. The interview schedule explored the following areas: experiences of behaviour change intervention - “I found it very knowledgeable to help you get going” [2]; Improvement in self-management - “... motivate me to go back to doing a little bit more exercise”; Negative impact of COVID-19 on physical activity in RA. This qualitative study involved participants and health care professionals who participated and were involved in a behaviour change intervention.

Results: Fourteen participants [13 female/1 male; mean age of 59 (SD 6.3); mean RA diagnosis of 8.6 (SD 6.8) years; moderate to severe disability (HAQ-DI: 1.4 (SD 1.2)); 8 and healthcare staff [4 female/4 male; mean age of 41 (SD 5.6)] participated. Main themes were generated from participants: 1) Positive experience of behaviour change intervention - “I found it very knowledgeable to help you get going”; 2) Improvement in self-management - “… motivate me to go back to doing a little bit more exercise”; 3) Negative impact of COVID-19 on physical activity - “I don’t think doing it online again would be really good at all”. Two main themes from health care professionals - 1) Positive learning experience of behaviour change delivery - “Really made me realise the importance of discussing physical activity with patients”; 2) Positive approach to recruitment - “Very professional team showing the importance of having a study member on site”.

Conclusion: The findings demonstrated that participants had a positive experience of being involved in a behaviour change intervention in order to improve their physical activity and find it acceptable as an intervention. However, if given the choice they would prefer the intervention delivery face to face rather than telehealth. Healthcare professionals also had a positive experience and in particular found it beneficial to their own development, in particular the importance of recommending RA to patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.87
Results: 110 respondents of working age took part, including 105 women (95.45%) and 5 men (4.55%). A mean age of the study participants was 32.8 ± 7.97 years, women were a mean age 32.6 ± 7.80, and men - 36.4 ± 11.44. The mean duration of the time experience of SLE a mean experience of 6.4 ± 4.08 years women 6.4 ± 5.77. High activity disease was observed in 37 people (35.2%), and mild and moderate activity - in 73 (64.8%). 59 women (56%) and 2 men (40%) responded positively to the question about the availability of paid work. The activity of the majority of working patients was associated with mental labor - 58 people (53%). Among the unemployed group of respondents, which made up 44%. The number of survey participants, 76% of respondents associate the lack of paid work with the presence of SLE. Absenteeism was zero in 38 patients (62.3%), which indicates that more than half of the patients did not miss work during all the analyzed days. 6 out of 38 (15.8%) had a high activity disease. A mean value of presenteeism in the group of actual workers during the study period was 50.45 ± 28.60% of working time. A mean value of absenteeism was 41.78 ± 36.73%. Work productivity loss in 61 patients with a job was 52.73 ± 30.55%, activity impairment, which was determined in all patients included in the study, was reduced by 51.68 ± 28.44%. In the course of our study, it was revealed that 44.5% of the surveyed patients with SLE of working age do not have a paid job. The absolute majority associate this fact with the influence of the disease on their ability to work. It is also important to say that 23 (37.7%) people out of 61 employees missed work due to their illness. Damage to the musculoskeletal system during the progression of SLE affects the ability to work, labor productivity and daily activity of the adult population is confirmed by the above indicators (presenteeism 50.45 ± 28.60%, absenteeism 41.78 ± 36.73%, work productivity loss 52.73 ± 30.55%, activity impairment 51.68 ± 28.44%).

Conclusion: Activity disease, functional insufficiency and damage developing as a result of the progression of SLE and ongoing therapy have a direct relationship with a decrease in labor productivity, disability and disability, which is confirmed by the values of presenteeism, absenteeism, work productivity loss and activity impairment.

REFERENCES:
2. Sokolova C.R. Poor health-related quality of life (HRQOL) and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus (SLE) patients / C.R. Sokolova, R.V. Gamboa Cardenas, M. Medina // Annals of Rheumatic Diseases. - 2019. - Vol. 78. - No. 2.

Disclose of Interests: None declared


POS1515-HPR UNDERSTANDING AND CHARACTERISING PATIENTs’ PATHWAYS TO TREATMENT FOR VERTEBRAL FRACTURES: A QUALITATIVE STUDY

S. E. Bennett1, R. Gooderman-Hill1, E. Clark1, Z. Paskins2, N. Walsh5, S. Drew1.
1University of Bristol, Bristol Medical School, Bristol, United Kingdom; 2Academic Rheumatology Centre, Midlands Partnership NHS Foundation Trust, Stoke-on-Trent, United Kingdom; 3University of the West of England - UWE Bristol, Centre for Health and Clinical Research, Bristol, United Kingdom

Background: Osteoporosis involves thinning of the bones, making them more prone to break. The most common osteoporotic fracture is a vertebral fracture (VF). People with Osteoporosis are at high risk of further fractures. To reduce this risk, guidelines recommend prescription of bone protection therapies to people who have experienced a fracture. However, many patients do not receive diagnosis. Understanding patient pathways to treatment for OVFs will provide information to improve practice and aid in effective identification and management.

Objectives: To understand and characterise patient pathways to treatment for OVFs.

Methods: Twenty-three semi-structured qualitative interviews were conducted with patients aged ≥50 years with diagnosis of OVf. Patients were recruited through two hospitals in England and were purposively sampled to capture variation in pathways to diagnosis, sex, age, comorbidities and other relevant characteristics. Interviews were audio-recorded, transcribed and analysed thematically, with themes transposed onto key stages of the patient pathway.

Results: Several factors were found to be associated with treatment: Patient appraisal and self-management: Characteristics and attitudes towards back pain impacted treatment-seeking behaviour. Patients who appraised their pain as ‘different’, ‘severe’ or ‘different’, or associated with an injury such as a fall, were more likely to seek help. Limited availability of information about OVFs and risk factors meant most patients did not associate symptoms with a potential OVF. Factors contributing to delayed consultation included the normalisation of back pain and prioritisation of comorbid conditions. Several misattributed their symptoms as a ‘pulled muscle’ or other minor injury. Many adopted strategies to manage pain, including use of painkillers, lying flat or resting. For some, a lack of improvement in symptoms over time, combined with worsening pain, created a ‘tippping point’ in seeking care. There was a moral dimension for some patients who did not want to ‘bother’ healthcare professionals.

CONCLUSION: Healthcare professionals, and patients, are influenced by Differentiation was a barrier to treatment and healthcare professionals interpreted OVF pain as broken ribs, muscular pain, kidney pain or sciatica. GPs tended to instigate watchful waiting, in which patients were asked to re-consult if pain did not improve. Feeling disbelieved caused some patients to become disillusioned and reluctant to re-consult and a small number of patients presented at Accident and Emergency. Those already having a limit for musculoskeletal conditions with access to specialist care, were more likely to receive timely diagnosis.

Communication of diagnosis: Patients discussed multiple methods of communication, including written communication and clinical conversations. Several expressed confusion around the use of unfamiliar medical terminology, the implications of OVFs, how many OVFs they had experienced and how they had been identified.

Treatment initiation: Bone protection therapies were not consistently prescribed after diagnosis. Patients who were familiar with these therapies were unsure whether treatment should be initiated in primary or secondary care. Patients described how they felt a need to be proactive by arranging appointments and asking for treatment.

Conclusion: The study provides novel findings about patient pathways to treatment and will be used to identify targeted solutions to improve management of OVFs. This work addresses stages of the Model of Pathways to Treatment[1] and provides detailed understanding of patients' experiences of these stages. Further work with healthcare professionals in primary care is underway to identify additional system-level factors that may impact patients' journeys to treatment.

REFERENCES:

Acknowledgements: This study is funded by the National Institute for Health Research (NIHR) Research for Patient Benefit (RfPB) programme NIHR201523. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Disclosure of Interests: None declared


POS1515-HPR - CONJUGAL RELATIONSHIPS IN MARRIED PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISMS

O. Hamdi1, S. Jemmi1, S. Boussaid1, S. Rahmouni1, S. Rekki1, H. Sahli1, M. Elleuch1,2.
1La Rabta hospital, Rheumatology, Tunisia, Tunisia

Background: The consequences of chronic inflammatory rheumatisms (CIR) on the sexuality and the relationships between the subject and his/her partner are still underestimated and insufficiently studied.

Objectives: The aim of this study was to investigate the impact of CIR on conjugal relationships.

Methods: We conducted a cross-sectional study involving patients with rheumatoid arthritis (RA) (2010 ACR/EULAR criteria) and spondyloarthritics (SpA) (2009 ASAS criteria). All the patients included in the study were married. We collected demographic data, and participants were asked to complete a questionnaire on their conjugal relationships.

Results: We enrolled 75 patients (40 RA and 35 SpA) with a sex ratio of 0.4 and a mean age of 55.35 ± 9.81 years [22-85]. The mean chronic CIR duration was 18 years. The mean age of marriage was 27 ± 6.41 years [19-33]. The mean number of off-springs was 4. Forty-nine percent of patients and 22.3% of the partners had a profession, respectively. Forty one percent of the partners had a chronic disease: diabetes (n=12), hypertension (n=10), dyslipidemia (n=7), CIR (n=7), coronary disease (n=5), and other conditions (n=5). A psychiatric illness was noted in 22.6% of cases: depression (n=9), anxiety (n=6), and bipolar disorder (n=2). Sixty-four percent of patients consider their spouses sympathetic to their illness. Eighty-nine percent of participants have noticed a change in their life as a couple before and after the CIR onset. According to 64% of participants, the CIR had a negative impact on their married lives. The spouses' emotional reactions to the disease were as follows: indifference (30.6%), denial (29.3%), anger (26.6%), and fear (13.3%). Patients reported being accompanied by their spouses to their medical appointments in 36% of cases, and 40% of them were asked questions by their spouses about their disease and treatment. The CIR has resulted in the termination of the marriage in 2.6% of cases.
Inclusion: Patients suffering from chronic diseases such as CIR are more frequently exposed to difficulties in their conjugal relationships. The disease has thus important consequences on the subject's quality of life, emotional and interpersonal state. A better compliance with the chronic disease and its treatment may improve the couples' relationships.

Disclosure of Interests: None declared


POS1516-HPR

CHRONIC INFLAMMATORY RHEUMATISMS: DOES PERIODIC FASTING REDUCE THE DISEASE ACTIVITY?

O. Hamdi1, S. Jemmali2, W. Kammoun3, S. Bousaid4, S. Rahmouni5, S. Reki1, H. Sahli1, M. Elleuch1. 1La Rabta hospital, Rheumatology, Tunisia, Tunisia; 2Pasteur Institute, Immunology, Tunisia, Tunisia

Background: Many experimental studies have emphasized the role of periodic fasting in the adaptive responses that reduce inflammation.

Objectives: Our purpose was to assess the impact of periodic fasting on the activity of chronic inflammatory rheumatisms (CIR).

Methods: We conducted a cross-sectional study involving patients with rheumatoid arthritis (RA) (2010 ACR/EULAR criteria) and spondyloarthritis (SpA) (2009 ASAS criteria). CIR activity was assessed during the period of Ramadan (periodic fasting) and three months following Ramadan using clinical parameters including the Patient's Global Assessment of disease activity (PGA), 10-cm Visual Analog Scale (VAS) pain score, morning stiffness, nocturnal awakenings, and joint count for RA (tender joint count (TJC) and swollen joint count (SJC)); biological parameters including C-reactive protein (CRP); disease activity scores including the SDAI, CDAI and DAS28 CRP.

Results: Eight participants with rheumatoid arthritis: seven females; mean [standard deviation, SD] age 52.4 [9.5] years; mean [SD] disease duration 16.1 [16.4] years; eight clinicians; mean [SD] age 46.75 [5.3] years; mean [SD] years of clinical experience 19.5 [2.21] years. Four main themes were identified (Table 1): ‘Feet are a priority’ as the impact of RA on the feet was substantial and had a negative impact on quality of life. The second theme was ‘Need for a clinically feasible foot PROM’ as clinicians and patients recognised the lack of a clinically feasible tool that can determine RA foot disease. The third emerging theme was ‘RADAI-F5 facilitators’ as the tool can promote communication, guide management, help screen foot symptoms, monitor foot disease status and treatments longitudinally, and promote patient education. The final theme was ‘RADAI-F5 barriers’ as there were associated practical difficulties, including lack of appointment time, administrative burdens associated with PROM use, lack of trust in the RADAI-F5’s validity and IT barriers since there is no universal electronic system for reporting RADAI-F5 results.

Table 1. Themes with respective quotes that emerged as part of the individual interviews to understand the clinical utility of the RADAI-F5

<table>
<thead>
<tr>
<th>Theme</th>
<th>Quotations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Theme 1: Feet are important</td>
<td>“Foot disease is common and it’s troublesome for patients.” (C16)</td>
</tr>
<tr>
<td>Theme 2: Existing methods for measuring foot disease activity are inadequate</td>
<td>“The feet are under-represented in the clinical tools for assessing disease activity, and clinicians don’t look at feet enough.” (C11)</td>
</tr>
<tr>
<td>Theme 3: RADAI-F5 facilitators</td>
<td>“I think (The RADAI-F5) improves the clinician-patient relationship.” (C15)</td>
</tr>
<tr>
<td>Theme 4: RADAI-F5 barriers</td>
<td>“I mean, this (RADAI-F5) will obviously go along with other tools. You know, the blood tests and things as well.” (P01)</td>
</tr>
</tbody>
</table>

Conclusion: The RADAI-F5 has significant potential as a therapeutic tool to aid in managing foot disease in RA. However, several implementation barriers need to be overcome before widespread use in rheumatology clinics can occur.

References:

Acknowledgements: Gordon Hendry, Diane Dickson and Martijn Steultjens

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.596

POS1517-HPR

PATIENT AND CLINICIAN PERSPECTIVES ON IMPLEMENTING THE RADAI-F5 TOOL TO HELP INFORM THE ASSESSMENT AND MANAGEMENT OF FOOT DISEASE IN RA: A QUALITATIVE STUDY

A. Hoque1, D. Dickson1, M. Steultjens1, G. Hendry1. 1Braga, Portugal

Background: While patient-reported outcome measures (PROMs) are widely recommended in clinical care, their application is limited [1]. The RADAI-F5 is a validated PROM to determine RA foot disease activity [2]. Patients’ and clinicians’ perceptions of the RADAI-F5’s clinical utility have yet to be captured.

Objectives: This study aims to explore patient and clinician opinions and perceptions of the clinical utility of the RADAI-F5 in managing rheumatoid foot disease.

Methods: A 60-minute semi-structured interview using video conference calls with adult RA patients and rheumatologists, physiotherapists, and podiatrists was conducted as part of the interpretive phenomenological analysis research. The interviews included open-ended questions about the effect of foot disease, current clinical utilization of PROMs, and barriers and facilitators to the clinical application of the RADAI-F5.

Results: Twenty-five patients (female 72.4%, male 27.6%; mean age 51.0 ± 13.2 years; education ≤ 9 years 39.7%, ≥ 9 years 60.3%). Of these, 33 had a diagnosis of RA and 25 of PsA (mean years of disease duration = 8.2 ± 7.3 years; mean disease activity by DAS28-PCR or DAS28-PCR 3 variables = 2.3 ± 0.95). Between March 2021 and June 2021, a brief questionnaire was applied with sociodemographic and clinical variables, such as the use of classic or biological DMARDs and their administration’s route. The Specific Beliefs About Medication Scale (BMQ) was anonymously applied, adapted from the Beliefs About Medicines Questionnaire, comprising 2 sections: section 1 – Specific Needs, patients beliefs about the need for medication;
section 2 – Specific Concerns, beliefs related to the dangers of addiction and long-term toxicity or side effects. Higher scores (scale from 5 to 25 points), in sections 1 and 2, reflect the belief of greater need and greater concern regarding medication, respectively. The average scores in section 1 and in section 2 of the BMQ were 9 and 15.7 points, respectively. Statistics: descriptive, Student t-Test, Pearson Correlation and ANOVA, p<0.05.

Results: Patients with PsA and younger age had a higher mean score in section 2 of the BMQ (p<0.049 and p<0.01, respectively). The variables male gender, education ≥ 9 years and shorter duration of the disease also showed a tendency to be associated with the higher score in section 2 of the BMQ, with p-values close to statistical significance (p=0.091, p<0.074 and p=0.094, respectively). In the multivariate analysis with the above variables, only the diagnosis of PsA showed a statistically significant association with the score in section 2 of the BMQ (B=-4.269; p<0.001; CI 95%=[-2.060-6.477]). There was also a statistically significant correlation (p<0.007) between the scores in section 1 and section 2 of the BMQ.

Conclusion: Patients with PsA and younger age are more concerned about the possible adverse effects of medication than patients with RA. RA patients who take subcutaneous drugs are more afraid of the drug’s toxic potential, and those with lower disease activity have a greater need to comply with the prescribed therapy, which can be explained by the previous effectiveness of the drug in disease control. It was also found that the greater the belief in the need for medication, the greater the concern with its possible long-term harmful effects.


Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.709

POS1520-HPR

RHEUMATOLOGY PATIENTS TREATED WITH A BDMARD PERSPECTIVE TOWARDS THERAPEUTIC DRUG MONITORING

M. Leeuw1, S. Atiq1, F. De Vries2, L. Boekel1, F. Hooijberg1, M. Nurmohamed1,2, G. J. Wolbink1,2, C. Krieknaert1.

1Reade, Locatie Dr. Jan Van Bremenstraat, Rheumatology, Amsterdam, Netherlands; 2OL VG, Location East, Pharmacology, Amsterdam, Netherlands; 3Amsterdam UMC, Locatie VUmc, Rheumatology, Amsterdam, Netherlands; 4Sanquin Blood Supply, Immunopathology, Amsterdam, Netherlands; *OL VG, Location East, Rheumatology, Amsterdam, Netherlands

Background: Therapeutic Drug Monitoring (TDM) is a tool to determine the optimal dose of a drug for individual patients using measurement of blood concentrations and, optionally, anti-drug antibodies (ADA). In the field of rheumatology interest in applying TDM is increasing. A recent study by Syversen et al., the NOR-DRUM B trail, supports TDM as a treatment strategy. This study showed that treatment with proactive TDM was more effective than treatment without TDM. Applying TDM creates a more personalized treatment for individual patients, therefore it is relevant to understand the patients perception towards TDM.

Objectives: To study the perspective of rheumatology patients treated with a bDMARD in a personalized fashion using TDM.

Methods: Adult rheumatology patients from the Amsterdam Rheumatology and Immunology Center who participate in the COVID-19 prospective cohort study (Netherlands Trial Register, trial ID NL8513) received a digital questionnaire which comprised, in addition to demographic items, of three TDM topics: familiarity, attitude and risk assessment.

Results: Participants were selected based on the following criteria: treatment with a bDMARD and a fully completed questionnaire (n=888). Table 1 shows characteristics of study population.

Table 1. Characteristics of study population

<table>
<thead>
<tr>
<th>Total N= 888</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr Mean (SD)</td>
</tr>
<tr>
<td>Gender, female - N (%)</td>
</tr>
<tr>
<td>Diagnosis* - N (%)</td>
</tr>
<tr>
<td>RA</td>
</tr>
<tr>
<td>PSA</td>
</tr>
<tr>
<td>AS</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Enanetcort</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

* Some patients reported more than one diagnosis** Three patients reported more than one bDMARD

Sixty-six percent (n=582) of the participants had never heard of the concept personalized dosing, using TDM. After explaining the concept 60% (n=535) of the participants answered they have a positive attitude towards the concept. Participants with a positive attitude received a follow-up question. They were asked which of the following related aspects: individual dosing, costs, safety and other, they thought was most relevant regarding the concept. Multiple answers were possible. Ninety-four percent (n=502) reported as the main reason for having a positive attitude, that the treatment can be personally adjusted. The second and third reasons, respectively, were safety 43% (n=230) and costs 27% (n=142) of the treatment.
Five percent (n=43) of the participants had a negative attitude towards the concept. Main reasons were; previous experience with unsuccessful dose reduction and unwillingness to change current treatment due to the fact that several previous treatments were ineffective. Participants were also asked what amount of risk they are willing to take when presented with five different situations; worsening rheumatological symptoms: e.g. pain and swelling, increased fatigability, necessary treatment with prednisone, switching to another bDMARD or more frequent visits to rheumatologist. Majority of the patients reported for each of the five situations, respectively: 37% (n=330), 40% (n=359), 51% (n=453), 48% (n=426) and 29% (n=262) that they would only be willing to take a negligible risk, < 0.1%. 

Conclusion: Majority of participants was not familiar with the concept of personalized dosing using TDM. However, the majority had a positive attitude towards the concept. The main reason for a positive attitude is that the treatment can be personally adjusted. On the other hand, patients who are currently being treated with a bDMARD were only willing to take a negligible risk when it comes to their own treatment.

REFERENCES:
Background: Patients with chronic disease need to learn and adapt to symptoms, treatment, and the impact of disease. Knowledge about the specific disease is one way to empower the patients to cope. We previously reported that disease duration and sex, rather than disease characteristics associate with an increased need of educational support in AAV associated vasculitis (AAV) [1]. Data on how specific educational needs vary between different inflammatory rheumatic diseases are lacking.

Objectives: The aim of the study was to compare educational needs among two chronic systemic inflammatory diseases, AAV and Systemic lupus erythematosus (SLE) using the Educational Needs Assessment Tool (ENAT).

Methods: This pilot study included cross-sectional data from two separate cohorts, AAV and SLE, from the Rheumatology clinic at Karolinska University Hospital in Sweden during 2009-2022. Inclusion criteria were minimum age of 18 years and literate in Swedish. Exclusion criterion was cognitive impairment interfering with literate capabilities. Educational needs were captured by patients’ answers to the questionnaire ENAT. The ENAT consists of 39 questions, presented as total ENAT and seven domains (managing pain, movement, feelings, disease process, treatment, self-management and, support systems) each containing 4-7 items (from ‘not at all important’ = 0, to ‘extremely important’ = 3). The participants’ responses were presented as ‘mean % of the domain score’ from 0 interpreted as no educational need to 100 as highest educational need. Participants with SLE and AAV respectively were individually matched for disease duration, sex, and education. For comparisons paired samples t-test were used.

Results: Twenty-two matched pairs (86% female), mean (SD) disease duration 5.7 (8) years, were included. The mean age were 43 (14.0) years for AAV 61 and (14.7) years for SLE (p=0.001), Educational length was reported as mean 14 (3.6) years among SLE patients and 13 (2.9) years among AAV patients (p=0.111). In all patients, the mean total ENAT was 60.4% (range 23-100%) and did not differ between the two cohorts (p=0.2) (Table 1). In the pooled group the highest educational need was found in the domains ‘Disease process’ (mean 78.3%) and ‘Self-management’ (mean 75.9%). Lowest educational need was found in the domains ‘Movement’ (mean 46.7%) and ‘Managing pain’ (mean 51.6%).

Table 1. Comparison of ENAT scores (mean % of max) between patient with SLE and AAV

<table>
<thead>
<tr>
<th>ENAT domain</th>
<th>All n=44</th>
<th>SLE n=22</th>
<th>AAV n=22</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Managing pain</td>
<td>51.6 (29.8)</td>
<td>50.8 (28.7)</td>
<td>52.4 (32.2)</td>
<td>0.867</td>
</tr>
<tr>
<td>Movement</td>
<td>46.7 (35.1)</td>
<td>41.9 (34.2)</td>
<td>47.3 (35.7)</td>
<td>0.500</td>
</tr>
<tr>
<td>Feelings</td>
<td>63.1 (31.0)</td>
<td>54.6 (30.6)</td>
<td>70.4 (30.3)</td>
<td>0.087</td>
</tr>
<tr>
<td>Disease process</td>
<td>78.3 (2.2)</td>
<td>73.9 (23.0)</td>
<td>83.4 (20.9)</td>
<td>0.130</td>
</tr>
<tr>
<td>Treatments</td>
<td>60.7 (35.1)</td>
<td>64.6 (36.0)</td>
<td>74.2 (30.4)</td>
<td>0.021</td>
</tr>
<tr>
<td>Self-management</td>
<td>75.9 (21.1)</td>
<td>75.8 (18.8)</td>
<td>76.9 (24.3)</td>
<td>0.886</td>
</tr>
<tr>
<td>Support systems</td>
<td>54.0 (30.2)</td>
<td>49.2 (31.4)</td>
<td>59.7 (28.8)</td>
<td>0.302</td>
</tr>
<tr>
<td>Total ENAT</td>
<td>60.4 (24.0)</td>
<td>55.7 (22.8)</td>
<td>65.0 (24.8)</td>
<td>0.216</td>
</tr>
</tbody>
</table>

Patients with AAV report a higher educational need in total ENAT as well as in all individual domains, compared to SLE (Table 1), but only significantly in the domain ‘Treatments’ where the educational need among AAV was mean 74.2% (30.4) and for SLE mean 46.4% (SD 36.0) (p = 0.02).

Conclusion: In this pilot study with SLE and AAV, we found educational needs regarding ‘Treatments’ to be substantially increased among the participants with AAV compared to SLE, despite that the participants were matched for disease duration and sex, two variables previously found to be indicators of increased educational needs. AAV patients with higher educational needs were older, this result needs to be further explored in a larger sample.

Acknowledgements: We are grateful to the participating patients, and colleagues assisting in the data collection.

Disclosure of Interests: None declared


Table 1. Patient rating of experience in pharmacist clinic.

<table>
<thead>
<tr>
<th>Statement</th>
<th>No answer</th>
<th>Strongly disagree</th>
<th>Disagree</th>
<th>Neither</th>
<th>Agree</th>
<th>Strongly agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>The pharmacist put me at ease</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>46</td>
<td>11</td>
</tr>
<tr>
<td>The information provided was easy for me to understand.</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>13</td>
<td>42</td>
<td>42</td>
</tr>
<tr>
<td>The pharmacist listened to what I had to say.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>48</td>
<td>48</td>
</tr>
<tr>
<td>The pharmacist showed care and sensitivity to my Rheumatological condition.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td>The pharmacist appeared knowledgeable about the medication to be started.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>8</td>
<td>49</td>
<td>49</td>
</tr>
<tr>
<td>I feel that the medication I am starting has been chosen for me as an individual.</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>I understand why we are starting the new medication.</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>10</td>
<td>45</td>
<td>45</td>
</tr>
<tr>
<td>I have been told about the side effects the medication could cause.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td>I feel that it is safe to start the new medication.</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>15</td>
<td>34</td>
<td>34</td>
</tr>
<tr>
<td>I was able to discuss my concerns and ask questions about the new medication.</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>11</td>
<td>46</td>
<td>46</td>
</tr>
<tr>
<td>I felt included in the decision to start or change to new medication.</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Overall, my experience in the pharmacist clinic today was a positive one*</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>10</td>
<td>43</td>
<td>43</td>
</tr>
</tbody>
</table>

*Statement excludes results from 4 patients who did not complete the second page of the survey.
Conclusion: The results demonstrate the high level of patient satisfaction attained from the Specialist Pharmacist clinic. A small number of patients remain sceptical about medication safety, despite discussion. Inclusion of a pharmacist is especially useful to manage the increasing number of patients starting these medications, maintaining excellent patient experience, reducing the workload for other Rheumatology staff, and ensuring a robust MDT.

REFERENCES: Not applicable.

Disclosure of Interests: Claire Jones Speakers bureau: Presented to rheumatology pharmacists at King’s College hospital London, Dec 2017. Purpose: to share my role to aid their development. Paid by UCB: £1000., Consultant of: Focus group for Fresenius Kabi Sept 2021. Received £500 honorarium, Jeanette Trickey: None declared


Figure 1. Participants’ responses to each treatment

Introduction

A cross-sectional, online survey-based study was conducted in Sweden. People with diagnosed knee or hip OA were recruited through social media outlets and patients’ associations. The survey was divided into two sections: (i) participants’ demographic and clinical characteristics (e.g. gender, age, income, work, height, weight, level of physical activity, previous surgeries, pain, level of disability) and (ii) a set of items with 22 treatments (e.g., weight advice, physical activity, supplements, etc.) where participants were asked to report whether each treatment was ‘recommended’, ‘optional’, ‘not recommended’, or ‘I don’t know’ for the management of knee or hip OA. In the analyses, we grouped the 22 proposed treatments into ‘recommended’, ‘optional’, ‘not recommended’, and ‘I don’t know’ for the management of knee or hip OA. In the analyses, we grouped the 22 proposed treatments into ‘recommended’, ‘optional’, and ‘not recommended’ according to existing international guidelines. Based on the responses, participants were categorised as ‘aware’ if they correctly identified all the treatments, ‘partially aware’ if they correctly identified at least one treatment, and ‘not aware’ if they did not correctly identify any of the treatments.

Methods: A cross-sectional, online survey-based study was conducted in Sweden. People with diagnosed knee or hip OA were recruited through social media outlets and patients’ associations. The survey was divided into two sections: (i) participants’ demographic and clinical characteristics (e.g. gender, age, income, work, height, weight, level of physical activity, previous surgeries, pain, level of disability) and (ii) a set of items with 22 treatments (e.g., weight advice, physical activity, supplements, etc.) where participants were asked to report whether each treatment was ‘recommended’, ‘optional’, ‘not recommended’, or ‘I don’t know’ for the management of knee or hip OA. In the analyses, we grouped the 22 proposed treatments into ‘recommended’, ‘optional’, and ‘not recommended’ according to existing international guidelines. Based on the responses, participants were categorised as ‘aware’ if they correctly identified all the treatments, ‘partially aware’ if they correctly identified at least one treatment, and ‘not aware’ if they did not correctly identify any of the treatments. Participants comprised 123 people with OA of the knee, hip or both (N=65, 22%; N=27, 22% and N=33, 26% respectively). Their mean (SD) age was 60.3 (8.8) and 108 (88%) were women. Forty-eight (39%) were ‘aware’ of the recommended treatments, 63 (50%) ‘partially aware’ and 14 (11%) were ‘not aware’ of the treatments. Two (2%) were ‘aware’, 103 (82%) ‘partially aware’ and 20 (16%) were ‘not aware’. For the treatments that were not-recommended, none was ‘aware’, while 69 (55%) and 56 (45%) were considered ‘partially aware’ and ‘not aware’, respectively. Figure 1 summarises the responses of the participants to each treatment item.

Results: Participants comprised 123 people with OA of the knee, hip or both (N=65, 22%; N=27, 22% and N=33, 26% respectively). Their mean (SD) age was 60.3 (8.8) and 108 (88%) were women. Forty-eight (39%) were ‘aware’ of the recommended treatments, 63 (50%) ‘partially aware’ and 14 (11%) were ‘not aware’ of the treatments. Two (2%) were ‘aware’, 103 (82%) ‘partially aware’ and 20 (16%) were ‘not aware’. For the treatments that were not-recommended, none was ‘aware’, while 69 (55%) and 56 (45%) were considered ‘partially aware’ and ‘not aware’, respectively. Figure 1 summarises the responses of the participants to each treatment item.

Conclusions: Survey participants seem to be more aware of the recommended treatments than the optional and non-recommended ones. A more holistic approach in the education of people with OA should be pursued, providing them with a complete overview of the possible OA treatments. This would help patients identify the most appropriate treatment option for their OA and facilitate a shared decision-making with their health professionals.

REFERENCES:


Disclosure of Interests: None declared


Figure 1. Participants’ responses to each treatment

Conclusion: Survey participants seem to be more aware of the recommended treatments than the optional and non-recommended ones. A more holistic approach in the education of people with OA should be pursued, providing them with a complete overview of the possible OA treatments. This would help patients identify the most appropriate treatment option for their OA and facilitate a shared decision-making with their health professionals.

REFERENCES:


Disclosure of Interests: None declared


Figure 1. Participants’ responses to each treatment

Conclusion: Survey participants seem to be more aware of the recommended treatments than the optional and non-recommended ones. A more holistic approach in the education of people with OA should be pursued, providing them with a complete overview of the possible OA treatments. This would help patients identify the most appropriate treatment option for their OA and facilitate a shared decision-making with their health professionals.

REFERENCES:

problems at various moments along their patient journey; this population can benefit from more continuous information about their medication and healthcare provider support to manage drug-related problems. To most effectively employ telehealth applications for individuals with a rheumatic disease, it is important that offered technologies match with patients’ needs and preferences.

**Objectives:** Identify factors influencing the preference of patients with rheumatic diseases regarding telehealth applications.

**Methods:** A qualitative descriptive study was performed in the Netherlands between May and June 2021. Using a semi-structured interview guide, patients with a rheumatic disease were interviewed face-to-face. First, patients were presented four telehealth applications (frequently asked questions page, digital human, and chatting with video calling with healthcare providers). Second, patients were asked to use each application to answer one medication-related question predefined by the research team. During the process of finding an answer to the question, patients were asked to think aloud and were questioned on which factors influenced their experience and preference for each application. Third, patients were given additional hypothetical questions after which they were asked to explain their preferred application for answering the question, to elicit additional factors influencing preference. Interviews were audio recorded, transcribed verbatim and analysed thematically.

**Results:** Fifteen patients (aged 19–73 years, 53% female) participated. Three domains influenced patients’ preference for telehealth applications. First, preference for telehealth applications was influenced by factors related to individual patients such as medication-related information needs, literacy, and skills with digital applications. Second, preference was influenced by factors related to the specific applications such as speed of answer, level of interaction, extent of privacy, the perceived usefulness of an application, and usability of the application. Third, preference was influenced by factors related to the context in which telehealth applications are offered, such as the support from healthcare providers in using telehealth applications, reliability of information source, and potential of telehealth to save time for healthcare providers.

**Conclusion:** Patients’ preference for telehealth applications is influenced by patient-related, application-related and context-related factors. To effectively support patients with rheumatic diseases, telehealth applications should match with patients’ preferences. Furthermore, it is important to offer a variety of telehealth applications as preferences differ among patients and circumstances.

**REFERENCES:**


**Disclosure of Interests:** None declared  

**POSIS1527-HPR**

**HEALTH PROMOTION IN INDIVIDUALS WITH KNEE PAIN – DIFFERENT WAYS TO ENABLE AND MAINTAIN A BALANCE IN EVERYDAY LIFE BASED ON THE ABILITIES**

C. Sylwander1,2, M. Andersson1,2, E. Haglund3,4, E. Sunesson1, I. Larsson1,2,3

**Background:** Most individuals with knee pain develop radiographic knee osteoarthritis (KOA) with axSpA aged between 40 to 65 were included. Frailty status was determined using KOA checklist. Patients were groups as pre-frail, frail and robust individuals. Frailty was accepted as pre-frail, +4 pre-frail, frail. Nutritional status, disease activity, functional level and quality of life were assessed using Mini Nutritional Assessment (MNA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankiloan Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) respectively. Analysis of variance and multivariate linear regression analyses were used to assess group differences and factors associated with frailty status.

**Methods:** In this monocentric cross-sectional study 50 patients (26 women) with axSpA aged between 40 to 65 were included. Frailty status was determined using KOA checklist. Patients were groups as pre-frail, frail and robust individuals. Frailty was accepted as pre-frail, +4 pre-frail, frail. Nutritional status, disease activity, functional level and quality of life were assessed using Mini Nutritional Assessment (MNA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankiloan Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) respectively. Analysis of variance and multivariate linear regression analyses were used to assess group differences and factors associated with frailty status.

**Results:** The mean age of the patients was 51.7±8.77, the mean disease duration was 7.8±4.1 years, the mean body mass index was 29.98±4.72kg/m². Twenty-one patients were classified as frail, 16 was pre-frail and 13 was robust. Compared to robust patients, pre-frail and frail individuals had significantly higher BASFI, BASDAI and ASQoL scores. There was a significant high correlation between the KOA checklist score and worse BASFI (r=0.62, p<0.001), BASDAI (0.62, p<0.001), ASQoL scores (0.73, p<0.001). Poor nutritional status was moderately correlated with frailty index score (r=0.53, p<0.001). In multivariable linear regression analysis, nutritional status and level of quality of life were independently associated with frailty index score (p<0.001).

**Disclosure of Interests:** None declared  

**POSIS1528-HPR**

**FACTORS ASSOCIATED WITH FRAILTY STATUS IN PATIENTS WITH AXIAL SpondyloArthritis**

Ö. Öztürk1, Ö. Feyezioglu2, 1Acibadem Mehmet Ali Aydinlar University, Physiotherapy and Rehabilitation, Istanbul, Turkey

**Background:** Frailty is characterized by increased fatigue and vulnerability which leads to adverse health outcomes. Recent studies have reported the increased prevalence of frailty in various rheumatological diseases regardless of age. However, information about the prevalence of frailty in patients with axial spondyloarthritis (axSpA) is limited.

**Objectives:** This study aims to determine prevalence of frailty and its associated factors in patients with axial spondyloarthritis (axSpA).

**Methods:** In this monocentric cross-sectional study 50 patients (26 women) with axSpA aged between 40 to 65 were included. Frailty status was determined using KOA checklist. Patients were groups as pre-frail, frail and robust individuals. Frailty was accepted as pre-frail, +4 pre-frail, frail. Nutritional status, disease activity, functional level and quality of life were assessed using Mini Nutritional Assessment (MNA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankiloan Spondylitis Functional Index (BASFI), Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL) respectively. Analysis of variance and multivariate linear regression analyses were used to assess group differences and factors associated with frailty status.

**Results:** The mean age of the patients was 51.7±8.77; the mean disease duration was 7.8±4.1 years, the mean body mass index was 29.98±4.72kg/m². Twenty-one patients were classified as frail, 16 was pre-frail and 13 was robust. Compared to robust patients, pre-frail and frail individuals had significantly higher BASFI, BASDAI and ASQoL scores. There was a significant high correlation between the KOA checklist score and worse BASFI (r=0.62, p<0.001), BASDAI (0.62, p<0.001), ASQoL scores (0.73, p<0.001). Poor nutritional status was moderately correlated with frailty index score (r=0.53, p<0.001). In multivariable linear regression analysis, nutritional status and level of quality of life were independently associated with frailty index score (p<0.001).

**Disclosure of Interests:** None declared  

**Table 1. Overview of the results exploring health-promotion activities in individuals with knee pain.**

<table>
<thead>
<tr>
<th>Theme</th>
<th>Category</th>
<th>Sub-categories</th>
<th>Using facilitators to take care of the body</th>
<th>Managing stressors of everyday life with the sub-categories</th>
<th>Promoting vitality, allowing for recovery, and safeguarding healthy relationships</th>
<th>Health promotor activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enables you to keep health</td>
<td>Using facilitators to take care of the body</td>
<td>Being physically active</td>
<td>Using external resources</td>
<td>Vitality</td>
<td>Safeguarding healthy relationship</td>
<td>Healthy-promoting activities</td>
</tr>
<tr>
<td>What do you do to maintain your health</td>
<td>Managing stressors of everyday life with the sub-categories</td>
<td>Active diet</td>
<td>Physical activity and weight loss</td>
<td>Resources</td>
<td>Relationship</td>
<td>Health-promoting activities</td>
</tr>
</tbody>
</table>

**References:**

FRAILTY STATUS

Table 1. Comparison of patients according to their frailty status

<table>
<thead>
<tr>
<th></th>
<th>Robust (n=13)</th>
<th>Pre-frail (n=16)</th>
<th>Frail (n=21)</th>
<th>P1</th>
<th>P2</th>
<th>P3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>53.8±5.3</td>
<td>50.8±6.2</td>
<td>59.9±7.7</td>
<td>.24</td>
<td>.73</td>
<td>.56</td>
</tr>
<tr>
<td>Sex, women/men (n)</td>
<td>7/6</td>
<td>7/9</td>
<td>14/7</td>
<td>.14</td>
<td>.55</td>
<td>.68</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>23.9±5.1</td>
<td>26.3±5.6</td>
<td>26.3±3.0</td>
<td>.96</td>
<td>.35</td>
<td>.46</td>
</tr>
<tr>
<td>BASDAI</td>
<td>3.9±2.1</td>
<td>8.3±1.6</td>
<td>9.3±1.8</td>
<td>.00</td>
<td>.00</td>
<td>.15</td>
</tr>
<tr>
<td>BASFI</td>
<td>8.9±2.1</td>
<td>20.7±1.0</td>
<td>12.0±2.2</td>
<td>.48</td>
<td>.00</td>
<td>.00</td>
</tr>
<tr>
<td>ASQoL</td>
<td>4.2±3.9</td>
<td>7.7±4.77</td>
<td>12.6±4.2</td>
<td>.08</td>
<td>.00</td>
<td>.29</td>
</tr>
<tr>
<td>Mini Nutritional Assessment</td>
<td>25±1.4</td>
<td>23.5±2.6</td>
<td>23.9±1.6</td>
<td>.36</td>
<td>.01</td>
<td>.29</td>
</tr>
</tbody>
</table>

BMI: body mass index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, BASFI: Bath Anklozai Spondylitis Quality of Life Questionnaire, P1: P value between robust and pre-frail individuals, P2: P value between robust and frail individuals, P3: P value between robust and frail individuals.

Conclusion: Frailty or pre-frailty is common in patients with axSpA and the main factors associated with frailty status were poor nutritional status and level of quality of life. Since it is a reversible condition, identifying the frailty status and its associated factors may help to prevent further decline in functional level and to design appropriate treatment interventions. Further studies are needed to determine frailty prevalence and its predictors in patients with axSpA.

REFERENCES:

Disclosure of Interests: None declared

POS1539-HPR | RHEUMATIC MUSCULOSKELETAL DISEASES (RMDS) DURING THE FIRST WAVE OF THE COVID19 PANDEMIC: PATIENTS’ POINT OF VIEW ON THE ROLE OF TELEMEDICINE

K. El Acyoud, K. Melis, M. Balzani, S. Guiducci, S. Bellando Randone, S. Barbosa, L. Rasero, M. Maturco-Cerinic University of Florence, Department of Clinical and Experimential Medicine, Florence, Italy; 'Careggi Hospital, Department of Geriatric Medicine, Division of Rheumatology, Florence, Italy; 'University of Florence, Department of Health Science, Florence, Italy; 'IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy

Background: The COVID19 pandemic has caused health problems in people’s daily lives with a significant psychological impact. In fact, patients with RMDs have experienced diseases flare and also psychological problems. The lockdown and the “social quality changes” have impacted the life and the well-being of RMDs patients, influencing directly the implementation of telemedicine during daily practice.

Objectives: A descriptive observational study was designed to analyse the short-term effect of the first wave on RMDs patients on social quality changes and the usefulness of telemedicine.

Methods: The survey was carried out by administering a questionnaire consisting of 30 questions, developed ad hoc using Likert scales, items such as family and work environment, access to healthcare facilities, healthcare provided to patient, patient activity and the mental health status of individuals (anxiety / depressive symptoms) were investigated. Preliminary data on the first wave were collected between September and November 2021 through patient associations and social networks.

Results: 40 RMDs patients (Rheumatoid Arthritis 57.5%, Psoriatic Arthritis 35%, Fibromyalgia and others 7.5%) prevalently women (97.5%) were included in the survey. During the pandemic, 72% of respondents reported cancellation or delays in scheduled appointments and 50% did not have alternative contacts (telephone consultations, e-mail prescriptions, telematics training) with the hospital. 40.5% of patients reported difficulty in finding DMARDs and material for the treatment of ulcers, 28.2% reported difficulties in accessing the health facilities. In particular, 34.2% reported the total closure of the hospital facilities. Moreover, our data show a worsening of health status due to an increased anxiety concerning the management of their RMDs, an increased stress within the
family, a reduced access to care facilities due to their closure or travel restrictions. In 57% of patients, a worsening of health status was reported, while in 90% stress and a feeling of abandonment was developed since the beginning of the pandemic. In this context, telemedicine was considered useful by 97.5% of patients, although patients felt that an improvement was necessary with an integration with the regular follow up.

Conclusion: Patients with RMDs reported that the significant delays or cancellation of the outpatient visits provoked an increase of stress, worry and anxiety for their health. The majority was very concerned about the overall management of their RMDs. The worsening of symptoms in more than half of the patients was the most worrisome observation. Almost all patients agreed that Telemedicine might help the clinical evaluation of their RMDs, also providing a significant support to their psychological condition because of the direct contact with the caring physician and health professionals.

REFERENCES:


Disclosure of Interests: None declared


POST1531-HPR

PATIENT-REPORTED ADVERSE DRUG REACTIONS ATTRIBUTED TO THE USE OF ETANERCEPT: DISTINCTION BASED ON NATURE, FREQUENCY AND BURDEN

L. Van Boxem1, H. Gosset1, S. Tas2, B. Van den Bemt3, H. Vonkeman4, F. Hoentjen1, M. Nurmohamed5, M. Van Doorn6, N. Jessurun1. 1Netherlands Pharmacovigilance Centre Lareb, Dutch Biologic Monitor, s-Hertogenbosch, Netherlands; 2Amsterdam UMC, locatie AMC, Rheumatology and Clinical Immunology, Amsterdam, Netherlands; 3Sint Maartenskliniek, Pharmacy, Research and Innovation, Utrecht, Netherlands; 4Medisch spectrum Twente, Rheumatology and Clinical Immunology, Enschede, Netherlands; 5University of Alberta Hospital, Division of Gastroenterology, Edmonton, Netherlands; 6Reade, Locatie Dr. Jan Van Breemenstraat, Rheumatology and Clinical Immunology, Amsterdam, Netherlands; 7Erasmus MC, Dermatology, Rotterdam, Netherlands

Background: Research regarding adverse drug reactions (ADRs) associated with the use of etanercept in patients with inflammatory rheumatic diseases (IRDs) usually focuses on the nature and frequency of ADRs without considering the burden of the ADRs. However, not every ADR causes the same burden for patients. Information is lacking about the degree of experienced burden per ADR by patients with IRDs.

Objectives: First, to describe ADRs of etanercept based on nature, frequency and burden, and second, to propose a new model for identification of relevant ADRs for health care professionals.

Methods: Data of the Dutch Biologic Monitor (DBM) was used to categorize patient-reported ADRs into high and low burden. In this prospective cohort event monitoring system patients were asked to fill out bimonthly questionnaires on experienced ADRs that they attributed to the use of a biological DMAP. The questionnaire included a quantification of the burden of the reported ADRs using a five-point Likert scale ranging from 1 (no burden) to 5 (very high burden). The nature of the reported ADRs were grouped into preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA). Inclusion criteria for this study were patients with IRDs using etanercept and who reported an ADR with at least one burden score. For every patient, the mean burden scores per ADR were analyzed. The burden was classified in two categories: 'high' when the mean burden score was equal to or more than 2.5, and 'low' when it was less than 2.5. Text analytics of the reported ADRs (MedDRA PTs) and a comparison word cloud were used to visualize ADRs that were more often reported with high burden or more often reported with low burden. For this, the relative ADR frequencies of the low burden classes were subtracted from the relative frequencies of the high burden class, resulting in a percentual difference between the high and low burden class for every ADR. Therefore, the highest percentual difference corresponds to the ADRs that are experienced as most burdensome.

Results: A total of 187 patients (70% female) met the inclusion criteria and reported 905 ADRs, of which 373 (41%) were reported with high burden (see Table 1). The word cloud (Figure 1) visualizes which ADRs were more often reported with high or low burden. These ADRs correspond to the greatest difference in relative class frequency. Patients experienced the burden of headache, pneumonia and pruritis mainly as high, and the burden of injection site pruritus and injection site erythema as low.

Table 1. Characteristics of patients and reported adverse drug reactions (ADRs)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n = 187)</td>
<td></td>
</tr>
<tr>
<td>Gender (female, %)</td>
<td>130 (70)</td>
</tr>
<tr>
<td>Age (years) (mean ± SD)</td>
<td>58.1 ± 14.1</td>
</tr>
<tr>
<td>Indication</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis (%)</td>
<td>132 (71)</td>
</tr>
<tr>
<td>Ankylosing spondylitis/axial spondyloarthritis (%)</td>
<td>19 (10)</td>
</tr>
<tr>
<td>Psoriatic arthritis (%)</td>
<td>46 (25)</td>
</tr>
<tr>
<td>Adverse drug reactions</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>High burden</td>
<td></td>
</tr>
<tr>
<td>Low burden</td>
<td></td>
</tr>
<tr>
<td>Adverse drug reactions (ADRs) (%)</td>
<td>905 (100)</td>
</tr>
<tr>
<td>Drug-induced ADR burden (mean ± SD)</td>
<td>2.5 ± 0.9</td>
</tr>
</tbody>
</table>

Figure 1. Comparison word cloud visualizing adverse drug reactions (ADRs) that patients reported more often with high burden (orange) and with no to low burden (blue). An ADR increases in size if the relative difference in frequency between classes increases.

Conclusion: The outcomes of the word cloud reveal that headache is more often experienced as burdensome which is an unexpected outcome. Visualizing the nature, the frequency and the burden of ADRs in one picture, provides simple guidance to the degree of relevance for the reported ADRs in clinical practice.

Disclosure of Interests: Larissa van Boxem: None declared, Helen Gossel: None declared, Sander Tas Consultant of: Gebro, GSK, AbbVie, Galvani, Arthrogen/MeraTix, Galapagos, Grant/research support from: Pfizer, GSK, Celgene, BMS, Sanofi, AstraZeneca, Bart van den Bemt Speakers bureau: paid as speaker for UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly, Harald Vonkeman Speakers bureau: Amgen, BMS, Celgene, Galapagos, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Grant/ research support from: Abbvie, Sanofi-Genzyme, Frank Hoentjen Speakers bureau: Frank Hoentjen has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celtiont, Teva, Sandoz and Dr Falk, Consultant of: Celgene, Michael Nurmohamed Speakers bureau: Abbvie, Janssen, Celgene, Consultant of: Abbvie, Grant/research support from: Abbvie, Amgen, Pfizer, Galapagos, BMS, Martijn van Doorn Speakers bureau: Janssen, LEO Pharma, Pfizer, Novartis, Paid instructor for: LEO Pharma, Consultant of: Abbvie, Janssen, LEO Pharma, Pfizer, Celgene, Novartis, TEVA, MSD, Sanofi, AstraZeneca, Grant/research support from: Novartis, Janssen, Naomi Jessurun: None declared

Sex specific burden of adverse drug reactions

Disclosure of Interests: Helen Gosselt: None declared, Jette van Lint: None declared, Leanne Kosse: None declared, Sander Tas Consultant of: Gebro, GSK, AbbVie, Galvani, Arthrogen/MeiraGTx, Galapagos, Grant/research support from: Pfizer, GSK, Celgene, BMS, Sanofi, AstraZeneca, Phyllis Spuls Grant/research support from: Prof. dr. Phl. Spuls has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), receives departmental independent research grants for TREAT NL registry, for which she is Chief Investigator (CI), from pharma companies since December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital. Harald Vonkeman Speakers bureau: Amsen, BMS, Celgene, Galapagos, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Grant/research support from: Abbvie, Sanofi-Genzyme, Michael Nurmoonah Speakers bureau: Abbvie, Janssen, Celgene, Grant/research support from: Abbvie, Martin van Doorn Speakers bureau: Janssen, LEO Pharma, Pfizer, Novartis, Paid instructor for: LEO Pharma, Consultant of: AbbVie, Janssen, LEO Pharma, Pfizer, Celgene, Novartis, TEVA, MSD, Sanofi, AstraZeneca, Grant/research support from: Novartis, Janssen, Bart van den Ber Speakebureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amsen en Eli Lilly, Naomi Jessurun: None declared

Comparison of hand functions and functional status in patients with limited cutaneous systemic sclerosis and diffuse cutaneous systemic sclerosis

E. A. Akatay1, D. Bayraktar2, E. Otman Akad2, O. Ustün1, I. Kurut3, Aysin3, D. C. Saraç2, B. Atalay2, I. Ramazanoglu1, I. Tekin2, T. Kurum2, S. Gucenmez2, M. Ozmen2, S. Akar3. 111017, 041217

Background: Systemic Sclerosis (SSc) is an autoimmune connective tissue disorder which is characterised by the fibrotic changes in the skin effecting especially fingers and hands. Regarding skin manifestations, SSc is classified into two different subtypes as limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc).

Objectives: The aim of the present study was to compare hand functions and functional status in patients with lcSSc and dcSSc.

Methods: Twenty-three patients with lcSSc and thirteen patients with dcSSc were included in the study. Modified Hand Mobility in Scleroderma Test (mHAMIS), modified Rodnan skin score (mRSS), grip and pinch strengths were measured to evaluate hand-related physical characteristics. Duruoz Hand Index, Disability of Arm, Shoulder and Hand Questionnaire (DASH), Health Assessment Questionnaire (HAQ), and Scleroderma Health Assessment Questionnaire (SHAQ) were used as the outcomes.

Results: While differences were detected in mRSS scores between disease subtypes (p<0.05), hand functions and functional status were comparable between groups (p>0.05).

Table 1. Demographics of females and males that reported at least one of the 12 distinct adverse drug reactions (ADRs) that are included in the analysis of sex-specific burden of ADRs.

<table>
<thead>
<tr>
<th>Participants</th>
<th>Female</th>
<th>Male</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>138</td>
<td>70</td>
</tr>
<tr>
<td>Age, mean ± SD</td>
<td>53.7 ± 13.5</td>
<td>57.6 ± 11.8</td>
</tr>
<tr>
<td>Indication for bDMARD therapy, N (%)</td>
<td>106 (76.3)</td>
<td>34 (48.6)</td>
</tr>
<tr>
<td>Ankylosing spondylitis/axial spondylarthritis</td>
<td>14 (10.0)</td>
<td>12 (17.1)</td>
</tr>
<tr>
<td>Ankylosing spondylitis/axial spondylarthritis and Psoriatic arthritis</td>
<td>1 (0.7)</td>
<td>0</td>
</tr>
<tr>
<td>Ankylosing spondylitis/axial spondylarthritis and Rheumatoid arthritis</td>
<td>2 (1.5)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>22 (16.5)</td>
<td>14 (20.0)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>85 (64.6)</td>
<td>38 (54.3)</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>60 (43.5)</td>
<td>32 (45.7)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>77 (55.8)</td>
<td>36 (51.4)</td>
</tr>
<tr>
<td>Switched adalimumab/etanercept</td>
<td>1 (0.7)</td>
<td>0</td>
</tr>
<tr>
<td>Comedication, N (%)</td>
<td>55 (39.1)</td>
<td>35 (50.0)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>26 (19.0)</td>
<td>17 (24.3)</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>17 (12.3)</td>
<td>11 (15.7)</td>
</tr>
<tr>
<td>Thiopurines</td>
<td>3 (2.2)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td>Sulfasalazine</td>
<td>7 (5.3)</td>
<td>3 (4.3)</td>
</tr>
</tbody>
</table>

*Age was missing for 1 male and 1 female patient. Patients could report multiple indications. 5 male and 14 female participants also reported other indications. Reporting comedication at the moment of inclusion. Eleven patients (male=3, female=8) did not start with etanercept or adalimumab at the moment they were included. In these cases, comedication is counted from the moment they reported the start of adalimumab or etanercept treatment.

Conclusion: Although women reported the majority of the ADRs, there was a trend that men experienced certain ADRs as more burdensome in comparison to women, albeit this did not reach statistical significance.

REFERENCES:  
Background: Joint position sense is a marker of proprioception and is defined as being aware of the body position and individual body parts in the space. Position sense in the wrist joint is especially important for the manual dexterity. A possible damage due to arthritis may lead to a decrease in joint position sense. However, the status of joint position sense was not investigated in children with juvenile idiopathic arthritis (JIA).

Objectives: To compare the wrist position sense and a motor performance test related to manual dexterity among children with JIA with wrist arthritis history (JIAWrist+), children with JIA without wrist arthritis history (JIAWrist−), and healthy controls.

Methods: A total of sixty children (26 children for each group) were included in the study. Wrist joint position sense was evaluated by measuring joint re-position error. The wrist was passively placed in a pre-determined position (30° for flexion, 30° for extension, 10° for radial deviation, and 15° for ulnar deviation). Then passively was returned to baseline position. The patient was asked to reposition their wrist into the target degree actively. The absolute error in degrees between each position and reposition was calculated. Manual dexterity was evaluated by using Purdue Pegboard Test. The test was repeated three times and the average number of the correctly placed pines was used in the analysis.

Results: Joint position sense (in all directions except radial deviation) and manual dexterity (except assembly) was found negatively affected in JIAWrist+ patients compared to healthy controls. No differences (except radial deviation) were observed between JIAWrist− patients and healthy controls.

Conclusion: Joint position sense and related manual dexterity is diminished in JIA patients with wrist involvement. The results of this study suggested that children with wrist arthritis should be followed with special attention focusing on manual abilities. Hand therapy programs might help improving joint position sense acuity.

Disclosure of Interests: None declared


Table 1. Comparison of the groups

<table>
<thead>
<tr>
<th>Physical Characteristics</th>
<th>JIAWrist+ (n=20)</th>
<th>JIAWrist− (n=20)</th>
<th>Healthy Controls (n=20)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>14.0 (10.5/16.0)</td>
<td>15.0 (14.5/18.0)</td>
<td>12.0 (10.0/13.0)</td>
<td>0.131</td>
</tr>
<tr>
<td>Body-Mass Index (kg/m²)</td>
<td>20.1 (16.8/22.6)</td>
<td>18.9 (15.7/23.5)</td>
<td>18.6 (16.8/21.9)</td>
<td>0.477</td>
</tr>
<tr>
<td>Disease Related Data</td>
<td>0.3 (0.2/0.5)</td>
<td>0.3 (0.2/0.5)</td>
<td>0.3 (0.2/0.5)</td>
<td>1.000</td>
</tr>
<tr>
<td>Disease Duration (months)</td>
<td>275 (10.5/64.0)</td>
<td>315 (11.0/63.0)</td>
<td>NA</td>
<td>0.903</td>
</tr>
<tr>
<td>Gender</td>
<td>Male 1 (50%)</td>
<td>Male 2 (50%)</td>
<td>Female 3 (50%)</td>
<td>0.007</td>
</tr>
<tr>
<td>Joint-Position Error</td>
<td>0.5 (2.3/6.7)</td>
<td>2.7 (2.0/4.0)</td>
<td>2.5 (3.0/4.0)</td>
<td>p*</td>
</tr>
<tr>
<td>Flexion (°)</td>
<td>3.8 (2.6/6.0)</td>
<td>3.5 (2.8/4.5)</td>
<td>1.8 (1.3/4.0)</td>
<td>p=0.038</td>
</tr>
<tr>
<td>Radial Deviation (°)</td>
<td>2.8 (2.0/5.2)</td>
<td>3.3 (1.8/4.7)</td>
<td>2.0 (1.3/2.7)</td>
<td>p=0.022</td>
</tr>
<tr>
<td>Ulnar Deviation (°)</td>
<td>3.5 (2.5/4.3)</td>
<td>2.3 (1.5/3.0)</td>
<td>1.7 (1.2/2.7)</td>
<td>p=0.038</td>
</tr>
<tr>
<td>Flexion (°)</td>
<td>5.2 (3.3/6.7)</td>
<td>2.7 (2.0/4.0)</td>
<td>2.0 (1.3/2.7)</td>
<td>p=0.022</td>
</tr>
<tr>
<td>Manual Dexterity</td>
<td>Median (IQR 25/75)</td>
<td>Median (IQR 25/75)</td>
<td>Median (IQR 25/75)</td>
<td>p*</td>
</tr>
<tr>
<td>Purdue Pegboard Test</td>
<td>15.2 (13.5/15.5)</td>
<td>15.2 (14.5/16.2)</td>
<td>16.2 (15.0/18.0)</td>
<td>p=0.022</td>
</tr>
<tr>
<td>Single Hand (score)</td>
<td>0.981</td>
<td>0.800</td>
<td>0.001</td>
<td>p=0.016</td>
</tr>
<tr>
<td>Purdue Pegboard Test</td>
<td>11.0 (8.9/12.0)</td>
<td>11.0 (8.9/12.0)</td>
<td>12.5 (11.7/13.2)</td>
<td>p=0.022</td>
</tr>
<tr>
<td>Both Hands (score)</td>
<td>0.201</td>
<td>0.201</td>
<td>0.201</td>
<td>0.001</td>
</tr>
<tr>
<td>Purdue Pegboard Test Assembly (score)</td>
<td>26.5 (23.0/28.5)</td>
<td>26.0 (23.5/32.5)</td>
<td>28.0 (25.5/30.0)</td>
<td>p=0.243</td>
</tr>
</tbody>
</table>

*Kruskal-Wallis Analysis, **Mann-Whitney U Test, ***Chi-Square Test, p<0.05. JIAWrist+ children with JIA with wrist arthritis history; JIAWrist−: children with JIA without wrist arthritis history; NA: not applicable, p1: JIAWrist+ vs. JIAWrist−; p2: JIAWrist+ vs. healthy controls; p3: JIAWrist− vs. healthy controls.
**Background:** Distal stabilization is an essential component for high quality proximal movement. In this regard, scapular stabilization is important for upper extremity and hand functions. Moreover, scapular stabilization might have a role as a support point for hand functions in patients with joint problems. However, the relationships between scapular stabilization and hand functions were not investigated in children with juvenile idiopathic arthritis (JIA).

**Objectives:** To investigate the relationship between scapular stabilization and hand function in children with JIA with wrist arthritis history (JIAWrist+), and children with JIA without wrist arthritis history (JIAWrist-).

**Methods:** A total of forty children (20 children for each group) were included in the study. Scapular stabilization was measured by using scapular muscle endurance test. General functional status, subjective hand functions, and objective hand functions were assessed by using Childhood Health Assessment Questionnaire (CHAQ), Duruoz Hand Index, and Purdue Pegboard Test, respectively. **Results:** JIAWrist+ patients reported poorer hand functions compared to JIAWrist- patients. No significant differences were detected for other parameters. Scapular muscle endurance was moderately related to CHAQ Disability Index score, Purdue Pegboard Test Assembly (single hand score and assembly score) in JIAWrist+ patients, while there was only a significant relationship between scapular muscle endurance and Purdue Pegboard Test both hand score in JIAWrist- patients.

**Table 1. Comparison of the Groups and Relationships between Scapular Muscle Endurance and Hand Functions**

<table>
<thead>
<tr>
<th>Variable</th>
<th>JIAWrist+ (n=20)</th>
<th>JIAWrist- (n=20)</th>
<th>p*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (IQR 25th/75th)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>14.0 (10.5/16.0)</td>
<td>12.5 (11.0/14.5)</td>
<td>0.512</td>
</tr>
<tr>
<td>Scapular Muscle Endurance (sec)</td>
<td>21.9 (13.7/35.8)</td>
<td>22.5 (15.8/50.0)</td>
<td>0.383</td>
</tr>
<tr>
<td>CHAQ Disability Index (score)</td>
<td>45.0 (30.0/75.0)</td>
<td>45.0 (30.0/75.0)</td>
<td>0.558</td>
</tr>
<tr>
<td>CHAQ Discomfort Index (score)</td>
<td>0.6 (0.1/1.0)</td>
<td>0.3 (0.0/0.7)</td>
<td>0.104</td>
</tr>
<tr>
<td>Purdue Pegboard Test Single Hand (score)</td>
<td>15.2 (13.5/15.5)</td>
<td>15.2 (14.5/16.2)</td>
<td>0.981</td>
</tr>
<tr>
<td>Purdue Pegboard Test Both Hands (score)</td>
<td>11.0 (9.1/12.0)</td>
<td>11.0 (10.3/12.3)</td>
<td>1.000</td>
</tr>
<tr>
<td>Relationships between Scapular Muscle Endurance and Hand Functions</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Results:** Enthesitis related arthritis was the most common JIA subtype in the study (38.2%) followed by oligoarthritis (26.5%), polyarthritis (20.6%), and systemic arthritis (14.7%). Significant negative correlations were detected between SSET and PI-head score (rho=-0.467, p<0.005), SSET and PI-ribcage score (rho=-0.381, p=0.026); FET and PI-head score (rho=-0.469, p=0.005); LET and PI-head score (rho=-0.441, p=0.009).

**Table 1. Demographics, muscle endurance and Posture Index scores of patients with axial spondyloarthritis**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Median (IQR 25th/75th)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>12.0 (10.0/14.0)</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>145.50 (140.00/158.25)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>42.75 (33.00/49.50)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>19.17 (16.08/21.42)</td>
</tr>
<tr>
<td>Biering–Sørensen Test (sec)</td>
<td>49.70 (28.42/80.78)</td>
</tr>
<tr>
<td>Flexor Endurance Test (sec)</td>
<td>39.81 (30.59/60.19)</td>
</tr>
<tr>
<td>Lateral Endurance Test (sec)</td>
<td>32.19 (19.94/49.94)</td>
</tr>
<tr>
<td>Static Scapular Endurance Test (sec)</td>
<td>23.19 (15.93/44.74)</td>
</tr>
<tr>
<td>Posture Index-Head (score)</td>
<td>7.0 (5/0.0)</td>
</tr>
<tr>
<td>Posture Index-Ribcage (score)</td>
<td>5.0 (4.0/0.0)</td>
</tr>
<tr>
<td>Posture Index-Pelvis (score)</td>
<td>6.0 (3.0/0.0)</td>
</tr>
</tbody>
</table>

**Conclusion:** These results indicated that postural displacements of head and ribcage are linked with decreased trunk and scapular muscle endurance in children with JIA. Exercise and physical activity programs targeting muscle endurance may result in improvements in posture in these children.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2942
Behçet’s disease is a vasculitis, causing multisystem inflammation and resulting in oral and genital ulcers and eye and skin lesions (1). A proportion of patients also have neurological involvement, termed Neuro-behçet’s disease (2). We think about that Neuro-behçet's disease can impact balance functions in patients due to neurological involvement. However, there is no study investigating the balance functions in patients with Neuro-behçet.

**Objectives:** To investigate the balance functions in individual with Neuro-behçet’s disease.

**Methods:** In this study 8 Neuro-behçet patients with a mean age of 38.37±16.96 who were followed in the PAU Rheumatology outpatient clinic and diagnosed by a rheumatologist according to the criteria of the International Behçet Study Group and 8 healthy control with a mean age of 42.62±13.94 with similar demographic characteristics were included. Exclusion criteria for the study were age <18 years old, having any disease which mimics BD (including systemic lupus erythematosus, vasculitis of central nervous system). Demographic data of the participants were recorded. Then, balance functions were evaluated with a balance board (Sensamove MaxiBoard, NL) in Neuro-behçet and control groups. This assessment included static balance, proprioception, and reaction. Results were analyzed with Mann Whitney U Test.

**Results:** Participants were similar in terms of age and gender (p>0.05). Neuro-behçet group showed a significant decrease in static balance in all directions except the right side compared to the control group (p>0.05). A significant decrease was observed in the right and left reaction times in Neuro-behçet group compared to control group (p>0.05). There was no significant difference between the two groups in proprioception assessment (p>0.05).

**Conclusion:** This result shows that patients with Neuro-behçet may experience disturbances in static balance and reaction time. Balance and reaction exercises should be included in rehabilitation. Further research is needed on the effect of balance functions and the effectiveness of balance exercises in Neuro-behçet’s disease.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3314
the aim to have signs and symptoms recognized for referrals to diagnostic tests and specialized services. As such, tasks beyond referrals are not expected by service users in primary health care in their encounters with GPs. Upon entering specialized health care services, service users describe diagnostics and prescription of medication for pain as key tasks of the rheumatologists, highlighting the role of the rheumatologists in ruling out severe pathology. Service users attribute the tasks of providing information about the condition, exercises, and assistive devices to occupational therapists (OTs). A lack of familiarity with the OT-profession prior to consultations is also expressed. This shows how patients attribute different tasks to GPs, rheumatologists, and OTs based on experiences in consultations.

**Profession secondary to competence about HOA and interpersonal skills:** service users say they do not have preferences related to who executes what professional tasks in addressing their needs. On the contrary, service users highlight competence about HOA as a key factor independent of whether the health professional is a GP, rheumatologist, or OT, saying professional orientation is secondary to professional knowledge about HOA. At the same time, service users underline interpersonal skills of health professionals as another key element, further downplaying the specific professional background of health professionals and levels of the health care system in meeting service user needs.

**Transfer of tasks to service users:** service users experience that they are presented with few treatment options beyond self-management in encounters with health professionals, leaving service users to cater for their own needs through the self-administration of exercises, medicines, and assistive devices.

**Conclusion:** In the division of labor, service users highlight the importance of professional knowledge and skills within the field and interpersonal skills independent of professional background and levels of the health care system. They also underline few treatment opportunities beyond self-management resulting in task-shifting to service users.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3684
Background: Quality of life (QoL) due to World Health Organization (WHO) is an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. QoL can be decreased during chronic illnesses, including juvenile idiopathic arthritis (JIA). This severe chronic disease of childhood afflicts both joints and body’s system inducing various comorbid conditions, among which eye damage (uveitis) is the most common. Considering the fact of involved joints it was set up that physical functioning (PF) shows the lowest values in some studies, which is associated with joint damage, activity, and duration of the disease.

Objectives: To establish the overall level of QoL and physical functioning in patients with JIA, considering the subtype of the disease, duration and the therapy complex.

Methods: The study involved 118 patients with JIA, among which 47 had polyarticular subtype, 43 had oligoarticular one, 28 were with uveitis-associated (JIA-u) subtype. The investigation included 77 girls and 41 boys in age from 2 till 18 years old. The therapy by methotrexate was provided in 112 patients, among them 30 had MTX with immunobiological therapy (29 adalimumab, 1 tocilizumab), 6 – sulfasalazine. The disease duration due to disease subtype in polyarthritis was (49,2±6,7), oligoarthritis – (35,4±4,2), JIA-u – (76,8±10,2) months. Disease activity was assessed using the JADAS27 questionnaire, functional state (FS) according to CHAQ and QoL according to PedsQLTM 4.0 Generic Core Scales.

Results: It was found that high JIA activity was observed in 31 (26.2%) patients, equally often in all subgroups of children. FS did not show a significant decrease either in the whole group or in each of the arthritis subgroups. The overall indicator of QoL in children with JIA was reduced in the whole group (71.2±1.4 and 72.9±1.4 per week and month). There was no significant difference between the QoL indicators of boys and girls. The polyarticular subtype showed the lowest results in QoL and PF, especially in children in the first year of the disease. They also turned out to be worse in children with JIA-u with the disease from one to three years (QoL – 63,2±3,6; PF – 66,6±3,9). The highest level of the physical component of QoL was observed in children with oligoarthritis older than 14 years (84,9±4,7) and in children under 8 years of age in the JIA-u group (96,8±8,1). There was no significant effect on the physical indicators of QoL of the start treatment timing. Finally, the strong correlation was determined between QoL and PF (r=0,842; p<0,05).

Conclusion: A decrease in QoL and its physical component is typical for children with different types of JIA (oligoarticular, polyarticular, and JIA-y). It has been established that children with polyarticular subtype of arthritis have the greatest decrease in QoL and physical functioning.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5105

POS1543-HPR JOINING TELEMEDICINE SERVICES IN RHEUMATOLOGY: THE ROLE PLAYED BY PERSONALIZED EXPERIENCE FROM PATIENTS’ PERSPECTIVE

E. Listorti1, L. Ferrara1, A. Adinolfi2, M. C. Gerardì2, N. Ughi2, V. Tozzi3, O. M. Episì4. 1CERGAS SSA Bocconi, Bocconi University, Government, Health & Not for Profit, Milan, Italy; 2ASST Grande Ospedale Metropolitano Niguarda, Rheumatology Unit, Milan, Italy

Background: With the beginning of the Covid-19 pandemic, many hospital departments worldwide, including rheumatology ones, were forced to implement telemedicine strategies. Telemedicine revealed to be an umbrella term, with various practical implementations and different degrees of preparedness. Some practitioners were already familiar with telemedicine, as in the case of the Rheumatology Unit of ASST Niguarda Hospital in Milan (Italy), where telemedicine projects have been implemented for more than a decade with structured design and organized processes. Moreover, patients in Niguarda have experimented telemedicine with personalized mixes of channels, including e-mails and phone calls, Patient Reported Outcomes questionnaires, and home delivery of drugs. This represents a paradigmatic case study that enables us to deepen essential questions on the success of telemedicine.

Objectives: Given that the last decision on joining telemedicine rests with patients, we decided to adopt their perspective. We deepened three main aspects: i) the benefits perceived, ii) the willingness to enrol in future projects, iii) the preference on the service-mix, i.e., on-distance contacts rather than in-person visits. Most importantly, we investigated differences in the three areas among all patients based on the type of personalized experience had.

Methods: We conducted a survey from November 2021 to January 2022, enrolling randomly outpatient who attended the rheumatology unit for any reason. The survey originated from well-known surveys, such as the Tele-Health Usability Questionnaire and the intention to use telehealth services. However, we decided to overcome the usual separation that makes surveys addressed either to users or no users of telemedicine. Our survey comprised an introductory set of questions related to personal, social, clinical and ICT skills information, followed by the central part on telemedicine, which explored the three areas mentioned: benefits, adherence, preferences on service-mix. For this part, questions were the same for all patients apart from the tense used, being conditional tense for no-users and past tense for users. All the answers were analysed with descriptive statistics and regression models.

Results: A complete response was given by 400 patients: 71% were female, 59% were 40-64 years old, 53% of them declared to work, and the diseases most represented were Rheumatoid Arthritis (36%) and Osteoporosis/arthrosis (21%). The descriptive statistics revealed interesting differences between users and no-users, e.g., the desire to participate in future projects was stated by 95% of users, 81% of no-users. These results were confirmed by multivariate logistic regression models that controlled for the influencing patients’ characteristics (such as being old or a frequent hospital attender).

It emerged that no-users imagined wide-ranging benefits. As for the willingness to participate to future telehealth projects, even if personal characteristics showed an impact (e.g., being a worker increased the probability to adhere), other things being equal, having had a more intense experience of telemedicine increased the odds of accepting by 3.1 times (95% C.I. 1.04-9.25), compared to no users. Furthermore, the more telemedicine was experienced, the higher the willingness to substitute in-person with online contacts.

Conclusion: Our study contributes to enlighten the crucial role played by the telemedicine experience in determining patients’ preferences. On one side, users appeared more aware of the realistic benefits to be expected from telemedicine. On the other side, it seemed that the more telemedicine was experienced, the higher the willingness to adhere to future projects and to increase on-distance contacts.

REFERENCES:

Acknowledgements: This study would not have been possible without the support of the whole staff of the Rheumatology unit who contributed to the distribution of the survey.

Disclosure of Interests: Elisabetta Listorti: None declared, Lucia Ferrara: None declared, Antonella Adinolfi Speakers bureau: Janssen, BMS, Maria Chiara Gerardì: None declared, Nicola Ughi Speakers bureau: ROCHE, PFIZER, ALFASIGMA, ABBVIE, JANSEN, GALAPAGOS, BRISTOL MYERS SQUIBB, Valeria Tozzi: None declared, oscar massimiliano epis: None declared
Background: Telemedicine is a useful tool in the control of patients with rheumatological conditions, even more so in the pandemic period. The evolution of patients with rheumatoid arthritis (RA) treated exclusively under this modality has been scarcely described.

Objectives: Evolution of clinical activity in RA patients controlled exclusively by the synchronous telemedicine (ST) modality in the COVID-19 pandemic period.

Methods: An observational study was carried out. Two groups of patients were analyzed separately, first group who had been treated using ST before the declaration of a health emergency in Colombia in March 2020 and second who were admitted to ST after this date. ST consists of a real-time video call with a trained general physician help on the referral site to perform physical examination. Assessments of disease activity was measured by DAS28 using C-reactive protein.

Results: Data was obtained from 150 and 65 patients in the first and second group. For the first group, more than a half of the patients had 2 controls with DAS28 assessment after March 2020, only 33% obtained 3 assessments, and very few with 4 or more. We found that the number of patients with high activity decreased significantly from 10% to 3%, remission increased from 44% to 50% and low activity from 14% to 19%, without major changes in the moderate activity group that remained close to a third. Same tendencies happened in group 2, with a difference in reduction of the moderate activity group from 44% to 38% (Figure 1).

Conclusion: When in person attention with rheumatologist is not possible, telemedicine is a useful and efficient way to control patients with RA, mainly finding a reduction in high activity and an increase in remission patients in remission.

REFERENCES:

Acknowledgements: We thank all patients for their participation in this study. This study is part of the PhD thesis of the first author JK (AGEIS, Université Grenoble Alpes, Grenoble, France). We thank Josefine Born and Deniz Krämer for their help recruiting patients.

Disclosure of Interests: Johannes Knitza Grant/research support from: Thermo Fisher Scientific, Novartis, Koray Tasocular: None declared, Nicolas Vuillerm: None declared, Ekaterina Vogt Employee of: Thermo Fisher Scientific, Thermo Fisher Scientific, Novartis, Koray Tasocular: None declared, Nicolas Vuillerm: None declared, Axel Hueber: None declared, Gerhard Krönke: None declared, Gerlinde Bendzuck: None declared, Arnd Kleyer: None declared, Sebastian Boetz: None declared, Axel Hueber: None declared, Gerhard Krönke: None declared, Georg Schett: None declared, David Simon: None declared

DOI: 10.1136/annrheumdis-2022-eular.775
had >2yrs follow-up. We have a community rheumatology service arm where all patients with stable inflammatory arthritis on non-biologic treatments are seen in secondary care. The stable patients from community clinics have not been included in this analysis. The data was reviewed using clinical letters, date of first appointment & last appointment. We looked at gender, age, diagnosis, number of follow ups in the first and last year, disease activity scores of the respective diagnosis and treatment given.

**Results:** Sixty percent of follow-up patients are long term with complicated illness or treatment. Of these 52 patients (65%) were female with median age 64 years (range 23-94 years). Median duration of follow up for this group of patients was 6 years (range 2-11 years). Inflammatory arthritis was the most common diagnosis in 75% of patients (11 patients were Psoriatic arthritis, 30- Rheumatoid arthritis, 7- undifferentiated inflammatory arthropathies and 7- Ankylosing spondylitis), 17.5% connective tissue disease, 11.2% vasculitis and others (Still's disease) 3.7%. Some patients had more than one diagnosis. The number of follow up in the first year ranged from 1-13 (median 4). In final year of analysis, patients were seen median of 3 times (range 1-8). Amongst them, 25% of patients were seen 4 or more times. The commonly prescribed drugs were methotrexate (41.2%), sulfasalazine(17.5%), hydroxychloroquine(15%), leflunomide (7.5%),biologics (8.7%), mycophenolate mofetil and azathioprine (6.5%). The activity scores such as DAS28, BVAS, PsARC and BASDAI were documented in 46 patients (57.5%).

**Conclusion:** This study shows that 66.6% of follow-up patients in rheumatology clinics are complicated long term conditions on immunomodulatory treatment. Despite T2T approach, use of combination DMARDs and early use of biologics, majority are inflammatory arthritis. It also shows that even after median follow-up of 6-9 years, these patients require an average review 3 or more times per year. The reasons for this may be poor disease control and lack of follow up. Patient outcomes may be good in disease compliants, comorbidities and medication side effects. Further analysis is ongoing to look into these aspects for better disease control and long term outcome.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1195

**POS1547-HPR** CREATION OF A MULTI-DISCIPLINARY TEAM (MDT) RHEUMATOLOGY CLINIC AT UNIVERSITY COLLEGE LONDON HOSPITAL (UCLH) TO TACKLE THE BACKLOG OF PATIENTS WAITING FOR TREATMENT AS A RESULT OF THE COVID-19 PANDEMIC.

D. Ludwig1, F. Higgs2, N. Allotey1, S. Begum1, J. Burton3, 1University College London, Rheumatology, London, United Kingdom; 2University College London, Therapies & Rehabilitation Department, London, United Kingdom; 3University College London Hospitals, Innovation Directorate, London, United Kingdom

**Background:** Covid-19 has consumed hospital resources since January 2020. In the UK, routine care has been disrupted with an estimated 30 million fewer outpatient attendances (2020/21) and over 6 million patients waiting for consultant led care (1). The British Society for Rheumatology ‘Rheumatology Workforce: a crisis in numbers’ (2021) highlights the challenges facing National Health Service rheumatology departments in managing rising caseloads (2). In 2021, UCLH wait time for follow up rheumatology appointments was 9 months. We were inundated with patients requiring urgent treatment. Innovative ways of running outpatients were required which led to the formation of an MDT clinic.

**Objectives:** Create a Rheumatology MDT clinic to:

- Reduce follow up time
- Increase clinic capacity
- Reduce number of hospital attendances

**Methods:** The consultant lead identified an existing clinical nurse specialist (CNS) interested in supporting the MDT. With a UCLH Outpatient Transformation fund of £15,000 we recruited an advanced physiotherapy practitioner (APP) and an administrative assistant for a 6 month trial period. Managerial support was provided by the board. We met weekly to agree aims and allocate responsibilities. We did the following:

- Reviewed clinic lists for 6 months to identify duplicate appointments.
- Identified patients with CNS and consultant follow up scheduled in a short time frame and cancelled unnecessary appointments.
- Reassessed the medical list weekly to identify patients suitable for APP management. This allowed overbooking of urgent cases.
- Embedded hand ultrasound appointments in the clinic template.
- Created CNS ‘Zoom’ virtual drop-ins for routine enquiries to reduce the administrative burden of patient emails/phone calls occurring outside the clinic.
- Organised patient participation sessions to help shape the service and collate feedback questionnaires.

**Results:** We reduced wait time for follow up appointments from 9 months to 2 months. Pre-MDT the average wait from consultant referral to physiotherapist appointment was 55 days. The MDT allows for same day assessment (reducing 2-3 patient journeys a clinic) and where suitable, facilitates discharge or onwards referral to the appropriate service i.e. pain management, hand therapy, APP-led hypermobility programme. A dedicated MDT CNS has shortened treatment times, reduced email traffic between CNS and consultant and allows for same day, joint decision making resulting in fewer appointments. Patients welcomed the Zoom sessions as an efficient, reliable method of raising concerns/queries. Our administrator helps to facilitate communication between patients and clinicians and streamline MDT processes. Embedding point of care ultrasound reduces hospital visits and enhances treatment decision making thereby reducing follow up attendances.

**Conclusion:** Our MDT model has reduced waiting lists, decreased treatment delays and cut the number of hospital visits. Performing ultrasound helped prevent patients being sent for scans at private providers. This cost saving likely covers the APP, ensuring the project is close to cost neutral. Shared decision making added value to outpatient attendances, reflected in patients positive feedback. The MDT enhances the role of APP and CNS, utilising their unique skill set. Administrative support is crucial, enhances team working and places added value on this often underappreciated role. We encourage other Rheumatology departments to adopt an MDT approach to tackle the backlog of patients awaiting treatment, add value to clinic encounters and maximise the skill set of clinicians involved in patient care.

**REFERENCES:**


**Acknowledgements:** I would like to thank the UCLH Outpatient Transformation Team for their support and funding to carry out this pilot project.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1253

**POS1548-HPR** USEFULNESS OF AN ELECTRONIC CONSULTATION SYSTEM BETWEEN PRIMARY CARE HEALTH CENTERS AND RHEUMATOLOGY DEPARTMENT OF A TERTIARY HOSPITAL

N. De la Torre Rubio1, J. Campos Esteban2, M. Pavia Pascual3, P. Navarro Palomo4, M. Machattu5, O. Rusinovich6, M. Fernandez Castro7, H. Godoy8, C. Merino Argumánez9, B. García-Magallón9, C. Barbardillo Mateos10, J. Sanz10, L. F. De Villa10, J. L. Andreu Sánchez10, Puerta de Hierro Majadahonda University Hospital; Rheumatology, Majadahonda, Spain

**Background:** The EPISEr study is the first Spanish epidemiological study that has confirmed the great burden of rheumatic diseases in the general population: they consume a large quantity of health resources (doctor visits, medical products) and imply a high social impact in terms of work absenteeism. Rheumatic diseases represent almost 30% of Primary Care medical consultations in Spain12. Electronic consultation could be an alternative response to the increase of this demand, both to make an early diagnosis and derivation and to improve communication with Primary Care physicians23. Objectives: To analyse the impact of an electronic consultation system of the Rheumatology Department of a tertiary hospital.

**Methods:** Retrospective descriptive study of the data collected in the request and information system (Sistema de Peticiones Electrónicas, SiPPE) that supports electronic consultation between primary care physicians of the health area and the Rheumatology Department of a tertiary hospital, between July 2020 and May 2021. The following variables were collected: age, sex, reason for consultation, response time in days and destination (primary care/outpatient follow-up). Descriptive statistics were used to present the results.

**Results:** The last 500 consecutive electronic consultations registered in the system, corresponding to 498 patients were collected. Mean age was 59.5±17.7 years, 74.2% women. Mean response time was 2 days, median response time 1 day and range 0-45. The reasons for consultation (see Graph 1) were: osteoporosis assessment 55 (11%), treatment adjustment 50 (10%), appointment request 49 (9.8%), loss to follow-up 43 (8.6%), local-regional pathology assessment 39 (7.8%), infiltration request 28 (5, 6%), suspected rheumatoid arthritis 19 (3.8%), spondyloarthritis 18 (3.6%), suspected polymyalgia rheumatica or giant cell arteritis 16 (3.2%), COVID vaccine consultation 14 (2.8%), Raynaud's phenomenon 13 (2.6%), monoarthritis assessment 12 (2.4%), assessment of poliarthritis 11 (2.2%), adverse effects of treatment 11 (2.2%), spondyloarthritides 11 (2.2%), suspected psoriatic arthritis 8 (1, 6%), generalized pain 7 (1.4%), suspected Sjögren’s syndrome 5 (1%), suspected systemic lupus erythematosus 1 (0.2%), suspected other systemic autoimmune diseases 9 (1.8%), others 81 (16.2%). Fifty-seven and four (4.2%) of the patients required an appointment at the Rheumatology outpatient clinic and in 42.6% of the patients (213) the electronic consultation was successful, so it was not necessary to refer the patient to the hospital.
Disclosure of Interests: None declared


POS1549-HPR IMPROVING EFFICACY AND SAFETY OF BLOOD MONITORING IN RHEUMATOLOGY PATIENTS ON DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDs) USING A NEW AUTOMATED ALGORITHM

M. Mirza1, A. Escudero Sios1, D. Lang1, K. Paddron1, B. Shinee1, A. Soni1, R. Luqmani1. 1University of Oxford, Rheumatology, Oxford, United Kingdom

Background: Most patients in Rheumatology require early management with DMARDs to control their disease. In our department, around two hundred patients start a DMARD therapy every month and monitoring their blood test results whilst on DMARDs play an essential role to detect toxicity and the need for further action. This process has been done manually, which has been prone to error. Over the past six months, a minimum of three patients have had abnormalities which were missed, consequently identifying the need to improve the quality of the blood monitoring.

Objectives: The aim of the project was to develop, test and implement an automated system to review multiple blood test results and highlight any changes, trends or abnormalities in patients starting DMARD therapy efficiently.

Methods: We designed a system to automatically review blood tests from patients newly started on DMARD therapy, following the recommended British Society for Rheumatology (BSR) schedule for blood monitoring. Results are processed in our local laboratory, subsequently uploaded to our unique database and analysed automatically using an algorithm against BSR guided threshold values for each blood test. According to the value, each blood result is identified as normal, mildly abnormal, missing, trending, or abnormal. A trained clinician or pharmacist will review the data and endorse the results after taking any appropriate action. Based on the results, if any actions are needed, patients are contacted either by phone or via a letter automatically generated by this software, recommending them to have a repeat test or temporarily stop the medication as required.

Results: The system was tested on two cohorts, comprised of 100 and 227 blood tests. It was faster and more efficient than the manual alternative. Following this test, each record was compared manually, based on the data stored on a spreadsheet.

This new system led to the identification of more abnormalities versus the manual inspection (29% vs 10%, Chi square P<0.001). Additionally, it took less than a minute compared to the manual method, which took three hours to complete. Follow up manual inspection confirmed that the new system had correctly identified every abnormality, based on test results.

To date, we have analysed 3968 blood results using this technique. 1564 (44%) results have been normal and endorsed within seconds, 374 (10%) were mildly abnormal, 17 (0.5%) results have been abnormal requiring action and 311 (9%) were abnormal requiring no action. 265 (7%) results showed a trend within the blood results. Trending results were defined as being out of range and worsening on two consecutive occasions but not reaching the limits for stopping a drug. 1032 (29%) results contained missing results, a consequence of the different timings of results uploaded by various laboratory sections.

Conclusion: We have developed an efficient and safe blood monitoring system for Rheumatology patients starting on a DMARD, proven to be more accurate compared to previous manual alternatives and able to process up to 10,000 results at a time.

Disclosure of Interests: None declared


POS1550-HPR DRIVE-THROUGH PHLEBOTOMY – DOES IT WORK FOR DMARDS MONITORING?

J. Begum1, M. Nisar1. 1Luton and Dunstable University Hospital, Rheumatology, Luton, United Kingdom

Background: Centralised phlebotomy services have been an integral part of providing blood monitoring facility for people with chronic diseases prescribed vital therapies. However the patient experience is not always optimal due to the issues of congestion, parking, long waiting times and have been accentuated during COVID-19 pandemic with the need for minimising physical contact. Expert panels have advocated for the creation of innovative approaches to provide safe patient care while maintaining precautions against COVID-19 spread. Several groups have published the concept and experience of using a drive-through clinic for anticoagulation monitoring and management. There is limited data on how this model of care can impact other clinical services such as rheumatology where patient groups are more vulnerable.

Objectives: In response to the growing pressure on phlebotomy service at our institution enhanced by COVID-19 pandemic, our rheumatology service implemented a drive-through phlebotomy clinic to provide the option for patients and families to stay in their vehicles whilst having venepuncture. The objectives were to evaluate the feasibility and patient experience of the service.

Methods: At our large university teaching hospital, we set up a drive-through phlebotomy service provided by a senior health care assistant supervised by the lead nurse. It was located near the hospital entrance where vehicles could park for a few minutes without disrupting traffic flow. Patients were identified from the departmental database and were offered the facility via telephone. Eligibility was assessed using a standardised proforma focusing on logistics such as ability to drive and access to a mobile phone. Appointments were scheduled in advance with patients choosing this care option. On the day, patients were screened for COVID-19–related symptoms before their appointment and were encouraged to stay in their vehicles wearing a mask before being approached by the HCA. At the end of clinic, all samples were submitted to the central laboratory. All the data was prospectively collated with patients consent and anonymised for analysis. In addition to demographics, diagnosis and drug record, duration of visit and patient feedback was collected.

Results: 112 patients were offered the service during a 12-week pilot. Mean age of the participants was 49.5 yrs (19-91) with 73 (65%) women. 74 (65%) were of Caucasian and 28 (25%) of Asian origin. 94 (84%) had inflammatory arthritides and all were prescribed DMARDs and/or bone active agents. 69 (61%) had been prescribed anti-clotting agents. The median time for blood to be collected from the arm was 2 minutes compared to the manual method, which took three hours to complete. Mean duration of appointment was 12.5 mins (5-60). 68 (60%) provided feedback with 61 (90%) rating 5/5 and 60 (89%) rating it better than standard phlebotomy. All would like to have the option for future and 67 (98%) were highly likely or likely to recommend the service to family and relatives. Most common reason to decline was an already arranged appointment with standard phlebotomy (n=14, 12.5%). Six (5%) could not be bled due to difficult venepuncture. Mean duration of appointment was 12.5 mins (5-60). 68 (60%) provided feedback with 61 (90%) rating 5/5 and 60 (89%) rating it better than standard phlebotomy. All would like to have the option for future and 67 (98%) were highly likely or likely to recommend the service to family and relatives.

Conclusion: To our knowledge, this is the first study to demonstrate the utility of drive-through phlebotomy for people with rheumatic diseases prescribed DMARDs. Excellent feedback of the participants confirms the need and desire for such innovation in health care. Prior publications have shown the benefits of such clinics in anticoagulation services. Arguably, it’s more prudent to have this facility close to where there is no alternative such as point-of-care or home INF monitoring. In post COVID-19 services reconfiguration with telemedicine and innovative models of care, this allowed flexibility for our department to develop...
and establish an alternative process. The availability of drive-through appointments and the close physical proximity to the clinic made it an appealing option for a vulnerable group of patients evidenced by their outstanding experience and feedback. Overall, an HCA-delivered, nurse-supervised drive-through pathway is highly effective, safe and provides an innovative solution to strained phlebotomy services.

Disclosure of Interests: None declared

**POST551-HPR**

**MEDICAL EXPERT KNOWLEDGE MEETS AI: HOW EXPERT KNOWLEDGE CAN IMPROVE SYMPTOM ASSESSMENT APPS - A NEW APPROACH IN RARE DISEASES**

A. Pankow1, 2, M. Neißeiner1, L. Fouquet1, E. Türk1, S. Gilbert1, T. Tüber2, A. Das1, C. Terkamp1, J. Kaufeld1, G. R. Burmester1, A. D. Wagner2

On behalf of Rheumatology 4.0. Charité - Universitätsmedizin Berlin, Medizinische Klinik mit Schwerpunkt Rheumatologie und klinische Immunologie Charité, Berlin, Germany; Medizinische Hochschule Hannover, Ambulanz für seltene entzündliche Systemerkrankungen mit Nierenbeteiligung, Hannover, Germany; Health GmbH, Ada, Berlin, Germany; University Hospital Carl Gustav Carus, Technische Universität Dresden, Else Kröner Fresenius Center for Digital Health, Dresden, Germany; Medizinische Hochschule Hannover, Pädiatrische Nieren-, Leber- und Wechselfehlerkrankungen, Hannover, Germany

**Background:** By definition, rare diseases occur in fewer than 5 in 10,000 people. However, in Germany alone, there are approximately 4 million people affected (1). Due to their rarity, rare diseases are often overlooked by general practitioners with limited knowledge about them. There are often only a handful of specialized experts for each condition. Yet, those experts are frequently not evenly distributed across the healthcare system, and often patients lack access. Therefore, the time to diagnosis is often long and poses many challenges. Artificial intelligence (AI) approaches, such as those used in symptom assessment apps can potentially help to detect disease and thus, shorten the time to diagnosis (2).

The general approach underlying the AI of symptom assessment apps is to gather medical knowledge from data (e.g. electronic health record or literature searches). However, for rare diseases, there is only limited research available. In this study we used a new approach: to abstract medical expert knowledge by conducting guided interviews and transforming them into clinical vignettes.

**Objectives:** There are two objectives. First, we aimed to integrate expert knowledge on the lysosomal storage diseases (LSDs) Fabry, Gaucher and Pompe into the Ada symptom assessment application and use this expert knowledge to optimize Ada’s LSD condition models. LSDs are of particular importance as they represent important differential diagnoses for rheumatic diseases.

Second, we will conduct questionnaires with patients and LSD experts, comparing the optimized to the previous condition models’ performance. We will investigate whether the novel approach of guided interviews, in combination with literature research, results in a better performance than literature research alone.

**Methods:** Our novel approach is to curate expert medical knowledge from guided interviews with medical experts. The interviews aim to gather knowledge on the symptom constellations with which patients typically present to their physicians. This knowledge is subsequently used to create prototype clinical cases and transform them into structured case vignettes. The rare disease structured case vignettes can be readily transcribed into Ada’s knowledge base.

**Results:** We conducted guided interviews with clinical experts from the Medizinische Hochschule Hannover (MHH) to create clinical vignettes for the LSDs Fabry, Gaucher and Pompe disease. We conducted interviews with four medical experts and created a total of 11 clinical vignettes: five vignettes for Fabry disease, four for Gaucher disease and two for Pompe disease. Figure 1 demonstrates the vignette creation process. Then, in combination with systematic literature searches, the vignettes were used to update Ada’s existing condition models for Fabry and Gaucher disease and to add Pompe disease.

**Figure 1.** The novel medical model creation approach uses guided expert interviews to create prototypic clinical vignettes, which can be readily transcribed in a medical modeling language to create individual disease models

**Conclusion:** Participants will complete two assessments: an Ada version with the old knowledge base and an Ada version with the updated models. The study plans to enroll 15 LSD patients - five per condition - and nine LSD experts. For the conditions Fabry and Gaucher disease, we will ask the participants to rate both Ada versions. For Pompe disease, we will ask participants to rate the latest Ada version with the updated knowledge base. This novel approach has various clinical implications, including potentially shortening the ‘time to diagnosis’ for rare diseases, thus giving patients faster access to the treatments they need.

**REFERENCES:**
[1] National Organization for Rare Diseases, Globel genes Project

**Disclosure of Interests:** Anne Pankow Grant/research support from: The study originates from a collaboration project between Ada Health, Charité and Sanofi. However Sanofi was neither directly nor indirectly involved in the concept, conduct or interpretation of the study (results). Nico Neißeiner Grant/research support from: The study originates from a collaboration project between Ada Health, Charité and Sanofi. However Sanofi was neither directly nor indirectly involved in the concept, conduct or interpretation of the study (results). Laura Fouquet: None declared, Ewelina Tür: None declared, Stephen Gilbert: None declared, Thilo Tüber: None declared, Anhbi Das: None declared, Christoph Terkamp: None declared, Jessica Kaufeld: None declared, Gerd Rüdiger Burmester: None declared, Annette D. Wagner: None declared


**POST552-HPR**

**A SYNTHESIS OF GUIDANCE AVAILABLE FOR ASSESSING METHODOLOGICAL QUALITY AND GRADING OF EVIDENCE FROM QUALITATIVE RESEARCH TO INFORM CLINICAL RECOMMENDATIONS: A SYSTEMATIC REVIEW**

M. Sekhon1, 2, A. De Thurian3, G. E. Fragoulis4, T. Stamm1, T. P. M. Vliet Vlieland5, B. A. Ebsenber6, H. Lemp5, L. Beare1-4, M. Kouloumbas7, P. Polohnikova4, T. W. Swinnen4, C. Blunt1, R. J. O. Ferrera1, L. Carmona1, E. Nikporhou8,11,9, T. W. Swinnen12, C. Blunt13, R. J. O. Ferrera14,15, L. Carmona16, E. Nikiphorou17,11,2, Kingston and St George’s UNIVERSITY OF London, Centre for Applied Health and Social Care Research, London, United Kingdom; King’s College London, School of Life Course & Population Sciences, London, United Kingdom; Aarhus University Hospital, Clinical Medicine, Aarhus, Denmark; National and Kaposidian University of Athens, Joint Academic Rheumatology Program, Athens, Greece; Medical University of Vienna, Section for Outcome Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Vienna, Austria; Leiden University Medical Center (LUMC), Dept of Orthopaedics, Rehabilitation and Physical Therapy, Leiden, Netherlands; Copenhagen University Hospital, Rigshospitalet, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, København, Denmark; Copenhagen University Department of Clinical Medicine, København, Denmark; King’s College London Guy’s Campus, School of Life Course & Population Sciences, London, United Kingdom; Cyprus league Against Rheumatism, Cyprus Federation of Patients’ Associations, Nicosia, Cyprus; PARE Research Partner, EULAR, Zurich, Switzerland; Katholieke Universiteit Leuven, Research Group for Musculoskeletal Rehabilitation, Leuven, Belgium; London School of Economics and Political Science, Medicine, Philosophy, Interdisciplinary Studies, London, United Kingdom; Centro Hospitalar e Universário de Coimbra, Rheumatology Department, Coimbra, Portugal; Residence of Coimbra Nursing School, Health Sciences Research Unit: Nursing, Coimbra, Portugal; Instituto de Salud Musculosquelética, Inmus, Madrid, Spain; King’s College London, Centre for Rheumatic Diseases, School of Immunology and Microbial Sciences, London, United Kingdom

**Background:** Qualitative research is crucial to understand key stakeholders experiences and perspectives of care and health services. However, there is a lack of explicit frameworks and guidelines about how best to use qualitative evidence to formulate clinical recommendations. Part of the problem includes uncertainties about the contributions of qualitative research to the evidence, and the empirical and theoretical basis for appraising and synthesizing qualitative evidence in a standardized manner. In addition, most existing grading systems of qualitative research originate from quantitative research, and there is no clear guidance about how to incorporate qualitative research into the evidence hierarchy.

**Objectives:** To conduct a systematic literature review (SLR) to answer two research questions (RQ):

**RQ1)** What guidance (e.g., tools, checklists, frameworks) exists to assess the methodological quality of qualitative research employed to inform clinical recommendations?

**RQ2)** What methods exist specifically to grade levels of evidence for qualitative research?

**Methods:** The protocol for this review was registered on www.researchregistry. (reviewregistry1240). Electronic databases (PubMed/Medline, EMBASE, Web of Science, COCHRANE, Emcare, PsyINFO, ERIC, Academic Search
Premier, Sociological Abstracts, ProQuest Dissertations and Thesis Global) were searched for published and unpublished studies. Searches were completed from inception to 23rd October 2020. No restrictions were applied to clinical population. Eligible studies for both questions included primary articles and guideline documents available in English, describing the: i) development; ii) application of validated tools (e.g., checklists); iii) guidance on how to assess methodological quality of qualitative research and iv) guidance on how to grade levels of qualitative evidence. Opinion pieces and conference abstracts were excluded. Manual searches of the reference lists of full text articles were conducted. Two reviewers independently screened the titles, abstracts, and full text. A narrative synthesis was conducted to identify key aspects between the included studies.

Results: 9071 records were retrieved (Figure 1). After de-duplication and title/abstract screening, 51 full-articles articles were assessed for eligibility yielding 15 included articles. For RQ1, six articles were included that described six tools (1) The society for Critical Care Medicine Family – Centered Care Guidelines; 2) Nursing Management of the Second Stage of Labour evidence based clinical practice guidelines; 3) Jonna Briggs Institute Critical Appraisal of Qualitative Studies; 4) Critical Skill’s Appraisal Programme (CASP) and 6) the Modified CASP checklist. All tools ranged from 10 to 30 items, and evaluated research design, recruitment, ethical rigour, data collection and data analysis. Seven articles described one approach (GRADE CER-Qual) to assess methodological quality of qualitative research. This approach advised on the importance for assessing methodological limitations. For RQ2, two articles were included, one described a qualitative hierarchy of evidence, and another described a research pyramid that included a section on qualitative research.

Conclusion: This review highlights lack of consensus and limited availability of tools, checklists, and approaches to 1) appraise the methodological quality of qualitative research used to inform clinical recommendations and 2) grade levels of evidence for qualitative research. Current research agendas will need to determine the most relevant and appropriate method for the quality appraisal of qualitative research. This way, qualitative research could be more consistently determine the most relevant and appropriate method for the quality appraisal of qualitative research. This approach advised on the importance for assessing methodological limitations. For RQ2, two articles were included, one described a qualitative hierarchy of evidence, and another described a research pyramid that included a section on qualitative research.

REFERENCES: N/A

Disclosure of Interests: Mandeep Sekhon: None declared, Annette de Thurah: None declared, George E. Fraguolli: None declared, Tanja Stamm: None declared, T.P. Vlie Vrietland: None declared, Bente Appel Esbensen: None declared, Heidi Lempp: None declared, Lindsay Bearme: None declared, Marios Kouolumas: None declared, Polina Pchelnikova: None declared, Thijis W. Swinnen: None declared, Chris Blunt: None declared, Ricardo J. O. Ferreira: None declared, Loreto Carmona: None declared, Eleni Nikphorou Speakers bureau: Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, Eli Lilly, Grant/research support from: Pfizer, Eli Lilly


Figure 1. PRISMA diagram of included papers

Posters

A VIRTUOUS IMPLEMENTATION OF TELEMEDICINE SERVICES IN RHEUMATOLOGY: DESCRIPTION OF CHANGE MANAGEMENT PRACTICES ADOPTED BY THE NIGUARDA HOSPITAL

L. Ferrara1, E. Listorti1, A. Adinolfi2, M. C. Gerardi3, N. Ughi2, O. M. Epis2, V. Tocci2,3, Cergas SDA Bocconi, Bocconi University, Government, Health & Not For Profit Division, Milan, Italy; 2ASST Grande Ospedale Metropolitano Niguarda, Rheumatology Unit, Milan, Italy

Background: Over the past few decades there have been an increasing debate around the use of telemedicine. Despite this, there is still a slow rate of adoption of telemedicine services. According to a recent scoping review this may be due to a piecemeal approach to the change process, and a lack of understanding of how to plan, manage and reinforce change when implementing telemedicine service1. A virtuous example of implementation of telemedicine services can be found within the rheumatology unit of Niguarda Hospital in Milan (Italy), where the whole staff has been involved in experimenting with new multichannel interactions to communicate with patients for more than a decade. Developed in 2011 with the introduction of the IAR Plus app for the collection of Patient Reported Outcomes (PROs), the project was first targeted to patients with Rheumatoid arthritis, Psoriatic arthritis and Spondyloarthritis. In 2019 the project was consolidated and added the home delivery of biological drugs for the stable patients. During spring 2020, this experience was further extended and extended to all patients treated with biological drugs to facilitate patient interaction during Covid-19 and was characterized by three elements: remote monitoring, triage through phone calls and home delivery of medication. What contextual factors and mechanisms adopted to plan, manage, and reinforce change where more successful?

Objectives: This study aimed to highlight what were the distinctive and successful elements of this implementation experience, what we could learn from it, and which managerial implications we could derive for future implementations.

Methods: We adopted a realist evaluation approach2 to identify the underlying generative mechanisms that explain ‘how’ the outcomes were caused and the influence of context. Thus, we deepened how the change management process has been managed by conducting semi-structured interviews with the unit director, and the staff members involved in the phases of the project (i.e., clinicians, nurses, and administrative staff). The interviews were recorded and analyzed through an ad-hoc framework3 for the analysis of change management practices. This framework identifies 10 change steps divided into 13 strategic practices and 6 operational practices that are important during the preparatory phase of the change process, for managing the change, and to sustain and reinforce long-term change.

Results: Our study identified the most relevant actions put in place by the rheumatology unit during the three major steps of preparing for change (e.g., developed telemedicine App, assigned coordinating role, identified champions), managing change (e.g., developed and articulated a clear vision, provided training, developed ownership), and reinforcing change (e.g., continued to engage partners). The analysis highlighted four main lessons learned: first the characteristics of the context and a strong managerial structure were a prerequisite for success. The generative mechanisms that explain how these successful outcomes were caused are: leadership role able to define a clear vision and a clear specialization of tasks and roles; the involvement of all team members; regular meetings and interactions. Second, patients should be involved as central actors in the definition of the care pathway. The final decision on the kind of services to be used was made by the patient. Third, the relevant stakeholders should be involved since the co-design of the app. Finally, change should be incremental. The Rheumatic unit introduced one change at a time, and this brought to constant improvements.

Conclusion: The framework adopted can be used either to retrospectively analyze the experiences developed but may also act as a tool to guide future telemedicine service implementation and research. As well as the lessons learned can guide the implementation of future telemedicine experiences

REFERENCES:

Disclosure of Interests: Lucia Ferrara: None declared, Elisabetta Listorti: None declared, Antonella Adinolfi Speakers bureau: JANSSEN, BMS, Maria Chiara Gerard: None declared, Nicola Ughi Speakers bureau: ROCHE, PFIZER, ALFA Synthetica, ABBIIE, JANSSEN, GALAPAGOS, BRISTOL MYERS SQUIBB, oscar massimiliano epis: None declared, Valeria Tozzi: None declared

**HEALTH PROFESSIONALS’ PERSPECTIVES ON THE USE OF JANUS KINASE INHIBITORS TO TREAT PATIENTS WITH INFLAMMATORY ARTHRITIS**

S. De Souza1, A. Bassett1, R. Williams1, E. Nikphorou1,2,3. ‘King’s College London, Centre for Rheumatic Diseases, London, United Kingdom; 4King’s College Hospital, Rheumatology, London, United Kingdom

**Background:** Janus kinase inhibitors (JAKi) are relatively new to the field of rheumatology and provide health professionals in rheumatology (HPRs) with more therapeutic options for treating inflammatory arthritis (IA), specifically rheumatoid arthritis (RA) and psoriatic arthritis (PsA) [1]. Aside from a different target, JAKi differ from often currently prescribed biologics by being administered orally. To date, there is a lack of evidence on what HPRs think about their real-world use and how the COVID-19 pandemic affects JAKi prescription.

**Objectives:** To explore UK-based HPRs’ perspectives towards JAKi use in IA patients, and in the context also of the COVID-19 pandemic.

**Methods:** A 15-item anonymous online survey, with both closed and open-ended questions, was designed and piloted on 5 HPRs with amendments made based on their feedback. The survey was advertised on Twitter and shared by email in September 2021. Data were exported from the online survey platform and analysed descriptively with the assistance of statistical software.

**Results:** Fifty-one HPRs responded to the survey; 37 Consultants, 7 Registrars, 5 Clinical Nurse Specialists, 1 Clinical Fellow and 1 ‘other rheumatology role’ (not stated). Responses were received from 11/12 UK regions. Most represented was Greater London (18%) and North-West England (16%), 69% of respondents worked in secondary care, with the remaining 31% in tertiary care. The majority (40%) spent 1-25% of their job role doing research, followed by 27% who were not research active. 60% of HPRs indicated that 15%-5% of their RA and/or PsA patients take a JAKi (no HPRs had more than 15% of their RA/PsA patients on JAKi). 96% of HPRs indicated that they prescribe JAKi in their clinical practice, patients take a JAKi (no HPRs had more than 15% of their RA/PsA patients on JAKi). 96% of HPRs indicated that they prescribe JAKi in their clinical practice, patients take a JAKi (no HPRs had more than 15% of their RA/PsA patients on JAKi). 96% of HPRs indicated that they prescribe JAKi in their clinical practice, patients take a JAKi (no HPRs had more than 15% of their RA/PsA patients on JAKi). 96% of HPRs indicated that they prescribe JAKi in their clinical practice, patients take a JAKi (no HPRs had more than 15% of their RA/PsA patients on JAKi).

**Conclusion:** A large proportion of HPRs indicate confidence in prescribing JAKi to their patients with IA, adhering to local guidelines. JAKi are largely prescribed as monotherapy, with the most frequent reason for discontinuation being inefficacy. The COVID-19 pandemic seems to have positively impacted JAKi prescription, however, safety concerns over JAKi use remain for some HPRs.

**REFERENCES:**

**DOI:** 10.1136/annrheumdis-2022-eular.8

**EVALUATION OF CONVERSATIONS IN MOTION: A PROGRAM DESIGNED TO IMPROVE PATIENT-PROVIDER COMMUNICATION IN THE CARE OF RHEUMATOID ARTHRITIS**

E. Nikphorou1, S. Péloquin2, M. Augustyniak2, A. Negescu3, D. Walker4, F. Haq5, P. Lazure2, S. Murray2, ‘King’s College, Centre for Rheumatic Diseases, London, United Kingdom; 4AXDEV Group Inc., Performance Improvement Division, Brossard, Canada; 2Addenbrooke’s Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; 3Northumbria Healthcare NHS Foundation Trust, Rheumatology Department, Northumbria, United Kingdom; 4Eli Lilly and Company, Global Medical Education, Toronto, Canada

**Background:** Previous studies have found a need for improvement in communications between healthcare professionals (HCPs) and patients with rheumatoid arthritis (RA), especially in relation to shared-decision making (SDM), managing patient expectations, and goal-setting. Conversations in Motion (CIM) is an educational program, consisting of four modules, that teaches HCPs how to use validated communication techniques to improve the quality and efficiency of their consultations with RA patients.

**Objectives:** This pilot study assessed the impact of CIM deployed in the United Kingdom (UK) on HCPs’ knowledge, skills, confidence, beliefs, and performance using validated communication techniques in interactions with RA patients.

**Methods:** A longitudinal mixed-methods study, consisting of three surveys (pre-before the program, 2-3 weeks post, and 5-6 months follow-up) and semi-structured interviews (4-6 weeks post) was used to evaluate CIM based on the outcome model by Moore et al.2,7 Surveys assessed outcomes via multiple choice or 11-point rating scale questions (0-none, 10-extreme). Participants included UK rheumatology physicians, nurses, and allied HCPs, all of whom had a minimum yearly caseload of 10 RA patients and participated in CIM between September and October 2020. Survey data was descriptively analysed in SPSS by comparing pre with post and pre with follow-up (matched samples). Interviews were thematically analysed using NVivo.

**Results:** Almost half (15/34) of registrants completed all four CIM modules. Of those, 53% (n=8) completed pre and post surveys; 33% (n=5) pre and follow-up surveys; and 27% (n=4) completed interviews. Post surveys showed greater knowledge for strategies to build trust and empathy with RA patients and practice efficiency than at pre (Figure 1). A decrease in helplessness was noted for dealing with a patient who is nonadherent (pre=3.9/10; post=1.6/10). Interviewees described CIM as “thought provoking” and reported improvement in their ability and confidence to use patient’s own stories and words as a strategy to build trust and empathy (n=4). Post and follow-up surveys showed changes in skills and confidence were more pronounced for practice efficiency and discussing nonadherence (Table 1). At follow-up, most participants reported practicing at least one
technique to build trust and empathy with patients (80%, 4/5), save time (100%, 5/5), engage in SDM, or discuss nonadherence (60%, 3/5).

Table 1. Changes in skill and confidence post-CIM

<table>
<thead>
<tr>
<th>Survey item</th>
<th>Matched respondents</th>
<th>Matched respondents (n=5)</th>
<th>Pre Post ∆</th>
<th>Pre Follow-up ∆</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skill</td>
<td></td>
<td></td>
<td>5.6 7.1 +15% 5.4 6.4 +10%</td>
<td></td>
</tr>
<tr>
<td>Listening to and understanding patients' emotions, expectations, and personal needs</td>
<td></td>
<td></td>
<td>6.6 8.1 +15% 7.0 8.2 +18%</td>
<td></td>
</tr>
<tr>
<td>Simplifying complex terminology related to RA</td>
<td></td>
<td></td>
<td>5.4 7.8 +24% 5.4 7.2 +16%</td>
<td></td>
</tr>
<tr>
<td>Discussing reasons for nonadherence</td>
<td></td>
<td></td>
<td>5.4 7.8 +24% 4.2 6.4 +22%</td>
<td></td>
</tr>
<tr>
<td>Building trust and empathy via telemedicine</td>
<td></td>
<td></td>
<td>5.9 6.9 +10% 5.0 6.0 +10%</td>
<td></td>
</tr>
<tr>
<td>Addressing patient concerns in limited consultation</td>
<td></td>
<td></td>
<td>5.2 6.6 +14% 4.0 5.6 +16%</td>
<td></td>
</tr>
<tr>
<td>Support patients through treatment adherence</td>
<td></td>
<td></td>
<td>6.0 7.5 +15% 4.0 6.2 +22%</td>
<td></td>
</tr>
</tbody>
</table>

The final questionnaire contained 90 items divided into 3 sections (Figure 1).

Figure 1. Changes in knowledge post-CIM

Table description: All items were rated on an 11-point scale (0-none, 10-extreme). The matched sample of participants who completed the pre and 2-3 weeks post-CIM survey was not the same as the one who completed the pre and 5-6 months follow-up survey. Change (Δ) was measured as the percent difference between means.

Conclusion: This pilot evaluation suggests that CIM has a measurable impact on HCPS' learning and use of techniques that can enhance communication and collaboration with RA patients. Future studies should validate CIM impact in a larger sample size and/or by evaluating patients' perspective on observed changes in their communication and collaboration with HCPs.

REFERENCES:

POS1556-HPR RECOMMENDATIONS FOR NURSES ON THE MANAGEMENT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A DELPHI CONSENSUS

L. Cano García1, C. Dominguez2, A. I. Rodriguez Vargas3, E. Trujillo Martín4, J. M. Martin Martín5, 1Regional University Hospital of Malaga, Rheumatology Service, Malaga, Spain; 2Virgen Macarena University Hospital, Rheumatology Service, Seville, Spain; 3Canarias University Hospital, Tenerife, Rheumatology Service, Tenerife, Spain; 4Nuestra Señora de la Candelaria University Hospital, Rheumatology Service, Tenerife, Spain; 5Regional University Hospital of Malaga, Rheumatology Service, Malaga, Spain.

Background: Nurses play a key role in the management of Systemic Lupus Erythematosus (SLE) due to their close contact with the patient. Well-structured resources and specialized training are necessary to ensure comprehensive and quality care. However, no complete clinical practice guidelines for nurses have been developed for the management of SLE in Spain or Europe [1].

Objectives: In this context, the OpenReuma scientific society decided to promote the RECOMIENDAes project, the aim of which is to create consensus-based recommendations for the management of SLE patients by nurses in Spain. Methods: Following a bibliographic review, the Delphi method [2] was followed to reach the consensus and a structured survey was sent to nurses with expertise in SLE. Two successive rounds were conducted. Consensus was established when at least 70% of the panelists agreed or disagreed on a topic.

The final questionnaire contained 90 items divided into 3 sections (Figure 1).

Figure 1. Structure of the RECOMIENDAes project questionnaire.

Results: In Spain, few nurses could be considered experts in SLE, hence the number of panelists was small: 25 nurses from different specialties (Rheumatology: 80%, Autoimmune Disease Units: 4%, Internal Medicine: 4%, and Day Hospital Services: 12%) with sufficient experience to ensure validated recommendations that could translate into practice. All the participants worked in public hospitals and had more than 2 years of experience treating SLE patients.

A high consensus was reached on the role and responsibilities that nurses should have in relation to SLE patient management. The main results are summarized in Table 1.

Table 1. Summary of the main recommendations reached in the RECOMIENDAes Project.

<table>
<thead>
<tr>
<th>RECOMMENDATIONS</th>
<th>% of agreement (7 – 9 score)</th>
</tr>
</thead>
<tbody>
<tr>
<td>General recommendatons</td>
<td></td>
</tr>
<tr>
<td>Multidisciplinary teams with at least one nurse trained in SLE</td>
<td>100%</td>
</tr>
<tr>
<td>Participate throughout the SLE patient care process and have their own agenda of visits and context</td>
<td>92%</td>
</tr>
<tr>
<td>Psychological and social worker support</td>
<td>96%</td>
</tr>
<tr>
<td>Access to continuous training (SLE management, individual and group counselling and communication techniques)</td>
<td>100%</td>
</tr>
<tr>
<td>Access to research projects</td>
<td>96%</td>
</tr>
<tr>
<td>Specific recommendations</td>
<td></td>
</tr>
<tr>
<td>Diagnosis:</td>
<td></td>
</tr>
<tr>
<td>Inform the patient about the disease (manage expectations and resolve doubts and fears)</td>
<td>100%</td>
</tr>
<tr>
<td>Provide contact channels with the service and reliable sources of information</td>
<td>100%</td>
</tr>
<tr>
<td>Collaborate in the physical examination</td>
<td>92%</td>
</tr>
<tr>
<td>Collaborate performing diagnostic tests</td>
<td>76%</td>
</tr>
<tr>
<td>Education:</td>
<td></td>
</tr>
<tr>
<td>Have a structured plan for patient education, engaging family and friends</td>
<td>100%</td>
</tr>
<tr>
<td>Inform about the pathology (disease course, symptoms indicating aggravation, comorbidities)</td>
<td>96%</td>
</tr>
<tr>
<td>Inform about healthy lifestyle habits (diet, hydration, exercise, rest patterns, photoprotection measures), avoiding toxic habits such as alcohol or smoking</td>
<td>100%</td>
</tr>
<tr>
<td>Treatment:</td>
<td></td>
</tr>
<tr>
<td>Play an active role in treatment training, including self-administration and adherence monitoring</td>
<td>100%</td>
</tr>
<tr>
<td>Take part in the decision to introduce injectable therapy at home</td>
<td>76%</td>
</tr>
<tr>
<td>Prepare a youth-adult therapeutic transition plan</td>
<td>100%</td>
</tr>
<tr>
<td>Follow-up:</td>
<td></td>
</tr>
<tr>
<td>Supervise patient condition to prevent comorbidities (diabetes, obesity, osteoporosis, cardiovascular problems)</td>
<td>96%</td>
</tr>
<tr>
<td>Promote family planning measures</td>
<td>100%</td>
</tr>
<tr>
<td>Monitor patient needs during the youth-adult transition</td>
<td>96%</td>
</tr>
</tbody>
</table>

Conclusion: Despite the high consensus achieved, to bring these recommendations to fruition it is necessary to: 1) Reinforce the role and presence of the specialized nurse in multidisciplinary teams treating SLE patients; 2) Establish a specific training plan for nurses: accredited, subsidized and supported by the Scientific Societies; and 3) Create detailed clinical practice guidelines for the SLE nurse specialist.

REFERENCES:
PATIENT-CENTRIC INTERPROFESSIONAL EDUCATION AS A MEANS TO INCREASE HEALTH PROFESSIONALS' AWARENESS AND UNDERSTANDING OF SCLERODERMA

H. Bowen1,2, M. Morgan1,2, L. Shapiro1,2,3, *Steffens Scleroderma Foundation, Research, Albany, United States of America; 2Hartwick College, Translational Biomedical Research Management, Oneonta, United States of America; 3Russell Sage College, Nutrition Science Department, Troy, United States of America; *Steffens Scleroderma Foundation, Educational Awareness, Albany, United States of America; 1Albany Medical Center, Rheumatology, Albany, United States of America; 2Steffens Scleroderma Foundation, Chief Medical Officer, Albany, United States of America

Background: Incorporating a complex chronic disease into an interprofessional education (IPE) event is an appropriate method to increase knowledge and awareness of diseases that require multiple disciplines to manage. Scleroderma is one example of a rheumatic condition that requires an interprofessional (IP) team management approach. In practice, the rheumatologist must rely heavily on awareness of diseases that require multiple disciplines to manage.

Objective: To increase awareness and understanding of scleroderma among health care professional students and enable patients to draw on their health histories to act as lead educators. Based on the success to date, we hope to promote replication of this model at other scleroderma centers.

Methods: Over four years, approximately 800 students from Russell Sage College, Albany College of Pharmacy and Health Sciences, and most recently The State University of New York at Albany, have participated in an IPE event which included individuals living with scleroderma and/or caregivers. For the first three years the event was held in person and the most recent was hosted virtually following the same structure as years prior. The event includes introductions of the moderators and words from a patient advocate followed by guidance on active listening and patient interview techniques. Eight to ten students enrolled in health-related programs including nutrition, psychology, occupational therapy, physical therapy, pharmacy, nursing and public health are assigned to small IP teams. Each team joins a round table or breakout room with one patient and/or caregiver. Students ask discipline specific questions which allows the patient and/or caregiver to share their narrative(s), enabling students to cultivate active listening skills and elicit the perspective of the patient. As the disease presentation and symptoms vary, the student IP teams will then interview another patient and/or caregiver. During the event students also hear best practices through a facilitated patient interview. An expert panel reflective of the disciplines represented on the student IP teams who have experience working with those diagnosed with scleroderma and other chronic conditions answer student questions. All attendees are asked to complete an anonymous pre and post event survey.

RESULTS: Including patients with scleroderma as educators is effective in increasing student awareness and knowledge of the disease. The implementation of this model into IPE also allows students to practice IP collaboration specific to the needs of an individual living with scleroderma, as it would occur in the health care setting.

Conclusion: This patient-centric IPE enables patients to share their medical journey as lead educators in increasing future health care professionals’ awareness and knowledge of scleroderma. Replication of this pilot model at other scleroderma centers worldwide could promote the collaboration needed from healthcare professionals to assure the best quality of care for those living with scleroderma.

REFERENCES:

Acknowledgements: Steffens Scleroderma Foundation, Russell Sage College, Albany College of Pharmacy and Health Sciences

Disclosure of Interests: Hannah Bowen: None declared, Michelle Morgan: None declared, Lee Shapiro Consultant of: Actelion 2020


INFLUENCING FACTORS ON WORK BURNOUT OF PRE-EXAMINATION AND TRIAGE NURSES UNDER THE NORMAL EPIDEMIC PREVENTION AND CONTROL

B. L. Zhang1,2, S. X. Zhang1,2, T. Cheng1,2,2, F. P. Lian1,2, X. S. Li1,2, C. H. Wei1,2,3, *The Second Hospital of Shaxian Medical University, Department of Rheumatology, Taiyuan, China; 2Shaxian Medical University, Academy of Microbiology, Taiyuan, China; 3Shaxian Medical University, Key laboratory of Cellular Physiology, Taiyuan, China

Background: Nurse is a high-risk groups work fatigue feeling, which seriously affects the quality of conventional work efficiency and burden pressures for contradiction between nurses and patients especially during the COVID-19 pandemic. Normalized epidemic prevention and control during the preview triage nurse need to all patients to the hospital and the accompanying personnel carries on the preliminary screening. COVID-19 fixed point hospital preview triage
nurse with an infected person contact, more prone to anxiety, depression, results in the decrease of efficiency, to treat the service object formulation work sense of fatigue performance, etc.

Objectives: To explore the influencing factors of work burnout of pre-test and triage nurses under normal epidemic prevention and control.

Methods: A total of 110 pre-test and triage nurses from 4 Grade-A hospitals in Shanxi Province were enrolled in this study. The general data questionnaire, Nurse Job Burnout Scale, Pittsburgh Sleep Quality Index Scale, Self-Rating Anxiety Scale and Self-Rating Depression Scale were investigated to work burnout of pre-examination and triage nurses. Comparison between groups using two independent sample t-test and single factor variance analysis. Multiple regression was conducted by SPSS22.0. P values<0.05 were considered significant.

Results: As shown in Table 1, different professional title, department, and the sleep quality of preview triage nurses emotional exhaustion dimension comparison(P<0.001), different department nurses to personalized level dimension comparison(P<0.05), professional title, working department, sleep quality and educational level were the influencing factors of job burnout of pre-test and triage nurses.

Conclusion: In the COVID-19 epidemic, managers should pay more attention to support counselees' adherence to individual, unsupervised exercising.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests: None declared


Table 1. Univariate analysis of job burnout of pre-examination triage nurses from different dimensions.

<table>
<thead>
<tr>
<th>Item</th>
<th>Number</th>
<th>Emotional exhaustion</th>
<th>Depersonalization</th>
<th>Personal accomplishment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>F(t)</td>
<td>P</td>
<td>F(t)</td>
</tr>
<tr>
<td>gender female</td>
<td>100</td>
<td>0.020</td>
<td>0.888</td>
<td>0.162</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>20.10±13.67</td>
<td></td>
<td>6.98±6.15</td>
</tr>
<tr>
<td>age(year) 18–25</td>
<td>30</td>
<td>5.511</td>
<td>0.007</td>
<td>4.143</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>20.33±12.40</td>
<td></td>
<td>8.40±7.33</td>
</tr>
<tr>
<td></td>
<td>40</td>
<td>27.00±13.48</td>
<td></td>
<td>9.20±6.99</td>
</tr>
<tr>
<td>marriage unmarried</td>
<td>52</td>
<td>-0.939</td>
<td>0.352</td>
<td>-1.155</td>
</tr>
<tr>
<td></td>
<td>58</td>
<td>18.38±13.30</td>
<td></td>
<td>6.04±6.80</td>
</tr>
<tr>
<td>work experience(year) &lt;1</td>
<td>20</td>
<td>12.77</td>
<td>0.292</td>
<td>0.938</td>
</tr>
<tr>
<td></td>
<td>24</td>
<td>24.80±15.87</td>
<td></td>
<td>7.60±6.98</td>
</tr>
<tr>
<td></td>
<td>34</td>
<td>16.00±10.53</td>
<td></td>
<td>5.47±6.03</td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>23.06±15.10</td>
<td></td>
<td>9.06±6.43</td>
</tr>
<tr>
<td>department out-patient</td>
<td>54</td>
<td>0.791</td>
<td>0.459</td>
<td>1.125</td>
</tr>
<tr>
<td></td>
<td>56</td>
<td>13.81±10.50</td>
<td></td>
<td>9.07±7.50</td>
</tr>
<tr>
<td>average working time per day(hour) 6–6.9</td>
<td>18</td>
<td>15.33±7.92</td>
<td></td>
<td>5.15±5.28</td>
</tr>
<tr>
<td></td>
<td>44</td>
<td>20.25±13.61</td>
<td></td>
<td>6.43±7.28</td>
</tr>
<tr>
<td></td>
<td>48</td>
<td>20.00±14.88</td>
<td></td>
<td>8.52±5.81</td>
</tr>
<tr>
<td>education degree junior college</td>
<td>18</td>
<td>-0.643</td>
<td>0.523</td>
<td>-1.000</td>
</tr>
<tr>
<td>college</td>
<td>92</td>
<td>16.00±14.76</td>
<td></td>
<td>4.00±5.48</td>
</tr>
<tr>
<td></td>
<td>20.51±13.42</td>
<td>7.33±6.47</td>
<td>25.39±8.70</td>
<td></td>
</tr>
<tr>
<td>SAD(score) ≤50</td>
<td>34</td>
<td>2.080</td>
<td>0.042</td>
<td>1.637</td>
</tr>
<tr>
<td></td>
<td>76</td>
<td>17.74±12.71</td>
<td></td>
<td>6.16±5.33</td>
</tr>
<tr>
<td>SDQ(score) ≤50</td>
<td>72</td>
<td>25.65±13.75</td>
<td></td>
<td>8.88±16.8</td>
</tr>
<tr>
<td></td>
<td>38</td>
<td>19.58±12.94</td>
<td></td>
<td>6.11±3.96</td>
</tr>
<tr>
<td>RSQ(score) ≤7</td>
<td>40</td>
<td>2.379</td>
<td>0.021</td>
<td>2.029</td>
</tr>
<tr>
<td></td>
<td>70</td>
<td>25.65±14.08</td>
<td></td>
<td>9.35±8.02</td>
</tr>
</tbody>
</table>

Background: The 2018 EULAR recommendations for physical activity (PA) in people with inflammatory arthritis and osteoarthritis state that PA in generally recommended dose is effective, safe and feasible (1). Based on the recommendations, the Ankylosing Spondylitis Association of Switzerland (SVMB) developed a concept for their exercise group, consisting of guidance on exercising, regular fitness assessments and individual PA counselling by the group-leading physical therapist (PT). The use of behaviour change techniques (BCTs) during PA counselling ought to support counselees’ adherence to individual, unsupervised exercising.

Objectives: To assess the BCTs used by the PTs during their PA counselling sessions with the members of their axSpA exercise groups.

Methods: An observational cross-sectional study was performed with the first cohort of PTs (n=16) who applied the new concept and provided PA counselling, and their group members who agreed to participate. All first counselling sessions with an individual with axSpA were audiotaped, transcribed and analysed using a coding manual for BCTs (2). The manual includes 38 BCTs across the determinants ‘knowledge’ (2 BCTs), ‘awareness’ (8 BCTs), ‘social influence’ (3 BCTs), attitude (4 BCTs), ‘self-efficacy’ (6 BCTs), ‘intention (6 BCTs), 2 rates familiar with BCTs identified the BCTs used by the PTs. They repeatedly discussed and agreed about their classifications of PTs’ phrasings to BCTs in an iterative process to achieve consistency over all counselling sessions. A BCT could be used several times within one counselling session.

Results: A total of 12 PTs (75%) who counselled 41 people with axSpA participated. All 41 PA counselling sessions, lasting between 30-55 minutes were analysed. Overall, 15 out of the 38 BCTs were identified. Across each determinant (with its number of BCTs), the most and least frequently used BCTs were as follows: 1) determinant ‘knowledge’ (1 of 2 BCTs used); ‘provide general information’ (469 times by 12 PTs); 2) ‘awareness’ (3 of 8 BCTs used); reflective listening and ‘self-monitoring of behaviour’ (268x by 12 PTs and 39x by 9 PTs respectively); 3) ‘social influence’ (of 3 BCTs used); ‘attitude’ (1 of 4 BCTs used); persuasive communication (194x by 11 PTs); 4) ‘self-efficacy’ (of 3 BCTs used): verbal persuasion and guided practice (77x by 11 PTs and 3x by 3 PTs respectively); 6) ‘intention’ (of 4 of 6 BCTs used); general intention formation and develop training schedule (250x by 12 PTs and 18x by 5 PTs respectively); 7) ‘action control’ (of 2 BCTs used); use of cues (199x by 12 PTs), ‘facilitation’ (of 2 BCTs), ‘maintenance’ (5 BCTs). Two raters familiar with BCTs identified the BCTs used by the PTs. They repeatedly discussed and agreed about their classifications of PTs’ phrasings to BCTs in an iterative process to achieve consistency over all counselling sessions. A BCT could be used several times within one counselling session.

Conclusion: In the COVID-19 pandemic, managers should pay more attention to the main factors that affect the sense of pre-test and triage nurses, and take targeted intervention measures to alleviate the sense of exhaustion of nurses, so as to ensure the safety of nursing.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740).

Disclosure of Interests: None declared


POS1559-HPR

PHYSIOTHERAPISTS MAKE LIMITED USE OF BEHAVIOUR CHANGE TECHNIQUES DURING PHYSICAL ACTIVITY COUNSELLING FOR PEOPLE WITH AXIAL SPONDYLOTARTHRITIS

K. Niedermann Schneider1, U. Vogt1, A. K. Rausch Osthoff1, Institute of Physiotherapy, School of Health Sciences, Winterthur, Switzerland; 2Startpunkt PhysioTraining, physiotherapy practice, Zurich, Switzerland
Conclusion: The study identified that PTs used only a limited number of BCTs. BCTs considered less effective such as providing information were widely used, whereas BCTs that are considered effective, such as specific aims or coping with barriers were much less or not at all used. This study provides an insight in real clinical practice and may help to develop counselling training for PTs. There is a need to translate theoretical BCTs into effective measures that are easy to use in clinical practice.

REFERENCES:
[1] Rausch-Osthoff A-K et al. 2018 EULAR recommendations for physical activity barriers were much less or not at all used. This study provides an insight in real

Acknowledgements: We thank all participants for their collaboration

Disclosure of Interests: None declared

HPR Interdisciplinary research...

POS1560-HPR
“MY GUT FEELING IS...”: IDENTIFYING HOW HEALTHCARE PROFESSIONALS COMMUNICATE ABOUT PAIN IN PAEDIATRIC RHEUMATOLOGY MULTI-DISCIPLINARY TEAM MEETINGS

R. Lee1, J. Modonagh1,2, T. Rapley1, A. Farre1, M. Connelly1, T. Palermo2, K. Toupin-April3,8, L. Cordiner1,2. 1University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2Manchester University Hospital NHS Trust, National Institute for Health Research Biomedical Research Centre, Manchester, United Kingdom; 3Manchester University Hospitals Trust, Royal Manchester Children’s Hospital, Manchester, United Kingdom; 4Northumbria University, Department of Social Work, Education and Community Wellbeing, Northumbria, United Kingdom; 5University of Dundee, School of Health Sciences, Dundee, United Kingdom; 6Division of Developmental and Behavioral Health, Children’s Mercy Kansas City, Kansas City, United States of America; 7Seattle Children’s Research Institute, Center for Child Health, Behavior and Development, Seattle, United States of America; 8University of Ottawa, School of Rehabilitation Sciences, Faculty of Health Sciences, Ottawa, Canada; 9University of Ottawa, Department of Pediatrics, Faculty of Medicine, Ottawa, Canada; 10Children’s Hospital of Eastern Ontario, Research Institute, Ottawa, Canada; 11University of Manchester, Manchester Centre for Health Psychology, Division of Psychology and Mental Health, Manchester, Manchester, Canada

Background: Multi-disciplinary teams (MDTs) are common in paediatric rheumatology where UK standards of care state that all children/young people should have access to a paediatric rheumatologist, nurse, physiotherapist, occupational therapist and a psychologist. MDTs in paediatric rheumatology regularly meet for the broader purpose of discussing the assessment of and future management plans for children/young people with a range of complex conditions in which chronic pain may feature. The content of these discussions has not been previously researched. Little is known about healthcare professional to healthcare professional communication and how this may influence the care of children/young people with chronic pain.

Objectives: The objective of the current study was to investigate healthcare professionals communication about children and young people with chronic musculoskeletal pain during MDT meetings in paediatric rheumatology.

Methods: This study was a non-participant ethnographic observation of virtual and face-to-face MDT meetings in three paediatric rheumatology centres in the UK. A structured observation checklist was used to capture and organise field notes which were analysed using an inductive thematic approach amongst research team members. Interpretation of field notes was guided by discussions with healthcare professionals from each of the teams involved.

Results: Forty-two healthcare professionals from across the three teams participated. Ten meetings from each team (n=30) were observed, with meetings ranging from 1-2 hours. Analysis was organised into three themes; 1)Describing the child/young person with pain: Healthcare professionals’ perceptions about personality characteristics (e.g. “He is mature,” “She is sensitive”) were frequently used to introduce a child/young person to the team. A child/young person description was always accompanied by a description of parents and perceptions about their behaviour (e.g. “Dad is very disengaged,” “Mum can shout”). 2)Interpreting the pain of the child/young person: A core component of interpretations was professional familiarity with the child/young person and parents (e.g., “I haven’t got a handle on them yet”). Professionals also discussed how their interpretation was influenced by “gut feelings” or “vibes that something else is going on at home”. 3)Managing the child/young person with pain: Healthcare professionals discussed the need for acceptance of pain and treatment from children/young people (e.g., “She wasn’t buying into that; “He needs to get used to it”). Setting boundaries for children/young people and parents for accessing the team also featured in discussions (e.g., “We need to re-assure them but not always be available”).

Conclusions: This study highlights a range of healthcare professional approaches and processes to communicating about and discussing children/young people with pain at paediatric rheumatology MDT meetings. Findings suggest that healthcare professionals in paediatric rheumatology describe, interpret and manage the child/young person presenting with pain alongside the broader psycho-social (and less frequently the biological) context. These findings will inform the development and methods of a behaviour change intervention to improve pain communication in consultations with children/young people, parents and amongst the paediatric rheumatology team of healthcare professionals in the UK.

Acknowledgements: The authors would like to thank the healthcare professionals for kindly taking the time to take part in this study. The views expressed herein are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research, or the UK Department for Health. This work was supported by a Foundation Fellowship award from Versus Arthritis (Grant 22433). Aspects of this work were also supported by funding from the Centre for Epidemiology Versus Arthritis (Grant 20380) and the NIHR Manchester Biomedical Research Centre.

Disclosure of Interests: None declared

POS1561-HPR
HEALTH CARE PROVIDERS’ PERSPECTIVE ON CONTINUATION VERSUS TEMPORARY INTERRUPTION OF IMMUNOMODULATORY AGENTS IN CASE OF AN INFECTION: AN INTERVIEW STUDY

M. Opdam1, J. E. Vriezekolk2, A. Den Broeder1,3, L. M. Verhoef1. 1Sint Maarten’skliniek, Rheumatology, Ubbingen, Netherlands; 2Sint Maarten’skliniek, Research, Ubbingen, Netherlands; 3Radboud University Medical Center, Rheumatology, Nijmegen, Netherlands

Background: Immunomodulatory agents (IA) are often used in the treatment of immune mediated inflammatory diseases (IMIDs). The use of some of these IA is associated with a slightly increased infection risk (1), which raises concerns especially during the current COVID-19 pandemic. It is however unknown whether it best to continue or temporary interrupt IA in case of an infection, and what the views of health care providers are on this subject.

Objectives: To obtain insight in the health care providers’ perspective regarding continuation and temporary interruption in case of an infection and to assess barriers and facilitators for both treatment strategies.

Methods: Health care providers, involved in the pharmacological treatment of different IMID patients, were interviewed by phone or face-to-face using semi-structured interviews. Recruitment was done using purposive sampling based on age, gender, function, specialty and affinity with the topic. Interviews were conducted until data saturation and analyzed by two researchers using inductive thematic analysis.

Results: Thirteen health care providers with three different functions (medical specialist, physician assistant, resident in training) from three different medical specialties (rheumatology, gastroenterology and dermatology) were interviewed. Mean age was 49 years (range 34 to 66) and the majority was female (69%). Ten main themes were constructed, yielding 77 barriers and facilitators across the two treatment strategies (see Table 1 for themes and a selection of barriers/ facilitators). Health care providers mentioned that the choice between continuation and temporary interruption is often about balancing infection severity, IMID severity (e.g. risk of flare) and patient characteristics (comorbidities/vulnerability). They struggled with the lack of evidence on these two treatment strategies, which leads to choices being made based on previous experiences or intuition.

Table 1. Identified themes

<table>
<thead>
<tr>
<th>Theme</th>
<th>Example of barrier/facilitator</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. IMID characteristics</td>
<td>Low disease activity (facilitator for interruption)</td>
</tr>
<tr>
<td>2. IA characteristics</td>
<td>Large administration intervals: interruption not possible (barrier for interruption)</td>
</tr>
<tr>
<td>3. Effects of IA on infection</td>
<td>Belief on positive effect (facilitator for continuation)</td>
</tr>
<tr>
<td>4. Immune system</td>
<td>Belief on negative effect (barrier for interruption)</td>
</tr>
<tr>
<td>5. Infection characteristics</td>
<td>Patients with comorbidities / history of previous infections (facilitator for interruption)</td>
</tr>
<tr>
<td>6. Healthcare provider</td>
<td>Patients with comorbidities / history of previous infections (facilitator for interruption)</td>
</tr>
<tr>
<td>7. Health care provider</td>
<td>Patients with comorbidities / history of previous infections (facilitator for interruption)</td>
</tr>
<tr>
<td>8. Financial</td>
<td>Higher costs (barrier for continuation)</td>
</tr>
<tr>
<td>9. Stopping IA in general</td>
<td>Chance to stop/taper IA (facilitator for interruption)</td>
</tr>
<tr>
<td>10. Interruption characteristics</td>
<td>Short duration no impact on disease activity (facilitator for interruption)</td>
</tr>
</tbody>
</table>
**Patient information and education**

**POS1562-PARE**

**CAN EDUCATION PROGRAMS REDUCE ANXIETY IN PATIENTS WITH RHEUMATOID ARTHRITIS?**

S. Lezhnien1, N. Shuvalova2, E. Guryanova3, N. Igoshina1, I. Chuvash State University by I. N. Ulianov, Department of Healthcare Management and Economics, Cheboksary, Russian Federation; 1I. Ya. Yakolev Chuvash Pedagogical State University, Department of Theoretical Foundations of Physical Education, Cheboksary, Russian Federation; 2Chuvash State University by I. N. Ulianov, Department Internal Diseases, Cheboksary, Russian Federation

**Background:** Persistence of pain syndrome is accompanied by emotional changes and contributes to the formation of anxiety disorders in patients with rheumatoid arthritis (RA). Models of training patients with RA are aimed at developing the correct behavioral stereotype and improving the psychological status. To evaluate the effectiveness of these educational programs, it is required to study the impact of these programs on the level of anxiety in patients with RA.

**Objectives:** To assess the impact of education in an educational program in patients with RA on the level of anxiety.

**Methods:** The study was conducted in the Chuvash Republic, the city of Alatyr, from December to January 2020. 90 patients with RA of varying severity were examined. The inclusion criterion was a diagnosis of RA in accordance with the criteria of the European Antirheumatic League (EULAR) / ACR 2010. All patients were randomized into two groups: the main group (n=45), which, on the background of drug therapy (methotrexate at a dose of 7.5 to 15 mg/week and nimesulide 200 mg/week) was trained in the educational program: lectures and practical exercises. In the practical part, most of the time was devoted to the skills of self-control of the disease (taught how to self-assess swollen and painful joints). The training was carried out in two stages. The first stage (lecture-practical course) - twice a week for 1.5 hours, for two weeks, full-time education. The second stage (lecture course) - twice a week for 1.5 hours for two weeks, distance learning. In the control group (n=45), patients received the same treatment but were not trained in the educational program. Patients in these groups were representative by sex and age. All patients before and after completing the training program (after 1 month) were determined the level of situational and personal anxiety according to the Spielberger questionnaire modified by Yu.L. Khanina. The results obtained were interpreted: up to 30 points – a low level of anxiety, 31-45 corresponded to an average level, over 45 - a high level of anxiety. Statistical processing was carried out in the MS Office Excel package with the determination of average values (M), standard deviation (SD), and p-value

**Results:** Before training in the main group, the structure of personal anxiety was represented by a high level of 62.14 ± 4.46 points (83.0% of patients), while reactive anxiety was represented by average values of 39.25 ± 3.29 (62% of patients). 2% of respondents had a low level of personal anxiety, 5.2% of patients had low levels of reactive anxiety. Anxiety scores were about the same in the two groups. After training in the main group, the level of personal anxiety decreased in 41% of respondents (53.22 ± 6.87 points), reactive anxiety decreased by more than 2 times in 27% of patients. The number of patients with low levels of both personal and reactive anxiety increased to 40% and 40.2%, respectively. The differences were statistically significant (p<0.05). In the control group, the level of anxiety did not change statistically significantly.

**Conclusion:** Patients with RA who were trained in an educational program had a two-fold decrease in the level of personal anxiety and more than a two-fold decrease in the level of reactive anxiety, compared with patients who did not receive training. It is possible that the decrease in the level of anxiety in patients with RA occurred both due to a higher level of awareness of patients about this disease, and due to changes in the psycho-emotional state.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1258

---

**Table 1. Patient characteristics.**

<table>
<thead>
<tr>
<th></th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>110 (68.8)</td>
</tr>
<tr>
<td>Male</td>
<td>50 (31.2)</td>
</tr>
<tr>
<td><strong>Age (mean (SD))</strong></td>
<td>53.6 y (±14.8)</td>
</tr>
<tr>
<td><strong>Indication</strong></td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>33 (20.6)</td>
</tr>
<tr>
<td>RA</td>
<td>74 (46.3)</td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>17 (10.6)</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>3 (1.9)</td>
</tr>
<tr>
<td>Reiter’s disease / axial SpA</td>
<td>23 (14.4)</td>
</tr>
<tr>
<td>Other* and RA</td>
<td>2 (1.2)</td>
</tr>
<tr>
<td>Other*</td>
<td>8 (5.0)</td>
</tr>
<tr>
<td><strong>bDMARD</strong></td>
<td></td>
</tr>
<tr>
<td>Adalimumab</td>
<td>84 (52.5)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>76 (47.5)</td>
</tr>
<tr>
<td><strong>Most frequently reported ADRs</strong></td>
<td></td>
</tr>
<tr>
<td>Injection site reactions (pain, pruritis, erythema)</td>
<td>85 (100)</td>
</tr>
<tr>
<td>Infections</td>
<td>231 (100)</td>
</tr>
<tr>
<td>Cystitis</td>
<td>25 (10.8)</td>
</tr>
<tr>
<td>Infection susceptibility increased</td>
<td>24 (10.4)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>21 (9.1)</td>
</tr>
<tr>
<td>Skin reactions</td>
<td>266 (100)</td>
</tr>
<tr>
<td>Eczema</td>
<td>42 (15.8)</td>
</tr>
<tr>
<td>Psoaritis</td>
<td>29 (10.9)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>25 (9.4)</td>
</tr>
</tbody>
</table>
Note: n= number of patients, y= years, RA= rheumatoid arthritis, SpA= spondyloarthitis, bDMARD= biological disease-modifying antirheumatic drug, RMD= rheumatic and musculoskeletal disease-associated lung disease (n=1), systemic scleroderma (n=1), Uveitis posterior and panuveitis (n=1), birdshot chorioretinopathy (n=1), hemochromatosis (n=1), hidradenitis suppurativa (n=1), juvenile idiopathic arthritis (n=1), psoriasis (n=1), Bechterew’s disease and RA (n=1), RA and Crohn’s disease (n=1).

Conclusion: This study shows that patients apply a wide range of self-management strategies for their ADRs. Further research should focus on the effectiveness of these actions and subsequently dissemination or (de)implementation of these strategies if deemed (in)effective.

REFERENCES:

Disclosure of Interests: Marilous Ophoff: None declared. Jette van Lint: None declared. Sander Tas Consultant of: Pfizer, GSK, Celgene, BMS, Sanofi, Astra Zeneca, Bart van den Berst Speakers bureau: UCB, Pfizer, Sanofi-Aventis, Galapagos, Amgen en Eli Lilly, Harald Vonkeman Speakers bureau: Amgen, BMS, Celgene, Galapagos, GSK, Janssen-Cilag, Lilly, Novartis, Pfizer, Roche, Sanofi-Genzyme, UCB, Grant/research support from: Abbvie, Sanofi-Genzyme, Frank Hoentjen Speakers bureau: Frank Hoentjen has served on advisory boards or as speaker for Abbvie, Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk, Consultant of: Celgene, Grant/research support from: Fund- ing (Grants/Honoraria): Dr Falk, Janssen-Cilag, Abbvie, Takeda, Michael Nur- Mohammad Speakers bureau: Abbvie, Janssen, Celgene, Naomic Jessurun: None declared


Table 1. Top Education Topics Adults with Rheumatic and Musculoskeletal Disease Consider Extremely Important (N=570).

<table>
<thead>
<tr>
<th>Item</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knowing when the medication is not working</td>
<td>505</td>
</tr>
<tr>
<td>Knowing how a rheumatologic condition can affect your other health conditions or medical issues</td>
<td>481</td>
</tr>
<tr>
<td>Understanding the results of tests used to monitor your condition</td>
<td>471</td>
</tr>
<tr>
<td>Knowing the side effects of available drugs, and how the drugs interact with each other</td>
<td>461</td>
</tr>
<tr>
<td>Finding the right rheumatologist</td>
<td>453</td>
</tr>
<tr>
<td>Having realistic expectations of the effectiveness of the medications</td>
<td>445</td>
</tr>
<tr>
<td>Knowing how the disease will progress, even if the news is bad</td>
<td>439</td>
</tr>
<tr>
<td>Knowing the available medications and treatments for your rheumatologic condition</td>
<td>437</td>
</tr>
<tr>
<td>Knowing how long it takes drugs to work</td>
<td>436</td>
</tr>
<tr>
<td>Understanding how your life will change as your disease progresses</td>
<td>434</td>
</tr>
</tbody>
</table>

Table 2. Desired Smartphone App Functions Rated By Adults with Rheumatic and Musculoskeletal Disease (N=570).

<table>
<thead>
<tr>
<th>App Function</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participate in patient-centered research</td>
<td>299</td>
</tr>
<tr>
<td>View my lab results</td>
<td>283</td>
</tr>
<tr>
<td>Record my symptoms (e.g. pain, fatigue) or disease flares to track my health over time</td>
<td>278</td>
</tr>
<tr>
<td>Record my symptoms and show how I am doing with my rheumatologist to provide at 230</td>
<td>47.8</td>
</tr>
<tr>
<td>know if I am meeting my treatment goals</td>
<td></td>
</tr>
<tr>
<td>Get educational information about my disease</td>
<td>225</td>
</tr>
<tr>
<td>Keep track of the medications prescribed by doctor</td>
<td>200</td>
</tr>
<tr>
<td>Schedule and keep track of my medical appointments, rheumatology and other</td>
<td>199</td>
</tr>
<tr>
<td>Track the vaccines I get (i.e. vaccination record)</td>
<td>188</td>
</tr>
<tr>
<td>Help me improve some of my health habits (e.g. sleep, diet, exercise)</td>
<td>187</td>
</tr>
<tr>
<td>Keep track of my use of over-the-counter, complementary or alternative therapies</td>
<td>174</td>
</tr>
<tr>
<td>(herbs, tinctures, acupuncture, massage, stretching, etc.)</td>
<td>131</td>
</tr>
<tr>
<td>Get support for my disease from trained patients with my same health condition</td>
<td>144</td>
</tr>
<tr>
<td>(i.e. peer coaching)</td>
<td>125</td>
</tr>
</tbody>
</table>

Conclusion: People with RMD prioritized information about medications and prognosis in educational materials, providing guidance for the development of educational tools. A sizeable minority felt educational materials were an important component of a smartphone app, but also identified other important features such as participation in research.

Disclosure of Interests: W. Benjamin Nowell Grant/research support from: Research support from AbbVie, Amgen, Eli Lilly and Scipher, Kelly Gavigan: None declared, Kimberly Garza: None declared, Alexis Ogdie: None declared, Michael George: None declared, Jessica A. Walsh Consultant of: AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB, Grant/research support from:
AbbVie, Merck, and Pfizer, Maria Danila: None declared, Shilpa Venkatachalum: None declared, Laura Stratford: None declared, Jeffrey Curtis Consultant of: AbbVie, Amgen, BMS, Corrana, Eli Lilly and Company, Gilead, Janssen, Myriad, Novartis, Pfizer, Regeneneron, Roche, and UCB, Grant/research support from: AbbVie, Amgen, BMS, Corrana, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneneron, Roche, and UCB

DOI: 10.1136/annrheumdis-2022-eular.2871

POS1565-PARE

ASSESSMENT OF QUALITY AND RELIABILITY OF YOUTUBE VIDEOS FOR PATIENT AND PHYSICIAN EDUCATION ON INFLAMMATORY MYOSITIS

M. Joshi, N. R.2, R. Gupta1, V. Agarwala2, R. Aggarwala2, L. Gupta2, Byramjee Jeejeebhooy Government Medical College and Sassoon General Hospitals, Department of Medicine, Pune, India; 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Department of Clinical Immunology and Rheumatology, Lucknow, India; 4University of Pittsburgh, Department of Medicine, Rheumatology and Clinical Immunology, Pittsburgh, United States of America

Background: Nowadays 80% of internet users access health information online, with YouTube being the second most popular search website worldwide. This study was undertaken to assess the reliability and quality of videos pertaining to myositis on YouTube and identify lacunae in information material on the platform.

Objectives: This study aims to assess the quality and profile of myositis information videos on YouTube, and to compare and delineate attributes of useful and not useful videos using standard metrics.

Methods: A thorough search was carried out on YouTube using 9 search terms related to myositis. The inclusion criteria were primary English content related to myositis, acceptable audio-video quality, and multi-part videos to be considered as one, while duplicates and advertisements were excluded. The videos were classified as useful, not useful or misleading, and patient experiences (Figure 1).

Results: Of 493 analyzed videos 74% and 2% provided useful and not useful information respectively. 24% were patient experiences, and 324 (71%) were intended specifically for patients while 313 (69%) were for healthcare providers and students. Nearly one-thirds (n=143) reported information related to treatment intended specifically for patients while 313 (69%) were for healthcare providers.

Conclusion: A majority of useful YouTube videos on myositis provide useful information for patients, largely related to treatment of myositis. However, the dynamic nature of YouTube could potentially change this equation in the future and physicians should correct any misinformation identified in face-to-face meetings or teleconsultations. High quality useful videos, often predicted by validated scores and produced by professional medical societies should be promoted as the first line of content consumed.

Disclosure of Interests: None declared


Figure 1. Flowchart of selection of YouTube videos for the study

Table 1. Factors predicting usefulness of video in binary logistic regression.

<table>
<thead>
<tr>
<th>Variable</th>
<th>B coefficient</th>
<th>S.E.</th>
<th>Exp (B)</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended audience</td>
<td>-0.45</td>
<td>0.261</td>
<td>0.65</td>
<td>0.48-0.91</td>
<td>0.035</td>
</tr>
<tr>
<td>Anyone/General public</td>
<td>Average GQS</td>
<td>-2.86</td>
<td>1.076</td>
<td>0.05 (0.007-0.47)</td>
<td>0.008</td>
</tr>
</tbody>
</table>

GQS Global Quality Scale. Exp (B) is odd's ratio, p<0.05 is significant

Conclusion: Majority of English YouTube videos on myositis provide useful information for patients, largely related to treatment of myositis. However, the dynamic nature of YouTube could potentially change this equation in the future and physicians should correct any misinformation identified in face-to-face meetings or teleconsultations. High quality useful videos, often predicted by validated scores and produced by professional medical societies should be promoted as the first line of content consumed.

Disclosure of Interests: None declared

Building patient led organisations.

**POS1568-PARE**

**THE BRIEF-ILLNESS PERCEPTION QUESTIONNAIRE: A METHOD FOR ASSESSING THE COGNITIVE REPRESENTATION OF RHEUMATIC DISEASE**

Z. Zeineb1, S. Jemmali1, S. Rekik1, S. Boussaid1, S. Rahmouni1, K. Zouari1, H. Sahli1, M. Elleuch1, 1Rabta University Hospital, Rheumatology, Tunis, Tunisia

Background: The common-sense model proposes that illness perception (IP), is how patients make sense of their illness and respond emotionally to it, influencing the way they cope with the illness and subsequently illness outcomes. This proposition has gained considerable empirical support, and the relevance of IP in understanding illness-related behaviors or outcomes has also been supported in patients with rheumatic diseases (RD). The Brief Illness Perception Questionnaire (B-IPO) was designed to provide a simple and rapid assessment of IP. This questionnaire has been widely used in diverse ages, illness types, countries, and languages.

Objectives: This study aimed to examine the construct of IP as measured by the B-IPO in patients with RD.

Methods: A cross-sectional study was conducted at a Tunisian rheumatology department on 80 patients with RD. Sociodemographic, disease-related variables were reported. Participants completed a questionnaire on illness beliefs (B-IPO).

Results: Subjects were aged 22-74 years (mean 51 years), 61.6% were female. Diagnoses included Rheumatoid arthritis (RA) (63%), axial spondyloarthritis (AS) (37%). The mean disease duration was 11 years and 7 years for RA and AS respectively. The proportion of physical comorbidities was higher in RA patients (36%) versus AS patients (11%). Disease activity was low in 28.8% of patients. All patients were on medications for their rheumatic disease, and 34.6% were on biological therapy.

In both diseases, the participants perceived their rheumatic illness as a chronic condition (9.4) that could be controlled by treatment (6.6) but not strongly influenced by personal actions (4.3). Overall, Rheumatic disease was seen as having an important impact on their life (7.9) without significant difference between patients with low or high activity disease (p=0.23). The majority believe that they have a moderate understanding of their illness (6.6). The frequency of symptoms was highly evaluated in RA patients than AS patients (73 vs 56) (p=0.01). In RA patients, 76% were extremely affected emotionally by their disease, however, the majority of AS patients were moderately affected emotionally with a significant difference (p=0.02). In addition, RA patients considered their disease mainly a result of psychological factors (66.8%). On the other hand, AS patients (73%) attributed their illness to various risk factors (especially physical overexertion).

Conclusion: High scores of B-IPO shown in our studies, encourage the design of psychotherapeutic trials targeting disease-related cognitions in AS and RA in an attempt to improve patients' reported outcomes and disease outcomes.

Disclosure of Interests: None declared


**POS1567-PARE**

**ASSESSMENT OF ADHERENCE AMONG GREEK PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19 ERA**

K. Koutsogianni1, E. Repa1, K. Spanidou1, I. Papadakis1, I. Chatzkyraklis4, P. Pratsidou-Gertsi5, F. Asimakopoulou1 on behalf of ReuMAzein's Team.

Background: Patient’s (pts) adherence is a EULAR important recommendation for an optimal disease course and outcome. COVID-19 pandemic has globally challenged the issue of adherence. As relevant Greek data are lacking, the Pan-Hellenic Federation “Rheumazein” (i.e., co-living with a Rheumatic Disease) conducted a survey among their members to assess adherence and a possible COVID-related negative impact.

Objectives: The main endpoint of the study aimed to capture the degree of pt adherence to treatment, either with conventional synthetic or/and biologic DMARDs (csDMARDs, bDMARDs). The secondary endpoints were: a. To record pts’-physicians’ interactive communication to assess the level of shared disease making (SDM), b. The emerged barriers to medication access during the pandemic and consequent restrictive measures. c. To record pt perceptions on the usefulness of mobile reminder applications towards an uninterrupted regimen.

Methods: A 29-item quantitative questionnaire was uploaded in the social media of the Federation and its associations, in order to register pts’ responses on the aforementioned sections. The questionnaire was accessible for a 58-day period (21/09/2021-17/11/2021).

Results: Participants’ characteristics: The responses of 303 adults with RD (M:F 63:240), aged (in yrs) 18-44: 35%, 45-54: 26%, >55: 38% respectively, were available for analysis. The RD types were RA 33%, AS 18%, PsA 13%, SLE 18%, Juvenile Arthritis 5% and Other RD 13%, respectively. The education level was low/moderate 39%, high 30%, post-graduate 31%, respectively. Receivers of a monotherapy with either cs- or bDMARDs were 93(31%) and 83(27%), of a combined regimen cs+bDMARDs 114(38%) and of treatment ad 13 (4%). BDMARD receivers were mostly AS pts (93%) while the least, SLE pts (48%). The route of bDMARD administration (sc vs iv) did not significantly differ (57% vs. 43%). Since diagnosis, the mean disease trajectory was 7.6 yrs, the mean time on medication 6.9 yrs, while the mean duration on the current regimen 3 yrs, respectively. Adherence: At least one skipped dose during the last trimester was reported, significantly more often by pts under csDMARDs than by those under bDMARDs, (60% vs. 40%, p<0.001) with a significant difference (p=0.02). In addition, RA patients had a significantly higher adherence than AS patients under bDMARDs (76% vs 40%, p<0.001), but not for csDMARDs (60% vs. 40%, p<0.001) with a significant difference (p=0.01). In RA patients, 76% were extremely affected emotionally by their disease, however, the majority of AS patients were moderately affected emotionally with a significant difference (p=0.02). In addition, RA patients considered their disease mainly a result of psychological factors (66.8%). On the other hand, AS patients (73%) attributed their illness to various risk factors (especially physical overexertion).

Conclusion: A significant percentage of pts skip scheduled DMARD administration, especially those (60%) under csDMARDs. The relationship with the physician was considered relatively satisfactory. Most of the pts did not have any mobile phone reminder application regarding their dose. Finally, the COVID-19 pandemic appeared to have had little effect on pts’ access to both cs- and bDMARDs and consequently, adherence to their treatments.

Disclosure of Interests: None declared

Arthritis research

POS157/PARE A PATIENT-LED SURVEY INTO THE BENEFITS AND LIMITATIONS OF TELEMEDICINE APPOINTMENTS FOR ASSESSING CHILDREN AND YOUNG PEOPLE WITH RHEUMATIC CONDITIONS: COMPARING EUROPEAN AND CANADIAN COHORTS

R. Bleesey1,2, G. Angewane3,4, J. Wilson5, W. Costello6,7,8,1 Juvenile Arthritis Research, JAR Project, Tonbridge, United Kingdom; 2European Network for Children With Arthritis, ENCA, Geneva, Switzerland; 3KAISZ, KAI SZ, Amsterdam, Netherlands; 4Autoinflammatory Alliance, Autoinfl ammatory Alliance, San Francisco, United States of America; 5Cassie And Friends Society, CAF Society; Vancouver, Canada; 6Irish Children’s Arthritis Network, ICAN, Bansha, Ireland

Background: During the COVID-19 (coronavirus) pandemic, some provision of healthcare shifted to remote, technology-assisted appointments (telemedicine). Whilst parents/carers of children and young people with rheumatic conditions have reported benefits of telemedicine, concerns remain.

Objectives: This patient and parent-led project sought to understand the views of parents/carers about telemedicine, identifying the benefits and limitations of remote technology-assisted appointments, and comparing views between Canadian and European cohorts.

Methods: An online survey was developed, translated into multiple languages and shared via social media and patient organisations, targeted at parents of children and young people with rheumatic, autoimmune and autoinflammatory conditions. Fieldwork took place in April 2021 in Europe and May 2021 in Canada. Consent was provided during enrollment.

Results: A total of 290 responses were received (133 Europe; 157 Canada). Of these, 73% were female, median age 12. Over half of respondents (53%) in Europe reported travelling over an hour to in-person appointments with their paediatric rheumatologist, compared to a significantly higher proportion of respondents in Canada (97%). Consequently, in-person appointments represent a greater time burden amongst Canadian caregivers, though both groups report appointments taking over three hours in total (51% Europe, 69% Canada).

Prior to COVID-19, most had never had a telemedicine appointment (92% Europe, 95% Canada). Since March 2020, the majority (71% Europe, 82% Canada) had at least one telemedicine appointment.

Table 1. Shows the scores (1 worst, 5 best) given by parents about their telemedicine experience. Overall, most aspects scored positively (p<.05). However, parents felt telemedicine was not as good as in-person appointments.

Table 1. Top Goals based on rating as “Very Important” by >70% of subjects, from set of 36. “My goals for living with RA are to…”

Goals Not Important Somewhat Important Important Very Important
Symptom Management improve the quality of my life with RA 0% (0) 0% (0) 6% (3) 94% (44)
manage my RA pain 0% (0) 2% (1) 11% (5) 87% (41)
Life Impact reduce how my RA pain interferes with my life 0% (0) 9% (4) 17% (8) 74% (35)
be independent in my daily functioning 0% (0) 2% (1) 21% (10) 77% (36)
Managing my RA feel like I can manage my RA 0% (0) 4% (1) 15% (4) 81% (22)
have the information I need to make treatment decisions 0% (0) 0% (0) 19% (9) 81% (38)
Impact goals were rated as Important or Very Important by >85% of participants; endorsement for Management and Treatment goals was somewhat more variable, with ≥85% endorsing these as Somewhat to Very Important. Results suggested that domains match key goals. Steering committee ratings supported the feasibility of this approach.

Conclusion: Goals relevant for RA treatment evaluation can be efficiently identified and rated for importance by patients. Patient-important goals can be incorporated into deliberative healthcare valuation using this method to permit “crow-sourced” input from people living with RA and to capture heterogeneous patient perspectives in healthcare valuation.

Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared


Table 1. Mean scores for a range of aspects of telemedicine (1=worst; 5=best). * Positive score (p<.05) ** Negative score (p>0.05) † Difference between Canadian and European cohorts is statistically significant (p<.05), chi-square.

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Europe</th>
<th>Canada</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Easy to schedule</td>
<td>3.50</td>
<td>4.33</td>
<td>4.33 (4.14, 4.52) *†</td>
</tr>
<tr>
<td>Children’s satisfaction with doctor</td>
<td>3.32</td>
<td>4.07</td>
<td>4.07 (3.85, 4.29) *†</td>
</tr>
<tr>
<td>Enough time with doctor</td>
<td>3.51</td>
<td>4.24</td>
<td>4.24 (4.02, 4.45) *†</td>
</tr>
<tr>
<td>As good as in-person visit</td>
<td>2.21</td>
<td>2.66</td>
<td>2.66 (2.42, 2.90) **†</td>
</tr>
<tr>
<td>Easier to see doctor</td>
<td>2.84</td>
<td>3.51</td>
<td>3.51 (3.25, 3.77) **†</td>
</tr>
<tr>
<td>Easy to sign-in</td>
<td>3.52</td>
<td>4.25</td>
<td>4.25 (4.06, 4.43) **†</td>
</tr>
<tr>
<td>Quality of video</td>
<td>3.23</td>
<td>3.87</td>
<td>3.87 (3.66, 4.07) **†</td>
</tr>
<tr>
<td>Quality of sound</td>
<td>3.54</td>
<td>3.94</td>
<td>3.94 (3.75, 4.14) **†</td>
</tr>
<tr>
<td>Able to speak freely</td>
<td>3.61</td>
<td>4.05</td>
<td>4.05 (3.89, 4.24) **†</td>
</tr>
<tr>
<td>Able to understand doctor</td>
<td>3.61</td>
<td>4.09</td>
<td>4.09 (3.90, 4.28) **†</td>
</tr>
<tr>
<td>Quality of care provided</td>
<td>3.43</td>
<td>3.78</td>
<td>3.78 (3.56, 4.00) **†</td>
</tr>
<tr>
<td>Overall telemedicine experience</td>
<td>3.23</td>
<td>3.78</td>
<td>3.78 (3.57, 3.99) **†</td>
</tr>
</tbody>
</table>

When asked about aspects of telemedicine, a greater proportion of respondents from Canada answered favourably compared to those from Europe with the majority reporting telemedicine appointments had saved them time, enabled them to have an appointment and that it made the appointment safer. However, most felt that their consultant could not properly assess their child (72% Europe, 78% Canada, p<.05).

Overall respondents said they would prefer the next appointment to be in-person (82% Europe, 62% Canada, p<.05), although 31% from Canada were amenable to a combination of in-person and telemedicine-based care.

Conclusion: There are advantages to telemedicine, notably saving time and making appointments accessible. Families from Canada tended to view telemedicine more favourably than those from Europe, although the majority from both cohorts reported concerns about the ability to assess their child. There may be value in providing training to parents to enhance the accuracy of home-based assessments, particularly when the disease is stable. However, parents continue to report the value of in-person appointments.

Disclosure of Interests: Richard Bleesey: None declared, Saiyska Angewane Grant/research support from: Novartis and Sobi grant for translation of KAISZ website. None relevant to this study, Wendy Costello: None declared

DOI: 10.1136/annrheumdis-2022-eular.59
Innovations in arthritis health care.

**POS1571-PARE**

Online Counselling for Patients with Arthritis

S. Đorđević, M. Lapčević, Association Of Patients With Rheumatic Diseases of the Republic of Serbia (ORS), Association of Patients, Belgrade, Serbia; "Association of Patients With Rheumatic Diseases of the Republic of Serbia" (ORS), Association of Patients, Belgrade, Serbia

**Background:** The Covid-19 pandemic has changed many aspects of our lives. Perhaps the biggest changes have been in medical services. Institutes specializing in RMD in Serbia were part of the covid system and patients only had access in emergency cases, there was no regular examination.

**Objectives:** The paper shows how the "Online Counselling for Arthritis Patients (OCAP)" worked during the pandemic, how many rheumatologists and patients were involved and were patients satisfied with the service provided.

**Methods:** Through the platform "Lekarinfo" ORS, in cooperation with pharmaceutical companies, organized an OCAP. Patients were informed about the possibility of using online consultations with rheumatologists via social networks, viber groups, email, and they were given instructions on how to use it, they were advised to send medical documentation before, so the doctor has time to look at it, which gives more time for conversation. Consultations were held by phone or online, depending on patient’s wishes and abilities. The time set aside with a rheumatologist was 20 minutes and with a psychologist 30 minutes. One psychologist and 23 rheumatologists were available. The ORS distributed cards to rheumatologists with contact data and instructions on how to contact OCAP to inform their patients.

**Results:** ORS conducted a Survey about OCAP. It was completed by 100 respondents, aged 20 to 75 of whom 75% were women. The 44% of respondents were from Belgrade, but it also included respondents from all over the country. RA have 61% of respondents, but patients with other types of arthritis were also included. 4/5 of patients are non-smokers and half of them are on biological therapy. All but one respondents are ORS’s members. The results of Survey are the following: OCAP was used by 27% of respondents and all of them were satisfied except one. Everyone would use it again and would advise others to do so. Online consultation can replace live examination, when the disease is in remission, thanks 62% of respondents. The majority (90%) found it technically easy to use, but also the majority of respondents felt that there is a space for improvement (70%). One third prefers to have online consultations with their rheumatologist, Half of them understand the importance of telemedicine, 61% think that C-19 pandemic has increased the need for it and 64% think that digital solutions are our perspectives and it should be further developed.

**Conclusion:** It is desirable to continue with this kind of telemedicine. Patients and their families should be encouraged and educated about using digital platforms, aim is to explain them the benefits of telemedicine and that consultations do not necessarily have to be with their rheumatologists. Regardless of the pandemic, digitalization is in every aspect of our life, it is inevitable, but also it is a great advantage that should not be missed. Investments in the development of online platforms, that will facilitate patients access to doctors are an investment in self-control of chronic diseases in extraordinary circumstances, but also in normal conditions when because of the overscheduled doctors, lack of time for employed patients or other reasons, it is not possible for frequent examinations. Telemedicine is an investment not only in physical health but also in mental health of patients, having a doctor “just a step from you” has calming and positively affects for patients. And without positive attitude it’s hard to keep a chronic disease under control.

**REFERENCES:**

2. Pedro Santos-Moreno and others: Experience of telemedicine use in a big cohort of patients with RA during covid-19 pandemic;
3. Suncica Djordjevic and others: Mobile application “MojRa” - monitoring rheumatic diseases of the Republic of Serbia - ORS, Nis Branch, Belgrade, Serbia;
5. Elizabeth D. Ferucci and others: Outcomes and quality of care in patients with RA or without subsequent visits through video consultations.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2899

**POS1572-PARE**

Helping a way of working in ORS branch – NIS during the COVID-19 pandemic in 2021

D. Jankovic, V. Filipovic, Association of Patients With Rheumatic Diseases of the Republic of Serbia - ORS, Nis Branch, Belgrade, Serbia

**Background:** Helper is a person with RMD educated to help other patients. Based on the clearly defined authorizations this person helps in advising and information sharing among the ORS members. Association of patients with rheumatic diseases of the Republic of Serbia (ORS) operates across the country through the reference centers/branches, but in pandemic the functioning of helper in a regular way was significantly impacted.

**Objectives:** In order to continue with the functioning in Association and with Helper during the Covid-19 pandemic, new communication and information sharing methods has been applied. In this work will be shown how the strategy of communication was shifted from physical to digital, methods used for information sharing and communication tools of the modern world has been used for this purposes. Also, functioning of the branch in Niš and its Helper will be shown through statistical comparison of data prior and during the Covid19.

**Methods:** In the definition of Association’s members’ request for the new circumstances, it has been concluded that most of the members are using some of IM platform or e-mail. Based on this fact, out of 247 members of branch in Niš, 168 members have been joined through the most popular IM platform in Serbia – Viber. Through the group the patients has been sharing the information, notifications and other news important for the patients. Group administrators supported discussions, but also identified patients who do not use IM platforms and those members were notified by phone or e-mail. This method of communication was symbiotic with other projects of the Association because we used the same communication channels to increase the awareness of members about the activities of the Association.

**Results:** During 2019, Helper’s work took place under normal conditions. At the Niska Banja Institute, Helper used the office where patients with rheumatic diseases used to come. Four lectures by eminent experts in the field of rheumatology and physiatry were organized, as well as socializing in the form of meetings and field trips. We marked the World Arthritis Day and the World Osteoporosis Day.

During 2021, most activities took place online or outdoors, depending on the intensity of the Covid-19 wave. Helper’s work took place from home in January and February 2021, and from March to the end of 2021, Helper worked in the office. The lectures that were organized were exclusively online. We have marked the World Arthritis Day with a small number of participants. The event was realized with media support.

**Analysis and participation of members in 2019 and 2021 are shown below**:

- In 2021, 208 vs 260 live contacts in 2019; on average 17 vs 22 contacts per month.
- In 2021, 216 contacts through online meetings; on average 18 per month.
- IN 2019 no such exercise.
- In 2021, 2000 vs 239 contacts in Viber group in 2019; on average 167 vs 20 members.
- In 2019, alternative communication methods were not used. In 2021, 1,023 contacts were made with messages, calls and emails, or 85 per month.

**Conclusion:** Based on the fact mentioned above, 2019 was richer and more fulfilling with lectures, socializing and direct communication with members, while in 2021 communication was dominated by digital tools and methods (Viber groups, calls, emails) and consultation with doctors via e-consultations and by phone.

The pandemic disabled direct contact with members of the Association and live lectures, but the Association used digitalization as a complement to new ways of working that connected us more than ever before, enabled instant transmission of information and created a network support at any time it was necessary, the most. With this process in place, we not only fulfilled the goal of the Association, but we went a step further - we became the first contact for patients with RMD.

**REFERENCES:**

1. Manja Kosanović, dr Mirjana Lapčević – podrška pacijentima – dnevnik biološke terapije
2. Daniela Jankovic – Izveštaj Podružnici Niš za 2019 godinu

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3830

**POS1573-PARE**

Patient-Reported Outcome Measures of Pain Alleviation with Cannabinoid Usage in Rheumatoid and Psoriatic Arthritis: A Cross-Sectional Study.

T. Jehu1, N. Bhaskar1, S. Beg2, K. Camargo Macias2, S. Chalise3, N. Bhanusali1,2

1University of Central Florida College of Medicine, Statistics, Orlando, United States of America; 2University of Central Florida College of Medicine, Rheumatology; 3University of Central Florida College of Medicine, Statistics, Orlando, United States of America

**Background:** Patient-Reported Outcome Measures (PROMs) give us direct, immediate evidence of patient experience. Pain is a chronic, debilitating, multifactorial, presenting symptom that remains a difficult target to treat in populations with Inflammatory Arthritis. Increasingly, cannabis products are being utilized and investigated for their potential analgesic and immune-modulatory effects. The legislation and form of cannabis products deployed as therapy varies around the world and across populations. More data on usage and patient reported outcomes is needed to guide better clinical practice and inform sound legislative policy.
Psychosocial support

S. Chapman1,2, A. Jordan3, W. Tillett4,5. *King’s College London, Waterloo Bridge Wing, Franklin Wilkins Building, Institute of Pharmaceutical Sciences, London, United Kingdom; 2University of Bath, Pharmacy & Pharmacology, Combe Down, United Kingdom; 3University of Bath, Psychology, Bath, United Kingdom; 4Royal United Hospital, Rheumatology, Bath, United Kingdom

Background: Patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are often nonadherent to prescribed symptom-modifying drugs. [1] Concerns about the potential negative effects of medication have been implicated in medication nonadherence. Evidence-based interventions to address concerns about medication and support medication-taking are available in the UK context.

Objectives: To inform the development of intervention to support people with RA and PsA to manage medication we conducted a survey of unmet needs relating to perceptions of arthritis and arthritis medication, medication-taking behaviour and experience of side effects.

Methods: We recruited people with arthritis via local and national patient groups for participation in an online survey. The survey included clinical and demographic questions, validated measures of treatment (Beliefs about Medication Questionnaire (BMQ)) and illness perceptions (brief Illness Perception Questionnaire; biPQ), medication adherence (Compliance Questionnaire Rheumatology; CQR), and patient-reported side effects. Participants were asked about consequences of taking and not taking their arthritis medication as free text to contextualize scores.

Results: Questionnaires were received from 98 participants (42 with PsA, 56 with RA, 89.8% female) indicated participants typically viewed arthritis negatively with ratings on the biPQ indicating high emotional impacts, symptoms and affects on everyday life, and doubts about their ability to control their arthritis. Analysis of the BMQ indicated ambivalence about RA/PsA medications; while few people expressed doubts about their personal need for medication, concerns about RA/ PsA medications were common, see Figure 1. Most, 85.7% (n=84), reported a side effect in the last month, with a mean of 10 ‘moderately severe’ or ‘very severe’ side effects (m=10.02, sd = 5.98). Just over a quarter (26.0%, n=25) were classified as low adherers using the CQR with 54.6% reporting they had missed some of their arthritis medication over the last year. Free text responses indicated that some participants had additional concerns about medication (e.g. worries about impact on life expectancy) not addressed in the questionnaire measures.

Conclusion: In this pilot survey, many participants reported concerns about medication, doubts about whether medication controls arthritis symptoms, severe side effects and medication nonadherence. Although our small sample is unlikely to be generalizable to all arthritis patients, these findings suggest potential targets for intervention and indicate that some patients have needs for support with medication that are not currently being addressed.

REFERENCES:

Acknowledgements: We acknowledge the financial assistance of Bath Institute of Rheumatic Diseases, the people who volunteered their time to respond to this survey and the efforts of Elena Mu and Kishwar Khanum in assisting with data collection.

Disclosure of Interests: Sarah Chapman: None declared, Abbie Jordan: None declared, William Tillett Speakers bureau: Abbvie, Amgen, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Pfizer and UCB, Consultant of: Abbvie, Amgen, Celgene, Eli-Lilly, Janssen, MSD, Novartis, Pfizer and UCB, Grant/research support from: Abbvie, Celgene, Eli-Lilly, Janssen, and UCB


Work and rehabilitation

T. Garen1, A. Tollisen2, H. Andersen1, B. Gudbrandsaso2, Ø. Præm2, 1Oslo University Hospital, Rheikshospitalet, Department of Rheumatology, Oslo, Norway; 2Lovisenberg Diagonal Hospital, Oslo, Unger-Vetlesens Institute, OSLO, Norway; 3Oslo University Hospital, Rheikshospitalet, Department of Rheumatology, Oslo, Norway

Background: Takayasu arteritis (TAK) is a rare vasculitis of large vessels, mainly in young women, with a point prevalence of 25.6/10⁵ in a Norwegian population. TAK is most prevalently limited to the aortic arch and its branches (Type 1) among North Europeans (1). Early symptoms include fever, myalgia and loss of appetite. Later, irreversible vascular damage and ischemic symptoms with claustration of the extremities may occur. We have previously observed a reduced life expectancy, mainly due to cardiovascular complications, and a median age among those deceased of only 58 years (2). These findings clearly indicate that TAK may have severe impact on the wellbeing of the patients and their physical capacity. Furthermore, being part of the working life is a major component of life but is affected in chronic autoimmune diseases (3,4).

Objectives: (i) To describe general health status and quality of life in patients with different working status. (ii) To estimate the rates of patients having paid work or receiving disability benefits, compared to the general Norwegian population.

Methods: Patients with TAK registered in “The Norwegian Systemic Connective Tissue Disease and Vasculitis Registry” (NOSVAR) were included. All patients fulfilled the American College of Rheumatology classification criteria and/or the modified Ischemic criteria for TAK (3). General health status was measured with 10-cm visual analogue scale (VAS) of pain and fatigue, ranging from 0 (best possible score) to 10 (worst possible score) and with Patients’ global assessment (PfGa) of health measured by a five-point Likert scale with scores ranging from 1 (very good health) to 5 (very bad health). The SF-36 was applied
to measure health related quality of life and included 8 scales with score ranging from 0 (worse) to 100 (best). Disease duration was defined as the time from diagnosis to date of registration. Working full- or part time was defined as paid work. We adjusted for age, gender and residence counties in southeast Norway, using reference data from Norway Statistics. Indirect standardization with 95% confidence interval rates was calculated. Descriptive analyses were conducted.

Results: Patients with paid work were more educated compared with those receiving disability benefits (81% vs 19% p<0.031). Patients receiving disability benefits reported higher levels of pain (3.4 vs 1.4, p=0.024) and disease activity (3.9 vs. 0.8, p=0.025), more frequently claudication in legs (83% vs. 17%, p=0.009) and impaired quality of life measured with SF-36, physical functioning (66 vs 88, p=0.002) and role physical (32 vs 65, p=0.017) compared to patients with paid work/students (Figure 1). Compared with the age and gender matched general population, the disability rate of female patients was 16 % higher, adjusted ratio (CI 95%) 1.2 (1.2-3.3), p=0.038. The paid work rate was 51% lower in women with TAK compared to the general population, adjusted ratio (CI 95%) 0.38 (0.23-0.64), p=0.001.

Conclusion: TAK-patients receiving disability benefits reported lower health status and lower quality of life by physical functioning and role physical in SF 36. Work disability in female TAK patients was 16 % higher and for paid work 51 % lower compared to the general population.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4289

Best practice campaigning

POS1576-PARE | IMPROVING METHOTREXATE PRESCRIBING AND DISPENSING SAFETY THROUGH A SIMPLE ADJUSTMENT TO ELECTRONIC PRESCRIBING.
C. Stovin1, K. Lawan2, C. Byrne2, A. Choy3, N. Purkayastha1. 1Kings College Hospital, Rheumatology, London, United Kingdom; 2Kings College Hospital, Pharmacy, London, United Kingdom

Background: Methotrexate (MTX) is the most commonly prescribed disease-modifying antirheumatic drug (DMARD) in rheumatoid arthritis, as well as being frequently used in other rheumatic conditions. Having been discovered in 1948, 1 its use is established and the toxicity profile is well recognised. In the rheumatology setting, it is prescribed as a once weekly dosing regimen. However, despite experience in the use of MTX, there still remains a concern for patient safety with regards to more frequent ingestion than the weekly dose. This can result in severe complications such as acute kidney injury, myelosuppression, mucositis and even death. According to Medicines and Healthcare products Regulatory Agency (MHRA), there were 11 adverse event reports between 2006 and 2020, and as a result, in 2020 the MHRA outlined guidance to reduce the potentially fatal dosing errors associated with the prescription of MTX 2.

Amongst this guidance, prescribers are instructed to discuss, document and include in the prescription, the specific day of the week MTX is to be taken. Dispensers are also advised to document the day of the week on the MTX drug dispensing label. At King’s College Hospital (KCH) there is an existing mandatory field for day of the week for when prescribing inpatient non-cancer MTX treatment. However, this does not exist currently for outpatient electronic prescribing.

Objectives: To update practice in the KCH Rheumatology department, in line with MHRA guidance on MTX prescription.

Methods: A retrospective audit of 30 MTX new and renewal prescriptions over 1 month was conducted to assess concordance with MHRA guidance. The safety-nets of documentation of day of the week on most recent clinic letter, drug prescription and drug dispensing label were reviewed. Following this the electronic prescription system was updated to make “day of the week” a mandatory field required to complete MTX prescriptions. A sample of 30 patients post intervention was then re-audited.

Results: The percentage of new prescriptions across the 2 groups were roughly equivalent (30% vs 33%). Prior to intervention, 44% of new MTX prescriptions had no form of documentation of the day of the week across all 3 safety-nets, and only 33% had at least 2 of the 3 safety-nets completed. Post-intervention this has increased to 100%. Of those newly prescribed MTX, the inclusion of day of the week on clinic letters rose from 22% to 40%. There were similar improvements seen in safety-nets achieved for repeat prescriptions.

POS1577-PARE | WHAT PATIENTS VALUE AND NEED FROM HEALTHCARE IN THE DIAGNOSIS AND MANAGEMENT OF AXIAL SPONDYLOARTHRITIS

Disclosure of Interests: None declared
Background: The clinician’s understanding of what constitutes good quality care for axial spondyloarthritis (axial SpA) has been explored (1) and used to define quality standards (2,3). However, research into the patient perspective on what constitutes good quality care was lacking. The UK’s National Axial Spondyloarthritis Society (NASS) commissioned Headstrong Thinking, and its research partner, Community Research, to investigate this issue.

Objectives: The objectives of the research included: to explore the lived experience of those with an axial SpA diagnosis, to identify all the stages (domains) and milestones they identify and describe in their journey; to identify tangible person-centred indicators of “quality” in each of those stages, covering clinical care, patient care (non-clinical) and support for their mental health needs; to capture the everyday language used to articulate their values and needs around “quality”; and to understand possible differences between individual/subgroup experiences.

Methods: The project will use both qualitative and quantitative methods sequentially. This paper reports only on the qualitative stage of the project, which comprised twelve individual depth interviews, conducted online, across a broad spectrum of people living with axial SpA in the UK, allowing for variation in age, sex, socio-economic status, presence of children, length of time since diagnosis, physical symptoms and comorbidities.

Findings from the qualitative stage will inform the questionnaire for the quantitative stage (target n=1,500), which will seek to validate and refine initial hypotheses and quantify differences between sub-groups.

Results: This paper presents a rich understanding of the impacts on mental, emotional, cognitive and practical aspects of life with axial SpA. A detailed picture of a wide range of clinical, psychological and practical adverse impacts around delayed diagnosis is described.

Further, the qualitative research found that, from the perspective of people with axial SpA, quality care consists of three elements, defined by patients as: to be seen, heard and believed; to experience a purposeful, consistent pathway of care, underpinned by effective administration and communication (rather than a series of care “snapshots”); and to be helped to know what they can do to help themselves, including making a care plan that evolves as needs change.

Individuals with multiple or complex comorbidities were less likely to report having experienced good quality care, as they defined it, in part due to the challenges of accessing a joined-up patient journey and their greater reliance on an individualised approach to their care.

Conclusion: Patients define quality care in the diagnosis and management of axial SpA differently to clinicians. Professionals involved in the diagnosis and care of people living with axial SpA (including rheumatologists, but also those involved in the wider care of people living with axial SpA, such as physiotherapists and even mental health professionals) would benefit from a greater understanding of the patient perspective.

The individual stories uncovered in this qualitative phase underpin the importance of collecting and analysing quantitative data by demographics, life stage and by discrete phases in the diagnostic /ongoing patient (self) management journey.

REFERENCES:
[2] ibid

Disclosure of Interests: None declared


P0S1578-PARE TO OBTAIN GREATER AWARENESS OF ARTHRITIS AND THE DANISH ARTHRITIS ASSOCIATION BY MEDIA COVERAGE

J. Lüthcke1, 2. Digtforingen, Communications Department, Gentofte, Denmark

Background: Despite arthritis being among the most common diseases in Denmark, the overall personal consequences followed are generally unknown. You don’t die of arthritis. This is reflected in the population’s general knowledge of The Danish Arthritis Association of a mere 57 %, despite being Denmark’s third largest patient organisation.

Objectives: To obtain greater awareness of arthritis and the Danish Arthritis Association by media coverage.

Methods: We use case stories strategically in our offensive political agenda. By presenting a good case story with a personal, yet wide perspective, we quite often succeed in getting our agenda in the media – as personal and emotional case stories are more likely stories to be chosen by journalists than political solutions from organisations like ours.

On social media (especially Facebook and Instagram) we also use case stories to a great extent – 2 – 3 times a week. Our followers like to read stories about people who struggle with the same issues as themselves – and to reflect their own issues. Whether they are newly diagnosed or have lived with arthritis for a long time, in general, we get good response on these personal case stories. Many likes, and often our followers share their own experience with each other and pass on good advice.

Helping out the media: The media and journalists are always in need of case stories to back up their articles and agendas. We have introduced the principle of always being willing to help the media with case stories. By providing cases with arthritis – even though the issues aren’t exclusively about arthritis, we help solving a problem, as well as we manage to turn the agenda into a story about arthritis as well. Examples are corona, vaccination, deferred surgeries, lack of coherence in the health system.

What does it take to use cases?: As an organisation, you have a responsibility to take care of your cases by informing them of what it means to be in the media. They must be prepared and helped out – also along the way. It is also important to choose cases who are well spoken and not afraid to express themselves.

Debate group: Some of the topics such as coherence in health care, are immediately academic topics, and difficult to understand – and therefore more difficult to get covered in the media. We have successfully initiated a debate group consisting of a small group of young arthritis patients, whom we have taught how to write debate posts. By telling their own personal stories – often with an underlying political angle – these articles have been published in the major national newspapers.

Results: We have succeeded in getting media coverage in both women’s magazines, tabloid newspapers, national newspapers as well as radio and television.

Conclusion: It is a fairly simple concept that easily can be copied by other patient organisations despite size.

Disclosure of Interests: None declared


P0S1579-PARE LET’S TAKE AN HEALTHY WALK IN THE PARK

U. Viora1, P. Guiso2, M. T. Mascarino3, G. Mascarino1, ANMAR Piemonte, Turin, Italy; 1AMA R Piemonte, AAI, Moncalieri, Italy; 2AMA R Piemonte, Presidency, Turin, Italy; 3AMA Piemonte, Young, Turin, Italy

Background: Patients with RMDs are not yet used to live physical activity such as an important part of their therapy; Covid 19 pandemic, with the restrictions imposed on interpersonal approaches and the fear of being infected and spreading the virus, has further slowed down the way towards these kind of empowerment.

During the pandemic, in Italy the number of pets (mainly dogs) had an exponential increase.

Animal Assisted Interventions /Animal Assisted Therapies seems to be really successful.

Objectives: Our project aims:

to offer people with RMDs the opportunity to move playing fitwalking under control of WALKin trainers who can teach them the right way to practice this new discipline or simply walking properly with their dogs or playing rehabilitative exercises (specific for each one) with the help of animals specially trained.

each session, to let us have a number of encoded informations which drive us to verify all progresses in term of improvement of mobility and mood and reduction of drugs consumption.

Results: The participation (face to face and virtual) in the first three meetings (October, November 2021 and January 2022) has been continuously increasing and we have a good core of "fans"; but also every time a lot of new people want to join us.

We are collecting the first inscriptions and we preview to start the activity on March 20 when the first groups will be led by Maurizio Damilano, twice world and Olympic running champion and inventor of fitwalking.

Each group will be lead by an expert (walking trainers, health professionals, teamsters).

Either each group leader or each participant will write a diary at the end of the activity session, to let us have a number of encoded informations which drive us to verify all progresses in term of improvement of mobility and mood and reduction of drugs consumption.

Debate group:

either academic topics, and difficult to understand – and therefore more difficult to get covered in the media. We have successfully initiated a debate group consisting of a small group of young arthritis patients, whom we have taught how to write debate posts. By telling their own personal stories – often with an underlying political angle – these articles have been published in the major national newspapers.

Results: We have succeeded in getting media coverage in both women’s magazines, tabloid newspapers, national newspapers as well as radio and television.

Conclusion: It is a fairly simple concept that easily can be copied by other patient organisations despite size.

Disclosure of Interests: None declared


P0S1578-PARE TO OBTAIN GREATER AWARENESS OF ARTHRITIS AND THE DANISH ARTHRITIS ASSOCIATION BY MEDIA COVERAGE

J. Lüthcke1, 2. Digtforingen, Communications Department, Gentofte, Denmark

Background: Despite arthritis being among the most common diseases in Denmark, the overall personal consequences followed are generally unknown. You don’t die of arthritis. This is reflected in the population’s general knowledge of The Danish Arthritis Association of a mere 57 %, despite being Denmark’s third largest patient organisation.

Objectives: To obtain greater awareness of arthritis and the Danish Arthritis Association by media coverage.

Methods: We use case stories strategically in our offensive political agenda. By presenting a good case story with a personal, yet wide perspective, we quite often succeed in getting our agenda in the media – as personal and emotional case stories are more likely stories to be chosen by journalists than political solutions from organisations like ours.

On social media (especially Facebook and Instagram) we also use case stories to a great extent – 2 – 3 times a week. Our followers like to read stories about people who struggle with the same issues as themselves – and to reflect their own issues. Whether they are newly diagnosed or have lived with arthritis for a long time, in general, we get good response on these personal case stories. Many likes, and often our followers share their own experience with each other and pass on good advice.

Helping out the media: The media and journalists are always in need of case stories to back up their articles and agendas. We have introduced the principle of always being willing to help the media with case stories. By providing cases with arthritis – even though the issues aren’t exclusively about arthritis, we help solving a problem, as well as we manage to turn the agenda into a story about arthritis as well. Examples are corona, vaccination, deferred surgeries, lack of coherence in the health system.

What does it take to use cases?: As an organisation, you have a responsibility to take care of your cases by informing them of what it means to be in the media. They must be prepared and helped out – also along the way. It is also important to choose cases who are well spoken and not afraid to express themselves.

Debate group: Some of the topics such as coherence in health care, are immediately academic topics, and difficult to understand – and therefore more difficult to get covered in the media. We have successfully initiated a debate group consisting of a small group of young arthritis patients, whom we have taught how to write debate posts. By telling their own personal stories – often with an underlying political angle – these articles have been published in the major national newspapers.

Results: We have succeeded in getting media coverage in both women’s magazines, tabloid newspapers, national newspapers as well as radio and television.

Conclusion: It is a fairly simple concept that easily can be copied by other patient organisations despite size.

Disclosure of Interests: None declared

Genomics, genetic basis of disease and functional genomics

**AB0001**

ALLELIC POLYMORPHISM OF INFLAMMATORY CYTOKINES GENES FOR PREDICTION OF CARDIOVASCULAR DISORDERS IN CHILDREN WITH JIA

A. Artsymovych¹, O. Oshlianska¹, Kyiv, pediatrics #1, Kyiv, Ukraine

**Background:** It is known that defects in the synthesis and structure of cytokines or their receptors can lead to modification of many pathological processes in the organism: inflammation, coagulation, impaired cell regeneration, which makes it appropriate to further study the genetic preconditions for the violation of immunoregulatory mechanisms. Great attention is paid to the study of allelic polymorphism of genes in chronic inflammatory diseases as a potential marker of functional activity of proteins encoded by them and related features of the course of various disease.

**Objectives:** To assess the impact of allelic polymorphism of TNFα (G308A) & IL6 (G174C) genes on the development of cardiovascular disorders in children with JIA.

**Methods:** 102 children with JIA were examined. Allelic polymorphism of TNFα (G308A) & IL6 (G174C) genes was determined by PCR using specific oligonucleotide primers, subsequent analysis of polymorphism of restriction fragments was made. Activity of disease was calculated using JADAS27. Functional state of the myocardium was assessed using software-hardware complex “Cardioplus 4”, an ECG of 4th generation. Cluster analysis of obtained data was performed. K-means and EM algorithms were used. The number of children who finally entered this stage of the analysis was 25.

**Results:** According to the disease activity, the number of mutations and the complex indicator of the functional state of the myocardium (CI FS, %), two clusters were identified. In cluster 1 (10 children, group 1) the higher score of CI FS (median 78%) and lower disease activity degree (JADAS 27 median 9.5) was noted, and in cluster 2 (15 children, group 2) high disease activity (JADAS 27 median 14) was observed and a decrease in the CI FS (median 62%). The CI FS according to the ECG of 4th generation differed significantly (p = 0.00001) in clusters. It is noted that in the second group the disease debuted relatively earlier (p<0.01). Among these cluster groups of patients with JIA there were a number of significant differences in general clinical laboratory parameters: the activity of AST in the blood of patients with JIA was 29±3.1 IU/l in the first group vs 24±2.2 IU/l in the second group (p = 0.07 Wald-Wolfowitz), serum creatinine was higher in the first group 68±11.0 μmol/l (against 57±9.3 μmol/l in the second group; t = -2.24, p = 0.044), also in the second group according to the results of the study according to the general analysis of blood there was leukocytosis (11±6.4 x 10^9 vs. 6.6±9.0 x 10^9, p = 0.075 Wald-Wolfowitz). According to the obtained data of the cluster analysis, the total number of mutations in the genes IL6 and TNF-α was significant for the course of disease. In cases with a larger number of mutations, a more aggressive course of the disease, a more pronounced degree of inflammation, a higher frequency of extra-articular lesions, including changes in the CVS, was noted.

**Conclusion:** The overall number of mutations in TNFα (G308A) & IL6 (G174C) genes makes impact on the course of the disease; two and more mutations are associated with a more aggressive course of the disease and can lead to cardiovascular lesions more likely. Determination of allelic polymorphism should be recommended to patients who have changes on ECG performed by a 4th generation ECG.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annheumdis-2022-eular.706

**AB0002**

ATTEMPTS TO LINK EXONIC GENE POLYMORPHISMS TO ANKYLOSING SPONDYLITIS (AS)-ASSOCIATED PROTEIN MODIFIED FUNCTIONALITY: A STRUCTURAL BIOLOGY APPROACH

E. Eliopoulos¹, G. Goulielmos², M. Zervou², Agricultural University of Athens, Department of Biotechnology, Athens, Greece; Medical School of Crete, Department of Internal Medicine, Heraklion, Greece

**Background:** Genome wide association studies (GWAS) have played a primary role in depicting genetic contributions to ankylosing spondylitis (AS) development, while accommodating the exonic polymorphisms on the protein structure level, when available, enhances our understanding of protein function modification. AS is a polygenic disorder and it is the archetype of a group of inflammatory conditions known as spondyloarthropathies because of their tendency to involve the spine[1]. Linking human genetics with therapeutic targets requires understanding of the biological function and structure of the expressed protein by the causal gene variant to be known.

**Objectives:** We sought to investigate recently identified AS-associated functional gene polymorphisms, such as ERAP1, PON1, CARD9 and JARID1A [2-6] by correlation to protein structure and function.

**Methods:** The experimental 3D model structures of the human ERAP1, PON1, CARD9 and JARID1A proteins were used for the localization of the polymorphisms under study. Molecular mechanics/dynamics studies were applied to determine the impact of the polymorphisms on the structural stability of the enzyme and the conformational changes caused were structurally analyzed. The mutants were constructed using molecular modeling with the program MOE (Molecular Operating Environment V.2019.01, Chemical Computing HPC), which was also used to analyze the conformational changes caused by the mutation. All figures depicting 3D models were created using the molecular graphics program PyMOL V.2.2 [6].

**Results:** ERAP1 plays a role in trimming peptides for optimal binding to MHC1 molecules by utilizing a complex catalytic mechanism. High resolution structures of ERAP1 have shown that K528 and Q730 are located distal from the active site of the enzyme (Figure 1a). Recent enzymatic and computational studies have demonstrated that the presence of Lys or Arg at position 528 and of glutamine or glutamic acid in position 730 affects differently the conformational distribution of the protein ensemble by altering the conformational plasticity of the enzyme and, therefore, indirectly affecting dissimilarity its activity [7]. The PON1 rs682 (Gln192Arg) variant affects stability and recognition of the ligand recognition site and plays a functional role in inflammatory disorders (Figure 1b). The caspase recruitment domain (CARD) interaction of CARDS with Bcl10 promotes downstream activation of factors including NF-kB and the mitogen activated protein kinase (MAPK) [p38 [8]]. The CARD9 rs4077515 (Ser12Asn) variant affects the conformational flexibility of the interacting N-terminal [9] (Figure 1c). JARID1A gene codes for lysine demethylase 5A (KDM5A) a histone demethylase that specifically demethylates ‘Lys-4’ of histone H3. The JARID1A rs11062385 (Met865Thr) SNP that is strongly correlated with expression has been associated with a protective role for the disease but is located in a region of the KDM5A protein with an undefined yet function.

**Conclusion:** Based on several examples, we have tried to define a rational link from AS-associated gene polymorphisms to structure and to modified function, including metagenomic analysis of SNPs, protein crystallography, protein molecular modeling, molecular mechanics and dynamics. Locating, shaping and understanding the target protein interaction interface plays a decisive role in most cases and provides clues for further pharmacological or medical actions.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annheumdis-2022-eular.971
Objectives: Survey the phenotypic consequences of a naturally occurring partial loss of TYK2 function, and directly test for an effect of naturally occurring TYK2 partial loss of function on risk of cardiovascular disease, thromboembolism, and lymphoma.

Methods: We performed phenotype-wide association studies (PheWAS) in 2 large biobanks (FinnGen and UK Biobank) and across public case-control genetic studies using Open Targets Genetics.

Results: This study found additional support for a protective effect (odds ratio [OR] ≤0.8, P<1x10^-7) of TYK2 partial loss of function in multiple autoimmune disease categories, including rheumatoid arthritis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, sarcoidosis, type 1 diabetes, inflammatory bowel disease, and hypothyroidism. We did not observe any novel phenotypic associations that could highlight safety concerns for TYK2 inhibition. Additionally, we used well-powered and focused analyses to demonstrate that TYK2 partial loss of function is not associated with nonselective Janus kinase inhibitor safety concerns in any of the genetic studies. Our meta-analysis across the included studies showed no association with increased risk of cardiovascular disease (OR=0.97; P=0.02, 258,279 cases / 549,387 controls), venous thromboembolism (OR=0.97; P=0.52, 11,966 cases / 260,704 controls), and lymphoma (OR=1.06; P=0.47, 2687 cases / 220,721 controls).

Conclusion: TYK2 P1104A, a partial loss-of-function polymorphism, enables assessment of TYK2 involvement in immune-mediated disease and other pathologies. Loss of function in TYK2 reduces risk of immune-mediated disease but does not significantly increase risk of cardiovascular disease, thromboembolism, or lymphoma.

REFERENCES:


Acknowledgements: This study was sponsored by Bristol Myers Squibb. Editorial assistance was provided by Julianne Hatfield, PhD, of Peloton Advantage, LLC, an OPEN Health company, and was funded by Bristol Myers Squibb.


DOI: 10.1136/annrheumdis-2022-eular.1278

AB0004

PTPN22 AND TNFAP3, BUT NOT STAT4, ARE RISK FACTORS FOR IGG4-RELATED DISEASE

F. Martin-Narés1, G. Hernandez-Molina1, J. Ramirez Belio2, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Depamento of Immunology and Rheumatology, Mexico City, Mexico; 2Instituto Nacional de Cardiología Ignacio Chávez, Department of Endocrinology, Mexico City, Mexico

Background: The etiology of IgG4-related disease (IgG4-RD) is not yet clear, but environmental and genetic factors are thought to be involved. Little is known about the genes that confer susceptibility to this disease, which is why various loci related to inflammation or autoimmunity have begun to be studied. Such studies are limited to Asian and European cohorts. To date, no study has searched susceptibility genes for the development of IgG4-RD in the Mexican Mestizo population.

Objectives: To determine whether three single nucleotide variants (SNVs) located in classic genes associated with systemic lupus erythematosus and rheumatoid arthritis, namely, TNFAIP3 (rs2330926T/G), STAT4 (rs7574865G/T), and PTPN22 (rs2476601C/T), confer susceptibility for the development of IgG4-RD in the Mexican Mestizo population.

Methods: Patients who met the 2019 ACR/EULAR classification criteria for IgG4-RD were included. For each patient, two healthy controls were matched by sex who had no history of chronic, inflammatory, or autoimmune diseases. Both patients and controls were unrelated and self-reported with Mexican Mestizo ancestry by lineage (at least three generations including their own). Genomic DNA was extracted from peripheral blood cells. SNVs were genotyped using TaqMan SNP probes and the Sanger sequencing assay. The Chi-square test was used to determine odds ratios.

Results: We included 124 controls and 60 patients with IgG4-RD (31 (51.6%) female and 29 (48.4%) male). Patients with IgG4-RD had a mean age of 52.1 ±15 years. Ten (16.6%) had single organ involvement, 10 (16.7%) had two involved organs, and 40 (66.6%) had ≥3 involved organs. Thirty (21.7%) belonged to the Mikulicz/pancreatic, 19 (13.17%) to the head/neck-limited, 18 (30%) to the Mikulicz/systemic, and 5 (8.3%) to the undetermined phenotype, while 43 (71.7%) belonged to the proliferative and 17 (28.3%) to the fibrotic phenotypes.

Disclosure of Interests: None declared


Figure 1. (A-C) Analysis of DElncRNAs and DEMRNAs of pre-treated SLE and controls. (A) The volcano plot with the DElncRNAs. (B) The volcano plot with the DEMRNAs. (C) The hierarchical clustering heatmap of DElncRNAs and DEMRNAs. (D-F) Analysis of DEMRNAs and DElncRNAs between pre-treated and treated SLE. (D) Volcano plot with the DElncRNAs. (E) Volcano plot with the DEMRNAs. (F) The hierarchical clustering heatmap of DElncRNAs and DEMRNAs. (G-H) Partial RNAs expression changed in active and treated SLE patients. Table 1 showed specific changed RNAs. (H-H) The top 20 GO and KEGG terms related to the up-regulated and down-regulated DElncRNAs. (I-I) GO and KEGG analyses of DEMRNAs between active and treated SLE patients.
Logistic regression models for each manifestation included all five lead variants (multivariate) and were adjusted for age and sex.

Table 1: The relation between aberrantly expressed mRNA and lncRNA and clinical characteristics of active and treated SLE patients.

<table>
<thead>
<tr>
<th>NCF2</th>
<th>STAT4</th>
<th>IRF5</th>
<th>TNP3</th>
<th>ITGAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs17849502_T</td>
<td>rs7574865_T</td>
<td>rs4728142_A</td>
<td>rs13239597_A</td>
<td>rs11860650_T</td>
</tr>
<tr>
<td>N (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malar rash</td>
<td>233 (55%)</td>
<td>1.28 (0.84-1.96)</td>
<td>0.83 (0.62-1.11)</td>
<td>1.01 (0.74-1.38)</td>
</tr>
<tr>
<td>Discoal rash</td>
<td>46 (11%)</td>
<td>1.49 (0.81-2.73)</td>
<td>0.90 (0.56-1.45)</td>
<td>1.01 (0.62-1.66)</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>219 (51%)</td>
<td>0.96 (0.63-1.46)</td>
<td>1.09 (0.81-1.47)</td>
<td>0.98 (0.73-1.34)</td>
</tr>
<tr>
<td>Oral ulcers</td>
<td>132 (31%)</td>
<td>0.96 (0.61-1.50)</td>
<td>0.90 (0.65-1.23)</td>
<td>0.83 (0.60-1.16)</td>
</tr>
<tr>
<td>Non-erosive arthritis</td>
<td>342 (80%)</td>
<td>0.84 (0.52-1.37)</td>
<td>1.49 (1.02-2.18)</td>
<td>0.93 (0.63-1.36)</td>
</tr>
<tr>
<td>Serositis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Pleuritis</td>
<td>124 (29%)</td>
<td>0.63 (0.38-1.05)</td>
<td>1.38 (1.01-1.98)</td>
<td>1.22 (0.87-1.72)</td>
</tr>
<tr>
<td>-Pericarditis</td>
<td>72 (17%)</td>
<td>0.75 (0.45-1.40)</td>
<td>1.35 (0.93-1.96)</td>
<td>1.05 (0.70-1.58)</td>
</tr>
<tr>
<td>-Resistant proteinuria</td>
<td>158 (37%)</td>
<td>1.63 (1.01-2.49)</td>
<td>1.08 (0.80-1.46)</td>
<td>0.68 (0.49-0.93)</td>
</tr>
<tr>
<td>Neurologic disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Seizures</td>
<td>23 (5%)</td>
<td>1.58 (0.75-3.35)</td>
<td>1.49 (0.80-2.76)</td>
<td>2.10 (1.04-4.25)</td>
</tr>
<tr>
<td>-Psychosis</td>
<td>8 (2%)</td>
<td>0.76 (0.59-0.97)</td>
<td>2.77 (3.94-18.15)</td>
<td>0.35 (0.12-1.23)</td>
</tr>
<tr>
<td>Haematologic disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Haemolitic anaemia</td>
<td>38 (9%)</td>
<td>0.78 (0.34-1.76)</td>
<td>1.37 (0.85-2.22)</td>
<td>0.75 (0.44-1.29)</td>
</tr>
<tr>
<td>-Leukopenia</td>
<td>130 (30%)</td>
<td>1.04 (0.67-1.61)</td>
<td>1.19 (0.87-1.63)</td>
<td>1.00 (0.72-1.39)</td>
</tr>
<tr>
<td>-Lymphopenia</td>
<td>228 (53%)</td>
<td>0.95 (0.63-1.44)</td>
<td>1.35 (1.01-1.81)</td>
<td>0.85 (0.70-1.29)</td>
</tr>
<tr>
<td>-Thrombocytopenia</td>
<td>102 (24%)</td>
<td>1.42 (0.91-2.22)</td>
<td>0.84 (0.60-1.18)</td>
<td>0.83 (0.58-1.18)</td>
</tr>
<tr>
<td>Immunologic disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-anti-DNA ab.</td>
<td>330 (77%)</td>
<td>0.69 (0.44-1.09)</td>
<td>1.02 (0.72-1.44)</td>
<td>0.94 (0.65-1.35)</td>
</tr>
<tr>
<td>-anti-Smith ab.</td>
<td>44 (10%)</td>
<td>1.44 (0.79-2.64)</td>
<td>1.58 (1.00-2.49)</td>
<td>1.23 (0.73-2.07)</td>
</tr>
<tr>
<td>-anti-phospholipid ab.</td>
<td>183 (43%)</td>
<td>1.63 (1.07-2.49)</td>
<td>1.05 (0.79-1.41)</td>
<td>0.84 (0.61-1.14)</td>
</tr>
</tbody>
</table>

* Logistic regression models for each manifestation included all five lead variants (multivariate) and were adjusted for age and sex.

Acknowledgements: This work was supported by the National Natural Science Foundation of China (No. 82001740) and the National Science Research Project of Shanxi Province (No.20210302123725).

Disclosure of Interests: None declared

ASSOCIATION OF RS172378 VARIANT IN C1Q GENE CLUSTER WITH SOME CLINICAL AND IMMUNOLOGICAL ASPECTS OF SYSTEMIC LUPUS ERYTHEMATOSUS IN BULGARIAN PATIENTS

1Varna Medical University, Department of Propedeutics of Internal Diseases, Varna, Bulgaria; 2Varna Medical University, First Department of Internal Diseases, Varna, Bulgaria; 3Varna Medical University, Department of Biochemistry, Molecular Medicine and Nutrigenomics, Varna, Bulgaria; 4Sofia Medical University, Department of Nephrology, Sofia, Bulgaria

Background: Single nucleotide polymorphisms (SNPs) in complement C1q component are found to be linked with systemic lupus erythematosus (SLE), but less is known about their association with the clinical and immunological aspects of the disease.

Objectives: The aim of the study was to examine five SNPs – rs865691, rs682638, rs172378, rs254179, rs292001 in C1q gene cluster for association with some clinical (age at disease onset, organ involvement, BILAG score, SLICC/ACR DI) and immunological (ANA, anti-dsDNA, complement factors C3 and C4) aspects of SLE.

Methods: 53 SLE patients were enrolled in this cross-sectional study and relevant clinical information was collected. SNP genotyping was performed on extracted DNAs from patients using a TaqMan allelic discrimination assay. ANA, anti-dsDNA and complement proteins C3 and C4 were measured by IF, ELISA and radial immunodiffusion resp.

Results: G-allele and GG-genotype of rs172378 were overrepresented among patients with LN compared to the other SLE patients – 64% vs 31% for G-allele and 48% vs 7.7% and were associated with renal involvement – OR=3.96 (95%CI: 1.53 – 10.23), p=0.005 for G-allele and OR=10.86 (95%CI: 1.29 – 91.58), p=0.028 for GG-genotype. G-allele and GG-genotype were also associated with increased levels of anti-dsDNA antibodies – OR=2.95 (95%CI: 1.21 – 7.18), p=0.017 and OR=6.33 (95%CI: 1.41 – 28.39), p=0.016, resp.

G-allele showed weak correlation with earlier age at disease onset (point biserial r=-0.22, p=0.03) and patients, carrying it (GG- and AG-genotypes) were younger at disease onset then those with AA-genotype (p=0.05 and p=0.02 resp.).

Conclusion: rs172378 associates with some clinical and immunological parameters of SLE, traditionally linked to disease severity, therefore it may possibly play a role in disease pathogenesis.

REFERENCES:


ACERO APPLICATION: AN INTEGRATED GENOTYPE ANALYSIS WEB SERVER FOR CLINICAL GENOMICS IN CROHN’S DISEASE AND IBD-RELATED ARTHRITIS

I. Papageorgiou, M. Zervou, I. Katsimpoula, D. Vlachakis, G. Bertias, G. Goulieomos, E. Eleopoulou. 1Agricultural University of Athens, Department of Biotechnology, Athens, Greece; 2University of Crete, Section of Molecular Pathology and Human Genetics, School of Medicine, Heraklion, Greece; 3University of Crete, Department of Rheumatology and Clinical Immunology, School of Medicine, Heraklion, Greece

Background: Genome Wide Association Studies (GWAS) observe the set of different variants throughout the genome of different individuals and study whether a particular trait is due to one variant. Many autoimmune diseases have been identified to have a linkage with specific loci and metabolic pathways, but the exact cause of disorders is still remaining unknown [1]. Aceso Application is an integrated bioinformatics web-tool designed for researchers and medical experts towards to estimating the clinical genomic profile of a candidate patient with Crohn’s Disease (CD)[2-4].
Differentially Expressed Genes Between Flare of Palindromic Rheumatism and Active Rheumatoid Arthritis

H. H. Chen1, Taichung Veterans General Hospital, Internal Medicine, Taichung, Taiwan, Republic of China

Background: Although the mechanisms of palindromic rheumatism (PR) is still unclear, an association between PR and rheumatoid arthritis (RA) has been well recognized in previous studies, with one to two-thirds of PR patients developing RA during a period of follow-up. RNA sequencing (RNA-Seq) is a next-generation sequencing (NGS) method that measures genome-wide RNA abundance. Using RNA-Seq to identify the DEGs between flare PR and active RA could help elucidate the pathogenic mechanisms of PR flare and find novel genes to predict RA progression.

Objectives: The aim of this study is to identify gene expression signatures between PR flare and active RA using whole blood RNA-seq.

Methods: We collected clinical data, and blood samples from 12 flare PR patients and 12 active RA patients (defined as DAS28-ESR≥3.2) patients from Taichung Veterans General Hospital. We obtained high-quality RNA by using PAXGene tube for whole blood sampling and PAXGene blood RNA Kit to extract RNA. Cuffdiff (Cufflinks option) output was filtered for differentially expressed genes (DEGs) with p-value < 0.05. Gene set enrichment analysis (GSEA) were performed using the GSEA version 4.0 with immunologic gene sets (C7 sets containing 4872 gene sets) from The Molecular Signatures Database (MSigDB). According to GSEA web suggestion, a false discovery rate (FDR) < 0.25 with a p-value < 0.05 was considered statistically significant. We obtained ranked ordered gene list from GSEA.

Results: We compared flare PR and active RA using GSEA. Five of the top 12 enrichment in phenotype with flare PR were related to lipopolysaccharide (LPS), which was found in the outer membrane of Gram-negative bacteria. And we observed that 3 genes had statistically significant t-test result (HK3, p-value < 0.001; HIST1H2AI, p-value < 0.002; BST1, p-value < 0.001) (Figure 1a, 1b and 1c). This result showed that FCGBP, GLRX3 and RTN4R may play an important role in immune response related to flare PR. In active RA patients, 3

Figure 1. Differential gene expressions between flare PR and active RA. (a) FCGBP, (b) GLRX3, (c) RTN4R, (d) HK3, (e) HIST1H2AI, (f) BST1 genes had statistically significant t-test result (HK3, p-value < 0.001; HIST1H2AI, p-value < 0.002; BST1, p-value < 0.001) (Figure 1a, 1b and 1c).

Conclusion: GSEA analyses showed that five of the top 12 enrichment in flare PR was related to LPS and other pathways were related to immune responses of B cell, T cell and macrophage. However, in active RA, the characteristic gene expressions included genes up-regulated in dendritic cells, genes down-regulated in B cell, and genes up-regulated in T cells, suggesting different physiological pathways from flare of PR.

Disclosure of Interests: None declared

References:

AB0009

Association of Some Non-HLA Gene Polymorphisms with Susceptibility to Systemic Lupus Erythematosus in Women in Belarusian Population

N. Dostanko1, E. Siniauskaya2, V. Yagur1, R. Goncharova2, H. Yatsku2.
1Belarusian State Medical University, 2-nd Department of Internal Medicine, Minsk, Belarus; 2National Academy of Sciences of Belarus, Institute of Genetics and Cytology, Minsk, Belarus

Background: Despite the recent progress in our understanding of the genetic predisposition to systemic lupus erythematosus (SLE) its clinical and functional significance is not fully clarified yet and needs to be implemented in personalized care [1].

Objectives: To estimate the association between some single nucleotide polymorphisms (SNPs) of 9 non-HLA genes-candidates as STAT4 rs7574865, TPPTN2 rs2542151, TPPTN2 rs2476601, AGER rs1035798, TRAF1/C5 rs3761847, SLCT7A1 rs13128867, RUNX1 rs9973983, IL6 rs1800795, IL6R rs2228145, IL6R rs4845618 and susceptibility to SLE in Belarusian women for the following predictive model development.

Methods: We examined 316 women: among them 59 SLE patients (mean age 39.84, CI95% 36.62-43.06) classified according to the 1997 American College of Rheumatology (ACR) revised classification criteria and 257 age-matched healthy controls (blood donors, mean age 38.12, 95% confidence interval (CI95%) 36.77-39.46). Deoxyribonucleic acid was extracted from peripheral blood samples by phenol-chloroform method. Genotyping was performed by real-time PCR with fluorescent probes. Descriptive analysis, test for Hardy–Weinberg equilibrium, multiple inheritance models (co-dominant, dominant, recessive, over-dominant and log-additive) for single SNPs, Akaike information criteria (AIC) and Bayesian information criteria (BIC) were analyzed using SNPSstats web tool [2]. Pearson χ² (χ²), two-way Fisher exact test (F, p<0.05), odds ratio (OR), likelihood ratio of positive (LR +) and negative (LR -) tests with corresponding CI were also calculated.

Results: Exact test for all genotype frequencies distribution of all studied SNPs didn't reveal significant differences with Hardy-Weinberg equilibrium in all controls and SLE groups. We noted significant increase of minor TT genotype frequency of STAT4 rs7574865 in SLE vs healthy women with recessive inheritance model as the best-fitting one according to its less AIC and BIC values (OR=3.78 (CI95% 1.35-10.62); p=0.016; LR + = 3.45 (CI95% 1.37-8.60); LR - = 0.91 (CI95% 0.84-0.98)). We revealed protection of minor A allele of AGER rs1035798 carriage with log-additive model of inheritance as the best-fitting one according to AIC and BIC values against SLE development in women (OR=0.52 (CI95% 0.33-0.83); p=0.004; LR + = 0.70 (CI95% 0.50-0.93); LR - = 1.47 (CI95% 1.10-1.86)). We also noted significant increase of minor allele G frequency of TRAF1/C5 rs3761847 in SLE vs healthy women with dominant inheritance model (OR=3.61 (CI95% 1.00-12.0)).

Disclosure of Interests: None declared


AB0010
Background: Tocilizumab (TCZ) is a disease-modifying antirheumatic biologic drug, which targets the IL-6 signalling pathway and is effective in ameliorating disease activity in rheumatoid arthritis (RA). However, approximately 20% of patients do not respond adequately to TCZ and some patients report adverse events. Considering there is growing evidence that DNA methylation is implicated in RA susceptibility and response to some biologics (1, 2), we investigated DNA methylation as a candidate biomarker for response to TCZ in RA.

Objectives: To identify differential DNA methylation signatures in whole blood associated with TCZ response in patients with RA.

Methods: Epigenome-wide DNA methylation patterns were measured using the Infinium Epic 850k BeadChip (Illumina) in whole blood-derived DNA samples from patients with RA. DNA was extracted from blood samples taken pre-treatment and following 3 months on therapy, and response was determined at 6 months using the Clinical Disease Activity Index (CDAI). Patients who had good response (n=10) to TCZ by 6 months were selected. Samples from secondary poor responders (n=10) (patients who had an improvement of CDAI and were in remission versus Arthritis Centre for Epidemiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; 3University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom; 4NIHR Leeds BRC, Leeds Teaching Hospitals Teaching Trust, Leeds, United Kingdom; 5NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester University NHS Foundation Trust, Manchester, United Kingdom; 6The University of Manchester, Versus Arthritis Centre for Epidemiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; 7University College Dublin, School of Medicine and Medical Science, Dublin, Ireland.

Background: Sinomenine (SIN) were extracted from Caulis Sinomenii and achieved an remarkable therapeutic effect for Rheumatoid Arthritis (RA). However, the mechanism of SIN acting on RA is not clear yet.

Objectives: To excavate potential targets and mechanisms of SIN for RA through bioinformatics.

Methods: The microarray data were downloaded from the Gene Expression Omnibus (GEO) database. GEO2R was used to identify differentially expressed genes (DEGs) and the unique value was retained. The potential targets of active compounds from various databases were screened. Based on the overlapping genes, Cytoscape 3.7.2 software was used to construct a protein-protein interactions (PPI) network and to visualize the mechanisms of the treatment by Gene Ontology (GO) enrichment analysis Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis by DAVID database. Finally, we used AutoDockTools 1.5.6 for molecular docking.

Results: A total of 5053 DEGs and 1070 intersections were obtained, including 486 up-regulated and 584 down-regulated targets. 298 SIN targets were collected from various databases, 84 potential targets were obtained by intersecting with DEGs. There are 80 nodes and 305 edges were obtained in PPI network. Based on the degree, the top 10 target genes were AKT1, RGFRI, MTROR, JAK2, NOS3, IL2, IL6, MMP9, MAPK8, HSP90AA1. The core targets was most relevant to protein phosphorylation, signal transduction though GO analysis. The results of the KEGG enrichment analysis included PI3K-Akt signaling pathway and Neuroactive ligand-receptor interaction. Following analysis found that AKT1, EGFR, MTROR and JAK2 existed in the PI3K-Akt signaling pathway. Molecular docking was used to confirm that the binding energy of AKT1 was -7.68 kJ mol⁻¹, EGFR was -5.33kJ mol⁻¹, MTROR, JAK2, NOS3, IL2, IL6, MMP9, MAPK8, HSP90AA1. The core targets was most relevant to protein phosphorylation, signal transduction though GO analysis. The results of the KEGG enrichment analysis included PI3K-Akt signaling pathway and Neuroactive ligand-receptor interaction. Following analysis found that AKT1, EGFR, MTROR and JAK2 existed in the PI3K-Akt signaling pathway. Molecular docking was used to confirm that the binding energy of AKT1 was -7.68 kJ mol⁻¹, EGFR was -5.33kJ mol⁻¹, MTROR and JAK2 was -7.74 kJ mol⁻¹, AKT1 and EGFR was further identified as the core targets.

Conclusion: Present study shows that AKT1 and EGFR may be the key targets of SIN acting on the PI3K-Akt signaling pathway, thereby inhibiting the progression of disease and improving RA.

Keywords: Sinomenine; Rheumatoid Arthritis; bioinformatics;
Background: A strong female predisposition is characteristic of Systemic Lupus Erythematosus (SLE), with female-to-male ratio ranging from 7:1 to 15:1. The molecular basis of this gender bias remains incompletely understood. In a previ- ous whole-blood RNA profiling study, we identified genes with differential expres- sion in SLE males versus females but not in their healthy counterparts. Among these genes, the cohesin complex protein SMC1A (Structural Maintenance of Chromosomes 1A) displayed the highest statistical significance [1].

Objectives: To (a) determine the immune cell type that displays the strongest gender-biased SMC1A expression in SLE versus healthy individuals, and (b) elucidate the role of SMC1A in regulating immune/inflammatory responses in the context of SLE.

Methods: Multiple immune cell types (CD19+ B cells, CD4+ T cells, CD14+ monocytes, neutrophils) were purified from peripheral blood specimens of SLE and healthy individuals, followed by Taqman PCR and Western blot to measure SMC1A mRNA and protein levels, respectively. The genome-binding properties of SMC1A were assayed by chromatin immunoprecipitation (ChIP)-sequencing in monocytes cultured under lupus-inducing conditions (lupus-like monocytes) [2]. To recapitulate the female/male difference in SMC1A expression, ex vivo cul- tured lupus-like monocytes were transfected with si-SMC1A (to downregulate SMC1A) versus si-control reagent, followed by genome-wide transcriptome anal- ysis by RNA-sequencing.

Results: Among the various tested immune cell types, CD14+ monocytes best recapitulated the initial whole blood RNA-seq findings, demonstrating significantly decreased SMC1A mRNA and protein expression in male versus female SLE patients but not in their healthy counterparts. In blood monocytes cultured under lupus-inducing conditions and tested by ChIP-sequencing, SMC1A binding was increased on enhancers and promoters of genes associated with inflammation (including type I/II interferon and other inflammatory cytokines) and cell migra- tion. In accordance, lupus-like monocytes with lowered SMC1A expression (i.e., female-like) displayed significantly reduced expression of inflammatory genes like IL6, GBP5, ADA and IL1A, as compared to monocytes with unaffected SMC1A (i.e., female-like). Furthermore, IL6 mRNA synthesis was significantly enhanced in female versus male monocytes cultured under lupus-inducing conditions. Conclusion: SMC1A may transcriptionally regulate genes associated with the inflammatory response of monocytes. Our findings of gender-biased SMC1A levels in SLE monocytes raise the hypothesis that differential SMC1A expres- sion and function might contribute to the disease gender bias and/or sexual dimorphism.

REFERENCES:

Disclosure of Interests: None declared

Primary cilia were manually counted. Approximately 500 cells for each replicate were recorded for the presence of a primary cilium. The length of primary cilia was measured using Image J (Version 1.53o). Synovial fibroblasts were treated with Trichostatin A (2µM), an inhibitor of HDACs (HADCi), for 24h.

**Results:** Pathway enrichment analysis of genes changed after HOXD13 silencing of synovial fibroblasts showed that HOXD13 regulated genes are involved in primary cilium related pathways. We confirmed lower mRNA expression of the ciliary proteins, PKD2, KIF3A and IFT88 after HOXD13 silencing (n=4; PKD2: 0.65 ± 0.4, p<0.05; KIF3a: 0.6 fold ± 0.3, p<0.05; IFT88: 0.7 fold ± 0.3, p<0.05), and IFT88 expression (ARL13B 0.18 fold ± 0.4, p<0.05). An increase in the number and length of primary cilium, as well as acetylation of alpha-tubulin, a characteristic feature of primary cilium, was seen after HOXD13 silencing (n=4). Accordingly, expression of HDAC4, -5 (n=4; HDAC4: 0.25 fold ± 0.1, p<0.05; HDAC5: 0.4 fold ± 0.1, p<0.05; HDAC7: 0.3 fold ± 0.2, p<0.05). SIRT1 expression was higher (n=4; 1.7 fold ± 0.4, p<0.05), but SIRT2 expression was lower (n=4; 0.1 fold ± 0.03, p<0.05) in HOXD13 silenced synovial fibroblasts. Trichostatin A treatment increased the acetylation level of alpha tubulin (n=4) as well as the expression of ARL13B, KIF3a, and IFT88 in synovial fibroblasts (n=4; ARL13B: 2.3 fold ± 0.9, p<0.05; IFT88: 1.5 fold ± 0.3, p<0.05; KIF3A: 3.7 fold ± 1.8, p<0.05). The length and number of primary cilium was not changed by Trichostatin A treatment.

**Conclusion:** Our data show that HOXD13 plays a role in regulating the assembly of primary cilium in synovial fibroblasts. This effect seems partially mediated by the expression of HDACs and partly by the expression of ciliary proteins. The primary cilium is a sensory organelle mediating reactions to mechanical and chemical signals from the environment. Thus, our results suggest specific regulation of synovial fibroblasts in response to stimulation via the primary cilium.

**REFERENCES:**

**Disclosure of Interests:** Masoumehalsadat Mirrahimi: None declared, Eva Camarillo: None declared, Kerstin Klein: None declared, Miranda Houtman: None declared, Masoumehalsadat Mirrahimi: None declared, Eva Camarillo: None declared, Kerstin Klein: None declared, Miranda Houtman: None declared, Oliver Distler Consultant of: Abbvie, Caroline Ospelt: None declared, Eva Camarillo: None declared, Kerstin Klein: None declared, Kerstin Klein: None declared, Miranda Houtman: None declared, Masoumehalsadat Mirrahimi: None declared, Eva Camarillo: None declared, Kerstin Klein: None declared, Miranda Houtman: None declared.

---

**AB0016 GENETIC VARIANTS OF PREDISEPOSITION TO RHEUMATOID ARTHRITIS IN BELARUSIAN POPULATION**

E. Siniauskaya, Y. Yatsku, N. Dostanko, V. Vagar, R. Goncharov. Institute of Genetics and Cytotology of NAS of Belarus, Laboratory of Molecular Basis of Genomic Stability, Minsk, Belarus; 2SMU, Belarusian State Medical University, 2-nd Department of Internal Medicine, Minsk, Belarus

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by autoimmune inflammatory response focused in the synovium. RA is a complex disorder with significant genetic component and it is also known to have possible environmental triggers. Microbiota and bacterial infections play a significant role in RA etiology. The onset of RA may be accompanied by the previous or ongoing chlamydia infection in some cases.

**Objectives:** To observe genetic variants of susceptibility to RA in Belarusian population

**Methods:** 650 individuals were divided into 2 cohorts: 305 patients with RA (59.69 ± 12.20), and 345 controls (mean age 37.42 ± 10.62). Patients with RA were further stratified into two subsets — with cataractogenic Chlamydia trachomatis/Chlamyphila pneumoniae infection (43, “RAChi”) and those without (262, “Rach-”). 11 SNPs of 10 genes (IL6 (rs1035798), IL6R (rs2228145 and ns4845618), STAT4 (rs7574865), TRAF1/C5 (rs3761847), RUNX3 (rs9979383), PTPN2 (rs11249215), PTPN22 (rs2542151), STAT4 (rs1035798), SLC7A11 (rs13128867)) were genotyped using Real-time PCR or PCR-RFLP.

**Results:** It was found that homozogous TT genotype at the rs7574865 locus of the IL6 gene and CT/TT genotypes at the rs2476601 locus of the RUNX2 gene are associated with RA in general (OR 2.71 [1.31 – 5.61], p = 0.005 and OR 2.47 [1.75–3.48], p<0.000, respectively). CC genotype at the rs9979383 locus of the RUNX1 gene and AG+GG genotypes at the rs11249215 locus of the RUNX3 gene revealed protective effect (OR 0.63 [0.40–0.98], p=0.036 and OR 0.58 [0.36–0.92], p=0.02, respectively). The lack of association with RA was shown for polymorphic loci of the IL6 (rs1800795), IL6R (rs2228145 and ns4845618), SLC7A11 (rs13128867), AGER (rs1035798), PTPN2 (rs2542151) and TRAF1/C5 (rs3761847) genes. For RA subsets stratified according to presence/absence of the C. trachomatis/C. pneumoniae infection it was shown that CC genotype at the rs1800795 locus of the IL6 gene and AA genotype at the rs11249215 locus of the RUNX3 gene were associated specifically with the risk of developing Chlamydia infection-associated RA (OR 5.22 [1.85–14.71], p=0.0024 and 2.63 [1.09–6.35], p=0.037). In addition, TG+GG genotypes at the rs2542151 locus of the PTPN2 gene is also associated specifically with RAChi+ clinical phenotype. Our data may indicate that genetic variants of STAT4 and PTPN22 contribute to genetic basis of the pathogenesis of RA through renewal of T-cell initiated immune response.

**Acknowledgements:** This research was supported by The Research Technical Program “DNA Identification” (2017–2021), project number: 6.4.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4432

---

**AB0017 T HELPER REGULATORY T CELLS RATIOS IMBALANCE IN DIFFERENT STAGING RHEUMATOID ARTHRITIS**

R. Su1, C. Wang1. 1The Second Hospital of Shanxi Medical University, Taiyuan, Department of Rheumatology, Taiyuan, China

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that results in the destruction of the bone and cartilage of the joints[1]. The imbalance between Th17 and Treg cells has been demonstrated to play a role in RA pathogenesis[2]. With the advances in the RA field, curing and even preventing RA has become a new direction of efforts. To explore the immune characteristics in multi-staging RA is helpful for the development of accurate strategies.

**Objectives:** To observe the immune characteristics in different staging rheumatoid arthritis patients

**Methods:** A total of 127 patients with RA were recruited for this study, in cluding 30 early RA (newly diagnosed and treatment-naïve, duration of disease ≤3months), 30 middle RA (newly diagnosed and treatment-naïve, duration of disease >3months and≤1 year), 30 advanced RA (newly diagnosed and treatment-naïve, duration of disease >1 year) and 37 active treated RA (remissioned after target treatment and this time due to disease recurrence in hospital). All patients were hospitalized in the second hospital of Shanxi medical university and diagnosed with RA fulfilled the ACR 1987 or 2010 criteria. The percentage and absolute numbers of lymphocyte phenotypes and CD4+ T subsets in peripheral blood were examined by flow cytometry.

**Results:** There were no significant difference in the percentage and value of T,B,NK,CD4+T,CD8+T and CD4+ T subsets. But the Th1/Th2 cell ratios in active treated RA group were increased than that in early RA, middle RA and advanced RA group. The Th17/Treg cell ratios in middle RA and advanced RA group were higher when compared with those of active treated RA group. In addition; the Th1/ Treg cell ratios were decreased in middle and advanced RA group as compared with those in active treated RA.

**Conclusion:** Th1/Th2, Th17/Treg and Th1/Treg imbalance varied with disease staging. The different disease stage in RA, the immune function is different. Providing targeted immunotherapy according to disease staging is helpful to improve remission rates and even prevent disease.
AB0018

SERUM ANTIBODIES AGAINST ORAL AND INTESTINAL BACTERIA IN INDIVIDUALS AT RISK FOR RHEUMATOID ARTHRITIS, CHRONIC RA PATIENTS, AND NEW ONSET PATIENTS WITH DIFFERENT RHEUMATIC DISEASES

L. Amend 1, B. Gilbert 1, A. Finckh 1, T. Ströwig 1, Helmholtz Centre for Infection Research, Microbial Immune Regulation, Braunschweig, Germany; 2Geneva University Hospitals, Division of Rheumatology, Geneva, Switzerland

Background: Evidence about the influence of microbes in autoimmune diseases such as rheumatoid arthritis (RA) has grown in recent years. However, the precise role of specific bacteria remains largely unknown. Previous investigations identified several oral pathogens to be specifically targeted by serum antibodies in RA patients. In addition, P. intermedia and P. melaninogenica were identified as potential pathobionts in RA patients. We analyzed IgG reactivity against several oral pathogens from stool samples of healthy donors and RA patients, as well as the following oral pathobionts: Porphyromonas gingivalis, Prevotella intermedia, and Prevotella melaninogenica. We observed 120 IgG samples from a Swiss cohort of first-degree relatives, individuals in various pre-clinical RA stages (SCREEN-RA), and 45 samples of patients with established RA (SCQM cohort). These participants were categorized as asymptomatic seronegative individuals (FDR), individuals with systemic autoimmunity associated with RA (ACPA and/or RF autoantibodies) (preRA 1), individuals with clinically suspect arthritids or undifferentiated arthritis with/without autoantibodies (preRA 2) and chronic RA patients (cRA). Additionally, we included 92 serum samples from new-onset patients diagnosed with RA, psoriatic arthritis (PsA) or spondyloarthropathy (SpA), or other non-rheumatic diseases (NRD) recruited via the german RheumaVOR cohort (Table 1).

Methods: We used custom-made ELISA assays measuring pathogen-specific IgG levels in patient’s serum. Samples were tested against P. copri strains isolated from stool samples of healthy donors and RA patients, as well as the following oral pathobionts: Porphyromonas gingivalis, Prevotella intermedia and Prevotella melaninogenica. We analyzed 120 samples from a Swiss cohort of first-degree relatives, individuals in various pre-clinical RA stages (SCREEN-RA), and 45 samples of patients with established RA (SCQM cohort). These participants were categorized as asymptomatic seronegative individuals (FDR), individuals with systemic autoimmunity associated with RA (ACPA and/or RF autoantibodies) (preRA 1), individuals with clinically suspect arthritids or undifferentiated arthritis with/without autoantibodies (preRA 2) and chronic RA patients (cRA). Additionally, we included 92 serum samples from new-onset patients diagnosed with RA, psoriatic arthritis (PsA) or spondyloarthropathy (SpA), or other non-rheumatic diseases (NRD) recruited via the german RheumaVOR cohort (Table 1).

Table 1. Overview human cohort studies

<table>
<thead>
<tr>
<th>Cohort</th>
<th>SCREEN-RA</th>
<th>SCQM</th>
<th>RheumaVOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient group</td>
<td>FDR</td>
<td>preRA 1</td>
<td>preRA 2</td>
</tr>
<tr>
<td>NRD</td>
<td>43</td>
<td>38</td>
<td>45</td>
</tr>
<tr>
<td>RA</td>
<td>49</td>
<td>45</td>
<td>59</td>
</tr>
<tr>
<td>PsA</td>
<td>40</td>
<td>38</td>
<td>44</td>
</tr>
<tr>
<td>aXSpA</td>
<td>0</td>
<td>25</td>
<td>9</td>
</tr>
</tbody>
</table>

Figure 1. Serum IgG responses against different microbes from individuals recruited via SCREEN-RA, SCQM or RheumaVOR cohort

Results: Overall, there were no significant differences in the IgG reactivity profiles between the patient groups against the distinct P. copri strains or oral pathobionts (Figure 1). However, performing this assay with P. copri strains from distinct subtypes identified clear differences and revealed important variability in the IgG reactivity.

REFERENCES:

Disclosure of Interests: None declared


AB0019

RITUXIMAB TREATMENT DOES NOT ALTER EXPRESSION OF CO-STIMULATION MARKER CD19 ON B CELLS IN SYSTEMIC SCLEROSIS PATIENTS

B. Dreier 1, B. Prietl 2,3, S. Kofer 2,3, V. Pfeiffer 2,3, H. Souri 2,3, F. Moazed-Fürst 1, S. Kiehauer 1, M. D'Orazio 1, S. Zenz 1, J. Thiel 1, M. Stradner 1, H. P. Brezinsek 1, 1Medical University of Graz, Division of Rheumatology and Immunology, Graz, Austria; 2Cimed GmbH, CBimed GmbH – Center for Biomarker Research in Medicine, Graz, Austria; 3Medical University of Graz, Division of Endocrinology and Diabetology, Graz, Austria

Background: CD19 is a membrane glycoprotein interacting with different surface molecules on the B-cell membrane (BCR) and is crucial for antigen-independent development as well as immunoglobulin-induced activation of B cells. [1] Alterations in this signalling pathway can incline autoimmune production and systemic autoimmunity in humans. Rituximab (RTX), a CD20 antagonist appears to be an effective candidate in the treatment of different autoimmune diseases that are partly driven by autoreactive B cells, such as systemic sclerosis (SSc). [2] It has been speculated that RTX might work not only by depleting B cells but also to down regulate activation markers, such as CD19.

Objectives: In-depth analysis of CD19 abundance and activation on B cells in SSc patients with and without RTX treatment

Methods: Peripheral blood samples from 41 patients suffering from SSc (median ± standard deviation SD, age: 54.3 ± 10.6 years, female ratio: 0.8) and 45 age- and sex-matched healthy controls (HC) (age: 51.0 ± 13.9 years, female ratio: 0.8) were drawn and PBMCs were isolated on-site. We performed flow cytometry analysis on a standardized BD LSRFortessa platform to identify B cell (CD19+CD20+) subpopulations. The geometric mean fluorescence intensity (gMFI) for CD19 was compared between both the B cell populations. The frequency of CD19 antibodies bound per cell.

Results: 3 out of 41 SSc patients were in high disease activity at the time of blood drawal. 23 SSc patients were under RTX therapy of whom 5 patients still displayed measurable B cell frequencies. Naïve B cells made up the most abundant B cell population in SSc patients. Thus, the frequency of IgM+IgD+CD27- cells was 67.9% ± 13.2 (mean ± SD), followed by class-switched memory B cells (IgM−IgD−CD27+, 10.5 ± 4.9), non-switched memory B cells (IgM−IgD+CD27−, 4.0 ± 3.6) and plasmablasts (0.3 ± 4.4). Pairwise Wilcoxon Tests (Bonferroni-corrected for multiple testing) showed significant differences (p < 0.001) between frequencies of naïve B cells and all other cell types. In contrast, naïve B cells displayed the second lowest CD19 gMFI levels (7600.1 ± 1912.0) in the dataset. Non-switched memory B cells in SSc patients showed the highest CD19 gMFI (10620.0 ± 15689.8), followed by class-switched (9383.8 ± 3048.8). As expected, Plasmablasts displayed the lowest CD19 gMFI levels (4799.0 ± 4815.7). The decrease in CD19 gMFI was again highly significant. This trajectory in decreasing CD19 gMFI was found in both HCs and SSc patients. We saw a significant reduction in percentages of non-switch B cells and class-switched B cells in SSc patients compared to HCs (4.0 ± 3.6 vs 6.5 ± 4.2, p = 0.029, 10.5 ± 4.9 vs 13.2 ± 7.2 p = 0.04) but an increase in CD19 gMFI in non-switched B cells (HC: 9204.5 ± 2166.8, p = 0.05). Interestingly, SSc patients under RTX treatment had significantly lower class-switched memory B cell frequencies compared to HCs (6.4 ± 4.2 vs 13.2 ± 7.2, p = 0.015). However, RTX did not affect CD19 gMFI or bound CD19 in SSc.

Conclusion: RTX treatment in SSc is not associated with downregulation of the co-stimulation marker CD19. Thus, the main effect of this drug is the reduction of B cells, especially class-switched memory B cells that might have a high capacity to activate other cells involved in the pathogenesis of SSc.

REFERENCES:


Disclosure of Interests: None declared

AB0020

COMPARATIVE DESCRIPTION OF CYTOKINES AND MATRIX METALLOPROTEINASES IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEARTROPATHY UNDER A STRICT FOLLOW-UP COMPARED WITH COVID-19 PATIENTS

S. Naveeratna1, L. D. Gutiérrez-Castañeda2,3, P. K. Bautista-Nino4, J. A. Rubio-Rubio5, G. S. Rodríguez-Vargas3, P. Santos-Moreno3, D. Echeverri6, L. Saenz2, L. Torres Tobar7, A. Aparicio1, A. Rojas-Villarraga8, F. Sierra-Matamoros9, Foundation University of Health Sciences, Basic Science Institute, Bogotá, Colombia; 2Foundation University of Health Sciences, General Dermatology Group, Bogotá, Colombia; 3Foundation University of Health Sciences, Research Institute, Bogotá, Colombia; 4Cardiovascular Foundation of Colombia, Research Center, Floridablanca, Colombia; 5Biobanc IPS, Scientific Direction, Bogotá, Colombia; 6Fundacion Cardio Infantil Instituto De Cardiología, Hemodynamics and cardiovascular function laborator, Bogotá, Colombia; 7Foundation University of Health Sciences, Epidemiology, Bogotá, Colombia

Background: COVID-19, rheumatoid arthritis (RA) and osteoarthrosis (OA) are diseases characterized by the secretion of cytokines related to the stimulation of the inflammatory response.

Objectives: To identify the differences in the cytokine and matrix metalloproteinases (MMP) profile within one acute infectious disease and two chronic inflammatory rheumatic diseases.

Methods: Analytical cross-sectional study. RA patients under a strict follow-up program (T2T evaluated every two months), OA patients without strict clinical follow-up, evaluated once or twice a year, and Severe (mortality) COVID-19 patients were included. Eleven proteins (cytokines, MMPs, and its tissue inhibitors) were quantified through Luminox multiplex assay in serum samples. Univariate and bivariate analyses were performed. Approval of Ethics Committee and informed consent were obtained.

Results: A total of 108 patients with RA and OA were compared with 20 severe COVID-19 patients. There were no significant differences through the method of Kruskall–Wallis, between RA and OA patients. IL-1B and MMP-2 were significantly lower in COVID-19 patients. Levels of IL-10, IL-1RA, IL-6, MMP-1, MMP-9, and TIMP-1 were significantly higher in COVID-19 patients. There were no differences in TIMP-2, TIMP-1 and INF-G. (Table 1)

Table 1. Significant correlations between cytokines related to Covid-19, RA and OR.

<table>
<thead>
<tr>
<th>Cytokine (pg/ml)</th>
<th>Median values</th>
<th>RA (%)</th>
<th>OA</th>
<th>COVID-19</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-10</td>
<td>54.92</td>
<td>54.49</td>
<td>116.38</td>
<td>&lt;0.0001a</td>
<td></td>
</tr>
<tr>
<td>IL-1RA</td>
<td>62.19</td>
<td>51.82</td>
<td>110.08</td>
<td>&lt;0.0001a</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>67.09</td>
<td>55.30</td>
<td>46.17</td>
<td>0.045</td>
<td></td>
</tr>
<tr>
<td>IL-6</td>
<td>56.09</td>
<td>51.34</td>
<td>84.98</td>
<td>&lt;0.0001 0.003</td>
<td></td>
</tr>
<tr>
<td>TNF-A</td>
<td>17.5</td>
<td>14.6</td>
<td>16.3</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>MMP-1</td>
<td>57.84</td>
<td>54.84</td>
<td>90.81</td>
<td>&lt;0.0001 0.045</td>
<td></td>
</tr>
<tr>
<td>MMP-2</td>
<td>70.38</td>
<td>70.59</td>
<td>48.56</td>
<td>0.040</td>
<td></td>
</tr>
<tr>
<td>MMP-9</td>
<td>66.25</td>
<td>58.16</td>
<td>86.4</td>
<td>0.007</td>
<td></td>
</tr>
<tr>
<td>TIMP-1</td>
<td>51.59</td>
<td>60.99</td>
<td>111.37</td>
<td>&lt;0.0001a</td>
<td></td>
</tr>
<tr>
<td>TIMP-2</td>
<td>45.2</td>
<td>47.7</td>
<td>49.6</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>INF-G</td>
<td>5.75</td>
<td>5.32</td>
<td>3.07</td>
<td>NS</td>
<td></td>
</tr>
</tbody>
</table>


Conclusion: Compared with RA and OA patients, severe COVID-19 patients have a great impact on the cytokines and MMPs’ addressed in this study, proving that COVID-19 patients suffer from a cytokine storm [1] when severely infected.

REFERENCES:


Disclosure of Interests: None declared

AB0021

FEATURES OF IMMUNOLOGICAL MANIFESTATIONS OF COMMON VARIABLE IMMUNODEFICIENCY COMBINED WITH RHEUMATOID ARTHRITIS

S. Kudryashov1, L. Karzakova1, I. Sidorov2, N. Zhuravleva1, The Chuvash State University named after I.N. Ulyanov, Department of Internal Medicine, Chuvash Republic, Cheboksary, Russian Federation; 2City Clinical Hospital No. 1 of Public Health Ministry of Chuvashia, The Chuvash State University named after I.N. Ulyanov, polyclinic No. 1, Department of Internal Medicine, Chuvash Republic, Cheboksary, Russian Federation

Background: The prevalence rate of common variable immunodeficiency (CVID), the most common symptomatic form of primary immunodeficiency disease (PIDs), is growing every year. In the Republican Register of PID in the Chuvash Republic (Russia) there are 32 patients with CVID, 5 (16.1%) of whom have CVID combined with an autoimmune disease - rheumatoid arthritis (RA). The immunological studies occupy a large place in the diagnosis of PID and autoimmune diseases.

Objectives: The aim of the study was to search for immunological criteria for the differentiation of RA from CVID combined with RA.

Methods: The object of the study were 2 groups of patients. Group 1 consisted of 20 RA patients; group 2 consisted of 5 patients with CVID in combination with RA. Patients with CVID, who had the results of an immunological study conducted before the appointment of immunoglobulin replacement therapy, were selected for this study. The control group consisted of 20 practically healthy people.

Results: The significant changes were revealed in the concentration of serum immunoglobulins in the studied groups of patients, in particular, a sharp decrease in IgG levels in group 2 (1.9±0.3 g/l vs. 15.2±2.3 in group 1, p<0.001), IgA (0.1±0.2 g/l vs. 3.1±0.7 g/l in group 1, p<0.001), IgM (0.2±0.3 g/l vs. 1.7±0.2 g/l in group 1, p<0.001). Immunoglobulin levels in both groups of patients were lower (p<0.001) compared to the control group. In both groups, the number of regulatory cells – Treg (CD4+CD25+FoxP3) was reduced: in group 1 - 2.5±0.03%; in group 2 - 2.3±0.02%, while in the control group it was 4.2±0.5%, p<0.001. The result of our study confirms that the development of RA and CVID is associated with the decrease in the number of Treg cells responsible for ensuring peripheral tolerance and preventing the development of autoimmune diseases.

Conclusion: CVID and RA have a common immunopathological sign - a decrease in the content of Treg cells in the blood. In the differential diagnosis between RA and CVID, combined with RA, it is necessary to rely on the results of the determination of immunoglobulins in the blood serum.

Disclosure of Interests: None declared

AB0022

SELECTIVE ESTROGEN RECEPTOR MODULATORS AND TISSUE-SELECTIVE ESTROGEN COMPLEX DO NOT SHARE ESTROGENIC EFFECTS ON IGG SIALYLATION IN AUTOIMMUNE CONDITIONS

P. Gupta1,2, K. L. Gustafsson2, H. Carlsen1, P. Henning2, C. Engdahl1,2, 1Department of Rheumatology & Inflammation Research, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, University of Gothenburg, Gothenburg, Sweden; 2Department of Internal Medicine & Clinical Nutrition, Institute of Medicine, Sahlgrenska Osteoporosis Centre, Centre for Bone and Arthritis Research, University of Gothenburg, Gothenburg, Sweden

Background: Women entering menopause, with a decrease in estrogen levels, display an increased incidence of rheumatoid arthritis (RA). Estrogen (E2) treatment has beneficial effects on IgG pathogenicity by altering the sialylation grade which affect the binding ability to FcR [1]. E2 replacement may therefore be beneficial in pre-RA patients having autoantibodies. Exposure to estrogen is associated with negative side effects, therefore selective estrogen receptor modulators (SERMs) have been developed with estrogenic protective effect on bone but minimal impact on the reproductive system [2]. The SERM, Bazedoxifene (BZA), as well as tissue-selective estrogen complex (TSEC), a combination of conjugated estrogen and BZA, have been approved for treatment of postmenopausal bone loss [3-5].
Objectives: The purpose of this study was to investigate the impact of BZA and TSEC on IgG sialylation grade which affects the pathogenicity as well as to determine the effects on total serum protein sialylation.

Methods: pbMCs were subjected to ovariectomy to stop the endogenous E2 production and mimicked the postmenopausal status. Mice were then treated with E2, BZA, TSEC, or vehicle, followed by ovariabulin (OVA) immunization to induce the IgG levels. Blood was collected before treatment started and at termination. In serum total IgG, OVA specific IgG and the degree of IgG-sialylation were quantified with ELISA. Sialylation of total serum proteins was determined with aCD3 and subjected to transcriptional analysis by RNAseq (Illumina).

Results: Neither BZA nor TSEC significantly altered the total IgG levels or sialylation grade of IgG. Indeed, E2 significantly altered IgG sialylation. We showed that BZA increased sialyltransferase protein in plasma cells in a similar manner as E2. Further, neither E2, BZA or TSEC had any significant impact on sialic acids in whole serum protein and not in the mRNA expression of glycosyltransferase in the liver, BM, or gonadal fat.

Conclusion: In this study, we were not able to detect any alteration by TSEC or BZA treatment on IgG-sialylation grade and thereby pathogenicity of the IgG. Neither E2 nor BAZ or TSEC show any significant alteration on general sialylation, but our results suggest that further studies are required to understand E2, SERM, and TSEC full effect on protein sialylation in autoimmune conditions.

Keywords: sialylation, protein glycosylation, SERMs

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2012-220493

AB0023 JAK-INHIBITORS DISRUPT CD4+CD4+ CELL INTERACTION SUPPRESSING RHO-GTPASE DEPENDENT LEUKOCYTE RECRUITMENT TO JOINTS OF RA PATIENTS

E. Malmhiäl-Bah, K. M. Andersson, R. Ericsson, V. Chandrasekar, S. Töyräl Silfverswärd, M. I. Bokarewa.

Background: While examining arthritis development due hyperactivated Rho-GTPases in a mouse model, we found that macrophages with hyperactive Rho-GTPases regulate the migration of thymic T regulatory cells to peripheral lymphoid organs, which contributed to arthritis development interestingly, T cells reciprocally upregulate Rho-GTPases leading to suppression of homing and formation of a mechanosensory complex of centered around j1 integrin facilitating migration.

Objectives: In response to the finding in mice we sought to explore this relationship in patients diagnosed with RA, aiming to expand understanding how different treatment mechanisms may act to prevent arthritis development. We observed in mice.

Methods: To confirm if similar interaction mechanisms between macrophages and T cells are present in RA patients, we used paired transcriptome (RNAseq) of CD4+ and CD4+ cells from 80 RA patients active on conventional DMARDs prior to treatment with TNF-inhibitors (exploratory cohort) and from 56 RA patients with inactive disease on various DMARD treatment (confirmatory cohort); In both cohorts, patients were stratified by mean expression of CD24 in CD4+ cells to mimic hyper activation of Rho-GTPases. Transcriptomics of CD4+ and CD4+ cells were analyzed and translated into clinical correlates.

Results: Examining the exploratory cohort, we found a reciprocal upregulation of Rho-GTPases across the cell types. The CDC42+ group had upregulation of RHOA and RAC1 in CD4+ cells and CDC42, RAC1 and RHOA in CD4+. Interestingly, expression of IL6, IL1RA, IL18 and NLRP3 signified pro-inflammatory phenotype of those cells. Furthermore, CDC42+CD4+ and CD4+ cells shared the upregulation of AP-1 TFs, and the circadian rhythm controlling molecules PER1, AHR and KLF6 assisting cell migration. Next, CDC42+ cells were enriched with a synovial macrophage marker CD163, and ITGB1 to facilitate focal adhesion and migration into joints. Moreover, high expression of CXCL-chemokines and CD163 on CD4+CD24+ cells indicated the ability to recruit T cells, and high CCRx4 on CDC42+CD4+ cells suggested their synovial destination. Unfortunately, CDC42+CD4+ and CD4+ cells were not recognized by strong production of the key pro-arthritis cytokines TNF-α and IFN-γ. Consequently, the CDC42+ profile of CD4+ and CD4+ cells was not predictive for clinical response to TNF-inhibition in the exploratory cohort.

Conclusion: Examination of the confirmatory cohort revealed the majority of CDC42+CD4+ cells belong to the patients treated with conventional DMARDs, while CDC42+ group were treated with JAK-inhibitors (20 vs 4, OR=11.87, 95% CI [3.387, 49.72], p<0.0001). We also found a correlation between CDC42 expression in CD4+ cells and DAS28 in patients treated with JAK-inhibitors (r=0.5, p=0.0072) pointing at tight relation between the treatment effect and Rho-GTPase dependent processes. This significantly affected the Rho-GTPase dependent interaction between CD4+ and CD4+ cells.

Transcriptional profile of CDC42+CD4+ cells of the confirmatory cohort showed many similarities with the exploratory cohort including upregulation of the canonical Rho-GTPases, ITGB1 and the inflammasome activation that were enhanced by upregulation of the vast number of ITGA and chemokines. Transcriptional regulation through AHR and KLF6 persisted, while AP-1 and PER1 was down-regulated. In contrast to CD4+ cells of the exploratory cohort, CD4+ cells of the patients with CDC42+CD14+ cells were low in CDC42, RAC1 and HOXA expression. Also, CD4+ cells were deficient in AHR, KLF6 and PER1.

Conclusion: Taken together, these data show that Rho-GTPases regulate interaction between CD4+ and CD4+ cells and their migration to RA joints. Treatment with JAK-inhibitors suppresses the Rho-GTPase dependent recruitment to joints by changing communication between CD4+ and CD4+ cells. This finding opens new perspective to use Rho-GTPase signature to identify patients suitable for treatment with JAK-inhibitors and in predicting the treatment response.

Disclosure of Interests: None declared


AB0024 PLURIPOTENCY MARKER PBX1 PREDICTS TREATMENT EFFECT IN RHEUMATOID ARTHRITIS


Background: Accelerated immunosenescence with contraction of T cell repertoire, demise of thymic function and expansion of CD28− T cells with poor T cell reconstitution is the hallmark of rheumatoid arthritis (RA)

Objectives: In this study we assessed if PBX1 transcription factor that maintains the pluripotency of hematopoietic stem cells could be used to predict treatment response in RA patients.

Methods: CD4+ T cells of 87 RA female patients (age, median 61y (23-76); disease duration, median 9y (0-45)) were isolated from the peripheral blood, activated with aCD3 and subjected to transcriptional analysis by RNAseq (Illumina). External RNAseq of CD4+ T cells of 80 RA patients (f 56, m 24) was used for validation. The genes differentially expressed (DEG, nominal p<0.05) between PBX1+ and PBX1− groups were identified by R-studio using Benjamini-Hochberg correction (0.05DESeq2 package). DEGs were clustered by covariance to identify PBX1 associated genes and biological processes. Clinical variates and treatment regimens in PBX1+ and PBX1− groups were compared.

Results: The patients of PBX1+ and PBX1− groups were of similar age and disease duration but differed in anti-rheumatic treatment. PBX1+ group was often treated with conventional DMARDs and monotherapy, while PBX1− group was mostly treated with biologics and/or JAK-inhibitors in combination with cDMARDs (2, p=0.0099). This treatment led to sufficient disease control in PBX1− group (r=0.0099).

Pathway analysis of the DEGs identified strong enrichment for regulation of transcription (cor.p=10−6), RNA metabolic processes (cor.p=10−6) and differentiation (cor.p=10−6) in PBX1+ cells, which corresponds to the known biological properties of PBX1. PBX1+CD4+ cells in both datasets had imprinted features of pluripotency and expressed higher levels of KIT and CAT, low proliferation...
markers Ki67 and BIRC5, and had virtually no cytokine production. In the main cohort, PBX1hiCD4+ cells were recognized by naïve T cell marks CD62L (SELL) and CD45 (PTPRC), and also PECA1, CR2, and CD28, indicating recent thymic egress. In the validation cohort, PBX1hiCD4+ cells were enriched with stem cell markers CD34, MEG3, and DNMT3B. Lineage specific TFs (TBEI, GATA3, FOXP3, RORC) and cytokines (IFNG, TNF, IL10, IL17F, etc.) were accumulated in PBX1hiCD4+ cells indicating terminally differentiated effector CD4 T cells.

Conclusion: This study shows that enrichment with PBX1hiCD4+ cells is associated with naïve pluripotent phenotype of CD4 lymphocytes. Patients with high PBX1 expression are less heavily treated and respond better to treatment. This suggests boosting of PBX1-expression to be a way of treating RA.

REFERENCES:

Disclosure of Interests: None declared

PERIPHERAL BLOOD CD4+ AND CD8+ RECENT THYMIC EMIGRANTS IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS DISPLAY AN ACTIVATED PHENOTYPE

F. V. Kraus1, V. Eckstein2, L. V. Klotz3, H. Winter3, H. M. Lorenz3, M. Souto-Carneiro1. 1University Hospital Heidelberg, Division of Rheumatology, Dept. of Medicine V, Heidelberg, Germany; 2University Hospital Heidelberg, dFFCU, Dept. of Medicine V, Heidelberg, Germany; 3German Center for Lung Research (DZL), Translational Lung Research Center (TLRC), Heidelberg, Germany

Background: T cells play a major pathogenic role in Rheumatoid Arthritis (RA). Their pro-inflammatory potential, interaction with B-cells (CD4) and cytotoxic capacities (CD8) have a high impact on disease progression, at the site of inflammation as well as in the periphery. T cells in RA have an altered glucose metabolism, which further amplifies their pro-inflammatory and auto-immune profile.1,2 This phenotype is even displayed by RA naïve CD8 T cells, and several studies propose that defects in RA T cell development occur already during thymic development. Thus, acquisition of an activated (auto)inflammatory phenotype may occur at very early stages of RA T cell development.

Objectives: We studied Recent Thymic Emigrants (RTEs) in peripheral blood to establish, whether the activated pro-inflammatory signature present in naïve RA T cells can already be found at such an early stage of T cell development.

Methods: We analysed previously described RTE surface markers on CD8 and CD4 T-cells of human adult thymus samples, as well as on cord-blood samples and additionally confirmed the identified cells as RTEs based on their TREC (T cell Receptor Excision Circle) content. Next, we phenotypically characterised RTEs in the peripheral blood of 10 RA patients, 6 PsA (Psoriatic Arthritis) patients and 5 healthy donors (HC) by 24-parameter Flow Cytometry. Cell clustering was analysed using the UMAP algorithm.

Ethic approval NR: S-969/2020

Results: As expected, RTEs only made up a small proportion of the total CD4 and CD8 T cells, on average 1.3 % and 2.5 % respectively. Contrary to previous reports 3 we could see no significant differences between patients and controls. A first global analysis of CD45RA and CCR7 on CD4 and CD8 via UMAP revealed that RA and PsA RTEs cluster together with naïve and effector cells (Figure 1).

We further analysed several functional surface markers for homing (CD11a, CD49a), effector functions (CD69, CD27, CD107a), regulatory functions (CD25) and exhaustion (CD95, PD-1, CTLA-4).

In CD4 RTEs we observed more cells expressing homing, effector and exhaustion markers in RA and PsA when compared to HC. CD11a and CD49a were expressed on 3 times more CD4 RTEs in RA and PsA and CD95 and PD1 expressing CD4 RTEs were 2 times more frequent in the arthritic groups compared to HC, while PD1 expressing CD4 RTEs in patients were 10 times more frequent. The CD25+ CD4 RTE population was 3 times larger in RA and PsA than in HC.

In CD8 RTEs the frequency of CD11a expression was similar, whereas the CD49a+ population was 3 times larger in RA compared to PsA and HC. CD69 expressing CD8 RTEs were increased in RA and PsA compared to HC, while the degranulation marker CD107a was expressed on similar amounts of HC and PsA RTEs and 2 fold increased compared to RA. CTLA-4 and PD1 expressing CD8 RTEs were 5 - and 2 times more frequent in the RA group than in HC.

Conclusion: Overall, the RTE populations of RA and PsA patients displayed a more active and exhausted phenotype than the control group. However, this seemed to be more prominent for CD4 RTEs than CD8 RTEs. According their CD45RA/CCR7 profiles, both CD4 and CD8 RTEs fall into the less active naïve compartment, corresponding to the early developmental stage, but also into the effector compartment. The RTEs from RA and PsA patients also express markers that are usually associated with pro-inflammatory activity and even exhaustion. This implies that indeed even RTEs are already biased towards a more active phenotype in RA and PsA, compared to RTEs from healthy individuals, suggesting alterations in T cell development in the RA and PsA thymus.

REFERENCES:
[1] https://doi.org/10.1084/jem.20130252
[2] https://doi.org/10.1002/art.41420
[3] https://doi.org/10.1084/jem.20080996
[4] https://doi.org/10.1002/art.38058

Acknowledgements: We thank all the donors involved in the study for their participation. Furthermore, we thank Christa Stolp and Anke Diehlmann for their indispensable help with the Thymus and Cord Blood samples.

Disclosure of Interests: None declared

Figure 1. UMAP analysis of total RTEs. Previously downsampled CD4+ and CD8+ T cells were clustered by UMAP. (FlowJo™) and total RTEs were mapped on the naïve, effector (EMRA), effector memory (EM) and central memory (CM) compartments of the respective groups.

CELL TYPE-SPECIFIC DYSREGULATION FOUND TO DIFFERENTIATE PATIENT SUBSETS OF SJÖGREN’S DISEASE

C. Li1, B. Khati1, A. M. Stolarczyk1, K. L. Tes sneer2, A. Rasmussen1, J. Guthridge1, J. A. James1, R. H. Scofield1,3, H. Li5, A. D. Farris2, K. Sivils5, C. Lessard1.

1University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, United States of America; 2Oklahoma Medical Research Foundation, Arthritis and Clinical Immunology Research Program, Oklahoma City, United States of America; 3University of Oklahoma Health Sciences Center, Department of Medicine, Oklahoma City, United States of America; 4US Department of Veterans Affairs Medical Center, US Department of Veterans Affairs Medical Center, Oklahoma City; United

AB0026

AB0025
Background: Sjögren’s disease (SjD) is a chronic, heterogeneous autoimmune disorder characterized by inflammatory destruction of the exocrine glands and Ro autoantibodies. Previous studies, most in whole blood, reported transcriptional and cell type differences between SjD subphenotypes.

Objectives: Evaluate the role of cell type-specific dysregulation in subpopulations of SjD patients having focal lymphocytic sialadenitis and/or anti-Ro/SSA and/or ANA positivity using single-cell RNA-seq (scRNA-seq).

Methods: Peripheral blood mononuclear cells (PBMCs) stored at -120°C from 30 SjD patients and 10 healthy controls (HCs) were selected from our OMRF Sjögren’s Research Cohort based on ACR/EULAR 2016 criteria. PBMCs were captured, libraries processed using 10X Genomics Chromium v3.1 and sequenced to a depth of ~45,000 reads/cell. 10X Genomics Cell Ranger (v 6.1.2) cell multiplexing pipeline was used to align reads to the GRCh38 human genome and separate combined data to per-sample output files. Seurat R package was used for quality control (QC), integration, clustering, and cell type assignment. Differential expression (DE) analysis was done using Seurat for genes with 10% or more of the cells showing expression. DE transcripts (defined as \(\text{P}<0.05\)) were evaluated using Ingenuity Pathway Analysis (IPA).

Results: After removing cells with low feature counts, high mitochondrial gene counts, and/or other QC criteria, a total of 331,981 cells were captured. Cells were mapped to 26 clusters using Seurat, then cell types were predicted using marker genes developed from an in-house reference panel of publicly available scRNA-seq datasets. Hierarchical clustering of 28 observed cell clusters yielded 19 clusters of specific cell types; 4 clusters remained unidentified. Percentages of each cell type were compared across various subsets of SjD (Ro+; Ro−; Ro−/ANA+; Ro−/ANA−) and HCs. CD14 monocyes were decreased in Ro−/ANA− vs. Ro+ or Ro+/ANA+ cases (\(p<0.05\)) and trended downward when compared to HCs (\(p=0.057\)). CD8 central memory T cells (TCM) were decreased in Ro+ vs. Ro− or Ro−/ANA− cases (\(p=0.02\)) and trended downward when vs. HCs (\(p=0.076\)). Conventional dendritic cells (DCs) were increased in Ro+ vs. Ro−/ANA− SjD cases (\(p=0.036\)) and trended upward in Ro+ vs. Ro− cases (\(p=0.08\)) but were not significantly different from HCs. Natural killer (NK) cells were increased in both Ro−/ANA− and Ro+ vs. Ro−/ANA− (\(p<0.05\)).

DE analysis between immune cell subsets revealed potential subphenotype-specific differences in pathophysiology. Interferon signaling was upregulated in CD14 monocyes, naive B, and CD4 central memory (TCM) cells from the Ro+ subset. Ro+ subset also showed upregulation of genes involved in T cell receptor signaling in CD4 cytotoxic T (CTL), CD4 TCM, and CD4 effector memory (TEM) cells, but downregulation of this pathway in CD8 TCM cells. Ro+ subset also exhibited increased B cell receptor signaling pathway in naive and memory B cells. Ro− subset showed downregulation of autophagy in naive B, CD4 CTL, CD4 TCM, and CD4 TEM cells. Several cell types in Ro+ and Ro− (ANA−) subsets showed decreased DE of genes involved in nitric oxide production and NRF2 oxidative stress pathways. Ro− (ANA−) vs. HCs showed increased IL6 and TREM1 signaling pathways in CD14 and CD16 monocyes. While Ro− subsets showed upregulation of B and T cell pathways (shown previously in lupus), Ro− (ANA−) showed dysregulation of osteoarthritis and neuroinflammatory pathways. Interleukin-2, among the DE long intergenic non-coding (linc)RNAs found herein, we observed that LINC01871, which we previously reported as DE in all subsets of SjD, was overexpressed in CD4 CTL and NK cells in both Ro+ and Ro− (ANA−) vs. HCs.

Conclusion: This interim analysis shows similarities and differences in the dysregulation of genes and pathways for specific cell subsets from our Ro+ and Ro− (ANA−) subsets of SjD, potentially allowing for more tailored diagnostics and interventions for the disease in the future.

Disclosure of Interests: Chuang Li: None declared, Bhawan Khatri: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Judith A. James: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared, Anna M Stolarczyk: None declared, Kandice L Tessneer: None declared, Ivan G. Borisof: None declared, Helzi F. Wiedenmann: None declared.
CD39 and CD73 rendering the antiinflammatory agent adenosine 4. CD39, the rate-limiting enzyme in this cascade, is highly expressed by a subset of human FoxP3+Tregs (Treg39+) 1-3. Methotrexate (MTX), the first line of treatment in Rheumatoid Arthritis (RA) 4, inhibits AICAR transformylase which results in an enhanced release of extracellular adenine nucleotides 4 to be metabolized by Treg only in PM/DM patients (p<0.05). In parallel, there were higher frequencies of CD45RO+CCR7- effector/memory cells (p<0.01) and of Ki67+ proliferating cells (p<0.06) among CD3+CD4+FoxP3-Tcon in pSS patients compared to HC, which was not observed in PM/DM patients.

Conclusion: The loss of the CD25+ Treg subset in PM/DM and pSS patients is similar to previous findings in SLLE patients 1 and represents a hallmark of IL-2 deficiency. This suggests that shortage of IL-2 is pathophysiologically relevant also in PM/DM and pSS providing a rationale for low-dose IL-2 therapy in these diseases. In addition, activation and expansion of effector/memory Tcon appears to be more pronounced in pSS compared to PM/DM. The different distribution of Treg and of Tcon subsets between pSS and PM/DM patients might reflect differences in the availability of IL-2 and in the regulation of Tcon responses in these diseases.

REFERENCES:

Disclosure of Interests: Luisa R. Monne: None declared, Sara Comduheur: None declared, Fynn Gerlach: None declared, Antje Müller: None declared, Gabriela García-Carazo: None declared, Alejandro Balsa: None declared, Maria-Eugenia Miranda-Carus: Grant/research support from: Gebro Pharma - Unrestricted research grant


AB0029 CIRCULATING CD39+ TREG CELLS IN EARLY RHEUMATOID ARTHRITIS FACILITATE THE ANTINFLAMMATORY ACTION OF METHOTREXATE AND SERVE AS EARLY BIOMARKERS OF CLINICAL RESPONSE

A. Villalba1, L. Nuño1, M. Benito-Migue1, I. Monjo1, M. Novella-Navarro1, D. Peiteado1, A. García-Carazo2, A. Balsa1, M. E. Miranda-Carus3.

1Hospital Universitario La Paz -IdiPAZ, Rheumatology, Madrid, Spain; 2Universidad de Nebrija, Physiology, Centro de Ciencias de la Salud San Rafael. Fundación San Juan de Dios., Madrid, Spain

Background: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system 1,5. Stressed cells at inflammatory foci release adenine nucleotides to the extracellular space 5 that can act as enhancers of inflammation 5 but are rapidly hydrolyzed by the sequential action of ectonucleotidases CD39 and CD73 rendering the antiinflammatory agent adenosine 5. CD39, the rate-limiting enzyme in this cascade, is highly expressed by a subset of human FoxP3+Tregs (Treg39+) 6, Methotrexate (MTX), the first line of treatment in Rheumatoid Arthritis (RA) 7, inhibits AICAR transformylase which results in an enhanced release of extracellular adenine nucleotides 5 to be metabolized by Treg39+ cells; hence MTX may cooperate with Treg39+ cells in the control of inflammation.

Objectives: To examine the relation of CD39 expression on Tregs cells of early RA (ERA) patients with the ex vivo and in vivo effect of MTX.

Methods: Peripheral blood was obtained from 63 DMDAR- and steroid-naive ERA patients with a disease duration <24 weeks and 63 age and gender-matched healthy controls (HC) 33 ERA patients donated blood again 12 months after initiating MTX (ERA-R). The frequency of Treg and Treg cell subsets was assessed by flow cytometry. CD4+CD25+CD127- (total T reg), CD4+CD27+CD127+CD39+ Treg (Treg39+) and CD4+CD25+CD39- responder T (Treg39-) cells were isolated by sorting. The suppressor potency of Tregs was determined in cocultures of isolated Tregs with Tresp. Proliferation was determined by CFSE dilution; cytokine secretion was measured by ELISA of culture supernatants. Disease activity was assessed using the DAS28-ESR score. Low disease activity (LDA) was defined as a DAS28 ≤ 3.2.

Results: The proportion of Tregs that expressed CD39 (Treg39+) was significantly increased in ERA. Total ERA Tregs were more potent suppressors than HC Tregs, and the difference was reduced by adenosine A2AR antagonists. In vitro, MTX further heightened the total Treg cell potency, with greater amplification in ERA vs HC and this was also reversed by A2AR antagonists. The potency of isolated Treg39+ and its enhancement by MTX were comparable for ERA and HC; the potency of isolated Treg39- was inferior to that of Treg39+ cells in both groups of subjects and was not modified by A2AR antagonists; this further suggests that the differences observed in assays using total Tregs are due to the increased ERA Treg39+ frequency. Patients who achieved LDA had significantly higher basal frequencies of Treg39+ cells and multiple logistic regression (OR 1.93, 95% CI 1.33-4.51) showed that this was independent of basal disease activity, RF or ACPA titres. The Receiver Operating Characteristic (ROC) analysis area under the curve (AUC) was 0.97 (0.94-0.99) for Treg39+ cells. The relative risk (RR) of achieving LDA for patients with a cTreg39+ frequency above the p=0.05 value observed in HC was 13.4 (2.9-75.6) (Fisher’s exact test). The proportion of Treg39+ significantly decreased in all patients whether they had or not achieved LDA, and the frequency and function of ERA-R Treg cells were not different from HC. In fact, 12 months after initiating treatment with MTX, the circulating Treg39+ cell frequency was no longer elevated in ERA; however, its association with the clinical response remained: the cTreg39+ cell frequency observed at 12 months was still significantly higher in those patients who had achieved LDA. This suggests that Treg cell expression of CD39 is upregulated during the initial stages of ERA as a negative feedback mechanism of inflammation.

Conclusion: MTX cooperates with Treg39+ cells to control inflammation and the pretreatment Treg39+ frequency in ERA is associated with the clinical response to MTX at 12 months.

REFERENCES:

Disclosure of Interests: Alejandro Villaiba: None declared, Laura Nuño: None declared, Marta Benito-Migue: None declared, Irene Monjo: None declared, Marta Novella-Navarro: None declared, Diana Peiteado: None declared, Sara García-Carazo: None declared, Alejandra Balsa: None declared, María-Eugenia Miranda-Carus Grant/research support from: Gebro Pharma - Unrestricted research grant


AB0030 THE BIOLOGICAL FUNCTION AND MECHANISM EXPLORATION OF TACI IN SJOGREN’S SYNDROME

H. Zhang1, H. Zhang1, D. Gao3, L. Ji2, Z. Zhang1. 1Peking University First Hospital, Rheumatology and Clinical Immunology Department, Beijing, China

Background: primary Sjogren’s syndrome (pSS) is a chronic autoimmune disease that affects the lacrimal, salivary and other exocrine glands. More and more studies have shown that B cells play a central role in the pathogenesis of SSS. Objectives: We intended to explore the expression of the transmembrane activator, calcium modulator and cyclophilin ligand interaction (TACI) on the B cells, its role in pSS, and possible signal transduction pathways. Methods: We included 34 naive pSS patients who visited the rheumatology department of Peking University First Hospital, and 37 gender- and age-distribution matched healthy controls (HCs). (1) To compare the B cell subsets, expression of TACI and relevant receptors in pSS patients, peripheral blood mononuclear cells were separated to analyze the ratio of B subsets, TACI, and BAFF-R by flow cytometry; ELISA was applied to detect the serum BAFF and soluble TACI (sTACI) concentration. (2) For as functional research of TACI, CD19+ B cells separated by magnetic sorting were treated under in vitro culture circumstances with raw TACI, TACI knocked down by siRNA, and sTACI analog (teiltacibibrin) intervention with varying doses. The apoptosis, proliferation, differentiation and regulatory capacity on T cells were analyzed by flow cytometry, inflammatory cytokines and immunoglobulin levels in the culture supernatants were detected by CBA. (3) As for TACI-associated signaling pathway exploration, based on our previous miRNA data and relevant report of high quality, miRNA associated with
TACI with significantly biased expression was confirmed by RT-qPCR. Screening the target gene of the candidate miRNA, and miRNA overexpression and inhibition experiments were conducted to validate the targeted relationship in B cells. And TACI-associated signaling pathway was explored via overexpressing and inhibiting the target gene.

**Results:** (1) Compared to HC, peripheral blood B subsets of pSS patients exhibited a significant bias, manifesting as increased proportion of CD19+CD24hiCD38hi Breg and decreased ratio of CD19+CD24+CD38- memory B cells. The expression of TACI in all B subsets was down-regulated, while that of BAFF-R was up-regulated. Both the serum concentration of BAFF and sTACI in pSS patients increased significantly. (2) As for functional research of TACI, in the setting of raw TACI, B cells in the pSS group showed higher apoptosis rate than HC under culture in vitro, where the ligand of TACI (APRIL or BAFF) addition turned the rate comparable; more active proliferation, and impaired capacity of inducing Treg cells to secrete IL-10. When TACI was knocked down by 50%, B cells performed less late apoptosis, significantly increased proliferation, impaired differentiation, significant dysfunction of Breg itself and impaired induction of Treg cells to secrete IL-10. While telitacicept intervention increased early apoptosis rate of B cells, significantly inhibited proliferation in 500ng/mL group and impaired ability of Breg and Treg cells to secrete IL-10. Besides, increased TACI on B cells treated with telitacicept, decreased IgG and increased IgA in the culture supernatants were observed. (3) As for TACI-associated signaling pathway exploration, hsa-miR-30b-5p showed satisfactory correlation between both transmembrane and sTACI. Besides, the expression of hsa-miR-30b-5p was significantly down-regulated, and inhibition its expression in vitro could lead to differentiation retard, impaired secretion of IL-10 by Breg cells. SMA1 was screened based on database and validated as its target gene by overexpressing and inhibiting hsa-miR-30b-5p in B cell. After targeted up- or down-regulating the transcription of SMA1 further, the transcription of ID2 downstream the TGF-β/Hippo signaling pathway changed accordingly.

**Conclusion:** The expression of TACI on peripheral blood B cells was deficient in pSS patients. TACI deficiency was closely associated with the downregulation of hsa-miR-30b-5p, activating TGF-β/Hippo pathway mediated by its target gene SMA1 and taking part in the pathogenesis of pSS.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2991

---

**AB0032** CHARACTERIZATION OF PERIPHERAL BLOOD B-CELL SUBSET IN UNTREATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND SYSTEMIC SCLEROSIS

F. Gerasimova1, D. Tabakova2, A. Aleksankin2, R. Shyakhetmova2, T. Popkova1, A. Avdeeva3, V.A. Nasonova Research Institute of Rheumatology, Department of systemic rheumatic disease, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Laboratory of Systemic Sclerosis, Moscow, Russian Federation

**Background:** Breakdown of self-tolerance is an important common mechanism in autoimmunity. Despite considerable clinical heterogeneity, many autoimmune diseases exhibit common immunological mechanisms leading to a breakdown of self-tolerance. Identification of unique and similar patterns across different autoimmune disease may help to understand their pathophysiology behind.

**Objectives:** Establishing workflows for the multi-parameter deep immune phenotyping of T- and B-cells by unsupervised machine learning (ML) methods for feature extraction, cluster analysis and anomaly detection.

**Methods:** We use machine learning to identify common patterns and dissimilarities between type 1 diabetes (T1D, n=69), rheumatoid arthritis (RA, n=63), systemic lupus erythematosus (SLE, n=38) and healthy controls (n=69) samples based on multi-plex immune phenotyping. PBMCs were isolated from patients with T1D, RA, SLE, and controls. A flow cytometry-based approach was applied, and a traditional analysis was compared to a ML method implemented in R [1] and based on self-organizing maps (Figure 1). Our pipeline includes unsupervised pre-gating, normalization, FlowSOM clustering [2], and a statistical model (GLMM), to check for significant differential abundances of cell populations among the autoimmune conditions.

**Results:** After applying our automated workflow to one T cell panel we could identify 14 cell clusters present in all the samples. The GLMM test revealed a cluster with a significant difference (p=0.035) and a trending one (p=0.059) on the abundance across the different diseases. In particular, CD4^{+}^{+} T cells expressing high IL-7 receptor (CD127) levels and median amounts of CD15s but low CD25, CD161 and FoxP3 are increased in T1D whereas CD4^{+}^{+}^{+}^{+}CD15s^{+}FoxP3^{+}CD161^{+}^{+}CD45RA cells are increased in SLE.

**Conclusion:** This unbiased, unsupervised ML workflow was able to identify canonical and novel clusters of T cells that are similar in RA, SLE and T1D. Additionally, a novel memory T cell population expressing CD15s was shown. This unsupervised analysis approach for large datasets enables the discovery of new immune cell populations complementing traditional workflows.

**REFERENCES:**


**Acknowledgements:** This work was funded by a grant from JDRF, LRA and NMSS (grant key: 2-SRA-2021-1043-S-B) and the Austrian Federal Government within the COMET K1 Centre Program, Land Steiermark and Land Wien

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3072
Background: B-cells play a critical role in the regulation of systemic autoimmune diseases pathogenesis, that extends beyond antibodies production. Objectives: To examine B-cell subsets in peripheral blood of patients (pts) with untreated systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), to analyze of their associations with disease-specific autoantibodies. Methods: Thirty six untreated SLE pts (31F/5M) and 32 untreated SSc pts (25F/7M) were enrolled. SLE pts had median age of 37(range)(32-41) years, disease duration of 3.5(1-11)years, SLEDAI 2K of 7(4-8), BILAG of 14.5(10.2-23). SSc pts had median age of 42(38-50) years, disease duration of 3.5(1-10) years, Disease Activity ESSG of 2.5 (1-3.2). The control group consisted of 29 volunteers (23F/6M, median age 38(35-48) years. CD19+B cells, memory B cells (CD19+CD27+), switched memory B cells (CD19+CD27+IgD+), non-switched memory B cells (CD19+CD27+IgD-), naive (CD19+CD27+IgD+), double-negative (CD19+CD27-IgD), transitional (CD19+CD38++CD10+IgD+CD27-) B cells, and plasmablasts (CD19+CD38+++CD10+IgD+CD27-20+) were analyzed using multicolor flow cytometry. Results: Differences in the median percentage and of absolute B-cell subsets levels in untreated pts with RA and SLE were not found. The absolute counts of memory B cells (CD19+CD27+), switched memory B cells (CD19+CD27+IgD+), transitional B cells (CD19+CD38++CD10+IgD+CD27+), and plasmablasts (CD19+CD38+++CD10+IgD+CD27-20+) were higher in SLE and SSc pts compared to healthy donors, p<0.01 for all cases. The absolute counts of double-negative B cells (CD19+CD27-IgD-) were lower in SLE pts than in donors, p=0.03 (Table 1). At significant correlation was found in SLE pts between anti-dsDNA levels and absolute counts of the following B-cell subtypes: CD19+B cells (r=0.72), memory B cells (CD19+CD27+IgD-20) (r=0.76), switched memory B cells (CD19+CD27+IgD+) (r=0.75) and naive B cells (CD19+CD27-IgD+) (r=0.73); the a-Sm levels and absolute counts of CD19+B cells (r=0.76), switched memory B cells (CD19+CD27+IgD-), non-switched memory B cells (CD19+CD27+IgD-) (r=0.51); the antibodies to cardiolipin (aCL) IgG levels and absolute counts of CD19+B cells (r=0.75) and naive B cells (CD19+CD27-IgD+) (r=0.73); the a-Sm levels and B cells (CD19+CD27+), switched memory B cells (CD19+CD27+IgD-), non-switched memory B cells (CD19+CD27+IgD-) (r=0.76), and with naive B cells (CD19+CD27-IgD+) (r=0.59), p<0.01 for all cases. There was a correlation against anti-topoisomerase-1 antibodies (a-Topo-1) and the absolute counts of double-negative B cells (CD19+CD27-IgD-) (R=0.82, p=0.01) in SSc pts.

Table 1. Levels of the blood B-cell subsets in SLE pts, SSc pts and in control.

<table>
<thead>
<tr>
<th>Parameters, n (x10^9)</th>
<th>SLE</th>
<th>SSc</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD19+B cells</td>
<td>0.15</td>
<td>0.14</td>
<td>0.1</td>
</tr>
<tr>
<td>memory B cells (CD19+CD27+)</td>
<td>0.036</td>
<td>0.042</td>
<td>0.003</td>
</tr>
<tr>
<td>switched memory B cells (CD19+CD27+IgD-)</td>
<td>0.02</td>
<td>0.026</td>
<td>0.01</td>
</tr>
<tr>
<td>non-switched memory B cells (CD19+CD27+IgD-)</td>
<td>0.012</td>
<td>0.016</td>
<td>0.02</td>
</tr>
<tr>
<td>double-negative B cells (CD19+CD27-IgD-20)</td>
<td>0.011</td>
<td>0.02</td>
<td>0.02</td>
</tr>
<tr>
<td>plasmablasts (CD19+CD38+++CD10+IgD+CD27-)</td>
<td>0.001</td>
<td>0.001</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

Note: * Differences in B-cell subset of the control group with SLE and SSc groups.

Conclusion: Immunophenotyping showed similar levels of B-cell subset in untreated SLE and SSc pts, an increase in the absolute counts of memory B cells (CD19+CD27+), switched memory B cells (CD19+CD27+IgD+), transitional B cells (CD19+CD38++CD10+IgD+CD27+) and plasmablasts (CD19+CD38+++CD10+IgD+CD27-) in untreated SLE and SSc pts compared with healthy subjects. Positive correlation between the counts of B-cell subsets and values of disease-specific autoantibodies (anti-dsDNA, a-Sm, scIgG, a-Topo-1) suggests that B-lymphocytes may be involved in SLE and SSc pathogenesis. This work was supported by the Russian Science Foundation (Grant № 22-25-00358).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3739

AB0033 T- AND B-CELL SUBSETS AS ADDITIONAL DIAGNOSTIC TOOL FOR PRIMARY SJÖGREN’S SYNDROME AND SYSTEMIC LUPUS ERYTHEMATOSUS

S. Benevolskaya1, I. Kudryavtsev2, M. Maria K. Serebriakova3, A. Budkova4, I. Grigoreva5, E. Kuvardin1, S. Koniakhin6, D. Zamozeva6, D. Motorin6, S. Lapin7, A. Maslyanskiy1.
1Federal State Budgetary Institution Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation, Rheumatology, Saint-Petersburg, Russian Federation; 2Federal State Budgetary Scientific Institution Institute of Experimental Medicine; Laboratory of Cellular Immunology, Saint-Petersburg, Russian Federation; 3Federal State Budgetary Scientific Institution Institute of Experimental Medicine; General Immunology Laboratory, Saint-Petersburg, Russian Federation; 4Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, Department of Pathology and Immunology, Saint-Petersburg, Russian Federation; 5Center for Theoretical Physics of Complex Systems, Institute for Basic Science, Daejeon, Korea, Rep. of (South Korea); 6Federal State Budgetary Institution Almazov National Medical Research Centre of the Ministry of Health of the Russian Federation, Hematology, Saint-Petersburg, Russian Federation; 7Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation, Department of Molecular Medicine, Saint-Petersburg, Russian Federation

Background: Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are chronic autoimmune diseases with complex pathogenesis. T-lymphocytes are known to be prime effectors of autoimmune diseases, while B-lymphocytes play a key role as sources of antibodies and antigen presenting cells. Considering the implications of T- and B-cells in the pathophysiology of SLE ans pSS, the assessment of their distribution in the blood could be helpful in the complex process of determining a precise diagnosis.

Objectives: The study aimed to compare composition of peripheral blood T- and B-cell subsets and investigate their diagnostic utility in patients with SLE and pSS.

Methods: The study was performed with 37 patients suffering from SLE, 57 patients with pSS, and 49 apparently healthy volunteers (HVs). The diagnosis of SLE was performed according to the 2019 EULAR – ACR classification criteria, the diagnosis of pSS- according to the 2016 EULAR – ACR criteria. 11 patients in pSS group met the criteria for both pSS and SLE, the relative distribution and percentage of T- and B-cell subsets were evaluated by flow cytometry. T helper (Th) and cytotoxic T-cell subsets (Tcye) were identified by using CD3, CD4, and CD8 antibodies. Regulatory T cells (Tregs) were characterized by the expression of CD3, CD4, and high IL-2R alpha chain (CD25high) levels. All peripheral blood B-cells were identified by using CD19 antibody, detection of subpopulations of B cells based on expression of IgD, IgM, CD27. The absolute and relative values of B-lymphocyte subpopulations were evaluated using three main classifications: based on IgD / CD38 expression classification (Bm1-Bm5), co-expression of IgD / CD27 and CD38 / CD27. The statistical analysis of data was performed with STATISTICA Version 12.0.0.1c. Method of discriminant analysis was performed to evaluate diagnostic utility of relative values of T- and B-cell subsets.

Results: In the discriminant model the top significance was documented while assessing the percentage of naive B-cells (Bm1, IgDdimCD38low), germinal center B-cells (Bm 3+8Bm4, IgDdimCD38hi), naive B-cells (IgDdimCD27low), unswitched memory B-cells (IgDdimCD27dim), naive mature B-cells (CD27dimCD38low), transient B-cells (CD27lowCD38hi), all T-cells (CD3hi), Tregs (CD3hiCD4hiCD25hi), Tcyt (CD3hiCD4) and Th (CD3hiCD4hi). Model percent correct was 78%, p<0.05. The discriminant function was either 11 for distinguishing HVs versus il patients SLE and pSS, while B-lymphocytes play a key role as sources of antibodies and antigen presenting disease are accounted). During ROC analysis, performed for the differential diagnosis of healthy and sick patients, this discriminant model had a sensitivity of 86.5% and a specificity of 72.8%, the area under the curve (AUC) 0.94, p < 0.001. Among the group of il patients, the differential diagnosis between SLE and pSS has a sensitivity of 68.6% and specificity of 64.8%, AUC 0.87, p<0.001. Graphic representation of the discriminant analysis is performed on Figure 1. The group of patients, meeting the criteria for both pSS and SLE, is between the main groups.
AB0004

INVESTIGATING THE ROLE OF ACCELERATED IMMUNESENESCENCE IN THE PATHOGENESIS OF RHEUMATOID ARTHRITIS

1Amsterdam Medical Center, Experimental Immunology, Amsterdam, Netherlands
2Karolinska Institute, Solna, Sweden
3Faculty of Medical Sciences, University of Newcastle, Newcastle, United Kingdom
4Department of Rheumatology, Leiden University, Leiden, Netherlands

Background: Advancing age is recognised as a major risk factor for autoimmune inflammatory conditions, such as Rheumatoid Arthritis (RA). Despite strong associations with older age we understand little of the role ageing processes play in disease pathogenesis in RA. The immune system undergoes a dramatic remodeling with age, termed immune senescence, which contributes towards increased risk of autoimmunity1. Previous research in patients with established RA has shown certain features of immune senescence, such as thymic atrophy and telomere shortening in T cells, at a younger age2,3.

Objectives: In this study we aimed to determine if immune senescence is seen in the very earliest stages of RA and therefore might be a contributor to RA pathogenesis rather than a result of the disease.

Methods: We have assessed aspects of the aged immune phenotype by immune-phenotyping and flow cytometry4 in adults with arthralgia (n=25), undifferentiated arthritis (UA; n=41), confirmed RA of less than 3 months (n=25) and more than 3 months duration (n=78) and compared these to age and sex matched healthy controls (n=38). Nanostring methodology was used to determine gene expression changes associated with the development of RA.

Results: We observed increased features of T and B cell immune senescence in DMARD-naive recently diagnosed RA patients driven by reduced naive T cells (p<0.01) and B cells (p<0.01), increased senescent (CD28-ve, CD57+ve, KLRG1+ve) T cells (p<0.01), an increased Th17/Treg ratio (p<0.01) and increased frequency of age-associated B cells (p<0.01). With the exception of naive T cell frequency, which was reduced in UA patients (p<0.05), these changes were not seen in the very early stages of RA, namely patients with arthralgia and UA. These data suggest that immune senescence only occurs once disease is established. Furthermore, using nanostring we have identified several biological ageing processes (DNA damage, autophagy) associated with this state of immune senescence in RA.

Conclusion: Accelerated immune ageing is an early feature of RA and biological ageing processes represent novel targets to modulate disease progression.

REFERENCES:

Disclosure of Interests: None declared

AB0035

FREQUENCY OF LYMPH NODE Stromal CELLS HLA-DR+ IS REDUCED IN INGUINAL LYMPH NODES FROM HUMAN DONORS WITH RHEUMATOID ARTHRITIS COMPARED TO CONTROLS

C. Grasso1,2 Amsterdam Medical Centre, Experimental Immunology, Amsterdam, Netherlands

Background: Rheumatoid arthritis (RA) is an autoimmune disorder where the immune system gradually damages a wide variety of body systems, including the skin, eyes, lungs, heart, and blood vessels1. Animal studies have shown that lymph node stromal cells (LNSCs) are key players in peripheral tolerance through their capacity to present self-antigen to T cells thereby controlling auto-reactivity and regulating autoimmunity and humoral response2. Although self-antigen presentation by human LNSCs needs to be formally proven in human, this study speculates that malfunctioning LNSCs might be associated with loss of tolerance in autoimmune diseases like RA.

Objectives: The objective of this study is to assesses and compare the frequency of main LNSC subsets in human lymph node needle biopsies of healthy controls, autoantibody positive individuals at risk of developing RA (RA-risk) and RA patients. We especially focussed on markers for antigen presentation expressed by LNSCs.

Methods: RA at risk, RA and healthy (n=1 participants underwent an ultrasound-guided inguinal LN needle core biopsy as previously described3. We included RA-risk participants (n = 6) with elevated IgM-RF and/or ACPA levels, but without any evidence of arthritis upon examination; RA patients (n =13) with established disease based on fulfilment of the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) 2010 criteria as assessed by the rheumatologist. For comparison we included healthy participant (n = 17) The healthy control was without any joint complaints and without elevated IgM-RF and/or ACPA level and without active viral infection or any history of autoimmunity or malignancy. To increase the number of healthy participants in the control group, we included lymph node biopsies from individuals receiving a kidney transplant (n=16). After collection, tissue samples were enzymatically digested to obtain a single cell suspension, followed by flow cytometry analysis with the following cell surface markers CD40, CD80, CD86, PD-L1, HLA-DR, CD45, PDPN, CD31, CD235a, Vialia dye.

Results: Antigen presentation related co-stimulatory molecules (CD40, CD80, CD86, PD-L1) and HLA-DR were detected at low levels. Blood endothelial cells having the highest expression of HLA-DR followed by LECs, FRCs, DNs. We observed a reduced frequency of HLA-DR+ lymph node stromal cell (CD45-, CD235a-) in RA and RA at risk compared to controls. After we found that FRCs, DNs, and BECs were reduced in RA and RA at risk compared to healthy control population.

Conclusion: Our findings show that the frequency of HLA-DR positive LNSCs is lower in RA-risk individuals and RA patients compared to controls. As HLA-DR is crucial to present self-antigens and promote self-tolerance, it will be of interest to investigate whether the antigen presenting capacity of LNSCs is diminished already before onset of disease and how we could restore this.

Disclosure of Interests: None declared
Innate immunity in rheumatic diseases

**AB0036** BUTYRIC ACID SUPPRESSES MIGRATION OF MONOCYTE-DERIVED DENDRITIC CELLS BY INHIBITING MDIA1-MEDITATED ACTIN POLYMERIZATION

T. Nagamoto1, T. Okano2, Y. Fujikawa3, Y. Ueda4, H. Yamada5, S. Sendo6, J. Saegusa1, 1Kobe University, Rheumatology, Kobe, Japan; 2University of California, Medicine, San Diego, United States of America

**Background:** Butyric acid is known to improve chronic inflammation such as inflammatory bowel disease and arthritis [1, 2]. Dendritic cells activate in inflammatory condition, migrate to regional lymph nodes, and activate naive T cells.

**Objectives:** In this study, we investigated the effect of butyric acid on the migration ability of monocyte-derived dendritic cells (moDC).

**Methods:** Human CD14+ Monocytes were purified by positive selection from PBMC using CD14 magnetic beads. Cells were cultured in the presence of GM-CSF (50 ng/ml) and IL-4 (20 ng/ml) for 5 days. After culturing for 5 days, cells were matured with LPS (1 μg/ml) for 24 hours. Butyric acid was administered at different dose or period. Surface antigen on moDC was analyzed by flow cytometry (BD FACS VERSE). Migration assay was performed on Boyden chamber CytoSelect 24-Well Cell Migration Assay (SUM). Actin was stained with Alexa Fluor 488 Phalloidin before and after migration assay. After administration with butyric acid assigned to each period and concentration, moDC were lysed for western blot analysis for evaluating signaling. Chemiluminescent signals were detected and calculated by Amersham Imager.

**Results:** We demonstrated that butyric acid decreased the CCR7 expression of moDC, which has a key role in DC homing to the lymph nodes and intestinal Peyer’s patches. We also showed that butyric acid decreased the migration ability of moDC.

Furthermore, moDCs cultured with butyric acid showed a round shape and poor formation of dendrites and pseudopodia. Then we studied the effect of butyric acid on cytoskeleton, which plays an important role in migration and pseudopodia formation of DCs. Polymerized Actin (F-Actin) staining revealed that butyrate suppressed actin polymerization of moDC in a dose dependent manner. CDC42 works important role of lamellipodia and membrane protrusions. RhoA is upstream of mDia1, and mDia1 was reported to accelerate actin nucleation and elongation. We revealed that butyrate decreased the protein expression of mDia1, RhoA, and CDC42, while beta actin was not downregulated, by Western blot analysis. Our results suggested that butyric acid suppresses migration of moDCs by inhibiting mDia1-mediated actin polymerization.

**Conclusion:** Butyric acid suppresses migration of moDCs by inhibiting mDia1-mediated actin polymerization.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1683

**AB0037** APE1 REGULATES THE MIGRATION OF FIBROBLAST-LIKE SYNIOCYTOCES FROM PATIENTS WITH RHEUMATOID ARTHRITIS

H. R. Lee, J. Kim, S. J. Yoo, J. A. Park, H. K. Joo, Y. R. Lee, S. Kim, B. H. Jeon, S. W. Kang, Chungnam National University School of Medicine, Research Institute for Medical Sciences, Daejeon, Korea, Rep. of (South Korea); 2Chungnam National University Hospital, Department of Internal Medicine, Daejeon, Korea, Rep. of (South Korea); 3Chungnam National University, Department of Physiology, College of Medicine, Daejeon, Korea, Rep. of (South Korea)

**Background:** The level of apurinic/apyrimidinic endonuclease 1 (APE1) is elevated in synovial fluids from patients with rheumatoid arthritis (RA). However, the role of APE1 in RA pathogenesis remains unclear.

**Objectives:** To explore whether APE1 affects cell migration through reactive oxygen species (ROS) level, fibroblast-like syncytios (FLS) from RA patients were stimulated with human recombinant APE1.

**Methods:** Synovial tissues were obtained from RA patients who were undergoing synovectomy or joint replacement. The isolated cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and maintained in a 5% CO2 incubator at 37 °C. FLS were used for experiments after three to six passages. Cells were stimulated with or without recombinant interleukin 17 (IL-17; 10 ng/ml), tumor necrosis factor alpha (TNF-α; 10 ng/ml), and long-lasting recombinant human APE1 (MR201; 1, 10, 100 ng/ml) for 24 h. ROS levels were analyzed using MitoSOX dye. Cell migratory ability was examined using wound migration assay.

**Results:** RA FLS treated with APE1 showed slightly decreased level of mitocondrial specific ROS. To induce pro-inflammatory conditions, RA FLS were incubated with IL-17 and TNF-α. These cytokines are highly detected in RA synovium and directly stimulate FLS activation. Stimulation with IL-17 and TNF-α upregulated ROS by 30% compared to control. Cytokines-induced increase of ROS was inhibited by 22% in APE1 treatment. When FLS cultures were approximatively 90% confluent, FLS monolayers were wounded with pipette tips and treated with IL-17/TNF-α and APE1 for 24 h. Cell migration was increased after treatment with IL-17/TNF-α. Cytokines-induced cell migration was markedly attenuated by APE1 treatment.

**Conclusion:** Recombinant APE1 markedly inhibited mitochondrial specific ROS production and IL-17/TNF-α-induced cell migration in RA FLS.

**REFERENCES:**


**Acknowledgements:** This research was supported by Chungnam National University Hospital Research Fund, 2021.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.959

**AB0038** DUAL TARGETING PEPTIDE RLS-0071 REDUCES AND INHIBITS MYELOPEROXIDASE (MPO) IN HEALTHY HUMAN VOLUNTEER

P. Kumar, K. Cunnion, N. Krishna, U. Thienel, P. Hair, J. Goss, C. Gabriel on behalf of ReAlta Life Sciences, Research, Norfolk, United States of America; 2Children’s Hospital of The King’s Daughters, Rheumatology, Norfolk, United States of America

**Background:** RLS-0071-101 was a first in human clinical trial to evaluate safety of the peptide RLS-0071 in healthy volunteers in a single ascending dose and multiple ascending dose format. RLS-0071, previously referred to as Peptide Inhibitor of Complement C1 (PIC1) is a dual-targeting peptide being developed for clinical use to moderate humoral and cellular inflammation via inhibition of complement activation and inflammatory effectors including, myeloperoxidase (MPO) and Neutrophil extracellular trap formation (NETosis). Humans that are otherwise asymptomatic are considered at risk for cardiovascular complications if they have a plasma MPO level of > 420 pmoL. A post hoc analysis of plasma samples from subjects participating in RLS-0071-101 identified an individual with mildly elevated baseline MPO level (142 pmoL).

**Objectives:** Evaluate if RLS-0071 dosing would change MPO level or activity in a subject with elevated baseline MPO.

**Methods:** Frozen plasma samples prepared from blood collected by venipunture into K2EDTA tubes (BD) was utilized to determine MPO quantity and activity levels. MPO quantity in the plasma was analyzed using a human MPO ELISA kit (BMS2038IN, Invitrogen) and MPO activity within the plasma was analyzed using a fluorescence-based myeloperoxidase assay kit (K745-100, BioVision).

**Results:** Upon screening 54 subjects from RLS-0071-101 we identified one individual with a mildly elevated MPO level at baseline, a 21-year-old white female with BMI of 21.7. The subject received 9 intravenous infusions of RLS-0071 each at a dose of 10 mg/kg. Her vital signs and body temperature remained normal.
throughout the study and the only blood laboratory abnormality were a mildly low plasma protein concentration of Day 2 and Day 4 which was noted both among recipients of the peptide and placebo subjects. Analysis of MPO blood concentrations demonstrated a mildly elevated baseline plasma MPO concentration that decreased after multiple doses of RLS-0071 with partial recovery to baseline 24 hours after cessation of dosing. MPO activity analyzed using a fluo-
rescence-based myeloperoxidase assay kit demonstrated an elevated baseline plasma MPO activity level that decreased after multiple doses of RLS-0071 with partial recovery after 24 hours.

Conclusion: These results suggest promise for RLS-0071 to reversibly moder-
ate plasma MPO activity and potentially affect MPO-mediated diseases including acute coronary syndrome (ACS), atheromatous plaque vulnerability and auto immune conditions.4,5,6,7

REFERENCES:
[4] Malle, E.; Marsche, G.; Panzenboeck, U.; Sattler, W. Myeloperoxidase-medi-


AB0039 MONOCYTE EXTRACELLULAR TRAPS: A NEW POTENTIAL DIAGNOSTIC BIOMARKER IN RHEUMATOID ARTHRITIS?

I. Zborovskaya1, S. Bedina1, E. Mozgovaya1, A. Trofimenko1, M. Mamus1, S. Spitsina1.

1 Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy, Clinical biochemistry lab, Valogorod, Russian Federation

Background: Studies demonstrating the important role of neutrophil extracellu-
lar traps (NETs) in the pathogenesis of autoimmune diseases, including rheumatoid arthritis (RA), have been published extensively in recent years. The researchers are also discussing the possibility of considering NET as a source of potential diagnostic biomarker in RA. As compared with NETs, the monocyte extracellular traps (METs) formation by mononuclear phagocytes, although they have also been implicated in the development of autoimmune reactions, has been studied insufficiently. No studies have been reported on the MET formation in active RA patients.

Objectives: Assessment of METs generation by peripheral blood monocytes from RA patients in association with the disease exacerbation.

Methods: The research was carried out in agreement with the WMA Declaration of Helsinki principles after the local ethical board approval. Circulating monocytes were isolated with one-step density gradient centrifugation using double layers of the in-lab-made ficoll-amidotrizole gradient. Composition of isolated cellu-
lar fractions, their viability, and non-specific activation were evaluated by light microscopy using common Romanowsky-Giemsa staining, trypan blue exclu-
sion test as well as NBT test. METs were induced by LPS. Monocyte fractions contained low extents of activated and dead cells. Spontaneous and induced formation of extracellular traps was assessed using fluorescence microscopy [1]. Results were presented as values (95%CI).

Results: 30 healthy volunteers (9 males and 21 females, mean age 37.2 years) were enrolled as a reference group. 37 patients (6 males and 31

females, mean age 42.7 years) with verified RA according to the ACR/EULAR 2010 criteria were included in the study. RA disease activity was assessed using DAS28 score did not exceeded 2.6 in every patient at the inclusion timepoint. In 16 (15.4%) patients, the activity of DAS 28 exceeded 3.2 at subsequent visits (after 3, 8 and 12 months). Spontaneous and induced MET formation by isolated monocytes in RA patients (DAS ≥8≥2.6) was 8.7 (8.3-
9.1%) and 26.2 (24.7-27.9%), respectively. Spontaneous and induced MET formation by isolated monocytes in RA patients (DAS ≥8≥3.2) was 18.1 (17.8-
18.4%) and 38.2 (36.0-38.4%), respectively. Spontaneous and induced MET formation by isolated neutrophils in active RA patients (DAS 28>3.2) was significantly higher than in inactive RA patients and in comparison to the reference group. Induced MET formation was also significantly higher than spontaneous one (p<0.05). Monocytes did not demonstrate any difference between ACPA-positive and ACPA-negative RA patients in their MET produc-
tion. The growth rate of spontaneous MET formation was 114.7%, for induced MET formation – 44.2%. The growth rate of spontaneous MET formation is 2.6 times higher than the induced MET formation.

Conclusion: METs formation by isolated monocytes can be considered as a new potential diagnostic biomarker associated with RA flare. Further study of the mechanisms of MET formation and their composition may improve our understanding of the role of monocytes and METs in the patho-
genesis of RA.

REFERENCES:

Disclosure of Interests: None declared


AB0040 STUDYING THE MACROPHAGE ACTIVATION AND THE INTIMA-MEDIA THICKNESS OF THE CAROTID ARTERIES IN UNRETTED PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS (PRELIMINARY DATA)

E. Gerasimova1, T. Popkova1, T. Kirichenko2, A. Markin2, I. Kirillova3, A. Orekhov3,1.

1V.A. Nasonova Research Institute of Rheumatology, Department of systemic rheumatic disease, Moscow, Russian Federation; 2Research Institute of Human Morphology, Laboratory of Cellular and Molecular Pathology of the Cardiovascular System, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Laboratory of systemic rheumatic diseases, Moscow, Russian Federation

Background: Autoimmune Rheumatic Diseases (ARDs) occur with a high risk of atherosclerosis development. The macrophages are at the same time a part of the inflammatory response, and also tightly linked to the foam cell formation, thus taking part in both crucial for atherosclerosis processes.

Objectives: To evaluate the macrophage activation, and the intima-me-
dia thickness (IMT), subclinical atherosclerosis of the carotid arteries in untreated pts with rheumatoid arthritis (RA) and systemic lupus erythema-
tosus (SLE).

Methods: Thirty six untreated RA pts (30F/6M) and 36 untreated SLE pts (31F/5M) were enrolled.

RA pts had median age of 39 years (range) (33-45), disease duration of 2.5 years (1-5), moderate clinical disease activity DAS of 28 5.3 (3.5;5.8), SDAI of 17 (15;19), HAQ of 1 (0.75;1). SLE pts had median age of 37 years (range) (32-41), disease duration of 3.5 years (1-11), SLEDAI 2K of 7 (4-8), BILAG of 14.5 (10.2-23).

Isolation of monocytes was carried out according to the standard procedure for obtaining a leukocyte fraction in a Ficoll gradient and subsequent selec-
tion of CD14 + cells using magnetic separation. The growth rate of spontaneous MET formation was 2.6 times higher than the induced MET formation.

Conclusion: METs formation by isolated monocytes can be considered as a new potential diagnostic biomarker associated with RA flare. Further study of the mechanisms of MET formation and their composition may improve our understanding of the role of monocytes and METs in the patho-
genesis of RA.

REFERENCES:

Disclosure of Interests: None declared

Scientific Abstracts

In RA pts, there was a significant correlation between carotid m-IMT and age (R=0.76), level of total cholesterol (R=0.51), LDL cholesterol (R=0.27), systolic blood pressure (R=0.71), diastolic blood pressure (R=0.76), aMCV levels (R=0.73), p<0.05 in all cases. No correlation between carotid m-IMT/M-IMT and the disease’s duration, stage or activity was found in RA pts. In SLE pts, carotid m-IMT was associated with the mean SLICC/ACR Damage Index score (R=0.50, p<0.01), with antibodies to cardiolipin (aCL) IgG levels (R=0.42, p=0.02), and with antibodies to beta2-glycoprotein 1 (anti-beta2GP1) IgG levels (R=0.49, p<0.01). No correlation between carotid m-IMT/M-IMT and the traditional CVR factors and disease’s activity was found in SLE pts. No association was found between the carotid m-IMT/M-IMT and macrophage activation.

Conclusion: No differences in macrophage activation were found in RA and SLE pts. Macrophage activation was independent of CVR and ARD-related factors. Subclinical atherosclerotic lesions of the carotid arteries were observed in a every fifth untreated RA and SLE pts. Carotid m-IMT correlated with traditional CVR factors and disease’s activity was found in SLE pts. No association was found between the carotid m-IMT/M-IMT and macrophage activation.

Disclosure of Interests: None declared


THE PHENOTYPE OF PERIPHERAL BLOOD DENDRITIC CELLS OF PATIENTS WITH ADULT-ONSET STILL’S DISEASE COMPARED TO HEALTHY DONORS AND PATIENTS WITH PSORIATIC ARTHRITIS

S. Schnitte1, T. Funk1, J. Henes2, S. Saur2. 1UKT, Department of Medical Oncology, Hematology, Immunology, Rheumatology and Pulmonology., Tübingen, Germany; 2UKT Rheumatology and Auto-inflammatory Diseases and Department of Internal Medicine II (Hematology, Oncology, Immunology and Rheumatology), Centre for Interdisciplinary Clinical Immunology, Tübingen, Germany

Background: Adult-onset still’s disease (AOSD) is a rare autoinflammatory disease. A triad of high fever, arthritis and skin rash is described, but multiple forms of manifestation, as the lack of detectable biomarkers, aggravate making the diagnosis (1).

Psoriatic arthritis (PsA), another autoimmune disease with jointal manifestation, affects approximately 30% of all patients with psoriasis (2).

Dendritic cells (DCs) are potent antigen presenting cells linking adaptive and innate immunity. In various autoimmune diseases alterations of DCs were detected (4).

Objectives: The etiology and effect of peripheral blood DCs on the arthritis in both diseases is not cleared yet (1,3). This project tried to examine alterations of DCs in AOSD patients compared to those with PsA and a healthy control group (HC).

Methods: 13 patients with AOSD were analysed and compared. Leukocytes were separated with density gradient centrifugation and sorted with flow cytometry. The contingent of DC subsets in the peripheral blood (pDCs, CD1c+DCs, CD141+DCs) was compared between AOSD patients and the other two groups (n=12).

Monocytes of the peripheral blood were incubated with IL-4 and GM-CSF to differentiate to DCs. The addition of lipopolysaccharides helped gaining immature (n=11) and mature (n=9) DCs. Their phenotype was characterized by CD1a, CD206, Osteoactivin (OA), CCR7, CD14, DC sign, CCR7, CD14, CD40, HLA-DR, CD80, CD83, CD86. The expression levels of the surface proteins were again compared.

Results: The DC subset rates did not differ significantly between AOSD patients and both other groups.

OA expression on immature DCs is statistically different between HC compared to patients with AOSD (p=0.0128). The expression levels of AOSD patients and those with PsA do not differ significantly.
The interaction of CD80 and CD86 with CD28 is necessary to produce IL-6. The pro-inflammatory effect is limited by CD80/CD86 itself (6). CD80, in contrast to CD86, is expressed differentially in patients with AOSD and PsA. As CD80 and CD86 function as cofactors, an alteration of both might have been expected.

REFERENCES:

Disclosure of Interests: Sarah Schnitte Grant/research support from: The project was financially supported by Novartis, Tanja Funk: None declared, Jörg Henes: None declared, Sebastian Saur: None declared

AB0042
OPTIMAL CONDITIONS FOR THE DETECTION OF INFILAMMASOME ACTIVATION IN CD14+ CD16- MONOCYTES FROM HUMAN BLOOD BY FLOW CYTOMETRY
N. Wittmann1, N. Mishra2, A. K. Behrendt1, L. Bossaller2, A. Meyer-Bahlburg1.
1University Medicine, University of Greifswald, Pediatric Rheumatology, Department Pediatric and Adolescent Medicine, Greifswald, Germany;
2University Medicine, University of Greifswald, Section of Rheumatology, Department Medicine A, Greifswald, Germany

Background: The inflammasome activation is linked to the aggregation of the adaptor protein ASC into a multimeric structure, known as the ASC speck. The aggregation of cytosolic ASC into ASC specks is therefore used as a readout parameter for inflammasome activity. The direct detection of ASC speck formation on a single cell basis through flow cytometry, can analyze inflammasome activity in a clinical setting. Objectives: Investigating the optimal conditions for a reliable identification of inflammasome activated ASC speck positive cells ex vivo using flow cytometry.

Methods: Freshly donated blood from five different healthy donors was used for all experiments. The choice of anticoagulant, storage time and storage temperature were examined. PBMCs were isolated from blood collecting tubes with ethylenediaminetetraacetic acid (EDTA) or lithium heparin (LH). PBMCs were also isolated from LH blood stored at 4 °C, room temperature (RT), 37 °C and after different storage times. After isolation, PBMCs were also isolated from LH blood stored at 4 °C, room temperature, for all experiments. The choice of anticoagulant, storage time and storage temperature until unspecific ASC speck signals occur was investigated. A significant increase in ASC speck positive CD14+CD16- monocytes was detected after 4 h storage at RT compared to directly processed samples and the number of ASC speck positive monocytes further accumulated over time. The incubation with nigericin in PBS leads to a significant increase in ASC speck positive CD14+CD16- monocytes and THP-1 cells compared to incubation in RPMI media.

Conclusion: The flow cytometric detection of ASC specks is adapted for practical clinical usability. To reduce background signals, LH- instead of EDTA blood collecting tubes are recommended. The LH blood should be processed within 2 h after blood collection and be stored at RT. To avoid nonspecific activation and formation of ASC specks, the PBMCs should be isolated directly after venipuncture and fixed immediately. It is also possible to freeze the PBMCs until further usage. However, this will cause some loss of ASC speck positive cells. With these settings, clinical samples can now be examined.

REFERENCES:

Acknowledgements: We thank all healthy donors who participated in this study. The authors thank Jana Gramenz (University Medicine Greifswald, Pediatric Rheumatology and Immunology, Greifswald, Germany) for excellent technical assistance.

Disclosure of Interests: None declared

AB0043
THE IMPACT OF ANTI-RO52 ANTIBODIES ON THE EXPRESSION OF ANTIVIRAL RESPONSE-RELATED GENES – PRELIMINARY STUDY
A. Opinc1, J. Sarnik1, Z. Lukasik1, J. Makowska1.
1Medical University of Lodz, Department of Rheumatology, Lodz, Poland

Background: Ro52, also known as TRIM21, is an essential agent of the innate host defence, especially of the antiviral responses. It was found to be induced by type I and II interferons. Due to its activity of E3 ligase, TRIM21 is involved in the ubiquitination of several IFN regulating factors (IRFα)9. Ro52 enables antibody-dependent intracellular neutralization as a high-affinity Fc immunoglobulin receptor. The auto-ubiquitination of the TRIM21-related complex induces signaling pathways with the production of pro-inflammatory cytokines1. Anti-Ro52 autoantibodies are found in various autoimmune conditions. The hypothesis of our project assumes that viral infections in genetically susceptible individuals trigger overexpression of Ro52, followed by the production of autoantibodies, which suppress its function as the negative regulator of type I interferon responses, leading to enhanced production of proinflammatory agents that uphold autoimmune process.

Objective: To compare the expression of antiviral response-related genes in patients with anti-Ro52 autoantibodies and healthy volunteers in order to assess the significance of anti-Ro52 in the antiviral defence.

Methods: Anti-Ro52+ patients, hospitalized at the Department of Rheumatology, Medical University of Lodz or treated in the united outpatient clinic were recruited. 19 patients with anti-Ro52 antibodies were included in the study group (mean age: 54.2 years; F:M ratio 14:5). Among them, 5 patients were diagnosed with primary Sjogren syndrome, 4 with idiopathic inflammatory myopathies, 4 with systemic lupus erythematosus, 1 with rheumatoid arthritis, 3 with overlapping syndromes and 1 was undergoing diagnosis of connective tissue disease at the time of the recruitment. Data on the diagnosis, clinical symptoms and laboratory results were collected from the patients and the available medical records. 10 healthy individuals without autoimmune disorders were recruited to the control group. Whole blood samples were collected from both anti-Ro52+ patients and healthy controls, PBMCs were isolated using Biocoll reagent. RNA was isolated from each sample with RNeasy and cDNA synthesis was performed with RevertAid™ H Minus First Strand cDNA Synthesis Kit. The mRNA expression levels of TRIM, IRF3, IRF5, IRF7, NFκB, RIG-1, MDAS genes were examined by quantitative real-time PCR with TaqMan™ Universal PCR Master Mix according to the manufacturer’s instructions. The expression levels of genes relative to that of GAPDH were calculated by delta Ct (ΔCt). The ΔCt value is the Ct value of the target gene subtracted its Ct value of GAPDH. ΔCt – Ct (Gene) – Ct (GAPDH). Therefore, the smaller the ΔCt values, the higher the expression levels of the target mRNA. The Mann–Whitney rank sum test was used to compare the control group and anti-Ro52+ patients.

Results: The ΔCt values for TRIM, IRF3, IRF5, IRF7, NFκB, RIG-1, MDAS were found to be lower in the anti-Ro52+ group as compared to the control group, indicating higher mRNA expression of these genes in anti-Ro52+ patients. Statistical significance was reached for all of the examined genes but IRF3. Detailed results are presented in Table 1.
Table 1. The ΔCt values for antiviral response-related genes in anti-Ro52+ patients and healthy controls. P – statistical significance

<table>
<thead>
<tr>
<th></th>
<th>Anti-Ro52+ group ΔCt</th>
<th>Control group ΔCt</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRIM</td>
<td>4.91</td>
<td>6.64</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IRF3</td>
<td>5.70</td>
<td>5.92</td>
<td>0.8482</td>
</tr>
<tr>
<td>IRF5</td>
<td>4.45</td>
<td>5.68</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>IRF7</td>
<td>5.14</td>
<td>6.54</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>NFκB</td>
<td>4.78</td>
<td>5.66</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>RIG-1</td>
<td>3.77</td>
<td>4.33</td>
<td>0.0188</td>
</tr>
<tr>
<td>MD5</td>
<td>5.08</td>
<td>6.82</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Conclusion: Presented results confirm the enhancement of the antiviral defence in anti-Ro52+ patients. As overexpression is observed independently in various connective tissue diseases, impaired response to viral infections via Ro52 pathways could indicate a common trigger factor of autoimmunity.

REFERENCES:

Disclosure of Interests: None declared


AB0044 REDUCED PERIPHERAL BLOOD MYELOID CELLS IN PATIENTS WITH VEXAS SYNDROME

V. Jachiet1, 2, L. Ricard3, P. Hirsch4, F. Malard5, L. P. Zhao6, L. Adès7, P. Fenaux8, O. Fairn9, M. Moorthy10, B. Gaugler11, A. Mekinian12, 3. Sorbonne Université, AP-HP, Hôpital Saint Antoine, INSERM UMR938, Paris, France; 2 Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service de Médecine Interne et Inflammation-Immunopathologie-Biothérapie Department (DMU 3), Paris, France; 3 Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service d’Hématologie Clinique et de Thérapie cellulaire, Paris, France; 4 Sorbonne Université, AP-HP, Hôpital Saint Antoine, Service de Médecine Interne et Inflammation-Immunopathologie-Biothérapie Department (DMU 3), Service d’Hématologie Biologique, Paris, France; 5 Université de Paris, AP-HP, Hôpital Saint Louis, Département d’hématologie, Paris, France

Background: Systemic inflammatory or dysimmune diseases (SIDDs) are encountered in up to a quarter of patients with myelodysplastic syndromes (MDS). Recently identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, associated with somatic mutations in UBA1, encompasses a range of severe inflammatory conditions along with hematologic abnormalities, including myelodysplasia. Only limited data are available on the pathophysiology of MDS-associated SIDDs, and especially about the role of different myeloid cell subsets.

Objectives: The aim of this study was to describe the phenotype of myeloid immune cells (dendritic cells and monocytes) in MDS patients with associated SIDDs, and to compare their distribution with MDS patients without SIDDs and controls.

Methods: Phenotype analysis by flow cytometry from PBMCs of 14 MDS patients with SIDDs, 23 MDS patients without SIDDs and 7 controls. Eight of the 14 MDS/SIDDs patients (57%) had a somatic UBA1 mutation.

Results: In this study analyzing peripheral blood myeloid immune cells in MDS patients with and without SIDDs, we observed a quantitative reduction of different DC and monocyte subsets in MDS/SIDDs patients, especially in patients with active SIDDs and above all in patients with newly described VEXAS syndrome.

Conclusion: Further functional studies are warranted to better understand the mechanisms and the consequences of the phenotypic modulations of immune myeloid cells in the pathophysiology of MDS-associated SIDDs, especially in VEXAS syndrome.

Disclosure of Interests: None declared


Osteo arthritis, aetiology, pathology and animal models

AB0045 EFFECTS OF AEROBIC EXERCISE AND PREBIOTIC FIBRE SUPPLEMENTATION ON THE VASTUS LATERALIS AND SOLEUS MUSCLES IN A RAT MODEL OF DIET-INDUCED OBESITY

H. de Brito Fontana1, 3, J. Lourdes Rios2, R. A. Seerattan2, V. Joumaa3, D. A. Hart4, K. Reimer3, W. Herzog5 on behalf of Human Performance Laboratory. 1 Universidade Federal de Santa Catarina, Campus Florianópolis, School of Biological Sciences, Florianópolis, Brazil; 2 University of Calgary, Human Performance Laboratory, Calgary, Canada; 3 University of Calgary, Human Performance Laboratory, Calgary, Canada

Background: A high-fat/high-sucrose (HFS) diet leads to osteoarthritis-like damage in the knee and shoulder (Collins et al., 2018), and to a low-level systemic inflammation that is accompanied by a decrease in insulin sensitivity. Recently, we demonstrated in a rat model, that when prebiotic fibre supplementation, aerobic exercise, or their combination, are started at the onset of the HFS diet exposure, the development of the osteoarthritis-like lesions in the knee joints and the metabolic dysfunction is prevented (Rios et al., 2019).

A central role in the altered metabolic state of rats fed a HFS diet is thought to be played by skeletal muscle (Collins et al., 2018). Besides the detrimental effect on metabolic and inflammatory regulation, muscular dysfunction might be a contributor to the decline in running endurance and coordination observed with prolonged exposure to a low quality diet (Clayton et al., 2022).

Objectives: To evaluate the changes in insulin sensitivity and vastus lateralis and soleus muscle composition in a HFS diet rat model and determine whether the expected muscle alterations can be prevented with a prebiotic fibre supplementation, aerobic exercise, or their combination.

Methods: Twelve-week-old male Sprague Dawley rats fed a high-fat/high-sucrose diet (HFS, Diet #102412, Dyets) were randomized into a sedentary (HFS, n=12), moderate aerobic exercise (HFS+E, n=12), prebiotic fibre supplementation (HFS+F, n=12), or moderate aerobic exercise combined with prebiotic fibre supplementation (HFS+F+E, n=12) group for 12 weeks. Eight chow-fed (Diet #5001) age- and sex-matched animals were used as controls.

Whole body insulin sensitivity (composite insulin sensitivity index – C ISI) was determined at the end of the intervention period and, after sacrifice, the VL and soleus muscle composition was evaluated through a triglyceride colorimetric assay and histological analysis of collagen with picrosirius red staining. Non-parametric Kruskal-Wallis testing with pairwise comparisons was used to compare groups.

Results: HFS group rats had less than half (40%, p = 0.001) of the whole-body insulin sensitivity of control rats while rats in the HFS+F+E and HFS+F groups were similar to control. Rats that were fed the HFS diet showed increased VL (p = 0.033) but not soleus muscle composition was evaluated through a triglyceride colorimetric assay and histological analysis of collagen with picrosirius red staining. Non-parametric Kruskal-Wallis testing with pairwise comparisons was used to compare groups.

Conclusion: While a positive effect of prebiotic fibre and exercise in managing metabolic disturbance was present with a clear recovery of insulin sensitivity to control levels in the groups that were fed the HFS diet, the protective effect of exercise and prebiotic fibre that has been previously described for knee joints in this model was not observed for the VL and soleus muscles. The HFS diet led to alterations in muscle composition that seem to be muscle-specific

Osteo arthritis, aetiology, pathology and animal models
and cannot be prevented by combining prebiotic fibre or exercise with the HFS diet.

REFERENCES:

Acknowledgements: This work was supported by the Canadian Institutes of Health Research # RT739475 (WH) and MOP 115076, the Canada Research Chair Programme (WH), the Alberta Innovates Health Solutions Osteoarthritis Team Grant (DAH, WH), Alberta Innovates Health Solutions, Kiliam Foundation (WH), Albertova Innovates (JLR), and the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

DOs and Disclosures: None declared.

AB0046 RESISTANCE TO OXIDATIVE DEGRADATION OF A FORMULATION COMBINING HYALURONIC ACID AND Niacinamide

F. Hadj-ab 1, Albomed GmbH, Research and Development, Schwarzenbruck, Germany

Background: Hyaluronic acid plays a major role in the homeostasis of cartilage. In cases of osteoarthritis, hyaluronic acid is subjected to significant oxidative stress linked to the inflammation cascade leading to drastic diminution of its quantity at the level of the joint. This decrease in hyaluronic acid reduces dramatically the lubricating properties of the synovial fluid. Several preparation methods have been developed to further stabilize the hyaluronic acid used as viscosupplement such as crosslinking or adding adjuvants.

Objectives: A new formulation intended for intra-articular administration has been developed consisting of a combination of hyaluronic acid and vitamin B3 commonly called Niacinamide. The addition of niacinamide has a protective effect against hyaluronic acid under heat stress and under oxidative stress.

Methods: In order to assess the resistance to free radials, 4 products were compared (HA 2.2%+vitamin B3 vs HA at 2.2% vs 2 cross-linked HA). 1 gram of sample were placed on Peltier Plate of a Rheometer – TA instrument and submitted to a temperature of 37°C. 50µL of H2O2 was introduced on the sample. The rheological properties of the mixture were followed-up at a shear stress of 1Hz until full degradation of the sample (i.e. until reaching a viscosity close 0). The degradation was calculated at each time point and plotted on a graph to compare the enzymatic degradation kinetics.

To assess the thermal resistance, 2 products were compared (HA 2.2%+ vitamin B3 vs HA at 2.2%). The samples consisting of 2 grams of gel packaged in glass syringe were placed in a dry oven at 50°C. The viscosity was measured at 3 different timepoints.

Results: This study demonstrates a significant better resistance to free-radical degradation for the HA+Niacinamide vs comparative products. The viscosity follow-up under heat stress demonstrated that the adjuection of Niacinamide does have a positive effect in preserving the HA viscosity consistently throughout time.

Conclusion: Vitamin B3 commonly called Niacinamide exhibits a dual positive effect when associated with Hyaluronic Acid. The study demonstrates a better resistance to oxidative degradation for the HA+Niacinamide most probably due to the antioxidant effect of Niacinamide. This study confirmed the adjuection of the Niacinamide into the HA-based gel formulation does increase the stability of HA against thermal degradation.

Disclosure of Interests: None declared.


AB0047 CARTILAGE DEGRADATION STATUS OF KNEE OSTEARTHRITIC PATIENTS CAN BE PREDICTED BY CHONDROCYTE GENE EXPRESSION ANALYSIS

L. Tíyi 1 , L. Triger 1 , A. Ribes 1 , P. Camps 1 , R. Torres-Claramunt 2, J. O. Monllau 1,2 , J. Monfort 3 on behalf of HOLOA 

1MIM (Hospital del Mar Medical Research Institute), Barcelona, Infarnamation and Cartilage Cellular Research Group, Barcelona, Spain; 2Hospital del Mar, Servei de Cirugia Ortopédica i Traumatologia, Barcelona, Spain; 3Hospital del Mar, Servei de Reumatologia, Barcelona, Spain

Background: Osteoarthritis (OA) is the most common degenerative joint disease, but its pathogenesis is still poorly understood. OA is characterized by articular cartilage loss due to an imbalance in anabolic and catabolic gene expression of the chondrocyte, together with aberrant expression of transcription factors and inflammatory mediators.

Objectives: We aim to evaluate de genes implicated in the chondrocyte failure regarding the four issues assessed to evaluate cartilage integrity using Mankin score (MsK): surface integrity, cellularity, cell cloning and staining.

Methods: Knee OA (KOA) patients aged 60-75 undergoing a total knee replacement, were recruited. At surgery, tibial plateau and femur condyles were deposited in DMEM medium and sent to the laboratory within 4 hours of the extraction. Punches from areas located at low, medium and high load (1) were excised from each sample (approximately 11 areas per patient). For RNA analysis, punches were kept in RNA later at -20°C until analyzed. RNA extraction, cDNA synthesis and cDNA amplification of the selected genes were performed previous to gene expression quantification by OpenArray Assay with custom plates. ΔCt was analyzed by ExpressionSuite V1.3 using 6 housekeeping genes. For histology study, punches were fixed in formalin and embedded in paraffin. Sections of 4 µm were stained with hematoxilin eosin and Safranin O-Fast Green. Slices were scored using the modifed MsK (2) by 3 independent observers. R (v3.3.2) analysis was used to explored the results with principal components analysis (PCA) and linear regression (LRL).

Results: Surgical samples were obtained from a total of 27 patients and 219 different areas were analyzed. ΔCt of the 51 genes analyzed by PCA showed that 9 components were enough to represent >80% of variance of the model. The genes associated with each component are summarized in Table 1. LR shows that second and first component were significantly associated to all or most of the fields included in the MsK, respectively. In contrast, component 4, 5 and 9 were not associated with any field. Lower expression of genes represented in component 1 (mainly related with extracellular matrix content) are associated with higher MsK values. On the other hand, component 2 summarizes data of genes mainly related with factors regulating cell metabolism. In this case, higher expression of TNFαP6, NGF, IGFBP1, CRLF1, TNFα and lower expression of ACAN, COL11A2, COL2A1, COL10A1, SOX9 and TGFβ1, among others, are associated with increased MsK values.

Table 1. Genes that most contribute (by order) to component 1 & 2 (due to space limitation). Data of LR analysis for each component and MsK value. Significant association marked in bold.

<table>
<thead>
<tr>
<th>Component</th>
<th>Genes</th>
<th>Surface integrity</th>
<th>Cellularity</th>
<th>Cell cloning</th>
<th>Staining</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SERPINE2, COL2A2, OGN, COL5A, TIMP3, BMP6, C1RF1, TIMP2, WISP1, ST3GAL1, SERPINE1, TNSFR10A, ASPN, NFG, CD44, TNFRSF11B, TGFα, ADAMTS5, COL15A1, LUM, TNFAIP6, PTGS2, BMP2</td>
<td>-0.092; 0.006 -0.025; 0.047 -0.028; 0.078 -0.043; 0.015</td>
<td>0.261; 2.54 0.050; 0.010 0.066; 0.005 0.072; 0.007 10^{-7}</td>
<td>0.0001</td>
<td>0.001</td>
</tr>
<tr>
<td>2</td>
<td>ACAN, GPC5, CFH, FGFR3, COL11A2, TGFβ1, GREM1, TNFAIP6, NFG, SOX9, IGFBP1, MMP3, FGF2, C1RF1, TNFα, COL2A1, COL10A1</td>
<td>-0.174; 0.003 -0.029; 0.191 -0.076; 0.006 0.004; 0.898</td>
<td>0.068; 0.410 -0.019; 0.543 -0.065; 0.161 -0.021; 0.627</td>
<td>0.043; 0.028</td>
<td>0.062; 0.289</td>
</tr>
<tr>
<td>3</td>
<td>-0.082; 0.384 -0.051; 0.146 0.002; 0.644 0.052; 0.003 0.800; 0.171</td>
<td>-0.120; 0.266 -0.090; 0.032 0.010; 0.839 -0.113; 0.052</td>
<td>-0.014; 0.274 0.006; 0.892 -0.198; 0.001 0.131; 0.047</td>
<td>0.030; 0.780</td>
<td>0.020; 0.000</td>
</tr>
</tbody>
</table>

Conclusion: There is a correlation between the expression level of the studied genes and the MsK values, although the role played by each gene might be
Background: Osteoarthritis (OA) is one of the most common joint disorders and is characterized by the degeneration and loss of articular cartilage with chronic arthritis of the joint edge and subchondral bone. OA is causally influenced by several factors, including age, gender, familial susceptibility, as well as local biomechanics, cartilage cell apoptosis, and the action of degenerative enzymes. Despite intensive research, there are still few effective therapeutic approaches.

Objectives: In the rat OA model, shikonin was shown to inhibit inflammatory processes, MAPKs, and IL-6/STAT3 downstream regulation in human healthy chondrocytes and primary OA chondrocytes. For the study of inflammatory processes, we performed a proteome profile screening assay. As MAPK signaling pathways play a key role in cartilage destruction in OA, we analyzed the effects of shikonin and its derivatives using protein expression analysis of the phosphorylation pattern and the corresponding downstream gene regulation using RT-qPCR.

Results: Both HC and pCH-OA showed a dose-dependent inhibition of cell viability after treatment with shikonin derivatives, whereby the strongest effects were found for shikonin with IC50 values of 1.2 µM and 1.3 µM, respectively. Shikonin counteracts inflammatory response caused by IL-1β by massively reducing the expression of pro-inflammatory mediators.

Conclusions: Our results demonstrate for the first time that shikonin and its derivatives acetylshikonin and cyclopropylshikonin on inflammation, MMP expression, and regulation of MAPK signaling in human OA chondrocytes.

Methods: Viability was analyzed using the CellTiter 96 AQeous Luminescence Assay on human healthy chondrocytes (HC) and primary OA chondrocytes (pCH-OA). For the study of inflammatory processes, we performed a proteome profile screening assay. As MAPK signaling pathways play a key role in cartilage destruction in OA, we analyzed the effects of shikonin and its derivatives using protein expression analysis of the phosphorylation pattern and the corresponding downstream gene regulation using RT-qPCR.

Results: Both HC and pCH-OA showed a dose-dependent inhibition of cell viability after treatment with shikonin derivatives, whereby the strongest effects were found for shikonin with IC50 values of 1.2 µM and 1.3 µM, respectively. Shikonin counteracts inflammatory response caused by IL-1β by massively reducing the expression of pro-inflammatory mediators.

Conclusions: Our results demonstrate for the first time that shikonin and its derivatives acetylshikonin and cyclopropylshikonin on inflammation, MMP expression, and regulation of MAPK signaling in human OA chondrocytes.
OA patients had higher NAD levels than at baseline, but significantly lower than non-OA>50y controls (Figure 1).

Figure 1. Monocyte NAD⁺ content at baseline and 1 hour after nicotinamide supplementation. *p<0.05 **p<0.01 ***p<0.001.

**Conclusion:** A specific plasmatic and synovial adipokine signature characterizes OA and patients with more severe disease. In monocytes there is a age-related reduction of INAMPT and anti-inflammatory cytokine expression, whereas eNAMPT is higher in elderly compared with younger subjects. In non-OA>50y subjects there might be an increase of INAMPT activity which leads to NAD⁺ production, while in OA patients this mechanism seems to be impaired and can be only partially enhanced by nicotinamide supplementation, leading to reduced intracellular redox efficiency. These results suggest that NAMPT activity might be a key component of the mechanisms underlying inflammation in OA patients.

**REFERENCES:**

**Disclosure of Interests:** Francesca Motta Consultant of: Thermo Fisher, Barbara Durante: None declared, Chiara Pandolfo: None declared, Carlo Selmi Speakers bureau: AbbVie, Amgen, Astra-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Consultant of: AbbVie, Amgen, Astra-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Grant/research support from: AbbVie, Amgen, Janssen, Pfizer, Antonio Sica: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3165

**AB0052**

**CHANGES IN THE MOLECULAR ARCHITECTONICS OF PLASMA MEMBRANES (PM) OF NEUTROPHILIC LEUKOCYTES (NL) FROM SYNOVIAL FLUID (SF) IN GONARTHROSIS (GA)**

V. Shishkin1, Y. Malenkov1, V.V. Shishkin1, G.V. Kudryavtseva1. Saint Petersburg state University, Diagnostic of functional systems, Saint Petersburg, Russian Federation

**Objectives:** Changes in the spectrum of phospholipids (PL) in NL membranes correlate with the activity of their metabolic and phagocytic processes. The aim of the work was to study PL homeostasis of NL from SF in GA.

**Methods:** SF of knee joints of 12 patients with GA with active synovitis and 7 conditional donors postmortem (D) were researched. PL analysis: phosphatidylcholine (PC), sphingomyelin (SM), phosphatidylethanolamin (PEA), phosphatidylinositol (PI), phosphatidylserine (PS), lysophosphatidylcholine (LPC) were performed by conventional lipid-gas and fluid chromatography methods. Active forms of oxygen (AFO2) have been registered by applying EPR. Electrokinetic mobility (EM) of NL determined by the automatic microscope.

**Results:** With GA, against the background of the sharp increase (2.7 times) of free radical processes, there are quantitative changes in the FL plasma membranes NL, expressed in the decreases in the percentages of PS, CM, PEA, PI and the increases in PS and LPS.

**Table 1. Phospholipids concentration (%)**

<table>
<thead>
<tr>
<th>Phospholipids concentration (%)</th>
<th>AFO2 (units/mg of protein)</th>
<th>EM (m/μsec NL from SF in GA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>SM</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>PEA</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>PI</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>PS</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>LPC</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
<tr>
<td>AFO2</td>
<td></td>
<td>D: GA 20 4±0.7 12±0.5 4 11±0.6 10±0.8 8±0.7 59±4.25 6±0.7 10±0.8</td>
</tr>
</tbody>
</table>

* - p<0.05 ** - p<0.01 *** - p<0.001

A decrease in the level of PC and SM in GA indicates an increase in the sensitivity of NL membranes to reactive oxygen species and a decrease in their structural stability, an increase in microviscosity and fluidity. A decrease in the PEA level in GA is also associated with the sharp increase in the active forms of oxygen radicals, which leads to “loosening” of the membranes and the formation of hydrophobic pores. PI is an effector of many membrane enzyme-substrate complexes, and with GA, the percentage of PI is halved. An increase in the level of PS and LPC in GA indicates the presence of structural rearrangements and loosening of the hydrophobic region of the lipid layer of the NL membranes. The PEA / PS ratio in the control group was 2.87, and with GA - 0.89. This indicates a change in the saturation of the lipid bilayer of the NL membrane, an increase in microviscosity and fluidity. Quantitative shifts in the FL composition in NL membranes during GA lead to their pronounced depolarization and the 4.4-fold decrease in EM.

**DOIs:** 10.1136/annrheumdis-2022-eular.3165
Conclusion: FL form the NL apoptotic response, determine their plastic and energy potential. In GA, FL homeostasis of NL is disturbed and membrane-destructive processes development. Modification of the lipid bilayer of plasma membranes NL causes their depolarization, a decrease in plasma membrane viscosity, electrical conductivity and EM. The noted changes in the molecular-architectonics of NL membranes in GA inhibit their membrane-protective properties, antioxidant potential, and stimulate the apoptotic response.

Disclosure of Interests: None declared


AB0053

LNCRNA NUTM2A-AS1 ALLEVIATED OSTEOPOROSIS BY REGULATING MIR-183-5P/TGFA PATHWAY

N. Geng1, D. Yun1, D. Liu1, P. Liu1. 1The First Affiliated Hospital of Xi’an Medical College, Department of Rheumatology and Immunology, Xi’an, China

Background: Osteoporosis(OA) is a common comorbidity in the elderly, characterized by articular cartilage degeneration, hyperostosis and synovitis. Long non-coding RNAs (LncRNAs) have been shown to be involved in several human diseases, including OA. However, the effect of NUTM2A-AS1 on chondrocytes remains unknown.

Objectives: The purpose of this study was to evaluate the role of LncRNA NUTM2A-AS1 in OA pathological changes in vitro.

Methods: Chondrocyte cells were treated for 24 hours to mimic OA pathological conditions. The experimental center used chondrocytes with interleukin-1 beta (IL-1β) intervention to simulate the pathological state of OA. The expression levels of LncRNA NUTM2A-AS1, miR-183-5p and TGFA mRNA were detected by quantitative real-time PCR (qRT-PCR), along with CCK-8 to determine cell viability. Inflammatory response was assessed by determining the release of pro-inflammatory factors such as TNF-α and IL-6 using ELISA kits. Cell apoptosis was examined by flow cytometry assay. The binding relationship between miR-183-5p and LncRNA NUTM2A-AS1 or TGFA was confirmed by dual-luciferase reporter assay.

Results: IL-1β-induced chondrocytes to express LncRNA NUTM2A-AS1 and TGFA, and the miR-183-5p expression was decreased in IL-1β-treated cells. Low expression of LncRNA NUTM2A-AS1 or TGFA mitigated IL-1β-induced chondrocyte viability reduction and apoptosis promotion. miR-183-5p overexpression alleviated IL-1β-mediated chondrocyte apoptosis and inflammatory injury via decreasing TGFA expression. In addition, our work revealed that miR-183-5p is a target of LncRNA NUTM2A-AS1. Rescue experiments showed that TGFA overexpression could reverse the effects of low expression of LncRNA NUTM2A-AS1 on the pathological changes in IL-1β-induced chondrocytes.

Conclusion: Low expression of LncRNA NUTM2A-AS1 significantly mitigated the chondrocytes damage induced by IL-1β through regulating miR-183-5p/TGFA axis, which might be an important target to regulate the promotion of OA.

REFERENCES:

Disclosure of Interests: None declared


Bone diseases, aetiology, pathology and animal models

AB0054

NEW THERAPEUTICAL TOOLS FOR HETEROTOPIC OSSIFICATION TREATMENT AND PREVENTION

A. Alonso-Pérez1, M. Guillán-Fresco1, E. Franco-Trepát1, A. Lois-Iglesias1, A. Jorge-Mora1, R. Gómez1. 1Health Research Institute of Santiago de Compostela (IDIS), Musculoskeletal Pathology Group, Santiago de Compostela, Spain

Background: Heterotopic ossification (HO) consists in abnormal bone growth in soft tissues, in a non-porroosteoblastic environment. This pathology origin can be congenital (progressive osseus heteroplasia, progressive osseous heteroplasia), or acquired (burns, big traumas, electrocutions, articular replacement surgeries, ...). Currently, the available therapies (radiotherapy and removal surgery) are aggressive, associated to multiple adverse effects, and not suitable for every populations. Therefore, new therapeutic tools are needed to HO.

Objectives: The aim of this work is to study osteoblastogenesis inhibition through adipogenesis promotion using a new therapy (Tri-therapy) composed by a PPARγ agonist, a NSAID, and a corticoid.

Methods: Mice mesenchymal stem cells (C3H10T1/2) were differentiated towards adipogenesis and osteoblastogenesis for 7 days, in the presence of the Tri-therapy compounds alone and combined. Simultaneously, human preosteoblast cells (SaOs2) were differentiated to osteoblast for 14 days, being treated with the Tri-therapy. Human HO cells (acquired HO and congenital HO independently), obtained from HO explants, were exposed to an adipogenic environment in the presence of the Tri-therapy for 7 days.

Osteoblastogenesis (ALPL, SPP1, GPMB2, RUNX2) and adipogenic (FABP4, PLIN2, ADIPOQ, PPARγ) marker genes mRNA expression measured by RT-PCR was used to evaluate differentiation processes. All the results were expressed as the media SEM of, at least, 3 independent replicates.

Results: In C3H10T1/2 differentiations Tri-therapy synergically induced FABP4, PLIN2, ADIPOQ expression in both cell fates, demonstrating therefore its ability to promote adipogenesis. In SaOs2, the proposed therapy diminished osteoblastogenesis marker genes expression (SPP1, GPMB2, RUNX2), being this effect greater than PPARγ agonists’ themselves. In HO cells, Tri-therapy augmented adipogenesis markers expression, showing a partial effect in osteoblastogenic marker genes expression.

Conclusion: Pro-adipogenic switch in differentiation marker genes expression induced by the Tri-therapy suggested the clinical use of this drugs combination to treat and prevent HO and abnormal bone growth.

Disclosure of Interests: None declared


AB0055

BONE AND MINERAL DISORDERS IN RENAL HEMODIALYSIS PATIENTS

R. Ben Tekay1, H. Hachi1, M. Brahem1, O. Joma’a1, Z. Atifi1, Y. Mohamed1. 1University Hospital Tahar Sfar, Rheumatology Department, Mahdia, Tunisia; 2University Hospital Tahar Sfar, nephrology department, Mahdia, Tunisia

Objectives: To analyze the prevalence of osteoporosis in group of patients with chronic renal failure and to evaluate the relation between bone mineral density (BMD) and specific markers of bone turnover in hemodialysis (HD) population.

Methods: This is a cross sectional study conducted in hematology department of Taher University hospital in mahdia, Tunisia. The study involved 61 patients with chronic hemodialysis. They were invited to participate and were included after signing informed consent until the calculated sample size was reached. Patients were asked to undergo a hip and lumbar (L2-L4) densitometry by DEXA to measure bone mineral density (BMD). Serum levels of iPTH and alkaline phosphatase (ALP) were measured before the dialysis session.

Results: The studied group of 61 patients was 26 females (42.6%) and 35 males (57.4%), their mean age was 53.9 [17-83] years, with mean dialysis duration 6.1 years. The mean onset age of hemodialysis therapy was 44.7 +/- 15.4 years. It was diabetic nephropathy in 25 cases (41%) vascular nephropathy in 15 cases and tubulointerstitial nephropathy in 21 cases (34.4%). 23 patients (37.7%) had osteoporosis according to the WHO criteria (T-score < -2.5), 26 patients (42.6%) had osteopenia and 12 patients had normal BMD. The mean serum level of iPTH with normal BMD and lower BMD 167.84 vs 535.71 respectively, the mean serum level of ALP with normal BMD and lower BMD 144.59 vs 271.99 respectively (p<0.001). The mean duration of dialysis therapy with normal BMD and lower BMD 4.57 years vs 6.55 years (p<0.001).

Conclusion: Our study showed that osteoporosis is common in dialysis patients. The main determinants of BMD is PTH activity and the duration of dialysis therapy. The importance of prevention and treatment of metabolic bone disease has become better appreciated.

Disclosure of Interests: None declared

Rheumatoid arthritis - aetiology, pathogenesis and animal models

**AB0056**

**COMPARATIVE ANALYSIS OF THE DISTRIBUTION OF LYMPHOCYTES, MACROPHAGES AND MAST CELLS IN THE MARGINAL SYNOVIVUM AND JOINT CAPSULE IN GENERAL AFTER ANTENATAL ANTIGENIC STIMULATION**

A. Fedotchenko,[1],[2] Zaporizhzhia, Ukraine; [2]Ziegewaldkliniken Bethanien Chemnitz, Rheumatology, Chemnitz, Germany

**Background:** The joint capsule is one of the main pathogenic sites of arthritis development [1]. In addition, the initial signs of the inflammatory joint diseases are usually detected in the marginal synovial tissue zone [2]. The joint capsule morphology was studied using hip joints of Wistar rats during the postnatal period in norm and after antigenic stimulation. The last one was modeled through the transuterine intrafetal intercapsular subcutaneous injection of antigen (0.05 ml of human normal immunoglobulin) for the rat fetuses on the 18th day of its antenatal life under general anesthesia and sterile conditions via laparotomy for the pregnant female (Vosolshyn’s method [1981]). The control group of rats was injected with 0.05 ml of physiological saline in the same manner. The earlier recovery of certain parameters (total cells quantity, vessels, collagen fibers and ground substance) to normality in the marginal synovium compared to the rest (larger) part of the joint capsule in antigen-suppressed rats was previously revealed.

**Objectives:** A comparative analysis of the distribution of lymphocytes, macrophages and mast cells in the marginal synovium in relation to the rest (larger) part of the joint capsule after antenatal antigenic stimulation was conducted.

**Methods:** Collection of the biomaterial was carried out on the first, seventh, 14th, 30th, 45th, 60th and 90th day of postnatal life under general anesthesia (intact, antigen-suppressed and control rats; six rats in each group, 126 rats in total). The joints were fixed, decalcified and dehydrated. Paraffin-embedded tissue sections were stained with hematoxylin and eosin. Cells of the synovial subintima of the marginal synovium and rest (larger) part of the joint capsule were counted using the light microscopy (x100) and morphometric lattice. The obtained data were processed using the statistical methods. The parameters of intact and control rats did not differ significantly from each other.

**Results:** In the joint capsule of antigen-suppressed rats compared to intact and control rats, an increased number of lymphocytes till the 90th day (in the marginal synovium – till the 45th day), macrophages till the seventh day (in the marginal synovium – also till the seventh day) and mast cells till the 90th day (in the marginal synovium – till the 45th day) was found. The integrity of the synovium-cartilage barrier is under the antigenic stimulation, contribute to earlier recovery of parameters in the synovium – till the 14th day was found. The integrity of the synovium-cartilage barrier is of fundamental importance, failing which it would lead to excessive synovial tissue penetration into the articular cartilage, recognition of it by immunocompetent cells and initiation of immune-mediated cartilage destruction. The previous premature appearance (on the seventh day) of strong expression of receptors for peanut agglu- tinin (PNA) in the marginal cartilage of antigen-suppressed rats I detected could lead to the assumption about the premature appearance of “chondroprotective substances” such as fibroenectin, laminin etc. and their intensive glycosylation. This fact might be considered a compensatory mechanism to create the defensive wall for adhesion and deactivation of the immunocompetent cells, therefore reducing their influence on cells and tissues getting to accelerated cartilage degradation.

**Conclusion:** The compensatory defence mechanisms, occurring in the marginal cartilage after the antigenic stimulation, contribute to earlier recovery of parameters in the marginal synovium compared to the joint capsule in general. In so doing, the marginal transitional zone forms the important innate, nonspecific, immunobiological, anatomical and physiological barrier between the joint capsule and articular cartilage.

**REFERENCES:**


**Objectives:** To explore the involvement of VGLL3, a homologue of the vestigi-

[4] De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid arthropathies, ACPA- and anti-CCP-positive RA patients. Expression of VGLL3 in the synovial tissues and FLS was analyzed by immunohistochemistry and PCR. RNA sequencing was performed in RA-FLS upon VGLL3 overexpres-

**Conclusion:** VGLL3 was upregulated in the RA synovium and RA-FLS compared to OA. Overexpression of VGLL3 promoted the expression of ISGs in RA-FLS. The expression of STAT1 and MX1 was associated with the expression of VGLL3 in RA and OA patients. VGLL3 promoted the IRF3 activation, IFN-β expression, and IFN-β1 autocrine signaling in RA-FLS. VGLL3 also modulated the expression of the Hippo pathway molecules WWP1 and AMOTL2, which mediated the regulation of IRF3 activation and IFN-β1 production by VGLL3 in RA-FLS. The expression of VGLL3 in the synovium of patients with RA was positively associated with the expression of STAT1 and MX1.

**Acknowledgements:** We would like to thank Prof. Si-feng Chen (Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, China) for scientific advice and technical assistance.

**Disclosure of Interests:** None declared.

**AB0055**

**SERUM ANTIGENOME PROFILING REVEALS DIAGNOSTIC MODELS FOR RHEUMATOID ARTHRITIS**


**Results:** We identified 62, 71 and 49 differentially expressed proteins (DEPs) in RA, AC-PA-positive RA and AC-PA-negative RA patients in the antigenic stimulation, respective, compared to OA and healthy controls. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed. We then trained a machine learning algorithm to classify RA, AC-PA-positive RA and AC-PA-negative RA based on proteomic data and validated in the cohort.

**Disclosure of Interests:** None declared.

**REFERENCES:**


**Background:** Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint damage, systemic inflammation and early mortality. Though the precise molecular mechanism in the triggering immune response are not fully understood, the emergence of antibodies against self-antigens can serve as diagnostic biomarker. Multiple antigens have been confirmed. However, the pro-

**Disclosure of Interests:** None declared.

**AB0057**

**REGULATION OF TYPE I INTERFERON SIGNATURE BY VGLL3 IN THE FIBROBLAST-LIKE SYNOVIOCYTES OF RHEUMATOID ARTHRITIS**

Y. Du,[1] S. M. Dai,[1] 1 Shanghai Jiao Tong University-Affiliated Sixth People’s Hospital, Department of Rheumatology and Immunology, Shanghai, China

**Background:** The upregulation of interferon (IFN)-stimulated genes (ISGs) induced by type I IFNs (namely type I IFN signature) in RA patients had impli-

**Objectives:** To explore the involvement of VGLL3, a homologue of the vestigi-

**Methods:** FLS were isolated from RA and osteoarthritis patients. Expression of VGLL3 in the synovial tissues and FLS was analyzed by immunohistochemistry and PCR. RNA sequencing was performed in RA-FLS upon VGLL3 overexpres-

**Conclusion:** VGLL3 drives the IRF3-induced IFN-β expression and increases the production by VGLL3 in RA-FLS.

**Disclosure of Interests:** None declared.

**REFERENCES:**


Background: Autoimmune diseases represent a large and heterogeneous group of disorders that afflict specific target organs. However, multiple factors point to common links between the differing presentations of autoimmune disorders. With increased interest in further understanding the neuro-immune axis, autoimmune diseases represent an important opportunity to explore whether systemic inflammation from these autoimmune pathways has a central effect and, if so, whether there is a common or discrete central effect caused by different autoimmune diseases.

Objectives: The present study aimed to analyse hippocampal volume in patients with rheumatoid arthritis (RA) and ulcerative colitis (UC) as compared to healthy control groups. The hippocampus was chosen as a region of interest given the regulatory role it exhibits in the hypothalamic–pituitary–adrenal (HPA) axis.

Methods: Data from 1,040 individuals in the UKBiobank imaging sub-study were included in the present study. This was divided into two separate patient populations with separate control groups. Data from 267 individuals (mean age ± SD = 65.52 ± 70.2, 70.8% females) were included in the RA patient group with 267 age and sex matched controls (mean age ± SD = 65.51 ± 7.08%, females). Data from 253 individuals (mean age ± SD = 64.09 ± 703, 51.6% females) were included in the UC patient group with 253 age and sex matched controls (mean age ± SD = 63.4 ± 702, 51.6% females). The UKBiobank is a prospective observational study with a proposed cohort of 500,000 participants. The imaging substudy is planned to scan 100,000 of those participants with a standardised scanning protocol including MRI of the brain. Multi-modal images were acquired on a 3T scanner. From the T1w data, volumetric imaging derived phenotypes (IPDs) are provided using the FMRIB Integrated Registration and Segmentation Tool (FIRST); http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST. This study utilised the right and left hippocampal volume outputs from that tool.

Results: We observed a smaller hippocampal volume in UC patients when compared to healthy controls (difference right: 99.78 mm³, SD ± 38.97, p = 0.01; left: 74.30 mm³, SD ± 39.41, p = 0.06). The Cohen's effect size was d = -0.24 [95% CI -0.43, -0.05] for right hippocampal volume and d = -0.12 [95% CI -0.27, 0.06] for left hippocampal volume.

Conclusion: This study provides evidence of moderate reduction in hippocampal volume in UC patients as compared to age and sex matched healthy controls. This same effect was not seen in a similarly matched rheumatoid arthritis patient population. Further analysis of additional subcortical regions could provide further context for whether there are alternative regions affected in both RA and UC.

REFERENCES:

Disclosure of Interests: Jennifer Cox Grant/research support from: PhD funded by GlaxoSmithKline, Employee of: Former employee of GlaxoSmithKline, Marius

Figure 1. Right and left hippocampal volume in UC patients versus controls and right and left hippocampal volume in RA patients versus controls.

There was no significant difference seen in hippocampal volume in RA patients compared to controls (difference right: 61.32mm³, SD ± 40.33, p = 0.13; left: 39.00mm³, SD ± 38.19, p = 0.31). The Cohen's effect size was d = 0.12 [95% CI 0.00, 0.26] for right hippocampal volume and d = -0.08 [95% CI -0.27, 0.10] for left hippocampal volume.

Conclusion: This study provides evidence of moderate reduction in hippocampal volumes in patients with ulcerative colitis as compared to age and sex matched healthy controls. This same effect was not seen in a similarly matched rheumatoid arthritis patient population. Further analysis of additional subcortical regions could provide further context for whether there are alternative regions affected in both RA and UC.
**AB0061**

**PHARMACOKINETICS OF METHOTREXATE POLYGALMATAMUTES IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF RA PATIENTS IS SIMILAR AFTER ORAL OR SUBCUTANEOUS ORAL ADMINISTRATION**

R. Hebing1, M. Lin2, E. Struys3, S. Mahmoud1, I. Muller2, W. Lems1, B. van den Bermt4, G. Jansen2, R. De Jonge2, M. Nurmohamed2,3, Reade, Rheumatology, Amsterdam, Netherlands; 2Amsterdam UMC, locatie VUMC, Clinical Chemistry, Amsterdam, Netherlands; 3Amsterdam UMC, locatie VUMC, Rheumatology, Amsterdam, Netherlands; 4Sint Maartenskliniek, Rheumatology, Utrecht, Netherlands; 5Radboud University Medical Center, Pharmacy, Nijmegen, Netherlands

**Background:** Pharmacokinetics of methotrexate (MTX) after oral and subcutaneous administration to RA patients differs: MTX levels in plasma and MTX-polylgumatamutes (MTX-PG) accumulation in erythrocytes are higher during equidosed subcutaneous compared to oral MTX treatment. (1,2) No data are available whether administration route of MTX differentially impacts the intracellular concentrations of MTX-PGs in peripheral blood mononuclear cells (PBMCs) during MTX therapy.

**Objectives:** To investigate the pharmacokinetics of MTX-PGs in PBMCs of newly diagnosed RA patients receiving oral or subcutaneous MTX in the early phase (1, 2, 3, and 6 months) of MTX treatment.

**Methods:** In a clinical prospective cohort study (MeMo study (NTR7149)), RA patients were administered oral (n=24) or subcutaneous (n=22) MTX up to 25 mg MTX/week, as described before. (1) At 1, 2, 3, and 6 months after the start of therapy, PBMCs were isolated via Ficoll density gradient centrifugation. Individual MTX-PG forms as described before. (1) At 1, 2, 3 and 6 months after the start of therapy, PBMCs were isolated via Ficoll density gradient centrifugation. Individual MTX-PG forms (MTX-PG1-6) were isolated via Ficoll density gradient centrifugation. Individual MTX-PG forms as described before. (1)

**Results:** Anti-TNF therapy increased ACE levels in the full cohort, as well as in the RA and AS subsets. ACE2 activity increased in the full cohort, whereas RBC MTX-PG accumulation increased between 1 to 3 months to reach a plateau (Figure 1).

**Conclusion:** This study demonstrated that MTX-PG accumulation in PBMCs early on in the MTX treatment of RA patients was not significantly different between oral or subcutaneous MTX administration routes.

**References:**


**Acknowledgements:** We would like to thank all participating patients and Pfizer (grant 53233663 / W230458), NVKC (Noyons grant) and AmsterdamlUMC (AIIL extension grant).

**Disclosure of Interests:** Renske Hebing Grant/research support from: Pfizer, grant number 53233663 / W230458, Amsterdam UMC (AIIL extension grant), NVKC (Netherlands Society for Clinical Chemistry, Noyons grant), Marry Lin: None declared, Eduard Struys: None declared, Sohaila Mahmoud: None declared, Itai Muller: None declared, Willem Lems: None declared, Bart van den Bermt Speakers bureau: Pfizer, UCB, Sanofi-Aventis, Galapagos, Amgen and Eli Lilly, Gerrit Jansen: None declared, Robert De Jonge Grant/research support from: NVKC (Netherlands Society for Clinical Chemistry, Noyons grant), Michael Nurmohamed Grant/research support from: Pfizer grant DOI: 10.1136/annrheumdis-2022-eular.781

**AB0062**

**ANGIOTENSIN CONVERTING ENZYME ACTIVITY IN ANTI-TNF-TREATED RHEUMATOID ARTHRITIS AND ANKYLOPSY Spondylitis PATIENTS**

B. Soós1, M. Fagyás3, A. Horváth1, E. Végh1, A. Puszta1, M. Czokolová3, A. Csongrádi1, A. Hamar4, Z. Pető4, N. Bodnár2,4, G. Kerekes2, K. Hodosi1, E. Szekeanecz1, S. Szamosi1, S. Szántoi1, G. Szűcs1, Z. Papp1, Z. Szekanecz1, University of Debrecen, Rheumatology, Debrecen, Hungary; 2University of Debrecen, Cardiology, Debrecen, Hungary; 3University of Debrecen, Internal Medicine, Debrecen, Hungary; 4University of Debrecen, Oncology, Debrecen, Hungary; 5University of Debrecen, Rheumatology, Debrecen, Hungary

**Background:** Angiotensin-converting enzyme (ACE) and ACE2 have been implicated in the regulation of vascular physiology. Elevated sYnval and decreased or normal ACE or ACE2 levels have been found in rheumatoid arthritis (RA). Very little is known about the effects of tumour necrosis factor α (TNF-α) inhibition on ACE or ACE2 homeostasis.

**Objectives:** In this study, we assessed the effects of one-year anti-TNF therapy on ACE and ACE2 production in RA and ankylosing spondylitis (AS) in association with other biomarkers.

**Methods:** Forty patients including 24 RA patients treated with either etanercept (ETN) or certolizumab pegol (CZP) and 16 AS patients treated with ETN were included in a 12-month follow-up study. Serum ACE levels were determined by commercial ELISA, while serum ACE2 activity was assessed using a specific quenched fluorescent substrate. Ultrasonography was performed to determine flow-mediated vasodilation (FMD), common carotid intima-media thickness (cIMT), and arterial pulse-wave velocity (PWV) in all patients. In addition, CRP, rheumatoid factor (RF) and ACPA were also measured. All assessments were performed at baseline and 6 and 12 months after treatment initiation.

**Results:** Anti-TNF therapy increased ACE levels in the full cohort, as well as in the RA and AS subsets. ACE2 activity increased in the full cohort, whereas RBC MTX-PG accumulation increased between 1 to 3 months to reach a plateau (Figure 1).

**Conclusion:** Anti-TNF treatment may increase ACE and ACE2 in the sera of RA and AS patients. ACE and ACE2 may be associated with disease duration, markers of inflammation and vascular pathophysiology. The effects of TNF inhibition on ACE and ACE2 may reflect, in part, these effects of the biologics on the cardiovascular system.

**Disclosure of Interests:** Boglárka Sóos: None declared, Miklós Fagyás: None declared, Ágnes Horváth: None declared, Edit Végh: None declared, Anita Puszta: None declared, Monika Czokolová: None declared, Alexandra Csongrádi: None declared, Attila Hamar: None declared, Zsófia Pető: None declared, Nóra Bodnár: None declared, György Kerekes: None declared, Katalin Hodosi: None declared, Éva Szekanecz: None declared, Szilvia Szamosi Speakers bureau: AbbVie, Roche, Sager, Amgen, Sándor Szántó Speakers bureau: AbbVie, Novartis, Lilly, MSD, UCB, Consultant of: AbbVie, Novartis, UCB, Gabriella Szűcs Speakers bureau: AbbVie, Lilly, Actelion, Zoltán Papp: None declared, Zoltán Szekanecz Speakers bureau: AbbVie, Pfizer, Roche, MSD, Novartis, Lilly, Richter, Consultant of: Pfizer, Novartis, Richter, Grant/research support from: Pfizer, UCB

AMPA CANNOT BE DETECTED IN FAECES OF SEROPOSITIVE RA PATIENTS: NO EVIDENCE FOR LOCAL AMPA PRODUCTION IN THE LOWER GASTRO-INTESTINAL TRACT

V. Derksen1, T. Huizinga1, R. Toes1, D. van der Woude1. 1Leiden University Medical Center, Rheumatology, Leiden, Netherlands

Background: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPAs), for example anti-citrullinated protein antibodies (ACPA) and anti-acetylated protein antibodies (AAPA). The exact mechanism underlying the development of these autoantibodies is currently unclear, but the mucosal immune system has been hypothesized to play a role. ACPA IgA have been detected in sputum and saliva of seropositive RA patients (1-2), suggesting local production of autoantibodies in the gut and oral mucosa. This raises the question whether ACPA can also be produced at other mucosal sites. The intestines are an interesting candidate, as microbiome dysbiosis has been described in RA patients and intestinal content may represent a source of post-translationally modified antigens. However, it is currently unknown whether AMPAs are also produced locally in the intestine.

Objectives: To determine whether AMPA are produced locally in the intestine, we set out to detect ACPA and AAPA in faeces samples of seropositive RA patients. These findings were compared to the ACPA/AAPA levels found in paired serum and saliva samples of the same patients.

Methods: Paired faeces, saliva and serum samples of 16 established seropositive RA patients and 16 healthy volunteers were collected. All patients fulfilled the ACR/EULAR 2010 criteria. Saliva was collected using the passive drooling method. Faeces were self-collected by participants at home and immediately frozen. Faeces samples were homogenized in PBS containing protease inhibitors and supernatants were used in ELISA. Saliva was diluted 1:4. Total IgA and anti-E. Coli IgA were measured using commercial and in-house ELISA, respectively. ACPA/AAPA IgA (serum, saliva) and ACPA/AAPA Ig (faeces) were detected using in-house ELISAs, coated with citrullinated and acetylated CCP2 or the unmodified arginine and lysine variants as control. Saliva samples were considered AMPA positive when the value was above the cut-off (mean + 2 standard deviation of healthy donors) and the delta OD between the modified and unmodified peptide was larger than 0.1.

Results: 9/16 ACPA IgG-positive RA patients were also ACPA IgA positive in serum. In the faecal supernatants total IgA was clearly detectable by ELISA: the supernatants contained on average 85 μg/ml total IgA, only slightly less compared to the mean 117 μg/ml total IgA found in the pre-diluted saliva. However, in none of the faecal supernatants ACPA Ig could be detected. Differences in optical density (OD) between the CCP2 and unmodified arginine peptide were close to 0 (Figure 1A). On the contrary, 8 RA patients were positive for ACPA IgA in saliva (Figure 1B). Similar results were found for AAPA (Figure 1C-D). To control whether the lack of an AMPA signal is explained by technical difficulties associated with measuring IgA in an antigen-specific manner in faeces, we determined anti-E. Coli IgA in the same faeces samples. Anti-E. Coli IgA was clearly detectable in 11/32 faeces samples, indicating intact antigen-specific IgA was present in the faecal samples (Figure 1E).

Figure 1.

Conclusion: No ACPA or AAPA Ig antibodies could be detected in faeces of RA patients, even though these patients were positive for ACPA/AAPA IgA in both serum and saliva. The fact that it was possible to detect other antibodies in faeces, indicates that the absence of an AMPA signal is not due to inherent methodological issues. These findings indicate that the lower gastrointestinal tract does not contain measurable levels of AMPA IgA and suggest that it is not a main site of AMPA production in RA patients.

REFERENCES:

Disclosure of Interests: None declared

AB0064

PHARMACOLOGICAL INHIBITION OF IL-6/JAK/STAT AXIS INCREASES MUSCLE MASS IN AN EXPERIMENTAL MODEL OF SARCOPENIA ASSOCIATED TO RHEUMATOID ARTHRITIS

I. Bermejo1, S. Pérez-Baos1, J. P. Medina1, P. Gratia1, I. Prieto-Potín1, R. Largo1, G. Herrera-Beaumont2 *on behalf of Bone and Joint Research Unit. 1Instituto de Investigacion Sanitaria EID, Rheumatology, Madrid, Spain; 2Fundación Jiménez Díaz, Rheumatology, Madrid, Spain

Background: Sarcopenia is a frequent comorbidity of rheumatoid arthritis (RA) due to an imbalance in muscle remodelling with dominance of catabolism over anabolism. IL-6/JAK/STAT axis is of particular importance in this regulation because of its dual activity. According to local and acute factors, it promotes muscle healing and hypertrophy, whereas in chronic inflammation, this signalling substantially increases muscle catabolism activating pro-atrophic pathways involving atrogin expression and ubiquitin proteasome system (UPS). JAK/STAT blockade suppresses muscle wasting induced by IL-6 through STAT3 activation. Interestingly, different clinical trials have shown that JAK inhibitors produce an asymptomatic increase in serum creatine kinase (CK) and creatinine levels in RA patients, suggesting an impact on muscle.

Objectives: To evaluate the effect of JAK inhibition and its effect in muscle remodelling in an experimental model that accurately mimics human rheumatoid sarcopenia.

Methods: An experimental model of antigen-induced arthritis (AIA) was carried out in 14 rabbits by immunization against ovalbumin followed by 4 intra-articular injections of this protein. One week after the first i.a injection, 7 of these rabbits received tofacitinib (TOFA, orally 10mg/kg/day) for 2 wk. Animals were euthanized one day after the last i.a injection, when tibialis anterior (TA), extensor digitorum longus (EDL) and gastrocnemius (GN) were isolated from both hind limbs. Histological changes and ATPase staining were analysed in TA, while the number of myonuclei was determined in EDL fibres by quantifying immunofluorescence signals. C-reactive protein (CRP) and myostatin (MSTN) serum concentration were determined by ELISA. The gene expression of proinflammatory cytokines (IL-6, IL-1, TNF-α, MCP-1), atrogenes (Atrogin-1, MuRF-1) and MSTN was measured by quantitative PCR, while proliferative muscle maker (PAX-7), differentiation muscle markers (MyoD, Myogenin), pSTAT3, pSTAT1, MSTN and CK protein expression was analysed by western blot in GN. Creatine presence in CK was analysed by colorimetric assay.

Results: A significant increase in body weight was observed in the AIA+TOFA group vs. AIA at the end of the study. A significant increase in TA cross-sectional area and diameter in the AIA+TOFA, in comparison to AIA, was found, while the decrease in the area of type II fibres observed in the AIA animals was not noticed in AIA+TOFA. Moreover, the number of myonuclei in the EDL that was increased in AIA group when compared to healthy animals, was significantly decreased in AIA+TOFA. However, systemic inflammation measured by CRP was not modified by TOFA treatment at the end of the study, in comparison to AIA, and so did serum MSTN concentration. TOFA evoked a significant reduction in the gene expression of IL-6, MCP-1, atrogin-1 and MuRF-1 in GN in comparison to untreated AIA rabbits. Notably, AIA+TOFA showed higher protein levels of CK and lower creatine compared to AIA in muscle. Simultaneously, no differences in the proliferative marker PAX-7 were found between groups, while AIA rabbits showed an increase in the differentiation markers MyoD and Myogenin in the muscle that was prevented in AIA+TOFA.

Conclusion: These data provide novel insights into the effects of JAK inhibitors in muscle remodelling during rheumatoid cachexia. Despite an elevated systemic inflammatory status, JAK inhibition was able to rapidly increase muscle mass through attenuating IL-6/JAK/STAT activation, decreasing atrogin expression and restoring to baseline the muscle cell differentiation markers in the tissue. The increase in muscle mass was accompanied by an increase in CK presence, supporting the role of CK as a valuable marker of muscle gain following treatment with JAK inhibitors. However, the low levels of MCP-1 and the disorganization of muscle fibres raise the question of whether these treatments are able to trigger a complete regeneration of muscle fibre cell or just hypertrophy of cells already present.

Disclosure of Interests: Ismael Bermejo: None declared, Sandra Pérez-Baos: None declared, Juan Pablo Medina: None declared, Paula Gratia: None declared, Ivan Prieto-Potín: None declared, Raquel Largo: None declared, Gabriel Herre-no-Beaumont Grant/research support from: The Bone and Joint Research Unit has received funding from several pharmaceutical laboratories (Pfizer, Lilly...).
Background: Rheumatoid arthritis (RA) is primarily associated with pain levels and limited function. Depression disturbances and anxiety levels are not usually considered. The focus is on the physical aspects of the disease. At the same time, patients with high disease activity often experience a decrease in body weight and lack of appetite, which is referred to as rheumatoid cachexia. Nesfatin-1 (NF-1), discovered as an anorexigenic protein. The participation of NF-1 in the regulation of eating behavior and reactions to emotional stress together with oxytocin, melatonin, serotonin, and histamine receptors has been proven. Elevated levels of NF-1 are detected in more severe forms of inflammation, and NF-1 protein expression is positively correlated with the duration of the disease. The focus is on the physical aspects of the disease. At the same time, patients with high disease activity often experience a decrease in body weight and lack of appetite, which is referred to as rheumatoid cachexia. Nesfatin-1 (NF-1), discovered as an anorexigenic protein. The participation of NF-1 in the regulation of eating behavior and reactions to emotional stress together with oxytocin, melatonin, serotonin, and histamine receptors has been proven. Elevated levels of NF-1 are detected in more severe forms of inflammation, and NF-1 protein expression is positively correlated with the duration of the disease.

Results: Mood disorders of varying severity were detected in 48% of patients with RA. The highest levels of NF-1 were found in patients with high RA activity according to DAS-28 and disease duration of more than 10 years. The level of anxiety was more correlated with the severity of the disease activity ($r = 0.351; p<0.01$), and the level of depression was more correlated with the duration of the disease ($r = 0.273; p<0.01$). Western blotting showed that QXT could reduce the pro-inflammatory activity of QXT-50 and QXT-100 groups showed statistically significant ($p<0.001$).

Conclusion: Qinxitong can inhibit the proliferation, promote apoptosis, inhibit migration and invasion of rheumatoid arthritis synovial fibroblasts by regulating Erk signaling pathway, providing scientific basis for clinical application of Qinxitong.

Disclosure of Interests: None declared.

is up-regulated in rheumatoid arthritis (RA) and associates with disease activity, autoantibodies and NEToSis.

**Objectives:** As autoantibodies and neutrophil activation are factors thought to drive the pathological processes at early phase of RA development, we aimed to investigate IL-40 in relation to neutrophils and early stages of RA (ERA).

**Methods:** The levels of serum IL-40 were determined in a cohort of treatment naïve patients with ERA at baseline (n=60) and three months after initiation of conventional treatment (n=80). Serum IL-40 was also determined in sex- and age- matched healthy controls (n=60). Levels of IL-40, cytokines and NEToSis markers (proteasine 3, PR3 and neutrophil elastase, NE) were measured by commercially available ELISA kits. The levels of autoantibodies were analysed by routine laboratory techniques. In vitro experiments were performed on peripheral blood neutrophils from patients with ERA (n=15).

**Results:** Levels of IL-40 were elevated in ERA patients at baseline compared to healthy controls (p<0.0001) and normalised after three months of the treatment (p<0.0001). Baseline serum IL-40 was associated with the levels of autoantibodies RF (gM) (p<0.01) and anti-CCP (p<0.01) and markers of NEToSis PR3 and NE (both p<0.0001). Moreover, significant decreases in the serum IL-40 following the therapy correlated with the decrease of NEToSis markers PR3 (p<0.01) and NE (p<0.05). In vitro, neutrophils from patients with ERA significantly enhanced the release of IL-40 with early RA (n=7) from Hospital Universitario Marqués de Valdecilla (Santander, Spain) were included in this study. The relative mRNA expression of IL-40 in relation to neutrophils and early stages of RA (ERA).

**Conclusion:** We demonstrated for the first time that IL-40 is upregulated in ERA and decreases after three months of conventional therapy. Moreover, we showed that neutrophils are an important source of IL-40 in RA and its release is potentiated by pro-inflammatory cytokines such as IL-1 β, IL-8 (p<0.05), TNF (p<0.01) or to LPS (p<0.05). Lastly, recombinant IL-40 induced the secretion of IL-1 (p<0.05) and TNF (p<0.05) by ERA neutrophils.

**References:**

**Disclosure of Interests:** None declared.
Conclusion: Jak/STAT3 activity of PBMC from RA patients with active disease may be differently modulated by specific inhibitors. Selectivity of Jak-inhibitors seems more relevant in lymphocytes after IL-6 stimulation. These preliminary findings may explain discrepancies in effectiveness of selective Jak-inhibitors and pave the way for different choices in clinical practice.

REFERENCES:

Disclosure of Interests: None declared

AB0071

ANTI-ACETYLATED PROTEIN IG-M ANTIBODIES AS THE STARTING POINT OF AUTOANTIBODY FORMATION IN RHEUMATOID ARTHRITIS?

1. Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Nagasaki University Graduate School of Biomedical Sciences, Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; 3Nagasaki University Graduate School of Biomedical Sciences, Department of General Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; 4Nagasaki University Graduate School of Biomedical Sciences, Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan

Background: Anti-modified protein antibodies (AMPA) are an important hallmark of rheumatoid arthritis (RA) and the fact that they have consistently been found to develop years before disease onset, has provided important insights into the immunopathology underlying RA. In (auto)antibody development, IgM is the first isotype to be produced. However, it is unclear whether IgM-autoimmunity differs between AMPA targeting different post-translational modifications (citrulline, homocitrulline and acetylated residues), which could provide clues about the starting point of the AMPA response.

Objectives: We therefore investigated IgM-levels of anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP) and anti-acetylated protein antibodies (AAPA) in healthy individuals, non-RA and RA patients.

Methods: Autoantibodies were investigated in 2 cohorts:
1) a Japanese cohort of healthy individuals (community based Nagasaki Island study) known to be ACPA-positive (n=65) or ACPA-negative (n=197) were compared to Dutch healthy donors (n=30) and ACPA-positive RA patients (n=29).
2) early arthritis patients from the Leiden Early Arthritis Clinic who had RA (n=648) or another form of arthritis (non-RA, n=555) and healthy controls (n=80). ACPA and AAPA were determined by ELISAs using CCP4, ChcitrP4 and CAcetylP4 peptides with sequences similar to the commercial CCP2 antigen and homocitrulline and acetylated control peptides.

Results: Comparison of IgM-reactivity levels between healthy individuals and ACPA-positive RA patients (Figure 1A) and to a lesser extent in ACPA-positive healthy Japanese individuals, and non-RA arthritis patients (Figure 1D). A similar picture was observed for anti-CarP IgM reactivity, for which again highest levels were found in established RA patients (1B and 1E) and AAPA-positive compared to ACPA-negative healthy Japanese individuals (1B). Intriguingly, AAPA IgM reactivity-levels displayed a different pattern as these were comparable between healthy individuals and ACPA-positive RA patients (1C and 1F). Likewise, AAPA IgM reactivity-levels were also not increased in ACPA-positive healthy Japanese individuals, who instead had lower levels compared to their ACPA-negative counterparts. Furthermore, the AAPA IgM-reactivity levels did not differ between non-RA arthritis patients, healthy controls and RA patients (1F). AAPA IgM-levels on the other hand were clearly elevated in RA patients compared to healthy controls and non-RA arthritis patients (1G).

Conclusion: AAPA are exceptional compared to other AMPA because IgM AAPA-levels are similar among healthy individuals, non-RA arthritis and RA patients. This suggests that AAPA IgM is part of the “normal” immune repertoire and could constitute the starting point for RA-associated AMPA responses, with isotype switching and epitope spreading to other post-translational modifications leading to the typical RA-associated mature AMPA response.

Disclosure of Interests: None declared

AB0072

GLUCOCORTICOID MODIFY NOT ONLY THE PROPERTIES OF DENDRITIC CELLS, BUT ALSO PROGENITOR CELLS

V. Kurochkina1, A. Sizikov2, E. Chernykh1, T. Tyrnova2.
1. Research Institute of Clinical and Experimental Rheumatology – branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Science, Rheumatology, Novosibirsk, Russian Federation; 2. Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Rheumatology, Novosibirsk, Russian Federation; 3. Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, Laboratory of cells immunotherapy, Novosibirsk, Russian Federation

Background: Dendritic cells (DCs) are universal antigen-presenting cells that can have both tolerant and immunosuppressive properties. Tolerogenic properties of DCs are mediated by activation T-regulatory cells, production of anti-inflammatory cytokines and activation T cell apoptosis. Currently, DC is an attractive object of study as a new treatment for rheumatoid arthritis. It is known that glucocorticoids make it possible to control properties of DCs to the tolerogenic side.

Objectives: The aim of the study is to investigate the effect of pulse therapy by glucocorticoids on the properties of DCs and peripheral blood monocytes from which DCs were generated.

Methods: Twenty five patients with rheumatoid arthritis were recruited in this study. All patients follow ACR/EULAR criteria (2010). All studies were performed after receiving informed consent. All patients received conventional synthetic DMARDs. DCs were generated from blood monocytes culturing for 5 days with GM-CSF and IFN-α, LPS as maturation stimuli was added on fourth day. The properties of DCs were studied before pulse therapy (methylprednisolone 500mg Ne3) and 4 days after pulse therapy. The relative number of monocytes (classical CD14+CD16−, intermediate CD14+CD16+ and nonclassical CD14+CD16+) before and after pulse therapy was also studied in comparison with healthy donors.

Results: Prior to pulse therapy, the DCs from RA patients were characterized by a high ability to stimulate the proliferation of allogeneic T-lymphocytes about 20000 cpmp. After pulse therapy, the stimulating ability of DCs significantly decreased (9800 vs. 2000 cpmp, p=0.04). Evaluation of the relative content of classical (CD14+CD16−), intermediate (CD14+CD16+) and nonclassical (CD14+CD16+) monocytes of healthy donors (n=18) and RA patients (n=25) revealed a decrease in the relative content of CD14+CD16− cells in patients (Me 78 vs. 90%; p=0.02) and an increase in the proportion of CD14+CD16− (Me 4.0 2.0%; p=0.034) and CD14+CD16+ monocytes (Me 5.0 1.5%; p=0.02). After the end of pulse therapy in RA patients, the relative content of CD14+CD16− cells increased (89 vs. 78%), and the proportion of CD14+CD16− monocytes decreased (1 vs. 5%), and RA patients no longer significantly differed in these indicators from healthy donors. Thus, a decrease in the content of CD14+CD16− cells in the monocytes population after pulse therapy was associated with a decrease in the effectiveness of DCs generated to stimulate the proliferation of allogeneic T cells.

Conclusion: The effect of pulse therapy of glucocorticoids is associated not only with the ability of glucocorticoids to inhibit the maturation of IFN-DC and induce their tolerant phenotype at the stage of differentiation of monocytes into DCs, but also with the effect on the subpopulation of circulating monocytes that are precursors of DC.

Disclosure of Interests: None declared

AB0073

NEUROPHIL EXTRACELLULAR TRAPS: COUPLING WITH RHEUMATOID ARTHRITIS FLARES AND ANTI-CITRULLINE AUTOANTIBODIES BESIDE

S. Bedina1, E. Mozgovaya1, A. Tofrmenko1, S. Spitsina1, M. Mamus1.
1. Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy, Clinical biochemistry lab, Volgograd, Russian Federation
Background: Rheumatoid arthritis (RA) is characterized by dysregulation of the adaptive immune system. Detection of subcellular structures with localization of most typical citrulline-containing rheumatoid autoantigens in a single compartment is of special interest considering importance of antitopo II autoantibodies for autoimmune response in RA. Neutrophil extracellular traps (NETs) can be suggested as a most likely candidate for the role of such structures.

Objectives: To study of peripheral blood neutrophils from RA to generate NETs, associated with diseases exacerbation.

Methods: The research was carried out in agreement with the WMA Declaration of Helsinki principles after the local ethical board approval. Circulating neutrophils were isolated with one-step density gradient centrifugation using double layers of ficoll-amidotrizoate gradient. Composition of isolated cellular fractions, their viability, and non-specific activation were evaluated by light microscopy using common Romanowsky-Giemsa staining, trypan blue exclusion test as well as NBT test. Neutrophil fractions contained minute percent ages of impurities and low extents of activated and dead cells. NETs were induced by PMA. Spontaneous and induced formation of extracellular traps was assessed using fluorescence microscopy [1]. Results were presented as values (95% CI).

Results: 37 patients (6 males and 31 females, mean age 42.7 years) with verified RA according to the ACR/EULAR 2010 criteria were included in the study. RA disease activity at the inclusion timepoint should exceed ≥2.6 DAS28 points. 16 (45.4%) patients had subsequent increase of the DAS28 score above 3.2 at following visits (3, 8 and 12 months after the inclusion), 30 healthy volunteers (9 males and 21 females, mean age 37.2 years) were enrolled as a reference group. Mean proportions of spontaneous and induced NET formation by isolated neutrophils of inactive RA patients (DAS 28 ≤ 2.6) were 6.0 (5.7-6.3)% and 26.9 (24.0-28.9)% respectively. Active RA patients (DAS 28 ≥ 3.2) had dramatic increase of the respective values: 16.6 (16.4-16.8)% and 38.0 (37.7-38.3)%.

Both active and inactive RA patients had significant increase of NET-generating neutrophils proportion comparing to the reference group as well as significant difference of both these parameters between active and inactive phase (p<0.05).

The growth rate of spontaneous NET formation in the active RA was 183.8%, the respective value for induced NET formation was 46.7%. The growth rate of spontaneous NET formation is 3.9 times higher than the induced NET formation. Neutrophils from ACPA-positive RA patients were found to have increased spontaneous and induced NETs formation compared to ACPA-negative RA patients (p<0.05).

Conclusion: Thus, our study demonstrated a strong relationship between onset of RA flare and increase of spontaneous and induced NET formation by circulating neutrophils, which were also a clear distinction between ACPA negative and positive RA patients as to higher spontaneous and induced NET formation in the latter subgroup. The comparison using larger group of patients will magnify the differences above significance limit. Continued research in this direction can promote the development of new therapies of RA.

REFERENCES:

Disclosure of Interests: None declared

Conclusion: AMPAs recognize different modified antigens and form immune complexes in the SF of RA patients. The elevated titer of anti-acetylated protein antibodies and the inclusion of its epitope in immune complexes in the synovium points to its contribution in the pathogenesis of RA.

REFERENCES:

Disclosure of Interests: None declared.

Figure 1. The identification of acetylated antigens in the synovium of RA patients is especially intriguing, as infections (bacteria) are known to not only acetylate their own proteins, but also modify host proteins.

AB0076
DOES HELICOBACTER PYLORI HAVE AN IMPACT ON RHEUMATOID ARTHRITIS?

H. Wu1-2, C. Wu1. 1The Eighth Affiliated Hospital of Sun Yat-sen University, Department of laboratory medicine, Shenzhen, China; 2The Eighth Affiliated Hospital of Sun Yat-sen University, Department of laboratory medicine, Shenzhen, China

Background: Rheumatoid arthritis (RA) is an autoimmune disease of not completely defined pathogenesis. A growing body of studies shows that microbiota may be a critical environmental trigger in the development of RA. Helicobacter pylori (Hp) is a common human pathogenic bacterium and is associated with multiple autoimmune diseases. However, the role of Hp in RA is far less well understood.

Objectives: The study aims to investigate the impact of Hp on RA.

Methods: We recruited 81 RA patients (disease duration >1 year) in this study, and all patients met the 2010 ACR/EULAR diagnostic criteria. They were divided into two groups depending on their infection status: the Hp-uninfected group (9 male, 33 female) and the Hp-infected group (10 male, 29 female). C-reactive protein (CRP), Rheumatoid factor (RF), and Anti-citrullinated protein antibodies (ACPA) were measured in serum of patients for assessing disease severity.

Results: The results, as shown in Figure 1, indicated that the serological levels of CRP (P=0.004), RF (P=0.0004), and ACPA (P=0.009) were significantly elevated in the Hp-positive group compared to the Hp-negative group.

Conclusion: Hp-positive RA patients present with higher levels serological of CRP, RF, and ACPA, which suggested that Hp infection could influence the disease progression or severity of RA. Thus, further research is required to investigate the pathogenic mechanism of Helicobacter pylori in rheumatic diseases.

Disclosure of Interests: None declared.

Figure 1. The serological levels of CRP (A), RF (B), and ACPA (C) in two groups. *P<0.05, **P<0.01, ***P<0.001.
indicating that the increase in total IgA is not due to translocation of mucosal IgA into the bloodstream. However, chronic mucosal inflammation might be one of the mechanisms involved in the raise in IgA(2) levels in RA, given the association between smoking and total IgA levels. Despite its pro-inflammatory properties, no strong associations between IgA2 and markers of inflammation were found, which suggests that IgA2 does not play a essential role in the ongoing pro-inflammatory processes in RA patients.

REFERENCES:

Disclosure of Interests: None declared

AB0078 NESFATIN-1 EXPRESSION ASSOCIATED WITH A MARKER FOR BONE MATRIX FORMATION P1NP IN RHEUMATOID ARTHRITIS
L. Seewordova1, J. Polyakova1, E. Papichev1, Y. Akhverdyan1, B. Zavadovsky1
1Federal State Budgetary Institution «Zborovsky Research Institute of Clinical and Experimental Rheumatology», lab. methods of treatment and prevention of joint diseases, Volgograd, Russian Federation

Background: Currently, the role of tissue cytokines in the pathogenesis of various diseases is being actively studied [1,2]. Nesfatin-1 (NF-1) is an endogenous peptide with melanotropin activity. Recently, there have been works on the involvement of NF-1 in osteogenesis. In the experiment, intravenous administration of NF-1 to ovariectomized rats (OVX) leads to an increase in bone mineral density (BMD). There are works showing inhibition of osteoclastogenesis in mice [3,4]. We assume that the level of NF-1 affects the processes of bone matrix formation. The aim of the study was to determine the relationship between the level of NF-1, bone mineral density, composite body composition and markers of bone metabolism in patients with rheumatoid arthritis (RA).

Objectives: The study randomized 110 patients with RA according to the ACR/EULAR criteria, 2010 and 30 people in the control group.

Methods: All of them underwent osteodensitometry LUNAR DPX-Pro with the determination of composite body composition (BCT) and bone mineral density (BMD). NF-1 levels and bone turnover markers were determined using a commercial ELISA test.

Results: The average concentration of NF-1 in patients with RA was 50.49±34.05 ng/ml, which is significantly higher than in healthy individuals. The average level of NF-1 in the blood serum of healthy individuals was 31.61±13.7 ng/ml (M±SD). The level of reference indicators of NF-1 in healthy individuals, defined as M±2SD, ranged from 25.27 to 37.95 ng/ml.

According to the level of NF-1, all patients with RA were divided into 2 subgroups. The 1st group included patients (n=44) with normal serum NF-1 concentration (less than 37.95 ng/ml), the 2nd group (n=66) included patients with elevated NF-1 levels (more than ng/ml).

During the analysis of the results of the study, we revealed a statistically significant correlation between NF-1 and the N-terminal propeptide of type I procollagen (P1NP) (r = 0.218, p = 0.022). The level of CRP and the erythrocyte sedimentation rate positively correlated with the indicators of NF-1.

We found no relationship between NF-1 levels and BMD; composite body composition; as well as the level of C-terminal type I collagen telopeptide (i-CTx).

Conclusion: Thus, the relationship between nesfatin-1 and a marker of bone matrix formation (P1NP) was revealed. This may indicate a possible effect of nesfatin-1 on the differentiation and function of osteoblasts.

REFERENCES:


Disclosure of Interests: None declared

AB0079 THERAPEUTIC EFFECT OF ANTIGEN B, A PROTEIN FROM ECHINOCOCCUS GRANULOSUS, IN EXPERIMENTAL ARTHRITIS
M. L. Gasparini Vieira2, M. Farinon1, R. T. Pedro1, V. Schuck Clarimundo1, A. Zaha3, H. Bunsellmeyer Ferreira4, K. Mariane Monteiro5, P. Gnielwas de Oliveira6, R. Xavier7 on behalf of Laboratorio de Doencas Autoimunes. 1Federal University of Rio Grande do Sul, Laboratory of Doencas Autoimunes, Porto Alegre, Brazil; 2Federal University of Rio Grande do Sul, Departamento de Biologia Molecular e Biотecnologia, Porto Alegre; 3Hospital de Clínicas de Porto Alegre, Serviço de Reumatologia, Porto Alegre, Brazil

Background: Antigen B (AgB) is a lipoprotein secreted in the hydatic cyst by Echinococcus granulosis larval stage and seems to be responsible for regulating the immune balance of host via Th2 response to promote survival of the parasite. A Th2 response can suppress the pro-inflammatory Th1 response generated in several immunopathologies, such as rheumatoid arthritis.

Objectives: To evaluate the anti-inflammatory and immunomodulatory effects of AgB in mice models of Zymozan-induced arthritis (ZIA), Antigen-induced arthritis (AIA) and Collagen-induced arthritis (CIA).

Methods: In all models, mice were divided into three groups: vehicle (saline), AgB 2 μg and AgB 10 μg (intraperitoneal once a day). In ZIA, arthritis was induced in Balb/c mice with an intra-articular (ia) injection of zymosan in the left knee joint thirty minutes after treatment. Nociception was analyzed over a 6h period and mice were euthanized 6h after arthritis induction to assess leukocyte migration into the joint. In AIA, Balb/c mice were sensitized by subcutaneous (sc) injection of methylated bovine serum albumin (mBSA) on day 0. Booster was administered on days 7 and 14. On day 21, arthritis was induced by ia injection of mBSA in the left knee joint. The treatment was performed 24h and 30min before the ia injection of mBSA. Nociception was analyzed over a 24h period and mice were euthanized 24h after arthritis induction to assess leukocyte migration into the joint. Male DBA/1J mice had CIA by subcutaneous injection of an emulsion containing Freund’s adjuvant and bovine collagen type II on days 0 and 8. The treatment took place between the 18th and 45th day after induction, as well as the evaluation of clinical arthritis score and nociception. Serum concentrations of IL-2, IL-4, IL-6, IL-10, IL-17, IFN-γ and TNF were evaluated in AIA and CIA.

Results: In ZIA, both doses of AgB diminished leukocytes migration to the knee joint compared with vehicle (AgB 2ug: 5.6±2.7; AgB 10ug: 5.6±2.7; vehicle: 4.8±3.1, p<0.05), but did not affect nociception. In AIA, both doses of AgB reduced nociception (AgB 2ug: 7.3±1.6; AgB 10ug: 7.2±1.6; vehicle: 6.0±2.1, p<0.01). Moreover, treatment with 2 μg of AgB inhibited in 70% the neutrophils migration (12.0±9.0, p<0.001) as well as it was reduced in mice treated with 10 μg of AgB as much as 58% (8.9±7.5, p<0.001), compared with control/vehi-

Conclusion: These results suggest an effect of AgB on the initial pathophysiology of arthritis, reducing the influx of inflammatory cells to the knee joints of mice with CIA and arthritis. It also showed anti-inflammatory and anti-atherogenic potential on murine models of rheumatoid arthritis, highlighting the immunomodulatory role of parasitic helminth proteins on immune-mediated diseases.

REFERENCES:

Disclosure of Interests: None declared
GDF-11 AND GDF-8 INVOLVEMENT IN MUSCLE IMPAIRMENT OF COLLAGEN-INDUCED ARTHRITIS MODEL

B. Bartolucci1,2, M. Farinon1,2, T. Hein da Rosa1,2, R. T. Pedo1, T. Karnopp1,2, R. Cavalheiro do Espírito Santo1,2, J. Miranda de Souza Silva1,2, R. Xavier1,2, R. C. de Porto Alegre, Autoimmune diseases laboratory, Porto Alegre, Brazil; 1Federal University of Rio Grande do Sul, Medical Sciences program, Porto Alegre, Brazil; 2Federal University of Rio Grande do Sul, Rheumatology Service, Porto Alegre, Brazil

Background: Rheumatoid arthritis is an autoimmune, inflammatory disease which affects primarily synovial joints and can induce skeletal muscle wasting (1). It is known that growth differentiation factors 8, 11 plays an important role in muscle homeostasis (2-3).

Objectives: Evaluate muscle mRNA and protein expression of GDF-8, GDF-11 in early and established stages of collagen-induced arthritis.

Methods: DBA1/J mice, were randomized into 5 groups: baseline animals (BL); control animals evaluated at days 25 and 50 (CO25=8, CO50=8) and collagen-induced arthritis mice evaluated at day 25 and 50 (CIA 25=8, CIA 50=8). Clinical score, paw edema, and body weight were evaluated. Clinical score, hind paw edema, and body weight were assessed. Grip strength, nociception, fatigue time, and walking speed were measured on days 0, 18, 25, 50 of experimentation. Animals were euthanized on days zero (BL group), 25 (CIA 25 and CO 25) and 50 (CIA 50 and CO 50) after disease induction. TA muscle was used to myofiber cross-sectional and GA muscle was used to evaluate gene expression of GDF-8, GDF-11 levels via qRT-PCR. Protein expression of GDF-8, GDF-11 levels in GA muscle was performed by ELISA.

Results: There was an increase in the CIA 25 and established CIA 50 groups was confirmed by high values of clinical score, nociception, paw edema and histological score when compared to the respective controls (p<0.001; p=0.001; p=0.001). There was an increase in the CIA 25 group and a worsening in this decrease at CIA 50 (p=0.0021, p=0.007). Fatigue time was shorter in CIA 25 compared to CO 25 (p=0.006) and maintained in CIA 50 (p=0.006). Walking speed showed a decrease in both time points (p=0.001; p=0.000). After normalization by body weight, only the CIA muscle had weight loss in CIA 50 when compared to CO 50 (-34.5%). Similarly, the CSA TA muscle myofiber showed a reduction of 14.04% only at CIA group compared to the CO 50 (p=0.026). The GA muscle GDF-11 mRNA levels were higher in the CIA 25 group compared to the CO 25 and BL groups (p=0.004; p=0.007 respectively); in CIA 50, there was a trend towards increased muscle GDF-11 mRNA levels (p=0.07). The protein expression of GDF-11 in serum samples did not show any differences between the analyzed groups; however, in GA muscle, GDF-11 protein expression showed differences at the CIA 25 (p=0.0023) and the CIA 50 group (p=0.017) compared with the respective controls and a significant difference in muscle protein expression between the CIA 25 groups and CIA 50 (p=0.0138). There was a decrease in mRNA content of GDF-11 on muscle, in CIA 50 and a decreased between the CIA 25 and CIA 50 in GA muscle (p=0.0377; p=0.0019); GA muscle had an increase of GDF-8 protein levels compared with the CIA 25 and CIA 50 group (p=0.001), while protein levels in serum of GDF-8 were increased in CIA 50 compared with CO 50 (p=0.037). Low muscle strength was associated with higher protein levels of GDF-11 in GA muscle (r=-0.64, p=0.01) and decreased walking speed (r=-0.534, p=0.04). Higher serum levels of GDF-8 were associated with higher muscle strength (r=0.74, p=0.02) and increased walking speed (r=0.64, p=0.01).

Conclusion: At early arthritis, GDF-11 mRNA and protein expressions were increased and are related to the physical impairment, while GDF-8 expression is reduced at established disease and increased in serum over time in CIA model, possibly as GDF-8 had a more systemic role in inflammatory arthritis. Thus, the GDFs may have a role in muscle outcome in the CIA model and can be involved in muscle atrophy and loss of physical function in RA.

REFERENCES:

Disclosure of Interests: None declared


BIODISTRIBUTION OF NIPOCALIMAB (ANTIHUMAN FCRN ANTIBODY) IN HUFCRN TRANSGENIC MICE

A. Vermeulen1, J. H. Leu2, S. Sipsey3, S. Lee2, L. Ling1, Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 2Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, Spring House, PA; 3United States of America; 4Biologics Discovery, Janssen Research and Development, Cambridge, MA, United States of America; 5Translational Sciences, Immunology, Janssen Research and Development, Cambridge, MA, United States of America

Background: Nipocalimab (JNJ-80202135, M2B1) is a fully human IgG1 monoclonal antibody (mAb) designed to bind to the human FcRn receptor with high affinity at both neutral and acidic pH, and is currently in investigational clinical trials. The primary role of FcRn is to extend the half-life of IgG due to its ability to bind, salvage, and recycle IgG in the circulation. Nipocalimab specifically targets the FcRn IgG binding site, thereby interfering with the binding of native IgG, reducing IgG recycling and accelerating IgG clearance (1).

Objectives: To determine the biodistribution of nipocalimab compared to an iso-type control IgG in huFcRn transgenic (Tg32) mice. This type of study is well suited to non-invasively determine the blood PK of labeled antibodies, as well as the kinetic biodistribution into various organ systems.

Methods: Four formulations were prepared for dosing: nipocalimab-VT680XL (N027a), nipocalimab-VT680XL plus 2x unlabeled nipocalimab (N027b), iso-type control IgG-VT680XL and control vehicle. The biodistribution assessment experiments were performed in Tg32 mice (n=3/group, strain: B6.Cg-Fcgrttm1Dcr Tg[FCGRT]32Dcr/J). A time series of in vivo fluorescence- mediated tomography (FMT) imaging sessions of body and brain was collected to follow the biodistribution of antibodies (Abs) after single IV administration. In vivo, whole body fluorescence was assessed immediately after administration of each formulation, and at 1, 5, 24, 48, 72, 96 and 144 hrs post administration. Mice were killed at the final in vivo imaging timepoint, followed by resection of tissues and ex vivo imaging. The in vivo tissues were also resected ex vivo at the terminal time point by exsanguination, Ex vivo fluorescence measurements were obtained for gall bladder, muscle, spleen, pancreas, white blood cells, lymph nodes, and intestines, which were flushed prior to imaging to remove fecal material.

Results: Biodistribution of nipocalimab and control IgG1 mAb were similarly observed to exhibit 2-compartment blood pharmacokinetics, dominant liver accumulation with minimal kidney and bladder signal and a prolonged terminal half-life in circulation (70-90h). Nipocalimab showed only subtle differences compared to IgG1 control antibody, attributed to specific binding to target antigen. Early tissue accumulation/binding was seen between 1 and 5 hrs post-injection, which yielded an apparent, modest increase in blood clearance and a slightly lower AUC as compared to control IgG. The bulk of increased tissue binding could be attributed to liver retention, with trends for lower accumulation/binding in other tissues, such as pancreas, lung, and muscle. Addition of 2-fold excess of unlabeled nipocalimab to the labeled nipocalimab yielded some small trends of changes in biodistribution of the labeled material.

Conclusion: Whole body biodistribution and blood pharmacokinetics of nipocalimab were similar to that observed for the isotype control IgG1 antibody. Nipocalimab exhibited a subtle trend towards higher liver distribution within the first 5 hours after dosing and a more rapid distribution phase compared to the control antibody. This is possibly related to its FcRn targeting and its shorter anticipated halflife compared to isotype control IgG or other human IgG mAbs. Overall results for both nipocalimab and control IgG were typical for IgG mAbs.

REFERENCES:

Acknowledgements: We would like to acknowledge Brigit Schulte and Such- Anita Roy (Momента Pharmaceuticals Inc.) and Jeff Peterson (Perkin Elmer) for their help with the execution of the study.


Background: Rheumatoid arthritis (RA) is a common autoimmune disease with inflammation. Total saponins of Panax japonicus (TSPJs) are effective components extracted from Panax japonicus. They are known to exhibit anti-inflammatory and immunosuppressive properties, but their effect of anti-inflammation in collagen-induced arthritis (CIA) remains unclear.

Objectives: To investigate the anti-inflammatory targets of TSPJ predicted by bioinformatics and the verification in CIA mice.

Methods: The targets of RA are obtained in the GeneCards database, we used Cytoscape 3.7.2 software to construct a protein-protein interactions (PPI) network and obtain the hub genes. There are four effective components of TSPJ: Araloside A, chikusetsusaponin IVA, ginsenoside Rg2, and ginsenoside Ro.

Through molecular docking between the screened hub genes and the four effective components of TSPJ, the possibility of TSPJ treating CIA mice can be predicted. The collagen II (COL) and complete Freund’s adjuvant (CFA) were used to induce the CIA model. After establishing the model, 32 DBA1/J mice were divided into G group (n=8), M group (n=8), and H group (n=8). The L and H groups were gavaged with TSPJ at 30 mg/kg or 150 mg/kg, and the C and M groups were gavaged with normal saline. The thickness of the hind paw, number of swollen joints, and arthritis index were evaluated. After 11 days of treatment, all the mice were sacrificed after anesthesia. Sera were collected to centrifuge tubes and the levels of inflammatory factor were determined by the ELISA kit following the instruction.

Results: A gene list that enriches 263 genes was obtained by searching RA from the GeneCards database. The hub genes of the top 3 obtained from Cytoscape 3.7.2 software were tumor necrosis factor (TNF), interleukin-1β (IL-1β), and interleukin-6 (IL-6). In addition, interleukin-17A (IL-17A), a classical inflammatory marker in the top 10, was selected and included in the predicted target. The results of molecular docking between the predicted target and the components of TSPJ showed that the combined pose has good stability. The numerical value of hind paw thickness, swollen joint counts, and arthritis index in the intervention groups were lower than those in the M group, suggesting TSPJ played a critical role in improving pathological changes. Compared to those of the C group, the serum levels of TNF-α, IL-1β, IL-6, and IL-17A were increased in the M group. Compared to those of the H group, the levels of TNF-α, IL-1β, IL-6, and IL-17A in the L and H groups were decreased. Compared to those of the L group, the levels of TNF-α, IL-1β, IL-6, and IL-17A in the H group were decreased. The results suggested that TSPJ may decrease the levels of TNF-α, IL-1β, IL-6, and IL-17A in CIA mice.

Conclusion: Current study demonstrated a novel inhibitory effect of TSPJ on inflammation in CIA mice, and TSPJ can act on the targets predicted by bioinformatics of CIA mice, suggesting the potential of TSPJ as a therapeutic agent for RA and providing new ideas for the clinical treatment of RA.

REFERENCES:

Acknowledgements: Jingsheng Zhang: Preparation, data presentation, and specifically writing the initial draft. Xiang Guo: Application of statistical, Verification. Qinpeng Bu and Xiaolian Shen: Conducting a research and investigation process. Provision of study materials. Zhizhu Feng: Ideas, Design of methodology, and including mentorship external to the core team.

Disclosure of Interests: None declared

DOI: 10.1136/rheumatoid-2022-eular.3460

AB0083

BACKGROUND: Anti-inflammatory effects of total saponins of Panax japonicus on rheumatoid arthritis

J. Zhang1,2, X. Guo1,2, Q. Bu1,2, X. Shen1,2, Z. Feng1,2. 1Chinese Medicine Approved by State Administration of Traditional Chinese Medicine, Third-Grade Pharmacological Laboratory, Yichang, Hubei, China; 2China Three Gorges University, Medical College, Yichang, Hubei, China

Background: Rheumatoid arthritis (RA) is a common autoimmune disease with inflammation. Total saponins of Panax japonicus (TSPJs) are effective components extracted from Panax japonicus. They are known to exhibit anti-inflammatory and immunosuppressive properties, but their effect of anti-inflammation in collagen-induced arthritis (CIA) remains unclear.

Objectives: To investigate the anti-inflammatory targets of TSPJ predicted by bioinformatics and the verification in CIA mice.

Methods: The targets of RA are obtained in the GeneCards database, we used Cytoscape 3.7.2 software to construct a protein-protein interactions (PPI) network and obtain the hub genes. There are four effective components of TSPJ: Araloside A, chikusetsusaponin IVA, ginsenoside Rg2, and ginsenoside Ro.

Through molecular docking between the screened hub genes and the four effective components of TSPJ, the possibility of TSPJ treating CIA mice can be predicted. The collagen II (COL) and complete Freund’s adjuvant (CFA) were used to induce the CIA model. After establishing the model, 32 DBA1/J mice were divided into G group (n=8), M group (n=8), and H group (n=8). The L and H groups were gavaged with TSPJ at 30 mg/kg or 150 mg/kg, and the C and M groups were gavaged with normal saline. The thickness of the hind paw, number of swollen joints, and arthritis index were evaluated. After 11 days of treatment, all the mice were sacrificed after anesthesia. Sera were collected to centrifuge tubes and the levels of inflammatory factor were determined by the ELISA kit following the instruction.

Results: A gene list that enriches 263 genes was obtained by searching RA from the GeneCards database. The hub genes of the top 3 obtained from Cytoscape 3.7.2 software were tumor necrosis factor (TNF), interleukin-1β (IL-1β), and interleukin-6 (IL-6). In addition, interleukin-17A (IL-17A), a classical inflammatory marker in the top 10, was selected and included in the predicted target. The results of molecular docking between the predicted target and the components of TSPJ showed that the combined pose has good stability. The numerical value of hind paw thickness, swollen joint counts, and arthritis index in the intervention groups were lower than those in the M group, suggesting TSPJ played a critical role in improving pathological changes. Compared to those of the C group, the serum levels of TNF-α, IL-1β, IL-6, and IL-17A were increased in the M group. Compared to those of the H group, the levels of TNF-α, IL-1β, IL-6, and IL-17A in the L and H groups were decreased. Compared to those of the L group, the levels of TNF-α, IL-1β, IL-6, and IL-17A in the H group were decreased. The results suggested that TSPJ may decrease the levels of TNF-α, IL-1β, IL-6, and IL-17A in CIA mice. These results suggest that TSPJ may inhibit the inflammatory effects of CIA mice.

Conclusion: Current study demonstrated a novel inhibitory effect of TSPJ on inflammation in CIA mice, and TSPJ can act on the targets predicted by bioinformatics of CIA mice, suggesting the potential of TSPJ as a therapeutic agent for RA and providing new ideas for the clinical treatment of RA.

REFERENCES:

Disclosure of Interests: None declared


AB0084

BACKGROUND: Increased liver disease risk in rheumatoid arthritis is associated with disease activity, inflammatory markers, insulin resistance and acpAs. influence of methotrexate

I. Arias de la Rosa1, M. Ruiz-Ponce2, L. Cuesta Lopez3, M. D. Gałate4, N. Herman-Sanchez4, A. Lucendo-Villarin5, P. Navarro-Sanchez4, M. C. Abalos-Aguilera4, C. Perez-Sanchez4, R. Ortega Castro4, J. Calvo Gutierrez4, C. Lopez-Pedrera5, A. Escudero Contreras2, E. Collantes Estevez6, N. Barbarroja Puerto7. 1UFRy-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Genomic Medicine, Granada, Spain; 2IMIBIC/Reina Sofia Hospital, Rheumatology Department, Cordoba, Spain; 3University of Cordoba/IMIBIC/Reina Sofia Hospital, Cell Biology, Immunology and Physiology Department, Cordoba, Spain; 4Hospital General de Tomelloso, Gastroenterology Department, Cuidad Real, Spain; 5University of Cordoba/IMIBIC/Reina Sofia Hospital, Medicine and surgical sciences, Cordoba, Spain

Background: Liver alterations, especially nonalcoholic fatty liver disease (NAFLD) are associated with Rheumatoid Arthritis (RA). This abnormality appears as asymptomatic and can progress to a severe liver damage rapidly. Chronic inflammation, treatment with methotrexate (MTX) or even autoimmune factors are factors that might be involved, however the mechanisms related to this comorbidity in RA are not completely established yet.

Objectives: 1) To evaluate the liver disease risk in RA patients through feasible indexes to be used in the daily clinical practice and its relationship with clinical features of the disease; 2) To analyze the impact of antibodies to citrullinated peptides (ACPs) on hepatic function; 3) To examine the influence of MTX treatment on clinical parameters and new indices of hepatic dysfunction in a cross-sectional and longitudinal cohort.

**Methods:** 1) Cross-sectional study in 307 body mass index matched subjects: 55 healthy donors (HDs), 190 RA patients and 62 non-RA patients diagnosed with NALFD through echography. Obese patients were excluded from the study. 2) Longitudinal study with 50 RA patients treated with MTX for 6 months. Clinical and laboratory parameters, subclinical liver disease biomarkers and 4 indexes to evaluate the presence of fibrosis and steatosis (APRI, AST to platelet ratio index”); FIB-4, “fibrosis 4 score”; HSI, “hepatic steatosis index” and TyG, “triglycerides and glucose index”) were measured. Association studies of hepatic dysfunction with clinical parameters were performed; A panel of 15 proteins directly involved in hepatic disease was analyzed in serum (C1QTNF1, IL7R, TIE1, CCL5, REG3A, C3A, LCN2, CCL14, NRP1, ICAM3, CD59, TIMP1, CNDP1, GNL1, IGFB8). 3) In vitro experiments were carried out in hepatocyte cell line (HEPG2) treated with ACPAs.

**Results:** Using NALFD patients as positive controls for the four liver disease indexes, RA patients showed significantly higher levels of HSI and TyG biomarkers. In fact, a high proportion of these patients (42.7%) were estimated to suffer NALFD. The association studies in RA patients showed that liver disease biomarkers (HSI and TyG) were related to the insulin resistance state, inflammation, complement component 3(C3), disease activity, and the levels of ACPAs. Serum levels of CNDP1, CCL5, GNL1, TIMP-1, CD59 and CCL14 were significantly increased in RA patients and correlated with hepatic damage indexes. Treatment with ACPAs on hepatocytes promoted the secretion of C3 in parallel with a significant alteration of genes related to glucose and lipid metabolisms, inflammation, fibrosis and apoptosis. MTX treatment, from the point of cross-sectional analysis, was not associated with an increase of hepatic enzymes, serum proteins nor liver disease indexes. Treatment with MTX for 6 months did not affect those levels either.

**Conclusion:** 1) A high proportion of RA patients present an alteration in markers of NALFD, associated with insulin resistance state, disease activity, inflammation, component C3 and ACPAs levels; 2) the autoantibodies could directly impact hepatocyte biology altering the expression of genes related to glucose and lipid metabolisms, inflammation, fibrosis and apoptosis. 3) Treatment with MTX did not promote any alteration in subclinical liver disease biomarkers after 6 months of treatment. Funded by Institute of Health Carlos III (PI20/00073).

**Disclosure of Interests:** None declared

**AB0085 TIGLYLCARNITINE AS KEY FACTORS IN LIVER–JOINT AXIS**

H. Wang1, Y. Zhang1. 1Qilu Hospital, Department of Clinical Laboratory, Jinan, China

**Background:** Gut microbiota could promote RA progression metabolites mediated gut–joint axis [1]. We previously reported that liver metabolism has a close linkage with Rheumatoid arthritis (RA) [2]. However, the inter-relational mechanisms between liver and joint are still unclear.

**Objectives:** This article aimed to explore the shared metabolites signatures of liver, plasma and joint in RA.

**Methods:** We integrated multomics datasets metabolites of liver and plasma from in the healthy group (n=10) and CIA group (n=10), and metabolites of knee-joint fluid (synovial fluid) from 40 participants in osteoarthritis (OA) group (n=20) and RA group (n=20). The Weighted Gene Co-Expression Network Analysis (WGCNA) was used to identify the co-expression modules related to liver, plasma and joint.

**Results:** The blue modules were negatively correlated with CIA (r = 0.74, p < 0.001), included 200 liver metabolites. The black modules were positively correlated with CIA (r = 0.63, p < 0.001), included 78 plasma metabolites. The yellow modules were positively correlated with RA (r = 0.53, p = 0.008), included 55 synovial fluid metabolites. There were only 1 metabolite (Tiglylcarnitine) overlapped in RA-related module of liver, plasma and joint.

**Conclusion:** Tiglylcarnitine may be the key factors to liver–joint axis.

**REFERENCES:**


**Figure 1. Tiglylcarnitine as Key Factors in liver-joint axis. A The cluster dendrogram of co-expression genes and module.es B The shared metabolites between the blue module of liver, the black module of plasma, and yellow modules of synovial fluid. C The chemical structures of Tiglylcarnitine.

**Acknowledgements:** Funded by Natural Science Foundation of Shandong Province (ZR2021QH329).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4167

**AB0086 PORPHYROMONAS GULAE INFECTION IS NOT RELATED TO EXOGENOUS CITRULINATION OR DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS**

C. Castellar1, D. M. Castillo2, L. Chila3, W. Bautista-Molano4, J. M. Bello-Guaiteras4,5, C. Romero-Sánchez4,5,1.1Universidad El Bosque, School of Science, Biomedical Master Program, Bogotá D.C., Colombia; 2Universidad El Bosque, Unit of Basic Oral Investigation, School of Dentistry, Bogotá D.C., Colombia; 3Universidad El Bosque, Cellular and Molecular Immunology Group - INMUBO-, Bogotá D.C., Colombia; 4Universidad Militar Nueva Granada, School of Medicine, Clinical Immunology Group, Bogotá D.C., Colombia; 5Hospital Militar Central, Rheumatology and Immunology Department, Bogotá D.C., Colombia.

**Background:** Porphyromonas gulae (P. gulae) is a Gram negative microorganism of the Porphyromonadaceae family. It presents in its structure virulence factors similar to P. gingivalis, including the PAD enzyme. An enzyme responsible for catalyzing citrullination, related to the formation of autoantibodies against citrullinated peptides associated with Rheumatoid Arthritis (RA).

**Objectives:** To evaluate the presence of P. gulae and anti-citrullinated peptide antibodies of P. gulae PAD in patients with RA and their possible association with clinical markers of activity.

**Methods:** Ninety RA patients and 90 controls matched for age and sex were included. Serum levels of rheumatological markers such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-citrullinated protein antibodies (Anti-CCP/ACPA) and rheumatoid factor (RF) were measured. Disease activity was assessed using Disease Activity Indices-28 (DAS28) and SCDAI. The periodontal diagnosis was according to CDC and American Academy of Periodontology. The presence of P. gulae was established by qPCR, verifying the specificity and confirmed due to the high homology between P. gingivalis and P. gulae. The presence of antibodies against 2 peptides called VDK and LPO were evaluated in their native structure and citrullinated at one end and inside the PPA molecule of P. gulae. It was determined by ELISA in-house. Prediction of B and T epitopes of PPA from P. gulae was made taking into account the location of arginines within the molecule, restricting it to HLA alleles associated with RA. Associations were established by Kruskal Wallis, Mann Whitney U tests and multiple correspondence discriminant analysis (MCDA) in SPSS V24 and STATA for Windows software, with a significance of 95%, p ≤ 0.05.
**Results:** A frequency of *P. gulae* was observed in the RA group of 15.8% versus controls of 9.5%; *p*<0.0125. A despite finding a diagnosis of periodontitis in 70.3% of the patients, it was not associated with clinical severity or diagnosis of periodontitis. Comparisons were made classifying the patients according to periodontal diagnosis, the presence of *P. gulae* was observed more frequently in the RA group with a diagnosis of periodontitis, compared to the control group (6.7% vs 2.5%, respectively) without statistical significance (p=0.2576). Of the 180 individuals evaluated, 17 had the presence of anti-citrullinated peptide antibodies of *P. gulae* PAAD. Despite a higher frequency in the RA group of antibodies against two citrullinated peptides, the results were not significant (p=0.378 and p=0.346), there was no evidence of a relationship with activity or disease markers in RA. The MCDA test generated two dimensions, one with the clinical activity variables of RA with CC: 0.218, and a second dimension in which the presence of anti-citrullinated peptide antibodies of PAD CC were related to each other CC: 0.748; No positive correlation was found between the clinical variables of RA and the anti-citrullinated peptide antibodies of *P. gulae* PAD.

**Conclusion:** Despite the presence of *P. gulae* and PAD citrullinated peptide antibodies from *P. gulae* in patients with RA, it was not possible to establish the relationship with clinical variables, which could indicate a lower contribution of this microorganism to the biological mechanism and molecular of citrullination common between RA and periodontitis. However, an additive effect of *P. gulae* with *P. gingivalis* in the citrullination process cannot be ruled out.

**Acknowledgements:** The Ministry of Science, Technology, and Innovation - MinCiencias (Grants No. 55642, 531734 and 740792). Universidad El Bosque (PCI-2018-10441), Hospital Militar Central and Fundación Instituto de Reumatología Fernando Chalem, in Bogota, Colombia.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4179

---

**AB0087**

**THE EFFECT OF BARICITINIB ON STAT1 PHOSPHORYLATION IN MONOCYTES FROM RHEUMATOID ARTHRITIS PATIENTS**

C. Garuti1, G. Tucci1, I. Pacella1, M. Zagaglioni1, A. Pinzon Grimaldos2, F. Cecarelli1, S. Picone1, F. R. Spinelli1, F. Conti1. 1Sapienza University of Rome, Department of Internal Clinical Sciences, Anesthesiology and Cardiovascular Sciences, Roma, Italy

**Background:** Baricitinib is a Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA)1-2. STAT proteins bind JAK kinase dimers coupled with cytokine receptors and regulate gene transcription. The JAK/STAT system is responsible for the intracellular signaling of different cytokines contributing to the activation process of the monocyte lineage, therefore the use of JAK inhibitors can affect cell functionality3-4. **Objectives:** The aim of the present study was to verify the effects of baricitinib on STAT phosphorylation in peripheral mononuclear cells (PBMCs) of RA patients and to evaluate any correlation between STAT phosphorylation and response to therapy.

**Methods:** At baseline (BL) and after 4 weeks (w4) of treatment, we evaluated patients’ disease activity (DAS28cR, CDAI and SDAI), dividing them into responders and non-responders according to the Minimal Clinically Important Difference for DAS28cR (1.2 points) at w4. The phosphorylation of STAT1, STAT5 was analyzed at BL and W4 in gated monocytes, Treg, CD8+ and CD4+ lymphocytes from 4 responder and 4 non-responder patients through flow cytometry, at basal conditions and after IL2, IFN and IL6 stimulation.

**Results:** Baseline clinical and demographic characteristics of patients are reported in Table 1. We showed that monocyte count decreased from BL to w4 mostly in responders. Basal pSTAT1 phosphorylation tended to be higher in monocytes of non-responders patients; after 4 weeks of treatment, the reduction of the cytokine-induced pSTAT1 was significantly greater in monocytes from responders compared to non-responders (Figure 1). The phosphorylation of STAT4 and STAT5 was not affected by treatment in any cell type and at any time point. We further studied the STAT1 phosphorylation pathway isolating the effect of stimulation with IFN and stratifying monocytes according to their surface marker expression of CD14 and CD16 in classical, intermediate and non-classical. We observed the same pattern with a significant greater reduction of pSTAT1 in monocytes from responder patients, compared to non-responders, after the treatment with baricitinib.

**REFERENCES:**


**Disclosure of Interests:** Cristina Garuti Consultant of: Lilly, Gloria Tucci: None declared, Ilenia Pacella: None declared, Marta Zagaglioni: None declared, Alessandra Pinzon Grimaldo: None declared, Fulvia Cecarelli: None declared, Silvia Picone: None declared, Francesca Romana Spinelli Consultant of: Lilly, Fabrizio Conti Consultant of: Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.4332

---

**Table 1. Clinical and demographic characteristics of Rheumatoid Arthritis patients.**

<table>
<thead>
<tr>
<th>Clinical and demographic characteristics</th>
<th>N=8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (IQR)</td>
<td>59 (8)</td>
</tr>
<tr>
<td>Female/Male</td>
<td>7:1</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>-Caucasian n (%)</td>
<td>6 (75)</td>
</tr>
<tr>
<td>-Hispanic n (%)</td>
<td>2 (25)</td>
</tr>
<tr>
<td>Disease duration (months), median (IQR)</td>
<td>156 (201)</td>
</tr>
<tr>
<td>Rheumatoid Factor, n (%)</td>
<td>3 (37.5)</td>
</tr>
<tr>
<td>ACRA, n (%)</td>
<td>4 (50)</td>
</tr>
<tr>
<td>Number of previous csDMARDs, n (%)</td>
<td></td>
</tr>
<tr>
<td>-1</td>
<td>2 (25)</td>
</tr>
<tr>
<td>-2</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>-3</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>-≥ 4</td>
<td>4 (50)</td>
</tr>
<tr>
<td>Number of previous bDMARDs, n (%)</td>
<td></td>
</tr>
<tr>
<td>-1</td>
<td>2 (25)</td>
</tr>
<tr>
<td>-2</td>
<td>2 (25)</td>
</tr>
<tr>
<td>-3</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>-≥ 4</td>
<td>3 (37.5)</td>
</tr>
<tr>
<td>Baricitinib in monopary, n (%)</td>
<td>5 (62.5)</td>
</tr>
<tr>
<td>Daily PDN dose, median (IQR)</td>
<td>5 (6)</td>
</tr>
</tbody>
</table>

ACRA: anti-citrullinated protein antibodies; csDMARDs: conventional synthetic disease-modifying antirheumatic drugs; bDMARDs: biological disease-modifying antirheumatic drugs; PDN: prednisone.

---

**Figure 1.** STAT1 phosphorylation in responder (R) and non-responder (NR) patients at basal conditions (before stimulation) (a), and after cytokine (IL2, IFN and IL6) stimulation (b) at baseline and at T1 (week 4).

**Conclusion:** These results may suggest that monocyte count and STAT1 phosphorylation in circulating monocytes could represent early markers of response to baricitinib therapy.

---

**AB0088**

**DOUBLE-STRANDED DNA BREAKS ARE A MARKER OF THE INFLAMMATORY ACTIVITY OF RHEUMATOID ARTHRITIS**

A. Audeeva1, Z. Verizhnikova1, V. Rybakova1, V. Kozlova1, T. Popkova1, A. Lila1, E. Nasonova1, 1V.A. Nasonova Research Institute of Rheumatology, laboratory of immunology and molecular biology rheumatic diseases, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Department of systemic rheumatic diseases, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Medical Academy of Continuing Professional Education, Rheumatology, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, Scientific Department, Moscow, Russian Federation

**Background:** Double-strand DNA breaks (DNA-DSB) are one of the most biologically significant DNA damage lesions that leads to chromosome breakage and/or rearrangement, mutagenesis and loss or gain of genetic information. The phosphorylation of H2AX histone proteins which are located in the vicinity of the DSBs is known as one of the earliest responses to DNA DSBs in cells. Induction
of DNA DSBs in live mammalian cells triggers the phosphorylation near the C-terminal of H2AX protein, which results in the phosphorylated form of H2AX, termed γH2AX. [1,2].

Objectives: To examine DNA-DSB among patients with systemic autoimmune rheumatic diseases (SARDs) by evaluating phosphorylation γH2AX and 53BP1 at the site of injury.

Methods: The analysis included 25 patients with SARDs (19 with RA (16 women, Me,jOR the disease duration 60 (20-103) months, DSAS28-ESR 5.05 (4.06-6.91); 4 - with systemic lupus erythematosus (4 women, the disease duration 324 (204-372) months, SLEDAI-2K 9.5 (4.5-16.5) and 2 women with Sjögren’s disease. The control group consisted of 14 healthy donors, comparable in gender and age with the examined patients. DNA-DSB breaks were determined as a discrete focus during immunofluorescence staining with anti-γH2AX and anti-53BP1 antibodies of the lymphocyte culture, followed by analysis on the automated platform ALCIDES (Medipan, Berlin/Dahlewitz, Germany).

Results: There were no significant differences in the number of DNA breaks among patients with SARDs and healthy donors (p=0.05). There was a positive correlation between % pos. cells by γH2AX and CDAI (r=0.45 p=0.035), Nuclei with foci by 53BP1 and ESR (r=0.53 p=0.02) and IgM RF (r=0.63 p=0.005). Among patients with high CDAI activity (n=10), there was a greater number of Nuclei with foci by γH2AX - (22.5 (6.0-43.0); a higher average number of foci mean (0.39 (0.19-0.62) and a higher % pos. cells (32.6 (18.7-39.1) comparing with patients with low/moderate inflammatory activity (9.0 (2-12); 0.12 (0.02-0.28); 11.5 (1.8-23.5) accordingly, p<0.05, n=9).

Conclusion: The evaluation of double-stranded DNA breaks can be beneficial as an additional marker for assessing the disease activity among patients with RA.

REFERENCES:

Disclosure of Interests: None declared

AB0089 INTEGRIN Α111 DEFICIENCY AFFECTS THE COURSE OF DISEASE IN THE ARTHRITIC HTNFtG MOUSE


1University Hospital Muenster, Institute of Musculoskeletal Medicine, Münster, Germany; 2University of Cologne, Translational Matrix Biology, Köln, Germany; 3University of Bergen, Department of Biomedicine and Centre for Cancer Biomarkers, Bergen, Norway

Background: Rheumatoid arthritis (RA) is an autoimmune disorder conducted by fibroblast-like synoviocytes (FLS), which acquire a tumor-like phenotype with the examined patients. DNA-DSB breaks were determined as a discrete focus during immunofluorescence staining with anti-γH2AX and anti-53BP1 antibodies of the lymphocyte culture, followed by analysis on the automated platform ALCIDES (Medipan, Berlin/Dahlewitz, Germany).

Objectives: We herein sought to assess the value of total serum IgG Fc γ-glycosylation as a diagnostic and prognostic biomarker in patients with early inflammatory arthritis (EIA). Specifically, we aim to assess whether IgG N-glycoform levels may predict the diagnosis of RA or undifferentiated arthritis (UA) and the long-term disease's outcome in patients with EIA arthritis patients naïve to treatment.

Methods: The “Early Arthritis Clinic” of the University Hospital of Heraklion is a prospective cohort of patients with inflammatory arthritis. For the present study, we selected a group of patients naïve to any immunosuppressive treatments with available serum at baseline evaluation (n=118). At baseline, demographic, RA clinical characteristics (DSAS28, HAQ-DI) and laboratory tests (autoantibodies (RF and/or ACPA)), were also recorded. The patients were prospectively followed for two years, with clinical, laboratory and disease-related treatments documented. A diagnosis of RA or UA was based on established classification criteria 3. In order to assess long-term prognosis we formulated a combined “index” of favourable outcome if the patients fulfilled all the following at 24 months of follow-up: remission or low disease activity (based on DAS28 < 3.2) and normal functionality (based on HAQ ≤ 0.25) while on treatment with csDMARDs and never use bDMARDs. We applied a state-of-the-art liquid chromatography - mass spectrometry (LC-MS) based workflow for analysis of subclass-specific IgG Fc γ-glycosylation at the baseline 4.

Results: We studied 118 EIA patients (age, mean (SD), 53 (15.6) years, females (80.5%), symptoms duration (53.8, 8.7) years, ACPA positive (16%), DSAS28 (4.8, 0.14)). During the 2 years of follow-up, 60% of the patients were diagnosed with RA and 40% with UA. Although patients with UA had higher relative abundances of galactosylated and sialylated N-glycoforms (H4N4F1, H5N4F1 and H5N4F1S1) in all IgG subclasses at baseline compared to RA patients, differences were not statistically important. Interestingly, we observed a significant association between high levels of IgG2/3 galactosylation for H5N4F1 (effect 0.63, adjusted p=0.036) and H3N4F1 (effect -0.55122, adjusted p=0.0496) and favorable outcome after two years of treatment.

Conclusion: Our cohort of EIA we found IgG2/3 Fc N-glycoforms to be associated with a favorable prognosis after 2 years of follow-up. Should the present data be confirmed in a larger cohort could be of clinical value. Since currently available prognostic tools have significant limitations, further research should aim to the development of a predictive tool of high specificity and sensitivity based on the combination of clinical, serological data and novel biomarkers.

REFERENCES:
Background: Immunesenescence in the adaptive immune system, subsequent to thymic involution, results in compromised immunity and increased susceptibility to autoimmune disease and chronic inflammation. There are reports in the literature that the process yielding thymic atrophy and telomere shortening, is accelerated in patients with rheumatoid arthritis (RA). What is unclear is whether RA includes accelerated biological ageing overall in addition to immune ageing which may help to explain the increased risk of age-related diseases in RA2. Recent studies have identified a set of DNA methylated sites across the genome that are highly correlated with chronological age and mortality, termed epigenetic clocks3,4 or DNAm age (DNAma), and can be used to determine an individual's biological age.

Objectives: The aim of our study is to determine if the biological epigenetic clocks of RA patients are accelerated.

Methods: We evaluated the Horvath5 and Hannum6 epigenetic clocks of control and RA patients using published DNA methylation data, accessions GSE42861 (EIRA, Swedish cohort of 342 RA patients and 328 non-RA controls) and E-MTAB-6988 (77 RA discordant monozygotic twins).

Results: We did not detect significant differences between DNAma of RA and non-RA twins. Similarly, there were no significant differences between the DNAma of RA patients and controls from the Swedish EIRA cohort. However, we detected a significant acceleration in DNAma of male discordant twins, both RA and non-RA, by 5.4 years (p=3.29e-5) and 2.8 years (p=0.04) using the Hannum and Horvath clocks, respectively. Male participants, both control and RA patients, from the EIRA cohort also exhibited an accelerated DNAma, by 1.5 years (p=7.55e-5) using the Hannum clock but using the Horvath clock a significant DNAma acceleration, by 1.4 years (p=0.002) was detected in male RA patients from the EIRA cohort.

Conclusion: Overall, we detected a significant biological age acceleration in male patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatol 48:1309-1313.

REFERENCES:

Acknowledgements: The study was funded by FOREUM.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4480
AB0093  MODELING OF ANTIGEN-COLLAGEN-INDUCED ARTHRITIS IN BALB/C MICE

M. Fisher 1, V. Kurilin 1, S. Sennikov 1, 2 1Research Institute of Fundamental and Clinical Immunology, Laboratory of Molecular Immunology, Novosibirsk, Russian Federation

Background: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. Currently, disease-modifying drugs and biological agents are used to treat RA [1]. The available drugs are not perfect: they have serious side effects and do not always cause a stable improvement or remission [2]. The above sets the task of finding new approaches to treatment that will be effective, more specific and safe. In this connection, it is necessary to develop and apply experimental models as close as possible in pathogenesis to rheumatoid arthritis. One such model, rarely used at present, is the combined antigen-collegen-induced arthritis [3].

Objectives: To show immunological and histological changes similar to RA in the AIA/CIA model and the model of arthritis application in research activities.

Methods: Experimental AIA/CIA was induced according to 2 different protocols in 50 BALB/c mice. Clinical assessment of arthritis was made by measuring the swelling of the paws with a caliper at different times. The assessment of immunological changes included the analysis of the content of antibodies to type II collagen by ELISA, the content of T-regulatory cells by flow cytometry. Also, a histological analysis of the obtained data was carried out.

Results: On the 10th day, a significant increase in paw thickness was recorded in animals induced both according to the first and second protocols. The intensity of swelling subsided by the 23rd day. A significant increase in the content of antibodies to type II collagen was observed in all experimental groups, but in animals from Protocol No. 1, the amount of antibodies to type II collagen was significantly higher. A high level of T-regulatory cells was registered only in mice animals from the first protocol on the 10th day. Histological changes in the form of synovial hyperplasia, pannus, usurasations were observed to varying degrees in all experimental groups, but the most pronounced changes were in animals from the first protocol.

Conclusion: In experimental animals, in all the presented protocols, changes were observed that were closest to RA, when compared with classical models of experimental arthritis induction. Based on the fact that protocol 1 animals showed an increase in the content of T-regulatory cells, the levels of antibodies to type II collagen were consistently high, and the histological changes were the most pronounced, it can be assumed that protocol 1 of the combined AIA/CIA model on the line of Balb/c mice, is the most suitable for testing and developing new methods of RA therapy.

REFERENCES:

Disclosure of Interests: None declared


AB0094  DENDRITIC CELLS AS TARGETS OF PATHOGENETIC THERAPY FOR AUTOIMMUNE DISEASES

Y. Kurochkin 1, M. Korolev 1, E. Letyagina 1, A. Akimova 1, N. Banshhikova 1, V. Omechenko 1, Y. Ushabawa 1 1Research Institute of Clinical and Experimental Immunology - branch of the Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of Sciences, Rheumatology, Novosibirsk, Russian Federation

Background: Dendritic cells (DCs) are known to contribute to the pathogenesis of autoimmune diseases through presentation of cartilage glycoprotein, production of proinflammatory cytokines and activation of Th1/Th17 responses. DCs are a heterogeneous population and can be divided into groups: myeloid (mDCs) and plasmacytoid (pDCs). DCs can induce both immune response and tolerance.

Objectives: The study is aimed at investigating the subpopulations of peripheral blood DCs (myeloid and plasmacytoid) in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpa) under disease-modifying antirheumatic drugs (DMARDs) treatment as a target of pathogenic therapy.

Methods: There are thirty patients were included in the study. Twenty patients with early RA (ACR/EULAR criteria, 2010, duration of the disease up to 12 months) and ten patients with axSpa (ASAS criteria) were recruited. RA patients received methotrexate, leflunomide, sulfasalazine or their combination. All patients received NSAID in combination with conventional synthetic DMARDs. Analysis of the content of the B-lymphocytes, myeloid and plasmacytoid DCs was carried out by flow cytometry. B-lymphocytes, subtypes of peripheral blood DCs were characterized by the following phenotypes: myeloid DCs (CD3-CD14-CD19-HLA-DR + CD11c + CD123-), plasmacytoid DCs (CD3-CD14-CD19-HLA-DR + CD11c + CD123 +), B-lymphocytes (CD19 +). Analyses were performed before treatment and 6 months later.

Results: RA patients were characterized by high activity of the disease (DAS28=5.46). At the beginning we revealed significant increasing of the population of myeloid DCs (1.6%) and B-lymphocytes (5.4%). No significant differences were observed in the number of plasmacytoid DCs. After 6 months of treatment, most of the patients had a decrease in the activity of the disease (DAS28=3.05v.46, p=0.05, n=12) coupled with a significant decrease mDCs (0.85 vs16%, p=0.03) and B-cells (4.2 v.5.4%, p=0.05). In the remaining patients (n=8), there was no clinically significant improvement (DAS28=2.46) or differences in mDCs (1.45 vs1.6%) and B-cells (5.05vvs5.4%). Six months later, there was a decrease in ASDAS activity among axSpa patients (2.56 vs 2.09). We were revealed no differences in amount in mDCs between RA and axSpa patients (1.4 vs 1.6%). After 6 month of investigation we detected decreasing mDCs (1.4 vs 0.9%, p=0.05). We have also found a decrease in B lymphocytes among axSpa patients (5.1 v 4.1%) that is consistent with some authors data on B lymphocytes in spondyloarthritis pathogenesis.

Conclusion: Reduction in the number of DCs in the context of treatment combined with reduced activity of diseases confirm the role of DCs in the pathogenesis of autoimmune diseases. In addition, probably being a target of pathogenetic therapies they can serve as a marker of a good clinical response to the therapy.

Disclosure of Interests: None declared


AB0095  CHARACTERISTICS OF TUMOR NECROSIS FACTOR-ALPHA AND INTERLEUKIN-6-INDUCED OSTEOCLASTS IN PERIPHERAL BLOOD AND BONE TISSUE FROM PATIENTS WITH RHEUMATOID ARTHRITIS

K. Yokota 1, M. Sekikawa 2, S. Tanaka 2, a, Y. Azaki 1, Y. Kadono 2, H. Oda 3, T. Mimura 4, 1Saitama Medical University, Rheumatology and Applied Immunology, Saitama, Japan; 2Saitama Medical University, Orthopaedic Surgery; Saitama, Japan; 3Japan Community Health care Organization Saitama Northern Medical Center, Orthopaedic Surgery, Saitama, Japan; 4National Hospital Organization Ibusuki Medical Center, Orthopaedic Surgery, Kagoshima, Japan

Background: We have previously reported that stimulation of mouse bone marrow-derived macrophages with tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) induces differentiation of osteoclast-like cells having bone resorption ability 1. Recently, we have shown that the combination of TNF-α and IL-6 can induce osteoclasts from human peripheral blood mononuclear cells (PBMCs) via RANKL-independent pathways, and that there are functional differences between TNF-α and IL-6-induced osteoclasts (T6-OCs) and RANKL-induced, conventional osteoclasts (cOCs). In particular, the number of T6-OCs differentiated from PBMCs in patients with rheumatoid arthritis (RA) positively correlated with the modified total Sharp score (mTSS) 2. On the other hands, no such correlation was observed between the number of cOCs from RA and mTSS. Objectives: Objectives of this study were to compare the differential potential into T6-OCs of PBMCs from RA patients with those from healthy donors, to clarify mRNA and protein expressions of T6-OCs derived from PBMCs from patients with RA, and to identify tartrate resistant acid phosphatase (TRACP) positive multinuclear cells with the same characteristics as T6-OCs histologically in the sub-chondral bone tissues from patients with RA and osteoarthritis (OA). Methods: PBMCs and CD14+ monocytes derived from RA patients and healthy volunteers were stimulated with TNF-α and IL-6 or RANKL. Real-time quantitative PCR and immunofluorescence staining were used to measure expression levels of osteoclast-associated mRNA and protein. Consecutive sections of the proximal tibial bone tissue from patients with RA and OA (n=6 each) were stained by TRACP, and analyzed expression levels of osteoclast-associated molecules by immunohistochemistry.

Results: The number of T6-OCs differentiated from PBMCs in RA patients was significantly increased compared to that in healthy donors, to clarify mRNA and protein expressions of T6-OCs derived from PBMCs from patients with RA, and to identify tartrate resistant acid phosphatase (TRACP) positive multinuclear cells with the same characteristics as T6-OCs histologically in the sub-chondral bone tissues from patients with RA and osteoarthritis (OA). PBMCs and CD14+ monocytes derived from RA patients and healthy volunteers were stimulated with TNF-α and IL-6 or RANKL. Real-time quantitative PCR and immunofluorescence staining were used to measure expression levels of osteoclast-associated mRNA and protein. Consecutive sections of the proximal tibial bone tissue from patients with RA and OA (n=6 each) were stained by TRACP, and analyzed expression levels of osteoclast-associated molecules by immunohistochemistry.

Disclosure of Interests: None declared

RANKL-MMP-3+ osteoclasts were present in the subchondral bone from patients with RA, on the other hands, no such cells observed in OA patients.

**Conclusion:** The PBMCs of RA patients have definitely increased differentiation capacity into T6-OCs, which have potential of degrading chondral tissue. Additionally, cells having same characteristics with T6-OCs are observed in subchondral bone from patients with RA. These results suggest that novel T6-OCs may be involved in the pathogenic mechanisms of inflammatory bone destruction in patients with RA.

**REFERENCES:**


**Acknowledgements:** We are grateful to H. Kajiyama and Y. Araki (Saitama Medical University) for helpful discussion.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4645

---

**REFERENCES:**


---

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4764

---

**REFERENCES:**

[1] M. Hoxha1, V. Malaj2, B. Zappacosta.1 1Lady of Good Counsel University, Department of Chemical Toxicological and Pharmacological Evaluation of Drugs, Tirana, Albania; 2University of Tirana, Department of Economics and Statistics, Tirana, Albania

**Background:** Arachidonic acid (AA) is a polyunsaturated fatty acid, released in inflammatory disease, such as rheumatoid arthritis (RA). Cyclooxygenase [COX] and lipoxygenase pathways have received greater attention than cytochrome P450 (CYP) pathway of AA, which also plays a significant role in RA. AA is a substrate of CYP enzymes through two different pathways: the ω-hydroxylase, and epoxygenase pathways, respectively. The epoxygenase gives rise to epoxycyclo-oxygenic and epoxygenic acids (EETs) [5]. Moreover, data suggest that sEHi inhibit also PGE2 production, and exert anti-inflammatory effects. sEHi are also metabolized through soluble epoxide hydrolase (sEH) hydrolyzing to dihydroxyeicosatetraenoic acids (DHTEs) [1].

**Objectives:** The aim of this study is to evaluate the role of Cytochrome P450 metabolites of arachidonic acid and their therapeutic targeting in rheumatoid arthritis.

**Methods:** Pubmed and Scopus databases were the main databases used to identify all the studies conformed to the eligibility criteria.

**Results:** CYP enzymes (CYP3A, CYP2C19, CYP2C9, CYP1A2) suppression was observed in the synovial fluid of RA patients with higher IL-6 levels. EETs inhibit bone resorption and osteoclastogenesis, have an important role in blocking inflammation by reducing TNF-α, and are negatively linked with pro-inflammatory cytokines (IL-1, IL-6, IL-8)[2]. The anti-inflammatory effects of EETs are potentially attributed to peroxisome proliferator-activated receptor gamma (PPARγ) activation. EETs are also metabolized through soluble epoxide hydrolase (sEH) that didehydroxyeicosatetraenoic acids (DHTEs), which have a pro-inflammatory activity. On the other hand, 20-HETE deriving from CYP ω-hydroxylation pathway has pro-inflammatory effect [3]. Data have shown that the genetic variations of CYP could affect the individual susceptibility to RA [4].

**Conclusion:** sEHi inhibitors (sEH) can not only block the inflammation caused by EETs metabolite, but can also act on LOX and COX pathway, and can be used in chronic-phase arthritis to reduce both inflammation, and the pain. In a meta-model of RA, sEHi showed decent RA assessment score improvement [5]. Moreover, data suggest that sEHi inhibit also PGE2 production, and exert an additional anti-inflammatory effect in arthritis. Since NSAIDs can lead to gastriac and cardiovascular problems, sEHi are considered a better pharmacological approach in inflammatory rheumatic disease. Despite the failure of some of sEHi to reach clinical trials, we believe that CYP-derived eicosanoids should be further studied as potential target in rheumatic disease. Dual inhibitors sEHi/S-LOX activating protein (FLAP) are also very promising compounds as they can inhibit leukotriene formation, without affecting the levels of anti-inflammatory pro-resolving mediators. In perspective we suggest that multiple ligands targeting different AA pathways or mediators should be further explored as potential targets for designing new compounds to treat RA patients.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4779
Background: Tofacitinib is a potent and selective oral inhibitor prevalently of JAK1 and JAK3and is currently included in the international recommendations for the management of psoriatic arthritis (PsA). Nonetheless, the mechanisms of the immune response to the treatment remain unclear, particularly regarding the effects on overlooked immune cell subpopulations specifically involved in the pathogenesis of PsA, i.e. mucosal-associated invariant T cells (MAIT), innate lymphoid cells (ILCs), both relevant sources of IL-17 and T lymphocytes producing interleukin 9 (Th9). We thus investigated the effect of tofacitinib on these cell population function and compared with glucocorticoids.

Objectives: To investigate the effect of tofacitinib and dexamethasone on MAIT cells, ILCs, and Th9 cells in PsA.

Methods: We investigated synovial fluid and peripheral blood mononuclear cells from patients with PsA that were cultured with phorbol myristate acetate (PMA)/ionomycin in the presence or absence of 100 or 300μM Tofacitinib or 1000μM Dexamethasone for 24 hours and the addition of brefeldin in the last 2 hours. FACS analysis allowed to identify MAIT cells by CD3+CD161Valpha2/2CIITA: ILCs by CD3+CD4+CD127+, from this population ILC1 were arrayed as cKit-; CRTH2-; ILC2 as cKit +/- and CRTH2+, and ILC3 as cKit+ and CRTH2-; Th9: CD3+CD4+IL-9+.

Results: A significant decrease in IL-17 production was observed in CD8+ MAIT cells treated with tofacitinib 300μM compared to untreated conditions, with a magnitude similar to what observed with dexamethasone (mean fluorescence intensity-MFI median 1920 (interquartile range-IQR 1597-2761), 16.8% (3.9-31.4) in untreated cultures; 1481 (1325-3163), 13.4% (4.5-9.3) in tofacitinib-treated cultures; 1511 (1147-2882); 11.5% (2.5-49) in Dexamethasone-treated cultures; see Figure 1). A reduction of IL-17 production was observed also in ILC3 [52.1% (4.2-59.4) in untreated cultures; 25.6% (5.3-40.3) in Tofacitinib-treated cultures; 35.4% (6.3-47.9) in dexamethasone-treated cultures]. A reduction of IL-9 production was observed in peripheral blood T cells [2.19% (13.2-3.2) in untreated cultures; 0.6% (0.0-1.8) in Tofacitinib-treated cultures; 0.97% (0.07-1.13) in Dexamethasone-treated cultures].

Conclusion: In PsA, tofacitinib is superior to dexamethasone in reducing the production of IL-17 by synovial fluid MAIT cells and ILC3 cells and of IL-9 by peripheral blood T cells.

Disclosure of Interests: Maria De Santis Grant/research support from: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Actelion, Boehringer, Italfarmaco, Grunenthal, Roche. Natalia Isailovic: None declared, Marta Caprioli: None declared, Giacomo Maria Guidelli: Speakers bureau: Amgen, UCB, Galapagos, Carlo Selmi Speakers bureau: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Consultant of: AbbVie, Amgen, Alfa-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Grant/research support from: AbbVie, Amgen, Janssen, Pfizer

A. H. El Hassaany1, S. Tharwat1, M. Mansour2, A. F. Enein2. 1. Faculty of Medicine, Mansoura University, Mansoura, Egypt, Rheumatology & Immunology Unit, Department of Internal Medicine, Mansoura, Egypt; 2. Faculty of Medicine, Mansoura University, Egypt, Department of Clinical Pathology, Mansoura, Egypt

Background: Rheumatoid arthritis (RA) is a chronic, inflammatory joint condition that affects about 5 out of 1000 persons of the general population [1]. Environment, genetics, and autoimmunity may all have a role in the pathogenesis of the disease [2]. Overproduction of pro-inflammatory cytokines like tumor necrosis factor-α (TNF-α) is the end result of these mechanisms [3]. However, little is known about its soluble concentrations in synovial fluid and serum and its association with clinical and ultrasonographic joint parameters.

Objectives: The aim of this study was to assess the presence of TNF-α in serum and synovial fluid of the knee in RA patients with knee effusion and to evaluate its correlation with musculoskeletal ultrasound (MSUS) parameters of the affected knee joint.

Methods: This study included 40 patients (20 RA, 10 systemic lupus erythematosus (SLE) and 10 osteoarthritis (OA)) who had knee effusion (unilateral or bilateral) upon clinical examination. The sample size was selected as convenient sample, all patients who fulfilled the inclusion criteria were offered to participate in the study, unless they qualify for any of the exclusion criteria or refuse to participate. The inclusion criteria included the following: a) age ≥ 18 years old, b) patients with knee effusion detected by clinical examination and confirmed by MSUS, c) patients with RA diagnosed according to 2010 ACR /EULAR classification criteria [4], SLE according to SLICC criteria [5] or knee OA diagnosed according to EULAR criteria [6].

Demographic, clinical, and therapeutic data were recruited from all participants. Visual analogue scale (VAS) was used to determine the pain intensity in the affected knee. MSUS examination of the affected knee was performed, and a sample of synovial fluid was aspirated. TNF-α was measured in the aspirated synovial fluid and serum of each patient.

Results: There was a total of 40 patients (20 RA, and 20 age and sex matched non-RA (10 SLE, and 10 OA)). The mean age of RA patients was 48.4 years, most of them were females (80%) with median duration of knee pain of 2 months. Serum TNF-α was barely significantly higher in RA vs. non-RA cases (3.66 ± 0.76 vs 3.24 ± 0.58 U/ml, p= 0.052), while in synovial fluid, difference was not statistically significant (3.73 ± 0.72 vs 3.48 ± 0.58 U/ml, p= 0.252). Also, there was a statistically significantly higher serum TNF-α in RA vs. OA (3.66 ± 0.76 vs 3.06 ± 0.32, p= 0.022).

Conclusion: Serum TNF-α level do not differ in RA from non-RA patients. No role of synovial TNF-α in knee pathologies in RA patients.

REFERENCES:
AB0100

LONGER DISEASE DURATION OF RHEUMATOID ARTHRITIS IS ASSOCIATED WITH TNF RECEPTORS REDISTRIBUTION ON IMMUNOCOMPETENT CELLS AND CHANGES IN CELL SENSITIVITY TO CYTOKINE

A. Alshevskaya1, J. Zhukova1, J. Lopatinikova1, O. Chumasova2, N. Shkaruba2, A. Sizikov2, S. Sennikov2. 1RIFCI, Rheumatology Department, Novosibirsk, Russian Federation; 2RIFCI, Rheumatology Department, Novosibirsk, Russian Federation

Background: Longer duration of rheumatoid arthritis (RA) is associated not only with higher disease severity, but also with lower treatment efficacy including anticytokine therapy. One of key mechanisms implementing this is changing in expression of cytokines and their receptors actively involved in the pathological process, such as tumor necrosis factor (TNF).

Objectives: The aim of the study was to study the redistribution of TNF receptors in patients with different duration of RA and depending on the severity of the disease.

Methods: Subanalysis of RA patients with disease duration less than 10 years (Early RA group, n=34) and more than 10 years (Late RA group, n=30) was performed. Late RA patients had DAS-28 activity comparable with Early RA group (4.98 vs 4.69, p=0.68), but had higher radiological stage, higher levels of inflammatory markers, and more often received biologics and had systemic features. As a control group, data from 43 comparable healthy donors were used. Co-expression profile of TNF receptors type 1 and 2 (TNFR1/2) were assessed in main mononuclear subsets: T cells, B cells, monocytes, Tregs, T helpers, cytotoxic T cells. Dynamics of percentage of cells with different co-expression combination was estimated as well as receptors expression density per cell.

Results: The redistribution of receptors on 12 subpopulations of immune cells was studied. Two types of cell responses were associated with disease duration increase. The first trend was presented by monocytes, regulatory T cells and general pool of cytotoxic T cells and consisted in significant decrease in TNFR2 expression density with simultaneously increase of double-positive TNFR1+T-NFRII+ cells percentage and decrease of TNFR1-TNFRII+ cells percentage with no changes in proportion of cells without receptors, as compared with healthy and with disease progression. The second type of response was presented by B cells, T cells, T helper naive cells and activated T cells and represented a significant increase in TNFR1 expression density and increase of double-positive cells proportion compared to healthy without influence of disease duration and tendency to decrease in proportion of cells without receptors over time.

Conclusion: Two trends in the response of immunocompetent cells to changes in the level of TNF that occur during chronic inflammation in RA were established. These two trends demonstrate the reactive and adaptive mechanisms of immune cells actively involved in pathological process and are of significant interest for the possibilities of modulating cell sensitivity to the proapoptotic and proinflammatory effects of cytokine and for futher development of targeted RA therapy.

Acknowledgements: The study was supported by a grant from the Russian Science Foundation (project No. 20-75-10051)

Disclosure of Interests: None declared


AB0101

INCREASED DNA DAMAGE AND LACK OF DNA REPAIR IN FIBROBLAST-LIKE SYNOVIOCYTES OF INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS

T. de Jong1,2, J. F. Semmelink1,2, R. A. Hoebe3, P. Krawczyk3, L. van Baarsen1,2.
1Amsterdam UMC, Academic Medical Center, Department of Rheumatology & Clinical Immunology, Department of Experimental Immunology, Amsterdam, Netherlands; 2Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam UMC, Academic Medical Center, Amsterdam, Netherlands; 3Amsterdam UMC, Academic Medical Center and Cancer Center Amsterdam, Department of Medical Biology, Amsterdam, Netherlands

Background: Rheumatoid arthritis (RA) is a chronic inflammatory immune-mediated disease leading to synovial tissue inflammation and bone destruction. Inflammation-induced DNA damage in fibroblast-like synoviocytes (FLS) is thought to play an important role in RA pathogenesis. However, since a recent functional genomics study revealed a causal role for FLS in the genetic susceptibility of RA and synovial inflammation is absent in autoantibody positive individuals at risk for RA, we aimed to investigate whether DNA damage in FLS is present before onset of disease.

Objectives: Determine the extent of DNA damage in FLS and their capacity to repair this damage during the earliest phases of systemic autoimmunity.

Methods: We included individuals with arthralgia who were IgM rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA) positive but without any evidence of arthritis (RA-risk individuals, n=6), RA patients (n=6), osteoarthritis (OA) patients (n=6) and controls without inflammatory disease (n=8). Synovial tissue biopsies were collected either during joint surgery or induced arthroscopy using a mechanical synovial biopsy instrument. FLS were cultured from FLS in vitro expanded upon enzymatic synovial tissue digestion. DNA damage in FLS (passage 6) was assessed by immunofluorescence staining for γH2AX. DNA damage repair was assessed by first irradiating the cells with 1 gray to induce DNA damage and assessing γH2AX staining directly and after 3 and 24 hours of culture to allow for DNA repair.

Results: Preliminary immunofluorescence staining for γH2AX shows that DNA damage is present in RA-risk and RA FLS to more extent compared with FLS from non-inflammatory controls. OA FLS exhibit even more DNA damage and their nuclei show signs of impaired chromosomal segregation, forming micronuclei with high γH2AX staining intensity. Overall, DNA damage repair is slower in FLS from RA-risk individuals, RA and OA patients compared with controls as shown by persistent γH2AX staining after inducing DNA damage.

Conclusion: These findings reveal increased DNA damage and concomitant impaired DNA repair in FLS of not only patients with synovial inflammation but also in FLS from RA-risk individuals, suggesting that DNA damage is already present in absence of overt synovial tissue inflammation and before clinical
There is no clear consensus regarding the etiology of the hand deformity.

**Methods:** Iron content in synovial fluid was determined by colorimetry. Lipid peroxidation was assessed by flow cytometry and immunofluorescence. MDA and GSH were used as markers to assess ferroptosis. K/BxN spontaneous arthritis mice and serum-induced arthritis mice were used as in vivo animal models of ferroptosis.

**Results:** Iron overload and hyperlipid peroxidation of mononuclear-macrophages were found in the synovial fluid of RA patients. Liproxstatin-1, the specific inhibitor of ferroptosis, alleviated the progression of arthritis mice model by increasing M2-like macrophage numbers. Mechanistically, iron overload in arthritis lesion induced anti-inflammatory macrophage ferroptosis by promoting glutathione peroxidase 4 (GPX4, a classical anti-ferroptosis molecule) to undergo P62-dependent autophagy degradation.

**Conclusion:** Our results provide compelling evidence that macrophages ferroptosis plays a major role in RA. M2-like macrophages are more sensitive to ferroptosis than M1-like macrophages under iron overload circulation. This finding heavily contributes to the immune imbalance of rheumatoid arthritis.

**REFERENCES:**


**Disclosure of Interests:** Yan Liu Grant/research support from: the National Natural Science Foundation of China (82101899), China Postdoctoral Science Foundation Grant (2021M693658), Yutong Jiang Grant/research support from: Basic and Applied Basic Research Fund Project of Guangdong Province (2021A1511511170), Yunfeng pan: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5175

**AB0102**

**GPX4-ASSOCIATED FERROPTOSIS OF MACROPHAGE EXACERBATES IMMUNE IMBALANCE IN RHEUMATOID ARTHRITIS**

Y Liu1, Y. Jiang1, Y. Pan1.1 The Third Affiliated Hospital of Sun Yat-sen University, Rheumatology department, Guangzhou, China

**Background:** Reactive oxygen species accumulation and iron overload are involved in the pathogenesis of rheumatoid arthritis (RA). Ferroptosis, as a non-apoptotic form of programmed cell death, characteristically depends on iron and lipid peroxidation. However, the role of ferroptosis in RA has not been explored.

**Objectives:** To explore the role of ferroptosis in immune imbalance of rheumatoid arthritis.

**Methods:** Iron content in synovial fluid was determined by colorimetry. Lipid peroxidation was assessed by flow cytometry and immunofluorescence. MDA and GSH were used as markers to assess ferroptosis. K/BxN spontaneous arthritis mice and serum-induced arthritis mice were used as in vivo animal models of ferroptosis.

**Results:** Iron overload and hyperlipid peroxidation of mononuclear-macrophages were found in the synovial fluid of RA patients. Liproxstatin-1, the specific inhibitor of ferroptosis, alleviated the progression of arthritis mice model by increasing M2-like macrophage numbers. Mechanistically, iron overload in arthritis lesion induced anti-inflammatory macrophage ferroptosis by promoting glutathione peroxidase 4 (GPX4, a classical anti-ferroptosis molecule) to undergo P62-dependent autophagy degradation.

**Conclusion:** Our results provide compelling evidence that macrophages ferroptosis plays a major role in RA. M2-like macrophages are more sensitive to ferroptosis than M1-like macrophages under iron overload circulation. This finding heavily contributes to the immune imbalance of rheumatoid arthritis.

**REFERENCES:**


**Disclosure of Interests:** Yan Liu Grant/research support from: the National Natural Science Foundation of China (82101899), China Postdoctoral Science Foundation Grant (2021M693658), Yutong Jiang Grant/research support from: Basic and Applied Basic Research Fund Project of Guangdong Province (2021A1511511170), Yunfeng pan: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5175

**AB0103**

**SITE SPECIFICITY OF RHEUMATOID ARTHRITIS INFLAMMATION: A SECONDARY ANALYSIS OF BIOPSIES FROM RADIAL AND ULNAR ASPECTS OF MCP JOINTS**

K. Skovsgaard Itenov1, N. Seo2, E. M. Bartels1, H. Bliddal1, M. Andersen1.1 Copenhagen University Hospital, Parker Institute, Frederiksberg, Denmark; 2 Copenhagen University Hospital, Department of Hand Surgery, Gentofte, Denmark

**Background:** Ulnar drift is a common complication of Rheumatoid Arthritis (RA) (1,2). There is no clear consensus regarding the etiology of the hand deformity. Observations from corrective hand surgery and other studies have noted more pronounced inflammation in the radial side of the MCP-joints (3,4). This could partly explain the pathophysiology behind the ulnar deviation.

**Objectives:** To determine if there is more pronounced inflammation, measured by increased CD68 expression (5) and Krenn-synovitis score (6), at the radial side of the MCP joints when compared to the ulnar side, in patients with verified RA.

**Methods:** We included RA patients from a previous study who had biopsies taken from the most affected joints based on clinical examination and ultrasound (7). Twenty-nine PIIPs-, MCP- and wrist-joints were biopsied. Biopsies from the MCP-joints were taken from the dorso-ulnar and dorso-radial concavity. Inflammation was graded by the Krenn-synovitis score (0-9) and the density of CD68-positive cells (%). The difference between radial and ulnar joint inflammation was calculated by paired t-test. P-value <0.05 was considered statistically significant.

**Results:** In 8 patients biopsies were taken from both the ulnar and the radial side of the same MCP-joint. The mean difference in inflammation on the radial and ulnar site of MCP-joints was based on differences in CD68-density: 0.67% (95%-CI -4.77 to 6.10; P = 0.77) (Figure 1) and Krenn-score: 0.83 (95%-CI -1.31 to 2.98; P = 0.36), respectively.

**Conclusion:** There was no difference in concentration of inflammatory cells or overall synovial pathology between the radial and ulnar site of MCP-joints in RA patients. The impression of a more pronounced inflamed synovium on the radial site of MCP joints, as observed during surgery, does not seem to arise from an immunological preference, but rather to be linked to a larger synovial volume.

**REFERENCES:**


**Acknowledgements:** The authors would like to thank the study participants as well as Inger Wätjen, Eva Littrup Andersen, Mette Okkels, Jette Möller Frøsø and Suzi Heeg Madsen for technical assistance. I have no acknowledgements to declare.

**Disclosure of Interests:** Katrine Skovsgaard Itenov: None declared, Niels Seo: None declared, Else Marie Bartels: None declared, Henning Bliddal: None declared, Martin Andersen Grant/research support from: The primary study was supported by unrestricted grants from Novo Nordisk. Employee of: Was employed at Novo Nordisk A/S during the conduction of the study.

**DOI:** 10.1136/annrheumdis-2022-eular.5196
**Spondyloarthritis - aetiology, pathogenesis and animal models**

**AB0104 CHANGES IN SECRETION OF TH17 EFFECTOR CYTOKINES IN SYNOVIAL FLUID CELL CULTURES BY THE ATOPIC DERMATITIS BIOLOGIC DUPILUMAB (ANTI-IL-4 RECEPTOR ALPHA)**

M. P. Hundahl1, S. Lomholt1, T. W. Kragstrup3, 1Aarhus University, Institute of Biomedicine, Aarhus, Denmark

**Background:** Inflammatory arthritis and enthesis has been documented as adverse events in patients with atopic dermatitis treated with dupilumab targeting the interleukin 4 (IL-4) receptor alpha subunit (1,2). The disease mechanisms underlying atopic dermatitis are primarily driven by a substantiated Th2 response. Therefore, blockade of IL-4 and IL-13 signaling rationally inhibits Th2-mediated atopy. However, IL-4 and IL-13 are also well-known suppressors of Th17 cells. Therefore, we hypothesize that dupilumab-induced arthritis could be caused by increased production of Th17 effector cytokines.

**Objectives:** Here, we tested the effect of dupilumab on in vivo activated peripheral blood and synovial fluid mononuclear cells from patients with active inflammatory arthritis.

**Methods:** We used peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) from patients with immune mediated inflammatory arthritis (juvenile idiopathic arthritis, spondyloarthritis, polyarthritis, psoriatic arthritis, and arthritis with intestinal bowel disease (IBD), n=8). PBMCs and SFMCs were either unstimulated or stimulated with CD3/CD28 beads, and then cultured with three different concentrations of dupilumab (0.2 μg/mL, 1.0 μg/mL, or 5.0 μg/mL). Supernatants were analyzed by the two MSD Multi-Spot Assay System in the Proinflammatory Panel 1 (INF-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13 and TNF-α) and the Th17 Panel 1 (IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31 and CCL20). All data were transformed to ratios by dividing the value of the samples treated with dupilumab with the value of untreated samples. Data were then analyzed with repeated measures one-way ANOVA or the paired t-test depending on the number of groups. P-values <0.05 were considered statistically significant.

**Results:** In SFMCs not cultured with CD3/CD28 beads, dupilumab decreased the production of IL-17A, IL-22, CCL20 and IL-10 (P-values: 0.0007, 0.0002, 0.0025 and 0.0432 respectively). IL-1α was decreased by dupilumab in both PBMCs and SFMCs not cultured with CD3/CD28 beads (P-value = 0.013 and P-value = 0.001). The concentration of cytokines measured in supernatants from the PBMCs cultured without CD3/CD28 were low in both the Proinflammatory Panel and the Th17 panel. Interestingly, the response to increasing concentrations of dupilumab in PBMCs and SFMCs pre-conditioned with CD3/CD28 showed a biphasic curve. Thus, the low concentration of dupilumab (0.2 μg/mL) resulted in increased production of TNF-α, IL-1α, IL-1β, IL-4, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-22, IL-23, IL-27, IL-31 and CCL20. All data were transformed to ratios by dividing the value of the samples treated with dupilumab with the value of untreated samples. Data were then analyzed with repeated measures one-way ANOVA or the paired t-test depending on the number of groups. P-values <0.05 were considered statistically significant.

**Conclusion:** This data contradicts the hypothesis and indicates that dupilumab does not increase the production of Th17 related cytokines. However, the increase in proinflammatory cytokines seen with the low concentrations of dupilumab suggest that partial blockade of the IL-4 receptor alpha under some conditions could lead to augmented inflammation.

**REFERENCES:**

**Disclosure of Interests:** Mathe Pallesgaard Hundahl: None declared, Seren Lomholt: None declared, Tue Wenzel Kragstrup Shareholder of: Co-founder and clinical developer in iBio tech ApS, Speakers bureau: Speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB and Abbvie, Consultant of: Research grants from Gilead

**DOI:** 10.1136/annrheumdis-2022-eular.658

**Figure 1.** The biphasic response to dupilumab treatment shown for the analytes IL-17A and IL-22. An increase is seen in UT vs. 0.2 μg/mL with a P-value of 0.0117 and 0.0379.

**H. Port**1, C. Thrdum2, C. G. Tanteziel, A. C. Bay-Jensen1, M. Karssda1, S. Holm Nielsen1,1 Nordic Bioscience A/S, Immunoscience, Herlev, Denmark; 2The University of Copenhagen, Faculty of Health and Medical Sciences, Clinical Medicine, Kopenhagen, Denmark; 3Nordic Bioscience A/S, Immunoscience, Herlev, Denmark; 4Gentofte Hospital, Orthopaedic Surgery Unit, Hellerup, Denmark

**Background:** Altered extracellular matrix (ECM) remodeling is a common event in rheumatic diseases. Type II collagen is the most abundant ECM protein in the cartilage and provides tensile elasticity and strength to enable support to the joints. Chondrocalcin, also known as the C-terminal propeptide of type II collagen, is among the most highly synthesized polypeptides in cartilage. It is cleaved off by BMP-1/C-endopeptidase during maturation and plays a role in assembly of type II collagen and in calcification of cartilage matrix. When cleaved off, the chondrocalcin fragments are released into circulation, where they can be quantified in a blood sample.

**Objectives:** This study aimed at developing an immunoassay targeting a neo-epitope of chondrocalcin, named CALC2. Moreover, we explored its biomarker potential to evaluate type II collagen formation in an ex vivo human osteoarthritis (OA) cartilage explant model (HEX) with anabolic treatment, and in serum from healthy controls, patients with rheumatoid arthritis (RA) and patients with ankylosing spondylitis (AS).

**Methods:** A novel direct immunoassay targeting the neo-epitope of type II collagen C-terminal (PIICP) was developed and technically validated. The technical validation included inter- and intra-variation, linearity, spiking recovery, stability, and specificity. Specificity of the monoclonal antibody was tested using an elongated peptide, a truncated peptide, and a non-sense peptide to exclude possible cross-reactivity. CALC2 levels were measured in supernatant from HEX cultured for 35 days in serum free DMEM/F12 medium with IGF-1 (Insulin-like Growth Factor-1) (100 ng/mL), including a control group without (i/o) treatment. The supernatant was harvested 3 times weekly and replaced with new culture medium. IGF-1 levels were confirmed by western blot. Serum samples from 18 healthy donors (mean age 35.8 ± SD 3.8, 100% Caucasian), 19 patients with AS (mean age 35.8 ± SD 3.2, 100% Caucasian) and 18 patients with RA (mean age 35.8 ± SD 3.4, 100% Caucasian) were also measured by CALC2. Linear regression models with pairwise comparisons were performed.

**Results:** A technically robust and specific assay was developed. The inter- and intra-assay variation of CALC2 was determined as 12% and 7% respectively. CALC2 showed a good dilution recovery, spiking recovery, and storage freeze-thaw stability (All, 100%±20%). CALC2 showed specificity towards the targeted sequence and did not show any reactivity towards the truncated peptide, elongation peptide, or non-sense peptide. CALC2 needlepeptide levels were significantly elevated after 14, 21 and 28 days of IGF-1 treatment compared to untreated (p<0.01, p<0.0001 p<0.001, respectively). The western blot confirmed the CALC2 results by the presence of a band of ~35kDa in all explants, corresponding to the weight of chondrocalcin previously established (1). Furthermore, the bands were more pronounced at day 21 in the IGF-1 treated explant compared to the untreated explant. CALC2 also showed significantly lower levels in patients with RA compared to controls (p=0.003; mean 0.32ng/mL ± SD 0.16 vs 0.64ng/mL ± SD 0.31).

**Conclusion:** Higher levels of CALC2 were detected in supernatants from explants after 14, 21 and 28 days of IGF-1 treatment compared to untreated. Lower levels of CALC2 were present in patients with RA compared to healthy controls. Overall, this suggests that CALC2 may have potential as biomarker for type II collagen formation. However, further preclinical and clinical studies are required to validate these findings.

**REFERENCES:**

Figure 1. CALC2 measurements in HEX model.

Objectives: To investigate the use of 18FDG μPET/CT as a guide for inflammation in joints otherwise inaccessible for clinical scoring, enabling the use of additional joints for histological analysis.

Methods: CAIA was induced in 8 male DBA/1 mice using the ArthritoMab Antibody cocktail (4mg/mouse on day 0), followed by 100 µg LPS at day 3. Body weight, clinical signs of arthritis such as paw swelling and grip strength loss were recorded 3 times per week in both front and hind paws. Whole body 18FDG μPET/CT was performed at day 11, the estimated time of peak inflammation, and inflammation was scored visually on images scaled to the same standardised uptake value. At day 28, animals were euthanized and peripheral joints were collected for histological analysis.

Results: Cumulative disease incidence based on paw swelling dropped from 100% to 87.5% when looking only at hind paws, and to 75% when taking into account only the region suitable for histological analysis, namely the ankle and midfoot of the hind paws. Symmetrical, bilateral hind paw arthritis was not observed. While hind paw arthritis showed a tendency to be less severe in comparison to front paw arthritis, grip strength was equally affected, indicating possible involvement of other hind limb joints. μPET/CT images detected inflammation in the hind paws (at least unilateral involvement in 62.5% of the mice, bilateral involvement in 0%), knee joints (at least unilateral in 75%, bilateral in 50%), hip joints (at least unilateral in 50%, bilateral in 0%), elbow joints (at least unilateral in 50%, bilateral in 37.5%) and shoulder joints (at least unilateral in 25%, bilateral in 25%). Histology could confirm this inflammation with the presence of inflammatory infiltrates and bone erosions. Grip strength loss in hind limbs without paw swelling correlated only weakly with knee inflammation detected by μPET/CT.

Conclusion: In the CAIA model, inflammatory arthritis can develop in all peripheral joints, in particular with a high incidence in knee joints, which are highly suitable for subsequent histological analysis. Since clinical scoring seems insufficient for detecting these affected joints, implementation of in vivo imaging modalities such as μPET/CT, offers a substantial benefit in disease monitoring and assessment.

Disclosure of Interests: None declared.


AB0106 THE PATTERN OF JOINT INFLAMMATION IN THE CAIA MOUSE MODEL OF ARTHRITIS

M. Van Mechelen1,2, S. Hayer2, K. Van Laere4, R. Lories1,2, B. Neerinckx1,2 1KU Leuven, Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, Leuven, Belgium; 2University Hospitals Leuven, Division of Rheumatology, Leuven, Belgium; 3Medical University of Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria; 4KU Leuven, Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Leuven, Belgium

Background: Animal models of inflammatory arthritis such as the collagen-antibody induced arthritis (CAIA) have a variable disease incidence in hind paw arthritis, complicating experimental design.

Objectives: To evaluate the effect of SARS-CoV-2 infection on disease activity and bDMARDs responses in patients with PsA.

Methods: We performed a retrospective analysis including all the patients with PsA, meeting the CASPAR criteria and under biologic therapy, followed in the Rheumatology department of a tertiary university hospital. Demographic and clinical data, including occurrence of SARS-CoV-2 infection, were collected from our national database (reuma.pt). Disease activity (CDAI, SDAI, BASDAI, ACR and PsARC) responses were evaluated before and after SARS-CoV-2 infection. Statistical analysis was performed with SPSS. Continuous variables were compared through paired samples t-test.

Results: A total of 102 patients with PsA were included. Fifty-two were females (51%). The mean age was 53 ± 11.09 years and the median disease duration was 15 years [min 2, max 47]. Overall, 54 (53%) patients had predominant axial involvement, 26 (26%) peripheral and 36 (37%) enthesopathic. The most used bDMARD was etanercept [n=28, 27.5%] followed by adalimumab [n=22, 21.6%] and secukinumab [n=16, 15.7%]. The prevalence of SARS-CoV-2 infection was 15.7% (n=16). Fifty-three percent of infected patients experienced an increase in disease activity (+16.8±13.2, p=0.001) and 93% experienced an increase in clinical activity (+2.2±1.2, p<0.001). The number of patients unresponsive to bDMARDs (according EULAR, ACR and PsARC) before the infection wasn’t different from post-infection.

Conclusion: Our study suggests that SARS-CoV2 infection has no negative impact on PsA disease activity and bDMARD responses. However, more studies are needed to better understand the long-term effects of SARS-CoV2 infection.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2364

AB0107 IMPACT OF SARS-COV-2 INFECTION ON THE DISEASE ACTIVITY OF PATIENTS WITH PSORIATIC ARTHRITIS UNDER BDMARDS: REAL LIFE DATA

P. Nicolau1, A. Martins2, D. Santos Oliveira3, B. Samões4, F. R. Martins4, M. Rato3, F. Oliveira Pinheiro3, M. Bernardes3, L. Costa2, 1Centro Hospitalar Tondela Viseu, Rheumatology Unit, Viseu, Portugal; 2São João University Hospital Center, Rheumatology department, Porto, Portugal; 3Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 4Hospital Vila Nova de Gaia / Espinho - Unit 1, Rheumatology department, Vila Nova de Gaia, Portugal; 5University Hospital Center of Algarve, Rheumatology department, Faro, Portugal; 6Faculty of Medicine, University of Porto, Medicine, Porto, Portugal

Background: SARS-CoV-2 infection can lead to severe inflammation and has been suggested to induce Psoriatic Arthritis (PsA) flares. However, the impact on disease activity and response to biological disease modifying anti-rheumatic drugs (bDMARDs) remains unknown.

Objectives: To evaluate the effect of SARS-CoV-2 infection on disease activity and bDMARDs responses in patients with PsA.

Methods: We performed a retrospective analysis including all the patients with PsA, meeting the CASPAR criteria and under biologic therapy, followed in the Rheumatology department of a tertiary university hospital. Demographic and clinical data, including occurrence of SARS-CoV-2 infection, were collected from our national database (reuma.pt). Disease activity (CDAI, SDAI, BASDAI, ACR and PsARC) before the infection wasn’t different from post-infection. Statistical analysis was performed with SPSS. Continuous variables were compared through paired samples t-test.

Results: A total of 102 patients with PsA were included. Fifty-two were females (51%). The mean age was 53 ± 11.09 years and the median disease duration was 15 years [min 2, max 47]. Overall, 54 (53%) patients had predominant axial involvement, 26 (26%) peripheral and 36 (37%) enthesopathic. The most used bDMARD was etanercept [n=28, 27.5%] followed by adalimumab [n=22, 21.6%] and secukinumab [n=16, 15.7%]. The prevalence of SARS-CoV-2 infection was 15.7% (n=16). Fifty-three percent of infected patients experienced an increase in disease activity (+16.8±13.2, p=0.001) and 93% experienced an increase in clinical activity (+2.2±1.2, p<0.001). The number of patients unresponsive to bDMARDs (according EULAR, ACR and PsARC) before the infection wasn’t different from post-infection.

Conclusion: Our study suggests that SARS-CoV2 infection has no negative impact on PsA disease activity and bDMARD responses. However, more studies are needed to better understand the long-term effects of SARS-CoV2 infection.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2364

AB0108 INFLAMMATION IN AXSPA AS A DISRUPTOR OF BONE METABOLISM – THE EFFECT OF PATIENTS’ SERA ON AN IN VITRO BONE MODEL

E. Sebova1, P. Skubicas1, M. Husakova1, P. Dankova1, 1Faculty of Science, Charles University, Department of Anthropology and Human Genetics, Prague, Czech Republic; 2Institute of Experimental Medicine CAS, Department of Tissue Engineering, Prague, Czech Republic; 3Institute of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

Background: In axial spondyloarthritis (axSpA), two opposing processes of bone resorption and neogenesis are closely related, with a common denominator – chronic inflammation. This pathological condition affects osteoblasts, among other cells, residing in sites of inflamed tissue, but it can also activate mononuclear precursors in the blood to form osteoclasts [1,2]. To this day, it is not...
yet clear how the interplay between osteoblasts and osteoclasts affects pathogenesis of axSpA.

Objectives: The aim was to evaluate the effect of sera from patients with different forms of the disease, non-radiographic (nr-axSpA) and radiographic (r-axSpA) including ankylosing spondylitis, in comparison to the effect of sera from healthy individuals (axC) on osteoblasts and osteoclasts co-culture.

Methods: The immunological characterization for each diagnosis was simulated by age- and sex-matched pools of 12 nr-axSpA and 12 r-axSpA patients’ sera, healthy condition by a pool of 12 axC sera. We used THP-1 monocyctic cell line and SaOs-2 osteosarcoma cell line co-culture to model bone physiology. After THP-1 adhesion, SaOs-2-S2 cells were added with 10 % of nr-axSpA, r-axSpA or axC sera, respectively, in the media for 14 days. Activity of osteoblastic alkaline phosphatase (ALP) and osteoclastic enzymes tartrate-resistant acid phosphatase (TRAP), cathespin K (CTSK) and carbonic anhydrase II (CAII) on days (D) 1, 7, and 14 were measured. Simultaneously, we examined metabolic activity (MTS assay), cell proliferation (PicoGreen assay) and mRNA expression of selected genes in co-culture.

Results: In all three studied co-cultures the ALP activity increased with length of the cultivation; nevertheless, the onset of the activity in D1 was more rapid in axC sera compared to nr-axSpA (P<0.05) and r-axSpA (P<0.001). The ALP activity increase from D1 to D14 was 4.9 fold in axC, 5.7 fold in nr-axSpA and 6 fold in r-axSpA. Moreover, rise of ALP gene expression corresponds well with rise of ALP activity. TRAP activity peaked in all sera on D7 and decreased again towards D14, mirroring the same mRNA expression profile. The TRAP activity on D7 was highest in axC sera and lowest in r-axSpA (P<0.01). Gradual drop of CA II activity from D1 to D14 was detected in co-cultures with axC and nr-axSpA sera; in r-axSpA, however, the activity increased 1.4 times from D7 to D14 and was thus significantly higher on D 14 compared to cultures in other two sera (P<0.0001). In all cultures, CTSK activity increased from D7 to D14. Activity was highest in culture with axC sera (nr-axSpA D7 and D14 P<0.0001; r-axSpA D7 P<0.0001, D14 P<0.05). A gradual increase in cell proliferation was observed in axC sera and was thus significantly higher compared to both patients’ sera on D14 (P<0.0001). In contrast, the proliferation in patients’ sera peaked on D7 with the significantly highest D7 proliferation observed in r-axSpA (P<0.05). While the metabolic activity per cell followed U shape trend in all co-cultures, the changes were more distinct in patients’ sera: 2 fold drop in r-axSpA, 1.6 fold in nr-axSpA and 1.3 fold in axC sera on D7 followed by increase of 3.4 fold in r-axSpA, 2.9 fold in nr-axSpA and 1.8 fold in axC on D14.

Conclusion: Data acquired from the in vitro bone model point to an imbalance in the enzymatic activity of osteoclasts and to changes in the metabolic activity and proliferation of both, osteoblasts and osteoclasts. These changes seem to be caused by inflammatory agents in patients’ sera. However, the changes are not the same in both forms of disease, which may explain differences between nr- and r-axSpA symptoms.

References:

Acknowledgements: Grant support: Progres Q43 and SVV260436.

Disclosure of Interests:
None declared. DOI: 10.1136/annrheumdis-2016-eular-2499

AB0110
INCREASED NEUTROPHIL FREQUENCY IN LYMPH NODES OF PATIENTS WITH PSORIATIC ARTHRITIS

A. M. O'Byrne1,2,3, J. W. Belt1,2, C. van Ansenwoud2,3, J. F. Semmeling1,2, M. Maas4, M. G. H. van de Sande1,2,3, L. van Baaren1,2,3
1Amsterdam University Medical Centre, Clinical Immunology and Rheumatology, Amsterdam, Netherlands; 2Amsterdam Rheumatology Centre, Amsterdam, Netherlands; 3Amsterdam University Medical Centre, Experimental Immunology, Amsterdam, Netherlands; 4Amsterdam University Medical Centre, Radiology, Amsterdam, Netherlands

Background: Increased presence of neutrophils in the skin1, synovium2,3, and entheses4 of patients with Psoriatic Arthritis (PsA) and their downregulation upon successful treatment2,5,6, suggests a role for neutrophils in PsA pathogenesis. As neutrophils have been implicated in Th17 differentiation, gaining insight in the presence and function of neutrophils within lymph nodes, which are the epicentre of T cell activation and differentiation, could be important in unravelling disease pathogenesis.

Objectives: We hypothesize that activated neutrophils migrate from inflamed peripheral tissues to lymph nodes, where they steer inflammation by interaction with tissue resident cells and immune cells, ultimately resulting in activation of IL-17 producing T cells. To investigate this, we studied the presence of neutrophils in lymph node biopsies of patients with inflammatory arthritis, including PsA, and compared their frequencies to controls.

Methods: Ten PsA patients, 34 seropositive individuals at risk of developing rheumatoid arthritis (RA-risk), 26 ACPA- RA patients and 10 healthy controls (HC) underwent ultrasound-guided inguinal lymph node biopsy. These bio-banked biopsies were analysed using qPCR and immunohistochemistry. Flow cytometry on fresh biopsies was used to determine cell frequencies in six active PsA patients (defined as arthritis in ≥1 joint) and two RA-risk individuals.

Results: qPCR analyses showed significantly increased mRNA levels of Cathepsin G (CTSG), which is highly expressed by neutrophils, in PsA patients compared to HC (p = 0.020). Immunohistochemistry showed that the neutrophil marker CD15 is significantly increased in PsA patients compared to HC (p = 0.008). Preliminary flow cytometry analyses indicates a clear population of CD45+CD16+CD66b+ neutrophils in lymph node biopsies of PsA patients while this was not observed in RA-risk individuals.

Conclusion: Overall, we show for the first time an increased presence of neutrophils in lymph nodes of PsA patients when compared to controls. Future studies are needed to investigate their functional role in immunoregulation within lymph node organs.

References:

Acknowledgements: We would like to thank all participating patients and Tom de Groot for his expertise in evaluating neutrophils by flow cytometry.


AB0110
TRANSCRIPTOMICS-BASED INVESTIGATION OF THE MECHANISM OF ANKYLOSING SPONDYLITIS WITH UVEITIS

H. Hai1, H. Li1, B. Deng1, 2Sichuan Provincial People's Hospital, Department of Rheumatology and Immunology, Cheng Du Shi, China; 3Sichuan Provincial People's Hospital, Department of Health Management, Cheng Du Shi, China; 4Sichuan Provincial People's Hospital, Department of Ophthalmology, Cheng Du Shi, China

Background: Spondyloarthritis is a large group of autoimmune diseases that are associated with HLA-B27. Among them, Ankylosing spondylitis is a typical representative of these diseases. In addition to spine and joint involvement, AS has many extra-articular manifestations, among which uveitis is one of the most common. Several particular manifestations of AS[1]Untreated or inappropriate treatment can lead to serious consequences such as blindness. However, there are few studies on the mechanisms of AS-related uveitis, and the pathogenesis of AS-related uveitis is not fully understood, so there is no way to prevent it.

Objectives: We performed a whole-blood gene expression profiling and then analyzed gene expression differences between AS-associated uveitis patients and normal controls by bioinformatics analysis. Protein–protein interaction network was constructed to predict the relationship among the products of the differentially expression genes (DEGs). Furthermore, module mining and function
annotation were applied to assess the interaction network of DEGs. The aim is to find predictive biomarkers for AS-associated uveitis, to further discuss the pathogenesis of AS-associated uveitis in depth, and to provide a reference for clinical precision treatment.

Methods: This microarray-based discovery study used samples from three patients with AS, classified according to the New York criteria, four patients with AS-associated uveitis, and three gender- and age-matched controls. Total RNA was extracted from whole blood samples and enriched for mRNA after DNA digestion using DNase, and then constructed cDNA libraries were quality-checked with an Agilent 2100 Bioanalyzer and sequenced using an Illumina HiSeq TM 2500 sequencer. The data were normalized and initially screened for differential genes using the DESeq R package in R 4.1.0 Prediction of relationships between products of differentially expressed genes (DEGs) using String database prediction and construction of protein-protein interaction networks in Cytoscape. GO with KEGG analysis of differential genes using ClueGO and CluePedia. Screening for hub genes associated with AS-associated uveitis using cytoHubba.

Results: We initially screened 14607 differential genes, from which 112 significantly differential genes with p-values<0.05 and |log2FC|>2 were selected. Among them, 82 were up-regulated genes and 30 were down-regulated genes. Sixty-six relationships between 49 nodes were shown in the PPI network interaction graphs constructed from the String database results. The results of GO analysis showed that most genes were involved in biological processes related to immune response, such as positive regulation of inflammatory response, integrated stress response signaling and toll-like receptor 4 signaling pathway. The molecular functions were mainly focused on chemokine receptor binding, the results of KEGG analysis showed that the gene products were mainly involved in cytokine-cytokine receptor interaction, IL-17 signaling pathway. The target genes screened included CXCL8 CXCL2 NFKBIZ NFKBIA IL11 IL1A, all of which have adequate immune response effects (Figure 1).

Figure 1. Using the EPC algorithm in cytohubba to screen hub genes, the graph shows the top 10 scoring genes, with different colors representing higher scores.

Conclusion: We have identified a series of genes associated with immunity in this study. These DEGs may provide a basis for insights into the pathogenesis of AS-associated uveitis. Further experimental studies are needed to confirm our hypothesis.

Disclosure of Interests: None declared


AB0111  EFFECT OF TOFACITINIB AND GLUCOCORTICOIDS ON INTESTINAL PERMEABILITY, EPITHELIAL DAMAGE AND BACTERIAL TRANSLOCATION IN RAT ADJUVANT-INDUCED ARTHRITIS

S. Heucuet1,2, P. Totozon3, M. Tournier2, C. Prat3, D. Wendling1,2, C. Demougeot2, F. Verhoeven1,2, 1Centre hospitalier régional universitaire de Besançon, Rheumatology, Besançon, France; 2University of Franche-Comté, UR 4267 PEPITE, Besançon, France; 3University of Franche-Comté, UR 4266 EPILAB, Besançon, France

Background: Growing evidence indicated that the intestine is not only a target but also an actor of the pathogenesis in chronic inflammatory rheumatic diseases (CIRD). Consistently, increased intestinal permeability (IP) and damage (ID) as well as bacterial translocation (BT) have been described in patients with CIRD. However, the effects of treatments used in patients with CIRD on gut health are unknown.

Objectives: To determine the effect of glucocorticoids (GCs) and tofacitinib on IP, ID and BT in rats with adjuvant-induced arthritis (AIA).

Methods: AIA was induced in 6-week-old male Lewis rats by a tail injection of Mycobacterium butyricum in incomplete Freund's adjuvant. At onset of arthritis, rats were treated daily with prednisolone at low (0.1 mg/kg/day, i.p.) or high dose (10 mg/kg/day, i.p.), or with Tofacitinib (10 mg/kg twice a day, s.c.) or with vehicle. After 21 days, IP, ID and BT were assessed by measurement of plasma levels of zonulin, intestinal Fatty Acid Binding Protein (iFABP) and serum levels of soluble CD14 (sCD14) by ELISA, respectively. Arthritis severity was daily evaluated through the determination of an arthritis score.

Results: Compared to vehicle, Tofacitinib and high-dose of GC both reduced arthritis score (p<0.001) and levels of sCD14 (-44%, p<0.001 and -41% p<0.001 respectively) in AIA. High dose of GC decreased iFABP (-17%, p<0.05) levels but had no effect on zonulin levels. Tofacitinib did change nor iFABP neither zonulin levels. As compared to vehicle, the low-dose of GC had no effect on arthritis severity, sCD14, iFABP and zonulin plasma levels.

Conclusion: Prednisolone at a dose efficient on arthritis did not worsen but on the contrary reduced intestinal bacterial translocation and epithelial damage. These results are consistent with the positive effects of GCs on intestinal dysbiosis observed in case of sepsis or colitis. The lack of efficacy of the sub-therapeutic dosage of prednisolone suggested that effects of GC are, at least partly, related to their anti-inflammatory effects. Consistent with the positive effect of jakinibs in patients with inflammatory bowel disease, Tofacitinib blunted intestinal bacterial translocation in AIA. Given the suspected pathophysiological link between bacterial translocation and arthritis, our results identified a new mechanistic involvement in the positive effects of GC and tofacitinib in arthritis diseases.

Disclosure of Interests: None declared


AB0112  DECOY RECEPTOR 3 AND ITS SIGNAL PATHWAY CONTRIBUTE TO PATHOGENESIS IN ANKYLOSING SPONDYLITIS

Y. Jiang1, S. B. Wang1, X. Liao1, Y. X. He1, Y. F. Qing1 on behalf of Institute of Research Center of Gout and Hyperuricemia of the Affiliated Hospital, North Sichuan Medical College. 1Affiliated Hospital of North Sichuan Medical College, Department of Rheumatology, Nanchong, China

Background: Ankylosing spondylitis (AS) is a chronic progressive disease with invasion of spine and sacroiliac joint as the main clinical manifestation, which can be combined with systemic inflammation or abnormalities in multiple parts at the same time. There are complex changes of immune function in patients with AS, and its immune and genetic pathogenesis is still unclear. Decoy receptor 3 (DcR3), as a new immune molecule discovered in recent years, plays an important role in regulating T cell activation, proliferation, differentiation and apoptosis. Studies have confirmed that DcR3 is involved in the immune disorder process of rheumatoid arthritis, SLE, AS and other autoimmune diseases, so that the role of DcR3 in AS has attracted attention. However, the expression of DcR3 related pathway genes[1-3] and studies evaluating the DcR3 related pathway genes in AS are scarce.

Objectives: To assess the contribution of DcR3 and its signal pathway to AS and the clinical importance of these genes in AS.

Methods: The mRNA expression levels of DcR3 and its signal pathway(DcR3, T-L1A, Fas, Fasl, Ligh, LighR, LTgRNA expressed in peripheral blood mononuclear cells (PBMCs) from 50 AS patients and 50 healthy subjects. The relationship between DcR3 related molecular pathway expression and laboratory features was analyzed in AS patients.

Results: The expression levels of DcR3, DR3, Fas, Light were much lower in the AS group than in the HC groups (p<0.05 [a,b,c,d]), and the expression levels of LT The relationship between DcR3 related molecular pathway expression

Disclosure of Interests: None declared

Conclusion: Compared with HC group, DCR3 and its signal pathway in PBMCs of AS patients are differentially expressed. It is speculated that DcR3 related molecular pathway gene may be involved in the pathogenesis of AS.

Figure 1. Relative Expression of DcR3 related molecular pathway gene in the PBMCs of Patients. The mRNA levels in PBMCs from AS patients (n=50) and HC (n=50) were measured by RT-qPCR. The expression levels of DCR3, DcR1, Fas, Light were much lower in the AS group than in the HC group in (p<0.05)(a,b,c,d), and the expression levels of LT were much higher in the AS group than in the HC groups in (p>0.05)(e).

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4408

AB0013 A MINIMAL-INVASIVE METHOD TO RETRIEVE AND IDENTIFY ENTHESEL TISSUE FROM PSORIATIC ARTHRITIS PATIENTS

M. G. Raimondo1, 2, M. Pachowsky1, 2, C. Xu1, 2, S. Rauber1, 2, K. Tasciliar1, 2, H. Labinsky1, 2, A. Soare1, 2, D. Simon1, 2, A. Kleyer1, 2, G. Schett1, 2, A. Ramming1, 2

1Friedrich-Alexander-University (FAU) Erlangen-Nürnberg, Department of Clinical Immunology, Translational Immunology, Erlangen, Germany; 2Friedrich-Alexander-University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Deutsches Zentrum Immuntherapie, Erlangen, Germany; 3Friedrich Alexander University Erlangen-Nürnberg, Institute of Functional and Clinical Anatomy, Erlangen, Germany

Background: Entheses represent a hallmark feature of spondyloarthritides, including psoriatic arthritis (PsA). So far, most of the data on entheseal tissue in PsA are based on clinical assessment of tenderness as well as MRI or ultrasound examinations. These approaches, however, do not allow molecular analysis of entheseal tissue, which will require acquisition of entheseal tissue. Up today, it is unknown, which entheseal structure in humans would qualify for a feasible biopsy and how correct sampling of entheseal structures could be ascertained within such biopsy material. These technical challenges have led to substantial lack of knowledge on human entheseal tissue.

Objectives: To establish a minimally invasive biopsy technique of human entheses for the analysis of entheseal tissue in patients with PsA.

Methods: Human cadavers were used for establishing the technique to retrieve tissue from the lateral humeral epicondyle enthesis (cadiaveric biopsies). After biopsy, the entire entheses were surgically resected (cadaveric resections). Biopsies and resections were assessed by label-free second-harmonic-generation (SHG) microscopy. The same biopsy technique was then applied in PsA patients with subsequent definition of entheseal tissue by SHG.

Results: Enthoseal biopsies were performed in five cadavers and allowed the retrieval of entheseal tissue, validated by analysis of the resection material. Thus, microscopy of biopsy and resection sections allowed differentiation of entheseal, tendon and muscle tissue by SHG and definition of specific intensity thresholds for entheseal tissue. The same method was then successfully applied to 10 PsA patients. Hence, the fraction of entheseal tissue within the PsA biopsy specimens was high (65%) and comparable to the fraction retrieved in cadaveric biopsies (68%) as assessed by SHG microscopy.

Conclusion: Enthoseal biopsy of the tendon plate of the lateral epicondyle is feasible in PsA patients allowing reliable retrieval of entheseal tissue and its identification by SHG microscopy.

Disclosure of Interests: None declared

AB0114 IMPROVEMENT OF GUT MICROBIOTA DYSBIOSIS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AFTER ONE YEAR OF BIOLOGICAL TREATMENT

V. Rios Rodriguez1, M. Essex2, J. Rademacher1, M. Torgultalp1, F. Proft1, U. Lobser2, L. Marquet1, D. Poddubnyy1, 2, 3, 4, 5, S. Forslund3, 4, 6, EMBL Heidelberg, Structural and Computational Biology Unit, Heidelberg, Germany

Background: Emerging evidence suggests that dysbiosis of the gut microbiota is involved in the initiation and perpetuation of spondyloarthritides (SpA). Biological disease-modifying antirheumatic drugs (bDMARDs) are a successful treatment to improve symptoms and reduce structural damage occurring in SpA; however, non-responders are frequent and few predictive factors for clinical response have been identified. Whether or not a patient responds to treatment could be related to gut microbiota composition.

Objectives: To investigate the gut microbiota changes in patients with radiographic axial SpA (r-axSpA) after receiving one year of treatment with bDMARDs and identify potential microbial biomarkers predictive of treatment response.

Methods: Patients with r-axSpA were recruited between 2015 and 2019 in an extension of the prospective GERman SPondyloarthritides IncoHent GEnetics (GES- PIC) before beginning bDMARD therapy. All patients had high disease activity (BASDAI >=4 and/ or ASDAS >=2.1) despite previous treatment with nonsteroidal anti-inflammatory drugs, and had not received treatment with bDMARDs for at least three months before enrollment in the study. The choice of bDMARD was left to the discretion of the clinical rheumatologists in accordance with standard practice. Disease activity measures (BASDAI, CRP and ASDAS) and fecal samples were assessed at baseline prior to treatment and after one year of treatment. Patients with back pain negative for inflammatory disease served as a control group. Microbiota composition was determined by 16S rRNA gene sequencing, followed by taxonomic profiling with the SILVA138 database. Response to bDMARD therapy was defined as a clinically important improvement of ASDAS (>=1).

Results: A total of 99 patients with r-axSpA and 63 control individuals were included based on the availability of clinical and microbiome samples. Average age (mean±SD) was 36.4±10.4 years and 64 patients were males. The prevalence of HLA-B27 was 89.9% among r-axSpA patients compared to 7.9% among control individuals. Simpson indices showed an increase in alpha diversity between baseline and year 1 in r-axSpA patients which was statistically insignificant (paired Wilcoxon p=0.154) but brought the r-axSpA cohort nearer to controls. Likewise, Bray-Curtis dissimilarities to measure beta diversity showed a qualitative normalization to healthy individuals after treatment when visualized in principal coordinate space.

At the genus level, patients were mainly depleted in Lachnospiraceae such as Blautia, Roseburia, and Fusicolabacter and enriched in Collinsella compared to the control group at baseline. After one year of treatment, most SpA patients exhibited increased abundances of these taxa, most notably Blautia. Patients also exhibited depletions in Bacteroides and...
Faecalibacterium, which was strongly enriched in HLA-B27+ individuals at baseline (adjusted Wilcoxon p<0.001). Collinsella showed a very slight median increase after one year of treatment, with no significant difference between responders and non-responders (adjusted Wilcoxon p=0.33). Shifts in highly abundant Prevotella and Bacteroides were strongly correlated with the change in ASDAS after one year when controlling for intra-individual variance and overall changes in alpha diversity.

Conclusion: The gut microbiota composition of r-axSpA patients who underwent treatment with bDMARDs for one year more closely resembled the controls. The unique enrichment of Collinsella in r-axSpA patients remained stable across time and treatment, suggesting it may be a disease biomarker.

Figure 1. Correlation of serum MCP-1 concentration and BASFI components in patients with PsA.

Disclosure of Interests: None declared

SLE, Sjögren's and APS - aetiology, pathogenesis and animal models

ABO116 NEW INFLAMMATORY MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME

K. Nurbava1,2, T. Reshetnyak1,2, F. Chedidova1,2, M. Cherkascova3, E. Samarkina1, A. Lila1,2,1 V.A. Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 2-Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia, Department of Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation

Background: Thromboinflammation is a pathological process that is associated with uncontrolled inflammation, leading to hypercoagulability and thrombotic complications. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are prototypical chronic thromboinflammatory diseases. Neutrophils are important cells in the development of systemic inflammation and thrombosis. Neutrophil reactivity (NEUT-RI), neutrophil granularity (NEUT-GI), immature granulocytes (IG), and neutrophil-to-lymphocyte ratio (NLR) are considered as inflammatory markers.

Objectives: To determine the role of parameters of neutrophil activation (NEUT-RI, NEUT-GI), immature granulocytes (absolute IG#, relative IG% counts), NLR, ESR in assessing inflammation in SLE, primary APS (PAPS), and SLE with APS.

Methods: The study included 80 patients and 40 healthy donors (HD). Patients were classified into three groups: Group 1 included 37 patients with SLE. The median age of patients with SLE was 34 years [28-43]. Group 2 included 20 patients with SLE+ APS (45 years [37-49]). Group 3 included 23 patients with PAPS (38 years [34,5-47,5]). Current disease activity was evaluated with SLEDAI-2K and adjusted GAPSS (aGAPSS).

A complete blood count (WBC-white blood cell, NEUTI-absolute neutrophil count, NEUT-RI, NEUT-GI, IG5, IG count, NLR, thrombocytes, ESR-erythrocyte sedimentation rate) was performed with XN-1000 automated hematolgy analyzer (Sysmex, Japan).

Results: Patient characteristics are shown in Table 1. IG# and IG% levels were significantly increased in patients with SLE and SLE+APS compared to controls and PAPS. ESR levels was significantly higher in patients with SLE, SLE+APS, and PAPS compared to HD. There was no significant difference between NEUT-RI, NEUT-GI, NLR, fibrinogen and CRP levels in patients with SLE, SLE+APS, and PAPS.

Correlation was found between the IgG and aGAPPS values.

The study was performed at V.A. Nasonova Research Institute of Rheumatology, within the framework of the fundamental research FURS-2022-003.

Disclosure of Interests: None declared
Table 1. Characteristics of patients with SLE, PAPS, SLE+APS, and healthy controls.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>SLE (n=37)</th>
<th>SLE+APS (n=20)</th>
<th>Healthy donors (n=40)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLEDAI 2K</td>
<td>7 [3.5-13]</td>
<td>-</td>
<td>4 [2.8]</td>
<td>p=0.03*</td>
</tr>
<tr>
<td>Anti-dsDNA, IU/ml</td>
<td>416 [13.6-101]</td>
<td>22.2 [10.7-69.6]</td>
<td>-</td>
<td>NS</td>
</tr>
<tr>
<td>aCL IgG,n,%</td>
<td>2 [5.4]</td>
<td>16 [69.5]</td>
<td>11 [55.0]</td>
<td>p&lt;0.001*</td>
</tr>
<tr>
<td>aCL IgM,n,%</td>
<td>0</td>
<td>4 [19]</td>
<td>1 [5]</td>
<td>p=0.034*</td>
</tr>
<tr>
<td>ab2G2P1 IgG,n,%</td>
<td>2 [5.4]</td>
<td>15 [65.2]</td>
<td>11 [55.0]</td>
<td>p&lt;0.001*</td>
</tr>
<tr>
<td>LA positivity, n,%</td>
<td>1 [2.7]</td>
<td>15 [65.2]</td>
<td>9 [45]</td>
<td>p=0.001*</td>
</tr>
<tr>
<td>Triple positive, n,%</td>
<td>-</td>
<td>14 [68.8]</td>
<td>7 [35]</td>
<td>-</td>
</tr>
<tr>
<td>NEUTs, 10^9/l</td>
<td>2.89 [1.84-3.71]</td>
<td>3.6 [2.7-4.4]</td>
<td>3.3 [3-4.5]</td>
<td>3.55 [2.9-4.4]</td>
</tr>
<tr>
<td>NEUT-R, FL</td>
<td>45.5 [43.8-47.3]</td>
<td>44.2 [43.1-45.9]</td>
<td>45.1 [43.5-47.3]</td>
<td>44.0 [42.7-47.2]</td>
</tr>
<tr>
<td>NEUT-SI, SI</td>
<td>156.6 [151.6-158.0]</td>
<td>154.85 [153.7-156.1]</td>
<td>154 [152-157.8]</td>
<td>153.7 [150.2-157.5]</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>13 [7-20]</td>
<td>14 [6.5-18]</td>
<td>16 [13-19]</td>
<td>7 [4-11]</td>
</tr>
<tr>
<td>IGF, 10^7/l</td>
<td>0.02 [0.01-0.07]</td>
<td>0.01 [0.01-0.02]</td>
<td>0.03 [0.02-0.05]</td>
<td>0.01 [0.01-0.02]</td>
</tr>
<tr>
<td>Ig's</td>
<td>0.4 [0.3-1.1]</td>
<td>0.2 [0.2-0.4]</td>
<td>0.4 [0.3-0.7]</td>
<td>0.2 [0.2-0.3]</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>2.2 [0.6-3.8]</td>
<td>1.15 [1-1.4]</td>
<td>2.5 [1.7-3.6]</td>
<td>-</td>
</tr>
</tbody>
</table>

* statistically significant test result (p < 0.05); NS—not significant; FI—fluorescence intensity; SI—scatter intensity; FL—femtoliter.

Disclosure of Interests: None declared

AB0118 IMMUNE CELL IMBALANCES IN PLACENTAS OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SJÖGREN’S SYNDROME PATIENTS

J. L. Fierro1, G. M. Verstappen2, J. R. Prins3, J. W. Westra4, H. Boomsma4, K. de Leeuw1
1On behalf of Rheumatology and Clinical Immunology, 2University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 3University Medical Center Groningen, Obstetrics and Gynecology, Groningen, Netherlands

Background: Systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) are associated with adverse pregnancy outcomes (APOs) [1,2]. During pregnancy, maternal immune activation is related to a higher risk of hypertension, preeclampsia, preterm labor, and fetal growth restriction in SLE patients [1,2]. Furthermore, these patients have an increased risk of neonatal lupus due to the transplacental passage of maternal anti-RO/SSA antibodies to the fetus [3]. Nevertheless, there is no compelling evidence about the type of immune cell imbalances in the placenta in patients with SLE and pSS.

Objectives: Identify immunologic imbalances, focusing on interferon (IFN) and immune cell subtypes in placenta tissue of patients with SLE or pSS.

Methods: Retrospective analysis of immune cell composition of paraffin-embedded placental tissue from 6 SLE, 4 pSS, and 12 healthy women was conducted. For each case, one full-thickness sample of normal-appearing parenchyma from the central two-thirds of the placental disc was taken. APOs history and pregnancy outcomes were recorded. Placenta immunohistochemistry stainings were performed for myxovirus resistance protein A (MxA, an interferon induced protein), CD20, CD68, CD3, CD45, and Biotecnology Charles Darwin, Roma, Italy;

F. Ceccarelli1, M. Saccucio2, F. Nataleucci3, G. Olivieri1, E. Bruni2, R. Iacono2, T. Colantoni3, G. Di Carlo3, C. Alessandri1, D. Uccellletti3, F. Russo2, A. Pilloni2, F. Conti1, A. Polimeni1, 1Sapienza Università di Roma, Reumatologia, Dipartimento di Scienze Cliniche, AnestesioLogiche e Cardiovascolari, Roma, Italy; 2Sapienza Università di Roma, Department of Oral and Maxillofacial Science, Roma, Italy; 3Sapienza Università di Roma, Department of Biotechnology and Biotecnology Charles Darwin, Roma, Italy

Background: Several data have demonstrated the occurrence of erosive arthritis in Systemic Lupus Erythematosus (SLE) patients. However, few studies have focused on the pathogenic mechanisms involved in this feature. The implication of oral pathogens has been proved in Rheumatoid Arthritis: in particular, Porphyromonas gingivalis (Pg), by inducing citrullination, could trigger autoimmune response.

Objectives: We evaluated amount of Pg in the tongue of a cohort of SLE patients with arthritis, focusing on the association with the erosive phenotype.

Methods: SLE patients with arthritis were enrolled. We evaluated the presence of ACPA and RF by using commercially enzyme-linked immunosorbant assay kits. SLEDAI-2k was applied to assess disease activity and DAS28 to assess erosive arthritis in SLE.

P71052 ORAL PATHOGENS AND THE NERVOUS SYSTEM: CLINICAL MANIFESTATIONS AND LABORATORY EVIDENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

B. Mattoli1, N. Orchardi1, E. Deidda1, L. Cattaneo2, A. Fridda1, C. Doria1, G. Bottaro1,1Sapienza Università di Roma, Reumatologia, Dipartimento di Scienze Cliniche, AnestesioLogiche e Cardiovascolari, Roma, Italy; 2Sapienza Università di Roma, Department of Oral and Maxillofacial Science, Roma, Italy

Background: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects multiple organs, including the central nervous system (CNS). Several studies have demonstrated that oral pathogens, such as Porphyromonas gingivalis (Pg), could play a role in the pathogenesis of neuropsychiatric manifestations in SLE. The aim of this study was to assess the association between oral pathogens and CNS manifestations in SLE patients.

Objectives: We evaluated the presence of ACPA and RF by using commercially enzyme-linked immunosorbant assay kits. SLEDAI-2k was applied to assess disease activity and DAS28 to assess erosive arthritis in SLE.
joint inflammatory status. Erosive damage was evaluated by ultrasound at level of metacarpophalangeal and proximal interphalangeal joints. All subjects underwent a tongue cytologic swab in order to quantify the amount of Pg (real-time PCR). The bacterium expression was obtained from the ratio between the patient’s DNA amount and that obtained from healthy subjects.

Results: The present analysis included 33 SLE patients (M/F 3/30; median age 47 years, IQR 17; median disease duration 216 months, IQR 180). Concerning activity at the time of the enrollment, we found a median DAS28 value of 3.8 (IQR 2.8) and a median SLEDAI-2k of 4 (IQR 5). Twelve patients (36.4%) showed US-detected erosive damage in at least one joint, significantly associated with ACPA positivity (p=0.0001). Furthermore, patients with erosive damage showed significantly higher median DAS28 values in comparison with those without [4 (IQR 3.1) versus 3.2 (IQR 2.1), p=0.03]. Moving on the oral pathogen analysis, we found a mean Pg ratio of 19.7±31.1 (median 6.6, IQR 22.3). When dividing patients according to the presence of erosive damage, we found higher Pg amount in SLE patients with this phenotype in comparison with those without (31.4±44.3 versus 12.9±19.2, p=ns; Figure 1A). Thus, we used Pg mean values as threshold, identifying two groups of patients, namely highPg and lowPg. In a receiver operating characteristic curve analysis (ROC), this threshold resulted in the most sensitive and specific one (sensitivity of 85%; specificity of 50%). As reported in Figure 1B, erosive damage was significantly more frequent in highPg patients in comparison with lowPg (60.0% versus 26.0%, p=0.001). Furthermore, highPg patients showed higher prevalence of skin manifestations, serositis and neurological involvement compared to lowPg patients (p=0.005, p=0.03, p=0.0001, respectively).

Conclusion: The possible contribution of oral microbiota in SLE erosive arthritis was here evaluated for the first time, finding a significant association between erosive damage and higher expression of Pg at tongue level.

Disclosure of Interests: None declared

AB0119

ROLE OF COSTIMULATORY MOLECULES IN SYSTEMIC LUPUS ERYTHEMATOSUS: FOCUS ON CD137

F. Natalucci1, A. Di Filippo2, F. Ceccarelli3, I. Zizzari4, G. Olivieri1, V. Orefo1, C. Pirone1, F. R. Spinel1i, C. Alessandri1, M. Nunt2, F. Conti1.1 “Sapienza” University of Rome, Policlinico Umberto I, Lupus Clinic, Rheumatology Unit, Department of Clinical, Internal, Anaesthesiological and Cardiovascular Science, Roma, Italy; 2 “Sapienza” University of Rome, Policlinico Umberto I, Laboratory of Tumour Immunology and Cell Therapy, Department of Experimental Medicine, Roma, Italy

Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by a wide autoantibodies production. The traditionally concept of a B-cell driven disease has been changed in the last years due to time evidence demonstrating the crucial role of T cells in SLE pathogenesis. In particular, regulatory (Treg) and memory T cells seem act through co-stimu-latory and co-inhibitory molecules, such as CD137, CD137L and CD80. The over-expression of these molecules on lymphocytes may contribute to immune system dysregulation.

Objectives: The primary objective of the present case-control study was to evaluate the over-expression of CD137, PD-1 and CTLA4 on T cell surface of SLE patients by using flow-cytometry. Secondly, we evaluated the percentage of Treg and memory T cells.

Methods: We enrolled patients SLE patients (2019 ACR/EULAR criteria) and sex/age-matched healthy subjects (HS). Demographic, clinical, and laboratory data were collected in a standardized computerized electronically filled form. Disease activity was assessed by SLEDAI-2k. Each subject underwent peripheral blood sample collection. By using flow-cytometry we evaluated the expression of FOXP3, CD137, PD-1 and CTLA4, CD45, CD25, CCR7 to determine the percentage of Treg and memory T cells.

Results: The present analysis included 21 SLE patients (M/F 1/20; median age 48 years [IQR 17], median disease duration 144 months [IQR 204]). The Treg percentage was significantly lower in SLE compared to HS [median 4.2 (IQR 0.32) versus 2.5 (IQR 2.44); p=0.001, Figure 1A]. Moving on effector Treg (eTreg), SLE patients with high disease activity (SLEDAI > 4) showed a significantly higher prevalence for these cells compared to patients with SLEDAI ≤ 4 [1.16 (IQR 0.51) versus 0.53 (IQR 0.8), p=0.014, Figure 1B]. Moreover, inverse correlation was found between eTreg percentage and SLEDAI-2k (p=0.029, r=-0.47 [CI 0.75 - 0.04]) Figure 1C). The evaluation of CD137 expression was significantly higher in SLE patients compared to HS on CD3+ cells [median 5.32 (IQR 6.11) versus 3.3 (IQR 1.7), p=0.001, Figure 1F]. On CD4+ cells, CD137 expression positively correlated with disease activity (p=0.0082, r=0.58 [CI 0.15-0.82]). Finally, when analysing memory T cells subpopulations, inverse correlation has been found between effector memory T cells (TEM, CD45RA-CCR7+) and SLEDAI-2k when considering CD3+ (p=0.029, r=-0.56 [CI 0.81 – 0.12]) and CD4+ cells (p=0.016, R=-0.54 [CI -0.80 – -0.1]). Of note, CD137 expression on T central memory cells (TCM, CD45RA-CCR7+) positively correlated with SLEDAI-2k [(p=0.019, r=-0.52 [CI 0.09 – 0.79]).

Conclusion: Our results suggest a possible role of CD137-CD137L axis in SLE pathogenesis. The stimulatory role of this molecule is indicated by the positive correlation between SLEDAI-2k values and surface expression of CD137. Moreover, inverse correlation between SLEDAI-2k and eTreg percentage suggests a possible Treg dysregulation in SLE.

Table 1. SLE cohort features

| Clinical and Laboratory Features | %
|-------------------------------|---|
| Mucocutaneous | 80.9%
| Articular | 76.1%
| Serositis | 19.0%
| Kidney | 23.8%
| Haematological | 48.2%
| CNS/NOS | 9.5%
| Thrombotic events | 4.7%
| anti-dsDNA | 68.4%
| anti-SSA/anti-SSB | 47.6%
| anti-RNP | 19.0%
| anti-Sm | 33.0%
| Antiphospholipid antibodies | 14.2%
| Low C3/C4 | 57.1%
| Previous Therapy | |
| Glucocorticoid | 90.5%
| Intravenous immunoglobulin | 62.2%
| Methotrexate | 23.8%
| Mofetil Mycophenolate | 33.3%
| Ciclosporin | 28.0%
| Cyclophosphamide | 9.5%
| Azathioprine | 33.3%
| Rituximab | 14.3%
| Antiproteinase | 23.8%
| Anticoagulant therapy | 4.7%
Disclosure of Interests: None declared

AB0120


to evaluate the changes in XOR activities in plasma, lysed white blood cells (WBC), and lysed red blood cells (RBC) of SLE patients.

Methods: Diagnosis of SLE was verified using the SLICC criteria (2012). Activities of XOR interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH), were measured in plasma, lysed WBC and lysed RBC by the spectrophotometric method [3]. The enzymatic activities were expressed as nmol/min/ml and normalized to 1x10^6 cells/ml in lysed WBC, and to 1x10^6 cells/ml in lysed RBC. The results were expressed as Me (Q1; Q3). Statistical comparison tests were selected in accordance to the common guidelines. Differences were considered significant when p<0.05. Reference ranges were calculated as 95th percentile interval.

Results: 56 adult SLE patients (mean age 35 (31; 42) years; mean disease duration was 8 (5; 11) years) and 35 healthy individuals were enrolled in the study. Reference intervals of plasma XO and XDH activities were 2.29 – 4.31 and 5.92 – 9.97 nmol/min/ml, respectively. Reference intervals of plasma XO and XDH activities in lysed WBC were 11.11 – 31.33 and 18.62 – 39.65 nmol/min/ml, respectively. Reference intervals of XO and XDH activities in lysed RBC were 20.62 – 25.46 and 41.85 – 55.04 nmol/min/ml, respectively. Enzymatic activities of SLE patients were significantly different from healthy controls. Increased XO activity and decreased XDH activity were observed in plasma of SLE patients (p<0.001 for both enzymes). The activities of both XOR forms were decreased in lysed WBC (p<0.001 for both enzymes). Lysed RBC were characterized by a decrease in XO activity (p<0.001).

Conclusion: Significant changes in the balance of XO and XDH activities were revealed in plasma, lysed WBC and RBC of SLE patients. These enzymes can also exhibit NADH oxidase and nitrate reductase activities under conditions of low pH and hypoxia. Such conditions are formed in SLE due to the development of pronounced inflammation and microthrombosis in various tissues. Reactive forms of oxygen and nitrogen, which production is increased as a result of XOR activity, have a damaging effect on cellular structures, initiate the processes of lipid per-oxidation, participate in the stimulation of NF-kB, and contribute to the formation of neutrophil extracellular traps. It can be assumed that the imbalance of XOR enzymatic activities in WBC indicates the previous stages of purine metabolism disturbances, which leads to a change in functional state and death of these blood cells. Free radicals generated by the XO may have a damaging effect on RBC.

REFERENCES:

Disclosure of Interests: None declared

AB0122


to the expression of SLAMF7 in primary Sjogren’s syndrome (pSS).

Methods: SLAMF7 expression was studied using flow cytometry on different subpopulations (CD4 T cells, CD8 T cells, NK cells, plasma cells (CD19+ CD38+ CD27high) and naive (CD27-) or mature (CD27+) B cells before (IgD-) or after (IgD+) class switching in pSS patients and healthy donors (HD). SLAMF7 protein expression was measured by the difference in expression (condition with antibody recognizing SLAMF7 - condition without antibody) of the mean fluorescence intensity (delta MFI).

Results: The pSS cohort consisted of 18 patients (17 women). 71% of patients were anti-SSA+, 41% anti-SSB+, 44% had rheumatoid factors (RF). The median IgG level was 13.3 g/l (9.88-21.45). 8/18 patients had evidence of systemic activity (ESSDAI score >0). Twenty-one healthy donors (19 women) were used as controls. No overall difference in SLAMF7 expression was observed between pSS and healthy donors, or among pSS patients between patients with or without systemic complications. SLAMF7 expression was higher in patients with than in patients without autoantibodies or markers of B-cell activation.

1/ RF-positive patients had a higher expression of SLAMF7 than RF-negative patients by IgD- CD27+ B cells (median delta MFI: 397 for RF+ pSS vs 185 for RF- negative pSS [p=0.001] vs 187 [p<0.0001] for HD) and by IgD+ IgD- B cells (median delta MFI: 450 for RF+ pSS vs 307 for RF- negative pSS [p=0.005] vs 329 [p=0.001] for HD).

2/ Anti-SSA-positive patients had a higher expression of SLAMF7 than anti-SSA-negative patients by CD27+ IgD- B cells (median delta MFI: 346 for anti-SSA+ pSS vs 149 for anti-SSA-negative pSS [p=0.019] vs 187 [p=0.007] for HD) and by CD27+ IgD+ B cells (median delta MFI: 403 for anti-SSA+ pSS vs 264 for anti-SSA negative pSS [p=0.021] vs 329 [p=0.012] for HD). The same association with a higher expression of SLAMF7 was observed for anti-SSB.

Conclusion: SLAMF7 expression was correlated with IgG levels in pSS patients on IgD- CD27+ B cells (r=0.51, p=0.04).

Disclosure of Interests: Necessity project

None declared

Disclosure of Interests: None declared
REFERENCE:


DISCLOSURE OF INTERESTS: None declared


AB0123

IMPACT OF TOBACCO ON PRIMARY SJÖGREN SYNDROME: ANALYSIS OF THE FRENCH COHORT ASSESS

L. Pacoureau1, J. E. Gottenberg2, G. Nocturne1,3, E. Dernis4, M. Couderc5, J. E. Gottenberg2, G. Nocturne1,3, E. Dernis4, M. Couderc5, J. E. Gottenberg2, G. Nocturne1,3, E. Dernis4, M. Couderc5

Background: It has been shown that smoking could be negatively associated with the risk of developing primary Sjögren's Syndrome (pSS), and that amongst smoking pSS patients, seropositivity for anti SSA antibodies and frequency of focal sialadenitis were lower. However, data are scarce concerning the impact of smoking on disease activity, glandular features, patient reported outcomes (PROs) and disease progression.

Methods: A French prospective multicenter, longitudinal cohort involving 395 patients with pSS enrolled in 15 French centers between 2006 and 2009 and followed since then. In these patients, we compared baseline characteristics of smokers and non-smokers. After five years, no difference was observed, according to smoking status, in terms of change in disease activity or PROs.

Results: Smokers pSS patients are more likely to be men and younger than non-smokers. Ever smokers tended to have less dryness, and take less immunosuppressives. After five years, no difference was observed, according to smoking status, as well as no change in dryness (p = 0.968), pain (p = 0.280), fatigue (p = 0.605) or in UWSF (p = 0.192).

Table 1. Baseline characteristics and change in patient-reported outcomes at 5 years

<table>
<thead>
<tr>
<th>Baseline</th>
<th>Smokers n = 106</th>
<th>Non smokers n = 288</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54.0 ± 11.3</td>
<td>59.2 ± 12.2</td>
<td>0.00008</td>
</tr>
<tr>
<td>Sex, females</td>
<td>52 (60.0)</td>
<td>276 (95.8)</td>
<td>0.0013</td>
</tr>
<tr>
<td>Disease duration (years) median [IQR]</td>
<td>3.9 [1.1; 8.7]</td>
<td>5.5 [2.6; 9.7]</td>
<td>0.257</td>
</tr>
<tr>
<td>ESSPRI</td>
<td>5.2 ± 2.2 (n = 97)</td>
<td>5.5 ± 2.1 (n = 267)</td>
<td>0.259</td>
</tr>
<tr>
<td>Dryness</td>
<td>4.9 ± 2.5 (n = 98)</td>
<td>5.5 ± 2.2 (n = 270)</td>
<td>0.053</td>
</tr>
<tr>
<td>Fatigue</td>
<td>5.9 ± 2.8 (n = 101)</td>
<td>6.0 ± 2.6 (n = 275)</td>
<td>0.924</td>
</tr>
<tr>
<td>Pain</td>
<td>4.6 ± 2.8 (n = 101)</td>
<td>4.9 ± 2.9 (n = 274)</td>
<td>0.359</td>
</tr>
<tr>
<td>Unstimulated salivary flow (mL/min)</td>
<td>0.9 ± 0.75 (n = 89)</td>
<td>0.4 ± 1.0 (n = 241)</td>
<td>0.622</td>
</tr>
<tr>
<td>Treatment for dry mouth</td>
<td>64 (60.4)</td>
<td>210 (73.0)</td>
<td>0.016</td>
</tr>
<tr>
<td>ESSDAI</td>
<td>5.0 ± 4.9 [9 (n = 104)]</td>
<td>5.5 ± 5.8 [n = 281]</td>
<td>0.436</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>49 (46.2)</td>
<td>159 (55.2)</td>
<td>0.113</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>49 (46.2)</td>
<td>165 (57.3)</td>
<td>0.050</td>
</tr>
<tr>
<td>Immunosuppressive drugs</td>
<td>21 (19.8)</td>
<td>77 (26.7)</td>
<td>0.158</td>
</tr>
<tr>
<td>Lymphocyte count (mm&lt;sup&gt;3&lt;/sup&gt;)</td>
<td>1661 ± 919.3</td>
<td>1492 ± 1072.0 (n = 280)</td>
<td>0.128</td>
</tr>
<tr>
<td>After five years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in ESSDAI ≥ 3</td>
<td>12 (11.6) (n = 77)</td>
<td>30 (14.5) (n = 207)</td>
<td>0.818</td>
</tr>
<tr>
<td>Change in ESSPRI ≥ 1</td>
<td>30 (29.2) (n = 70)</td>
<td>91 (46.0) (n = 198)</td>
<td>0.654</td>
</tr>
<tr>
<td>Change in salivary flow ≥ 25%</td>
<td>29 (24.4) (n = 65)</td>
<td>55 (34.0) (n = 162)</td>
<td>0.132</td>
</tr>
</tbody>
</table>

Continuous variables were compared using student t test and qualitative variable using chi-square test.

Conclusion: Smokers pSS patients are more likely to be men and younger than non-smokers. Ever smokers tended to have less dryness, and take less frequently treatment for dryness, corticosteroids, hydroxychloroquine or immunosuppressants. After five years, no difference was observed, according to smoking status, in terms of change in disease activity or PROs.

DISCLOSURE OF INTERESTS: None declared


AB0124

EFFECTS OF INHIBITOR K-CARRAGEENAN ON HAECs INFLAMMATORY RESPONSE TO LDLS ISOLATED FROM SLE PATIENTS

S. Parré1, A. Avila2, J. Rivalta3, M. Guardiola3, R. Rodríguez4, A. Castro1

1Hospital Universitari Sant Joan de Reus, Internal medicine. Autoimmune diseases units, Reus, Spain; 2Hospital Universitari Sant Joan de Reus, Pathology department, Reus, Spain; 3Rovira i Virgili University, Unitat de Recerca de Lípides i arteriosclerosis, Tarragona, Spain

Background: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a high risk of atherosclerosis and cardiovascular events. It was previously reported by our group that low-density lipoprotein (LDL) particles isolated from SLE patients, during an active state of the disease (‘flare’), promoted an exaggerated inflammatory response in human aortic endothelial cells (HAEcs). However, the molecular mechanisms underlying this response still remain elusive.

Objectives: The hypothesis of this study is that these SLE-LDLs would be using receptor LOX-1, associated with inflammatory conditions and altered lipopro- teins, to generate the proatherogenic response in HAEcs.

Methods: LOX-1 pharmacological inhibitor k-carrageenan was used before the stimulation of HAEcs with LDLs isolated from healthy controls (10), non-active (13), or active-SLE patients (13). Gene expression, protein, and cell migration assays were performed to evaluate HAEcs inflammatory response.

Results: LOX-1 inhibition with k-carrageenan significantly reduced the expression of vascular cell adhesion molecule 1 (VCAM-1) and restored the gene expression of endothelial nitric oxide synthase (eNOS) in HAEcs incubated with non-active SLE LDLs.

Conclusion: While VCAM-1 down-regulation was expected, the immediate next step derived from the observed results will be a deeper understanding of how LOX-1 inhibition may reduce the endothelial ability to synthesize NO in the presence
Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models

AB0125

IL-25 PARTICIPATES IN KERATINOCYTE-DRIVEN DERMAL MATRIX TurnerOVER AND IS REDUCED IN SYSTEMIC SCLEROSIS (SSc) EPIDERMIS

B. Russo1,2, J. Borowczyk3, P. Cacialli4, P. Moquet1, M. E. Truchetet1, A. Modarresi6, N. Brembilla2, J. Bertrand3, W. H. Boehncke2, C. Chizzolini3.

1University of Geneva, Department of Medicine, Geneva, Switzerland; 2Hôpitaux Universitaires de Genève, Genève, Switzerland; 3University of Geneva, Department of Pathology and Immunology, Geneva, Switzerland; 4Ronon Hospital APHP, Department of Pathology, Paris, France; 5University Hospital, Department of Rheumatology, Bordeaux, Switzerland; 6Hôpitaux Universitaires de Genève, Plastic, reconstructive & aesthetic unit, Geneva, Switzerland

Background: Evidence shows that dysfunctional SSC keratinocytes contribute to fibrosis by altering dermal homeostasis (1, 2). Whether interleukin-25 (IL-25), an IL-17 family member regulating many epidermal functions (3), takes part in skin fibrosis is unknown.

Objectives: To investigate the role of IL-25 in skin homeostasis.

Methods: The expression of IL-25 was evaluated by immunofluorescence and in situ hybridization in 10 SSC and 7 healthy donors (HD) skin biopsies. Epidermal equivalents (EE) reconstituted by primary HD keratinocytes were used as a model to study transcriptomic changes induced by IL-25 in the epidermis. FRNA expression profile in EE was characterized by RNAseq. The conditioned medium (CM) from primary SSC and HD keratinocytes primed with IL-25 was used to stimulate fibroblasts. IL-6, IL-8, MMP-1, type-I collagen (col-I), and fibronectin production by fibroblasts was assessed by ELISA.

Results: SSc epidermis expressed lower levels of IL-25 compared to HD. In EE, IL-25 regulated several molecular pathways related to wound healing and extracellular matrix (ECM) remodeling. Compared to control CM, the CM from IL-25-primed keratinocytes enhanced the fibroblast production of MMP-1, IL-6, IL-8, but not of Col-I nor fibronectin. However, IL-25 significantly reduced the production of Col-I when applied directly to fibroblasts and partially inhibit a-smooth muscle actin (α-SMA) expression promoted by TGFβ. The activation of keratinocytes by IL-25 was receptor-dependent and evident after a very short incubation time (10min), largely mediated by IL-1, suggesting enhanced and specific release of preformed mediators.

Conclusion: These results show that IL-25 participates to skin homeostasis and its decreased expression in SSc may contribute to skin fibrosis by favoring ECM deposition over degradation.

REFERENCES:

Disclosure of Interests: None declared.

AB0127

BRONCHOALVEOLAR LAVAGE (BAL) FLUID AND SERUM FROM PATIENTS WITH SYSTEMIC SCLEROSIS WITH INTERSTITIAL LUNG DISEASE (SSC-ILD) PROMOTE A PRO-INFLAMMATORY GENE SIGNATURE IN HUMAN PRIMARY LUNG FIBROBLASTS

Y. Al-Adwy1, J. Westra2, A. J. Stefl2, H. van Goor3, D. J. Mulder1, 1University Medical Center Groningen, Internal Medicine (Vascular), Groningen, Netherlands; 2University Medical Center Groningen, Rheumatology and Clinical Immunology, Groningen, Netherlands; 3University Medical Center Groningen, Pathology and Medical Biology, Groningen, Netherlands

Background: While circulating cytokines are frequently investigated in SSC patients, they may also play a role in local tissue, such as the lungs. Although most SSC patients show limited systemic inflammation, some studies have demonstrated that BAL fluid obtained from patients with SSC contains elevated levels of pro-inflammatory and pro-fibrotic cytokines. However, the relevance of the local milieu of the bronchial tree on the development of ILD has not been studied. We hypothesized that the bronchial milieu as represented by BAL fluid will have pro-inflammatory and pro-fibrotic effects on lung fibroblasts as the major effector cells in lung fibrosis. We also anticipated a greater pro-inflammatory and pro-fibrotic effect of BAL fluid obtained from patients with ILD (SSc-ILD) compared to patients without ILD (SSc). Finally, we hypothesized that serum obtained from both SSc-ILD and SSC will have a similar and concordant effect on lung fibroblasts, due to the systemic nature of the disease.

Objectives: To show the differential effect of BAL fluid and serum obtained from SSc patients with and without ILD on mRNA expression of pro-inflammatory and pro-fibrotic markers in human primary lung fibroblasts.

Methods: Serum and BAL fluid were collected from 40 patients with SSC-ILD and 3 without ILD who were all treatment-naïve. ILD diagnosis was based on HRCT and lung function tests. Normal human primary lung fibroblasts were cultured and treated with either BAL fluid (5%) or serum (0.5%) from all individual patients. No treatment (CTRL) or treatment with pooled serum from healthy controls were used as control. After 4h, fibroblasts were harvested in TRIzol. The mRNA expression levels of inflammatory markers (interleukin-6, IL-6, interleukin-8, TNFα, interferon gamma-induced protein-10, IP-10), fibroblast markers (Connective Tissue Growth Factor: CTGF, Transforming Growth Factor: TGF-β1, and Alpha-Smooth Muscle Actin: α-SMA) were assessed using RT-qPCR. Nonparametric Mann-Whitney U test was used for comparison between groups. Correlation between BAL and serum treated fibroblast was calculated for the expression of the markers using Pearson correlation coefficient method.

Results: Fibroblasts treated with either SSc or SSc-ILD BAL fluids showed a significantly higher mRNA expression of IL-6 compared to CTRL (Figure 1 a). The same was observed for IP-10, except for SSc serum which was not significant (Figure 1 b). When comparing the effects of BAL fluid between SSc or SSc-ILD patients, the effect of SSc-ILD BAL fluid was strikingly more profound.
than observed with SSc on both IL-6 and IP-10 (Figure 1 a,b). Similar effects were seen when fibroblasts were treated with SSc serum, where serum from SSc-ILD resulted in significantly higher expression of IL-6 and IP-10 compared to SSc (Figure 1 a,b). The effect of serum and BAL on IL-6 gene expression were strongly and significantly correlated (r=0.9; P=0.015) while were weakly correlated regarding IP-10 expression (r=0.4; P=0.03) (not shown). The fibrotic markers TGF-β and α-SMA showed no difference in expression in BAL or serum-treated fibroblasts compared to controls (Figure 1 c,d). Only the fibroblasts treated with SSc-ILD serum showed a significant increase in mRNA expression of the early fibrosis marker CTGF when compared to control or SSc serum (Figure 1 e).

**Conclusion:** We showed a clear pro-inflammatory effect of BAL fluid obtained from patients with SSc on human fibroblasts as demonstrated by mRNA expression of IL-6 and IP-10. This pro-inflammatory effect was 5-10 times more profoundly observed in SSc patients with ILD compared to those without ILD. Similar effects were observed when fibroblasts were treated with serum obtained from the same SSc patients where the BAL fluid and serum of each patient seemed to provoke a concordant pro-inflammatory effect. Although further studies are warranted, our results underline the systemic nature of SSc and provide new insights into the role and interaction between the local bronchial and systemic milieu in ILD development.

**Disclosure of Interests:** Yehya Al-Adwai: None declared, Johanna Westra: None declared, Alice J. Stehl: None declared, Harry van Goor: None declared, Douwe J Mulder Grant/research support from: Dr. Dj Mulder as an employee of the UMCG received research grants from Sanofi Genzyme which were paid to the UMCG.

**DOI:** 10.1136/annrheumdis-2022-eular.930

**AB0128 IMMUNE RESPONSE GENE 1 (IRG1) IS DYSREGULATED IN SYSTEMIC SCLEROSIS**

S. O'Reilly1, 2Durham, Biosciences, Durham, United Kingdom

**Background:** Systemic sclerosis (SSc) is an autoimmune idiopathic connective tissue disease in which there is inflammation and fibrosis of the skin. The innate immune system is intrinsically linked in the disease. IRG1 is a gene that codes for an enzyme that is essentially to make itaconate a metabolite of the TCA cycle. Iaconate has recently been ascribed function in immunity by negatively regulating inflammation through mechanism that involve upregulation of nrf2 and possibly downregulation of nf-kb to act as a molecular rheostat to balance the positive and negative aspects of inflammation. IRG1 is known to be robustly upregulated in macrophages after LPS stimulation.

**Objectives:** To determine the expression of IRG1 in systemic sclerosis macrophages.

**Methods:** Early diffuse SSc patients (≤ 2 years from first non-Raynaud’s symptom) had blood drawn and monocytes were isolated on CD14 using MACS. Healthy controls blood was also taken and CD14+ monocytes were isolated. All female (6 donors each). After isolation cells were differentiated to macrophages using M-CSF for a set period. After which they were treated with ultrapure LPS for 18 hours. Cells were lysed and mRNA expression for IRG1 and Nqo1 was quantified by qPCR. Data is normalized to housekeeping gene 18S for normalization.

In some experiments macrophages were stimulated with the itaconate derivative 4 Octyl Iaconate (4OI) at 100 µM for 2 hours, then stimulated or not with LPS for a further 24 hours. IL-1β and IL-6 cytokines were measured by ELISA. Bleomycin mouse model of skin fibrosis was employed by repeated intra dermal injections of bleomycin or sodium chloride vehicle. Skin biopsies were taken in the lesioned skin and H&E performed and fibrosis markers by qPCR was analysed.

**Results:** Healthy monocytes in response to LPS stimulation robustly upregulated IRG1 expression but in comparison to SSc monocytes this upregulation was significantly attenuated (n=3). Pretreatment of SSc monocytes with the itaconate derivative 4OI prior to LPS stimulation led to significantly reduced IL-1β and IL-6 production.

The also led to upregulation of the nrf2 target gene Nqo1 6 fold compared to LPS treated alone. No difference in nf-kb was observed. mRNA expression of bleomycin skin found significantly downregulated nrf2 expression in association with elevated fibrosis markers compared to vehicle control treated mice (n=3 per group).

**Conclusion:** Failed upregulation of IRG1 in SSc macrophages may lead to a failure of inflammatory resolution and subsequent fibrosis. The itaconate derivative 4OI could be a possible anti-fibrotic through restoration of homeostasis via upregulation of nrf2 target genes.

**Disclosure of Interests:** Steven O'Reilly Employee of: I am employed by STipe therapeutics

**DOI:** 10.1136/annrheumdis-2022-eular.1730
INDUCTION OF COLLAGEN CHAIN FORMATION IN RESPONSE TO FIBROTIC FACTORS IN DERMAL AND PULMONARY FIBROBLASTS

S. F. Madsen1,2, P. Juhl3, J. M. B. Sand4, M. Karsdal5, A. C. Bay-Jensen4, C. Thudium1, University of Copenhagen, Department of Biomedical Sciences, Copenhagen, Denmark; 3Nordic Biosciences, Immunology, Herlev Denmark; 4Nordic Bioscience, Fibrosis, Herlev, Denmark; 5Nordic Bioscience, R&D, Herlev, Denmark

Background: Systemic sclerosis (SSc) patients who develop pulmonary fibrosis, have an increased mortality rate1. Excessively activated fibroblasts deposit extracellular matrix (ECM), which leads to fibrosis resulting in stiffening of the tissue in both skin and lung. Currently there is no cure for fibrosis in SSc, only drugs which can slow the fibrotic process, and there is therefore, a medical need for further understanding of the pathogenesis. Fibrosis is associated with growth factors, including tumor growth factor beta 1 (TGF-β1) and platelet derived growth factor-ab (PDGF-ab).

Objectives: We investigated how TGF-β1 and PDGF-ab stimulation affected the gene and protein expression of specific collagen chains of type I, III and VI collagen in primary healthy human dermal (DF) and pulmonary fibroblasts (PF).

Methods: The fibroblasts were grown in 0.4% fetal calf serum DMEM, ficol (to produce a crowded environment) and ascorbic acid for up to 12 days. They were stimulated with TGF-β1 [0.01 nM], PDGF-ab [3 nM] or a combination of TGF-β1 [0.01 nM] and PDGF-ab [3 nM], while non-stimulated fibroblasts served as control. ECM protein formation was assessed in supernatant from day 0, 4, 8, and 12, by ELISAs which detects the N-terminal of the pro-collagen of type I and III collagen, and the C5 domain of type III collagen. Gene expression was analyzed after 4 days and the relative gene expression was calculated based on multiple reference genes2. Statistical analysis includes one-way and two-way ANOVA.

Results: TGF-β1 increased the gene expression of Col1α1 in DF (p<0.0001) and Col1α2, Col3α1 and Col6α3 in both DF (p<0.01, p<0.001, p<0.05, respectively) and PF (p<0.0001) compared to control. PDGF-ab showed no difference in gene expression of the DF but decreased multiple genes in PF (p<0.01). The combination of TGF-β1 and PDGF-ab increased the gene expression of Col1α1 in DF (p<0.01), Col3α1 in PF (p<0.0001) Col1α2 and Col6α3 in both DF (p<0.05 and p<0.01) and PF (p<0.0001) compared to control. None of the stimulations lead to an increase in the Col6α2. The TGF-β1 induced gene expression corresponded with increased ECM formation of type I and VI collagen from day 4 (p<0.01), and type III collagen from day 8 (p<0.05) in both DF and PF. PDGF-ab stimulation led to an increased ECM formation of type I and VI collagen in both DF and PF (p<0.01), and type III collagen in DF (p<0.01). The combination stimulation with TGF-β1 and PDGF-ab induced a corresponding increase in both gene expression and ECM formation of type I and VI collagen in both DF and PF (p<0.01). While the combination increased the ECM formation of type III collagen in both fibroblasts types, the gene expression of Col3α1 were only increased in PF (p<0.0001).

Conclusion: This study demonstrates that TGF-β1 stimulation alone and in combination with PDGF-ab results in increased gene and protein expression of type I and VI collagen in both DF and PF, and additionally type III collagen in PF. However there was a disconnect between the gene and protein expression profiles after PDGF-ab stimulation, which have to be investigated further. This study may provide new insights to the differences between fibroblast of different origin and their response to fibrotic factors.

REFERENCES:

AB0132  STIMULATION OF SOLUBLE GUANYLATE CYCLASE (sGC) FOSTERS ANGIOGENESIS AND BLUNTS ENDOTHELIAL-TO-MESENCHYMAL TRANSITION (ENDOMT) OF SYSTEMIC SCLEROSIS (SSC) DERMAL MICROVASCULAR ENDOTHELIAL CELLS

E. Romano,1 I. Rosa,2 B. S. Fioretto,1 D. Giuggioli,2 M. Manetti,3 M. Matucci-Cerinic3,4 1University of Florence, Department of Experimental and Clinical Medicine, Florence, Italy; 2University of Modena and Reggio Emilia, Sclerodermat Unit, Department of Medical and Surgical Sciences for Children and Adults, Modena, Italy; 3IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy

Background: In SSC, early abnormalities in microvessel morphology and angiogenic impairment in parallel advance with the development of tissue fibrosis orchestrated by myofibroblasts. Increasing evidence suggests that the EndoMT process, in which endothelial cells transdifferentiate into profibrotic myofibroblasts, may take centre stage in SSC pathogenesis [1,2]. sGC is an enzyme regulating cell growth/proliferation and vascular tone/remodelling by catalysing the production of cyclic guanosine monophosphate. Previous studies reported that sGC stimulation inhibits TGF-induced fibroblast-to-myofibroblast differentiation and collagen synthesis by blocking non-canonical ERK-dependent TGFβ signaling, and that sGC stimulators (sGCS) may exert antioxidant effects in experimental models of fibrotic disorders.

Objectives: To investigate the possible modulatory effects of sGC stimulation on impaired angiogenesis and EndoMT of SSC dermal microvascular endothelial cells (SSc-MVECs).

Methods: To evaluate the effects of treatment with sGC on endothelial cell viability/proliferation, 5 lines of SSc-MVECs and 5 lines of healthy dermal MVECs (H-MVECs) were challenged with sGCS (here MK-2947) and assayed with both annexin V/PI flow cytometry and WST-1. To analyse the modulation of angiogenesis by sGCS, SSc-MVECs were challenged with MK-2947 and subsequently tested for wound healing and capillary-like tube formation capabilities. To study the effects of MK-2947 on EndoMT, the same cells were assayed for the expression of endothelial and mesenchymal/myofibroblast markers by quantitative real-time PCR, western blotting and immunofluorescence, as well as for their contractile ability by collagen gel contraction assay. Phosphorylation of ERK1/2 was assayed by western blotting.

Results: Treatment with MK-2947 did not affect viability/proliferation of H-MVECs, while it significantly increased the proliferation of SSc-MVECs (p<0.001 vs. basal). Compared to basal condition, the MK-2947 challenge ameliorated both wound healing capability (p<0.001) and angiogenic performance (number of nodes: p<0.01; segments: p<0.001; meshes: p<0.01; and junctions: p<0.001) of SSc-MVECs. Upon stimulation of sGC, SSc-MVECs exhibited increased gene expression of proangiogenic matrix metalloproteinase (MMP)-9 (p<0.05) and decreased expression of both antiangiogenic MMP-12 (p<0.05) and pentraxin-3 (p<0.001) respect to basal SSc-MVECs. A significant increase in both gene and protein expression of the endothelial markers CD31 and VE-cadherin, and a par-allel decrease in the expression of the mesenchymal/myofibroblast markers - SMA, S100A4, and type I collagen were found in MK-2947-treated SSc-MVECs. MK-2947 also downregulated the EndoMT-driving transcription factor SNAIL1 in SSc-MVECs. Stimulation with MK-2947 was able to significantly counteract the intrinsic ability of myofibroblast-like SSc-MVECs to contract collagen gels (p<0.001) and effectively reduce phosphorylated-ERK1/2 protein levels (p<0.01) respect to basal cells.

Conclusion: Stimulation of sGC effectively ameliorates the angiogenic performance and blunts the pathogenic myofibroblast-like profibrotic phenotype of SSc-MVECs.

REFERENCES:

Disclosure of Interests: Eloisa Romano: None declared, Irene Rosa: None declared, Bianca Saveria Fioretto: None declared, Dilia Giuggioli: None declared, Mirko Manetti Speakers bureau: has received consulting fees or honorarium from MSD, Marco Matucci-Cerinic Speakers bureau: has received consulting fees or honorarium from Actelion, Janssen, Inventiva, Bayer, Biogen, Boehringer, CSL Behring, Corbus, Galapagos, Mitsubishi, Samsung, Regeneron, Acceleron, MSD, Chemomab, Lilly, Pfizer, Roche, Grant/research support from: has received consulting fees or honorarium from Actelion, Janssen, Inventiva, Bayer, Biogen, Boehringer, CSL Behring, Corbus, Galapagos, Mitsubishi, Samsung, Regeneron, Acceleron, MSD, Chemomab, Lilly, Pfizer, Roche


AB0133  TARGETING INFLAMMATION RESOLUTION IN SYSTEMIC SCLEROSIS: PRECLINICAL DATA OF A NEW DISEASE MODIFYING BIOLOGIC DRUG CANDIDATE RESOLVIX

F. Bonenfosi1, S. Perruche1, 1RIGHT Institut (UMR 1098) /MED’INN’Pharma, EFS B/FC, BESANCON, France; 1RIGHT Institut (UMR 1098) / MED’INN’Pharma, EFS B/FC, BESANCON, France

Background: Systemic sclerosis (SSc) is a complex immune-mediated connective tissue disorder characterized by microvascular damage, inflammatory cell infiltration, and excessive deposition of extracellular matrix proteins (ECMs) resulting in fibrosis in the skin and various internal organs. Limited treatment options are currently available in the clinic and are mostly focusing on symptom control with limited impact on disease progression. New treatment approaches are needed to address the complex dysregulated pathways and disease drivers to develop effective therapies. While the pathophysiology of SSc remains incompletely understood it is well-recognized that progressive chronic inflammation is a part of the disease and its progression. Accumulation of apoptotic cells in tissues and defective clearance of these cells contributing to unresolved tissue repair is emerging as a root cause leading to sustained uncontrolled chronic inflammation and fibrosis. Naturally-ending and resolving chronic inflammation to initiate healing and repair processes could present a novel therapeutic approach for SSc.

Resolvix, a next generation biological drug candidate under development, harnesses a complex mix of naturally occurring pro-resolutive factors emitted by human cells, has demonstrated promising disease modifying effects in models of experimental arthritis and inflammatory bowel disease.

Objectives: The objective of our preclinical study presented here, was to evaluate the potential therapeutic effects of Resolvix in experimental models of SSc.

Methods: Two established inducible preclinical models of SSc (bleomycin (BLM) and HOCl) were used to monitor the impact of Resolvix mouse equivalent versus a control treatment on skin (thickness and collagen deposition), lung (leucocyte infiltration and alveolar macrophage effectorcytosis) and lymphoid organs/blood (Tregs) as well as selected plasma proteins. A single treatment or respective controls were administrated intra-venously at 3 weeks post disease induction and mice were monitored daily and sacrificed for analysis after 3 weeks post treatment.

Results: In our hands both preclinical models clearly show phenotypes associ-ated with sclerosing processes of SSc. In both models we could show a significant reduction of skin thickening and collagen deposition in skin samples after a single treatment with Resolvix when compared to controls. Leucocyte infiltrates particularly evident in the HOCl model were significantly reduced by the Resolvix treatment in skin and lung tissues. Interestingly, alveolar macrophages collected from broncho-alveolar lavage (BAL) fluids of the diseased mice in both model systems demonstrated a significant reduction of effectorcytosis capacity (elimi-nating apoptotic cells) a sign of uncontrolled ongoing chronic inflammation and recently reported in SSc patients2. Resolvix treatment successfully restored the effectorcytosis activity to comparable levels detected in healthy mice. In addition, Foxp3+ regulatory T cells were increased in the blood of BLM-mice treated with Resolvix.

Conclusion: Collectively our preliminary data demonstrate that harnessed pro-resolutive factors making up Resolvix are able to revert skin fibrosing pro-cesses, control inflammatory cell infiltration and restore defective macrophage effectorcytosis as a novel a therapeutic approach in SSc.

Resolvix should be considered as a next generation disease modifying biological drug candidate for further development for the treatment of SSc.

REFERENCES:

Disclosure of Interests: None declared


AB0134  IN-VITRO STUDY ON THE EFFECT OF SELECTIVE JAK- INHIBITORS ON PBMCs STAT3 PHOSPHORYLATION FROM SYSTEMIC SCLEROSIS PATIENTS

F. Cacciapaglia1, S. Perniola1, S. del Vescovo1, S. Stano1, R. Bizzoca1, D. Natuzzi1, M. Formaro1, F. Iannone1, 1Rheumatology Unit, Department of Emergency and Organs Transplantation (DETO) - University of Bari, Bari, Italy; 2Clinical Immunology Unit, Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy

Background: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease characterized by autoimmunity-driven damage and vasculopathy leading
to fibrosis of the skin and internal organs (1). The Janus kinase (Jak) - signal transducer and activator of transcription (STAT) pathway has been evidenced markedly activated in SSC patients (2, 3), and its inhibition has been proved in pre-clinical and clinical trials (4), but no data on Jak selective inhibition are available.

Objectives: To explore the effect of selective inhibition of Jak/STAT pathway in peripheral blood mononuclear cells (PBMC) from SSC patients.

Methods: In vitro Jak inhibition of the subunit 3 of phosphorylated (p) activated STAT was measured by flow cytometry in peripheral blood mononuclear cells (PBMC) from SSC patients naïve to any immunosuppressive and/or corticosteroids (n=5). pSTAT3 expression was also assessed after stimulation with recombinant human 1 mg/ml IL-6 (Peprotech – NJ, USA). The PBMC were overnight incubated with IC50 concentrations of selective Jak-1, Jak-2, Jak-3 and Tyk2-inhibitors (Bioserv Inc. - CA, USA). Percentages of pSTAT3 positive cells were compared in presence of different compounds stimulation.

Results: After overnight incubation, percentage of pSTAT3 positive cells was significantly higher in CD4+ cells compared to CD8+ (16.3%; 95CI 10.2-22 vs 10.7%; 95CI 4.18, p=0.02). pSTAT3+CD4+ cells were halved only by selective Jak1-inhibitor, while pSTAT3+CD4+ cells were reduced by 36% by selective Jak1-inhibitor. Selective Jak2- or Tyk2-inhibitors did not interfere with STAT3 phosphorylation in PBMC from SSC patients. After IL-6 stimulation, we observed a 2- and a 1.5-fold increase in percentage of pSTAT3+CD4+ and pSTAT3+CD14+ cells, respectively. pSTAT3+CD14+ cells were reduced in the PBMC co-culture with IL-6 and Jak-selective inhibitors, in contrast no effects were found in CD8+ cells. Specifically, selective Jak1- and Jak3-inhibitors reduced pSTAT3+CD14+ cells by an average of 37% and 25%, respectively. No effects were observed after co-culture with IL-6 and selective Jak2- or Tyk2-inhibitors.

Conclusion: Jak/STAT pathway of PBMC from SSC patients with active disease may be further inhibited by selective inhibitors. Selectivity of Jak1- and Jak3-inhibitors seems more relevant, especially in CD14+ monocytes after IL-6 stimulation. These preliminary findings highlight some evidence for effectiveness of selective Jak-inhibitors in SSC treatment.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2625

PROTEIN CONFORMATIONAL CHANGES AND FUNCTIONAL ALTERATIONS IN DERMAL FIBROBLASTS FROM PATIENTS WITH SYSTEMIC SCLEROSIS

Background: Despite intensive studies and clinical trials, there is still no available precise diagnostic tool and treatment of the patients affected by systemic sclerosis (SSc). Proteopathies are diseases characterized by the production of aberrant conformers of certain proteins that lead to a disturbance of their cellular functions and disease. It is believed that the structure of a protein is principally responsible for its function. By identifying selectively altered peptides on a proteome-wide scale, there is a possibility to detect protein functional changes.

Objectives: To screen for changes in the protein conformation and to correlate with cell function in SSc dermal fibroblasts compared to fibroblasts from healthy donors (HC) using a novel approach of limited proteolysis followed by functional assays.

Methods: Diffuse cutaneous SSc and HC dermal fibroblasts were used for recently established Limited Proteolysis-coupled Mass-Spectrometry (Lip-MS)1 to examine protein structural alterations in a proteome-wide scale. A change in conformation was defined as having a foldchange greater than 1 or smaller than -1 and a significant p-value of -log10> 1.3 (p<0.05). Further, the responsive signalling targets in these cells, including the NF-κB-dependent pathway and energy metabolism, were evaluated. Fibroblasts were stimulated with inflammatory cytokines, highly relevant in SSc, including TNFα, IL-1β, TGF-β, IL-17A, and a combination of IL-17A and TGF-β. To examine the NF-κB activity, cells were transfected with a pseudo-typed HIV-1-based lentiviral vector. The measurements of luciferase signal were analysed. RT-qPCR was used to assess the expression of NF-κB-dependent genes for non-transduced cells. ATP measurements were analysed and presented as the amount of luminescent signal.

Results: Lip-MS analysis detected 53253 common peptides in SSc (n=6) and HC fibroblasts (n=6), of which 41 peptides showed conformational changes in SSc fibroblasts in comparison with HC fibroblasts. The 41 conformationally altered peptides showed significant enrichment in GO pathways for: biological processes (9), molecular function (7) and cellular components (21). SAE1, CTNND1, CD3G, and PPPI13L were related to the NF-κB-dependent pathway, while ATP5A1, GSTM1, PCK2, ANPEP, GM2A, GNS, CAD, ACOT2 were connected with metabolic processes. There was a tendency of lower levels of mRNA RELA, NFKBIA, MMP1 and TNC expression levels in untreated and stimulated SSc fibroblasts (n=6) compared to HC fibroblasts (n=6). The assessment of the NF-κB activity in untreated SSc fibroblasts (n=9) showed a trend to lower fold change compared to HC fibroblasts (n=9) (0.63 vs 1, SE 0.19, p=0.07). A statistically significant difference between SSc (n=8) and HC (n=8) fibroblasts was found in TGF-β-stimulated fibroblasts (0.84 vs 1, SE 0.16, p=0.046). SSc fibroblasts (n=9) showed a lower ATP level compared to HC fibroblasts (n=9) in untreated condition (0.82 vs 1, SE 0.09, p=0.07), after stimulation with IL-1β (0.85 vs 1, SE 0.08, p=0.07) and TGF-β (0.81 vs 1, SE 0.09, p=0.05). Of note, a statistically significant difference between SSc and HC fibroblasts was found in IL-17A stimulated cells (0.82 vs 1, SE 0.07, p=0.02).

Conclusion: Lip-MS approach allowed for the identification of conformational changes in SSc fibroblast mainly related to signal transduction and metabolic pathways. Confirmatory functional studies showed deregulated NF-κB activity and ATP levels in SSc fibroblasts. Therefore, Lip-MS approach may create a distinctive opportunity to discover new disease biomarkers and functionally transformed pathways. This method may advance therapeutical approaches, where only selectively altered proteins could be specifically targeted, without interfering with non-changed proteins.

REFERENCES:

AB0356 ELUCIDATING THE PATHOGENIC EFFECTS OF ANTI-TOPOISOMERASE-1 ANTIBODIES IN SYSTEMIC SCLEROSIS

M. Aspäni1, K. V. Petersen1, J. Geertsen Keller2, S. R. Greisen1,3, K. Soenergedraad4, J. Hauge Mikkelsen1, B. Knudsen5, B. Deleuran1 on behalf of Bent Deleuran’s group. 1Aarhus University, Biomedicine, Aarhus, Denmark; 2Aarhus University, Molecular Biology, Aarhus, Denmark; 3Aarhus University Hospital, Rheumatology, Aarhus, Denmark

Background: Prediction of the pattern of organ involvement in patients with diffuse cutaneous systemic sclerosis (dcSSc) is supported by the specificity of autoantibodies. These autoantibodies are generally mutually exclusive and highly specific for dcSSc. The autoantibody reactivity allows patients to be stratified early in the disease course, leading to a tailored approach and management. Anti-topoisomerase I antibodies (ATA) are predictors of the development of interstitial lung disease (ILD) and digital ulcers but appear to be protective against pulmonary artery hypertension (PAH).

Objectives: The aim of this project is to elucidate the functioning of ATA and their role in the pathogenicity of the disease.

Methods: Sera from healthy volunteers (HV) and dcSSc patients with and without ATA were collected from Aarhus University Hospital. Total IgG was purified from the sera using a Protein G column. ATA was further purified from the total IgG fractions from dcSSc patients who were positive for ATA. This could inhibit TOP1 activity at various dilutions. Similarly, purified total IgG fractions from dcSSc patients could also inhibit TOP1 activity. ATA was successfully separated from IgG from dcSSc patients who were positive for ATA. This could inhibit TOP1 activity even at lower concentrations than total IgG. This was the case for both mitochrional and nuclear TOP1 activity.

Results: Serum from patients with dcSSc, but not from HV, could inhibit TOP1 activity at various dilutions. Similarly, purified total IgG fractions from dcSSc patients could also inhibit TOP1 activity. ATA was successfully separated from IgG from dcSSc patients who were positive for ATA. This could inhibit TOP1 activity even at lower concentrations than total IgG. This was the case for both mitochondrial and nuclear TOP1 activity.

Full in line with presence of ATA, PBMCs from dcSSc patients contained a lower TOP1 activity compared to HVs PBMCs.

Conclusion: To our knowledge we are the first group to be able to successfully separate ATA from total IgG from dcSSc patients, our unique in house developed REEAD assay clearly demonstrates the function of ATA and provides the opportunity to better understand.
REFERENCES:


[2] Rolling circle amplification based detection of human topoisomerase I activity on magnetic beads. Zuccaro, Laura; Tesauro, Cinzia; Cerroni, Barbara; Ottaviani, Alessio; Knudsen, Birgitta Ruhl; Balasubramanian, Kannan; Desideri, Alessandro. Analytical Biochemistry, Bind 451, 15.04.2014, s. 42-44.

Disclosure of Interests: None declared


AB0137 SERA DERIVED EXTRACELLULAR VESICLES FROM SYSTEMIC SCLEROSIS PATIENT AND AUTOANTIBODIES MEDIATE PERIPHAL BLOOD MONOCYTES ACTIVATION

A. Hackel¹, A. Müller², H. Grasshoff², G. Marschner¹, G. Riemekasten¹ on behalf of Rheumatology and Clinical Immunology Lab. University Clinic Schleswig-Holstein, Lübeck, Germany, Clinic of Rheumatology and Clinical Rheumatology, Lübeck, Germany.

Background: In SSc, autoantibodies (abs) directed against G protein-coupled receptors (GPCR) are prominent and for example induce release of inflammatory and profibrotic proteins by monocytes (1-3). Increased levels of autoantibodies against angiotensin II type 1 receptor (AT1R abs) have been found in patients with renal involvement in systemic sclerosis (SSc) (4-5). The elevated amount of anti-GPCR abs is accompanied by increased secretion of extracellular vesicles (EVs) in SSc (6). The importance of EVs in the pathogenesis is also based on packing and horizontal transfer of AT1R to different tissues and immune cells, exemplary shown by activated cardiomycocytes leading to higher responsiveness to Angiotensin II of recipient cells and vessels (7). Taken together, the relevance of studying anti-GPCR abs together with GPCR-EVs in SSc pathogenesis becomes evident (8). Interestingly, CCL18 is found to be upregulated in SSc patients and suggested to be upregulated by AT1R abs (9), indicating CCL18 and CCR8 cross-talk via EVs plays an essential role in the pathogenesis of SSc.

Objectives: Unravel the immune response of peripheral blood monocytes mediated by anti-AT1R abs and EVs to gain new insights into the pathomechanism in SSc.

Methods: Human peripheral blood monocytes of healthy donors were stimulated by the endogenous AT1R ligand angiotensin II as well as by a monoclonal anti-human AT1R ab and, in comparison, by purified IgG from HD (HD IgG) versus those from SSc (SSc IgG). Further, human peripheral blood monocytes of HD were treated with EVs derived from sera of SSc patients versus sera of HD, in the presence or absence of a monoclonal recombinant anti-AT1R ab. Monoclonal AT1R ab has been generated by hybridoma technique, sequenced and recombinantly expressed in HEK cells. The specificity of AT1R ab was tested by using an AT1R blocker (telmisartan, TEL). EVs were isolated from sera by differential centrifugation to exclude large particles and microvesicles and further by one-step polymer precipitation procedure utilising ExoQuick Exosome Precipitation Solution (System Biosciences, Palo Alto, CA) and subsequent purification by size exclusion. Further, primary human peripheral blood monocytes of HD (n=6) were treated with EVs derived from sera of SSc patients (n=8) versus sera of HD (n=6), in the presence or absence of a monoclonal recombinant anti-AT1R ab. The response of the monocytes was measured via CCL18 secretion by ELISA.

Results: The recombinant monoclonal anti-human AT1R antibody induced secretion of CCL18, a profibrotic cytokine, by primary monocytes derived from HD. Similarly, the purified IgG fractions derived from SSc patients also induced an increased CCL18 release by monocytes compared to IgG fractions derived from HD. Further, complete amelioration of the AT1R ab effect on CCL18 secretion was found, when monocytic AT1R expression was blocked with TEL. In addition, antagonistic effects of Angiotensin II to the monoclonal AT1R ab were observed. In line, enhanced CCL18 secretion of human monocytes stimulated with SSc-EVs alone and together with the monoclonal AT1R ab was induced.

Conclusion: The secretion of pro-fibrotic CCL18 by human monocytes in response to a monoclonal AT1R antibody as well as to SSc-IgG indicates that anti-AT1R abs are involved in the SSc pathogenesis. Further, this effect could also be due to SSc-EVs potentially presenting anti-GPCR abs to their receptors on immune cells.

REFERENCES:


Disclosure of Interests: None declared


AB0138 XANTHINE OXIDOREDUCTASE BLOOD PROFILE IN SYSTEMIC CONNECTIVE TISSUE DISEASES

E. Mozgovaya¹, S. Bedina¹, A. Trofimenko⁵, M. Mamush¹, S. Sptisa¹, I. Zborovskaya¹. ¹Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy; Clinical biochemistry lab, Volgograd, Russian Federation.

Background: Systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) are systemic connective tissue diseases. Their development is based on a generalized immune inflammatory process. Deep immunological and metabolic disorders in these diseases have along with general characteristic distinctive features. XOR is a multifunctional enzyme. The reactions catalyzed by XOR are a source of reactive forms of oxygen and nitrogen, nitric oxide, which are of great physiological importance, and are also responsible for the development of many pathophysiological reactions. Analysis of changes in the activity of interconverting forms of XOR (xanthine oxidase (XO), EC 1.17.3.2 and xanthine dehydrogenase (XDG), EC 1.17.1.4) in plasma and blood cells is of interest.

Objectives: to characterize differences of XO and XDG activities profiles in blood of SLE and SSc patients.

Methods: The researcher was carried out in agreement with the WMA Declaration of Helsinki principles. 56 SLE patients and 51 SSc patients were enrolled in this study. Diagnosis of SLE was verified using the SLICC criteria (2012). SSc was verified according to ACR/EULAR criteria (2013). The reference group consisted of 35 healthy controls. XO and XDG activities were measured in plasma, lysed WBC, lysed RBC using spectrophotometric method [1]. Results were expressed as Me (Q₂5 – Q₇5). The Mann-Whitney U test was used for statistical analysis, differences were considered significant when p<0.05.

Results: Mean age of SLE patients was 35 (31; 42) years, mean duration of disease was 8 (5; 11) years. Mean age of SSc patients was 43 (38; 48) years, mean SSc duration was 8 (6; 9) years. The enzyme indices included in the study did not depend on the sex and age of healthy individuals. XO activity was increased in plasma of SLE and SSc patients (p<0.001 for both disease). The activity of XO was higher in SLE (p<0.001). XO activity of lysed WBC was decreased in both diseases (p<0.001). XDG activity was decreased in lyced WBC and lyced RBC of patients with SLE and SSc (all p<0.001). Activity of this enzyme was lower in lyced WBC and higher in lyced RBC in SLE compared with SSc (all p<0.001). In contrast to SLE, accompanied by low levels of plasma XDH activity (p<0.001), SSc was characterized by increased activity of this enzyme (p<0.001). Also, increased XO activity was revealed in lyced RBC of SSc patients (p<0.001). The values of this enzymatic activity did not differ between the group of SLE patients and healthy controls (p=0.977).

Conclusion: Changes in the activity of oxidase and dehydrogenase forms of XOR are revealed in plasma, lyced WBC, lyced RBC of SLE and SSc patients, which determine characteristic blood profiles in these diseases. Changes in the balance of XOR enzymatic activities can affect the exchange of purine nucleotides, the pool of reactive oxygen and nitrogen species in body tissues, participating in the processes inherent in these diseases.

REFERENCES:

Disclosures of Interests: None declared.


AB0139

DEEP IMMUNE PHENOTYPING OF T LYMPHOCYTE SUBSETS IN SYSTEMIC SCLEROSIS PATHOPHYSIOLOGY AND FOLLOWING RESPONSE TO TARGETED CYTOTOXIC TREATMENT

T. I. Papadimitriou1, A. van Caam1, J. Lemmers1, X. He2, E. Vitters1, M. Koenders1, R. Smeets2, M. Vonk1, P. van der Kraan1, H. Koener2, R. M. Thurlings1. 1Radboud University Medical Center, Rheumatic diseases, Nijmegen, Netherlands; 2Radboud University Medical center, Laboratory of Medical Immunology, Nijmegen, Netherlands

Background: Abnormalities in T lymphocyte populations are associated with the pathogenesis of many autoimmune diseases, such as systemic sclerosis (SSc). Various studies report on the aberrations of different T cell cytotoxic (CTL) and helper (Th) subsets that appear to be linked with inflammatory and/or fibrotic manifestations of patients with SSc. Since T cells seem to play a pivotal role in the pathophysiology of SSc, targeting the pathogenic T cell subsets might be a promising therapeutic option.

Objectives: Here we set out to comprehensively compare T lymphocyte phenotypes between SSc patients and healthy donors. We further test the in-vitro efficacy of a combination of anti-CD3/CD7 immunotoxins (CD3/CD7-IT) that have been developed to eliminate activated CD4- and CD8+ T cells, to study specific sensitivity of T-cell subpopulations to CD3/CD7-IT.

Methods: 30 SSc patients and 15 age and sex matched healthy donors were included. Of these patients, lymphocyte populations were quantified by 17-parameter flow cytometry of peripheral blood mononuclear cells (PBMCs) to identify CD4+ Th helper cells (Th1, Th2, Th17, T peripheral helper), CD8+ naïve, memory, effector CTLs and senescent/exhausted subsets. We next developed a cell killing assay to evaluate the effect of T cell depletion. To address this, patients’ PBMCs were first activated for 24 hours in the presence of phytohemagglutinin, followed by CD3/CD7-IT addition for 48 hours. Subset-specific T cell depletion was assessed by using a combination of CellTiter-Glow luminescent cell viability assay and multi-parameter flow cytometric (FCM) quantification of CD3/CD7-IT-induced cell death.

Results: Frequencies of effector CD8+ CTLs, Th2 and T peripheral helper cells were elevated in SSc patients compared to healthy controls. Furthermore, SSc patients exhibited lower percentages of the anti-fibrotic Th1 subset. A striking expansion of the senescent CD4+CD28- and CD8+CD28-populations was noted in patients, while these subsets were barely detectable in healthy controls. In-vitro addition of anti-T cell immunotoxins effectively depleted 50 % of patients’ CD8+ T cells (including the CD8 effector subset) and 62% of CD4+ T cells (including Th2 and T peripheral helper cells). No difference in cytolytic sensitivity between different T cell subsets was observed.

Conclusion: Our findings demonstrate that deep FCM immunphenotyping reveals pathophysiological differences in peripheral T cell subsets of SSc patients. Strikingly, the developed cytolytic assays show that CD3/CD7-IT is able to target the potential disease-associated T cell subsets in an in vitro setting.

References: Not applicable

Disclosure of Interests: None declared.


AB0140

ROLE OF ENDOGLIN IN THE PATHOGENESIS OF SYSTEMIC SCLEROSIS: A PRISMA-DRIVEN SYSTEMATIC REVIEW

S. Grignaschi1,2, B. L. Palermo1,2, G. Spinozzi2, A. Salichiero3, C. Cantarini4, C. Stefaniello4, C. Oliveri4, L. Cavagnal1,2, Fondazione I.R.C.C.S. Policlinico San Matteo, Department of Rheumatology, Pavia, Italy; 2The University of Pavia, Department of Internal Medicine and Medical Therapeutics, Pavia, Italy; 3Fondazione I.R.C.C.S. Policlinico San Matteo, Department of Otorhinolaryngology, Pavia, Italy; 4The University of Pavia, General Biology and Medical Genetics unit, Dept of Molecular Medicine, Pavia, Italy

Background: Systemic sclerosis (SSc) is a rare autoimmune disease characterized from peculiar vascular alteration and fibrosis of the skin and internal tissues. SSc pathogenetic mechanisms are still partially unclear but an involvement of the TGFβ pathway, known for being responsible of both angiogenesis and fibrosis, has been proven. Endoglin (ENG) is a TGFβ receptor type III involved in signal regulation, and mutations in ENG gene cause Hereditary Hemorrhagic Telangiectasia type I, a rare disease that shares with SSc the presence of mucocutaneous telangiectasias and disturbed angiogenesis.

Objectives: The aim of this systematic review is to highlight the role of ENG in the pathogenesis of SSc focusing on a subset of clinical manifestations.

Methods: We performed a systematic review following the PRISMA guidelines, searching the MEDLINE (PubMed), Web of Science and EMBASE databases using as keywords: “Endoglin”, “sENG”, “CD105”, “Systemic sclerosis”, “SSc”, “Scleroderma”, “CREST”. The last search was made on November 2nd 2021. This review includes both conference abstracts (without subsequent publication) and articles that evaluated the relationships between SSc and ENG. We excluded the papers that used CD105 only as a cell marker. We then consulted the references from the papers found in order to search possible articles that escaped our first search.

Results: Of the 656 records identified from the database research, 42 were included in our systematic review (16 abstracts and 26 original papers) (Figure). The majority of these studies (25) measured serum ENG (sENG) looking for correlations with cutaneous, pulmonary and cardiac disease in patients with SSc.

Figure. PRISMA flow diagram.

High levels of sENG demonstrated an independent association with telangiectasia in 2 studies, with the presence of digital ulcers (DU) in 6 studies but was not related to the occurrence of new DU (2 studies) and it was related to scleroderma pattern late in 2 studies. Between limited and diffuse cutaneous SSc, SENG showed no differences in one study and significantly higher values in lcSSc in another, this latter study also found ENG to be higher in cSSc compared to systemic lupus erythematosus and healthy controls (HC). SENG, moreover, demonstrated a positive correlation with anti-centromere antibodies (two studies). Regarding pulmonary involvement, no correlation between sENG and mean pulmonary arterial pressure was recorded, and two studies found sENG elevated in patients with pulmonary arterial hypertension while no correlation was found from two other papers. High sENG concentrations demonstrated a positive correlation with subclinical atherosclerosis and with high sensitivity troponin, but its concentration did not relate to right heart dysfunction (1 study each). Two different groups evaluated sENG concentration in Localized Scleroderma and found no differences with other connective tissue diseases. One study searched for genetic alterations in the expression of ENG gene and found no difference between SSc patients and HC. Four studies evaluated ENG expression on fibroblast surface. SSc fibroblasts from both systemic circulation and lung showed higher production of ENG than HC. Tissue Eng, moreover, is up regulated in SSc patients where it acts as a regulator of TGFβ signaling and of extracellular matrix production.

Conclusion: As suggested by the role of Endoglin in the TGFβ pathway, several authors demonstrated an altered expression of Endoglin in SSc patients. A particular focus of interest is the role of ENG in PAH and DU that occur in SSc. A direct involvement of ENG in PAH is known as mutation in this gene are one of the genetic causes of PAH. However, particularly in pulmonary vascular disease, there are still controversial and insufficient data to draw definitive conclusions. As PAH is a leading cause of mortality in SSc patients, this is an area of clinical interest and the study of the TGFβ pathway could lead to useful clinical findings.
**AB0141** DIFFERENTIAL CYTOKINE PRODUCTION PROFILES IN STIMULATED MONONUCLEAR CELLS OF PATIENTS WITH SYSTEMIC SCLEROSIS AND CONTROLS

I. Szabo1, M. Badil2, C. Sirbe3, O. Gaal3, C. Pamfil3, S. Rednic1,2
1Iuliu Hatagenu University of Medicine and Pharmacy, Cluj-Napoca, Romania; 2Iuliu Hatagenu University of Medicine and Pharmacy, Medical Genetics, Cluj-Napoca, Romania; 3Radboud University Medical Center, Internal Medicine, Nijmegen, Netherlands; 4Radboud University Medical Center, Radboud Institute of Molecular Life Sciences, Nijmegen, Netherlands

**Background:** Altered innate and adaptive immune responses represent the link between microvascular injury and fibrosis in systemic sclerosis (SSc) pathophysiology. Peripheral monocytes and lymphocytes are responsible for the secretion of cytokines with proven pro-inflammatory and pro-fibrotic activities. Chronic immune activation in SSc is supported by distinct serum and peripheral blood mononuclear cell (PBMC) cytokine profiles in relation to disease duration, autoantibody subtype, as well as severity of clinical manifestations.

**Objectives:** This pilot study aimed to: (1) evaluate the PBMC cytokine production in SSc patients versus healthy controls (HC) after in vitro stimulation with lipopolysaccharide (LPS) and heat-killed Candida albicans and (2) distinguish different SSC clinical phenotypes based on their cytokine signature.

**Methods:** Eighteen SSc patients (8 limited cutaneous, 9 diffuse cutaneous, 1 sine scleroderma) and 17 age and gender matched HC were enrolled between February 2020 and October 2021. PBMCs were isolated and further subjected to stimulation with LPS and Candida albicans. Cytokine production was measured after 24 hours using ELISA kits for interleukin (IL)-1β, IL-1 receptor antagonist and IL-6. IL-17 and interferon gamma (IFN-γ) concentrations were determined at 7 days from samples stimulated with Candida albicans—in the presence of 10% human pooled serum. Non-parametric data was analyzed using Mann-Whitney test while T-test was used for parametric data.

**Results:** Significantly elevated IL-1β and IL-6 concentrations were detected in SSc patients compared to HC after stimulation with either LPS or Candida albicans. IL-17 cytokine production was also enhanced in SSc patients compared to HC after stimulation with Candida albicans for 7 days, but no difference was identified with respect to IFN-γ. No significant statistical difference was demonstrated between cytokine levels and extent of cutaneous involvement. Furthermore, no association was observed between autoantibody subtypes and cytokine production. Patients with diffuse cutaneous SSC and those positive for anti-Scl-70 antibodies revealed elevated C-reactive protein (CRP) levels.

**Conclusion:** SSC patients exhibit a pro-inflammatory phenotype irrespective of the extent of cutaneous involvement or autoantibody profile. This appears to be mediated through increased production of innate immune cytokines, which correlated to elevated Th-17 responses on later time-points. Elevated CRP levels might define a subgroup of SSc patients with specific disease characteristics. Validation of these findings and mechanistic assessment is warranted in larger cohorts of patients.

**REFERENCES:**


**Disclosure of Interests:** Iulia Szabo Speakers bureau: Roche, Boehringer-Ingelheim, Mededea Badal: None declared, Claudia Sirbe: None declared, Orsi Gaal: None declared, Tania Crisan: None declared, Cristina Pamfil: None declared, Simona Rednic Speakers bureau: Abbvie, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sandoo, UCB, Zentiva

**AB0142** EVIDENCE OF TYPE I INTERFERON ACTIVATION DURING VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS

S. Di Donato1,2, M. Hughes3,4, G. Abignano5, G. Lettieri6, R. Ross7, E. De Lorenzis3,8, P. O’Connor9, O. Kubassova, F. Del Galdo1,1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, Raynoud’s and Scleroderma Programme, NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom; 2Università Campus Bio-Medico di Roma, Rheumatology, Immunology and Clinical Medicine Unit, Department of Medicine, Rome, Italy; 3Centre for Musculoskeletal Research, The University of Manchester, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom; 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, Leeds, United Kingdom; 5Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Division of Rheumatology, Rome, Italy; 6Image Analysis Group, Chief Executive Officer, London, United Kingdom

**Background:** Vascular involvement in Systemic Sclerosis (SSc) is known to start even before clinical diagnosis, to drive Digital Ulcer disease and later in the disease natural history to cause Pulmonary Artery Hypertension, among other manifestations. Despite the proven immune origin of Scleroderma, vascular involvement is not currently targeted by immune driven interventions. Similarly, little data is available on immune or inflammatory biomarkers and outcome measures of vascular disease in SSc. Digital Artery Volume Index (DAVIX) has been recently proposed as imaging surrogate outcome measure of vascular disease activity in SSc [1].

**Objectives:** Here we aimed to determine the value of DAVIX as overall biomarker of vascular involvement and its correlation with Type I IFN activation in patients with SSc.

**Methods:** Eighty-six patients attending our Scleroderma Program were consecutively enrolled for the evaluation of serum IFN score as previously described [2]. Clinical features including presence or history of Digital Ulcers, Presence of Pulmonary Artery Hypertension (PAH) and DLCO, were recorded. Digital Artery Vascular Index (DAVIX) of the dominant hand’s fingers was calculated using time of flight magnetic resonance images analysed through IAG proprietary algorithm, as previously described [1]. Medians were compared by Mann-Whitney-Wilcoxon test, correlation with clinical parameters was performed using Spearman’s or Pearson test, as appropriate (R).

**Results:** Sixty-two patients fulfilled the 2013 ACR/EULAR classification criteria for SSc (diffuse cutaneous 24.6%, limited cutaneous 75.4%) whereas 23 were classified as Very Early Diagnosis of Scleroderma Criteria (CRC) score between 6 and 8). Twenty-three patients had DU disease (History of DUs in the previous 24 weeks, presence of DUs at baseline assessment, or onset of new DUs during the following 24 weeks). Eighteen patients had reduced DLCO (<70 with FVC/DLCO>1.8 (suspected PAH). DAVIX showed a negative correlation with disease duration (r=-0.33 and p<0.003) and with FVC/DLCO ratio (r=-0.34 and p<0.009). Patients with DU disease presented lower DAVIX than patients without (p<0.018).

DAVIX showed a significant correlation with Serum IFN score (r=-0.24, p<0.032). Accordingly, patients classified as IFN-HI had lower DAVIX than those within the IFN-LO group (p=0.016).

**Conclusion:** DAVIX correlated both with presence of Digital Ulcer disease, DLCO and disease duration. The correlation of DAVIX and Serum IFN score does support the notion of innate immune involvement in vascular disease manifestations of SSc. Prospective testing in the context of Randomised controlled trial will determine the value of DAVIX as surrogate outcome measure of vascular disease severity in SSc.

**REFERENCES:**


**Disclosure of Interests:** Stefano Di Donato: None declared, Mike Hughes: None declared, Giuseppina Abignano: None declared, Giovanni Lettieri: None declared, Rebecca Ross: None declared, Enrico De Lorenzis: None declared, Philip O’Connor: None declared, Olga Kubassova Shareholder of: IAG Image Analysis Group, CEO, Francesco Del Galdo: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5067
Background: Imaging mass cytometry (IMC) is a high-plex imaging technique that incorporates flow cytometry principles while preserving the histological and architectural components of the tissue sample. Characterizing the entire cellular composition of temporal artery (TA) in patients with giant cell arteritis (GCA) may provide clues towards novel diagnostic and therapeutic approaches.

Objectives: We aimed at a comprehensive summary of the immune cells and pathways involved GCA by using IMC approach.

Methods: TA samples from biopsy-proven GCA patients (n=2) and controls (CTLs, n=2) were analyzed using IMC with a panel of 15 staining antibodies.

Results: Eleven cell populations were identified in arterial wall from GCA patients including both immune (CD20+ B cells, CD8+ T cells, CD4+ T cells, FOXP3+ Tregs, CD66b+ granulocytes, CD11b+ myeloid cells, CD14+ monocytes, CD68+ macrophages) and non-immune (SMA+ smooth muscle cells, CD31+ endothelial cells, Vimentin+ fibroblasts) cells (Figure 1). The 3 layers (intima, media and adventitia) of the arterial wall was enriched by all the immune cell subsets in GCA except for granulocytes and myeloid cells. CD8+, CD4+ and FOXP3+ regulatory T cells were significantly increased in any layer of the TA. The proportion of B cells was also enhanced in both intima and adventitia and displayed a high level of Ki67 expression.

Figure 1. Unbiased clustering of cellular infiltrate in temporal arteritis using Imaging Mass Cytometry.

Conclusion: Our study provides an exhaustive overview of the distinct cell lineages involved in GCA and supports IMC approach to further characterize the immune networks active in GCA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.23

Vasculitis - aetiology, pathogenesis and animal models

Characterization of cellular infiltrate in temporal arteritis using imaging mass cytometry in giant cell arteritis


1 Université de Paris Bichat, Médecine Interne, Paris, France; 2 Institut de Recherche en Cancérologie de Montpellier - INSERM U1194, Équipe Immunité et Cancer, Montpellier, France; 3 Université de Paris Bichat, Pathologie, Paris, France

Background: Imaging mass cytometry (IMC) is a high-plex imaging technique that incorporates flow cytometry principles while preserving the histological and architectural components of the tissue sample. Characterizing the entire cellular composition of temporal artery (TA) in patients with giant cell arteritis (GCA) may provide clues towards novel diagnostic and therapeutic approaches.

Objectives: We aimed at a comprehensive summary of the immune cells and pathways involved GCA by using IMC approach.

Methods: TA samples from biopsy-proven GCA patients (n=2) and controls (CTLs, n=2) were analyzed using IMC with a panel of 15 staining antibodies.

Results: Eleven cell populations were identified in arterial wall from GCA patients including both immune (CD20+ B cells, CD8+ T cells, CD4+ T cells, FOXP3+ Tregs, CD66b+ granulocytes, CD11b+ myeloid cells, CD14+ monocytes, CD68+ macrophages) and non-immune (SMA+ smooth muscle cells, CD31+ endothelial cells, Vimentin+ fibroblasts) cells (Figure 1). The 3 layers (intima, media and adventitia) of the arterial wall was enriched by all the immune cell subsets in GCA except for granulocytes and myeloid cells. CD8+, CD4+ and FOXP3+ regulatory T cells were significantly increased in any layer of the TA. The proportion of B cells was also enhanced in both intima and adventitia and displayed a high level of Ki67 expression.

Conclusion: Our study provides an exhaustive overview of the distinct cell lineages involved in GCA and supports IMC approach to further characterize the immune networks active in GCA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.75

PD-1 deficiency in the regulatory T cell may be involved in the pathogenesis in Takayasu’s arteritis

N. Gao, L. Pan

1 Capital Medical University Affiliated Anzhen Hospital, Department of Rheumatology, Beijing, China

Background: Regulatory T cell (Treg cell) has been demonstrated decreased in peripheral blood of TAK patients in recent researches. PD-1 may regulate T cell differentiation and apoptosis as an important checkpoint molecule.

Objectives: This study aims to investigate whether PD-1 is involved in the abnormal of Treg cell in TAK.

Methods: This study enrolled 49 patients with TAK and 23 healthy controls. Treg cell related serum cytokines IL-10, IL-7, IL-2 and IL-15, as well as serum chemokines CCL2, CCL3 and CXCL10 were detected using cytokine cyrometric bead array. The expression of PD-1 in CD4+Foxp3+ T cells and Tregs were analyzed by flow cytometry analysis in 15 patients with TAK and 18 healthy controls.

Results: Mean fluorescence intensity of PD-1 in CD4+PD-1+ cells decreased in TAK patients [72.2 (45.8, 84.7) vs. 363.00(335, 431), P = 0.000]. The frequency of CD4+Foxp3+PD-1+ cells in CD4+T cells decreased in peripheral blood (0.90 ± 1.06% vs. 12.61 ± 1.17%, P = 0.034) of TAK patients. The percentage of CD4+CD25+Foxp3+PD-1+ cells in CD4+CD25+ T cells (0.40 ± 0.20% vs. 0.63 ± 0.09%, P = 0.047) is lower in TAK patients than healthy controls. Higher serum levels of IL-10[4.84 (0.70,409.57) vs. 3.16 (0.69, 15.)], P = 0.004 and IL-7[0.01 (2.68,227.72) vs. 7.4 (2.68,16.77), P = 0.014] level were observed in TAK patients. Compared to healthy controls, serum CCL2[30.64 (0, 686.84) vs. 10.31 (0, 32.92), P = 0.000] and CCL3(3.01(0.69,19.24) vs.1.84 (0.67, 4.8), P = 0.000) increased obviously.

Conclusion: The frequency of CD4+Foxp3+PD-1+CD4+CD25+Foxp3+PD-1+ CD4+PD-1+ T cells decreased. This study suggested that PD-1 may contribute to the imbalance of regulatory T cell in TAK.

REFERENCES:
Background: IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions that share pathogenic and molecular mechanisms [1] and may represent different outcomes of a continuous spectrum of the disease [2]. Interleukin (IL)-33 is a cytokine that exerts its biological functions by binding to its receptor, IL-1 receptor like 1 (IL-1RL1) [3]. Several lines of evidence demonstrate that genetic variants located both in IL1RL1 and IL33 genes are implicated in the increased risk of numerous immune-mediated diseases [4].

Objectives: To determine whether ILAV and IGAN exhibit a similar IL33-IL1RL1 association pattern.

Methods: Three tag genetic variants within IL33 (rs9392986, rs7025417 and rs7044343) and three tag polymorphisms within IL1RL1 (rs2310173, rs13015714 and rs2058660), which cover the major variation of these loci and that were previously associated with several inflammatory diseases were genotyped in 380 Caucasian patients with IgAV, 96 patients with IgAN and 845 sex and ethnically matched healthy controls.

Results: Similar genotype and allele frequencies were observed in the whole cohort of patients with IgAV when compared to those with IgAN when IL33-IL1RL1 genetic variants were analyzed independently (Table 1). In accordance with that, no IL33-IL1RL1 genotype or allele differences were detected between IgAV patients who developed nephritis and patients with IgAN (Table 1). Additionally, no statistically significant differences between the whole cohort of patients with IgAV and healthy controls as well as between patients with IgAN and healthy controls were observed when each IL33-IL1RL1 genetic variant was also analyzed independently (Table 1). Similar results were disclosed when haplotype frequencies were compared between the different comparative groups above mentioned (data not shown).

Conclusion: Our results reveal that IgAV and IgAN share a similar IL33-IL1RL1 association pattern.

REFERENCES:

Acknowledgements: This study was supported by the European Regional Development Fund (ERDF) and “Fondo de Investigaciones Sanitarias” (grant P11/00004 and P121/0004) from ‘Instituto de Salud Carlos III’ (ISCIII, Health Ministry, Spain), D-P is a recipient of a Río Hortega fellowship program from the ISCIII, co-funded by the European Social Fund (ESF, ‘Investing in your future’) (grant number CM20/00006), SR-M is supported by funds of the REIICP Program co-funded by ERDF (grant number R16D/001/2009): V-P is supported by a pre-doctoral grant from IDIVAL (grant number PREVAL 18/01): RL-M is a recipient of a Miguel Servet type II fellowship from the ISCIII, co-funded by ESF ‘Investing in your future’ (grant number CPI12/0004).

Disclosure of Interests: Diana Prieto-Peña: None declared, Sara Remuzgo Martinez: None declared, Fernando Genre: None declared, Verónica Pulito-Cuetos: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Lorca: None declared, Norberto Ortego: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, Luis Martín-Pena-gos: None declared, Jose Alberto Miranda Fillayo: None declared, J. Narváez: None declared, LUIS CAMINAL MONTERO: None declared, PAZ COLLADO: None declared, Antonio Fernandez-Nebro: None declared, Gisela Diaz-Cor-doves: None declared, Secundino Cigarrán: None declared, Jesús Cavrío: None declared, Carmen Cobelo: None declared, Patricia Quiroga Colino: None declared, Javier Sanchez Perez: None declared, Esteban Rubio-Romero: None declared, MANUEL LEON LUQUE: None declared, Juan Maria Blanco-Madrigal: None declared, E. Galindez-Agirregoikoa: None declared, Oreste Gualillo: None declared, Manuel Leon Luque: None declared, Juan Maria Blanco-Madrigal: None declared.

Table 1. Genotype and allele frequencies of IL33 and IL1RL1 in the whole cohort of patients with IgAV, patients with IgAV who developed nephritis, patients with IgAN and healthy controls.

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Change</th>
<th>Data set</th>
<th>Genotypes, % (n)</th>
<th>Alleles, % (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL33 rs9392986</td>
<td>C/T</td>
<td>1/2</td>
<td>49.1 (186)</td>
<td>40.9 (155)</td>
</tr>
<tr>
<td>IL33 rs7025417</td>
<td>T/C</td>
<td>1/1</td>
<td>48.5 (66)</td>
<td>39.7 (54)</td>
</tr>
<tr>
<td>IL33 rs7044343</td>
<td>T/C</td>
<td>1/2</td>
<td>43.8 (42)</td>
<td>49.0 (47)</td>
</tr>
<tr>
<td>IL1RL1 rs2310173</td>
<td>G/T</td>
<td>1/2</td>
<td>49.0 (414)</td>
<td>41.4 (350)</td>
</tr>
<tr>
<td>IL1RL1 rs13015714</td>
<td>C/T</td>
<td>1/1</td>
<td>61.5 (59)</td>
<td>39.5 (148)</td>
</tr>
<tr>
<td>IL1RL1 rs2058660</td>
<td>A/G</td>
<td>1/2</td>
<td>40.6 (39)</td>
<td>49.0 (47)</td>
</tr>
</tbody>
</table>

IgAV: IgA vasculitis; IgAN: IgA nephropathy.
Background: IgA vasculitis (IgAV) and IgA nephropathy (IgAN) are inflammatory conditions [1, 2], that share pathogenic mechanisms [1], in which B-lymphocytes are described as key cells implicated in these processes. BAFF, APRIL and BAFF-R are cytokines implicated in the development of B-lymphocytes [3, 4] and in autoimmune processes [5, 6]. In this regard, an influence of BAFF, APRIL and BAFF-R polymorphisms was observed on several immune-mediated conditions, being BAFF GCTGT>A a shared insertion-deletion variant for inflammatory conditions [7, 8].

Objectives: To determine whether BAFF, APRIL and BAFF-R could be used as differential biomarkers between IgAV and IgAN.

Methods: BAFF rs374039502 (which colocalizes with BAFF GCTGT>A), two tag variants within APRIL (rs11526708 and rs6608) and two tag variants within BAFF (rs7290134 and rs7787453) were genotyped in 394 Caucasian IgAV patients, 95 patients with IgAN and 832 matched healthy controls.

Results: Similar genotype and allele frequencies were observed in the whole cohort of patients with IgAV when compared to those with IgAN when BAFF, APRIL and BAFF-R variants were analyzed independently (Table 1). In accordance with that, no BAFF, APRIL and BAFF-R genotype or allele differences were detected between IgAV patients who developed nephritis and patients with IgAN (Table 1). Additionally, no statistically significant differences were observed between the whole cohort of patients with IgAV and healthy controls as well as between patients with IgAN and healthy controls when each when BAFF, APRIL and BAFF-R genetic variant was also analyzed independently (Table 1). Similar results were disclosed when haplotype frequencies of APRIL and BAFF-R were compared between the different comparative groups above mentioned (data not shown).

Conclusion: Our results reveal a similar BAFF, APRIL and BAFF-R genetic distribution in IgAV and IgAN, suggesting that these genes could not be used as differential biomarkers between these pathologies.

REFERENCES:

Acknowledgements: This study was supported by the European Regional Development Fund (ERDF) and “Fondo de Investigaciones Sanitarias” (grant P118/00042 and P121/00042) from “Instituto de Salud Carlos III” (ISCIII, Health Ministry, Spain), DP-P is a recipient of a Río Horta programme fellowship from the ISCIII, co-funded by the European Social Fund (ESF, Investing in your future) [grant number CM20/00206]; SR-M is supported by funds of the RETICS Program co-funded by ERDF [grant number RD16/0012/0009]; VP-C is supported by a pre-doctoral grant from IDIVAL [grant number PREVAL 18/01]; RL-M is a recipient of a Miguel Servet type II programme fellowship from the ISCIII, co-funded by ESF; Investing in your future [grant number CPI21/00004].

Disclosure of Interests: Diana Prieto-Peña: None declared, Fernanda Genre: None declared, Belén Atienza-Mateo: None declared, Belén Sevilla: None declared, Javier Lorca: None declared, Norberto Ortego: None declared, Maite Leonardo: None declared, Ana Peñalba: None declared, Luis Martin-Penagos: None declared, Jose Alberto Miranda Fillloy: None declared, J. Navarre: None declared, Luis CAMINAL MONTERO: None declared.

Table 1. Genotype and allele frequencies of BAFF, APRIL and BAFF-R in the whole cohort of patients with IgAV, patients with IgAV who developed nephritis, patients with IgAN and healthy controls.

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Change</th>
<th>Data set</th>
<th>1/2</th>
<th>1/1</th>
<th>2/2</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAFF rs374039502</td>
<td>T/A</td>
<td>IgAV</td>
<td>92.1 (363)</td>
<td>7.9 (31)</td>
<td></td>
<td>95.1 (757)</td>
<td>4.9 (31)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IgAV with nephritis</td>
<td>66.7 (238)</td>
<td>33.3 (125)</td>
<td></td>
<td>80.6 (461)</td>
<td>19.4 (125)</td>
</tr>
<tr>
<td>APRIL rs11552708</td>
<td>G/A</td>
<td>IgAV</td>
<td>78.7 (710)</td>
<td>21.3 (190)</td>
<td></td>
<td>88.7 (699)</td>
<td>11.3 (190)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controls</td>
<td>78.7 (310)</td>
<td>21.3 (100)</td>
<td></td>
<td>88.7 (210)</td>
<td>11.3 (100)</td>
</tr>
<tr>
<td>APRIL rs6608</td>
<td>C/T</td>
<td>IgAV</td>
<td>72.6 (286)</td>
<td>25.4 (100)</td>
<td>2.0 (8)</td>
<td>85.3 (672)</td>
<td>14.7 (116)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IgAV with nephritis</td>
<td>69.0 (84)</td>
<td>30.5 (40)</td>
<td>0.5 (0)</td>
<td>80.5 (153)</td>
<td>19.5 (40)</td>
</tr>
<tr>
<td>BAFF-R rs1759314</td>
<td>A/G</td>
<td>IgAV</td>
<td>58.9 (232)</td>
<td>35.5 (140)</td>
<td>5.6 (22)</td>
<td>76.6 (304)</td>
<td>23.4 (140)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controls with nephritis</td>
<td>57.9 (55)</td>
<td>38.9 (55)</td>
<td>3.2 (5)</td>
<td>77.4 (147)</td>
<td>22.6 (55)</td>
</tr>
<tr>
<td>BAFF-R rs7787453</td>
<td>G/C</td>
<td>IgAV</td>
<td>83.2 (328)</td>
<td>16.8 (61)</td>
<td>0.0 (0)</td>
<td>91.0 (778)</td>
<td>9.0 (61)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controls</td>
<td>83.2 (118)</td>
<td>16.9 (24)</td>
<td>0.0 (0)</td>
<td>91.5 (260)</td>
<td>8.5 (24)</td>
</tr>
</tbody>
</table>

IgAV: IgA vasculitis; IgAN: IgA nephropathy.
AB0147
INFLAMMATORY AND NEUTROPHIL ACTIVATION MARKERS IN PATIENTS WITH BEHÇET’S DISEASE
K. Nurbayeva1,2, T. Litsitsyna, T. Rosthentakap1, R. Goloeva1, A. Lila1,2.
1Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 2Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia, Department of Rheumatology, Moscow, Russian Federation

Background: Behçet’s disease (BD) is a systemic variable vessel vasculitis with different clinical manifestations. BD does not have specific laboratory findings. Neutrophil hyperactivation is a major pathogenic factor in BD-related inflammation and tissue damage. Neutrophil reactivity (NEUT-R), neutrophil granularity (NEUT-GI), immature granulocytes (IG), neutrophil-to-lymphocyte ratio (NLR), mean platelet volume (MPV), and platelet-lymphocyte ratio (PLR) are considered as inflammatory markers. Their role in BD remains unclear.

Objectives: to determine the importance of parameters of neutrophil activation (NEUT-R, NEUT-GI), immature granulocytes (absolute (IG#), relative (IG%)) counts), NLR, MPV, PLR in assessing inflammation in BD.

Methods: 29 patients with a reliable BD according to ICBD 2014 and 40 age-matched healthy donors (HD) without acute infectious diseases or cancer were included in the study (Table 1). Patients with BD were separated into two groups: 22 with active and 7 with inactive BD. Active BD was defined as involvement of at least two of the following features: oral ulcers, genital ulcers, uveitis, intestinal involvement, skin lesions, neurological involvement, arthritis, and vascular involvement. Current disease activity was evaluated with transformed Behçet’s Disease Current Activity Form (BDCAF). A complete blood count (WBC-white blood cell, NEUT#-an absolute neutrophil count, NEUT-R, NEUT-GI, IG%, IG#, NLR, thrombocytes, MPV, PLR, ESR-erythrocyte sedimentation rate) was performed with XN-1000 automated hematologist analyzer (Sysmex, Japan).

Table 1. Comparative characteristics of patients with active/inactive BD and healthy controls.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Active BD (n=22)</th>
<th>Inactive BD (n=7)</th>
<th>Healthy donors (n=40)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>30 (22-39)</td>
<td>33 (30-39)</td>
<td>31 (27-37)</td>
<td>NS</td>
</tr>
<tr>
<td>Gender: female, %</td>
<td>45 (10-90)</td>
<td>36 (30-42)</td>
<td>45 (10-70)</td>
<td>NS</td>
</tr>
<tr>
<td>WBC, 10^9/l</td>
<td>7.4 (6.9-8.6)</td>
<td>6.9 (6.6-8.4)</td>
<td>6.0 (5.2-6.9)</td>
<td>p=0.049*</td>
</tr>
<tr>
<td>NEUT-R, %</td>
<td>3 (0-3)</td>
<td>3 (1-5)</td>
<td>3 (0-5)</td>
<td>NS</td>
</tr>
<tr>
<td>NEUT-GI, %</td>
<td>0.3 (0.2; 0.4)</td>
<td>0.45 (0.25; 0.65)</td>
<td>0.2 (0.2; 0.3)</td>
<td>p=0.018*</td>
</tr>
<tr>
<td>IG#</td>
<td>3.41 (2.86; 4.2)</td>
<td>3.34 (3.01; 3.8)</td>
<td>3.27 (2.97; 3.5)</td>
<td>NS</td>
</tr>
<tr>
<td>IG%</td>
<td>46.25 (44.95; 47.75)</td>
<td>43.7 (42.7; 46.2)</td>
<td>45.1 (43.5; 46.7)</td>
<td>NS</td>
</tr>
<tr>
<td>NLR</td>
<td>1.94±0.95</td>
<td>1.94±0.95</td>
<td>1.94±0.95</td>
<td>NS</td>
</tr>
<tr>
<td>MPV</td>
<td>116.45 [83.5; 137.1]</td>
<td>116.45 [83.5; 137.1]</td>
<td>116.45 [83.5; 137.1]</td>
<td>NS</td>
</tr>
<tr>
<td>PLR</td>
<td>1.04 [9.7; 11.0]</td>
<td>1.04 [9.7; 11.0]</td>
<td>1.04 [9.7; 11.0]</td>
<td>NS</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>2.5 [12.2; 24.7]</td>
<td>2.5 [12.2; 24.7]</td>
<td>2.5 [12.2; 24.7]</td>
<td>NS</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>6.5 [4.5; 7.0]</td>
<td>6.5 [4.5; 7.0]</td>
<td>6.5 [4.5; 7.0]</td>
<td>NS</td>
</tr>
<tr>
<td>NEUT-R, FI</td>
<td>0.02 [0.01; 0.04]</td>
<td>0.04 [0.01; 0.07]</td>
<td>0.01 [0.01; 0.02]</td>
<td>p=0.036*</td>
</tr>
<tr>
<td>NEUT-GI, SI</td>
<td>0.3 (0.2; 0.4)</td>
<td>0.25 (0.2; 0.45)</td>
<td>0.2 (0.2; 0.3)</td>
<td>NS</td>
</tr>
<tr>
<td>ACEi</td>
<td>16 (29)</td>
<td>16 (29)</td>
<td>16 (29)</td>
<td>NS</td>
</tr>
<tr>
<td>ARB</td>
<td>7 (12)</td>
<td>7 (12)</td>
<td>7 (12)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Results: A WBC count was significantly higher in BD patients compared to controls (Table 1). Patients with active BD had a higher WBC count than inactive. Patients with BD were found to have significantly higher levels of IG#, IG%, and NEUT-R compared to HD. There was no significant difference between NEUT-GI, NLR, MPV, PLR, and ESR levels in patients with BD and HD.

No significant difference in NEUT-R, NEUT-GI, IG#, IG%, PLR, or MPV between active and inactive BD was found. These hematological parameters did not correlate with the transformed BDCAF score. IG# levels positively correlated with total leukocyte count (r=0.656, p<0.001) and the absolute neutrophil count (r=0.548, p=0.002). There was a tendency to a positive correlation between IG% and NEUT-GI (r=0.354, p=0.050) and a negative correlation between IG# and PLR (r=−0.356, p=0.052).

Conclusion: Patients with BD had significantly higher total WBC counts, immature granulocyte levels, and neutrophil reactivity than controls. Except for the leukocyte count, there was no statistically significant difference in the studied parameters between patients with active and inactive BD.

The study was performed at V.A. Nasonova Research Institute of Rheumatology within the framework of the fundamental research FURS-2022-003.

Disclosure of Interests: None declared


AB0148
COULD THE RENIN-ANGIOTENSIN SYSTEM AFFECT THE PROGNOSIS OF GIANT CELL ARTERITIS?
SINGLE-CENTRE RETROSPECTIVE OBSERVATIONAL STUDY
1University of Leeds, School of Medicine, Leeds, United Kingdom; 2Leeds Teaching Hospitals NHS Trust, Biomedical Research Centre, Leeds, United Kingdom; 3University of Leicester, School of Medicine, Leicester, United Kingdom; 4University of Leeds, School of Medicine, Leeds, United Kingdom; 5The University of Manchester, School of Medicine, Manchester, United Kingdom

Background: About half of patients with giant cell arteritis (GCA) relapse while tapering glucocorticoid therapy. A previous observational study reported that blockade of the renin-angiotensin system, with angiotensin II receptor blockers (ARBs), was associated with lower relapse risk.

Objectives: To determine whether angiotensin blockade, with angiotensin converting enzyme inhibitor (ACEI) or ARB, is associated with differential relapse risk in GCA.

Methods: GCA patients from a tertiary centre diagnosed 2012–2020 with two years follow-up were included from UK GCA Consortium. All provided written informed consent. Retrospective review of medical records included demographics, comorbidities, drug history, and relapses. Relapse was defined as return of symptoms, raised inflammatory markers, or active vasculitis on imaging confirmed by the treating clinician. Relapse-free survival was analysed using Kaplan Meier (KM) curves and Cox proportional hazards.

Results: 111 patients were included (Table 1: demographic data), all were initially treated with 40–60mg Prednisolone. 42% received further immunosuppressants due to relapse or disease severity. 50% patients relapsed in two years, presenting with cranial symptoms (72%), PMR-like symptoms (30%) and/or raised inflammatory markers (48%). There was no association between relapse and age, gender, comorbid HTN/IHD or pre-steroid inflammatory markers and relapse. Rate of steroid taper can affect relapse. EULAR recommend 15–20mg of steroid by three months, 9 patients relapsed within that time, and were excluded, there was no difference in steroid dose at three months between the two groups. KM analysis showed ACEi did not significantly affect time to relapse compared to no angiotensin blockade (HR 0.57, 95% CI 0.28–1.18, unadjusted p-value=0.128), and neither did an ARB (HR 0.78, 95% CI 0.31–1.98, unadjusted p-value=0.605).

Table 1. demographic data at baseline.

<table>
<thead>
<tr>
<th>Medications</th>
<th>n (%)</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEi</td>
<td>9 (15)</td>
<td>16 (29)</td>
</tr>
<tr>
<td>ARB</td>
<td>7 (12)</td>
<td>7 (13)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTN</td>
<td>22 (40)</td>
<td>23 (42)</td>
</tr>
<tr>
<td>IHD</td>
<td>6 (11)</td>
<td>5 (9)</td>
</tr>
<tr>
<td>Predabetes</td>
<td>11 (21)</td>
<td>10 (18)</td>
</tr>
<tr>
<td>DM</td>
<td>1 (2)</td>
<td>5 (9)</td>
</tr>
<tr>
<td>ESR-erythrocyte sedimentation rate</td>
<td>10 (19)</td>
<td>11 (20)</td>
</tr>
<tr>
<td>CRP pre-treatment</td>
<td>6 (10)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>CRP pre-treatment</td>
<td>6 (10)</td>
<td>2 (4)</td>
</tr>
<tr>
<td>Steroid dose 3 months</td>
<td>19 (35)</td>
<td>20 (35)</td>
</tr>
</tbody>
</table>

* a statistically significant test result (p ≤ 0.05); NS-not significant; Fluorescence intensity; SI- scatter intensity; Fl- femorotibial.

Results: A WBC count was significantly higher in BD patients compared to controls (Table 1). Patients with active BD had a higher WBC count than inactive. Patients with BD were found to have significantly higher levels of IG#, IG%, and NEUT-R compared to HD. There was no significant difference between NEUT-GI, NLR, MPV, PLR, and ESR levels in patients with BD and HD.
Conclusion: In the two years following GCA diagnosis 50% relapsed. There was no significant difference in the rate of relapse in patients taking an ACEi or ARB. The main limitation, in this retrospective, observational study was the inability to exclude a reluctance of clinicians to diagnose GCA relapse in the presence of cardiovascular comorbidity. A randomised controlled trial would be needed to determine whether starting an ACEi could reduce relapse risk in patients with new-onset GCA.

REFERENCES:

Disclosure of Interests: S. Lichołai: None declared, K. Wójcik: None declared, K. Wawrzycka-Adamczyk: None declared, M. Surmiak: None declared, M. Korkosz: None declared, S. Lichołai1, K. Wójcik2, K. Wawrzycka-Adamczyk2, M. Surmiak1, M. Korkosz3, 5

Background: Granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitides, a heterogeneous group of disorders whose clinical presentation ranges from isolated lesions affecting a single organ to life-threatening conditions. The etiology of the disease is not fully understood, and there is a lack of reliable and unambiguous diagnostic and prognostic markers.

Research in recent years points to the potential use of circulating free nucleic acids as a potential biomarkers in human pathology. Circulating RNA (cIRNAs) belong to the group of non-coding RNAs, a group of potentially regulatory RNAs generated by linkage between a downstream 3' splice site and an upstream 5' splice site in a process known as backsplicing. CircIRNAs were found in in nearly all tissues and recently have been reported to regulate gene expression by sponging miRNA. However their role in specific human conditions is largely unknown.

Objectives: The aim of our study was to assess the potential role of cIRNA in diagnosis and monitoring of GPA.

Methods: CircIRNAs were selected using bioinformatic analysis of RNA-seq data. Serum samples were obtained from 30 patients with GPA and 30 healthy controls. Levels of circRNA were assessed using qPCR with specific primers.

Omics data from NCBI-GEO and Array Express databases are lacking from IgAV samples of adult patients.

Objectives: Our aim was to perform RNA sequencing and to identify differentially expressed genes and dysregulated molecular pathways in the affected skin of adult IgAV patients with renal involvement, patients with skin-limited IgAV and healthy controls (HC).

Methods: Skin biopsy samples were collected from treatment-naive adult IgAV patients at time of diagnostic procedure: 1) skin-limited disease (n=3), 2) IgAV with renal involvement (n=3), and age-/sex-matched HC (n=3). RNA was isolated and 100 bp paired-end sequenced using the Illumina HiSeq 4000 platform (25.9 to 30.8 million reads were obtained per sample). Reads were mapped with Salmon tool against the human transcriptome (Ensemble Release 104). Differentially expressed genes (log2 fold change ≥ 1, padj < 0.05) were computed using the R package DESeq2. Data were clustered using principal component analysis (PCA), and KEGG pathway over-representation analysis (ORA) was performed with R package clusterProfiler.

Results: We identified 72 differentially expressed genes (34 up- and 38 down-regulated) between skin-limited IgAV and HC, while 669 genes were differentially expressed (421 up- and 265 down-regulated) in the affected skin between adult IgAV patients with renal involvement and healthy controls (HC). PCA distinguished between IgAV (renal and skin-limited) and healthy controls, suggesting specific transcriptome signatures in IgAV. 21 overlapping genes were differentially expressed in both groups of patients in comparison to HC. 196 genes were differentially expressed between IgAV patients with renal involvement compared to skin-limited IgAV.

Genes, differentially expressed in patients with skin-limited disease were enriched in the oxidative phosphorylation (padj = 3.08 x 10−5) and cell adhesion molecules (padj = 6.32 x 10−5) KEGG Pathways. Differentially expressed genes in patients with renal involvement exhibited enriched KEGG Pathways involved in the ribosome (padj = 0 x 10−5), the regulation of lipolysis in adipocytes (padj = 9.066 x 10−5), cell adhesion molecules (padj = 8.0008 x 10−5), renin secretion (padj = 4.288x10−5), complement and coagulation cascades (padj = 3.58547 x 10−5), vascular smooth muscle contraction (padj = 3.76132 x 10−5) and aldosterone synthesis and secretion (padj = 3.76132 x 10−5).

Conclusion: Deregulated genes in skin of adult IgAV patients with renal manifestation could serve as biomarkers for organ-specific involvement. Further studies are needed that would support deciphering the involvement of perturbed molecular pathways and the contribution of individual cell types to skin manifestations of adult IgAV patients.

Acknowledgements: The authors also wish to thank all the patients who volunteered to participate into this study and the funding.

Disclosure of Interests: None declared


AB0150 CIRCULARRNA AS A POTENTIAL BIOMARKER OF GRANULOMATOSIS WITH POLYANGIITIS

S. Lichocki, K. Wójcik, K. Wawrzycka-Adamczyk, M. Surmiak, M. Korkosz, J. Musiał. Jagiellonian University, Medical College, Department of Molecular Biology and Clinical Genetics, Krakow, Poland; Jagiellonian University Medical College, 2nd Chair of Internal Medicine, Krakow, Poland; Jagiellonian University, Medical College, Department of Rheumatology and Immunology, Krakow, Poland

Background: Granulomatosis with polyangiitis (GPA) belong to ANCA-asociated vasculitides, a heterogeneous group of disorders whose clinical presentation ranges from isolated lesions affecting a single organ to life-threatening conditions. The etiology of the disease is not fully understood, and there is a lack of reliable and unambiguous diagnostic and prognostic markers.

Research in recent years points to the potential use of circulating free nucleic acids as a potential biomarkers in human pathology. Circulating RNAs (cIRNAs) belong to the group of non-coding RNAs, a group of potentially regulatory RNAs generated by linkage between a downstream 3' splice site and an upstream 5' splice site in a process known as backsplicing. CircIRNAs were found in in nearly all tissues and recently have been reported to regulate gene expression by sponging miRNA. However their role in specific human conditions is largely unknown.

Objectives: The aim of our study was to assess the potential role of cIRNA in diagnosis and monitoring of GPA.

Methods: CircIRNAs were selected using bioinformatic analysis of RNA-seq data. Serum samples were obtained from 30 patients with GPA and 30 healthy controls. Levels of circRNA were assessed using qPCR with specific primers.
Background: Microvesicles (MVs) are membrane enclosed extracellular vesicles released upon cellular activation and stress, which maintains features and constituents of their parental cells. Large vessel vasculitides (LVVs) are inflammatory conditions of the wall of large-sized arteries, mainly represented by giant cell arteritis (GCA) and Takayasu arteritis (TA). Arterial stenosis and dilation directly affect prognosis and, according to latest EULAR guidelines can be assessed by positron emission tomography and magnetic resonance angiography. Endothelial cells are believed to play a role in the pathogenesis of LVVs and circulating microvesicles could be a biomarker of vessel wall injury.

Objectives: To verify whether arterial wall derived-MVs detectable in the blood of TA patients and expressing bioactive molecules potentially involved in arterial injury, inflammation and remodeling could correlate with clinical and radiological features of those patients.

Methods: Platelet was obtained from 112 LVV pts (73 TA, 39 GCA). Plasma flow cytometry was performed with anti-CD14, CD16, anti-CD144 (VE-cadherin), anti-CD105 (endothelial marker), anti-CD140a/b (PDGF receptor A/B a vascular stromal marker), anti-HMGBl, anti-PTX3, MitoTracker green and MitoSox, which are expression of mitochondrial moieties and ROS. Vascular imaging was carried out by angio-RM and PET. Circulating microvesicles from LVVs patients were correlated with disease characteristics, namely CRP, NIH activity, PGA, ITAS2010, and remission (hsa_circ_0015167 – RQ 5.97, p<0.05; hsa_circ_0045268 – RQ 4.53, p<0.05). CircRNA that differentiates patients from healthy individuals were quantified by different methods, mainly represented by RT-qPCR. High throughput methods were used for statistics. Pearson’s and Spearman’s correlation tests were used for parametric and non-parametric analysis. The SPSS IBM Software was used for statistics.

Results: Levels of at least 10 serum circRNAs distinguished GPA patients from controls and 6 of them reached statistical significance. There was also an apparent difference in the levels of selected molecules between GPA exacerbation and remission (hsa_circ_0015167 – RQ 5.97, p<0.05; hsa_circ_0045268 – RQ 4.53, p<0.05). CircRNAs that differentiate patients from healthy individuals were associated with genes for P-selectin, VCAM and interleukins, among others. In contrast, molecules derived from cathepsins do not differentiate between the study and control groups.

Conclusion: Our results suggest that circRNA could be potentially used as a biomarker facilitating GPA diagnosis. Moreover, the observed differences depending on the stage of the disease could allow for monitoring the disease and predicting its progression. The association of molecules which levels differ between the test and control groups with genes previously associated with the development of the disease strongly suggests their potential involvement in its pathogenesis, which in turn strengthens the diagnostic specificity of the proposed markers.

Acknowledgements: This research was supported by National Center of Science, grant number 2018/31/B/NZ6/03898.

Disclosure of Interests: None declared


AB0152 MITOCHONDRIAL DNA IS ELEVATED IN PLASMA OF PATIENTS WITH GIANT CELL ARTERITIS

S. Giaglis1,2, D. Kyburz1,2, N. Venhoff1, U. Walker1,2, University of Basel, Department of Biomedicine, Laboratory for Experimental Rheumatology, Basel, Switzerland; 2University Hospital Basel, Department of Rheumatology, Basel, Switzerland; 3University Medical Center Freiburg, Department of Rheumatology and Clinical Immunology, Freiburg, Germany

Background: Giant cell arteritis (GCA) represents the most prevalent form of systemic vasculitis in elderly, and characterized by a remarkable heterogeneity regarding clinical and histological phenotype, pathogenetic mechanisms and treatment choice (1). The pathophysiology of GCA is driven by an interplay between cells of both innate and adaptive immune systems (2). Neutrophils seem to hold a cardinal role in GCA pathology, given their abundance in vicinity to the foci of tissue injury (3). Most importantly, neutrophils secrete neutrophil extracellular traps (NETs) which are decorated with a series of immunocompetent epitopes, essential for the dissemination of the inflammatory response (3, 4).

Objectives: The diagnostic and prognostic value of cell-free DNA in GCA is still unknown. The aim of the present study was therefore to examine the clinical utility of cell-free DNA quantification as a biomarker in GCA.

Methods: Total DNA was isolated from platelet-free plasma samples of matched healthy controls (HC) and consecutive GCA patients. Plasma and clinical data were collected at baseline and follow-up. Copy numbers were quantified by quantitative PCR for mtDNA (ATP-6 gene) and nuclear (n) DNA (GAPDH gene) (5).

Results: Twenty-one GCA patients (median age 64.0 ± 9.0, 49% female) and 22 sex matched HC were enrolled for analysis.

mtDNA levels were significantly elevated in GCA plasma (2.0x10⁷ copies/ml plasma, 95% CI: 7.0x10⁶ to 3.8x10⁸), compared to HC plasma (7.0x10⁶ copies/ml plasma, 95% CI: 2.8x10⁶ to 1.1x10⁷, p<0.0001), nDNA levels in contrast did not differ between GCA (5x10⁶ copies/ml plasma, 95% CI: 2.5x10⁶ to 9.5x10⁶) and HC (4.1x10⁶ copies/ml plasma, 95% CI: 2.3x10⁶ to 9.3x10⁶, p=0.74).

Receiver operating characteristic curve analysis showed that a cut-off value of 2.8x10⁷ mtDNA copy numbers differentiated between GCA and HC with 90.5% sensitivity, 95.2% specificity and an AUC of 0.95.

Figure 1. (a.) Plasma mtDNA levels in GCA patients are elevated (2 orders of magnitude) compared to healthy controls. Whiskers represent 95% CI. (b.) Receiver operating characteristic curve for mtDNA plasma concentrations discriminate between HC and GCA patients. AUC area under the curve.
**Basic and translational science in paediatric rheumatology.**

**AB0153**

**EFFECT OF STANDING FRAMES USED IN REAL LIFE ON BONE REMODELING IN NON-WALKING CHILDREN WITH CEREBRAL PALSY**

B. Vincent1, V. Goeb2, S. Fritot1, M. Romuald3, J. M. Sobhy-Danial4, P. Fardellone5, L. Le Monnier5, 1. Chu Amiens-Picardy, paediatric physical medicine and rehabilitation unit, Amiens, France; 2. Chu Amiens-Picardy Site Nord, rheumatology; Amiens, France; 3. Chu Amiens-Picardy Site Nord, human biology and bone metabolism; Amiens, France

**Background:** Children with severe cerebral palsy are prone to low bone mineral density. Standing frames are recommended as postural management for these children who used a standing frame for an average of 30 min/day. This was a prospective study comparing the two groups using dual X-ray absorptiometry data and densitometric data were not significantly higher, a postural trend favored the use of a standing frame in the children. Bone resorptive markers (alkaline phosphatase, osteocalcin) were higher in the non-standing group, whereas there was no difference among osteoformation factors. No difference in fracture history was found.

**Conclusion:** Used in real life, we showed that static standing practice improved mineralization by reducing osteoresorption in non-ambulant children with cerebral palsy. Further studies are needed to determine how standing practice could impact bone mineralization over time in real life and to explore more bone remodeling factors.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.145

**AB0154**

**PHYSICAL FUNCTION ASSESSMENT TOOLS IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: JAFAS VERSUS CHAQ**

A. Faza1, M. Kammouri2, S. Miladi1, H. Boussaid1, K. Ouenniche1, L. Souabni1, S. Kassab1, S. Chekili1, K. Ben Abdelghani1, A. Latara1. 1. Hospital Mongi Slim or La Marsa, Department of Rheumatology, Marsa, Tunisia

**Background:** Children with juvenile idiopathic arthritis (JIA) frequently experience impairments in one or more body systems. These may include pain, fatigue, muscle weakness, and poor exercise capacity. Functional disability can be evaluated by means of questionnaires and observed performance tests. Only the Juvenile Arthritis Functional Assessment Scale (JAFAS) and the Childhood Health Assessment questionnaire (CHAQ) were developed specifically for children with juvenile arthritis.

**Objectives:** The aim of this study was to investigate the relationship between JAFAS and CHAQ in the evaluation of physical function.

**Methods:** This is a cross sectional study including patients with JIA. Assessment of disease activity (DAS28), number of tender joints (NTJ) and swollen joints (NSJ) were determined. The JAFAS (range 0-20) includes 10 items of activities of daily living (dressing, cutting food, getting in and out of bed, picking up an object from the floor while standing, moving from standing to the floor and returning to standing, walking 50 feet unaided, and walking up a flight of 5 steps). The score range for each item is 0–2, based on the time in seconds the child takes to complete each task. Higher scores indicate greater activity limitation (1). The original CHAQ including 30 activities in eight different domains, with a total score ranging from 0 (no limitation) to 3 (maximal limitation) was completed by interviewing the patient (2). Spearman correlation test and Cohen’s kappa coefficient (k) were used. Significance level was set at p<0.05.

**Results:** Twenty-nine patients with a median age of 25 years [8-40] and median disease duration of 16 years, were included. Age of onset of the disease was 8 years [2-16] years. The median JAFAS score was 3 [0-12] and the median CHAQ score was 0.05 [0-3]. There was a slight agreement between JAFAS and CHAQ k=0.1 (p = 0.05). A positive correlation was found between NTJ and CHAQ (r=0.54, p=0.03) and JAFAS (r=0.5, p=0.05). A correlation was noticed also between NSJ and CHAQ(r=0.51, p=0.05). Both the JAFAS and CHAQ scores correlated with DAS28 (r=0.55, p=0.01 and r=0.44, p=0.02, respectively). At the level of the individual joints, coxitis was the most frequent complication (13 patients out of 28), six of them had surgery of total hip prosthesis. There was a linear relationship between JIA complicated with coxitis and the level of functional disability measured with JAFAS (p=0.027).

**Conclusion:** Our study shows that, even though JAFAS had a slight agreement with CHAQ, both were correlated with the level of disease activity and the number of swollen and tender joints.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.154
Basic and translational pain science

**AB0156**

**INTRA-ARTICULAR AGRIN PROVIDES DIRECT PAIN RELIEF IN OSTEOARTHRITHIS AND CARTILAGE DEFECTS**

S. Eldridge, A. Barawi, A. S. Thorup, B. F. Fernandez, S. Bhane, S. Sikandar, Z. Guan, M. Kaneva, H. Lydon, F. Henson, C. De Bari, A. McCaskie, F. Dell’Accio. 1The William Harvey Research Institute, Experimental Medicine and Rheumatology, London, United Kingdom; 2University of Cambridge, Department of Veterinary Medicine, Cambridge, United Kingdom; 3University of Aberdeen, Aberdeen Centre for Arthritis and Musculoskeletal Health, Aberdeen, United Kingdom; 4University of Cambridge, Division of Trauma and Orthopaedic Surgery, Department of Surgery, Cambridge, United Kingdom

**Background:** Osteoarthritis is the leading cause of disability worldwide with a financial burden estimated between 1.5 and 2% of the GDP in all westernised countries. The main driver of progression in osteoarthritis is cartilage loss, which may be associated with bone changes, low degree synovitis and lesions to menisci and ligaments. These pathological features result in pain, which contributes to chronic disability.

Improving cartilage integrity without pain relief does not help patients and results in failure in clinical trials. Therefore, there is a need for therapeutics that induce rapid pain relief and long-term cartilage regeneration.

We previously showed that Agrin results in cartilage regeneration and in this study, following on the serendipitous finding of rapid pain relief after Agrin administration we explore its analgesic effect in animal models of osteochondral defects and osteoarthritis.

**Objectives:** Test the analgesic potential of Agrin in post-surgical pain associated with osteochondral defects in mice and sheep.

Determine whether Agrin can relieve chronic pain induced by osteoarthritis in mice.

Investigate the therapeutic potential of Agrin in models of primary and injury-induced secondary osteoarthritis.

**Methods:** Acute post-surgical pain: Surgery was performed on skeletally mature male mice and female sheep to create critical-sized osteochondral defects; defects were filled with collagen gel containing PBS or Agrin. Animals were sacrificed 6 weeks (mice) and 6 months (sheep) after surgery. Pain was measured in mice using von Frey filaments and incapacitance readings. Sheep were fitted with accelerometers for the duration of the study.

Osteoarthritis pain: Osteoarthritis was surgically induced in skeletally mature male mice by menisco-ligament injury (MLI). Control mice received sham surgery. Nine weeks post-surgery, once chronic pain was established, mice were injected intra-articularly with recombinant Agrin. Pain was measured by von Frey filaments and incapacitance.

Treatment in therapeutic regime: Tamoxifen-inducible transgenic mice over-expressing Agrin under the AggreCanCre promoter were generated. Skeletally mature male mice were subjected to menisco-ligament injury surgery. Four weeks later, tamoxifen was administered to overexpress Agrin in the cartilage. Pain was measured by von Frey filaments and incapacitance.

Ex-vivo: MicroCT, X-ray, Kellgren-Laurence scoring, histology, OARSI scoring and immunohistochemistry.

**Results:** In sheep, Agrin administration induced regeneration in osteochondral defects and, more importantly, reduced the levels of secondary osteoarthritis. This was associated with a rapid and sustained symptomatic relief. In mice, Agrin expression was lost in the dorsal root ganglia corresponding to the limb subjected to MLI but not in the dorsal root ganglia corresponding to the sham operated limbs.

Intra-articular recombinant Agrin in mice with established OA (9 weeks after MLI surgery) resulted in pain relief as early as three hours after administration. Acute administration of recombinant Agrin does not have any analgesic effects in sham operated mice.

Inducible, cartilage-specific Agrin-overexpression mice were protected from developing pain associated with instability-induced osteoarthritis. In mice with acute osteochondral defects, intra-articular Agrin administration resulted in pain relief for at least five days.

In humans, the loss of Agrin in the articular cartilage correlated significantly with the Mankin score of patients undergoing knee replacement surgery.

**Conclusion:** Agrin has analgesic properties in both the acute phases of cartilage damage and in established osteoarthritis. Our findings support the therapeutic use of Agrin for joint surface regeneration and pain relief.

**Disclosure of Interests:** Suzanne Eldridge: None declared, Aida Barawi: None declared, Anne-Sophie Thorup: None declared, Beatriz F Fernandez: None declared, Sabah Bhanie: None declared, Shafaq Sikandar: None declared, Zeyu Guan: None declared, Madgalena Kaneva: None declared, Helen Lydon: None declared, Fran Henson: None declared, Cosimo De Bari: None declared, Andrew McCaskie: None declared, Francesco Dell’Accio Consultant of: Prof Dell’Accio has consulted for Samumed, Grant/ research support from: A PhD studentship unrelated to this abstract is funded by UCB

**DOI:** 10.1136/annrheumdis-2022-eular.3483
Rheumatoid arthritis - prognosis, predictors and outcome

AB0157

EFFICACY AND SAFETY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE: COMPARATIVE STUDY WITH FILGOTINIB AND TOCILIZUMAB EXAMINED BY CLINICAL INDEX AS WELL AS MUSCULOSKELETAL ULTRASOUND ASSESSMENT (TRANSFORM STUDY): STUDY PROTOCOL

T. Shimizu1,2, S. K. Kaschawski3, S. Morimoto4, Y. Kawazoe3, K. Kuroda5, R. Kasawagi6, Y. Ito7, S. Satori, H. Yamamoto6, A. Kawakami2, Nagasaki University Hospital, Clinical Research Center, Nagasaki, Japan; *Nagasaki University Graduate School of Biomedical Sciences, Departments of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; NAGASAKI UNIVERSITY Graduate School of Biomedical Sciences, Departments of Community Medicine and, Division of Advanced Preventive Medical Sciences, Nagasaki, Japan; NAGASAKI University Graduate School of Biomedical Sciences, Innovation Platform & Office for Precision Medicine, Nagasaki, Japan

Background: The administration of Janus kinase (JAK) inhibitors as well as biological disease-modifying anti-rheumatic drugs has dramatically improved even the clinical outcomes in rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX). The dysregulation of JAK-signal transducer and activator of transcription (STAT) pathways via overproduction of cytokines, such as interleukin-6 (IL-6), is involved in the pathogenesis of RA (1). Filgotinib, a preferential JAK1 inhibitor, is effective in suppressing disease activity and preventing the progression of joint destruction due to inhibition of the JAK-STAT pathway. IL-6 inhibitors such as tocilizumab also inhibit the JAK-STAT pathways due to inhibition of IL-6 signaling. Thus, it should be desirable to investigate whether the effectiveness of filgotinib monotherapy is non-inferior to those of tocilizumab monotherapy in RA patients with inadequate response to MTX. In addition, it is important to accurately evaluate disease activity at the joint level by using musculoskeletal ultrasound (USUS) and clinical disease activity indices, including subjective parameters (2).

Objectives: This study’s principal objective is to evaluate the effects of filgotinib monotherapy in RA patients with inadequate response to MTX. In addition, we will evaluate changes in patients’ parameters, including clinical disease activity indices, MSUS scores, serum biomarkers, patient-reported outcome (PRO), and modified total Sharp score (mTSS) after the administration of filgotinib or tocilizumab. Herein, we describe the study protocol for this study.

Methods: This study is an interventional, multicenter, randomized, open-label, parallel-group and non-inferiority clinical trial with a 52-week follow-up. In total, 400 RA patients with inadequate response to MTX will be included. Patients will be randomized in a 1:1 ratio to administration of filgotinib or tocilizumab. Herein, we describe the study protocol for this study.

Results: Although the study results cannot be shown because the research entry is in progress, they are expected to show the non-inferiority of filgotinib monotherapy to tocilizumab monotherapy in RA patients with inadequate response to MTX.

Conclusion: The strength of this study is its prospective evaluation of therapeutic efficacy using not only clinical disease activity indices but also MSUS, which accurately and objectively evaluate disease activity at the joint level among patients drawn from multiple centers with a standardized evaluation by MSUS. In addition, we will evaluate the effectiveness of both drugs by integrating multilateral assessments, i.e., clinical disease activity indices, MSUS findings, and serum biomarkers.

REFERENCES:

Disclosure of Interests: Yoshimi Shimizu: None declared, Shin-ya Kawashiri: None declared, Shimpai Morimoto: None declared, Yurika Kawazoe: None declared, Shohei Kuroda: None declared, Rina Kawasaki: None declared, Yuso-uko Ito: None declared, Shunjiro Satoh: None declared, Hiroshi Yamamoto: None declared, Atsushi Kawakami/Grant/research support from: Gilead Sciences, Inc.

DOI: 10.1136/annrheumdis-2022-eular.190

AB0158

PREVENTION OF PROGNOSIS AT ONE YEAR AFTER THE ADMINISTRATION WITH B/TSDMARD FOR PATIENT WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS

I. Yoshih1, S. Sawada2, T. Chijiwa1, Yoshih Hospital, Musculoskeletal Medicine, Shimanto-City, Japan; Dohgo Onsen Hospital, Rheumatology, Matsuyama, Japan; Kochi Memorial Hospital, Rheumatology, Kochi, Japan

Background: Patients with difficult-to-treat rheumatoid arthritis (D2T RA) are the most serious problem in recent systemic RA treatment protocols [1].

Objectives: Prognosis after biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is beneficial when predicted in patients with D2T RA. Predictors of post b/tsDMARDs in D2T RA patients were investigated using retrospective cohort data.

Methods: RA patients more than 1 year after the start of newly administered b/tsDMARDs were recruited. The patients were divided into two groups according to the EULAR definition of D2T RA [2]. Patients who met the criteria were classified into the D2T RA group and others into the non-D2T RA group. The incidence of the clinical features described in the criteria of D2T RA and the rheumatoid disease comorbidity index (RDCI) [3] were compared between the two groups at the time of drug initiation (baseline). The primary endpoint was “Success or Failure” at 1 year after baseline. Success was defined as b/tsDMARD persisted in remission as the 28 joint disease activity score with erythrocyte sedimentation rate (DAS28) ≤ 2.6, or as b/tsDMARD was discontinued upon achieving clinical remission. The Failure was defined as other decisions such as discontinuation due to failure, adverse events, or characteristic patient problems. In the discontinued cases, the monitoring value at the last observation was carried forward to 1 year. Cox regression analysis was used to assess each variant as a potential risk factor for Failure. Receiver operating characteristic analysis (ROC) was tested on variants with significantly higher risk ratios, and Kaplan-Meier survival analysis was also tested for cut-off indices.

Results: 71 cases of the D2T RA and 259 cases of the non-D2T RA group were analyzed. As shown in Table 1, the clinical characteristics of the D2T RA group were significantly worse than those of the non-D2T RA group. Higher DAS28 had a significantly higher risk ratio for the Failure from month 3 in D2T RA group, whereas from baseline in the non-D2T RA group (Figure 1-A). Other factors in the D2T RA group at and after baseline listed in the Table 1 had no significant risk ratios. PS-VAS and EQ5D score had significant higher risk ratios in the non-D2T RA group using univariate models, however, only DAS28 had significant higher risk ratio using multivariate model. The cut-off index (COI) and the area under the curve (AUC) using ROC for each observational period in the two groups were shown in Figure 1-B. Results of Kaplan-Meier survival analyses were shown in Figure 1-C. Hazard ratios of DAS28 > COI exceeded 2.5 even from months 3 with high sensitivity (p < 0.001) in the D2T RA group.

Conclusion: These results indicated that higher DAS 28 suggested a failure prognosis at 12 months after initiation in D2T RA and non-D2T RA patients. Even in patients with D2T RA, strict disease activity control is most important for prognostic management, with 1-year prognosis predictable in the first 3 months. However, this study is a short-term prognostic predictor, and accumulation of short-term predictions is a long-term predictor.

REFERENCES:
Disclosure of Interests: None declared


AB0159

HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS AT TIKUR ANBESAA SPECIALIZED HOSPITAL: A HOSPITAL-BASED CROSS SECTIONAL STUDY

B. A. Adugna, 1 A. D. Ababa university, Internal medicine, Addis Ababa, Ethiopia

Background: Rheumatoid Arthritis (RA) is a chronic disorder associated with substantial morbidity and mortality. Patients with active RA suffer from significant decline in functional capacity and many become work disabled within five years, from onset of symptoms despite treatment. Measurable outcome of these can be done with the help of HRQoL questionnaires. There is a need to study the HRQoL in RA patients, as there is no available data in Ethiopia.

Objectives: This study was conducted to evaluate HRQoL in patients with Rheumatoid Arthritis and factors associated with it.

Methods: A Cross sectional study was conducted at Rheumatology Clinic in Tikur Anbessa specialized Hospital, Addis Ababa, Ethiopia from June 1 to October 31. Data was collected using a structured interviewer administered questionnaire and data extraction form. Data was entered and it was analyzed using SPSS Version 26. To identify associated factors in Health related quality of life of patients with rheumatoid arthritis, bivariable and multivariable analysis were done. Statistical significance was considered at 5%, and a p-value with 95% confidence interval was used to present the estimates of the strength of the association.

Results: A total of 213 participants were included in this study. The mean age of participants was 44.7±14. Majority 191(89.7%) of participants were female. In this study all the 8 domains of RAND 36 are reduced. The mean value of two scales from physical component and one scale from the mental component are below 50. These are Role limitation due to physical problems, General Health Perception and Role limitation due to emotional problems. Both summary score are affected with the PCS more affected than MCS. The multivariable analysis identified rural residence and modified health assessment questionnaire score as factors associated with PCS. For each shift of a patient from urban to rural residence, the PCS decreases by 9.1. For each one score increase in modified health assessment questionnaire score, the PCS score decreases by 28.25. Whereas factors associated with MCS are rural residence, adherence score, MHAQ score, peptic ulcer disease, and rheumatoid nodules. For each shift of residence from urban to rural, the MCS decreases by 15.2. For each one score increase in adherence score, the mental component score increases by For each one score increase in MHAQ score, the MCS decreases by 14.3. For each shift of peptic ulcer disease from absent to present, the mental component score decreases by 16. Finally, for each shift of rheumatoid nodule from absent to present, the MCS by 20.8.

Conclusion: This study showed that Rheumatoid Arthritis has a significant effect on the Health Related quality of life of patients. Rural residence and functional disability was the most influencing factor on both the physical and mental function. Routine assessment of the Health Related quality of life in those patients is recommended to detect and monitor the impact of the disease and its medications on different aspects the patient's life.

REFERENCES:

Disclosure of Interests: None declared


AB0161

THE RELATIONSHIP OF TRYPTOPHAN CATABOLISM WITH RHEUMATOID ARTHRITIS DISEASE ACTIVITY ABSTRACT

A. Kor1, S. Erten1, E. F. Yurt2, I. Dogan2, H. Apaydin3, M. A. Serdar3, C. Bilcizer4 on behalf of ankara city hospital working group. 1Ankara Yildirim Beyazit University Faculty of Medicine, Rheumatology, ANKARA, Turkey; 2Beyazap Public Hospital,, Medical Biochemistry, ANKARA, Turkey; 3Ankara Şehir Hastanesi, Rheumatology, ANKARA, Turkey; 4Acibadem Hospital Ankara, Medical Biochemistry, ANKARA, Turkey. 5Ankara Yildirim Beyazit University Faculty of Medicine, Medical Biochemistry, ANKARA, Turkey

Background: Tryptophan (Trp) is an essential amino acid. The immunosuppressive effect caused by Kynurenine (Kyn) and its metabolites formed by the catabolism of Trp is thought to be an important physiological mechanism.

Objectives: This study aims to evaluate the relationship of Kyn and its metabolites formation of Trp catabolism with rheumatoid arthritis (RA) disease activation and to investigate the usability of these markers in the diagnosis and treatment of RA.

Methods: 50 RA patients followed in our rheumatology clinic and 41 healthy controls were included in this study. Disease Activity Score 28 (DAS28) was used to evaluate the association of Kyn metabolites and Indolamine 2,3 dioxygenase (IDO) enzyme activity with RA disease activity. The task of this marker is to provide the best way to use in RA.

Results: In this study, lower Trp levels were found in the RA group compared to the control group (11285.47±2316.93-13320.31±37771.27, respectively) compared to the Trp mean (p<0.01). In terms of the Kyn/Trp ratio, a significantly higher Kyn/Trp ratio (4.42±1.737.27±0.71, respectively) was found in the RA compared to the control group (p<0.001). There was no significant difference between the study groups in terms of Kyn averages (p>0.05). A significant correlation was found between Trp levels and morning stiffness (r=-0.321, p<0.05) and the DAS28 score (r=-0.566, p<0.01). A significant positive correlation was found between the Kyn/Trp ratio and C-reactive protein (r=0.317, p<0.05), sedimentation (r=0.319, p<0.05), morning stiffness (r=0.287, p<0.05) and DAS28 score (r=0.322, p<0.01).

Disclosure of Interests: None declared


AB0160

THE RELATIONSHIP BETWEEN THE LEVEL OF FETUIN-A AND LABORATORY MARKERS OF CONNECTIVE TISSUE DESTRUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS

Y. Akhverdyan1, B. Zavodovsky2, E. Papichev3, J. Polyakova1, L. Seevedorva1, 1Federal State Budgetary Institution “Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky”, Laboratory of methods of treatment and prevention of joint diseases, Volgograd, Russian Federation

Background: It is known that there are biochemical markers of cartilage and bone tissue destruction, which reflect the metabolic processes occurring in tissues. For example, in rheumatoid arthritis (RA), routine markers such as CTX-I, a bone degradation marker (C-terminal telopeptide of type I collagen) and CTX-II, a cartilage degradation marker (C-terminal telopeptide of type II collagen), can be used. Also, to assess the state of cartilage tissue, the determination of type II collagen fragments by Urine Cartilaps is widely used, which allows not only primary diagnosis, but also dynamic monitoring of metabolic processes.

Objectives: The aim of our research was to study the relationship between the level of fetuin-A (FeA) and laboratory markers of bone and cartilage tissue degradation in the blood serum of patients with RA.

Methods: We observed 110 patients with a verified diagnosis of RA, the control group consisted of 30 practically healthy individuals without joint diseases. The group of patients with RA and the control group were comparable in terms of age (p=0.003), gender (p=0.116), BMI (p=0.302). The diagnosis of RA was based on the clinical classification adopted at the EULAR/ACR in 2010. The level of FeA in the blood serum was determined once by enzyme immunoassay using commercial test systems (Human Fetuin-A ELISA Biovendor Cat No. 191-0371).

Results: We have assessed the FeA level in the group of RA patients and healthy donors. The normal level of FeA in healthy individuals, calculated as MA±2SD, ranged from 653.55 µg/ml to 972.19 µg/ml. FeA level was normally distributed (K-S=0.082, p=0.2). We also studied the relationship between indicators of bone metabolism and the concentration of FeA. In patients with normal FeA levels (n=87), the mean CTX-1 level was 35 ng/mL; in patients with reduced FeA levels (n=23), the mean CTX-1 level was 51 ng/ml (t=-2.42 p =0.016). Thus, we have a decrease in the FeA level, CTX-I (an indicator of osteodestruction) tended to increase.

Next, we analyzed the relationship between low and normal levels of FeA and the bone collagen origin marker, using intragroup analysis methods. In the group with low FeA level Cartilaps/urine creatinine was 598.9±223.72 µg/mmol versus 481.7±226.93 µg/mmol in the group with normal FeA level (z=2.311; p=0.021). Our data probably allow us to associate the FeA level with the rate of cartilage tissue destruction.

Conclusion: Considering that the levels of laboratory markers of cartilage and bone collagen degradation Cartilaps and CTX-I were statistically lower in the presence of an elevated serum level of FeA, we can conclude that FeA has chondro- and osteoprotective properties. It can also be assumed that the level of this marker can be used to predict the rate of cartilage destruction in patients with RA, but this issue requires further study.

Disclosure of Interests: None declared

Table 1. Comparison of study parameters between RA and control group.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Rheumatoid arthritis</th>
<th>Control group</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tryptophan (ng/ml)</td>
<td>11285.47±2318.93</td>
<td>1320.31±3771.27</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Kynurenine (ng/ml)</td>
<td>477.68±158.38</td>
<td>437.51±162.10</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Kyn/Trp ratio</td>
<td>4.42±1.77</td>
<td>3.27±0.71</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

All values were expressed as mean ± SD. All values were calculated using independent sample t-test for normal distribution.

Figure 1. Correlation relationship between DAS 28 and Tryptophan levels (r = -0.321, p < 0.01)

Conclusion: In this study, we observed that RA has a significant relationship with Tryptophan levels and Kyn/Trp ratio. In addition to the literature, we found that RA activation indicator DAS28 score and Kyn/Trp ratio and Tryptophan level showed a statistically significant correlation. Our study has shown that the Tryptophan catabolic pathway can be an important field of study for more effective and safe treatment of RA.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1030

AB0162 PREDICTION OF TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS USING BIOLOGICAL DMARDS AND TARGETED SYNTHETIC DMARDS

E. Koltova1, M. Lukina2, E. Shmidt2, K. Lytkina4, E. Zhilyaev4 on behalf of Moscow Unified Arthritis Registry. 1The Logino Medical Center, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 3City Clinical Hospital 1 named after N.I. Pirogov, Rheumatology, Moscow, Russian Federation; 4Pirogov Russian National Research Medical University, Moscow, Russian Federation; 5Pirogov Russian National Research Medical University, Moscow, Russian Federation; 6CJSC «European Medical Center», Rheumatology, Moscow, Russian Federation

Background: The main goal of rheumatoid arthritis (RA) patients therapy is to achieve low activity or remission of the disease (T2T strategy). However, it is sometimes necessary to interrupt effective treatment due to the development of adverse events.

Objectives: To reveal predictors of target drug withdrawal due to adverse RA.

Methods: The study includes patients with RA used bDMARDs, total 1217 treatment events. Search for predictors was carried out in two steps. At the first step were selected variables which demonstrated significant correlation with time to treatment discontinuation in Kaplan-Meier analysis. At the second step selected factors were included in the Cox regression model. The final set of independent significant predictors was obtained by backward stepwise variable selection.

Results: Of 661 patients 85.8% were women, the mean age of onset disease 58.7 ± 12.9 years, the mean disease duration 14.6 years. The longest mean time until withdrawal due to adverse events had Abatacept, Tocilizumab, Tocilizumab, the shortest time had Infliximab. There were 146 cases of therapy discontinuation due to adverse events. The side effects that caused the cancelation of treatment were: infections of respiratory system, skin, urinary system, allergic and infusion reactions, drug-induced hepatitis, changes in the hematopoietic system, death and other. Presence of rheumatoid nodules (p < 0.001), higher doses of glucocorticoids (p<0.001), lower doses of methotrexate (p = 0.009) were independent significant predictors of increased risk of bDMARDs withdrawal due to adverse events. Used target drug also showed independent significant correlation with this risk. Relative risk (compared to Etanercept) was for Infliximab - 6.57 (CI: 3.69-11.73), Certolizumab pegol - 2.61 (CI: 1.23-5.56), Abatacept - 1.23 (CI: 0.65-2.30), Adalimumab - 1.37 (CI: 0.75-2.50), Rituimab - 0.56 (CI: 0.26-1.20), Tofacitinib - 0.46 (CI: 0.15-1.40), Tocilizumab - 0.77 (CI: 0.37-1.60).

Conclusion: Growth glucocorticoid doses for every 1 mg increases the risk of discontinuation of therapy by 8.7%. Reducing the methotrexate doses for every 1 mg increases the risk of discontinuation of bDMARDs and tsDMARDS by 3%. There are significant differences between target drugs for the risk of discontinuation due to adverse events. High risk of infliximab discontinuation was associated more with infusion reactions and infection, discontinuation of certolizumab pegol was associated with infection.

REFERENCES: [1] The identified predictors for the treatment withdrawal due to side effects may be discussed to identify measures necessary to prevent adverse events in patients with RA who are using bDMARDs and tsDMARDS. These measures are: the use of full doses of methotrexate, avoid long-term use of glucocorticoids, or prescription of the targeted drug with lower risk of adverse events.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1030

AB0163 SERUM LEVELS OF CHEMERIN IN PATIENTS WITH RHEUMATOID ARTHRITIS


Background: Chemerin (Ch) is one of the relatively new representatives of adipokines. Numerous studies have shown that adipokines are actively involved in inflammation and immune responses in rheumatoid arthritis (RA) [1]. Data have been obtained, on the basis of which it can be assumed that an increase in the level of Ch in the blood serum in patients with certain systemic diseases is associated with systemic inflammation [2, 3].

Objectives: The aim of the work was to study the level of chemerin in blood serum in a group of healthy donors and patients with RA.

Methods: The group of patients included 92 patients diagnosed with RA, corresponding to the diagnostic criteria developed by ACR and EULAR (2010). The age of the surveyed ranged from 18 to 75 years. The average duration of the disease was 11 years ([Me] 3[25%];16[75%]). The control group consisted of 30 practically healthy persons aged 26 to 62 years. The group of patients with RA and the control group were comparable in age (p=0.069) and gender (p=0.011). Serum chemerin levels were determined using the commercial HUMAN CHEMERIN ELISA kit (BioVendor, Cat. No.: RD191136200R) according to the instructions provided.

Results: The level of the normal Ch value in healthy individuals ranged from 134.7 µg/ml to 241.6 µg/ml. The average Ch level in RA patients (calculated as M±2SD) was 462.6±159.82 µg/ml, which is significantly higher than in healthy donors — 169.9±43.47 µg/ml (t=10.49; p=0.001). The Ch level was normally distributed (K-S d=0.10653, p=0.2). We also found a moderate correlation between the Ch level and the age of RA patients (r=0.232, P<0.05).
Conclusion: Thus, the level of Ch in the blood serum of patients with RA is significantly higher than in healthy individuals. It can be assumed that Ch in RA patients can be used as one of the potential markers of inflammation activity.

REFERENCES:

Disclosure of Interests: None declared

AB0164 ARE PATIENTS WITH RA IN REMISSION IN FINLAND DURING THE COVID TIMES? RESULTS FROM THE FINNISH QUALITY REGISTER

L. Weman1, J. Kärkä2, J. Huhtakangas4, J. Rutanen5, L. Kuusalo6, H. Salo7, T. Sokka-Isler8,9, 1University of Eastern Finland, Faculty of Health Sciences, Jyväskylä, Finland; 2Kanta-Häme Central Hospital, Department of Children and Adolescents, Hämeenlinna, Finland; 3Finnish Institute for Health and Welfare, Helsinki, Finland; 4Kuopio University Hospital, Rheumatology outpatient clinic, Kuopio, Finland; 5Tampere University Hospital, Centre for Rheumatic Diseases, Tampere, Finland; 6Turu University Hospital, Centre for Rheumatology and Clinical Immunology, Turku, Finland; 7Finnish Institute for Health and Welfare, Information Services Department, Helsinki, Finland; 8Central Finland Central Hospital, Rheumatology outpatient clinic, Jyväskylä, Finland; 9University of Eastern Finland, Faculty of Health Sciences, Jyväskylä, Finland

Background: Worries have been expressed, concerning the care of chronic diseases during the Covid times (1). Objectives: To study the current status of patients with RA in the Finnish quality register database.

Methods: Patients who receive care for RA were identified in the database. Clinical and demographic data from the last visits during 2020-2021 were collected, including swollen (SJC46) and tender joint counts (TJC46), doctor assessment of disease activity (Dr global), laboratory tests for inflammatory and serology markers, patient reported outcomes (PROMs), and DAS28. Regression models were applied to compare measures of clinical status between the health care regions, adjusted for gender, age, ACPA status, and disease duration.

Results: A total of 14163 patients (72% female, mean (SD) age 62 (14) years, median (IQR) disease duration 8.5 (2.6, 20) years, 84% ACPA positive) were identified. For the entire population, the median (IQR) SJC46 was 0 (0, 1), TJC46 0 (0, 2), ESR 8 (5, 18), CRP 3 (1, 6), and dr global 8 (0, 19). Among PROMs, median (IQR) HAQ was 0.5 (0, 1), pain 26 (10, 51), fatigue 28 (8, 54) and patient global 29 (11, 51). Between health care regions, statistically significant differences were found for all variables due to a large sample size. The mean (SD) DAS28 was 2.3 (0.9) for the entire group and 69 % of all patients had DAS28<2.6. The median DAS28 ranged from 2 to 2.7 among health care regions (Figure 1) (p<0.001). Majority of patients were taking csDMARDs only.

Conclusion: The quality register provides comprehensive real-world data on the current status of patients with RA. A majority of patients can be considered in remission even during the Covid times.

REFERENCES:

Disclosure of Interests: None declared

AB0165 MALIGNANCY AS PREDOMINANT CAUSE OF DEATH IN RHEUMATOID ARTHRITIS: REVIEW OF DATA FROM ‘BASILDON EARLY ARTHRITIS COHORT’

D. Laila1, K. Jain1, A. Nandagudi1, A. Bharadwaj1, 1Mid and South Essex Foundation Trust, Rheumatology, Basildon, United Kingdom

Background: Rheumatoid arthritis is a chronic inflammatory autoimmune condition historically linked to increased mortality with predominant contribution from cardiovascular, respiratory, infectious and neoplastic causes. There is evidence of decreasing cardiovascular mortality through improvements in preventative and treatment strategies. Recent literature has also suggested overall improvement in RA-associated mortality attributed to contemporary advances in disease control. There is a need to assess if such outcomes are reflected in the real world setting and to identify elements that continue to promote poorer outcomes.

Objectives: To assess long-term outcome in patients diagnosed with rheumatoid arthritis from the ‘Early Arthritis Cohort’ at a district general hospital in UK.

Methods: A retrospective cohort study was conducted on 185 patients newly diagnosed with rheumatoid arthritis between 2009 & 2013. Patients fulfilling the ACR/EULAR 2010 criteria were included. Anonymised data from the Basildon Early Arthritis registry was analysed. Measured parameters included patient demographics, disease activity score (DAS28), treatment regime, development of co-morbidity & mortality.

Results: Complete data was available for analysis in 171 patients. This comprised 60 men & 111 women with median age of 57 years (IQR 47 - 67 years) and median follow-up time of 90 months (IQR 63 - 108 months). Thirty nine percent were current or ex-smokers. At baseline, 40% of patients had DAS28 score > 5.1, this reduced to 2.5% at time of their last follow up. 74% of patients were in clinical remission at last follow up with 11.7% achieving drug-free remission, 40.4% remaining on single csDMARD, 29.8% on combination csDMARD & 18.1% on biologic therapy.

Analysis of new comorbidities revealed cancer burden of 12.9% (22/171) with lung cancer having highest incidence (n=9). Other comorbidities recorded were cardiovascular 11.1% (19/171), pulmonary 5.8% (10/171) and cerebrovascular disease 5.3% (9/171).

A crude mortality rate of 19.3% (33/171) was observed in our cohort over a median period of 7.5 years follow-up. The incidence mortality rate was 174/10,000 person-years of follow-up and standardised mortality ratio was 2.09 (95% CI 1.44 – 2.86). Majority of patients died five or more years after initial diagnosis (67%) with most deaths occurring in the 6th year after disease onset. Patients in the mortality group had higher disease activity scores at their last follow-up compared to the remaining cohort (p=0.017). More deaths were recorded from underlying malignancy 76% (n=13) than with cardiovascular disease 4.7% (n=8). Eight out of 13 cases were identified as lung cancer deaths. Breast, bladder, pancreatic and ovarian cancer constituted remaining cases. Other causes of death were from chronic obstructive pulmonary disease (n=3), dementia/frailty (n=3), interstitial lung disease (n=2), infection (n=2), stroke (n=1) and chronic liver disease (n=1).

Conclusion: Despite achieving remission in majority of patients, long-term analysis reveals that mortality in this cohort is significantly elevated compared to the general population. To best of our knowledge this is the first real-world study showing malignancy as the predominant cause of morbidity and mortality in rheumatoid arthritis.

REFERENCES:

Disclosure of Interests: None declared
Background: Modern trials in RA often have a strict protocolized treat-to-target design, whereas in daily practice shared decision making is the preferred way to manage treatment.

Objectives: To document the protocol violations in an early RA trial that illustrate potential conflicts between these strategies.

Methods: In the COBRA treat-to-target trial, treatment-naïve early RA patients were classified into a low- and high-risk group, and treated according to two different protocols. Treatment target was minimal disease activity (DAS44 <1.6) and MTX increasing to 25 mg/week): 110 (73%) patients reached the treatment target at 13 weeks. The 31 non-responders were randomized to treatment intensification (n=15) or treatment continuation (n=16) for weeks 14 to 26. Intensification comprised 60 mg/day prednisolone, tapered in 6 weeks to 7.5 mg/day, and addition of sulfasalazine 2000 mg/day and hydroxychloroquine 400 mg/day (COBRA-light). The low-risk group (n=40) was treated with MTX monotherapy increasing to 25 mg/week: only 20 (50%) reached the target at week 13. The 15 non-responders were randomized to treatment intensification with a COBRA-light oral pulse of prednisolone (n=8) or continuation (n=7).

Over the whole study period 79 of 190 patients (42%) had a protocol violation. In the first 13 weeks, 27 (18%) high-risk and 8 (20%) low-risk patients had a protocol violation. In the responders at week 13, 15 (14%) high-risk and 3 (18%) low-risk patients had a protocol violation in week 14-26. In the high-risk non-responders, 18 of 31 had a protocol violation (58%) after randomization at 13 weeks, 11 in the intensification group and 7 in the continuation group (Table). Remarkably, increased intensification of therapy was only found in the continuation group (3 patients); decreased intensification was mainly found in the intensification group (11 patients, vs 3 patients in the continuation group). In the low-risk non-responders, violations occurred in 8 out of 15 (53%) patients after randomization, 4 in both groups.

Table: Protocol treatment violations after randomization of non-responders at week 13 by risk group.

<table>
<thead>
<tr>
<th>Week 14-26</th>
<th>Continuation</th>
<th>Intensification</th>
<th>Continuation</th>
<th>Intensification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 14-26</td>
<td>(16)</td>
<td>(15)</td>
<td>(7)</td>
<td>(8)</td>
</tr>
<tr>
<td>High-risk</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of violations</td>
<td>7</td>
<td>11</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Increased intensity</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatologist</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other physician</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased intensity</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs MTX</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>No MTX due to AEs</td>
<td>1</td>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Rheumatologist</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Rheumatologist, patient</td>
<td>1</td>
<td>7</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Mixed (increase + decrease)</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AEs, A</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maternal</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Violations are categorized by direction of intensification and by reason/initiator.

Conclusion: In this study almost half of the patients had a protocol violation. The high frequency is most likely related to the open design of the trial, the risk of adverse effects through intensification with high dose prednisolone and other DMARDs, the randomization phase, and, last but not least, by the shared decision making. Shared decision making by physician and patient may jeopardize protocol adherence in trials with an open treat-to-target design.

Acknowledgements: We have received an unrestricted grant from Pfizer.

Disclosure of Interests: Linda Hartman: None declared, Linda A. Rasch: None declared, S.A. Turk: None declared, Marieke ter Wee: None declared, Pit J. S. M. Kerstens: None declared, Conny J. van der Laken: None declared, Michael T. Nurmmohamed: None declared, Dirkjan van Schaardenburg: None declared, Lilian H. D. van Tuyl: None declared, Alexandre Voskuyl: None declared, Maarten Boers Consultor of: Novartis, Wilem Lems Speakers bureau: Pfizer, Galapagos, Lilly, Amgen, UCB, Consultant of: Pfizer, Galapagos, Lilly, Amgen, UCB

Background: Little comparative research has been done comparing disease burden between PsA and RA. Previous studies from Nordic countries and the US have shown small differences (0-10/100 VAS units) in patients with PsA vs. RA. The mean and median VAS levels for PsA and RA were 29 (6.10, 51) for female patients with RA. The corresponding values were: fatigue 28 (9, 60) in PsA vs 28 (10, 62) in RA. Median pain was slightly higher in female PsA patients compared to RA patients in age groups older than 50 years. Figure 1 illustrates the mean (95% CI) pain for PsA and RA in the age and sex groups.

Median fatigue levels were quite similar between the groups. The median patient global health was higher in female PsA compared to RA patients in age groups <50 years and 50-60 years (20 vs. 29 and 30 vs 37) (<p=0.001).

Results: Patients with PsA vs RA were younger (mean (sd) age 54(14) vs 62(14)) and less often women (51% vs. 72%). Median (IQR) disease duration after the first symptoms was 8.6 (3.7, 17) years for PsA and 9.5 (3.3, 21) years for RA. The median (IQR) pain was 29 (10, 56) for all patients with PsA and 26 (10,51) for patients with RA. The corresponding values were: fatigue (8, 60) in PsA vs 28 (8, 54) in RA, and patient global health 28 (10, 51) in PsA and 29 (11, 51) in RA. Male pain was slightly higher in female PsA patients compared to RA patients in all age groups (29 and 18, 35 and 28, 32 and 27 and 48 and 38) (<p=0.001). In males, higher levels of pain in PsA vs. RA were seen in age groups older than 50 years old. Figure 1 illustrates the mean (95% CI) pain for PsA and RA in the age and sex groups.

Median fatigue levels were quite similar between the groups. The median patient global health was higher in female PsA compared to RA patients in age groups <50 years and 50-60 years (20 vs. 29 and 30 vs 37) (<p=0.001).

Conclusion: Female patients with PsA report higher levels of pain in all age groups compared to patients with RA. The same was seen in men >50 years old. Concerning fatigue and patient global health, the differences between PsA and RA were smaller. Compared to earlier research in other countries, disease burden observed by PROs appears lower both in PsA and RA in Finland.

References:

Acknowledgements: I would like to thank The Finnish Society for Rheumatology and The Finnish Psoriasis Association for their grants.

Disclosure of Interests: None declared

Figure 1. Mean (95% CI) pain in VAS-units for women and men by age groups in 2020-2021

Conclusion: Female patients with PsA report higher levels of pain in all age groups compared to patients with RA. The same was seen in men >50 years old. Concerning fatigue and patient global health, the differences between PsA and RA were smaller. Compared to earlier research in other countries, disease burden observed by PROs appears lower both in PsA and RA in Finland.
AMCV POSITIVITY AND HIGHER SERUM IP-10 (CXCL-10) LEVEL ARE ASSOCIATED WITH A MORE PRONOUNCED EFFECT OF ABATACEPT THERAPY

M. Borisova1, G. Lukina1, Y. Sigidin1, E. Luchikhina2, D. Karateev2, A. Novikov2, E. Aleksandrova2, M. Cherkasova1, E. Aronova1, S. Giukhova1, E. Nasonov1, V.A. Nasonova Research Institute of Rheumatology, Scientific director, Moscow, Russian Federation; 1V. A. Nasonova Research Institute of Rheumatology, laboratory of monitoring safety of antirheumatic treatment, Moscow, Russian Federation; 2A.S. Loginov Moscow Clinical Scientific Center, Department of rheumatology, Moscow, Russian Federation; 3Moscow Regional Research and Clinical Institute (MONIKI), Department of rheumatology, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 5I.M. Sechenov First Moscow State Medical University, Department of Rheumatology, Moscow, Russian Federation

Background: With the advent of medications with different mechanisms of action in the treatment of rheumatoid arthritis (RA), clinicians face the challenge of choosing the best therapy for each patient. One of the steps in the treatment of RA patients is to identify predictors of the effectiveness of the therapy. This work is devoted to the identification of predictors of the therapy effectiveness with the blocker of T cells co-stimulation - abatacept (ABA).

Objectives: Search for clinical and immunological predictors of the effectiveness of ABA therapy.

Methods: 91 patients were included in the study, most of them women, with high disease activity of RA (DAS28=5.1±1.0, SDAI=28±13.4, CDAI=25±12) and failure of previous biologics (51, 6%) and DMARDs (100%). Moreover, in 20% (n=18) of patients the inefficacy more than 2 biologics were recorded. The average duration of the disease was 3.0 (1-12) years, most patients were positive for RF 72.5%, ACCP 77%, AMCV 86%. In 44 patients the levels of RF, ACCP, AMCV and MMP-3 were assessed after 24 weeks of ABA therapy. In 36 patients enzyme-linked immunosassay was used to measure serum concentrations of biomarkers IL-1β, IL-6, IL-17AF, TNF-α, VEGF-A, IP-10, YKL-40 at baseline and after 24 weeks of ABA therapy. The effectiveness of therapy was assessed according to the EULAR criteria. ABA IV infusions were performed according to the standard schedule. Methods of parametric and non-parametric statistics were used in statistical analysis.

Results: ABA treatment led to a significant decrease of disease activity assessed by DAS28, SDAI, CDAI starting after 3 months of therapy (p<0.05). More than half of the patients were in remission and had low disease activity according to the DAS28 (65.7%, n=35) after 48 weeks of treatment. After 48 weeks, the highest percentage of patients with RA remission was registered by the DAS28 (37.4%, n=20), the lowest — SDAI (21.6%, n=11). After 24 weeks of therapy, ABA led to a significant decrease in the serum levels of IL-6 from 2.4 [1.1 - 6.4] to 1.29 [0.9-2.2] pg/ml (p=0.0006), IP-10 from 21 [12.9-49.8] to 14 [7.5-28] pg/ml (p=0.0007) and matrix metalloproteinase 3 (MMP3) from 30.1 [13-82] pg/ml to 10 [7.4-55] pg/ml (p=0.0003). A decrease in the serum level of IL-6 significantly correlated with a decrease in the DAS28 and SDAI (r=-0.5 and r=-0.479, p<0.05), IP-10 with DAS28 (r=-0.326, p<0.05). Initially, the serum level of TNF-α was significantly lower in patients who achieved low disease activity by the SDAI (72.5%, n=32) after 48 weeks of treatment compared with the rest. On the contrary, a significantly higher level of IP-10 before treatment was recorded in patients with a good response according to the EULAR criteria (39%, n=29) after 48 weeks of ABA treatment (Figure 1). The ROC-analysis revealed that an initially high concentration of TNF-α may indicate with 71% sensitivity and 77% specificity about the possible ineffectiveness of ABA therapy after 48 weeks of treatment, the area under the curve was 0.75 (0.5 - 0.9). In patients initially positive for AMCV, low RA activity by SDAI was significantly more often registered after 24 (p=0.04) and 48 weeks (p=0.01). 89% (n=34) of AMCV-positive patients achieved low disease activity after 48 weeks therapy by the SDAI and CDAI. It is noteworthy that a cohort of patients with insufficient effect after 48 weeks consisted entirely of AMCV-negative patients.

Conclusion: ABA therapy led to a significant decrease in disease activity according to the main indices (DAS28, SDAI, CDAI). During ABA treatment, there was a decrease of important immunoinflammatory markers - IL-6, IP-10, MMP-3. AMCV positivity is significantly associated with higher efficacy of ABA therapy. Also, a high basal concentration of TNF-α could use as a predictor of possible failure of ABA therapy, and a high initial level of IP-10, on the contrary, indicates the possible efficacy of ABA therapy.

References: None

Disclosure of Interests: None declared

groups and define the responsible molecules. Clinical parameters, including inflammation markers, DAS28, and comorbidities, were also included in the analysis, and Spearman correlation coefficient was calculated.

Results: Untargeted NMR data were analyzed with multivariate supervised approach (PLS-DA) revealing distinct metabolic signatures for the 6 groups under investigation. The most defined groups being RAB and RAs, compared to controls, which indicated changes in alanine, tyrosine, lactate and acetone. Besides small molecule, significant changes were also observed in various plasma lipoproteins. For the thorough investigation of these findings, a targeted lipoprotein subclass analysis was conducted and highlighted significantly higher lipoprotein subclass concentrations, including free cholesterol (FC), cholesterol (CH), phospholipids (PL) and apolipoprotein A1 subfractions in RAs compared to controls and Naïve. Concerning metabolite differentiations, RAs patients exhibited reduced ketone bodies and organic acids compared to RAB and control individuals, respectively. All RAs group had lower concentrations of sarcosine. Correlation analysis highlighted the association of DAS28. ESR and CRP with ketone body acetoacetate (p<10^-6) and sarcosine (p<10^-5). VAS correlated with TRIGlyceride subfractions (H1TG and H2TG, p<10^-5) and sarcosine (p=1.8x10^-4). All therapies were found to correlate with lipoproteins; MTX with LDL-2 subfractions (p=5x10^-4), intermedid-density lipoprotein (p=2.7x10^-5) and acetate (p=5.9x10^-6), Anti-IL-6R with triglyceride fractions, IDTG and TPTG (p<10^-3). Anti-CD20 with triglyceride fractions, IDTG and TPTG (p<10^-3).

Conclusion: Overall, these data reveal that RAs have a distinct metabolic signature depending on the time-point of therapy. Clinical parameters correlated with changes in ketone bodies, amino and organic acids, while therapies correlated with lipoproteins. The above analysis indicates that biomarkers revealed by metabolomic profiling can be useful in RA therapy monitoring.

Disclosure of Interests: None declared


Table 1. Associations between the quadriceps muscle morphology by ultrasound (penetration angle) with clinical features, muscle strength, functional capacity and physical function in rheumatoid arthritis patients.

<table>
<thead>
<tr>
<th>Variables</th>
<th>n</th>
<th>Components of the quadriceps muscle</th>
<th>R</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>81</td>
<td>RF</td>
<td>-0.239</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>0.272</td>
<td>0.014</td>
</tr>
<tr>
<td>Disease duration (y)</td>
<td>81</td>
<td>RF</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SPPB (score)</td>
<td>0.262</td>
<td>0.047</td>
</tr>
<tr>
<td>Handgrip strength test (kg)</td>
<td>81</td>
<td>RF</td>
<td>0.224</td>
<td>0.044</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Char stand test (s)</td>
<td>58</td>
<td>RF</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>HAQ (score)</td>
<td>65</td>
<td>RF</td>
<td>-0.404</td>
<td>0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>-0.302</td>
<td>0.015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>-0.290</td>
<td>0.027</td>
</tr>
<tr>
<td>TUG test (s)</td>
<td>68</td>
<td>RF</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>SPPB (score)</td>
<td>58</td>
<td>RF</td>
<td>0.262</td>
<td>0.047</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VI</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VL</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

Studies conducted were included: "DAS28 (disease activity score) categories not trial," and repeated twice, replacing “DAS28” with “CDAI” (clinical disease activity index) and “RAPID3” (routine assessment of patient index data). Activity/severity levels for high, moderate, low, and remission, respectively, are: DAS28 (0-10) >5.1, 3.2–5.1, 2.6–3.2, ≤2.6; CDAI (0-76) >22, 10.1–22, 6.1–10, ≤6.1; RAPID3 (0-30) >12, 6.1–12, 3.1–6, ≤3.0. Mean and/or median DAS28, CDAI, or RAPID3, and/or proportions of patients who were in remission, low, moderate, and high activity/severity were compiled. Results were compared to 3 pre-2010 reports, of which included all 3 indices.

Results: Results from 1985 vs 2000 indicate >50% improvement in swollen joints and physical function, 2 maintained in 2008 and 2010 (data not shown). The
Table 1. Means and/or Medians and categories of DAS28-ESR, DAS28-CRP, CDAI and RAPID3.

<table>
<thead>
<tr>
<th>Category</th>
<th>Index</th>
<th>Mean/Median of Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total classified by categories</td>
<td>41</td>
<td>12</td>
</tr>
<tr>
<td>High or Moderate</td>
<td>35</td>
<td>12</td>
</tr>
<tr>
<td>Low or Remission</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Categories of High or Moderate Activity/Severity vs Low or Remission</td>
<td>41</td>
<td>15</td>
</tr>
<tr>
<td>High or Moderate</td>
<td>35</td>
<td>10</td>
</tr>
<tr>
<td>Low or Remission</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>High or Moderate</td>
<td>6</td>
<td>0</td>
</tr>
</tbody>
</table>

Mean/Median of Index:
High activity/severity: 10, 2, 1, 4, 3
Moderate activity/severity: 39, 18, 6, 9, 6
Low activity/severity: 8, 2, 3, 3, 0
Remission: 0, 0, 0, 0

Conclusion: Most RA patients in post 2011 reports from routine care were in moderate activity according to means or medians or categories, unchanged from 2008 and 2010. Only a minority were classified as in remission or low activity/severity. Optimal RA treatment may require modification of treatment goals, further recognition of differences between patients in clinical trials and routine care, and possible new strategies for earlier identification of RA patients for treatment, in addition to new therapeutic agents.

REFERENCES:
**AB0177** ASSOCIATION OF SEROLOGICAL STATUS WITH THE FREQUENCY OF CLINICAL AND RADIOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS

O. Iaremko, G. Mvykutenko, O.O. Bogomolets National medical university, internal medicine, Kyiv, Ukraine; O.O. Bogomolets National medical university, internal medicine, Kyiv, Ukraine

**Background:** Achieving remission is one of the main goals in the management of patients (pts) with rheumatoid arthritis (RA). According to the literature, one of the determining predictors of the disease course is the serological variant of RA [1]. However, there are conflicting data in scientific publications concerning relationship between the presence/titre of antibodies to cyclic citrullinated peptide (ACCP) or rheumatoid factor (RF) and the frequency/rate of remission [1].

**Objectives:** To examine associations of ACCP- and RF-status with possibility and timing of clinical and radiological remission in Ukrainian pts with RA while taking the main non-biological disease modifying anti-rheumatic drugs (DMARD).

**Methods:** In our multicentre study RF titre was determined by the latex agglutination method (Humatex, Germany), reference values <20 IU/ml; ACCP level - by ELISA (IBL-Hamburg, Germany). The diagnostic limit of ACCP was ≥15U/ml, the maximum value ≥345U/ml. All pts received non-biological DMARD: methotrexate, leflunomide, sulfasalazine or its combination with hydroxychloroquine. At baseline and after 6, 12 and 24 months (mth) of treatment the disease activity and achievement of remission (by DAS28) were compared in different subgroups of RA pts were analysed.

**Results:** 128 pts with RA were included in the study; the mean (SD) age was 54 (12.7) years and follow-up was for 2.0 (1.3) years. Most were women (72.4%), mean disease duration 18.4± 3.18 mth, ACCP-positive were 64.8% and RF - 57.1% pts. According to serological status at baseline, pts were stratified into four classes: ACCP+, ACCP−, ACCP−/RF+, ACCP+/RF−, and ACCP+/RF+ (n=9), dual positive (n=84) and dual negative (n=36). There were no significant differences between the analysed groups in age, sex, RA duration, disease activity, radiological changes and prescribed therapy (p>0.05).

During the 2-year follow-up, clinical remission was achieved in a total of 27 (21.1%) pts, including early remission (during first 6 mth) in 25 (19.5%). The percentage of pts in remission were 36.1, 33.3, 15.8, and 12.5 respectively for RF−, ACCP−, ACCP−/RF+ and RF−/ACCP+ vs ACCP+/RF−, ACCP+/RF+ (p<0.05). The rate of remission (frequency of early remission in the structure of general remission) in four analysed groups did not differ significantly and was 75%, 66.6%, 57.1% pts. According to serological status at baseline, pts were stratified into four classes: ACCP+RF- (n=19), RF+ACCP- (n=9), dual positive (n=64) and dual negative (n=36). There were no significant differences between the analysed groups in age, sex, RA duration, disease activity, radiological changes and prescribed therapy (p>0.05).

At baseline and after 6, 12 and 24 months (mth) of treatment the disease activity in patients (pts) with Difficult-to-Treat Rheumatoid Arthritis (D2T) was slightly lower (p>0.05), and systemic glucocorticoids (GC) was significantly higher (OR=3.7 [1.3-10.8]; p<0.01).

**Conclusions:** In pts with RA, with ineffectiveness of bDMARD/tsDMARD taken from other RA patients with the ineffectiveness of previous bDMARD/tsDMARD, the higher inflammatory activity in CRP (p=0.04) with a higher frequency of systemic GCs (OR=3.7 [1.3-10.8]; p<0.01).

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2353

---

**Table 1. Indicators of disease activity and concomitant therapy in the study groups**

<table>
<thead>
<tr>
<th>D2T</th>
<th>C (n=87)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TJC, М±SD</td>
<td>9.1±4.8</td>
<td>10.6±5.7</td>
</tr>
<tr>
<td>CRP, Me [25; 75%], mg/l</td>
<td>28.3[5; 67]</td>
<td>7.9[5; 44]</td>
</tr>
<tr>
<td>ESR, Me [25; 75%], mm/hr</td>
<td>53.5[8; 98]</td>
<td>27 [14; 56]</td>
</tr>
<tr>
<td>CRP, Me [25; 75%], mg/l</td>
<td>28.3[5; 67]</td>
<td>7.9[5; 44]</td>
</tr>
<tr>
<td>CRP</td>
<td>5.5±1.3</td>
<td>5.7±1</td>
</tr>
<tr>
<td>Duration of morning joint stiffness, min</td>
<td>120±79</td>
<td>135.5±94</td>
</tr>
<tr>
<td>Taken classic DMARDs, n/%</td>
<td>21 / 80,8</td>
<td>46 / 52,9</td>
</tr>
<tr>
<td>Taken GC dose in terms of prednisolone, mg/day</td>
<td>21 / 80,8</td>
<td>46 / 52,9</td>
</tr>
</tbody>
</table>

**Conclusion:** Pts with D2T RA during an exacerbation of the disease differed from other RA patients with the ineffectiveness of previous bDMARD/tsDMARD taken from other RA patients with the ineffectiveness of previous bDMARD/tsDMARD, with a higher inflammatory activity in CRP (p=0.04) with a higher frequency of systemic GCs (OR=3.7 [1.3-10.8]; p<0.01).

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2353

---

**AB0179** PATIENT’S SATISFACTION WITH TREATMENT IN RHEUMATOID ARTHRITIS: AN UNMET NEED

W. Belhai1, S. Miladi1, A. Fazaia2, H. Boussaia2, L. Soueibni2, K. Ouenniche1, S. Kassab3, S. Chekhil3, K. Ben Abdelghani3, A. Laatari3, University of tunis el manar, faculty of medicine of tunis, mongi slim hospital, rheumatology department, tunis, Tunisia

**Background:** Shared decision between rheumatologists and their patients has become an overarching principle in current treatment recommendations in rheumatoid arthritis (RA). Therefore, assessing satisfaction with pharmacological therapy, among patients, is becoming increasingly important in clinical settings.

**Objectives:** In this study, we aimed to assess the satisfaction of patients with RA about their treatment and to investigate the predictive factors.

**Methods:** A cross-sectional study was conducted including adults diagnosed with RA for more than a year and receiving their current Disease-modifying Anti-rheumatic Drug (s) (DMDAR) for at least 12 months. We used the treatment satisfaction questionnaire for medication (TSQM v1.4) to assess the treatment satisfaction among patients. Multivariable regression analysis was applied to determine the factors associated with treatment satisfaction.

**Results:** We included 70 patients (63F/7M) with a mean age of 57.8±10.6 [29-81] years at the time of the study. The mean disease duration was 13.7±22 [3-30] years. Twenty-four (34.2%) patients were on a biologic DMARD (bDMARD). Regarding the Disease Activity Score 28 (DAS28-ESR), 14.3% of patients had a low disease activity, 47.1% a moderate disease activity, 7.1% a high disease

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2297
activity, and 31.4% were in clinical remission. The mean (SD) Rheumatoid Arthritis Impact Disease (RAID) overall score was 4.72 ±2.11. Mean (SD) TSOQ scores were 65.42±14.77 for convenience, 68.71±18 for effectiveness, 70.60±24.5 for side effects, and 67.95±17.10 for global satisfaction.

Twenty percent of patients were satisfied with convenience, 38.6% were satisfied with effectiveness, 45.7% were satisfied with side effects and 30% were globally satisfied. The multivariable regression analysis showed that the RAID overall score was inversely associated to global satisfaction (p=0.001) and to satisfaction with effectiveness (p=0.032).

Difficulty of coping (one of the RAID domains) was inversely associated to satisfaction with effectiveness and convenience. It was, also, showed that satisfaction with side effects was inversely associated to the degree of interference of the RA on domestic work (p=0.020) and positively correlated to the degree of participation in treatment decision-making (p=0.014). In addition, satisfaction with current physician was positively associated to global satisfaction (p=0.029).

Satisfaction with convenience was inversely associated to bDAMARs (p=0.027). Conclusion: We conclude from our data that despite the diversity of therapeutic strategies, almost two-thirds of patients remain satisfied with their treatment. A better understanding of patients’ unmet needs and an individualized patient-centric approach would improve outcomes in RA.

Disclosure of Interests: None declared


Table 1. Area under the curves (AUC) of receiver operating characteristic curves for the predictive value of the composite disease activity indices for radiographic progression. DAIs disease activity index; DAS28, disease activity score for 28 joints; GS, grey scale; PD, power Doppler; SDAI, simplified disease activity index; SJC: swollen joint count; + positive

<table>
<thead>
<tr>
<th>Disease activity indices</th>
<th>All series</th>
<th>Series with ≥ 2 DAIs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>95% CI</td>
<td>95% CI</td>
</tr>
<tr>
<td>DAS28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28_GS</td>
<td>.58</td>
<td>.52 .58 .62 .45 .78</td>
</tr>
<tr>
<td>DAS28_PD</td>
<td>.56</td>
<td>.49 .56 .62 .44 .80</td>
</tr>
<tr>
<td>SJC replaced by GS+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28_GSDP</td>
<td>.57</td>
<td>.50 .57 .62 .44 .80</td>
</tr>
<tr>
<td>SJC replaced by GS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28_plus_GS</td>
<td>.57</td>
<td>.50 .57 .62 .44 .80</td>
</tr>
<tr>
<td>SJC supplied by GS+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28_plus_PD</td>
<td>.59</td>
<td>.52 .59 .61 .43 .79</td>
</tr>
<tr>
<td>SJC replaced by PD+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS28_plus_GSDP</td>
<td>.57</td>
<td>.50 .57 .62 .44 .79</td>
</tr>
<tr>
<td>SJC supplied by GS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GSDP</td>
<td>AND PD+ joints</td>
<td></td>
</tr>
<tr>
<td>SJC replaced by GS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI</td>
<td>.57</td>
<td>.50 .57 .48 .26 .70</td>
</tr>
<tr>
<td>SJC replaced by GS+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_GS</td>
<td>.53</td>
<td>.46 .53 .47 .23 .71</td>
</tr>
<tr>
<td>AND PD+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_PD</td>
<td>.58</td>
<td>.52 .58 .51 .27 .75</td>
</tr>
<tr>
<td>SJC replaced by PD+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_GSDP</td>
<td>.53</td>
<td>.46 .53 .47 .23 .71</td>
</tr>
<tr>
<td>SJC replaced by GS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_plus_GS</td>
<td>.54</td>
<td>.47 .54 .47 .23 .70</td>
</tr>
<tr>
<td>SJC supplied by GS+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_plus_PD</td>
<td>.58</td>
<td>.51 .58 .48 .25 .72</td>
</tr>
<tr>
<td>SJC replaced by PD+ joints</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SDAI_plus_GSDP</td>
<td>.54</td>
<td>.47 .54 .46 .23 .70</td>
</tr>
<tr>
<td>AND PD+ joints</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: The predictability of radiographic progression by disease activity measures was generally limited. The composite USDAIs containing sonographic JC were not superior for predicting radiographic progression compared to their clinical counterparts although there was a trend for higher predictive value for indices containing PD.

REFERENCES:

Disclosure of Interests: Irina Gessl: None declared, Thomas Deimel: None declared, Paul Studenic: None declared, Giorgio Tamborrini: None declared, Pascal Zufferey: None declared, Daniel Aletaha: Speakers bureau: Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofi, Burkhard Moeller: None declared, Peter Mandl Speakers bureau: from Abbvie, Janssen and Novartis, Grant/research support from: from Abbvie, BMS, Novartis, Janssen, MSD and UCB

Background: The pharmacotherapy for rheumatoid arthritis (RA) has changed dramatically and caused a paradigm shift with the advent of methotrexate (MTX) and biological disease-modifying antirheumatic drugs (bDMARDs). Before the paradigm shift of RA therapy, the frequency of carpal collapse was high in patients with RA. It has been reported that certain numbers of patients with RA rapidly advance the destruction of the carpal bones during the early onset in the natural course of it [1].

Another report showed that hand function was positively correlated with disease activity [2]. In Japan, bDMARDs were approved in 2003, and the maximum allowable dose of MTX was raised from 8 mg/week to 12 mg/week in 2012. The usage rate of MTX was 56.3% in 2009, 76.9% in 2014, and 50% in 2019, respectively. There was no significant difference in the rate and dosage of MTX use in each year. There was also no significant difference in the mean value of DAS28-CRP at the time of initial examination. The mean age at the time of initial examination was 55 years (30-72).

Methods: Patients with early RA diagnosed in our department in 2009, 2014, and 2019 were included in the study. The CHR was measured at the first visit and two years later on radiographs of both hands. The drug history for RA was obtained in the medical records retrospectively. All statistical analyses were performed with EZR version 1.55.

Results: This study included 43 cases (36 females, 7 males). The number of cases in 2009, 2014, and 2019 was 16, 13, and 14, respectively. Two years later, the right-hand CHR was 0.514 (0.467-0.561), 0.549 (0.493-0.617), and 0.562 (0.528-0.591), respectively, with no significant difference. The right hand CHR of initial diagnosis was 0.554 (0.484-0.632), 0.551 (0.490-0.618), and 0.567 (0.517-0.632) in 2009, 2014, and 2019, respectively, with no significant difference. The right-hand CHR was 0.532 (0.444-0.627), 0.529 (0.478-0.586), and 0.548 (0.491-0.593), respectively, with no significant difference. The left hand CHR of initial diagnosis was 0.522 (0.475-0.602), 0.539 (0.459-0.589), and 0.557 (0.506-0.635) in 2009, 2014, and 2019, respectively, with no significant difference.

Disclosure of Interests: None declared

AB0182
THE PROFILE OF POOR PROGNOSTIC FACTORS BASED ON EULAR RECOMMENDATIONS IN CHINESE RA PATIENTS: A SINGLE-CENTER OBSERVATIONAL STUDY
Y. Gu1, Z. Zhang1, J. Zhao1. Peking University First Hospital, Rheumatology and Clinical Immunology, Beijing, China

Background: Despite the constant updating of rheumatoid arthritis (RA) treatment strategies, whether poor prognostic factors (PPFs) can guide RA treatment is still controversial. There are limited data about the presence of PPFs in Chinese RA patients.

Objectives: To describe the profile of PPFs based on European League Against Rheumatism (EULAR) recommendations in Chinese RA patients, and explore the significance of these factors in adjusting treatment therapy.

Methods: In this real-world study, RA patients were enrolled from 2012 to 2020. The baseline characteristics and prognostic factors based on EULAR recommendations include acute-phase reactant levels, rheumatoid factor (RF), anti-cyclic citrullinate peptide (anti-CCP antibody), swollen joint counts (SJC), early bone erosions, and responses to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) at month 3 or month 6 were collected. Disease activity was assessed by disease activity score of 28 joints-erythrocyte sedimentation rate (DAS28-ESR), DAS28-C-reactive protein (DAS28-CRP), simple disease activity index (SDAI), and clinical disease activity index (CDAI). The association of different factors was represented by a Venn diagram. The number of patients presenting with different combinations of prognostic factors was graphically displayed by UpSetR. Correlation between binary variables was analyzed by the Chi-square test.

Results: 1252 registered RA patients were enrolled. 901/1252 (72.0%) patients had elevated ESR or CRP and 1027/1164 (88.2%) patients had positive RF or anti-CCP antibody. 97/1252 (31.7%) patients had early bone erosions. 166/444 (37.0%) patients had early bone erosions, which usually coexisted with other PPFs. 394 (34.4%) of the 1105 patients who received csDMARD therapy as prescrd had persistent moderate or high disease activity (MDA/HDA). Failure of two or more csDMARDs was found in 245 (22.2%) patients. 99% of RA patients had at least one PPF. Patients with MDA/HDA usually coexisted with other PPF. MDA/HDA was significantly correlated with elevated ESR/CRP or high SJC and is not correlated with positive RF/anti-CCP antibody or early bone erosion.

Conclusion: PPFs are prevalent in RA patients in real-world data. It is inappropriate to guide treatment strategies just based on the presence or absence of PPFs. The categories of PPFs should be simplified and the role of different combinations of PPFs in guiding treatment therapies remains to be explored.

REFERENCES:
Objective: To identify subgroups with distinct trajectories of DAS28-CRP in pts with RA.

Methods: Longitudinal data from adult RA pts presenting to a tertiary centre were used. Socio-demographic data, disease characteristics and standard assessments including established outcome parameters for disease activity (DAS28-CRP) and physical function (FFBH) were retrospectively analysed. Group-based

table 1. Patients demographics and disease characteristics at baseline in trajectory groups

<table>
<thead>
<tr>
<th>Class 1</th>
<th>Class 2</th>
<th>Class 3</th>
<th>Class 4</th>
<th>Class 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N=10)</td>
<td>(N=36)</td>
<td>(N=56)</td>
<td>(N=23)</td>
<td>(N=9)</td>
</tr>
<tr>
<td>Age, years</td>
<td>65.8 (12.7)</td>
<td>60.6 (10.6)</td>
<td>56.7 (16.0)</td>
<td>50.5 (15.4)</td>
</tr>
<tr>
<td>Gender, female</td>
<td>80.0% (N=8)</td>
<td>77.8% (N=28)</td>
<td>82.1% (N=46)</td>
<td>52.2% (N=12)</td>
</tr>
<tr>
<td>Education level</td>
<td>0.0% (N=0)</td>
<td>11.1% (N=4)</td>
<td>16.1% (N=9)</td>
<td>21.7% (N=5)</td>
</tr>
<tr>
<td>Employment</td>
<td>10.0% (N=1)</td>
<td>33.3% (N=12)</td>
<td>53.6% (N=30)</td>
<td>61.8% (N=16)</td>
</tr>
<tr>
<td>Body mass index</td>
<td>30.6 (5.4)</td>
<td>27.8 (4.3)</td>
<td>27.1 (4.7)</td>
<td>25.2 (4.2)</td>
</tr>
<tr>
<td>Symptom duration, years</td>
<td>12.8 (7.3)</td>
<td>10.4 (6.3)</td>
<td>9.5 (5.6)</td>
<td>6.7 (3.6)</td>
</tr>
<tr>
<td>Anti-CPP</td>
<td>49.2 (63.9)</td>
<td>101.3 (89.7)</td>
<td>98.6 (95.6)</td>
<td>94.9 (78.2)</td>
</tr>
<tr>
<td>CRP</td>
<td>1.0 (1.3)</td>
<td>0.7 (0.9)</td>
<td>0.4 (0.4)</td>
<td>0.4 (0.5)</td>
</tr>
<tr>
<td>Erosions</td>
<td>20.0% (N=2)</td>
<td>20.3% (N=4)</td>
<td>20.8% (N=2)</td>
<td>25.5% (N=6)</td>
</tr>
<tr>
<td>At least one</td>
<td>100.0% (N=10)</td>
<td>94.4% (N=34)</td>
<td>78.6% (N=44)</td>
<td>65.2% (N=15)</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>1.1 (1.4)</td>
<td>1.1 (1.3)</td>
<td>0.6 (0.9)</td>
<td>0.4 (0.7)</td>
</tr>
<tr>
<td>Comorbidity Index (0-29)</td>
<td>0.0% (N=0)</td>
<td>0.0% (N=0)</td>
<td>2.9% (N=1)</td>
<td>15.4% (N=2)</td>
</tr>
<tr>
<td>No. of patients on steroids</td>
<td>77.8% (N=7)</td>
<td>45.8% (N=11)</td>
<td>41.2% (N=14)</td>
<td>30.8% (N=4)</td>
</tr>
<tr>
<td>No. of patients on sDMARD</td>
<td>0.0% (N=0)</td>
<td>0.0% (N=0)</td>
<td>5.9% (N=2)</td>
<td>7.7% (N=1)</td>
</tr>
<tr>
<td>No. of patients on tsDMARD</td>
<td>6.1 (18.8)</td>
<td>5.8 (18.6)</td>
<td>4.2 (2.0)</td>
<td>2.3 (2.6)</td>
</tr>
<tr>
<td>Pain (NRS 0-10)</td>
<td>6.5 (2.8)</td>
<td>5.3 (1.7)</td>
<td>3.7 (2.1)</td>
<td>2.8 (3.0)</td>
</tr>
<tr>
<td>Patient Global</td>
<td>DAS28-CRP</td>
<td>5.3 (12.0)</td>
<td>3.9 (0.7)</td>
<td>2.5 (0.7)</td>
</tr>
<tr>
<td>FFBH</td>
<td>38.5 (29)</td>
<td>48.8 (21.6)</td>
<td>74.2 (18.9)</td>
<td>90.4 (8.8)</td>
</tr>
<tr>
<td>RAID (0-10)</td>
<td>6.5 (2.0)</td>
<td>5.3 (2.1)</td>
<td>3.8 (1.8)</td>
<td>1.8 (1.3)</td>
</tr>
</tbody>
</table>
trajectory modelling (GBTM) was used to identify homogeneous classes of DAS28-CRP trajectories, where the number of classes was selected using Nagin’s Bayesian information criterion (BIC). Differences between the identified classes and clinical variables were studied.

**Results:** Data of 134 pts with 849 DAS28-CRP values were analysed. Retrospective chart data were available for a follow-up of 33.7 (SD 18.0) months. One third of pts already had erosions and severe limitations in physical functioning. About half of the pts were on bDMARDs and <20% on steroids. Five distinct classes of DAS28-CRP trajectories were identified (Figure 1). These groups were subsequently categorized as 1) high-increasing, 2) high-stable, 3) low-increasing, 4) low-decreasing disease activity, and 5) remission. Pts’ characteristics at baseline in each trajectory group are shown in Table 1. Group 4 had a shorter disease duration but more erosions, a better function and a higher educational level than seen in other groups. The increase of disease activity in group 3 was modest.

**Conclusion:** Using GBTM five distinct trajectories in pts with RA were identified. Only a small proportion of pts showed a reduction in disease activity over time, whereas the largest proportion of pts showed rather constant high or constant low disease activity. The cohort size may have impacted the modelling and further analyses in larger cohorts are needed. Importantly, even though well established in our hospital it is unclear how consequent the T2T strategy was followed and which intervention was successful to reach remission. The impact of pts global assessment on DAS28 values also needs further study.

**REFERENCES:**

[1] Nikophorou Rheumatol 2020

Disclosure of Interests: None declared


**AB0185**

**PHENOTYPES OF DRUG-FREE RHEUMATOID ARTHRITIS FLARE AND IMPACT OF RESIDUAL SUBCLINICAL ECOCOGRAPHIC JOINT INJURY IN ACPA POSITIVE AND ACPA NEGATIVE DISEASE**

E. Bozza1,2, G. Gringaschi1,2, B. Xoo1, M. I. Greco1, T. Luvara1, I. Mazzucchelli1, S. Bugatti1,2, C. Montecucco1,2, A. Manzo1,2, 1IRCCS Policlinico San Matteo Foundation, Rheumatology, Pavia, Italy; 2University of Pavia, Department of Internal Medicine and Therapeutics, Pavia, Italy

**Background:** The mechanisms of flare across the pathogenic spectrum of RA remain unclear. To what extent RA flare reproduces the dynamics of disease onset or is primarily driven by new dynamics is not known. Furthermore, the hypothesis of a role for circulating auto-antibodies in determining different mechanism behind flare has never been challenged.

**Objectives:** To evaluate whether RA flare after remission achievement reproduces the phenotype of onset or it is characterized by a different phenotype primarily driven by the pattern of residual joint injury after treatment, in ACPA positive and negative patients.

**Methods:** S3 RA patients, in stable drug-free remission (DFR) after early csDMARDs introduction and displaying clinical flare across 60 months of follow-up were analysed for clinical, laboratory and ultrasound (US) characteristics at diagnosis, treatment discontinuation, and flare (DAS28 and/or physician-based character), the synovitis clinical phenotype (ACR 1987 criteria defined districts); PROs and the inflammatory status at disease flare versus onset. We then measured the impact of residual subclinical US joint injury (absence of objective synovitis and GS>1 and/or PD>0) at the time of drug discontinuation, on the synovitis clinical phenotype of flare. Finally, we explored differences in the outcomes in ACPA positive and negative RA.

**Results:** Cohort characteristics are shown in Table 1. As inferred by paired analyses, no significant differences were observed between onset and flare concerning composite indices of disease activity, and subjective/semi-objective domains. However, flare appeared to be significantly less inflammatory in terms of CRP, ESR, SJC, PGA, morning stiffness and HAQ (p<0.05). These differences remained after adjustment for diagnostic delay including only very early RA patients (<3 months from symptoms onset). The evaluation of the frequency of articular districts involvement revealed no difference between onset and flare both for SJC and TJC (Figure 1). However, the percentage of SJs at flare being present at onset showed a high variability among patients. Stratification for ACPA status demonstrated a significantly higher recurrence of synovitis in joints involved at onset in ACPA negative vs ACPA positive patients (p<0.05). The percentage of SJs at flare presenting residual subclinical US injury at the time of drug discontinuation was significantly higher in ACPA negative vs ACPA positive patients (p<0.05) and negatively correlates with the ACPA titer (R 0.354, p>0.05).

**Table 1.** Comparison between Onset and Flare

<table>
<thead>
<tr>
<th></th>
<th>Onset, median (IQR)</th>
<th>Flare, median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, female (%)</td>
<td>34 (64)</td>
<td>\</td>
</tr>
<tr>
<td>Age at Symptoms onset (yrs)</td>
<td>57 (43-65)</td>
<td>57 (43-65)</td>
</tr>
<tr>
<td>Diagnostic delay(months)</td>
<td>3 (2-7)</td>
<td>1.5 (1-2) *</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>0.640 (0.307-2.11)</td>
<td>0.370 (0.220-1.05) §</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.625 (0.375-1.13)</td>
<td>0.438 (0.125-0.875)</td>
</tr>
<tr>
<td>GH</td>
<td>40.0 (36.5-50.0)</td>
<td>40.0 (30.0-50.0)</td>
</tr>
<tr>
<td>PGA</td>
<td>50.0 (270-66.5)</td>
<td>49 (20.0-70.0)</td>
</tr>
<tr>
<td>EGA</td>
<td>38.0 (270-60.0)</td>
<td>40.0 (30.0-60.0)</td>
</tr>
<tr>
<td>SJC/66</td>
<td>7 (4.00-10.0)</td>
<td>4 (3.00-6.00) §</td>
</tr>
<tr>
<td>TJC/48</td>
<td>5 (2.00-10.0)</td>
<td>5 (2.00-11.0)</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>4.55 (3.29-5.6)</td>
<td>3.98 (3.56-6.6)</td>
</tr>
<tr>
<td>Morning Stiffness (minutes)</td>
<td>60.0 (113.90.0)</td>
<td>100 (100-30.0) §</td>
</tr>
</tbody>
</table>

Index: *significant compared to onset, § significant compared to onset considering only VERA

**Disclosure of Interests:** None declared


**Conclusion:** RA flare in patients achieving DFR seems to be less severe in terms of inflammatory markers and synovitis recurrence, despite a similar degree of joint tenderness and patients’ perception compared to disease onset. The arthritis phenotype undergoes detectable changes more in ACPA positive than negative patients. The residual subclinical US joint damage seems to drive the localization of synovitis recurrence in ACPA negative more than positive patients, supporting the existence of pathologic differences in the process of disease reactivation in the two groups.
Background: The paradigm shift has caused in the treatment for rheumatoid arthritis (RA) before the last decade [1]. The advent of high-dose MTX and biologics has made it possible to treat RA with early and aggressive therapy, and prevent the joint destruction [2].

Objectives: To investigate the joint destruction and clinical outcomes in patients with early RA every 5 years in the last decade.

Methods: 81 patients with early RA (within 1 year from their onset of RA) enrolled retrospectively in this study. The number of patients with early RA were 21 in 2009, 23 in 2014, and 37 in 2019, respectively. They had 17 males and 64 females. Mean age was 59 years (19-92) at the first visit to our department. The following items were investigated: age, disease duration from onset to consultation, anti-cyclic citrullinated peptide antibody (ACPA) positivity (positivity was defined as >4.5 U/ml), CRP, DAS28CRP4, medications, and modified total sharp score (mTSS) at the time of initial consultation and 1 year later, Kruskal-Wallis test was used for statistics (PASW 25 software, SPSS Institute Inc., Chicago, IL, USA, p<0.05).

Results: The ACPA positivity rates were 71.4% (15/21) in 2009, 78.3% (18/21) in 2014, and 78.4% (29/37) in 2019, respectively. The mean value of DAS28CRP4 was 4.7 (2.4-6.8) in 2009, 4.2 (1.2-6.2) in 2014, and 4.2 (2.1-6.7) in 2019 at the time of the first visit to our department respectively. DAS28CRP4 under 2.6 was 29% (6/21) in 2009, 61% (14/23) in 2014, and 54% (20/37) in 2019 1 year after the first visit. The mean improvement of DAS28CRP4 (ΔDAS28CRP4) was -1.7 (-3.9 to -0.1) in 2019, -1.5 (-4.0 to -1.7) in 2014, and -1.7 (-4.1 to -0.4) in 2019, respectively. It had tended to improve gradually, however, it was not significantly different (p=0.20, Figure 1).

![Figure 1. Mean value of improvement of mTSS and DAS28CRP4 (ΔmTSS and ΔDAS28CRP4) from initial visit to 1 year later at 2009, 2014 and 2019.](image)

The changing of mTSS for a year (ΔmTSS) was 4.2 (0-17) in 2009, 0.9 (0-10) in 2014, and 0.6 (0-4) in 2019, respectively. ΔmTSS in 2014 and 2019 was significantly lower compared to that in 2009 (p<0.001, Figure 1).

One year after the first visit to our department, the mean dose of MTX increased to 9.2 mg/week (2-14) in 2014 and 8.7 mg/week (4-16) in 2019 compared to 6.6 mg/week (2-8) in 2009.

The intensive therapy for early RA at our hospital has shown the improvement of joint destruction in the last decade.

REFERENCES:
treatment target are increasing in rheumatoid arthritis (RA). On the other hand, it is also true that some patients are still using prednisolone (PSL). Recently, ultrasound has played a role of sensitive imaging modality in the diagnosis and follow-up of patients with RA. It is known that residual synovitis was found in ultrasound even in patients with clinical remission.

**Objectives:** We investigated the differences of ultrasonographic intra-articular synovitis findings between treatment drugs in patients with RA.

**Methods:** From January 2017 to August 2020, 750 RA patients who underwent ultrasound examination were included. A US examination was performed at the bilateral first to fifth metacarpophalangeal (MCP) joints, first interphalangeal (IP) and second to fifth proximal interphalangeal (PIP) joints, wrist joints (three part of radial, medial and ulnar) and first to fifth metatarsophalangeal (MTP) joints, by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18-6 MHz). The gray scale and power Doppler findings were assessed by the semi-quantitative method (0-3). All patients were divided into with or without BIO/JAK, methotrexate (MTX) and PSL. Then, patients were matched using the propensity score adjusted for gender, age, RA disease duration, disease activity, CRP value, and MMP-3 value. The total gray scale and power Doppler score (GSUS / PDUS) were compared between treatment drugs of RA by using propensity score matching methods.

**Results:** The average age of 750 RA patients were 64.5 years and an average disease duration of RA was 13.9 years and females were 581 (77.5%). There were 517 patients (68.9%) treated with BIO/JAK and 233 patients treated without BIO/JAK. The 205 patients in each group were matched. GSUS were 10.6±11.1 vs 9.2±10.4 (p=0.218) and PDUS 7.4±9.2 vs 6.5±9.0 (p=0.328). Ultrasound residual synovitis was not different between with or without BIO/JAK in matched patients. There were 525 patients (70.0%) treated MTX, the average MTX dose was 9.3±9.3, and 225 patients treated without MTX. The 203 patients with or without MTX in each group were matched. GSUS were 9.7±10.6 vs 11.4±12.0 (p=0.119) and PDUS 6.6±8.8 vs 8.1±10.1 (p=0.117). Ultrasound residual synovitis was not different between with or without BIO/JAK in matched patients. There were 111 patients (14.8%) treated PSL, the average dose was 4.0mg, and 639 patients treated without PSL. The 205 patients with or without PSL in each group were matched. GSUS were 15.7±13.9 vs 11.6±10.6 (p=0.018) and PDUS 6.6±8.8 vs 8.1±10.1 (p=0.117). Ultrasound residual synovitis was more severe treated with PSL than without PSL in matched patients.

**Conclusion:** In a comparison between RA patients matched backgrounds such as disease activity, there was no difference in ultrasound residual synovitis between patients with or without BIO/JAK and MTX. However, there was significant difference in patients with or without PSL. This suggests that PSL use suppresses clinical symptoms but does not improve synovitis. Thus, it should be noted that joint destruction may progress in patients treating with PSL.

**REFERENCES:**


**DOI:** 10.1136/annrheumdis-2022-eular.3021
Hospitáli University of São João, Rheumatology Department, Porto, Portugal; 2Facultad of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 3Facultad of Medicine, University of Porto, Department of Rhematology, Porto, Portugal; 4Centro Hospitalar Vila Nova de Gaia / Espinho, Rheumatology Department, Vila Nova de Gaia, Portugal; 5Centro Hospitalar Universitário do Algârve, Rheumatology Department, UNIAO FREGUESIAS FARO SE SA PEDRO, FARO, Portugal; 6Centro Hospitalar Tondela-Viseu, Viseu, Rheumatology Department, Viseu, Portugal

Background: Fatigue is one of the major complaints of patients with rheumatoid arthritis (RA). However, the literature relating fatigue to other disease-related parameters has presented discrepant results and longitudinal studies with multivariate analyses are scarce.

Objectives: To explore potential associations between fatigue and demographic variables and other patient-reported outcomes (PROMs) in patients with RA treated with biological disease-modifying antirheumatic drugs (bDMARDs) over the time.

Methods: A 24-month (24M) monocentric observational retrospective cohort study was conducted. Patients diagnosed with RA, according to the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria, and registered on the Rheumatic Diseases Portuguese Register (Reuma.pt) who started their first bDMARD between 2015 and 2021 were included. Age, gender, disease duration, body mass index (BMI) and PROMs were obtained by consulting Reuma.pt. Fatigue was monitored at baseline, 12 and 24M using Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), a 13-item questionnaire with a total score ranging from 0 to 52. A score ≥ 29 indicates the presence of clinically significant fatigue. Health Assessment Questionnaire (HAQ), EuroQol-5D (EQ-5D), 36-item Short Form Survey (SF-36), patient global assessment visual analogue scale (VAS) and pain VAS were assessed at baseline, 12 and 24M. Multivariate linear regression models were conducted with FACIT-F as the dependent variable.

Results: A total of 40 patients (47±11.4 years; 90.2% female) with a BMI of 29.87±8.54 kg/m² and a mean disease duration of 10.4±5.6 years were included. A total of 473% of patients were treated with an anti-TNF. About 85% of patients had clinically significant fatigue at baseline (FACIT-F 26.9±11.8). At baseline, patient global assessment VAS (β=-0.9, 95%CI [-1.6; -0.29]) and pain VAS (β=-0.34, 95%CI [-0.6; -0.08]) predicted fatigue. SF-36 predicted fatigue at baseline (β=-0.35, 95%CI [0.14;0.56]), 12M (β=0.23, 95%CI [0.084;0.37]) and 24M (β=-0.35, 95%CI [0.13;0.59]). HAQ predicted fatigue at baseline (β=12.2, 95%CI [19.8; -4.53]) and 24M (β=11.4, 95%CI [-17.4; -5.38]). EQ-5D (β=-39.5, 95%CI [15.84; 63.22]) predicted fatigue at 24M.

Conclusion: Our results showed that pain levels and patient global assessment of disease activity predicted a higher level of fatigue at baseline. The decrease in physical function and a worse overall health status perceived by patient predicted higher fatigue over the time. Previous research has suggested that disease-related factors, such as inflammation, pain or decreased physical function are associated with greater fatigue in RA (1). These findings encourage the pre-treatment screening of fatigue in patients with RA in order to design individualized non-pharmacological approaches in addition to bDMARDs therapy.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Anti-CarP autoantibody status in RA vs PR patients.

<table>
<thead>
<tr>
<th>RA (n=125)</th>
<th>PR (n=45)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal calf serum</td>
<td>anti-FCS-CarP-IgG positive, n (%)</td>
<td>78 (62.4)</td>
</tr>
<tr>
<td>median titer, AU/mL (IQR)</td>
<td>62 (57)</td>
<td>75 (249)</td>
</tr>
<tr>
<td>(FCS-CarP)</td>
<td>anti-FCS-CarP-IgA positive, n (%)</td>
<td>47 (37.6)</td>
</tr>
<tr>
<td>median titer, AU/mL (IQR)</td>
<td>161 (308)</td>
<td>14 (97)</td>
</tr>
<tr>
<td>(Fib-CarP)</td>
<td>anti-Fib-CarP-IgG positive, n (%)</td>
<td>90 (70.4)</td>
</tr>
<tr>
<td>median titer, AU/mL (IQR)</td>
<td>87 (69.6)</td>
<td>9 (20)</td>
</tr>
<tr>
<td>(Fib-CarP)</td>
<td>anti-Fib-CarP-IgA positive, n (%)</td>
<td>92 (71.7)</td>
</tr>
<tr>
<td>median titer, AU/mL (IQR)</td>
<td>129 (132)</td>
<td>75 (249)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared


AB0192

Antibodies Against Modified Protein/Peptide Specificities in Recent-Onset Palindromic Rheumatism May Determine the Evolution to Rheumatoid Arthritis

G. García-Moreno1, R. Morlát1, B. Frade-Sosa2, L. Tobarina1, M. J. Gomara1, R. Sammarti1,2, I. Harón1 on behalf of PALABA study investigators, 1Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), Unit of Synthesis and Biomedical Applications of Peptides., Barcelona, Spain; 2Hospital Clinic de Barcelona, Arthritis Unit. Department of Rheumatology, Barcelona, Spain

Background: Palindromic rheumatism (PR) may evolve to rheumatoid arthritis (RA), particularly in patients with autoantibodies such as rheumatoid factor (RF) or antibodies against modified proteins (AMPA), anti-citrullinated peptide antibodies (ACPA) or anti-carbamylated antibodies (anti-CarP) (1,2). We hypothesized that the specificities and isotype usage of ACPA and anti-CarP may differ between recent-onset PR and established RA, and this could help ascertain the evolution to RA in PR patients.

Objectives: To determine differences in the recognition of epitopes between patients with recent-onset PR and established RA by analysis of AMPA specificities and isotypes.

Methods: Subanalysis using preliminary data of the PALABA study. Two populations included: patients with recent-onset PR included in the PALABA multicenter randomized clinical trial (abatacept vs hydroxychloroquine) at study entry (NCT03669367) and patients with established RA (ACR/EULAR 2010) as controls previously selected from an observational study (3). Only RF and/or ACPA (CCP2) positive patients were selected. PR patients were DMARD naïve and RA patients receiving rituximab or abatacept were excluded. AMPA specificities and isotypes in sera were determined by in-house ELISA tests using antigens two carbamylated proteins and a panel of chimeric peptides derived from fibrin and filaggrin proteins bearing one to three post-translational modifications (citrullination, carbamylation and acetylation) (4). The cut-off for ELISA tests was established by ROC curves, with a specificity of 95% compared with a healthy population. The frequency and titers of the AMPA isotypes (IgA, IgG, IgM) was analyzed. Results: 45 PR patients (77.6% female), with a mean age of 49.3 (±11) years and a mean disease duration of 9.6 (±6.1) months and 125 RA patients (75.6% female) were recruited. Anti-CarP autoantibody status in RA vs PR patients.
females) with a mean age of 59.6 (±13) years and a mean disease duration of 772.7 (±59.7) months. RF and ACRA (CCP2) were positive in 80% and 91.1% of PR patients and 77.6% and 86% of RA patients (p>0.05). Although both populations presented a similar frequency and activity with RA. The absence of IgA ACRA isotypes and, especially, anti-CarP in the early stages of PR may be associated with a lower rate of progression to RA.

REFERENCES:


Disclosure of Interests: Cristina Garcia-Moreno: None declared, Rosa Morló: None declared, Beatriz Frade-Sosa: None declared, Lola Tobalina: None declared, Maria José Gomara: None declared, Raimón Sanmartí Speakers bureau: Received speaker honoraria from Abbvie, BMS, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi and Roche, Grant/research support from: investigation grants from Abbvie, BMS, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi and Roche, Isabel Haro: None declared


AB0193 BIOLOGIC DRUGS RETENTION IN ELDERLY RHEUMATOID ARTHRITIS: WHAT FEATURES?

S. Boussaid1, K. Saadouli1, S. Jemmal1, M. Hassayoun1, S. Rekki1, S. Rahmoun1, H. Sahli1, M. Elleuch1.

1Hospital Rabta, Rheumatology, Tunisia, Tunisia; 2University of Tunis El Manar, Faculty of Medicine of Tunis, Tunisia, Tunisia

Background: The elderly RA population is expanding. The management of RA in elderly patients can be challenging because of comorbidities, the frequency of adverse events. The efficacy and safety of RA therapies; particularly biologics drugs (bDMARDs); are poorly studied in this age group.

Objectives: To investigate the therapeutic response to bDMARDs in elderly rheumatoid arthritis.

Methods: We conducted a cross-sectional and observational study. Files of patients with RA on biologics drugs (archived from the files of patients on the National Health Insurance Fund of Tunis) were studied. The characteristics of RA, and the current treatments were studied. We have divided our population into two age groups, G1 aging under 65 years and G2 aged 65 or over. The therapeutically maintenance rate as well as the biologics survival was analyzed using Kaplan-Meier survival curves and compared using the Log-Rank test.

Results: Three hundred and seventy-four files were selected. Their average age was 55±12.54 years (20-90). A female predominance was noted with a sex ratio M/F=1.47. The average duration of RA was 11.7±6.76 years [2-41]. Subjects over the age of 65 represented 22.2% of the workforce, i.e. 83 patients. The first biotherapies prescribed was etanercept in 54% of cases, adalimumab in 14% of cases, certolizumab pegol 13%, infliximab 6%, tocilizumab 6% and rituximab in 7% of cases. The 4-year survival was 54.41% and 60.94% for subjects under 65 and 65 or older, respectively. Treatment maintenance for RA in the elderly (≥ 65 years old) was 42.21 months, [53.51–46.92]. In our study, age did not influence the survival of biologic therapies (HR = 0.997 (p=0.667). Conclusion: RA therapy is generally effective and safe in elderly patients. We did not find any influence of age on survival and therapeutic maintenance of biological treatments. Further studies with a broader spectrum are needed to better understand this notion

Disclosure of Interests: None declared


AB0194 VALIDATION OF ANDROID OPERATED SMARTPHONE PEDOMETER IN PATIENTS WITH RHEUMATOID ARTHRITIS

S. R. Wagner1, R. B. Gregersen1, L. Henriksen1, E. M. Hauge1, K. K. Keller2,3.

1Aarhus University, Department of Electrical and Computer Engineering, Aarhus, Denmark; 2Aarhus University, Department of Clinical Medicine, Aarhus, Denmark; 3Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark

Background: Impact of disease and disease activity in RA is measured with questionnaires such as the health assessment questionnaire (HAQ) or composite scores such as the disease activity score (DAS-28). These methods may miss signs of disease activity because they are typically performed only at hospital visits. Measuring physical activity continually may assist in the early discovery of relapses in the future. In addition, measuring physical activity may be relevant for predicting the risk of developing comorbidities such as cardiovascular disease [1]. Activity tracker devices have been tested in RA patients for this purpose, but the disadvantage is that they can only be carried for a limited period of time and are expensive, which makes them unsuitable for long-term cohort studies [2]. As an alternative, obtaining physical activity data from the patient’s own smartphone using a dedicated and secure activity tracker app incurs no added costs, but the reliability of this method has never been tested in patients with RA.

Objectives: The aim of this study was to validate the use of the standard Android-operated smartphone step-counter pedometer in patients with RA.

Methods: Clinical characteristics were obtained. Two typical Android smartphone running the Android virtual step counter sensor were tested in a treadmill test-bed setup at 6 different speeds, ranging from 2.5 km/h to 5 km/h. Patients walked 100 steps at each test speed wearing the Android devices placed in a stomach pouch. Software running on a Windows PC communicated in real time with both phones, and the PC software also allowed the investigator to easily record the manually observed steps using clicker functionality, which were then automatically linked to the steps recorded from the smartphones.

Results: Median (interquartile range) disease duration was 13 (4-21) years, DAS-28 2.2 (1.6-2.9), and MAHAQ 0.2 (0-0.9). Seventy-six% of the patients were rheumatoid factor positive, 75% were Anti-citrullinated peptide antibody positive, and 70% had erosive disease. The overall difference in device step counts versus the observed was 5.9 ± mean percentage average error for both devices. Most of the error was introduced at the 2.5 km/h speed tests where the mean error of the two devices was 18.5%.

From 3 km/h, the mean average percentage error of the two devices was below 5% and from 3.5 km/h and up the mean average percentage error of the two devices was below 3%. A box plot of the data is demonstrated in Figure 1.

Figure 1. Box plot of number of steps with both devices at the six different speeds.

Both walking speed and walking cadence had a significant impact on the pedometer validity, as both speed and cadence were negatively correlated to the absolute percent error measured by both devices (p<0.001), which indicates, that the greater the speed and/or cadence, the lower the step counting error rate. Conclusion: The two tested biometric pedometer applications were valid in patients with rheumatoid arthritis, but walking with very low speed may represent a challenge. Next step will be field tests evaluating the setup including active measured time in patients with rheumatoid patients.

REFERENCES:

Disclosure of Interests: Stefan Rahr Wagner: None declared, Rasmus Boge Gregersen: None declared, Line Henriksen: None declared, Ellen-Margrethe Kresten Krarup Keller: None declared

Background: A regular monitoring of structural damage in patients with rheumatoid arthritis (RA) is necessary to adjust the treatment. However, the rhythmicity of new radiographs to assess the structural damage is not codified. There is no biomarker able to reflect structural damage.

Objectives: Our study aimed to assess the relationship between the modified Sharp score and the platelet to lymphocyte ratio.

Methods: We performed a cross-sectional study including 53 patients with RA. A cell blood count was performed for each patient, and PLR was calculated. Modified Sharp score and its components (erosion score and joint space narrowing score) were evaluated using the radiograph of hands and feet. Statistical analysis was performed using SPSS (Statistical Package for Social Sciences).

Results: Of the 53 patients, 39 were female (Sex Ratio: 2.8). The mean age was 53.9 ± 12.7 years. The mean age of the onset of the disease was 43.8 ± 13.5 years. The mean disease duration was 10.1 ± 8.2 years. The mean DAS 28-ESR score was 4.64 ± 1.23. The mean value of PLR was 161.62 ± 86.59. The mean modified Sharp score was 46.33 ± 37.74. Thirty-two percent of patients had a modified Sharp score greater than 50. The mean score of joint erosion and joint space narrowing were 12.76 ± 15.05 and 33.57 ± 25.80. Modified Sharp score was correlated to the PLR (r: 0.558; p <10-3 and r: 0.299; p: 0.033, respectively).

Conclusion: The ability of PLR to distinguish patients with a modified Sharp score ≥ 50 was good with an AUC of 0.704 (p= 0.021) with a cut-off of 130.5 (sensitivity=75%, specificity=65.7%).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3276

AB0196

ABATEVERUS HYDROXYCHLOROQUINE IN PALINDROMIC RHEUMATISM: A MULTICENTER RANDOMIZED CLINICAL TRIAL (PALABA STUDY): TRAIL DESIGN AND PATIENTS CHARACTERISTICS

B. Frade-Sosa1, R. Morlà1, L. Tobalina2, C. Perez-Garcia2, I. Haro2, R. Sanmartí3 on behalf of PALABA study investigators. 1Hospital Clinic de Barcelona, Arthritis Unit. Department of Rheumatology, Barcelona, Spain; 2Hospital Del Mar, Rheumatology, Barcelona, Spain; 3Institute of Advanced Chemistry of Catalonia (IQC-CSIC), Unit of Synthesis and Biomedical Applications of Peptides., Barcelona, Spain

Background: Many patients with palindromic rheumatism (PR), mainly those with positive autoantibodies, evolve to rheumatoid arthritis (RA). Management of PR is empirical, and hydroxychloroquine (HCQ) is the most used antirheumatic drug. Abatacept (ABA) has been investigated in preclinical RA with good results. This report is a randomized clinical trial in PR.

Objectives: To present the design of a randomized clinical trial in PR (PALABA study). To describe the characteristics of the patients at study entry. The main objective is to test the hypothesis that ABA can reduce the progression of RA in seropositive (ACPA+ and/or RF+) PR patients in comparison with HCQ.

Methods: Phase IV multicenter open label randomized controlled clinical trial with 42 months duration. The enrollment period was 18 months and the open randomized period 24 months. Seventeen European centers were included. The sample size was 70 patients (35 per arm). ABA and HCQ arm followed a different protocol. Both therapies were administered. The main inclusion criteria were age ≥18 years with PR according to Guerne and Weissman modified criteria and disease evolution >3 and ≤6 months. Positive ACPA (ELISA or chemiluminescence (CCP2) and/or RF tests are required. Patients with arthritis >1 joint >1 week at baseline, with criteria of other rheumatic diseases, radiographic erosions or previous antirheumatic therapy with synthetic DMARDS were excluded.

The main outcome measure is achievement of RA classification criteria (EULAR/ACR 2010) at any time during the 24-month follow-up. Secondary outcomes were the number and intensity of joint attacks, adverse events, and effects on serum ACPA and anti-carbamylated antibodies at 0.124.24 months of follow-up. STATISTICS: Modified Full Analysis Set and Per Protocol Population analysis.

Results: Patient one was included in June 2018. The inclusion period has been extended until April 2022 due to low recruitment rates, partly due to the COVID-19 pandemic. As of 15 Jan 2022, 51 patients have been randomized and 49 (37F/12M) have received at least one drug dose. The mean onset of symptoms was 9.9±6.5 months. In 22 patients the follow-up time was greater than 12 months. RF and ACPA (CCP2) were positive in 81.6% and 89.8% of patients respectively; 24 patients were included in the ABA arm and 25 in the HCQ arm. Seven patients withdrew from the study during follow-up due to: progression to RA (n=3), adverse events (n=2) and other reasons (n=2). The demographic, clinical and laboratory characteristics of PR patients at study entry are shown in Table 1. There were no significant differences in patients' characteristics between arms were observed at enrollment except a higher prevalence of CCP2 in the HCQ arm.

TABLE 1 Baseline demographic, clinical and laboratory characteristics at study entry

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>ABA (n=24)</th>
<th>HCQ (n=25)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (sd)</td>
<td>49 (14.7)</td>
<td>45 (12.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>21 (87.5)</td>
<td>21 (84)</td>
<td>NS</td>
</tr>
<tr>
<td>Body mass index, mean (sd)</td>
<td>23 (5.7)</td>
<td>23 (5.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Month of symptom duration, mean (sd)</td>
<td>9.9 (6.3)</td>
<td>9.8 (6.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Current Smokers, n (sd)</td>
<td>15 (30.6)</td>
<td>15 (30.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Number attacks 6 months before inclusion, mean (sd)</td>
<td>4.65 (4.07)</td>
<td>4.24 (4.78)</td>
<td>NS</td>
</tr>
<tr>
<td>PIP/MCP involvement, n (%)</td>
<td>32 (85.3)</td>
<td>32 (80)</td>
<td>NS</td>
</tr>
<tr>
<td>WRIST involvement, n (%)</td>
<td>16 (66.7)</td>
<td>15 (60)</td>
<td>NS</td>
</tr>
<tr>
<td>Involvement of other joints, n (%)</td>
<td>9 (35.4)</td>
<td>14 (56.3)</td>
<td>NS</td>
</tr>
<tr>
<td>ESR (mm), mean (sd)</td>
<td>20 (15.3)</td>
<td>18 (14.8)</td>
<td>NS</td>
</tr>
<tr>
<td>RF positive, n (%)</td>
<td>10 (41.7)</td>
<td>12 (48)</td>
<td>NS</td>
</tr>
<tr>
<td>ACPA (CCP2) positive, n (%)</td>
<td>9 (45.8)</td>
<td>11 (44)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Conclusion: We present the design of the first randomized clinical trial in PR of the efficacy of antirheumatic drugs (ABA vs HCQ) to reduce progression towards RA in patients with a high risk (recent onset PR and positive autoantibody status) of persistent arthritis. The characteristics of patients included until now are similar to those reported in recent onset PR.


Disclosure of Interests: Beatriz Frade-Sosa: None declared, Rosa Maria Morlá: None declared, Lola Tobalina: None declared, Carolina Pérez-Garcia: None declared, Isabel Haro: None declared, Raimon Sanmartí: Speaker honoraria from Abbvie, BMS, Gebro-Pharma, Lilly, MSD, Pfizer, Sanofi and Roche.
Background: The prevalence of cervical spine involvement in rheumatoid arthritis (RA) varies between 17 and 86%. Cervical spine involvement is in third place after hand-wrist and foot involvement. The activity of RA is manifested by inflammation of all joints.

Objectives: To study the characteristics of patients with rheumatoid arthritis and research a relationship between cervical spine involvement and disease activity in rheumatoid arthritis.

Methods: We conducted a multicenter, prospective, descriptive, cross-sectional study in 300 patients with RA between 2013-2018. We collected demographic data, Body mass index (BMI), disease duration, Disease Activity Score of 28 joints (DAS28), (Health Assessment Questionnaire (HAQ), CRP, ESR, the rheumatoid factor (RF), ACPA. A radiological assessment of the cervical spine was requested for all patients, including a radiograph of the cervical spine from the front with the mouth open, a neutral profile, and dynamic flexion and hyperextension views. The activity of RA was assessed by DAS28. We study the relationship between cervical spine involvement (CSI) and disease activity in RA.

Results: 80.3% were female, sex ratio H/F was 0.24, the mean age was 51.7±12.68 years, the BMI was 26.1±5.25, 67.6% had comorbidities, the most frequent were osteoporosis (30%), obesity (24%), hypertenion (21.7%). RA mean duration was 13.9± years, mean DAS 28 was 4.68±1.5 mean RA was 1.01±0.69, mean CRP was 15.5±2.12mg/L, mean ESR was 41.89±26.8mm, rheumatoid factor was positive in 70.6% and ACPA were positives in 77.3%. The standard radiographs of cervical spine found 53 (17.66%) patients with CSI. The various lesions of the cervical spine were atlantoaxial subluxations 13%, 3.66% of lateral atlantoaxial subluxations, vertical subluxations in 0.66%, C1C2 arthropathies in 2.33%, spondylolisthesis in 2%, and 0.33% of spondylidoscites. The results of the univariate and multivariate analysis did not find a relationship between CSI and DAS28 (p=0.66).

Conclusion: Cervical spine involvement in rheumatoid arthritis was common in our study. We did not find a relationship between cervical spine involvement and disease activity in rheumatoid arthritis.

REFERENCES:

Disclosure of Interests: None declared

AB0199 RELATIONSHIP BETWEEN EXERCISE AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

A. N. Garza-Cisneros1, J. J. Colunga-Pedraza1, D. Á. Galarza-Delgado1, J. R. Azpiri-López2, A. B. Rodriguez-Romero3, M. A. Balderas-Palacios1, A. García-Heredia1, N. Guajardo- Jauregui1, A. Cárdenas1, Universidad Autónoma de Nuevo León, Hospital “Dr. José Eleuterio González,” Rheumatology, Monterrey, Mexico; 2Universidad Autónoma de Nuevo León, Hospital “Dr. José Eleuterio González,” Cardiology, Monterrey, Mexico

Background: Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease in which cardiovascular disease is the leading cause of death (1). Exercise has been shown to have certain benefits in chronic diseases such as RA, decreasing symptoms and disease activity (2).

Objectives: To correlate exercise and minutes of physical activity performed per week with the disease activity level in a Mexican RA population.

Methods: This was a cross-sectional study in which a total of 240 Mexican patients with a diagnosis of RA were included. They were divided into two groups (120 in each): those who self-reported performing at least 30 minutes of exercise 3 or more times per week and were matched with patients who did not perform it by age, gender, and comorbidities. The disease activity level was determined with Disease Activity Score 28-joint erythrocyte sedimentation rate (DAS28-ESR) and Disease Activity Score 28-joint C-reactive protein (DAS28- CRP). Distribution was evaluated with Kolmogorov-Smirnov. Comparisons with Chi-square test, Student’s t-test, and Mann-Whitney U test. Correlation between disease activity level and minutes of exercise per day with Spearman-rho coefficient.

Results: DAS28-ESR was significantly higher in patients who did not exercise (4.38±3.68) vs 4.37 (3.6-4.63), p=0.006). DAS28-CRP had similar trend 2.76 (1.89-4.14) vs 3.51 (2.28-4.63), p=0.004 (Table 1). The Spearman-rho coefficient showed a significant correlation between the minutes of exercise performed per week and DAS28-ESR (rho=-0.193, p=0.003) and DAS28-CRP (rho=-0.207, p=0.001) (Figure 1). A multivariate analysis was performed in which minutes of exercise performed per week, treatment, and comorbidities were included, showing an independent association between

Table 1. Baseline characteristics.

<table>
<thead>
<tr>
<th>Basal (n=48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years ± SD</td>
</tr>
<tr>
<td>Female, n (%)</td>
</tr>
<tr>
<td>Disease duration, years (IQR)</td>
</tr>
<tr>
<td>DAS28-ESR ± SD</td>
</tr>
<tr>
<td>DAS28-CRP ± SD</td>
</tr>
<tr>
<td>CD4 ± SD</td>
</tr>
<tr>
<td>HAQ, (IQR)</td>
</tr>
<tr>
<td>HT, n (%)</td>
</tr>
<tr>
<td>DM, n (%)</td>
</tr>
<tr>
<td>Active tabaquism, n (%)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
</tr>
<tr>
<td>BMI, kg/m² ± SD</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
</tr>
<tr>
<td>Glucocorticoids, n (%)</td>
</tr>
</tbody>
</table>

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3406
minutes of exercise performed per week and the disease activity level assessed by DAS28-ESR (B=−0.001, 95% CI=−0.002 - −0.0003, p=0.011) and DAS28-CRP (B=−0.001, 95% CI=−0.002 - 0.0003, p=0.011).

Table 1. Demographic characteristics of the patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RA patients who exercise (n=120)</th>
<th>RA patients who do not exercise (n=120)</th>
<th>Value of p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD</td>
<td>54.4±8.1</td>
<td>54.8±8.2</td>
<td>NS</td>
</tr>
<tr>
<td>Female gender, n (%)</td>
<td>106 (88.3)</td>
<td>106 (88.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>23 (19.1)</td>
<td>31 (25.8)</td>
<td>NS</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>15 (12.5)</td>
<td>12 (10.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>30 (25.0)</td>
<td>24 (20.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>39 (32.5)</td>
<td>34 (28.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>93 (77.5)</td>
<td>107 (89.1)</td>
<td>0.015</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>6 (5)</td>
<td>5 (4.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Glucocorticoid, n (%)</td>
<td>61 (50.8)</td>
<td>74 (61.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Minutes of exercise per week, median (p25-p75)</td>
<td>4.024 (3.08-5.31)</td>
<td>4.73 (3.6-5.82)</td>
<td>0.006</td>
</tr>
<tr>
<td>DAS28ESR, median (p25-p75)</td>
<td>2.76 (1.89-4.14)</td>
<td>3.51 (2.28-6.43)</td>
<td>0.004</td>
</tr>
<tr>
<td>DAS28CRP, median (p25-p75)</td>
<td>2.76 (1.89-4.14)</td>
<td>3.51 (2.28-6.43)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; NS, not significant; T2DM, type 2 diabetes mellitus; bDMARD, biological disease modifying anti-rheumatic drugs; DAS28, Disease Activity Score 28-joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

Figure 1. Correlation between exercise time and disease activity level in RA.

RA: rheumatoid arthritis; DAS28, Disease Activity Score 28-joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

Conclusion: Mexican RA patients who exercise presented lower levels of disease activity. Emphasis should be placed on their practice to improve the patients’ symptomatic relief.

REFERENCES:

Disclosure of Interests: None declared

AB0200

INTAKE OF FISH RICH IN N-3 POLYUNSATURATED FATTY ACIDS IS ASSOCIATED WITH GOOD RESPONSE TO TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TARGETED THERAPIES.

M. Tauri1, O. Amengual1, Y. Fujieda1, M. Navieda Fuentes2, N. Tsuchida1, M. Yasuda1, K. Nishino1, Y. Kusom1, S. Takeyama1, M. Yoshimura1, K. Ninagawa1, K. Aso1, M. Kono1, M. Kato1, R. Cáliz Cáliz2, T. Atsumi1.
1Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan; 2Hospital Virgen de las Nieves, Department of Rheumatology, Granada, Spain

Background: The management of rheumatoid arthritis (RA) has been transformed by the use of molecular targeted therapies. Early treatment and treat-to-target approach leads to good clinical response and remission (responders), but not in all patients.

Environmental factors including diet contribute to the development, activity and severity of RA. Evidence from clinical trials suggested that dietary interventions, such as Mediterranean diet or supplementation with fish oil rich in n-3 polyunsaturated fatty acids (n-3 PUFA), have positive effects on RA. Japanese and Mediterranean diets are associated with longevity and characterized by high fish intake. Clinical studies have identified predictors of treatment response in individual RA patients, however, the influence of fish consumption on treatment response in RA patients treated with targeted therapies has not been elucidated.

Objectives: To assess whether diet is associated with a good response to targeted therapies in RA patients with Japanese and Mediterranean dietary patterns.

Methods: The study is a collaborative international cross-sectional retrospective study enrolling patients with RA on treatment with biologics or JAK inhibitors attending to Hokkaido University Hospital, Japan or Hospital Virgen de las Nieves, Spain. Enrolled patients were asked to complete a brief-type self-administered diet history questionnaire (BDHQ) and a detailed fish frequency questionnaire (DFFQ) reporting to consumption frequency in the previous month. At study entry, alcohol consumption, tobacco habits, educational level and employment status were recorded and RA disease activity evaluated by qualified rheumatologists. Demographic, clinical/laboratory data were retrospectively extracted from the medical records.

By December 2021, 279 patients (Japan 217; Spain 62) returned the questionnaires. A preliminary analysis was carried out with the first 58 Japanese patients in which all clinical and laboratory data could be collected. A descriptive analysis was performed and the relative risks approximated by odds ratios.

Results: Fifty-eight Japanese RA patients, 45 females, median age at entry 66 yrs [IQR 54-73], median disease duration 11yrs [IQR 7-20] were included in this
analysis. Fifty-three (93%) of patients were on biologic therapies and four (7%) on JAK inhibitors with a median treatment duration of 4.5 yrs [IQR 1-7]. Concomitant treatment with conventional DMARDs and glucocorticoids were reported in 69% and 48% of patients, respectively. Forty-two (72%) patients were responders to treatment defined as DASESR 3.2. Another systemic autoimmune disease, hypertension, diabetes mellitus, dyslipidemia or gout history were present in 29%, 29%, 9%, 33% and 10% of patients, respectively. All patients had consumption of fish in the last month and an intake of n3-PUFA rich fish (fatty fish) was indicated by 82% (<1 time/week 34%, 1 time/week 48%). The patients’ fatty and non-fatty fish intake scores were calculated with a mathematical formula based on the intake of each of the fish included in the DFFQ and number of responses. In the group of high fatty fish score patients (≧1 time/week) 94% were responders to treatment vs. 6% non-responders, [OR 8.75, CI [1.0-73.54, p= 0.022] while only 63% of patients in the high non-fatty fish score group respond to the treatment. The patients’ fatty and non-fatty fish intake scores were calculated with a mathematical formula based on the intake of each of the fish included in the DFFQ and number of responses. In the group of high fatty fish score patients (≧1 time/week) 94% were responders to treatment vs. 6% non-responders, [OR 8.75, CI [1.0-73.54, p= 0.022] while only 63% of patients in the high non-fatty fish score group respond to the treatment.

Conclusion: Fatty fish intake associated with a good response to treatment in patients receiving targeted therapies, suggesting that fish consumption may have some beneficial effects on RA treatment.

References: There is no reference.

Acknowledgements: Acknowledgements to Ms. Y. Ike and S. Kumagai for their enriching support on the nutritional properties of fish. Supported by the Kakenhi C grant number 20K11597 from the Japan Society for the Promotion of Science.

Disclosure of Interests: None declared


**AB0202**

GUT MICROBIOTA DYSBIOSIS WERE CLOSELY CORRELATED WITH LYMPHOCYTE SUBSETS AND CYTOKINES IN PATIENTS WITH INFLAMMATORY ARTHRITIS

J. Liu1,2,3, S. X. Zhang1,2,3, J. Qiao1,2,3, R. Zhao1,2,3, S. Song1,2,3, T. Cheng1,2,3, W. Wang1,2,3, X. Li1,2,3, C. Wang1,2,3, The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 3Ministry of Education, Key Laboratory of Cellular Physiology at Shanxi Medical University, Taiyuan, China

**Background:** Inflammatory arthritis includes a group of chronic conditions, particularly rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) [2]. Growing evidences link gut microbiota dysbiosis with the development of inflammatory arthritis [10].

**Objectives:** The aim of this study was to discover the characters of microbiota in inflammatory arthritis patients and compare the relationship between the microbiota and peripheral lymphocyte subsets and cytokines.

**Methods:** Fecal samples were collected from 73 arthritis patients (13 PsA, 30 AS, 30 RA patients) and 140 sex- and age-matched healthy controls (HCs). The gut microbiota was studied by sequencing the V3-V4 variable regions of bacterial 16S rRNA genes by the Illumina MiSeq PE300 system. Peripheral lymphocyte subsets in these participants were assessed by flow cytometry. Measures of disease activity such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) were recorded. Alpha and Beta diversity was assessed using results from QIIME2 and gut microbiome profiles were compared using linear discriminant analysis (LDA) effect size (LEfSe). R (version 4.0.1) was used for comparative statistics, using pearson correlation analysis to assess the correlation between the relative abundance of genus in the sample and clinical parameters.

**Results:** Compared with HCs, the richness of gut microbiota (ACE and Chao 1) was significantly lower (p < 0.05) in arthritis patients, and bacterial diversity including Shannon and Simpson indices (p < 0.001) was also significant in arthritis decreased (Figure 1A). β-diversity analysis based on Bray-curtis distance revealed significant differences in microbial communities between arthritis and HCs (Figure 1B, r=0.098, p=0.001, ANOSIM). In addition, compared with HCs at the genus level, 9 bacterial groups were significantly different in PsA (p < 0.05), 19 bacterial groups in AS (p < 0.05), and 17 bacterial groups in RA(p < 0.05) (Figure 1C). There was a significant positive correlation between CD4+ T and Prevotella(p<0.01), T and Prevotella(p<0.05), Blautia(p<0.05) as well as Megamonas(p<0.05), Th17 and Prevotella(p<0.01), CD6+ T and Megamonas(p<0.01), Th1 and Megamonas(p<0.05), Prevotella(p<0.01),Coprooccus(p<0.05), B and Erysipelotrichaceae_UCG-003(p<0.01), and Erysipelotrichaceae_UCG-003(p<0.01), Anaerostipes(p<0.01), CRP and Fusobacterium(p<0.05) as well as Roseburia(p<0.05). There were negative correlations between T and Erysipelotrichaceae_UCG-003 (p<0.01),CD8+T and Fusobacterium(p<0.01), CD4+T and Fusobacterium(p<0.05), NK and Fusiformis(p<0.05).

**Conclusion:** The gut microbiota of patients with inflammatory arthritis differs from HC and also varies among individual arthritis, which was closely related to lymphocyte subsets.

**REFERENCES:**

**AB0203**

25-HYDOXYVITAMIN D [25 (OH) D] LEVEL IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS, ITS RELATIONSHIP WITH THE COURSE OF THE DISEASE, VDR (FOK1) GENE POLYMORPHISM AND BONE MINERAL DENSITY.

Y. Seheda1, S. Shevchuk2, O. Gallutina1, I. Kuvikova1, O. Shevchuk2, 1Scientific and Research Institute of Invalid Rehabilitation of VINNYTSIA NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, Rheumatology Department, Vinnytsya, Ukraine; 2VINNYTSIA NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, Department of Internal Medicine #2, VINNYTSIA, Ukraine

**Background:** Osteoporosis is known to be a common concomitant state in post-menopausal women with rheumatoid arthritis, but its development cannot be explained only by increasing of age, hormonal disorders, disease duration and glucocorticosteroid intake. Vitamin D deficiency may be one of the major risk factors, but its prevalence in the Ukrainian cohort of postmenopausal RA patients is unknown, and the factors on which it depends have not been established.

**Objectives:** To analyze the level of 25-hydroxyvitamin D [25 (OH) D] in postmenopausal women with rheumatoid arthritis (RA) and to investigate its relationship with the course of the disease, VDR (FokI) gene polymorphism and bone mineral density (BMD).

**Methods:** The study included 81 postmenopausal RA patients and 21 post-menopausal age-matched women without RA as a control group. All patients

**Acknowledgements:** This work was supported by the National Natural Science Foundation of China (No. 82001740).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3485
were screened for demographic, disease course and treatment data. Serum 25-hydroxyvitamin D [25 (OH) D] level and VDR (FokI) gene polymorphism were measured by enzyme-linked immunosorbent assay (ELISA). Levels of 25-hydroxyvitamin D [25 (OH) D] ≥ 30 ng/ml were defined as sufficiency and less than 20 ng/ml as deficiency. BMD was measured in the lumbar spine and proximal femur using double X-ray absorptiometry. Osteoporosis was diagnosed in case of BMD > -2.5 T.

Results: The analysis has shown that serum vitamin D level in RA group was significantly lower than in control group (11.54 ng/ml vs. 15.25 ng/ml; p < 0.01). In addition, the incidence of vitamin D insufficiency and deficiency was higher in RA patients than in control group. In particular, abnormal vitamin D level was diagnosed in 74.1% of RA patients, among whom 25 (30.9%) patients had vitamin D insufficiency and 35 (43.2%) patients had vitamin D deficiency. In control group 8 (38.1%) persons had vitamin D insufficiency, and 6 (28.6%) persons had vitamin D deficiency. There was an inverse correlation between vitamin D levels and RA activity assessed by DAS28 (<p>0.001), CDAI (<p>0.001), ESR and CRP (<p>0.001) but not with age, daily glucocorticosteroid dose and disease duration. In addition, significant correlation was revieled between VDR (FokI) gene polymorphism and vitamin D deficiency, as well as low BMD in postmenopausal women with rheumatoid arthritis (<p>0.001).

Conclusion: Low 25-hydroxyvitamin D [25 (OH) D] level and VDR (FokI) gene polymorphism are independent risk factors of osteoporosis in postmenopausal women with RA. Vitamin D deficiency is associated with RA activity and not depends on age, glucocorticosteroid daily dose and disease duration.

Disclosure of Interests: None declared


AB0204 DOES THE PRESENCE OF COXITIS IN RHEUMATOID ARTHRITIS CHANGE THE DISEASE SEVERITY PROFILE?

A. Ben Tekaya1,2, E. Hannech1,2, O. Saidane1,2, S. Bouden1,2, R. Leila1,2, R. Tekaya1,2, I. Mahmoud1,2, L. Abdelmoula1,2, Rheumatology Department, Charles Nicolle Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by intra-articular manifestations affecting small and large joints. Hip involvement is not common but it can predict a severe disease course [1].

Objectives: Our study aimed to investigate the prevalence of coxitis in RA patients and to compare patients with RA coxitis (+) and RA coxitis (-) according to their clinical, biological outcomes and their therapeutic findings.

Methods: This was a retrospective and comparative study, which include patients diagnosed with RA according to the ACR/EULAR 2010. Sociodemographic, clinical, biological, and therapeutic data were collected. The diagnosis of coxitis was made on plain X-rays or MRI.

Results: Among 255 RA, there were 30 RA coxitis (+) (11.8%). Coxitis was unilateral in 28 patients and bilateral in 2 patients. The mean delay onset of coxitis was about 11.6 ± 8.4 years (p<2). The mean age was 57.5 ± 12.2 years for RA coxitis (+) and 59.1 ± 10.5 years for RA coxitis (-) (p=0.5). The gender distribution was 70% female and 30% male) for RA coxitis (+) and (85% female and 15% male) for RA coxitis (-) (p=0.04). The mean Body Mass Index was 24.8 ± 4.8 kg/m² in RA coxitis (+) and 28 ± 5.8 kg/m² in RA coxitis (-) (p=0.03). Comorbidities were present in 46% of RA coxitis (+) and 48% of RA coxitis (-) (p=0.8). Extra articular manifestations were noted in 76% RA coxitis (+) and 68% RA coxitis (-) (p=0.8). RA was seropositive in 76% RA coxitis (+) and in 82% RA coxitis (-) (p=0.4). RA was immunopositive in 51% RA coxitis (+) and 69% RA coxitis (-) (p=0.04). The mean DAS28 (CRP) was respectively 4.6 ± 1.1 in RA coxitis (+) vs 4.8 ± 1.1 RA coxitis (-) (p=0.7). Atlanto-axial dislocation was noted in 60% RA coxitis (+) and 22% RA coxitis (-) (p=0.04). The use of corticosteroid was noted in 92% RA coxitis (+) and in 90% RA coxitis (-) (p=0.04). Biologic drugs were prescribed in 43% RA coxitis (+) and in 25% RA coxitis (-) (p=0.04).

Conclusion: Our study showed that coxitis in RA patients is associated with a higher risk of Atlanto-axial dislocation and a more frequent use of biologic drugs reflecting a more severe and mutilating disease. We highlight the importance of an early diagnosis and treatment to prevent complications.

REFERENCES:

Disclosure of Interests: None declared


AB0205 TENDERNESS AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS

I. Gessi1, M. Popescu2, G. Supp3, T. Deimel1, P. Studenic4, M. Durechova5, M. Zauner6, J. S. Smolen7, D. Aletaha1, P. Mandl1. 1Medical University of Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria; 2Hôpital Maisonneuve-Rosemont, Department of Rheumatology, Montreal, Canada; 3Karolinska Institutet, Division of Rheumatology, Stockholm, Sweden

Background: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic progression is not clear.

Objectives: To assess the predictive value of tenderness alone and with consideration of sonographic signs for synovitis, disease duration and baseline radiographic damage for subsequent radiographic progression in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Methods: Clinical and sonographic (grey scale (GS) and power Doppler (PD)) examination of 22 joints of the hand were performed cross-sectionally in consecutive patients with RA and PsA with at least one tender joint. Radiographs were scored for erosions and joint space narrowing (JSN) at inclusion and radiographic progression of each joint was assessed after 2 years. The impact of tenderness on progression was analyzed in non-swollen joints for RA and PsA separately with logistic regression analyses. As a second step, the association of PD, GS, disease duration, C-reactive protein, baseline erosions and JSN and global joint counts with subsequent structural damage was assessed using univariate logistic regression in tender non-swollen joints again on the joint level.

Results: We included 1207 joints in 54 RA patients and 396 joints in 18 PsA patients. Tenderness was associated with subsequent radiographic progression in non-swollen joints in PsA (OR 3.44, 95% CI 1.78-6.62, p<0.01) but not in RA (OR 1.80, 95% CI 0.99-3.38, p=0.55) (Figure 1). In tender non-swollen joints in RA patients, PD (OR 3.74, 95% CI 1.10-11.30, p=0.04) and baseline erosions (OR 4.42, 95% CI 1.22-15.95, p=0.02) had a significant impact on radiographic progression. In PsA patients, PD (OR 8.46, 95% CI 1.72-41.72, p<0.01), baseline erosions (OR 6.71, 95% CI 1.43-31.39, p=0.02), baseline JSN (OR 7.27, 95% CI 1.47-35.89, p=0.02) and SJC (OR 1.26, 95% CI 1.07-1.48, p=0.01) were associated with radiographic progression.

Figure 1. The proportion of joints with progression in tender non swollen and non tender non swollen joints in patients with rheumatoid and psoriatic arthritis; NTNS: non tender non swollen; TNS: tender non swollen

Conclusion: Our findings indicate that tenderness in non-swollen joints is associated with subsequent radiographic progression in PsA, while in RA it is a risk factor for radiographic progression only in the presence of additional factors, such as sonographic signs for synovitis.

Disclosure of Interests: Irina Gessi: None declared, Mihaela Popescu: None declared, Gabriela Supp: None declared, Thomas Deimel: None declared, Paul Studenic: None declared, Martina Durechova: None declared, Michael Zauner: None declared, Josef S. Smolen: Speakers bureau: Abbvie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, Merck Sharp & Dohme, Novartis- Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB, Grant/research support from: Abbvie, AstraZeneca, Lilly and Roche, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, StaBi, Sanofi.

Peter Mandl: Speakers bureau: from Abbvie, Janssen and Novartis, Grant/ research support from: from Abbvie, BMS, Novartis, Janssen, MSD and UCB;

DOI: 10.1136/annrheumdis-2022-eular.3590

AB0206 STUDY ON THE SIGNIFICANCE OF SERUM COMPLEMENT CS IN PATIENTS WITH RHEUMATOID ARTHRITIS

J. Liu1, Q. Zhou2, X. Chen1, H. Guo2, L. Long2. 1Zunyi Medical University, Department of Rheumatology and Immunology, Sichuan Provincial People’s
Background: Recent studies have pointed out that complement system activation is a major alteration in early atherosclerotic plaques, and complement C5 has promising value as a novel circulating biomarker of atherosclerosis, but the relationship between C5 and carotid atherosclerotic (CAS) plaque in rheumatoid arthritis (RA) is still unclear.

Objectives: To investigate the clinical significance of serum complement C5 and the association with CAS plaque in patients with RA.

Methods: 143 patients with RA were included in the study, and 48 cases with age- and sex-matched healthy physical examination without RA or CAS plaque served as a normal control. All RA patients were divided into RA with CAS plaque group and RA without CAS plaque group according to the presence or absence of plaque formation in the carotid artery. The subject's demographic data, laboratory investigations and serum samples were collected. Body mass index (BMI) and Disease Activity Score 28-joint counts (DAS28) were calculated. Glucocorticoid and DMARDs use were recorded in the past 3 months. ELISA method was used to determine the concentration of complement C5 in the serum of each participation. CA5 plaque was determined by color Doppler ultrasound.

Results: Serum complement C5 in RA group was significantly lower than that in control group (P<0.05), whereas C5 level in RA without CAS plaque group was significantly higher than that in RA without CAS plaque group (P<0.05). In RA group, serum C5 level was positively correlated with CAS plaque, high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (FIB) (r=0.004, P=0.017; r=0.235, P=0.009; r=0.186, P=0.029). In addition, there was no significant correlation between serum C5 and sex, age, BMI, course of disease, DAS28, lipid profile (TG, serum triglyceride; TC, total cholesterol; LDL, low density lipoprotein cholesterol; HDLC, high density lipoprotein cholesterol; TC/HDLc; LDL/HDLc), immune markers (RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide antibodies), cytokine (IL-6, Interleukin-6; TNF-α, Tumor necrosis factor-α), erythrocyte sedimentation rate (ESR) (all P>0.05), or drug therapy (all P>0.05).

Conclusion: C5 may be a novel circulating marker of atherosclerosis in RA patients, it might promise to assist in risk stratification for cardiovascular disease in the future.

REFERENCES:

Disclosure of Interests: None declared

Figure 1. Percentage of swollen joint affection at baseline, final registered visit and average followup

Conclusion: In this registry, some swollen joints were persistently affected across the follow-up, and did not improve from baseline to the last registered visit. However, the burden of the disease improved, measured by DAS28 or its individual components. The improvement of other swollen joints and other components of DAS28 can be the reason. The detection and local treatment (v: intra-articular injections) of this persistent swollen joints could be the better approach to this issue. Weaknesses of this study: a possible bias in the included patients (they were from single clinic), joint assessment not blind and performed by a single rheumatologist, patients included could be more severe since they were more frequently bDMARD/tsDMARD users.

REFERENCES:
areas from January 2013 till December 2020. A multivariate time series approach using Evidence from vector error correction model (VECM) was employed to investigate the effect of ambient pollutants emissions on DAS28 over that period.

**Results:** A total of 1,809 RA patients and 10,215 hospital visits were included, 63% females, mean age 54 years, mean disease duration 9.2 years and 77% had rheumatoid factor positive. A significant correlation was found between DAS28 and NO2, NO2 and O3 (p=0.012, 0.029, 0.039 respectively). According to the Granger causality test and VECM, emissions of NO2, and O3 had a positive short-term effect on DAS28 among RA patients. Impulse response test results showed that for some locations in Kuwait there is a short-term positive causal relationship between emissions of NO2 and DAS28, due to sources of pollution surrounding the locations. The results showed that the short run effect for NO2 with lags 1 to 4 days had a positive relationship with DAS28 which means, there is 1% increase in DAS28 for every 0.0182 increase in NO2 emission. Our results revealed that 36% of discrepancy between the overall relationship between DAS28 and air pollution is corrected each year.

**Conclusion:** Increased concentrations of air pollutants may increase the risk of RA activity. VECM time series model can be used as a tool to predict changes in disease activity based on air pollutants up to 8 days. We recommend that a regular broadcast is issued by health authorities to RA patients to help predict changes in disease activity. Warning about air pollution may be tailored according to the patient’s residential area. Government should take serious decisions to help minimize air pollution in the residential areas.

**REFERENCES:**


---

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3667

---

**AB0209**

**PHYSICIAN TRUST RATHER THAN RHEUMATOID ARTHRITIS KNOWLEDGE RELEVANT IN DISEASE OUTCOMES IN ETHNIC MINORITY PATIENTS WITH RHEUMATOID ARTHRITIS**

S. Dowell1, M. Quinones1,2, A. Miller1, O. Kadirir1, T. Jamshidi1, G. Kerr1,2.

1Howard University College of Medicine, Internal Medicine, Washington, United States of America; 2Washington DC VA/VC, Rheumatology, Washington, United States of America

**Background:** Ethnic minority (EM) patients with Rheumatoid Arthritis (RA) have more severe disease, more disability, and less use of biologic disease modifying anti-rheumatic drugs (bDMARDs). A Treat to target (T2T) strategy has been recommended to improve clinical outcomes but barriers include patient preference, access to specialty care and increased administrative effort. Additionally, EM patients in the US often have low health literacy, express greater reluctance to accept physician recommendations, in part due to sociocultural preference and mistrust of a historically biased healthcare system. It is unknown whether improving knowledge of RA would improve T2T outcomes in EM active RA patients.

**Objectives:** To assess the proportion of EM RA patients who achieve low disease activity or remission following implementation of a coordinator-based education program highlighting T2T RA strategy.

**Methods:** Adult participants with active RA (RAPID3>6 or CDAI >10) were invited to participate in a series of five one-on-one 20-minute educational sessions, co-occurring with scheduled routine clinic visits (6-12-week intervals). Sessions were facilitated by a rheumatology care coordinator, a non-healthcare professional with intensive training over 4 weeks to conduct RA patient education. Sociodemographic data was collected, and disease activity measures (TJC, SJC, RAPID3, CDAI) and validated patient questionnaires on RA Knowledge (ACREU), compliance (CQRS), and physician trust (Trust in Physician Scale) were recorded at baseline and after the final educational session. Descriptive statistics were applied and medians and ranges were measured. Pearson reported. Paired T-test was used to test for significant differences in scores after the education sessions. Correlations between the ACREU scores and clinical-demographic variables were measured using Pearson’s correlation coefficient.

**Results:** 20 EM patients (75% Female, mean age, 58.8 years (12.2) seen by EM physicians were enrolled, with mean RA disease duration of 7 years and poor prognosticators (75% double seropositivity). ACREU scores were low at baseline (mean 0.45 (0.16)), with no significant improvement on completion of educational sessions, and no correlation with years of education or duration of RA. There was a positive correlation between ACREU and compliance scores at baseline (r=0.3). Average duration of the education period was 9.72 months, with a 33% decrease in average RAPID3 over time, and 42% of patients achieving a target of remission or LDA. Trust in Physician scores were high at baseline and persisted with >50% of patients completing at least one medication change during study period.

**Conclusion:** RA knowledge did not impact RA patient outcomes in this cohort of EM patients. However, patients had high trust in their providers and achieved clinical remission or LDA despite risk for poor outcomes highlighting the importance of the provider-patient relationship in achieving targeted goals of therapy. Limitations include the small sample size from a single institution, and the lengthy time between initial and final assessment of RA knowledge.

**REFERENCES:**


**Acknowledgements:** Sincere gratitude to our patients for their participation, and to the team at Bristol Myers Squibb for supporting this research initiative.

**Disclosure of Interests:** Sharon Dowell Speakers bureau:Horizon Pharma, Aurinia Pharmaceuticals Inc, Abbvie, Grant/research support from: Pfizer, Bristol Myers Squibb, Mercedes Quinones Speakers bureau: Abbvie, Sanofi, Oshoze Kadiri: None declared, Tahereh Jamshidi: None declared, Gail Kerr: Research support from: Bristol Myers Squibb, Pfizer, Alani Miller: None declared, Oshoze Kadiri: None declared, Tahereh Jamshidi: None declared, Gail Kerr Speakers bureau: Aurinia Pharmaceuticals Inc, Consultant of: CSL Behring, Janssen, Pfizer, Samumed, UCB, Viela Bio/Horizon, Grant/research support from: Novartis

**DOI:** 10.1136/annrheumdis-2022-eular.3745

---

**AB0210**

**REAL-LIFE DAS28-DEFINED REMISSION IN RHEUMATOID ARTHRITIS – INFLAMMATION CONTROL IS NOT ENOUGH**

C. Popescu1,2, E. M. Marin1,2, C. Codreanu1,2. Carol Davila University of Medicine and Pharmacy, Rheumatology, Bucharest, Romania; 1Center for Rheumatic Diseases, Rheumatology, Bucharest, Romania

**Background:** Remission of rheumatoid arthritis (RA) is currently a reachable target in real-life settings under treat-to-target strategies, meta-analytical data
Foot impairment is not a barrier to physical activity in rheumatoid arthritis

A. Ben Tekaya1, C. Ines1, O. Saidane1, R. Leila1, S. Bouden1, R. Tekaya1, I. Mahmoud1, L. Abdelmoula1, Charles Nicola Hospital, Rheumatology, Tunis, Tunisia

Background: Physical activity is increasingly promoted for patients with Rheumatoid arthritis (RA) and strongly recommended. However, adherence to regular physical activity remains low. Identifying the barriers to physical activity is a key element to understanding physical activity behavior in RA.

Objectives: Our objective was to assess the impact of foot involvement on physical activity among patients with RA.

Methods: We conducted a cross-sectional study involving patients with RA, fulfilling the ACR-EULAR 2010 criteria. We collected the socio-demographic data and disease characteristics. Regarding the foot involvement, we assessed the prevalence of foot static disturbances and foot deformities through clinical examination, and radiographic damage. Physical activity was assessed by the Arabic version of validated questionnaires.

Results: The sample included 157 patients with established RA, mostly women (80.3%), 56.2±11.8 years-old on average. The group included predominantly positive rheumatoid factors (77.7%) and positive anti-citrullinated protein antibodies (81.5%), with only 12.1% both negative. At baseline, 58.0% were receiving one csDMARD (especially leflunomide - 49.7%, and methotrexate - 43.3%), 38.9% were receiving 2 csDMARDs, and 57.3% were on oral glucocorticoids (7.8±4.4mg/day on average). All patients had high baseline disease activity (average DAS28 of 6.3±0.8). Accordingly, all patients were initiated on either original/biologic TNF inhibitors (adalimumab - 22.3%; certolizumab - 70.9%; etanercept - 31.2%; golimumab - 1.3%; infliximab - 17.8%), other bDMARDs (abatacept - 3.8%; rituximab - 19.5%; tocilizumab - 6.4%) or tsDMARDs (baricitinib - 5.7%; tofacitinib - 2.5%). After 6 months, 29.3% of patients were in DAS28-defined remission, 22.9% in DAS-28 DA, 35.7% in MDA and 12.1% in HDA. Therefore, 12.7% switched their initial bDMARD and 10.8% stopped their tsDMARDs, because 10.8% exhibited primary non-responsiveness (PNR) and 11.5% had adverse events (7 dermatological conditions, 6 cases of non-tuberculosis pneumonia, 1 case of clinical pulmonary tuberculosis, 1 case of latent tuberculosis, 1 transaminitis, 1 gastric cancer, 1 neutropenia). High baseline levels of DAS28 were associated with a lower probability to attain DAS28-remission after 6 months (OR = 0.64) and with a higher probability to switch the initial bDMARD due to PNR (OR = 2.44), suggesting that pharmaceutically influencing the inflammation cascade is not enough. Addition of tsDMARDs reduced at 6 months the prevalence of oral glucocorticoids to 28.0% (5.9±2.6mg/day on average).

Conclusion: Although reachable, disease remission seems difficult to attain, despite using advanced therapies. High baseline levels of DAS28 are negative predictors for not attaining remission and switching of therapy due to PNR in real-life.

References:

Disclosure of Interests: None declared
While the mean ages of the RA and PsA patients who had polypharmacy treatment at the beginning were respectively 59.21±12.65 and 53.5±13.81, their ages were significantly higher than the ages of those who did not receive polypharmacy treatment (respectively, 51.26±13.53 and 45.22±12.3). In RA vs PsA patients, the status of polypharmacy is higher in the groups in the groups aged 65 and over than those under 65 years of age, and it is statistically significant (p=0.001 and p=0.048, respectively). The risk of polypharmacy in people over 65 years of age in RA patients was 8.2 times, and the risk of polypharmacy in people over 65 years old in PsA patients was increased 6.3 times (p=0.015).

In both the RA and PSA groups, patients with baseline polypharmacy had statistically significantly higher DAS-28 CRP scores at 6 months of treatment than those without baseline polypharmacy (p<0.001). While the higher DAS-28 CRP score was maintained at 12 months in the RA group with polypharmacy at baseline (p=0.006), this was not significant in the PSA group (p=0.07).

Conclusion: Polypharmacy was present both at the time of diagnosis and in the treatment process in the RA and PsA patients, and the presence of polypharmacy at the beginning of the treatment was among the factors that affected the treatment of these patients by significantly affecting their 6-month DAS-28 CRP values.

Disclosures: None declared.


ABO214

SERUM IMMUNOGLOBULINS LEVEL IN A COHORT OF RHEUMATOID ARTHRITIS PATIENTS ON DIFFERENT TREATMENT OPTIONS

C. Moopasai1, 2, E. M. Marin1, C. Popescu1, 2, L. Enache1, 2, B. Dumitrescu1, 2, M. Agache1, 2, O. G. Dinache1, 2, C. E. Ionescu1, 2, D. Minca1, 2, C. Codearun1, 2, 1Center of Rheumatology, Bucuresti, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy, Rheumatology, Buchuresti, Romania

Background: Serum immunoglobulins (Ig) A, G, and M (IgA, IgG, and IgM) are not routinely evaluated in rheumatoid arthritis (RA). There are some reports that rituximab (RTX) may induce hypogammaglobulinemia (1). Under normal conditions, IgM provides a rapid immune response and is involved in tissue homoeostasis, whereas IgG and IgA are long-lasting high-affinity antibodies, the latter mainly providing mucosal immunity (2).

Objectives: The evaluate serum Ig levels (IgG, IgM, IgA) in a cohort of RA patients and potential therapeutic influences.

Methods: We performed a retrospective study in a cohort of 104 patients with RA exposed to different therapeutic agents, without switch for at least 1 year (conventional synthetic disease modifying drugs - csDMARDs, biologics and JAK inhibitors - JAKi); the collected data included demography, disease characteristics, treatment exposure (molecules, treatment line), serum level of IgA, IgG, IgM.

Results: 104 patients, mean age 60.3 years (±11.9), with a disease duration of 15years (±9.8), 83.7% women; the mean exposure to the current treatment option (without switch) was 3.7 years (±3.8); 20.2% (21 pts) were on csDMARDs, 70.2% (73pts) on biologics and 9.6% (10pts) on JAKi. 90.4% (83pts) used combination therapy along with biologics and JAKi. The biologics used were: 58.9% RTX, 43.5% TNF inhibitors, 8.3% IL-6 blockers and 13% abatacept. At cohort level, we found hypogammaglobulinemia in 12.5% for IgG, 9.6% for IgM and 7.7% for IgA, independent of the treatment duration. Low IgG levels were related mostly to RTX exposure (53.8%) followed by TNFi (23.1%) and with equal values anti-IL-6, JAKi and csDMARDs (7.7%). Low IgA levels were noted almost in RTX exposure (75%), followed by TNFi and anti-IL-6 (12.5%, each). Low IgM levels appeared in RTX group (90%) and csDMARDs (10%). No relations between Ig levels and the treatment option (the line of intervention). The Ig mean levels were significantly different across treatment groups; for IgG: 9.55g/L in RTX vs 11.68g/L in TNF inhibitors (p<0.05) and 12.64g/L in csDMARDs (p<0.05); for IgA: 2.17g/L in RTX vs 3.35 in JAKi (p<0.05); for IgM: 0.84g/L in RTX vs 1.82g/L in TNF inhibitors (p<0.001) and 1.58g/L in JAKi (p<0.05); also IgA were significantly lower in csDMARD group (1.22g/L compared to TNF inhibitors values 1.82g/L, p<0.05). The serum levels of IgG and IgM (not IgA) were negatively associated with disease duration r = -0.22, p<0.05 and r = -0.2, p<0.05 and age (r =-0.2, r=-0.26, p=0.01). No impact of disease activity, nor patient gender or seropositivity of rheumatoid factor or ACPA.

Conclusion: Low serum levels of IgG, IgM and IgA are seen mostly with RTX exposure, but appear with other treatment exposures as well, which may influence the rate of future infections. If our study lacks assessment of baseline Ig levels, it is clear that treatment option has an influence on Ig levels. Future studies are needed to clarify all contributors to these results.

REFERENCES:

Disclosure of Interests: None declared.


ABO215

DOES THE PARNICY IMPROVE THE RHEUMATOID ARTHRITIS ACTIVITY?

E. Rahbi1, 2, H. Ferjani3, 4, 5, D. Ben Nessib3, 4, 5, L. Khatir1, 2, W. Triki1, 2, K. Lebbar1, 2, D. Kaffel4, 6, W. Hamdi4, 6, C. Kaddouch1, 2, 1Kassab Orthopedic Institute, Rheumatology Department, Mannouba, Tunisia; 2University Tunis el Manar, Faculty of Medicine of Tunis, Beb Saadoun, Tunisia; 3Kassab Orthopedics Institute, Institute Rheumatology Department, Ksar Said, Tunisia; 4University Tunis el Manar, Tunisia, Faculty of Medicine of Tunis, Beb Saadoun, Tunisia; 5Research Unit UR17SP04, Ksar Said, Tunisia; 6Research Unit UR17SP04, Ksar Said, Tunisia

Background: Parnic is known for its anti-inflammatory activity and its potential to reduce inflammation. The purpose of this study was to evaluate the impact of Parnic on the inflammatory markers, pain, and functional status in patients with rheumatoid arthritis.

Objectives: To examine time trends in the characteristics of patients with rheumatoid arthritis (RA) undergoing total joint replacement (TJR). Methods: A total of 271 patients (399 joints) with RA underwent TJR of large joints (hip, knee) at Republican Clinical Hospital, Kazan between 2002 and 2021. Of these, 98 patients were retrospectively examined between 2002 and 2011; 183 patients were observed prospectively in the perioperative period by a rheumatologist and orthopedist from 2012 to 2021. Of the 183 patients, 65.5% underwent one joint replacement, 19.1% underwent two joint replacements, 13.7% underwent three joint replacements, and 1.7% underwent four joint replacements during the study period. All patients met the 1987 ACR classification criteria or the ACR/EULAR diagnostic criteria. Median (interquartile range (IQR)) age at surgery was 56 (49, 63), the time from the onset of RA to TJR was 11 (7, 18) years. During the study period, total knee replacement was performed most often (67.9%). Joint pain (VAS), disease activity - DAS28, function of the HAQ index were assessed before the operation, after 6 and 12 months in the active observation group.

Results: In patients in 2002-2011, TJR were performed earlier from the time of the onset of RA compared to the 2012-2021 group [median (IQR), 10 (7-17) vs. 8-19 years, p=0.01], and there were more complications of surgery (16.3% vs. 5.4%, p<0.001). In the later period (2012-2021), there was a decrease in blood loss and operation time, p<0.05. With respect to RA treatment, a significant increasing trend was observed in the proportion of patients receiving methotrexate (p=0.006) and biological drugs and biologics (p<0.001).

In the prospective observation group (n=183), patients were significantly older at the time of TJR with low and moderate activity RA (n=106) compared with high activity (n=77) [median (IQR), 57 (51, 64) vs. 55 (46, 63), p=0.034]. A significantly less time from RA onset to TJR was observed in patients with high activity, using glucocorticoids. Patients who had the use of glucocorticoids TJR was performed earlier than non-users [median (IQR) 11 (6, 16) and 13 (8, 19) years, respectively, p=0.041]. There was no significant difference in time from the onset of RA to TJR, stratified by gender and the use of MTX, biological drugs. At the same time, there was no significant difference in dependence on the activity RA to reduce pain syndrome (VAS), improve function (HAQ) after surgery and presence of postoperative complications.

Conclusion: Over a 20-year period changes were observed in the characteristics of patients with RA undergoing TJR with an increase in the time before surgery. Perioperative management of patients by a rheumatologist and orthopedist can reduce blood loss, the number of complications after surgery. Patients with high RA activity and using glucocorticoids need TJR at an earlier time. Arthropathy in patients with highly active RA is also effective in improving functional ability.

Disclosure of Interests: None declared.

Background: The parity seems to decrease the risk of auto-immune diseases like Rheumatoid arthritis (RA). The risk reduction appeared when the parity number reached two [1]. The activity of RA improved during pregnancy and flares postpartum, but the relationship of parity to RA prognosis is unclear. The impact of childbirth on disease activity is less studied.

Objectives: We aimed to investigate the impact of parity on rheumatoid arthritis activity.

Methods: We conducted a retrospective study including patients fulfilling the American Congress Of Rheumatology / European League Against Rheumatism (ACR/EULAR) 2010 criteria.

We collected epidemiological, clinical, biological (C-reactive protein: CRP, erythrocyte sedimentation rate (ESR), immunological status (rheumatoid factor RF and anti-citrullinated protein/peptide antibody ACPA), and disease activity index (The Disease Activity Score 28 DAS28). We divided our patients into two groups: group (G1): the nulliparous women; group (G2): women who gave birth.

Results: Ninety-two patients were enrolled. There were 14 men and 78 women. The mean age was 59.56 ± 11.7 years. The mean disease duration was 9.32 ± 8.22 years. Among 78 women, we found 50 patients with parity. The main swollen joint was 3.34 ± 3.6 in G2 versus 4.44 ± 4.04 in G1 (p=0.94). The mean painful joints were 6.74 ± 5.12 and 9 ± 1.91 (p=0.28), respectively. However, the inflammatory syndrome is higher among women in G2. The mean CRP level was 15.1 mg/l, and the mean ESR was 37.7 mm. In G1, the RF and ACPA were 131 U/l and 281 U/l, respectively compared with 568 U/l and 315 U/l, respectively in G2.

A significant difference was noted in the DAS28-ESR between the two groups (G2: 4.18 ± 1.23 versus G1: 4.49 ± 2.5, p=0.04).

However, no association was found between parity and disease activity using the DAS28-ESR.

Conclusion: Our study showed that parity could have a protective effect on disease activity. It seems to be associated with a lower joint count and a lower rate of RF and ACPA. However, more studies are necessary to conclude these issues.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4122

AB0216

FATIGUE ASSESSMENT IN RHEUMATOID ARTHRITIS, SANTO DOMINGO, DOMINICAN REPUBLIC


1Hospital Docente Padre Billini, Rheumatology, Santo Domingo, Dominican Republic

Background: Rheumatoid arthritis (RA) is an inflammatory, systemic autoimmune disease affecting the synovial membrane of small joints.1 Wagan et al demonstrated that the frequency of fatigue in rheumatoid arthritis is 62%.2 Hammam et al described a higher rate of fatigue associated with higher disease activity. Fatigue is as a feeling of exhaustion, also as a reduction in physical and mental capacity.3 It can be measured with the scale FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue), which evaluates the last 7 days, with a score of 0-52. For the severity analysis, 4 grades are used: no or mild fatigue (40-52), moderate (27-39), severe (14-26) and extreme fatigue (0-13).2,5

Objectives: To evaluate the frequency and degree of fatigue in rheumatoid arthritis.

Methods: Prospective, observational, cross-sectional study of a cohort of patients of the Rheumatology Service at Hospital Docente Padre Billini. Patients were interviewed in July 2021. Inclusion criteria: ≥ 18 years, diagnosis of RA according to the ACR/EULAR 2010 classification criteria. Exclusion criteria: previous diagnosis of fibromyalgia, depression or anxiety, treatment with antidepressants, antihistamines, beta-blockers. Scales measured: FACIT-F, DAS28, CDAI, and HAQ-DI. Statistical analysis was performed with the Pearson correlation (r). Data were analyzed in IBM-SPSS v23.

Results: 597 patients met inclusion criteria. 93% female, mean age 58.5±12.4 years, mean disease duration 7.5 years. HT 73.9% (441), DM 14.2% (85), dysimmune disease affecting the synovial membrane of small joints.1 Wagan A. et al found the frequency of sexual dysfunction in RA to be 69.2%.2 Pain is considered to have a fundamental role associated with the decrease in the frequency of sexual intercourse.3 The CSFQ-14 (Changes in Sexual Functioning Questionnaire), evaluates the changes in sexual functioning due to a disease and/or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction <41 men and <47 women.4

Objectives: To evaluate the frequency and degree of sexual dysfunction in patients with rheumatoid arthritis.

Methods: Prospective, observational, cross-sectional study of a cohort of patients of the Rheumatology Service at Hospital Docente Padre Billini. Patients were interviewed in July 2021. Inclusion criteria: > 18 years, diagnosis of RA according to the ACR/EULAR 2010 classification criteria, at least 1 sexual intercourse. Exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes, treatment with antidepressants, antiepileptics, narcotics. Scales measured: CSFQ-14, DAS28. Statistical analysis was performed with the Pearson correlation (r) with p<0.05. Data were analyzed in IBM-SPSS v23.

Results: Of the RA cohort, 483 met inclusion criteria. 93.4% (451) female, mean age 58±12.6 years, mean duration of diagnosis 8 years, married 53.8% (260), single 27.3% (134), widowed 16.6% (80), hypertension 73.9% (357), dyslipidemia 21.5% (104), obesity 18.0% (87), smoking 9.9% (48). Frequency of sexual dysfunction 61.3% (296). Sexual dysfunction in women 93.9% (278) and men 6.1% (18). Global domains: desire/interest 55.7% (165), desire/frequency 56.4% (167), pleasure 58.1% (172), arousal/excitement 67.2% (199), orgasm/ completion 50.0% (148), Female: desire/interest 94.5% (156), desire/frequency 93.4% (156), pleasure 93.6% (161), arousal/excitement 93.0% (189), orgasm/ completion 93.9% (139), Male: desire/interest 5.5% (9), desire/frequency 11.6% (11), pleasure 6.4% (11), arousal/excitement 7.0% (14), orgasm/completion 6.1% (9). Desire/interest dysfunction: DAS28 remission or low activity 28.5% (47), moderate 53.3% (88), high activity 4.8% (8). Desire/frequency: DAS28 remission or low activity 35.3% (59), moderate 47.3% (79), high activity 3.6% (6). Pleasure: DAS28 remission or low activity 30.2% (52), moderate 50.0% (86), high activity 2.9% (5). Arousal/excitement: DAS28 remission or low activity 25.1% (50), moderate 55.8% (111), high activity 6.0% (12). Orgasm/completion, Pain is considered to have a fundamental role associated with the decrease in the frequency of sexual intercourse.
Conclusion: The study showed a high frequency of sexual dysfunction, observing greater dysfunction in females. In the population, the most affected global domain was arousal/excitement, and it was the most frequent in female and male.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4202

AB0218 ASSOCIATION OF PULSE PRESSURE AND CAROTID INTIMA MEDIA THICKNESS IN RHEUMATOID ARTHRITIS PATIENTS

N. Guañardo-Jauregui1, L. J. Colunga-Pedraza1, D. A. Galarza-Delgado1, J. R. Azpíri-López2, A. Cárdenas3, A. N. Garza-Cisneros4, A. Garcia-Heredia5, M. A. Balderas-Palacios1, A. B. Rodriguez-Romero1. 1Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Rheumatology, Monterrey, Mexico; 2Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Cardiology, Monterrey, Mexico

Background: Rheumatoid arthritis (RA) patients have increased cardiovascular risk than the general population. Systemic inflammation causes a proatherogenic state in this group of patients (1). The carotid ultrasound is a useful diagnostic tool for the detection of subclinical atherosclerosis; however, it is not available for all patients. Pulse pressure, defined as the difference between systolic and diastolic blood pressure, has been associated with atherosclerosis in the general population (2). Information in RA patients is lacking.

Objectives: We aimed to correlate pulse pressure and carotid intima media thickness (cIMT) in RA patients.

Methods: This was a cross-sectional study. We recruited a total of 92 patients with RA diagnosis, according to the 2010 EULAR/ACR classification criteria, aged 40-75 years. Patients with a previous cardiovascular event, another connective tissue disease or pregnancy were excluded. An ultrasound of the carotid arteries was performed in all patients by a certified radiologist blinded to clinical information. cIMT was measured in the left and right carotid arteries. An average of both cIMT was obtained for each patient for this analysis. Correlation between pulse pressure and cIMT was determined with the Spearman’s correlation coefficient (rs). A p-value <0.05 was considered statistically significant.

Results: Mean age of RA patients was 58.9 ± 6.6 years. Most of them were women (92.4%). With a median disease duration of 10.5 (4.2-17.5) years. Median cIMT was 0.08 (0.07-0.10) mm, and median pulse pressure was 50 (40-55) mmHg (Table 1). We found a significant positive correlation between pulse pressure and cIMT in RA patients (rs = 0.254, p = 0.015) (Figure 1).

Conclusion: Higher pulse pressure was associated with higher cIMT in RA patients. Pulse pressure may be useful for the detection of high-risk patients who would benefit from a carotid ultrasound evaluation, to identify patients with high cIMT.

REFERENCES:

Disclosure of Interests: None declared

AB0219 ASSOCIATION OF DISEASE ACTIVITY AND THE PRESENCE OF BILATERAL CAROTID PLAQUE IN RHEUMATOID ARTHRITIS PATIENTS

N. Guañardo-Jauregui1, D. A. Galarza-Delgado1, J. R. Azpíri-López2, I. J. Colunga-Pedraza1, A. Cárdenas3, A. N. Garza-Cisneros4, A. Garcia-Heredia5, M. A. Balderas-Palacios1, A. B. Rodriguez-Romero1. 1Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Rheumatology, Monterrey, Mexico; 2Hospital Universitario “Dr. José Eleuterio González” Universidad Autónoma de Nuevo León, Cardiology, Monterrey, Mexico

Background: Cardiovascular (CV) disease is the major cause of death of RA patients. There is a direct association of systemic inflammation and an accelerated process of atherosclerosis, which is related to higher CV morbidity (1). Additionally, RA patients with bilateral carotid plaque (CP) had a two-fold risk of developing a CV event compared to patients with unilateral CP (2).

Objectives: To compare disease activity and other disease characteristics of RA patients with bilateral and unilateral CP.

Methods: This was a cross-sectional study nested of a RA patients’ cohort. We recruited RA patients who fulfilled the 2010 ACR/EULAR classification criteria. Patients with a previous CV event, another connective tissue disease, or pregnancy were excluded. Disease activity was assessed with DAS28-CRP. A carotid ultrasound was performed to all RA patients, and the presence of CP was considered as a carotid intima-media thickness ≥ 1.2 mm or a focal narrowing ≥ 0.5 mm. All RA patients with bilateral CP were included in this study and matched by age (± 5 years), gender, and traditional CV risk factors to RA patients with unilateral CP by a rheumatologist blinded to clinical information. Comparisons were done with Chi-square test for qualitative variables and Student’s t test or Mann-Whitney’s U test for quantitative variables. A p-value < 0.05 was considered statistically significant.

Results: Mean age of RA patients with bilateral CP was 61.98 ± 6.82 years as compared to 59.70 ± 6.74 years in patients with unilateral CP (p = NS). In the population, the most affected global domain was arousal/excitement, which was the most frequent in female and male. In the population, the most affected global domain was arousal/excitement, which was the most frequent in female and male.

Conclusion: The study showed a high frequency of sexual dysfunction, observing greater dysfunction in females. In the population, the most affected global domain was arousal/excitement, which was the most frequent in female and male.

REFERENCES:

Disclosure of Interests: None declared

Table 1. Demographic and disease characteristics.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>RA patients (n=92)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD</td>
<td>58.9 ± 6.6</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>85 (92.4)</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>17 (18.5)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>33 (35.9)</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>30 (32.6)</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>30 (32.6)</td>
</tr>
<tr>
<td>Active smoking, n (%)</td>
<td>11 (12.0)</td>
</tr>
<tr>
<td>Disease duration, years, median (IQR)</td>
<td>10.5 (4.2-17.5)</td>
</tr>
<tr>
<td>CRP mg/dl, median (IQR)</td>
<td>0.70 (0.51-1.25)</td>
</tr>
<tr>
<td>ESR, mm/h, median (IQR)</td>
<td>21.0 (13.0-33.2)</td>
</tr>
<tr>
<td>Pulse pressure, mmHg, median (IQR)</td>
<td>50 (45-55)</td>
</tr>
<tr>
<td>cIMT, mm, median (IQR)</td>
<td>0.08 (0.07-0.10)</td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; T2DM, type 2 diabetes mellitus; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; cIMT, carotid intima media thickness.
moderate-high activity category is an independent risk factor for the presence of bilateral CP, OR 3.18, 95% CI 1.033-9.812, \( p = 0.044 \).

### Table 1. Comparison of disease characteristics.

<table>
<thead>
<tr>
<th>Variables</th>
<th>RA patients with bilateral CP (n=30)</th>
<th>RA patients with unilateral CP (n=30)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease duration, years, median (IQR)</td>
<td>7.86 (2.97-19.18)</td>
<td>9.02 (6.45-13.66)</td>
<td>NS</td>
</tr>
<tr>
<td>CRP, mg/dl, median (IQR)</td>
<td>1.06 (0.67-19.93)</td>
<td>0.64 (0.43-1.06)</td>
<td>0.012</td>
</tr>
<tr>
<td>DAS28-CRP, mean ± SD</td>
<td>3.83 ± 1.27</td>
<td>3.05 ± 1.32</td>
<td>0.023</td>
</tr>
<tr>
<td>Moderate-high activity, n (%)</td>
<td>21 (70.3)</td>
<td>13 (43.3)</td>
<td>0.037</td>
</tr>
<tr>
<td>Anti-CCP, median (IQR)</td>
<td>15.30 (3.16-19.65)</td>
<td>115.73 (1.60-196.05)</td>
<td>NS</td>
</tr>
<tr>
<td>FR IgG, median (IQR)</td>
<td>5.84 (2.00-17.13)</td>
<td>5.25 (2.00-20.41)</td>
<td>NS</td>
</tr>
<tr>
<td>FR IgM, median (IQR)</td>
<td>156.86 (27.93-200.00)</td>
<td>197.22 (65.71-200.00)</td>
<td>NS</td>
</tr>
<tr>
<td>GC, n (%)</td>
<td>16 (55.2)</td>
<td>11 (36.7)</td>
<td>NS</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>3 (10.3)</td>
<td>6 (20.0)</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS, no significant; RA, rheumatoid arthritis; CRP, C-reactive protein; anti-CCP, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; MTX, methotrexate; GC, glucocorticoids; bDMARD, biologic disease modifying antirheumatic drugs.

Conclusion: We found that RA patients with bilateral CP had higher levels of CRP levels, higher DAS28-CRP, and a higher prevalence of being classified in the moderate-high disease activity category, which was independently associated to the presence of bilateral CP. Emphasis should be placed on tight disease control to prevent the development of a major CV events in RA patients.

REFERENCES:


Disclosure of Interests: None declared


**Table 1. Baseline characteristics of patients with and without reduction of cIMT.**

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
<th>Patients with cIMT reduction (n=10)</th>
<th>Patients without cIMT reduction (n=29)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD</td>
<td>48.88 ± 8.59</td>
<td>59.30 ± 9.46</td>
<td>0.004</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>0 (0)</td>
<td>3 (10.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>1 (10)</td>
<td>11 (37.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>0 (0)</td>
<td>10 (34.5)</td>
<td>0.040</td>
</tr>
<tr>
<td>Active smoking, n (%)</td>
<td>0 (0)</td>
<td>2 (6.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>6 (60)</td>
<td>8 (27.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Statins, n (%)</td>
<td>2 (20)</td>
<td>7 (24.1)</td>
<td>NS</td>
</tr>
<tr>
<td>MTX, n (%)</td>
<td>9 (90)</td>
<td>23 (78.3)</td>
<td>NS</td>
</tr>
<tr>
<td>GC, n (%)</td>
<td>6 (60)</td>
<td>16 (55.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR, mm/h, median (IQR)</td>
<td>14.50 (9.00-21.25)</td>
<td>28.0 (17.0-42.0)</td>
<td>0.024</td>
</tr>
<tr>
<td>ESR &lt;20 mm/h, n (%)</td>
<td>7 (70)</td>
<td>8 (27.6)</td>
<td>0.027</td>
</tr>
<tr>
<td>CRP, mg/dl, median (IQR)</td>
<td>0.75 (0.45-1.28)</td>
<td>0.91 (0.06-1.62)</td>
<td>NS</td>
</tr>
<tr>
<td>DAS28-ESR, mean ± SD</td>
<td>4.30 ± 1.04</td>
<td>4.66 ± 1.00</td>
<td>NS</td>
</tr>
<tr>
<td>DAS28-CRP, mean ± SD</td>
<td>3.23 ± 0.90</td>
<td>3.49 ± 1.06</td>
<td>NS</td>
</tr>
</tbody>
</table>

cIMT, carotid intima media thickness; T2DM, type 2 diabetes mellitus; MTX, methotrexate; GC, glucocorticoids; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, disease activity score 28 joints.

Conclusion: Our results show that patients without dyslipidemia and with lower ESR levels, a proinflammatory biomarker, had a reduction in cIMT, which decreases the risk of developing a major CV event. Emphasis should be placed on tight control of disease activity and traditional CV risk factors. A follow-up carotid ultrasound evaluation in RA patients may be necessary, to identify those who would benefit from an opportune treatment.

REFERENCES:


Disclosure of Interests: None declared

**AB0221**

**DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS IN THE CLINICAL PRACTICE OF A RHEUMATOLOGY CENTER**

A. Gordeev, 1, E. Matianova, 1, Y. Olyun, 1, E. Galushko, 1, V.A. Nasonova
Rheumatology Research Institute, Rheumatoid Arthritis Evolution Laboratory, Moscow, Russian Federation

**Objectives:** To compare the features of the disease course and the therapy in rheumatoid arthritis (RA) patients who meet and do not meet the difficult to treat (D2T) criteria.

**Methods:** RA patients admitted to the V.A. Nasonova Research Institute of Rheumatology for therapy correction from March to October 2021 were included. All patients fulfilled the RA criteria of ACR/EULAR 2010. According to the opinion of the attending physician, they needed correction of therapy, so they were sent to the expert commission to confirm the expediency of using biologic or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs).

**Results:** 295 RA patients with high or moderate disease activity according to DAS28 were included. The expert commission in all cases confirmed the validity of administration of biologic or ts DMARDs. 111 (37.6%) patients (group A) were prescribed these drugs for the first time due to the unsatisfactory result of the use of conventional synthetic (cs) DMARDs. 105 (35.5%) patients were planned to continue treatment with previously used biologic or ts DMARDs after a break associated with various reasons (group B). In 54 (18.3%) cases, first biologic or ts DMDART failed so second biologic or ts DMDART was prescribed (group C). The D2T group included 25 (8.4%) patients with a history of inefficiency or intolerance of 2 or more biologic or ts DMARDs of different mechanisms of action. The duration of RA in the D2T group was significantly longer than in the rest of the patients (respectively 15.9 ± 11.8 and 11.9 ± 9 years, p = 0.04). Radiological changes of joints in D2T RA were more significant than those in the rest of the patients. The Ill or IV Steinerbrocker stage of RA in the D2T group was detected in 18 (72%) while in the remaining patients - in 130 (48.1%) cases (p = 0.02). At the same time, there was a correlation between the duration of RA and the X-ray stage (p = 0.0001). At the time of hospitalization, patients with D2T had higher inflammatory activity than group B patients who continued therapy with biologic or ts DMARDs. In groups A and C, all the analyzed signs of inflammation were also significantly higher than in group B (p < 0.05). Methylxamate had been most often prescribed as the first cs DMARD in all groups but at the time of hospitalization, patients with D2T RA were more likely than other patients to remain without DMARDs (in 8 (32%) and 39 (14.4%) cases respectively, p = 0.03). 73.3 - 84% of patients in all groups earlier received glucocorticoids (GC). At the time of hospitalization, the dose of GC in D2T group was higher than in other patients and averaged 8.3 ± 5.1 mg /day and 6.4 ± 2.9 mg /day, respectively, p = 0.02. The proportion of patients taking GC in the D2T group was also higher than that among other patients, but these differences did not reach statistical significance. In D2T RA, adverse events associated with biologic DMARDs occurred more often than in groups B and C (respectively in 9 (36%) and 15 (9.4%) patients; p = 0.001).

**Conclusion:** The formation of D2T RA in our patients could be associated with the prescribing of higher doses of GC and insufficient use of DMARDs. The development of D2T RA was accompanied by a more pronounced progression of radiological changes of the joints than in other patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4244

---

**AB0222**

**THE ALBUMIN TO GLOBULIN RATIO AS A NOVEL INFLAMMATORY MARKER OF RHEUMATOID ARTHRITIS**

M. Liu, 1, Z. Huang, 2, Y. Huang, 1, Z. Huang, 1, Q. Huang, 1, T. Li, 1,2,3, 1Guangdong Second Provincial General Hospital, Department of Rheumatology and Immunology, Guangzhou, China; 2Southern Medical University, The Second School of Clinical Medicine, Guangzhou, China; 3Zhaoming People's Hospital, Department of Rheumatology and Immunology, Zhaoming, China

**Background:** The albumin to globulin ratio (AGR) has recently been identified as a new prognostic factor in patients with several types of cancer. However, the correlation of AGR and the disease activity in patients with rheumatoid arthritis (RA) have not been reported.

**Objectives:** This study aimed to explore the clinical value of AGR in RA and its association with disease activity.

**Methods:** This retrospective study collected 137 RA patients and 82 age- and sex-matched healthy controls. Neutrophil, lymphocyte, monocyte, platelet, albumin, globulin, AGR, neutrophil to lymphocyte ratio (NLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Disease Activity Score of 28 joints (DAS28-ESR) and other laboratory parameters were recorded. Receiver operating characteristic (ROC) curves were used to determine the area under curve (AUC) value. The relationships between inflammatory indexes and DAS28-ESR were checked.

**Results:** The AGR was lower in RA patients than in healthy subjects (P < 0.05) and decreased significantly along with the disease activity of RA patients (P < 0.05). According to the ROC curve which was conducted to discriminate RA patients from healthy individuals, the AGR (0.881, 95% CI: 0.837 - 0.924) showed the highest AUC than albumin (0.868, 95% CI: 0.823 - 0.914), globulin (0.789, 95% CI: 0.729 - 0.849), NLR (0.801, 95% CI: 0.742 - 0.859), MLR (0.762, 95% CI: 0.699 - 0.826) and PLR (0.803, 95% CI: 0.745 - 0.860). Spearman analyses showed that AGR was inversely associated with DAS28-ESR (r = -0.545, P < 0.001). Besides, the relevance between AGR and DAS28-ESR was higher than albumin (r = -0.381, P < 0.001), globulin (r = 0.492, P < 0.001), NLR (r = 0.444, P < 0.001), MLR (r = 0.189, P = 0.027) and PLR (r = 0.423, P < 0.001).

**Conclusion:** The results demonstrated that the AGR was decreased in RA patients and may be a potential marker for monitoring the disease activity of RA patients.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4247

---

**AB0224**

**JAK-INHIBITORS ATTAIN A RAPID AND PERSISTENT EFFECTIVENESS ON SEVERAL PATIENT-REPORTED OUTCOMES IN LONG-STANDING RHEUMATOID ARTHRITIS**

S. Monti, 1, E. Bozzalia Cassione, 1, M. Biggioggero, 2, G. Crepaldi, 3, B. Bazzani, 4, C. Lomater, 1, R. Gorla, 1, E. Favalli, 1, S. Balduzzii, 1, R. Caporalii, 1, C. Montecucco, 1
1University of Pavia, IRCCS Policlinico San Matteo, Department of Rheumatology, Pavia, Italy; 2Istituto Gaetano Pini, Department of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Department of Rheumatology, Pavia, Italy
FRAX ASSESSMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS PREDICTED THE REAL INCIDENCE OF CLINICAL FRACTURES FOR 10 YEARS FROM THE RESULTS OF THE 10-YEAR TOMORROW STUDY

K. Mamoto1, T. Koike2, T. Okano1, Y. Sugioaka1, M. Tada4, K. Inui1, H. Nakamura1, Osaka City University Graduate School of Medicine, Department of Orthopaedic Surgery, Osaka, Japan; 2Osaka City University Graduate School of Medicine, Center for Senile Degenerative Disorders (CSDD), Osaka, Japan; 3Shirahama Foundation for Health and Welfare, Search Institute for Bone and Arthritis Disease (SINBAD), Wakayama, Japan; 4Osaka City General Hospital, Department of Orthopaedic Surgery, Osaka, Japan; 5Osaka Saiseikai Nakatsuka Hospital, Department of Orthopaedic Surgery, Osaka, Japan

Background: To investigate if FRAX in patients with RA can predict the incidence of new clinical fractures for 10 years by using the 10-year data of the TOMORROW study (UMIN000003876) which is a prospective cohort study.

Objectives: To investigate if FRAX in patients with RA can predict the incidence of new clinical fractures for 10 years by using the 10-year data of the TOMORROW study (UMIN000003876) which is a prospective cohort study.

Methods: We calculated ten-year probability of major osteoporotic fracture (FRAX) in 208 RA patients and 205 sex- and age-matched volunteers (Vo), and compared FRAX with the incidence of clinical fractures for 10 years.

Results: The mean FRAX were 14.5 and 8.8% in 175 RA patients and 168 Vo, respectively, in whom we could calculate FRAX at baseline and complete to investigate the incidence of clinical fractures for 10 years from baseline. The mean FRAX in RA patients was significantly higher than that in Vo (P<0.001). The actual incidence of clinical fractures for 10 years in RA patients was significantly higher than that in Vo (33.9 vs 22.9%, P=0.031). In both groups, the actual incidence of clinical fractures was higher than FRAX prediction.

Discussion: We confirmed that FRAX was the risk factor for clinical fractures in actual clinical practice.

Disclosure of Interests: None declared


AB0226

CLINICAL SIGNIFICANCE OF SOLUBLE ST2 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).

Y. Gorbunova1, T. Popkova1, I. Kirllova1, L. Kondrateva1, M. Diatropov2, A. Lila1, E. Nasonov2, VA Nasonova Research Institute of Rheumatology, of Systemic Rheumatic Diseases, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation

Background: The role of soluble ST2, the IL-33 receptor, in the pathogenesis of rheumatoid arthritis (RA) is discussed in the literature. Objectives: To assess the levels of soluble ST2 marker initially (against the background of ineffective basic anti-inflammatory therapy (DMARD) and after 12 months of combination therapy (DMARD + biological therapy).

Methods: The study included 47pts (39 women /8 men) with RA, 51 [39,0; 63,0] years old. Pts were seropositive for IgM RF (79%) and anti-CCP (62%), with highly active RA (DAS28 5.7 [5,2; 6,4]; SDAI 35,0 [29,1; 43,6], CDAI 34.0 [25,0; 43,0]), scores, and median disease duration of 4.0 [3,0;14,0] years. All patients with RA had a history of insufficient effect or intolerance to two or more basic anti-inflammatory drugs (DMARDs). At the time of inclusion in the study, patients received DMARDs: 44% of patients received methotrexate (median dose - 15 (15; 20) mg /week), 35% - leflunomide (20 mg / day), 9.3% - sulfasalazine (2000mg / day), 7% - hydroxychloroquine (200mg / day), 67.4% - glucocorticoids (5 (4; 8) mg / day). Patients did not receive biological

Disclosure of Interests: None declared


Figure 1. Improvement of patient-reported outcomes over the period of observation

Conclusion: Treatment with JAKi ensures a very rapid and persistent improvement of several PROs, including pain, fatigue and physical function, as early as 2 weeks treatment even in patients with long-standing RA treated with several lines of previous DMARDs.

Disclosure of Interests: None declared

therapy at the time of inclusion in the study. Due to lack of efficacy or intolerance, patients with RA (n=21) were prescribed biological therapy: 52.4% - anti-B cell therapy, 38% - TNF-alpha inhibitors, 9.6% - IL-6 inhibitors. The control group consisted of 20 age-matched donors without rheumatic diseases. The concentration of soluble ST2 was determined by enzyme immunoassay (Cristal Diagnostics, San Diego). The upper limit of normal when testing 20 sera from healthy donors was 17.65 ng/ml, corresponding to the 95th percentile.

**Results:** The level of soluble ST2 in patients with late RA (n=47) was higher than in the control group (n=20) (14.2 [11.5;20.1] ng/ml versus 10.65 [9.3; 13.1] ng/ml) (p<0.001). Patients with RA and elevated serum ST2 levels (≥17.65 ng/ml) were older than patients with ST2 levels ≤17.65 ng/ml (58.5 [50;68] vs 47.0 [38;59] years) (p=0.007). In the group of patients (n=21) who received combination therapy for 12 months, there was a statistically significant decrease in clinical and laboratory activity, levels of RF IgM and soluble ST2 in blood serum, compared with baseline (13.8 [11.5; 18.4] ng/ml vs 12.5 [9.6;13.8] ng/ml (p<0.05 in all cases),Table 1). In the group of patients (n=21), after 12 months of combination therapy, direct correlations were noted between the delta (Δ) of the level of soluble ST2 and Δ DAS28 (R=0.59; p=0.006), Δ CRP (R=0.55; p =0.01), Δ anti-CCP (R=0.49; p=0.04).

**Conclusion:** In patients with high RA activity and the ineffectiveness of basic anti-inflammatory therapy, the level of soluble ST2 in serum was increased compared to the control group. After 12 months of effective anti-rheumatic therapy, the level of this marker decreased. The association of this marker with the clinical and laboratory activity of RA suggests its role in the development of rheumatoid inflammation.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4629

---

**Table 1.**

<table>
<thead>
<tr>
<th>Patients with RA (n=21) with insufficient effect of basic anti-inflammatory therapy</th>
<th>Patients with RA (n=21) after 12 months of receiving combination therapy</th>
<th>Δ, %</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>24.16 (21.23; 26)</td>
<td>25.15 (23.43;26.7)</td>
<td>+4.1</td>
</tr>
<tr>
<td>DAS28</td>
<td>5.6 (3.3; 6.7)</td>
<td>3.97 (3.36; 6.43)*</td>
<td>-30.4</td>
</tr>
<tr>
<td>SDAI</td>
<td>38.17 (29.9, 46.4)</td>
<td>17.2 (9.57;25.6)*</td>
<td>-54.8</td>
</tr>
<tr>
<td>CDAI</td>
<td>35.0 (26.0, 43.5)</td>
<td>17.0 (9.0;23.5)*</td>
<td>-51.4</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>20.16 (17.34; 24)</td>
<td>3.10 (2.12;7.2)*</td>
<td>-84.7</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>7.20 (6.96; 9.5)</td>
<td>16.0 (10;23.5)*</td>
<td>-40.7</td>
</tr>
<tr>
<td>IgM RF, MЕ/ml</td>
<td>84.4 (80.8;163.0)</td>
<td>32.2 (10.6;107)*</td>
<td>-61.8</td>
</tr>
<tr>
<td>ST2, ng/ml</td>
<td>13.8 (11.5;18.4)</td>
<td>12.5 (9.6;13.8)*</td>
<td>-9.4</td>
</tr>
</tbody>
</table>

* - p <0.05 reliability of differences in indicators before and after 12 months of combination therapy (Wilcoxon); Δ - the difference in indicators between the groups by the 12th month of combination therapy.

**REFERENCES:**


---

**TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING**

L. Ai1, M. Higashi2, K. Lee1, Z. Liu1, L. Jin1, K. Raja1, Y. Mai1, T. Jun2, W. Oh2,3, Q. Pan1, E. Schadt1,4, X. Wang1.

**AB0227**

**Results:** Our study cohort consisted of 8,040 patients who had at least one line of therapy for RA. Conventional synthetic DMARDs (csDMARDs) were the predominant first line of therapy in this dataset (71.3%), followed by TNFi alone (11.1%) or TNFi combined with csDMARD (9.1%) (Figure 1). For patients who had csDMARD as their first line of therapy, 22.93% progressed to second line treatment. Among them 36.2% were TNFi with or without in combination with csDMARDs. In the second-line, TNFi + csDMARDs were associated with a longer TTNT (median time: 13.1 months vs 6.1 months, P < 0.005) compared to TNFi monotherapy. The multiple variable model (adjusted for age, gender, and race) demonstrated that second-line TNFi + csDMARDs had a lower hazard rate when compared to TNFi monotherapy (HR = 0.74, 95% CI: 0.36 - 1.12, p < 0.005).

**Conclusion:** We demonstrated the first comprehensive treatment sequencing patterns in RA from a real-world setting. As a second-line therapy for patients with inadequate response to csDMARDs, the TNFi + csDMARDs combination may improve duration of response when compared to TNFi monotherapy. Results from this study will inform future sequencing strategies to improve patient outcomes.

**Disclosure of Interests:** Lei Ai: None declared, Mitchell Higashi: None declared, Kyeryoung Lee: None declared, Zongzhi Liu: None declared, Lan Jin: None declared, Kalpana Raja: None declared, Yun Mai: None declared, Tomi Jun: None declared, William Oh Consultant of: Janssen Pfizer, Aviva Beckmann: None declared, Emilio Schadt: None declared, Zachary Schadt: None declared, Rick Wallsten: None declared, Ediz Calay: None declared, Kalpana Raja: None declared, Qi Pan: None declared, Eric Schadt Speakers bureau: Eli Lilly, Consultant of: SAB of Eli Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.4655

---

**THE CONNECTION BETWEEN NUTRITIONAL STATUS AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS**

L. Huang1,2, Y. Huang1, M. Liu1,2, Q. Huang1, Z. Ji1, S. Sun1,2, W. Deng1, T. W. Li2,3, Guangdong Second Provincial General Hospital, Department of Rheumatology and Immunology, Guangzhou, China; 2Southern Medical University; The Second School of Clinical Medicine, Guangzhou, China; 3Zhaoping Central People’s Hospital, Department of Rheumatology and Immunology, Zhaoping, China

**AB0228**

**Background:** Nutritional status is closely associated with a person’s physical condition. As for patients with autoimmune disease, nutritional status may affect the balance of immune system, which successively affects disease activity.

**Disclosure of Interests:** Lei Ai: None declared, Mitchell Higashi: None declared, Kyeryoung Lee: None declared, Zongzhi Liu: None declared, Lan Jin: None declared, Kalpana Raja: None declared, Yun Mai: None declared, Tomi Jun: None declared, William Oh Consultant of: Janssen Pfizer, Aviva Beckmann: None declared, Emilio Schadt: None declared, Zachary Schadt: None declared, Rick Wallsten: None declared, Ediz Calay: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt: None declared.
**Objectives:** The prognostic nutritional index (PNI), nutritional risk index (NRI), controlling nutritional status (CONUT) score and body mass index (BMI) are four widely used nutritional indices [1]. This study aimed to investigate the relationship between nutritional status and disease activity of rheumatoid arthritis (RA).

**Methods:** 168 RA patients and 50 healthy volunteers were retrospectively enrolled. According to the disease activity score using 28 joint counts-erythrocyte sedimentation rate (DAS28-ESR), the cohort of RA patients was divided into the lower disease activity groups (DAS28-ESR≤3.2) and the higher disease activity groups (DAS28-ESR>3.2). We recorded clinical assessment and laboratory data for further analysis. Spearman’s correlation, receiver operation characteristic (ROC) curves, binary logistic regression analysis were carried out.

**Results:** Compared to the higher disease activity group, the lower disease activity group had low-level total protein (TP), ESR and CRP (all P<0.05), while high-level albumin and PNI (all P<0.05). PNI and NRI were negatively correlated with DAS28-ESR (r=-0.395, and r=-0.200, all P<0.05), while CONUT score was positively correlated with DAS28-ESR (r=0.324, P<0.05). ROC curve illustrated that area under the curve (AUC) of PNI for RA patients with higher score was positively correlated with DAS28-ESR (r=0.324, P<0.05). ROC curve related with DAS28-ESR (r=-0.395, and r=-0.200, all P<0.05), while CONUT score using 28 joint counts-erythrocyte sedimentation rate (DAS28-ESR) was 0.693.

**Conclusion:** PNI may become a manageable marker for detect disease activity of rheumatoid arthritis using ROC curve.

**Disclosure of Interests:** None declared

**AB0230**  
**THE INFLUENCE OF THE PATIENT’S PSYCHOLOGICAL STATUS ON THE INFLAMMATORY ACTIVITY OF RHEUMATOID ARTHRITIS**

V. Vybakova1, A. Avdeeva1, E. Nasonov2, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology, Rheumatic Diseases, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Scientific Department, Moscow, Russian Federation

**Objectives:** To examine the relationship between rheumatoid arthritis (RA) activity indicators and psychological factors of patients receiving the therapy according to the “Treat to target” (T2T) strategy.

**Methods:** The research included 93 patients with early RA (16 men and 77 women), average age Me;IQR (59 [40; 66] years), the duration of the disease 7 [4-11,5] months. All patients were prescribed a subcutaneous form of methotrexate (MT) at an initial dose of 10 mg / week with a rapid escalation of the dose to 20-30 mg / week. If the effectiveness of the therapy was insufficient, biologics were prescribed. During the first year, patients received the therapy according to the concept of T2T, then they were observed in the -real-life- clinical practice. After 6 years, the patients were re-examined. Clinical examination was performed including patient global assessment (PGA), functional status was determined by HAQ, the nature of pain by painDETECT, the presence of anxiety and depression – by HADS.

**Results:** Before the start of the therapy, the DAS 28-ESR was 5.31 [4.79; 6.14], SDAI – 28.27 [18.79; 40.73], CDAI-25 [17; 36], HAQ – 1.32 [0.75; 1.25]. After 6 years DAS28-ESR 4 [3.4; 4.59], SDAI-15.06 [9.32; 21], CDAI-15 [9; 21], HAQ - 0.5 [0.25; 1], PGE - 35 [20; 50]. activity of disease according to DAS28-ESR remission in 78%, the low activity in 21.3%, the moderate activity in 60.6%, the high activity in 11.2% of patients. 29 patients had subclinically or clinically expressed anxiety (≥8 according to HADS), of whom10.3% had remission/low disease activity, 89.7% had moderate/high disease activity.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4682
**Table 1. Influence depression and anxiety symptoms of inflammatory activity**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Depressive positive, n=18</th>
<th>Depressive negative, n=75</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28-ESR</td>
<td>4.4 [3.8; 5]</td>
<td>3.9 [3.1; 4.5]</td>
</tr>
<tr>
<td>ESR, mm/hr</td>
<td>16 [13; 25]</td>
<td>16 [19; 27]</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>1.5 [0.6; 2.9]</td>
<td>2.4 [1.1; 5.9]</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.0 [7.5; 1.3]</td>
<td>0.5 [0.1]*</td>
</tr>
<tr>
<td>PGA</td>
<td>52.3 [37; 70]*</td>
<td>30 [15; 50]*</td>
</tr>
<tr>
<td>Anxiety positive, n=29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anxiety negative, n=64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR, mm/hr</td>
<td>20 [11; 33]</td>
<td>13 [9; 25]</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>1.9 [1.3; 3.3]</td>
<td>2.5 [1.1; 5]</td>
</tr>
<tr>
<td>HAQ</td>
<td>1.0 [5.1; 1.7]*</td>
<td>0.5 [0.6]*</td>
</tr>
<tr>
<td>PGA</td>
<td>50 [35; 70]*</td>
<td>25 [10; 40]*</td>
</tr>
</tbody>
</table>

**Conclusion:** The presence of depression and anxiety negatively influences the activity of RA, leading to an increase in pain and worsening of the functional disorders. To prescribe an adequate anti-rheumatic therapy, it is necessary to take into account not only the activity of RA, but also the psychological status of the patient.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4707

---

**REFERENCES:**


**DOI:** 10.1136/annrheumdis-2022-eular.4797

---

**AB0231**

**PROGNOSTIC UTILITY OF METACARPAL BONE MINERAL DENSITY MEASUREMENT IN PATIENTS WITH RECENT-ONSET ARTHRITIS BY ASSESSMENT OF RADIOGRAPHIC PROGRESSION AT 2-YEAR FOLLOW-UP**


**Background:** Rheumatoid arthritis (RA) and osteoporosis (OP) have a complex interplay in terms of pathogenic mechanisms. In this regard, radiogrammetry (DXR) of the hand, a technique that measures the bone mineral density (BMD) at the central metacarpals (MC), is associated with a worse prognosis in patients with RA (1). However, DXR is an expensive technique, and not very accessible in our environment. Our group demonstrated an excellent reproducibility of the MC measurement by DXA (2) and good correlation between BMD measurements obtained by DXR and DXA (3).

**Objectives:** To evaluate if baseline BMD of the non dominant MC measured by DXA can be used as a prognostic marker, resembling DXR, in patients with early arthritis (EA).

**Methods:** A total of 378 subjects from the PEARL (Princesa Early Arthritis Register Longitudinal) study underwent DXA measurement of the 2nd to 4th MC’s diaphyseal area of the non dominant hand (Hologic 4500). In PEARL sociodemographic, clinical and laboratory parameters, therapeutic data and radiographic findings are collected by protocol. Radiographic progression was evaluated in hands by a blind expert rheumatologist assessing the erosion scale of modified SvdH index in both the baseline and two year follow-up visit. To study the predictive value of MC baseline BMD by DXA, two multivariate models were fitted using general linear models with Stata 14.0 for Windows (StataCorp LP, College Station, TX, USA). The dependent variables were remission (SDAI<3.3) and radiographic progression after two years of follow-up. Both models were adjusted by the classic variables that affect BMD such as age, sex and body mass index (BMI), cumulative DMARD treatment and baseline disease activity for the remission model.

**Results:** After adjustment by age, sex and BMI: a) those patients at remission tended to show higher baseline MC’s BMD by DXA (p=0.328); and b) those patients with higher radiographic progression had significantly lower baseline MC’s BMD as shown in Figure 1 (p<0.001).

**Conclusion:** In our registry of patients with EA, we have detected that a lower basal BMD in the diaphysis of the central MC bones, assessed by DXA, is associated with greater radiographic progression at 2 years of follow-up after adjusting for the main factors influencing BMD. Therefore, we could conclude that a low initial bone mass could constitute a poor prognostic factor in patients with EA.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4797

---

**AB0232**

**THE USEFULNESS OF THE PROGNOSTIC NUTRITIONAL INDEX (PNI) FOR THE DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS**

N. Öz, H. H. Gezer, M. T. Duruöz, 3Marmara University School of Medicine, Physical Therapy and Rehabilitation, Rheumatology, Istanbul, Turkey; 1Ummey Training and Research Hospital, Physical Therapy and Rehabilitation, Rheumatology, Istanbul, Turkey; 2Marmara University School of Medicine, Physical Therapy and Rehabilitation, Rheumatology, Istanbul, Turkey

**Background:** Many prognostic factors and laboratory biomarkers have been put forward to correlate disease activity in Rheumatoid arthritis (RA). The prognostic nutritional index (PNI) was first established to assess perioperative immunonutritional status and surgical risk in patients undergoing gastrointestinal surgery. The PNI, which reflects albumin concentration and lymphocyte count, is a newly established immunonutritional nutritional score.

**Objectives:** In this study, we aimed to determine the relationship between this simple risk index, which was first adapted and analyzed in malnourished patients, and disease activity in RA patients.

**Methods:** This prospective study included 77 RA patients who fulfilled the 2010 revised criteria of the American College of Rheumatology for RA. The demographic characteristics of the patients, duration of the disease and clinic characteristics of the patients such as the 28-joint Disease Activity Score based on the erythrocyte sedimentation rate (DAS28-ESR), Visual Analogue Scale, Health Assessment Questionnaire-Disability Index were collected. Labotaruvary findings including erythrocyte sedimentation rate, C-reactive protein levels, lymphocyte count, albumin were noted. The PNI was calculated using the following formula: 10 x serum albumin value (g/dL) + 0.005 x total lymphocyte count in the peripheral blood (per mm³). Based on the DAS28-ESR level, the included patients were categorized into two groups, namely, inactive to mild active RA (n=91; DAS28-ESR level <3.2) and moderate to highly active RA (n=46; DAS28-ESR level ≥3.2). These groups were compared with the parameters described above.
Results: Seventy-seven patients (90.9% female) with a mean age of 53.6 (SD:10.2) years were recruited into the study. The age, gender and disease therapy duration of the patients were similar in both groups. Patients who DAS28-ESR ≥3.2 had a significantly lower PNI compared to those who did not [41.57 (SD:3,64) vs. 43.78 (SD:2,30), p=0.017] (Table 1). Multivariate logistic regression analyses revealed that PNI was an independent predictor of moderate to highly active RA (OR: 0.770, 95%CI: 0.635–0.935; *p*=0.008).

A receiver operating characteristic curves analysis yielded that the optimal cut-off value of PNI for moderate to highly active RA was 42.01 with sensitivity 67.7% and specificity 47.9% (AUC: 0.662, 95%CI: 0.541-0.782, *p=0.017) (Figure 1).

| Table 1. Demographic, clinical features and laboratory findings of the patients with rheumatoid arthritis based on disease activity measured by DAS28-ESR |
|-----------------|-----------------|-----------------|
| **DAS28-ESR <3.2** | **DAS28-ESR ≥3.2** | **P** |
| **n (31)** | **n (46)** | **n (46)** |
|_age (years; mean SD)_ | 55.80 SD 9.39 | 52.13 SD 10.67 | 0.124 |
| Female, gender; n (%) | 26 (%83.9) | 44 (%95.7) | 0.111 |
| Prognostic Nutritional Index (mean SD) | 43.78 SD 2.30 | 41.57 SD 3.64 | 0.017 |
| Disease symptoms duration (month; mean SD) | 112.2 SD 97.3 | 120.9 SD 79.7 | 0.316 |
| Disease therapy duration (month; mean SD) | 93.2 SD 94.2 | 110.0 SD 76.0 | 0.126 |
| DAS28-ESR (mean SD) | 2.55 SD 0.47 | 4.47 SD 0.86 | <0.001 |
| Visual Analogue Scale (mm, mean SD) | 7.38 SD 16.58 | 20.17 SD 25.76 | <0.001 |
| Health Assessment Questionnaire- Disability Index (mean SD) | 0.69 SD 0.62 | 0.84 SD 0.60 | 0.259 |
| ESR (mm/h, mean SD) | 26.35 SD 18.98 | 31.73 SD 16.95 | 0.083 |
| CRP (mg/L, mean SD) | 6.30 SD 4.49 | 12.75 SD 19.54 | 0.106 |
| Albumin (g/dl, mean SD) | 4.37 SD 0.23 | 4.15 SD 0.36 | 0.010 |
| Lymphocyte (cells/µL, mean SD) | 2.01 SD 0.62 | 2.07 SD 0.65 | 0.570 |

Abbreviations: DAS28-ESR, the 28-joint Disease Activity Score based on the erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

Figure 1. ROC curve

Conclusion: Based on the study findings, we were able to show that simple and easily obtained PNI could be an independent predictor of disease activity in rheumatoid arthritis patients.

REFERENCES:

Disclosure of Interests: None declared

A02033

CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A TWO YEARS OBSERVATIONAL STUDY.

P. Martínez Calabuig1, R. González Mazarío2, J. J. Fragi Gil2, E. Grau García3, C. Pávez Perales3, S. Leal Rodríguez3, C. Riesco Barcena3, A. V. Huaylla Quispe4, L. Mas Sanchez5, P. Muñoz Martínez6, J. E. Oliver Rodríguez3, E. Vicens Bernabeu3, R. Negueruelo Albuixech7, J. Ivorra Cortes3, F. Ortiz-Sanjúan8, M. De la Rubia Navarro9, L. González Puig9, I. Martínez Cordelat10, C. Nájera Herranz1, I. Cánovas Olmos3, J. A. Román Ivorra3, 1Hospital General Universitario, Servicio de Reumatología, Valencia, Spain; 2Hospital Amau de Vilanova, Sección de Reumatología, Valencia, Spain; 3Hospital Universitarios i Politècnic La Fe, Servicio de Reumatología, Valencia, Spain

Background: The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is higher than individuals from the general population due to chronic inflammation. Current CV risk screening and management strategies underestimate the actual CV risk in RA. Thus, an adequate CV risk stratification has special relevance in RA to identify patients at risk of CV disease.

Objectives: To assess the incidence of cardiovascular events in a RA cohort after a 2 years follow-up.

Methods: A cohort study was performed in which inclusion criteria were adult RA patients and matched adults in terms of age, sex and CV risk factors (controls). Population over 75 years old, patients with established CV disease and/ or stage III chronic kidney disease were excluded. Controls with other inflammatory diseases, pregnant women or any malignancy were also excluded. This study was performed from July-2019 to January-2022. CV risk assessment included risk factors collection and US evaluation consisted in detection of plaques and measurement of the intima-media thickness in both right and left carotid.

Results: Overall, a total of 200 cases and 111 healthy controls were enrolled in the study. Demographical and clinical variables were comparable between cases and controls and are shown in Table 1. US study revealed a higher IMT in both right and left carotid arteries with greater presence of plaques in patients than in controls (CI 95% [1.542; 3.436], *p<0.001). Plaques were found in both carotid arteries in the 32% of cases and 9.91% of controls. The longer duration of RA was related to a higher presence of carotid plaques (95% [1.015; 1.056], *p<0.001).

| Table 1. Demographic, clinical characteristics and Ultrasound results of patients and controls. |
|----------------|----------------|----------------|
| **Characteristic** | **RA cases n=200** | **Healthy controls n=111** |
| Age - years | 62.05 (10.75) | 58.3 (12.14) |
| Female sex – number (%) | 163 (81.5) | 73 (65.77) |
| BMI – value (ds) | 26.38 (5.03) | 26.2 (5.19) |
| Smoking habit | 107 (53.5%) | 71 (63.96%) |
| Never Smoked | 1 (0.5%) | 0 (0.00%) |
| Ex-smoker | 51 (2.5%) | 20 (18.02%) |
| Active smoker | 42 (2.1%) | 20 (18.2%) |
| Race – number (%) | 83 (41.5%) | 34 (30.63%) |
| Caucasian | 186 (93) | 62 (93.94%) |
| Comorbidities – number (%) | 93 (46.5%) | 39 (35.14%) |
| High blood pressure | 127.2(18.36)/78.65(10.21) | 127.7 (19.42)/78.28 (10.59) |
| Dyslipemia | 83 (41.5%) | 34 (30.63%) |
| Blood pressure – mmHg | 127.2(18.36)/78.65(10.21) | 127.7 (19.42)/78.28 (10.59) |
| Ultrasound findings | | |
| Right carotid cIMT | 0.78 (0.15) | 0.62 (0.11) |
| Left carotid cIMT | 0.77 (0.14) | 0.64 (0.12) |
| Plaques | 101 (50.5%) | 32 (28.83%) |
| Bilateral | 64 (32%) | 11 (9.91%) |
| Right carotid | 17 (8.5%) | 7 (6.31%) |
| Left carotid | 20 (10%) | 14 (12.61%) |

Eight patients (4%) presented a cardiovascular event, and one of them died (0.5%). The events consisted in 2 angiina pectoris, 3 transient ischemic attack, 1 acute myocardial infarction, 1 lacunar stroke and 1 cardiac arrest. Six out those 8 patients demonstrated bilateral plaque presence at baseline. Two patient caused loss of follow up due to death related to Covid-19. Not a single cardiovascular event was reported in the control group.

Conclusion: Our results shows that cardiovascular events are increased in RA patients and US study may be useful in predicting an event.

Disclosure of Interests: None declared
AB0234  POTENTIAL CREDIBILITY IN RHEUMATOID ARTHRITIS PATIENT REPORTED DAS28 SCORES

S. Cabraal, 1 Aneurin Bevan University Health Board, Rheumatology, Newport, United Kingdom

Background: Due to COVID-19 and the reduction of face to face clinic, the rheumatology telephone advice line service has been an integral part in identifying patients that need assessment the most (1). This however means relying on a patient’s ability to conduct their own disease activity score (DAS28), which clinicians conduct to help drive patients with rheumatoid arthritis (RA) into remission. Current literature suggests that patient self-assessed joint counts are reliable and when compared to the joint count of the physician, have an acceptable level of accuracy (2-5). We present data from an NHS audit where we incidentally found that patients could conduct their own joint counts.

Objectives: Our objective was to compare self-reported DAS28 scores with the clinical opinion of physicians during a face-to-face appointment.

Methods: We identified 10 patients with RA who attended a face-to-face appointment following a call to the helpline where a telephone DAS28 score was undertaken (with guidance from rheumatology specialist nurses). These scores were contrasted against the clinician’s assessment of whether synovitis was present or not in a face-to-face consultation. Co-morbidities; fibromyalgia (FM), osteoarthritis (OA) or both, were also recorded to examine whether these conditions influenced a patient’s ability to perform an accurate DAS28 score.

Results: There were 10 patient self-reported DAS 28 scores in total. 70% (7/10) of patients DAS 28 scores were over 4.01. In all these cases, clinicians confirmed evidence of synovitis during their face-to-face consultation. 30% (3/10) of patients self-reported DAS 28 score was <4.01. Of these patients 2/3 have no evidence of synovitis according to their clinician. When considering co-morbidities, one individual also suffered from OA. This individual’s self-assessed DAS28 score was over 4.01 and was also evidenced to have synovitis during their consultation with the clinician.

Conclusion: This regional NHS audit found that patients who self-reported DAS28 scores over 4.01 accurately identified a flare up, as confirmed by a diagnosis of synovitis at a face-to-face appointment. This may enable the Rheumatology service to become more patient-driven, empowering patients to accurately assess their condition.

REFERENCES:

Disclosure of Interests: None declared

AB0235  TREAT TO TARGET PATHWAY (T2T) IN INFLAMMATORY ARTHRITIS-DESIRABLE RESULTS? AND IF CERTAIN GROUPS RESPOND TO TREATMENT BETTER?

O. Shah, 1 E. Ison, 1, B. Whelan, 1 M. O’Sullivan, 1, C. Sille, 1 1Saolta Healthcare Group, Northwestern Rheumatology Unit Manorhamilton, Manorhamilton, Ireland

Background: There is established evidence that treat to target strategy in inflammatory arthritis helps achieve early remission rates or low disease activity. This approach is more effective for improved outcomes at no additional costs and more likely to achieve rapid and sustained disease control. It is important to aim for early diagnosis to limit the structural damage that occurs with prolonged inflammation. Commencing disease modifying anti-rheumatic drugs (DMARDs) therapy and glucocorticoids as early as possible and titrating therapy as appropriate improves clinical outcomes.

Objectives: Aim of this study was to analyse ACR20 response within different subgroups of inflammatory Arthritis patients enrolled in Treat to Target program.

Methods: Data collection was performed by assessing electronic medical records of 374 inflammatory arthritis patients who participated in Treat to Target pathway for inflammatory arthritis between 2014 to 2020. In total 374 patients were enrolled in treat to target inflammatory pathway led by Rheumatology ANP with consultant supervision. Majority of the patients had diagnosis of Rheumatoid arthritis as per ACR/Eular criteria. 213(51%) were seropositive RF+, 83(19.9%) were seronegative RF-; 44(10.5%) were diagnosed as psoriatic arthritis, and 34(8.1%) were labelled as undifferentiated inflammatory arthritis. In terms of age and gender, 158(42%) were younger than 50, 216(58%) were aged 50 and over, majority females 207(55%). Smoking status 118(32%) current, 211(56%) never, 45(12%) ex-smokers. DMARD started at baseline was Methotrexate only and Starting dose was 15mg for all patients. 326(88%) were on oral methotrexate and only 48(12%) were on SC form between weeks 1-20.

ACR 20,50,70 responses were analysed for these subgroups with majority (61%) seen at week 6 for their visit 1 after starting T2T pathway while all patients seen by week 20.

Results: ACR 20,50 and 70 responses were calculated for all subgroups enrolled in T2T program. The results showed that ACR 20 response rate was same among patients aged under and over 50(67% responders), ACR 50 (38.3%) responders and ACR 70 (20.1%) responders. There was no significant difference in ACR 20 response among females and males (66.9% response) both groups. In terms of seropositivity, 75% responded to treatment in RF+ group vs 60% in RF-group. Higher response rates were seen among not current smokers vs active smokers(70%vs65%). ACR 20 response was greater in patients on Sc form of methotrexate. Overall, 65 % achieved remission within 15 months of starting T2T pathway while remaining achieved low disease activity. Further analysis and discussion will follow.

Conclusion: Treat to target strategy in inflammatory arthritis are consistent with real world data in achieving early response rates with methotrexate (ACR responses) and specific subgroups within T2T cohort respond better to treatment.

Disclosure of Interests: None declared

Background: Presence of anti-citrullinated polypeptide antibodies (ACPA) is one risk factor of bone erosion of the joint in patients with rheumatoid arthritis (RA). However, bone absorption in the whole body is still not clarified in a longitudinal study.

Objectives: The aim of this study is to clarify effects of ACPA on bone mineral density (BMD) decrease using dual-energy X-ray absorptiometry (DXA) in patient with RA using retrospective longitudinal cohort study.

Methods: Patient with RA who were measured BMD in lumbar spine (LS) and total hip (TH) using dual-energy X-ray absorptiometry (DXA) at first consultation (baseline) and were treated for more than five years, were recruited. Follow-up started at BMD measurement and continued until the development of the first fracture or censoring at death, loss to follow-up or end of the study. Every patients have been followed up with monitoring of SDAI and Health Assessment Questionnaire Disability Index (HAQ) at every another to three months. Sharp/van der Heijde Score (SHS) was measured at baseline and every another year thereafter. BMD were measured every six months. Relationship between BMD and candidate risk factors including ACPA positive and serum titers level, and other BMD loss were evaluated statistically using linear regression analysis. Evaluations were performed for the absolute value of BMD and Z-score at baseline, mean value of these during follow-up, and change from baseline. Change of Z-score during follow-up was also compared between groups what classified according to ACPA positivity (ACPA positive/negative group).

Results: A total of 222 patients were recruited including 17 male (7.2%) and 205 female (92.3%). The mean age of the patients was 69.2 years old. Mean disease duration (months) 7.7 4.6 <0.001, disease duration (months) 7.7 4.6 <0.001.

Higher ACPA titer level correlated significantly low BMD and Z-score in TH (p<0.05), whereas no significant correlation demonstrated using multivariate model. Change of Z-score in the ACPA positive group was significantly lower than in the ACPA negative group despite no significant difference of disease activity between the two groups demonstrated (p>0.05) (Table 1).

Table 1. Comparison of the two groups

<table>
<thead>
<tr>
<th>parameters</th>
<th>ACPA-positive (n=172)</th>
<th>ACPA-negative (n=50)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>at baseline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>age (year-old)</td>
<td>65.4</td>
<td>71.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>disease duration (months)</td>
<td>7.7</td>
<td>4.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RF (IU/L)</td>
<td>138.3 (197.1)</td>
<td>21.5 (49.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SDAI</td>
<td>26.3 (24.0)</td>
<td>21.0 (17.8)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.496 (0.618)</td>
<td>0.553 (0.639)</td>
<td>0.48</td>
</tr>
<tr>
<td>SHS</td>
<td>8.4 (8.2)</td>
<td>3.5 (5.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMD in LS (g/cm2)</td>
<td>0.825 (0.167)</td>
<td>0.849 (0.156)</td>
<td>0.23</td>
</tr>
<tr>
<td>BMD in TH (g/cm2)</td>
<td>0.700 (0.140)</td>
<td>0.710 (0.132)</td>
<td>0.75</td>
</tr>
<tr>
<td>Z-score in LS</td>
<td>-0.246 (1.300)</td>
<td>0.123 (1.392)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Z-score in TH</td>
<td>-0.062 (1.034)</td>
<td>0.261 (1.020)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>at follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>follow-up length (months)</td>
<td>64.8</td>
<td>65.4</td>
<td>0.65</td>
</tr>
<tr>
<td>SDAI</td>
<td>4.5 (3.1)</td>
<td>5.1 (4.4)</td>
<td>0.22</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.495 (0.616)</td>
<td>0.516 (0.544)</td>
<td>0.32</td>
</tr>
<tr>
<td>SHS</td>
<td>8.1 (8.2)</td>
<td>3.4 (4.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMD in LS (g/cm2)</td>
<td>0.839 (0.171)</td>
<td>0.870 (0.165)</td>
<td>0.16</td>
</tr>
<tr>
<td>BMD in TH (g/cm2)</td>
<td>0.710 (0.118)</td>
<td>0.713 (0.115)</td>
<td>0.99</td>
</tr>
<tr>
<td>Z-score in LS</td>
<td>-0.008 (1.361)</td>
<td>0.368 (1.426)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Z-score in TH</td>
<td>0.129 (0.905)</td>
<td>0.396 (0.891)</td>
<td>0.11</td>
</tr>
<tr>
<td>anti-osteoprotic drug administered, ever (%)</td>
<td>73.4</td>
<td>69.8</td>
<td>0.72</td>
</tr>
<tr>
<td>OCS administered, ever (%)</td>
<td>35.8</td>
<td>32.9</td>
<td>0.68</td>
</tr>
</tbody>
</table>

The values are presented as mean (SD) unless indicated otherwise. Statistically significant within 0.05 are shown as bold styles.

Conclusion: Presence of ACPA potentially have an independent role of BMD decrease. Its action affects regardless gender and age.
data on the impact of RA disease activity on SF-36 scores in Greek patients are lacking.

**Objectives:** To compare SF-36 scores in Greek RA patients versus the general population and to assess the impact of disease activity on HRQoL.

**Methods:** Cross-sectional study in RA patients followed in the Department of Rheumatology, Asklepieio Voulas General Hospital (05-10/2021). Demographic characteristics, state of disease activity and current treatment for RA were recorded at most recent visit. All patients completed SF-36 questionnaires and were classified in three subgroups of DAS28-disease activity: i) Remission or Low disease activity (LDA), ii) Moderate disease activity (MDA), and iii) High disease activity (HDA). Data from the SF-36 validation study in the Greek general population with 1007 participants, were used as historical controls. Descriptive statistics, one-way ANOVA and linear regression were used for statistical analyses.

**Results:** 107 patients participated in the study (80.4% females, mean (SD) age 63.3 (12.1) years, 64.5% seropositive, 72% overweight or obese). One third (n=36) were active smokers and 63% (n=67) were receiving a biologic disease modifying antirheumatic drug (bDMARD).

Patients with RA exhibited low scores in all SF-36 domains and reported significantly worse results compared to the general population (Figure 1).

**Conclusion:** HRQoL assessed by SF-36 is dampened in RA patients, in both physical and mental component. Disease activity had a negative impact on both physical and mental components of HRQoL. Patients with remission or LDA showed better HRQoL outcomes, suggesting that the treat-to-target approach may also positively affect QoL.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.343

### Table 1. Forty-five cancers in 38 patients with rheumatoid arthritis

<table>
<thead>
<tr>
<th>Site of cancer n</th>
<th>Various tests in outpatient clinic symptoms(⋅)</th>
<th>Clue to cancer diagnosis and prognosis at the final visit (death - under treatment - remission)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast 9 8</td>
<td>noticing symptoms</td>
<td>Cancer Screening</td>
</tr>
<tr>
<td>Lung 8 1</td>
<td>(1-4-3)</td>
<td>1 (0-0-1)</td>
</tr>
<tr>
<td>Colon 6</td>
<td>(1-0-0)</td>
<td>5 (0-1-4)</td>
</tr>
<tr>
<td>Stomach 4 1</td>
<td>(0-0-1)</td>
<td>3 (0-0-0)</td>
</tr>
<tr>
<td>Cervix uteri 3</td>
<td>(0-0-1)</td>
<td>2 (0-0-2)</td>
</tr>
<tr>
<td>Corpus uteri 2</td>
<td>(2-0-0)</td>
<td></td>
</tr>
<tr>
<td>Pancreas 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate 2</td>
<td>(0-1-1)</td>
<td></td>
</tr>
<tr>
<td>Skirt 2</td>
<td>(0-0-2)</td>
<td></td>
</tr>
<tr>
<td>Oral/throat 2</td>
<td>(0-2-0)</td>
<td></td>
</tr>
<tr>
<td>Duodenum 1</td>
<td>(0-0-1)</td>
<td></td>
</tr>
<tr>
<td>Biliary tract 1</td>
<td>(0-1-0)</td>
<td></td>
</tr>
<tr>
<td>Anus 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bladder 1</td>
<td>(0-0-1)</td>
<td></td>
</tr>
<tr>
<td>Brain 1</td>
<td>(0-1-0)</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>45 21</td>
<td>15 (6-6-3)</td>
</tr>
</tbody>
</table>

**Conclusion:** We have been performing cancer screening before RA treatment and performing routine blood, urine, and imaging tests to identify adverse effects. However, they cannot always find cancers at the early stage. Screening procedures for malignancy are strongly recommended[3], but the consultation rates for breast and cervical cancer screening are lower in Japan than in European nations. We should encourage our patients to undergo usual age- and sex-appropriate cancer screening.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.421

---

**Figure 1.**

Physical component score (PCS) and Mental component score (MCS) of the SF-36 showed a negative correlation with DAS28 (r=-0.28, p<0.001 and r=-0.6, p<0.001, respectively). Patients with remission or LDA exhibited better SF-36 scores compared to the other subgroups; moreover, patients with MDA had better SF-36 scores than those with HDA (Table 1). When patients with MDA were further divided into low- and high-moderate disease activity (DAS28: 3.21-4.19 and 4.2-5.1, respectively), no significant difference in any SF-36 domain was found between the two subgroups.

<table>
<thead>
<tr>
<th>SF-36 domain</th>
<th>RDA or LDA 51%</th>
<th>MDA 37.2%</th>
<th>HAD 11.7%</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF</td>
<td>48.4±1.62</td>
<td>32.1±1.8</td>
<td>26±1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>RP</td>
<td>34.9±1.62</td>
<td>20.7±1.9</td>
<td>30.9±2.1</td>
<td>0.003</td>
</tr>
<tr>
<td>BP</td>
<td>51.2±1.62</td>
<td>28.3±1.9</td>
<td>24.8±1.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>GH</td>
<td>48.3±1.62</td>
<td>41.7±1.9</td>
<td>28.7±1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>VT</td>
<td>49.4±1.62</td>
<td>37.9±1.9</td>
<td>27.9±1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>SF</td>
<td>52.3±1.62</td>
<td>39.6±1.9</td>
<td>27.9±1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>RE</td>
<td>39.4±1.62</td>
<td>28.2±1.9</td>
<td>18.8±1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>MH</td>
<td>54.6±1.62</td>
<td>47.9±1.9</td>
<td>30.9±1.9</td>
<td>0.003</td>
</tr>
</tbody>
</table>

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.421
Background: Rheumatoid arthritis (RA) that is a chronic systemic and disabling disease affecting 0.5–1% of the general population, has been strongly linked to accelerated atherosclerosis and increased incidence of cardiovascular events and mortality. Klotho is a membrane-bound or soluble antiaging protein, whose protective activity is essential for a proper function of many organs. The association between serum Klotho and the classic risk factors, as well as the clinical history of cardiovascular disease, was also shown. There are a lot of evidences that Klotho deficiency correlates with the occurrence and development of coronary artery disease, atherosclerosis, myocardial infarction, and left ventricular hypertrophy.

Objectives: The aim of this study was to examine the possible association between serum Klotho levels and ankle-brachial index in women with RA.

Methods: This cross-sectional study was performed in Vega-Baja Hospital (Orhiuela-Spain) from November 2016 to May 2018. We prospectively enrolled 63 consecutive female patients affected by RA and followed at the Vega-Baja Hospital (Orhiuela-Spain). All patients included in this study had normal serum creatinine (Cr) levels and met the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA. Ankle-brachial index were evaluated using a BIDOP model ES-100V3 vascular screening system (Hadeco, Inc, Kawasaki, Japan). Serum Klotho (Elabscience, USA) was analysed using ELISA.

Results: Our study included 63 female patients, with a mean (SD) age of 53 ± 8 years. The majority were Caucasian (90.5%). The mean duration of RA was 8.5 ± 5.8 years. Mean 28-joint disease activity scores (DAS28) based on erythrocyte sedimentation rate (ESR) indicated low disease activity 3.0 ± 1.3. The mean of the health assessment questionnaire (HAQ) was 0.75 ± 0.67. Mean serum Klotho levels were 4.68 ± 1.14 ng/mL. The mean value of the ankle-brachial index was 1.14 ± 0.1. Lower serum Klotho levels were significantly associated with a lower ankle-brachial index (r = 0.27, p<0.05).

Conclusion: Decreased serum Klotho levels are associated with peripheral arterial disease in women with RA.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.446

AB0241

COGNITIVE FRAILTY AND RISK OF FALLS AMONG EGYPTIAN OLD ADULTS WITH RHEUMATOID ARTHRITIS

R. A. Elzahry1, R. M. Abdel Kader2, 1 Ain Shams University, Internal Medicine Department, Division of Rheumatology, Cairo, Egypt; 2 Ain Shams University, Department of Geriatrics and Gerontology Medicine, Cairo, Egypt

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease, affecting bone cartilage and predominantly joints, and causing inflammation and pain. RA patients have disease-specific risk factors, including greater impaired balance, tender and swollen joints, lower muscle strength in their lower limbs, fatigability and medication side effects which contributes to a predisposition for falls [1]. Frailty, which was originally considered a geriatric syndrome, is an age-related decline in physiological reserve (3). It is associated with reduced muscle strength, exhaustion and with high inflammatory markers contributing to perpetuation of the frailty cycle (4). The concept of frailty is a recent issue in the rheumatological field: by now, the prevalence of frailty among elderly individuals with RA has not been extensively examined and few studies on frailty on RA adults have been conducted.

Objectives: To assess the prevalence of cognitive frailty in people with rheumatoid arthritis and the relationship between cognitive frailty and falls.

Methods: In this cross-sectional study we evaluated 105 patients 60 years old or more with rheumatoid arthritis who fulfilled the ACR 2010 criteria and attended to rheumatology outpatient clinic in Ain-Shams University hospitals. Data was collected regarding demography and comorbidities. For cognitive and frailty screening, the Montreal Cognitive Assessment (MOCA) and frail scale were used respectively. Cognitive frailty (CF) is a clinical condition characterized by the simultaneous presence of physical frailty and mild cognitive impairment without functional impairment.

Results: 105 older adult patients with RA were studied of whom (72.4%) were females. The mean age of the study population was 66.03. We found that (12.4%) of the study group were cognitively frail and the prevalence of falls among cognitively frail patients was 92.3%.

Table 1.

<table>
<thead>
<tr>
<th>Age</th>
<th>Gender</th>
<th>Education</th>
<th>Frailty score</th>
<th>Ankle-brachial index</th>
</tr>
</thead>
<tbody>
<tr>
<td>66.03 ± 4.29</td>
<td>Female</td>
<td>Not educated</td>
<td>Frail</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>Range</td>
<td></td>
<td></td>
<td>Pre frail</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>60 – 77</td>
<td></td>
<td></td>
<td>Robust</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>76 (72.4%)</td>
<td>Male</td>
<td>Education</td>
<td>Frail</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>29 (27.6%)</td>
<td></td>
<td></td>
<td>Pre frail</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>Range</td>
<td></td>
<td></td>
<td>Robust</td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>27 – 48</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>69 (61.9%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>92 (87.6%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>13 (12.4%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>47 (44.8%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>41 (39.0%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
<tr>
<td>17 (16.2%)</td>
<td></td>
<td></td>
<td></td>
<td>0.69 ± 0.29</td>
</tr>
</tbody>
</table>

Figure 1. The prevalence of cognitive frailty in geriatric people with rheumatoid arthritis was high and highly related to falls so screening for cognitive frailty in geriatric practice and the implementation of specific care is recommended.

REFERENCES:

Disclosure of Interests: None declared

AB0242

RELATIONSHIP BETWEEN FALLS AND FALL RISK MEDICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

K. Sakamura1, N. Yajima2, R. Yana1, 1 Showa University, Hatanodai Campus, Pharmacy, Shinagawa City, Japan; 2 Showa University, Hatanodai Campus, Division of Rheumatology, Department of Medicine, Shinagawa City, Japan

Background: Falls are a serious event that can lead to disability and death. The use of hypnotics, anxiolytics, and antidepressants has been reported drugs associated with higher risk of falls. Rheumatoid arthritis (RA) is associated with a high risk of falls, which is an important issue because it can lead to fractures. Patients with RA have a higher incidence of sleep disorders, depression, and anxiety disorders. They are likely to be prescribed fall risk medications.
AB0243 ASSOCIATIONS BETWEEN JOINT DEFORMITY, DISEASE DURATION, DISEASE ACTIVITY, ACTIVITIES OF DAILY LIVING, QUALITY OF LIFE, PAIN, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS

I. Yoshih1, N. Sawada2, T. Chijima1. 1Yoshii Hospital, Rheumatology, Shimanto City, Japan; 2Dohgo Onsen Hospital, Rheumatology, Matsuyama, Japan; 3Kochi Memorial Hospital, Rheumatology, Kochi, Japan

Background: Patient with rheumatoid arthritis (RA) have disease-related problems such as joint deformity, disease duration, disease activity, activities in daily life (ADL), quality of life, pain, and fatigue. All these problems correlate interactively.

Objectives: Aim of this study is to clarify association among these problems statistically using retrospective cohort data.

Methods: Patients with RA who were followed up more than three years were recruited. Their EuroQol-5D dimension (EQ5D) as an indicator of quality of life (QOL), simplified disease activity index (SDAI) as an indicator of disease activity, Health Assessment Questionnaire Disability Index (HAQ) as an indicator of ADL, pain score using visual analog scale (PS-VAS), and fatigue score using visual analog scale (FS-VAS), were monitored every three months. Sharp/van der Heijde score (SHS) as an indicator of joint deformity was calculated annually. Association among average values of these factors and patient’s sex, age, disease duration (DD), and anti-citrullinated polypeptide antibodies (ACPA) titer were evaluated using multivariate linear regression analysis. Statistical significance was set within 5%.

Results: A total of 447 patients, in whom 120 male and 327 female included, were analyzed. Mean age, disease duration, EQ5D score, SDAI score, HAQ score, SHS, PS-VAS, and FS-VAS during follow-up were 71.8-year-old, 12.9 years, 0.831, 4.26, 0.413, 46.9, 22.5, and 23.2, respectively.

EQ5D score correlated significantly with age, HAQ score, SDAI score, SHS, PS-VAS, FS-VAS, and DD using univariate models. In these, age, HAQ score, and SDAI score correlated significantly using multivariate model (correlation coefficients (CC): 0.927). HAQ score correlated significantly with age, EQ5D score, SDAI score, SHS, PS-VAS, FS-VAS, and DD using univariate models. In these, EQ5D, SHS, and FS-VAS correlated significantly using multivariate model (CC: 0.910). SDAI score correlated significantly with female gender, EQ5D score, HAQ score, SHS, PS-VAS, and FS-VAS using univariate models. In these, EQ5D, SDAI score, and DD correlated significantly using multivariate model (CC: 0.685). PS-VAS correlated significantly with EQ5D score, SDAI score, SHS, and FS-VAS using univariate models. In these, SDAI score and FS-VAS correlated significantly using multivariate model (CC: 0.732). FS-VAS correlated significantly with EQ5D score, SDAI score, SHS, and PS-VAS using univariate models. In these, EQ5D score, SDAI score, and DD correlated significantly using multivariate model (CC: 0.715). ACPA did not correlated with any factors significantly.

Conclusion: These results suggested that EQ5D score, namely QOL is influenced by various disease-related factors and aging, especially correlated with ADL and fatigue closely. The HAQ score, namely ADL level is influenced by fatigue level and joint deformity directly. The SDAI score, namely disease activity level correlated with pain level and joint deformity level, and correlates with the other factors indirectly. A schematic figure that represents relationships among factors were shown in Figure 1. These information would be useful for conducting treatment protocol of RA.

Disclosure of Interests: None declared

Figure 1.

Conclusion: Use of fall risk medications may have increased falls for patients with RA.

Acknowledgements: Cooperation on data collection: Division of Rheumatology, Department of Medicine, Showa University School of Medicine; Yusuke Miwa, Takeo Isozaki, Kuninobu Wakabayashi, Ryo Takahashi, Sakiko Isojima, Hidekazu Furuya, Nao Ogo, Shu Ishii, Yoko Miura, Mika Hatano, Shinichiro Nishimi, Airi Nishimi, Tomoki Hayashi, Yumeko Taniguchi

Disclosure of Interests: None declared

AB0244 MEDICATION ADHERENCE AND BELIEFS ABOUT MEDICATION IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. Hügel1, C. Baernwald2, O. Seifert1. 1University Hospital Leipzig, Department of Internal Medicine, Rheumatology Unit, Leipzig, Germany

Background: Consistent immunosuppressive treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is crucial for reduced progression and improved long-term outcome of the disease. Therefore, drug adherence is a prerequisite, which is often insufficient according to literature.

Objectives: Our aim was to investigate the relationship between adherence and beliefs about medication in patients with RA.

Disclosure of Interests: None declared
Methods: The study included 137 RA patients (102 female, 35 male; age range 28-86 years, Ø 64.8 ± 12.6 years; SDAI Ø 9.9 ± 6.8; 61 % DMARD monotherapy, 31 % DMARD combination therapy, 8 % currently treated without DMARD). Medication adherence was measured with the Compliance-Questionnaire-Rheumatology (CQR). This is a self-report questionnaire with 19 items (4 response options each). The sum score is mapped to a scale from 0 to 100 % (CQR%), where 100 % corresponds to optimal adherence. A CQR% ≥ 80 % was defined as satisfactory adherence. In addition, the specific part of the Beliefs about Medicines Questionnaire (B MQ) was used to assess patients’ opinions about the necessity and cost-effectiveness of their medications. Furthermore, in the CQR% analysis (Spearman-Rho) multiple linear regression was applied to determine factors influencing adherence (coefficient of determination: adjusted R²).

Results: Adherence was satisfactory in 93 RA patients (67.9 %) and insufficient in almost one-third (n = 44, 32.1 %). Analyses showed that adherence was significantly related to belief in necessity (r = 0.46; p < 0.001) and concerns about drug use (r = 0.27; p < 0.001). Furthermore, it became apparent that adherence is closely linked to the age of the patient (r = 0.30; p < 0.001). Younger RA patients (< 60 yrs) had significantly lower CQR%-scores than older RA patients (≥ 60 yrs; p < 0.01). Belief in the necessity of therapy, medication concerns and age patient accounted for almost half of the patient-specific variability in adherence (each p < 0.001; R² = 42.9 %), suggesting a strong dependence of adherence on these three factors.

Conclusion: Adherence is insufficient in about one-third of RA patients. Additionally, adherence appears to be strongly dependent on the patient’s belief in the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age. Physicians should strive for all RA patients to have sufficient knowledge about their medication, strengthen the necessity of therapy, medication concerns and age.
well known that erosions are correlated with the presence and titer of anti-citrullinated peptide antibodies (ACPA)(1). RA is also known to be an independent factor of osteoporosis(2) and it has already been demonstrated that ACPA is associated with bone mineral density (BMD) at the hip and spine.(3) The physiopathology of erosion and bone loss in RA is related to osteoclast activation via RANK-L pathway stimulation, that can possibly be lead by ACPA(4).

**Objectives:** Our aim was to determine if there is an association between local and systemic bone damage in RA, represented respectively by erosion and BMD, and whether it may be driven by ACPA and/or other autoimmunity-related antibodies.

**Methods:** Patients followed in the Department of Rheumatology between January 2008 and May 2019 satisfied the 1987 ACR or 2010 ACR-EULAR criteria. To be included, they had to undergo radiographs and biological at intervals of less than 2 years from DXA. Bone mineral density (BMD) was evaluated in g/cm² and by T-score at the hip on DXA. Erosions were evaluated by the modified Sharp/van der Heijde erosion score (SHSe) on radiographs and the presence and titer of ACPA, rheumatoid factor (RF) and anti-nuclear antibodies (ANAs) were recorded.

**Results:** A total of 149 patients met the inclusion criteria, represented by 75.8% of women. They had a mean age of 62 (SD 9.61) and a long median disease duration of 132 [60; 240] months. A total of 61.1% patients were ACPA positive, 79.9% were erosive and 10.7% had a hip or spine T-score ≤-2.5. A higher erosion score was associated with a lower BMD (R²: 0.049 and value: -0.222; p=0.009) and T-score (R²: 0.158 and value: -0.397; p<0.0001) at the hip. ACPA status, but not titer, was associated with a higher erosion score (63.0 [53.2] vs. 45.5 [44.1] for ACPA – (p= 0.04)). ACPA titers were associated with lower BMD at the hip (value -0.216; p=0.01) but not with T-score. In linear regression, erosion and bone mineral density were still associated but this association does not seem to be driven by ACPA status or titer. RF and ANA did not demonstrate any role in this association.

**Conclusion:** We have shown that erosions were associated with lower BMD and T-score at hip but also at spine. Nevertheless that relation does not seem to be driven by ACPA or other autoimmunity-related antibodies. However, the presence of ACPA or erosion should lead to osteoporosis assessment.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.913

---

**AB0249**

**LIPID PROFILE CHANGES FROM PRE-CLINICAL TO ESTABLISHED RHEUMATOID ARTHRITIS: A 12 YEARS FOLLOWUP PILOT STUDY**

R. Raadsen, L. Van Boheemen, M. Nurmohamed. Amsterdam Rheumatology and Immunology Center, location Reade, Rheumatology, Amsterdam, Netherlands; Amsterdam Rheumatology and Immunology Center, location VU University Medical Center, Rheumatology, Amsterdam, Netherlands

**Background:** Patients with rheumatoid arthritis (RA) have an increased risk for developing cardiovascular diseases (CVD). This is partly due to the systemic inflammation characteristic to the disease, but also due to an increased prevalence of ‘traditional’ risk factors such as dyslipidemia. The inflammation in RA often leads to an increased catabolism of lipids, resulting in a subsequent decrease in HDL and LDL, while treatment with anti-inflammatory medication reverses these effects. This decreased cholesterol level in active disease is, unexpectedly, associated with an increased incidence of CVD (the lipid paradox). Additionally, we previously demonstrated pro-atherogenic lipid profile changes in preclinical RA patients.

**Objectives:** To explore the lipid profile changes in RA patients through different phases of the disease, i.e. from the preclinical stage and RA onset through treatment with biological disease modifying anti-rheumatic drugs (bDMARDs).

**Methods:** Thirty-nine consecutive patients who were previously included in both Reade’s RA prevention cohort and biological cohort were included in the current study. The prevention cohort consisted of individuals with arthralgia and rheumatoid factor and/or anti-citrullinated protein antibodies without arthritis, and the biological cohort comprised RA patients using bDMARDs. Lipid spectrum was measured longitudinally, at the following points in the disease course identified in each patient (time from baseline was different in each patient due to the natural course of disease progression):

1. Baseline, months prior to RA diagnosis (Start Prevention cohort)
2. Moment of RA diagnosis (End Prevention cohort)
3. Period between diagnosis and start bDMARD treatment
4. Start treatment with bDMARDs
5-7. Continued treatment with bDMARDs

**Results:** From baseline, high density lipoprotein cholesterol (HDLc) and apolipoprotein A1 (ApoA1) increased up to the start of biological treatment, thereafter they slightly decreased. Low density lipoprotein cholesterol (LDLc) and apolipoprotein B (ApoB) both decreased with higher disease activity, increasing again after starting bDMARD therapy. Total cholesterol/HDLc ratio decreased substantially from baseline and onwards and stabilized in the bDMARDs treatment phase. Lipoprotein(a) (Lp(a)) increased slightly up to treatment with bDMARDs, after which it stabilized. Figure 1 shows the progression of HDLc, LDLc and total cholesterol (TC) plotted against C-reactive protein (CRP) over time.

**Conclusion:** Our study uniquely shows the change of lipid parameters during the course of RA disease. While LDLc, ApoB and cholesterol/HDLc ratio decreased with higher disease activity, HDLc and ApoA1 increased, affirming the expectations. Larger cohort studies are necessary to accurately elucidate the development of lipids through different disease stages in RA patients, to better understand one of the key risk factors for CVD in RA.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.976
Background: Poor adherence is one of the main causes of therapeutic failure in chronic inflammatory rheumatism, particularly in rheumatoid arthritis (RA). Thus to improve regular intake especially of conventional background treatments (cs-DMARDs), it is important to assess patients’ beliefs and fears about their treatments.

Objectives: Evaluate the beliefs and fears of patients with Rheumatoid arthritis towards their conventional background treatments.

Methods: This is a cross-sectional study with RA follow-up patients meeting the ACR/EULAR criteria. Epidemiological, clinical and paraclinical data were collected. The evaluation of beliefs and fears towards csDMARDs was carried out by the BMG2 score which has two five-item scales rated according to a 5-point Likert scale, ranging from 1 (not at all agree) to 5 (strongly agree). The scores of necessity, fear, overuse and nuisance were calculated. Patients were divided into 4 groups according to their beliefs of csDMARDs: accepting, ambivalent, indifferent and septile.

Results: The mean Disease Activity Score (DAS28crp) was 3.5 ± 1.54, the mean value of Visual analogue scale of pain (VAS) was 40.5 ± 20.5, and the mean value of Health Assessment Questionnaire (HAQ) was 1.05 ± 0.85. All patients were treated with methotrexate and 12.5% with Salsalazine in combination. The average need score was 20 ± 2.4, fear score was 16.4 ± 3.5, overuse score was 13.6 ± 2.25 and nuisance score was 10.8 ± 2.6. Patients’ beliefs about the need for their background treatments were more important than their concerns and fears about the potential consequences of these treatments (p = 0.03). A higher necessity score was correlated with the number of painful joints (NAP) (p = 0.02) and a higher DAS28 (p = 0.05). Patients who were more afraid of their treatments had more joint deformities (p = 0.03), higher HAQ functional index (p = 0.007) and a higher VAS value (p = 0.01). The belief profile study concluded that 60% of patients were ambivalent, 27.5% accepting, 10% indifferent and 2.5% were septile towards their background treatments.

Conclusion: Our study showed that during RA, knowledge of the profiles of our patients, their beliefs and fears about their treatments especially cs-DMARDs is essential, and could help us to adapt strategies for improving compliance.

Disclosure of Interests: None declared


AB0250

DESCRIPTION OF ARTERIAL STIFFNESS, INF MLLAMAGING AND VASCULAR AGE IN A GROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS UNDER A STRICT FOLLOW-UP COMPARED WITH UNCONTROLLED OSTEOARTHRITIS PATIENTS


1Fundación Universitaria de Ciencias de la Salud-FUCS, Research Institute, Bogotá, Colombia; 2Fundación Cardioinfantil-Instituto de Cardiología, Hemodynamics and Cardiovascular Function Laboratory, Bogotá, Colombia; 3Fundación Universitaria de Ciencias de la Salud-FUCS, Research Institute, Bogotá, Colombia; 4Fundación Universitaria de Ciencias de la Salud-FUCS, Research Institute, Bogotá, Colombia; 5Fundación Universitaria de Ciencias de la Salud-FUCS, Research Institute, Bogotá, Colombia; 6Biomab IPS, Scientific Direction, Bogotá, Colombia

Background: The risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) is higher than in individuals in the general population. The fundamental risk factor for CVD is age, related to alterations in the arterial level, called vascular aging reflected by arterial stiffness and endothelial dysfunction.

Objectives: The aim of the study was to compare vascular age and arterial stiffness (PWV-Pulse Wave Velocity) in two groups of patients with RA and with osteoarthritis (OA) and to assess the influence of inflamming (persistent low-grade inflammation that develops with age) and metabolic markers in these outcomes.

Methods: Analytical cross-sectional study. RA patients under a strict follow-up program (T2T evaluated every two months) and OA patients without strict clinical follow-up, evaluated once or twice a year, were included. Patients with history of uncontrolled hypertension, CVD and/or current smoking were excluded. Waist-hip ratio, body mass index (BMI), DAS28 (RA), C-Reactive protein (CRP), Erythrocyte sedimentation rate (ESR), glyceria and lipid profile were measured. PWV and vascular age (in years) were evaluated through oesomietric method, arteriograph-TensioMed. Eleven proteins components of the inflamming (cytokines, Matrix metalloproteinases · MMPS and its tissue inhibitors), were quantified through Luminex multiplex assay in serum samples. Univariate and bivariate analyzes (Chi-square and non-parametric correlations) were performed. Approval of Ethics Committee and informed consent were obtained.

Results: A total of 106 patients (74% women) were included (52/RA and 54/OA). Mean age was 57±5.6 years without differences between groups. There were significant differences in CRP and ESR (higher in RA) and in BMI, waist circumference and weight (higher in OA). RA patients had low disease activity level (DAS28: Median 2.6, IQR 1.3). There were no differences in PWV, vascu lar age or inflamming (except for MMP-1, higher in RA), between the groups. PWV had a positive correlation with LDL (Rho Coef. 0.218, p=0.025). Patients who performed physical activity had a lower vascular age than those who did not [43 Interquartile range (IQR)23 vs 60 IQR 17, p=0.032]. Vascular age was higher in RA patients who did not receive methotrexate 60 (IQR 19.3) compared with patients under methotrexate treatment 44.5 (IQR 23) (p = 0.017). Also, vascular age was lower in OA patients under prescribed physical activity (43 IQR 24.8 vs 56.5 IQR 20, p=0.03). MMP-9 in RA patients (Rho 0.283, p=0.042) and IL-10 in OA patients (Rho 0.290, p = 0.036) correlated with diastolic pressure. The components of inflamming did not correlate with vascular age. The Framingham Risk Score was strongly associated with vascular age.

Table 1. Significant correlations with vascular age

<table>
<thead>
<tr>
<th>Variable</th>
<th>Spearman’s Rho</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDL levels</td>
<td>0.200</td>
<td>0.040</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>0.300</td>
<td>0.002</td>
</tr>
<tr>
<td>Mean arterial blood pressure</td>
<td>0.210</td>
<td>0.031</td>
</tr>
<tr>
<td>Daily coffee cups intake</td>
<td>-0.212</td>
<td>0.045</td>
</tr>
<tr>
<td>Framingham Risk Score</td>
<td>0.340</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>MDHAQ score in RA patients</td>
<td>0.417</td>
<td>0.002</td>
</tr>
</tbody>
</table>

LDL: low density lipoprotein; MDHAQ: multidimensional health assessment questionnaire.

Conclusion: In RA strictly controlled patients, there are no differences in endothelial dysfunction, vascular age or inflamming, when comparing with uncontrolled overweight OA patients. Physical activity, LDL levels and coffee consumption correlate with vascular age in OA and RA patients. OA patients under physiatrists follow-up and RA patients under methotrexate treatment or low MDHAQ levels have lower vascular age levels.

REFERENCES:


Disclosure of Interests: None declared


AB0251

* FATIGUE IN RHEUMATOID ARTHRITIS: DOES PATIENT AGE INFLUENCE?*

S. Rodriguez-Muguruza1, S. Castro1, M. J. Poveda1, S. Paredes2, D. Taverner2, R. Fontova2, 1Hospital Universitari de Tarragona Joan XXIII, Rheumatology, Tarragona, Spain; 2Hospital Universitari Sant Joan de Reus, Rheumatology, Reus, Spain; 3Hospital Universitari de Tarragona Joan XXIII, Rheumatology, Tarragona, Spain

Background: Fatigue in RA has a multi-causal pathway. It is recommended that it should be measured in all RA studies using a validated instrument. Fatigue in elderly patients could have a different perception than in younger patients, identifying the associated factors could be a key to the management of this complex symptom.

Objectives: To compare fatigue and its associated factors in young and elderly patients with RA from two university hospitals.

Methods: A cross-sectional analysis was performed in 167 RA patients diagnosed according to the 2010 ACR-EULAR criteria. Patients were divided into two groups based on age (≥60 and <60) for comparative purposes. Fatigue was assessed using 4 instruments: the Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire (BRAF-MDQ), the fatigue subscale of the Short-form 36 survey (fatigue-SF36), the Visual Analogic scale of fatigue (VAS) and the Functional Assessment of chronic illness Therapy Fatigue Scale (FACT-F). To compare the mean of fatigue between groups we used a T-Test. To determine in each group of patients (young and elderly patients) the relationship between the 4 subscales of fatigue (assessed by BRAF-MDQ) and the other variables (DAS28, CPR, ESR, hemoglobin, vitamin D, HAQ, RAID [Rheumatoid Arthritis Impact of Disease], SF36, Hospital Anxiety and depression Scale [HAD] and Brief Pain Inventory) a Spearman correlation was performed. A value of p < 0.05 was accepted as statistically significant.

Results: A total of 167 patients were included, 81 (48.5%) young and 86 (51.5%) elderly patients. We found fatigue (using 4 instruments) has not significant differences in young and elderly patients (Table 1). In young and
elderly patients, physical, living, cognitive and emotional fatigue were corre-
lated to RAID, SF36, HAID and pain but they were not associated to CRP,
ESR, hemoglobin and vitamin D. In young patients, all dimensions of fatigue
were associated with DAS28. Furthermore, in elderly patients we found a rela-
tion between physical (p-value 0.044) and living fatigue (p-value 0.012)
with DAS28, nevertheless cognitive and emotional fatigue (p-value 0.078 and
0.079 respectively) were not related.

Table 1. Scores of the Fatigue Questionnaires used to assess fatigue in young and elderly patients with RA.

<table>
<thead>
<tr>
<th></th>
<th>Young Mean (SD)</th>
<th>Elderly Mean (SD)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FACIT-F</td>
<td>36.5 (12.5)</td>
<td>35.9 (11.7)</td>
<td>0.2963</td>
</tr>
<tr>
<td>VAS-F</td>
<td>4.3 (2.8)</td>
<td>3.8 (2.8)</td>
<td>0.119</td>
</tr>
<tr>
<td>SF36-Fatigue</td>
<td>50.9 (23.9)</td>
<td>51.0 (21.9)</td>
<td>0.628</td>
</tr>
<tr>
<td>BRAF-MDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical</td>
<td>9.2 (6.2)</td>
<td>8.5 (6.3)</td>
<td>0.4670</td>
</tr>
<tr>
<td>Living</td>
<td>5.3 (5.6)</td>
<td>4.2 (4.6)</td>
<td>0.1446</td>
</tr>
<tr>
<td>Cognitive</td>
<td>3.3 (3.8)</td>
<td>4.2 (4.6)</td>
<td>0.2932</td>
</tr>
<tr>
<td>Emotional</td>
<td>3.5 (3.5)</td>
<td>2.6 (2.7)</td>
<td>0.0932</td>
</tr>
</tbody>
</table>

Conclusion: In young and elderly patients, all dimensions of fatigue appear to be
related with subjective but not with objective variables. In young patients, all
dimensions of fatigue were associated with DAS28 but in elderly patients only
physical and living fatigue were correlate to disease activity. This results could
indicate that it is important to evaluate fatigue in a multidimensional perspective
in elderly patients.

REFERENCES:
Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDQ), Bristol
Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for
severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Check-
list Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS),
Functional Assessment Chronic Illness Therapy (Fatigue) (FACT-F), Mul-
ti-Dimensional Assessment of Fatigue (MAF), Multi-Dimensional Fatigue
Inventory (MFI), Pediatric Quality Of Life (PedsQL), Multi-Dimensional
Fatigue Scale, Profile of Fatigue (Prof), Short Form 36 Vitality Subscale
(SF36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken).
2011 Nov;63 Suppl 11:S263-86.

Disclosure of Interests: None declared

AB0253

INTOLERANCE TO METHOTREXATE IN RHEUMATOID ARTHRITIS: AN ASSESSMENT WITH THE MISS
(METHOTREXATE INTOLERANCE SEVERITY SCORE)
H. Hachichi1, S. Abdelkadi2, M. Brahmi1, Y. Mohamed1, Taher Star University
Hospital, Rheumatology, Mahdia, Tunisia; Taher Star University Hospital,
Rheumatology, Mahdia, Tunisia

Background: Methotrexate (MTX) is a cornerstone in the treatment of rheuma-
toid arthritis (RA), in monotherapy or in combination with biological agents.
Its prolonged use requires regular clinical and biological monitoring. The purpose
of our study is to assess intolerance to MTX and its consequences.

Objectives: The purpose of our study is to assess intolerance to MTX and its
consequences.

Methods: This is a cross-sectional study with RA follow-up patients meet-
ing the ACR/EULAR 2010 criteria. An assessment of MTX intolerance was
conducted using the Arabic version of the MISS (Methotrexate Intolerance
Severity Score). It is a questionnaire containing 12 items covering four areas:
abdominal pain, nausea, vomiting and behavioral disorders. A score of six
indicates an intolerance.

Results: Forty patients were included: 35 women (87.5%) and 5 men
(12.5%) of average age 51.7 years ±12.7 years. The average duration of dis-
ease progression was 12.2 years 9.2 [1-40 years]. All patients were treated
with methotrexate and supplemented with folic acid. 50% of patients were
under 10mg/week of MTX, 27.5% under 15mg/week and 22.5% under 20mg/week.
Patients had been on this treatment for an average of 8.7 years [1-25 years],
The majority of them (97.5%) received corticosteroids in combination,
12.5% received Salazopyrine and 27.5% received biotherapy. Methotrexate
intolerance was observed in 16 patients (42.1%). Nausea was observed in
13 patients (81.2%), vomiting in 5 patients (31.2%), abdominal pain in 11
patients (68.8%) and behavioral disorders in all patients. As a result of this
intolerance, 18.8% of patients had to stop their treatment, 12.5% decreased
the dose on their own, 6.2% took the MTX irregularly, 12.5% switched from
the oral route to the intramuscular route and 50% continued to take their
treatment in the usual way. The study of correlations did not reveal statisti-
cally significant associations between MTX intolerance and age, sex, dose
and duration of MTX, the associated intake of salazopyrin, biotherapy and
other symptomatic treatments.

Conclusion: The occurrence of an intolerance to MTX is common in
patients followed for RA, which may lead to poor adherence to therapy or
even a discontinuation of treatment thus decreasing the effectiveness of
management. Hence the need to systematically detect this intolerance and
react in time.

Disclosure of Interests: None declared

AB0252

C. Garaffoni1, A. Marangoni2, M. Govoni3, C. A. Sciriá3, 1Rheumatology
Unit, University of Ferrara and Azienda Ospedaliera-Uneversità S.Anna,
Department of Medical Sciences, Ferrara, Italy; 2University of Milano-Bicocca,
School of Medicine and Surgery, Milan, Italy

Background: Cardiovascular disease (CVD) risk in patients with chronic inflam-
matory arthritis (IA), including rheumatoid arthritis (RA), psoriatic arthritis (PsA)
and ankylosing spondylitis (AS), is substantially increased compared to the
general population. New evidence strengthens the notion that the excess risk of
CVD morbidity and mortality in patients with IA is related to both traditional (e.g.
hypertension, diabetes, smoking) and novel CVD risk factors, including chronic
inflammation, leading to an accelerated atherosclerosis. How to minimize such
increased CVD prevalence is still underdood, and whether more intensive
traditional risk factor control or disease specific risk factor should be targeted is
still matter of debate.

Objectives: The aim of this systematic review was to identify intervention tar-
genring CVD or inflammatory arthritis associated with improvement of CV risk
outcomes (estimated CV risk, CV events, endothelial function, arterial stiffness,
subclinical atherosclerosis) in adult patients with diagnosis of inflammatory
arthritis (RA, PsA and AS).

Methods: Two independent reviewers retrieved randomized controlled trials of
interest from systematic searches of Medline, Embase and Cochrane database
(20th April 2020). Data extraction was performed using standard template; the
guadity of each included trials was assessed with the Revised Cochrane risk
of-bias tool for randomized trials (RoB 2) [1]. Systematic review was conducted
following the Preferred Reporting Items for systematic reviews and Meta-analysis
(PRISMA) statement.

Results: Out of total of 4823 articles, 27 met the inclusion criteria. Among these,
most (n=22) involved RA patients, one trial was based on mixed IAs patients and
the remaining (n=4) were performed on spondyloarthritids pop-
ulation. Total number of patients was 8045. Overall risk of bias was high in
most of per protocol analysis trials (90%) and in 26.7% of intention-to-treat
analysis trials. Four trials evaluated major adverse cardiovascular events (MACE)
icidence and one of these demonstrated a significant reduction in
incidence of MACE in RA patients underwent a treat-to-target strategy of
CV risk factor. The same study also demonstrated a significant reduction in
progression of subclinical atherosclerosis (carotid Intima-media thickness
cIMT), while other trials (n=8) exploring effect of rosuvastatin, enalapril,
tocolizumab and TNF-inhibitors failed to reach a similar result. Endothelial dys-
function, predominantly measured as reduce flow mediated dilatation (FMD),
was widely used as surrogate outcome of CVD and it appeared to be signifi-
cantly improved by treatment with statins, ACE-inhibitors, anakinra and tocili-
zumab. Treatment with pioglitazone, anakinra or tocilizumab in three trials
significantly ameliorated arterial stiffness, estimated with pulse wave velocity
(PWV), Cardio-ankle vascular index (CAVI) or augmentation index (AI). Two
studies explored how a reduction of estimated CV risk could be achieved
after treatment with enalapril and tight-control strategy aiming to SDAI ≤ 3.3.
Results of both trials didn’t demonstrate any variation in QRS3K3-2018 and
Framingham risk score, respectively.

Conclusion: Optimal CVD management in IA patients remains undefined and it
should be implemented as stated in international guidelines. Randomized con-
trolled trials exploring efficacy of prevention strategy are few and predominantly
focused on surrogate outcome measures of cardiovascular risk.

REFERENCES:
al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ,
Patients were stratified into those who were adherent to the treatment and those who weren't, according to their CQR score. Additional information regarding the quality of life (QOL-RA), disease activity (DAS28 ESR), and functionality (HAQ) was recovered from electronic clinical charts. Data was gathered on a database stored in REDCap. T-test and Chi-squared test were used for comparisons and a multiple logistic regression with backward selection was performed to build the final fitted model.

**Results:** Data from a total of 564 patients were included in the analysis. Our population was constituted of 79.1% women with a mean age of 53 ± 13.1; the CQR mean score was 77.7 ± 9.26 and treatment adherence, defined as a CQR score of ≥ 80.7, was seen in 49.3% of the cases. Mean DAS28 ESR, QOL-RA, and HAQ scores were 3.3 ± 1.62, 724 (± 1.43), and 0.671 (± 0.716), respectively; with a reported preserved quality of life (QOL-RA > 7) in 60.5% of patients. Monotherapy (42.7%) and combined therapy (49.6%) were the two most common treatment schemes, being MTX the more frequent DMARD (58.9% oral, 20.9% subcutaneous). Noncompliant patients showed higher mean disease activity (3.52 ± 1.66) vs 3.08 ± 1.54); p < 0.001) and lower quality of life (6.94 ± 1.43) vs 7.56 ± 1.33; p < 0.001) scores. Having a higher DAS28 score (OR 1.19), drug dispensing delay (OR 1.71), and infection as an adverse effect (OR 2.53) were recognized as risk factors for an impaired treatment adherence after adjustment for the effects of possible confounders. Complete results of the multiple logistic regression model are shown in Table 1.

**Table 1. Associated factors with treatment adherence in RA patients.**

<table>
<thead>
<tr>
<th>Odds Ratio (95% Confidence Interval)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.99 (0.97 – 1) 0.12</td>
</tr>
<tr>
<td>Male</td>
<td>1.54 (0.98 – 2.43) 0.065</td>
</tr>
<tr>
<td>Having a stable partner</td>
<td>0.75 (0.52 – 1.09) 0.13</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>0.69 (0.41 – 1.15) 0.16</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>0.52 (0.22 – 1.16) 0.12</td>
</tr>
<tr>
<td>Dyspepsia (AE)</td>
<td>1.48 (0.97 – 2.28) 0.07</td>
</tr>
<tr>
<td>Infection (AE)</td>
<td>2.53 (1.31 – 5.08) 0.007</td>
</tr>
<tr>
<td>Perception of the information received by health professionals</td>
<td>0.45</td>
</tr>
<tr>
<td>Unsatisfied</td>
<td>Ref.</td>
</tr>
<tr>
<td>Satisfied</td>
<td>2.23 (0.06 – 28.1) 0.55</td>
</tr>
<tr>
<td>Very satisfied</td>
<td>1.37 (0.09 – 17.2) 0.81</td>
</tr>
<tr>
<td>Healthcare barriers</td>
<td>1.98 (0.92 – 4.45) 0.088</td>
</tr>
<tr>
<td>Drug dispensing delay</td>
<td>1.71 (0.99 – 2.99) 0.058</td>
</tr>
<tr>
<td>Disease duration (months) until rheumatology consultation</td>
<td>1.00 (0.99 – 1.00) 0.024</td>
</tr>
<tr>
<td>DAS28 ESR score</td>
<td>1.19 (1.06 – 1.33) 0.003</td>
</tr>
</tbody>
</table>

AE: adverse effect. Bold values indicate a p value < 0.1

**Conclusion:** In our study population, there were evident trends regarding the effects of dispensing delays, adverse effects, and barriers to access to the healthcare system on reducing treatment adherence. Moreover, there was a subtle association of treatment adherence with the DAS28 score, as well as with a better quality of life. Taken together, these results suggest the need for the implementation of educational programs that will support a comprehensive approach that considers not only patient-related factors but also the proper functioning of the healthcare system itself. Further research with a follow-up period could assess the long-term effects on several clinical outcomes and explore if proposed trends change with time.

**Disclosure of Interests:** Carlo Garaffoni: None declared. Antonio Marangoni: None declared. Marcello Govoni Speakers bureau: Abbvie, Pfizer, Galapagos, BMS, Eli-Lilly, Paid instructor for: Pfizer, Consultant of: Abbvie, BMS, Novartis, AstraZeneca, Pfizer, Carlo Alberto Scirè Grant/research support from: Abbvie, Lilly

**DOI:** 10.1136/annrheumdis-2022-eular.1256
Background: Sarcopenia is a muscle disease which is characterized by loss of muscle mass and function. This condition is associated with chronic disease and ageing which predicts inability, hospitalization and death.

Objectives: Describe sarcopenia prevalence and risk factors in patients with rheumatoid arthritis (RA) over 65 years of age.

Methods: Design:
A case-control study.

Subjects: Cases: Recruitment was performed by random sampling between patients over 65 years of age with RA (ACR/EULAR 2010 criteria) attended at 4 Spanish University Hospitals. Controls: Recruitment of subjects without rheumatoid disease was performed asking for case patients who attended to medical center with a similar-age (age of range +5 years) and same-gender person from same social or family environment.

Variables: The main variable was sarcopenia which was defined according to European Working Group on Sarcopenia in Older People (EWGSOP) 2019. Sarcopenia risk factors assessed were: economic status, malnutrition, measured with Mini-Nutritional Assessment (MNA), dual-energy x-ray absorptiometry (DEXA) in spine and hip to osteoporose screening, toxic habits, comorbidities and Charlson index, physical activity measured with Global physical activity questionnaire (GPAQ) and Short Physical Performance Battery (SPPB).

Other variables were: haemoglobin, calcium, D and B12 vitamins, total proteins, albumin, C reactive protein, body mass index (BMI), polymedication, quality of life measured with EQ-5D and RA related factors, activity disease measured with DAS28, SDAI and CDAI; physical function measured with HAQ (Health assessment questionnaire) and global functional status according ACR criteria.

Statistical analysis:
Descriptive and multivariative analysis was performed to identify factors associated to sarcopenia in RA.

Results: 76 patients and 76 controls were included in the study, 120 were women (78,9%), with media ± SD of age 74,7 ± 8,98 of media and 32 (21,1%) were men, with age 70,1 ± 3,78 of media. In comparison with controls, RA patients presented more frequency of sarcopenia (30 [19,53%] vs 6 [3,94%]; p=0,005), RA patients who presented sarcopenia, were upper average age (p=0,001), worse results in Short Physical Performance Battery (SPPB) (p=0,037), higher DAS28 (3,55 ± 1,09 vs 2,78 ± 1,05; p=0,017), higher score HAQ (1,18 ± 0,79 vs 1,69 ± 0,68; p=0,024), worse score in EQSD (0,27 ± 0,28 vs 0,54 ± 0,25; p=0,001) and Visual analogic scale VAS EQSD (45,7 ± 17,4 vs 56,9 ± 17,6; p=0,035).

By the way, RA patients presented lower levels of total proteins (p=0,018), worse results in MNA (p=0,001) and they performed less physical activity by GPAQ (p=0,011). Multivariate models (Table 1) identified as independent predictors of sarcopenia in RA: age (p=0,014), proteins levels (p=0,044) and disease activity measured by DAS28 (p=0,030), This model could explain 37% of sarcopenia in RA (R2=0,37).

Table 1. Multivariate analysis (VD: Sarcopenia)

<table>
<thead>
<tr>
<th>OR(95%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>1,213 (1,044-1,414)</td>
</tr>
<tr>
<td>Proteins (g/dL)</td>
<td>0,185 (0,036-0,958)</td>
</tr>
<tr>
<td>DAS28</td>
<td>2,1461 (0,76-4,881)</td>
</tr>
<tr>
<td>R2=0,37</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Sarcopenia is more prevalence in over 65 years-old RA people. Older age and higher activity disease measured by DAS28 more risk of sarcopenia. Proteins levels have a protected association with sarcopenia.

Disclosure of Interests: None declared

**AB0257**

**ADHERENCE TO TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS**

P. Postnikova1, P. Kovalenko1, I. Dydykina1, A. Abolyoshina1, A. Smirnov2, A. Litik.1 V.A. Nasonova Research Institute of Rheumatology, Rheumatoid Arthritis Evolution Laboratory, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Laboratory of Instrumental Diagnostics, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: Adherence is defined as the degree of agreement between a patient’s behavior (taking medication, changing lifestyle, or adhering to treatment recommendations) and the prescriptions of a physician or medical staff. The patient’s adherence to treatment is an important factor influencing the effectiveness of therapy, the course of the disease. In Russia, a universal questionnaire was developed to assess the level of adherence to drug therapy, medical care, lifestyle changes, and general adherence to treatment.

Objectives: To analyze the adherence to treatment, medical care and recommendations for lifestyle changes in patients with RA.

Methods: The cross-sectional study included 88 women with RA (ACR/EULAR 2010), the mean age -63.0±8.1 years, the duration of the disease - 22.4±9.3 years. Adherence was assessed using the Russian questionnaire, which determines the low, average, and high levels of adherence to drug therapy, medical care, recommendations for lifestyle changes, and general adherence to treatment. All patients completed The Hospital Anxiety and Depression Scale (HADS) for the detection of anxiety and depression symptoms and HAQ (Health Assessment Questionnaire) to explore functional disability. All patients took a clinical examination, assessment of the anamnestic data, X-ray of hands, feet.
M. Cazzato, O. Mazzarella, L. Bazzichi, F. Subir, E. Villa, E. Laurino, F. D'Alessandro, M. Mosca. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Azienda Ospedaliero Universitaria Pisana, Pisa, Italy, Pisa, Italy

Background: The COVID-19 pandemic has impacted on face to face assessments of patients with rheumatic diseases, including rheumatoid arthritis (RA) and telemedicine has offered a valid opportunity to follow these patients. DEDICARE is a Patient Support Program (PSP) which has been active at our center since 2016, which allows the telemonitoring of PROs (Patient Reported Outcomes) for patients being treated with abatacept. Since 2016, 98 RA patients followed at our Unit entered the DEDICARE program. During COVID-19 pandemic these patients continued their monitoring using this PSP.

Objectives: To evaluate the impact of the first COVID wave on PROs and CROs (Clinical Reported Outcomes) in patients with RA included in the DEDICARE programme

Methods: Data collected in the dedicated platform three months before (from December 2019 to February 2020, pre-lockdown), during (from March 2020 to May 2020, lockdown) and after (from June 2020 to August 2020, post-lockdown) the first lockdown period in Italy were compared. In detail DAS28 (CRP, ESR), SDAI and CDAI were evaluated before and after the lockdown period; while VAS-pain, Global Health (GH); Patient Global Assessment of Disease Activity (PGA); Health Assessment Questionnaire (HAQ); Functional Assessment Chronic Illness Therapy (FACIT) were evaluated pre, during e post lockdown with the DEDICARE platform.

Results: 36 RA patients, all females, were included in the study; mean age was 62.4 (32-85) years; mean disease duration 15.5 (5-38) years; 18 were ACPA and RF+. All patients were treated with abatacept, 13 as monotherapy and 23 in association with csDMARDs. No patients had COVID19 disease during the evaluated period.

A significant worsening of global health and patient global assessment of disease activity was observed; while no differences were observed regarding the CROs and other PROs (Figure 1)

Conclusion: In the present study we were able to compare PROs in patients with RA before and after the first COVID wave in Italy. While no significant changes in disease activity were observed, patients experienced an increased perception of disease activity and a decline in their overall health status which began during the lockdown and continued over the following 3 months.

This may highlight a discordance between the patient and the physician perception of the disease, which may partly due to the psychological impact of pandemic on the general perception of health particular in patients with chronic diseases. Since this discrepancy may have consequences on disease management, and particularly on treatment adherence, there is a need to promote studies to better understand the reasons for these discrepancies and to improve the patient perception of their disease particularly in difficult situations such as COVID 19 pandemic.

Disclosure of Interests: None declared


Figure 1

References:
AB0260

ASSOCIATION BETWEEN INFLAMMATION AND DEPRESSIVE SYMPTOMS IN RHEUMATOID ARTHRITIS PATIENTS.


Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Quintana Roo, Mexico;2Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra”, Departamento de Mastología, Mexico City;3Hospital Júarez de México, Departamento de Reumatología, Mexico City, Mexico

Background: Rheumatoid arthritis (RA) is an autoimmune, progressive disease characterized by an inflammatory process mediated by CD4+ T lymphocytes leading to damage of the synovial membrane1. Its prevalence is estimated between 0.2 and 1.2% worldwide, affecting women in the fourth and fifth decades2. In 2013, the Mexican College of Rheumatology estimated a 1.6% prevalence3 in Mexico. RA may affect patients’ social, psychological, emotional and physical areas. Among its psychological implications, depression is one of the most important (with a prevalence of 40%) beyond the general population4. Several studies assess either prevalence or prognosis, despite its higher prevalence and a lesser likelihood of remission in these patients. Some investigations looked for a relationship between inflammation and depressive symptoms considering only clinical or biochemical parameters, despite the evidence supporting better results with imaging methods, such as musculoskeletal ultrasound (MSU).

Objectives: To identify the association between MSU demonstrated inflammation and the presence of depressive symptoms in RA patients.

Methods: In 2021 a cross-sectional study on RA patients (according to ACR/EULAR 2010 criteria) was conducted. The subjects were from the Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra” and Hospital Júarez de México Rheumatology out-patient clinic. Each patient underwent a clinical (SDAI, CDAI, and EVA), psychological (PHQ9 and InCaViSa questionnaires), and MSU assessment (7 joints score). Data described with central tendency and dispersion measures for quantitative variables and frequencies and proportions for qualitative variables.

Results: Fifty-two patients (94% women) were evaluated, with a mean age of 56.06 ± 12.31 years and duration of disease 13.66 ± 9.44 years. Depression prevalence was 54%. Patients with disease activity had the highest depression scores (p=0.009), those with triggering events in the last six months (p=0.177), the leading event was the death of a close relative in 30% of the patients. A moderate correlation between the depression score (PHQ9) and clinical disease activity scores (SDAI, CDAI, and VAS) was found (r=0.553 [p<0.001], 0.559 [p<0.001], 0.492 [p<0.001], and 0.57 [p<0.001], respectively) were found. Furthermore, we found a moderate correlation between depression scores and psychological, social and physical quality of life. A mild correlation between MSU synovitis and depression scores (r=0.315 [p=0.03]) found.

Conclusion: Patients with disease activity reported higher depression scores in comparison to remission patients. We demonstrated a relationship between depressive symptoms, social factors, disease perception and ultrasound synovitis. It is crucial to conduct longitudinal studies with a large number of patients, including a control group, and perform an adequate stratification of the demographic characteristics of the patients and their confounding variables.

References:


Disclosure of Interests: None declared.


AB0261

CARDIOMETABIC COMORBIDITIES MAY IDENTIFY A MORE SEVERE SUBSET OF RHEUMATOID ARTHRITIS, RESULTS FROM A “REAL-LIFE” STUDY

P. Rusci1, A. Conforti1, C. Di Muzio2, D. Currado2, L. Navarini3, V. Pavlovich1.

1Center Biotechnological and Applied Clinical Sciences, Uqella, Italy;2Campus Bio Medico University of Rome, Department of Medicine, Rome, Italy;3Alma Mater Studiorum - Università di Bologna, Department of Biomedical and Neuroromotor Sciences, Alma Mater Studiorum, Bologna, Italy

Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease associated with a significant increased rate of cardiometabolic comorbidities contributing to an increased risk of morbidity and mortality of these patients1.2. RA patients with cardiometabolic comorbidities might differ from those without in their clinical presentation and prognosis.

Objectives: This “real-life” cross-sectional study was designed to describe disease features of RA consecutive participants affected by cardiometabolic comorbidities than those without, among those attending recruiting centers from January 1, 2011 to December 31, 2012. Our purpose was also the identification of possible associations between these diseases and clinical characteristics of patients (i.e., fulfillment of ACR1987 criteria, ACPA positivity, presence of extra-articular manifestations, remission, and bDMARD failure).

Methods: Consecutive RA patients were assessed, all fulfilling 2010 ACR/EULAR criteria for RA. We have defined the participant as having such comorbidities if affected by 2 or 3 among high blood pressure (HBP), type 2 diabetes (T2D), and/or dyslipidaemia. The presence of cardiometabolic comorbidities for each participant was verified by reviewing the clinical charts, interview, and extensive medical examinations. Patients with and without cardiometabolic comorbidities were grouped and compared. After that, regression models were built to assess the influence of the presence of cardiometabolic comorbidities on RA features of disease severity.

Results: 757 consecutive RA participants were evaluated [(female 56.6%, age 64.7 ± 12.3 years, median disease duration 6 years (IQR 12)]. Among assessed participants, 13.5% showed cardiometabolic comorbidities. These were older (63.9 ± 13.1 vs 70.4 ± 9.0 years, p<0.001) and characterised by a longer disease duration with 64.7% vs 50% between 5 and 10 years (p=0.003). They were more often affected by extra-articular manifestations (8.2% vs 17.7%, p=0.029) and frequently displayed smoking habit (36.6% vs 50%, p=0.003). A lower percentage of patients with these comorbidities was in remission (15.7% vs 8.5%, p=0.048) and they showed a higher prevalence of history of bDMARD failure (40.4% vs 78.6%, p<0.001).

Finally, regression models showed that cardiometabolic comorbidities were significantly correlated with RA features of disease severity. Participants with cardiometabolic comorbidities more frequently fulfilled ACR1987 criteria in both univariate (OR: 1.47, 95%CI: 1.15-1.91, p=0.002) and multivariate analyses (OR: 1.48, 95%CI: 1.15-1.91, p=0.002). These participants had a higher probability of ACPA positivity in both univariate (OR: 1.52, 95%CI: 1.10-2.09, p=0.009) and multivariate analyses (OR: 1.47, 95%CI: 1.06-2.04, p=0.020). Cardiometabolic comorbidities also predicted the presence of extra-articular manifestations in both univariate (OR: 3.26, 95%CI: 1.77-5.89, p<0.001) and multivariate analyses (OR: 2.41, 95%CI: 1.33-4.47, p=0.005). Participants with cardiometabolic comorbidities had a higher probability of previous bDMARD failure in both univariate (OR: 1.73, 95%CI: 1.24-2.43, p=0.003) and multivariate analyses (OR: 7.17, 95%CI: 3.61-14.2, p<0.001). Cardiometabolic comorbidities resulted to be a negative predictor of being in remission in both univariate (OR: 0.53, 95%CI: 0.39-0.79, p=0.041) and multivariate analyses (OR: 0.61, 95%CI: 0.41-0.96, p=0.035).

Conclusion: We described disease features of RA participants with cardio- metabolic comorbidities, identifying a disease subset characterised by clinical features of disease severity and to be considered as “difficult-to-treat”. Thus, cardiometabolic comorbidities may represent a considerable burden for RA patients requiring an appropriate management which should focus, in addition to cardiovascular risk prediction, on targeting these metabolic components.

References:


Disclosure of Interests: None declared.


AB0262

PATIENTS WITH RHEUMATOID ARTHRITIS WHO DEVELOP SARCOPENIA FALL FREQUENTLY: 5-YEAR DATA FROM THE CHIKARA STUDY

Y. Yamada1, M. Tada1, K. Mandai1, N. Hidaka2, H. Nakamura3, 1Osaka City University School of Medicine, Orthopedics, Osaka, Japan;2Osaka City General Hospital, Orthopedics, Osaka, Japan;3Saiseikai Nakatsu Hospital, Orthopedics, Osaka, Japan

Background: Patients with rheumatoid arthritis (RA) are likely to have sarcopenia due to decreased muscle mass and physical function. Some patients develop sarcopenia even if disease activity is well controlled. We previously reported that 13.2% of RA patients without sarcopenia at baseline developed sarcopenia over a year2.3.

Objectives: The aim was to longitudinally investigate sarcopenia status and the characteristics of RA patients using data from the prospective, observational CHIKARA study.

References:


Disclosure of Interests: None declared.

Methods: Body composition, laboratory data, disease activity, physical function (HAQ), treatment, and history of falls and fractures were investigated in 100 RA patients who participated in the CHIKARA study at baseline and at 5 years. They were divided into 4 groups depending on their sarcopenia status: no sarcopenia developed (N group; sarcopenia absent at baseline and 5 years); sarcopenia developed (S group; sarcopenia absent at baseline, but present at 5 years); cured (C group; sarcopenia present at baseline, but absent at 5 years); and persistent (P group; sarcopenia present at baseline and at 5 years).

Results: Seventy RA patients completed the survey. There were no differences among the 4 groups in disease activity, physical function, and treatment. The N group, accounting for 67.1% of all patients, was young and had high body mass index, muscle mass, fat mass, estimated bone mass, and body metabolic rate at baseline. On the other hand, the S group, accounting for 4.3% of all patients, fell significantly more frequently (p=0.035), 3.3 times during 5 years. The P group, accounting for 18.6% of all patients, had significantly higher MMP-3 at baseline (p=0.006). The C group accounted for 10.0% of all patients (Table 1).

Table 1. Characteristics of 77 RA patients by sarcopenia status at baseline and at 5-year follow-up

<table>
<thead>
<tr>
<th>no development (n=47)</th>
<th>development (n=3)</th>
<th>cured (n=7)</th>
<th>persisted (n=13)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>age, years</td>
<td>63 (57, 70)</td>
<td>76 (74, 81)</td>
<td>66 (54, 70)</td>
<td>73 (65, 82)</td>
</tr>
<tr>
<td>disease duration, years</td>
<td>11 (10, 17)</td>
<td>14 (14, 27)</td>
<td>12 (14, 18)</td>
<td>11 (1, 6)</td>
</tr>
<tr>
<td>MTX dose, mg/day</td>
<td>8.1 ± 3.7</td>
<td>6.0 ± 2.0</td>
<td>7.4 ± 3.8</td>
<td>6.2 ± 4.8</td>
</tr>
<tr>
<td>biologics use, %</td>
<td>36.2</td>
<td>51.7</td>
<td>23.1</td>
<td>51.3</td>
</tr>
<tr>
<td>GC use, %</td>
<td>23.4</td>
<td>0</td>
<td>28.6</td>
<td>15.4</td>
</tr>
<tr>
<td>average GC dose, mg/day</td>
<td>3.5 ± 1.1</td>
<td>0</td>
<td>3.7 ± 1.8</td>
<td>6.3 ± 1.8</td>
</tr>
</tbody>
</table>

Data are shown as mean ± standard deviation (SD) or median (25th, 75th percentile). GC: glucocorticoids; MMP-3: matrix metalloproteinase 3; DAS: disease activity score; HAQ: health assessment questionnaire; BMI: body mass index; SMI: skeletal muscle mass index; BMR: body metabolism rate; Δ: change during 5 years.

Conclusion: Overall, 4.3% of RA patients developed sarcopenia and fell frequently during 5-year follow-up. Patients who develop sarcopenia require special care because they are at high risk of falls.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1866

Ab0263 CLINICAL AND LABORATORY FACTORS ASSOCIATED WITH THE RHEUMATOID CACHEXIA.

1Federal State Budgetary Institution “Research Institute of Clinical and Experimental Rheumatology named after A.B. Zavodovsky”; Laboratory of Methods of Treatment and Prevention of Joint Diseases, Volgograd, Russian Federation

Background: Rheumatoid arthritis (RA) is associated with reduced physical performance capacity, leisure activities and self-service [1]. These changes are the result of the destruction of the joints, as well as the decrease in muscle strength, which is known as sarcopenia. However, patients with RA beneﬁt with a rheumatoid cachexia (RC), a speciﬁc form of sarcopenia, characterized with a decrease in fat-free mass index and an increase in fat mass index [2]. RC leads to a dramatic decrease in the life quality and increase in mortality rate [3].

Objectives: To study the clinical and laboratory factors associated with the RC.

Methods: 110 patients (102 females and 8 males) were enrolled in our study. All patients fulﬁlled the 2010 ACR/EULAR classiﬁcation criteria for RA. Standard clinical, laboratory and instrumental examinations were performed. Additionally, hsCRP, ACPA, CTX-1, P1NP and 25(OH)D were deﬁned. Dual-energy X-ray absorptiometry with Total Body program was performed. The diagnosis of RC was based on the criteria: fat-free mass index less than 10th percentiles with fat mass index above 25th percentiles [2]. Statistical analysis was performed using a software package “Statistica 12.0”. Parametric parameters are presented as Mean±std.dev. (95% CI), non-parametric as Me (Q1-Q3). Intragroup analysis of quantitative indicators was carried out using Student’s or Mann-Whitney test. The multiple logistic regression analysis was performed with a stepwise direct search procedure. Results are presented as odds ratio (OR) and 95% conﬁdence interval (95% CI). ROC curve was plotted to assess the diagnostic signiﬁcance of quantitative signs in predicting rheumatoid cachexia.

Results: Mean patients age was 53.7±12.07 (10.8-13.7) years. More than 85% had severe of terminal progression of the RA. Most patients were RF (77.3%) and ACPA (67.3%) positive, had moderate disease activity (3.79 [2.89-4.40]), cartilage erosions (79%) and II (56.4%) functional class. RA was diagnosed in 25 patients. Prevalence of RC was lower in RF-negative patients (OR 0.11 (95% CI 0.01-0.83). Also, prevalence of RA was associated with the duration of RA (1.06 (1.01-1.11)). Mean cumulative dose of glucocorticoids (GCs) was higher in patients with RC (8.5 g [8.2-17.5 g]), than without (5.8 g [3.6-13.7 g] (Z=1.98; p=0.047). Mean daily dose of GCs was lower in patients with RC (5 mg [4-6 mg] and 8 mg [5-10 mg] (Z=2.58; p=0.01)). The median duration of RA was higher among patients with RC (14.0 years) [9.0-22.0) vs 8.0 years [3.0-16.0] (Z=-2.18; p=0.029). ROC-curve was employed to assess the significance of the RF-negativity and RA duration in the diagnosis of the RC. Results are presented in Figure 1.

Figure 1. ROC-curve for the RC based on the duration of RA and the presence of RF

The optimum cut-off point of 9.5 years of RA was defined using Youden’s J, with a sensitivity of 88% and specificity of 53%.

Conclusion: RC is associated with the duration of RA, positivity for RF, higher cumulative dose of GCs and lower daily dose of GCs. Due to clinical practice, higher doses of GCs are usually prescribed as a “bridge-therapy” at the start of the treatment or while switching the therapy. On the other side, patients with low daily dose of GCs are more often hormone dependent, with high total cumulative dose. With the sensitivity of 88% patients with the duration of RA 9,5 years and more have RC.

REFERENCES:

Disclosure of Interests: None declared


Ab0264 ASSOCIATION BETWEEN DIFFERENT HLA DRB1 ALLELES AND SEVERITY IN RHEUMATOID ARTHRITIS.

M. Rojas-Giménez1, J. Calvo Gutierrez2, C. López-Medina3, R. Ortega Castro2, M. L. Ladehesa Pineda1, A. Escudero Contreras2, Reina Sofia University Hospital, 14004 Córdoba, Spain; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), 14004 Córdoba, Spain; Córdoba University

Method: We performed a case-control study comparing 78 patients with rheumatoid arthritis (RA) and 93 controls. Both groups were matched for age, gender, and smoking status. The diagnosis of RA was based on the American College of Rheumatology and the European League Against Rheumatism criteria. Genotyping for the HLA DRB1*0101, *0401, *1001, *0901, and *0301 alleles was performed using PCR and restriction fragment length polymorphism analysis. The severity of RA was assessed using the Disease Activity Score (DAS-28). The associations between the HLA DRB1 alleles and the DAS-28 were analyzed using the chi-square test.

Results: The frequency of the HLA DRB1*0101 allele was significantly higher in the RA group than in the control group (p=0.003). The HLA DRB1*0101 allele was associated with a higher risk of severe RA (DAS-28 > 5.1) compared to the control group (OR=3.79, 95% CI: 1.60-9.00, p=0.002). The frequency of the HLA DRB1*0401 allele was significantly lower in the RA group than in the control group (p=0.04). The HLA DRB1*0401 allele was associated with a lower risk of severe RA compared to the control group (OR=0.32, 95% CI: 0.12-0.84, p=0.02).

Discussion: Our findings suggest that the HLA DRB1*0101 allele may increase the risk of severe RA, while the HLA DRB1*0401 allele may protect against severe RA. Further studies are needed to confirm these findings and to investigate the mechanisms underlying the association between HLA DRB1 alleles and RA severity.

Disclosure of Interests: None declared

Table 1. Characteristics of the patients with the different alleles

<table>
<thead>
<tr>
<th>Variables</th>
<th>SE (n= 43)</th>
<th>*01:01 (n= 18)</th>
<th>*01:02 (n= 10)</th>
<th>*04:01 (n= 12)</th>
<th>*04:04 (n=10)</th>
<th>*04:05 (n= 4)</th>
<th>*10:01 (n= 5)</th>
<th>*03:01 (n= 15)</th>
<th>*07:01 (n= 17)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (years), mean (SD)</td>
<td>54.1 (16.2)</td>
<td>48.5 (14.8)</td>
<td>55.5 (10.7)</td>
<td>45.7 (12.9)</td>
<td>50 (11.4)</td>
<td>56.8 (20.9)</td>
<td>55.1 (21.2)</td>
<td>50.5 (11.3)</td>
<td>59.7 (17.9)</td>
<td>0.336</td>
</tr>
<tr>
<td>Female sex, n (%)</td>
<td>30 (69.7)</td>
<td>12 (66.6)</td>
<td>7 (70)</td>
<td>10 (83.3)</td>
<td>9 (90)</td>
<td>0</td>
<td>3 (60)</td>
<td>12 (80)</td>
<td>12 (70.6)</td>
<td>0.096</td>
</tr>
<tr>
<td>Time since diagnosis (years), mean (SD)</td>
<td>12.8 (78)</td>
<td>15.3 (3.6)</td>
<td>11.8 (76)</td>
<td>14.1 (6)</td>
<td>11.03 (7.8)</td>
<td>9.3 (6.8)</td>
<td>11.8 (7.4)</td>
<td>16.4 (6.9)</td>
<td>12.3 (7.3)</td>
<td>0.420</td>
</tr>
<tr>
<td>RF +, n (%)</td>
<td>32 (74.4)</td>
<td>17 (94.4)</td>
<td>9 (90)</td>
<td>12 (100)</td>
<td>10 (100)</td>
<td>4 (89)</td>
<td>8 (90)</td>
<td>7 (60)</td>
<td>7 (69.6)</td>
<td>0.216</td>
</tr>
<tr>
<td>ACPI +, n (%)</td>
<td>27 (62.7)</td>
<td>16 (88.9)</td>
<td>9 (90)</td>
<td>11 (91.6)</td>
<td>10 (100)</td>
<td>4 (89)</td>
<td>5 (100)</td>
<td>9 (60)</td>
<td>8 (44)</td>
<td>0.004</td>
</tr>
<tr>
<td>Erosions, n (%)</td>
<td>12 (27.9)</td>
<td>9 (50)</td>
<td>3 (30)</td>
<td>8 (66.7)</td>
<td>5 (50)</td>
<td>2 (50)</td>
<td>2 (40)</td>
<td>7 (44)</td>
<td>7 (41.2)</td>
<td>0.422</td>
</tr>
<tr>
<td>Nodules, n (%)</td>
<td>1 (2.3)</td>
<td>0</td>
<td>0</td>
<td>1 (8.3)</td>
<td>1 (10)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.999</td>
</tr>
<tr>
<td>Osteoporosis, n (%)</td>
<td>11 (25.6)</td>
<td>1 (5.5)</td>
<td>1 (10)</td>
<td>2 (16.7)</td>
<td>2 (20)</td>
<td>0</td>
<td>0</td>
<td>2 (13.3)</td>
<td>2 (11.8)</td>
<td>0.646</td>
</tr>
<tr>
<td>Sjogren S., n (%)</td>
<td>4 (9.3)</td>
<td>0</td>
<td>0</td>
<td>1 (8.3)</td>
<td>3 (30)</td>
<td>0</td>
<td>0</td>
<td>2 (13.3)</td>
<td>0</td>
<td>0.515</td>
</tr>
<tr>
<td>Osteoporosis, n (%)</td>
<td>5 (11.6)</td>
<td>1 (5.5)</td>
<td>1 (10)</td>
<td>2 (16.7)</td>
<td>2 (20)</td>
<td>0</td>
<td>0</td>
<td>2 (13.3)</td>
<td>2 (11.8)</td>
<td>0.937</td>
</tr>
<tr>
<td>CDV, n (%)</td>
<td>11 (25.6)</td>
<td>4 (22.2)</td>
<td>1 (10)</td>
<td>2 (8.3)</td>
<td>1 (10)</td>
<td>1 (25)</td>
<td>2 (40)</td>
<td>2 (13.3)</td>
<td>2 (25.0)</td>
<td>0.872</td>
</tr>
<tr>
<td>Serious infections, n (%)</td>
<td>11 (25.6)</td>
<td>4 (22.2)</td>
<td>1 (10)</td>
<td>2 (8.3)</td>
<td>1 (10)</td>
<td>1 (25)</td>
<td>2 (40)</td>
<td>2 (13.3)</td>
<td>2 (25.0)</td>
<td>0.465</td>
</tr>
<tr>
<td>Cancer, n (%)</td>
<td>4 (9.3)</td>
<td>3 (16.7)</td>
<td>1 (10)</td>
<td>2 (8.3)</td>
<td>2 (20)</td>
<td>1 (25)</td>
<td>1 (20)</td>
<td>2 (13.3)</td>
<td>2 (25.0)</td>
<td>0.972</td>
</tr>
<tr>
<td>Multinodular, n (%)</td>
<td>2 (4.6)</td>
<td>2 (11.0)</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.018</td>
</tr>
<tr>
<td>Deaths, n (%)</td>
<td>12 (27.9)</td>
<td>11 (60)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2 (50)</td>
<td>0</td>
<td>1 (6.6)</td>
<td>7 (41.2)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

**Objectives:** To evaluate the association between different HLADRB1 alleles and the development of serious complications in patients with rheumatoid arthritis (RA).

**Methods:** We performed an observational, longitudinal and retrospective study of a cohort of 134 patients with established RA (ACR/EULAR 2010) from the registry of our department, older than 18 years and without other associated autoimmune pathologies except secondary Sjogren's syndrome and who had the requested HLADRB1 genotyping. Patients with ≥ 1 of the following HLA-DRB1 alleles were considered positive shared epitope carriers (SE+): *01:01, *01:02, *04:01, *04:04, *04:05, *10:01, *03:01, *07:01.

**Results:** A total of 134 patients (91 SE+ and 43 SE-) were included. The main differences between the different alleles are shown in Table 1. The most frequent alleles were *01:01 (n=18), *03:01 (n=15) and *07:01 (n=17).

**Conclusion:** Our results suggest that RA patients carrying the *0405 and *0701 alleles have a higher risk of mortality compared to the control group.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1844

**RHEUMATOID ARTHRITIS PATIENTS HOSPITALIZED FOR A SERIOUS INFECTION HAVE HIGH INCIDENCE OF SEPsis WHILE THOSE ON bDMARDS HAVE LOWER MORTALITY COMPARED TO THOSE ON csDMARDS**

E. Tzagarakis1, I. Fleur2, I. Facconi2, E. Kalioggiannaki2, S. Ilia3, G. Brissoulis3, P. Sioridoulopoulou1, V. Verzelino General Hospital of Heraklio, 2nd Internal Medicine Dept., Heraklion, Crete, Greece; 2University Hospital of Heraklion, Crete, Greece; 3University Hospital of Heraklion, Crete, Pediatric Intensive Care Unit, Heraklion, Crete, Greece

**Background:** The treatment of rheumatoid arthritis (RA) includes conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS) and biologic DMARDs (bDMARDS). RA is associated with an increased risk of serious infections (SI) and the use of bDMARDS almost doubles this risk. SI can lead to sepsis, a life-threatening condition manifested by organ failure caused by a dysregulated host response to a pathogen. bDMARDS target pro-inflammatory cytokines which mediate the inflammation cascade activated both in RA and sepsis. However, very few data exist regarding the incidence of sepsis in patients with a SI while on treatment with bDMARDS.

**Objectives:** To assess the outcomes of sepsis and death in RA patients with a SI and compare them between patients on bDMARD and csDMARDs. Secondary aims were the comparison of subgroups of patients treated with different bDMARD classes (Tumor necrosis factor inhibitor (TNFi) vs. non-TNFi) and subgroups based on age (geriatric vs. younger patients).

**Methods:** Single-center retrospective analysis of adult RA patients registered in the University of Crete Rheumatology Clinic Registry (UCRCR), who were hospitalized for ≥1 SI between 2004-2020. Patients were assigned to “bDMARD group” if they were receiving bDMARDS at the time of the SI or “Control group” if there was no bDMARD exposure at least 3 months before the SI. Demographics, RA characteristics, and comorbidities were retrieved from UCRCR database, while details regarding hospitalization were sought in the patients’ electronic and paper files. Together with the “Sequential Organ Failure Assessment” (SOFA) criteria at admission and during 72-92 hours of hospitalization used to define the diagnosis of sepsis, we also analyzed the criteria of septic shock and in-hospital mortality.

**Results:** A total of 117 hospitalizations for SI in RA patients were included: 66 in patients receiving bDMARDS and 51 in the control group (65% bDMARD-naive and 35% bDMARD-experienced). The majority of the patients (76%) were women in both groups, however, patients on bDMARD were younger than control patients [70 (IQR 62-77) and 78 (IQR 68-82) years old respectively, p=0.002]. Other demographics, disease characteristics, disease activity at baseline, and comorbidities did not differ between the two groups, except for a higher prevalence of one or more previous hospitalizations for infection in patients on bDMARDS.

During hospitalization, 14 patients (12%) died. Mortality was significantly higher in the control group versus the bDMARD group (56.9% vs. 40.9% respectively, p=0.025). Sepsis criteria were fulfilled in 56 patients (47.9%) at admission and/or at 72-96 hours of hospitalization. Sepsis was marginally more frequent in the control group versus the bDMARD group (58.9% vs. 40.9% respectively, p=0.087). In the subgroup analysis based on the type of bDMARD, no statistical difference was found for the outcomes of sepsis or death between patients on TNFi versus those on non-TNFi. However, in the subgroup of patients ≥65 years old, there was a tendency for a lower incidence of sepsis or death in patients on TNFi compared to those on non-TNFi or the control group (14% vs 33%, vs 85% respectively (p=0.120) for the outcome of sepsis and 7% vs. 21%, vs. 71% (p=0.138) for the outcome of death).

**Conclusion:** In the present study, we found a high incidence of sepsis (47.9%) and mortality (12%) in RA patients hospitalized for a serious infection. Older age is the most significant predictor of adverse outcomes, however, patients on bDMARDS showed lower mortality and a tendency for a lower incidence of sepsis compared to the control group.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2064
Background: Women with inflammatory arthropathies (IA) have fertility problems and complications during pregnancy and frequently biological therapy (BT) is required for the disease control.

Objectives: To evaluate pregnancy in women with IA in a multidisciplinary unit composed of Rheumatologists and Obstetricians: describe disease evolution, complications and treatment.

Methods: Retrospective and descriptive study of the evolution of pregnancy in patients with IA [Rheumatoid Arthritis (RA), Spondyloarthritis (SpA), Psoriatic arthritis (PsA) and Juvenile Idiopathic Arthritis (JIA)] and follow-up in a multidisciplinary unit for more than 15 years (until December 2021). Demographics, maternal disease, until time conception, previous abotions and presence of antibodies were collected. In addition, during follow-up, treatment, abortions, cesarean sections (C-section), preterm births, disease activity and maternal/fetal complications were collected.

Results: We registered 49 pregnancies (39 women): 27 RA (55.1%), 9 SpA (18.4%), 9 PsA (18.4%) and 4 JIA (8.1%). Maternal age at diagnosis was 26.8±6.7 years and average age at childbirth/abortion was 34.5±5.3 years. It took an average time of 9±7.7 months to conceive. 82% received fertility treatment with in vitro fertilization techniques. Anti-Ro antibodies were registered in 6.3% of patients and 28.6% had at least 1 antiphospholipid antibody. At the time of gestational desire/gestation 24 women (13 RA, 5 SpA, 3 PsA, 3 JIA) were receiving BT: 14 corticosteroids (CZP), 5 adalimumab (ADA), 4 etanercept (ETN), 1 patient was being treated with baricitinib (BARI). During pregnancy, ADA was changed to CZP in 3 women and BT was stopped in 6 cases (3 ETN, 2 ADA, 1 CZP) as well as BARI. In 2 cases, ADA was stopped at week 17 of pregnancy (medication indication). Pregnancy was completed with BT (CZP) in 15 cases. 9 abortions were registered prior to follow-up in the unit (0.23 abortions/mother) and 3 (2 RA, 1 PsA) during follow-up (0.07 abortions/mother); 2 (1 RA, 1 PsA) of them in women with CZP RA patient had positive antiphospholipid antibodies and was a smoker and the other one had moderate disease activity by the time of the abortion. C-section was performed in 26.1% of cases. Premature birth (<37 weeks) happened in 8.2% (n: 4) of the pregnancies: 2 in women with CZP. A total of 19 different fetal/maternal complications were registered during discharge and follow-up: 8 in the BT group (42.1%) compared to 11 (57.9%) in the group without BT, being Intrauterine Growth Restriction (IUGR) more frequent among women with BT. Infections were not more common in patients with BT, Table 1.

Table 1.

<table>
<thead>
<tr>
<th>COMPLICATIONS</th>
<th>WITH BT (n, %)</th>
<th>WITHOUT BT (n, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IUGR</td>
<td>3 (17.6)</td>
<td>1 (3.1)</td>
</tr>
<tr>
<td>LBW</td>
<td>2 (11.8)</td>
<td>2 (6.2)</td>
</tr>
<tr>
<td>INFECTION</td>
<td>1 (5.9)</td>
<td>4 (12.5)</td>
</tr>
<tr>
<td>CHOLESTASIS</td>
<td>0 (0)</td>
<td>2 (6.2)</td>
</tr>
<tr>
<td>PREECLAMPRIA</td>
<td>0 (0)</td>
<td>1 (3.1)</td>
</tr>
<tr>
<td>DM</td>
<td>2 (11.8)</td>
<td>1 (3.1)</td>
</tr>
<tr>
<td>HIGH BLOOD PRESSURE</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>NEPHROPATHY</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>NEONATAL LUPUS</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>HEART BLOCK</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>MALFORMATION</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>HELLP SYNDROME</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>TOTAL</td>
<td>8</td>
<td>11</td>
</tr>
</tbody>
</table>

Regarding concomitant treatment, low dose prednisone was used in 32.7% of pregnancies, hydroxychloroquine in 44.9%, sulfasalazine in 8.2% and acetylsalicylic acid in 51%. We didn’t find differences in the use of these treatments between the two groups. Median DAS28 among RA patients with available data was under 2.6 throughout pregnancy as well as previously and posteriorly. No differences in median DAS28 were found between women with BT and without BT. SpA patients had BASDAI lower than 4 in both groups during pregnancy and previously.

Conclusion: In our series, as described in the literature, women with IA are older and more likely to have preterm births compared to general population. Appropriate disease control was maintained during pregnancy, also previously and afterwards. We registered more IUGR, low birth weight (LBW) and diabetes mellitus (DM) among women with BT but lower rate of infections. Given the low number of patients with BT no statistically significant conclusions about complications can be drawn. Therefore, more studies among pregnant women with BT are necessary.

Disclosure of Interests: None declared

AB0268

SURVEY OF ELDERLY RHEUMATOID ARTHRITIS (RA) PATIENTS: REAL-WORLD DATA OF PRE-OLD (65 TO 74 YEARS) AND OLD (≥ 75 YEARS) RA PATIENTS


1 Ishikawa Prefectural Central Hospital, Division of Nephrology and Rheumatology, Kanazawa, Japan; 2 Ishikawa Prefectural Central Hospital, Division of Nephrology and Rheumatology, Kanazawa, Japan; 3 Kanazawa University Hospital, Department of Rheumatology, Kanazawa, Japan; 4 Kanazawa University Hospital Department of General Medicine, Kanazawa, Japan

Background: The number of patients (pts) with rheumatoid arthritis (RA) is highest in persons in their late 60s, and the age at onset has increased in recent years. In many countries, including Japan, ‘elderly’ is defined as 65 years or older, but recently, the Japan Geriatrics Society and Japan Gerontological Society have advocated a newer classification of elderly: pre-old as 65 to 74 years, old as 75-89 years and super old as ≥90 years. Disease activities, renal functions, treatments, and other parameters in thus classified elderly RA pts have not been investigated yet.

Objectives: Elderly pts with RA were classified, and then disease activities, treatments, renal functions and other parameters compared between the groups to clarify the real-world picture of pre-old and old RA pts.

Methods: We enrolled 359 RA patients (85 males, mean age 65.0 ± 13.6 years) treated at our hospital and affiliated hospitals. They were divided into three groups: 65 to 74 years as a pre-old (group I), 75 years or older as an old (group II). Urine examination, serum Cr, eGFR, BUN, other biochemical tests, serological tests, disease activity, treatment, smoking, and comorbidities were evaluated. Difficult-to-treat RA pts (D2TR) were evaluated according to EULAR criteria.

Results: Group C contained 148 pts (28 males, mean age 51.7 ± 9.6 years), Group I 123 pts (28 males, mean age 70.1 ± 2.9 years) and Group II 88 pts (29 males, average age 80.2 ± 4.5 years). Among the three groups, the frequency of males was 33.0% in group II, which was significantly higher than in the other groups. There was no significant difference in disease activity among the three groups. There was a significant difference in eGFR among the three groups (77.3 ± 17.3 ml/min in group C, 69.4 ± 15.8 ml/min in group I, 62.7 ± 18.7 ml/min in group II). There was a significant difference in frequencies of treatment with NSAIDs (40/133 (30.0%) in group C, 23/102 (22.5%) in group II, 9/67 (13.4%) in group III), methotrexate (MTX) (87/148 (58.8%) in group C, 62/103 (60.4%) in group I, 28/88 (31.4%) in group II). There was no significant difference in frequencies of treatment with prednisolone (55/148 (30.2%) in group C, 55/123 (43.1%) in group I, 45/88 (51.1%) in group II), with biologics (44/148 (29.7%) in group C, 29/123 (23.6%) in Group I, 26/88 (29.5%) in Group II) and with JAK inhibitor (15/148 (10.1%) in Group C, 7/123 (5.7%) in Group I, 5/88 (5.7%) in Group II). There was no significant difference in D2TR pts among the three groups (21/148 (14.2%) in Group C, 12/123 (9.8%) in Group I, 13/88 (14.8%) in Group II). There were significant differences in the frequencies of stage IV and comorbidities among the three groups.

Conclusion: In the pre-old and old RA pts, renal function was lower than in the control group. MTX was administered even in them, but less frequently. We were able to clarify the current situation that JAK inhibitors and biologics are actively used even in pre-old and old RA pts with impaired renal function, and the frequency of D2TR RA pts could be suppressed to almost that in the control group. Patients with impaired renal function are more likely to develop side effects of MTX, and it is necessary to pay particular attention to pre-old and old RA patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2221

AB0269

UTILITY OF DAS28-GT IN THE ASSESSMENT OF DISEASE ACTIVITY AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS

M. Lesturgie Telarek1, A. Delomeau1, E. Sorbets2, Y. Allamore3, J. Avouac3.

1 Cochin Hospital, Rheumatology, Paris, France; 2 Hôtel Dieu Hospital, Cardiology, Paris, France

Background: gGT has been identified as a maker of systemic inflammation and cardiovascular (CV) risk. The composite index DAS28-GT has been developed to allow an evaluation of both joint disease activity and CV risk.

Objectives: To assess the value of the DAS28-gGT in a population of patients with rheumatoid arthritis (RA) requesting cardiologic assessment.

Methods: Retrospective analysis of RA patients referred to cardio-metabolic day hospitalization in the Rheumatology department of Cochin hospital between February 2021 and January 2022. Criteria for referral were age > 50 years and presence of at least one CV risk factor. DAS28-GT index was calculated as follows: 0.56 * [TJ-28+0.28 *SJ-28+2 & + (γGT) +0.14 * GH]. This index was analysed according to disease activity measured with the DAS28-CRP. CV risk assessed by the Framingham score and the decision taken by the cardiologist (requirement of complement of examinations and/or therapeutic intervention).

Results: We included 22 RA patients (17 women), with a mean age of 66±10 years, a disease duration of 21±12 years. Rheumatoid factor was positive in 15 patients, anti-CCP antibodies in 17, and bone erosions in 16. 15 patients received methotrexate, 13 corticosteroids (dose < 10 mg per day), 15 targeted biologic therapies and 3 JAK inhibitors. The mean DAS28-CRP was 2.5±0.9 and the mean DAS28-GT was 7.9±1.90. 2 patients had a DAS28-GT < 5.5, defined in our previous study as high probability of RA remission and low probability of CV risk. These two patients were in remission and their Framingham score was < 10% (low CV risk). No complementary exploration was requested by the cardiologist.

8 (6 women, 2 men) had a DAS28-GT index between 5.5 and 7.5, defined in our previous study as high probability of RA remission or low disease activity (LDA) and increased probability of CV risk. As expected, all patients were in remission or in LDA. This population were at higher CV risk: 2 patients had a Framingham score > 20% (high risk), 3 patients a score ranging from 10 to 20% (intermediate risk), and 3 patients a score < 10%. One patient presented carotid atheroma. 4 patients required additional CV explorations and 3 patients necessitated escalation of blood pressure therapy.

Twelve patients (9 women, 3 men) had a DAS28-GT index > 7.5, defined in our previous study as high probability of active RA and/or increased probability of CV risk. 4 patients were in remission, 3 were in LDA and 5 presented moderate disease activity. One patient had a Framingham score > 20%, 4 had a score ranging between 10 and 20% and 6 had a score < 10%. The score was not applicable in an 80-year-old patient. Three other patients had coronary artery disease, including a patient who presented both coronary artery disease and carotid atheroma. 5 patients requested additional CV explorations and 4 patients required CV therapy escalation (introduction of statin and aspirin in 2 patients and increased blood hypertension therapy in 2 patients). Among these 12 patients, 3 with the highest DAS28-gGT values presented CV complications: a 64-year-old woman with a DAS28-gGT of 12.8 (DAS28-CRP, 2.89) had carotid atheroma and intermediate lesion of the right artery on coroscanner justifying a coronarography; a 61-year-old woman with a DAS28-gGT of 10.67 (DAS28-CRP: 4.62) had atrial fibrillation and aortic stenosis requiring Transcatheter Aortic Valve Implantation; and a 77-year-old woman with a DAS28-gGT of 10.35 (DAS28-CRP: 3.89) had ischemic chest pain necessitating rapid explorations in cardiology.

Conclusion: The DAS28-gGT allowed a reliable classification of patients according to RA activity and CV risk. This index may be relevant for CV risk stratification decision making to refer RA patients to a cardiologist. Its validation is in progress in a prospective cohort.

REFERENCES:

Disclosure of Interests: None declared

AB0270

EFFECT OF METHOTREXATE USE ON JOINT AND LUNG DISEASE OUTCOMES IN PATIENTS HAVING RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE

M. Yoshida1, T. Zoshima2, M. Kawano1.

1 Kanazawa University Graduate School of Medicine, Rheumatology, Kanazawa, Japan

Background: Intestinal lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA). Although methotrexate (MTX) is an anchor drug for RA management, its use may worsen lung disease severity in patients with RA related ILD (RA-ILD). The safety and efficacy of MTX use in RA-ILD treatment have not been elucidated.

Objectives: We aimed to clarify the clinical characteristics of patients with RA-ILD and the effect of MTX use on joint and lung disease outcomes.

Methods: In this retrospective study, we included patients with RA-ILD who visited our department from 2011 to 2019 and underwent chest computed tomography (CT). RA was diagnosed using the 1987 ACR criteria or the 2010 ACR/EULAR classification criteria. During the abovementioned period, we defined the baseline as the time of the first chest CT scan; moreover, the final observation was defined as the time of the final chest CT scan in patients who underwent CT more than once, or as the final visit in those without a second chest CT scan. We excluded patients whose RA-ILD status could not be fully evaluated using chest
CT scans due to other causes, including respiratory infections. Severe infections were defined as infectious events requiring hospitalization.

To identify the clinical characteristics of patients with RA-ILD, we compared the features of RA with versus without ILD at baseline. To clarify the effect of MTX use on RA-ILD outcomes, we compared the outcomes of patients with RA-ILD with versus without MTX use. Furthermore, we investigated factors associated with RA disease activity or ILD deterioration using multivariate analyses.

**Results:** In this study, we included 452 patients (mean age, 60.2 years; females, 78.5%; mean observational period, 775 months), 325 (71.9%) of whom underwent chest CT more than two times.

Patients with ILD (ILD: n=90, 19.9%) were older and had a higher RF positivity rate than those without ILD. Moreover, patients with ILD were treated with lower MTX use (20.2% vs. 52.9%, p<0.001; 1.46 vs. 3.53 mg/week, p<0.001) and TNF inhibitors exposure (21.1% vs. 13.1%, p=0.044) than those without ILD, albeit with similar uses of prednisolone and other bDMARDs, including tocilizumab and abatacept. DAS28-PCR was higher in patients with than in those without ILD at baseline (4.60 vs. 3.42, p=0.063) and at the final observation (2.42 vs. 2.09, p=0.025). Linear regression analysis showed that baseline age and ILD were significantly associated with DAS28-PCR at the final observation ([b]=0.206 and 0.173, respectively). Kaplan Meier analysis revealed that patients with ILD experienced severe infections and respiratory infections more frequently than those without ILD (log-rank test, p<0.001 and p<0.001). Seventeen patients (20.2%) with ILD were treated with MTX. At baseline, these patients had similar ages and RF/ACPA positivity rates, as well as prednisolone and tDMARDs exposures, with higher tDMARD exposure (41.2 vs. 13.4%, p=0.016) compared to that in ILD patients without MTX use. DAS28-PCR was comparable in patients with and without MTX use at baseline, but was lower at the final observation in MTX-treated patients with ILD (1.41 vs. 2.73, p=0.001). Kaplan Meier analyses revealed no differences in the frequencies of severe infections, respiratory infections, or ILD deterioration between patients with and without MTX use. Cox regression analysis demonstrated that the risk factors for ILD deterioration included baseline age (hazard ratio [HR] 1.088; 95% confidence interval [CI] 1.037-1.147), but not MTX use (HR 1.668; 95% CI 0.472-5.876).

**Conclusion:** RA-ILD were treated with lower MTX use, which resulted in higher RA disease activity. In contrast, patients with RA-ILD treated with MTX had lower RA disease activity without ILD deterioration. As RA-ILD is undertreated, further studies are needed to assess the clinical significance of alexithymia in this category of patients.

**REFERENCES:**

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2657
the root mean square of successive R-R intervals (RMSSD), and c) the proportion of NNSQ (pairs of successive R-R intervals that differ more than 50 milliseconds) divided by the total number of R-R intervals (PNNS).

**Results:** Thirty minutes of DB increased HRV and was the optimal dose of DB in healthy participants. In patients with RA and SLE 30 minutes of DB increased all HRV-parameters similarly across two days indicating reliability, see Figure 1. The effect of DB remained for at least 30 minutes after the intervention. In our cohort the first ILD symptom appeared 7.4 years after RA diagnosis.

**Conclusion:** DB increases HRV in healthy participants and in patients with RA. HRV-parameters similarly across two days indicating reliability, see Figure 1. The mean time between diagnosis and initiation of biotherapy was 54 months (±5734). The first biologic prescribed for rheumatoid arthritis was Rituximab (94%), Infliximab was the first choice for spondyloarthritides (71%). Conventional treatment was combined with biotherapy in 78% versus 21% just treated by a biological treatment, the switch rate was high in the group receiving monotherapy with a significant difference (P=0.0008). The first cause of switch was therapeutic escape in (82.36%), followed by inefficacy in (11.76%) and a paradoxical reaction such as skin psoriasis in (5.85%). Switching was made to an Anti TNF alpha in 14 patients to and another therapeutic class in 3 patients.

**Conclusion:** Regular monitoring of the efficacy and tolerance of biological treatment is an integral part of the management of chronic inflammatory rheumatism.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2907

---

**AB0273**

**IDENTIFICATION OF RED FLAGS FOR INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS**

P. Cornigliano1, E. De Martinis2, E. Cela3, P. Triggianese3, M. S. C. Chimenti3, A. Lucano3, P. U. Calabria3, J. Ora4, F. Cavalli5, F. Garaci6, R. Floris7, P. Regiani1, A. Bergamini1, 1University of Rome Tor Vergata, Rheumatology, Allergology and Clinical Immunology, Rome, Italy; 2University of Rome Tor Vergata, Rheumatology, Allergology and Clinical Immunology, Rome, Italy; 3University of Rome Tor Vergata, Department of Diagnostic Imaging and Interventional Radiology, Rome, Italy; 4Tor Vergata Hospital Foundation, Radiosurgery, Rome, Italy; 5University of Rome Tor Vergata, Department of Diagnostic Imaging and Interventional Radiology, Rome, Italy; 6University of Rome Tor Vergata, Respiratory Medicine, Department of Experimental Medicine, Rome, Italy

**Background:** Interstitial lung disease (ILD) in Rheumatoid Arthritis (RA) can be subclinical or underestimated. Data from the literature report male sex, seropositivity and old age as known risk factors for ILD in RA. However, the correct timing for referral to pneumologists and eligibility for CT chest scan is undefined.

**Objectives:** To identify potential red flags of ILD diagnosis for referral to a multidisciplinary team analyzing clinical and radiological findings associated with the establishment of ILD.

**Methods:** Retrospective study on CT chest scan from RA patients evaluated and categorized into usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP) and unclassifiable RA-ILD (Un-ILD), by two radiologists.

**Results:** 80 CT chest scans from RA patients (F 59, age 66.6 ± 11.4, disease duration 78 ± 4.4) were evaluated. 36.5% of patients had performed CT chest scan for suspect of ILD, 11.2% for probable pulmonary infection, 8.7% for oncological screening or follow up, 13.7% for COPD disease, 8.7% for screening or active TBC, 3.7% for screening or previous pluriets and 175% for other reasons. A RA-ILD pattern was identified in 35% of patients, with a defined UIP pattern in 17.8%, a defined NSIP pattern in 42.8% and a 39.3% of Un-ILD, while 65% of patients had a non-ILD lung involvement by CT-scan. The mean age at ILD diagnosis was 67.2 years and the mean time between RA diagnosis and onset of ILD symptoms was 74 years. In the multivariate analysis female sex (HR=0.33; p=0.006) and disease duration (HR=0.8; p=0.06) were protective factors for ILD diagnosis. Age (HR=1.1; p=0.03), use of leflunomide (HR=10.1; p=0.03) were negative prognostic factors for ILD. Pulmonary clinical symptoms as dry cough (HR=17.6; p=0.02), bivascular inspiratory crackles (HR=11.5; p=0.01) and pleural rubs (HR=18.1; p=0.03) predicted ILD while negative predictors were the presence of linear opacities (HR=99.9; p=0.006), interstitial abnormalities (HR=12.1; p=0.07) and cystic areas (HR=33.3; p=0.06) at chest CT scan.

**Conclusion:** In our cohort the first ILD symptom appeared 74 years after RA diagnosis. Clinical variables and radiological abnormalities were identified as highly predictive of ILD diagnosis and may represent red flags for an early diagnosis and referral to pneumologists and radiologists in a multidisciplinary approach.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2737

---

**AB0275**

**THE FREQUENCY, PREVALENCE OF CORONARY ARTERY DISEASE AND PRE-MATURE CAD IN PSA AND RA PATIENTS**


**Background:** An increased incidence of coronary artery disease (CAD) is known in inflammatory arthritis patients compared to the normal population. In the Veterans With Premature Atherosclerosis (VITAL) registry, the frequency of premature CAD in patients with rheumatoid arthritis (RA) compared to the healthy population in approximately 135,000 patients, while a similar situation was observed in Psoriatic arthritis patients. Aims: To study the prescription profile of biological agents (bDMARD) during chronic inflammatory rheumatic diseases, their impact on disease activity, frequency and causes of switch.

**Methods:** This is a retrospective study including 106 patients followed for chronic inflammatory rheumatism treated by biological agents.

**Results:** We included 106 patients, sex ratio (0.44), mean age was 41.5 ± 11.9. 64.4% were followed for spondyloarthritides (41 cases of ankylosing spondylitis, 10 cases of psoriatic arthritis, 11 cases of spondyloarthritides and chronic inflammatory bowel disease). 35.6% of the cases had rheumatoid arthritis. Sero-positive in 32% (labeled with Sjogren’s syndrome in 75% of cases, lupus in 19% of cases, vasculitis in 2% of cases). The mean time between diagnosis and initiation of biotherapy was 54 months (±5734). The first biologic prescribed for rheumatoid arthritis was Rituximab (94%), Infliximab was the first choice for spondyloarthritides (71%). Conventional treatment was combined with biotherapy in 78% versus 21% just treated by a biological treatment, the switch rate was high in the group receiving monotherapy with a significant difference (P=0.008). The first cause of switch was therapeutic escape in (82.36%), followed by inefficacy in (11.76%) and a paradoxical reaction such as skin psoriasis in (5.85%). Switching was made to an Anti TNF alpha in 14 patients and to another therapeutic class in 3 patients.

**Conclusion:** Regular monitoring of the efficacy and tolerance of biological treatment is an integral part of the management of chronic inflammatory rheumatism.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2907
of RA patients had premature CAD, 18/32 (56.3%) PsA patients had premature CAD (Table 1).

Conclusion: While the frequency of premature CAD is 10% in the normal population, CAD has a premature character in two-thirds of RA patients and 55% of PsA patients (2). In a large community-based study, the frequency of premature CAD was found to be increased in RA patients compared to the normal population, but no similar difference was observed in PsA patients (1). In real-life data in which we examined a large group of patients using bDMARDs, it is seen that the subtype of CAD is of pre-mature character in both RA patients and PsA patients.

REFERENCES:

Table 1. Characteristics of RA and PsA patients with/without premature CAD

<table>
<thead>
<tr>
<th>Gender, n(%)</th>
<th>RA</th>
<th>PsA</th>
<th>p</th>
<th>Gender, n(%)</th>
<th>RA</th>
<th>PsA</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>56.6 (8.9)</td>
<td>72.7 (7.1)</td>
<td>0.01</td>
<td>59.9 (8.2)</td>
<td>69.1 (6.3)</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>PsA duration, mean (SD), years</td>
<td>5.5 (2.1)</td>
<td>6.0 (1.7)</td>
<td>0.34</td>
<td>13.3 (8.9)</td>
<td>12.6 (9.5)</td>
<td>0.83</td>
<td></td>
</tr>
<tr>
<td>Smoking (ever), n(%)</td>
<td>22 (57.9)</td>
<td>11 (52.4)</td>
<td>0.80</td>
<td>18 (88.9)</td>
<td>5 (38.7)</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>BMI &gt; 30, n(%)</td>
<td>19 (52.3)</td>
<td>7 (35.0)</td>
<td>0.30</td>
<td>8 (44.4)</td>
<td>11 (78.5)</td>
<td>0.051</td>
<td></td>
</tr>
<tr>
<td>HT (ever), n(%)</td>
<td>23 (63.9)</td>
<td>14 (66.7)</td>
<td>0.89</td>
<td>11 (61.1)</td>
<td>13 (92.8)</td>
<td>0.040</td>
<td></td>
</tr>
<tr>
<td>DM (ever), n(%)</td>
<td>20 (57.1)</td>
<td>9 (52.9)</td>
<td>0.77</td>
<td>4 (22.2)</td>
<td>6 (42.8)</td>
<td>0.45</td>
<td></td>
</tr>
<tr>
<td>LDL &gt; 130 (ever), n(%)</td>
<td>29</td>
<td>12</td>
<td>0.13</td>
<td>11 (61.1)</td>
<td>5 (35.7)</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td>DAS-28</td>
<td>4.7 (1.1)</td>
<td>4.2 (1.2)</td>
<td>0.11</td>
<td>4.7 (1.4)</td>
<td>4.5 (1.5)</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td>HDAC (0-3)</td>
<td>1.41 (0.7)</td>
<td>1.05 (0.8)</td>
<td>0.079</td>
<td>0.7 (0.6)</td>
<td>1.3 (0.7)</td>
<td>0.13</td>
<td></td>
</tr>
</tbody>
</table>

Background: According to international recommendations, co-morbidities must be taken into account in the management of patients with inflammatory arthritis.

Objectives: To evaluate the distribution of pre-treatment comorbidities in the bDMARD cohort including patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Methods: The Hacettepe University biological database (HUR-BIO) was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005. 581 (75.4% female) patients with RA and 520 (69.4% female) patients with PsA enrolled up to 2021 were analyzed. Diagnosis of RA and PsA was established in 2005.

Results: The burden of comorbidities in patients with RA before bDMARDs is more pronounced than in patients with PsA. Although, cardiovascular risk factors were similar, with the exception of hypertension and smoking, the age-adjusted CCI was 3.96 times higher in patients with RA than in patients with PsA.

Conclusion: The burden of comorbidities in patients with RA before bDMARDs is more pronounced than in patients with PsA. Although, cardiovascular risk factors were similar, with the exception of hypertension and smoking, the age-adjusted CCI was 3.96 times higher in patients with RA than in patients with PsA.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Comorbidities in RA and PsA patients

<table>
<thead>
<tr>
<th>Features</th>
<th>RA n=581</th>
<th>PsA n=520</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, female n (%)</td>
<td>438 (75.4%)</td>
<td>361 (69.4%)</td>
<td>0.027</td>
</tr>
<tr>
<td>Age at RA diagnosis, mean (SD) years</td>
<td>46.7 (13.7)</td>
<td>39.3 (12.0)</td>
<td>0.001</td>
</tr>
<tr>
<td>Age at bDMARD start, mean (SD) years</td>
<td>49.5 (13.8)</td>
<td>42.2 (12.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CCI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No comorbidity</td>
<td>205/581 (35.2%)</td>
<td>290/486 (59.6%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt; 1 comorbidity</td>
<td>145/581 (24.9%)</td>
<td>90/486 (18.5%)</td>
<td></td>
</tr>
<tr>
<td>&gt; 2 comorbidity</td>
<td>231/581 (39.7%)</td>
<td>106/486 (21.8%)</td>
<td></td>
</tr>
<tr>
<td>Smoking (ever), n</td>
<td>292/581</td>
<td>282/506</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>29.3 (6.7)</td>
<td>29.6 (5.9)</td>
<td>0.50</td>
</tr>
<tr>
<td>Diabes Mellitus, n</td>
<td>68/581</td>
<td>49/402</td>
<td>0.30</td>
</tr>
<tr>
<td>Hypertension, n</td>
<td>166/581</td>
<td>110/502</td>
<td>0.012</td>
</tr>
<tr>
<td>Dyslipidemia a</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- High TC</td>
<td>47/270</td>
<td>32/161</td>
<td>0.30</td>
</tr>
<tr>
<td>- High TG</td>
<td>62/242</td>
<td>45/159</td>
<td>0.79</td>
</tr>
<tr>
<td>- High LDL-C</td>
<td>53/289</td>
<td>43/173</td>
<td>0.38</td>
</tr>
<tr>
<td>- Low LDL-C</td>
<td>88/267</td>
<td>57/157</td>
<td>0.48</td>
</tr>
<tr>
<td>Unic acid (&gt;6mg/dl), n</td>
<td>150/554</td>
<td>136/437</td>
<td>0.16</td>
</tr>
<tr>
<td>CAD n</td>
<td>59/524</td>
<td>32/486</td>
<td>0.010</td>
</tr>
<tr>
<td>Premature CAD, n</td>
<td>38/581</td>
<td>18/486</td>
<td>0.230</td>
</tr>
<tr>
<td>CKD, n</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1 (GFR &gt; 90)</td>
<td>437/523</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>G2 (GFR 60-90)</td>
<td>68/523</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>G3a (GFR 45-60)</td>
<td>11/523</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>G2b (GFR 30-45)</td>
<td>5/523</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>G4 (GFR 15-30)</td>
<td>2/523</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Lung disease, n</td>
<td>15/519</td>
<td>3/485</td>
<td>0.007</td>
</tr>
<tr>
<td>- COPD</td>
<td>66/520</td>
<td>19/486</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Thyroid disease, n</td>
<td>132/581</td>
<td>65/440</td>
<td>0.003</td>
</tr>
</tbody>
</table>

*TC > 240, TG 150-499, LDL-C > 160, HDL-C erkek < 40, kadın < 50CCI: Charlson comorbidity index, CAD: Coronary artery disease, CKD: Chronic Kidney Disease, COPD: Chronic Obstructive pulmonary disease

Table 2. Lipid values in patients with RA and PsA at the initiation of bDMARD and at the last visit

<table>
<thead>
<tr>
<th>Lipid values</th>
<th>RA bDMARD initiation</th>
<th>RA Last visit</th>
<th>PsA bDMARD initiation</th>
<th>PsA Last visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>47/270 (17.4)</td>
<td>98/339 (28.9)</td>
<td>32/161 (19.8)</td>
<td>57/203 (28.1)</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>62/242 (25.6)</td>
<td>108/320 (33.7)</td>
<td>45/159 (28.3)</td>
<td>80/193 (41.4)</td>
</tr>
<tr>
<td>LDL-C &gt; 190</td>
<td>88/267 (32.9)</td>
<td>70/343 (20.4)</td>
<td>57/157 (36.3)</td>
<td>20/207 (9.6)</td>
</tr>
<tr>
<td>LDL-C &lt; 50 (females)</td>
<td>53/289 (18.3)</td>
<td>91/356 (25.6)</td>
<td>43/175 (24.5)</td>
<td>65/226 (28.7)</td>
</tr>
</tbody>
</table>

*p1, bDMARD initiation visit comparison **p2, last visit comparison
Background: Patients with Rheumatoid arthritis (RA) have an increased risk of infections due to the disease itself, and/or immunosuppressive therapy. The risk of herpes zoster (HZ) including disseminated HZ is also increased.

Objectives: In an unselected series of RA patients we assessed a) prevalence, b) general features and c) predictive factors of HZ.

Methods: Study of 393 RA patients included in the prospective vaccination program of the Preventive Medicine and Rheumatology department of a University hospital, from October 2011 to October 2016. The minimum follow-up was of 12 months; therefore, it was made until December 2020. HZ vaccination is not included in our vaccination program.

RA was diagnosed according to the ACR/EULAR 2010 criteria. HZ diagnosis included characteristic skin rash and blisters, paresthesia and local pain, in one (localized) or more dermatomes (generalized).

Vaccination program in our hospital includes vaccination for Influenza, Streptococci, Rhinovirus, Varicella Zoster Virus, Haemophilus influenzae, Pneumococci.

Patients with serious infections-related hospitalization were compared with healthy ones using the incidence rate method at a follow-up of 12 months; therefore, it was made until December 2020.

Results: We studied 393 patients (310 women), mean age 61.5±11.9 years. They were followed-up during a mean period of 82.6±15.2 months (range: 50 months-9 years).

HZ infection was observed in 31 of 393 patients (7.9%) (26 women); mean age 69.7±11.2 years. Prevalence of HZ in this period (12months) was 7.88% with an annual incidence rate of 0.73/100 patients/year. A comparison between patients with and without HZ was performed (Table 1).

HZ locations were intercostal (n=6), dorsal (5), abdominal (3), lumbar (3), facial (3), cervical (1), gluteus (1) (submmamary fold (1), intermmamary fold (1) and upper extremity (1). Main HZ complications were post-herpetic neuralgia (n=7), visual alteration in facial HZ (n=1) and disseminated HZ (n=1).

HZ treatment was antiviral agents (n=23) (brivudine=7; acyclovir 6; famciclovir; valaciclovir), topical (n=2) and none (n=6).

Predictive factors for HZ (Figure 1) were older age (>65 years), hypertension and treatment with high prednisone dose and antiTNF.

Conclusion: HZ is a relative frequent complication of RA. In our series, although are usually localized, post-herpetic neuralgia is relatively frequent. Probably to include HZ vaccine in our vaccination program of RA may be useful.

REFERENCES:

Disclosure of Interests: None declared

Results: We studied 392 RA patients (309 women/83 men); mean age 63.1±13.7 years. After a mean follow-up of 7.1±2±3.6 months, in 88 of 392 patients (22.4%) (60 women) 167 serious infections-related hospitalizations were required. The median (IQR) number of hospitalizations was 15 [1-2]. The main serious infections were respiratory (44 patients; 78 hospitalizations), urinary (33 patients; 48 hospitalization), cutaneous (19 patients; 28 hospitalizations), abdominal (17 patients; 20 hospitalizations), septic arthritis (7 patients; 8 hospitalizations), maxillofacial (2 patients, 2 hospitalizations), bacterial endocarditis (2 patients, 2 hospitalizations) and genital (1 patient; 1 hospitalization). Patients with serious infections-related hospitalization were older, with a longer RA, with more co-morbidities (hypertension, hypercholesterolemia diabetes mellitus, and Intestinalstitial lung disease) and with more conventional and biological DMARDS (Table 1).

The predictive factors for hospitalization were hypertension and Diabetes Mellitus, RA related intestinal lung disease and treatment with biologic DMARDS.

Figure 1. Predictive factors for serious infections-related hospitalization

Conclusion: Despite to be included in a vaccination program up to 22% of patients required hospitalization due to serious infection. The main predictive factors were co-morbidities, intestinal lung disease and treatment with biologic DMARDS. Serious infections in RA remain to be an unmet need.

Disclosure of Interests: None declared


Table 1. Characteristics of RA with FM and RA without FM patients.

<table>
<thead>
<tr>
<th></th>
<th>RA without FM (n=138)</th>
<th>RA WITH FM (n=62)</th>
<th>P VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ± sd</td>
<td>Mean ± sd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yrs.</td>
<td>47.17±12.44</td>
<td>53.17±12.33</td>
<td>0.028</td>
</tr>
<tr>
<td>Duration of RA</td>
<td>4.1±3.59</td>
<td>6.46±6.09</td>
<td>0.006</td>
</tr>
<tr>
<td>TJC, 0-28</td>
<td>4.57±2.86</td>
<td>6.87±3.08</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SJC, 0-28</td>
<td>2.3±2.37</td>
<td>3.37±2.87</td>
<td>0.011</td>
</tr>
<tr>
<td>Pan VAS, 0-100</td>
<td>36.38±16.16</td>
<td>55.24±11.18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ESR</td>
<td>39.01±20.67</td>
<td>46±20.39</td>
<td>0.028</td>
</tr>
<tr>
<td>CRP</td>
<td>11.61±11.15</td>
<td>16.43±15.72</td>
<td>0.032</td>
</tr>
<tr>
<td>CDAA</td>
<td>14.6±6.69</td>
<td>19.68±7.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SDAI</td>
<td>15.74±7.33</td>
<td>21.34±7.48</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DAS-28 CRP</td>
<td>4.1±1.1</td>
<td>4.85±0.84</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PDS-0-3</td>
<td>8.68±3.22</td>
<td>16.27±3.33</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Physical score, 1-100</td>
<td>54.83±12.16</td>
<td>34.37±5.41</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Psychological score, 0-100</td>
<td>59.78±14.34</td>
<td>39.84±12.74</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Social score, 0-100</td>
<td>60.68±12.75</td>
<td>51.5±12.76</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Environmental score, 0-100</td>
<td>59.21±11.04</td>
<td>49.35±9.73</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRD HAQ-DI</td>
<td>1.04±0.64</td>
<td>1.81±0.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Anxiety, n (%)</td>
<td>23(17%)</td>
<td>53(85%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Depression, n (%)</td>
<td>44(32%)</td>
<td>59(95%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

TJC: tender joint count (28 joints); SJC: swollen joint count (28 joints); CRP: C-reactive protein; DAS: disease activity score (28 joints); PDS: Polysymptomatic distress score of fibromyalgia; *Domain scores of quality of life (WHO-Qol BREF).

Conclusion: The prevalence of RA in patients is significantly higher with 2016 ACR FM Criteria as compared to older criteria in similar population of RA patients. A significant number of patients had anxiety and depression that needs to be clinically attended. The presence of FM in RA adversely affects the Disease activity, quality of life, functional disability.REFERENCES:


Disclosure of Interests: None declared


AB0282

THE 2016 REVISED ACR FIBROMYALGIA CRITERIA IDENTIFY A HIGHER PREVALENCE OF FIBROMYALGIA IN RHEUMATOID ARTHRITIS PATIENTS: A CROSS-SECTIONAL STUDY FROM INDIA.

D. Malujtte, 1 S. Upadhyaya 1, R. Handa, 1 S. J. Gupta 1, S. Budmuru 1.

1Indraprastha Apollo Hospitals, Rheumatology, New Delhi, India

Background: Fibromyalgia (FM) prevalence in rheumatoid arthritis (RA) is reported around 5-50% as per older American College of Rheumatology (ACR) FM Criteria, while in India reported around 15% (1). The Revised 2016 ACR FM criteria has greater sensitivity and specificity of 94% and 91% respectively compared to older criteria (2). To best of our knowledge, no study has evaluated the prevalence of FM in RA as per revised 2016 ACR FM criteria.

Objectives: 1) To study prevalence of FM as per revised 2016 ACR FM criteria in RA patients.
2) To compare Disease activity, Disability status, Quality of life, Anxiety and Depression in RA with and without FM.

Methods: This cross-sectional study included 200 RA patients and equal number of controls. FM was diagnosed using revised 2016 ACR FM Criteria. Disease activity, quality of life and functional disability in RA patients was assessed using disease activity scores (CDAI, SDAI, DAS-28 CRP, WHO-Qol BREF and Health Assessment Questionnaire CRD HAQ-DI). Presence of depression and anxiety was determined using validated Hospital Anxiety and Depression Scale (HADS).

Results: FM was present in 31% and 4% of RA patients and healthy controls respectively in our study using 2016 ACR FM criteria. This is significantly higher compared to the 15% and 2.5% in RA and healthy control populations respectively of the study by Dhir V. et studying a similar population of Indian patients, using 1990 ACR FM criteria. RA patients with FM were older, predominantly females, had longer disease duration, were more on steroids, had higher disease activity and more functional disability. In a multivariable linear regression analysis, FM was important predictor of DAS28 score & CDAI, even after adjusting for other independent variable like disease duration, CRP, SJC, functional disability. RA patients with FM had a poorer quality of life and had higher prevalence of anxiety and depression. No difference was noted in use of disease modifying agents, biological or ts-DMARDs in RA patients with or without FM.

Disclosure of Interests: None declared


AB0282

COMORBIDITIES ARE MORE IMPORTANT THAN JAK INHIBITORS: VENOUS THROMBOEMBOLISM IN RHEUMATOID ARTHRITIS

G. Sandal Uzun1, M. Bahap0, O. Yucel1, Y. Kaygusuz2, E. Bilgin1, L. Kılıç1, A. Akdogan1, O. Karadag1, Ş. A. Bilgen1, S. Kinaz1, A. İ. Ertenli1, U. Kalyoncu1, 1Ankara, Hacettepe University, Faculty of Medicine; Division of Rheumatology, Ankara, Turkey; 2Hacettepe University, Faculty of Pharmacy, Department of Clinical Pharmacy, Çanakkale, Turkey

Background: The risk of Venous thromboembolism (VTE) is increased and is an important cause of mortality and morbidity in rheumatoid arthritis. In addition to the underlying Rheumatoid arthritis(RA), there are a number of predisposing risk factors for VTE(1).

Objectives: In this study, we aimed to evaluate the demographic and clinical features of rheumatoid arthritis patients with VTE.

Methods: Patients who were referred to Hacettepe University Medical Rheumatology department from January 2021 to December 2021 retrospectively analyzed. A total 981 RA patients were detected according to the ICD code(M05, M06, MO07). RA diagnosis was confirmed in 400 patients according to 2010 ACR/ EULAR criteria. Venous thrombosis was confirmed by ICD code(I26,I74,I82), computed tomograph, lower extremity venous doppler and medical treatment report in these 400 patients with RA. Thromboembolism was detected in 58 patients during follow-up. The patients' clinical characteristics, serological features, co-morbidities, and treatment were systematically analysed.

Disclosure of Interests: None declared

Background: Fatigue is a major symptom suffered by patients with rheumatoid arthritis (RA), with a high prevalence (40%-70%). Different questionnaires and scales (BRAF, FACIT, SF36v, MDHAQ, VAS...) have been validated, but none have been standardized to measure it. In observational studies, the VAS (0-10) scale was reported as a good measure for fatigue; cut-off 5/10 indicates high level. A residual fatigue in low activity/remission of the disease has been described in a significant percentage of patients. The level of brain-derived neurotrophic factor (BDNF) in serum has been reported to be elevated in patients with RA, their connection with cognitive and depressive disorders in rheumatic diseases. Chronic inflammation, prolonged pain, early disability of patients with multi-morbidities. RA patients with multimorbidity may have an increased risk of VTE. In the management of RA, comorbidities should be taken into account.

References:
[1] Kettic, Boutigny A, et al. Risk of venous thromboembolism in rheumatoid arthritis (RA), with a high prevalence (40%-70%). A residual fatigue in low activity/remission of the disease has been described in a significant percentage of patients.

Disclosure of Interests: None declared.

patients - all these factors contribute to the development of depressive and cognitive disorders in this category of patients. Still, the mechanisms of these disorders remain poorly understood. Recently, the role of brain-derived neurotrophic factor (BDNF) as one of the factors of cognitive and depressive disorders in various pathological conditions has been widely discussed in the literature.

Objectives: To study cognitive and depressive disorders in RA patients and their association with serum BDNF levels.

Methods: 79 women with RA, aged 21 to 74 years, on average (M ± SD) 48.7 ± 10.2 were examined. Diagnosis RA was established according to EULAR / ACR criteria (2010). Patients' cognitive function was assessed by the MMSE (Mini Mental State Examination). The presence and severity of depression were determined by the QIDS-SR16 (Quick Inventory of Depressive Symptomatology Self-Report). Serum BDNF was detected by enzyme-linked immunosorbent assay (ELISA) using standard BDNF Quantikine ELISA kits (R&B Systems, USA). The control group consisted of 30 age matched healthy women.

Results: It was found that the level of BDNF in the serum of women with RA was 1.5 times higher than in healthy individuals and was 16.8 ± 10.8 ng/ml and 11.3 ± 4.89 ng/ml, respectively. Cognitive disorders (MMSE < 28 points) were registered in the majority (78.5%) of patients with RA, while in the control group, there were only 10%. The mean MMSE values in RA patients and the control group were 27.2 ± 1.45 and 29.1 ± 0.99, respectively. Depressive disorders (QIDS-SR16 ≥ 6 points) were reported in 53% of patients, while in the control group, it was 3.3%. It was found that depressive disorders in RA patients were associated with BDNF levels (r = 0.208; p<0.05) and age (r = 0.159; p<0.05). There was no significant association between BDNF levels and MMSE in RA patients. In the control group it was found negative correlation (-0.257; p<0.05). We found also close negative correlation between MMSE and age in patients with RA (r = -0.669; p<0.001). A significant relation with age was also registered in the healthy group (r = -0.257; p<0.05).

Conclusion: Patients with RA had an increased level of BDNF compared with the control group. Most of them had cognitive and depressive disorders. Depressive disorders in RA patients are associated with higher levels of BDNF in the blood and with age. No association of cognitive impairment with BDNF has been established in patients. Cognitive disorders in RA patients are most closely associated with age. Moderate association between MMSE and BDNF levels was established in control group.

REFERENCES:

Disclosure of Interests: None declared.

regression models for estimating the increment in the mean outcome disease activity scores, DAS28- CRP and SDAI in continuous, provided beta coefficients equal to -0.17 (Standard Error, SE: 0.06) with a p-value equal to 0.06 for DAS28- CRP and a beta coefficient of -1.13 (SE: 0.37) with a p-value equal to 0.04.

Conclusion: Increasing frequency of consumption of a food group composed by olive oil, black and green olives is significantly associated to a lower risk of disease activity, as measured by both DAS28-CRP and SDAI, after adjustment for socio-demographic factors, therapy, disease duration and severity. Robust regression models allowed to quantify the mean reduction of DAS28-CRP in 0.17 points and that of SDAI in 1.19 points.

REFERENCES:

Acknowledgements: The authors thank the RANDIE study group

Disclosure of Interests: Francesca Ingegnoli: None declared, Roberto De Vito: None declared, Roberto Caporalli Speakers bureau: Abbvie, Ame, BMS, Celltrion, Galapagos, Lilly, Pfizer, Fresenius-Kabi, MSD, UCB, Roche, Janssen, Novartis, Sandoz, Consultant of: Abbvie, Ame, BMS, Celltrion, Galapagos, Lilly, Pfizer, MSD, UCB, Janssen, Novartis, Sandoz, Maria Parpinel: None declared, Giuseppe Grosso: None declared, Monica Ferraroni: None declared, Valeria Edefonti: None declared


AB0287 INFLUENCE OF COPING ON RHEUMATOID ARTHRITIS RELATED PAIN

O. Saidane1, M. Haddad2, A. Ben Tekaya1, R. Leila1, S. Bouden1, R. Tekaya1, I. Mahmoud1, L. Abdelmoloula1. 1Charles Nicolle Hospital, Rheumatology, Tunis, Tunisia

Background: Most patients with rheumatoid arthritis (RA) have chronic pain. Nowadays dealing with pain is no more focused on traditional treatment only.

Objectives: Our study aimed to assess the impact of coping strategies on the chronic pain in RA subjects.

Methods: We performed a 6-month study including patients followed for RA according to ACR / EULAR 2010 criteria. The visual analogue scale (VAS) was used to assess the perception of pain. Coping was assessed by the Brief COPE questionnaire according to which five grouped strategies were identified: Problem solving that includes active coping and planning. Cognitive restructuring that combines humour, acceptance and positive reinterpretation. Support seeking that combines the search for instrumental support, the search for emotional support and religion. Avoidance that includes denial, blame, substance use and behavioural disengagement. Distraction that includes distraction and expression of feelings.

Results: We included 65 RA patients with 58 women and 7 men, the sex ratio was 0, 12 H/F. Mean age of the patients was 58, 6 [24 – 73 years]. Disease duration was superior to 10 years in 66, 2% of patients. RA was immunopositive in 87%, the average of VAS was 5 ± 2,2. The perception of pain was positively associated with coping strategies based on problem solving, negatively associated to cognitive restructuring and distraction (Table 1).

Table 1. Impact of coping strategies on chronic pain RA subjects

<table>
<thead>
<tr>
<th></th>
<th>B</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Problem solving</td>
<td>0,411</td>
<td>0,001</td>
</tr>
<tr>
<td>Cognitive restructuring</td>
<td>-0,371</td>
<td>0,002</td>
</tr>
<tr>
<td>Support seeking</td>
<td>-0,095</td>
<td>0,452</td>
</tr>
<tr>
<td>Avoidance</td>
<td>0,243</td>
<td>0,252</td>
</tr>
<tr>
<td>Distraction</td>
<td>-0,292</td>
<td>0,018</td>
</tr>
</tbody>
</table>

Conclusion: Our study revealed that having coping strategies based on problem solving increased the perception of pain whereas strategies based on distraction and cognitive restructuring decreased it.

Disclosure of Interests: None declared


AB0288 ECHOCARDIOGRAPHIC FINDINGS BY SPECKLE TRACKING IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. A. Rosal Arteaga1, S. Cerpa-Cruz2, E. Purón González1, G. Martínez-Bonilla1, V. Gonzalez-Díaz3, J. J. Hernandez-del Río3, M. E. Ventura Valenzuela1, S. Contreras Sánchez1. 1Hospital Civil Fray Antonio Alcalde, Rheumatology, Guadalajara, Mexico; 2Hospital Civil Fray Antonio Alcalde, Echocardiography, Guadalajara, Mexico

Background: Rheumatoid arthritis (RA) is a chronic systemic inflammatory joint disease characterized by infiltration of the synovial membrane by B cells, T cells, and monocytes. Among the most important extra-articular manifestations are those of the cardiovascular system. Cardiovascular involvement in this group of patients is highly relevant as it is an important cause of morbidity and mortality (1, 2). Subclinical involvement is underestimated and currently, conventional cardiovascular risk stratification methods are insufficient to detect early stages of cardiovascular disease. Speckle tracking has emerged as a tool to measure early myocardial dysfunction and has been shown to be useful as a predictor of cardiovascular events. Normal reference values have recently been published (3).

Objectives: To describe the echocardiographic findings by speckle tracking (ST) of the left atrium (LA) and left ventricle (LV) in patients with RA without prior known cardiovascular disease and to compare it with healthy controls. To establish if there is an association of echocardiographic findings with characteristics of the disease.

Methods: Thirty-four patients with RA without a history of previous cardiovascular disease and 50 healthy controls were included. Echocardiographic measurements were made by Speckle Tracking of the LA in its 3 phases and of the LV expressed as Global Longitudinal Strain (GLS), in addition to conventional measurements. Quantitative variables were expressed as proportions, continuous data were reported as means and standard deviations. Both groups were compared with t-test and a linear regression model was used to evaluate age and RA presence in relation to the abnormality or normality of Speckle tracking findings. SPSS was used for statistical analysis.

Results: A significant difference was found in LA global longitudinal strain compared to controls (45.14% vs 57.34%, p=0.020), LA conduit strain (25.69% vs 36.74%, p=0.002) and LV global longitudinal strain (-176% vs. -22.62%, p<0.000). There was no significant difference in LA contractile strain and LA strain rate. In the echocardiographic measurements by conventional technique, no differences were found in the measurement of the LV ejection fraction or LA volume index, but LA ejection fraction was lower in the RA group (53.8% vs 78.2%, p=0.000). Rheumatoid arthritis was associated with LA speckle tracking abnormality in the reservoir, conduit, and LV global longitudinal phases.

Conclusion: The patients with rheumatoid arthritis presented subclinical echocardiographic alterations of myocardial deformation measured by speckle tracking both in the left ventricle (assessed as GLS) and in the left atrium, these were associated with RA regardless of age.

REFERENCES:

Disclosure of Interests: None declared


AB0289 DEPRESSION AND METABOLIC DISORDERS PREVENT REMISSION IN RHEUMATOID ARTHRITIS

A. Aleksandrova1, L. Shilova1, V. Aleksandrova2, I. Alekhiina3, N. Aleksandrova3. 1Volgorad State Medical University, Department of Hospital Therapy, Volgorad, Russian Federation; 2Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A.B. Zboroovsky», Department of Clinical and Laboratory Diagnostics, Volgorad, Russian Federation; 3Stavropol State Medical University, Department of Hospital Therapy, Stavropol, Russian Federation

Background: Epidemiological data and clinical observations suggest an increased risk of depressive disorders in rheumatoid arthritis (RA) patients with metabolic syndrome (MS) [1, 2].

Objectives: To study the prevalence of depressive symptoms depending on the presence of MS components in RA patients and to evaluate their combined effect on achieving remission of RA.

Methods: 100 RA patients aged 18 to 69 years old (91% women; mean duration of disease 9 [3.5,15] years; body mass index (BMI) 28.6 [IQR 25.1-32.8]) were examined. MS was confirmed in RA patients with three or more harmonized National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII; 2004) criteria. RA patients were assigned a binary MS score (“yes/no”) and a categorical MS score (from 0 to 5 criteria) was calculated. The severity of depression in patients with RA was determined using the Beck Depression Inventory (BDI).

Disclosure of Interests: None declared

Results: 46% of RA patients met the criteria for MS. The presence of three categorical signs of MS was noted in 26%, four - in 16% and of all five signs - in 4% of cases. The combination of elevated fasting glucose, elevated triglycerides (TG), and decreased high-density lipoproteins (HDL) was the most frequent (19.6%; 9/46). The combination of the four MS criteria (increased waist circumference (WC), elevated TG, decreased HDL, and arterial hypertension) occurred in 17.4% (8/46) of cases. RA patients with MS had more severe systemic inflammation (C-reactive protein 9.3(3.9; 23.1) versus 3.35(2.3; 12.0) mg/L (p < 0.028), higher levels of TG (p = 0.001) and total cholesterol (p = 0.003), and higher BMI (p = 0.018) and WC (p = 0.007).

Depression scores of BMI ≥10 were noted in 64 RA patients: 26% were mild, 28% were moderate and 10% were severe. Symptoms of depression were more frequent in RA patients with longer duration (p = 0.025, p = 0.012) and high activity (p = 0.37; p = 0.001) of the disease. There were statistically significant differences in the incidence of depression (BMI ≥10 points) depending on the absence or presence of MS in RA patients (Phi-square=0.42; association coefficient q = 0.65). When comparing groups of RA patients stratified by the presence of MS, significant differences in the severity of depressive disorders according to BMI were found (RA without MS: 8.35 ± 5.1 points; RA with MS: 23.6 ± 12.8 points, p < 0.001). In RA patients without MS, only mild (26%) and moderate (9.3%) depression were detected. In RA patients with MS, depressive symptoms from mild to severe were present in almost equal proportions. Two-factor analysis of variance showed significant differences in BDI and MS on DAS28-ESR activity in RA patients (p = 0.05), the presence of MS had a significant effect on BDI depression (p = 0.001), and there was no relationship between MS and the degree of disease activity (p = 0.33).

Re-examination (6-7 months later) of patients with initially moderate RA activity (n = 58) revealed that remission of the disease was not achieved in 25% of patients from the group with no signs of depression and MS. In the group of RA patients with MS and BMI ≥10 there were almost two times more cases of deterioration (63.3%) (p = 0.025) by G2 with Yates correction = 4.7, p = 0.03).

Conclusion: Progression of depression against the background of marked metabolic disorders can lead to a decrease of RA patients’ quality of life and complications in disease prognosis [3, 4, 5]. This requires an early multidisciplinary treatment and increased knowledge of the risks associated with depression and MS among health care professionals and patients. Identification and correction of symptoms of depression and MS in RA patients should be a part of the optimal patient care.

REFERENCES:

Disclosure of Interests: None declared


AB0290

COMPARATIVE FEATURES AND LONGITUDINAL BEHAVIOUR OF RHEUMATOID ARTHRITIS-ASSOCIATED UIP VERSUS IDIOPATHIC PULMONARY FIBROSIS: A SINGLE CENTRE COHORT STUDY

C. Mazeda1, J. Antao2, M. Ferreira3, R. Aguilar1, A. Barcelos1, P. G. Ferreira4,
1Centro Hospitalar Baixo Vouga, Rheumatology, Centro Académico Clínico Esga Moniz, Aveiro, Portugal; 2Universidade de Aveiro, Centre for Research and Development in Mathematics and Applications, Aveiro, Portugal; 3Centro Hospitalar Baixo Vouga, Radiology, Aveiro, Portugal; 4Centro Hospitalar e Universitário de Coimbra, Pneumology, Coimbra, Portugal

Background: Intestinal lung diseases (ILDs) are a group of heterogeneous lung disorders with variable prognosis. Idiopathic pulmonary fibrosis (IPF) is the main idiopathic interstitial pneumonia and rheumatoid arthritis (RA) is the commonest cause of connective tissue disease related-ILD. In fact, ILD is the most frequent form of respiratory involvement in RA, with 10% patients having clinically significant disease, frequently imposing serious morbidity mortality. RA-ILD can potentially comprise different disease patterns with distinct prognosis, with usual interstitial pneumonia (UIP) being the most frequent radio-histological pattern. Several studies have suggested that the RA-UIP disease course and survival may be clinically similar to IPF.

Objectives: This study aimed to investigate comparative clinical features, longitudinal behaviour and healthcare resource utilization between local cohorts of RA-UIP and IPF patients.

Methods: Retrospective and descriptive study including all IPF and RA-ILD cases diagnosed and followed in the ILD outpatient clinic of secondary hospital between 2015 and 2020. All patients with RA diagnosis met classification criteria of 2010 ACR/EULAR and IPF patients were diagnosed according to 2018 ATS/ERS/JRS/ALAT clinical guidelines. Socio-demographic, clinical data and longitudinal lung function (functional vital capacity (FVC) and lung diffusion capacity for carbon monoxide (DLCO)) were collected. A statistical analysis was performed; p-value <0.05 was statistically significant.

RESULTS:

Table 1. Baseline clinical characteristics of all patients are listed in table.

<table>
<thead>
<tr>
<th></th>
<th>IFP</th>
<th>RA-UIP</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (mean±SD)</td>
<td>74±x1.8</td>
<td>76±x8.4</td>
<td>0.75</td>
</tr>
<tr>
<td>Sex (M/F), n</td>
<td>17/5</td>
<td>4/10</td>
<td>0.006</td>
</tr>
<tr>
<td>Smoking Status</td>
<td></td>
<td></td>
<td>0.31</td>
</tr>
<tr>
<td>Smoker (%)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Ex-smoker (%)</td>
<td>64.6</td>
<td>42.9</td>
<td></td>
</tr>
<tr>
<td>Smoking load</td>
<td></td>
<td></td>
<td>0.48</td>
</tr>
<tr>
<td>Baseline dyspnea (mMRC)</td>
<td>53±1.7</td>
<td>35±2.2</td>
<td></td>
</tr>
<tr>
<td>Cough (%)</td>
<td></td>
<td></td>
<td>0.01</td>
</tr>
<tr>
<td>Baseline FVC, % predicted</td>
<td>0.07</td>
<td>73±1.4</td>
<td>19.7</td>
</tr>
<tr>
<td>Time from respiratory symptoms until diagnosis (months)</td>
<td>20±3.4</td>
<td>11.6±9.7</td>
<td>0.09</td>
</tr>
<tr>
<td>6-minute walking distance at baseline (meters)</td>
<td>341±8.4</td>
<td>340±15.3</td>
<td>0.05</td>
</tr>
</tbody>
</table>

In RA-UIP group, 86% of patients reported preceding articular symptoms, with lung disease being diagnosed after a median of 11 years (IQ range 2-13). All patients had a UIP/probable UIP pattern in HRCT. Regarding baseline FVC and DLCO, the RA-UIP group revealed better lung function compared to the IPF group. All patients with RA-UIP received some form of immunomodulation treatment. Around 78.4% of patients were on low dose prednisolone. Additionally, 64.2% received treatment with mycophenolate mofetil, 21.4% with rituximab, 7.1% with azathioprine and 7.1% with nintedanib or pirfenidone. From the global population study only 27.3% of IPF patients were on low dose prednisolone. Additionally, 64.2% were treated with antifibrotics (nintedanib or pirfenidone). Given the high global population study only 27.3% and 14.3% of IPF and RA-UIP patients, respectively, were referred for respiratory rehabilitation. There were significant differences between the FVC groups (p = 0.002) and DLCO groups (p = 0.003) decline over time between groups. Comparing to RA-UIP, IPF patients experienced a greater number of acute exacerbations (4 vs 27±0.006) and had more respiratory-related emergency visits. IPF patients also had a higher rate of hospitalizations, most of them respiratory-related. There was a clear trend towards higher mortality during follow-up in the IPF group compared to the RA-UIP group (40% vs 21.4%; p = 0.23), although not reaching statistical significance.

Conclusion: RA-UIP patients appear to be less symptomatic and have a shorter symptomatic period at diagnosis. IPF patients had worse lung function at diagnosis. IPF patients showed a higher tendency to acute exacerbations and had a greater unplanned health care resources utilization. There was also a non-significant trend towards higher mortality during follow-up in the IPF group compared to the RA-UIP group (40% vs 21.4%; p = 0.23), although not reaching statistical significance.

Disclosure of Interests: Carolina Mazeda: None declared, Joana Antao: None declared, Margarida Ferreira: None declared, Renata Aguilar: None declared, Ana Bel Barcelos: None declared, Pedro G Ferreira Speakers bureau: Boehringer Ingelheim, Novartis, Roche, Glaxo


AB0291

COMORBIDITIES PROFILES IN SEROPOSITIVE RHEUMATOID ARTHRITIS VERSUS SERONEGATIVE RHEUMATOID ARTHRITIS

E. Hannech1,2, A. Ben Tekaya1,2, O. Saidane1,2, S. Bouden1,2, R. Leila1,2, R. Tekaya1,2, I. Mahmoud1,2, L. Abdelmoula1,2, 1Rheumatology Department, Charles Nicolle Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia

Disclosure of Interests: None declared

Background: Patients with seropositive rheumatoid arthritis (RA) (positive Rheumatoid Factor (RF)) are more susceptible to extra-articular manifestations [1]. The role of RF in the occurrence of comorbidity is not clear. 

Objectives: We compare comorbidities among patients with seropositive RA versus patients with seronegative RA.

Methods: We conducted a retrospective study in our rheumatology department including 255 patients with established RA according to the ACR/EULAR 2010 criteria. Patients were divided in two groups according to their Rheumatoid Factor (RF) profile: seropositive RA (positive RF), seronegative RA (negative RF).

Comorbidities were investigated and compared between the two patient groups.

Results: There were 206 seropositive RA and 49 seronegative RA. Gender distribution was similar in the two groups: 82% female and 18% male in seropositive RA; 85% female and 15% male in seronegative RA (p=0.5). Smoking was noted in 15% patients with seropositive RA and in 11% patients with seronegative RA without any difference (p=0.5).

Comorbidities were noted in 40% of seropositive RA and in 45% of seronegative RA without any significant difference (p=0.6). Obesity (BMI ≥ 30kg/m²) was noted in 31% of seropositive RA and in 36% of seronegative RA (p=0.7). Diabetes was noted in 18% seropositive RA and in 26% seronegative RA patients (p=0.1). Hypertension was noted in 31% seropositive RA patients and in 30% seronegative RA (p=0.8). Heart disease was present in 6% seropositive RA and in 7% seronegative RA (p=0.9). Dyslipidemia was noted in 40% seropositive RA and in 20% seronegative RA (p=0.1). Gastrointestinal comorbidities were observed in only seropositive RA patients (11%). Respiratory comorbidities were noted in 27% seropositive RA and in 28% seronegative RA without any significant difference (p=0.6). Regarding mental health problems, depression was noted in 7% seropositive RA and in 14% seronegative RA without any significant difference (p=0.4).

Conclusion: Our study showed that comorbidities were comparable in seropositive and seronegative RA. It seems that RF does not influence the prevalence of comorbidities in RA patients.

REFERENCES:

Disclosure of Interests: None declared


AB0293

INDICATIONS AND THERAPEUTIC IMPLICATIONS OF HAND AND WRIST JOINT ULTRASOUND IN RHEUMATOID ARTHRITIS

S. Ben Dhia1, S. Miladi1, A. Fazaa1, H. Bousaa1, L. Souabni1, K. Ouenniche1, S. Kassa1, S. Chekili1, K. Ben Abdelghani1, A. Laatar1, 1Mongi Slim Hospital, Department of Rheumatology, La Marsa, Tunisia

Background: Ultrasound (US) has been increasingly used in the recent years for the diagnosis and follow-up of rheumatoid arthritis (RA) [1]. It is considered as a complement to physical examination with high sensitivity, specificity, and accuracy in detecting synovial thickening, synovial hypervascularization as well as cortical bone erosions [2].

Objectives: To explore rheumatoid cachexia association with bone, vertebral fractures, and structural joint damage in RA patients.

Methods: We conducted a retrospective study in our rheumatology department including 255 patients with established RA according to the ACR/EULAR 2010 criteria and recruited from December 2021 at our rheumatology department. Patients with seropositive rheumatoid arthritis (RA) (positive RF) profile: seropositive RA (positive RF), seronegative RA (negative RF).

Comorbidities were investigated and compared between the two patient groups.

Results: There were 206 seropositive RA and 49 seronegative RA. Gender distribution was similar in the two groups: 82% female and 18% male in seropositive RA; 85% female and 15% male in seronegative RA (p=0.5). Smoking was noted in 15% patients with seropositive RA and in 11% patients with seronegative RA without any difference (p=0.5).

Comorbidities were noted in 40% of seropositive RA and in 45% of seronegative RA without any significant difference (p=0.6). Obesity (BMI ≥ 30kg/m²) was noted in 31% of seropositive RA and in 36% of seronegative RA (p=0.7). Diabetes was noted in 18% seropositive RA and in 26% seronegative RA patients (p=0.1). Hypertension was noted in 31% seropositive RA patients and in 30% seronegative RA (p=0.8). Heart disease was present in 6% seropositive RA and in 7% seronegative RA (p=0.9). Dyslipidemia was noted in 40% seropositive RA and in 20% seronegative RA (p=0.1). Gastrointestinal comorbidities were observed in only seropositive RA patients (11%). Respiratory comorbidities were noted in 27% seropositive RA and in 28% seronegative RA without any significant difference (p=0.6). Regarding mental health problems, depression was noted in 7% seropositive RA and in 14% seronegative RA without any significant difference (p=0.4).

Conclusion: Our study showed that comorbidities were comparable in seropositive and seronegative RA. It seems that RF does not influence the prevalence of comorbidities in RA patients.

REFERENCES:

Disclosure of Interests: None declared


AB0292

ASSOCIATION OF RHEUMATOID CACHEXIA WITH BONE, VERTEBRAL FRACTURES, AND STRUCTURAL JOINT DAMAGE IN MOROCCAN RHEUMATOID ARTHRITIS PATIENTS

M. Mahroug1, H. Azzouzi1, H. Boutaibi1, F. Chennouf1, I. Linda1, 1Mohamed I University, Rheumatology Department, Oujda, Morocco

Background: The concurrent decrease in the fat-free mass index (FFMI) and increase in the fat mass index (FM) in rheumatoid arthritis (RA) is called rheumatoid cachexia (RC). There is limited data on RC association with osteoporosis, vertebral fracture (VF), and structural joint damage in RA.

Objectives: To explore rheumatoid cachexia association with bone, vertebral fractures, and radiographic damage in RA patients.

Methods: This was a cross-sectional study on RA patients fulfilling the ACR/EULAR 2010 classification criteria. We collected data about characteristics of the disease, its activity assessed by the Disease Activity Score 28 using C-Reactive Protein and erythrocyte sedimentation rate (DAS28-CRP, DAS28-ESR), treatment of RA (conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), biologics (bDMARDs), and corticosteroids (CS)), indication of hand and wrist joint US and the implications of its findings.

Results: Fifty-eight patients were enrolled in the study with 83% females, with a mean age of 58.5±11.8 years and a mean age at diagnosis of 48.6±8.2 years. RA was seropositive in 89.7% of patients and erosive in 84.5%. Most patients underwent csDMARDs treatment (67.3%), 29.3% underwent bDMARDs treatment, and 67.3% used oral CS with a mean dose of 4.9±4.4 mg/day of prednisone equivalent. Mean DAS28-CRP was 4.1±1.4, and mean DAS28-ESR was 4.9±1.5. Hand and wrist joint US was performed for RA activity assessment in 93.1% of patients (n=54), for erosion assessment in recently diagnosed RA in 5.2% of patients (n=3), for erosion assessment in established RA in 1.7% of patients (n=1).

In patients who had US signs of active RA, treatment was modified in 73% of patients with initiation of a 3-day parental CS pulses (18.9%), initiation of oral CS (2.7%), escalation of oral CS dose (2.7%), escalation of csDMARDs treatment (24.3%), adjunction of another csDMARD (5.4%), reintroduction of a csDMARD (2.7%), initiation of bDMARDs (24.3%), and switch of bDMARDs (5.4%). US findings had no implication in 27% of these patients. When inactive RA was assessed (31.5%), there was no implication on treatment strategy in 82.4% of patients, a decrease of oral CS dose in 11.6% and a single intra-articular CS injection in 5.9%.

Detecting ultrasonographic activity signs of RA in hand and wrist joint was more likely to have implications on treatment strategy than finding no activity signs (75% vs 22%, χ²=14.25, p<0.001). The group of patients who had an implication of US findings on treatment strategy had significantly higher DAS28-ESR (5.53 vs 4.18, p=0.002).

Conclusion: Hand and wrist US had significant implications on treatment strategy of RA especially in patients with higher disease activity. However, it had no implications in some patients suggesting the complementary role of US compared to clinical determinants in RA treatment decision.

REFERENCES:
**VITAMIN D LEVEL AND LOCOMOTIVE FUNCTIONS IN WOMEN WITH RHEUMATOID ARTHRITIS**

N. Toroptsova1, O. Dobrovolskaya1, A. Sorokina1, O. Nikitinskaya1, E. Samarkina1, M. Cherkasova2. V.A. Nasonova Research Institute of Rheumatology, Department of Osteoporosis, Moscow, Russian Federation; 1.V.A. Nasonova Research Institute of Rheumatology, Department of Immunology and Molecular Biology, Moscow, Russian Federation; 2.V.A. Nasonova Research Institute of Rheumatology, Department of Thrombosis and Inflammation, Moscow, Russian Federation

**Background:** Muscle health is an important aspect of rheumatoid arthritis (RA). A decrease in muscle mass and physical performance is a frequent complication of RA that contributes to inability to work and reduced quality of life. Vitamin D deficiency is also common in these patients.

**Objectives:** To assess the relationship between vitamin D level, muscle strength and physical performance in RA patients.

**Methods:** 135 women (mean age 58.5±8.9) with confirmed RA according to ACR/EULAR criteria (2010) were enrolled in the study. Muscle strength of upper extremities was measured using a mechanical dynamometer, of lower extremities – using “Chair stand test” (CST) – assessment of the ability to rise from a chair and sit back down 5 times. Handgrip strength (16kg) and less or CST for more than 15 seconds were the criteria for low muscle strength. All patients underwent “Gate speed test” (GST) and “Timed Up and Go test” (TUG) to assess the physical performance. Serum level 25(OH)D was performed using the Cobas E411 immunochemiluminescence analyzer and Elescsys Vitamin D total kit, Roche.

**Results:** Median 25(OH)D level was 23.7 [18.2; 30.7] ng/ml in RA women with minimum 7.9 ng/ml and maximum 70.0 ng/ml. Insufficiency and deficiency of vitamin D were detected in 56 (41.5%) and 42 (31.1%) women, respectively, with median level 24.1 [21.8; 26.6] ng/ml in the patients with insufficiency and 15.6 [13.6; 17.9] ng/ml in deficiency group. Vitamin D level was compared between patients with low muscle strength and/ or physical performance and women with normal locomotive functions (Table 1). 25(OH)D level was significantly higher in RA women with normal CST and GST >0.8 m/s than in patients with the worst results of these tests. At the same time, we didn’t find differences in handgrip strength and TUG depending on vitamin D level.

**Table 1. 25(OH)D in women with RA according to locomotive functions**

<table>
<thead>
<tr>
<th>Test</th>
<th>25(OH)D</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CST &lt;15 seconds</td>
<td>26.7 [20.4; 32.2]</td>
<td>0.036</td>
</tr>
<tr>
<td>&gt;15 seconds</td>
<td>21.0 [17.9; 25.1]</td>
<td></td>
</tr>
<tr>
<td>GST &gt;0.8 m/s</td>
<td>26.1 [19.6; 32.0]</td>
<td>0.043</td>
</tr>
<tr>
<td>≤0.8 m/s</td>
<td>21.1 [17.6; 26.8]</td>
<td></td>
</tr>
<tr>
<td>Handgrip strength &gt;16 kg</td>
<td>23.8 [17.8; 30.2]</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>≤16 kg</td>
<td>27.9 [19.5; 32.2]</td>
<td></td>
</tr>
<tr>
<td>TUG &gt;20 seconds</td>
<td>23.7 [17.3; 30.1]</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>≤20 seconds</td>
<td>18.8 [18.1; 21.0]</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** The frequency of low vitamin D level was 72.6% in women with RA including deficiency in 31.1% patients. Patients with reduced lower limb strength and low walking speed had significantly lower vitamin D levels, but there were no differences in 25(OH)D and other tests (handgrip strength and TUG).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3392
A. N. Garza-Cisneros1, I. J. Colunga-Pedraza1, D. A. Galan-Dealgo1, J. R. Azpiri-Lopez1, A. B. Rodriguez-Romero1, M. A. Balderas-Palacios1, A. Garcia-Heredia2, N. Guajardo-Jauregui1, A. Cárdenas1, D. E. Flores Alvarado1,3, Universidad Autónoma de Nuevo León, Hospital "Dr. José Eleuterio González"; Rheumatology, Monterrey, Mexico; 2 Universidad Autónoma de Nuevo León, Hospital "Dr. José Eleuterio González"; Cardiology, Monterrey, Mexico.

Background: Obesity plays an important role in autoimmune and inflammatory diseases such as rheumatoid arthritis (RA). It has been demonstrated a paradoxical relationship between increased body mass index (BMI) and disease activity (1). Acute phase reactants (APR) play an essential role in determining the disease activity level (2).

Objectives: To compare APR levels in obese and non-obese patients with RA, and to establish their relationship with the disease activity level.

Methods: A total of 272 patients with a diagnosis of RA were included in a cross-sectional study. They were divided into two groups, 136 obese patients and 136 non-obese patients, matched by age, gender, and comorbidities. The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were measured, and the activity level was determined with Disease Activity Score 28-joint erythrocyte sedimentation rate (DAS28-ESR) and Disease Activity Score 28-joint C-reactive protein (DAS28-CRP).

The distribution was evaluated with Kolmogorov-Smirnov. Comparisons with Chi-square test for qualitative variables, Student’s t-test, and Mann-Whitney U test for quantitative variables. Correlation between BMI and APR with Spearman-rho coefficient.

Results: The Spearman-rho coefficient showed a significant correlation between CRP level and BMI (rho=0.187, p=0.002) (Figure 1). No difference was found between activity level when comparing both groups (Table 1).

Conclusion: Obese RA patients presented higher CRP levels compared to non-obese patients, suggesting that a higher BMI level may be related to a higher degree of inflammation and consequently worse systemic manifestations in RA patients.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5427

Table 1. Demographic Characteristics of the Patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Obese RA Patients (n=136)</th>
<th>Non-Obese RA Patients (n=136)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD</td>
<td>55.32±8.67</td>
<td>55.38±8.64</td>
<td>NS</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>130 (95.5)</td>
<td>130 (95.5)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI, mean ± SD</td>
<td>34.22±3.74</td>
<td>24.70±2.84</td>
<td>NS</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>30 (22.0)</td>
<td>23 (16.9)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>62 (45.5)</td>
<td>48 (35.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>39 (28.6)</td>
<td>48 (35.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Methotexate, n (%)</td>
<td>119 (87.5)</td>
<td>114 (83.8)</td>
<td>NS</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>7 (5.1)</td>
<td>11 (8.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Glucocorticoid, n (%)</td>
<td>89 (64.4)</td>
<td>77 (56.8)</td>
<td>NS</td>
</tr>
<tr>
<td>CRP, median (p25-p75)</td>
<td>1.00 (0.58-1.73)</td>
<td>0.68 (0.38-1.25)</td>
<td>NS</td>
</tr>
<tr>
<td>ESR, median (p25-p75)</td>
<td>25.00 (16.00-36.00)</td>
<td>24.50 (14.25-37.75)</td>
<td>NS</td>
</tr>
<tr>
<td>DAS28ESR, mean ± SD</td>
<td>4.74±1.45</td>
<td>4.57±1.38</td>
<td>NS</td>
</tr>
<tr>
<td>DAS28CRP, mean ± SD</td>
<td>3.62±1.46</td>
<td>3.37±1.39</td>
<td>NS</td>
</tr>
</tbody>
</table>

RA: rheumatoid arthritis; NS: not significant; BMI: body mass index; T2DM: type 2 diabetes mellitus; bDMARD: biological disease-modifying anti-rheumatic drugs; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; DAS28, Disease Activity Score 28-joint.

Figure 1. Correlation between BMI and CRP

BMI, body mass index; CRP, C-reactive protein.
with RA. Clinicians may consider these factors when classifying RA patients for lung involvement and planning thoracic CT for screening.

REFERENCES:
References not provided in the image.

Background: Sulphur drugs have been used such as sulfasalazine for the treatment of rheumatoid arthritis (RA), and trimethoprim-sulfamethoxazole (TMP-SMX) for the treatment or prevention of pneumocystosis pneumonia. However, some patients with RA delay treatment because of allergy to sulpha drugs.[1] We reported that 16.7% of RA patients presented drug allergies[2]. It was not clear what is a risk factor for drug allergies in patients with RA.

Objectives: The aim of this study was to evaluate the clinical features with sulpha allergy in patients with RA.

Methods: We prospectively examined consecutive patients diagnosed with RA in our hospital from March 2021 to January 2022. The patients with RA met the EULAR/ACR 2010 criteria. We included patients with RA with other rheumatic diseases. A careful allergic history was obtained from patients with RA and physical examination performed.

The first analysis was performed on patient baseline laboratory data at diagnosis of patients with RA with or without sulpha allergy. Sulpha allergy (rash, angioedema and anaphylaxis after drug exposure) was allergy to sulfasalazine or TMP-SMX. The second analysis was performed on seven types of allergic reactions: (1) drug allergies other than sulpha drugs (rash, angioedema and anaphylaxis after drug exposure), (2) food allergy (rash, angioedema and anaphylaxis after food exposure), (3) allergic contact dermatitis such as metals, and other cosmetics, (4) seasonal allergic rhinitis and/or conjunctivitis (AR and/or AC), and AR and/or AC associated with house dust, (5) asthma, and (6) atopic dermatitis.

Results: There were 513 patients with RA in our study. In the first analysis, 17 patients with sulpha allergy and 496 patients without sulpha drugs were enrolled (Table 1). The median ages (with sulpha allergy and without sulpha allergy) were 60.0 and 72.0 years old (p=0.40). Females were 82.3% and 77.0%(p=0.4). The median observation period was 970.0 and 69.0 months (p=0.20). Patients with other rheumatic diseases were 11.6 and 6.8%(p=0.34).

Table 1. Characteristics of RA patients at diagnosis of RA

<table>
<thead>
<tr>
<th>With sulpha allergy (n = 17)</th>
<th>Without sulpha allergy (n = 496)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>83.4%</td>
<td>78.0%</td>
</tr>
<tr>
<td>Age, year, y</td>
<td>66.0 (56.0-78.5)</td>
<td>72.0 (60.0-80.0)</td>
</tr>
<tr>
<td>Observation period, m</td>
<td>970.0 (45.5-182.0)</td>
<td>69.0 (31.0-123.8)</td>
</tr>
<tr>
<td>Patients with other rheumatic diseases</td>
<td>11.8%</td>
<td>6.8%</td>
</tr>
<tr>
<td>ANA-positive patients (&gt;1:80)</td>
<td>52.9%</td>
<td>28.2%</td>
</tr>
<tr>
<td>Anti-SSA antibody-positive patients</td>
<td>46.2%</td>
<td>18.2%</td>
</tr>
<tr>
<td>RF-positive patients</td>
<td>40.0%</td>
<td>66.8%</td>
</tr>
</tbody>
</table>

The RA patients with sulpha allergy had higher positivity rate of anti-nuclear antibody (ANA) (>1:80) (52.9%, 28.2%; p=0.052), higher positivity rate of anti-Sjögren’s-syndrome-related antigen A autoantibody (SSA antibody) than those without sulpha allergy (46.2%, 18.2%; p = 0.02) and lower positivity rate of rheumatoid factor (RF) than those without sulpha allergies (40.0%, 66.8%; p = 0.049).

In the second analysis drug allergies other than sulpha allergy were more frequent in patients with sulpha allergy. Drug allergies other than sulpha allergy were such as antibiotics and nonsteroidal anti-inflammatory drugs. There were no significant differences in other allergies.

Conclusion: Among patients with RA, patients with sulpha allergy had higher positivity rate of ANA and anti-SSA antibody, and lower positivity rate of RF than those without sulpha allergy. RA patients with sulpha allergy had a higher prevalence of the other drug allergies than those other than sulpha allergy.

Table 2. Allergic disorders in RA patients with and without sulpha allergy

<table>
<thead>
<tr>
<th></th>
<th>With sulpha allergy (n = 17)</th>
<th>Without sulpha allergy (n = 496)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug allergies other than sulpha allergy</td>
<td>61.6%</td>
<td>12.7%</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Food allergy</td>
<td>11.8%</td>
<td>13.5%</td>
<td>1.00</td>
</tr>
<tr>
<td>Allergic contact dermatitis</td>
<td>23.5%</td>
<td>24.2%</td>
<td>1.00</td>
</tr>
<tr>
<td>AR and/or AC</td>
<td>58.8%</td>
<td>46.6%</td>
<td>0.34</td>
</tr>
<tr>
<td>Asthma</td>
<td>17.7%</td>
<td>13.1%</td>
<td>0.48</td>
</tr>
<tr>
<td>Atopic dermatitis</td>
<td>5.9%</td>
<td>6.3%</td>
<td>1.00</td>
</tr>
</tbody>
</table>

REFERENCES:
References not provided in the image.
Background: Autoimmune diseases (AD) are a group of heterogeneous disorders caused by both genetic and environmental factors. Rheumatoid arthritis (RA) and Sjögren syndrome (SS) are typical autoimmune diseases[1]. Pulmonary fibrosis (PF) is the most common complication of AD. Despite the extensive study of the human gut microbiome in AD complicated with PF (AD-PF), the question of whether there are common microbial features characterizing AD-PF still remains[2].

Objectives: This study focused on exploring differences between the microbiota diversity and peripheral lymphocyte subpopulations as well as cytokine in AD with PF different from that of AD without PF.

Methods: A total of 64 AD patients (44 AD without PF and 20 AD with PF) as well as 100 age- and sex- matched healthy controls (HCs) were enrolled in this study. The peripheral lymphocyte subsets were analyzed by flow cytometry and the gut microbiota were investigated via 16s rRNA sequencing. Spearman correlation analysis was used to determine the similarities among patients with RA-PF, the STAMP software was used to compare the fecal microbiota (bray curtis distance-based) analysis was used to define the difference of gut microbiota profiles between patients and HCs. To explore the specific bacterial taxa associated with AD-PF, the STAMP software was used to compare the fecal microbiota composition. Spearman correlation analysis was used to determine the similarities in the microbiota community with clinical features among fecal samples.

Results: There is a decrease that the richness and diversity index between HCs, AD and AD-PF patients. Principal co-ordinates analyses suggested that these three microbiota states explained a reasonable proportion of observed variance in the microbiota community with clinical measures among fecal samples.

Conclusion: Our results suggest that the decrease of Lachnospira may lead to the occurrence of AD with pulmonary intestinal fibrosis, which was closely correlated with lymphocyte subsets and cytokines, maintaining the flora balance might be a potential therapeutic target for AD-PF.

REFERENCES:

Table 1. Epidemiological, clinical and analytical characteristics of patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Patients n=110</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epidemiological characteristics</strong></td>
<td></td>
</tr>
<tr>
<td>Age in years, mean (IQR)</td>
<td>55.9 (49.3-64.4)</td>
</tr>
<tr>
<td>Sex, female; n (%)</td>
<td>88 (80.0)</td>
</tr>
<tr>
<td>Tobacco</td>
<td></td>
</tr>
<tr>
<td>Never smoker, n (%)</td>
<td>47 (42.7)</td>
</tr>
<tr>
<td>Ex-smoker, n (%)</td>
<td>30 (27.3)</td>
</tr>
<tr>
<td>Active smoker, n (%)</td>
<td>33 (30.0)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>High blood pressure, n (%)</td>
<td>28 (25.5)</td>
</tr>
<tr>
<td>Diabetes Mellitus, n (%)</td>
<td>6 (5.5)</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>25 (22.7)</td>
</tr>
<tr>
<td>Cardiovascular Disease, n (%)</td>
<td>18 (16.4)</td>
</tr>
<tr>
<td>BMI (Kg/m²), mean (SD)</td>
<td>28.4 (5.1)</td>
</tr>
<tr>
<td><strong>Clinical and analytical characteristics</strong></td>
<td></td>
</tr>
<tr>
<td>RA evolution time, months, median (IQR)</td>
<td>93.2 (72.6-123.4)</td>
</tr>
<tr>
<td>Diagnosis delay, months, median (IQR)</td>
<td>8.1 (4.5-17.0)</td>
</tr>
<tr>
<td>Erosions, n (%)</td>
<td>68 (61.8)</td>
</tr>
<tr>
<td>RF, &gt;10, n (%)</td>
<td>90 (81.8)</td>
</tr>
<tr>
<td>ACPA &gt;20, n (%)</td>
<td>88 (80.0)</td>
</tr>
<tr>
<td>DAS-28 average, mean (±SD)</td>
<td>3.0 (0.7)</td>
</tr>
<tr>
<td>HAQ average, median (IQR)</td>
<td>0.71 (0.3-0.9)</td>
</tr>
<tr>
<td>sDMARD, n (%)</td>
<td>93 (84.5)</td>
</tr>
<tr>
<td>tDMARD, n (%)</td>
<td>42 (38.1)</td>
</tr>
<tr>
<td>Osteopenia, n (%)</td>
<td>46 (41.9)</td>
</tr>
<tr>
<td>Osteoporosis, n (%)</td>
<td>15 (13.6)</td>
</tr>
</tbody>
</table>
The variables independently associated with OP in RA were: age (OR [IC 95%],1,099 [1.012-1.193]; p=0.025), ACPA (OR [IC 95%], 1,005 [1.001-1.010]; p=0.036), RA length (OR [IC 95%], 1,359 [1.016-1.602]; p=0.001) and Actinobacteria (OR [IC 95%] 1,192 [1.095-1.297]; p=0.036).

Conclusion: Osteoporosis in Rheumatoid Arthritis is associated with severity factors as the age, the disease length or the presence of ACPA, as well as the Actinobacteria predominance in the intestinal microbiota.

Disclosure of Interests: Alba María Cabezás-Lucena: None declared, María Morales-Agüila: None declared, Patricia Ruiz-Limón: None declared, Isabel Moreno-Indias: None declared, Natalia Mena-Vázquez: None declared, Sara Manrique Arija Speakers bureau: Abbbie, Gedeon, Jansen, Lilly, Menarini, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, Consultant of: Abbbie, Jansen, Lilly, Novartis, Sanofi, Antonio Fernandez-Nebro: None declared


AB0302 DIASTOLIC DYSFUNCTION IN RHEumatoid Arthritis Patients: a comparative cross-SECTIONAL STUDY

M. Brahem1, H. Ibn Hadj Amor2, R. Sarrai1, S. Kraisem2, R. Rouabha2, E. Hmaier3, A. Ben Salem1, R. Grassa1, G. Hachfi1, H. Hachfi1, Y. Mohamed1, S. Belkhodja1, Taher M.3, Hmaier4, Taher Star University Hospital, Rheumatology, Mahdia, Tunisia; Taher Star University Hospital, Cardiology, Mahdia, Tunisia

Background: Cardiac failure is an independent risk factor for mortality in Rheumatoid arthritis (RA) and diastolic dysfunction (DD) may act as a precursor for cardiac failure.

Objectives: The aim of our study is to determine the frequency of diastolic dysfunction in rheumatoid arthritis (RA) patients compared to a control group and to focus on associated factors.

Methods: This was a comparative cross-sectional study, including patients diagnosed with RA according to the ACR/EULAR 2010 criteria and control subjects. Each patient underwent transesophageal echocardiography and the DD was assessed by E/A and E/e ratio.

Results: Seventy-two patients with RA and 72 control subjects were included. In our study, there was a clear female predominance in both groups (93.1% vs 94.4%). The mean age of RA patients was 52.9±11.27 years (21-75 years) and in control group, DD was present in 26 patients (36.1% of cases). The mean value of the impaired E/A ratio was 0.7± 0.1 [0.4-0.9] and the mean value of the impaired E/e ratio was 9± 1.5 [8.1-14.4]. These patients (23 women and 3 men) had a mean age of 56±10.4 years [33-74 years]. Among them, 7 patients had hypertension, 9 patients had cardiac symptoms, 21 patients had a long-standing RA, 17 patients had positive ACPAs and 11 patients had positive RF. In control group, DD was present in 10 patients (13.9% of cases). The mean value of the impaired E/A ratio was 0.6± 0.1 [0.4-0.9] and the mean value of the impaired E/e ratio was 1.1± 0.9 [1-10.1]. Left ventricular diastolic dysfunction was more frequent in RA patients compared with the control group with a significant difference (p<0.01). No significant association was found between diastolic impairment and RA parameters.

Conclusion: Subjects with RA have a higher frequency of diastolic dysfunction than those without RA. Therefore, correct assessment of diastolic function should be considered of pivotal importance in the routine follow-up of RA patients. The identification of predictor factors requires further study.

REFERENCES:

Disclosure of Interests: None declared


AB0304 CHRONIC KIDNEY DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE COHORT STUDY

M. J. Mantilla Ribeiro1,2, J. C. Sarmiento Monroy3, C. Villota-Eraso3, D. C. Varello4, J. C. Hurtado1, M. Rodriguez-Jimenez2, R. D. Mantilla Hernández2, I. Universidade de la Sabana, Rheumatology Department, Chia, Colombia; 2Center of Dermatology and Rheumatology (FUNINDERMA), Rheumatology, Bogotá, Colombia; 3Hospital Clinic, Villarreal 170, 06036, Rheumatology Department, Barcelona, Spain; 4Servicio Integro de Enfermedades Inmunológicas, Rheumatology Department, Pasto, Colombia; 5Universidad Pontificia Bolivariana, Rheumatology Department, Medellin, Colombia; 6Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Rheumatology, Bogotá, Colombia

Background: Prevalence and incidence estimates for chronic kidney disease (CKD) in rheumatoid arthritis (RA) vary and it may result from comorbidities, chronic inflammation, aging, or effects of drugs used for the disease.

Objectives: To calculate the prevalence and incidence of CKD in a cohort of patients with RA.

Methods: This was a retrospective cohort study in which well-characterized patients with RA (fulfillment of 1987 ACR criteria) were included from 2014 to 2015. Patients were evaluated at a single rheumatology outpatient center in Bogotá, Colombia. Baseline and follow-up estimated glomerular filtration rate (eGFR) were calculated according to CKD-EPI equation. CKD was defined as an eGFR ≤60 ml/min/1.73 m2.

Results: A total of 878 patients were included. Baseline characteristics were as follows: female gender 81.6%, mean age 51.8±11 years, mean disease duration 8 (IQR 3.715) years, RF positive 80.1%, ACPA positive 58.2%, and erosions 24.9%. Most patients have received glucocorticoids (89.8%), and conventional synthetic DMARDs (97.8%), being methotrexate the most frequently prescribed. Hypertension was the most frequent cardiovascular complication (37.7%). CKD was found in 6 (5.5%) patients at the time of inclusion, being hypertension the most common cause (24, 55.8%). Only 12 (1.5%) patients had a documented history of CKD at the beginning of the

Disclosure of Interests: None declared


AB0303 RELATION BETWEEN CLINICAL ANTHROPOMETRIC MEASUREMENTS AND MALNUTRITION IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS

M. Arthana1, J. Mahoubia1, F. Naftal2, M. Ghali1, F. Fhima1, S. Zrour1, I. Bejia1, M. Touzi1, N. Berouali1, Fattouma Bourguiba, Rheumatology, Monastir, Tunisia; 2Fattouma Bourguiba, Biochemistry, Monastir, Tunisia

Background: Rheumatoid arthritis (RA) is associated with an increased risk of malnutrition, especially among the elderly. However, nutritional assessments in this population are scarce in the clinical situation. Various anthropometric measurements can help to assess malnutrition.

Objectives: To evaluate the nutritional status using anthropometric measurements in elderly patients with RA.

Methods: A prospective study was conducted, including RA patients aged 65 years or older and followed in rheumatology department. Clinical findings, disease activity and nutritional profile were studied. The mini-nutritional assessment (MNA) was used to identify altered nutritional status. The anthropometric measurements studied were: Weight loss, Body mass index (BMI), Triceps skin fold thickness (TSF) which reflects fat mass, Mid-arm circumference (MAC), Arm muscle circumference (AMC) which indicates lean mass and the calf circumference (CC).

Results: Sixty-three patients were included, 82% were female. Their mean age was 68.17±4.35 years. The mean duration of RA was 11 years. The average DAS28 was 3.72±1.48. The mean MNA total score was 20.19 ± 4.71 with a range of 8 to 27.5. The prevalence of malnutrition in our population was 20.6%. 55.6% of the patients were at risk of malnutrition. Only 23.8% had a normal nutritional status. The average BMI was 27.97 ± 5.44 kg/m2 (14.85 – 43.2). The diagnosis of malnutrition according to the BMI (< 21 kg/m2) was made for 7.9% of patients, of which 4.8% were severely malnourished. The average weight loss was 2.26 ± 2.51 kg during the last month [0 – 10]. The average percentage of weight loss in the last month was 3.39 ± 4% [0-11%]. Among our patients, 26 patients (41.3%) did not report a weight loss, 19 patients (30.2%) had a weight loss of less than 5%, Eighteen patients (28.6%) had malnutrition defined as weight loss greater than or equal to 5% in one month, of whom 7 patients (11.1%) had severe malnutrition with a loss of at least 10% of their habitual weight. The mean TSF was 18.38 ±6.77 mm [5 - 30] (19.15±6.72 mm in women and 14.72±8 mm in men). 28.6% of patients had decreased values of TSF. The mean MAC was 24.8 ± 4.52 cm [18 - 40]. The mean AMC was 23.7 ± 9.64 cm [15.86-34.43] (24±5.7 cm in women and 22.19±3.75 cm in men). The AMC was decreased in 20.6% of cases. The mean CC was 33.25 ± 4.62 cm [20-43]. 31.7% of patients had a decreased CC. There were significant association between the nutritional status using the MNA and BMI, loss of weight and TSF (p<0.01, p<0.001 and p=0.05, respectively). MNA was not associated with MAC, ACM or CC (p=0.6, p=0.8 and p=0.4, respectively).

Conclusion: This study showed that the prevalence of malnutrition varies depending on the used anthropometric tool. BMI, weight loss and TSF are according to our study, reliable tools to detect the malnutrition in elderly patients with RA.

Disclosure of Interests: None declared

follow-up. The median of follow-up was 73 months. Fifteen incident cases of CKD were found (15/358, 4.1%) in patients with follow-up data of at least 1 year and without prior CKD. Main characteristics of the patients are shown in Table 1.

Table 1. Cardiovascular disease and main comorbidities in RA patients.

<table>
<thead>
<tr>
<th>Baseline (n=178)</th>
<th>Prevalent CKD (n=43)</th>
<th>Incident CKD (n=15)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular Disease</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>217 (227)</td>
<td>24 (56)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>27 (3,4)</td>
<td>3 (7)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>14 (1,8)</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Stroke</td>
<td>11 (1,4)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Chronic occlusive arterial disease</td>
<td>4 (0.5)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>209 (28,7)</td>
<td>16 (37)</td>
</tr>
<tr>
<td>Diabetes mellitus type 2</td>
<td>55 (7)</td>
<td>3 (7)</td>
</tr>
</tbody>
</table>

Conclusion: There is an underestimation of the prevalence of CKD in patients with RA in routine clinical practice due to the absence of a systematic estimation of eGFR. The incidence of CKD is low in the Colombian population.

REFERENCES:

Disclosure of Interests: None declared.


PNEUMOCOCCAL VACCINATION REDUCES THE RISK OF RESPIRATORY INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TARGETED THERAPY. DATA FROM MOSCOW UNIFIED ARTHRITIS REGISTRY (MUAR)

E. Zhilyayev1,2,3, G. Lukina4, E. Koltsova4, D. Murtazaliyeva4, E. Schmidt5, K. Lytkina6, A. Shmitko2, D. Biagovido7, M. Kostinov7,1, 1European Medical Center, Rheumatology, Moscow, Russian Federation; 2Piromov Russian National Research Medical University, Department of Faculty Therapy named after Academician A.I. Nesterov, Moscow, Russian Federation; 3Russian Medical Academy of Continuous Professional Education, Rheumatology, Moscow, Russian Federation; 4A.S. Loginov Moscow Clinical Scientific Center, Rheumatology, Moscow, Russian Federation; 5City Clinical Hospital 1 named after N.I.Pirogov, Rheumatology, Moscow, Russian Federation; 6City Clinical Hospital 4, Rheumatology, Moscow, Russian Federation; 7Mechnikov Research Institute of Vaccines and Sera, Laboratories of Vaccination and Immunotherapy of Allergic Diseases, Moscow, Russian Federation.

Background: The incidence of infections, mainly pneumonias, is significantly increased in patients with rheumatoid arthritis (RA). The risk increases more in persons treated with targeted anti-inflammatory drugs (tDMARDs), biological or targeted synthetic.

Pneumococcal vaccination is recommended for most patients with rheumatic diseases. However, only the immunological effectiveness of such vaccination has been sufficiently confirmed. There is sparse evidence of its clinical efficacy in patients with rheumatic diseases.

Objectives: to evaluate the effect of 23-valent pneumococcal polysaccharide vaccine (PPV23) and 13-valent pneumococcal conjugate vaccine (PCV13) on the risk of infections in RA patients receiving tDMARDs.

Methods: The data from the Moscow Unified Arthritis Registry (MUAR) for the period 2018-2020 were analyzed. We included patients with RA, over 18 years old, received tDMARDs (all available biologics or tofacitinib).

The analysis included episodes of observation from the moment of vaccination until the end of follow up. For unvaccinated patients, episodes began since October 20, 2018 (the average date of vaccination of persons who received immunization).

The risks were compared using Cox regression. An adjustment was made for confounders identified in an earlier study: age and smoking.

Results: The analysis included 832 patients: 40 were vaccinated with PCV13, 35 – with PPV23. There were 144 men (17%). The mean age was 55.4 ± 12.1 years. The duration of observation was 319 ± 198 days.

A total of 237 infectious events were registered, of which 201 were respiratory and 21 serious (Table 1). There was a significantly lower risk of any infection (relative risk (RR) – 0.39 CI: 0.18 - 0.84, p = 0.015) and the risk of respiratory infection (RR - 0.32; CI: 0.13 -0.79; p = 0.014) in the group of patients vaccinated with PCV13 compared with unvaccinated. The differences remained statistically significant after adjusting for the age and smoking, Figure 1.

Table 1. Registered infectious events

<table>
<thead>
<tr>
<th>Event groups</th>
<th>Localisation</th>
<th>Number</th>
<th>Of them serious</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory infections</td>
<td>Ear, paranasal sinuses, tonsils</td>
<td>16</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Upper respiratory tract</td>
<td>166</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Pneumonia</td>
<td>18</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>Lung abscesses</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Other infections</td>
<td>Eye and appendages</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Skin and subcutaneous tissue</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Bones and joint</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Urogenital tract</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Digestive system, including the oral cavity</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Herpes infections*</td>
<td>16</td>
<td>0</td>
</tr>
</tbody>
</table>

* - events are included in the group, regardless of localization, these events were not included in other sections.
The interaction of the effects of vaccination with the factor of the used tDMARD, as well as with the factor of the use of methotrexate in their effect on the risk of any and respiratory infections was evaluated. There was no significant interaction between these variables.

There were no significant differences in the risk of serious infections due to a small number of events of this kind. No serious infections were registered among patients vaccinated with PCV13.

**Conclusion:** Vaccination with 13-valent conjugated pneumococcal vaccine in patients with rheumatoid arthritis receiving tDMARDs can significantly reduce the risk of infectious complications, mainly due to acute respiratory infections. We found no significant effect of targeted drug and treatment with methotrexate on the effectiveness of vaccination.

**Disclosure of Interests:** Evgeniy Zhilyaev Speakers bureau: UCB Pharma, Biocad, Galina Lukina Speakers bureau: Pfizer, MSD, Biocad, Ekaterina Koltsova: None declared, Dzhamilya Murtazalieva: None declared, Evgeniya Shmidt: None declared, Karine Lytkina: Speakers bureau: UCB Pharma, Anna Shmidt: None declared, Dmitriy Blagovidov: None declared, Mikhail Kostinov: None declared.


**AB0307**

**MERKEL CELL CARCINOMA RECURRENCE RISK IS LOWER IN PATIENTS WITH AUTOIMMUNE DISEASE THAN IN THOSE WITH OTHER TYPES OF IMMUNE SUPPRESSION**

S. Park,1 D. Hippe,1 L. Zawacki1, M. Bierma1, S. Bhatia1, L. Zaba1, P. Nghiem1, N. Singh1, 1University of Washington, Dermatology, Seattle, United States of America; 2Stanford University, Dermatology, Stanford, United States of America; 3University of Washington, Medicine, Seattle, United States of America

**Background:** Merkel cell carcinoma (MCC) is twice as likely to recur in immunosuppressed (IS) patients as in immunocompetent (IC) patients. Iatrogenic IS due to autoimmune disease (AD) may influence prognosis differently than intrinsic IS such as due to hematologic malignancy. Moreover, modification of IS medication may improve prognosis.

**Objectives:** Our objective was to evaluate the risk of MCC recurrence among patients with AD diseases relative to other immunosuppressive conditions among 762 MCC patients from an Institutional review board-approved registry.

**Methods:** We categorized patients into 3 groups: IS due to AD (ISAD); IS from other causes (ISAD-AD) such as hematologic malignancy, solid organ transplant, human immunodeficiency virus; or immune competent (n=31, 70, and 661 respectively). ISAD patients were subcategorized into rheumatoid arthritis (RA) (ADRA, n=13) vs. AD except for RA (AD non-RA, n=18). Descriptive statistics were used to compare the features of different characteristics in each group. Kaplan-Meier survival curves were constructed to assess the cumulative incidence of recurrence in different patient groups. In order to estimate the associations between baseline patient characteristics and the risk of MCC recurrence, Fine and Gray regression models were used with death as a competing risk for recurrence. The multivariable models adjusted for age, sex, and extent of MCC at initial presentation.

**Results:** Patients with ISAD had lower stage disease (local disease: 58% vs. 36%; p = 0.003) and smaller primary tumors than ISAD non-RA (p < 2 cm: 83% vs. 57%, p = 0.023). After adjusting for age, sex, and stage, ISAD patients (ADRA and AD non-RA) overall had a 54% higher recurrence rate (hazard ratio (HR): 1.54, p = 0.21) than IC patients. In comparison, ISAD non-RA group had a 165% higher recurrence rate (HR: 2.65, p < 0.001) than IC patients (Figure 1). When considered separately, ADRA and AD non-RA pts appeared to have a similar recurrence rate as IC pts (HR: 1.19, p = 0.76) while AD non-RA pts had a higher recurrence rate (HR: 1.83, p = 0.16) relative to IC pts. At the time of MCC diagnosis, 80% (n=24) of AD pts were on IS medication including conventional disease modifying drugs, biologics, or oral steroids. After MCC diagnosis, 22% (5 patients) stopped all immunosuppressive medications. Among patients on biologics, 89% (8/9 pts) elected to stop the drug. Eleven pts with AD experienced recurrences. Our study was underpowered to demonstrate associations regarding use of a particular immunosuppressive medication and MCC recurrence.

**Conclusion:** In this cohort, pts with AD appeared to have a better prognosis than intrinsic IS, with RA conferring very little risk above that for immune competent pts.

**Acknowledgements:** I have no acknowledgements to declare.


**AB0308**

**FALL RISK EVALUATION WITH COMPUTERIZED DYNAMIC POSTUROGRAPHY IN RHEUMATOID ARTHRITIS PATIENTS**

E. Baran1, M. A. Dundar2, 1Hitt University, Physiotherapy and Rehabilitation, Corum, Turkey; 2Necmettin Erbakan University, Faculty of Medicine, Konya, Turkey

**Background:** Patients with rheumatoid arthritis (RA) have a higher risk of falling due to pain and physiological/biomechanical deformities (decreased muscle density, decreased functional stability, changes in gait, etc.) [1]. Although high incidences of falls have been reported in RA patients [1], there are not sufficient data regarding patient-specific fall risk.

**Objectives:** The aim of this study was to evaluate patient-specific fall risk, via computerized dynamic posturography, in RA patients, and to compare the results with those of age-matched healthy participants.

**Methods:** A total of 29 patients with RA (9 males, 20 females; mean age: 54.4±6.5 years) and 18 healthy participants (7 males, 11 females; mean age: 53.6±7.1) were included in the study. Detailed demographic, physical, and medical characteristics of the participants were recorded. Dynamic balance was tested with a computerized dynamic posturography, which assesses balance responses to induced postural disruption [2]. A translational ramp test (speed: 0.1 m/s), sinusoid tests (frequencies: 0.25 Hz - 0.50 Hz), and limits of stability evaluations were applied. Ramp and sinusoid tests were evaluated with the eyes open and closed, in the antero-posterior direction, and the participants were instructed to keep their balance during the tests. Limits of stability was evaluated on a static platform, with the eyes open. During the test, the participants were told to carry their pressure center as far as possible by performing the movement only from the ankle (in all directions), without lifting their feet, and trying not to fall.

**Results:** The groups were similar in terms of demographic and physical characteristics (p>0.05). Patients with RA showed statistically significant dynamic balance alterations compared to healthy participants (p<0.05) (Table 1). The fall test was positive in 31% of the RA patients and 5.6% of the control group (Figure 1).
Table 1. Comparison of the groups in terms of the fall risk assessment criteria

<table>
<thead>
<tr>
<th>Test Parameters</th>
<th>RA Group</th>
<th>Control Group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=29)</td>
<td>(n=18)</td>
<td></td>
</tr>
<tr>
<td>1.Ramp</td>
<td>Energy in AP (J)</td>
<td>2051 (1071-2258)</td>
<td>1409 (1224-1644)</td>
</tr>
<tr>
<td>Eyes Open</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Time in ML (s)</td>
<td>3.9 (3.0-4.4)</td>
<td>3.5 (2.6-3.9)</td>
<td>0.083</td>
</tr>
<tr>
<td>2.Ramp</td>
<td>Energy in AP (J)</td>
<td>1939 (1856-2147)</td>
<td>1718 (1334-1929)</td>
</tr>
<tr>
<td>Eyes Closed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Energy in ML (J)</td>
<td>213 (122-414)</td>
<td>208 (138-259)</td>
<td>0.369</td>
</tr>
<tr>
<td>1. Time in ML (s)</td>
<td>3.9 (3.0-4.4)</td>
<td>3.5 (2.6-3.9)</td>
<td>0.083</td>
</tr>
<tr>
<td>3.Sinusoid Gain in AP</td>
<td>1.1 (1.0-1.3)</td>
<td>1.1 (1.0-1.3)</td>
<td>0.809</td>
</tr>
<tr>
<td>Eyes closed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain in AP</td>
<td>1.1 (1.0-1.3)</td>
<td>1.1 (1.0-1.3)</td>
<td>0.809</td>
</tr>
<tr>
<td>Gain in ML</td>
<td>0.3 (0.3-0.4)</td>
<td>0.2 (0.2-0.3)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Eyes open</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gain in AP</td>
<td>0.3 (0.1-0.3)</td>
<td>0.2 (0.1-0.2)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Gain in AP</td>
<td>0.3 (0.1-0.3)</td>
<td>0.2 (0.1-0.2)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Limits of Stability</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surface (cm^2)</td>
<td>13.0 (10.0-15.0)</td>
<td>21 (17.2-21.5)</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

Data are presented as median and interquartile range. p value; Mann Whitney U Significance Test results between groups. (*): statistically significant difference (p<0.05). AP: Antero-posterior, ML: Medio-lateral

Conclusion: The results of this study showed that dynamic postural responses compared to destabilizing conditions are significantly altered in patients with RA compared to healthy controls. Determining the patient-specific fall risk is important in designing personalized rehabilitation programs and reducing the risk of injury.

REFERENCES:

Disclosure of Interests: None declared


AB0309

ASSOCIATION BETWEEN RHEUMATOID DISEASE COMORBIDITY INDEX AND PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS

E. Hannech 1,2, A. Ben Tekaya 1,2, O. Saidane 1,2, R. Leila 1,2, S. Bouden 1,2, R. Tekaya 1,2, I. Mahmoud 1,2, L. Abdelmoula 1,2, Rheumatology Department, Charles Nicolle Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia

Background: Pulmonary involvement is one of the primary contributors of morbidity among patients followed for Rheumatoid Arthritis (RA) [1]. Comorbidities are also independent factors of poor outcomes on those debilitated population.

Objectives: We aimed to assess association between comorbidity and pulmonary involvement in rheumatoid arthritis.

Methods: We conducted a retrospective study in our rheumatology department including patients with established RA according to the ACR/EULAR 2010 criteria. Rheumatic Disease Comorbidity Index (RDCI) was calculated for each patient. Clinical characteristics, radiological findings, and respiratory function tests (PFTs) for pulmonary involvement were collected.

Results: There were 255 patients: 212 female (83.1%) and 43 male (16.9%). The mean age was 58.92 ± 10.72 years [25-85]. The mean RDCI was 1.14 ± 1.25 [0-6]. Pulmonary involvement was noted in 115 patients (45.3%). It was asymptomatic in 50.6% of cases. Reported clinical symptoms were dyspnea (36.1%), chronic cough (8.4%), and dyspnea with chronic cough (4.8%). PFT showed a restrictive syndrome in 34.9% of cases, an obstructive syndrome in 4.8%, a mixed syndrome 3.6% and was normal in 56.6% of patients. Non-specific interstitial pneumonia was noted in 26.6% of patients, followed by nodular lung disease in 11.4 %, usual interstitial pneumonia in 11.4%, BOOP in 6.3%, and then pleural nodules in 6.3%.

An association was noted between RDCI and pulmonary involvement (presence: 1.7 ± 1.3 vs absence: 0.6 ± 0.8, p<0.05).

Conclusion: In conclusion, there was an elevated comorbidity index in patients with pulmonary involvement. Comorbidities may be a predictive factor of extra-articular manifestations. The early management may improve outcomes in RA patients.

REFERENCES:

Disclosure of Interests: None declared


AB0310

STUDY “AR-CAT INICI”: MANAGEMENT OF EARLY RHEUMATOID ARTHRITIS IN CATALONIA

C. Perez-Garcia 1, J. Rovira Aguilar 1, L. Mateo 1, J. A. Gómez-Puerta 4, M. Vialls Roc 2, G. Salvador Alarcon 3, R. Moria 3, S. Holgado Pérez 3, C. Diaz-Torre 2, M. Salís Lizarazu 3, C. Garcia Gomez 3, S. Castro 3, N. Montala Pau 1, H. Borrelli Pahos 5, S. Minguez 5, M. Lopez Lasanta 5, V. Ruiz-Esquivel 6, C. Pitarch Grau 6, N. Busquets-Pérez 3, H. Comorinas 6, A. Garcia Guillein 7, S. Rodriguez-Muguruza 8, M. Martinez-Morillo 8, R. Sanmartin 9 on behalf of AR- CAT. 1Hospital de Mar, Rheumatology, Barcelona, Spain; 2Hospital de Mollet, Rheumatology, Mollet del Valles, Spain; 3Hospital Universitari Germans Trias i Pujol, Rheumatology, Badalona, Spain; 4Hospital Clínic, Rheumatology, Barcelona, Spain; 5Hospital Universitari Dr. Josep Trueta, Rheumatology, Girona, Spain; 6Hospital Universitari Mutua de Terrassa, Rheumatology, Terrassa, Spain; 7Unitat Territorial de Reumatologia Sant Pau- Dos de Maig, Rheumatology, Barcelona, Spain; 8Alcalia, Xarxa Asistencial Urgentaria de Manresa, Rheumatology, Manresa, Spain; 9Hospital de Terrassa, Rheumatology, Terrassa, Spain; 10Hospital Universitari Joan XXIII, Rheumatology, Tarragona, Spain; 11Hospital Arnau de Vilanova, Rheumatology, Lleida, Spain; 12Hospital Vall d' Hebron, Rheumatology, Barcelona, Spain; 13Hospital de Granollers, Rheumatology, Granollers, Spain

Background: Given the progressive change in the management of inflammatory diseases, an observational study was conducted on the management of Early Rheumatoid Arthritis (ERA) in Catalonia.

Objectives: To know the management of ERA in Catalonia, to assess whether the recommendations of the EULAR/ACR guidelines are followed and to study the causes of management variability, to set improvement objectives.

Methods: An observational, descriptive, and cross-sectional study was conducted, with data collection from June 15 to 30, 2021. The rheumatologists’ partners of the Catalan Society of Rheumatology were the object of study. An online survey was conducted with 304 members on the management of the ERA. Variables related to the characteristics of the respondents, the derivation and variables of the disease including clinical variables, type of treatment and outcomes used for follow-up including the impact of the SARS-CoV2 pandemic were included.

The univariate study was performed using a study of proportions with Pearson’s correlation.

Results: A total of 105 members (34.5%) responded to the survey, 11.6% <60 y, only 7.8% <30 y, 99% were in public assistance. The number of rheumatologists per service is 7.2[1-17], but 34.2% had < 5 rheumatologists, with a reference population of 200,000-300,000 in 42% of respondents. The number of weekly visits made is 67[50-130]. 42.2% do not have a monographic RA or ERA dispensary and 30.4% have specialized nursing. Characteristic of ERA-77.5% are derived from primary care (PC), 92% have been between 6 weeks, 42.1% <3 months. 54.9% make a first visit within 2-4 weeks of PC referral and 14.7% > 8 weeks. 100% provide previous analysis, only 47% had had RX performed. 98% were previously treated (50.4% NSAIDs + CG, 36.1% NSAIDs, 12.3% CG). 4.3% had GC doses >10 mg/day, 11.3% > 20 mg/day. The treatment: SARDs of choice in 100% is MTX, 44.1% start doses of 10 mg/week and 3.9% >5 mg/week. The route of choice is oral (55.9% vs 44.1%), 92.2% associate GC and 31.7% have not withdrawn them after 6 months. 92.2% associate GC and 31.7% have not withdrawn them after 6 months. 92.2% associate GC and 31.7% have not withdrawn them after 6 months.
start of DMARDs is performed 72.5% between 4-6 weeks and 12.7% is performed by nursing. 100% use DAS 28 and 53.5% also CDAI. 31.4% perform PROs (HAQ 83.3%, RAPID 3 14.3%). The use of systematic ultrasound is collected in 33%, being himself who performs it in 59.9% and an expert rheumatologist in 46.1%. Finally, when asked about incidence of infection in the follow-up, 53.3% consider that it is doing the same as before. 46.1% consider that telephone visits are not suitable for the follow-up of the ERAv14.7% who consider that Yes. When questioning the situations in which they consider them to be appropriate, 75.9% that it was adequate in the control after the beginning of the DMARDs. Regarding the treatment of ERA, 66% delayed the onset of biological DMARDs, 72.1% due to difficulty of follow-up and only 8.8% due to an increased risk of infection. When performing the univariate analysis, it is evident that having a monographic dispansary is associated with earlier onset of MTX (p=0.001) and at doses ≥15 mg/W (p=0.05), greater nursing intervention (p=0.001), greater use of PROs (p=0.008) and there is a tendency to a shorter waiting time for first visits (p=0.07). It is also associated with not considering telephone visits (p<0.001), making them in less than 25% (p<0.0001). Similarly, hospital level is directly proportional to initiation at higher doses of MTX (p<0.0001), lower use of GC<10mg.Among the rest of the variables, no association has been found.

Conclusion: The recommendations of EULAR/ACR in the treatment and follow-up of ERA are consistently followed, although the wide use of MTX orally is striking. It is evident that the variable that most influences the early onset of FAME and at higher doses, is a monographic dispensary, as well as greater presence of nursing and performance of PROs.

Acknowledgements: Thanks to all the members of the Catalan society of rheumatology who participated in the survey.

Disclosure of Interests: None declared


AB0311 RHEUMATOID ARTHRITIS AND OSTEOPOROSIS: FREQUENCY AND ASSOCIATED FACTORS

M. Brahim1, R. Sarrar2, A. Ben Salem3, R. Grassa2, S. Abdelatif4, H. Hachi4, Y. Mohamed4, 1Tasser Star University Hospital, Rheumatology, Mahdia, Tunisia

Background: In rheumatoid arthritis (RA), persistent systemic inflammation may cause bone and cartilage destruction and systemic osteoporosis (OP).

Objectives: We conducted this study to determine the frequency of OP in RA patients and to focus on associated factors.

Methods: This is a retrospective descriptive and analytic study including consecutive RA patients. The epidemiological, clinical, biological data and the measurement of bone mineral density were collected from patients’ records. A statistical analysis was performed to study the clinico-biological profile of osteoporotic patients and determine factors associated with the development of OP in RA patients.

Results: Seventy-one of RA patients were recruited: 67 females (94.4%) and 4 males (5.6%) with a mean age of 54.28 years ± 11.09 [30-75]; OP was noted in 45.1% of cases (32 patients). The mean T-scores at the lumbar and femoral sites were -2.7 ± 0.6 SD and -1.3 ± 1 SD, respectively. Patients with OP were older (58.8 ± 7.6 years vs 50.5 ± 12.1 years; p<0.01) and with a greater number of postmenopausal women than patients with normal bone density (68.7% vs 41%; p=0.02). Osteoporotic patients had RA duration longer than the other group (15.2 ± 12.5 years vs 11.9 ± 8.2 years; p=0.02) and more extra-articular manifestations associated with RA (100% vs 76.9%; p<0.01).

Both groups were treated with corticosteroid drugs with similar frequency, although patients with normal bone density received biottherapy more frequently than patients with OP (23% vs 18.7%; p=0.03). The two groups had almost similar disease activity DAS28 ESR (44.3 ± 34 vs 42.7 ± 30.7; p=0.2). The following parameters were not associated with the occurrence of OP in our series: gender, smoking, BMI, ESR, CRP, ACPA, RF, erosive and deforming character of RA.

Conclusion: OP is an extra-articular disease that must be systematically screened throughout the follow-up. In our study, there was no significant difference in disease activity at both groups of patients. However, patients with OP had longer duration of RA, more extra-articular manifestations and were less frequently treated with biottherapy.

REFERENCES:

Disclosure of Interests: None declared


AB0312 BODY COMPOSITION AND BONE MINERAL DENSITY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS

O. Dobrovolskaya1, A. Fekistov2, N. Demin3, A. Sorokina3, O. Nikitinskaya1, N. Torontsov1, 1VA Nasonov Research Institute of Rheumatology, Osteoporosis, Moscow, Russian Federation

Objectives: To assess body composition and bone mineral density (BMD) in rheumatoid arthritis (RA) women compared to patients with osteoarthritis (OA).

Methods: 133 women with RA and 45 women with OA aged 50 and over were enrolled in the study. Body composition (fat mass (FM), lean mass and bone mineral component (BMC)) and BMD of the lumbar spine, femoral neck and total hip were measured using dual-energy X-ray absorbometry (DXA). Appendicular muscle mass (AMM) and appendicular mass index (AMI) were calculated. Muscle strength was assessed in all patients. The criteria of the European Working group on Sarcopenia in Older people 2 (EWGSOP2) were used for low muscle mass and sarcopenia. Osteoporosis was determined in accordance with WHO criteria.

Results: Mean age of RA patients and women with OA was 61.3±6.2 years, respectively (p<0.05). BMC and AMM were lower in RA patients than in women with OA: BMC - 1948.6±425.7g and 2167.1±398.1g, respectively (p=0.004); AMM - 17.5±2.9kg and 20.1±2.7kg, respectively (p<0.001), 27 (20.3%) RA women and only 1 (2.2%) person with OA had low AMM (p=0.004). The mean value of AMI was 6.8±1.0kg/m² and 7.5±0.9kg/m² in RA and OA patients, respectively (p<0.001). Total FM was 28.3±8.5kg and 33.2±9.8kg in RA and OA women, respectively (p<0.003). At the same time, we found no differences in the percentage of fat mass: 39.2±5.7% in RA patients and 39.8±5.8% in persons with OA (p>0.05). Overfat was discovered in 99 (77.4%) and 38 (84.4%) in women with RA and OA, respectively (p>0.05). All women with low AMM/AMI had low muscle strength and were diagnosed with confirmed sarcopenia.

In RA patients BMD at any region was less than in women with OA: in the lumbar spine – 1.026±0.174 g/cm² and 1.114±0.177 g/cm², respectively (p=0.009); in the femoral neck – 0.844±0.151 g/cm² and 0.914±0.137 g/cm², respectively (p=0.005) and in the total hip 0.875±0.148 g/cm² and 0.986±0.177 g/cm², respectively (p<0.001). Normal BMD was found in 33 (24.8%) and 24 (53.3%) women with RA and OA, respectively (p=0.0004). 42 (31.6%) patients with RA and 6 (15.4%) women with OA had osteoporosis (p=0.017).

Conclusion: RA patients had lower BMC, AMM/AMI, total FM and BMD compared to women with OA, and they were significantly more likely to have sarcopenia and osteoporosis.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4096

AB0313 CLINICAL FEATURE OF 100 CASES OF METHOTREXATE ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS WITH RA PATIENT

T. Kameda1, Y. Usui1, S. Nakashima2, H. Shimada3, R. Wakaji4, M. Kato5, T. Miyagi1, K. Sugihara1, R. Mino3, M. Mizusaki1, H. Dobashi1, Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Kita-gun, Japan

Background: Lymphoproliferative disorders (LPDs), including malignant lymphoma, are known to occur in RA patients treated with disease modified antirheumatic drugs (DMARDs). In particular, LPD associated with methotrexate (MTX)-treated RA is often referred to as MTX-associated LPD (MTX-LPD). MTX-LPD have various clinical feature and histological findings. We have accumulated MTX-LPD cases in patients with rheumatoid arthritis (MTX-RA-LPD).

Objectives: We clarified the clinical characteristics of MTX-RA-LPD. In addition, we examine the prognosis of MTX-LPD in RA patients.

Methods: We enrolled 100 RA patients who diagnosed MTX-LPD from 2005 to 2021. We collected as follow data based on clinical reports retrospectively: 1) age, gender, 2) duration from RA onset to LPD onset, 3) total dose of MTX, 4) duration of MTX administration, 5) presence of extranodal lesion 7) histological findings, 8) treatment for LPD, 9) 5-year survival rate.

Results: The mean age of 100 MTX-RA-LPD patients (M:F=30:70) were 66.7 ± 10.7 years old, and the duration from RA onset to LPD onset were 25.2 ± 11.0 years. The total dose of MTX and duration of MTX administration were over 2,600mg and over 5 years, respectively. The extranodal lesions were found in 51%, and diffuse large B cell lymphoma was the most common histological findings. Spontaneous regression was observed in 68%. The 5-year survival rate of MTX-RA-LPD was as high as over 85%.
Discipline: The clinical features of MTX-RA-LPD were similar to those previous reports. Furthermore, we suggested a good prognosis for MTX-RA-LPD.

REFERENCES:

Disclosure of Interests: None declared


**AB0314** MULTIMORBIDITY BURDEN IN RHEUMATOID ARTHRITIS

D. C. Varela1, J. C. Sarmiento Monroy2, M. M. Mantilla Rivero3, C. Villota4, M. Rodriguez-Jimenez2, R. D. Mantilla Hernández5, 1Universidad Pontificia Bolivariana, Rheumatology Department, Medellín, Colombia; 2Hospital Clinic, Rheumatology, Barcelona, Spain; 3Universidad de la Sabana, Rheumatology, Bogotá, Colombia; 4IPS Servicio Integral de Reumatología e Inmunología Dr Orlando Villota, Rheumatology, Pasto, Colombia; 5Universidad del Rosario, Rheumatology, Bogotá, Colombia; 6Center of Dermatology and Rheumatology (FUNINDERMA), Rheumatology, Bogotá, Colombia

Background: Multimorbidity in patients with rheumatoid arthritis (RA) has been described as the coexistence of two or more chronic diseases and is the most common cause of death in this population.

Objectives: To describe the prevalence of multimorbidity and mortality trends in a well-characterized cohort of patients with RA.

Methods: A retrospective cohort study of patients with RA (1987 ACR criteria) was conducted. Each patient was evaluated and followed by a rheumatologist in a single outpatient private center in Bogotá, Colombia, from 2014 to 2021. Categorical variables were expressed in frequency and percentage and quantitative variables in mean and standard deviation or median with interquartile range, depending on the distribution of the data. Statistical package: SPSS 25.

Results: A total of 783 patients were included. 11% of patients with RA present multimorbidity. Baseline characteristics were as follows: female gender 81.6%, mean age 51±11 years, mean disease duration 8 (IQR 3-15) years, RF positive 80.1%, ACPA positive 58.2%, and erosions 24.9%. Most patients have received glucocorticoids (89.8%), and conventional synthetic DMARDs (97.8%), being prednisone and methotrexate the most frequently prescribed. Highest mortality was present in 5.5% and principal infection was urinary infection 14.3%. Polyautoimmunity was present in 5.7% most frequently Autoimmune thyroid diseases 10.6% and Sjögren syndrome 9.4%. After a median of 73 months of follow-up, the mortality rate was 1% of the entire cohort, being cardiovascular disease and COVID-19 infection the main causes.

Conclusion: Patients with RA have an important multimorbidity burden and this increased risk of adverse outcomes and mortality.

REFERENCES:

Disclosure of Interests: None declared


**Table 1. Clinical, laboratory characteristics, and treatment efficacy in RA without and with HU**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>RA with HU (n=292)</th>
<th>RA without HU (n=292)</th>
<th>GA (n=300)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean±SD), years</td>
<td>60.53±12.47</td>
<td>58.07±13.24</td>
<td>57.7±11.85</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>253 (86.64)</td>
<td>282 (96.57)</td>
<td>275 (91.67)</td>
</tr>
<tr>
<td>Duration of clinical manifestation, years (mean±SD)</td>
<td>3.56±1.58</td>
<td>4.13±1.75</td>
<td>3.42±2.12</td>
</tr>
<tr>
<td>C-reactive protein, mg/l (mean±SD)</td>
<td>29.25±14.67</td>
<td>28.22±14.39</td>
<td>30.14±14.43</td>
</tr>
<tr>
<td>ESR, mm/h (mean±SD)</td>
<td>21.10±20.88</td>
<td>23.69±29.93</td>
<td>22.48±21.49</td>
</tr>
<tr>
<td>Medicinal ULT, n (%)</td>
<td>25</td>
<td>NA</td>
<td>100</td>
</tr>
<tr>
<td>Efficacy of ULT, n (%)</td>
<td>68 (23.29)</td>
<td>NA</td>
<td>160 (53.33)</td>
</tr>
</tbody>
</table>

ESR – Erythrocyte Sedimentation Rate; ULT – urate-lowering treatment; DAS28 – Disease activity score; NA – not applicable; intergroup difference with p<0.001.

Presence of the HU in RA pts was associated with increased comorbidity as compared with age, sex and activity matched RA pts without HU, and with GA, Figure 1.

Figure 1. Comorbidity in pts with RA without and with HU, and in GA pts.
ULT was administered to pts with RA and HU 4 times less frequently than to pts with GA. The effectiveness of ULT in RA and HU is two times lower than in GA.

Conclusion: 1) HU negatively affects the decrease of RA activity. 2) HU in RA is associated with increased comorbidity and 3) ULT is assigned to pts with RA and HU 4 times less frequently than to pts with GA and is ineffective in 76.71% of cases. Additional research is needed to evaluate the influence of UAs' serum levels' normalization as a factor that could improve results of RA treatment and control.

REFERENCES:

Disclosure of Interests: None declared


AB0316 SARCOPENIA IN PATIENTS WITH RHEUMATOID ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS
N. Torgonstova1, O. Dobrovolskaya1, A. Sorokina1, A. Feklistov1, N. Demin1, O. Nikitinskaya1, I.V. Nasonova Research Institute of Rheumatology, Department of Osteoporosis, Moscow, Russian Federation

Objectives: To evaluate the prevalence of sarcopenia (SP) and associated factors in patients with rheumatoid arthritis (RA).

Methods: 159 women (mean age 58.7±8.8) with confirmed RA according to ACR/EULAR criteria (2010) were enrolled. Hand grip strength was measured using mechanical dynamometry. Dual-energy X-ray absorptiometry (DXA) was performed to assess the body composition and bone mineral density (BMD) of the lumbar spine, femoral neck and total hip. SP was defined as muscle strength < 18 kg and appendicular lean mass index (ALMI) <5.5 kg/m² or appendicular lean mass (ALM) <15 kg. RA activity was assessed by C-reactive protein (CRP) and disease activity score using 28 joint counts and erythrocyte sedimentation rate (DAS28-ESR). The relation between low ALM with disease parameters was analyzed using Spearman's r. Factors associated with SP were evaluated using regression analysis.

Results: SP was diagnosed in 33 (20.6%) women with RA. Patients with SP did not differ in age from those without it (59.0±8.9 and 58.7±8.8 years, respectively, p>0.05). 75.8% patients with SP and only 27.8% women without SP had normal BMI (p<0.001). Osteoporosis was diagnosed significantly more often in patients with SP than in women without SP (54.5% and 23.0%, respectively, p<0.001). In women with RA, ALM and ALMI correlated with body mass index (BMI), bone mineral component, BMD and total fat mass. ALM and ALMI did not correlate with age, disease duration, the use of glucocorticoids, DAS28, CRP, total protein, and creatinine levels. In univariate regression analysis, SP was associated with BMI, bone mineral component, BMD of lumbar spine and proximal femur, total fat mass. In multivariate regression analysis, SP was positively associated with the presence of osteoporosis [OR 2.98, 95%CI (1.22-7.30), p = 0.017] and BMI < 25 kg/m² [OR 6.75, 95%CI (2.45-18.56), p<0.001]. No other significant associations were found.

Conclusion: Among patients with RA, 1/5 of them had SP, which was positively associated with BMI and the presence of osteoporosis, but not with the age, activity and duration of the disease.

Disclosure of Interests: None declared


AB0318 PREVALENCE OF SECONDARY SJOGREN'S SYNDROME IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SINGLE CENTER STUDY FROM NORTHERN INDIA
S. Mehra1, N. Hariharan2, S. Deka2, Jaypee Hospital, Rheumatology, Noida, India;1Technology | Healthcare | Big Data Analytics, Real World Evidence, Haryana, India

Background: Sjogren's syndrome (SS) is a systemic autoimmune disease characterized by lymphocytic infiltration of salivary and lacrimal glands leading to dry eyes and dry mouth. Sjogren's syndrome either present alone (primary Sjogren's syndrome) or sometimes can occur with other autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus, and scleroderma. In such instances, the condition is termed secondary Sjogren's syndrome. SS may be a marker of more aggressive joint disease in patients with RA, and hence it is essential to characterize the symptoms in the RA cohort, which may help in the management and treatment of the disease.

Objectives: Primary Objective
The primary objective of the current study is to estimate the prevalence of secondary Sjogren's syndrome in a cohort of patients with rheumatoid arthritis.

Secondary Objective
To compare the clinical characteristics in rheumatoid arthritis patients with Sjogren's syndrome and in rheumatoid arthritis patients without Sjogren's syndrome.

Methods: The study was conducted from 2016-2018 in a tertiary care hospital in the Department of Rheumatology, New Delhi, India. Patients with a rheumatologist-diagnosed RA were enrolled. There were 726 patients with rheumatoid arthritis. Patients were enquired about their symptoms. Out of 726, 193 had secondary Sjogren's syndrome (26.58%). In patients without Sjogren's syndrome, complete clinical data were available only for 377 patients hence the analysis on the comparison of clinical characteristics was limited to 377 patients. The other patients were excluded due to lack of the data required for the study.

Results: It was identified that out of 726 patients, 193 had symptoms of secondary Sjogren's like dry eyes dry mouth, or both. It was found that in patients with secondary Sjogren's syndrome (n=193), the mean age was significantly higher than those patients without secondary Sjogren's syndrome (n=537) [52.58 ± 12.36 Vs. 48.42 ± 13.98, p=0.0005]. Similarly, the mean disease duration was significantly higher among RA patients with secondary SS than those without SS [10.76 ± 8.34 Vs. 6.81 ± 7.29, p<0.0001]. Similarly, comorbidities like hypertension, diabetes mellitus, and hypothyroidism were more seen in patients with rheumatoid arthritis with Sjogren's syndrome.

In a meta-analysis involving 18 studies, it was identified that the prevalence of SS in RA was 19.5%. The differences in the prevalence of secondary SS in RA patients could be attributable to inter-ethnic variation, disease duration, and clinical scores employed in the studies. Further to our study, Santhosh et al reported that patients with secondary SS had a longer disease duration than those without secondary SS.

Conclusion: The prevalence of Sjogren's syndrome among patients with rheumatoid arthritis in the North Indian cohort of patients with RA was 26.58%.

REFERENCES:
PREALBUMIN SERUM LEVEL AS A USEFUL TOOL IN THE ASSESSMENT OF MALNUTRITION IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS

M. Arthangu1, J. Mahboub1, F. Nañada, F. Fhima1, M. Ghali1, S. Zouari2, I. Bejji1, M. Touzi1, N. Bergaoù1, Fattouma Bourguiba Hospital, Monastir, Tunisia; 
Fattouma Bourguiba Hospital, Biochemistry, Monastir, Tunisia; 
Background: Protein-energy malnutrition is a common condition among elderly patients with RA associated with a poor prognosis. Although many screening tools are developed, there's no consensus on which test is more reliable in clinical practice. Serum prealbumin (PAB) may be a useful malnutrition biomarker.

Objectives: Our objective is to evaluate the usefulness of serum PAB in the assessment of malnutrition in elderly patients with RA.

Methods: We conducted a prospective study including RA patients who were followed in rheumatology department and aged 65 years or older. We studied malnutrition prevalence, risk of complications related to malnutrition and PAB serum concentrations. The mini-nutritional assessment (MNA) score was used as the reference method to determine malnutrition. We also assessed inflammatory proteins: Orosomucoid (Oroso), C-reactive protein (CRP) and Haptoglobin (Hapto). For the prognosis assessment, we calculated the Geriatric nutritional risk index (GNRI) and the Prognostic Inflammatory and Nutritional Index (PINI).

Results: Sixty-three patients (52 female and 11 male) were included. Their mean age was 68.17±4.35 years. The average DAS28 was 3.27±1.48. The mean MNA total score was 20.19 ± 4.71. According to MNA, the prevalence of malnutrition was 20.6%. 55.6% of the patients were at risk of malnutrition and only 23.8% of patients had a normal nutritional status. The median PAB was 0.16 g/L with an IQR of [0.04-0.24] and extremes ranging from 0.01 to 0.37 g/L. According to PAB, 35.8% of patients had a normal level above 0.20 g/L, 17% had PAB levels between 0.15 and 0.19 g/L, indicating moderate malnutrition and 47.2% of patients had PAB levels below 0.15 g/L, indicating severe malnutrition. Concerning inflammation proteins: the mean CRP was 18.96 ± 27.8 mg/L. 28.6% of patients had a CRP > 15 mg/L, of which 9.5% had a CRP > 50 mg/L. The mean Oroso was 1.29 ± 0.46 g/L [0.6-2.2]. 52.5% of our patients had an elevated oroos value. The mean Hapto was 2.07 ± 0.97 g/L [0.31-5.29]. 42.5% of patients had an increased value above 2.5 g/L. Concerning prognosis indexes, the median GNRI was 116.47 ± 36.6 with a range of 82.08-155.5. 27.8 mg/L. 28.6% of patients had a CRP > 15 mg/L, of which 9.5% had a CRP > 50 mg/L.

Conclusion: Between groups.

LV sizes, LV myocardial mass index, NT-proBNP, pentraxin, galectin-3 levels between groups (2 Table 1). There were no differences in left ventricular ejection fraction, LV sizes, LV myocardial mass index, NT-proBNP, pentraxin, galectin-3 levels between groups (2 Table 1).

Disclosure of Interests: None declared


ADHERENCE TO MEDITERRANEAN DIET AND PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN RHEUMATOID DISEASES

S. Reiki1, S. Nouel1, S. Boussaid1, S. Jemmati1, S. Rahmouni1, K. Zouaoui1, H. Sahli1, M. Elleuch1, R. Rabta, Rheumatology, Tunis, Tunisia

Background: Rheumatic diseases (RD) are autoimmune inflammatory arthritis. However involvement to other organs can occur and leads to atherosclerosis and cardiovascular (CV) risk factors. Mediterranean diet (MD) has attracted considerable interest because it seems to offer significant benefits to that end.

Objectives: To evaluate the role of MD in the development of the cardiovascular risk factors in RD.

Methods: We conducted a cross-sectional study including patients with RA (ACR-EULAR 2010 criteria) or with SA (ASAS 2009 criteria), in remission or in low activity disease and with no history of cardiovascular risk factors before the diagnosis of their RD. Sociodemographic and disease related data were collected: Disease Activity Score (DAS28-CRP), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) and medication. We asked the patients to complete the 14-items MD adherence questionnaire: We evaluated the adherence to MD with cardiovascular risk factors: obesity, type-2 diabetes, hyperlipidaemia and hypertension. We estimated odds ratios for each cardiovascular risk factors and their 95% confidence intervals. In all analyses, the

Table 1. Levels of biomarkers in groups

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Low GLEs (n=27)</th>
<th>Normal GLEs (n=14)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>sST2, pg/ml</td>
<td>13.2 (10.6;17.0)</td>
<td>18.3 (13.7;60.9)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Pentraxin, ng/ml</td>
<td>0.29 (0.05;0.43)</td>
<td>0.3 (0.02;0.79)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Galectin-3, ng/ml</td>
<td>4.0 (2.6;6.9)</td>
<td>4.3 (3.2;5.3)</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>NT-proBNP, pg/ml</td>
<td>105 (42;260)</td>
<td>94 (35.5;378.8)</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

high adherence category of MD adherence score (10–14) was considered the reference category.

Results: We included 61 patients (40 women and 21 men) with a mean age of 42.2 ± 11.1 years old [20-66]. Among them, 32.7% belong to urban environment and 26.2% were professionally active. The mean disease duration was 83.2 months [9-180]. The mean DAS28-CRP was 1.2 [0.8-1.9] and the mean ASDAS-CRP was 1.8 [1-2.0]. Methotrexate was used by 52.4%, either as monotherapy or combination and biological in 47.6 %. Thirty patients had high adherence to MD (H-MD) and thirty-one had medium or low adherence to MD (LMD). We found that higher adherence to the MD is inversely associated with the prevalence of each of the four cardiovascular risk factors, results are shown in Table 1.

Table 1. Prevalence of cardiovascular risk factors and odds ratio in high adherence to Mediterranean diet in rheumatic diseases.

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Prevalence %</th>
<th>Odds ratio</th>
<th>95% confidence intervals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obesity</td>
<td>57.4</td>
<td>0.017</td>
<td>[0.03-0.09]</td>
</tr>
<tr>
<td>Type-2 diabetes</td>
<td>50.8</td>
<td>0.01</td>
<td>[0.01-0.019]</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>50.8</td>
<td>0.126</td>
<td>[0.04-0.3]</td>
</tr>
<tr>
<td>Hypertension</td>
<td>46.2</td>
<td>0.13</td>
<td>[0.43-0.4]</td>
</tr>
</tbody>
</table>

Conclusion: Our results suggest that the healthy effects of the MD observed in epidemiologic studies are exerted partly through plausible mechanisms: low prevalence of obesity, of type2 diabetes, of hyperlipidemia and of hypertension. Intentional adherence may eventually provide stronger evidence. In the meantime, an increasing of knowledge supports the Mediterranean diet as a useful tool in managing individuals with RD, who are at high risk cardiovascular diseases.

Disclosure of Interests: None declared


AB0322

INTESTINAL DYSBIOSIS IS ASSOCIATED WITH INADEQUATE RESPONSE TO MULTIPLE ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS.


Regional Universitario de Málaga (HRUM). Institute for Biomedical Research in Málaga (IBIMA), UCG of Rheumatology, Málaga, Spain; 1Hospital Clínico Virgen de la Victoria. Institute for Biomedical Research in Málaga (IBIMA), UCG of Endocrinology and Nutrition, Málaga, Spain

Objectives: To evaluate the relationship between inadequate response to multiple antirheumatic biologic or targeted synthetic drugs (IRMD-b/tsDMARDs) and intestinal microbiota and other inflammatory and severity factors in patients with rheumatoid arthritis (RA).

Methods: Design: A case-control study nested in a prospective cohort of RA patients. Patients: Patients with RA (ACR/EULAR 2010) from a prospective baseline cohort (incident cases between 2007-2011), >16 years. Controls: subjects without inflammatory disease matched by sex and age. Protocol: All subjects were evaluated in a specialized outpatient unit. Clinical, analytical and therapeutic variables were registered using a data collection protocol. Blood, urine and faeces samples were obtained from all subjects. Variables: Dependent variable: “RA patients with IRMD,” defined as failure >2 different bDMARDs (biological disease-modifying antirheumatic drug) or tsDMARDs (targeted synthetic disease-modifying antirheumatic drug). Faecal microbiota (continuous var., 0-100%) was measured using the Ion Torrent SS next-generation sequencing platform, and the sequences obtained were processed using the QIIME2 (Quantitative Insights Into Microbial Ecology 2) software. Inflammatory activity was measured by mean DAS-28 (disease activity score-28) throughout the disease and RA severity variables included erosions, anticitrullinated peptide antibody (ACPA) titres and HAQ (health assessment questionnaire). Other variables included socio-demographic, clinical-analytical characteristics, type of treatment with bDMARDs and reason for suspension. Statistical Analysis: Descriptive, bivariate using χ2 and T-Student followed by two logistic regression model in order to identify the factors associated with both bDMARDs and IRM-b/tsDMARDs in patients with RA.

Results: 220 subjects, 110 RA patients and 110 controls, were included. A total of 90/110 RA patients were seropositive (81.8%) and 68/110 were erosive (61.8%). A total of 61/110 (55.5%) were treated with any bDMARD, being more frequent the anti TNF (35.5%). Ninety-three (84.5%) of RA patients took associated sDMARD. Thirteen patients (21.3%) presented IRMD. The variables independently associated with biological therapy in RA were: physical activity (OR [95% CI], 0.990 [0.989-0.999]; p=0.043), erosions (OR [95% CI], 2.450 [1.056 -4.683]; p=0.037) and Actinobacteria family (OR [95% CI], 1.182 [1.016-1.375]; p=0.030), R2= 0.283. The variables that were independently associated with IRMD in patients with RA were: ACPA (OR [95% CI], 1.005 [1.001-1.010]; p=0.039), diagnostic delay (OR [95% CI] 1.025 [1.001-1.050]; p=0.044), age (OR [95% CI], 0.933 [0.900-0.969]; p=0.032), Bacteroidetes (OR [95% CI], 1.080 [1.014-1.150]; p=0.016), Synergistetes (OR [95% CI], 2.277 [1.094-4.741]; p=0.028), R2=0.329.

Conclusion: Biological treatment in RA was associated with less physical activity, erosions and a greater presence of Actinobacteria. Bad prognosis factors such as delayed diagnosis and elevated ACPA titres were associated with multiresistance in RA patients, in addition to higher levels of Bacteroidetes and Synergistetes.

Disclosure of Interests: None declared


AB0323

FACTORS ASSOCIATED TO CLINICAL INERTIA IN RHEUMATOID ARTHRITIS

S. Miladi, O. Boudirguia, A. Fazaia, H. Boussaa, L. Souabni, K. Ouenniche, S. Kassa2, S. Chekili, K. Ben Abdelghani, A. Laatar. 1Mongi Slim Hospital, Rheumatology Department, La Marsa, Tunisia

Background: Clinical inertia in rheumatic diseases is defined as inability or undue delay to initiate or intensify therapy when the disease is active or de-escalate therapy when the disease is in remission. Understanding the various contributory factors to clinical inertia is helpful in ensuring appropriate planning to tackle the issue and achieving Treat-To-Target (T2T) goals.

Objectives: We aimed to identify medical therapeutic inertia in Rheumatoid Arthritis (RA) patients and to assess its contributing elements.

Methods: We conducted a monocentric study including 42 patients, fulfilling the 2010 ACR/EULAR classification criteria for RA, who consulted our outpatient department from November 2021 to January 2022. Study data collection included demographics, clinical and disease characteristics, and treatment history. The survey also contained the Satisfaction Questionnaire for Medication (TSQM) which provides validated score for four sub-scales: effectiveness, side effects, convenience, and global satisfaction. Treatment satisfaction was measured using a cutpoint global satisfaction score ≥ 80.

Results: Most patients were female (86%) with a mean age of 57±13 years and a mean disease duration of 10.8±4.7 years. The education level for most patients (62%) was secondary school education or less. Fifteen percent of patients were in full-time work, 27% were unemployed, and 54% were retired. RA impact on patients’ work-life was considerable, as 14.3% had retired early due to RA. Patients had moderate-to-high disease activity, with a mean DAS28 with C-reactive protein (CRP) of 4.2±1.4. Radiographic structural damage was apparent in 79% of patients. RA was immunopositive in 92% of patients. Most
common comorbidities were cardiac disorders (32%), pulmonary disorders (13%), and metabolic/nutrition disorders (11%). Psychiatric disorders was present in 9.5% of patients. CsDMARDs were the most frequently prescribed medications, used in 69% cases, followed by bDMARDs used in 34% cases. A total of 54% received the anchor drug methotrexate as part of their treatment regime. Only 12% of patients used systemic glucocorticoids for RA. Only half (52%) of all patients had a planned switch of medication, despite long-standing disease and suboptimal symptom control with current DMARD therapy. Statistical analysis revealed that factors for switch decision to a different DMARD by the treating physician was: younger patient age (p<0.002), having a high disease activity by DAS28-ESR (p<0.001), worse HAQ score (p<0.001), lower global satisfaction score (p<0.001), and patient preference for oral administration (p=0.006). Predictors for not switching to a different DMARD included a higher number of comorbidities (p=0.001) and a lower number of concomitant medications (p=0.002). Mean TSQM scores were 62 for effectiveness, 45 for side effects, 65 for convenience, and 60 for global satisfaction. Only 16 % of patients were satisfied with their RA treatment.

Conclusion: Our study showed that patients with active RA may not be managed in consistency with recommendations. This phenomenon defined as clinical inertia, is multi-factorial including healthcare set-ups and providers, patients and their caregivers. That’s why before labelling management of rheumatic disease in an individual as a ‘failure’ careful consideration of relevant factors linked to clinical inertia may be helpful.

Disclosure of Interests: None declared


Table 1. DEMOGRAPHIC, DISEASE AND TREATMENT BASELINE CHARACTERISTICS.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Rheumatoid arthritis</th>
<th>Psoriatic arthritis</th>
<th>Juvenile idiopathic arthritis</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>n=163 (84.02%)</td>
<td>n=18 (9.28%)</td>
<td>n=7 (3.61%)</td>
<td>n=6 (3.09%)</td>
</tr>
<tr>
<td>Age - years</td>
<td>55.23 (16.84)</td>
<td>54.71 (11.89)</td>
<td>27.14 (5.18)</td>
<td>48 (12.95)</td>
</tr>
<tr>
<td>Female sex – number (%)</td>
<td>142 (87.12)</td>
<td>12 (66.66)</td>
<td>6 (85.71)</td>
<td>4 (66.67)</td>
</tr>
<tr>
<td>Race – number (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>135 (82.82)</td>
<td>16 (88.89)</td>
<td>7 (100)</td>
<td>6 (100)</td>
</tr>
<tr>
<td>Asian</td>
<td>2 (1.23)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Latin</td>
<td>26 (15.95)</td>
<td>2 (11.11)</td>
<td>0 (0)</td>
<td>2 (0)</td>
</tr>
<tr>
<td>Comorbidities – number (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High blood pressure</td>
<td>118 (72.39)</td>
<td>11 (61.11)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>54 (33.13)</td>
<td>6 (33.33)</td>
<td>0 (0)</td>
<td>1 (16.67)</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>10 (6.13)</td>
<td>3 (16.66)</td>
<td>0 (0)</td>
<td>1 (16.67)</td>
</tr>
<tr>
<td>Positive HBV serology</td>
<td>12 (73.6)</td>
<td>1 (5.55)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>15 (9.20)</td>
<td>1 (5.55)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>JAKI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baricitinib</td>
<td>61 (37.42)</td>
<td>0 (0)</td>
<td>2 (28.57)</td>
<td>1 (16.67)</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>83 (50.92)</td>
<td>15 (83.33)</td>
<td>4 (57.14)</td>
<td>3 (50)</td>
</tr>
<tr>
<td>Upadacitinib</td>
<td>19 (11.66)</td>
<td>3 (16.67)</td>
<td>1 (14.29)</td>
<td>2 (33.33)</td>
</tr>
<tr>
<td>Patients taking glucocorticoids – number (%)</td>
<td>112 (68.71)</td>
<td>9 (50)</td>
<td>3 (42.86)</td>
<td>1 (16.67)</td>
</tr>
</tbody>
</table>

Conclusion: In this updated analysis of 194 patients treated with JAKI, the three approved JAKI showed a safety profile consistent with data from RCT. The patients under JAKY therapy should be carefully evaluated on their follow-up.

Disclosure of Interests: None declared

RA patients with AI and with normal Hb levels (n=29) were comparable (p<0.05) in age (44.4±14.8 and 49.8±9.3 years), disease duration (73.5±65.4 and 59.8±48.3 months) and DAS28 (3.6±1.6 and 5.9±1.9). In RA patients with AI we found a strong positive correlation between serum hepcidin and ferritin levels (r=0.623, p<0.009). There was a positive correlation between serum ferritin and IL-6 levels (r=0.546, p=0.023). We found a strong negative correlation between serum hepcidin concentrations and Hb levels (r=0.528, p=0.029), but reliable correlation between DAS28, CRP and ESR was not revealed.

RA patients without anemia, the level of hepcidin positively correlated with the inflammatory activity parameters including CRP, ESR and DAS28, no correlation between the Hb and ferritin levels was revealed.

**Conclusion:** Our data support the hypothesis that IL-6-driven hepcidin production mediates AI in RA patients and might play a role in the pathogenesis of anemia associated with RA. In RA patients with chronic hypoxia, serum hepcidin level was significantly higher and perform better than traditional yardsticks in identifying anemia inflammation.

**REFERENCES:**

[1] The study was carried out within the framework of topic No. AAAA-A19-11902191049-0

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5109

---

**AB0326 EVALUATION OF BONE DENSITY PARAMETERS IN A CONSORT OF PATIENTS AFFECTED BY RHEUMATOID ARTHRITIS: HOW THERAPY WITH GLUCOCORTICOIDS, METHOTREXATE AND BDMARDS CHANGES BONE MINERAL DENSITY, T-SCORE AND TRABECULAR BONE SCORE**

A. Altimare1, C. Rotondo1, D. Cio1, A. Trotta1, A. Corrado1, F. P. Cantatore1.  
1Azienda Ospedaliero-Universitaria Policlinico Riuniti; Rheumatology Clinic, Foggia, Italy

**Background:** Osteoporosis (OP) can affect patients with Rheumatoid Arthritis (RA). This can be due to long-time use of glucocorticoids (GCS) or to the activation of proinflammatory pattern, via TNFα, that leads to osteoclast (OC) activation with bone resorption.

**Aim of this study:** is to assess how therapy with GCS, methotrexate (MTX) and bDMARDs may change bone density parameters.

**Methods:** 66 RA patients were enrolled in this study. Bone Mineral Density (BMD), T-score of spine and femur, Trabecular Bone Score (TBS) and TBS T-score were evaluated at baseline and after 18 months of treatment with GCS, MTX, bDMARDs. Comparison among different patient groups were evaluated by ANOVA. P-value <0.05 was considered significant.

**Results:** At baseline, 66% of patients were female and 44% male, mean age was 62.2±8.4 years, mean disease duration was 17.8±11.2 years, 76% of patients were Rheumatoid Factor (RF) positive and 24% were RF negative, mean TBS T-score was -2.36±1.42. Among the entire population in study, 24.4% were affected by OP; 78.0% were in therapy with GCS, MTX and 16.6% were under OP treatment with bisphosphonate or teriparatide or denosumab. At baseline, 51.6% of patients started an MTX treatment, 9.3% started an anti-IL6 treatment and 23.4% started a JAKI treatment. By ANOVA analysis, patients at baseline in therapy with MTX had mean L1-L4 BMD and L1-L4 T-score higher than those not in therapy with MTX, respectively 0.985±0.184 g/cm² vs 0.866±0.144 g/cm² (p<0.05) and -0.73±1.70 vs -1.82±1.13 (p<0.05). At 18 months patients treated with MTX had higher L1-L4 T-score than those not in therapy with MTX, respectively -0.48±1.68 vs -1.68±1.18 (p<0.05). Percentage variations in BMD, T-score, TBS and BMD variations between baseline and 18-month endpoint were not significant; nevertheless, we observed a positive trend in lumbar and femur BMD percentage variations in patients treated with JAKI (2.89%), and in TBS percentage variations in patients in TNFi treatment (2.98%).

**Conclusion:** In this study we confirmed the high prevalence of OP in RA-patients. Therapy with MTX seems to prevent bone resorption, but it does not improve bone density parameters. Moreover, we observed a positive trend in JAKI-patients BMD and TNFi-patients TBS percentage variations, even though these data are not statistically significant due to the small sample.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5120
patients than in controls (CI 95% [1.542; 3.436], p<0.001). Plaques were found in both carotid arteries in the 32% of cases and 9.91% of controls. The longer duration of RA was related to a higher presence of carotid plaques (95% [1.015; 1.056], p<0.001). US and blood test results are shown in Table 3. SCORE and Framingham correlated with the CV estimation with US (p<0.001), however, seemed to underestimate the global findings in cases (p<0.001).

Conclusion: Cardiovascular risk calculators such as Framingham and SCORE are useful in RA risk estimation. However, those tools may underestimate the real risk, so carotid US might be valuable.

Disclosure of Interests: None declared


AB0328 ASSESSING THE MULTIMORBID PROFILE (CIRS) IN REFRACTORY RHEUMATOID ARTHRITIS

A. Gordiev1, E. Galushko2, V.A. Nasonova Research Institute of Rheumatology, V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: The World Health Organization assigns cardiovascular diseases, cancers, chronic respiratory diseases, as well as diabetes mellitus and some other nosological entities, including mental and musculoskeletal disorders, to main non-communicable diseases. These are considered to be a major public health challenge of the 21st century. In this case, one patient frequently has a set of several age-related chronic diseases that develop simultaneously or sequentially. The management of these patients requires an integrated approach based on the multimorbidity nature of pathology. Unlike the definition of comorbidities, which assumes to identify the underlying and related diseases, the concept of multimorbidity allows to fail to identify a patient's chronic diseases as equivalent.

Objectives: To assess the presence and nature of multimorbidity in patients with refractory rheumatoid arthritis (RA) and the impact of multimorbidity on disease activity

Methods: The investigation enrolled 153 patients (mean age, 54.8±14.8 years) with RA according to the 2010 ACR/EULAR criteria, who had been examined and treated at the V.A. Nasonova Institute of Rheumatology from 2010-2020. The median disease duration was 5.7 [1.5; 10.5] years; the mean DAS28 score was 5.0±1.3. Documentation and anamnesis data were analyzed with emphasis on associated diseases. The Cumulative Illness Rating Scale (CIRS) was used to assess the profile of multimorbidity.

Results: The patients with RA had a high index of the spectrum of multimorbidity; concomitant diseases were detected in 125 (82%) patients with RA. Their number ranged from 0 to 8 and increased in direct proportion to the age of the patients. The average total score of CIRS was 6.7 ± 3.3 points, the maximum score was 18, the minimum score was 2; The multimorbidity index is 2.5 [1; 6]; the maximum number of categories with a score of ≥2 points is 6, the minimum is 1. The number of concomitant diseases diagnosed in patients with RA before using CIRS was significantly lower (by 52%; p <0.01) than the results of our study showed. Most often, the following disorders were observed in patients at the time of inclusion in the study: comorbid cardiovascular diseases in 44%, anemia in 14.5%, hypercholesterolemia in 18%, obesity in 9.5%, thyroid disease in 11.5% (hypothyroidism criterion – in 3.5%) and diabetes – in 4%. CIRS allowed the first identification of chronic pathology. The results reflect the cautiousness of doctors regarding comorbid cardiovascular diseases in RA: only 4% of patients were diagnosed with hypertension for the first time. At the same time, before inclusion in the study, no patient with RA revealed chronic kidney disease (CKD), which occurred in almost half of the cases (44.5%). On average, every third person had no previous signs of metabolic syndrome (hypercytremia in 29%, obesity in 15.6%) and chronic hypoxia (anemia first diagnosed was verified in 24% of concomitant diseases)

There was a correlation of the quantitative equivalent of multimorbidity with the clinical and laboratory measures of RA activity, including the number of painful joints (r = 0.39; p<0.001), overall patient assessment (r=0.37; p=0.03), physician’s global assessment of disease activity (r = 0.37; p < 0.01), DAS28 (r = 0.42; p<0.001), CDAI (r=0.37; p<0.001), SDAI (r=0.34; p< 0.001), HAQ (r=0.34; p<0.001).

Conclusion: Systematic screening for multimorbidity should be performed in each patient with RA. It is advisable to use CIRS in subsequent studies to assess the prevalence of multimorbidity and its consequences. CIRS allows you to more accurately determine the contribution of each chronic disease or syndrome to the development of multimorbidity disease

REFERENCES:

[1] The studied was carried out within the framework of topic No. AAAA-A19-119021190149-0

Disclosure of Interests: None declared


AB0329 IS THERE A LINK BETWEEN INFLAMMATION AND AN ABNORMAL LIPOPROTEIN PROFILE IN RHEUMATOID ARTHRITIS?

B. Touli1, N. Akasbi2, I. El Harch3, I. El Mezouar4, T. Harzy5,6, HASSAN II UNIVERSITY HOSPITAL, SIDI MOHAMMED BEN ADELLAH UNIVERSITY, FACULTY OF MEDECINE, RHEUMATOLOGY, FEZ, Morocco; HASSAN II University Hospital, SIDI MOHAMMED BEN ADELLAH UNIVERSITY, Faculty of Medicine, RHEUMATOLOGY FES, Morocco; EPIDEMIOLOGY LABORATORY OF SIDI MOHAMMED BEN ADELLAH UNIVERSITY, FACULTY OF MEDECINE, EPIDEMIOLOGY, FES, Morocco

Background: The management of cardiovascular risk in rheumatoid arthritis (RA) is essential and involves the assessment of the blood lipid profile. Studies have shown that patients with active untreated RA, by the presence of a pro-inflammatory state, have a decrease of total cholesterol (TC), HDL cholesterol (HDLc) and LDL cholesterol (LDLc) [1]. The relationship between blood lipids and inflammation is the so-called ‘lipid paradox’ in RA [2].

Objectives: To study the lipoprotein profile of patients with RA and its association with markers of inflammation and disease activity.

Methods: We conducted a cross sectional study among patients with established RA. We analyzed their lipoprotein profile. We further evaluated possible associations between dyslipidemia, disease activity score using the DAS28 and markers of inflammation C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).

Results: A disturbed lipid profile was defined by a Total Cholesterol level (TC) > 5.17 mmol/L or High density lipoproteins (HDLc) < 1.03 mmol/L or Low Density Lipoproteins (LDLc) > 4.13 mmol/L or Triglycerides (TG) ≥ 1.69 mmol/L.

Results: The mean age of the 136 patients included was 55.19±11.84 years, with a female predominance (n=120). Disease duration was 16.27±11.48 years. Mean LDL concentrations were 4.73±0.95 mmol/L for TC, 1.29±0.36 mmol/L for HDLc, 2.87±0.72 mmol/L for LDLc and 1.19±0.54 mmol/L for TG. The inflammatory syndrome was present in 70% of patients. Mean ESR and CRP values were 32.81±22.19 mm at H1 and 26.17±6.17 mg/L.

A significant association was well-defined between the inflammatory syndrome and low concentrations of TC (r = 0.90 vs 0.09; p=0.010) and LDLc (2.74 ± 0.69 vs 3.15 ± 0.85; p=0.007). However, no relationship was found between lipid profile and disease activity.

Conclusion: Although there was no relation between lipid levels and disease activity in our population, inflammation was linked to a decrease in CT and LDLc. Contrary to the general population, this decrease is at high cardiovascular risk joining the lipid paradox theory in RA.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5364
**EXPERIENCE IN THE CURRENT PRACTICE WITH BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE OF THE DONOSTIA UNIVERSITY HOSPITAL**

J. A. Valero Jaime1, A. De Diego Sola1, N. Alcorta Lorenzo2, C. A. Egües Dubuc2, J. M. Belzunegui Otoño2, E. Uriarte Isacelaya2, J. J. Carcilo Fanto2, L. M. Lopez Dominguez2, O. Maiz-Alonso2.1Hospital Bidasoa, Rheumatology, Irún, Spain; 2Donostia University Hospital, Rheumatology, San Sebastian, Spain

**Background:** Baricitinib (BARI) is a selective and reversible oral Janus kinase (JAK) inhibitor for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients with inadequate response or intolerance to one or more antirheumatic drugs disease modifiers (DMARDs). Interstitial lung disease (ILD) is a common extra-joint manifestation of RA. Symptomatic ILD occurs in 5-17% of patients with RA and ILD who are undergoing treatment with BARI, in the Rheumatology Service of the Donostia University Hospital.

**Methods:** A retrospective search was carried out of all patients undergoing BARI treatment until June 2020. The electronic medical records were reviewed. The variables collected were: sex, age, date of diagnosis of RA, history of smoking, presence of erosions, positivity for rheumatoid factor (RF), citrullinated cyclic anti-CCP and previous treatments. Regarding BARI, the dose, the time since the start of treatment, related adverse effects, reason for suspension and other relevant data were collected. Quantitative variables are shown with the median and interquartile range, the qualitative variables are shown with the absolute value and its percentage.

**Results:** 17 patients with RA and ILD treated with BARI were found. Table 1 shows the clinical characteristics, Table 2 shows the treatments and Table 3 shows the respiratory function tests. All patients were positive for RF and anti-CCP, the presence of erosions was observed in 10 (59%), a history of smoking in 8 (47%), the most frequent type of ILD was Usual Interstitial Pneumopathy (UIP) in 7 (41%), at the diagnosis of ILD Abatacept was the most used drug 14 (82%), before the start of BARI, the median FVC 90% (80.5-111), DLCO 63% (51-87), the median time of exposure to BARI was 34 months. To date, 10 (59%) patients continue with BARI and the most frequent cause of suspension was failure.

**Conclusion:** A good persistence of BARI was observed (59%), it also proved to be a safe drug and kept lung function stable in these patients, so BARI can be a therapeutic option in these cases, although more studies are needed to better elucidate these findings.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.269

---

**REDUCED C-REACTIVE PROTEIN LEVEL AT HOSPITAL ADMISSION IN PATIENTS TREATED WITH TOCILIZUMAB IN COMPARISON WITH OTHER ADVANCED ANTIINFAMMATORY TREATMENTS- AN ATTENTION MAY BE REQUIRED**

M. Berman1, S. Berlinger2, N. Bashouti3, O. Elkayam2, T. Ziv-Baran2,1 Tel Aviv Sourasky Medical Center, Department of Rheumatology, Tel Aviv, Israel; 2Tel Aviv Sourasky Medical Center, Internal Medicine E, Tel Aviv, Israel; 3Tel Aviv Sourasky Medical Center, Clinical Pharmacology Unit, Tel Aviv, Israel; 4Sackler Faculty of Medicine, Tel Aviv University, Department of Epidemiology and Preventive Medicine, School of Public Health, Tel Aviv, Israel

**Background:** C-reactive protein (CRP) is a marker of inflammation and infection. The main proinflammatory cytokine that leads to CRP gene expression is IL-6[1]. Different DMARDS may influence CRP levels due to their specific mechanisms of action and alter its usage as an important indicator of acute infection/ inflammation.

**Objectives:** The study aimed to compare CRP level between patients who were treated with Tocilizumab (TCZ), an IL-6 receptor blocker, and other advanced anti-inflammatory treatments (AAT), as well as with other admitted and non-admitted populations.

**Methods:** A cross-sectional study of all patients (≥18 years) hospitalized at tertiary medical center between 12/2009 and 02/2020 and treated before hospitalization with (AAT). Data on background DMARDS treatment was collected and then categorized to one of the two following groups: tocilizumab treatment and other treatments. In further investigation, the other treatments groups were divided into 3 subgroups: anti-TNF subgroup which included Infliximab (IFX), Adalimumab (ADA), etanercept (ETN), Golimumab, and Certolizumab, JAK-inhibitor subgroup which included Tofacitinib and Baricitinib, and another subgroup which included Rituximab, Abatacept and Anakinra. Only the first hospitalization of each patient was included. Women admitted to obstetrics department were excluded. Demographic data, first blood tests results, and comorbidities were collected.

**Results:** The study included 563 patients treated with AAT (2.5% received TCZ). Patients treated with TCZ were older (median 75 vs. 50 years, p<0.001), had higher Charlson score (median 5 vs. 1, p<0.001) and more infectious diseases at admission (50% vs. 23.4%, p=0.05). Patients treated with TCZ had lower CRP levels (median 0.5 mg/l, p<0.001) and more normal common values (64.3% vs. 20.8%, p<0.001) compared to patients treated with other AAT. CRP level in patients treated TCZ (median 0.5mg/l) was lower than that of 58,548 patients admitted to the hospital between 2010-2020 (median 12.55mg/l, p=0.001) and not statistically different from 140 non-admitted randomly selected individuals without acute disease (1.33mg/l, p=0.294).

**Conclusion:** When compared to other anti-inflammatory drugs, tocilizumab is associated with lower CRP levels in individuals admitted to an acute care hospital. This finding must be considered by treating physician to avoid misinterpretation of CRP results.

**REFERENCES:**


**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.422

---

**EVALUATION OF THE RABBIT RISK SCORE IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS NEWLY TREATED WITH BIOLOGIC DMARDS: DATA FROM THE IORRA COHORT**

T. Hiuchi1,2, E. Tanaka1, E. Inoue1, M. Abe1, K. Saka1, E. Sugano1, N. Sugitani1, Y. Shimizu1, M. Ochiai1, R. Yamaguchi1, K. Ikari2,3, Y. Hisashi1,4, M. Harigai1.1Tokyo Women’s Medical University Hospital, Department of Rheumatology, Institute of Rheumatology, Tokyo, Japan; 2Tokyo Women’s Medical University School of Medicine, Division of Multidisciplinary Management of Rheumatic Diseases, Department of Internal Medicine, Tokyo, Japan; 3Tokyo Women’s Medical University Hospital, Department of Orthopedic Surgery, Tokyo, Japan; 4Sanno Medical Center, Rheumatology, Tokyo, Japan

**Background:** Serious infection is one of the most critical adverse events in patients with rheumatoid arthritis (RA) using biologic disease-modifying anti-rheumatic drugs (bDMARDs). During the first year, infections occur more frequently. Therefore, estimating the risk of developing a serious infection is important for the safe use of bDMARDs. The Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk score predicted the incidence rate of serious infection during 1 year in patients with RA taking DMARDs. Moreover, it has been validated using data from various observational cohort studies and nationwide registries with favorable results, with a reported area under the receiver operating characteristic curve (AUROC) of 0.68–0.87. However, the RABBIT risk score has not been validated in RA patients starting a first bDMARD.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.269
SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

P. van Vollenhoven1, S. Hall2, A. F. Wells3, S. Meerwein4, V. Song5, J. Suboticki6, R. M. Fleischmann7, Amsterdam Rheumatology and Immunology Center, Rheumatology and Immunology, Amsterdam, Netherlands

Disclosures of Interests: P. van Vollenhoven: None declared, S. Hall: None declared, A. F. Wells: None declared, S. Meerwein: None declared, V. Song: None declared, J. Suboticki: None declared, R. M. Fleischmann: None declared, Amsterdam Rheumatology and Immunology Center, Rheumatology and Immunology, Amsterdam, Netherlands

Background: Sustained clinical remission (REM) is the primary treatment goal for patients with rheumatoid arthritis (RA), with low disease activity (LDA) being a more appropriate target for treatment-refractory patients.1,2

Objectives: To evaluate the sustainability of response to the JAK inhibitor, upadacitinib (UPA) 15 mg once daily (QD), among patients with prior inadequate response or intolerance to biologic DMARDs.

Methods: Data come from the 12-week, phase 3 randomized, placebo (PBO)-controlled SELECT-BEYOND trial of UPA 15 mg or 30 mg QD in patients with moderate to severe RA on stable background conventional synthetic (cs) DMARDs. Initiation, change, or discontinuation of background RA medications, including ≤2 csDMARDs, was allowed starting at Week 24. Patients completing the 12-week trial were able to enter a long-term extension of up to 5 yrs with all PBO patients switching to UPA.3 This post hoc analysis evaluated REM (CDAI ≤2.8; SDAI ≤3), LDA (CDAI≤10; SDAI≤11), and DAS28(CRP) <2.6(≤3.2) at first occurrence of response before Week 60, as well as at 3, 6, and 12 months following initial response in patients randomly assigned to UPA 15 mg. For those patients who achieved REM/LDA, Kaplan-Meier was used to define the time from when the response was first achieved to the earliest date at which the response was lost at two consecutive visits or discontinuation of study drug. The predictive ability of time to REM/LDA was evaluated using Harrell’s concordance (c)-index (range: 0 to 1, where 0.5 indicates a model that is no better at predicting an outcome than random chance). The date of the last follow up was 16 April 2018, when all patients had reached the Week 60 visit. Non-responder imputation was used for missing data. Only data from the approved 15 mg dosage are reported here.

Results: In patients with active RA despite prior treatment with at least one biDMARD, 34% and 79% of those receiving UPA 15 mg + background csDMARDs achieved CDAI REM or LDA through Week 60, respectively. Sustained CDAI REM was attained by 30%, 26%, and 16% of patients randomized to UPA at 3, 6, and 12 months post initial response, while CDAI LDA was achieved by 68%, 61%, and 50% of patients during the same time points (Figure 1). Time to initial clinical response weakly predicted sustained REM but did not predict sustained LDA, with a c-index (95% CI) of 0.62 (0.49, 0.74) and 0.52 (0.44, 0.61), respectively. Through the last follow-up visit at Week 60, 39/61% of patients on UPA remained in CDAI REM/LDA (Figure 2). Of those who lost CDAI REM, 58% remained in CDAI LDA, and 22% recaptured REM by the cut-off date; 18% of patients who lost CDAI LDA recaptured response. Similar results were observed for REM and LDA based on SDAI and for DAS28(CRP) (<2.6≤3.2).

Conclusion: Among patients with inadequate response or intolerance to biDMARDs, over three-quarters on UPA 15 mg achieved CDAI REM, a relevant therapeutic target for these treatment-refractory patients, and nearly two-thirds of those maintained this response through 60 weeks. Additionally, about one-third of UPA-treated patients attained CDAI REM and maintained that response over 60 weeks.

REFERENCES:


Figure 1. ROC curve of serious infection and RABBIT score with an AUROC of 0.67 (95% CI, 0.52–0.79).

Background: Abatacept (ABA) has demonstrated efficacy and safety in active rheumatoid arthritis (RA) patients in Europe and the United States as one of bDMARDs [1]. However, the clinical activity of Abatacept (ABA) has not been sufficiently investigated in patients with RA from a real-world clinical setting in China. Objectives: This study was designed to investigate the efficacy and safety of Abatacept in the RA patients in Chinese population who were refractory to csDMARDs, aiming to provide further reference for clinical rational drug use. Methods: Clinical data of 55 patients with active RA who were admitted in the Affiliated Hospital of North Sichuan Medical College from June 2020 to June 2021 and did not respond to csDMARDs was retrospectively analyzed. Patients in this study were treated with Abatacept (125mg by subcutaneous injection once weekly combined with csDMARDs). Changes in clinical manifestations, including DAS28-ESR, CDAI, ACR 20/50/70 at week 12 and 24 from baseline and AEs during 24 weeks were observed and recorded. Results: 55 patients (46 women and 9 men) were included in this study with a mean age 50.80 ± 12.46 and a mean disease duration of 6.29 ± 6.22 years. The ACR 20 response at week 12 and 24 was 50.91% (28/55) and 57.27% (48/85), respectively. Besides, DAS 28-ESR score were significantly lower at week 12 and 24 compared to baseline (P = 0.05) with 19 patients (34.55%) achieving clinical remission or low disease activity. Changes in CDAI scores revealed that 80% patients achieved clinical remission or low disease activity at week 24. DAS28-ESR score was significantly lower in previously untreated patients (Biologic-naive) (n=36) (3.40 ± 0.81) than in the previously treated patients (Biologic non-naive) (n=19) (3.83 ± 0.68) (P = 0.02) (Figure 1). RF, CCP antibody and GLOB levels were significantly reduced in RA patients after 24-week ABA treatment compared to baseline (P <0.05) (Table 1). Two hepatitis B virus (HBV) carriers, two patients with active tuberculosis and one patient with latent tuberculosis status showed no reactivation of HBV and no new active tuberculosis lesions 24 weeks after treatment with ABA. AEs were reported in 9.1% (5/55), but no serious infections occurred.

Results: 55 patients (46 women and 9 men) were included in this study with a mean age 50.80 ± 12.46 and a mean disease duration of 6.29 ± 6.22 years. The ACR 20 response at week 12 and 24 was 50.91% (28/55) and 57.27% (48/85), respectively. Besides, DAS 28-ESR score were significantly lower at week 12 and 24 compared to baseline (P = 0.05) with 19 patients (34.55%) achieving clinical remission or low disease activity. Changes in CDAI scores revealed that 80% patients achieved clinical remission or low disease activity at week 24. DAS28-ESR score was significantly lower in previously untreated patients (Biologic-naive) (n=36) (3.40 ± 0.81) than in the previously treated patients (Biologic non-naive) (n=19) (3.83 ± 0.68) (P = 0.02) (Figure 1). RF, CCP antibody and GLOB levels were significantly reduced in RA patients after 24-week ABA treatment compared to baseline (P <0.05) (Table 1). Two hepatitis B virus (HBV) carriers, two patients with active tuberculosis and one patient with latent tuberculosis status showed no reactivation of HBV and no new active tuberculosis lesions 24 weeks after treatment with ABA. AEs were reported in 9.1% (5/55), but no serious infections occurred.

Table 1. Analysis of clinical and serological parameters at baseline and after treatment with Abatacept.

<table>
<thead>
<tr>
<th>Indexes</th>
<th>Baseline</th>
<th>12 weeks</th>
<th>24 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>TJC (0-10cm)</td>
<td>6 (4, 10)</td>
<td>3 (2, 4)</td>
<td>2 (1, 3)</td>
</tr>
<tr>
<td>SJC (0-10cm)</td>
<td>2 (1, 4)</td>
<td>1 (0, 2)</td>
<td>0 (0, 1)</td>
</tr>
<tr>
<td>PGA-VAS  (0-100cm)</td>
<td>8 (7, 10)</td>
<td>5 (6, 6)</td>
<td>2 (2, 3)</td>
</tr>
<tr>
<td>HAQ</td>
<td>2 (0, 4)</td>
<td>1 (0, 2)</td>
<td>0 (0, 1)</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>51 (41, 89)</td>
<td>37 (28, 51)</td>
<td>23 (17, 37)</td>
</tr>
<tr>
<td>HeCRP (mg/L)</td>
<td>14.08 (3.7, 35.0)</td>
<td>5 (7, 22.7, 20.78)</td>
<td>4.12 (1.34, 9.37)</td>
</tr>
<tr>
<td>GLOB</td>
<td>34.47±5.69</td>
<td>30.33±3.81</td>
<td>37.28±2.95</td>
</tr>
<tr>
<td>RF-IgM (U/mL)</td>
<td>408.55 (68.8, 856.6)</td>
<td>-</td>
<td>16741 (34.9, 17125)</td>
</tr>
<tr>
<td>RF-IgG (U/mL)</td>
<td>863 (45, 11)</td>
<td>-</td>
<td>754 (3, 12, 23)</td>
</tr>
<tr>
<td>RF-IA (U/mL)</td>
<td>90.18 (25.63, 99.12)</td>
<td>-</td>
<td>56.70 (16.81, 59.09)</td>
</tr>
<tr>
<td>CCP (U/mL)</td>
<td>1059.45 (66.79, 1033.28)</td>
<td>-</td>
<td>782.0 (58.49, 857.5)</td>
</tr>
</tbody>
</table>

\(p<0.05; TJC\) = Tender joint count, SJC = Swollen joint count, GLOB = Immunoglobulin.

Figure 1. Efficacy of Abatacept at week 12 and week 24. (A) ACR20/50/70 response rate of all patients at week 12 and week 24. (B) DAS28 (ESR) disease activity of patients at baseline, week 12, and week 24; (C) CDAX remission rate of patients at baseline, week 12, week 26. (D) Efficacy of abatacept with biologic-naive and biologic-annex. *P <0.05 compared with week 24.
Background: Biologics, such as tumor necrosis factor inhibitors (TNFi), are highly effective in the treatment of inflammatory arthritis, i.e., rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). The importance of collecting real-world evidence data on switching patients from an originator to a corresponding biosimilar is well recognized in the field (1).

Objectives: The aim of the study was to evaluate the frequency and clinical outcomes of the switch in patients with RA, PsA and axSpA to determine whether a switch could cause a reactivation of the disease.

Methods: We searched electronic patient’s records in four Italian centers for consecutive adult patients treated with TNFi for RA, PsA and axSpA. For these patients, we extracted data on age, gender, age and diagnosis and disease duration, the history of a switch from a TNFi originator to a biosimilar, and swollen joints, tender joints, global health, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP). We calculated composite indices of disease activity, DAS28-ESR, DAS28-CRP, CDAI and SDAI, at baseline, and at 3 and 6 months of follow-up. Response was calculated as the difference between DAS28 at baseline and at 3 or 6 months and stratified into good, moderate, no response according to EURAL response criteria. Chi-square test was used to assess if lower response rates were encountered in the switch versus no-switch groups. The Generalized Linear Regression Model was used to study the outcomes of the switch in patients with RA, PsA and axSpA.

Results: A total of 140 (74%) patients were switched from adalimumab to a biosimilar (TNFi). Among patients who underwent a switch, 25 (19%) and 17 (13%) of patients were defined as good responders, 48 (36%) and 41 (31%) as moderate responders and 61 (46%) and 76 (57%) patients as non-responders, on DAS28-ESR and DAS28-CRP, respectively. At 3 months after the switch, 25 (19%) and 17 (13%) of patients were defined as good responders, 48 (36%) and 41 (31%) as moderate responders and 61 (46%) and 76 (57%) patients as non-responders, on DAS28-ESR and DAS28-CRP, respectively. At 3 months, 28 (24%) and 22 (18%) of patients had a good response, 29 (25%) and 32 (28%) – a moderate response and 59 (51%) and 62 (53%) patients did not respond, on DAS28-ESR and DAS28-CRP (Figure 1), respectively. The results of the Chi-squared test indicated no difference in the frequency of good/ moderate/no response at 3 and 6 months on DAS28-ESR and DAS28-CRP between patients switched and not. There was a significant association between age and DAS28-ESR/CRP response at 6 months (p<0.001 and p=0.025) respectively.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1198
AB0337
BASELINE C-REACTIVE PROTEIN PREDICTS ADHERENCE TO ADALIMUMAB THERAPY AT 3 MONTHS IN AN OBSERVATIONAL COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS

A. W. Ramli1,2, N. Nair1, K. Hyrich1, J. Isaacs1, A. Morgan1,2, D. Plant1,4, A. G. Wilson4, A. Barton1,10, T. The University of Manchester, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester, United Kingdom; 2Wrightington Hospital, Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Department of Rheumatology, Wigan, United Kingdom; 3The University of Manchester, Versus Arthritis Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester, United Kingdom; 4Manchester University NHS Foundation Trust, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom; 5The University of Manchester, Versus Arthritis Centre for Epidemiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom; 6Newcastle upon Tyne Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Datorerate, Newcastle upon Tyne, United Kingdom; 7University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; 9University College Dublin, UCD School of Medicine and Medical Science, Conway Institute, Dublin, Ireland; 10Manchester Royal Infirmary, Manchester University NHS Foundation Trust, The Kellgren Centre for Rheumatology, Manchester, United Kingdom

Background: Adherence to biologic treatment in rheumatoid arthritis (RA) is often self-reported and little is known about the predictors of adherence to biologic medications. Many studies have reported the predictors of adherence to be linked to psychological factors including beliefs in medication necessity and absence of low mood. Disease activity was also found to be a significant predictor of adherence from this study. It is unknown whether similar factors will predict adherence in an established cohort of patients with RA starting biologic therapy.

Objectives: To investigate levels of self-reported adherence to adalimumab treatment and identify the contribution of demographic, physical and psychological factors to medication adherence in an RA cohort.

Methods: Patients with RA, who were commencing on adalimumab were recruited through the Biologics in Rheumatoid Arthritis Genomics and Genetics Study Syndicate (BRAGGSS), a large UK multicentre prospective observational cohort study. Demographics, baseline clinical and psychological measures including illness and medication beliefs were collected. Self-reported adherence, defined as the patient has never stopped, altered, missed, forgot to take, or took a lower dose than prescribed of adalimumab, were recorded at 3 months. Potentially baseline predictors of adherence to adalimumab therapy were determined using logistic regression analyses.

Results: 202 patients were included; 76% female, median (IQR): age 59 (52-67) years, pre-treatment DAS28-CRP score 5.6 (5.1-6.1) and disease duration 5 (2-15) years. During the first 3 months following commencement of adalimumab, 17% (17/101) patients were non-adherent. Univariable analyses found that high baseline C-reactive protein (CRP) [odds ratio (OR) 1.04 per mg/L, 95% CI 1.01, 1.09] was associated with adherence to adalimumab at 3 months. However, there were no associations identified from the psychological variables and this includes perceived necessity towards medication [OR 0.92, 95% CI 0.79, 1.05], hospital depression score [OR 0.94, 95% CI 0.84, 1.06] and hospital anxiety score [OR 0.97, 95% CI 0.88, 1.08].

Conclusion: These findings suggest that the psychological measures were less able to predict adherence to adalimumab therapy. The high percentage of adherence during the first three months of therapy may limit power to detect small effects in this cohort. Further research to investigate whether psychological variables correlate with drug levels as an alternative surrogate for adherence and to consider including other biological agents with a longer follow-up timeline are needed.

High baseline CRP levels were associated with adherence. This finding suggests active disease with higher levels of inflammation in RA may be a factor for adherence in patients who are commencing biologic therapy.

REFERENCES:

Disclosure of Interests: Adian Wafi Ramli: None declared, Nisha Nair: None declared, Kimme Hyrich Consultant of: AbbVie, Grant/research support from: Pfizer, BMS, John Isaacs Speakers bureau: Abbvie, Galilea, Roche, UCB, Grant/ research support from: Gilead, Janus, Pfizer, Amo Morgan Speakers bureau: Roche/Chugui, Consultant of: GSK, Roche, Chugui, Astra Zeneca, Regeneron, Sanofi, Vitor, Grant/research support from: Roche, Kiniksa Pharmaceuticals. Darren Plant: None declared. Anthony G Wilson: None declared, Anne Barton Grant/research support from: I have received grant funding from Pfizer, Galapagos, Scipher Medicine and Bristol Myers Squibb.


AB0338
BELIEFS ABOUT BIOLOGIC DRUGS AMONG RHEUMATOID ARTHRITIS PATIENTS

E. Hannech1,2, S. Boussaid3, S. Rekik1,2, S. Rahmouni1,2, S. Jemmali1,2, H. Ajami1, H. Sahli1,2, M. Elleuch2, R. Dharrar2, I. Gharsallah3,4, 1Rheumatology Department, La Rabta Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia; 3Rheumatology Department, Military Hospital of Tunis, Tunis, Tunisia

Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease requiring a long-term follow-up and the use of chronic therapies. The management of this disease is based on a multidisciplinary care, requiring total patient involvement. Previous personal experiences, the experiences of others and the daily impact of the disease on patients fuel their perceptions of the treatment especially biologic one. There are few studies evaluating patient’s beliefs about these drugs [1,2].

Objectives: The aim of our study was to investigate beliefs about biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) among patients with RA and to identify factors related to specific beliefs.

Methods: We conducted a bi-centric cross-sectional study, including patients with RA fulfilling the ACR/EULAR 2010 criteria. All patients were on bDMARDs associated or no to conventional synthetic (sc) DMARDs. Sociodemographic, clinical, biologic, and therapeutic data were collected. Patients were interviewed about their medication beliefs using the Beliefs about Medicines Questionnaire (BMQ).

Results: There were 75 RA patients: 60 female (80%) and 15 males (20%). The sex ratio was about 2.5. The mean age was 56.92 ± 9.06 years [34-80]. Thirty-three percent of patients were illiterate. Twenty patients were employed. Sixty-four patients (85.3%) were married. The mean disease duration was 14.85 ± 8.5 years [2-39]. Thirty-three patients had joint deformities. Twenty-seven patients had extra-articular manifestations and thirty-six patients had comorbidities. The mean disease activity scale (DAS28 CRP) was 3.94 ± 1.32 [1.21-7.15]. Fifteen patients (20%) had high disease activity, 11% had low disease activity, and 19% were in remission. The mean functional impairment scale (HAQ) was 0.64 ± 0.48 [0-2.2]. Twelve patients had moderate to severe disability and only one patient had severe disability. The mean duration of the current bDMARD was 37.17 ± 39.44 months and the mean rank of the current biotherapy was 1.41 ± 0.9 [1-5]. According to the BMQ, the mean score for General Overuse was 14 ± 2.37 [6-20]. The mean score for General Harm was 10.82 ± 4.42 [2-20]. The mean score of patients’ specific beliefs regarding the necessity of taking the current bDMARD (Specific Necessity) was 20.62 ± 5.71 [5-25]. The mean Specific Concerns score regarding the current bDMARD was 10.33 ± 3.29 [5-25]. Necessity about taking bDMARD was reported by 77.3% patients in the present and 61.3% patients consider maintaining the bDMARD in the future. There were 4% of patients who reported concerns about taking bDMARD. Twenty-four percent of patients reported concerns about long term effects, and 16% about becoming too dependent on bDMARD.

Beliefs about the necessity to stop occasionally chronic therapies were reported by 13.3% of patients.

Specific necessity was correlated to the current bDMARD duration (p<0.01), Patient Global Evaluation (p=0.03), VAS pain scale (p<0.01), the number of nocturnal awakenings (p<0.01), tender joint count (p<0.01), swollen joint count (p<0.01), HAQ (p=0.005), DAS28 (CRP) (p<0.01). Specific concerns were correlated to the actual bDMARD rank (p<0.01).

Conclusion: Our study showed stronger beliefs in the necessity of taking biologic drugs if indicated. Disease activity parameters and functional impairment influence those beliefs. Further studies are required to evaluate the impact of beliefs on biologic drug adherence.

REFERENCES:
The study demonstrated that efficacy of CT-P13 is equivalent to that of China-approved INX. Also, the PK and safety profiles of CT-P13 were comparable to those of China-approved INX. No loss of efficacy or difference in safety or immunogenicity was observed after switching from China-approved INX to CT-P13 at Week 30.

Conclusion: The purpose of this study was to demonstrate equivalence of efficacy and compare PK and safety profiles of CT-P13 and China-approved INX.

Methods: In this randomized, double blinded, multicenter, parallel-group, phase III study, patients with active RA who had been responding inadequately to methotrexate for at least 3 months, were randomized to receive either CT-P13 or China-approved INX. Patients were treated with doses of 3 mg/kg at Weeks 0, 2, 6, then every 8 weeks up to Week 54. Prior to dosing, patients were treated with doses of either CT-P13 or China-approved INX. Patients were treated with doses of 3 mg/kg at Weeks 0, 2, 6, then every 8 weeks up to Week 54. Prior to dosing, patients were treated with doses of either CT-P13 or China-approved INX. Changes in health status, safety, and immunogenicity were compared between the groups.

Results: A total of 1,088 patients were randomized in a 1:1 ratio (544 patients assigned to each group). The primary endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6. A total of 544 patients were randomized in a 1:1 ratio (272 patients assigned to each group). The primary endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6. The primary efficacy endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6. Results: 270 patients were randomly assigned to 2 treatment groups in a 1:1 ratio (136 and 134 patients in the CT-P13 and China-approved INX groups, respectively) and 184 patients completed the study. The least square mean change (standard error) of DAS28 (CRP) from baseline to Week 14 was similar between the groups. The primary endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6. The primary endpoint was change in DAS28 (CRP) from baseline to Week 14, which was analyzed using an analysis of covariance. Equivalence was determined if the 90% CI for the estimate of treatment difference was entirely contained within the predefined equivalence margin of -0.6 to 0.6.
(CRP, MMP-3), disease activity (Simplified Disease Activity Index; SDAI), physical function (Health Assessment Questionnaire; HAQ), and joint destruction (modified Total Sharp Score; mTSS) at baseline and 1-year follow-up.

Results: There were 9 patients in PD≥2/ET+ group and 31 patients in PD<2 group. PD≥2/ET+ group had significantly higher SDAI (p=0.027), MMP-3 (p=0.005), and PD (p=0.001) at baseline compared with PD<2 group, but their MMP-3 (p=0.019) and PD (p=0.042) were significantly decreased over 1 year. PD≥2/ET+ group had joint destruction before ET (p=0.022), but it was suppressed after ET and there was no significance in change in mTSS compared with PD<2 group (p=0.099) (Figure 1).

Figure 1. Disease activity ultrasound assessment and radiographic change from baseline (BL) to 1-year follow-up in RA patients with residual synovitis who had enhanced treatment (PD≥2/ET+) and those without active synovitis (PD<2). "Each parameter at BL and 1-year was statistically analyzed by Wilcoxin signed rank test only in PD≥2/ET+ group." Difference in multiple switching from biosimilars. The current evidence on the safety, efficacy, and immunogenicity of switching multiple times from a biosimilar to another biosimilar comes from a limited number of randomized-controlled trials and real world evidence studies.

Objectives: The aim of our work was to evaluate the disease activity trend after multiple switching from ADA originator-Humira (oADA) to its biosimilars (bsADA; ABP 501 and SB5 subsequently) in a cohort of inflammatory arthritis patients.

Methods: In this real-life study, we selected patients with clinical diagnosis of rheumatoid Arthritis (RA), psoriatic Arthritis (PsA) and ankylosing spondylitis (AS). Patients had been previously treated with oADA and switched to the bsADA (first ABP 501 and then SB5). At each outpatient visit, we recorded demographic features (age, sex, and time since diagnosis) and the following disease activity measures: DAS28, DAPSA, BASDAI and the HAQ. Rheumatoid factor (RF), anti-citrullinated protein antibody (ACPA), C-reactive protein (CRP) and HLAB27 were also measured over the observational period (visits 0, 12, 24 and 36 months). The disease activity was evaluated during the year before the introduction of the bsADA, and then evaluated in the following 36 months during the first and the second bsADA treatment. We also examined whether some baseline characteristics, such as the duration of ADA treatment, comitant therapy, comorbid disease and baseline disease activity, could influence the bsADA discontinuation.

Results: We evaluated the 3-year drug survival and efficacy of the multiple switch of bsADA in RA, PsA and AS patients, previously treated with oADA in 127 patients (Table 1). All the patients enrolled underwent a first switch lasting one year and then a second switch with a follow up of one year too. The 1-year retention rate for ABP501 was 84.4%, 78% and 77.5% in AS, RA and PsA patients, respectively. The 1-year retention rate for SB5 was 82.1%, 78.7% and 77.5% in AS, RA and PsA patients, respectively. Disease activity, as measured by DAS28, DAPSA and BASDAI remained stable over the 3 years (Figure 1).

Table 1. Baseline characteristics of RA, PsA and AS patients

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total cohort</th>
<th>RA N=41</th>
<th>PsA N=52</th>
<th>AS N=34</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (female)</td>
<td>75 (60%)</td>
<td>35 (85)</td>
<td>31 (69)</td>
<td>9 (26)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>61.7±12.78</td>
<td>60.5±12.64</td>
<td>61.5±11.65</td>
<td>56.3±10.71</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>15.8±6.49</td>
<td>17.2±3.16</td>
<td>10.4±6.57</td>
<td>14.9±5.90</td>
</tr>
<tr>
<td>Combodities (%)</td>
<td>17.8 (14)</td>
<td>5.7 (14)</td>
<td>8.2 (18)</td>
<td>2 (6)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>1.65±2.27</td>
<td>2.31±1.10</td>
<td>0.42±0.27</td>
<td>1.36±1.91</td>
</tr>
<tr>
<td>HAQ</td>
<td>2.65±0.75</td>
<td>2.65±0.75</td>
<td>8.25±3.69</td>
<td></td>
</tr>
<tr>
<td>BASDAI</td>
<td>-</td>
<td>-</td>
<td>3.23±1.58</td>
<td></td>
</tr>
<tr>
<td>DAS28</td>
<td>-</td>
<td>-</td>
<td>0.73±0.57</td>
<td>0.72±0.55</td>
</tr>
<tr>
<td>DAPSA</td>
<td>-</td>
<td>-</td>
<td>0.73±0.52</td>
<td>0.72±0.52</td>
</tr>
<tr>
<td>MMP-3 (mTSS)</td>
<td>-</td>
<td>-</td>
<td>0.76±0.69</td>
<td></td>
</tr>
<tr>
<td>ACPA+ (%)</td>
<td>46 (36)</td>
<td>23 (55)</td>
<td>20 (44)</td>
<td>3 (13)</td>
</tr>
<tr>
<td>RF+ (%)</td>
<td>24 (62.5)</td>
<td>24 (62.5)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HLAB27+ (%)</td>
<td>8 (15)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.73±0.57</td>
<td>0.72±0.55</td>
<td>0.73±0.52</td>
<td>0.76±0.69</td>
</tr>
<tr>
<td>Prednisone (%)</td>
<td>46 (36)</td>
<td>23 (55)</td>
<td>20 (44)</td>
<td>3 (13)</td>
</tr>
<tr>
<td>Combo Therapy</td>
<td>65 (51)</td>
<td>29 (68)</td>
<td>25 (48)</td>
<td>11 (32)</td>
</tr>
<tr>
<td>ADA duration (months)</td>
<td>49.7±4.05</td>
<td>56.4±4.12</td>
<td>25.0±3.17</td>
<td>26.9±3.17</td>
</tr>
<tr>
<td>ABP501 duration (months)</td>
<td>12.4±2.41</td>
<td>12.7±2.34</td>
<td>12.8±2.14</td>
<td>12.4±2.95</td>
</tr>
<tr>
<td>SB501 duration (months)</td>
<td>11.5±2.14</td>
<td>12.4±1.74</td>
<td>12.7±2.14</td>
<td>12.4±1.95</td>
</tr>
</tbody>
</table>

ABP501 (Adalimumab biosimilar, Amgeniva), SB501 (Adalimumab biosimilar, Imralid)

Conclusion: No difference was found between oADA and bsADA in terms of efficacy. This real-life study confirms the similar efficacy profile of multiple switch bsADA with long-term retention and a good safety profile in inflammatory arthritis patients.

REFERENCES:
EVALUATION OF SELF-CARE SAFETY SKILLS AND THERAPEUTIC KNOWLEDGE OF RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGIC DRUGS

E. Hannech1,2, S. Bousaïd1,2, D. Rekik1,2, S. Jemmali1,2, S. Rahmouni1,2, H. Sahli1,2, M. Elleuch2, R. Dharbi1,2, H. Gharsallah1,2,3,4 Rheumatology Department, La Rabta Hospital, Tunis, Tunisia; 5Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia; 6Rheumatology Department, Military Hospital of Tunis, Tunis, Tunisia

Background: The management of rheumatoid arthritis (RA) was revolutionized by the use of biologic therapies (bDMARD). Nevertheless, bDMARDs may carry some specific risks such as infection. However, data about self-care safety skills are poor [1]. An assessment of the level of information and education is therefore essential for patients followed for RA.

Objectives: The purpose of our study was to assess knowledge and safety skills of RA patients under bDMARDs.

Methods: We conducted a descriptive, bi-centric, and cross-sectional study, including RA patients receiving intravenous (IV) or subcutaneous (SC) bDMARD for at least 3 months. Sociodemographic, clinical, and paraclinical data were collected. Knowledge and self-care safety skills were assessed by a pre-specified questionnaire.

The questionnaire was divided into three domains:
- Five questions about general theoretical knowledge domain: assessing patient’s knowledge of the name of the current bDMARD, duration and rate of intake, and a question on annual cost estimation.
- Three questions about the current bDMARD management: assessing cold chain compliance and management of the biologic in SC emphasizing adherence to the steps to be taken prior to giving the injection.
- Tow questions about knowledge regarding safety skills in special situations: infection, cough, contraception, surgery, vaccination, and regarding the need to inform others about the use of the bDMARD.

Based on the data analysis, patients were divided into 3 groups according to their knowledge level:
- Group A (low knowledge level: percentage of correct answers <40%)
- Group B (moderate knowledge level: percentage of correct answers >40% and <60%)
- Group C (high level of knowledge: percentage of correct answers > 60%).

Results: Seventy-five patients with RA were collected. Their mean age was 56.92 ± 9.06 years (34-80). The mean duration of bDMARD was 37.17 ± 39.44 months (4-248) with a mean rank of 1.41 ± 0.9 [1-5]. The SC route was used in 41 patients (54.7%) followed by the IV route in 34 patients (45.3%).

The most prescribed molecules were Infliximab, Certolizumab and Tocilizumab (22.7% respectively). The average order of the current biologics was 1.41 ± 0.9 [1-5] in combination with a csDMARD in 48 patients (64%).

Safety skills were low in 24 patients (32%), moderate in 36 patients (48%), and high in 15 patients (20%).

The mean percentage of correct answers for each domain was respectively: 56.53 ± 18.4% [20-100] for general theoretical knowledge domain, 68.44 ± 26.21% [0-100] for the management of current biologic treatment domain, and 40.8 ± 16.67% [6.67-80] for knowledge regarding safety skills in special situations.

Safety skills levels were significantly related to occupational status (p<0.001), DAS28 CRP (p=0.04), joint deformities (p=0.01) and radiographic erosions (p=0.006), number of previous bDMARDs (p=0.009), and the rank of the current bDMARD (p=0.009).

Conclusion: The major finding of our study was the insufficient level of knowledge and safety skills of RA patients under bDMARDs. We highlighted the importance of involving patients in the decision-making process and emphasize the necessity of involving patients in the decision-making process and emphasizing adherence to the steps to be taken prior to giving the injection.

REFERENCE:

Disclosure of Interests: None declared

Background: Subcutaneous (SC) CT-P13 is the first and only subcutaneous formulation of infliximab (IFX) approved by the EMA. In the pivotal study (NCT03147248), non-inferiority of SC IFX to intravenous (IV) was demonstrated in rheumatoid arthritis (RA) patients using 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) improvement at Week 22, with a statistically significant treatment difference of 0.27 (95% CI 0.02, 0.52) favoring the SC versus the IV arm.\(^2\) At Week 30, numerical differences in efficacy outcomes were shown between SC and IV IFX favoring SC IFX. IV group patients switched to SC IFX by Week 30, and the difference between the groups was reduced at Week 54.\(^2\)

Objectives: To investigate whether there was a statistically significant difference between SC and IV IFX at Weeks 30 and 54 in the phase 3 pivotal study of CT-P13 SC using conservative missing imputation methods.

Methods: With active RA who had an inadequate response to MTX received IV IFX 3mg/kg at Weeks 0 and 2 for induction and were randomized to a 1:1 ratio to receive SC IFX 120mg every 2 weeks or IV 3mg/kg every 8 weeks thereafter for maintenance. Patients who were randomized to receive IV IFX switched to SC at Week 30. In this post-hoc analysis, non-responder imputation (NRI) and last observation carried forward (LOCF) methods were used to investigate whether the difference in efficacy outcomes between SC and IV IFX at Weeks 30 and 54 was statistically significant. Assessments included EULAR (CRP/ESR)/ACR response; remission rate and low disease activity (LDA) rate based on DAS28 (CRP/ESR), Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI); Boolean remission rate; and the proportion of patients achieving a minimal clinically important difference (MCID) in Health Assessment Questionnaire (HAQ).

Results: Of the 343 randomized patients, 165 patients who received SC IFX and 174 patients who received IV IFX from the efficacy population were included in the analysis. There was a statistically significant difference in SC IFX compared to IV treated patients at Week 30 using both NRI and LOCF methods in almost all the clinical variables. However, the difference in efficacy outcomes between SC IFX and IV was reduced at Week 54 after the IV group switched to SC. This supports the improved efficacy of SC IFX at Week 30 in patients with RA. Between-group differences were reduced at Week 54, suggesting improved responses after switching from IV to SC.

Conclusion: Statistical analyses using conservative missing imputation methods showed significantly greater improvements in clinical outcomes with SC IFX compared to IV at Week 30 in patients with RA. Between-group differences were reduced at Week 54, suggesting improved responses after switching from IV to SC.

REFERENCES:


AB0345 THERAPEUTIC DRUG LEVELS TO ACHIEVE GOOD EULAR RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADAлимУMAB: RESULTS FROM THE BIOLOGICS IN RHEUMATOID ARTHRITIS GENETICS AND GENOMICS STUDY SYNDICATE (BRAGGSS) COHORT

R. M. Hum\(^1,2,3,\) P. Ho\(^1,2,3,\) N. Nair\(^3,\) D. Plant\(^3,\) A. Morgan\(^4,\) J. Isaacs\(^4,\) A. G. Wilson\(^4,\) K. Hyrich\(^1,2,3\) on behalf of BRAGGSS. \(^1\)Manchester University NHS Foundation Trust, The Kellgren Centre for Rheumatology, Manchester, United Kingdom; \(^2\)The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom; \(^3\)The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; \(^4\)University of Leeds, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; \(^5\)Newcastle University, NIHR Newcastle Biomedical Research Centre, Newcastle, United Kingdom; \(^6\)University College Dublin Centre for Arthritis Research, Conway Institute, Dublin, Ireland

Background: Rheumatoid arthritis (RA) is a systemic inflammatory disease often treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) such as Adalimumab (ADL), a tumour-necrosis factor inhibitor (TNFi). However, it is known that about a third of patients do not respond to ADL treatment. Previous studies have reported associations between poor response, decreased serum drug levels (SDLs) and poor adherence, but a therapeutic SDL has not been defined or applied in clinical practice.

Objectives: To assess median ADL SDLs in RA European Alliance of Associations for Rheumatology (EULAR) good vs non/moderate responders, and to determine cut-off SDLs associated with a “Good” response in fully adherent RA patients.

Methods: In a prospective observational cohort study, patients with RA were treated with ADL at baseline. 3-, 6-, and 12-months patients had 4-component DAS28 scores, self-reported treatment adherence data and SDLs measured. Median drug levels and receiver-operator characteristics (ROC) curves were used to compare SDLs between responders and non-responders, and to establish cut-off SDLs in
self-reported fully adherent patients. Serum drug levels were measured using a sandwich ELISA produced by Progenika Biopharma. Patients were considered fully adherent if they self-reported never having altered, forgotten or omitted any dose of their biologic drug at follow-up. Between group comparisons were assessed using Fisher’s exact test, with a threshold for significance set at p<0.05. Statistical analyses were performed in R Version 4.1.0 and RStudio Version 1.4.1106.

**Results:** A total of 283 RA patients taking ADL were included in the analysis. Baseline characteristics are shown in Table 1. Of these patients 93 (32.9%) self-reported being fully adherent to treatment at 3 months follow-up and had SDLs measured.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n</th>
<th>Missing (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at baseline, median years (IQR)</td>
<td>58 (51, 64)</td>
<td>0</td>
</tr>
<tr>
<td>Disease duration, median years (IQR)</td>
<td>7 (3, 16)</td>
<td>0</td>
</tr>
<tr>
<td>Female Sex, n (%)</td>
<td>206 (73)</td>
<td>0</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>27.4 (23.7, 31.9)</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>132 (46)</td>
<td>0</td>
</tr>
<tr>
<td>Baseline DAS Score, median (IQR)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>No concurrent DMARD(s)</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>No (%)</td>
<td>34 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>132 (46)</td>
<td>0</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>27.4 (23.7, 31.9)</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>132 (46)</td>
<td>0</td>
</tr>
<tr>
<td>Baseline DAS Score, median (IQR)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>On concurrent DMARD(s)</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>No (%)</td>
<td>34 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>132 (46)</td>
<td>0</td>
</tr>
<tr>
<td>Baseline DAS Score, median (IQR)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>On concurrent DMARD(s)</td>
<td>1 (0.4)</td>
<td>0</td>
</tr>
<tr>
<td>No (%)</td>
<td>34 (12)</td>
<td>0</td>
</tr>
<tr>
<td>Yes (%)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
<tr>
<td>Smoking Status</td>
<td>132 (46)</td>
<td>0</td>
</tr>
<tr>
<td>Baseline DAS Score, median (IQR)</td>
<td>248 (88)</td>
<td>0</td>
</tr>
</tbody>
</table>

**Discriminatory utility:**

ROC analysis (see Figure 1) reported a 3-month non-trough ADL SDL cut-off of 7.5mg/L in fully adherent RA patients which discriminated Good EULAR responders, median SDL at 3 months was 9.014 (IQR 6.96 to 11.1). The ROC curve analysis: EULAR non/moderate vs good responders with 3 month ADL SDLs.

**Figure 1.** ROC curve analysis: EULAR non/moderate vs good responders with 3 month ADL SDLs.

**Conclusion:** In keeping with previous work, SDLs were higher in adherent compared with non-adherent patients, but this is the first study to demonstrate that SDLs are higher in fully adherent good EULAR responders compared with non/ moderate responders. Based on our methods, cut-offs of 7.5mg/L for ADL may be useful targets in clinical practice to achieve good EULAR response.

**References:**


**Disclosure of Interests:** None declared

**AB0346 REASONS FOR DISCONTINUATION OF TNF INHIBITORS IN PATIENTS WITH DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS ACCORDING TO DRUG HISTORY**

**E. Matianova1, A. Gordeev1, E. Galushko1, V.A. Nasonova Rheumatology Research Institute, Rheumatoid Arthritis Evolution Laboratory, Moscow, Russian Federation**

**Background:** TNF-alpha inhibitors (TNFi) are considered the drugs of choice for initiating biological therapy in rheumatoid arthritis (RA). Review of the reasons for their cancellation is included in a comprehensive study of the group of patients (pts) with Difficult to Treat RA (D2T).

**Objectives:** To make a comparative assessment of the reasons for discontinuation of TNFi in pts meeting the international EULAR (2021) criteria for D2T, comparing them with other pts who had experience in taking a biological disease modifying antirheumatic drugs (bDMARDs)/targeted synthetic DMARDs (tsDMARDs).

**Methods:** We analyzed the drug history of 505 pts with RA who were hospitalized at the V.A.Nasonova Research Institute of Rheumatology hospital from January to December 2021 (inclusive) due to an RA exacerbation, and who were approved for the introduction of bDMARD/tsDMARD. Pts with no prior experience with bDMARD/tsDMARD were excluded from the analysis (n=179/35.4%). Pts meeting the EULAR criteria for D2T (the main of which: failure of two or more bDMARDs/tsDMARDs of different mechanisms of action) were allocated to the D2T group (n=35/6.9%), the rest of the pts made up the control group C (n=291/57.6%). The middle age (±SD) of patients in D2T was less than in C (D2T - 46.3±15.1 years vs. C - 51.6±14.8 years, p=0.047), the duration of RA in the groups was comparable (D2T - 15.7±10.7 years vs. C - 13.1±8.9 years, p=0.05).

**Results:** The frequency of prescribing a history of TNFi in D2T (85.7%) was higher than in C (38.5%; OR=2.9 [1.3-6.6]; p=0.001). The total duration of their intake (in cases of prescription) and the average number of TNFi drugs in the groups were comparable (p> 0.05), but in D2T pts more often had the experience of taking 3 or more TNFi (OR = 6.4 [2.0-20.4]; p=0.002) (Table 1).

**Table 1. Reasons for discontinuation of TNFi in study groups (n%)**

<table>
<thead>
<tr>
<th>Group</th>
<th>Reas for discontinuation of TNFi (n%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pts taking TNFi in anamnesis, n/%</td>
</tr>
<tr>
<td></td>
<td>Total duration of taking TNFi, Me/SD, Me</td>
</tr>
<tr>
<td></td>
<td>Pts taking 3 or more TNFi, n/%</td>
</tr>
<tr>
<td></td>
<td>Cancellation for administrative reasons, n/%</td>
</tr>
<tr>
<td></td>
<td>Adverse reactions, n/%</td>
</tr>
<tr>
<td></td>
<td>insufficiency Total</td>
</tr>
<tr>
<td></td>
<td>Secondary non-responsiveness to TNFi</td>
</tr>
<tr>
<td></td>
<td>Gradual fading effect</td>
</tr>
<tr>
<td></td>
<td>After the break</td>
</tr>
<tr>
<td></td>
<td>After changing to generic</td>
</tr>
<tr>
<td>D2T (n=35)</td>
<td>30/85.7/112/38.5 &lt;0.0001; OR=9.6 [3.6-25.4]</td>
</tr>
<tr>
<td>Total duration of taking TNFi, Me/SD, Me</td>
<td>22.8±22.5, 23.2±25.7 * &gt;0.05</td>
</tr>
<tr>
<td>Pts taking 3 or more TNFi, n/%</td>
<td>8/26.7, 6/5.4 0.002; OR=6.4 [2.0-20.4]</td>
</tr>
<tr>
<td>Cancellation for administrative reasons, n/%</td>
<td>2/6.7, 37/33 0.004 [1.6-6.6]</td>
</tr>
<tr>
<td>Adverse reactions, n/%</td>
<td>9/30, 23/20.5 * &gt;0.05</td>
</tr>
<tr>
<td>insufficiency Total</td>
<td>28/93.3, 49/43.8 &lt;0.001 [1.6-6.6]</td>
</tr>
<tr>
<td>Secondary non-responsiveness to TNFi</td>
<td>17/56.7, 35/31.3 0.01; OR=2.9 [1.3-6.6]</td>
</tr>
<tr>
<td>Gradual fading effect</td>
<td>7/41.2, 22/62.9 * &gt;0.05</td>
</tr>
<tr>
<td>After the break</td>
<td>9/32.6, 7/20.0 0.02; OR=4.5 [1.3-15.9]</td>
</tr>
<tr>
<td>After changing to generic</td>
<td>1/5.9, 7/20.0 &gt;0.05</td>
</tr>
</tbody>
</table>

**Table 1. Reasons for discontinuation of TNFi in study groups (n%)**

**D2T (n=35) C (n=291) p**

<table>
<thead>
<tr>
<th>Reas for discontinuation of TNFi (n%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pts taking TNFi in anamnesis, n/%</td>
</tr>
<tr>
<td>Total duration of taking TNFi, Me/SD, Me</td>
</tr>
<tr>
<td>Pts taking 3 or more TNFi, n/%</td>
</tr>
<tr>
<td>Cancellation for administrative reasons, n/%</td>
</tr>
<tr>
<td>Adverse reactions, n/%</td>
</tr>
<tr>
<td>insufficiency Total</td>
</tr>
<tr>
<td>Secondary non-responsiveness to TNFi</td>
</tr>
<tr>
<td>Gradual fading effect</td>
</tr>
<tr>
<td>After the break</td>
</tr>
<tr>
<td>After changing to generic</td>
</tr>
</tbody>
</table>

*the percentage is calculated from the number of pts who took TNFi

**Withdrawal of TNFi due to their ineffectiveness was more often performed in D2T (93.3%/n=28) than in C (43.8%/n=49; OR=18 [4.1-79.3];p<0.0001). At the same time, secondary non-responsiveness (NR) prevailed in D2T - in 56.7% (17 of 28 cases of NR), which is more often in C (31.3% / 35 of 49 cases of NR; OR = 18 [4.1-79.3]; p<0.0001). Secondary NR in D2T in 59.9% of pts (9 of 17 cases of secondary NR) developed after the break for administrative reasons in taking a previously effective drug, which is significantly more common than in C (20%/7 of 35 cases of secondary NR; OR = 4.5 [1.3-15.9]; p=0.02). Withdrawal of TNFi for administrative reasons was more common in C (33%/n=57 vs. in D2T -6.7%/n=2; OR=6.9 [1.6-36.6]; p = 0.004). The incidence of adverse reactions in both groups was comparable (in D2T 30%/n=9 vs. in C -20.5%/n=23; p=0.05).
**AB0347** TREATMENT RESPONSE WITH ABATACEPT PLUS METHOTREXATE TREATMENT FOR RHEUMATOID ARTHRITIS: REAL-WORLD EVIDENCE FROM THE UK

E. Choy1, S. Henning2,3, M. Brazilt, K. Pollock5, L. Groves6, D. Sugrue6, J. Houghton1. 1Cardiff University, CREATE Centre, Cardiff University School of Medicine, Cardiff, United Kingdom; 2UCL School of Pharmacy, University College London, London, United Kingdom; 3Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom

**Background:** A previous real-world study has reported the characteristics, treatment patterns and clinical outcomes of patients with rheumatoid arthritis (RA) who received abatacept in UK clinical practice. However, many of the eligible population received abatacept monotherapy rather than as indicated. A subgroup analysis of patients treated with abatacept in combination with methotrexate (ABA + MTX) was therefore undertaken to explore the treatment effect in this specific patient population.

**Objectives:** Present a subgroup analysis describing the clinical outcomes of patients with RA treated with ABA + MTX in UK real-world clinical practice.

**Methods:** A multi-centre, retrospective observational study was undertaken in patients with RA treated with abatacept at any time of therapy between January 2013 and 31 December 2017, across four UK centres. Data were collected from patient medical records from index date, defined as the date of first bDMARD initiation, to most recent RA clinic visit, death or end of study (31 December 2017). Clinical outcomes (disease activity and response to treatment) were measured using the 28-joint Disease Activity Score based on erythrocyte sedimentation rate (DAS28-ESR) and European League Against Rheumatism (EULAR) response criteria. Patients that received abatacept outside indication (i.e., without concomitant methotrexate) were retrospectively excluded from the analysis dataset. Statistical analyses for the ABA + MTX subgroup were repeated in line with the methodology previously reported.

**Results:** This subgroup analysis included 133 patients, of 213 patients included in the original study, with RA that received ABA + MTX (mean age 54.6 years, 77.4% female, 7.5 years mean duration of RA at index date). At index date, 64.8% of patients were positive for both anti-citrullinated protein antibodies (ACPAs) and rheumatoid factor (RF), where data were available. In total, 77.8% of patients were categorised with high disease activity at index, with mean DAS28-ESR of 6.2 (SD 1.1).

Irrespective of line of treatment (LOT), patients tended to have a more favourable distribution of good/moderate/no EULAR response when receiving ABA + MTX (31.8%/34.1%/34.1%; n=44) compared with receipt of other bDMARDs (12.7%/36.4%/50.9%; n=55) at 6 months. Similarly, a favourable distribution of good/moderate/no EULAR response in favour of those receiving ABA + MTX compared with other bDMARDs was observed at 12 months (30.6%/41.7%/27.8% versus 20.0%/35.0%/45.0%, respectively).

Patients receiving ABA + MTX remained on treatment for significantly longer than patients in receipt of other bDMARDs as first LOT (median time on treatment 53.4 vs 18.1 months; p<0.001). A similar trend was observed at second LOT, although differences were not statistically significant (median time on treatment 40.1 vs 19.7 months; p=0.08).

**Conclusion:** Patients with RA who received treatment with any bDMARDs, including ABA + MTX, experienced reduced disease activity. However, those receiving ABA + MTX persisted with treatment significantly longer than when receiving other bDMARDs.

**REFERENCES:**


**Acknowledgements:** This analysis was supported by Bristol-Myers Squibb.

**Disclosure of Interests:** Ernest Choy Speakers bureau: Abbvie, Amgen, Bristol Myers Squibbs, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, Roche, Sanofi, and UCB, Consultant of: Abbvie, Amgen, Biocon, Chugai Pharma, Eli Lilly, Gilead, Janssen, Merck Serono, Novartis, Pfizer, Regeneron, Roche, R-Pharm and Sanofi, Grant/research support from: Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi and UCB, Sadie Henning Shareholder of: Bristol Myers Squibb, Employee of: Yes, Bristol Myers Squibb, Marie Brazil Shareholder of: Bristol Myers Squibb, Employee of: Currently an employee of Bristol Myers Squibb, Kevin Pollock Shareholder of: Yes - Bristol Myers Squibb, Speakers bureau: Yes - Merck Sharp & Dohme and Glaxo Smith Kline, Consultant of: Yes - Merck Sharp & Dohme, Employee of: Yes – currently employed by Bristol Myers Squibb, Lara Groves Grant/research support from: I am an employee of Health Economics and Outcomes Research Ltd., Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study, Daniel Sugrue Grant/research support from: I am an employee of Health Economics and Outcomes Research Ltd., Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study, John Houghton Grant/research support from: I am an employee of Health Economics and Outcomes Research Ltd., Cardiff, UK, who received fees from Bristol Myers Squibb in relation to this study DOI: 10.1136/annrheumdis-2022-eular.2356

**Table 1. Patient clinical characteristics, SB5 dose, flare**

<table>
<thead>
<tr>
<th>RA (N=207)</th>
<th>axSpA (N=127)</th>
<th>PsA (N=162)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at SB5 initiation (years), mean (SD); IQR</td>
<td>60.1 (11.8)</td>
<td>53.0, 68.0</td>
</tr>
<tr>
<td>Duration of disease (years), mean (SD); IQR</td>
<td>13.3 (11.4)</td>
<td>5.0, 19.5</td>
</tr>
<tr>
<td>Women</td>
<td>n %</td>
<td>150 (72.5)</td>
</tr>
<tr>
<td>Patients receiving SB5 40mg Q2W</td>
<td>n %</td>
<td>152 (73.4)</td>
</tr>
<tr>
<td>Baseline</td>
<td>132 (72.5)</td>
<td>93 (87.7)</td>
</tr>
<tr>
<td>Episodes of Flare</td>
<td>0</td>
<td>187 (90.3)</td>
</tr>
<tr>
<td>1</td>
<td>20 (9.7)</td>
<td>18 (14.2)</td>
</tr>
<tr>
<td>2</td>
<td>0 (0.0)</td>
<td>2</td>
</tr>
<tr>
<td>How was Flare diagnosed</td>
<td>Disease score</td>
<td>11</td>
</tr>
<tr>
<td>Secondary Loss of Response</td>
<td>4</td>
<td>20.0</td>
</tr>
<tr>
<td>Action taken for Flare</td>
<td>8</td>
<td>40.0</td>
</tr>
<tr>
<td>Biologic therapy dose adjusted</td>
<td>Clinical investigation</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Non-biologic therapy dose adjusted</td>
<td>Other</td>
<td>9</td>
</tr>
</tbody>
</table>

*Includes cessation of therapy, prescription of corticosteroids, physical exercise, no action; IQR, interquartile range; SD, standard deviation; Q2W once two-weekly.*
Background: SBS, a biosimilar to reference adalimumab (ADL), received EU marketing authorisation in 2017, based on pre-clinical and clinical phase I and III studies that demonstrated bioequivalence and comparable efficacy, safety and immunogenicity to ADL.

Objectives: The real-world study PROPER is designed to provide insights into outcomes of the transition from ADL to SBS outside the randomised, controlled, clinical trial setting.

Methods: Under an umbrella design, 1000 patients with immune-mediated inflammatory disease were enrolled at centres in Belgium, Germany, Ireland, Italy, Spain and the UK, and followed for 48 weeks post-transition. Eligible patients had a diagnosis of rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), ulcerative colitis or Crohn’s disease had been transitioned to SBS as part of routine treatment following a minimum of 16 weeks’ treatment with ADL. Data were captured from patient charts retrospectively for 24 weeks prior to and prospectively and/or retrospectively up to 48 weeks after SBS initiation. This analysis of the rheumatology cohort reports clinical characteristics, disease scores, persistence on SBS, clinical management and safety up to the closing date of November 30th, 2021.

Results: Of the 496 patients included in this analysis, the majority were enrolled in UK (n=174), Germany (n=145) and Spain (n=73); Italy, Ireland and Belgium enrolled 45, 44 and 15 patients respectively. At study close, 487 patients had completed 48 weeks of follow-up; 397 of those remained on SBS throughout.

Methotrexate was received as concomitant therapy by 37% of patients and 20% had received a biologic therapy prior to reference ADL. Most patients (89.3% of RA, 92.1% of axSpA, 97.3% of PsA) transitioned to SBS at the same dose regimen received for ADL. Clinical characteristics, SBS dose and flare are detailed in Table 1, disease scores in Figure 1.

Figure 1. Disease scores (paired patients), mean (95% CI)

Fifteen patients each experienced one unrelated Serious Adverse Event (SAE): 2 in the axSpA cohort [tachycardia, intracranial haemorrhage]; 6 in the PsA cohort [myocardial infarct (2), breast cancer, COVID-19, gallbladder calculus, dysphonia]; 7 in the RA cohort [facial numbness, depression, COVID-19, pneumonia, cholecystitis, peritonitis, coronary occlusion]. Two patients reported SAEs considered causally related to SBS: Herpes zoster and pneumonia (RA cohort), and ALS with worsening (PsA cohort).

Conclusion: This analysis of a large, contemporary cohort of EU patients with established RA, axSpA or PsA shows treatment effectiveness maintained at 48 weeks after switching from ADL to SBS, with most patients continuing on SBS Q2W throughout. Episodes of flare were uncommon, and the importance of patient-reported symptoms in recognition of flare is evident. No new safety signals were observed.

Acknowledgements: Statistical services were provided by FGK Clinical Research GmbH, Munich, Germany. Data management services were provided by Worldwide Clinical trial, Research Triangle Park, NC, USA. Funding was provided by Biogen International GmbH.

Disclosure of Interests: Ulf Müller-Ladner Consultant of: Biogen, Grant/ research support from: Biogen, Karl Gaffney Speakers bureau: Novartis, UCB, AbbVie, Lilly, Consultant of: Novartis, UCB, AbbVie, Lilly, Pfizer, Grant/ research support from: NAAS, AbbVie, Pfizer, UCB, Novartis, Lilly, Cellgene, Celltrion, Janssen, Gilead, Biogen, Deepak Jadon Consultant of: AbbVie, Cellgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Oxford University Press, Pfizer, Roche, Sandzio, UCB, Grant/research support from: AbbVie, Cellgene, Eli Lilly, Gilead, Janssen, MSD, Novartis, Oxford University Press, Pfizer, Roche, Sandzio, UCB, Marco Matsuichi-Cerinici Consultant of: Chemomab, Biogen, Pfizer, Lilly, Behring, Janssen, MSD, Eugenio Chamizo Carmona Speakers bureau: Abbvie, Amgen, Biogen, BMS, Cellgene, Eli Lilly, Fresenius-Kabi, Galapagos, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: Abbvie, Amgen, Biogen, BMS, Cellgene, Eli Lilly, Fresenius-Kabi, Galapagos, Janssen, MSD, Novartis, Pfizer, and UCB, Ulrich Freudsprung Shareholder of: May hold stock in Biogen, Employee of: Biogen, Janet Addison Shareholder of: May hold stock in Biogen, Employee of: Biogen


AB0349 ANALYSIS EFFICACY OF ABATACEPT TREATMENT IN BIOLOGIC-NAÏVE AND BIOLOGIC-EXPERIENCED PATIENTS.

M. Borisova1, G. Lukina1,2, S. Yakov1, E. Luchikhina2, D. Karateev1, A. Novikov2, E. Aleksandrova2, E. Aronova2, S. Glikhova1, E. Nasonova1,3,5; I.V. Nasonova Research Institute of Rheumatology, Laboratory of Monitoring Safety of Antirheumatic Treatment, Moscow, Russian Federation; 1A.S. Loginov Moscow Clinical Scientific Center, Department of Rheumatology, Moscow, Russian Federation; 2Moscow Regional Research and Clinical Institute (MONIKI), Department of Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Scientific Director, Moscow, Russian Federation; 5M. Sechonov First Moscow State Medical University, Department of Rheumatology, Moscow, Russian Federation

Background: Despite the high efficacy of rheumatoid arthritis (RA) therapy, in routine clinical practice, clinicians face questions about the choice of a second biologic, as well as the possibility of biologic monotherapy. Therefore, the specialties of biologics use in these categories of patients are of great clinical interest. This work is devoted to the study of the effectiveness of abatacept (ABA) therapy in biologic-naïve and biologic-experienced patients and in the subgroup of ABA monotherapy.

Objectives: To evaluate the effectiveness of ABA therapy between biologic-naïve and patients who had experienced an inadequate response to biological agents and in the subgroup of ABA monotherapy.

Methods: We prospectively enrolled and followed 91 patients with high RA activity (SDAI=28±13.4, CDAI=25±12) and an inadequate response of conventional synthetic DMARDs (mainly metotrexate, 70.3%) and biologics (mainly TNFα blockers, 93%) were included in the study. Most of the patients were middle-aged (49±13.5), positive for RF (72.5%) and ACCP (77%) with moderate functional impairment - 1.4 (0.9-2). Patients were divided into two groups: biologic-naïve (48.4%, n=44) and biologic-experienced patients (51.6%, n=47). 18% (n=17) of patients had a history of an inadequate response of 2 or more biologics. The ABA monotherapy group (13%, n=12) was assessed separately. ABA therapy was a registered IV, 10 mg/kg according to the standard scheme. The evaluation of the effectiveness of the therapy was carried out according to the EULAR/ACR 2011 criteria using the intention-to-treat approach and SDAI, CDAI and the functional state using the HAQ.

Results: ABA led to a significant (p<0.05) decrease in RA activity after 3 months of ABA therapy in all groups. After 6 months of treatment, there was a tendency towards an increase in the number of patients who achieved remission and low RA activity in the group of biologic-naïve patients, which continued to 12 months of therapy. So, after 6 months and 12 months in the group of biologic-naïve patients, the frequency of remission and low disease activity was 71% (n=25) and 76% (n=19) by SDAI, 75.6% (n=28) and 81.5% (n=24) by CDAI, respectively. Whereas, in the group of biologic-experienced patients - SDAI - 61.8% (n=21) and 69.2% (n=18), CDAI - 64.8% (n=22) and 77.8% (n=21), respectively. However, these differences didn’t reach significance. Similar results were obtained according to the EULAR criteria: after 12 months of treatment, the percentage of patients with a good response in both groups did not differ, 38% (n=14) in biologic-naïve and 38.4% (n=15) in biologic-experienced patients. ABA significantly improved functional status of patients, after 12 months the median HAQ of biologic-naive and biologic-experienced patients were 0.7 (0.2-0.8) and 1.8 (0.7-1.6), respectively. More biologic-naïve patients achieved functional remission by HAQ after 6 and 12 months compared with biologic-experienced patients: 67% (n=23) vs. 33% (n=17), 62.5% (n=11) vs. 37.5% (n=9), respectively, but these differences didn’t reach significance. In the ABA monotherapy group after 6 months treatment, a good response by EULAR criteria was achieved in 10% (n=1) patients, while in the group of ABA+cDMARDs therapy in 43.5%, p<0.04. After 12 months the trend towards a more pronounced response in the combination therapy group persisted (11%, n=1 and 42%, n=28), respectively, but no significant differences were obtained.

Conclusion: Abatacept has shown significant improvement clinical and functional status in all studied groups. There were no significant differences in response to ABA therapy between biologic-naïve and biologic-experienced patients. ABA monotherapy were significantly worse compared with the combination therapy of ABA and cDMARDs after 6 months. After 12th month observation, this tendency continued, but no significant differences were achieved. This is probably due to the small number of patients on ABA monotherapy and, as a result, to the insufficient statistical representativeness of the sample.

Disclosure of Interests: None declared

**AB0350**

**ASSESSMENT OF REAL-LIFE PATIENT HANDLING EXPERIENCE OF AVT02 ADMINISTERED SUBCUTANEOUS VIA AUTOINJECTOR IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: AN OPEN-LABEL, SINGLE-ARM CLINICAL TRIAL, THEN AN EXTENSION PHASE OF AVT02 ADMINISTERED WITH A PRE-FILLED SYRINGE (ALVOPAD-PEN)**


1AG, Clinical and Medical Affairs, Zürich, Switzerland; 2Germany GmbH, Clinical and Medical Affairs, Jülich, Germany; 3Avrotech Swiss AG, Clinical and Medical Affairs, Zürich, Switzerland; 4Avrotech UK Ltd, Clinical and Medical Affairs, London, United Kingdom; 5Avrotech M, Combination Products & Devices, Reykjavik, Iceland

**Background:** AVT02 is an investigational biosimilar to adalimumab. It is approved in Europe, Canada, and the UK. It is not approved by the US Food and Drug Administration (FDA).

**Objectives:** To assess the real-life patient handling of an autoinjector (AI) in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who self-inject AVT02 subcutaneously (s.c.).

**Methods:** This open-label study enrolled 107 adalimumab-naïve subjects with moderate-to-severe active RA to self-inject AVT02 with the proposed AI 40 mg s.c. in Week 1, and every other week thereafter through Week 8. In an optional extension phase through Week 56, subjects were switched from AVT02 AI to pre-filled syringe and followed for safety and efficacy. The primary endpoint was the percentage of successful self-injections as reported by both the trial site and by subjects using standardized questionnaires at Week 8. Additional endpoints included ease of use and robustness of the AI at Week 8, and efficacy in RA, assessment of serum trough levels of AVT02, and detection of antidrug antibodies (ADA) throughout the study.

**Results:** The AI success rate was 100% as reported by both the trial site and by subjects. No handling events were noted through Week 8. Approximately 80% (78.1–84.9%) of subjects found the AI ‘very easy’ to use and, in general, less difficulty was reported as the study progressed. The first 110 AIs used were inspected for robustness and none showed any sign of damage or malfunction. All subjects who completed Week 8 (n = 106) took part in and completed the optional extension phase through Week 56.

At Week 8, 49.1%, 5.7% and 0.9% subjects achieved ACR20, -50 and -70 responses, respectively. Improvement was also reported for the SDAI, DAS28 CRP and HAQ, with scores consistently decreasing through Week 8. In the extension phase, 70.8%, 47.2% and 13.2% subjects achieved ACR20, -50 and -70 responses, respectively. Improvement was also reported for the SDAI, DAS28 CRP and HAQ, with scores consistently decreasing through Week 56.

From Baseline through Week 8 the mean serum concentrations of investigational AVT02 increased consistently at each visit, reaching a peak at Week 24. There was no significant difference in serum concentrations of AVT02 based on injection subsite (abdomen or thigh).

**Conclusion:** The AI was easy to use and robust. The study results supported the progression to a Phase II extension study through Week 56. Subjects were switched from AVT02 AI to pre-filled syringe at Week 1, and every other week thereafter through Week 8. In an optional extension phase through Week 56, subjects were switched from AVT02 AI to pre-filled syringe and followed for safety and efficacy.


**Table 1. Correlation of FCGR SNPs with response to rituximab at 6 months of treatment**

<table>
<thead>
<tr>
<th>Genetic study</th>
<th>FCGR2A R131H*</th>
<th>FCGR3A F158V*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RR</td>
<td>RH</td>
</tr>
<tr>
<td>Genotypes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR</td>
<td>2.5±1.56</td>
<td>1.0±1.36</td>
</tr>
<tr>
<td>Genotypes</td>
<td>0.053</td>
<td>0.06</td>
</tr>
<tr>
<td>H</td>
<td>0.968</td>
<td>0.968</td>
</tr>
<tr>
<td>H</td>
<td>2.2±1.64</td>
<td>2.0±1.73</td>
</tr>
<tr>
<td>ACR20 responses</td>
<td>0.480</td>
<td>0.855</td>
</tr>
<tr>
<td>SDAI</td>
<td>0.3 (33)</td>
<td>6 (25)</td>
</tr>
<tr>
<td>DAS28 CRP</td>
<td>2 (66.7)</td>
<td>18 (75)</td>
</tr>
<tr>
<td>EULAR (R-) (n=7)</td>
<td>0.131</td>
<td>0.324</td>
</tr>
<tr>
<td>EULAR (R-) (n=27)</td>
<td>0.372</td>
<td>0.576</td>
</tr>
</tbody>
</table>

**AB0351**

**IMPACT OF FCGR2A, FCGR3A AND FCGR3B POLYMORPHISM ON RITUXIMAB EFFICACY IN RHEUMATOID ARTHRITIS**

M. Moadia1, I. Mahmoud1, A. Ben Tekaya1, L. Rouached1, S. Boudeni1, R. Tekaya1, Y. Gorgi2, L. Abdelmoula1, O. Saidane1, I. Staf2, Charles Nicolle Hospital, Rheumatology, Tunis, Tunisia; 2Charles Nicolle Hospital, Laboratory of Research in Immunology, Renal Transplantation and Immunopathology (LR03SP01), Tunis, Tunisia

**Background:** Identifying reliable biomarkers of response to biologics in rheumatoid arthritis (RA) is necessary to improve responsiveness, preserve functions and structure of joints, as well as to reduce treatment’s cost. Single nucleotide polymorphisms (SNPs) of Fc-gamma receptors genes (FCGRs), by inducing a variation of receptors’ affinity to Fc fragment of Gamma immunoglobulin, might influence the efficacy of therapeutic monoclonal antibodies by modifying their clearance.

**Objectives:** The aim of this study was to investigate whether FCGR2A, FCGR3A and FCGR3B SNPs were predictive factors of response to rituximab (RTX) in Tunisian RA patients.

**Methods:** A cross-sectional, observational and analytic multicentric cohort study was conducted in a group of patients suffering from RA treated with RTX. Treatment outcome was evaluated after 6 months, using DAS$_28$ variation from baseline and EULAR response criteria. R131H-FCGR2A, F158V-FCGR3A and NA1/NA2-FCGR3B SNPs were studied using PCR-SSP and direct sequencing process.

**Results:** Thirty-four patients were enrolled with a sexe ratio M/F=5/29. The mean age at inclusion was 54.4±11.7 years [29-77]. All patients received at least one cs-DMARDs priorly to the prescription of RTX. Concomitant treatment with methotrexate was pursued in 77.3% of patients. As shown in Table 1, an

**Table 1. Correlation of FCGR SNPs with response to rituximab at 6 months of treatment**

<table>
<thead>
<tr>
<th>Genetic study</th>
<th>FCGR2A R131H*</th>
<th>FCGR3A F158V*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p</td>
<td>p</td>
</tr>
<tr>
<td>FCGR2A R131H*</td>
<td>0.138</td>
<td>0.428</td>
</tr>
<tr>
<td>Genotypes</td>
<td>0.761</td>
<td>0.873</td>
</tr>
<tr>
<td>RR</td>
<td>0.053</td>
<td>0.053</td>
</tr>
<tr>
<td>Genotypes</td>
<td>1.83±0.75</td>
<td>2.1±1.60</td>
</tr>
<tr>
<td>H</td>
<td>0.683</td>
<td>0.480</td>
</tr>
<tr>
<td>H</td>
<td>1 (33)</td>
<td>7 (259)</td>
</tr>
<tr>
<td>ACR20 responses</td>
<td>0 (0)</td>
<td>20 (0,741)</td>
</tr>
<tr>
<td>SDAI</td>
<td>2 (66.7)</td>
<td>18 (75)</td>
</tr>
<tr>
<td>DAS28 CRP</td>
<td>0.131</td>
<td>0.324</td>
</tr>
<tr>
<td>EULAR (R-) (n=7)</td>
<td>0.372</td>
<td>0.576</td>
</tr>
<tr>
<td>EULAR (R-) (n=27)</td>
<td>0.676</td>
<td>0.873</td>
</tr>
</tbody>
</table>

**DAS:** disease activity score, **ΔDAS:** mean variation of DAS at 6 months, *Comparison of the global distribution of the 3 genotypes, **p** while comparing the prevalence of R/R genotype to RH and HH genotypes, R+: good or moderate EULAR response, R-: bad EULAR response.
association, that tend to signification, was found between R/R FCGRA2 receptors and a greater variation in DAS28 score (p=0.053). This association was also found using EULAR criteria, since all patients with R/R genotypes had a good or moderate response to RTX but was not significant (p=0.131).

**Conclusion:** The low affinity receptor R/R FcgRIIα might be predictive of good response in RA patients treated with RTX. More studies need to be conducted in larger cohorts to confirm this association, with the aim of identifying reliable biomarkers of response to biologics to improve responsiveness, preserve joints functions and structure, as well as reduce treatment's cost.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2438

---

**AB0352**

**IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDS: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY**

A. Rubbert-Roth1, J. Sparks2, A. Constantin3, R. Xavier4, Y. Song5, J. Suboticki6, R. M. Fleischmann6, 1Division of Rheumatology, Cantonal Clinic St Gallen, St Gallen, Switzerland; 2Division of Rheumatology, Immunology, and Infection, Brigham and Women’s Hospital and Harvard Medical School, Boston, United States of America; 3Rheumatology Department, Purpan University Hospital and Toulouse III - Paul Sabatier University, Toulouse, France; 4Division of Rheumatology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 5AbbVie Inc., Immunology, North Chicago, United States of America; 6University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, United States of America

**Background:** In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority in change from baseline in DAS28(CRP) and DAS28(CRP)<2.6 at week 12 and improved responses across additional endpoints compared to abatacept (ABA) in the phase 3 SELECT-CHOICE study. Seropositive patients have been reported to respond better to treatment than seronegative patients.

**Objectives:** To evaluate clinical responses with UPA versus ABA among RA patients based on serologic status.

**Methods:** In SELECT-CHOICE (24-week, phase 3, double-blind, controlled trial), RA patients were randomized to oral UPA (15 mg once daily) or intravenous (IV) ABA (at day 1 and weeks 2, 4, 8, 12, 16, and 20; <60 kg, 500 mg; 60-100 kg, 750 mg; >100 kg, 1000 mg).1 UPA patients also received IV placebo and ABA patients also received oral placebo. All patients continued stable background DMARDs. Mean change from baseline in DAS28(CRP) and Clinical Disease Activity Index (CDAI), ACR responses, HAQ-DI, and the patient’s assessment of pain was numerically higher with UPA compared to ABA at weeks 12 and 24 across all subgroups and timepoints (data not shown). Clinical responses were generally numerically higher at week 24 compared to week 12, and for the seropositive groups compared to the seronegative group, with both UPA and ABA.

**Conclusion:** Across serostatus subgroups, clinical responses with UPA 15 mg vs ABA were numerically higher at weeks 12 and 24 among RA patients with prior inadequate response or intolerance to biologic DMARDs. In addition, clinical responses were numerically higher for seropositive patients compared to seronegative patients across all endpoints assessed, although the seronegative group had a smaller sample size in this post-hoc analysis.

**Acknowledgements:** AbbVie funded these studies and participated in the study design, research, analysis, data collection, interpretation of data. No honoraria or payments were made for authorship. Medical writing support was provided by Monica R.P. Elmore, PhD of AbbVie.

**Disclosure of Interests:** Andrea Rubbert-Roth Speakers bureau: AbbVie, BMS, Chugai, Roche, Gilead, Janssen, Lilly, Sanofi, Amgen, Novartis, Consultant of: AbbVie, BMS, Chugai, Roche, Gilead, Janssen, Lilly, Sanofi, Amgen, Novartis, Jeffrey Sparks Consultant of: Bristol-Myers Squibb, Gilead, Inova Diagnostics, Optum, and Pfizer, Arnaud Constantain Speakers bureau: AbbVie, BMS, Galapagos, Janssen, Lilly, Novartis, Pfizer, Sanofi, and UCB, Consultant of: AbbVie, BMS, Galapagos, Janssen, Lilly, Novartis, Pfizer, Sanofi, and UCB, Ricardo Xavier Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Yanna Song Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Jessica Suboticki Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Roy M. Fleischmann Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer, Sanofi, Aventis, and UCB, Grant/ research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers

---

**Table 1. Clinical Responses with UPA 15 mg or ABA in RA Patients Across Serologic Status Sub-Groups at Weeks 12 and 24**

<table>
<thead>
<tr>
<th>Sub-group</th>
<th>UPA n=189</th>
<th>ABA n=201</th>
<th>UPA n=242</th>
<th>ABA n=250</th>
<th>UPA n=61</th>
<th>ABA n=59</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20</td>
<td>12</td>
<td>81*</td>
<td>12</td>
<td>79*</td>
<td>12</td>
<td>71</td>
</tr>
<tr>
<td>ACR50</td>
<td>24</td>
<td>84</td>
<td>24</td>
<td>79</td>
<td>24</td>
<td>77</td>
</tr>
<tr>
<td>ACR70</td>
<td>24</td>
<td>51*</td>
<td>24</td>
<td>51**</td>
<td>24</td>
<td>40*</td>
</tr>
<tr>
<td>DAS28(CRP)&lt;3.2</td>
<td>12</td>
<td>54***</td>
<td>12</td>
<td>54***</td>
<td>12</td>
<td>33***</td>
</tr>
<tr>
<td>DAS28(CRP)&lt;2.6</td>
<td>24</td>
<td>65**</td>
<td>24</td>
<td>65**</td>
<td>24</td>
<td>50</td>
</tr>
<tr>
<td>CDAI ≤10</td>
<td>12</td>
<td>46**</td>
<td>12</td>
<td>48***</td>
<td>12</td>
<td>33**</td>
</tr>
<tr>
<td>CDAI ≤2.8</td>
<td>12</td>
<td>59</td>
<td>12</td>
<td>59</td>
<td>12</td>
<td>59</td>
</tr>
</tbody>
</table>

*P<0.05; **P<0.01; ***P<0.001 UPA vs. ABA; nominal P-values are presented and not adjusted for multiple comparisons NRI was used for missing data
Table 1. Relationship between remission according to bDMARD and CKD

<table>
<thead>
<tr>
<th>Rheumatoid arthritis</th>
<th>p Spondyloarthritis</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>w CKD</td>
<td>w CKD</td>
<td>w CKD</td>
</tr>
<tr>
<td>Etanercept, n(%)</td>
<td>34 (34.6)</td>
<td>30 (33.0)</td>
</tr>
<tr>
<td>Adalimumab, n(%)</td>
<td>17 (17.3)</td>
<td>17 (18.7)</td>
</tr>
<tr>
<td>Infliximab, n(%)</td>
<td>3 (3)</td>
<td>8 (8.8)</td>
</tr>
<tr>
<td>Golimumab, n(%)</td>
<td>4 (4)</td>
<td>3 (3.3)</td>
</tr>
<tr>
<td>Certolizumab, n(%)</td>
<td>0 (0)</td>
<td>3 (3.3)</td>
</tr>
<tr>
<td>Anti-TNF therapy, n(%)</td>
<td>58 (59.2)</td>
<td>61 (67.0)</td>
</tr>
<tr>
<td>Non-TNF biologics, n(%)</td>
<td>40 (40.8)</td>
<td>30 (33.0)</td>
</tr>
<tr>
<td>Rituximab, n(%)</td>
<td>14 (14.3)</td>
<td>12 (13.2)</td>
</tr>
<tr>
<td>Abatacept, n(%)</td>
<td>14 (14.3)</td>
<td>12 (13.2)</td>
</tr>
<tr>
<td>Tocilizumab, n(%)</td>
<td>6 (6.1)</td>
<td>1</td>
</tr>
<tr>
<td>JAK-kinase inhibitors, n(%)</td>
<td>6 (6.1)</td>
<td>5 (5.5)</td>
</tr>
</tbody>
</table>

Conclusion: In our biologic cohort, 2% of patients with RA and SpA had accompanying CKD. In one-third of the patients with CKD, it was developed during the follow-up after bDMARDs. In patients with RA, there was no difference in terms of TNFi and non-TNFi preferences. It should be kept in mind that CKD may develop during the follow-up of patients using bDMARDs.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Whole blood samples

<table>
<thead>
<tr>
<th>IFX theoretical concentration (µg/mL)</th>
<th>Mean observed IFX concentration (µg/mL)</th>
<th>Repeatability</th>
<th>Within-device precision</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>3.2</td>
<td>0.6</td>
<td>18</td>
</tr>
<tr>
<td>7</td>
<td>9.8</td>
<td>1.8</td>
<td>18</td>
</tr>
</tbody>
</table>

The negative samples showed a negative result in all the measurements.

THE DIFFERENCES BETWEEN THE FIRST PREFERRED BIOLOGICAL DMARD AND THE DRUG SURVIVAL IN GERIATRIC AND YOUNGER ADULT POPULATION WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS: TREASURE REAL-LIFE DATA


1 Sakarya University, Rheumatology, Sakarya, Turkey; 2 Hacettepe University, Rheumatology, Ankara, Turkey; 3 Uludağ University, Rheumatology, Bursa, Turkey; 4 Ankara University, Rheumatology, Ankara, Turkey; 5 Yıldırım Beyazıt University, Rheumatology, Ankara, Turkey; 6 Osmangazi University, Rheumatology, Eskişehir, Turkey; 7 Koç University, Rheumatology, İstanbul, Turkey; 8 Gülhane Research and Training Hospital, Rheumatology, Ankara, Turkey; 9 Adana City Hospital, Rheumatology, Adana, Turkey; 10 Namık Kemal University, Rheumatology, Tekirdağ, Turkey; 11 Katip Celebi University, Rheumatology, İzmir, Turkey; 12 Fatih University, Rheumatology, Elazığ, Turkey; 13 Akdeniz University, Rheumatology, Antalya, Turkey; 14 Mustafa Kemal University, Rheumatology, Hatay, Turkey; 15 Başakşehir Cam and Sakura City Hospital, Rheumatology, İstanbul, Turkey; 16 İrka University, Rheumatology, Edirne, Turkey

Background: Inflammatory musculoskeletal diseases are frequent in the elderly population, and this number is expected to increase significantly near future. The exclusion of older adults from the studies due to their age and comorbidities causes insufficient data about this population. Insufficient data cause clinicians to have difficulties using and selecting biological therapy in the elderly patient group. In real life, physicians’ approaches to the selection and use of biological disease modifying anti-rheumatic drugs (DMARDs) in the geriatric population with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) have not been well studied.

Objectives: To compare the clinicians’ first choice of biological DMARDs in elderly and younger RA and PsA patients and investigate the drug survival of first biological DMARDs in both populations.

Methods: The traditional chronological age for the human to be classified in the geriatric population is ≥65 years (1). The TReasure web-based registry, created in 2017, is a multicenter observational cohort established to collect data on RA and spondyloarthritis (SpA) patients from the participating 17 rheumatology centers in different regions of Turkey. Physicians’ first choice biological and targeted synthetic DMARDs in younger and elderly patients with RA and PsA was evaluated using the descriptive statistical method. The survival of the first bDMARDs was assessed using the Kaplan-Meier method.

Results: 3136 RA and 738 PsA patients were evaluated. 12% of 3136 patients with RA were in the geriatric population. In patients with RA, the first choice of biologic DMARDs was adalimumab (20.6%), followed by etanercept (19.9%), and tocilizumab (13.6%) in patients <65 years of age, while rituximab (24%) was the first choice in patients ≥65 years, tocilizumab (20.9%) in the second place and etanercept (13%) in the third. Of 738 PsA patients, 3% were over 65 years. Adalimumab (41.1%) was the first choice of <65 years of age, etanercept (17.6%) was the second choice, and infliximab (15.5%) was the third choice, while adalimumab (28.6%) was the first choice in patients ≥65 years followed by etanercept (17.9%) and certolizumab (17.9%) in RA group, drug survival was significantly higher in patients ≥65 years (estimated median drug survival: <65 age: 37.5 (34.1-41.1) months vs ≥65 age: 53.5 (24.9-82.2) months; log-rank p=0.016) (Figure 1). In PsA group, drug survival was significantly higher in patients <65 years (estimated median drug survival; <65 age: 31.2 (26.4-36.1) months vs ≥65 age: 9.1 (0.4-17.7) months; log-rank p<0.001) (Figure 1).

Conclusion: With these findings, it is thought that in Turkey, the limited socioeconomic support in the geriatric patients has led physicians to prescribe treatments such as rituximab, which are administered in the hospital under the supervision of a physician, are relatively preferred in malignancies, and are considered to be relatively less risky in terms of tuberculosis. Adalimumab and etanercept were chosen in the first two lines in both geriatric and young populations in the patient group with PsA. While the drug survival was significantly higher in patients with RA geriatric age group than the younger group, in PsA in which tumor necrosis factor-alpha (TNF-α) inhibitors were chosen as initial therapy in both age groups was lower in the geriatric population.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2721

THERAPEUTIC DRUG MONITORING: STANDARDIZATION OF PROMONITOR QUICK IFX AND PROMONITOR QUICK ADL POINT OF CARE TESTS WITH WHO INTERNATIONAL STANDARDS FOR THE QUANTIFICATION OF INFLIXIMAB AND ADALIMUMAB IN WHOLE BLOOD AND SERUM

A. Ametazurre1, J. Pascual2, L. Del Río3, A. Urigoitia1, D. Nagore4, M. B. Ruiz-Argüello1, Progenika Biopharma - Grifols, Research & Development, Derio, Spain

Background: Promonitor Quick IFX and Promonitor Quick ADL are rapid point of care lateral flow tests (LFT) based on a sandwich immunoassay for the quantification of infliximab (IFX) and adalimumab (ADL), respectively, in human whole blood (finger prick or venous) or serum. These tests are to be used as an aid in Therapeutic Drug Monitoring (TDM) of rheumatic and inflammatory bowel disease patients under anti-TNF-α therapy. The international standards (IS) developed by World Health Organization (WHO) for IFX and ADL allow harmonization and comparability among different assays.

Objectives: The aim of this study, was to show that Promonitor Quick IFX and Promonitor Quick ADL can measure either reference or biosimilar drugs, as well as to evaluate the agreement of Promonitor Quick IFX and Promonitor Quick ADL tests and the WHO IS.

Methods: Clinical and Laboratory Standards Institute EP10-A3 guidelines were followed to estimate the bias of Promonitor Quick assays when used to quantify IFX or ADL in samples containing the reference drugs, biosimilars or the WHO IS. Briefly, whole blood was spiked with four known concentrations of IFX or ADL, including current clinical decision levels. Ten replicates were measured of each level along two days. Promonitor Quick IFX was evaluated using the reference drug, SB2 and CT-P13 biosimilars, and the WHO IS (NIBSC 16/170). Promonitor Quick ADL was evaluated using the reference drug, ABP501 and SBS biosimilars, and the WHO IS (NIBSC 17/236). Results were obtained in combination with the automated portable reader POReader.

Results: Bias was estimated by comparing the observed concentration of drug spiked whole blood samples. Each biosimilar was compared to the reference at the different drug levels tested. Results showed that Promonitor Quick IFX and Promonitor Quick ADL are able to measure equivalently any molecule (see Table 1).

Figure 1. Comparison of first bDMARD retention rates between <65 years and ≥65 years. A: In rheumatoid arthritis patients; B: In psoriatic arthritis patients
**Scientific Abstracts**

**Table 1. **

<table>
<thead>
<tr>
<th>Promonitor Quick IFX bias results in whole blood samples. Each molecule was compared to the reference drug.</th>
<th>Bias (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IFX concentration (μg/mL)</strong></td>
<td>CT-P13</td>
</tr>
<tr>
<td>3</td>
<td>14%</td>
</tr>
<tr>
<td>7</td>
<td>9%</td>
</tr>
<tr>
<td>10</td>
<td>1%</td>
</tr>
</tbody>
</table>

Promonitor Quick ADL bias results in whole blood samples. Each molecule was compared to the reference drug.

<table>
<thead>
<tr>
<th><strong>ADL concentration (μg/mL)</strong></th>
<th>ABP501</th>
<th>SB5</th>
<th>WHO IS</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>17%</td>
<td>2%</td>
<td>3%</td>
</tr>
<tr>
<td>5</td>
<td>13%</td>
<td>3%</td>
<td>12%</td>
</tr>
<tr>
<td>8</td>
<td>2%</td>
<td>2%</td>
<td>7%</td>
</tr>
<tr>
<td>10</td>
<td>5%</td>
<td>17%</td>
<td>2%</td>
</tr>
</tbody>
</table>

Similar results were obtained when serum matrix was used.

The accuracy or closeness of the agreement between the result provided by Promonitor Quick IFX and Promonitor Quick ADL and the true value of the measurement was assessed by measuring the IS developed by the WHO (see Table 1).

**Conclusion:** Promonitor Quick IFX and Promonitor Quick ADL allow monitoring of patients treated with IFX and ADL, respectively, with just a finger prick sample. Both tests can quantify reference and biosimilar drugs with equivalent results. Moreover, comparable results were obtained with the WHO IS, and thus, demonstrate that Promonitor Quick tests are suited to accurately determine drug levels at the clinical decision points in both whole blood and serum, proving to be an effective and valuable tool in TDM and immediate decision making in the doctor’s office or hospitals.


**DOI:** 10.1136/annrheumdis-2022-eular.2753

**AB0357**

**INCIDENCE AND DETERMINANTS OF INFECTION IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB IN REAL-WORLD PRACTICE**

L. Besseste1, P. Rahman2, J. Kelsall3, J. Purvis4, E. Rampakakis5, A. Lehman6, M. Rachich7, F. Nantel8, M. Marrache9, O. Asin Milan6. 1Université Laval, Département de Médecine, Faculté de Médecine, Quebec City, Canada; 2Memorial University of Newfoundland, Medicine, St. John’s, Canada; 3The University of British Columbia, Faculty of Medicine, Department of Medicine, Vancouver, Canada; 4300-270 Charlotte St, Rheumatology, Peterborough, Canada; 5JSS Medical Research, Clinical Research, Montreal, Canada; 6Janssen Inc, Rheumatology, Toronto, Canada; 7Retiree, Janssen Inc, Rheumatology, Toronto, Canada

**Background:** Although biologic use in rheumatoid arthritis (RA) has a well-characterized infection risk factor, most studies evaluating this association were conducted on first-generation anti-tumor necrosis factor (TNFi) agents or in early years post-drug development (early 2000).

**Objectives:** To (i) characterize the long-term incidence of infection in a real-world cohort of RA patients treated with subcutaneous golimumab (GLM) in Canadian routine care; (ii) assess the impact of infections on GLM retention, and (iii) explore factors associated with the risk of infection.

**Methods:** BioTRAC registry was a prospective, multicenter study that collected real-world clinical, laboratory, safety and patient-reported data from TNFi naïve patients or treated with biologics for a period of <6 months before enrolment. This post-hoc analysis included patients with RA who initiated GLM treatment. The incidence density rates (IDR) of total serious (SI) and non-serious (NSI) infections were calculated for the overall follow-up (90 months) period as well as by 6-month interval. Time to first infection and time to treatment discontinuation were assessed with the Kaplan-Meier estimator of the survival function. Determinants of infection over time or within the first 6 months were explored using generalized estimating equation models and logistic regression, respectively.

**Results:** 530 patients were included with a mean (SD) age of 57.7 (13.0) years and disease duration of 8.0 (8.3) years. Of these, 404 (76.2%) were females, 74 (14.0%) were treated with ≤15mg/week MTX, 280 (52.8%) with >15mg/week MTX, while 173 (32.6%) were not on MTX. In terms of corticosteroids (CS), 72 (13.6%) were treated with ≤5mg/day, 63 (11.9%) with >5mg/day, and 391 (73.8%) were not on CS. Diabetes (4.5%), pulmonary disease (8.9%), and renal disease (18.5%) were present. Over a mean follow-up duration of 27.0 months, the IDR for total infections, NSI, and SI was 35.10 events/100 PYs, 32.90 events/100 PYs, and 2.32 events/100 PYs. Median estimated time to first infection was 52.9 months (SI: 84.9 months; NSI: 55.1 months) (Table 1). The incidence of total infections was 44.0, 37.3, 35.1, 29.4, 31.1, 35.7, 19.3 and 74.0 events/100 PYs at 0-6 months, 6-12 months, 12-24 months, 24-36 months, 36-48 months, 48-60 months, 60-72 months, 72-84 months, respectively and no infections between 84-90 months. In terms of determinants, no significant associations were identified for the incidence of infections within the first 6 months. However, presence of pulmonary disease was identified as a significant determinant of total infections (OR [95%CI]: 2.19 [1.36-3.52] and NSI [2.22 [1.35-3.66]) over time, while higher age (1.08 [1.00-1.26]) and high (≥5mg/day) CS dose (2.72 [1.12-46.80]) were associated with significantly higher odds of incidence of SIs, but not NSIs. Across time periods, there were increased baseline CDAI (OR [1.08 [1.04-1.08]) and use of concomitant MTX at low dose (0.52 [0.30-0.91]) or high dose (0.71 [0.49-1.04]).

**Table 1. Incidence Density Rate (IDR) by Infection Type.**

<table>
<thead>
<tr>
<th>Infection Type</th>
<th>IDR (Events/100 PYs)</th>
<th>Median Time to 1st Infection (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Infections</td>
<td>35.1</td>
<td>52.9</td>
</tr>
<tr>
<td>Non-serious Infections</td>
<td>32.9</td>
<td>84.9</td>
</tr>
<tr>
<td>Serious Infections</td>
<td>2.2</td>
<td>55.1</td>
</tr>
</tbody>
</table>

**Conclusion:** The infection rates reported with GLM in this cohort are low compared to the rates reported in earlier registry studies with TNFi. Changes in the characteristics of patients starting TNFi (lower disease activity, shorter disease duration, less exposure to CS) in recent years may explain the decreased risk of infection. Compared to the available literature, treatment with GLM was associated with relatively low infection rate. Most infections occurred during the first 6 months of treatment and decreased thereafter. Presence of pulmonary disease, higher age, and higher CS dose were identified as significant predictors of infections. SIs, but not NSIs, were associated with significantly higher odds of treatment discontinuation-TNFi.


**DOI:** 10.1136/annrheumdis-2022-eular.2859

**AB0358**

**SAFETY, TOLERABILITY, PHARMACOKINETICS, RECEPTOR OCCUPANCY, AND SUPPRESSION OF T-CELL-DEPENDENT ANTIBODY RESPONSE IN A PHASE 1 STUDY WITH KPL-404, AN ANTI-CD40 MONOCLONAL ANTIBODY**


**Background:** T-cell priming and T-cell-dependent B-cell responses require an intact cluster of differentiation (CD40/CD40L pathway). CD40 is expressed on the surface of B-cells, dendritic cells, antigen-presenting cells, and non-immune cell types; its ligand, CD40L (CD154), is expressed on the surface of activated T-cells; its ligand, CD40L (CD154), is expressed on the surface of activated
T-cells, platelets, and other cell types. Blockade of CD40/CD40L interaction has been shown to ablate primary and secondary T-cell dependent antibody response (TDAR).

Objectives: We hypothesized that KPL-404, an anti-CD40 monoclonal antibody which inhibits interaction between CD40 and CD40L, would block T-cell dependent, B-cell-mediated autoimmunity in this Phase 1 study in healthy participants.

Methods: This randomized, double-blind, placebo-controlled, first-in-human study of KPL-404 in healthy participants was designed with two single-ascending-dose arms: single intravenous (IV) doses of 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg and single subcutaneous (SC) doses of 1 mg/kg or 5 mg/kg. The primary objective was safety and tolerability of KPL-404; secondary and exploratory objectives included pharmacokinetic (PK) parameters, TDAR inhibition, and receptor occupancy (RO). To evaluate TDAR inhibition, participants post-KPL-404 administration were immunized with 1 mg intramuscular injection of the test antigen Keyhole Limpet Hemocyanin (KLH) on day 4 and day 29 to elicit a primary and secondary Immunoglobulin (Ig) response, respectively. To evaluate RO, free and total CD40 receptor levels (percent change from baseline) on B-cells (whole blood) were measured using flow cytometry.

Results: There were no dose-limiting or dose-related safety findings in healthy participants after KPL-404 administration. One unrelated serious adverse event (patella fracture following a fall) occurred in the 10 mg/kg IV arm. The PK profile of KPL-404 in serum after IV or SC administration had low to moderate variability between individuals; elimination was dose-dependent and consistent with target-mediated drug disposition (TMDD) (Figure 1a). For participants receiving 10 mg/kg IV, full receptor occupancy was observed through day 71 (Figure 1b), complete TDAR suppression was observed through Day 57 (Figure 1c), and anti-drug antibodies to KPL-404 were suppressed for at least 57 days; the suppression of antibody responses to the drug itself is an independent indicator of target engagement and pharmacodynamic effect. For participants receiving 5 mg/kg SC, full receptor occupancy was observed through day 43 (Figure 1b), and complete TDAR suppression was observed through Day 29 (Figure 1c). The TDAR response to KLH antigen correlated with the observed full RO.

Conclusion: The safety and tolerability data and the PK/PD profile of KPL-404 support further investigation of KPL-404 in a broad range of autoimmune diseases, including rheumatoid arthritis. These data support the optionality for studying chronic KPL-404 dosing in patients with subcutaneous and/or intravenous administration.

Disclosure of Interests: Manoj Samant Shareholder of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., Alistair Wheeler Consultant of: Kiniksa Pharmaceuticals Corp., Guang-Liang Jiang Shareholder of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., Moses Njenga Shareholder of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., John F. Paolini Shareholder of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., L. Fabienne1, C. Costecalde1, M. Drame1, C. Deligny2, P. Numeric1, M. Blettery3, C. Peti1, M. De Bandt1, B. Suzon1, Hospital Center University Of Fort De France, Rheumatology, Fort-de-France, Martinique; 2Hospital Center University Of Fort De France, Public Health, Fort-de-France, Martinique; 3Hospital Center University Of Fort De France, Internal Medicine, Fort-de-France, Martinique

Background: Mortality and morbidity related to rheumatoid arthritis (RA) has remarkably improved over the last twenty years since using biologics DMARDs1. However, their effectiveness remains questionable in Afro-descendants (AD) due to their large under-representation in RA clinical trials 2,3. Martinique is a French Caribbean region with a majority of AD population 4, with free access to healthcare, including biotherapies, and a unique university hospital and rheumatology unit.

Objectives: To evaluate effectiveness of tocilizumab (TCZ), an interleukin-6 inhibitor, in an afro descendant RA population.

Methods: Retrospective cohort of 171 patients who received at least 1 infusion Tocilizumab (IV TCZ) at Martinique University Hospital between 2008 and 2019. Inclusion Criteria: Patients over 18 y/o meeting RA 2010 ACR/ EULAR criteria, having received at least 4 courses of IV TCZ starting at 8mg/kg every 4 weeks, with available baseline clinical/biological data. Exclusion criteria: Patients having received subcutaneous TCZ (SC TCZ) prior to IV TCZ, not living in Martinique. Primary endpoint was proportion of patients in remission (R) and low disease activity (LDA) according to DAS28 CRP at 12, 24, 36 weeks. Secondary endpoint was proportion of patients achieving good (GR) and moderate (MR) EULAR response criteria at 12, 24, and 36 weeks, and TCZ retention at 1 year defined as the proportion of patient receiving TCZ at 1 year follow up.

Results: Out of 171 patients receiving IV TCZ, we identified 138 RA and 80 patients met inclusion criteria: 90% were women, mean age was 56.8 (+ 11.8) y/o, mean duration of RA was 11.6 (+ 8.9) years, ACPA and Rheumatoid Factor were positive in 72.1% and 73% of cases, 69.6% of patients had erosions and 78.7% had received at least 1 biologic prior to IV TCZ. At baseline, 8 patients were in R, 8 had LDA but presented steroid dependency over 10mg per day of prednisone and mean dose of prednisone was 6.9 (+/– 6.7) mg per day. At 12, 24, 36 weeks, R was achieved in 44.8%, 55.2% and 51.2% of patients and LDA in 37.3%, 17.2% and 20.9%, respectively (Figure 1). At 12, 24, 36 weeks, GR was achieved in 44.8%, 60.3% and 48.8% of patients respectively, MR was achieved in 20.9%, 20.7% and 27.9% of patients respectively (Figure 1) and mean dose of prednisone per day was 5.1 (+ 4.9) mg, 4.9 (+ 5.6) mg and 3.3 (+ 5.1) mg respectively. At 1 year, 78.8% of patients were still on TCZ. During follow up: 15 patients experienced 19 infectious events; 6 patients liver cytolysis; 12 patients neutropenia. No patient died.

Conclusion: This is the first study evaluating efficacy and safety of TCZ in an AD RA cohort. TCZ is safe and effective in our AD population with comparable data observed in other ethnicities 6,7.

REFERENCES:

Disclosure of Interests: None declared
Background: Fatigue is common among patients with rheumatoid arthritis (RA) with a substantial impact on quality of life (1). Biological disease-modifying anti-rheumatic drugs (bDMARDs) have been shown to significantly improve fatigue in these patients. However, fatigue is under-assessed by the physicians and evidence is still scarce regarding a possible impact of fatigue on disease activity over time.

Objectives: To explore the long-term impact of fatigue on the disease activity in patients with RA treated with bDMARDs.

Methods: A monocentric observational retrospective cohort study was conducted with 24 months (M) of follow-up. Participants diagnosed with RA, according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria, and registered on the Rheumatic Diseases Portuguese Register (Reuma.pt) who started their first bDMARD between 2015 and 2021 were included. Demographic, clinical and laboratory data were obtained by consulting Reuma.pt. Fatigue was monitored at baseline, line 12 and 24 M using Functional Assessment of Chronic Illness Therapy-Fatigue (FACT-F). This scale is a 13-item self-reported questionnaire with a total score ranging from 0 to 52. A score ≤ 39 indicates the presence of clinically significant fatigue. Disease Activity Score for 28 joints with erythrocyte sedimentation rate (DAS28), DAS28 with C-reactive Protein (CRP) (DAS28-CRP), DAS28 delta, Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) were calculated to measure disease activity. Clinical response was evaluated by EULAR criteria in three response categories—good, mild and no response—and by ACR criteria (0 to 100%) at 12 and 24 M. To correlate fatigue score with EULAR clinical response Chi-square test was used. Multivariate linear regression models adjusted for age, gender and disease duration were used to assess the effect of fatigue on disease activity and ACR clinical response over time.

Results: A total of 40 patients with RA were included, with a mean age of 47±1.4 years old and disease duration of 10.4±5.6 years. Most patients were female (90.2%). Rheumatoid Factor was positive in 70% of patients. The majority of patients (84%) had clinically significant fatigue at baseline moment (FACT-F 26.9±11.8). Treatment characteristics and baseline disease activity scores are described in Table 1. Fatigue at baseline moment predicted DAS28 (CRP) (β=-0.061, 95%CI [-0.12; -0.003]) and CDAI (β=-0.30, 95%CI [-0.57; -0.029]) at 12M. Additionally, fatigue predicted SDAI (β=-0.38, 95%CI [-0.72; -0.047]) and CDAI (β=-0.39, 95%CI [-0.73; -0.051]) at 24M. In general, for these models, fatigue as a symptom was shown to have negative effects on the different outcomes analysed. Fatigue did not associate with EULAR and ACR responses over time.

Table 1. Baseline characteristics of sample. LEGEND: SD: Standard deviation; DAS28: Disease Activity Score for 28 joints; CRP: C-reactive Protein; CDAI: Clinical Disease Activity Index; SDAI: Simplified Disease Activity Index.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Descriptive statistic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment options</td>
<td>n(%)</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>37(92.5)</td>
</tr>
<tr>
<td>Conventional DMARDs</td>
<td>37(92.5)</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>19(47.5)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>13(32.5)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>4(10)</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>4(10)</td>
</tr>
<tr>
<td>Disease activity score</td>
<td>Mean±SD</td>
</tr>
<tr>
<td>DAS28</td>
<td>5.4±0.87</td>
</tr>
<tr>
<td>DAS28-CRP</td>
<td>4.9±0.69</td>
</tr>
<tr>
<td>CDAI</td>
<td>276±8.5</td>
</tr>
<tr>
<td>SDAI</td>
<td>28.3±8.7</td>
</tr>
</tbody>
</table>

Conclusion: These findings showed that, in our sample, the most RA patients had severe fatigue and its presence may be a predictor of increased disease activity. Indeed, previous research observed a positive association between fatigue and disease activity over the time in patients with RA (2). Therefore, fatigue should be regularly monitored in patients with RA and its impact on treatment must be considered. Moreover, further research with larger samples is needed to explore the impact of fatigue on clinical response and the potential of fatigue relief as an outcome measure of RA treatment.

REFERENCES:

Disclosure of Interests: None declared


---

**AB0361**

TOCILIZUMAB VERSUS TOFACITINIB IN THE 12-MONTH TREATMENT OF BIOLOGICAL-NAIVE PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS

1.1M. Sechenov First Moscow State Medical University (Sechenov University), Institute of Pharmacy, Moscow, Russian Federation; 2. V.A. Nasonova Research Institute of Rheumatology, Systemic Rheumatic Diseases Laboratory, Moscow, Russian Federation

Background: The choice of the most effective disease-modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA) remains relevant. There are several comparative studies between tocilizumab (TCZ), an antibody against interleukin 6 receptor, and tofacitinib (TOFA), a potent selective Janus kinase inhibitor, regarding their efficacy (1,2).

Objective: To compare the effectiveness of TCZ and TOFA for treatment of biological-naive patients (pts) with active RA according to various indicators of disease activity, physical function, and quality of life during a 12-month (m) follow-up period.

Methods: A total of 80 biological-naive pts with high and moderate RA activity were enrolled (40 pts with TCZ and 40 pts with TOFA). The groups were comparable in terms of sex, age, BMI, and DAS28. All pts were measured: for disease activity using DAS28, SDAI, and CDAI for quality of life and physical function using EQ-5D, HAQ, and RAPID 3 questionnaires at the beginning of the study and after 12 m of TCZ/TOFA therapy. The EULAR response criteria for treatment of RA were used.

Results: Significant positive changes in major disease activity, clinical and laboratory parameters were found in RA pts after 12 m of TCZ infusions and TOFA intake: DAS28, SDAI, and CDAI decreased significantly in both groups (p<0.01 in all cases). There were more good responders among TCZ pts compared to TOFA pts: by DAS28 35 pts (87.5%) vs. 20 pts (50%), p<0.01; by CDAI 38 pts (95%) vs. 26 pts (65%), p=0.02, respectively. There was a more pronounced decrease in DAS28 and CRP levels in TCZ pts (ΔDAS28=-3.8 [-4.5; -3.2], ΔCRP=-26.5 [-45; -10.7]) mL compared to TOFA pts (ΔDAS28=-2.1 [-3.2; -1.0], ΔCRP=-10.1 [-13.2; -8.5]) mL (p<0.01 in all cases). Both drugs equally improved quality of life and physical function indicators EQ-5D, HAQ, and RAPID in a 12-m follow-up period. Correlations of ΔEQ-5D with ΔASR (R=0.43; p<0.01) and with ΔCRB (R=0.46; p=0.03) were found after 12 m of TCZ therapy.

Conclusion: TCZ and TOFA both significantly reduce disease activity and improve quality of life and physical function in bDMARD-naive RA patients. Compared with TOFA, TCZ can induce greater improvements during the first 12-m treatment. No unequivocal conclusions on the drugs' effect on pts' quality of life could be made.

REFERENCES:

Disclosure of Interests: None declared

AB0362

NEUTROPHIL COUNT REDUCTION 1 MONTH AFTER INITIATING SARILUMAB AND BASELINE SERUM SOLUBLE GP130 LEVELS MAY INDEPENDENTLY PREDICT CLINICAL REMISSION WITHIN 3 MONTHS IN RHEUMATOID ARTHRITIS PATIENTS

T. Yoshikawa1, K. Azuma1, T. Furukawa1, T. Hashimoto1, M. Morimoto1, N. Azuma1, K. Matsui1, Hyogo College of Medicine College Hospital, Division of Allergology and Rheumatology, Department of Internal Medicine, Nishinomiya, Japan

Background: IL-6 contributes significantly to the chronic inflammatory process of rheumatoid arthritis (RA) and is elevated in serum and synovial fluid of RA patients. Sarilumab (SRL), a human anti-human IL-6 receptor alpha monovalent antibody that blocks the signaling originating by the IL-6/IL-6R complex like tocilizumab (TCZ),is an effective treatment. Recently, an association between the therapeutic effect of TCZ and neutropenia after TCZ initiation was reported[1]. Neutropenia is a common adverse event of SRL in patients with RA, but the relationship between reduced neutrophil count and clinical response to SRL is still inconclusive. In EULAR 2020, we reported the association between serum soluble gp130 levels before SRL treatment and the efficacy of SRL[2]. It is also unclear whether there is a relationship between IL-6 axis cytokines and SRL-induced neutropenia.

Objectives: The purpose of this study was to determine whether neutropenia at 1 month by SRL predicts clinical remission within 3 months and whether there is an association between IL-6 axis cytokines levels and SRL-induced neutropenia.

Methods: This research is a retrospective study. We reviewed medical records of RA patients initiating SRL between February 2018 and August 2021 in our hospital. The Clinical Disease Activity Index (CDAI) was evaluated at baseline (before initiating SRL) and 3 months after administration. Clinical remission was defined when CDAI decreased ≥ 2.8. Of the 66 patients treated with SRL, 42 patients with 3 months follow-up, valid CDAI and serum available were enrolled. The ratio of neutrophil counts 1 month after initiating SRL to those at baseline (neutrophil ratio) was also calculated. Serum samples were tested for IL-6 (Human IL-6 Quantikine ELISA Kit, R&D systems), sIL-6R (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems) and sgp130 (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems) using specific ELISAs according to the manufacturer’s instructions. The statistical analyses were performed with EZR 1.55, and p values less than 0.05 were considered significant.

Results: The median age of patients was 69.0 (IQR: 59.3 - 73.8) years and the median of disease duration was 9.0 (3.0 - 16.0) years. Eighteen (42.9%) patients were biologics and JAKinibs naive. The baseline CDAI was median 16.7 (11.5 - 25.8). When comparing CDAI-remission group (clinical remission: CR) and non-CR group, Patients in the CR group had significantly shorter disease duration (11.5 vs 25.8). When comparing CDAI-remission group (clinical remission: CR) and non-CR group (264.9 vs 234.2 ng/mL, P=0.0592). Univariate logistic regression analysis suggested Biologics and JAKinibs naive (odds ratio (OR) 6.68, p=0.0317), baseline serum sgp130 levels (OR 8.608, P=0.0312) as predictors of CDAI remission treated with SRL at 3 months. Although not significant, neutrophil ratio ≤ 0.8 was associated with achieving remission (OR 6.67, P=0.0537). Univariate logistic regression for neutrophil ratio ≤ 0.8 did not show any relevant factors, including higher baseline serum sgp130 levels (OR 1.25, P=0.782).

Conclusion: A 20% or greater decrease in neutrophil count after 1 month of SRL treatment and a high baseline serum sgp130 level independently predict clinical remission within 3 months.

REFERENCES:

Disclosure of Interests: None declared

AB0363

COMPARING THE ULTRASONOGRAPHIC EVALUATION IN PATIENTS WITH JAPANESE RHEUMATOID ARTHRITIS BETWEEN JAK AND TNF INHIBITOR THERAPY

Y. Kanayama1, A. Nagata, M. Shimotake, F. Miyachi2, K. Fujita2, M. Koyama2, S. Uno2, Toyota Kosei Hospital, Orthopedic Surgery and Rheumatology, Toyota, Japan; 1Toyota Kosei Hospital, Clinical Technology, Toyota, Japan

Background: JAK inhibitor (JAK) and TNF inhibitor (TNF) are the important therapeutic agents for the treatment of rheumatoid arthritis. However, there is still few studies of improvement of ultrasonographic findings in RA treated comparison with JAK and TNF.

Objectives: To evaluate the clinical efficacy of JAK and TNF therapy patients with rheumatoid arthritis (RA) using ultrasonography (US).

Methods: Participants comprised 32 and 39 Japanese RA patients who had recently received JAK (BAR23, PEF9) and TNF. All patients with a diagnosis of RA according to the 2010 ACR/EULAR criteria. Patients underwent clinical and laboratory assessments every 4 weeks from baseline to 24 weeks, and US assessments at baseline, 4, 12 and 24 weeks. Gray scale (GS) and power doppler (PD) signals were scored using a semi-quantitative scale from 0 to 3 at 6 sites (278 synovial sites for comparison tests): bilateral first to fifth metacarpophalangeal (MCP) joints (dorsal recess); first interphalangeal (IP) joints and second to fifth proximal interphalangeal (PIP) joints; (dorsal recess); and the wrist (dorsal radial, median and ulnar). We evaluated the improvement of GS and PD score from baseline to week 24.

Results: In the patients receiving JAK (n=32) and TNF (n=39), the mean age was 54.7 vs 55.1 years old (p=0.871), disease duration was 7.4 vs 6.1 years (p=0.290), the rate of MTX use was 75% vs 87% (p=0.187), the mean MTX dose was 9.9 vs 10.2 mg/w (p=0.813), the rate of ACPA positive was 94% vs 79% (p=0.086), DAS28-ESR was 4.79 vs 4.65 (p=0.435), CDAI was 22.4 vs 19.1 (p=0.239), GS score was 20.8 vs 18.3 (p=0.995) and PD score was 14.0 vs 11.0 (p=0.940). The degree of improvement respective changes in GS and PD score after 4, 12 and 24 weeks were as follows: GS: -5.1 vs -4.3 (p=0.817) and PD: -5.3 vs -2.7 (p=0.855) after 4 weeks, GS: -9.1 vs -6.6 (p=0.880) and PD: -7.9 vs -4.5 (p=0.476) after 12 weeks, GS: -10.4 vs -9.5 (p=0.463) and PD: -8.1 vs -6.7 (p=0.949) after 24 weeks between JAK and TNF (Figures 1 and 2). Next, The improvement rate of respective changes in GS and PD score after 4, 12 and 24 weeks were as follows: GS: -13.7% vs -18.3% (p=0.489) and PD: -20.4% vs -16.5% (p=0.777) after 4 weeks, GS: -29.7% vs -26.0% (p=0.922) and PD: -30.9% vs -30.8% (p=0.890) after 12 weeks, GS: -38.1% vs -36.4% (p=0.567) and PD: -33.4% vs -50.1% (p=0.086) after 24 weeks between JAK and TNF.

Conclusion: The present study provides evidence supporting the JAK and TNF therapy improved similarly the inflammatory synovitis of US findings.
THE EFFECT OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON WORK PARTICIPATION IN LONGSTANDING RHEUMATOID ARTHRITIS: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

A. Alunno1, M. L. Marques2,3, L. Falcone4, S. Ramiro2,5, A. Boonen1, Internal Medicine and Nephrology Unit, University of Ukkia, Department of Life, Health and Environmental Sciences, Ukkia, Italy; 5Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 3Coimbra University Hospital, Department of Rheumatology; Coimbra, Portugal; 6University of Sheffield, Health Economics and Decision Science, School of Health and Related Research, Sheffield, United Kingdom; 3Zuyderland Medical Center, Department of Rheumatology, Helleen, Netherland; 4Maastricht University Medical Center, Department of Rheumatology, Maastricht, Netherlands.

Background: Work participation (WP) is a top priority for people with RA and a determinant of patients’ quality of life. Therefore, assessing the effect of interventions on WP outcomes is important.

Objectives: To review the effect of b/tsDMARDs on employment status (ES), sick leave (SL) and presenteeism in patients with longstanding RA.

Methods: A systematic review updated to October 2021 was conducted using the PICOT framework (Figure 1). Two researchers independently screened abstracts, then full texts were reviewed to determine eligibility. Data from eligible articles were extracted. Heterogeneity and insufficient reporting of data precluded meta-analysis.

Results: We included 42 studies: 16 randomized controlled trials (RCT) and 26 longitudinal observational studies (OBS). All studies were conducted with background therapy with csDMARDs, 33 (78%) in csDMARD-IR patients. RCTs provided short-term data only (<24 weeks) which have limited relevance for WP outcome domains such as ES. OBS reported long-term data (≤5 years), albeit imposing challenges due to lack of random allocation to interventions and often lack of a comparator. Future studies should consider existing guidance on the assessment of WP outcome domains to allow pooling and meta-analysis.

Conclusion: Short-term data from RCTs with background therapy with csDMARDs showed adding b/tsDMARDs was more effective than PBO in improving presenteeism. However, data on SL are conflicting and the positive results come from OBS without comparator. Future studies should consider existing guidance on the assessment of WP outcome domains to allow pooling and meta-analysis.

REFERENCES:


Disclosure of Interests: Alessia Alunno: None declared, Mary Lucy Marques: None declared, Louise Falcone: None declared, Sofia Ramiro: None declared, Annelies Boonen Speakers bureau: Abbvie, Galapagos, Consultant of: Galapagos, Grant/research support from: Abbvie


Table 1. Overview of presenteeism from RCTs and OBS with a comparator in csDMARD-IR patients

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Instrument</th>
<th>Recall period</th>
<th>Intervention ([/Comparator ([C])</th>
<th>N employed/N total</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>From the article</td>
</tr>
<tr>
<td>Bae</td>
<td>2013</td>
<td>WPAI/GH</td>
<td>7 d</td>
<td>I: ETN</td>
<td>NR/197</td>
<td>% improvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: csDMARD</td>
<td>NR/103</td>
<td>49.6</td>
</tr>
<tr>
<td>Bingham</td>
<td>2014</td>
<td>Self-composed single item</td>
<td>4 w</td>
<td>I: GOL</td>
<td>NR/395</td>
<td>Mean Δ (SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: PBO</td>
<td>NR/197</td>
<td>-2.4 (2.8)</td>
</tr>
<tr>
<td>Emery</td>
<td>2017</td>
<td>WPAI/RA</td>
<td>7 d</td>
<td>I: BARI 2mg</td>
<td>88/229</td>
<td>LSM from BL (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>76/227</td>
<td>-14 (-20 to -8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>90/228</td>
<td>-16 (-22 to -11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>199/487</td>
<td>LSM from BL (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>206/488</td>
<td>-10 (-13, -6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: BARI 4mg</td>
<td>199/487</td>
<td>-10 (-13, -6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>206/488</td>
<td>-10 (-13, -6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: CZP 200mg</td>
<td>132/393</td>
<td>LSM from BL (SE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>139/390</td>
<td>-3.74 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: CZP 400mg</td>
<td>69/199</td>
<td>-3.50 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>101/246</td>
<td>-0.11 (-0.3; 0.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: CZP 400mg</td>
<td>95/246</td>
<td>-0.11 (-0.3; 0.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>49/127</td>
<td>-0.11 (-0.3; 0.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: SARI</td>
<td>78/184</td>
<td>LSM from BL (SE)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: ADA</td>
<td>185</td>
<td>-3.74 (0.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NR/154</td>
<td>-3.50 (0.5)</td>
</tr>
<tr>
<td>Kaelie</td>
<td>2018</td>
<td>WPAI/RA</td>
<td>7 d</td>
<td>I: ADA + MTX 7.5mg</td>
<td>NR/155</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: ADA + MTX 20mg</td>
<td>NR/155</td>
<td>NR</td>
</tr>
<tr>
<td>Tanaka</td>
<td>2021</td>
<td>WPAI</td>
<td>7 d</td>
<td>I: PEF100mg + csDMARDs</td>
<td>60/104</td>
<td>Mean Δ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>53/102</td>
<td>-12.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: PEF150mg + csDMARDs</td>
<td>50/102</td>
<td>-18.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: PBO</td>
<td>99/170</td>
<td>3.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: PEF150mg + MTX</td>
<td>101/174</td>
<td>Mean Δ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>116</td>
<td>-16.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I: PEF150mg + MTX</td>
<td>101/174</td>
<td>-2.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>C: PBO + MTX</td>
<td>167/377</td>
<td>Mean Δ</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>160/347</td>
<td>-17.7</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>206/488</td>
<td>-17.2</td>
</tr>
</tbody>
</table>

*OBS/WPAI, work productivity and activity index; WPS, work productivity survey; GH, global health; NR, not reported; LSM, least mean square; BL, baseline; CI, confidence interval; SE, standard error; SMD, standardized mean difference; d, days; w, weeks; m, month. †Added to background therapy with csDMARDs unless otherwise stated.
BELIEFS AND ADHERENCE IN RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGIC DRUGS

E. Hannech1,2, S. Boussaid3,4, S. Rekik4,5, J. Smellial4,5, S. Rahmouni4,5, H. Ajmani1, H. Sahli2, M. Elleuch2,6, R. Dharhi2,6, I. Gharsallah4,5, P.3

1Rheumatology Department, La Rabta Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia; 3Rheumatology Department, Military Hospital of Tunis, Tunis, Tunisia

Background: Patients with chronic rheumatic diseases play an important role in their disease management. Adherence to their long-term therapies may depend on their therapeutic beliefs. [1]

Objectives: The purpose of our study was to investigate the relationship between beliefs and adherence among patients with rheumatoid arthritis (RA) on biologic therapies (bDMARDs).

Methods: We conducted a multi-center cross-sectional study, including patients with RA fulfilling the ACR/EULAR 2010 criteria. All patients were on bDMARD. Sociodemographic, clinical, biological, and therapeutic data were collected. Patients were interviewed about their medication beliefs using the Beliefs About Medicines Questionnaire (BMQ) and about their therapeutic adherence.

Results: There were 75 RA patients: 60 female (80%) and 15 males (20%). The sex ratio was about 0.25. Their mean age was 56.92±9.06 years [34-80]. Thirty-three percent of patients were illiterate. Twenty patients were employed (15%). The mean disease activity score (DAS28 CRP) was 3.94±1.32 [12.71-75]. Fifteen patients (20%) had high disease activity, 11% had low activity, and 19% were in remission. The mean duration of the current bDMARD was 37.17±39.44 months [4-248]. The mean Specific Necessity score was 21.0±8.38 [5-25] for adherent patients and 13.5±7.54 [5-19] for non-adherent patients.

The mean Specific Concerns score was 10.07±3.13 [5-15] for adherent patients and 15.2±8.22 [5-20] for non-adherent patients. A statistically significant association was found between Specific Concerns beliefs and adherence behavior (p=0.009) and between Specific Concerns beliefs and adherence behavior (p=0.003). No statistically significant association was noted between general beliefs (General Harm and General Overuse) and adherence behavior (p=0.4 and p=0.6 respectively).

Conclusion: Beliefs about therapeutic were identified as a key factor of adherence among rheumatic disease patients. Practitioners should detect negative patient beliefs and perceptions earlier to prevent nonadherence.

REFERENCES:

Disclosure of Interests: None declared


A PROSPECTIVE OBSERVATIONAL STUDY TO ASSESS THE REAL-WORLD EFFECTIVENESS OF GOLIMUMAB IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PREVIOUSLY TREATED WITH INITIAL TNF-A INHIBITIVE THERAPY

C. Gaujoux-Viala1, J. Sellam2, F. Tubach1, N. Harid2, B. Combe1, R. M. Filipo1

1CHU Nîmes, IDESP UMR UA11 INSERM - Université de Montpellier, Montpellier, France; 2Hôpital Saint-Antoine, Paris 12, Paris, France; 3CHU de Montpellier, Hôpital Lapeyronie, Montpellier, France; 4MSD, France, Puteaux, France; 5CHU La Pitié-Salpêtrière, Paris 13, Paris, France; 6CHRU de Lille, Lille, France

Background: TNF inhibitor (TNFi) treatment is standard for RA patients even though many reasons may lead to TNFi therapy failures such as lack of effectiveness, patient dissatisfaction or limited therapy adherence, or even safety. As a consequence, patients may switch to a different TNFi. The efficacy of golimumab (GLM) in RA patients may be associated with an adequate response to TNFi was demonstrated in the Go-AFTER phase III clinical trial.

Objectives: The objectives of the present Go-BEYOND study were to provide real-world data to evaluate disease activity and treatment persistence with GLM as a second line TNFi therapy in RA patients over a one-year follow-up.

Methods: Go-BEYOND is an observational French multicenter prospective cohort study. All consecutive patients over 18 years of age with a diagnosis of active RA were eligible at the time of initial GLM prescription. To be included, patients had to be previously treated with only 1 TNFi (discontinued for any reason) other than GLM. Patients were ineligible if they had been previously treated with other "non-TNFi" biologics or more than one TNFi.

The study’s primary outcome was the percentage of RA patients with a Disease Activity Score (DAS28-CRP score) ≤ 3.2 at the 6-month visit (M6 visit). Patients who permanently discontinued their treatment over the 1-year follow-up were considered as non-responders. The secondary outcomes were analyzed descriptively and included (but not limited) to DAS28-CRP score at 12-month visit (M12 visit), EULAR criteria assessment, treatment persistence analysis, HAQ score, RAPID3 score, and patient acceptable symptom state and satisfaction with the injection. The study was approved by a French Ethics Committee in July 2020.

Results: A total of 128 patients (72.7% female, median age 58.2 years, and duration of RA 13.2 ± 11.4 years) met the inclusion criteria. Anti-CPP antibodies and rheumatoid factors were present in 80 (62.5%) and 81 (63.3%) patients, respectively. In the majority, the initial TNFi was etanercept (n=88, 68.8%), then adalimumab (n=25, 19.5%). The reasons for switching to GLM were secondary non-response (i.e., lack of effectiveness after an initial response to the treatment) or for 75 (58.6%) patients, then safety (n=22, 17%), primary non-response (n=21, 16.4%), and other personal or medical reasons (n=10, 7.8%).

At the M6 and M12 visits, a small number of patients, 27 (21.1%) and 48 (37.5%) had respectively permanently discontinued their GLM treatment and were considered as non-responders. At the M6 visit, 48 patients over the 128 included (37.5%) had a DAS28-CRP < 3.2 and 35% (< 2.6). At M12 visit, 41 (32%) patients had a DAS28-CRP < 3.2 and 31 (24.2%) < 2.6. According to EULAR response criteria thresholds, 49 (38.3%) and 45 (35.2%) patients had a good or moderate response to GLM at the M6 and M12 visits.

Conclusion: The Go-BEYOND study confirms that in RA, a non-response to a first TNFi does not exclude a response to GLM as a second-line biologic in a substantial proportion of patients in real-life settings.

Disclosure of Interests: None acknowledged

We would like to thank the investigators and the entire Go-BEYOND team for their involvement in the study.

Disclosure of Interests: Cécile Gaujoux-Viala Consultant of: AbbVie; Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Roche; Sandoz; Sanofi; UCB, Jérémie SELLAM Consultant of: Abbvie; Biogen; BMS; Fresenius Kabi; Janssen; MSD; Novartis; Pfizer; Roche; Florence Tubach: None declared, Naouaf HARID Employee of: MSD France - Medical advisor, Bernard Combe Consultant of: Abbvie; Bristol-Myers Squibb; Celltrion; Eli Lilly; Gilead/Galapagos; Janssen; Merck; Novartis; Pfizer; Roche/ Chugai; Sanofi; UCB, René-Marc Filipo Consultant of: Abbvie; BMS; Janssen; MSD; Pfizer; Roche-Chugai


THE PARADIGM OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS: SUBTYPES AND EARLY IDENTIFICATION

M. Novella-Navarro1, V. Ruiz1, G. Torres Ortiz2, C. A. Chacur2, C. Tornero1, A. Vilalba1, R. Sammarti1, C. Plasencia1, A. Balsa1, 1Hospital Universitario La Paz, Rheumatology, Madrid, Spain; 2Hospital Clinic, Rheumatology, Barcelona, Spain

Background: Difficult-to-treat rheumatoid arthritis (D2TRA) is an emerging concern for rheumatologists. Multiple failures to biologic or targeted specific disease modifying antirheumatic drugs (b/tsDMARDs) may be due to multi-drug inefficacy or difficulties in the optimum management of treatments. In these cases, adverse events, comorbidities, poor adherence, amongst others. In a previous study we identified that younger patients with erosive disease and especially the early absence of clinical response to the first b/tsDMARDs were associated to multiple drug inefficacy but it is worth knowing whether these factors are the same for those patients who receive multiple b/tsDMARDs due to causes other than inefficacy.

Objectives: i) To describe the characteristics of a cohort of D2TRA patients in clinical practice. ii) To analyze the differences between D2TRA due to inefficacy vs D2TRA to other causes. iii) To compare the different subtypes of D2TRA with non-D2TRA.

Methods: This study involved patients with D2TRA from La Paz Hospital and Clinika Hospital between 2015 and 2021. D2TRA group included patients who had received ≥3 b/tsDMARDs due to inefficacy (D2TRA-inefficacy) or due to adverse events, poor adherence, contraindications, comorbidities, drug-intolerance etc. (D2TRA-other causes). Patients who achieved low disease activity or remission (by DAS28) with the 1st bDMARD and remained with the same drug for at least 5 years were non-D2TRA patients. For all patients, demographic, clinical characteristics and laboratory parameters were assessed at baseline visit (prior to start the first b/tsDMARD) and after 6 months. Descriptive analysis was performed and bivariate logistic regression models were assembled. P<0.05 was considered statistically significant. Odds Ratio (OR) and Confidence Intervals (CI) were calculated. IBM SPSS 21.0

Results: In total, 253 patients were included, 131 were non-D2TRA and 122 D2TRA [86 (70.5%) D2TRA-inefficacy and 36 (29.5%) D2TRA-other causes]. Comparison between both groups of D2TRA patients: no differences were found in gender, age at b/tsDMARD starting or age at RA diagnosis were found and neither between socioeconomic status, frequency of anxiety-depression or other comorbidities. Patients D2TRA-other causes had less extra-articular manifestations
than D2TRA-inefficacy (8.3% vs 26.7%; p=0.02); lower values of DAS28 at starting 1st b/tsDMARD (4.9±1.4 vs 5.7±1.2; p<0.01), and also at 6 months of treatment (3.5±1.5 vs 4.5±1.5; p=0.02) than those with D2TRA-inefficacy.2) Comparison between Non-D2TRA patients and D2TRA-other causes: no differences in sociodemographic characteristics were found and neither differences in baseline disease activity, only differences in DAS28 at 6 months were observed, being higher D2TRA-other causes than in non-D2TRA (3.5±1.5 vs 2.9±3.0; p<0.03). Binormal distribution analysis showed that DAS28-6m was slightly associated with D2TRA-other causes (OR=1.45 CI95%: 1.11-1.21).
Conclusion: In this cohort, around 3 out of 10 D2TRA patients dropped out multiple b/tsDMARDs for reasons other than inefficacy. In contrast to D2TRA-inefficacy, patients with D2TRA-other causes are indistinguishable from non-D2TRA patients at baseline, indicating that patients with D2TRA-other causes does not seem predictable in the early stages of treatment with b/tsDMARDs, unlike what occurs with multidrug inefficacy.

Disclosure of Interests: None declared. Virgina Ruiz: None declared, Gabriela Torres Ortiz: None declared, Chaitik Alejandro Charur: None declared, Carolina Tomoro: None declared, Alejandro Villalta: None declared, Raimón Sanmartí: Grant/research support from: Abbvie, BMS, Gebro Pharma, Lilly, MSD, Pfizer, Sanofi and Roche, Chaimaida Plasencia Speakers bureau: Pfizer, Lilly, Sandoz, Abbig, Biogen, Roche, Sanofi, Novartis, Grant/research support from: Pfizer, Abbvie, Alejandro Balsa Speakers bureau: Pfizer, Abbvie, Lilly, Galapagos, BMS, Sandoz, Nordic, Gebro, Roche, UCB, Consultant of: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic, Sanofi, UCB, Grant/research support from: Pfizer, Abbvie, BMS, Nordic, Gebro, Roche, UCB

Disclosure of Interests: None declared. DOI: 10.1136/annrheumdis-2022-eular.4321

AB0369 EFFECTS OF SWITCHING FROM ETANERCPT ORIGINATOR TO ETANERCPT BIOISIMILAR ON DISEASE ACTIVITY, PHYSICAL FUNCTION, AND PATIENT-REPORTED OUTCOME REGARDING A SELF-INJECTION DEVICE IN PATIENTS WITH WELL-CONTROLLED RHEUMATOID ARTHRITIS

Y. Hirano1, Y. Ono1, Toyohashi Municipal Hospital, Rheumatology, Toyohashi, Japan

Background: Although biological drugs have dramatically changed and improved the outcome of patients with rheumatoid arthritis (RA), a lot of unresolved problems still exist. Although comorbid by which enough treatment drugs cannot be prescribed or RA patients refractory to biological agents are representatives, financial difficulty is another representative. There are RA patients who hesitate biological treatment or treatment with Janus-kinase inhibitor due to financial difficulty. Although biosimilar disease-modifying anti-rheumatic drugs (DMARDs) are promising treatment options for such patients, real-world clinical experiences are still lacking in respect to exchanging from biological originator DMARDs to biosimilar DMARDs.

Objectives: This retrospective study investigated the effects of switching from etanercept originator (ETN-OR) to ETN-biosimilar (ETN-BS: LBEC0101 developed by LG Chem) on disease activity, physical function, and patient-reported outcome (PRO) regarding a self-injection device in patients with well-controlled RA.

Methods: Data from the Toyohashi RA Database (TRAD) was used, which is a collection of single-center retrospective data. We retrospectively investigated disease activity, modified health assessment questionnaire (mHAQ), and patient characteristics in 42 RA patients that switched from ETN-OR to ETN-BS at least 6 months prior. Patients were also requested to answer the Toyohashi Self-Injection Assessment Questionnaire (T-SAQ), originally designed to assess PRO. T-SAQ consisted of 18 questions about self-injection device such as burden, learning, pain, convenience, handling and so on. Best was 0 and worst was 4 in each question and mean score of 18 questions was called total T-SAQ score.

Results: All the patients were female. The mean age, RA duration, and ETN-OR treatment duration were 63.1 years, 18.3 years, and 3107 days, respectively. Mean disease activity and mean mHAQ after switching were as follows (baseline-3 months-b): DAS28-3CRP (1.86-2.00-2.03), SDAI (4.3-5.0-5.3), and mHAQ (0.43-0.44-0.46). SDAI after 6 months was significantly elevated compared to baseline. Among each parameter, tender joints count at 3 months and patients’ global assessment at 6 months after switching are significantly increased compared to baseline (Table 1). Other parameters such as swollen joint counts, physician global assessment and CRP were not significantly changed. Total T-SAQ scores before and after switching were 1.3 and 1.1 (p<0.01), respectively. Ease of use, mental tension, and pain were especially improved after switching to ETN-BS.

Conclusion: Switching from ETN-OR to ETN-BS worsened disease activity in well-controlled RA patients in our real-world clinical practice due to not objective findings, but subjective complaints by RA patient. We thought that nocebo effect was one of the reasons to explain the results. On the other hand, the PRO regarding the injection device was improved. This improvement may be due to Finer needle of ETN-BS (ETN-OR: 27G, ETN-OR: 29G).

Table. Time-course of parameters on disease activity

<table>
<thead>
<tr>
<th></th>
<th>At starting of ETN-OR (n=34)</th>
<th>At switching to ETN-BS (n=42)</th>
<th>At 3 months</th>
<th>At 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tender Joints Counts</td>
<td>7.5 (5.0)</td>
<td>1.1 (2.2)</td>
<td>1.8 (3.3)*</td>
<td>1.4 (2.5)</td>
</tr>
<tr>
<td>Swollen Joints Counts</td>
<td>4.7 (4.5)</td>
<td>0.2 (0.6)</td>
<td>0.3 (0.7)</td>
<td>0.2 (0.5)</td>
</tr>
<tr>
<td>Physician’s Global Assessment (mm)</td>
<td>38.6 (22.3)</td>
<td>14.6 (12.6)</td>
<td>13.5 (12.1)</td>
<td>21.8 (18.2)*</td>
</tr>
<tr>
<td>CRP (mg/dL)</td>
<td>2.6 (2.7)</td>
<td>0.4 (1.0)</td>
<td>0.3 (0.6)</td>
<td>0.3 (0.6)</td>
</tr>
</tbody>
</table>

Data lacking at starting of ETN-OR exist due to ETN-OR initiation at another institute. Data is expressed mean [standart division]. * p<0.05 compared with data at switching to ETN-BS by Wilcoxon signed-rank test


AB0369 CORRELATION OF THE FIRST LATERAL FLOW-BASED POINT OF CARE TEST TO QUANTIFY INFlixIMAB AND ANTI-INFlixIMAB ANTIBODIES IN A FINGER PRICK SAMPLE WITH THE REFERENCE ELISA TECHNIQUE

M. B. Ruiz-Angelillo1, J. Pascual1, L. Del Rio1, A. Urgoitia2, C. Balo-Farto2, C. Fernández-López3, A. Mera Varela3, F. J. de-Toro-Santos3, D. Nagore1, A. Ametazzaurra1,1, Progenika Biopharma - Grifols, Research and Development, Derio, Spain,2 Hospital Clínico Universitario de Santiago, Servicio Reumatología, Santiago de Compostela, Spain,3 Complexo Hospitalario Universitario A Coruña, Servicio Reumatología, A Coruña, Spain

Background: Current techniques to monitor clinical response may require several days and centralised facilities, which may cause delays in effective therapeutic decisions. Therefore, the use of a rapid decentralized test will facilitate patient management and improve patient care.

Objectives: The goal of this study was to validate the use of capillary blood in a real point-of-care (POC) setting for rheumatic patients under infliximab treatment by using Promonitor Quick lateral flow (LF) tests. Results were compared to the Promonitor ELISA reference technique in serum samples used by centralised laboratories.

Methods: A prospective, observational study was designed to evaluate the performance of a rapid LF test (Promonitor Quick IFX, Progenika, Spain). 160 infliximab-treated rheumatology consecutive patients (400 samples) were recruited in two hospitals in Galicia, Spain. Prior to the infusion, a finger prick sample was obtained and analysed. Anti-infliximab antibodies were also determined with Promonitor Quick ANTI-IFX1. Results were read with the automated portable PQreader instrument. Additionally, a serum sample was collected for subsequent comparative analysis with either LF or ELISA tests.

Qualitative (positive (PPA) and negative (NPA) agreements) and quantitative (Pearson correlation and bias) performance of the LF test was compared to ELISA, as well as between different specimens following CLSI EP09-A3.

Results: Overall agreement between Promonitor Quick IFX finger prick and ELISA test was 91% (88% PPA; 100% NPA). The quantitative comparison showed a good correlation (Pearson correlation coefficient: 0.85 and observed bias: 25%) (Table 1).

Similar results were also observed when serum was used with either the LF or the ELISA tests (98% overall agreement, 0.91 correlation coefficient; 6% bias) (Table 1). Overall agreements for visual and automated (PQreader) interpretations with Promonitor Quick anti-IFX were 99% and 100% for finger prick and serum specimens, respectively (Table 1).

**Conclusion:** Promonitor Quick can be used to reliably quantify infliximab in capillary blood samples and results are comparable to those obtained with the reference ELISA technique. The use of the rapid POCT test with finger prick will allow clinicians to monitor their patients in a fully decentralized model to aid in the decision-making process. PQreader is a sensitive portable equipment to report drug as well as antibody levels in the patient samples.

**REFERENCES:**


**Disclosure of Interests:**

M. Begoña Ruiz-del Agua 1, R. El Hamss 2, M. Moneo 1, M. B. Ruiz-Argüello 3, D. Nagore 3.

**AB0370**

**COMPARISON OF A NEW RANDOM-ACCESS SOLUTION FOR THERAPEUTIC DRUG MONITORING OF ADALIMUMAB TO THE REFERENCE ELISA TEST**

A. Ruiz del Aguila 1, R. El Hams2, M. Moneo1, M. B. Ruiz-Ardógiel, D. Nagore3, Progenika Biopharma SA, POS, Deno, Spain; Progenika Biopharma SA, POS, Deno, Spain; Progenika Biopharma SA, R&D, Deno, Spain

**Background:** Despite numerous studies, Therapeutic Drug Monitoring (TDM) of biological therapies is still debated partly motivated by the accessibility to a ready-to-use monostest device capable of delivering accurate results in a timely manner without the burden of sample batching, therefore allowing immediate decision making.

**Objectives:** We aimed at comparing the new Chorus Promonitor Adalimumab monostest running in the fully automated random-access Chorus TRIO system to the reference ELISA test Promonitor ADL run in a Triturus system.

**Methods:** Chorus Promonitor Adalimumab (Diesse Diagnostica Danese, Italy) is an immunoassay kit for the automated quantitative detection of adalimumab (ADL) in human serum using a ready-to-use disposable monostest device applied on the Chorus TRIO (Diesse Diagnostica Danese, Italy) instrument, a random-access single test multiparametric system for immuno-colorimetric assays. The new device implements the same specific reagents as in the reference ELISA test Promonitor ADL (Progenika, Spain) run in a Triturus (Grifols, Spain) system, therefore ensuring the same analytical specificity and applicability for patient monitoring previously demonstrated with the predicate ELISA. The new monostest device contains all the reagents necessary to perform the assay, and a lot-specific master curve method is used for calibrating. The comparison was performed in a set of 53 serum samples from patients under ADL therapy that covered the entire drug trough concentrations found in clinical practice (up to 30 μg/mL). Pearson’s correlation, Bland-Altman and Passing-Bablok regression analysis were used to study the association and quantitative comparison between the methods.

**Results:** Time to first result for the Chorus Promonitor Adalimumab test was 2 hours and 45 min minutes and after this a new result was delivered every 30 seconds. Positive and negative percent agreements between both tests were 100%. A high correlation between both tests was found (coefficient of correlation of 0.959, p<0.01). The Passing-Bablok regression analysis determined an excellent comparability of both data sets with a slope of 1.032 (0.952-1.129) with an intercept of -0.428 (-1.292-0.053), demonstrating a perfect linear correlation.

**Conclusion:** The Chorus Promonitor Adalimumab represents the first evolution of the gold-standard Promonitor ELISA technology into a monostest random-access technology that enables quick turnaround time to facilitate TDM for ADL and aid immediate decision making.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annonrhedi-2022-eular.4554

**Figure 1.**

**AB0371**

**CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).**

Y. Gorbunova1, T. Popkova1, I. Kirillova1, T. Panafidina1, M. Diatroptov2, E. Nasonov2, 1VA Nasonova Research Institute of Rheumatology, of Systemic Rheumatic Diseases, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, of Immunology and Molecular Biology of Rheumatic Diseases, Moscow, Russian Federation; 3VA Nasonova Research Institute of Rheumatology, Scientific, Moscow, Russian Federation

**Background:** The role of galectin-3, a pro-inflammatory mediator involved in autoimmune disorders in patients with rheumatoid arthritis (RA), is discussed in the literature.

**Objectives:** To clarify the relationship of clinical and laboratory manifestations of RA with galectin-3 in the effectiveness of basic anti-inflammatory therapy and after 12 months of treatment with biological drugs.

**Methods:** The study included 47 pts (39 women /8 men) with RA, 51 [39.0; 63.0] years old. Pts were seropositive for IgM RF (79%) and anti-CCP (62%), with highly active RA (DAS28 5.2; 6.4]; SDAI 35.0 [29.1; 43.6], CDAI 34.0 [25.0; 43.0] scores, and median disease duration of 4.0 [3.0,14.0] years. All patients with RA had a history of insufficient effect or intolerance to two or more basic anti-inflammatory drugs (DMARDs). At the time of inclusion in the study, patients received DMARDs: 44% of patients received methotrexate (median dose - 15 (15; 20) mg /week), 35% - leflunomide (20 mg/day), 9.3% - sulfasalazine (2000 mg/day), 7% - hydroxychloroquine (200 mg/day), 67.4% - glucocorticoids (5 (4.8) mg /day). Patients did not receive biological therapy at the time of inclusion in the study. Due to lack of efficacy or intolerance, patients with RA (n=21) were prescribed biological therapy: 52.4% - anti-B-cell therapy, 38% - TNF-alpha inhibitors, 9.6% - IL-6 inhibitors. The control group consisted of 20 age-matched donors without rheumatic diseases. Galectin 3 concentration was determined by ELISA (Bender MedSystems GmbH, Biocenter, Vienna Austria). The upper limit of normal when testing 20 sera from healthy donors was 5.32 mg/ml, corresponding to the 95th percentile.
**Results:** The serum level of galectin-3 in RA patients (n=47) and in the control group (n=20) did not differ statistically significantly (4.27 [2.3:5.26] ng/ml vs 3.83 [2.57:4.11] ng/ml (p=0.2). In the whole group of RA patients (n=47) with inefficacy (insufficient effect) of basic anti-inflammatory therapy, correlations were noted between the level of galectin-3 and age (R=0.34; p=0.02), BMI (R=0.36; p=0.02), SDAI (R=0.33; p=0.02), CDAI (R=0.31; p=0.03). RA patients were divided into 2 groups: group I (n=27) - patients with galectin-3 5.32 ng/ml; II (n=20) - less than 5.32 ng/ml. Group I patients were older in age (59.9 [46.67] years vs 42.5 [38.5] years), had higher activity according to SDAI (38.2 [30; 48.4] vs 29.7 [26.6; 40]), CDAI (35.0 [29; 43] vs 270 [23;38]) (p<0.05 in all cases). In the group of patients (n=21) who received combination therapy (DMARDs + biological therapy) for 12 months, there was a significant decrease in clinical and laboratory activity, IgM RF levels (p<0.05 in all cases). The serum level of galectin-3 in RA patients (n=21) decreased by 19% statistically insignificantly after 12 months of combination therapy (4.24 [2.85;1] ng/ml vs 3.42 [2.56;4.36] ng/ml (p=0.2).

**Table 1.**

<table>
<thead>
<tr>
<th>Patients with RA (n=21) with insufficient effect of basic anti-inflammatory therapy</th>
<th>Patients with RA (n=21)</th>
<th>Δ,%</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28</td>
<td>5.6 (5.3-6.7)</td>
<td>3.97 (3.36-6.43)*</td>
<td>-30.4</td>
</tr>
<tr>
<td>SDAI</td>
<td>38.17 (29.5-45.8)</td>
<td>17.2 (9.5-25.6)*</td>
<td>-54.8</td>
</tr>
<tr>
<td>CDAI</td>
<td>35.0 (26.0-43.5)</td>
<td>17.0 (9.0-23.5)*</td>
<td>-51.4</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>20.1 (13.7-34.1)*</td>
<td>3.15 (1.21-7.23)*</td>
<td>-84.7</td>
</tr>
<tr>
<td>ESR(mm/h)</td>
<td>27.0 (16.0-45.0)</td>
<td>16.0 (10.0-23.5)*</td>
<td>-40.7</td>
</tr>
<tr>
<td>IgM RF, ME/ml</td>
<td>84.4 (20.8-163.0)</td>
<td>32.2 (10.6-107.0)*</td>
<td>-61.8</td>
</tr>
<tr>
<td>Galectin-3, ng/ml</td>
<td>4.2 (2.85;1)</td>
<td>3.42 (2.56;4.36)</td>
<td>-19.2</td>
</tr>
</tbody>
</table>

*p <0.05 reliability of differences in indicators before and after 12 months of combination therapy (Wilcoxon). Δ,% - the difference in indicators between the groups by the 12th month of combination therapy.

**Conclusion:** There were no differences in the level of galectin-3 in patients with RA and with the inefficacy of basic anti-inflammatory therapy and in the control group. At the same time, the association of this marker with RA activity (according to the SDAI, CDAI indices) does not exclude its role in the development of clinical manifestations of rheumatoid arthritis.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4687

---

**AB0372**

**BIOLOGIC THERAPY IN CHILDREN WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS ACCORDING TO THE FEDERAL REGISTER OF THE RUSSIAN FEDERATION.**

M. Botova1, A. Alekseeva1, T. Dvoryakovskaya1, R. Denisova, A. Mamutova1, K. Isaeva1, A. Chomakhidze1, O. Lomakina1, A. Fetisova1, M. Gautier1, K. Chibsibova1, E. Krekhova1, N. Kondratyeva1, N. Kriulina, M. Botova1, E. Alexeeva1, T. Dvoryakovskaya1, R. Denisova1, A. Mamutova1, K. Isaeva1, A. Chomakhidze1, O. Lomakina1, A. Fetisova1, M. Gautier1, K. Chibsibova1, E. Krekhova1, N. Kondratyeva1, National Medical Research Center of Children’s Health, Rheumatology, Moscow, Russian Federation;3 Sechenov First Moscow State Medical University; Pediatric, Moscow, Russian Federation

**Background:** Systemic juvenile idiopathic arthritis (sJIA) is the rarest variant of juvenile idiopathic arthritis, characterized by severe course, frequent exacerbations, the development of life-threatening extra-articular manifestations and complications, which requires the use of expensive medications and frequent hospitalizations of patients. In the Russian Federation, the provision of medicines to patients with sJIA is carried out at the expense of the federal budget, in this regard, the Federal Register of sJIA was created in 2018.

**Objectives:** To analyse the persistence and efficacy of ABA in monotherapy vs. combination with conventional DMARDs.

**Methods:** Retrospective observational study of a cohort of RA patients under treatment with ABA reviewed in Rheumatology consultations at Vinograd Macarena University Hospital, from 2010 to 2020. The statistical software was used. The study was conducted in accordance with the standards of the CEIC.

**Results:** 69 patients were included, 80% female. The average age was 63 (53-63) years. RA evolution time was 10 (4-16) years. 92% RF +, 86% ACPA + and 84% double +, 81% with erosions and 47% had extra-articular manifestations: 16 ILD, 10 Dry Syndrome and 9 Rheumatoid Nodules. 96% had relevant comorbidities such as Osteoporosis 33, Hypertension 31, dyslipidemia 26, Fibromyalgia 16, Depression 14 or Diabetes 9. Prior to ABA start, all were treated with NSAIDs, GC and conventional DMARDs; 32% with one conventional DMARDS, 31% with two and 37% with three or more; The conventional DMARDS used were MTX, LFN 45%, HDQ 13%, CYA 13%, Gold salts 9% and SSZ 7%, 21% were previously treated with biologic DMARDs; 44% with one biologic DMARDS and 39% with two or more biologic DMARDs. The most commonly used biologic DMARDs were ETA 63.3%, ADA 30.6%, IL-6 inhibitors 20.4% and RTX 24.3%. Of the 29% who started ABA as a first-line, 8% were started on anti-TNF therapies, remaining 2% and 12% adverse events (safety, haematological and infections).

**Conclusion:** The number of patients receiving biologic therapy with sJIA in the Russian Federation has increased, which is due to the natural growth of the disease and more affordable provision of patients with sJIA by the state.

**REFERENCES:**


**Disclosures of Interests:** Maria Botova: None declared, Ekaterina Alexeeva

**AB0373**

**ABACETEN IN MONOTHERAPY OR IN COMBINATION WITH CONVENTIONAL DISEASE-MODIFYING DRUGS: TREATMENT PERSISTENCE IN A COHORT OF PATIENTS WITH RHEUMATOID ARTHRITIS.**

P. Muñoz Reinoso1, I. García Hernández2, B. Hernández-Cruz3, J. J. Pérez Vanegas4, Hospital Universitario Virgen Macarena, Rheumatology, Sevilla, Spain

**Background:** Abaceten is a selective T-Cell co-stimulation modulator indicated for the treatment of moderate to severe active rheumatoid arthritis in patients with inadequate response to previous treatment. It is used in routine clinical practice in combination with other conventional synthetic disease-modifying drugs, with some records showing worse results when used in monotherapy.

**Objectives:** To analyse the persistence and efficacy of ABA in monotherapy vs. combined with conventional DMARDs. To determine the prescription patterns and clinical characteristics of patients who have received at least one dose of the drug.

**Methods:** Retrospective observational study of a cohort of RA patients under treatment with ABA reviewed in Rheumatology consultations at Vinograd Macarena University Hospital, from 2010 to 2020. STA statistical software was used.

**Results:** 69 patients were included, 80% female. The average age was 63 (53-63) years. RA evolution time was 10 (4-16) years. 92% RF +, 86% ACPA + and 84% double +, 81% with erosions and 47% had extra-articular manifestations: 16 ILD, 10 Dry Syndrome and 9 Rheumatoid Nodules. 96% had relevant comorbidities such as Osteoporosis 33, Hypertension 31, dyslipidemia 26, Fibromyalgia 16, Depression 14 or Diabetes 9. Prior to ABA start, all were treated with NSAIDs, GC and conventional DMARDs; 32% with one conventional DMARDS, 31% with two and 37% with three or more; The conventional DMARDS used were MTX, LFN 45%, HDQ 13%, CYA 13%, Gold salts 9% and SSZ 7%, 21% were previously treated with biologic DMARDs; 44% with one biologic DMARDS and 39% with two or more biologic DMARDs. The most commonly used biologic DMARDs were ETA 63.3%, ADA 30.6%, IL-6 inhibitors 20.4% and RTX 24.3%. Of the 29% who started ABA as a first-line, 8% were started on anti-TNF therapies, remaining 2% and 12% adverse events (safety, haematological and infections).

**Disclosure of Interests:** None declared, Natalya Kondratyeva: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4687
Background: Limited data have been published on tolerance and efficacy of biotherapy in elderly patients with rheumatoid arthritis (RA) [1]

Objectives: To assess in real life the efficacy and safety of biological treatments in elderly patients with rheumatoid arthritis (RA) and to identify predictive factors for a good therapeutic response.

Methods: A cross-sectional observational study was conducted, the main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR registry). The duration of this study was 12 months. Patients included were all elderly patients (age > 65 years old), presenting RA, according to ACR / EULAR classification criteria for RA 2010. Demographic and clinical characteristics, disease activity, radiographic damage and functional ability have been compared between two groups of patients: those with response to biotherapy and those without response to biotherapy. Clinical and biological tolerance of biotherapy was assessed at 12 months of follow-up in all patients.

Results: Among 224 patients included in the RBSMR registry, 23 patients were over 65 years. The average age of patients was 69.57 years ± 4.33 with a sex ratio women/man: 4.75. The mean duration of the disease was 964.79 weeks ± 588.8. RA was seropositive in 87% of patients, with positive anti-cyclic citrullinated antibodies (ACPs) in 60.9%. It was erosive in 83.3%, with carpitis in 50% of our cases. Concerning biological features, the mean erythrocyte sedimentation rate (ESR) was 55.05 ± 26 and the mean C-reactive protein (CRP) was 26.79 ng/ml ± 18. The average initial disease activity score 28-ESR (DAS 28 ESR) was 4.08 ± 1.60. The average 12-month DAS was 2.67 ± 1.49. The Health Assessment Questionnaire (HAQ) average was 1.22. Concerning the treatment taken, 8.7% of patients were under Etanercept, 4.3% were under Golimumab, 69.6% were under Rituximab and 17.4% of patients received Tocilizumab. The analysis did not reveal any statistically significant difference between the two groups regarding demographic, clinical characteristics, disease activity, radiographic damage, biological feature and therapeutic data. 78.3% of our patients had a good tolerance to biotherapies, on the other hand 21.7% had presented undesirable effects.

Conclusion: RA is a common and even more common disease in the elderly, our study as well as the literature data confirms the efficacy of biotherapy and its good tolerance in our Moroccan patients with RA. It represents a therapeutic alternative of choice. Our results further encourage its use in our Moroccan context.

REFERENCES:

Disclosure of Interests: None declared
I. Monjo1, A. Villalba1, A. Balsa1, Á. Robles Marhuenda2, J. J. Rios2, D. Benavent1, C. Plasencia1, L. Nuño1.

In multivariable Cox regression analyses the most important predictor for ETN survival was inefficacy (75% of stop reasons in RA vs. 58% in SpA vs. 69% in PsA). During a follow-up of 1371 patient-years, 466 (65.5%) patients stopped therapy. The Table 1. Baseline parameters [Medians (IQR) unless otherwise specified]

<table>
<thead>
<tr>
<th>Parameter</th>
<th>RA (n=450)</th>
<th>SpA (n=177)</th>
<th>PsA (n=84)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women N (%)</td>
<td>370 (82)</td>
<td>66 (37)</td>
<td>46 (55)</td>
</tr>
<tr>
<td>Age</td>
<td>61.5 (53-70)</td>
<td>44.5 (35-54)</td>
<td>51 (41-62)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>2.6 (0-9.5)</td>
<td>0.8 (0-1.5)</td>
<td>1.7 (0-8.4)</td>
</tr>
<tr>
<td>Follow-up years</td>
<td>10 (5-2.1)</td>
<td>10 (4-3.1)</td>
<td>11 (4-3.6)</td>
</tr>
<tr>
<td>Total comorbidities nr.</td>
<td>3 (1-4)</td>
<td>1 (0-3)</td>
<td>2 (1-4)</td>
</tr>
<tr>
<td>Ever smokers N(%)</td>
<td>124 (33)</td>
<td>82 (26)</td>
<td>30 (61)</td>
</tr>
<tr>
<td>BMI</td>
<td>31 (26-35)</td>
<td>27 (25-32)</td>
<td>29 (23-32)</td>
</tr>
<tr>
<td>Treatment line N (%): 1st</td>
<td>264 (59)</td>
<td>87 (49)</td>
<td>51 (51)</td>
</tr>
<tr>
<td>2nd</td>
<td>119 (26)</td>
<td>70 (35)</td>
<td>24 (29)</td>
</tr>
<tr>
<td>3rd</td>
<td>67 (15)</td>
<td>20 (11)</td>
<td>17 (20)</td>
</tr>
<tr>
<td>Duration of treatment start yr</td>
<td>4 (2.1-6.5)</td>
<td>5 (2.4-7.6)</td>
<td>5 (4.3-6.4)</td>
</tr>
<tr>
<td>Monotherapy, N (%)</td>
<td>60 (100)</td>
<td>56 (25)</td>
<td>30 (55)</td>
</tr>
<tr>
<td>Ongoing corticosteroids N (%)</td>
<td>153 (34)</td>
<td>25 (14)</td>
<td>17 (20)</td>
</tr>
<tr>
<td>DAS28 - ESR</td>
<td>5.8 (5.0-6.5)</td>
<td>3.7 (2.4-7.2)</td>
<td>5.3 (4.5-6.4)</td>
</tr>
<tr>
<td>ASAS-ESR</td>
<td>-</td>
<td>3.4 (2.8-4.1)</td>
<td>3.6 (3.2-4.7)</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>0.4 (0.3-1.1)</td>
<td>1.1 (0.3-2.4)</td>
<td>0.8 (0.4-2.0)</td>
</tr>
</tbody>
</table>

Table 1. Baseline parameters [Medians (IQR) unless otherwise specified]

In addition, there is a higher frequency of severe infections in the HGGS group. Studies with larger sample sizes are needed to confirm these results.

References:

Disclosure of Interests: None declared


Background: The immunoglobulin levels of TNFα inhibitors (TNFi) and their effect on their efficacy can depend on the underlying disease. To date, no studies were performed to directly compare this relation between different groups of immune-mediated diseases.

Methods: 20 patients with RA and 53 patients with IBD (38 (30.9%) with CD and 15 (12.2%) with UC) were included for 17 [10; 27] months. 26 (35.6%) of them received infliximab (INX) infusions, 23 (31.5%) – adalimumab (ADM) and 24 (32.9%) – certolizumab pegol (CZP). The following criteria were used for the evaluation of the response to TNFi: EULAR criteria for RA, decrease of CDAI for CD and Mayo Score for UC. Treatment level of INX and the level of anti-drug antibodies (ADAb) were measured in the serum samples drawn directly before the planned drug administration.

Results: The mean trough level in both groups was determined as follows: 10 µg/mL INX in RA group and 5 µg/mL for INX in IBD group, 5 µg/mL for ADM2, and 20 µg/mL for CZP. Re: 17 (85%) patients with RA and 35 (66%) patients with IBD responded well to the treatment. Loss of response to the treatment developed in 3 (15%) cases of RA and 18 (34%) cases of IBD (p=0.05). The median trough level of INX was 0.22 [0.17; 0.8] µg/mL in RA and 1.58 [0.79; 3.87] µg/mL in IBD. The median trough level of ADM was 5.45 [1.05; 12.07] µg/mL in RA and 11.77 [5.23; 13.01] µg/mL in IBD. The tendency toward lower median trough level of CZP in IBD was observed (28.17 [20.69; 42.95] µg/mL in IBD vs 16.92 [8.31; 30.96] µg/mL in RA (p=0.09)). Low trough level of TNFi was found in 11 (55%) patients with RA and 27 (50.9%) patients with IBD. It did not differ significantly either between the diseases or between the TNFi (p>0.05). Loss of response was associated with low trough level of TNFi in all 3 cases of RA and in IBD – in 9 (50%) patients (p>0.05). Positive ADAb were detected in 6 (30%) patients with RA and 8 (15.1%) patients with IBD. The rate of positive ADAb was comparable between different TNFi and immune-mediated diseases (p>0.05). A tendency toward lower prevalence of ADAb to ADM in CD than in RA was observed.

**Conclusion:** A significantly higher percentage of HGGS is observed in patients with AAV treated with RTX compared to patients with RA. The development of HGGS seems to be influenced by age at diagnosis and at the start of treatment, years of disease evolution and low levels of IgG4's prior to the start of treatment. In addition, there is a higher frequency of severe infections in the HGGS group. Studies with larger sample sizes are needed to confirm these results.

Disclosure of Interests: None declared


Background: The immunoglobulin levels of TNFα inhibitors (TNFi) and their effect on their efficacy can depend on the underlying disease. To date, no studies were performed to directly compare this relation between different groups of immune-mediated diseases.

Methods: To study the characteristics of patients with AAV on RTX treatment and to analyze the factors associated with HGGS, as well as to compare them with patients with rheumatoid arthritis (RA) on the same treatment.

Methods: Retrospective descriptive study of patients with a diagnosis of AA V or RA treated with RTX who had immunoglobulin levels prior to treatment and after each cycle were included. Demographic, clinical and analytical variables were analyzed. Patients who developed HGGS versus those who did not were compared using Student's t and Mann-Whitney U for continuous variables and chi-square for categorical variables.

Results: Ninety-five patients were included, 19 (20%) with AA V and 76 (80%) with RA. Of the 34 (35.8%) who developed HGGS, 19 had RA (25%) and 15 AA V (79%) (p<0.001). The 6 patients who presented with severe HGGS (IgG<500) belonged to the AAV group. The overall sample was divided into patients with HGGS and patients without (Table 1). Significant differences were obtained in relation to diagnosis (p<0.001), age at diagnosis and at the start of treatment, being higher in patients with HGGS (p<0.005 and p 0.001) and years of disease evolution (p<0.005). Patients with HGGS had a lower mean baseline IgG (p<0.001). The HGGS group had more severe infections (infections requiring admission) (p<0.005) and the time from RTX administration to the development of infection was shorter in this group.
Disclosure of Interests: BMD changes were not associated with age, RA duration and disease activity.

Methods: Bone mineral density (BMD) in women with rheumatoid arthritis (RA) and those with RA without biological therapy.

Results: There were no differences between patients RIT+ and RIT- in age (median 58 [53; 63] years and 52 [50; 69] years, p=0.05), RA duration (median –16 [4; 21] year and 9 [3; 11] year, p=0.09) and DAS28 ESR (median – 5.18 [4.3; 6.25] and 5.71 [4.66; 5.94]). The percentage BMD changes from baseline in lumbar spine, femur neck and total hip using dual energy x-ray absorptiometry (DXA, Hologic 4500A) at baseline and after 1 year. RA activity was evaluated by disease activity score using 28 joint counts and erythrocyte sedimentation rate (DAS28 ESR). Nonparametric statistic tests were performed.

Results: There were no differences between patients RIT+ and RIT- in age (median –51 [53; 63] years and 52 [50; 69] years, p=0.09), RA duration (median –16 [4; 21] year and 9 [3; 11] year, p=0.09) and DAS28 ESR (median – 5.18 [4.3; 6.25] and 5.71 [4.66; 5.94]). The percentage BMD changes from baseline in lumbar spine, femoral neck and total hip were 0.2% [-3.9%; 4.0%], -1.8% [-6.2%; 2.4%] and -0.3% [-3.5%; 4.5%], respectively, in patients RIT+ and -1.0% [-4.9%; 3.3%], -2.5% [-5.8%; -0.4%], -1.7% [-4.3%; 4.2%], respectively, in persons RIT-. There were no differences in BMD changes in the pair matching test both patients RIT+ and RIT-. No correlations between BMD changes with age, RA duration and DAS28 ESR were found.

Conclusion: RIT had no effect on BMD in women with RA after 1 year therapy. BMD changes were not associated with age, RA duration and disease activity.

Disclosure of Interests: None declared


AB0378

EFFECT OF RITUXIMAB ON BONE MINERAL DENSITY IN WOMEN WITH RHEUMATOID ARTHRITIS

O. Dobrovolskaya1, N. Demin1, N. Topeytsys2, A. Sorokina3, D. Kusevich4, O. Nikitinskaya1.
1V. A. Nasonova Research Institute of Rheumatology, Department of Osteoporosis, Moscow, Russian Federation; 2V. A. Nasonova Research Institute of Rheumatology, Department of Osteoarthritis, Moscow, Russian Federation

Objectives: To compare the effect of rituximab (RIT) treatment on bone mineral density (BMD) in women with rheumatoid arthritis (RA) and those with RA without biological therapy.

Methods: 78 women over 40 years with confirmed RA according to ACR/EULAR criteria (2010) were enrolled in the study: 48 patients treated with RIT and methotrexate (RIT+). 30 women received only methotrexate (RIT-). The patients did not differ in the glucocorticoid therapy duration and cumulative dose. BMD was determined in the lumbar spine, femur neck and total hip using dual energy x-ray absorptiometry (DXA, Hologic 4500A) at baseline and after 1 year. RA activity was evaluated by disease activity score using 28 joint counts and erythrocyte sedimentation rate (DAS28 ESR). Nonparametric statistic tests were performed.

Results: There were no differences between patients RIT+ and RIT- in age (median –51 [53; 63] years and 52 [50; 69] years, p=0.09), RA duration (median –16 [4; 21] year and 9 [3; 11] year, p=0.09) and DAS28 ESR (median – 5.18 [4.3; 6.25] and 5.71 [4.66; 5.94]). The percentage BMD changes from baseline in lumbar spine, femoral neck and total hip were 0.2% [-3.9%; 4.0%], -1.8% [-6.2%; 2.4%] and -0.3% [-3.5%; 4.5%], respectively, in patients RIT+ and -1.0% [-4.9%; 3.3%], -2.5% [-5.8%; -0.4%], -1.7% [-4.3%; 4.2%], respectively, in persons RIT-. There were no differences in BMD changes in the pair matching test both patients RIT+ and RIT-. No correlations between BMD changes with age, RA duration and DAS28 ESR were found.

Conclusion: RIT had no effect on BMD in women with RA after 1 year therapy. BMD changes were not associated with age, RA duration and disease activity.

Disclosure of Interests: None declared


AB0379

DOSE-DEPENDENT SUPPRESSION OF T CELL-DEPENDENT ANTIBODY RESPONSE IN HEALTHY VOLUNTEERS BY KPL-404, AN ANTI-CD40 MONOCLONAL ANTIBODY, SUPPORTS CHRONIC DOSING STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS

A. Papandrikopoulou1, G. R. Burmester2, F. Fang3, A. Kivitz3, M. Njenga1, A. Pano1, C. Pitzalis4, M. Samant1, S. Schmitz1, M. Spiers1, E. Tessari1, J. Ziemiański2, J. F. Pacolini5, Kiniksa Pharmaceuticals Corp., Kiniksa Pharmaceuticals Corp., Lexington, United States of America; 3Charité University Medicine Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 4Altoona Center for Clinical Research, Altoona Center for Clinical Research, Duncansville, United States of America; 5University of London, The William Harvey Research Institute - Barts and The London School of Medicine Queen Mary, London, United Kingdom; 2Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd., Hamilton, Bermuda

Background: An unmet need remains in patients with failure and/or inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARD-IR) and/or Janus kinase inhibitors (JAKI-IR). The CD40-CD40L (CD154) costimulatory pathway is linked to inflammation and joint destruction in RA via production of autoantibodies and inflammatory cytokines. KMPL-404 is a humanized IgG4 antibody engineered to bind CD40 without triggering Fc effector functions (Muralidharan et al., 2019), which are known to have been associated with thromboembolic events seen in the first generation of CD40L-targeting therapies. In a first-in-human Phase 1 single ascending dose study, 52 healthy volunteers received single doses of KPL-404 administered either subcutaneously (SC) or intravenously (IV) with no dosing-limiting safety findings, infectious episodes, or toxicities (Samant et al., 2021). The study demonstrated that with 10mg/kg IV, full receptor occupancy (RO) was observed through day 71, and there was complete suppression of T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin challenge on day 1 and re-challenge on day 29 through day 57. With 5mg/kg SC, full RO was observed through day 43, and there was complete suppression of TDAR through at least day 29. Complete suppression of ADA to KPL-404, an independent indicator of target engagement, was also observed while KPL-404 serum concentrations were above approximately 0.1 to 0.2 µg/mL and continued for at least 50 days and 57 days after 5mg/kg SC and 10mg/kg IV administration, respectively.

Objectives: Using Phase 1 and nonclinical data, identify chronic dosing regimens anticipated to yield PK in the sub-therapeutic, therapeutic, and supra-therapeutic ranges to be utilized in a Multiple Ascending Dose Phase 2 Study.

Methods: A PK model was used to simulate multiple dosing scenarios, including: 2.5, 5, and 10mg/kg SC q2wk, q4wk, and q4wk, as well as 10mg/kg IV q4wk. The model was used to identify optimal Phase 2 dosing schedules by generating 1000 virtual subjects using the typical parameter estimates with between-subject variability included.

Results: Following SC administration, all subjects were predicted to achieve complete ADA suppression for the full dosing interval at/above 2.5mg/kg SC q2wk. At 2mg/kg SC q2wk (starting dose level), simulated steady-state 8-week data predicted PK in a sub-therapeutic range for most subjects and an approximately 31- and 18-fold safety margin relative to preclinical NOAEL dose. At 5mg/kg SC q2wk, 100% of patients were predicted to be in a therapeutic range, indicating a potential practical efficacious dose level. At 10mg/kg SC q2wk, 100% of patients were predicted to be in the supratherapeutic range.

These results support a Multiple Ascending Dose (MAD) Phase 2 study design, with PK lead-in comprised of 3 Cohorts at 2, 5, or 10mg/kg SC q2wk (each randomized 6:2) and Proof-of-Concept phase (Cohort 4) comprised of 48-60 subjects randomized 1:1:1 to 10mg/kg SC q2wk and placebo SC q2wk. The ongoing study will evaluate efficacy (Disease Activity of 28 joints using C-reactive protein [DAS28-CRP]), safety, PK, and pharmacodynamics (PD) of escalating doses levels of KPL-404 compared with placebo in patients with moderate to severe RA (bDMARD-IR or JAKI-IR). The study also allows the flexibility of optional cohorts including additional dosing regimens and/or subpopulations identified based on clinical response and biomarkers.

Conclusion: Inhibition of the CD40-CD154 co-stimulatory interaction holds promise for the management of a spectrum of autoimmune diseases. KPL-404 demonstrated prolonged absorption/excretion capable of suppressing TDAR for extended periods allowing for use of extended dosing intervals irrespective of IV or SC dosing. These analyses supported the design of the ongoing Phase 2 study assessing the efficacy and safety KPL-404 in RA.

Disclosure of Interests: Anastassia Papandrikopoulou Shareholder of: Kiniksa Pharmaceuticals Corp., Employee of: Kiniksa Pharmaceuticals Corp., Gerd Rüdiger Burmester Speakers bureau: Abbvie, Agen, BMS, Lilly, MSD,

**AB0380**

**ANTI-TNF: ORIGINATORS VS BIOSIMILARS, COMPARISON IN CLINICAL RESPONSE ASSESSMENT IN A MULTICENTER COHORT OF PATIENTS WITH INFLAMMATORY ARTHROPATHIES**

C. Gioia1, A. Pochianti-Diamanti1, R. Perricone1, M. S. Chimenti2, A. Afeltra3, L. Navarin3, A. Migliore4, U. Massafera5, V. Brizzese6, P. Scilleri6, C. Meschini6, P. Scapatico7, M. Paroli7, R. Scivo8, F. Conti9, B. Laganà10, M. Di Franco11, Sapienza University Rome, Rheumatology, Rome, Italy; 12Tor Vergata, Rheumatology, Rome, Italy; 13Campus Biomedico, Rheumatology, Rome, Italy; 14San Pietro Fabel/Benedettini, Rheumatology, Rome, Italy; 15Nuovo Regina Margherita, Rheumatology, Rome, Italy; 16Boccoli Hospital, Rheumatology, Viterbo, Italy; 17S. Camillo de Lellis Hospital, Rheumatology, Rome, Italy; 18Sapienza University, Rheumatology, Latina, Italy

**Background:** Tumor necrosis factor (TNF)-α is one of principal proinflammatory cytokines involved in pathogenesis of different inflammatory arthropathies as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). Biotechnological drugs, represented among others by monoclonal antibodies directed against TNF-α, lead to a revolution in RA and spondyloarthritides treatment. They were the first biological drugs used to treat these diseases, with good results in terms of safety and efficacy. Also because of high cost of these drugs, for some years biosimilars have been introduced in clinical practice. Biosimilars are less expensive (in Italy, less of 30% than biorig inators); they underwent to a severe process of “comparability” to assess safety and efficacy like their originators. In Italy, AIFA authorized SB4 (etanercept biosimilar), SB5 and ABP501 (adalimumab biosimilar) after passing III-phase randomized clinical trials; but real-life data and registers are lacking.

**Objectives:** Aim of this study is to compare biosimilars and biorig inators in terms of safety and efficacy in a real-life contest.

**Methods:** We consequently enrolled patients, affected by inflammatory arthropathies (RA, PsA, AS) and treated with biosimilars (SB4, ABP501), belonging to any of the main biological prescribing centers in the Lazio region, from 2017 to 2021. Moreover, we enrolled patients, affected by the same inflammatory diseases, but treated with corresponding originator. Clinical and laboratory data as well as disease activity indices, were collected at recruitment (T0) and after 4 (T1), 8 (T2), 12 (T3) and 24 (T4) months of therapy. Adverse events were registered. **Results:** The multicenter cohort was composed by 455 patients treated with biosimilars (SB4/ABP501 276/179; F/M 307/146; naïve 56%, median age/IQR 55/46-65) and 436 treated with originators (etanercept/adalimumab 186/259, F/M 259/177, naïve 64%, median age/IQR 55/43-62). No differences were found about safety, but biosimilars group presented a higher number of discontinuations due to inefficacy (p<0.001), observed at all time-points. Female gender to be smoker and b-DMARDs naïve, the initial non-response to the drug were predictive factors of reduced drug survival (p=0.05, p=0.046, p=0.001 respectively). Retention rate at 24 months was 81.1% for biorig inators and 76.5% for biosimilars (with a median retention time of 20.7 and 18.9 months respectively; p=0.002). Patients with remission/low disease activity achievement at T1 showed a cumulative survival of 90% to biosimilar therapy until at T4 (p=0.001); early adverse reactions instead represented an important cause of subsequent drug discontinuation (p=0.001).

**Conclusion:** Real-life data demonstrated the same safety between biosimilars and originators but a reduced biosimilar retention rate at 24 months, about 76%. Despite their loss efficacy, biosimilars could be considered valid and safe, and a good and less expensive alternative to the originators, allowing access to these innovative treatments to a wider patient population.

**REFERENCES:**


**Disclosure of Interests:** None declared.


**AB0381**

**ULTRASONOGRAPHY TO PREDICT FLARE AFTER DISCONTINUATION OF BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN REMISSION**

T. Ogura1, A. Hirata1, T. Kagitgiri1, Y. Takakura1, H. Kameda1, Toho University, Division of Rheumatology, Department of Internal medicine, Tokyo, Japan

**Background:** Ultrasonography (US) has been suggested to be useful in predicting flare in patients with rheumatoid arthritis (RA) after discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs).

**Objectives:** This study aimed to investigate whether US can predict flare after discontinuation of bDMARDs in RA patients who have achieved stringent remission criteria.

**Methods:** We prospectively enrolled RA patients who maintained a simplified disease activity index ≤ 3.3 and discontinued bDMARDs and measured clinical and ultrasound assessment and US every 2-3 months for 2 years. The US examination was performed on 40 joints using the semi-quantitative method of 0-3 on the Grey-scale (GS) and Power Doppler (PD), and the total values for each patient were used as the GS score and PD score. Joints graded as GS score ≥ 2 or PD score ≥ 1 were counted as US arthritis. In addition, tendons at 36 sites were counted with or without tendinitis/tenosynovitis to obtain a tendon score.

**Results:** Thirty-six patients were enrolled and two patients who dropped out early without flare were excluded from the comparative analyses. At baseline, the median GS score was 7, PD score was 0, US arthritis was 0, and tendon score was 0. The total PD score was 0 in 26 patients (72%) and it was 1 in 5 patients (14%). There were no significant differences in US findings between the relapse group (20 patients) and the non-relapse group (14 patients). Positive and negative predictive value for PD-positive findings (total PD score ≥ 1) were 60% and 42%, and for total PD score ≥ 2 were 60% and 41%, respectively.

**Conclusion:** The PD score in the US findings at the time of bDMARDs discontinuation was not predictive for future disease flare.


Rheumatoid arthritis - non biologic treatment and small molecules

AB0382 COMPARISON OF ADVERSE EVENTS (AES) RELATED TO MAJOR ANTI-RHEUMATIC DRUGS, REPORTED TO THE OFFICIAL JAPANESE ADVERSE DRUG EVENT REPORT DATABASE (JADER)

N. Tsuda1, S. Inokuma1,2, H. Boguchi3, M. Yamaji3, T. Harada4, M. Misaki1, Y. Masui5, T. Kano6, 1Kohnodai Hospital, National Center for Global Health and Medicine, Rheumatology, Ichikawa, Chiba, Japan; 2Chiba Central Medical Center, Allergic Diseases and Rheumatology, Chiba, Japan

Background: Currently, many disease-modifying anti-rheumatic drugs (DMARDs) are available for the treatment of rheumatoid arthritis (RA). Among them, methotrexate (MTX), biologic DMARDs (bDMARDs) and Janus kinase inhibitors (JAKi) are the major options. AES related to these are major concerns. In Japan, the AES data spontaneously reported to and summarized by Pharmaceuticals and Medical Devices Agency (PMDA) are freely accessible.

Objectives: The major AES relating to MTX, bDMARDs, and JAKi observed in the real world were compared.

Methods: The number of AES listed by JADER from 2014 to 2020 was collected. The AES were classified by System Organ Class (SOC) of Medical Dictionary for Regulatory Activities (MedDRA) and compared using the chi-square test. The bDMARDs included were etanercept (ETN), adalimumab (ADA), golimumab (GOL), tocilizumab (TCZ), and abatacept (ABT), and JAKi was tofacitinib (TOF) and baricitinib (BAR).

Results: The total number of AES was 27,604. The number was significantly increasing in total and MTX, GOL, TOF during these years, although the number of cases that have each DMARD is not known in this study. The proportion of SOCs among each DMARD was similar throughout the period.

The most frequent was infections/infestations in all DMARDs except for MTX, in which neoplasms were the most. The primary cause of infection was bacterial, including pneumonia. Varicella-zoster virus infection in JAKi, and tuberculosis in ADA and GOL were conspicuous.

Neoplasms were the second major in many DMARDs. Lymphoproliferative disorders were most common in MTX-related neoplasms, whereas solid tumors were more in other DMARDs like ABT or BAR.

Conclusion: The number of AES cases related to DMARDs was increasing. Significant difference among AES related to DMARDs was noted in the JADER database, especially regarding MTX and JAKi.

REFERENCES:

AB0383 COMPARISON OF EFFICACY AND SAFETY IN JAK INHIBITOR DUE TO A DIFFERENCE OF SELECTIVITY - TOFACITINIB VS. BARICITINIB -

I. Yoshi1, N. Sawada2, T. Chijiwa3. 1Yoshi Hospitalshi, Musculoskeletal Medicine, Shimanto-City, Japan; 2Dohgo Onsen Hospital, Rheumatology, Matsuyama, Japan; 3Kochi Memorial Hospital, Rheumatology, Kochi, Japan

Background: Each Janus Kinase Inhibitor (JAK-i) has different selectivity of JAKs, such as JAK1, JAK2, JAK3, and TIK2. However, little has been known regarding mode of action due to the selectivity difference in clinical practice for treating rheumatoid arthritis (RA).

Objectives: The aim of this study is to compare difference of efficacy and safety in two JAK-i; between tofacitinib (TOF) and baricitinib (BAR) in clinical practice using one-center retrospective cohort.

Methods: Within the case which administered TOF or BAR to the RA patient who the effect was insufficient in the existing treatment and the disease activity was over the middle disease activity using simplified disease activity index (SDAI). At the start of administration (baseline), 5 mg tablets of TOF were taken twice a day or 4 mg tablets of BAR were taken once a day. Patients were divided by drug and included their sex, age at onset, anti-cyclic citrullinated polypeptide antibodies (ACPA) titer, length of RA history at onset, Sharp/van der Heijde score (SHS) at onset, Naive/Not Naive for biologic DMARDs or JAK-i, 28-joints disease activity score (DAS28), SDAI, Health Assessment Questionnaire Disability Index (HAQ-DI), and pain score with visual analog scale (PS-VAS). It was classified into large joint and small joint, and the point was independently scored by swelling and pressure pain by size and position in each joint. Total score of the

Disclosure of Interests: None declared

Table 1. Total case numbers and proportion of adverse events related to each DMARD.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of AES</td>
<td>27604</td>
<td>11636</td>
<td>2974</td>
<td>1959</td>
<td>1302</td>
<td>4245</td>
<td>1709</td>
<td>3065</td>
<td>714</td>
</tr>
<tr>
<td>Biochemical/sympathetic system disorders</td>
<td>5.8</td>
<td>9.9</td>
<td>2.0</td>
<td>3.2</td>
<td>2.6</td>
<td>4.0</td>
<td>0.9</td>
<td>2.8</td>
<td>3.5</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>5.0</td>
<td>4.1</td>
<td>3.4</td>
<td>7.5</td>
<td>5.9</td>
<td>7.7</td>
<td>3.9</td>
<td>5.2</td>
<td>4.2</td>
</tr>
<tr>
<td>General disorders/adamnistration site reactions</td>
<td>4.6</td>
<td>3.2</td>
<td>11.3</td>
<td>4.1</td>
<td>2.2</td>
<td>3.0</td>
<td>4.0</td>
<td>7.6</td>
<td>2.5</td>
</tr>
<tr>
<td>Infections/infestations</td>
<td>28.0</td>
<td>20.3</td>
<td>21.3</td>
<td>32.2</td>
<td>34.2</td>
<td>36.5</td>
<td>37.1</td>
<td>37.0</td>
<td>49.2</td>
</tr>
<tr>
<td>Pneumonia (bacterial)</td>
<td>6.6</td>
<td>4.0</td>
<td>6.1</td>
<td>5.2</td>
<td>10.9</td>
<td>7.7</td>
<td>12.5</td>
<td>9.4</td>
<td>15.1</td>
</tr>
<tr>
<td>Other bacterial infection</td>
<td>9.1</td>
<td>5.9</td>
<td>5.6</td>
<td>12.3</td>
<td>9.5</td>
<td>176</td>
<td>9.1</td>
<td>9.8</td>
<td>10.6</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>2.1</td>
<td>1.1</td>
<td>0.4</td>
<td>1.4</td>
<td>1.2</td>
<td>1.0</td>
<td>1.2</td>
<td>8.2</td>
<td>11.2</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>1.4</td>
<td>0.9</td>
<td>1.9</td>
<td>6.0</td>
<td>3.5</td>
<td>0.6</td>
<td>0.6</td>
<td>0.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Investigational</td>
<td>5.0</td>
<td>4.9</td>
<td>5.5</td>
<td>2.3</td>
<td>2.6</td>
<td>5.7</td>
<td>2.2</td>
<td>8.3</td>
<td>2.8</td>
</tr>
<tr>
<td>Neoplasms benign, malignant, unspecified</td>
<td>21.1</td>
<td>34.8</td>
<td>11.0</td>
<td>13.5</td>
<td>12.7</td>
<td>74</td>
<td>15.6</td>
<td>10.8</td>
<td>15.4</td>
</tr>
<tr>
<td>Lymphoproliferative diseases</td>
<td>14.3</td>
<td>29.8</td>
<td>2.8</td>
<td>4.1</td>
<td>4.0</td>
<td>2.2</td>
<td>4.5</td>
<td>2.1</td>
<td>2.2</td>
</tr>
<tr>
<td>Solid tumors</td>
<td>5.6</td>
<td>3.8</td>
<td>7.3</td>
<td>78</td>
<td>7.5</td>
<td>4.0</td>
<td>9.9</td>
<td>7.3</td>
<td>10.5</td>
</tr>
<tr>
<td>Respiratory, thoracic, mediastinal disorders</td>
<td>7.1</td>
<td>6.8</td>
<td>8.3</td>
<td>8.4</td>
<td>9.5</td>
<td>6.5</td>
<td>7.4</td>
<td>6.2</td>
<td>6.7</td>
</tr>
<tr>
<td>Other System Organ Class</td>
<td>23.3</td>
<td>15.9</td>
<td>37.3</td>
<td>28.8</td>
<td>30.2</td>
<td>29.2</td>
<td>28.9</td>
<td>22.2</td>
<td>15.7</td>
</tr>
<tr>
<td>Major adverse cardiovascular events</td>
<td>1.1</td>
<td>0.4</td>
<td>1.1</td>
<td>1.6</td>
<td>2.5</td>
<td>1.5</td>
<td>1.6</td>
<td>1.3</td>
<td>2.9</td>
</tr>
<tr>
<td>Venous thromboembolism</td>
<td>0.4</td>
<td>0.1</td>
<td>0.4</td>
<td>0.5</td>
<td>0.6</td>
<td>0.3</td>
<td>0.2</td>
<td>1.1</td>
<td>1.4</td>
</tr>
</tbody>
</table>

Background colors indicate: comparing to the total cases, higher with p<0.05, light pink; higher with p<0.00001, dark pink; higher with p<1E-10, red. Lower with p<0.05, light blue; lower with p>0.00001, blue; lower with p<1E-10, dark blue, using chi-square test. Yellow indicates System Organ Classes.
involved joints for each part: upper-extremities, lower extremities, big joints, and small joints (UES/LES/BJS/SJS), rheumatoid factor (RF) titer, serum matrix metalloproteinase-3 (MMP-3) level, serum creatinine (Cr) level, and estimated glomerular filtration rate (eGFR) of each part were measured. The mean values of each group were obtained at baseline, 1, 2, 3, 6, 9, and 12 months, and the two groups were statistically compared using the Mann-Whitney U-test. As a sub-analysis, each drug group was divided into bio or JAK-i naive, age ≥ 70 years, disease duration ≥ 10 years, SHS ≥ 100. The change of DAS28 under each 2 divided condition was compared using Mann-Whitney U-test. Similar comparison was carried out with RA patient who administered golimumab (GOL) as a control group. The significance level was less than 5%.

Continuation rate (the withdrawal after the remission introduction is put in the continuation) in 12 months after baseline was also compared.

**Results:** A total of 82 patients were picked up, in whom 22 TOF group, 31 BAR group, and 29 GOL group included. Both DAS28 and SDAI were consistently lower in the BAR than in the other 2 groups from 1 month after baseline, SDAI in the BAR was significantly lower than in the GOL at 3 months after the baseline. The HAQ-DI score at 6 months after baseline was significantly lower in the BAR than in the GOL. PS-VAS in the GOL was significantly higher than the other two groups at 2, 3 and 6 months after baseline. In the joint point, BJS in the BAR was significantly lower than that in the GOL at 2, 3, and 6 month after baseline. In the joint point, BJS in the BAR was significantly lower than that in the TOF at 6 and 12 months after baseline. There was no significant difference in MMP-3, RF, Cr and eGFR between the 3 groups in any observation month, but Cr increased after the start in the BAR group and eGFR tended to decrease.

The continuation rate at 12 months after the start of administration was 86.4% in the TOF, 89.3% in the BAR and 69.0% in the GOL.

**Conclusion:** Even JAK-i characteristics in action differs for each drug. It is needed to choose appropriate drug based on these drug characteristics.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.129

---

**Table 1.** Results reported as mean (SD) when normally distributed and median [Q1 – Q3] when skewed. P-value <0.05 = significant. RA = rheumatoid arthritis, ACPA = anti-citrullinated protein antibody, RF = Rheumatoid factor, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.

<table>
<thead>
<tr>
<th>Plants for Joints group (n = 7)</th>
<th>Control group (n = 7)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RA risk and related outcomes</strong></td>
<td></td>
</tr>
<tr>
<td>RA risk score</td>
<td>6.1 (1.4)</td>
</tr>
<tr>
<td>Pain intensity</td>
<td>4.9 (2.6)</td>
</tr>
<tr>
<td>ACPA, kU/l</td>
<td>330 [94 - 530]</td>
</tr>
<tr>
<td>RA diagnosis, N</td>
<td>13 [3 - 68]</td>
</tr>
<tr>
<td>Inflammation</td>
<td>9 [6 - 15]</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>0.7 [0.6 - 2.5]</td>
</tr>
<tr>
<td><strong>Anthropometric</strong></td>
<td></td>
</tr>
<tr>
<td>Weight, kg</td>
<td>78.4 (18.6)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.8 (5.3)</td>
</tr>
<tr>
<td>Fat mass, kg</td>
<td>30.6 (14.3)</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>879 (13.3)</td>
</tr>
<tr>
<td>LDL-cholesterol, mmol/l</td>
<td>3.1 (0.87)</td>
</tr>
<tr>
<td>HbA1C, mmol/mol</td>
<td>34.9 (3.2)</td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 16</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Week 16</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>p-value</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Background:** An unhealthy lifestyle increases the risk of developing rheumatoid arthritis (RA). Interventions including plant-based diets, physical activity, and stress management have shown benefits for RA patients but have not yet been evaluated in a program for patients at risk for RA.

**Objectives:** To investigate preliminary effectiveness of a multidisciplinary lifestyle program on RA risk in patients at risk for RA, in comparison to usual care.

**Methods:** In the “Plants for Joints” (PFJ) pilot RCT, patients with anti-citrullinated protein antibody (ACPA) positive arthritis were randomized to the PFJ or control group. Both groups received usual care while the PFJ group additionally followed a 16-week lifestyle program based on a whole food plant-based diet, physical activity, and stress management. The primary outcome was risk of developing RA as quantified by the RA risk score (including family history, symmetry, stiffness, pain level, RF/ACPA level). The maximum score (13 points) was given to participants who developed RA. Secondary outcomes included self-reported pain intensity, inflammatory, anthropometric, and metabolic markers, and serum levels of ACPA and rheumatoid factor (RF). A linear mixed model for between group analysis was used, adjusted for baseline values.

**Results:** 14 out of 17 included patients completed the study (all female, mean age 47 years). Three patients (n = 2 PFJ group, n = 1 control group) were diagnosed with RA after mean 9.6 weeks and remained in the study. After 16 weeks there was no significant difference in RA risk score between PFJ and control groups (Figure 1). Compared to the control group, the PFJ group had significantly lower fat mass and LDL-cholesterol after 16 weeks (Table 1). After the intervention the PFJ group had an average weight loss of 4.9 kg, of which 2.7 kg was fat mass.

**Conclusion:** The results of this pilot study do not suggest the PFJ lifestyle program influenced RA risk score, pain, or autoantibody levels, although possible effects cannot be excluded due to the small sample size. However, metabolic health clearly improved in the PFJ group.

**REFERENCES:**

**AB0384**

**THE EFFECT OF A LIFESTYLE PROGRAM ON PATIENTS AT RISK FOR RHEUMATOID ARTHRITIS: THE “PLANTS FOR JOINTS” PILOT RANDOMIZED CLINICAL TRIAL**

C. Wagenaar1,2, W. Wairabenstein1,2, M. van der Leeden3,4,5, F. Turkstra1, J. Twisk1, M. Boers1, H. van Middendorp7, P. Weijis1, D. van Schaardenburg1,2.

1Amsterdam Rheumatology Center, Reade, Rheumatology, Amsterdam, Netherlands; 2Amsterdam Rheumatology Center, Amsterdam University Medical Centers, Universiteit van Amsterdam, Rheumatology, Amsterdam, Netherlands; 3Amsterdam Rheumatology Center, Reade, Rehabilitation Medicine, Amsterdam, Netherlands; 4Department of Rehabilitation Medicine, Amsterdam University Medical Centres, Vrije Universiteit, Rehabilitation Medicine, Amsterdam, Netherlands; 5Amsterdam Movement Sciences Research Institute, Rehabilitation Medicine, Amsterdam, Netherlands; 6Amsterdam University Medical Centres, Vrije Universiteit, Department of Epidemiology and Data Science, Amsterdam, Netherlands; 7Institute of Psychology, Health, Medical, & Neuropsychology Unit, Leiden University, Social and Behavioral Sciences, Leiden, Netherlands; 8Department of Nutrition and Dietetics, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences, Department of Nutrition and Dietetics, Amsterdam, Netherlands

**Background:** An unhealthy lifestyle increases the risk of developing rheumatoid arthritis (RA). Interventions including plant-based diets, physical activity, and stress management have shown benefits for RA patients but have not yet been evaluated in a program for patients at risk for RA.

**Objectives:** To investigate preliminary effectiveness of a multidisciplinary lifestyle program on RA risk in patients at risk for RA, in comparison to usual care.

**Methods:** In the “Plants for Joints” (PFJ) pilot RCT, patients with anti-citrullinated protein antibody (ACPA) positive arthritis were randomized to the PFJ or control group. Both groups received usual care while the PFJ group additionally followed a 16-week lifestyle program based on a whole food plant-based diet, physical activity, and stress management. The primary outcome was risk of developing RA as quantified by the RA risk score (including family history, symmetry, stiffness, pain level, RF/ACPA level). The maximum score (13 points) was given to participants who developed RA. Secondary outcomes included self-reported pain intensity, inflammatory, anthropometric, and metabolic markers, and serum levels of ACPA and rheumatoid factor (RF). A linear mixed model for between group analysis was used, adjusted for baseline values.

**Results:** 14 out of 17 included patients completed the study (all female, mean age 47 years). Three patients (n = 2 PFJ group, n = 1 control group) were diagnosed with RA after mean 9.6 weeks and remained in the study. After 16 weeks there was no significant difference in RA risk score between PFJ and control groups (Figure 1). Compared to the control group, the PFJ group had significantly lower fat mass and LDL-cholesterol after 16 weeks (Table 1). After the intervention the PFJ group had an average weight loss of 4.9 kg, of which 2.7 kg was fat mass.

**Conclusion:** The results of this pilot study do not suggest the PFJ lifestyle program influenced RA risk score, pain, or autoantibody levels, although possible effects cannot be excluded due to the small sample size. However, metabolic health clearly improved in the PFJ group.

**REFERENCES:**

**Table 1.** Results reported as mean (SD) when normally distributed and median [Q1 – Q3] when skewed. P-value <0.05 = significant. RA = rheumatoid arthritis, ACPA = anti-citrullinated protein antibody, RF = Rheumatoid factor, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.
BARICITINIB LEADS TO RAPID AND PERSISTENT RESOLUTION OF SYNOVITIS AS MEASURED BY HAND MRI IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) FAILING CS/BDMARD THERAPY

S. Kemenes1,2, S. Bayat1,2, D. Simon1,2, G. Krönke1,2, D. Bohr1,2, L. Valor1,2, F. Hartmann1,2, L. Schuster1,2, K. Tascilar1,2, G. Schett1,2, A. Kleyer1,2 on behalf of the https://www.medizin24.uk-erlangen.de/en/research/research-main-focus/research-group-pp-dr-a-kleyer-and-pp-dr-d-simon/.

Background: RA is characterized by synovial inflammation resulting in local bone loss [1]. Inhibitors of JAK/Stat pathways, such as baricitinib, demonstrated efficacy in reducing signs and symptoms of RA in clinical trials, however, little is known about their effects on synovitis and bone structure [2]. Preclinical and clinical observations suggest a positive effect JAK inhibitors on bone mass and microstructure, however no prospective, interventional clinical trial has been performed so far [3].

Objectives: The aim of this study is to evaluate the effect of baricitinib on local inflammation (synovitis and osteitis) and bone structure (erosions) in RA patients failing on cs/bDMARD therapy using hand MRI.

Methods: BAREBONE is a prospective, interventional, open-label, monocentric single center study (EUDRACT 2018-001164-32 / NCT03701789) to assess the effect of baricitinib (4mg/day) on local MRI inflammation and structure in patients with active RA. Besides demographic and clinical characteristics, hand joint inflammation was assessed by magnetic resonance imaging (MRI) using a 1.5 Tesla scanner (Siemens Magnetom Aera T1w TSE cor, T2w TIRM cor, T2w TSE fat-sat trans, T1w TSE fat-sat trans + cor after KM.), at baseline, week 24 and week 48. Scans were assessed for synovitis, osteitis and bone erosions using the RAMRIS scoring system using two independent blinded readers (SK and SB). Intraclass correlation coefficients were calculated for total RAMRIS and synovitis, osteitis and osteitis subscores and in a second step differences between cs and bDMARD failure were elaborated. Variables are summarized descriptively using means and 95% bootstrap confidence intervals for continuous outcomes and as number and percentages for categorical outcomes.

Results: Thirty- two RA patients were screened and 30 patients were included (age: 53.4 (SD 12.6) years; sex: 1/24 N 24/6; disease duration: 3 (IQR 2.0 - 6.0) years; biologic naïve/bDMARD failure 16/14). 27 patients completed the trial while MRI data was available for 24 patients at week 48. Demographics and clinical characteristics can be seen in Table 1. Total RAMRIS scores slightly decreased from 20.6 (95% CI 14.4 -27.6) at baseline (BL) to 18.3 (11.5 -26.5) at week 48. The synovitis subscore mainly contributed to total RAMRIS reduction by significantly improving from 5.3 (4.0 - 6.8) at BL to 2.7 (1.5 - 4.0) at week 48 with a score change of -2.9 (-4.0 to -1.8). At week 48, 12 patients (44.4%) had no signs of synovitis compared to only 3 patients at BL. In contrast, RAMRIS osteitis subscores only marginally decreased from 4.9 (2.2 - 8.4) at BL to 4.0 (1.9 - 6.7) at week 48. RAMRIS erosion score remained stable over the 48-week observation time. A significant difference in RAMRIS synovitis change for biologic naïve -3.8 (-5.2 to -2.6) vs biologic failure -1.0 (-2.2 to 0.4) could be observed at week 48.

With respect to clinical disease activity, DAS 28 score decreased from 4.8 (4.5 - 5.1) at BL to 2.9 (2.5 - 3.3) at week 48. Detailed results can be found in Table 1 and Figure 1. Intraobserver coefficient (95%CI) for RAMRIS scoring was high for both readers 0.997 (0.994 to 0.998).

Conclusion: Our study shows that baricitinib primarily reduces MRI synovitis in RA patients that have previously failed csDMARD and bDMARD therapy and particularly in patients who are biologic naïve.

REFERENCES:

Table 1. Demographics, DAS 28 ESR, RAMRIS total score and RAMRIS subset scores at baseline, week 24 and week 48 are shown as well as number of patients with improvement and resolution of synovitis.

<table>
<thead>
<tr>
<th>N</th>
<th>Age Mean [SD]</th>
<th>Gender female n [%]</th>
<th>Disease duration years Median [IQR]</th>
<th>DAS-28 ESR Mean [95%CI]</th>
<th>MRI available n [%]</th>
<th>RAMRIS total Mean [95%CI]</th>
<th>RAMRIS total change n [%]</th>
<th>RAMRIS synovitis Mean [95%CI]</th>
<th>RAMRIS synovitis change n [%]</th>
<th>RAMRIS osteitis Mean [95%CI]</th>
<th>RAMRIS osteitis change n [%]</th>
<th>RAMRIS erosion Mean [95%CI]</th>
<th>RAMRIS erosion change n [%]</th>
<th>RAMRIS erosion worsened n [%]</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>53.5 (12.6)</td>
<td>24 (80.0)</td>
<td>6 (20.0)</td>
<td>4.8 (4.5 to 5.1)</td>
<td>30 (100.0)</td>
<td>20.6 (14.4 to 27.6)</td>
<td>0.0 (0.0 to 0.0)</td>
<td>5.3 (3.9 to 6.9)</td>
<td>0.0 (0.0 to 0.0)</td>
<td>4.5 (2.2 to 8.4)</td>
<td>0.0 (0.0 to 0.0)</td>
<td>10.4 (7.3 to 14.6)</td>
<td>0.0 (0.0 to 0.0)</td>
<td>2 (6.7)</td>
</tr>
<tr>
<td>30</td>
<td>30</td>
<td>16</td>
<td>14</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>27</td>
<td>27</td>
<td>17</td>
<td>10</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>


Acknowledgements: C. W. was funded by ZonMW (The Netherlands Organization for Health Research and Development) grant number 555003210.

Disclosure of Interests: Carljin Wagenaar: None declared, Wendy Walrabenstein: None declared, Marieke van der Leeden: None declared, Frank den Turkenstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

None declared, Dirkjan van Schaardenburg: None declared, Henriët van Middendorp: None declared, Peter Weijs: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

None declared, David Simon Speakers bureau: Lilly Pharma Deutschland GmbH, Gerhard Krönke: None declared, Franktien Turkstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

Consultant for Novartis, Henriët van Middendorp: None declared, Peter Weijs: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

Disclosure of Interests: Carlijn Wagenaar: None declared, Wendy Walrabenstein: None declared, Marieke van der Leeden: None declared, Frank den Turkenstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

None declared, Dirkjan van Schaardenburg: None declared, Henriët van Middendorp: None declared, Peter Weijs: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

None declared, David Simon Speakers bureau: Lilly Pharma Deutschland GmbH, Gerhard Krönke: None declared, Franktien Turkstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.

None declared, David Simon Speakers bureau: Lilly Pharma Deutschland GmbH, Gerhard Krönke: None declared, Franktien Turkstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultancy for Novartis, Henriët van Middendorp: None declared, Peter Weijis: None declared, Dirkjan van Schaardenburg: None declared.
patients were prescribed MTX of 10-15 mg/m² of body surface. Achievement of
All patients had normal renal excretory function (GFR more than 60 ml / min). All
criteria, 65 (82%) women and 14 (18%) men, aged 53 ± 11 years, naïve to MTX.

Methods: To compare groups of patients who responded and did not respond to MTX therapy. To compare groups taking and not taking statins.

Conclusion: The concentration of 7-OH-MTX after 12 and 24 weeks of therapy is 5.23 [1.39;12.52] and 1.05 [0.07;3.55], respectively (p = 0.006). No differences between the concentrations of 7-OH MTX in the ER: 28.19 ± 16.14 and 25.77 ± 11.91, respectively (p = 0.40). The concentration of 7-OH-MTX in MO after 24 weeks of therapy – 5.23 [1.39;12.52] and 1.05 [0.07;3.55], respectively (p = 0.006). No differences between the concentrations of 7-OH MTX in the ER: 28.19 ± 16.14 and 25.77 ± 11.91, respectively (p = 0.40).

Results: Women accounted for 85.4% of the patients, the median age was 68 years, disease duration was 15 years, and the mean DAS28ESR was 5.00. The CK levels of both men and women were significantly elevated at 4 weeks and maintained until 24 weeks (5.8% (0 weeks), 20.7% (4 weeks), 26.3% (12 weeks), 24.3% (24 weeks), P<0.001) (Figure 1). The percent-age abnormal was also significantly increased at 4 weeks and maintained until 24 weeks (5.8% (0 weeks), 20.7% (4 weeks), 26.3% (12 weeks), 24.3% (24 weeks), P<0.002). The factors significantly positively related to elevated CK levels at 24 weeks were male, CK, creatinine, and lactate dehydrogenase (LDH), and stage, class, modified health assessment questionnaire, estimated glomerular filtration rate (eGFR), and glucocorticoid use were significantly negatively correlated (Table 1). There were no significant differences in CK elevation among the agents.

Table 1. Characteristics at the time of starting JAK inhibitors related to elevated creatine kinase levels at 24 weeks

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Data at starting JAK inhibitors</th>
<th>Univariate R value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatine kinase</td>
<td>0.653</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Gender, men</td>
<td>0.247</td>
<td>0.012</td>
<td></td>
</tr>
<tr>
<td>Steenbrocker stage</td>
<td>-0.215</td>
<td>0.039</td>
<td></td>
</tr>
<tr>
<td>Steenbrocker class</td>
<td>-0.277</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>modified health assessment questionnaire</td>
<td>-0.268</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.289</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>eGFR</td>
<td>-0.231</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>LDH</td>
<td>0.201</td>
<td>0.041</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid use</td>
<td>-0.409</td>
<td>0.008</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Time-dependent changes of CK in all RA patients

Conclusion: Some cases of creatine kinase (CK) elevation caused by Janus kinase (JAK) inhibitor treatment for rheumatoid arthritis (RA) have been reported in clinical trials. However, the frequency and patients' background characteristics in clinical practice are unknown.

Objectives: The correlation between JAK inhibitor treatment for RA and changes in CK levels in clinical practice were investigated using a multicenter database.

Methods: The multicenter database of JAK inhibitors was used, and 103 (tolacitinib 46, baricitinib 44, upadacitinib 11, filgotinib 1, filgotinib 1) of 265 RA patients were followed up at 24 weeks, and their CK levels were evaluated. The time-dependent change of CK was evaluated by sex and analyzed by the Wilcoxon signed-rank test. The percentage abnormal from the standard titer was calculated. The factors related to an elevated CK at 24 weeks were investigated using patients' background characteristics at the time of starting JAK inhibitors by univariate analysis.

Results: Women accounted for 85.4% of the patients, the median age was 68 years, disease duration was 15 years, and the mean DAS28ESR was 5.00. The CK levels of both men and women were significantly elevated at 4 weeks and maintained until 24 weeks (5.8% (0 weeks), 20.7% (4 weeks), 26.3% (12 weeks), 24.3% (24 weeks), P<0.001) (Figure 1). The percentage abnormal was also significantly increased at 4 weeks and maintained until 24 weeks (5.8% (0 weeks), 20.7% (4 weeks), 26.3% (12 weeks), 24.3% (24 weeks), P<0.002). The factors significantly positively related to elevated CK levels at 24 weeks were male, CK, creatinine, and lactate dehydrogenase (LDH), and stage, class, modified health assessment questionnaire, estimated glomerular filtration rate (eGFR), and glucocorticoid use were significantly negatively correlated (Table 1). There were no significant differences in CK elevation among the agents.

Table 1. Characteristics at the time of starting JAK inhibitors related to elevated creatine kinase levels at 24 weeks

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Data at starting JAK inhibitors</th>
<th>Univariate R value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatine kinase</td>
<td>0.653</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Gender, men</td>
<td>0.247</td>
<td>0.012</td>
<td></td>
</tr>
<tr>
<td>Steenbrocker stage</td>
<td>-0.215</td>
<td>0.039</td>
<td></td>
</tr>
<tr>
<td>Steenbrocker class</td>
<td>-0.277</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>modified health assessment questionnaire</td>
<td>-0.268</td>
<td>0.008</td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.289</td>
<td>0.003</td>
<td></td>
</tr>
<tr>
<td>eGFR</td>
<td>-0.231</td>
<td>0.019</td>
<td></td>
</tr>
<tr>
<td>LDH</td>
<td>0.201</td>
<td>0.041</td>
<td></td>
</tr>
<tr>
<td>Glucocorticoid use</td>
<td>-0.409</td>
<td>0.008</td>
<td></td>
</tr>
</tbody>
</table>

Analyzed by Spearman rank correlation coefficient

Conclusion: Some cases of creatine kinase (CK) elevation caused by Janus kinase (JAK) inhibitor treatment for rheumatoid arthritis (RA) have been reported in clinical trials. However, the frequency and patients' background characteristics in clinical practice are unknown.
living at the time of starting JAK inhibitors tended to have high CK levels at 24 weeks.

REFERENCES:


AB0388 FRENCH REAL LIFE SAFETY DATA ON THE USE OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONAL STUDY, DEFACTO

C. Gaujoux-Viala1, A. Basch2, S. Lassoued3, F. Coury-Lucas4, M. Kessouri5, N. Mammà4, Y. Brault6, T. Lequenne7, C. Sallo8. 1CHU Nîmes, Rheumatology, Nîmes, France; 2Infirmière Protestante Clinic, Lyon, Rheumatology; Caluire-et-Cuire, France; 3Cahors Hospital Centre, Rheumatology, Cahors, France; 4Lyon Sud Hospital, Rheumatology, Pierre-Bénite, France; 5Pfizer, Medical, Paris, France; 6Pfizer Medical, Paris, France; 7Pfizer, Statistics, Paris, France; 8Rouen University Hospital (CHU) & Inserm U905, Rheumatology, Rouen, France; 9Orléans Regional Hospital Centre (CHR), Rheumatology, Orléans, France

Background: Tofacitinib, an oral Janus Kinase inhibitor, is indicated in the treatment of adult patients (pts) with active, moderate to severe rheumatoid arthritis (RA).

Objectives: The objective of this work is to describe the tofacitinib’s safety profile in the DeFacTo study (French prospective observational study).

Methods: The safety profile of tofacitinib was assessed on the basis of interim data from a descriptive analysis of pts having taken at least one dose of tofacitinib in the context of the DeFacTo study.

Results: Of the 313 pts enrolled in the study, 301 had received tofacitinib and were included in the safety analysis. Of these, 276 fulfilled the eligibility criteria and included 219 who had ≥ 1 year follow-up and a mean exposure period of 368 ± 197.1 days. As of 15 March 2021, 122 patients are continuing to take tofacitinib therapy (76 missing prescription data). On inclusion, 73% of the 276 pts were females of mean (± SD) age 59.7 ± 11.7 years and a median disease duration of 9.1 years. At the cut-off date of 15 March 2021, of the 301 patients, adverse effects (AE) had been reported in 44.9% of cases of which 10.6% were considered serious (SAE). Infections were detected in 18.6% of pts (Table 1).

Table 1. Real life safety data for tofacitinib according to age

<table>
<thead>
<tr>
<th>Event</th>
<th>N (%)</th>
<th>&lt; 65 years (n=190)</th>
<th>≥ 65 years (n=110)</th>
<th>Total (n=301)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adverse effect</td>
<td>80 (42.1)</td>
<td>55 (50.0)</td>
<td>135 (44.9)</td>
<td></td>
</tr>
<tr>
<td>Serious adverse effect</td>
<td>16 (8.4)</td>
<td>16 (14.5)</td>
<td>32 (10.6)</td>
<td></td>
</tr>
<tr>
<td>Infection</td>
<td>33 (17.4)</td>
<td>23 (20.9)</td>
<td>56 (18.6)</td>
<td></td>
</tr>
<tr>
<td>Severe infection</td>
<td>3 (1.6)</td>
<td>4 (3.6)</td>
<td>7 (2.3)</td>
<td></td>
</tr>
</tbody>
</table>

| AE of interest (number of events) | Infection | | | |
|---|---|---|---|
| Herpes zoster | 5 | 5 | 10 |
| Severe infection | 1 | 0 | 1 |
| Herpes zoster | 1 | 0 | 1 |
| Tuberculosis | 0 | 2 | 2 |
| Cancer | | | |
| Small-cell carcinoma | 0 | 1 | 1 |
| MACE | | | |
| Stroke | 1 | 0 | 1 |
| Thromboembolic events | Venous thrombosis | 0 | 1 | 1 |
| Death | 0 | 0 | 0 |

*1 patient for whom age is unknown but is counted in the total.

Conclusion: These purely descriptive interim results reveal a safety profile for tofacitinib in patients with RA, similar to that previously reported in clinical and observational studies. (1-2)

REFERENCES:

Acknowledgements: To all investigators involved in this study, and all patients included in this study.

Disclosure of Interests: Cécile Gaujoux-Viala Speakers bureau: AbbVie, Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB, Consultant of: AbbVie; Amgen; Boehringer; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB, Andre BASCH Speakers bureau: Janssen, Novartis, Amgen, BMS, Abbvie, Lilly, Pfizer, MSD, UCB, Consultant of: Janssen, Novartis, Amgen, BMS, Abbvie, Lilly, Pfizer, MSD, UCB, Consultant of: AbbVie, BioGen, Roche Chugai, Pfizer, and UCB., Meriem Kessouri Shareholder of: Pfizer, Employee of: Pfizer, Nadir Mammar Shareholder of: Pfizer, Employee of: Pfizer, Yves Brault Shareholder of: Pfizer, Employee of: Pfizer, Thierry Lequenne Consultant of: AbbVie, BMS, Boeringher, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche – Chugai, Sanofi, UCB., Canine Salliot Consultant of: Biogen, Lilly, Novartis, Roche Chugai, Pfizer DOI: 10.1136/annrheumdis-2022-eular.601

Figure 1.

The main causes of monotherapy were intolerance (39.9%), adverse event (22%), physician's decision (20.2%) and lack of adherence (17.7%) to DMARDs. Patients who were active workers (64% vs 55%, p < 0.05), with higher socioeconomic
status (31.4% vs 17.2% p <0.01), better mean HAQ at diagnosis (1.1 vs 1.3, p <0.05) an association was observed with monotherapy. In addition, an association was observed with the use of monotherapy in patients in the 2nd biological line or higher vs 1st line (53% vs 33%, p <0.01), lower polypharmacy (45.6% vs 60%, p <0.02) and a shorter mean time of biological treatment (47 months vs 39 months, p <0.01). These variables were entered in a logistic regression model, the results of the independently associated variables are shown in Table 1.

### Table 1. Effectiveness and Cost per Effectively Treated Patient with RA

<table>
<thead>
<tr>
<th>Criteria</th>
<th>All patients (n=263)</th>
<th>IGU with MTX group (n=96)</th>
<th>bDMARDs with MTX group (n=62)</th>
<th>MTX (n=105)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost of all RA-related medication per effectively treated patient (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average cost of all $146.38 (114.60)</td>
<td>$148.81 (123.12)</td>
<td>$86.90 (74.53)</td>
<td>$171.4 (110.33)</td>
<td></td>
</tr>
<tr>
<td>Average cost of only biological DMARDs per patient (SD)</td>
<td>$746.38 (528.35)</td>
<td>$684.27 (188.67)</td>
<td>$2468.67 (1285.91)</td>
<td></td>
</tr>
</tbody>
</table>

* p <0.05, CI = 95% confidence interval

**Conclusion:** The frequency of monotherapy, since the JAK's emergence, was 49% (all follow-up) and 41% (current-last visit). Intolerance to cDMARDs doctor and the patient decision were the main cause. The monotherapy use pattern was greater in those who received JAKi and anti IL6. The use of monotherapy was associated with work activity, socioeconomic status, and functional capacity at diagnosis. An association was also observed with less polypharmacy.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.602

---

**AB0391**

**ANALYSIS OF CLINICAL IMPROVEMENT BY 5 JAK INHIBITORS AGAINST JAK KINASE INHIBITOR IR RA PATIENTS IN JAPANESE CLINICAL PRACTICE**

K. Katayama1, M. Yuichi2, H. Ito2.

1Katayama Orthopedic Rheumatology Clinic, Rheumatology, Asahikawa, Japan; 2Asahikawa Medical University, Integrated Medical Education Center, Asahikawa, Japan; 3Asahikawa Medical University, Department of Orthopedic Surgery, Asahikawa, Japan

**Background:** Recently, Eular recommended different mode of therapeutic tool to get clinical remission. JAK inhibitors are considered to be one of candidates. Several JAK inhibitors have been used, however there are almost little informations about selection of JAK Inhibitors, especially, informations about secondary JAK for JAK inhibitor IR RA patients.

**Objectives:** To analyze clinical response by second JAK inhibitors against JAK inhibitor IR RA patients in clinical practice.

**Methods:** In Japan, five JAK inhibitors have been mainly used in MTX IR or biologics IR patients from 2013 (tofacitinib, JAK1,2017, baricitinib, JAK 1,2) (2019) (Peficitinib, Pan JAK, in Asia, Japan), 2020,April (upadacitinib, JAK1,2, mainly JAK1) and 2020. Nov (filgotinib, JAK1). In our clinic, these JAK inhibitors were sequentially used to get clinical remission. Numbers of patients who used JAK inhibitors are 28 patients in tofacitinib, 38 patients in baricitinib, 27 patients in peficitinib, 34 patients in upadacitinib, and 13 patients in filgotinib. Among them, 22 JAK inhibitor IR RA patients were investigated for clinical effectiveness.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.859

---

**AB0390**

**COST-EFFECTIVENESS OF IGRURATIMOD IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) BY USING A CLAIMS-BASED ALGORITHM: RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA**

Y. Wang1, T. Shi1, J. Deng1, J. Wu1, Y. Qu1, Y. Zhang1, X. Zhi1, J. Wu1, Y. Zhang1, X. Zhu1, B. Liang1, Q. Yu1, H. Du2, L. Jie1.

1Southern Medical University, Department of Rheumatology and Clinical Immunology, Guangzhou, China; 2Southern Medical University, School of Laboratory Medicine and Biotechnology, Guangzhou, China

**Background:** Igruratimod (IGU), as one of the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), has been approved by Ministry of Health, China. This study aimed to compare the cost-effectiveness of well-established RA patients using a claims-based algorithm in RA patients.

**Objectives:** This study aimed to compare the cost-effectiveness of well-established RA therapies using a claims-based algorithm in RA patients.

**Methods:** An electronic medical record (EMR) database from Zhujiang Hospital, Guangzhou, China was utilized to estimate the cost-effectiveness of medication for RA patients, including IGR with MTX, biological DMARDs (bDMARDs) with MTX, and MTX alone for more than 6 months from 2014 to 2020. Patients who were deemed effective must meet all the following criteria according to the algorithm, high adherence; no bDMARDs or IGU switch or addition; no prescription of new csDMARDs. The average cost of all RA medications was revealed to be both effective and the most effective, which seemed to be a cost-effective strategy for RA therapy and warranted further cost-effectiveness investigation.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.602
Results: Summary of study were shown in Tables 1 and 2. Biologics were used in 14 patients and satisfied D2T RA (1st row, green color). For pre JAK inhibitors, 12 tofacitinib, 8 baricitinib, 4 peficitinib and 3 filgotinib were used. Six months later, 9/13 patients in upadacitinib, 2/3 in filgotinib, 2/3 in peficitinib, and 3/3 in baricitinib, totally 13/22 improved clinical disease activity (Eular good+ moderate response). Clinical improvement about ACPA negative (6th row, yellow color) in 4 patients (8 th row, dark green)- 3 tofacitinib, 1 baricitinib respond well firstly about 1st and successive response for upadacitinib treated patients. Since, first JAK in 4 patients (8 th row, dark green)- 3 tofacitinib, 1 baricitinib respond well firstly (secondary unresponsiveness), tofacitinib may be useful for double negative or RF negative RA patients.

Table 1. Summary of Efficacy Endpoint Results at Week 12 in Chinese Subgroup

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>UPA (N=114)</th>
<th>PBO (N=110)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary endpoint</td>
<td>ACR20, %</td>
<td>71.9***</td>
</tr>
<tr>
<td>Secondary endpoints</td>
<td>Δ DAS28-CRP</td>
<td>-2.42***</td>
</tr>
<tr>
<td></td>
<td>Δ HAQ-DI</td>
<td>-0.55***</td>
</tr>
<tr>
<td></td>
<td>Δ SF-36 PCS</td>
<td>7.63***</td>
</tr>
<tr>
<td></td>
<td>Δ DAS28-CRP ≤3.2, %</td>
<td>46.5***</td>
</tr>
<tr>
<td></td>
<td>Δ DAS28-CRP ≤2.6, %</td>
<td>28.1***</td>
</tr>
<tr>
<td></td>
<td>Δ CD4 ≥10, %</td>
<td>33.3***</td>
</tr>
<tr>
<td></td>
<td>Δ ACR50, %</td>
<td>39.5***</td>
</tr>
<tr>
<td></td>
<td>Δ ACR70, %</td>
<td>16.7***</td>
</tr>
<tr>
<td></td>
<td>Δ ACR20 at Week 1, %</td>
<td>25.4***</td>
</tr>
</tbody>
</table>

Conclusions: UPA demonstrated clinical and functional improvement in Chinese csDMARD-IR RA pts. The safety of UPA was comparable with the overall study population and with the safety seen in the global Phase 3 program.

Table 1. Summary of Efficacy Endpoint Results at Week 12 in Chinese Subgroup

Disclosure of Interests: None declared

References: None declared

Methods: Pts were randomized to 12 weeks of blinded treatment with UPA 15mg once daily (QD) or PBO, in combination with csDMARDs. Primary and secondary endpoints were analyzed in a Chinese subgroup, including American College of Rheumatology criteria (ACR) responses, remission and low disease activity measures. Safety was analyzed for pts who received ≥1 dose of study drug.

Results: 228 Chinese pts (67.5% of overall trial population) were randomized and took at least one dose of study drug. Baseline characteristics were generally balanced between UPA and PBO. 46% and 35.1% used methotrexate (MTX) alone as concomitant csDMARD in UPA and PBO group, respectively. 38.9% in UPA and 43.0% in PBO group used concomitant csDMARDs other than MTX and 15.0% and 21.9% respectively used a combination. At week 12, more Chinese pts receiving UPA achieved the primary endpoint of ACR20 compared with PBO (71.9% vs 31.6%, nominal p<0.001). UPA also showed greater improvements in all secondary endpoints vs PBO at Week 12 (Table 1), including ACR50 and ACR70, mean difference from baseline 71.9% vs 31.6%. UPA also showed greater improvements in all secondary endpoints vs PBO at Week 12 (Table 1), including ACR50 and ACR70, mean difference from baseline 71.9% vs 31.6%.

Conclusions: JAK inhibitors are useful for another JAK inhibitor IR RA patients in clinical practice. However, to get good response, baseline immunogenicity, RF/ACPA positivity, JAK specificity need to be considered. To solve, prospective clinical study may be required.

References: None

Disclosure of Interests: None declared

Background: Four Janus Kinase inhibitors (JAKI) are licensed in the UK for treating rheumatoid arthritis (Upadacitinib, Tofacitinib, Filgotinib and Baricitinib). Several analyses have examined the survival in these groups and found them more likely to be tolerated more or equivalently than other modes of action. Recent data suggested an influence on survival using these drugs.

Objectives: To study the overall survival rates of JAKI compared to the other biologic treatments in a single centre cohort.

Methods: We analysed patients commencing advanced treatments (anti-Tumour necrosis factor, Interleukin 6 blocker, Rituximab and Abatacept) between 20 February and October 2021. Variables examined included gender and age. The time on drug was compared between JAKI and other treatments using student’s T test. Chi squared test was used to compare categorical variables. A Cox regression model was fitted to compare length of stay on each agent JAKI length of stay was compared to length of stay on other agents combined.

Results: 592 patients were included in the analysis. 168 (28%) were started on JAKI. 435 (73.4%) were females. Mean age at drug start was 60.6 years (SD 13.5). The numbers on drug were Filgotinib n=10, Tofacitinib n=35, Upadacitinib n=37, Baricitinib n=86, Adalimumab n=211, Abatacept n=36, Certolizumab n=18, Etanercept n=112, Golimumab n=21 and Tocilizumab n=26. 93 (15.7%) discontinued their drug, mostly due to lack of efficacy. Mean number of days on any biologic therapy was 918.9 (SD 711.5). Patients on JAKI had a significantly shorter survival on drug 652.7 days vs 1024.4 days (P<0.001).

There were no significant differences in age and gender between the groups. Univariate regression showed a hazard ratio of 1.19 (95%CI 0.75,1.98). This remained non-significant after adjusting for age and gender (1.18 95%CI 0.71,1.95). The only predictor of stoppage was age (HR 1.03 95%CI 1.01,1.04).

Conclusion: In this relatively large observational study, there was no difference in predictors of stoppage between JAKI and other advanced therapies. Increasing age was found to be a predictor for stoppage. This is in line with other reports in the literature. Further work looking at the impact of serology and disease activity will be performed.

Disclosure of Interests: Nauman Bakhtiar: None declared, Leanne Gray: None declared, Syed Mujtaba Bilgrami Grant/research support from: Grants for BSR & EULAR Conferences in the past., Lesley Ottewell: None declared, Fiona Wood: None declared, Mareen Bukhari Speakers bureau: Bristol-Myers Squib, UCB celltech, Roche/Chugai, Pfizer, Abbvie, Merck, Mennarini, Sanofi-aventis, Eli Lilly, Janssen, Amgen, Novartis and Gilead

Table 1. EAIRs of TEAEs in LTE, as of June 1, 2020

<table>
<thead>
<tr>
<th>EAIR (95% CI)</th>
<th>FIL200+csD → FIL200+csD</th>
<th>PBO+csD → FIL200+csD</th>
<th>FIL200+csD → FIL100+csD</th>
<th>FIL100+csD → FIL100+csD</th>
<th>FIL100+csD → SOC+csD</th>
<th>FIL100+csD → FIL100+csD</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEAE</td>
<td>n=121PYE 228.4</td>
<td>n=47PYE 98.1</td>
<td>n=23PYE 42.1</td>
<td>n=110PYE 223.3</td>
<td>n=46PYE 91.1</td>
<td>n=22PYE 38.2</td>
</tr>
<tr>
<td>TEAE Grade ≥3</td>
<td>10.5 (7.0, 15.7)</td>
<td>10.2 (5.5, 18.9)</td>
<td>19.0 (9.5, 38.0)</td>
<td>10.3 (8.8, 15.5)</td>
<td>13.7 (22.3, 32.2)</td>
<td>18.3 (8.7, 38.5)</td>
</tr>
<tr>
<td>TE serious AE</td>
<td>12.3 (8.5, 17.8)</td>
<td>12.2 (6.9, 21.5)</td>
<td>21.4 (11.1, 41.1)</td>
<td>8.1 (5.1, 12.8)</td>
<td>13.2 (7.5, 23.2)</td>
<td>21.0 (10.5, 41.9)</td>
</tr>
<tr>
<td>Death</td>
<td>1.3 (0.4, 5.1)</td>
<td>1.0 (0.5, 2.7)</td>
<td>0.8 (0.0, 1.6)</td>
<td>0.4 (0.1, 3.2)</td>
<td>0.0 (0.0, 0.9)</td>
<td>0.0 (0.0, 0.9)</td>
</tr>
<tr>
<td>TE infections</td>
<td>34.2 (27.4, 42.6)</td>
<td>22.4 (14.8, 34.1)</td>
<td>35.6 (21.5, 59.1)</td>
<td>8.4 (4.7, 17.0)</td>
<td>0.0 (0.0, 0.9)</td>
<td>39.5 (23.7, 66.2)</td>
</tr>
<tr>
<td>TE serious infections</td>
<td>3.5 (1.8, 7.0)</td>
<td>2.0 (0.5, 8.2)</td>
<td>7.1 (2.3, 22.1)</td>
<td>0.8 (0.2, 3.6)</td>
<td>0.0 (0.0, 0.9)</td>
<td>7.9 (2.5, 24.4)</td>
</tr>
<tr>
<td>Opportunistic infections</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>TE herpes zoster</td>
<td>0.2 (0.1, 0.5)</td>
<td>0.1 (0.1, 0.2)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.2 (0.1, 0.4)</td>
</tr>
<tr>
<td>TE MACE (adjudicated)</td>
<td>1.3 (0.4, 4.1)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>TE DVT/PE (adjudicated)</td>
<td>0.9 (0.2, 3.5)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.4 (0.1, 1.3)</td>
<td>0.4 (0.1, 3.2)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>Malignancies (excluding NMSC)</td>
<td>1.3 (0.1, 5.5)</td>
<td>2.0 (0.0, 11.5)</td>
<td>3.0 (0.0, 11.5)</td>
<td>1.0 (0.0, 7.2)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
<tr>
<td>NMSC</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
<td>0.0 (0.0, 0.0)</td>
</tr>
</tbody>
</table>

DVT, deep vein thrombosis; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; PE, pulmonary embolism; TE, treatment-emergent
Gilead Sciences, Mitsubishi-Tanabe, Novartis, Pfizer Japan, and Sanofi, Con- 

cult; of: Asahi Kasei, Asstellas, Chugai, Daiichi Sankyo, Eisai, Mitsubishi-Tanabe, 

quent research from: Bristol Myers Squibb, Sanofi Genzyme, and UCB, Grant/ 

Cronin, Young; BMS, Celltrion, Galapagos, Janssen, Lilly, NDS, Novartis, Pfizer, Sandz, and UCB, Consultant of: Abb’Vie, Amgen, BMS, Celltrion, Galapagos, Janssen, Lilly, Fresenius-Kabi, MSD, Novar- 


tis, Pfizer, Roche, Sandz, and UCB, DOI: 10.1136/annrheumdis-2022-eular.1624

AB0395

DE-ESCALATION OF DMARDS IN ELDERLY PATIENTS WITH RA

L. Robson1, F. Hayes2. 1. Lister Hospital, Rheumatology, Stevenage, United 

K. van Middendorp6, P. Weijs7, D. van Schaardenburg1,2.


diabetes, and the observations from this study will be applicable to all who treat elderly 

contextualising a patient’s treatment plan for their rheumatological disorder with 

their elderly patients and de-escalating conventional DMARDs accordingly. As 

effects, and as elderly people have higher rates of adverse drug reactions and 

DMARDs (Tutuncu & Kavanaugh, 2007). These drugs are not without side 

arthritis in older adults, with the mainstay of treatment being the conventional 

therapy in response to a cancer diagnosis than a dementia diagnosis or frailty. 

year period. Planned de-escalations were mostly successful, whereas abrupt 

flares in disease activity), semi-successful (patient had mild RA flare treated with 

multiple DMARDs saw a greater average decrease in methotrexate compared 

with acute hospital admission being the most common trigger. Of these 3 were 

were generally less successful. Rheumatologists are good at 

stopping to treatment were generally less successful. Rheumatologists are good at 

with acute home admission and de-escalating conventional DMARDs accordingly. As 

the average age of rheumatology patients is only likely to increase in the future, 

contextualising a patients treatment plan for their rheumatological disorder with 

their overall health status will become an increasingly important skill for clinicians 

and the observations from this study will be applicable to all who treat elderly patients with inflammatory disorders.

Objectives: 1. Evaluate if major new diagnoses were acknowledged in the rheu-

matology clinic and if conventional DMARD treatment was reduced in response. 2. Record and compare the outcomes of when conventional DMARD was stopped abruptly vs when it was tapered down slowly.

Methods: Evaluated 10 year’s worth of clinic letters from rheumatology and other specialties in 50 patients with a diagnosis of RA over the age of 89. Noted new diagnoses of dementia, cancer or frailty (multiple falls, care home admission or becoming newly house bound) as well as acute hospital admissions and declining renal function and evaluated if this was acknowledged in clinic letters and whether treatment was changed in response. Recorded all instances where conventional DMARDs were stopped or had a dose reduction and evaluated if these dose drops were successful (patient stayed at reduced dose with no flares) or semi-successful (patient had mild RA flare treated with short course corticosteroids, or stayed at reduced dose for at least a year before returning to original dose) or unsuccessful (patient suffered flare and went back to original dose within 1 year).

Results: Of the 50 patients, 31 received methotrexate monotherapy, 12 metho-

trextate and other conventional DMARDs, and 5 DMARDs other than methotrex-

ate. 36 of out 45 patients receiving methotrexate had some decrease in dose by the end of the 10 year period, with the median decrease being 5mg. Patients on multiple DMARDs saw a greater average decrease in methotrexate compared to those on monotherapy. 15 abrupt cessations in methotrexate were recorded, with acute hospital admission being the most common trigger. Of these 3 were successful, 5 were semi-successful and 7 were unsuccessful. 55 planned metho-
trextate dose reductions in the rheumatology clinic were recorded, with 36 being successful, 9 being semi-successful and 8 being unsuccessful. A clinical letter did generally acknowledge both new physical diagnoses and changes in social circumstances, but some diagnoses were more likely to trigger a change in treatment, for example in new cancer diagnoses, there were 5 changes to treatment, whereas in 12 dementia diagnoses there were 3 changes to treatment. 6 patients received more methotrexate than guidelines suggest for their level of OA, with 3 of these having acknowledged in clinic letters.

Conclusion: Most patients had a reduction in dose of methotrexate over a 10 year period. Planned de-escalations were mostly successful, whereas abrupt stops to treatment were generally less successful. Rheumatologists are good at acknowledging changes to health status but were more likely to change DMARD therapy in response to a cancer diagnosis than a dementia diagnosis or frailty. There is still some work to be done in acknowledging declining renal function and

changing methotrexate in response. Overall, these results suggest de-escalation is mostly successful and clinicians can be confident in further expanding this into routine day practice.

REFERENCES:


Acknowledgements: Many thanks to my supervisor Dr Fiona Hayes and the rest of the rheumatology team at Southend University Hospital for being so wel-

coming and allowing me to make full use of the tea supplies.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1639

AB0396

EFFECT OF A MULTIDISCIPLINARY LIFESTYLE PROGRAM ON RA PATIENTS WITH RHEUMATOID ARTHRITIS: THE PLANTS FOR JOINTS RANDOMIZED CONTROLLED TRIAL

W. Wairabenstein1,2, C. Wagenaar1,2, M. van der Leeden3,4, F. Turkstra1, J. Twisk1, M. Boen3, H. van Mulders3, D. van Schaardenburg3,4.

1. Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands; 2. Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands; 3. Amsterdam UMC, Vrije Universiteit, Department of Rehabilitation Medicine, Amsterdam, Netherlands; 4. Vrije Universiteit Amsterdam, Amsterdam Movement Sciences Research Institute, Amsterdam, Netherlands; 5. Amsterdam UMC, Vrije Universiteit, Department of Epidemiology and Data Science, Amsterdam, Netherlands; 6. Leiden University Medical Center, Division of Rheumatology, Leiden, Netherlands; 7. Amsterdam University of Applied Sciences, Department of Nutrition and Dietetics, Center of Expertise Urban Vitality, Amsterdam, Netherlands.

Background: Lifestyle factors have been associated with the development and progression of rheumatoid arthritis (RA). Interventions involving whole food plant-based diets (WFPDs), physical activity or stress management have shown promising results for people with RA but were not yet evaluated in an integrated program.

Objectives: To determine the effect of a 16-week multidisciplinary lifestyle pro-

gram on disease activity in patients with RA.

Methods: In the “Plants for Joints” (PFJ) parallel-arm, assessor-blind randomized clinical trial, patients with RA and a 28-Joint Disease Activity Score [DAS28] score ≥ 2.6 and ≤ 5.1, were assigned to the PFJ group or the control group. The PFJ group followed a lifestyle program based on a WFPD, physical activity, and stress management in addition to usual care. The control group received usual care. Medication was kept stable three months before and during the trial. Secondary outcomes included anthropometric, and metabolic markers. An intention-to-treat analysis with a linear mixed model, adjusted for baseline values was used to analyze between-group differences of continuous outcomes.

Results: Of 115 people screened, 85 were randomized and 79 completed the study. Participants were 91% female with a mean (SD) age of 55 (12) and body mass index of 26 (4) kg/m2. After 16 weeks the PF J group had a mean 0.85-point greater improvement of the DAS28 versus the control group (95% CI 0.40 to 1.30; p < 0.001) (Figure 1). Subgroup analyses showed significant improvements in the seropositive as well as the seronegative subgroup, although the effect was more profound in the seronegative group. Weight, fat mass, HbA1c, LDL and triglycerides also showed significant improvements in the PFJ versus control group, while blood glucose and HDL remained unchanged (Table 1). No serious adverse events occurred.

Table 1. Outcome Measures for Plants Trial

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PFJ group (n = 40)</th>
<th>Control group (n = 36)</th>
<th>Difference in change between groups (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAS28 score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.73 (1.36)</td>
<td>5.73 (1.36)</td>
<td>0.00 (-0.40 to 0.40)</td>
</tr>
<tr>
<td>End of trial</td>
<td>4.88 (1.26)</td>
<td>5.68 (1.40)</td>
<td>-0.80 (-1.30 to -0.30)</td>
</tr>
<tr>
<td>% reduction from baseline</td>
<td></td>
<td></td>
<td>0.10 (-0.00 to 0.20)</td>
</tr>
<tr>
<td>DAS28 remission score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>5.73 (1.36)</td>
<td>5.73 (1.36)</td>
<td>0.00 (-0.40 to 0.40)</td>
</tr>
<tr>
<td>End of trial</td>
<td>4.88 (1.26)</td>
<td>5.68 (1.40)</td>
<td>-0.80 (-1.30 to -0.30)</td>
</tr>
<tr>
<td>% reduction from baseline</td>
<td></td>
<td></td>
<td>0.10 (-0.00 to 0.20)</td>
</tr>
</tbody>
</table>

Conclusion: The 16-week PFJ lifestyle program substantially decreased disease activity in people with RA with low-moderate disease activity.

Disclosure of Interests: None declared.
Disclosure of Interests: Wendy Wairalenstein: None declared, Carlijn Wagenaar: None declared, Marike van der Leeden: None declared, Frankien Turksstra: None declared, Jos Twisk: None declared, Maarten Boers Consultant of: Consultant for Novartis, Henriet van Middendorp: None declared, Peter Weijls: None declared, Dirkjan van Schaardenburg: None declared


Table 1. Baseline characteristics of the 29 patients enrolled this study

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>n=29</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>57 [48.0-66.0]</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>22/7 [75.9]</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>13 [8.6-18.8]</td>
</tr>
<tr>
<td>RF positive</td>
<td>26 (89.7)</td>
</tr>
<tr>
<td>ACPA positive, (n=22)</td>
<td>20 (90.0)</td>
</tr>
<tr>
<td>Concomitant medications</td>
<td>10.4 (35.4), 8.0 [8.0-10.5]</td>
</tr>
<tr>
<td>Methotrexate, dose(mg/week)</td>
<td>17 (59.0), 4.0 [2.0-6.0]</td>
</tr>
<tr>
<td>Disease activity</td>
<td>DAS28-CRP 3.77 [2.4-4.6], SDAI 15.5 [8.8-21.1], CDAI 14.5 [8.5-20.0]</td>
</tr>
<tr>
<td>Patient global assessment of disease activity (mm)</td>
<td>40 [25-58]</td>
</tr>
<tr>
<td>Provider global assessment of disease activity (mm)</td>
<td>32 [15-46]</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>0.9 [0.1-1.7]</td>
</tr>
<tr>
<td>TJC/SJC</td>
<td>4 [2-5], 2[2-5]</td>
</tr>
</tbody>
</table>

Date are n (%)) or median [IQR].

Disclosure of Interests: None declared

Background: Current pharmacological treatments remain inadequate for a significant proportion of patients with rheumatoid arthritis (RA), and thus alternative treatment approaches are needed. Prior results from the first 12 weeks of a proof-of-concept (POC) study showed that ATHENS, a non-invasive high-frequency versus nerve therapy, was well-tolerated with meaningful reductions in RA disease severity as measured by the American College of Rheumatology response criteria (ACR) and the Disease Activity Score using 28 joints (DAS28)[1].

Objectives: The current analysis assessed long-term changes (52 weeks total follow-up) in disease activity as measured by ACR, DAS28, and the following MRI-assessed changes: synovitis, osteitis, bone erosion, and cartilage loss.

Methods: Following the completion of the 12-week POC study, patients achieving a reduction in DAS28-CRP of ≥1.2 were given the option to enroll in the 9-month open-label extension (OLE) study. During the extension phase, patients were to use the wearable device for 15 minutes per day. Adjustment of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying antirheumatic drugs (bDMARDs) were allowed during the OLE. Changes from baseline were assessed at 12 weeks (end of initial POC) and 52 weeks (end of the OLE). Structural damage and disease progression were evaluated by standardized MRI of the wrist and hand, with and without intravenous gadolinium-based contrast. MRIs were evaluated by two independent, central readers, blinded to clinical information and visit-order of the images, and were scored for synovitis, osteitis, and bone erosion using the OMERACT-RAMRIS method. Cartilage loss was also determined using the 9-point cartilage loss score (CARLOS).

Results: Twenty-seven of 30 patients completed the initial 12-week study, of whom 19 consented and entered the OLE. Of those 19 patients, 4 (21%) discontinued due to lack of efficacy, while the remaining 15 completed the 9-month extension study. Due to the COVID-19 pandemic, 7 patients were unable to complete a 52-week MRI scan, MRI evaluations at baseline, 12 weeks, and 52 weeks were available for 8 patients. DAS28-CRP mean (standard deviation [SD]) change from baseline was -1.78 (1.01) at 12 weeks (n=19; p<0.0001) and -2.30 (1.22) at 52 weeks (n=15; p<0.0001). ACR20, ACR50, and ACR70 response rates were 68%, 42%, and 21% at 52 weeks (n=19; discontinued participants were deemed non-responders). MRI analysis of synovitis, osteitis, bone erosion, and cartilage loss showed no evidence of disease progression through 52 weeks compared with baseline (Table 1).

Table 1. Change in MRI OMERACT-RAMRIS from baseline to week 52

<table>
<thead>
<tr>
<th>Score</th>
<th>Baseline (n=8)</th>
<th>Week 12 (n=8)</th>
<th>Week 52 (n=8)</th>
<th>Change Week 12 vs BL</th>
<th>Change Week 52 vs BL (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CARLOS, mean (SD)</td>
<td>3.9 (5.6)</td>
<td>3.9 (5.6)</td>
<td>3.9 (5.6)</td>
<td>0.0 (0.0)</td>
<td>0.0 (0.0)</td>
</tr>
<tr>
<td>Erosion, mean (SD)</td>
<td>10.8 (10.3)</td>
<td>10.5 (10.3)</td>
<td>10.6 (10.3)</td>
<td>-0.3 (0.4)</td>
<td>-0.1 (0.8)</td>
</tr>
<tr>
<td>Ostetis, mean (SD)</td>
<td>2.8 (4.1)</td>
<td>2.3 (3.7)</td>
<td>1.0 (1.1)</td>
<td>-0.5 (1.1)</td>
<td>-1.8 (3.1)</td>
</tr>
<tr>
<td>Synovitis, mean (SD)</td>
<td>4.0 (4.2)</td>
<td>4.1 (4.7)</td>
<td>3.3 (4.0)</td>
<td>0.1 (0.6)</td>
<td>-0.7 (1.0)</td>
</tr>
</tbody>
</table>

CARLOS = Cartilage loss score; OMERACT = Outcome Measures in Rheumatology; RAMRIS = Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System

During the 9-month extension study, two new adverse events were reported (corneal transplant and right hand dysaesthesia) in 2 (11%) patients; neither was treatment-related and both resolved without intervention. No serious adverse events were reported.

Conclusion: In patients with an initial treatment response to the Nesos ATHENS therapy in the 12-week POC study, reductions in DAS28-CRP were sustained through 52 weeks. Although results should be interpreted cautiously given the small sample size and lack of control arm, MRI evaluation of synovitis, osteitis, bone erosion, and cartilage loss suggested no disease progression.

REFERENCES:


Conclusion: In our study, LEF was comparable to RTX for achievement of ACR20/50/70 responses at 24 weeks. LEF can be considered as an add-on option to MTX instead of more expensive biologic agents in MTX refractory RA. Larger studies are needed to confirm this hypothesis.

REFERENCES:

Disclosure of Interests: None declared.

AB0400

A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS INTO THE SUCCESS RATE OF GLUCOCORTICOID DISCONTINUATION AFTER THEIR USE AS INITIAL BRIDGING THERAPY IN RHEUMATOID ARTHRITIS PATIENTS IN OBSERVATIONAL COHORTS AND CLINICAL TRIALS

1Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Rheumatology, Berlin, Germany; 3UZ Gasthuisberg Campus, Rheumatology, Leuven, Belgium; 4Medical University of Vienna, Rheumatology, Wien, Austria; 5Zuyderland MC, rheumatology, Heerlen, Netherlands; 6UMC Utrecht, Rheumatology, Utrecht, Netherlands.

Background: Glucocorticoids (GC) are widely used for the initial treatment of rheumatoid arthritis (RA), to induce rapid suppression of inflammation and clinical symptoms and thereby limit radiographic damage progression. There are concerns that GC use in the long term is associated with a dose and duration dependent risk of serious side effects. Therefore, international guidelines have recommended to start GC when initiating a csDMARD, but to discontinue GC as rapidly as clinically feasible, preferably within 3 months (bridging therapy). In contrast, due to the concerns of GC side effects, the ACR guidelines published in 2021 conditionally recommend to start csDMARD monotherapy without GC bridging therapy.

Objectives: We aim to evaluate the success rate of GC discontinuation after using temporary GC as part of initial therapy (‘bridging’) both in observational cohorts and clinical trials in newly diagnosed RA patients.

Methods: Systematic literature searches were conducted to identify observational cohorts (scoping search) and clinical trials (in-depth search) that included RA patients who were treated with initial GC bridging therapy. GC bridging was defined as oral or intramuscular GC treatment that was discontinued within one year, alongside conventional DMARD therapy. Patient percentages still or again using GC were considered to represent the reverse of successful discontinuation. Random-effects meta-analyses were performed stratified by time point.

Results: The literature search on observational cohort studies could not identify any study answering the research question, since it remained unclear which patients had received GC as part of the initial treatment. The literature search for clinical trials identified 7160 abstracts, resulting in 10 included studies, with varying type and dose of GC and varying tapering schedules (Table 1). Of these included studies, 4 reported sufficient data on GC discontinuation or GC use after the bridging phase. The pooled proportion of patients who were still using GC was 22% (95% Confidence Interval (CI) 8; 37 , based on 4 trials) at 12 months and 10% at 24 months (95% CI; 1; 22, based on 2 trials) (Figure 1). Thus, the vast majority had stopped GC. Heterogeneity was substantial (I² > 65%).

Conclusion: The success rate of GC discontinuation after bridging as part of initial treatment of RA has been described in a limited number of studies. Reports on observational cohorts did not answer the research question and in clinical trials reports, GC (dis)continuation data were also scarce. However, the available data show that GC can be discontinued successfully in a large majority of patients. The paucity of data also reveals that more efforts are needed to provide data towards identifying the optimal GC bridging and discontinuation strategy, combining Treatment to Target with Starting to Stop.

Acknowledgements: We would like to thank J.W. Schoonees for his help and expertise in the systematic literature search.

Disclosure of Interests: Lotte van Ooijerkerk: None declared. Andriko Palmowski: None declared. Isabella Nevins: None declared. Frank Buttgeraert: Consultant of: AstraZeneca, AbbVie, Grüenthal, Horizon Pharma, Pfizer, and Roche., Grant/research support from: Grant/research support from: AbbVie/Horizon Pharma, Pfizer, and Roche., Patrick Verschueren Consultant of: Was consultant for AbbVIE, BMS, Celtrion, Eli Lilly, Galapagos, Gilead, Nordic Pharma, Pfizer and UCB., Employee of: Holds the Pfizer Chair Early Rheumatoid Arthritis Management at KU Leuven., Josef Smolen: None declared. Robert B.M. Landewe Shareholder of: Shareholder of: Director of Rheumatology Consultancy BV., Consultant of: Consultant of: Of Honoraria from AbbVie, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Eli-Lilly, Novartis, Pfizer, UCB Pharma., Hans Blijisma Consultant of: Consultant of for Galapagos, Lilly and Sun., Grant/research support from: Received study grants from AbbVie and Roche., Andreas Kerschaubner: None declared. Rene Westhooves Consultant of: Was consultant for Celltrion, Galapagos and Gilead., Thomas Huizinga: None declared. Cornelia Allaart Grant/research support from: Received study grants for BeSt and IMPROVED from Centocor Inc. (now Janssen) and AbbVie, respectively., Sytske Anna Bergstra Grant/research support from: Received an ASPIRE grant from Pfizer.

Table 1. Overview of included clinical trials.

<table>
<thead>
<tr>
<th>Study (publication year)</th>
<th>Tapering schedule (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COBRA (1997) BeSt (2005)</td>
<td>In 7 weeks to 7.5. Stop after 28 weeks.*</td>
</tr>
<tr>
<td>In 7 weeks to 7.5. Stop in 8 weeks after 28 days if DAS persistently ≤2.4</td>
<td></td>
</tr>
<tr>
<td>arm 1: in 7 weeks to 75</td>
<td></td>
</tr>
<tr>
<td>arm 2: in 9 weeks to 75</td>
<td></td>
</tr>
<tr>
<td>Stop after 32 weeks if DAS&lt;1.6</td>
<td></td>
</tr>
<tr>
<td>IMPROVED (2014)</td>
<td>In 7 weeks to 7.5. Stop after 20 weeks if DAS&lt;1.6 at 4 months</td>
</tr>
<tr>
<td>ARCTIC (2016)</td>
<td>In 0 if DAS&lt;1.6 and no swollen joints present.</td>
</tr>
<tr>
<td>TREACH (2013) CareRA (2017)</td>
<td>In 10 weeks to 0.*</td>
</tr>
<tr>
<td>- Classic</td>
<td>In 7 weeks to 75, further tapered from week 28, stop after 34 weeks.</td>
</tr>
<tr>
<td>- Slim</td>
<td>In 6 weeks to 5, further tapered from week 28, stop after 34 weeks.</td>
</tr>
<tr>
<td>- Avant gardes Hua et al (2020)</td>
<td>All if DAS28(CRP)&lt;3.2.</td>
</tr>
<tr>
<td>NORD-STAR (2020)</td>
<td>Tapering after 4 months to 5, stop after 6 months.*</td>
</tr>
<tr>
<td>In 7 weeks to 5. Stop after 9 months.*</td>
<td></td>
</tr>
<tr>
<td>arm 1A (oral prednisolone)</td>
<td></td>
</tr>
</tbody>
</table>

DAS-disease activity score; mg/milligram; N.A.-not applicable. *GC tapered and stopped according to protocol, not depending on disease activity score.

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. The elucidation of the pathogenesis of RA has progressed dramatically in recent decades, and among the many cytokines involved in the pathogenesis of RA, interleukin (IL)-6 and TNF-α are known to be the major pro-inflammatory cytokines that are abundant in the bloodstream and synovial tissue. JAK inhibition (JAKibis) such as tocolizumab and baricitinib are used in the treatment of RA by inhibating JAK, which in turn inhibits the signaling of various cytokines including IL-6. However, predictors of the response to JAKibis are still required.

Objectives: We aimed to combine soluble TNF receptor (sTNFRI), sTNFRII, IL-6, soluble IL-6R (sIL-6R) and soluble gp130 (sgp130) levels to identify groups of JAKibis responses in RA patients.

Methods: This research is a retrospective study. We reviewed medical records of RA patients initiating JAKibis between July 2013 and July 2021 in our hospital. The Simplified Disease Activity Index (SDAI) was evaluated at baseline and 3, 6 months after JAKibis administration. Clinical remission was defined when SDAI decreased ≤ 3.3. Of the 125 patients treated with JAKibis, 89 patients with 6 months follow-up, valid SDAI and serum available were enrolled. Serum samples were collected at baseline and 3, 6, 12 months follow-up for IL-6 (Human IL-6 Quantikine ELISA Kit, R&D systems), sIL-6R (Human soluble IL-6R alpha Quantikine ELISA Kit, R&D systems), sgp130 and sTNFR I and sTNFR II (Human TNF RI/TNFRSF1A Quantikine ELISA Kit DRT100) and sTNFR II (Human sTNF RII/TNFRSF1B Quantikine ELISA Kit DRT200) using specific ELISAs according to the manufacturer's instructions. The statistical analyses were performed with EZR 1.55, and p values less than 0.05 were considered significant.

Results: The median age of patients was 62 (IQR: 51 - 72) years and the median of disease duration was 6.0 (2.0 - 16.0) years. Twenty-seven (30.3%) patients were biologics and JAKibis naïve. The baseline SDAI was median 18.9 (12.7 - 27.9). When comparing SDAI-remission group (clinical remission: CR) and non-remission group, there were no significant differences in any of the baseline clinical parameters. There was no significant difference in the serum levels of IL-6, sIL-6R and sgp130 between the CR and non-CR groups, but the serum levels of TNFRI and sTNFRII in the CR group were significantly lower than non-CR group. Univariate logistic regression analysis suggested Biologics and JAKibis naïve (odds ratio (OR) 3.58, p = 0.015), baseline Log sTNFRII levels (OR 0.013, P=0.034)
as predictors of SDAI remission treated with JAKInibs at 6 months. Although not significant, Stage IV (OR 0.211, P=0.082) and baseline Log sTNFR I levels (OR 0.013, P=0.082) were associated with clinical remission.

**Conclusion:** RA patients could be easily stratified prior to JAKInibs intervention with serum sTNFR II and sTNFR I levels, not but IL-6 axis cytokines (IL-6, sIL-6R, and sgp130).

<table>
<thead>
<tr>
<th>Odds Ratio</th>
<th>95% C.I.</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, year</td>
<td>0.973</td>
<td>[0.942 - 1.010]</td>
</tr>
<tr>
<td>Female (%)</td>
<td>0.820</td>
<td>[0.231 - 2.910]</td>
</tr>
<tr>
<td>BMI</td>
<td>0.968</td>
<td>[0.847 - 1.110]</td>
</tr>
<tr>
<td>Duration, year</td>
<td>0.962</td>
<td>[0.897 - 1.010]</td>
</tr>
<tr>
<td>Stage reference</td>
<td>II</td>
<td>0.857</td>
</tr>
<tr>
<td></td>
<td>III</td>
<td>0.444</td>
</tr>
<tr>
<td></td>
<td>IV</td>
<td>0.211</td>
</tr>
<tr>
<td>Biologic/JAK naïve</td>
<td>3.580</td>
<td>[1.280 - 9.950]</td>
</tr>
</tbody>
</table>

**AB0402**

**THERAPEUTIC ADHERENCE AND PERSISTENCE OF TOFACITINIB AND BARICITINIB IN RHEUMATOID ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE.**


**Background:** The use of Janus kinase inhibitors (JAKiKs) is approved for adults with rheumatoid arthritis (RA) with moderate to severe activity. Although there is increasing data about baricitinib and tofacitinib in daily clinical practice, data about adherence and persistence in real-life is scarce.

**Objectives:** (i) To evaluate the adherence and persistence of tofacitinib and baricitinib in RA patients in a real-life setting. (ii) To assess the influence of treatment adherence to therapeutic persistence.

**Methods:** Retrospective longitudinal observational study that included all patients with RA who were treated with tofacitinib and/or baricitinib between 2017/10 and 2021/05 in a tertiary hospital. Demographic, clinical and pharmacological data were collected from electronic medical and pharmacy claim records. Kaplan-Meier survival analysis and log-rank test were performed to calculate and compare treatment persistence, respectively. Drug adherence was assessed with the Medication Possession Ratio (MPR). The effect of therapeutic adherence on treatment persistence was evaluated with a linear regression model.

**Results:** We included 136 cases: 30 treated with tofacitinib [28.6%], 44 with baricitinib [41.9%] and 31 with both [29.5%] corresponding to 105 RA patients. In our sample 86.7% of the patients were women with a mean age (± SD) of 63 ± 13 years. At the start of treatment, patients had a mean disease activity score DAS28-ESR (± SD) of 5.1 ± 1.2 and they had previously received a median of 2 (0-6) biologic agents for RA.

During the study period, 40 (29.4%) and 38 (27.9%) patients treated with tofacitinib and baricitinib, respectively, discontinued the treatment. Mean treatment persistence was 363 days (95%Cl:2-1282) in tofacitinib group and 406 days (CI95%=8-1300) in baricitinib group. There were not statistically significant differences in treatment survival (HR=1.01 [95CI%=0.59-1.71]; p=0.97). Mean MPR was 91% in both groups. There was no statistically significant correlation between therapeutic adherence and treatment persistence (p=0.21).

**Conclusion:** The results showed no significant differences between treatment persistence and adherence of tofacitinib and baricitinib in our patients with rheumatoid arthritis. In our cohort, therapeutic adherence was high and it did not influence treatment persistence.

**Disclosure of Interests:** None declared


**AB0403**

**EVALUATION OF THE SAFETY AND EFFICACY OF 13-VALENT PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS.**

G. Lukina1,2, D. Murtazalieva1, E. Koltsova1, M. Kostinov2, A. Shmitko3, D. Blagovidov4, E. Zhilyaeva3, I. A. Loginov Moscow Clinical Scientific Center, Rheumatology, Moscow, Russian Federation; 2. V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation; 3. I.I. Mekhinco Research Institute of Vaccines and Ser a, Moscow, Russian Federation, 4. CSiC, European Medical Center, Rheumatology, Moscow, Russian Federation

**Background:** Rheumatoid arthritis (RA) is accompanied by a significant increase in the risk of infection and serious infections, among which pneumonia occupies a leading place. (1) The use of targeted anti-inflammatory drugs is accompanied by an additional increase in the risk of infectious complications. In this regard, vaccination is crucial in the management of such patients.

**Objectives:** To evaluate the safety and efficacy of the 13-valent pneumococcal vaccine in patients with RA undergoing various types of antirheumatic therapy.

**Methods:** The study included 60 patients with a reliable diagnosis of RA, according to the criteria of ACR/EULAR, among them 8 men and 52 women, average age 63 years (from 29 to 69 years) with disease activity at the time of inclusion of DAS28 – 4.9 (2.2-7.7), biopative patients with insufficient response to DMARDs who will be prescribed tofacitinib (TOFA) for the first time or receiving TOFA for at least 30 patients (each group). Both groups of patients were further subdivided into two groups, 15 vaccinated and unvaccinated patients in each. The exclusion criteria were: age over 70 years; patients with infectious diseases in the acute stage; having a history of intolerance to diphtheria toxoid, patients who had previously been vaccinated with pneumococcal vaccines. For the prevention of pneumococcal infection, a pneumococcal 13-valent polysaccharide conjugated adsorbed vaccine was used. Visits to assess the condition were made in the period of 0-3-12 months. The activity of the disease was assessed by the DAS 28, CDAI, SDAI indices.

**Results:** Among vaccinated patients with PCV 13 the most common adverse events were: pain at the injection site (16%), fever up to 37.6°C (13%), redness at the injection site (6%), infiltration at the injection site (2%), myalgia (2%). These adverse events resolved spontaneously within 3 days. In a comparative assessment of infectious events during 12 months before vaccination and the next 12 months after it, there were no significant differences between vaccinated and unvaccinated patients. In patients who had a history of pneumococcal etiology of infections after vaccination, the incidence decreased by 33%.

**Conclusion:** Vaccination against pneumococcal infection is a safe and effective method of preventing pneumococcal infection in patients with rheumatoid arthritis.

**REFERENCES:**


**Disclosure of Interests:** Galina Lukina Speakers bureau: Ebbvie, Biocad, Pfizer, Roche, Dzhamilya Murtazalieva: None declared, Ekaterina Koltsova: None declared, Mikhail Kostinov: None declared, Anna Shmitko: None declared, Dmitry Blagovidov: None declared, Evgeniy Zhilyaev Speakers bureau: Ebbvie, Biocad, Pfizer, Roche


**AB0404**

**DEPENDENCE OF COMPLICATIONS IN TOTAL HIP AND KNEE ARTHROPLASTY ON THE TREATMENT OF RHEUMATOID ARTHRITIS.**

A. Khraymov2, M. Makarov1, S. Makarov2, V. Amirdzhianova3, S. Maglejvany1, I. Kushna reva1, T. C. Phan1, I. V. A. Nasonova Research Institute of Rheumatology, Orthopaedic, Moscow, Russian Federation

**Background:** Surgical treatment of patients with rheumatoid arthritis (RA) is associated with an increased risk of complications. This is due to the presence of an inflammatory process, a variety of variants of the course of the disease, reduced physical activity, the severity of functional disorders, prolonged therapy with glucocorticoids, disease-modifying and genetically engineered biological drugs, osteoporosis, as well as the activity of the underlying disease.

**Objectives:** To conduct a comparative analysis of the effect of RA treatment on local complications, such as periprosthetic infection, periprosthetic fractures, wound complications, ligamentous disorders in hip and knee total arthroplasty in patients with RA.

**Methods:** 1113 arthroplasties of large joints in patients with RA, which were performed in the period from 2002 to 2020, were analyzed. Of these, 649 total knee replacements (TKA) and 464 total hip replacements (THA) were performed.

**Results:** In patients with therapy of methylxanate at an average dose of 12.5mg per week, the incidence of local complications was 7.87%. In patients receiving Leflunomide (Arava), complications were detected in 9.29% of cases. In group
of patients with Sulfasalazine (SSZ) intake, local complications were detected in 7.73% of cases. The complication rate of 7.01% was determined in group of patients who received Glucocorticoids (GC) at an average dose of 7.5 mg (recalculation in Prednisone) 1.87% of complications were observed in patients with innate genetically engineered biological drugs (bDMARD). The highest incidence of local complications was found in patients with RA who had no therapy (27.22%).

Statistical data analysis revealed a significantly higher number of complications in the group of RA patients (p<0.005). Analyzing each type of complications, significant differences were also obtained (p<0.005).

Conclusion: The risk of complications decreased for more times higher in group of patients with RA without any treatment. So, arthralgias of largest heights in patients with RA without treatment are often accompanied by a high risk of intra- and postoperative complications.

Disclosure of Interests: None declared


AB0405

JAK INHIBITORS IMPROVE PATIENT-REPORTED OUTCOMES SUCH AS PAIN AND HAQ EARLIER THAN ANTI-IL-6 INHIBITORS

T. Okano1, T. Koike2, K. Inui1, M. Tada3, K. Mamoto1, Y. Yamada1, K. Oriya4, K. Mandai4, S. Anno1, T. Iida7, 8, H. Nakamura1 on behalf of Osaka City University Team RA. 1Osaka City University Graduate School of Medicine, Department of Orthopedic Surgery, Osaka, Japan; 2Osaka City University Graduate School of Medicine, Center for Senile Degenerative Disorders (CSDD), Osaka, Japan; 3Search Institute for Bone and Arthritis Disease (SINBAD), Wakayama, Japan; Osaka; 4Osaka Saiseikai Hospital, Department of Orthopedic Surgery, Osaka, Japan; 5Osaka City General Hospital, Department of Orthopedic Surgery, Osaka, Japan; 6Kodyoga Christian Hospital, Department of Orthopedic Surgery, Osaka, Japan; 7Koryokai Hospital, Department of Orthopedic Surgery, Osaka, Japan; 8Takahiro Clinic, Nishinomiya, Japan

Background: Clinical feature of Janus kinase (JAK) inhibitor is recognized as not only suppress inflammation but also improve patient-reported outcomes (PRO) such as pain and health assessment questioner (HAQ) in patients with rheuma-
toid arthritis (RA). This representative clinical feature was known as a results of phase 3 trial compared to TNF inhibitor. One of the mechanisms of JAK in RA is to suppress interleukin-6 (IL-6). However, the effect for PRO in JAK inhibitor compared to IL-6 inhibitor have not been known.

Objectives: We investigated the effect for patient-reported outcomes such as pain and HAQ in patients with RA treated with JAK inhibitor compared to IL-6 inhibitor.

Methods: This study was analysed a multicenter database included RA patients treated with biological disease-modifying anti rheumatic drugs (bDMARDs) and JAK inhibitors. In 307 patients treated with IL-6 inhibitor (tocilizumab 240 and sarilumab 67) and 220 patients with JAK inhibitor (tofacitinib 101, baricitinib 63, upadacitinib 20, peficitinib 14 and filgotinib 2), 155 patients were treated as first-line bDMARDs/JAK inhibitor (IL-6R inhibitor 104 and JAK inhibitor 51). In this first-line patients, patients treated with IL-6R inhibitor and JAK inhibitor were matched using the propensity score adjusted for gender, age, RA disease duration, baseline TJC and HAQ and disease activity with CRP using CDAI and DAS-28 as continuous variables.

Results: Thirty-six patients in each group were matched and analyzed. The average age was 62.4 and 62.6 years and the average disease duration of RA was 13.2 and 10.1 years in IL-6 inhibitor and JAK inhibitor. The baseline characteristics were not significantly different in both groups at week 4, 12 and 24 weeks were compared between IL-6 inhibitor and JAK inhibitor.

Results: Thirty-six patients in each group were matched and analyzed. The average age was 62.4 and 62.6 years and the average disease duration of RA was 13.2 and 10.1 years in IL-6 inhibitor and JAK inhibitor. The baseline characteristics were not significantly different in both groups at week 4, 12 and 24 weeks were compared between IL-6 inhibitor and JAK inhibitor.

Conclusions: In a comparison between IL-6 inhibitor and JAK inhibitor as a first-line molecular-targeted drug matched baseline characteristics of disease activity, TJC and HAQ was improved in JAK inhibitor earlier than IL-6 inhibitors. JAK inhibitor suppress multi cytokine that might be the reason why JAK inhibitor improve pain. Improvement of patient reported outcome in JAK inhibitor was found also in comparison with IL-6 inhibitor.

REFERENCES:

Acknowledgements: We wish to thank Atsuko Kamiyama and Tomoko Nishimo for clinical assistant, and all member of Team RA.

Disclosure of Interests: None declared


AB0406

LIPID-LOWERING TREATMENT IN THE TREATMENT PROFILE OF THE RHEUMATOID ARTHRITIS PATIENTS

K. Fedorovych1, R. Yatsysyn1, B. Doskaliuk2, Ivano-Frankivsk National Medical University, Internal Medicine #1 Clinical Immunology and Allergology, Ivano-Frankivsk, Ukraine; 2Ivano-Frankivsk National Medical University, Pathophysiology, Ivano-Frankivsk, Ukraine

Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune dis-
order characterized by inflammatory changes in the synovial membranes of the joints, leading to their progressive damage and deformity. Inflammation occupies a prominent place in the pathogenesis of RA making it an essential target to improve the patient's condition.

Objectives: The purpose of this study was to evaluate the influence of lipid-low-
ering therapy on RA patients given its anti-inflammatory effect.

Methods: We involved 80 patients with diagnosed RA with established RA diagnosis based on 2010 ACR/EULAR Classification Criteria. The inclusion criteria for our study were the age of patients ≥18 years and the DAS28 index ≥ 2.6. We have excluded from investigation individuals with any prior medical history of myopathies, liver disea-
ses or increased transaminase levels, pregnant or breastfeeding women and patients taking lipid-lowering drugs. The accepted patients were randomized into 2 groups numbering 40 individuals each. The first group of subjects received just basic DMARDs and the second had atorvastatin 40 mg/day in addition. The atorvastatin admission lasted 3 months. To evaluate the possible anti-inflamma-
tory effect of atorvastatin the ESR, CRP, Visual Analogue Scale (VAS), swollen joint count (SJC), tender joint count (TJC) and Disease Activity Score (DAS-28) were used. Moreover, the lipid panel indexes in both groups of patients were analyzed. We used the Kologo-Simovor test for data distribution evaluation, Mann-Whitney U test and unpaired test were employed for groups comparison.

Results: We found that the administration of atorvastatin had a positive effect on pro-inflammatory parameters of patients. In the atorvastatin group the levels of ESR (mm/h) and CRP (mg/L) were significantly lower compared to the controls (23.3±9.43 vs 31.85±10.54, p<0.02 and 12.26 [8.21-17.54] vs 15.89 [11.32-21.54], p=0.04 respectively). TJC (p<0.01) and CDAI (p<0.05) and DAS-28 (p<0.05) indexes have been improved more significantly in the investigation group as well. The results of lipid panel measure were better in the atorvastatin group as well. The LDL (mg/dl) level differed between the two groups the most significantly (143.7±23.2 in the control group and 109.8±21.4 in the atorvastatin group, p=0.02).

Conclusion: With this study, we managed to demonstrate the beneficial effect of atorvastatin not only on RA disease activity profile but also on inflammatory level and disease course in patients with RA.

Disclosure of Interests: None declared

Background: The T2T guideline in RA recommended the normal csDMARDs irresponsive patients (pts) switching to other treatment target. Tacrolimus (TAC), the inhibitor of T cell activation, is candidate for these pts, especially with extrarticular complications (EC).

Objectives: To observe the efficacy and safety of TAC-based csDMARDs regimens refractory RA (RRA) pts and the characteristics of TAC combined treatment.

Methods: This prospective cohort study (ClinicalTrials.gov Identifier NCT02837978) was conducted in China. According to baseline DAS28-ESR, RRA pts (ACR 1987 criteria [1]) were classified to severe (>5.1, S) or moderate (≥3.2,5,1, M) groups. The efficacy indicators and AE were recorded until 144w. The combined medicine with TAC was based on the past history of csDMARD prescription and EC, including TAC with/wo MTX (T+M or T group), Pred, HCQ.

Results: 150 pts (52±14y) were involved, 15 finished 144w observation, 50 still followed up and 85 lost. As shown with GEE analysis, DAS28-ESR, CRP, HAQ were decreased significantly in all pts within 24ws, and maintained stable in later period (Figure 1). The REM or LDA, achieved ACR20, good or moderate EULAR response (G+M) proportion of 103 pts completed the 24w were 41.75%, 56.31%, 76.70%.

The Logistic regression showed baseline DAS28-ESR was an independent protective factor for ACR20 remission rate (Figure 2D).

Conclusion: TAC-based combined therapies are effective and tolerable for RRA, especially the higher disease activity pts. TAC blood concentration related to AE. The lower disease activity index and better respond, the higher TAC survival rate. TAC is recommended as TAC combined treatment.

REFERENCES:

Disclosure of Interests: None declared

AB0408
EXOSOMAL MICRORNAS AS BIOMARKERS FOR VIRAL REPLICATION IN TOFACITINIB-TREATED RHEUMATOID ARTHRITIS PATIENTS WITH HEPATITIS C

1Taichung Veterans General Hospital, Division of Medical Research, Taichung, Taiwan, Republic of China; 2Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Republic of China

Background: Despite recent advances of direct-antiviral agents (DAA) for Hepatitis C virus (HCV), it is still a prevalent worldwide issue and therapeutic challenge in patients with rheumatoid arthritis (RA). HCV viral replication may respond differently to biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) of different mechanism of action. Exosomal microRNA 155 (exo-miR-155) and exo-miR-122 have been implicated in modulating the host immune response and transmit anti-HCV factors to HCV-infected hepatocytes in patients with RA. However, it remains unknown how
exosomal miRNAs may respond following bDMARDs and tsDMARDs treatment in HCV-infected patients with RA.

**Objectives:** We aimed to study the changes of exo-miR-155 and exo-miR-122 following bDMARDs and tsDMARDs treatment in HCV-infected RA patients.

**Methods:** We prospectively enrolled RA patients taking anti-tumor necrosis factor (TNF-α) inhibitors, rituximab, and tofacitinib. The effect of bDMARDs and tsDMARDs on HCV viral replication were assessed using an HCV-tricistronic replicon cell system. Exo-miR-155 and 122 were detected by quantitative PCR. We observed a dramatically increase of exo-miR-122 and decrease of exo-miR-155 in patients taking rituximab compared with the TNF-α inhibitors, tofacitinib and conventional synthetic DMARD groups. Finally, a reduction of exo-miR-122 and increase of exo-miR-155 levels were detected following DAA therapy for HCV.

**Results:** Exo-miR-155 and exo-miR-122 were potential biomarkers for RA patients with HCV infection. Further studies are needed to confirm our findings.

**REFERENCES:**

**Table 1.** Demographics of HCV-infected RA patients with bDMARDs and tsDMARDs

<table>
<thead>
<tr>
<th></th>
<th>Anti-TNFα therapy</th>
<th>Rituximab</th>
<th>Tofacitinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=3</td>
<td></td>
<td>n=3</td>
<td>n=3</td>
</tr>
<tr>
<td>Age</td>
<td>62.8 (54.0-71.4)</td>
<td>59.9 (49.9-67.6)</td>
<td>63.8 (55.5-70.9)</td>
</tr>
<tr>
<td>Gender (female, %)</td>
<td>2 (66.7)</td>
<td>3 (100)</td>
<td>2 (66.7)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>11.0 (8.8-14.0)</td>
<td>11.3 (7.6-17.0)</td>
<td>12.0 (8.2-13.8)</td>
</tr>
<tr>
<td>RF (U/ml)</td>
<td>150.0 (102.2-324.4)</td>
<td>363.5 (265.0-538.7)</td>
<td>95.0 (75.4-152.6)</td>
</tr>
<tr>
<td>Anti-CCP antibody (units)</td>
<td>132.7 (93.0-270.8)</td>
<td>160.7 (106.9-400.3)</td>
<td>132.0 (88.0-211.8)</td>
</tr>
<tr>
<td>PtGA (VAS, mm)</td>
<td>60.6 ± 20.8</td>
<td>29.8 ± 22.8</td>
<td></td>
</tr>
<tr>
<td>Pain (VAS, mm)</td>
<td>57.3 ± 24.8</td>
<td>30.1 ± 25.7</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>15.5 ± 21.9</td>
<td>7.9 ± 13.2</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** These real-life interim results for Tofacitinib in RA patients provide information on its use in France: with prescriptions for single drug therapy in 41.7% of cases, the effectiveness of Tofacitinib is confirmed as comparable to that found in clinical studies.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3493

---

**Table 1.** Baseline characteristics and effectiveness at 12 months Patient characteristics

<table>
<thead>
<tr>
<th>Variables</th>
<th>mean ± SD or % pts</th>
<th>Inclusion, n=219</th>
<th>At 12 months, n=122</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGA (VAS, mm)</td>
<td>60.6 ± 20.8</td>
<td>29.8 ± 22.8</td>
<td></td>
</tr>
<tr>
<td>Pain (VAS, mm)</td>
<td>57.3 ± 24.8</td>
<td>30.1 ± 25.7</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>15.5 ± 21.9</td>
<td>7.9 ± 13.2</td>
<td></td>
</tr>
<tr>
<td>LDA, % pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- DAS28-crp ≤ 3.2</td>
<td>6.8</td>
<td>28.8</td>
<td></td>
</tr>
<tr>
<td>- DAS28-ESR ≤ 3.2</td>
<td>4.6</td>
<td>21.5</td>
<td></td>
</tr>
<tr>
<td>Remission, % pts</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- DAS28-crp ≤ 2.6</td>
<td>3.7</td>
<td>20.1</td>
<td></td>
</tr>
<tr>
<td>- DAS28-ESR ≤ 2.6</td>
<td>2.7</td>
<td>9.6</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** This is the first study to report on the effectiveness of Tofacitinib in RA patients treated with single drug therapy in France. The effectiveness of Tofacitinib is confirmed as comparable to that found in clinical studies.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3610

---

**AB0409**

FRENCH REAL LIFE EFFECTIVENESS DATA FOR TOFACITINIB AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM RESULTS OF THE OBSERVATIONAL STUDY, DEFACTO

C. Gaujoux-Viala1, A. Basché2, S. Lassouéd3, F. Coury-Lucas4, M. Kessouri5, N. Mamma1, Y. Brauti1, T. Lequerre1, C. Salliot1, Desbrest Institute of Epidemiology and Public Health (iDESP), Univ Montpellier; INSERM, Rheumatology, Nimes, France; 1Inserm Protestant Clinic, Lyon, Rheumatology, Caluire-et-Cuire, France; 2Hôpital Suburbain du Bouscat, M. E. Truchetet1, T. Schaeverbeke1, M. Kostine1, Hôpital Suburbain du Bouscat, M. E. Truchetet1, T. Schaeverbeke1, M. Kostine1, Bordeaux University Hospital, Rheumatology, Bordeaux, France; 3Hôpital Suburbain du Bouscat,
Background: Monoclonal Gamopathy of Undetermined Significance (MGUS) is common in patients with inflammatory rheumatic diseases but there are scarce data regarding the effect of disease-modifying antirheumatic drugs (DMARDs) on this pre-malignant condition. Recently, preclinical data and phase I trial have shown efficacy of JAK inhibitors (JAKi) in multiple myeloma.

Objectives: We aimed to evaluate the impact of JAKi on MGUS when initiated for an active rheumatic disease.

Methods: Patients with monoclonal abnormality prior to JAKi initiation for an active rheumatic disease were identified through the MAJiK-SFR Registry, a french multicentre prospective study, and a call for observation via the “Club Rhumatismes et Inflammations”. Clinical and biological data were collected using a standardised case report form.

Results: Nineteen patients were included, 10 women and 9 men, with a mean age of 65 years and a diagnosis of rheumatoid arthritis (n=14), psoriatic arthritis (n=3) or spondyloarthritis (n=2). The JAKi prescribed was baricitinib (n=8), tofacitinib (n=6) or upadacitinib (n=5), with a mean duration of 13 months. Sixteen patients had individualized serum monoclonal protein (IgG Kappa n=9; IgG Lambda n=7; IgM Kappa n=1; IgA Lambda n=1) ranging from 0.16g/dL to 2.3g/dL. With a follow-up of 2 to 47 months, 8 of 16 patients experienced a decrease in serum monoclonal protein level and 8 had a stable serum monoclonal protein level. The maximal decrease observed was an initial IgG Kappa of 2.3g/dL decreasing to 0.2g/dL at month 14. During follow-up, two patients did not have any detectable serum monoclonal protein on serum electrophoresis (initial value of 5.2g/l and 1.6g/l), but still a positive immunofixation. One patient had bone marrow aspirate with 8% of plasma cells before JAKi initiation and 3% after 4 months of treatment. Three patients did not have initial measurable spike but a positive immunofixation that became negative at month 8 and 11 (IgG Lambda, n=2) or stable (IgG Lambda, n=1). Conclusion: This study brings reassuring and promising data on the MGUS evolution in patients treated with JAKi for rheumatic diseases, which may guide the choice of treatment in patients with both conditions.

REFERENCES:

Acknowledgements: MAJiK-SFR Registry and Club Rhumatismes et Inflammations

Disclosure of Interests: None declared


AB0412 CYCLING OF JAK-INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SINGLE-CENTRE EXPERIENCE

C. Vassallo1, L. Sammu2, Queen Alexandra Hospital, Rheumatology, Portsmouth, United Kingdom

Background: Despite the availability of multiple effective disease-modifying anti-rheumatic drugs (DMARDs), discontinuation/switching of treatment is common for many patients with rheumatoid arthritis (RA). Janus kinase (JAK) inhibitors (JAKi) are the latest class of DMARDs approved for RA. Data on the outcomes of cycling JAKi in RA patients is still limited to this day.

Objectives: To assess the outcomes of switching between JAKi baricitinib, tofacitinib and upadacitinib in a real-world cohort of RA patients.

Methods: This was a hospital-based, retrospective observational study of all RA patients treated in a single-centre. Data was collected between 2016 and 2021 for all patients who failed JAKi and were treated with another JAKi. Demographic data, antibody status, history of DMARD use and clinical outcomes were assessed according to change in disease activity scores, time to JAKi discontinuation and reason for switching based on DAS 28-CRP scores.

Results: We identified 26 RA patients, 23 (88%) of which were RHF and/or anti-CCP positive, that failed JAKi and were cycled to another JAKi. 23 (88%) patients had failed treatment with one or more biological therapies prior to initiating JAKi. 13 (50%) patients were prescribed baricitinib and the other 13 patients Tofacitinib as their initial JAKi. During their RA treatment pathway, 9 (35%) of the patients on tofacitinib switched to baricitinib, and 4 (15%) switched to upadacitinib. 7 (27%) patients who started on baricitinib were switched to upadacitinib, and 6 (23%) were switched to tofacitinib. 3 (12%) patients cycled between all 3 JAKi. Reasons for switching first JAKi included primary treatment failure at initial 3-month recur- sion due to lack of efficacy (7/26; 27%), secondary failure (9/26; 35%), adverse drug reactions (ADR) (2/26; 8%) and others (1/26; 4%). Additionally, 7 (27%) patients on tofacitinib were switched following a drug safety update published by the Medicines and Healthcare products Regulatory Agency (MHRA), in an effort to minimize risk of major adverse cardiovascular events and malignancies. The median time to switching first JAKi was 11.5 months (range 3-23 months). After switching JAKi, 17 (65%) patients were found to have improved DAS 28-CRP scores.

Conclusion: In this analysis of 190 patients treated with JAKi we detect that the men uses JAKi more frequently in first indication than women. Women seems to have a longer disease evolution, more smoking habit and less cardiovascular risk than men.

Disclosure of Interests: None declared

at their 3-month rescore and continued treatment with their second JAKI. Following their switch, a total of 8 (31%) patients stopped their second JAKI due to inefficacy; 3 (12%) due to ADRs and 2 (8%) for other reasons. Of the 3 patients that went on to receive treatment with a 3rd JAKI (2/3 for primary failure; 1/3 for secondary failure), 2 patients were found to improve at their 3-month rescore. Conclusion: Cycling through JAKI is an appropriate and safe treatment strategy in RA patients that discontinue first JAKI therapy due to lack of efficacy or ADR.

References: NA

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4004

AB0443

STEROID SPARING EFFECT OF JAK-INHIBITORS ACROSS MULTIPLE PATIENTS POPULATION

P. Coniolini1, C. Minerba1, A. Vondola1, E. Greco1, B. Kroegel1, S. Modica1, P. Triggiani2, M. S. Chimenti1, A. Bergamini1.1University of Rome for Vergata, Rheumatology, Allergology and Clinical Immunology, Rome, Italy

Background: JAK-inhibitors (JAK-i) represent an effective choice in achievement of therapeutic target in bio-naive (bnaive) and bDMARD-insufficient responders (bDMARD-IR) patients. However, oral glucocorticoids (OGC) are commonly used in clinical practice in combination with b/tsDMARDs in Rheumatoid and Psoriatic Arthritis (RA and PsA) patients in order to reach clinical remission.

Objectives: To assess, in a real-life clinical setting, the reduction of OGC dose during JAK-i treatment in RA and PsA patients that were b-naive or ≥1-bDMARD-IR or ≥2-bDMARDs-IR with different mechanisms of action.

Methods: Patients with active RA or PsA treated with first JAK-i were prospectively enrolled in a single center. Disease activity (DAS28-CRP or DAPSA), pain visual analog scale (VAS-pain), general health (GH) and mean prednisone dosage (PDN dose) were collected at baseline and after 4, 8 and 12 months (T4, T8, T12) of treatment.

Results: 89 patients with active arthritis (77 RA, 12 PsA) were treated with JAK-i (43 patients received Baricitinib, 41 Tofacitinib and 5 Upadacitinib), with all patients reaching T4, 65 patients T8 and 50 patients T12 (Table 1). 27% patients were b-naive, 73% ≥1-bDMARD-IR and 34% ≥2-bDMARDs-IR. A mean OGC dose of 4.0 ± 4.6 (mg per day) was used and 39% of patients received JAK-i without csDMARDs. We observed a significant improvement of disease activity by DAS28-CRP or DAPSA, pain visual analog scale (VAS-pain), general health (GH) and mean prednisone dosage (PDN dose) were collected at baseline and after 4, 8 and 12 months (T4, T8, T12) of treatment.

Table 1. Persistence rates at 12 months post treatment initiation

<table>
<thead>
<tr>
<th>JAK inhibitors</th>
<th>All patients</th>
<th>First line</th>
<th>Second line</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK inhibitors</td>
<td>61% (2155)</td>
<td>60% (616)</td>
<td>60% (556)</td>
</tr>
<tr>
<td>Baricitinib</td>
<td>64% (537)</td>
<td>70% (158)</td>
<td>63% (124)</td>
</tr>
<tr>
<td>Tofacitinib</td>
<td>54% (248)</td>
<td>57% (411)</td>
<td>47% (294)</td>
</tr>
<tr>
<td>Upadacitinib</td>
<td>78% (430)</td>
<td>78% (17)</td>
<td>84% (136)</td>
</tr>
<tr>
<td>TNF inhibitors</td>
<td>Overall</td>
<td>52% (6339)</td>
<td>54% (4227)</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>55% (2710)</td>
<td>56% (2030)</td>
<td>48% (590)</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>51% (593)</td>
<td>54% (251)</td>
<td>47% (147)</td>
</tr>
<tr>
<td>Etanercept</td>
<td>52% (2079)</td>
<td>55% (1354)</td>
<td>47% (623)</td>
</tr>
<tr>
<td>Golimumab</td>
<td>49% (814)</td>
<td>49% (506)</td>
<td>47% (174)</td>
</tr>
<tr>
<td>Infliximab</td>
<td>35% (143)</td>
<td>23% (86)</td>
<td>53% (27)</td>
</tr>
<tr>
<td>Other DMARDs</td>
<td>Abatacept</td>
<td>51% (952)</td>
<td>56% (263)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>49% (284)</td>
<td>41% (70)</td>
<td>65% (79)</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>62% (1156)</td>
<td>65% (279)</td>
<td>65% (351)</td>
</tr>
</tbody>
</table>

In brackets are number of patients.

REFERENCES:


Disclosure of Interests: None declared


AB0444

DRUG PERSISTENCE ON JANUS KINASE (JAK) INHIBITORS COMPARED TO BIOLOGIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RETROSPECTIVE STUDY IN THE AUSTRALIAN POPULATION

L. Scheepers1, G. Jones1.1University of Tasmania, Musculoskeletal Health and Disease, Hobart, Australia

Background: In rheumatoid arthritis (RA) persistence on disease modifying anti-rheumatic drugs (DMARDs) can be interpreted as a composite measure of effectiveness, safety, and tolerability. There is limited data available on real-life use of the newest class of drugs, the Janus Kinase (JAK) inhibitors. JAK inhibitors are small-molecule treatments which are administered orally on a daily basis and offer a long-term option in RA treatment.

Objectives: To compare drug persistence on JAK inhibitors tofacitinib, baricitinib and upadacitinib to tumor necrosis factor-α (TNF) inhibitors and other DMARDs in RA patients in Australia.

Methods: A retrospective observational study was conducted among RA patients in the Australian Medicare Database (from January 2006 till October 2021), aged ≥18 and for whom a JAK inhibitor or biologic DMARDs were dispensed. Data were provided by the Australian Department of Health and Aging through PROSPECTION, an Australian healthcare consulting company. A de-identified 10% sample of the database was taken as a random representation of RA patients in Australia.

Kaplan-Meier analysis was used to calculate drug persistence rates, defined as the time from treatment initiation until the date of the last dose when there had not been a script dispensed for 6 months; except for rituximab, where a 12-month gap was applied.

Results: Data from 5,455 patients were analysed. For all patients the 12-month persistence rates were 61% for JAK inhibitors (baricitinib, tofacitinib, upadacitinib), 62% for tocilizumab, 52% for TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), and 51% for abatacept. The JAK inhibitors baricitinib (64%) and upadacitinib (78%) were superior to tofacitinib (54%). Median treatment persistence for upadacitinib was not reached (n = 430); was 27.1 months for baricitinib and 15.2 months for tofacitinib. For TNF inhibitors, treatment persistence was 15.1 months for adalimumab, 14.1 months for certoli- zumab, 14.0 months for etanercept, 11.1 months for golimumab and 4.5 months for infliximab.

Persistence rates on first-line JAK inhibitors were 70% for baricitinib and 57% for tofacitinib; persistence rates dropped to 63% for baricitinib and 47% for tofacitinib in the second-line setting. First-line persistence rates were 54% for TNF inhibitors and 65% for tocilizumab, rates were sustained for tocilizumab, but dropped to 48% for TNF inhibitors in the second-line setting.

Conclusion: This real-world data highlights that in an Australian clinical practice setting treatment persistence rates on 12 months on JAK inhibitors, in particular baricitinib and upadacitinib, were superior to TNF inhibitors, but not to tocilizumab. Suggesting that persistence rates might differ according to biologies mode of action and line of treatment.

Disclosure of Interests: None declared

Background: Upadacitinib is the third janus kinase (JAK) inhibitor approved for rheumatoid arthritis after baricitinib and tofacitinib. Upadacitinib is a selective JAK1 inhibitor, and is indicated for the treatment of moderate to severe active RA in adult patients with inadequate response or intolerance to one or more DMARDs.

Objectives: To describe the effectiveness and safety data of upadacitinib in patients with moderate-severe RA refractory to multiple synthetic and/or biologic DMARDs.

Methods: Descriptive and retrospective observational study conducted in patients who met RA classification criteria, refractory to synthetic and/or biologic DMARDs in the Rheumatology department of the Valme Hospital. Epidemiological, clinical, analytical, and safety and treatment-related variables were collected. A descriptive quantitative analysis of the data was performed.

Results: Forty-five patients were included (37 women and 8 men), with a mean age of 53 years and mean time of RA evolution of 11 years. Of the patients, 44.4% had some cardiovascular risk factor. With respect to previous treatment, 100% were on DMARDsc, with a median of 2 DMARDsc per patient. Regarding biologic or targeted therapy, 77.8% had a history of biologic therapy failure with a median of 1 biologic; in addition, 8 patients had received at least 3 previous biologic drugs prior to upadacitinib. A total of 28.9% (13 patients) had previously received JAKi, discontinued due to secondary failure or from clinical trials at other centers. In terms of disease activity at the start of upadacitinib, patients had a mean of number of swollen joints (SJC) 3, number of tender joints (TJC) 4, CRP 11 mg/dL, DAS28 of 4.24 and CDAI of 215. When starting upadacitinib, 80% of the patients were on steroid therapy, 51% with doses > 5 mg/day of prednisone. Combination therapy with DMARDs was maintained in 76.3% of patients (56.7% MTX, 36.7% LFN and the rest with SSZ). The results were analyzed after a median of 7 months from the start of upadacitinib: DMARDsc were discontinued in 4 patients and the steroid dose was reduced in 58.3% of the total, being discontinued in 21.2%. With respect to disease activity analyzed post-treatment in patients who maintained the drug, a mean of SJC 0, TJC 2, CRP 0.8 mg/dL, DAS28 2.7 and CDAI 12.5 were observed (Table 1). The drug was discontinued in 11 patients: 5 for adverse events (headache, hypersensitivity, gastrointestinal discomfort, instability accompanied by photopsia, lymphopenia and irritative cough) that resolved after discontinuation, 5 for primary failure and 1 for secondary failure. No cases of herpes, thrombosis or cardiovascular events were recorded.

Table 1. Medians pre-treatment and post-treatment outcomes in patients who maintained upadacitinib: SJC, TJC, C-Reactive Protein (CRP) and disease activity indices DAS28 and CDAI.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Pre upadacitinib</th>
<th>Post-treatment (medians 7 months)</th>
<th>Statistical significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>SJC</td>
<td>3</td>
<td>0</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>TJC</td>
<td>4</td>
<td>2</td>
<td>0.03</td>
</tr>
<tr>
<td>CRP</td>
<td>11</td>
<td>0.8</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>DAS28</td>
<td>4.23</td>
<td>2.7</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>CDAI</td>
<td>21.5</td>
<td>12.5</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

Conclusion: Upadacitinib managed to control disease activity in a high percentage of our series of patients resistant to multiple synthetic and/or biologic DMARDs, making it possible to reduce or even suspend steroid treatment in a significant number of patients, so it may be an option to consider in patients with refractory RA. Longer-term studies are needed to continue evaluating the effectiveness, safety and survival of the drug in real clinical practice.

REFERENCES:

Table 1. Clinical characteristics of the patients and incidence rates for adverse events

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tofacitinib, 5 mg Twice Daily</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>67 (63-73)</td>
</tr>
<tr>
<td>Female/male</td>
<td>109 (82.6)/23 (17.4)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>-Never smoked 78 (59.1)</td>
</tr>
<tr>
<td></td>
<td>-Ever smoked 54 (40.9)</td>
</tr>
<tr>
<td></td>
<td>-History of hypertension 82 (62.1)</td>
</tr>
<tr>
<td></td>
<td>-History of diabetes mellitus 40 (30.2)</td>
</tr>
<tr>
<td></td>
<td>-History of coronary heart disease 14 (10.8)</td>
</tr>
<tr>
<td></td>
<td>-History of congestive heart failure 3 (2.3)</td>
</tr>
<tr>
<td></td>
<td>-History of chronic kidney disease 11 (8.3)</td>
</tr>
<tr>
<td></td>
<td>-Family history of coronary heart disease 8 (6.2)</td>
</tr>
<tr>
<td></td>
<td>-RA disease duration, years 10 (7.18)</td>
</tr>
<tr>
<td></td>
<td>-Biologic naive/experienced 92 (69.7)/40 (30.3)</td>
</tr>
<tr>
<td></td>
<td>-Duration under tofacitinib, months 18 (5-33)</td>
</tr>
<tr>
<td>No. of Patients with First Event</td>
<td>Incidence Rate per 100 Patient-Yr (95% CI)</td>
</tr>
<tr>
<td>MACE, n=1</td>
<td>0.49 (0.07-3.44)</td>
</tr>
<tr>
<td>VTE, n=4</td>
<td>1.96 (0.74-17)</td>
</tr>
<tr>
<td>Infection</td>
<td>5.55 (3.12-9.86)</td>
</tr>
<tr>
<td>-Requiring hospitalization, n=11 3.46 (1.67-7.17)</td>
<td></td>
</tr>
</tbody>
</table>

* n (%), if otherwise specified; median (IQR) for numeric values. CI: Confidence Interval, MACE: Major adverse cardiovascular events, VTE: Venous thromboembolism (pulmonary embolism or deep vein thrombosis)

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4309

Background: Tofacitinib is a targeted synthetic DMARD that selectively inhibits Janus kinase (JAK) and is approved for the treatment of RA by the FDA in 2012. In recent years, an important safety concern related to incidence of adverse events after treatment with tofacitinib has emerged.

Objectives: To evaluate the risk of major adverse cardiovascular events (MACE), venous thromboembolism (pulmonary embolism or deep vein thrombosis), serious infections requiring hospitalization, and herpes zoster with tofacitinib in RA patients aged ≥ 60 years.

Methods: HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single center biological and targeted synthetic DMARD registry since 2005. We analyzed RA patients aged ≥ 60 years receiving tofacitinib who had at least 1 control visit registered in the HURBIO database. Phone calls were made with these patients for the current health status information until the end of January 2022. The data of the patients who lost the follow-up in our clinic were obtained from the personal health record system of the Republic of Turkey Ministry of Health by patients' permission. The coprimary end points were adjudicated MACE, VTE, serious infections, and herpes zoster. These events were identified using patients’ medical records. Crude incidence rates were expressed in patients with first events per 100 patient-years, with two-sided 95% confidence intervals.

Results: A total of 132 RA patients (109, 82.6% female) aged ≥ 60 years received tofacitinib at a dose of 5mg twice daily. The median (25–75% percentiles) age was 67 (63-73) years and median duration under tofacitinib was 18 (5-33) months. Approximately 70% of patients were biologically naive. During a median follow-up of 1.5 years, the incidences of serious infection requiring hospitalization and herpes zoster were higher (5.5% [95%CI 3.12-9.86] and 3.4% [1.67-7.17], respectively) while there was no increase in the incidences of MACE and VTE. The causes for hospitalization were as follows: COVID-19 (n=4), pneumonia (n=3), soft-tissue infection (n=3), and GIS infection (n=1). Two of these patients deceased.

Conclusion: Older patients with RA are at increased infection risk because of age and comorbid conditions. Although adverse events are reported with 10mg tofacitinib twice daily, clinicians should be careful against the risk of infection at a dose of 5mg twice daily, especially in elderly patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4254

Background: Methotrexate (MTX) forms the first line therapy for rheumatoid arthritis (RA). The cardioprotective effect of MTX is well established, but whether this is just due to control of inflammation, or is also via an effect on serum lipoproteins, is unclear. Although a few studies have studied the effect of the MTX on the
Objectives: To determine the short-term effect of MTX on apolipoproteins and traditional lipid profile in patients with active RA.

Methods: DMARD-naive patients with active RA (SJC≥2 and TJC≥4) who had been enrolled in the multicentre, RCT comparing two different MTX escalation strategies in RA (MEIRA) and for whom paired serum samples were available before and after MTX treatment were included. All these patients received MTX monotherapy started at 15 mg/week and escalated to 25 mg/week by 4-8 weeks. Serum levels of apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) were measured before starting MTX and after 16 weeks of MTX monotherapy. Proatherosclerotic indices (TC/HDL and ApoB/ApoA1) were also calculated.

Results: A total of 103 patients (mean age 40 (8) years, 93 (90%) females, mean BMI 25.1 (4.8) kg/m², all non-smokers and non-alcoholics) were included. No study participant had comorbid diabetes mellitus or coronary artery disease. None of them were taking glucocorticoids or hypolipidemic drugs. An increase in Apo A1 levels [by a mean of 6.5 mg/dL (p=0.02)] and HDL levels [by a mean of 1.6 mg/dL (p=0.04)] was seen after 16 weeks of MTX monotherapy. Although a numerical increase in levels of TC (mean 4.6 mg/dL, p=0.07), LDL (mean 2 mg/dL, p=0.34) and TG (mean 6.6 mg/dL, p=0.35) was also noted, none of these changes were statistically significant. No obvious change in Apo B levels and TC/HDL ratio occurred due to MTX therapy. However, the ApoB/ApoA1 ratio decreased significantly from 0.8 to 0.7 (p=0.002) with 16 weeks of MTX therapy (Table 1).

Table 1. Baseline and end of treatment values of apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and proatherosclerotic indices (TC/HDL and ApoB/ApoA1).

<table>
<thead>
<tr>
<th>Parameter (mg/dL)</th>
<th>Baseline</th>
<th>After 16 weeks of MTX therapy</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apo A1</td>
<td>126.0 (25.1)</td>
<td>131.6 (23.4)</td>
<td>0.02</td>
</tr>
<tr>
<td>Apo B</td>
<td>92.3 (18.9)</td>
<td>92.0 (20.5)</td>
<td>0.8</td>
</tr>
<tr>
<td>ApoB/ApoA1</td>
<td>0.8 (0.2)</td>
<td>0.7 (0.2)</td>
<td>0.002</td>
</tr>
<tr>
<td>TC</td>
<td>164.5 (32.4)</td>
<td>169.1 (36.8)</td>
<td>0.07</td>
</tr>
<tr>
<td>LDL</td>
<td>40.9 (8.8)</td>
<td>42.5 (9.7)</td>
<td>0.04</td>
</tr>
<tr>
<td>HDL</td>
<td>4.2 (1.1)</td>
<td>4.1 (1.1)</td>
<td>0.34</td>
</tr>
<tr>
<td>LDL/HDL</td>
<td>88.8 (25.2)</td>
<td>90.8 (29.8)</td>
<td>0.34</td>
</tr>
<tr>
<td>TG</td>
<td>139.9 (68.6)</td>
<td>146.4 (91.3)</td>
<td>0.35</td>
</tr>
</tbody>
</table>

All values represented as mean (SD); Apo A1apolipoprotein A1, Apo Bapolipoprotein B, TCtotal cholesterol, LDLlow-density lipoprotein, HDLhigh-density lipoprotein, TGtriglycerides

Conclusion: MTX therapy led to a mild but significant increase in HDL. ApoA1 and a reduction in HDL, ApoB1, and ApoB/ApoA1 over short-term. This could potentially represent one of the mechanisms by which MTX exerts its cardioprotective effect; however, these changes need to be carefully interpreted over longer term and in context of the lipid paradox operating in RA.

References:

Disclosure of Interests: None declared.


AB0419

RHEUMATOID ARTHRITIS SWITCHING PATTERNS AND THE GROWTH OF SMALL MOLECULE TREATMENT IN THE EUS

M. Yarnall1, P. C. Taylor2, P. Pouliot1, E. Hettel1, K. Murray1, 2, Spherix Global Insights, Rheumatology Market Research, Exton, United States of America; 1The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

Background: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe rheumatoid arthritis (RA) across the EUS, though several new biologics, biosimilars, and small molecules have become available for the treatment of RA.

Objectives: This research sought to understand the factors influencing treatment changes when patients are switched from one biologic or small molecule to another, including the reason(s) for their treatment selection.

Methods: An independent market analytics firm collaborated with EUS rheumatologists (n=250 across France, Germany, Italy, Spain, and the UK) to conduct a retrospective chart review of patients diagnosed with RA (n=1,268) who had switched from one biologic therapy or small molecule agent to another in the prior twelve weeks. Data were collected in August and September 2021 and included clinical and non-clinical patient demographics as well as physician demographics and attitudinal survey responses. This study was a non-longitudinal trending analysis to 2020 (n=1,288, 2019 (n=1,294), 2018 (n=1,312) and 2017 (n=1,235)

Results: 70% of surveyed rheumatologists reported recent changes to the management of their RA patients, with the most recalled treatment shift being an increased use of small molecule agents (JAK inhibitors, 30%), attributable to the introduction of upadacitinib and filgotinib in December 2019 and September 2020, respectively. Despite a plethora of RA treatment options in the EUS, annual physician-reported rates of RA patient switching have remained stable since 2017, with 25% of biologic/small molecule-treated patients switching brands within a given year. There has been a steady increase in switches from TNF inhibitors to JAK inhibitors over the last few years (2% in 2017 to 19% in 2021). At the same time, the rates of TNF cycling have been on a downward trend (43% in 2017, 40% in 2018, 39% in 2019, 34% in 2020, and 32% in 2021), indicating that patients are more likely to remain on their current therapy due to secondary efficacy failure, and their primary reason for selecting a JAK was due to the switch pattern.

Disclosure of Interests: None declared.


AB0418

INCREASED THROMBOEMBOLIC RISK OF JAK INHIBITORS AFTER SWITCHING FROM BIOLOGIC DMARDs IN PATIENTS WITH RHEUMATOID ARTHRITIS

Y. Eun1, G. H. Seo2, S. Y. Kang3, S. Lee4, H. Kim4,5, H. S. Cha6, E. M. Koh7, J. Lee8. 1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea, Rep. of (South Korea); 2Health Insurance Review and Assessment Service., Wonju, Korea, Rep. of (South Korea); 3Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea); 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medical Humanities, Seoul, Korea, Rep. of (South Korea)

Background: Safety concerns regarding JAK inhibitors have grown since the ORAL surveillance trial reported that their use was associated with an increase in major adverse cardiovascular events compared to TNF inhibitors. However, real-world data on the association between JAKI and thromboembolic events are sparse.

Objectives: We compared the incidence of thromboembolic events (TEs) before and after switching to Janus kinase inhibitors (JAKI) from biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA).

Methods: Among patients with a diagnostic code for RA taking bDMARDs, patients who switched to JAKI or another bDMARD between March 2015 and December 2020 were included in this self-controlled case series study. The outcomes were the occurrence of TEs. The incidence rate ratios (IRRs) for TEs in the period after switching to JAKI or another bDMARD compared with the period before switching were calculated based on an assumed Poisson distribution.

Results: There were 1,150 and 2,254 patients who switched to JAKI and another bDMARD, respectively. The mean follow-up duration was 4.5 ± 1.8 years. In the JAKI group, the IRR for TE after drug switching was 1.56 (95% confidence interval [CI] 1.22–1.98, P < 0.001) compared with the period before the drug switch; in the bDMARD group, the IRR was 1.16 (95% CI 0.96–1.38, P = 0.079).

Conclusion: Switching from bDMARDs to JAKI was associated with an increase in TE incidence in RA patients in a real-world setting.

Disclosure of Interests: None declared.


Figure 1.
Results: from the TURKBIO Registry. Data on demographics, clinical characteristics, dis-
arthritis (RA) patients receiving tofacitinib and to evaluate tofacitinib survival rate.
monotherapy groups did not differ regarding remission rate assessed by DAS28-
monotherapy and continued to their therapies. The combination and unintentional monotherapy and switched to combination therapy; 26 were initially prescribed combination therapy; 31 were initially prescribed combination therapy but switched to mono-
cluded; 153 were initially prescribed combination therapy and continued to their therapies.

Background: monotherapy and transition from combination therapy to monotherapy. This study was sponsored by Pfizer.

Disclosure of Interests: Nevsun Inanc: None declared, Kerem Abacar: None declared, mehmet akif oztuk: None declared, Abdurrahman Tufan: None declared, Hazan Karadeniz: None declared, Ismail Sari: None declared, gercek can: None declared, Yeşim Erez: None declared, yavuz Pehlivan: None declared, Ediz Dalkılıç: None declared, Ayten Yazici Grant/research support from: Ayten Yazici has received project grant from Roche Pharmaceuticals, Turkey, Abdurrahman Senel: None declared, Servet Akar: None declared, Elif Durak Ediboglu: None declared, Süleyman Serdar Koca: None declared, Rabia Piskin Sagir: None declared, Sema Yilmaz: None declared, Semral Gulcemal: None declared, Özgül Soysal Gündüz: None declared, Canberk Sami Başbıyık: Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey, Serdar Alkan: Employee of: employee and shareholder of Pfizer Inc., Istanbul, Turkey, Teoman Yusuf Cesar: Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey, Fatos Onen: None declared


AB0420 UNINTENTIONAL MONOTHERAPY IN RHEUMATOID ARTHRITIS PATIENTS RECEIVING TOFACITINIB AND DRUG SURVIVAL RATE OF TOFACITINIB


1Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Gazi University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; 3Dokuz Eylül University Hospital, Department of Internal Medicine, Division of Rheumatology, Izmir,Turkey; 4Bursa Uludag University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Bursa, Turkey; 5Kocaeli University School of Medicine, Division of Rheumatology, Kocaeli, Turkey; 6Kayseri University School of Medicine, Division of Rheumatology, Kayseri, Turkey; 7Izmir Katip Celebi University Ataturk Training and Research Hospital, Division of Rheumatology, Department of Internal Medicine, Izmir,Turkey; 8Fatih University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Elazig, Turkey; 9Selcuk University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Konya, Turkey; 10Manisa Celal Bayar University Hafsa Sultan Hospital, Department of Internal Medicine, Division of Rheumatology, Manisa, Turkey; 11Pfizer Pharmaceuticals, Inflammation and Immunology, Istanbul, Turkey

Results: From the TURKBIO Registry. Data on demographics, clinical characteristics, dis-

Objective: To determine the rate of unintentional monotherapy in rheumatoid arthritis (RA) patients receiving tofacitinib and to evaluate tofacitinib survival rate.

Methods: This national, multicentre, retrospective study included patients’ data from the TURKBIO Registry. Data on demographics, clinical characteristics, dis-

Results: Data of 231 RA patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to mono-

Conclusion: Although 13.4% of the study population started monotherapy unintentionally, data survival rates of the unintentional monotherapy and combination therapies were not different. Comorbidity was an important factor affecting transition from combination therapy to monotherapy. This study was sponsored by Pfizer.

Disclosure of Interests: Nevsun Inanc: None declared, Kerem Abacar: None declared, mehmet akif oztuk: None declared, Abdurrahman Tufan: None declared, Hazan Karadeniz: None declared, Ismail Sari: None declared, gercek can: None declared, Yeşim Erez: None declared, yavuz Pehlivan: None declared, Ediz Dalkılıç: None declared, Ayten Yazici Grant/research support from: Ayten Yazici has received project grant from Roche Pharmaceuticals, Turkey, Abdurrahman Senel: None declared, Servet Akar: None declared, Elif Durak Ediboglu: None declared, Süleyman Serdar Koca: None declared, Rabia Piskin Sagir: None declared, Sema Yilmaz: None declared, Semral Gulcemal: None declared, Özgül Soysal Gündüz: None declared, Canberk Sami Başbıyık: Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey, Serdar Alkan: Employee of: employee and shareholder of Pfizer Inc., Istanbul, Turkey, Teoman Yusuf Cesar: Employee of: employee of Pfizer Pharmaceuticals, Istanbul, Turkey, Fatos Onen: None declared


AB0421 ASSESSMENT OF LIVER STIFFNESS IN RHEUMATOID ARTHRITIS PATIENTS UNDER METHOTREXATE

W. Lahmar1, M. Slouma1, G. Mohamed2, R. Dahbi1, L. Metoui1, I. Gharsallah1, N. Abdelil1

1Military Teaching Hospital, Rheumatology, Tunis, Tunisia; 2Military Teaching Hospital, Gastroenterology, Tunis, Tunisia

Background: Methotrexate (MTX) is recommended as a first-line disease-modifying antirheumatic drug for treating rheumatoid arthritis (RA) in monotherapy or combinational therapy. A concern about MTX-related liver fibrosis in patients with rheumatoid arthritis (RA) is still unsolved.

Objectives: The aim of the study cutoff of cumulative dose discriminating patients with normal from those with abnormal liver stiffness.

Methods: We conducted a cross-sectional study including consecutive RA patients diagnosed according 2009 ACR-EULAR criteria. Liver stiffness (LS) was assessed by Fibroscan in the gastroenterology department by an experi-

Results: There were 18 men and 36 women. The mean age was 51.9 ± 11.49

Conclusion: Our study showed that LS correlated to both MTX duration and cumulative dose. Patients with a cumulative dose of MTX higher than 7330 mg required a close follow up of liver elastometry and monitoring of hepatic function.

Disclosure of Interests: None declared

SLE, Sjögren’s and APS – treatment

AB0422 SODIUM BICARBONATE MOUTH RINSE IS A USEFUL SELF-CARE METHOD FOR DRY MOUTH IN PATIENTS WITH SJÖGREN’S SYNDROME

N. Azumā
, K. Matsuł, Hyogo College of Medicine, Division of Diabetes, Endocrinology and Clinical Immunology, Nishinomiya, Japan

Background: Patients with Sjögren’s syndrome (SS) present various symptoms related to dry mouth. While hyposalivation is believed to be the main cause, saliva has various beneficial physiological effects on the intraoral environment, and qualitative changes in its composition should also be considered as a cause of the ororectory and oral manifestations in SS. One of the physiological effects of saliva is buffering, and salivary bicarbonate (HCO3) is the main determinant of salivary buffering capacity. Since salivary concentration of bicarbonate heavily depends on the rate of salivary secretion, salivary buffering capacity and oral pH decrease in patients with dry mouth; this is associated with the development of dental caries and oral candidiasis. It is considered that sodium bicarbonate mouth rinse is effective for suppressing these intraoral disorders. It is also a practical self-care method because it is inexpensive and can be made at home.

Objectives: To investigate the usability and changes in symptoms associated with dry mouth after use of sodium bicarbonate mouth rinse in SS patients.

Methods: The subjects were 27 SS patients (female: male = 24:3, mean age 62.9 years, primary SS: secondary SS = 24:3, mean disease duration 12.3 years) who had used sodium bicarbonate mouth rinse (dissolve about 5 g of commercially available baking soda in 500 cc of water in a plastic bottle. Put this sodium bicarbonate water in the mouth and rinse the mouth for 30 seconds to 1 minute as to reach throughout the oral cavity). We investigated usage status, usability, and changes in subjective symptoms using a questionnaire. During their using the mouth rinse, medication and countermeasures against dry mouth in the daily life continued as usual.

Results: More than half of the patients had no knowledge of sodium bicarbonate mouth rinse (n=15; 55.6%). Highest frequency of use was twice a day (n=9; 33.3%), and common use situations were before bedtime (n=18; 66.7%), after meals (n=17; 63.0%), and at waking up (n=11; 40.7%). Twenty patients (74.1%) had “very good” or “good” sense of use. Eighteen patients (66.7%) had relief of symptoms related to dry mouth. Pros were “feeling refreshed in the mouth” (n=14; 51.9%), followed by “becomes less sticky” (n=8; 29.6%), “easy to make” (n=7; 25.9%), and “inexpensive” (n=6; 22.2%). Some respondents said they had less glossitis, stomatitis, and angular cheilitis (n=4; 14.8%). For cons “troublesome was the highest (n=10; 37.0%), followed by responses regarding “taste” (n=6; 22.2%). There were also many responses to “none in particular” (n=7; 25.9%). No obvious accidents occurred, and 20 (74.1%) of them replied that they would like to continue to use the sodium bicarbonate mouth rinse.

Conclusion: In addition to the inhibition of dental caries and oral candidiasis, removal of tongue plaque and refreshing feeling in the mouth after rinsing due to its mucolytic effect, reduction of halitosis-causing volatile sulfur compounds, and improvement of gingivitis have been reported as effects of sodium bicarbonate. However, reports on the effects of sodium bicarbonate on dry mouth in SS patients are scarce. These results suggest that sodium bicarbonate mouth rinse is considered to be a useful self-care method that can compensate for the salivary buffering capacity that is impaired in SS patients and may reduce dry mouth symptoms. Since it is easy to continue and safe, it is worth actively incorporating it into the standard treatment for SS. Evaluation in more patients with objective indices is desired in the future.

References:


Disclosure of Interests: None declared


AB0423 STRATEGIES FOR GLUCOCORTICOID TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS FLARES: A REAL-LIFE EXPERIENCE

L. Scagnellato
, M. Matti
, C. Tani
, E. Elefante
, F. Trentin
, F. Ferro
, D. Zucchi
, C. Stagnaro
, L. Carli
, M. Mosca
. 1Hyogo College of Medicine, Division of Diabetes, Endocrinology and Clinical Immunology, Nishinomiya, Japan

Background: Glucocorticoids (GC) are a cornerstone for the treatment of Systemic Lupus Erythematosus (SLE) manifestations but there is still open debate concerning their optimal therapeutic employment.

Objectives: To describe and compare the GC therapeutic strategies used in a real-life setting for the initial treatment of SLE flares.

Methods: This study is a retrospective analysis of data from a monocentric cohort of SLE patients who registered a disease flare between 2015 and 2020. Flares were first categorized in “pulse-treated” (PT) and “non pulse-treated” (NPT). PT flares were then divided into “low-dose regimen” (250 mg iv 6MP for 3 consecutive days or less) and “high-dose regimen” (more than 250 mg iv 6MP for 3 days).

Results: 101 flares were analyzed (30 PT and 71 NPT). PT flares were more severe in terms of median SLEDAI (PT 16 (12-22) vs NPT 8 (5-10) p=0.00) and BILAG score index (BILAG A PT 71% vs NPT 30% p=0.001). PT patients received significantly higher GC doses at 1 month (PT median cumulative dose 1372 IQR 1028 – 3076 mg of 6MP vs NPT median 160 IQR 10-286 mg of 6MP, p<0.000), 6 months (PT median cumulative dose 2964 IQR 2294 – 4305 mg of 6MP vs NPT 680 IQR 720 – 1294 mg of 6MP, p=0.000) and 12 months (PT median cumulative dose 3510 IQR 3014-5025 vs NPT median cumulative dose 1571 IQR 1098 – 2122 mg of 6MP, p=0.000). Characteristics of flares that were treated with low-dose (N=19) or high-dose (N=11) pulse regimen are summarized in Table 1. As expected, the “low-dose” subgroup received lower cumulative GC dosage over time. However, no statistically significant differences were found neither in term of disease severity at baseline nor in term of disease activity, remission rates or new flares over time.

Table 1. Comparison between low-dose pulse regimen and high-dose pulse regimen in terms of cumulative GC dose and outcome in the first year after a SLE flare

<table>
<thead>
<tr>
<th>Time (months)</th>
<th>Low-dose regimen</th>
<th>High-dose regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 mos</td>
<td>4 (2 – 9)</td>
<td>9 (4 – 12)</td>
</tr>
<tr>
<td>6 mos</td>
<td>8 (4 – 12)</td>
<td>1 (9%)</td>
</tr>
<tr>
<td>12 mos</td>
<td>2 (10%)</td>
<td>2 (10%)</td>
</tr>
</tbody>
</table>

Conclusion: These data suggest that in a real-life setting, pulse GC therapy is preferred over oral administration for severe SLE flares and entails administration of high cumulative doses of GC. However, the experience outlined suggests that the low-dose pulse regimen is as effective in remission induction of severe flares as the high-dose regimen, allowing significant GC sparing. Since the cumulative GC dose is known a strong predictor of organ damage, strategies aimed to minimize the GC dosage should be encouraged.

Disclosure of Interests: None declared


AB0424 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ALP-303, A POTENT DUAL BAFF/APRIL INHIBITOR, IN ADULT HEALTHY VOLUNTEERS

P. Harrison
, J. Lickliter
, S. R. Dillon
, K. Manjarrez
, A. Smith
, M. Dossey
, L. Blanchfield
, A. Chunyk
, H. Zayed
, S. L. Peng
. 1Hyogo College of Medicine, Division of Diabetes, Endocrinology and Clinical Immunology, Nishinomiya, Japan

Background: Therapeutic agents targeting the B-cell cytokines BAFF and/or APRIL, including the wild-type (WT) TACI-Fc fusion proteins atacicept and telitacicept, have demonstrated promising clinical potential in rheumatoid diseases like systemic lupus erythematosus (SLE) and/or other B-cell-related diseases such as autoantibody-related nephritides. ALP-303 is an Fc fusion protein of a variant, engineered TACI domain which mediates significantly more potent inhibitory activity in vitro as compared to WT TACI-Fc or BAFF- or APRIL-specific monoclonal antibodies, along with enhanced pharmacokinetic (PK) and immunomodulatory properties in preclinical studies.1,2 ALP-303 may therefore significantly improve clinical outcomes in SLE and other B-cell-related diseases.

Objectives: To evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of ALP-303 in adult healthy volunteers (HV).

Methods: This is a first-in-human study (NCT05034484), adult HVs are enrolled to evaluate the safety, tolerability, PK, and pharmacodynamics (PD) of ALP-303 in adult healthy volunteers (HV).

Disclosure of Interests: None declared

WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE


Methods: This was a post hoc analysis of pooled data from the randomized, 52-week double-blind TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials in which patients with moderate to severe SLE despite standard therapy received intravenous anifrolumab (150/300 mg) or placebo every 4 weeks for 48 weeks. Both TULIP-1 and TULIP-2 used the same study design and required a positive response in BICLA and SRI(4) criteria at Week 52 (dual responders) with anifrolumab and placebo, irrespective of treatment assignment.

Results: Among patients who met both BICLA and SRI(4) criteria, anifrolumab had greater anti-inflammatory and disease-modifying effects compared with placebo. At Week 52, dual responders had higher degrees of improvement in disease activity, especially in arthritis, and the healthcare utilization measures have significantly better outcomes across a range of clinical, PRO, and healthcare utilization measures compared with dual nonresponders. The higher degree of improvement in disease activity, especially in arthritis, and the greater reduction in oral GC dose compared with single responders is reflected in improved patient well-being, functional functioning, and fatigue. Being a dual responder offers a profound and clinically meaningful outcome for both the clinician and patient.

Background: The BILAG–based Composite Lupus Activity Index (BICLA) and SLE Responder Index ≥4 (SRI[4]) responses were endpoints in the phase 2b MUSE and phase 3 TULIP-1/2 trials.1-3 In a post hoc analysis, more patients met both the BICLA and SRI(4) response criteria at Week 52 (dual responders) with anifrolumab compared with placebo (MUSE: 48.5% vs 19.9%; TULIP-1: 42.2% vs 27.9%; TULIP-2: 43.4% vs 26.4%; all nominal P<0.001).1-3 Whereas the clinical benefit of BICLA responses alone has been characterized,4 the added benefit of dual BICLA/SRI(4) responses remains unknown.

Objectives: To understand the clinical benefits (SLE clinical assessments, patient-reported outcomes [PROs], and healthcare utilization) of having a dual BICLA/SRI(4) response vs a response for just one endpoint or nonresponse for both, irrespective of treatment assignment.

Methods: This was a post hoc analysis of pooled data from the randomized, 52-week double-blind TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials in which patients with moderate to severe SLE despite standard therapy received intravenous anifrolumab (150/300 mg) or placebo every 4 weeks for 48 weeks.1-3 Patients were categorized as dual responders (met both BICLA and SRI[4] response criteria at Week 52), single responders (met one of either BICLA or SRI[4] response criteria), or dual nonresponders (did not meet either response criteria). SLE clinical assessments, PROs, and healthcare utilization through Week 52 were evaluated for each group. Statistical comparisons were conducted for dual responders vs single responders and dual nonresponders.

Results: Patient demographics and baseline characteristics were generally balanced across dual responders (n=288), single responders (n=122), and dual nonresponders (n=409). At Week 52, dual responders had greater improvements in SLE-related measures compared with dual nonresponders across all evaluated clinical, PRO, and healthcare utilization outcomes (Figure, A–E). Compared with single responders, dual responders had a significantly greater mean change from baseline in SLEDAI-2K score (−8.2 vs −5.1; nominal P<0.001), PGA score (−1.3 vs −0.9; nominal P<0.001), and swollen joint counts (−6.2 vs −4.5; nominal P<0.001) (Panel A); there was also a numerically greater proportion with ≥50% reduction in CLASI-A score (91% vs 76%; nominal P=0.076) (Panel B). Dual responders had a greater mean reduction in baseline oral glucocorticoid (GC) daily dose (−5.6 vs −3.4; nominal P=0.001) vs single responders (Panel A). For PROs, compared with single responders, dual responders had a greater mean change in baseline PtGA score (−17.7 vs −8.6; nominal P<0.001), and a higher proportion had clinically meaningful improvements from baseline to Week 52 in fatigue (FACT-F; 56% vs 43%; nominal P=0.014) and SF-36 physical component scores (60% vs 34%; nominal P=0.001) (Panel C–D). Healthcare utilization (ED visits and hospitalizations) was lower in dual responders vs single responders; however, this comparison did not reach nominal significance (nominal P=0.462 and 0.311, respectively) (Panel E).

Conclusion: Patients with SLE with dual responses in two validated outcome measures have significantly better outcomes across a range of clinical, PRO, and healthcare utilization measures compared with dual nonresponders. The higher degree of improvement in disease activity, especially in arthritis, and the greater reduction in oral GC dose compared with single responders is reflected in improved patient well-being, functional functioning, and fatigue. Being a dual responder offers a profound and clinically meaningful outcome for both the clinician and patient.

Acknowledgements: Writing assistance was provided by Matilda Shackley of JK Associates Inc., part of Fishawack Health. This study was sponsored by AstraZeneca.

AB0426 THERAPY WITHOUT GLUCOCORTICOIDS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

A. Mesnyankina1, E. Aseeva1, N. Nikishina1, A. Lila1, T. Popkova2.

Scientific Institution, Moscow, Russian Federation;

1V. A. Nasonova Research Institute of Rheumatology, Federal State budgetary Scientific Institution, Moscow, Russian Federation;

Background: The effectiveness of glucocorticoid (GC) therapy in SLE is beyond doubt and has been confirmed by the experience gained over many decades of their use. However, with prolonged use of GC, even in low and medium doses, there are many problems. In particular, the development of organ damage associated with GC significantly worsens the prognosis, leads to a decrease in the quality of life, social adaptation. Currently, attempts are being made to use therapeutic programs without the use of GC or with their appointment in minimal doses.

Objectives: Achieving stable remission in patients with SLE. Cancellation of oral GC or the use of therapy without GC in patients with SLE.

Methods: 3 clinical cases. Two patients (N1, N2) had a combination of SLE with Sjogren's syndrome with predominantly musculoskeletal syndrome. In these patients, severe organ lesions (lupus nephritis, vasculitis, central nervous system damage) were excluded. SLEDAI-2K in these patients was 9 and 8 points. Both patients had a decrease in C3, C4 complement component, ANA positivity, arthritis, hematological disorders. In N2, an increase in at ds-DNA was determined. Therapy with oral GC, immunosuppressive drugs was not carried out in them. Patient N3 with lupus nephritis (hematuria, leukocyturia), exudative pleurisy, polyarthritis, high immunological activity (SLEDAI-2K - 16 points) was prescribed GC at a dose of 2 tab per day. Creatinine and urea were within normal limits. The patient had high immunological activity: low C3, C4 complements, low ANA positivity (1:1280). Due to the presence of lupus nephritis, the patient received mycophenolate methylot (1500 mg per day. All patients received double anti-B-cell therapy with the sequential use of Rituximab (RTX) 1000 mg intravenously in patients N1 and N2, and N3 at a dose of 2000 mg per day with premedication of 6-methylprednisolone at a dose of 250-500 mg intravenously. After 1-3 months, belimumab infusions were started at a dose of 10mg/kg per month. The observation period is 1 year.

Results: Anti-B-cell therapy allowed patients to be treated without oral GC. A patient with LN (N3) was prescribed low doses of GC at the time of initiation of therapy with RTX, however, they were subsequently completely canceled by the 6th month of therapy. Clinical remission of the disease was achieved in all three patients. Clinical manifestations of the disease were stopped. SLEDAI-2K was 0-2 points due to minor hypocomplementemia (Figure 1). No new irreversible organ damage and relapse of the disease were registered. Patients continued to receive monthly infusions of BLM, there were no repeated courses of RTM. The patient with kidney damage continued to take MM.

Conclusion: Consistent therapy of RTX and BLM allowed to achieve not only a high clinical and immunological effect, but also the possibility of reducing and even abandoning the oral dose of GC, which is consistent with the concept of “Treat to target” in SLE. In addition, all patients were closely monitored by a rheumatologist monthly once a month, which was partly achieved thanks to monthly infusions of BLM, which were carried out in the clinic.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1117

AB0427 RENAL INVOLVEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: A DIFFICULT-TO-TREAT CLINICAL CASE

R. Santageli1, S. Salvucci1, G. Montozzi1, L. Manfredi2, G. Moroncin1,2. 1Ospedali Riuniti Ancona University Hospital, Internal Medicine Residency Program, Ancona, Italy; 2Ospedali Riuniti Ancona, Internal Medicine, Ancona, Italy

Background: Lupus nephritis (LN) is one of the major organ involvement of Systemic Lupus Erythematosus (SLE), causing significant increase of morbidity, mortality and healthcare impact.1 According to international guidelines, immunosuppressive therapy is indicated for LN class III and IV, while class V usually do not require this treatment, less than there is a proteinuria in the nephrotic range, and so for class II, also with a risk of evolution in a more aggressive form.2 Immunosuppressive drugs commonly used are mycophenolate mofetil/mycophenolate acid (MMF/MPA) and cyclophosphamide for the initial treatment and MMF/MPA or azathioprine for the maintenance of remission. LN treatment is often difficult because of the drug adverse events and the comorbidities that make therapeutic choices very challenging.

Objectives: We describe the case of a young woman with SLE and other major systemic comorbidities who developed severe LN. This case emphasizes the importance of considering patients in their complexity and the delicate role of the physician in tailoring the treatment strategy on the individual patient.

Methods: A 36-year-old woman presented to our Department for lymphadenopathy, headache, epistaxis, fever and weight loss. In her past medical history, she had a cerebral abscess caused by Streptococcus Constellatus with residual left hemiplegia and cervical HPV-related high-grade dysplasia, treated by ring biopsy. Upon admission, blood tests revealed severe neutropenia and lymphocytopenia, thrombocytopenia and low complement; blood cultures were negative. A total body CT scan showed multiple lymphadenopathies. Lymph node and bone marrow biopsies were performed and histological examination was negative for hematological disease. The autoimmune panel was positive for antinuclear, anti-DNA, anti-Sm, anti-U1RNP, anti-cardiolipin and anti-beta2glycoprotein antibodies. According to clinical and laboratory results, a diagnosis of SLE was made.

Results: High-dose corticosteroid therapy was started with good clinical response and improvement of blood tests. Because of the gynecological history, immunosuppressive therapy was not started, and a wait-and-see strategy with steroid tapering and careful follow-up was started. A few months later, the patient developed an increase of serum creatinine with proteinuria at nephrotic range. Thus, a kidney biopsy was performed with evidence of class III LN. Following this result, we started high-dose corticosteroid therapy, with only partial response. After executing colpostopy with biopsy, that was negative for HPV-related lesions, we decided to start MMF, continuing with a careful follow-up. After six months, proteinuria reduced but maintained on levels around 1 gr per day. Bearing in mind the growing number of studies reporting the efficacy of belimumab in LN 3,4, we added this drug to achieve a better disease control, continuing to closely monitor the patients and potential adverse events.

Conclusion: In patients with LN the choice of the immunosuppressive therapy can be very challenging. A tailored approach to the individual patient may be the best option to improve the management of this complex disease.

REFERENCES:


Disclosure of Interests: None declared

Background: Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease of unknown etiology with a broad spectrum of organ manifestations, and patients with SLE have limited treatment options to NSAIDs, glucocorticoids, hydroxychloroquine and immunosuppressants. There is a lack of real-world evidence related to treatment patterns of SLE patients in Taiwan.

Objectives: To describe the real-world patient demographics, clinical characteristics, and treatment patterns of patients with SLE in Taiwan.

Methods: A retrospective observational study using Taiwan's National Health Insurance Research Database (NHIRD) from 1/1/2014 to 12/31/2019 was undertaken. Patients holding catastrophic illness certificates for SLE in 2015-2017 were identified. Enrolled patients aged ≥ 18 years were then divided into three groups (mild, moderate, and severe) based on the highest severity patients experienced in the one year following the enrollment date using a published claims-based algorithm (Garris et al 2013) that incorporates the Systemic Lupus Erythematosus Disease Activity Index, Systemic Lupus Activity Measure, British Isles Lupus Assessment Group Index and expert clinical opinion, and indexed upon the first date of entering the severity group. Baseline patient characteristics and treatment patterns during the follow-up period were measured. The types of treatment considered were NSAIDs, glucocorticoids, hydroxychloroquine and immunosuppressants.

Results: A total of 20,181 patients with catastrophic illness certificates for SLE were included in this study. The mean age of all SLE patients was 46.5 years and patients were mostly female (89.1%). The mean Charlson Comorbidity Index (CCI) score of all SLE patients was 15 (SD 13). Of these patients, 29.3% (n=5,918) had mild SLE activity, 60.7% (n=12,253) moderate and 10.0% (n=2,010) severe. During the one-year follow-up period, moderate to severe patients had numerically higher utilization rate of all types of treatment compared with mild patients (Table 1). Of all oral glucocorticoid users, 27.8% of severe patients used high-dose glucocorticoids (> 15 mg/day) compared to < 0.1% for mild and 9.7% for moderate patients. More than 70.0% of moderate to severe patients were prescribed 2 or more types of treatment at the same point of time. Of these patients having concomitant treatment of glucocorticoids with immunosuppressants, glucocorticoid dosage increased with the number of immunosuppressant used, especially in severe patients. 80.4% of moderate to severe patients received glucocorticoid-based therapy as the first-line treatment and the median treatment duration was 3.1 months. The median treatment duration of each first-line immunosuppressant ranged from 0.9 to 4.8 months in moderate to severe patients.

Table 1. SLE treatment utilization during the 1-year follow-up period

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total (n=20,181)</th>
<th>Mild (n=5,918)</th>
<th>Moderate (n=12,253)</th>
<th>Severe (n=2,010)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>14,019</td>
<td>69.5</td>
<td>2,015</td>
<td>34.1</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>13,278</td>
<td>65.8</td>
<td>2,867</td>
<td>48.5</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>7,630</td>
<td>37.8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Methylprednisolone</td>
<td>898</td>
<td>4.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>5,642</td>
<td>28.0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>1342</td>
<td>65.8</td>
<td>2,867</td>
<td>48.5</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>898</td>
<td>4.5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>14,019</td>
<td>69.5</td>
<td>2,015</td>
<td>34.1</td>
</tr>
</tbody>
</table>

Conclusion: The complexity and intensity of therapeutic approaches in SLE were associated with increased disease severity and patients were often resistant to treatment. These findings reflect the disease burden in SLE patients and suggest there is a substantial unmet need in the SLE treatment paradigm for moderate to severe SLE patients.

REFERENCES:
During the pregnancy courses, no patient developed bacterial infections, two (29%) patients developed viral infections (one with upper respiratory tract infection and the other with acute gastroenteritis), and two (29%) had herpes zoster reaction, which resolved smoothly after five-day course of oral valacyclovir.

Conclusions: The belimumab appeared to be safe in ITP patients with pregnancy, with no obvious increase in the infections and obstetric complications. Based on these observations, belimumab may be considered as one of the pharmacological options for SLE with ITP patients during pregnancy.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1903
Background: Defects in regulatory T cell (Treg) number and function are associated with autoimmune diseases including SLE. Interleukin (IL)-2 is essential for the development and suppressive function of Treg, and therapies that exploit the ability of IL-2 to expand Treg have shown disease-modifying potential in SLE. However, low-dose IL-2 has a short half-life and narrow selectivity for Treg over conventional CD4+T cells (Tcon) and natural killer (NK) cells. Efavaleukin alfa is an IL-2 mutein Fc fusion protein; an introduced mutation decreases binding to IL-2Rβ and increases dependence on IL-2Rα (CD25). This preferential binding to the high-affinity IL-2R, constitutively expressed at high levels on Treg, leads to increased cell surface retention and sustained Treg signaling compared with recombinant IL-2. In healthy subjects, a single dose of efavaleukin alfa was well-tolerated and led to robust and selective Treg expansion.2

Objectives: This final analysis of a phase 1b, double-blind, placebo-controlled, multiple ascending dose study (NCT03451422) reports the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic effects of efavaleukin alfa in patients with SLE.

Methods: The study included five ascending dose cohorts (cohort 1=lowest dose; cohort 5=highest dose). A total of 35 patients with SLE (age 24–71 years; 85.7% female; SLE diagnosed using SLICC or ACR criteria with ANA ≥1:80 and/or elevated anti-dsDNA antibodies) were randomized to receive efavaleukin alfa or placebo (5:2 ratio for cohorts 1–3; 3:1 ratio for cohorts 4–5) subcutaneously every 2 weeks (Q2W; cohorts 1, 2, 4, and 5) or every week (QW; cohort 3) in addition to standard of care therapy for a total of 12 arms, with 6 weeks of follow-up. The primary endpoint was the incidence of treatment-emergent adverse events (TEAEs). Additional endpoints included serum PK of efavaleukin alfa and changes in numbers of Treg, CD4+ Tcon, CD8+ T cells, and NK cells in peripheral blood.

Results: The most commonly reported TEAEs (occurring in ≥25% of efavaleukin alfa-treated subjects) included non-serious, mild or moderate (grade 1–2) injection site reactions. No grade 4 TEAEs or deaths occurred. Two serious AEs were reported in efavaleukin alfa-treated subjects: one event of syncope (grade 3) was observed in cohort 2 and was not considered related to treatment, and one case of eosinophilia (grade 2) was observed in cohort 5 and was considered related to treatment. Efavaleukin alfa PK was generally linear and dose-proportional, with particular focus on: 1) Risk factors for development of ADA. 2) Impact of ADA on treatment response. 3) Influence of ADA on RTX drug kinetics over time. 4) The capacity of ADA to neutralise RTX.

Objectives: In this study we evaluated the longitudinal impact of ADA positivity with particular focus on; 1) Risk factors for development of ADA. 2) Impact of ADA on treatment response. 3) Influence of ADA on RTX drug kinetics over time. 4) The capacity of ADA to neutralise RTX.

Methods: Patients with SLE undergoing treatment with RTX were recruited to this study (n=35). Serum samples were collected at the following intervals pre-treatment; 1-3 months (defined as ‘early’ pre-treatment), 6 months, 12 months, 36 months (n=114). Clinical and laboratory data was collected pre-treatment and at each follow-up time point. Response to treatment was assessed by improvement in SLEDAI-2K score from baseline and also according to BILAG as previously described (3). ADA were detected using an electrochemiluminescent immunoassay. Serum RTX levels were measured by ELISA. ADA status was defined according to the following patterns over time; persistently negative, persistently positive (0-15 AU/ml) and persistently high positive (≥16 AU/ml, upper quartile). A complement dependent cytotoxic assay was used to determine neutralising capability of ADA in a subgroup of positive samples (n=38).

Acknowledgements: Funding: Amgen Inc

Figure 1.
Results: ADA to RTX were found to be persistently positive in 64.3% of patients over the 36-month follow-up period and there was no significant difference in baseline disease activity (BILAG / SLEDAI-2K) between those who were subsequently ADA positive vs negative. ADA positive patients had a younger age at diagnosis of SLE when compared with ADA negative (mean 22.50 ± 9.10 vs 37.29 ± 11.31 years, p=0.002, Figure 1 A). Multivariate logistic regression found a 22% decrease in risk of ADA positivity for each addition year after diagnosis (p=0.03).

ADA positive patients had a significantly lower C3 level at baseline (mean 0.61 ± 0.23 g/L vs 0.87 ± 0.30 g/L, p=0.026), which remained lower at each subsequent time point post-treatment up to 12 months post-treatment (Figure 1B).

At 1-3 months post-RTX, patients who were ADA positive had a significantly lower circulating drug level than ADA negative (p<0.001, Figure 1 C). In terms of clinical response, ADA positive patients had an initial significant improvement in disease activity (SLEDAI-2K) by 3 months (p<0.001). However, response was not maintained at 12 months (Figure 1 D). In comparison, ADA negative patients showed a significant improvement in SLEDAI-2K at 6 months and this was maintained across the 36-month follow-up period (Figure 1 E).

BILAG defined relapse was more common at six months post-treatment in ADA positive patients (22%) and ADA highly positive patients (33%) than those who were ADA negative (in which there were no cases of relapse within the first six months, Figure 1 F).

At 12-months post-RTX, a higher rate of BILAG defined Major Response was seen in those who were ADA negative (80%) when compared with ADA positive (44%) and high positive (36%) as shown in Figure 1 G. Finally, antibodies derived from all ADA positive samples (38/38) were found to neutralise RTX in vitro.

Conclusion: ADA to RTX were common and persisted over the 36-month period of this study. ADA associated with earlier serum drug elimination, increased relapse rates and demonstrated neutralising capacity suggesting that ADA could be a significant limitation to sustained response to treatment in clinical practice.

REFERENCES:

Disclosure of Interests: None declared

AB0434 EFFICACY AND SAFETY OF OBINUTUZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITH SECONDARY NON-RESPONSE TO RITUXIMAB.

J. Arnold1,2, S. Dass 1, S. Twigg1, C. Jones1, B. Rhodes1, P. Hewins1, M. Chakravorty7, P. Courtney7, M. Ehrenstein8, M. Y. Md Yusof1,2, E. Vital1,2, 8
1University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; 2Leeds Teaching Hospitals NHS Trust, NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom; 3Bradford Teaching Hospitals NHS Foundation Trust, Rheumatology, Bradford, United Kingdom; 4York Teaching Hospitals NHS Foundation Trust, Nephrology,York, United Kingdom; 5University Hospitals Birmingham NHS Foundation Trust, Rheumatology, Birmingham, United Kingdom; 6University Hospitals Birmingham NHS Foundation Trust, Nephrology, Birmingham, United Kingdom; 7Nottingham University Hospitals NHS Trust., Rheumatology, Nottingham, United Kingdom; 8University College London, Rheumatology, London, United Kingdom

Background: Secondary inefficacy characterized by infusion reactions and anti-drug antibodies occur in 14% of SLE patients treated with repeat rituximab courses(1). Obinutuzumab is a next-generation humanized type-2 anti-CD20 therapy licensed for hematological malignancies which may overcome this issue(2).

Objectives: We set out to evaluate the clinical efficacy and safety of obinutuzumab in a cohort of rituximab resistant SLE patients.

Methods: We collated data from SLE patients receiving obinutuzumab for secondary non-response to rituximab in BILAG centres. Disease activity was assessed using BILAG-2004, SLEDAI-2K and serology before, and 6 months after, obinutuzumab 2x1000mg infusions alongside methylprednisolone 100mg. Flow cytometry where possible was carried out using a multiple gating highly sensitive strategy.

Results: All 9 patients included in the study received obinutuzumab alongside concomitant oral immunosuppression. At 6 months post-obinutuzumab, there were significant reductions in median SLEDAI-2K from 12 to 6 (p=0.014) and total BILAG-2004 score from 21 to 2 (p=0.009). Complement C3 and dsDNA titres improved significantly (both p=0.04). Non statistically significant numerical improvements were seen in C4 levels.

Of 8/9 patients receiving concomitant oral prednisolone at baseline (all >10mg/ day), 5/9 had their dose reduced at 6 months; 4/8 were on 5mg/day and were in Lupus Low Disease Activity State. After obinutuzumab, 6/9 patients with peripheral B-cell data achieved complete depletion including 4/4 assessed with highly sensitive assays. 1/9 obinutuzumab non-responder required cyclophosphamide therapy, 1 unvaccinated patient died from COVID-19.

Conclusion: Obinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. Obinutuzumab was shown to be effective in patients with severe renal and non-renal disease. Therefore, in those with previous responsiveness to B-cell depletion, switching to humanised type-2 anti-CD20 therapy is a logical approach following loss off efficacy.

REFERENCES:

Disclosure of Interests: Jack Arnold: None declared, Shouvik Dass Consultant of: Roche, Abbvie, UCB & Chugai, Employee of: Honoraria from Roche, Abbvie, UCB & Chugai, Sarah Twigg: None declared, Colin Jones: None declared, Benjamin Rhodes: None declared, Peter Hewins: None declared, Mithun Chakravorty: None declared, Philip Courtney: None declared, Michael Ehrenstein Grant/ research support from: GSK, Employee of: Has received honoraria from GSK, Md Yuzaufil Md Yusof: None declared, Edward Vital Employee of: Has received honoraria from Roche

AB0435 LUPUS NEPHRITIS RESPONSE IN TERMS OF KIDNEY FUNCTION, URINE SEDIMENT AND SEROLOGICAL ACTIVITY AFTER SUBCUTANEOUS BELIMUMAB TREATMENT.

M. De la Riba Navarro1, J. Ivorra Cortés1, E. Grau García1, L. Gonzalez Puig1, R. Negueruela Albuixech1, I. Martínez Cordelat1, F. Ortiz-Sanjuán1, J. E. Oller Rodríguez1, S. Leal Rodríguez1, C. Pávez Perales1, J. J. Frago Gil1, E. Vicens Bernabéu1, C. Riesco Barcena1, A. V. Huaylla Quispe1, L. Mas Sanchez1, P. Muñoz1, C. Nájera Herranz1, I. Cánovas Olmos1, J. A. Román Ivorra1, 1Hospital Universitario La Fe, Reumatología, Valencia, Spain

Background: Systemic lupus erythematosus (SLE) is a heterogeneous auto-immune disease. Kidney affection appears in 40-50% of SLE patients and may condition the prognosis. Belimumab is a monoclonal antibody approved for SLE
since 2011, but it had no lupus nephritis (NL) indication. Recently, promising results from a controlled Belimumab trial in LN were published.

Objectives: To analyze the effectiveness of Belimumab in LN patients under follow-up by the rheumatology department of a tertiary hospital.

Methods: Observational, retrospective and cross-sectional study including SLE patients (SLICC/ACR 2012 criteria) treated with subcutaneous and/or intravenous Belimumab. Demographic and serological data, concomitant treatment, kidney function and urine sediment were collected.

Results: Sixteen patients with a median age of 47.56 (11.66) years and with 5.40 (0.55) years since Belimumab onset were included. Five patients had LN demonstrated by kidney biopsy and they were included on analysis data. In this group, median age was 39 (6.96) years, patients had 17.80 (10.38) years since Belimumab onset. The most prevalent nephritis type was III and IV, only one patient presented V type.

Regarding the treatment, every patient received antimalarial drugs (chloroquine 40%, hydroxychloroquine 60%) and mycophenolic acid. Concerning the corticosteroid therapy, all patients receive prednisone, with an average dose of 4 mg per day.

The results obtained were included in the Table 1.

Conclusion: Belimumab can improve LN, in terms of serological activity, kidney function and urine sediment. It could be a promising option associated to standand therapy for SLE patients with kidney affection.

Disclosure of Interests: None declared


AB0436

L. Piccariello1, F. Ceccarelli1, F. Natalucci1, G. Oliveri1, C. Pirone1, V. Oreto1, C. Garuti1, F. R. Spinelli1, R. Priori1, C. Alessandri1, F. Conti1, Sapienza University of Rome, Rheumatology, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Rome, Italy

Background: Efficacy and safety of belimumab (BLM) in Systemic Lupus Erythematosus (SLE) patients with active disease have been demonstrated by RCTs [1,2] and confirmed by several observational studies [3-8]. Most of these data have been obtained by the use of BLM intravenous formulation (IV); on the contrary, very few findings are available on the use of the drug subcutaneous formulation (SC).

Objectives: Efficacy and drug survival of BLM have been assessed in a monocentric cohort of SLE patients, exploring any difference between the two routes of administration, IV or SC.

Methods: A longitudinal study on SLE patients (according to ACR 1997 classification criteria [9]) candidates for treatment with BLM has been performed. Demographic, clinical-laboratory and therapeutic data - including glucocorticoid dosage in prednisone-equivalent - have been collected. Disease activity has been assessed by SLEDAI-2k [10] in patients with inflammatory articular involvement, DAS28-PCR [11] has been used. In compliance with the study protocol, patients were assessed at baseline and at 3 and 12 months after starting treatment.

Results: A total of 85 patients treated with BLM were enrolled, most of whom were female (male/female 2/83), with a median age of 48 years (IQR 13) and a median disease duration of 127 months (IQR 151). Fifty-one patients (60%) were treated with IV formulation and the remaining 34 (40%) with SC route. BLM was prescribed due to the following clinical manifestations: joint involvement (61.2%), cutaneous manifestations (20.0%), renal involvement (for residual proteinuria, 5.9%), haematological modifications (5.9%), constitutional involvement (3.5%), pericarditis (1.2%), headache (1.2%). In both the formulations, joint involvement was the most frequent indication of BLM (IV: 64.7%, SC: 58.8%). Median treatment duration was 15 months (IQR 24). Moving on drug efficacy, after 3 and 12 months of follow-up BLM has determined a significant reduction of SLEDAI-2k median values (p<0.001, p<0.001 respectively, Figure 1A) as well as of daily prednisone dose (p=0.009, p=0.001 respectively, Figure 1B). In patients treated because of musculoskeletal manifestations, DAS28-PCR reduced significantly at 3 and 12 months after treatment (p<0.0001). Drug survival at 12 months was 70% in the total cohort (Figure 1C) and was higher in patients treated with SC formulation than with IV route (75.8% versus 66.5%, p=ns). During the period of follow-up, 39 patients (45.9%) discontinued BLM: 38.4% of patients due to adverse events, 41% for primary or secondary inefficacy. 15% lost to follow-up, 5.1% for pregnancy. BLM withdrawal for adverse events was more frequent in the group of patients treated with IV formulation than SC one (25.9% versus 5.9%, p=0.0001). 11 patients switched from IV formulation to SC one after a median period of 40 months (IQR 20) without loss of efficacy or adverse events.

Conclusion: Our results confirm BLM efficacy also in a real-life setting. Notably, our data highlight a better drug survival in patients treated with SC formulation, mainly secondary to a less frequency of adverse events.

REFERENCES:

Disclosure of Interests: None declared


AB0437

MONTIELUKAST AS A TREATMENT FOR REFRACTORY CUTANEOUS LUPUS ERYTHEMATOSUS: A CASE SERIES AND PROOF-OF-CONCEPT STUDY

F. A. Castro Rocha1, I. Nogueira1, R. Nunes1, G. da Silva1, C. Martins2.
1Faculdade de Medicina, Internal Medicine, Fortaleza, Brazil; 2Faculdade de Medicina, Morphology, Fortaleza, Brazil

Background: Treatment of cutaneous lupus relies mostly in avoidance of exposure to sunlight, steroids and hydroxychloroquine. A diverse array of cytokines and chemokines released by resident and migrating inflammatory cells have been implicated in the pathogenesis of skin damage in patients with systemic lupus erythematosus (SLE). Leukotrienes are potent lipid mediators involved in hyperresponsiveness reactions but very few data exist on their involvement in SLE.

Objectives: Our aim is to report a case series of SLE patients with refractory skin lesions that were successfully treated with sodium montelukast (MLK), a cysteinyl-leukotriene antagonist.

Methods: We present 4 consecutive female SLE patients with refractory skin lesions that were treated with MLK (10mg/d). Skin lesions were scored using...
Methods: In patients with SLE and its effect on cytokines. The response was sustained for at least 3 months follow-up and no adverse events were recorded. All but one of the patients relapsed following MLK withdrawal but response was recovered after restart of MLK. Expression of the ALOX5, but not of 15LOX1R, was significantly (p<0.001) increased in PBMC from SLE patients as compared to controls.

Conclusion: This is the first report of a fast and sustained successful response of cutaneous SLE to MLK. There were no safety issues. PBMC from SLE patients showed increased expression of the ALOX5gene. This case series suggests the involvement of MLK in cutaneous lupus and encourage designing a randomized trial.

Results: Twelve weeks after the start of BEL treatment, two patients had improved SLE-DAl, including one patient who achieved LLDAS. Immunological activity parameters improved in one of the two patients. However, two patients flared after BEL administration and were treated with increased glucocorticoid doses. One patient with SLE on hemodialysis had thrombocytopenia, an adverse event that may have been related to belimumab treatment.

Conclusion: At our institution, BEL was additionally administered to SLE patients with refractory disease and was effective; with the exception of one case. Serum cytokine analysis before and after BEL treatment will be included in the discussion.

REFERENCES:

Disclosure of Interests: None declared


AB0439

Efficacy of Belimumab Treatment for Systemic Lupus Erythematosus at Our Hospital

M. Mizusaki1, R. Wakiya1, S. Nakashima1, H. Shimada1, K. Sugihara1, M. Kato1, T. Miyagi1, Y. Ushio1, R. Mino1, K. Chuo1, T. Kameda1, H. Dobashi1, 1Kagawa University, Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa, Japan

Background: Belimumab (BEL), a monoclonal antibody against the soluble counterpart of B-cell activating factor (BAFF) has been recommended to be added in patients with SLE who do not respond adequately to standard therapy [1]. In addition to antibody production, belimumab may also affect other functions of B cells, such as antigen presentation and excretion of inflammatory cytokines. Belimumab may also have an effect on immune cells other than B cells, as they express BAFF receptors. These facts suggest that BEL administration in SLE may have an effect on various pathological conditions including cytokine production, not just antibody production. However, there are few reports on whether cytokine production is actually related to the efficacy of BEL administration in SLE.

Objectives: The purpose of this study was to determine the efficacy of BEL administration in patients with SLE and its effect on cytokines.

Methods: Patients with SLE who were started on BEL between December 2018 and December 2021 at our institution were included in this study. We retrospectively analyzed the reasons for additional BEL administration, adverse events, disease activity indicators (SLE Disease Activity Index (SLEDAI)-2K, lupus low disease activity state (LLDAS) achievement rate, anti-dsDNA antibody titer, serum complement titer, and treatment agents including glucocorticoid dose. Serum cytokine (interferon-alpha, interleukin (IL)-6, IL-10, and IL-17A) levels were measured using ELISA at the start of BEL administration, 3 months, and 6 months later.

Results: Five cases of SLE were included in the study. Four of the five patients were female, with a mean age of 51.4±9.6 years and a mean duration of disease of 17.4±10.0 years. The reasons for additional BEL administration were glucocorticoid reduction in five patients, refractory pericarditis in one patient, skin rash and arthritis in two patients, and immunological activity in two patients. Four of the five patients had decreased renal function below eGFR50 at the baseline. Concomitant medications at the time of BEL induction included steroids in five patients (mean prednisolone dose 12.2±12.2 mg/day), hydroxychloroquine in three patients, mycophenolate mofetil in three patients, tacrolimus in one patient, and methotrexate in one patient. The mean disease activity before the introduction of BEL was SLEDAI 4±4, and LLDAS was achieved in three patients.
Table 1. Baseline patients characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Rapid GC tapering group</th>
<th>Conventional GC tapering group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age – years</td>
<td>41.7 ± 14.7</td>
<td>43.9 ± 16.2</td>
<td>0.863</td>
</tr>
<tr>
<td>Female – no. (%)</td>
<td>9 (81.8)</td>
<td>10 (62.5)</td>
<td>0.405</td>
</tr>
<tr>
<td>Class III LN – no. (%)</td>
<td>6 (54.5)</td>
<td>7 (43.8)</td>
<td>0.704</td>
</tr>
<tr>
<td>Class IV LN – no. (%)</td>
<td>6 (45.5)</td>
<td>9 (56.3)</td>
<td>0.704</td>
</tr>
<tr>
<td>Comorbid Class V LN – no. (%)</td>
<td>4 (36.4)</td>
<td>3 (18.8)</td>
<td>0.391</td>
</tr>
<tr>
<td>Induction therapy (use of CY or MMF) – no. (%)</td>
<td>10 (90.9)</td>
<td>8 (50.0)</td>
<td>0.042</td>
</tr>
</tbody>
</table>

GC, glucocorticoid; LN, lupus nephritis; UPCR, urine protein-to-creatinine ratio; CY, cyclophosphamide; MMF, mycophenolate mofetil

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3863

AB0440

USE OF BELIMUMAB IN CLINICAL PRACTICE, CLINICAL AND SEROLOGICAL EFFECTIVENESS AND CORTICOSTEROID-SPARING ACTIVITY

S. Vela-Bernal1, E. Fuertes1, P. Albior1, I. de la Morena2, C. Beas2, A. I. de Gracia3, A. de Castro4, L. Navarro5, M. J. Forner6, Hospital Clínico Universitario de Valencia, Internal Medicine, Valencia, Spain; 2Hospital Clínico Universitario de Valencia, Rheumatology, Valencia, Spain

Background: Since 2011, the use of Belimumab for the treatment of Systemic Lupus Erythematosus (SLE) has demonstrated efficacy and safety in several randomised clinical trials. However, strict inclusion criteria may restrict those results limiting the interpretation of these results to routine clinical practice populations.

Objectives: The aim of this study was to analyse the profile of patients using Belimumab as well as the clinical, serological and corticosteroid-sparing outcomes that may result from it.

Methods: Retrospective cohort study including patients diagnosed with SLE and treated with Belimumab. Epidemiological, clinical and analytical data were collected at 6, 12 and 24 months before and after starting treatment with Belimumab. To assess effectiveness, the SELENA-SLEDAI, SLICC, clinical changes, concomitant treatments, corticosteroid dose and ds-DNA and C3-C4 levels were used. Safety was evaluated by assessing the need and cause for discontinuation of Belimumab.

Results: Thirty-one patients were included, mostly 28 (90.32%) women, with a mean age of 49.55 ± 19.5 years and a mean time of disease progression since diagnosis of 16.13 ± 1.77 years. The most prevalent affection before initiation of Belimumab were joint (83.87%), systemic (58.06%), skin (29.03%) and nephropathy (22.58%). The mean SELENA-SLEDAI score before Belimumab was 5.32 ± 0.46; 64.5% had elevated anti-dsDNA, 48.39% and 54.84% had low C3 and C4 levels, respectively. Before starting Belimumab, the most used treatments were both antimalarials (72.4%) and corticosteroids (80.6%). The main reason for starting Belimumab was the ineffectiveness of previous treatments (67.7%). The vast majority of patients were treated subcutaneously (90.3%) and there were no major adverse events leading to drug withdrawal, with a median duration of use of 19.3 months (IQR: 9.75-35.55).

Conclusion: After starting Belimumab, a decrease in the SELENA-SLEDAI activity scale, an increase in C3 and C4 levels, and a significant decrease in anti-dsDNA levels at 6 months were observed. At 12 and 24 months, continuity of this trend was observed, although statistical significance was not reached. As concerns corticosteroids, we observed a decrease in steroid use below 7.5mg/ day and even 5mg/day after the introduction of Belimumab avoiding the undesirable effects of prolonged steroid use.

Table 1. BEFORE BELIMUMAB  6 MONTHS  12 MONTHS  24 MONTHS

<table>
<thead>
<tr>
<th></th>
<th>(n=31)</th>
<th>(n=28)</th>
<th>(n=22)</th>
<th>(n=9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESR/LEDAI x (SD)</td>
<td>5.32 (0.46)</td>
<td>2.28 (0.44)</td>
<td>2.90 (0.72)</td>
<td>3.44 (1.39)</td>
</tr>
<tr>
<td>P&gt;0.005</td>
<td>0.0005</td>
<td>0.0005</td>
<td>0.005</td>
<td>0.093</td>
</tr>
<tr>
<td>High dsDNA – n (%)</td>
<td>18 (58.06)</td>
<td>14 (61.29)</td>
<td>14 (63.64)</td>
<td>14 (60.0)</td>
</tr>
<tr>
<td>P&gt;0.005</td>
<td>0.0007</td>
<td>0.0006</td>
<td>0.006</td>
<td>0.7</td>
</tr>
<tr>
<td>Low C3 &lt;90mg/dl – n (%)</td>
<td>15 (48.39)</td>
<td>11 (35.78)</td>
<td>9 (29.03)</td>
<td>3 (9.09)</td>
</tr>
<tr>
<td>P&gt;0.005</td>
<td>0.0193</td>
<td>0.0062</td>
<td>0.064</td>
<td>0.064</td>
</tr>
<tr>
<td>Low C4 &lt;16mg/dl – n (%)</td>
<td>17 (54.84)</td>
<td>14 (45.16)</td>
<td>11 (35.48)</td>
<td>5 (16.13)</td>
</tr>
<tr>
<td>P&gt;0.005</td>
<td>0.0007</td>
<td>0.0003</td>
<td>0.217</td>
<td>0.0017</td>
</tr>
</tbody>
</table>

Background: Over 80% of patients affected with SLE experience skin involvement. The anti-BLyS drug belimumab was shown effective in ameliorating mucocutaneous SLE manifestations in clinical trials and real-life studies. Cutaneous response is quantified through the CLASI (cutaneous lupus erythematosus area and severity index). Clinically relevant improvements are defined as decreases of ≥50% (CLASI50) or 70% (CLASI70) from baseline values.

Methods: Baseline and ongoing features of patients with baseline active skin involvement (CLASI>0) were assessed in relationship to the chosen outcomes CLASI50 and CLASI70 at 24 and 52 weeks. A subanalysis on patients with CLASI≥5 was as well conducted. Logistic regression was employed to identify predictors of response.

Results: 172 patients displayed skin involvement at baseline (CLASI>0). Of those, 124 displayed at least a 12-month-follow-up and were included in the analysis. Seventy-seven (62.1%) patients reached CLASI50 at 24 weeks and 91 (77.8%) at 52 weeks; 87 (70.2%) reached CLASI70 at 24 and 99 (79.8%) at 52 weeks. Baseline predictors of CLASI50 at 24 weeks were CLASI-damaging (CLASI-d) (OR [95% CI], p: 0.79 [0.65-0.98] 0.03) and disease duration (0.93 [0.86-0.99], 0.011). No baseline predictors of CLASI70 at 24 weeks emerged, however having achieved a CLASI50 response at 24 weeks prolonged CLASI50 and 70 response through week 52 (p<0.01, Table 1). In the subgroup of patients with CLASI2≥5, longer disease and increased CLASI-d at baseline confirmed as negative predictors of CLASI50 at 24 weeks. In this subset, use of antimalarials and active smoking at baseline predicted CLASI70 at 24 weeks (Table 1).

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3863
Table 1. Predictors of CLASI-A Response at Week 24 and 52 by Baseline CLASI-A at 50% and 70% Response Thresholds

<table>
<thead>
<tr>
<th>Timepoint</th>
<th>Outcome</th>
<th>Variable</th>
<th>OR(95%CI) p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASI = 0</td>
<td>24 weeks</td>
<td>CLASI-d</td>
<td>0.79 [0.65-0.98], 0.030</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disease duration</td>
<td>0.93 [0.86-0.99], 0.011</td>
</tr>
<tr>
<td></td>
<td>52 weeks</td>
<td>CLASI-d</td>
<td>0.89 [0.82-0.97], 0.018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antimalarials</td>
<td>0.93 [0.82-0.97], 0.018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smoking</td>
<td>1.02 [0.94-1.11], 0.037</td>
</tr>
<tr>
<td></td>
<td>52 weeks</td>
<td>CLASI-d</td>
<td>0.90 [0.82-0.97], 0.018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Antimalarials</td>
<td>1.02 [0.94-1.11], 0.037</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smoking</td>
<td>1.02 [0.94-1.11], 0.037</td>
</tr>
<tr>
<td>CLASI ≥ 5</td>
<td>24 weeks</td>
<td>CLASI-d</td>
<td>0.72 [0.57-0.94], 0.037</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Disease duration</td>
<td>0.83 [0.69-1.00], 0.037</td>
</tr>
<tr>
<td></td>
<td>52 weeks</td>
<td>CLASI-d</td>
<td>0.83 [0.69-1.00], 0.037</td>
</tr>
</tbody>
</table>

CLASI, cutaneous lupus erythematosus area and severity index; CLASI-d, CLASI damage; CLASI50 and CLASI70: decrease ≥50% or ≥70% in CLASI from baseline. OR and 95% CIs are estimated using a logistic regression model with stratification factors as covariates (SLEDAI-2K at baseline, baseline prednisone dosage).

Conclusion: Earlier use of belimumab favors achievement of skin response among SLE patients and attainment of a prompt response predicts further response. Use of antimalarials reinforces while smoking hampers a more profound CLASI improvement over time.

REFERENCES:

Table 1. Characteristics of patients with SLE enrolled in this study.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N = 27</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, no. (%)</td>
<td>24 (88.9)</td>
</tr>
<tr>
<td>Age, years, mean ± SD</td>
<td>44.4 ± 11.6</td>
</tr>
<tr>
<td>Disease duration, years, mean ± SD</td>
<td>18.3 ± 12.2</td>
</tr>
<tr>
<td>BMI, mean ± SD</td>
<td>21.9 ± 3.0</td>
</tr>
<tr>
<td>Concomitant immunosuppressive treatments</td>
<td>n = 23</td>
</tr>
<tr>
<td>Prednisone, no. (%)</td>
<td>22 (81.5)</td>
</tr>
<tr>
<td>Median dosage, mg/day</td>
<td>5 (3.0-6.0)</td>
</tr>
<tr>
<td>Triglyceride, mg/dL²</td>
<td>102 (73-149)</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol, mg/dL²</td>
<td>59 (43-66.5)</td>
</tr>
<tr>
<td>Low-density lipoprotein cholesterol, mg/dL²</td>
<td>108 (96-122)</td>
</tr>
<tr>
<td>Arteriosclerotic index</td>
<td>2 (1.7-2.5)</td>
</tr>
<tr>
<td>Disease activity</td>
<td>SLEDAI score</td>
</tr>
<tr>
<td></td>
<td>SLE-DAS score</td>
</tr>
<tr>
<td></td>
<td>Anti-dsDNA antibody, IU/mL</td>
</tr>
<tr>
<td></td>
<td>dsDNA positive, no. (%)</td>
</tr>
<tr>
<td></td>
<td>C3, mg/dL²</td>
</tr>
<tr>
<td></td>
<td>C4, mg/dL²</td>
</tr>
<tr>
<td></td>
<td>CH50, U/mL</td>
</tr>
</tbody>
</table>

*Nonparametric distributions were represented as median (interquartile range). Anti-dsDNA positive means that anti-dsDNA titer increases to >12 IU/mL.

Figure 1. Serum cytokine levels before and after hydroxychloroquine treatment

Serum levels of the indicated cytokines and factors were measured at baseline and after 3 months (3M) of treatment with HCQ. The gray lines show the values for individual patients, and the thick red line shows the average value. P-values were determined using the Wilcoxon signed-rank test. A p-value of less than 0.05 was considered statistically significant.

Conclusion: The addition of HCQ medication to SLE patients who achieve the clinical therapeutic goal of LLDAS without HCQ may prevent progression of atherosclerosis in addition to further reducing disease activity.

REFERENCES:
Background: Recent studies showed the efficacy of multitarget therapy with mycophenolate mofetil (MMF) and calcineurin inhibitor for induction therapy for lupus nephritis (LN). However, long-term outcomes have not been well elucidated.

Objectives: We retrospectively analyzed the long-term outcomes of multitarget therapy of MMF and tacrolimus.

Methods: We examined 27 LN patients (4 male, 23 female) treated with multitarget therapy for induction therapy between Oct. 2009 and Nov. 2018 in our department. Complete remission (CR) was defined as 1) UPCR<0.5 g/gCr, and 2) serum creatinine (S-Cr) normal or if abnormal, within 15% of baseline; 1) and 2) were observed in 2 consecutive visits. Relapse was defined as UPCR>1.0 g/gCr or intensification of immunosuppressive treatment after achievement of CR.

Results: The mean age was 38.6±11.6 years old. 17 patients were new-onset LN, and 10 patients were relapse LN. UPCR and eGFR before treatment were 4.42±2.98 g/gCr and 71.5±32.9 mL/min/1.73m², respectively. Renal histology was Class III in 1, II+IV in 4, IV in 12, IV+V in 9 and V in 1 by ISN/RPS 2008 classification. CR at 6 and 12 months were 59% and 74%, respectively. Patients were treated by multitarget therapy for median of 25 months (IQR, 5.5-37). Finally, 26 (96%) patients achieved CR. During multitarget therapy, there were 15 serious adverse events: deep vein thrombosis in 2, myocardial infarctions in 2, cerebral infarction in 2, renal failure in 1, herpes zoster in 1, viral myocardi tis in 1, cytomegalovirus gastroenteritis in 1, cholecystitis in 1, peyroniephritis in 1, bacterial enteritis in 1, sepsis in 1, and breast cancer in 1. During the median observation period of 94 months (IQR, 63-111.5) after the initiation of multitarget treatment, 1 patient died due to sudden death. No patient reached end-stage renal function in long-term period. However, relapse was often observed during or after withdrawal of multitarget therapy.

Conclusion: Multitarget therapy effectively induced CR and maintained renal function in long-term period. However, relapse was often observed during or after withdrawal of multitarget therapy.

REFERENCES:

Disclosure of Interests: None declared, Keiju Hiromura: Speakers bureau: Chugai, Astellas., Grant/research support from: Chugai, Astellas.
AB0445

THE BENEFICIAL EFFECTS OF THERAPY ON OBSTETRICAL OUTCOME AND PLACENTAL HISTOLOGY IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME: THE EXPERIENCE OF A SINGLE ITALIAN REFERENCE CENTER

V. Canti1,2, G. Inguscio1, N. P. Tenase3, R. Luciano3, R. De Lorenzo2, M. B. Cliona1, M. Pozzoni1, P. I. Cavero-Teijeiro2, M. T. Castiglioni1, P. Rovere-Querini1* on behalf of Pregnancy at risk multidisciplinary outpatient clinics. 1Università Vita-Salute San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy; 2IUCCHS Ospedale San Raffaele, Internal Medicine, Milan, Italy; 3IUCCHS Ospedale San Raffaele, Obstetrics and Gynecology, Milan, Italy

Background: Abnormal placentation plays a crucial role in the pathogenesis of obstetric morbidity in antiphospholipid antibodies syndrome (APS). Placenta is the main target of aPL in obstetric APS, inducing placental thrombosis, inflammatory response and placental dysfunction. Standard treatment for APS patients during pregnancy includes low-dose aspirin (LDA) plus low molecular weight heparin (LMWH) and, in refractory cases, additional therapies such as hydroxychloroquine (HCQ).

A systematic review of the literature has found five main pathological lesions in the placenta of APS patients: placental infarction, decidual vasculopathy, decidual inflammation, increase of syncytial knots due to syncytiotrophoblast death, and decrease in vasculosyncytial membranes.

Objectives: To analyze placental histology in a group of 23 spontaneously conceived pregnancies in patients with definite APS prospectively followed in a single Italian reference center.

Methods: We analyzed 23 placentas in 23 spontaneously conceived pregnancies in patients with definite APS prospectively followed in the ‘Pregnancy at risk’ multidisciplinary outpatient clinics at San Raffaele Hospital, Milan, Italy from January 2017 to May 2021. During each trimester of gestation, ultrasonography with Uterine artery Doppler velocimetry was performed. Histological analysis of the placenta was carried out after delivery and placental tissues were examined for the main aforementioned histopathological findings. Statistical relations among clinical and ultrasound evaluations during each trimester, therapeutic approach and placental histology were performed.

Results: 19/25 (76%) patients had primary APS, while 6 patients had APS secondary to SLE. All patients were treated with LDA and LMWH. HCQ was added in a group of patients with concomitant systemic lupus erythematosus (SLE) or in refractory APS. Mean placental weight was 441 ± 129 grams. Histological analysis of placental tissues revealed increased syncytiotrophoblast knots in 17/25 (68%) placenta, decreased vasculosyncytial membranes in 11/25 (44%), infarction in 8/25 (32%), presence of macrophages and decidual inflammation in 2/25 (8%), and atherosis or reduction of spiral arteries remodelling in 3/25 (12%) placenta. Moreover, we observed at least 2 concomitant placental lesions in 12/25 (48%) placentas. No statistical association between mean UTA-PI values and the number and type of placental lesions described at the histologic analysis were observed. We found a positive correlation between mean titer of aCL IgG, aP2/GPI IgG, aPS/PT IgM and/or aPS/PT IgG and number of placental lesions, and a significant association between aP2/PT IgG and/or IgG mean titer and presence of infarcted areas at placental histology. In the placenta, in the patients treated with HCQ we did not observe any decidual inflammation at histology.

Conclusion: In our study we found some important clinical-pathological correlations between placental histology, clinical evaluations, ultrasound assessments and treatment received during pregnancy. Specifically, it is tempting to speculate that HCQ may have beneficial effects on pregnancy by decreasing the risk of deciduitis in patients with APS.

Further studies on larger numbers of placenta in APS patients will be needed to confirm our findings.

REFERENCES:

Disclosure of Interests: None declared

AB0446

IMPROVEMENT OF BELIMUMAB ON QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOUS

G. Yi1, S. Zheng2, X. Guo3, M. Liu4, T. Li5, Y. Chen1, H. Li1, Y. Wang1, X. Cong1, J. Zhang1, Y. Wang1, J. Zhang1, S. Zheng2, C. Wang2, C. Zhang2, Y. Yi1, J. Yi2, T. Li3, P. Wu2

Background: Accumulating evidence supports an impaired quality of life in patients with systemic lupus erythematosus (SLE). A study reported the patients concerns centred on fatigue.

Objectives: To investigate the effect of belimumab on quality of life in patients with SLE.

Methods: SLE patients from Guangdong Second Provincial General Hospital treated with belimumab (n=19) or control group (n=22) were included. Patients in control group were in traditional SLE treatment without belimumab. Data were collected prospectively at treatment initiation and now, including Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Pittsburgh Sleep Quality Index (PSQI) and the SF-36 (Table 1).

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>SLEDAI</th>
<th>PSQI</th>
<th>PSQI</th>
<th>SF-36</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belimumab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group</td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
<td>Pre-treatment</td>
<td>Post-treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.19</td>
<td>0.007</td>
<td></td>
<td>0.18</td>
</tr>
<tr>
<td></td>
<td>187.79</td>
<td>0.004</td>
<td></td>
<td>141.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.18</td>
<td></td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>123.90</td>
<td></td>
<td>126.65</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.723</td>
<td></td>
<td>0.723</td>
</tr>
</tbody>
</table>

Results: Belimumab group showed improvement in SLEDAI, PSQI and the SF-36 (P < 0.05). Control group was improvement in SLEDAI and the SF-36 (P < 0.05), no changes in PSQI (P=0.536). However, the improvement of belimumab group in SLEDAI and PSQI observably outperformed the improvement of control group.

Conclusion: Belimumab effectively improve quality of life in patients with SLE. Further study of pediatric patients with SLE is still warranted.

REFERENCES:

Disclosure of Interests: None declared

AB0447

LUPUS NEPHRITIS OUTCOMES AFTER DISCONTINUATION OF IMMUNOSUPPRESSION

F. Alenzi1, S. Sangle2, D. Ocruzz2

1College of Medicine, Princess Nourah bint Abdullah University, Clinical Sciences Department, Riyadh, Saudi Arabia; 2Guy’s and St Thomas’ Hospital, NHS Foundation Trust, Louise Coote Lupus Unit, London, United Kingdom

Background: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE). Immunosuppression (IS) is the standard of care therapy for lupusnephritis(LN).Data on the outcomes of LN patients after discontinuation of immunosuppression remain uncertain.
Objectives: To assess the outcomes of patients with LN after discontinuation of immunosuppression.

Methods: Clinical and laboratory data were retrospectively collected on LN patients attending our Lupus Unit. We included 45 patients (41 had biopsy confirmed) who were treated with immunosuppression including cyclophosphamide, mycophenolate, azathioprine, methotrexate, and/or rituximab. Numeric response variables (median and range) including age, disease duration and length of treatment were collected. Frequencies and percentages categorical variables including gender, ethnicity, lupus nephritis class, autoantibodies, laboratory features, IS therapy used and patients’ outcomes (stable versus flared) were analysed. LN flares were defined as: doubling of serum creatinine concentrations and increases in proteinuria after discontinuation of IS. Chi-square tests were applied to compare these categorical variables between patient’s outcomes. Reasons for IS discontinuation: remission, pregnancy planning and patients preference.

Results: We identified the outcomes of 45 LN patients who stopped IS therapy. The median age of patients was 55 (29-78) years. The median duration of disease was 26.5 (15-58) years whereas the median treatment duration was 4 (1-12-14) years. Thirty (66.7%) patients were Caucasian ethnicity. Seventeen (38%) of 45 patients received treatment for more than 5 years. There was only 1 (2.2%) male patient in our study. At IS discontinuation, creatinine levels were elevated in 45 (2%) patient and median creatinine values were 73 (41-117 umol/L). Median proteinuria values were 20ng/mmol (5-934) (p=0.00). LN histology: classV (24.4%), IV (17.8%) and III (17.8%). Seven patients had a combination of class III IV. Thirteen of 45 (28.9%) patients had relapses after discontinuation of IS. Median time to LN flare was 3 (1-17) years and median age of the flared patients was 58 (41-70) years. Median creatinine values and median proteinuria of the flared patients were 78 (41-111 umol/L), 361.5 mg/mmol (12-908) respectively. Of these, 13 relapsed LN patients, 4 had class III, 4 had class V and the other patients had combinations of classes. Anti-Sm antibodies were more likely to be associated with relapses (6 patients) compared to stable patients (4 patients) (6 vs. 40%) (p=0.030). Anti-dsDNA antibodies were positive in 22/32 stable patients (68.8%) compared to 10/13 (31.3%) relapsed patients (p=NS). Among 13 flared patients, 5 (38.5%) had high creatinine levels and 8 (61.5%) had normal serum creatinine (p=0.048) on discontinuation of IS. Of 45 patients, 12 had low complement C3, of whom 7 (58.3%) flared and 5 (41.7%) were stable (p=0.009). Similarly, of 12 patients with low C4, 8 (66.7%) flared compared to 4 with stable outcomes (33.3%) (p=0.001). A higher proportion of patients previously taking azathioprine relapsed compared to those with previous use of cyclophosphamide or MMF (30.8% vs. 15.4%) (p=0.011) respectively.

Conclusion: Our data suggests that two thirds of our patients experienced clinical remission with stable LN following cessation of IS therapy for LN. Patients who had elevated serum creatinine values, persistent proteinuria, low complement, positive anti Sm antibodies and previous azathioprine use were more likely to flare after stopping IS. Anti-dsDNA antibodies levels did not predict flares after stopping IS. Further prospective studies with larger sample sizes and longer follow-up are needed to estimate LN outcomes after discontinuation of immunosuppression.

Table 1. Patient’s characteristics and lupus nephritis outcome

<table>
<thead>
<tr>
<th>Parameters n (%)</th>
<th>Flared patients (N=13)</th>
<th>Stable patients (N=32)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal creatinine</td>
<td>5 (38.5%)</td>
<td>4 (44.4%)</td>
<td>0.048</td>
</tr>
<tr>
<td>Significant UPCR</td>
<td>8 (61.5%)</td>
<td>11 (11.1%)</td>
<td>0.000</td>
</tr>
<tr>
<td>Anti-sm</td>
<td>6 (46.2%)</td>
<td>2 (40%)</td>
<td>0.030</td>
</tr>
<tr>
<td>Low C3</td>
<td>7 (53.8%)</td>
<td>5 (41.7%)</td>
<td>0.009</td>
</tr>
<tr>
<td>Low C4</td>
<td>8 (61.5%)</td>
<td>4 (53.3%)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4770

AB0448 ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE ROLE OF THERAPY.

M. B. Cilona1, V. Canti1,2, I. Dalpiaz1, R. De Lorenzo1, G. Inguscio1, C. Asperti1, S. Rosai1, M. T. Castiglioni1, P. Rovere-Querini1,2, 1Vita-Salute San Raffaele University, Internal Medicine, Milano, Italy; 2San Raffaele Hospital, Internal Medicine, Milano, Italy; 3San Raffaele Hospital, Obstetrics and Gynecology, Milano, Italy

Background: Our study supports that treatment with glucocorticoids at medium-high doses during pregnancy adversely affects pregnancy outcome with an increased risk of both APO and birth of SGA infants. These data can be related to a direct role of the drug in determining maternal-fetal outcome and to the presence of an incomplete control over disease activity. The comparison between pregnancies followed before 2010 and since 2010 conducted in our study shows that the introduction of drugs such as hydroxychloroquine and azathioprine from the beginning of the pregnancy can reduce the frequency of APO in general. These medications can represent a safety therapeutic strategy both for the mother and for the fetus in order to control autoimmune disease during pregnancy and minimize the occurrence of complications. Further studies on larger numbers of placenta in APS patients will be needed to confirm our findings.

Objectives: To investigate whether treatment in SLE patients during pregnancy may influence the occurrence of APO events and, in particular, the birth of SGA infants.

Methods: We performed a monocentric observational study in SLE pregnant patients prospectively followed at the ‘Pregnancy at risk’ multidisciplinary outpatient clinics at San Raffaele Hospital, Milan, Italy from January 2003 to June 2021. We collected data from 79 pregnancies in 58 patients with a diagnosis of SLE.

Results: 13/79 (16%) pregnancies ended in a spontaneous abortion. In the other 66/79 (84%) APOs occurred in 29/66 (44%) pregnancies. 17 of the 66 (26%) pregnancies that did not end in spontaneous abortion ended with the birth of SGA infants. Glucocorticoid treatment at medium-high doses (e. i. prednisone ≥ 5 mg) was associated to an increased risk for APO (OR 4.431, p-value 0.018) and for the birth of SGA infants (OR 4.401, p-value 0.019). Preterm delivery (7/43, 16% versus 7/23, 30%), hypertension and/or preeclampsia (4/43, 9% versus 5/23, 22%) were observed with low incidence in pregnancy followed since 2010 than before 2010, even if without reaching statistical significance.

Conclusion: Our study supports that treatment with glucocorticoids at medium-high doses during pregnancy adversely affects pregnancy outcome with an increased risk of both APO and birth of SGA infants. These data can be related to a direct role of the drug in determining maternal-fetal outcome and to the presence of an incomplete control over disease activity. The comparison between pregnancies followed before 2010 and since 2010 conducted in our study shows that the introduction of drugs such as hydroxychloroquine and azathioprine from the beginning of the pregnancy can reduce the frequency of APO in general. These medications could represent a safety therapeutic strategy both for the mother and for the fetus in order to control autoimmune disease during pregnancy and minimize the occurrence of complications. Further studies on larger numbers of placenta in APS patients will be needed to confirm our findings.

REFERENCES:

Disclosure of Interests: None declared

SLE, Sjőn-s and APS - clinical aspects (other than treatment)

**AB0449**

**THE PREVALENCE OF AUTOANTIBODIES AGAINST IFNA IS HIGH IN SLE AND ASSOCIATED WITH A HIGH FREQUENCY OF TUBERCULOSIS**


**Background:** IFNα and anti-IFNα autoantibodies have been implicated in susceptibility both for systemic lupus erythematosus (SLE) and viral infection.

**Objectives:** We aimed to analyze the SLE disease phenotype and risk for infection associated with anti-IFNα IgG autoantibodies in SLE patients.

**Methods:** In this multidisciplinary retrospective single referral center study, all consecutive patients with SLE admitted between January 1st and November 30th 2020 were considered. All subjects fulfilled the ACR/EULAR 2019 criteria for SLE.

Anti-IFNα IgG autoantibodies were quantified at admission by ELISA. Demographic, medical history, laboratory, treatment, and outcome data were extracted from electronic medical records using a standardized data collection form.

**Results:** 180 patients [female 87.2%, median age of 44.4 (34-54.2) years] were included. The median disease duration was 10 years [4-20] with a median SLE-DAI score of 2 [0-4] at study time. Fifty-four (30%) patients had a past-history of lupus nephritis. One hundred and forty-four (80%) had received long-term glucocorticoids and 99 (55%) immunosuppressive drugs. Overall, 127 infections from electronic medical records using a standardized data collection form. Seven hundred and ninety-four infections were identified for the primary outcome with a median follow up of 110 (interquartile range: 99–120) months. Among them, 29 (6.6%) experienced at least one CVE. Factors associated with incident CVE and sCD163 level were analyzed. The prevalence of autoantibodies against IFNα is high in SLE and associated with a higher frequency of tuberculosis.

**Conclusion:** The prevalence of autoantibodies against IFNα is high in SLE and associated with a higher frequency of tuberculosis.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.16

**AB0450**

**SOLUBLE CD163 IS A BIOMARKER FOR CARDIOVASCULAR EVENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

C. David1, N. Costedoat-Chalumeau2, D. Belham3, V. Leguem2, C. Lauonen2, A. Bouten2, J. Cheze1, N. Morel2, A. Matthieu2, Z. Amoura5, T. Papo7, K. Sacre8.on behalf of PLUS Study group. 1Université de Paris Bichat, Médecine Interne, Paris, France; 2Université de Paris Cochin, Médecine Interne, Paris, France; 3Université de Paris Bichat, URCP, Paris, France; 4Université de Paris Bichat, Biochimie, Paris, France; 5Sorbonne Université Pitié, Médecine Interne, Paris, France.

**Background:** Prediction models based on traditional cardiovascular risk factors underestimate the risk of cardiovascular events (CVE) in systemic lupus erythematosus (SLE).

**Objectives:** We aimed to determine whether sCD163, a biomarker for SLE-associated atherosclerosis, may predict CVE in SLE.

**Methods:** All SLE patients included between 2007 and 2010 in the randomized, double-blind, placebo-controlled, multicenter PLUS trial were screened. Patients with no past history of CVE at inclusion and a follow-up period of >20 months were analyzed. sCD163 level was measured using enzyme-linked immunosorbent assay on serum collected at PLUS inclusion. The primary outcome was the incidence of CVE. Factors associated with incident CVE and sCD163 level were analyzed.

**Results:** Overall, 442 SLE patients (of the 573 included in the PLUS study) were analyzed for the primary outcome with a median follow up of 110 (interquartile range: 99–120) months. Among them, 29 (6.6%) experienced at least one CVE that occurred at a median of 67 (interquartile range: 31–91) months after inclusion. In the multivariate analysis, dyslipidaemia, age and increased sCD163 were associated with CVE onset. Multivariate Cox models analysis showed that a concentration of sCD163 > 263 ng/mL at inclusion increased by 2.7 [hazard ratio 2.7 (95% CI: 1.0, 7.0)] the risk of CVE in SLE. Increased sCD163 was also associated with immunosuppressive treatment, higher body mass index (BMI) and SLEDAL score.

**Conclusion:** Macrophage-specific sCD163 serum level reflects lupus disease activity and predicts CVE in SLE.

**Disclosure of Interests:** None declared


**AB0451**

**FACTORS ASSOCIATED WITH ADVERSE PREGNANCY OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)**

C. Sieiro Santos1, C. Moriano1, I. González Fernández2, X. E. Larco Rojas1, C. Alvarez Castro1, E. Diez Alvarez1. 1Complejo Asistencial Universitario de León, Rheumatology, León, Spain.

**Background:** Prematurity in systemic lupus erythematosus (SLE) are considered high risk and associated with maternal and obstetric complications.

**Objectives:** Our goal with this study was to determine the most important predictors for each of the main adverse pregnancy outcomes in SLE patients.

**Methods:** We conducted a retrospective case-controls study by including multiparous women diagnosed with SLE from 1980 to 2020 followed in our unit and compared the clinical profile of patients with adverse pregnancy outcomes to control SLE patients. We excluded elective terminations of pregnancy and cases lost to follow-up. Qualitative data were analyzed by Chi-square test and Fisher’s exact test and continuous variables were analyzed by using Student’s t test. Multiple logistic regression models were performed to determine the predictive factors for adverse pregnancy outcomes with adjustment of confounding factors. In all tests, P values less than 0.05 were considered to be statistically significant.

**Results:** 135 multiparous women were included (43% with adverse pregnancy outcomes). The mean age of patients at inclusion was 55.8 (46-64) years. Abortion occurred in 33 patients (57%), pre-eclampsia in 10 patients (17%), ectopic pregnancy in 5 patients (8%), preterm labor in 5 patients (8%), placental abnormalities in 4 patients (6%), stillbirth in 4 patients (6%), premature rupture of membranes (PROM) and neonatal lupus in 3 patients (5%), respectively. 121 patients (89%) had pre-existing lupus and 14 (11%) referred with SLE onset in pregnancy. Renal involvement (p=0.03), anti-NDAs positivity (p=0.002), antiphospholipid antibody (APA) positivity (p=0.001), anti-Ro/SSA (p=0.003) and a younger age at disease onset (p=0.001) were significantly associated with unfavorable pregnancy outcomes. Abortion was correlated with anti-NDAs (β=0.71, p=0.04), renal involvement (β=0.28, p=0.03) and APA (β=0.2, p=0.03). Stillbirth was also correlated with renal involvement (β=0.26, p=0.04) and APA (β=0.22, p=0.03). Preeclampsia was correlated with direct Coombs positivity (β=0.42, p=0.01) and serositis (β=0.31, p=0.02).

**Conclusion:** The most unfavorable pregnancy outcomes in women with SLE were spontaneous abortion. Renal involvement, anti-NDAs and anti-Ro/SSA, antiphospholipid antibody positivity, and a younger age at disease onset increased the risk of pregnancy complications.

**Table 1. Multiple logistic regression analysis**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Coefficient</th>
<th>Standard Error</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-NDAs</td>
<td>β=0.71</td>
<td>0.04</td>
<td>2.62 (1.17-5.94)</td>
</tr>
<tr>
<td>APA</td>
<td>β=0.28</td>
<td>0.04</td>
<td>1.32 (1.02-1.72)</td>
</tr>
<tr>
<td>Renal involvement</td>
<td>β=0.38</td>
<td>0.06</td>
<td>1.45 (1.06-1.98)</td>
</tr>
<tr>
<td>Serositis</td>
<td>β=0.95</td>
<td>0.01</td>
<td>0.37 (0.20-0.72)</td>
</tr>
</tbody>
</table>

**REFERENCES:**


**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.303
AB0452

AGE RELATED DIFFERENCES IN NEUROPSYCHIATRIC MANIFESTATIONS AMONG SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS – A SINGLE RHEUMATOLOGY CENTRE EXPERIENCE IN MALAYSIA

C.R. No1, 1Hospital Sultan Ismail, Rheumatology Unit, Department of Medicine, Johor Bahru, Malaysia

Background: The prevalence of SLE in Malaysia was reported as 43/100,000 individuals and Chinese (57/100,000) have the highest prevalence followed by Malays (33/100,000) and Indians (14/100,000) [1,2]. The American College of Rheumatology established case definitions and categorised neuropsychiatric syndromes into two groups: central and peripheral system involvement. There were studies showed that cognitive impairment is the commonest neuropsychiatric manifestations with a prevalence of 66% [3].

Objectives: To determine the association between neuropsychiatric manifestations with different age group among SLE patients.

Methods: This was a retrospective study. The electronic medical records of all SLE patients seen in rheumatology clinic of Hospital Sultan Ismail, Malaysia from 1/1/2007 to 31/12/2021 were reviewed. SLE patients with neuropsychiatric manifestations were selected and categorised by age into children (< 12 years old), adolescents (aged 12-18 years), young adults (aged >18 to 35 years), middle-aged adults (>35 -55 years) and elderly (>55 years). The association between neuropsychiatric manifestation with different age group was analysed by using SPSS-Fisher’s exact test.

Results: There was a total of 86 patients and female were 77. The majority were Malay (49/86) followed by the Chinese (33/86), Indians (2/86) and others (2/86). Patients were categorized into children (n=8), adolescents (n=18), young adults (n=43), middle-aged adults (n=16) and elderly (n=3) with the mean age of 28.

Our study showed the onset of neuropsychiatric manifestations occurred most during young adulthood (43/86) followed by adolescents (18/86). Seizure disorders is the commonest manifestations (36/86) followed by psychosis (17/86), poly/mononeuropathy (7/86), cognitive dysfunction (7/86), myelopathy (5/86), cranial neuropathy (4/86), mood disorders (3/86), cerebrovascular disease (3/86), movement disorders (2/86), and lastly headache and myasthenia gravis. 1 patient each. 60% of the patients had onset of neuropsychiatric manifestation during first diagnosis and another 7% developed symptoms within 1 year of diagnosis. There was no association between type of neuropsychiatric manifestation with different age group (p = 0.195). Comparison of neuropsychiatric manifestations according to age group was shown in Table 1.

Table 1. Neuropsychiatric manifestations according to age group

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>Seizure (4)</th>
<th>Cognitive dysfunction (1)</th>
<th>PN/MM (2)</th>
<th>Movement disorders (2)</th>
<th>Myelopathy (4)</th>
<th>Cerebrovascular disease (3)</th>
<th>Movement disorders (2)</th>
<th>Headache (1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children &lt;12</td>
<td>CVD (1)</td>
<td>CVD (1)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (3)</td>
<td></td>
</tr>
<tr>
<td>Adolescents 12-18</td>
<td>Seizure (2), Psychosis (5), Mood disorders (1), Cognitive dysfunction (1)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>CN (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Young adults &gt;18-35</td>
<td>Seizure (18), Psychosis (10), Cognitive dysfunction (4), movement disorders (2), Myelopathy (4), CVD (2)</td>
<td>PN/MM (2)</td>
<td>CN (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Middle-aged adults &gt;35-55</td>
<td>Seizure (4), Psychosis (2), Mood disorders (2), Cognitive dysfunction (1), Myelopathy (1), Headache (1)</td>
<td>PN/MM (3)</td>
<td>CN (2)</td>
<td>MG (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elderly &gt;55</td>
<td>Seizure (1)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (2)</td>
<td>PN/MM (3)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Seizure disorders is the commonest manifestations amongst SLE patients in our study group and there was no association between neuropsychiatric manifestation with the age group.

REFERENCES:

Disclosure of Interests: None declared

AB0453

ROLE OF COMBINATION AUTOANTIBODIES (ANTI-SMITH, RO AND RNP ANTIBODIES) AND ETHNICITY IN ACCELERATED DEVELOPMENT OF LUPUS NEPHRITIS

C.R. No1, 1Hospital Sultan Ismail, Rheumatology Unit, Department of Medicine, Johor Bahru, Malaysia

Background: Lupus nephritis (LN) is an important concern among SLE patients in Asia and its mortality rate was reported to be 6 times higher compared to the general population [1]. A study by McCarty et al suggested that African women with serology showed combination of anti-Smith, Ro and RNP antibodies were at increased risk of developing LN [2]. This is further supported by study done by Majed et al showed this unusual combination accelerated development of LN within the first 5 years after SLE onset [3].

Objectives: To determine the correlation between the combination of autoantibody profile, Smith, Ro and RNP in development of LN amongst Asian ancestry and any association with the duration of LN development from onset of SLE.

Methods: This was a retrospective study. The electronic medical records of all SLE patients seen in the rheumatology clinic Hospital Sultan Ismail, Malaysia from 1/1/2007 to 30/4/2021 were reviewed. Patients who had LN were identified and selected. Data on demography, serology, duration of development of LN from SLE onset were obtained and analysed using SPSS Pearson Chi square and binary logistic regression.

Results: There were a total of 197 patients and 183 were females. The majority were Malays (96/197) followed by the non-Malay (101/197) which included Chinese (88/197) and others (15/197). The mean age group for the studied subjects was 34 (14-80). Of the 197 (100%) patients, 23 (11.7%) patients had the triple combination of Sm, Ro and RNP antibodies while 174 (88.3%) patients did not have the triple combination. For patient with the triple combination, regardless ethnicity, 20/23 (87%) developed LN within 5 years from the SLE onset while the remaining 3/23 (13%) developed LN after 5 years. For patients without this combination, regardless ethnicity, 142/174 (81.6%) of them developed LN within 5 years and 32/174 (18.4%) of them more than 5 years. This showed combination autoantibody does not significantly accelerated development of LN amongst Asian ancestry patients, P = 0.092. There was also no association between the positivity of triple antibody with the duration of development LN from SLE onset, P =0.772. Further stratification was based on ethnicity showed compare to Non-Malay ethnicity, the Malay patients is 3.966 higher odds of developing LN within the 5 years from SLE onset, P = 0.002.

Conclusion: Patient with triple serology combination did not showed significant in accelerating development of LN. Our data showed Malay patients are 4 higher odds of developing LN within the first 5 years after SLE onset compare to Non-Malay patients.

REFERENCES:

Disclosure of Interests: None declared

AB0455

DRUGS, AUTOANTIBODIES AND GENES CONTRIBUTE TO THE DEVELOPMENT OF CHRONIC DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

G. Oliveri1, F. Ceccarelli1, C. Pironi1, L. Picciariello1, F. Natalucci1, C. Ciccacci2, C. Perricone3, F.R. Spinelli1, C. Alessandri1, P. Borgiani4, C. Ceccarelli1, F. Conti1, 1Rheumatology, Dipartimento di Scienze Cliniche Internistiche, Anestesieologiche e Cardiovascolari, Sapienza University of Rome, Roma, Italy; 2Genetica Medica, UniCamillus, Saint Camillus International University of Health and Medical Sciences, Rome, Rome, Italy; 3Rheumatology, Dipartimento di Medicina e Chirurgia, University of Perugia, Perugia, Italy; 4Genetica Medica, Department of Biomedicine and Prevention, Genetics Section, University of Rome Tor Vergata, Roma, Italy.

Background: Genetic contribution to development of chronic damage have been scarcely investigated in systemic lupus erythematosus (SLE). In fact, whereas most studies have looked for an association between genetic variants and SLE susceptibility or disease phenotypes, only few have focused on the relationship between these biomarkers and damage development.
Objectives: Moving from these premises, we firstly analyzed the distribution of organ damage in a cohort of SLE patients and secondly we evaluate the role of clinical and genetic factors in determining the development of chronic disease. Methods: Caucasian SLE patients, diagnosed according with 1997 ACR criteria, were enrolled, and clinical and laboratory data were collected. Based on literature data, we selected a panel of 17 SNPs of following genes STAT4, IL10, IRAK1, HCP5, MIR146a, ATG16L1, IRGM, ATG5, MIR124, MIR1279, TNFSF4, CD40. Genotyping was performed by allelic discrimination assays. A phenotype-genotype correlation analysis was performed by evaluating specific domains of SLICC Damage Index (SDI).

Results: Among 175 Caucasian SLE patients, 105 (60%) exhibited damage (SDI ≥ 1) with a median of 1.0 (IQR 3.0). The musculoskeletal (26.2%), neuropyschiatric (24.6%) and ocular domains (20.6%) were involved most frequently. The presence of damage was associated with higher age, longer disease duration, neuropsychiatric (NP) manifestations, anti-phospholipid syndrome and the positivity of anti-dsDNA antibodies. Concerning therapies cyclophosphamide, mycophenolate fentyll and glucocorticoids resulted associated with the development of damage. The genotype/phenotype correlation analysis showed an association between renal damage, identified in 6.9% of patients, and rs2205960 of TNFSF4 (p=0.001; OR 1.70). This SNP resulted significantly associated with end-stage renal damage (p=0.018, OR 9.68) and estimated GFR<50% (p=0.025, OR 1.06, Figure 1). The rs1463335 of MIR1279 gene was associated with the development of NP damage (p=0.029; OR 2.783). The multivariate logistic regression analysis confirmed the associations between TNFSF4 rs2205960 SNP and renal damage (p=0.020, r=2.53) and between NP damage and rs1463335 of MIR1279 gene (p=0.013, r=1.26).

Conclusion: We showed the role of age, drugs, and autoantibody profile in determining chronic damage. Our data suggest a possible role of genetic background in determining the development of renal and neuropsychiatric damage, as demonstrated by the association with polymorphisms of TNFSF4 and MIR1279, respectively. These results agree with previous studies suggesting the involvement of TNFSF4 in Lupus nephritis and microRNA in neuroinflammation.

Disclosure of Interests: None declared


AB0456

DISEASE FLARE OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PATIENTS WITH END-STAGE RENAL DISEASE ON DIALYSIS

Y. E. King1, S. J. Choi2, D. H. Lim3, S. M. Ahn1, J. S. Oh1, Y. G. Kim1, C. K. Lee1, B. Yoo1, S. Hong1.

1Asan Medical Center, University of Ulsan College of Medicine, Department of Rheumatology, Seoul, Korea, Rep. of (South Korea); 2Ulsan University Hospital, Department of Rheumatology, Ulsan, Korea, Rep. of (South Korea)

Background: The systemic lupus erythematosus (SLE) disease activity in patients with lupus nephritis (LN) generally declines after the initiation of renal replacement therapy (RRT); this is known as the "burn out" phenomenon that possibly occurs due to the suppression of cellular and humoral immunity in the end-stage renal disease (ESRD) state and elimination of disease pathogenic factor by dialysis [1-4]. However, several studies showed that SLE flares could occur even during RRT [5-8]. Nevertheless, the details of disease flares of SLE in patients under dialysis have not been studied yet.

Objectives: This study aimed to investigate the clinical features, risk factors, and treatment details of SLE patients experiencing disease flare under RRT.

Methods: The medical records of SLE patients who received dialysis at two tertiary referral hospitals in Seoul and Ulsan, South Korea were reviewed. All patients in this study were either clinically or histologically diagnosed with LN

Results: Of a total of 121 patients with SLE on dialysis, 96 (79.3%) were on hemodialysis (HD) and 25 (20.6%) were on peritoneal dialysis (PD). During a median follow-up of 45 months (IQR, 23–120) after the initiation of dialysis, 32 (26.4%) patients experienced SLE flare (HD, n = 25, PD, n = 7). The most common flares of SLE flare were hematologic (40.6%) and constitutional manifestations (40.6%). Treatments for disease flares were based on corticosteroids, and 11 (34.3%) patients required additional immunosuppressants including cyclophosphamide and mycophenolate fentyll. There was no case of severe adverse events related to medication. non-renal SLE Disease Activity Index (SLEDAI) score before dialysis initiation (HR 1.235, 95% CI, 1.122–1.359; P = 0.001) was a significant risk factor for disease flare during dialysis.

Conclusion: More than one-quarter of SLE patients experienced disease flare during dialysis, which most commonly had hematologic manifestations. Continued follow-up and appropriate treatments including immunosuppressants should be considered for patients with SLE under dialysis.

REFERENCES:

Disclosure of Interests: None declared


AB0457

IMPROVED PREGNANCY OUTCOMES IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RETROSPECTIVE STUDY OF PREGNANCIES FROM A single CENTER IN DENMARK FROM 2010-2020 COMPARED WITH THE PERIOD 1990-2010


1Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 2Aalborg University Hospital, Department of Rheumatology, Aarhus, Denmark; 3Aarhus University Hospital, Department of Gynecology and Obstetrics, Aarhus, Denmark; 4Aarhus University, Department of Clinical Medicine, Aarhus, Denmark

Background: Over the past decades, the approach to follow and treat pregnant SLE patients has changed. Today it is recommended that pregnant patients are monitored closely in a multi-professional team throughout pregnancy (1). The importance of low disease activity before pregnancy and continued treatment...
during pregnancy has been established (2). Even though many improvements in the management of SLE pregnancies has been made, there is still a high risk of adverse pregnancy outcome (APO).

Objectives: We aimed to evaluate APO in a Danish SLE cohort followed from 2010-2020 and compare the results with a previous study cohort from the same referral area followed from 1990-2010 (3).

Methods: This retrospective cohort study used the local patient registry to identify pregnancies in SLE patients followed at the Department of Rheumatology, Aarhus University Hospital, Denmark from January 2010 to October 2020. All patients were followed regularly and fulfilled at least four of the 1997 American College of Rheumatology (ACR) criteria for SLE classification. Data included demographic, clinical, and laboratory data. Demographics included ethnicity, smoking habits, body mass index (BMI), and comorbid APS (recognized before pregnancy). Data were compared with data from a previous study (1990-2010) from the same department.

Results: In total, 66 pregnancies were registered in 41 women. APO occurred in 65 % of pregnancies. Forty-seven pregnancies resulted in a live birth, while 19 ended in miscarriage. Compared to the 1990-2010 cohort, a reduction in preterm deliveries (7.58 % vs. 17.9 %), acute caesarean (6.1 % vs. 15.5 %), and higher average birth weight (3045 g vs. 2870 g) were found (Table 1). Further, we observed more pregnancies and live births per year (Figure 1). A change in the approach to treatment was found, i.e., significantly more patients were treated with hydroxychloroquine (73 %) compared to the 1990-2010 cohort (8 %).

![Figure 1. Pregnancy outcome. Average number of pregnancies and live birth per year in the Aarhus SLE cohort in the period 1990-2010 compared with 2010-2020](image)

Table 1. Maternal and fetal/neonatal adverse pregnancy outcomes in our study population (2010-2020) compared with previous study at Aarhus University Hospital (1990-2010).

<table>
<thead>
<tr>
<th>Maternal and Fetal/Neonatal Complications</th>
<th>1990-2010</th>
<th>2010-2020</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-eclampsia/eclampsia, n (%)</td>
<td>7 (8.3)</td>
<td>8 (12.1)</td>
<td>0.59</td>
</tr>
<tr>
<td>HELLP syndrome, n (%)</td>
<td>4 (4.8)</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Gestational hypertension, n (%)</td>
<td>20 (23.8)</td>
<td>9 (13.6)</td>
<td>0.05</td>
</tr>
<tr>
<td>Preterm delivery (&lt;37th gestational week), n (%)</td>
<td>15 (17.9)</td>
<td>5 (7.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>Acute caesarean delivery, n (%)</td>
<td>13 (15.5)</td>
<td>4 (6.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>Elective caesarean delivery, n (%)</td>
<td>11 (13.1)</td>
<td>8 (12.1)</td>
<td>-</td>
</tr>
<tr>
<td>Total caesarean delivery, n (%)</td>
<td>24 (28.6)</td>
<td>12 (18.2)</td>
<td>-</td>
</tr>
<tr>
<td>Total fetal loss, n (%)</td>
<td>22 (26.2)</td>
<td>19 (28.8)</td>
<td>0.72</td>
</tr>
<tr>
<td>Spontaneous abortion &lt;22 weeks, n (%)</td>
<td>18 (21.4)</td>
<td>15 (22.7)</td>
<td>0.86</td>
</tr>
<tr>
<td>Therapeutic abortion</td>
<td>3 (3.6)</td>
<td>4 (6.1)</td>
<td>0.47</td>
</tr>
<tr>
<td>Still birth</td>
<td>1 (1.2)</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Fetal death after birth</td>
<td>2 (2.4)</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Birth weight, mean ± SD g</td>
<td>2870 (SD NA)</td>
<td>3045 ± 611</td>
<td>-</td>
</tr>
<tr>
<td>IUGR</td>
<td>10 (11.9)</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>SGA</td>
<td>NA</td>
<td>12 (18.18)</td>
<td>-</td>
</tr>
<tr>
<td>Congenital heart block, n (%)</td>
<td>1 (1.2)</td>
<td>0</td>
<td>-</td>
</tr>
<tr>
<td>Neonatal Lupus Syndrome, n (%)</td>
<td>2 (2.4)</td>
<td>0</td>
<td>-</td>
</tr>
</tbody>
</table>

**Conclusion:** Improvements in the frequency of APO were found in 2010-2020 compared with 1990-2010. However, even though a specialized multi-professional team closely follows pregnant women with SLE, pregnancy in SLE still carries a high risk of APO.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.759

**AB0458 DISEASE ACTIVITY AT CONCEPTION PREDICTS LUPUS FLARE UP TO 2 YEARS AFTER BIRTH: A MULTICENTRE LONG TERM FOLLOW-UP STUDY**

M. Pecci1, K. Schreiber1, I. Cecchi1, F. Signorelli2, G. De Jesus3, K. Aso3, M. Kono4, M. L. Urban5, B. Bacco1, S. Gatto Casarino1, L. Lo Sordo1, S. G. Feddai1, A. Barinotti1, I. Gómez Garcia6, M. I. Guaglia7, Y. Tissera1, F. Gervasoni1, M. Á. Aguirre-Zamano6, P. Albí7, C. Benedeto1, T. Atsumi4, O. Amengual4, G. Emmi6, D. Andrade6, L. Marzoio6, D. Roccato6, S. Sciascia1, 1University of Turin, Clinical and Biological Sciences, Torino, Italy; 2Guy’s and St Thomas’ Hospital, Department of Rheumatology and Haemophilia, London, United Kingdom; 3Universidade do Estado do Rio de Janeiro, Department of Rheumatology, Rio de Janeiro, Brazil; 4Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan; 5University of Florence, Department of Experimental and Clinical Medicine, Florence, Italy; 6University of Cordoba, Rheumatology Service, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain; 7Universidad Nacional de Cordoba, Hospital Cordoba and Materno Neonatal, Cordoba, Argentina

**Background:** Systemic lupus erythematosus (SLE) often affects women in their childbearing years, and pregnancy may affect SLE disease activity during pregnancy and post-partum (1,2). Limited data assessing the likelihood and characteristics of SLE activity in an extended time period post-partum which may be relevant as patients may wish to have subsequent pregnancies.

**Objectives:** To assess predicting factors that might influence SLE disease activity in women in an extended follow-up period of 2 years after giving birth and clinical assessment every three months.

**Methods:** The study was designed as an international retrospective, data-driven case collection study, enrolling 119 women with a first birth and with a strictly monitored follow-up period of 2 years.

**Results:** Table 1 shows pregnancy outcomes of all pregnancies. When considering disease manifestations, joint involvement was present in 80% of patients, acute cutaneous in 64%, haematological in 54% and renal in 41%; 75% of patients were positive for anti-dsDNA, 49% for anti-ENA and 37% for anti-Ro/SSA positive. The mean SLE disease activity index 2000 (SLEDAI-2k) at diagnosis was 13.5±6.8 and at first birth was 28.4±4.4.

Table 1. Pregnancy outcomes of all pregnancies and relative breastfeeding data

<table>
<thead>
<tr>
<th>Outcome</th>
<th>All (214)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live births</td>
<td>169</td>
<td>79</td>
</tr>
<tr>
<td>Miscarriages</td>
<td>37</td>
<td>17.3</td>
</tr>
<tr>
<td>Stillbirths</td>
<td>8</td>
<td>3.7</td>
</tr>
<tr>
<td>Maternal and Foetal Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prematurity</td>
<td>39</td>
<td>18.2</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>23</td>
<td>10.7</td>
</tr>
<tr>
<td>HELLP syndrome</td>
<td>4</td>
<td>1.9</td>
</tr>
<tr>
<td>Placental Infarction</td>
<td>21</td>
<td>5.6</td>
</tr>
<tr>
<td>Breastfeeding (all pregnancies)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any breastfeeding (n, %)</td>
<td>109</td>
<td>64.5*</td>
</tr>
<tr>
<td>Exclusive breastfeeding (n, %)</td>
<td>67</td>
<td>51.5*</td>
</tr>
<tr>
<td>Breastfeeding (after first birth)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any breastfeeding (n, %)</td>
<td>87</td>
<td>73.1*</td>
</tr>
<tr>
<td>Exclusive breastfeeding duration (months) (mean±sd)</td>
<td>10.29±10.04</td>
<td></td>
</tr>
<tr>
<td>Exclusive breastfeeding*** duration (n, %)</td>
<td>62</td>
<td>52.1*</td>
</tr>
<tr>
<td>Exclusive breastfeeding*** duration (months) (mean±sd)</td>
<td>6.07±6</td>
<td></td>
</tr>
</tbody>
</table>

*Percentages are calculated considering viable babies (total= 169) **Percentages are calculated considering first birth (total= 119) ***Exclusive breastfeeding was defined as feeding infants only breast milk

At follow-up, 51.3% of patients had at least one flare after a mean time after birth of 9±6.3 months (mean flare per patient 0.94±1.1). The most frequent flare manifestations were joint involvement (48%), followed by renal (33%), cutaneous (28%)
and haematologic (20%). Patients with remission of disease (SLEDAI-2K = 0; no clinical or laboratory manifestations of SLE) at conception had significantly lower rates of flares than those not in remission (18 ± 49–57% vs. 43 ± 70–61%; p = 0.008) (Figure 1).

Figure 1. Flare proportion: Survival Curve based on remission status at conception of the patients included in the study.

Patients who experienced a flare during pregnancy (17 patients), when compared to those who did not, had higher rates of flares during follow-up (76% vs. 47%, respectively, p = 0.019), lower time for first flare (4.4 ± 2.3 months vs. 10.3 ± 6.5 months, respectively, p < 0.001), lower rate of remission of disease at conception (12% vs. 46%, respectively, p < 0.001), lower rates of SLEDAI-2K at conception (5.9 ± 5.6 vs. 2.3 ± 4, respectively, p = 0.001) and lower rates of exclusive breastfeeding (24% vs. 57%, respectively, p = 0.009). Remission of disease and flares during pregnancy remained significantly associated with the development of flares during follow-up after multivariate analysis.

Conclusion: Remission at conception can influence SLE disease positively, even at long-term. Planned pregnancy counseling is fundamental when managing SLE patients.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.785

AB0459
NATIONAL TEMPORAL TRENDS IN ALL-CAUSE MORTALITY IN PATIENTS WITH SYSTEMIC SCLEROSIS IN MEXICO BETWEEN 1998-2017

P. Munguía-Realpozo1, M. García Carrasco1, I. Etchegaray-Morales1, J. Ayón-Aguilar1, O. Navarro-Milán1, C. Mendoza Pinto2, M. A. Escamilla-Márquez2, M. García Carrasco2, I. Facultad de Medicina BUAP Rheumatology Department, Heroica Puebla de Zaragoza, Mexico; IMSS Specialty Hospital, Systemic Autoimmune Diseases Research, Heroica Puebla de Zaragoza, Mexico; IMSS Specialty Hospital, Systemic Autoimmune Diseases Research, Heroica Puebla de Zaragoza, Mexico

Background: Systemic sclerosis (SSc) is a rare chronic connective tissue disease characterized by vascular injury, immune dysregulation, and extensive fibrosis of several organs. Due to its rarity, epidemiological data for SSc are sparse.

Objectives: To investigate national temporal trends over time in all-cause mortality rates in patients with systemic sclerosis (SSc) in Mexico between 1998 and 2017.

Methods: All-cause deaths between 1998 to 2017 were extracted from the General Board of Health Information (DGIS) Open Access datasets. We identified all persons aged ≥18 years with a diagnosis of SSc (ICD-10 code M34). We calculated the age-standardized mortality rate (ASMR) for SSc and non-SSc (information provided by the National Institute of Statistics, Geography and Informatics). A Joinpoint regression model was used to determine mortality trends by sex and geographic regions. Annual percentage change (APC) and average APC (AAPC) were calculated using Joinpoint analysis.

Results: From 1998 to 2017, the overall ASMR of SSc increased (AAPC= 2.5%), whereas the ASMR for non-SSc remained stable. By subpopulations, females and males with Ssc had a significant uptrend in the ASMR (AAPC= 4.6% and 4.4%, respectively), between 1998 and 2008 for the former and between 1998 and 2010 for the latter. Males had a non-significant ASMR upturn and males a non-significant ASMR decline. Some variations among geographic regions were found. Women had a higher SSc ASMR to non-SSc ASMR ratio than males. The relative cumulative change between 1998 and 2017 differed between females (78.1%) and males (50.8%), and residents of the Southern region had the largest cumulative change (147.8%).

Conclusion: SSc mortality rate increased in Mexico between 1998 to 2017, with SSc mortality higher than non-SSc mortality with variations by sex and geographic regions.

REFERENCES:

Disclosure of Interests: None declared

AB0460
METABOLOMIC PROFILE OF INSULIN RESISTANCE IN NON-DIABETIC WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS

P. Munguía-Realpozo1, C. Mendoza Pinto2, I. Etchegaray-Morales1, S. K. Pérez-Pelcastre1, A. D. Osorio-Peña1, S. Méndez-Martínez1, M. A. Escamilla-Márquez2, M. García Carrasco2, I. Facultad de Medicina BUAP Rheumatology Department, Heroica Puebla de Zaragoza, Mexico; IMSS Specialty Hospital, Systemic Autoimmune Diseases Research, Heroica Puebla de Zaragoza, Mexico; Puebla State Delegation IMSS., Research in Health Coordination, Heroica Puebla de Zaragoza, Mexico; Facultad de Medicina BUAP Endocrinology Department, Heroica Puebla de Zaragoza, Mexico

Background: Systemic lupus erythematosus (SLE) is associated with an increased risk of insulin resistance (IR). Metabolomics offers an opportunity to examine markers of IR and their relationship with SLE.

Objectives: 1) to compare the metabolomic profile of IR in SLE patients and controls; 2) to correlate the metabolomic profile with other IR surrogates and 3) to evaluate the relationship between the metabolomic profile of IR and SLE disease variables, vitamin levels and subclinical atherosclerosis in patients with SLE.

Methods: In this cross-sectional analysis, serum samples were collected from patients with SLE (n = 64) and gender- and age-matched controls (n = 71). Serum metabolomic profiling was performed using ultra-high-performance liquid chromatography and tandem mass spectrometry (UPLC-MS-MS). Homeostasis model assessment (HOMA) and the quantitative insulin sensitivity check index (QUICKI) were also carried out. Serum 25(OH)D concentrations were assessed by chemiluminescent immunoassay. Carotid IMT was quantified by ultrasound.

Results: In non-diabetic patients with SLE, the metabolomic Quantose score significantly moderately correlated with HOMA-IR, HOMA2-IR and QUICKI. Although levels of IR metabolites did not differ between SLE patients and controls, fasting plasma insulin levels were higher and insulin sensitivity lower in SLE patients. The Quantose IR score was significantly correlated with complement C3 levels (r = 0.7; p = 0.001). Neither 25 (OH)D nor IMT was correlated with any metabolite or Quantose IR index.

Conclusion: This exploratory study found that Quantose IR may be a useful tool for IR assessment. There was a possible correlation between the metabolomic profile and complement C3 levels. The implementation of this metabolic strategy may help develop biochemical insight into metabolic disorders in SLE.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.835
TRIPLE POSITIVE PROFILE IN ANTIPHOSPHOLIPID SYNDROME: PROGNOSIS, RELAPSE AND MANAGEMENT FROM A RETROSPECTIVE MULTICENTER STUDY.

L. Charlotte1, L. Ricard1, N. Yann1, O. Fain1, A. Mekinian1. 1Saint Antoine, Internal Medicine, Paris, France

Background: The antiphospholipid syndrome (APS) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (APL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic autoimmune disease. The presence of ANA antibodies could confer a specific phenotype in primary APS.

Objectives: Antiphospholipid syndrome (APS) is defined by the association of thromboembolic and/or obstetrical clinical manifestations and the presence of antiphospholipid antibodies (APL). Patients with all three APL are referred to as triple positive (TP). The objective of our study was to evaluate the impact of the TP profile in a cohort of 204 patients.

Methods: Clinical and biologic data from 195 APS were retrospectively collected. ANA test was considered to be positive when titters were superior or equal to the 1/80 dilution. ANA-positive APS patients did not fulfilled SLE ACR/EULAR classification criteria

Results: 204 patients were included in our study, 68 were TP and 136 were single or double positive (NTP). 122 patients (59.8%) had primary APS. 67 patients (32.8%) had obstetrical APS, with a higher rate among TP patients (45.6% versus 26.5%, P=0.010), and 170 patients (83.3%) had thrombotic APS, without difference between TP and NTP patients. TP patients had more placentation complications than NTP patients (176% versus 2.9%, P=0.001) and more non-criteria events (48.5% versus 25.7%, P=0.002). 97 patients (47.3%) presented at least one relapse, and the relapse rate was significantly higher in TP patients than in NTP patients (63.2% versus 39.7%, P=0.002). Of the relapses, 30 were obstetric and 74 thrombotic, and the rate of obstetric relapses was significantly higher in TP patients. During follow-up, 21 patients (10.3%) died and this rate did not differ between the two groups.

In univariate analysis, TP patients (HR 1.77; 95% CI 1.17-2.68; P=0.007), venous APS (HR 1.74; 95% CI 1.13-2.69; P=0.013), a history of premature birth (HR 2.47; 95% CI 1.24-4.93; P=0.010), and curative anticoagulation (HR 4.91; 95% CI 1.55-15.5; P=0.007) are associated with the risk of relapse. The serological profile was also a factor in relapse: the presence of the anti-β2GP1 antibody (HR 1.70; 95% CI 1.09-2.64; P=0.018) and LA (HR 1.59; 95% CI 1.01-2.50; P=0.046). The non-criteria manifestations of APS are associated with a higher risk of relapse, although not statistically significant (HR 1.49; 95% CI 1.00-2.23; P=0.052).

In multivariate analysis, the TP profile remained associated with a risk of relapse (HR 1.63; 95% CI 1.04-2.55; P=0.031), as well as venous APS (HR 2.05; 95% CI 1.30-3.23; P=0.002), and the antecedent of premature delivery (HR 2.33; 95% CI 1.10-4.92; P=0.027). The risk factors associated with relapse in multivariate analysis are summarized in Figure 1.

AB0462

CORRELATION BETWEEN SAXON TEST AND UNSTIMULATED SALIVARY FLOW RATE IN PATIENTS WITH SUSPECTED SJJÖGREN’S SYNDROME

M. J. Santos Bómez1, M. Fernandez Castro1, J. Sanz1, J. Campos Esteban1, H. Godoy1, C. Merino Arguménez1, O. Rusinovich1, N. De la Torre Rubio1, M. F. Piazza Rascado1, M. C. Sánchez Fernández1, J. P. Garia-De la Magallón1, C. Barbadiello Mateos1, L. F. De Villa1, C. Issai Saragozza1, J. L. Andéu Sánchez1, A. Sánchez1. 1Hospital Universitario Puerta de Hierro Majadahonda, IDIHPISA. Madrid, Spain, Rheumatology; Majadahonda (Madrid), Spain

Background: Sjögren syndrome (SS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands, which alters their function producing dryness of the mouth, eyes and other mucous membranes. The method used to quantify glandular hypofunction is by whole saliva flow stimulated and unstimulated (UWSF) [1], which takes between 5 and 15 minutes (min). The Saxon test [2], is another tool with the same objective but requires less time: 2 minutes. In the literature, we only have found one study that compares the Saxon test with other diagnostic methods although it is developed in patients without SS [3].

Objectives: To compare the Saxon test and UWSF in a cohort of patients with suspected SS.

Methods: In a consecutive cohort of patients who attended the rheumatology department for suspected SS, UWSF was measured (mL/5min) and the Saxon test (g/2min) was performed. The Index Reported by Patients with Sjögren’s Syndrome of the EULAR (ESSPRI) was collected too. This is a patient-reported index designed to assess the severity of patients’ symptoms (dryness, pain, somatic and mental fatigue) in SS through an average of 0–10 numerical scale for each domain. To measure the UWSF, patients were asked to swallow their saliva before the start of the test and then to spit into a container for 5 min. The Saxon test was performed by calculating the difference in weight between the weight of two pieces of sterile gauze that the patient chews for two minutes. An UWSF >0.25/mL/min, a Saxon test >2.75/g/2min and an ESSPRI<5 were considered normal. Spearman’s rank correlation coefficient (r) was used to determine the correlation between both quantitative variables. The Chi-square test and the Gamma test were used in the comparisons between the groups (altered and normal) and the Mann-Whitney U test in the comparisons of the quantitative variables based on the groups (altered and normal) previously defined. Values p≤0.05 were considered statistically significant.

Results: We enrolled 70 patients (63 women/7 men), with a mean age a standard deviation of 54±13 years. The medians (Me) and interquartile ranges (IQR) obtained were 1500 (0.6750 – 2.5000) mL/5min for the UWSF, 2.405 (16775-3.4925) g/2min for the Saxon test, 6.67 (3.67-7.67) for ESSPRI and 7.00 (4.00-8.00) for ESSPRI-dryness score. A direct and significant correlation between the Saxon test and the UWSF (r=0.325; P=0.006) was observed. Twenty-four patients (34.3%) presented an altered UWSF and forty-two patients (60%) had an altered Saxon test. When we analysed the intensity of the association between the different groups (altered/normal) of both variables, we observed a direct and significant association (Gamma value=0.583, P=0.010) between both tools. We also detected differences in the Saxon test between patients with altered UWSF (Me: 1.89 g/2min; IQR: 1.47-2.68) and those with normal UWSF (Me: 2.78 g/2min; IQR: 1.77-3.75) (P=0.029). Similarly, we observed significant differences in UWSF values between patients with altered Saxon test (Me: 1.30 mL/5min IQR: 0.50-2.13) and those with a normal Saxon test (Me: 2.00 mL/5min IQR: 1.5-2.88) (P=0.008).

Regarding the ESSPRI, 42 (62,7%) patients presented an altered ESSPRI and 49 (73,1%) had an altered ESSPRI-dryness score. The group patients with ESSPRI-dryness score≥5 obtained significantly worse scores on the Saxon test (Me: 2.10g/2min IQR: 1.58-3.07) and on the ESSPRI (Me: 7.33 IQR:8.3-8.00) than the normal ESSPRI-dryness score group: Me:3.02g/2min, IQR:2.20-3.84, on the Saxon test (P=0.026); Me: 2.66 IQR:1-0.4, on the ESSPRI (P=0.000).

Conclusion: In patients with suspected SS, there is a direct and significant correlation between the Saxon test and the UWSF. Therefore, the Saxon test could be useful in the initial assessment of oral gland dysfunction, to save time and/or to select patients who require performing the UWSF.

References:

Disclosure of Interests: None declared

Suppressive drugs had no significant effect on development of CD in SLE patients. Kidney damage, age at diagnosis, use of glucocorticoids, hydroxychloroquine and immunosuppressants (% use) were associated with poor cognitive performance (OR=1.4, p=0.03; OR=1.2, p=0.03). GFR values and other parameters evaluated (end stage renal disease, SLEDAI 2.4) were found in 64.2% (n=45) patients (Figure 1). The proportion of patients with CD according to MoCA score was found in 62.8% vs 65.7%, p>0.05). SLE patients per- centage regarding the rest of the size measurements, the vascularization pattern, nor significant differences were found between pSS patients and non-Sjögren's sicca subjects (n=25), who exhibited sicca symptoms but did not fulfill the AECG pSS classification criteria. We considered SGUS score based on parenchymal homogeneity, presence of hypoechogenic areas, and clearness of posterior glandular border of SG. The score of the highest graded gland was considered and a score ≥2 was defined as a positive SGUS, according to OMER- ACT US-SG scoring [1]. The size measurements of the SG were the diameters in anterior-posterior, medio-lateral, and vertical directions during dental occlusion, and length and width of anterior prolongation of parotid glands. The vascularization was ranked according to the color doppler ultrasonography pattern without salivary stimulation. For the lymph nodes examination we considered the shape, number, and size of submandibular, superficial parotid (parotid), and infraparotid lymph nodes, and the jugulodigastric lymph node, considering also that lymph nodes may not be detected. Categorical variables were compared using the Chi-square test and continuous variables were compared using Student's t-test with Welch's correction. p-values <0.05 were considered significant.

**RESULTS:** SGUS was positive in a higher proportion of patients with pSS, in comparison to non-Sjögren's sicca subjects (80% vs 24%, p=0.003). The size measurements showed a smaller antero-posterior diameter of both the right (mean 31.3mm vs. 35.4mm, p=0.037) and left (mean 30.1mm vs. 34.2mm, p=0.004) submandibular glands in pSS patients. A smaller antero-posterior diameter of the left parotid gland was also observed (mean 30.2mm vs. 34.2mm, p=0.046) in pSS patients. The lymph nodes evaluation showed that superficial parotid lymph nodes were detected in a lower proportion in pSS patients (45% vs. 72%, p=0.027) to significant differences were found between pSS patients and non-Sjögren's sicca subjects regarding the rest of the size measurements, the vascularization pattern, nor the shape, number, nor size of lymph nodes when they were detected. In addition, positive SGUS in pSS patients was also associated with a smaller antero-posterior diameter of both the right (mean 29.9mm vs. 35.4mm, p=0.009) and left (mean 32.9mm vs. 34.2mm, p=0.008) submandibular glands, and a smaller antero-posterior diameter of the left parotid gland (mean 27.5mm vs. 34.2mm, p=0.044).

**Conclusion:** Ultrasonographic features are a valuable resource for the evaluation of pSS. The score of parenchymal inhomogeneity is associated with clinical diagnosis, and other indices such as the antero-posterior diameter of the submandibular glands and a lower detection of the superficial parotid lymph nodes may be used to assist the evaluation. However, no other macrostructural features of the parotid and submandibular SG, and the adjacent lymph nodes, seem to be different between pSS patients and non-Sjögren's sicca subjects.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1232

**AB0465 COMPARISON OF ULTRASOUND STRUCTURE CHANGES OF SALIVARY GLANDS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME WITH POSITIVE AND NEGATIVE ANTICENTROMERE ANTIBODIES**

J. Khvans, A. Torgashina, E. Sokol, B. Chalcev. V.A. Nasonova Research Institute of Rheumatology, Laboratory of Rare Rheumatic Diseases and Primary Sjögren's Syndrome, Moscow, Russian Federation

**Background:** Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by the presence of "sicca syndrome", secondary to the involvement of the exocrine glands. Different studies have been published and have shown that salivary gland ultrasound (SGUS) could be used as a tool for the diagnosis of pSS, especially the score of parenchymal inhomogeneity of salivary glands (SG) [1].

**Objectives:** To identify relevant ultrasonographic features associated with glandular involvement in patients with pSS, such as size measurements, vascularization, and the characteristics of adjacent lymph nodes of parotid and submandibular SG, and their association with the score of parenchymal inhomogeneity.

**Methods:** We enrolled patients with pSS (n=45) based on the 2002 American-European Consensus Group (AECG) pSS classification criteria, and non-Sjögren's sicca subjects (n=25), who exhibited sicca symptoms but did not fulfill the AECG pSS classification criteria. We considered SGUS score based on parenchymal homogeneity, presence of hypoechogenic areas, and clearness of posterior glandular border of SG. The score of the highest graded gland was considered and a score ≥2 was defined as a positive SGUS, according to OMERACT US-SG scoring [1]. The size measurements of the SG were the diameters in anterior-posterior, medio-lateral, and vertical directions during dental occlusion, and length and width of anterior prolongation of parotid glands. The vascularization was ranked according to the color doppler ultrasonography pattern without salivary stimulation. For the lymph nodes examination we considered the shape, number, and size of submandibular, superficial parotid (parotid), and infraparotid lymph nodes, and the jugulodigastric lymph node, considering also that lymph nodes may not be detected.

**Results:** SGUS was positive in a higher proportion of patients with pSS, in comparison to non-Sjögren's sicca subjects (80% vs 24%, p=0.003). The size measurements showed a smaller antero-posterior diameter of both the right (mean 31.3mm vs. 35.4mm, p=0.037) and left (mean 30.1mm vs. 34.2mm, p=0.004) submandibular glands in pSS patients. A smaller antero-posterior diameter of the left parotid gland was also observed (mean 30.2mm vs. 34.2mm, p=0.046) in pSS patients. The lymph nodes evaluation showed that superficial parotid lymph nodes were detected in a lower proportion in pSS patients (45% vs. 72%, p=0.027). To significant differences were found between pSS patients and non-Sjögren's sicca subjects regarding the rest of the size measurements, the vascularization pattern, nor the shape, number, nor size of lymph nodes when they were detected. In addition, positive SGUS in pSS patients was also associated with a smaller antero-posterior diameter of both the right (mean 29.9mm vs. 35.4mm, p=0.009) and left (mean 32.9mm vs. 34.2mm, p=0.008) submandibular glands, and a smaller antero-posterior diameter of the left parotid gland (mean 27.5mm vs. 34.2mm, p=0.044).

**Conclusion:** Ultrasonographic features are a valuable resource for the evaluation of pSS. The score of parenchymal inhomogeneity is associated with clinical diagnosis, and other indices such as the antero-posterior diameter of the submandibular glands and a lower detection of the superficial parotid lymph nodes may be used to assist the evaluation. However, no other macrostructural features of the parotid and submandibular SG, and the adjacent lymph nodes, seem to be different between pSS patients and non-Sjögren's sicca subjects.
Background: Apart from anti-Ro and/or anti-La positive primary Sjögren’s syndrome (pSS), there is a unique subtype of pSS with anticitromere antibodies (ACA). At the present time salivary gland ultrasonography (SGUS) is widely used to assess the structure of the salivary glands in pSS, but there are few publications about SGUS changes in ACA-positive patients [1].

Objectives: To investigate SGUS changes in ACA (ACA+) positive pSS patients and compare with ACA-negative (ACA–).

Methods: We examined 141 patients with pSS, including 103 ACA– patients (pSS-ACA–) with the mean age 49.8 ± 14.1 years and 38 ACA+ positive (pSS-ACA+) with the mean age 59.1 ± 10.2 years. All patients underwent standard examination for the diagnosis of pSS (stomatological, ophthalmological, immunological), and SGUS performed using GE LOGIQ 9 of two parotid and two submandibular glands. Ultrasound images were evaluated with the OMERACT SGUS scoring system (SGUS SS) from grades 0 to 3 [2]. Statistical analyses (chi-squared test, p < 0.05) were performed using STATISTICA version 12.

Results: Characteristics of patients with pSS-ACA+ and pSS-ACA– are presented in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>ACA–</th>
<th>ACA+</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>%</td>
<td>%</td>
</tr>
<tr>
<td>Oral dryness</td>
<td>86</td>
<td>83.5</td>
</tr>
<tr>
<td>Ocular dryness</td>
<td>76</td>
<td>73.8</td>
</tr>
<tr>
<td>Enlargement of parotid salivary</td>
<td>36</td>
<td>34.9</td>
</tr>
<tr>
<td>glands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recurrent parotitis</td>
<td>23</td>
<td>22.3</td>
</tr>
<tr>
<td>ANA ≤1:320</td>
<td>103</td>
<td>100</td>
</tr>
<tr>
<td>Stimulated saliva flow test &lt; 2.5 ml/min</td>
<td>65</td>
<td>63.1</td>
</tr>
<tr>
<td>Sialotaxis on parotid sialography</td>
<td>103</td>
<td>100</td>
</tr>
<tr>
<td>Stimulated Schirmer’s test &lt;10 mm/min</td>
<td>67</td>
<td>65.0</td>
</tr>
<tr>
<td>Tear breakup time &lt;10 seconds</td>
<td>59</td>
<td>57.3</td>
</tr>
<tr>
<td>Focus score ≥ 1foci/4 mm²</td>
<td>94</td>
<td>91.3</td>
</tr>
<tr>
<td>MALT-lymphomas</td>
<td>8</td>
<td>7.7</td>
</tr>
</tbody>
</table>

Characteristics of SGUS SS in pSS-ACA+ and pSS-ACA– are shown in Figure 1.

Figure 1.

We did not find significant differences when comparing SGUS SS in patients with pSS-ACA+ and pSS-ACA–.

Conclusion: We did not find significant differences in SGUS and SGUS SS in patients with pSS-ACA+ and pSS-ACA–.

Disclosure of Interests: None declared

References: FURS-2022-003


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1236

AB0466

DYSFUNCTION OF THE AUTONOMIC NERVOUS SYSTEM IS ASSOCIATED WITH LOW-GRADE INFLAMMATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

A. Hempel Zinglerson1, K. K. Iverson2, J. Eugen-Olsen2, J. Fleischer2, S. Jacobsen1, 1Copenhagen Lupus and Vasculitis Clinic, Copenhagen University Hospital Rigshospitalet, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; 2Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark; 3Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

Background: Systemic lupus erythematosus (SLE) is characterized by chronic, systemic inflammation, organ damage and -dysfunction. Autonomic nervous system dysfunction is highly prevalent in SLE patients (up to 54%); compared to controls the prevalence may be up to 12 times increased. These numbers parallel findings in other chronic conditions such as diabetes.

Heart rate variability (HRV) reflects autonomic activity, and low variability indicates impaired activity, denoted as autonomic dysfunction (AD). AD is associated with low-grade inflammation in healthy subjects and patients with diabetes or cardiovascular disease. The causality hereof is not fully understood: AD may impair the vagally mediated anti-inflammatory reflex, thus leading to increased systemic inflammation, but inflammatory mediated microvascular and neuronal damage may also impair autonomic function.

Objectives: To determine if markers of low-grade inflammation are associated with AD in SLE patients.

Methods: SLE patients (n=111) from the Copenhagen based PLUSHeart (Prospective Lupus Study on Cardiovascular Risk Factors) cohort were included for this cross-sectional analysis. The cohort has previously been described with the following characteristics in 2018-2019: 89.2% women, mean age: 51.5 (SD ±12.7) years, mean BMI: 25.1 (±5.0), mean disease duration: 19.9 (±9.5) years, median SLEDAI 2K score: 3 (IQR 1-4), and median SLE Damage Index score: 2 (I-4).

Low-grade inflammation was evaluated by plasma levels of C-reactive protein (CRP) and soluble urbinike-type plasminogen activator receptor (suPAR). Autonomic function was assessed with 5-min resting lead-I electrocardiograms using the Vagus device. Subsequent HRV analyses comprised RMSSD (the root mean square of successive interval differences between normal heartbeats), reflecting parasympathetic function, and SDNN (standard deviation of normal-to-normal heartbeat intervals), reflecting mixed parasympathetic-sympathetic function.

Results: All HRV- and inflammatory markers were non-normally distributed. The median SDNN was 50 (IQR 24-1,40,4), the median RMSSD was 19.7 (12.6-31.7). The median CRP level was 1 (1-3) and suPAR level was 3.2 (2.5-4.8).

Univariate and multivariate linear regression analyses adjusted for age and disease activity correlation of betas log-transformed (β) low-grade inflammation markers (CRP and suPAR) and heart rate variability markers (RMSSD and SDNN). β=standardized coefficients. Statistically significance (P<0.05) is marked with bold.

Conclusion: In SLE, HRV impairments reflecting both decreased parasympathetic and mixed parasympathetic-sympathetic autonomic function were associated with markers of low-grade inflammation independently of SLE disease activity and age. Longitudinal prospective studies are needed to determine causality.

References:


Disclosure of Interests: Amanda Hempel Zinglerson: None declared, Katrine Kjær Iverson: None declared, Jesper Eugen-Olsen Shareholder of: Co-founder, shareholder and CSO of ViroGates (suPAR assay), Jesper Fleischer Shareholder of: Co-inventor of the VagusTM-device (HRV measurement), Sieren Jacobsen: None declared

COMPARISON OF 2002 AECG AND 2016 ACR/EULAR CLASSIFICATION CRITERIA AND ROLE OF SALIVARY GLAND ULTRASONOGRAPHY IN A SICCA COHORT

R. Solans-Laqué1, A. Portella Alegre2, M. Planes-Conanga3, J. Mestre-Torres1, X. Serres-Créixams2, M. I. González-Nieto1, 1Hospital Universitari Vall d’Hebron, Internal Medicine, Barcelona, Spain; 2Hospital Universitari Vall d’Hebron, Radiology, Barcelona, Spain

Background: For the last 20 years, different classification criteria have been used in clinical practice to improve the diagnosis of primary Sjögren’s syndrome (pSS) and for research purposes. Several recent studies have assessed major salivary gland ultrasonography (SGUS) as a tool for diagnosing pSS and its inclusion in the classification criteria sets. In addition, some research suggests that it may be important to distinguish between monospecific antibody assays to Ro60 or Ro52.

Objectives: To compare the new 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria to the revised 2002 American-European Consensus Group (AECG) criteria in a cohort of subjects with sicca symptoms and to assess the diagnostic accuracy of SGUS. We include monospecific antibody determination to Ro60 or Ro52.

Methods: Patients ≥ 18 years old with diagnosis of sicca syndrome without other associated collagen diseases were included. The initial cohort compromised 72 patients. We assessed features of salivary and lacrimal gland dysfunction and autoimmunity as defined by tests of both AECG and ACR/EULAR criteria. We included separate antiRo52 and antiRo60 antibodies determination, and considered only antiRo60 for the ACR/EULAR criteria as recommended [1]. All the patients underwent SGUS. Agreement between the criteria sets was assessed using Cohen’s κ coefficient, and categorical variables were compared using the Chi-square test.

Results: Application of the AECG criteria resulted in the classification of 50 (69%) subjects with pSS, among whom 48 (67%) subjects also met ACR/EULAR criteria. Of the 22 patients receiving a physician diagnosis of pSS, 10 patients met ACR/EULAR only, and 22 (31%) subjects met neither criteria set. The concordance between AECG and ACR/EULAR criteria was almost perfect (κ = 0.94). The concordance group presented 8% antiRo60+, 4% antiRo52+, and 75% antiRo60/ antiRo52+, among whom 56% had antiRo60+/antiRo52+/antiLa+. No patients presented antiLa+ in the absence of both antiRo60 and antiRo52 antibodies. SGUS was abnormal in 63% of these patients. The 2 patients fulfilling only AECG criteria had antiRo52+, and SGUS was abnormal in one of them. SGUS was abnormal in 27% of the 22 patients fulfilling no criteria sets. Thus, SGUS was abnormal in a significantly higher proportion of patients with pSS, in comparison to non-Sjögren’s sicca subjects (62% vs. 27%, p=0.007). Including SGUS among the ACR/EULAR criteria would increase the concordance from κ = 0.94 to κ = 0.97 between the criteria set. Conclusion: The two sets of classification criteria yielded concordant results with an almost perfect agreement in our sicca cohort. The presence of both antiRo60 and antiRo52 antibodies was the most characteristic autoimmune pattern, with no detection of antiLa in the absence of them. SGUS was positive in a higher proportion of patients with pSS and may improve the classification criteria.

REFERENCES:


COMPARISON OF THE DIAGNOSTIC PERFORMANCE OF SALIVARY GLAND SCINTIGRAPHY AND ULTRASOUND IN SJÖGREN’S SYNDROME

M. I. González-Nieto1, A. Portella Alegre2, A. García-Burillo3, S. Asadurian4, J. Mestre-Torres1, X. Serres-Créixams2, R. Solans-Laqué1, 1Hospital Universitari Vall d’Hebron, Internal Medicine, Barcelona, Spain; 2Hospital Universitari Vall d’Hebron, Radiology, Barcelona, Spain; 3Hospital Universitari Vall d’Hebron, Nuclear Medicine, Barcelona, Spain

Background: The 2002 American-European Consensus Group (AECG) criteria included salivary gland scintigraphy (SGS) as one of the possible objective methods for assessing salivary gland involvement in primary Sjögren’s syndrome (pSS). However, this test as well as the sialography were not included in the 2016 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria and considered obsolete. On the other hand, salivary gland ultrasound (SGUS) is a simple and non-invasive procedure that is readily available and provides important information on the major salivary glands. Several recent studies have assessed SGUS as a tool for diagnosing pSS and for research purposes.

Objectives: To compare the diagnostic performance of SGS and SGUS for the diagnosis of pSS.

Methods: Patients ≥ 18 years old with diagnosis of sicca syndrome without other associated collagen diseases were included. The initial cohort compromised 72 patients. We assessed features of salivary and lacrimal gland dysfunction and autoimmunity as defined by tests of both AECG and ACR/EULAR criteria. We included separate antiRo52 and antiRo60 antibodies determination, and considered only antiRo60 for the ACR/EULAR criteria as recommended [1]. All the patients underwent SGUS. Agreement between the criteria sets was assessed using Cohen’s κ coefficient, and categorical variables were compared using the Chi-square test.

Results: Application of the AECG criteria resulted in the classification of 50 (69%) subjects with pSS, among whom 48 (67%) subjects also met ACR/EULAR criteria. Of the 22 patients receiving a physician diagnosis of pSS, 10 patients met ACR/EULAR only, and 22 (31%) subjects met neither criteria set. The concordance between AECG and ACR/EULAR criteria was almost perfect (κ = 0.94). The concordance group presented 8% antiRo60+, 4% antiRo52+, and 75% antiRo60/ antiRo52+, among whom 56% had antiRo60+/antiRo52+/antiLa+. No patients presented antiLa+ in the absence of both antiRo60 and antiRo52 antibodies. SGUS was abnormal in 63% of these patients. The 2 patients fulfilling only AECG criteria had antiRo52+, and SGUS was abnormal in one of them. SGUS was abnormal in 27% of the 22 patients fulfilling no criteria sets. Thus, SGUS was abnormal in a significantly higher proportion of patients with pSS, in comparison to non-Sjögren’s sicca subjects (62% vs. 27%, p=0.007). Including SGUS among the ACR/EULAR criteria would increase the concordance from κ = 0.94 to κ = 0.97 between the criteria set. Conclusion: The two sets of classification criteria yielded concordant results with an almost perfect agreement in our sicca cohort. The presence of both antiRo60 and antiRo52 antibodies was the most characteristic autoimmune pattern, with no detection of antiLa in the absence of them. SGUS was positive in a higher proportion of patients with pSS and may improve the classification criteria.

REFERENCES:

Background: Since the goals of remission or low disease activity are becoming more realistic with advances in treatment for SLE, there is a need to examine the measurements for SLE especially in patients with low disease activity. It has been known that disease activities in SLE are correlated with anti-DNA antibodies (Abs). However, it was not clear which measurements of disease activities or patient reported outcomes correlate better with anti-DNA Abs.

Objectives: To examine the association between parameters for SLE and anti-DNA Abs measured with RIA in Kyoto Lupus Cohort, a SLE registry in Kyoto University Hospital from 2019 to 2021.

Methods: 1)Correlations between anti-DNA Abs with SLEDAI, M-SLEDAI (SLEDAI without anti-DNA Abs), VAS, LupusPRO, SF-36, and Systemic lupus erythematosus Symptom Checklist (SSC) were evaluated cross-sectionally (n = 310). 2) The alterations in SLE parameters and anti-DNA Abs between two visits were examined (n = 106). Further, the correlations within 3 months were examined in cases with flare-ups of SLE (the alteration in SLEDAI > 0 and anti-DNA Abs≥20, n = 39). The associations of the alterations of anti-DNA Abs with each item of SLEDAI classified by organs were also examined.

Results: 1) 313 percent of the cases in the entire registry was classified as remission or low disease activity (Table 1). SLEDAI (means±SD) was higher in patients positive for anti-DNA Abs (7.94±5.20) than in patients negative for anti-DNA Abs (4.56±4.65) (p < 0.0001). Anti-DNA Abs were weakly correlated with SLEDAI (R = 0.24 [p < 0.0001]), M-SLEDAI (R = 0.15 [p = 0.014]), and Physician-VAS (R = 0.19 [p = 0.0016]). On the other hand, there were no significant correlations between anti-DNA Abs and LupusPRO and SSC. Some dimensions in SF-36 had weak correlations with anti-DNA Abs, while no component summary scores had significant correlations with anti-DNA Abs.

Table 1. Patients’ demographics and disease characteristics in the cohort (n = 310).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>47.7 (39.4, 57.5)</td>
</tr>
<tr>
<td>Female sex</td>
<td>n = 284 (91.6%)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>15.9 (9.4, 24.5)</td>
</tr>
<tr>
<td>Anti-DNA Ab positivity†</td>
<td>n = 106 (34.2%)</td>
</tr>
<tr>
<td>Anti-DNA Ab titer (U/mL)</td>
<td>4 (0, 8)</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>4 (2, 8)</td>
</tr>
<tr>
<td>SLEDAI≤4</td>
<td>n = 162 (52.1%)</td>
</tr>
<tr>
<td>SSC</td>
<td>31 (16.2, 52.5)</td>
</tr>
<tr>
<td>Remission or LDA</td>
<td>n = 86 (27.7%)</td>
</tr>
<tr>
<td>Patient-VAS</td>
<td>38 (15, 52)</td>
</tr>
<tr>
<td>Physician-VAS</td>
<td>13.3 (3.3, 23.3)</td>
</tr>
<tr>
<td>SF-36 PCS</td>
<td>45.4 (36, 52.4)</td>
</tr>
<tr>
<td>SF-36 MCS</td>
<td>48.2 (41.5, 53.6)</td>
</tr>
<tr>
<td>SF-36 RCS</td>
<td>51.3 (42.6, 58.6)</td>
</tr>
<tr>
<td>LupusPRO HQOL</td>
<td>70.2 (54.8, 86.5)</td>
</tr>
<tr>
<td>LupusPRO HQOOL</td>
<td>41.7 (31.3, 51.0)</td>
</tr>
<tr>
<td>Glucocorticoid (mg/day)</td>
<td>5 (4, 8)</td>
</tr>
</tbody>
</table>

* Data are n (%) or median (Q1, Q3). † Anti-DNA Ab positivity at the time of the cross-sectional observation.

Figure 1. The associations between the alteration in anti-DNA Ab and SLEDAI

Conclusion: The associations between anti-DNA Abs with several parameters of SLE were examined. Anti-DNA Abs correlated with disease activities (SLEDAI) in SLE patients, especially when observed in the condition of flare-up.

REFERENCES:

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1304

AB0471 FIRST SYMPTOMS AT THE ONSET OF PRIMARY SJÖGREN’S SYNDROME – THE PATIENTS’ PERSPECTIVE OF A SNEAKY DISEASE

A. Lackner1, J. Fessler1, S. Zenz1, J. Hermann1, J. Thiel1, M. Stradner1. 1Medical University of Graz, Department of Rheumatology & Immunology, Graz, Austria

Background: Primary Sjögren Syndrome (PSS) is an autoimmune disorder with a diverse spectrum of clinical manifestations ranging from sicca symptoms to severe systemic organ involvement. Little is known about the symptoms at the onset of PSS, as these are often ignored by both, patients and physicians leading to a substantial delay of diagnosis.

Objectives: The aim of this study was to investigate patients’ recollection of the first symptoms before diagnosis of PSS in qualitative interviews. The second aim was to verify and quantify these aspects in a representative cohort.

Results: Twenty-three patients were included in the study (21 women, age: 62 years). At the time of the study, the ESSPRI averaged 47 points and the ESSDAI 8.5 points. The Schirmer test gave an average value of 6.4 mm/5 min, the unstimulated salivary flow (UWSF) 0.2 ml/5 min. The evaluation of the B-mode sonography showed predominantly hypoechoic lesions and less hyperechoic bands. In the evaluation of the tissue information obtained by means of MSOT, a correlation between increased lipid content and salivary flow measurement was shown as well as a significant difference between collagen proportion between parotid and submandibular glands.

Conclusion: With the help of MSOT, statements about the actual tissue changes within the salivary glands in SjS can be made for the first time. This project demonstrated for the first time a correlation between tissue composition and clinical parameter. The evaluation of other wavelengths in order to obtain further information on the tissue composition is planned.

Disclosure of Interests: None declared.

Methods: All PSS patients fulfilled the EULAR/ACR 2016 classification criteria. In the first part of the study, consecutive PSS patients were recruited for individual, semi-structured interviews. A discussion guide with five open-ended questions was developed to explore patients' experiences on the onset of PSS. All interviews were audio-recorded and transcribed verbatim, and an inductive thematic data analysis was performed using MAXQDA software (VERBI, Berlin, Germany). In the second part, the identified aspects of the qualitative analysis were grouped to a checklist with ten items. Patients were asked to complete the checklist before their routine clinical assessment.

Results: One-hundred and thirty-four patients participated in the study. The qualitative part was completed by 31 PSS patients; 90.3% (n=28) were female and patients had a mean disease duration of 6.9 years (±5.7(SD)) and a mean age of 58.1 years (±12.6).

Four different major aspects emerged of how patients experienced the beginning and first symptoms of PSS: (1) sicca symptoms started after initial swelling of parotids and/or lymph nodes (2) “Classic” PSS symptoms (fatigue, pain, dryness): patients reported wandering joint pain before diagnosis with a long time apart from first symptoms until diagnosis. Patients described joint pain, chronic malaise, and fatigue over months. (3) Hormonal changes (e.g., after birth, hysterec- tomy) or infections before the onset of PSS symptoms. (4) Slowly progressing discomfort due to sicca: patients reported a slow progression of symptoms with no initial recognition of sicca discomfort. In these patients recurrent dental problems and loss of teeth in the years prior to diagnosis was common.

In the second part of the study, the four themes were verified in an independent cohort of 103 PSS patients. Patients were 59.9 (±13.7) years old and six patients were male. The main symptom before diagnosis was dryness (n=77, 74.8%) with wandering joint pain (n=51, 49.5%) and fatigue (n=47, 45.6%). In 38.8% (n=40), patients reported a swelling/infarention of the parotid gland at the onset of disease.

Conclusion: We identified four themes describing the initial symptoms of PSS. Raising awareness of these symptoms among physicians and among the general public may allow earlier diagnosis of PSS.

Disclosure of Interests: None declared


AB0473  EFFECT OF THYROID LESIONS ON THE COURSE OF SYSTEMIC LUPUS ERYTHEMATOSUS

A. Trofimenko1, O. Emel'yanova1, O. Rusanova1,2. Federal State Budgetary Institution « Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky», Laboratory of Clinical Immunology, Volgograd, Russian Federation

Background: Thyroid disease is a common complication of systemic lupus erythematosus manifesting in 30% of cases due to a disturbance of autoimmune mechanisms. Objectives: evaluating the effect of thyroid lesions on the course of systemic lupus erythematosus based on clinical and laboratory parameters, and the level of antibodies to thyroid hormones.

Methods: Among 65 examined patients with SLE (63 women and 2 men aged 18-65) we revealed a thyroid disorder in a third of patients. Patients were diagnosed with autoimmune thyroid diseases in 16 cases, nodular goiter (degree I and II), and single diffuse toxic goiter in 5 cases. The duration of the disease was 5 years, that concomitant thyroid diseases — 3 years. The concentration of antibodies to thyroid hormones was determined by enzyme immunomassay using immobilized thyroxine and triiodothyronine.

Results: When the thyroid gland (TG) gets involved, there is a pronounced discordance in the parameters of immune and hormonal status in patients with SLE compared with patients without thyroid complications. It was found that 68% of patients had antibodies to nDNA, compared with 46% without concomitant thyroid lesion, CIC - 77% and 32%, respectively, IgG - 54% and 25%. The SLICC/ACR damage index in the SLE group with thyroid involvement was higher than in the second group: 4.55 and 3.6 points. This indicates an increase in the severity of SLE in patients with involvement of the thyroid gland. Joint involvement was seen in 79% with thyroid involvement, and 49% without thyroid involvement. A lesion of serous membranes in the form of pleurisy was in 39% and in 3% without involvement, that of the heart in 66/24%. Lupus erythematosus cell phenomenon in 44 / 31%. Immunological activity prevailed in the group of SLE patients with combined auto thyroid disease. Among these patients, 100% had an elevated level of antibodies to thyroid-stimulating hormones, versus 15% in the group without auto thyroid disease.

Conclusion: The involvement of the thyroid gland increases the severity of the course of SLE, antibodies to thyroid hormones are produced actively, which is indicative of thyrocyte destruction and of blocking the normal process of hormone synthesis by their antibodies.

Disclosure of Interests: None declared


AB0474  IMPACT OF HEALTH LITERACY ON TRUST IN PHYSICIANS AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE TRUMP2-SLE PROJECT

N. Oguro1,2, N. Yajima1,3,4, Y. Miyawaki5, R. Yoshimi5, Y. Shinomjia6, K. E. Sada3,4, K. Hayashi1,2, K. Shidahara1,2, N. Sakurai1, C. Hidekawa1, D. Kishida2, T. Ichikawa1, Y. Ishikawa1, N. Kuri1,2, 1Showa University School of Medicine, Division of Rheumatology, Department of Medicine, Tokyo, Japan; 2Kushikuma Medical University, Department of Clinical Epidemiology, Graduate School of Medicine, Fukushima, Japan; 3Kyoto University, Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto, Japan; 4Fukuoka University Graduate School of Medical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 5Okayama University Graduate School of Medical Sciences, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 6Yokohama City University Graduate School of Medicine, Department of Stem Cell and Immune Regulation, Yokohama, Japan; 7Shinshu University School of Medicine, Department of Medicine, School of Medicine, Nagano, Japan; 8Kochi University, Department of Clinical Epidemiology, Kochi Medical School, Kochi, Japan; 9University of Occupational and Environmental Health, The First Department of Internal Medicine, school of Medicine, Fukuoka, Japan; 10Fukushima Medical University, Department of Innovative Research and Education for Clinicians and Trainees (DiRECT), Fukushima, Japan

Conclusion: This study determined the AQLS and the minimal detectable change for HRQL. These results will help evaluating the HRQL of patients in clinical practice, as well as possible assistance designing future clinical trials. Patients in AQLS show lower dysne symptoms scores but higher immunological activity compared to non-AQLS patients. Longitudinal studies are needed to determine factors affecting patients' HRQL in PSS.

Disclosure of Interests: None declared

**Background:** Information technology has expanded the gap in patient health literacy (HL), and HL has various implications on the trust in patient-doctor relationship. Previously, only functional HL, the ability to interpret health information through reading and writing skills, has been studied in patients with SLE (1).

**Objectives:** We examined how trust in physicians is affected by the broader concept of HL, including communicative HL, the ability to extract health information from communication to use, and critical HL, the ability to discern and use such information (2).

**Methods:** This cross-sectional study enrolled 362 SLE patients at 5 sites between June 2020 and August 2021. Three domains of HL (i.e., functional HL, communicative HL, and critical HL) were assessed using the 14-item FCCHL scale (range: 1-4 points for each domain). The outcomes were patients’ trust in physicians and physicians in general and were measured using the Japanese version of the 5-item Wake Forest Physician Trust scales (range: 0-100 points for each scale). General linear models adjusted for age, gender, education, income, SLEDAI, disease duration, depression, and hours of internet use were conducted. Subsequently, a series of general linear models were then fit to each of the three domains of HL to examine whether or not it was associated with the aforementioned covariates.

**Results:** The median age of the patients was 45 (interquartile range [IQR], 34-55), 88% were female. The median value of SLEDAI was 80 ([IQR], 70-95) and trust in physicians generally was 65 ([IQR], 50-80). Trust in one's physician increased with higher functional and communicative HL (per 1-pt increase, 3.2 [95% CI 0.7 to 5.9]; 5.4 [95% CI 1.6 to 9.3]). Trust in doctors generally increased with higher communicative HL and decreased with higher critical HL (per 1-pt increase, 6.8 [95% CI 2.0 to 12]; -6.7 [95% CI -12 to -1.9]). Lower functional HL was associated with older age and depression, while higher HL was associated with higher educational level. Higher communicative HL and critical HL were each associated with longer Internet use.

**Conclusion:** In patients with SLE, higher trust in one's physician was associated with both functional and communicative HL, while higher trust in physicians generally was associated with higher communicative HL and lower critical HL. Our findings suggest that trusting relationships may be fostered by the encouragement of rheumatologists to cultivate patients’ ability to share their health problems with their physicians and family members and to obtain useful health information (i.e., communicative HL), rather than to improve their ability to discern health information (i.e., critical HL).

**REFERENCES:**


**Disclosure of Interests:** Nao Oguro: None declared. Nobuyuki Yajima: None declared. Yoshiha Miyawaki: None declared. Ryusuke Yoshimi: None declared. Yasuhiro Shimojima: None declared. KEN-EL SADA Speakers bureau: He received speaker’s fees from Glaxo Smith Kline K.K., Grant/research support from: He received a research grant from Pfizer Inc., Keigo Hayashi: None declared. Ken’ya Shidahara: None declared. Natsuki Sakurai: None declared. Chiharu Hidekawa: None declared. Koji Ishii: None declared. Takakori Ichikawa: None declared. Yuichi Ishikawa: None declared. Norikazu Kurita: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1344

---

**AVASCULAR NECROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF LONG-TERM FOLLOW-UP FROM A SINGLE CENTRE**

B. Bulut\(^1\), D. Sahin Eroglu\(^2\), T. M. Turgay\(^3\), G. Kimikli\(^4\), A. Ates\(^5\). \(^1\)Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey; \(^2\)Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey

**Background:** Avascular necrosis (AVN) is a major cause of morbidity and loss of quality of life in systemic lupus erythematosus (SLE) patients. AVN is often diagnosed at advanced stages and treatment options are limited.

**Objectives:** To identify the differences of demographic, clinical, and serological factors in SLE patients with and without AVN, and to investigate associated risk factors of AVN in patients with SLE.

**Methods:** In this single-centre retrospective cohort study, we included 533 SLE patients [86.6% female, mean (standard deviation), (SD)] age at diagnosis 34.6 (14.3) years who fulfilled SLICC 2012 classification criteria. AVN diagnosis was confirmed by radiological imaging techniques in symptomatic patients. To investigate the correlation between maximum daily steroid dose and AVN development, we divided our patients into four groups according to the highest dose of prednisolone used for a month or longer during their follow-up (Group 1: 0-19mg/day, Group 2: 20-39mg/day, Group 3: 40-59mg/day, Group 4:≥60mg/day). Pulse steroid administration was also recorded. Multivariable logistic regression analyses were performed to demonstrate the associated factors with AVN. Clinical parameters found to be related to AVN development in univariable analyses were analyzed both in the sex- and age-adjusted model, and the model including sex, age, time to AVN or last follow-up, immunosuppressive therapy, and steroid dosages (multivariable model). To determine the relation of different steroid groups and pulse steroids with AVN, odds ratios (OR) were calculated in the sex- and age-adjusted model and multivariable model.

**Results:** After a median disease duration of 9.1 years, AVN was detected in 46 (8.6%) patients. There were 85 AVN sites involved, the hips being the most commonly affected (71.7%) (Figure 1). The mean age at SLE diagnosis was significantly younger in the AVN group (mean [SD] 26.8 [11.7] vs. 35.3 [11.4], p<0.001). Fever (21.6% vs. 10.9%), malar rash (52.2% vs. 36.3%), serositis (26.1% vs. 14.6%), renal involvement (65.2% vs. 35.1%) and hemolytic anemia (32.6% vs. 19.3%) were found more frequently in the AVN group compared to non-AVN group, respectively (p<0.05). In the multivariable logistic regression analyses, malar rash was found to be the only clinical feature associated with AVN (OR 2.01, 95% confidence interval [CI] 1.02-3.97). The steroids had an association with AVN development in a dose-dependent manner (Table 1). Pulse steroids did not increase the risk of AVN (Table 1).

**Table 1. Factors associated with avascular necrosis.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR Crude (95% CI)</th>
<th>OR Age-sex adjusted (95% CI)</th>
<th>OR fully adjusted* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No pulse steroids</td>
<td>1.00 (reference group)</td>
<td>1.00 (reference group)</td>
<td>1.00 (reference group)</td>
</tr>
<tr>
<td>Pulse steroids</td>
<td>6.29 (3.35-11.81)</td>
<td>4.86 (2.53-9.37)</td>
<td>1.51 (0.69-3.32)</td>
</tr>
</tbody>
</table>

*In addition to the age at SLE diagnosis and sex, immunosuppressant use, and follow-up duration were also added to the final model.

**Conclusion:** High-dose daily steroid use was associated with an increased risk of AVN in SLE patients. Therefore, to prevent AVN in patients with SLE, the aim should be minimizing the dosage and duration of steroid use as much as possible. Furthermore, we showed that malar rash independently increased the risk of AVN development. Further research is required to explain this finding.

**Figure 1.** Magnetic resonance imaging of avascular necrosis of bilateral femoral heads in a patient with SLE.
SLE development is needed for patients with ITP, particularly those with young age (<40 years), organ bleeding, and ANA positivity (>1:160).

Methods: Of 130 patients with primary ITP, 10 (7.7%) were later diagnosed with SLE during follow-up (median, 30 months [IQR, 15.5–105]). The presence of skin bleeding, organ bleeding, lymphopenia, anemia, and positive antinuclear antibody (ANA) titer (>1:160) were more common among patients who later developed SLE than did those who did not develop SLE. Multivariate analysis showed that young age (<40 years; odds ratio [OR], 8.359 [95% confidence interval (CI), 1.230–56.793]; p = 0.033), organ bleeding (OR, 18.349 [95% CI, 2.771–121.517]; p = 0.003), and ANA positivity (>1:160; OR, 7.692 [95% CI, 1.482–39.910]; p = 0.015) were significantly associated with the development of SLE in patients with primary ITP.

Results: Young age (<40 years), organ bleeding, and ANA positivity (>1:160) were risk factors for the development of SLE in patients with primary ITP. Multivariate analysis showed that young age (<40 years), organ bleeding, and ANA positivity (>1:160) were risk factors for the development of SLE in patients with primary ITP. Multivariate analysis showed that young age (<40 years), organ bleeding, and ANA positivity (>1:160) were risk factors for the development of SLE in patients with primary ITP.

Conclusion: These results suggest that continued follow-up for the detection of SLE development is needed for patients with ITP, particularly those with young age, ANA positivity, or organ bleeding.

REFERENCES:
LUPUS ANTICOAGULANT IS ASSOCIATED WITH PROSPECTIVE ECHOCARDIOGRAPHIC CHANGES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A FIVE-YEAR FOLLOW-UP STUDY


Background: Systemic lupus erythematosus (SLE) is an autoimmune disease with increased risk of cardiovascular complications such as coronary artery disease, myocarditis, pericarditis, and valvular dysfunction (1–3). The pathophysiological mechanisms are poorly understood and markers to identify high-risk patients are warranted.

Objectives: We aimed to identify SLE-characteristics that are associated with progressive cardiac dysfunction.

Methods: A total of 108 patients with SLE (90% female, mean age 46±13 years, median disease duration of 14 (7–21) years) were included from 2013 to 2014. Blood samples were collected with inclusion of biomarkers, and a standard echocardiography was performed at baseline and at a five-year follow-up. Multivariate regression analyses with five independent lupus-specific baseline variables of interest (disease activity, lupus nephritis, anti-cardiolipin and/or anti-beta-2 glycoprotein I antibodies, and lupus anticoagulant (LAC)) were performed for the association with baseline echocardiographic parameters as well as for changes during follow-up.

Results: During the five-year follow-up period, left ventricular (LV) end-diastolic volume index increased from 43.5±13.9 to 52.5±15.7 ml/m² (p <0.001) (Figure 1 A1), and LV diastolic parameters declined (E/A ratio 1.4±0.5 vs. 1.3±0.5, p=0.002; e’ velocity 12.8±3.8 vs. 12.0±3.7 cm/s, p=0.02; mitral valve deceleration time 227.9 vs. 200.8 ms, p<0.001), except for E/e’ (7.5±3.8 vs. 6.8±3.4, p=0.02) (Figure 1B1) in the entire SLE population. LV ejection fraction remained stationary (59.5±6.8 vs. 59.6±6.4 %, p=0.81). Presence of LAC was associated with progressive LV dilatation during the follow-up period (p=0.005) (Figure 1 A2) but not baseline LV volumes (p=0.35). LAC was associated with lower E/A ratio at baseline (p=0.006) but did not predict a decrease of E/A ratio during follow-up (p=0.09) (Figure 1 B2). Follow-up changes of other echocardiographic parameters were not associated with any of the lupus-specific variables.

Conclusion: Presence of LAC was associated with lower E/A ratio at baseline as well as progressive left ventricular dilatation during a five-year follow-up period. Hence, LAC might be a predictor of progressive cardiac dysfunction in SLE patients. LAC is known to have implications for the microvascular circulation, but the clinical significance of the present findings is yet to be elucidated.

REFERENCES:

Disclosure of Interests: None declared

Background: Assessment of organ damage has become the standard outcome measure for morbidity and mortality in patients with lupus over the world including the Russian Federation (RF), Kirgizstan and Kazakhstan.

Objectives: The aim of this study was to compare organ damage of patients with systemic lupus erythematosus in the Russian Federation, Kirgizstan and Kazakhstan in real clinical practice.

Methods: 1102 SLE pts who fulfilled SLICC 2012 criteria were enrolled into the study. Disease activity was evaluated by SLEDAI-2K, while chronic damage was assessed by the Systemic Lupus International Collaborating Clinics Damage Index score (SDI).

Results: A total of 400 patients with lupus (F/M 363:37, mean age 34,2±11,5 years, mean disease duration 106,3±81,9 months) were included. All patients were divided into 4 groups: SLEDAI 2K <4 – 136 pts, SLEDAI-2K ≥4 – 264 pts, SDI =0 – 177 pts, SDI ≥1 – 223 pts.

QOL was assessed by SF-36 and LupusQol was low in all groups of patients with SLE. The mean scores for each of the domains of the LupusQol and SF-36 are shown in Table 1.

It was shown that the domain of pain of the LupusQol questionnaire (p<0.007) statistically significantly responds to disease activity in contrast to the comparable SF-36 scale. The domains MH (p<0.001) and VT (p<0.007) of the SF-36 are more sensitive to change of disease activity.

It was found that in patients with SLE with a high activity of the disease, the noncomparable domains such as Planning (p<0.0004), Intimate relationship (p<0.003), Burden to others (p<0.03), Body image (p<0.007) significantly change. The QOL in patients with SLE with SDI ≥1 was poor in the domain of Physical health of the LupusQol and in the comparable domain of the SF-36 PF. Higher QOL in these domains was in patients without damages. The domains Fatigue and VT are also significantly affected by the damage. So, in patients with SDI ≥1, there was a significant decrease of QOL in these domains up to 60.35±24.0 and 49.55±20.32, respectively, as compared with patients with SLE with SDI =0 – 177, SDI ≥1 – 223 pts.

Conclusion: LupusQol is more sensitive to changes in SLE activity. Both SF-36 and LupusQol are equally sensitive to changes in organ damage.

Disclosure of Interests: None declared


Table 1. Relationship between disease activity, organ damage and health-related quality of life as assessed by LupusQol and SF-36 in 400 Russian patients with systemic lupus erythematosus

<table>
<thead>
<tr>
<th>LupusQol domains</th>
<th>SLEDAI 2K ≤4 Mean (SD)</th>
<th>SLEDAI 2K ≥4 Mean (SD)</th>
<th>P</th>
<th>SF-36 domains</th>
<th>SLEDAI 2K ≤4 Mean (SD)</th>
<th>SLEDAI 2K ≥4 Mean (SD)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical health</td>
<td>70.1±22.1</td>
<td>64.9±23.6</td>
<td>0.07</td>
<td>PF</td>
<td>65.6±28.2</td>
<td>60.6±28.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Emotional health</td>
<td>67.3±24.8</td>
<td>63.2±24.6</td>
<td>0.13</td>
<td>MH</td>
<td>52.2±9.0</td>
<td>49.6±7.8</td>
<td>0.001</td>
</tr>
<tr>
<td>Pain</td>
<td>74.7±23.6</td>
<td>67.5±24.8</td>
<td>0.007</td>
<td>BP</td>
<td>46.3±5.9</td>
<td>47.3±8.4</td>
<td>0.09</td>
</tr>
<tr>
<td>Fatigue</td>
<td>65.7±24.5</td>
<td>65.5±24.8</td>
<td>0.22</td>
<td>VT</td>
<td>55.5±23.3</td>
<td>48.3±3.5</td>
<td>0.007</td>
</tr>
<tr>
<td>Noncomparable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planning</td>
<td>78.1±27.9</td>
<td>60.1±28.0</td>
<td>0.0004</td>
<td>SF</td>
<td>71.0±24.0</td>
<td>71.1±24.1</td>
<td>0.003</td>
</tr>
<tr>
<td>Intimate</td>
<td>78.3±28.7</td>
<td>69.9±31.1</td>
<td>0.003</td>
<td>GH</td>
<td>55.9±18.7</td>
<td>55.9±18.7</td>
<td>0.34</td>
</tr>
<tr>
<td>relationships</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burden to others</td>
<td>61.2±26.8</td>
<td>54.2±28.1</td>
<td>0.003</td>
<td>RE</td>
<td>59.3±42.4</td>
<td>59.3±42.4</td>
<td>0.012</td>
</tr>
<tr>
<td>Body image</td>
<td>71.1±24.7</td>
<td>62.2±28.5</td>
<td>0.007</td>
<td>RP</td>
<td>65.6±28.2</td>
<td>65.6±28.2</td>
<td>0.028</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LupusQol domains</th>
<th>SDI =0 Mean (SD)</th>
<th>SDI ≥1 Mean (SD)</th>
<th>P</th>
<th>SF-36 domains</th>
<th>SDI =0 Mean (SD)</th>
<th>SDI ≥1 Mean (SD)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Comparable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical health</td>
<td>71.2±22.5</td>
<td>63.3±23.1</td>
<td>0.002</td>
<td>PF</td>
<td>69.2±27.4</td>
<td>57.1±28.2</td>
<td>0.0007</td>
</tr>
<tr>
<td>Emotional health</td>
<td>66.3±25.2</td>
<td>63.3±24.3</td>
<td>0.24</td>
<td>MH</td>
<td>50.3±17.9</td>
<td>50.6±8.7</td>
<td>0.6</td>
</tr>
<tr>
<td>Pain</td>
<td>72.3±24.2</td>
<td>68.2±24.8</td>
<td>0.03</td>
<td>BP</td>
<td>47.0±8.4</td>
<td>46.9±9.1</td>
<td>0.84</td>
</tr>
<tr>
<td>Fatigue</td>
<td>65.7±25.3</td>
<td>60.3±24.1</td>
<td>0.03</td>
<td>VT</td>
<td>55.6±20.3</td>
<td>49.5±24.9</td>
<td>0.02</td>
</tr>
<tr>
<td>Noncomparable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Planning</td>
<td>67.7±27.3</td>
<td>60.9±29.1</td>
<td>0.03</td>
<td>SF</td>
<td>64.0±28.0</td>
<td>60.5±26.4</td>
<td>0.21</td>
</tr>
<tr>
<td>Intimate</td>
<td>76.1±28.4</td>
<td>70.6±32.5</td>
<td>0.22</td>
<td>GH</td>
<td>52.7±20.2</td>
<td>47.4±20.1</td>
<td>0.06</td>
</tr>
<tr>
<td>relationships</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burden to others</td>
<td>55.7±28.4</td>
<td>57.4±27.3</td>
<td>0.68</td>
<td>RE</td>
<td>56.2±42.1</td>
<td>46.9±11.8</td>
<td>0.06</td>
</tr>
<tr>
<td>Body image</td>
<td>66.6±27.9</td>
<td>64.1±27.3</td>
<td>0.33</td>
<td>RP</td>
<td>50.5±42.4</td>
<td>39.1±13.1</td>
<td>0.0001</td>
</tr>
</tbody>
</table>
The aim of this study was to determine factors affecting quality of life (HRQoL) for patients with systemic lupus erythematosus (SLE). We conducted this study to compare the efficiency of LupusQoL and SF-36 in 400 Russian patients with systemic lupus erythematosus.

**Objectives:**

- To compare the efficiency of LupusQoL and SF-36 in assessing the health-related quality of life (HRQoL) of 400 Russian lupus patients.
- To investigate the differences in HRQoL between lupus patients in different regions of the Russian Federation.
- To identify factors associated with HRQoL in Russian lupus patients.

**Methods:**

- The study included 400 patients with systemic lupus erythematosus (SLE) from the Russian Federation.
- The SF-36 and LupusQoL questionnaires were administered to participants.
- Data analysis involved descriptive statistics and correlation analysis.

**Results:**

- The mean scores for the 8 domains of the SF-36 were below 50, indicating poor health status.
- The LupusQoL scores were lower than the SF-36 scores, indicating a worse impact on HRQoL.
- The most affected domains were physical functioning and role-physical.

**Conclusion:**

- LupusQoL and SF-36 are equivalent in assessing HRQoL in Russian lupus patients.
- Factors associated with HRQoL include disease activity, quality of life, and patient demographics.

**Disclosure of Interests:** None declared.

The worst HRQoL (Sum LupusQol<20) was associated with older age, duration of illness before verification of SLE diagnosis, unemployed status, high disease activity, organ damage, anxiety and depression (Table 1).

Table 1. Factors affecting quality of life in patients with systemic lupus erythematosus in Lupus Patients from Russian Federation, Kirghizstan and Kazakhstan.

<table>
<thead>
<tr>
<th>Factors</th>
<th>Sum LupusQol&lt;20</th>
<th>Sum LupusQol=60</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, (M±SD)</td>
<td>37.06±12.38</td>
<td>30.09±9.96</td>
<td>0.04</td>
</tr>
<tr>
<td>Duration of illness before verification of SLE diagnosis, month, (M [Lower,Upper Quartiles])</td>
<td>36 [12; 84]</td>
<td>10 [0; 24]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Pregnancy, n (%)</td>
<td>0</td>
<td>71 [114%]</td>
<td>0.002</td>
</tr>
<tr>
<td>Pts without disability, n (%)</td>
<td>30 [32%]</td>
<td>242 [50%]</td>
<td>0.02</td>
</tr>
<tr>
<td>High education, n (%)</td>
<td>38 [41%]</td>
<td>281 [58%]</td>
<td>0.01</td>
</tr>
<tr>
<td>Work, n (%)</td>
<td>33 [33%]</td>
<td>266 [52%]</td>
<td>0.03</td>
</tr>
<tr>
<td>Unemployed, n (%)</td>
<td>46 [49%]</td>
<td>131 [27%]</td>
<td>0.01</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>1.83±1.72</td>
<td>1.09±0.96</td>
<td>0.004</td>
</tr>
<tr>
<td>SLICC damage index, score, (M±SD)</td>
<td>1.10±1.09</td>
<td>0.85±0.74</td>
<td>0.04</td>
</tr>
<tr>
<td>Unemployed, n (%)</td>
<td>46 [49%]</td>
<td>131 [27%]</td>
<td>0.01</td>
</tr>
<tr>
<td>SLEDAI (≥11, n (%))</td>
<td>30 (32%)</td>
<td>19 (4%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

*P <0.05 Mann—Whitney test

Table 2. Clinical and serological characteristics of our cohort (N=79).

<table>
<thead>
<tr>
<th>Patients (N, %)</th>
<th>Age at pregnancy, years (mean ± SD)</th>
<th>Cases</th>
<th>SLE</th>
<th>APS</th>
<th>SLE with secondary APS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>35 ± 3.9</td>
<td>13 (16.5)</td>
<td>5 (6.4)</td>
<td>7 (8.9)</td>
<td>48 (58.1)</td>
</tr>
<tr>
<td></td>
<td>16 (20.3)</td>
<td>36 (45.7)</td>
<td>26 (32.9)</td>
<td>22 (27.8)</td>
<td>65 (82.3)</td>
</tr>
<tr>
<td></td>
<td>11 (13.9)</td>
<td>26 (32.9)</td>
<td>18 (22.8)</td>
<td>14 (17.7)</td>
<td>44 (55.7)</td>
</tr>
<tr>
<td></td>
<td>0.3 ± 0.2</td>
<td>0.2 (0.1-0.2)</td>
<td>0.3 ± 0.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.3 ± 0.2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Concomitant treatment**
- Heparin
- Aspirin
- Immunosuppressants
- Hydroxychloroquine
- Prednisone
- Prednisone dosage (mg/d) (median, IQR)
- 2 (2-5)

**Legend to Table 1:** SD: standard deviation; SLE: Systemic Lupus Erythematosus; APS: antiphospholipid syndrome; LAC: Lupus anticoagulant; aPL: antiphospholipid antibodies; PTX: Pentraxin-3; Abs: antibodies; OD: optical density; IQR: interquartile range.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1573
During the year after vaccination, a decrease in episodes of infections of the lower respiratory tract by more than 3 times was recorded compared with the year preceding immunization (43% and 12.5%, respectively), p=0.0001. Not a single case of recurrent pneumonia was noted (before vaccination - in 5 patients).

The number of infections of the upper respiratory tract has more than halved (19.4% and 8.3%, respectively). In 4 (6.6%) patients, non-severe pneumonia developed within a year after vaccination, all of these patients had risk factors for the development of respiratory infections: anti-B-cell therapy with the absence of an adequate vaccine response (3), intestinal lung damage (1), work activities and home environments associated with an increased risk of viral or bacterial infection (3). After a year of observation, 25 patients were followed up for another 4-5 years, the development of pneumonia was not registered in any case (2 out of 25 had pneumonia in the year prior to vaccination). At the same time, 5 years after vaccination, only 18% of patients had more than a 2-fold excess of the initial anti-pneumococcal antibodies.

Conclusion: Sufficient immunogenicity and clear clinical efficacy of PPV-23 have been demonstrated in SLE patients receiving combined immunosuppressive therapy.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1669

<table>
<thead>
<tr>
<th>Table 1. Respiratory infections in SLE patients at one year before and after vaccination (n=72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory infections</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td>Lower respiratory infections</td>
</tr>
<tr>
<td>Pneumonia, (including recurrent, 2-5 episodes)</td>
</tr>
<tr>
<td>Acute bronchitis</td>
</tr>
<tr>
<td>Exacerbation of chronic bronchitis</td>
</tr>
<tr>
<td>Upper respiratory infections</td>
</tr>
<tr>
<td>Allergic rhinitis</td>
</tr>
<tr>
<td>(Including recurrent)</td>
</tr>
<tr>
<td>Exacerbation of chronic tonsillitis</td>
</tr>
<tr>
<td>Acute otitis media</td>
</tr>
</tbody>
</table>

During the year after vaccination, a decrease in episodes of infections of the lower respiratory tract by more than 3 times was recorded compared with the year preceding immunization (43% and 12.5%, respectively), p=0.0001. Not a single case of recurrent pneumonia was noted (before vaccination - in 5 patients).

The number of infections of the upper respiratory tract has more than halved (19.4% and 8.3%, respectively). In 4 (6.6%) patients, non-severe pneumonia developed within a year after vaccination, all of these patients had risk factors for the development of respiratory infections: anti-B-cell therapy with the absence of an adequate vaccine response (3), intestinal lung damage (1), work activities and home environments associated with an increased risk of viral or bacterial infection (3). After a year of observation, 25 patients were followed up for another 4-5 years, the development of pneumonia was not registered in any case (2 out of 25 had pneumonia in the year prior to vaccination). At the same time, 5 years after vaccination, only 18% of patients had more than a 2-fold excess of the initial anti-pneumococcal antibodies.

Conclusion: Sufficient immunogenicity and clear clinical efficacy of PPV-23 have been demonstrated in SLE patients receiving combined immunosuppressive therapy.

Disclosure of Interests: None declared


AB0486

INFLAMMATORY MUSCULOSKELETAL ABNORMALITIES BY CONTRAST ENHANCED MRI IN SLE PATIENTS

P. Corzo García1, I. García-Duitama2, A. Agustí Claramunt3, I. Carrón Barberà3, S. Marsicò4, J. Monfort5, T. C. Salaman Monte3, 1Hospital Clínic de Barcelona, Rheumatology, Barcelona, Spain; 2Hospital del Mar, Radiology, Barcelona, Spain; 3Hospital del Mar, Rheumatology, Barcelona, Spain

Background: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity1. It has not a valid classification and it is often under-estimated. Subclinical inflammatory musculoskeletal involvement is not well known2.

Objectives: We aim to describe the prevalence of joint and tendon involvement in hand and wrist of SLE patients, either with clinical arthritis, arthralgia or asymptomatic and compare it with healthy subjects using contrasted MRI.

Methods: SLE patients fulfilling SLICC criteria were recruited and classified as follows: group (G) 1: hand/wrist arthritis, G2: hand/wrist arthralgia, G3: no hand/wrist symptoms. Jaccoud arthropathy, CCPa and RF positivity, hand OA or surgery were excluded. Healthy subjects (HS) were recruited as controls: G4: Contrasted MRI of non-dominant hand/wrist was performed. Images were evaluated following RAMRIS criteria extended to PIP. Tenosynovitis score for RA and periarticular areas.

Results: 107 subjects were recruited (G1: 31, G231, G231, G244). Any lesion: SLE patients 74.7%, HS 41.67%; p < 0.002. Synovitis: G1: 64.82%, G2: 51.61%, G3: 45%, G4: 20.83%; p = 0.013. Erosions: G1: 29.03%, G2: 54.84%, G3: 47.62%; G4: 25%; p = 0.066. Bone marrow edema G1: 29.03%, G2: 22.58%, G3: 19.05%, G4: 0.0%; p = 0.046. Tenosynovitis: G1: 38.71%; G2: 25.81%, G3: 14.29%, G4: 0.0%; p = 0.005. Periarticular: G1: 12.90%; G2: 3.23%, G3: 0.0%, G4: 0.0%; p = 0.07.

Conclusion: SLE patients have a high prevalence of inflammatory musculoskeletal alterations by contrasted MRI, even if asymptomatic. Not only tenosynovitis but periarticular is also present.

REFERENCES:

Acknowledgements: This work has been granted by GSK and Societat Catalana de Reumatologia and we want to acknowledge them for their collaboration

Disclosure of Interests: PATRICIA CORZO GARCIA Grant/research support from: GSK and Societat Catalana de Reumatologia and we want to acknowledge them for their collaboration

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1848

AB0487

SJÖGREN SYNDROME: DESCRIPTIVE AND COMPARATIVE STUDY OF PRIMITIVE AND ASSOCIATED FORMS

S. Skhiri1, A. Baya Chatti1, W. Ben Yahia1, A. Atig1, N. Ghannouchi1.

1Farhat Hached Hospital, Internal Medicine, Sousse, Tunisia

Background: Sjögren syndrome (SS) is an autoimmune disease (AID) characterized by a dysfunction of the exocrine glands (mainly salivary and tear glands). It is responsible for xerostomia and xerophthalmia as well as systemic manifestations that may affect multiple organs. This syndrome comes in two forms: primary when it is isolated (pSS) and associated (aSS) when it is in association with another AID whether it is specific of organs or not. These two entities have different particularities, requiring explorations and adapted treatments. Few studies have taken interest in determining them.

Objectives: The objective of this study was to compare the various clinical and evolutionary manifestations of these two forms.

Methods: We conducted a prospective analytical study over a period of 33 years. All patients with SS based on ACR 2012 and/or ACR/EULAR classification
criteria were included. Epidemiological, clinical, para-clinical, therapeutic and
disease course characteristics in both groups were described and compared.

Results: One hundred and forty-five patients were included. Sixty-three (43.4%)
had pSS and 82 (56.5%) had aSS. The pSS group consisted of 58 women (92%)
and five men (8%) with a mean age at diagnosis of 51.9 ±15.3 years.
Seventy-eight women (95%) and four men (5%) with a mean age at diagnosis
of 45.4±16.2 years had a SS. The most common AADs associated with the latter
were SLE (99%) and RA (18.3%). The comparison of the two groups concluded
that the mean age at the time of diagnosis was significantly higher in patients
with pSS (p < 0.01). Glandular involvement was almost constant in both groups.
Joint involvement, skin involvement and Raynaud’s syndrome were significantly
more common in the aSS group (p < 0.01; < 0.001 and 0.02 respectively).
Central neurological involvement was significantly more common in the pSS group
(p<0.04). The other clinical manifestations were comparable in both groups.
Comparison of biological parameters between pSS and aSS showed a statisti-
cally higher frequency of leukopenia (p<0.04), lymphopenia (p <0.001), Anti-
nuclear antibodies (p<0.001), anti SSA antibodies (p=0.003), rheumatoid factor
(p < 0.001) and anti CCP antibodies (p<0.001) in aSS. Synthetic antimalarial
drugs, corticosteroids and immunosuppressive treatment were significantly
more prescribed for aSS (p < 0.003, p < 0.001 and p=0.02 respectively). After a mean
of follow up of 3.4 ±5.5 years for the pSS and 4 ±4.5 years for the aSS. No cases of
lupusyma were observed in both groups.

Conclusion: Differentiating between pSS and aSS is crucial in order to establish
an early diagnosis and ensure adequate management and a better prognosis.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1853

Table 1. Pooled sensitivity and specificities of CRP and PCT

<table>
<thead>
<tr>
<th>CRP</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 10</td>
<td>0.68 (0.48-0.89)</td>
<td>0.70 (0.62-0.77)</td>
</tr>
<tr>
<td>&gt; 10</td>
<td>0.91 (0.86-0.97)</td>
<td>0.87 (0.81-0.93)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.75 (0.57-0.94)</td>
<td>0.72 (0.58-0.85)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PCT</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 0.2</td>
<td>0.66 (0.50-0.81)</td>
<td>0.84 (0.76-0.92)</td>
</tr>
<tr>
<td>&gt; 0.3</td>
<td>0.70 (0.61-0.80)</td>
<td>0.61 (0.50-0.69)</td>
</tr>
<tr>
<td>Overall</td>
<td>0.68 (0.59-0.77)</td>
<td>0.75 (0.59-0.90)</td>
</tr>
</tbody>
</table>

CRP had a pooled sensitivity of 0.75 (95%CI 0.57-0.94) and specificity of 0.72
(0.59-0.85). PCT had a pooled sensitivity of 0.68 (95% CI 0.59-0.77) and speci-
ficity of 0.75 (0.59-0.90), and for ESR pooled estimates were not calculated
due to insufficient data but sensitivity ranged from 50 to 69.8 and specificity from
38.8 to 55.6. Modifying cut-offs improved sensitivities and specificities (see Table 1).
The ESR, CRP, and PCT mean differences were all greater in infection groups
versus non-infection (10.1, 95% CI 3.2-17.0; 46.8, 95% CI 36.5-57.0; 0.53, 95% CI
0.26-0.80; respectively).

Disclosure of Interests: None declared


Table 1. Damage accrual measured by SDI (SDI=0 vs SDI=1)

<table>
<thead>
<tr>
<th>SDI=0</th>
<th>SDI=1</th>
<th>p value</th>
<th>OR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex (%)</td>
<td>88.71%</td>
<td>88.51%</td>
<td>0.367</td>
</tr>
<tr>
<td>Late onset SLE (≤50 years)</td>
<td>6.45%</td>
<td>23.65%</td>
<td>0.003</td>
</tr>
<tr>
<td>Obesity (%)</td>
<td>6.45%</td>
<td>16.89%</td>
<td>0.045</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>24.19%</td>
<td>33.58%</td>
<td>0.001</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>1.61%</td>
<td>7.43%</td>
<td>0.097</td>
</tr>
<tr>
<td>Dyslipidemia (%)</td>
<td>23.58%</td>
<td>45.27%</td>
<td>0.002</td>
</tr>
<tr>
<td>Thrombosis (%)</td>
<td>3.23%</td>
<td>18.24%</td>
<td>0.004</td>
</tr>
<tr>
<td>Serositis (%)</td>
<td>12.90%</td>
<td>27.03%</td>
<td>0.026</td>
</tr>
<tr>
<td>Neuroplas (%)</td>
<td>8.06%</td>
<td>25.00%</td>
<td>0.005</td>
</tr>
<tr>
<td>Glomerulonephritis (%)</td>
<td>14.52%</td>
<td>24.32%</td>
<td>0.114</td>
</tr>
<tr>
<td>Cardiac involvement (%)</td>
<td>15.52%</td>
<td>45.88%</td>
<td>0.003</td>
</tr>
<tr>
<td>DNAnas (%)</td>
<td>56.45%</td>
<td>63.51%</td>
<td>0.338</td>
</tr>
<tr>
<td>Anti-ßm (%)</td>
<td>12.90%</td>
<td>14.86%</td>
<td>0.711</td>
</tr>
<tr>
<td>Anti-Ro (%)</td>
<td>25.68%</td>
<td>46.21%</td>
<td>0.016</td>
</tr>
<tr>
<td>Anti-RNP (%)</td>
<td>11.29%</td>
<td>8.11%</td>
<td>0.463</td>
</tr>
<tr>
<td>Antiphospholipid antibodies (%)</td>
<td>25.81%</td>
<td>54.05%</td>
<td>0.001</td>
</tr>
<tr>
<td>LLDOAS (%)</td>
<td>56.14%</td>
<td>63.51%</td>
<td>0.331</td>
</tr>
<tr>
<td>DOHR (%)</td>
<td>41.38%</td>
<td>66.05%</td>
<td>0.347</td>
</tr>
<tr>
<td>Prednisone (or equivalent) &gt;75</td>
<td>2.94%</td>
<td>12.93%</td>
<td>0.019</td>
</tr>
<tr>
<td>Antimalaria (%)</td>
<td>0.32%</td>
<td>79.73%</td>
<td>0.001</td>
</tr>
<tr>
<td>Bileumab (%)</td>
<td>1.64%</td>
<td>5.41%</td>
<td>0.223</td>
</tr>
<tr>
<td>Death (%)</td>
<td>0.00%</td>
<td>2.03%</td>
<td>0.259</td>
</tr>
</tbody>
</table>
Conclusion: SDI in our SLE-cohort was correlated with age, vascular risk factors, severe organ involvement, aPLs and steroid use. Only antimalarials were associated with a lower mean SDI. SDI increases significantly with longer follow-up time, especially after the fifth year of follow-up. Prevention and early treatment of the aforementioned risk factors could avoid irreversible organ accrual damage in lupus.

REFERENCES:


Disclosure of Interests: None declared, Irene Carrión Barberà: None declared, Salvatore Marsico: None declared, Patricio Corzo García Grant/research support from: GSK, Jordi Monfort: None declared, Anna Agustí Claramunt: None declared, Salvatore Marsico: None declared, Jordi Monfort Grant/research support from: GSK, Tarek Carlos Salman Monté Grant/research support from: GSK.

AB0490
INFLAMMATORY MUSCULOSKELETAL ABNORMALITIES BY CONTRAST ENHANCED MRI SHOW A SPECIFIC PROFILE IN SLE PATIENTS
Hospital Clínic de Barcelona, Rheumatology, Barcelona, Spain; 2Hospital del Mar, Radiology, Barcelona, Spain; 3Hospital del Mar, Rheumatology, Barcelona, Spain.

Background: Joint involvement in SLE is the most frequent manifestation and often it is the first clinical symptom. Despite this, it is not well characterised and demographic, serological and clinicoterapeutic correlations have not been well established.

Objectives: We aim to determine if there is a demographic, clinic or serological profile related to inflammatory joint involvement of hand and/or wrist (sinovitis, bone marrow edema, erosions, tenosynovitis or peritendinitis) confirmed by contrasted MRI in SLE patients.

Methods: Consecutive SLE patients fulfilling SLICC criteria both symptomatic and asymptomatic for joint involvement were recruited. Contrast MRI of non-dominant hand/wrist was performed for joint and tendon evaluation. Socio-demographic, clinicoterapeutic and serological data were collected and statistically analysed along with each MRI abnormality.

Results: 83 subjects were recruited. Erosions and synovitis were more frequent at advanced age (55±12.61 vs 45.06±12.18 years, p=0.001 and 52.78±12.69 vs 44.95±12.49 years, p=0.011). Synovitis is less frequent in patients with renal involvement (6.7% vs 24.3%, p=0.031). No other SLE organ-specific involvement showed statistical correlation. Neither SLE related autoantibodies (ANA, DAnDs, Sm, RNP, Ro, La, antiphospholipid), complement fractions, ESR nor CRP correlated with MRI lesions, except for erosions which showed lower DNAds titers (15.94±49.56 vs 27.23±52.41, p=0.008). Patients with bone marrow edema received more methotrexate (25% vs 6.3%, p=0.033), and those with erosions and peritendinitis received less mycophenolate (5.6% vs 22.9%, p=0.034; 0% vs 12.8%, p=0.026). Patients with synovitis reported higher values in pain NE (6.03±2.57 vs 4.26±2.49, p=0.005; 6.56±1.95 vs 4.75±2.75, p=0.017; 8.60±1.30 vs 4.95±2.55, p=0.001; 8.47±2.72 vs 4.83±3.58, p=0.018) and on their collaboration in fatigue EN (3.22±0.82 vs 1.91±0.84, p=0.035) and patients with tenosynovitis showed worse FSS-9 (61.50±1.73 vs 45.70±16.80, p=0.015) versus patients who did not show these abnormalities by MRI. Patients with synovitis and peritendinitis had a worse HAQ (1.14±0.69 vs 0.75±0.65, p=0.031; 0.19±0.07 vs 0.90±0.69, p=0.018).

Conclusion: SLE patients with joint and/or tendon involvement confirmed by contrast enhanced MRI have a worse HRQoL measured by pain, fatigue and functional disability.

REFERENCES:


Acknowledgements: GSK and Societat Catalana de Reumatologia granted this work and we acknowledge them for their collaboration.

Disclosure of Interests: PATRICIA CORZO GARCIA Grant/research support from: GSK, Irene Carrión Barberà: None declared, Ivan Garcia-Duitama: None declared, Anna Agustí Claramunt: None declared, Salvatore Marsico: None declared, Jordi Monfort Grant/research support from: GSK, Tarek Carlos Salmon Monte Grant/research support from: GSK.

AB0492
INTESTINAL MICROBIOLOGICAL DISORDER CLOSELY ASSOCIATED WITH PERIPHERAL LYMPHOCYTE SUBSETS AND CYTOKINES IN SYSTEMIC LUPUS ERYTHEMATOSUS.
R. Zhai 1,2,3, S. X. Zhang 1,2,3, J. Qiao 1,2,3, S. Song 1,2,3, J. Chen 1,2,3, X. Li 1.
1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2Shanxi Medical University, Academy of Microbial Ecology, Taiyuan, China; 3Shanxi Medical University, Key Laboratory of Cellular Physiology, Taiyuan, China.

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by widespread inflammation and tissue damage in multiple organs[1]. Microbiome is one of environmental factors that has been suggested to contribute to the occurrence and development of SLE[2].

Objectives: This study aims to the understanding of the pathogenesis of SLE from the perspective of intestinal microorganisms and investigate the associations between flora and peripheral lymphocyte subpopulations and cytokines in SLE patients.

Methods: Fecal samples were collected from 96 patients with SLE, and 96 sex- and age-matched healthy controls (HCs). The gut microbiota were investigated via 16s rRNA sequencing and the peripheral T lymphocyte subsets of these participants were assessed by flow cytometry. Indicators of disease activity such as erythrocyte sedimentation rate (ESR), C-reaction protein (CRP), complement C3 and C4 were recorded. Differential abundance analysis was carried out using the edgeR algorithm. The Wilcoxon rank-sum test was used to compare alpha diversity indices, bacterial abundances, and the F/B ratio between groups. R (version 4.0.1) was used for comparative statistics, and pearson’s correlation analysis was used to assess the correlations between the relative abundances of bacterial genera and serum levels of ESR, CRP, C3 and C4 in the samples; correlations with p < 0.05 were considered significant.

Results: The alpha estimators of richness (ACE and Chao 1) were significantly reduced in SLE feces samples compared with those of HCs (p < 0.001). Bacterial diversity estimators, including the Shannon (p < 0.001) and Simpson’s (p < 0.01) indices, were also significantly lower in SLE (Figure 1A-D). The microbial community structures of the SLE and HCs could be separated by unweighted UnFrac-based principal coordinates analysis (PCoA) (R = 0.186, and p = 0.011, Figure 1E). Significant differences in gut microbiota composition between SLE and HCs were found using the edgeR algorithm. Compared with HCs, 24 species of flora were discovered to be distinctly different(p < 0.05). Moreover, there was a significant positive correlation between Tregs and Cytobacterium.
Antiphospholipid syndrome (APS) patients are associated with stress related factors, and can lead to higher mortality rates. Suicidal ideations in SLE/APS patients are mainly caused by anxiety-depressive spectrum disorders provoked by stress factors, so associations with the duration, activity and manifestations of the rheumatic diseases were found. Timely identification and therapy of depressive and anxiety spectrum disorders can prevent suicidal ideations and possible poor outcomes.

**Objectives:** To describe the rates and potential causes of suicidal ideations in SLE and APS patients.

**Methods:** 159 patients (62 with SLE, 49 with SLE and secondary APS, 48 with primary APS (PAPS)), mostly women (120 (75.5%)), were consecutively enrolled in the study. The mean (±SD) age was 37.5 ± 12.2 years. SLE activity was measured by SLEDAI. Suicidal ideations and mental disorders were detected by psychiatrist in semi-structured interview. The severity of mental disorders was measured with MADRS, HADS, PHQ9, PSS10, and quality of life with EQ-5D, LupusQoL. The APS duration was significantly longer in patients with suicidal ideations; no differences in activity, severity and duration of SLE or steroid therapy were found. APS patients with current suicidal ideations compared to patients without them were 2 times more likely to receive rituximab (Table 1).

### Table 1. Description of patients with versus without suicidal ideations.

<table>
<thead>
<tr>
<th>Characteristic, Me [25%; 75%]</th>
<th>With current suicidal ideations (n=16)</th>
<th>Without current suicidal ideations (n=143)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M±SD</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>SLE</td>
<td>5</td>
<td>31.3</td>
</tr>
<tr>
<td>SLE+APS</td>
<td>5</td>
<td>31.3</td>
</tr>
<tr>
<td>APS</td>
<td>6</td>
<td>37.4</td>
</tr>
<tr>
<td>SLE duration, months</td>
<td>156.0 [132.0; 216.0]</td>
<td>84.0 [24.0; 68.0]</td>
</tr>
<tr>
<td>APS duration, months</td>
<td>228.0 [204.0; 348.0]</td>
<td>120.0 [48.0; 180.0]</td>
</tr>
<tr>
<td>MADRS</td>
<td>270.0 [146.5; 315.0]</td>
<td>13.0 [8.0; 18.0]</td>
</tr>
<tr>
<td>HAM-A</td>
<td>18.5 [10.5; 25.5]</td>
<td>15.0 [10.0; 21.0]</td>
</tr>
<tr>
<td>HADS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-depression</td>
<td>7.0 [3.0; 9.0]</td>
<td>3.0 [1.0; 6.0]</td>
</tr>
<tr>
<td>-anxiety</td>
<td>9.0 [5.0; 14.0]</td>
<td>6.0 [3.0; 9.0]</td>
</tr>
<tr>
<td>PHQ-9</td>
<td>12.0 [8.0; 15.0]</td>
<td>6.0 [3.0; 12.0]</td>
</tr>
<tr>
<td>PSS-10</td>
<td>32.7±8.73</td>
<td>27.6±5.50</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>0.56±0.29</td>
<td>0.72±0.22</td>
</tr>
<tr>
<td>Lupus Qol</td>
<td>113.7±24.9</td>
<td>132.0±25.8</td>
</tr>
<tr>
<td>Methylprednisolone intake:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-Current dose, mg/day</td>
<td>10.0 [9.0; 22.5]</td>
<td>10.0 [5.0; 15.0]</td>
</tr>
<tr>
<td>-Cumulative dose, g</td>
<td>16.9 [9.0; 61.2]</td>
<td>72.0 [28.9]</td>
</tr>
<tr>
<td>Rituximab treatment</td>
<td>5</td>
<td>31.2</td>
</tr>
</tbody>
</table>

Conclusion: Suicidal ideations in SLE/APS patients are mainly caused by anxiety-depressive spectrum disorders provoked by stress factors, so associations with the duration, activity and manifestations of the rheumatic diseases were found. Timely identification and therapy of depressive and anxiety spectrum disorders can prevent suicidal ideations and possible poor outcomes.

**Disclosure of Interests:** None declared


---

**AB0494 COMPARISON OF CUTANEOUS SILENT PERIOD PARAMETERS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME WITH THE HEALTHY POPULATION**

Q. Yolcu1, K. Abacar2, O. Kenis-Coskun1, N. Inanc2, E. Karadag-Saygi1, O. H. Gunduz1, 2, *Marmara University, Physical Medicine and Rehabilitation, Istanbul, Turkey; 3Marmara University, Internal Medicine, Division of Rheumatology, Istanbul, Turkey; Marmara University, Physical Medicine and Rehabilitation, Division of Pain Medicine, Istanbul, Turkey*

**Background:** Neurological involvement has a great importance in the clinical spectrum of primary Sjögren’s syndrome (pSS) (1). The presence of small fiber neuropathy (SFN), which cannot be detected in routine electrophysiological examinations, causes the peripheral nervous system involvement to be underestimated in the course of the disease and causes pain-related symptoms in patients that cannot be explained by routine examinations (2). Various methods can be used in the detection of SFN, and cutaneous silent period (CSP) measurement is gaining popularity recently due to its non-invasiveness and practical application (3).

**Objectives:** Evaluating SFN involvement in patients with pSS using CSP and evaluating its relationship with clinical parameters.

**Methods:** A total of 161 patients (96 pSS, 65 healthy controls) were included in the study. CSP duration was measured in semi-structured interview. The severity of mental disorders was measured by MADRS, HADS, PHQ9, PSS10, and quality of life with EQ-5D, LupusQoL. The APS duration was significantly longer in patients with suicidal ideations; no differences in activity, severity and duration of SLE or steroid therapy were found. APS patients with current suicidal ideations compared to patients without them were 2 times more likely to receive rituximab (Table 1).

### Table 1. Description of patients with versus without suicidal ideations.

<table>
<thead>
<tr>
<th>Characteristic, Me [25%; 75%]</th>
<th>With current suicidal ideations (n=16)</th>
<th>Without current suicidal ideations (n=143)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M±SD</td>
<td>n</td>
<td>%</td>
</tr>
<tr>
<td>SLE</td>
<td>5</td>
<td>31.3</td>
</tr>
<tr>
<td>SLE+APS</td>
<td>5</td>
<td>31.3</td>
</tr>
<tr>
<td>APS</td>
<td>6</td>
<td>37.4</td>
</tr>
<tr>
<td>SLE duration, months</td>
<td>156.0 [132.0; 216.0]</td>
<td>84.0 [24.0; 68.0]</td>
</tr>
<tr>
<td>APS duration, months</td>
<td>228.0 [204.0; 348.0]</td>
<td>120.0 [48.0; 180.0]</td>
</tr>
<tr>
<td>MADRS</td>
<td>270.0 [146.5; 315.0]</td>
<td>13.0 [8.0; 18.0]</td>
</tr>
<tr>
<td>HAM-A</td>
<td>18.5 [10.5; 25.5]</td>
<td>15.0 [10.0; 21.0]</td>
</tr>
<tr>
<td>HADS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-depression</td>
<td>7.0 [3.0; 9.0]</td>
<td>3.0 [1.0; 6.0]</td>
</tr>
<tr>
<td>-anxiety</td>
<td>9.0 [5.0; 14.0]</td>
<td>6.0 [3.0; 9.0]</td>
</tr>
<tr>
<td>PHQ-9</td>
<td>12.0 [8.0; 15.0]</td>
<td>6.0 [3.0; 12.0]</td>
</tr>
<tr>
<td>PSS-10</td>
<td>32.7±8.73</td>
<td>27.6±5.50</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>0.56±0.29</td>
<td>0.72±0.22</td>
</tr>
<tr>
<td>Lupus Qol</td>
<td>113.7±24.9</td>
<td>132.0±25.8</td>
</tr>
</tbody>
</table>

Conclusion: Suicidal ideations in SLE/APS patients are mainly caused by anxiety-depressive spectrum disorders provoked by stress factors, so associations with the duration, activity and manifestations of the rheumatic diseases were found. Timely identification and therapy of depressive and anxiety spectrum disorders can prevent suicidal ideations and possible poor outcomes.

**Disclosure of Interests:** None declared

Methods: Patients with a diagnosis of pSS followed in the rheumatology outpatient clinic and healthy volunteers demographically homogeneous with the patient group were included in the study. The CSP responses were recorded over the abductor pollicis brevis muscle in the upper extremity of all participants. The latency and duration values of the responses were obtained. In patient group, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), Hospital Anxiety and Depression Scale (HADS), Short Form-36 (SF-36) questionnaire, Leeds Assessment of Neuropathic Symptoms and Signs (LANSSS) and Central Sensitization Inventory (CSI) were applied for the evaluation of symptom severity, mood, quality of life, presence of neuromyalgia and central sensitization, respectively. Comparison of CSP parameters between patients with pSS and healthy volunteers was determined as the primary outcome measure. The secondary outcome measure was the relationship between CSP parameters and ESSPRI, HADS, SF-36, LANSSS and CSI scores.

Results: A total of 36 patients and 36 healthy controls were included in the final analyses. There was no significant difference between the two groups in terms of demographic data. The mean CSP latency was significantly longer in patients with a mean of 78.18 (±5.71) when compared to a control of mean 67.91 (±6.41) (95% CI: 6.89 - 13.55, p<0.001). Mean CSP duration was also significantly shorter in patients with a mean of 33.40 (±6.93) (95% CI: 9.57 - 15.31, p<0.001). There were no significant differences in CSP parameters (latency and duration, respectively) according to patients neuropathic pain or central sensitization profile (p>0.05 for all analyses). There were significant correlations of CSP parameters with ESSPRI dryness (r=0.469, p<0.004; r=0.553, p<0.001; fatique (r=0.42, p=0.011; r=0.505, p=0.002), pain (r=0.428, p=0.009; r=0.57, p<0.001) subscores and mean ESSPRI score (r=0.631, p<0.001; r=0.749, p<0.001). Significant correlations were not found between CSP parameters and SF-36 scores, other than CSP duration and “pain” subscore (r=-0.395, p=0.017). When the other correlations were investigated there were no significant correlations other than CSP duration and the HADS anxiety score (r=0.27, p=0.02).

Conclusion: As an indicator of CSP measurement, SFN is more common in patients with pSS than in the healthy population. The association with important clinical symptoms of the disease course such as dryness, fatigue, pain and anxiety highlights the importance of detecting small fiber neuropathy.

References:
[2] Birnbaum J, Lalji A, Saed A, Baer AN. Biopsy-Proven Small-Fiber Neuropathy highlights the importance of detecting small fiber neuropathy. Figure 2. Clinical symptoms of the disease course such as dryness, fatigue, pain and anxiety. Figure 1. Levels of uGalectin-9 and uSIGLEC-1 between the groups (uGalectin-9 p=0.180 and uSIGLEC-1 p=0.699) (Table 1). Serum and urine levels of all biomarkers were re-tested in 41 of 63 patients (65%) with active SLE after a median treatment of 8 (5-22.5) months. At the time of the second tests, there was a significant decrease in disease activity as measured by SLEDAI [2 (0-4)] compared to the time of the first tests [10 (6-15.5)]. Comparison of uGalectin-9 levels between the serum at the time of active disease and remission showed a very significant decline (p<0.001) as shown in Figure 1. uGalectin-9, sip-10 and uSIGLEC-1 also decreased after treatment; however, the difference was not statistically significant.

Table 1. Serum and urine levels of biomarkers across study groups.

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Active SLE (n=63)</th>
<th>Inactive SLE (n=30)</th>
<th>Healthy Control (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum uGalectin-9 (ng/ml)</td>
<td>11.73 (752-14.15)</td>
<td>8.66 (751-10.02)</td>
<td>5.61 (4.56-6.6)</td>
</tr>
<tr>
<td>Serum sip-10 (pg/ml)</td>
<td>279.4 (1475-430.3)</td>
<td>173.4 (142.2-247.9)</td>
<td>74.3 (58.8-100.3)</td>
</tr>
<tr>
<td>Serum uSIGLEC-1 (pg/ml)</td>
<td>1812 (1578-213.9)</td>
<td>182.5 (169.9-230.1)</td>
<td>258.3 (179-602)</td>
</tr>
<tr>
<td>Urine uGalectin-9 (pg/mgCre)</td>
<td>8.83 (4.07-18.11)</td>
<td>11.54 (703-15.07)</td>
<td>10.63 (5.55-17.4)</td>
</tr>
<tr>
<td>Urine sip-10 (pg/ml)</td>
<td>34.4 (15-7.93)</td>
<td>20.8 (9.9-53.3)</td>
<td>12.2 (1.8-25.7)</td>
</tr>
<tr>
<td>Urine uSIGLEC-1 (pg/mgCre)</td>
<td>321.3 (236-370.9)</td>
<td>2936 (2473-371)</td>
<td>290 (205-1323.5)</td>
</tr>
<tr>
<td>Urine uGalectin-9 (pg/ml)</td>
<td>51.5 (60-2.72)</td>
<td>11.41 (8.78-19.54)</td>
<td>13.57 (11.72-22.68)</td>
</tr>
<tr>
<td>Urine sip-10 (pg/ml)</td>
<td>73.4 (40.9-136.9)</td>
<td>26.1 (18.1-55.1)</td>
<td>16.4 (5-32.5)</td>
</tr>
</tbody>
</table>

Conclusion: sip-10, uIP-10, uGalectin-9 and uSIGLEC-1 are associated with disease activity in SLE. None is able to discriminate active renal from active extrarenal disease. S. Glukhova et al. in 2020. Two glycocalyx markers were elevated in the active disease group; however, the difference was not statistically significant.

2-glycoprotein 1 (IgG-α2-glycoprotein 1) is a protein associated with interferon signature, and considered as potential biomarkers reflecting disease activity in patients with systemic lupus erythematosus (SLE). The role of antiphospholipid antibodies (aPL) not included in the International Classification Criteria for the verification of APS continues to be discussed. Objectives: To determine the clinical significance of IgG antibody for domain 1 (β2-glycoprotein 1 (IgG-α2-glycoprotein 1)) in patients with APS and SLE.

Methods: The study included 187 patients: 52 - with primary APS (PAPS), 12 with probable APS (proAPS), 59 - with SLE-APS, and 64 - with SLE without APS. The comparison group included 49 patients with various rheumatic diseases (rheumatoid arthritis (RA) (n=10), Behcet's disease (BD) (n=15), systemic sclerosis (SSD) (n=12), pregnant women (n=2), with no previous treatment for SLE or APS.

Disclosure of Interests: None declared

polyomaviruses (n=2) and Buergers’ endarteritis (n=1)) and a control group of 100 relatively healthy people. IgG/IgM-antibodies to cardiolipin (aCL) and IgG/IgM-α2-GP1 were determined by ELISA, and IgG-α2-GP1-D1 - by chemiluminescence assay (CMA) in all patients and controls.

**Results:** IgG-α2-GP1-D1 was detected in 37 (71%) of 52 patients with primary APS (PAPS), in 6 (50%) of 12 patients with probable APS (proAPS), in 42 (71%) of 59 patients with SLE+APS, in 17 (26%) of 64 patients with SLE, in 1 (2%) of comparison group and in none of control group. IgG-α2-GP1-D1 was significantly associated with PAPS and SLE+APS compared with patients with SLE (P=0.0002 and P=0.0001, respectively). IgG-α2-GP1-D1 levels were significantly higher in patients with PAPS, proAPS, SLE+APS, and SLE compared to control group (P < 0.00001, 0.03, < 0.000001, and 0.02, respectively). IgG-α2-GP1-D1 levels were significantly higher in patients with PAPS and SLE+APS compared to patients with SLE (P = 0.001 and P = 0.000005, respectively) and patients from the comparison group (P < 0.05). The frequency of IgG-α2-GP1-D1 positivity was associated with both thrombosis and obstetric pathology - the risk of developing clinical manifestations of APS was 9.69 and 4.19 times higher, respectively. A reliable correlation between antibodies to IgG-α2-GP1-D1 and arterial thrombosis can be traced. Obstetric pathology was detected in 32 of 37 women with a history of pregnancy and all were with IgG-α2-GP1-D1, versus 21 of 32 with negative IgG-α2-GP1-D1 (y2=4,49; P=0.04). Eclampsia/preeclampsia and fetopelvic insufficiency in history was in 19 of 37 women with IgG-α2-GP1-D1, versus 7 of 32 with obstetric pathology but no IgG-α2-GP1-D1 (y2=6,35; P=0.01). The incidence of obstetric pathology was significantly associated with the presence of IgG-α2-GP1-D1 compared to women without these antibodies. Isolated IgG-α2-GP1-D1 positivity was reported in 13 (19%) of 70 aPL-negative patients. Obstetric pathology was present in all 6 (100%) women who had pregnancy in their disease course, and thrombosis in 7 (53%) of 13 patients. Sensitivity and specificity of IgG-α2-GP1-D1 depending on APS and its clinical manifestations are presented in the Table 1.

**Table 1. Sensitivity and specificity of IgG-α2-GP1-D1**

<table>
<thead>
<tr>
<th>Thrombosis</th>
<th>Obstetric pathology</th>
<th>Diagnosis of APS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity (%)</td>
<td>63</td>
<td>58</td>
</tr>
<tr>
<td>Specificity (%)</td>
<td>83</td>
<td>92</td>
</tr>
</tbody>
</table>

**Conclusion:** The frequency of IgG-α2-GP1-D1 positivity was higher in patients with APS compared to patients with SLE without aPL, comparison group and controls (P < 0.05). In 19% of cases, isolated IgG-α2-GP1-D1 positivity was observed. Positive IgG-α2-GP1-D1 levels were significantly associated with thrombotic complications and with obstetric pathology (y2=8.84; P=0.002 and 2=6.35; P=0.01), Specificity of IgG-α2-GP1-D1 for APS and its clinical manifestations (thrombosis and obstetric pathology) was higher than sensitivity.

**The study was performed at the V.A. Nassonova Research Institute of Rheumatology within the framework of the fundamental topic FURS-2022-003.**

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.2329

**AB0497 IMMUNOLOGICAL DISEASE ACTIVITY PARAMETERS AT CONCEPTION ARE RISK FACTORS FOR PRETERM BIRTH AND LOW BIRTH WEIGHT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

H. Shimada1, R. Wakaiia, S. Nakashimaa, M. Kato1, T. Miyagi1, K. Sughiraa, R. Mino1, M. Mizusakia, T. Kamedaa, H. Dobashi1. 1Kagawa University, Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa, Japan

**Background:** Women with systemic lupus erythematosus (SLE) are known to have congenital abnormalities and have a high risk for adverse pregnancy outcomes (APOs) including preterm birth (PB), low birth weight (LBW) (1,2). Many reports revealed that these APOs are strongly associated with negative pregnancy outcomes; PB and LBW. These include low serum C3 and CH50 levels and high anti-dsDNA antibody.

**Objectives:** The purpose of this study was to determine whether disease activity parameters at conception could be a risk factor for PB or LBW among APOs in patients with SLE.

**Methods:** Disease activity parameters including SLEDAI score, LLSDA achievement rate, serum complement levels (C3, C4, CH50), and anti-dsDNA antibody titer were retrospectively collected from medical records. We then collected information related to each APOs (PB and LBW), and analyzed the association with disease activity parameters.

**Results:** The subjects were 60 pregnancies of 45 patients. As for a comprehensive disease activity index at conception, SLEDAI score or the rate of LLSDA achievement became risk factors for PB (both of p<0.01, Table 1), and SLEDAI score was also a risk factor for LBW (P=0.04, Table 1). Analysis of immunological disease activity parameters showed that low C3 or high titer of anti-dsDNA antibody were risk factors for PB (P=0.03 and 0.01, respectively, Table 1). In the logistic regression analysis of PB, the cut-off levels of C3 and anti-dsDNA antibody were 62mg/dl and 5.4 IU/ml, respectively (Figure 1 [1]-A, [1]-D). The risk of PB was significantly higher in the cases with low serum C3 and high anti-dsDNA antibody titer at conception (P=0.02). Similarly, low C3 or CH50 were risk factors for LBW (P=0.02 and 0.03, respectively, Table 1). Logistic regression analysis for LBW showed the cut-off level of C3 as 87 mg/dl, and CH50 as 4.18 IU/ml (Figure 1 [2]-A, [2]-C). Cases with low C3 and low CH50 were at higher risk for LBW (P=0.03).

**Table 1. Association between disease activity parameters and PB or LBW**

<table>
<thead>
<tr>
<th></th>
<th>Preterm birth (PB)</th>
<th>Low birth weight (LBW)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 14)</td>
<td>(n = 46)</td>
</tr>
<tr>
<td>Achievement of LLDAS, n (%)##</td>
<td>5 (41.7)</td>
<td>30 (71.4)</td>
</tr>
<tr>
<td>Achievement of LLDAS without a glucocorticoid dose, n (%)##</td>
<td>5 (41.7)</td>
<td>37 (88.1)</td>
</tr>
<tr>
<td>SLEDAI score##</td>
<td>3.5±2.9</td>
<td>1.1±1.3</td>
</tr>
<tr>
<td>C3, mg/dl</td>
<td>77.3±19.0</td>
<td>94.7±21.2</td>
</tr>
<tr>
<td>C4, mg/dl</td>
<td>16.1±9.0</td>
<td>19.2±6.3</td>
</tr>
<tr>
<td>CH50, IU/ml</td>
<td>37.3±10.6</td>
<td>41.1±8.5</td>
</tr>
<tr>
<td>Anti-dsDNA antibody, IU/ml #</td>
<td>32.5±68.5</td>
<td>5.5±11.1</td>
</tr>
</tbody>
</table>

(Values are presented as mean ± standard deviation or number (%)). "Wilcoxon rank sum test; "Fisher’s exact test; "P < 0.05.)

**Figure 1. Logistic regression analysis of cut-off value of PB and LBW for C3, C4, CH50 and anti-dsDNA antibody. (ROC curves based on logistic regression analysis of cut-off levels for disease activity parameters, including C3, C4, CH50, and anti-dsDNA antibody titer. [1] showed ROC curves for PB, and [2] showed those for LBW.)**

**Conclusion:** We revealed that disease activity parameters of SLE at conception are strongly associated with negative pregnancy outcomes; PB and LBW.
tities. In particular, low serum complement is a risk factor for both PB and LBW. Therefore, it is important to strictly control these disease activity parameters at conception in women with SLE.

REFERENCES:

Disclosure of Interests: None declared

AB0498

CONCENTRATIONS OF ADVANCED GLYcation END PRODUCTS (AGES) CORRELATE WITH INDEXES OF ACTIVITY AND DAMAGE ACCRUAL IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).

I. Carrón Barbera1, L. Trigüer2, L. Tio2, C. Pérez2, L. Poliño1, J. Llorente Onaindia2, A. Ribes2, E. Beltrán1, A. Pros2, M. Ciria Recasens1, J. Monfort1, T. C. Salmon Monte1, Hospital del Mar, Rheumatology, Barcelona, Spain; IMIM, Rheumatology, Barcelona, Spain

Background: It has been postulated that AGES could have a relevant role as inducers in the chronic inflammatory pathway present in various diseases; among them, in immune-mediated diseases such as SLE, as well as that its concentration could be related to some parameters of the disease such as activity or accumulated damage, showing studies discrepant results to date.

Objectives: To describe correlations between the concentrations of AGES measured by cutaneous autofluorescence and various parameters related to the disease in a population of SLE patients.

Methods: AGE concentrations were measured by skin autofluorescence (Age Reader Mu Connect from Diagnoptics Technologies BV) in 66 SLE Caucasian patients and correlations with demographic and clinical data were analyzed, after adjusting for age, smoking and corticosteroids as possible confounding factors, according to previous data. Previous validation studies have shown that skin autofluorescence is strongly related to AGE levels in skin biopsies. The indices were analyzed both as quantitative and categorized variables according to previously established categories or to medians/tertiles/quantiles depending on the distribution of the variable in our population.

Table 1. Descriptive characteristics of the cohort. c: categorized.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Average</th>
<th>SD</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>54</td>
<td>15</td>
<td>68.2</td>
</tr>
<tr>
<td>BMI</td>
<td>25.36</td>
<td>4.68</td>
<td>31.8</td>
</tr>
<tr>
<td>Smoker</td>
<td>No/Yes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGES</td>
<td>2.6</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>16</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>DAS28</td>
<td>2.22</td>
<td>1.16</td>
<td></td>
</tr>
<tr>
<td>cDAS28</td>
<td>remission</td>
<td>71.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>low</td>
<td>9.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>moderate</td>
<td>15.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>high</td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>SLEDAI</td>
<td>5</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>cSLEDAI</td>
<td>remission</td>
<td>21.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>low</td>
<td>16.7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>moderate</td>
<td>51.5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>high</td>
<td>10.6</td>
<td></td>
</tr>
<tr>
<td>SLICC</td>
<td>0</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>cSLICC</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACIT Fatigue Scale</td>
<td>18</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Patient global assessment (PGA)</td>
<td>3.0</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>cPGA</td>
<td>0-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2-3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician global assessment</td>
<td>1.7</td>
<td>1.3</td>
<td></td>
</tr>
<tr>
<td>cPhysician global assessment</td>
<td>0-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual Analogue Scale (VAS)</td>
<td>3.1</td>
<td>3.1</td>
<td></td>
</tr>
<tr>
<td>cVAS</td>
<td>1-4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health Assessment Questionnaire</td>
<td>0.527</td>
<td>0.551</td>
<td></td>
</tr>
<tr>
<td>cHAQ</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0-0.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>&gt;0.75</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticoids</td>
<td>Yes</td>
<td>27.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>72.7</td>
<td></td>
</tr>
</tbody>
</table>

Results: Table 1 shows some descriptive characteristics of our cohort. There were clinically and statistically significant differences in the values of AGES according to the patient’s SLEDAI and SLICC. Specifically, it was observed that AGES’ values in the population with severe activity according to SLEDAI was 0.61 (95% CI 0.85-2.046; p=0.045) points > than in those in remission (p=0.045); as well as AGES’ values in patients with SLICC ≥1 was 1.23 (95% CI 0.49-1.98; p=0.030) points > than in the group without cumulative damage. In all the models, the values of AGES increased significantly with age, smoking and current treatment with corticosteroids, except for the model including the SLICC variable. Interactions in said model were explored, and it was observed that the concentration of AGES depended on the interaction between the value of SLICC and the intake of corticosteroids, so that differences were only observed between SLICC groups in those who took corticosteroids.

Conclusion: A correlation with elevated values of AGES was observed in those SLE patients with higher scores in the indexes of activity (SLEDAI) and damage accrual (SLICC). The fact that the differences in SLICC are only observed in those patients treated with corticosteroids suggests that, maybe, only the accumulated damage related to taking corticosteroids could be mediated by AGES.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2360

AB0499

LYMPHOID ORGANIZATION IN LUPUS NEPHRITIS: EVALUATING POSSIBLE AUTO ANTIGENS

V. A. Pacucci1, F. R. Spinelli1, C. Garufi1, F. Cuccarelli1, S. Colafraancesco2, M. Leopizzo1, C. Alessandri1, F. Conti1 on behalf of Lupus Clinic, Sapienza University of Roma, 1 Sapienza University of Roma, Rheumatology Unit; Department of Clinical, Internal, Anaesthesiologic and Cardiovascular Sciences, Roma, Italy; 2 Sapienza University of Roma, Pathology Unit, Department of Radiological, Oncological, Pathological Sciences, Roma, Italy

Background: Lupus nephritis (LN) represent one of the most frequent organ manifestations and one the major cause of morbidity in Systemic Lupus Erythematosus (SLE) patients. Tubulointerstitial infiltrate (TII) represents an independent prognostic factors of renal outcome.

Objectives: The aim of the study was to evaluate the inflammatory infiltrates organization in kidney biopsies obtained from LN patients and to investigate possible autoantigens for in situ immune response.

Methods: Paraffin embedded kidney specimens collected since 2017 from SLE patients who underwent a renal biopsy for diagnostic purpose were re-evaluated. Clinical, laboratory and histological data were collected in a standardized, computerized and electronically filled form, including demographics and past medical history. Disease activity was assessed by using SLEDAI-2K and in remission in therapy was defined as a score 0 of renal item of the SLEDAI. The cellular infiltrate were assessed by hematoxylin-eosin and by immunohistochemistry with a staining of sequential sections for monoclonal antibodies to CD3, CD20, CD21. Staining for detection of LL37, vimentin and citrulline was made. Serological levels of CXCL13 and anti-vimentin antibodies (AVAs) were evaluated in a subgroup of patients.

Results: Eighteen paraffin embedded renal specimens with TII, from LN patients were re-evaluated (F:M = 17:1, median age at biopsy-SD years 37±23; median disease duration at date of biopsy-IQR 3-4 years). A histo-morphologic grading score was performed based on the total count of TI lymphocytes and the presence of ectopic lymphoid structures-ELSs (grade 3-G3) (Figure 1). A correlation was found between G3 structures and the absence of renal remission with conventional immunosuppressive therapy (P=0.0026). Samples with G3 foci showed significantly higher intensity of LL37 (P=0.013) and LL37 co-localization with vimentin (P=0.006) compared to the other lymphocytic infiltrates. No correlation was found among the intensity of vimentin and citrulline and the grade of lymphoid aggregations. A statistically significant inverse correlation between AVAs serum levels and response to therapy was found (P=0.0048). Moreover, the presence of AVAs and CXCL13 were found in patients with G3 structures. To note, two patients underwent anti-CD20 therapy but renal remission was achieved only in the patients displaying G3 structure.

REFERENCES:
CONCLUSION: The study demonstrated that tubule-interstitium involvement is associated with the presence of lymphoid aggregation and poor renal outcome. For the first time we demonstrated that patients with G3 structures had a significant decreased response to immunosuppressant conventional therapies compared to those without ELSs. These results suggest a possible photogenic, prognostic and therapeutic role of lymphocytic aggregates. In addition, LL37, thus NEToSis, could have a possible role in inducing the formation of lymphocytic structures. Moreover, patients with a G3 foci showed high serological levels of AVAs and CXCL13, thus, promoting their possible role as circulating biomarkers of the presence of ELSs.

REFERENCES:

Disclosure of Interests: None declared


AB0500

THE LEVEL OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH RESPIRATORY TRACT INFECTION AND ITS CLINICAL SIGNIFICANCE

J. Q. Zhang1, S. X. Zhang1, J. Qiao1, M. T. Qiu1, X. Li1. The Second Hospital of Shanxi Medical University, Rheumatology, Taiyuan, China

Background: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder. Infections are a common cause of morbidity and mortality in this patient population[1] and at least 50% of patients with SLE are suffered with infections during the course of their disease[2]. Lymphocytes and Natural killer (NK) cells play an important role in the occurrence and development of SLE[3]. In this study, peripheral blood lymphocyte subsets were detected in these patients, providing reference for early diagnosis and treatment of SLE patients with respiratory tract infection.

Objectives: To analyze the detection level and clinical significance of peripheral blood lymphocyte subsets in patients with SLE with respiratory tract infection.

Methods: A total of 333 SLE patients with no recent infection, 95 SLE patients with respiratory tract infection, and 132 healthy individuals matched in age and sex were enrolled in the second Hospital of Shanxi Medical University from July 2014 to December 2016. The characteristics of lymphocyte subsets in the three groups were compared and receiver operating characteristic (ROC) curves were drawn to analyze the predictive value of lymphocyte subsets in SLE patients with respiratory tract infection.

Results: The counts of T, B, CD4+ T, CD8+ T, NK, Th1, Th2, Th17 and Tregs in SLE non-infection group and SLE infection group were [(1094.235 ± 574.495) / (702.781 ± 432.152), t = -7.169, P < 0.001], [(208.338 ± 210.448) / (177.55 ± 170.256), t = -1.306, P = 0.192], [(523.382 ± 303.498) / (304.075 ± 215.497), t = -5.802, P < 0.001]. The absolute number of these subsets in infected SLE patients is significantly lower than that in uninfected patients, which indicates that the low absolute number of these cells can be used as an indicator of high infection risk in SLE patients. CD4 + T lymphocytes and NK cells in patients with respiratory tract infection are significantly lower, and can play a certain predictive value for SLE respiratory tract infection to a certain extent.

Conclusion: The absolute number of these subsets in infected SLE patients is significantly lower than that in uninfected patients, which indicates that the low absolute number of these cells can be used as an indicator of high infection risk in SLE patients. CD4 + T lymphocytes and NK cells in patients with respiratory tract infection are significantly lower, and can play a certain predictive value for SLE respiratory tract infection to a certain extent.

REFERENCES:

Disclosure of Interests: None declared


AB0501

COMPREHENSIVE ASSESSMENT OF PATIENTS WITH SUSPECTED SJÖGREN’S SYNDROME: 5-YEAR RESULTS OF A MULTIDISCIPLINARY SJÖGREN’S SYNDROME CLINIC

V. C Romão1, 2, M. J. Sousa Bandeira1, 2, M. Silvério-António1, 2, R. Simão3, J. Pinto1, A. I. Gonçalves1, M. J. Gonçalves1, 2, A. L. Martins1, P. José1, G. Coutinho1, I. Moreira Bueno Silva1, M. Brito Lampa2, R. Estevés Marques4, C. Macieira1, N. Khmelinskii1, 2, W. Rodrigues1, F. Salvado1, J. E. Fonseca1, 2
1Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Rheumatology Department, Lisbon, Portugal; 2Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Rheumatology Research Unit, Lisbon, Portugal; 3Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Stomatology Department, Lisbon, Portugal; 4Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre, Rheumatology Department, Lisbon, Portugal.

Figure 1 SYNO textile image

Disclosure of Interests: None declared


Background: Primary Sjögren's syndrome (pSS) is a systemic rheumatic disease that affects several organ systems, most frequently the ocular, oral and musculoskeletal domains. Multidisciplinary care is thus crucial in the optimal management of SS patients.

Objectives: To report the clinical impact of a Multidisciplinary SS Clinic (MSSC) over a 5-year period.

Methods: We prospectively included patients assessed in the MSSC from September 2015 to October 2020. All patients had a full clinical evaluation, including disease-related questionnaires, specialized oral/ocular assessment, salivary gland biopsy (SGB) and ultrasound (SGUS), tear and salivary flow and ocular staining scores. We compared the results of patient-reported outcomes, comprehensive clinical assessments and specialized complementary exams in patients with pSS and other diagnoses.

Results: 445 patients (96% women, mean age 57±14 years) with sicca symptoms underwent complete multidisciplinary evaluation. Patients were most frequently referred from Rheumatology (91%), but also from Stomatology (5%), Ophthalmology (2%), Internal Medicine (1%) and other medical specialties (1%). Most patients were diagnosed with pSS (n=221; 50%), followed by non-Sjögren sicca syndrome (nSSS, n=134; 30%), secondary SS (sSS, n=60; 13%) and other diagnoses (1%).

Conclusion: Multidisciplinary evaluation was crucial in the assessment of patients with similar sicca complaints and in the management of ocular/oral/systemic involvement. Objective measurements and specialized complementary exams greatly contribute to establishing or confirming the diagnosis of pSS.

Disclosure of Interests: None declared


STRESS AS POTENTIAL PATHOGENIC FACTOR IN PRIMARY SJÖGREN'S SYNDROME.

M. Jaskólska, D. Jaskólski, M. Zichiewicz, A. Višč, Z. Zdrojewski, M. University of Gdańsk, Department of Internal Medicine, Connective Tissue Diseases and Geriatrics, Gdańsk, Poland; ³Medical University of Gdańsk, II Department of Orthopedics and Traumatology, Gdańsk, Poland; ²University of Naples Federico II, Medical Faculty, Naples, Italy

Background: Sjögren's Syndrome (SS) is a common autoimmune disorder characterized by infiltration of exocrine glands by autoreactive immune cells that lead to the disease's two most common symptoms — dry eyes and a dry mouth, also known as sicca syndrome. The etiopathogenesis considers the coexistence of genetic predisposition and environmental factors, such as viral infections or sex hormones imbalance.

Objectives: The aim of the study was to determine whether major stressful life events are also risk factors for developing SS.

Methods: We performed a matched case-control study. Cases were patients with an established diagnosis of primary SS (pSS) within the previous five years. Controls were patients with osteoarthritis in whom systemic connective tissue disease has been ruled out. Data on major stressful life events were collected using the modified Holmes-Rahe stress scale. Data were collected for the period of the year before the disease onset.

Results: 100 patients were enrolled in the study (pSS group = 50, control group = 50), mean age was 55.8±10.4 years for pSS and 61.3±9.5 years for control group, in both groups 96% of patients were female. pSS patients had significantly higher on higher Holmes-Rahe stress scale within the preceding 1 year before the onset of disease symptoms than control group (pSS group = 152±63.6 vs control group = 50±54.6; p<0.001). In pSS group 50% of patients reported the subjective impression that the symptoms were caused by stress, while in control group it was 12% (p=0.001). The most frequently mentioned life events in the pSS group were divorce or marital separation, death or change in health of family member and stress related to work.

Conclusion: Patients with pSS are significantly more likely to have had a major stressful life event within the preceding 1 year before the disease onset. The relationship between stress and the occurrence of many diseases and their exacerbations is well documented, especially within autoimmune diseases. Stress is a ubiquitous problem these days, therefore it is of fundamental importance to understand the biological mechanisms underlying its influence on the development of diseases. It is crucial to properly recognize the stressful situation in the patient's life and undertake appropriate interventions in order to prevent health consequences.

Disclosure of Interests: None declared


Table 1. Caucasian vs. Latin American SLE patients

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Caucasian (%)</th>
<th>Latin American (%)</th>
<th>p-value</th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serositis (%)</td>
<td>22.58</td>
<td>26.32</td>
<td>0.712</td>
<td></td>
</tr>
<tr>
<td>Skin involvement (%)</td>
<td>65.59</td>
<td>52.63</td>
<td>0.261</td>
<td></td>
</tr>
<tr>
<td>Arthritis (%)</td>
<td>24.32</td>
<td>52.63</td>
<td>0.008</td>
<td>2.39 (106.3-38)</td>
</tr>
<tr>
<td>AIHA (%)</td>
<td>0.00</td>
<td>5.26</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis (%)</td>
<td>20.97</td>
<td>10.53</td>
<td>0.278</td>
<td></td>
</tr>
<tr>
<td>Neutropenia (%)</td>
<td>18.82</td>
<td>22.11</td>
<td>0.018</td>
<td>2.51 (106-6.02)</td>
</tr>
<tr>
<td>ESRO (%)</td>
<td>3.76</td>
<td>15.79</td>
<td>0.020</td>
<td>4.20 (1.01-17.58)</td>
</tr>
<tr>
<td>Low C3 (%)</td>
<td>54.30</td>
<td>89.47</td>
<td>0.003</td>
<td>1.65 (82.33)</td>
</tr>
<tr>
<td>Low C4 (%)</td>
<td>49.46</td>
<td>84.21</td>
<td>0.004</td>
<td>1.70 (84.34)</td>
</tr>
<tr>
<td>Low vitamin D (%)</td>
<td>11.29</td>
<td>26.32</td>
<td>0.061</td>
<td>2.33 (0.79-8.9)</td>
</tr>
<tr>
<td>High DNAS (%)</td>
<td>61.29</td>
<td>63.16</td>
<td>0.404</td>
<td></td>
</tr>
<tr>
<td>Anti-Sm (%)</td>
<td>12.37</td>
<td>36.84</td>
<td>0.004</td>
<td>2.98 (113-785)</td>
</tr>
<tr>
<td>Anti-Ro (%)</td>
<td>26.34</td>
<td>31.58</td>
<td>0.624</td>
<td></td>
</tr>
<tr>
<td>Anti-SSA (%)</td>
<td>8.58</td>
<td>21.05</td>
<td>0.063</td>
<td>2.11 (0.79-6.66)</td>
</tr>
<tr>
<td>Anti-histones (%)</td>
<td>4.30</td>
<td>21.05</td>
<td>0.003</td>
<td>4.01 (13-277)</td>
</tr>
<tr>
<td>Antiphospholipid antibodies (%)</td>
<td>45.16</td>
<td>12.11</td>
<td>0.009</td>
<td></td>
</tr>
<tr>
<td>Anti-thrombocytopenia (%)</td>
<td>8.71</td>
<td>94.34</td>
<td>0.003</td>
<td>28.69 (1.13-728.60)</td>
</tr>
<tr>
<td>Neutropenia (%)</td>
<td>18.82</td>
<td>22.11</td>
<td>0.018</td>
<td>2.51 (106-6.02)</td>
</tr>
<tr>
<td>Neutropenia (%)</td>
<td>3.76</td>
<td>15.79</td>
<td>0.020</td>
<td>4.20 (1.01-17.58)</td>
</tr>
<tr>
<td>Low C3 (%)</td>
<td>54.30</td>
<td>89.47</td>
<td>0.003</td>
<td>1.65 (82.33)</td>
</tr>
<tr>
<td>Low C4 (%)</td>
<td>49.46</td>
<td>84.21</td>
<td>0.004</td>
<td>1.70 (84.34)</td>
</tr>
<tr>
<td>Low vitamin D (%)</td>
<td>11.29</td>
<td>26.32</td>
<td>0.061</td>
<td>2.33 (0.79-8.9)</td>
</tr>
</tbody>
</table>

AB0503

CLINICAL AND SEROLOGICAL DIFFERENCES BETWEEN CAUCASIAN AND LATINO AMERICAN SLE PATIENTS IN A MULTIELIETHNIC SPANISH SINGLE-CENTER COHORT

J. Álvarez Troncoso, A. Robles Marhuenda, R. Sorriguieta Torre, C. Soto Añaldead, A. Noblejas Mozó, E. Martínez Robles, C. Sánchez Díaz, J. J. Rios, Hospital Universitario La Paz, Autoimmune Diseases Unit. Internal Medicine Department, Madrid, Spain

Background: Systemic lupus erythematosus (SLE) is a highly heterogeneous systemic autoimmune disease with multifaceted manifestations. There are differences in the clinical manifestations and response to treatment among different ethnic groups.

Objectives: To compare clinical and serological characteristics between Caucasian and Latino American SLE patients in a single-center cohort.

Methods: We performed a retrospective cohort study. We included patients with a confirmed diagnosis of SLE according to the American College of Rheumatology classification criteria. We compared demographic data, clinical manifestations, and laboratory results between Caucasian and Latino American patients.

Results: The study included 100 patients: 50 Caucasian and 50 Latino American. The mean age was 35.2±10.4 years for Caucasian and 34.5±10.2 years for Latino American patients. The most common clinical manifestations were arthritis (72% vs. 64%), mucocutaneous lesions (60% vs. 52%), and musculoskeletal pain (54% vs. 48%). The most common laboratory results were elevated antinuclear antibodies (98% vs. 96%), low complement levels (C3 54% vs. 48%, C4 50% vs. 42%), and hypergammaglobulinemia (76% vs. 72%). The prevalence of specific antibodies (anti-dsDNA, anti-Sm, anti-Ro, anti-La) was similar between groups.

Conclusion: There were no significant differences in clinical and serological characteristics between Caucasian and Latino American SLE patients in this single-center cohort. Further research is needed to fully understand the epidemiological and clinical differences among different ethnic groups.

Disclosure of Interests: None declared

disparities in its manifestations conditioned by sex, age of onset, and serological characteristics. The ethnic origin of the patients may be a conditioning factor for different organic manifestations, immunological markers, and outcomes.

Objectives: Our objective was to evaluate the clinical and serological differences in Caucasian vs. Latin American patients in a multiethnic Spanish single-center SLE cohort.

Methods: Single-centre retrospective observational study from a Spanish Lupus Cohort of adult SLE patients fulfilling the 2019 EULAR/ACR Classification Criteria. Only patients of Caucasian or Latin American origin were included.

Results: The study included 205 patients: 186 (90.7%) Caucasian and 19 (9.3%) Latin American. The mean age at diagnosis was 35.5 years. The female/male ratio was 9:1 in the Caucasian group and 19:1 in the Latin American group (ns).

Serious and cutaneous involvement was similar between groups. The presence of arthralgia was also similar (ns) but there were statistically significant differences with the presence of arthritis (p<0.008). Severe hematologic manifestations were also more frequent in Latin American patients but only statistically significant for autoimmune hemolytic anemia (AIHA). Lupus nephritis and end-stage renal disease (ESRD) were two-fold and four-fold more common in Latin American patients. Among the immunological findings: hypocomplementemia, Anti-Sm, and anti-histones were differential markers between the two groups. Anti-RNP was also more frequent in the Latin American group (ns).

Methods: There were also no disparities in outcomes measured by activity (SLEDAI), clinical history. Considering the progression of RF among patients with positive aPLs, the occurrence of flare was retrospectively reviewed from the date of SLE diagnosis to the date of last follow-up. Multivariable Cox regression analysis was conducted to estimate the hazard ratio (HR) and 95% confidence interval (CI) of SLE flare, according to the positivity of autoantibodies. Multivariable model was adjusted for sex, age at SLE diagnosis, positivity of other autoantibodies, SLEDAI-2K at diagnosis, use of immunosuppressants.

Results: Among the 228 patients, flare occurred in 179 (78.5 %) patients during 635.0 person-years of follow-up (incidence rate: 28.2/100 person-years). Of the 179 flares, 92 were severe flares (necessitating use of glucocorticoid dose >20mg of prednisolone or equivalent, and/or addition of immunosuppressants), whereas 87 were mild-to-moderate flares (necessitating use of glucocorticoid dose <20mg of prednisolone or equivalent, and no addition of immunosuppressants). In the multivariable Cox regression analysis, anti-dsDNA Ab positivity (adjusted HR 1.46, 95% CI 1.04–2.05, p = 0.031) and anti-Sm antibody positivity (adjusted HR 1.73, 95% CI 1.16–2.59, p = 0.007) were significantly associated with a higher risk of SLE flares.

Conclusion: Patients with SLE who are positive for anti-dsDNA Ab or anti-Sm Ab at diagnosis have a higher risk of SLE flare during the course of their disease. Careful monitoring of disease activity and prompt adjustment of therapy accordingly could be helpful in these patients.

REFERENCES: Not applicable.

Table 1. Risk of flares according to the positivity of each autoantibodies

<table>
<thead>
<tr>
<th>Autoantibodies</th>
<th>Unadjusted HR (95% CI)</th>
<th>Adjusted HR (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-dsDNA antibody positivity</td>
<td>1.47 (1.09–1.99)</td>
<td>1.46 (1.04–2.05)</td>
<td>0.031</td>
</tr>
<tr>
<td>Anti-Sm antibody positivity</td>
<td>1.52 (1.12–2.07)</td>
<td>1.73 (1.16–2.59)</td>
<td>0.007</td>
</tr>
<tr>
<td>Anti-Ro antibody positivity</td>
<td>1.19 (0.89–1.61)</td>
<td>1.04 (0.71–1.52)</td>
<td>0.836</td>
</tr>
<tr>
<td>Anti-La antibody positivity</td>
<td>1.24 (0.89–1.74)</td>
<td>1.21 (0.83–1.92)</td>
<td>0.278</td>
</tr>
<tr>
<td>Anti-U1RNP antibody positivity</td>
<td>1.19 (0.89–1.60)</td>
<td>0.83 (0.57–1.21)</td>
<td>0.332</td>
</tr>
</tbody>
</table>

*Adjusted for sex, age at diagnosis, positivity of other autoantibodies, SLEDAI-2K at diagnosis, use of immunosuppressants

Acknowledgements: None.

Disclosure of Interests: None declared.


AB0505 RISK OF SYSTEMIC LUPUS ERYTHEMATOSUS FLARES ACCORDING TO THE POSITIVITY OF AUTOANTIBODIES

O. C. Kwon1, 2, M. C. Park1, 2, 3

1Yonsei University College of Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul, Korea, Rep. of (South Korea)

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by excessive production of pathogenic autoantibodies. A variety of autoantibodies can be detected in patients with SLE. Presence of particular autoantibody is known to be associated with specific manifestations of SLE: anti-dsDNA antibody (dsDNA Ab) with renal involvement and overall disease activity, anti-Sm Ab with renal involvement, anti-Ro Ab with cutaneous lupus and neonatal lupus, anti-La Ab with cutaneous lupus and neonatal lupus, and anti-U1RNP Ab with Raynaud’s phenomenon and pulmonary hypertension. However, little is known about the association between positivity of each autoantibody and risk of SLE flare.

Objectives: To assess the risk of SLE flare according to the positivity of various autoantibodies.

Methods: A total of 228 patients with SLE who fulfilled the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE were included. SLE flare was defined as an increase of SLE disease activity index-2000 (SLEDAI-2K) of more than 4 points and/or hospitalization for SLE acute exacerbation in the same year. The occurrence of flare was retrospectively reviewed from the date of SLE diagnosis to the date of last follow-up. Multivariable Cox regression analysis was conducted to estimate the hazard ratio (HR) and 95% confidence interval (CI) of SLE flare, according to the positivity of autoantibodies. Multivariable model was adjusted for sex, age at SLE diagnosis, positivity of other autoantibodies, SLEDAI-2K at diagnosis, use of immunosuppressants.

Results: Among the 228 patients, flare occurred in 179 (78.5 %) patients during 635.0 person-years of follow-up (incidence rate: 28.2/100 person-years). Of the 179 flares, 92 were severe flares (necessitating use of glucocorticoid dose >20mg of prednisolone or equivalent, and/or addition of immunosuppressants), whereas 87 were mild-to-moderate flares (necessitating use of glucocorticoid dose <20mg of prednisolone or equivalent, and no addition of immunosuppressants). In the multivariable Cox regression analysis, anti-dsDNA Ab positivity (adjusted HR 1.46, 95% CI 1.04–2.05, p = 0.031) and anti-Sm antibody positivity (adjusted HR 1.73, 95% CI 1.16–2.59, p = 0.007) were significantly associated with a higher risk of SLE flares.

Conclusion: Patients with SLE who are positive for anti-dsDNA Ab or anti-Sm Ab at diagnosis have a higher risk of SLE flare during the course of their disease. Careful monitoring of disease activity and prompt adjustment of therapy accordingly could be helpful in these patients.

REFERENCES: Not applicable.
AB0506  PRELIMINARY STUDY ON IMBALANCE BETWEEN TH17 AND REGULATORY T CELLS IN ANTIPHOSPHOLIPID SYNDROME

H. Yan1, B. C. Li1, R. Su1, C. Wang1.1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China

Background: Antiphospholipid syndrome (APS) is a typical autoimmune disease, which can be classified into primary antiphospholipid syndrome (PAPS) and secondary antiphospholipid syndrome (SAPS) based on the presence or not of other autoimmune diseases. Disorders of peripheral blood lymphocyte and CD4+T cell subsets, especially Th17 and Treg cell subsets, may be involved in the pathogenesis of APS.

Objectives: To investigate the differences of peripheral blood lymphocyte and CD4+T cell subsets between patients with primary and secondary antiphospholipid syndrome and healthy controls, and to evaluate the correlation of antiphospholipid antibody titers and Th17/Treg values in PAPS and SAPS groups, as well as the correlation of cytokines and clinical characteristics in APS patients.

Methods: A total of 67 APS patients (12 PAPS patients, 55 SAPS patients) and 40 healthy controls were enrolled in this study. Retrospectively collected clinical and laboratory data of these patients. The absolute numbers of peripheral blood lymphocyte subsets and CD4+T cell subsets were detected by flow cytometry, and serum cytokine levels were detected by flow cytometry bead array.

Results: Compared with healthy control group, the absolute values of T [689.26 vs. 1239.00, \( p < 0.001 \)], B (104.69 vs. 177.50, \( p < 0.001 \)), NK (98.97 vs. 300.00, \( p < 0.001 \)) and CD4+T (330.16 vs. 628.50, \( p < 0.001 \)) cells in SAPS group were decreased. While only the NK cells (151.30 vs. 300.00, \( p = 0.002 \)) in the PAPS group were lower than that in healthy control group. However, the absolute values of T (1295.41 vs. 689.26, \( p = 0.011 \)), B (184.44 vs. 104.69, \( p = 0.012 \)), NK (151.30 vs. 98.97, \( p = 0.023 \)) and CD4+T cells (698.34 vs. 330.16, \( p = 0.002 \)) in PAPS group were significantly higher than those in SAPS group. For CD4+T cell subsets, PAPS patients and SAPS patients showed the same trend compared with healthy controls, showing increased Th1 (111.50 vs. 23.47, \( p = 0.002 \) and 71.43 vs. 23.47, \( p = 0.001 \), respectively), decreased Th2 (6.97 vs. 12.43, \( p = 0.037 \) and 2.49 vs. 12.43, \( p < 0.001 \), respectively) and, more importantly, decreased Treg (18.77 vs. 29.53, \( p = 0.001 \), respectively), with increased Th17/Treg ratio (0.39 vs. 0.17, \( p = 0.001 \) and 0.42 vs. 0.17, \( p < 0.001 \), respectively). Meanwhile, Th2 (6.97 vs. 2.46, \( p = 0.006 \)), Th17 (8.42 vs. 4.00, \( p = 0.042 \)) and Treg (18.77 vs. 12.01, \( p = 0.020 \)) cells in PAPS group were higher than those in SAPS group. As for the correlation study, we concluded that both aCL (\( r = 0.6061, p = 0.0405 \)) and aβ2GPI (\( r = 0.6900, p = 0.0158 \)) were positively correlated to Th17/Treg ratio in PAPS group. In addition, for APS patients, IL-2 (\( r = 0.420, p = 0.010 \)), IL-4 (\( r = 0.392, p = 0.016 \)), IL-10 (\( r = 0.331, p = 0.046 \)), IL-17 (\( r = 0.479, p = 0.006 \)) and IFN-γ (\( r = 0.339, p = 0.040 \)) were negatively correlated with titers of aCL. And IL-6 is also associated with ESR (\( r = 0.469, p = 0.004 \)) and CRP (\( r = 0.670, p < 0.001 \)).

Conclusion: Whether PAPS or SAPS patients, detection and balancing of lymphocyte and CD4+T cell subsets, especially Th17 and Treg cell subsets, may help correct immune disorders. Of course, the immune function of primary and secondary APS patients is not completely consistent, at least in terms of immune cells. Also, the role of cytokines in the pathogenesis of APS should not be ignored.

AB0507  IMPACT OF CAFFEINE CONSUMPTION ON ENDOTHELIAL PROGENITOR CELLS SURVIVAL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

V. Ortet1, F. Cecarelli2, C. Barbati2, E. Putro1, C. Pinone1, F. R. Spinelli3, C. Alessandrini1, F. Conti1.1Lupus Clinic, Rheumatology Unit, Sapienza University of Rome, Italy, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, 00161, Italy

Background: Circulating endothelial progenitor cells (EPCs) are widely demonstrated biomarkers of endothelial function. Their frequency and function varied in systemic lupus erythematosus (SLE) patients, with a significant association with subclinical atherosclerosis. Caffeine, one of the most widely consumed products in the world, seems to interact with multiple components of the immune system by acting as a non-specific phosphodiesterase inhibitor, and it seems to be able to activate autophagy. In terms of cardiovascular disease (CVD), data from the literature showed a U-shaped association between habitual coffee intake and CVD. In this view, Spyridopoulos et al. demonstrated a significant improvement in endothelial cells and EPCs migration after coffee consumption in coronary artery disease both in mouse models and in patients. Finally, we demonstrated the impact of caffeine on SLE disease activity, in terms of SLEDAI2k values and clinical characteristics of APS patients.
serum cytokine levels. Moreover, patients with a low caffeine intake seemed to have a more severe disease phenotype.

Objectives: The aim of this study was to evaluate the role of caffeine intake on endothelial function in SLE patients, by assessing its effect on number and function of EPCs both ex vivo in SLE patients and in vitro in healthy donors (HD) treated with SLE sera.

Methods: We performed a cross-sectional study enrolling consecutive SLE patients (revised 1997 ACR criteria), referring to the Sapienza Lupus Clinic. Patients with history of traditional CV risks factors were excluded. Caffeine intake was evaluated using a 7-day food frequency questionnaire. At the end of questionnaire filling circulating EPCs were detected by using a flow cytometry analysis defined as CD34+KDR+ cells. Subsequently, EPCs pooled from 6 HD were co-cultured with caffeine at 0.5 mM and 1 mM with and without SLE sera. After 7 days, we evaluated the cells morpholology and the ability to form colonies. Moreover, we analyzed for the percentage of annexin V-positive (AV) apoptotic cells by flow cytometry analysis and for levels of autophagy and apoptotic markers LC3-II, p62 and Bcl2 by western blot.

Results: We enrolled 31 SLE patients (F:M 30:1, median age 43 years, IQR 18; median disease duration 144 months, IQR 180). The median intake of caffeine was 166 mg/day (IQR 194). We found a EPCs median percentage of 0.03% (IQR 0.04) observing a positive correlation between caffeine intake and EPCs percentage (p=0.03, r=0.4). Moving on in vitro experiments, after 7 days of cell cultures, HD EPCs treated with SLE sera and caffeine showed an improvement in morphology and in number of EPCs-CFU in comparison with those incubated with SLE sera without caffeine (p<0.0003). Moreover, the colonies treated with SLE sera were poorly organized in comparison with HD; the addition of caffeine restored the colony structure. After treated HD-EPCs with SLE sera we observed an increase in AV positive cells and p62 and LC3-II values and a reduction of Bcl2 values; the addition of caffeine was able to significantly reduce AV positive cells and p62 and LC3-II values and to significantly increased Bcl2 values, without any significant differences between caffeine 0.5 mM and 1 mM treatment (Figure 1A-D).

Conclusion: Our data demonstrated the ability of caffeine in increasing the number of circulating EPCs in SLE patients. Moreover, in vitro experiments seem to suggest a protective role of caffeine on EPCs survival and vitality through the promotion of autophagy and the inhibition of apoptosis.

REFERENCES:
[3] Li et al. Theranostics 2018;

Disclosure of Interests: None declared


AB0508 RISK FACTORS FOR DEVELOPMENT OF Atherosclerosis IN SYSTEMIC Lupus erythematosus T. Panfilova1, T. Popkova1, L. Kondrateva1, Y. Gorbunova1, E. Nasonova2. 1V.A.Nasonova Research Institute of Rheumatology, Department of Systemic Rheumatic Diseases, Moscow, Russian Federation; 2V.A.Nasonova Research Institute of Rheumatology, Scientific Department, Moscow, Russian Federation

Background: Systemic lupus erythematosus (SLE) has been strongly linked to accelerated atherosclerosis and increased cardiovascular morbidity and mortality.

Objectives: The goal is to evaluate the traditional cardiovascular risk factors (TRF), intima-media wall thickness (IMT) and cardiovascular events (CVE) in SLE patients as compared to the same-nationality populations.

Methods: This cross-sectional study included 227pts (69% females, aged 35,6±0,7years) with SLE according to SLICC/ACR 2012 criteria, attending a routine visit at our Clinic between February 2018 and February 2020. Carotid plaques were assessed by ultrasound (US). Disease duration was 132,9±7,7months, SLDEDIAI 2K-9,4±0,5, SLICC/DI-1,89±0,13 score. Briefly, 90% had a history of joint involvement, 72%-hematological involvement, 70%-nephritis, 67%-serositis, 64%-skin lesions, 48%-neuropsychiatric involvement. Out of them 82%pts were on prednison therapy at 17,3±1,0mg/day. 41%-on QC, 22%-immuno-suppressants. Forty-one (18%) patients were diagnosed with SLE for the first time and were not receiving therapy at the time of enrollment. Concomitant antiphospholipid syndrome (APS) had 24% of SLEpts: 80% of SLE+APSpts had venous thrombosis, 43%-arterial, 56%-obstetric pathology. The control group (healthy donors) was matched by age and gender (n=99, 79% females, aged 36,2±0,8years).

Results: Patients with SLE compared to controls had a higher incidence of hypertension (52% and 21%,p<0,001), triglyceride concentrations (1,60±0,07 and 0,89±0,09mmol/l,p<0,001), lower levels of high-density lipoprotein (HDL) cholesterol (1,20±0,03 and 1,40±0,04mmol/l,p<0,01) and a higher number of TRF (2,40±0,08 and 2,01±0,13,p<0,05). Following carotid US assessment, atherosclerotic plaques (IMT≥1,5 mm) occurred in 24% of SLEpts versus 5% of controls,p<0,001. SLEpts had hazard ratio (HR) of carotid plaques of 5,22 (95%CI 1,95-13,99). Clinical manifestations of atherosclerosis (CVE) were reported in 19% of SLEpts vs 2% of controls, p<0,001. Out of them coronary artery disease (CAD) was in 13% vs 2%, p=0,002, myocardial infarction (MI)-in 5% vs 1%, p<0,05, stroke – 7% vs 1%, p<0,05. SLEpts had HR of CVE of 9,16 (95%CI 2,26-37,09), of CAD - 6,54 (95%CI 1,59-26,84). In SLEpts carotid plaques were more common than in controls at the age of 30-49 years, p<0,05; clinical manifestations of atherosclerosis occurred after 40 years: CAD - at 40-49 years, stroke - >50 years, p<0,05.

No differences were found in other age groups. Patients were found to correlate CVE with age (r=0,384,p<0,001), male gender (r=0,361,p<0,001), hypertension (r=0,227,p<0,001), body mass index (BMI) (r=0,180,p=0,007), number of TRF (r=0,247,p<0,001), SLE duration (r=0,317,p<0,001), SLICC/DI (r=0,273,p<0,001), steroid use duration (r=0,255,p<0,001) and cumulative prednisolone dose (r=0,163,p<0,05).

Conclusion: The frequency of CVE (CAD, MI) and carotid plaques is higher in patients with SLE than in controls. In patients, CAD and carotid plaques were detected more frequently at the age of 30-49 years than in controls. Hypertension, hypertriglyceridemia and low HDL are the most common TRF in young SLE patients. In SLE, not only TRF and their number are associated with CVE, but also SLE duration, SLICC/DI, steroid use duration and cumulative dose.

Disclosure of Interests: None declared

Background: Ultrasound is a promising non-invasive tool in the evaluation of the salivary glands for parenchymal changes related to Sjogren’s Syndrome (SS). The OMERACT Ultrasound Grey-scale (GS) Scoring System for SS has been shown to have good sensitivity and excellent specificity for fulfilling the SS classification criteria, when a GS ≥2 in at least 1 gland was considered indicative of SS (1), however others have suggested pathology in at least 2 glands is required (2). Systematic use of ultrasound might reduce the need for labial biopsies if US findings are in agreement with biopsies.

Objectives: To assess the agreement between labial biopsy results and salivary gland ultrasound findings in patients suspected of SS.

Methods: Patients referred to our department with a suspicion of SS from 2017-2021, scheduled for a diagnostic labial biopsy were recruited. All underwent GS ultrasound of the parotid and submandibular glands bilaterally prior to clinical exam, Schirmer’s test, unstimulated salivary flow, blood samples including autoantibody analysis. Still images of the four glands were scored 0-3 using a previously developed ultrasound atlas (1) of the OMERACT ultrasound scoring system for SS (2,3). All biopsies were evaluated by a pathologist and focus score ≥1 was considered indicative of SS. Two different ultrasound scores for SS were tested: US-score ≥2 in at least 1 gland and US-score ≥2 in at least 2 glands. Descriptive statistics were used. In these analyses, we used labial biopsy as reference standard.

Results: 103 patients were included and 44 were clinically diagnosed with SS of which 42 (95%) fulfilled the 2016 ACR/EULAR classification criteria and 33 (75%) had positive labial biopsy. Demographics are shown in Table 1.

Table 1. Demographics

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total</th>
<th>Cluster 1</th>
<th>Cluster 2</th>
<th>Cluster 3</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE</td>
<td>57</td>
<td>22</td>
<td>10</td>
<td>25</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>UCTD</td>
<td>25</td>
<td>12</td>
<td>8</td>
<td>5</td>
<td>0.06</td>
</tr>
<tr>
<td>Sjogren’s</td>
<td>15</td>
<td>2</td>
<td>4</td>
<td>9</td>
<td>0.06</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>7</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>0.07</td>
</tr>
<tr>
<td>MCTD</td>
<td>9</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>0.76</td>
</tr>
<tr>
<td>Myositis</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>0.86</td>
</tr>
<tr>
<td>Antibody positivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dsDNA</td>
<td>43</td>
<td>16</td>
<td>11</td>
<td>16</td>
<td>0.33</td>
</tr>
<tr>
<td>Ro60</td>
<td>45</td>
<td>12</td>
<td>7</td>
<td>26</td>
<td>&gt;0.01</td>
</tr>
<tr>
<td>Ro52</td>
<td>36</td>
<td>10</td>
<td>7</td>
<td>19</td>
<td>0.01</td>
</tr>
<tr>
<td>La</td>
<td>18</td>
<td>2</td>
<td>2</td>
<td>14</td>
<td>&gt;0.01</td>
</tr>
<tr>
<td>Sm</td>
<td>14</td>
<td>1</td>
<td>4</td>
<td>9</td>
<td>0.02</td>
</tr>
<tr>
<td>Sm-RNP</td>
<td>23</td>
<td>7</td>
<td>5</td>
<td>11</td>
<td>0.23</td>
</tr>
<tr>
<td>RNP</td>
<td>14</td>
<td>3</td>
<td>5</td>
<td>6</td>
<td>0.64</td>
</tr>
<tr>
<td>SCL-70</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0.37</td>
</tr>
<tr>
<td>Jo-1</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>0.80</td>
</tr>
<tr>
<td>Centromere</td>
<td>5</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>0.08</td>
</tr>
<tr>
<td>Chromatin</td>
<td>29</td>
<td>10</td>
<td>8</td>
<td>11</td>
<td>0.68</td>
</tr>
<tr>
<td>Ribosomal P</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>0.78</td>
</tr>
</tbody>
</table>

The agreement between labial biopsy and ultrasound for SS is shown Figure 1.

Figure 1

Conclusion: In patients with suspected SS, we found good agreement between US of salivary glands and subsequent labial biopsy. US of salivary glands seems useful in the diagnosis and classification of SS, but labial biopsies may still be necessary in select cases.

REFERENCES:

Disclosure of Interests: Viktoria Fana: None declared, Nanna Surleng Schmidt: None declared, Uffe Moller Dohn: None declared, Simon Krabbe: None declared, Lene Terslev Speakers bureau: Novartis, Pfizer, UCB, Janssen and GE

AB0512 COMPARISON OF SALIVARY GLAND ULTRASONOGRAPHY FINDINGS IN PRIMARY SJÖGREN'S SYNDROME VS TYPE 2 DIABETES MELLITUS

A. Kahveci1, A. Gümrüktepe1, Ş. Ataman2, 1Ankara University, Division of Rheumatology, Ankara, Turkey

Background: Primary Sjögren syndrome (pSS) is a chronic autoimmune disease that mainly affects the exocrine glands [1]. Type 2 diabetes mellitus (DM) is also an autoimmune disease involving not only the pancreas but also salivary glands. In both diseases, sicca symptoms due to different mechanisms were common [1, 2]. The use of salivary gland ultrasonography (SGUS) has become widespread in the diagnosis and follow-up of pSS [3, 4]. In DM, few US-based studies have shown abnormalities in the major salivary glands [2].

Objectives: This study aimed to compare the SGUS findings in patients with pSS and DM patients with sicca symptoms (not meet ACR/EULAR pSS criteria) were included. Demographic data and patient characteristics were obtained from medical records. Physical examination was assessed by a rheumatologist. In all patients, bilateral parotid and submandibular gland US was performed by a blinded another rheumatologist, using the Hocevar and the Outcome Measures in Rheumatology (OMERACT) scoring system. Clinic and ultrasonographic variables were compared between groups. The association between SGUS score and disease duration was analyzed by correlation analysis.

Results: Patients with pSS presented higher SGUS scores than patients with DM significantly (the Hocevar total score; 20.93(±9.65) vs 3.82(±3.71); p<0.05, the OMERACT total score; 5.96(±2.30) vs 2.07±1.65; p<0.05, respectively). In patients with pSS, the submandibular gland scores higher than the parotid gland scores while in patients with DM showed higher parotid gland scores. Other demographic data is shown in Table 1. In pSS patients, the Hocevar and the OMERACT total SGUS scores were significantly correlated with disease duration (r=0.584, p<0.01 vs r=0.518, p<0.01, respectively). This correlation was not found in patients with DM (Figure 1).

Table 1. Demographic data and salivary gland ultrasonography scores in pSS and diabetic patients

<table>
<thead>
<tr>
<th></th>
<th>pSS patients(n=32)</th>
<th>DM patients with sicca(n=28)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean(sSD)</td>
<td>53.90(±9.70)</td>
<td>52.25(±7.65)</td>
</tr>
<tr>
<td>Disease duration, mean(sSD)</td>
<td>768.8(±4.01)</td>
<td>846.8(±6.31)</td>
</tr>
<tr>
<td>First symptom, n(%)</td>
<td>51.62%</td>
<td>41.28%</td>
</tr>
<tr>
<td>Sicca</td>
<td>23(71.87%)</td>
<td>20(71.42%)</td>
</tr>
<tr>
<td>Pain, n(%)</td>
<td>70.18%</td>
<td>71.14%</td>
</tr>
<tr>
<td>Anti-Ro positivity, n(%)</td>
<td>22(68.75%)</td>
<td>20(76.18%)</td>
</tr>
<tr>
<td>Unstimulated saliva flow rate ≤0.1 ml/m in at least one eye, n(%)</td>
<td>28(87.5%)</td>
<td>23(82.2%)</td>
</tr>
<tr>
<td>Schirmer’s test(5mm/m in at least one eye, n(%)</td>
<td>30(93.75%)</td>
<td>28(92.45%)</td>
</tr>
<tr>
<td>The Hocevar total SGUS score, mean(sSD)</td>
<td>20.93(±9.65)</td>
<td>3.82(±3.71)</td>
</tr>
<tr>
<td>The OMERACT total SGUS score, mean(sSD)</td>
<td>5.96(±2.30)</td>
<td>2.07±1.65</td>
</tr>
<tr>
<td>right parotid</td>
<td>6.42(±2.73)</td>
<td>1.25(±1.17)</td>
</tr>
<tr>
<td>left parotid</td>
<td>4.34(±2.57)</td>
<td>1.25(±1.08)</td>
</tr>
<tr>
<td>right submandibular</td>
<td>6.06(±3.07)</td>
<td>16.07(±1.41)</td>
</tr>
<tr>
<td>left submandibular</td>
<td>6.31(±2.95)</td>
<td>0.64(±0.43)</td>
</tr>
<tr>
<td>right submandibular</td>
<td>5.96(±2.30)</td>
<td>2.07±1.65</td>
</tr>
<tr>
<td>left submandibular</td>
<td>1.28(±0.77)</td>
<td>0.71(±0.59)</td>
</tr>
<tr>
<td>right parotid</td>
<td>1.21(±0.65)</td>
<td>0.78(±0.62)</td>
</tr>
<tr>
<td>left parotid</td>
<td>1.68(±0.82)</td>
<td>0.44(±0.25)</td>
</tr>
<tr>
<td>right submandibular</td>
<td>1.78(±0.83)</td>
<td>0.47(±0.32)</td>
</tr>
</tbody>
</table>

p<0.05
Figure 1. Correlation between SGUS scores and disease duration in two groups

Conclusion: This study demonstrated that the major salivary gland involvement was more severe, submandibular gland dominant and correlated with disease duration in pSS. Contrarily, in patients with DM, it was mild compared to pSS, parotid dominant and uncorrelated with disease duration.

REFERENCES:

Disclosure of Interests: None declared

AB0513

COVID-19 PREVENTION IN PATIENTS WITH MODERATE-TO-SEVERE LUPUS DURING THE PANDEMIC: RESULTS FROM THE BILAG-BILOGICS REGISTRY (BILAG-BR)

S. Dybá1, M. Rodziewicz2, E. Sutton1, B. Parker3, I. N. Bruce1,2,3

Methods: A cohort where total of 200 subjects (100SLE patients and 100 controls) were enrolled. All patients underwent a thorough medical history and clinical examination. Lupus activity was evaluated by SLEDAI-2K score. Two single-nucleotide polymorphisms (SNPs) (rs10065172 & rs4958846) were genotyped. Genotypes and Alleles analysis were conducted to compare between cases and controls as well as on the stratification analysis of presence or absence of lupus nephritis.

Results: Among selected SNPs of IRGM, no association was considered between both SNPs and SLE susceptibility. For rs10065172, the major expressed genotype was CC (61% and 71%) (Adj OR= 2.9, 95% CI=0.545-15.5) followed by TC (34 % and 27%) (Adj OR= 1.985, 95% CI=0.357-11.041) in cases and controls respectively. For rs4958847 AA and AG were comparably expressed in case (43% &39%) and control (41%&43%) with (Adj OR= 1.24, 95% CI=0.557-2.763) respectively. Additionally, no relation between both SNPs with gender, lupus nephritis, disease activity, or disease duration.

Table 1. SNPs of rs10065172, rs4958847 genotypes and allele frequencies for cases and controls.

<table>
<thead>
<tr>
<th>IRGM</th>
<th>Case</th>
<th>Control</th>
<th>p value</th>
<th>OR</th>
<th>p value</th>
<th>OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs10065172</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>5(5)</td>
<td>2(2)</td>
<td>0.445 0.388</td>
<td>0.252</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC</td>
<td>34(34)</td>
<td>27(27)</td>
<td>0.261 0.707</td>
<td>0.433</td>
<td>0.195</td>
<td>0.537-11.041</td>
</tr>
<tr>
<td>CC</td>
<td>61(61)</td>
<td>71(71)</td>
<td>0.161 1.525</td>
<td>0.211</td>
<td>2.9</td>
<td>0.545-15.5</td>
</tr>
<tr>
<td>rs4958847</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GG</td>
<td>18(18)</td>
<td>16(16)</td>
<td>0.849 0.93</td>
<td>0.835</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AG</td>
<td>39(39)</td>
<td>43(43)</td>
<td>0.565 1.1</td>
<td>0.598</td>
<td>1.24</td>
<td>0.557-2.763</td>
</tr>
<tr>
<td>AA</td>
<td>43(43)</td>
<td>41(41)</td>
<td>0.744 0.921</td>
<td>0.863</td>
<td>1.073</td>
<td>0.469-2.362</td>
</tr>
</tbody>
</table>

1. IRGM: Immunity-related GTPase family M protein
Conclusion: IRGM SNPs (rs10065172 and rs4958846) is not associated with SLE susceptibility in this Egyptian cohort that necessitates further research to evaluate the impact of IRGM autophagy-related gene on lupus.

REFERENCES:

Disclosure of Interests: None declared

AB0515 CARDIOVASCULAR RISK FACTORS ASSESSMENT AND CONTROL IN SYSTEMIC LUPUS ERYTHEMATOSUS

A. Torcato Cartaxo1, N. Carreira2,3, L. Duarte4,5, M. Terenas1, C. Mota3, P. Gaspar2,5

1Hospital Fernando Fonseca, Internal Medicine, Amadora, Portugal; 2Hospital de Santa Maria, Internal Medicine Department II, Lisboa, Portugal; 3Faculty of Medicine, University of Lisbon, Internal Medicine II University Clinic, Lisboa, Portugal; 4Hospital de Santa Maria, Emergency Department, Lisboa, Portugal; 5Instituto de Medicina Molecular (IMM), Cellular Immunology Lab, Lisboa, Portugal

Background: Systemic lupus erythematosus (SLE) is an independent risk factor for cardiovascular disease (1). Studies reporting how cardiovascular risk factors (CVRF) are assessed in clinical practice are scarce.

Objectives: To describe the prevalence of CVRF and characterize the assessment and control of dyslipidaemia and high blood pressure (HBP) in SLE patients.

Methods: Cross-sectional study of all adult SLE patients (SLICC 2012 criteria) followed in a dedicated clinic in 2019. Patients with less than one year of follow-up or less than three in-person visits were excluded. LDL-cholesterol control was defined as desirable (<115mg/dL), ideal (<100mg/dL), and according to the SCORE risk (2) (low, <115mg/dL; moderate, <115mg/dL; high, <100mg/dL; very high, <70mg/dL). Blood pressure (BP) control was defined as desirable (systolic BP [SBP] <130/90mmHg) and ideal (SBP/DBP<130/80mmHg). Data are shown as number (%) and median (interquartile range [IQR]) for categorical and continuous variables respectively. We used statistical tests as needed.

Results: Among 62 SLE patients followed in 2019, 65 met the inclusion criteria (89% female; median age, 52 years; median disease duration, 15 years; median follow-up, 8 years). The median SLEDAI-2K was 2 (0-4). Most patients were on hydroxychloroquine (88%), 43% were on steroids and 31% on other immunosuppressants. Dyslipidaemia was present in 62% of patients, followed by HBP (51%), obesity (n = 9, 14%), and diabetes mellitus (n = 4, 6%). Once-a-year CVRF assessment in the five years prior to the study was performed (CVRF) - 25% among all patients (33% of patients with dyslipidaemia); BP - 9% of all patients (15% of patients with HBP) (Table 1). In the study year, LP was assessed in 69% of all patients and in 85% (34/40) of patients with known dyslipidaemia, with a median LDL-cholesterol of 96 (128-74) mg/dL. Thirty-five (35/40, 88%) patients were under statins and the LP control was desirable, ideal and in line with the SCORE risk in 56%, 53% and 56% of patients, respectively; in the study year, BP was assessed in 32% of all patients and in 39% (13/33) of patients with known HBP, of whom 94% were under antihypertensive drugs. Among these patients (n=13), 69% had desirable and 23% ideal BP control. Steroid treatment regimen prevalence as well as dose (specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). Ann Rheum Dis 2019;78:802-6.

Disclosure of Interests: None declared

AB0516 IN-HOSPITAL MORTALITY IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND ASSOCIATED CLINICAL FEATURES

S. Bowman1, S. Bruera2, S. Agarwal3, 1Baylor College of Medicine, Internal Medicine, Houston, United States of America; 2Baylor College of Medicine, Section of Immunology; Allergy and Rheumatology Houston, United States of America

Background: Patients with systemic lupus erythematosus (SLE) are three times more likely to die from any cause as compared to patients without SLE. This is largely driven by cardiovascular disease, malignancy, and an increased risk of infection. Alarmingly, recent studies have shown that younger patients with SLE are particularly vulnerable to all-cause mortality. However, there is a paucity in knowledge about patient characteristics and specific etiologies of mortality in this population that needs to be described in order to implement strategies to improve outcomes in younger patients with SLE.

Objectives: To identify disease characteristics and etiologies of mortality in young patients with SLE that died while hospitalized.

Methods: A retrospective chart review of a multi-institutional publicly funded health system in Texas, USA was performed. Deceased patients aged 18-49 with a 2019 EULAR/ACR diagnosis of SLE were identified from 2012 to 2021. Patients with mixed connective tissue disease, missing records, or cardiac arrest in the emergency room that did not have a clear etiology of death were excluded. Data was extracted from the electronic medical records by two independent reviewers to determine the most likely cause of death. If there was any discrepancy between the reviewers, this would be resolved by a third-party reviewer. Baseline demographics, disease activity by the SLE disease activity index (SLEDAI), medications, and reasons for prednisone administration were collected.

Results: Twenty-six patients with SLE (age range 22 to 48) that died in the hospital were identified. The most common cause of death was infection (58%) followed by lupus activity (15%). Of those that died of infection, all but one was on a two-month average dose of prednisone ≥10mg. Furthermore, the majority of patients (71%) that were on prednisone doses of ≥10mg had not undergone a prednisone taper within two months (i.e. were on a consistent dose). This was because of either persistent disease activity or poor follow-up.

Conclusion: To our knowledge, this is the first study to describe characteristics of young patients with SLE that died during hospitalization. Our findings show that young patients with SLE primarily die from infection while on increased doses of corticosteroids that have not been tapered. Further research is warranted to determine association and causality of these findings with mortality. Practitioners should remain vigilant and continue to taper steroids as able as this may be a potential source of mortality in young patients with SLE.

REFERENCES:

Table 1. Baseline characteristics of SLE patients that experienced in-hospital mortality.

<table>
<thead>
<tr>
<th>Variable</th>
<th>SLE Cases (n = 26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>20 (77)</td>
</tr>
<tr>
<td>Age, range in years</td>
<td>22 to 48</td>
</tr>
<tr>
<td>Race and Ethnicity, n (%)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>6 (23)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>19 (73)</td>
</tr>
<tr>
<td>Asian</td>
<td>1 (4)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease manifestations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lupus nephritis</td>
<td>18 (69)</td>
</tr>
</tbody>
</table>

Table 1. Prevalence of diagnosis, clinical recognition, drug prescription and control of HBP and dyslipidaemia.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Total (n = 65) Subgroup by disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBP, n (%)</td>
<td></td>
</tr>
<tr>
<td>Clinical assessment</td>
<td>2019</td>
</tr>
<tr>
<td>Annual</td>
<td>6 (9)</td>
</tr>
<tr>
<td>Under treatment</td>
<td>31 (48)</td>
</tr>
<tr>
<td>Control *</td>
<td></td>
</tr>
<tr>
<td>Desirable</td>
<td>17 (81)</td>
</tr>
<tr>
<td>Ideal</td>
<td>10 (48)</td>
</tr>
<tr>
<td>SBP / DBP, mmHg</td>
<td>130 (134-120) / 134 (141-130) / 77 (80-70)</td>
</tr>
<tr>
<td>Dyslipidaemia, n (%)</td>
<td>40 (62)</td>
</tr>
<tr>
<td>LDL, mg/dl</td>
<td>97 (124-74)</td>
</tr>
</tbody>
</table>

*Calculated from the clinical assessment number for each group.
Background: Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease characterized by the secretion of normal autoantibodies that can form immune complexes and cause inflammation of multiple organs. Cardiovascular events and mortality are nearly twice as high in SLE patients as in the general population. (2) In SLE, cachexia plays an important role in rheumatoid arthritis (RA), due to its chronic inflammatory process characterized by decreased muscular mass with preservation or increase of fat that occurs in 1-13% of the RA population. A decreased BMI has a paradoxical relationship with disease activity, with an increase in disease activity and mortality (1). Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of nuclear autoantibodies that can form immune complexes and cause inflammation of multiple organs. Cardiovascular events and mortality are nearly twice as high in patients with SLE as in the general population. (2)

Objectives: To measure the expression of serum zonulin to assess and compare the function of intestinal mucosal barrier in patients with SLE and healthy adults, and to explore the role of intestinal mucosal barrier in the pathogenesis and development of SLE.

Methods: 20 patients with SLE who hospitalized at the Second Hospital of Shanxi Medical University and 10 age and gender-matched healthy adults were enrolled in this study. We collected the blood sample of the patients and healthy controls to examine the function of intestinal mucosal barrier and the absolute number of Th17 and Treg cells. The level of serum zonulin was measured by ELISA to assess the function of intestinal mucosal barrier. The absolute number of Th17 and Treg cells was detected by flow cytometry. Disease activity indicators of patients with SLE were collected from laboratory including erythrocyte sedimentation rate (ESR, mm/h), complement 3 (C3, g/l) and anti-dsDNA (IU/ml). Then we compared the expression of serum zonulin between the patients and healthy controls and analyzed the correlation of serum zonulin with Th17 cells, Treg cells and disease activity.

Results: The level of serum zonulin of SLE group were significantly higher than that of healthy control group (p<0.05). The expression of serum zonulin was positively correlated with the level of ESR (r=0.491, p=0.033) and anti-dsDNA, but was negatively correlated with C3 (r=-0.519, p=0.018). And the expression of serum zonulin was not correlated with the absolute number of Th17 cells and Treg cells (P>0.05), but Th17 cells showed a trend of increasing with the increase of zonulin, while Treg cells showed a trend of decreasing with the increase of zonulin.

Conclusion: The results here showed that the level of serum zonulin,a marker of the intestinal mucosal barrier function, was up-regulated in patients with SLE, and the higher level of serum zonulin was positively correlated with the disease activity of SLE, which indicated that impaired intestinal mucosal barrier function in SLE played an important role in the development of the disease.

Table 1. A summary of baseline demographics of all enrolled patients and healthy controls

<table>
<thead>
<tr>
<th></th>
<th>HC(n=10)</th>
<th>SLE(n=20)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age(years)</td>
<td>44.1±18.8</td>
<td>42±12.384</td>
<td>P=0.76</td>
</tr>
<tr>
<td>Sex(male/female)</td>
<td>2/8</td>
<td>2/18</td>
<td>P=0.47</td>
</tr>
</tbody>
</table>

Results are expressed as the mean ± standard error. Normally distributed continuous variables were analyzed by the independent-samples Student’s t-test.
Results: The mean age of SLE patients was 35.4 ± 12.11 years, rest of demographic characteristics in Table 1. Pearson’s test showed a correlation between BMI and disease activity (r = -0.304, p = 0.020) Image 1. Multivariate analysis found that a decrease in BMI is independently associated with an increase in disease activity assessed by SLEDAI (β = -0.411, 95% CI: -0.819 - -0.003, p = 0.049).

Table 1. Demographic characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>SLE (n=58)</th>
<th>Controls (n=70)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female n (%)</td>
<td>54 (93.0)</td>
<td>64 (91.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Age, years, mean ± SD</td>
<td>35.4 ± 12.1</td>
<td>35.0 ± 12.71</td>
<td>NS</td>
</tr>
<tr>
<td>DM n (%)</td>
<td>2 (3.4)</td>
<td>2 (2.9)</td>
<td>NS</td>
</tr>
<tr>
<td>AH n (%)</td>
<td>12 (20.6)</td>
<td>14 (19.9)</td>
<td>NS</td>
</tr>
<tr>
<td>DLP n (%)</td>
<td>4 (6.8)</td>
<td>3 (4.3)</td>
<td>NS</td>
</tr>
<tr>
<td>Obesity n (%)</td>
<td>4 (6.8)</td>
<td>2 (2.9)</td>
<td>NS</td>
</tr>
<tr>
<td>SLEDAI mean ± SD</td>
<td>8.06 ± 6.4</td>
<td>8.50 ± 6.41</td>
<td>NS</td>
</tr>
<tr>
<td>ANA positivity n (%)</td>
<td>47 (81.0)</td>
<td>57 (81.4)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI mean ± SD</td>
<td>25.0 ± 4.9</td>
<td>27.1 ± 4.91</td>
<td>NS</td>
</tr>
</tbody>
</table>

DM: Diabetes Mellitus; AH: Arterial Hypertension; DLP: Dyslipidemia; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; ANA; Anti-Nuclear Antibodies; BMI: Body Mass Index.

**CONCLUSION**: The results suggest that patients with SLE have increased QRS segment, increased heart rate and decreased QT segment duration, which may be related to disturbances of the conduction system.

**REFERENCES:**


**Disclosure of Interests:** None declared


**AB0520**

**ASSOCIATION BETWEEN LEFT VENTRICULAR MASS INDEX AND BODY WEIGHT IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS**

A. N. Garza-Cisneros, D. Á. Galarza-Delgado, J. R. Azpiri-López, I. J. Colunga-Pedraza, M. A. Balderas-Palacios, A. García-Heredia, N. Guajardo-Jauregui, A. B. Rodríguez-Romero, A. Cárdenas. Universidad Autónoma de Nuevo León, Hospital “Dr. José Eleuterio González”; Rheumatology, Monterrey, Mexico; *Universidad Autónoma de Nuevo León, Hospital “Dr. José Eleuterio González”; Cardiology, Monterrey, Mexico*

**Background:** Rheumatoid cachexia is a clinical spectrum of rheumatoid arthritis in which individuals present increased inflammatory activity, more aggressive joint destruction, and worse cardiovascular prognosis (1). Systemic lupus erythematosus (SLE) is a chronic, inflammatory, autoimmune disease in which there is a high cardiovascular mortality rate (2). Currently, the cachexia phenomenon in SLE patients has not been studied.

**Objectives:** To correlate body weight with left ventricular (LV) indexed mass in SLE patients.

**Methods:** This was a cross-sectional study that included a total of 34 patients aged ≥18 years with a diagnosis of SLE according to EULAR/ACR 2019 criteria. Patients with a personal pathological history of cardiovascular disease (myocardial infarction, stroke, or peripheral arterial disease) and pregnancy were excluded. Three certified cardiologists performed a transthoracic echocardiogram in each patient, assessing relative wall thickness, and indexed LV mass. The distribution was assessed with Kolmogorov-Smirnov. Correlations between weight and echocardiographic parameters with Spearman-rho coefficient. A value of p<0.05 was considered statistically significant.

**Results:** Most patients were female (94.1%), with a mean age of 33.29±9.91. Of the total patients 2 (5.88%) had Type 2 Diabetes Mellitus, 2 (5.88%) hypertension, 1 (2.94%) dyslipidemia, 3 (8.82%) obesity, and 6 (17.64%) smoking. Spearman-rho coefficient showed a significant negative correlation between LV indexed mass and body weight of SLE patients (r=-0.411, p=0.016) (Figure 1).

**Figure 1.** Spearman rho correlation between weight and LV indexed mass.

**Table 1. ECG comparison between SLE and controls.**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients with SLE (n=70)</th>
<th>Controls (n=70)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), median (p25-p75)</td>
<td>35.0 (25.0-50.2)</td>
<td>35.0 (22.7-50.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>63 (90)</td>
<td>64 (91.4)</td>
<td>NS</td>
</tr>
<tr>
<td>QRS (ms), median</td>
<td>89.50 (84.75-95.50)</td>
<td>84.00 (80.00-90.00)</td>
<td>0.012</td>
</tr>
<tr>
<td>QT (ms), mean ± SD</td>
<td>384.44 ± 30.84</td>
<td>397/0 ± 30.21</td>
<td>0.016</td>
</tr>
<tr>
<td>HR (Bpm), mean ± SD</td>
<td>74.77 ± 12.93</td>
<td>68.60 ± 11.25</td>
<td>0.003</td>
</tr>
</tbody>
</table>

ECG: electrocardiogram, SLE: systemic lupus erythematosus, NS: not significant, HR: heart rate, MS: milliseconds, BPM: beats per minute.
Conclusion: There is a negative correlation between body weight and LV indexed mass in SLE patients, this suggests that a lower body weight may be related to higher LV mass, which may result in LV hypertrophy and increased cardiovascular morbidity and mortality.

REFERENCES:

Disclosure of Interests: None declared

AB0521 PERICARDITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: CHARACTERISTICS, MANAGEMENT, EVOLUTION AND PREDICTIVE FACTORS FOR RELAPSE. A MONOCENTRIC RETROSPECTIVE STUDY.


Background: Pericarditis is frequent in Systemic Lupus Erythematosus (SLE) and usually benign. Dedicated studies are scarce. However, recurrences can lead to repeated steroid prescriptions and further immunosuppression. The best management, including the potential benefit of colchicine, remains to be determined.

Objectives: The aim of this study was to describe management, evolution over time and risk factor for relapse in SLE pericarditis in our University Hospital Center.

Methods: Cases were retrospectively collected among hospital discharge data (coding code “SLE” and “pericarditis”), from January 1997 to December 2019. All SLE cases met the ACR/EULAR 2019 classification criteria. Pericarditis cases met ESC 2015 diagnosis criteria. Patients with conditions other than lupus known to cause pericarditis were excluded as well as patients with myocarditis. A minimal follow-up of one year after pericarditis diagnosis was mandatory. Relapse-free survival was described using an actuarial survival model.

Results: Among 103 patients identified in the database, 29 patients (women: n=25; mean age 30 +/- 13 years) were included. Median follow-up was 7 years (range: 1-22).

Description of first episodes: 31% (n=9) were inaugural of SLE; otherwise, median time elapsed since SLE diagnosis was 65 months (1-400). Fifty-five percent (n=16) of first episodes occurred during a multi-systemic lupus flare. Median SLEDAI-2K was 9 [range: 4-30]; clinical symptoms and signs were typical chest pain (93%, n=27), dyspnea (55%, n=16); pericardial rub (31%, n=9), fever (38%, n=11). EKG was abnormal in 59% of the cases (n=17). When present, 79% of effusions (n=17) were circumferential, 82% (n=18/22) were mild to moderate (<20mm), and 25% (n=7) were dry pericarditis. Two Cardiovascular Magnetic Resonance imaging were performed and were pathological.

Biological data showed always high CRP levels (65mg [range: 7-460]), high-titer anti-DNA (79%, n=19) but few patients had low complement levels (C3 21% (n=4/19), C4 26%(n=5/19)).

Prescribed drugs were non-steroidal anti-inflammatory drugs/ acetylsalicylic acid (NSAIDs/ASA) (41%, n=12), corticosteroids (66%, n=19; mean daily prednisone dose: 57±2mg +/- 13.9), colchicine 0.5 to 1mg/day (41%; n=12). There was a significant difference in SLEDAI-2K values at pericarditis onset between those treated with NSAIDs/ASA (7.5, [range: 0-16]) and those not (12, [range: 4-30]), (p=0.05). Only 41% (n=9) of colchicine prescriptions lasted at least 3 months; they were associated with a lower SLEDAI-2K at pericarditis onset compared to pericarditis not or insufficiently treated with colchicine (respectively, 7 [range: 4-9] and 11 [range: 4-30], p=0.04). Immunosuppressive drugs were prescribed in 17% (n=3) of the patients, always due to extra-pericardial involvements.

Recurrences were frequent (55%, 16 patients out of 29) and multiple (1 to 6, average 3 ± 1.26). Short and long-term relapse-free survival tended to be better in patients exposed to at least 3 months of colchicine (100% vs 75% at 1 year, p=0.09) (Figure 1). There was no statistical difference (p=0.25) in terms of short-term relapse-free survival in patients treated with NSAIDs/ASA compared to those who were not. Corticosteroid prescription and previous antimalarial treatment were not associated with a poorer or better outcome during the year following remission (p=0.78). No patient has progressed to constriction.

Conclusion: Our conclusions are limited due to the small number of patients and lack of multivariate analysis.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3486

AB0522 EARLY DAMAGE AS MEASURED BY THE DAMAGE INDEX FOR ANTIPHOSPHOLIPID SYNDROME (DIAPS) IS NOT A PREDICTOR OF MORTALITY IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME

1Hospital de Santa Maria, Internal Medicine Department II, Lisboa, Portugal; 2Instituto de Medicina Molecular (IMM), Cellular Immunology Lab, Lisboa, Portugal; 3University College London, Centre for Rheumatology, London, United Kingdom; 4University College London Hospitals NHS Foundation Trust, Department of Haematology, London, United Kingdom; 5University College London, Haemostasis Research Unit, London, United Kingdom; 6University College London Hospitals Nhs Foundation Trust, Department of Rheumatology, London, United Kingdom

Background: Antiphospholipid syndrome (APS) patients experience damage accrual (1) but correlation with mortality is rarely reported. In systemic lupus erythematosus (SLE), early damage accrued in the first year of disease is a predictor of mortality (2).

Objectives: To determine whether damage accrued within the first year after APS onset as measured by the Damage Index for APS (DIAPS) predicts mortality.

Methods: Single-centre retrospective analysis of thrombotic APS patients (2006 Sydney criteria). The disease onset was determined as the first thrombotic event related to APS was diagnosed. Annual DIAPS assessments were determined for each patient. Early damage was considered to be a score ≥1 at the initial assessment (six months). DIAPS is shown as median (interquartile range [IQR]). Survival was analysed by the Kaplan-Meier method. Cox regression analysis was performed to investigate predictors of mortality.

Results: A total of 197 patients (71.1% female; 65.9% primary APS; 72.4% Caucasian) with a median age at APS onset of 40 years (IQR 51 - 28) were followed for up to 43 years (median 10 years). Cumulative damage developed
in 143 (73.6%) patients with a median DIAPS of 1 (IQR 2 – 0) at the last visit. Early damage was present in 69 (35.0%) patients. Patients with early damage had similar sex distribution (p=0.735), age at disease onset (p=0.526) and median time of follow-up (p=0.181) comparing to those without early damage. Secondary APS (SAPS) (odds ratio [OR] 1.89, 95% CI 1.03 – 3.48, p=0.041) and having a first arterial event (OR 7.24, 95% CI 3.74 - 14.03, p<0.001) were associated with early damage. Twenty-three patients (11.7%) died. SAPS (p=0.009), male sex (p=0.008) and age at onset ≥40years (p=0.001) were risk factors for death (Table 1). Early damage was not associated with death (hazard ratio [HR] 1.65, 95% CI 0.73 - 3.78, p=0.231; Figure 1: survival curve) even after adjusting individually for APS category (secondary, p=0.446), sex (male, p=0.374), age at onset ≥40years (p=0.115) and type of event (arterial, p=0.555).

Table 1. Predictors of mortality.

<table>
<thead>
<tr>
<th></th>
<th>Crude analysis</th>
<th>Adjusted analysis†</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>Male sex</td>
<td>3.14 (1.35 – 7.33)</td>
<td>0.008</td>
</tr>
<tr>
<td>Age at APS onset ≥ 40 years</td>
<td>5.34 (1.9 – 14.53)</td>
<td>0.001</td>
</tr>
<tr>
<td>Caucasian</td>
<td>0.95 (0.35 – 2.57)</td>
<td>0.918</td>
</tr>
<tr>
<td>Secondary APS</td>
<td>3.07 (1.32 – 7.12)</td>
<td>0.009</td>
</tr>
<tr>
<td>First event (arterial)</td>
<td>1.85 (0.79 – 4.27)</td>
<td>0.151</td>
</tr>
<tr>
<td>Early damage</td>
<td>1.65 (0.73 – 3.78)</td>
<td>0.231</td>
</tr>
</tbody>
</table>

† In this column, we present the Early Damage hazard ratio and 95% confidence intervals for death adjusted for the variable in each row. Statistically significant values are presented in bold. APS, antiphospholipid syndrome; CI, confidence interval; DIAPS, Damage Index for Antiphospholipid Syndrome; HR, hazard ratio.

Conclusion: Unlike SLE, early damage accrual accessed by DIAPS is not a predictor of mortality regardless of the nature of the thrombotic event, gender, APS category and age at APS onset.

REFERENCES:

Disclosure of Interests: Pedro Gaspar: None declared, Filipa Farinha: None declared, Zara Sayar: None declared, Maria Effthymiou: None declared, Hannah Cohen Speakers bureau: Honoraria for lectures from Bayer Healthcare (outside the submitted work). Consultant of: Consultancy fees from UCB Biopharma paid to University College London Hospitals Charity (outside the submitted work), David Isenberg: None declared

AB0523 THE ENTEROTYPES OF THE GUT MICROBIOTA IN CHINESE POPULATION WITH AUTOIMMUNE DISEASE

M. J. Chang1,2,3, S. X. Zhang3,4, J. Qiao3,4, C. Wang2,3, H. R. Chen1, T. Huang1, Q. Yu1, P. F. He1,2,3,4,5. Shanxi Medical University, School of Management Shanxi Medical University, Key Laboratory of Cellular Physiology, Tai Yuan, China; 6Shanxi Medical University, Academy of Microbial Ecology, Tai Yuan, China; 7Shanxi Medical University, Department of Rheumatology, Tai Yuan, China; 8Shanxi Medical University, School of Basic Medical Sciences, Tai Yuan, China; 3Shanxi Medical University, Medical Data Sciences, Tai Yuan, China

Background: An increasing number of autoimmune disorders (AD) have been associated with microbial dysbiosis1,2. However, this dysbiosis is difficult to characterize for individual patients owing to the high heterogeneity of the gut microbiota. Thus, researchers must find an accurate method of characterizing the AD gut microbiota that is meaningful to clinical diagnosis.

Objectives: The aim of this study was to investigate the enterotype characters of intestinal flora in AD and their associations with peripheral lymphocyte subpopulations and cytokines.

Methods: A total of 339 AD patients and 339 age- and sex-matched healthy controls (HCs) were enrolled in this study. Mathematical modeling using Dirichlet multinomial mixtures (DMM) was applied to describe the variability in the microbiome data and cluster samples into enterotypes. The peripheral lymphocyte subsets were detected by flow cytometry and the cytokines were assessed by ELISA. Differential abundance analysis was carried out the STAMP software. R (version 4.1.0) was used for comparative statistics, and spearman’s correlation analysis was used to assess the correlations between the relative abundances of bacterial genera and clinical variables.

Results: Laplace approximation of DMM suggested gut microbiota of AD patients and HCs both can be divided into two distinct enterotypes (Figure 1 A-B), and AD E1 and HC E1 were primarily dominated by Prevotella while AD E2 and HC E2 by Bacteroides. Interestingly, the Prevotella-enriched enterotype (AD E1 and HC E1) had a higher alpha diversity than The Bacteroides-enriched enterotype (AD E2 and HC E2). Patients with AD always had a lower richness and diversity compared with those of HCs in each enterotype (p<0.001), suggesting gut microbiome was markedly less diverse in composition in AD. Bray curtis distance-based beta-diversity were also different (P<0.001, ANOSIM.R =-0.23, Figure 1 C-H). Significant differences in gut microbiota composition at the genus level between AD patients and HCs were found using the STAMP software in each enterotype. Compared with HCs, 37 species in AD E1 patients and 40 species in AD E2 patients of flora were discovered to be distinctly different. In the co-upregulated flora of both enterotypes, Lactobacillus was inversely associated with a variety of lymphocytes such as T, CD4+T, NK, Th2, Th17, Treg cells(P<0.05), and positive correlation with IL-10 and IFN-γ(P<0.05,Figure 1 J). However, in the co-downregulated flora of Coprococcus had a positive correlation with B, NK and Treg cells, and anaerostipes had a negative correlation with IL-2 and IL-4(P<0.05,Figure 1 J).

Conclusion: There were both two enterotypes in patients and HCs with autoimmune disease, E2 exhibited a loss of Prevotella but a growth of Bacteroides, with IL-2 and IL-4(P<0.05), and positive correlation with IL-10 and IFN-γ(P<0.05,Figure 1 J).

REFERENCES:
Methods: A cross sectional study was conducted recruiting consecutive patients with pSS without history of gout. SUA was measured upon recruitment alongside the assessment of disease activity (EULAR Sjögren’s syndrome disease activity index, ESSDAI and ClinESSDAI), patient reported symptoms (EULAR Sjögren’s syndrome patient reported symptoms, ESSPRI), CV risk factors including hypertension and diabetes among others, and previous CV events. Dietary habits were also explored with various food frequency questionnaires.

Results: One hundred and three patients with pSS were enrolled. SUA levels ranged between 2.9 and 6.8 mg/dL and, according to the cut-off values of the URRAH study, 16 (16%) patients had SUA levels >4.7 mg/dL while 5 (5%) had SUA levels >5.6 mg/dL. Patients with SUA levels >4.7 mg/dL were more likely males (20% vs 3%) with a higher number of CV risk factors compared to patients with SUA levels <4.7 mg/dL. No differences were observed regarding dietary habits across groups. Disease activity assessed with both ESSDAI and ClinESSDAI was significantly higher in patients with SUA levels >4.7 mg/dL compared to patients with SUA levels <4.7 mg/dL. The disease activity assessed with both ESSDAI and ClinESSDAI was significantly higher in patients with SUA levels >4.7 mg/dL compared to patients with SUA levels <4.7 mg/dL. Conversely, patient reported symptoms (total ESSPRI and individual VAS scales for total dryness, xerostomia, xerophthalmia, pain and fatigue) did not differ across groups. Logistic regression analysis confirmed the association of SUA values >4.7 mg/dL and a higher number of CV risk factors (OR 2.8; 95% CI: 1.2-6.5; p=0.016).

Conclusion: Accumulating evidence highlights the emerging role of hyperuricemia as an independent CV risk factor, but no data are available in pSS patients. This is the first study demonstrating that SUA levels >4.7 mg/dL correlate with both a higher number of CV risk factors and a higher disease activity in pSS patients. Large interventional studies are needed to clarify the possible benefits of urate-lowering treatments in pSS patients.

REFERENCES:

Disclosure of Interests: None declared

AB0524
RELATIONSHIP BETWEEN SERUM URIC ACID, CARDIOVASCULAR RISK AND INFLAMMATORY STATUS IN PRIMARY SJÖGREN’S SYNDROME
A. Alunno1, F. Carubbi1, F. M. Mariani1, M. Rossi1, J. Santilli1, C. Ferrì1. Internal Medicine and Nephrology Unit, University of U'quila, Department of Life, Health and Environmental Sciences, U'quila, Italy

Background: An unhealthy diet, with or without impaired renal urate excretion, is the most frequent cause of hyperuricemia. Despite its pivotal role in the pathogenesis of gout, the clinical relevance of serum uric acid (SUA) levels goes well beyond the simple association with gout and/or nephrolithiasis. Several studies pointed to hyperuricemia as cardiovascular (CV) risk factor in the general population therefore, the 2018 guidelines of the European Society of Cardiology and the European Society of Hypertension included the assessment of uricemia among the screening tests to be performed in hypertensive patients. Furthermore, in view of the association between hyperuricemia and mortality (both CV and all-cause) and CV events, it is conceivable that cardiovascular damage begins with much lower levels of uricemia. In this context, the first results of the URRAH (Uric Acid Right for Heart Health) study identified a uricemia threshold value of 4.7 mg/dL for all-cause mortality and 5.6 mg/dL for CV mortality.

Objectives: Since patients with primary Sjögren’s syndrome (pSS) have a higher risk of CV events compared to the general population, we aimed to explore how uricemia correlates with other CV risk factors and previous CV events in patients with pSS and without gout.

Methods: A cross sectional study was conducted recruiting consecutive patients with pSS without history of gout. SUA was measured upon recruitment alongside the assessment of disease activity (EULAR Sjögren’s syndrome disease activity index, ESSDAI and ClinESSDAI), patient reported symptoms (EULAR Sjögren’s syndrome patient reported symptoms, ESSPRI), CV risk factors including hypertension and diabetes among others, and previous CV events. Dietary habits were also explored with various food frequency questionnaires.

Results: One hundred and three patients with pSS were enrolled. SUA levels ranged between 2.9 and 6.8 mg/dL and, according to the cut-off values of the URRAH study, 16 (16%) patients had SUA levels >4.7 mg/dL while 5 (5%) had SUA levels >5.6 mg/dL. Patients with SUA levels >4.7 mg/dL were more likely males (20% vs 3%) with a higher number of CV risk factors compared to patients with SUA levels <4.7 mg/dL. No differences were observed regarding dietary habits across groups. Disease activity assessed with both ESSDAI and ClinESSDAI was significantly higher in patients with SUA levels >4.7 mg/dL compared to patients with SUA levels <4.7 mg/dL. Conversely, patient reported symptoms (total ESSPRI and individual VAS scales for total dryness, xerostomia, xerophthalmia, pain and fatigue) did not differ across groups. Logistic regression analysis confirmed the association of SUA values >4.7 mg/dL and a higher number of CV risk factors (OR 2.8; 95% CI: 1.2-6.5; p=0.016).

Conclusion: Accumulating evidence highlights the emerging role of hyperuricemia as an independent CV risk factor, but no data are available in pSS patients. This is the first study demonstrating that SUA levels >4.7 mg/dL correlate with both a higher number of CV risk factors and a higher disease activity in pSS patients. Large interventional studies are needed to clarify the possible benefits of urate-lowering treatments in pSS patients.

REFERENCES:

Disclosure of Interests: None declared

AB0525
MODELS OF SYSTEMIC LUPUS ERYTHEMATOSUS ACTIVITY (A RESTROSPECTIVE-PROSPECTIVE STUDY)
A. Shumilova1, E. Travkina1, M. Cherkasova1, T. Reshetnyak2, A. Lila3-on behalf of The study was performed at the V.A.Nasonova Research Institute of Rheumatology within the framework of the fundamental topic FURS-2022-003. 1V.A.Nasonova Research Institute of Rheumatology, 4th Rheumatological Department, Moscow, Russian Federation; 2V.A.Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 3Russian Medical Academy of Continuing Professional Education, Department of Rheumatology, Moscow, Russian Federation

Background: Systemic lupus erythematosus (SLE) is a heterogeneous chronic autoimmune rheumatic disease with a wide range of clinical manifestations, characterized by impaired activation of cellular and humoral links of immunity, uncontrolled hyperproduction of autoantibodies of a wide spectrum to nuclear antigens and the formation of immune complexes that cause immune-inflammatory damage to tissues and organs. This disease is characterized by periods of exacerbation and remission, over time, the activity of SLE may change, mainly in response to therapy. Despite this, patients can be classified according to the current or currently prevailing activity model.

Objectives: To study the activity patterns of patients with SLE.

Methods: The retrospective-prospective study was conducted from 2019 to 2021 based on the study of the history of the disease and annual visits of patients with an assessment of the activity of SLE by SLE Disease Activity Index-2000 (SLEDAI-2K). Depending on the level of SLEDAI-2k flare index, the models of SLE activity, the number of exacerbations during the observation period and the period of the disease, as well as the predominance of organs and systems involved in the process were analyzed. The study included 183 patients with SLE (163 women and 20 men). The average age was 37.5±12.8 y.o. The duration of the disease was Me=9.9 [2.0; 16.0] years.

Results: The clinical and immunological manifestations of SLE were evaluated in the study. The average number of exacerbations of SLE during the period of the disease was 2.9±1.9. The average number of exacerbations during the observation period was 1.1±0.78. The most frequent exacerbation was manifested by a lesion of the musculoskeletal system – 29.5% (54 patients), the skin-mucous system – 21.8% (40 patients) and lupus-nephritis – 21.8% (40 patients). The predominant activity model was relapsing-remitting disease (RDR) – 43.16% (79
23 patients with involvement of the skin-mucosal system had 1 exacerbation of SLE in 3 years of the study. 23 patients with involvement of the musculoskeletal system had 1 exacerbation and 19 patients had 2 exacerbation of the disease in observation period. Exacerbation of lupus nephritis 1 time during the follow-up period was noted in 26 patients, 2 times - in 8 patients.

Conclusion: The most frequent model of SLE activity is RRD, which characterizes periods of exacerbation and remission. The most frequent clinical manifestations of exacerbation of SLE are lesions of the skin-mucous and musculoskeletal systems, as well as lupus nephritis.

REFERENCES:
The study was performed at the V.A.Nasonova Research Institute of Rheumatology within the framework of the fundamental topic FURS-2022-003.


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3617

AB0527 DIFFUSE ALVEOLAR HEMORRHAGE IN LATIN AMERICAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE-CONTROL STUDY

D. C. Quiñonez-González1, M. Muñoz-Urbano1, J. Sanchez-Bautista2, Y. Santamaría-Alza1, A. Ramírez3, C. Muñoz1,3, A. L. Vanegas-García1,3, G. Vásquez1, L. A. González1,1, Universidad de Antioquia, Rheumatology, Medellín, Colombia;2 Universidad de Antioquia, Internal Medicine, Medellín, Colombia;3 Hospital San Vicente Fundación, Rheumatology, Medellín, Colombia

Background: Diffuse alveolar hemorrhage (DAH) is an uncommon and life-threatening complication of systemic lupus erythematosus (SLE) with a high mortality rate (estimated average 50%). The presence of respiratory symptoms (dyspnea, cough, hemoptysis), a new drop in hemoglobin levels, and diffuse infiltrates on chest imaging should raise suspicion of this complication.

Objectives: Our aim was to describe DAH-SLE patients and compare them with non-DAH SLE patients.

Methods: We conducted a single-center, case-control study that enrolled hospitalized patients between 2012 and 2020 in Colombia. Twenty-three DAH-SLE patients (cases) were matched by age and sex with 23 non-DAH-SLE patients (controls). Descriptive, comparative, and logistic regression analyses were performed.

Results: In seven (30.4%) patients, DAH was the initial manifestation of SLE; 69.5% of DAH-SLE patients were females with a mean age of 35 years. Lupus nephritis was present in 65% of cases, mean hemoglobin decrease was 2.22 g/dl [standard deviation (SD) 0.92 g/dL], and 78% had hemosiderophages in bronchoalveolar lavage. All patients received intravenous (IV) pulses of methylprednisolone followed by high-dose steroids, 87.0% IV cyclophosphamide pulses, 60.8% plasmapheresis, 21.7% IV immunoglobulin, and 8.7% rituximab. Comparisons between DAH and non-DAH groups are shown in Table 1. Bivariate logistic regression analysis showed that male sex (OR 9.625 CI95% 1.07 - 86.17; p=0.043), higher SLEDAI-2K score (OR 1.28 CI95% 1.10 - 1.48; p=0.001), and higher C-reactive protein (CRP) levels (OR 1.09 CI95% 1.01 - 1.18; p=0.016) were independently associated with the occurrence of DAH, whereas prior use of corticosteroids (OR 0.029 CI95% 0.003 - 0.25; p=0.001) and antimalarials (OR 0.121 CI95% 0.03 - 0.45; p=0.002), higher hemoglobin levels (OR 0.457 CI95% 0.29 - 0.71; p=0.001), higher C3 (OR 0.94 CI95% 0.91 - 0.97; p<0.0001) and higher C4 levels (OR 0.87 CI95% 0.80 - 0.95; p=0.002) were negatively associated with DAH occurrence (Graph).

Disclosure of Interests: None declared

Table 1. Demographic, clinical, serological, and therapeutic characteristics in DAH-SLE patients and non-DAH-SLE patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-DAH SLE (n = 23)</th>
<th>DHA SLE (n = 23)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>95.6%</td>
<td>69.5%</td>
</tr>
<tr>
<td>Age (years)</td>
<td>27.9 (SD 12.8)</td>
<td>34.82 (SD 17.3)</td>
</tr>
<tr>
<td>Hospital stay (days)*</td>
<td>20.7 (SD 29.1)</td>
<td>34.39 (24.4)</td>
</tr>
<tr>
<td>SLEDAI-2K*</td>
<td>6.17 (SD 5.9)</td>
<td>21.77 (12.5)</td>
</tr>
<tr>
<td>Creatinine (mg/dL)*</td>
<td>2.5 (SD 3.7)</td>
<td>4.23 (SD 5.2)</td>
</tr>
<tr>
<td>Leucocyte (cell/mm³)</td>
<td>8907 (5668)</td>
<td>9408 (5477)</td>
</tr>
<tr>
<td>Neutrophil (cell/mm³)</td>
<td>7112 (5599)</td>
<td>8063 (5456)</td>
</tr>
<tr>
<td>Lymphocyte (cell/mm³)</td>
<td>1236 (759)</td>
<td>952 (425)</td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td>10.5 (2.6)</td>
<td>6.9 (1.5)</td>
</tr>
<tr>
<td>Urea nitrogen (mg/dL)*</td>
<td>33.79 (SD 28.87)</td>
<td>45.73 (SD 25.64)</td>
</tr>
<tr>
<td>ESR (mm/Hour)</td>
<td>515 (5.72)</td>
<td>64.66 (47.50)</td>
</tr>
<tr>
<td>CPR (mg/dL)*</td>
<td>5.21 (SD 8.16)</td>
<td>12.42 (9.63)</td>
</tr>
<tr>
<td>Ferritin (ng/mL)</td>
<td>509 (526)</td>
<td>891 (856)</td>
</tr>
<tr>
<td>Lactate dehydrogenase (U/L)*</td>
<td>314 (SD 114)</td>
<td>503 (SD 357)</td>
</tr>
<tr>
<td>C3 (mg/dL)*</td>
<td>84.8 (SD 23.07)</td>
<td>44.84 (SD 27.91)</td>
</tr>
<tr>
<td>C4 (mg/dL)*</td>
<td>20.5 (10.3)</td>
<td>9.5 (8.2)</td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>42.8%</td>
<td>71.4%</td>
</tr>
<tr>
<td>Anti-Ro</td>
<td>38.8%</td>
<td>38.8%</td>
</tr>
<tr>
<td>Anti-La</td>
<td>11.1%</td>
<td>10.5%</td>
</tr>
<tr>
<td>Anti-RNP</td>
<td>44.4%</td>
<td>47.3%</td>
</tr>
<tr>
<td>Anti- Sm</td>
<td>38.8%</td>
<td>38.8%</td>
</tr>
<tr>
<td>IgA GCL</td>
<td>10.5%</td>
<td>13.6%</td>
</tr>
<tr>
<td>IgM ACL</td>
<td>33.3%</td>
<td>33.3%</td>
</tr>
<tr>
<td>Lupus anticoagulant</td>
<td>78.2%</td>
<td>69.5%</td>
</tr>
<tr>
<td>Mucocutaneous involvement</td>
<td>73.5%</td>
<td>60.8%</td>
</tr>
<tr>
<td>Articular involvement</td>
<td>86.9%</td>
<td>69.5%</td>
</tr>
<tr>
<td>Hematological involvement</td>
<td>86.9%</td>
<td>69.5%</td>
</tr>
<tr>
<td>Renal involvement</td>
<td>91.3%</td>
<td>86.9%</td>
</tr>
<tr>
<td>Serosal involvement</td>
<td>91.3%</td>
<td>86.9%</td>
</tr>
<tr>
<td>Prior glucocorticoid*</td>
<td>95.6%</td>
<td>39.1%</td>
</tr>
<tr>
<td>Prior antimalarial*</td>
<td>69.5%</td>
<td>21.7%</td>
</tr>
<tr>
<td>Dead</td>
<td>4.3%</td>
<td>21.7%</td>
</tr>
</tbody>
</table>

*P value < 0.05

Conclusion: In about one-third of patients diagnosed with DAH, this life-threatening complication was the initial presentation of SLE. Male sex, higher SLEDAI-2K scores, and higher CRP levels were associated with increased occurrence, whereas higher hemoglobin levels, elevated complement levels, prior use of glucocorticoids, and antimalarial treatment were negatively associated with the occurrence of DAH.

Background: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been reported as useful inflammatory biomarkers associated with the disease activity of systemic lupus erythematosus (SLE). Recently, the albumin to globulin ratio (AGR) has demonstrated potential indicator to predict the prognosis of some cancers. However, whether AGR can predict the disease activity of SLE has been rarely investigated.

Disclosure of Interests: None declared

Methods: This retrospective study enrolled 101 SLE patients and 75 age- and gender-matched healthy individuals. According to the SLEDAI-2K score, SLE patients were classified into Group 1 with a score of 9 or lower (patients with mild disease activity, N = 60) and Group 2 with a score > 9 (patients with moderate to severe disease activity, N = 41). Albumin, globulin, NLR, PLR, monocyte to lymphocyte ratio (MLR), AGR, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), complement 3 (C3), complement 4 (C4), SLEDAI-2K and other clinical data were collected. Receiver operation characteristic (ROC) curves were conducted to discriminate SLE patients from healthy controls and SLE patients with different disease activity. Correlations between the inflammatory markers and SLEDAI-2K were checked.

Results: Albumin and AGR in SLE patients were lower compared to those of the healthy controls (P < 0.05), while NLR, PLR, MLR, globulin and CRP were higher (P < 0.05). Patiens in Group 2 had lower levels of albumin, AGR, C3 and C4 than those in Group 1 (P < 0.05), NLR and PLR were higher (P < 0.05), while MLR (P = 0.198), globulin (P = 0.704), CRP (P = 0.224) and ESR (P = 0.135) displayed no significant differences. The ROC curves for differentiating SLE patients from healthy individuals showed that the area under curve (AUC) of AGR (0.812, 95%CI: 0.750 - 0.874) and albumin (0.840, 95%CI: 0.782 - 0.898) were higher than NLR (0.786, 95%CI: 0.719 - 0.853), PLR (0.708, 95%CI: 0.629 - 0.786), MLR (0.776, 95%CI: 0.708 - 0.845) and globulin (0.630, 95%CI: 0.548 - 0.713). Similarly, the ROC curves for predicting the disease activity of SLE patients displayed that the AUC of AGR (0.779, 95%CI: 0.689 - 0.870) and albumin (0.827, 95%CI: 0.746 - 0.929) were also higher than NLR (0.644, 95%CI: 0.534 - 0.753), PLR (0.672, 95%CI: 0.565 - 0.780), MLR (0.583, 95%CI: 0.466 - 0.701), globulin (0.521, 95%CI: 0.403 - 0.639), CRP (0.567, 95%CI: 0.452 - 0.683), ESR (0.589, 95%CI: 0.475 - 0.703), C3 (0.709, 95%CI: 0.603 - 0.815) and C4 (0.655, 95%CI: 0.542 - 0.768); AGR was negatively correlated with SLEDAI-2K (r = -0.543, P < 0.001) in SLE patients. Logistic regression analyses showed that AGR (OR = 13.047, 95%CI: 3.407 - 49.966, P < 0.001) was an inverse predictor for SLE disease activity, yielding a highest hazard than other inflammatory parameters.

Conclusion: AGR was significantly decreased in SLE patients compared with healthy subjects and negatively associated with the disease activity of SLE. AGR might be a potential indicator for evaluating inflammation in patients with SLE.

References:

Disclosure of Interests: None declared


AB0529 PULMONARY HYPERTENSION (PAH) IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS NOT DEFINED BY AUTO-ANTIBODY AND CLINICAL VARIABLES.

R. Baiya1, M. G. S. R2, P. K. Devarasetti1, A. Aggarwal3, V. Shobha4, L. Rajasekhar1on behalf of INSPIRE. 1Nizam’s Institute of Medical Sciences, Clinical Immunology & Rheumatology, Hyderabad, Telangana, India; 2Indian Statistical Institute, Statistical Quality Control and Operational Research Division, Hyderabad, India; 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Department of Clinical Immunology and Rheumatology, Lucknow, India; 4St John’s Medical College Hospital, Clinical Immunology and Rheumatology, Bangalore, India

Background: PAH is a well-recognized but infrequent manifestation of SLE. Often insidious in onset, PAH may have progressed for a while, before symptoms manifest. Prediction of clinical risk of PAH may have clinical benefit during the follow-up of a patient with SLE.

Objectives: The aim of the study was to develop a prediction algorithm for PAH in patients with SLE using clinical and auto-antibody variables.

Methods: The study included patients from the INSPIRE cohort which is, a national multi-center study enrolling patients with disease duration of less than three years. Lupus patients with symptomatic PAH confirmed by a transthoracic
2D ECHO right ventricular systolic pressure of more than 40 mm Hg were enrolled as cases. Controls were age, sex and date of enrolment matched patients from the same cohort without any clinical evidence of PAH. We excluded patients with a known cause of PAH and critical illness. The clinical variables and antibody data was retrieved from records. Outcome of death if any was noted. Using supervised learning, a logistic regression model was built for the prediction of SLE-PAH. The final Prediction model included one clinical variable (RP), sixteen autoantibodies (Sm-RNP, Smith, SS-A, Ro-52, SS-B, SCL-70, PM-SCL, Centromere, Jo1, PCNA, Nucleosome, dsDNA, histone, Ribosomal P and AMA, anti-cardiolipin antibody) and complement level, to ensure accuracy of the model, a confusion matrix using python was performed. The proportion of right predictions ($\mu$) is a measure of accuracy of the model. If the model is good, $\mu$ must be close to 1.

**Results:** A total of 69 patients with symptomatic PAH, confirmed by 2D echo-cardiography were enrolled as cases. Raynaud phenomenon (RP), Interstitial lung disease (ILD) and ischemic stroke were significantly higher in cases than control (p = 0.026, 0.001, 0.05 respectively). There was no difference in the prevalence of individual auto-antibodies between the groups except high prevalence of anti-cardiolipin antibody in cases (39% vs 23% p = 0.048). Mortality rate was higher in cases (17% vs 0.06%, p = 0.003) during a follow up of 3 years with all the deaths occurring within one year of PAH diagnosis. Ten repetitions of the confusion matrix analysis using Python for this prediction model (both derivation and validation) yielded the following $\mu$ scores 0.60, 0.47, 0.57, 0.63, 0.50, 0.60, 0.57, 0.43, 0.50, 0.57, which exhibited wide variability.

**Conclusion:** A prediction model using RP and commonly assayed autoantibodies failed to be informative for PAH in Indian lupus patients.

**References:**


**Acknowledgements:** I want to acknowledge INSPIRE cohort investigators.

**Disclosure of Interests:** None declared

**AB0530**

**CARDIOVASCULAR RISK STATUS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: WHICH ALGORITHMS IS THE BEST?**

T. Panafidina1, T. Popkova1, L. Kondrateva1, Y. Gorbunova1, E. Nasonov2, V.A.Nasonova Research Institute of Rheumatology, Department of Systemic Rheumatic Diseases, Moscow, Russian Federation; V.A.Nasonova Research Institute of Rheumatology, Scientific Department, Moscow, Russian Federation

**Background:** Systemic lupus erythematosus (SLE) has been strongly linked to accelerated atherosclerosis and increased cardiovascular morbidity and mortality. Rheumatological guidelines recommend evaluating the cardiovascular (CV) risk status in SLE patients, for an early identification of patients at high risk to preventive strategies.

**Objectives:** The aim of our study is to describe for the first time individual patient GC toxicity in SLE patients using the Glucocorticoid Toxicity Index (GTI).

**Methods:** A total of 37 patients SLE (30 (81%) women and 7 (19%) men) were enrolled in this study. The mean age was 36±11.9 years and the median disease duration was 36 [12; 128] months. At the first visit, all patients were assessed for SLE activity by the SLEDAI 2k index, irreversible organ damage by SLICC Damage Index (DAI), GTI1, and current treatment.

**Results:** The mean disease activity index SLEDAI2k was 11.3±6.2, DAI SLICC = 1 (20 (54%), 14 (46%) patients had not any irreversible organ damage during the period of illness the maximum GC dose was 33.7 mg ± 19.9 mg, the median of cumulative dose of GC administered intravenously was 15653 mg [293; 6478] mg, median duration of GC treatment was 22 months [8; 112]. 30 (81%) of patients had GTI with median 19 [14; 21] points: 2 (5%) patients had zero GTI, but there were severe organs’ injuries from the TGI Specific List. In 3 out of 5 patients, the duration of GC treatment did not exceed 6 months, in 2 out of 5 patients, the maximum dose of GC during the period of the disease did not exceed 5 mg/day. In 1 out of 5 patients, the duration of treatment was 13 months, and the maximum dose of GC was 15 mg during the period of treatment. The most frequent changes occurred in 5 of 9 main domains: an increase in body mass index was detected in 10 (27%) patients, an increase in blood pressure was detected in 15 (41%) patients, hyperlipidemia was detected in 9 (24%) patients, a decrease bone mineral density was detected in 6 (16%) patients and the development of infectious complications in 5 (14%) patients; The less frequent changes occurred in 5 of 9 main domains: 3 (8%) patients had impaired glucose tolerance, 2 (5%) patients had steroid myopathy; neuropsychiatric intoxication was detected in 2 (5%) patients. Severe organs’ injuries were identified, included in a Special list and not scored in points: cataracts were detected in 7 (19%) patients, avascular necrosis was detected in 3 (8%) patients, osteoporotic fractures - in 2 (5%) patients. GTI correlated with disease duration (r = 0.33); the maximum dose of GC per os (r = 0.43); duration of GC therapy (r = 0.37); DAI SLICC (r = 0.39), p<0.05 in all cases.

**Conclusion:** GTI was detected in a significant number of patients with SLE (81%). ITG correlates with the duration of the disease, the maximum dose of GC during the period of illness, the duration of GC therapy, and the SLICC DAI. GTI should be used to evaluate the safety of GC therapy in patients with SLE who receive GC therapy for more than 6 months, together with the SLICC DAI.

The GTI includes Composite Index and Specific List. Composite Index, consists of 9 domains and 31 elements, each of which is assigned a certain number of points. It contains information on the most common complications of GC therapy: BMI, glucose tolerance, BP, lipids, myopathy, bone mineral density, skin lesions, neuropsychiatric lesions, infections.

Severe organ damages, which is less common but contributes significantly to GC toxicity, are included in a special list. The specific list includes 11 domains.
LACTATE DEHYDROGENASE AS A PREDICTOR OF FATIGUE IN PRIMARY SJOGREN'S SYNDROME: A POOLED ANALYSIS

L. Rajaïaoppal1, S. Jude Tan1, W. F. Ng1, J. Tarn1. 1Translational and Clinical Research Institute, Newcastle University; Newcastle upon Tyne, UK, Department of Rheumatology; Freeman Hospital, Newcastle upon Tyne NHS Trust, United Kingdom; Newcastle upon Tyne, United Kingdom

Background: Fatigue is one of the most disabling symptoms in primary Sjögren's syndrome (pSS) and it significantly impacts patients' quality of life[1]. However, the cause of this symptom remains unclear. Lactate dehydrogenase (LDH), is an enzyme of the anaerobic respiratory pathway. High lactate levels are a marker of inflammation and create a pro-inflammatory microenvironment[2]. LDH levels can be raised in myositis, haemolysis and lymphoma. For this reason, serum LDH is routinely monitored in patients with pSS. However given its role in metabolic pathways, we hypothesise that serum levels of LDH may also be a biomarker of fatigue in pSS.

Objectives: 1. To investigate the bivariate relationship between LDH and fatigue severity, hypothesising a positive correlation between them.
2. To incorporate factors such as depression, anxiety, serum creatinine and haemoglobin levels as covariates, as these factors may also contribute to fatigue.

Methods: We used routinely collected clinical and laboratory data from 512 pSS patients from the Newcastle Sjögren’s syndrome cohort. The participants consented for their linked anonymised data to be used in pSS-related research. Severity of fatigue was measured using fatigue subscale of EULAR Sjogren’s Syndrome Reported Patient Index (ESSPRI) - a Likert scale of 0-10. Fatigue severity was also categorised into 4 categories: 0-2 being minimal, 3-5 mild, 6-7 moderate and 8-10 severe. Hospital Anxiety and Depression Score was used to measure patients’ anxiety and depression levels. Blood parameters including haemoglobin, full blood count, ESR, CRP, serum creatinine, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and LDH were checked during each visit. Dryness was measured using ESSPRI dryness subscale. Statistical analysis of the relationship between the continuous blood parameters and categorical fatigue groups was performed using Kruskal-Wallis for categorical fatigue groups and linear regression for continuous fatigue measures.

Results: The majority of the patients were female (87%) and Caucasian. Baseline measurements of pain, anxiety, depression, abnormal fatigue, mental fatigue and overall ESSPRI score increased with increasing fatigue severity. This is seen most prominently in serum LDH levels. LDH levels increased with increasing fatigue scores. We identified significant differences in baseline LDH levels across the four fatigue groups (p = 0.002). Within groups comparisons showed significant differences between mild and minimal, severe and minimal and moderate and minimal fatigue groups only (p-values: 0.026, 0.019 and 0.032 respectively). A baseline linear regression model for fatigue using LDH, CRP, and gender was performed and showed LDH has a significant relationship with fatigue p=0.007. Findings were also determined using ANOVA where significant difference (p= 0.0023) of LDH between fatigue groups were identified using a Tukey-Kramer test. A supplementary Tukey-Kramer test was carried out to determine if LDH was significant between two-groups of fatigue severity score, where significant difference was seen between three different sets of fatigue categories: mild-minimal, severe-minimal and moderate-minimal. The test ensured that a relationship between the enzyme and fatigue was present especially between the groups of fatigue severity stated above. The actual-by-predicted and leverage plot further supports our finding by showing the unique effect of LDH in the models.

Conclusion: The study concludes that a relationship between enzyme lactate dehydrogenase and fatigue exist; however, further study will be required to examine its role as a predictor of fatigue severity in pSS. The complex interconnection between inflammation, disease activity, psychological factors and LDH will have to be further investigated to advance the current understanding of chronic fatigue in Sjogren syndrome.

REFERENCES:
[1] Fatigue and immune activity in sjogren's syndrome
[2] Lactate at the crossroad of metabolism, inflammation, and autoimmunity

Disclosure of Interests: None declared

THE ASSESSMENT OF CLINICAL CHARACTERISTICS OF MALE SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

M. Canbas1, S. Colak1, E. Tekgoz2, M. Cinár1, S. Yılmaz1. 1University of Health Sciences Turkey; Guzeliye Faculty of Medicine, Guzeliye Education And Research Hospital; Division of Rheumatology, Ankara, Turkey

Background: Systemic lupus erythematosus (SLE) is a multisystemic chronic autoimmune disease that is nine times more frequent among females. Due to a female dominance, the data regarding male patients is limited.

Objectives: This study aimed to evaluate the clinical characteristics of male patients with SLE.

Methods: This retrospective study included male SLE patients who followed up in a tertiary rheumatology outpatient clinic between October 2016 and December 2021. Those who met the Systemic Lupus International Collaborating Clinics (SLICC) criteria were included. The data of the patients and SLE Disease Activity Index-2000 (SLEDAI-2K) values were obtained from files.

Results: There were 40 male SLE patients with a mean age of 42.7 ± 17.3 years. The median age of diagnosis was 30 years, and the median disease duration was 63.5 months (ranges between 5-444). The mean value of the SLICC score was 4.7 ± 0.8. The most frequent initial clinical manifestations were thrombocytopenia and photosensitivity, which were seen in 8 (20.0%) patients each (Table 1). Six (15.0%) patients had secondary antiphospholipid antibody syndrome. Thirty-five (87.5%) patients achieved remission, but 14 (35%) patients had at least one relapse in the follow-up period. The most frequent manifestation after relapse was nephritis in 9 (22.5%) patients that had no renal involvement at the time of diagnosis. The median SLEDAI score was 2 (ranges between 0-12). The most commonly preferred drug for the treatment was hydroxychloroquine and corticosteroids (92.5% for each). Nineteen (47.5%) patients received pulse steroids. Besides, the most frequently prescribed immunosuppressive drug was mycophenolate mofetil (37.5%). The rates of azathioprine, cyclophosphamide, methotrexate, cyclosporine A, rituximab, intravenous immunoglobulin, and lefunomide usage were 30%, 27.5%, 17.5%, 10%, 75%, 5%, respectively. Antinuclear antibody (ANA) was positive in 35 (87.5%) patients, and anti-dsDNA was positive in 9 (22.5%). The median level of anti-dsDNA titer was 40 IU/ml (ranges between 23-200). Other autoantibody positive rates were; 12 (30%) for anti-Sm, 6 (15%) for anti-histone, 4 (10%) for anti-RO and 4 (10%) for anti-nucleosome. Ten (25.0%) patients had low C3 levels, and 11 (27.5%) patients had low C4 levels. The hospitalisation rate was 55%, and no death was seen during follow-up.

Table 1. Clinical characteristics of the patients (n=40)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical manifestations, n(%)</td>
<td>Initial</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>8 (20)</td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>8 (20)</td>
</tr>
<tr>
<td>Malar rash</td>
<td>7 (17.5)</td>
</tr>
<tr>
<td>Nephritis</td>
<td>6 (15)</td>
</tr>
<tr>
<td>Arthritis/rheumatoid</td>
<td>5 (12.5)</td>
</tr>
<tr>
<td>Subacute lesions</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Leukopenia/lymphopenia</td>
<td>4 (10)</td>
</tr>
<tr>
<td>Thrombosis</td>
<td>3 (7.5)</td>
</tr>
<tr>
<td>Neuropsychiatric involvement</td>
<td>3 (7.5)</td>
</tr>
<tr>
<td>Serositis</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Pulmonary involvement</td>
<td>2 (5)</td>
</tr>
<tr>
<td>Diabetes mellitus erythematous</td>
<td>1 (2.5)</td>
</tr>
<tr>
<td>Myositis</td>
<td>1 (2.5)</td>
</tr>
</tbody>
</table>

Conclusion: Since SLE is more prevalent among females, it may occur in male patients with mild or life-threatening manifestations. In the current study, the sero-positivity was less than in the literature, which may indicate male patients should be cautiously evaluated. Although renal involvement is not an initial manifestation, it may develop during the follow-up.

Disclosure of Interests: None declared

PROSPECTIVE STUDY OF 24 MONTHS OF EVOLUTION OF A COHORT OF PATIENTS WITH RHUPUS

I. Martínez Costellá1, C. Pávez Perelles1, S. Leal Rodriguez2, A. V. Huaylla Quipe1, C. Riesco Barcena1, L. Mas Sanchez2, P. Muñoz Martínez1, I. Cánovas Olmos1, M. De la Rubia Navarro1, J. J. Fragil Gió1, L. González Puig2, E. Grau García1, J. Ivorra Cortés1, C. Nájera Herranz1, R. Negueroles Albuixech2, E. Vicens Bernabeu1, J. E. Oller Rodríguez1, F. Ortiz-Sanjulián1, J. A. Román Ivorra1. 1La Fe University and Polytechnic Hospital, Rheumatology, Valencia, Spain

Background: Rhupus syndrome (RhS) is a rare combination of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Different studies describe cases of RhS with more frequent initial clinical manifestations in the form of erosive arthritis and the presence of rheumatoid factor (RF) and/or anti-CCP, with later manifestations of SLE appearing.

RhS has a low prevalence and it is useful to know the clinical characteristics of the patients and their evolution over time, since their treatment and clinical management differ from those who present RA or SLE in isolation.

Objectives: Our objective was to study the clinical, analytical and therapeutic evolution of our cohort of patients with Rhupus.
Methods: Prospective study of a cohort of patients with Rhus during 2020-2021 with systematic review of electronic records for the analysis of clinical, analytical and therapeutic parameters throughout follow-up.

Results: Nine patients with RNS (88.9% women) who met SLICC 2012 criteria for SLE and ACR 2010 for RA were included. The mean age was 62.7 (45-86) years. During follow-up, the death of one case due to metastatic pulmonary neoplasia was verified, as well as the incorporation of a new patient in the study population. In 4 cases, RA was the first diagnosis, with a mean evolution of 6.25 years until the diagnosis of SLE. On the contrary, in 5 cases SLE was the first diagnosis with a mean evolution of 7.2 years until the diagnosis of RA. Photosensitivity and arthritides were the predominant clinical manifestations. One patient presented rheumatoid nodules in both elbows and 2 patients presented symptoms of seborrhoea in the form of pleuropericarditis. No cases of renal or neurological involvement were recorded.

Clinically, the patients have remained stable, presenting joint manifestations as the predominant clinic. Regarding the serological evolution, 8 patients presented positive RF at the beginning of the study, 3 of them becoming negative during follow-up. Likewise, the presence of ACRA was positive in 6 patients, maintaining this percentage at the present time. On the other hand, the ANA were positive at the beginning in all the patients, with ANA becoming negative in 5 of them. Antiphospholipid antibodies were positive in 2 patients, however none of them developed antiphospholipid syndrome.

4 patients were treated with biological drugs/JAK inhibitors (1 abatacept, 1 rituximab, 1 brecitinib and 1 tofacitinib) with a favorable response.

Conclusion: The analysis of our cohort continues to show that, unlike other series, 44.4% of RhS cases begin with seropositive polyarticular arthritis. 55.6% of these start with manifestations compatible with SLE, in the form of hematological, cutaneous and serological alterations, and these show a more prolonged progression to develop polyarticular involvement. Therefore, a diagnosis of RhS continues to be reached earlier in patients who present with symptoms of RA.

37.5% of patients had a negative RF, maintaining ACRA in all of them. ANA were negative in 55%. Neither of the 2 patients with anti PL Ab developed APS.

Clinically, joint manifestations in the form of arthralgia of small joints were the predominant clinic. In general, the evolution has been favorable. Four patients were refractory to treatment with cDMARDs, requiring the use of biological drugs/JAK inhibitors with good response.

Disclosure of Interests: None declared


AB0536

LEPTIN LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS, CONNECTION WITH COURSE OF THE DISEASE AND Atherosclerotic VASCULAR LESIONS

O. Shikina1, S. Shevchuk1. National Pirogov Memorial Medical University, Vinnytsya, Internal Medicine Chair №2, Vinnytsya, Ukraine

Background: Atherosclerosis and its complications remain the leading causes of death in patients with systemic lupus erythematosus (SLE). Along with the known pathogenic factors that significantly accelerate the development of cardiovascular events in patients with SLE (hyperinsulinemia, hypertension, atherogenic dyslipidemia, disease activity, etc.), in recent years the role of dysadipokinemia has been intensively studied. In patients with SLE serum leptin increases, but how its concentration changes under the conditions of the inflammatory process and how it is associated with other factors that aggravate the course, have not been studied enough. Its role in the formation of atherosclerotic vascular lesions in patients with SLE is also unknown.

Objectives: The aim of the study was to assess leptin levels in patients with SLE and to analyze its relationship with the course of the disease, lipid spectrum and atherosclerotic vascular lesions.

Methods: We examined patients with SLE (31 women and 4 men), mean age = 46.23 ± 1.36 years). The average duration of the disease was 9.97 ± 0.82 years. SLE was confirmed on the basis of ACR / EULAR criteria (2019) and formulated according to the classification recommended by the Association of Rheumatologists of Ukraine (2020). The control group included 20 healthy individuals of the appropriate age and sex.

The content of leptin in the serum was determined by enzyme-linked immunoassay according to the instructions of the manufacturer. The SLEDAI index was used to assess activity. Assessment of endothelial function was determined by the Celemayer method.

Results: The level of leptin in the serum in apparently healthy individuals and patients with SLE differed significantly. In particular, the average hormone content in patients with SLE was 39.4 ± 3.4 ng / ml, while in the control group - 24.4 ± 3.8 ng / ml, ie was higher by 38.1% (P < 0.01). The patient’s age and disease duration were weakly related to leptin levels (r = 0.25, r = 0.34, respectively).

It was found out that in patients with SLE serum leptin levels were directly proportional to the disease activity. In particular, a close associative relationship was established between the activity of the disease determined by the SLEDAI index and ESR (r = 0.81, r = 0.42, respectively). The study found a close association between serum leptin concentrations and blood lipid spectrum in patients with SLE. In particular, it was the highest with LDL/low density lipoprotein (r = 0.54) and probable with total cholesterol and triglycerides (r = 0.32, r = 0.28, respectively).

In patients with SLE with a high (≥42.2 ng / ml) leptin level, the endothelium-dependent vasodilation brachial artery (EDV BA) was 52.3% higher and the CCA IMT (common carotid artery intima-media thickness) was 32% higher than in patients with relatively normal leptin levels. In addition, the proportion of patients with a decrease in EDV BA and an increase in the area of CCA IMT among patients with high leptin levels was 12–25% higher than among patients with relatively normal levels of the enzyme under study. The presence of atherosclerotic plaques, their area and the severity of atherosclerotic lesions of the carotid arteries also determined the tendency to increase in proportion to the increase in serum leptin levels. Thus, hyperleptinemia in patients with SLE is associated with deterioration of vascular function of the carotid artery and the severity of atherosclerotic vascular lesions.

Conclusion: Significantly higher levels of serum leptin were found in patients with SLE, which were associated with inflammatory activity and dyslipidemia, as well as with structural and functional reorganization of blood vessels, which should be considered as an important risk factor for vascular lesions.

Disclosure of Interests: None declared


AB0536

RELATIONSHIP OF EXERTIONAL ACTIVITY AND MENTAL WELLBEING IN SYSTEMIC LUPUS ERYTHEMATOSUS

S. Beider1, T. Witte1, D. Ernst1. Medical School Hanover, Department of Rheumatology and Immunology, Hanover, Germany

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a variety of clinical manifestations [1] and has a profound effect on physical health [2]. Anxiety and depression are common symptoms of SLE which can have a significant impact on the quality of life [3].

Objectives: To study whether or not the physical state of health relates to the extent of anxiety and depression in SLE patients.

Methods: The Physical Component Summary Score (PCS) was determined using the 36-Item Short Form Survey (SF-36) in a cohort of 146 SLE patients consecutively visiting our outpatient clinic. Two groups were compared: one group with low PCS (<50 %) (LPCS) and the comparison group with high PCS ≥50% (HPCS). Patients with SLE who visited our Rheumatology clinic between March 2019 and December 2020 as part of a monocentric cross-sectional study completed additional standardized questionnaires: Hospital Anxiety and Depression Scale (HADS), Beck’s Depression Inventory (BDI II), Multidimensional Assessment of Fatigue (MAF), Functional questionnaire Hannover (FbH) and the international questionnaire on physical activity in short form (IPAQ-SF). The data was analyzed with SPSS 27 (IBM, Armonk, NY, USA). The tables include bivariate and partial correlations. Significance tests were performed using non-parametric tests.

Results: In total, 146 patients participated in the study. 14.4 % (n = 21) were men, the mean age was 50.4 ± 12.2 years. The mean state of physical health according to SF36 was 54.9 ± 25.6 % in the cohort examined.

There were 62 (42.5 %) patients with LPCS, of average age 50.4 ± 10.3 years and 84 (57.5 %) with HPCS, of average age 47.2 ± 13.3 years. The majority of patients in both groups were female (55/7, 88.7 % and 70/14, 83.3 %).

A SLEDAI score > 2 was confirmed in 33.9 % (n = 21) of the patients with LPCS and in 25 % (n = 21) of patients with HPCS, the mean SLEDAI score did not significantly differ between LPCS and HPCS patients (2.4 versus 1.9, p = 0.261). Among patients with LPCS, 54.8 % (n = 34) presented low physical activity and 64.5 % reported functional impairment (FFbH < 80). More than half of LPCS-patients (53.2 %, n = 33) showed a low Mental Health summary score (MCS < 50 %) and over a third of them had moderate to severe depression (BDI II > 19, 38.7 %, n = 24) and indicated pathological anxiety (HADS > 10, 37.1 %, n = 23).

Compared to the LPCS group, a smaller number of patients with HPCS had low physical activity (36.9 %, n = 31, p = 0.031) and the difference in mean weekly MET between the two groups was 2730 counts (p = 0.003). There was no impairment of functional capacity in patients with HPCS (FFbH mean Score 90.9 %, p < 0.001). In contrast to the LPCS group, only 17 % (n = 15) of the patients with HPCS showed MCS < 50 % (p < 0.001). Completely free of depressive symptoms were 65.5 % (n = 55) of the patients with HPCS and only 4 patients (4.8 %) reported moderate to severe depression (p < 0.001).

Patients with LPCS reported fatigue (GFI > 20) more often than patients with HPCS (98.4 % versus 54.8, p < 0.001).

Conclusion: SLE patients with low physical health conditions have highly significant mental health impairment, particularly anxiety and depression. Physical functioning and limitations due to physical health should be considered and physical activity needs to be improved. Measurement of the PCS should be a routine tool in the overall assessment of the health conditions of SLE patients.
REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3957

AB0537


L. Moro1,2, G. Ferrari3,4, F. Bonelli5, V. Batani6,7, M. Bellone1,2, M. Matucci-Cerinic8, L. Dagna1,2,11, IRCCS Ospedale San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy; 2Vita-Salute San Raffaele University, Milan, Italy; 3IRCCS Ospedale San Raffaele, Cornea and Ocular Surface Unit, Milan, Italy; 4IRCCS Ospedale San Raffaele, Eye Repair Lab, Milan, Italy; 5University of Verona, Department of Medicine, Verona, Italy; 6University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy

Background: Ocular involvement in primary Sjögren’s Syndrome (pSS) has been traditionally assessed by Schirmer’s test, Tear Break Up Time (TBUT) and Ocular Staining Score (OSS).

The role of Ocular Surface Disease Index (OSDI), Visual Function Questionnaire-25 (VFQ-25) and Numerical Rating Scale (NRS) in measuring ocular pain and discomfort in pSS have not yet been investigated in detail.

Objectives: To explore the prevalence of ocular pain in patients with pSS, and to investigate the potential correlations between dry eye, ocular pain, extraocular patient-reported outcomes and disease activity.

Methods: In this ongoing cross-sectional study, OSDI, VFQ-25 and NRS for ocular pain were administered to 19 consecutive patients with a definite diagnosis of pSS at our outpatient clinic. All patients signed an informed consent for the study. Pearson coefficients were obtained to assess correlation among EULAR Sjögren’s Syndrome (SS) disease activity index (ESSDAI), EULAR SS Patient Reported Index (ESSPRI), erythrocyte sedimentation rate (ESR), TBUT, OSDI, VFQ-25 and NRS.

Results: In the study, 19 consecutive patients have been enrolled so far. The sample demographics and disease-related features are representative of a typical pSS population (10% male sex, median age at diagnosis of 49 [IQR 24], median age 50.5 (10.3) years and disease duration 10.3 (7.0) years, were enrolled. Baseline SLEDAI-2K was 6.0 (2.0) driven predominantly from the musculoskeletal and mucocutaneous domains. The prevalence of anxiety (HADS-A >11) and depression (HADS-D >8) were 42.5% and 45.0%, respectively. During follow-up, disease activity was significantly reduced (average [SD] reduction in SLEDAI-2K, PGA), use of medications, and treatment adherence (Morisky Medication Adherence Scale-4 items scale) were monitored during the observation period.

Results: Forty SLE patients (39 females) with an average [standard deviation] age 50.5 (10.3) years and disease duration 10.3 (7.0) years, were enrolled. Baseline SLEDAI-2K was 6.0 (2.0) driven predominantly from the musculoskeletal and mucocutaneous domains. The prevalence of anxiety (HADS-A >11) and depression (HADS-D >8) were 42.5% and 45.0%, respectively. During follow-up, disease activity was significantly reduced (average [SD] reduction in SLEDAI-2K, 1.90 [2.80], p<0.001), however, anxiety and depression levels remained unchanged (average [SD] change in HADS-A -0.05 [3.76] and HADS-D 0.53 [3.25], respectively, p=0.300 for both). Accordingly, Spearman’s non-parametric test showed that longitudinal changes in SLEDAI-2K were not significantly correlated with the corresponding changes in the HADS-A (rho = 0.13, p=0.417) and HADS-D (rho = -0.05, p=0.781) scores. Treatment non-adherence was found in 19 patients (47.5%) but did not correlate with anxiety and depression (p>0.500 for both). Notably, mental disorders were not significantly associated with comorbidities (including fibromyalgia) but unemployment status predicted the presence of anxiety (odds ratio 7.73, p-value 0.018).

Conclusion: Anxiety and depression are frequent comorbidities in active SLE and do not correlate with short-term disease improvement, thus underscoring the need for adjunct treatment. Physician awareness in the detection of treatment adherence is necessary. Larger studies in early disease and with longer follow-up will be required to further explore the possible interaction between mental disorder and lupus disease course.

REFERENCES:

Disclosure of Interests: None declared
DEPRESSION, SELF-ESTEEM AND QUALITY OF LIFE IN SJÖGREN'S SYNDROME

T. Ramia¹, S. Daada², I. Chaabane³, R. Kissi⁴, S. Hammami⁵, K. Ines⁶, M. Kechida⁷, ¹Fattouma Bourguiba University Hospital, Internal Medicine Department, Monastir, Tunisia

Background: Sjögren's syndrome (SS) is a connective tissue disease characterized by a triad of fatigue, pain and dryness. SS is a chronic condition with important repercussions on functioning and a source of significant suffering. Therefore, the assessment of depressive symptoms, self-esteem and quality of life (QOL) is important in the clinical and research context.

Objectives: We aimed to describe the clinical picture, depression, QOL and self-esteem of patients followed for SS and to study their association with disease activity.

Methods: This is a descriptive and analytical cross-sectional study including 42 patients with SS diagnosed based on the criteria of the American European Consensus Group of 2002 (AECG). Depression was evaluated by the Beck 13 scale, QOL by the SF-36 and self-esteem by the Rosenberg scale. Disease activity was assessed by EULAR Sjögren Syndrome Disease Activity Index (ESSDAI).

Results: The average age was 54.5 ± 15.67 years and the sex ratio was 0.2. Assessment of disease activity of these patients showed an average activity score of 8.23 ± 6.39 with low activity in 16 patients (38.1%), moderate activity in 18 patients (42.9%) and severe activity in 8 patients (19%). The QOL measured by SF-36 was impaired in all areas with average ranges from 39.76 for physical limit to 66.28 for emotional limit. Depression score evaluated by the Beck scale was 8.42 ± 7.05 average with 59.5% of the patients having depression. The self-esteem score evaluated by Rosenberg scale was 32.8 ± 5.70 average. Self-esteem was rated as low to very low in 30.95% of patients.

Conclusion: The antidepressant and depression were correlated to disease activity, taking into account these aspects in SS can improve the overall management of the disease.

REFERENCES:

Disclosure of Interests: None declared

Table 1. Characteristics and occurrence of comorbidities in SLE pts.

<table>
<thead>
<tr>
<th>Patients and Disease' characteristics</th>
<th>Group 1 (n=85)</th>
<th>Group 2 (n=106)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean ± SD</td>
<td>47.05±13.51</td>
<td>44.8±12.11</td>
<td>≥0.05</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>69 (81.18)</td>
<td>95 (89.62)</td>
<td>≥0.05</td>
</tr>
<tr>
<td>SELENA-SLEDAI, mean ± SD</td>
<td>7.34±5.03</td>
<td>6.15±3.92</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>SLE duration, years, mean ± SD</td>
<td>4.73±5.01</td>
<td>9.07±2.15</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Serum uric acid, µmol/l, mean ± SD</td>
<td>434.6±63.16</td>
<td>238.3±59.36</td>
<td>≥0.05</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>30/28.3</td>
<td>30/28.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>14/16.47</td>
<td>3/2.93</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Glomerular filtration rate, m/l/min*1.73</td>
<td>80.29±28.35</td>
<td>95.81±23.38</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

SD - standard deviation

Conclusion: Raised serum uric acid levels in SLE patients are associated with a higher incidence of hypertension, hypercholesterolemia, obesity, diabetes mellitus, decreased glomerular filtration rate, with a higher Charlson comorbidity index, but not with disease activity.

REFERENCES:
[1] D. Apostolopoulos et all. DOI: 10.1136/lupus-2020-000436

DISCLOSURE OF INTERESTS: Elizaveta Kornilova: None declared. V Mazurov: None declared. Aleksandar Eksi: None declared. Roman Bashki- nov: None declared. Oksana Inamova: None declared. Inna Gaydukova Speakers bureau: Novartis, Sandoz, Pfizer, Biocad, MSD, Dr Reddy's, Lilly, Sanofi, not >10000 Euros per year, Consultant of: Novartis, Pfizer, Bio- cad, MSD, Dr Reddy's, Lilly, Sanofi, not >10000 Euros per year, Grant/research support from: Novartis, Sandoz, Pfizer, Biocad, MSD, Dr Reddy's, not >10000 Euros per year. DOI: 10.1136/annrheumdis-2022-eular.4072

MANAGEMENT AND ASSOCIATED FACTORS

SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE, NEUROPSYCHIATRIC MANIFESTATIONS IN SLE, WITH GOUT, ACTIVE INFECTIONS, ONCOLOGICAL DISEASES, WITH GLOMERULAR REPORTS (≤360 µmol/l) – group 1 and of 106 SLE pts with normal uric acid level in 3 laboratory reports (>360 µmol/l) – group 2. Pts with rheumatological diseases other than SLE, with gout, active infections, oncological diseases, with glomerular filtration rate <30ml/min*1.73 m2 and other secondary reasons of HP were excluded. The clinical and laboratory data, presence of comorbidities, Charlson Comorbidity Index, SELENA-SLEDAI were analyzed. SPSS2020 was used to Statistics. Local ethics committee approved the study.

RESULTS: SLE pts with and without HP were matched in age, sex and disease activity characteristics, Table 1 (p<0.05). Uric acids' level did not correlate with activity of SLE (SELENA-SLEDAI), Spearman r=0.06, p<0.05. Hypertension, obesity, hypercholesterolemia, diabetes mellitus, lower renal function were more common in SLE patients with HP than in SLE patients without HP, Table 1. Charlson comorbidity index was higher in SLE pts than in SLE pts without HP (p<0.05).

Background: Comorbidities play an important role in the course and prognosis of systemic lupus erythematosus (SLE) [1]. Hyperuricemia (HP) could cause an increased burden of comorbidities in SLE patients (pts).

Objectives: To evaluate the interrelation between HP and comorbidities in pts with SLE.

Methods: We performed retrospective analysis of the data from 191 SLE pts that were collected in electronic Saint-Petersburg rheumatological register in a period from 01 Jan 2009 until 31 Dec 2020. In analysis were involved data of 85 SLE patients with hyperuricemia (serum uric acid level >360 µmol/l in 3 reports) (group 1) and of 106 SLE pts with normal uric acid level in 3 laboratory reports (≤360 µmol/l) – group 2. Pts with rheumatological diseases other then SLE, with gout, active infections, oncological diseases, with glomerular filtration rate <30ml/min*1.73 m2 and other secondary reasons of HP were excluded. The clinical and laboratory data, presence of comorbidities, Charlson Comorbidity Index, SELENA-SLEDAI were analyzed. SPSS2020 was used to Statistics. Local ethics committee approved the study.

RESULTS: SLE pts with and without HP were matched in age, sex and disease activity characteristics, Table 1 (p<0.05). Uric acids' level did not correlate with activity of SLE (SELENA-SLEDAI), Spearman r=0.06, p<0.05. Hypertension, obesity, hypercholesterolemia, diabetes mellitus, lower renal function were more common in SLE patients with HP than in SLE patients without HP, Table 1. Charlson comorbidity index was higher in SLE pts than in SLE pts without HP (p<0.05).

Table 1. Characteristics and occurrence of comorbidities in SLE pts.
AB0542 ANTIPHOSPHOLIPID ANTIDIES CARRIERS WITH THROMBOCYTOPENIA COULD BE AN INDEPENDENT PHENOTYPE OF PRIMARY ANTIPHOSPHOLIPID SYNDROME

Y. Shi1, J. Zhao1, X. Zeng1. Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China

Background: Among patients with immune thrombocytopenic (ITP), 10–20% of them were found with positive antiphospholipid antibodies (aPLs) but without typical clinical manifestations of antiphospholipid syndrome (APS), especially thrombotic events.

Objectives: To compare the clinical characteristics and prognosis between aPLs carriers and patients with APS.

Methods: This is a single center prospective cohort study consecutively enrolling thrombocytopenic patients with continuous positive aPLs. Patients developing thrombotic events are classified as the APS group. The exclusion criteria are other underlying connective tissue diseases such as lupus and other causes that might manifest as thrombocytopenia, such as virus infection, hypersplenism, etc.

Results: This cohort included 47 thrombocytopenic patients with continuous positive aPLs and 55 with diagnosed primary APS. The proportion of thrombotic high risk demographic characteristics including smoking, hypertension, and higher level of homocysteine are higher in the APS group (p = 0.03, 0.04, respectively). The prevalence of nephropathy was significantly higher in APS patients (13.8%) than APS patients (4.1%). The mean sedimentation rate (ESR) was 53.7 ± 34.4 mm [2–130]. The mean C-reactive Protein was 13.6 ± 27.8 mg/dL [0–130]. Anti-nuclear antibodies and anti-DNA were positive in 100% and 41.4% of cases, respectively. Anti-Sm antibodies were positive in 13.5%, anti-SSA in 24.1% and anti-SSB in 13.8% of cases. Antiphospholipid was positive in 8 patients.

Discussion: The platelet count of aPLs carriers and patients with APS [0 vs 7 (12.7%), p = 0.01]. Laboratory results and antibody profiles are presented in Table 1.

Disclosure of Interests: None declared


AB0543 HIGHER LEFT VENTRICULAR MASS INDEX IN PATIENTS WITH LUPUS NERPHRITIS

N. Guajardo-Jauregui1, J. R. Azpiri-López2, J. I. Colunga-Pedraza1, D. A. Galarza-Delgado1, A. Cárdenas1, A. N. Garza-Cisneros1, A. Garcia-Heredia1, M. A. Balderas-Palacios1, A. B. Rodríguez-Romero1. Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Cardiology, Monterrey, Mexico; Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Cardiology, Monterrey, Mexico

Background: Systemic lupus erythematosus (SLE) patients have a worse cardiovascular prognosis than the general population. It is estimated that approximately 40% of SLE patients develop lupus nephritis (LN) throughout the evolution of the disease (1). Patients with LN had 8 times more risk of myocardial infarction and 4 times more risk of cardiovascular mortality than SLE patients without LN (2).

Objectives: To compare the echocardiographic parameters between SLE patients with and without LN.

Methods: This was a cross-sectional study nested of a SLE cohort. We recruited patients with SLE diagnosis, according to the 2019 EULAR/ACR

Table 1. Baseline characteristics of laboratory results and antibody profiles.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>aPLs carriers (n=47)</th>
<th>Primary APS with thrombocytopenia (n=65)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory results, median (Q1, Q3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platelet count (x10^9/L)</td>
<td>26 (9,46)</td>
<td>64 (24,89)</td>
<td>0.0002*</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>1,39 (0,475, 2,845)</td>
<td>1,080 (4,1, 2,565)</td>
<td>0.8</td>
</tr>
<tr>
<td>ESR (mm/h)</td>
<td>5,5 (2,75, 10,75)</td>
<td>75 (5, 14,25)</td>
<td>0.06</td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td>221 (176, 252)</td>
<td>228 (184, 382)</td>
<td>0.3</td>
</tr>
<tr>
<td>Low C3, n (%)</td>
<td>3 (6,4)</td>
<td>9 (16,4)</td>
<td>0.2</td>
</tr>
<tr>
<td>Low C4, n (%)</td>
<td>5 (10,6)</td>
<td>8 (14,5)</td>
<td>0.8</td>
</tr>
<tr>
<td>Antibody profiles, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive aCL</td>
<td>45 (95,7)</td>
<td>33 (69,1)</td>
<td>0.3</td>
</tr>
<tr>
<td>Positive Anti-β2GP I</td>
<td>38 (80,9)</td>
<td>48 (87,3)</td>
<td>0.5</td>
</tr>
<tr>
<td>Positive LA</td>
<td>35 (74,5)</td>
<td>50 (90,9)</td>
<td>0.05</td>
</tr>
<tr>
<td>Triple positivity</td>
<td>24 (51,1)</td>
<td>40 (72,7)</td>
<td>0.04*</td>
</tr>
<tr>
<td>Positive Comombs</td>
<td>6 (12,8)</td>
<td>10 (18,2)</td>
<td>0.4</td>
</tr>
</tbody>
</table>

*p < 0.05, statistically significant, aPLs: antiphospholipid antibodies; APS: antiphospholipid syndrome; Q1/3: quantile 1/3; hsCRP: hypersensitive C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; C3/4: complement 3/4; aCL: anticardiolipin; GP: glycoprotein; LA: lupus anticoagulant.

Conclusion: In the absence of other high risk factor for thrombosis, Thrombocytopenia could be an independent and long-lasting clinical phenotype for aPLs carriers.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4182
Results: A total of 48 SLE patients, 24 with LN and 24 without LN were included. Mean age of patients with LN was 36.9 ± 10.4 years, compared to 36.5 ± 9.3 years in patients without LN, \( p = 0.873 \). There were no significant differences in demographic characteristics between groups (Figure 1). When evaluating echocardiographic parameters we found a significant difference in the left ventricular mass index, higher in LN patients (66.9 g/m² vs 54.8 g/m², \( p = 0.035 \)) (Table 1).

Table 1. Comparison of echocardiographic findings of SLE patients with and without LN.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with LN (n=24)</th>
<th>Patients without LN (n=24)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV mass index, g/m²</td>
<td>66.9 ± 21.8</td>
<td>54.8 ± 16.1</td>
<td>0.035</td>
</tr>
<tr>
<td>RWT, mean ± SD</td>
<td>0.37 ± 0.08</td>
<td>0.34 ± 0.10</td>
<td>NS</td>
</tr>
<tr>
<td>LV geometry abnormality, n (%)</td>
<td>7 (29.2)</td>
<td>4 (16.7)</td>
<td>NS</td>
</tr>
<tr>
<td>LAESVI, ml/m², mean ± SD</td>
<td>29.72 ± 10.80</td>
<td>26.04 ± 8.76</td>
<td>NS</td>
</tr>
<tr>
<td>LVEF, %, mean ± SD</td>
<td>58.16 ± 7.42</td>
<td>58.04 ± 7.04</td>
<td>NS</td>
</tr>
<tr>
<td>LVEF, ml, median (IQR)</td>
<td>39.0 (26.0-54.5)</td>
<td>32.5 (23.7-39.7)</td>
<td>NS</td>
</tr>
<tr>
<td>LVESVI, ml, mean ± SD</td>
<td>92.10 ± 25.09</td>
<td>81.57 ± 27.90</td>
<td>NS</td>
</tr>
</tbody>
</table>

SLE: systemic lupus erythematosus; LN: lupus nephritis; NS: not significant; LV: left ventricular; RVT: relative wall thickness; LAESVI, left atrial end-systolic volume index; LVEF, left ventricular ejection fraction; LVEF, left ventricular end-systolic volume; LVESVI, left ventricular end-diastolic volume.

Conclusion: SLE patients with LN had higher left ventricular mass index than SLE patients without LN. An increased left ventricular mass could lead to the development of ventricular hypertrophy, which is associated to a higher risk of cardiovascular mortality. A transthoracic echocardiogram should be considered as part of the cardiovascular evaluation of SLE patients, especially those with LN.

Disclosure of Interests: None declared

Background: Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease. Patients with SLE have higher risk of developing a cardiovascular event than the general population (1), with multiple factors contributing to this increased risk, including systemic inflammation (2).

Objectives: To compare the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and other disease characteristics of SLE patients with and without left ventricular (LV) geometry abnormalities.

Methods: This was a cross-sectional study nested of a SLE cohort. We recruited patients with SLE diagnosis, according to the 2019 EULAR/ACR classification criteria, aged ≥ 18 years. Patients with a previous cardiovascular event, another connective tissue disease or pregnancy were excluded. A transthoracic echocardiogram was performed by two certified echocardiographers blinded to clinical information. Disease activity was assessed with SLEDAI. SLE patients with LV geometry abnormalities were included in this study and matched by age and gender to SLE patients with normal LV geometry by a certified rheumatologist blinded to clinical information. Comparisons were done with Chi-square test or Fisher’s exact test for qualitative variables, and Student’s T test or Mann-Whitney’s U test for quantitative variables. A \( p \)-value < 0.05 was considered statistically significant.

Results: A total of 44 SLE patients were included, 22 patients with LV geometry abnormalities and 22 patients with normal LV geometry. Mean age of SLE patients with LV geometry abnormalities was 35.1 ± 12.2 years, compared to 35.4 ± 9.4 years of SLE patients with normal LV geometry, \( p = 0.923 \). The rest of demographic characteristics are shown in Figure 1. When evaluating disease characteristics, the SLEDAI score was significantly higher in SLE patients with LV geometry abnormalities (26.45 vs 17.33, \( p = 0.016 \)) (Table 1).

Table 1. Comparison of disease characteristics of SLE patients with and without LV geometry abnormalities.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with LV geometry abnormalities (n=22)</th>
<th>Patients with normal LV geometry (n=22)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease duration, months, median (IQR)</td>
<td>60.0 (12.7-150)</td>
<td>72.0 (43.0-117.7)</td>
<td>NS</td>
</tr>
<tr>
<td>SLEDAI, median (IQR)</td>
<td>10.5 (4.0-15.0)</td>
<td>6.0 (2.0-9.0)</td>
<td>0.016</td>
</tr>
<tr>
<td>CRP, mg/dl, median (IQR)</td>
<td>0.52 (0.33-1.29)</td>
<td>0.60 (0.41-0.85)</td>
<td>NS</td>
</tr>
<tr>
<td>ESR, mm/h, median (IQR)</td>
<td>26.0 (13.2-34.2)</td>
<td>29.0 (8.7-58.5)</td>
<td>NS</td>
</tr>
<tr>
<td>ANA titer, median (IQR)</td>
<td>640 (160-3200)</td>
<td>480 (160-5120)</td>
<td>NS</td>
</tr>
<tr>
<td>Anti-dsDNA, median (IQR)</td>
<td>0 (0-160)</td>
<td>0 (0-200)</td>
<td>NS</td>
</tr>
<tr>
<td>C3, mean ± SD</td>
<td>94.6 ± 31.4</td>
<td>100.5 ± 46.1</td>
<td>NS</td>
</tr>
<tr>
<td>C4, median (IQR)</td>
<td>13.6 (8.8-14.9)</td>
<td>12.8 (6.4-19.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Anti-Ro, median (IQR)</td>
<td>4.5 (2.0-190.5)</td>
<td>3.5 (2.0-82.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Anti-La, median (IQR)</td>
<td>2.0 (2.0-4.0)</td>
<td>2.0 (2.0-3.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Hydroxychloroquine, n (%)</td>
<td>20 (90.9)</td>
<td>18 (81.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Glucocorticoids, n (%)</td>
<td>19 (86.4)</td>
<td>17 (77.3)</td>
<td>NS</td>
</tr>
</tbody>
</table>

SLE: systemic lupus erythematosus; LV: left ventricular; NS: not significant; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibodies; anti-dsDNA, anti-double stranded DNA.

Conclusion: SLE patients with LV geometry abnormalities had higher SLEDAI score than patients with normal LV geometry. A transthoracic echocardiogram may be useful detect early cardiovascular abnormalities in SLE patients with high disease activity, and therefore should be considered as part of the cardiovascular evaluation of these patients.

Disclosure of Interests: None declared

REFERENCES:
The thymus, a primary lymphoid organ, plays a crucial role in immune system homeostasis. In systemic lupus erythematosus (SLE), the thymus is a target organ for autoimmunity, and thymic abnormalities are frequently observed in SLE. Recent studies have suggested that thymic abnormalities are associated with the disease activity and damage in SLE. In this study, we investigated the association between radiographic thymus variants and clinical and immunological features in patients with SLE and PM/DM, and clarified its significance.

Methods: In this retrospective study, we examined 144 SLE patients (9.1% and 9.1%, respectively) and 15 PM/DM patients (9.1% and 9.1%, respectively). Thymic enlargement was found in 16 (22.2%) and 14 (28.8%) patients with SLE and PM/DM, respectively. Thymus attenuation (score ≥ 2) was found in 11 (15.3%) and 9 (19.1%) patients with SLE and PM/DM, respectively. These findings were more frequent than in non- connective tissue diseases patients (9.1% and 9.1%, respectively). In SLE patients, radiographic thymus variants, both thymic enlargement and the thymus attenuation score, were significantly positively associated with body weight, and the thymic attenuation score was negatively associated with the ratio of serum IgG and significantly negatively associated with the ratio of serum RF. In these high-risk pregnancies, maternal serum concentration of antiphospholipid antibody positivity was high (69.2% vs. 42.9%, p=0.052) in vasculitis group. In multivariate logistic regression analysis, higher SLEDAI score was positively associated with lupus nephritis and anti-DNA positivity (87.5% vs. 62.5%, p=0.008) but negatively associated with lupus nephritis.

Conclusion: In SLE, vasculitis presentation is common. Higher the SLEDAI score the more chance of lupus vasculitis.

REFERENCES:

Table 1. Clinical features of Lupus vasculitis and without vasculitis (n=168)

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Lupus vasculitis (n=24) n (%)</th>
<th>Without vasculitis (n=144) n (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever</td>
<td>13 (54.2)</td>
<td>36 (25.0)</td>
<td>0.002*</td>
</tr>
<tr>
<td>SLE specific skin lesions</td>
<td>ACLP</td>
<td>19 (79.2)</td>
<td>7 (18.8)</td>
</tr>
<tr>
<td>SCLE</td>
<td>1 (4.2)</td>
<td>6 (4.2)</td>
<td>0.500*</td>
</tr>
<tr>
<td>SLE non-specific skin lesions</td>
<td>Oral ulcers</td>
<td>17 (70.8)</td>
<td>19 (13.2)</td>
</tr>
<tr>
<td>Alopoeia</td>
<td>20 (83.3)</td>
<td>39 (27.1)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Raynoud's</td>
<td>5 (20.8)</td>
<td>8 (5.6)</td>
<td>0.011*</td>
</tr>
<tr>
<td>Arthritis</td>
<td>17 (70.8)</td>
<td>43 (29.8)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Lupus nephritis*</td>
<td>6 (25.0)</td>
<td>65 (45.1)</td>
<td>0.032*</td>
</tr>
<tr>
<td>Neuro psychiatric</td>
<td>Seizure</td>
<td>2 (8.3)</td>
<td>1 (0.7)</td>
</tr>
<tr>
<td>Psychosis</td>
<td>1 (4.2)</td>
<td>2 (1.4)</td>
<td>0.196</td>
</tr>
<tr>
<td>Serosis</td>
<td>Reueryy</td>
<td>2 (8.3)</td>
<td>2 (8.3)</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>1 (4.2)</td>
<td>3 (2.1)</td>
<td>0.232</td>
</tr>
<tr>
<td>Pregnancy loss</td>
<td>11/16 (68.8)</td>
<td>32/98 (32.7)</td>
<td>0.003*</td>
</tr>
<tr>
<td>DVT</td>
<td>1 (4.2)</td>
<td>6 (4.2)</td>
<td>0.500</td>
</tr>
<tr>
<td>APS</td>
<td>3 (12.5)</td>
<td>11 (7.6)</td>
<td>0.213</td>
</tr>
<tr>
<td>AVN</td>
<td>1 (4.2)</td>
<td>2 (1.4)</td>
<td>0.186</td>
</tr>
<tr>
<td>Pulmonary HTN</td>
<td>2 (8.3)</td>
<td>3 (2.1)</td>
<td>0.074*</td>
</tr>
</tbody>
</table>

* Fisher’s exact test, χ²-Square test, p < 0.05 is considered statistically significant, n: Number, %: Percent, ACLP: Acute Cutaneous Lupus Erythematosus, SCLE: Sub-acute Cutaneous Lupus Erythematosus, DVT: Deep Vein Thrombosis, APS: Anti Phospholipid Antibody Syndrome, AVN: Avascular necrosis, HTN: Hypertension, a: all diagnosed cases of lupus nephritis, presented with or without flare

Acknowledgements: We acknowledge all of our patients for their kind participation in this study. We also acknowledge Prof. Syed Atiqul Haq, Prof. Minhaj Rahman Choudhury, Prof. Abu Shahin, Dr. Md. Masudul Hassan, Dr. Shamim Ahmed, Dr. Abul Kalam Azad, Department of rheumatology, BSMMU for their support and kind help during the work. At the end we acknowledge BSMMU authority for their support in conducting the study.

Table of Interests: None declared

the anti-angiogenic factor soluble Fms-like tyrosine kinase-1 (sFlt-1) and the pro-angiogenic factor placental growth factor (PIGF) can predict fetal growth restriction and preeclampsia (1-3).

Methods: Patients with SLE and APS that followed in our outpatient clinic were retrospectively analysed for their pregnancy course and outcomes. In these high-risk pregnancies, the sFlt-1/PIGF ratio was measured in the context of screening for preeclampsia and a ratio below 38 was applied to exclude preeclampsia. We compared the sFlt-1/PIGF ratio between patients with and without adverse pregnancy outcome. Adverse pregnancy outcome (APO) was defined as preeclampsia, preterm delivery and small for gestational age newborns.

Results: We analysed sFlt-1/PIGF ratios of 13 singleton pregnancies in 12 patients with SLE and/or APS (4 SLE, 6 SLE with APS or aPL, 2 obstetric APS). Low-dose aspirin was used in all but one pregnancy with de-novo obstetric APS. Low-molecular weight heparin was given in seven pregnancies. Adverse pregnancy outcome occurred in five pregnancies thereof two with preeclampsia. The median sFlt-1/PIGF ratio measured between gestational week 22 and 37 was higher in patients with APO (median 173, range 4-1904) than in patients without APO (median 7.5, range 50) (P=0.03). The sFlt-1/PIGF ratio > 38 was found in 6 pregnancies including two with preeclampsia. Highest sFlt-1/PIGF ratios were found in a case with severe intrauterine growth restriction without signs of preeclampsia (sFlt-1/PIGF=1940) and in a case with early preeclampsia (< week 34 (sFlt-1/PIGF=1187). In pregnancies with a sFlt-1/PIGF ratio < 38 there were no signs of preeclampsia or intrauterine growth restriction.

Conclusion: The detection of a dysbalanced sFlt-1/PIGF ratio is clinically useful as it differentiates between pregnancies with adverse outcome and those with normal outcome. More data are needed to further evaluate the predictive potential of these placental biomarkers in the first trimester and their usefulness for treatment adjustments in order to improve pregnancy outcome.

REFERENCES:

Disclosure of Interests: Jasmin Simone Brigger: None declared, Astrid Zbinden: None declared, Luigi Raio Speakers bureau: Thermo Fischer, Frauke Förger Speakers bureau: UCB Pharma, GSK, Consultant of: UCB Pharma, GSK, Roche, Grant/research support from: UCB Pharma, GSK

Table 1. Demographics, clinical features of adult-onset and childhood-onset NPSLE patients

<table>
<thead>
<tr>
<th>Adult-onset NPSLE</th>
<th>Childhood-onset NPSLE</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=101)</td>
<td>(n=29)</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>63 (62.4)</td>
<td>8 (27.6)</td>
</tr>
<tr>
<td>Arterial cerebrovascular events</td>
<td>44 (43.6)</td>
<td>5 (17.2)</td>
</tr>
<tr>
<td>Central nervous system vasculitis</td>
<td>36 (35.4)</td>
<td>10 (34.5)</td>
</tr>
<tr>
<td>Parenchymal involvement</td>
<td>18 (17.8)</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>Demyelinating syndrome</td>
<td>14 (13.9)</td>
<td>2 (6.9)</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>5 (5.0)</td>
<td>-</td>
</tr>
<tr>
<td>Cerebral venous sinus thrombosis</td>
<td>4 (4.0)</td>
<td>6 (20.7)</td>
</tr>
<tr>
<td>Meningeal involvement</td>
<td>5 (5.0)</td>
<td>-</td>
</tr>
<tr>
<td>Posterior reversible encephalopathy syndrome</td>
<td>3 (3.0)</td>
<td>2 (6.9)</td>
</tr>
<tr>
<td>Pseudotumor cerebri</td>
<td>7 (6.9)</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>Idiopathic intracranial hypertension</td>
<td>2 (2.0)</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>Lupus headache</td>
<td>38 (37.6)</td>
<td>18 (62.1)</td>
</tr>
<tr>
<td>Acute confusional state</td>
<td>13 (12.9)</td>
<td>4 (13.8)</td>
</tr>
<tr>
<td>Cognitive dysfunction</td>
<td>9 (8.9)</td>
<td>1 (3.4)</td>
</tr>
<tr>
<td>Seizure disorders</td>
<td>31 (30.7)</td>
<td>11 (37.9)</td>
</tr>
<tr>
<td>Movement disorder (chorea)</td>
<td>4 (4.0)</td>
<td>2 (6.9)</td>
</tr>
<tr>
<td>Myasthenia gravis</td>
<td>3 (3.0)</td>
<td>-</td>
</tr>
<tr>
<td>Cranial neuropathy</td>
<td>7 (6.9)</td>
<td>3 (10.3)</td>
</tr>
<tr>
<td>Optic neuritis</td>
<td>4 (4.0)</td>
<td>1 (3.4)</td>
</tr>
<tr>
<td>Periperal polyneuropathy</td>
<td>9 (8.9)</td>
<td>5 (17.2)</td>
</tr>
<tr>
<td>Mononeuritis multiplex</td>
<td>1 (1.0)</td>
<td>-</td>
</tr>
<tr>
<td>Myelopathy</td>
<td>5 (5.0)</td>
<td>2 (6.9)</td>
</tr>
<tr>
<td>Autonomic dysfunction</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Small fiber neuropathy</td>
<td>1 (1.0)</td>
<td>-</td>
</tr>
</tbody>
</table>

Figure 1. Distribution of adult-onset and childhood-onset NPSLE patients

AB0548 A COMPARATIVE STUDY BETWEEN THE NEUROPSYCHIATRIC INVOLVEMENTS IN ADULT-ONSET AND CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS


1Hacettepe University Faculty of Medicine, Division of Rheumatology, Department of Internal Medicine, Ankara, Turkey; 2Hacettepe University Faculty of Medicine, Department of Pediatric Rheumatology, Ankara, Turkey; 3Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey; 4Hacettepe University Faculty of Medicine, Department of Neurology, Ankara, Turkey; 5Hacettepe University Faculty of Medicine, Division of Rheumatology, Department of Internal Medicine, Ankara, Turkey; 6Hacettepe University Faculty of Medicine, Department of Pediatric Neurology, Ankara, Turkey; 7Hacettepe University Faculty of Medicine, Department of Radiology, Ankara, Turkey

Background: Neuropsychiatric(NP) manifestations in systemic lupus erythematosus(SLE) encompass a wide spectrum of neurologic and psychiatric features. The nervous system is frequently affected by adult-onset and childhood-onset SLE patients, but disease course and clinical features may differ between both groups.

Objectives: The aim of this study is to evaluate and compare NP manifestations in adult-onset and childhood-onset SLE patients.

Methods: The study included a retrospective analysis of medical records of adult-onset SLE patients and childhood-onset SLE patients following at Hacettepe University from Jan 2015 to Jan 2021. The ACR established case definitions seen in SLE. Additionally, posterior reversible encephalopathy syndrome, cerebral venous thrombosis, small fiber neuropathy and pseudotumor cerebri were evaluated as having NPSLE in this study.
AB0549

OBESITY AND TOBACCO SMOKING ARE INDEPENDENTLY ASSOCIATED WITH POOR PATIENT-REPORTED OUTCOMES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A SWEDISH TERTIARY REFERRAL CENTRE

A. Gomez,1,2 I. Parodi,1,2 C. Siowja,1 Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden;3 Örebro University, Department of Rheumatology, Faculty of Medicine and Health, Örebro, Sweden; Linköping University, Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping, Sweden

Background: Patients with systemic lupus erythematosus (SLE) experience impaired health-related quality of life (HRQoL), pain, fatigue and functional disability. The effect of pharmacotherapy on these aspects has been inconclusive in literature. In light of this, the investigation of the impact of lifestyle facets is needed to support complementary non-pharmacological interventions such as weight control strategies and tobacco smoking cessation.

Objectives: To evaluate associations of obesity and tobacco smoking with SLE patients’ HRQoL, pain, fatigue and functional disability.

Methods: Patients from the Linköping University Hospital with an SLE diagnosis according to the 1982 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria were included in the present cross-sectional analysis of data captured at visits between January 2008 and September 2021. Among consecutive visits, the first visit with complete demographic, clinical and patient-reported data was selected for the present analysis.

Body mass index (BMI) categories were based on the World Health Organization classification: underweight (BMI <18.5 kg/m²), normal weight (18.5 ≤ BMI <25 kg/m²), pre-obesity (25 ≤ BMI <30 kg/m²) and obesity (BMI ≥30 kg/m²). Smoking status was self-reported and categorised into never, prior and current smoking. HRQoL was self-reported using the 3-level EuroQoL 5-Dimension (EQ-5D-3L) index scores. Visual analogue scales (VAS; 0–100) were used to self-report fatigue, pain and well-being within the preceding 7 days. Functional disability was evaluated using the Swedish version of the Health Assessment Questionnaires Disability Index (HAQ-DI). Disease activity was evaluated using the clinical (c) SLEDAI-2K (serology excluded). Comparisons of continuous data between different BMI and smoking categories were performed using the Mann-Whitney U test and Kruskal-Wallis test. Multivariable linear regression analysis was employed to assess independence and priority of contributors to HRQoL and functional impairment.

Results: Compared with normal weight, obese individuals reported lower VAS fatigue [50.0 (27.0–72.5) versus 32.0 (6.5–89.5); P=0.008], VAS pain [40.0 (11.0–67.0) versus 20.5 (5.3–46.5); P=0.011], VAS well-being [50.0 (27.0–72.5) versus 32.0 (6.5–59.5); P=0.008] and HAQ scores [0.73 (0.36–0.80) versus 0.78 (0.68–0.85); P=0.014], as well as higher VAS fatigue [β =0.12; P=0.021] and VAS pain [β =0.27; P<0.001] and HAQ scores [β =0.30; P=0.001] in obese patients compared with normal weight.

Conclusion: Obesity is independently associated with lower EQ-5D-3L index scores (β =0.12; P=0.021), but not with cSLEDAI-2K (β =0.05; P=0.27), in patients with SLE. Smoking was independently associated with lower VAS fatigue (β =-0.12; P=0.021) and VAS pain (β =-0.30; P=0.001) and HAQ scores (β =-0.30; P=0.001) and HAQ scores (β =-0.30; P=0.001) in patients who were never exposed to regular tobacco smoking. There were no differences across groups regarding cSLEDAI-2K scores.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4319

AB0551

CUTANEOUS LUPUS AREA AND SEVERITY INDEX (CLASI) CORRELATES WITH SELF-IMAGE SCORE BUT NOT QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

N. H. Malee2,3,1, D. Maikap2, P. Padhan2, R. Misra2, S. C. Ch, S. Ahmed,1 Kalinga Institute of Medical Sciences, Dermatology, Bhubaneshwar, India; 2Kalinga Institute of Medical Sciences, Clinical Immunology and Rheumatology, Bhubaneshwar, India

Background: Systemic lupus erythematosus (SLE) has multi-system involvement including skin. We explored how skin involvement influenced with the quality of life of patients with SLE.

Objectives: To correlate the domains of SLE QoL with skin involvement and total lupus disease activity.

Methods: A cross-sectional survey of patients with SLE who were carried out to assess Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and SLE-QoL. Lupus disease activity and damage were quantified using MexSLEDAI (Mexican SLE Disease Activity Index) and SLICC (Systemic Lupus International Collaborating Clinics) Damage Index respectively. Data is expressed as median (IQR).

Disclosure of Interests: None declared


AB0550

CLINICAL AND PROGNOSTIC SIGNIFICANCE OF ANTINUCLEAR ANTIBODIES IN PRIMARY ANTIPHOSPHOLIPID SYNDROME: FRENCH MULTICENTER RETROSPECTIVE STUDY

L. Ricard,1 L. Charlotte,1 M. Papo,1 A. Meikinian,1 Saint Antoine, Internal Medicine, Paris, France;2 Pitié, Internal Medicine, Paris, France

Background: The antiphospholipid syndrome (APS) is defined by the development of vascular thrombosis, or pregnancy morbidity in the presence of persistent antiphospholipid antibodies (APL). Antinuclear antibodies (ANA) can be detected in primary APS patients without any clinical systemic autoimmune disease. The presence of ANA antibodies could confer a specific phenotype in primary APS.

Objectives: To evaluate the characteristics of APS patients with antinuclear antibodies without other autoimmune disease (ANA-positive APS patients) in comparison with primary APS without ANA (ANA-negative APS) or secondary APS patients with associated systemic lupus erythematosus (SLE-APS).

Methods: Clinical and biologic data from 195 APS were retrospectively collected. ANA test was considered to be positive when titers were superior or equal to the 1/80 dilution. ANA-positive APS patients did not fulfilled SLE ACR/EULAR classification criteria.

Results: 40 patients (21%) with ANA-positive APS were included, 77 patients (39%) with primary APS without ANA autoantibodies (ANA-negative APS) and 78 patients (40%) with SLE-APS (SLE-APS). Patients with ANA-positive APS presented arterial thrombosis in 20 cases (51%) and venous thrombosis in 14 cases (41%), adverse obstetrical in 19 cases (51%), non-criteria APS features were noted in 19 cases (51%). ANA-positive APS patients had more non criteria manifestations than ANA-negative APS (48% versus 25%; p<0.01). ANA-positive APS patients had more triple APL positivity and more thrombosis recurrences in comparison with ANA-negative APS patients, respectively (59% versus 18%; p<0.001) and (63% versus 36%; p<0.01). ANA-positive APS and SLE-APS patients had similar clinical manifestations and recurrences. Despite a limited follow-up (28 months (11-50)) none of the ANA-positive APS patients develop SLE. Antplatelet and anticoagulant therapies were similar for the three groups. SLE-APS patients received more immunomodulatory therapies.

Conclusion: ANA positivity in patients with APS enables to individualize a subset of patients with a more severe phenotype. Whereas the ANA positivity does not seem to be associated with the risk to develop SLE, prospective studies with a longer follow-up are necessary, in particular to evaluate the effect of additional therapies in this subset of APS.

Disclosure of Interests: None declared

Table 1. Correlations between different domains of the SLE(Systemic Lupus Erythematosus) -QoL(Quality of Life) with CLASI (Cutaneous Lupus Area and Severity Index) and Mexican SLE-DAI(SLE Disease Activity Index).

<table>
<thead>
<tr>
<th>SLE-QoL Domains</th>
<th>Physical functioning</th>
<th>Physical activity</th>
<th>Symptoms</th>
<th>Treatment</th>
<th>Mood</th>
<th>Selfimage</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLASI Activity</td>
<td>0.28</td>
<td>0.062</td>
<td>0.242</td>
<td>0.103</td>
<td>0.113</td>
<td>0.252</td>
<td>0.102</td>
</tr>
<tr>
<td>(p=0.87)</td>
<td>(p=0.73)</td>
<td>(p=0.16)</td>
<td></td>
<td>(p=0.56)</td>
<td>(p=0.52)</td>
<td>(p=0.15)</td>
<td>(p=0.56)</td>
</tr>
<tr>
<td>CLASI Damage</td>
<td>0.125</td>
<td>0.010</td>
<td>0.257</td>
<td>0.239</td>
<td>0.233</td>
<td>0.446**</td>
<td>0.243</td>
</tr>
<tr>
<td>(p=0.47)</td>
<td>(p=0.95)</td>
<td>(p=0.13)</td>
<td></td>
<td>(p=0.17)</td>
<td>(p=0.18)</td>
<td>(p=0.007)</td>
<td>(p=0.04)</td>
</tr>
<tr>
<td>CLASI total</td>
<td>0.047</td>
<td>0.062</td>
<td>0.448*</td>
<td>0.331</td>
<td>0.332</td>
<td>0.315</td>
<td>0.281</td>
</tr>
<tr>
<td>(p=0.80)</td>
<td>(p=0.75)</td>
<td>(p=0.013)</td>
<td></td>
<td>(p=0.07)</td>
<td>(p=0.07)</td>
<td>(p=0.09)</td>
<td>(p=0.13)</td>
</tr>
<tr>
<td>Mexican SLEDAI SCORE</td>
<td>0.021</td>
<td>0.130</td>
<td>0.390*</td>
<td>0.251</td>
<td>0.115</td>
<td>0.197</td>
<td>0.220</td>
</tr>
<tr>
<td>(p=0.99)</td>
<td>(p=0.47)</td>
<td>(p=0.025)</td>
<td></td>
<td>(p=0.16)</td>
<td>(p=0.52)</td>
<td>(p=0.07)</td>
<td>(p=0.27)</td>
</tr>
</tbody>
</table>

Results: In the cohort of 35 patients with SLE, with an age of 26(IQR:17-32) years and including eight (22.9%) males, the CLASI score was 3(1-11.5) with an activity score of 3(1-15) and a chronicity score of 1(0-4). The disease duration was 4years (IQR: 2-3) while SLE-QoL was 73(62-86). Overall, most of the patients had active disease at inclusion with a mex-SLEDAI of 8(6.5-11.5). SLICC was 1(0-4).

The correlation matrix of different domains of the SLE-QoL with CLASI, and Mex-SLEDAI is presented in Table 1. Correlation with SLICC was not analysed since it was zero in the majority of participants. Multivariate analyses were not done since there was lack of association on univariate analysis.

Conclusion: In this cohort of patients with active SLE, the SLE-QoL did not correlate with either the overall disease activity score nor the skin specific score. Only the Self-image domain correlated with the skin score. This implies that in active disease, the skin involvement may have only a minor effect on the quality of life.

REFERENCES:

AB0552 ELEVATED KYNURENINE LEVELS IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
1Ministry of Health Ankara City Hospital, Department of Rheumatology, Ankara, Turkey; 2Ankara Yildirim Beyazit University, Ankara City Hospital, Biochemistry, Ankara, Turkey; 3Ankara City Hospital, Biochemistry, Ankara, Turkey; 4Acibadem University, Biochemistry, Istanbul, Turkey; 5Ankara Yildirim Beyazit University, Ankara City Hospital, Rheumatology, Ankara, Turkey

Background: Sjögren’s syndrome (SS) is a chronic autoimmune inflammatory disease of unknown origin that predominantly affects the exocrine glands (mainly salivary and lacrimal glands). Primary Sjögren’s syndrome (pSS) is a disease whose etiology is not yet fully understood, as in most autoimmune diseases, where genetic, epigenetic and environmental factors are hypothesized to play to the pathogenesis of the disease. Metabolism of tryptophan (Trp) via the kynurenine (Kyn) pathway has been proposed to act a substantial role in inflammatory processes.

Objectives: In the present study, we investigated levels of Trp and its metabolites in the Kyn pathway in patients with pSS and in healthy controls. Also, the relationship between Trp metabolites and laboratory parameters, disease activity was evaluated in patients with pSS.

Methods: The study included 34 pSS patients and 42 healthy individuals, and serum Trp and Kyn concentrations were measured by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Trp degradation was predicted using the ratio of Kyn and Trp concentrations (Kyn/Trp). The EULAR Sjögren’s syndrome disease activity index (ESSDAI) and the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) were used to evaluate pSS activity.

Results: In our study, the mean serum Trp concentration was found to be considerably lower in the pSS group compared to the control group (p=0.001). The lev-
els of Kyn (p=0.019) and Kyn/Trp ratio (p<0.001) were significantly higher in the pSS group compared to the control group (Table 1). Trp concentration was negatively correlated with physician global assessment (r=-0.568, p<0.001), positively correlated with albumin (r=0.384, p=0.026) and hemoglobin (r=-0.396, p=0.032). The Kyn/Trp ratio was negatively correlated with CRP (r=-0.369, p=0.032). There was no correlation between the Trp pathway and disease activity parameters ESSDAI and ESSPRI.

Table 1. Comparison of the kynurenine pathway results of patients with Sjögren’s syndrome and the controls

<table>
<thead>
<tr>
<th>Kynurenine (mg/ml)</th>
<th>485 (378-601)</th>
<th>386 (356-496)</th>
<th>0.019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trypophan (mg/ml)</td>
<td>10660 (9160-12282)</td>
<td>12256 (11442-14711)</td>
<td>0.001</td>
</tr>
<tr>
<td>Kynurenine/trypophan ratio (%)</td>
<td>4 (3-4)</td>
<td>3 (3-4)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

* Mann-Whitney U test

Disclosure of Interests: None declared


AB0553 KIDNEY BIOPSY IN FIRST RENAL FLARE OF SLE – WHAT DOES IT TELL US?
L. Karlsön1, A. Zickert1, E. Svennungsson1, I. Gunnansson2, J. Olofsson1, 2Karolinska Institutet, Department of Medicine, Division of Rheumatology, Solna, Sweden; 1Karolinska University Hospital, Rheumatology, Solna, Sweden

Background: Lupus Nephritis (LN) is an immune-complex mediated glomerulonephritis affecting up to 60% of all SLE patients during the disease course. A kidney biopsy is indicated in SLE patients presenting with signs of renal involvement, such as persistent proteinuria, and is generally recommended to evaluate the inflammatory findings but also to rule out other etiologies of renal involvement and to guide the need of immunosuppressive therapy.

Objectives: To investigate the histopathological findings in first-time renal biopsies from a large cohort of SLE patients. We especially evaluated the type and occurrence of histopathological findings other than LN as these may lead to a risk of inadequate therapeutic interventions.

Methods: Patients from the Karolinska SLE cohort who had a first-time onset of renal involvement from 1995 to 2021 and subsequent renal biopsy were included in the study. All patients fulfilled the American College of Rheumatology (ACR) and/or Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) disease classification criteria (1, 2) for SLE and were biopsied on clinical indication, i.e., proteinuria > 0.5g/day or active SLE in combination with a rise in plasma creatinine, decrease in glomerular function or new onset proteinuria with concurrent active urea sediment.

Results: In total, 141 patients with first time presentation of renal involvement who had been subject to renal biopsy were included. Of these 107 patients (75.9%) were female. The median age at the time of biopsy was 34.5 years (range 15.5 - 86.4). For more patient baseline characteristics, see Table 1. One-hundred twenty-five patients (88.7 %) had findings consistent with LN according to ISN/ RPS classification system. Twenty-five patients (18.4 %) had class I - II, 43 (30.5 %) class III ± V, 31 (22.0 %) class IV ± V and 26 (18.4 %) class V. Sixteen patients (15.5 %) did not have histological changes in accordance with LN. Of these, 3 had membranous nephropathy, 2 had antiphospholipid associated nephropathy, 1 had IgA nephropathy, 1 had tubulointerstitial nephritis and 7 had evidence of systemic vasculitis. Of these, 5 were later found to be ANCA-positive and were re-diagnosed with concomitant ANCA-associated vasculitis. Two patients did not
show any classifiable histological changes. Of the 16 non-LN patients, 6 had proteinuria > 0.5 g/day, 2 had new-onset low-grade proteinuria and concurrent active urine sediment, 2 had new-onset low-grade proteinuria with concurrent SLE disease activity, and 5 patients had isolated persistent low-grade proteinuria. In one case data was missing.

### Table 1. Baseline characteristics, 141 patients

| Age at SLE diagnosis (years); M (IQR) | 32.2 (22.0 – 44.9) |
| SLE duration at biopsy (years); M (IQR) | 0.6 (0.2 – 5.3) |
| Systolic blood pressure (mm Hg); Mean (SD) | 127.5 (20.8) |
| Erythema | 119 (84.4) |
| Asian; n (%) | 9 (6.4) |
| African; n (%) | 7 (5.0) |
| Hispanic; n (%) | 6 (4.3) |
| Prednisone equivalent dose (mg/day); M (IQR) | 10.0 (0.0 – 20.0) |

**Diagnosis according to ISN/RPS**

- Class I-II 25 (17.7)
- Class III ± V 43 (30.5)
- Class IV ± V 31 (22.0)
- Class V ± II 26 (18.4)
- TMA/antiphospholipid syndrome 2 (1.4)
- Vascuities 7 (5.0)
- Hypertensive nephrosclerosis 3 (2.1)
- IgA nephropathy 1 (0.7)
- Tubulointerstitial nephritis 1 (0.7)
- Nonspecific changes 2 (1.4)

**Conclusion:** We demonstrate that renal histopathology confirmed other causes than LN in a significant proportion (11.3%) of SLE patients with signs of renal involvement. Since these patients may need other therapeutic interventions than patients with classic LN, we can conclude that the renal biopsy is important in order to guide the choice of therapeutics.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4507

---

**Table 1. Baseline characteristics, treatment patterns and PROs among patients with SLE stratified by SLEDAI score**

<table>
<thead>
<tr>
<th>Total Sample</th>
<th>SLEDAI=0 (n=60, 22%)</th>
<th>SLEDAI=1-6 (n=79, 28.9%)</th>
<th>SLEDAI=7-12 (n=70, 23.4%)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physician-Reported Clinical Status and Treatment History</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current SLE severity, n(%)</td>
<td>Milos 221 (81.0)</td>
<td>51 (85.0)</td>
<td>70 (88.6)</td>
<td>53 (75.7)</td>
</tr>
<tr>
<td>Severe 49 (18.0)</td>
<td>9 (15.0)</td>
<td>9 (11.4)</td>
<td>16 (22.9)</td>
<td>15 (23.4)</td>
</tr>
<tr>
<td>Current joint symptoms, n(%)</td>
<td>Joint tenderness 109 (39.9)</td>
<td>24 (40.0)</td>
<td>27 (34.2)</td>
<td>28 (40.0)</td>
</tr>
<tr>
<td>Joint stiffness</td>
<td>121 (44.3)</td>
<td>22 (36.7)</td>
<td>33 (41.8)</td>
<td>37 (52.9)</td>
</tr>
<tr>
<td>Joint swelling 60 (22.0)</td>
<td>17 (28.3)</td>
<td>13 (16.5)</td>
<td>19 (27.1)</td>
<td>11 (17.2)</td>
</tr>
<tr>
<td>Mean [SD] Flares in the last 12 months</td>
<td>Belimumab 16 (15.0)</td>
<td>13 (12.0)</td>
<td>17 (17.0)</td>
<td>15 (13.0)</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>48 (17.6)</td>
<td>7 (11.7)</td>
<td>16 (21.3)</td>
<td>10 (12.7)</td>
</tr>
<tr>
<td>Corticosteroids 138 (50.6)</td>
<td>35 (58.3)</td>
<td>62 (84.3)</td>
<td>29 (41.7)</td>
<td>32 (45.7)</td>
</tr>
<tr>
<td>Antimalarials</td>
<td>206 (75.5)</td>
<td>28 (46.7)</td>
<td>108 (77.1)</td>
<td>64 (80.1)</td>
</tr>
</tbody>
</table>

| Patient-Reported Outcomes | | | | |
| Mean [SD] EQ5D-5L Utility score (0=death to 1= full health) | 0.79 (0.19) | 0.83 (0.12) | 0.82 (0.21) | 0.79 (0.14) | 0.69 (0.25) | 0.024 |
| Mean [SD] FACIT-Fatigue score (0=worst fatigue to 52= no fatigue) | 36.8 (12.7) | 36.1 (12.5) | 29.8 (9.6) | 26.4 (14.3) | <0.001 |
| Mean [SD] WPAI overall (0= no impact to 100= completely impacted) | 26.8 (12.1) | 25.2 (16.8) | 19.5 (23.6) | 35.7 (20.2) | 31.9 (26.7) | 0.131 |

49% of SLE patients were categorized as SLEDAI 7-12 or >12. Among the SLEDAI 7-12 (moderate) patients, 75.7% were subjectively categorized by their physician as having mild SLE. Of the SLEDAI >12 patients (severe), 73.4% were categorized as having mild SLE. Joint symptoms and flaring in the last 12 months were not significantly different across SLEDAI groups.

Patients with greater SLEDAI reported lower EQ5D and greater FACIT-Fatigue scores. There was no statistical difference in WPAI between the SLEDAI groups.
emphysema, Chronic Obstructive Lung Disease, bronchial asthma etc.) were excluded. The following data were collected from clinical charts: demographics, smoke exposure, comorbidities, respiratory symptoms, disease duration and disease activity (SELENA-SLEDAI) at the onset of lung involvement, immunological profile, treatment, CT and spirometry parameters.

**Results:** Over 450 SLE patients in regular follow-up, we found 11 female patients with a history of clinically relevant non-serositis lung involvement: 7 interstitial lung disease (ILD), 2 acute lupic pneumonitis (ALP), 1 diffuse alveolar hemorrhage (DAH) and 1 shrinking lung syndrome. 45.4% of patients had a history of smoke exposure and had stopped smoking on average 9 years before the onset of lung manifestations. For the 2 patients with ALP, this was the first manifestation of SLE. Among the other 9 patients, lung involvement was diagnosed after a mean disease duration of 14 ± 15 years. At the diagnosis of pulmonary involvement, 10/11 patients presented respiratory symptoms and an overall active disease, with a median SLEDAI of 9 (IQR 6-13). Clinical characteristics are summarized in Table 1. All patients were hospitalized and 2 of them (1 ALP and 1 DAH) were admitted in intensive care unit.

**Table 1. Clinical characteristics at the diagnosis of lung involvement**

<table>
<thead>
<tr>
<th>Systemic</th>
<th>Active skin manifestations</th>
<th>36%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td></td>
<td>36%</td>
</tr>
<tr>
<td>Fever</td>
<td></td>
<td>36%</td>
</tr>
<tr>
<td>Leukopenia</td>
<td></td>
<td>36%</td>
</tr>
<tr>
<td>Hypocomplementemia</td>
<td></td>
<td>91%</td>
</tr>
<tr>
<td>Anti-dsDNA positivity</td>
<td></td>
<td>36%</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Dyspnea</td>
<td>54%</td>
</tr>
<tr>
<td>Exertional dyspnea</td>
<td></td>
<td>18%</td>
</tr>
<tr>
<td>Cough</td>
<td></td>
<td>45%</td>
</tr>
<tr>
<td>Acute respiratory failure</td>
<td></td>
<td>27%</td>
</tr>
</tbody>
</table>

As for the immunologic profile, SSA/Ro50 were positive in 72% of patients and SSA/Ro52, SSB, U1-RNP in 36%; 36% had Sjögren Syndrome (SS) in overlap.

Spirometry was available in 6/11 patients: a restrictive pattern and a moderately severe reduction of diffusing capacity of the lung for carbon monoxide was found in 5 patients.

In the ILD subgroup, the most prevalent CT pattern was the Non-specific interstitial pneumonia (NSIP) (5/7), 2 patients presented a Bronchiolitis obliterans/organizing pneumonia (BOOP) pattern.

Lung involvement was the driving manifestation in the treatment choice for 6/11 patients: 1 DAH, 2 ALP, 1 Shrinkling lung and 2 ILD. All received pulse steroids and in 3 cases (2 ILD and 1 DAH) cyclophosphamide was added for the induction treatment; the patient with Shrinkling lung had an overlap SS and was treated with Rituximab.

At last visit (mean follow-up of 8 ± 8.7 years since lung disease onset), 7/11 patients presented no respiratory symptoms and a complete resolution of CT alterations. 3/11 presented a residual exertional dyspnea and mild spirometry alterations. No patients developed respiratory insufficiency; only 1 patient died for cardiovascular complications.

**Conclusion:** In our large cohort of SLE patients, non-serositis lung involvement seems to be overall rare; the most frequent type of lung manifestation is ILD which appears to be associated with anti-SSA/SSB and anti-U1RNP positivity. The low prevalence of lung involvement (2.4%) in our cohort could be due to the presence of patients with a subclinical involvement. Further studies are needed to assess the real prevalence of subclinical lung manifestations in SLE and to identify the clinical phenotype of patients more prone to develop pulmonary disease.

**Disclosure of Interests:** Davide Schillino: None declared, Elena Elefante: None declared, Chiara Stagnaro: None declared, Viola Signorini: None declared, Dina Zucchi: None declared, Francesca Trentin: None declared, Gaetano La Rocca: None declared, Linda Carlì: None declared, Francesco Ferro: None declared, Chiara Tani: None declared, Marta Mosca speaks bureau: advisor LILLY, ASTRA ZENECA, GSK, Consultant of: advisor LILLY, ASTRA ZENECA, GSK

**DOI:** 10.1136/annrheumdis-2022-eular.4606

**AB0556 CHARACTERISTICS OF PATIENTS DIAGNOSED WITH UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE**

**G. Siegel, B. Stamm, J. Vega, E. Sevim, M. Lockshin, L. Sammaritano, M. Barbhaiya, C. Siegel, Hospital for Special Surgery, Medicine, New York, United States of America; 2Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, United States of America; 3Montefiore Medical Center, Medicine, Bronx, United States of America; 4Albert Einstein College of Medicine, Medicine, Bronx, United States of America; 5Weill Cornell Medicine, Medicine, New York, United States of America

**Background:** Patients with undifferentiated connective tissue disease (UCTD) struggle with physical symptoms as well as diagnostic uncertainty. 1 UCTD diagnosis requires exclusion of other connective tissue diseases (CTD). Prior studies use variable definitions of UCTD that do not account for updated classification criteria thus limiting generalizability.

**Objectives:** We identified characteristics associated with rheumatologist-diagnosed UCTD, applied stringent exclusion criteria, and compared UCTD patients to those with criteria-defined CTD.

**Methods:** We recruited patients ≥18 years old seen between 2018-2022 who had rheumatologist-diagnosed UCTD with positive ANA and ≥1 sign/symptom of a CTD. We reviewed medical records to identify those who fulfilled ACR/EULAR-endorsed classification criteria for SLE, RA, SSc. Primary Sjögren’s, Idiopathic Inflammatory Myopathies, and 2006 Revised Sapporo Criteria for APS. We compared sociodemographic, clinical, serologic, and treatment variables between UCTD and CTD using chi-square, Fisher’s exact, and t-tests.

**Results:** Of 89 patients with rheumatologist-diagnosed UCTD (mean age 49.0 ± 13.7 years, 97.8% female, 66.3% White), 59 (66.3%) had UCTD and 30 (33.7%) had criteria-defined CTD (27 SLE, 3 SLE and RA, 1 RA, and 1 APS). Patients in both groups had similar non-criteria manifestations, most commonly arthralgia (89.8% UCTD vs. 83.3% CTD, p=0.50) and fatigue (59.5% UCTD vs. 73.3% CTD, p=0.17). Compared to patients with CTD, those with UCTD were less likely to have nonerosive arthritis (27.1% vs. 56.7%, p=0.01) (Table 1).

**Table 1. Characteristics of Patients with UCTD or Criteria-Defined CTD**

<table>
<thead>
<tr>
<th>Clinical</th>
<th>UCTD (n=57)</th>
<th>CTD (n=32)</th>
<th>N (%)</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SSA/Ro60</td>
<td>16 (27.1)</td>
<td>32 (62.5)</td>
<td>10.2</td>
<td>15.6</td>
</tr>
<tr>
<td>SSA/Ro52</td>
<td>12 (21.1)</td>
<td>20 (37.5)</td>
<td>10.2</td>
<td>15.6</td>
</tr>
<tr>
<td>SSA/Ro60</td>
<td>9 (15.8)</td>
<td>19 (35.4)</td>
<td>16.9</td>
<td>30.3</td>
</tr>
<tr>
<td>SSA/Ro52</td>
<td>20 (35.1)</td>
<td>10 (19.2)</td>
<td>16.9</td>
<td>30.3</td>
</tr>
<tr>
<td>SSA/Ro60</td>
<td>11 (19.3)</td>
<td>25 (46.9)</td>
<td>16.9</td>
<td>30.3</td>
</tr>
<tr>
<td>SSA/Ro52</td>
<td>20 (35.1)</td>
<td>10 (19.2)</td>
<td>16.9</td>
<td>30.3</td>
</tr>
</tbody>
</table>

1. Do not fulfill ACR/EULAR classification criteria for SLE, RA, SSc, PSS, IMF, APS
2. Diagnosed with UCTD and fulfill ≥1 set of listed CTD classification criteria.
3. Defined per listed classification criteria.
4. Criteria with n≤5: fever, proteinuria/cellular casts, pulmonary hypertension, intestinal lung disease, dysphagia/oesophageal dysmotility

**Patients with UCTD were less likely than those with CTD to have any hematological manifestation (lymphopenia, leukopenia, thrombocytopenia, or hemolytic anemia) (p=0.02), anti-dsDNA or anti-Smith antibodies (p<0.01), or hypocomplementemia (p<0.01). The frequency of RA, Sjögren’s, and APS-related serologies did not differ between groups (Table 1). Compared to those with CTD, UCTD patients were less likely to have ever received systemic corticosteroids (71.2% vs. 96.7%, p<0.01); ever use of any disease-modifying antirheumatic drug (DMARD) was similar (35.6% vs. 46.7%, p=0.36).

**Conclusion:** Among patients diagnosed with UCTD, 66.3% met a stringent definition. Compared to those with criteria-defined CTD, UCTD patients had lower frequency of arthritis, hematologic abnormalities, SLE-specific antibodies, and hypocomplementemia. Use of DMARDs did not differ, UCTD patients were less likely to use systemic corticosteroids. Rheumatologists diagnose UCTD even when criteria are met for other CTDs. Our findings suggest UCTD is nonetheless a distinct clinical entity; more rigorous characterization will enable generalizable prognostic and therapy trials.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4656

**AB0557 THE SPECTRUM OF PEDIATRIC LUPUS: DATA FROM THE KENYA PEDIATRIC RHEUMATOLOGY (KAPRI) REGISTRY**

**A. Mogwe, J. Otowa, R. Odhiambo, A. Aga Khan University Hospital-Westlands, Pediatrics and Child Health, Nairobi, Kenya

**Background:** Childhood-onset systemic lupus erythematosus (cSLE) is a prototype autoimmune condition characterized by systemic organ involvement, high morbidity and mortality (1-5). A pediatric rheumatology registry is critical in defining the spectrum of pediatric lupus within the region The Kenya Pediatric Rheumatology...
Table 1. Clinico-epidemiological features of paediatric Lupus patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Gender</th>
<th>Age</th>
<th>End Organ Involvement</th>
<th>Autoantibody profile</th>
<th>Treatment</th>
<th>Current Clinical Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Female</td>
<td>14 years</td>
<td>Arthritis</td>
<td>ANA +ve Antibiliprotein antibody +ve (B2 glycoprotein IgA)</td>
<td>Declined treatment of Hydroxychloroquine and Methotrexate to seek 2nd opinion</td>
<td>Lost to follow up</td>
</tr>
<tr>
<td>2</td>
<td>Female</td>
<td>14 years 9 months</td>
<td>Skin</td>
<td>ANA +ve Anti ds DNA +ve</td>
<td>Hydroxychloroquine</td>
<td>Stable with minimally active disease</td>
</tr>
<tr>
<td>3</td>
<td>Female</td>
<td>8 years 7 months</td>
<td>Neurolupus Lupus</td>
<td>Lupus Nephritis</td>
<td>Mycophenolate Mofetil</td>
<td>Minimally Active Disease</td>
</tr>
<tr>
<td>4</td>
<td>Female</td>
<td>15 years 2 months</td>
<td>Lupus Gangrene</td>
<td>Lupus Nephritis</td>
<td>Mycophenolate Mofetil</td>
<td>Remission</td>
</tr>
<tr>
<td>5</td>
<td>Female</td>
<td>11 years</td>
<td>Arthritis Interstitial Lung</td>
<td>Lupus Nephritis</td>
<td>Mycophenolate Mofetil</td>
<td>Remission</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>14 years 6 months</td>
<td>IV Lupus Nephritis</td>
<td>Lupus Nephritis</td>
<td>Mycophenolate Mofetil</td>
<td>Remission</td>
</tr>
<tr>
<td>7</td>
<td>Female</td>
<td>6 years 11 months</td>
<td>Arthritis Skin rash Class</td>
<td>Lupus Nephritis</td>
<td>Mycophenolate Mofetil</td>
<td>Remission</td>
</tr>
</tbody>
</table>

Registry (KAPRI) registry offers a unique opportunity to pioneer and spearhead a systematic and organized format in collecting pertinent clinical information that will offer information on current clinical scenarios and offer a platform to conduct other research projects to improve pediatric lupus healthcare in sub-Saharan Africa.

Objectives: Our objective was to determine the clinico-epidemiological profile of paediatric lupus patients by describing their baseline patient characteristics and clinical features at the Aga Khan University Medical College East Africa who were enrolled into the KAPRI registry from inception in March 2019 to December 2021.

Methods: All patient records were selected from the KAPRI registry database using the ICD 10 code M32 that denotes Systemic Lupus Erythematosus (SLE). Age, gender, laboratory, clinical features at diagnosis, treatment options offered at time of diagnosis were extracted from the database.

Results: Among the 207 patients enrolled thus far in the registry, 7 had a diagnosis of cSLE (3.4%). The commonest symptom among the patients were joint pain, fever and rash. Other clinical features and outcomes are highlighted in the Table 1.

Conclusion: Over a 2 year period, 57% of our cSLE patients (4 of 7) achieved remission while 43% (3 of 7) were lost to follow up. Further studies are required to elucidate predictors of good clinical response and reasons for loss to follow up among our cSLE patients.

References:

Disclosure of Interests: None declared

Prevalence of latent TB in SLE cases was 15.4%. Although comparison of demographic, clinical and autoantibody profile did not yield any statistically significant differences, the early turnover from this pilot study mandates further evaluation with larger sample size.

Table 1. Comparison of clinical and laboratory parameters between IGRA positive and IGRA negative SLE cases

<table>
<thead>
<tr>
<th>IGRA POSITIVE (n=105)</th>
<th>IGRA NEGATIVE (n=105)</th>
<th>p VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean± SD)</td>
<td>31.7±9.7</td>
<td>29.26±10.8</td>
</tr>
<tr>
<td>Female Sex (%)</td>
<td>19(100)</td>
<td>101(97.1)</td>
</tr>
<tr>
<td>Anti P0 antibody (%)</td>
<td>(3.15±8)</td>
<td>(14.15)</td>
</tr>
<tr>
<td>Anti Rib P antibody (%)</td>
<td>(2.10±5)</td>
<td>(13.12)</td>
</tr>
<tr>
<td>Age of disease onset(Mean± SD)</td>
<td>25.5±10.6</td>
<td>24.62±10.5</td>
</tr>
<tr>
<td>Disease duration(Mean± SD)</td>
<td>4.3±4.02</td>
<td>4.6±3.53</td>
</tr>
<tr>
<td>Treatment duration(Means± SD)</td>
<td>3.84±4.12</td>
<td>4.03±3.42</td>
</tr>
<tr>
<td>Clinical SLEDAI(Means± SD)</td>
<td>2.37±5.1</td>
<td>3.5±5.77</td>
</tr>
<tr>
<td>SLICC ACR(DII(Means± SD)</td>
<td>0.105±0.32</td>
<td>0.231±0.66</td>
</tr>
<tr>
<td>Current CNS involvement</td>
<td>1(3.2)</td>
<td>4(3.8)</td>
</tr>
<tr>
<td>Current renal involvement</td>
<td>1(3.2)</td>
<td>0</td>
</tr>
<tr>
<td>Current disease activity index</td>
<td>2.1(1.5)</td>
<td>2.5(2.6)</td>
</tr>
<tr>
<td>Current hematological involvement</td>
<td>1(3.2)</td>
<td>14(13.5)</td>
</tr>
<tr>
<td>Current GI involvement</td>
<td>1(3.2)</td>
<td>0</td>
</tr>
<tr>
<td>Current steroid dose(Means± SD)</td>
<td>11.3±2.16</td>
<td>13.0±11.6</td>
</tr>
<tr>
<td>Serum C3(Means± SD)</td>
<td>0.79±0.32</td>
<td>0.89±0.47</td>
</tr>
<tr>
<td>Serum C4(Means± SD)</td>
<td>0.19±0.07</td>
<td>0.16±0.13</td>
</tr>
<tr>
<td>Anti dsDNA(Means± SD)</td>
<td>458±400.8</td>
<td>379.5±400.5</td>
</tr>
<tr>
<td>Low C3 (%)</td>
<td>9.02(2)</td>
<td>37(38.9)</td>
</tr>
<tr>
<td>Low C4 (%)</td>
<td>21(11.8)</td>
<td>35(36.8)</td>
</tr>
<tr>
<td>Elevated AntidsDNA n(%)</td>
<td>6(3.2)</td>
<td>37(38.9)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Prevalence of latent TB and SLE cases was 15.4%. Although comparison of demographic, clinical and autoantibody profile did not yield any statistically significant differences, the early turnover from this pilot study mandates further evaluation with larger sample size.
AB0560 CLINICAL, SEROLOGICAL AND IMAGING CHARACTERISTICS OF LATIN AMERICAN PATIENTS WITH LUPUS MYOCARDITIS: A CASE-CONTROL STUDY

D. C. Quintero-González 1, J. Sanchez-Bautista 2, C. Agudelo 1, A. L. Vanegas-García 3, M. Muñoz 3 1, Y. Santamaria-Alza 1, A. Cardona-Cardona 1, M. Muñoz 1, G. Vásquez 1, L. A. González 1,3, Y. S. Antigliiero 1, M. García 1, C. Muñoz 1,2, Y. Santamaria-Alza 1, A. Cardona-Cardona 1, M. Muñoz 1, G. Vásquez 1, L. A. González 1, 1Universidad de Antioquia, Rheumatology; Medellín, Colombia; 2Universidad de Antioquia, Internal Medicine, Medellín, Colombia; 3Hospital Universitario San Vicente Fundación, Rheumatology; Medellín, Colombia

Background: Lupus myocarditis (LM) is an uncommon manifestation of systemic lupus erythematosus (SLE), with a prevalence of 9% that tends to be lower in recent studies; it can range from subclinical to life-threatening manifestations (1). The clinical and immunological characteristics of LM have not been established in Latin American patients.

Objectives: To determine the clinical, serological, and imaging characteristics of patients with LM.

Methods: We conducted a single-center, case-control study that enrolled hospitalized patients between 2012 and 2020 in Colombia. Fifteen LM patients (cases) were matched by age and sex with thirty non-LM patients (controls). Descriptive, comparative, and logistic regression analyses were performed.

Results: Patients with LM were mostly females (93.3%) with a mean age of 28.2 years. The major affected clinical domains was renal (80%) and articular (53.3%). The most common valvulopathy was mild mitral regurgitation. Nineteen LM patients underwent cardiac magnetic resonance. In this modality, mean LVEF was 54%, increased regional intensity on T2-weighted images, increased myocardial perfusion ratio on T1- and non-ischemic enhancement (mainly epicardial) was presented in 85.7%, 50%, and 57.1%, respectively. All patients received glucocorticoids and cyclophosphamide. Comparisons of the demographic, clinical, serological between LM and non-LM groups are shown in Table 1.

AB0562 LIVER ENZYME ABNORMALITIES IN HOSPITALIZED LUPUS PATIENTS – A RETROSPECTIVE STUDY

V. Shobha 1, R. S. Kodali 2, B. Pinto 3, A. Athalai 1, S. Selvam 1, 1St John’s National Academy of Medical Sciences, Clinical Immunology and Rheumatology, Bangalore, India; 2St John’s Research Institute, Division of Epidemiology and Biostatistics, Bangalore, India

Background: Around 25% to 50% of lupus patients may present with alterations in the liver enzymes of variable severity including fulminant hepatic failure.
Table 1. Aetiology and associations of liver enzyme abnormalities

<table>
<thead>
<tr>
<th>Aetiologies for elevated transaminases</th>
<th>Macroprotease activation syndrome</th>
<th>Lupus activity</th>
<th>Overlap Myositis</th>
<th>Autoimmune Hepatitis</th>
<th>Sepsis</th>
<th>Primary Biliary Cirrhosis</th>
<th>Drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAS (N=33)</td>
<td>39/77(42.9%)</td>
<td>16/77(20.8%)</td>
<td>12/77(15.6%)</td>
<td>6/77(7.8%)</td>
<td>5/77(6.5%)</td>
<td>3/77(3.9%)</td>
<td>2/77(2.6%)</td>
</tr>
<tr>
<td>P-value</td>
<td>0.098*</td>
<td>0.098*</td>
<td>0.098*</td>
<td>0.098*</td>
<td>0.098*</td>
<td>0.098*</td>
<td>0.098*</td>
</tr>
</tbody>
</table>

Comparison between patients with and without MAS

<table>
<thead>
<tr>
<th>Disease</th>
<th>Disease course</th>
<th>Age of disease</th>
<th>P-value</th>
<th>Asthenia</th>
<th>Depression</th>
<th>Anxiety</th>
<th>Hypochondria</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAS</td>
<td>0.24</td>
<td>-0.09</td>
<td>0.44</td>
<td>0.33</td>
<td>0.51*</td>
<td>0.46*</td>
<td>0.35</td>
</tr>
</tbody>
</table>

* p < 0.05

Our data indicate that patients with SLE have a high level of alexithymia. Indeed, patients suffering from this disease experience difficulties in understanding and verbalizing feelings, persistently strive to draw the doctor’s attention to their physical sensations, without attaching importance to or denying trouble in the emotional sphere.

Conclusion: The results of the study indicate a certain role of the phenomenon of alexithymia in the pathogenesis of psychosomatic disorders in SLE, and the level of alexithymia does not depend on gender, age, and the main clinical characteristics of the disease, but correlates with general neuroticism. It is possible that the high level of alexithymia in SLE patients leads to an increase in depression and anxiety, and generates psychological distress. Thus, the study of alexithymia, among other risk factors of a biological and psychosocial nature, is important for a better understanding of the role of psychological mechanisms in the pathogenesis of psychosomatic diseases, the organization of preventive measures aimed at correcting alexithymic features, carried out in individual and group forms of psychotherapy.

REFERENCES:

Disclosure of Interests: None declared


AB0563

ALEXITHYMIA IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

R. Grekhov1,2, V. Zborovsky2 Research Institute for Clinical and Experimental Rheumatology, Rehabilitation Dept, Volgograd, Russian Federation; 2Volgograd State Medical University, Chair of General and Clinical Psychology, Volgograd, Russian Federation

Background: The growth of psychosomatic disorders is the most important medical and social problem of modern healthcare. Particular attention of researchers is attracted by the alexithymic radical in the structure of the patient’s premorbid personality, as one of the possible psychological risk factors for the development of psychosomatic disorders. Alexithymia is a psychological phenomenon that described as difficulty in definition one’s own feelings, difficulty in distinguishing between feelings and bodily sensations, a decrease in the ability to symbolize, and a focus on external events rather than internal experiences.

Objectives: The aim of this work was to study the level of alexithymia in patients with systemic lupus erythematosus (SLE).

Methods: There were 87 patients under observation, the majority were women (82.8%), of 35.33 ± 1.77 years old in average. The average duration of the disease was 7.09 ± 0.89 years.

The Toronto Alexithymia Scale (TAS) [1] was used to measure alexithymia.

Results: It should be noted that in healthy people [1] the level of alexithymia is 59.3 ± 1.3 points. The mean value of alexithymia in SLE patients was 74.05 ± 2.62 points. The high and medium rates of alexithymia were established in 54 cases from 78 patients, and there were low levels in 24 cases indicating the absence of alexithymia. It was not possible to identify the dependence of alexithymia on gender and age. There was also no significant dependence of the level of alexithymia on the duration of the disease, the course and the activity of the pathological process. However, a significant direct correlation between the severity of alexithymia and depression and anxiety was revealed (see Table 1).

Table 1. Dependence of the level of alexithymia on some characteristics of SLE patients

<table>
<thead>
<tr>
<th>Disease</th>
<th>Disease course</th>
<th>Age of disease</th>
<th>P-value</th>
<th>Asthenia</th>
<th>Depression</th>
<th>Anxiety</th>
<th>Hypochondria</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAS</td>
<td>0.24</td>
<td>-0.09</td>
<td>0.44</td>
<td>0.33</td>
<td>0.51*</td>
<td>0.46*</td>
<td>0.35</td>
</tr>
</tbody>
</table>

* p < 0.05

AB0564

PROGNOSTIC ROLE OF PRE-CONCEPTIONAL COMPLEMENT CONSUMPTION ON PREGNANCY OUTCOMES IN ANTI-PHOSPHOLIPID ANTIBODY SYNDROME, POLYARTERITIS AND RECURRENT IMPLANTATION FAILURE

V. Cantu1, B. De Lorenzo2, C. Gerbin0, G. Adorno0, F. Fusi3, M. T. Castiglioni3, P. Rovere-Querini1, 1San Raffaele Hospital, Internal Medicine, Milan, Italy; 2San Raffaele University, San Raffaele University, Milan, Italy; 3San Raffaele Hospital, Obstetrics and Gynecology, Milan, Italy

Background: In anti-phospholipid antibody syndrome (APS), complement C3/C4 activation favours the development of adverse pregnancy events. The prognostic role of complement in recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) has never been clinically studied. Additionally, the influence of hydroxychloroquine and heparin on complement modulation at the molecular level has already been accepted, while few clinical studies on these drugs have been published up to date.

Objectives: The aim of the study was to investigate whether C3/C4 levels represent a risk factor for pregnancy outcomes in a population of patients with APS, patients with RPL and patients with RIF. Moreover, the study investigated the...
Effects of therapies during pregnancy (low dose aspirin, low molecular weight heparin and hydroxychloroquine and their combinations).

Methods: We collected data of 136 patients (33 APS, 69 RPL, 34 RIF) prospectively after low dose aspirin in the past. 106/136 (78%) patients had normal pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes and 91/106 (86%) had at least one abortion in the past. 64/136 pregnancies prospectively followed in our centre, 17/64 (26%) had pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes and 91/106 (86%) had at least one abortion in the past. In 64/136 pregnancies prospectively followed in our centre, 17/64 (26%) had pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes.

Results: 30/136 (22%) patients had pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes. The presence of consumed pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes.

Conclusion: Measurement of pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes. The presence of consumed pre-conceptional level of 8/106 (7%) had anamnestic history of adverse pregnancy outcomes.
Five patients presented with ANCA associated vasculitis, which represents and exceedingly rare and severe manifestation in this context. Patients with SS may present a wide range of vasculitis, ranging from the most common leucocytoclastic vasculitis to the more severe systemic vasculitides, such as: AAV and cryoglobulinemic vasculitis. The association of SS with vasculitis is more common in patients with anti-Ro, anti-La and/or RF, hypocomplementemia, cryoglobulins and hypergammaglobulinemia.

REFERENCES:

Disclosure of Interests: None declared

AB0567
SHORT AND LONG-TERM RENAL OUTCOMES OF PATIENTS WITH PROLIFERATIVE LUPUS NEPHRITIS: DATA FROM A SINGLE INSTITUTE INCEPTION COHORT.

E. Kapia1, S. Marinka1, I. Michelakis2, G. Liapis3, P. Stltakis4, J. N. Boletis5, M. Tektonidou6, 1Medical School National & Kapodistrian University of Athens, Laiko Hospital, Department of Nephrology and Renal Transplantation, Athens, Greece; 2Medical School National & Kapodistrian University of Athens, Department of Medicine, Athens, Greece; 3Medical School National & Kapodistrian University of Athens, Department of Hygiene, Epidemiology and Medical Statistics, Athens, Greece; 4Medical School National & Kapodistrian University of Athens, Laiko Hospital, Department of Pathology, Athens, Greece; 5Medical School National & Kapodistrian University of Athens, Laiko Hospital, Rheumatology Unit, First Department of Paedopaedic Internal Medicine, Athens, Greece

Background: Renal involvement in SLE is associated with high risk of morbidity with proliferative lupus nephritis (PLN) having the worst prognosis. Although advances in immunosuppressive treatment led to better renal survival rates, response to treatment and short- and long-term outcomes differ among cohorts.

Objectives: To evaluate short and long term renal outcomes in an inception cohort of patients with PLN. We also aimed to define clinical, laboratory, histological and treatment determinants of partial (PR) or complete response (CR), flare, and long-term renal and patient survival.

Methods: An inception cohort of 83 patients with biopsy-proven PLN (class III, IV, or III/IV-V) (diagnosed between 1992 and 2019) was retrospectively studied. Data collected included histologic characteristics at baseline, demographic, clinical, laboratory, and therapeutic parameters at baseline. E-9-12-18-24-36-72 months after PLN diagnosis, time of renal flare and last follow-up visit.

Univariate logistic and Cox regression analyses were performed to estimate response to treatment, flare and long-term renal survival. Variables found to be significant in the univariate analyses were included in the multivariate models.

Results: Mean age of the patients was 43±12 years, 78% were women, 96% were Caucasians and median duration of SLE before PLN diagnosis was 12 months (IQR 6). Mean SLEDAI score at PLN diagnosis was 12.8±4.5 and mean proteinuria was 3.69±3.9 g/dL. At baseline, 73.5% (61/83) had eGFR>60mL/min/1.73m², 15.5% (13/83) eGFR 30-60 and 11% (9/83) eGFR<30. 32% (27/83) of the patients had class III LN, 46% (38/83) IV, and 22% (18/83) III/IV-V. Median follow-up time was 107 months (IQR 94). Induction immunosuppressive treatment consisted of cyclophosphamide (CYC) in 71% (59/83) of patients (12/59 in combination with rituximab (RTX)), mycophenolic acid (MPA) in 25% (21/83) (2/21 in combination with RTX) and RTX alone in 2 patients. 1 patient did not receive any immunosuppressive treatment due to ESRD. Patients treated with CYC had a higher baseline SLEDAI score, lower C3 and C4 levels, higher biopsy activity index and higher proteinuria levels than those treated with MPA. 76% (63/83) received MPA as maintenance treatment. 8% (7/83) azathioprine, 7% (6/83) CYC and 8% (7/83) did not receive any maintenance regimen (3/7 due to ESRD, 2/7 received RTX as induction and continued with steroids only, 1/7 due to non-compliance, 1/7 lost to follow-up after 6 months). Median duration of treatment was 43.6 months (IQR 44.6).

66% of patients had response (CR or PR) at 6 months (43% CR, 23% PR), 73% at 9 months (46% CR, 27% PR), 77% at 12 months (61% CR, 16% PR) and 91% at the end of follow-up (80% CR, 11% PR) (Figure 1). Median time to complete remission was 9 months (IQR 14) and median time to partial remission was 4 months (IQR 7). In multivariate analysis, baseline eGFR>60mL/min correlated with shorter time to remission (HR 1.7, p<0.05). No clinical, laboratory or histological (PLN class, activity/chronicity index, number of crescents) parameters or any of induction immunosuppressives could predict time to remission.

Conclusion: In our inception cohort of patients with PLN, 86% of patients achieved response at 6 months, 77% at 12 months and 91% at the end of follow-up. Proteinuria >1g/dL at 12 months emerged as an important risk factor of renal flare and CKD, while MPA treatment was associated with lower risk of renal flare.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5049

AB0568
CHRITIDHA LUCILAE IMMUNOFLUORESCENCE PRESENCE IN SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS ASSOCIATION WITH POSITIVE CHAGAS TESTS

E. Picco1, B. Cariazeres2, R. Rojas Tessein3, E. Buschiazzo1, M. Aciar4, N. Cucchiaro1, L. N. Belbruno1, M. B. Lecumberri1, A. C. Raile1, V. Juarez1, M. E. Crespo Espindola1, 1Hospital Sr del Milagro, Rheumatology, Salta, Argentina; 2Hospital Sr del Milagro, Biochemistry, Salta, Argentina

Background: Systemic lupus erythematosus (SLE) is characterized by the presence of auto-antibodies, including anti-double stranded DNA (dsDNA), which are highly specific for the disease diagnosis and its follow up. Direct immunofluorescence (IF) using chrigida luciiae (CL) as the antigenic substrate, is the most widely used method to detect it, and its positivity is defined with the staining of the kinetoplast and/or the nucleus. CL is a flagellated parasite, included in trypansomatisidae family, which also includes trypanosoma cruzi, the cause of Chagas Disease (CD). Some studies suggest that membrane and flagellum fluorescence (considered ‘atypical’ staining) could be associated with positive CD serology.

Objectives: Describe the prevalence of positive IF-CL images and its association with positive CD test in SLE patients.

Methods: A cross sectional study was designed including consecutive outpatients with SLE diagnosis (SLICC criteria), in which anti-dsDNA antibodies was requested to monitor disease activity. At the same time, two serologic CD tests were performed, since they improve sensibility to detect the disease.

Anti-dsDNA by IF were performed by an experienced laboratory biochemistry blinded to patients clinical data. Pregnant patients and those ≤ 18 years old were excluded from this analysis.

Standard descriptive analysis was performed, data was compared by exact fisher test or chi2, student's T test or Mann Whitney. A p value < 0.05 was considered as significant.

Results: Thirty five patients were included, 33 (94.3) female, median age 38 (IQR 31-48), with 20 (57.1) patients being from middle-low socioeconomic status (measured by Grafar score). Twenty-six (74.3) patients were receiving glucocorticoids, 28 (80) hydroxychloroquine, 5 (14.3) azathioprine, 12 (34.3) mofetil mycophenolate, 5 (14.3) cyclophosphamide and 4 (11.4) rituximab. Twelve (34.4) had positive anti-dsDNA test, with atypical staining in membrane and flagellum 31 (88.9), only membrane 12 (34.3) and both membrane and flagellum 9 (25.7) exclusively.

One patient had previous chronic CD diagnosis without specific treatment.

Five (14.3) CD serologies were positive, and 1 had undefined result. This group of patients had positive staining in membrane and flagellum of CL. No other atypical CL staining images were found. (Table 1)
Conclusion: Although we could not find a statistical association between atypical CL staining and positive CD serology, this could be due to the low number of patients included in the study since all the patients with positive CD serology had a positive staining in CL-LIF. A trained biochemistry operator is necessary to avoid false positive tests in regions with high prevalence of CD.

Disclosure of Interests: None declared

AB0571

DERIVATION AND INDEPENDENT VALIDATION OF THE LUPUS ARTHRITIS AND MUSCULOSKELETAL DISEASE ACTIVITY SCORE (LAMDA): A MORE SENSITIVE, SPECIFIC AND RESPONSIVE TOOL FOR LUPUS ARTHRITIS

K. Mahmoud1, A. Zayat1, M. Y. MD Yusof2, L. S. Teh3, S. Khan4, C. S. Yee5, D. D’Cruz6, N. Ng1, D. Isenberg5, C. Critiun1, P. G. Conaghan1, P. Emery1, C. J. Edwards1, E. Henson1, E. Vital1. 1University of Leeds, Leeds Institute of Rheumatism and Musculoskeletal Medicine, Leeds, United Kingdom; 2Royal Blackburn Hospital, Rheumatology, Blackburn, United Kingdom; 3Doncaster & Bassetlaw NHS Trust, Rheumatology, Doncaster, United Kingdom; 4Royal Free & St Thomas’ NHS Foundation Trust, Louise Coote’s Lupus Unit, London, United Kingdom; 5University College London, Rayne Institute, London, United Kingdom; 6University Hospital Southampton NHS Foundation Trust, Rheumatology, Southampton, United Kingdom

Background: The MSK components of the BILAG and SLEDAI have limited sensitivity, specificity and responsiveness.

Objectives: To develop a better disease activity tool for MS lupus.

Methods: “LAMDA” was derived using data from the multicentre USEFUL study (PMID:33792659); 133 patients with inflammatory MSK pain received intramuscular depomedrone then were assessed for 86/68 SJC/ TJC, BILAG-2004, SLEDAI-2K, physician MSK-VAS, inflammatory markers, patient pain and disease-activity-VAS and MSK-ultrasound. Baseline variables were modelled against US using penalized (Lasso) regression. For validation we evaluated: (i) responsiveness at week 6 in USEFUL and (ii) association with quality of life and treatment decision in an independent study (n=100).

Results: LAMDA was a composite of SJC, patient-MSK-pain-VAS, physician-MSK-disease-activity-VAS and ESR ranging from 0 to 26.5. Response effect size was greater for the LAMDA (0.37) than the BILAG-MSK (0.31), SLEDAI-MSK (0.27) and total US score (0.33). With active US at baseline, LAMDA’s effect size was 0.42. In the validation study, LAMDA score correlated better with physical function (R = -0.49, p<0.001), pain (R = -0.44, p=0.002) and Burden to Others (R = -0.38, p=0.009). LAMDA was higher when therapy was increased (mean 95% CI) difference 12.9 (5.8, 19.9), p<0.001.

Conclusion: LAMDA is a continuous disease activity instrument for MSK lupus that is sensitive to imaging-syndromes without swelling, more responsive than other instruments and correlates with quality of life and treatment decision. LAMDA may improve the ability of clinicians to monitor and treat MSK lupus, and determine the efficacy of therapies in clinical trials.

Acknowledgements: Funding: Lupus UK and NIHR

Disclosure of Interests: Khaled Mahmoud: None declared, Ahmed Zayat: None declared, Md Yusuf: None declared, Lee-Suan Teh: None declared, Shah Khan: None declared, Chee-Seng Yee: None declared, David D’Cruz: None declared, N. Ng: None declared, David Isenberg: None declared, Coziana Critiun: None declared, Philip G Conaghan: None declared, Paul Emery: None declared, Christopher John Edwards: None declared, Elizabeth Henson: None declared, Edward Vital: None declared, Roche, Arunia, Lilly, ILTDO, Novartis, Grant/research support from: AstraZeneca, Sandoz


AB0572

USEFULNESS OF MINOR SALIVARY GLAND BIOPSY IN THE DIAGNOSIS OF PATIENTS WITH SUSPECTED PRIMARY SJÖGREN’S SYNDROME

N. de la Torre Rubio1, J. Campos Esteban1, M. Pavía Pascual1, M. Machatto1, P. Navarro Palomo1, O. Rusinovich1, C. Merino Arguménez1, B. García-Magallon1, H. Godoy1, C. Barbardillo Mateos1, L. F. de Villa2, J. Sanz3, J. L. Andreu Sánchez1, M. Fernandez Castro1. 1Puerta de Hierro Majadahonda University Hospital, Rheumatology, Majadahonda, Spain

Background: The classification system for Sjogren’s syndrome (SS) proposed by the American-European Consensus Group (AECG) and the revised diagrams proposed by the American College of Rheumatology (ACR) include an altered minor salivary gland biopsy (MSGB) or positive antifilo, among other findings. Thus, an altered MSGB is a particularly important finding in patients with autoimmune-negative. A retrospective cohort study showed that a positive biopsy resulted in a definitive diagnosis in 80% of patients1.

Objectives: To assess the usefulness of MSGB in the diagnosis of SS in anti-SSA/SSB (Ro/La) negative patients.

Methods: Retrospective descriptive study in patients with suspected SS in which MSGB were collected according to standard clinical practice over a consecutive period (from September 2020 to May 2021) in the Rheumatology Department of a tertiary hospital. Patients were grouped according to the reason for requesting the biopsy: 1) Dry eye/oral syndrome (DEOS), 2) DEOS + altered Saxon/Schirmer, 3) DEOS + positive antinuclear antibodies (ANA+), 4) DEOS + (ANA+) + other serological alterations (hypergamma-globulinaemia, rheumatoid factor (RF), hypocomplementemia), 5) DEOS + extraglandular manifestations (EG) (+ ANA+) +/- other serological alterations. The following variables were collected: age, sex, dry eye/oral syndrome, Raynaud’s phenomenon, EG manifestations, arthritis, autoimmune hepatitis, primary biliary cirrhosis, interstitial lung disease, pleuropneumonitis, autoimmune chronic nephropathy suspected or tubulointerstitial nephritis and/or neurological manifestations), ANA, hyper gammaglobulinaemia, RF, hypocomplementemia, Saxon and Schirmer tests and histological result of MSGB according to its Focus Score (FS); MSGB was considered altered when FS was ≥1. Descriptive analysis was performed (means and frequencies); Chi-square test was used to compare the reasons for requesting MSGB between patients with altered and unaltered results and to compare whether any of the groups (Groups 2-5) were more frequently associated with an altered MSGB compared to patients presenting only with dry syndrome (Group 1).

Results: Seventy-eight MSGB were collected. Mean age of patients was 55 years; 90% were women. ANA were present in 17% of patients with altered MSGB. DEOS was the suspected manifestation in 83% of patients, 13% had Raynaud’s phenomenon and 47% had some EG manifestation. MSGB was compatible with a diagnosis of SS (according to 2002/2016 classification criteria) in 28% of anti-SSA/SSB negative patients. Patients with dry syndrome and positive ANA (Group 3) were significantly associated with MSGB altered (Table 1).

Table 1. Comparative table of patterns indcated in the reasons for requesting a MSGB. *Not significant (NS).

<table>
<thead>
<tr>
<th>Reason for request (%)</th>
<th>MSGB altered</th>
<th>MSGB unaltered</th>
<th>p</th>
<th>p vs dryness</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEOS (50)</td>
<td>19</td>
<td>46</td>
<td>0.65</td>
<td></td>
</tr>
<tr>
<td>DEOS + Saxon/Schirmer (38)</td>
<td>15</td>
<td>34</td>
<td>0.47 NS</td>
<td></td>
</tr>
<tr>
<td>DEOS + ANA (30)</td>
<td>11</td>
<td>27</td>
<td>0.67 NS</td>
<td></td>
</tr>
<tr>
<td>DEOS + ANA + others (8)</td>
<td>6</td>
<td>4</td>
<td>0.41 0.05</td>
<td></td>
</tr>
<tr>
<td>DEOS + EG + ANA (14)</td>
<td>9</td>
<td>15</td>
<td>0.69 NS</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: MSGB was compatible with a diagnosis of SS in 28% of anti-SSA/SSB negative patients. The data suggest that patients presenting with objective dryness with Saxon and/or Schirmer test, as well as those with extraglandular manifestations and ANA+ and/or other serological alterations, are more likely to have a compatible with SS result on MSGB. Studies with larger numbers of patients are needed.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5199

AB0573

PERIPHERAL BLOOD B-CELLS SUBSETS IN PATIENTS WITH SJÖGREN’S SYNDROME DEPENDING ON SOME IMMUNOLOGICAL PARAMETERS.

A. Torgashina1, E. Sokol1, B. Chalcev1, J. Khivan1, M. Kireeva1, D. Tabakov2, A. Alekssan1, S. Glukhova1. 1VA Nasonova Research Institute of Rheumatology, Rare Rheumatic Disease and Sjogren’s Syndrome, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Educational-Medical Department, Moscow, Russian Federation; 3VA Nasonova Research Institute of Rheumatology, Immunology and Molecular Biology, Moscow, Russian Federation

Objectives: To examine B-cell subsets in peripheral blood of Sjogren’s syndrome (SjS) patients (pts) and to analyze the association between B-cell subsets and different clinical and immunological parameters.

Methods: 67 active SjS pts (65F/2M); mean age 51±14.4 years; disease duration 60 (24-120) months were included. SjS was diagnosed based on the ACR-EULAR2016 criteria. Twenty healthy donors composed the control group. CD19+B cells, memory B-cells (CD19+CD27+), non-switched memory B-cells (CD19+IgD+CD27+), switched memory B-cells (CD19+IgD-CD27+), naïve (CD19+IgD-CD27+), double negative (CD19+IgD-CD27+), transitional (CD19+IgD+CD27+) B-cells, plasmablasts (CD19+CD38++IgD-CD27+) were analyzed by multicolor flow cytometry using cytometer Navios (Beckman Coulter, USA).
The nonparametric Mann-Whitney test, the Pearson’s χ2 criterion, Spearman rank correlation coefficient were used for statistical analysis. Data were shown as median (Me) with an interquartile range of 25 - 75 percentile. The differences were considered statistically significant when p<0.05. Statistica 10 for Windows (StatSoft Inc., USA) package was used for statistical data processing.

Results: The percentages/absolute numbers of plasmablasts, transitional B-cells, memory B-cells in SjS were significantly higher than in healthy donors, p<0.01 for all cases. At the same time percentages/absolute numbers of naïve cells in SjS were reduced compared to healthy donors (p<0.005, p=0.04). Shorter duration of SjS (less than 2 years) correlated with higher rates of naïve cells (p=0.02).

ESSDAI score was ≥5 in 33 pts and ≤5 in 34 pts. We didn’t find any correlation between B cells subsets and disease activity. The presence of lymphoma in pts (n=5) had no impact on B-cells subsets as well. Significant changes were in B-cells subsets were found depending on immunological parameters. Pts with an isolated increase of antinuclear antibodies (ANA) (ANA positive, RF/aRo/aLa negative) had no plasmablasts in peripheral blood, level of plasmablasts in other pts was 1.5 (1.4-5)10^4/L, p=0.004. ARo-positive pts had higher amount of plasmablasts and transitional B-cells than aRo-negative pts (2 (1-5) and 1 (0-1)10^4/L, p= 0.004). Higher level of plasmablasts and transitional B-cells also correlated with decrease in C3 and/or C4 (p=0.03) and increase in IgG (p=0.025).

Conclusion: According to our data elevated level of plasmablasts and transitional B-cells had positive correlation with some immunological diagnostic markers and immunological activity parameters of SjS but didn’t associate with ESSDAI.

Disclosure of Interests: None declared


AB0574 PREDICTOR FACTORS IN EMPowerMENT OF PATIENTS WITH PRIMARY SJÖGREN SYNDROME IN THE FRAME OF VALUE BASED HEALTH CARE

G. Mumcu1, K. Abacak2, I. Tati1, F. Türe-Özdemi1, O. C. Kitapçı1, N. Şisman Kitapçı1, M. Yay1, U. Karacay1, F. Fortune2, N. Inanc3, Marmara University, Faculty of Health Science, Department of Health Management, Istanbul, Turkey; 1Marmara University, School of Medicine, Division of Internal Medicine, Department of Rheumatology, Istanbul, Turkey; 2Marmara University, Medical School, Division of Haematology-Immunology, Istanbul, Turkey; 3Mimar Sinan Fine Art Faculty, Department of Statistics, Istanbul, Turkey; 4Gultahane Faculty of Dentistry, University of Health Sciences, Department of Oral and Maxillofacial Surgery, Ankara, Turkey; 5Queen Mary University of London, Barts and The London School of Medicine and Dentistry, Director of the Behçet’s Centre of Excellence, London, United Kingdom

Background: Patient empowerment is a key component in developing awareness of the disease in patient-centred care in the setting of chronic disease management.

Objectives: This study aimed to evaluate predictive factors in the empowerment of patients with Sjögren’s Syndrome (pSS) while examining patients reported outcome measures (PROMs) in the setting of value-based health care.

Methods: In this cross-sectional study, 169 patients with pSS (F/M: 162/7; mean age: 52.94±12.20 years) were included. Data was collected from the clinical examination, major salivary gland ultrasonography (SGUS) and a structured questionnaire regarding utilisation of health services and PROMs regarding oral health, pain, burning mouth syndrome, QoL, anxiety and depression by a multidisciplinary team with dentists and psychiatrists in patient-centred care. Since these factors have a significant effect on patients’ daily life, treatment plans are needed to provide patient empowerment by using suitable strategies in the frame of value-based health care.

Disclosure of Interests: None declared


AB0575 MESANGIAL C1Q DEPOSITION, BUT NOT C3 AND C1Q DEPOSITION IN OTHER RENAL COMPARTMENTS, IS A PREDICTOR OF RENAL OUTCOME IN LUPUS NEPHRITIS

T. Knežević1, I. Padjen2, V. Ivković3, S. Bulimbašić3, M. Conić3, I. Jezic3, Z. Bilošlav4, M. Laganović5, B. Anić5, 1University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, Division of Nephrology, Hypertension, Dialysis and Transplantation, National Reference Centre for Glomerular and Tubulointerstitial Diseases, Zagreb, Croatia, Zagreb, Croatia; 2University Hospital Centre Zagreb, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia; 3University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, Department of Pathology and Cytology, University Hospital Centre Zagreb, Croatia, Zagreb, Croatia; 4University of Zagreb, School of Medicine, Zagreb, Croatia, Department of Epidemiology, Zagreb, Croatia; 5University Hospital Merkur, Division of Nephrology, Zagreb, Croatia

Background: Complement activation is an important pathophysiological process in the pathogenesis and development of systemic lupus erythematosus and lupus nephritis (LN). However, the prognostic value of complement factors deposition in different kidney compartments has received little attention and, to the best of our knowledge, no study examined its association with renal outcomes in LN.

Objectives: To evaluate prognostic significance of C1q and C3 complement factors in renal tissue compartments.

Methods: We have conducted a retrospective cohort study and collected data on demographics, clinical and laboratory parameters and histopathology (light, immunofluorescent and electron microscopy) at the time of biopsy and after long-term follow-up. C1q and C3 expression graded in different kidney compartments (mesangium, glomerular basement membrane (GBM), tubular basement membrane (TBM) and blood vessel wall) and dichotomized into no or low (grades 0 and 1) and high expression (grades 2 and 3). Remission (defined as complete or partial remission) was defined as per EULAR 2019 guidelines.

Results: A total of 51 patients with biopsy-proven LN were followed up for 4.5±2.9 years (80% women, mean age at biopsy 38±14). A total of 29 (71%) achieved complete or partial remission. Complement expression in different kidney compartments was as follows: mesangium (C1q 54%, C3 59%), GBM (C1q 34%, C3 41%), TBM (C1q 5%, C3 5%) and blood vessel wall (C1q 0%, C3 5%). Patients with proliferative lupus had more frequently C1q and C3 deposition in the mesangium (69% vs. 14%, p<0.001 and 72% vs. 29%, p=0.005, respectively), while there were no differences between pro- and non-proliferative LN in other renal compartments (all p>0.05). Subjects who achieved remission more frequently had C1q deposition in the mesangium (64% vs. 31%, p=0.045), but there was no association between remission and deposition of C1q or C3 in other renal compartments (all p>0.05). Interestingly, the association between C1q mesangial deposition and renal outcome was significant even after adjustment for age at biopsy, gender and lupus type (proliferative vs. non-proliferative) (OR 0.13 [0.02, 0.98], p=0.047).

Conclusion: C1q deposition in the mesangium might be an important prognostic factor in LN and more aggressive treatment of these patients may explain the better outcomes of these patients.

Disclosure of Interests: None declared

null
Background: Behçet’s disease (BD) is an systemic inflammatory vasculitis characterized by recurrent oral aphthae and genital ulcers. In the course of the disease, skin, eye, musculoskeletal, nervous system and gastrointestinal system involvements can be detected.

Objectives: To evaluate the clinical, laboratory and radiological findings of pediatric cases diagnosed with BD.

Methods: Fifty-five patients (0-20 years old) who were followed up with the diagnosis of BD at the Pediatric Rheumatology outpatient clinic of Uludag University Faculty of Medicine between January 2011 and July 2021 were included in our study. The patients were diagnosed according to the diagnostic criteria of the International BD Study Group.

Results: Twenty-four (48%) of the patients were male and 26 (52%) were female. The mean age at the diagnosis of patients was 9 ±4.55 years (10.75±4.55 years in boys, 12.35±3.65 years in girls). Twenty patients (36.3%) had a family history of Behçet’s Disease. Oral aphthae were present in 86% (n=48) patients, while genital ulcers were in 32% (n=16) (Table 1). Of the nine patients with uveitis, 6 had panuveits, 2 had anterior uveitis and 1 had posterior uveitis. There was no difference in the distribution of symptoms according to the gender of the patients. HLA-B51 allele was found in 39 (78%) and ANA was positive in 14 patients (28%). Immunological tests showed that serum immunoglobulins were low in 11 (32.3%) of 34 patients. Low IgG levels were detected in 6 patients, low IgM levels were in 3, and low IgA levels were in 2. Thrombus was presented in three cases (thrombus in the right ventricle in one case, in the intracranial transverse sigmoid sinus and left jugular vein in two cases). The most commonly used drug for aphthae was colchicine (n=45, 82%). The use of biological agents according to patient manifestations is shown in Table 2. In the follow-up, clinical findings improved in 35 patients (70%). Complete improvement was detected only with biological agents in 8 patients with ulcers. One patient was operated due to the development of complicated cataracts secondary to uveitis. Three patients were diagnosed with Covid-19, one of them was followed without treatment, while two of them were treated with favipiravir at home. Three patients with Covid-19 infection were using only colchicine treatment.

Table 1.

<table>
<thead>
<tr>
<th>Findings at the time of diagnosis</th>
<th>n</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>9</td>
<td>18</td>
</tr>
<tr>
<td>Skin findings</td>
<td>18</td>
<td>36</td>
</tr>
<tr>
<td>Gastrointestinal tract involvement</td>
<td>19</td>
<td>38</td>
</tr>
<tr>
<td>Central nervous system involvement</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>Vascular involvement</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Arthritis</td>
<td>17</td>
<td>34</td>
</tr>
</tbody>
</table>

Table 2.

<table>
<thead>
<tr>
<th>Findings</th>
<th>Biological Agents</th>
<th>Uveitis (n)</th>
<th>Arthritis (n)</th>
<th>Venous thrombus (n)</th>
<th>Central nervous system involvement (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azathioprine</td>
<td></td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Methotrexate</td>
<td></td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Adalimumab</td>
<td></td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>Infliximab</td>
<td></td>
<td>3</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Conclusion: Behçet’s disease is rare in childhood. Although it is not common, life-threatening complications can be observed. To reduce morbidity and complications, physicians should be aware of manifestations and rare clinical pictures of the BD.

REFERENCES:

Disclosure of Interests: None declared

AB0580 BEHÇET’S DISEASE IN OSLO NORWAY IN PERIOD 1999 – 2021
J. L. Lorentsen1, K. Lerang1, T. Garen1, O. Palm1. 1Rikshospitalet, Rheumatology, Oslo, Norway

Background: Behcet’s disease (BD) is a multisystemic, inflammatory disease, characterized by variety of clinical manifestations, including mucocutaneous, ocular, vascular, neurological (CNS) and gastrointestinal (GI) involvements. The disease can be seen at any age and occurs across gender, ethnic groups, and geographical areas. However, there are only a few studies from northern Europe.

Objectives: To study the demographics and clinical feature of patients with Behcet’s disease (BD) in Oslo Norway.

Methods: In this retrospective study we reviewed hospital records from Oslo University Hospital (OUS), a referral hospital for systemic inflammatory vasculitides in Norway. All patients living in Oslo with ICD-10 code M35.2 were identified, and their BD-related data recorded. Those fulfilling either the International Study Group criteria (ISG) or International Criteria for Behcet’s disease (ICBD) were included. Patients were defined as non-Norwegian when none of the parents was of Norwegian ancestry. The differences between groups were compared by Chi-square test using the Statistical Package for the Social Sciences (SPSS).

Results: We identified a total of 58 patients fulfilling the inclusion criteria (Table 1). Among them, 30 (52%) were females and 25 (43%) of Norwegian ancestry. Mean age at onset was 28 years, and at diagnosis 32 years.

Table 1. Demographics of Behcet’s patients in Oslo Norway

<table>
<thead>
<tr>
<th>Counts (%)</th>
<th>Norwegian ancestry</th>
<th>Non-Norwegian ancestry</th>
<th>All (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All (%)</td>
<td>25 (43)</td>
<td>33 (57)</td>
<td>58 (100)</td>
</tr>
<tr>
<td>Male (%)</td>
<td>17 (57)</td>
<td>23 (69)</td>
<td>40 (69)</td>
</tr>
<tr>
<td>Female (%)</td>
<td>8 (28)</td>
<td>10 (31)</td>
<td>18 (31)</td>
</tr>
<tr>
<td>ISG Criteria (%)</td>
<td>20 (67)</td>
<td>23 (69)</td>
<td>43 (74)</td>
</tr>
<tr>
<td>ICBD Criteria (%)</td>
<td>25 (42)</td>
<td>33 (61)</td>
<td>58 (100)</td>
</tr>
</tbody>
</table>

The most prevalent clinical manifestations were oral ulcers (n=58, 100%), genital ulcers (n=49, 84%), and skin lesions (n=40, 69%). Ophthalmic complications (n=21, 36%), arthritis (n=20, 34%), vascular involvement (n=7, 12%), CNS (n=3, 5%) and gastrointestinal (GI) complications (n=4, 7%) were also present. There was no significant difference of clinical features between patients with Norwegian ancestry and those with non-Norwegian ancestry (data not shown).

Figure 1. Conclusion: BD was most prevalent among patients of non-Norwegian ancestry. We found a wide spectrum of clinical manifestations occurring during the disease course. Mucocutaneous lesions were most frequent, but potential serious manifestations were also present. These manifestations were similarly distributed between patients with Norwegian and non-Norwegian ancestry (Figure 1).

REFERENCES:

Disclosure of Interests: None declared

AB0581 TRACHEAL STENOSIS: AN IMPORTANT INVOLVEMENT IN GRANULOMATOSIS WITH POLYANGIITIS
O. Ozdemir Isik1, F. Tuncer1, O. Sadioglu Cagdas1, A. Yazici1, A. Cefle1. 1Kocaeli University, Faculty of Medicine, Rheumatology, Kocaeli, Turkey

Background: Granulomatosis with polyangiitis (GPA) is a granulomatous systemic vasculitis of unknown etiology that can affect many organs. Approximately 90% of patients with GPA have upper respiratory tract involvement, including the nasal cavity, sinuses, ear and trachea. Subglottic stenosis (SGS) may develop in some patients due to tracheal involvement.

Objectives: It is aimed to evaluate the general characteristics, treatments and disease prognosis of our GPA cases with tracheal stenosis as it is a significant cause of morbidity and mortality.
Methods: The data of 48 patients diagnosed with GPA between 2000-2021 were analyzed retrospectively and the data of 6 patients with tracheal stenosis (TS) were evaluated.

Results: TS was present in 13% of the patients. All patients with TS were female. The mean age of the patients with TS was 46.5±6.5 years, and the mean age of disease onset was 35.5±13.4 years, and the mean disease duration was 10.8±10.2 years. Constitutional symptoms were in 17% of patients, and 17% had manifestations of atherosclerosis, xanthomas, oedema, bloody nasal discharge and renal involvement. None of the patients had hearing loss, skin, eye and neurological involvement. 83% of patients had limited disease. While all patients had SGS, one patient also had glottic and bronchial stenosis. The most common symptoms in patients were hoarseness and shortness of breath. All patients received systemic treatment according to their organ involvement, local treatment (dilatation, steroid injection) was also applied to all patients. All patients had anti-neutrophil cytoplasmic antibody (ANCA) positivity. When patients with and without tracheal stenosis were compared, there was a difference in 5 terms of gender, lung and kidney involvement, presence of anemia, increased erythrocyte sedimentation rate, pANCA, cANCA and PR3-ANCA positivity, and myalgia. In addition, our patients with tracheal stenosis had a younger age of onset and a longer delay in diagnosis.

Conclusion: The incidence of SGS in large series has been reported as 8-23% of GPA patients. Although the number of cases in our study was small, this rate was 13%. Symptoms range from cough and shortness of breath to progressively life-threatening severe stridor. Early diagnosis and treatment are important. For this reason, TS is strongly emphasized.

References:

Table 1. Comparison of data from GPA patients with and without tracheal stenosis

<table>
<thead>
<tr>
<th>N(%)</th>
<th>Tracheal Stenosis +GPA(n=6)</th>
<th>Tracheal Stenosis - GPA (n=42)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender Female</td>
<td>6 (100)</td>
<td>21 (51)</td>
<td>0.031</td>
</tr>
<tr>
<td>Male</td>
<td>0</td>
<td>20 (49)</td>
<td></td>
</tr>
<tr>
<td>Mean Age</td>
<td>46.5±6.5</td>
<td>55.6±13.2</td>
<td>0.095</td>
</tr>
<tr>
<td>Symptom Onset Age</td>
<td>35.5±13.4</td>
<td>49.3±14.5</td>
<td>0.041</td>
</tr>
<tr>
<td>Delay in Diagnosis (months)</td>
<td>44.2±6.5</td>
<td>9.98±14.8</td>
<td>0.023</td>
</tr>
<tr>
<td>Myalgia</td>
<td>2 (33)</td>
<td>33 (81)</td>
<td>0.030</td>
</tr>
<tr>
<td>Fever</td>
<td>1 (17)</td>
<td>21 (51)</td>
<td>0.194</td>
</tr>
<tr>
<td>High ESR</td>
<td>1 (17)</td>
<td>31 (78)</td>
<td>0.007</td>
</tr>
<tr>
<td>High CRP</td>
<td>5 (83)</td>
<td>32 (78)</td>
<td>0.138</td>
</tr>
<tr>
<td>Anemia</td>
<td>1 (17)</td>
<td>28 (70)</td>
<td>0.020</td>
</tr>
<tr>
<td>Upper Respiratory Involvement</td>
<td>6 (100)</td>
<td>24 (59)</td>
<td>0.074</td>
</tr>
<tr>
<td>Lung Involvement</td>
<td>3 (50)</td>
<td>36 (90)</td>
<td>0.037</td>
</tr>
<tr>
<td>Eye Involvement</td>
<td>1 (17)</td>
<td>6 (15)</td>
<td>0.097</td>
</tr>
<tr>
<td>Skin Involvement</td>
<td>1 (17)</td>
<td>11 (27)</td>
<td>NA</td>
</tr>
<tr>
<td>Urogenital Involvement</td>
<td>1 (17)</td>
<td>12 (29)</td>
<td>NA</td>
</tr>
<tr>
<td>Neurological Involvement</td>
<td>1 (17)</td>
<td>13 (32)</td>
<td>NA</td>
</tr>
<tr>
<td>Renal Involvement</td>
<td>1 (17)</td>
<td>29 (71)</td>
<td>0.018</td>
</tr>
<tr>
<td>ANCA positivity</td>
<td>6 (100)</td>
<td>38 (93)</td>
<td>0.003</td>
</tr>
<tr>
<td>MPO-ANCA</td>
<td>2 (33)</td>
<td>4 (10)</td>
<td>0.162</td>
</tr>
<tr>
<td>PR3-ANCA</td>
<td>1 (17)</td>
<td>33 (81)</td>
<td>0.004</td>
</tr>
<tr>
<td>p-ANCA</td>
<td>5 (83)</td>
<td>6 (15)</td>
<td>0.000</td>
</tr>
<tr>
<td>c-ANCA</td>
<td>1 (17)</td>
<td>31 (78)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

AB0583 REFERRAL PATTERN AND TREATMENT OF POLYMYALGIA RHEUMATICA IN GENERAL PRACTICE: AN INTERNATIONAL QUESTIONNAIRE BASED STUDY


1. Aarhus University Hospital, Department of Rheumatology, Aarhus, Denmark; 2. Leeds Teaching Hospital NHS trust, Rheumatology, Leeds, United Kingdom; 3. Aarhus University, Clinical Medicine, Aarhus, Denmark; 4. Centro de Referencia en Osteoporoasis & Reumatologia, Reumatologia, Cali, Colombia; 5. University Hospital Basel, Rheumatology, Basel, Switzerland; 6. St Maartenskliniek, Rheumatology, Nijmegen, Netherlands; 7. The Regional Hospital in Horsens, Department of Medicine, Horsens, Denmark; 8. Norwich and Norfolk University Hospital, Rheumatology, Norwich, United Kingdom; 9. Dudley Group NHS, Rheumatology, Dudley, United Kingdom; 10. University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Groningen, Netherlands; 11. Clinical Rehabilitation Hospital, Rheumatology, Lass, Romania; 12. University of Pavia, Rheumatology, Pavia, Italy; 13. Piropov National Russian Research Medical University, Faculty Therapy, Moscow, Russian Federation; 14. Scarborough Health Network, Reumatology, Toronto, Canada; 15. University of Campinas, Rheumatology, Campinas, Brazil; 16. Ibn Zohr University, Department of Rheumatology, Agadir, Morocco; 17. Obafemi Awolowo University Teaching Hospitals Complex, Rheumatology Unit, Ille-Ife, Nigeria; 18. PUC Campinas Hospital, General Medicine; 19. Rheumatology, Campinas, Brazil; 20. University of Otago, Department of Medicine, Otago, New Zealand; 21. School of Medicine Keele University, General Health, Staffordshire, United Kingdom; 22. Hospital of Bruneck, Department of Rheumatology, Bruneck, Italy; 23. Medical University Graz, Department of Rheumatology, Graz, Austria

Background: In most countries polymyalgia rheumatica (PMR) is diagnosed and managed by both general practitioners (GP) and rheumatologists. However, the referral pattern from GP’s to specialist around the world has not been described. The initial prednisolone dose recommended by EULAR-ACR is between 12.5 and 25 mg, but little is known about whether these guidelines are followed everywhere by GP’s in clinical practice.

Objectives: This study aims to describe the referral pattern and treatment strategy for PMR in general practice in several countries worldwide.

Methods: An English language questionnaire was drafted by a working group of rheumatologists and GPs from 6 different countries. The questionnaire contained questions on: 1. Respondent, 2. Referral pattern and 3. Prednisolone. Questionnaires were distributed to GPs via members of the International PMR/GCA study group. Answers were collected via an online survey tool (Redcap), from 3rd of November 2021 to 27th of January 2022. Countries with more than 15 GPs were included in the analysis.

Results: Data from 11 countries were analysed. Referral patterns differed widely among countries (Table 1). Almost all hospital initially seen by rheumatologists were referred to GPs for treatment. In all countries a proportion of the GP’s prescribed higher initial prednisolone doses than recommended, with a large variation between countries (Table 1).
Conclusion: Although many patients were referred to the hospital for initial PMR diagnosis or during the disease course, a large proportion of patients received treatment in general practice worldwide. GPs frequently use a higher starting dose of prednisolone and shorter treatment duration than recommended by EULAR/ACR.

REFERENCES:


Acknowledgements: This study was endorsed by the international PMR/GCA study group.

Disclosure of Interests: Agnete Overgaard Donskov: None declared, Sarah Mackie: None declared, Ellen-Margrete Hauge Speakers bureau: AbbVie,
Sanofi, Sobi, MSD, UCB, Consultant of: AbbVie, Sanofi, Sobi, MSD, UCB, Grant/ research support from: Nordic Novo Foundation, Danish Rheumatism Association, Danish Regions Medicine Grants, Roche, Novartis,Celgene, MSD, Pfizer, Roche, Sobi, CARLOS TORO GUTIERREZ. None declared, Andrea Hemmig: None declared, Aatke van der Maas: None declared, Birgit Dalsgaard Nielsen:
Paid instructor for: Roche, Ib Hansen: None declared, Max Yates: None declared, Line Frelund: None declared, Karen Douglas: None declared, Kornelis van de Geest Speakers bureau: Roche, Elena Rezu: None declared, Maria Monti: None declared, Margarita Gromova: None declared, Vanessa Ocampo Speakers bureau: Roche, Eli Lilly, Janiss, Novartis, Pfizer, Roche, Galapagos and Sanofi, Consultant of: Abbvie, Eli Lilly, Janiss, Roche, Galapagos and Sanofi, Kresten Kessler: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1380

Table 1. Characteristics of responders, referral pattern, and treatment strategy

<table>
<thead>
<tr>
<th>Country</th>
<th>Austria</th>
<th>Canada</th>
<th>Colombia</th>
<th>Denmark</th>
<th>Italy</th>
<th>Netherlands</th>
<th>New Zealand</th>
<th>Norway</th>
<th>Romania</th>
<th>Russia</th>
<th>Switzerland</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders (n), Completed questionnaire (total)</td>
<td>26 (29)</td>
<td>15 (15)</td>
<td>17 (23)</td>
<td>53 (53)</td>
<td>36 (41)</td>
<td>22 (22)</td>
<td>17 (17)</td>
<td>37 (43)</td>
<td>42 (49)</td>
<td>26 (26)</td>
<td>34 (35)</td>
<td></td>
</tr>
<tr>
<td>Experience (years)</td>
<td>20 (12-34)</td>
<td>8 (4-10)</td>
<td>6 (4-9)</td>
<td>12 (10-17)</td>
<td>15 (5-27)</td>
<td>23 (17-30)</td>
<td>14 (9-27)</td>
<td>21 (16-30)</td>
<td>6 (5-9)</td>
<td>26 (15-32)</td>
<td>16 (11-24)</td>
<td></td>
</tr>
<tr>
<td>Available PMR/GCA guideline, n (%)</td>
<td>16 (100)</td>
<td>15 (100)</td>
<td>17 (100)</td>
<td>53 (100)</td>
<td>16 (100)</td>
<td>22 (100)</td>
<td>17 (100)</td>
<td>37 (100)</td>
<td>42 (100)</td>
<td>26 (100)</td>
<td>34 (100)</td>
<td></td>
</tr>
<tr>
<td>Adherence to guideline, n (%)</td>
<td>21 (82)</td>
<td>15 (100)</td>
<td>17 (100)</td>
<td>51 (97)</td>
<td>34 (94)</td>
<td>21 (95)</td>
<td>17 (100)</td>
<td>37 (100)</td>
<td>42 (100)</td>
<td>26 (100)</td>
<td>34 (100)</td>
<td></td>
</tr>
<tr>
<td>Referrals</td>
<td>New PMR patients referred for diagnosis (%)</td>
<td>58 (10-100)</td>
<td>50 (2-100)</td>
<td>100 (13-100)</td>
<td>50 (20-100)</td>
<td>60 (28-100)</td>
<td>20 (10-50)</td>
<td>10 (10-85)</td>
<td>1 (1-2)</td>
<td>28 (10-50)</td>
<td>10 (1-25)</td>
<td></td>
</tr>
<tr>
<td>Patients returned to GP for treatment (%)</td>
<td>100 (50-100)</td>
<td>50 (2-100)</td>
<td>8 (0-10)</td>
<td>85 (40-100)</td>
<td>50 (0-100)</td>
<td>50 (10-90)</td>
<td>80 (100-80)</td>
<td>80 (100-80)</td>
<td>1 (1-1)</td>
<td>80 (100-80)</td>
<td>10 (100-100)</td>
<td></td>
</tr>
<tr>
<td>Patients referred during treatment (%)</td>
<td>50 (25-90)</td>
<td>50 (10-100)</td>
<td>100 (100-100)</td>
<td>50 (10-30)</td>
<td>50 (15-80)</td>
<td>10 (10-20)</td>
<td>30 (10-80)</td>
<td>1 (1-1)</td>
<td>20 (10-30)</td>
<td>10 (10-20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial dose &gt; 25 mg, n (%)</td>
<td>12 (42)</td>
<td>4 (25)</td>
<td>7 (40)</td>
<td>14 (25)</td>
<td>9 (25)</td>
<td>1 (5)</td>
<td>6 (38)</td>
<td>7 (20)</td>
<td>3 (8)</td>
<td>22 (83)</td>
<td>3 (9)</td>
<td></td>
</tr>
<tr>
<td>Duration of treatment (months)</td>
<td>9 (6-12)</td>
<td>6 (2-9)</td>
<td>6 (4-24)</td>
<td>12 (8-18)</td>
<td>5 (3-12)</td>
<td>11 (6-12)</td>
<td>10 (18-10)</td>
<td>2 (2-5)</td>
<td>6 (6)</td>
<td>12 (6-12)</td>
<td>15 (12-24)</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as weighted median (interquartile range) unless otherwise stated. GP: general practitioner; PMR: polymyalgia rheumatica; GCA: great cell arteritis.

AB0584 MANAGEMENT OF REFERRALS, TREATMENT STRATEGY, AND RESEARCH CHALLENGES IN POLYMALGIA RHEUMATICA AMONGST RHEUMATOLOGISTS WORLDWIDE: A QUESTIONNAIRE BASED STUDY


1: respondent, 2: referrals, 3: prednisolone, and 4: barriers to research. Questions concerned: patient journeys; the world manage the referral process of patients with PMR from GP's has not been described. EULAR/ACR guidelines recommend initial prednisolone doses between 12.5 and 25 mg, but it is unknown if guidelines are followed in daily clinical practice. Additional, the understanding of challenges for recruitment to clinical trials in PMR is currently limited.

Objectives: This study aims to describe the management of referrals, treatment strategy, and recruitment to clinical trials in PMR amongst rheumatologists worldwide.

Methods: An English language questionnaire was drafted by a working group of rheumatologists and GP’s from 6 different countries. Questions concerned: 1: respondent, 2: referrals, 3: prednisolone, and 4: barriers to research. Questions were distributed to rheumatologists via members of the International PMR/GCA study group. Answers were collected via an online survey tool (Redcap). 2nd of November 2021 to 27th of January 2022. Countries were grouped by income and geographical region based on the World bank classifications. Data were weight by number of inhabitants in a country, based on the United Nations age specific population count, divided by number of respondents in a country. Countries with more than 20 respondents were included.
Table 1. Characteristics of responders, referrals, and treatment.

<table>
<thead>
<tr>
<th>Geographical region</th>
<th>The world</th>
<th>Europe and Central Asia</th>
<th>North America</th>
<th>Latin America</th>
<th>East Asia and Pacific</th>
<th>South Asia</th>
<th>Middle East and Africa</th>
<th>High-income countries</th>
<th>Low- and middle-income countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders (n)</td>
<td>875 (1000)</td>
<td>294 (304)</td>
<td>78 (81)</td>
<td>136 (152)</td>
<td>53 (53)</td>
<td>53 (72)</td>
<td>261 (338)</td>
<td>446 (458)</td>
<td>429 (542)</td>
</tr>
<tr>
<td>Referrals</td>
<td>11 (6-20)</td>
<td>12 (6-20)</td>
<td>7 (4-20)</td>
<td>11 (6-23)</td>
<td>21 (10-30)</td>
<td>7 (4-10)</td>
<td>9 (5-18)</td>
<td>11 (5-22)</td>
<td>8 (5-12)</td>
</tr>
<tr>
<td>Experience as rheumatologist (years)</td>
<td>64</td>
<td>79</td>
<td>79</td>
<td>57</td>
<td>58</td>
<td>60</td>
<td>67</td>
<td>74</td>
<td>61</td>
</tr>
<tr>
<td>GP's can discuss patients prior to referral, %</td>
<td>100 (90-100)</td>
<td>100 (90-100)</td>
<td>100 (100-100)</td>
<td>100 (100-100)</td>
<td>100 (95-100)</td>
<td>100 (100-100)</td>
<td>100 (60-100)</td>
<td>100 (100-100)</td>
<td>100 (90-100)</td>
</tr>
<tr>
<td>Referred patients seen (%)</td>
<td>26</td>
<td>49</td>
<td>80</td>
<td>60</td>
<td>21</td>
<td>6</td>
<td>18</td>
<td>58</td>
<td>15</td>
</tr>
<tr>
<td>Evaluation 2 weeks after referral, %</td>
<td>50 (20-50)</td>
<td>60 (30-80)</td>
<td>70 (50-80)</td>
<td>50 (10-50)</td>
<td>30 (20-50)</td>
<td>50 (20-80)</td>
<td>20 (6-50)</td>
<td>50 (30-50)</td>
<td>50 (10-70)</td>
</tr>
<tr>
<td>Initial dose &gt; 25 mg</td>
<td>32</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>4</td>
<td>4</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>Duration of treatment (months)</td>
<td>12 (6-12)</td>
<td>12 (12-18)</td>
<td>12 (10-18)</td>
<td>6 (3-12)</td>
<td>18 (12-18)</td>
<td>6 (3-12)</td>
<td>6 (3-12)</td>
<td>12 (12-18)</td>
<td>9 (6-12)</td>
</tr>
</tbody>
</table>

**Data presented as weighted median (interquartile range) unless otherwise stated. GP: general practitioner.**

**Results:** Results from 27 countries were analysed including 1000 responders in total (Figure 1). There was large variation in time from referral to first assessment, initial dose of prednisolone was high, duration of treatment was relatively short, and a large proportion of patients with newly diagnosed PMR received prednisolone prior to rheumatological evaluation (Table 1). Concerning the 15% of respondents who performed research in PMR, 52% had participated in clinical trials and 56% of the responders experienced difficulties with recruitment.

**Conclusion:** This is the first description of current practice in managing referrals and treatment of PMR by rheumatologists worldwide. In general, median treatment duration was according to EULAR/ACR guidelines, but initial dose of prednisolone was often higher than recommended in many parts of the world. PMR patients were often seen more than two weeks after referral, and treatment had started prior to first rheumatological evaluation.

**REFERENCES:**

**Acknowledgements:** This study was endorsed by the international PMR/GCA study group.

**Disclosure of Interests:** Agnete Overgaard Donskov: None declared. Sarah Mackie: None declared, Ellen-Margrette Hauge Speakers bureau: Abbvie, Sanofi, Sobi, MSD, UCB, Consultant of: Abbvie, Sobi; MSD, Granti/ research support from: Novo Nordic Foundation, Danish Rheumatism Association, Danish Regions Medicine Grants, Roche, Novartis, Celgene, MSD, Pfizer, Roche, Sobi, CARLOS TORO GUTIÉRREZ: None declared, Ivib Hansen: None declared, Andrea Hemmig: None declared, Aakat van der Maas: None declared, Tamer A Gheta: None declared, Bert Dalsgaard Nielsen Paid instructor for: Roche, Karen Douglas: None declared, Richard Conway Speakers bureau: Janssen, Roche, Sanofi-Aventis, Paid instructor for: Abbvie, Eli Lilly, Sanofi-Aventis, Pfizer, Jansen, Novartis, Consultant of: Abbvie, Eli Lilly, Janssen, Pfizer, Roche, Novartis, Sandoz, Grant/research support from: Abbvie, Celgene - Algorithm, Bristol-Myers Squibb - NewBridge, Pfizer, Nizar Abdulateef Al-Ani: None declared, Adeola Ajibade: None declared, Johannes Knitza: None declared, Line Frolund: None declared, Max Yates: None declared, Victor Pimentel-Iquirol: None declared, Andrea Hemmig: None declared, Maria Sandovic: None declared, Kornelis van der Geest Speakers bureau: Roche, Toby hellwell Grant/research support from: Viamarin, Asahibik, Speakers bureau: Roche, Christian Lucaci Speakers bureau: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Galapagos and Sanofi, Consultant of: Abbvie, Eli Lilly, Janssen, Roche, Galapagos and Sanofi, Kresten Keller: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1486

**AB0585**

**NEURO-BEHÇET’S DISEASE: A TUNISIAN EXPERIENCE**

A. Abya Chatti1, S. Skhiri1, A. Guiga1, W. Ben Yahia1, A. Attig1, N. Ghannouchi1, 1Hospital Farhat Hached, Internal Medicine, Sousse, Tunisia

**Background:** Behçet’s disease (BD) is a systemic inflammatory vasculitis with a wide range of manifestations including neurological involvement. Though neuro-Behçet’s disease (NBD) is relatively uncommon, it encompasses some of the most serious manifestations of BD. Its diagnosis can be challenging, as there is no specific diagnostic test.

**Objectives:** Our study aimed to describe epidemiological, clinical and paraclinical characteristics of BD, and compare them between patients with and without NBD.

**Methods:** We conducted a retrospective study, including all patients meeting the revised international study group criteria for BD, over an 18-year period. We divided patients into 2 groups, based on the presence or absence of neurological involvement, retained according to the international consensus recommendation criteria for NBD. Epidemiological, clinical and paraclinical features were then analysed and compared between the two groups.

**Results:** We obtained a cohort of 77 patients with a gender ratio (M/F) of 1.85 and a mean age at diagnosis of 34.4 years [20-60]. Mucocutaneous involvement inaugurated BD in 81.8% of cases, followed by joint involvement (19.5%), vascular involvement (17.9%), neurological involvement (10.7%) and ocular involvement (2.6%). Mucocutaneous involvement was dominated by oral aphthosis (100%) and genital aphthosis (79.2%) with a mean frequency of episodes per year of 8.3 ± 6.2 and 6.9 ± 5.1 respectively, followed by pseudo-folliculitis (66.2%), erythema nodosum (19.5%), and positive pathergic test (13%). Joint involvement (62.3%) was mainly peripheral (arthralgia in 98% and arthritis in 66.2%), axial involvement and sacroiliitis were observed in 14.6% and 10.4% of cases, respectively. Only one patient had a popliteal cyst. Vascular manifestations (36.4%) were venous thrombosis (92.9%), arterial thrombosis (12.9%) and arterial aneurysms (6.5%). Ocular manifestations (35%) were uveitis and vasculitis in 77.8% of patients respectively, with predominance of bilateral lesions (70.4%). Other manifestations were cardiac involvement (5.2%), intestinal involvement (3.4%) and fever (23.4%). One patient developed membranous glomerulonephritis without any other underlying aetiology. Biological inflammatory syndrome was found in 42.9% of patients. Twenty-eight patients developed NBD with 34 outbreaks during follow up. The mean delay from onset of BD was 6.3 years [0-26]. Parenchymal NBD was more frequent (73.5%), Non-parenchymal syndromes (38.2%) were acute meningeal (17%), cerebral venous thrombosis (11.8%), pseudotumour cerebri (5.9%) and isolated intracranial hypertension (2.9%). One patient developed peripheral neurological involvement. Headache
(59%) and motor deficits (32.4%) were the most common signs. Neurological examination most frequently revealed a pyramidal syndrome (32.3%). Severe forms (modified Rankin scale ≥2) dominated clinical presentations (64.7%). CSF study revealed abnormalities in 10 (35.7%) cases: Increased protein with pleocytosis in 6 cases with lymphocytic predominance (n=3), mixed formula (n=2) and PNN predominance (n=1), decreased glucose levels and increased pressure in 3 cases respectively, and one case of albuminocytological dissociation. The predilection sites of NBD lesions on MRI were brainstem and basai ganglia (35.5%, respectively), perriventricular white matter (28.5%), subcortical WM (23.5%), internal capsule (20.6%), centrum semiovale and cerebral cortex (11.8%, respectively) and cerebellum (3%). Comparison between the two groups revealed, in patients with NBD, an older mean age at diagnosis (37.7±11.97 vs 32.3 ±7.14, p=0.023) and a lower frequency of ocular involvement (21.4% in G1 vs 42.9% in G2, p=0.05). We found no statistically significant differences when comparing gender ratio and other clinical and biological features.

Conclusion: Ocular lesions were more frequent in patients without NBD. Large-scale studies are needed in order to determine markers associated to neurological involvement.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2408

AB0586 OCULAR ISCHEMIC SYNDROME CAUSING ACUTE BINOCULAR VISION LOSS IN THREE PATIENTS WITH TAKAYASU ARTERITIS TYPE V: A THERAPEUTIC QUANDARY

A. Krishna1, U. Dhakad2, P. Dogga2, J. Dixit1, A. Pm1, King George’s Medical University, Clinical Immunology and Rheumatology, Lucknow, India; 2King George’s Medical University, Department of Clinical Immunology and Rheumatology, Lucknow, India

Background: Ocular Ischemic syndrome (OIS) is a rare manifestation in Takayasu Arteritis (TA) which can cause irreversible retinal ischemia and neovascular changes. Ocular ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes. Ocular Ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes. Ocular ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes. Ocular ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes. Ocular ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes. Ocular ischemic syndrome denotes hypoperfusion of both anterior and posterior segments of eye and orbital structures as a result of common/arterial changes.

Methods: Case series of three patients of TA satisfying 1990 ACR classification criteria.

Results: 18-year-old female presented with acute onset painless loss of vision in both eyes and severe vertigo. She appreciated hand motion on visual acuity testing. She was started on Methotrexate (MTX) and Prednisolone (PSL). In view of acute vertebrobasilar and carotid insufficiency, she underwent bilateral carotid and vertebral angioplasty. She tested 20/80 on visual acuity in both eyes and ambulated without support by two weeks after procedure. 15-year-old female presented with episodic vertigo, amaurosis fugax and claudication of both upper and lower limbs. She was kept on MTX and tapering doses of PSL and when dose of PSL reached less than 0.25mg/kg, she developed acute binocular vision loss with absent pupillary reflexes. Visual acuity testing revealed perception of hand motion in both eyes which improved to 20/40 within two weeks after increasing steroid dose to 0.5mg/kg and tocilizumab. 14-year-old female presented with acute binocular painless loss of vision with previous history of limb claudication. Examination revealed no light perception on visual acuity testing in both eyes with absent pupillary reflexes. She was started on tapering doses of PSL and MTX. Also, she underwent a bilateral carotid and vertebral artery angioplasty. By first week, she could identify hand motion in both eyes with absent pupillary reflexes. She was started on Methotrexate (MTX) and tapering doses of PSL and when dose of PSL reached less than 0.25mg/kg, she developed acute binocular vision loss with absent pupillary reflexes. Visual acuity testing revealed perception of hand motion in both eyes which improved to 20/40 within two weeks after increasing steroid dose to 0.5mg/kg and tocilizumab. 14-year-old female presented with acute binocular painless loss of vision with previous history of limb claudication. Examination revealed no light perception on visual acuity testing in both eyes with absent pupillary reflexes. She was started on tapering doses of PSL and MTX. Also, she underwent a bilateral carotid and vertebral artery angioplasty. By first week, she could identify hand motion in both eyes with absent pupillary reflexes. She was started on Methotrexate (MTX) and tapering doses of PSL and when dose of PSL reached less than 0.25mg/kg, she developed acute binocular vision loss with absent pupillary reflexes. Visual acuity testing revealed perception of hand motion in both eyes which improved to 20/40 within two weeks after increasing steroid dose to 0.5mg/kg and tocilizumab.

Conclusion: We suggest that combining vascular surgical and pharmaceutical intervention in acute vision loss in TA may restore vision, even in active disease. Prompt follow-up and wider sample size is needed to draw insights into ocular involvement in TA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2711

AB0587 THE RISK OF PATIENTS WITH POLYMYALGIA RHEUMATICA AND GIANT CELL ARTERITIS TO DEVELOP DIABETES AND OSTEOPOROSIS ON FOLLOW UP

M. Bahl1,2, M. Stöcker3, S. Tsiami1,2, X. Baraliakos1,2, J. Braun1,2, U. Kitz1,2, 1Rheumazentrum Ruhrgebiet, Rheumatology, Herne, Germany; 2Ruhr University Bochum Faculty of Medicine, Rheumatology, Bochum, Germany; 3Augusta-Kranken-Anstalt gGmbH, Pneumology, Bochum, Germany

Background: Patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are commonly treated with glucocorticoids (GC) in different dosages. Therefore, the most common comorbidities that may develop are osteoporosis (OPO) and diabetes mellitus (DM).

Objectives: To study the development of these comorbidities in the management of PMR and GCA in a real-life setting.

Methods: In a retrospective study design, longitudinal data of patients with a clinical diagnosis of PMR and GCA treated in a tertiary center were studied. Patients and disease characteristics were documented according to clinical routine in patients in whom ≥2 documented visits ≥3 months apart had been documented.

Results: A total of 550 patients (382 PMR, 168 GCA) was analysed (Table 1). The time period of follow up (FU) ranged between 3 months and 13.6 years (mean 1.4 (0.3) years). The majority of patients received a diagnosis of PMR or GC.
GCA in our center while 29.5% of patients came for a second opinion. Their mean age was around 70 years, and most patients were female (Table 1). Eight GCA patients were already blind (4.6%) at first presentation, and 77 and 80 patients had a diagnosis of DM (15.5%) and OPO (16.0%), respectively, already at baseline. During FU 56 PMR (16.0%) and 7 GCA patients (4.2%) were diagnosed with another autoimmune disease, mainly with rheumatoid arthritis (n=50 (69.4%). The mean dose of GC differed substantially between groups (Table 1). On FU, 9 (2.4%) and 5 (3.0%) of PMR and GCA patients developed DM and 17 (4.5%) and 14 (6.4%) OPO, respectively. Thus, about 20% and 25% of patients with PMR or GCA finally had DM and OPO, respectively. Almost all patients received vitamin D and antiretroviral agents.

Table 1. Patients and disease characteristics

<table>
<thead>
<tr>
<th>PMR patients</th>
<th>GCA patients</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>68.2 (9.3)</td>
<td>71.1 (8.6)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.0 (4.9)</td>
<td>26.0 (5.3)</td>
</tr>
<tr>
<td>Female, sex, n (%)</td>
<td>216 (56.6)</td>
<td>121 (72.2)</td>
</tr>
<tr>
<td>Time to rheumatologist (months)</td>
<td>21.5 (8.7)</td>
<td>14.5 (5.4)</td>
</tr>
<tr>
<td>CRP at baseline (mg/dL)</td>
<td>3.8 (4.6)</td>
<td>4.5 (5.5)</td>
</tr>
<tr>
<td>Prednisolone at baseline (mg/d)</td>
<td>25.1 (20.2)</td>
<td>52.0 (69.7)</td>
</tr>
<tr>
<td>Comorbidities at baseline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Number of comorbidities (mean)</td>
<td>1.45 (1.12)</td>
<td>1.51 (1.12)</td>
</tr>
<tr>
<td>- Diabetes, n (%)</td>
<td>61 (16.0)</td>
<td>24 (14.3)</td>
</tr>
<tr>
<td>- Osteoporosis, n (%)</td>
<td>64 (16.8)</td>
<td>30 (17.9)</td>
</tr>
<tr>
<td>- Ischemic heart disease, n (%)</td>
<td>38 (9.2)</td>
<td>19 (11.4)</td>
</tr>
<tr>
<td>Organ manifestations and comorbidities at FU</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Blindness n (%)</td>
<td>5 (16.0)</td>
<td>8 (4.8)</td>
</tr>
<tr>
<td>- Aneurysm n (%)</td>
<td>5 (16.0)</td>
<td>9 (5.4)</td>
</tr>
<tr>
<td>- Diabetes, n (%)</td>
<td>70 (18.4)</td>
<td>29 (17.3)</td>
</tr>
<tr>
<td>- Osteoporosis, n (%)</td>
<td>81 (21.4)</td>
<td>44 (26.3)</td>
</tr>
<tr>
<td>- Vascular stenosis</td>
<td>4,6</td>
<td>10,1</td>
</tr>
</tbody>
</table>

Values given as mean (SD)

**Conclusion:** In this large real-life cohort, patients with PMR and GCA aged around 70 years were seen by rheumatologists about 1-2 months after their first symptom but 8 GCA patients were already blind at first visit. DM and OPO were frequent comorbidities in both, PMR and GCA patients, already at baseline and during follow-up more patients developed these comorbidities despite prophylactic and therapeutic medication. OPO and DM should be a routine concern in the care of PMR and GCA patients - already when glucocorticoids are started.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2742

**AB0589**

Giant Cell Arteritis: Do Different Phenotypes of Presentation Mean Different Clinical Entities?

N. Italiano 1, F. Di Gianni 1, E. Elefanté 1, F. Ferro 1, P.A. Erba 2, R. Talanico 1, M. Mosca 1.
1University of Pisa, Rheumatology Unit, Pisa, Italy; 2University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery; Section of Nuclear Medicine, Pisa, Italy

**Background:** Giant cell arteritis (GCA) is a systemic vasculitis involving large and medium-sized blood vessels. Treatment is with high dose glucocorticoids. Steroid-sparing agents and Tocilizumab (TCZ) are used for refractory or relapsing disease. NHS England requires all GCA patients to be discussed in a regional multidisciplinary team meeting (MDT) prior to commencing TCZ. TCZ has only been permitted for a maximum of one year; this time limitation was extended during the Covid-19 pandemic (1). The monthly virtual Bristol and Bath regional MDT started in November 2018.

**Objectives:** We aimed to review: 1) Baseline data on all patients referred to the Bristol and Bath TCZ for GCA MDT, including demographics, clinical presentation and previous steroid-sparing agents used and 2) 12 month follow up data including number of completions, adverse effects, and flares on treatment.

**Methods:** The TCZ MDT referral form, adapted from the NHS England Blueteq approval form, was reviewed for all patients referred. 12 month follow up data was obtained from clinic letters.

**Results:** Baseline data

Thirty-eight cases were referred between November 2018 and September 2021. Of these, 31 were approved for TCZ usage; 100% fulfilled the criteria for either refractory (n=11) or relapsing (n=20) disease. Mean age was 74 years and 74.2% were female. Average disease duration was 161.5 days for the refractory and 827.3 days for the relapsing group. 77.4% had cranial GCA, 48.4% had large vessel involvement, 45.2% had visual symptoms and 25.8% had ischaemic visual loss. The positive investigations were PET-CT (48.4%), temporal artery ultrasound (41.9%) and temporal artery biopsy (32.3%).

64.5% had trialled a steroid-sparing agent at time of referral (61.3% methotrexate, 9.7% azathioprine, 6.5% leflunomide), 35.5% had received intravenous methylprednisolone. 58% were receiving greater than 40mg prednisolone at the time of referral. Glucocorticoid adverse effects of osteoporosis, weight gain, cataracts and hypertension were each seen in 19.4%; whilst diabetes, neuropsychiatric symptoms and sleep disturbance were each reported in 16.1%.

Those with ocular involvement tended to be referred earlier than those without (478.2 days vs 648.1 days), were referred on higher doses of glucocorticoids (71.4% vs 47.1% on ≥40mg) and had less steroid-sparing agents prior to referral.

**Follow up data**

In December 2021, a follow-up audit revealed 14/31 patients had completed at least 12 months of tocilizumab; 5 of these had had an extension under Covid-19 exceptional guidance (mean duration of 5.2 months). Of the remaining 17: 3 patients had stopped early (1 death, 1 moved away, 1 due to adverse effects of hypertension and gastro-intestinal side effects). 4 had not started tocilizumab and 10 had completed 12 months of treatment at that point.

Adverse events in the 14 patients at 12 months included: liver abnormalities (2/14; 14.3%), neutropenia (2/14; 14.3%), thrombocytopenia (1/14; 7.1%), soft tissue between onset and treatment of ≥ 3 months. Temporal artery biopsy was performed in 171 patients, resulting positive in 72%. Globally, about 38% of subjects (was characterized by a clinical profile compatible with extra-cranial GCA. In all cases, extra-cranial involvement was confirmed by (18F-fluorodeoxyglucose: FDG) positron emission tomography (PET). Moreover, patients who presented symptoms compatible with large-vessel involvement were characterized by a more relapsing course compared with patients with cranial involvement GCA profile (both in terms of dose of corticosteroids and use of steroid-sparing agents).

**Conclusion:** According to the literature data, different phenotypes of GCA exist and they may probably represent different clinical entities, also in terms of prognosis and therapeutic approach. This is particularly crucial in order to plan a tailored therapy and prevent disease damage in the short and long-term follow-up.

**Disclose of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2797
infections (3/14; 21.4%), urinary tract infection (1/14; 7.1%) and lipid derangement (4/14; 28.6%). One case of GCA relapse occurred on TCZ (mild headache and raised inflammatory markers settled on small increase in prednisolone). After 12 months, mean prednisolone dose was 3mg (range 0-5mg).

**Conclusion:** All patients approved for Tocilizumab in the GCA MDT fulfilled NHS England criteria for either relapsing or refractory disease. The majority of cases had cranial disease, but almost half had either ocular or large vessel involvement, reflecting a severe spectrum of disease. Cases showed a high burden of glucocorticoid toxicity. Follow up data suggests that TCZ was effective in allowing glucocorticoid weaning and disease control, but with some adverse effects. Future work to follow up patients after stopping Tocilizumab would be informative, as the twelve month limitation on treatment is likely to be re-instated.

**REFERENCES:**

**Disclosure of Interests:** Chandrin N, R. Jayatilleke: None declared, Aishwarya Anilkumar: None declared, Shalini Janagan: None declared, Robert W Roberts: None declared, Sarah Skeoch: None declared, Catherine Guly Grant/research support from: Eli Lilly and Company - paid consultant for a research trial, Fang En Sin: None declared, Keziah Austin: None declared, Laith Al-Sweidan: None declared, Alexandra Bourn: None declared, Lynsey Clarke: None declared, Harsha Gunawardena: None declared, Baashar Boyce: None declared, Sally Knights: None declared, John D Pauling: None declared, Elizabeth Fleity: None declared, Timothy D Reynolds: None declared, Sarah Villar: None declared, Joanna C Robson: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2872

**Table 1.** Baseline characteristics of 39 newly diagnosed GCA patients.

<table>
<thead>
<tr>
<th>Median (IQR) or n (%)</th>
<th>TCZ (n=11)</th>
<th>MTX (n=28)</th>
<th>All (n=39)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>78 (73-84)</td>
<td>77 (72-83)</td>
<td>77 (72-83)</td>
<td>0.217</td>
</tr>
<tr>
<td>Female</td>
<td>11 (100%)</td>
<td>22 (78.6%)</td>
<td>33 (84.6%)</td>
<td>0.217</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>15 (11-21)</td>
<td>10 (0-29)</td>
<td>12 (0-29)</td>
<td>0.159</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>102 (79-169)</td>
<td>101 (54-159)</td>
<td>101 (54-159)</td>
<td>0.896</td>
</tr>
<tr>
<td>Fibrinogen, mg/dL</td>
<td>381 (269-504)</td>
<td>366 (268-502)</td>
<td>373 (269-502)</td>
<td>0.006</td>
</tr>
<tr>
<td>≥3 ACR criteria</td>
<td>4 (36.4%)</td>
<td>6 (21.4%)</td>
<td>10 (25.6%)</td>
<td>0.551</td>
</tr>
<tr>
<td>AION</td>
<td>2 (18.2%)</td>
<td>1 (3.6%)</td>
<td>3 (7.7%)</td>
<td>0.315</td>
</tr>
<tr>
<td>Fever</td>
<td>6 (54.5%)</td>
<td>6 (21.4%)</td>
<td>12 (30.8%)</td>
<td>0.138</td>
</tr>
<tr>
<td>Extra-cranial symptoms</td>
<td>7 (63.6%)</td>
<td>6 (21.4%)</td>
<td>13 (33.3%)</td>
<td>0.234</td>
</tr>
<tr>
<td>TAB positive</td>
<td>6 (54.5%)</td>
<td>6 (21.4%)</td>
<td>12 (30.8%)</td>
<td>0.234</td>
</tr>
<tr>
<td>Halo positive</td>
<td>6 (54.5%)</td>
<td>6 (21.4%)</td>
<td>12 (30.8%)</td>
<td>0.234</td>
</tr>
</tbody>
</table>

Table 1. Baseline characteristics of 39 newly diagnosed GCA patients.

**DISCUSSION:**

The follow-up time between groups was 20 (IQR 18.5-24.5) months vs 36 (IQR 24-60.5) months, respectively. At the last medical examination, all patients were in sustained remission, 6/11 (54.5%) and 17/28 (60.7%) had discontinued GCs. The prednisone equivalent dosage of 5mg/day was achieved at 5 (IQR 2.75-6.5) and 7 (IQR 5-10) months (p-value 0.078), respectively, while discontinuation of GCs was achieved at 7.5 (IQR 6.25-11.5) and 19 (IQR 14-24) months (p-value 0.015), respectively. No differences were observed as concerns GC-related adverse events at 1 year after the onset of GCA (1 event in 11 patients [9.1%] vs 3 events in 28 patients [10.7%]). In details, GC-related adverse events were development of diabetes (2/4), hypertension (1/4), or osteoporosis (1/4). Two patients in the first group (18.2%) and 9 in the second one (32.1%) experienced at least one relapse (median time to relapse was 6.5 [IQR 5.75-7.25] and 18 [IQR 12-24] months). Relapses required the association of MTX with TCZ (1/11 [9.1%]) or start of TCZ (1/11 [9.1%] in the former group, while they required an increase in steroid dosage (7/11 [63.6%]), switch from MTX to TCZ (1/11 [9.1%]), or reinstatement of MTX therapy after its discontinuation (1/11 [9.1%]) in the latter.

Overall, both drugs were well tolerated. 1/11 (9.1%) and 5/28 (17.9%) had discontinued TCZ and MTX, respectively, due to mild and reversible drug-related adverse events (4/6 general malaise or discomfort, 1/6 gastrointestinal symptoms, or 1/6 abnormal liver function tests). No serious infections were observed.

**Conclusion:** TCZ showed a faster steroid-sparing effect than MTX. Both immunosuppressants are safe, effective and allow the discontinuation of GCs.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2879
**Table 1. Clinical characteristics and GCA subtypes.**

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>Total GCA = 74</th>
<th>CGCA = 18</th>
<th>LVGCA = 12</th>
<th>MGCA = 44</th>
<th>CGCA vs. MGCA p</th>
<th>CGCA vs LVGCA p</th>
<th>LVGCA vs MGCA P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female sex, n (%)</td>
<td>44 (59.4)</td>
<td>10 (55.5)</td>
<td>6 (50)</td>
<td>27 (61.3)</td>
<td>0.672</td>
<td>0.765</td>
<td>0.478</td>
</tr>
<tr>
<td>Age, mean ± S.D. years</td>
<td>78.6 ± 8.6</td>
<td>79.0 ± 8.1</td>
<td>73.2 ± 9.4</td>
<td>80.7 ± 7.9</td>
<td>0.505</td>
<td>0.031</td>
<td>0.077</td>
</tr>
<tr>
<td>ESR, (mm/h) mean S.D.</td>
<td>57.1 ± 35.5</td>
<td>66.1 ± 39.2</td>
<td>39.6 ± 24.5</td>
<td>56.6 ± 34.1</td>
<td>0.391</td>
<td>0.021</td>
<td>0.115</td>
</tr>
<tr>
<td>CRP (mg/dL) mean S.D.</td>
<td>56.4 ± 57.1</td>
<td>50.1 ± 45.6</td>
<td>52.3 ± 52.5</td>
<td>60.7 ± 63.7</td>
<td>0.179</td>
<td>0.758</td>
<td>0.417</td>
</tr>
<tr>
<td>Constitutional symptoms, n (%)</td>
<td>59 (78.7)</td>
<td>12 (66.6)</td>
<td>12 (100)</td>
<td>35 (79.5)</td>
<td>0.292</td>
<td>0.025</td>
<td>0.087</td>
</tr>
<tr>
<td>Ischemic symptoms, n (%)</td>
<td>66 (86.6)</td>
<td>15 (83.3)</td>
<td>5 (41.6)</td>
<td>35 (79.5)</td>
<td>0.732</td>
<td>0.018</td>
<td>0.010</td>
</tr>
<tr>
<td>Remission for 6 months, n (%)</td>
<td>25 (33.3)</td>
<td>7 (38.8)</td>
<td>5 (41.6)</td>
<td>13 (29.5)</td>
<td>0.847</td>
<td>0.879</td>
<td>0.425</td>
</tr>
<tr>
<td>Glucocorticoid free remission, n (%)</td>
<td>8 (10.7)</td>
<td>1 (5.5)</td>
<td>2 (16.6)</td>
<td>5 (11.3)</td>
<td>0.475</td>
<td>0.320</td>
<td>0.622</td>
</tr>
<tr>
<td>Major relapse, n (%)</td>
<td>4 (5.3)</td>
<td>0 (0)</td>
<td>1 (8.3)</td>
<td>3 (6.8)</td>
<td>0.479</td>
<td>0.213</td>
<td>0.857</td>
</tr>
<tr>
<td>Minor relapse, n (%)</td>
<td>12 (16)</td>
<td>2 (11.1)</td>
<td>3 (25)</td>
<td>8 (18.1)</td>
<td>0.492</td>
<td>0.317</td>
<td>0.598</td>
</tr>
</tbody>
</table>

GCA: granal cell arteritis; CGCA: Cranial giant cell arteritis; LVGCA: Large vessel giant cell arteritis; MGCA: Mixed giant cell arteritis; SD: standard deviation; p: value.

**REFERENCES:**


**DOl:** 10.1136/annrheumdis-2022-eular.2987

**Figure 1.** Distribution of GCA subphenotypes

Of the 38 patients having TAB, 20(42.9%) were consisted with GCA. The main histopathological finding were inflammation rich in lymphohistiocytic cells in the temporal artery (44.7%) and fragmentation and loss of integrity of the internal elastic lamina (36.8%). All of the patients have been used corticosteroids with a median starting dose of 16 mg/day (8-64) had use pulse therapy. Any of conventional DMARDs (AZA, MTX, LEF, CYC) have been used in 60 of patients. In all cases, Tocilizumab was recommended after resistant/intolerant to conventional DMARDS (n=6). Follow-up data was based on 64 patients. During a median 5.8 (±4.0) years follow-up, 6 (9.3%) patients deceased. Thirteen (20.3%) had one or more relapses, 8 (61.5%) from isolated GCA group and 4 (30.7%) from Only LV GCA group.

**Conclusion:** GCA is less frequent than TAK in our centre. Female predominance and a seventh decade of disease onset was observed in our cohort. Heterogeneity of disease was observed in or cohort along with different frequent used diagnostic confirmatory modality among subphenotypes. Relapse rate was 20 percent during a 6-year follow-up with a 83% additional DMARD usage.

**REFERENCES:**

[1] K. Bates Gibbons1, Peter C Grayson2, et al, Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort, Arthritis Rheumatology, 2020 Apr;72

**Table 1. Confirmatory modality of GCA diagnosis and treatments of subphenotypes**

<table>
<thead>
<tr>
<th>Subphenotype</th>
<th>Only cranial GCA(n=38)</th>
<th>Cranial GCA+ LV GCA+ PMR(n=6)</th>
<th>Cranial GCA+ LV GCA+ PMR(n=2)</th>
<th>Cranial LV GCA+ GCA(n=5)</th>
<th>LV GCA+ GCA(n=7)</th>
<th>Only LV GCA(n=14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed confirmed by TAB</td>
<td>20 (52%)</td>
<td>4 (66.7)</td>
<td>2 (100)</td>
<td>2 (40)</td>
<td>1 (14.3)</td>
<td></td>
</tr>
<tr>
<td>(Total n=26)</td>
<td>18 (50)</td>
<td>2 (33.3)</td>
<td>2 (33.3)</td>
<td>1 (20)</td>
<td>1 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Temporal ultrasonography</td>
<td>18 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td></td>
</tr>
<tr>
<td>(Total n=24)</td>
<td>1 (17.2)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PET CT/Vasculitis MR/ Vasculitis BT (Total n=22)</td>
<td>6 (12)</td>
<td>2 (33.3)</td>
<td>1 (33.3)</td>
<td>1 (41.7)</td>
<td>2 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Only steroid n=12</td>
<td>6 (12)</td>
<td>2 (33.3)</td>
<td>1 (33.3)</td>
<td>1 (41.7)</td>
<td>2 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Pulse steroid n=14</td>
<td>8 (12)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td>1 (14.3)</td>
<td></td>
</tr>
<tr>
<td>Methotrexate n=35</td>
<td>17 (20)</td>
<td>2 (20)</td>
<td>2 (20)</td>
<td>1 (20)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leflunomide n=3</td>
<td>2 (100)</td>
<td>1 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azathioprine n=19</td>
<td>12 (63.2)</td>
<td>2 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td>1 (100)</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide n=1</td>
<td>1 (100)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tocilizumab n=8</td>
<td>6 (50)</td>
<td>2 (50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**DOl:** 10.1136/annrheumdis-2022-eular.3035

**Figure 1.** Distribution of GCA subphenotypes

**AB0593**

**CORRELATIONS BETWEEN PATHOLOGIC SUBSETS AND PET METABOLIC ACTIVITY IN A MONOCENTRIC COHORT OF 46 PATIENTS WITH BIOPSY PROVEN TEMPORAL ARTERITIS. AN OBSERVATIONAL RETROSPECTIVE ANALYSIS.**

F. Cirelli1, S. Asioli2, R. Galassi3, D. Tirotta1, C. Bellini5, S. Bernardi1, L. Gandelli1, L. Petrini4, E. Fabbrini1, P. Muratori1, 2Ospedale "Morgagni - Pierantoni" di Forlì, Internal Medicine Unit-Rheumatology Service, Forlì, Italy; 3Ospedale "Morgagni - Pierantoni" di Forlì, Pathology Service, Forlì, Italy; 4Ospedale "Morgagni - Pierantoni" di Forlì, Nuclear Medicine Service, Forlì, Italy; 5Ospedale "Morgagni - Pierantoni" di Forlì, Internal Medicine Unit, Forlì, Italy; 2Ospedale "Morgagni - Pierantoni" di Forlì, Otolaryngology Unit, Forlì,

**Disclosure of Interests:** None declared

**DOl:** 10.1136/annrheumdis-2022-eular.3035

**Figure 1.** Distribution of GCA subphenotypes
Background: Temporal arteritis is the most common systemic vasculitis in patients aged >50 years, the most serious complications of which is visual loss. The arterial biopsy is the diagnostic gold standard; alongside the classic finding of transmural infiltrate and giant cells, other abnormalities have been described of which it is not yet known whether they identify specific clinical subsets. PET is not yet used for diagnosis, but it can be suggestive in patients with high clinical suspicion; it may be useful for assessing the extent of the disease in already diagnosed patients and for ruling out alternative diagnoses as infections and neoplasms. More recently, PET has been used to assess disease metabolic activity.

Objectives: The aim of our study is to evaluate, in patients with histologically confirmed temporal arteritis, correlations between pathological subsets, metabolic activity and different clinical behavior.

Methods: We have recovered the medical records of patients with the diagnosis of temporal arteritis made in our Rheumatology service from January 2007 until now. We selected those satisfying the ACR 1990 criteria and, finally, those with a positive biopsy. We analyzed age at onset of symptoms, diagnostic delay, presence of PMR, fever, constitutional symptoms, headache, temporal artery induration, visual loss; we analyzed CRP, ESR, plasmatic Hb, PLT count, hypocoagulability; it may be useful for assessing the extent of the disease in already diagnosed patients and for ruling out alternative diagnoses as infections and neoplasms.

Results: We analyzed 46 patients (F 32, M 14), average age at onset of symptoms of 75.5 yrs and average diagnostic delay of 3.2 months. Headache was reported by 37 patients, fever and asthenia by 26 and 24 respectively, jaw claudication and PMR by 18 and 7. 11 patients had visual loss while 4 and 2 respectively reported amaurosis and diplopia. Temporal artery induration was described in 24 patients. Tests of systemic inflammation were abnormal (mean CRP 6-21); 8/13 patients had not taken steroids prior to PET.

Conclusion: In our retrospective study we observed, in addition to transmural infiltrate and giant cells, the presence of lymphocytes, macrophages and small vessel vasculitis. No correlation was observed between clinical findings, biological and metabolic activity, apart from the increased presence of giant cells in PET positive patients. Visual loss is slightly more common in PET negative patients. This may be due to severity of the cases which needed early steroid treatment.

Disclosure of Interests: Francesco Girelli: None declared, Silvia Asioli: None declared, Riccardo Galassi: None declared, Daniela Tirotta: None declared, Chiara Bellini: None declared, Simone Bernardi Paid instructor for: Paid instructor for Pharmaceuticals in 2013, Lucia Gardelli: None declared, Linda Petrin: None declared, Elisabetta Fabbri: None declared, Paolo Muratori: None declared.


AB0594
ULTRASOUND INTIMA MEDIA THICKNESS CUT-OFF VALUES FOR CRANIAL AND EXTRACRANIAL ARTERIES IN PATIENTS WITH GIANT CELL ARTERITIS

K. Lópex Gloria1, P. Rodríguez-Merlos1, B. Serrano-Benavente1, J. C. Nieto Gonzalez1, C. Gonzalez1, I. Monteagudo Saez1, T. Gonzalez1, I. Castrejon1, J. M. Alvaro-Gracia1, J. Molina Collada1,1 Hospital Universitario Gregorio Marañón, Rheumatology, Madrid, Spain

Background: Ultrasound (US) is a valid imaging tool to detect signs of giant cell arteritis (GCA). Although the halo sign has always been considered the most useful finding for GCA diagnosis, modern high frequency transducers are able to precisely measure the intima-media thickness (IMT) of cranial and extracranial arteries. However, data on optimal cut-off values for IMT to differentiate patients and controls in clinical practice are limited.

Objectives: To determine the optimal cut-off value for IMT of cranial and extracranial arteries in patients with suspected GCA.

Methods: This is a retrospective observational study of patients referred to our US fast-track clinic with suspected GCA. All patients underwent bilateral US examination of the cranial and extracranial (carotid, subclavian and axillary) arteries within 24 hours per protocol. The exam was performed using an Esaote MyLab® with a 12-18 MHz frequency transducer for cranial arteries and an 8-14 MHz frequency transducer for extracranial arteries. The IMT was measured in gray scale mode and the presence of a non-compressible halo sign was checked in all arteries. The gold standard for GCA diagnosis was clinical confirmation by the referring rheumatologist after 6 months follow-up. Mean IMT values of each artery were compared between patients with and without GCA by independent samples T-Test. Receiver operating characteristics analysis was performed and the Youden index was used to determine the optimal cut-off value for IMT of each artery.

Results: Of the 157 patients with suspected GCA (67.5% female, mean age 73.7 years) referred to the fast-track clinic, 47 (29.9%) had GCA clinical confirmation after 6 months. 41 (87.2%) patients with GCA had positive US findings (61.7% had cranial involvement, 44.7% extracranial involvement and 19.1% a mixed pattern of cranial and extracranial arteries). The following IMT cut-off values showed the highest diagnostic accuracy: 0.44mm for the common superficial temporal artery; 0.34 mm for the frontal branch; 0.36 mm for the parietal branch; 1.1 mm for the carotid artery: 1 mm for the subclavian and axillary arteries. The area under the ROC curve of the IMT for a clinical diagnosis of GCA was 0.984 (95% CI 0.959 - 1) for common superficial temporal artery, 0.989 (95% CI 0.978 - 1) for frontal branch, 0.991 (95% CI 0.980 - 1) for parietal branch, 0.977 (95% CI 0.961 – 0.993) for carotid, 0.99 (95% CI 0.979 - 1) for subclavian and 0.996 (95% CI 0.991 - 1) for axillary arteries (Table 1).

Table 1. Optimal IMT cut-off values for cranial and extracranial arteries

<table>
<thead>
<tr>
<th>Artery</th>
<th>Side</th>
<th>Patients without GCA</th>
<th>Patients with GCA</th>
<th>Cut-off (mm)</th>
<th>AUC (CI 95%)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common superficial</td>
<td>Right</td>
<td>0.33 (0.06)</td>
<td>0.68 (0.28)</td>
<td>0.43</td>
<td>0.997 (0.988 - 1)</td>
<td>100</td>
<td>97.1</td>
</tr>
<tr>
<td>Temporal artery mm, mean (SD)</td>
<td>Left</td>
<td>0.35 (0.11)</td>
<td>0.57 (0.21)</td>
<td>0.45</td>
<td>0.966 (0.905 - 1)</td>
<td>100</td>
<td>92.3</td>
</tr>
<tr>
<td></td>
<td>Both</td>
<td>0.34 (0.08)</td>
<td>0.63 (0.25)</td>
<td>0.44</td>
<td>0.964 (0.959 - 1)</td>
<td>94.7</td>
<td>95.1</td>
</tr>
<tr>
<td>Frontal branch mm, mean (SD)</td>
<td>Right</td>
<td>0.26 (0.05)</td>
<td>0.40 (0.18)</td>
<td>0.34</td>
<td>0.985 (0.962 - 1)</td>
<td>96.1</td>
<td>95.1</td>
</tr>
<tr>
<td></td>
<td>Left</td>
<td>0.27 (0.05)</td>
<td>0.40 (0.18)</td>
<td>0.34</td>
<td>0.989 (0.976 - 1)</td>
<td>100</td>
<td>96.6</td>
</tr>
<tr>
<td></td>
<td>Both</td>
<td>0.26 (0.05)</td>
<td>0.40 (0.18)</td>
<td>0.36</td>
<td>0.994 (0.981 - 1)</td>
<td>100</td>
<td>98.8</td>
</tr>
<tr>
<td>Subclavian mm, mean (SD)</td>
<td>Right</td>
<td>0.27 (0.05)</td>
<td>0.42 (0.17)</td>
<td>0.36</td>
<td>0.991 (0.980 - 1)</td>
<td>100</td>
<td>98.3</td>
</tr>
<tr>
<td>Carotid mm, mean (SD)</td>
<td>Right</td>
<td>0.08 (0.17)</td>
<td>0.90 (0.29)</td>
<td>1</td>
<td>0.974 (0.949 – 0.999)</td>
<td>100</td>
<td>92.6</td>
</tr>
<tr>
<td></td>
<td>Left</td>
<td>0.45 (0.20)</td>
<td>1 (0.42)</td>
<td>1.2</td>
<td>0.982 (0.961 - 1)</td>
<td>90.9</td>
<td>96.2</td>
</tr>
<tr>
<td>Subclavian mm, mean (SD)</td>
<td>Right</td>
<td>0.81 (0.16)</td>
<td>0.96 (0.36)</td>
<td>1.1</td>
<td>0.977 (0.961 – 0.993)</td>
<td>90</td>
<td>94</td>
</tr>
<tr>
<td></td>
<td>Left</td>
<td>0.67 (0.17)</td>
<td>0.9 (0.35)</td>
<td>1.1</td>
<td>0.991 (0.975 - 1)</td>
<td>100</td>
<td>98.3</td>
</tr>
<tr>
<td>Axillary mm, mean (SD)</td>
<td>Right</td>
<td>0.70 (0.16)</td>
<td>0.94 (0.4)</td>
<td>1</td>
<td>0.99 (0.979 - 1)</td>
<td>100</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>Left</td>
<td>0.67 (0.17)</td>
<td>0.94 (0.49)</td>
<td>1</td>
<td>0.98 (0.985 - 1)</td>
<td>100</td>
<td>98.3</td>
</tr>
<tr>
<td></td>
<td>Both</td>
<td>0.68 (0.17)</td>
<td>0.99 (0.49)</td>
<td>1</td>
<td>0.996 (0.991 - 1)</td>
<td>100</td>
<td>97.1</td>
</tr>
</tbody>
</table>
BACKGROUND: Takayasu arteritis (TA) is a large vessel vasculitis rarely reported in children, and its incidence is extremely low in infants. Most articles on pediatric TA have not focused on infants. We present the largest case series of infantile TA aiming to characterize demographic and clinical data and compare it with existing data on older children.

OBJECTIVES: Characterize demographic and clinical data regarding TA and compare it with existing data on older children.

METHODS: We conducted an international multi-center retrospective cohort study. Epidemiological and clinical data were collected from patient charts by doctors from six centers.

RESULTS: Twelve patients (50% female) meeting the ACR criteria of TA were included. Median age of symptom onset was 11 months, with a diagnostic delay of 4 months and median time of follow-up of 7.5 years. The most common symptoms at presentation were hypertension (67%), BP difference between upper and lower limbs, and fever. The arteries most commonly involved at diagnosis were the ascending aorta, renal artery, and superior mesenteric artery. Different medications used included steroids, conventional and biological DMARDs, and immunosuppressive therapies. Half of the patients received biologic agents of which infliximab had the highest complete remission rate (40%). Other medications resulting in complete remission were cyclophosphamide (40%) and methotrexate (33%). None of the patients died.

CONCLUSION: This study presents the largest series of infantile TA. Compared to reported series on older children, infants with TA were more likely to receive biologic agents, develop complications and require invasive interventions.

Disclosure of Interests: None declared


AB0595
INFANTILE TAKAYASU: CLINICAL FEATURES AND LONG TERM OUTCOME

A. Miller Barma1, F. Sztabnik2, S. Ōzen2, Z. Balik2, A. Borzutzky3,6, L. Fogel2, G. Goldberg2, Y. Butbul1,8,9, 1 Federal University of Rio de Janeiro, Rheumatology Unit, Rio de Janeiro, Brazil; 2 Rambam Medical Center, Pediatrics B, Haifa, Israel; 3 Federal University of Rio de Janeiro, Federal Rheumatology Unit, Rio de Janeiro, Brazil; 4 Hacettepe University, Pediatric Rheumatology, Ankara, Turkey; 5 Pontifical Catholic University of Chile, Department of Pediatric Infectious Diseases and Immunology, Santiago, Chile; 6 Washington University in St. Louis, Pediatrics, St. Louis, United States of America; 7 Kaplan Medical Center, Pediatric Rheumatology Unit, Rehovot, Israel; 8 Rambam Medical Center, Pediatric Rheumatology Unit, Haifa, Israel; 9 Technion - Israel Institute of Technology, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel

Disclosure of Interests: None.

OBJECTIVES:

1. To describe clinical features and long-term outcomes of Takayasu arteritis in children.
2. To determine how these features compare with the adult population.

BACKGROUND:

Takayasu arteritis (TA) is a chronic inflammatory vasculitis of unknown etiology that affects the aorta and its main branches. It is more common in East Asian populations and can affect both children and adults. The disease is characterized by progressive stenosis and occlusion of the affected arteries, leading to organ ischemia and potential organ damage. Early diagnosis and appropriate management are crucial to prevent complications and improve long-term outcomes.

METHODS:

A retrospective analysis of children diagnosed with TA in a tertiary pediatric rheumatology center in Israel was conducted. A total of 13 children were included in the study, with a median age at diagnosis of 9.2 years (range: 2-15 years). The clinical features and outcomes were compared with the adult population.

RESULTS:

The most common initial symptoms were fever, fatigue, and constitutional symptoms. Pain in the chest and limbs was also frequent. Five out of 11 children had hypertension as an initial symptom. On examination, the most common finding was auscultation of bruits over the affected vessels. Laboratory findings included anemia, leukocytosis, and elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Arterial imaging using magnetic resonance angiography (MRA) was the most common imaging technique used to confirm the diagnosis and monitor disease activity.

Conclusion:

The clinical presentation and long-term outcomes of Takayasu arteritis in children are similar to those in adults. Early diagnosis and appropriate management are crucial to prevent complications and improve long-term outcomes.

Disclosure of Interests: None declared


AB0596
AORTIC MANIFESTATIONS IN GIANT CELL ARTERITIS: SINGLE CENTRE 10-YEAR EXPERIENCE

F. Coath1, A. Sharma2, R. Enshad3, J. Mo3, J. Davies3, B. Dasqupta1. 1 Southend University Hospital, Mid and South Essex NHS Foundation Trust, Rheumatology, Southend-on-Sea, United Kingdom; 2 Southend University Hospital, Mid and South Essex NHS Foundation Trust, Radiology, Southend-on-Sea, United Kingdom; 3 Southend University Hospital, Mid and South Essex NHS Foundation Trust, Radiology, Southend-on-Sea, United Kingdom

Disclosure of Interests: None.

BACKGROUND:

Giant cell arteritis (GCA) is a non-infectious inflammatory condition affecting the aorta and its branches. It typically affects older patients, with a peak incidence in the seventh and eighth decades. The disease is characterized by the infiltration of granulomatous lesions, predominantly affecting the outer muscular layers of the affected arteries. GCA is often associated with polymyalgia rheumatica (PMR), and its diagnosis is typically based on typical clinical features, temporal artery biopsy, and laboratory findings. The aim of this study is to report the long-term outcomes of GCA patients managed in a single centre over a 10-year period.

METHODS:

A retrospective analysis of all patients with a diagnosis of GCA managed at the Southend University Hospital, UK, between 2011 and 2021 was performed. Data collected included demographics, clinical features, treatment, and outcomes. The primary outcome measures were freedom from recurrence and the need for steroid-sparing treatment. All patients were followed up at least annually, with a median follow-up of 5.2 years.

RESULTS:

A total of 126 patients were identified. The mean age at diagnosis was 72 years (range: 46-91 years), and 81 (64%) were women. PMR was present in 49 (39%) patients. The most common presenting symptoms were headache (59%), jaw claudication (31%), and visual disturbance (12%). Temporal artery biopsy was positive in 83 (66%) patients. Aortic involvement was present in 76 (61%) patients, with 24 (19%) having aortic root dilatation. The most common sites of aortic involvement were the arch (36%) and descending thoracic aorta (31%). At follow-up, 12 (9%) patients had recurrence, and 22 (18%) required steroid-sparing treatment. Freedom from recurrence at 5 years was 91% (95% CI: 86-95).

Conclusion:

This study highlights the importance of early and aggressive treatment in preventing recurrence and the need for steroid-sparing treatment in GCA. Further research is needed to identify predictors of recurrence and to optimize treatment strategies.

Disclosure of Interests: None declared


AB0597
FDG-PET/CT IN THE DIAGNOSIS AND FOLLOW UP OF TAKAYASU VASCULITIS

B. Gudbrandsson1, O. Palm2, O. Molberg3, H. Gilvedt4, M. Rehev5. 1 Östfold University Hospital, Rheumatology, Fredrikstad, Norway; 2 Rikshospitalet, Rheumatology, Oslo, Norway; 3 Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, Norway; 4 Rikshospitalet, Division of Radiology and Nuclear Medicine, Oslo, Norway

Disclosure of Interests: None declared

BACKGROUND:

Takayasu vasculitis (TAK) is a chronic disease, where clinic and serological markers as CRP/ESR may fail to predict development of new vascular lesions in the disease course (1). Similarly, 18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) studies show conflicting results on the association between vessel uptake of FDG and clinical and laboratory finding. A study on new FDG-PET activity scoring system, PETVAS was newly published but has not been validated in other cohorts (2). To date there are limited data on FDG-PET/CT finding at time of diagnoses before treatment induction and 18-FDG uptake and development of new stenosis during followup.

OBJECTIVES:

The goal of this study was to see 1) FDG-PET/CT uptake in newly diagnosed patients before any treatment start 2) FDG-PET/CT uptake and development of new vascular lesions during follow up magnetic resonance angiography (MRA) 3) assess PETVAS score before and after treatment induction.

METHODS:

All patients in a population-based TAK cohort with FDG-PET/CT at the time of diagnosis and after treatment induction were identified. Disease activity was assessed with the NIH activity score (1). Patients who had clinical, laboratory and MR-angiography prior to or right after FDG-PET/CT and a minimum of one follow up MRA. The clinical report from the FDG-PET/CT and MRA were reviewed and arteries/aorta regions of interest (sacrospinal arteries, aorta, iliac and femoral arteries) scored from 0-3, where 0 represent no uptake, 1 less then liver, 2 same as liver and 3 higher than liver and finally summarized these to PETVAS score.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3598
Results: Twenty-three patients fulfilled the study’s inclusion criteria. Twenty-one of the patients were females (91%) and twenty-two were European Caucasian. The mean age was 39.3 (SD 14) at the time of diagnosis (Table 1). Five patients were in clinical and laboratory remission at diagnosis (NIH=0). Correspondently, none of them had sign of active FDG vessel uptake at PET-CT. They had a median 7 in PETVAS (range 0-3.1). The remaining 17 patients had clinical active disease (NIH>1) at diagnoses. All 17 patients had uptake on PET/CT in at least one artery/aorta region. The mean PETVAS score at diagnosis was 21.5 (SD 8). At last imaging the patients had developed median 2 new lesions. All the arteries that developed new lesion had active uptake on the original PET/CT. Fourteen patients had FDG PET/CT after treatment start. The PETVAS score decreased from 22.4 (SD 8.7) to 10.7 (SD 6.8) after treatment start (p<0.001).

<table>
<thead>
<tr>
<th>Table 1.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>13</td>
</tr>
<tr>
<td>14</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>17</td>
</tr>
</tbody>
</table>

Conclusion: All patients with clinical active disease at diagnoses had pathological FDG uptake. Only arteries with increased FDG uptake in the vascula wall subsequently developed new lesion. The study also showed that the PETVAS score fell significantly after treatment induction.

REFERENCES:

Disclosure of Interests: None declared


AB0598 ASSOCIATION OF PROLONGED DISEASE DURATION AND TG/HDL-C RATIO IN ACCELERATING Atherosclerosis IN PATIENTS WITH TAKAYASU’S ARTERITIS
J. Du1, L. Pan2. 1Beijing An Zhen Hospital, Affiliated of Capital University of Medical Sciences, Rheumatology and Immunology, Beijing, China; 2Beijing An Zhen Hospital, Affiliated of Capital University of Medical Sciences, Rheumatology and Immunology, Beijing, China

Background: Takayasu’s arteritis (TA) is an autoimmune vasculitis that frequently occur in young women. Multiple previous studies have demonstrated that accelerated atherosclerotic changes were commonly found in TA patients1-4. More specifically, data indicated that as much as 27% of all TA patients developed carotid artery plaque, while which was only 2% in the age- and sex-matched healthy individuals[1]. In addition, up to 20% of TA patients developed stroke and/or transient ischemic attack(TIA), which had both been known to be associated with atherosclerotic lesions[5,6]. Inflammation of the vascular wall may promotes atherosclerosis (As) in TA,which accelerates the development of As.Higher triglyceride (TG)/HDL-C ratio was found to be associated with presence of endothelial dysfunction and As[7,8].

Objectives: This study aimed to identify the risk factors associated with the development of atherosclerosis in TA.

Methods: This retrospective study enrolled a total of 101 TA patients. All patients were divided into two groups according to the absence or presence of atherosclerosis[43 vs 58]. Baseline demographic features and clinical characteristics were compared between two groups. A logistic model was applied to determine the risk factors associated with the development of atherosclerosis.

Results: Our data suggested that the disease duration of patients in the atherosclerosis group was significantly longer than that of patients in the non-atherosclerosis group [96(18.00,180.00) vs 48.00(12.00,111.00) months] (p<0.015). In addition, the average age of patients with atherosclerosis was significantly older compared to patients without atherosclerosis [44.00 (38.00,48.00) vs 28.50 (24.00,37.00) years] (p<0.001). Logistic regression analysis showed that the risk of developing atherosclerosis increased by 9.2% per 1 year increase in the disease duration(p<0.005, OR 1.092,95%CI:1.027-1.162).Patients with TG/HDL-C ratio more than 0.8875 were associated with a 5.861 fold increase of risk developing atherosclerosis(p<0.001, 95%CI:2.299-14.939).

Conclusion: Our study indicated that prolonged disease duration and elevated TG/HDL-C ratio are associated with the development of atherosclerosis in TA patients.

REFERENCES:

Disclosure of Interests: None declared


AB0599 THE VALUE OF ULTRASOUND IN GCA FOLLOW-UP: RESULTS FROM A SCOTTISH SINGLE CENTRE.
A. Neville1, A. Ciechomska2. 1University of Glasgow, Institute of Infection, Immunity & Inflammation, Glasgow, United Kingdom; 2University Hospital Wishaw, Rheumatology Department, Wishaw, United Kingdom

Background: Ultrasound (US) is important diagnostically in GCA, but its value during follow-up is unclear1. In our centre, ad hoc follow-up US has been performed routinely.

Objectives: To describe how US appearances i) changed over time (at defined timepoints), ii) correlated with clinical relapse (at any time), iii) were affected by tocilizumab.

Methods: Patients diagnosed with GCA in NHS Lanarkshire, November 2018 - October 2021, were included. Treatment was in accordance with international guidelines2. Follow-up visit data included clinical status (remission, stable, relapse), treatment, and (when US performed) temporal artery (TA) and axillary artery (LV) intima media thickening (IMT) (TA~IMT>0.5MM; LV~IMT>1.0mm). Follow-up US were compared to baseline, pre-relapse or pre-tocilizumab.

Results: 55 patients were diagnosed with GCA; mean (SD) age 73.1 (8.0) years; 31 female (56.4%). Mean (SD) follow-up was 63.8 (40.6) weeks. All patients had baseline US (48 positive (TA+ or LV+)); 7 negative; 36 (65.5%) had ≥1 follow-up US. 7 patients had US at 6-12 weeks; all were clinically stable; all had positive baseline US; at 6-12 weeks, 3/7 remained TA+, 1/7 remained LV+ (TA-LV+). 25 patients had US at 16-36 weeks; 9/25 were in remission, 11/25 stable, 5/25 relapsing. Of remission patients, 7/9 had positive baseline US; at 16-36 weeks, 2/7 remained TA+. Of stable patients, all had positive baseline US; at 16-36 weeks, 4/11 remained TA+, 3/11 remained LV+. Of relapsing patients, 5/5 had positive baseline US; at 16-36 weeks, 2/5 remained TA+, 1/5 LV remained LV+.
Table 1. Follow-up and corresponding baseline ultrasound results, at defined timepoints, grouped by clinical status.

<table>
<thead>
<tr>
<th>Time</th>
<th>Clinical status</th>
<th>N°</th>
<th>TA+</th>
<th>LV+</th>
<th>TA-</th>
<th>LV-</th>
<th>TA+</th>
<th>LV+</th>
<th>TA-</th>
<th>LV-</th>
</tr>
</thead>
<tbody>
<tr>
<td>42-62 week</td>
<td>All stable</td>
<td>7</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>All</td>
<td>25</td>
<td>17</td>
<td>0</td>
<td>6</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Remission</td>
<td>9</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Stable</td>
<td>11</td>
<td>7</td>
<td>0</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Relapse</td>
<td>5</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>16-36 week</td>
<td>All</td>
<td>25</td>
<td>17</td>
<td>0</td>
<td>6</td>
<td>2</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Stable</td>
<td>8</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Relapse</td>
<td>3</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>6-12 week</td>
<td>All</td>
<td>15</td>
<td>11</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Stable</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Relapse</td>
<td>3</td>
<td>3</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

a. Number of patients scanned.

15 patients had USS at 42-62 weeks; 8/15 were in remission, 3/15 stable, 4/15 relapsing. Of remission patients, 7/8 had positive baseline USS; at 42-62 weeks, 3/7 remained TA+. Of stable patients, 3/3 had positive baseline USS; at 42-62 weeks, 1/3 was TA-LV+, 1/3 remained TA-LV-. Of relapsing patients, 4/4 had positive baseline USS (3/4 TA+, 1/4 LV-); at 42-62 weeks, all were TA-LV+. The Table 1 below provides additional detail for each timepoint. 11 patients in total had clinical relapse (any time) and contemporaneous USS; mean (SD) time to relapse was 36.6 (18.3) weeks; median (IQR) prednisolone dose 7mg (4.9). At relapse, 2/11 were TA-LV+, 6/11 LV+, 3/11 TA-LV+. Comparing relapse USS to most recent USS pre-relapse, 4/11 were newly LV+, while other positive findings were seen previously. 11 patients treated with tocilizumab had ≥1 USS post-initiation of tocilizumab, which included at approx. 12 months follow-up. Ad hoc follow-up scans therefore appear unreliable in isolation, but the value of systematic longitudinal scanning warrants further study. Emergence of LV positivity was seen in several cases of relapse and may characterise an evolution in disease phenotype. Positive USS findings largely persisted at approx. 6 months despite disease control on tocilizumab.

Conclusion: While many patients had rapid normalisation of USS changes with treatment, others remained abnormal despite stable disease or remission, including at approx. 12 months follow-up. Ad hoc follow-up scans therefore appear unreliable in isolation, but the value of systematic longitudinal scanning warrants further study. Emergence of LV positivity was seen in several cases of relapse and may characterise an evolution in disease phenotype. Positive USS findings largely persisted at approx. 6 months despite disease control on tocilizumab.

REFERENCES:

Disclosure of Interests: Andrew Melville Grant/research support from: Dr Melville is a MRC GSK EMINENT clinical training fellow, with project funding outside the submitted work., Anna Ciechomska Speakers bureau: Dr Ciechomska has received speaker, travel and registration fee sponsorship from Novartis, Abbvie, Chugai Pharma, Colgene, Roche and Lilly.


AB0600

ANALYSIS OF RISK FACTORS AND PROGNOSIS IN PATIENTS OF TAKAYASU’S ARTERITIS WITH CORONARY ARTERY LESIONS

J. Du1, L. Pan1, 1Beijing An Zhen Hospital, Affiliated of Capital University of Medical Sciences, Rheumatology and Immunology, Beijing, China

Background: Takayasu's arteritis (TA) can involve coronary artery lesions. The pathogenesis is complex and lacks the best treatment strategy. The coronary artery lesions were typical seen in the os/a of the left and right coronary arteries which were major risk factors for sudden death and ischaemia heart failure[1-2]. Coronary artery lesions is an important predictor of poor prognosis in TA patients.[3-4]. The prevalence of metabolic syndrome and its related characteristics (including dyslipidemia, diabetes and hyperinsulinemia) in TA patients are higher compared with healthy people.[5]. Thus, under the action of vascular inflammation and traditional risk factors, coronary artery stenosis or even occlusion occurs earlier, which can lead to MACE events.

Objectives: The aim of our study is to investigate the risk factors and prognosis of coronary artery lesions in TA patients.

Methods: This retrospective study enrolled a total of 120 TA patients. All patients were divided into two groups according to the absence or presence of coronary artery lesions in TA patients (61 vs 59). A logistic model was applied to determine the risk factors associated with the incidence of coronary artery lesions in TA patients. According to the before and after imaging comparison of TA with coronary artery lesions, the influencing factors of improving TA with coronary artery lesions were analyzed.

Results: The incidence of coronary artery lesions in TA patients increased by 1.618 times for each additional year (p=0.018, 95%CI: 1.199-2.132). The age and gender were more common in type IIb coronary artery lesions. The incidences of coronary artery lesions were more common in type IIb coronary artery lesions (21.70±1.71 years, p=0.001). TNF-α and interleukin-6 were significantly higher in the group with improved coronary imaging than in the group without improved coronary imaging (26.40(10.08 , 165.90) vs 21.70(pg/ dl,p=0.047;12.50(5.83 , 19.30) vs7.13(2.80 , 4.40)pg/dl,p<0.001).Numano type V (75.00% vs 27.27%, p=0.022) and vascular calcification (56.25% vs 9.09%, p=0.016) were significantly higher than those in the group without improved coronary imaging, while numano type lib in the group with improved coronary imaging was significantly higher than that in the group without improved coronary imaging(45.45% vs 6.25%, p<0.027).

Conclusion: Hyperlipidemia and age are the risk factors of coronary artery lesions in Takayasu arteritis.Numano type V and vascular calcification are not conducive to the improvement of TA with coronary artery lesions.All patients with TA of numano type lib should be screened for coronary artery. Early control of inflammation is more conducive to the improving imaging of arteritis coronary artery lesions.

REFERENCES:

Figure 1.

Disclosure of Interests: None declared


Background of hyperlipidaemia indicated 10.124 fold higher risk of coronary artery lesions. According to the before and after imaging comparison of TA with coronary artery lesions, the influencing factors of improving TA with coronary artery lesions were analyzed.

According to the before and after imaging comparison of TA with coronary artery lesions, the influencing factors of improving TA with coronary artery lesions were analyzed.

According to the before and after imaging comparison of TA with coronary artery lesions, the influencing factors of improving TA with coronary artery lesions were analyzed.
BACKGROUND: Behçet syndrome (BS) is a unique vasculitis that can affect arteries and veins of all sizes. Thrombosis is an important component of vascular involvement in BS. Although several studies were conducted to highlight the mechanism of thromboinflammation in BS, it is still not fully understood.

OBJECTIVES: We performed a systematic review and meta-analysis of studies investigating thrombotic, fibrinolytic, and endothelial factors in BS.

METHODS: We searched PubMed and EMBASE with the keyword “Behçet” in title and/or abstract, from their inception up to April 2020. Titles and/or abstracts of all studies were screened independently by two reviewers (GGO and BY), and conflicts were solved by a third reviewer (GH). Studies comparing BS patients with and without thrombosis and studies comparing BS patients with thrombosis and patients with thrombosis due to other causes were analyzed separately. The pooled odds ratios (OR) with 95% confidence interval (CI) were calculated for binary outcomes and standardized mean difference (MD) for continuous outcomes using RevMan 5.3. We categorized the factors into 4 groups based on acting mechanism 1- those that decrease anticoagulant activity 2- those that increase procoagulant activity 3- those that decrease the activity of fibrinolytic system 4- pathogenic/endothelial factors.

RESULTS: Of 15848 articles, 15157 were excluded due to duplication and inappropriate study design after reviewing titles and abstracts. Full text review of the remaining 391 articles yielded 103 papers meeting our predetermined inclusion criteria. Factors significantly associated with BS thrombosis compared to BS without thrombosis were high frequency of factor V Leiden mutation (15 studies, OR 2.55, 95% CI 1.66-3.93), high homocysteine level (14 studies, MD: 4.27, 95% CI 2.31-6.22), high protein C level (5 studies, SMD: 0.80, 95% CI 0.15-1.45) and high alpha-antitrypsin level in Group 1; high factor level 8 (4 studies, MD: 17.17, 95% CI 7.79-6.55), high thrombin level (1 study, MD: 35.90, 95% CI 12.40-59.40), high neutrophil/lipophilicocyte ratio (2 studies, MD: 1.37, 95% CI 0.24-2.50) and high platelet/neutrophil complex level (1 study, MD: 10.50, 95% CI 0.76-20.24) in Group 2; high TAFI activity (1 study, MD: 28, 95% CI 4.12-51.88) in Group 3; high VEGF level (2 studies, SMD: 1.63, 95% CI 0.21-3.05), high CEC concentration (2 studies, SMD: 1.00, 95% CI 0.22-1.77), high MCP-1 level (1 study, MD: 74.16, 95% CI 61.29-87.03), high anti-C1q level (1 study, MD: 9.11, 95% CI 0.51-17.71), high platelet microaggregate formation (1 study, MD: 75.00, 95% CI 762-142.38), high frequency of P-selectin glycoprotein ligand 1 gen polymorphism (heterozygous (AB+AC+BC)) (1 study, MD: 1.88, 95% CI 1.07-3.31), high ADMA level (1 study, MD: 0.16, 95% CI 0.08-0.24), high PCAM-1 level (1 study, MD: 59.30, 95% CI 3.35-115.29) and low brachial artery flow-mediated (endothelium-dependant) dilatation (1 study, MD: -3.22, 95% CI -5.18-1.26) in Group 4.

Factors that were associated with BS thrombosis compared to thrombosis due to other causes including JAK-2 mutation, circulating endothelial cells, activated protein C resistance, tPA, and PAI were assessed in 1 study each. Age (y, median (IQR)) 74 (65, 81) 74 (65, 80) 74 (65, 81) (Figure 1). For these patients, hospital site showed a trend to be a significant factor (p = 0.08). Despite this, we observed that the number of patients with BS who had thrombosis was lower in Group 4 than in Groups 1 and 2.

CONCLUSION: Several factors were identified that may potentially be associated with thrombosis in BS. However, the cut-offs used for defining the normal level for these factors, time of blood collection (during acute or chronic stage of thrombosis, use of anticoagulants) and the type of thrombosis (arterial, venous, or cerebral sinus) were not uniform across the studies. Studies investigating these factors together, in a large number of patients, and together with appropriate controls are needed to confirm these results.

DISCLOSURE OF INTERESTS: None declared.

DOI: 10.1136/annrheumdis-2022-eular.3897

TEMPORAL ARTERY BIOPSY POSITIVITY RATES VARY MORE BETWEEN SIMILAR HOSPITALS THAN BY LENGTH, WITH PARTICULAR VARIATION BETWEEN GEOGRAPHIC REGIONS

C. McMaster, V. Yang, R. Malik, E. Norman, C. Fraser, B. Sutu, A. Sammel, D. Liew, A. Austin Health, Rheumatology, Heidelberg, Australia; A. Austin Health, Clinical Pharmacology and Therapeutics, Heidelberg, Australia; University of Melbourne, The Centre for Digital Transformation of Health, Parkville, Australia; Sydney Eye Hospital, Sydney Eye Hospital, Sydney, Australia; UNSW Sydney, Port Macquarie Clinical School, Sydney, Australia; University of Newcastle, Medicine and Public Health, Callaghan, Australia; Prince Of Wales Hospital, Rheumatology, Randwick, Australia; Save Sight Institute, Save Sight Institute, Sydney, Australia; The Royal Melbourne Hospital, Rheumatology, Parkville, Australia; UNSW Sydney, Prince of Wales Clinical School, Sydney, Australia; University of Melbourne, Medicine, Parkville, Australia

BACKGROUND: Clinical practice surrounding giant cell arteritis (GCA) diagnosis, including the use of temporal artery biopsy (TAB) where appropriate, needs to be consistently accurate to minimise both GCA-related end-organ damage and unnecessary glucocorticosteroid toxicity in all patients. Despite this imperative, the delivery of such clinical care, which can be measured by diagnostic investigation performance characteristics such as TAB positivity rates, varies substantially between different hospitals as it is traditionally reliant on unstructured clinical intuition. While clinical care practices possibly might be more consistent between neighbouring hospitals given they frequently exchange medical staff and use common teaching sources, these factors are less likely to be applicable when comparing hospitals in different geographical regions within a country, even though educational standards, online information resources, and access to clinical care should be consistent. It therefore stands to reason that variation of diagnostic practice might be greater between geographically distant hospitals.

OBJECTIVES: To compare clinical practice surrounding GCA diagnosis, using TAB positivity rates, between similar hospitals in the same city and a geographically distant city in a different region, to understand the contribution of geographic separation to variation in practice.

METHODS: TAB histopathological reports were reviewed at three tertiary referral hospital centres: two with neighbouring catchments in the same city, and one in a different city in a neighbouring geographical region in the same country. All three had similar resourcing and catchment demographics during the study period, and none used formal clinical risk stratification scores for GCA pre-test probability. Characteristics including age, sex, biopsy laterality, biopsy length, and hospital were captured, in addition to key histopathological features. Multivariable logistic regression with site-varying intercept was performed, using cubic splines for biopsy length to account for the non-linearity observed.

RESULTS: TAB reports from 708 patients were captured between the three hospitals in two geographical regions. All three sites had a median age of 74 years, had 67-69% of patients being female, and reported median biopsy length between 1.2-2.0cm (Table 1). Despite these similarities, they reported positivity rates varying widely (16% and 24% in Region 1, 29% in Region 2). Apart from age, hospital site was the strongest contributing factor to TAB positivity, with length having little effect outside the very extreme high end and 90% of patients had a biopsy length <4.8cm (Figure 1). For these patients, hospital site differentiated TAB positivity across all biopsy lengths, with Region 2 reporting the highest TAB positivity odds ratio of 2.36 (95% CI: 1.37-4.19).

Table 1.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Site1Region1 N = 218</th>
<th>Site2Region1 N = 361</th>
<th>Site1Region2 N = 129</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bilateral laterality (%)</td>
<td>66 (30%)</td>
<td>105 (29%)</td>
<td>1 (0.8%)</td>
</tr>
<tr>
<td>Biopsy length (cm, median (IQR))</td>
<td>2.0 (1.4, 3.0)</td>
<td>17 (12, 3.5)</td>
<td>17 (14, 2.2)</td>
</tr>
<tr>
<td>Female sex (%)</td>
<td>149 (68%)</td>
<td>249 (69%)</td>
<td>96 (67%)</td>
</tr>
<tr>
<td>Age (y, median (IQR))</td>
<td>74 (65, 81)</td>
<td>74 (65, 80)</td>
<td>74 (68, 81)</td>
</tr>
<tr>
<td>TAB positivity (%)</td>
<td>54 (16%)</td>
<td>88 (24%)</td>
<td>38 (29%)</td>
</tr>
</tbody>
</table>

Figure 1. Marginal probabilities of positive TAB obtained from the multivariable logistic regression model (A) across biopsy lengths, with 80% of observed lengths falling between the two vertical red lines (10% and 90% deciles); (B) across hospital sites; (C) across patient age.

CONCLUSION: Hospital site contributes more greatly to variation in GCA diagnosis clinical practice than demographics or other clinical features do, with particular variation between geographical regions. As part of clinical care standards, using
Inclusion of Raynaud's Phenomenon in Giant Cell Arteritis, Possibly Associated with Large Vessel Giant Cell Arteritis.

B. Stijlhuus1, M. Sandovic1, A. Eman Abdulle2, K. van der Geest3, E. Brouwer4, D. J. Mulder5
1University Medical Center Groningen, Internal Medicine, Groningen, Netherlands; 2University Medical Center Groningen, Rheumatology, Groningen, Netherlands

Background: Large Vessel Giant Cell Arteritis (LV GCA) can cause significant narrowing of the subclavian and axillary arteries, either by inflammation or remodelling, which reduces blood pressure in the arms. Also, Raynaud's phenomenon (RP) has been observed in GCA patients.

Objectives: This study aims to investigate the presence of Raynaud's phenomenon in patients with GCA.

Methods: Patients diagnosed with GCA were given a validated questionnaire (CSQ) on symptoms fitting RP, divided into the different phases of RP (white, non, warm, and rush) in patients with GCA.

Results: 30 GCA patients were included, with a mean age of 68.6 ± 6.5 years, when diagnosed. 76.7% were female. Of the 30 GCA patients, 12 (40%) reported monophasic discoloration. Of these 12 GCA patients, 2 (6.7%) patients reported bi- or triphasic discoloration. Of the 12 GCA patients with at least monophasic discoloration, 6 patients reported a new onset RP (<1 year of diagnosis). Imaging data of these 6 patients showed severe Large Vessel GCA (with subclavian and axillary involvement) in all of these patients, without displaying cranial GCA. Of these 6 patients, 1 was examined with US, 3 with PET-CT, and 2 had both US and a PET-CT. 3 patients reported that the RP complaints, disappeared during treatment of the GCA, 3 still had complaints. Interestingly all these 3 patients had stenosis of either the subclavian, the axillary, or both.

Conclusion: We found an increased prevalence of monophasic Raynaud's phenomenon in GCA patients that is 3.7 times higher, when compared to a local background population.

Disclosure of Interests: Berend Stijlhuus: None declared, Maria Sandovic: None declared, Amaal E. Abdulle: None declared, Kornelis van der Geest: None declared, Douwe J. Mulder: Consultant of: as an employee of the UMCG received research grants from Sanofi which were paid to the UMCG.


Table 1. Presence of Raynaud's phenomenon in GCA.

<table>
<thead>
<tr>
<th>GCA new onset (n=6)</th>
<th>GCA pre-existing RP (n=10)</th>
<th>GCA Without All GCA (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years at diagnosis (mean (SD))</td>
<td>73 (±3.4)</td>
<td>63.5 (±4.9)</td>
</tr>
<tr>
<td>Gender, women, n (%)</td>
<td>5 (83.3%)</td>
<td>5 (83.3%)</td>
</tr>
<tr>
<td>Fingers Unusually sensitive to cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Have your fingers ever shown any unusual colour changes in the cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Monophasic RP, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour white? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour rush? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>LV GCA, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
</tbody>
</table>

Table 1. Clinical characteristics of the study population.

<table>
<thead>
<tr>
<th>LV GCA (n=18)</th>
<th>GCA Without LV GCA (n=18)</th>
<th>Controls (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years at diagnosis, mean (SD)</td>
<td>73 (±3.4)</td>
<td>70.3 (±3.9)</td>
</tr>
<tr>
<td>Gender, women, n (%)</td>
<td>5 (88.2%)</td>
<td>5 (88.2%)</td>
</tr>
<tr>
<td>Finger sensitive to cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Have your fingers ever shown any unusual colour changes in the cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Monophasic RP, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour white? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour rush? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>LV GCA, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Berend Stijlhuus: None declared, Maria Sandovic: None declared, Amaal E. Abdulle: None declared, Kornelis van der Geest: None declared, Douwe J. Mulder: Consultant of: as an employee of the UMCG received research grants from Sanofi which were paid to the UMCG.


Conclusion: The constitutional syndrome was always present in LVGCA but it is also very common in subtypes with cranial involvement. The ischaemic syndrome occurs preferentially in groups with cranial vessel involvement, but not exclusively. The thickening of the arterial wall of the cranial arteries shows no difference between CGA and MGCA; and the same occurs in the large vessels between the LVGCA and the MGCA. Serious adverse effects due to ischaemia showed a similar risk regardless of whether it was CGA or MGCA.

REFERENCES:

Disclosure of Interests: None declared


Table 1. Clinical characteristics of the study population.

<table>
<thead>
<tr>
<th>LV GCA (n=18)</th>
<th>GCA Without LV GCA (n=18)</th>
<th>Controls (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years at diagnosis, mean (SD)</td>
<td>73 (±3.4)</td>
<td>70.3 (±3.9)</td>
</tr>
<tr>
<td>Gender, women, n (%)</td>
<td>5 (88.2%)</td>
<td>5 (88.2%)</td>
</tr>
<tr>
<td>Finger sensitive to cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Have your fingers ever shown any unusual colour changes in the cold, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Monophasic RP, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour white? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>Was the colour rush? n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
<tr>
<td>LV GCA, n (%)</td>
<td>6 (100%)</td>
<td>6 (100%)</td>
</tr>
</tbody>
</table>

Disclosure of Interests: Berend Stijlhuus: None declared, Maria Sandovic: None declared, Amaal E. Abdulle: None declared, Kornelis van der Geest: None declared, Douwe J. Mulder: Consultant of: as an employee of the UMCG received research grants from Sanofi which were paid to the UMCG.


Conclusion: The constitutional syndrome was always present in LVGCA but it is also very common in subtypes with cranial involvement. The ischaemic syndrome occurs preferentially in groups with cranial vessel involvement, but not exclusively. The thickening of the arterial wall of the cranial arteries shows no difference between CGA and MGCA; and the same occurs in the large vessels between the LVGCA and the MGCA. Serious adverse effects due to ischaemia showed a similar risk regardless of whether it was CGA or MGCA.

REFERENCES:

Disclosure of Interests: None declared

AB0605
GIANT CELL ARTERITIS. PREVALENCE OF EXTRACRANIAL LARGE VESSEL VASCULITIS DIAGNOSED WITH 18-FDG POSITRON EMISSION TOMOGRAPHY.

V. Aldazabal1, M. J. García Velloso2, J. A. Richter Echevarría3. Hospital Universitario de Navarra, Rheumatology, Pamplona, Spain; 2.Clinica Universidad de Navarra, Nuclear Medicine, Pamplona, Spain

Background: The prevalence of extracranial involvement in giant cell arteritis (GCA) is unknown although there are series that has published prevalences of 20–65% depending on the technique used (1).

Objectives: To assess the prevalence of extracranial large vessel vasculitis (LVV) in GCA diagnosed by positron emission tomography (PET) and to describe clinical and radiological features.

Methods: Prospective and descriptive study of newly diagnosed GCA patients who underwent PET between july 2020 and october 2021. 1990 ACR criteria (2) and/or physician criteria was used to classified patients as having GCA. Clinical and radiological features were described. All patients should not be taken any other immunosupressant drug but glucocorticoids (GCs).

Results: Fourteen consecutive patients were diagnosed as GCA. Eight patients were female with a median age of 64.4 years. All patients but one underwent temporal artery biopsy (TAB) with a positive result in 54%, PET was positive in 85.7% patients. The median dose of GCs when PET was done was 31.4 (0-45) mg/day and the median delay in PET performance was 8 days (0-22). The 2 patients with negative PET had positive TAB. Proximal thoracic aorta involvement was observed in all patients with positive PET. Late PET images were taken in 6 patients with a median dose of GCs of 43,3 mg/day and median delay of 11,3 days with positive result in all of them (Table 1).

Table 1. PET late images

<table>
<thead>
<tr>
<th>PET LATE IMAGES</th>
<th>N=6</th>
</tr>
</thead>
<tbody>
<tr>
<td>-SEX (female) %</td>
<td>66</td>
</tr>
<tr>
<td>-AGE [years]</td>
<td>60.1</td>
</tr>
<tr>
<td>-BAT (positive) %</td>
<td>40</td>
</tr>
<tr>
<td>-PET RESULT (positive) %</td>
<td>100</td>
</tr>
<tr>
<td>-GCs DOSE (mg)</td>
<td>43.3 (40-45)</td>
</tr>
<tr>
<td>-DAYS OF DELAY</td>
<td>11.3 (2-32)</td>
</tr>
</tbody>
</table>

Conclusion: Despite the high dose of GCs and the delay in PET performance, in our serie PET has diagnosed LVV in 85.7% of GCA patients. PET within 3 days after start GCs, has been useful to diagnose extracranial involvement in GCA (3). In our series the prevalence of extracranial involvement diagnosed by PET in GCA has been higher than others published until now (2). Further patients are needed to confirm these data.

REFERENCES:

Acknowledgements: The authors thank the Spanish Foundation of Rheumatology, Roche and Janssen for providing funds to make this study.

Disclosure of Interests: Vicente Aldasoro Speakers bureau: Roche, Lilly, Novartis, MSD, Janssen, Abbvie, Paid instructor for: Roche, Lilly, Grant/research support from: Roche, Janssen, Maria José García Velloso: None declared, Jose Angel Richter Echevarria: None declared


AB0606
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RITUXIMAB-INDUCED REMISSION OF ANCA-ASSOCIATED VASCULITIS: REGISTRY-BASED COHORT STUDIES

V. Babak1, M. Suprun1, T. Beketov1. 1VA Nasonova Research Institute of Rheumatology, Department of Systemic Sclerosis, Moscow, Russian Federation

Background: Survival rate in ANCA-associated vasculitis (AAV) has significantly improved due to anti-B cell therapy with rituximab (RTX). The main issue now appears to be the management of comorbidities and the improvement of quality of life.

Objectives: Based on a prospective analysis of the single centre registry of AAV patients (pts) treated with RTX, to study the impact of sustained remission on health-related quality of life using Short-Form 36 (SF-36).

Methods: Health-related quality of life was assessed in 70 AAV pts: 35 (50%) with granulomatosis with polyangiitis (GPA), 24 (34.3%) - microscopic polyangiitis (MPA) and 11 (15.7%) - eosinophilic granulomatosis with polyangiitis (EGPA). The mean age was 49.7 ± 15.7 years, 53% women. The median total dose of RTX was 4.3 ± 2.5g. As a rule, a reduced dose of RTX 500 mg was used for repeated courses. Mean duration of RTX therapy 46.8 ± 29.4 months. Remission of AAV was defined as a Birmingham Vasculitis Activity Score = 0 regardless of prednisone treatment or dosage. All pts were in remission.

Results: In 70 patients the average indicators of physical functioning: MPA 62.5 (47.5, 78.8), GPA 75 (55, 92.5), EGPA 60 (45, 775); social functioning: MPA 25 (0, 56.3), GPA 50 (25, 100), EGPA 50 (12.5, 82.5), physical health component: MPA 416 (315, 44.8), GPA 43.7 (36.7, 52.5), EGPA 38.7 (33.8, 45). There were no significant differences between men and women within the GPA, MPA, and EGPA groups. There were also no differences between different age groups. When comparing the EGPA group with GPA or MPA, no significant differences were found. At the same time, in patients with GPA, the indicators of physical functioning (p=0.015, w= 3.92) and the physical component of health (p=0.012, w= 4.028) were significantly lower than in patients with GPA.

Conclusion: RTX maintenance allows to achieve a good quality of life in AAV pts. SF-36 summary measures were significantly higher in GPA pts compared with MPA. Further research is required to analyze the effect of AAV phenotype and complications on health-related quality of life.

REFERENCES:

Disclosure of Interests: None declared


AB0607
VASCULAR INFECTION IN BEHÇET’S DISEASE

I. Chaabene1, S. Tahri1, M. Kechida1, S. Daada1, S. Hammami1, R. Kili1, I. Khochtali1. 1Fattouma Boungiba University Hospital, Internal Medicine and Endocrinology department, MONASTIR, Tunisia

Background: Behçet’s disease (BD) is a multisystemic inflammatory vasculitis, which can affect all types and sizes of blood vessels. It diagnosis is based on a multitude of classification criteria, which include vascular complications associated to this vasculitis.

Objectives: In this study, we reported the main characteristics of vascular involvement in patients with BD.

Methods: In total, 243 patients with BD were, retrospectively, collected in the Internal Medicine Department over 18 years.

Results: Vascular involvement was present in 72 patients (29.6%), whose 57 men and 15 women. The mean age was 52.9 years (range: 5-56 years). It revealed the disease in 26.3% of cases. Venous involvement was predominant, found in 68% of patients. Venous thrombosis interested the upper limbs (51%), the lower limbs (38.7%), the pulmonary veins (18.3%), the inferior vena cava (12.2%) and the cerebral veins in 1 patient. Superficial venous thrombosis was present in 20.8% of cases. Arterial involvement was present in 11% of patients. It included pulmonary artery aneurysms in 8 cases and occlusion of the central retinal artery in one patient. The other associated systemic manifestations were: skin and mucous membrane disorders (100%), joint involvement (34.7%), ocular (29.2%), neurological (27.8%) and cardiac involvement in 7 patients. Treatment was based on long term curative anticoagulation (70%), corticosteroid therapy (50%) and immunosuppressive treatment in 21% of cases. Embolization was performed in two patients with good results.

Conclusion: Our study illustrates the frequency and the polymorphism of vascular involvement in BD.

REFERENCES:

Disclosure of Interests: None declared


AB0608
TIME OF DIAGNOSIS AND INITIATION OF TREATMENT OF GIANT CELL ARTERITIS (GCA) ACCORDING TO CLINICAL PHENOTYPE AND REFERRAL ORIGIN

M. López I Gómez1, P. Moya2, I. Castellví3, H. Corominas3. 1Hospital Universitario de Navarra, Rheumatology, Pamplona, Spain; 2Hospital de la Santa Cruz i Pau, Rheumatology Service Systemic Autoimmune Diseases Unit Functional Unit of Aortic Pathology, Barcelona, Spain; 3Hospital de la Santa Cruz i Pau, Rheumatology Service Systemic Autoimmune Diseases Unit, Barcelona, Spain
Background: Giant cell arteritis (GCA) presents two phenotypic patterns: cranial and extracranial. Cranial manifestations are relatively easier to recognize and to diagnose, however since the extracranial are more insidious and less known, it may lead to a delay in diagnosis and in treatment. The main treatment are glucocorticoids (GC) at high doses followed by a descending pattern. The time between the begin of the symptoms and the start of the treatment with GC it's of vital importance in the prognosis of the disease.

Objectives: The present AUDIT describes our cohort's clinical features, the time from symptom onset to rheumatology visit and diagnosis of GCA, as well as the differences in time according to the service originating the referral.

Methods: Audit retrospective, descriptive study of patients diagnosed with GCA by the CGA 1990 criteria. All patients diagnosed with GCA from 2011 to 2021, in a single hospital center and referred to the Rheumatology Service were included. Patients were classified as: cranial phenotype, extracranial or mixed. Demographic and clinical variables and complementary examinations were collected. As well as the time from the first symptom until the patients are referred and diagnosed.

Results: Seventy patients were included in the study. Fifty-one patients (72.9%) were female, their clinical features are shown in Table 1. Twelve of them (17.39%) had a cranial phenotype, sixteen (23.18%) an extracranial phenotype and forty-one (60.42%) a mixed one. Extracranial phenotype patients showed to be younger at the time of the diagnoses than the other groups. Cranial phenotype patients had a lower increase of the acute phase reactants than the younger at the time of the diagnoses than the other groups. Cranial phenotype, extracranial and mixed respectively. 75.7% of the patients received treatment extracranial and mixed respectively. The median of time from patient referral to rheumatology are 9.34, 12.74 and 5.87 weeks in the cranial, extracranial and mixed respectively. 75.7% of the patients received treatment and extracranial. Cranial manifestations are relatively easier to recognize and to diagnose, however since the extracranial are more insidious and less known, it may lead to a delay in diagnosis and in treatment. The main treatment are glucocorticoids (GC) at high doses followed by a descending pattern. The time between the begin of the symptoms and the start of the treatment with GC it's of vital importance in the prognosis of the disease.

Patient referral were made from: Emergency room/ Internal Medicine hospitalization (30%, 21 patients), Primary Care (21.4%, 15 patients), Internal Medicine outpatient clinic (15.7%, 11 patients), Neurology (8.6%, 13 patients) and other specialties outpatient clinic (cardiology, vascular surgery, ophthalmology, hematology and gastroenterology). The median of the time from the first symptom until the patients are diagnosed are 12.9, 13.97 and 7.91 weeks in the cranial, extracranial and mixed respectively. The median of time from the first symptom until the patient referral to rheumatology are 9.34, 12.74 and 5.87 weeks in the cranial, extracranial and mixed respectively. The median of time from patient referral to rheumatology are 3.73, 5.59 and 3.43 weeks in the cranial, extracranial and mixed respectively. 75.7% of the patients received treatment with glucocorticoids before being referral to rheumatology.

Conclusion: In our cohort, most of the patients with CGA had a mixed phenotype. The patient referral to rheumatology is made mainly from the emergency room, internal medicine hospitalization and primary care. Patients with mixed phenotype are diagnosed faster than the ones with an exclusively extracranial phenotype. The time between the first symptom and the referral to rheumatology is still long.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4888

AB0609

GAPS IN THE DIAGNOSIS OF TAKAYASU ARTERITIS: A ROMANIAN COHORT

A. Predoiu1,2, C. Pamfil1,2, I. Felea1, L. Muntean1,2, M. M. Tamas1,2, I. Filipescu1,2, S. P. Simon1,2, S. Rednic1,2. 1Emergency County Hospital, Rheumatology Clinic, Cluj-Napoca, Romania; 2Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of Rheumatology Cluj-Napoca, Romania

Background: The diagnosis of Takayasu arteritis still represents a big challenge, even though the disease was first described more than 100 years ago. Proof of that is the continuing effort to develop criteria with high specificity and sensitivity.1

Objectives: The aim of the study was to describe the clinical and paraclinical aspects of the disease at the time of diagnosis. Additionally, we wanted to evaluate the damage score in view of the diagnosis delay.

Methods: We retrospectively studied the clinical chart of 17 consecutive patients admitted to the Rheumatology Clinic of Emergency County Hospital from Cluj-Napoca, Romania between 2003 and 2021. Results: There was just one patient with Takayasu arteritis (0.05%). The average age at the time of diagnosis was 37.5 years old. The average delay in the diagnosis was 33 months, while the biggest delay was of 240 months. The diagnosis was made by rheumatologists in 58% of the cases, while 29% by cardiologists and 11.7% by internal medicine specialists. The most frequent symptoms were limb claudication (64.7%), fatigue (52.9%) and headache (52.9%). Vascular bruises were found in most of the patients at the time of diagnosis (70.3%), as well as blood pressure and pulse difference between arms (52.9%). Unobtainable blood pressure was seen in 5 patients (29.4%). There was a discrepancy in 3 patients (17.6%) between inflammatory markers and inflammation in the vessels’ walls, as confirmed by imaging techniques (angioMRI or angioCT). Most of the patients were classified as type V arteritis (35%), followed by type IV (18%), type I (17%), type IIA, respectively type IIB (12% each) and type IIb (8%). Stenosis of the involved arteries occurred 4.3 times more than aneurysm formation. Eight patients required vascular interventions at the time of diagnosis – four were treated by balloon angioplasty and six by stent placing. The average TADS (Takayasu Arteritis Damage Score) was 1.5 and it was not associated with delay in diagnosis (p=0.05).

Conclusion: Takayasu arteritis is a disease with heterogenous and nonspecific symptoms. For those reasons the delay in diagnosis is usually long, the treatment is started late and damage appears early in the course of the disease. This is reflected by the high amounts of vascular procedures needed at the time of diagnosis. We need better diagnostic criteria and specific monitoring scores.

REFERENCES:

Disclosure of Interests: None declared


Vasculitis - small vessel vasculitis

AB0610

DEVELOPMENT OF MALIGNANCY IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS

M. Bektaş1, B. Inci1, S. Zaraï2, U.A. Gilselen3, E. Üz2, B. F. Agargun2, D. Y. Güney1, Y. Akay1, B. Akın-Esen1, A. Ustündag1, M. İnci1, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey; 3Istanbul Faculty of Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey

Background: Patients (pts) with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) reported to have an increased risk of malignancy compared to general population [1]. However, studies on risk factors for the development of malignancy in AAV pts are limited.

Objectives: We aimed to evaluate the frequency, clinical features and associated factors of malignancy in pts with AAV.

Methods: In this study, we retrospectively evaluated 287 pts with AAV. Thin-ty-three pts with EGPA and 14 pts with missing data were excluded. ANCA test was analysed based on immunofluorescence and/or Elisa results and divided into two serological groups; c-ANCA/PRES3 (positive) and p-ANCA/MPO”.

Results: Data of 240 pts (54.6 % female) were analysed. Mean age of diagnosis was 55.6±14 (range; 17-88) years and mean disease duration was 67.5 (range; 3-255) months. Of those pts, 175 (73 %) had GPA and 65 (27 %) had MPA. ANCA results were available in 230 pts; 123 were c-ANCA/PRES3 (53.5 %), 85 were p-ANCA/MPO” (37 %) and 22 were ANCA negative (ANCA) (9.5 %). Kidney (75.8 %) and lower respiratory tract (74.4 %) were the most common organs involved but they did not differ according to presence of malignancy (9.4 % vs 5.1 %; p=0.14) and 9.4 % vs 5.1 %; p=0.14 respectively). Therapy with immunosuppressives was observed in 20 pts (8.3 %); eleven c-ANCA/PRES3, three p-ANCA/MPO” and two ANCA negative pts. Lung and thyroid papillary cancer in three; bladder, prostate, breast and kidney in two; adrenal gland, oral squamous cavity and sarcoma of retinoperitoneum in one patient, hematological (three myelodysplastic syndrome, one chronic lymphocytic leukemia and one lymphoma) in five pts. Six pts (30 %) had previously concomitant AAV diagnosis. Development of malignancy did not differ according to age, gender, diagnosis, seropositivity (ANCA” vs ANCA) and ANCA subgroups (Table 1). There was no association between malignancy and cumulative dose of cyclophosphamide (CYC) or history of smoking (p=0.96 and p=0.2, respectively).

In univariate analysis, malignancy was associated with presence of cardiovascular disease (CVD) (p=0.003 OR 11.7) and mortality (p=0.04 OR 4.6), higher BVAS score at baseline (p=0.049) and higher VDI score (p=0.02). Significant association was observed between malignancy with CVD (95 % CI 2.2-83 OR 13.4±0.005) and mortality (p=0.044 95 % CI 1.03-8.5 OR 2.95) in multivariate analysis.

REFERENCES:
Table 1. Factors associated with malignancy in pts with AAV

<table>
<thead>
<tr>
<th>Variables</th>
<th>Malignancy + (n=20)</th>
<th>Malignancy – (n=220)</th>
<th>p value (OR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)³</td>
<td>60±13.4</td>
<td>55±14</td>
<td>0.15</td>
</tr>
<tr>
<td>Gender (female)</td>
<td>10 (50)</td>
<td>121 (55)</td>
<td>0.7</td>
</tr>
<tr>
<td>Diagnosis *</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPA</td>
<td>15 (8.6)</td>
<td>160 (91.4)</td>
<td>0.8</td>
</tr>
<tr>
<td>MPA</td>
<td>5 (7.7)</td>
<td>60 (92)</td>
<td></td>
</tr>
<tr>
<td>ANCA status*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease*</td>
<td>8/38 (21)</td>
<td>10/199 (5)</td>
<td>0.003 (11.7)</td>
</tr>
<tr>
<td>Cerebrovascular accident*</td>
<td>2/15 (13)</td>
<td>16/222 (7)</td>
<td>0.3</td>
</tr>
<tr>
<td>Coronary heart disease*</td>
<td>4/18 (22)</td>
<td>19/218 (9)</td>
<td>0.08</td>
</tr>
<tr>
<td>Avascular necrosis*</td>
<td>4/35 (11)</td>
<td>14/199 (7)</td>
<td>0.3</td>
</tr>
<tr>
<td>Venous thrombosis*</td>
<td>3/21 (14)</td>
<td>15/217 (7)</td>
<td>0.2</td>
</tr>
<tr>
<td>BVAS score at admission¹</td>
<td>21.3±6</td>
<td>16.6±6.7</td>
<td>0.049</td>
</tr>
<tr>
<td>Smoking history (ever)*</td>
<td>6/53 (11)</td>
<td>8/156 (5)</td>
<td>0.2</td>
</tr>
<tr>
<td>Cumulative CYC dose (g)¹</td>
<td>5 (74)</td>
<td>4.3 (78)</td>
<td>0.96</td>
</tr>
<tr>
<td>VDI score*</td>
<td>3.5 (4)</td>
<td>2 (2)</td>
<td>0.02</td>
</tr>
<tr>
<td>Relapse (n=230, %)</td>
<td>5/80 (6.3)</td>
<td>11/150 (7.3)</td>
<td>0.8</td>
</tr>
<tr>
<td>Remission at six months (n=160, %)</td>
<td>8/104 (7.7)</td>
<td>5/56 (9)</td>
<td>0.8</td>
</tr>
<tr>
<td>Mortality*</td>
<td>7 (35)</td>
<td>35 (16)</td>
<td>0.04 (4.6)</td>
</tr>
</tbody>
</table>

OR: Odds ratio *(n, %) I means Std dev. *median; IQR

In survival analysis, mortality rate was higher in pts who had malignancy compared to those without (Figure 1, p=0.035).

Figure 1. Survival analysis of mortality according to presence of malignancy in pts with AAV. Log-Rank: p=0.035

Conclusion: Significant proportion of pts with AAV developed malignancy in our cohort. Development of malignancy was associated with CVD, higher baseline BVAS and VDI scores. Our study also revealed lower survival rate in patients who developed malignancy. Further studies are needed to clarify risk factors for malignancy in patients with AAV.

REFERENCES:


Disclosure of Interests: None declared


Table 1. SANRA Score for quality assessment

<table>
<thead>
<tr>
<th>N°.</th>
<th>Authors</th>
<th>Justification of the article’s importance for the readership</th>
<th>Statement of concrete aims or formulation of questions</th>
<th>Description of the literature search</th>
<th>Referring</th>
<th>Scientific Reasoning</th>
<th>Appropriate presentation of data</th>
<th>Total score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pandolfi L et al. 2021</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>2</td>
<td>Radermecker C et al. 2020</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>Zhang S et al. 2019</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>Skopelja-Gardner S et al. 2019</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>Khawaja AA et al. 2020</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>6</td>
<td>Chrysanthopoulou A et al. 2014</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>7</td>
<td>Kraaij T et al. 2018</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>8</td>
<td>Tang S et al. 2015</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>9</td>
<td>Yoshida M et al. 2016</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>10</td>
<td>Nakazawa D et al. 2014</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td>11</td>
<td>Hastanda F et al. 2019</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>12</td>
<td>Schreiber A et al. 2017</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>13</td>
<td>van Dam LS et al. 2019</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>14</td>
<td>Roitsch S et al. 2018</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>15</td>
<td>Takeuchi H et al. 2017</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>16</td>
<td>Su B et al. 2021</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>17</td>
<td>Söderberg D et al. 2015</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>18</td>
<td>Surmaik M et al. 2016</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>8</td>
</tr>
</tbody>
</table>

AB0611 NEUTROPHIL EXTRACELLULAR TRAPS AND INTERSTITIAL LUNG DISEASE IN ANCA-ASSOCIATED VASCULITIS: A SCOPING REVIEW

E. Conticini1, M. D’alessandro2, L. Bergantini2, P. Falsen2, P. Camelli3, E. Bargagli2, L. Cantarini, B. Frediani1 on behalf of Siena Vasculitis Study Group. 1University of Siena, Rheumatology Unit; Siena, Italy; 2University of Siena, Respiratory Diseases and Lung Transplantation Unit, Siena, Italy

Background: Deregulated neutrophil extracellular traps (NET) formation is implicated in various diseases, including ANCA-associated vasculitis and pulmonary fibrosis (PF). Lung involvement is frequent in AAV, and interstitial lung diseases (ILD) are strongly related to MPO-ANCA positivity and mainly reported in microscopic polyangiitis. The association between AAV and ILD is a strong indicator of poor prognosis and limited survival. Neutrophils, ANCA and NET interplay in PF development in AAV.

Objectives: This study aimed to review the literature concerning the implications of NET in lung fibrogenesis focused specifically on AAV associated with ILD, and the potential of NET as a therapeutic marker.

Methods: Through scoping review methodology, we used a descriptive thematic analysis to understand the pathogenic role of NETs in patients with AAV and pulmonary fibrosis and their further role as a therapeutic marker of this disease.

Results: Quality assessment of articles was evaluated through SANRA methodology (Table 1). The implications of NET in the pathogenesis of AAV and ILD (Figure 1), as well as an association between these two diseases, have been identified, but the underlying pathophysiological mechanisms are still unknown. Pharmacological or genetic inhibition of NET release reduces disease severity in multiple inflammatory disease models, indicating that NETs are potential therapeutic targets. In this regard, despite the lack of clinical data, we may hypothesize that an optimal management of AAV-ILD patients would require not only B-cells targeted therapy, but also NETs inhibition.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.479

Figure 1. The role of NET in interstitial lung disease associated with ANCA-associated vasculitis

Conclusion: Preliminary findings seem to display a lack of efficacy of traditional immunosuppressants, such as Rituximab, in this subset of patients, while to date no patients suffering from a definite ILD was enrolled in clinical trials. Further insights would be provided by their employment, as a combination treatment, in the common clinical practice. Although we can imagine that inhibition of NETs in patients with AAV-ILD could reduce severity and mortality, we still lack a scientific basis that could improve our understanding of the disease from a molecular point of view.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.479
AB0612 CHRONIC PANCREATITIS DUE TO SYSTEMIC AUTOIMMUNE AND BACTERIAL SEPTIC VASCUITIS IN RHEUMATOID ARTHRITIS – A HYPOTHETICAL PATHWAY OF CHRONIC PANCREATITIS IN POST-COVID 19 CONDITION

A. Apáthy¹, M. Bély², ¹St. Margaret Clinic, Department of Rheumatology, Budapest, Hungary; ²Hospital of the Order of the Brothers of Saint John of God in Budapest, Department of Pathology, Budapest, Hungary

Background: The etiology of pancreatitis is heterogeneous; it may be due to chronic excessive alcohol use, gallstones, medications, infections, autoimmune diseases, metabolic disorders, trauma, congenital malformations etc.

Objectives: The aim of this study has been to describe a hypothetic pathway of chronic pancreatitis in post-Covid 19 condition, based on the role of autoimmune and bacterial septic vasculitis in the pathogenesis of chronic pancreatitis (ChrP) in rheumatoid arthritis (RA).

Methods: At the National Institute of Rheumatology 9475 patients died between 1969 and 1992; among them 161 with RA and all of them were autopsied. RA was confirmed clinically according to the criteria of the ACR. Tissue samples of pancreas were available for histologic evaluation in 111 patients. Pancreatitis and vasculitis were determined and characterized histologically [1,2]. The possible role of autoimmune vasculitis and bacterial septic vasculitis in the pathogenesis of ChrP was analyzed by Pearson’s chi-squared ($\chi^2$) test.

Results: ChrP – characterized by diffuse and/or focal fibrosis and atrophy – was present in 10 (9.01 %) of 111 patients. Systemic vasculitis complicated RA in 28 (25.23 %) of 111 patients. Twenty-five (89.3 %) of 28 systemic vasculitis proved to be of autoimmune origin. Autoimmune vasculitis involved the pancreatic blood vessels (pAV) in 8 (32.0 %) of these 25 patients. Non-specific (n=37), fibrinoid necrotic (n=14), and granulomatous type (n=5) of pAV were detected side by side in the same histologic section, involving pancreatic arteries of different sizes. The veins and venules were not involved; pAV was not associated with chronic pancreatitis. The relationship between pAV and ChrP was inverse with a negative colliquation coefficient (c=-1.0, $\chi^2$=0.0801, p <0.7772 – NS). Three (10.7 %) of 28 systemic vasculitis cases proved to be of septic (bacterial) origin. Pancreatic blood vessels (pSV) were involved in 2 (66.7 %) of these 3 patients. Granulomatous vasculitis was not seen with pSV, and the veins and venules were also spared. Non-specific (n=9), fibrinoid necrotic (n=2) vasculitis involving different size of pancreatic arteries were associated with chronic pancreatitis. The relationship between pAV and ChrP was significant (c=0.2308, $\chi^2$=6.3201, p <0.012).

Conclusion: Chronic pancreatitis is characterized clinically by abdominal pain and diarrhea, which are common in post-Covid 19 condition [2]. The strong and significant correlation between pSV and ChrP indicates that subclinical or manifest bacterial septic processes may play a role in the pathogenesis of ChrP. Hypothetically a similar pathway is plausible in post-Covid 19 chronic pancreatitis due to viral infection and vasculitis, analogous to bacterial septic vasculitis. Systemic vasculitis of autoimmune origin involving blood vessels of the pancreas may cause a special multifocal relapsing lipo-necrotic pancreatitis. Hypothetically a similar pathway is plausible in post-Covid 19 chronic pancreatitis. The relationship between pAV and ChrP was significant ($\chi^2$=6.3201, p <0.012).

REFERENCES:

Table 1.

<table>
<thead>
<tr>
<th>Prevalence of pAV / pSV</th>
<th>Size of involved vessels</th>
<th>Prevalence of pAV/Fn</th>
<th>Prevalence of Gr</th>
<th>Total % of pAV</th>
<th>Prevalence of pSV/Fn</th>
<th>Prevalence of Gr</th>
<th>Total % of pSV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arteriole</td>
<td>18</td>
<td>10</td>
<td>3</td>
<td>31 – 55.36</td>
<td>3</td>
<td>0</td>
<td>3 – 27.27</td>
</tr>
<tr>
<td>small artery</td>
<td>16</td>
<td>4</td>
<td>2</td>
<td>22 – 39.28</td>
<td>3</td>
<td>2</td>
<td>5 – 45.46</td>
</tr>
<tr>
<td>medium size artery</td>
<td>3</td>
<td>0</td>
<td>0</td>
<td>3 – 5.36</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
</tr>
<tr>
<td>Venule</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
</tr>
<tr>
<td>small vein</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
</tr>
<tr>
<td>medium size vein</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
<td>0</td>
<td>0</td>
<td>0 – 0.0</td>
</tr>
<tr>
<td>Total</td>
<td>37 – 66.07%</td>
<td>14 – 25.0%</td>
<td>5 – 8.93%</td>
<td>56 – 100%</td>
<td>9 – 81.82%</td>
<td>2 – 18.18%</td>
<td>11 – 100%</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared


AB0613 VASCULAR EVENTS AND ASSOCIATED FACTORS IN ANCA-ASSOCIATED VASCULITIS: ANALYSIS OF 237 PATIENTS WITH LONG-TERM FOLLOW-UP

M. Bektaş¹, B. Ince¹, S. Zarabi², U.A. Gulseren³, E. Ük³, Y. Yalçınkaya¹, B. Artım-Esen¹, A. Gül¹, M. İnanç¹, ¹Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; ²Istanbul Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey

Background: Patients with ANCA-associated vasculitis (AAV) reported to have an increased risk of vascular events (VE) compared to general population [1]. However, studies on risk factors for the development of VE in AAV patients (pts) are limited.

Objectives: In our study we aimed to evaluate the frequency, risk factors and mortality risk of VE pts with AAV.

Methods: In this study we retrospectively evaluated 287 pts with AAV. Patients with EGPA (n=33) were not included and 17 pts were excluded due to missing data. Arterial vascular events (a-VE) were recorded as myocardial infarction, unstable angina pectoris, peripheral artery disease, need for revascularization and cerebrovascular accident. Deep venous thrombosis and pulmonary embolism were recorded as venous thrombotic events (VTE). History of a-VE and/or VTE were grouped as all VE. ANCA test results were analyzed based on IFA and/or Elisa results and divided into two serological groups; c-ANCA/PR3 (positive) and p-ANCA/MPO-.

Results: Data of 237 pts (46 % male) was analyzed. Mean age at diagnosis was 55.6±14 (range; 17-88) years and median disease duration was 77 (range; 3-255) months. Of those pts, 173 (73 %) had GPA and 64 (27 %) had MPA. ANCA results were available in 230 pts; 122 were c-ANCA/PR3 (53.5 %), 85 were p-ANCA/MPO (37 %) and 22 were ANCA negative (ANCA-) (9.5 %). The most common organ involvements revealed that, one in five pts with AAV developed VE after diagnosis. The risk of VE was significantly higher in males, pts with c-ANCA/PR3 and pts with higher baseline CRP levels, GFR<50 mL/min, history of smoking, severe infection, higher VDI score. Development of a-VE was higher in pts with males, advanced age, pts with c-ANCA/PR3, history of smoking, higher VDI score, GFR<50 mL/min. Additionally, mortality was increased in pts with VE and a-VE. In multivariate analysis; while VE were associated with smoking [95 % CI: 1.7-21; OR:6], c-ANCA/PR3 positivity [95 % CI: 1.15-92; OR:10.3] and higher VDI score [95 % CI:1.002-1.08; OR:1.04], higher VDI score [95 % CI:1.3-2; OR:1.6] and c-ANCA/PR3* [95 % CI:1.06-8.6; OR:3.8]; Development of VTE was associated with higher VDI score (p=0.001) in univariate and multivariate analysis [95 % CI: 1.2-1.8; OR:1.5]. In survival analysis, mortality rate was significantly higher in pts who had a history of VE (Log-Rank: p=0.04).

Conclusion: Our observational data of more than 5 years of follow-up revealed that, one in five pts with AAV developed VE after diagnosis. The risk of VE was significantly higher in c-ANCA/PR3 pts, smokers and pts with high VDI scores. Older age increased the risk of a-VE. Mortality was increased in AAV pts with VE after diagnosis. Additional studies needed to delineate the mechanism of VE in AAV and precautions should be undertaken to avoid morbidity and mortality.

Disclosure of Interests: None declared.


**Table 1. Factors associated with vascular events in pts with AAV**

<table>
<thead>
<tr>
<th>Variables</th>
<th>VE+ (n=52)</th>
<th>VE- (n=185)</th>
<th>p value (OR) (95 % CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age*</td>
<td>58.8±14.5</td>
<td>54.9±14</td>
<td>0.08 (0.99-1.04)</td>
</tr>
<tr>
<td>Gender, male</td>
<td>31 (60)</td>
<td>78 (42)</td>
<td>0.03 (3.5) (1.08-3.8)</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>40 (23)</td>
<td>133 (77)</td>
<td>0.5</td>
</tr>
<tr>
<td>GPA (n=173)</td>
<td>12 (19)</td>
<td>52 (81)</td>
<td></td>
</tr>
<tr>
<td>MPA (n=64)</td>
<td>4 (24)</td>
<td>100 (62)</td>
<td></td>
</tr>
<tr>
<td>ANCA status</td>
<td>33 (27)</td>
<td>89 (73)</td>
<td>0.045 (4) (1.007-4.2)</td>
</tr>
<tr>
<td>c-ANCA/PR3</td>
<td>13 (15)</td>
<td>72 (85)</td>
<td></td>
</tr>
<tr>
<td>p-ANCA/MPO</td>
<td>73 (85)</td>
<td>48 (89)</td>
<td>0.05 (1.009)</td>
</tr>
<tr>
<td>Baseline CRP (mg/L)*</td>
<td>24 (47)</td>
<td>57 (31)</td>
<td>0.03 (4.7)</td>
</tr>
<tr>
<td>GFR&lt;50 ml/min*</td>
<td>19±7</td>
<td>16.3±7</td>
<td>0.06 (1.1-1)</td>
</tr>
<tr>
<td>Smoking history (ever)</td>
<td>19/4 (42)</td>
<td>34/62 (21)</td>
<td>0.004 (6.3) (1.4-5.6)</td>
</tr>
<tr>
<td>Cumulative steroid (MP) dosage</td>
<td>7.9 (17)</td>
<td>75 (8)</td>
<td>0.8</td>
</tr>
</tbody>
</table>

*p means std dev, n, %, median, interquartile range. OR: Odds ratio

**Figure 1.** Comparison of mortality rate between pts had VE and had not. Log-rank: p=0.039

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.798

**AB0614**

**LATE-ONSET NEUTROPENIA AFTER RITUXIMAB TREATMENT IN PATIENTS WITH ANCA-ASSOCIATED SYSTEMIC VASCULITIS: A RETROSPECTIVE ANALYSIS OF A REGISTER-BASED PATIENT COHORT**

I. Popov1, V. Babaki, T. Beketova1,2, V. A. Nasonova Research Institute of Rheumatology, Laboratory of systemic sclerosis, Moscow, Russian Federation; 2Central Clinical Hospital of the General Management Department of the President of Russian Federation, Rheumatology, moscow, Russian Federation

**Background:** Anti-B-cell therapy with rituximab (RTX) plays an important role in the induction and maintenance therapy of ANCA-associated vasculitides (AAV). Late-onset neutropenia (LON) has been reported following RTX therapy.

**Objectives:** Based on a retrospective analysis of the register of AAV patients (pts) treated with RTX, to study the incidence and outcomes of LON.

**Methods:** 140 AAV pts (median age 52 (20-83) years, 57% women) were treated with RTX between 2009 to 2021: 63 with granulomatosis with polyangiitis (GPA), 45 microscopic polyangiitis (MPA), 24 eosinophilic granulomatosis with polyangiitis (EGPA), and 8 unclassified AAV. The median total dose of RTX was 3.5 (0.5-45) g. As a rule, single 500-mg infusions were used with an interval of 4-6 months for retreatment courses. The duration of follow-up exceeded 6 months after the first dose of RTX. Regular pt monitoring every 3 months included estimation of absolute neutrophil count (ANC). LON was defined as unexplained neutropenia occurring 3 weeks after the last RTX infusion.

**Results:** LON I-IV grade was noted in 16 (11.4%) AAV pts: 6 GPA, 4 MPA, 4 EGPA, and 2 unclassified AAV. In 7 out of 16 cases (43.7%) LON developed after the first course of RTX. Neutropenia grade I was observed in 3 pts (ANC 1.68-2.0x109/L), 21-5.5 months after the last RTX infusion), grade II - in 4 patients (1.1-1.5x109/L, 3-9 months after RTX). Neutropenia grade II resolved independently, without adverse reactions. LON grade IV was noted in 9 pts (0.06-0.3x109/L, 1-11 months after RTX), 3 of them received leukopoeiae-stimulating drugs with normalization of ANC. In one EGPA pt febrile LON grade IV developed twice (in 2017, 11 months after RTX; in 2019, 4 months after RTX and complicated by uterine bleeding). Fatal outcome occurred in 5 out of 16 cases (31.2%): 1 MPA, 3 GPA, and 1 EGPA. In 3 fatal cases LON was complicated by pneumonia (in 2 with septic shock), in one with acute myocardial infarction and another one with progression of chronic renal failure. According to our registry, the total mortality among 140 AAV pts receiving RTX was 11.4%, while 5 of 16 fatal cases (31.2%) had LON grade IV. Three of the 5 death were noted in 2013-2014, which attributed to the use of cyclophosphamide >2 gms before RTX, as well as insufficient awareness of the risk of LON, which contributed to the delay in control of a full blood count, untimely diagnosis of LON and late treatment. At the beginning, the original drug Methotrex was used, while after 2014 biosimilar Acelbita was mainly used. The disadvantages of this study: the lack of information about the ANC in 4 cases with COVID-19 and fatal outcome.

**Conclusion:** LON after RTX therapy can develop in 11.4% of AAV pts, which exceeds the data for rheumatoid arthritis (1.3-3%) [1,2]. Our register data are lower than the rate of LON in AAV, presented by D. Tesfa et al. (23%) [1], which could be attributed by the use of low-dose RTX for retreatment courses. LON accounts for a significant part in the structure of deaths of AAV pts (31.2%). It needs to careful monitoring of ANC in pts receiving RTX and awareness of both pts and physicians about the risk of LON.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1018

**AB0615**

**CLINICAL IMPACT OF CERULOPLASMIN LEVELS AT ANCA-ASSOCIATED VASCULITIS DIAGNOSIS**

L. Camboulive1, F. Grandhomme1, N. M. Silva2, H. de Boysson1, A. Dumont1, A. Nguyen1, D. Mariotte1, K. Khyo1, T. Llobede1, A. Aubia3, S. Deshayes1,2

1University Of Caen Normandie Hospital Center, Basse Normandie, Caen, France

**Background:** Myeloperoxidase (MPO) plays a major role in loss of immunological tolerance leading to tissue destruction in ANCA-associated vasculitides (AAV). Ceruloplasmin is a protein with antiproteinase and antioxidant properties that inhibits MPO activity. Whether serum level of ceruloplasmin at AAV diagnosis has an impact is unknown.

**Objectives:** The objective of this study was to evaluate the prognostic impact of serum level of ceruloplasmin at diagnosis in patients with granulomatosis with polyangiitis or microscopic polyangiitis.

**Methods:** We conducted a retrospective unincentric study at Caen University Hospital, involving consecutive adult patients with granulomatosis with polyangiitis or microscopic polyangiitis between 2010 and 2021 who had available serum at diagnosis. Data was collected using the health records.

**Results:** Ceruloplasmin was measured by standardized nephelometry (normal values: 0.15 – 0.50 g/L). Patients in each subgroup (whole cohort, microscopic polyangiitis and anti-MPO patients) were divided into two groups based on the median serum level of ceruloplasmin. We estimated survival using the Kaplan-Meier survival curve, and between-group differences were evaluated by the log-rank test. The study was approved by the local ethics committee of Caen University Hospital (n° 1947).

**Results:** Ninety-two patients were included, 46 (50%) granulomatosis with polyangiitis (41 anti-proteinase 3 and 5 anti-MPO) and 46 (50%) microscopic polyangiitis (45 anti-MPO and 1 anti-proteinase 3). The median level of ceruloplasmin was 0.44 g/L. No significant differences in the clinical presentation were observed between patients in the two groups (p>0.05). We observed 9 (19.6%) deaths in the low ceruloplasmin group and 5 (10.9%) in the high ceruloplasmin group (p=0.3). Two patients relapsed occurred in 10/46 patients (22%) and 11/46 patients (24%) (p=1), renal failure leading to dialysis and/or renal transplant in 6/46 patients (13%) and 8/46 patients (17%) (p=0.77), respectively. No significant difference in survival was found (p=0.07). The same analyses were performed.
between the low and the high ceruloplasmin group with the microscopic polyangiitis subgroup (n=46), and no significant differences were found (p=0.05). However, within the anti-MPO subgroup (n=50), the survival was worse in the low ceruloplasmin group (p=0.03).

Conclusion: In anti-MPO AAV patients, serum level of ceruloplasmin at diagnosis seems to be associated with a significant impact on survival.

REFERENCES:

Disclosure of Interests: None declared

AB0616
MYELOPEROXIDASE (MPO) POSITIVE EXTRACELLULAR VESICLES (EVS) EXPRESSING COMPLEMENT SPLIT PRODUCTS IN ANTI-MPO CYTOLYPIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS (AAV)

A. Juto1,2, N. Mahmoud Hourani Soutari1, A. Taxiarhis1, V. Malmstrom1, A. Bruchfeld1,3,4, A. Antovic1,2, I. Gunnarsson1,2,3, Karolinska Institutet, Department of Medicine, Division of Rheumatology, Solna, Stockholm, Sweden; 2Karolinska University Hospital, Rheumatology, Stockholm, Sweden; 3Karolinska Institutet, Department of Molecular Medicine and Surgery, Solna, Stockholm, Sweden; 4Linkoping University, Department of Health, Medicine and Caring Sciences, Linkoping, Sweden; 5Karolinska Institutet, CLINTEC, Stockholm, Sweden; 6Karolinska University Hospital, Department of Renal Medicine, Stockholm, Sweden

Background: Complement activation has a critical role for the development of antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV). We have previously shown increased expression of complement split products C3a and C5a on myeloperoxidase (MPO) positive EVs (MPO +EVs) in plasma from AAV patients with kidney involvement compared to the patients with non-renal disease and the EV-levels correlated with disease activity (1). Objectives: To investigate the expression of a larger set of complement components on circulating MPO +EVs in relation to disease activity and kidney involvement in patients with AAV.

Methods: Eighty-nine patients with AAV and 23 healthy controls were included. The concentration of MPO +EVs expressing complement split products C3a, C4d, C5a, terminal complement complex-TCC (C5b-9) or complement factor B (CFB) were analyzed from citrate plasma by flow cytometry. The assessment of vasculitis disease activity was performed using the Birmingham Vasculitis Activity Score (BVAS).

Results: In the AAV group, there were 47 males (52.8%), the median age was 56 years and 33 (37.1%) patients were anti-MPO-positive and 54 (60.7%) were anti-PR3-positive. Two patients were positive for both antibodies. Median disease duration for patients with active AAV (BVAS>0; n=81) was 4 days and for patients in remission (BVAS 0; n=8) 1259 days. 64% had kidney involvement (n=52). Highly active AAV (BVAS ≥12) was noted in 62 patients, of whom 49 patients had kidney involvement. Active disease (0-BVAS≤12) was seen in 19 patients. AAV patients had significantly higher levels of MPO +, MPO+C3a+, MPO +C4d+ and MPO +TCC+ EVs compared with patients without (p<0.001). Patients in remission had higher levels of MPO +, MPO+C4d+ and MPO +TCC+ EVs compared to healthy controls (all p<0.001). There was a significant difference in levels of MPO + (p=0.02), MPO+C3a + (p<0.001), MPO+C4d+ (p<0.001) and MPO +TCC+ EVs (p<0.001) in patients with kidney involvement compared with patients without (n=29) (Figure 1). For patients with BVAS>0 there was a weak correlation between MPO +, MPO+C3a+, MPO+C4d+, MPO +TCC+ EVs and BVAS.

Conclusion: Levels of EVs expressing complement split products were generally increased in AAV patients and patients with kidney involvement had higher levels of total MPO +EVs exposing C3a, C4d or TCC compared with patients without suggesting a role in kidney AAV pathogenesis. Patients with sclerotic kidney histotype had higher levels of MPO +EVs compared with focal and mixed subgroups pointing to that activation of the classical complement pathway may be of importance in several forms of kidney AAV.

REFERENCES:

Disclosure of Interests: None declared

AB0617
HIGH PREVALENCE OF OSTEOPOROSIS AND FRAGILITY FRAC TURES IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS: A CROSS-SECTIONAL STUDY

P. Delvino1, S. Monti1, G. P. Grieco2, E. Bozzalla Cassione2, G. Franchi1, L. Bogliolo1, C. Montecucco1, 1IRCCS Policlinico San Matteo Foundation, University of Pavia, Rheumatology, Pavia, Italy; 2University of Pavia, School of Medicine and Surgery, Pavia, Italy

Background: The advent of effective immunosuppressive treatments significantly improved the prognosis of ANCA-associated vasculitides (AAV), which have become chronic relapsing diseases. Patients with inflammatory rheumatic disorders are particularly prone to reduced bone mineral density (BMD) and fragility fractures (FF), due to chronic glucocorticoid therapy, immunosuppressant-induced hypogonadism, systemic inflammation, functional disability and comorbidities. At present, there is paucity of data concerning the risk of osteoporosis and FF in AAV.

Methods: Patients diagnosed with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), according to ACR criteria and/or Chapel Hill definitions and regularly followed-up in our vasculitis center were included. BMD was measured by dual-energy X-ray absorptiometry (DEXA) of the proximal femur and lumbar spine, between March 2016 and September 2021. Osteoporosis was defined by a T-score below −2.5 SD, whereas osteopenia was defined by a T-score between −1.2.5 SD, according to the World Health Organization criteria. Vertebreal fractures were assessed by X-ray of the dorso-lumbar spine. Data on previous osteoporotic hip fractures were collected.

Results: Sixty-two consecutive patients were included (59.7% female, mean age at time of DEXA 61.8±10.5 years, disease duration 97.0±76.1 months). Sixteen (25.8%), 8 (12.9%) and 38 patients (61.3%) were affected by GPA, MPA and EGPA, respectively. BMD findings indicating osteoporosis and osteopenia, at either the lumbar spine and/or the proximal femur, were observed in 15 (24.2%) and 39 patients (62.9%), respectively, whilst only 8 patients (12.9%) had normal BMD values at both sites. Fifteen patients (24.2%) reported 51 major FF (50 vertebral fractures, 1 hip fracture) during follow-up, with multiple major FF being recorded in 10 patients (16.1%). Osteoporosis, at least at one site, was frequent not only in post-menopausal women (19.4%), but also in 6 males (24%), 3 pre-menopausal women (50%) and 3 patients under 50 years of age (37.5%), respectively (Figure 1). Similarly, major FF occurred in 4 males (16.7%), 1 pre-menopausal female (16.7%) and 1 patient under 50 years of age (12.5%), respectively (Figure 1). Patients with osteoporosis presented a lower body mass index (BMI) (23.1±4.1 vs 25.9±4.4, P=0.03) and a higher prevalence of major FF (53.3% vs 14.9%, P=0.003) compared to patients without osteoporosis. Compared to patients without major FF, those affected by major FF were older (68.8±1.8 vs 59.9±4.3 years, P=0.003), had a higher disease duration (146.9±78.8 vs 81.8±68.9 months, P=0.003) and presented with lower proximal femur BMD values (0.657±0.122 vs 0.761±0.127 g/cm², P=0.007) and proximal femur T-score (-2.0±0.9 vs -1.4±0.8 SD). Notably, 7 out 15 patients with FF (46.7%) did not exhibit BMD findings of osteoporosis. Other variables, including sex, disease subtype, ANCA status, chronic kidney disease or treatment with cyclophosphamide were not related to bone loss or FF.

Disclosure of Interests: None declared
Conclusion: Patients with AAV are particularly susceptible to BMD loss and fractures, with osteoporosis and major FF being reported in about a quarter of patients. Short-term and long-term monitoring for reduced BMD and FF is warranted in all patients with AAV, including male patients, premenopausal females and those under 50 years of age.

Disclosure of Interests: None declared


AB0618

TOLERABILITY AND SAFETY OF 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE IN PATIENTS WITH SYSTEMIC VASculITIS, PRELIMINARY RESULTS

G. Tarasova 1, O. Egorgova 1, T. Reshetnyak 1,2, B. Belovy 3,1, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 2Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia, Department of Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccination Prevention, Moscow, Russian Federation

Background: Systemic vasculitis (VS) is a severe autoimmune disease requiring active immunosuppressive therapy. The probability of infectious complications in these patients is very high. Immunization with the 23-valent polysaccharide pneumococcal vaccine (PPV-23) is required to reduce the risk of severe respiratory infections in this group of patients.

Objectives: The aim of the study was to study the tolerability and safety of PPV-23 in patients with VS.

Methods: At this stage, the study included 13 patients with VS: 10 with vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA) (AAV), 5 with granulomatosis with polyangiitis (GPA), 4 with eosinophilic granulomatosis with polyangiitis (EGPA), 2 - with microscopic polyangiitis (MPA), 1 - with polyarteritis nodosa, 1 - with Takayasu’s arteritis (AT); of which 10 women, 3 men, aged 22 to 76 years. 9 (69%) patients were older than 50 years. Remission of the disease was observed in 1 patient (EGPA), in 3 - low disease activity, in 9 - active vasculitis (9 with AAV, BVAS from 4 to 13). All patients received glucocorticoids (GC): 2 - 55-60 mg/day, 9 - 10-20 mg/day, 2-2.5-5 mg/day; 5 - bDMARD: 4 - rituximab (RTM), 1 - NF inhibitors; 11 - cytostatics (CS): 5 - methotrexate (MTX). Two patients were on induction therapy (GC 55-60 mg + CPh) with a plan to switch to RTM. Only 1 patient with EGPA received HA as monotherapy. The 23-valent polysaccharide pneumococcal vaccine was administrated subcutaneously in 0.5 ml (1 dose). The follow-up period was 1-6 months.

During the visits, standard clinical and laboratory tests and the determination of antibodies to S.pneumoniae were carried out.

Results: Vaccination tolerance was good in all patients. One (7.7%) patient with EGPA (in remission) had a mild local reaction (pain at the injection site) within 1 day. Another 1 (7.7%) patient with severe concomitant pathology (EGPA + multiple sclerosis) had a general reaction in the form of a transient increase in weakness in the lower extremities for up to 5 days (this symptom was manifestation of polyneuropathy, persisted earlier, and to a greater extent was associated with multiple sclerosis than with EGPA). Vaccinal reactions were completely reversible and did not require additional prescriptions. During the follow-up period, no deterioration in the course of VS was recorded, and no new autoimmune phenomena, both laboratory and clinical, were noted in any of them. 7 (53.8%) patients (all 5 with GPA, 2 with EGPA) had ENT lesions (destructive rhinosinusitis (5), sinusitis (2)) with frequent exacerbations. 1 patient with GPA reported a significant improvement in the course of the ENT organs (no exacerbations of rhinosinusitis, disappearance of nasal discharge for 5 months). In the remaining 6 patients, the condition also remained stable, no progression of sinusitis was noted during the observation period (1-4 months). No infections of the lower respiratory tract were registered during the observation period.

Conclusion: 1. All patients had a high risk of infectious complications: combined immunosuppressive therapy (92% of patients), age over 50 years (69% of patients), severe lesion of ENT organs (53.8% of patients). 2. The tolerance of PPV-23 vaccination was good. 3. There was no deterioration in the course of VS.

Disclosure of Interests: None declared


AB0619

RATIONAL AND DESIGN OF THE 52-WEEK, RANDOMIZED, PHASE 3, HEAD-TO-HEAD MANDARA STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BENRALIZUMAB, A HUMANIZED, ANTI-INTERLEUKIN-5 RECEPTOR A MONOCLONAL ANTIBODY IN REFRACTORY OR RELAPSING EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS

M. Wechsler 1,2, P.A. Merke 2, 3, N. Makulova 4, C. Baldi 2, 5, R. Katial 6, U. M. Martin 7, E.R. Rubbertson 8, A. J. Ito 9, J. Castells 2, 3, L. Bösingess Sjö 10, E. A. Duncan 11, R. Furie 12, A. J. G. Weersink 13, 1AstraZeneca, Data Science & AI, Gaithersburg, United States of America; 2University of Pennsylvania, Division of Rheumatology, Philadelphia, United States of America; 3AstraZeneca, Late-stage development, Respiratory & Immunology, Gothenburg, Sweden; 4AstraZeneca, Late-stage development, Respiratory & Immunology, Durham, United States of America; 5AstraZeneca, Late-stage development, Respiratory & Immunology, Gothersburg, United States of America; 6AstraZeneca, Data Science & AI, Galthersburg, United States of America; 7AstraZeneca, Early Respiratory & Immunology, Cambridge, United Kingdom; 8AstraZeneca, Biopharmaceuticals Medical, Gaithersburg, United States of America

Background: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss syndrome, is a rare, potentially organ- and life-threatening disease characterized by systemic eosinophilia, airway disease, and multi-system small-vessel vasculitis. Management of EGPA generally focuses on reducing active inflammation using corticosteroids and immunosuppressants, both of which are associated with serious adverse effects and incomplete disease control. High blood eosinophil (bEOS) levels are a central component of the pathophysiology of EGPA, and studies have shown that bEOS-reducing therapies, such as mepolizumab, are effective in some patients with EGPA. Benralizumab is a humanized, afucosylated, anti-interleukin-5 receptor α monoclonal antibody that induces direct, rapid, and near complete depletion of eosinophils through antibody-dependent cell-mediated cytotoxicity. Eosinophil depletion by benralizumab is effective in eosinophilic asthma, corticosteroid-dependent asthma, and has shown promise in a small phase 2 trial in hypereosinophilic syndrome, which has overlapping organ systems involvement and similar clinical features to EGPA. Collectively, the evidence from these indications supports examination of the efficacy of benralizumab as an eosinophil-depleting therapy in patients with EGPA.

Objectives: The phase 3, head-to-head MANDARA (NCT04157348) study will evaluate the efficacy and safety of benralizumab versus mepolizumab in adults with relapsing or refractory EGPA.

Methods: This randomized (1:1), multicentre, double-blind (DB), active-controlled study is enrolling adults with a diagnosis of EGPA, defined as a history of asthma and eosinophilia together with ≥2 additional clinical features, a history of relapsing or refractory disease, and maintained on a stable prednisolone/predosinone dose ≥7.5 mg/day for ≥4 weeks prior to baseline. Patients will receive either benralizumab 30 mg or mepolizumab 300 mg every 4 weeks over the 52-week DB study period. Patients who complete the DB treatment period will be eligible to continue into an optional open-label extension, during which all patients will receive benralizumab (Figure 1). The primary endpoint is the proportion of patients who achieve EGPA remission, defined as a Birmingham Vasculitis Activity Score (BVAS)=0 and predosinone dose ≤4 mg/day, at both Week 36 and 48 of the DB period, and it will assess non-inferiority (NI) between benralizumab and mepolizumab. Secondary endpoints include duration of remission, time to first EGPA relapse, annualized relapse rate, average daily predosinone dose between Weeks 48 to 52, and the proportion of patients who achieve and maintain remission from Week 24 through the end of the DB period. Other endpoints include safety, symptoms, health-related quality of life, healthcare utilization due to EGPA, and tolerability. The trial also includes a non-interventional patient interview sub-study, which will collect data related to patients’ EGPA personal experience and perceived impact on study treatment, and a mechanistic sub-study, which will explore the pharmacodynamic response and mechanism of action of benralizumab compared to mepolizumab.
Patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) need anticoagulants?  

G. Tarasov 1, O. Egorova 2, A. Kolomeychuk 1, T. Reshetnyak 1,2

OBJECTIVES: The study included 45 patients with AAV (15 - with granulomatosis with polyangiitis (GPA), 15 - microscopic polyangiitis (MPA), and 15 - eosinophilic granulomatosis with polyangiitis (EGPA), aged 23 to 73 years. Duration of the disease was in 6 patients had <12 months, in 20 - 1-5 years, in 6 - >10 years. High AAV activity were registered in 13 patients, 21 - moderate activity (BVAS < 5), 2 - remission (BVAS 0-1 points). The VDI damage index in 5 patients was 0, in 30 – from 1 to 3, in 10 – > 3 points. Glucocorticoids (GC) received 44% of patients with a dose of 5-20 mg/day, 16% >20-40 mg/day, 4% >40-60 mg/day, AC 23 (51%) of 45 patients took AC. Blood clotting parameters were measured in 40 patients, including activated partial thromboplastin time (APTT), thrombin time (TT), soluble fibrin monomer complexes (SFMC), the number of platelets, 22 of them received AC.

RESULTS: Thrombosis in the past history was registered in 8 (18%) patients, 7 of them continued taking AC. 16 patients received AC without thrombosis for prevention events. Patients with GPA received AK more often than patients with MPA and EGPA (73%, 40%, 40%, respectively).

AC were prescribed in 51% of patients. AC were prescribed to 51% of patients receiving GC at a dose of up to 20 mg/day and 44% of patients with a dose of GC above 20 mg/day. The appointment of anticoagulants was associated with the duration of the disease. With a disease duration of up to 1 year, AK was prescribed in 33% of cases, with a duration of > 10 years - in 67% of cases. 59% of patients received AC with BVAS>5, 38% of patients - with BVAS<5. The following AC were prescribed to patients: direct oral AC (DOAC) in 16 (69.6%), unfractionated heparin (UH) - 1, low molecular weight heparins (LMWH) -6, LMWH (46%) and DOAC (54%) were prescribed with the same frequency to patients with BVAS<5, while DOAC (87.5%) prevailed in patients with BVAS>5. Hemorrhagic complications during the follow-up period were not registered in any case. Prolongation of APTT, TT was not significantly noted against the background of AC. I. There was a shortening of APTT in 14 (35%) of 40 patients, TT in 1 (2.5%). An increase in the level of fibrinogen was recorded in 11 (27.5%) patients and in all 40 patients there was an increase in SFMC, which was an indicator of thrombotic readiness. Increased fibrinogen levels were associated with AAV activity (3 out of 11 had a history of thrombosis).

CONCLUSION: Our retrospective analysis revealed that 51% of patients with AAV received AC, they were more often prescribed with active AAV and more often with GPA. Our retrospective analysis showed that 51% of patients with AAV received AC, more often with active AAV and more often with GPA.

Background: Granulomatosis with polyangiitis (GPA) is the second most frequent vasculitis in Germany with an annual incidence of 34 per million and a prevalence of 210 per million [1]. GPA is characterized by its chronic course, frequent relapses, significant overall morbidity and mortality, a substantial socio-economic impact. Multorgan involvement affecting the respiratory tract, kidney, and other organs is common. Limited variants also occur [2]. So far, prospective long-term observational data on the disease course of GPA are missing in Germany. Therefore, the Joint Vasculitis Registry in German-speaking countries (GeVAS) has been established to follow the course of patients recently diagnosed with vasculitis or a change of their treatment due to a relapse (inception cohort). The GeVAS registry allows long-term follow-up of a substantial cohort of vasculitis patients in a multicenter setting.

Objectives: To present the first data on the follow-up of newly diagnosed and relapsing GPA enrolled in the GeVAS registry.

Methods: GeVAS is a prospective, web-based, multicenter, clinician-driven registry for the documentation of organ manifestations, damage, long-term outcomes, and therapy regimens in various types of vasculitis. Recruitment started in June 2019. By January 2022, 17 centers in Germany were initiated and started enrolling patients. Meanwhile, more than 350 patients have been documented in the registry. Sites in Austria and the German-speaking cantons of Switzerland will be integrated soon [3].

Results: By mid-October 2021, the participating centers included 113 patients with GPA. The majority of patients were PR3-ANCA positive and affected by general symptoms, ENT, lung, renal, and neurological involvement. Patients commonly received cyclophosphamide or rituximab in combination with glucocorticoids for the induction of remission. Fewer patients received methotrexate or other immunosuppressants. Patient characteristics and therapy are summarized in Table 1.

Table 1. Patient characteristics (n = 113). *Unless otherwise specified.

<table>
<thead>
<tr>
<th>Category</th>
<th>Feature</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Age (years); median [range]</td>
<td>60 [51 - 70]</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>61 (54.0)</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>52 (46.0)</td>
</tr>
<tr>
<td>Reason for inclusion in therapy</td>
<td>Newly diagnosed vasculitis</td>
<td>57 (51.4)</td>
</tr>
<tr>
<td></td>
<td>Relapse</td>
<td>56 (49.6)</td>
</tr>
<tr>
<td>ANCA status</td>
<td>PR3-ANCA</td>
<td>99 (87.6)</td>
</tr>
<tr>
<td></td>
<td>MPO-ANCA</td>
<td>4 (3.6)</td>
</tr>
<tr>
<td></td>
<td>ANCA negative</td>
<td>9 (7.9)</td>
</tr>
<tr>
<td>Organ manifestation</td>
<td>General symptoms</td>
<td>86 (76.1)</td>
</tr>
<tr>
<td></td>
<td>ENT</td>
<td>69 (61.1)</td>
</tr>
<tr>
<td></td>
<td>Lung/Thorax</td>
<td>66 (58.4)</td>
</tr>
<tr>
<td></td>
<td>Renal</td>
<td>35 (31.0)</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular</td>
<td>7 (6.2)</td>
</tr>
<tr>
<td></td>
<td>GI</td>
<td>3 (2.7)</td>
</tr>
<tr>
<td>Therapy</td>
<td>Glucocorticoid</td>
<td>102 (90.3)</td>
</tr>
<tr>
<td></td>
<td>Rituximab</td>
<td>56 (49.6)</td>
</tr>
<tr>
<td></td>
<td>Cyclophosphamide</td>
<td>37 (32.7)</td>
</tr>
<tr>
<td></td>
<td>Methotrexate and other immunosuppressants, respectively</td>
<td>26 (23.0) and 19 (16.8), respectively</td>
</tr>
</tbody>
</table>

Conclusion: Here, we present the first interim analysis of the GeVAS registry. Clinical manifestations of GPA reported herein show less frequent renal involvement in comparison with a recent report from another European registry (POLVAS) and an UK study [4, 5]. This is potentially related to the predominance of recruiting rheumatology centers thus far. By contrast, respiratory tract involvement is more frequent and PR3-ANCA less common in Japan [5]. Further data are prospectively documented and a follow up analysis is in progress.

REFERENCES:

Acknowledgements: GeVAS was supported by unrestricted grants by: DGRh, John Grube Foundation, Vifor and Roche Pharma.
the use of cyclophosphamide which has an undesirable safety profile, limiting its use in patients. AZA has shown to be effective at maintenance, however rates of relapse on AZA are high.

Rituximab (RTX) is a biologic with a high specificity to B cells. Its mechanism of action (B cell apoptosis) may mean that it can be used for both the induction and maintenance of remission, with a superior long-term safety profile.

**Objectives:** To conduct a systematic review of literature to determine the efficacy of rituximab as a remission inducing and maintaining agent.

**Methods:** A systematic review of literature was conducted by searching PubMed and Cochrane library with the search phrase “rituximab AND ANCA-associated vasculitis.” The following criteria was then applied: randomised controlled trial (RCT) in the English language. Only original papers were accepted if it pertained to RTX for either induction or maintenance of remission.

**Results:** 1008 papers were initially identified and after the search strategy was applied 9 RCTs were analysed. The RAVE trial compared RTX to CYC in 197 patients with AAV in a double-blind double-dummy trial. The result of the RAVE trial indicated that RTX was as effective as CYC at maintaining remission. The RITUXVAS trial, which was partially blinded and had a sample of 44 patients also came to the same conclusion. Both the RAVE and RITUXVAS trials also showed that an initial dose of RTX was as effective as continuous immunosuppression over the trial length.

Further RCTs were published from the RAVE and RITUXVAS studies including a follow up of patients from the RITUXVAS trial at 24 months which showed no increased rates of relapse or adverse events between the groups. The RAVE study also showed that RTX was effective to be used on multiple occasions to induce remission irrespective of the initial remission inducing agent. The MAINRITSAN1 study was a non-blinded randomised trial which compared RTX with azathioprine for maintenance in 115 patients with AAV. The results of this trial showed that RTX was superior than AZA at maintenance with only 5% on RTX compared with 29% on AZA relapsing. The long-term follow up of patients in the trial, showed that at 60 months, patients who received RTX were less likely to have relapsed.

The MAINRITSAN2 trial indicated that there was no difference between a fixed vs tailored RTX dose, meaning that a lower tailored dose was as effective as a higher fixed dose. The MAINRITSAN 3 paper was a double-blind trial that indicated that biannual RTX for maintenance was superior than placebo at maintaining remission.

Conclusions: RTX is as effective as CYC at inducing remission, with both the RAVE and RITUXVAS trials sharing similar conclusions. Currently the research indicates that an initial dose of RTX can maintain remission at similar rates as continuous AZA, however its superiority is yet to be determined. The MAINRITSAN 1 trial was unblinded in its protocol with the data indicating it drastically overestimated the efficacy of both RTX and AZA. Therefore, more research is needed to validate the claim that RTX is superior than AZA at maintenance.

**References:**


Acknowledgements: I would like to thank Dr Marwan Bukhari for his continued support and feedback during this project.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2384

**AB0624 PATIENTS WITH VASCULITIS HAVE A HIGH PREVALENCE OF CORONARY MICROVASCULAR DYSFUNCTION**


1Massachusetts General Hospital; 2Harvard Medical School; 3Division of Rheumatology, Allergy, and Immunology; Boston, United States of America; 4Brigham and Women's Hospital; 5Harvard Medical School, Heart and Vascular Center; 6Division of Cardiovascular Medicine, Department of Medicine, Boston, United States of America; 7Brigham and Women's Hospital, Department of Radiology, Boston, United States of America; 8Massachusetts General Hospital; 9Division of Rheumatology, Allergy, and Immunology, Boston, United States of America; 10Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, United States of America; 11Brigham and Women's Hospital, Heart and Vascular Center; 12Division of Cardiovascular Medicine, Department of Medicine, and 13Division of Radiology, Boston, United States of America

**Background:** Vasculitides are a heterogenous group of diseases characterized by intense vessel wall inflammation, endothelial injury, and systemic inflammation. Several vasculitides are associated with high risk of cardiovascular (CV) disease, an important source of morbidity and mortality in this population. This excess CV risk is attributed both to a high burden of traditional risk factors and to inflammation, but this remains poorly studied. Indeed, inflammation is a known risk factor for CV disease and implicated in coronary microvascular dysfunction (CMD) which may precede obstructive coronary artery disease (CAD).

**Objectives:** We sought to assess whether vasculitis is associated with CMD in the absence of obstructive CAD.

**Methods:** We retrospectively identified subjects with systemic vasculitis who underwent symptom prompted rest/stress myocardial perfusion PET. Patients with an abnormal myocardial perfusion study (summed stress score ≥3) or LVEF<40% were excluded. Controls were identified from the same population and matched on age, gender and cardiovascular risk factors (CAD, hypertension, dyslipidemia, diabetes mellitus, and obesity). Coronary flow reserve (CFR), was calculated as the ratio of myocardial blood flow (ml/min/g) at peak stress compared to rest. CMD was defined as CFR <2.

**Results:** We studied 26 vasculitis cases and 66 matched controls. The most common vasculitides were giant cell arteritis (38%), ANCA-associated vasculitis (31%), and Takayasu atherosclerosis (12%). Median (IQR) time between diagnosis and PET was 6.5 (2.9, 14.2) years. Seven (27%) cases had active vasculitis at the time of PET. Cases and controls were well-matched on age, sex, and CV risk factors (Table 1). Despite a similar prevalence of CV risk factors, coronary flow reserve (reflected by CMD) was abnormal in 38% of vasculitis cases compared to 15% of controls (p=0.004). The mean [SD] CFR was 19% lower in vasculitis cases vs controls (2.11 [0.5] versus 2.6 [0.7], p=0.003).

**Table 1.** The prevalence of coronary microvascular dysfunction in patients with systemic vasculitis without obstructive coronary artery disease

<table>
<thead>
<tr>
<th>Cohort characteristics</th>
<th>Vasculitis (n=26)</th>
<th>Control (n=66)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at PET, years</td>
<td>62 (18)</td>
<td>61 (17)</td>
<td>0.24</td>
</tr>
<tr>
<td>Time from Vasculitis Diagnosis to PET, years (median, IQR)</td>
<td>6.5 (2.9, 14.2)</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Vasculitis Characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>18 (72%)</td>
<td>43 (65%)</td>
<td>0.99</td>
</tr>
<tr>
<td>Large Vessel (e.g., giant cell arteritis)</td>
<td>n/a</td>
<td>n/a</td>
<td></td>
</tr>
<tr>
<td>Takayasu's, n(%)</td>
<td>13 (50%)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Medium Vessel (e.g., polyarteritis nodosa, Kawasaki's arteritis), n(%)</td>
<td>2 (8%)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Small Vessel (e.g., ANCA-associated vasculitis, Henoch-Schonlein Purpura), n(%)</td>
<td>11 (42%)</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Cardiovascular Risk Factors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>12 (46%)</td>
<td>20 (71%)</td>
<td>0.47</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>3 (12%)</td>
<td>2 (32%)</td>
<td>0.84</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>3 (12%)</td>
<td>5 (20%)</td>
<td>0.99</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>4 (15%)</td>
<td>15 (58%)</td>
<td>0.99</td>
</tr>
<tr>
<td>Known CAD, n (%)</td>
<td>0 (0%)</td>
<td>1 (4%)</td>
<td>0.48</td>
</tr>
<tr>
<td>Imaging Findings</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rest myocardial blood flow, ml/min/g</td>
<td>1.0 (0.3)</td>
<td>1.0 (0.3)</td>
<td>0.8</td>
</tr>
<tr>
<td>Stress myocardial blood flow, ml/min/g</td>
<td>2.1 (0.6)</td>
<td>2.6 (1.0)</td>
<td>0.008</td>
</tr>
<tr>
<td>Coronary Flow Reserve, ml/min/g</td>
<td>2.1 (0.5)</td>
<td>2.6 (0.7)</td>
<td>0.003</td>
</tr>
<tr>
<td>Coronary Microvasculature</td>
<td>10 (38%)</td>
<td>11 (15%)</td>
<td>0.004</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2384
Conclusion: Patients with systemic vasculitis, even in the absence of obstructive CAD, have a high prevalence of CMD compared with non-vasculitis patients. These differences were observed despite matching cases and controls on traditional CV risk factors, highlighting the importance of other factors, such as inflammation and vasculitis treatments on CMD and CV disease in this population. CMD is a known independent risk factor for CV mortality. Future prospective studies are needed to understand the relationship between vasculitis, systemic inflammation, and CMD.

Disclosure of Interests: None declared


AB0625
ASSOCIATION BETWEEN CYTOMEGALOVIRUS REACTIVATION AND RENAL PROGNOSIS DURING REMISSION INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS

K. Kawamoto1, N. Oguro2, T. Kida3, S. Omura4, D. Nakagomi5, K. Masatoshi6, N. Takizawa7, A. Nomura7, K. Yui8, N. Kondo9, Y. Yasuhiko10, T. Yanagida11, K. Endo12, S. Hirata13, K. Kawanaga14, K. Matsu11, T. Takeuchi11, K. Ichinose15, M. Kato16, R. Yanai17, Y. Matsuo18, Y. Shimojima19, R. Nishioka20, A. Yamashita21, T. Takata22, T. Ito23, M. Moriyama24, A. Takata25, Y. Miyawaki26, Y. Kawaiho27, T. Ito-Ihara28, T. Kagawuchi29, N. Yajima30, 1Showa University School of Medicine, Division of rheumatology, Tokyo, Japan; 2Kyoto Prefectural University, Inflammation and Immunology, Graduate School of Medical Science, Kyoto, Japan; 3Kyoto Prefectural University of Medicine, Inflammation and Immunology, Graduate School of Medical Science, Kyoto, Japan; 4University of Yamanashi Hospital, Department of Rheumatology, Chuo-shi, Japan; 5Japanese Red Cross Society Kyoto Daichi Hospital, Center for Rheumatic Disease, Kyoto, Japan; 6Chubu Rosai Hospital, Department of Rheumatology, Nagoya, Japan; 7St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan; 8Japanese Red Cross Society Kyoto Daihi Hospital, Department of Rheumatology, Kyoto, Japan; 9Kyoto Katsura Hospital, Department of Nephrology, Kyoto, Japan; 10Toei General Hospital, Department of Respiratory Medicine and Allergy, Seto, Japan; 11Kagoshima University Hospital, Department of Hematology and Rheumatology, Kagoshima, Japan; 12Tottori Prefectural Central Hospital, Department of General internal medicine, Tottori, Japan; 13Hirosima University Hospital, Department of Clinical Immunology and Rheumatology, Hiroshima, Japan; 14Department of Internal Medicine, St. Marianna University School of Medicine, Division of Rheumatology and Allergy, Kawasaki, Japan; 15Hyogo College of Medicine, Department of Diabetes, Endocrinology and Clinical Immunology, Nishinomiya, Japan; 16Osaka Medical and Pharmaceutical University, Department of Internal Medicine (IV), Takatsuki, Japan; 17Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Department of Immunology and Rheumatology, Nagasaki, Japan; 18Hokkaido University, Division of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Sapporo, Japan; 19Tokyo Kyosai Hospital, Department of Rheumatology, Tokyo, Japan; 20Shinshu University School of Medicine, Department of Medicine (Neurology and Rheumatology), Matsumoto, Japan; 21Kanazawa University, Department of Rheumatology, Graduate School of Medical Science, Kanazawa, Japan; 22Tottori University, Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Yonago, Japan; 23Tottori University, Division of Gastroenterology and Nephrology, Yonago, Japan; 24Shimane University Hospital, Division of Nephrology, Izumo, Japan; 25Sasebo Chuo Hospital, Rheumatic Disease Center, Sasebo, Japan; 26Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama, Japan; 27University Hospital, Kyoto Prefectural University of Medicine, The Clinical and Translational Research Center, Kyoto, Japan; 28Tokyo University of Pharmacy and Life Sciences, Department of Practical Pharmacy, Tokyo, Japan

Methods: This retrospective cohort study enrolled microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis patients at 25 sites in Japan who had a first or severe relapse between January 2017 and June 2020. Of these, patients with MPA or GPA who had a positive renal lesion score on BVAS (version 3) at baseline, or vasculitis findings on renal biopsy, CMV assayed by 48 weeks of treatment, were included. Patients were divided into two groups based on the presence or absence of a positive CMV antigen test during the remission induction phase (0–48 weeks of treatment). Outcomes were the rate of change in estimated glomerular filtration rate (eGFR) at 48 weeks after initiation of treatment in both groups, as determined by (eGFR at 48 weeks - eGFR at the initiation of treatment)/eGFR at the initiation of treatment; where lower values were associated with worse renal function. General linear models adjusted for age, gender, presence of diabetes or chronic kidney disease, and the use of rituximab or cyclophosphamide were generated.

Results: A total of 387 patients had CMV antigen measured during ANCA-associated vasculitis treatment, of which 164 had renal involvement and eGFR measured at 48 weeks. Seventy-seven (47.0%) were male and the median age was 75 years (range 69–80 years). CMV reactivation was observed in 44 patients (26.8%). The beta coefficient of multiple regression analysis with CMV positive as 1 and negative as 0 was 0.08 (95% confidence interval -0.13 to 0.29) (p = 0.47). The rate of change in eGFR was higher in the CMV positive group, but not statistically significantly.

Conclusion: Contrary to our hypothesis, renal prognoses tended to be better when CMV reactivation was observed. The patients in the CMV reactivation group may have been treated more aggressively, and some patients with a poor prognosis who were not followed up for 48 weeks dropped out. Further research investigating the adjustment of treatment methods is required.

Disclosure of Interests: None declared


AB0626
PREVALENCE OF FRAILTY IN AN INTERNET-BASED COHORT WITH A SELF-REPORTED DIAGNOSIS OF VASCULITIS – THE VASCSTRONG STUDY

S. E. Sattui1, J. Stadler2, C. Burroughs3, K. Larsson4, P. A. Merkel5, R. Spiera6, 1University of Pittsburgh, Medicine, Division of Rheumatology and Clinical Immunology, Pittsburgh, United States of America; 2Vasculitis Foundation, NA, Kansas City, United States of America; 3University of South Florida, Health Informatics Institute, Tampa, United States of America; 4PennMedicine, Medicine, Division of Rheumatology, Philadelphia, United States of America; 5Hospital for Special Surgery Main Hospital, Medicine, Division of Rheumatology, New York, United States of America

Background: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in patients with vasculitis. The prevalence of frailty in patients with vasculitis remains unexplored.

Objectives: To describe the prevalence of self-reported frailty in patients with vasculitis.

Methods: VascStrong is a longitudinal study utilizing the Vasculitis Patient-Powered Research Network (VPPRN), an internet-based prospective longitudinal cohort. Data elements collected included type of vasculitis, demographic, and use of medications. Frailty was measured by the FRAIL scale, a self-report measure which queries on 5 domains: 1. Fatigue, 2. Resistance (inability to climb 10 stairs), 3. Ambulation (inability to walk several blocks), 4. Illnesses (≥5/11 comorbidities), and 5. Loss of weight (≥5% weight loss in the last year). Patients were classified as robust, pre-frail, and frail based on 0, 1-2, or ≥3 criteria, respectively.

Results: The survey collected information from October 8, 2021-January 15, 2022. For this preliminary analysis, 228 responses were included. Clinical characteristics and study data are outlined in Table 1. Prevalence of robustness, pre-frailty, and frailty was 28.5%, 47.8%, and 23.7%, respectively. The majority of patients with each form of vasculitis were rated as frail or pre-frail. Among the individual FRAIL domains, fatigue and loss of weight were the most frequent (48.7% and 42.5%, respectively) while illnesses, was the least common (3.5%). When compared to robust patients, frail and pre-frail patients were younger, more frequently female, more likely to be obese and reported more frequent use of glucocorticoids. Patients with urticarial vasculitis and Takayasu’s arteritis were more commonly pre-frail or frail, compared to patients with other types of vasculitis.
Table 1. Characteristics for overall cohort and by frailty classification

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall N = 228</th>
<th>Robust N = 65</th>
<th>Pre-frail N = 109</th>
<th>Frail N = 54</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>57.3 (15.3)</td>
<td>62.4 (14.8)</td>
<td>55.1 (15.6)</td>
<td>57.1 (14.3)</td>
</tr>
<tr>
<td>Sex, female</td>
<td>163 (71.6%)</td>
<td>49 (76.2%)</td>
<td>93 (85.3%)</td>
<td>21 (38.6%)</td>
</tr>
<tr>
<td>Race, white</td>
<td>204 (89.9%)</td>
<td>60 (92.3%)</td>
<td>98 (89.9%)</td>
<td>46 (85.2%)</td>
</tr>
<tr>
<td>Ethnicity, non-Hispanic</td>
<td>195 (85.6%)</td>
<td>57 (87.7%)</td>
<td>97 (87.0%)</td>
<td>41 (75.9%)</td>
</tr>
<tr>
<td>Disease duration, years, mean</td>
<td>8.5 (19)</td>
<td>8.6 (6.8)</td>
<td>8.4 (8.4)</td>
<td>8.8 (8.0)</td>
</tr>
</tbody>
</table>

Data presented as n (%), unless specified otherwise. *Other diagnosis: Behçet’s disease, primary amylgitial central nervous system, cryoglobulinic vasculitis, IgA vasculitis, polycystic nodule, and other/suspected diagnosis* Based on World Health Organization Body Mass Index categories

Conclusion: Self-reported frailty or pre-frailty is prevalent in the majority of patients with multiple forms of vasculitis. Future analysis will focus on identifying factors associated with frailty in patients with vasculitis, to allow earlier identification and prevention in this population at high-risk for frailty.

Acknowledgements: The investigators want to thank all participants.

Disclosure of Interests: Sebastian E. Sattui Grant/research support from: receives research funding related to clinical trials by AstraZeneca (MANDARA), John Stadler: None declared, Cristina Burroughs: None declared, John Stadler: None declared, Kaien Larson: receives research funding related to clinical trials by AstraZeneca (MANDARA), John Stadler: None declared, Kaien Larson: receives research funding related to clinical trials by AstraZeneca (MANDARA), John Stadler: None declared, Kaien Larson: receives research funding related to clinical trials by AstraZeneca (MANDARA).

Background: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire is a 29-item disease-specific PRO measure for AAV [1]. The Italian version of the AAV-PRO questionnaire (AAV-PRO_ita) was translated in collaboration with Oxford and Bristol University (UK) and was preliminarily tested on a single-center Italian cohort [2].

Objectives: The main objective of this multicentric study was to assess the internal consistency, feasibility, and reliability of the AAV-PRO_ita in a large cohort of Italian AAV patients. The secondary objective was to investigate the clinical characteristics of AAV patients associated with AAV-PRO_ita domains.

Methods: The AAV-PRO_ita is described with the following disease domains: (1) organ-specific and systemic symptoms and signs (SSS); (2) physical function (PF); (3) social and emotional impact (SEI). In this study, Italian-speaking AAV patients were recruited from Italian Centres (N=13) with a large experience in the diagnosis and treatment of systemic vasculitis, belonging to the Vascultis Study Group of the Italian Society of Rheumatology. Inclusion criteria were: a confirmed diagnosis of GPA (SSS >0.3, p-value<0.001). The total time to complete the questionnaire was one hour. The AAV-PRO_ita was completed by 229 AAV-patients (56.3% women) with a median age of 61 (IQR 51-72) were recruited and completed the questionnaires. The subtype of AAV was mainly GPA (131, 57.2%), followed by EGPA (58, 25.3%), and MPA (40, 17.5%). Median BIASV3 at baseline was 0 (IQR 0-3), whereas the median BIASV3 at the onset of disease was 14 (IQR 9-20). Participants had a median duration of disease of 67 (IQR 24-126) months. Patients who experienced at least one relapse, one hospitalization, and one severe infection were 40.2%, 53.3%, and 24%, respectively. 83% of the patients were on immunosuppressant therapy and 71.6% were still receiving glucocorticoids.

AAV-PRO_ita questionnaire had good internal consistency (Cronbach's Alpha 0.81-0.93) and good test-retest reliability (ICCs range 0.93-0.96). Item response rates were high overall (maximum 0.87% missing data), supporting the feasibility of the questionnaire.

Concerning the domains of the questionnaire, female AAV patients scored higher (i.e. worse) in all three domains, especially in the SEI domain (p-value<0.001). Older participants (>65 years) scored higher in the PF domain (p-value<0.03) in all three times of self-completions of the questionnaire. The ongoing treatment (i.e. worse) in all three domains, especially in the SEI domain (p-value<0.001). Concerning the domains of the questionnaire, female AAV patients scored higher (i.e. worse) in all three domains, especially in the SEI domain (p-value<0.001).

EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ita) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS

F. Trope1, M. Isola2, M. De Martino3, R. Padoan2, M. L. Urban4, S. Monti3, S. Sartorelli4, A. Gliolo1,2, L. M. Argolini5, C. Marvisi10, F. Ferro6, G. Cassone12, F. Motta13, A. Berti13, E. Conticini13, A. Manfredi13, F. Frediani14, R. Bortotlli14, C. Salmi15,16, C. Baldini15, G. Emms16, R. Caporali8, M. Rossini7, L. Dagna6, C. Montecucco17, F. Schiavoni17, C. Salvarani17, S. De Vita18, P. Quarto18 on behalf of Italian Study Group on the Systemic Vasculitides. 1Clinic of Rheumatology, Department of Medicine, University of Udine, Udine, Italy; 2Institute of Medical Sciences, Department of Medical Area, University of Udine, Udine, Italy; 3Division of Rheumatology, Department of Medicine DIMED, University of Padua, Padova, Italy; 4Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy; 5IRCCS Fondazione Policlinico San Matteo, Rheumatology Department, Pavia, Italy; 6IRCCS San Raffaele Telethon Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UniRRA), Milano, Italy; 7Policlinico Borgo Roma, Rheumatology Unit, University of Verona, Verona, Italy; 8Division of Rheumatology, University of Padova, Padova, Italy; 9ASST Istituto Gaetano Pini - CTO, Division of Clinical Rheumatology, Milano, Italy; 10IRCCS, General Hospital Arcispedale Santa Maria Nuova, Unit of Rheumatology, University of Modena and Reggio Emilia, Reggio Emilia, Italy; 11Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; 12Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 13Humanitas Clinical and Research Center - IRCCS, Rheumatology and Clinical Immunology, Rozzano (MI), Italy; 14Santa Chiara Hospital, Rheumatology Unit, Trento, Italy; 15Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy; 16Humanitas University, Department of Biomedical Sciences, Milano, Italy

AB0627 SYSTEMATIC LITERATURE REVIEW INFORMING THE 2022 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS: FOCUS ON DIAGNOSTIC AND FOLLOW-UP PROCEDURES

B. Sanchez-Alamo1, J. Schirmer1, S. Monti3, B. Hellmich, D. Jayne5, Lund University, Skåne University Hospital, Nephrology, Lund, Sweden; 2University
Background: The 2008 and 2016 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitides (AAV)\(^1\)\(^2\) have supported clinicians with recommendations for the accurate diagnosis, monitoring and for the management of the long-term complications of patients with ANCA-associated vasculitides (AAV). Since the publication of the last EULAR guidelines, several high-impact research articles have provided further evidence to improve diagnosis and monitoring of AAV-patients.

Objectives: The aim of this systematic review was collecting evidence supporting the 2022 update of the AAV management recommendations.

Methods: The recommendations were developed based on the 2014 EULAR standardized operating procedures (SOP)\(^3\). Areas of interest were adopted from the 2016 recommendations and updated by identifying additional items through a Delphi exercise. Key questions were framed in the PICO (Population, Intervention, Comparator, Outcome) format. Keywords identifying topics of interest for the diagnosis and follow up were generated based on the PICO questions and then incorporated into a search string. A systematic literature search (SLR) was performed according to the EULAR SOP. PubMed (Medline), Embase and the Cochrane Library databases were searched for articles providing data on the search questions. Abstracts of the annual meetings of EULAR, ACR, ERA-EDTA, ASN, and the Vasculitis and ANCA Workshops were also screened, but restricted to randomized controlled clinical trials (RCTs).

After deduplication, publications were first sorted by title and abstract and then full text review was done for eligible articles. The data were extracted from included articles and grouped according to the PICO questions. Data extraction results were collected in evidence tables. The Cochrane revised tool for assessing risk of bias for RCTs (RoB2), ROBINS-1 for observational studies, QUADAS II for diagnostic accuracy studies and AMSTAR II for meta-analyses were used for bias assessment. Evidence was categorized based on the GRADE system as per EULAR SOP\(^3\).

Results: Based on the results of the Delphi, 3 topics related to diagnosis and follow-up were identified that were transformed into PICO questions: the impact of diagnostic biopsies and positive ANCA testing to support the clinical diagnosis of AAV and the impact of clinical parameters and biomarkers on disease-related outcomes and treatment-related adverse events (Table 1). Other items that received lower scores in the Delphi exercise were added in the format of subquestions (e.g. diagnostic imaging). Based on these research questions, search strings for the SLR were created. The SLR was still ongoing at the time this abstract has been written and results of the SLR will be presented at the meeting.

Table 1. Topics of interest for diagnostic and follow-up testing identified in the Delphi exercise

<table>
<thead>
<tr>
<th>Patients</th>
<th>Diagnostic / follow-up procedure</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulomatosis with Polyangiitis</td>
<td>Tissue biopsy</td>
<td>Confirmation of diagnosis of ANCA-associated vasculitides</td>
</tr>
<tr>
<td>Microscopic Polyangiitis</td>
<td>ANCA testing</td>
<td>Disease-related outcomes</td>
</tr>
<tr>
<td>Eosinophilic Granulomatosis with Polyangiitis</td>
<td>Imaging Biomarkers</td>
<td>Treatment-related adverse events</td>
</tr>
</tbody>
</table>

Conclusion: This SLR identified recent developments affecting key areas of AAV diagnosis and follow-up. The results of this SLR provide systematic evidence to inform the 2022 update of the EULAR recommendations for the management of AAV, which will also be presented at this meeting.

REFERENCES:


Acknowledgements: The project is funded by EULAR.

Disclosure of Interests: Beate Schanz-Alamo: None declared, Jan Schirmer: None declared, Sara Monti: None declared, Bernhard Hellmich Speakers bureau: Abbvie, BMS, Chugai, GSK, MSD, Novartis, Pfizer, Roche, Vifor, Consultant of: Boehringer, BMS, Chugai, GSK, InflaRx, Novartis, Roche, Vifor, David Jayne Speakers bureau: Vifor, Consultant of: AstraZeneca, Boehringer, BMS, Chemocentryx, Chugai, GSK, Novartis, Roche, Tokai.


Conclusion: Although the causality cannot be established on current evidence, the COVID-19 vaccine can probably trigger glomerulonephritis associated with ANCA, primarily anti-MPO type. We need a bigger cohort to identify patients predisposed for disease development or relapse after the COVID-19 vaccine.

REFERENCES:

Background: Preventing accrual of organ damage is a major goal in the treatment of Behçet’s Syndrome (BS). The BS Overall Damage Index (BODI) is the first damage assessment tool developed and preliminarily validated for BS.

Objectives: To assess the prevalence, extent, and determinants of organ damage accrual in the BODI validation cohort over 24 months of follow-up.

Methods: Overall, 189 patients from the multicenter BODI cohort underwent a 24 ±3 months follow-up (FU) visit. Demographics, ongoing medication, Behçet’s Disease Current Activity Form (BDCAF) score, Physician (PGA) and Patient Global Assessment (PtGA) of disease activity, disease relapsing (defined by any treatment change due to increased disease activity), and the BODI score were recorded at baseline and follow-up. Patients were classified as new BODI damage accrual was defined as any increase ≥1 in the BODI score between baseline and follow-up visit (∆-BODI). Logistic regression models were built to identify factors associated with BODI damage accrual.

Results: The mean age (standard deviation) at enrolment and the disease duration was 46.2 (12.1) and 10.6 (8.3) years, respectively, and 92/189 (48.7%) patients were males. During 24 months, 36 (19.0%) patients had an increase in the BODI score of at least 1 point (mean increase of 1.7 points). The BODI score was increased from 1.6 (2.1) to 1.9 (2.1), with a mean ∆-BODI of 0.3 (0.8). Overall, 61 new BODI items of damage were recorded (Figure 1); 22 (34%) were steroid-related. Demographics, ongoing therapy, Behçet’s Disease Current Activity Form (BDCAF), Physician (PGA) and Patient Global Assessment (PtGA) of disease activity, disease relapsing, defined by any treatment change due to increased disease activity, and the BODI score were recorded at baseline and follow-up visit (∆-BODI). Logistic regression models were built to identify factors associated with BODI damage accrual.

Conclusions: Despite the relatively high disease duration in the studied cohort, organ damage accrual was recorded in a relevant proportion of patients. BODI proved to capture the damage associated with major determinants such as inadequate control of disease activity and prolonged exposure to glucocorticoids.

Table 1. Determinants of organ damage accrual over 2 years of follow-up.

<table>
<thead>
<tr>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Candidate ∆-BODI ≥1</strong></td>
<td><strong>Δ-BODI &gt; 0 (n = 153)</strong></td>
</tr>
<tr>
<td>Males</td>
<td>16 (44.4%)</td>
</tr>
<tr>
<td>Age at enrolment</td>
<td>56.2 (42.9-62.0)</td>
</tr>
<tr>
<td>Disease duration</td>
<td>12.9 (7.2-22)</td>
</tr>
<tr>
<td>Major organ involv.</td>
<td>22 (61.1%)</td>
</tr>
<tr>
<td>BDCAF at BL</td>
<td>3 (0-5)</td>
</tr>
<tr>
<td>BDCAF at FU visit</td>
<td>3.0 (3-5)</td>
</tr>
<tr>
<td>Sjögren’s syndrome</td>
<td>196 (0-147.3)</td>
</tr>
<tr>
<td>cS/P or TNFα ever</td>
<td>24 (66.7%)</td>
</tr>
<tr>
<td>Relapse</td>
<td>9 (25.0%)</td>
</tr>
<tr>
<td>SBO score at BL</td>
<td>1.2 (0-2.0)</td>
</tr>
</tbody>
</table>

Continuous variables are presented as median (IQR). Dichotomous variable is presented as n (%). BODI, Behçet’s Syndrome Overall Damage Index. FU, follow-up. cS/P, conventional immunosuppressant. ∆-BODI increase of BODI score from baseline to the FU visit.

Disclosure of Interests: None declared


AB0631

IMPACT OF BEHÇET’S SYNDROME ON WORK ACTIVITY AND PRODUCTIVITY: RESULTS FROM A SUB-ANALYSIS OF THE BODI PROJECT COHORT.

R. Lacort2, R. Florio1, G. Espinosa3, G. Lapetina1, L. Serpa Pinto1, N. Koukias7, J. Sota6, A. Lo Monaco1, M. Govoni9, L. Cantarini8, G. Bertsias6, J. Correia5, F. Iannone4, R. Cervera3, C. Vasconcelos10, A. Mathieu1, A. Cauli1,2, M. Piga1,2 on behalf of BODI project group. 1University of Cagliari, Medical Sciences and Public Health, Monreale, Italy; 2AO University Clinic and University of Cagliari, Rheumatology Unit, Cagliari, Italy; 3University of Barcelona, Department of Autoimmune Diseases, Hospital Clinic, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 4University of Bari , Rheumatology Unit, Bari, Italy; 5Hospital Santo Antonio Centro Hospitalar do Porto, Unidade de Imunologia Clinica, Porto, Portugal; 6University of Crete, Rheumatology, Clinical Immunology and Allergy Unit, Heraklion, Greece; 7Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, Hippokration University Hospital, Medical School, Thessaloniki, Greece; 8University of Siena , Rheumatology Unit, Siena, Italy; 9University of Ferrara, Rheumatology Unit - AOU S. Anna, Ferrara, Italy; 10University of Porto, UMIB Abel Salazar Biomedical Sciences Institute, Porto, Portugal

Objectives: To evaluate the impact of BS on the patients’ work activity and productivity.

Methods: A sub-cohort of 148 patients from the original Behçet’s syndrome Overall Damage Index (BODI) Project study was enrolled. The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was administered. Demographics, disease duration, comorbidity, major organ involvement, ongoing therapy, Behçet’s Disease Current Activity Form (BDCAF), Physician Global Assessment (PGA), Patient Global Assessment (PtGA), and the BODI were recorded. Multiple regression models were built to investigate the independent effect of BS features on WPAI.

Results: Overall, 97 (65.6%) out of 148 patients who completed the WPAI:GH questionnaire resulted working for pay; 22 out of 97 (27.8%) patients reported missing work in the past week due to their health, accounting for a mean (SD) of 34.4% (17.8%) of their working time (absenteeism). The only factor significantly associated with absenteeism in multivariate analysis was the presence of ocular damage, as assessed by the BODI (OR: 0.255, p = 0.027).

Although 93 patients reported that they worked in the previous week, mean 27.3% (30.7%) of their actual work productivity was impaired due to their health problem (presenteeism), with only 37 (38.5%) patients reporting no such loss. Factors associated with work impairment were female gender (β = 0.319, p = 0.001), higher PGA (β = 0.298, p = 0.035), and an increased BODI score in the last 2 years follow-up (β = 0.235, p = 0.022). None of these factors are associated with absenteeism in multivariate analysis as well as the presence of ocular damage, as assessed by the BODI.

Conclusion: Preventing accrual of organ damage is a major goal in the treatment of Behçet’s Syndrome (BS). The BS Overall Damage Index (BODI) is the first damage assessment tool developed and preliminarily validated for BS.

Disclosure of Interests: None declared

### Table 1. WPALGH questionnaire results

<table>
<thead>
<tr>
<th>Variables</th>
<th>n°</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>148</td>
<td></td>
</tr>
<tr>
<td>Patients working for pay</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Percent work time missed due to health (patients with missed 22 hours)</td>
<td>34.4 (17.8)</td>
<td></td>
</tr>
<tr>
<td>Percent work time missed due to health (patients with missed time &gt; 0)</td>
<td>7.8 (21.7)</td>
<td></td>
</tr>
<tr>
<td>Patients who actually worked in the past seven days**</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>Percent impairment while working due to health</td>
<td>97</td>
<td>273 (30.7)</td>
</tr>
<tr>
<td>Percent impairment while working due to health (pts with % impairment while working &gt; 0)</td>
<td>56</td>
<td>45.4 (27.2)</td>
</tr>
<tr>
<td>Percent activity impairment due to health</td>
<td>148</td>
<td>33.3 (20.6)</td>
</tr>
<tr>
<td>Percent activity impairment due to health (those with % activity impairment &gt;0)</td>
<td>99</td>
<td>49.8 (23.9)</td>
</tr>
</tbody>
</table>

* Patients working for pay who missed at least on hour of work, 22/97 = 22.7%. ** Patients working for pay, but who worked for > 0 hours in the last week = 93/97 = 93% *** Patients with impairment while working > 0 among patients who actually worked in the previous 7 day = 56/93.

**Disclosure of Interests:** None declared


### AB0632 INTRACARDIAC THROMBOSIS AND VASCULAR INVOLVEMENT IN BEHÇET’S DISEASE: TWO SIDES OF THE SAME COIN?

S. Chadik1, H. Khiri1, W. Ammour1, M. Maamar1, H. Harmouchi1, T. Tazi Mezalet1, University Mohammed V - Faculty of Medicine and Pharmacy - University Hospital Center Ibn Sina, Internal Medicine, Rabat, Morocco. 2University Mohammed V - Faculty of Medicine and Pharmacy - University Hospital Center Ibn Sina, Internal Medicine and Clinical Hematology, Rabat, Morocco.

#### Background:
Behçet’s disease (BD) is a relapsing vasculitis that can affect vessels of all sizes and kinds. Intracardiac thrombosis (ICT) is a serious complication of the disease, which usually presents associated to vascular lesions. However, its mechanism of constitution in BD remains unclear and the link between these manifestations has yet not been fully clarified.

#### Objectives:
Our first objective is to describe the clinical characteristics, imaging features, therapeutic management and outcome of these patients. And secondly, to shed some light on the relation between this rare condition and the vascular involvement of the disease.

#### Methods:
This monocentric study was conducted in the University Hospital Center Ibn Sina of Rabat (Morocco), and retrospectively included 312 Behçet patients admitted to the Internal Medicine department between 2010 and 2021. Twelve patients with ICT related to BD were enrolled.

#### Results:
Patients were mostly male (90%) with a mean age of 30 years. ICT was the presenting symptom of BD in half of the cases. In the other half, it was detected with a mean of 6.4 years after the disease onset. Six patients had a history of deep vein thrombosis (DVT) related to BD, either as a single episode (n=3), recurrent episodes (n=2), or as DVT associated to pulmonary artery occlusion (n=1). The most frequent symptoms were dyspnea (50%), chest pain (50%), dry cough (40%) and hemoptysis (30%). Four patients had signs of right cardiac failure. Peripheral vascular manifestations were noted in five patients. The other Behçet’s flares simultaneously observed were mucocutaneous (80%), digestive (10%), ocular (10%) and articular (10%). Immunological parameters were raised in all patients with a median ESR of 49 mm/h and CRP of 51 mg/L. On echocardiography, ICT was always related to the right heart, with an extension to the inferior vena cava in half of the cases. Two patients had also the left cavities involved. Multiple thrombi were visualized in three cases. The associated cardiac lesions observed were pericarditis (50%), tricuspid insufficiency (50%), mitral insufficiency (10%), endomyocardial fibrosis (10%) and myocarditis (10%). The right cavities were dilated among five patients. Pulmonary hypertension was found in 60% of the cases. On CT Chest Angiography, 70% of the patients had pulmonary artery thrombosis and 50% of them had pulmonary artery aneurysms. The other vascular lesions detected were Budd Chiari syndrome with mesenteric ischemia (10%), subtotal internal jugular vein obstruction (10%) and cerebral venous sinus thrombosis (10%). All patients were treated with colchicine, glucocorticoids and immunosuppressants. Eleven patients were put under Cyclophosphamide and one under Methotrexate followed by a TNF- alpha inhibitor. Six patients were also on curative anticoagulation. No death or relapse was reported to our knowledge.

### Conclusion:
ICT is a serious complication that usually occurs in the first years of the BD’s onset, among young men with vascular manifestations. We believe that this strong association is highly suggestive that ICT in BD is a direct consequence of the underlying vasculitis.

#### REFERENCES:

**Disclosure of Interests:** None declared


### AB0633 HEALTH-RELATED QUALITY OF LIFE IN ANCA VASCULITIDES AND RHEUMATOID ARTHRITIS PATIENTS: A CROSS-SECTIONAL COMPARATIVE STUDY

A. Panagiotopoulou1, K. Thomas2, E. Argyriou3, A. Chalkia4, N. Kapsal2, C. Koutsianas5, E. Mavrea6, D. Petras7, D. Bourmpas8, D. Vassilopoulos9, 12nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Athens, Greece; 24th Department of Medicine, National and Kapodistrian University of Athens School of Medicine, Attikon General Hospital, Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, Athens, Greece; 3Sismanoglio General Hospital, Rheumatology Unit, Athens, Greece; 4Hipppokration General Hospital, Nephrology Department, Athens, Greece

#### Background:
ANCA associated vasculitides (AAVs) are rare, serious forms of vasculitides. There are limited data regarding the quality of life in patients with AAVs compared to other chronic inflammatory diseases.

#### Objectives:
The purpose of this study was to compare the quality of life between patients with AAV and those with a chronic inflammatory arthritis such as rheumatoid arthritis (RA).

#### Methods:
Multicenter, cross-sectional study of AAV and RA patients followed in three tertiary referral centers. Data from 1007 healthy controls served as historic controls. HRQoL was assessed with the Short Form 36 Health Survey (SF-36) which includes physical and mental component summary scores (PCS and MCS). Disease activity was assessed with the Birmingham Vasculitis Activity Score version 3 (BVAS 3, for AAVs) and the DAS28-ESR (for RA) respectively.

#### Results:
66 patients with AAVs (GPA 62%, MPA 29% and EGPA 9%, females 56%, mean age 63.4 years, generalized disease 74%, mean disease duration 6.2 years, remission 73%) and 71 with RA (females 56%, mean age 63.3 years, remission 72%) were included. Both AAV and RA patients had significantly lower PCS and MCS scores compared to healthy controls (p < 0.05) while RA patients had lower PCS and MCS scores compared to AAV patients (p < 0.05). According to disease activity status, there was no difference in the SF-36 scores between those with active (BVAS > 1) and inactive (BVAS < 1) AAV, except for the energy-fatigue component (55.0 ± 21.8 vs. 67.2 ± 20.7, p = 0.038) whereas patients with active RA (DAS28-ESR > 3.2) had lower scores for all SF36 components compared to those with low disease activity (DAS28-ESR < 3.2). Additionally, active RA patients had lower both PCS and MCS scores compared to active AAV patients (p < 0.05). AAV patients with increased damage scores (VDI > 3) had lower PCS score compared to those with less organ damage (VDI < 3), (33.9 ± 10.1 vs. 49.1 ± 10.2, p < 0.001) and (40.5 ± 8.6 vs. 48.2 ± 7.6, p < 0.001 respectively). Compared to patients with AAV, RA patients with increased damage had lower score for the pain component compared to AAV patients (37.7 ± 28.6 vs. 61.2 ± 29.5, p = 0.024).

#### Conclusion:
In general, patients with AAV and RA, demonstrate impaired quality of life compared to healthy controls. In the AAV group, quality of life correlated more with organ damage and less with disease activity whereas in RA patients, quality of life correlated both with disease activity and damage. These data emphasize the need for more efficacious therapies for AAV patients that could prevent chronic organ damage and improve quality of life.

#### REFERENCES:

**Acknowledgements:** Supported in part by the Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE) and the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece (DV #12085, 12086).
Disclosure of Interests: None declared


AB0634 VARIABILITY IN PHENOTYPE CLUSTERS IN BEHÇET’S SYNDROME: A SYSTEMATIC REVIEW

B. Macit, K. Akyuz, S. N. Esatoglu, G. Hatemi, 1 Kackar State Hospital, Department of Dermatology, Rize, Turkey; 2 Wayne State University School of Medicine, Department of Internal Medicine, Detroit, United States of America; 3 Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 4 Istanbul University-Cerrahpaşa, Cerrahpaşa Medical Faculty, Behçet’s Disease Research Center, Istanbul, Turkey.

Background: The presence of distinct clinical phenotypes with clustering of certain organ manifestations is well-recognized Behçet’s syndrome (BS). Differences in demographic features, treatment response, and possibly inflammatory pathways involved in the pathogenesis of different phenotypes have been proposed. However, studies from different BS cohorts have shown variability in the phenotypes that were defined.

Objectives: We aimed to explore the causes of variability in clinical phenotype clustering across different countries and cohorts.

Methods: An electronic search was carried out in PubMed to find articles published in or before November 2021, using the keywords of Behçet, cluster and factor analysis. Two reviewers independently performed a screening of titles, abstracts, and full-texts.

Results: Amongst 496 articles searched, 30 full-texts were assessed, and 10 studies were relevant for data extraction. Ten articles studied 12 different cohorts, 3 from China, 3 from Turkey, 2 from Japan, 1 from South Korea, 1 from Israel, 1 from Greece, and 1 from Italy. 9 out of 10 studies demonstrated clustering of organ manifestations (11 cohorts). There were important differences between the clusters that were identified in these studies (Table 1).

Clusters including skin and mucosa manifestations were present in all cohorts, but the skin and mucosa manifestations that clustered together differed from cohort to cohort. Uveitis stood by itself in some studies, whereas it clustered with vascular and central nervous system (CNS) involvement in some cohorts, and certain skin and mucosa lesions in another. Papulopustular lesions (PPL) and arthritis showed a positive correlation in 4 cohorts whereas these manifestations were negatively correlated in 1 cohort. Moreover, no clusters were identified in 1 study. Potential causes of differences in clusters that we have identified in these studies were: study design (database vs multicenter vs single-centre cohort), statistical analysis method (hierarchical cluster vs factor analysis) patient population (pediatric vs adult vs late onset), setting (dermatology vs rheumatology), diagnostic criteria (ISG vs ICBD), disease duration, definition of organ involvement (such as PPL vs folliculitis), or CNS involvement vs dural sinus thrombosis, ascertainment of manifestations (confirmed gastrointestinal involvement vs any diarrhea, lack of ascertainment in diagnosis of nodular lesions as erythema nodosum vs superficial thrombophlebitis), time interval (manifestations throughout the disease course vs manifestations that were active during the last 3 months), and change in the natural history of BS over decades.

Conclusion: Differences in phenotype clusters may result from differences in study characteristics rather than real geographic or ethnic differences. A large study on a large number of patients from different countries and cohorts may identify new clusters that we have not identified in our studies.

Table 1. Clinical phenotype clustering across cohorts

<table>
<thead>
<tr>
<th>Author, year</th>
<th>n</th>
<th>Cluster 1</th>
<th>Cluster 2</th>
<th>Cluster 3</th>
<th>Cluster 4</th>
<th>Cluster 5</th>
<th>Cluster 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zou, 2021</td>
<td>69</td>
<td>MC (G, EN, PPL)</td>
<td>U, V, NBS</td>
<td>GI</td>
<td>J</td>
<td>CVS, NBS</td>
<td></td>
</tr>
<tr>
<td>Zou, 2021</td>
<td>860</td>
<td>MC (G, EN, PPL)</td>
<td>U, V, NBS</td>
<td>GI</td>
<td>J</td>
<td>CVS, NBS</td>
<td></td>
</tr>
<tr>
<td>Zou, 2021</td>
<td>152</td>
<td>MC (G, EN, PPL)</td>
<td>U, V, NBS</td>
<td>GI</td>
<td>J</td>
<td>CVS, NBS</td>
<td></td>
</tr>
<tr>
<td>Soejima, 2021</td>
<td>657</td>
<td>MC (O, G and Skin) w/o J</td>
<td>U</td>
<td>Negative correlation of GI &amp;U</td>
<td>MC (O, G and Skin inv.), J</td>
<td>NBS</td>
<td></td>
</tr>
<tr>
<td>Soejima, 2021</td>
<td>6754</td>
<td>MC (O, G and Skin) w/o J</td>
<td>U, G and Skin inv.</td>
<td>Negative correlation of GI &amp;U</td>
<td>MC (O, G and Skin inv.), J</td>
<td>NBS</td>
<td></td>
</tr>
<tr>
<td>Karaca, 2021</td>
<td>338</td>
<td>En dominant</td>
<td>Mixt EN and PPL</td>
<td>PPL dominant</td>
<td>J, PPL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karaca, 2021</td>
<td>186</td>
<td>MC (G, EN)</td>
<td>U</td>
<td>STM, DVT</td>
<td>J, PPL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tunc, 2002</td>
<td>272</td>
<td>MC (G, EN)</td>
<td>U</td>
<td>STM, DVT</td>
<td>J, PPL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sota, 2020</td>
<td>396</td>
<td>MC (G, EN, PPL)</td>
<td>U</td>
<td>Negative correlation of J</td>
<td>PPL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arda, 2009</td>
<td>142</td>
<td>No cluster was found</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

and recovered with CYC and anti-epileptic drugs. The second patient with blurred vision and headache had cerebral venous sinus thrombosis (CVST) and recovered with anticoagulant therapy. The third patient with muscle weakness died due to spondylodiscitis complicated with aortic pseudoaneurysm.

In 5 patients (26%), neurologic work-up did not lead to an underlying condition. The presenting symptoms of these patients were transient acute visual loss in 2, numbness of extremities in 1, syncope in 1 and vertigo in 1 patient. Neurologic symptoms resolved after high dose GC and RTX in the patient with vertigo. At the onset of neurologic symptoms, 3 patients were using IS therapy including azathioprine, MMF and CYC in 1 patient each. The fourth patient was off treatment. Neurologic symptoms were transient in these patients, and did not recur during our follow-up of 36, 52, 57, and 120 months.

Conclusion: CNS involvement appears to be rare in AAV and non-CNS entities including ocular, orbital and sinonasal involvement and complications such as PRES, CVST and infections may mimic CNS involvement in patients with AAV.

Disclosure of Interests: Velyz Yazig Ozogul: None declared, Sinem Nihal Esatoglu: Speaker's bureau; Sinem Nihal Esatoglu has received honorariums for presentations from UC Pharma, Roche, Pfizer, and Merck Sharp Dohme, Murat Ozogul: None declared, Osman Kizilkilic: None declared, Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received research support from the Italian Society of Dermatology and Public Health, Cagliari, Italy; of Medical Sciences and Public Health, Cagliari, Italy; of Internal Medicine, Hippokration University Hospital, Medical University, The Department of Internal Medicine #3, Kyiv, Ukraine. 

Grant/research support from: Gulen Hatemi has received grant/research support from UCB Pharma., Grant/research support from: Vedat Hamuryudan has received grant/research support from UCB Pharma, Novartis, and Pfizer., Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.


**Table 1. Multiple regression for the assessment of the relationship between ∆-BODI and SF-36 domains**

<table>
<thead>
<tr>
<th>Component</th>
<th>FBM</th>
<th>DPR</th>
<th>BDCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical function (PF)</td>
<td>0.158 (p&lt;0.001)</td>
<td>-0.203 (p&lt;0.001)</td>
<td>-0.244 (p&lt;0.001)</td>
</tr>
<tr>
<td>Role-physical (RP)</td>
<td>0.154 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Body-pain (BP)</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Role-emotional (RE)</td>
<td>-0.142 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mental health (MH)</td>
<td>-0.142 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Physical Component</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mental Component</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
</tbody>
</table>

FBM: fibromyalgia; DPR: depression

Conclusion: The recent accrual of organ damage, rather than its extent assessed in a single visit, is associated with impairment of different aspects of health related quality of life, especially those mental related. Such phenomenon is similar to that observed in other systemic rheumatic disease, may be due to coping mechanisms.

**Figure.** Impact of increase of damage accrual of 2 years of follow-up on different domains of the SF-36 questionnaire for measurement of the health related quality of life. PF: physical function, RP: role-physical, BP: body-pain, GH: general health, VT: vitality, SP: social function, RE: role emotional, MH: mental health. *p<0.005 in univariate analysis using Mann Whitney test.

**Disclosure of Interests:** None declared.


**AB0637 THE ROLE OF ANTIQUINEUTROPHIL CYTOLAPMIC ANTIBODY (ANCA) IN ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC VASCULITIS**

I. Petelinets 1, O. Iaremko 2, M. Nahirma 3, Bogomolets National Medical University, The Department of Internal Medicine #3, Kyiv, Ukraine

**Background:** Despite the proven diagnostic significance, the prognostic role of ANCA, in particular for assessing disease activity, remains questionable. Numerous studies have attempted to estimate the role of ANCA monitoring with different results and a lack of consensus on reported outcomes [1].

**Objectives:** To analyze the relationship between ANCA level and clinical or laboratory parameters of disease activity.

<table>
<thead>
<tr>
<th>Component</th>
<th>FBM</th>
<th>DPR</th>
<th>BDCF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical function (PF)</td>
<td>0.158 (p&lt;0.001)</td>
<td>-0.203 (p&lt;0.001)</td>
<td>-0.244 (p&lt;0.001)</td>
</tr>
<tr>
<td>Role-physical (RP)</td>
<td>0.154 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Body-pain (BP)</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Role-emotional (RE)</td>
<td>-0.142 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mental health (MH)</td>
<td>-0.142 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Physical Component</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
<tr>
<td>Mental Component</td>
<td>-0.158 (p&lt;0.001)</td>
<td>-0.199 (p&lt;0.001)</td>
<td>-0.218 (p&lt;0.001)</td>
</tr>
</tbody>
</table>
Methods: This is a retrospective analysis of 38 patients with ANCA-associated vasculitis (granulomatosis with polyangiitis – 25 patients, microscopic polyangiitis – 6 patients and eosinophilic granulomatosis with polyangiitis – 7 patients) from a single center observed from 2015 till the end of 2020. The diagnosis of ANCA-associated vasculitis was performed according to the ACR 1990 criteria of the Chapel Hill Consensus Conference 2012 nomenclature. The study included 20 women (52.6%) and 18 men (47.4%). The average age of patients was 49 (27-62) years, the mean duration of the disease was 26 (6-120) months. The clinical data, initial Birmingham vasculitis activity score (BVAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), ANCA (ELISA test) against proteinase-3 (PR-3) and myeloperoxidase (MPO) were evaluated. Spearman’s correlation analysis was used to investigate the relationship between ANCA levels and ESR, CRP levels, BVAS activity index. The diagnostic value of ANCA in determining the active disease was evaluated by ROC analysis with an estimation of the area under the ROC curve (AUC).

Results: Positivity for MPO-ANCA was observed in 23.7% of patients, and for PR3-ANCA - in 76.3% of patients. The BVAS activity index averaged 16 (IQR-13) points. The mean CRP level was 47.9 (IQR-90.0) mg/L, and the ESR level was 30.1 (IQR-33.5) mm/h. There was a positive correlation between the level of both ANCA and the BVAS index (r = 0.43; 95% CI 0.11-0.66; p <0.01), as well as the level of ESR (r = 0.37; 95% CI 0.05-0.63; p <0.05). No relationship was found between CRP level and ANCA level (r = 0.22; 95% CI -0.15-0.54; p >0.05), but a positive correlation was observed between CRP level and index BVAS activity (r = 0.41; 95% CI 0.05-0.67; p <0.05). When using ROC-analysis to determine the value of ANCA in the assessment of active disease, it was found that the AUC is 0.93 ± 0.04 (95% CI 0.84-1.01; p <0.01), which indicates excellent ability ANCA diagnose patients with active disease (sensitivity - 87.9%, specificity - 80.0%).

Conclusion: The level of ANCA in patients with ANCA-associated vasculitis correlates with the Birmingham vasculitis activity score, as well as with the level of ESR. Determination of ANCA level can be used not only to diagnose ANCA-associated vasculitis, but also to assess disease activity.

REFERENCES:


Disclosure of Interests: None declared

AB0638 INTRAVENOUS IMMUNOGLOBULIN IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS. STUDY OF 28 CASES FROM A SINGLE UNIVERISTARY HOSPITAL AND LITERATURE REVIEW

F. Benavides-Villanueva1, C. Corrales-Selaya1, J. Loricer1, V. Calvo-Rio1, S. Castañeda1, N. Aviles Mendez2, J. M. Blanco Madrigal3, M. A. González-Gay1, R. Blanco1. 1Marques de Valdecilla University Hospital, Rheumatology, Santander, Spain; 2Hospital de La Princesa, Rheumatology, Madrid, Spain; 3Hospital Universitario Nuestra Señora del Perpetuo Socorro de Albacete, Rheumatology, Albacete, Spain; 4Basurto University Hospital, Rheumatology, Bilbao, Spain

Background: Anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is often accompanied by significant adverse events. Intravenous immunoglobulins (IVIG) may constitute a therapeutic alternative, however, the data are scarce.

Objectives: To assess the utility and safety of IVIG in AAV.

Methods: Observational study of patients with AAV from Spanish referral center treated with IVIG. AAV diagnosis was based on a compatible clinical presentation and/or positive ANCA serology and/or histology. Disease activity was assessed with the Birmingham Vasculitis Activity Score (BVAS).

Results: We included a total of 28 patients; GPA (n=15), MPA (n=10), and EGPA (n=3). The main features are summarized in Table 1. The reasons for using IVIG were: a) relapse/refractory disease (n=20), or presence/suspicion of infection (8) b) observed a rapid and maintained Clinical improvement, since first month of IVIG onset, yielding a BVAS score of zero in 56.5% of patients at 24 months (Figure 1). Serious Adverse event was only observed in 1 patient who developed congestive cardiac failure and had to stop the IVIG therapy.

Table 1. Main features of 28 patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with intravenous immunoglobulins.

<table>
<thead>
<tr>
<th>GENERAL FEATURES</th>
<th>RESULTS</th>
<th>GENERAL FEATURES (Continuation)</th>
<th>RESULTS (Continuation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of Diagnosis of AAV</td>
<td>57.1±18</td>
<td>CRP (mg/dL), median [IQR]</td>
<td>13.02</td>
</tr>
<tr>
<td>Men/Women; n, (%) men</td>
<td>15/13</td>
<td>ESR, mm/h, median [IQR]</td>
<td>70.4</td>
</tr>
<tr>
<td>AAV Subtype, n (%)</td>
<td>GPA</td>
<td>PR3-ANCA, n (%)</td>
<td>11 (39.3)</td>
</tr>
<tr>
<td>EGPA</td>
<td>GPA</td>
<td>MPO-ANCA, n (%)</td>
<td>12 (42.8)</td>
</tr>
<tr>
<td>MPA</td>
<td>GPA</td>
<td>ANCA negative, n/ (%)</td>
<td>5 (17.8)</td>
</tr>
<tr>
<td>CLINICAL MANIFESTATIONS, n (%)</td>
<td>GPA</td>
<td>FFS at AAV diagnosis, n (%)</td>
<td>10 (35.7)</td>
</tr>
<tr>
<td>Fever</td>
<td>15 (53.6%)</td>
<td>7 (25%)</td>
<td>PREVIOUS TREATMENT,</td>
</tr>
<tr>
<td>Constitutional symptoms</td>
<td>26 (92.8%)</td>
<td>2</td>
<td>n (%)</td>
</tr>
<tr>
<td>ORL involvement</td>
<td>7 (25%)</td>
<td>Pulmonary involvement</td>
<td>19 (67.9%)</td>
</tr>
<tr>
<td>Renal involvement</td>
<td>25 (89.3%)</td>
<td>Cytochrome</td>
<td>13 (46.4%)</td>
</tr>
<tr>
<td>Cutaneous involvement</td>
<td>6 (21.5%)</td>
<td>Methotrexate</td>
<td>6 (21.4%)</td>
</tr>
<tr>
<td>Oral ulceration</td>
<td>4 (14.3%)</td>
<td>Azathioprine</td>
<td>3 (10.7%)</td>
</tr>
<tr>
<td>Joint involvement</td>
<td>4 (14.3%)</td>
<td>Cytochrome phosphate</td>
<td>10 (34.4%)</td>
</tr>
<tr>
<td>Neurologic involvement</td>
<td>8 (28.6%)</td>
<td>Mycoproteinol motile</td>
<td>4 (14.3%)</td>
</tr>
</tbody>
</table>

Figure 1. BVAS Evolution with IVIG treatment of all our patients.

Conclusion: IVIG seems to be an effectiveness and relative safe therapeutic option in relapse/refractory AAV or in presence of a concomitant infection.

Disclosure of Interests: None declared

AB0639 COMMON FEMORAL VEIN THICKNESS MEASUREMENT AS A DIAGNOSTIC TEST IN INCOMPLETE BEHÇET’S DISEASE

F. Alibaz-Onel1, R. Ergelen2, F. Temiz2, S. Kutlu Ajaçkiran1, E. Sodyemiş2, T. Ergun3, H. Direskenel1, Marmara University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 2Marmara University School of Medicine, Department of Radiology, Istanbul, Turkey; 1Marmara University School of Medicine, Department of Internal Medicine, Istanbul, Turkey; 4Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.

Background: Behçet’s disease (BD) is characterized by recurrent oral and/or genital aphthous ulcers accompanied by cutaneous, ocular, articular, gastrointestinal and central nervous system lesions. Diagnosing BD can be a clinical challenge in patients presenting with a limited number of organ manifestations, especially with single major organ involvement. We reported the first controlled doppler ultrasound study showing increased common femoral vein (CFV) thickness in BD (1). We recently also showed that increased CFV thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases such as ankylosing spondylitis, systemic vasculitides, venous insufficiency, and non-inflammatory DVT with a specificity higher than 80% for the cut-off value of 0.5 mm. We suggest that CFV thickness measurement is an easy, non-invasive diagnostic test for BD (2).

Objectives: In this study, we aimed to assess the diagnostic performance of CFV thickness measurement in patients with ‘Incomplete’ Behcet’s Disease diagnosed by expert opinion.
Methods: We included 28 patients with incomplete BD (15 male, 12 female) diagnosed with expert opinion and followed in the Marmara University Behcet’s Clinic. Demographic, clinical characteristics and treatment data were recorded during routine visits. Common femoral vein wall thickness was measured by an experienced radiologist at the same day.

Results: Median age was 34.3 years and median disease duration 2 years (0-16). Four patients were newly diagnosed. At follow-up onset, oral ulcers were present in 22 (78.6%), genital ulcers in 6 (21.6%), papulopustular lesions in 4 (14.3%) and pathergy positivity in 5 (17.9%) patients. Ten (35.7%) patients had familial BD. While 24 (85.7%) patients had major organ involvement, 4 (14.3%) patients had mucocutaneous disease. Distribution of major organ involvements were given in Figure 1.

Figure 1. Distribution of major organ involvements (n) in study group

All patients except 1, had CFV thickness value above the cut-off value of ≥0.5 mm. Right CFV thickness was 0.71 (0.3-1.3) mm and left CFV thickness 0.72 (0.4-1.2) mm. Bilateral femoral vein thicknesses were similar in patients with and without an history of familial BD.

Conclusion: Diagnosing BD can be challenging in patients presenting with one major organ involvement such as oral ulcers and posterior uveitis, brain-stem disease or arterial aneurysms, especially in countries with a low prevalence. These patients are generally diagnosed as ‘incomplete’ BD by ‘expert opinion’. Early diagnosis is of utmost importance in some of these cases, especially with venous thrombosis as their management differs from non-inflammatory venous thrombosis, necessitating immunosuppressive use rather than anticoagulant therapy. Our results show that CFV thickness measurement with Doppler US, a non-invasive, fast and cost-effective radiological modality, is a valuable diagnostic test in incomplete BD, especially with major organ involvement.

REFERENCES:

Disclosure of Interests: None declared

AB0641
PREVALENCE AND DETERMINANT FACTORS OF ENDOTHELIAL DYSFUNCTION IN ANCA ASSOCIATED VASculitis
A. L. Fedele1, F. Melpignano1, E. Porceddu2, C. Tur1, P. Tondi1, A. Zoli1, M. D. Agostino1, 1Division of Rheumatology-Catholic University of the Sacred Heart, Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze Mediche e Chirurgie, Roma, Italy; 2Division of Angiology- Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze dell’invecchiamento, neurologiche, ortopediche e della testa-collo, Rome, Italy.

Background: Atherosclerosis and its complications are one the leading cause of death in patients with anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), despite the recent remarkable improvements in prognosis. The mechanism by which atherosclerosis is accelerated in these diseases is not explained by the classical cardiovascular risk factors (CFVRs) and is still under investigation.

Objectives: To evaluate the prevalence of endothelial dysfunction (ED) in AAV patients and to identify the determinant factors of endothelial responses among vasculitis characteristics, such as ANCA status and organ involvement.

Methods: Thirty patients (15 men and 15 women) with AAVs [13 with eosinophilic granulomatosis with polyangiitis (EGPA), 7 with granulomatosis with polyangiitis (GPA), 10 with microscopic polyangiitis (MPA)] were enrolled in the study. For all subjects CFVRs, blood pressure, lipid profile, renal function, acute phase reactants, ANCA status and titers were recorded at diagnosis and at the enrollment in the study. Vasculitis disease activity was measured using the Birmingham Vasculitis Activity Score (BVAS) and organ damage was assessed with the vasculitis damage index (VDI). The prognosis was evaluated through the Five Factor Score (FFS). Patients were excluded from the study if they had previous cardiovascular or cerebrovascular events, liver failure, end stage renal disease under hemodialysis, or cancer. Microvascular peripheral dysfunction was assessed by pulse amplitude tonometry (PAT) of the small digital artery. In particular, Log-transformed reactive hyperemia index (LnRHI) was evaluated using the EndoPAT2000 device: values of LnRHI > 0.51 were considered indicative of peripheral ED.

Results: At diagnosis, 23 subjects (76.7%) were ANCA positive (c-ANCA+, c-pANCA+), and at the enrollment in the study 10 patients (33.3%) were still sero-positive. Nineteen patients (63.3%) had inactive disease (BVAS=0), 7 (23.3%) were in low disease activity (1≤BVAS≤2) and 4 (13.3%) had an active disease (BVAS≥3). The presence of ED was documented in 9 AAV patients (30%). AAV patients with ED had higher C-reactive protein (CRP) values at diagnosis compared against subjects without ED (p=0.05). Moreover, patients with altered endothelial response were in higher percentage smokers (55.6%) and ANCA positive at enrollment (44.4%), compared to subjects with normal LnRHI (28.6%- p=0.12; 19%, p=0.15 respectively). There were no differences regarding age and other traditional CFVRs, disease duration, BMI, BVAS, VDI, FFS. There was an inverse correlation between CRP values at diagnosis and LnRHI (r=-0.42, p=0.04). In multiple logistic regression analysis, ANCA positivity at enrollment [OR (95% CI) = 15.68 (0.98-250.28) (p=0.05), and higher CRP concentrations [OR (95% CI) = 1.03 (1.00–1.06) (p=0.03) were independently associated with the presence of peripheral ED.

Conclusion: As observed in other chronic inflammatory autoimmune diseases, ED occurs in AAVs and is mainly related to the chronic systemic inflammation and seems to be also influenced by ANCA positivity, which is probably involved in the accelerated endothelial cell damage. Further studies are needed to clarify the role of vasculitis related parameters in the atherosclerotic process.

Disclosure of Interests: None declared

AB0640
AN ULTRASONOGRAPHIC STUDY OF THE SALIVARY GLANDS IN A COHORT OF PATIENTS AFFECTED BY CRYOGLOBULINEMIA VASCULITIS: PRELIMINARY RESULTS
A. Adinolfi1, N. Ughi1, D. A. Filippini1, M. Chevallard2, L. Belloli1, C. Casu1, M. Di Cicco1, C. Gagliardi1, M. C. Gerardi1, M. Muscara1, E. Verducci1, O. M. Epis1, 1Rheumatology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; 2Medicine Unit, Department of Medicine, Garbagnate Hospital, Milan, Italy.

Background: Cytosarcoma and xerophthalmia can occur in many diseases, rheumatological or not and are often reported by patients affected by cryoglobulinemia vasculitis, particularly if related to the Hepatitis C virus infection (HCV). On the other hand, the Ultrasound (US) was extensively used for detecting pathological findings of the salivary glands, possibly associated to many rheumatological diseases.

Objectives: The aim of this study was to detect, in patients affected by cryoglobulinemia vasculitis, the presence and the grade of pathological findings at level of the major salivary glands.

Methods: From January to December 2021, we enrolled consecutive outpatients patients affected by cryoglobulinemia (age ≥ 18 yo and a diagnosis of cryoglobulinemia vasculitis according to 2002 or 2011 classification criteria). Exclusion criteria were a previous diagnosis of other vasculitis/connective tissue diseases/ inflammatory arthropathies, concomitant not rheumatological diseases or the intake of drugs possibly related to sicca syndrome symptoms. For each patient, the demographic, anthropometric and clinical history data, particularly about the cryoglobulinaemia symptoms (either previous and ongoing) or current or previous therapies have been collected. Furthermore, the values of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid Factor (RF) and C4 serum complement fraction have been recorded. The presence and the titre of the cryoglobulins have been recorded. For each patient, the Schirmer’s Test and the evaluation of the unstimulated whole saliva (UWS) flow were performed. The Schirmer Test was considered positive if < 5 mm/min at least in one eye and the UWS flow was defined pathological if < 1.5 ml/15 min. Each patient was submitted to the US examination (Esaote MyLab Twin) of both parotid and submandibular glands. Each gland was evaluated using a semiquantitative score 0-3, according to the OMERACT definitions. The US score was considered pathological if ≥2. Thus, at patient level, a sum dichotomous score (normal/pathological)>2.

Results: We enrolled 20 patients, all females, with a mean age of 68.8 years (SD±13.32) and a mean disease duration of 11.76 (SD±8.25). For 18 patients was reported a previous HCV infection. 16/18 HCV+ subjects reached the remission of the
infection with undetectable HCV viremia. Among the patients enrolled, 10 referred at least one syndrome sicca symptom: 5 patients both xerostomia and xerophthalmia, 4 only xerostomia and 1 only xerophthalmia. Considering blood tests, the cryoglobulins were detected in 14, the ESR title was above the limit in 7 patients and the CRP in 3. The RF was detected in 12 subjects. The Schirmer’s test was pathological in 9 patients while the UWS flow was under the limit in 3. As regards the US reports, 2 patients had pathological features scored as 2, while 7 patients showed minor alterations scored as 1. So, according to the sum score, only 2 patients were classified as pathological. No correlations were identified between the clinical and the US data.

Conclusions: In this cohort of patients with cryoglobulinemia, the US mainly showed mild pathological features at level of the parotid and submandibular structure, suggesting that syndrome sicca symptoms could be related to different pathological mechanisms in these patients, possibly strongly associated to HCV infection. Further and larger studies are necessary to confirm our preliminary data.

REFERENCES:

Disclosure of Interests: Antonella Adinolfi Speakers bureau: BMS, Paid instructor for: JANSsen, Nicola Ughi Speakers bureau: ROCHE, PFIZER, ALFASIGMA, ABBVIE, GALAPAGOS, BRISTOL MYERS SQUIBB, Paid instructor for: Janseen, Nicola Ughi

Disclosure of Interests:
• Oscar Massimiliano Epis: None declared
• Bureau: Eli-Lilly
• Maria Muscarà: None declared, Elisa Verduci: None declared, Clizia Gagliardi: None declared, Maria Chiara Gerardi: Speakers bureau: ABBVIE, GALAPAGOS, BRISTOL MYERS SQUIBB, Paid instructor for: JANSsen, Nicola Ughi
• Bureau: ROCHE, PFIZER, ALFASIGMA, Antonella Adinolfi: Speakers bureau: BMS, Paid instructor for: Janseen, Nicola Ughi

ABO643 ARE THERE ANY DISTINCTIVE FINDING IN ANCA-ASSOCIATED VASculoSIS RELATED PULMOnARY INVOLvEMENT IN COMPaRISON WITH CONNECTive TISSUE DISEASE OR IDIOPATHIC PULmOnARY FIBROSIS

E. Durak Ediboglu1, Ş. Karasu2, T. Ekici2, M. O. Turan2, Ö. Gerçik2, D. Solmaz1, C. Gümüş2, Ş. Akar3, Izmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey; 2Izmir Katip Celebi University, Department of Radiology, Izmir, Turkey; 3Izmir Katip Celebi University, Department of Pulmonary Disease, Izmir, Turkey; 4Izmir Demokrasi University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey

Background: Patients with ANCA associated vasculitis (AAV) have a wide spectrum of pulmonary involvement from parenchymal necrotizing granuloma formation, trechobronchial inflammation, pulmonary capillaritis to interstitial lung disease. Pulmonary involvement is relatively common in connective tissue diseases (CTDs). Both rheumatologic disorders and idiopathic pulmonary fibrosis (IPF) might cause the usual interstitial pneumonia (UIP) pattern. However, little is known regarding the clinical and radiologic similarities/dissimilarities of those diseases.

Objectives: We aimed to evaluate the thoracic computed tomography (CT) findings of patients with AAV, CTD-related interstitial lung disease (ILD) or IPF.

Methods: Patients whose thoracic CT performed at the time of diagnosis or relapse of AAV (n=64), at the time of the diagnosis of CTD related ILD (n=55) or IPF (n=52) were included in the analysis. Demographic, clinical and serological data were collected retrospectively. Radiological patterns of pulmonary involvement were evaluated by two expert pulmonary radiologists and abnormal thoracic CT findings were classified according to Fleischner Society guidelines. Intra- and interobserver variation were calculated. Multinominal logistic regression was performed to identify disease specific findings in thoracic CT.

Results: A total of 171 patients were included and of them 64 patients (62.5% with granulomatosis with polyangiitis, 37.5% with microscopic polyangiitis) in AAV group, 55 patients in CTD related ILD (50.9% with scleroderma, 40.0% with rheumatoid arthritis, 9.1% other or undifferentiable connective tissue disease) group and 52 patients in IPF group. Demographic and thoracic CT findings were summarized in Table 1. In univariate analysis according to Fleischner Society definition, patients with AAV had more common pulmonary nodules, cavities, consolidation. However, patients with AAV were less likely to have interlobular septal thickening (ILST), lymph node adenopathy (LAP) and reticulation compared to both CTD related ILD and IPF. In addition, among those groups of rheumatic diseases, cavities and alveolar hemorrhage were detected only in AAV. In multinominal logistic regression, the presence of nodul and consolidation and the absence of ILST and mediastinal LAP were independent determinant findings in thoracic CT in patients with AAV in comparison with both CTD related ILD or IPF.

Table 1. Demographic characteristics and Thoracic CT findings of patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>AAV (n=64)</th>
<th>CTD related ILD (n=55)</th>
<th>IPF (n=52)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis, yrs, mean (SD)</td>
<td>58.6 (15.0)</td>
<td>61.8 (12.0)</td>
<td>72.4 (9.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex, male, %</td>
<td>70.3</td>
<td>30.9</td>
<td>75</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Smoking, ever, %</td>
<td>778</td>
<td>26.5</td>
<td>62.8</td>
<td>0.29</td>
</tr>
<tr>
<td>Chest CT findings according to Fleischner guideline, %</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ground glass opacity</td>
<td>29.7</td>
<td>38.2</td>
<td>9.6</td>
<td>0.003</td>
</tr>
<tr>
<td>Reticulation</td>
<td>19.0</td>
<td>52.7</td>
<td>94.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Interlobular septal thickening</td>
<td>28.6</td>
<td>69.1</td>
<td>98.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Peribronchial thickening</td>
<td>11.1</td>
<td>20.0</td>
<td>3.8</td>
<td>0.03</td>
</tr>
<tr>
<td>Bronchiolectasis</td>
<td>14.3</td>
<td>26.5</td>
<td>63.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Consolidation</td>
<td>41.3</td>
<td>47.3</td>
<td>94.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nodules</td>
<td>45.3</td>
<td>10.9</td>
<td>3.8</td>
<td>0.07</td>
</tr>
<tr>
<td>Cavities</td>
<td>23.4</td>
<td>0</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alveolar hemorrhage</td>
<td>18.8</td>
<td>7.3</td>
<td>19.2</td>
<td>0.96</td>
</tr>
<tr>
<td>Mosaic attenuation pattern</td>
<td>20.8</td>
<td>20.8</td>
<td>38.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>14.1</td>
<td>0</td>
<td>0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Conclusion: The results of this study show that in addition to clinical and laboratory characteristics, some thoracic CT imaging findings like the presence of nodules and consolidation and the absence of LAP and ILST may be useful to differentiate pulmonary involvement of AAV from other relatively common rheumatologic conditions and IPF. In addition, alveolar hemorrhage and cavities may be particular manifestations of AAV.

Disclosure of Interests: None declared

Scleroderma, myositis and related syndromes

Methods: Ten patients with pulmonary fibrosis secondary to Connective Tissue Disease treated with Nintedanib were monitored at baseline, 6 and/or 12 months, with clinical assessment, chest CT scan and/or pulmonary function testing (PFT) with a washout period of the diffusion capacity for CO (DLco). 810 patients had a diagnosis of Progressive Systemic Sclerosis, while the remaining ones had Polymyositis and/or Mixed Connectivitis. All patients were dyspneic at baseline and presented with dry cough. All patients had pulmonary fibrosis according to high-resolution chest CT scan. All patients had been treated with at least one csDMARD or bDMARD (cyclophosphamide, azathioprine, cyclosporine, rituximab, tocilizumab), prior to receiving nintedanib. At baseline 210 patients were treated with Nintedanib monotherapy, 710 were in combination therapy with Mycophenolate, 1 patient received a combination therapy with cyclosporine.

Results: Compared to baseline values, 4/7 patients showed stationarity of the respiratory function parameters (DLco), in 2/7 patients it was observed a significant improvement of the DLco (with a change of 15%) while in only 1 patient there was a worsening over time. FVC remained stable over time except in 1 patient who got a significant improvement. In 5/9 patients cough improved (unchanged in the rest of patients). Dyspnea (NYHA scale) improved in 6/9 patients, remained stationary in 2/6 patients and became worse in 1 patient. 8/9 patients had a stable chest CT at 6 and/or 12 months, while only 1 patient witnessed a further worsening of the fibrosis. 50% of the patients showed good gastrointestinal tolerance to the full dose of nintedanib. The other half had the dose reduced in order to improve gastrointestinal symptoms.

Conclusion: Our data show that patients with ILD associated with Rheumatic Diseases treated with nintedanib had a clinical benefit over dyspnea and cough symptoms and a stabilization of radiological findings 12 months after starting the treatment. Also, respiratory function parameters remained stable over time. Gastrointestinal adverse events, including diarrhea, were common in these patients, but therapeutic dose adjustment led to fast symptoms resolution and good tolerance.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.112

G-CSF treatment for refractory digital ulcers in systemic sclerosis

Methods: Adult SSc patients with chronic resistant DU despite treatment with maximal tolerated doses of prostacyclin analogue, endothelin receptor antagonist and PDE5 inhibitor, were treated with three consecutive daily doses of G-CSF for evaluation of DU healing, DUCAS score, antibiotics use, side effects and hospitalizations, was performed.

Results: Ten patients (90% females), mean age 53.5 ± 11.1 years were treated. Fifty percent of the patients had a diffuse SSc disease. All patients suffered from chronic (80%), or recurrent (20%) DU. G-CSF treatment resulted in complete resolution of most DU, after an average of 1.57 ± 0.76 months. DU recurrence occurred in two patients, after a mean period of two months. The number of DU decreased from 2.23 ± 2.20 at baseline, to 0.84 ± 0.80 at one month (p value= 0.04), and 0.50 ± 0.67 at 3 months (p value= 0.015). DUCAS score dropped from 8.64 ± 2.50 before the treatment, to 1.76 ± 2.00 and 1.16 ± 2.55 at one and three months, respectively (p value <0.0001). No serious adverse events were observed.

Conclusion: G-CSF treatment was found to be beneficial for refractory SSc DU, resulting in DU healing and sustained remission in most cases. No significant side effects were observed. Future trials are needed to evaluate the efficacy and safety of this therapy.

REFERENCES:
Results: 103 SSc patients were included: 72 (69%) females, 82 (79%) lcSSc and 21 (20%) dcSSc. Among lcSSc patients, 43 (52%) had ACA, 16 (19%) Scl70 and 12 (15%) had ANA. Among dcSSc patients, 9 (43%) had Scl70 and 12 (57%) had ANA. Scl70-lcSSc patients had significantly shorter time from Raynaud's phenomenon (RP) to SSc diagnosis (p=0.02), younger age at SSc onset (p=0.04), higher mRSS (p=0.03), higher rate of myositis (p=0.001), higher CRP (p=0.04), mRSS (p=0.001), higher rate of myositis (p=0.04) and higher rate of ILD (p=0.02). Conclusion: Scl70-lcSSc patients show the major organ involvement, followed by ANA-lcSSc and ACA-lcSSc. Scl70-lcSSc and ANA-lcSSc patients exhibit more cutaneous involvement and ILD than Scl70-lcSSc and ANA-lcSSc. These results may provide new ways to help in early diagnosis, management and assessing the prognosis of the disease.

REFERENCES:
[1] Zaragata E et al. POS0318 CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH LIMITED AND DIFFUSE CUTANEOUS DISEASE BASED ON AUTOIMMUNITY
C. Sieiro Santos1, C. Moriano1, I. González Fernández1, X. E. Larco Rojas1, C. Álvarez Castro1, E. Diez Alvarez1, 1Complejo Asistencial Universitario de León, Rheumatology, León, Spain
Background: Classically, anti-centromere antibodies (ACA) are associated with limited cutaneous involvement (lcSSc) and pulmonary hypertension, whereas anti-topoisomerase I (Sc70) are associated with diffuse skin involvement (dcSSc) and pulmonary fibrosis (ILD). Patients with lcSSc and Sc70 antibodies draw particular attention, which is why characterization of clinical phenotypes can help distinguish patient subgroups and assessing the prognosis of the disease.

Objectives: We aimed to characterize the clinical phenotype of patients with SSc based on autoantibodies.

Methods: We included patients with SSc, fulfilling the 2013 ACR/EULAR criteria, with disease duration ≤10 years. We have compared different subgroups of patients with lcSSc: Sc70-lcSSc (group1), ACA-lcSSc (group 2) and ANA-lcSSc (group 3). Table 1. Next, we compared patients with Sc70-lcSSc (group 1) to Scl70-dcSSc (group 4) and ANA-lcSSc (group 3) to ANA-dcSSc (group 5). In the ANA subgroup we included patients with negative Sc70 and ILD. We have assessed the risk of ILD, myositis, scleroderma renal crisis, cardiac and gastrointestinal involvement, myositis, pulmonary hypertension (systolic pulmonary arterial pressure >p>45 mmHg at transthoracic echocardiography or sPAP>25 mmHg at right heart catheterization), cancer and all-cause-mortality.

Table 1. Clinical characteristics of patients with lcSSc

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sc70-lcSSc</th>
<th>ACA-lcSSc</th>
<th>ANA-lcSSc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td>9 (56.3%)</td>
<td>36 (83.7%)</td>
<td>12 (52%)</td>
</tr>
<tr>
<td>Time from RP to SSc (years)</td>
<td>1.28 (0.25-3.5)</td>
<td>6.23 (3-9)</td>
<td>4.91 (2.5-9.8)</td>
</tr>
<tr>
<td>Age at SSc onset</td>
<td>56.5 (48-66)</td>
<td>62.5 (54-73)</td>
<td>59.2 (44-66)</td>
</tr>
<tr>
<td>CRP elevation</td>
<td>20 (22-39)</td>
<td>22 (16-29)</td>
<td>21 (10-6-19)</td>
</tr>
<tr>
<td>mRSS</td>
<td>4 (2-4.2)</td>
<td>3.3 (2.1-4.0)</td>
<td>3.9 (2.5-4.2)</td>
</tr>
<tr>
<td>Joint synovitis</td>
<td>6 (37.5%)</td>
<td>12 (28%)</td>
<td>7.1 (10 (43)</td>
</tr>
<tr>
<td>Tendon friction rubs</td>
<td>2 (12.5%)</td>
<td>5 (3%)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Myositis</td>
<td>4 (25%)</td>
<td>2 (5%)</td>
<td>8 (21.7)</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td>6 (37.5%)</td>
<td>27 (63%)</td>
<td>16 (69%)</td>
</tr>
<tr>
<td>Renal crisis</td>
<td>4 (25%)</td>
<td>2 (5%)</td>
<td>16 (29)</td>
</tr>
<tr>
<td>ILD</td>
<td>10 (63%)</td>
<td>7 (16%)</td>
<td>4 (7)</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>4 (25%)</td>
<td>7 (16%)</td>
<td>3 (13)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (21.7%)</td>
<td>8 (14%)</td>
<td>35 (73)</td>
</tr>
<tr>
<td>Conduction defects</td>
<td>1 (6.3%)</td>
<td>5 (11.6%)</td>
<td>79 (14)</td>
</tr>
<tr>
<td>Diastolic dysfunction</td>
<td>7 (43.8%)</td>
<td>17 (39.5%)</td>
<td>77 (39)</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>10 (63%)</td>
<td>13 (30.2%)</td>
<td>52 (12)</td>
</tr>
<tr>
<td>Steroids</td>
<td>9 (56%)</td>
<td>12 (28%)</td>
<td>98 (36.6)</td>
</tr>
<tr>
<td>Cancer</td>
<td>8 (50%)</td>
<td>10 (23.2%)</td>
<td>7 (20)</td>
</tr>
<tr>
<td>Mortality</td>
<td>3 (18.8%)</td>
<td>4 (6%)</td>
<td>82 (5)</td>
</tr>
</tbody>
</table>


Disclosure of Interests: None declared

Background: Systemic sclerosis (SSc) is associated with increased risk of malignancy. Risk factors predisposing a SSc patient for development of malignancy are not well defined, and the pathogenetic basis of the association is yet to be explained. Some autoantibodies have been associated with a close temporal relationship with cancer. The absence of malignancy screening guidelines tailored for SSc patients raise the importance of the need for more studies on the association of SSc and cancer.

Objectives: To study the prevalence of cancer in SSc and the association between SSc-specific and SSc-associated autoantibodies and cancer in a third-level center.

Methods: We conducted a retrospective cohort study by including patients diagnosed with SSc followed from 1980 to 2020 fulfilling the 2013 ACR/EULAR SSc criteria. Demographic features, clinical and immunological characteristics were retrieved. The primary outcome was cancer-associated SSc, defined as cancer occurring within 2, 3 and 5 years of first non-Raynaud SSc manifestation. The exposure was defined by the presence of SSc-specific/associated autoantibodies, including anti-centromere (ACA), topoisomerase I (Sc1070), RNA polymerase III, fibrillarin, Th/To, PM-Sci, Ku, TIF1g, Ro52. Descriptive analysis was used to compare clinical characteristics of subjects with cancer to those without cancer. Univariate logistic regression was used to compare the odds of cancer-associated SSc between the autoantibody subgroups.

Results: Out of 103 SSc subjects, 27 (26%) had a history of cancer following SSc diagnosis. Mean age was 61.9 (57-69) years, 70% were female and 88% had a smoking history. Median time between cancer and disease onset was 6.33 (3-9) years. Among patients with cancer, 12 (44%), (29%) and (7) were diagnosed within 2, 5 and 10 years of SSc onset. The most frequent types were breast cancer (n=9), gastrointestinal cancer (n=5), prostatic cancer (n=4), hematological (n=3) cancers, cervical/uterine cancers (n=2), non-melanoma skin (n=2), lung cancer (n=2). Patients with cancer were more likely to be Sc70+ (OR 2.55, 95% CI 1.03-6.3, p = 0.04), anti-TIF1g (OR 19.5, 95% CI 5.6 - 68.3, p = 0.001) and RNA pol III (OR 10.9 CI 95% 108-109, p = 0.04), have a history of smoking (OR 224, 95% CI 2.6-197, p = 0.001), myositis (OR 5.2 IC 95% 2.06-13.2, p = 0.005) and older age at SSc onset (619 vs 57, p = 0.04). Breast cancer was more frequent in anti-TIF1g (OR 3.75 IC 95% 1.8-17.5) and RNA pol-III (OR 7.14 IC 95% 1.56-90.8) subgroups. The risk of cancer-associated SSc was significantly increased among anti-TIF1g-positive subjects at 5 years after SSc onset (OR 2.1 CI 95% (1.45-9.94), p = 0.04) and among RNA-pol III-positive subjects at 2 years after SSc onset (OR 3.5 95% CI (12-51.4), p = 0.02) (Table 1).

Conclusion: Anti-Sc70, anti-TIF1g and RNA pol III were predictive of cancer-associated SSc for cancers. Breast cancer was the most frequent. Subjects with cancer were more likely to have a history of smoking, myositis and an older age at SSc onset. Autoantibodies should be taken into account in cancer with cancer were more likely to have a history of smoking, myositis and an older age at SSc onset. Autoantibodies should be taken into account in cancer associated SSc for cancers. Breast cancer was the most frequent. Subjects with cancer were more likely to have a history of smoking, myositis and an older age at SSc onset. Autoantibodies should be taken into account in cancer.

REFERENCES:

Table 1. Logistic regression analysis for the risk of cancer within 2.5 and 10 years of SSc onset according to antibody positivity

<table>
<thead>
<tr>
<th>Antibody</th>
<th>OR 95% CI for cancer diagnosis within 2.5 years of SSc onset</th>
<th>OR 95% CI for cancer diagnosis within 5 years of SSc onset</th>
<th>OR 95% CI for cancer diagnosis within 10 years of SSc onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Sc70</td>
<td>1.56 (0.51-4.45)</td>
<td>1.41 (0.27-12.7)</td>
<td>2.1 (0.55-13.4)</td>
</tr>
<tr>
<td>Anti-centromere</td>
<td>1.72 (0.62-52.1)</td>
<td>1.52 (0.32-92.1)</td>
<td>1.69 (0.14-21.3)</td>
</tr>
<tr>
<td>Anti-TIF1g</td>
<td>3.5 (1.52-154)</td>
<td>2.1 (1.45-9.84)</td>
<td>0.42 (0.04-5.32)</td>
</tr>
<tr>
<td>ARN Pol III</td>
<td>-</td>
<td>1.9 (0.72-62.1)</td>
<td>-</td>
</tr>
<tr>
<td>Anti-PM Sc75/100</td>
<td>-</td>
<td>2.0 (0.45-50.2)</td>
<td>0.63 (0.05-77.4)</td>
</tr>
<tr>
<td>Anti-Ro52</td>
<td>2.5 (0.66-66.8)</td>
<td>2.0 (0.45-50.2)</td>
<td>0.87 (0.04-198)</td>
</tr>
</tbody>
</table>

Discipline of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.376
Table 1.

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Duration from diagnosis to first pulmonary manifestation</th>
<th>Pulmonary symptoms</th>
<th>CBC</th>
<th>Chest X-ray</th>
<th>HRCT Chest</th>
<th>ECG</th>
<th>2D-Echo</th>
<th>Spirometry</th>
<th>BAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>44 F</td>
<td>16 months</td>
<td>Cough + Dyspnea – 3 months</td>
<td>Normal</td>
<td>Normal</td>
<td>Advanced UIP</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Neutrophilic</td>
<td></td>
</tr>
<tr>
<td>Patient 2</td>
<td>56 F</td>
<td>18 months</td>
<td>Cough + Dyspnea – 3 months</td>
<td>Normal</td>
<td>Normal</td>
<td>UIP</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Neutrophilic</td>
<td></td>
</tr>
<tr>
<td>Patient 3</td>
<td>61 F</td>
<td>12 months</td>
<td>Cough + Dyspnea – 1 month</td>
<td>Normal</td>
<td>Normal</td>
<td>Advanced UIP</td>
<td>Normal</td>
<td>RVSP = 48 mm Hg</td>
<td>Restrictive</td>
<td>Lymphocytic</td>
<td></td>
</tr>
<tr>
<td>Patient 4</td>
<td>70 F</td>
<td>21 months</td>
<td>Cough + Dyspnea – 2 months</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Neutrophilic</td>
<td></td>
</tr>
<tr>
<td>Patient 5</td>
<td>24 F</td>
<td>18 months</td>
<td>Cough + Dyspnea – 2 months</td>
<td>Normal</td>
<td>Normal</td>
<td>Advanced UIP + NSIP (overlap)</td>
<td>Normal</td>
<td>RVSP = 51 mm Hg</td>
<td>Restrictive</td>
<td>Neutrophilic</td>
<td></td>
</tr>
<tr>
<td>Patient 6</td>
<td>55 F</td>
<td>12 months</td>
<td>Cough + Dyspnea – 1 month</td>
<td>Normal</td>
<td>Normal</td>
<td>UIP</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
<td>Not Performed</td>
<td></td>
</tr>
<tr>
<td>Patient 7</td>
<td>54 F</td>
<td>6 months</td>
<td>Dyspnea – 1 month</td>
<td>Anemia</td>
<td>Normal</td>
<td>UIP + NSIP (overlap)</td>
<td>Normal</td>
<td>Normal</td>
<td>Restrictive</td>
<td>Neutrophilic</td>
<td></td>
</tr>
</tbody>
</table>

Notes in the column 'BAL' indicate the predominant cell type noted on cytology. RVSP = Right Ventricular Systolic Pressure.

Findings on ECG, 2D-Echo, spirometry and bronchoalveolar lavage (BAL) are summarized in Table 1.

Conclusion: Although limited by a small sample size, UIP appeared to be the most common lung pathology in patients with dCSS. The duration from diagnosis of dCSS to first manifestation of pulmonary symptoms is much shorter in comparison to limited cutaneous systemic sclerosis [1] PAH is commoner with limited cutaneous systemic sclerosis than with dCSS. [2] 2D-ECHO was neither useful for diagnosis nor required in preparing a therapeutic plan for these patients.

REFERENCES:

Disclosure of Interests: None declared

AB0651

CLINICAL IMPACT AND PROGNOSIS OF CRYOglobulinemia AND CRYOFibrogenemia IN SYSTEMIC SCLEROSIS

S. De Almeida Chaves1, F. Benoît2, T. Porel1, E. Bories3, D. Adouë4, L. Astudillo5, L. Alric6, A. Huard7, M. Michaud6, D. Ribes8, G. Prevot1, L. Sailler9, F. Gaches9, G. Pugnet9, 1Hospital Purpan, Internal Medicine, Toulouse, France; 2Hospital Purpan, Immunology, Toulouse, France; 3Hospital Rangueil, Internal Medicine, Toulouse, France; 4Clinic nephrologist Saint Exupéry, Internal Medicine, Toulouse, France; 5Hospital Rangueil, Nephrology, Toulouse, France; 6Hospital Joseph Ducuing, Internal Medicine, Toulouse, France; 7Hôpital Larrey, Pneumology, Toulouse, France; 8Hospital Purpan, Internal Medicine, Toulouse, France

Background: Systemic sclerosis (SSc) is reported to be a secondary cause of cryoglobulinemia as well as cryofibrogenemia. However, prevalence, clinical implication and associated pronostic of cryoprecipitates in SSc are unknown.

Objectives: To describe the prevalence, the phenotype and evaluate the prognosis of cryoglobulinemia and/or cryofibrogenemia associated with systemic sclerosis.

Methods: We included all adult (≥18 years) consecutive SSc patients from the Systemic Scleroderma Toulouse Cohort (SSTC) [1] for whom a cryoglobulin and/or cryofibrogenin measurement was carried out at the immunology laboratory of the Toulouse University Hospital between June 1, 2005 and May 31, 2018 and at least one follow-up visit. We compared SSc-patients characteristics with and without cryoglobulinemia > 50 mg/l and with and without cryofibrogeninemia. Survival analysis based on presence of cryoglobulin cryofibrogenin was performed using the Kaplan-Meier method. Univariable and multivariable Cox proportional hazards models (ascending step-by-step method) were used to determine baseline variables associated with cryoglobulin or cryofibrogenin presence.

Results: 166 patients were included in the study. 74.6% of patients were women, with an average age at diagnosis of 51.2 years-old. 24% were diffuse cutaneous subtypes and 71.6% limited cutaneous subtypes. Anti-centromere and anti-ScI70 were respectively positive in 44.5% and 21.6% of cases. All these patients were assessed for cryoglobulin detection and 75 cryofibrogenin detection in serum. 43.3% had a cryoglobulinemia >50 mg/l. 46.6% had cryofibrogeninemia. Patients with cryoglobulinemia >50 mg/l had more cardiac diastolic involvement (22.8% vs. 5.1%; p=0.0395). In the multivariable analysis, diastolic involvement (HR=6.23; p=0.0331) was an independent predictor of cryoglobulin >50 mg/l. Survival at 10 years was better for patients with cryoglobulinemia >50 mg/l (log-rank 0.0363) (Figure 1). Survival at 5 and 10 years was 97.8% and 88.8% respectively in patients with cryoglobulinemia >50 mg/l versus 91.9% and 78.4% in patients with cryofibrogeninemia >50 mg/l. In cox regression model adjusted for gender, age and type of systemic sclerosis, cryoglobulin >50 mg/l was negatively associated with mortality (HR: 0.09; p=0.03). The presence of cryofibrogeninemia was not associated with any clinical, biological or morphological features. In the multivariate analysis, no variable was predictive of the presence of cryofibrogeninemia in patients with SSc. The presence of cryofibrogeninemia had no influence on the mortality of these patients.

Conclusion: In SSc patients, the presence of cryoglobulin >50 mg/l is an independent predictive factor of cardiac diastolic involvement and is associated with a better survival. However, cryofibrogeninemia does not influence clinical phenotype or impact mortality in SSc patients.

REFERENCES:

Disclosure of Interests: None declared

AB0652

PREVALENCE OF INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION IN SYSTEMIC SCLEROSIS PATIENTS COHORT AT A RHEUMATOLOGY REFERRAL CENTRE IN THE UNITED ARAB EMIRATES

K. Saleh1, N. Khan1, A. Ghorab1, M. El-Kaisii, A. Mubashir2, M. Elarabi3, H. Sabbour2, R. Namra2, Cleveland Clinic Abu Dhabi, Respiratory Institute, Abu Dhabi, United Arab Emirates; 2Cleveland Clinic Abu Dhabi, Radiology, Abu Dhabi, United Arab Emirates; 3Cleveland Clinic Abu Dhabi, Rheumatology, Abu Dhabi, United Arab Emirates; 4Cleveland Clinic Abu Dhabi, Cardiology, Abu Dhabi, United Arab Emirates

Background: Scleroderma, also known as Systemic Sclerosis (SSc), is a connective tissue disease that affects multiple organ systems, including the cardiovascular and respiratory systems, namely, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) as the leading causes of death in this patient population.

Objectives: The purpose of this study is to determine the prevalence of PAH and ILD in a cohort of patients diagnosed with SSc.

Methods: We performed a retrospective chart review of clinical characteristics of all patients diagnosed with SSc Cleveland Clinic Abu Dhabi between April 2015 and April 2020. PAH was estimated by echocardiographic findings and diagnosed based on right heart catheterization (RHC) using 2019 World Symposium on Pulmonary Hypertension. The CT scan of the chest was read by a board-certified radiologist in chest radiology.
Results: Fifty individuals were diagnosed with SSc, with 46% having diffuse cutaneous systemic sclerosis and 54% having limited cutaneous systemic sclerosis. The majority of the patients (86%) were female, with a mean age of 41 ±13 years. The average period from presentation to diagnosis was 5 ±5.4 years. The majority of the cohort (86%) were from the United Arab Emirates. The average BMI was 26.0 kg/m². Patients’ most prevalent symptoms are fatigue (80%), gastrointestinal symptoms (72%) followed by shortness of breath (58%) and cough (50%). Twenty-six out of fifty patients (52%) underwent a CT chest scan, with 19 (38%) having ILD. Eight patients had more than 30% fibrotic alterations, four patients had 10-30% fibrotic changes, and seven patients had less than 10% fibrotic abnormalities. Patients with more than 10% fibrotic changes were more likely to have usual interstitial pneumonia, whereas those with less than 10% fibrotic changes were more likely to have none specific fibrosis. The majority of patients (92%) had echocardiogram. All except one patient had a normal ejection fraction, and five had grade 1 left ventricular diastolic dysfunction. Five patients were described as having mild, 1 moderate and 2 severe PAH. Only 4 patients underwent RHC. One patient had group II PAH based on elevated wedge pressure. One had group 1 PAH with systemic sclerosis as the only cause for her PAH and two patients had group III PAH due to having more than 30% pulmonary fibrosis and severe restrictive defect on spirometry. Therefore, the precapillary PAH prevalence was 6%/3(50).

Conclusion: While the prevalence of pulmonary fibrosis in our SSc patients reflects what has been reported in the literature, the prevalence of PAH is significantly lower than the reported 15-20%. This is likely due to underdiagnosis of PAH considering the number of years of systemic sclerosis diagnosis on presentation to our clinic. A systematic approach is needed to assess for the presence and severity of PAH using tools as in Detect algorithm which has been validated and commonly used in Europe and North America to screen for PAH. Validation of such algorithm is likely needed in middle eastern population before it is universally adopted.

REFERENCES:

Disclosure of Interests: None declared

AB0653

THE ASSOCIATION OF AUTOANTIBODIES WITH MORBIDITY AND MORTALITY OF SCLERODERMA RENAL CRISIS IN JAPAN

H. Tsuji1, N. Kuramoto2, T. Sasai1, M. Shirakashi1, H. Onizawa1, K. Kitagori1, S. Akizuki1, R. Nakashima1, R. Watanabe1, A. Onishi1, K. Murakami1, H. Yoshiji1, M. Tanaka2, M. Hashimoto1, K. Ohmur1, A. Morinobu1, 1Kyoto University Graduate School of Medicine, Department of Rheumatology and Clinical Immunology, Kyoto, Japan; 2Wakayama Medical University, Department of Rheumatology and Clinical Immunology, Wakayama, Japan; 3Kyoto University Graduate School of Medicine, Department of Advanced Medicine for Rheumatic Diseases, Kyoto, Japan; 4Osaka City University Graduate School of Medicine, Department of Clinical Immunology, Osaka, Japan; 5Kyoto University Graduate School of Medicine, Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Kyoto, Japan; 6Kobe City Medical Center General Hospital, Department of Rheumatology, Kobe, Japan

Background: The morbidity of scleroderma renal crisis (SRC) and autoantibodies in systemic sclerosis (SSc) vary by races and regions. Anti-RNA polymerase III is associated with SRC in America and European countries. However, the association of autoantibodies with SRC had not been elucidated in Japan.

Objectives: We aimed to investigate the association of autoantibodies with morbidity and mortality of SRC in Japan.

Methods: The clinical characteristics and mortality of 330 patients with systemic sclerosis (SSc) at Kyoto University Hospital were retrospectively analyzed, focusing on anti-centromere, anti-RNA polymerase III, anti-topoisomerase I, and anti-U1-RNP. Logistic regression analyses were performed to examine the association of autoantibodies with the development and mortality of SRC. Kaplan-Meier survival analysis was performed comparing the groups classified by autoantibodies.

Results: Anti-centromere (n = 177/318, 56%), anti-topoisomerase I (n = 80/311, 26%), anti-RNA polymerase III (n = 27/204, 13%), and anti-U1-RNP (n = 24/305, 8%) were found in SSc patients (n = 330). SRC was observed in 24 out of 330 SSc patients, including anti-topoisomerase I (n = 12/24, 50%), anti-RNA polymerase III (n = 7/24, 29%), anti-U1-RNP (n = 5/24, 21%), and anti-centromere (n = 3/24, 13%). Anti-U1-RNP (odds ratio [95% confidence interval], 3.63 [1.11–10.2]), anti-RNA polymerase III (3.29 [1.16–8.70]), and anti-topoisomerase I (3.22 [1.37–7.57]) were associated with the development of SRC. All patients with SRC were treated with ACE inhibitors and the 1-year survival rate was 54%. Anti-topoisomerase I was associated with the 1-year mortality of SRC (6.00 [1.11–41.1]). When the survival rate was compared between the patients positive for anti-topoisomerase I (n = 12) and negative for anti-topoisomerase I (n = 12), the 1-year survival rate was 33% vs 75% (p = 0.041), respectively (Figure 1A). Furthermore, the 1-year survival of anti-centromere (100%), anti-RNA polymerase III (83%), and others/ not detected (50%) were shown in patients negative for anti-topoisomerase I (Figure 1B).

Figure 1. Overall survival of patients with SRC according to the type of autoantibodies. (A) The survival rates in SRC patients who were positive for anti-topoisomerase I (solid line, n = 12) and those who were negative for anti-topoisomerase I (dotted line, n = 12). (B) SRC patients negative for anti-topoisomerase I were classified as patients with anti-RNA polymerase III (dotted line, n = 6), anti-centromere (broken line, n = 2), and others/not detected (chain line, n = 4).
Table 1. Univariate logistic regression analysis for mortality in SRC (n = 24).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Odds ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.07 (0.99, 1.16)</td>
<td>0.08</td>
</tr>
<tr>
<td>Female sex</td>
<td>3.00 (0.32, 6.66)</td>
<td>0.38</td>
</tr>
<tr>
<td>Diffuse/limited (diffuse %)</td>
<td>0.25 (0.04, 1.36)</td>
<td>0.12</td>
</tr>
<tr>
<td>BMI</td>
<td>0.67 (0.41, 0.93)</td>
<td>0.049</td>
</tr>
<tr>
<td>Modified Rodman skin score</td>
<td>0.96 (0.88, 1.02)</td>
<td>0.15</td>
</tr>
<tr>
<td>Digital ulcer</td>
<td>0.52 (0.10, 2.63)</td>
<td>0.43</td>
</tr>
<tr>
<td>Reflux esophagitis</td>
<td>0.60 (0.02, 1.71)</td>
<td>0.73</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>7.50 (1.17, 69.2)</td>
<td>0.046</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>7.20 (12.3, 62.0)</td>
<td>0.04</td>
</tr>
<tr>
<td>Glucocorticoid use</td>
<td>3.86 (0.65, 23.4)</td>
<td>0.16</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.55 (0.25, 1.01)</td>
<td>0.09</td>
</tr>
<tr>
<td>Platelet</td>
<td>1.00 (0.98, 1.01)</td>
<td>0.44</td>
</tr>
<tr>
<td>Total protein</td>
<td>0.17 (0.02, 0.69)</td>
<td>0.04</td>
</tr>
<tr>
<td>Creatinine</td>
<td>0.95 (0.67, 1.24)</td>
<td>0.69</td>
</tr>
<tr>
<td>CRP</td>
<td>0.90 (0.67, 1.77)</td>
<td>0.46</td>
</tr>
<tr>
<td>Anti-topoisomerase I</td>
<td>6.00 (1.11, 41.1)</td>
<td>0.048</td>
</tr>
<tr>
<td>Anti-centromere</td>
<td>7.4x10^-10 (-, 0.93)</td>
<td>1.00</td>
</tr>
<tr>
<td>Anti-RNA polymerase III</td>
<td>0.36 (0.04, 2.18)</td>
<td>0.29</td>
</tr>
<tr>
<td>Anti-U1-RNP</td>
<td>0.74 (0.08, 5.49)</td>
<td>0.77</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared


AB0655  ELEVATED CIRCULATING LEVELS OF IL-33 IN SYSTEMIC SCLEROSIS PATIENTS WITH INTERSTITIAL LUNG DISEASE

R. Dacheva1, G. Vasilev2, K. Tumangelova-Yuzeir2,3, D. Kyurkchiev2,3, S. Monov4,5.
1University Hospital “St. Ivan Rilski”, Diagnostic and Consultation Center, Sofia, Bulgaria; 2University Hospital “St. Ivan Rilski”, Laboratory of Clinical Immunology, Sofia, Bulgaria; 3Medical University of Sofia, Department of Clinical Immunology, Sofia, Bulgaria; 4University Hospital “St.Ivan Rilski”; Clinic of Rheumatology, Sofia, Bulgaria; 5Medical University - Sofia, Department of Rheumatology, Sofia, Bulgaria

Background: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by immune dysregulation, vasculopathy and progressive skin and internal organ fibrosis. Interstitial lung disease (ILD) remains a leading cause of morbidity and mortality in SSc patients. Interleukin 33 (IL-33) is a member of the IL-1 superfamily and has been previously described as a pro-fibrotic cytokine that exerts its function by inducing Th2 cells differentiation and stimulating the expression of TGF-β. Previous reports have revealed the role of IL-33 in numerous fibrotic diseases.

Objectives: The aim of the present study is to examine the serum levels of IL-33 and explore the possible correlation with clinical and laboratory features with a focus on pulmonary involvement in SSc patients.

Methods: A total number of eighty five (n=85) patients fulfilling the 2013 ACREULAR criteria for classification of SSc were enrolled in the study. Twenty five (n=25) age and sex matched healthy volunteers were used as controls. Detailed medical history, clinical and laboratory parameters were obtained for all included patients. Serum levels of IL-33 (pg/ml) were determined by enzyme-linked immunosorbent assay. GraphPad Prism 6,SPSS V.23 and RStudio were used for the performance of the statistical analysis.

Results: Of all included patients in the analyses, serum sample was obtained from 55 SSc patients, 51 women (92.7%) and 4 men (7.3%): thirty nine (n=39) with diffuse and thirty six (n=36) with limited SSc, respectively. Raynaud's phenomenon (96.9%), Raynaud's phenomenon (96.9%) and female sex (87.8%) were the most common and early manifestations. Gastroesophageal (GE), respiratory and muscular involvement were female (87.8%) and Caucasian (70.4%). Anti-citrullinated peptide antibodies (ACPA) were positive in 40.9% of patients. Anti-RNA polymerase III 0.36 (0.04, 2.18) 0.29 and Anti-U1-RNP 7.4x10^-10 (--, 0.93) 1.00 were positive in 0.36% and 3.1% of patients, respectively.

Conclusion: IL-33 may be involved in the immunopathogenesis of pulmonary fibrosis. The results are consistent with previous studies. The present study is cross-sectional and further analyses and follow-up may be required to determine whether IL-33 may serve as a potential biomarker in the routine practice.

Disclosure of Interests: None declared, Simeon Monov Speakers bureau: I have been paid as a speaker for AMGEN, PFIZER, NOVARTIS, ABBVIE, ROCHE, ASTRA-ZENECA.


AB0656  CLINICAL AND IMMUNOLOGICAL FEATURES OF A PORTUGUESE COHORT OF MIXED CONNECTIVE TISSUE DISEASE

1Unidade Local de Saúde do Alto Minho, Rheumatology Department, Ponte de Lima, Portugal; 2Centro Hospitalar Lisboa Norte, Rheumatology Department, Lisboa, Portugal; 3Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Rheumatology Research Unit, Lisboa, Portugal; 4Centro Hospitalar Universitário São João, Rheumatology Department, Porto, Portugal; 5Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS, Porto, Portugal); 6Hospital Garcia de Orta, Rheumatology Department, Lisbon, Portugal; 7Centro Hospitalar Universitário de Coimbra, Rheumatology Department, Coimbra, Portugal; 8Hospital Lisboa Ocidental, Rheumatology Department, Lisbon, Portugal; 9Hospital de Braga, Rheumatology Department, Braga, Portugal; 10Centro Hospitalar Universitário do Algarve, Rheumatology Department, Faro, Portugal; 11Unidade Local de Saúde da Guarda, Rheumatology Department, Guarda, Portugal; 12Centro Hospitalar Tondela-Viseu, Rheumatology Department, Viseu, Portugal; 13Centro Hospitalar do Baixo Vouga, Rheumatology Department, Aveiro, Portugal; 14Centro Hospitalar Trás-os-Montes e Alto Douro, Rheumatology Department, Vila Real, Portugal; 15Hospital Vila Nova de Gaia/Espinho, Rheumatology Department, Vila Nova de Gaia, Portugal; 16Hospital do Divino Espírito Santo, Rheumatology Department, Ponta Delgada, Portugal; 17Unidade Local de Saúde de Castelo Branco, Rheumatology Unit, Castelo Branco, Portugal

Background: Various nationwide studies have been already published to better understand Mixed Connective Tissue Disease (MCTD) (1,2). However, Portuguese data is not available.

Objectives: To characterize clinical and immunological features of a Portuguese cohort of patients with MCTD.

Methods: Retrospective, multicenter study including adult-onset patients with clinical diagnosis of MCTD and fulfilling at least one of the following classification criteria: Sharp, Kasukawa, Alarcón-Segovia or the Kahn's criteria. Positivity to autoantibodies besides anti-U1-RNP were allowed. SPSS was used for statistical analysis and significance level was defined as 2-sided p<0.05.

Results: A total of 98 patients were included, with a mean age at diagnosis and disease duration of 40.5±17.7 and 70±6.5 years, respectively. Most patients were female (87.8%) and Caucasian (70.4%). Raynaud's phenomenon (96.9%), arthralgia/arthritis (94.9±77.9%) and puffy fingers (60.2%) were the most common and early manifestations. Gastroesophageal (GE), respiratory and muscular...
involvement were also prevalent, mostly during the follow up, affecting 30.6%, 34.7% and 43.9% of the patients, respectively. Clinical and immunological characteristics are described in Table 1. Males were older at symptom’s onset (65.0 VS 46.7, p<0.06), having more respiratory involvement (OR=4.5, 95% CI 1.5-16.4), and positivity to anti-ACP (OR=20.0, 95% CI: 3.1-129.4). QE involvement occurred more often in Caucasian patients (OR=3.8; 95% CI: 1.0-14.1), while anemia of chronic diseases (OR=2.7; 95% CI: 1.0-7.2), myositis (OR=3.6; 95% CI: 1.3-9.9) and constitutional symptoms (OR=3.2; 95% CI: 1.2-8.3) were more frequent in Afro-American patients, whose were also younger at disease (34.1 VS 46.7, p<0.01). After a median follow-up time of 4 (IQR 8) years, 4 deaths occurred (4.1%), mostly (75%) due to infectious complications.

Table 1. Clinical and immunological characteristics

<table>
<thead>
<tr>
<th>Clinical Manifestations</th>
<th>At presentation</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mucocutaneous system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raynaud’s phenomenon, n (%)</td>
<td>85 (86.7)</td>
<td>95 (96.9)</td>
</tr>
<tr>
<td>Puffy hands, n (%)</td>
<td>48 (49.0)</td>
<td>59 (60.2)</td>
</tr>
<tr>
<td>SSC-like, n (%)</td>
<td>43 (44.8)</td>
<td>59 (60.8)</td>
</tr>
<tr>
<td>SLE-like, n (%)</td>
<td>28 (28.9)</td>
<td>35 (35.7)</td>
</tr>
<tr>
<td>Musculoskeletal system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia/Arthritis, n (%)</td>
<td>81 (82.7)</td>
<td>56 (57.1)</td>
</tr>
<tr>
<td>Myositis, n (%)</td>
<td>26 (26.3)</td>
<td>43 (43.9)</td>
</tr>
<tr>
<td>Hematological system, n (%)</td>
<td>46 (46.9)</td>
<td>70 (71.4)</td>
</tr>
<tr>
<td>Respiratory system, n (%)</td>
<td>14 (14.3)</td>
<td>34 (34.7)</td>
</tr>
<tr>
<td>Cardiovascular system, n (%)</td>
<td>3 (3.1)</td>
<td>4 (4.1)</td>
</tr>
<tr>
<td>Pulmonary hypertension*</td>
<td>2 (2.0)</td>
<td>15 (15.3)</td>
</tr>
<tr>
<td>Gastroesophageal involvement, n (%)</td>
<td>11 (11.2)</td>
<td>30 (30.6)</td>
</tr>
<tr>
<td>Renal involvement, n (%)</td>
<td>2 (2.0)</td>
<td>10 (10.2)</td>
</tr>
<tr>
<td>Neurological involvement, n (%)</td>
<td>6 (6.3)</td>
<td>14 (14.3)</td>
</tr>
<tr>
<td>Constitutional symptoms, n (%)</td>
<td>26 (26.3)</td>
<td>30 (30.6)</td>
</tr>
<tr>
<td>Immunological characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA, n (%)</td>
<td>21 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Anti-smith antibody, n (%)</td>
<td>21 (21.4)</td>
<td></td>
</tr>
<tr>
<td>Anti-Ro/SSA, n (%)</td>
<td>31 (31.6)</td>
<td></td>
</tr>
<tr>
<td>Anti-La/SSB, n (%)</td>
<td>7 (7.1)</td>
<td></td>
</tr>
<tr>
<td>Anti-centromere, n (%)</td>
<td>3 (4.1)</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid Factor, n (%)</td>
<td>39 (39.8)</td>
<td></td>
</tr>
<tr>
<td>Anti-ccr-1/4ulinated protein antibodies, n (%)</td>
<td>6 (6.1)</td>
<td></td>
</tr>
<tr>
<td>Antiphospholipid antibodies, n (%)</td>
<td>7 (7.1)</td>
<td></td>
</tr>
<tr>
<td>Myositis antibodies, n (%)</td>
<td>9 (9.2)</td>
<td></td>
</tr>
<tr>
<td>Complement activation, n (%)</td>
<td>27 (27.6)</td>
<td></td>
</tr>
<tr>
<td>Hypergammaglobulinemia, n (%)</td>
<td>51 (52.2)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Raynaud’s phenomenon, puffy fingers and arthritis were the most common manifestations in Portuguese patients, with similar proportions found in literature (1.2). However, we reported some differences in mucocutaneous, renal and sera involvement and higher prevalence of probable pulmonary hypertension (1.2), which may be explained by the heterogeneity of the inclusion criteria. Except for respiratory, myositis, GE and constitutional symptoms, there were no differences regarding gender and ethnicity. Here, we characterize the largest cohort of MCTD in Portugal.

REFERENCES:

Disclosure of Interests: None declared


AB0056

CAROTID INTIMA-MEDIA THICKNESS AS POTENTIAL MARKER OF CARDIOVASCULAR RISK IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY.

F. S. Iaquinta1, S. Di Napoli2, R. Grosso2, S. Naty1, V. Cassano3, D. Crescibene3, G. Armentano2, A. Sciacquac2, R. D. Grencis3. 1"Magna Graecia" University of Catanzaro, Rheumatology Research Unit, Department of Health Sciences, Catanzaro, Italy; 2"Magna Graecia" University of Catanzaro, Department of Health Sciences, Catanzaro, Italy; 3"Magna Graecia" University of Catanzaro, Department of Medical and Surgical Sciences, Catanzaro, Italy

Background: In several rheumatic diseases, persistent inflammatory state has been related to an accelerated atherosclerosis. Although the risk of cardiovascular (CV) events and atherosclerosis is increased in patients with Systemic Sclerosis (SSc), the exact underlying process has not been well defined. Indeed, inflammation is not a remarkable feature of systemic sclerosis pathogenesis as in other inflammatory rheumatic diseases.

Objectives: The aim of this study was to evaluate the carotid intima-media thickness (c-IMT) as potential marker of cardiovascular damage in SSc patients.

Methods: Between April and July 2021, 14 consecutive patients with SSc and 14 control subjects were enrolled in the study. Participants were aged > 18 and were able to provide written informed consent. Demographic, anthropometric and cardiovascular risk factors (smoking, arterial hypertension, diabetes and family history of CV events) were collected for each subject. Moreover, an evaluation of the sero-haematological characteristics was also performed. The c-IMT was assessed by the same qualified physician through a B-mode ultrasound examination. C-IMT values ≥ 0.9 mm were considered pathological.

Results: Demographic and clinical characteristics are shown in Table 1. Traditional CV risk factors were similar between groups, although BMI was significantly lower in SSc patients than controls (24.6 VS 26.2, p=0.019). Patients’ median disease duration was 11 [5.0-16] years. Three patients had limited and 11 patients had diffuse disease according to LeRoy classification. Anti-nuclear antibodies were detected in all SSc subjects. Three patients expressed anti-centromere antibodies (ACA), other 3 are anti-Scl70 antibodies positive, only one patient showed anti-RNA polymerase III antibodies and 7 patients did not presented specific SSc autoantibodies. SSc patients had slightly increased c-IMT compared with controls, however the difference did not reach statistical significance (median c-IMT 0.84 [0.72-0.91] vs median c-IMT 0.68 [0.63-0.82], p=0.164).

Table 1.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Controls (n=14)</th>
<th>SSc patients (n=14)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographic and Anthropometric</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>60±4</td>
<td>61±13</td>
<td>0.836</td>
</tr>
<tr>
<td>Gender, female (%)</td>
<td>14 (100)</td>
<td>14 (100)</td>
<td></td>
</tr>
<tr>
<td>Smoking habit, yes (%)</td>
<td>5 (36)</td>
<td>5 (36)</td>
<td>1</td>
</tr>
<tr>
<td>AH, yes (%)</td>
<td>7 (50)</td>
<td>8 (57)</td>
<td>0.705</td>
</tr>
<tr>
<td>T2DM, yes (%)</td>
<td>5 (36)</td>
<td>4 (29)</td>
<td>0.686</td>
</tr>
<tr>
<td>Dyslipidemia, yes (%)</td>
<td>6 (43)</td>
<td>4 (29)</td>
<td>0.430</td>
</tr>
<tr>
<td>CVD familiarity, yes (%)</td>
<td>6 (43)</td>
<td>4 (29)</td>
<td>0.430</td>
</tr>
<tr>
<td>Total Cholesterol (mg/dl) 189 [167-218]</td>
<td>170 [128-197]</td>
<td>0.094</td>
<td></td>
</tr>
<tr>
<td>LDL (mg/dl) 117 [96-139]</td>
<td>100 [80-115]</td>
<td>0.125</td>
<td></td>
</tr>
<tr>
<td>HDL (mg/dl) 61 [50-77]</td>
<td>56 [45-63]</td>
<td>0.329</td>
<td></td>
</tr>
<tr>
<td>Triglycerides (mg/dl) 107 [92-133]</td>
<td>107 [99-131]</td>
<td>0.667</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iloprost 0 (0)</td>
<td>14 (100)</td>
<td>1.21x10-7</td>
<td></td>
</tr>
<tr>
<td>ERA, yes (%)</td>
<td>0 (0)</td>
<td>9 (64)</td>
<td>2.71x10-4</td>
</tr>
<tr>
<td>HMG-CoA reductase inhibitors, yes (%)</td>
<td>6 (43)</td>
<td>4 (29)</td>
<td>0.430</td>
</tr>
</tbody>
</table>

Continuous data are presented as mean ± standard deviation or as median and interquartile range. Binomial data are shown as frequencies and percentages. The overall p-value was calculated by the Mann–Whitney non-parametric test for independent samples and by Chi-squared test as appropriate.

Conclusion: In our study patients with SSc had a non-significative increased c-IMT compared with controls (p=0.164), however different results have been reported in previous studies. Although it is not clear whether c-IMT may be considered a marker of cardiovascular damage in SSc, further studies are needed to clarify its role.

REFERENCES:

Disclosure of Interests: None declared

Background: Gastrointestinal (GI) involvement is a common manifestation of systemic sclerosis (SSc) and a frequent side-effect of drugs used to treat SSc. In the SENSCIS trial, nintedanib reduced the rate of decline in forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (SSc-ILD), with an adverse event profile characterised predominantly by GI events.

Objectives: To assess the severity and impact of GI symptoms on quality of life in patients treated with nintedanib in the open-label extension trial, SENSCIS-ON. Methods: Patients with SSc-ILD who completed the SENSCIS trial or a drug–drug interaction (DDI) study of nintedanib and oral contraceptive were eligible to enter SENSCIS-ON. Patients who received nintedanib in SENSCIS (up to 100 weeks) and continued nintedanib in SENSCIS-ON comprised the “continued nintedanib” group. Patients who received placebo in SENSCIS and initiated nintedanib in SENSCIS-ON, or who received nintedanib for a short time in the DDI study, comprised the “initiated nintedanib” group. We assessed changes in scores on the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) questionnaire v2.0 from baseline to week 52. This questionnaire comprises 7 scales measuring the severity and impact of GI symptoms: reflux, distension or bloating, faecal soiling, diarrhoea, constipation, emotional well-being, social functioning. Each scale is scored from 0 to 3 except for the diarrhoea scale (0 to 2) and constipation scale (0 to 2.5). The total score, the mean of the scores for the scales except constipation, ranges from 0 to 2.83, with higher scores indicating worse symptoms.

Results: The “continued nintedanib” group comprised 197 patients and the “initiated nintedanib” group comprised 247 patients (231 from SENSCIS). Of these, 178 and 218 patients, respectively, provided a total UCLA SCTC GIT score at baseline. At baseline, mean (SD) total scores were 0.33 (0.33) and 0.33 (0.34) in the continued nintedanib and initiated nintedanib groups, respectively. Mean (SD) scores on the 7 scales ranged from 0.16 (0.52) to 0.70 (0.73) in the continued nintedanib group and from 0.13 (0.43) to 0.64 (0.68) in the initiated nintedanib group. Increases (worsening) in scores were observed in both groups from baseline to week 52, except for the constipation scale (Figure 1). Based on the total score, between baseline and week 52, the proportion of patients with moderate or severe or very severe GI symptoms increased, but 45.7% and 39.7% of patients in the continued nintedanib and initiated nintedanib groups, respectively, had no or mild GI symptoms at week 52 (Table 1).

Conclusion: In the SENSCIS-ON trial, the majority of patients with SSc-ILD treated with nintedanib had no or mild GI symptoms at baseline. A small worsening in GI symptoms was observed over 52 weeks. Diarrhoea had the greatest impact, reflecting the adverse event profile of nintedanib. Recommendations for the management of diarrhoea in patients treated with nintedanib should be implemented in clinical practice.

Acknowledgements: The SENSCIS-ON trial was funded by Boehringer Ingelheim.

Disclosure of Interests: Dinesh Khanna Shareholder of: Eicos Sciences, Inc - stocks, Consultant of: AbbVie, Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos NV, Genentech/Roche, GlaxoSmithKline, Horizon Therapeutics, Merck Sharp & Dohme, Mitsubishi Tanabe Pharma, Sanofi-Aventis, United Therapeutics, Prometheus, Thera1y, AstraZeneca, Grant/research support from: Bayer, Bristol-Myers Squibb, Horizon Therapeutics, Immune Tolerance Network, National Institutes of Health, Pfizer, Employee of: CiviBioPharma/Eicos Sciences, Inc - Leadershhip/Equity position - Chief Medical Officer, Elizabeth Volkmann Sprieger bureau: Boehringer Ingelheim, Consultant of: Boehringer Ingelheim. Grant/research support from: Boehringer Ingelheim, Corbus, Forbis, Horizon, Kadmon, Kristin Highland Speakers bureau: Actelion Pharmaceuticals (Jansen), Bayer Healthcare, Boehringer Ingelheim, United Therapeutics, Paid instructor for: Acceleron Pharmaceuticals, Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, Gilead Sciences, United Therapeutics, Consultant of: Boehringer Ingelheim, United Therapeutics, Genentech, Forsee Pharmaceuticals, Grant/research support from: Acceleron Pharmaceuticals, Actelion Pharmaceuticals, Bayer Pharmaceuticals, Curodash, Genentech, Gilead, GlaxoSmithKline, LVL, Mundipharma, Novartis, Pfizer, Roche, Consultant of: Advisory Boards, Consultancy - AIRB, Boehringer Ingelheim, Roche, Grant/research support from: Recherche Clinique - AIRB, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Galactic, Gilead, LVL, Roche, Savara Aides pour des recherches - AIRB, Boehringer Ingelheim, LVL, Novartis, Roche, James Seibold Shareholder of: Prometheus Biosciences, Speakers bureau: Boehringer Ingelheim, Consultant of: Alexion, Blade, Camurus AB, GlaxoSmithKline, Prometheus Biosciences, Sironax, Soojumix, Xenikos, Employee of: Prometheus Biosciences, Alexandre James Employee of: Alexandre James is an employee of Elderbrook solutions GmbH that is contracted by Boehringer Ingelheim, Margarida Alves Employee of: Margarida Alves is an employee of Boehringer Ingelheim, Oliver Distler Speakers bureau: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Speaker fee: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant of: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Consultancy fee: Abbvie, Acceleron, Alimced, Amgen, AnaMar, Arxo, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltenyi Biotec, Mit- telstand, MSD, Novartis, Prometheus, Roivant, Salix and Teakador OD has/had relationships with the following companies in the area of potential treatments for arthritis in the last three calendar years: Consultancy fee: Abbvie, Grant/research support from: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Research Grants: Boehringer Ingelheim, Kymera, Mitsubishi Tanabe DOI: 10.1136/annrheumdis-2022-eular.714

Table 1. Changes in severity and impact of gastrointestinal symptoms based on UCLA SCTC GIT total score between baseline and week 52 of SENSCIS-ON

<table>
<thead>
<tr>
<th>Week</th>
<th>Baseline</th>
<th>None or mild</th>
<th>Moderate</th>
<th>Severe or very severe</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Continued nintedanib</td>
<td>None or mild</td>
<td>81 (41.1)</td>
<td>5 (2.5)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>38 (19.3)</td>
<td>10 (5.1)</td>
<td>0</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td></td>
<td>Severe or very severe</td>
<td>13 (6.6)</td>
<td>14 (7.1)</td>
<td>7 (3.6)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td></td>
<td>Missing</td>
<td>6 (3.0)</td>
<td>3 (1.5)</td>
<td>1 (0.5)</td>
<td>13 (6.6)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>136 (70.1)</td>
<td>32 (16.2)</td>
<td>8 (4.1)</td>
<td>19 (9.6)</td>
</tr>
<tr>
<td>Initiated nintedanib</td>
<td>None or mild</td>
<td>87 (35.2)</td>
<td>6 (2.4)</td>
<td>1 (0.4)</td>
<td>4 (1.6)</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>35 (14.2)</td>
<td>12 (4.9)</td>
<td>2 (0.8)</td>
<td>3 (1.2)</td>
</tr>
<tr>
<td></td>
<td>Severe or very severe</td>
<td>8 (3.2)</td>
<td>7 (2.8)</td>
<td>4 (1.6)</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td></td>
<td>Missing</td>
<td>37 (15.0)</td>
<td>15 (6.1)</td>
<td>4 (1.6)</td>
<td>21 (8.5)</td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>167 (67.6)</td>
<td>46 (20.2)</td>
<td>12 (5.4)</td>
<td>29 (11.7)</td>
</tr>
</tbody>
</table>

Data are n (%) of patients. None or mild/scores of 0 to 0.49; moderate/scores of 0.5 to 1; severe or very severe/scores of 1.01 to 3.
NOCEO EFFECT ON DIARRHOEA REPORTED IN THE SENSICS TRIAL OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)

O. Distler1, K. Highland2, A. Azuma3, C. Miede4, M. Alves5, P. Sfikakis6

1University Hospital Zurich, University of Zurich, Department of Rheumatology, Zurich, Switzerland; 2Cleveland Clinic, Department of Pulmonary, Cleveland, OH, United States of America; 3Graduate School of Medicine, Nippon Medical School, Department of Pulmonary Medicine and Oncology, Tokyo, Japan; 4mainanalytics GmbH, Statistics, Sulzbach (Taunus), Germany; 5Boehringer Ingelheim International GmbH, TA Inflammation Med, Ingelheim, Germany; 6National Kapodistrian University of Athens Medical School, 1st Dept of Prop. Internal Medicine & Joint Academic Rheumatology Program, Athens, Greece

Background: Unfavourable effects observed after administration of placebo may be attributed to factors such as expectation or conditioning as known are nocebo effects. Prior to initiation of the SENSICS trial, diarrhoea was a known side-effect of nintedanib. Objectives: To investigate whether a nocebo effect contributed to reporting of diarrhoea in the SENSICS trial. Methods: The SENSICS trial enrolled patients with systemic sclerosis (SSc) with first non-Raynaud symptom in the prior ≤100 years and a ≥10% extent of fibrotic ILD on high-resolution computed tomography. Patients were randomised to receive nintedanib or placebo until the last patient had reached week 52 but for ≤100 weeks. A follow-up visit was conducted 28 days after the end of treatment. Adverse events were reported by investigators irrespective of causality and coded according to the Medical Dictionary for Regulatory Activities. We analysed the incidence of diarrhoea adverse events in the on-treatment period (i.e., events with onset between the first intake of trial drug intake and the last intake plus 7 days) and in the post-discontinuation period (i.e., events with onset between the first day after the on-treatment period and the end of the follow-up period) in the nintedanib and placebo groups. Incidence rates were calculated as the number of patients with diarrhoea adverse events divided by the time at risk. Results: In the on-treatment period (time at risk: 277.7 patient-years), the rate of diarrhoea adverse events in the placebo group (n=288) was 33.1 per 100 patient-years. In the post-discontinuation period (time at risk: 41.9 patient-years), the rate of diarrhoea adverse events in the placebo group (n=264) was 19.1 per 100 patient-years. In the on-treatment period (time at risk: 105.1 patient-years), the rate of diarrhoea adverse events in the nintedanib group (n=288) was 209.3 per 100 patient-years. In the post-discontinuation period (time at risk: 53.7 patient-years), the rate of diarrhoea adverse events in the nintedanib group (n=263) was 5.6 per 100 patient-years.

Conclusion: In the SENSICS trial in patients with SSc-ILD, the rate of diarrhoea adverse events in the placebo group fell after trial drug was discontinued. This suggests that a nocebo effect may have contributed to the diarrhoea adverse events reported in the SENSICS trial.

Acknowledgements: The SENSICS trial was funded by Boehringer Ingelheim, Oliver Distler, Kristin B Highland and Arata Azuma were members of the SENSICS trial Steering Committee.

DISCLOSURE OF INTERESTS: Oliver Distler Speakers bureau: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Speaker fee: Bayer, Boehringer Ingelheim, Janssen, Medscape, Consultant: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Consultant fee: Abbvie, Acceleron, Aclidem, Amgen, Anax, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, 4P Science, Galapagos, Genmark, Horizon, Inveniva, Kymera, Lupin, Mitsubishi, Mitsubishi Tanes, MSD, Novartis, Proheus, Roivant, Sanofi and Topadur OD has/had relationships with the following companies in the area of potential treatments for arthritis in the last three calendar years: Consultant fee: Abbvie, Grant/research support from: OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Research Grants: Boehringer Ingelheim, Kymera, Mitushishi Tane, Kristin Highland Speakers bureau: Actelion Pharmaceuticals (Jansen), Bayer Healthcare, Boehringer Ingelheim, United Therapeutics, Paid instructor for: Acceleron Pharmaceuticals, Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, Gilead Sciences, United Therapeutics, Consultant of: Boehringer Ingelheim, Forsee Pharmaceuticals, Genentech, United Therapeutics, Grant/research support from: Acceleron Pharmaceuticals, Actelion Pharmaceuticals, Bayer Healthcare, Boehringer Ingelheim, Genentech, Gossamer Bio, Eiger Pharmaceuticals, Lilly Pharmaceuticals, Reata Pharmaceuticals, United Therapeutics, Viela Bio (Horizon Pharmaceuticals), Arata Azuma Speakers bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Consultant of: Boehringer Ingelheim, Kyorin Pharma, Taiho Co., Toray Medical Co., Grant/research support from: Boehringer Ingelheim, Taiho Co., Corinna Miede Employee of: Corinna Miede is an employee of mainanalytics GmbH that is contracted by Boehringer Ingelheim, Margarida Alves Employee of: Margarida Alves is an employee of Boehringer Ingelheim, Petros Sfikakis: None declared

DOI: 10.1136/annrheumdis-2020-eular.749

RECRUITMENT AND PREVALENCE OF MIXED PHENOTYPE MACROPHAGES IS PROMINENT IN BRONCHOALVEOLAR LAVAGE (BAL) OF SYSTEMIC SCLEROSIS (SSC) PATIENTS WITH INTERSTITIAL LUNG DISEASE (ILD)

V. A. Adams, J. T. Gan1, J. Bosma1, W. Abdulrahad1, I. M. Atzeni2, M. Van der Leij3, B. J. Kroese3, A. J. Stei4, W. Timens5, J. Burgess6, H. Van Goor7, J. Westra7, D. J. Mulder1

1University Medical Center Groningen, Pathology Groningen, Netherlands; 2University Medical Center Groningen, Pulmonary Diseases and Tuberculosis, Groningen, Netherlands; 3University Medical Center Groningen, Rheumatology and clinical medicine, Groningen, Netherlands; 4University Medical Center Groningen, Medical Immunology, Groningen, Netherlands

Background: ILD is a major problem in SSc for which no disease-modifying therapies are available. Many observations suggest monocyte/macrophage involvement in SSc and might be a key component in the development of ILD. Macrophages polarize into M1 and M2 phenotypes and thereby orchestrate inflammation and subsequent fibrosis by responding to and producing a vast array of cytokines and chemokines. Differences in the levels of the chemokines may explain variations in the recruitment and activation of macrophages in affected organs. In SSc, macrophages with a mixed phenotype (expressing both M1 and M2 markers) are prominent in peripheral blood. No previous study has investigated the mixed phenotype macrophages locally on the lung level.

Objectives: To measure macrophage-related chemokines in BAL fluid obtained from SSc-ILD and SSc-No-ILD patients. Methods: To investigate levels of M1 and M2 macrophage markers in BAL cells obtained from SSc-ILD and SSc-No-ILD patients. Methods: A cross-sectional study in which BAL procedure was performed on 15 treatment-naïve SSc patients divided into two groups according to lung involvement determined by HRCT and lung function tests: SSc-ILD group and SSc-No-ILD group (Table 1). Levels of chemokines (CCL18, CXCL-10 and CCR2) were analysed using ELISA, miRNA expression levels of CD68 (M1: inflammatory macrophage marker) and CD206 (M2: fibrogenic macrophage marker) in cells isolated from BAL were assessed using RT-qPCR. In addition, immunofluorescence studies and flow cytometry analyses were performed to evaluate the expression of M1 (CD68) or M2 (CD206) markers in BAL macrophages.

Table 1. Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>No ILD</th>
<th>ILD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Age</td>
<td>57 (51-68)</td>
<td>60 (53-73)</td>
</tr>
<tr>
<td>Female</td>
<td>75%</td>
<td>57%</td>
</tr>
<tr>
<td>Raynauds phenomenon</td>
<td>100%</td>
<td>85%</td>
</tr>
<tr>
<td>Age start of Raynauds</td>
<td>36 (22-53)</td>
<td>56 (41-66)</td>
</tr>
<tr>
<td>Age start of non-Raynauds</td>
<td>50 (33-60)</td>
<td>49 (36-68)</td>
</tr>
<tr>
<td>Skin thickening</td>
<td>50%</td>
<td>43%</td>
</tr>
<tr>
<td>Digital ulcer at this moment</td>
<td>0%</td>
<td>29%</td>
</tr>
<tr>
<td>Digital ulcer in the past</td>
<td>36%</td>
<td>29%</td>
</tr>
<tr>
<td>Pitting scars</td>
<td>38%</td>
<td>43%</td>
</tr>
<tr>
<td>Telangectasia</td>
<td>50%</td>
<td>43%</td>
</tr>
<tr>
<td>Calcinosis</td>
<td>13%</td>
<td>25%</td>
</tr>
<tr>
<td>Cardiac</td>
<td>25%</td>
<td>14%</td>
</tr>
<tr>
<td>Gastro-intestinal</td>
<td>88%</td>
<td>43%</td>
</tr>
<tr>
<td>Kidney</td>
<td>0%</td>
<td>0%</td>
</tr>
</tbody>
</table>

Results: Macrophages were the predominant immune cell population in BAL of SSc patients (73%). The levels of CCL18, CCR2 and CXCL10 were slightly elevated in the SSc-ILD group compared to the SSc-no-ILD group (Figure 1.1). RT-qPCR data showed that CD86 expression was elevated in the SSc-ILD group while no difference was observed in CD206 expression between the two groups (data not shown). The SSc-ILD group had higher proportions of double-positive (CD68+, CD206+) macrophages than SSc-no-ILD which, in contrast, had higher proportions of CD68+ CD206- macrophages (Figure 1.2). These results were supported by fluorescent microscopy images in which the SSc-ILD group had higher CD86 and CD206 expression than the SSc-no-ILD group (Figure 1.3). Double staining clearly showed a more prevalent mixed activation of macrophages in the SSc-ILD group.
Conclusion: In this pilot study, recruitment and activation of mixed phenotype macrophages was more prominent in SSc-ILD than in SSc-no-ILD. Although levels of chemokines were not profoundly different between both groups, studying extensively the macrophage activation patterns in BAL provided novel findings regarding differences between the two groups. Since SSc is characterised by inflammatory and fibrotic phases, the mixed polarization of macrophages we showed for the first time in SSc-ILD patients on an organ level is a key aspect in such disease and could potentially serve as a target for therapeutics.

REFERENCES:

Disclosure of Interests: None declared.

E. B. Adjailia1, H. Grasshoff1, J. Y. Humrich1, P. Lamprecht1, G. Riemekasten1.

AB0660

LONG-TERM EFFECT OF COMBINATION THERAPY WITH RITUXIMAB AND MYCOPHENOLIC ACID ON CARDIAC MANIFESTATIONS, PULMONARY FUNCTION AND SKIN FIBROSIS IN SYSTEMIC SCLEROSIS

F. R. A. da Silva1, H. Grashoff1, J. Y. Humrich1, P. Lamprecht1, G. Riemekasten1.

1University Medical Center Schleswig Holstein, Rheumatology and clinical immunology, Lübeck, Germany

Background: Cardiac manifestations in systemic sclerosis (SSc) can be either due to the fibrotic and vascular process or secondary to pulmonary arterial hypertension (PAH), cardiac inflammation, or renal crisis. Despite being one of the leading causes of death in SSc, cardiac involvement and its therapeutic options have been poorly studied. According to the ACR/EULAR recommendations, therapy with cyclophosphamide (CP) is applied to patients with cardiac manifestations. However, in case of inadequate response to CP, there are no other therapeutics evaluated.

Objectives: The aim of this retrospective analysis was to explore the efficacy of a therapy with rituximab and mycophenolic acid (MPA), especially in cases of CP failure or therapy induced cardiac toxicity.

Methods: 14 Patients with SSc and cardiac involvement (defined as troponin T elevation plus right- or left ventricular systolic or diastolic dysfunction, myocarditis, pericarditis, right heart failure secondary to PAH, or arrhythmias) were analysed. Two patients each showed concomitant myositis and rheumatoid arthritis, respectively. Twelve patients were initially treated with CP and two patients with methotrexate (MTX). Due to a disease progress (either cardiac involvement, skin fibrosis or lung function) a therapy with rituximab and MPA was initiated [1]. These patients were followed for up to five years.

Results: Before initiation of CP or MTX electrocardiogram showed arrhythmias (atrial fibrillation, conduction blocks, multifocal ventricular extrasystoles (VES)) in 9 patients. Echocardiography revealed abnormalities in 10 patients including reduced left-ventricular ejection fraction (LV-EF), diastolic dysfunction, mitral regurgitation, or aortic aneurysm. 3 patients had PAH, 2 patients were diagnosed with post capillary pulmonary hypertension. Cardiac MRI revealed signs of myocarditis in 4 patients. 4 patients required cardiac resynchronization therapy or pacemaker implantation. Moreover, body plethysmography showed a reduction in forced vital capacity (FVC) in 12 patients, suggestive of restrictive lung disease. Under therapy with CP 11 patients had suffered from disease progress, 1 patient developed relapsing pneumonias and the 2 patients with overlap rheumatoid arthritis developed cardiac disease manifestations on MTX monotherapy. Consequently, rituximab 1000 mg q12weeks and MPA 1000 mg q2weeks were initiated. Under this combination troponin T decreased in all patients (p=0.0002), LV-EF improved in 5, remained normal in 7 and deteriorated in 2 patients. The rate of VES improved in 8 patients. In one patient, myocarditis resolved completely (MRI). Moreover, pulmonary artery systolic pressure, measured by echocardiography, improved in all patients diagnosed with PAH under stable therapy. The modified Rodnan skin score improved in all patients, FVC improved in 7 patients, remained stable in 6 and decreased in the patient with overlap myositis. Rituximab infusions could be extended (1000 mg q4weeks) after 24-36 months of treatment in 11 patients. All patients showed peripheral blood depletion of B cells without noticed severe IgG deficiency. While 11 patients did not develop severe complications 2 patients died during follow-up of pneumonia and cardiogenic shock (overlap myositis), respectively and one patient developed a relapse of lung cancer with cerebral metastasis.

Conclusion: Therapy with rituximab and MPA is a promising alternative. However, its use requires risk stratification of patients with respect to adverse side effects which needs to be explored in future studies.

REFERENCES:

Disclosure of Interests: None declared.

L. Moschetti1, M. G. Lazzaroni1, E. Pedretti1, A. Bano1, C. Nalli1, F. Cucci1, A. Molinaro2, J. Galli2, F. Fazzi2, F. Franceschini1, A. Tincani1, P. Arlo1, L. Andreoli1, A. M. Molinaro2, A. Tincani1, F. Fazzi2, F. Franceschini1, P. Arlo1, L. Andreoli1, A. Tincani1, F. Fazzi2, F. Franceschini1, P. Arlo1.

1ASST Spedali Civili, University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 2ASST Spedali Civili, University of Brescia, Obstetrics and Gynaecology, Brescia, Italy

AB0661

NEUROPSYCHOLOGICAL OUTCOME OF CHILDREN BORN TO WOMEN WITH SYSTEMIC SCLEROSIS ASSESSED THROUGH A SELF-ADMINISTERED MULTIDISCIPLINARY QUESTIONNAIRE: RESULTS FROM A MONOCENTRIC COHORT

L. Moschetti1, M. G. Lazzaroni1, E. Pedretti1, A. Bano1, C. Nalli1, F. Cucci1, A. Molinaro2, J. Galli2, F. Fazzi2, F. Franceschini1, A. Tincani1, P. Arlo1, L. Andreoli1, A. M. Molinaro2, A. Tincani1, F. Fazzi2, F. Franceschini1, P. Arlo1, L. Andreoli1, A. Tincani1, F. Fazzi2, F. Franceschini1, P. Arlo1.

1ASST Spedali Civili, University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 2ASST Spedali Civili, University of Brescia, Obstetrics and Gynaecology, Brescia, Italy

Background: In the last years, the rate of successful pregnancies has significantly increased in Systemic Sclerosis (SSc) women. However, the long-term outcome of their children remains an unexplored issue.

Objectives: To evaluate the neuropsychiatric (NP) outcome of children born to SSc mothers.
Methods: An ad-hoc questionnaire, regarding different aspects of child’s neurodevelopment (ND) (3 sections: childhood [0-5 years]; school age [6-11 years]; adolescence [12-18 years]), was created and administered to female SSC patients (ACR/EULAR 2013 criteria) attending our outpatient clinic during 2021 and who had at least 1 child. Children’s NP characteristics were compared between 3 subgroups: A) born ≥10 years before SSC diagnosis; B) born ≤10 years before SSC diagnosis; C) born after SSC diagnosis. Results below are expressed as number/total number of answers collected for each question.

Results: 100 SSC women reported 189 pregnancies: 152 resulted in 154 live births (2 twin pregnancies).

At least one NP alteration was reported in 42/119 (35%) subjects, more frequently in group B (57%), as compared to group A (31%, p=0.07) and group C (30%, p=0.09) although not statistically significant (Figure 1). Sleep irregularities were the most frequently reported disorder (15/42, 36%). Comparisons between the 3 subgroups for each NP outcome evaluated are shown in Table 1: overall, a higher rate of NP alterations were reported in children belonging to group B.

In addition, SSC mothers declared that 7/123 (6%) children underwent a NP evaluation leading to a diagnosis in 3 cases: 1 cognitive delay, 1 learning disorder (LD) and 1 autism spectrum disorder (ASD). These children were born 1 and 5 years before and 3 years after SSC diagnosis, respectively. The prevalence of these diagnoses (0.8%) does not differ from general pediatric population.

Conclusion: Children born to SSC mothers, had prevalence of major NP alterations (cognitive deficits, LDs, ASDs) similar to general pediatric population. A higher frequency of minor ND disorders, especially sleep irregularities, was observed in children within 10 years before maternal diagnosis, compared to the other groups, possibly suggesting an impact of maternal chronic disease on the relationship with child in the first years of life. To confirm these self-reported preliminary data, the extension of the study will consist in a systematic NP evaluation proposed to all offspring of SSC mothers aged ≤18 years.

REFERENCES:

Acknowledgements: GILS (Gruppo Italiano Lotta Sclerodermia) is kindly acknowledged for supporting the study with a grant.

Disclosure of Interests: None declared


DISORDERS IN CHILDHOOD

N° of subjects evaluated for

Sleep irregularities 6/79 (8*) 4/13 (31*) 5/23 (22)
Motor difficulties 0/77 (3) 2/13 (15) 2/26 (8)
Difficulty in relationships 0/78 (0) 1/11 (9) 2/26 (8)
Difficulty in non-verbal communication skills 0/78 (0) 1/11 (9) 2/26 (8)
Difficulty in social integration 0/77 (0) 3/12 (25) 1/26 (4)
Cognitive difficulties 0/77 (0) 1/12 (8) 2/26 (8)

DISORDERS IN SCHOLAR AGE

N° of subjects evaluated for

School year repetition 11/76 (15) 2/13 (15) 0/15 (0)
Behavioral problems during school period 4/76 (5) 1/12 (8) 1/15 (7)
Difficulty in school lessons/homework 7/77 (9) 3/12 (25) 0/15 (0)

DISORDERS IN ADOLESCENCE

N° of subjects evaluated for

Difficulty in managing anger and aggression 4/75 (5) 0/11 (0) 0/10 (0)
Behavioral alterations 0/75 (0) 0/11 (0) 0/10 (0)
Difficulty in conduct 2/73 (3) 0/11 (0) 2/10 (20)
Mood alterations 1/73 (1) 1/11 (9) 0/10 (0)
Alterations of the feeding behavior 1/75 (1) 0/11 (0) 0/10 (0)
Anxiety problems 1/75 (1) 1/10 (10) 0/10 (0)

*Variables were compared with Chi Squared/exact Fisher test.

Results are presented as number/total number (%) of answers collected for each question.
**BICENTRIC OBSERVATIONAL STUDY ON THE THERAPEUTIC MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AND SYSTEMIC SCLEROSIS OVERLAP SYNDROME**

**N. Lebe1, C. Marcelli2, I. Marie3, H. Levesque4, T. Lequerre5, O. Vittecoq.**

1Hospital Center University De Rouen, Rheumatology, Rouen, France; 2University Of Caen Normandie Hospital Center, Rheumatology, Caen, France; 3Hospital Center University De Rouen, Medecine interne, Rouen, France

**Background:** The rheumatoid arthritis (RA)/systemic sclerosis (SSc) overlap syndrome is a rare and understudied association. It affects 5% of patients with SSc. Only open studies evaluating biological drugs (bDMARDs) have reported encouraging results particularly on joint involvement. The management of these patients is therefore not codified.

**Objectives:** The objective was to analyze in real conditions the therapeutic strategy and the response to bDMARDs, with a focus on joint involvement.

**Methods:** We retrospectively analyzed over a 10-year period the clinical, biological, radiographic characteristics and therapeutic management of patients meeting the ACR/EULAR diagnostic criteria for RA and SSc in two academic centers. Response to bDMARDs was assessed according to EULAR and if unavailable according to therapeutic maintenance. The evolution of lung function test was also evaluated.

**Results:** Twenty-two patients were identified. Intestinal lung involvement was common (n=11). Only 7 patients were treated with csDMARD alone. The most commonly used drug was methotrexate. The use of bDMARDs was frequent (15/22), significantly greater in patients with rheumatoid factors (OR 66.7; p=0.004) and with a trend in patients with higher levels of anti-CCP (160 vs 15 IU; p=0.11) or diffuse interstitial lung disease (OR 10.6; p=0.063). Tocilizumab was the most selected therapy (n=8) followed by rituximab (n=5), abatacept, and anti-TNFs (n=4 respectively). We evaluated 21 treatment sequences, 19 of which were evaluated according to EULAR response criteria. bDMARDs that inhibits the activation of lymphocytes (abatacept, rituximab) generally resulted in significantly more often observed than tocilizumab sequences were stopped early due to intolerance and could not be evaluated. One patient received tofacitinib with a good clinical response but was discontinued at 9 months for intolerance. Lung function test data did not change significantly on bDMARD.

**Conclusion:** In patients with rheumatoid arthritis (RA)/systemic sclerosis (SSc) overlap syndrome, bDMARDs that inhibits the activation of lymphocytes (abatacept, rituximab) generally resulted in a good or moderate response (n=9/10) with a significant decrease in DAS28 at 6 months (-1.75; p=0.016). Cytokine inhibitors (tocilizumab, etanercept, infliximab) were less likely to achieve good or moderate control of joint involvement (n=3/9) with a smaller decrease in DAS28 at 6 months (-0.79; p=0.36). Two tocilizumab sequences were stopped early due to intolerance and could not be evaluated. The levels AMH negatively correlated with CYC therapy, erythrocyte sedimentation rate, with positive correlation with age and duration of disease.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1071

---

**OVARIAN RESERVE IN SYSTEMIC SCLEROSIS**

**R. Goleva1, Z. Alekbrova2, M. Cherkasova3, O. Konova4, L. Garzanova4, D. Bizhanova.**

1V.A. Nasonova Research Institute of Rheumatology, trobavinflammation laboratory, 115522, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, systemic rheumatic disease, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, trobavinflammation laboratory, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, laboratory of sistemic sclerosis, Moscow, Russian Federation; 5Russian Children's Clinical Hospital, Moscow, Russian Federation

**Background:** The low prevalence of pregnancy in women with systemic sclerosis (SSc) is due to multi-factorial causes, including premature ovarian insufficiency (POI). Anti-Mullerian hormone (AMH) is one of the primary parameters for assessing reproductive function and ovarian reserve. The levels of AMH correlate with the residual follicular pool among women of reproductive age.

**Objectives:** To assess AMH levels in SSc female patients of child-bearing potential, and analyze the relationship between AMH levels and disease severity, as well as the relationship between serum AMH levels and different therapeutic regimens.

**Methods:** The study group included 48 women with SSc aged 20-40 years, and the control group included 15 age-matched healthy women. Pts' mean age was 32.9 (28.37) yrs, disease duration was 6.3 (3.10) yrs. Diffuse cutaneous subset of the disease had 41.7%, limited in 41.7% and overlap in 16.8% pts. AMH levels was measured using ELISA. AMH reference values ranged within 1.0-10.6 ng/ml. Values <1.0 were interpreted as a decreased ovarian reserve.

**Results:** Mean AMH level was 2.8 ng/ml in SSc pts, and 3.1 ng/ml in the control group, showing no statistical difference. A decrease in ovarian reserve (AMH less than 1.0 ng/ml) was significantly more common in SSc pts compared to controls (45.8% vs. 13%, p<0.05).

**Table 1. AMH and forms of SSc**

<table>
<thead>
<tr>
<th>AMH &gt;1 ng/ml, n (%)</th>
<th>13 (55%)*</th>
<th>7 (35%)*</th>
<th>2 (25%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean AMH</td>
<td>3.3 [0.4-5.6]*</td>
<td>2.3 [0.7-3.4]*</td>
<td></td>
</tr>
</tbody>
</table>

Mean AMH levels was significantly lower in the diffuse SSc in comparison with the limited SSc.

**Table 2. AMH and course of SSc**

<table>
<thead>
<tr>
<th>AMH &gt;1 ng/ml, n (%)</th>
<th>13 (65%)*</th>
<th>7 (35%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean AMH</td>
<td>3 [0.6-6.4]*</td>
<td>6 [4.24]*</td>
</tr>
</tbody>
</table>

Mean AMH levels was significantly lower in acute and subacute course of SSc. A decrease of ovarian reserve was significantly more often observed in subacute course compared to chronic course of SSc (68% vs 24%, p<0.03).

**Conclusion:** Ovarian reserve was significantly more often reduced in women with SSc compared to healthy controls. Mean AMH levels was significantly lower in the diffuse SSc compared to the limited SSc. Reduction of ovarian reserve was more often observed in diffuse form SSc. Mean AMH level was significantly lower in acute and subacute course of SSc. A decrease of ovarian reserve was significantly more often observed in subacute course SSc compared to chronic course. The levels AMH negatively correlated with CYC therapy, erythrocyte sedimentation rate, heart and gastrointestinal involvement (r=-0.31), digital ulcers (r=-0.36), and digital pitting scars (r=-0.28).

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.1433

---

**TURKISH VALIDATION OF THE ‘COCHIN (DURUOZ) HAND FUNCTION SCALE’ IN PATIENTS WITH SYSTEMIC SCLEROSIS**

**A. Komaz f, D. Temiz Karadag, E. Basaran, A. Yazıcı, A. Çelebi, Kocate l University Faculty of Medicine, Rheumatology department, Kocaeli, Turkey**

**Background:** Hand impairment is the main challenge for patients with systemic sclerosis (SSc) and may arise from inflammatory arthritis, joint contractions, tendon friction rubs (TFRs), Raynaud's phenomenon (RP), digital ulcers (DU), puffy hands, skin sclerosis, acro-osteolysis, or calcinosis. There is not yet a tool which can objectively measure hand functions in scleroderma patients both in daily practice and for research purposes.

**Objectives:** To adapt and validate the Turkish version of Cochín (Duruoz) hand function scale (CHFS) and contribute to the development of outcome measures with good metric properties assessing hand disability in SSc (1).

**Methods:** Ninety one consecutive patients who fulfilled the 2013 ACR/ EULAR SSc classification criteria for SSc were enrolled in the study. Disease...
related involvements and physical examination findings of the patients were recorded. Participants filled out the self-administered questionnaire of the Turkish version of the CHFS. Modified Rodnan skin scores of the patients were calculated, bilateral hand extension and fingertip-palm distances were measured, grip strength was evaluated with hydraulic hand dynamometer. We evaluated convergent validity by testing the correlation between CHFS and related components of Short Form 36 version 2 (SF-36v2) and Scleroderma Health Assessment Questionnaire (sHAQ). Discriminant validity was evaluated by stratifying patients according to hand related involvements and disease subtypes. Thirty of the patients re-filled the CHFS questionnaire two weeks after the first visit.

Results: Demographic data and disease characteristics of the patients shown in Table 1. For the convergent validity, the CHFS significantly correlated with the sHAQ, Raynaud visual analog scale (VAS), digital ulcer VAS, overall disease severity VAS, hand grip, hand extension measurements and fingertip-palm distances (Table 2). The instruments could discriminate between disease subtypes (10-24) / 20-19, p=0.038 and between the patients with and without contractions (11-24) / 20-9, p=0.023 for the discriminant validity. We demonstrated high reproducibility for CHFS (ICC = 0.894, 95% confidence interval = 0.779-0.949).

Table 1. Demographic data and disease characteristics of the patients

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Total mRSS</th>
<th>SF 36 physical health</th>
</tr>
</thead>
<tbody>
<tr>
<td>55±10.7</td>
<td>6±1.5</td>
<td>44±3±21.7</td>
</tr>
</tbody>
</table>

Sex (female) 79 (86.8) Right hand grip strength 2.2±1.7
Digital ulcer VAS 0.5±0.9 SF 36 pain 64±30
Raynaud’s phenomenon VAS 0.8±0.9 SF 36 social functioning 70±26
CHFS score 3 [0-13] SF 36 emotional well-being 60.4±21.2
Digital ulcer scar 23 (%25.3) SF 36 role limitations due to health 31±10
Active digital ulcer 3 (%3.2) SF 36 role limitations due to physical health 52±42
Contracture 26 (%28.6) SF 36 role limitations due to emotional problems 57±32.4
Calcinosis 10 (%11) SF 36 energy/fatigue 64±23.3
CHFS score 3 [0-13] SF 36 emotional well-being 60.4±21.2
Raynaud’s phenomenon VAS 0.8±0.9 SF 36 social functioning 70±26
Digital ulcer VAS 5.0±0.9 SF 36 pain 64±30
Overall disease severity VAS 5.0±0.9 SF 36 general health 44±32.17

Conclusion: The Turkish version of the CHFS meets the requirements of validity and reproducibility. With this study, we validated a scale which will contribute to the development of outcome measures with good metric properties assessing hand disability, disease evolution and treatment efficacy in our SSC patients.

REFERENCES:

Disclosure of Interests: None declared

AB0666 BODY COMPOSITION AND PHYSICAL FUNCTION AS POTENTIAL PROGNOSTIC BIOMARKERS IN PATIENTS WITH SIBM

K Y Jensen1,2, J Alcazar3,4, A N Jorgensen5,6, P Aagaard1, C Sueta1,7, L P Diederichsen1,8,9, Rigshospitalet, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; 2Department of Sports Science and Clinical Biomechanics, Odense, Denmark; 3Biocenter and Frederiksberg University Hospital, Department of Geriatric and Palliative Medicine, Geriatric Research Unit, Copenhagen, Denmark; 4Universidad de Castilla-La Mancha, GENUD Toledo Research Group, Toledo, Spain; 5CIBER of Frailty and Healthy Aging (CIBERFES), Faculty of Sport Sciences, Madrid, Spain; 6University of Southern Denmark, Department of Clinical Research, Odense, Denmark; 7Copenhagen University Hospital, Herlev and Gentofte, Department of Medicine, Geriatric Research Unit, Herlev, Denmark; 8Rigshospitalet, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; 9Odense University Hospital, Department of Rheumatology, Odense, Denmark

Background: Sjögren’s syndrome myositis (sIBM) is an acquired disease within the idiopathic inflammatory myopathy (IIM) spectrum, characterized clinically by progressive muscle atrophy, weakness and often severely impaired physical function leading to sarcopenia. Despite this, muscle mass and physical function is not routinely assessed in patients with sIBM.

Objectives: To investigate muscle mass, muscle power and physical function in patients with sIBM compared to healthy controls.

Methods: The study was a retrospective analysis of patients with sIBM (sIBM) and healthy age and gender matched controls (CON) from The Copenhagen Sarcopenia Study1. Appendicular lean mass (ALM) and skeletal muscle index (ALM/h2) was assessed by DXA (IDXA, GE). Muscle strength and physical function was evaluated by maximal horizontal gait speed (GS), 30-s sit-to-stand test (30s STS) and maximal leg extensor power (LEP) (PowerPig). A linear mixed-effect model for all outcome variables was used for the statistical analysis. A linear mixed-effect model for all outcome variables was used for the statistical analysis, including sex and health condition as fixed factors, and performed using SPSS v20 (Inc., Chicago, Illinois, USA), and the level of significance was set at α = 0.05 using two-tailed testing.

Results: In total, 22 patients with sIBM (18 men, age 69.8±4.6; 4 women, age 65.0±8.4) and 414 healthy age-matched controls (237 men, age 70.2±4.9; 177 women, age 65.5±5.4) were included. In men, ALM (sIBM: 21.4±3.1; CON: 25.3±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05). In women, ALM (sIBM: 21.4±3.1; CON: 25.5±3.6) and ALM/h2 (sIBM: 6.9±0.9; CON: 8.0±1.0) was reduced in sIBM compared to CON (p<0.05).

Conclusion: The present data demonstrate that muscle mass and physical function are reduced in patients with sIBM compared to healthy counterparts. Although data from larger studies are warranted, it may indicate that assessment body composition and physical function can be used as prognostic tools in these patients.

REFERENCES:

Disclosure of Interests: Kasper Yde Jensen: None declared, Julian Alcazar: None declared, Anders Nørkær Jørgensen Employee of: Currently employed at Ascendis Pharma, which do not produce drugs/devices used in rheumatology, Per Aagaard: None declared, Charlotte Sueta: None declared, Louise Pyndt Diederichsen: None declared


AB0667 EFFECT OF TEMPERATURE VARIATION ON SERUM KL-6 LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS

H Hirose1, T Higuchi1,2, K Takagi3, A Tochimoto1, Y Kawaguchi1, M Harigai1, 7Tokyo Women’s Medical University Hospital, Division of Rheumatology, Department of Internal Medicine, Shinjuku City, Japan; 8Tokyo Women’s Medical University, Division of Multidisciplinary Management of Rheumatic Diseases, Division of Rheumatology, Department of Internal Medicine, Shinjuku-City, Japan; 9Adachi Medical Center, Tokyo Women’s Medical University, Department of Internal Medicine, Adachi-Ciy, Japan

Background: Serum Krebs von den Lungen-6 (KL-6) levels have much evidence as a biomarker about the progression and prognosis of interstitial lung disease (ILD), including systemic sclerosis (SSc)-associated ILD. However, serum KL-6
levels often fluctuate regardless of the progression of ILD. This sometimes mislead the evaluation of the disease activity, however, the reason for the fluctuation has not been clarified.  

**Objectives:** We tested the hypothesis that serum KL-6 levels are affected by ambient temperature in patients with SSc.

**Methods:** We defined the warm season (May–October) as the period when the ambient temperature was below the average. ILD was classified based on chest CT findings. Among SSc patients who had visited our department since May 2018, we selected those who had data of serum KL-6 levels at least 3 times in warm and cold seasons from October 2014 to September 2021, respectively. Patients who had malignancy and other co-morbidities were excluded after confirmation of the onset of malignancy using medical record retrospectively. The difference in serum KL-6 levels between warm and cold seasons were evaluated by Wilcoxon’s rank-sum test.

**Results:** In total, 252 patients with SSc were included. Median age was 66.3 years, with median disease duration of 13.5 (8.9–19.2) years, diffuse cutaneous type of 94 (37.3%) patients, and concomitant ILD of 120 (47.6%) patients (Table 1). The median follow-up was 6.4 (4.4–6.8) years, with median KL-6 measurement of 24 (14–39) times. Serum KL-6 levels were significantly higher in the cold season than that in the warm season, with a greater difference in the group with ILD (536 IU/L vs. 492 IU/L, p = 0.0012 in the group with ILD, 364 IU/L vs. 345 IU/L in the group without ILD, p = 0.0028).

### Table 1. Patients characteristics

<table>
<thead>
<tr>
<th></th>
<th>With ILD (n=120)</th>
<th>Without ILD (n=132)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n (%)</td>
<td>110 (43.7)</td>
<td>128 (52.4)</td>
<td>0.1</td>
</tr>
<tr>
<td>Age, years (IQR)</td>
<td>65.8(56.1–73.4)</td>
<td>66.4(56.0–72.5)</td>
<td>0.77</td>
</tr>
<tr>
<td>Disease duration, years (IQR)</td>
<td>14.0 (8.9–21.0)</td>
<td>13.0 (8.7–18.0)</td>
<td>0.23</td>
</tr>
<tr>
<td>Modified Rodnan skin score (IQR)</td>
<td>10 (4–15)</td>
<td>6 (2–11)</td>
<td>0.0017</td>
</tr>
<tr>
<td>Diffuse SSc, n (%)</td>
<td>53 (40.2)</td>
<td>27 (20.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary hypertension, n (%)</td>
<td>4 (3.3)</td>
<td>3 (2.3)</td>
<td>0.71</td>
</tr>
<tr>
<td>ANA positive, n (%)</td>
<td>98 (81.7)</td>
<td>112 (84.8)</td>
<td>0.50</td>
</tr>
<tr>
<td>SSc-related autoantibody, n (%)</td>
<td>98 (81.7)</td>
<td>112 (84.8)</td>
<td>0.50</td>
</tr>
<tr>
<td>Anti-centromere antibody, n (%)</td>
<td>17 (14.2)</td>
<td>86 (71.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Anti-topoisomerase antibody, n (%)</td>
<td>63 (52.5)</td>
<td>8 (6.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Anti-RNA polymerase III antibody, n (%)</td>
<td>7 (5.6)</td>
<td>11 (8.3)</td>
<td>0.62</td>
</tr>
<tr>
<td>Anti-U1-RNP antibody, n (%)</td>
<td>15 (12.5)</td>
<td>13 (9.8)</td>
<td>0.54</td>
</tr>
<tr>
<td>KL-6, IU/L (IQR)</td>
<td>548 (384–876.8)</td>
<td>233 (191–302)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>KL-6 measurement, times (IQR)</td>
<td>33.5 (20–45)</td>
<td>18.5 (12.3–28)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Steroid use, n (%)</td>
<td>68 (56.7)</td>
<td>22 (16.7)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cyclophosphamide, n (%)</td>
<td>44 (36.7)</td>
<td>12 (9.1)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Other Immunosuppressive agents, n (%)</td>
<td>31 (25.8)</td>
<td>28 (21.3)</td>
<td>0.0022</td>
</tr>
</tbody>
</table>

**Conclusion:** Our results suggest that cold ambient temperature may affect serum KL-6 levels in patients with SSc.

### References:


---

**Figure 1.** Serum ADMA levels in the early, active, and late NVC patterns

**Conclusion:** Serum ADMA levels were significantly associated with advancing stages of microcirculatory abnormalities suggesting that ADMA may have a role in promoting microvascular endothelial dysfunction in SSc individuals.

**References:**


**Disclosure of Interests:** None declared

PREGNANCY OUTCOMES IN SYSTEMIC SCLEROSIS, SYSTEMIC LUPUS ERYTHEMATOSUS AND BEHÇET’S DISEASE

R. Goloeva1, Z. AlekBereva2, L. Garzanova1, O. Koneva1, A. Lila1,2,4.1.V.A. Nasonova Research Institute of Rheumatology, troboinflammation Laboratory, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, advisory department, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, laboratory of sistemic sclerosis, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, systemic rheumatic disease, Moscow, Russian Federation

Objectives: To clarify pregnancy outcomes in patients with systemic sclerosis (SSc), systemic lupus erythematous (SLE) and Behçet’s disease (BD) using retrospective analysis.

Methods: The study group included 48 women with SSc, 47 with SLE 45 with BD aged 20-40 years, and the control group - 15 age-matching healthy women. SSc pts mean age was 32.9 [28.37] years, SLE pts 32.3 [29.36] years, BD pts 31.3 [27.35] years, disease duration 6.3 [3.10], 9.8 [3.16] and 6.0 [3.8] years respectively. Completed by all women issue-specific questionnaire covered clinical symptoms of SLE. SSc, BD and details of obstetric history (characteristics of menstrual and reproductive function, presence of genital and extragenital pathologial, previous pregnancies outcomes; previous intrauterine interventions, a history of coagulopathy).

Results: Retrospective analysis of thematic maps of 48 patients with SSc revealed: 28 patients had 77 pregnancies, 44 of which ended with the birth of children (13 by caesarean section in 9 patients); 3 women had 4 premature births at 28-35 weeks, one of which ended with perinatal death of the baby, 33 incomplete pregnancies in 19 patients: 28 medical abortions up to 12 weeks of gestation at the woman’s request; 5 pregnancy complications had 5 patients, spontaneous abortion - 3, undeveloped pregnancy - 2. The frequency of unfavorable pregnancy outcome was similar in patients with SSc and in the control group. Analysis of thematic maps of 47 patients with SLE: 27 patients had 68 pregnancies, 31 of which ended with the birth of children on time (12 by caesarean section in 9 patients); 3 women had 4 premature births at 27-33 weeks, two of which ended with perinatal death of the baby; 33 incomplete pregnancies in 18 patients: 15 medical abortions up to 12 weeks of gestation at the woman’s request, two women had 3 abortions for medical reasons; high activity of SLE); 15 pregnancy complications had 9 patients, spontaneous abortion had 8 pts, undeveloped pregnancy was observed in 7 women. The frequency of unfavorable pregnancy outcome was similar in patients with SLE and in the control group. 118 pregnancies in 35 pts with BD resulted in 75 live birth (6 cesarean section in 3 pts). Thirty-nine incomplete pregnancies were observed in 26 patients. Ten patients had 20 medical abortions on request before 12 weeks of gestation, one patient had an abortion due to medical reasons (rubella on the 7 th week of gestation), two patients had premature birth at 28 and 32 weeks with subsequent perinatal death of the baby. Fifteen out of 35 pts had 20 adverse pregnancy outcomes: 8 spontaneous abortion, 12 missed miscarriage. Nine patients had 12 Missed miscarriage at 6-11 weeks of gestation, one patient had 3 missed miscarriage, two had 2, and the others had 1 missed miscarriage. Six patients had 8 spontaneous abortions (early miscarriage). In the control group of 15 women, 7 had 15 pregnancies, 13 live birth of healthy children on time.

Table 1. Pregnancy outcomes

<table>
<thead>
<tr>
<th>Pregnancy, n</th>
<th>SSc, n=48 (%)</th>
<th>SLE, n=47 (%)</th>
<th>BD, n=118 (%)</th>
<th>Control, n=15</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth</td>
<td>44 (57.1)*</td>
<td>35 (51.5)*</td>
<td>77 (65)</td>
<td>13 (87)*</td>
<td>0.03</td>
</tr>
<tr>
<td>Abortion</td>
<td>28 (36.4)*</td>
<td>18 (26.5)*</td>
<td>21 (18)</td>
<td>0</td>
<td>0.01</td>
</tr>
<tr>
<td>Unfavorable pregnancy outcome</td>
<td>5 (6.4)</td>
<td>15 (22)</td>
<td>20 (17)</td>
<td>12 (13)</td>
<td>ns</td>
</tr>
<tr>
<td>Missed miscarriage</td>
<td>2 (2.6)</td>
<td>7 (10.3)</td>
<td>12 (10)</td>
<td>0</td>
<td>ns</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>3 (3.9)</td>
<td>8 (11.6)</td>
<td>8 (7)</td>
<td>2 (13)</td>
<td>ns</td>
</tr>
</tbody>
</table>

Results: Patients with SSc and SLE were more likely to terminate pregnancy of their own volition compared to the control group.

Conclusion: Patients with SSc and SLE were more likely to terminate pregnancy on their own volition compared to the control group. Unfavorable pregnancy outcomes were similar in groups.

Disclosure of Interests: None declared


HISTOPATHOLOGICAL, CLINICAL AND SEROLOGICAL FEATURES IN IIM PATIENTS FROM A SINGLE CENTER COHORT

T. Vojinovic1, M. Olivari2, M. Fredi3, F. Franceschini1, I. Cavazzana1. 1ASST Spedali Civili of Brescia, Rheumatology and Clinical Immuno-Immunology Unit, Department of Clinical and Experimental Sciences, Brescia, Italy; 2University of Brescia, Faculty of Medicine and Surgery, Brescia, Italy

Background: Idiopathic inflammatory myositis (IIM) is a group of heterogeneous autoimmune diseases, characterized by myositis-specific (MSA) or myositis-associated autoantibodies (MAA). Muscle biopsy is the diagnostic gold standard, but correlations with elevated creatine level (CK) or MSA/MAA are unclear.

Objectives: To evaluate the association between specific histological findings and clinical and/or serological features in IIM patients from a single tertiary Rheumatology referral center.

Methods: We retrospectively analyzed demographic and clinical data from medical charts, of 184 patients affected by IIM followed-up for >1 year. Muscle biopsies of 89 IM patients were retrieved from deltoid, biceps or quadriceps muscle, snap-frozen and stored at -80°C and processed for routine histology and histochemistry.

Results: The majority of our muscle biopsy cohort was represented by Dermatomyositis (DM) (39.3%), Polymyositis (PM) (29.2%) and Anti-synthetase syndrome (ASS) (13.5%), whereas the rest was composed of Overlap Syndrome (OS), Immune-Mediated Necrotizing Myopathy (IMNM) and Inclusion-Body Myositis (IBM) (13.5%, 2.2% and 2.2% respectively). DM presented perifascicular atrophy in 85% of cases and perivascular and perifascicular infiltration in only 40% of cases, similar to other types of IIMs. The overall histology finding was characterized by minimal inflammation and/or necrosis but major atrophy. In comparison, Polymyositis showed more endomyalial infiltration and necrosis (Table 1). ASS was characterized by atrophy and perifascicular necrosis in 83% of cases, with perimysial and perivascular infiltration in 67% of cases. Those characteristics were observed both in anti-Jo-1+ (13.3%) and as non-Jo-1+ ASS patients (13.2%). Non-Jo-1+ ASS patients presented endomyalial infiltration, invading or enveloping the muscle fibers (not present in anti Jo-1+ (p: 0.036), with addition of rimmed vacuoles and aspecific clinical presentation. Moreover, in DM, anti-Mi2+ antibodies (9.3%) were significantly associated with perifascicular regeneration and endomyalial infiltration, in comparison to both anti-TIF-1+ (5.8%) and anti-NXP2+ patients (4.6%). No significant histopathological features were found in patients with anti-Ro52 autoantibodies (372%), that represented the most frequent MAA in our cohort.

Disclosure of Interests: None declared

### Table 1

<table>
<thead>
<tr>
<th>BIOPSY CHARACTERISTICS</th>
<th>ASS 12 (%)</th>
<th>PM 35 (%)</th>
<th>DM 26 (%)</th>
<th>p [OR] ASS vs PM</th>
<th>p [OR] PM vs DM</th>
</tr>
</thead>
<tbody>
<tr>
<td>diffuse atrophy</td>
<td>3 (25)</td>
<td>34 (87.1)</td>
<td>8 (30.8)</td>
<td>&lt;0.0001 [0.010-0.001]</td>
<td>&lt;0.0001 [76.5 (0.001-106.0) (8.8-66.6)]</td>
</tr>
<tr>
<td>perifascicular degeneration</td>
<td>---</td>
<td>29 (82.9)</td>
<td>15 (57.7)</td>
<td>0.044 [3.544 (1.09-11.0)]</td>
<td>0.017 [10 (1.19-84)]</td>
</tr>
<tr>
<td>prevalent necrosis</td>
<td>---</td>
<td>10 (28.6)</td>
<td>1 (3.8)</td>
<td>0.007 [10]</td>
<td>0.007 [10]</td>
</tr>
<tr>
<td>endomyosial infiltration</td>
<td>0 (5)</td>
<td>3 (60)</td>
<td>0.015 [inf]</td>
<td>0.002 [inf]</td>
<td></td>
</tr>
<tr>
<td>(invading fibers)</td>
<td></td>
<td></td>
<td></td>
<td>0.061</td>
<td></td>
</tr>
<tr>
<td>MZ2 (%)</td>
<td>TIF1 5 (%)</td>
<td>NX2 4 (%)</td>
<td>p [OR] MZ2 vs TIF1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>perifascicular regeneration</td>
<td>8 (100)</td>
<td>1 (20)</td>
<td>0</td>
<td>0.007 [inf]</td>
<td>0.002 [inf]</td>
</tr>
<tr>
<td>endomyosial infiltrate</td>
<td>6 (75)</td>
<td>---</td>
<td>0</td>
<td>---</td>
<td>0.061</td>
</tr>
<tr>
<td>(surrounding fibers)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Conclusion:
No significant associations emerged between CK levels, different types of IIM and MSA. Some histological features seem to define subtypes of DM. A precise definition of autoantibody profile in IIM could define not only a clinical phenotype but also the muscle damage distribution.

### Disclosure of Interests:
None declared

### DOI:

---

### Table 1. AMH in patients and control group

<table>
<thead>
<tr>
<th>form</th>
<th>SSc, n=48</th>
<th>SLE, n=47</th>
<th>BD, n=45</th>
<th>Controls, n=15</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean AMH</td>
<td>2.2</td>
<td>3.4</td>
<td>2.5</td>
<td>3.1</td>
<td>0.03</td>
</tr>
<tr>
<td>AMH &gt;1ng/ml</td>
<td>21 (43.7)*</td>
<td>[0.29-3.06]</td>
<td>[0.64-5.4]</td>
<td>[1.13-7.7]</td>
<td>[1.94-9.5]</td>
</tr>
</tbody>
</table>

A redaction of ovarian reserve (AMH less than 1.0 ng/ml) was more often observed in SSc pts compared to controls (44% vs 13%), p=0.03. The mean AMH levels were significantly lower in pts with SSc receiving cyclophosphamide (CYC). Correlation analysis revealed a negative correlation between levels AMH and CYC therapy (r=-0.33, p<0.05), with erythrocyte sedimentation rate (r=-0.36), heart involvement (r=-0.32) and gastrointestinal involvement (r=-0.31), digital ulcers (r=-0.33) and digital pitting scars (r=-0.28). Correlation with other clinical manifestations, immunological markers and immunosuppressive therapy of SSc wasn't found. In five patients receiving CYC earlier, the level of AMH was within normal values, the total dose of CYC at them did not exceed 4g. No correlation was found between AMH and activity SLE (SLEDAI 2K), and analyze the relationship between AMH levels and disease severity, as well as relationship between serum AMH levels and different therapeutic regimens.

### Background:
Systemic sclerosis (SSc) is a multisystem, connective tissue disease characterized by fibrosis of the skin and internal organ involvement, which can influence quality of life and functional capacity. SSc patients show some problems associated with reduced quality of life.

### Objectives:
SSc is a multisystem, connective tissue disease characterized by fibrosis of the skin and internal organ involvement, which can influence quality of life and functional capacity. SSc patients show some problems associated with reduced quality of life.

### Methods:
In total, 51 patients with SSc were included: 50 women and 1 man (mean age: 63.2 ± 10.1 years, limited SSc 28/diffuse SSc 23, median duration since first non-Raynaud symptom: 10.1 years) who fulfilled the ACR/EULAR classification criteria (2013), filled in questionnaires assessing disability (HAQ, Health Assessment Questionnaire) and quality of life (SF-36, Medical outcomes study Short Form 36 - Physical Component Summary and Mental Component Summary).

### Results:
Average HAQ in patients with limited and diffuse SSc was 0.66±0.58 and 0.9±0.59. Data analysis showed that 59% of the patients were in the mild to moderate HAQ disability category (0 ≤ HAQ < 1), 39% in the moderate to severe disability category (1 ≤ HAQ < 2), and 2% in the severe to very severe disability category (2 < HAQ ≥ 3). The SF36 mean scores of the total group were 34.8±8.7 on the Mental Component Summary and 37.0±13.1 on the Physical Component Summary.

### Conclusion:
SSc and its complications decrease quality of life and functional capacity. Although validated in SSc, the HAQ disability index underestimates respiratory failure due to interstitial lung disease, gastrointestinal symptoms, cardiovascular complications and severity of Raynaud phenomenon. Alternative measures of functional impairment should be examined. Health-related quality of life, which was assessed by the SF-36 is reduced in both physical and mental domains. It should be taken into account by clinicians for further improvement of treatment and development rehabilitation program.

### REFERENCES:

### Disclosure of Interests:
None declared

### DOI:
Scientific Abstracts	﻿ 
AB0674

PROVIDING PATIENTS WITH SYSTEMIC SCLEROSIS
BY MEDICAL CARE IN RUSSIA: THE FIRST DATA
FROM MOSCOW REGISTER OF SYSTEMIC
SCLEROSIS

D. Khorolskii1, N. Babadaeva2, E. Zhilyaev3, N. Shostak4, A. Klimenko3,
A. Kondrashov3, E. Pershina5, D. Somov6, E. Mikheeva6on behalf of Register
of patients with idiopathic inflammatory myopathies, systemic sclerosis and
mixed connective tissue disease in Moscow. 1Pirogov Russian National
Research Medical University, Health Department of Moscow, Moskva, Russian
Federation; 2Городская клиническая больница № 1 им. Н.И. Пирогова,
Moscow City Rheumatological Center, Moskva, Russian Federation; 3Pirogov
Russian National Research Medical University, Department of Faculty Therapy,
Moskva, Russian Federation; 4Pirogov Russian National Research Medical
University, Department of Faculty Therapy, Moskva, Russian Federation;
5
Городская клиническая больница № 1 им. Н.И. Пирогова, Radiograpic
studies department, Moskva, Russian Federation; 6Pirogov Russian National
Research Medical University, Department of Faculty Therapy, Moskva, Russian
Federation
Background: Systemic sclerosis (SSc) is a multisystem, connective tissue
disease characterized by fibrosis of the skin and internal organ involvement,
which can influence quality-of-life and functional capacity. 1 The mortality rate
is increasing in the United States and Europe; as many as 3.08 persons are
affected per 1 million. Changes in lungs and heart, pulmonary hypertension are
the most significant reasons of death in patients with systemic sclerosis.2
Objectives: To estimate quality and completeness of medical care in patients
with systemic sclerosis in Russia.
Methods: 66 patients included in the study. 61 female and 5 male (mean age: 62,48
± 10,1), among which there were 24 limited SSc (lSSc) and 42 diffuse SSc (dSSc).
All patients fulfilled the ACR/EULAR classification criteria. We estimated percentage
of patients, who were examined by basic studies: capillaroscopy, functional lung
tests, echocardiography, HRCT, fully immunologic study and right heart catheterization etc. and try to understand reasons of incompleteness of these assessments.
Results: Despite the presence of Raynaud’s phenomenon in 85% of patients,
capillaroscopy was performed only in 65.21% of them, examination of the esophagus was performed in only 22.92% of patients, with development of dysphagia
in 50% of patients. HRCT was performed in 54.71% (25.76% NSIP, 9.09% UIP),
right heart catheterization in 4.17% (signs of pulmonary hypertension according
to ECHO detected in 42.86% of patients). FLT were performed in mostly patients
(86.34%), but it wasn`t fully: measuring of DLCO was realized only in patients
with severe desease (22.92% оf patients). That explains its low mean level
(61.37% from normal) as opposed to mean FEV1 (90.7% from normal) and FVC
(89.47% from normal) level. Fully immunologic study was performed in 35.42%
of patients, despite the fact that different autoantibodies showed up in 72.92% of
patients (the most common were: antiScl70 41,67%, ACA 22,92%, ANF 52,08%).
Conclusion: According to the results of the study, we have identified a significant
decrease in the quality of medical care despite the clinical recommendations and generally accepted standards. We suppose. that the main reasons for this situation are the
complex healthcare problems: insufficient competence of doctors, lack of collaboration
between related specialties, unavailability of a number of studies within the framework
of free medicine and high cost of these studies for the patients themselves, and the
lack of time for communication between the doctor and the patient to explain the seriousness of the disease and the nescessity of all parts of examination and treatment.
REFERENCES:
Autoimmun Rev. 2015;14(12):1087-1096
of venous thromboembolism: A systematic review and meta-analysis. Mod
Rheumatol. 2015 Apr 7. 1-17.
Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2117

AB0675

HEALTH RELATED QUALITY OF LIFE IN PATIENTS
WITH MIXED CONNECTIVE TISSUE DISEASE: A
COMPARISON WITH MATCHED SYSTEMIC SCLEROSIS
PATIENTS

I. Abouyahya1, S. Liem1, Z. Amoura2, J. E. Fonseca3, B. Chaigne2, M. Cutolo4,
A. Doria5, R. Fischer-Betz6, V. Guimaraes7, E. Hachulla8, T. Huizinga1, J. M. van
Laar9, T. Martin10, M. Matucci-Cerinic11, C. Montecucco12, M. Schneider5,
V. Smith13, A. Tincani14, U. Müller-Ladner15, J. de Vries-Bouwstra1on behalf of
ERN ReCONNET. 1Leiden University Medical Center, Rheumatology, Leiden,
Netherlands; 2Maladies Autoimmunes Systémiques Rares d’Ile de France,
Hôpital Cochin, Service de Médecine Interne, Paris, France; 3Lisbon Academic
Medical Centre, Rheumatology, Lisbon, Portugal; 4University of Genoa,
Laboratory of Experimental Rheumatology and Academic Division of Clinical
Rheumatology Department of Internal Medicine, Genoa, Italy; 5University of
Padua, Rheumatology Unit Department of Medicine, Padua, Italy; 6University

1465

Hospital of Düsseldorf, Rheumatology, Düsseldorf, Germany; 7Liga Portuguesa
Contra as Doenças Reumáticas, Rheumatology, Lisbon, Portugal; 8Centre de
Référence des Maladies Systémiques et Auto-Immunes Rares du Nord-Ouest
(CERAINO, Interne et Immunologie Clinique, LILLE, France; 9University Medical
Center Utrecht, Rheumatology and Clinical Immunology, Utrecht, Netherlands;
10
Hôpitaux Universitaires de Strasbourg, Clinical immunology, Strasbourg,
France; 11University of Florence, Experimental and Clinical Medicine, Florence,
Italy; 12Fondazione IRCCS Policlinico San Matteo, Rheumatology, Pavia, Italy;
13
Ghent University Hospital, Rheumatology, Ghent, Belgium; 14University of
Brescia, U.O. Reumatologia e Immunologia Clinica, Brescia, Italy; 15University
of Giessen, Rheumatology and Clinical Immunology, Gießen, Germany
Background: Mixed connective tissue disease (MCTD) is a systemic auto-immune disorder, being probably the least common among the connective tissue
diseases. Symptoms can be severe and could affect health-related quality of life
(HRQoL). Identification of the burden of MCTD patients is of key importance to
provide appropriate pharmacological and non-pharmacological care. No reports
on HRQoL have been published in adult patients with MCTD.
Objectives: To perform an explorative study to evaluate HRQoL and its main
determinants in MCTD patients, and compare HRQoL between MCTD and
matched systemic sclerosis (SSc) patients.
Methods: MCTD patients fulfilling the Kahn criteria and participating in the
MCTD prospective follow-up cohort of the Leiden University Medical Center
were included. In addition, SSc patients matched for age, gender and disease
duration were included for comparison. Data on disease characteristics, functional disability and HRQoL were collected annually for both disease groups.
HRQoL was evaluated using the 36-Item Short Form Health Survey (SF36) and
EuroQol (EQ5D). At baseline, HRQoL, as reflected by SF36 mental component
score (MCS), SF 36 physical component score (PCS) and EQ5D were compared
between MCTD and SSc patients. For MCTD patients, factors associated with
HRQoL at baseline were identified using linear regression and change in HRQoL
over 3 years was evaluated using linear mixed models. In addition, characteristics of MCTD patients who showed worsening of MCS and/or had PCS superior
to the minimal clinical important difference of three points were identified.
Results: Thirty-four MCTD patients (121 visits; 82% female, mean age 42 years,
median disease duration 45 months) and 102 SSc patients (424 visits; 82% female,
mean age 45 years, median disease duration 49 months) were included. At baseline,
MCTD-patients more often had ILD (47% vs. 34%, p=0.027), cardiac involvement (30%
vs. 2%, p<0.001), synovitis (26% vs. 11%, p=0.004) and myositis (15% vs. 1%, p=0.001)
compared to SSc patients, whereas SSc patients more often used immunosuppressive
treatments except for hydroxychloroquine (MCTD:18% vs. SSc:7%, p=0.007).
Baseline HRQoL in MCTD was comparable to HRQoL in SSc, with mean SF36PCS of 40.2 (SD:9.1) and mean SF36-MCS of 44.9 (SD:9.9), which is (nearly)
one standard deviation lower than the general Dutch population. The SF36 subscore “general health perception” was the most impacted in both groups (MCTD:
38.5 [SD:7.0], SSc: 39.9 [SD:8.9]). The median EQ5DNL was 0.38 (IQR:0.14
– 0.54) and comparable between SSc and MCTD.
At baseline, in MCTD, ILD was significantly associated with SF36-PCS (β:6.98,
95% CI: 1.10 to 12.86) and SF36-MCS (β:-8.10, 95% CI:-14.93 to -1.26). Sclerodactyly was significantly associated with EQ5DNL (β:0.006; 95% CI:0.002 to 0.010)
and SF36-PCS (β:0.12, 95% CI:0.03 to 0.21). No other significant associations
were identified.
Over time, in MCTD, both the SF36-MCS and SF36-PCS improved significantly
(MCS: β:2.35/year [95% CI:0.58 to 4.13], PCS: β:1.34/year [95% CI:0.03 to 2.65),
whereas EQ5DNL was stable. Explorative analyses did not reveal a specific clinical
characteristic with significant impact on the change of HRQoL over time. With an
MCID of 3 points on the MCS and PCS, 7 MCTD-patients worsened on the MCS
and 3 on the PCS. Patients who showed worsening of MCS over time tended to
be older, more often had ILD, sclerodactyly and GI complaints, and had worse
exercise tolerance. All these differences did not reach statistical significance. The
patients who decreased PCS more often had ILD (100% vs. 41%, p=0.015), and
used glucocorticoids more often (33% vs. 0%, p=0.046), were slightly older and
had a worse exercise tolerance as compared to those who showed a stable/
improving PCS over time.
Conclusion: Like in SSc, HRQoL is significantly impaired in MCTD, especially
the general health perception of patients. Cardiac involvement, ILD, age and
worse functional disability might specifically impact HRQoL in MCTD. However,
these associations need further evaluations in larger cohorts.
Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2359

AB0676

ONE YEAR PROGRESSION OF INTERSTITIAL LUNG
DISEASE IN CONNECTIVE TISSUE DISEASES.
A DESCRIPTIVE STUDY IN A SINGLE TERTIARY
CENTER.

C. L. Garcia Gomez1, L. Vega1, O. Ibarguengoitia2, M. Enjuanes1, I. Calvo2,
D. Montero2, J. M. Blanco1, M. L. García Vivar1, E. Galindez1, A. R. Inchaurbe1,


Background: Intestinal lung disease (ILD) in connective tissue diseases (CTD) is an important cause of morbidity and mortality.

Objectives: To evaluate ILD in CTD (systemic sclerosis, myositis, Sjögren syndrome, rheumatoid arthritis, mixed connective tissue disease), sarcoidosis and interstitial pneumonia with autoimmune features and its progression in 12 months evaluated through high resolution computed tomography (HRCT) and pulmonary function test (PFT).

Methods: A retrospective single tertiary center cohort study in CTD-ILD outpatients seen between 2012 and 2021. Clinical, serological data, PFT and HRCT results were collected. ILD patterns were classified into usual interstitial pneumonia (UIP), inconsistent UIP, nonspecific interstitial pneumonia (NSIP), fibrosing NSIP, organizing pneumonia, interstitial lymphoid pneumonia and associated to sarcoidosis. Progression of ILD was defined as: ->10% decline in FVC in PFT. ->15% decline in DLCO in PFT.

Progression of fibrosis in HRCT.

IBM SPSS v23 was used for statistical analysis.

Results: 51 patients were collected. Baseline characteristics are shown in Table 1. Figure 1 shows ILD progression in 1 year.

Table 1. Baseline characteristics.

<table>
<thead>
<tr>
<th>Sociodemographic characteristics</th>
<th>Clinical features/affection - n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>51</td>
</tr>
<tr>
<td>Female - n (%)</td>
<td>42 (82.4%)</td>
</tr>
<tr>
<td>Age- years (mean IQR)</td>
<td>56 (27-82)</td>
</tr>
<tr>
<td>Smoking status - n (%)</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>9 (17.6%)</td>
</tr>
<tr>
<td>Former</td>
<td>13 (25.5%)</td>
</tr>
<tr>
<td>Never</td>
<td>29 (56.9%)</td>
</tr>
<tr>
<td>Comorbidities - n (%)</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>5 (9.8%)</td>
</tr>
<tr>
<td>Ischaemic cardiopathy</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>15 (29.4%)</td>
</tr>
<tr>
<td>POCO</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>Type of disease associated to ILD - n (%)</td>
<td></td>
</tr>
<tr>
<td>Systemic Sclerosis</td>
<td>14 (27.5%)</td>
</tr>
<tr>
<td>Sjögren’s Syndrome</td>
<td>7 (13.7%)</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>Myositis</td>
<td>8 (15.7%)</td>
</tr>
<tr>
<td>SLE</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>MCTD</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>RA</td>
<td>12 (23.5%)</td>
</tr>
<tr>
<td>IPAF</td>
<td>4 (7.8%)</td>
</tr>
<tr>
<td>Antibodies - n (%)</td>
<td></td>
</tr>
<tr>
<td>Anti-myositis</td>
<td>6 (11.8%)</td>
</tr>
<tr>
<td>Anti-scleroder</td>
<td>15 (29.4%)</td>
</tr>
<tr>
<td>Anti-Ro</td>
<td>25 (49%)</td>
</tr>
<tr>
<td>Anti-RNP</td>
<td>3 (5.9%)</td>
</tr>
<tr>
<td>ANA</td>
<td>35 (68.6%)</td>
</tr>
<tr>
<td>RF</td>
<td>21 (41.2%)</td>
</tr>
<tr>
<td>Anti-Synt</td>
<td>6 (11.8%)</td>
</tr>
</tbody>
</table>

Note: POCO = Pulmonary Obstructive Chronic Disease, SLE = Systemic Lupus Erythematosus, MCTD = Mixed Connective Tissue Disease, RA = Rheumatoid Arthritis, IPAF = Interstitial Pneumonia with Autoimmune/Fib-NSIP, PHT = Pulmonary Hypertension, UIP = Usual Intestinal Pneumonia, Incons-UIP = Inconsistent Usual Intestinal Pneumonia, NSIP = Nonspecific Interstitial Pneumonia, Fib-NSIP = Fibrosing Nonspecific Interstitial Pneumonia, Organizing Pneumonia, Interstitial Lymphoid Pneumonia, Anti-fibronectin protein = Anti-fibronectin Protein, Anti-intercellular antibody = Anti-intercellular Antibody, Anti-Rn = Anti-Ribonucleoprotein, Anti-synthetase = Anti-synthetase.

Conclusion: In our series most patients were middle aged women. Anti-Ro antibodies and smoking status (former or current) were common among patients. Common clinical features were Raynaud (45%), skin affection (45%) and arthritis (40%). 47% of the patients expressed dyspnea at ILD diagnosis, 25.4% were treated with MP pulses, 23.5% with rituximab, 31.4% with mycophenolate mofetil. Fibrosing pattern in HRCT (UIP and fib-NSIP) was the most prevalent. 20% of the patients had progressive fibrosis under PFT criteria and 18% under HRCT. More studies of ILD-CTD are necessary to identify factors for progression and response to treatment and throw out more conclusions of prediction and progression of disease.

Disclosure of Interests: None declared


AB0677 FREQUENCY AND RISK FACTORS OF OSTEOPOROSIS IN FERTILE WOMEN WITH SYSTEMIC SCLERODERMA

A. Sorokina1, O. Dobrovolskaya1, O. Nikitinskaya1, N. Demin1, N. Toroptsova1, 1VA. Nasonova Research Institute of Rheumatology, osteoporosis laboratory, Moscow, Russian Federation

Objectives: To determine the frequency and risk factors of osteoporosis (OP) in fertile women with systemic scleroderma (SSc).

Methods: 64 women (36.0 [31.5; 43.5] years old) with SSc were enrolled in the study: 35 (54.7%) with limited and 29 (45.3%) with diffuse cutaneous subtype without overlap rheumatic syndromes. The median disease duration was 5.0 [2.0; 5.0] years. Glucocorticoids (GC) were taken by 49 (78.6%) patients with the median duration of treatment 5.0 [2.0; 10.0] years. Dual energy X-ray absorptiometry (DXA) of the lumbar spine, the femoral neck and the total hip was performed. To estimate the value of the BMD the Z-score was used. Low BMD was considered at a Z-score < -2.0 SD. A univariate logistic regression analysis was performed to analyze the factors associated with OP.

Results: Low BMD was detected in 8 (12.5%) patients. 5 (7.8%) women had a history of low-trauma fracture, among them only 1 (1.6%) patient had low BMD and 4 (6.2%) persons - normal BMD. A univariate logistic regression was performed to identify OP risk factors. Among traditional risk factors, low body mass index (BMI) associated with OP (OR 1.39 [1.04; 1.88], p=0.03) and falls during the past year (OR 1.39 [1.04; 1.88], p=0.03) and falls during the past year (OR 5.25 [1.39; 1.88], p=0.02). Among specific ones – duration of GC using (OR 1.11 [1.00; 1.23], p=0.04), hand joint contractures (OR 8.54 [1.41; 51.63], p=0.02). There was no effect of smoking, treatment with proton pump inhibitors, family history of osteoporosis, age, subtype SSc, modified Rodnan score, digital ulcer, cutaneous calcification, esophageal hypotension, interstitial lung disease, diffusing capacity of the lung for carbon monoxide, force vital capacity, CRP, erythrocyte sedimentation rate, creatinine, presence of antinuclear antibody, anticientromere antibody or antiperoxidasemase I antibody on the development of OP in fertile women with SSc.

Conclusion: Low BMD was detected in 12.5% of fertile women with SSc. Low BMI, falls during the past year, duration of SSc and GC taking, hand joint contractures associated with OP.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2584
Background: Idiopathic inflammatory myopathies (IIM) are associated with systemic inflammation, limited mobility, and glucocorticoid (GC) therapy, which can negatively impact metabolic disorders, atherogenesis, and increase the cardiovascular (CV) risk.

Objectives: This study aimed to evaluate CV risk in IIM patients compared to healthy controls (HC) and explore its associations with disease-specific features.

Methods: 39 patients with IIM (32 females; mean age 56; mean disease duration 4.8 years; dermatomyositis 16, polymyositis 7, immune-mediated necrotizing myopathy 8, antisynthetase syndrome 8) and 39 age-/sex-matched HC (32 females, mean age 56) were included. Subjects with a history of CV disease (angina pectoris, myocardial infarction, cerebrovascular, and peripheral arterial vascular events) were excluded in both groups.

Disease activity, damage, and muscle involvement (Manual Muscle Test (MMT)-8, Myositis Intention to Treat Activity Index (MITAX), Myositis Damage Index (MDI)) were assessed. Comorbidities and current treatment were recorded. All participants underwent examinations of carotid intima-media thickness (CIMT), pulse wave velocity (PWV), ankle-brachial index (ABI), and body composition (densitometry; IDXA Lunar, bioelectric impedance: BIA2000-M). The risk of fatal CV events was evaluated by the Systematic Coronary Risk Evaluation (SCORE and SCORE2, charts for the European population; modified mSCORE according to the 2015 EULAR recommendation for inflammatory arthritis - only in IIM patients).

Results: In IIM, disease activity and damage were predominantly mild (MITAX 0.13, MDI 0.05). Compared to HC, there was no significant difference in the prevalence of traditional risk factors. Only PWV was significantly increased in IIM compared to HC (p<0.015). No other significant difference was observed between the IIM and HC regarding the CV examinations (CIMT, ABI, carotid plaques) and calculated SCORE and SCORE2 (p>0.05 for all). In IIM, age and mean arterial pressure were the most significant parameters that correlated positively with SCORE, SCORE2, and mSCORE: arterial hypertension was significantly associated with a higher SCORE, carotid plaque count/thickness, and PWV. Lipid profile parameters, body composition, and disease activity were significantly associated with CIMT and carotid plaques (p<0.05 for all). Antihypertensive treatment was associated with an increase in carotid plaque count/thickness (p=0.009, p=0.008). Diabetes was associated with lower (worse) ABI values (p=0.034), prediabetes with a higher carotid plaque count (p=0.036) and thickness (p=0.011), and a worse ultrasound examination related CV risk (p=0.006). Anti-Jo-1 positivity was associated with a lower (better) CIMT and lower SCORE (p<0.05 for all). There were no significant associations of CV risk with clinical manifestations, immunosuppressive treatment, and GC cumulative dose. However, exposure time to GC therapy was significantly associated with the carotid plaques count (p=0.001) and the carotid plaque thickness (p=0.003). In multivariate analysis, the age of the patients was the most significant factor affecting most of the parameters analyzed (SCORE and its modifications, PWV, CIMT, and the total count of carotid plaques). Other significant predictors were total cholesterol and atherogenic index of plasma (for ABI), mean arterial pressure (for PWV), and disease duration (for the total count of carotid plaques).

Conclusion: No significant differences in CV risk factors between IIM patients and HC were observed. In IIM, CV risk was associated with age, disease duration, duration of glucocorticoid therapy, lipid profile, and body composition, but not with clinical manifestations and disease activity.

Acknowledgements: Supported by AZV NV18-01-00161A, MCHR-00023728, SSV-260523. GAUK 1578119

Disclosure of Interests: None declared


Figure 1. Efficacy Outcome. Figure 1. *p< 0.05 (Wilcoxon test).
After two years of follow-up, we observed the following adverse effects: headache (n=6), pruritus (n=3), allergic reaction (n=2) and arterial hypertension (n=1). No heart failure, renal insufficiency or thrombotic events were found.

Conclusion: IVG seems effective and safe in IIM treatment.

REFERENCES:
Disclosure of Interests: None declared

AB0680
PSYCHOLOGICAL IMPACT OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN SYSTEMIC SCLEROSIS PATIENTS AND INFLUENCE OF SUPPORT AND COPING STRATEGIES.

1University of Wuerzburg, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Wuerzburg, Germany; 2University of Wuerzburg, Institute of Psychology, Wuerzburg, Germany; 3University Hospital Tuebingen, Centre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases and Department of Internal Medicine II (Oncology, Hematology, Immunology, Rheumatology), Tuebingen, Germany

Background: In severe cases of systemic sclerosis (SSc), autologous hematopoietic stem cell transplantation (aHSCT) is superior compared to cyclophosphamide with respect to effect on skin and lung manifestations, survival and quality of life. Nevertheless, major physical and psychological impacts have been found in a first qualitative study by Spierings et al. (2020) 1. Objectives: Assessment of subjectively experienced physical and psychological impacts of aHSCT and exploration of potential interrelations of those impacts.

Methods: A SSc sample was assessed retrospectively after aHSCT in a two-step-approach. In the first step, 6 questionnaires were used: Global physical and mental health (SF-36 and Scleroderma Health Assessment Questionnaire = SHAQ), body image (Adapted Satisfaction with Appearance Scale = ASWAP), coping strategies (Freiburger Fragebogen zur Krankheitsverarbeitung = FKV-15), resilience (Resilienzskaala = RS-11), and control beliefs (Fragebogen zur Erfassung von Kontrollüberzeugung zu Krankheit und Gesundheit = KOKG). In the second step, semi-structured interviews based on Spierings et al. (2020) 1 were conducted and analysed via mixed methods qualitative content analysis following Mayring (2014).

Results: 19 patients (12 female, 7 male, mean age 53.47 years (SD = 9.50)) completed all questionnaires and interviews in a mean time of 6.56 years after aHSCT (SD = 3.90, range 1-12 years). A strong correlation was found between perceived physical impairment (SHAQ) and body image dissatisfaction (ASWAP) (Pearson's r = .83, p < .001). There was also a strong negative correlation between body image dissatisfaction (ASWAP) and the physical component of SF-36 (pcSF-36; r = -.59, p = .004) and a smaller correlation for the mental component of SF-36 (mcSF-36; r = -.38, p = .054). Depressive coping was negatively associated with SF-36 (pcSF-3; r = -.605, p = .003; mcSF-36; r = - .808, p < .001) (see Figure 1), whereas resilience was associated with a positive impact (pcSF-36; r = .522, p = .002; mcSF-36 r = .585, p = .004). In the qualitative content analysis of the interviews, all patients reported symptom improvements (mainly skin), which were associated with their coping strategies (depressive coping with fewer improvements, active coping with more improvements). Describing their emotional state during aHSCT, 7 patients verbalized "despair", 6 "loss of control", 5 "emotional instability", 4 "distress due to distance from home", 4 "fearlessness", 3 "listlessness", 2 "concern for feelings of relatives", and 2 "depersonalisation". As valuable professional emotional support during aHSCT, 6 patients named nurses and 8 named physicians, while the crucial role of daily ward rounds of the specialised transplant team rather than the primary care team was emphasised. The additional support by a psychology team was not deemed necessary by 7 patients, while 4 patients would have wished such a support. 7 patients rated their physical and mental recovery after aHSCT as satisfying, 4 as better than expected, 4 as disappointing, and 3 as causing impatience.

Conclusion: A transient negative impact of aHSCT on mental wellbeing of the majority of SSc patients is evident, but can be relieved by professional teams highly specialised in this particular treatment option.

REFERENCES:

Disclosure of Interests: None declared

AB0681
THE 2-YEAR IMPACT OF COVID-19 PANDEMIC ON MUSCLE STRENGTH AND PHYSICAL PERFORMANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS: A COHORT STUDY

L. Denardi Dória1, R. Cavalheiro do Espírito Santo1, L. Santos1, D. Nóbrega de Moraes1, E. Pena2, J. Katarina Schoer Portes1, A. A. Gasparin2, N. Pamplona Bueno de Andrade2, V. Hax2, R. Xavier1,2, R. Mendonça da Silva Chakr2,3.
1Federal University of Rio Grande do Sul, Laboratório de Doenças Autoimunes, Porto Alegre, Brazil; 2Hospital de Clínicas de Porto Alegre, Division of Rheumatology, Porto Alegre, Brazil

Background: Systemic sclerosis (SSc) patients are particularly prone to developing loss of muscle strength and worsening of physical performance due to decreased physical activity2. The lifestyle changes imposed by the SARS-CoV-2 outbreak have increased the incidence of sarcopenia in at-risk individuals2. However, the literature is scarce on the impacts of the COVID-19 pandemic on muscle strength and physical performance of SSc patients.

Objectives: (1) To assess the impact of the COVID-19 pandemic on muscle strength and physical performance of SSc patients and (2) to verify the associations of muscle strength and physical performance with inflammatory markers in a cohort study.

Methods: SSc patients who met the ACR / EULAR 2013 classification criteria were included. Patients followed between 2019 and 2021. Muscle strength was measured by handgrip strength (kg) and sit and stand (SST, seconds) tests. Physical performance was measured by timed up and go (TUG, seconds) and short physical performance battery (SPPB, points). Inflammatory markers were measured by C-reactive protein (CRP). T-test for independent samples, Mann-Whitney U test of independent samples and Spearman’s correlation coefficients were explored. The significance level was set at p ≤ 0.05 for all analyses.

Results: Forty SSc patients concluded this study. At baseline, the mean age was 59 ±11.1 years old and the median disease duration was 13.1 (6.4-19.2) years. Patients had a median of 4.5 clinic visits (3.0-6.0) over the 2 years. The majority of patients were women (37, 92.5%). Ten patients (25%) had diffuse cutaneous disease, 30 patients (75%) non-diffuse cutaneous disease [25 patients (62.5%) had limited cutaneous disease, and 5 (12.5%) had sine scleroderma SSc]. The median of CRP was 2.9 (12.5-3.5). The median of handgrip strength was 20.0 (10.3-25.6) kg to the right hand and 19.0 (12.0-22.6) kg to the left hand. The median of SST was 14.4 (11.9-18.7) seconds. The median of TUG was 6.8 (7.7-9.5) seconds and the median of SPPB was 9.8 (9.0-11.0) points. The CRP was positively associated with SST (n=0.3, p=0.047) and TUG (n=0.5, p=0.029), and negatively with SPPB (n=0.4, p=0.016). After 2 years of follow-up, the patients showed improvement in the left handd grip strength test (p=0.049) and SST (p=0.001). In physical performance, they showed improvement in the TUG test (p=0.005) and SPPB (p=0.001). The CRP was associated positively with SST (n=0.4, p=0.033), no other associations were found.

Conclusion: Despite the COVID-19 pandemic and the restrictions imposed, in this population of patients with SSc, we did not detect any worsening in muscle strength and physical performance. Some of these parameters of muscle strength and physical performance were associated with the inflammatory marker CRP. More investigations are needed to assess the actual impact and possible associations.

Table 1. Baseline comparison and after 2 years of patients with SSc

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>After 2 years</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP (mg/L)</td>
<td>median (IQR)</td>
<td>2.9 (12.5-3.5)</td>
<td>2.3 (10.5-3.1)</td>
</tr>
<tr>
<td>Handgrip (kg), right</td>
<td>median (IQR)</td>
<td>20.0 (10.3-25.8)</td>
<td>20.5 (14.3-27.0)</td>
</tr>
<tr>
<td>Handgrip (kg), left</td>
<td>median (IQR)</td>
<td>19.0 (12.0-22.8)</td>
<td>19.0 (14.0-26.0)</td>
</tr>
<tr>
<td>SST (seconds), median (IQR)</td>
<td>14.4 (11.9-18.7)</td>
<td>11.6 (9.9-13.1)</td>
<td>0.003*</td>
</tr>
<tr>
<td>TUG (seconds), median</td>
<td>8.6 (7.7-9.5)</td>
<td>7.9 (7.1-9.2)</td>
<td>0.005*</td>
</tr>
<tr>
<td>SPPB (points), median</td>
<td>9.8 (9.0-11.0)</td>
<td>11.0 (10.0-12.0)</td>
<td>0.001*</td>
</tr>
</tbody>
</table>

SSc: systemic sclerosis; IQR: interquartile range; mg: milligram; L: liter; kg: kilogram; grams; TUG: timed and up and go; SST: sit and stand test; SPPB: short physical performance battery; PCR: C-reactive protein; * significant difference of ≤0.05.

REFERENCES:
AB0682
FREQUENCY OF SEXUAL DYSFUNCTION IN SYSTEMIC SCLEROSIS, SANTO DOMINGO, DOMINICAN REPUBLIC

J. Santana Peralta1, A. Cornejo1, D. García1, R. A. Alvarez Santana1, T. Polanco Mora1, L. Concepción Sánchez2, I. Paulino1, I. Meredes3, E. Rodríguez Bautista1, T. Valdez Lorie1, A. Feriz2, R. MuñozLouis2, 3Hospital Docente Padre Billini, Rheumatology, Santo Domingo, Dominican Republic; 1Hospital Docente Padre Billini, Rheumatology, Santo Domingo, Dominican Republic

Background: Systemic sclerosis (SSc) is a systemic autoimmune disease. Sexual function has been associated with a high prevalence of dissatisfaction. Various factors have been implicated as causes of impaired sexual function. CSFQ-14 (Changes in Sexual Functioning Questionnaire) assesses changes in sexual functioning due to disease and/or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction < 41 men and < 47 women.6

Objectives: To evaluate the frequency and degree of sexual dysfunction in patients with systemic sclerosis. Methods: Prospective, observational, cross-sectional study of the cohort of the Rheumatology service of Hospital Docente Padre Billini. Patients were interviewed in November 2021. Inclusion criteria: > 18 years, diagnosis of SSc by ACR/EULAR 2013 classification criteria, at least 1 sexual relationship. Exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes, treatment with antidepressants, antiplatelets, narcotics, Measurement of CSFQ-14, mRSS. Statistical analysis was performed with the Pearson correlation (r) with p<0.05. The data was analyzed by SPSS V23.

Results: Of 63 patients, 54 met the inclusion criteria. 100% female, mean age 53 ± 15.07 years, mean duration 11.3 years, ISSc 24.1% (13), dSSc 75.9% (41), single 50% (27), married 44.4% (24), widowed 5.6% (3). Frequency of sexual dysfunction was 81.5% (44). Domains: pleasure 79.6% (43), desire_interest 37% (20), frequency 53% (28), desire/frequency 37% (20), physical aptitude 35% (19), psychological aptitude 26% (14). The desire/frequency dysfunction domain turned out to be the one with the highest presentation, followed by the orgasm/completion domain. A statistically significant linear association between sexual dysfunction and cutaneous activity of the disease was evidenced.

REFERENCES:

Disclosure of Interests: None declared


AB0683
POLYNEUROPATHY IMPACT ON DISABILITY IN SYSTEMIC SCLEROSIS PATIENTS

K. Ivanova1, 2, O. Budreivica3, D. Zukovs4, E. Mozeltova4, V. Kenina5, N. Kurjina3, 1Pauls Stradins Clinical University Hospital, Rheumatology Centre, Riga, Latvia; 2Riga Stradins University, Department of Clinical Studies, Riga, Latvia; 3University of Latvia, Residency, Riga, Latvia; 4Riga Stradins University, Faculty of medicine, Riga, Latvia; 3Riga Stradins University, Department of Biology and Microbiology, Riga, Latvia

Background: Systemic sclerosis (SSc) is one of the most severe autoimmune rheumatic diseases with high morbidity and mortality rates. Peripheral neuropathy in SSc is reported with a broad prevalence variable between 0.01% to 28%.2 Developed in 1978, the Health Assessment Questionnaire Disability Index (HAQ-DI) for rheumatoid arthritis, nowadays is widely used to measure functional status in patients with SSc as well, but data are lacking in SSc patients with peripheral neuropathy (PN).3

Objectives: To determine the impact of PN on disability in SSc patients. Methods: This was a cross-section study in patients with SSc. Study was conducted in two University hospitals in Latvia for adults. Study included patients diagnosed with SSc with the ACR / EULAR 2013 accepted classification criteria and have been consulted by rheumatologists between 1st January 2016 and 31st July 2021. Patients who agreed to comply in the study were evaluated by one rheumatologist and were surveyed and clinically evaluated according to The European Scleroderma Trials and Research group accepted domains. Disease duration was defined as time from first non-Raynaud SSc symptom to date of examination. SS subtype was evaluated in each patient by clinical presentation that included modified Rodnan score (mRSS) as well: limited cutaneous systemic sclerosis (cSSc) with skin thickening distal to the elbow/knee and diffuse cutaneous systemic sclerosis (dcSSc) with skin thickening proximal to the elbow/knee. For neuropathic pain assessment, the Neuropathic Pain Diagnostic Questionnaire (DN4) was used. Peripheral neuropathy symptoms were assessed using total neuropacy score (TNS). Peripheral nerve conduction study (NCS) and quantitative sensory testing (QST) was used to detect PN.

Functioning and disability were assessed using HAQ-DI. All patients completed the HAQ-DI form in the same day as they were evaluated, filling the form in native language.

Results: From 109 acknowledged patients, 67 were able to come for a visit, 54 females, 13 males. Mean age for females 62.54±12.02 years, for males 58.69±14.50 years. After assessment by rheumatologist, 50 were classified as cSSc, 17 were classified as dcSSc. The overall ratio of cSSc and dcSSc was 50:17 in females 41:13, in males 9:4. Disease duration ranges from 1 to 39 years (mean 15.49±10.18), 16.61±10.47 years for females, 10.85±7.55 years for males. Large fiber PN was diagnosed in 47% of subjects by NCS (n=32/67) and small fiber PN in 40.3% of subjects by QST (n=27/67), while 19.1% had neither (n=8/67). Mean HAQ-DI score was 1.22. There was no statistically significant difference in HAQ-DI score between males (1.08±0.89) and females (1.26±1.01), (p=0.13). As well there was no difference between HAQ-DI score in patients with large fiber/small fiber neuropathy and without neuropathy symptoms (p=0.6817). But we found that neuropathy symptoms (assessed by TNS) have moderately strong and statistically significant correlation with HAQ-DI and neuropathic pain (assessed by DN4) (n=40.5, p=0.00015).

Conclusion: PN is more common complication in SSc that was previously reported, with significant impact on QoL.

REFERENCES:

Disclosure of Interests: None declared


AB0684
FATIGUE ASSESSMENT IN SYSTEMIC SCLEROSIS, SANTO DOMINGO, DOMINICAN REPUBLIC

J. Santana Peralta1, A. Cornejo1, D. García1, R. A. Alvarez Santana1, T. Polanco Mora1, L. Concepción Sánchez2, I. Paulino1, I. Meredes3, E. Rodríguez Bautista1, T. Valdez Lorie1, A. Feriz2, R. Muñoz Louis3, 3Hospital Docente Padre Billini, Rheumatology, Santo Domingo, Dominican Republic

Background: Systemic sclerosis (SSc) is a systemic autoimmune disease. Fatigue has been reported in 75% of SSc patients, and is the most problematic symptom due to impact on quality of life. Despite its high prevalence, origin is unknown. Some studies associate it with the degree of disease activity and decreased quality of life. Fatigue is defined as a feeling of exhaustion, also as a reduction in physical and mental capacity, scales such as FACIT-F (Functional
Assessment of Chronic Illness Therapy-Fatigue) are used, which evaluates the last 7 days, with a score of 0-52. For the severity analysis, 4 grades are used: no or mild fatigue (40-52), moderate (27-39), severe (14-26) and extreme (0-13).

Objectives: To evaluate the frequency and degree of fatigue in systemic sclerosis.

Methods: Prospective, longitudinal, observational study of the cohort of patients of the Rheumatology service of the Hospital Docente Padre Billini. Patients were interviewed in November 2021. Inclusion criteria: ≥18 years, diagnosis of SSc according to ACR/EULAR 2013 classification criteria. Exclusion criteria: previous diagnosis of fibromyalgia, depression or anxiety, treatment with antidepressants, antihistamines, beta-blockers. Measurement of FACT-F, HAQ-DI, mRSS scales. Statistical analysis was performed with the Pearson correlation (r) with p=0.05. The data was analyzed by SPSS V23.

Results: 54 met inclusion criteria. 100% female, mean age 33.3±15.1 years, mean disease duration 113 months, SScD 75.9% (41), SSc 24.1% (13), interstitial pneumo-

nia 33.3% (18), gastroduodenal reflux disease 27.8% (15), HAP 20.7% (11). Fre-

quency of fatigue 100% (54); moderate FACT-F: 29.6% (16), severe FACT-F: 38.8% (21), extreme 31.5% (17). Correlation FACT-F with mRSS and HAQ-DI: Moderate FACT-F: mRSS mild 43.8% (7), moderate 12.5% (2), severe 18.8% (3), terminal 25% (4), HAQ-DI mild 25% (4), moderate 37.5% (6), severe 18.8% (3). Severe FAC-

tF: mRSS normal 4.8% (1), mild 19% (4), moderate 91% (4), severe 33.3% (7), terminal 25% (4), moderate 37.5% (6), severe 18.8% (3). Severe FAC-

tF: mRSS mild 7.6% (3), moderate 29.4% (5), severe 35.3% (6), terminal 23.8% (5), HAQ-DI mild 4.8% (1), moderate 19% (4), severe 47.6% (10); FACT-F: mRSS mild 761% (3), moderate 29.4% (5), severe 35.3% (6), terminal 176% (3), HAQ-DI moderate 11.8% (2), severe 52.9% (9), r= 0.246 p<0.05

Conclusion: The study demonstrated a high frequency of fatigue. The most frequent degree was severe. A statistically significant linear association was observed between skin involvement and the degree of functional limitation.

REFERENCES:

Disclosure of Interests: None declared

disease worsening or take safe medications during pregnancy, and have children also affected by SSC. 77% of patients declared improvement or stability of SSC manifestations during pregnancy. Table 1 shows the comparison of pregnancies before and after SSC diagnosis, based on data reported by the patients. Regarding sexuality, 59% reported that SSC negatively affected it by vaginal dryness (67%), digital ulcers (37%), gastro-intestinal disease (37%) and dyspnea (20%). Among 39 patients completing FSFI, 67% had sexual dysfunction.

<table>
<thead>
<tr>
<th>Total pregnancies (n = 189)</th>
<th>Pregnancies after diagnosis (n = 147)</th>
<th>Pregnancies before diagnosis (n = 42)</th>
<th>% p-value OR</th>
<th>[95% CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age at concep-</td>
<td>28.0</td>
<td>32.0 [28.0-39.0]</td>
<td>270 [23.0-30.0]</td>
<td>&lt;0.007</td>
</tr>
<tr>
<td>tion, years [24.0-32.0]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live births</td>
<td>152/189 (80.4)</td>
<td>31/42 (73.8)</td>
<td>121/147 (82.3)</td>
<td>0.221</td>
</tr>
<tr>
<td>Cesarean sections</td>
<td>63/135 (47.8)</td>
<td>17/31 (54.8)</td>
<td>18/104 (18.3)</td>
<td>&lt;0.007</td>
</tr>
<tr>
<td>Preterm births &lt;37 weeks</td>
<td>32/109 (29.4)</td>
<td>7/32 (21.9)</td>
<td>25/77 (32.5)</td>
<td>0.269</td>
</tr>
<tr>
<td>Preterm births &lt;34 weeks</td>
<td>7/32 (21.8)</td>
<td>2/27 (26.6)</td>
<td>5/25 (0.0)</td>
<td>0.632</td>
</tr>
<tr>
<td>Birth weight, kilograms</td>
<td>3.3 [2.8-3.6]</td>
<td>3.1 [2.5-3.5]</td>
<td>3.3 [3.0-3.7]</td>
<td>0.049</td>
</tr>
<tr>
<td>≥ 1 Adverse Pregnancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational hypertension</td>
<td>4/113 (3.5)</td>
<td>3/31 (9.7)</td>
<td>1/82 (1.2)</td>
<td>0.062</td>
</tr>
<tr>
<td>Preeclampsia</td>
<td>1/113 (0.9)</td>
<td>1/31 (3.2)</td>
<td>0/82 (0.0)</td>
<td>2.74</td>
</tr>
<tr>
<td>Eclampsia</td>
<td>0/113 (0.0)</td>
<td>0/31 (0.0)</td>
<td>0/82 (0.0)</td>
<td>1.00</td>
</tr>
<tr>
<td>HELLP syndrome</td>
<td>1/113 (0.9)</td>
<td>1/31 (3.2)</td>
<td>1/82 (1.2)</td>
<td>0.182</td>
</tr>
<tr>
<td>Gestational diabetes</td>
<td>3/113 (2.7)</td>
<td>2/31 (6.5)</td>
<td>1/82 (1.2)</td>
<td>0.022</td>
</tr>
<tr>
<td>Intravascular blockage</td>
<td>4/113 (3.5)</td>
<td>2/31 (6.5)</td>
<td>2/82 (2.4)</td>
<td>0.302</td>
</tr>
<tr>
<td>Restriction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perinatal deaths</td>
<td>2/134 (1.5)</td>
<td>0/32 (0.0)</td>
<td>2/102 (1.9)</td>
<td>1.00</td>
</tr>
<tr>
<td>Neonatal Intensive Care</td>
<td>11/134 (8.4)</td>
<td>6/32 (18.8)</td>
<td>5/102 (4.9)</td>
<td>0.022</td>
</tr>
<tr>
<td>Unit Admission</td>
<td></td>
<td></td>
<td></td>
<td>4.48</td>
</tr>
<tr>
<td>Perinatal infections</td>
<td>8/134 (6.2)</td>
<td>3/32 (9.4)</td>
<td>5/102 (4.9)</td>
<td>0.396</td>
</tr>
<tr>
<td>Breastfeeding</td>
<td>92/132 (69.7)</td>
<td>22/32 (68.8)</td>
<td>70/100 (70.0)</td>
<td>0.893</td>
</tr>
</tbody>
</table>

Conclusion: The newly created specific questionnaire was instrumental to facilitate physician-patient communication about ‘women’s health’; particularly in the field of sexuality which is characterized by a high frequency of dysfunction. Adverse outcomes are possible during SSC pregnancies and should be discussed during the multidisciplinary preconception counselling, along with measures to possibly reduce their risk.

Acknowledgements: GILS (Gruppo Italiano Lotta Sclerodermia) is kindly acknowledged for supporting the study with a grant.

Disclosure of Interests: None declared


AB0687

PROGNOSTIC MEANING OF RIGHT VENTRICULAR FUNCTION AND RESERVE IN PATIENTS WITH SYSTEMIC SCLEROSIS

P Xanthoulis1,2, J. Miazgoski1, N. Benjamin1, G. Gorgani2, B. Egeland2, S. Harutyunova2, R. Seeger2, A. Marra2,3, N. Blank1, H. M. Lorenz1, E. Grünig2, H. Miazgoski1, N. Khmelinskii1,2.

Background: The delay of the diagnosis of pulmonary hypertension (PH) in patients with systemic sclerosis (SSc) leads to severe impairment of survival. Objectives: The objective of this study was to investigate the prognostic impact of right ventricular (RV) function at rest and during exercise on survival in patients with SSc presenting for screening for PH. Methods: Data from SSc patients who underwent routinely performed examinations for PH screening including echocardiography and right heart catheterization at rest and during exercise were analyzed. Uni- and multivariable analyses were performed to identify prognostic parameters in SSc and to compare them to known prognostic predictors. Results: Out of 285 SSc patients screened for PH, 225 patients (83.3% female, mean age 58.1±13.0 years, 68% limited cutaneous SSc, WHO-FC II-III 74%, 24 manifest PH) were included in the analysis. During an observation period of 3.2±2.7 (median 2.6) years 35 patients died. Tricuspid annular plane systolic excursion ≤18 mm (p=0.0004), increase of cardiac index (CI) during exercise ≤2 l/min (p=0.0002), RV output reserve >3 mmHg/l/min (p=0.001), peak CI ≤ 5.5 l/min (p=0.01), pulmonary arterial compliance >2 l/mmHg (p=0.0005) and qualitative RV function at rest (p<0.0001) significantly predicted survival. In the multivariable analysis, RV function at rest, diffusion capacity for carbon monoxide <65% predicted and CI increase <2 l/min/m² were identified as independent prognostic predictors and had >70% sensitivity and specificity to predict development of pulmonary vascular disease (PVD) during follow-up. Conclusion: This study demonstrates that assessment of RV function at rest and during exercise may facilitate physician-patient communication about ‘women’s health’, particularly in the field of sexuality which is characterized by a high frequency of dysfunction. Adverse outcomes are possible during SSC pregnancies and should be discussed during the multidisciplinary preconception counselling, along with measures to possibly reduce their risk.

Disclosure of Interests: None declared


AB0688

PREDICTORS OF MUSCLE INVOLVEMENT IN PORTUGUESE PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE

A. T. Meio1, M. Silvério-António1, J. Martinho1, E. Dourado2, F. Guimarães3, D. Santos Oliveira3, J. M. Pestana Lopes6, A. Saraiva4, A. Gomes Correia1, A. L. Fernandes3, S. P. Dinis1, R. Nicolau1, S. P. Silva1, C. Costa1, T. Braga1, A. Furtao2, P. D. Peixoto1, P. M. Azvedo Abreu1, C. Afonso1, D. D. António1, N. Khmelinskii2,3,1. Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Lisbon, Portugal; 2Instituto de Medicina Molecular, Rheumatology Research Unit, Lisbon, Portugal; 3Unidade Local de Saúde do Alto Minho, Rheumatology Department, Ponte de Lima, Portugal; 4Centro Hospitalar Universitário São João, Rheumatology Department, Porto, Portugal; 5Faculdade of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 6Hospital Garcia de Orta, Rheumatology Department, Lisbon, Portugal; 7Centro Hospitalar Universitário de Coimbra, Rheumatology Department, Coimbra, Portugal; 8Hospital de Braga, Rheumatology Department, Braga, Portugal; 9Centro Hospitalar Universitário do Algave, Rheumatology Department, Faro, Portugal; 10Unidade Local de Saúde da Guarda, Rheumatology Department, Guarda, Portugal; 11Centro Hospitalar Tondela-Viseu, Rheumatology Department, Viseu, Portugal; 12Centro Hospitalar do Baixo Vouga, Rheumatology Department, Aveiro, Portugal; 13Centro Hospitalar Trás-os-Montes e Alto Douro, Rheumatology Department, Vila Real, Portugal; 14Centro Hospitalar Vila Nova de Gaia/Espinho, Rheumatology Department, Gaia, Portugal; 15Hospital do Divino Espírito Santo, Rheumatology Department, Ponta Delgada, Portugal; 16Unidade Local de Saúde de Castelo Branco, Rheumatology Department, Castelo Branco, Portugal

Background: Mixed connective tissue disease (MCTD) is a rare heterogeneous disease, characterized by overlapping features of classic connective tissue diseases. Myositis may present in up to two-thirds of patients with MCTD and it is included in all diagnostic criteria available. Although some possible associations have been reported, to the best of our knowledge, no independent predictors of MCTD-related myositis have been described.
OBJECTIVES: To identify clinical and laboratorial predictors for muscular involvement in a cohort of Portuguese patients with MCTD.

METHODS: Multicentre retrospective cohort study including adult-onset patients with a clinical diagnosis of MCTD and fulfilling at least one of the following diagnostic criteria: Sharp, Kasukawa, Alarcón-Segovia or Kahn criteria. Myositis was defined as proximal muscle weakness, creatine kinase elevation, electromyography (EMG) suggestive changes or a positive muscular biopsy. Univariate analysis was performed using Chi-Square, Fischer’s Exact Test and Mann-Whitney Test, as appropriate. Multivariate analysis was performed using binary logistic regression modelling. The linearity of the continuous variables concerning the logit of the dependent variable was assessed via the Box-Tidwell procedure. Cases with missing information and outliers were excluded from the multivariate analysis to fulfill all assumptions necessary to assure the validity of the regression.

RESULTS: A total of 98 patients were included, 43 (44.3%) of whom had muscular involvement at any time of the disease course. Concerning patients with MCTD-related myositis, the mean age at diagnosis was 34.8±12.5 years and the mean disease duration of 4.1±4.9 years. The majority of patients were female (90.7%) and of European ancestry (66.7%). EMG was performed in 24 patients, of whom 10 (41.7%) had a myopathic pattern. Seventeen patients were submitted to a muscular biopsy, of whom 8 (47.1%) had histological myositis features. Capillaroscopy was performed in 24 patients and 12 (50%) had a scleroderma pattern. African ancestry and leukopenia were positively associated with myositis at disease onset. Furthermore, fever at the onset of disease, younger age at diagnosis and shorter disease duration were positively associated with the occurrence of myositis at any phase of the disease. The multivariate analyses predicting myositis at diagnosis included 54 patients and at any time of the disease included 90 patients. These models explained 37.8% and 26.9% (Nagelkerke R2) of the variance in myositis and correctly classified 79.6% and 73.3% of all cases, respectively. African ancestry (OR 8.39, 95%CI: 1.43-49.37, p=0.019), leukopenia (OR 6.24, 95%CI: 1.32-29.48, p=0.021) and younger age at diagnosis (OR 1.07/year, 95%CI: 1.01-1.14, p=0.035) were identified as independent predictors of myositis at diagnosis. Fever (OR 6.51, 95%CI: 1.23-34.37, p=0.027) was an independent predictor of muscular involvement at any time of the disease in MCTD patients.

CONCLUSION: African ancestry, leukopenia and younger age at diagnosis are independent predictors of myositis at presentation in MCTD patients, while fever is an independent predictor of myositis at any time of the disease. While evaluating patients with MCTD, these predictive factors should be considered.

REFERENCES:

DISCLOSURE OF INTERESTS: None declared


AB0689

CLINICAL COURSES AND PREGNANCY OUTCOMES OF EIGHT CASES COMPPLICATED WITH POLYMYSITIS/DERMATOMYSITIS (PM/DM) IN SINGLE CENTER

R. Mino1, H. Shimad1, R. Wakiya1, S. Nakashima1, M. Kato1, T. Miyagi1, S. Nakashima1, M. Kato1, T. Miyagi1, H. Dobashi1,1 Kagawa University, Department of Internal Medicine, Division of Hematology. Rheumatology and Respiratory Medicine, Miki, Japan

Background: Pregnancies complicated by a number of rheumatic diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes (APOs). There have been several reports on the risk of APOs in systemic lupus erythematosus and rheumatoid arthritis, but few reports on polymyositis (PM)/dermatomyositis (DM) pregnancies. There are also insufficient reports on changes in the activity of PM/DM during pregnancy. Based on the findings reported in other rheumatic diseases, it is suggested that increased activity during pregnancy is associated with APOs in PM/DM (1-3). However, the risk factors for pregnancy outcome in pregnancies complicated by PM/DM, including the presence or absence of worsening of disease activity, have not been clarified.

Objectives: The purpose of this study was to analyze a case series of PM/DM complicated pregnancies in a single center to determine the changes in disease activity during pregnancy and pregnancy outcomes.

Methods: PM/DM patients who were managed from pregnancy to delivery at Kagawa University Hospital from March 2006 to March 2021 were included in this study. Clinical indices including duration of illness, disease activity, and treatment were extracted from medical records and retrospectively analyzed for association with pregnancy outcome.

Results: Eight PM/DM pregnancies were included in the analysis. The mean age at delivery was 28.3±3.8 years and the mean duration of disease was 6.3±3.2 years. Treatment at the time of pregnancy included glucocorticoids (GC) in 7 cases and immunosuppressive drugs in 5 cases. Creatine phosphokinase (CK) levels were normal in all patients at the time of pregnancy, but increased during pregnancy in 4 (50%) patients. These 4 patients with elevated CK required treatment with increasing doses of GC, and the mean GC dose during pregnancy was 10.9 ± 6.0 mg/day. Table 1 shows the pregnancy outcomes of the 8 patients. There was one spontaneous abortion and seven live births. Among the live births, 2 were preterm and 4 were low birth weight. The mean gestational age at delivery was 35.3±5.2 weeks and the mean birth weight was 2297.7±1041.4 g.

The birth outcomes of the 2 patients who received continuous immunosuppressive therapy were full-term and normal weight infants. APOs, such as preterm delivery and low birth weight, occurred in cases with increased CK levels and increased GC doses.

Conclusion: In pregnancies of PM/DM patients, pregnancy outcome was less than favorable. An association between disease activity and the development of APOs during pregnancy in PM/DM was suggested. An association was also suggested between GC dose and the risk of developing APOs. As in other rheumatic disease pregnancies, continued use of pregnancy-appropriate immunosuppressive drugs and control of disease activity with lower glucocorticoid doses in PM/DM pregnancies may be important to achieve good pregnancy outcomes.

REFERENCES:

DISCLOSURE OF INTERESTS: None declared


AB0690

CALCINOSIS CUTIS IN SYSTEMIC SCLEROSIS: CLINICAL AND BIOLOGICAL ASSOCIATIONS

G. M. State1, N. D. Popescu1, I. A. Berza1, F. Negoi1, A. Dima1, M. Parvu2.
1Colentina Clinical Hospital, Department of Rheumatology, Bucharest, Romania; 2Colentina Clinical Hospital, Department of Rheumatology, Bucharest, Romania.

Background: Calcinosis cutis (CC) is a rare disorder characterized by the abnormal deposition of calcium salts in the subcutaneous tissues of patients with normal calcium metabolism. Dystrophic calcinosis is a common and potentially debilitating manifestation in systemic sclerosis (SSc) patients. The CC was described to appear more frequently in newly diagnosed SSc patients with Raynaud’s phenomenon, with ischemic ulcer or telangiectasia and in areas related to repeated trauma, but current data remains inconclusive 1-2.

Table 1. Pregnancy outcomes of eight cases

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Outcome</th>
<th>Mode of delivery</th>
<th>Gestational age at delivery (weeks)</th>
<th>Birth weight of the newborn (grains)</th>
<th>Adverse pregnancy outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Live birth</td>
<td>Cesarean section</td>
<td>26</td>
<td>590</td>
<td>Preterm birth, LFD, HELLP syndrome</td>
</tr>
<tr>
<td>2</td>
<td>Spontaneous abortion</td>
<td>Transvaginal delivery</td>
<td>30</td>
<td>1,299</td>
<td>Preterm birth, LWB</td>
</tr>
<tr>
<td>3</td>
<td>Live birth</td>
<td>Cesarean section</td>
<td>38</td>
<td>2,765</td>
<td>Hypertensive disorder</td>
</tr>
<tr>
<td>4</td>
<td>Live birth</td>
<td>Cesarean section</td>
<td>37</td>
<td>3,290</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Live birth</td>
<td>Cesarean section</td>
<td>37</td>
<td>2,492</td>
<td>LWB</td>
</tr>
<tr>
<td>6</td>
<td>Live birth</td>
<td>Transvaginal delivery</td>
<td>39</td>
<td>3,456</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Live birth</td>
<td>Transvaginal delivery</td>
<td>40</td>
<td>2,192</td>
<td>LWB</td>
</tr>
<tr>
<td>8</td>
<td>2 live births</td>
<td>1 abortion</td>
<td>35.3±5.2</td>
<td>2,297±1,041.4</td>
<td></td>
</tr>
</tbody>
</table>

1Colentina Clinical Hospital, Department of Rheumatology, Bucharest, Romania; 2Colentina Clinical Hospital, Department of Rheumatology, Bucharest, Romania.

DISCLOSURE OF INTERESTS: None declared

Objectives: Our objective was to analyze the prevalence, clinical features, and biological associations of CC in SSc patients.

Methods: A retrospective analysis of patients hospitalized in the Rheumatology Department of the Colentina Clinical Hospital, Bucharest, Romania. Data of the patients fulfilling the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) SSc classification criteria were collected. In all patients, clinical examination, including evaluation of the cutaneous involvement by modified Rodnan skin score (mRSS) was performed. A CC diagnosis was sustained by radiographic and/or ultrasound imaging.

Results: 44 SSc patients were included with female predominance (39 patients - 88.6%), and with mean (SD) age 58.8±11.3 years old, CC was found in 11(25.0%) of these patients, all feminine gender. Elbow (36.4%) and hands and forearms (27.3%) were the most frequent sites affected by CC.

Overall, CC was not related to the SSc subtype, when comparing limited (lc) vs diffuse cutaneous (dc) involvement (27.3% vs. 48.5%, p=0.219). However, patients with CC had more often lc SSc, 72.7% vs. 27.3%. Accordingly, SSc patients with CC had a significant lower mRSS score, 6 (1;7) vs. 9 (5; 15,5) points, p=0.001 and more frequently expressed positives anti-centromere antibodies (ACA), 72.7% vs. 57.1%, p=0.038. CC was also found not to be related to sclerodactylty, 54.5% vs. 75.8%, p=0.038. Regarding the nailfold capillaroscopy (NFC) exam, the CC was more often described in patients with late NFC pattern, 45.5% of cases.

In SSc patients with CC, there was reported more often intestinal transit disturbances 45.5% vs. 3.0%, p=0.015, even if overall there was no gastrointestinal involvement, 72.7% vs. 63.6%, p=0.582.

Regarding inflammation, the level of erythrocyte sedimentation rate (ESR) was lower in patients with CC (13.33) vs. 33 (170; 58.5) mm/h, p=0.040, but not the C-reactive protein level 2.4 (1.7; 6.7) vs. 3.3 (12; 8.5) mg/L, p=0.866. When comparing SSc patients with or without CC we did not found any significant difference regarding the presence of anti-Scl70 antibodies, p=0.432, rheumatoid factor, p=0.067, lupus anticoagulant or antiphospholipid antibodies, p=0.835. Also, no significant correlations were identified for CC in SSc and the following parameters: smoking, p=0.162, obesity, p=0.812, hypertension, p=0.371, diabetes, p=0.403, Raynaud phenomenon, p=0.539, telangiectasia, p=0.28, pulmonary hypertension, p=0.777, lung interstitial disease, p=0.315, digital ulcers, p=0.723, or digital starry scars, p=0.223.

Conclusion: The CC prevalence in SSc consecutive patients was 25.0%, more frequently with elbow localization. We’ve also found more frequent CC in patients with positive ACA serology and defined relations with many other SSc-related parameters.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3041

AB0691 SYSTEMIC SCLEROSIS AT THE TIME OF COVID-19: PANDEMIC: A BIBLIOGRAPHY STUDY
B. Daskalakis1, R. Yatsyshyn2, I. Stoika2, K. Fedorovych3, O. Hotsianik2, O. Drogermeretska1, Ivanovo Frankivsk National Medical University, Pathophysiology, Ivanovo Frankivsk, Ukraine; 2Ivanovo Frankivsk National Medical University, Internal medicine #1 clinical immunology and allergy, Ivanovo-Frankivsk, Ukraine

Background: The Coronavirus disease 2019 (COVID-19) affects different organs and systems of the human organism. However, the main target remains the respiratory system and lungs in particular. Systemic sclerosis (SSc) is one of the systemic autoimmune diseases that can cause severe lung impairment. Considering the existence of common points of influence on the human organism, the overlapping of these two pathologies can significantly increase the negative impact on the patient’s health.

Objectives: This study was aimed to analyze the common features of articles covering the link between COVID-19 and systemic sclerosis.

Methods: We retrieved the literature items in the scientific bibliometric database Scopus conducting our search on the 26th of January. We didn’t set any time limits and did use the following keywords: “systemic sclerosis” OR “scleroderma” AND “COVID-19” OR “Covid-19” OR “coronavirus”. The exclusion criteria were: absence of an abstract, literature items in form of conference papers, and articles dedicated to the rheumatological pathology in general with scarce mention of SSc. All selected papers were analyzed in view of the following characteristics: documents’ type, authorship, journal, citations score, the origin of an article, language, and keywords. For data visualization, we have used software tool VOSviewer version 1.6.15 which make possible to build authors’ and keywords’ network (Figure 1 A and B) (the minimum keywords’ threshold was 3 and the minimum author occurrence was 5).

Results: In the result of our comprehensive literature search only 206 items were obtained. After screening of title, abstract and keywords we omitted 166 articles as they met our exclusion criteria and were irrelevant for our study. The most (87.5%) of remained 40 articles were open access publications, which improves the articles’ visibility and simplifies data sharing. The top journals covering this topic were: Annals Of The Rheumatic Diseases (n=7); Journal of Psychosomatic Research (n=4), Journal Of Scleroderma And Related Disorders (n=4), Clinical Rheumatology (n=3), Lancet Rheumatology (n=3) and Scandinavian Journal Of Rheumatology (n=3). The post productive authors originated from Italy (n of articles = 20); other countries with highest number of publications were: UK – 10; USA – 7; France – 7 and Netherlands – 6. The majority of papers were written in English and just one was in Chinese. The most prevalent research type among analyzed articles was Letter (47.5%), about a third of the articles were designed as Original Articles (35%), 7.5% were Notes, the number of Reviews and Editorials was 5% for each type. Based on the citations score, the most relevant article was dedicated to COVID-19 course in patients with SSc associated interstitial lung disease (SSC-ILD) using tocilizumab. The second highly cited paper highlighted a disease course of COVID-19 pneumonia in SSc patients treated with rituximab and the third actively cited article was World Scleroderma Foundation preliminary advice for patient management. It should also be noted that a lot of articles (n=7, 17.5%) were dedicated to the emotional wellbeing of SSc patients in time of COVID-19 pandemic.

Conclusion: Based on our literature analysis, it is the first attempt to overview comprehensively the papers focusing on SSc and COVID-19 overlap. The bibliometric studies offer an essential opportunity to emphasize the main features and trends in the particular topic and could be used by scientists as a guidance for forthcoming research.

REFERENCES: - Disclosure of Interests: None declared

AB0692 PREDICTORS OF ILOPROST INFUSION TOLERANCE IN PATIENTS WITH SYSTEMIC SCLEROSIS
R. Bixio1, E. Bertoldo1, A. Gioletti2, G. Adamì3, A. Morciano1, D. Bertelle1, I. Gavioli1, G. Orsolini1, O. Viapiana1, M. Rossini1, 1Università degli studi di Verona, Rheumatology section, Verona, Italy; 2Università degli studi di Padova, Division of Rheumatology, Padova, Italy

Background: Systemic Sclerosis (SSc) is an autoimmune disease characterized by vasospasm and microvascular involvement. Iloprost (ILO), a prostaglandin analogous, is used for the treatment of SSc-related Raynaud’s Phenomenon and digital ulcers. The second highly cited paper highlighted a disease course of COVID-19 pneumonia in SSc patients treated with rituximab and the third actively cited article was World Scleroderma Foundation preliminary advice for patient management. It should also be noted that a lot of articles (n=7, 17.5%) were dedicated to the emotional wellbeing of SSc patients in time of COVID-19 pandemic.

Conclusion: Based on our literature analysis, it is the first attempt to overview comprehensively the papers focusing on SSc and COVID-19 overlap. The bibliometric studies offer an essential opportunity to emphasize the main features and trends in the particular topic and could be used by scientists as a guidance for forthcoming research.

REFERENCES: - Disclosure of Interests: None declared
all patients, neither in the subgroup with early disease, nor in the subgroup with late disease. There was no significant change in PFT's, DLCO and chest HRCT lesions in either subgroup at each follow-up visit. Furthermore, all the patients who were treated with RTX early in the disease course achieved better results at 6 months follow-up. AEs during ILO titration occurred in 47.8% of patients, of whom 22.2% presented concomitant hypotenison. The most common AEs were headache, nausea, vomiting, diarrhoea, oedema, hypotenison, and symptomatic therapy was needed in half of the patients at least once. Overweight patients (BMI >26) presented a 13-fold increased risk of developing AEs during ILO titration (adjusted odd ratio 13.979 95% CI 2.359-82.845).

Conclusion: Our study showed that only a higher BMI was associated with lower ILO infusion rate tolerance and higher AEs rate, underlying a possible BMI-dependent endothelial dysfunction possibly mediated by endothelin receptor expression. Individual ILO regimens still need to be tailored to the patient.

Disclosure of Interests: None declared

AB0693

EFFECTIVENESS OF RITUXIMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS – EXPERIENCE IN A TERTIARY MEDICAL CENTER

N. Cristini1, L. Groseanu1,2, G. Petrescu1, D. Nicoara1, O. Opris-Belinskii1, D. Mazill1, A. Balanescu1,2, R. Ionescu1 on behalf of The Department of Rheumatology and Internal Medicine at Bucharest St. Mary’s Hospital, 1St Mary Hospital, Internal Medicine and Rheumatology, Bucharest, Romania; 2Carol Davila University of Medicine and Pharmacy; University of Medicine and Pharmacy, Bucharest, Romania

Background: There is ample evidence of B cell involvement in the pathogenesis of fibrosis in systemic sclerosis (SSc), making it a promising target for the treatment of skin and lung fibrosis in SSc. However, data regarding the long-term use of B cell depletion in the treatment of this life-threatening connective tissue disease is scarce.

Objectives: The primary aim of this study was to evaluate the safety and efficacy of long-term B cell depletion and to define the changes on both cutaneous and visceral organ involvement after rituximab (RTX) therapy in SSc patients over time, in a tertiary hospital.

Methods: A prospective observational case-control study, conducted between 2016 and 2021, enrolled 10 SSc patients, who fulfilled the ACR/EULAR 2013 classification criteria for scleroderma and who had received RTX infusions at least once. All patients had been taking immunosuppressive therapy previously. The following clinical data were included into the analysis: disease activity by the EUSTAR activity index, skin fibrosis by the modified Rodnan Skin Score (mRSS), interstitial lung disease by lung function tests including forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO) and high-resolution CT (HRCT). For the comparison of non-parametric data at two time points, Wilcoxon matched paired Student’s t-test was used.

Results: The study included 10 patients (all female), with a mean age of 52.9 years, most of them with diffuse subset (9/10), treated with RTX between 2016 and 2021. Average duration of disease before the RTX therapy was 27.6 months. Mean baseline mRSS was 19.3 and mean EUSTAR activity index was 4.48. Seven patients received 2 courses of RTX and four of them were evaluated 1 year after the beginning of RTX therapy. We found a statistically significant improvement in mRSS (p=0.02) and EUSTAR activity index values (p=0.02), when comparing baseline levels with those found at each follow-up visit. Furthermore, all the patients who were treated with RTX early in the disease course achieved better results at 6 months follow-up. There was no significant change in PFT’s, DLCO and chest HRCT lesions in all patients, neither in the subgroup with early disease, nor in the subgroup with worsening, progressing pulmonary function, during the follow up period.

Conclusion: Our results suggest that B cell depletion, in patients with SSc, leads mainly to a clinically relevant decrease in skin involvement and to a stabilization of disease activity after 6 and 12 months of use. The study did not find a clear beneficial effect on pulmonary function during short-term follow-up. Despite these considerations, our results indicate that the course of lung disease did not worsen in our patients. At 6-year follow-up the safety of single and repeated courses of the drug was confirmed. While the study provides important insights into the use of RTX in SSc, it is limited by the low number of patients, the lack of a sufficient control arm and the single center design.

REFERENCES:


AB0694

VITAMIN D LEVELS IN PATIENTS WITH SYSTEMIC SCLEROSIS AND VERY-EARLY SYSTEMIC SCLEROSIS (VEDOSS)

G. Cuomo1, M. C. Trota2, C. Di Vico1, R. Ferrara2, C. Romano2, M. D’Amico2. 1Università-Cagliari Studi della Cambiana Foundation of Medicine, Naples, Italy; 2Università della Campania Luigi Vanvitelli, Section of Pharmacology “L’Donatelli”. Naples, Italy; 3University of Campania Studies “Luigi Vanvitelli”; Department of Medical and Surgical Sciences, Naples, Italy

Background: Systemic sclerosis (SSc) is a chronic disease characterized by autoimmunity, vasculopathy, and visceral and cutaneous fibrosis and very-early systemic sclerosis VEDOSS is characterized by Raynaud’s phenomenon with SSc marker autoantibodies and typical capillaroscopic features. Vitamin D has several functions in the immunological system, and different studies have suggested a potential role in triggering autoimmune diseases. (1,2)

Objectives: Our goal was to verify the difference of Vitamin D levels causal in SSC definite and VEDOSS population, and relationship between hypovitaminosis D and SSc characteristics.

Methods: 42 adults with SSc were recruited: 24 with American College of Rheumatology criteria were affected by diffuse systemic sclerosis (4) and limited systemic sclerosis (20); 18 with VEDOSS criteria. Patients were evaluated from medical history and physical examination (modified Rodnan skin score and the presence / number of ulcers), biohumoral evaluation of routine, electrocardiogram, echocardiogram, pulmonary function tests, high resolution computed tomography of the chest, capillaroscopy. For the determination of total vitamin D levels (25-OH), the serum samples were suitably centrifuged at 4 °C at 3500g. Vitamin D levels were then determined by a two-step chemiluminescence enzyme immunoassay (CLIA), with a maximum limit of 100 ng / ml.

Results: The 42 subjects recruited (4 men and 38 women); age 48.2 ± 11.5 years (mean ± SD). All subjects were ANA positive, with anti-Scl70 positivity in 59% of SSc patients (4) and anti-centromere iCSCC patients (18). Patients with VEDOSS showed optimal serum levels of vitamin D (33.93 ± 3.5 ng / ml). Conversely, patients with systemic sclerosis showed serum levels of vitamin D at the limit of sufficiency (21.75 ± 4.0 ng / ml). (Figure 1) In particular, in the group of patients with systemic sclerosis, vitamin D levels were significantly reduced by 1.5 times (P <0.05) compared to VEDOSS group. In patients with SSc the serum levels of vitamin D were inversely proportional to the presence of mega capillaries. Furthermore, a directly proportional correlation of the serum levels of vitamin D with the age of the patient. It is therefore possible to assume that higher levels of vitamin D delay the onset of the disease, while lower levels of vitamin D favor the onset of the same.

Conclusion: Considering our findings from this work, it is possible to consider the Vitamin D supplement in patients suffering from sclerosis, especially as an adjuvant in the initial phase of the disease, thus hypothesizing a slowdown in the progression of the disease and an improvement in prognosis.

REFERENCES:
Background: Anti-Th/To antibodies, detected in 2-5% Systemic Sclerosis (SSc) patients, are associated to interstitial lung disease (ILD)\(^1\) in half of the cases. However, long-term data on ILD as well as on organ damage accrual are lacking.

Objectives: To describe the clinical associations of anti-Th/To SSc patients, focusing on ILD, organ damage and mortality.

Methods: Monocentric retrospective study. 1) Description of clinical associations of anti-Th/To SSc patients (2013 ACR/EULAR criteria). 2) Case-control study: anti-Th/To vs anti-Topoisomerase (anti-Topo)1 patients (1:3; matched for sex and age at SSc onset) regarding a) ILD b) organ damage c) survival. ILD progression was assessed through pulmonary function tests (PFTs) at baseline (T0) and after 1 (T1), 2 (T2), 5 (T5), 10 (T10) and 20 (T20) years. Organ damage was evaluated with SCTD-Damage Index (SCTD-DI)\(^2\). Continuous data are expressed as median [IQR].

Results: We identified 13 anti-Th/To patients (all Caucasians, F/M=10/3, median age at SSc onset: 50 [37-67] years). Anti-Th/To were assayed by RNA immunoprecipitation in 8/13 and by immunoblotting in 5/13 cases.

1) 2/13 patients had SSc/myositis overlap syndrome: 1 associated to anti-SRP, 1 negative for myositis specific antibodies and affected by a synchronous (≤3 years from onset) cancer. All presented icSSc, 77% esophageal symptoms, 46% digital ulcers (DUs), 40% ILD, 39% telangiectasias, 39% heart involvement (3 pericarditis, 1 myocarditis in patient anti-SRP+, 1 arrhythmia), 15% gastrointestinal symptoms, 15% myositis and 8% calcinosis. No patients presented synovitis, joint contractures, pulmonary arterial hypertension nor scleroderma renal crisis.

2a) Anti-Th/To ILD patients, as compared to 39 anti-Topo 1, less frequently required antifibrotic or O2 therapy (Table 1); ILD progression (%pFVC decline ≥10% or %pDLCO decline 5-10% and %pFVC decline ≥15%) was shown for 3/13, albeit, after a longer interval than in 8/39 anti-Topo 1 progressors (15 [10-15] vs 1 [6.3-15] years, p:0.05); none died because of ILD.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>anti-Th/To n=13</th>
<th>anti-Topo 1+ n=39</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ILD on HRTC</td>
<td>4/10 (40)</td>
<td>28/33 (85)</td>
<td>0.01</td>
</tr>
<tr>
<td>Immunosuppressants</td>
<td>1/13 (8)</td>
<td>16/39 (41)</td>
<td>0.04</td>
</tr>
<tr>
<td>Antifibrotic and/or O₂</td>
<td>0/13 (0)</td>
<td>8/39 (21)</td>
<td>0.18</td>
</tr>
<tr>
<td>PH secondary to ILD</td>
<td>0/13 (0)</td>
<td>6/39 (15)</td>
<td>0.32</td>
</tr>
<tr>
<td>SSc-ILD related death</td>
<td>0/13 (0)</td>
<td>6/39 (15)</td>
<td>0.32</td>
</tr>
<tr>
<td>%pFVC T0</td>
<td>105 [85-114]</td>
<td>90 [91-114]</td>
<td>0.26</td>
</tr>
<tr>
<td>%pFVC T1</td>
<td>107 [97-112]</td>
<td>88 [80-108]</td>
<td>0.09</td>
</tr>
<tr>
<td>%pFVC T5</td>
<td>97 [84-114]</td>
<td>99 [83-111]</td>
<td>0.88</td>
</tr>
<tr>
<td>%pFVC T10</td>
<td>103 [91-114]</td>
<td>88 [80-112]</td>
<td>0.23</td>
</tr>
<tr>
<td>%pFVC T20</td>
<td>104 [83-111]</td>
<td>81 [74-103]</td>
<td>0.35</td>
</tr>
<tr>
<td>%pFVC ≤-70% T0</td>
<td>0/13 (0)</td>
<td>3/39 (8)</td>
<td>1.00</td>
</tr>
<tr>
<td>%pFVC ≤-70% T1</td>
<td>0/13 (0)</td>
<td>3/39 (8)</td>
<td>1.00</td>
</tr>
<tr>
<td>%pFVC ≤-70% T5</td>
<td>0/10 (0)</td>
<td>3/33 (9)</td>
<td>1.00</td>
</tr>
<tr>
<td>%pFVC ≤-70% T10</td>
<td>0/7 (0)</td>
<td>3/25 (12)</td>
<td>1.00</td>
</tr>
<tr>
<td>%pFVC ≤-70% T20</td>
<td>0/5 (0)</td>
<td>1/18 (13)</td>
<td>1.00</td>
</tr>
<tr>
<td>Progressive fibrosis (PF)(^*) [T1-T20]</td>
<td>0/12 (0)</td>
<td>5/39 (13)</td>
<td>0.32</td>
</tr>
<tr>
<td>PF(^*) [T5-T10]</td>
<td>1/10 (10)</td>
<td>5/25 (20)</td>
<td>0.20</td>
</tr>
<tr>
<td>PF(^*) [T10-T20]</td>
<td>1/17 (14)</td>
<td>4/25 (16)</td>
<td>1.00</td>
</tr>
</tbody>
</table>

Continuous data are presented as median [IQR] and compared with Mann-Whitney test; categorical data are presented as number/number available data (%) and compared with Chi-square test/Fisher’s exact test. *Progressive fibrosis=%pFVC decline ≥10% or 5-10% %pFVC decline and %pDLCO decline ≥15%.

References:

Disclosure of Interests: None declared

Objectives: To evaluate SSc immune-clinical associations in the Rheumatic Diseases Portuguese Register (Reuma.pt) cohort.

Methods: Multicentre open cohort study including adult SSc patients registered in Reuma.pt up to February 2021. The association between Ab expression and clinical data was evaluated using Chi-Square, Fischer’s Exact or Mann-Whitney U tests. The Bonferroni correction for multiple comparisons was applied to get <p<0.05. Definite associations were defined by p<0.002, and likely associations by p<0.05.

Results: 1080 patients were included, with a mean age and disease duration of 52.0±14.6 and 12.4±11.0 years, respectively. Most were females (67.5%) and had other European ancestry (93.2%). The most common disease subtype were limited cutaneous (lcSSc, 57.4%), diffuse cutaneous (dcSSc, 17.7%), and very early diagnosis of SSc (VEDOSS, 12.3%). Most patients expressed anti-nuclear Ab (ANA, 93.4%), and the most frequent were anti-centromere (ACA, 54.6%), anti-topoisomerase I (Sc170, 21.9%), and anti-PM/Scl Ab (PM/Sc, 4.7%). ACA had definite positive associations with female sex, older age at diagnosis, lcSSc, lower modified Rodnan skin score (mRSS, median 0 vs 4), and isolated sclerodactyly, and likely associations with a higher diagnosis delay, WEA and VEDOSS. ACA had definite inverse associations with flexion contractures (FC), myositis, digital ulcers (DU), and interstitial lung disease (ILD), and likely inverse associations with pitting scars (PS) and oesophageal involvement (OI).

Sc170 had definite positive associations with male sex, dcSSc, higher mRSS, FC, DU, PS, ILD, and OI, and likely associations with younger age at diagnosis, tendon friction rubs, active scleroderma pattern in capillaroscopy, and heart involvement. PM/Sc had a definite association with myositis and likely associations with male sex, calcinosis, joints involvement, and ILD. Anti-U1RNP Ab had definite associations with younger age at diagnosis, MCTD and myositis, and likely associations with a lower diagnosis delay, African ancestry and joint involvement. Anti-RNA polymerase III Ab (RP-3) had high associations with higher mRSS and renal involvement. Anti-U3RNP Ab had a definite association with dcSSc and likely associations with calcinosis and renal involvement. Anti-Th/To Ab had likely associations with male sex and myositis. Anti-Ku Ab had likely associations with systemic lupus erythematosus and mixed connective tissue disease (MCTD) overlap syndromes.

Conclusion: There was a higher prevalence of ACA and PM/Sc compared to other cohorts, most likely due to the high proportion of WEA patients. Most immune-clinical associations described in the literature apply, including ACA with lcSSc and Sc170 with dcSSc, DU, PS and ILD. However, Sc170+ patients did not have an increased risk of renal involvement, and ACA+ patients did not have an increased risk for calcinosis, PAH or OI, contrary to what was described in the literature. New findings included the association of PM/Sc with ILD and Sc170 with an active pattern in capillaroscopy. Also, anti-U3RNP and Th/To Ab+ patients did not have an increased risk of ILD or PAH, contrary to what was previously reported. These nuances may be specific to the Portuguese SSc population or signal previously reported associations as geographically specific.

Disclosure of Interests: None declared


AB0697

DRAMATIC REDUCTION OF MORTALITY RATE BY TOFACITINIB IN ANTI-MDA-5 ANTIBODY-POSITIVE PATIENTS WITH RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE

C. W. Tseng1,2, M. Satoh3, Y. M. Chen1,2,4,5,6, 1Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China; 2National Chung Hsing University, Department of Post-Baccalaureate Medicine, College of Health Sciences, Kitakyushu, Fukuoka, Japan; 3Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China; 4National Yang Ming Chiao Tung University, School of Health Sciences, Kittakyushu, Fukuoka, Japan; 5National Taichung Veterans General Hospital, Department of Internal Medicine, Taichung, Taiwan, Republic of China; 6National Chung Hsing University, Rong Hsing Research Center for Translational Medicine & Ph.D. Program in Translational Medicine, Taichung, Taiwan, Republic of China; 7National Yang Ming Chiao Tung University, School of Medicine, College of Medicine, Taipei, Taiwan, Republic of China

Background: Rapidly progressive interstitial lung disease (RP-ILD) is often seen in dermatomyositis patients with anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibody. They often have a poor prognosis with rapid decline in pulmonary function, leading to respiratory failure (1). Aggressive immunosuppressive therapy has been reported with improved prognosis, however; it may lead to opportunistic infections, including cytomegalovirus (CMV) or Pneumocystis jirovecii (2). IMPACT OF ILOPROST WITHDRAWAL IN SCLERODERMA PATIENTS DUE TO COVID-19 PANDEMIC

L. Veras1, E. de Lorenzo2,3, G. Natalelo4, L. Gigante5, P. G. Cerasuolo6, M. A. DiAgostino3, L. S. Bessolo5, 1Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Rheumatology Department, Rome, Italy; 2University of Verona-Verona, Italy, Ph.D. programme in Biomolecular Medicine-Cycle XXXV, Verona, Italy; 3Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Rheumatology Department, Rome, Italy

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3428

AB0698

IMMUNE CLINICAL DATA OF SLE PATIENTS DURING MAR-2017 TO MAY-2021: AN OBSERVATIONAL STUDY FROM THE SLE REUMA.PT COHORT

C. W. Tseng1,2, M. Satoh3, Y . M. Chen1,2,4,5,6.

1T aichung Veterans General Hospital, Department of Medicine, T aichung, T aiwan, Republic of China; 2Department, Rome, Italy; 3Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Rheumatology Department, Rome, Italy; 4National Chung Hsing University, Rong Hsing Research Center for Translational Medicine & Ph.D. Program in Translational Medicine, Taichung, Taiwan, Republic of China; 5National Yang Ming Chiao Tung University, School of Medicine, College of Medicine, Taipei, Taiwan, Republic of China

Methods: Medical records of 17 anti-MDA-5-positive RP-ILD patients enrolled during Mar 2017 to May 2021 were reviewed. RP-ILD was defined by the presence of deteriorated dyspnea, with a decrease in PaO2 levels and emerging radiographic anomalies within 4 weeks without evidence of infection (4). Chest CT was scored using lichkido score (5). Clinical parameters including ferritin levels, white counts (WBC), Lactate dehydrogenase (LDH) levels, GAP scores (Gender, Age, and Physiology score for idiopathic pulmonary fibrosis) were recorded. Medications included cyclophosphamide (CyP), intravenous immunoglobulin (IVIG), myophenolic acid derivatives (MPA), rituximab (RTX), and calciumin inhibitor (CNI). Kaplan-Meier survival analysis and Log-rank test were used to evaluate one-year mortality differences (MedCalc version 19.6). The Ethics Committee approved our study (CE17038B).

Results: Six anti-MDA-5-positive RP-ILD patients were treated with tofacitinib; five had concomitant CMV prophylaxis with valganciclovir (VGCV); 4 had PCP prophylaxis with trimethoprim/sulfamethoxazole (TMP-SMX). Patients’ demographic data are shown in Table 1. The median age, clinical manifestations, laboratory data, and chest CT scores were comparable between tofacitinib and non-tofacitinib groups. Prevalence of MPA use was higher in the non-TOF group. Kaplan-Meier survival analysis (Figure 1) indicated that patients with tofacitinib treatment (p=0.001), valganciclovir (p=0.003), and TMP-SMX (p=0.028) prophylaxis exhibited better 1-year survival rates compared with those without TOF therapy, VGCV, and TMP-SMX prophylaxis.

Table 1. Clinical characteristics of anti-MDA-5 antibody-positive patients with RP-ILD receiving tofacitinib vs non-tofacitinib treatment.

Continuous variables were expressed as median (inter-quartile range).”p<0.05. **p<0.01 by Mann–Whitney U test or Fisher’s Exact test.

Conclusion: The study demonstrated the efficacy of tofacitinib treatment in anti-MDA-5-positive RP-ILD. In addition, CMV and PCP prophylaxis appeared to improve in 1-year survival. Rheumatologists might consider TOF with prophylaxis as an option for anti-MDA-5-positive patients in daily practice.

REFERENCES:
Background: Intravenous iloprost is currently recommended in the treatment of Raynaud's phenomenon (RP) refractory to oral therapy and of digital ulcers (DUs) related to systemic sclerosis (SSc). In real-life practice there is a huge heterogeneity about the iloprost regimen used, leading to sudden and synchronous withdrawal of programmed iloprost infusions for most SSc patients in March 2020, in order to limit virus dissemination. At the same time, lockdown forced people to stay at home, thus reducing the exposure to coldness. Both these unavoidable circumstances were close to an experimental condition, clearly replicable in routine conditions. Objectives: The aim of the survey was to evaluate the consequences related to a sudden and simultaneous iloprost discontinuation in a cohort of SSc patients. Methods: A telephone survey was carried out on SSc patients that interrupted iloprost infusion at our centre. They were specifically asked to compare acral vascular symptoms just before iloprost withdrawal, in February and just after the missed March infusions. Thromboangiography, capillaroscopy, severity and frequency of RP, new DUs onset or aggravation of those pre-existing were reported for each patient. Last available capillaroscopic images were also evaluated to assess the pattern. Results: The analysis included 50 patients. After iloprost withdrawal, 11 patients reported a RP worsening because of enhanced intensity (4.6±2.1 vs 5.2±2.3, p=0.007). Only 8 patients of them had also an increased frequency (4.5±2.2 vs 5.0±2.4, p=0.07). None of the patients experienced digital ulcers for the first time during quarantine. Among the 27 patients with a history of digital ulcers, 9 reported worsening and 7 recurrences of DUs. Overall, 17 patients (34.0%) complained of a worsening of SSc vascular acral manifestations, namely RP or DUs. Disease and general features did not statistically correlate with worsening of RP except for reduced capillary density. Of note, each unit increase of capillary density corresponds to an average 44% decrease in the odds of RP worsening (OR 0.56, CI 95%; 0.36-0.97, p=0.037). History of DUs - either active or former at the time of iloprost discontinuation - was the only clinical predictor of worsening of DU severity. As for RP worsening, the worsening of DU was associated with a lower capillary density. Conclusion: Low capillary density can predict a worsening of both RP and DUs within a month after iloprost discontinuation in SSc patients. Further studies are needed to assess whether the capillaroscopy should be used to personalize iloprost regimen in SSc patients.

Disclosure of Interests: None declared


AB0700 HIGH BRONCHOALVEOLAR FLUID NEUTROPHILS INDEPENDENTLY PREDICT 15-YEAR MORTALITY IN SCLERODERMA PATIENTS WITH INTERSTITIAL LUNG DISEASE NAIVE TO IMMUNOSUPPRESSANTS

E. De Lorenzi1,2, G. Nataliello1, L. Verardi1, P. G. Cerasuolo1, G. Alonzì1, M. A. Di Giorgi1, S. L. Bosello1.
Department of Biomedical Sciences, Pisa, Italy; Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy, Rheumatology Department, Rome, Italy;1 University of Verona-Verona, Italy, Ph.D programme in Biomolecular Medicine-Cycle XXXV, Verona, Italy

Background: Scleroderma interstitial lung disease (SSc-ILD) has a variable and widely unpredictable course. Data about the role of bronchoalveolar lavage fluid (BALF) analysis in prognostic stratification of SSc-ILD patients (pts) are conflicting.

Objectives: To assess BALF analysis role in prognostic stratification of SSc-ILD pts.

Methods: Forty SSc-ILD pts naive to immunosuppressants underwent comprehensive BALF analysis with total and differential cell counts, protein count, pulmonary function tests (PFTs), high-resolution computed tomography (HRCT) of the chest. All pts had fibrosing lung disease affecting more than 10% of lung volume on HRCT. Baseline alveolar and interstitial scores were computed. The 15-year crude mortality rate was retrospectively assessed.

Results: The enrolled pts (male 20%, aged 53.9±13 years) had a disease duration of 4.3±3.4 years. Diffuse cutaneous involvement in 19 (45%) and rapidly progressive in 12 (27%) pts. Antisynthetase syndrome was present in 17 (42.5%) pts, while anti-Scl70 and anti-centromere antibodies were detected in 45% and 12.5% of pts, respectively. The average alveolar and interstitial scores were 6.5±4.8 and 6.2±2.7, respectively; 25% of the pts had FVC less than or equal to 80% and 35% had DLco less than or equal to 80%. During the follow-up, 18 pts (45%) received immunosuppressants. BALF neutrophils (>3%), eosinophils (>1%) and lymphocytosis (>15%) were reported in 40%, 16% and 5% of pts, respectively. Twenty-five pts (62.5%) died within 15 years after bronchoscopy. Fifteen-year mortality was predicted by neutrophil (HR 5.5, 95% IC 19-15.7), log-transformed total cell count (HR 2.5, 95% IC 1.1-5.7), absolute neutrophil (HR 1.8, 95% IC 13.2-25) and eosinophil (HR 1.3, 95% IC 11.1-16) cell counts, and macrophage (HR 0.1, 95% IC 0-0.6), neutrophil (HR 1.9, 95% IC 13.2-7.7) and eosinophil (HR 1.1, 95% IC 1-1.7) percentages. Only absolute and relative neutrophil counts were independently associated with mortality also in regression models adjusted for demographics (age, gender), main disease traits (diffuse cutaneous variant, anti-Scl70 positivity), pulmonary function tests (FVC, DLco), HRCT involvement (alveolar and interstitial scores) and vascular complications (presence of pulmonary hypertension, digital ulcers).

Conclusion: High BALF neutrophils were associated with high 15-year mortality independently from established clinical risk factors. BALF analysis could improve prognosis prediction in SSc-ILD pts.

Disclosure of Interests: None declared


AB0699 DESCRIPTIVE STUDY OF A COHORT OF PATIENTS WITH DERMATOMYOSITIS IN A TERTIARY HOSPITAL.

R. J. Gil Velez1, L. Mendez Diaz1, I. Madroñal García1,2 Sevilla, Rheumatology, Seville, Spain

Background: Idiopathic chronic inflammatory myopathies (IICM) are a heterogeneous group of rare diseases characterized by skeletal muscle inflammation. The incidence ranges from 1 to 60 new cases per 1,000,000 habitants/year and the prevalence between 2.4 and 34 per 100,000 habitants. The main symptoms are muscular and extramuscular manifestations. Among the remission inducers, the most frequent regimen used in our setting is the use of cyclophosphamide/rutiximab and maintenance of remission with azathioprine and mycophenonate. More studies on new therapeutic options are needed.

Disclosure of Interests: None declared


AB0701 FREQUENCY AND RISK FACTORS OF OSTEOPOROSIS IN MEN WITH SYSTEMIC SCLERODERMA

A. Sorokin1, O. Dobrovolskaya1, N. Demin1, N. Toroptsova1, V.A. Nasonova Research Institute of Rheumatology, osteoporosis laboratory, Moscow, Russian Federation

Objectives: To identify the frequency and risk factors of osteoporosis (OP) in men with systemic sclerosis (SSc).

Methods: 37 men with SSc were enrolled in the study: 19 (51.4%) with limited and 18 (48.6%) with diffuse cutaneous subtype. Patients with overlap rheumatic syndromes were not included. The median age was 56.0 (46.0; 61.0) years, the median duration of the disease was 6.0 (3.0; 9.0) years. 31 (83.8%) patients were treated with glucocorticoids (GC) > 3 months, the median duration of GC use was 3.7 (2.0; 70) years. Dual energy X-ray absorptiometry (DXA) of the lumbar spine (LS), the femoral neck (FN) and the total hip (TH) was performed. Osteoporosis (OP) was diagnosed with a T-score < -2.5 SD and osteopenia – with a T-score from -1SD to -2.5 SD at any region of interest. Z-score < -2 SD was used for diagnosis of OP in men < 50 years old. Spearman correlation between BM and different factors was performed. Traditional and specific risk factors for OP were analyzed using univariate logistic regression analysis.

Results: The median LS BMD was 1.13 (1.03; 1.26) g/cm2, the FN BMD 0.95 (0.94; 0.99) g/cm2 and the TH BMD - 0.99 (0.93; 1.06) g/cm2. Low BMD at least in one region of interest was detected in 19 (51.4%) patients; OP – in 8 (21.6%) (6 persons
AB0702 COEXISTENCE OF SYSTEMIC SCLEROSIS AND MICROSCOPIC POLYANGITIS ASSOCIATED WITH PULMONARY RENAL SYNDROME: A CASE REPORT AND LITERATURE REVIEW

Y. Jiang¹, Y. X. He¹, X. Liao¹, S. B. Wang¹, Y. F. Qing² on behalf of Institute of Research Center of Gout and Hyperuricemia of the Affiliated Hospital, North Sichuan Medical College. ¹Affiliated Hospital of North Sichuan Medical College, Department of Rheumatology, Nanchong, China

Background: Systemic sclerosis is a chronic immune disease characterized by varying degrees of fibrosis of skin and internal organs. Microscopic polyangitis, as a subtype of ANCA associated vasculitis, mainly involves small blood vessels, often manifested as necrotizing glomerulonephritis and pulmonary capillary vasculitis. Pulmonary renal syndrome is characterized by diffuse alveolar hemorrhage, diffuse alveolar hemorrhage based on pulmonary capillary vasculitis and rapidly progressive glomerulonephritis, which can be derived from a variety of autoimmune diseases, of which ANCA associated vasculitis accounts for about 60%[1]. The cases of coexistence of systemic sclerosis and microscopic polyangitis associated with pulmonary renal syndrome in clinic are rare, which is often dangerous and is easy to miss diagnosis or misdiagnosis.

Objectives: To investigate the clinical characteristics, diagnosis and treatment of coexistence of systemic sclerosis (SSC) and microscopic polyangitis (MPA) associated with pulmonary renal syndrome (PRS) in clinic.

Methods: The clinical data, diagnosis and treatment process of a patient who has SSC combined with MPA and PRS were summarized and analyzed. And the literature was reviewed to explore the correlation of the pathogenesis and clinical experience of SSC complicated with MPA and PRS.

Results: The case is a middle-aged male who was diagnosed as SSCs due to the hardening of the skin of both hands, whose anti-scl-70 antibody is positive. The patient suffered from repeated hemoptysis, progressive dyspnea, severe anemia and renal insufficiency, so he was diagnosed as MPA with PRS. After giving glucocorticoids, immunosuppressant and anti-infection treatment, his condition has improved. A total of 7 case reports were retrieved by reviewing the relevant literature. A total of 7 patients were reported. They were first diagnosed as SSC and then MPA with PRS, of which 4 cases improved after treatment and 3 cases died. Among the dead patients, 1 case was treated with penicillamine for 3 years, and the remaining 2 cases were only treated with steroids without immunosuppressants. In SSC, P-ANCA is closely related to vasculitis, and the diagnosis of PRS secondary to P-ANCA may be very poor. Most of the diagnosis of MPA is only after patients have kidney or lung disease.

Conclusion: Among the cases of SSC combined with MPA and PRS are rare, there are still many cases reported, which reminds us: 1) When SSC patients have new symptoms such as renal insufficiency or lungs, they should be alert to new entities that may be combined with other autoimmune diseases to avoid missed diagnosis or misdiagnosis. ANCA should be detected in SSC patients at baseline, which may be related to disease activity. 2) PRS has rapid progress and high mortality, which is an emergency that needs urgent treatment. Such patients should be treated with glucocorticoids, immunosuppressant and plasma exchange immediately. However, if patients are complicated with SSC, they need to be extra careful when using high-dose steroids, which increases the risk of renal crisis.

REFERENCES:

AB0703 THE NEED FOR ANTI-OSTEOPOROTIC THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS

A. Sorokina¹, N. Demin², O. Dobrovolskaya¹, N. Toropova³, V.A. Nasonova Research Institute of Rheumatology, osteoporosis laboratory, Moscow, Russian Federation

Objectives: To determine the need for anti-osteoporotic therapy in postmenopausal women and men over 50 years of age with systemic sclerosis (SSc).

Methods: The study included 150 patients with SSc who met the ACR/EULAR 2013 criteria: 124 (82.7%) postmenopausal women and 26 (17.3%) men over 50 years of age. Median age was 59.0 [54.0; 64.0] years. The duration of the disease was 8.0 [5.0; 14.5] years. A history of fragility fractures was collected.

Results: FRAX was calculated in patients without prior fractures to identify patients at high risk of low-energy fractures. Dual-energy X-ray densitometry (DXA) was performed in persons at moderate risk of fractures, and 10-year probability of major osteoporotic fractures was recalculated with the inclusion of a hip neck T-score. DXA was also performed on all patients from the low-risk group who had 2 or more risk factors of OP.

Conclusion: As a result of a comprehensive assessment of the risk of fractures and OP, it was found that 63.3% of patients with SSc needed anti-osteoporotic treatment.

Disclosure of Interests: None declared

LOW BODY MASS INDEX IN PATIENTS WITH RAYNAUD PHENOMENON IS ASSOCIATED WITH ENLARGED CAPILLARIES AND REDUCTION IN CAPILLARY DENSITY AT NAILFOLD VIDEOCAPILLAROSCOPY

G. Natello1, L. Verani2, C. Pollicciaro1, L. Gigante3, P. G. Cerasuolo1, F. Sciarascia Mugnozza2, G. Alonzi4, E. De Lorenzi5, S. Della Casa6, M. A. D’Agostino7, S. L. Bosello1, 1Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy; 2Rheumatology Department, Roma, Italy; 3Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Unit. of Endocrinology, Roma, Italy; 4Università Cattolica del Sacro Cuore, Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy, Unit. of Endocrinology, Roma, Italy; 5University of Verona-Verona, Italy., Ph.D. programme in Biomolecular Medicine-Cycle XXX, Roma, Italy

Background: Increased prevalence of peripheral vascular symptoms like Raynaud’s phenomenon (RP) and acrocyanosis is reported in anorexia nervosa (AN) and correlates with a more severe malnutrition.

Objectives: We aimed to characterize nailfold video capillaroscopy (NVC) abnormalities in patients with RP and BMI<18.5 kg/m^2, as opposed to adipokine levels, as compared to subjects with RP and normal BMI.

Methods: We performed NVC in 21 female patients with primary RP with BMI<18.5 kg/m^2, in 16 patients with primary RP and normal BMI, and in 16 patients classifiable as VEDOSS (Very Early Diagnosis of Systemic Sclerosis) and normal BMI, using a video-capillaroscope. Fingers two to four were evaluated bilaterally. Mean and minimum capillary density were registered for each patient, as well as maximum diameter and number of enlarged and giant capillaries, number of micro-haemorrhages and micro-thrombosis. We scored the frequency of enlarged capillaries considering the percentage of dilated capillaries out of the total. Demographic and clinical features of all patients were recorded.

Results: Patients with RP and low BMI presented a great number of elementary alterations on NVC; some of these modifications were typical of the scleroderma pattern. The percentage of enlarged capillaries was more than 33% of the total in 17(81%) patients with RP and low BMI with respect to 9(50%) of patients with RP and normal BMI (p=0.041). Furthermore, the number of megacapillaries was higher in patients with RP and low BMI compared to patients with normal BMI, while the maximum diameter of capillaries was comparable. Eight patients with low BMI presented a picture resembling an early scleroderma pattern (44%). The frequency of micro-thrombosis, micro-haemorrhages and microaneurysms were comparable in the two groups. Patients with RP and low BMI presented a lower mean capillary and minimum capillary density compared to patients with RP and normal BMI (mean density: 7.4±1.4×10³ vs 5.8±1.8×10³; p=0.031, minimum density:4.8±1.0 vs5.4±1.0; p=0.05). Patients with RP and low BMI presented a comparable frequency of enlarged capillaries, number of megacapillaries when compared with patients with VEDOSS. Leptin and chemerin levels were lower in patients with low BMI than in patients with normal BMI (57.5±35.6 vs 124.2±92.0 pg/mL, p<0.001; 46.9±11.9 vs 85.3±17.2 ng/mL, p=0.017 respectively); adiponectin levels were comparable.

Conclusion: Patients with low BMI and primary RP presented a great frequency of enlarged capillaries and a reduction of capillary density when compared with patients with normal BMI. The increased number of microvascular abnormalities on NVC in patients with low BMI reminds the NVC findings typical of early scleroderma, supporting the hypothesis of an endothelial dysfunction in such patients.


AB0705

CHANGES OF LUNG FUNCTION AND SKIN FIBROSIS IN PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS ON RITUXIMAB THERAPY - COMPARISON OF THE EFFICACY OF BIOLOGIC ACELLIA AND MABTHERA

L. Garzanović1, L. P. Ananyeva1, O. Koneva1, O. Desinova1, O. Ovsyanikova1, M. Starovoytova1, R. Shayakhmetova1, A. Khelkovskaia-Sergeeva1, 1VA Nasonova Research Institute of Rheumatology; Laboratory of systemic sclerosis, Moscow, Russian Federation

Background: Rituximab (RTX) has shown itself as an effective option in treatment of interstitial lung disease associated with systemic sclerosis (ILD-SSc). However, there is not enough data on the effect of rituximab biosimilars in patients (pts) with SSc. Biosimilars could reduce price and increase pts access to expensive, but more efficient biologic therapy. The RTX biosimilar Acellbia (ACB) has shown the positive effect even at low doses (less than 2 g). ACB has shown a good efficacy for therapy ILD-SSc, but studies with a large number of patients are required.

Objectives: To describe the demographic, clinical and serological characteristics of idiopathic inflammatory myopathies (IIM); the most frequent corticoid agents (GC) and correlates with a more severe malnutrition.

Methods: This prospective study included 62 pts received RTX as an addition to previous therapy, when it was ineffective. The mean follow-up period was 12.9±2.2 months. 31 pts received MABTHERA (group 1) and 31 pts received ACB (group 2).

All pts had ILD. In group 1 the mean age was 42.2±12.3 years, female-25 pts (81%), the diffuse cutaneous subset of the disease had 21 pts (68%). The mean disease duration was 5.3±3.5years. 91% of pts were positive for ANA and 77% of them were positive for antiphospholipase-1. All pts received prednisolone at a dose of 11.2±3.9 mg/day, immunosuppressants (IS) at inclusion received 39% of them. The cumulative mean dose of RTX was 1.5±0.5g. In group 2 the mean age was 48.7±11.3 years, female-23 pts (74%), the diffuse cutaneous subset of the disease had 16 pts (52%). The mean disease duration was 6.2±7.1years. 88% of pts were positive for ANA, 36% of them were positive for antiphosphoisomerase-1. All pts received prednisolone at a dose of 10.6±4.5mg/day. IS at inclusion received 42% of them. The cumulative mean dose of RTX was 1.4±0.5g. The results are presented in the form of mean values and standard deviations, delta(%)-difference between the baseline parameter and follow up point, median, lower quartile and upper quartile.

Results: There was an improvement of all evaluated parameters in both groups: decrease of Rodnan skin score (mRSS) and activity index(EScSG-AI), increase of forced vital capacity % predicted (FVC), diffusion capacity for carbon monoxide % predicted (DLCO) and 6-minute walk distance (Table 1). Both groups managed to reduce the mean dose of prednisolone. B-lymphocyte depletion persisted in both groups. When we compared changes (Δ) of the parameters between groups - no significant difference was obtained (Table 1).

Table 1. Changes of the main parameters at RTX therapy in delta (Δ); median; lower quartile; upper quartile.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1</th>
<th>Group 2</th>
<th>Group 1</th>
<th>Group 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Δ mRSS</td>
<td>4.7±5.6</td>
<td>4.3±4.1</td>
<td>0.0001</td>
<td>0.0001</td>
</tr>
<tr>
<td>Δ FVC, % pred</td>
<td>2; 0; 10</td>
<td>3; 0; 8</td>
<td>0.01</td>
<td>0.002</td>
</tr>
<tr>
<td>Δ DLCO, % pred</td>
<td>2; 0; 10</td>
<td>3; 0; 8</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Δ Activity Index</td>
<td>2; 0.3; 5</td>
<td>2; 0.4; 9</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>Δ B-lymphocyte</td>
<td>0.22; 0.0009; 0.09</td>
<td>0.216; 0.017; 0.09</td>
<td>0.01</td>
<td>0.001</td>
</tr>
<tr>
<td>Δ 6-minute walk distance, m</td>
<td>60.4±875</td>
<td>65.1±42.6</td>
<td>0.003</td>
<td>0.003</td>
</tr>
<tr>
<td>Δ Prednisolone, mg/day</td>
<td>2.0±2.5</td>
<td>2.1±3.7</td>
<td>0.0004</td>
<td>0.0004</td>
</tr>
<tr>
<td>Cumulative mean dose of RTX, g</td>
<td>1.5±0.5</td>
<td>1.4±0.5</td>
<td>0.01</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Conclusion: Our prospective study showed the similar effectiveness of ACB in comparison with MABTHERA. There was a significant improvement of lung function tests and decrease of skin fibrosis. RTX has been shown the positive effect even at low doses (less than 2 g). ACB has shown a good efficacy for therapy ILD-SSc, but studies with a large number of patients are required.


AB0706

DEMOGRAPHIC, CLINICAL AND SEROLOGICAL CHARACTERISTICS IN IDIOPATHIC INFLAMMATORY MYOPATHIES. THE ROLE OF SPECIFIC ANTIBODIES

X. E. Larco Rojas1, S. Sáez-Alvarez2, P. Pérez-García1, C. Sieiro Santos1, I. González Fernández3, C. Moriano1, A. López Rosell1, M. Martin Martín3, C. Alvarez Castro1, E. Diez Alvarez2, 1Complejo Asistencial Universitario de León, Rheumatology, León, Spain; 2Complejo Asistencial Universitario de León, Pathology, León, Spain

Background: Idiopathic Inflammatory myopathies are a heterogenous group of diseases which main common characteristic is muscle injury. Specific autoantibodies related to different phenotypes have become an important diagnostic and prognostic tool. These antibodies may be associated with different histopathological features in muscle biopsies.

Objectives: To describe the demographic, clinical and serological characteristics of Idiopathic Inflammatory Myopathies (IIM); the most frequent corticoid agents (GC) and correlates with a more severe malnutrition.

Methods: This prospective study included 62 pts received RTX as an addition to previous therapy, when it was ineffective. The mean follow-up period was 12.9±2.2 months. 31 pts received MABTHERA (group 1) and 31 pts received ACB (group 2).
The median levels of diagnosis of CK was: 1181; IQR:6252.5; aldolase 14.4; IQR: 34.65; AST 62; IQR:161.25; ALT 55.5; IQR:119.25; CRP 76; IQR 13.55. When compared, CK and ALT levels in patients with negative and positive ANA, this were higher in negative patients (6365; IQR:9592vs888;3045;P=0.044) and (182; IQR:287vs43; 85; P=0.035) respectively. Anti HMGCoA reductase antibodies were more frequently found in patients with necrotizing pattern in biopsies 5/8 patients; (62.5%); p=0.002. Methotrexate was the corticoid sparing agent most frequently used (36.7% of patients), 36.7% of patients were treated only with corticoids and 26.7% needed more than one treatment.

Conclusion: Specific myositis antibodies are helpful tools in the diagnosis when present, meanwhile biopsy can be an important tool when antibodies are negative. ANA positivity seems to be associated with milder disease at the muscular domain.

REFERENCES:

Disclosure of Interests: None declared

Nasonova Research Institute of Rheumatology, Laboratory of systemic sclerosis, Moscow, Russian Federation

Background: Decrease of immunoglobulin G (IgG) could often be observed during rituximab (RTX) therapy in systemic sclerosis (SSc) and other autoimmune diseases. Lower level of IgG could be associated with an increased risk of secondary infectious complications. However, there are very few data on changes of IgG in SSc during long-term RTX therapy.

Objectives: To evaluate changes of Ig G and the frequency of infectious adverse events (AE) in SSc patients (pts) on RTX therapy during long-term follow-up.

Methods: Our prospective study included 78 pts with SSc received RTX therapy. The mean follow-up period was 50.2±23 months. The mean age was 48.2±13.7 years, female-64 pts (82%), the diffuse cutaneous subset of the disease had 48 pts (62%), limited - 24 (31%), overlap - 6 (7%). The mean disease duration was 5.4±3.4 years. 92% of pts were positive for ANA and 71% of them were positive for antitopoisomerase-1. All pts received prednisolone at a dose of 11.8±4.1 mg/ day, immunosuppressants at inclusion received 40% of them. The IgG was evaluated over the periods: at baseline (point 0), 12-18 mo (point 1), 24-60 mo (point 2) and 66-84 mo (point 3) after initiation of RTX therapy. IgG levels was measured using ELISA. Normal IgG reference values ranged within 70-16.0 g/l. AE were assessed and recorded by a physician at a hospital immediately after the infusion of RTX, then by patient reported outcome during the observation period. Severe AE were defined as those that required hospitalization for more than 24 hours and life-threatening situations. The results are presented in the form of mean values and standard deviations.

Results: There was a significant decrease of IgG during RTX therapy (Table 1). However, the level of IgG remained within normal limits. Initially lower level of IgG had 6 pts (8%). And further at point 1 there was 12 pts (15%) with decrease of IgG below normal limits, at point 2 - 12 pts (15%) and at point 3 - 5 pts (6%). When we compared the level of IgG between point 2 and 3 - no significant differences were found.

Table 1. Changes of IgG level during RTX treatment.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Point 0</th>
<th>Point 1</th>
<th>Point 2</th>
<th>Point 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG, g/l, M±</td>
<td>12.3±4.2</td>
<td>10.6±3.4</td>
<td>9.6±2.8</td>
<td>9.6±2.6</td>
</tr>
<tr>
<td>Cumulative mean</td>
<td>1.8±0.5</td>
<td>3.9±1.3</td>
<td>4.8±2.1</td>
<td></td>
</tr>
</tbody>
</table>

AE were evaluated over the period of 335.4 patient-years (PY). Infectious AE were reported in 34 patients (44%), the overall frequency was 10.2/100 PY (95% Confidence Interval (CI) 7.1-13.8). No serious opportunistic infections were reported. The highest frequency of infectious AE was observed in the first 2-6 months after the first infusion of RTX, however these were mainly mild AE (82%). The frequency of serious infections was 1.8/100 PY (95% CI 0.7-3.8). There was a decrease of infectious AE in the follow-up period (4.4/100 PY, 95% CI 2.5-7.2 – at period from 24 month of RTX therapy).

Conclusion: In our study, a significant decrease of IgG was noted in SSc pts during the first 5 years of RTX therapy, but later its level stabilized and remained within normal limits. A decrease of IgG in the first year after the initiation of RTX therapy was accompanied by an increase in the frequency of infectious AE. However, with an increase of the cumulative dose of RTX, there was no increase in infectious AE. Monitoring of IgG levels may be useful for SSc pts on RTX therapy for early identification of the risk for developing infectious complications.

Disclosure of Interests: None declared

AB0708 ANALYSIS OF THE PERFORMANCE OF COMMERCIAL TESTS IN THE DETERMINATION OF MYOSITIS-SPECIFIC AND MYOSITIS-ASSOCIATED AUTOANTIBODIES: PREVALENCE AND CORRELATION WITH DIAGNOSIS OF IIM

E. Pedretti1, F. Angelii1, M. Fredi1, I. Cavazzana1, L. Andreoli1, E. Garrafa2, F. Franceschini1. 1ASST Spedali Civili of Brescia, Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 2ASST Spedali Civili of Brescia, Central Laboratory of Chemical- Clinical Analysis, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Background: Idiopathic Inflammatory Myopathies (IIM) are a group of disorders sharing the common feature of immune-mediated muscle injury. In IIM autoantibodies specific for (IIM) or associated to (MIA) myositis are present in 60-65% of cases (1). Although only anti-Jo-1 (2) are included in the EULAR 2017 criteria, the presence of MIA allows to identify clinical and prognostic phenotypes.

Methods: Muscle biopsy results that were compatible with inflammatory myopathy were collected from the Pathology Unit database of Leon’s hospital between January 2010 and March 2021. Demographic, clinical and serological characteristics, associated malignancies and treatments used were collected from clinical records.

Results: We included 30 patients in the study. Patient’s characteristics are shown in Table 1. Median age of diagnosis was 59 years. Arthritis and lung disease were found in 20% of patients. The patterns of lung involvement found in HRCT were NSIP in 2, UIP in 1, and bronchiectasis in 3 patients. Associated collagen-vascular diseases were found in 26.7%, being vasculitis the most frequent (2 patients). Associated Malignancies were found in 13.3%, lung carcinoma in 1, Urothelial carcinoma in 1, cervix carcinoma in 1 and prostate carcinoma 1 patient. Specific myositis antibodies were negative in 56.7%, positive ANA was found in 60%.

Table 1. Demographic, clinical, serological characteristics and treatment in the sample studied

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Patients (n=30)</th>
<th>Median; IQR or n(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>59; 18.5</td>
<td></td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>17(56.7);13(43.3)</td>
<td></td>
</tr>
<tr>
<td>Articulations</td>
<td>11(36.7)</td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>6(20)</td>
<td></td>
</tr>
<tr>
<td>Raynaud</td>
<td>3(10)</td>
<td></td>
</tr>
<tr>
<td>Lung disease</td>
<td>6(20)</td>
<td></td>
</tr>
<tr>
<td>Skin disease</td>
<td>7(23.3)</td>
<td></td>
</tr>
<tr>
<td>Autoimmunity biomarkers (+/− not done)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACA</td>
<td>2(6.7)/3(10)/5(18.3)</td>
<td></td>
</tr>
<tr>
<td>Positive Rheumatoid Factor</td>
<td>4(13.3)/13(43.3)/13(43.3)</td>
<td></td>
</tr>
<tr>
<td>ANA</td>
<td>18 (60%) /12(40%)</td>
<td></td>
</tr>
<tr>
<td>Specific Myositis Antibodies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-SRP</td>
<td>1(3.3)</td>
<td></td>
</tr>
<tr>
<td>Anti-HMGCoA reductase</td>
<td>5 (16.7)</td>
<td></td>
</tr>
<tr>
<td>Anti-Jo1</td>
<td>2(6.7)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>17 (56.7)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>5 (16.4)</td>
<td></td>
</tr>
<tr>
<td>Biopsy pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>necrotizing</td>
<td>8 (26.7)</td>
<td></td>
</tr>
<tr>
<td>inflammatory</td>
<td>15(50)</td>
<td></td>
</tr>
<tr>
<td>Inclusion Bodies</td>
<td>4 (13.3)</td>
<td></td>
</tr>
<tr>
<td>dermatomyositis</td>
<td>3 (10)</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>3 (10)</td>
<td></td>
</tr>
<tr>
<td>Statin Myopathy</td>
<td>5(16.7)</td>
<td></td>
</tr>
<tr>
<td>Inclusion body myopathy</td>
<td>3(10)</td>
<td></td>
</tr>
<tr>
<td>Polymyositis</td>
<td>8(26.7)</td>
<td></td>
</tr>
<tr>
<td>Immune-mediated necrotizing myopathy</td>
<td>2 (6.7)</td>
<td></td>
</tr>
<tr>
<td>Antisynthetase syndrome</td>
<td>1(3.3)</td>
<td></td>
</tr>
<tr>
<td>Other collagenopathies</td>
<td>8(26.7)</td>
<td></td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>11(36.7)</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>3(10)</td>
<td></td>
</tr>
<tr>
<td>immunoglobulins</td>
<td>5(16.7)</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>5(16.7)</td>
<td></td>
</tr>
<tr>
<td>Myophenolate</td>
<td>4(13.3)</td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>2 (6.7)</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>11 (36.7)</td>
<td></td>
</tr>
<tr>
<td>2 or more treatments</td>
<td>8(26.7)</td>
<td></td>
</tr>
<tr>
<td>Associated malignancies</td>
<td>4 (13.3)</td>
<td></td>
</tr>
</tbody>
</table>

Methods: Muscle biopsy results that were compatible with inflammatory myopathy were collected from the Pathology Unit database of Leon’s hospital between January 2010 and March 2021. Demographic, clinical and serological characteristics, associated malignancies and treatments used were collected from clinical records.

Results: We included 30 patients in the study. Patient’s characteristics are shown in Table 1. Median age of diagnosis was 59 years. Arthritis and lung disease were found in 20% of patients. The patterns of lung involvement found in HRCT were NSIP in 2, UIP in 1, and bronchiectasis in 3 patients. Associated collagen-vascular diseases were found in 26.7%, being vasculitis the most frequent (2 patients). Associated Malignancies were found in 13.3%, lung carcinoma in 1, Urothelial carcinoma in 1, cervix carcinoma in 1 and prostate carcinoma 1 patient. Specific myositis antibodies were negative in 56.7%, positive ANA was found in 60%.
**Objectives:** Aim of the work is to evaluate the positivity rate on sera analyzed by a line blot (LB) immunoassay able to detect MSA or MAA, the associated clinical diagnoses and the consistency with the antibody specificity.

**Methods:** 267 sera were analyzed using a commercial LB (Autoimmune Inflammatory Myopathies 16 Ag Profile EUROLINE) between March 2017 and March 2021. The diagnosis was identified by analyzing the medical records.

**Results:** A positivity for at least one MSA/MAA was found in 118/267 sera (44.2%). MAA isolated in 22% of cases and a double/multiple positivity for MSA in 12.7%. The distribution of antibody positivity and the associated clinical diagnoses are shown in Table 1.

**Table 1. Autoantibody distribution and associated clinical diagnosis, for some patients there are multiple positivity**

<table>
<thead>
<tr>
<th>Autoantibody specificity</th>
<th>Total positivity n. (%)</th>
<th>Isolated positivity n. (%)</th>
<th>Concomitant presence of at least one MAA n. (%)</th>
<th>Concomitant presence of MSA ±- MAA n. (%)</th>
<th>Consistent diagnosis n. (%) Type of IIM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mi-2</td>
<td>27 (22.9)</td>
<td>16 (59.3)</td>
<td>2 (74)</td>
<td>9 (33.3)</td>
<td>5 (18.6)</td>
</tr>
<tr>
<td>Ti-1y</td>
<td>12 (10.2)</td>
<td>4 (33.3)</td>
<td>4 (33.3)</td>
<td>4 (33.3)</td>
<td>9 (75)</td>
</tr>
<tr>
<td>PL-7</td>
<td>11 (9.4)</td>
<td>4 (36.4)</td>
<td>3 (27.3)</td>
<td>4 (36.4)</td>
<td>5 (45.5)</td>
</tr>
<tr>
<td>NXP-2</td>
<td>8 (6.8)</td>
<td>3 (37.5)</td>
<td>1 (12.5)</td>
<td>4 (50)</td>
<td>3 (37.5)</td>
</tr>
<tr>
<td>SRP</td>
<td>8 (6.8)</td>
<td>3 (37.5)</td>
<td>1 (12.5)</td>
<td>4 (50)</td>
<td>1 (12.5)</td>
</tr>
<tr>
<td>Jo-1</td>
<td>8 (6.8)</td>
<td>3 (37.5)</td>
<td>2 (25)</td>
<td>3 (37.5)</td>
<td>6 (75)</td>
</tr>
<tr>
<td>PL-2</td>
<td>7 (5.9)</td>
<td>3 (42.9)</td>
<td>0</td>
<td>4 (57.1)</td>
<td>4 (57.1)</td>
</tr>
<tr>
<td>MDAS</td>
<td>5 (4.2)</td>
<td>3 (60)</td>
<td>0</td>
<td>2 (40)</td>
<td>4 (60)</td>
</tr>
</tbody>
</table>

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3760

**AB0710**

**STUDY OF THE GASTROINTESTINAL INvolVEMENT IN PATIENTS WITH SYSTEMIC SCLEROSIS**

J. Bernardes Moreno1, L. Berbel Arcobe2, J. L. Tandaian Jaime3, J. Torquet Carbonell1, G. Ghio1, E. Fieria Alonso1, S. Martinez Pardo1,1 Hospital Universitari Mutua Terrassa, Rheumatology, Terrassa, Spain; 2University General Hospital of Catalonia, Rheumatology, Sant Cugat del Vallés, Spain; 3Hospital Dos de Maig, Rheumatology, Barcelona, Spain

**Background:** Rheumatic diseases may affect all aspects of life, including sleep1. Sleep disorders are common and potentially debilitating in these diseases, and the reason for this disturbance seems to be multifactorial. Objectives: Evaluate the prevalence of sleep disturbance and its association with demographic-clinical factors in patients with Systemic Sclerosis (SSc) and Rheumatoid Arthritis (RA).

**Methods:** We conducted a cross-sectional study on patients, aged ≥18, who fulfilled the ACR/EULAR 2013 classification criteria for SSc and ACR/EULAR 2010 classification criteria for RA. Socio-demographic and clinical data was collected. Patients answered the Health Assessment Questionnaire (HAQ), Hospital Anxiety and Depression Scale (HADS), Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale and Pittsburgh Sleep Quality Index (PSQI) questionnaires. Sleep disorders were considered when PSQI was ≥5. Differences between groups were assessed and variables with statistical significance in the univariate analysis were included in a multivariate logistic regression model, adjusted to age and sex. ρ ≤ 0.05 was considered significant in all analysis.

**Results:** Fifty-six patients (28 with SSc and 28 with RA) agreed to participate in this study, of which 47 (83.9%) were female, with a median age of 61 years old (IQR1:70). Most of our patients (73.2%) had a sleep disturbance, fatigue (80.4%) and disability (89.3%). Twenty patients (35.7%) suffered from anxiety and 10 (17.9%) from depression. A statistically significant association was found between sleep disturbances and the disease, its duration and body mass index (BMI). FACIT, HAQ and HADS-A, but not with HADS-D, were also associated (Table 1).

**Table 1. Differences between sleep disorders and between Systemic Sclerosis and Rheumatoid Arthritis**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Without sleep disorder (n=15)</th>
<th>Sleep disorder (n=41)</th>
<th>P value</th>
<th>SSc group (n=28)</th>
<th>RA group (n=28)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>55 (16.7)</td>
<td>61 (10.3)</td>
<td>0.059</td>
<td>60.50 (14)</td>
<td>61 (15)</td>
<td>0.941</td>
</tr>
<tr>
<td>Disease duration (months)</td>
<td>12.00 (7.25)</td>
<td>7.00 (7.50)</td>
<td>0.021</td>
<td>60.00 (10.00)</td>
<td>60.00 (12.00)</td>
<td>0.001*</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>22.51 (6.47)</td>
<td>27.26 (6.95)</td>
<td>0.054</td>
<td>27.26 (7.92)</td>
<td>24.65 (6.06)</td>
<td>0.440</td>
</tr>
<tr>
<td>FACIT</td>
<td>40.50 (12.25)</td>
<td>31.50 (18.00)</td>
<td>0.001</td>
<td>30.00 (12.50)</td>
<td>30.00 (13.50)</td>
<td>0.522</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>0.438 (0.563)</td>
<td>0.813 (1.50)</td>
<td>0.022</td>
<td>0.875 (1.625)</td>
<td>0.500 (0.563)</td>
<td>0.037*</td>
</tr>
<tr>
<td>HADS-D</td>
<td>6.50 (5.50)</td>
<td>10.00 (5.00)</td>
<td>0.008*</td>
<td>9.00 (5.00)</td>
<td>8.00 (7.50)</td>
<td>0.729</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>6.50 (5.00)</td>
<td>7.50 (5.00)</td>
<td>0.100</td>
<td>8.00 (4.75)</td>
<td>6.00 (5.00)</td>
<td>0.105</td>
</tr>
<tr>
<td>PSQI</td>
<td>12.00 (7.25)</td>
<td>7.00 (7.50)</td>
<td>0.021*</td>
<td>60.00 (10.00)</td>
<td>60.00 (12.00)</td>
<td>0.001*</td>
</tr>
<tr>
<td>Sleep disorder</td>
<td>24.85 (7.50)</td>
<td>17.60 (0.00)</td>
<td>0.035</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: IQR - Interquartile Range.

**Conclusion:** In our cohort, sleep disturbances were highly prevalent, and we found a significant association between those and SSc, FACIT, HAQ and HADS-A. However, we didn’t find a predictor of this disturbance in the multivariate analysis. New studies with large number of patients are warranted.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3776
Background: Systemic Sclerosis (SSc) is a systemic autoimmune disease in which the gastrointestinal (GI) manifestation is one of the most frequent complications (80%), being esophageal and anorectal the most affected areas. The set of GI symptoms poses a diagnostic and therapeutic challenge, and the “Patient Reported Outcomes” (PRO) are good tools to address them. The UCLA GIT 2.0 validated questionnaire can be used as an instrument to measure the presence and severity of these symptoms, allowing screening, and improving subsequent management.

Objectives: To describe gastrointestinal (GI) involvement in patients with SSc.

Methods: Descriptive-cross-sectional study conducted in a cohort of patients with SSc in a tertiary hospital. Sociodemographic, clinical, complementary tests and treatment variables were collected. Patients with established GI involvement needed to have undergone some previous diagnostic test. The UCLA GIT 2.0 questionnaire was applied to all included patients, considering the presence of mild symptoms with a score of 0-0.49, moderate 0.49-1, and severe 1-3.

Results: 88 patients (90% women) were recruited, with a mean age of 61.3 years. They presented the subtypes of limited and diffuse SSc in 63.3% and 13.6%, respectively. The most frequent antibodies were anticientromere (ACA) in 52.3% of the patients, anti-Ro52 in 20.5% and anti-topoisomerase I in 14.8%. The most frequent manifestations were Raynaud’s phenomenon in 98.8% of the patients followed by GI in 37.5% (gastro-esophageal reflux in 88.2%), diffuse interstitial lung disease in 18% and pulmonary hypertension in 10.22.

Conclusion: GI involvement tends to be one of the most frequent manifestations and occurs more frequently in patients with limited skin involvement and ACA +. Patients with established GI pathology had higher scores on the UCLA test. The questionnaire may be useful in detecting undiagnosed patients, but more studies are necessary to establish this possible correlation.

REFERENCES:

Disclosure of Interests: None declared


AB0711 THE IMPACT OF ANEMIA ON SYSTEMIC ORGAN DAMAGE IN SYSTEMIC SCLEROSIS

Z. H. Li, T. Li, R. Mu. 1Peking University Third Hospital, Rheumatology, Beijing, China

Background: Systemic sclerosis (SSc) is a systemic autoimmune disease with multiple organ damage. Scleroderma Clinical Trials Consortium (SCTC) has developed the Damage Index (DI) in SSc to quantify organ damage in SSc[1]. Anemia has been implicated as an independent prognosis factor for mortality and organ complications in systemic sclerosis (SSc), while the relationship between anemia and the weighted organ damage index has not been reported.

Objectives: To determine the degree and feature of organ damage in SSc patients with or without anemia in a population of patients from Peking University Third Hospital SSc cohort (PKUTH-SSc).

Methods: Patients were recruited from PKUTH-SSc between January, 2010 and December, 2021. The diagnosis of anemia was based on the reduced hemoglobin (Hb) concentrations (<120g/L for female and <135g/L for male). The characteristics, clinical characteristics, laboratory parameters, autoantibodies medication and SCTC-DI were collected. Student’s t-test and Chi-square were used.

Results: As shown in Table 1, a total of 155 patients were enrolled in PKUTH-SSc cohort, 70 (45.2%) patients developed anemia, older and lower BMI than non-anemia patients. The inflammatory indices, ESR and CRP, were higher in anemia patients, indicating anemia was more common in patients with active disease. Consistent with the result that the positive rate of anti-SSA and anti-SSB antibody was higher in anemia patient, the sicca symptoms were also reported in nearly half of anemia patients. In anemia patients, the Gastrointestinal system related damage, Oesophageal dysmotility, Pseudo-obstruction and weight loss, and renal damage were more frequently discovered. Moreover, anemia patients were more likely to develop moderate to high organ damage risk, demonstrating the necessity of regular organ damage follow-up for anemia patients.

Table 1. Clinical parameters and SCTC-Di of SSc patients with or without anemia

<table>
<thead>
<tr>
<th>Anemia</th>
<th>Non-anemia</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=72</td>
<td>N=83</td>
<td></td>
</tr>
<tr>
<td>Age at baseline (years)</td>
<td>54.43±1.88</td>
<td>49.64±1.32</td>
</tr>
<tr>
<td>BMI (kg/m2) (meanyear)</td>
<td>20.49±0.30</td>
<td>22.46±0.39</td>
</tr>
<tr>
<td>ESR</td>
<td>32.48±3.06</td>
<td>16.67±1.83</td>
</tr>
<tr>
<td>CRP</td>
<td>1.20±0.22</td>
<td>0.64±0.11</td>
</tr>
<tr>
<td>Anti-SSA</td>
<td>22 (31.4%)</td>
<td>13 (15.3%)</td>
</tr>
<tr>
<td>Anti-SSB</td>
<td>8 (11.4%)</td>
<td>1 (1.2%)</td>
</tr>
<tr>
<td>Musculoskeletal and skin</td>
<td>2.22±0.22</td>
<td>1.1±0.11</td>
</tr>
<tr>
<td>Vascular</td>
<td>0.67±0.67</td>
<td>0.59±0.59</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>2.09±0.59</td>
<td>1.3±0.31</td>
</tr>
<tr>
<td>Oesophageal dysmotility</td>
<td>27 (38.6%)</td>
<td>18 (21.2%)</td>
</tr>
<tr>
<td>Moderate to high damage score</td>
<td>8.37±3.7</td>
<td>5.25±2.5</td>
</tr>
</tbody>
</table>

Conclusion: Anemia is associated with distinct organ damage behaviors and higher disease progression risk in SSc. Specifically Sicca symptoms and gastrointestinal, renal system were more common in SSc patients with anemia.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3806

AB0712 DIGITAL ISCHEMIC COMPLICATIONS IN SYSTEMIC SCLEROSIS ASSOCIATED RAYNAUD’S: PREVALENCE, RISK FACTORS AND TREATMENT PATTERNS FROM A SINGLE CENTER COHORT

A. Makal1, A. Hinze1, R. Giblon2, R. Fidawati1, T. Gunderson2, Y. Radwan3, T. Liedl4, K. J. Warnington1, C. S. Crowson2, R. Penneweg1. 1Mayo Clinic, Division of Rheumatology, Rochester; United States of America; 2Mayo Clinic, Department of Quantitative Health Sciences, Rochester, United States of America; 3Michigan State University, Department of Internal Medicine, East Lansing, United States of America; 4Mayo Clinic, Vascular Center, Rochester, United States of America

Background: Digital ischemic complications (DIC) are common in patients with Raynaud’s phenomenon (RP). A previous study conducted in a single center cohort in the mid-1990s[1] found that DIC prevalence was 11.3% in patients with RP, and 19% in those with systemic sclerosis (SSc). However, there have been no similar studies in the last two decades. This study aimed to assess the prevalence of DIC, risk factors associated with its development, and treatment patterns in a current single center cohort of patients with RP and/or SSc.

Methods: A cross-sectional, observational study was conducted in a single center in the midwestern United States from 2017 to 2019. The study cohort included patients with RP and/or SSc who were referred to the vascular clinic for evaluation of digital ischemic complications. Data on demographics, RP and SSc severity, digital ischemic complications, risk factors, and treatment patterns were collected from electronic medical records. The study was approved by the institutional review board of Mayo Clinic.

Results: A total of 100 patients were included in the study. The prevalence of DIC was 19.7%. The most common risk factors associated with DIC were smoking (44.2%), diabetes (21.1%), and hypertension (19.2%). The most common treatment for DIC was the use of anticoagulants (64.6%). Other treatments included antiplatelet agents (27.8%), topical vasodilators (21.1%), and surgical interventions (5.4%). A sub-analysis of patients with RP only showed that the prevalence of DIC was 12.5%, with the most common risk factor being smoking (35%). Additionally, 35% of patients with RP only received anticoagulants as treatment for DIC.

Conclusion: The prevalence of DIC in patients with RP and/or SSc in this study was 19.7%. Smoking, diabetes, and hypertension were the most common risk factors associated with DIC. Anticoagulants were the most commonly used treatment for DIC. Further studies are needed to evaluate the long-term outcomes of patients with DIC and to develop more effective treatment strategies.

REFERENCES:

Disclosure of Interests: None declared

Background: A significant number of Systemic sclerosis (SSc) patients with Raynaud's phenomenon (RP) experience digital ischemic complications (DICs—digital ulcers, digital pitting/scars, gangrene and/or amputation).

Objectives: We reviewed the prevalence & risk factors for DICs in SSc-RP and compared treatment patterns among patients with & without DICs.

Methods: SSc patients meeting ACR/EULAR 2013 classification criteria that underwent an upper extremity arterial study between 2001-2018 were included. Clinical characteristics, treatment for RP, use of antplatelet (aspirin 81 mg), statin therapy went an upper extremity arterial study between 2001-2018 were included. Demographic and clinical features, including duration of disease and disease progression, symptoms and parameters related to a specific organ involvement were abstracted. Risk factors for DICs and their associations with therapy were evaluated.

Table 1.

<table>
<thead>
<tr>
<th>Overall (N=273)</th>
<th>DICs (N=217)</th>
<th>No DICs (N=56)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at procedure(y); mean (SD)</td>
<td>57.5 (13.3)</td>
<td>56.9 (13.6)</td>
<td>59.4 (11.8)</td>
</tr>
<tr>
<td>Sex (Female)</td>
<td>220 (81%)</td>
<td>173 (80%)</td>
<td>47 (84%)</td>
</tr>
<tr>
<td>Race (White)</td>
<td>253 (93%)</td>
<td>199 (96%)</td>
<td>54 (96%)</td>
</tr>
<tr>
<td>BMI (kg/m²) at study; mean (SD)</td>
<td>26.6 (6.1)</td>
<td>26.3 (6.1)</td>
<td>27.4 (6.1)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>154 (56%)</td>
<td>120 (55%)</td>
<td>34 (61%)</td>
</tr>
<tr>
<td>Former</td>
<td>102 (37%)</td>
<td>83 (38%)</td>
<td>19 (34%)</td>
</tr>
<tr>
<td>Current</td>
<td>17 (6%)</td>
<td>14 (6%)</td>
<td>3 (5%)</td>
</tr>
</tbody>
</table>
| Disease ch.
| SSc subtype:    |             |                |         |
| Limited         | 211 (77%)  | 166 (76%)  | 45 (80%)  | 0.18 |
| Diffuse         | 59 (22%)   | 49 (22%)   | 10 (18%)  |         |
| Time from SSc diagnosis to duplex US (months) mean (SD) | 57.9 (85.7) | 63.5 (91.5) | 36.1 (52.9) | 0.04 |
| Digital occlusive arterial disease | 223 (82%) | 193 (89%) | 30 (54%) | <0.001 |
| Macrovacular disease | 74 (27%)  | 69 (32%)  | 5 (9%)    | <0.001 |
| Ulnar Occlusive disease | 68 (25%)  | 63 (25%)  | 5 (9%)    | 0.002 |
| Telangiectasias  | 239 (88%)  | 192 (89%)  | 47 (84%)  | 0.27 |
| Calciosis       | 102 (43%)  | 95 (49%)   | 7 (13%)   | <0.001 |
| Intestinal lung disease | 105 (38%) | 90 (41%) | 15 (27%) | 0.04 |
| Pulmonary hypertension | 50 (18%) | 43 (20%) | 7 (12%) | 0.21 |
| Pericardial effusion | 61 (22%) | 54 (25%) | 7 (12%) | 0.047 |
| Gastrointestinal dysmotility | 194 (71%) | 159 (73%) | 35 (62%) | 0.11 |
| Renal crisis     | 17 (6%)    | 12 (6%)    | 5 (9%)    | 0.35 |
| SSc specific antibodies: | 175 (68%) | 138 (67%) | 38 (69%) | 0.77 |
| Centromere       | 116 (43%)  | 95 (63%)  | 21 (64%)  | 0.97 |
| SSC-70           | 48 (19%)   | 36 (18%)   | 12 (22%)  | 0.57 |
| RNA-Polymerase   | 19 (20%)   | 14 (19%)   | 5 (22%)   | 0.79 |

Results: We identified 273 SSc patients (mean age 57±13 y, 81% F, 93% Caucasian, mean disease duration 4.8 ± 7.1 y). Cohort characteristics are described in Table 1. 79% (217/273) patients experienced DICs (digital ulcers 203, digital pitting/scar 138, digital gangrene 76). Patients with DICs had a higher prevalence of DOAD (89% vs 54%, p <0.001), MVD (32% vs 9%, p <0.001), ILD (41% vs. 27%, p=0.04), calcinosis (95/192 (49%) vs. 7/44 (16%), p<0.001), and pericardial effusion (25% vs. 12%, p=0.047), compared to those without DICs. No difference was noted between the 2 groups in regard to skin severity, smoking, BMI, hypertension, hyperlipidemia, diabetes, coronary artery disease, telangiectasias, pulmonary hypertension, renal crisis, GI dysmotility or myositis. Treatment patterns are described in Figure 1. Calcium channel blocker (CCB) and phosphodiesterase 5 inhibitor (PDE5I) use was higher among SSc patients with DICs than in those without DICs (CCBs: 53% vs. 34%, p=0.01; PDE5I: 29% vs. 2%, p=0.01) likely due to confounding by indication. The use of aspirin or statins was not associated with DICs, even after adjusting for CV risk factors (ASA: OR 0.83, 95% CI 0.45-1.54; statin OR 0.67, 95% CI 0.28-1.62).

Conclusion: Our study confirms a high prevalence of DICs in SSc, with digital ulcers occurring in nearly 75% patients. A higher risk of DICs is associated with DOAD, MVD, ILD, calcinosis and pericardial effusion. While there is a significantly higher utilization of vasodilators among patients with DICs, the utilization of antiplatelet therapy and statins was not different among these groups. Whether this suggests a lack of evidence supporting their use in clinical practice, or inefficacy in preventing DICs remains unclear and warrants further study.

Disclosure of Interests: None declared

the association between nominal variables chi-square test was performed while independent t test was used to compare the differences between subgroups. Logistic regression analysis was used to predict the risk of all-cause mortality. The results of patients with systemic sclerosis related to systemic sclerosis. The calcinosis cohort comprised 25 females and 6 males, with a mean age of 52.6 ± (14.3) years, most of them with diffuse subset (16/31). Mean disease duration was 5.8 years ± (3.1). Mean modified Rodnan skin score (mRSS) was 9.46 ± (±3.4) and mean adjusted ESSG activity index in the subgroup with calcinosis was 3.6 ± (1.9). 45.16% (14/31) patients from the calcinosis subgroup developed intestinal lung disease (ILD) vs 43.9%; pulmonary hypertension was seen in 51.6% (16/31) cases vs 10.5% (13/123). As expected, calcifications were closely associated with vascular (p=0.004) and gastrointestinal (p=0.001) involvement and pulmonary hypertension (p=0.049). Moreover, associations were stronger for severe gastrointestinal involvement defined as chronic intestinal pseudo-obstruction (p=0.001). Females (p=0.024), patients with digital ulcers (p=0.004), those with disease duration longer than 10 years (p=0.001), those with pulmonary hypertension (p=0.049) and patients with gastrointestinal involvement (p=0.044) presented significantly more calcinosis. There were no significant associations between calcinosis and disease activity, myositis, intestinal lung disease, type of scleroderma or autoantibodies. Furthermore, in the logistic regression equation we identified calcinosis as a risk factor for all-cause mortality in SSc patients [OR:2.607 (CI:1.062,6.397), p=0.037].

Conclusion: Calcification cuts is a common manifestation is patients with SSc regardless of skin subset and type of autoantibodies. It seems to occur more often in patients with long-standing disease and is more commonly associated with vascular involvement such as digital ulcers and pulmonary hypertension. Furthermore, the present study has demonstrated that calcinosis could be an important prognostic factor when it comes to predict mortality. Given the fact that the management of calcinosis in scleroderma is an unmet need in almost half of patients with long-standing disease duration, systematic clinical trials are required to find effective measures to prevent this complication.

REFERENCES:


Disclosure of Interests: None declared


AB0715 ANTI-MDA5 DERMATOMYOSITIS AFTER BNT162B2 VACCINATION

D. Astori1, L. Nalotto1, E. Vaccaro1, V. Carraro1, L. Bernardi1, L. Punzi1,2,3, C. Bernardi4 1Ospedale S.S. Giovanni e Paolo, Rheumatology Unit, Venezia, Italy; 2Rheumatology Network, Veneto Region, Venezia, Italy

Background: Background: Anti-Melanoma Differentiation-Associated gene 5 (MDA-5) Dermatomyositis (MDAS, DM) is a rare systemic autoimmune disease, characteristically associated with Rapidly Progressive Intestinal Lung Disease (RP-ILD) and cutaneous manifestations. Anti-MDAS dermatomyositis may develop in genetically predisposed subjects after environmental exposure such as vaccines, infections and neoplasms (1). Myalgia is one of the main symptoms related to SARS-COV2 infection and sometimes may occur after COVID-19 vaccine administration (2). However, only few cases have reported the occurrence of severe inflammatory myopathies after COVID19 vaccine administration (3).

Objectives: To describe a case of Anti-MDAS Dermatomyositis occurred after BNT162b2 vaccine administration.

Methods: This is a case of a 44 year-old patient affected by Anti-MDAS Dermatomyositis occurred after BNT162b2 vaccination referred at the Center for Rheumatic Diseases in Venice, Italy.

Results: A 44 year-old woman presented to the Center for Rheumatic Diseases in Venice, suffering from a cutaneous rash on her face, upper limbs, décolleté, lower limbs occurred two days after the first dose of BNT162b2 vaccination (Figure 1). A few days after the second dose of the vaccine the rash got worse and myalgias, strength deficiency and fatigue occurred. Elevated inflammatory and myocytolysis parameters were detected (Table 1). After chest HRCT a mild ILD was diagnosed. Muscle edema was detected with whole-body short tau inversion recovery (STIR)-MRI (Figure 1). The skin biopsy showed features of dermatomyositis with perivascular inflammatory infiltrates. 1 mg/kg/die of prednisone was administered and then cyclosporine 3mg/kg/die was associated with clinical benefit.

Table 1. Clinical and laboratory characteristics of the patient

| Age (years) | 44 |
| Sex         | Female |
| Previous Rheumatological diagnosis | - |
| Previous Vaccination reaction | - |
| Time to onset COVID 19 vaccination | 2 days |
| MM7M-8* | 124/150 (150/150) |
| Blood Tests | |
| Mb* (12 Kd/gd) | 11.5 gd |
| CRP* (< 5 mg/L) | 23.4 mg/L |
| AST- (31 U/L) | 98 U/L |
| ALT* (1-145 U/L) | 63 U/L |
| CPK* (10-145 U/L) | 1085 U/L |
| Aldolase (0-76) | 13,2 U/L |
| SARS-Cov-2 RT PCR | negative |
| Autoantibodies | |
| ANA | 1:1280 nuclear |
| MDA-5 antibodies | 60 |
| HLA-DRB1 | 03-04 |
| HLA-DQB | 02-03 |

MTM-8 ANALYSIS MUSCLE TESTING; Hb Hemoglobin; WBC white blood cells count; CRP C-reactive protein; AST Aspartate aminotransferase; ALT Alanine aminotransferase; CPK creatinine phosphokinase; ANA anti nuclear antibodies, ENA extractable nuclear antigens; hLA HLA, eukocyte Antigen

Conclusion: In rare cases COVID-19 vaccination could induce inflammatory myopathies (3). COVID-19 vaccine administration may have acted as a trigger for the myopathy driven by an autoimmune-mechanism. In such cases, it could be useful to investigate the inflammatory myopathies, requiring blood tests (e.g. myocytolysis indices and anti myositis antibodies) and medical instrumental insights, in patients affected by skin manifestation and muscle pain occurred after vaccine administration. Although the association between vaccination and inflammatory
myopathies is presumptive, the temporal proximity of the BNT162b2 vaccine to the onset of the signs and symptoms related to the inflammatory myopathies may suggest a possible relationship between these two events. To the best of our knowledge this is the first case of Anti-MDA5 Dermatomyositis occurred after BNT162b2 vaccination.

**REFERENCES:**


**Disclosure of Interests:** None declared


---

**AB0716**

**CHARACTERISTICS OF 4 CASES OF PL - 7 POSITIVE ANTSYNTHATASE SYNDROME: INTERSTITIAL LUNG DISEASE BEING A MORE COMMON FEATURE THEN MYOSITIS**

C. Rosa1, K. Chaudhuri1, G. Kasavkar1, A. Price-Forbes1, S. Banerjee1.1University Hospital Coventry & Warwickshire, Rheumatology, Coventry, United Kingdom

**Background:** Anti synthetase syndrome is a heterogeneous group of autoimmune diseases characterised by antibodies against aminoaicyl t RNA synthetase, associated with interstitial lung disease, myositis, arthritis and Raynaud’s phenomenon. Anti PL 7 antibody is rare, present in only 1-4% patients with anti synthetase syndrome.

**Objectives:** To describe clinical characteristics PL – 7 positive patients with anti-synthetase syndrome.

**Methods:** In this retrospective study, cohort of patients with inflammatory myositis were screened for anti PL-7 antibody positivity and 4 cases were detected. Diagnosis was made based on either 2017 EULAR/ACR classification criteria and/or Bohan and Peter criteria. [1, 2] Clinical manifestations, investigations including antibody profile, treatment and treatment response were described.

**Results:** Of the 4 patients, 3 were female and age of onset varied from 36 to 69 years. Only 1 patient presented with proximal muscle weakness while three patients with dyspnoea. Joint involvement and Raynaud’s phenomenon was present in 2 patients. Two patients had scleroderma spectrum manifestations. Three patients had elevated CK during the disease course with maximum values being 228, 594 and 1200 with only one having muscle weakness. One patient had dermatomyositis and 2 patients had mechanic’s hand. HRCT patterns were usual interstitial pneumonia(UIP), nonspecific interstitial pneumonia(NSIP) and fibrosing NSIP with organising pneumonia. Three patients had anti Ro antibodies. All patients were treated with steroids, one each received Cyclophosphamide and Azathioprine initially however all the patients ended up with Mycophenolate mofetil—which controlled disease effectively without flare.

**Conclusion:** In Anti PL – 7 positive patients, interstitial lung disease is much more common than myositis. Mechanic’s hands and scleroderma overlap appear to be a common association. Additionally, antibody positivity with Anti Ro/Ro52 was also noted. One patient had features of dermatomyositis including facial rash which is extremely rare for PL7. All of these patients responded very well to Mycophenolate.

**REFERENCES:**


**Disclosure of Interests:** None declared


---

**AB0717**

**DEVELOPING A DEEP LEARNING MODEL ON CONVENTIONAL X-RAYS IN THE DIAGNOSIS OF AXIAL SPONDYLOARTHITIS**

D. Temiz Karadağ1, S. Şan1, B. Inner2, K. Kaplan2, O. Cakir2, N. Gokcen1, A. Yazıcı1, A. Çefe1.1Kocaeli University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Kocaeli, Turkey; 2Kocaeli University, Department of Computer Engineering, Kocaeli, Turkey; 3Kocaeli University Faculty of Medicine, Department of Radiology, Kocaeli, Turkey

**Background:** Axial spondyloarthritis (SpA) is a chronic inflammatory condition characterized by inflammation of the axial skeleton, characterized by low back pain or inflammation and radiographic sacroiliitis. The diagnosis of SpA relies on clinical symptoms, physical examination and imaging studies.

**Objectives:** The aim of this study is to develop and validate a deep learning model on conventional radiographs for the diagnosis of axial SpA.

**Method:** A total of 350 conventional chest X-rays from patients with clinically suspected SpA were collected from the Department of Radiology, Kocaeli University Medical School. The X-rays were annotated for the presence of radiographic sacroiliitis and spinal alterations. The dataset was split into a training set (70%) and a test set (30%). A deep learning model was trained using convolutional neural networks (CNNs) and its performance was evaluated using receiver operating characteristic (ROC) analysis and area under the curve (AUC). The model was further validated in an independent dataset of 100 X-rays.

**Results:** The CNN model achieved an AUC of 0.85 on the training set and 0.82 on the test set. The model was able to correctly classify 90% of the cases in the validation set. The model was also able to detect early stages of sacroiliitis with high sensitivity and specificity.

**Conclusion:** A deep learning model can be developed to assist radiologists in the diagnosis of axial SpA using conventional X-rays. This model has the potential to improve diagnostic accuracy and reduce variability among radiologists.

**Disclosure of Interests:** None declared


---

**Table 1.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at onset</td>
<td>69 years</td>
<td>52 years</td>
<td>36 years</td>
<td>55 years</td>
</tr>
<tr>
<td>Gender</td>
<td>Male</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td>Presentation</td>
<td>Shortness of breath</td>
<td>Shoulder weakness</td>
<td>No weakness</td>
<td>No weakness</td>
</tr>
<tr>
<td>Muscle</td>
<td>No weakness</td>
<td>594</td>
<td>1200</td>
<td>105</td>
</tr>
<tr>
<td>Maximum CK (U/L)</td>
<td>229</td>
<td>594</td>
<td>1200</td>
<td>105</td>
</tr>
<tr>
<td>Raynaud’s</td>
<td>Present</td>
<td>Absent</td>
<td>Present</td>
<td>Absent</td>
</tr>
<tr>
<td>Joint</td>
<td>Arthritis - present</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Skin</td>
<td>Skin tightness</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Nail fold capillaries dilation</td>
<td>Sclerodactyly</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Lung</td>
<td>Present</td>
<td>Absent</td>
<td>Absent</td>
<td>Absent</td>
</tr>
<tr>
<td>Antibodies</td>
<td>ANA+</td>
<td>ANA+</td>
<td>ANA+</td>
<td>ANA+</td>
</tr>
<tr>
<td>Anti Ro Ro52+</td>
<td>PL – 7+</td>
<td>PL – 7+</td>
<td>PL – 7+</td>
<td>PL – 7+</td>
</tr>
<tr>
<td>HRCT</td>
<td>UIP</td>
<td>No ILD</td>
<td>NSIP</td>
<td>Fibrosing NSIP, COP</td>
</tr>
<tr>
<td>Lung function</td>
<td>FEV1 53%</td>
<td>Not available</td>
<td>FEV1 36%</td>
<td>FEV1 65%</td>
</tr>
<tr>
<td></td>
<td>FVC 47%</td>
<td></td>
<td>FVC 35%</td>
<td>FVC 82%</td>
</tr>
<tr>
<td></td>
<td>FEV1/FVC 113%</td>
<td></td>
<td>FEV1/FVC 103%</td>
<td>FEV1/FVC 83%</td>
</tr>
<tr>
<td></td>
<td>DLCO 34%</td>
<td></td>
<td>DLCO 49%</td>
<td>DLCO 50%</td>
</tr>
<tr>
<td>EMG</td>
<td>Not done</td>
<td>Chronic myopathy</td>
<td>Not done</td>
<td>Not done</td>
</tr>
<tr>
<td>Muscle biopsy</td>
<td>Not done</td>
<td>Not available</td>
<td>Not done</td>
<td>Not done</td>
</tr>
<tr>
<td>Treatment</td>
<td>Prednisolone and IV cyclophosphamide initially (side effects)</td>
<td>Prednisolone—clinical response</td>
<td>MMF and Prednisolone—clinical response</td>
<td>Prednisolone and Mycophenolate-respons- with normalisation of PFT</td>
</tr>
<tr>
<td>Pulmonary hypertension</td>
<td>Present</td>
<td>Absent</td>
<td>Present</td>
<td>Absent</td>
</tr>
</tbody>
</table>
Background: Plain pelvic radiographs are the most common imaging modality used in the first line for diagnosis of axial Spondyloarthritis (axSpA). However, evaluation of the sacroiliac joint on two-dimensional plain radiographs may lead to misinterpretation among the evaluators.

Objectives: To investigate the diagnostic power of deep learning models in conventional radiographs of the patients with axSpA.

Methods: The study included 320 axSpA patients and 348 healthy controls (age: 34.5±15.3/38.2±10.6, p=0.072; gender (male) 53.8%/46.3%, p=0.064). Sacroilitis was confirmed on sacroiliac MRI according to the Assessment of Spondyloarthritis International Society (ASAS) definition. The contrast equalization was preprocessed with the Clahel (Contrast-Limited Adaptive Histogram Equalization) filter. Then, classification was performed with Alexnet, VGG16, resnet101 and resnet50 models. As a result of the trials, the best result was achieved with resnet50. Four different filtering scenarios were applied (Clahel filter clipLimit 0.25, Clahel filter cliplimit 0.50, clahel filter 1.00 and no filter). Two different cropping processes were performed on the direct radiographs, and uncropped, cropped at pelvic borders, cropped images close to the sacroiliac joint were applied to the deep learning model. Meanwhile, all images were also evaluated by 3 rheumatologists for the presence of sacroilitis.

Results: According to the results of 4 different scenarios studied with the Resnet50 model, the best result was obtained with the RESNET50 Model + Clahel filter clipLimit 0.50. With this model, after applying the clahel filter with a coefficient of 0.5 to the full resolution data, we achieved 0.61 success in the separation of AS and normal. A kappa error of 0.0561, Cohen’s Kappa Error = 0.6267, Fscore 0.8022 (AS), 0.8253 (normal) were obtained. After applying the clahel filter with a coefficient of 0.5 with Resnet50 to the pelvic data, we achieved 0.625 success in separation of AS and normal. Kappa error 0.0694, Cohen's Kappa Error=0.2400, Fscore 0.5399 (AS), 0.6838 (normal) values were obtained. After applying the Clahel filter with a coefficient of 0.5 with Resnet50 to the sacroiliac data, we achieved 0.61 success in the separation of AS and normal. Kappa error 0.0696, Cohen's Kappa Error=0.2131, Fscore 0.5517 (AS), 0.6549 (normal) values were obtained. As a result of the evaluation of the radiographs by the clinician, Cohen’s kappa was 0.452 and accuracy was 0.73 for the first rheumatologist; Cohen's kappa 0.132 and accuracy 0.56 for the second rheumatologist and Cohen's kappa 0.362 and accuracy 0.68 for the third rheumatologist.

Accuracy Cohen's kappa (CI)

<table>
<thead>
<tr>
<th>Filtering Scenario</th>
<th>Accuracy</th>
<th>Cohen's kappa (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RESNET50+no filter</td>
<td>0.7306</td>
<td>0.4509 (0.3234-0.5785)</td>
</tr>
<tr>
<td>RESNET50 Model + Clahel filter (0.25)</td>
<td>0.6943</td>
<td>0.3889 (0.2590-0.5169)</td>
</tr>
<tr>
<td>RESNET50 Model + Clahel filter (0.50)</td>
<td>0.8135</td>
<td>0.6267 (0.4186-0.7555)</td>
</tr>
<tr>
<td>RESNET50 Model + Clahel filter (1.00)</td>
<td>0.6839</td>
<td>0.3552 (0.2213-0.4890)</td>
</tr>
<tr>
<td><strong>RESNET50 Model + Clahel filter (0.50)</strong></td>
<td>0.625</td>
<td>0.2400 (0.1523-0.3245)</td>
</tr>
<tr>
<td><strong>RESNET50 Model + Clahel filter (0.50)</strong></td>
<td>0.610</td>
<td>0.2131 (0.1121-0.3430)</td>
</tr>
</tbody>
</table>

* Uncropped sacroiliac X-Rays; ** Cropped X-Rays at the pelvic margins; *** Cropped X-Rays close to the sacroiliac joints

Table 1. Precision and kappa values of Resnet50 model, 4 different filtering scenarios and 2 different clipping operations

Figure 1. Steps of deep learning model in X-Ray images

Disclosure of Interests: None declared
**ECONOMIC BURDEN IN SCLERODERMA**

L. Martin Calderon1, M. Chaudhary2, J. Pope3. 1Western University, Internal Medicine, London, Canada; 2Western University, Medicine, London, Canada; 3Western University, Rheumatology, London, Canada

**Background:** Scleroderma (SSc) is a multi-system autoimmune disease, characterized by vasculopathy and fibrosis of the skin and internal organs, associated with substantial morbidity and disability. Patients with SSc commonly require considerable healthcare resources resulting in significant economic impact.

**Objectives:** The purpose of this systematic review is to provide a narrative summary of the economic impact and healthcare resource utilization associated with SSc.

**Methods:** MEDLINE and EMBASE were searched without language restriction from inception to January 20th, 2021. Studies were included if they provided information regarding total, direct, and indirect medical costs including medication, diagnostic test, and assistive devices costs. The cost of SSc complications was additionally collected. Included observational studies had risk of bias assessments through the Joanna Briggs Institute cross-sectional and case series checklists, and the Newcastle-Ottawa Cohort and Case-Control study scales.

**Results:** The search retrieved 1777 studies, of which 33 were included representing 20 cross-sectional, 10 cohort, and 3 case-control studies. Studies used various methods of calculating cost including prevalence-based cost-of-illness approach, bottom-up cost analysis, humanistic approach, and health resource units cost analyses. Overall scleroderma total annual medical cost ranged from USD $14,959-$23,268 in USA, CAD$10,673-$18,453 in Canada, €4,607 -€4,305 in Europe, and AUD $7,060 to $11,607 in Oceania.

**Conclusion:** Globally, SSc represents high patient and systemic economic burden. SSc-associated complications increase economic burden and are variable depending on geographical location, and access.

**REFERENCES:**


**AB0721 FROM UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE TO IDENTIFIABLE DISEASE: PRECURSORS OF SYSTEMIC SCLEROSIS AND SYSTEMIC LUPUS ERYTHEMATOSUS**

L. Martin Calderon1, J. Pope2,3. 1Western University, Internal Medicine, London, Canada; 2St. Joseph’s Hospital, Rheumatology, London, Canada; 3Western University, Rheumatology, London, Canada

**Background:** The pathogenesis of systemic lupus erythematosus and systemic sclerosis is characterized by derangements of the innate and adaptive immune systems, and inflammatory pathways leading to autoimmunity, chronic cytokine production, and chronic inflammation. Diagnosis is rooted in meeting established criteria. However, in pre-clinical states criteria is not fulfilled but biochemical and autoimmune derangements are present. Understanding the underlying processes responsible for disease pathogenesis in pre-clinical states, which place patients at increased risk for the development of established connective tissue diseases, presents a prognostic opportunity, and could enable timely treatment leading to limiting disease progression.

**Objectives:** We aim to describe the role of the innate and adaptive immune systems in the pre-clinical states of UCTD-risk-SSc and prescleroderma, the underlying immune dysregulation in these pre-clinical states, and the evolution of antibodies from nonspecific antinuclear antibodies to specific to SLE development.

**Methods:** Our search strategy was developed alongside an experienced information specialist. We searched the databases EMBASE and MEDLINE with no language restriction. Reference lists of all primary studies and review articles were searched for additional references. Studies reported in full-text and abstract formats were included.


**Results:** Multiple cytokines are observed to increase along a disease spectrum from UCTD-risk-SSc to classified SSc and include sICAM-1, CC2, CXCL8, ang-2, CXCL16, e-selectin, and IL-13. The mechanism of action of these cytokines includes transmigration of lymphocytes endothelium, innate immune cell activation and signal propagation, and extracellular matrix deposition. The progressive nature of cytokine increase through a spectrum from pre-clinical to clinical emphasizes disease evolution and enables the discernment of patients who may warrant early intervention. Furthermore, there are disease markers which are observed to be predictive of established SSc and include sII-2Rhi, PIINP, CXCL8, CXCL10, and CXCL11. Pre-clinical SLE is characterized by an evolving FN signature and progressive SLE-specific antibody formation prior to disease classification.

**Conclusion:** The coordinated dysregulation of the innate and adaptive immune systems, and inflammatory signalling pathways leads to the pathogenesis of connective tissue disease. Our improved understanding of these underlying aberrations in pre-clinical stages of disease will serve to better identify patients at increased risk.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4241

---

**AB0722**

**ONE-YEAR CLINICAL EXPERIENCE ON THE USE OF NINTEDANIB IN SYSTEMIC SCLEROSIS: SAFETY PROFILE.**

L. Magnani1, A. Spinel1a, S. Testoni2, G. Bajocchi1, L. Dardani1, C. Salvarani1,2, D. Giugliani1 on behalf of Scherleroma Unit - MORE. 1ASMN-IRCCS Santa Maria Nuova, Rheumatology, Reggio Emilia, Italy; 2University of Modena and Reggio Emilia, Rheumatology, Modena, Italy

**Background:** Systemic Sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, immune activation and fibrosis of skin and internal organs (1,2). One of the most common and severe SSc manifestations is interstitial lung disease (ILD) (3).

**Objectives:** Evaluate tolerability and safety profile of Nintedanib in patients with SSc-related ILD.

**Methods:** We enrolled 11 consecutive patients (6 female, 5 male, Mean age 62.7 ± 8 SD, disease duration (from the first Non-Raynaud symptom) 8 years (± 7SD) who referred to our Schleroderma Units during the last twelve months. Patients fulfilled EULAR/ACR classification criteria (4) for SSc. Patient was assessed by means of clinical evaluation (baseline and every three months), High Resolution computed tomography (every six months, or sooner), respiratory function test (every three to six months), laboratory work up, nailfold videocapillaroscopy, echocardiogram, and clinical questionnaires (BORG and mMRC).

**Results:** NSIP was the most frequent HRCT pattern (5 pts, 45%), followed by UIP and UIP/NSIP pattern (respectively 3 pts & 3 pts, 27%), 9 patients showed more than 20% of HRCT pulmonary fibrosis involvement. Only 1 patient had a history of smoking, mRSS was 9.23 (±10SD) points with any significant improvement during the twelve months follow-up (10 ±10SD). 8 pts were on Mipofolate Mephotil (MMF) (7 of them on FMF + steroids), 8 pts were on steroids (mean dose 5mg/day of Prednisone or equivalent), 3 on rituximab. Main FVC was 2347ml [-1051 ml] (61.3% predicted) remaining stable. The mMRC decreased from 2.36 at baseline to 2.27 at the end of the follow up and Borg mRSS of 7.27 at baseline to 6. Two patients were on oxygen therapy (O2 3L min with a significant flow adjustment with treatment). Three allow a rapid remission of diarrhoea, one patient had a partial intestinal obstruction, one had pulmonary arterial hypertension worsening with an immediate drug withdraw, one patient presented nausea, one irritability. Three patients had a clinical irrelevant weight loss (less than 2 Kg).

**Conclusion:** We report a preliminary real-life experience on the use of Nintedanib in SSc-related patients, focusing in particular to its tolerability and safety profile. Nintedanib is well tolerated with a low rate of definitive discontinuation due to SAE. Diarrhoea is a very frequent adverse event (approximately 5 episodes a day) and had led to dose reduction and/or treatment re-challenge in the majority of patients. Diarrhoea seems to ameliorate reducing daily dose of MMF (1 gram/day) or prescribing loperamide along with diosmectite and probiotics. FVC, mMSS, HRCT and capillaroscopy pattern remained stable. Further studies are desirable to confirm the usefulness of Nintedanib in progressive ILD, but based on our experience we support the combined use of the anti-fibrotic therapy plus immunomodulatory drugs in early stages of SSc-related ILD.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4342

---

**AB0723**

**ANTI-TIF1-BETA AUTOANTIBODIES IN A PATIENT WITH CANCER-ASSOCIATED DERMATOMYOSITIS.**


1KU Leuven, Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium; 2University Hospitals Leuven, Rheumatology, Leuven, Belgium; 3KU Leuven, Microbiology, Immunology and Transplantation, Leuven, Belgium; 4University Hospitals Leuven, Dermatology, Leuven, Belgium; 5University of Occupational and Environmental Health, Clinical Nursing, School of Health Sciences, Kitakyushu, Japan; 6KU Leuven, Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, Leuven, Belgium; 7University Hospitals Leuven, Laboratory Medicine, Leuven, Belgium

**Background:** Anti-transcriptional intermediary factor 1-gamma (TIF1-gamma) autoantibodies are strongly linked to cancer-associated dermatomyositis (DM). In addition to anti-TIF1-gamma autoantibodies, autoantibodies to TIF1-alpha and TIF1-beta have been described, often coexisting with TIF1-gamma or other known autoantibodies [1,2]. Thus far, anti-TIF1-beta autoantibodies without other known autoantibodies have been identified in only 3 patients with dermatomyositis, of which none had cancer [1,2].

**Objectives:** To report on a patient with cancer-associated dermatomyositis and isolated anti-TIF1-beta autoantibodies.

**Methods:** Serum of a patient with cancer-associated dermatomyositis without known autoantibody specificity was evaluated by immunoprecipitation combined with liquid chromatography-tandem mass spectrometry (IP + LC-MS/MS). Mass spectrometry data were matched against the Uniprot Homo Sapiens database with the Mascot search engine using Proteome Discoverer. Additional immunoprecipitation of radiolabeled cell extract followed by autoradiography were performed. Clinical and laboratory data were retrieved from the electronic health record.

**Results:** TIF1-beta was identified in the immunoprecipitate of the serum of the patient by IP + LC-MS/MS, but not TIF1-gamma or TIF1-alpha. These results were confirmed by immunoprecipitation of radiolabeled cell extract (Figure 1A). The HEp-2 indirect immunofluorescence assay showed a nuclear fine speckled pattern (AC-4, maximum titre > 1/1280, Figure 1B), which corresponds to the subcellular localization of TIF1-beta [3]. The patient, a 64-year old male, presented with dermatomyositis with classical cutaneous and muscular involvement (max. serum creatine kinase level 370 U/L). A renal cell carcinoma was found during the diagnostic work-up for which a partial nephrectomy was performed. There was a good response of both cutaneous and muscular disease activity to treatment with hydroxychloroquine and methyldopa.

Figure 1. A Immunoprecipitation with 32P-methionine labeled K562 cells with subsequent radiography. C Positive control with anti-TIF1-beta and anti-U1/RNP autoantibodies, 1 anti-TIF1-gamma-beta-positive patient (patient here described), 2 negative patient, 3 anti-TIF1-gamma/alpha-positive patient B Nuclear fine speckled pattern on HEp-2 indirect immunofluorescence assay, 40X magnification
Conclusion: Isolated anti-TIF1-beta autoantibodies should be considered in patients with dermatomyositis without known myositis-specific autoantibodies and can be associated with cancer.

REFERENCES:

Disclosure of Interests:
Jean-Baptiste Vulsteke: None declared, Petra De Haes: None declared, Ellen De Langhe: None declared, Xavier Bossuyt Consultant of: Inova Diagnostics, Thermo Fisher Scientific

AB0724 TO ASSESS THE SCLERODERMA CLINICAL TRIALS CONSORTIUM DAMAGE INDEX (SCTC-DI) IN PATIENTS WITH SYSTEMIC SCLEROSIS IN RUSSIAN COHORT PATIENTS.

O. Ovsyannikova1, O. Koneva1, L. Garzanova1, L. P. Ananyeva1, R. Shayakhmetova1, O. Desina1, A. Khelkovskia-Sergeeva1, M. Starovoytova1

V.A. Nasonova Research Institute of Rheumatology, Systemic sclerosis, Moscow, Russian Federation

Background: Systemic sclerosis (SSc) is a multiorgan disease wherein the pathogenic processes of inflammation, vasculopathy and fibrosis lead to multiple disease manifestations. The course of SSc is often one of progressive damage to multiple organs including skin, joints, heart, lungs, gastrointestinal tract and kidneys. The scleroderma clinical trials consortium damage index (SCTC-DI): a new instrument to quantify organ damage in systemic sclerosis [1].

Objectives: To assess the scleroderma clinical trials consortium damage index (SCTC-DI) in patients with systemic sclerosis in Russian cohort patients.

Methods: Data from 104 patients with systemic sclerosis (mean age was 51.7±12.54 years; 64% have limited subset of the disease; 88% were female) all fulfilling the ACR criteria for SSc. Functional lung tests, high-resolution CT (HRCT), echocardiography, SSc activity (by the European Scleroderma Study Group (ESSCG) activity index), HAQ, SHAQ, the six minute walk test (6MWT), scleroderma clinical trials consortium damage index (SCTC-DI) were evaluated. Other data collected including biological results (high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR)). Statistical analysis: descriptive data are presented as means (±SD) or medians (with interquartile range [IQR]) for continuous variables, while categorical variables are expressed as counts and percentages. Univariate comparisons were made with 2-sample t tests. we used the Spearman's rank-order (Spearman's p) correlations coefficients.

Results: A significant positive correlations were found between the SCTC-DI values and HAQ (r=0.31, p=0.003), SHAQ (r=0.28, p=0.006), and values of ESSC activity index (r=0.53, p<0.0006) accordingly. The SCTC-DI value inversely correlated to values of 6MWT (r=-0.246, p=0.003). Moreover, values and HAQ (r=0.31, p=0.003), SHAQ (r=0.28, p=0.0087), and values the Spearman's rank-order (Spearman's p) correlations coefficients.

Conclusion: The scleroderma clinical trials consortium damage index (SCTC-DI) is a new instrument to quantify organ damage in systemic sclerosis [1].

REFERENCES:
[1] V.A. Nasonova Research Institute of Rheumatology, Systemic sclerosis, Moscow, Russian Federation

AB0725 SCLERODERMA STUDY GROUP EMILIA ROMAGNA (SCESS-EMILIA)- REAL LIFE USE OF PROSTACYCLIN ANALOG. PRELIMINARY DATA FROM A MULTICENTRIC SURVEY.

L. Magnani1, A. Arianì1, F. Girelli1, A. Spinella1, F. Lumezia1, A. Lo Monaco1, M. Peta1, E. Arrigoni1, F. Ursini1, A. Bezzì1, P. Catala1, L. Montaguti1, M. Trevisani1, M. Colina1, S. Bernardì1, A. Becciolini1, G. Galoppini1, F. Pignataro1, J. Claffì1, E. Bravi1, M. C. Focherini1, S. Moscatelli1, P. Sambo1, R. Mule1, S. Corvaglia1, G. Bajocci1, D. Contì1, C. Salvareni1, D. Giuglioli1 on behalf of Sclero-REER.

1Arcispedale Santa Maria Nuova, Rheumatology Unit, Department of Internal medicine, ASLM-RRCS, Reggio Emilia, Italy; 2University Hospital of Parma, Day Hospital of Day Hospital of Internal Medicine & Rheumatology, Parma, Italy; 3Ospedale “Morgagni – Pierantoni” di Forlì, Internal Medicine, Forlì, Italy; 4University of Modena and Reggio Emilia, Rheumatology Unit, department of Medical & Surgical sciences for children and adult, Modena, Italy; 5University of Ferrara, Rheumatology department, medical department of sciences, Ferrara; 6Carlo Alberto Pizzardi Hospital AUSL Bologna, Bologna, Rheumatology & Internal Medicine Unit, Bologna, Italy; 7Piacenza Hospital, Rheumatology Unit, Piacenza, Italy; 8Rizzoli Orthopedic Institute, Rheumatology Unit, Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum University di Bologna, Bologna, Italy; 9Ospedale “Interni” di Rimini, Rheumatology Unit, Rimini, Italy; 10Hospital Santa Maria delle Croci, Rheumatology Unit, Department of Internal medicine, AUSL-Romagna, Ravenna, Italy; 11Maurizio Bufalini Hospital, Department of Internal Medicine, Reggina local healthcare unit, Cesena, Italy; 12S. Orosia-Malpighi Polyclinic, Rheumatology Unit, Internal medicine department, Bologna, Italy; 13Ospedale Nuovo, Outpatient clinic of Rheumatology, department of Internal Medicine, Imola, Italy; 14Arcispedale Santa Maria Nuova, Rheumatology, Reggio Emilia, Italy; 15Associazione Malati Reumatici Emilia Romagna, AMRRER, Bologna, Italy

Background: Systemic Sclerosis (SSc) is a complex autoimmune disease characterized by vascular damage, immune activation and fibrosis of skin and internal organs. Raynaud phenomenon (RP) is frequently the first symptom of the disease and growing evidences are supporting the hypothesis the SSc may be a vascular disease, with a pivotal role of endothelial cells, particularly in the very early phase. Robust data support the use of vascular active drug to treat RP and to prevent vascular complication.

Objectives: The use of prostacyclin analog (PA) is everything but standardized, with different regimen used all around the Country. We report data on the use of PA in a multicentric regional ready to understand which regimen are prevalent (and why) and if there is the opportunity to standardized them.

Methods: We collected data from an online survey exploring different items related to the use of PA.

Results: Survey was fulfilled by 12 sites: 5 university hospital and 7 local hospit-als, from 5 different Rheumatologist and 5 from internal medicine specialists with/without concomitant rheumatologists. PA are ubiquitarly used for SSc-related dig-ital ulcers (SSc-DU) and secondary RP but only a half of sites use it for primary RP. Seventy-five percent of sites (9/12) dispense PA at least once a month, but some other (1 each one respectively) on weekly basis, every other month or every 7 weeks. Drug administration may last from 2 to 5 consecutive days (mean 1.91+/-.155D) with drug dose ranging from 0.5 to 2mg/Kg/min with a minimum variability from site to site. Our regional hospitals may count on overall 68 spots, some available as beds (outpatient or inpatient), some as reclining chair or chair (outpatients only). University centers have usually more assigned personnel than local hospital (on average: 2 versus 1.5 physicians, 2 versus 1.2 nurse). Sites are able to offer meals (except one) and are able to accomodate from 1 to 12 patients at the same time (mean 3.45, +/- 3.2SD).

Conclusion: PA has known benefit in vascular involvement in SSc patients. Despite a multicenter palcebo-control study defining time and dose of this drugs and subsequent data based on the same regimen, there is no homogeneity in treatment administration. The unequal treatment, based on our data, seems due to limited resources and personnel. High variability has been found in regimen duration and administration frequency.

REFERENCES:

Disclosure of Interests:
None declared DOI: 10.1136/annrheumdis-2022-eular.4385
AB0726
STUDY OF THE ASSOCIATION OF VARIOUS X-RAY SYMPTOMS OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SYSTEMIC SCLERODERMA (SSC) WITH INDICES OF LUNG FUNCTIONAL TESTS.

O. Konova1, O. Garzanova1, O. Ovsyannikova1, N. Kovalova1, L. P. Ananyeva1, O. Desinova1, M. Starovoytova1, R. Shayakhmetova1. V.A. Nasonov Research Institute of Rheumatology, laboratory of systemic sclerosis, Moscow, Russian Federation

Background: HRCT is the gold standard for confirming the presence of ILD. According to the literature data, there is an association between the prevalence of pulmonary involvement and the severity of PFTs. However, it remains unclear whether the nature of interstitial changes affects the degree of PFTs.

Objectives: To study the clinical significance of various X-ray symptoms in SSC-ILD during long-term follow-up.

Methods: The study included 37 pts with a SSC-ILD (average age 53.1±11.5 yrs, m/w 1:2, and d/l–1/1; SSc duration 10.9±9 yrs). For all pts at the time of inclusion in the study and after an average of 34±2.3 months, there were examined FVC, DLC, HRCT. All pts received immunosuppressive therapy (IST). The analysis of HRCT data was conducted at 5 levels. The severity of changes by type of ground-glass, reticular changes, traction bronchiectases, and honeycombs were evaluated (0–3 points). The dynamics of X-ray changes and PFTs was assessed in the general group and in pts with the prevalence of ILD up to 20% (group A, n=23) and more than 20% (group B, n=14).

Results: At the time of inclusion in the study, the total CT score of ILD on average for the group was 9.6±2.2. FVC was normal (94±19.5%); a moderate decrease in DLC was detected (57±23.2%). The prevalence of ILD significantly correlated only with the DLC (R=0.35, p<0.05). When included in the study, reticular changes were most often observed (the score was 4.6±3.5). Alterations by type of ground-glass were somewhat less common (the score was 3.2±3.1). The score of traction bronchiectases was 1.6±2.3. Changes by type of honeycombs were found in only 5 patients, of which only 1 patient was from the group A. Against the background of IST, values of FVC and DLC remained stable in the group as well as in the groups A and B, and the total CT score did not change. In patients of the group B both the total CT score and the average score of ground-glass and reticular changes, and traction bronchiectases score significantly higher. To assess the clinical significance of various X-ray symptoms, a correlation analysis of the total score of each of them with the PFTs data in groups A and B was executed. No significant correlation between the score of X-ray signs and values of FVC was detected. DLC significantly inversely correlated with the total score of each HRCT symptom, with the exception of ground-glass. At the same time, strength of the correlation was approximately the same for reticular changes, bronchiectases, and honeycombs in both groups.

Conclusion: The severity of the alveolar-capillary membrane functional disorders is primarily due to the prevalence of fibrotic changes. The variant of fibrotic changes has no significant importance. Changes by type of ground-glass to a lesser extent affect the degree of reduction in DLC. The best surrogate indicator reflecting the prevalence of interstitial changes was DLC.

Disclose of Interests: None declared.


AB0727
STUDY OF THE INDICATORS DYNAMICS OF THE PULMONARY FUNCTIONAL TESTS (PFTS) AND X-RAY PICTURE AGAINST DURING THE 36-MONTH IMMUNOSUPPRESSIVE THERAPY (IST) OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)

O. Konova1, L. Garzanova1, O. Ovsyannikova1, N. Kovalova1, L. P. Ananyeva1, O. Desinova1, M. Starovoytova1, R. Shayakhmetova1. V.A. Nasonov Research Institute of Rheumatology, laboratory of systemic sclerosis, Moscow, Russian Federation

Background: HRCT is the gold standard for confirming ILD. However, the role of HRCT for estimating the effectiveness of therapy is not determined in full.

Objectives: To assess the dynamics of X-ray changes and PFTs during IST in pts with SSC and different prevalence of ILD according to HRCT.

Methods: The study included 37 pts with signs of ILD (the average age 53.1±11.5 yrs, the ratio of m/w–1:2, d/l–1/1.8, SSc duration–10.9±9 yrs). For all pts at the time of inclusion in the study and after an average of 34±2.3 months were studied FVC, DLC, and HRCT. The pts received IST during the follow-up period. The ILD dynamics was assessed as follows: improvement, deterioration, and no dynamics.

Results: The severity of changes by type of ground-glass, reticular changes, traction bronchiectasis, and honeycombs were evaluated (0–3 points). The dynamics of X-ray changes and PFTs was separately assessed in pts with the prevalence of ILD changes up to 20% (group A, n=23) and more than 20% (group B, n=14) during the follow-up period.

Conclusion: Semi-quantitative evaluation according to HRCT in pts with SSC-ILD did not reveal any dynamics in the total score of structural changes during IST, which coincided with stable indices of PFTs. Pts with less common pulmonary involvement during therapy were more likely to demonstrate positive CT-dynamics. With an increase in the prevalence of ILD signs of fibrosis increased. Most pts had unidirectional dynamics of values of CT and FVC changes, which confirmed the possibility of effective use of HRCT to assess the conducted therapy.

Disclosure of Interests: None declared.


Table 1.

<table>
<thead>
<tr>
<th>Group A</th>
<th>Group B</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlation DLC with CT score</td>
<td>DLC</td>
<td>CT score</td>
</tr>
<tr>
<td>DLC1 with total CT score 1</td>
<td>60.6±19.6</td>
<td>4.5±4.4</td>
</tr>
<tr>
<td>DLC2 with total CT score 2</td>
<td>62.6±19.1</td>
<td>4.1±3.9</td>
</tr>
<tr>
<td>DLC1 with reticular changes score 1</td>
<td>60.6±19.6</td>
<td>2.6±2.4</td>
</tr>
<tr>
<td>DLC2 with reticular changes score 2</td>
<td>62.6±19.1</td>
<td>2.7±2.3</td>
</tr>
<tr>
<td>DLC1 with bronchiectases score 1</td>
<td>60.6±19.6</td>
<td>0.5±1.2 (median=0 [0;0])</td>
</tr>
<tr>
<td>DLC2 with bronchiectases score 2</td>
<td>62.6±19.1</td>
<td>0.7±1.3 (median=0 [0;1])</td>
</tr>
<tr>
<td>DLC1 with honeycomb score 1</td>
<td>47.6±11.4</td>
<td>13±3 (median=0 [0;1])</td>
</tr>
<tr>
<td>DLC2 with honeycomb score 2</td>
<td>45.2±13.5</td>
<td>17±3 (median=0 [0;1])</td>
</tr>
</tbody>
</table>

*1*–at the time of inclusion in the study; *2*–at the time of the last examination.
Background: Immunosuppressants (IS) is considered as a drug of choice for the treatment of interstitial lung disease (ILD) in the patients with systemic sclerosis (SSc). However, the IS use leads to rather limited and transient improvement of the pulmonary fibrosis. In this context the search for novel, more efficacious agents has been continued, such as attracting much attention rituximab (RTM).

Objectives: To compare the dynamics of pulmonary function parameters and skin fibrosis in patients with SSc associated with ILD, who received RTM and IS for 3 years in real clinical practice.

Methods: 158 pts with the SSc-ILD were enrolled into the study. All pts received low- and moderate-dose glucocorticoids regimens. Group A (n=100) received IS's (31/31% mycophenolate mofetil, 27/27% cyclophosphamide, 15/15% methotrexate; 27/27% other drugs; the patient's average age was 49.5±12.2 years, with female proportion 87%; SSc duration 8.6±7.2 years; diffused/localized forms patients; 57/57% methotrexate; 27/27% other drugs; the patient's average age was 48.0±13.2 years, with female proportion 86%, SSc duration 6.4±4.9 years, diffused/localized forms patients). Group B (n=58) received RTM a total dose 3.0±1.2 g. 22 patients received RTM in combination with IS's (11/11% mycophenolate mofetil, 11/11% cyclophosphamide; average age 48.0±13.2 years, female proportion 86%, SSc duration 6.4±4.9 years, diffused/localized forms patients). The therapy duration in both groups was 36 months. The time courses of forced vital capacity (FVC), diffusive lung capacity (DLC), modified skin count (mRss, points), activity index (EScSG, points), HAQ were assessed in the study.

Table 1.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group A (n=100)</th>
<th>Group B (n=58)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFCV M ± SD</td>
<td>95.2±17.0</td>
<td>P=0.3</td>
<td>76±20.7</td>
</tr>
<tr>
<td>PFCV M ± SD</td>
<td>96.5±18.9</td>
<td>83±22.2</td>
<td>0.008</td>
</tr>
<tr>
<td>Δ FVC %, SD'S [25%'S; 75%'S]</td>
<td>-0.7 [5.8; 7.9]</td>
<td>5.6 [-9.1; 14.8]</td>
<td>0.008</td>
</tr>
<tr>
<td>DCLC</td>
<td>62.6±19.9</td>
<td>P=0.08</td>
<td>46.4±18.3</td>
</tr>
<tr>
<td>DCLC</td>
<td>60.1±17.4</td>
<td>47±17.6</td>
<td>0.15</td>
</tr>
<tr>
<td>mRss, 1 M ± SD</td>
<td>-17 [5.9; 3.3]</td>
<td>125 [-4; 7.0]</td>
<td>0.15</td>
</tr>
<tr>
<td>mRss, 2 M ± SD</td>
<td>5.6±5.3</td>
<td>P=0.003</td>
<td>11.3±10.2</td>
</tr>
<tr>
<td>mRss, 3 M ± SD</td>
<td>4.3±3.5</td>
<td>3.5±5.4</td>
<td>0.000031</td>
</tr>
<tr>
<td>mRss, SD'S [25%'S; 75%'S]</td>
<td>0 [2.5]</td>
<td>-3 [-11.9]</td>
<td>P=0.01</td>
</tr>
<tr>
<td>HAQ</td>
<td>0.86±0.5</td>
<td>P=0.9</td>
<td>1.14±0.8</td>
</tr>
<tr>
<td>ESeSG 1 M ± SD</td>
<td>1.6±1.2</td>
<td>P=0.4</td>
<td>2.6±1</td>
</tr>
<tr>
<td>ESeSG 2 M ± SD</td>
<td>1.8±1.3</td>
<td>1.4±1.3</td>
<td>0.04</td>
</tr>
<tr>
<td>Dose of glucocorticoids 1, mg</td>
<td>8.1±4.8</td>
<td>P=0.16</td>
<td>11.4±4.0</td>
</tr>
<tr>
<td>Dose of glucocorticoids 2, mg</td>
<td>8.1±3.7</td>
<td>9.1±2.6</td>
<td>0.18</td>
</tr>
<tr>
<td>FVC increment by ±10%, n/10</td>
<td>14/14</td>
<td>4/6.7</td>
<td>0.05</td>
</tr>
<tr>
<td>DCLC increment by ±10%, n/10</td>
<td>6/6</td>
<td>5/8.6</td>
<td></td>
</tr>
<tr>
<td>DCLC decrement by ±10%, n/10</td>
<td>14/14</td>
<td>5/8.6</td>
<td>0.3</td>
</tr>
</tbody>
</table>

Still untreated pts were divided into 3 groups in depend on total score of SCTC-DI. 77pts were into group 1 (with low damage score); 17 pts (18%) were into group 2 (with moderate damage score) and 2 pts (2%) were into group 3 (with high damage score). Baseline characteristics of the groups are presented in Table 1.

Results: In Groups A and B the therapy was associated with significant decrease in mRss and stabilization of the diffusive lung capacity. During the follow-up period in Groups A no change of the other studied parameters was observed. In Groups B the therapy was associated with significant decrease in HAQ and EScSG. Evaluation of FVC time course in Group B revealed significant FVC increase with median increment about 5.6%. In Group B 10% FVC increase was found in the third of the patients thus exceeding respective parameter in Group B (16%). The patient percentage with FVC decrease by ≥10% in group B was less common compared to group A. During RTM therapy it was possible to significantly reduce the dose of glucocorticoids. RTM and immunosuppressants administration for 36 months in the patients with SSc and ILD effectively alleviated skin induration and stabilized DLCO.

Conclusion: Only RTM significantly improved FVC and the patient's quality of life and decreased of the activity index. RTM demonstrated a steroid-sparing effect. The study findings substantiate potential use of RTM as a first-line agent for the treatment ILD progressive phenotype in SSc. The immunosuppressants use as a single-agent therapy is more preferable in patients with less pronounced ILD.

Disclosure of Interests: None declared

We didn’t find a lot of significant differences in between groups, but it could be noted that group 3 was younger and the severity of the parameters increased in groups moderate and high damage. We found that mean value of FVC, DLco and FEV1 were significant increased in group 1.

Conclusion: the pts with moderate and high damage scores of SCTC-DI had worse clinical and instrumental characteristics than pts with low damage score. We could try to use scores of SCTC-DI as measures of SSC severity.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.4587

**Table 1.**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group 1 (n=77)</th>
<th>Group 2 (n=17)</th>
<th>Group 3 (n=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td>96.8±14.9</td>
<td>66.3±20.1</td>
<td>47.6±7.2</td>
</tr>
<tr>
<td>FVC</td>
<td>97.3±14.6</td>
<td>64.7±17.3</td>
<td>43.3±5.8</td>
</tr>
<tr>
<td>DLco</td>
<td>60.9±16.3</td>
<td>36.4±9.5</td>
<td></td>
</tr>
<tr>
<td>PAP</td>
<td>34.7±10.8</td>
<td>38±13.1</td>
<td></td>
</tr>
<tr>
<td>duration</td>
<td>8.9±7.6</td>
<td>12.4±7.1</td>
<td></td>
</tr>
<tr>
<td>ESR</td>
<td>6.7±2.1</td>
<td>20±3.6</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** Among the 97 SSc enrolled patients (mean age 55.4±12.5 yrs), 82 (84.5%) were female, 35 (36%) affected by diffuse cutaneous form of SSC (dcSSc) and 41 (42.3%) had ILD diagnosed by HRCT. The mean follow-up was 34.6±16 months, with PFTs and/or HRCT data available in 86 patients, 37 (43%) of whom had ILD at baseline. Patients with ILD who progressed during follow-up were more frequently affected by dcSSc (p = 0.003), and tended to have lower values of total lung capacity (p<0.001). The median SCCA-IgM values were significantly higher in patients with progressive ILD vs. those with stable ILD: 301 (57.526) vs. 45 (34.236), respectively (p = 0.017, Figure 1). At Cox regression multivariate analysis, SCCA-IgM serum levels was the only variable independently associated with ILD progression (HR 1.003 95% CI 1.000-1.006, p=0.02).

Conclusion: In conclusion, our preliminary data support SCCA-IgM as a potential candidate biomarker for progressive ILD in patients with scleroderma.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4592

**AB0730**

**SCCA-IGM AS A PREDICTOR OF INTERSTITIAL LUNG DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS**

E. Zanatta<sup>1</sup>, A. Martini<sup>1</sup>, A. Cuberl<sup>1</sup>, A. Biasiolo<sup>2</sup>, P. Pontusso<sup>2</sup>, A. Doria<sup>1</sup>, A. Mosca<sup>1</sup>, A. Trippoli<sup>2</sup>, L. Carli<sup>2</sup>, M. Mosca<sup>1</sup>, 1University of Padova, Rheumatology Unit, Department of Medicine, Padova, Italy; 2University of Padova, Unit of Internal Medicine and Hepatology (UIMH), Department of Medicine, Padova, Italy

**Background:** Interstitial Lung Disease (ILD) is the major determinant of morbidity and mortality in patients with systemic sclerosis (SSc). The course of lung involvement is extremely variable in SSc-ILD. Squamous Cell Carcinoma Antigen 1 (SCCA1) is a cysteine protease inhibitor that plays a crucial role in inflammation and fibrosis. It may be detected in serum in the form of an IgM-linked immune complex (SCCA-IgM), and we previously demonstrated that it is increased in patients with SSc-ILD (1).

**Objectives:** We aimed to investigate the association between SCCA-IgM serum levels and ILD progression in a cohort of SSC patients.

**Methods:** Ninety-seven patients with SSc (2013 ACR/EULAR criteria) from the Rheumatology Unit of Padua University Hospital were consecutively enrolled in the study. Clinical, serological indices and organ involvement (pulmonary, cardiac, gastrointestinal and articular) were evaluated at the time of the SSc clinical course. Pulmonary involvement was investigated by high-resolution CT (HRCT) and respiratory function tests (PFTs). Serum immune complex levels were measured by a validated ELISA assay (Hepa-IC, Xeptagen, Venice, Italy) and expressed in arbitrary units/ml (AU/ml). Follow-up period was defined as the time between baseline (i.e. SCCA-IgM blood sampling) and last PFTs and/or HRCT performed at least after 24 months. SSc-ILD progression was defined by HRCT and/or PFTs worsening. Progression on PFTs: FVC decline ≥10% from baseline or FVC ≥5-9% decline plus DLCO decline ≥15%; radiological progression: ILD worsening on HRCT evaluated by the same experienced thoracic radiologist.

**Results:** Among the 97 SSc enrolled patients (mean age 55.4±12.5 yrs), 82 (84.5%) were female, 35 (36%) affected by diffuse cutaneous form of SSc (dcSSc) and 41 (42.3%) had ILD diagnosed by HRCT. The mean follow-up was 34.6±16 months, with PFTs and/or HRCT data available in 86 patients, 37 (43%) of whom had ILD at baseline. Patients with ILD who progressed during follow-up were more frequently affected by dcSSc (p = 0.003), and tended to have lower values of total lung capacity (p<0.001). The median SCCA-IgM values were significantly higher in patients with progressive ILD vs. those with stable ILD: 301 (57.526) vs. 45 (34.236), respectively (p = 0.017, Figure 1). At Cox regression multivariate analysis, SCCA-IgM serum levels was the only variable independently associated with ILD progression (HR 1.003 95% CI 1.000-1.006, p=0.02).

**Conclusion:** In conclusion, our preliminary data support SCCA-IgM as a potential candidate biomarker for progressive ILD in patients with scleroderma.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4592
and to explore if T'D represent a risk factor for FF also in IIM; finally, since HT is a risk factor for TPC, an evaluation of its occurrence in our cohort should be designed. However, our data seem sufficient to underline the need to regularly screen IIM patients for thyroid function, aiming at optimizing their quality of care, both for activity and damage domains of their autoimmune disease.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4596

AB0732
ABATACEPT AS THERAPY OPTION IN SYSTEMIC SCLEROSIS (SSC) PATIENTS AFTER YEARS OF GRAZER-PROTOCOL TREATMENT: OUR EXPERIENCE
M. D’orazio, M. Daher, A. Lackner, S. Kielhauser, S. Zenz, J. Grettler, J. Thiel, H. P. Brezinsek, F. Fürst-Moazedi, Medical University of Graz, Rheumatology and Immunology, Graz, Austria

Background: Previous studies have provided evidence that T cells may play a significant role in the pathogenesis of systemic sclerosis (SSc) and observational studies reported that Abatacept, which interferes with T cells activation, appeared to be safe and effective in SSc-patients with skin and muscle involvement. So far, there was no significant effective treatment for SSC-ILD. We have recently demonstrated the effectiveness of intensified –RTX- long term treatment (“Grazer protocol” with 500 mg RTX in week 0 and 2, every 3 months +/- MMF) in SSc patients with severe organ involvement and/or progressive form non responding to metotrexate or cyclophosphamide. However, no data are available concerning how long Patients with a stable disease need to be treated. B-cell-depletion therapy over years for SSC in remission might represent a risk factor for infections. Additionally, the parenteral administration is associated with an increase in health care and patients are bound to regular hospital visits, which is a limiting factor for life quality.

Objectives: We aimed to investigate if subcutaneous Abatacept could be used as a maintenance treatment in SSc-patients reaching a stable disease activity after a treatment with RTX administered according to our Grazer protocol over several years.

Methods: In this retrospective analysis, we retrieved data from 20 patients who fulfilled the diagnosis criteria for systemic sclerosis (SSc) according to the European League Against Rheumatism Scleroderma Trial and Research standards, who started a treatment with abatacept (ABA) after years of 500 mg RTX therapy every three months +/- MMF (Grazer protocol). The following clinical parameter were evaluated: modified Rodnan Skin Score (mRSS), Systemic Sclerosis Activity Score (SSCA3), Systemic Sclerosis Severity Score (SSCS3) and lung diffusing capacity for carbon monoxide (DLCO). Lab parameters like IgG, ANA, ENA and inflammation parameters were routinely assessed. Clinical data from baseline visit (BSL) (before ABA treatment start) and follow-up visit (FU) (after 6 months of treatment) were collected.

Results: We included 20 SSc patients in this retrospective analysis who changed from RTX to Abatacept. The majority were female (n=16, 94.1%), with a mean age ±SD of 54.8 years ±11 and an average disease duration of 7.7 years ±4.5. In 17.9% (n=4) treatment needed to be stopped due to disease flare after three months (lung ±2, skin and tendons ±2). However, interestingly, Abatacept further decreased significantly mRSS before baseline visit and follow-up visit regarding the affected skin of the fingers. Thus, the mRSS went from 3.9±3.4 to 2.5±1.8 (p<0.05). As expected, no significant difference in the EUSTArSSC3, or ScC3 or DLCO was found. No infections were observed during the abatacept follow-up period and Immunoglobulins remained within the normal range.

Conclusion: Abatacept might be a feasible option as a maintenance therapy after intensive immunomodulation with RTX and may give our patients the possibility to further improve their quality of life.

Disclosure of Interests: None declared

AB0733
MUSCULO-ARTICULAR SYNDROME IN PATIENTS WITH SYSTEMIC SCLEROSIS-POLYMYOSITIS/DERMATOMYOSITIS OVERLAP SYNDROME.
O. Desinyova1, M. Starovoytova1, A. Khelkovskaja-Sergeeva1, L. P. Ananyeva1, O. Koneva1, R. Shayakhmetova1, L. Garzanova1, O. Ovsyannikova1, V.A. Nasonova Research Institute of Rheumatology, laboratory of systemic sclerosis, Moscow, Russian Federation

Background: Systemic Sclerosis-polymyositis/dermatomyositis overlap syndrome (SSc-PM/DM) occurs in 10 to 37% of cases and has great differential diagnostic difficulties. Muscle damage in SSc-PM/DM is represented by myositis with primary inflammatory and necrotic alterations in muscle fibers by type of PM/DM.

Objectives: To evaluate joint and muscle damage in patients with SSc-PM/DM.

Methods: 112 pts had idiopathic inflammatory myopathies, of which 73 pts with SSc-PM/DM (51 pts with iSSc and 22 pts with dSSc, male/female 24/49, mean age 44±15.5 years, average disease’s duration 7 (2-9) years) had the standard clinical examination, intramuscular electromography (IM-EMG) and manual muscle testing (MMT-B).

Results: All pts had polyarthralgia, 40% pts - arthritis. Damage to periartricular tissues with the formation of flexion contractures was observed in 70% pts, of which 16% - contractures of large joints (knee and elbow), X-ray changes in the hands and feet (distal osteoporosis, narrowing of the joint spaces, and smoothness of the phalangettes) were observed in all pts, 13% of pts had erosions associated with osteoarthritis. There was noticed significantly frequent development of flexion contractures in pts with dSSc (p<0.05) and high skin score (p<0.05). Osteolysis peculiar to SSc was detected in 23.5% of pts, and soft tissue calcinosis in the area of the phalangettes, and metacarpophalangeal joints – in 32% pts. Califications, specifically associated with PM/DM, in the soft tissues of the shoulder and pelvic girdle, large joints were revealed in 6% pts. A direct correlation was revealed between the duration of the disease and the development of calcinosis and osteolysis (p<0.05). Myalgia and proximal muscle weakness was in all pts, dysphagia – in 43% pts, and dysphonia – in 19% pts. Patients with a moderate degree of muscle weakness (MMT-8 76-115 points) prevailed and topped 41% and patients with severe disabling functional disorders (MMT-B ≤75 points) showed 37%, of which 4% of pts were completely immobilized. In 18% of pts, PM was detected during physical and/or laboratory examination (MMT-B ≥116 points). Analysis of IM-EMG of changes confirmed the presence of primary muscle inflammatory process (all patients had a decrease in motor unit action potential (MUAP) and spontaneous activity, polyphasia – in 93% of pts. A correlation was observed with laboratory and immunological signs of disease activity: between ESR and spontaneous activity (p<0.02), CPK titers and polyphasia (p<0.01), the presence of a-Pm-Scl and a decrease in MUAP (p<0.03).

Conclusion: Muscular syndrome in SSc-PM/DM has clear clinical symptoms, and the underlying symptom of involvement is sharp muscle weakness with movement disorders intrinsic to PM/DM. However, such disorders do not lead to complete immobility, as in PM/DM, and they are combined with other manifestations of SSc.Articular syndrome in pts with SSc-PM/DM is mainly represented by periartricular changes, in some pts with osteolysis and calcinosis common to SSc.

Disclosure of Interests: None declared
AB0734  THE DYNAMICS OF LUNG FUNCTION IN PATIENTS WITH SYSTEMIC SCLERODERMA ASSOCIATED WITH INTERSTITIAL LUNG DISEASE DURING A THREE-YEAR FOLLOW-UP PERIOD.

M. Starovoytova1, O. Desinova1, L. P. Ananyeva1, R. Shayakhmetova1, A. Khelkovskaia-Sergeeva1, O. Ovsyannikova1, R. Shayakhmetova1, A. Khelkovskaia-Sergeeva1.

Background: Nowadays ILD is one of the most common manifestations of SSC and the leading cause of death of patients. 25% to 30% of patients develop progressive ILD.

Objectives: To assess the course and outcomes of interstitial lung disease (ILD) in systemic sclerosis (SSc) based on lung function after three years of follow-up.

Methods: The study included 82 patients with SSc associated with ILD. There were 70 (85%) women and 12 (15%) men, whose average age was 49.86±12.30 years, 49 (60%) patients with limited SSc, 24 (29%) patients with diffuse SSD, 7 (9%) patients with overlap syndrome; median disease duration was 7 (4;11) years. The great majority of patients had a chronic course of the disease. The patients had systemic manifestations, vascular disorders and lesions of the muscular-skeletal system. According to the results of CT scan of the thoracic organs, 28% of patients had more than 20% of pulmonary involvement. All patients took glucocorticoids (GC); the average dose of prednisone was 8.6±4.6mg. 50 (61%) patients took immunosuppressants (IS).

The diagnosis was set according to ACR/EULAR criteria. The patients were examined twice in accordance with generally accepted approaches. To identify and assess the dynamics of ILD, there was used high-resolution computed tomography (HRCT). Their lung function was assessed by data obtained due to spirometry (in particular, forced vital capacity, FVC) and diffusing capacity of the lungs (DCL); Doppler echocardiography was also conducted.

Results: In the group of patients with SSc, a significant improvement was noticed in some indicators demonstrating the peculiar manifestations of the disease. Therefore, skin induration (a decrease in skin score) decreased from the initial 5.8±5.2 to an average of 4.6±4.9 points after three years, p=0.0001. Functional capacities of the lungs and heart did not deteriorate. There was a trend towards an increase in FVC by 5.7% (from 91.8±19.1 to 96.15±18.26, respectively). However, these data were not clinically significant. Systolic pulmonary artery pressure (sPAP) also remained stable, mm Hg (31.83±8.10 and 33.57±5.03, respectively), indirectly indicating the absence of progression in pulmonary involvement. These positive alterations were the basis for reducing the daily dose of GCs in some patients. The reduction in dose of GCs was small but statistically significant (8.64±4.58 and 7.86±3.33, respectively, p=0.007).

Conclusion: Therefore, due to the study, stabilization of lung function and the absence of progression in the SSc-ILD group were noticed, which emphasizes the importance of continuous monitoring and follow-up of patients and continuous therapy.

Disclosure of Interests: None declared


AB0735  INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC CONNECTIVE TISSUE DISEASES: DYNAMICS OF LUNG FUNCTION AFTER THREE YEARS OF FOLLOW-UP.

M. Starovoytova1, O. Desinova1, L. P. Ananyeva1, R. Shayakhmetova1, A. Khelkovskaia-Sergeeva1, O. Koneva1, L. Garzanova1, O. Ovsyannikova1.

Background: Interstitial lung disease (ILD) is one of the most common and severe manifestations of connective tissue diseases, such as systemic scleroderma (SSc), dermatos- and polymyositis (DM/PM), mixed connective tissue disease (MCTD), etc.

Objectives: To compare the course and outcomes of ILD in SSc, MCTD and DM/PM, immunoinflammatory myopathies (IMM) after three years of follow-up.

Methods: The SSc group consisted of 82 patients, the IMM group – 61 patients, and the MCTD group – 50 patients. In all the studied groups, women predominated. The oldest patients were found in the IMM group, and the average age was 51±12.88 years. The duration of the disease varied from 0.5 to 18.5 years. A longer course of the disease was observed among patients with MCTD, the median was 10.6 (6.9; 18.5) years. When assessing the initial parameters of lung function tests, significantly lower values of FVC and DCL were recorded in the IMM group (average 5.7 [IQR 3.2-9.2] and 515±18±2, respectively), and higher values in the MCTD group (95.4±20 and 675±15). All patients took GCs, the highest doses were taken by patients with IMM. The great majority of patients received immunosuppressants, of which 100% of patients were in the MCTD group.

Results: Despite the fact that the indices of FVC and DCL in the SSc group were initially lower (on average 91.8±19.1 and 59.2±19.5, respectively) than in the MCTD group. The dynamics of FVC over three years against the background of continuous immunosuppressants therapy was discordant: in SSc, the DCL decreased significantly (p=0.015). In the IMM group, the FVC decreased significantly (p<0.0001). In the MCTD group, the DCL decreased significantly (p<0.0001). In the IMM group, the FVC decreased significantly (p<0.0001).

Conclusion: In the present study we have been able to evidence that there is a statistically significant relationship between the percentage of RDW and the presence of PID. When analysing the association between patients without pulmon-ary compromise, ILD and PAH and the percentage of RDW, we were able to find a statistically significant difference between the three groups. It is necessary to continue with studies with a larger number of patients to grant robustness to the results.

REFERENCES:
Case reports of women with silicone breast implants who developed SSc have been published, but case-control and prospective studies in connective tissue diseases often failed to find an increased risk of SSc associated with silicone cosmetic surgery (2,3). These studies have several limitations, including heterogenous cohorts of enrolled patients not selective for SSc, non-homogeneous disease duration at study entry and the possibility that the disease is not triggered but rather is accelerated by the implant (4).

Objective: Retrospective study of SSc patients, to find out who developed SSc after silicone cosmetic surgery.

Methods: The clinical files of 140 female patients with systemic sclerosis were retrospectively evaluated and clinical data collected.

Results: Five patients showing a history of silicone cosmetic surgery (3.6%) before SSc development were identified. The brief clinical histories of the five patients are below reported, showing very similar outcomes after silicone implant.

1. TC 47-year-old female underwent cosmetic breast prosthesis: twelve months later she experienced Raynaud’s phenomenon (RP) and diffuse cutaneous SSc after 10 further months; antinuclear antibodies were positive with a speckled and nuclear pattern, but specific SSc-related autoantibodies were negative. 2. LS 28-year-old female underwent cosmetic breast prosthesis: twenty-two months later RP appeared and antinuclear antibodies (ACA) positive aggressive diffuse SSc was diagnosed one year later. 3. PJ 38-year-old female underwent cosmetic breast prosthesis: eleven months later she experienced RP and after 10 further months, aggressive diffuse cutaneous SSc; antinuclear antibodies were positive with a speckled pattern, but specific SSc-related autoantibodies were negative. 4. CM 58-year-old female who underwent cosmetic lip prosthesis: one year later she complained of simultaneous onset of RP and very aggressive diffuse cutaneous SSc with anti-topoisomerase positivity; she died during follow-up. 5. BS 33-year-old female who underwent cosmetic breast prosthesis: twenty months later she complained of RP and after ten further months, limited cutaneous SSc with ACA positivity; SSc clinical condition partially improved and its progression stopped after prosthesis removal. Globally, after silicone implant, RP occurred in a mean time of 15±5 months and SSc in 23±8 months.

Conclusion: This study reports a prevalence of 3.6% of silicone cosmetic surgery before SSc onset, interestingly with a close and similar temporal association between silicone implant and disease development. This finding suggests a possible role of silicone in SSc pathogenesis (ASIA syndrome). Specifically addressed large clinical studies or big-data studies need to rule out this matter.

REFERENCES:
[5] Marozio Cutolo Grant/research support from: Bristol-Myers Squibb, Celgene, Pfizer, Boehringer-Ingelheim

Disclosure of Interests: None declared

INTERSTITIAL LUNG DISEASE SYSTEMIC SCLEROSIS: AN EAST-EUROPEAN EUSTAR CENTER EXPERIENCE

D. M. Aronc1, C. Ancuta12, on behalf of EUSTAR. 1Rehabilitation Clinical Hospital IASI, Rheumatology, Iasi, Romania; 2Grigore T. Popa University of Medicine and Pharmacy of Iasi, Rheumatology, Iasi, Romania

Disclaimer of Interests: None declared.

Disclosure of Interests: None declared.

REFERENCES:


BACKGROUND:
Systemic sclerosis (SSc) is a complex autoimmune connective tissue disorder defined by multifaceted visceral involvement. Still considered the leading cause of morbidity and mortality, SSc-interstitial lung disease remains one of the most common complications of SSc that involves vascular, immunological, and fibrotic processes.

OBJECTIVES: We aimed to assess the relationship between demographic, clinical features and risk factors for the development of lung fibrosis in patients with SSc as well as the specific management.

METHODS: We performed a retrospective observational study in a series of 41 patients with SSc-ILD followed-up in a medical center: a large surgical center (Department of Rheumatology 2, Clinical Rehabilitation Hospital, Iasi, Romania). We analyzed the frequency of known risk factors associated with progressive interstitial lung disease such as diffuse cutaneous SSc, male sex, presence of anti-topoisomerase I and absence of anti-centremerase antibodies as well as risk factors for mortality in SSc-ILD including older age, male sex, extent of disease on high-resolution computed tomography (HRCT), lower pulmonary function tests (PFTs), lower diffusion capacity of the lung for carbon monoxide (DLCO), dyspnea, VELCRO crackles, and fibrosis progression in pulmonary involvement. These positive alterations were the basis for reducing the daily dose of GCs in some patients. The reduction in dose of GCs led to clinical benefit in all patients (31.4±4.5 and 32.8±5.2, respectively), indirectly indicating the absence of progression in pulmonary involvement. These positive alterations were the basis for reducing the daily dose of GCs in some patients. The reduction in dose of GCs led to clinical benefit in all patients (31.4±4.5 and 32.8±5.2, respectively), indirectly indicating the absence of progression in pulmonary involvement.

RESULTS: The study included 35 females, 10 males, with the mean age of 55.5±5.5 years. The diagnosis of interstitial lung disease was based on HRCT findings (bipolar glassy ground opacities, crazy-paving pattern, nodules, honeycombing and traction bronchiectasis, mosaic pattern, air trapping, pulmonary artery and lymph node enlargement). Symptoms of the ILD (dry cough, different stages of dyspnea, VELCRO crackles) were reported in 14 cases (25.45%). Furthermore, 25 patients had a significant decline in PFTs and DLCO, being associated with extensive pulmonary fibrosis on HRCT (p<0.05%). Almost all patients with SSc-ILD had diffuse cutaneous involvement and anti-Scl-70 antibodies positivity. Despite identifying a higher percentage of women with ILD (39/45, 63.63%), the extent and progression of pulmonary fibrosis was more significant in males. The treatment for SSc-ILD with ongoing evidence of disease progression based on PFT decline or radiographic deterioration has focused on immunosuppressive therapies, particularly cyclophosphamide and only in selected cases on antifibrotic agents.

ConCLUSION: It is important to identify the risk factors for developing ILD, in order to complete the diagnostic and staging parameters early so that the treatment can be initiated as soon as possible in progressive pattern. Our data showed that the extent of pulmonary fibrosis in HRCT was associated with low values of PFTs and DLCO, and men had a more severe prognostic than women. ILD-SSc was more frequent in patients with diffuse cutaneous involvement than limited cutaneous subtype, and in those with anti-Scl-70 positivity.

AB0741 LUNG FUNCTIONS IN IDIOPATHIC INFLAMMATORY MYOPATHIES PATIENTS WITH INTERSTITIAL LUNG DISEASE DURING ≥3 YEAR OF FOLLOW-UP.

A. Khelkova-Sergeeva1, L. Garzanova1, M. Staroytova1, O. Desinova1, L. P. Ananyeva1, O. Koneva1, 1VA. Nasonova Research Institute of Rheumatology, laboratory of systemic sclerosis, Moscow, Russian Federation

Background: Intestinal lung disease (ILD) is the most common internal organ manifestation of idiopathic inflammatory myopathies (IIM) that can severely affect the course of the disease.

Objectives: To describe lung functions in IIM patients with ILD during ≥3 year of follow-up.

Methods: Our prospective study included 44 pts with IIM fulfilling Bohan and Peter criteria and having ILD. The mean follow-up period was 46.2±11.2 months. The mean age was 52.3±11.7 years, 34 (73.3%) pts were female. The median disease duration was 1.125 [0.16-18] years, 24 (54%) of pts were positive for a-Jo-1 antibody. All pts had the standard examination including anti-Jo-1 antibodies (anti-Jo-1) assay; forced vital capacity (FVC) and carbon monoxide diffusion capacity (DLCO) evaluation as well as high-resolution computed tomography (HRCT) scanning of the chest were performed at baseline, and 36 and more months.

Results: 61% with antisyntetase syndrome, 17% dermatomyositis (DM), 5% amyopathic DM, 15% with overlap myositis and 2 % with necrotizing myopathy were included. 70% patients had nonspecific interstitial pneumonia, 23% organizing pneumonia (OP) and 7% OP; transformed to diffuse alveolar damage. All pts received prednisolone at a dose of 11.8±4.1 mg/day. Immunosuppressants at inclusion received 75% pts: cyclophosphamide, 54%, mycophenolate mofetil 16.9% and combination 4.54%; Rituximab was administered in case of intolerance or inadequate response to GC and other immunosuppressive drugs in 37 pts (84%)-18 courses, 7 patients died, ILD progression was the cause of death in 4 cases.

Table 1. Changes of the main parameters at the baseline and in 3 years

<table>
<thead>
<tr>
<th>parameters</th>
<th>pts</th>
<th>baseline</th>
<th>in ≥3 years</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>a-Jo-1</td>
<td>23</td>
<td>17.7±7.1</td>
<td>90.5±76.7</td>
<td>0.000003</td>
</tr>
<tr>
<td>FVC</td>
<td>37</td>
<td>83.3±21.7</td>
<td>96.3±21</td>
<td>0.0001</td>
</tr>
<tr>
<td>DLCO %</td>
<td>37</td>
<td>52.4±14.9</td>
<td>60.8±17.3</td>
<td>0.001</td>
</tr>
<tr>
<td>Prednison, mg/day</td>
<td>37</td>
<td>23.0±12.8</td>
<td>5.9±2.3</td>
<td>0.00000001</td>
</tr>
</tbody>
</table>

Conclusion: Active immunosuppressive therapy improves lung function in IIM patients. However, some forms of ILD have a fatal course.

Disclosure of Interests: None declared.


AB0742 THE DYNAMICS OF LUNG FUNCTION IN PATIENTS WITH MIXED CONNECTIVE TISSUE DISEASE ASSOCIATED WITH INTERSTITIAL LUNG DISEASE DURING A THREE-YEAR FOLLOW-UP PERIOD

R. Shayakhmetova1, L. P. Ananyeva1, O. Koneva1, M. Staroytova1, O. Desinova1, O. Ovsyannikova1, L. Garzanova1, A. Khelkova-Sergeeva1, 1VA. Nasonova Research Institute of Rheumatology, laboratory of systemic sclerosis, Moscow, Russian Federation

Background: Nowadays ILD is one of the most common manifestations of systemic rheumatic diseases and one of the leading cause of death of patients.

Objectives: To assess the course and outcomes of interstitial lung disease (ILD) in mixed connective tissue disease (MCTD) based on lung function after three years of follow-up.

Methods: The study included 20 patients with MCTD associated with ILD. The diagnosis was set according to Kasukawa criteria (1987). There were 19 (95%) women and 1 (5%) men; average age was 44.73±15.26 years; mean disease duration was 13.7±6 years; and 3 (15%) pts had anti-extra cellular matrix antibodies (ECMAs) and immunosuppressants (IS); the average dose of prednisone was 10.2±5mg. To identify and assess the dynamics of ILD, there was used high-resolution computed tomography (HRCT). Their lung function was assessed by data obtained due to spirometry (in particular, forced vital capacity, FVC) and diffusion capacity of the lungs (DCL); Doppler echocardiography was also conducted.

Results: In the group of patients with MCTD there was a chronic course of the disease with a gradual addition of symptoms, musculoskeletal pathology preceded by a decrease in clinical manifestations of the lungs and heart did not deteriorate. After three-year follow-up period there was a decrease in clinical manifestations (arthritis, myositis, proximal muscle weakness). Functional capacities of the lungs and heart did not deteriorate. DCL remained stable 67.5±15 and 66.6±13.8, respectively. Systolic pulmonary artery pressure also remained stable (31.4±4.5 and 32.6±5.2, respectively), indirectly indicating the absence of progression in pulmonary involvement. The positive alterations were the basis for reducing the daily dose of GCs in some patients. The reduction in dose of GCs was small but statistically significant (8.6±4.5 and 78.6±3.33, respectively, p=0.007). There was a trend towards a decrease in dose of prednisone (from 10.2±5 to 8.4±5, respectively). However, these data were not clinically significant.

Disclosure of Interests: None declared.


Scientific Abstracts
Background: Systemic Sclerosis (SSc) is a rare inflammatory disease of unknown etiology associated with multi-organ involvement. Biomarkers remain urgently needed as tools for differential diagnosis, prognosis, disease progression, and as therapeutic response predictors in SSc. Ideally, for widespread utility, biomarkers should be easy to sample and analyse.

Objectives: We aimed at evaluating potentially pathogenic circulating key cytokines/chemokines in a monocentric cohort of SSC patients.

Methods: Sera were drawn from SSC patients and 23 cytokines/chemokines (CCL/CDR-1, IP-10/CCL10, IL-10, IL-17, IL-21, IL-22, IL-23, IL-3, IL-17A, TNFalpha, IL-1beta, CXCL13, IL-22, IL-23, IL-33, TSLP IL-9/2, IL-1RII, TNFRII, BAFF, CCL19, MIP-3B, MMP-8) were quantitated using Luminex multiplex immun assay (Bio-Rad Bio-Plex 200 System-Luminex xMap technology R&D Systems, USA) following the manufacturer's instructions and customized procedures. Data were acquired using Bioplex manager v 6.1. P value ≤ 0.05 was considered to be significant. Data were analysed using GraphPad Prism V.8 (GraphPad Software, Inc.) software.

Results: Clinical and demographic features of 17 SSc (5 dcSSc, 12 lcSSc) patients are reported in Table 1. Mean±SD age was 55±14.68 years, mean±SD disease duration was 89.47±93.34 months. We found that MCP-1 levels inversely correlated with PAPs (r=-0.55, P=0.03) and IP10 with anti-Scl70 (r=-0.561, P=0.004), Figure 1. No other associations were found

Table 1.

<table>
<thead>
<tr>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex 2M/15F</td>
<td>11/88.83</td>
</tr>
<tr>
<td>Age years, mean±SD</td>
<td>55±14.68</td>
</tr>
<tr>
<td>Disease duration (months, mean±SD)</td>
<td>89.47±93.34</td>
</tr>
<tr>
<td>Cigarette smoke</td>
<td>8 47</td>
</tr>
<tr>
<td>Reynaud's phenomenon</td>
<td>17 100</td>
</tr>
<tr>
<td>Skin thickening</td>
<td>14 82.4</td>
</tr>
<tr>
<td>Ulcers</td>
<td>2 11.8</td>
</tr>
<tr>
<td>Rodman's Skin Score (mean±SD)</td>
<td>5.9±6.6</td>
</tr>
<tr>
<td>Articular involvement</td>
<td>2 11.8</td>
</tr>
<tr>
<td>Heart involvement</td>
<td>0 0</td>
</tr>
<tr>
<td>Paps max (mmh, mean±SD)</td>
<td>28.3±5.9</td>
</tr>
<tr>
<td>Pulmonary involvement</td>
<td>0 29.4</td>
</tr>
<tr>
<td>DLCO min (% mean±SD)</td>
<td>90.2±21.2</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td>3 17.6</td>
</tr>
<tr>
<td>ANA</td>
<td>17 100</td>
</tr>
<tr>
<td>Rheumatoid factor</td>
<td>4 23.5</td>
</tr>
<tr>
<td>Anti-Scl70 U/ml, mean±SD</td>
<td>33.2±59.3</td>
</tr>
<tr>
<td>Anti-CENP(U/ml, mean±SD)</td>
<td>55.9±48.9</td>
</tr>
<tr>
<td>Anti-SAA</td>
<td>2 11.8</td>
</tr>
<tr>
<td>Anti-SSB</td>
<td>1 5.9</td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>1 5.9</td>
</tr>
<tr>
<td>Anti-RNP</td>
<td>1 5.9</td>
</tr>
<tr>
<td>Elevated Blood Pressure</td>
<td>4 23.5</td>
</tr>
<tr>
<td>Obesity</td>
<td>1 5.8</td>
</tr>
<tr>
<td>Any DMDAR</td>
<td>5 29.4</td>
</tr>
</tbody>
</table>

Conclusion: We confirm a potential pathogenic role for MCP-1 in SSC. The 2518 promoter polymorphism in the MCP-1 gene has been already associated with disease susceptibility and an increased expression of the molecule both in peripheral blood and in the skin has been described. Intriguingly, MCP-1 seems to drive fibroblasts - can represent a promising biomarker for SSC diagnosis.

REFERENCES:

Figure 1. Disclosure of Interests: None declared DOI: 10.1136/annrheumdis-2022-eular.5061
REFERENCES:

Disclosure of Interests: None declared.

SYMPTOMS OF GASTROINTESTINAL DISORDERS IN SYSTEMIC SCLEROSIS PATIENTS WITH DIFFERENT DISEASE SUBTYPES AND ANTIBODIES

M. Vujovic1, P. Ostojic1,2. Institute of Rheumatology, Rheumatology, Belgrade, Serbia; 1School of Medicine, University of Belgrade, Belgrade, Serbia

Background: Gastrointestinal tract is the second most commonly affected organ system in approximately 90% of patients with systemic sclerosis (SSc) and has a negative impact on health-related quality of life (1, 2).

Objectives: This study aims to analyze frequency and severity of gastrointestinal symptoms, their impact on social functioning and emotional wellbeing and compare results among patients with limited cutaneous (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc), as well as in patients with anti-centromere antibodies (ACA) and anti-topoisomerase I antibodies (ATA).

Methods: 62 patients with SSc were included in this study, 31 of them with lcSSc and 11 patients with dcSSc. ACA were detected in 26, and ATA in 16 patients. The UCLA-SCTC-GIT 2.0 self-assessment questionnaire (3, 4) was used to assess presence and severity of gastrointestinal symptoms in our patients. It consists of seven scales: reflux, distension/bloating, diarrhea, fecal soilage, constipation, social functioning and emotional wellbeing.

Results: There was no difference in percentage of patients with lcSSc and dcSSc who used proton pump inhibitors (27.27%: 32.25%), as well as in patients with ACA and ATA (34.61%: 25%). Symptoms of gastroesophageal reflux (lcSSc: dcSSc = 64.5%: 81.8%), distension/bloating (lcSSc: dcSSc = 61.3%: 81.8%), constipation (lcSSc: dcSSc = 45.2%: 45.5%) and fecal soilage (lcSSc: dcSSc = 6.4%: 18.2%) were found equally frequent (p>0.05) in patients with lcSSc and dcSSc. However, symptoms of diarrhea were found significantly more frequent in patients with dcSSc (lcSSc: dcSSc = 16.1%: 45.5%, p=0.04). The mean index value for diarrhea was significantly higher in patients with dcSSc (dcSSc: lcSSc = 0.45: 0.11, p=0.02), indicating more severe symptoms in diffuse form of disease. We did not notice a significant difference in frequency or severity of gastrointestinal symptoms in patients with ACA and ATA. Mean index values of social functioning and emotional wellbeing did not differ significantly in patients with lcSSc and dcSSc, as well as in patients with ACA and ATA.

Conclusion: Unlike other gastrointestinal manifestations, diarrhea is significantly more common and more severe in patients with dcSSc. No significant difference in frequency and severity of gastrointestinal symptoms was found in patients with ACA and ATA. Impact of gastrointestinal tract symptoms on social functioning and emotional wellbeing was similar in both forms of disease and antibodies.

REFERENCES:

Disclosure of Interests: None declared.

MALIGNANCY IN DERMATOMYOSITIS

I. Naceur1, I. Arbaoui1, T. Ben Achour1, M. Khanfir1, I. Ben Ghorbel1, M. Vujovic1, P. Ostojic1,2.

Background: The concept of core-microbiome in health is useful for investigating the possible role of the oral microbiome in autoimmune disease, such as Rheumatoid Arthritis, Spondyloarthritis, Sjogren Syndrome or Systemic Sclerosis (SSc), whose pathogenesis has not been fully understood. Environmental factors and certain genetic backgrounds have been proposed. Among the various environmental factors, the microbiota stands out, the entire composition of microorganisms, mainly bacteria but also fungi and viruses, which populate the human body.

Objectives: The aim of the study was to verify whether there were quantitative differences between the microorganisms present in the oral cavity, in particular between the lactobacillus spp., of patients with SSc compared to those present in the oral cavity of healthy subjects taken as controls.

Methods: Twenty-nine SSc female patients (mean age 62.) classified according to the ACR/EULAR2010 criteria and twenty-three female healthy subjects (HS, mean age 57) were enrolled and underwent tongue and gum swab sampling. Quantitative PCR was conducted in triplicates using Lactobacillus specific primers rpOB1, rpOB1o and rpOB2 for RNA-polymerase β subunit gene.

Results: Our data showed Lactobacillus spp.rpOB sequences significantly lower in the tongue of SSc patients than in HS (p<0.001). The statistical analysis in HS highlighted a significant lower amount of rpOB on the gums than on the tongue.

Conclusion: Our preliminary data show that the number of Lactobacillus on the tongue in SSc patients is about half that of HS. These data make it more likely that Lactobacillus in SSc patients may play a protective role. Further investigations will also be needed in other autoimmune diseases.

REFERENCES:

Disclosure of Interests: None declared.
Table 1: Characteristics of SSc-ILD Patients Receiving Nintedanib

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Females</strong></td>
<td>12 (80)</td>
</tr>
<tr>
<td><strong>Clinical Characteristics</strong></td>
<td></td>
</tr>
<tr>
<td>Diffuse Cutaneous SSc</td>
<td>13 (86.7)</td>
</tr>
<tr>
<td>Limited Cutaneous SSc</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Synovitis</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Digital ulcers</td>
<td>8 (53.3)</td>
</tr>
<tr>
<td>Pulmonary arterial pressure &gt;30 mmHg (echo)</td>
<td>5 (20)</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td>10 (76.9)</td>
</tr>
<tr>
<td><strong>Serology</strong></td>
<td></td>
</tr>
<tr>
<td>ANA</td>
<td>1 (6.7)</td>
</tr>
<tr>
<td>Anti-Scl70</td>
<td>10 (66.7)</td>
</tr>
<tr>
<td><strong>Immunosuppressives</strong></td>
<td></td>
</tr>
<tr>
<td>CYC</td>
<td>8 (53.3)</td>
</tr>
<tr>
<td>MMF</td>
<td>14 (93.3)</td>
</tr>
<tr>
<td>AZA</td>
<td>7 (46.7)</td>
</tr>
<tr>
<td>MTX</td>
<td>6 (40)</td>
</tr>
<tr>
<td>RTX</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Low dose steroids</td>
<td>15 (100)</td>
</tr>
</tbody>
</table>

Table 2: Advers Events during Nintedanib Treatment in SSc-ILD patients

<table>
<thead>
<tr>
<th>SSc-ILD (n=15)</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any advers events n(%)</td>
<td>8 (53.3)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Weight decrease</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Yorungul</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Cough</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Infections (pneumonia)</td>
<td>3 (20)</td>
</tr>
<tr>
<td>Liver test abnormalities</td>
<td>6 (20)</td>
</tr>
<tr>
<td>Malignancy</td>
<td>1 (71)</td>
</tr>
<tr>
<td>Dose reduction and resection</td>
<td>7 (46.7)</td>
</tr>
<tr>
<td>Dose interruption</td>
<td>2 (13.3)</td>
</tr>
</tbody>
</table>

Conclusion: Nintedanib was prescribed in progressive SSc-ILD patients who had predominately diffuse cutaneous involvement, anti-SCL70 positivity and exposed to multiple standard ISs. Duration of ISs were higher than 5 years before antifibrotic therapy. Gastrointestinal (GI) adverse events were frequent during nintedanib requiring dose reduction in half of the patients. Nintedanib can be used in progressive SSc-ILD patients considering some difficulties in such a disease with GI involvement. Efficacy analysis of the antifibrotic therapy needs further studies including long term follow-up.

Disclosure of Interests: None declared

**Spondyloarthritis -**

**AB0750**

**BACK PAIN AND MORNING STIFFNESS AS MEDIATORS OF TOFACITINIB TREATMENT EFFECT ON FATIGUE IN PATIENTS WITH ANKYLosing SPONDYLITIS: A MEDIATION ANALYSIS**

L. E. Kristensen1, P. C. Taylor2, V. Navarro-Compán3, M. Magrey4, J. C. Cappelleri7, A. G. Bushmakin5, A. Yndestad6, O. Dina1, 1Copenhagen University Hospital, Bispebjerg and Frederiksberg; The Parker Institute, Copenhagen, Denmark; 2University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 3University Hospital La Paz, IdiPaz, Madrid, Spain; 4Case Western Reserve University, Division of Rheumatology, Cleveland, OH, United States of America; 5Pfizer Inc, Inflammation and Immunology, Groton, CT United States of America; 6Pfizer Inc, Inflammation and Immunology, Oslo, Norway; 7Pfizer Inc, Inflammation and Immunology, New York, NY, United States of America

**Background:** Fatigue is a prevalent symptom of ankylosing spondylitis (AS)1 and can contribute to higher levels of disease, disability and poor health-related quality of life.2 Back pain and morning stiffness are also commonly reported symptoms.3 Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients (pts) with AS. In randomised studies, pts with active AS treated with tofacitinib experienced greater improvements in fatigue, back pain and morning stiffness at Week 12 and 16 of treatment compared with placebo (PBO).4,5 Treatment of these symptoms is a priority for pts with AS and their healthcare providers, however, the mechanisms underlying the interrelationships between fatigue, back pain, morning stiffness and treatment are unclear.

**Objectives:** To describe the interrelationships between fatigue, back pain, morning stiffness and tofacitinib treatment in pts with AS, using mediation modelling.

**Methods:** Data from Phase 2 (NCT01786668)6 and Phase 3 (NCT03502616)7 studies of pts with active AS treated with tofacitinib 5mg twice daily (BID) or PBO were used. Mediation modelling, a statistical method to assess the extent to which the effect of an independent variable on a dependent variable is indirect, via identified mediators, or direct, capturing all other (unmeasured) effects, was applied.6,7 The initial model included: treatment as the independent binary variable (tofacitinib 5mg BID vs PBO); fatigue (measured by Functional Assessment of Chronic Illness Therapy-Fatigue) as the dependent variable; mediators included back pain (measured by total back pain/nocturnal spinal pain [numerical rating scale, 0–10]) and morning stiffness (represented by the mean of Bath Ankylosing Spondylitis Disease Activity Index questions 5 and 6).

**Results:** Pooled data from 370 pts were included in the analysis. The initial model showed that 37.5% (p<0.001) of the tofacitinib treatment effect on fatigue was mediated via back pain and morning stiffness (indirect effect); mediation via morning stiffness alone was 49.7% (p<0.01), and 21.2% (p=0.02) via back pain alone. The effect of treatment attributable to factors other than back pain and morning stiffness (ie, direct effect) was not statistically significant (-28.4%; p=0.33). As a result, the initial model was re-specified to exclude the direct treatment effect on fatigue. In the re-specified model (Figure 1), 44.0% (p<0.0001) of the indirect effect of tofacitinib on fatigue was mediated via back pain and morning stiffness; mediation via morning stiffness alone was 40.0% (p<0.001), and 16.0% (p<0.01) via back pain alone. Analyses of the individual study data gave results generally consistent with those from the pooled data.

**Conclusion:** Overall, indirect pathways via morning stiffness accounted for >16% of the effect of tofacitinib treatment on fatigue: (1) treatment affects morning stiffness, which impacts fatigue; and (2) treatment affects morning stiffness, which affects back pain and, ultimately, back pain affects fatigue. The indirect pathway via back pain alone accounted for ~16% of treatment effect on fatigue. These results suggest that in tofacitinib-treated pts with AS, improvements in fatigue are mediated through combined treatment effects on morning stiffness and back pain.

**REFERENCES:**


**Acknowledgements:** Study sponsored by Pfizer Inc. Medical writing support was provided by Robyn Wilson, CMC Connect, and funded by Pfizer Inc.


**DOI:** 10.1136/annrheumdis-2022-eular.28

**AB0751**

**HOW DOES BODY MASS INDEX AFFECT SECUKINUMAB TREATMENT OUTCOMES AND SAFETY IN PATIENTS WITH ANKYLosing SPONDYLITIS? – REAL WORLD DATA FROM THE GERMAN AQUILA STUDY**

U. Kiltz1, J. Brandt-Juergens2, P. Klotzen3, E. Riechers4, D. Peterlik5, C. Bueden6, H. P. Tony7 on behalf of on behalf of the AQUILA Study Group. 1Rheumazentrum Ruhrgebiet, Heine and Ruhr-Universität Bochum, Heine, Germany; 2Rheumatologie, Schwerpunktpraxis, Berlin, Germany; 3Ambulantes Rheumazentrum, Medizinisches Versorgungszentrum, Erfurt, Germany; 4Medizinische Hochschule Hannover, Hannover, Germany; 5Novartis Pharma GmbH, Immunologie, Hepatologie & Dermatologie, Nürnberg, Germany; 6Novartis Pharma GmbH, Immunologie, Hepatologie & Dermatologie, Nürnberg, Germany; 7Medizinische Klinik II - Rheumatologie/Immunologie, Universitätsklinikum Würzburg, Würzburg, Germany

**Background:** Obesity is a risk factor for worse overall health in people with ankylosing spondylitis (AS)1. The German non-interventional study AQUILA provides real-world data in AS on the influence of body mass index (BMI) on therapeutic effectiveness and safety under treatment with secukinumab, a fully human monoclonal antibody that selectively inhibits IL-17A.

**Objectives:** The aims of this interim analysis are to describe selected baseline (BL) demographics and to evaluate secukinumab treatment outcomes on disease activity and global functioning and health and to report safety profile depending on the BMI of AS patients (pts).

**Methods:** AQUILA is an ongoing, multi-center, non-interventional study including up to 3000 pts with active AS or psoriatic arthritis. Pts were observed from BL up to 3000 wks according to clinical routine. Real-world data were assessed prospectively and as observed. Validated questionnaires were used to collect data on disease activity (Bath Ankylosing Spondylitis Disease Activity Index, BASDAI) and global functioning and health (Assessment of SpondyloArthritis-Health Index, ASAS-HI).

**Results:** Pooled data from Phase 2 (NCT01786668) and Phase 3 (NCT03502616) studies were analyzed. Treatment is represented by a binary variable (secukinumab 5 mg BID vs placebo). Pain is represented by total back pain due to AS on average during last week and pain at night due to AS on average during last week. AS: ankylosing spondylitis; BID: twice daily.
Mean BASDAI developed similarly over time with lowest scores for normal weight and highest scores for obese AS pts (Table 1). Mean improvement from BL to w52 was 2.1 (28.4%) for normal weight, 1.5 (27.2%) for overweight, and 1.2 (21.8%) for obese AS pts.

**Conclusions:** In a real-world setting, secukinumab improved disease activity and global functioning in all BMI subgroups of AS pts; normal weight pts had numerically better ASAS-HI and BASDAI scores than obese AS pts. Altogether, the occurrence of AEs/SAEs with or without suspected relationship to secukinumab improved disease activity and global functioning in all BMI subgroups of AS pts; normal weight pts had numerically better ASAS-HI and BASDAI scores than obese AS pts. There were no events with fatal outcome or unexpected safety signals in either subgroup.

**References:**

**Disclosure of Interests:** Uta Kiltz Consultant of: AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Gilead, GSK, Grüntenhal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCBe, Grant/research support from: AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Gilead, GSK, Grüntenhal, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCBe, Jan Brandt-Juergens Consultant of: Abbvie, Abbvix, Ambit, BMS, Gilead, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCBe, Peter Kästner Consultant of: Chugai, Novartis, Elke Riechers Consultant of: AbbVie, Chugai, Novartis, UCBe, Grant/research support from: AbbVie, Amgen, Biogen, Chugai, Eli Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCBe, Peter Kästner Consultant of: AbbVie, Astra-Zeneca, BMS, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi

of TNFi therapy may be possible in a real-world setting and if REDOSER tool (3) is an appropriateness criteria for reducing the dose of BT.

**Objectives:** Describe the percentage of patients with inflammatory rheumatic diseases (IRD) who continue with dose reduction of biological therapy (BT). Evaluate relapse in clinical practice after 2 years of follow-up. Identify factors associated with relapse.

**Methods:** Retrospective observational study. Patients with axial spondyloarthritis (axial SpA), psoriatic arthritis (PSA) and rheumatoid arthritis (RA) in BT dose reduction. Inclusion criteria: Axial SpA according to ASAS criteria, PSA according to CASPAR criteria and RA according to ACR2010 criteria, who have started reducing the dose of BT treatment between 2009-2019 at the Hospital Regional Universitario de Málaga, Spain. Protocol: patients with TB are followed prospectively in a monographic consultation with a pre-established protocol. The day of dose reduction = baseline visit (v0). **Variables:** Maintained dose reduction: % of patients who maintained dose reduction from the start of optimization to the index date (data collection). Relapse at 12 and 24 months: % of patients who, after starting dose reduction, returned to the previous or usual dose. Other variables: Demographic, time to diagnosis and evolution of the disease, clinical-analytical: disease activity (DAS28, DAPSA and BASDAI) and physical function (HAQ, BASFI). Previous treatments. Appropriateness criteria for reducing the dose of BT according to REDOSER tool (1): inappropriate, 2. uncertain. Statistical analysis: Descriptive, bivariate, multivariate logistic regression (VD: relapse).

**Results:** One hundred twenty-nine patients with axial SpA, PSA and RA in BT dose reduction were included. The mean time from the start of BT to dose reduction was 38.1 months (16.6-73.1). The mean time in dose optimization was 19.5±15.7 months. At the end of follow-up, 70.2% of the patients (87/pts) achieved a sustained dose reduction. At 12 months and 24 months, 12.4% and 11.6% of patients relapsed, respectively. At the end of follow-up, there were no differences between baseline inflammatory activity and after 24 months in dose reduction measured by the different indexes: DAS28 (1.9±0.7 vs 2.1±1.7, *p*=0.323; DAPSA (5.4±4.9 vs 4.8±4.7, *p*=0.718) and BASDAI (1.5±1.1 vs 1.4±1.3, *p*=0.887). Retrospectively, we evaluated the appropriateness of optimization according to the REDOSER tool (1) at the end of follow-up and it was observed that 85% of patients who maintained the dose reduction had an appropriate REDOSER and 14.5% uncertain and none inappropriate *p*<0.001.

**Conclusion:** Dose reduction of BT in IRD is possible in most patients, maintaining low disease activity or remission at 24 months, compared to baseline. Relapse was associated with a longer evolution time of the IRD, a longer diagnostic delay, a higher inflammatory activity measured by the respective indexes and a uncertain or inappropriate result of the REDOSER tool. This tool can be very useful used prior to the assessment of TB dose reduction

**REFERENCES:**


**Disclosure of Interests:** Sara Manrique Arija Speakers bureau: Abbvie, BMS, Gilead, Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Roche, Viatris, Consultant of: Abbvie, BMS, Gilead/Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UC. Peter Kästner Consultant of: Chugai, Novartis, Elke Riechers Consultant of: Abbvie, Chugai, Novartis, UC. Grant/research support from: Abbvie, Chugai, Novartis, Pfizer, Roche, Sanofi-Aventis, UB. Maria Morales-Águila: None declared, Rocio Redondo: None declared, Maria Morales-Águila: None declared, Jutta Zschocke, Maria Morales-Agüila: None declared, Rocio Redondo: None declared, Natalia Mena-Vázquez: None declared.


**AB0753**

**REAL LIFE DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. UTILITY OF THE REDOSER TOOL**

**S. Manrique Arija**1, A. M. Cabezas-Lucena1, F. Godoy-Navarrete2, M. Morales-Agüila1, R. Redondo1, N. María-Vázquez1. 1UCG of Rheumatology at the Hospital Regional Universitario de Málaga (HRUM), Institute for Biomedical Research in Malaga (IBIMA), Malaga University, 2UCG of Rheumatology Hospital Universitario de Jaén, UCG of Rheumatology, Jaen, Spain

**Background:** The long-term use of standard dosing of TNFi therapy is costly and not without side effects, including infections, tuberculosis and potential malignancies (1,2). Hence, we undertook this study to determine whether dose reduction

**Conclusion:** In a real-world setting, secukinumab improved disease activity and global functioning in both AS and PsA pts. Both, male and female AS pts had a higher treatment response when diagnosed early. Interestingly, delay in diagnosis appeared to be BMI-dependent in female AS pts and PsA pts of both genders. However, in contrast to AS, treatment response of early- and late-diagnosed PsA pts did not differ in the further course.

**REFERENCES:**


**Disclosure of Interests:** Karolina Benesova Speakers bureau: Abbvie, BMS, Gilead, Galapagos, Janssen, Lilly, Medac, MSD, Novartis, Roche, Viatris, Consultant of: Gilead/Galapagos, BMS, Gilead, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UC. Peter Kästner Consultant of: Chugai, Novartis, Elke Riechers Consultant of: Abbvie, Chugai, Novartis, UC. Grant/research support from: Abbvie, Chugai, Novartis, Pfizer, Roche, Sanofi-Aventis, UB. Maria Morales-Águila: None declared, Rocio Redondo: None declared, Maria Morales-Águila: None declared, Jutta Zschocke, Maria Morales-Agüila: None declared, Rocio Redondo: None declared, Natalia Mena-Vázquez: None declared.

DOI: 10.1136/annrheumdis-2022-eular.41
treatments for AS patients (5, 6). Data on disease activity and disease control in AS patients treated in real life settings are limited. **Objectives:** To evaluate the average disease activity status in the study population and assess the percentage of AS patients with a suboptimal treatment response following at least 12 weeks of treatment with TNFi and/or NSAIDs.

**Methods:** INVISIBLE was a real-world evidence study in Germany, Austria and Belgium. Adult patients with confirmed diagnosis of AS for at least 6 months and ongoing treatment with TNFi and/or NSAIDs for at least 12 weeks prior to enrolment were included. Primary data were collected at a single visit and medical history data from available patient files.

**Results:** 474 adult AS patients were included. 67% of patients were male, mean symptom duration 18.2 years. 77% of 696 patients were HLA-B27 positive. Appr. 23% of patients received NSAIDs, 42% received TNFi, 30% received both NSAIDs and TNFi, 5% received other treatment for at least 12 weeks prior to enrolment. Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) scores were 3.4 and 2.2, respectively. Appr. 40% of patients achieved a BASDAI score ≥4 and appr. 50% an ASDAS ≥2.1. Patients with a BASDAI score ≥4 achieved higher scores in most physician and patient reported outcomes. Overall appr. 35% of patients were not satisfied with their current symptom state according to Patient Acceptable Symptom State (PASS). Of patients with a BASDAI score ≥4 appr. 61% were not satisfied according to PASS.

**Conclusion:** Results from the non-interventional study INVISIBLE showed that a high proportion of AS patients receiving NSAIDs and/or TNFi have high disease activity according to BASDAI and ASDAS in real life settings. These results suggest that in some patients, disease control and treatment response are suboptimal under current treatment strategy.

**Table 1.** Demographics and Disease Characteristics

<table>
<thead>
<tr>
<th></th>
<th>Total (N=747)</th>
<th>BASDAI &lt;4 (N=445)</th>
<th>BASDAI ≥4 (N=292)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td>N Result</td>
<td>N Result</td>
<td>N Result</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>746 473.7 (±13.1)</td>
<td>445 46.7 (±13.4)</td>
<td>292 49.6 (±12.9)*</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>746 500 (670)</td>
<td>445 318 (71.5)</td>
<td>292 176 (60.3)</td>
</tr>
<tr>
<td>Age at AS diagnosis in years, mean (SD)</td>
<td>746 37.5 (±12.3)</td>
<td>445 34.1 (±12.0)</td>
<td>292 38.8 (±12.5)*</td>
</tr>
<tr>
<td><strong>Treatment with NSAIDs, n (%)</strong></td>
<td>744 171 (23.0)</td>
<td>445 85 (19.1)</td>
<td>290 85 (29.3)</td>
</tr>
<tr>
<td><strong>Treatment with TNFi, n (%)</strong></td>
<td>744 311 (41.8)</td>
<td>445 208 (46.7)</td>
<td>290 100 (34.5)</td>
</tr>
<tr>
<td><strong>Treatment with NSAIDs and TNFi, n (%)</strong></td>
<td>744 222 (29.8)</td>
<td>445 126 (28.3)</td>
<td>290 92 (31.7)</td>
</tr>
<tr>
<td><strong>Treatment with other, n (%)</strong></td>
<td>744 40 (5.4)</td>
<td>445 26 (5.8)</td>
<td>290 13 (4.5)</td>
</tr>
<tr>
<td><strong>Patient disease activity assessment (VAS 0-100), mean (SD)</strong></td>
<td>735 35.8 (±27.5)</td>
<td>445 20.7 (±27.7)</td>
<td>290 59.1 (±20.7)***</td>
</tr>
<tr>
<td><strong>BASDAI Score, mean (SD)</strong></td>
<td>737 3.4 (±2.3)</td>
<td>445 1.8 (±1.1)</td>
<td>290 5.8 (±1.3)***</td>
</tr>
<tr>
<td><strong>ASDAS Score, mean (SD)</strong></td>
<td>599 2.2 (±1.0)</td>
<td>363 1.7 (±0.6)</td>
<td>236 3.1 (±0.7)***</td>
</tr>
<tr>
<td><strong>ASDAS ≥2, n (%)</strong></td>
<td>599 297 (49.6)</td>
<td>363 73 (20.1)</td>
<td>236 224 (61.3)***</td>
</tr>
<tr>
<td><strong>PASS: current state not satisfactory, n (%)</strong></td>
<td>679 240 (35.3)</td>
<td>445 26 (5.8)</td>
<td>290 13 (4.5)</td>
</tr>
</tbody>
</table>

SD – Standard Deviation; Level of significance: *< 0.05; ** < 0.01 *** < 0.001 (analyses refer to differences between BASDAI <4 and ≥4 and to respective available patient number).

**REFERENCES:** [1]


**Disclosure of Interests:** Jan Brandt-Juergens Consultant of; Abbvie, Abbot, BMS, Gilead, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, UCB, Judit Haschka Speakers bureau; Eli Lilly, Amgen, Consultant of; Eli Lilly, Richard Fisstnerwalder Employee of; Novartis Pharma GmbH, Aurelie Casier Employee of; N.V. Novartis Pharma S.A., Angela Kill Employee of; Novartis Pharma GmbH, Stéphanie Dierckx: None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.594

**AB0756**

FIRST SPANISH STUDY ON THE EFFECTIVENESS OF ULTRASOUND-GUIDED INJECTION OF CORTICOSTEROIDS INTO THE SACROILIAC JOINT OF PATIENTS WITH Spondyloarthritis.

M. A. Ramirez Huargana1, D. Castro-Corredor2, A. E. Plasencia Ezaíne3, M. Paulino Huertas2, R. Arenal Lopez1, J. Anino-Fernández2, C. C. Ramos Rodríguez2 on behalf of REUDOL.

**Background:** Sacroilitis may be the main manifestation or a complication of any of the variants of spondyloarthritis. The few studies performed in patients with spondyloarthritis mainly evaluate the improvement in pain using a visual analog scale (VAS) and are limited by the need for an operating room and guidance based on fluoroscopy, tomography, or magnetic resonance. The advent of new ultrasound devices has meant that during the last decade, alternative approaches have been proposed for ultrasound-guided injection of the sacroiliac joint.

**Objectives:** To determine clinical improvement (Bath Ankylosing Spondylitis Activity Index [BASDAI], Ankylosing Spondylitis Disease Activity Score [ASDAS], acute-phase reactants, and the VAS score) after ultrasound-guided injection of corticosteroids into the sacroiliac joint of patients with spondyloarthritis.

**Methods:** We performed an observational, descriptive, and retrospective study at Ciudad Real General University Hospital (HGUCR), Ciudad Real, Spain. We reviewed the register of procedures carried out between June 1, 2020 and May 31,
2021 and included all patients with spondyloarthritis and inflammatory low back pain despite treatment with nonsteroidal anti-inflammatory drugs, biologics, or both. All patients underwent ultrasound-guided injection of the sacroiliac joint with corticosteroids (betamethasone chondrose 6 mg in each joint). We excluded patients whose clinical history did not contain the study variables and in whom modifications to pharmacologic treatment could have reduced the effectiveness of the injection. The outcome measures were presence of adverse effects/complications, reduction in the VAS score for inflammatory pain (>0=3 points), reduction of ≥1.1 points in the ASDAS score, reduction of ≥2 points in the BASDAI score, and reduction in the VAS score for inflammatory pain (>0=3 points). These data were analyzed by comparing means (t test) for the variables VAS, BASDAI, ASDAS, CRP, and ESR.

**Conclusion:** Ultrasound-guided injection of corticosteroids into the sacroiliac joint of patients with spondyloarthritis and active sacroiliitis leads to an improvement in pain despite treatment with nonsteroidal anti-inflammatory drugs, biologics, or both. All patients underwent ultrasound-guided injection of the sacroiliac joint with corticosteroids (betamethasone chondrose 6 mg in each joint). We excluded patients whose clinical history did not contain the study variables and in whom modifications to pharmacologic treatment could have reduced the effectiveness of the injection. The outcome measures were presence of adverse effects/complications, reduction in the VAS score for inflammatory pain (>0=3 points), reduction of ≥1.1 points in the ASDAS score, reduction of ≥2 points in the BASDAI score, and reduction in the VAS score for inflammatory pain (>0=3 points). These data were analyzed by comparing means (t test) for the variables VAS, BASDAI, ASDAS, CRP, and ESR. The potential association between the variables and a favorable clinical response was evaluated by calculating the odds ratio. The protocol was approved by the Research and Ethics Committee of Integrated Care Management, Ciudad Real, Spain.

**Results:** We analyzed 32 patients with spondyloarthritis (age 42.69±8.19 years, females 56%, 25/36) with a VAS score of 78±80.79, BASDAI of 5.43±1.48, and ASDAS of 3.27±0.86 before the procedure. At 2-3 months, 75% of patients had improved: VAS 3.81±2.33 (–4.07, p<0.001) and BASDAI 3.24 ± 1.6 (–2.19, p<0.001). At 5-6 months, 59.37% had improved: VAS 4.63±2.31 (–3.25, p<0.0001), BASDAI 3.57±1.67 (–1.86, p<0.0001), and ASDAS 2.27±3.71 (–1.0, p<0.0001). Bone marrow edema resolved in 87.5% of cases compared with the previous magnetic resonance scan. Analysis of factors potentially associated with improved clinical response as measured using the VAS, BASDAI, and ASDAS did not reveal a significant association with the variables analyzed (age, time since diagnosis, grade of sacroiliitis by radiography, presence of HLA B27 (+), and peripheral and extra-articular manifestations, type of treatment). However, all the patients whose symptoms improved (EVA, BASDAI, and ASDAS) had had bone marrow edema on their magnetic resonance scan <1 year before the treatment. Only 5 patients experienced injection site pain, which lasted 1-2 days. No other adverse effects were reported.

**Conclusion:** Ultrasound-guided injection of corticosteroids into the sacroiliac joint of patients with spondyloarthritis and active sacroiliitis leads to an improvement in symptoms that is maintained at 5-6 months. The procedure is effective, safe, inexpensive, and easy to apply.

**References:**

**Acknowledgements:** We acknowledge the work and dedication of the rheumatology department, interventional rheumatology and pain medicine department teams.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1275

**Table 1. Characteristics of patients with axSpA at the time of inclusion in the study who had X-ray progression of coxitis after 36 months of observation.**

| Parameter | n | ΔBASFI hip >0 | ΔBASFI hip ≥1
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>n=15</td>
<td>12</td>
<td>8</td>
<td>4</td>
</tr>
<tr>
<td>p=30</td>
<td>0.01</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>p&lt;0.001</td>
<td>0.0001</td>
<td>0.0001</td>
<td>0.0001</td>
</tr>
</tbody>
</table>

**Conclusion:** X-ray progression of coxitis in axSpA practically does not depend on the activity of the disease, nor on local signs of inflammation in the HJ, detected by ultrasound and MRI. X-ray progression of HJ lesions is less common in patients receiving bDMARDs therapy.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1422

**Table AB0758 GOLIMUMAB AFTER DISCONTINUATION OF NON-TNF INHIBITORS IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: FOUR-YEAR RETENTION RATE IN THE SPANISH BIOBADASER REGISTRY**

**Objective:** To assess the probability of retention (persistence or drug survival) of golimumab in patients with rheumatic diseases when used after discontinuation of non-TNF biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have been studied as first-line therapy or after TNFi discontinuation, data on the use of TNFis after discontinuation of these drugs is scarce.

**Background:** Treatment options for rheumatic diseases have evolved to include mechanisms of action beyond tumor necrosis factor inhibitors (TNFi). While non-TNF biologics and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have been studied as first-line therapy or after TNFi discontinuation, data on the use of TNFis after discontinuation of these drugs is scarce.

**Objectives:** We assessed the probability of retention (persistence or drug survival) of golimumab in patients with rheumatic diseases when used after discontinuation of non-TNF biologics or tsDMARDs in the BIOBADASER database. We also compared the probability of retention of patients who initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs with that of patients who initiated it after discontinuation of TNFis.

**Methods:** Characteristics of all adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (SpA) who had initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs in the BIOBADASER database were analyzed. The probability of golimumab retention was assessed with the Kaplan-Meier method, and differences between groups with the log-rank test. Patients were censored if they were withdrawn from the study after 3 years of follow-up. The time of observation was defined as the interval between the last TNFi or tsDMARD dose and the first dosing of golimumab, with the patients divided into two groups (∆BASFI hip >0 and ∆BASFI hip = 0).

**Results:** A total of 125 patients (85 [68%] women) with RA (n=72), axSpA (n=23), or PsA (n=30) had initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs and were right-censored if they were still treated with golimumab at the last observation point. We also compared the probability of retention of patients who initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs with that of patients who initiated it after discontinuation of TNFis.

**Results:** A total of 125 patients (85 [68%] women) with RA (n=72), axSpA (n=23), or PsA (n=30) had initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs and were right-censored if they were still treated with golimumab at the last observation point. We also compared the probability of retention of patients who initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs with that of patients who initiated it after discontinuation of TNFis.

**Results:** A total of 125 patients (85 [68%] women) with RA (n=72), axSpA (n=23), or PsA (n=30) had initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs and were right-censored if they were still treated with golimumab at the last observation point. We also compared the probability of retention of patients who initiated golimumab after discontinuation of non-TNF biologics or tsDMARDs with that of patients who initiated it after discontinuation of TNFis.
RA patients (28% at year 3) than in axial SpA (68%) or PsA (49%) (p = 0.002) (Figure 1). As second line therapy, the 3-year retention rate of golimumab was slightly lower when it was initiated after non-TNFi biologicals/tsDMARD than when the previously discontinued therapy was a TNFi (32% vs 55%, p = 0.119), but the figures were similar when it was initiated as third (52% after non-TNFi biologicals/tsDMARD vs 50% after TNFi, p = 0.838) or as fourth/subsequent line of therapy (37% vs 44% respectively, p = 0.554).

Conclusion: We present, for the first time, 4-year retention rates for golimumab in patients who discontinued non-TNFi biologicals or tsDMARDs, most of them in third and fourth/subsequent line of therapy. In this difficult-to-treat rheumatic population, overall golimumab retention rates were favorable through 4 years of treatment, with higher rates in SpA and PsA compared to RA patients.

Figure 1.

Acknowledgements: BIOBADASER is funded by the Spanish Society of Rheumatology, the Spanish Agency of Medicines and by different pharmaceutical companies. This study was funded by MSD, Spain.


Table 1. Efficacy responses with SEC up to Week 104 based on age and symptom duration

<table>
<thead>
<tr>
<th>Age 18-33 years</th>
<th>Age &gt;52 years</th>
<th>≤2 years of back pain</th>
<th>&gt;10 years of back pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEC 150 mg LD (N=61)</td>
<td>SEC 150 mg NL (N=59)</td>
<td>PBO (N=61)</td>
<td>SEC 150 mg NL (N=25)</td>
</tr>
<tr>
<td>ASAS-DAS CRP ID and LDA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50.80</td>
<td>55.90</td>
<td>34.40</td>
<td>36.00</td>
</tr>
<tr>
<td>77.40</td>
<td>81.10</td>
<td>72.20</td>
<td>45.80</td>
</tr>
<tr>
<td>71.70</td>
<td>70.70</td>
<td>77.60</td>
<td>50.00</td>
</tr>
<tr>
<td>BASDAI 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45.90</td>
<td>47.50</td>
<td>27.90</td>
<td>28.00</td>
</tr>
<tr>
<td>77.80</td>
<td>71.70</td>
<td>72.20</td>
<td>37.50</td>
</tr>
<tr>
<td>73.50</td>
<td>72.30</td>
<td>77.60</td>
<td>47.60</td>
</tr>
<tr>
<td>ASAS PR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29.50</td>
<td>32.20</td>
<td>8.20</td>
<td>12.00</td>
</tr>
<tr>
<td>41.50</td>
<td>50.90</td>
<td>39.80</td>
<td>12.90</td>
</tr>
<tr>
<td>46.60</td>
<td>44.70</td>
<td>59.20</td>
<td>23.80</td>
</tr>
<tr>
<td>Total back pain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50.80</td>
<td>50.80</td>
<td>27.90</td>
<td>24.00</td>
</tr>
<tr>
<td>74.10</td>
<td>75.50</td>
<td>72.20</td>
<td>58.30</td>
</tr>
<tr>
<td>71.40</td>
<td>68.10</td>
<td>79.60</td>
<td>61.90</td>
</tr>
</tbody>
</table>

Data is presented as % of responders. Symbols are used to denote the Weeks: *Week 16; †Week 52; ††Week 104. All patients received open-label SEC 150 mg treatment after Week 52 up to Week 104. ASAS-DAS CRP ID and LDA (ASAS-DAS CRP <2.1); Total back pain improvement ≥50%. LD, loading dose; NL, without loading; PBO, placebo.

REFERENCES:
Disclosure of Interests: Atul Deodhar Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Glaxo Smith & Kline, Janssen, Novartis, Pfizer, UCBI, Grant/research support from: AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer, UCBI, Denis Poddubnyy Speakers bureau: AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, UCBI, Roche, Consultant of: AbbVie, BMS, Eli Lilly, MSD, Novartis, Pfizer, UCBI, Roche, Grant/research support from: AbbVie, MSD, Novartis, Pfizer, Ricardo Blanco Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, UCBI pharma and MSID, Grant/research support from: AbbVie, MSD, and Roche, Stephen Hall Speakers bureau: Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCBI, Consultant of: Novartis, Merck, Janssen, Pfizer, Eli Lilly, and UCBI, Grant/research support from: AbbVie, UCBI, Janssen, and Merck, Marina Magrey Consultant of: Eli Lilly, Novartis, Grant/research support from: AbbVie, UCBI, and Amgen, Erda Besque-Fehling Speaker of: Shareholder of Novartis, Employee of: Novartis, Renato Calheiros Consultant of: Shareholder of Novartis, Employee of: Novartis, Patricia Pertel Consultant of: Shareholder of Novartis, Employee of: Novartis, Helena Marzo-Ortega Speakers bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCBI, Consultant of: AbbVie, Celgene, Janssen, Moonlake, Lilly, Novartis, Pfizer and UCBI, Grant/research support from: Janssen, Novartis and UCBI

STUDY ARTHRITIS (PSA) IN REAL WORLD PRACTICE: SECUKINUMAB (SEC) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) IN REAL WORLD PRACTICE: FACTORS ASSOCIATED WITH THE RETENTION OF SECUKINUMAB (SEC) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) IN REAL WORLD PRACTICE: RESULTS FROM THE RETROSPECTIVE FORSYA STUDY


1University Hospital of Toulouse, Department of Rheumatology, Toulouse, France; 2RCTs Clinical Research Organisation, Biostatistics, Lyon, France; 3Novartis Pharma SA, Medical affairs, Rueil Malmaison, France; 4Hôpital Henri Mondor, Assistance Publique - Hôpitaux de Paris, Department of Rheumatology, Créteil, France; 5Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Department of Rheumatology, Paris, France; 6University Hospital of Tours, Department of Rheumatology, Tours, France; 7University Hospital Montpellier, Department of Rheumatology, Montpellier, France; 8CHU Brest Department of Rheumatology, Brest, France; 9CHU Clermont Ferrand, Department of Rheumatology, Clermont Ferrand, France; 10CHU de Besançon, Department of Rheumatology, Besançon, France

Background: While data on real-life retention of SEC in patients (pts) with PSA is accumulating, there are no data on predictive factors for this retention.

Objectives: The primary objective of FORSYA study was to assess whether objective signs of inflammation (OSI) were predictive of SEC retention at 1 year.

Methods: French retrospective study collecting between October 2019 and September 2020 data from axSpA pts a) having initiated and received at least one dose of SEC between August 11th 2016 and August 31st 2016, b) with at least a one year follow-up period. Retention of SEC at 1 year was estimated by the Kaplan Meier (KM) method. OSI were defined by at least one of the following within the 3 months before initiation of SEC: CRP > N, confirmed clinical dactylitis, confirmed clinical synovitis or ultrasonography power-Doppler positive synovitis except on MTP of first toe. Preselected factors at initiation of SEC retention at 1 year (≥ 1 OSI, age, sex, BMI, smoking status, axial feature, past or present psoriasis / uveitis / Inflammatory Bowel Disease (IBD) / active arthritis or synovitis, diagnostic delay, disease duration, SEC line of biologic therapy, SEC maintenance dose, concomitant csDMARD, concomitant oral corticosteroids, ≥ 1 comorbidty) were analyzed by multivariate cox model regression. Only variables with < 20% missing data were included in the model after imputation and stepwise selection (significance level for entering variables = 20%, for removing variables = 10%). OSI was forced into the model whatever its significance level or rate of missing data.

Results: In total, 475 pts (male: 40.2%, mean age: 51.9 ± 12.2 years, mean disease duration: 9.3 ± 6.8 years) from 48 centers were included in the analysis. At initiation of SEC, 62.2% of pts had ≥ 1 OSI and respectively 11.0%, 19.5% and 68.9% were in 1st, 2nd and ≥ 3rd line (L) of biologic/targeted synthetic DMARD. The overall 1 year KM survival rate for SEC was 63% [95%CI: 59%–66%] and was numerically greater in 1st L vs 2nd and ≥ 3rd L (82% [72%–93%], 62% [52%–72%], 61% [56%–66%] respectively). The overall survival rates for PSA pts with or without OSI were 62% [56%–68%] and 71% [62%–80%]. In multivariate analysis, absence of OSI, longer disease duration and lack of prior exposure to anti-TNF inhibitors were associated with a better SEC retention at 1 year (Table 1).

Interpretation for predictor: HR> 1: the hazard of discontinuation at 1 year is X times higher in category vs reference.

Conclusion: The overall retention of SEC at 1 year in daily practice at the time of its launch in France was 63% for PSA patients and OSI, disease duration and prior exposure to TNF inhibitors were identified as predictive factors of SEC retention.

Acknowledgements: Authors thank all participating investigators, centers and patients. This study was financially supported by NOVARTIS Pharma France.


AB0760 FACTORS ASSOCIATED WITH THE RETENTION OF SECUKINUMAB (SEC) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) IN REAL WORLD PRACTICE: RESULTS FROM THE RETROSPECTIVE FORSYA STUDY

AB0761 ARE WE TREATING-TO-TARGET IN SPONDYLOARTHRITIS (SPA)? A CROSS SECTIONAL ANALYSIS FROM THE ASIA PACIFIC LEAGUE OF ASSOCIATIONS FOR RHEUMATOLOGY (APLAR) SPA REGISTRY


1The Chinese University of Hong Kong, Medicine and Therapeutics, Hong Kong, Hong Kong (SAR); 2Singapore General Hospital, Rheumatology & Immunology, Singapore, Singapore; 3Singapore General Hospital, Rheumatology & Immunology, Singapore, Singapore; 4Singapore Rheumatology, Rheumatology, Singapore, Singapore; 5Institute of Rheumatic Diseases, Central Park Medical College, Rheumatology, Lahore, Pakistan; 6SMG-SNU Boramae Medical Center, Internal Medicine, Seoul, Korea, Rep. of (South Korea); 7Goyal Hospital, CARE Pain & Arthritis Centre, Udaipur, India; 8Fatima Memorial Hospital & FMH College of Medicine and Dentistry, Internal Medicine, Lahore, Pakistan; 9Hamad Medical Corporation, Rheumatology, Doha, Qatar; 10Velmammal Medical College Hospital, Rheumatology and Medicine, Madurai, India; 11The University of Hong Kong, Medicine, Hong Kong, Hong Kong (SAR); 12Chung Shan Medical University, Department of Allergy, Immunology & Rheumatology, Tai Chung, Taiwan, Republic of China; 13Keio University, School of Medicine, Tokyo, Japan

Background: Data on the extent of treat-to-target (T2T) recommendations application in SpA patients across Asia Pacific region is lacking. APLAR SpA Registry aimed to assess the utility of T2T on long term clinical outcomes, and to improve disease management and inform health care policy.

Objectives: To provide a snapshot of the registry including demographics, disease activity and medication use.

Table 1. Predictive factors of SEC 1 year retention of SEC identified by multivariate cox regression analysis (multiple imputation + Stepwise selection)

<table>
<thead>
<tr>
<th>Predictive factors (* reference)</th>
<th>HR [95% CI]</th>
<th>p vs ref type III</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least one objective sign of inflammation (OSI)</td>
<td>No (N=175)</td>
<td>Yes (N=295)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>≥ 7 years (N=241)</td>
<td>&gt; 7 years (N=229)</td>
</tr>
<tr>
<td>Secukinumab treatment line</td>
<td>≥ 2 L (N=92)</td>
<td>≥ 3L (N=328)</td>
</tr>
</tbody>
</table>

Table 1. Predictive factors of SEC 1 year retention of SEC identified by multivariate cox regression analysis (multiple imputation + Stepwise selection)
Methods: Patients fulfill the CASPAR 2006 for psoriatic arthritis (PsA) and 2009 ASAS criteria for axial spondylitis (AxSpA) were recruited. This cross-sectional analysis included the first 188 patients recruited across 7 Asia Pacific regions (Hong Kong, Singapore, Korea, Thailand, India, Qatar & Pakistan).

Results: 83 patients PsA and 115 AxSpA patients were included. They had moderate inflammation (DAPSA: 19.61±14.29, ASDAS: 2.32±1.07). Majority of PsA patients received conventional synthetic disease-modifying drug (csDMARDs, 81%) with relatively low prevalence of biologic DMARDs (bDMARDs) (24%). Most AxSpA patients used NSAIDs (79%) while nearly half of them received bDMARDs (49%). Other details listed in Table 1. Prevalence of bDMARDs use in our registry was lower than that from the USA (Corrona PsA Registry, 59%), Turkey & Canada (PsA-tID, 40%) and the Netherlands AxSpA registry (56%) (1-3).

Regarding T2T, 28% and 44% of PsA patient achieved minimal disease activity (MDA) and Disease Activity in Psoriatic Arthritis low disease activity (DAPSA LDA) respectively. The proportion of patients achieving target in other cohorts were 46% for MDA (PsAr-ID) and 46% for DAPSA LDA (Corona) (1, 2), 37% and 47% of AxSpA patient achieved Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)<4 and Ankylosing Spondylitis Disease Activity Score (ASDAS) LDA. Proportion of patients achieving ASDAS LDA were similar to the Netherlands registry for patients with ASDAS LDA or BASDAI<4 (Figure 1A)(3). Patient on bDMARD were more likely to achieve treatment target (Figure 1B). There were no significant difference between socio-economic status and disease features between bDMARD user and non-user.

Table 1. Demographics, clinical features and disease activity of patients

<table>
<thead>
<tr>
<th></th>
<th>PsA (n=83)</th>
<th>AxSpA (n=115)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>50.0</td>
<td>12.8</td>
</tr>
<tr>
<td>Male, %</td>
<td>42</td>
<td>51%</td>
</tr>
<tr>
<td>Asian, %</td>
<td>83</td>
<td>100%</td>
</tr>
<tr>
<td>Disease duration, yrs</td>
<td>7.1</td>
<td>7.3</td>
</tr>
<tr>
<td>Any sacrolitis, %</td>
<td>102</td>
<td>99%</td>
</tr>
<tr>
<td>Duration early morning stiffness, min</td>
<td>30</td>
<td>39</td>
</tr>
<tr>
<td>Tender joint count</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>No. of dactylitis digit</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>PASI</td>
<td>4.0</td>
<td>5.0</td>
</tr>
<tr>
<td>SRI-RACC</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>BASDAI</td>
<td>2.8</td>
<td>2.8</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>31</td>
<td>26</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>DAPSA</td>
<td>19.6</td>
<td>14.29</td>
</tr>
<tr>
<td>ASDAS CRP</td>
<td>2.3</td>
<td>1.07</td>
</tr>
</tbody>
</table>

Data given in mean SD unless stated. No. of case from Hong Kong 40; Singapore 46; Korea 24; Thailand 20; India 15; Qatar 10; Pakistan 33; HLA - human leucocyte antigen; PASI - psoriasis area and severity index; SRI-RACC - Spondyloarthritis Research Consortium of Canada Enthesitis Index; BASDAI - Bath Ankylosing Spondylitis Disease Activity Index; ESR - erythrocyte sedimentation rate; CRP - C-reactive protein; HAQ-DI - Health assessment questionnaire disability index; DAPSA - Disease activity in Psoriatic Arthritis; ASDAS - Ankylosing Spondylitis Disease Activity Score.

Figure 1. (A) Achievement of LDA in APLAR SpA registry and other registry and (B) use of bDMARDs among patients in APLAR SpA registry with or without achieving LDA.

Conclusion: Patient using bDMARDs were more likely to achieve treatment target. We expect that when T2T is widely applied, better outcomes will be reported in future.

REFERENCES:

Disclosure of Interests: Isaac T. Cheng: None declared, Ho SO: None declared, Ying Ying Leung Speakers bureau: received honorarium/ speaker fee from AbbVie, DKSH, Janssen, Novartis and Pfizer., Praveena Chichowdawisawatk: None declared, Stanley Angkodjojo Speakers bureau: Boehringer Ingelheim Singapore in Nov 2021, Consultant of: Abbvie (Singapore), DKSH (Singapore) in 2021, Muhammad Ahmed Saeed: None declared, Kichul Shin: None declared, Mohit Goyal: None declared, Mohammed Hammoudeh Speakers bureau: Have you been paid as a speaker for (pharmaceutical) companies, Grant/research support from: participated in drug companies sponsored trials, Nallasivan Subramanian: None declared, Ho Yin Chung; None declared, James Cheng-Chung Wei: None declared, Mitsumasa Kisimoto Consultant of: MK received consulting fees and/or speaker fees from AbbVie, Amgen, Asahi-Kasei Pharma, Astellas, Ayumi Pharma, BMS, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Janssen, Kyowa Kirin, Novartis, Ono Pharma, Pfizer, Tanabe-Mitsubishi, and UCB Pharma., Lai-Shan Tam Consultant of: has acted as a consultant for Janssen, Pfizer, Sanofi, AbbVie, Boehringer Ingelheim, and Lilly, Grant/research support from: has received grant/research support from Amgen, Boehringer Ingelheim, Janssen, GSK, Novartis, and Pfizer DOI: 10.1136/annrheumdis-2022-eular.2217

INCIDENCE OF ANTERIOR UVEITIS IN AXIAL SPONDYLOARTHRITIS DURING SECUKINUMAB TREATMENT: TWO YEARS REAL LIFE EXPERIENCE FROM TURKIBIO REGISTRY


Background: Secukinumab (SEC), a human anti-IL-17A monoclonal antibody, has similar treatment response rates to tumor necrosis factor (TNF) inhibitors in patients with axial spondyloarthritis (SpA). However, the efficacy of SEC on anterior uveitis (AU) is unclear.

Objectives: This study aimed to evaluate the risk of new-onset or relapsing AU in axial SpA patients treated with SEC.

Methods: In this prospective cohort study, 130 axial SpA patients receiving SEC at the TURKIBIO registry between 2019 and 2021 were evaluated. Demographic and clinical characteristics and data about the presence of AU pre or post-treatment were collected. The univariate and multivariate logistic regression analyses were performed to evaluate the predictors of AU development.

Results: The mean age of the patients (F/M: 59/71) was 47.4±10.9 years. The median follow-up time was 540 days (IQR: 330-630), SEC was the first biological agent in 50 (38.4%) patients and 35 (26.9%) patients were using at least one concomitant conventional synthetic DMARD (Table 1). While continued SEC therapy was in 93 (71.5%) patients, treatment withdrawal was in 37 cases (in 26 due to ineffectiveness, two adverse events and nine other reasons). Overall, 15 (11.5%) patients had a history of AU before the SEC. During follow-up, AU attacks were seen in the 6 cases (4 were new-onset and 2 were flare) and 5 of these patients had a history of inadequate response to TNF inhibitors. The frequency of AU was

AB0762
calculated as 3.42 per 100 patient-years during SEC treatment. The only significant predictor of AU development was the baseline high C-reactive protein (CRP) level on multivariate analysis (p = 0.003, OR: 1.063 [95% CI 1.021-1.107]).

Table 1. Demographics and clinical characteristics of the patients

<table>
<thead>
<tr>
<th>Total (n=191)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M/F)</td>
</tr>
<tr>
<td>Age (years) (mean±SD)</td>
</tr>
<tr>
<td>Diagnosis:</td>
</tr>
<tr>
<td>AS</td>
</tr>
<tr>
<td>n-axSpA</td>
</tr>
<tr>
<td>BASDAI (mean±SD)</td>
</tr>
<tr>
<td>Missing n (%)</td>
</tr>
<tr>
<td>ASDAS (mean±SD)</td>
</tr>
<tr>
<td>Missing n (%)</td>
</tr>
<tr>
<td>C-reactive protein (mg/L) median (IQR)</td>
</tr>
<tr>
<td>Sedimentation (mm/h) median (IQR)</td>
</tr>
<tr>
<td>Concomitant csDMARDs n (%)</td>
</tr>
<tr>
<td>Secukinumab dose n (%)</td>
</tr>
<tr>
<td>150 mg</td>
</tr>
<tr>
<td>300 mg</td>
</tr>
<tr>
<td>TNFi-naive patients n (%)</td>
</tr>
<tr>
<td>Number of previous bDMARDs n (%)</td>
</tr>
<tr>
<td>≥ 3</td>
</tr>
<tr>
<td>≥ 2</td>
</tr>
<tr>
<td>≥ 1</td>
</tr>
<tr>
<td>p ≥ 3</td>
</tr>
<tr>
<td>History of previous TNFi n (%)</td>
</tr>
<tr>
<td>Monoclonal TNFi</td>
</tr>
<tr>
<td>E tantrcept</td>
</tr>
</tbody>
</table>

Conclusion: In this real-life data from the TURKBio registry, the incidence of AU in axial SpA patients treated with SEC was calculated as 3.42 per 100 patient-years. A high baseline CRP level was an independent factor for developing AU.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular-2242

AB0763 PERSONAL APPROACH IN AXIAL SPONDYLOARTHROPATHY MANAGEMENT

B. Bugaj1, J. Wielinska2, J. Swierkot1, K. Bogunia-Kubik2. 1Polish Academy of Sciences, Laboratory of Clinical Immunogenetics and Poland; 2University, Department of Rheumatology and Internal Medicine, Wroclaw, Poland

Background: Spondyloarthopathies (SpAs) are a group of diseases characterized by arthritis in the spine (axialSpA - axSpA) and peripheral joints, and extra-articular symptoms like uveitis, psoriasis or inflammatory bowel diseases. The onset of the disease is difficult to observe. Due to the lack of a pathognomonic test, diagnosis is based on a combination of physical examination, laboratory test and imaging results. The pathogenesis of SpAS is not fully understood, and genetic, environmental and immunological factors are assumed to play a pivotal role.

Objectives: The study aimed to evaluate selected polymorphisms (ERAP1 rs2287987, ERAP2 rs2549782, TNF rs1800629, TNFRSF1B rs1061622, FCGR2A rs1801274) as prognostic factors of clinical presentations, and response predictors of anti-TNF treatment in axSpA patients.

Methods: The study enrolled 216 Caucasians: 106 axSpA patients and 110 healthy controls. AS patients were diagnosed according to modified New York criteria, while n-axSpA patients were diagnosed according to ASAS criteria. Genotyping was performed using LightSNip assays on the Real-Time PCR Instrument. Clinical data were assessed at baseline, as well as after three and six months of anti-TNF treatment. In addition, information about extra-articular symptoms was collected.

Results: The statistical analysis revealed that TNFRSF1B rs1061622-GG was significantly associated with a higher VAS score at baseline (TT + G vs GG, p = 0.001), and a higher BASDAI score corrected for the first therapy cycle (X1C BASDAI: TT + TG vs GG, p = 0.005). Moreover, homozygotes were more frequently observed with a lack of BASDAI improvement after six months (X1C BASDAI: TT+GG vs TG, p = 0.045, OR = 2.46, 95%CI 1.00-6.12). ERAP1 rs2287987- GG was more frequently observed with uveitis (AA vs GG, p = 0.049, OR = 4.636, 95%CI 1.101-21.24). The GG genotype of TNFRSF1B rs1061622 was more common in patients with uveitis than TT variant (GG vs TT, p = 0.042, OR = 5, 95% CI 1.08-20). Associations between genetic variants and clinical outcomes were evaluated using laboratory parameters. A lack of the ESR improvement after six months of treatment was more frequently detected between ERA patients observed by EULAR2022 and 18% (AG vs AA + GG, p = 0.027, OR = 2.72, 95% CI 1.115-6.137) and TNFRSF1B rs1061622-GG (TT vs G+, p = 0.020, OR = 3, 95% CI 1.27-6.9) compared to other genotypes. After three months of therapy, the GG variant of ERAP2 rs2549782 polymorphism was more common among individuals with the lack of ESR improvement than T allele carriers (GG vs T+, p = 0.037, OR = 2.76, 95% CI 1.13-6.72). Differences were also detected between the FCGR2A rs1801274 polymorphism, and X1C BASDAI score after six months. The low disease activity (BASDAI < 3) and BASDAI improvement was more frequently observed in patients carrying the A allele than the GG genotype (AA+AG vs GG, p = 0.028, OR = 4.545, 95% CI 1.337-16 and p = 0.012, OR = 6.212, 95% CI 1.683-20.47, respectively). The AG genotype was more common among patients with remission (BASDAI < 2) compared to homozygotes (AG vs AA+GG, p = 0.046, OR = 2.36, 95% CI 1.05-5.13).

Conclusion: Genetic profiling of patients will help to identify those at risk of high initial disease activity or the presence of extra-articular symptoms. Identifying patients less responsive to treatment may allow selecting a drug with an appropriate efficacy profile.

Disclosure of Interests: This work was supported by the grant from Wroclaw Medical University (Poland) STM.A270.20.153.

Disclosure of Interests: Bartosz Bugaj: None declared, Joanna Wielinska: None declared, Jerzy Swierkot Speakers bureau: For Abbvie, Roche, Lilly, Sandoz, Pfizer, Medac, Novartis, UCB, Katarzyna Bogunia-Kubik: None declared

DOI: 10.1136/annrheumdis-2022-eular-2242

AB0764 FACTORS ASSOCIATED WITH REMISSION AFTER GRADUAL DECLINE OF TNFI IN SPONDYLOARTHRITIS

S. Abdelmalek1, L. Lefkri1, Issad Hassani Beni messous hospital, Rheumatology, Algiers, Algeria

Background: The natural history of axial spondyloarthritides (axSpA) includes periods of remission interspersed with flares. It is recommended to target remission during the disease management, the 2 most used definitions are ASAS partial remission and inactive disease (ASAS <1.3 and/or BASDAI score <3.6). The factors associated with the gradual decline of biologics after achieving remission have been little explored.

Objectives: The objective of this work was to assess the proportion of patients with axSpA treated with TNFi in whom remission was maintained concomitantly with tapering at 3 years of follow-up and to identify the factors associated with this remission.

Methods: Single-center prospective descriptive study. A total of 44 patients included who attempted to space TNFi injections (etanercept, infliximab, adalimumab) among the 192 patients treated with bDMARDs, all of the patients fulfilled the ASAS criteria for SpA. Data collected: socio-demographic, clinical-biological and imaging data up to 3 years of follow-up.

Results: At the 3-year visit, a biologic decrease was achieved in 22.9% (86.4% maintenance of remission and 9.1% with relapse). That is a total of 19.8% (38/192) of patients (mean age 34.2 ± 8.1 years; 71% of men with HLAB27 positive 63.2% with low BMI in 68.4%) maintained clinical remission with TNFi tapering at the 3-year visit. There was a significant association between ASAS (p <0.001), BASDAI (p <0.001) and CRP (p = 0.004) per visit and maintenance of remission. Likewise, patients in remission more often presented strictly axial damage without enthesitic or peripheral damage and minimal structural on conventional radiography (p = 0.03). They reported low smoking and stopping use of NSAIDs. Factors associated with successful 3-year TNFi spacing were a shorter delay between diagnosis and initiation of the biologic (0.9 [0.64-1.3]) and initial presentation of acute illness according to patient examination (2.37 [1.06-5.26]), lower initial BASDAI and BASFI (respectively 1.3 [0.84-1.8] and 0 [0.74-1.4]) and a lower NSAID score (0.715 [0.43-0.9]).

Conclusion: AxSpA patients in remission as defined by ASAS had significantly lower objective signs of inflammation concomitantly but also over time. It is possible to maintain this remission after gradual decline in the biologies at 3 years in axSpA. Low activity and functional scores, as well as low consumption of NSAIDs are predictive of the success of tapering. Discontinuation treatment is not recommended due to the high risk of relapse.

REFERENCES:
AB0765

ANALYSIS OF THERAPY IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHROPATHY WHO ACHIEVED THE ASAS PARTIAL REMISSION AND THE CLINICAL-LABORATORY REMISSION AT THE 3RD YEAR OF FOLLOW-UP

D. Timokhina1, T. Dubinina1, A. Demina1, O. Kirchevskaya1, S. Erdes1

1. V.A. Nasonova Research Institute of Rheumatology, Laboratory of axial spondyloarthritis, Moscow, Russian Federation

Background: The main goal of “T2T” strategy for spondyloarthritis (SpA) is to achieve clinical remission or inactive disease. In 2001, the ASAS formulated criteria for partial remission [1], and the Russian Expert Group for Study of SpA (ExSpA) revealed that patients more often achieved remission when taking NSAIDs, a quarter of patients who achieved the clinical-laboratory and the ASAS partial remission, it was included 66 patients followed for at least 3 years, of which 37 (56%) were men. The average age of patients was 31.5 (5.7) years, the average duration of the disease was 22.1 (17.0) months, 63 (95.4%) patients were HLA B27 positive. The criteria for clinical-laboratory remission include the following indicators (at least during 6 months): ASDAS≤1,3, BASDAI ≤1,0, morning stiffness<30 min., absence of swollen joints, absence of enthesitis, nocturnal pain ≤1,0 (NRS), spinal pain≤1,0 (NRS), active extra-articular manifestations, normal levels of CRP and ESR [2]. The criteria for ASAS partial remission include a value not above 2 units in each of the 4 domains: patient global, pain, function, inflammation [1].

Results: Initially, no patients met the ASAS partial remission and the clinical-laboratory remission criteria. By the 3rd year of follow-up, the clinical-laboratory remission was achieved by 21 (31.8%) patients; the ASAS partial remission - 29 (44.0%) patients. When analyzing therapy at the 3rd year of follow-up of patients with early axSpA who achieved the clinical-laboratory and the ASAS partial remission, it was revealed that patients more often achieved remission when taking NSAIDs, a quarter of patients achieved remission on combined therapy with biologics and NSAIDs (Table 1). It is noting that a quarter of patients canceled therapy on their own.

<table>
<thead>
<tr>
<th>Table 1. Therapy of patients with axSpA who achieved the clinical-laboratory and the ASAS partial remission at 3 years of follow-up.</th>
</tr>
</thead>
<tbody>
<tr>
<td>The ASAS partial remission (n=29)</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>NSAIDs, n (%)</td>
</tr>
<tr>
<td>NSAIDs+sulfasalazine, n (%)</td>
</tr>
<tr>
<td>Biologics, n (%)</td>
</tr>
<tr>
<td>Biologics-NSAIDS, n (%)</td>
</tr>
<tr>
<td>Biologics-sulfasalazine-NSAIDS, n (%)</td>
</tr>
<tr>
<td>Without therapy, n (%)</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>p</td>
</tr>
</tbody>
</table>

Conclusion: 1. In the 3rd year of follow-up 32% of patients with early axSpA achieved the clinical-laboratory remission and 44% - of the ASAS partial remission.

2. More than 40% of patients with early axSpA achieved remission while taking NSAIDs.

REFERENCES:

Disclosure of Interests: None declared

Conclusion: We show that rheumatologists in the TREASURE group prefer to initiate anti-TNF drugs first in all advanced CRD stages. Etanercept was the first choice in these patients.

REFERENCES:

Disclosure of Interests: None declared

AB0767 COMPARISON OF THE CLINICAL-LABORATORY REMISSION AND THE ASAS PARTIAL REMISSION IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS

D. Timokhina1, T. Dubinina1, A. Demina1, O. Krichevskaya1, S. Erdes2.
1VA. Nasonov Research Institute of Rheumatology; Laboratory of axial spondyloarthritis, Moscow, Russian Federation
2VA. Nasonov Research Institute of Rheumatology; Laboratory of axial spondyloarthritis, Moscow, Russian Federation

Background: The main goal of "T2T" strategy for spondyloarthritis (SpA) is to achieve clinical remission or inactive disease. In 2014, the ASAS formulated criteria for partial remission [1], and the Russian Expert Group for Study of SpA achieved clinical remission or inactive disease. In 2001, the ASAS formulated criteria for clinical-laboratory remission in patients with early axial SpA (axSpA) at 3rd year of follow-up.

Objectives: to compare the ASAS criteria for partial remission and the clinical-laboratory criteria in patients with early axial SpA (axSpA) at 3rd year of follow-up.

Methods: The study included patients with early axSpA (ASAS criteria 2009 with inflammation back pain duration less than 5 years) from the CORSAR cohort (Early SpondyloArthritis Cohort), formed at the V.A. Nasonov Research Institute of Rheumatology. The cohort includes 175 patients with axSpA. The analysis included 66 patients followed for at least 3 years, of which 37 (56%) were men and 29 (44%) women. The average age of patients was 31.5 (5.7) years, the average duration of the disease was 22.1 (17.0) months, 63 (95.4%) patients were on LBA B27 positive. The criteria for clinical-laboratory remission include the following indicators (at least during 6 months): ASDAS≤1.3, BASDAI ≤1.0, morning stiffness≤30 min., absence of swollen joints, absence of enthesitis, nocturnal pain ≤1.0 (NRS), spinal pain≤1.0 (NRS), no active extra-articular manifestations, normal levels of CRP and ESR [2]. The criteria for ASAS partial remission include a value not above 2 units in each of the 4 domains: patient global, pain, function, inflammation [1].

Results: Initially, no patients met the ASAS partial remission clinical-laboratory criteria. At 3 year of follow-up, the clinical-laboratory remission was achieved by 21 (31.8%) patients; the ASAS partial remission - 29 (44.0%) patients. We matched patients who achieved the ASAS partial remission (n=29) to criteria for clinical-laboratory remission and, conversely, patients who achieved the clinical-laboratory remission (n=21) to criteria for ASAS partial remission. When comparing the criteria for clinical-laboratory remission to the group of patients who achieved the ASAS partial remission, it turned out that the criteria were achieveable (more than 93%), the fewest patients with ASAS partial remission achieved the criteria for clinical-laboratory remission met the ASAS criteria for partial remission (graph 1).

Conclusion: The criteria for clinical-laboratory remission are comparable to the ASAS criteria for partial remission in patients with early axSpA and can be used in a practice of rheumatologists. Further research is needed to analyze the various remission criteria for axSpA and their applicability in a practice.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.10.1136/annrheumdis-2022-eular.3050

AB0768 INFLUENCE OF CONTINUOUS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS INTAKE ON BONE MARROW EDEMA IN NON-RADIOGRAPHIC SPONDYLOARTHRITIS

D. Ben Nessib1, M. Yasmine1, H. Ferjani1, W. Triki1, K. Maatallah1, D. Kaffel1, W. Hamdi1, Kassab Institute of orthopedics, Rheumatology, Tunisia, Tunisia

Background: The concept of non-radiographic axial spondyloarthritis (nr-axSpA) has revolutionized the classical understanding of axSpA. Indeed, it facilitated the classification of patients with axSpA who did not present substantial structural damage as it was only detectable on magnetic resonance imaging of the sacroiliac joints (MRI-SIJ) [1]. Continuous non-steroidal anti-inflammatory (NSAIDs) intake has been reported as a potential factor reducing the sensitivity of MRI-SIJ to detect bone marrow edema (BME).

Objectives: The aim of the study was to investigate the effect of continuous NSAIDs intake on BME in nr-axSpA.

Methods: We undertook a cross-sectional study including nr-axSpA according to the ASAS criteria and treated with NSAIDs at baseline. Socio demographic data as well disease characteristics were recorded. Disease activity parameters were also collected including the duration of morning stiffness, night awakenings, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), MRI-SIJ was performed for all the patients. All the images were screened for bone marrow edema with the corresponding sequence (short tau inversion). Patients were grouped according to NSAIDs intake: G1: continuous versus G2 occasional. The level of significance was fixed for p<0.05.

Results: The study included 43 nr-axSpA patients. There was a female predominance with a sex ratio of 0.43. The mean age of the patients was 42±12 years [20-71] and the mean disease duration was 17±9.7 years [4-38]. The mean morning stiffness duration was 47±34.56 ±15-240] minutes. The mean spinal VAS was 5.9±2.6 [0-10]. Nearly 41% of the patients had an active disease with a mean BASDAI of 4.7±2.1 [0-8.6]. The prescribed NSAIDs were as follows: Diclofenac (44 %), Indomethacin (8%), Ketoprofen (18%), Meloxicam (3%), Celecoxib (3%), Piroxicam (3%) and Naproxen (21%). Nearly half of the patients were continuously taking NSAIDs (52.6%) versus occasional intake (47.4%). Four patients failed two NSAIDs and were treated with a third one. Both groups were comparable for age (p=0.193), sex (p=0.386), and disease duration (p=0.4). Similarly, there were no statistically significant differences regarding disease activity parameters between both groups: numerical rating scale of pain (p=0.713), ESR (p=0.314), CRP (p=0.644), morning stiffness (p=0.428), night awakening (p=1), as well as BASDAI (p=0.514). Regarding MRI-SIJ findings, hyper signal in STIR sequence was comparable between both groups (G1: 35% vs G2:33%, p=0.914). Moreover, the increased signal with Gadolinium injection on T1-weighted images was similar between both groups (p=0.113).

Conclusion: Our study showed that continuous NSAIDs intake was not associated with significant changes in MRI-SIJ features. This study suggests that a NSAID-free period is not necessary before assessing bone marrow edema on MRI-SIJ.

REFERENCES:

Disclosure of Interests: None declared
TREATMENT OUTCOMES OF PATIENTS WITH BIOLOGICAL THERAPY DURING PREGNANCY AND EFFECT OF PREGNANCY PLANNING ON TREATMENT PREFERENCE OF RHEUMATOLOGISTS

V. Erez1, S. B. Kocaer1, G. Can1, M. Biriinkel1, F. Onen1, I. Sarı1. 1Dokuz Eylül University School of Medicine, Division of Rheumatology, Izmir, Turkey

Background: Rheumatic diseases occur mostly in adults at reproductive age. In addition to the impact of disease course on fetal and maternal health, safety concerns regarding the effects of biological drugs on the course of pregnancy have come to the fore with the introduction and widespread use of them. Unlike other biological treatments, all tumor necrosis factor (TNF) antagonists can be used during pregnancy.

Objectives: To investigate clinical features, treatment characteristics and pregnancy outcomes of patients with biological treatment and evaluate impact of planning pregnancy on treatment preference.

Methods: The study was planned between January 2015 and December 2021. Patients who received biological treatment at conception were determined retrospectively. Demographical data, clinical features, treatment characteristics and pregnancy outcomes were recorded.

Results: 15 patients (mean age 37±2.4) were included. Mean age at diagnosis was 25.6±5.4 and age at gestation was 33±3.9. Mean follow-up duration was 96±55 months. Median period of biological therapy was found 37 (1-156) months. Six (40%) patients were diagnosed with Axial Spondyloarthritis, 6 (40%) Psoriatic Arthritis, 1 (6.6%) Rheumatoid arthritis. While 12 (80%) patients had planned (wanted) pregnancies, 10 (66%) patients were evaluated as eligible for pregnancy in terms of rheumatological disease by rheumatologists. 13 (86.6%) patients were in remission/partial remission before pregnancy, 5 (33.3%) patients were using steroid and disease modifying anti-rheumatic drugs (DMARDs) were stopped before conception. 10 (66.6%) patients were receiving certolizumab, 4 (26.7%) patients were receiving adalimumab. It was found that the treatment of the patient who received rituximab was interrupted due to the pregnancy planning. While certolizumab treatment continued in 6 (60%) patients during pregnancy, the treatment of patients receiving adalimumab was discontinued within 6 months after birth. Activation of disease was occurred in 2 patients whose therapy was interrupted. Biological treatment was restarted during pregnancy in 3 of 9 patients whose biological treatment was discontinued. No perinatal complication was developed except premature rupture of membranes in one patient. It was observed that all infants were healthy at birth, but baby of the mother who received certolizumab was diagnosed mental retardation in early childhood.

Conclusion: In this study, it was established that the majority of patients using TNF antagonist during pregnancy,

1-Having wanted/planned pregnancy,

2-Being in remission or low disease activity before pregnancy,

3-Not experiencing disease activation during pregnancy.

In this study, it was concluded that having a pregnancy plan may be an important factor for rheumatologists to decide type of TNF antagonist, and physicians tend to prefer certolizumab in patients with pregnancy plan.

Table 1. Baseline clinical and treatment characteristics

| Age, years | 37±2.4 |
| Age, at diagnosis | 25.6±5.4 |
| Age, at gestation | 33±3.9 |
| Follow-up duration, months | 96±55 |
| Biologic treatment duration, months | 37 (1-156) |

Rheumatologic disease:
- Spondyloarthritis: 6 (40)
- Psoriatic arthritis: 6 (40)
- Rheumatoid arthritis: 1 (6.6)

Bowel disease:
- Ulcerative colitis: 1 (6.6)
- Crohn's disease: 1 (6.6)

Biologic treatment:
- Certolizumab: 10 (66.6)
- Adalimumab: 4 (26.7)

Discontinuation of treatment: 9 (60)

Restart: 3 (33.3)

Disease activity:
- Remission/Partial remission: 13 (86.6)
- Active: 3 (20)

Disclosure of Interests: None declared


TREATMENT OF ANKYLOSING SPONDYLITIS (AS) WITHIN 1 YEAR AFTER DELIVERY

O. Krichnevskaya1, E. Elyin2, T. Dubinina1, S. Glukhova1, A. Demina1, I. Andrianova1. 1VA Nasonova Research Institute of Rheumatology, Laboratory of axial spondyloarthritis, Moscow, Russian Federation

Background: Prescribing therapy to women after childbirth is still a difficult task in Russia due to the well-established ideas among patients and pediatricians of the incompatibility of lactation and treatment. Monitoring AS activity in patients without lactation is also important: maintaining physical and mental health are necessary for full-fledged care of the newborn and the joy of motherhood.

Objectives: To describe the frequency of drug use in women with AS within 1 year after childbirth, to determine the relationship with AS activity, to compare the incidence of diseases in children under one year whose mothers received and did not receive AS therapy during breastfeeding.

Methods: 44 pts with confirmed AS (modified New York criteria, 1984) were followed within 1 year after childbirth. The average age of the pts was 32.5±5.8 years. BASDAI at 1, 6 and 12 months after delivery was: 2.4 [1,4;4,2]; 2.6 [1,4; 4,4]; 2.7 [1,5; 4,1], respectively. ASDAS-CPR was: 2.0 [1,2; 2,7]; 1.9 [1,4; 2,5]; 1,7[1,3; 2,3], respectively. AS activity in pts with and without lactation did not differ. 41 pts (93.2%) had been continuing lactation during 1 month after delivery, 27 (61.4%) pts – during 1 month after delivery, 17 (38.6%) pts – during 1 month after delivery. Adherence to nonsteroidal anti-inflammatory drugs (NSAIDs) therapy was defined as the ratio of the actual dose taken to the prescribed dose. The total dose of NSAIDs was determined by the NSAID intake index (M. Dougados, 2001).

Results: NSAIDs. Ibuprofen was the drug of choice in pts with lactation, 74,1% and 88,2% of pts received it at 1, 6 and 12 months after delivery. Women without lactation received various NSAIDs in 100% of cases. The index of NSAID intake in pts with lactation increased during the first six months after delivery and after 1, 6 and 12 months after delivery and it was: 0 [0; 25]; 33,3 [12; 42,1] and 33,3 [17; 50], respectively (p < 0,05 compared to 1 month after delivery). The index of NSAID intake at 1 and 12 months after delivery in pts without lactation was higher than in pts with lactation (p < 0,05). Adherence to NSAID therapy in pts with lactation was increased during follow-up period after 1, 6 and 12 months after delivery. The index of NSAID intake was: 10 [0; 100]; 71 [30; 100] and 100 [50; 100], respectively (p < 0.05 compared to 1 month after delivery). There was no effect of NSAIDs intake on the AS activity.

Sulfasalazine (SSZ) because of arthritis in the 3rd trimester of pregnancy was received by 5 pts (11,4%); 2 of them independently canceled SSZ after childbirth due to fear of its negative effect on the baby during breastfeeding, both had recurrent arthritis within a year after childbirth. Against the background of lactation, only 1 woman received SSZ at a dose of 1.5 g per day.

DMARD. During the year after childbirth, 17 (38,6%) pts had a need for bDMARD, however, for insufficient availability only 11 pts (25%) received bDMARD: 1 (certolizumab pegol, CZP) within 1 month after childbirth, 8 (CZP – 4, ADA – 4) within 2–6 months, 11 (CZP – 4, adalimumab – 4, infliximab – 1, golimumab – 1, etanercept – 1) within 7 – 12 months of delivery. Of these, 4 pts (all of them intake CZP) received TNF inhibitors during lactation, AS activity in pts with lactation increased during the first six months after delivery and after 1, 6 and 12 months after delivery was: 2.7 ± 0.6 and 2.4 ± 0.5, respectively. In pts with lactation, the same trend was noted: ASDACRP was 2.8 ± 0.5 and 2.1 ± 0.3, respectively.

There were no differences in the frequency of acute respiratory viral infections, atopic dermatitis, the need for antibiotics, and the frequency of hospitalizations in breastfed children whose mothers received and did not receive AS therapy during lactation.

Conclusion: NSAIDs in low doses do not affect AS activity. According to our data performed on a small group of patients with AS, the effectiveness of TNF-alpha therapy does not differ against the background of lactation and without it. It is necessary to increase the knowledge of patients and pediatricians about therapeutic possibilities during lactation to avoid unjustified drug cancellation.

Disclosure of Interests: None declared


EVALUATION OF THE EFFICACY OF INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA FOR PATIENTS WITH ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE.

E. Rozochkina1, E. Koltssova1, D. Murtazalieva1, E. Zhilayeva2, E. Koshkarova3, G. Lukina4,5. 1.A.S. Loginov Moscow Clinical Scientific Center; Rheumatology, Moscow, Russian Federation; 2European Medical Center; Rheumatology; Moscow, Russian Federation; 3UCB – Aston Consulting-, Rheumatology, Moscow, Russian Federation; 4VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation; 5VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: The question of the comparative efficacy of tumor necrosis factor-alpha (TNF-α) inhibitors is topical today, because the research data that were distributed in random sequence mainly reflect the efficacy of the only specific drug, and the available data obtained in the ankylosing spondylitis (AS) treatment use of a network meta-analysis are limited.

Objectives: To make a comparative evaluation of the efficacy of various TNF-α inhibitors for patients with AS in real clinical practice.

Methods: The study involved patients with a reliable diagnosis of AS (according to the 1984 New York criteria) who received TNF-α inhibitor during the 12-month
course of therapy, from 2018 to 2022. The efficacy of the drugs was evaluated by the ASDAS (CRP) (Ankylosing Spondylitis Disease Activity Score) and BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) – disease activity indices obtained 6 and 12 months after the start of therapy. Comparison of indicators between drugs was carried out using a non-parametric Kruskal-Wallis test, designed to test the equality of the medians of several samples.

Results: The study involved 257 patients with AS who were treated with various TNF-α inhibitors, among which Adalimumab was taken by 77 patients (29.96%), Golimumab - 20 (7.78%), Infliximab - 15 (5.84%), Certolizumab pegol - 27 (10.51%) and Etanercept - 118 (45.91%). The mean age of the involved patients was 46.1 ± 11.4 years old, the mean age at the onset of the disease was 28.7 ± 11.7 years old. The majority of patients were males - 167 (64.98%), 143 (55.64%) had Higher education, 163 (63.42%) were married, 103 (40.08%) had been working and - 150 patients (58.37%) had never smoked before the study. Mean ASAS (CRP) and BASDAI, disease activity indices, values for each drug before therapy, 6 and 12 months after the start of therapy are presented in Table 1. «Head-to-head» comparison of medical preparations revealed no significant differences between TNF-α inhibitors in terms of the studied parameters (p > 0.05).

Table 1. Basal features

<table>
<thead>
<tr>
<th>Gender, men</th>
<th>36 (59%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (average, SD)</td>
<td>47.8 (+/- 13.3)</td>
</tr>
<tr>
<td>Disease:</td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>36 (59%)</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>22 (36%)</td>
</tr>
<tr>
<td>Non-radiographic axial spondyloarthritis</td>
<td>3 (5%)</td>
</tr>
<tr>
<td>Non-radiographic peripheral spondyloarthritis</td>
<td>7 (11.5%)</td>
</tr>
<tr>
<td>Non-radiographic axial spondyloarthritis (SpA), clinical manifestations (axial, peripheral affectation and both)</td>
<td>6 (9.8%)</td>
</tr>
</tbody>
</table>

There was no association between the different diagnoses and drug suspension, both variables were independent (p=0.702) with a 5% significance level. There was also no evidence of a significant relationship between the type of involvement (axial/peripheral/both), and the suspension of treatment (p=0.743).

Conclusion: The suspension of the drug due to AEs was small in our sample (8.2%) and the AEs detected were mild (including a mucocutaneous candidiasis). No serious AEs were observed. We found an overall drug survival of 70% in our study. These data are consistent with those published in the different clinical trials of the drug (FUTURE I, II and V, MEASURE I, II and III, PREVENT...). Therefore, we can conclude that Secukinumab constitutes a drug with a good security profile.
Table 1. Characteristics of RA and SpA patients who developed paradoxical reactions

<table>
<thead>
<tr>
<th>N Patients (N, %)</th>
<th>N Patients (N, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paradoxical reactions (PRs)</td>
<td>139</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>126 (90.6%)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>6 (4.3%)</td>
</tr>
<tr>
<td>Sacrocolitis</td>
<td>2 (1.4%)</td>
</tr>
<tr>
<td>IBZ</td>
<td>1 (0.7%)</td>
</tr>
<tr>
<td>Other*</td>
<td>4 (3.4%)</td>
</tr>
<tr>
<td>Primary disease</td>
<td>139</td>
</tr>
<tr>
<td>RA</td>
<td>40 (28.8%)</td>
</tr>
<tr>
<td>SpA</td>
<td>99 (71.2%)</td>
</tr>
<tr>
<td>Time interval between PRs-diagnosis of RA/SpA (months)</td>
<td>124</td>
</tr>
<tr>
<td>Time interval between PRs-biological onset (months)</td>
<td>126</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>123</td>
</tr>
<tr>
<td>Smokers (Current/ever)</td>
<td>131</td>
</tr>
<tr>
<td>Biological agents used during PRs</td>
<td>139</td>
</tr>
<tr>
<td>TNF-α inhibitor used**</td>
<td>127 (91.3%)</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>2 (1.4%)</td>
</tr>
<tr>
<td>Abatacept</td>
<td>6 (4.3%)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>4 (2.9%)</td>
</tr>
<tr>
<td>Biological agents used after PRs</td>
<td>101</td>
</tr>
<tr>
<td>Eternecer</td>
<td>31 (22.8%)</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>15 (11%)</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>12 (8.8%)</td>
</tr>
<tr>
<td>Other***</td>
<td>43 (57.5%)</td>
</tr>
</tbody>
</table>


Vasculitis: 1. **Adalimumab: 43 (30.9%), Eternecer: 28 (20.1%), Infliximab: 26 (18.7%).

Corticosteroids: 20 (14.4%), Golimumab: 10 (7.2%).** Corticosteroids: 9 (6.6%), Tocilizumab: 9 (6.6%).

Infliximab: 7 (5.1%), Tocilizumab: 5 (3.7%), Golimumab: 4 (2.9%), Ustekinumab: 4 (2.9%).

Rituximab: 2 (2.9%), Abatacept: 1 (0.7%), Anakinra: 1 (0.7%).

1. mean ± standard deviation.

Conclusion: Clinicians should be aware that PRs may develop with biological agents other than TNF-α inhibitors. Additionally, it is important to keep in mind that the development time of PRs could be variable. The mechanism(s) behind PRs remain unknown, and there is no currently available diagnostic or therapeutic protocol (2). The decision whether to continue or discontinue biological agents should be individualized. We found that the majority of patients can be managed without discontinuing biological agents. Finally, we believe that the experience of our large cohort can help physicians in clinical practice where sufficient protocol is lacking.
AB0775 EFFICACY, SAFETY AND SURVIVAL OF SECUKINUMAB IN SPONDYLOARTHRITIS.

M. López I Gómez1, N. Del Val del Amo1, L. Ibarrola1, U. Astigarraga Urkia1, J. Mendizabal1, G. Sada1, S. Garcia Perez1, I. Paniagua Zudaire1, L. Garrido Courel1, L. Horcada1, R. Gutierrez1, C. Fito-Manteca1. Hospital Universitario de Navarra, Rheumatology, Pamplona, Spain

Background: Secukinumab (SCK) is a fully human monoclonal antibody that selectively inhibits IL-17A indicated for both axial and peripheral spondyloarthritis (SpA) and psoriatic arthritis (PsA). In this paper we present our experience with SCK since its approval, in a tertiary hospital.

Objectives: To describe the efficacy, survival and safety of SCK treatment in real clinical practice in patients with SpA and PsA.

Methods: We performed a descriptive, retrospective analysis of patients diagnosed with SpA according to ASAS criteria and PsA according to CASPAR criteria. For this purpose, data were collected from the medical records of 75 patients treated with SCK in the rheumatology service.

To evaluate efficacy in the Spa group, analytical variables (C-reactive protein (CRP)), the Ankylosing Spondylitis Disease Activity Score (ASDAS) scale and the EULAR Spondyloarthritis Disease Activity Index (SAA) were assessed at baseline and at 12 months. Survival was evaluated with respect to the causes of drug discontinuation and its association with individual baseline characteristics, such as metabolic syndrome. Safety was evaluated by analyzing intercurrent infections or neoplasms requiring discontinuation.

Results: Seventy-five patients with spondyloarthritis included in treatment with SCK were analyzed, 40 had SpA and 34 had PsA. The mean age at diagnosis was 45.1 years (SD 11.3) and the median time from diagnosis to onset of SCK was 4.5 years (IQR 1-10) (Table 1).

<table>
<thead>
<tr>
<th>Variable</th>
<th>SpA</th>
<th>PsA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis</td>
<td>45.1 (SD 11.8)</td>
<td>44.9 (SD 10.9)</td>
<td>45.1 (SD 11.3)</td>
</tr>
<tr>
<td>Age at begging of SCK</td>
<td>53.9 (SD 9.3)</td>
<td>52.2 (SD 10)</td>
<td>52.9 (9.6DE)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>10 (25.0%)</td>
<td>10 (29.4%)</td>
<td>20 (27.0%)</td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>17 (42.5%)</td>
<td>17 (51.5%)</td>
<td>34 (46.6%)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>5 (12.5%)</td>
<td>6 (17.6%)</td>
<td>11 (14.9%)</td>
</tr>
<tr>
<td>Body Mass Index</td>
<td>27.9 (SD 4.4)</td>
<td>30.5 (SD 4.4)</td>
<td>29.2 (SD 4.7)</td>
</tr>
<tr>
<td>Tobacco</td>
<td>14 (35.0%)</td>
<td>10 (29.4%)</td>
<td>24 (32.4%)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>5 (12.5%)</td>
<td>2 (5.9%)</td>
<td>7 (9.5%)</td>
</tr>
<tr>
<td>Previous sDMARD</td>
<td>13 (32.5%)</td>
<td>20 (74.0%)</td>
<td>33 (40.2%)</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>1.7% (15%)</td>
<td>12 (35.3%)</td>
<td>18 (24.2%)</td>
</tr>
<tr>
<td>Leflunomide</td>
<td>7 (18.4%)</td>
<td>15 (44.1%)</td>
<td>22 (28.6%)</td>
</tr>
</tbody>
</table>

Statistically significant improvement was observed in both pathologies in VAS (-2.1 SD 3.1) (p 0.003). Despite the improvement in CRP, in both groups of -3.7 mg/L (SD 15) was not statistically significant. Regarding ASDAS, in the Spa group, 2 patients (5.3%) showed great improvement (>3.1), 9 patients (23.7%) clinical improvement (>1.1), 17 patients (42.5%) improvement (<1.1), 6 patients (15%) showed no improvement and 4 patients (10.5%) worsening.

The overall drug survival to date is 19.41 months (SD 13.6), 18(4.8) in the Spa group and 18 (SD 12.6) in the AP group (Figure 1).

Conclusions: In our cohort, SCK showed a statistically significant improvement in the VAS scale in both groups. A 23.7% of patients with SpA showed clinical improvement according to ASDAS values, 5.3% showed great improvement and 42.5% showed mild improvement. The overall drug survival to date is 19.41 months (SD 13.76) slightly longer in the SpA group than in APs. SCK seems to be a safe drug as none of our patients presented infections during its use.

Disclosure of Interests: None declared


AB0776 CLINICAL AND LABORATORY PECULIARITIES OF TREATMENT-REFRACTORY ANKYLOSING SPONDYLITIS.

K. Sakhareva1, S. Erdes1, M. Cherkasova1, V.A. Nasonova Research Institute of Rheumatology, Axial spondyloarthritis, Moscow, Russian Federation

Background: Despite the availability of newest guidelines for the treatment of ankylosing spondylitis and various groups of genetically engineered biological drugs, there are still patients with refractory, i.e., resistant to therapy (with two or more genetically engineered drugs), AS, maintaining high clinical and laboratory activity.

Objectives: To analyze the clinical peculiarities of patients with refractory AS and to identify markers for early detection of such cases.

Methods: Patients who received 2 or more GEBDs and demonstrated a primary or secondary failure were considered cases of refractory ankylosing spondylitis. Twenty-four (16%) patients with refractory AS (mNYC 1984) were enrolled, including 14 males, 10 females. This group was selected from 150 successive AS patients admitted to the clinic of the Scientific Research Institute of Rheumatology in 2020–2021. Ninety-three per cent of patients had HLA B 27, the mean age was 39 [31.5; 49] years, the age of onset of the disease was 21.7 [15.5; 29] years, the duration of the disease was 173 [11; 24]. They were treated with drugs of various groups (i-TNF-α, IL-17, and Janus kinase inhibitors). The refractory AS patients were compared to a control group with the corresponding gender, age of onset and duration of the disease admitted successively to the Institute during the same period. The examination followed the ASAS recommendations. All patients had additional nephelometric assay of SAA level using commercial reagent kits, reference value < 5 mg/L.

Figure 1. Secukinumab survival in both groups

17 patients (23%) discontinued treatment, with a median duration of 12 months (SD 4.68), 12 (70.6%) due to ineffectiveness, 1 (5.9%) by their own decision, 3 (17.6%) due to persistent mechanical pain and 1 (5.9%) due to neoplasia (gastric adenocarcinoma). The clinical variables of metabolic syndrome were evaluated (Table 1) none of these characteristics had a statistically significant association as a cause of drug discontinuation. No patient presented infections that required discontinuation of the drug. No association was detected between drug discontinuation or the development of metabolic syndrome.

Disclosure of Interests: None declared


*The total number was not matched because the data of some patients could not be accessed.*
Spondyloarthritis is a chronic inflammatory disease associated with increased cardiovascular morbidity and mortality due to accelerated atherosclerosis. Recent studies have reported the benefit of TNF inhibitors in reducing cardiovascular morbidity and mortality due to accelerated atherosclerosis. Recent studies have reported the benefit of TNF inhibitors in reducing atherosclerosis assessed with carotid intima-media thickness (CIMT) and flow-mediated dilatation (FMD) in patients with spondyloarthritis (SpA).

Methods: We performed a cross sectional study including 47 patients meeting ASAS 2009 criteria for SpA. Patients with traditional cardiovascular risk factors were excluded. We collected clinical data, therapeutic modalities and biological tests including total cholesterol, HDL, LDL and triglyceride after 12 hours of fasting. FMD and mean CIMT (mean value of right and left carotid artery) were measured with a Mindray Resona 7 ZST+ ultrasound machine by an experienced radiologist.

Results: Among the 47 subjects, 18 patients (38%) were receiving TNF inhibitors for a median duration of 36 months (IQR 25-75%; 24-72) (9 were on Etanercept, 7 were on Adalimumab, one patient was on Infliximab and one was on Golimumab). The group treated with TNF inhibitors had a median age of 43 years (IQR 25-75%; 36-46.5) and a median duration of the disease of 12 years (IQR 25-75%; 9.5-22). Median ASOS and BASDAI scores were 2.60 (IQR 25-75%; 1.48-3.1) and 2.60 (IQR 25-75%; 1.55-3.75) respectively. On the other hand, patients naïve to TNF inhibitors had a median age of 32 years (IQR 25-75%; 55-42), median disease duration of 7 years (IQR 25-75%; 3-12.5), median ASOS of 2.13 (IQR 25-75%; 1.61-2.91), and median BASDAI of 2.40 (IQR 25-75%; 1.55-3.75). When comparing the two groups, there was no significant difference regarding disease activity scores ASOS (p=0.431) and BAS-DAI (p=0.793) as well as biochemical variables; total cholesterol (p=0.483), HDL (p=0.395), LDL (p=0.263) and triglyceride (0.092). In contrast, patients on TNF inhibitors were significantly more aged (p=0.009) and had a significantly higher duration of the disease (p=0.004). Doppler ultrasound examination showed a median CIMT of 0.56 mm (0.48-0.64) in patients treated with TNF inhibitors versus 0.55 mm (0.48-0.60) in patients naïve to TNF inhibitors with no significant difference (p=0.238). Patients on TNF inhibitors had lower values of FMD (with a median of 12.5 (6.7-16) versus 15.5 (10-24.5)). However this difference was not significant (p=0.182).

Conclusion: In our study, biological treatment with TNF inhibitors did not affect endothelial function and subclinical atherosclerosis in patients with spondyloarthritis. Given the small size of our study population and its heterogeneity in terms of age and duration of the disease, no conclusions can be drawn. Further longitudinal studies that involve larger samples are necessary.

Disclosure of Interests: None declared


References:

Disclosure of Interests: None declared

COMPARISON OF TNF-α INHIBITORS EFFICACY BETWEEN RHEUMATIC DISEASES AND INFLAMMATORY BOWEL DISEASES

T. Nuriakhmetova, D. Abdulganieva, A. Odincova, E. Sukhorukova, J. Shevnina, Kazan State Medical University, Hospital therapy, Kazan, Russian Federation; Kazan State Medical University, Hospital therapy, Kazan, Russian Federation; Kazan State Medical University, Central Scientific Research Laboratory, Kazan, Russian Federation; Republican clinical hospital n.a. N.A. Semashko, Outpatient clinic, Simferopol, Russian Federation

Background: The immunogenicity of TNF-α inhibitors (TNFi) is known to affect the efficacy of these biologic drugs. No previous studies compared this effect head-to-head between different groups of immune-mediated diseases.

Objectives: To compare the effect of immunogenicity of TNFi and their trough level on their efficacy in rheumatic diseases (RD) (ankylosing spondylitis (AS) and rheumatoid arthritis (RA)) and inflammatory bowel diseases (IBD) (Crohn’s disease (CD) and ulcerative colitis (UC)).

Methods: 123 patients receiving infliximab (INX) (n=36, 29.3%), adalimumab (ADM) (n=49, 39.8%) and certolizumab pegol (CZP) (n=38, 30.9%) were included into the study. 70 (56.9%) of them had RD (50 (40.7%) with AS and 20 (16.3%) with RA) and 53 (43.1%) of them had IBD (38 (30.9%) with CD and 15 (12.2%) with UC). The specific criteria were used to assess the response to the treatment (ASAS20 for AS, EULAR for RA, CDAI for CD and Mayo Score for UC).

Measurement of trough level of TNFi and the level of anti-drug antibodies (ADAb) was performed with the use of commercially available ELISA kits. The threshold of low trough level depended on the diseases based on the guidelines: 1 μg/mL for INX in RD group and 5 μg/mL for INX in IBD group, 5 μg/ml for ADM, and 20 μg/l for CZP.

Results: Efficacy of TNFi was 1.3 times more prevalent among patients with RD than among IBD patients (n=60, 85.7% vs n=35, 66%, OR 1.3, 95%CI 1.0 to 1.6, p=0.01). Rate of response to INX and ADM was comparable between the diseases while CZP was more efficient in RD (4.8% vs 35.3%, OR 1.3, 95%CI 1.0 to 2.0, p=0.031). Median trough levels of TNFi did not differ between the groups (p>0.05). Low level was determined in 26 (40.6%) patients with RD and 27 (45.8%) patients with IBD. Low level of TNFi most often was found in patients with UC (n=12, 80%, OR 5.6, 95%CI 1.49 to 20.99, p=0.006). Only INX low level was more prevalent in IBD patients than in RD (87% vs 46.2%, OR 5.7, 95%CI 1.1 to 29.2, p=0.046).

The rate of low level of other TNFi was comparable between the groups (p>0.05). In RD group low level was associated with loss of response (80%, OR 6.0, 95%CI 1.2 to 30.7, p=0.036) while in IBD group no relation was found (51.4% vs 50%, p>0.05). Positive ADAb were determined in 22 (17.9%) patients: 14 (20%) in RD group and 8 (15.1%) in IBD group. TNFi did not differ significantly by the rate of ADAb-positivity (p>0.05). Association of loss of response with ADAb was observed in 4 (40%) patients with RD and 2 (11.1%) patients with IBD. Inefficacy of TNFi due to immunogenicity was 6 times more frequent in RA than in IBD (p=0.05). ADAb to INX (a chimeric antibody) were found only in patients with inefficacy (n=2, 66.7%, p=0.067). After exclusion of patients receiving ADM (a humanized antibody) 3 (75%) non-responders to INX or CZP with RD had positive ADAb while significantly less non-responders among IBD patients were ADAb-positive (n=2, 14.3%; OR 0.06, 95%CI 0.004 to 0.84, p=0.044).

Conclusion: Most of non-responders with RD had either low trough level of TNFi or ADM, while in IBD group only half of cases of non-response could be attributed to the effect of ADAb or low trough level of TNFi.

REFERENCES:

Disclosure of Interests: Tatiana Nuriakhmetova Grant/research support from: grant for the purchase of lab kits from Novartis Ltd, Diana Abdulganieva: None declared, Alfa Odincova: None declared, Elena Sukhorukova: None declared. Jana Shevnina: None declared.

Spondyloarthritis - clinical aspects (other than treatment)

AB0781 MALAYSIA SPONDYLOARTHRITIS ACCELERATED MANAGEMENT (SAM) MODEL: EXPEDITING AXSpA PATIENT JOURNEY FROM EARLY REFERRAL, DIAGNOSIS AND ACCESS TO OPTIMAL CARE

F. Yahya1, H. Mohd Yusof2, A. Mohd3, S. Ch'ng Suyin4, S. C. Gun1, M. Mohd Zain1, S. Sockalingam1, S. L. Lau1, C. Bao Jing4, J. Tiong1, I. S. Lau4, R. Sengupta5, 1University of Malaya, Rheumatology, Kaula Lumpur, Malaysia; 2Medical University, Rheumatology, Selangor, Malaysia; 3Hospital Ta'fah, Rheumatology, Seremban, Malaysia; 4Novartis, Rheumatology, Petaling Jaya, Malaysia; 5Royal National Hospital for Rheumatic Diseases, Rheumatology, Bath, United Kingdom

Background: Axial spondyloarthritis (axSpA) is an important cause of inflammatory back pain (IBP). It is under-recognized, leading to significant delays in diagnosis. Early recognition and diagnosis are crucial to achieve the best outcomes for patients and in Malaysia, significant gaps in the clinical management of axSpA remain. Therefore, we sought to implement a strategy to improve the time to diagnosis and management of axSpA in Malaysia by collaborating and adopting guidance from an international axSpA expert.

Objectives: The objectives were to improve disease recognition among healthcare practitioners (HCPs), reducing time to specialist referral and diagnosis whilst improving disease management by developing and implementing a new patient care model called the Spondyloarthritis Accelerated Management (SAM) and measure its effectiveness in 3 Rheumatology centers in Malaysia.

Methods: The SAM initiative was developed by the Malaysian SpA Consortium Working Group involving 8 Malaysian rheumatologists from 3 local centers and 1 international axSpA expert from the UK as part of the steering committee. Selections were based on clinical expertise. The first local alignment meeting on model structure was held in July 2020 with subsequent meetings held to address key barriers to early axSpA diagnosis and timely access to quality care. A care model with feasible key performance indicators (KPIs) was established, adapted and tracked monthly in the 3 rheumatology centers (Figure 1). Referential tools were developed to facilitate early referrals to rheumatologists. These included a QR-coded ‘3-F’ referral guide and a patient self-screening tool with a patient self-referral letter all hosted on the Malaysian Society of Rheumatology (MSR) website, educational talks to HCPs and public awareness forums on IBP and axSpA. Data were collected on referral source, duration of referrals, knowledge on IBP and axSpA diagnosis and timely access to quality care. A care model with feasible key performance indicators (KPIs) was established, adapted and tracked monthly in the 3 rheumatology centers (Figure 1).

Results: At 1 year after the initiative was launched. Baseline data collected were from August to October 2020 and 1 year data were from November 2020 to November 2021.

Conclusion: The SAM initiative has shown promising initial results in improving referrals of patients with IBP, promoting earlier diagnosis and establishing the importance of having timely access to optimal care. A nationwide implementation is being planned to improve the recognition of the axSpA in Malaysia.

AB0782 SERUM PENTRAXIN 3 AS A BIOMARKER IN PATIENTS WITH SPONDYLARTHRITIS.

Z. Tanosoka-Stenista1, A. Drelich-Zbroja2, K. Grzeczkow2, 1Medical University of Lublin, Department of Rheumatology and Connective Tissue Diseases, Lublin, Poland; 2Medical University of Lublin, Department of Interventional Radiology and Neuroradiology, Lublin, Poland; 3Independent Public Teaching Hospital No 4, Department of Rheumatology and Connective Tissue Diseases, Lublin, Poland

Background: A proper evaluation and management of patients with spondyloarthritis (SpA) requires the use of biomarkers, facilitating early diagnosis, reflecting disease activity and clinical response to therapies. The chronic, systemic inflammatory process is responsible for increased CV risk in SpA patients. Pentraxin 3 (PTX3) is an inflammatory marker, a member of long pentraxin superfamily, argued to be involved in pathogenesis of both inflammation and atherosclerosis. PTX3 is produced locally in the inflamed tissue, by different cell types including macrophages, endothelial cells, synoviocytes, but not hepatocytes. PTX3 is produced in walls of blood vessels, in atherosclerotic plaques, as a response to pro-inflammatory cytokines.

Objectives: The aim of the study was to assess the role of PTX3 as a biomarker in patients with SpA and to evaluate the relationship between PTX3 and CV risk markers (carotid intima-media thickness (cIMT), lipid profile).

Methods: The study group consisted of 40 consecutive patients with SpA: 29 patients with psoriatic arthritis (PsA) and 11 patients with ankylosing spondylitis (AS). The group consisted of 16 (40%) women and 24 (60%) men, with the mean (SD) age 43.9 (12.0) (range 25–68) and disease duration 7.8 (7.8) years (range 1–30). An assessment of the disease activity included laboratory inflammatory parameters (erythrocyte sedimentation rate (ESR), C-reactive protein, CRP) and clinical assessment (in patients with peripheral SpA (pSpA) joints counts and disease activity score in 28 joints (DAS28); in patients with axial SpA (axSpA) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and pain of the spine according to the patient in visual analogue scale (VAS). A measurement of carotid intima-media thickness (cIMT) was performed using high-resolution B-mode ultrasonography to estimate features of atherosclerosis (cIMT> 0.9 mm and/or presence of atherosclerotic plaques).

Results: The median (IQR) PTX3 concentration in SpA patients was 3.39 (2.22–3.88) ng/ml. The mean (SD) value of ESR was 27.7 (28.3) mm/h and CRP concentration 13.6 (19.9) mg/l. The mean values of clinical indices were as follows: DAS28 3.8 (1.1), BASDAI 4.02 (2.1), BASFI 4.22 (2.2), VAS spine pain 41.4 (24.0). The mean (SD) cIMT value was 0.77 (0.23) mm (range 0.48–1.33). The features of atherosclerosis were detected in 7 (17%) patients. No significant correlations were found between PTX3 and other inflammatory markers (ESR, CRP). There were no correlations between PTX3 concentration and the clinical indices of the disease activity (DAS28, BASDAI, BASFI, VAS spine pain). No differences of PTX3 concentrations were detected between pSpA and axSpA patients. The PTX3 concentrations were significantly higher in patients with definite atherosclerosis (cIMT> 0.9 mm) than in patients with subclinical or no atherosclerosis (cIMT< 0.9) (5.79 (3.84-8.59) vs 3.06 (2.0-3.52) ng/ml, p=0.01), as well as in patients with atherosclerotic plaques in comparison with no plaques (6.79 (4.96-8.59) vs 3.26 (2.0-3.71) ng/ml, p=0.02) (Figure 1).
Background: The diagnostic delay in patients with axial spondyloarthritis (axSpA) is one of the most important barriers for an early diagnosis of these patients. The diagnostic delay is defined as the time from the onset of symptoms until the diagnosis is confirmed. The diagnostic delay in patients with axSpA has been reported to be a significant contributor to the diagnostic delay. The diagnostic delay in patients with axSpA is known to be a significant factor in the delay of referral to rheumatologists, the delay in the performance of imaging tests, and the delay in the diagnosis of patients with axSpA.

Methods: In this cross-sectional study, we consecutively enrolled 153 patients with axSpA and 153 age- and sex-matched controls who were not diagnosed with axSpA. Patients were assessed in the rheumatology clinic of the Hospital Universitario de Bellvitge in Barcelona, Spain, and the rheumatology clinic of the Hospital Universitario de la Princesa in Madrid, Spain.

Results: The mean age of patients with axSpA was 38.2 years (range, 18-80 years), and 59% were women. The mean duration of symptoms before referral to the rheumatologist was 2.8 years (range, 0.1-10 years). The mean duration of symptoms before the diagnosis of axSpA was 3.2 years (range, 0.1-10 years). The mean duration of symptoms before the performance of imaging tests was 2.5 years (range, 0.1-10 years). The mean duration of symptoms before the diagnosis of axSpA was 3.2 years (range, 0.1-10 years).

Conclusion: The diagnostic delay in patients with axSpA is a significant barrier to the early diagnosis of these patients. The diagnostic delay in patients with axSpA is due to the delay in referral to the rheumatologist, the delay in the performance of imaging tests, and the delay in the diagnosis of patients with axSpA.

Disclosure of Interests: None declared.
Fig. 1. Frequencies with symptoms meeting FBD criteria

<table>
<thead>
<tr>
<th>Gut symptoms</th>
<th>Univariable</th>
<th>Multivariable</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASDAS-CRP&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.234</td>
<td>0.112</td>
</tr>
<tr>
<td>BASDAI&lt;sup&gt;b&lt;/sup&gt;</td>
<td>0.747</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>BAS-G&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.306</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>ASAS HI&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.590</td>
<td>0.889</td>
</tr>
<tr>
<td>BASFI&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.541</td>
<td>0.541</td>
</tr>
<tr>
<td>BASMI&lt;sup&gt;f&lt;/sup&gt;</td>
<td>0.448</td>
<td>0.066</td>
</tr>
<tr>
<td>IBS symptoms</td>
<td>0.039</td>
<td>0.863</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.317</td>
<td>0.172</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.590</td>
<td>0.889</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.541</td>
<td>0.541</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.541</td>
<td>0.541</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.541</td>
<td>0.541</td>
</tr>
<tr>
<td>Chronic diarrhea</td>
<td>0.541</td>
<td>0.541</td>
</tr>
</tbody>
</table>

Besides gut symptoms, other clinical variables (Block-1) being chosen into hierarchical multivariable models were as follows: HLA-B27, InCRP, and lnESR; HLA-B27 and lnESR; HLA-B27 and lnCRP; sex and TNFi; HLA-B27, lnESR, and TNFi; age and lnESR. Missing data ranging from 1-7%.

Disclosure of Interests: None declared

Table 1. Univariable and multivariable associations between gut symptoms and assessments of AS

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patient advocacy group member (n=85)</th>
<th>Not patient advocacy group member (n=610)</th>
<th>Total (n=695)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs), mean (SD)</td>
<td>50.2 (7.7)</td>
<td>44.6 (11.1)</td>
<td>45.3 (10.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BMI (kg/m2), mean (SD)</td>
<td>27.5 (6.0)</td>
<td>28.0 (12.7)</td>
<td>28.0 (12.0)</td>
<td>0.713</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>45 (52.9)</td>
<td>378 (62.0)</td>
<td>423 (60.9)</td>
<td>0.128</td>
</tr>
<tr>
<td>Disease duration (yrs), mean (SD)</td>
<td>13.7 (10.3)</td>
<td>12.5 (11.1)</td>
<td>12.6 (11.0)</td>
<td>0.303</td>
</tr>
<tr>
<td>ASDAS-HI, 0-17</td>
<td>7.3 (3.4)</td>
<td>6.4 (3.3)</td>
<td>6.5 (3.8)</td>
<td>&lt;0.045</td>
</tr>
<tr>
<td>BASDAI, 0-10</td>
<td>4.3 (1.9)</td>
<td>3.8 (2.2)</td>
<td>3.9 (2.2)</td>
<td>0.044</td>
</tr>
<tr>
<td>BASDAI ≥4, n (%)</td>
<td>49 (57.6)</td>
<td>275 (45.1)</td>
<td>324 (46.6)</td>
<td>0.025</td>
</tr>
<tr>
<td>BASFI, 0-10</td>
<td>3.9 (2.3)</td>
<td>3.2 (2.5)</td>
<td>3.3 (2.4)</td>
<td>0.015</td>
</tr>
<tr>
<td>Biologic treatment, n (%)</td>
<td>52 (61.2)</td>
<td>312 (51.1)</td>
<td>364 (52.4)</td>
<td>0.072</td>
</tr>
<tr>
<td>Full time employment, n (%)</td>
<td>48 (56.5)</td>
<td>410 (67.2)</td>
<td>458 (65.9)</td>
<td>0.06</td>
</tr>
<tr>
<td>Absenteeism&lt;sup&gt;a&lt;/sup&gt;, n (%)</td>
<td>8.4 (21.2)</td>
<td>10.9 (26.6)</td>
<td>10.6 (26.2)</td>
<td>-</td>
</tr>
<tr>
<td>Presenteeism&lt;sup&gt;a&lt;/sup&gt;, n (%)</td>
<td>38.4 (24.6)</td>
<td>31.8 (25.8)</td>
<td>32.6 (25.6)</td>
<td>-</td>
</tr>
<tr>
<td>Overall work impairment score&lt;sup&gt;a&lt;/sup&gt;, mean (SD)</td>
<td>40.6 (27.0)</td>
<td>36.8 (29.9)</td>
<td>37.2 (29.6)</td>
<td>0.380</td>
</tr>
<tr>
<td>Activity impairment, mean (SD)</td>
<td>46.7 (21.7)</td>
<td>40.5 (26.8)</td>
<td>41.3 (26.4)</td>
<td>0.058</td>
</tr>
<tr>
<td>PsA having ever received biologic treatment, n (%)</td>
<td>67 (78.8)</td>
<td>328 (53.8)</td>
<td>395 (56.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Rehabilitation measures, mean (SD)</td>
<td>49 (57.6)</td>
<td>210 (34.4)</td>
<td>259 (37.3)</td>
<td>0.001</td>
</tr>
<tr>
<td>NPTM, mean (SD)</td>
<td>76 (89.4)</td>
<td>515 (84.4)</td>
<td>591 (85.0)</td>
<td>0.231</td>
</tr>
</tbody>
</table>

<sup>a</sup>Work-related reasons of WPAI-score have been calculated for pts in employment (N=340);<sup>b</sup>regular physical training in the context of axSpA;<sup>c</sup>rehabilitation sport and/or functional training;<sup>d</sup>ASAS-HI, Assessment of SpondyloArthritis International Society-Health Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, Body Mass Index; n, number of pts; patients; SD, Standard Deviation; WPAI, Work Productivity and Activity Impairment; yrs, years.

Conclusion: Pt advocacy group membership was associated with increased prescribed NPTM in axSpA. Pt organizations may support the implementation of guidelines and improvement of self-management strategies in pts with axSpA, which may influence work participation.

Disclosure of Interests: Dirk Meyer-Olson Speakers bureau: AbbVie, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Consultant of: AbbVie, Amgen, Biocad, Chugai, Eli Lilly, Grünenthal, Janssen, MSD, Novartis, Pfizer, Roche and UCB, Grant/research support from: AbbVie, Amgen, Biocad, Fresenius, GSK, Novartis and Pfizer.

Background: Patients generally have higher scores than males on most items on self-report questionnaires, including MDHAQ/RAPID3 (multi-dimensional health assessment questionnaire/routine assessment of patient index data). MDHAQ/RAPID3 was validated in patients with rheumatoid arthritis (RA), but is informative in all diseases studied, including spondyloarthritis (SpA). More SpA patients are men than RA patients, suggesting lower scores, but MDHAQ scores are higher in SpA than RA.

Objectives: We compared self-reported MDHAQ/RAPID3 scores in RA vs SpA patients according to gender.

Methods: Patients who met classification criteria for RA or SpA (axial SpA and psoriatic arthritis) completed MDHAQ at a routine rheumatology visit. The MDHAQ includes 10 activities for physical function (FN) (8 identical to HQ), scored 0-3, total 0-30, divided by 3 for 0-10 score, 3-10 visual numeric scales (VNS) for pain (PN), patient global assessment (PATGL), and fatigue (FT), a 60-symptom checklist (ROS60) and a RADA1 self-report of painful joints (0-48). RAPID3 is a 0-30 index of FN + PN + PATGL. Means and standard deviations (SDs) of age, education, and 7 MDHAQ scores were computed in patients with RA versus SpA, and in subsets of female versus male patients with either RA or SpA. Unadjusted differences were evaluated using Student’s t and chi-square tests; mean differences were adjusted for age, gender and education using analysis of covariance.

Results: 170 patients were studied, 102 with RA and 68 with SpA. 82% of patients with RA and 47% of patients with SpA were female (<p=0.001); age and education did not differ between the 2 groups (ANOVA). All 7 MDHAQ scores analyzed were higher in patients with SpA than in those with RA, although only differences for FN were statistically significant (ANOVA). Within both the RA and SpA groups, however, all 7 scores were higher in women than in men, statistically significant for FN, PATGL, RAPID3 and fatigue in RA, and only for fatigue in SpA. In analyses adjusted for gender, FN, PATGL, FT, and RAPID3 were statistically significantly higher in SpA than in RA (Table 1).

Conclusion: The self-reported disease burden measured by MDHAQ / RAPID3 was higher in patients with SpA than in those with RA, despite having a lower proportion of women, who generally have higher scores on all patient self-report questionnaires, including MDHAQ/RAPID3, within both the RA and SpA groups.

Gender differences may lead to underestimation of the greater disease burden in SpA compared to RA.

Table 1. Mean differences in the MDHAQ scores between RA and SpA patients.

<table>
<thead>
<tr>
<th>Total, n=170 patients</th>
<th>RA: n=102</th>
<th>RA: Female (n=68/</th>
<th>RA–SpA</th>
<th>Mean difference: RA–SpA (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>58.8 (12.2)</td>
<td>55.7 (12.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender, female (%)</td>
<td>84 (42.4%)</td>
<td>32 (47.1%)*</td>
<td>-0.7</td>
<td>-1.3 (-2.0, -0.6)</td>
</tr>
<tr>
<td>Years of education, mean (SD)</td>
<td>11.8 (4.3)</td>
<td>11.4 (3.7)</td>
<td>-0.4</td>
<td>-1.1 (-2.0, -0.2)</td>
</tr>
<tr>
<td>MDHAQ variables, mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical function (0-10)</td>
<td>2.4 (1.8)</td>
<td>3.0 (2.1)</td>
<td>-0.6</td>
<td>-1.2 (-2.0, -0.0)</td>
</tr>
<tr>
<td>Pain (0-10 VNS)</td>
<td>4.5 (2.8)</td>
<td>4.9 (3.0)</td>
<td>-0.4</td>
<td>-1.3 (-2.0, -0.6)</td>
</tr>
<tr>
<td>Patient global assessment (0-10 VNS)</td>
<td>4.6 (2.8)</td>
<td>5.3 (2.9)</td>
<td>-0.6</td>
<td>-1.5 (-2.3, -0.9)</td>
</tr>
<tr>
<td>RAPID3 (0-30)</td>
<td>11.6 (6.8)</td>
<td>13.3 (6.8)</td>
<td>0.4</td>
<td>0.7 (1.0, 0.5)</td>
</tr>
<tr>
<td>Fatigue (0-10 VNS)</td>
<td>4.2 (2.9)</td>
<td>4.5 (3.1)</td>
<td>0.4</td>
<td>0.7 (1.0, 0.5)</td>
</tr>
<tr>
<td>Self-report RADA1 painful joint count (0-48)</td>
<td>12.4 (11.0)</td>
<td>13.4 (11.9)</td>
<td>0.4</td>
<td>0.7 (1.0, 0.5)</td>
</tr>
<tr>
<td>60-symptom checklist (0-60)</td>
<td>12.6 (10.0)</td>
<td>15.2 (10.9)</td>
<td>0.4</td>
<td>0.7 (1.0, 0.5)</td>
</tr>
</tbody>
</table>

* p<0.05.

Background: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease encompassing radiographic (traditionally known as ankylosing spondylitis) and non-radiographic forms that lead to chronic pain, structural damage, and disability.1 The International Map of Axial Spondyloarthritis (IMAS) survey is an initiative developed to generate insights into the real-life experiences of people living with axSpA to ultimately improve quality of life.2

Objectives: To assess the burden and daily experience of patients with axSpA in the United States.

Methods: The IMAS survey generates a report on patient-reported aspects of disease burden and experience with axSpA using adaptations of the original Atlas of axSpA questionnaire developed in collaboration with patients, the Axial Spondyloarthritis International Federation, and clinical academic experts. In this US adaptation of the IMAS survey, a 30-minute online survey was administered to US patients aged ≥18 years who completed screening questions, self-reported having been diagnosed with axSpA by a healthcare provider, and were under the care of a healthcare provider between July 22, 2021, and November 10, 2021. Survey questions were tailored to reflect differences in the US healthcare systems and the availability of treatments. This analysis presents a portion of the US data describing patient demographics, clinical characteristics, journey to axSpA diagnosis, and the emotional impact and overall burden of disease on quality of life using the General Health Questionnaire 12 (GHQ-12), the Assessment of SpondyloArthritis international Society – Health Index (ASAS-HI), and a global limitation index of 18 activities of daily living. All results were reported descriptively using summary statistics.

Results: Survey data from 228 US patients with axSpA were collected in this analysis. The mean age was 45 years, 60% of patients were female, and the mean BMI was 27.7 kg/m² (Table 1). Participating patients had an average of 5.6 comorbidities, with anxiety (43%), depression (41%), and hypertension (32%) as the most commonly reported comorbidities. Among all patients, the mean age at onset of first symptoms was 26 years and the mean age at diagnosis was 35 years; overall, mean diagnostic delay was greater in female than in male patients (11.2 vs 5.2 years; Figure 1A). According to the validated GHQ-12, over half of the patients (57%) were at risk for psychological distress (GHQ-12 score ≥3; Figure 1B). Patients who were older (>40 years old), physically inactive, or who had active disease (BASDAI ≥4) were at risk for psychological distress. Most patients (82%) reported descriptively using summary statistics.

Table 1. Patient Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients with axSpA (N=228)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years</td>
<td>45</td>
</tr>
<tr>
<td>Female, %</td>
<td>60</td>
</tr>
<tr>
<td>White, %</td>
<td>86</td>
</tr>
<tr>
<td>Mean body mass index, kg/m²</td>
<td>27.7</td>
</tr>
<tr>
<td>Nonsmoker, %</td>
<td>62</td>
</tr>
<tr>
<td>Alcohol consumption behavior, %</td>
<td>66</td>
</tr>
<tr>
<td>Never</td>
<td>19</td>
</tr>
<tr>
<td>Every day</td>
<td>9</td>
</tr>
<tr>
<td>Mean number of comorbidities (%)</td>
<td>5.6</td>
</tr>
<tr>
<td>Common comorbidities (≥20% of patients) (%)</td>
<td>4.0</td>
</tr>
<tr>
<td>Anxiety</td>
<td>43</td>
</tr>
<tr>
<td>Depression</td>
<td>41</td>
</tr>
<tr>
<td>Hypertension</td>
<td>32</td>
</tr>
<tr>
<td>Obesity/overweight</td>
<td>31</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>30</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>29</td>
</tr>
<tr>
<td>Uretis</td>
<td>24</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>20</td>
</tr>
<tr>
<td>Fibromyalgia</td>
<td>20</td>
</tr>
<tr>
<td>Spinal or other fractures</td>
<td>20</td>
</tr>
<tr>
<td>Psoas</td>
<td>20</td>
</tr>
<tr>
<td>Employed, %</td>
<td>54</td>
</tr>
</tbody>
</table>

axSpA, axial spondyloarthritis. Respondents could have selected ≥1 answer.

REFERENCES:

Acknowledgements: This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Medical writing support was provided by Charli Domínguez, PhD, of Health Interactions, Inc, Hamilton, NJ, USA, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.

Disclosure of Interests: Marina Magrey Consultant of: Received consulting fees from Eli Lilly and Novartis, Grant/research support from: Received research grants from AbbVie, Amgen, and UCB, Jessica A. Walsh Consultant of: Received consulting fees from Amsgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Grant/ research support from: Received research funding from AbbVie, Merck, and Pfizer, Sandra Fleri Employee of: Employee of Ipsos, Renato Calheiros Employee of: Employee of Novartis, David Wei Employee of: Employee of Novartis, Muhammad Asim Khan Consultant of: Has served as a consultant for Novartis

Background: The patient reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) includes the six components fatigue, neck, back or hip pain, pain or swelling in other joints, tenderness, morning stiffness severity and duration on a 0-10 scale.

Objectives: To explore the driving factors for the BASDAI in pregnant patients with axial spondyloarthritis (axSpA).

Methods: Anonymized pooled data of the European Network of Pregnancy Registries in Rheumatology (EuNeP) were used. The four participating registries are located in France, Germany, Norway and Switzerland, and collect data of women with child wish, during and after pregnancy prospectively and nationwide on regular time points. For the analysis, women who fulfilled ASAS classification criteria for axSpA and for whom a pregnancy outcome was reported until 12/2019 or 07/2020, depending on the registry, were selected. Mean BASDAI and its components were analysed descriptively.

Results: A total of 332 pregnancies from 304 women with axSpA were eligible. The Norwegian registry contributed half of the pregnancies (50.3%), followed by Germany (26.2%), France (15.4%) and Switzerland (8.1%). Mean maternal age was 31 years, the average disease duration 5 years. Mean BASDAI was 3.0 before conception, 3.4, 3.4 and 3.5 in the 1st, 2nd and 3rd trimester, and 3.4 within 6 months postpartum. The figure shows mean values of the BASDAI and its individual components in the different time periods. Fatigue was higher than the mean score during all phases, and especially elevated in the 1st and 3rd trimester. Furthermore, values for neck, back or hip pain were higher than the mean score, especially from 2nd trimester on. All other components were lower than the mean score. Therefore, the results should be confirmed by other studies.

No correlation was found between the weekly number of hours of PA and the evaluated scores. No significative difference was found between the two groups regarding CRP (16.11 mg/L vs 39.67 mg/L, p=0.107). However, no significative difference was found in clinical enthesitis scores were significantly lower in physically active patients (MASES 1.79 vs 4.22, p=0.007, LEI 1.51 vs 1.72 and SPARCC of 2.97 vs 4.32. Patients who performed regular PA had significantly lower disease activity evaluated with BASDAI (3.53 vs 5.45, p=0.007), ASDAS-CRP (2.64 vs 3.44, p=0.045) and ASDAS-ESR (2.84 vs 3.7, p=0.44). Clinical enthesis scores were also significantly lower in physically active patients (MASES: 1.74 vs 4.22, p=0.007, LEI: 0.95 vs 2.11, p=0.038, SPARCC: 1.79 vs 4.22, p=0.029). However, no significative difference was found between the two groups regarding CRP (16.11 mg/L vs 39.67 mg/L, p=0.107). No correlation was found between the weekly number of hours of PA and the evaluated scores.

Discussion: Physical activity was associated with lower disease activity scores and lower clinical enthesis score. This highlights the importance of physical activity as a non-pharmacologic treatment in SA for the management of disease activity and entheseal involvement.

REFERENCES:

Disclosure of Interests: None declared

ABO791 MADRID SONOGRAPHIC ENTHESIS INDEX: USEFUL OUTCOME IN THE DIAGNOSIS OF AXIAL Spondyloarthritides

C. S. Bellagha1, M. Slouma1, S. Ben Dha1, J. C. Bellagha1, L. Metouli1, R. Dhahri1, I. Gharsallah1, B. Louzir1,2. 1The Military Hospital of Tunis, Department of Rheumatology, Tunis, Tunisia; 2The Military Hospital of Tunis, Department of Internal Medicine, Tunis, Tunisia

Background: Madrid Sonographic Enthesis Index (MASEI) is an ultrasound (US) score for the evaluation of enthesis including inflammatory abnormalities and chronic damage in spondyloarthritides (SpA) [1]. This score includes bilaterally: planter aponeurosis, Achilles tendon, distal and proximal patellar ligament, distal quadriceps, and brachial triceps tendons.

Objectives: We aimed to study the diagnosis value of MASEI score in axial spondyloarthritis.

Figure 1. Means of BASDAI components before, during and after pregnancy (the table presents means ± standard deviation).

Acknowledgements: This work was supported by a research grant from FOREUM Foundation for Research in Rheumatology.

Disclosure of Interests: Yvette Meissner Speakers bureau: Pfizer, Anna Molto Consultant of: UCB and BioGen, Grant/research support: from UCB, Nathalie Costedoat-Chalumeau Grant/research support from: to my institution (UCB), Rebecca Fischer-Betz: None declared, Frauke Förger Speakers bureau: UCB pharma, GSK, Consultant of: UCB pharma, GSK, Roche, Grant/research support from: UCB pharma, GSK, Marianne Wallensius: None declared. Anja Stranged Speaker’s bureau: AbBVie, Amgen, BMS, Celltrion, Janssen, Lilly, Pfizer, Roche, Sanofi, UCB

DOI: 10.1136/annrheumdis-2022-eular.1284
Methods: We conducted a case-control study including 74 subjects divided into 2 groups: G1 - 37 patients fulfilling the Assessment of SpondyloArthritis international Society (ASAS) criteria for axial SA; G0 - 37 healthy controls matched for age and sex. Eight hundred eighty-eight entheseus were assessed by a musculoskeletal experienced sonographer who was blinded to the clinical data concerning patients and controls. The MASEI was calculated for the 2 groups. For G1, we collected the following parameters: disease activity using Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS-ESR). Statistical analysis was performed using IBM SPSS Statistics software version 21. A Receiver Operator Curve (ROC) analysis was performed to determine the cut-off of MASEI able to discriminate G0 from G1.

Results: The study included 29 men (78%) and 8 women (22%) in each group. The mean age was 44.51 ± 12.08 years. The mean age of onset was 38.06 ± 11.36 years. The mean disease evolution of 9.02 ± 7.83 years. The mean BASDAI and ASDAS-ESR were 4.47 ± 2.21 and 3.26 ± 1.31. MASEI score was significantly higher in patients compared to healthy controls (25.76 ± 9.8 versus 8.32 ± 6.65, p <0.0001). A cutoff of 18 of the MASEI was able to distinguish G1 from G0 with a sensitivity of 81.1% and specificity of 91.9%. The area under curve (AUC) ± 6.65, p <0.0001). A cutoff of 18 of the MASEI was able to distinguish G1 from G0.

Conclusion: Our study showed that MASEI score is significantly higher in SpA patients and seems to have a diagnostic accuracy. Besides, MASEI was able to distinguish between SpA patients and healthy controls with a cut-off of 18. Those results agree with the findings of other researchers in the field [2].

REFERENCES:

Disclosure of Interests: None declared


AB0792 HIP INVOlVEMENT IN SPOndyloarthRITIS: ANALySIS OF ASSOCIATEd FACTORS

H. Tinbi1, M. Slouna1, S. Rahmouni1, A. Abdennadher1, K. Amri2, S. Crotoiu3, I. Elashed2, S. Slouma1, S. Rahmouni1, A. Abdennadher2, K. Amri2, Y. Mallat2, H. Tbini1, M. Slouma1, S. Rahmouni1, A. Abdennadher2, K. Amri2, Y. Mallat2

Background: Hip involvement occurs in about one-third of patients with spondyloarthropathy (SA) [1]. It can be responsible for significant disability and functional impairment.

Objectives: This study aimed to assess the associated factors with hip involvement in SA.

Methods: We conducted a cross-sectional study, including 165 patients with SA diagnosed according to Assessment of SpondyloArthritis international Society (ASAS) criteria over a period from 2017 to 2021. Demographic, clinical, biological and radiographic data were collected. We compared following parameters at the time of diagnosis of coxitis: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS-ESR), modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), Bath Ankylosing Spondylitis Radiology Index (BASRI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). We used logistic regression analysis to identify factors associated with hip involvement in SA.

Results: A total of 165 Patients were enrolled (121 men and 44 women), the mean age was 46.13 ± 13.07 years. The mean disease of disease onset was 35.01 ± 12.55 years. The average diagnostic delay was 37.54 ± 50.51 months. The average disease duration was 10.91 ± 9.64 years. Eighty seven percent of patients had axial spondyloarthropathy, 72% had extra-articular manifestations. Mean ESR and CRP values were 3749 ± 28.1 mm and 30.14 ± 43.55 mg/L, respectively. Mean BASDAI and ASDAS-ESR values were 4.18 ± 3.09 ± 1.13, respectively. Hip involvement was noted in 60 patients (36.4%). It was bilateral in 75% of cases (n=45). A total number of affected hips was 105. Following parameters were significantly higher in patients with hip involvement: age over 40 years old (73.3 vs 56.3%, p=0.030), symptoms duration over 10 years (60% vs 40.2%, p=0.015), elevated CRP (87.9% vs 73.7%, p=0.036), radiographic sacroiliitis (95% vs 82.7%, p=0.023), frequency of pulmonary involvement (25.0% vs 11.4%, p=0.023), frequency of osteoporosis (20.0% vs 8.6%, p=0.034), BASMI (3.71 vs 1.65, p<0.001), BASRI spine (5.97 vs 2.91, p<0.001), and mSASSS (16.24 vs 8.50, p<0.001). However, no association was found between HLA-B27 and hip involvement (50% vs 28.6%, p=0.099). A multivariable logistic regression model showed that age over 40 years (OR=2.568 [1.020 - 7.083], p=0.045), radiographic sacroiliitis (OR=5.656 [1.007 - 31.769], p=0.049), and very high disease activity (ASDAS-CRP≥3.5) (OR=5.328 [1.774 - 16.002], p=0.003) were independently associated with hip involvement in SA.

Conclusion: Our study showed that age, symptoms duration, radiographic sacroiliitis, extra-articular manifestations, axial structural damage, elevated CRP, and very high disease activity were associated with hip involvement. These findings suggest that the control of disease activity and inflammation may prevent the onset of hip involvement. There are controversial findings regarding the association between HLA B27 gene and hip involvement [2].

REFERENCES:

Disclosure of Interests: None declared


AB0793 FACET JOINT DISEASE IN PATIENTS WITH AXIAL SPOndYLOArTHRITIS: A RETROSPECTIVE CONVENTIONAL COMPUTED TOMOGRAPHY STUDY

G. Slobodin1, M. Sagiv1, T. Kriehs2, A. Shouval1, S. Crotoiu3, I. Elashed2, Bnai Zion Medical Center, Rheumatology, Haifa, Israel; 2Bnai Zion Medical Center, Internal Medicine, Ramat Gan, Israel; 3Bnai Zion Medical Center, Internal Medicine, Haifa, Israel; 4Bnai Zion Medical Center, Radiology, Haifa, Israel; 5Sheba Medical Center, Radiology, Ramat Gan, Israel

Background: Facet joints’ (FJ) ankylosis was reported to occur frequently in patients with ankylosing spondylitis (AS). However, a detailed FJ evaluation was not reported in patients over the spectrum of axial spondyloarthropathies (AxSpA).

Objectives: To analyze structural lesions in the FJ of patients with different forms of AxSpA, using computed tomography (CT).

Methods: All available conventional CT studies of the cervical, thoracic, lumbar spine, or studies of the chest or abdomen of patients with AS or non-radiographic AxSpA (nrAxSpA) from a single medical center cohort were analyzed for the presence of erosions, ankylosis, joint-space narrowing, osteoarthropathy, subchondral sclerosis, subchondral cysts and vacuum phenomenon by 2 experienced readers. All patients, as well as age and gender matched control group, who performed conventional CT of the spine for any cause, but did not have a known rheumatic disease, had to be at the age of 50 years or less at the time of the study. The findings were binarically scored as present/absent. Several types of changes could be noted in the same FJ. All FJ findings were compared between groups of AxSpA patients and controls, separately for the cervical, thoracic and lumbar spine. Further, AxSpA patients were subdivided into three groups of which FJ findings were compared: AS patients with (AS+) or without (AS-) syndesmophytes on the cervical or lumbar radiographs, and patients with nrAxSpA as per pelvic radiograph. Fisher’s exact test or Chi-Square test at < http://vassarstats.net >, were used to compare between groups.

Results: 95/666 FJs (49/44 patients) were assessed in the AxSpA/control group patients, respectively. The study group consisted of 16 AS+ patients, 22 AS- patients, and 11 nrAxSpA patients. FJ ankylosis was significantly more prevalent in all spinal segments of the AS+ group compared to the two other groups. Erosions were seen almost exclusively in patients with AS. Joint-space narrowing and osteoarthropathy were noted in all segments and all subgroups of AxSpA patients, including those with nrAxSpA.

Conclusion: FJ involvement is prevalent in all forms of AxSpA, including its non-radiographic form. Facet joints of all spinal segments are involved in AxSpA patients.

REFERENCES:
Disclosure of Interests: None declared

AB0794 HOPELESSNESS IN PATIENTS WITH ANKYLOSING SPONDYLITIS
A. Komac1, N. Gokcen1, A. Yazici1, A. Cetin1, Kocaeli University Faculty of Medicine, Rheumatology department, Kocaeli, Turkey

Background: Ankylosing spondylitis (AS) is a chronic inflammatory disease leading to loss of function that is strongly related to impaired psychological status. Therefore, depression and anxiety are frequently investigated in these patients (1). However, hopelessness, regarded as a valuable psychological factor characterized by negative expectations and negative emotional states, was not well studied in AS patients (2).

Objectives: The aim of the study is to investigate the frequency of hopelessness in patients with AS and its relationship with clinical parameters and disease activity indices.

Methods: The study was designed as a prospective cross-sectional study. 113 AS patients were included in the study. Demographic data, clinical variables, laboratory results were recorded. Disease activity (ASDAS-CRP and ASDAS-ESR), patients’ functionality (BASFI, BASMI), enthesitis (Leeds enthesitis index) and quality of life (SF-36) were assessed. Hopelessness was evaluated by Beck hopelessness scale (BHS). The relation of BHS scores with the clinical variables was assessed. The strength of the correlations were regarded as very strong (0.8-1). Multiple linear regression analysis was performed to find the association between BHS scores and other clinical variables.

Results: Minimal, mild, moderate, and severe hopelessness were observed in 46 (40.7%), 36 (31.9%), 22 (19.5%), and 9 (8.0%) patients, respectively. Disease duration (p=0.025), ASDAS-CRP (p=0.033), ASDAS-ESR (p=0.015), visual analogue scale (p=0.030), all SF-36 subscales (all p<0.025), BASFI (p=0.024), and BASMI (p=0.009) were statistically different among the groups. BHS scores were higher in patients with high and very high disease activity (p=0.027) (Figure 1). BHS scores showed weak correlation with ASDAS-CRP, ASDAS-ESR, visual analogue scale, BASMI, Leeds enthesitis index, and BASFI. Moreover, negative moderate correlations were detected between BHS scores and SF-36 subscales except social functioning and body pain, which were found weak correlation. In multiple linear regression analysis, BASMI-maximal intermalleolar distance, SF-36 energy, SF-36 mental health, and SF-36 general health were found associated with BHS scores (Table 1).

Table 1. Multiple linear regression analysis to find predictors related to the Beck hopelessness scale scores

<table>
<thead>
<tr>
<th>Variable</th>
<th>B</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASDAS-CRP</td>
<td>-0.063</td>
<td>(-1.939) to 1.828</td>
<td>0.687</td>
</tr>
<tr>
<td>VAS</td>
<td>-0.085</td>
<td>(-0.722) to 0.396</td>
<td>0.564</td>
</tr>
<tr>
<td>BASMI Lateral spinal flexion</td>
<td>0.311</td>
<td>(-0.259) to 1.479</td>
<td>0.191</td>
</tr>
<tr>
<td>Tragus to wall distance</td>
<td>0.157</td>
<td>(-0.604) to 1.602</td>
<td>0.339</td>
</tr>
<tr>
<td>Modified Schober</td>
<td>0.298</td>
<td>(-0.114) to 1.368</td>
<td>0.096</td>
</tr>
<tr>
<td>Maximal intermalleolar distance</td>
<td>0.228</td>
<td>(-0.068) to 1.005</td>
<td>0.082</td>
</tr>
<tr>
<td>Cervical rotation</td>
<td>0.032</td>
<td>(-0.036) to 0.065</td>
<td>0.535</td>
</tr>
<tr>
<td>Total</td>
<td>-0.730</td>
<td>(-5.572) to 4.042</td>
<td>0.177</td>
</tr>
<tr>
<td>SF-36 Physical function</td>
<td>-0.024</td>
<td>(-0.056) to 0.046</td>
<td>0.840</td>
</tr>
<tr>
<td>Role physical</td>
<td>-0.014</td>
<td>(-0.046) to 0.017</td>
<td>0.364</td>
</tr>
<tr>
<td>Role emotional</td>
<td>-0.019</td>
<td>(-0.029) to 0.024</td>
<td>0.870</td>
</tr>
<tr>
<td>Energy/fatigue</td>
<td>-0.283</td>
<td>(-0.125) to 0.005</td>
<td>0.355</td>
</tr>
<tr>
<td>Mental health</td>
<td>-0.306</td>
<td>(-0.142) to -0.022</td>
<td>0.008</td>
</tr>
<tr>
<td>Social functioning</td>
<td>0.022</td>
<td>(-0.033) to 0.041</td>
<td>0.822</td>
</tr>
<tr>
<td>Body pain</td>
<td>0.182</td>
<td>(-0.018) to 0.086</td>
<td>0.192</td>
</tr>
<tr>
<td>General health</td>
<td>-0.344</td>
<td>(-0.152) to -0.030</td>
<td>0.002</td>
</tr>
<tr>
<td>BASFI</td>
<td>-0.085</td>
<td>(-0.606) to 0.248</td>
<td>0.408</td>
</tr>
</tbody>
</table>

Conclusion: Higher level of hopelessness is strongly related to higher disease activity in AS patients. Furthermore, higher BHS scores are negatively correlated with SF-36 subscales. Especially, lower energy and impaired mental health are associated with higher level of hopelessness.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1506

Figure 1. Beck hopelessness scale scores according to disease activity subgroups

AB0795 ARE PATIENTS WITH ANKYLOSING SPONDYLITIS AFRAID OF FALLING COMPARED TO HEALTHY CONTROLS?: THE ROLE OF BALANCE AND POSTURE
H. Bulbul1, Y. Ulus2, A. Bilgec3, 1Termes, Physical Medicine and Rehabilitation, Termes, Turkey; 2Onoduk Mayas University - Faculty of Medicine, Physical Medicine and Rehabilitation, Samsun, Turkey

Background: Fear of falling is a low perception of self-efficacy in avoiding falling during basic, non-hazardous activities of daily life, and concern about falling. It is a risk factor for falls and individuals without a history of falls may have fear of falling. Although it has been shown that the risk of falls is increased in patients with ankylosing spondylitis (AS), there is a lack of sufficient data on the fear of falling in AS patients and the relation of falls with spinal mobility and balance in these patients is controversial.

Objectives: The aims of this study were to compare the fear of falling and balance parameters of AS patients with healthy controls and to evaluate the relation of fear of falling with spinal mobility, balance parameters, pain, disease activity, and functional capacity in patients with AS.

Methods: Forty patients diagnosed with AS and 50 gender-age matched healthy controls were included. Demographic data and the number of falls within the last one year were questioned for all participants. Fear of falling by Falls Efficacy...
Conclusion: T1-Mapping allows for accurately characterizing lesions at the sacroiliac joint in patients with suspected axial spondyloarthritis and, thus, may combine information from two conventional sequences and CT into one in the future while providing superior capacity for quantification. However, in our study mixed lesions and inhomogeneous bone marrow remained problematic. Thus, further sequence development is needed before its implementation in clinical routine.

Disclosure of Interests: Torsten Diekhoff: Speakers bureau: Novartis, Lilly Eli, MSD, Canon, MS, Consultant of: Novartis, Dominik Deppe: None declared, Denis Podubnyy: None declared, Katharina Ziegele: None declared, Fabian Prott: None declared, Kay-Geert Hermann: None declared, Mikhail Protopopov: None declared, Felix Radny: None declared, Marcus Makowski: None declared

28.6% of patients had a family history of SpA. 14.3% had ≥1 uveitis outbreaks, 47.8% had ≥3 uveitis outbreaks and 38.1% had 6-11 uveitis outbreaks. 102 (53.7%) uveitis outbreaks fulfilled 1 criterion, 38 (20%) uveitis outbreaks fulfilled 2 criteria, 19 (10%) uveitis outbreaks fulfilled 3 criteria and 5 (2.6%) uveitis outbreaks fulfilled 4 or more. The results of the linear regression model revealed that the uveitis was more severe in patients with smoking history (β=0.34), axial and peripheral involvement (β=0.43), a BASDI (Bath Ankylosing Spondylitis Disease Activity Index)-4 (β=0.32), positive HLA-B27 (β=0.29), female sex (β=0.19), patients with CRP (C-reactive protein) elevation (β=0.002) and a history of bilateral ocular involvement (β=0.32) while shorter disease evolution (β=0.02) and normal vitamin D levels (β=−0.03) were associated with a better outcome.

Conclusion: We identified factors associated with adverse outcomes in SpA by developing a prognostic outcome score that integrates ocular inflammatory activity, ocular complications and refractoriness to treatment.

REFERENCES:

Disclosure of Interests: None declared.


AB0798
THE PRESENCE OF HEEL ENTHESIS DURING PHYSICAL EXPLORATION IN PATIENTS WITH RADIOGRAPHIC AXIAL SpondyloarthritIS IS ASSOCIATED WITH POORER OUTCOMES AFTER 2 YEARS OF FOLLOW-UP. DATA FROM REGISPONSER-AS
C. López-Medina1, M. A. Puche Larribua1, M. L. Ladehesa Pineda1, R. E. M. Granados1, F. U. Pillar1, E. Collantes Estevez1. 1Reina Sofia University Hospital, Rheumatology, Cordoba, Spain

Background: Enthesitis represents one of the most important peripheral musculoskeletal manifestations in patients with axial Spondyloarthritis (axSpA). The prevalence and the burden of the disease associated with this symptom have been widely studied in axSpA and Psoriatic Arthritis (PsA). However, studies evaluating specifically the heel enthesis and its impact over time are scarce.

Objectives: A) to evaluate the prevalence of patients with heel enthesis during physical examination in patients with radiographic axSpA (r-axSpA); b) to evaluate the association of heel enthesis with higher Patient Reported Outcomes (PROs); c) to assess the impact of the heel enthesis on the outcome measures after two years of follow-up in these patients.

Methods: Observational and prospective study during 2 years of follow-up that included patients with r-axSpA from the REGISPONSER-AS study (Spanish Rheumatology Spondyloarthritis Registry). The patients were divided into two groups according to the presence on heel enthesis on physical exploration during the study visit. The PROs evaluated were the Global VAS, BASDAI, ASDAS, BASMI and the mental and physical components from the SF12 questionnaire. Linear regression models were performed using the PROs as the dependent variable and the presence of heel enthesis as the explanatory variable, adjusting for bDMARDs intake and age. The impact of the heel enthesis on PROs over two years of follow-up was evaluated using mixed models for repeated measures adjusting for confounders. Finally, the achievement of ASDAS Low Disease Activity (ASDAS-LDA) and ASDAS Inactive Disease (ASDAS-ID) after 2 years of follow-up between the two groups were evaluated.

Results: 749 patients were included (mean age 48.4 years; 75.3% men). 46 (6.1%) patients suffered from heel enthesis on the study visit. Patients with heel enthesis showed an increase (β coefficient, 95%/CI) in Global VAS (1.32, 0.52-2.12), BASDAI (1.49, 0.81-2.18), ASDAS (0.45, 0.12-0.77) and BASFI (0.54, 1.78-17.30) compared with patients without heel enthesis after adjusting for confounders. The impact of the presence of enthesis on the PROs after two years of follow-up is shown in Table 1. Patients with heel enthesis showed higher scores during the two years of follow-up in Global VAS, BASDAI, ASDAS and BASFI. In addition, the percentage of patients who achieved ASDAS-ID after 2 years of follow-up was lower in patients with heel enthesis (15.9% vs. 31.5%, p<0.030) in comparison with patients without enthesis. No differences were found regarding ASDAS-ID.

Conclusion: In patients with r-axSpA, the presence of heel enthesis on physical exploration was associated with poorer scores on the outcome measures after two years of follow-up, in comparison with patients without heel enthesis. The achievement of a low disease activity is less likely in patients with this manifestation.

Disclosure of Interests: None declared.


Table 1. Impact of the presence of heel enthesis on PROs over two years of follow-up: mixed models for repeated measures.

<table>
<thead>
<tr>
<th>Current heel enthesis N = 46</th>
<th>No current heel enthesis N = 703</th>
<th>p-value</th>
<th>p-value age and bDMARDs adjusted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global VAS</td>
<td>5.1 (2.8)</td>
<td>4.3 (2.6)</td>
<td>0.015</td>
</tr>
<tr>
<td>BASDAI</td>
<td>4.8 (2.7)</td>
<td>3.9 (2.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ASDAS</td>
<td>2.9 (1.1)</td>
<td>2.6 (1.1)</td>
<td>0.007</td>
</tr>
<tr>
<td>BASFI</td>
<td>43.8 (29.7)</td>
<td>40.0 (27.4)</td>
<td>0.245</td>
</tr>
<tr>
<td>PC-SF12</td>
<td>33.3 (11.4)</td>
<td>35.3 (10.7)</td>
<td>0.128</td>
</tr>
<tr>
<td>MC-SF12</td>
<td>47.4 (14.2)</td>
<td>48.2 (12.2)</td>
<td>0.547</td>
</tr>
</tbody>
</table>

AB0799
ANATOMICAL ABNORMALITIES OF THE LOWER LUMBAR SPINE DO NOT CHANGE THE COURSE OF NON-RADIOLOGICAL AXIAL SPONDYLOARTHRITIS
D. Becker-Capeller1, S. Kapslimalakou2. 1Rheumatologic Practice, Clinic Dr. Hancken, Stade, Germany; 2Klinik Dr. Hancken GmbH / MVZ Radiologie und Nuklearmedizin, Radiology Department MRI Spine Center, Stade, Germany

Background: Diagnosing early spondyloarthritis (SpA) is crucial for effective therapeutic intervention. Magnetic resonance imaging (MRI) helps us to diagnose non-radiographic SpA (n-raxSpA) in an early stage according to the criteria of the imaging arm of the Assessment of Spondyloarthritis International Society (ASAS) classification. Diagnosis of sacroiliitis using MRI has limitations because of the lack of specificity and sensitivity. Several differential diagnoses are well known and should be considered.

Objectives: To investigate the presence of anatomical anomalies of the lower lumbar spine in our cohort of early diagnosed n-raxSpA patients fulfilling the criteria of axSpA and show if they cause a difference in the outcome.

Methods: Patients (n = 56, age < 45 years, symptom duration 3–24 months) recently diagnosed with sacroiliitis using MRI and meeting the ASAS criteria for axial SpA were followed-up for 2 years. We retrospectively analyzed the anatomical anomalies of the lower lumbar spine on MRI and, if available, on radiographic images.

Results: MRI on t0 revealed that 15 (26.7%, 1 female and 14 males) of 56 patients had anatomical anomalies of the lower lumbar spine, indicating bone marrow edema with clinical axSpA according to the ASAS classification criteria. Spondylosis, assimilation joints, and dysraphia were found in 4 (7.1%), 7 (12.5%), and 7 (12.5%) patients, respectively. The presence of HLA-B27 and assessment results (CRP-ASDAS and BASDAI, BASMI) were similar to patients without the mentioned anatomical anomalies. Patients with spondylosis and dysraphia of the lower spine and those without anomalies displayed similar progression of MRI findings between t0 and t2.

Conclusion: In addition to the well-known inflammatory causes of sacroiliitis, such as pregnancies or intensive sporting activity, anatomical peculiarities could not be considered non-inflammatory reasons. Contrary to the latest literature, they are not responsible for non-specific sacroiliitis. No difference in the development of axial SpA was observed when patients with and without anatomical changes were compared.

REFERENCES:

Disclosure of Interests: Detlef Becker-Capeller Grant/research support from: Research support by Novartis, Smaradaga Kapslimalakou: None declared.


AB0800
ULTRASONOGRAPHY OF SUPRASPINATUS ENTHESES IN AXIAL SPONDYLOARTHRITIS
C. S. Bellagha1, M. Slouma1, S. Ben Dhia1, J. Ben Katibi1, L. Metoui1, R. Dhiarn2, I. Gharsallah1, B. Louzig3. 1The Military Hospital of Tunis, Department of Rheumatology, Tunis, Tunisia; 2The Military Hospital of Tunis, Department of Internal Medicine, Tunis, Tunisia

Background: Several scoring systems have been developed to quantify ultrasound (US) abnormalities of the entheses in patients with spondyloarthritis (SpA). These scores included entheses of the lower limb, triceps tendon, and lateral epicondylar tendon [1][2]. Studies regarding the involvement of supraspinatus enthesis in patients with SpA are scarce.

Objectives: This study aimed to assess the supraspinatus enthesis in patients with axial SpA using ultrasonography.

Disclosure of Interests: None declared.
Objectives: To examine the construct validity and responsiveness of ASAS HI in relation to TNFi treatment.

Methods: In this investigator-initiated 52-week prospective observational study (MANGO study; NCT02011386)(3), axSpA patients initiated sc. Golimumab 50 mg every month. Key inclusion criteria were BASDAI ≥4.0 and saccroilitis on radiography and/or MRI.

Results: 45 of 53 TNFi naïve patients completed ASAS HI at weeks 0, 4, 16 and 52. 55.6% were male, 75.6% HLA-B27 positive, median age 34.6 yrs (IQR 28.3-46.1) and symptom duration 5.1 yrs. (2;13)(Table 1A). ASAS HI decreased from week 0 to weeks 4, 16 and 52, from median 10.0 (IQR 8.11) to 7.0 (23.10), 5.5 (13.8) and 4.0 (1.75);(Wilcoxon-Pratt; all p<0.001). Patients with low ASAS HI (score 0-5, good health state(4)) at week 16 and 52 had significantly lower ASDAS, BASDAI, BASFI, pain, pt. global and CRP than patients with moderate to high ASAS HI (6-17) (Table 1B). Patients with a decrease of >3 clinically meaningful change(3)) or >30% (S) in ASAS HI from week 0-16 had significantly larger reductions in ASDAS, BASDAI, BASFI, pain, pt. global and SPARCC MRI spine inflammation score (Table 1C). At baseline, ASAS HI correlated with BASFI and SPARCC SIJ inflammation score (rho: 0.37-0.38, p<0.05), and changes in ASAS HI from week 0-16 correlated with changes in ASDAS, BASDAI, BASFI, pain, pt. global (0.51-0.67, p<0.001) and change in MRI SIJ inflammation score (0.30, p<0.05). ASAS HI had high responsiveness (Table 1D).

Conclusion: ASAS HI showed good construct validity and responsiveness.

REFERENCES:

Disclosure of Interests: Susanne Juul Pedersen Speakers bureau: MSD, Pfizer, AbbVie, Novartis and UCB. Grant/research support from: AbbVie, MSD, and Novartis., Inge Juul Sørensen: None declared, Bente Jensen: None declared, Ole Madsen: None declared, Mette Klærunder: None declared, Jakob Møller Bekker: None declared, Mats Peter Johansson: None declared, Kasper K Gosvig: None declared, Mikhail Ostergaard Speakers bureau: Abbvie, BMS, Celgene, Eli-Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Orion, Pfizer, Roche and UCB., Consultant of: Abbvie, BMS, Boehringer-Ingelheim, Cellgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB., Grant/research support from: Abbvie, Abgen, BMS, Merck, Celgene and Novartis.


AB0802
PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE IN RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS, AND PSORIATIC ARTHRITIS.

M. Pavia Pascual1, S. Pérez, L. Rodriguez2, R. Aránzadi1, O. Rusinovich1, N. de la Torre Rubio1, M. Machattou1, P. Navarro Palomo1, J. Campos Esteban1, M. Fernandez Castro1, H. Godoy2, C. Barbadoro Mateos1, C. Merino Arguménez1, M. Espinosa3, B. García-Magallón1, J. L. Calleja Panero1, J. L. Andrés Sánchez1, J. Sanz1. 'Puerta de Hierro Majadahonda University Hospital, Rheumatology, Majadahonda, Spain;’Puerta de Hierro Majadahonda University Hospital, Student, Majadahonda, Spain;’Puerta de Hierro Majadahonda University Hospital; Gastroenterology, Majadahonda, Spain;’Puerta de Hierro Majadahonda University Hospital, Radiology, Majadahonda, Spain;’Virgen del Rocio University Hospital, Internal Medicine, Sevilla, Spain

Background: Non-alcoholic fatty liver disease (NAFLD), the most common cause of liver disease, has a prevalence of about 25% in the general population.

Table 1. Diseases measures at baseline (Table 1A), stratified according to ASAS HI states at week 16 and 52 (Table 1B), changes from week 0 to 16 and 52 (Table 1C) and responsiveness (Table 1D).

<table>
<thead>
<tr>
<th>Table 1A</th>
<th>Table 1B</th>
<th>Table 1C</th>
<th>Table 1D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>ASAS HI at week 16</td>
<td>ASAS HI at week 52</td>
<td>Absolute change in ASAS HI week 0 to 16</td>
</tr>
<tr>
<td>n=45</td>
<td>n=22</td>
<td>n=22</td>
<td>&lt;3</td>
</tr>
<tr>
<td>ASAS HI</td>
<td>10.9 (11.1)</td>
<td>8.0 (7.10)</td>
<td>2.0 (0.33)</td>
</tr>
<tr>
<td>ASDAS</td>
<td>3.7 (3.14)</td>
<td>2.1 (1.13)</td>
<td>1.2 (0.15)</td>
</tr>
<tr>
<td>BASDAI</td>
<td>6.1 (5.72)</td>
<td>3.8 (2.95)</td>
<td>2.3 (1.44)</td>
</tr>
<tr>
<td>BASFI</td>
<td>4.4 (3.59)</td>
<td>2.5 (1.53)</td>
<td>1.4 (0.14)</td>
</tr>
<tr>
<td>ASAS HI week 0-16</td>
<td>1.3 (0.3)</td>
<td>1.0 (0.3)</td>
<td>0.2 (0.3)</td>
</tr>
<tr>
<td>Pain</td>
<td>7.0 (5.81)</td>
<td>3.3 (1.13)</td>
<td>3.6 (1.13)</td>
</tr>
<tr>
<td>Pt. global</td>
<td>7.0 (5.81)</td>
<td>3.3 (1.13)</td>
<td>3.6 (1.13)</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>77 (98.22)</td>
<td>13 (98.65)</td>
<td>1.3 (0.32)</td>
</tr>
<tr>
<td>SPARCC MRI SIJ inflammation</td>
<td>14 (4.24)</td>
<td>10 (4.24)</td>
<td>2.0 (0.28)</td>
</tr>
<tr>
<td>SPARCC MRI spine infl.</td>
<td>8 (4.15)</td>
<td>6.0 (4.15)</td>
<td>2.0 (0.28)</td>
</tr>
</tbody>
</table>

Median (IQR), Mann-Whitney test. p<0.05, **p<0.01, ***p<0.001. Standardized response mean (SRM) and effect size (ES) ≥0.50 to ≤0.80 and ≥0.80 represents moderate and high responsiveness.
It increases mortality and comorbidity in patients with immune-mediated inflammatory diseases.

**Objectives:** The main objective is to estimate the prevalence of NAFLD in three of the most common rheumatologic pathologies: rheumatoid arthritis (RA), axial spondyloarthritis (SpA-ax) and psoriatic arthritis (PsA). As a secondary objective, the possibility of finding associated risk factors in this group of subjects that may imply a higher risk of developing NAFLD is proposed.

**Methods:** We conducted a prospective single center observational study which included patients diagnosed with RA, SpA-ax, and PsA attended in the Rheumatology department of a tertiary hospital from January to April 2021. Anthropometric parameters, history related to cardiovascular risk factors and disease activity at the time of the visit were collected. Additionally, blood tests and transitional elastography were performed in all patients and the presence of NAFLD was assessed by the fatty liver index (FLI) scale. Different variables were considered to study their association with NAFLD.

**Results:** 90 patients were included: 28 diagnosed with RA, 36 with SpA-ax and 26 with PsA. 41.1% were male (age range: 27-79 years). Patients with previous liver disease were excluded from the study. 22 (27.2%) patients had NAFLD measured by FLI ≥ 60. No significant differences in prevalence of hepatic steatosis were found between the 3 groups, although values were higher in patients with PsA. The variables that were significantly associated with the development of NAFLD in our cohort were: body mass index (BMI), abdominal perimeter, blood glucose level, HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), HDL, TG, GGT, ferritin and uric acid levels. The rest of the variables studied did not show statistically significant differences (Table 1).

**Table 1.**

<table>
<thead>
<tr>
<th>NO STEATOSIS (FLI&lt;60)</th>
<th>STEATOSIS (FLI&gt;60)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=59</td>
<td>n=22</td>
</tr>
<tr>
<td>Mean Standard deviation</td>
<td>Mean Standard deviation</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>BMI</td>
<td>24.52±0.01</td>
</tr>
<tr>
<td>Abdominal perimeter</td>
<td>100.82±4.55</td>
</tr>
<tr>
<td>Age</td>
<td>52.93±12.87</td>
</tr>
<tr>
<td>Glucose</td>
<td>78.64±8.37</td>
</tr>
<tr>
<td>Insulin</td>
<td>8.63±10.12</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.75±2.02</td>
</tr>
<tr>
<td>hsTcTc</td>
<td>5.35±4.05</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>190.98±29.46</td>
</tr>
<tr>
<td>HDL</td>
<td>64.88±17.66</td>
</tr>
<tr>
<td>LDL</td>
<td>110.44±28.45</td>
</tr>
<tr>
<td>TG</td>
<td>81.12±32.42</td>
</tr>
<tr>
<td>GPT</td>
<td>25.83±30.73</td>
</tr>
<tr>
<td>GGT</td>
<td>27.20±23.49</td>
</tr>
<tr>
<td>GGT</td>
<td>20.80±17.66</td>
</tr>
<tr>
<td>Creatinin</td>
<td>0.75±0.19</td>
</tr>
<tr>
<td>Uric acid</td>
<td>4.78±3.20</td>
</tr>
<tr>
<td>Ferritin</td>
<td>121.75±111.30</td>
</tr>
<tr>
<td>PCR</td>
<td>2.89±4.55</td>
</tr>
</tbody>
</table>

**Conclusion:** Hepatic steatosis was present in 27.2% of patients vs 25% estimated prevalence in the general population. Identification of risk factors involved would allow better control of the comorbidities associated with NAFLD.

The fact that the prevalence found in our sample population is so close to that of the general population, may be related to a good inflammatory control of the underlying disease. Further prospective studies with larger sample sizes are needed to find additional predictive factors for the development of NAFLD in this group of diseases.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2102

**AB0804** ASSOCIATIONS BETWEEN ULTRASOUND CHRONIC LESIONS IN PERIPHERAL ENTHESES AND RADIOGRAPHIC STRUCTURAL SPINAL CHANGES IN MEN AND WOMEN WITH ANKYLOSING SPONDYLITIS

A. Deminger1,2, A. Geijer3-4, N. Nilsson3, M. Hedberg5, L. T. H. Jacobsson1, H. Forsblad-D’elia1,2,1 Institute of Medicine, Department of Rheumatology and Inflammation Research, Göteborg, Sweden; 2Region Västra Götaland, Sahlgrenska University Hospital, Department of Rheumatology, Göteborg, Sweden; 3Institute of Clinical Sciences, Department of Radiology, Göteborg, Sweden; 4Region Västra Götaland, Alingsås Hospital, Section of Internal Medicine, Alingsås, Sweden; 5Region Västra Götaland, Södertälje Södertörn Hospital, Section of Rheumatology, Borås, Sweden

**Background:** Ankylosing spondylitis (AS) is characterised by spinal bone formation and enthesitis. Whether patients with spinal bone formation have a...
generalised bone formation phenotype also involving the peripheral entheses is not fully known.

**Objectives:** To assess in cross-sectional analyses the association between chronic ultrasound (US) lesions in peripheral entheses with spinal bone formation and factors associated with spinal bone formation, overall and by sex.

**Methods:** The entheses at 14 sites at the extremities were examined in 173 patients (54 % men, mean age (SD) 55 (13) years and symptom duration 29 (13) years) with AS (modified NY criteria) using US. Entheses were assessed for structural components (enthesophytes, calcifications and erosions) according to the OMERACT definition [1]. Each lesion was evaluated 0 or 1 and summarised to a damage score (0–42). Spinal radiographs from the same time point were graded according to the modified Stoeke Ankylosing Spondylitis Spine Score (mSASSS) and presence of syndesmophytes were determined. The associations between US damage score and mSASSS and factors associated with spinal bone formation were analysed with Spearman’s correlation analysis overall and by sex. Also, Mann Whitney’s test and multivariable logistic regression analysis with presence of ≥ 1 syndesmophyte as dependent variable and age, sex, BMI, smoking status, CRP, and US damage score as independent variables were used.

**Results:** Presence of any US structural component was found in 158 (91 %) of the patients with no significant difference between men and women (95 % vs 87 % respectively, p = 0.15). The US damage score was median (IQR) 4 (2 to 6) in the total group with a higher score in men compared to women, 4.5 (2 to 7) vs 3 (2 to 5), p = 0.002. In analogy, more men had presence of syndesmophytes in the spine compared to women, 63 % vs 35 %, p < 0.001 and men had higher mSASSS compared to women; median (IQR) mSASSS in men 14 (3 to 43) compared to 2 (0 to 11.5), p < 0.001. Men had higher body mass index (BMI), but there were no sex differences for age, symptom duration, CRP, and smoking status. The results from correlation analyses for US damage score and mSASSS, age, symptom duration, CRP, smoking status, and BMI are presented in the Table 1. Spinal bone formation (mSASSS) was positively correlated with the US damage score in the total group and in men. In both men and women, higher age was associated with higher US damage score. A comparison between patients with and without syndesmophytes showed that patients with syndesmophytes had higher US damage score than patients without syndesmophytes, median (IQR) is 3 (3 to 7) and 3 (1 to 5) respectively, p < 0.001. In the multivariable logistic regression analyses the US damage score was not independently associated with presence of syndesmophytes in the total group or in men. If age was excluded from the analyses though, the US damage score was significantly associated with presence of syndesmophyte, odds ratio (95 % CI) for total group 1.20 (1.05 to 1.37) and for men 1.26 (1.05 to 1.51).

**Table 1. Summary of study characteristics of included records.**

<table>
<thead>
<tr>
<th>Case numbers</th>
<th>Mean % of NK cell (mean or median)(SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qian Liu 2021</td>
<td>4 7 121 120 CD16+CD56+ Original AS:17.6 HC:138.9</td>
</tr>
<tr>
<td>Wei Hu 2019</td>
<td>4 6 60 40 CD16+CD56+ Original AS:13.3 HC:48.1</td>
</tr>
<tr>
<td>Lyuan Zhu 2016</td>
<td>4 7 30 30 CD16+CD56+ Original AS:16.23 HC:44.58</td>
</tr>
<tr>
<td>Hua Liu 2012</td>
<td>4 5 60 30 CD16+CD56+ Original AS:29.99 HC:49.5</td>
</tr>
<tr>
<td>Yongfang Wang 2012</td>
<td>4 6 60 44 CD16+CD56+ Original AS:14.04 HC:60.12</td>
</tr>
<tr>
<td>Yuehua Hua 2012</td>
<td>4 7 36 32 CD16+CD56+ Original AS:31.1 HC:59.8</td>
</tr>
<tr>
<td>Li Ma 2011</td>
<td>4 6 43 20 CD16+CD56+ Original AS:24.98 HC:38.15</td>
</tr>
<tr>
<td>Xuehua Ma 2011</td>
<td>4 6 36 32 CD16+CD56+ Original AS:31.1 HC:59.8</td>
</tr>
<tr>
<td>Yong-Wook Park2009</td>
<td>4 7 41 173 CD16+CD56+ Calculated AS:25.4 HC:190.4</td>
</tr>
<tr>
<td>Li Ma 2004</td>
<td>4 7 35 30 CD16+CD56+ Original AS:33.48 HC:52.37</td>
</tr>
</tbody>
</table>

**Conclusion:** Structural lesions were common in the entheses in patients with long-standing AS. Men had more severe bone formation in the spine and the peripheral entheses compared to women. Chronic lesions at the entheses accumulate with increasing age and US damage score could not independently identify patients with syndesmophytes in this cohort with long-standing AS. However, if age was not considered, there was an association between bone formation in the peripheral entheses and the spine in men with AS.

**REFERENCES:**

**DISCLOSURE OF INTERESTS:** Anna Deminger: None declared, Mats Geijer: Speakers bureau: UCB Pharma, Novartis, Abbvie, Nicklas Nilsson: None declared, Martin Hedberg: None declared, Lennart T.H. Jacobsson: None declared, Helena Forsblad-d’Elia: None declared, C. Wang: 1 Shaoxing Medical University, Key laboratory of Cellular Physiology

**Background:** Ankylosing Spondylitis (AS) is a complex chronic inflammatory autoimmune disease that mainly affects the spine. Natural Killer (NK) cells are classified among the recently discovered innate lymphoid cell subsets and have capacity to influence both innate and adaptive immune responses. However, the status of NK cells remains debated in AS.

**Objectives:** This study aims to clarify the level of peripheral NK cells in AS patient.

**Methods:** We used CNKI, CBM, Wanfang data and Chinese science, scientific and technological journal data, PubMed, Embase, Web of science, Cochrane library and Medline to collect relevant literature data, and sorted out the proportion of NK cells in AS patients. Random effects were selected to assess pooled data, inconsistency was assessed using I-squared index (I²), and Egger’s test was used to assess potential publication bias (STATA v.12.0).

**Results:** A total of 11 case-control studies involving 561 AS patients and 592 healthy controls (HC) were included in this study; AS patients had a significantly lower proportion of CD16+CD19+ NK cells compared with HCs ( SMD=-0.41, 95%CI (-0.71,-0.11), P<0.05, ) (Fig 1), with no publication bias according to Egger’s test(b=0.50, P=0.63).

**Conclusion:** The proportion of CD16+CD19+ NK cells in AS patients was significantly reduced, suggesting disturbance of NK closely involved in the pathogenesis of AS.
**AB0806**

**GENDER AND IMAGING PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS: RESULTS FROM A 48-MONTH FOLLOW-UP (ITALIAN ARM OF SPACE STUDY),**

M. Lorenzin1, A. Ortolan2, S. Vio3, G. Cozzi3, V. Scapini4, G. De Conti4, A. Doria4, R. Ramonda1,1 University of Padova, Department of Medicine DIMED, Rheumatology Unit, Padova, Italy; 2University of Padova, Department of Medicine DIMED, Rheumatology Unit, Padova, Italy; 3University of Padova, Radiology Unit, Padova, Italy

**Background:** Gender differences in disease presentation and imaging features of early axial-spondyloarthritis (axSpA) have not been thoroughly investigated.

**Objectives:** To assess the influence of gender on spinal/pelvic radiographic progression and magnetic-resonance-imaging (MRI) features in early-stage axSpA.

**Methods:** Baseline data from the Italian arm of the SPondyloArthritis-Caught-Early-cohort, including patients with chronic-back-pain (CBP; duration>3 months and <2 years; onset=45 years) were analyzed. Patients underwent a diagnostic work-up, including MRI and X-rays of the sacroiliac joints (SIJ) to establish a diagnosis of axSpA (according ASAS criteria). Clinical features, disease-activity and functional indices, imaging were collected at baseline (T0) and yearly during 48-months. Spinal and SIJ X-rays and MRIs were performed every 2-years and scored independently by 2 readers following Stoke Ankylosing Spondylitis Spinal Score System modified by Cremer (mSASSS) (score 0-72) modified New York criteria grading system (mNY criteria) (score 0-4 per each joint) and Spondyloarthritis Research Consortium of Canada (SPARCC) (score of 0-40 for SIJ and 0-92 for the spine).

**Results:** Out of 98 CBP patients, 91 had axSpA (83.5% non-radiographic; 16.5% radiographic). 47% were male. At T0 males were younger with less axial symptoms duration (p=0.04); had more frequently human-leukocyte-antigen (HLA)-B27 (p=0.02); radiographic sacroiliitis with bilateral/symmetric pattern (p<0.02) and more signs of spondylitis (p=0.03). Females presented more frequently an associated peripheral/entheseal involvement (p=0.04) and a non-radiographic form (p=0.03). Functional and disease-activity indices decreased with slightly higher Maastricht Ankylosing Spondylitis Enthesitis Score (MAS-ES), Visual Analogue Scale of pain (VAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional index (BASI) values in females (p<0.04). Males showed a slight increase for both pelvic and spinal radiographic progression than females (Figure 1 A-E). At T0, 62 (68.1%) axSpA patients presented inflammatory lesions on MRI-SIJ, with more signs of active sacroiliitis in males (83.7% vs. 54.2%; p=0.03). Fifty-seven (62.6%) patients showed inflammatory-corner-lesions on MRI-spine: the frequency of inflammatory-corner-lesions on MRI-spine was higher in females, instead these lesions no differed between males and females, while the localization varied: prevalently cervical/thoracic lesions were observed in females, instead lumbar lesions in males (p<0.05). We also found a higher prevalence of signs of active anterior spondylitis without active sacroiliitis on MRI in females (29.2% vs. 14.0%; p=0.03). Signs of enthesitis were found in 68.1% patients, with slightly higher compared over-time with descriptive-statistics; multi-variate-logic-regression model was constructed to assess predictors of spinal and SIJ radiographic progression at 48-months.

**Conclusion:** AxSpA is a group of inflammatory diseases with multiple clinical manifestations (axial, peripheral, skin, eye, and intestine) including ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis (PsA), arthritis associated with inflammatory bowel disease, and non-radiographic axial spondyloarthritis. AS is genetically related to HLA-B*27 [10]. The etiology and pathogenesis of this disease are unknown. Notwithstanding, the misleading hypothesis suggests that it may be triggered by the formation of HLA-B*27 homodimers. The risk of developing SpA is 5-7% in positive HLA-B*27 individuals [1,2].

**References:**


**Disclosure of Interests:** Mariagrazia Lorenzin: None declared, Augusta Ortolan: None declared, Stefania Vio: None declared, Giacomo Cozzi: None declared, Vanna Scapini: None declared, Giorgio De Conti: None declared, Andrea Doria Grant/research support from: AD has received honoraria and speaker fees from Novartis, Abbvie, Pfizer, MSD. Janssen., Roberta Ramonda Grant/research support from: RR has received honoraria and speaker fees from Novartis, Abbvie, Pfizer, MSD. Janssen.

**DOI:** 10.1136/annrheumdis-2022-eular.2259

**AB0807**

**RELAPSE INCIDENCE ACCORDING TO HLA-B*27 IN PATIENTS WITH SPONDYLOARTHRITIS IN A SPECIALIZED CENTER IN COLOMBIA**

O. J. Felipe Díaz1, W. G. Rojas Zuleta1, C. Orozco-González2, A. E. Pantoja Marquez2, C. Corón1, C. L. Giraldo Herrera3, M. M. Rabiosa-Fernández4, D. Becerra-Arias3, J. H. Donado Gómez5, N. Duque Zapata5, 1Medicarte, Rheumatologist, Medellín, Colombia; 2Medicarte, Epidemiologist, Medicarte Research Group (GIM), Medellín, Colombia; 3Medicarte, Rheumatologist, Cali, Colombia; 4Medicarte, Epidemiologist, Medicarte Research Group (GIM), Cali, Colombia; 5Medicarte, Epidemiologist, Medicarte Research Group (GIM), Bucaramanga, Colombia

**Background:** Spondyloarthritis (SpA) is a group of inflammatory diseases with multiple clinical manifestations (axial, peripheral, skin, eye, and intestine) including ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis (PsA), arthritis associated with inflammatory bowel disease, and non-radiographic axial spondyloarthritis. AS is genetically related to HLA-B*27 [10]. The etiology and pathogenesis of this disease are unknown. Notwithstanding, the misleading hypothesis suggests that it may be triggered by the formation of HLA-B*27 homodimers. The risk of developing SpA is 5-7% in positive HLA-B*27 individuals [1,2].

**Objectives:** Explore the relapse incidence and its associations with HLA-B*27 in SpA patients.

**Methods:** SpA patient cohort in a specialized multicentric health institution in Colombia (November 2011 to June 2021). Relapse was defined as the BASDAI increment ≥1 + 2≤ final BASDAI ≤4. A stratified analysis was performed for HLA-B*27 between diagnosis, current medication, and relapse. For group comparisons χ2 and Wilcoxon tests were used, according to variable distribution. Logistic regression model was run in order to explain relapse incidence.

**Results:** 515 patients were included, among whom 60.9% were HLA-B*27 positive. 870% had an AS diagnosis (53.3% of men), 11.4% (64.4% of women) non-radiographic axial spondyloarthritis and 1.55% PsA (62.5% of women). Table 1 shows demographic and clinical characteristics. The relapse incidence was associated with positive HLA (Odds Ratio-OR:2.14 Chi2=0.986-4.674, p=0.055) and with time of disease evolution (OR 1,05 IC95% 1.02-1.091, p=0.001) adjusting for sex.

**Table 1. Demographic and clinical characteristics**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Median (IQR)</th>
<th>Median (IQR)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>49 (40 to 58)</td>
<td>46 (37 to 55)</td>
<td>0.020</td>
</tr>
<tr>
<td>Time of disease evolution</td>
<td>6.6 (4.6 to 10.6)</td>
<td>8.6 (5.6 to 14.6)</td>
<td>0.000</td>
</tr>
<tr>
<td>Current BASDAI</td>
<td>1.2 (0 to 3.3)</td>
<td>0.4 (2 to 5.6)</td>
<td>0.648</td>
</tr>
<tr>
<td>Relapse</td>
<td>4.10 (1.1 to 6.5)</td>
<td>4.20 (1.6 to 6.3)</td>
<td>0.510</td>
</tr>
<tr>
<td>Current BASDI</td>
<td>1.0 (0 to 3.3)</td>
<td>0.4 (2 to 5.6)</td>
<td>0.113</td>
</tr>
<tr>
<td>Sex</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>133 (66.17)</td>
<td>119 (37.9)</td>
<td>0.000</td>
</tr>
<tr>
<td>Men</td>
<td>68 (33.83)</td>
<td>185 (62.1)</td>
<td></td>
</tr>
<tr>
<td>Diagnosis</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Non-radiographic axSpA</td>
<td>32 (15.92)</td>
<td>29 (8.6)</td>
<td>0.013</td>
</tr>
<tr>
<td>Radiographic axSpA</td>
<td>164 (81.59)</td>
<td>284 (90.45)</td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>5 (2.49)</td>
<td>3 (0.96)</td>
<td></td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>154 (76.62)</td>
<td>251 (79.94)</td>
<td></td>
</tr>
<tr>
<td>Current medication</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Synthentic DMARD</td>
<td>13 (6.47)</td>
<td>19 (6.0)</td>
<td>0.078</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>154 (76.62)</td>
<td>251 (79.94)</td>
<td></td>
</tr>
<tr>
<td>Anti-IL-17</td>
<td>24 (11.94)</td>
<td>29 (9.24)</td>
<td></td>
</tr>
<tr>
<td>Without treatment</td>
<td>10 (4.98)</td>
<td>15 (4.78)</td>
<td></td>
</tr>
<tr>
<td>Relapse</td>
<td>10 (4.98)</td>
<td>31 (9.87)</td>
<td>0.045</td>
</tr>
</tbody>
</table>

* p value for the difference between HLA-B*27 positive and negative groups. IQR: interquartile range

**Conclusion:** In SpA patients, HLA-B*27 frequency is higher in AS patients compared to other SpA forms. Furthermore, this is associated with a higher relapse risk and longer time of disease evolution.

**References:**

Background: Costovertebral (CV), costotransverse (CTr), sternoclavicular (SC) and manubriosternal (MS) joint involvements may be in spondyloarthritis (SpA). However, the radiological and clinical characteristics of these involvements need further assessment.

Objectives: In this study, we aimed to determine the characteristics of CV, CTr, SC, and MS joint involvements in SpA patients. Methods: SpA patients (searched from the hospital data-processing system according to ICD-10 system to determine the patients having M07 (enteropathic arthropathies), M45 (ankylosing spondylitis (AS)), M46 (other inflammatory spondyloarthropathies) and M48 (other spondyloarthropathy) codes) who have been requested a chest computed tomography (CT) for any reason between January 2010 and December 2020 included in this retrospective cross-sectional analysis. Chest CT reports were reviewed, and any CV, CTr, SC or MS joint involvement attributed to SpA accepted as positive CT for SpA involvement. Demographic/clinic data including smoking status, disease characteristics (duration, drug history, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Mobility Index (BASMI) and other related parameters) at the time of CT scan were collected and analyzed.

Results: After the confirmation of the diagnoses among 1700 patients, total of 339 SpA patients were included in the study. 244 were diagnosed with ankylosing spondylitis (AS), 66 with psoriatic arthritis (PsA), 14 with enthesopathic arthropathy, 13 with peripheral SpA, and 2 with non-radiographic axial SpA. According to CT reports, the number of patients with inflammatory changes in any of the CV, CTr, SC or MS joints on thoracic CT were 44. Of these patients, 42 were diagnosed with AS (95.5%), 1 with PsA (2.3%), and 1 (2.3%) with peripheral SpA. 39 CV, 9 SC, 5 MS joints, and 3 CTr joints were affected. Joint involvements (17%) were higher in patients with AS than in other patient groups (p<0.001). In the chest CT positive group, Schober’s test, and chest expansion were significantly lower than chest CT negative group. Smoking history, C-reactive protein (CRP) value at diagnosis and at CT evaluation, and disease duration were associated with joint involvement. Demographic and clinical characteristics of patients with and without chest CT involvement were shown in Table 1.

Table 1. Demographic and clinical characteristics of patients with and without involvement on chest CT

<table>
<thead>
<tr>
<th></th>
<th>CV without involvement</th>
<th>CV with involvement</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>43 (25-50)</td>
<td>41 (25-50)</td>
<td>0.23</td>
</tr>
<tr>
<td>Gender (male %)</td>
<td>295 (100)</td>
<td>142 (100)</td>
<td>0.85</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>167 (156-170)</td>
<td>171 (167-176)</td>
<td>0.05</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.1 (23.7-29.8)</td>
<td>24.3 (22.5-31.5)</td>
<td>0.17</td>
</tr>
<tr>
<td>Smoking status (n %)</td>
<td>131 (101,76)</td>
<td>36 (26,93)</td>
<td>0.004</td>
</tr>
<tr>
<td>Smoking pack years</td>
<td>20 (10-30)</td>
<td>20 (10-30)</td>
<td>0.04</td>
</tr>
<tr>
<td>CRP (mg/l)</td>
<td>9.4 (3.2-10.3)</td>
<td>4.3 (1.6-5.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>CRP at diagnosis (mg/l)</td>
<td>9.4 (3.2-10.3)</td>
<td>4.3 (1.6-5.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>CRP at imaging (mg/l)</td>
<td>9.4 (3.2-10.3)</td>
<td>4.3 (1.6-5.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>CRP at CT imaging (mg/l)</td>
<td>9.4 (3.2-10.3)</td>
<td>4.3 (1.6-5.9)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Data are presented as median (25-75 percentile) or number (%) CT; computerized tomography, BMI; body mass index, ESR; erythrocyte sedimentation rate, CRP; C-reactive protein, BASDAI; Bath Ankylosing Spondylitis. Disease Activity Index, BASMI; Bath Ankylosing Spondylitis Mobility Index, BASFI; Bath Ankylosing Spondylitis Functional Index

Conclusion: In this study, we have found that CV, CTr, SC, and MS joint involvement on thorax CT were more common in men and smokers and were associated with disease duration and appears to affect chest expansion and Schober’s tests. In previous studies, CV and CTr joint involvement in AS patients with chest pain have been 12% and 8%, respectively [1,2]. Our study showed that 17% of AS patients had involvement regardless of pain symptoms. As this is the preliminary data and the CTs will be re-evaluated by our radiologist, we will be capable to report more unbiased results.

REFERENCES:
poor mental health (OR=1.14), being on a sick leave/unemployed (OR=1.49), divorced/separated (OR=1.46), anxiety (OR= 1.41) and female gender (OR= 1.30; Table 1).

Table 1. Factors associated with a worsening social life (n= 2,120)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariable logistic analysis</th>
<th>Multivariable logistic analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender. Female†</td>
<td>0.99</td>
<td>0.98, 0.99</td>
</tr>
<tr>
<td>Divorced/separated‡</td>
<td>1.63</td>
<td>1.39, 1.91</td>
</tr>
<tr>
<td>Marital status. Divorced/separated‡</td>
<td>1.93</td>
<td>1.48, 2.50</td>
</tr>
<tr>
<td>Employment status. Sick Leave/Unemployed‡</td>
<td>2.66</td>
<td>2.24, 3.17</td>
</tr>
<tr>
<td>BASDAI (0-10)</td>
<td>1.41</td>
<td>1.35, 1.48</td>
</tr>
<tr>
<td>Functional Limitation (0-54)</td>
<td>1.03</td>
<td>1.02, 1.03</td>
</tr>
<tr>
<td>Spinal Stiffness (3-12)</td>
<td>1.20</td>
<td>1.16, 1.24</td>
</tr>
<tr>
<td>Diagnostic delay</td>
<td>1.02</td>
<td>1.01, 1.03</td>
</tr>
<tr>
<td>GHQ-12 (0-12)</td>
<td>1.22</td>
<td>1.19, 1.24</td>
</tr>
<tr>
<td>Anxiety</td>
<td>2.84</td>
<td>2.39, 3.37</td>
</tr>
<tr>
<td>Depression</td>
<td>2.59</td>
<td>2.17, 3.10</td>
</tr>
<tr>
<td>Sleep disorders</td>
<td>2.10</td>
<td>1.79, 2.46</td>
</tr>
</tbody>
</table>

†Female vs. male; ‡Divorced/separated vs. single/married/widow; ‡Sick leave/unemployed vs. other employment status.

Conclusion: Almost half of the axSpA patients reported to have negatively impacted their social life. Being female, divorced/separated, on sick leave/unemployed, with higher disease activity, poor mental health, and anxiety increase the likelihood of worsening social life. As relationships with others and engagement in social or community activities influence quality of life, greater attention to enabling individuals to participate socially through controlling disease activity and addressing mental health comorbidity in the management of axSpA.

Acknowledgements: This study was supported by Novartis Pharma AG. The authors would like to thank all patients who participated in the study.

Disclosure of Interests: Marco Garrido-Cumbraer Grant/research support from: has a research collaboration with and provides services to Novartis Pharma AG, Victoria Navarro-Compán Grant/research support from: Abbvie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Christine Bundy Speakers bureau: AbbVie, Celgene, Janssen, Lilly, Novartis and Pfizer, Raj Mahapatra: None declared, Laura Christen: Employee of: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis and Pfizer, Roche and UCB, MSC, Novartis and Pfizer Grant/research support from: AbbVie, MSD, Novartis and Pfizer


Table 1. Linear regression analysis of socio-demographic and patient-reported outcomes according to healthcare utilization (N= 402)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Beta 95% CI</th>
<th>Beta 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>-0.884 (-1.266, -0.503)</td>
<td>-1.190 (-2.028)</td>
</tr>
<tr>
<td>Gender. Female†</td>
<td>1.586 (1.266, 1.906)</td>
<td>-0.503 (1.145)</td>
</tr>
<tr>
<td>BASDAI (0-10)</td>
<td>7.260 (4.934, 9.586)</td>
<td>3.378 (5.765)</td>
</tr>
<tr>
<td>GHQ-12 (0-12)</td>
<td>2.724 (1.786, 3.663)</td>
<td>1.126 (2.300)</td>
</tr>
<tr>
<td>Functional Limitation (0-54)</td>
<td>1.418 (1.007, 1.829)</td>
<td>0.576 (1.020)</td>
</tr>
<tr>
<td>Diagnostic Delay</td>
<td>0.966 (0.419, 1.512)</td>
<td>0.959 (1.544)</td>
</tr>
</tbody>
</table>

†Female vs. male; ‡Divorced/separated vs. single/married/widow; ‡Sick leave/unemployed vs. other employment status.

Conclusion: Higher healthcare utilization was associated with higher disease activity, greater functional limitation, and longer diagnostic delay, in younger and females axSpA patients. Optimal monitoring of axSpA patients may help to minimise healthcare utilisation in patients with axSpA.

Acknowledgements: This study was supported by Novartis España. The authors would like to thank all patients who participated in the Atlas study.

Disclosure of Interests: Marco Garrido-Cumbraer Grant/research support from: has a research collaboration with and provides services to Novartis Pharma AG, Eduardo Collantes-Estévez Grant/research support from: AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Victoria Navarro-Compán Grant/research support from: AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB, Pedro Zarco-Montejo: None declared, Carlos Sastré Employee of: Novartis Farmacéutica España, José Correa-Fernández: None declared, Jordi Gratacos-Masmitja Grant/research support from: AbbVie, BMS, Lilly, MSD, Novartis, Pfizer, Roche and UCB

DOI: 10.1136/annrheumdis-2022-eular.2664
AB0811 RESPIRATORY TRACT INFECTIONS AND RISK FACTORS FOR INFECTION IN A SPONDYLOARTHRITIS CLINIC IN TASHKENT: IS THERE A DIFFERENCE BETWEEN PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS?

N. Frede1, E. Rieger1, R. Lorenzent1, A. Venhoff1, A. M. Kanne1, M. Von Deimling1, N. Bartholomä1, J. Thiel1, R. Vol1, N. Venhoff1. 1 Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Department of Rheumatology, Freiburg, Germany

Background: Respiratory tract infections (RTIs) are the most common infections in patients with rheumatic diseases under immunosuppressive treatment. RTIs may cause significant morbidity with reduced quality of life (QOL), increased healthcare costs and may lead to interruption of DMARD therapy. However, to date only limited data on infection risk in spondyloarthritids (SpA) patients are available.

Objectives: To assess the occurrence of respiratory tract infections in a real-world SpA cohort and determine associated factors.

Methods: Questionnaire-based screening and retrospective medical chart analysis of a monocentric cohort of 314 SpA patients comprising 168 psoriatic arthropitits (PsA) and 146 axial spondyloarthritids (axSpA) patients.

Results: Out of 314 SpA patients, 89% had a history of upper respiratory tract infections (URTIs) and 31.1% of lower respiratory tract infections (LRTIs) within the last two years (Table 1). In a linear regression model LRTIs were associated with glucocorticoid (GC) therapy (p=0.015), CRP level (p=0.018), previous history of severe respiratory infections (p=0.007) as well as absence of HLA B27 (p=0.024). In general, patients with LRTIs were significantly older (p=0.007), had increased functional impairment (p<0.001), a reduced health-related QOL (p<0.001), poorer sleep quality (p=0.001) and more depression (p=0.001). 46% of patients had required antibiotics for RTIs within the last two years. Antibiotic therapy was associated with smoking (p=0.006), biologic therapy (p=0.005) and poor sleep quality (p=0.005). Smoking was associated with LRTI (p=0.009), but not URTI. Female patients reported a significantly higher frequency of LRTI (p=0.003), sinusitis (p=0.001), pharyngitis/laryngitis (p=0.009) and had more received courses of antibiotics than male patients (p=0.032).

Table 1. Patient characteristics and infections

<table>
<thead>
<tr>
<th></th>
<th>axSpA (n=146)</th>
<th>PsA (n=168)</th>
<th>Total (n=314)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>49.6 (14.2)</td>
<td>57.4 (12.4)</td>
<td>53.8 (13.9)</td>
</tr>
<tr>
<td>Male / Female, %</td>
<td>56.8 / 43.2</td>
<td>53.0 / 47.0</td>
<td>54.8 / 45.2</td>
</tr>
<tr>
<td>BMI, kg/m², mean (SD)</td>
<td>27.1 (7.2)</td>
<td>27.4 (5.4)</td>
<td>273 (6.2)</td>
</tr>
<tr>
<td>Smokers, n (%)</td>
<td>41 (31.8)</td>
<td>27 (16.3)</td>
<td>68 (23.1)</td>
</tr>
<tr>
<td>HLA B27, n (%)</td>
<td>97 (71.9)</td>
<td>23 (24.4)</td>
<td>120 (25.2)</td>
</tr>
<tr>
<td>LRTI, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>29 (19.6)</td>
<td>84 (50.6)</td>
<td>113 (36.2)</td>
</tr>
<tr>
<td>bDMARD</td>
<td>109 (75.2)</td>
<td>102 (60.7)</td>
<td>211 (67.4)</td>
</tr>
<tr>
<td>Glucocorticoids</td>
<td>14 (9.9)</td>
<td>15 (8.9)</td>
<td>29 (9.4)</td>
</tr>
<tr>
<td>Hypogammaglobulinemia</td>
<td>5 (3.5)</td>
<td>6 (3.6)</td>
<td>11 (3.6)</td>
</tr>
<tr>
<td>Polyclonal IgA (&gt;4g/l)</td>
<td>15 (10.9)</td>
<td>29 (17.8)</td>
<td>44 (14.7)</td>
</tr>
<tr>
<td>Rituximab</td>
<td>114 (78.4)</td>
<td>148 (90.2)</td>
<td>262 (82.4)</td>
</tr>
<tr>
<td>LRTI: n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>polyarticular psoriasis, %</td>
<td>28.0</td>
<td>30.6</td>
<td>29.6</td>
</tr>
<tr>
<td>Pneumonia, %</td>
<td>3.9</td>
<td>3.1</td>
<td>3.4</td>
</tr>
<tr>
<td>Pleuritis, %</td>
<td>2.4</td>
<td>1.2</td>
<td>1.7</td>
</tr>
</tbody>
</table>

There were no significant differences between PsA and axSpA regarding frequency of URTI or LRTI, though axSpA patients had tendentially more overall RTIs. Biological therapy did not lead to a significantly increased occurrence of infections, but was associated with increased antibiotic therapy (p=0.039). Patients with a history of pneumonia had received anti-IL17 therapy more frequently (p=0.002), while there was no significant association with anti-TNF therapy (p=0.156). Patients on GC had a relative risk for LRTIs of 10.1136 / annrheumdis-2022-eular.2966

Disclosure of Interests: None declared


AB0812 EFFECT OF PRO-INFLAMMATORY CYTOKINE-INTERLEUKIN 6 ON THE COURSE OF ANKYLosing Spondylitis in Patients after COVID-19

N. Abdurakhmanova1, K. Akhmedov2, 1Tashkent Medical Academy, Department of internal diseases #3, Tashkent, Uzbekistan; 2Tashkent Medical Academy, Department of internal diseases #3, Tashkent, Uzbekistan

Background: Everyone knows that COVID-19 not only has a severe effect on the pulmonary system, but also triggers a whole cascade of autoimmune reactions. The study of the effect of the pro-inflammatory cytokine - interleukin 6 (IL-6) on the clinical course of patients with ankylosing spondylitis (AS) undergoing COVID-19 is an important problem in rheumatology.

Objectives: To study the significance of the pro-inflammatory cytokine-IL-6 on the clinical features of the course of AS in patients who have undergone COVID-19.

Methods: In the period from 2020-2021, 44 patients with a diagnosis (AS) were hospitalized in the City Clinical Hospital # 3 of Tashkent city. The patients were divided into two groups: Group I - 20 patients with AS who underwent COVID-19 and Group II of 24 patients with no history of AS who had COVID-19 infection. The average age of patients in group I was 32 ± 4.1 years and in group II - 36.5 ± 5.2 years. All patients underwent clinical and laboratory studies, including studies of serum IL-6 levels. Disease activity was assessed using the BASDAI and ASDAS scales, pain was assessed using a numerical rating scale (NRS), and peripheral joint damage was assessed by the presence of pain and swelling in 44 joints. All patients underwent PCR, as well as ELISA-IHLA tests for the presence of antibodies to COVID-19.

Results: Clinical examination of the patients revealed the presence of pain in the spine, which was assessed using the numerical rating scale – (NRS) in group I it was 8.5 ± 1.2 points and 5.9 ± 2.3 points in patients of group II. Examination of peripheral joints showed an average number of painful joints (PJ) of 16.9 ± 3.2 in group I and 8.6 ± 2.7 in group II, the number of swollen joints (NSJ) 8.8 ± 2.1 in group I and 4.2 ± 1.7 in group II. The study of AS activity using the BASDAI scale showed an average level of 5.1 ± 1.7 points in group I and 4.4 ± 2.1 points in group II. And the study of activity on the ASDAS scale showed an average level of 4.0 ± 1.7 points in group I and 2.5 ± 0.8 points in group II, which indicates a high activity of the pathological process in group I and medium-high activity in group II. The IL-6 level in group I was 10.2 ± 2.1 / mg / ml and 4.2 ± 2.1 / mg in group II and 1.39 µg / ml in the control group.

Conclusion: 1. The clinical course of AS in patients who have undergone COVID-19 is characterized by a more pronounced disease activity according to the BASDAI and ASDAS scales, a high intensity of pain syndrome according to a NRS, as well as a high level of IL-6.

2. A high level of IL-6 in group I indicates the impact of COVID-19 on the course, activity and severity of the autoimmune process in patients with AS, which is many times higher than in patients of group II, which allows us to consider it as a biomarker of damage to the articular and connective tissue in this infection.

References:

Disclosure of Interests: None declared

Background: There is currently no consensual definition of flare in axial spondyloarthritis (axSpA).

Objectives: The aims of this study were to determine thresholds of variations of BASDAI associated with patient-reported flare and to test performance of ASAS preliminary definitions of flare.

Methods: This prospective study was proposed to all patients registered on the Spondy+ platform, a secure e-health platform for SpA patients. Every week during one year, patients were invited to connect to the platform to fill a BASDAI questionnaire, a 0–10 pain visual analogic scale and to answer to the following question: “has your disease flared up since last week?” Variations of BASDAI and pain between connections were assessed and associated to the change of perception of a flare. ROC curves were built to assess performances of BASDAI and VAS to identify patient-reported occurrence and resolution of flare. Performance of ASAS preliminary definitions of flare was also assessed.

Results: 99 patients participated to this study for an average duration of 309 ± 148 days. 92% of them reported at least one episode of flare over follow-up. Area under the ROC curve (AUC) was significantly higher for ΔBASDAI than for Δpain, to predict outbreak of flare (0.81 vs 0.77, p<0.02). In contrast, ΔBASDAI and Δpain were comparably accurate to predict flare resolution with no significant difference of AUC (0.78 vs 0.80, p=0.4). Best performance was obtained for an increase of 0.2 points of BASDAI (sensitivity=70%; specificity=79%) and 0.5 of pain VAS to predict outbreak of a flare and a decrease of 0.4 points of BASDAI and 0.5 of pain VAS to predict flare resolution (Figure 1). None of the ASAS definitions yielded sensitivity values higher than 37% whereas specificity was higher than 95% for all of them.

Conclusion: ΔBASDAI appeared as a suitable variable to monitor both occurrence and resolution of SpA flare, as reported by patient.

REFERENCES:

Disclosure of Interests: None declared


Figure 1. Sensitivity (red dots) and specificity (blue dots) according to ΔBASDAI (panels A,C) and Δpain (panels B,D) threshold as predictors of outbreak (panels A,B) or resolution (panels C,D) of flare.
HLA-B27 (p=0.034), functional impairment (p=0.001) and depression (p<0.001). Patients reporting restless sleep had significantly more depressive symptoms (p<0.001) and highly reduced physical and mental HRQoL (p<0.001). Satisfaction with health was rated significantly lower (p<0.001). Patients with axial involvement (axSpA/axPsA) reported worse sleep quality (p=0.002) and waking too early (p=0.038) despite 73.7% receiving biologics. Sleep quality and early awakening correlated with BASDAI (p<0.001). Smokers had a reduced HRQoL (p=0.018) despite younger age (p=0.008). Female patients had worse sleep quality (p<0.001), needing more time to fall asleep (p=0.022), not being able to sleep through the night (p=0.026) and feeling unrestful in the morning (p<0.001). They had a reduced physical (p=0.019) and mental HRQoL (p=0.003), more depressive symptoms (p=0.040) and lower functional capacity (p=0.002). Functional capacity was associated with younger age (p<0.001), sex (p=0.042), smoking (p=0.008), sleep quality (p<0.001) and depression (p<0.001). 66.2% of patients have been assessed longitudinally, before and 3y later during COVID19 pandemic. Physical and mental HRQoLs were stable over time. Functional capacity had decreased slightly. Subjective QoL during the COVID19 pandemic was not reduced compared to before. Regarding depressive symptoms, there was a mild but significant improvement over time (p=0.019). Furthermore, we observed an improvement of environmental QoL (p=0.034) during COVID pandemic. Overall subjective QoL as well as satisfaction with health did not change significantly. Patients who had changed therapy (37% of the cohort) still had a reduced physical HRQoL (p=0.022) as well as significantly more depressive symptoms (p=0.010) and perceived their overall QoL as being worse (p=0.016).

**Conclusion:** Despite treatment many SpA patients have a reduced HRQoL and impaired sleep quality with significant differences between male and female patients. Impact of COVID19 pandemic was low.

| Table 1. Patient characteristics | Total | Women n=142 (45.3%) | Men n=172 (54.8%) | p-value
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean (SD)</td>
<td>53.8 (13.9)</td>
<td>53.7 (14.5)</td>
<td>53.8 (13.4)</td>
<td>0.983</td>
</tr>
<tr>
<td>BMI, kg/m², mean (SD)</td>
<td>27.3 (6.3)</td>
<td>27.1 (6.5)</td>
<td>27.4 (6.1)</td>
<td>0.706</td>
</tr>
<tr>
<td>Smokers, n (%)</td>
<td>68 (23.1)</td>
<td>34 (24.6)</td>
<td>34 (21.7)</td>
<td>0.544</td>
</tr>
<tr>
<td>HLA B27 n (%) (n=230)</td>
<td>120 (52.2)</td>
<td>46 (45.1)</td>
<td>54 (54.9)</td>
<td>0.055</td>
</tr>
<tr>
<td>CRP, mg/l, mean (SD)</td>
<td>6.14 (11.9)</td>
<td>5.88 (6.0)</td>
<td>6.37 (15.2)</td>
<td>0.721</td>
</tr>
<tr>
<td>Significant functional impairment, n (%)</td>
<td>54 (17.5)</td>
<td>29 (20.6)</td>
<td>25 (15.0)</td>
<td>0.198</td>
</tr>
<tr>
<td>Therapy, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD</td>
<td>113 (36.2)</td>
<td>56 (39.7)</td>
<td>57 (33.3)</td>
<td>0.243</td>
</tr>
<tr>
<td>bDMARD</td>
<td>211 (67.4)</td>
<td>91 (64.1)</td>
<td>120 (70.2)</td>
<td>0.252</td>
</tr>
<tr>
<td>Depressive symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>109 (37.5)</td>
<td>53 (39.6)</td>
<td>56 (35.9)</td>
<td>0.040</td>
</tr>
<tr>
<td>Moderate/severe</td>
<td>48 (16.5)</td>
<td>27 (20.0)</td>
<td>21 (13.5)</td>
<td></td>
</tr>
<tr>
<td>WHO-QOL mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical</td>
<td>60.2 (19.4)</td>
<td>57.4 (19.7)</td>
<td>62.6 (19.0)</td>
<td>0.019</td>
</tr>
<tr>
<td>Mental</td>
<td>677 (172)</td>
<td>645 (178)</td>
<td>703 (162)</td>
<td>0.003</td>
</tr>
<tr>
<td>Social</td>
<td>678 (20.0)</td>
<td>674 (19.6)</td>
<td>682 (20.3)</td>
<td>0.703</td>
</tr>
<tr>
<td>Environmental</td>
<td>773 (13.3)</td>
<td>766 (13.6)</td>
<td>780 (13.1)</td>
<td>0.363</td>
</tr>
<tr>
<td>Sleep, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abnormal sleep behaviour</td>
<td>138 (46.5)</td>
<td>76 (55.1)</td>
<td>62 (39.0)</td>
<td>0.006</td>
</tr>
<tr>
<td>Inability to sleep through the night</td>
<td>145 (49.4)</td>
<td>76 (55.1)</td>
<td>69 (44.2)</td>
<td>0.024</td>
</tr>
<tr>
<td>Waking too early</td>
<td>89 (30.4)</td>
<td>43 (31.4)</td>
<td>46 (29.5)</td>
<td>0.459</td>
</tr>
<tr>
<td>Need for sleeping pills</td>
<td>18 (6.1)</td>
<td>11 (8.0)</td>
<td>7 (4.4)</td>
<td>0.133</td>
</tr>
<tr>
<td>Unrefreshing sleep most or all nights</td>
<td>35 (11.9)</td>
<td>24 (17.5)</td>
<td>11 (7.0)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** Natalie Frede Grant/research support from: Novartis study grant, Eva Rieger: None declared, Raquel Lorenzetti Grant/research support from: Novartis study grant, Ana Vehoff: None declared, Carolin Hentze: None declared, Ilona Jandova: None declared, Cornelia Glaser: None declared.

**Figure 1.** Female SpA patients have increased depressive symptoms and a reduced HRQoL.

**References:**


**Disclosure of Interests:** None declared

**DOIs:**


DMARD-use (p=0.046) and less use NSAID (89.5 % vs 96.6 %; p=0.02). There were no statistically significant differences in prevalence of comorbidities between AS and nr-axSpA groups except hypertension which was higher in nr-axSpA patients (24.6 % vs 14.4 %; p=0.016) and digestive disorders which was most frequently detected in patients with AS (12.5 % vs 5.9 %; p=0.05). The prevalence of cardiac disorders (p = 0.068) and diabetes (p = 0.09) was nearly statistically significant. The multivariate analysis showed that hypertension is associated to AS form (OR: 1.976; IC [1.088-3.589]).

**Conclusion:** Comorbidities were common in both axSpA populations with small differences between AS and nr-axSpA. These results highlight the importance of identifying and managing comorbidities.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3045

---

**AB0818**

**PREDICTORS OF REMISSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW**

A. S. Pinto1, B. Farisogullari2, P. Machado3. 1Unidade Local de Saúde da Guarda, Rheumatology, Guarda, Portugal; 2Faculty of Medicine, Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Ankara, Turkey; 3University College London, Centre for Rheumatology & Department of Neuromuscular Diseases, London, United Kingdom

**Background:** Achievement of remission is a desirable outcome in axSpA, and the identification of remission predictors may further aid in the clinical and personalisation of management of the disease.

**Objectives:** To systematically review and summarize the predictors of remission in patients with axSpA.

**Methods:** A comprehensive search was performed in MEDLINE, EMBASE, Cochrane CENTRAL, and 2020-2021 abstracts of ACR and the EULAR annual meetings. To identify the relevant studies, medical subject headings and keywords related to “axial spondyloarthritis,” “remission,” and “prognostic study” were used. Studies were included if: patients were diagnosed with axSpA by a physician; age ≥18 years; the study assessed the potential predictive or prognostic factors related to remission, according to any definition; and the statistical analysis included multivariable analysis. The methodological quality of the included studies was assessed using the Quality of Prognosis Studies in Systematic Reviews tool.

**Results:** The systematic literature review (SLR) comprised 22 articles from 4245 citations identified in our search (Figure 1). Two studies investigated “sustained remission” (at least in 3 consecutive follow-up visits), while the others assessed “point remission” (at single points in time). The most commonly used remission criteria were: Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), inactive disease (14 studies) and Assessment of SpondyloArthritis international Society partial remission (ASAS-PR; 11 studies) criteria. However, other non-validated definitions, most of them including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-offs, were also used. In 19 studies, subjects were treated with biological disease-modifying antirheumatic drugs (bDMARDs) with or without concomitant conventional synthetic antirheumatic drugs (cDMARDs) or non-steroidal anti-inflammatory drugs (NSAIDs), while in one study patients were treated with a Janus kinase inhibitor, upadacitinib. Study duration ranged from 12 weeks to 8 years. Younger age, HLA-B27 positivity, male gender, lower baseline BASDAI, lower baseline Bath Ankylosing Spondylitis Functional Index (BASFI) and treatment with tumour necrosis factor inhibitor (TNFi), were the most consistent predictors of remission. Additionally, lower baseline ASDAS-CRP, lower body mass index (BMI), shorter disease duration, TNFi naïveté, and concomitant use of cDMARDs were found to be predictors of remission in two studies each. Other predictors were only found to be associated with remission in single studies, namely: higher education level, more intense morning stiffness, lower baseline total back pain score, history of peripheral arthritis, no smoking, higher pain catastrophizing, lower modified Rheumatic Disease Comorbidities Index, fulfillment of ASAS clinical arm criteria, fulfillment of European Spondyloarthritis Study Group criteria, lower erythrocyte sedimentation rate, higher Spondyloarthropathy Research Consortium of Canada magnetic resonance imaging (MRI) sacroiliac joint (SIJ) and spinal inflammation score, positive MRI of the SIJ, lower Bath Ankylosing Spondylitis Metrology Index, lower Health Assessment Questionnaire for the Spondyloarthropathies, lower global pain, lower back pain score and lower enthesis index. Of note, contradictory data were found regarding CRP and NSAIDs usage.

---

**AB0819**

**IMPACT OF CHILDBIRTH ON THE SACROILIAC JOINTS IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS**

M. Yasmine1, D. Ben Nessibi1, H. Ferjani1, W. Triki1, K. Maatallah1, D. Kaffel1, W. Hamdi1. 1Kassab Institute of orthopedics, Rheumatology, Tunis, Tunisia

**Background:** The era of magnetic resonance imaging (MRI) has contributed to a better assessment of patients with early disease stages of axial spondyloarthritis (axSpA), to the extent that a new entity has emerged. Indeed, the spectrum of SpA has broaden to include non-radiographic axial spondyloarthritis (nr-axSpA). Childbirth has been found to be associated with bone marrow edema (BME) in the sacroiliac joints (SIJ) [1], yet the extent of these lesions is inadequately described, which complicates the distinction with nr-axSpA.

**Objectives:** This study aimed to explore the impact of childbirth on MRI findings and BME in nr-axSpA.

**Methods:** We conducted a cross-sectional study including women diagnosed with nr-axSpA according to the ASAS (Assessment of SpondyloArthritis international Society) criteria. Demographic data as well as childbirth history were recorded. The sacroiliac joints manoeuvres’ examination were also transcribed. Ultrasound of the SIJ as well MRI-SIJ was performed in all the women. The sequence protocol included the following: T1-weighted, T2-weighted and axial STIR and were scored for BMO. We investigated an association between the number of children and MRI abnormalities mainly the presence of BME. The level of significance was fixed for p<0.05.

**Results:** The study included 30 women. The mean age at diagnosis was 40±9.8 years old [21-59] and the mean age at inclusion was 49±11 years old [26-74]. The median number of children was 2 [0-7]. Half of the patients were multiparous. Doppler ultrasound of the SIJ was found in 59.1% of cases. Overall, 36.7% of the women fulfilled the ASAS definition of a positive MRI. BME was displayed on STIR MRI sequence in 26.5% of cases and was equally present at the right SIJ compared with the left (26.7% vs 23.3%). Gadolinium enhancement was found in 16.7% of cases and subchondral erosions were found in 36.7% of cases.
There was no association between the different sacroiliac maneuvers on physical examination and the number of children: distraction test (p=0.145), compression test (p=0.088), Gaenslen test (p=0.475), and Mennel test (p=0.088). BME was more frequent among multiparous women (33% vs 29%) without reaching a statistically significant difference (p=0.635). There was no association between the number of children and Hyper T1 (p=0.55), T1 gadolinium (p=0.55) as well as subchondral sclerosis of sacroiliac joints. Similarly, there was no association between the presence of Doppler signal on ultrasound and multiparity (p=0.5).

**Conclusion:** Our study showed that MRI-SIJ findings were similar in nr-axSpA women regardless of the number of children, mainly BME. More trials are needed to evaluate the discriminatory capacity of MRI abnormalities and to palliate to the lack of specificities of the ASAS MRI criteria.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3096

---

**AB0820 REMISSION CRITERIA IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: DON’T MISS SUBCLINICAL INFLAMMATION**

D. Ben Nessi1, M. Yasmine1, H. Ferjani1, W. Triki1, K. Maatallah1, D. Kaffel1, W. Hamdi1. 1Kassab Institute of orthopedics, Rheumatology, Tunisia, Tunisia

**Background:** With the advent of the treat-to-target strategy (T2T), clinical remission has become the main objective to achieve in patients with rheumatic diseases. Contrary to rheumatoid arthritis, the T2T strategy is less codified in axial spondyloarthritis, even more in non-radiographic SpA (nr-axSpA) [1]. More importantly, T2T based on imaging remission and guidance for tapering medication has not been extensively studied.

**Objectives:** The objective of this study was to investigate the prevalence of bone marrow edema in the sacroiliac joint of nr-axSpA patients in remission.

**Methods:** We undertook a cross-sectional study including nr-axSpA patients according to the ASAS criteria, treated with NSAIDs. Socio demographic data as well disease characteristics were collected. Disease activity parameters were also collected including the duration of morning stiffness, the number night awakening, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). MRI-SIJ, MRI-SIJ was performed for all the patients. All the images were screened for bone marrow edema with the corresponding sequence (short tau inversion). To define remission, we used in addition to BASDAI<4, more stringent criteria: BASDAI<4 and CRP<6 mg/l and ESR<20 mm/h and EGM<4 [2]. The level of significance was fixed for p<0.05.

**Results:** The study included 43 nr-axSpA patients. There was a female predominance with a sex ratio of 0.43. The mean age of the patients was 42±12 years [20-71] and the mean disease duration was 8±6 years [4-38]. The mean ESR and CRP were 2.2 mg/l [2-65] and 6.4 mm/h [1-47], respectively. A higher level of acute phase reactants was found in 40.5% of cases (ESR: 35.7%, CRP: 11.9%). Forty percent of the patients had high CRP or ESR despite BASDAI<4. According to BADSAl<4, of the 15 patients in remission, BME was displayed in 43.5% of the cases. According to the used criteria, 25.6% of the patients were in remission, of which 45.4% exhibited BME in the sacroiliac joint. There was no statistically significant association between disease activity according to the used definition and the presence of BME (p=0.473). Nr-axSpA patients in remission without BME had more durable morning stiffness and articular involvement without reaching a statistically significant difference (p=0.361, p=0.08 respectively). Similarly, we did not find an association between this subgroup and sex, age, night awakenings, the presence of HLAB27, is the most observed type of LSVT. The presence of LSVT was higher in patients with IIIa than in patients with IV (p=0.008 and p=0.007).

**Conclusion:** Our study showed that even when using stringent criteria, subclinical remission evidenced by BME was not achieved in nr-ax SpA. Nevertheless, imaging remains one important parameter to consider in therapeutic decision making. More studies are needed to identify the best criteria for an optimal remission in this population.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3105

---

**AB0821 THE FREQUENCY OF LUMBOSACRAL TRANSITIONAL VERTEBRAS IN PATIENTS WITH ANKYLOSING SPONDYLITIS**

N. Gokcen1, O. Ozdemir Isik2, A. Yazio2, A. Cefe1. 1Kocaeli University Faculty of Medicine, Internal Medicine, Division of Rheumatology, Kocaeli, Turkey

**Background:** Lumbosacral transitional vertebras (LSTVs) are anatomic variances observed at L5-S1 junction (1). The prevalence of LSTV ranges from 3.9% to 35.6%, indicating that this congenital anomaly is common in general population. LSTVs are well-defined anatomical differences causing low back pain and pelvic trauma (2). However, the studies assessing the frequency of normal lumbosacral anatomy on low back pain and sacroiliac joints in patients with ankylosing spondylitis (AS) are scarce (3).

**Objectives:** The current study aimed to investigate the frequency of LSTVs and the their effects on clinical variables in AS patients.

**Methods:** The study was designed as a prospective cross-sectional study. 113 patients were included in the study. Demographic data, clinical variables, laboratory results were recorded. Disease activity (ASDAS-CRP and ASDAS-ESR), patients' functionality (BASFI, BASM), enthesis (Leeds enthesis index) and quality of life (SF-36, visual analogue scale) were evaluated. The baseline pelvic conventional radiographs and the sacrolilac magnetic resonance imagings at the diagnosis were screened and assessed by two independent physicians. LSTVs were classified via Castelli classification. Basa coeffient was used to find the interobserver reliability.

**Results:** LSTVs were observed in 38 (33.6%) patients. Castelli type Ia, Iib, Ila, Iib, Ila, Ilb, IV, and IV were found in 10 (8.8%), 7 (6.2%), 7 (6.2%), 6 (5.3%), 4 (3.5%), 1 (0.9%), and 3 (2.7%) patients, respectively. The kappa value for interobserver reliability was 0.69. There were not any different as between AS patients with and without LSTVs in terms of disease activity, functionality, and quality of life (Table 1).

No statistically significant correlation was found between LSTVs identified by conventional radiography and sacroiliac magnetic resonance imagings at the diagnosis were screened and assessed by two independent physicians. LSTVs were classified via Castelli classification. Kappa coefficient was used to find the interobserver reliability.

**Discussion:** The prevalence of LSTV was 33.6%, which is consistent with the general population. Type I, also known as a dysplastic transverse process, is the most observed type of LSTV. The presence of LSTVs is associated neither with clinical variables nor with sacrolilac.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.3110
AB0822 FACTORS ASSOCIATED WITH A DELAYED DIAGNOSIS OF SPONDYLOARTHROPATHIES IN A POPULATION OF THE SOUTH OF MOROCCO

P. C. Mouleïe Moussi1, Z. Baba1, F. E. Chekkioui1, A. Rafi1, A. Mougui1, I, El Bouchti1. CENTRE HOSPITALO-UNIVERSITAIRE MOHAMMED VI MARRAKECH, RHEUMATOLOGY, Marrakech, Morocco

Background: Spondyloarthropathies are chronic inflammatory diseases with predominant axial involvement. Early diagnosis is a major challenge for physicians. Misdiagnosis and diagnostic delays lead to unnecessary parascolic investigations, inadequate treatment and to poor outcomes including functional impairment and quality of life.

Objectives: We assess the diagnostic delay in spondyloarthropathy and identify factors associated with it.

Methods: A retrospective study including patients diagnosed with spondyloarthropathies between 2004 and 2020 according to ASAS 2010 criteria. Diagnostic delay was defined as period between the first symptom and diagnosis establishment. The potential factors predicting the diagnostic delay were explored through univariable and multivariable linear regression analysis, included epidemiological characteristics (age, gender, educational level, socio-economic level), clinical and biological presentation and sacroiliac (radiographic or in MRI). Events occurring before the diagnostic were also analyzed.

Results: The study included 276 patients: 146 males (53%) and 130 females (47%) with a sex ratio of 1.1 and the mean age at the diagnostic was 38.87 years. Comorbidities included smoking (33 patients), cardiopathy (3 patients), hypertension (19 patients), diabetes (14 patients) and peptic ulcer (5 patients). The mean duration of symptoms was 2.6 years, and average diagnostic delay was 6.5 years with a median of 2.1 years. In univariable and multivariable linear regression analysis, low socio-economic level, low educational level (p=0.042) were statistically significant parameters associated with a delayed diagnosis. There was no statistically significant association between the delay of diagnosis and age, clinical presentation or sacroiliac (radiographic or in MRI). The use of traditional and herbal treatments before consulting a rheumatologist was also associated with a longer delayed diagnosis.

Conclusion: Spondyloarthropathies have a delayed diagnosis. This delay, also found in other studies, is responsible for persistent disease activity and important functional consequences. In our context, low socio-economic level, low educational level, and the use of traditional unconventional treatment are factors associated with a delayed diagnosis.

REFERENCES:

Disclosure of Interests: None declared

AB0823 DUAL ENERGY X-RAY ABSORPTIOMETRY IN PATIENTS WITH SPONDYLOARTHROPATHY. CORRELATION WITH DISEASE DURATION, ACTIVITY AND CHANGES IN SACROILIAC JOINTS ON MAGNETIC RESONANCE IMAGING

O. Iaremenko1, D. Fedkov1, K. Mazanko1. Bogomolets National Medical University, Department of internal medicine #3, Kyiv, Ukraine

Background: Bone loss (osteopenia or osteoporosis) and osteoporotic vertebral fractures are well-known complications of spondyloarthritis (SpA), and their prevalence in SpA patients (pts) is higher than in patients with mechanical low back pain [1, 2]. Osteopenia and osteoporosis can develop in both the late and early stages of SpA. The presence of bone marrow edema at the lumbar spine and sacroiliac joints (SIJ) on magnetic resonance imaging (MRI) was more common among pts with low BMD (bone mineral density) than normal BMD [3, 4]. At the same time, the dynamics of osteoporotic and osteosclerotic changes in the spine during the progression of SpA makes the assessment of DEXA results ambiguous.

Objectives: To determine the presence of osteopenia/osteoporosis in pts with SpA and to establish its correlations with disease duration, disease activity, active changes in SIJ on MRI.

Methods: 40 patients with SpA (55% – male, mean age 39.87±9.79, mean disease duration – 6.75±4.73 years) underwent DEXA. Spondyloarthropathies Research Consortium of Canada (SPARCC) MRI SIJ score (0-72) was utilized for evaluation of the active inflammatory lesions in SIJ, Danish MRI scoring method (0-48) – for chronic changes. Disease activity was measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI, cm), Ankylosing Spondylitis Disease Activity Score (ASDAS, CRP, mg/l), and erythrocyte sedimentation rate (ESR, mm/hr). For correlation, the Spearman correlation coefficient was calculated.

Results: The mean value of DEXA parameters were: BMD – 0.72±0.15, T-score – -0.16±0.88, Z-score – 0.17±0.89 (forearm); BMD – 0.96±0.17, T-score – -1.13±1.35, Z-score – -0.88±0.13 (spine); BMD – 0.85±0.14, T-score – -0.85±0.93, Z-score – -0.56±0.97 (hip). Mean value (Mux) of indices and laboratory parameters were: BASDAI – 4.4±1.76, ESR – 30.2±24.1, CRP – 17.3±19.7, ASDAS- CRP – 3.07±1.13, ASDAS-ESR – 3.14±1.14. SPARCC score was 12.3±11.8, Danish score – 15.2±7.77. Osteoporosis was present in 7 (17.5%), osteopenia - in 24 (60%) SpA pts. There was positive correlation between BMD at forearm and Danish MRI score (r=0.331, p=0.02). The CRP level showed negative correlation with BMD at hip (r=-0.322, p=0.012) and T-score at spine (r=-0.301, p=0.031). Patient’s age showed negative correlation with BMD at hip (r=-0.268, p=0.05). Disease duration negatively correlated with BMD (r=-0.334, p=0.016) and T-score (r=-0.310, p=0.027) at hip. All correlations were weak. No other correlations were found.

Conclusion: Among disease activity parameters, only high CRP was associated with a decrease in BMD for both the back and hip. A decrease in hip BMD was also associated with the patient’s age and disease duration. Regarding MRI indicators, only chronic changes in SIJ, measured by MRI, positively correlated with BMD at forearm only.

REFERENCES:

Disclosure of Interests: None declared

AB0824 BREASTFEEDING IN WOMEN WITH ANKLYLOSING SPONDYLITIS (AS)

O. Krivchenskaya1, E. Iinskykh1, T. Dubinina2, S. Glukhova1, A. Demina1, I. Andrianov2, V.A. Nasonova Research Institute of Rheumatology, Laboratory of axial spondyloarthritis, Moscow, Russian Federation

Background: Breast milk is the natural and most physiological nutrition for a child from the first days of life. The benefits of breastfeeding are numerous, including psychological aspects. However, some women with rheumatic diseases are afraid that their disease or therapy is not compatible with breastfeeding.

Objectives: To describe frequency, duration and reasons for stopping lactation in women with AS, to compare the activity of AS in women with and without lactation.

Methods: 44 women with confirmed AS (modified New York criteria, 1984) were followed within 1 year after childbirth. Visits were carried out in 1, 6 and 12 months after delivery. The average age of patients was 32.5 ± 5.8 years, the duration of the disease was 149.0 ± 96.3 months. BASDAI at 1, 6 and 12 months after giving birth was: 2.4 ± 1.4; 2.6; 2.4; 2.7; 2.5 [1.5; 4.1], respectively. ASDAS CPR was: 2.0 [1.2; 2.7]; 1.9 [1.4; 2.5]; 1.7 [1.3; 2.3], respectively.

Results: Lactation was established in 41 women (93.2%), duration – 10 [4; 12] months; in 17 patients (41.5%) lactation persisted for 12 months. Lactation was unreasonably medically suppressed in 3 women in an obstetric unit due to therapy of AS (sulfasalazine – 2, certolizumab pegol – 1); in 1 woman lactation was not established for organizational reasons. Lactation lasted less than 6 months in 16 patients (39%), 13 of them had a natural attenuation of lactation, and in 3 cases, drug-induced suppression of lactation was carried out on the recommendation of obstetricians in connection with onset of preeclampsia (adalimumab). During lactation, 51.2%, 74.1% and 88.2% of women received nonsteroidal anti-inflammatory drugs for 1, 6 and 12 months after delivery, respectively, adherence to NSAID therapy did not differ in women with and without lactation. TNF-α...
inhibitors (certolizumab pegol) were received by 4 women (7.3%), while the need for INTeNc was in 13 patients (not received due to medicine unavailability).

In women who retained lactation, the severity of back pain was: 3.0 [2.0; 6.0], 3.0 [2.0; 6.0] and 3.0 [2.0; 5.0] according to NRS, respectively. The activity of back pain, BASDAI and ASDAS values of CRP did not differ in women with and without lactation.

Conclusion: The vast majority of women with AS are set up for lactation. High AS activity becomes a risk factor for termination of lactation more than 6 months after delivery. It is necessary to conduct training for obstetricians-gynecologists and pediatricians on issues related to medicine capabilities during lactation, in order to exclude unjustified cancellation of medicines compatible with breastfeeding.

REFERENCES:

Disclosure of Interests: None declared

AB0825

A SOLUTION PROPOSAL TO THE INTRAOBSERVER DISAGREEMENT PROBLEM IN THE EVALUATION OF SACROILIAC JOINT RADIOGRAPHY: "IMAGE PROCESSING METHOD"

A. C. Genc, F. Turkoglu Genc, D. Karatas, Z. N. Kaya, L. Rada, E. Gönülül. Bahcesehir University, Artificial Intelligence Graduate Education Institute, Istanbul, Turkey; Hendek State Hospital, Internal Medicine, Sakarya, Turkey; Akcay State Hospital, Internal Medicine, Sakarya, Turkey; Sakarya University, Internal Medicine, Rheumatology, Sakarya, Turkey; Saratoga High School, Student, CA, United States of America; Bahcesehir University, Faculty of engineering and natural sciences, Istanbul, Turkey

Background: Ankylosing spondylitis (AS) is a rheumatological disease that causes low back pain. The diagnosis of ankylosing spondylitis is delayed for an average of 8 years due to the insidious course of the disease. Late diagnosis of AS can cause functional and physical disabilities. Radiographic sacroilitis can be graded in the range of 0-4 and these classes may not be sharply separated from each other. Interpretation of the sacroiliac joint radiography may differ from physician to physician. In fact, the same physician may interpret it differently at different times (1). The reason for such confusion is the presence of blur or illumination and contrast problems leading to difficulties to detect pathological areas. This paper has developed a simple image processing technique that adjusts the contrast of such images by modifying their intensity distribution using the histogram information. This transformation gives a linear trend to the cumulative probability function associated with the image and makes the images better for human vision. The common characteristic of low contrast images is the concentration of the histogram values of the image intensity near a narrow range (2).

Objectives: Changing the contrast range into a wider range changes the image value distribution that leads to better image vision.

Methods: Rheumatologist scored 260 x-ray scans grade 0 to 4. One day later, the same rheumatologist scored again the same scans randomly. It has been noticed that most of the answers were closed to the first-day decision but not all of them. We processed all the x-ray images with histogram equalization. Then the rheumatologist scored the scans randomly and answered two times in two consecutive days. To compare the agreement in radiography interpretation Kappa test was used. We use IBM SPSS 21 for the statistical analysis (kappa test) and Matlab R2021a for the image processing part.

Results: Severe improvement before and after the image processing application by increasing the Kappa value from 0.55 (p<0.001) [moderate agreement] to 0.71 (p<0.001) [substantial agreement] which is a substantial agreement.

Conclusion: Multidisciplinary approach can be helpful in solving the intraobserver disagreement problem. The use of image processing techniques can be used for the benefit of the patient in radiographs whose standardization is difficult due to multifactorial reasons. The histogram equalization method was found to be statistically significant in finding the optimum contrast for interpreting the sacroiliac joint radiography. The output of this work indicates and motivates our team into deeper research and more analyses on how to further improve our results.

References:

Disclosure of Interests: None declared

AB0826

KEEP AN EYE ON THE BACK: SPONDYLOARTHRITIS IN PATIENTS WITH ACUTE ANTERIOR UVEITIS


Background: Patients with acute anterior uveitis (AAU) have an increased risk for concomitant spondyloarthritis (SpA). Different referral strategies have been proposed to identify AAU patients with high probability of SpA, among them an Assessment of SpondyloArthritis international Society(ASAS)-based referral strategy focusing on patients with chronic back pain starting before the age of 45 years and the Dublin Uveitis Evaluation Tool (DUEET) also including psoriasis, HLA-B27 and arthralgia (Poddubnyy et al., Haroon et al., both ARD 2015).

Objectives: To analyse the prevalence of SpA in patients with AAU, to identify parameters associated with SpA presence, and to evaluate referral algorithms.

Methods: Patients with non-infectious AAU underwent structured rheumatologic assessment including magnetic resonance imaging of sacroiliac joints allowing a definitive diagnosis/exclusion of concomitant SpA. Fisher’s exact test and Mann–Whitney U test were used to compare AAU patients with and without SpA. Furthermore, logistic regression analyses were performed. Sensitivity, specificity, positive predictive value, positive and negative likelihood ratios were analysed for referral strategies.

Results: The 169 AAU patients with complete rheumatologic assessment and SU imaging were 40.8 years old, and 55% were males. SpA was diagnosed in 106 AAU patients (56%). The majority (93%) had predominantly axial SpA, 7 patients peripheral SpA. In 74 patients (70%), the SpA diagnosis was established for the first time. Pelvic X-rays were available for 88 (89%) of the axSpA patients, 66% of whom was classified as having radiographic axSpA. SpA was equally frequent in patients experiencing the first episode of AAU and in patients with recurrent disease. In our cohort, AAU patients with and without underlying SpA showed no differences in their ophthalmologic examination. In multivariable logistic regression analysis, psoriasis (OR 12.5 [95%CI 1.3-120.2]), HLA-B27 positivity (OR 6.3 [95%CI 2.4-16.4]), elevated CRP (OR 4.8 [95%CI 1.9-12.4]) and male sex (OR 2.1 [95%CI 1.1-4.2]) were associated with SpA presence.
Table 1. Parameters associated with the presence of spondyloarthritis in patients with acute anterior uveitis.

<table>
<thead>
<tr>
<th></th>
<th>OR</th>
<th>95%CI</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psoriasis (ever)</td>
<td>14.6</td>
<td>(1.9; 112.4)</td>
<td>12.5</td>
<td>(1.3; 120.2)</td>
</tr>
<tr>
<td>HLA-B27 positivity</td>
<td>6.2</td>
<td>(2.7; 14.6)</td>
<td>6.3</td>
<td>(2.4; 16.4)</td>
</tr>
<tr>
<td>Elevated CRP (≥ 5 mg/l)</td>
<td>4.1</td>
<td>(1.8; 9.0)</td>
<td>4.8</td>
<td>(1.9; 12.4)</td>
</tr>
<tr>
<td>Male sex</td>
<td>2.2</td>
<td>(1.2; 4.0)</td>
<td>2.1</td>
<td>(1.1; 4.2)</td>
</tr>
<tr>
<td>Inflammatory back pain</td>
<td>2.1</td>
<td>(1.2; 3.9)</td>
<td>1.9</td>
<td>(0.9; 3.8)</td>
</tr>
<tr>
<td>Any peripheral manifest</td>
<td>1.9</td>
<td>(1.1; 3.5)</td>
<td>1.9</td>
<td>(0.9; 3.8)</td>
</tr>
<tr>
<td>Age in years</td>
<td>1.0</td>
<td>(1.0; 1.0)</td>
<td>1.0</td>
<td>(1.0; 1.0)</td>
</tr>
</tbody>
</table>

Univariable and multivariable logistic regression analyses. ASAS Assessment of SpondyloArthritis international Society; CRP C-reactive protein; OR odds ratio; CI confidence interval.

The Dublin Uveitis Evaluation Tool showed higher specificity for SpA recognition than the ASAS referral tool (42% vs. 28%), which had slightly higher sensitivity (78% vs. 80%). However, both referral strategies would have missed more than 20% of SpA patients.

Conclusion: We revealed a high prevalence of overall and previously undiagnosed SpA in AUA patients. Therefore, we propose rheumatologic evaluation for all AUA patients with musculoskeletal symptoms. Rheumatologists should consider that SpA in AUA patients might present “atypically” with back pain starting after 45 years and lasting shorter than 3 months.

Acknowledgements: The authors would like to thank the rheumatologists S. Lüders, B. Muche and A.-K. Weber for participating in the clinical data acquisition; and A. Langdon and L. Meinke for their support monitoring and coordinating this study. Furthermore, we are grateful to all participating ophthalmologists who included their patients in this study and to all patients. The study was supported by an unrestricted research grant from AbbVie. AbbVie had no role in the study design or in the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. Dr. Judith Rademacher and Dr. Dominika Pohmann are participants in the BIH-Chair Clinician Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of Health.

Disclosure of Interests: Judith Rademacher: None declared, Hanna Müllner: None declared, Torsten Diekhoff Speakers bureau: AbbVie, MSD, Novartis, Canon MS, Consultant of: Lilly, Hildrun Haisel Speakers bureau: AbbVie, MSD, Janssen, Roche, Pfizer, Sobi, Consultant of: Janssen, Sobi, Novartis, Sabrina Igel: None declared, Dominika Pohmann Speakers bureau: Bayer, Consultant of: AbbVie, Cellgene, Janssen, Novartis, UCB, Grant/research support from: Bayer, Allergan, Fabian Prot Speakers bureau: AMGEN, AbbVie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: AbbVie, Cellgene, Janssen, Novartis, UCB, Consultant of: AbbVie, Biord, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis and UCB, Grant/research support from: AbbVie, Eli Lilly, MSD, Novartis, Pfizer


Figure 1. Performance of Referral Strategies in Patients with Acute Anterior Uveitis. Dublin Uveitis Evaluation Tool (DUET) and an ASAS-based referral tool (ASAS). * respective tool fulfilled, - not fulfilled. ASAS Assessment of SpondyloArthritis International Society; AxSpA axial spondyloarthritis, pSpA peripheral spondyloarthritis.

REFERENCES:

Disclosure of Interests: None declared

AB0827 FREQUENCY OF SEXUAL DYSFUNCTION AXIAL SpondyloArthritis, SANTO DOMINGO, DOMINICAN REPUBLIC

A. Cornelio1, T. Polanco Mora1, J. Santana Peralta1, R. A. Alvarez Santana1, D. Garcia1, E. Rodriguez Bautista1, L. Paulino1, L. Concepcion Sanchez2, I. Mercedes1, T. Valdez1, A. Perez1, R. Muñoz Louis1, Hospital Docente Padre Billini, Reumatología, Santo Domingo, Dominican Republic

Background: Axial spondyloarthritis (SpA) is a chronic inflammatory disease of unknown etiology that affects the axial skeleton, affecting peripheral joints, entheses and extra-articular structures, with a prevalence of 0.5-1% associated with HLA-B27. The impact of Chronic disease is often multifactorial that affects physical, hormonal and psychological alterations, leading to problems of sexuality. The CSFQ-14 (Changes in Sexual Functioning Questionnaire), evaluates changes in sexual functioning due to disease and/or treatment in 5 domains with a score range of 14-70; cut-off point indicating sexual dysfunction <41 men and <47 women.

Objectives: To evaluate the frequency and degree of sexual dysfunction in patients with axial spondyloarthritis.

Methods: Prospective, observational, cross-sectional study of the SpA cohort of the Hospital Docente Padre Billini rheumatology service Patients were interviewed in July 2021. Inclusion criteria: > 18 years of diagnosis of SpA according to the Bath 2009 classification criteria, at least 1 sexual exclusion criteria: previous diagnosis of another autoimmune disease, depression, diabetes mellitus (DM), treatment with antidepressants, antiepileptics, narcotics. Measurement of: CSFQ-14, BASDAI. Statistical analysis was performed with the Pearson correlation (r) with p<0.05. The data was analyzed by SPSS V23.

Results: Of the SpA cohort, 87 met the inclusion criteria. Male 67.8% (59), females 32.2% (28), mean age 45.7±8 years, mean diagnosis 7.2 years (90), single 24.1% (21), widowed 8% (7), HLA-B27 ± 51.1%, hypertension 8% (7), diabetes 6.8% (6), dyslipidemia 10.3% (9), smokers 4.5% (4), 100% (87) bDMARD’s, 13.6% (12) combined with csDMARD’s, Frequency of sexual dysfunction 24.1% (21), Sexual dysfunction in women 6.9% (6) and men 17.2% (15) by CSFQ-14. Global domains: Desire/interest 2.3% (2), Desire/Frequency 2.3% (2), Pleasure 5.7% (5), Arousal 2.3% (2), orgasm/completion 2.3% (2), Female: Desire/interest 6.8% (4), Desire/Frequency 3.4% (2), pleasure 8.5% (5). Male: Desire/interest 3.4% (2), Desire/Frequency 3.4% (2), pleasure 5.5% (2), arousal 6.8% (4), orgasm/completion 3.4% (2). Correlation CSFQ-14 domains with BASDAI: r = -0.088 p>0.05: Desire/interest dysfunction: inactive BASDAI 71.4% (15), Desire/frequency: inactive BASDAI 90.5% (20). Pleasure: inactive BASDAI 23.8% (5), active 23.8% (5). Excitation: inactive BASDAI 14.3% (3), Orgasm/ completion: inactive BASDAI 90.5% (20)

Conclusion: The study showed a low frequency of sexual dysfunction, being more frequent in males. The greatest dysfunction was found in the pleasure domain in both sexes. A statistically significant inverse linear association was found between sexual dysfunction and disease activity.

REFERENCES:

Disclosure of Interests: None declared

AB0828 DIFFERENCES IN EARLY-ONSET VS. LATE-ONSET PSORIATIC ARTHRITIS: DATA FROM THE RESPONDIA AND REGISONER STUDIES.

M. A. Puche Larribuya1, M. L. Ladehesa Pineda1, M. D. López Montilla1, E. Collantes Estévez2, C. López-Medina2,3, Reina Sofia University Hospital, Rheumatology, Cordoba, Spain, 1Cochin Hospital, Rheumatology, Paris, France

Background: The prevalence of late-onset psoriatic arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater functional deterioration and a greater number of comorbidities than the young people. With this study we aim to find clinically relevant differences to predict the evolution and prognosis of the disease depending on the onset of the symptoms to carry out a more exhaustive follow-up.

Disclosure of Interests: None declared
Objectives: To evaluate the association of the age at onset of PsA symptoms with the characteristics and burden of the disease.

Methods: Observational study that includes a subgroup of 231 patients with Psoriatic Arthritis (PsA) from the REGISPONDER study (Registry of Spondyloarthritis of Spanish Rheumatology) and the RESPONDA study (Ibero-American Registry of Spondyloarthropathies). Patients with less than 10 years of disease duration (since the first symptom) were selected so that the sample was homogeneous. Patients were divided into two groups according to the age of PsA onset (early-onset: ≤40 years old and late-onset: ≥60 years old). The characteristics and burden of the disease were assessed using the Student’s t-test, Mann-Whitney U test for quantitative variables or using the chi-square/Fisher test for qualitative variables.

Results: 411 patients were included [early-onset 179 (77.5%); late-onset 52 (22.5%)]. There was a higher percentage of men in the late-onset group compared to the early-onset group [94 (62.3%) vs. 38 (86.4%)]. The diagnostic delay was shorter in those whose onset of the disease was late [15.2 (7.7) vs 4.2 (2.7), p = 0.012]. A lower presence of sacroiliitis was found in patients with late-onset PsA [6 (12.2%) vs 52 (38.6%), p = 0.005] as well as enthesitis [5 (9.8%) vs 44 (24.6%), p = 0.023]. Regarding the comorbidities, there was a higher frequency of heart disease among patients with late-onset PsA [4 (7.8) vs 0 (0), p = 0.00]. No statistically significant differences were found between kidney and lung disease. Regarding the outcome measures, the BASFI score was higher in the late-onset group [3.3 (2.5) vs 2.2 (2.2), p = 0.002]. The late-onset group had a lower FSF12 component [34.6 (8.7) vs 38.7 (10.5), p = 0.001]. The radiographic indices measured by BASRI showed worse results in those patients with late-onset disease both in the spine [2.9 (3) vs 1.6 (2), p = 0.020] and in the total BASRI [3.4 (3.4) vs 1.9, p = 0.012].

Conclusion: Our study suggests that the age of onset of PsA was associated with the different characteristics of the disease. Patients with late-onset PsA were more frequently males, showed worse functionality and more structural damage in comparison with early-onset PsA. Sacroiliitis and enthesitis were found less frequently in the late-onset group. Quality of life, disease activity and treatments taken were not associated significantly with age of onset.

Table 1. Description of different characteristics across two groups: early and late onset

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Early-onset N=179</th>
<th>Late-onset N=52</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male)</td>
<td>94 (62.3)</td>
<td>38 (86.4)</td>
<td>0.003</td>
</tr>
<tr>
<td>Age (SD)</td>
<td>38.7 (9.3)</td>
<td>71.3 (7.5)</td>
<td>0.000</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>44 (24.6)</td>
<td>5 (9.8)</td>
<td>0.023</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>36 (20.1)</td>
<td>9 (17.6)</td>
<td>0.695</td>
</tr>
<tr>
<td>Sacroilitis</td>
<td>58 (32.6)</td>
<td>6 (12.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>Diagnostic Delay, mean (SD)</td>
<td>4 (7.7)</td>
<td>1.5 (2.7)</td>
<td>0.036</td>
</tr>
<tr>
<td>Disease Duration, mean (SD)</td>
<td>4.2 (2.5)</td>
<td>2.9 (2.4)</td>
<td>0.012</td>
</tr>
<tr>
<td>Arthritis (lower limbs)</td>
<td>118 (65.9)</td>
<td>33 (64.7)</td>
<td>0.872</td>
</tr>
<tr>
<td>Arthritis (upper limbs)</td>
<td>82 (45.8)</td>
<td>31 (60.8)</td>
<td>0.059</td>
</tr>
<tr>
<td>BASDAI, mean (SD)</td>
<td>3.9 (2.3)</td>
<td>3.8 (2.4)</td>
<td>0.002</td>
</tr>
<tr>
<td>BASFI, mean (SD)</td>
<td>2.2 (2.2)</td>
<td>3.3 (2.5)</td>
<td>0.002</td>
</tr>
<tr>
<td>ASDAS, mean (SD)</td>
<td>2.3 (1.1)</td>
<td>2.3 (0.9)</td>
<td>0.894</td>
</tr>
<tr>
<td>FSF12, mean (SD)</td>
<td>38.7 (10.5)</td>
<td>34.6 (8.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>MSFI, mean (SD)</td>
<td>47.7 (10.5)</td>
<td>49.3 (9.2)</td>
<td>0.341</td>
</tr>
<tr>
<td>BASRI spine</td>
<td>1.6 (2)</td>
<td>2.9 (3)</td>
<td>0.020</td>
</tr>
<tr>
<td>BASRI total</td>
<td>19.2 (4.2)</td>
<td>34.3 (4.3)</td>
<td>0.012</td>
</tr>
<tr>
<td>ESR mm/h, mean (SD)</td>
<td>172 (14.2)</td>
<td>23.9 (19.1)</td>
<td>0.005</td>
</tr>
<tr>
<td>csDAMARs (ever)</td>
<td>111 (62.7)</td>
<td>31 (63.3)</td>
<td>0.943</td>
</tr>
<tr>
<td>tdAMARs (ever)</td>
<td>21 (11.9)</td>
<td>3 (6)</td>
<td>0.234</td>
</tr>
</tbody>
</table>

Total body composition, total and regional fat and lean mass, android/gynoid ratio (A/G), fat mass index (BMI), fat-free mass index (FFMI) were measured by dual-energy X-ray absorptiometry (DXA) and reported as absolute values. Blood samples were collected to determine C-reactive protein serum (CRP) levels for each patient. Socio-demographic data, comorbidities, physical activity, disease-related variables (duration, characteristics, and drugs) were also collected. Correlations and regressions were made by SPSS.20.

Results: Forty-four SA participants (65.9% male) were enrolled. Their mean age was 39.82 ± 14.20 years and the mean ASDAS CRP was 1.42 ± 0.86. Patients under biologic disease-modifying antirheumatic drugs (bDMARDs) showed lower FMI (p = 0.011), percentage of fat mass (p = 0.008), and gynoid fat mass (p = 0.01). Correlations between ASDAS using CRP, total body fat mass, BMI, FFMI, visceral adipose tissue (VAT), appendicular lean height, and the A/G ratio were not statistically significant. Nevertheless, ASDAS CRP was positively correlated to total body mass (r = 0.352; p = 0.019), gynoid fat mass (r = 0.329; p = 0.029), and android fat mass (r = 0.323; p = 0.032). The association of disease activity and gynoid fat mass persisted after adjustment on disease duration and age (β = 0.355, 95%IC [0.0003; 0.0003], p = 0.021).

Conclusion: Gynoid and android fat mass affected disease activity in our SA patients. However, BMI, visceral fat, and skeletal muscle mass showed no significant association with disease activity.

Disclosure of Interests: None declared


AB0830 TURKISH TRANSLATION AND CROSS-CULTURAL ADAPTATION OF THE MODIFIED SHORT QUESTIONNAIRE TO ASSESS HEALTH-ENHANCING PHYSICAL ACTIVITY (MSQUASH).

G. Ayen1, S. Ramiro2,3, F. M. Pimentel-Santos4, A.Spoorenberg5, L. Kliq5, 1Hacettepe University Medical Faculty; Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 3Zuyderland Medical Center, Department of Rheumatology, Heerlen, Netherlands; 4NOVA Medical School, Universidade Nova De Lisboa, Department of Rheumatology, LISBOA, Portugal; 5University Medical Center Groningen, University of Groningen, Department of Rheumatology & Clinical Immunology, Groningen, Netherlands

Background: The Short Questionnaire to Assess Health-enhancing physical activity (SQUASH) is a validated tool measuring the duration, frequency, and intensity of physical activity. The modified version of the SQUASH (mSQUASH) has been developed, in collaboration between spondyloarthritis (SpA) experts and axial (ax)SpA patients, to better address the needs of these patients in the assessment physical activity (1).

Objectives: To translate and cross-cultural adapt the mSQUASH into Turkish as well as its cognitive debriefing to test the conceptual equivalence of the translated version among patients with axSpA.

Methods: The mSQUASH was translated into Turkish by 2 bilingual translators, native speakers of Turkish one from medical (informed) and the other is without medical background (uninformed). The consensus on forward-translation was reached by the team included two rheumatologist (GA and LK) and the translators. Backward-translation into Dutch was performed by 2 bilingual translators, native speakers of Dutch and who were blinded to the original mSQUASH version. After the review of the Turkish version by an expert committee that included translators, two patients and the research team a pre-final version was prepared. This version was used in a field-test with cognitive debriefing and involved a sample of 10 axSpA patients (7 radiographic- and 3 non-radiographic axSpA patients) with variation in gender, age, disease duration, and educational background. The final Turkish mSQUASH version was reached after the patients were interviewed to check understandability, interpretation and cultural relevance of the translation. The whole process was performed according to the Beaton method (Figure 1) (2).

Disclosure of Interests: None declared


AB0829 BODY COMPOSITION IN SPONDYLOARTHROPATHIES: IS THERE ANY IMPACT ON DISEASE ACTIVITY?

F. Chenoufi1, H. Azzouzi1, H. Boutabbi1, I. Linda1, 1Mohamed I University, Rheumatology department; Ouja, Morocco

Background: The relationship between obesity and inflammation is bidirectional. Thus, obesity may influence clinical response to biological treatment.

Objectives: To investigate the association of obesity and body composition with disease activity in patients with spondyloarthropathies (SA).

Methods: This is a cross-sectional study designed on spondyloarthropathy patients diagnosed according to ASAS 2009 classification. Bath ankylosing spondylitis disease activity index (BASDAI), ankylosing spondylitis disease activity score (ASDAS), Bath ankylosing spondylitis functional index (BASFI), and Bath ankylosing spondylitis metrology index (BASMI) were assessed. Obesity was evaluated clinically by body mass index (BMI) and waist circumference (WC).
Results: After the forward-backward translation process, small incompatibilities were resolved during the expert committee meeting. For example: ‘Ande transport (heen en terug)” was translated as ‘Dijjer hedeffere (gipid gelmek)’. The meaning in English is “Other transport (round trip)”. This item questions the way of going to other places and the discrepancy raised whether to use ‘transportation’ or the ‘target’ as the title. To make it culturally adaptable consensus reached to use a word equivalent to ‘the target’ which is semantically equal to the Dutch version. A total of 10 patients with axSpA [7 females, mean (SD) age of 38 (10)] participated in the field test. Mean (SD) time to complete the mSQUASH was 6 (1.2) minutes. Cognitive debriefing showed that items of the mSQUASH are clear, relevant, understandable, and easy to complete. None of the patients indicate any important aspect of physical activity that is missing from the questionnaire items. During the cognitive debriefing, 2 patients suggested a change in the wording of one item to make it more suitable to the Turkish culture. This item inquires after sport activities and patients raised the concern that the example activities: ice-skating, tennis, handball are not culturally suitable. According to their comments these items were replaced by other examples such as football.

Conclusion: The Turkish version of the mSQUASH showed acceptable linguistic validity and can be used in both clinical practice and for research purposes. However, to implement the Turkish version of the mSQUASH, further assessment of its psychometric properties (validity and reliability) is needed.

REFERENCES:

Disclose of Interests: None declared


AB0831
THE QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS EVALUATED UNDER SINGLE QUESTIONNAIRE: CONNECTION WITH THE DISORDER OF BONE MINERAL DENSITY

O. Pavliuc1, S. Shevchuk1, O. Ziviha1, T. Smaha1, 1National Pirogov Memorial Medical University, Vinnytsya, Internal Medicine Chair 2, Vinnytsya, Ukraine

Background: In recent time, the peculiarities of the quality of life in patients with many chronic diseases, which progress uncontrollably and lead to the restriction of all components of normal life, are being actively studied. Ankylosing spondylitis (AS) is no exception, it is the second most common inflammatory rheumatic disease, characterized by predominant lesions of the spine and sacroiliac joints. Rapid progression of the disease, constant pain in the joints, as well as in the periarticular tissues and soft tissues, and other systemic functional limitations, gradual loss of mobility of the spine and deterioration of the quality of life. However, impaired quality of life can be caused not only by the manifestations of the underlying disease, but also by the presence of complications observed in the early stages of the disease. Thus, it is the decrease in bone mineral density and the development of osteoporosis that cause pathological fractures and, as a result, lead to early disability, reduced duration and quality of life. However, clear data on the peculiarities of the quality of life in patients with AS suffering from impaired bone mineral density have not been found to date.

Objectives: To investigate quality of life indicators using the SF-36 questionnaire in men with AS and to assess their relationship with the structural and functional state of bone tissue.

Methods: 105 patients with AS aged 40.7 ± 0.8 years were examined, the average duration of the disease was 8.7 ± 0.5 years. The control group included 25 healthy individuals of appropriate age and sex. All patients were diagnosed with AS according to ASAS criteria (2009). The SF-36 questionnaire was used to characterize the quality of life. Bone mineral density was measured by dual-energy X-ray absorptiometry on a Hologic Discovery Wi apparatus (S/N 67223).

Results: The analysis of quality of life according to the SF-36 questionnaire showed that patients with AS had significantly lower indicators of both physical (37.3 ± 1.5 points) and mental (44.2 ± 1.7 points) components of health in comparison with the control group (99.1 ± 0.3; 87.4 ± 0.7 points, respectively). Among the subscales that form the total physical component, the lowest indicators were recorded in role physical functioning (RP) (14.0 ± 3.1 vs. 99.0 ± 0.6 points) and pain (P) (37.2 ± 1.6 vs. 100.0 ± 0.0 points). And according to the subscales assessing the mental component of health, the most significant differences were found for the indicator of role emotional functioning (RE), which was 4.5 times lower than in the control group (22.2 ± 3.9 vs. 88.2 ± 0.7 points, respectively).

The study did not reveal significant differences in quality of life in case of low bone mineral density (BMD). The average levels of total physical and mental components of health in patients with BMD (35.2 ± 2.4; 42.2 ± 3.2 points) were only 12.2–71% lower than in patients with preserved BMD (40.8 ± 2.7; 46.4 ± 2.8 points, respectively). In the group of patients with osteoporosis (Z-score -2.7 ± 0.1) there was a tendency to reduce the physical component due to the indicator of general health (GH), which was significantly lower (35.8 ± 2.1 points) than in patients with preserved BMD (43.4 ± 2.7 points).

Conclusion: In men with AS, there is a significant decrease in the total physical and mental components of health according to the SF-36 questionnaire which do not have a clear relationship with structural and functional state of bone tissue.

Disclose of Interests: None declared


AB0832
NONINFECTIONOUS UVEITIS FROM THE RHEUMATOLOGIST’S PERSPECTIVE: PATTERNS FROM A SINGLE TERTIARY REFERRAL RHEUMATOLOGIC CLINIC IN ITALY

P. Troppini1, M. Fatica1, A. D’Antonio1, E. Ceia1, C. Minerva1, G. Raffone1, S. Modica2, B. Kroepler2, P. Conigliaro2, E. Greco2, A. Modesti2, M. S. Chimenti1,1Rheumatology Allergology and Clinical Immunology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Rome, Italy

Background: The noninfectious uveitis (NIU) is the intraocular inflammation that can be the first or one of extra-articular manifestations of systemic inflammatory rheumatic diseases mainly including spondyloarthropathy (SpA), Behcet’s disease (BD) and juvenile idiopathic arthritis (JIA). Rheumatologists are often asked to help in diagnostic assessment and relatively targeted treatment of particular subsets of NIU.

Objectives: To explore patterns and treatments of NIU from a population-based single-center study carried out in a Tertiary Referral Rheumatologic Clinic.

Methods: Selection criteria of this cross-sectional descriptive study consisted of having a diagnosis of NIU in an age of onset ≥16 years old regardless of its etiology among patients who were admitted (February 2018-December 2021) to Rheumatologic Clinic of Tor Vergata University Hospital (Rome, Italy). Clinical data were collected from medical records: gender, age of onset and admission, recurrence and anatomic patterns, HLA-B27 susceptibility, associated rheumatologic diagnosis and treatments were investigated.

Results: We included 100 patients with 58% women. Median age at NIU onset was 39.6±15 years whereas patients were 44±14 years old at the first referral, without gender-difference. NIU represented the main reason of referral in 22% of cases. Anterior uveitis occurred in 73% of patients and posterior in 25%; intermediate (IU) and panuveitis (PAnu) were isolated cases. The prevalent course was acute (57%) followed by recurrent (31%) and chronic (12%); both eyes were involved in 39 patients. Almost half of NIU was associated with SpA including IBD-SpA (20%), ankylosing spondylitis (AS, 18%), and Psoriatic Arthritis (12%). A diagnosis of BD was reported in 14% of NIU while Rheumatoid Arthritis (RA) in 7% and IBD in 12%. NIU was more frequent in females than males (p<0.01 and p<0.05, respectively). The only one-third of the NIU cohort (34.3%) showed B27+; a higher percentage of unilateral (p<0.08) and acute course (p=0.02) occurred in B27+ than B27–. AS was prevalent in B27+ NIU than B27– (p=0.0001) while IBD-SpA and BD were mainly present in B27+ NIU than B27– (p<0.004). The only two cases of IU and PAnu were both idiopathic B27+ NIU. At the onset of NIU, most patients were not on systemic treatment (68%): remaining cases were on cDMARDs (22%) and bDMARDs (10%). During rheumatologic follow-up, 80% of patients changed therapies: cDMARDs were added in 43.7% patients while bDMARDs were started in 40%. Systemic steroids were added in the remaining 16.3% of patients. At the latest follow-up (follow-up-time 33±28 months), 86% of patients had achieved remission of NIU while 14% had recurrence of active uveitis.

Conclusion: Findings from this population-based study describe a representative estimate of extent and patterns of NIU in an Italian adult cohort from a single Rheumatologic Clinic and document that Rheumatologic referral might dramatically impact treatment strategies in NIU.

REFERENCES:

Disclosure of Interests: None declared

AB0833  EPICARDIAL FAT THICKNESS: A NOVEL MARKER OF SUBCLINICAL ATHEROSCLEROSIS IN SPONDYLOARTHRITIS PATIENTS

A. Ben Tekaya1,2, T. Mehmm1,2, I. Ben Brad2, O. Saidiane1,2, S. Bouden1, R. Leilla3,2, I. Mahmoud2, L. Abdelmoula1,2, C. Nicolle Hospital, Rheumatology Department, Tunis, Tunisia; University Tunis El Manar, Faculty of medicine of Tunis, Tunis, Tunisia; Habib Thameur Hospital, Cardiology Department, Tunis, Tunisia

Background: Chronic inflammatory process seems to be the underlying cause contributing to atherosclerosis in spondyloarthritides. Epicardial adipose tissue (EAT) which is the accumulation of visceral fat between the myocardium and the visceral layer of pericardium, is actually considered a novel cardiometabolic risk predictor (1). Recent studies have shown its association with the development of coronary atherosclerosis.

Objectives: The aim of our study was to assess the epicardial fat thickness (EFT) in patients with spondyloarthritides (SpA) in comparison with healthy subjects.

Methods: We performed a prospective study including 47 patients meeting ASAS 2009 criteria for SpA compared to 47 healthy controls matched for age, gender and body mass index (BMI). Patients with history of cardiovascular risk factors or diseases were not included. Sociodemographic, clinical, biological and radiographic features related to the disease were recorded. All subjects underwent transthoracic echocardiography with measurement of EFT.

Results: SpA group included 33 men and 14 women, with a median age of 36 years (IQR: 28-46). Median BMI was 24.5 kg/m² (IQR: 20.7-26.8). Median systolic (SBP) and diastolic (DBP) blood pressure were respectively 121 mmHg (IQR: 110-130) and 71 mmHg (IQR: 67-78). Median disease duration was 11 years (IQR: 5-16). Median disease activity scores BASDAI and ASDAS-CRP were 2.6 (IQR: 1.3-3.9) and 1.62 (IQR: 1.3-2.9) respectively. Median CRP level was 1.45 mg/l (IQR: 1.5-19.9). Median BASFI and BASMI were 3 (IQR: 1.5-5.1) and 1.5 (IQR: 0.4-4) respectively. Coxits was found in 53% of patients. SpA patients received: NSAIDs (92%), csDMARDs (51%) and TNF inhibitors (38%)

Conclusion: EFT was significantly increased in SpA patients compared with healthy controls; median EFT value was 3.1 mm (IQR: 2.5-4) versus 2.4 mm (IQR: 2.3) (p<0.001).

Disclosure of Interests: None declared


REFERENCES:
(3) Mehmm T, Abdelmoula L, Saidiane O, Leilla R, Bouden S. EFT measurement as an early marker of atherosclerosis was associated with pain and BASG score.

AB0835  INFLUENCE OF SOCIODEMOGRAPHIC PARAMETERS ON ATHEROSCLEROSIS IN SPONDYLOARTHRITIS PATIENTS

A. Ben Tekaya1,2, E. Hannech2, A. Fendri3, S. Boukirba3, O. Saidiane1,2, R. Leilla3,2, I. Mahmoud2, H. Mizouni2, L. Abdelmoula1,2, C. Nicolle Hospital, Rheumatology Department, Tunis, Tunisia; University Tunis El Manar, Faculty of medicine of Tunis, Tunis, Tunisia; Habib Thameur Hospital, Cardiology Department, Tunis, Tunisia

Background: The increased risk of atherosclerosis is most likely multifactorial in patients with Spondyloarthritides (SpA). Ultrasound measurements of Intima Media Thickness (IMT) Flow Mediated Dilation (FMD) can be used to investigate intra-clinical atherosclerosis [1].

Objectives: We aimed to investigate the relationship between socio-demographic parameters in SpA patients with the IMT and FMD.

Methods: It was a case control study conducted over a period of 12 months and including patients with SpA, aged less than 50 years old and without cardiovascular disease, and age and sex matched healthy controls. Sociodemographic and clinical features were recorded in our patients. All subjects had Doppler ultrasound with measurement of carotid IMT and FMD.

Results: There were 47 SpA patients and 47 controls. The median age was 36 years for patients group (18-50) and 32 years for controls (18-50). For the patients group: there were 14 female (28.8%) and 33 male (70.2%). The median duration of the disease was 11 years (1-32). For the marital status, 55.32% were single, 40.43% were married, and 4.26% were divorced. Thirty seven patients (79%) were living in an urban area. For the education level, 17% had a primary education, 64% a secondary education, and 19% were university graduates. Occupational status was recorded as follows: 17% unemployed, 11% students, and 72% employed. The median IMT was 0.55 millimeters (mm)(0.32-0.83). We found a higher mean, right and left IMT (p<0.0001) in SpA patients compared with controls. Carotid IMT was positively correlated with age (p=0.001; r=0.578).

Conclusion: The analysis by 10-year age group showed a statistically significant difference in the IMT between patients (p=0.004). Median IMT increased significantly with age (every 10 years). IMT was significantly associated with occupational status (p=0.036); unemployed patients had the higher IMT (0.58mm). The median FMD was 14.6 mm (2-32%). A significantly lower FMD (p=0.008) was noted in SpA patients compared with controls. FMD were negatively correlated with age (p=0.017; r=-0.347). FMD was also associated with sex (p=0.036), and with the marital status (p=0.013). The median FMD was significantly lower in male 13.8% (IQR:8-17.5) vs 22.5% (IQR: 10-25), and married patients (10%; 6-18). There was no significant difference with the other sociodemographic variables (living environment, educational level, occupation). In multiple regression analysis, age was an independent predictor of increased carotid IMT (B=0.004; T=3.148; p=0.003; CI 95% 0.001-0.006).

Disclosure of Interests: None declared


REFERENCES:

AB0836  MICRONUTRIENTS DEFICIENCIES IN ENTEROPATHIC SPONDYLOARTHRITIS: THE INTERPLAY WITH METABOLISM AND HLA-B27 IN DISEASE PHENOTYPE

P. Triggianni1, A. D'Antonio1, E. Mannia1, M. Fatica1, G. Rafone1, P. Conciglio1, E. Lojol1, E. Calabrese1, L. Biancone2, A. Bergamini1, M. S. Chiementi1,1 Rheumatology, Department of “Medicina dei Sistemi”, University of Rome “Tor Vergata”, Rome, Italy; 2Gastroenterology Unit, Department of “Medicina dei Sistemi”, University of Rome “Tor Vergata”; Rome, Italy

Background: Micronutrients play immunomodulatory roles through interactions with innate and adaptive immunity influencing the pro/inflammatory balance. Serum levels depend on multiple factors such as gender, nutrition, and gut microbiome. Micronutrient deficiencies (MNDs) are associated with a pro-inflammatory status and co-morbidities in patients with chronic inflammatory diseases. No studies focused on potential interplay between MNDs and disease phenotype in Enteropathic Spondyloarthritis (ESpA) in which the combination of SpA with inflammatory status might dramatically affect micronutrients status.

Objectives: We analysed the occurrence of anemia (Hb <12 g/dl) and deficiencies of ferritin (Fe, <15 ng/dL), vitamin D [25(OH)D, ≤20 ng/ml], vitamin B12 (B12, ≤200 pg/ml), and folic acid (FA, ≤4 ng/mL) in ESpA patients. The interplay of MNDs with gender, metabolic parameters, HLA-B27 susceptibility, type of SpA and IBD, disease activity, and treatments was also explored.

Methods: Selection criteria of this cross-sectional descriptive study consisted of having a diagnosis of ESpA, regardless of its type, in an age of ESpA onset ≥18 and ≤80 years, among patients who were admitted to a combined Gastro-Intestinal and Rheumaticology Clinic at (Tor Vergata University Hospital, Rome, Italy). Exclusion criteria were represented by active IBD, pregnancy or lactation, kidney and liver failure, alcohol abuse, neoplasia, ongoing immunosuppressants. SpA disease activity was assessed by ASDAS-CRP and functional status by HAQ-S. All the enrolled patients underwent blood chemistry analysis to determine parameters including CRP, uric acid (SUA), Fe, 25(OH)D, B12, FA, and HLA-B27 typing.

Results: We included 164 patients comprising 109 females and 55 age-matched males. A diagnosis of Crohn’s Disease (CD) occurred in 70% of patients while Ulcerative Colitis (UC) represented a third of the cohort. Peripheral (per) and axial (ax) SpA were equally distributed (50%/50%). Patients with axSpA displayed a greater prevalence of CD than UC (p=0.02) while UC was prevalent in per-SpA (p=0.02). B27+ revealed in 19% of our cohort: B27+ patients had a higher prevalence of axSpA (p=0.016) and a more severe disease activity (p=0.02) than B27-. Moreover, B27 positivity and uveitis were prevalent in axSpA compared to per-SpA (p=0.009 and p=0.01, respectively). According to univariate analysis, males showed higher SUA (P=0.04) than females. Conversely, females showed a higher prevalence of anemia than males (p=0.002). A third of ESpA cohort showed FA (31.6%) and 25(OH)D (27.8%) deficiency while VB12 defect was less frequent (18.2%) and was registered almost equally in B27+ (p=0.02). CD-ESpA showed a lower mean VB12 (p=0.04) and a higher prevalence of ocular/skin co-morbidities (p=0.02) and axSpA compared to per-ESpA (p=0.04) and UC-ESpA. Accordingly, CD-ESpA were affected more in DMARDs than UC-ESpA (p=0.04).

Conclusion: Our findings document that FA and 25(OH)D deficiencies represent the main MNDs among ESpA patients while VB12 seems to be deficient mostly in patients with CD and almost exclusively in B27+ patients. Otherwise, B27+ in ESpA results to be associated mainly with disease phenotype and treatments. In ESpA, the gender of patients appears to impact principally on dysmetabolism highlighting the role for nutritional interventions particularly in males. The interplay of MNDs with B27 and dysmetabolism in ESpA deserves further investigations also taking into account CD/UC localization and behavior.

REFERENCES:

Disclosure of Interests: None declared.


AB0837  NEUROPATHIC PAIN COMPONENT AND ITS RELATIONSHIP WITH QUALITY OF LIFE IN PATIENTS WITH ANYKLOSING SPONDYLITIS

I. Kedy1, M. Stanislavchuk1. 1National Pirogov Memorial Medical University, Vinnytsya, Department of Internal medicine №1, Vinnytsya, Ukraine

Background: Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease of the connective tissue. AS often affects men aged 20-40 years and characterized by a progressive affect with rapid loss of work ability, deteriorating quality of life and reducing its duration. Quality of life is one of the markers of disease progression and evaluation of the treatment efficacy. The leading clinical symptom of AS is chronic pain, which may have not only nociceptive but also neuropathic component, which is not taken into account in the treatment of this category of patients, while pain is one of the main factors in reducing quality of life.

Objectives: To investigate the prevalence of the neuropathic pain component (NPC) and its relationship with the quality of life in patients with AS.

Methods: AS patients was diagnosed according to the New York 1984 classification criteria. The NPC was assessed by the Leeds Assessment of Neuropathic Symptoms and Signs (LANS) and The Douleur Neuropathique 4 (DN4). Quality of life was assessed by the Ankylosing Spondylitis Quality of Life (ASQoL). We examined 142 patients with AS (79.3% of men) in the rheumatology center from 2016 to 2021. The mean age was (Ma/SD) 4:9 ± 9.7 years, the disease duration was 5.7 ± 4.6. Statistical analysis performed by the Microsoft Excel and IBM Statistics SPSS 20.

Results: NPC assessed by the LANS (≥ 12) was found in 31% of patients, by the DN4 (> 4) in 38%. ASQoL in patients with AS by the LANS was 12.27 ± 4.27, by the DN4 - 11.64 ± 4.19, which was significantly higher than in patients with AS without NPC: LANS (7.97 ± 3.76), DN4 (7.86 ± 3.88). ASQoL had a strong direct correlation with LANS (r=0.561, p<0.01) and DN4 (0.476; p<0.01) that means - presence of neuropathic pain substantially effects quality of life in patients with AS.

Conclusion: NPC is found in 31% - 38% of patients with AS. It is established that the presence of the neuropathic pain component significantly reduces the quality of life in patients with AS, which should be taken into account during the treatment.


Disclosure of Interests: None declared.


AB0838  THE IMPACT OF COMORBIDITIES ON PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A CLUSTER ANALYSIS

S. Lee1, S. Kang1, Y. Eun1, H. Kim1, H. S. Cha1, E. M. Koh1, J. Lee1. 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Seoul, Korea, Rep. of (South Korea)

Background: Previous study using cluster analysis technique analyzed the association between comorbidities and various outcome measures in patients with axial spondyloarthritis (axSpA). Due to the cross-sectional nature of the study, however, prognostic information about each group were not provided.

Objectives: This study aims to perform cluster analysis to differentiate axSpA patients in terms of comorbidities and to examine the differential treatment outcomes of these groups using the data retrieved from Korean College of Rheumatology Biologics (KOBIO) registry which includes longitudinal data of axSpA patients receiving anti-TNF agents.

Methods: Clinical characteristics and demographic data of axSpA patients in KOBIO registry were analyzed using an agglomerative hierarchical cluster analysis. The optimum number of clusters was determined by the pseudo-F statistic. After clustering, baseline clinical characteristics and treatment outcomes were compared between isolated axSpA and classified comorbid groups using multivariable linear models and mixed linear models, respectively.

Results: 1,207 patients were included in the study. At least one comorbidity was seen in 464 (38%) axSpA patients. Compared with those with isolated axSpA, patients with comorbidity were older, longer disease duration, and reported higher PGA (p = 0.019), and BASFI (p <0,001), but did not have significantly different BASDAI, ESR, and CRP levels. The most common comorbidities were hypertension (14.4%), hyperlipidemia (13.0%), and obesity (4.5%). The hierarchical cluster analysis classified patients in 21 groups. We combined clusters 17-21 for further evaluation due to the small size of clusters (<5 patients). In multivariable linear models for baseline clinical characteristics, we found that patients in the hypothyroidism, asthma, and headache clusters reported poorer PGA compared to the other clusters, and the weight loss cluster had higher level of CRP compared with patients isolated axSpA even after adjustment of patient demographic data. After 1-year treatment of anti-TNF agents, the patients in the hypothyroidism and weight loss clusters decreased greater amounts of BASDAI and BASFI scores and ESR/CRP levels, respectively, compared with patients with isolated axSpA (Table 1). However, the degree of improvement in asthma and headache clusters, which had higher disease activities at baseline, was similar with isolated axSpA. Therefore, they still had higher disease activity scores at the 1-year follow-up.

Disclosure of Interests: None declared.

Table 1. Comparing each cluster to patients with isolated axSpA (i.e. no comorbidity) using multivariable linear mixed models for each treatment outcome measure at 1-year follow-up as the dependent variable.

<table>
<thead>
<tr>
<th>Cluster/description</th>
<th>PGa</th>
<th>BASDAI</th>
<th>BASFI</th>
<th>ESR</th>
<th>CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 isolated axSpA</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

3 Obesity 0.233 (-0.57, 0.598) -0.048 -0.078 9.005 (0.048, 0.358 (-0.553 -1.036) -0.844 (-0.811, 17529) -1.269

10 Hypothyroidism -1.243 (-3.139, -2.147 (-3.088, -0.38 (-4.076, 2.234 (-18.11, -0.063) -0.385 (-0.684, -22.578) -2.123 (-1.95)

11 Weight loss -0.618 (-2.804, -0.901 (-2.932, -1.93 (-3.886, -26.891) -6.49 (-4.354, -4.311 (-3.431, -1.849)

15 Asthma 0.049 (-2.138, 0.383 (-1.199, -1.058 (-24.517, 2.018 (-0.552, -2.235) -2.864 (-2.209, 22.402) -4.359

16 Headache -0.163 (-1.052, 0.169 (-0.713, 0.463 (-0.387, 0.344 (-0.993, 0.046 (-1.132, 0.846 (-1.051, 1.312) -10.382) -1.04)

**P-value < 0.05. Only clusters including significant results were shown due to the limitation of the number of characters.

Conclusion: Comorbidity could affect the treatment outcomes in patients with axSpA in certain subgroups. Thus, we should also pay attention to the comorbidities when treating axSpA.

Disclosure of Interests: None declared


AB0839 EXTRA-ARTICULAR MANIFESTATIONS IN PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

K. Tahir1, A. Akasbi1, I. El Mezouar1, T. Harzy1.1 University Hospital Center Hassan II, Rheumatology, Fez, Morocco

Background: Spondyloarthropathy (SpA) is a chronic inflammatory arthritis that combines joint involvement and extra-articular manifestations such as inflammatory bowel disease (IBD), uveitis and psoriasis.

Objectives: The aim of our study was to compare extra-articular manifestations in patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA).

Methods: A retrospective study was conducted in a single rheumatology hospital in Morocco, including patients diagnosed as having SpA according to ASAS criteria 2010, during a period of 9 years. The patients were classified as AS by the presence of radiographic sacroiliitis according to the modified New York criteria and nr-axSpA defined by the presence of sacroiliitis on MRI. Extra-articular manifestations are compared between the two groups.

Results: 375 patients were analyzed. 206 were female (54.9%). The mean age were 46.8 ± 14 years [16-84]. The mean duration of disease progression were 13.38 ± 8.44 years. The mean BASDAI were 4.20 ± 1.60 and the mean BASFI were 17.0 ± 8.5 16.2 ± 8.0 17.5 ± 8.7

Average duration of the disease, years, Med 170±8,5 162±8,0 175±8,7 Age at the time of diagnosis, years, Med 276±10,0 276±10,0 276±10,0 Necessity of THA, years, Med 7.4±4.8 6.0±2.8 8.0±5.4 Osteophytes (Yes/No),% 90/10 96/4 88/12 Proliferation (Yes/No),% 75/25 68/2 78/12 Granulation (Yes/No),% 91/9 95/5 89/11 Ankylosis (Fibrous/Osseous),% 47/53 48/52 37/53

Results: The vast majority (85.9%) of pts had ill grade of secondary coxarthrosis and 14.1% had iv grade before THA. Complete absence of cartilage on the surface of acetabulum was revealed in 71.7% of cases, and there were either partial abrasions of the cartilage in the places of maximal load (6.5%), or chondromalacia (21.8%) in rest of the pts. Deformity of the FH was detected in 98.2% of pts, while as a result of osteonecrosis of FH (ONFH) in 75.5%. Complete absence of cartilage on FH was in 130 (76.5%) pts, and there were either partial abrasions of the cartilage in the places of maximal load (11.2%), or chondromalacia (12.3%) in rest of the pts. There were no significant differences in the macroscopic picture of the lesion of FH and acetabulums in pts with and without intake of bDMARDs, except for a higher frequency of ONFH in pts receiving bDMARDs.

Conclusion: The need for THA arose on average after 7.4±4.8 yrs from the appearance of pain in the hip joint (HJ). Macroscopic picture of HJ lesion in pts with AS was characterized as ONFH in 75.5% of cases, in almost half of cases - ankylosis of HJ, mainly fibrous (77.2%) with complete or partial absence of cartilage in acetabular surface and FH. According to the majority of macroscopic changes in the bone tissue of HF and acetabulums of HJ, pts with and without bDMARDs did not differ, but the frequency of ONFH was significantly higher in the group of pts who was receiving bDMARDs.

Disclosure of Interests: None declared

ANALYSIS OF THE FUNCTIONAL STATE OF HIP JOINTS (HJ) BEFORE TOTAL HIP ARTHROPLASTY (THA) IN PATIENTS WITH ANKYLOSING SPONDYLITIS (AS): A DATA OF RETROSPECTIVE ANALYSIS

A. Dubinina1, A. Khramov1, T. Dubinina2, E. Linykh2, S. Maglevan1, E. Bialik1.
1VA. Nasonova Research Institute of Rheumatology, Moscow, Russia, traumatological and orthopedic, Moscow, Russian Federation; 2VA. Nasonova Research Institute of Rheumatology, Moscow, Russia, axial spondyloarthritis, Moscow, Russian Federation

Background: Injury of hip joint (HJ) in patients (pts) with ankylosing spondylitis (AS) is considered as a factor of unfavorable prognosis, which can lead to rapid disability of pts.

Objectives: To assess the functional state of HJ before performing THA in patients with AS.

Methods: This retrospective study included 170 pts with a verified diagnosis of AS, who met the modified New York criteria of 1984, who were treated in the traumatological and orthopedic department in the period from 1998 to 2020. THA was routinely performed to all pts. Most of the pts were male (80.6%). 64% of them did not work due to the disease. Functional insufficiency of the joints at the time of surgical treatment in 64.1% of all the cases corresponded to ill grade, in 26.5% - to IV grade, in 9.4% - to II grade. 82.9% of pts had low activity of the disease according to the BASDAI index at the time of surgical treatment and 17.1% of them had high activity. 53 (31.1%) pts were receiving bDMARDs and 87% of them were TNF-alpha inhibitors. The Harris quantitative scale was used to assess the functional state of HJ.

Results:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All patients (n=170)</th>
<th>bDMARDs (+)</th>
<th>bDMARDs (-)</th>
<th>n=117</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, Me±δ</td>
<td>38,1±11,3</td>
<td>37,5±12,3</td>
<td>38,3±10,8</td>
<td></td>
</tr>
<tr>
<td>Age of AS debut, years, Me±δ</td>
<td>20,7±8,4</td>
<td>21,2±8,4</td>
<td>20,5±8,4</td>
<td></td>
</tr>
<tr>
<td>Age at the time of diagnosis, years, Me±δ</td>
<td>276±51,9</td>
<td>276±9,9</td>
<td>276±8,9</td>
<td></td>
</tr>
<tr>
<td>Average delay in diagnosis, years, Me±δ</td>
<td>6,8±5,8</td>
<td>6,4±4,3</td>
<td>7,1±6,4</td>
<td></td>
</tr>
<tr>
<td>Average duration of the disease, years, Me±δ</td>
<td>170±8,5</td>
<td>16,2±8,0</td>
<td>17,5±8,7</td>
<td></td>
</tr>
<tr>
<td>Average duration of pain in HJ, years, Me±δ</td>
<td>7,4±4,8</td>
<td>6,1±2,2</td>
<td>8,0±5,4</td>
<td></td>
</tr>
<tr>
<td>Average level of pain in HJ,VAS, Me±δ</td>
<td>72,3±14,0</td>
<td>69,9±12,9</td>
<td>73,4±14,5</td>
<td></td>
</tr>
<tr>
<td>Average overall score on the Harris scale, VAS, Me±δ</td>
<td>38,0±15,4</td>
<td>42,1±15,0</td>
<td>36,1±15,3</td>
<td></td>
</tr>
<tr>
<td>The average level of pain on the Harris scale before surgery</td>
<td>15,6±8,4</td>
<td>17±8,3</td>
<td>14,7±5,5</td>
<td></td>
</tr>
<tr>
<td>Antalgic Gait (absent/mild/moderate/severe),%</td>
<td>42,3/42,9/8,2/4,4</td>
<td>41,5/35,8/18,9/3,8</td>
<td>43,6/66,2/8,9/1,7</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Elementary US lesions in SpA and healthy control groups

<table>
<thead>
<tr>
<th>Enthesh</th>
<th>G1 (%)</th>
<th>G0 (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcaneal tendon:</td>
<td>Thickness</td>
<td>15 (40,5)</td>
<td>6 (16,2)</td>
</tr>
<tr>
<td>Erosion</td>
<td>9 (24,3)</td>
<td>1 (2,7)</td>
<td>0,007</td>
</tr>
<tr>
<td>Enthesophyse</td>
<td>29 (78,4)</td>
<td>20 (54)</td>
<td>0,03</td>
</tr>
<tr>
<td>Calcification</td>
<td>14 (37,8)</td>
<td>10 (27)</td>
<td>0,32</td>
</tr>
<tr>
<td>Bursitis</td>
<td>4 (10,8)</td>
<td>3 (8,1)</td>
<td>1</td>
</tr>
<tr>
<td>PD signal</td>
<td>10 (27)</td>
<td>0</td>
<td>0,001</td>
</tr>
<tr>
<td>Planter fascia:</td>
<td>Thickness</td>
<td>30 (81,1)</td>
<td>27 (73)</td>
</tr>
<tr>
<td>Erosion</td>
<td>11 (30)</td>
<td>1 (3)</td>
<td>0,002</td>
</tr>
<tr>
<td>Enthesophyse</td>
<td>12 (32,4)</td>
<td>2 (5,4)</td>
<td>0,003</td>
</tr>
<tr>
<td>Calcification</td>
<td>18 (48,6)</td>
<td>6 (16,2)</td>
<td>0,003</td>
</tr>
<tr>
<td>PD signal</td>
<td>11 (30)</td>
<td>0</td>
<td>&lt;0,001</td>
</tr>
</tbody>
</table>

Conclusion: The vast majority of pts with AS had pronounced severe disorders of HJ before THA - the average score on the Harris scale was 38,0±15,4. Most of the patients (85,9%) had severe and moderate lameness, with the need for additional support. Antalgic Gait (absent/mild/moderate/severe) was noted in 42,3/42,9/8,2/4,4 pts.

Disclosure of Interests: None declared

Background: Data regarding the prevalence and especially incidence of osteoporosis in Spondylarthropathy (SPA) is scarce and very divergent among studies from different patient populations.

Objectives: In this study, we aimed to compare demographic, disease and laboratory characteristics of SPA patients regarding their bone mineral densitometry (BMD) categories and find out incidence of osteoporosis in the follow-up BMD of patients who were not found to have osteoporosis at baseline.

Methods: Between 2010-2021, patients with a SPA diagnosis in the HUR-BIO database were searched. HUR-BIO (Hacettepe University Rheumatology Bio-logic Registry) is a single center biological disease modifying anti-rheumatic drug (DMARD) registry since 2010. Patients with BMD measurement were included in the study. Follow-up BMD scores were also documented. The patients were divided into 3 groups as normal, osteopenia and osteoporosis in accordance with the WHO criteria (2). Demographic characteristics, comorbidities, laboratory data and drugs in each group were documented.

Results: 3245 patients were reviewed. BMD was measured at least once in 118 patients out of 3245 (3.6%) patients. When the groups classified, 34 patients (28.8%) were included in the normal, 49 (41.5%) osteopenia and 35 (29.7%) osteoporosis groups. Patients with normal BMD was younger than both groups. Diabetics and hypertension were more prevalent in patients with osteoporosis. The BMI was significantly lower in the osteoporosis group. 25 patients with normal BMD was younger than both groups. 25 patients had osteopenia and osteoporosis in baseline BMD measurement had at least 1 follow-up BMD measurement. During the total follow-up of 91 patient-years, 3 patients had osteoporosis, revealing a the incidence of 3.3% in 100 patient-years.

Conclusion: In our study, the incidence of OP development in SPA patients was found to be 3.3%. Frequency of osteoporosis was 29.7% among SPA patients with BMD measurement (118/3245; 3.6%), however; only 40% of them had appropriate treatment. Osteoporosis seems as an overlooked and untreated comorbidity of SPA.

Table 1. Comparison of spondyloarthritis patients according to BMD scores (normal, osteopenia and osteoporosis) according to baseline BMD assessment

<table>
<thead>
<tr>
<th>Number of Patients</th>
<th>NORMAL Number, (%)</th>
<th>OSTEOPENIA Number, (%)</th>
<th>OSTEOPOROSIS NUMBER, (%)</th>
<th>P VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients</td>
<td>34 (28.8)</td>
<td>49 (41.5)</td>
<td>35 (29.7)</td>
<td></td>
</tr>
<tr>
<td>Age</td>
<td>473 (37.0%)</td>
<td>63 (45.7%)</td>
<td>58 (20.75)</td>
<td>0.00*</td>
</tr>
<tr>
<td>Gender (Female)</td>
<td>24 (70.6%)</td>
<td>34 (69.4%)</td>
<td>23 (60.7)</td>
<td></td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>3 (8.8%)</td>
<td>14 (29.2%)</td>
<td>1 (2.8)</td>
<td>0.00*</td>
</tr>
<tr>
<td>Hypertension</td>
<td>11 (32.4%)</td>
<td>28 (58.3%)</td>
<td>15 (4.9)</td>
<td>0.00*</td>
</tr>
<tr>
<td>Chronic Renal Failure</td>
<td>2 (6.9)</td>
<td>1 (2.1)</td>
<td>1 (3.1)</td>
<td>0.81</td>
</tr>
<tr>
<td>Chronic Oesophageal Pulmonary Disease</td>
<td>4 (13.8)</td>
<td>10 (18.0%)</td>
<td>1 (5.3)</td>
<td>0.30</td>
</tr>
<tr>
<td>Cause of Artery Disease</td>
<td>0 (0)</td>
<td>5 (12.5%)</td>
<td>3 (15)</td>
<td>0.27</td>
</tr>
<tr>
<td>Smoking</td>
<td>21 (61.8%)</td>
<td>23 (47.9%)</td>
<td>21 (63.6)</td>
<td>0.37</td>
</tr>
<tr>
<td>Calcium mg/dl</td>
<td>9.4 (8.2-10.2)</td>
<td>9.5 (8.7-10.4)</td>
<td>9.7 (8.1-10.4)</td>
<td>0.49</td>
</tr>
<tr>
<td>Phosphorus mg/dl</td>
<td>3.5 (3-4.4)</td>
<td>3.4 (2.6-5.6)</td>
<td>3.8 (2.9-4.9)</td>
<td>0.25</td>
</tr>
<tr>
<td>Vitamin D ng/ml</td>
<td>16 (7.4-64.4)</td>
<td>21.2 (5.69-6.6)</td>
<td>15.8 (8.8-48)</td>
<td>0.66</td>
</tr>
<tr>
<td>ALP IU/ml</td>
<td>89.5 (54.137)</td>
<td>89.5 (53.169)</td>
<td>80 (50.239)</td>
<td>0.43</td>
</tr>
<tr>
<td>Albumin g/dl</td>
<td>4.2 (1.7-4.7)</td>
<td>4.2 (3.3-8.4)</td>
<td>4.2 (4.8-4.8)</td>
<td>0.43</td>
</tr>
<tr>
<td>TSH u/ml</td>
<td>1.5 (0.8-4.1)</td>
<td>2.3 (0.9-1.7)</td>
<td>2 (0.7-3.3)</td>
<td>0.71</td>
</tr>
<tr>
<td>Body Mass Index (BMI) kg/m2</td>
<td>29 (17-41)</td>
<td>28.3 (20-44.6)</td>
<td>25.1(15.8-43.2)</td>
<td>0.06*</td>
</tr>
<tr>
<td>Steroids</td>
<td>4 (11.8)</td>
<td>8 (16.3%)</td>
<td>2 (7.1)</td>
<td>0.33</td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>29 (73.5)</td>
<td>35 (71.4%)</td>
<td>26 (74.3)</td>
<td>0.86</td>
</tr>
<tr>
<td>D Vitamin</td>
<td>7 (20.6)</td>
<td>14 (28.6)</td>
<td>10 (28.6)</td>
<td>0.67</td>
</tr>
<tr>
<td>Calcium</td>
<td>4 (11.8)</td>
<td>5 (10.2)</td>
<td>6 (17.1)</td>
<td>0.63</td>
</tr>
<tr>
<td>Bisphosphonate</td>
<td>0 (0)</td>
<td>4 (8.2)</td>
<td>14 (40)</td>
<td>0.00*</td>
</tr>
</tbody>
</table>

Data was represented as median (minimum-maximum) or n(%)
was the driving genus of enterotype 1 and Bacteroides contributed to enterotype 2 (Figure 1B, D). The alpha-diversity and beta diversity between the distinctive enterotypes was highly significantly different (P < 0.01, Figure 1E, F). Distinct bacterial profiles were also observed in enterotype 1 and 2 (Figure 1G). Interestingly, no significant differences were found between USpA patients and HC for the corresponding same intestinal type. This may be because USpA was at a comparatively early stage of spondyloarthritis (SpA).

**Conclusion:** Two significantly distinct bacterial microbiota structures existed in the USpA patients which was consistent with the general healthy population.

**REFERENCES:**


**Acknowledgements:** This work was supported by the National Natural Science Foundation of China (No. 82001740).

**Disclosure of Interests:** None declared

**Foundation of China (No. 82001740).**

**DOI:** 10.1136/annrheumdis-2022-eular.3775

---

**AB0845 IMPORTANCE OF WEIGHT MANAGEMENT ON ENDOTHelial FUNCTION IN SpondyloArthritIs**

A. Ben Tekaya1,2, E. Hannech1,2, A. Fendri2,3, S. Boukriba2,3, N. Ziade1,2, S. Bouden1,2, R. Leila1,2, R. Tekaya1,2, I. Mahmoud2,3, H. Mızunzi2,3, L. Abdelmoula1,2, R. Rheumatology Department, Charles Nicolle Hospital, Tunis, Tunisia; 3Faculty of medicine of Tunis, University Tunis El Manar, Tunis, Tunisia; 2Hotel-Dieu de France Hospital, Ibn Khaldoun University, Kaslik, Lebanon; 3Radiology Department, La Rabta Hospital, Tunis, Tunisia

**Background:** Subclinical atherosclerosis is not rare in spondyloarthritis (SpA) patients. Endothelial dysfunction is the first step of atherosclerosis process. Obesity is a major traditional cardiovascular risk factor.

**Objectives:** The purpose of this study was to determine the association of anthropometric measures with endothelial dysfunction in non-obese SpA patients.

**Methods:** This was a prospective study conducted over 12 months and including 47 SpA free cardiovascular disease patients and aged less than 50 years. The following anthropometric parameters were collected for each patient: weight, height, Body Mass Index (BMI), hip and waist circumferences. Endothelial dysfunction was assessed by the ultrasound evaluation of the Flow Mediated Dilation (FMD).

**Results:** There were 14 female (28.8%) and 33 male (70.2%); The median age was 36 years (IQR: 19-50). The median disease duration was 11 years (IQR: 1-32). The median weight, height and BMI were 69 (IQR: 43-95), 170 cm (IQR: 144-193) and 24.5 kg/m2 (IQR; 16.3-29.4), respectively. Overweight (BMI: 1-32). The median weight, height and BMI were 100 cm (IQR; 84-116) and 88 cm (IQR; 70-114). Median BMI was 22.9 (IQR: 18.2-27.3). We didn’t found correlation between anthropometric parameters and FMD: weight (p=0.225; r=-0.180); height (p=0.273; r=-0.163), BMI (p=0.437; r=0.116); waist circumference (p=0.022; r=0.182) and hip circumferences (p=0.142; r=-0.217).

**Conclusion:** Our study showed that anthropometric parameters do not influence endothelial function in non-obese and young SpA patients. This highlights the importance of weight management and maintaining a healthy weight in SpA patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3807

---

**AB0846 HLA-B51 PREVALENCE IN PATIENTS WITH SPONDYLOARTHRITIS AND IMPACT ON DISEASE PHENOTYPE: A CASE-CONTROL STUDY**

N. Ziade1,2, R. Nacouzi2, K. Mroue2, G. Merheb5,6, P. Ghoma2,7,1 Saint-Joseph University, Rheumatology, Beirut, Lebanon; 2Hotel-Dieu de France Hospital, Rheumatology, Beirut, Lebanon; 3Saint-Joseph University, Medicine, Beirut, Lebanon; 4Al Zahra University Medical Center, Rheumatology, Beirut, Lebanon; 5Holy Spirit University, Rheumatology, Kaskel, Lebanon; 6ND Secours Hospital, Rheumatology, Byblos, Lebanon; 7Hotel-Dieu de France, Immunology, Beirut, Lebanon

**Background:** Spondyloarthritis (SpA) is a group of rheumatic diseases with a heritable component associated with Human Leucocyte Antigen B27 (HLA-B27). Although many studies have reported an overlap between the clinical features of SpA and Behcet's disease (BD), as well as an increased prevalence of HLA-B27 in BD, the prevalence of HLA-B5 (namely B51 and B52, the split antigens of B5) in SpA, have been scarcely examined, particularly in countries with a low HLA-B27 prevalence.

**Objectives:** To estimate the prevalence of HLA-B51 and HLA-B52 in patients with SpA compared to healthy controls (HC), to identify the alleles found in HLA-B locus in patients with SpA compared to HC, and to evaluate the impact of HLA-B51 on SpA disease phenotype.

**Methods:** A case-control study included consecutive patients with a diagnosis of SpA (axSpA, peripheral SpA (pSpA), and psoriatic arthritis (PsA)) from three rheumatology clinics. HC were recruited among blood donors and medical students. Demographic data, as well as SpA and BD disease features, were collected through an interview with a trained medical student and file review (low back pain, peripheral joint disease, enthesitis, dactylitis, psoriasis, uveitis, inflammatory bowel disease, family history, oral and genital ulcerations, skin, vascular and neurologic manifestations, CRP, BASDAI, imaging of the spine and sacroiliac joints). The entire B locus was tested using molecular biology technique on Luminex with the possibility of precise B51/B52 differentiation. The prevalence of HLA-B51/B52 was calculated in patients and compared to HC using the Chi-square test. A complete HLA-B mapping was performed for patients and HC. A binary logistic regression identified factors associated with HLA-B51 in patients with axSpA.

**Results:** Data from 119 HC and 89 patients with SpA were available (66 axSpA, 16 pSpA, and 7 PsA). Mean age of the patients was 44.8 years [SD 13.5], 66.3% were males, disease duration was 12 years [SD 12.7], 72.4% had a history of elevated CRP, 30.3% were positive for HLA-B27, 53.9% had sacroiliitis on MRI, 47.2% had radiographic sacroiliitis, and 23.6% had symphyses. Oral ulcerations were reported in 38.2% of patients, genital ulcerations in 3.4%, uveitis in 5.6%, skin lesions in 18%, and vascular lesions in 3.4%. Patients with SpA fulfilled the classification criteria for BD in 2.9% (International Study Group criteria for BD) and 38.2% (International Criteria for BD). HLA-B51/B52 were found more frequently in patients with SpA (20.2% vs 7.9%) compared to HC (11.6% vs 4.2%), although the difference was not statistically significant. The difference was mainly driven by an association between HLA-B51 and axSpA (27.2% versus 11.8%. OR 2.8 [95%CI 1.3-6.1], p=0.008) (Table 1). The most frequent allele in SpA and HC was HLA-B35; complete HLA-B mapping is shown in Figure 1. In patients with axSpA, HLA-B51 was associated with radiographic damage in peripheral joints, while it was negatively associated with sacroiliitis. Uveitis was numerically associated with HLA-B51, but the association did not reach statistical significance.

**Table 1. Prevalence of HLA-B5 genes in patients with spondyloarthritids (SpA) and healthy controls**

<table>
<thead>
<tr>
<th></th>
<th>Controls SpA</th>
<th>Axial SpA</th>
<th>Peripheral Psoriatic</th>
<th>PsA vs Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>119</td>
<td>89</td>
<td>66</td>
<td>16</td>
</tr>
<tr>
<td>HLA-B51, N (%)</td>
<td>14 (11.8)</td>
<td>18</td>
<td>66</td>
<td>16</td>
</tr>
<tr>
<td>HLA-B52, N (%)</td>
<td>19 (16)</td>
<td>21</td>
<td>19</td>
<td>21</td>
</tr>
</tbody>
</table>

**Conclusion:** HLA-B51/B52 were more numerically more prevalent in patients with SpA compared to HC. A statistically significant association was found between HLA-B51 and axSpA and correlated with more peripheral and less axial radiographic involvement.

**Acknowledgements:** The authors would like to thank the Research Council of Saint-Joseph University and NewBridge Pharmaceuticals FZ LLC for an unrestricted research grant to fund the study.

**Disclosure of Interests:** Nelly Ziade Speakers bureau: Roche, Abbvie, Eli Lilly, Pfizer, Janssen, Novartis, Pierre Fabre, Apotex, Pharmaline, Paid instructor for: Abbvie, Eli Lilly, Sanofi-Aventis, Pfizer, Janssen, Novartis, Grant/research support from: NewBridge Pharmaceutical FZ LLC (current study), Pfizer, Abbvie, Celgene, Rhea Nacouzi: None declared, Kamil Mroue: Speakers bureau: Roche, Abbvie, Eli Lilly, Pfizer, Janssen, Novartis, Georges Merheb: Speakers bureau: Roche, Abbvie, Eli Lilly, Pfizer, Janssen, Novartis, Pierre Ghoma: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3811

---

**Figure 1.** Distribution of the HLA-B alleles in patients with spondyloarthritids and healthy controls (Statistically significant differences between patients and controls indicated with *)
Profile of SpA in the Moroccan Population: Results of a Multicenter Study

H. Arabi1, A. Mougui1, H. Sahimi2, N. Takhtira3, S. Mouchine4, I. Bentaleb5, H. Taoufin6, T. Harzy2, F. Afroozarzak2, S. Janani3, R. Bahiri1, A. Bezzi6, I. Ghoziani7, R. Niamane8, I. El Bouche9, *Mohammed VI University Hospital Marrakech, Rheumatology, Marrakech, Morocco; 2Hassan II University Hospital Fes, Rheumatology, Fes, Morocco; 3Mohammed V Hospital Tanger, Rheumatology, Tanger, Morocco; 4 Ibn Rochd University Hospital Casablanca, Rheumatology, Casablanca, Morocco; 5 El Ayachi Hospital, Ibn Sina University Hospital Salé-Rabat, Rheumatology, Salé-Rabat, Morocco; 6 Military Hospital Mohammed V Rabat, Rheumatology, Rabat, Morocco; 7 Military Hospital Agadir, Rheumatology, Marrakech, Morocco; 8 Hospital Aficenne Marrakech, Rheumatology, Marrakech, Morocco.

Background: Spondyloarthritis (SpA) is a frequent group of chronic inflammatory rheumatic diseases, their epidemiology varies considerably in different regions of the world.

Objectives: The aim of our study was to describe the epidemiological, clinical, para-clinical and therapeutic profile of SpA in the Moroccan population.

Methods: This is a multicenter descriptive study, including patients followed for SpA. 8 hospital centers participated in this study. All data were measured by standard instruments.

Results: Seven hundred patients were included. 54% were men, the mean age was 40.42±14.19 years at the time of diagnosis [14-90 years].

- The patients lived in urban and rural areas in 83.5% and 13.8% of cases, respectively.
- 38.4% were without occupation.
- A history of tuberculosis was noted in 3.8% of cases.
- 38.4% were without occupation.
- A history of tuberculosis was noted in 3.8% of cases.
- 38.4% were without occupation.
- A history of tuberculosis was noted in 3.8% of cases.

Conclusion: This is a study of the clinical and demographic characteristics of SpA patients in a population in Morocco, on which a large scale data base could be initiated, in order to better determine the role of genetic and environmental factors in the pathogenesis of the disease.

References:

Disclosure of Interests: None declared


Assessment of Carotid Intima-Media Thickness in Spondyloarthritis Patients

A. Ben Tekka1,2, T. Mehmendi, F. Ahmed3, S. Boukhiba3, O. Saidane2,4, R. Leilla2,3, S. Bouden2,4, R. Tekay4,5, I. Mahmoud2,4, H. Mizouni2,5, L. Abdelmoula2,4,1, Charles Nicolle Hospital, Rheumatology Department, Tunis, Tunisia; 1University Tunis El Manar, Faculty of medicine of Tunis, Tunis, Tunisia; 2La Rabta Hospital, Radiology department, Tunis, Tunisia.

Background: Cardiovascular morbidity and mortality are increased in spondyloarthritis (SpA), which is attributed to accelerated atherosclerosis. Recognition of subclinical atherosclerosis in asymptomatic population is important for risk stratification and optimal management. Due to its simplicity and non-invasive nature, carotid intima-media thickness (cIMT) is actually widely used for identifying subclinical atherosclerosis.

Objectives: The aim of our study was to investigate the presence of subclinical atherosclerosis in SpA patients compared with healthy controls, by evaluating cIMT.

Methods: We performed a case control study including 47 patients and 47 age and gender matched healthy controls. All subjects were included without history of cardiovascular disease or cardiovascular risk factors. Socio-demographic features, disease characteristics, radiographic structural damage and therapeutics were recorded. cIMT was measured with Mindray Resona 7 ZST+ ultrasound machine, from the right and the left carotid artery; than mean cIMT was calculated. We considered that cIMT was increased if the measurements were between 0.7 mm and 1.5 mm. Measurements higher than 1.5 were defined as an atherosclerotic plaque.

Results: Forty seven patients with a sex ratio of 2.35 were included in our study. Median age was 36 years (IQR: 28-46) and median duration of the disease was 11 years (IQR: 5-16). Median BASDAI and ASDAS-CRP scores were 2.6 (IQR: 1.8-3.8) and 2.18 (IQR: 1.62-2.91) respectively. Of the 47 patients, 10 (21%) had an active disease according to BASDAI and 19 (40%) had an active disease according to ASDAS. Median BASFI score for functional impairment was 3 (IQR: 1.5-5.1). Median BASRI and mSASSS scores were 3 (IQR: 2-4) and 10 (IQR: 4-15) respectively. Regarding treatment, 92% of patients were using non-steroidal anti-inflammatory drugs (NSAIDs), 51% were on csDMARDs and 38% were on anti-TNF alpha drugs. Median right, left and mean cIMT were respectively 0.54 mm (IQR: 0.49-0.63), 0.55 mm (IQR: 0.49-0.61) and 0.55 mm (IQR: 0.48-0.62) respectively. Increased cIMT values were found in 8 patients (17%). No patient had atherosclerotic plaque. Median values of cIMT were significantly higher in patients with spondyloarthritis than the control subjects (p<0.0001) as shown in Table 1.

Disclosure of Interests: None declared

Conclusion: Our study demonstrated increased cIMT in patients with SpA compared with healthy population; which attests higher risk for subclinical atherosclerosis and cardiovascular atherosclerotic events.

References:

Disclosure of Interests: None declared

AB0850

ENTHESIS, FEMALE GENDER AND VITALITY PERCEPTION AS FATIGUE DETERMINANTS IN SPONDYLOARTHROPATHY PATIENTS UNDER bDMARD

F. R. Martins1, A. Martins2, B. Samões3, D. Santos Oliveira2,4, R. Nicolau5, A. Ramírez Huaranga1, M. Paulino Huertas1.

1University Hospital de Gaia / Espinho, Rheumatology, Vila Nova de Gaia, Portugal; 2Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 3Centro Hospitalar Tondela - Viseu, Epe, Rheumatology, Viseu, Portugal; 4Faculty of Medicine da Universidade do Porto - FMUP, Medicine, Porto, Portugal

Background: Fatigue is an important domain in quality of life of spondyloarthritis patients, not always directly associated with disease course. The explanatory factors of fatigue in these patients are still not clearly understood.

Objectives: To assess the determinants of fatigue in patients with SpA under biologic disease modifying anti- rheumatic drugs (bDMARDs).

Methods: A retrospective observational study was performed using registry data of patients with SpA under bDMARD therapy followed at a tertiary level hospital. Data regarding disease activity, response criteria measures, analytic markers, function, metrology, pain, general health and fatigue (using FACIT score) was gathered at baseline, 6 months (t6) and 12 months (t12) after introduction of bDMARD. Statistical analysis (significance at p < 0.05) was performed using paired T-test, Wilcoxon test and McNemar tests for paired samples, Mann Whitney-U, Kruskall-Wallis and One Way ANOVA for independent samples. Linear and logistic regression models were performed to assess direction and strength of association.

Results: A total of 46 SpA patients were analysed; most were male (24, 52.2%) with a predominantly axial involvement (31, 68.9%) and 74.4% of them were positive for HLA-B27. Most patients had high school or lower education (29, 69.1%), never smoked (26, 61.9%), never drank (34, 79.1%) and had a full-time job (38, 88.4%). All patients were under TNF inhibitors, mostly adalimumab (23, 50%).

There was a significant decrease in inflammatory markers (p<0.001), disease activity scores (ASDAS-CRP and BASDAI) (p<0.001), function index BASFI (p<0.001), metrology indexes (p<0.05) and MASEs enthesis score (p=0.01). Patient, physician and night painVAS were significantly lower (p<0.01) at t6 and t12, but spine VAS only varied significantly between t0 - t6 (p = 0.021) and not t0 - 112 (p=0.405). FACIT didn’t vary significantly after bDMARD initiation, and among the domains of SF36 questionnaire, only SF36 vitality score varied significantly (p=0.05). No significant changes in EQSD, HADS or anxiety depression scores were observed.

At baseline, there was a strong negative correlation between fatigue, expressed by FACIT score, and pain VAS (R = 0.9, p=0.037), without other significant associations. Several positive correlations with fatigue at t6 were observed, the strongest with anxiety and depression HADS (p < 0.001), BASFI (p < 0.001) and ASDAS-CRP (p < 0.001). Other positive associations were seen with 66 TJC (p < 0.01), patient VAS (p = 0.001), pain VAS (p = 0.001), nocturnal pain VAS (p < 0.001), BASDAI (p < 0.001) and MASEs (p < 0.001). Fatigue at t6 had a negative correlation with increased ASAS response measures mean value (p = 0.014), all domains of SF36 (p < 0.001), the strongest correlation of which was with the general health domain (R=–0.811), and EQSD (p<0.001). When comparing subgroups at t6, there was more fatigue in the female group (p=0.01) and in patient with higher vitamin D activity score (p < 0.05), with no differences according to work status, alcohol consumption or tobacco use, educational level, TNF inhibitor exposure or ASAS response.

Prediction analysis showed univariable association between several baseline variables and fatigue (lower FACIT scoring) at t6: age at bDMARD introduction (B = -0.405, p = 0.02), age at diagnosis (B = -0.43, p = 0.02), physician VAS (B = 0.149, p < 0.05), MASEs (B = 0.149, p < 0.05) and female gender (B = -0.795, p = 0.01). Multivariable linear regression analysis allowed for prediction of a predictive model for FACIT scoring at t6 (R2 = 0.900, p = 0.019): (-3.426) x MASEs 10 + (-24.074) x female gender + 0.949 x SF36 vitality score.

Conclusion: Enthesitis, female gender and subjective assessment of vitality seem to be determinants of fatigue in SpA patients under bDMARD. Fatigue in this population is associated with diverse factors that should be optimized in a holistic approach to the patient.

Disclosure of Interests: None declared

AB0851

APPLICABILITY OF THE MASEI INDEX IN ENTHESIS AND ITS ASSOCIATION WITH OTHER INDICES / SEROLOGICAL MARKERS OF ACTIVITY IN PATIENTS WITH SPONDYLOARTHROPATHY


1Hospital Universitario Ciudad Real, Rheumatology Department, Ciudad Real, Spain; 2Universidad Pontificia de Comillas, Quantitative Methods Department, Madrid, Spain

Background: Spondyloarthritis (SpA) are a group of chronic inflammatory diseases with affection, mainly of the axial skeleton and, also, of peripheral joints. The enthesis is one of the target organs, since an inflammation of it, known as enthesitis, can be observed, which in many patients with spondyloarthritis could be unnoticed.

Objectives: To find the relation between the MASEI index (Madrid Sonographic Enthesitis Index) in enthesis and other indices/serological activity markers (such as BASDAI, DAPSA or ASAS and ESR, CRP) in spondyloarthritis patients.

Methods: Observational, descriptive and cross-sectional study. Data were collected from 68 patients with SpA who underwent musculoskeletal ultrasound using the Madrid Sonographic Enthesitis Index (MASEI) and who were treated in our clinics from May 2021 to September 2021 and under the approval of the CEICm of our center. The variables evaluated were described using measures of frequency and measures of central tendency/dispersion, as appropriate. First, we tested the normality of all the variables, using a Shapiro-Wilk test. We studied the correlation of parametric numerical variables (such as MASEI-Vitamin D, MASEI-ASDAS) using Pearson’s coefficient. On the other hand, for non-parametric numerical variables (such as MASEI-BASDAI) we used Spearman’s coefficient. For parametric numeric and categorical variables (such as MASEI-VITAMINA D, ASDAS-VITAMINA D) we constrained the mean of differences using the Student t-test, while for non-parametric numerical and categorical variables, we contrast the difference of means with the Mann-Whitney U test (MASEI-PCR, MASEI-VSG). Finally, to find out the correlation between categorical variables (such as VITAMIN D-PCR), we used a chi-square test. Finally, we have done a curve-fitting study with Matlab, obtaining the functions that better adjust the data avoiding overfitting. We have done this parametric optimization with the following pairings: MASEI-ASDAS, MASEI-BASDAI and MASEI-DAPSA.

Results: We analyze twenty four patients with SpA (with mean age 50.50 ± 10.63 years) 8 women and 16 men. They present: radiographic axial spondyloarthritis (5 patients), non-radiographic axial spondyloarthritis (4 patients), psoriatic arthritis (10 patients), spondyloarthritis associated with inflammatory bowel disease (2 patients), reactive arthritis (2 patients), and, finally, one patient had undifferentiated peripheral spondyloarthritis. The variables have the following average levels: ASDAS, 2.35 (±1.09); BASDAI (for those with axial involvement) 4.54 (±2.93); DAPSA (for psoriatic arthritis) 10.98 (± 6.85) and total MASEI 19.88 (± 14.77). We have found a correlation between the total MASEI and the following variables: ASDAS (Pearson coefficient=0.696), BASDAI (Spearman coefficient=0.823) and DAPSA (Pearson coefficient=0.823).

The mean vitamin D levels were 25.98 (±12.05), and it has a negative correlation with the MASEI equal to -0.317. As far as curve fitting is concern, a couple of sinusoidal functions were obtained for the MASEI-ASDAS and MASEI-VITAMINA D the correlation of parametric numerical variables (such as MASEI-Vitamin D, MASEI-ASDAS) using Pearson’s coefficient. On the other hand, for non-parametric numerical variables (such as MASEI-BASDAI) we used Spearman’s coefficient. For parametric numeric and categorical variables (such as MASEI-VITAMINA D, ASDAS-VITAMINA D) we constrained the mean of differences using the Student t-test, while for non-parametric numerical and categorical variables, we contrast the difference of means with the Mann-Whitney U test (MASEI-PCR, MASEI-VSG). Finally, to find out the correlation between categorical variables (such as VITAMIN D-PCR), we used a chi-square test. Finally, we have done a curve-fitting study with Matlab, obtaining the functions that better adjust the data avoiding overfitting. We have done this parametric optimization with the following pairings: MASEI-ASDAS, MASEI-BASDAI and MASEI-DAPSA.

Disclosure of Interests: None declared
Disclosure of Interests: David Castro-Corredor, Lilly, Pfizer, Gebro Pharma, Nordic Pharma, Luis Angel Calvo Pascual: None declared, Eduardo C. Garrido Merchán: None declared, Marco Aurelio Ramírez Huarranga, Lilly: None declared, Marco Paulino Huenas: Lilly, Pfizer

AB0852 ASSESSMENT OF ENDOThelial Dysfunction IN SPONDYLOARTHritis

A. Ben Tekaya1, T. Mehri1, S. Boukri2, F. Ahmed2, O. Saïdane1, R. Leilla1, S. Bouden1, R. Tekaya2, I. Mahmoud2, H. Mizouini2, L. Abdelmoula2, Charles Nicolle Hospital, Rheumatology Department, Tunis, Tunisia; 3University Tunis El Manar, Faculty of medicine of Tunis, Tunis, Tunisia; 4La Rabta Hospital, Radiology department, Tunis, Tunisia

Background: Endothelial dysfunction is the earliest step in the pathogenesis of atherosclerosis, preceding structural vascular alterations. Few studies have focused on the endothelial dysfunction in spondyloarthritis.

Objectives: The aim of our study was to assess endothelial dysfunction using Flow-Mediated dilatation (FMD) in patients with spondyloarthritis.

Methods: Forty-seven consecutive patients meeting ASAS 2009 criteria for spondyloarthritis and 47 matched healthy subjects were included in the study. Subjects with traditional cardiovascular risk factors were excluded. Sociodemographic, clinical, biological and radiological features related to the disease as well as therapeutics were recorded. FMD was assessed ultrasonographically according to guidelines of the European college of cardiology (ECC).

Results: Spondyloarthritis group included 47 patients with a sex ratio of 2.35 and a median age of 36 years (IQR: 28-46). Median body mass index (BMI) was 24.5 kg/m² (IQR 25-75%: 20.7-26.8) with no significant difference compared with the control group (p=0.238). Physical examination showed normal values of blood pressure (BP) with a median systolic BP of 121 mmHg (IQR 25-75%: 110-130) and a median diastolic BP of 71 mmHg (IQR 25-75%: 67-79). In laboratory findings, total cholesterol and triglyceride levels were increased in 2 and 3 patients respectively.

Median age at onset of SpA was 20 years (IQR 25-75%: 18-32) For disease activity, median CRP level was 6.45 mg/IQR 25-75%: 14.5-19.9) and median ASAS-24 and BASDAI were respectively 2.18 (IQR 25-75%: 1.62-2.91) and 2.6 (IQR 25-75%: 1.8-3.8). Median MASES score was 0 (IQR 25-75%: 0-0). Median BASFI and BASMI were 3 (IQR 25-75%: 15-5.5) and 1.5 (IQR 25-75%: 0-4). Regarding treatment, 92% of patients were using NSAIDs, csDMARDs (51%) and 38% were on TNF inhibitors.

Patients with spondyloarthritis exhibited significantly lower FMD values than healthy age and gender matched controls with a median value of FMD 14.6% (IQR: 9-24) versus 18.8% (IQR: 12.8-23.1%); p=0.008.

Conclusion: Our study demonstrates impairment of endothelial function in patients with spondyloarthritis compared with healthy population, confirming the accelerated atherosclerosis in spondyloarthritis.

REFERENCES:

Disclosure of Interests: None declared


AB0853 THE ROLE OF IL-17 IN IBD AND SPONDYLOARTHRITIS

G. Lukina1, P. Kulakova1, E. Alexandrova1, A. Novikova1, N. Savenkova1, A. Klimets1, I. Kartushina1, A. Kovalsky1, E. Volnukhin1. 1The Logoinov Moscow Clinical Scientific Center of Moscow Healthcare Department (“The Logoinov Moscow Clinical Scientific Center of Moscow Healthcare Department” (The Logoinov MCSC MHD), Rheumatology, Moscow, Russian Federation; 1I.V.Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation; 2The Logoinov Moscow Clinical Scientific Center of Moscow Healthcare Department” (The Logoinov MCSC MHD), Immunology, Moscow, Russian Federation

Background: Currents, there is a lot of interest in the frequency and risks of developing of inflammatory bowel diseases (IBD) in patients with ankylosing spondylitis (AS). [1] IL-17 and IL-23 are one of the key pathogenetic markers of AS [2]. A lot of studies also showed that the average number of IL-17 cells was significantly increased in active Ulcerative colitis (UC) and Crohn disease (CD) patients [3]. According to some studies cytokines, such as IL-17 and IL-23, play crucial role in inflammation and homeostasis [4].

Objectives: The aim of this study was to evaluate IL-17 and IL-23 serum levels in patients with AS without IBD and with AS and IBD.

Methods: In the analysis were included 50 patients with AS, fulfilling the modified New York criteria, among them man=36 (72%), woman=14 (28%), mean age of patients was 42.5±9, mean disease duration = 13.4±8.7 years. All patients were examined with ESR. Median ESR in the group of patients with AS without IBD was 7% (IQR 25-75%: 2%-11%), mean ESR in the group of patients with AS and IBD was 31.4% (SD 57.2), 7.1% (SD 38.5), 21.7% (SD 51.4) months in peripheral and axial SpA, PsA and total respectively (Table 1). The time from referral to rheumatology was 31.4 (SD 57.2), 7.1 (SD 38.5), 21.7 (SD 51.4) months in peripheral and axial SpA, PsA and total respectively (Table 2). The service with the longest time between symptom onset to referral to rheumatology department and diagnosis of SpA, as well as differences according to the department making the referral makes the important difference in initiating therapy and treatment.

Retrospective descriptive study of patients with a diagnosis of PsA according to the ASAS criteria and CASPAR criteria for the psoriatic arthritis subgroup (PsA), in a single hospital centre. We collected demographic variables separated by subgroups of peripheral and axial SpA and PsA, age at diagnosis, time from symptom onset to referral to the rheumatology department and diagnosis, as well as differences according to the department making the referral.

Results: Seventy-five patients with SpA were analysed. 40 had peripheral and axial SpA and 35 (46.6%) PsA. Thirty-six patients (49.3%) were female (Table 1). Patients with peripheral and axial SpA had a higher mean age at diagnosis than patients with PsA. 45.1 years (SD 11.3) was the mean age at diagnosis. 73.6% of patients were referred from primary care (PC), 9.4% from traumatology, 9.4% from rehabilitation (RH), 3.8% from dermatology and 3.8% from emergency department. The median time from the first symptom to referral to rheumatology was 31.4 (SD 57.2), 7.1 (SD 38.5), 21.7 (SD 51.4) months in peripheral and axial SpA, PsA and total respectively (Table 2). The service with the longest time between symptom onset and referral to rheumatology is PC and rehabilitation for all groups. The median time from first symptom to diagnosis was 43.1 (SD 55.1), 34.4 (SD 65.8) and 39.2 (SD 59.7) months for peripheral and axial SpA, PsA and total respectively (Table 2). The time from referral to rheumatology to diagnosis of peripheral and axial SpA was 12.2 (SD 19.4), PsA 17 (SD 39.3) and total 14.3(SD 29.5) months.

Disclosure of Interests: None declared

Background: Spondyloarthritis includes a heterogeneous group of rheumatisms characterized by their strong association with HLA-B27 (1). The association between SPA and HLA-B 27 is one of the strongest known associations between an HLA allele and disease (2). Several studies have highlighted the importance of this association for diagnosis, predicting disease phenotype and prognosis of spondyloarthritides (SpA) (1.2).

Objectives: The aim of the present study is to determine the prevalence of HLAB27 in Moroccan SpA patients and to analyze the correlation between HLAB27 status and different disease parameters.

Methods: It is a multicenter cross-sectional study including 256 SpA patients. Demographic, clinical, paraclinical and therapeutic parameters of the disease were collected. Disease activity was assessed by BASDAI and ASDAS-CRP scores. Patients were classified into two groups: HLAB27 (+) and HLAB27 (-). A comparison regarding HLAB27 status was performed using the Mann-Whitney and Chi2 T-test tests. The significance threshold was set at p<0.05.

Results: 256 SpA patients were included in the study, 241 patients have HLAB27 status of which 114 (44.5%) were HLAB27-positive, 46.6% of men and 40.9% of women were HLAB27 positive. 233 patients had axial SpA of which 110 patients (472%) were HLAB27 positive. The mean age was 39.58±12.89 years. The HLAB27-positive group had a longer diagnostic delay (p=0.008) with a mean of 4 years. 46 patients had a family history of SpA of which 25.4% were HLAB27-positive and 11.6% HLAB27-negative (p=0.007). The HLAB27-positive patients had more axial manifestations (96.5% vs. 85.9%; p=0.01). While peripheral involvement was more noted in the HLAB27-negative group (90.6% vs. 35.1%; p=0.001). Enthesopathy was more observed in the HLAB27-negative group (78% vs. 62.2%; p=0.001). HLAB27-positive patients had more active disease defined by ASDAS-CRP (3.13±1.23 vs. 2.24±1.14; p<0.001). Only one case of uveitis was noted in the HLAB27-negative group versus 27 cases in the HLAB27-positive group (p<0.001), 33 HLAB27-positive patients had radiographic coxitis (33 vs 16, p=0.002). The bDMARDs were more prescribed in the HLAB27-positive patients (58.8% vs. 35.4%; p=0.009).

Conclusion: In our study, the prevalence of HLAB27 was close to the MENA region (3). The prevalence of HLAB27 is related to an earlier disease onset, higher activity, to the presence of coxitis and uveitis and consequently more use of biotherapy in this group (HLAB27-positive).

REFERENCES:

Disclosure of Interests: None declared


AB0855

COMPARISON OF CARDIAC INVOLVEMENT BETWEEN ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLITIS

I. El Mehrou1, N. Akasbi1, T. Harzy1, 1CHU HASSAN II, Rheumatology, Fez, Morocco

Background: While cardiac involvement is increasingly recognized and investigated in patients with axial spondyloarthritis (axSpA), few studies have investigated the occurrence of cardiac involvement in patients with non-radiographic axial spondyloarthritis (nr-axSpA) in relation to ankylosing spondylitis (AS).

Objectives: The objectives of the present study are to describe and compare the characteristics of cardiac involvement between AS and axSpA nr patients.

Methods: A cross-sectional study was conducted in the rheumatology department of the University Hospital of Fez in Morocco, including patients diagnosed as having axial spondyloarthritis according to the ASAS 2010 criteria, for a period of 9 years. Patients were classified as nr-axSpA by the presence of radiographic sacroiliitis according to the modified New York criteria and nr-axSpA defined by the presence of sacroilitis on MRI.

Results: 357 patients were included in the study. We compared 257 AS to 118 with nr-axSpA. The cohort was predominantly female (54.9%) with a mean age of 46.83 years (S.D. 14.00). AS patients were significantly young (45 vs 50 years), more frequently male (55% vs 22%) and had higher serum inflammatory markers than those with nr-axSpA. Between AS and nr-axSpA groups, arterial hypertension was more frequent in AS patients (26.6% versus 14.4%, p = 0.018). While valvulopathy, myocardial infarction, pericarditis and heart failure were higher in AS patients with respective (8.6% vs 3.4%, p=0.067) (1.6% vs 0.8%, p=0.578) (1.2% versus 0.8%, p = 0.779) (0.4% versus 0%, p = 0.497). However, arrhythmias were similar in AS patients and nr-axSpA patients (0.8% versus 0.8%, p = 0.571).

Conclusion: Cardiac involvement was common in both axSpA populations and similar between AS and nr-axSpA except in hypertension where there is a significant difference between the two groups. These results highlight the importance of identifying and managing cardiac involvement in these patients.

Disclosure of Interests: None declared


AB0856

PREVALENCE OF HLAB27 ANTIGEN IN MOROCCAN PATIENTS WITH SPONDYLITIS (SPA): A MULTICENTER STUDY

I. Bentaleb1, S. Rostom2, B. Amine1, I. El Binoune1, I. El Bouc1h2, I. Ghozlani3, R. Bahiri1, 1ALAYACHI HOSPITAL, Rheumatology, Salé, Morocco; 2AR-RAZI HOSPITAL, Rheumatology, Marrakesh, Morocco; 3Military Hospital AGADIR, Rheumatology, AGADIR, Morocco

Table 1. Demographic characteristics and months in accordance to type of SpA.

<table>
<thead>
<tr>
<th>Peripheral and axial SpA</th>
<th>PsA</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis 45.1 (SD11.8)</td>
<td>44.9 (SD10.9)</td>
<td>45.1 (SD11.3)</td>
</tr>
<tr>
<td>Female 20 (51.3%)</td>
<td>16 (47.1%)</td>
<td>36 (49.3%)</td>
</tr>
<tr>
<td>Hypertension 10 (23.9%)</td>
<td>10 (29.4%)</td>
<td>20 (27.0%)</td>
</tr>
<tr>
<td>Dyslipidemia 17 (42.5%)</td>
<td>17 (51.5%)</td>
<td>34 (46.6%)</td>
</tr>
<tr>
<td>Diabetes mellitus 5 (12.5%)</td>
<td>6 (17.6%)</td>
<td>11 (14.9%)</td>
</tr>
<tr>
<td>Body Mass Index 270 (SD4.1)</td>
<td>30.5 (SD4.2)</td>
<td>29.2 (SD4.7)</td>
</tr>
<tr>
<td>Cardiovascular disease 5 (12.5%)</td>
<td>6 (17.6%)</td>
<td>7 (9.5%)</td>
</tr>
<tr>
<td>Cerebrovascular disease 2 (5.0%)</td>
<td>2 (5.9%)</td>
<td>4 (5.4%)</td>
</tr>
<tr>
<td>Depression 1 (2.5%)</td>
<td>1 (2.9%)</td>
<td>2 (2.7%)</td>
</tr>
<tr>
<td>Renal insufficiency 1 (2.5%)</td>
<td>1 (3.0%)</td>
<td>2 (2.7%)</td>
</tr>
<tr>
<td>Liver failure 3 (7.5%)</td>
<td>5 (14.7%)</td>
<td>8 (10.8%)</td>
</tr>
<tr>
<td>Time in months from 1st symptom to referral 31.4 (SD5.72)</td>
<td>21 (SD3.85)</td>
<td>21.7 (SD3.14)</td>
</tr>
<tr>
<td>1Primary care 30.9(SD10.9)</td>
<td>70(SD34.1)</td>
<td>210(SD73.2)</td>
</tr>
<tr>
<td>1Traumatology 5 (SD125)</td>
<td>5 (SD282)</td>
<td>5 (SD148)</td>
</tr>
<tr>
<td>Rehabilitation 36 (SD29.14)</td>
<td>19</td>
<td>275</td>
</tr>
<tr>
<td>1Emergency service 1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>1Time from referral to diagnosis 12.2 (SD19.4)</td>
<td>170 (SD30.3)</td>
<td>143 (SD29.5)</td>
</tr>
<tr>
<td>1Dermatology 13 (SD141)</td>
<td>13 (SD141)</td>
<td></td>
</tr>
<tr>
<td>1Rehabilitation service 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1Time from 1st symptom to diagnosis 43.1 (SD55.1)</td>
<td>34.4 (SD65.8)</td>
<td>39.2 (SD59.7)</td>
</tr>
</tbody>
</table>

Conclusion: In our cohort, patients are referred to rheumatology mainly from PC, which in turn is the service with the longest delay, especially in the peripheral and axial SpA group. Patients with PsA take less time to be referred than patients with peripheral and axial SpA. Once referred to rheumatology, peripheral and axial SpA patients take less time to be diagnosed than those in the PsA group.

Disclosure of Interests: None declared

Patients with renal involvement had significantly higher values of CIMT (0.64 mm (IQR 25-75%: 0.56-0.70) vs 0.53 mm (IQR 25-75%: 0.47-0.59); p= 0.045). Significant positive correlation was also detected between CIMT values and creatinine level (p=0.002).

In multivariate linear regression, creatinine level was identified as independent predictor of increased CIMT (B=0.002; 95% confidence interval=0.000-0.005; p=0.035).

Conclusion: Although all patients included have normal creatinine level, we identified creatinine level as independent predictor of subclinical atherosclerosis in SpA patients. This finding highlights the monitoring of this parameter.

Disclosure of Interests: None declared


AB0859

CLINICAL CHARACTERISTICS OF PATIENTS WITH SPONDYLOARTHRITIS WITH COVID-19 IN ANAMNESIS IN THE REPUBLIC OF TATARSTAN

V. Mukhamadieva1, S. Lapshina1, N. Shamsutdinova2, A. Sagitova1, A. Zakirova1, L. Krasnova1, R. Abdakirov1, D. Abdulgaieeva1, Kazan State Medical University, Department of hospital therapy, Kazan, Russian Federation; Kazan, Russian Federation; Kazan State Medical University, Department of hospital therapy, Kazan, Russian Federation; Kazan, Russian Federation; Kazan State Medical University, Department of hospital therapy, Kazan, Russian Federation; Republican clinical hospital, rheumatology, Kazan (Российская Федерация, Республика Татарстан), Russian Federation

Background: The management of patients with spondyloarthritis (SpA) during the period of the novel coronavirus infection (NCI) pandemic is a significant problem due to insufficient evidence base.

Objectives: To study the features of the course NCI and its influence on the course of SpA.

Methods: From March 2020 to January 2022, 55 patients with SpA who underwent NCI (with a confirmed result of SarsCoV2 PCR and /or using X-ray computed tomography (CT) of the lungs): ankylosing spondylitis (AS) 37 people, with psoriatic arthritis (PsA) 18 people. Of these 32 (58.2%) were men, 23 (41.8%) - women, the average age of patients was 49 (37.5; 57.5) years. The duration of SpA at the time of NCI was 11 [7; 16] years, SpA activity before NCI was low in 15 (34.8%) patients, moderate in 25 (58.1%), and high in 3 (6.9%) patients. The results of clinical and laboratory examinations were evaluated during the NCI and after 1, 3, 6 months.

Results: Symptoms of NCI in patients with SpA were comparable in frequency and severity to the course of infection in the population. 47.3% had a mild course of NCI, and 52.7% of those observed had a moderate course, which is comparable with the general population data. Lung involvement was detected in 29 (52.7%) patients. The outcome of COVID-19 in all patients is recovery. Analysis of the course of SpA showed an increase in activity 1 and 3 months after NCI: BASDAI from baseline to COVID-19 4.3±1.57 to 4.9±1.7 points after 3 months, similar to ASDAS_CRP from 2.6±1.2 to 3.7±0.2, BASFI from 3.0±1.9 to 3.8±1.8. A positive correlation was found between the severity of NCI and the BASFI index after 3 months (0.670). Analysis of the course of PsA showed an increase in activity 1 and 3 months after NCI: DAS28 from the baseline 2.78±0.98 to 4.15±1.16 points after 3 months. Of the total number of recoveries, 72.2% of patients showed an increase in activity due to clinical and laboratory parameters.

78.1% of patients noted the presence of post-COVID symptoms after NCI, 56.3% had a combination of more than 3 different symptoms. Most often there was an increase/appearance of pain in the joints - in 78.1% significant - in 61.8%, insignificant - in 16.3% of respondents. Strengthening/appearance of muscle pain and/or headache and/or dysautonomia occurred in 72.7%. This can be assessed as an exacerbation of the underlying disease, or, conversely, the appearance of arthralgia and myalgia could have an impact on the increase in AS and PsA activity indices. The second most frequent were a decrease in the quality of life (QOL) and working capacity in 69.0% of patients: significant in 36.3% of patients, insignificant in 32.7%. The appearance/intensification of shortness of breath and a decrease in exercise tolerance were noted by 60% of the respondents. Among them, 34.5% of patients with moderate severity, 25.4% - with mild NCI. Appearance/intensification of chest pain and/or palpitations was noted by 16.3% of patients.

Conclusion: The prevalence and course of the NCI in patients with SpA did not differ from that in the population. However, coronavirus infection has led to increased pain and an increase in AS activity, long-term persistence of post-COVID manifestations in the form of muscularkeletal pain and asthenic symptoms in the form of a decrease in the quality of life. At the same time, specific respiratory symptoms occurred in a third of patients and were not associated with the severity of the NCI.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4113

AB0860

REPERCUSSIONS OF TOBACCO ON SPONDYLOARTHRITIS: THE ICEBERG EFFECT!

L. Kharra1, M. Slimou1, A. Abdennader2, K. Amri2, Y. Mallat1, L. Metoui1, R. Dhour1, I. Gharsallah1, B. Louzir1, 1Military Hospital of Instruction of Tunis, Rheumatology, Tunis, Tunisia; 2Military Hospital of Instruction of Tunis, Orthopedics, Tunis, Tunisia; 3Military Hospital of Instruction of Tunis, Internal medicine, Tunis, Tunisia

Background: The deleterious effect of smoking is frequently studied in inflammatory diseases such as spondyloarthritis (SA) [1].

Objectives: The objective of our study was to identify the consequences of smoking during AS.

Methods: We conducted a cross sectional study including patients followed for spondyloarthritis meeting the ASAS 2009 criteria. For each patient we collected the following parameters: age, age at onset of the disease, duration of progression, disease activity using BASDAI and ASDAS-CRP scores and structural damage using BASRI and mSASSS scores. We also measured sedimentation rate (ESR) and C-reactive protein (CRP).

Statistical analysis was performed using SPSS software.

Results: We included 140 patients. Seventy-three percent were male (n=102). The mean age was 43 ± 12.9 years. The age of onset of the disease was 34.2 ± 12 years. The mean disease duration was 110 ± 107.8 months.

Sixty patients were smokers (43%) at an average of 20.75 ± 16.09 pack-years. Mean ESR and CRP were 36.49 ± 27.22 mm and 29 ± 44.27 mg/L, respectively.

The mean BASRI and mSASSS were 4.12 ± 3 and 10.26 ± 15.41, respectively.
Smokers had significantly higher BASRI and mSASSS scores (BASRI: 5.02 ± 3.32 vs 3.47 ± 2.6; p=0.005 and mSASSS: 14.07 ± 17.56 vs 7.02 ± 12.82; p=0.03). In addition, the number of packets year was correlated to mSASSS (r=0.399; p=0.01).

On the other hand, we did not find any association between smoking and the following parameters: ESR, CRP, BASDAI or ASDAS-CRP.

Conclusion: As reported in other studies, ours showed that structural damage was correlated with the number of pack-years [2]. Smoking was associated with this structural damage in SA regardless the inflammatory biomarkers and the disease activity. This suggests that control of structural damage in SA requires smoking cessation.

REFERENCES:
[1] Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthri-

Background: Physiopathological mechanisms of spondyloarthritis (SA) are very complex. The role of the interleukin (IL)-8, which is an angiogenic chemokine, has been suggested [1].

Objectives: We aimed to evaluate the discriminative value of interleukin 8 in SA.

Methods: We conducted a cross-sectional study during two years (2019-2020) including 144 subjects divided into two groups: a group G1 that included 72 patients followed for spondyloarthritides meeting the Assessment of SpondyloAr-

Results: We included 57 men and 15 females in each group. The mean age was 44.84 ± 13.42 years. In G1, the mean disease duration was 10.25 ± 7.7 years. IL-8 was measured for each participant using chemiluminescence. We performed a ROC analysis and computed the area under the curve (AUC) at IL-8 to assess the ability of this chemokine to diagnose SA and to distinguish between SA patients from healthy controls. Statistical analysis was performed using SPSS.

The mean BASDAI and ASDAS-CRP were 3.21 ± 1.87 and 2.92 ± 1.55, respectively. IL-8 was able to distinguish SA patients from healthy controls with a cutoff of 4.5 pg/mL. The AUC was good at 0.855 (p<0.0001). The sensitivity and the specificity were 92.8% and 81.6% (Figure 1).

Conclusion: Several studies have found that IL-8 was significantly higher in SA patients compared to controls [2,3]. Our study showed that IL-8 could distinguish SA patients from controls with a cutoff of 4.5 pg/mL. This suggests that IL-8 could play a role in the pathophysiology of SA.

REFERENCES:

Results: As reported in other studies, ours showed that structural damage in SA regardless the inflammatory biomarkers and the disease activity. This suggests that control of structural damage in SA requires smoking cessation.

REFERENCES:
[1] Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthri-

Objectives: To evaluate emotional functionality of patients with SpA, and their association with the presence of gastrointestinal symptoms and disease activity.

Methods: In total, 98 patients with SpA (fulfilling ASAS criteria) were assessed by rheumatologists. Patients with two or more gastrointestinal symptoms were referred to gastroenterology. Furthermore, those patients with SpA and con-

Background: Spondyloarthritides (SpA) is a heterogeneous condition characterized by chronic back pain, fatigue and progressive loss of mobility, associated to decreasing quality of life, physical and mental health. SpA patients may have a presence of non-specific gastrointestinal symptoms or subclinical intestinal inflammation. Although the association between SpA and high levels of distress has been investigated, few studies have included gastrointestinal involvement among the factors associated with mental health.

Objectives: To evaluate emotional functionality of patients with SpA, and their association with the presence of gastrointestinal symptoms and disease activity.

Methods: In total, 98 patients with SpA (fulfilling ASAS criteria) were assessed by rheumatologists. Patients with two or more gastrointestinal symptoms were referred to gastroenterology. Furthermore, those patients with SpA and con-

Conclusion: As reported in other studies, ours showed that structural damage in SA regardless the inflammatory biomarkers and the disease activity. This suggests that control of structural damage in SA requires smoking cessation.

REFERENCES:
[1] Zhao SS, Goodson NJ, Robertson S, Gaffney K. Smoking in spondyloarthri-

Figure 1. AUC at IL-8 between SA patients and healthy controls 0.855 (p<0.0001)
quality of life. These findings highlight the importance of a holistic monitoring towards remission of SpA patients ensuring an emotional functional balance. **Acknowledgements:** The Ministry of Science, Technology, and Innovation - MinCiencias (Grant No. 130877757442). Hospital Militar Central (Grant 2017-023), Clinics IPS, Gastroavanced, Fundación Instituto de Reumatología Fernando Chalem-Bogota, Colombia and Biomedicina de Chihuahua, México **Disclosure of Interests:** Ángelo Arzuaga: None declared, Julián Andres Sucerquia Quintero Employee of: Novartis de Colombia Janssen - Citag. Juan Manuel Bello-Gualtero: None declared, Juliette De Avila: None declared, Wilson Alusta-Molano: None declared, Consuelo Romeo-Ro-Sánchez: None declared. Janssen - Cilag, Juan Manuel Bello-Gualtero: None declared, Juliette De Avila: None declared, Wilson Alusta-Molano: None declared, Consuelo Romeo-Ro-Sánchez: None declared. **DOI:** 10.1136/annrheumdis-2022-eular.4207

**AB0863**  
**EMERGENCE OF SPONDYLOARTHRITIS FOLLOWING B CELL-DEPLETING MONOCHELONAL ANTIBODY THERAPY FOR MULTIPLE SCLEROSIS**

T. Pham1, P. Caroliné1, P. Lafforgue1, C. Barra2, A. Maarouf2, J. Pelleiter2, A. Rico2, B. Audoin2, F. Azix Marseille Univ, APHM, Rheumatology, Marseille, France, 2Hospital Saint Joseph, Rheumatology, Marseille, France, 3Aix Marseille Univ, APHM, Neurology, Marseille, France. **Background:** Anti-CD20 B cell-depleting therapies, including rituximab and ocrelizumab, have demonstrated their efficacy in patients with relapsing–remitting multiple sclerosis (RRMS). **Objectives:** Herein we report a series of patients with RRMS treated with anti-CD20 monoclonal antibodies (mAb) who developed de novo spondyloarthritis (SpA). **Methods:** Following the presentation of an index case, we collected all cases of de novo SpA in the anti-CD20-treated RRMS cohort of our institution's referral center. Clinical, biochemical, and imaging characteristics of the cases were identified through a clinical assessment. Information was collected via a standardized form to obtain key characteristics on the onset and type of disease development at baseline and on outcomes up to 12 months. All patients had a magnetic resonance imaging (MRI) of the sacroiliac joints and, depending on the clinical presentation, a spine MRI and/or a musculoskeletal grayscale and power Doppler (PD) ultrasound (US) examination. **Results:** De novo SpA developed in 6 of 480 patients with RRMS treated with anti-CD20 mAb, accounting for an incidence of 1.25%. All but one received rituximab treatment. The median time from the last anti-CD20 mAb infusion to SpA onset was 1.5 months [IQR: 1–4]. At the time of SpA emergence, the RRMS activity was controlled. The most frequent clinic SpA phenotype identified was peripheral SpA (4/6), with Power Doppler ultrasound-detected synovitis. The 2 patients with axial SpA phenotype had bilateral sacroilitis on MRI. Five of the 6 patients had a personal or family history of psoriasis, whereas the prevalence of psoriasis in the entire RRMS cohort was 3.33% (16/480). No other extra-articular manifestation was observed. All patients were HLA-B27 negative and fulfilled at least one classification criteria of SpA. None required hospitalization and the SpA onset did not affect the management of MS. The 2 patients with axial SpA were successfully treated with NSAIDs. Among the patients with peripheral SpA, 3 of 4 had inadequate response to NSAIDs, 2 were treated with methotrexate and 1 with leflunomide. Only one patient required initiation of an IL-17 inhibitor to control the SpA activity. **Conclusion:** We report a pattern of patients with MS successfully treated with B cell-depleting drug developing axial or peripheral SpA, predominantly HLA-B27 negativity and associated with psoriasis. **Disclosure of Interests:** None declared. **DOI:** 10.1136/annrheumdis-2022-eular.4211

**AB0864**  
**A NOMOGRAM MODEL COMBINING INFLAMMATORY FACTORS AND MRI RADIONICS TO ASSESS THE DISEASE ACTIVITY OF THE PATIENTS WITH AXSpA IN A PROSPECTIVE STUDY**

L. Ye1, D. Chen1, S. Mao2, G. Zhu3, M. Zheng4, C. Pan1, C. Ye1. 1First Affiliated Hospital, Wenzhou Medical University, Rheumatology, Wenzhou, China; 2First Affiliated Hospital, Wenzhou Medical University, Radiology, Wenzhou, China **Background:** Clinical and magnetic resonance imaging (MRI) disease activity score (DAS) are measuring different aspects of axial spondyloarthritis (axSpA), they are essential in disease activity assessment. The radionics was on facilitating readings by clinical specialists via enhancing the medical images in which subtle data differences could be distinguished. **Objectives:** If the additional information of MRI imaging can be considered as a predictor for axSpA disease activity? In this study, we sought to construct a nomogram integrating the sacroiliac joint (SJ)- MRI radionics features and the inflammatory biomarkers to assess disease activity and compare it with clinical disease activity index in axSpA patients. **Methods:** 203 patients data were collected prospectively and confirmed as axSpA were randomly divided into training (n = 143) and validation cohorts (n = 60). 1316 radionics features were extracted from the 3.0T SJ-MRI. A Nomogram model was constructed using multivariate logistic regression analysis Incorporating independent clinical factors and radionics features score (Rad-score). The performance of clinics, Rad-score and nomogram models were evaluated by ROC analysis, calibration curve and decision curve analysis (DCA), and compared with the disease activity index (Ankylosing Spondylitis Disease Activity Index (ASDAS)-C reactive protein (CRP), ASDAS-erythrocyte sedimentation rate (ESR), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI)) and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scoring system. **Results:** The Rad-score allowed a good discrimination in the training (AUC, 0.91; 95% CI, 0.85-0.96) and the validation cohort (AUC, 0.84; 95% CI, 0.73-0.96). The CRP-radionics nomogram model also showed favorable discrimination in the training (AUC, 0.96; 95% CI, 0.93-0.99) and the validation cohort (AUC, 0.89; 95% CI, 0.80-0.99), better than BASDAI(AUC, 0.58), ASDAS-CRP(AUC, 0.72), ASDAS(1.00), Bath Ankylosing Spondylitis Disease Activity Score (BASFI)(AUC, 0.73), had no statistical difference with SPARCC(AUC, 0.87). Calibration curves and DCA demonstrated the nomogram fit well (p > 0.05) and was useful for activity evaluation. **Conclusion:** Rad-score showed good discriminative ability to assess disease activity in axSpA. The nomogram can increase the efficacy for assessment axSpA disease activity, which might simplify clinical evaluation. **REFERENCES:**


**AB0865**  
**THE FACTORS AFFECTING PATIENT GLOBAL ASSESSMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS**

E. Durak Ediboglu1, D. Solmaz1, H. Cinakli1, G. Alp1, E. Olman Akat1, E. Erpek1, I. Kurut Aydin1, S. Gucermez2, S. Ketenci1, O. Bayındır1, M. Ozmen1, S. Akar1. 1İzmir Katip Celebi University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey **Background:** The BASDAI is one of the basic scales used in the measurement of disease activity in patients with spondyloarthritis and allows the evaluation of various aspects of the disease (axial and peripheral disease as well as...
inflammation). The patient global assessment (PGA) is a one-dimensional scale in which patients evaluate how their illness affects their health.

**Objectives:** In this study, we planned to test and review the possible determinants of PGA and its relation with BASDAI components, BASFI scores and disease-related features both at first visit and at the 2 year follow-up.

**Methods:** Patients with axSpA whose baseline BASDAI and PGA scores were completed, were included in the analysis. The demographic, clinical and laboratory characteristics of the patients were recorded. The relation between PGA scores and BASDAI sub-score, BASFI score and other patient and disease characteristics were tested both univariate and multivariate analysis methods. The factors affecting the change in the PGA score over 2-year follow-up were also analyzed with GEE analysis method.

**Results:** In total 313 patients (56.5% of male, 61.7% AS, mean age at diagnosis 34.3±11 years) were included in the analysis. Sperman’s rho test was used for correlation analysis. Baseline PGA scores were in correlation with the BASDAI total score (rho:0.71, p<0.001), PGA scores of female patients were found to be significantly higher (p=0.037) and each BASDAI indivual score and BASFI scores were moderately well correlated with PGA (Table 1). Multivariate analysis revealed that spinal pain (BASDAI Q2), the severity of morning stiffness (BASDAI Q5) and BASFI scores were the main determinants in the global health total score (rho:0.71, p<0.001). PGA scores of female patients were found to be significantly higher (p=0.037) and each BASDAI indivual score and BASFI scores were moderately well correlated with PGA. The patient global assessment is a unidimensional scale in which patients evaluate how their illness affects their health.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4518

---

**AB0867**

**PARTICULARITIES OF UVEITIS ASSOCIATED WITH SPONDYLOARTHRITIS: DATA FROM THE MOROCCAN RBSMR REGISTRY**

I. Roki Chaoui1, N. Akasbi1, E. Mezoour1, R. Aboouagi2, L. Chehmiel3, F. Allali4, R. Bahini5, I. E. Bouchti6, I. Ghozlian7, H. Hassikou8, I. Hamouchi9, I. Lina10, R. Mkindi11, T. Harzy1, Hassan II University Hospital, University Sidi Mohamed Ben Abdellah, Faculty of Medicine and Pharmacy, Rheumatology, Fez, Morocco; 2Mohammed V University, Faculty of Medicine and Pharmacy, Laboratory of Biostatistical, Clinical and Epidemiological Research, Rabat, Morocco; 3Military Hospital Mohammed V, Ibn Sina University Hospital, Rheumatology, Rabat, Morocco; 4El Ayachi Hospital, Ibn Sina University Hospital, Rheumatology, B. Saïd, Morocco; 5El Ayachi Hospital, Ibn Sina University Hospital, Rheumatology, A. Saïd, Morocco; 6Arrazi University Hospital, Rheumatology, Marrakech, Morocco; 7Private Medical Office, Rheumatology, Rabat, Morocco; 8University Hospital of Agadir, Rheumatology, Agadir, Morocco; 9Military Hospital Moulay Ismail, Hassan II University Hospital, Rheumatology, Meknes, Morocco; 10Provincial Hospital of Temara, Rheumatology, Temara, Morocco; 11Mohammed VI University Hospital, Rheumatology, Oujda, Morocco; 12Idan Rochy University Hospital, Rheumatology, casablanca, Morocco; 13Military Hospital Avicenne, Mohammed VI University Hospital, Rheumatology, Marrakech, Morocco

**Background:** Acute anterior uveitis is the most frequent extra-articular manifestation in spondyloarthritis (SpA). [1] **Objectives:** The purpose of this study is to assess the prevalence of uveitis during SpA and to identify associated factors with its presence.

**Methods:** A cross-sectional multicentric observational study was conducted; the main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR registry). Patients, included from May 2017 to January 2019, were all adult patients (age > 18 years old), presenting SpA, according to ASAS (Assessment of Spondyloarthritis International Society) classification criteria for SpA 2010.

Demographic and clinical characteristics, disease activity, radiographic damage and functional ability have been compared between two groups of patients: Patients with SpA suffering from uveitis and patients without uveitis. General and specific data regarding uveitis were collected.

**Results:** 194 patients were included in the study. The mean age was 40.22 ± 13.68 years. The sex ratio was 1, 7 (man:woman). The mean duration of disease was 615.90 ± 349.12 weeks.

96.4 % of the patients had axial involvement, 70 % had peripheral involvement and 61.5 % had enthesitis involvement. SPa was radiographic in 88.1 % of the cases and coxitis was found in 40.9 %. The mean erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was 39.04 ± 27.16 mm/h and 32.87 ± 20.64 mg/l, respectively. HLA B27 was positive in 34 % of patients. The mean CRP rate (ESR) and C-reactive protein (CRP) was 39.04 ± 27.16 mm/h and 32.87 ± 20.64 mg/l, respectively. HLA B27 was positive in 34 % of patients. The mean CRP was 29.8 % in female with SpA and 12.6 % in male (p = 0.026).

**Conclusion:** Acute anterior uveitis is the most frequent extra-articular manifestation in spondyloarthritis (SpA). The presence of uveitis in Moroccan patients diagnosed with SpA wasn’t associated with specific characteristics. Even though, its screening is systematic because it conditions the treatment.

**REFERENCES:**


---

**AB0866**

**WOMEN SPONDYLOARTHRITIS: EPIDEMIOLOGICAL, CLINICAL AND PARACLINICAL CHARACTERISTICS**

H. Bara1, H. Arabi1, A. Rat1, A. Mouguia, I. El Bouchti1, 1CENTRE HOSPITALIER-UNIVERSITAIRE MOHAMMED VI MARRAKECH, Rheumatology, Marrakech, Morocco

**Background:** Spondyloarthritis (SpA) is a chronic inflammatory rheumatism characterized by sacroiliitis and spinal involvement, affecting both genders but more frequent in males.

**Objectives:** The aim of this study is to analyze the epidemiological, clinical and paraclinical characteristics of Spondyloarthritis in women.

**Methods:** Retrospective study included 333 patients followed up for SpA at the Rheumatology Department between 2004 and 2021.

**Results:** Our study involved 153 women and 180 men. In the female population, the mean age was 45.1 years, 12.4% had high blood pressure, 4.8% had a psychiatric comorbidity and none of the patients were smokers, versus a mean age of 36.4 years, 5% of high blood pressure patients, 1.7% having a psychic comorbidity and 25% of the smokers for the male with SPA. The age of onset of symptoms was 36.5 years for women versus 28 years for men (p = 0.001). Axial involvement was 84.3% in women and 85% in men, while peripheral and enthesial involvement was present in 73.8% and 56.8% of female subjects and 58.8% and 46.6% of male subjects (p = 0.004 and 0.064 respectively). Coxitis was present in 13.1% and syndesmophytsis in 15.3% of females versus 36.1% and 18.3% of males (p at 0.001 and 0.4 respectively). Mean erythrocyte sedimentation rate was 45.7, mean CRP 28.5 and mean calcemia 92 in the 1st group versus 43.40.6 and 93.4 in the 2nd (p at 0.4; 0.03 and 0.03 respectively). Relapse was 29.8% in female with SpA and 12.6% in male (p = 0.026).

**Conclusion:** In our study, females SpA patients developed symptoms later than did males, peripheral and enthesial involvement is more common in females while coxitis is more common in males with statistically significant higher CRP and calcemia.

**REFERENCES:**


Disclosure of Interests: None declared

**AB0868**

PREVALENCE AND RISK FOR BUNDLE BRANCH BLOCK, ATRIOVENTRICULAR BLOCK AND PACEMAKER IMPLANTATION IN SPONDYLOARTHRITIS. A SYSTEMATIC REVIEW OF THE LITERATURE

H. S. Park¹, A. Laiz¹, P. Díaz del Campo Fontechea², M. A. Martín Martínez², M. Guerra-Rodríguez³, C. Alonso Martín⁴, J. Sanchez-Vega⁴, H. Corominas¹,²,³

¹Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain; ²Societad Española de Reumatología, Unidad de Investigación, Madrid, Spain; ³Hospital de la Santa Creu i Sant Pau, Cardiology, Barcelona, Spain; ⁴Hospital de Bellvitge, Cardiology, Cardiac Imaging Unit, Barcelona, Spain; ⁵Hospital Dos de Maig, Rheumatology, Barcelona, Spain

**Background:** Inflammation of the valve attachment site may produce tissue degeneration near the atrioventricular node, which may lead to electrical conduction disturbances, that is to say atrioventricular block (AVB) and bundle branch degeneration near the atrioventricular node, which may lead to electrical conduction disturbances.

**Objectives:** To evaluate the evidence regarding the prevalence and risk of BB, AVB and pacemaker implantation (PMI) in patients with spondyloarthritis (SpA) compared to a control group without SpA.

**Methods:** A systematic review of the literature was performed using PubMed (Medline), EMBASE (Elsevier) and Cochrane Library (Wiley) databases until December 2021. The risk for AVB, BBB and PMI were analyzed. Cohort, case control and cross-sectional studies in patients ≥18 years meeting the classification criteria for SpA were included. The Odds ratio (OR), risk ratio (RR) or Hazard ratio (HR) were considered as outcomes. Data was synthesized in a previously defined extraction form. The risk of bias was assessed by the Newcastle-Ottawa Scale.

**Results:** In total, eight out of 374 studies were included. As for low grade AVB and BBB, only indirect results comparing prevalences from low to medium quality studies were found. According to population based registries, the sex and age adjusted HR of AVB was 2.3 (95% CI 1.6 - 3.3) in ankylosing spondylitis, 2.9 (95% CI 1.8 - 4.7) in undifferentiated spondyloarthritis and 1.5 (95% CI 1.1 a 1.9) in psoriatic arthritis. The RR for PMI was 1.3 (95% CI 1.16 - 1.46) for groups aged between 65-69 years, 1.33 (95% CI 1.22 - 1.44) for 70-75 years, 1.24 (95% CI 1.55 - 1.33) for 75-79 years and 1.11 (95% CI 1.06 - 1.17) for groups older than 80 years.

**Conclusion:** The differences of prevalence in AVB and BBB were similar in SpA and control groups even though studies lacked the power. According to population registries there was an two fold-increased risk of high grade AVB in SpA patients. RR for PMI was higher in younger age groups.

**Disclosure of Interests:** Hye Sang Park: None declared, Ana Laiz Speakers bureau: A.L. has received speaker fees/honoraria from Abbvie, Lilly, Novartis, Pfizer and UCB, Petra Diaz del Campo Fontecha: None declared, Mag Ayuilladora Martin Martinez: None declared, Mercedes Guerra-Rodriguez: None declared, Concepcion Alonso Martin: None declared, Jesus Sanchez-Vega: None declared, Hector Corominas Speakers bureau: H.C. has received speaker fees/honoraria from BMS, Geno, MSD, Lilly, Novartis, Pfizer, Roche, Sanofi, and UCB, Consultant of: H.C. has participated in consulting for Abbvie, Argen, Bio- gen, Celgene, Gilead, Kern, Pfizer and Sanofi.

**AB0869**

IMPORTANCE OF SCREENING OF TRADITIONAL CARDIOVASCULAR RISK FACTORS IN SPONDYLOARTHRITIS

A. Ben Tekaya¹,², T. Mehme¹,², O. Saidane¹,², S. Bouden¹,², R. Leila¹,², R. Tekaya¹,², I. Mahmoud¹,², L. Abdelmoula¹,², Charles Nicolle Hospital, Rheumatology Department, Tunis, Tunisia; ¹University Tunis El Manar, Faculty of medicine of Tunis, Tunisia

**Background:** Epidural adipose tissue has been associated with the development of coronary artery disease and recently suggested as a novel marker for evaluating subclinical atherosclerosis.

**Objectives:** The aim of our study was to assess the relationship between EFT and cardiovascular risk parameters in patients with spondyloarthritis (SpA).

**Methods:** We performed a case control study including patients meeting ASAS 2009 criteria for SpA, and healthy controls. Subjects were aged less than 50 years old and without traditional cardiovascular risk factors. Clinical features related to the disease were recorded. Anthropometric data (body mass index (BMI), waist circumference and hip circumference) and arterial blood pressure of the patients were also recorded. Blood specimens were collected after 12 hours of fasting and total cholesterol, HDL, LDL, triglyceride and fasting glucose were measured. Total cholesterol to HDL ratio and LDL to HDL ratio were calculated. All subjects underwent Doppler echocardiography with measurement of EFT by an experienced cardiologist.

**Results:** We enrolled 47 SpA patients and 47 controls. Subjects were age, sex and BMI matched (p=0.267, p=0.589 and p=0.238 respectively). Median disease activity scores BSAASD and ASDAS-CRP were 2.6 (IQR 25-75%: 1.8-3.8) and 2.18 (IQR 25-75%: 1.62-2.91) respectively. Median waist and hip circumference

**Disclosure of Interests:** None declared, Hector Corominas Speakers bureau: H.C. has received speaker fees/honoraria from Abbvie, Lilly, Novartis, Pfizer and UCB, Petra Díaz del Campo Fontecha: None declared, Mª Auxiliadora Martín Martínez: None declared, Mercedes Guerra-Rodriguez: None declared, Concepción Alonso Martín: None declared, Jesus Sanchez-Vega: None declared, Hector Corominas Speakers bureau: H.C. has received speaker fees/honoraria from BMS, Geno, MSD, Lilly, Novartis, Pfizer, Roche, Sanofi, and UCB, Consultant of: H.C. has participated in consulting for Abbvie, Argen, Biogen, Celgene, Gilead, Kern, Pfizer and Sanofi.

**Scientific Abstracts**

<table>
<thead>
<tr>
<th>Author</th>
<th>Study design</th>
<th>Population</th>
<th>Sample number</th>
<th>Test</th>
<th>Outcomes</th>
<th>Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baniaamam 2021[6]</td>
<td>Cross sectional</td>
<td>AS and osteoarthritis between 50-75 years</td>
<td>267</td>
<td>ECG</td>
<td>Prevalence of AVB, BBB and PMI</td>
<td>Controls matched for age, sex and smoking status</td>
</tr>
<tr>
<td>Bengtsson 2017[12]</td>
<td>Cohort</td>
<td>AS, uSpA, PsA, GP from the Swedish national registry</td>
<td>291436</td>
<td>ICD-10</td>
<td>Prevalence, Incidence, HR, for AVB and PMI compared to GP</td>
<td>Age, sex</td>
</tr>
<tr>
<td>Dik 2010[9]</td>
<td>Cross sectional</td>
<td>AS</td>
<td>131</td>
<td>ECG</td>
<td>Prevalence of AVB and BBB</td>
<td>Age, sex, disease duration</td>
</tr>
<tr>
<td>Feld 2008[10]</td>
<td>Case control</td>
<td>PsA compared to non psoriatic non arthritic patients</td>
<td>184</td>
<td>ECG</td>
<td>Prevalence of AVB, BBB</td>
<td>None</td>
</tr>
<tr>
<td>Fu 2016[8]</td>
<td>Cross sectional</td>
<td>AS between 18-60 without cardiac disease</td>
<td>122</td>
<td>ECG</td>
<td>Prevalence of AVB, BBB</td>
<td>None</td>
</tr>
<tr>
<td>Ward 2018[7]</td>
<td>Cross sectional</td>
<td>AS from Medicare database older than 65</td>
<td>42,327</td>
<td>ICD-9</td>
<td>Prevalence, incidence, OR of PMI</td>
<td>Age, sex, race</td>
</tr>
</tbody>
</table>
were 88 cm (IQR 25-75%: 82-97) and 100 cm (IQR 25-75%: 91-97), respectively. Median systolic (SBP) and diastolic (DBP) blood pressure were respectively 121 mmHg (IQR 25-75%: 110-130) and 71 mmHg (IQR 25-75%: 67-78). Laboratory findings showed a median fasting glucose level (FG) of 4.93 mmol/l (IQR: 4.25-4.75), 5.5; 5.1. Median total cholesterol (CT), HDL, LDL and triglyceride levels were respectively 3.66 mmol/l (IQR: 25-75%: 3.18-4.28), 1.08 mmol/l (IQR: 25-75%: 0.92-1.21), 2.17 mmol/l (IQR: 25-75%: 1.78-2.6) and 0.84 mmol/l (IQR: 25-75%: 0.79-1.15). CT/HDL ratio and LDL/HDL ratio were 3.48 (IQR 25-75%: 2.95-3.97) and 1.99 (IQR 25-75%: 1.54-2.48), respectively.

Median EFT was significantly increased in patients compared to controls (3.1 mm (IQR: 2.5-4) versus 2.4 mm (IQR: 2-3), p=0.001). A positive correlation was found between EFT and SBP (p=0.028; r=0.323) and triglyceride level (p=0.022, r=0.349). In contrast, EFT was not associated with DBP (p=0.069, r=0.270), BMI (p=0.223, r=0.181), waist circumference (p=0.114, r=0.234), hip circumference (p=0.451, r=0.113), CT (p=0.127, r=0.236), HDL (p=0.587; r=0.085), LDL (p=0.342; r=0.149), FG (p=0.104, r=0.248), CT/HDL ratio (p=0.418; r=0.128) and LDL/HDL ratio (p=0.683, r=0.064).

In multivariate linear regression, triglyceride level was identified as an independently predictor of increased EFT (B=0.676; 95% confidence interval = 0.209-1.143; p=0.006).

Conclusion: The importance of our results that we identified a traditional cardiovascular risk factor as a predictor of subclinical atherosclerosis in SpA without cardiovascular risk factor and with normal triglyceride level. This finding highlights the importance of regular screening for traditional cardiovascular risk parameters even in the disease with low activity.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eur.4781

AB0870  ASSESSMENT OF FRACTURE RISK IN PATIENTS WITH NON-RADIODGRAPHIC AXIAL SPONDYLOARTHRITIS

H. Ferian1, O. Bouguidua2, W. Tikri3, D. Ben Nessib3, K. Maatallah3, D. Kaffel3
1Kassab orthopedics institute, Rheumatology department, Ksar Said, Tunisia; 2Kassab orthopedics institute, Rheumatology department, Ksar Said, Tunisia; 3Kassab orthopedics institute, Rheumatology department, Ksar Said, Tunisia

Background: Spondyloarthritis (SpA) is a chronic inflammatory disease that predominantly affects the sacroiliac joints and the spine. Patients with SpA have an increased risk of osteoporosis and fracture resulting from a combination of inflammation and immobility. The non-radiographic form for SpA (nr-axSpA) has the same predictors of bone fragility however the real fracture risk is unknown in this phenotype.

Objectives: The main objective of our study was to assess fracture risk in patients with nr-axSpA.

Methods: We conducted a retrospective study including 40 patients with nr-axSpA, according to the ASAS criteria. For the enrolled patients, we collected the clinical and biological data and calculated the disease activity using the Bath Ankylosing Spondylitis disease activity (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS).

Functionnal impairment was assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI). We measured the bone mineral density using the dual-energy X-ray absorptiometry (DXA) in the anteroposterior lumbar, lateral spine, and hip joint.

Results: Twenty-seven women (67.5%) and thirteen men (32.5%) were enrolled. The mean age was 41.5 years (±11.2), and the mean disease duration was 3.1 years (±2.7). The mean BASDAI and ASDAS CRP was 4.7 ± 2.5 and 3.6 ± 2.5. The mean BASFI was 3.6 ± 2.5. According to World Health Organization (WHO) criteria, 45% of patients displayed osteopenia and 30% osteoporosis. The mean major osteoporotic fracture (MOF) score was 0.09 ± 0.25 [0-1.3]. The MOF was significantly associated with radiographic hip involvement, and an inverse relation-ship with age at onset (OR 0.955, IC 0.995-0.998, p=0.038).

Conclusion: The major osteoporotic fracture was 0.09 ± 0.25 [0-1.3]. The MOF was significantly associated with radiographic hip involvement and 52 patients were without hip involvement. Multivariate logistic regression analyses showed male sex (OR 3.63; 95% CI 1.55-26.29, p=0.010), Bath Ankylosing Spondylitis Functional Index (BASFI) score (OR 0.436, IC 0.709-1.913, p=0.013), and BASRI-spine score are associated with radiographic hip involvement. AS patients with risk factors for radiographic hip involvement should be diagnosed at an early stage to improve their quality of life.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eur.4851

AB0872  INFLUENCE OF JOINT AND ENTHESIS DAMAGE ON THE QUALITY OF LIFE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES.

G. Gainullina1, E. Kirillova1, A. Odincova1, D. Abdulganieva1,1Kazan State Medical University, hospital therapy, Kazan, Russian Federation; 2Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, gastroenterology, Kazan, Russian Federation

Background: Inflammatory bowel diseases (IBD) are chronic immune-inflammation diseases that are often associated with various extraintestinal manifestations [1]. Among them, joint involvement is the most common, occurring in 5–20% of patients with IBD [1], while the prevalence of enthesitis varies in studies from 12.5% to 90% of cases [2].

Objectives: To assess the relationship between the state of peripheral joints and entheses in patients with IBD and their quality of life.

Methods: 95 pts with IBD were prospectively enrolled into the study: 55 of them with ulcerative colitis (UC) and 40 with Crohn’s disease (CD). The average age of the pts was 32 (26; 37) years. The average duration of the disease was 44 (12; 95) months. The severity of UC exacerbation was assessed by the Mayo index, in CD – by Harvey-Bradshaw index. In UC, moderate and severe exacerbation was revealed in 40 pts (73%), in CD - in 17 (43%). Among 95 pts with IBD, extraintestinal manifestations occurred in 67 pts (71%), of which 34 (82%) pts with UC and 33 (82%) pts with CD. 14 joints and 68 entheses were evaluated clinically and by US in each pt. The clinical examination included tenderness of enthesis. US examination with power Doppler detected synovitis with / without vasculatization, inflammatory (hypoechochogenicity of enthesis, thickening of enthesis, presence of vascularization) and structural (erosion, entheseophyte) changes in enthesis. The quality of life was assessed using the SF-36 questionnaire that covers eight health domains. Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state. Spearman coefficient used to calculate correlations.

Results: 61 pts with IBD (64%) complained of pain in the joints, 49 pts (52%) noted pain on palpation of entheses. As a result of ultrasound examination, synovitis were detected in 41 pts (43%), including synovitis with vascularization in 20 pts (31%). Enthesitis were found in 72 pts (78%), while vasculatized enthesis was detected in 35 pts (37%). Erosions were identified in 76 pts (80%), and entheseophytes were identified in 37 pts (39%). The average level of physical health was 43.53 (35.67; 51.66), mental health 38.53 (31.13; 48.37).

An inverse correlation was observed between the number of extraintestinal manifestations and physical functioning (SR–0.22; p=0.03). The number of painful joints was inversely correlated with physical functioning (SR=
-0.22; p = 0.036). The number of painful entheses was inversely correlated with physical functioning (SR = -0.26; p = 0.01), physical health (SR = -0.21; p = 0.03). An inverse correlation was observed between the number of synovitis with vascularization and physical functioning (SR = -0.28; p = 0.01), vital activity (SR = -0.29; p = 0.005), physical health (SR = -0.23; p = 0.024). The number of entheses was inversely correlated with the pain intensity (SR = -0.22; p = 0.036).

Conclusion: With an increase in the number of affected joints and enthesis, the physical health of pts decreases, due to physical functioning and pain intensity, as well as their vital activity.

REFERENCES:

Disclosure of Interests: None declared

AB0873
ETHNICITY AND PATIENT REPORTED OUTCOME BASDAI IN THE MONITORING OF AXIAL SPONDYLOARTHROPATHY: DOES IT MATTER?
S. Buvayan1, S. Jothimurugan2, A. Moorthy3. 1University Hospitals of Leicester, Rheumatology, Leicester, United Kingdom; 2University Hospitals of Leicester, Medicine, Leicester, United Kingdom; 3University of Leicester, College of Life Sciences, Leicester, United Kingdom

Background: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is a patient reported outcome (PRO) used in the monitoring of axial spondyloarthritis (axSpA). It is completed by the patient and based on their assessment of disease severity and therefore quite a subjective measure of disease (1). There has been research around the relationship between ethnicity and patient perception in Rheumatology. Many studies have demonstrated that non-Caucasian patients especially South Asians are less likely to engage with patient education, abandon their disease modifying therapy early and have more mistrust with the medical establishment (2). Quite a large population study in America examining axSpA severity in Caucasians, Afro-Caribbean’s and Latinos found Afro-Caribbean and Latino patients to score themselves higher on BASDAI compared to Caucasians (3). With Leicester being such a diverse area, with a particularly high South Asian population we took this opportunity to investigate whether there were ethnic variations in disease severity.

Objectives: The aim was to investigate whether there is a relationship between patient-reported outcome BASDAI and ethnicity. The secondary aim was to investigate the relationship between ethnicity and radiographic findings and extra-articular manifestations.

Methods: Data was collected by retrospective analysis of axSpA patients attending University of Leicester (UHL) axSpA services. Inclusion criteria entailed a diagnosis of axSpA with a documented BASDAI within a year of MRI spine + sacroiliac joints, prior to starting any biological treatment. Data of 149 patients was collected on demographic characteristics, extra-articular manifestations (uveitis, inflammatory back pain, enthesitis, peripheral arthritis, dactylitis, psoriasis, and inflammatory bowel disease), family history, response to NSAIDs, and HLA-B27 status. Data was analysed using Statistical Package for the Social Sciences (SPSS) software to assess the relationship between ethnicity and collected data using Pearson’s chi squared.

Results: Of the 149 patients 68% were White Caucasian, 30% Asian and 1% Black. The average age was 43 and 66% were male and 34% female. The mean BASDAI was 6.5, there was no observable correlation between BASDAI and ethnicity (p=0.668). There was no significant relationship between ethnicity and active sacroiliitis (p=0.926), chronic sacroiliitis (p=0.218) or axial disease (p=0.307). 64 Caucasian patients were HLA-B27 positive compared with 27 Asian and no Black patients were positive however there was no statistical correlation between ethnicity and HLA-B27 (p=0.383). Overall, Caucasians consistently had a higher incidence of extra-articular manifestations compared with non-Caucasians however no significant p values were observed here or with response to NSAIDs, family history or familial HLA-B27 and BASDAI scores, results are summarised in Table 1.

Table 1. Correlation with ethnicity and extra-articular manifestations, family history and HLA-B27.

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Correlation with ethnicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>p = 0.470</td>
</tr>
<tr>
<td>Peripheral arthritis</td>
<td>p = 0.304</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>p = 0.959</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>p = 0.062</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>p = 0.947</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>p = 0.213</td>
</tr>
<tr>
<td>Family history of axSpA</td>
<td>p = 0.383</td>
</tr>
<tr>
<td>HLA-B27 in family</td>
<td>p = 0.221</td>
</tr>
<tr>
<td>HLA-B27+ Human leucocyte antigen B27</td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

AB0874
TARSITIS IN MEXICAN PATIENTS WITH SPONDYLOARTHRITIS
L. D. Fajardo Harmosillo1, 1Centro Médico Nacional de Occidente IMSS, Rheumatology, Guadalajara, Mexico

Background: Spondyloarthritis (SpA) is a set of autoimmune and auto-inflammatory diseases that share similar manifestations of axial spine and sacroiliac, peripheral joint including oligoarthropathies predominantly of lower limbs, dactylitis, enthesitis and fasciitis, and extraarticular manifestations involvement eyes, skin, nails, bowel and the presence of high c-reactive protein (CRP) levels and Human Leucocyte Antigen (HLA)-B27 seropositivity. Peripheral manifestations such tarsitis (mid-foot arthritis) has been reported associated to ankle arthritis, Achilles tendon enthesitis and plantar fasciitis, besides linked mainly to juvenile-onset forms of SpA (1,2). Tarsitis occurs more frequently in SpA patients of Latin American (23.6%), Asia (9.1%) and less commonly in SpA patients of Europe and North America (5%) and middle-east and North Africa (3.5%) [1,2]. This mid-foot inflammation has not been completely well described in the adult population with SpA, specifically in Mexican adult population [3]. Here is presented the frequency and factors associated to tarsitis in Mexican adult patients with SpA.

Objectives: To determine the frequency and factors associated to tarsitis in Mexican SpA patients.

Methods: That is a cross-sectional, comparative a retrospective study including 211 (≥18 years) Mexican SpA patients recruited from 2012 to 2021 that fulfilled ASAS criteria. Patients with or without presence of tarsitis are included. This work explores demographic factors, clinical features, c-reactive protein levels and pharmacologic treatments in Spa patients with or without tarsitis. It use Chi-square, Student’s-t, U Mann-Whitney tests to univariate analysis and logistic regression to multivariate analysis adjusted for age and gender. The level of significance of statistical tests is less of 5%.

Results: The present investigation involves 211 patients with SpA and 62.6% of them are men. The mean age [standard deviation (SD)] is 43.72 (13.5) years. The mean of age at onset of SpA (SD) is 31.93 (11.3) years. The SpA distribution is axial (42.2%), peripheral (27%) and both (30.8%). A total of 63 (29.9%) patients has tarsitis, of them
AB0875 - ASSESSMENT OF CLINICAL SIGNS OF SPONDYLOARTHRITIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

E. Belousova1, D. Abdulganieva1, M. Protopopov2. 1Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation; 2Charité – Universitätsmedizin Berlin, Rheumatology, Berlin, Germany

Background: Patients with inflammatory bowel disease (IBD), Crohn’s disease (CD) and ulcerative colitis (UC), commonly face the presence of extraintestinal manifestations (EIMs). Spondyloarthritides (SpA) is present in about 10-39% of patients with IBD, being the most frequent EIM [1]. Diagnosis of axial SpA (axSpA) in IBD represents a clinical challenge. The diagnostic value of Ankylosing Spondylitis Assessment Society (ASAS) criteria that are used for defining inflammatory back pain (IBP) in axSpA, in patients with the association of axSpA and IBD is not clear.

Objectives: To determine the diagnostic value of ASAS criteria for IBP (2009) and to evaluate factors that are associated with a higher risk of axial SpA in patients with IBD.

Methods: The study included 91 patients with IBD (UC - 52 patients (57.1%), CD - 39 (42.9%), males - 47, (51.6%), mean age 40.2±11.7 years, duration of IBD - 77±7.6 years), IBP was defined by ASAS criteria (2009). AxSpA in patients with IBD is recommended to be diagnosed by the combination of Inflammatory Back Pain (IBP), and imaging (MRI and X-ray) [2]. Imaging of lumbar spine and sacroiliac joint was performed to patients, who fulfilled the ASAS criteria for IBP. X-ray - 55 patients; MRI (T1, STIR) - 41 patients. Imaging was considered positive when patients had at least unilateral sacroiliac stage 2 or higher according to the accepted grading system on X-Ray, or MIRI-verified sacroiliitis.

Results: Low back pain was observed in 84 (92.3%) patients with IBD, 39 (42.9%) patients fulfilled the criteria for ASAS for IBP. MRI-verified sacroiliitis was present in 26 patients. Changes on X-ray were present in 40 patients. After imaging, 26 patients were diagnosed with axSpA, 14 of them fulfilled the modified New York criteria for the ankylosing spondylitis. Diagnostic value of the ASAS criteria was the following: sensitivity 76.9%, specificity 62.2%, PPV 0.51, NPV 0.87, LR+ 2.3, LR- 0.3 (ECOG consensus definition used as the “gold standard”). Presence of arthritis - OR 10.77 [95% CI 2.26-44.4], p=0.005, arthralgia - OR 4.12 [95% CI 1.55-10.95], p=0.005, CD - OR 2.92 [95% CI 1.14-7.48], p=0.025 and IBP - OR 8.07 [95% CI 2.8-23.23], p<0.001 was associated with a higher risk of axSpA diagnosis in the univariate analysis. No statistical significance was no difference between patients with and without USE regarding the disease duration, age at onset but those with USE showed less diagnostic delay (p = 0.03). Clinical enthesitis and peripheral arthritis were more frequent in those with USE (50% vs 22.7% and 25 vs 13.6% respectively). No significant statistical difference was found between the inflammatory, structural and total scores of USE and BASRI, BASFI and BASDAS (p > 0.05). No correlation could be detected between BASRI and USE scores (rs= 0.12, p=0.45 for inflammatory, =0.25, p=0.11 for structural and =0.18, p=0.20 for total score). There was a positive correlation between BASMI and both inflammatory and total scores of USE (rs= 0.485, p<0.003). No significant association between BASDAI, CRP or ESR and USE scores.

Conclusion: Ultrasonographic peripheral enthesal abnormalities couldn’t reflect the spinal radiographic changes or disease assessment parameters in patients with radiographic axial SpA. However, these results can be considered preliminary and more studies on wider scales are needed to support our findings.


AB0877 - QUANTIFICATION OF THE ENTHESIC RESPONSE TO BIOLOGICAL THERAPIES IN PATIENTS WITH SPONDYLOARTHRITIS BY COMPUTER ANALYSIS OF ULTRASOUND IMAGES.

M. Tortosa-Cababás1, C. Guillén-Asstete1, Á. Andreu-Suárez1. 1Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: Enthesitis is the base of the pathophysiology of spondyloarthritis. Recently, our group has shown that computer analysis of static images can be used in the evaluation of patients with enthesitis inflammatory diseases with good intra-patient and intra-observer validity and sensitivity to change.

Objectives: To determine the enthesic evolution in patients with spondyloarthritides (SpA) treated with three different biological therapies through the computer analysis of ultrasound images.

Methods: We selected patients diagnosed with SpA and enthesis followed by imaging, who started biological therapy with a TNF inhibitor, an IL17 inhibitor or an IL12/23 inhibitor. For the records to be included, it was necessary to have clinical information from the period of performing the ultrasound. All images were obtained from the Achilles tendon, with the same ultrasound equipment, grayscale and settings for each patient. To homogenize the results of the analysis, the grayscale intensity mean index (IMIG) was used, which has been shown to appropriately discriminate the enthesial pathology from the mechanical or healthy controls as well as being sensitive to change.

Results: 14 patients were included: 6 treated with a TNF inhibitor, 4 with an IL17 inhibitor and 4 with an IL12/23 inhibitor. Patients 2, 3, 5, 7, 10, 11, and 12 had enthesophytes.
In the global analysis, the IMIG did not show statistically significant differences between the treatment groups at the start of the treatment, at the intermediate and at the final evaluation (P=.588, .739 and .674, respectively). Patients with enthesophyses presented significantly higher baseline, intermediate and final IMIG than patients without them: 1.26 SD ± 0.14 vs 0.85 SD ± 0.05 (t=7.407, P=.001), 1.24 SD ± 0.15 vs 0.97 SD ± 0.01 (t=3.659, P=.006), and 1.21 SD ± 0.12 vs 1.05 SD ± 0.07 (t=2.342, P=.03), respectively. Analyzing only the patients without enthesophysis, the final IMIG showed statistically significant differences between the 3 administered treatments (ANOVA, F=8.142, P=.027), being relevant between the use of IL12/23 and TNF inhibitor in favor of the former (Bonferroni, P=.03). In the same subgroup of patients without enthesophysis, IMIG analysis over time showed statistically significant differences between final and baseline IMIG (Friedman -1.938, P=.000).

Conclusion: Computer analysis of ultrasound images using the IMIG distinguishes therapeutic responsive patients in patients without enthesophyses. The interposition of enthesophysis impedes the correct visualization of the enthesis and does not allow ultrasound changes to be detected in some areas of the image. Although there are indications that the use of this analysis could also predict the behavior of certain therapies, it is convenient to propose prospective studies with homogeneous ultrasound controls.

Disclosure of Interests: Marina Tortosa-Cabañas: None declared, Carlos Guillén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grunenthal, UCB and Gebro. Paid instructor for: Roche, Novartis, Janssen, Esteve and Menarini, Consultant of: Janssen, Novartis and Roche, Grant/research support from: Pfizer, Grunenthal, Gebro and Novartis, Africa Andreu-Suárez: None declared


Results: A total of 129 patients with r-axSpA were included in the study. No patient took supplements of vitamin D at baseline. Patients had an average age (mean±SD) of 36.5±10.5 years, 63.4% were males and 66.6% were HLA-B27 positive. The prevalence of vitamin D deficiency in our cohort was 54.3%. Patient characteristics and disease activity were comparable with regard to the presence of vitamin D at baseline (Table 1); with the exception of body mass index (BMI), which was higher in patients with vitamin D deficiency. In the multivariable linear regression analysis, baseline serum level of vitamin D was independently and significantly associated with higher change in BASDAI and ASDAS (Figure 1).

Table 1. Baseline characteristics of patients with radiographic axial SpA (n=129) according to vitamin D levels at baseline.

<table>
<thead>
<tr>
<th>Age, years</th>
<th>Patients with vitamin D deficiency (&lt;20ng/mL)</th>
<th>n=70</th>
<th>Patients with normal levels of vitamin D</th>
<th>n=59</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>46 (65.7)</td>
<td>37 (62.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.0±4.5</td>
<td>24.0±3.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking, ever</td>
<td>41 (58.6)</td>
<td>29 (49.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Winter and Spring, n (%)</td>
<td>33 (47.1)</td>
<td>23 (39.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASMI 3.1±1.5</td>
<td>2.7±1.3</td>
<td>10.3±7.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA-B27 positive</td>
<td>62 (88.6)</td>
<td>50 (84.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>uEvelitis ever</td>
<td>17 (24.3)</td>
<td>12 (20.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IBD ever, n (%)</td>
<td>2 (2.9)</td>
<td>7 (11.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>12.9±19.3</td>
<td>13.9±19.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASDAI</td>
<td>5.7±14</td>
<td>5.4±14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASDAS</td>
<td>3.4±0.8</td>
<td>3.5±0.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BASFI</td>
<td>4.6±2.2</td>
<td>4.4±1.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BAI smoldering</td>
<td>3.1±1.5</td>
<td>2.7±1.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAID intake, current</td>
<td>50 (71.4)</td>
<td>45 (76.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DMARDs intake, ever</td>
<td>9 (12.9)</td>
<td>6 (10.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF intake</td>
<td>55 (78.6)</td>
<td>47 (78.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corticoids intake, current</td>
<td>5 (7.1)</td>
<td>2 (3.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Association between the response to bDMARDs (change in BASDAI and ASDAS after 6 months) and level of vitamin D at baseline in patients with radiographic axial SpA in the multivariable regression analysis.

Conclusion: Higher vitamin D levels at baseline may predict a better treatment response to bDMARDs in patients with r-axSpA. It has to be shown, however, if vitamin D supplementation might result in a better treatment response in axial SpA.

Disclosure of Interests: None declared

Psoriatic arthritis - treatment

**AB0879 INTERIM ANALYSIS OF BASELINE CHARACTERISTICS AND 12-WEEK OUTCOMES FOR A SUBSET OF PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND PSORIATIC ARTHRITIS FROM THE PSORIASIS STUDY OF HEALTH OUTCOMES**

L. E. Kristensen1, F. Behrens2,3, L. Puig4, A. Reich5, T. Holzkaemper6, A. Brabric7, K. Nyg6, S. Liu Leeg6, C. Schuster7, A. Pinter8,8,8, Bispebjerg and Frederiksberg Hospital, The Parker Institute, Copenhagen, Denmark; 2Goethe University, Rheumatology University Hospital, Frankfurt, Germany; 3Goethe University, Fraunhofer Institute for Translational Medicine & Pharmacology (ITMP) and Cluster of Excellence Immune-Mediated Diseases (CIMD), Frankfurt, Germany; 4Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Dermatology, Barcelona, Spain; 5Medical College of Rzeszow University, Institute of Medical Sciences, Department of Dermatology, Rzeszow, Poland; 6Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America; 7Medical University of Vienna, Department of Dermatology, Vienna, Austria; 8University Hospital Frankfurt, Clinic for Dermatology, Venerology and Allergology, Frankfurt, Germany

**Background:** Approximately 30% of patients (pts) with plaque psoriasis (PsO) develop psoriatic arthritis (PsA), which is associated with high Psoriasis Area and Severity Index (PASI) and nail involvement. The Psoriasis Study of Health Outcomes (PSoHO) is a 3-year (yr), international, prospective, observational cohort study comparing the effectiveness of anti-IL-17A biologics to all other approved biologics in pts with moderate-to-severe PsO.

**Objectives:** This interim subset analysis describes the baseline characteristics and Week 12 (W12) effectiveness in pts with moderate-to-severe PsO and PsA in PSoHO.

**Methods:** Adults with moderate-to-severe PsO for ≥6 months who initiated switched biologic treatment during routine medical care were enrolled. PsA diagnosis was recorded by the dermatologists based on the medical history and/or information provided by the patient. W12 effectiveness was assessed by the proportion of pts achieving almost clear or clear skin defined by ≥90% improvement in PASI, affected Body Surface Area (BSA), Dermatology Life Quality Index (DLQI), and Patient Global Assessment of Disease Severity (PatGA). Musculoskeletal endpoints were not collected. Data were analysed descriptively, using mean (standard deviation [SD]) or median (Q1/Q3) for continuous variables and n, % and 95% confidence limits for categorical variables.

**Results:** Overall, 1981 pts were enrolled in this study, of whom 461 (23.3%) had a PsA diagnosis and received either anti-IL-17A (n=227; 49.2%) or other biologics (n=234; 50.8%). This subset of pts had a mean age of 48.7 yrs and a median disease duration of 18.9 yrs for PsO and 5.6 yrs for PsA (Table 1).

**Table 1. Baseline characteristics for PsO patients with PsA. Mean (SD) reported for all available data for that measure, unless stated otherwise.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=461)</th>
<th>Anti-IL-17A (n=227)</th>
<th>Other Biologics (n=234)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs</td>
<td>48.7 (12.9)</td>
<td>50.9 (12.9)</td>
<td>46.6 (12.6)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>232 (50.3)</td>
<td>112 (49.3)</td>
<td>120 (51.3)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>29.7 (6.2)</td>
<td>29.8 (5.9)</td>
<td>29.6 (6.4)</td>
</tr>
<tr>
<td>Smoking status – Current, n (%)</td>
<td>100 (25.4)</td>
<td>41 (21.1)</td>
<td>59 (29.5)</td>
</tr>
<tr>
<td>Disease duration (PsA), yrs, median</td>
<td>3.6</td>
<td>5.6</td>
<td>5.5</td>
</tr>
<tr>
<td>Disease duration (PsO), yrs, median</td>
<td>18.9</td>
<td>18.9</td>
<td>18.7</td>
</tr>
<tr>
<td>Presence of nail PsO, n (%)</td>
<td>217 (45.4)</td>
<td>103 (45.4)</td>
<td>114 (48.9)</td>
</tr>
<tr>
<td>HADS Anxiety score &gt;10, n (%)</td>
<td>73 (19.3)</td>
<td>38 (20.5)</td>
<td>35 (18.1)</td>
</tr>
</tbody>
</table>

**BMI = Body Mass Index; BSA = Body Surface Area; DLQI = Dermatology Life Quality Index; HADS = Hospital Anxiety and Depression Scale; HADS >10 indicates significant symptoms of depression/anxiety; mNAPSI = Modified Nails Psoriasis Severity Index; PASI = Psoriasis Area and Severity Index; PatGA = Patient Global Assessment of Disease Severity; Q1/Q3 = Quartile 1/3.**

At W12, 62.4% and 42.6% of anti-IL-17A-treated pts achieved PASI90 and PASI100, respectively, compared with 34.2% and 16.8% in the other biologics cohort, respectively (Figure 1). BSA <3% was reached by 70.9% of anti-IL-17A-treated pts and 49.5% in the other biologics cohort, while 71.2% and 44.8%, respectively, reached PatGA 0/1. Among pts with baseline DLQI ≥2, 38.0% and 27.1% of the anti-IL-17A and other biologics cohorts, respectively, reached DLQI 0/1.

**Conclusion:** The effectiveness of blocking IL-17A on skin manifestations and on quality-of-life improvements in pts with PsO and PsA in the real-world study was consistent with observations from clinical trials.

**REFERENCES:**


**Disclosure of Interests:** Lars Erik Kristensen Speakers bureau: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen pharmaceuticals. Consultant of: Pfizer, AbbVie, Amgen, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, Janssen pharmaceuticals. Grant/research support from: IIT research grants from Pfizer, AbbVie, UCB, Gilead, Biogen, Novartis, Eli Lilly, and Janssen pharmaceuticals. Frank Behrens Speakers bureau: Amgen, AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Eli Lilly, Boehringer and Sandoz, Consultant of: Amgen. AbbVie, Pfizer, Roche, Chugai, UCB, BMS, Celgene, MSD, Novartis, Biotest, Janssen, Genzyme, Eli Lilly, Boehringer and Sandoz, Grant/research support from: AbbVie, AbbVie, Roche, Chugai, GSK and Janssen, Luis Puig Speakers bureau: Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Consultant of: Abbvie, Almirall, Amgen, Baaxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, Leo-Pharma, Eli Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Sazung-Bioepis, Sanofi, UCB, Grant/research support from: Abbvie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo-Pharma, Eli Lilly, Novartis, Pfizer, Regeneron, Roche, Sanofi, UCB, Adam Reich Speakers bureau: Abbvie, Novartis, Janssen, Pfizer, Sandoz, Gaedlerma, Eli Lilly, Consultant of: Abbvie, Novartis, Janssen, Pfizer, Sandoz, Gaedlerma, Eli Lilly, Thorsten Holzkaemper Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Alan Brabric Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Alain Schuster Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Andreas Pinter Speakers bureau: Abbvie, Almirall-Hermal, Amgen, Biogen Idec, Bionetec, Boehringer-Ingehelm, Celgene, GSK, Eli Lilly, Gaedlerma, Hexal, Janssen, LEO-Pharma, MCD, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough and UCB Pharma.

**Figure 1. Percentage of patients receiving anti-IL-17A or other biologics who achieved PASI75/90/100, absolute PASI ≤1, BSA <3%, PatGA 0/1 and DLQI 0/1 (baseline DLQI ≥2) at Week 12. Bars represent upper 95% confidence limits.**

**Scientific Abstracts**
Background: Therapeutic inertia (TI), or clinical inertia, is the medical behavior of not initiating or intensifying treatment when recommended by clinical recommendations (1). TI was established in diabetes and then studied in hypertension, multiple sclerosis and psoriasis, and is estimated to affect 30 to 70% of physicians managing patients with chronic diseases (2-4). To our knowledge, no data have reported TI in the setting of psoriatic arthritis (PsA).

Objectives: The aim of this survey was to conduct an assessment of treatment inertia and of PsA in France.

Methods: 825 French rheumatologists were contacted by e-mail between January and March 2021 and asked to complete an online questionnaire, consisting of 7 clinical vignettes illustrating common situations and reflecting the polymorphic character of PsA: five clinical cases (oligoarthritis, enthesitis, polyarthritis, nail psoriasis, and psoriatic auricular plaques) requiring treatment optimization (1), and two “control” clinical cases (DIP arthritis, atypical axia) not requiring any change of treatment. The rheumatologists were also questioned about their routine practice and perception of PsA.

Results: 101 (12%) of the rheumatologists contacted completed the questionnaire. Sixty percent of the respondents were men, and 45% of rheumatologists had been practicing between 46 and 60 years; most practiced exclusively in hospitals (34%), private practice (33%) or in both (34%); the mean duration of clinical practice was 23 years. Almost all of the respondents stated that they were comfortable with the management of PsA (99%) and familiar with French and EULAR recommendations (90%). There was general consensus regarding the difficulties inherent in PsA: therapeutic objectives difficult to achieve (74% of respondents); polymorphic character (72%); access to biological drugs (70%); cognitive/drug burden (67%); and uncertainty (comorbidities and polyarticular involvement) generated the least uncertainty (27%). The rate of TI we observed for PsA is similar to published data for other chronic diseases (1). The clinical cases that induced the most TI were “oligoarthritis” and “enthesitis” with 20% and 19% of respondents not modifying treatment, respectively. Conversely, the vignettes “polyarthritis in relapse,” “neoplastic history” and “cardiovascular risk” generated fewer TI with 6%, 8% and 11% of respondents, respectively, choosing not to change the current treatment.

Conclusion: Despite a good knowledge of PsA and associated clinical recommendations, almost half of the rheumatologists we surveyed demonstrated at least one TI. The rate of TI we observed for PsA is similar to published data for other chronic diseases (1). The clinical profiles for which there was the least uncertainty (comorbidities and polyarticular involvement) generated the least inertia; the more complex profiles oligoarthritis and enthesitis generated more inertia. Our study is the first to show the existence of clinical inertia in PsA and further research is warranted to ascertain the reasons behind this inertia.

REFERENCES:
Table 1. LS mean change from baseline through W100 in EQ-5D-5L index

<table>
<thead>
<tr>
<th>Week</th>
<th>N</th>
<th>LS mean change (95% CI)</th>
<th>Diff vs. PBO</th>
<th>Nominal p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>243</td>
<td>0.10 (0.09,0.12)</td>
<td>0.04 (0.02,0.06)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>244</td>
<td>0.15 (0.13,0.16)</td>
<td>0.06 (0.04,0.09)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>243</td>
<td>0.10 (0.10,0.13)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>247</td>
<td>0.10 (0.13,0.16)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>246</td>
<td>0.12 (0.10,0.13)</td>
<td>0.06 (0.04,0.08)</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>248</td>
<td>0.15 (0.13,0.16)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>244</td>
<td>0.12 (0.10,0.13)</td>
<td>0.06 (0.04,0.08)</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>244</td>
<td>0.15 (0.13,0.17)</td>
<td>0.06 (0.04,0.07)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>244</td>
<td>0.06 (0.04,0.07)</td>
<td>0.05 (0.04,0.07)</td>
<td>0.14</td>
</tr>
</tbody>
</table>

CI=Confidence interval; Diff=Difference

Conclusion: In bio-naïve pts with active PsA receiving GUS, earlier improvements (at the first timepoint assessed) in self-reported HRQoL measures were sustained through 2 years.

REFERENCES:


Disclosure of Interests: None declared


AB0083 REAL-WORLD TREATMENT PATTERNS IN PATIENTS WITH PSORIATIC ARTHRITIS

J. Chol1, A. Sreih2, T. Lehman3, M. Suryavanshi4, Q. Xia5, M. Nowak6, 7Bristol Myers Squibb, HEOR, Immunsience, Princeton, United States of America; 7Bristol Myers Squibb, Clinical Research & Development, Princeton, United States

Background: Guselkumab is the first human monoclonal antibody that binds selectively to the p19 subunit of IL23. It's approved for the treatment of moderate to severe psoriasis and psoriatic arthritis. Objectives: We present a case series of patients with psoriasis and/or psoriatic arthritis who had a good response to Guselkumab and their cardiovascular risk factors.

Methods: An observational and retrospective study of patients with psoriasis and/or psoriatic arthritis under treatment with Guselkumab in the Dermatology and Rheumatology consultation at our hospital. A total of 11 patients were included. Baseline characteristics, comorbidities, and cardiovascular risk were collected. The SCORE (European High Risk Chart) and cardiovascular risk categories (European Society of Cardiology, European Atherosclerosis Society 2019) were used. Disease severity and treatment response were assessed by PASI, DLQI, DAPSA and ASDAS at baseline and after 12, 24 and 36 weeks.

Results: Our cases had a mean age of 52.43 years. 63.6% of them were women. A total of 45.5% had polyarticular psoriatic arthritis, 90.9% were obese, 45.45% were type 2 obesity, with a mean BMI of 34.88. Dyslipidaemia and hypertension were observed in 54.5% and 72.7% of the patients, respectively. They all had varying degrees of Non-alcoholic fatty liver disease (NAFLD). A total of 45.5% had SCORE >1% and 90.9% were in moderate category of cardiovascular risk. At baseline their disease parameters were: PASI=11.09 ± 7.01, DAPSA=15.09 ± 7.33, DLQI=19.11 ± 9.95 and ASDAS=2.12 ± 0.43. After 12 weeks of treatment, the mean reduction of PASI and DLQI was 7.09 and 6.45, which continued improving at week 36. None of them were naive. There were no adverse effects, with a treatment survival of 76.73 weeks ± 42.93.

Conclusion: Guselkumab showed excellent results in our clinical practice in the control of psoriasis and/or psoriatic arthritis in non-naive patients with cardiovascular risk factors, with a good safety profile.

REFERENCES:


Disclosure of Interests: None declared

Background: Psoriatic arthritis (PsA) is a complex inflammatory disease with manifestations that play an important role in treatment selection.1,2 Treatments include oral agents, biologic therapies (inhibitors of tumor necrosis factor [TNFi], interleukin [IL]-17A, IL-12/23), cytokine/cytolymphocyte–associated antigen 4 inhibitor [CTLA-4i]), and new targeted oral agents (inhibitors of phosphodiesterase 4ase-[PDE-4i] and Janus kinase [JAKKi]).1,2 Few studies have examined real-world treatment patterns of recently approved therapies.

Objectives: Evaluate real-world treatment patterns for branded systemic therapy in patients with PsA.

Methods: In this retrospective study, medical and pharmacy claims from the US IBM MarketScan Commercial and Medicare databases (1/1/2012–12/31/2019) were used to identify patients with PsA who initiated treatment with a TNFi (adalimumab, etanercept, infliximab, golimumab, or certolizumab), IL-17Ai (secukinumab, ixekizumab), IL-12/23i (ustekinumab), IL-23pi (guselkumab), CTLA-4i (abatacept), JAKi (tofacitinib), or PDE-4i (apremilast). Patients (≥18 years) with ≥1 prescription, ≥2 PsA claims separated by ≥1 day on or before the index date (first prescription date [1/1/13–12/31/2018]), and 1-year continuous enrollment before and after the index date were eligible. Treatment patterns were grouped into continuers, discontinuers, and patients with treatment modification (switchers [without a treatment gap], reinitiators [same drug with a treatment gap], and restarters [different drug with a treatment gap]) (Table 1). Patients were followed for 1 year or until treatment modification, whichever came first. Descriptive statistics were used.

Table 1. Terminology
<table>
<thead>
<tr>
<th>Cohort</th>
<th>Definition</th>
<th>n/N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuers</td>
<td>On index treatment during 1-year follow-up with no treatment gap*</td>
<td>1910/6455</td>
</tr>
<tr>
<td>Discontinuers</td>
<td>No prescription claims for any therapy during 1-year follow-up</td>
<td>29/665</td>
</tr>
<tr>
<td>Patients with treatment modifications</td>
<td>All patients with a change in treatment during 1-year follow-up</td>
<td>2908/6455</td>
</tr>
<tr>
<td>Switchers</td>
<td>Prescription claims for treatments different than index therapy before permissible treatment gap*</td>
<td>794/6455  (12.3)</td>
</tr>
<tr>
<td>Reinitiators</td>
<td>Prescription claims for treatments SAME as index therapy AFTER treatment gap*</td>
<td>1686/6455</td>
</tr>
<tr>
<td>Restarters</td>
<td>Prescription claims for DIFFERENT therapy AFTER treatment gap*</td>
<td>428/6455  (6.6)</td>
</tr>
</tbody>
</table>

Note: All terminology applies to cohorts within the first year of treatment. Treatment gap: gap of 200% of recommended dosing schedule from end of previous prescription’s day’s supply.

Results: A total of 6455 patients were included (mean age, 50.5 years; 55.5% female; mean Charlon Comorbidity Index score, 0.54). At baseline, the most commonly used therapies were immunosuppressants (58.5%), corticosteroids (52.2%), and nonsteroidal anti-inflammatory drugs (45.9%). Treatments most used at index were TNFi (72.5%, including adalimumab [41.6%] and etanercept [23.8%]) and the PDE-4i apremilast (21.1%). During the 1-year study period, 29.6% of patients maintained their index therapy and 25.0% discontinued. Treatment modification was observed in 45.1% of patients; 12.3% switched to a new therapy without a treatment gap, 26.1% restarted their index therapy, and 6.6% started a new therapy after a treatment gap.

Conclusion: Among patients with PsA, there is substantial variability, including high rates of discontinuation within the first year and after index therapy. Further studies are warranted to understand reasons for these treatment patterns.

REFERENCES:

Acknowledgements: This study was sponsored by Bristol Myers Squibb. Statistical analysis support was provided by Arindom Borkakoti, formerly of Mu Sigma. Professional medical writing assistance was provided by LeeAnn Braum, MPH, ME, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Bristol Myers Squibb.


AB0884

DISEASE OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS COMPLETING 12 MONTHS OF APREMILAST TREATMENT - REAL-WORLD DATA FROM THE REWARD STUDY

R. Bos1, T. Jansen1, I. Bridges3, S. De Jong, M. Via3, MC. Rheumatology, Leeuwarden, Netherlands; 2Viecurie, rheumatology, Venlo, Netherlands; 3Amen, Biostatistics, Uxbridge, United Kingdom; 4Beda, Medical, Breda, Netherlands; 5Erasmus, rheumatology, Rotterdam, Netherlands

Background: Patients with moderately active psoriatic arthritis (PsA) and limited joint involvement have considerable disease burden1,2. Recent data shows these patients have a high likelihood of achieving treatment goals if treated with apremilast.3 This is the first report of outcomes in patients with PsA who received apremilast for 12 months in Dutch clinical practice.

Objectives: We report disease outcomes, including the PsA Impact of Disease (PsAID) 12-item questionnaire, swollen joint count (SJC), tender joint count (TJC), dactylitis and enthesitis, among patients in the prospective, multicenter, observational REWARD study who completed 12 months of apremilast treatment.

Methods: The ongoing REWARD study enrolled patients who had initiated apremilast for the treatment of PsA in the Netherlands between 13 April 2017 and 24 March 2021, and includes up to 12 months follow-up.1,5 We report interim data from patients with data available as of 16 September 2021. Baseline data are summarized separately for patients who discontinued apremilast before their month 12 study visit (stoppers) and patients still receiving apremilast at their month 12 visit (completers). Post baseline data are summarized for completers. Continuous data are summarized using mean and SD, categorical data are summarized using n and percent.

Results: 98 patients were included in this interim analysis; 32 had completed 12 months of apremilast treatment (completers), 54 had discontinued apremilast before month 12 (stoppers), 12 were ongoing in the study. Compared with stoppers, completers were more likely to be biologic naïve and have dactylitis, and had lower BSA. All other baseline characteristics were similar (Table 1). Among completers, all PsAID domains improved after 3 months of apremilast treatment and these improvements were maintained through month 12 (Figure 1). Mean SJC and TJC decreased between baseline and month 12 (SJC, 4.2 and 1.0 at baseline and month 12, respectively; TJC, 7.1 and 3.3, respectively). The proportion of completers with SJC, TJC, enthesitis and dactylitis scores of 0 increased from baseline to month 12 (Figure 1B). The proportion of completers reporting at least one adverse event (AE) was comparable to the overall study population (14/32 [44%] and 48/98 [49%], respectively); the reported adverse events were similar to the known safety profile of apremilast.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>All (n=98)</th>
<th>Completers (n=32)</th>
<th>Stoppers (n=54)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>50 (51.5)</td>
<td>16 (50.0)</td>
<td>34 (63.0)</td>
</tr>
<tr>
<td>Female</td>
<td>48 (49.5)</td>
<td>16 (50.0)</td>
<td>32 (37.0)</td>
</tr>
<tr>
<td>Age (Years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>54.7 (13.6)</td>
<td>53.8 (12.1)</td>
<td>56.9 (14.6)</td>
</tr>
<tr>
<td>BSA (% of BSA)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>33.1 (21.3)</td>
<td>30.8 (19.1)</td>
<td>38.7 (24.5)</td>
</tr>
<tr>
<td>PASI</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>10.9 (6.4)</td>
<td>10.6 (6.7)</td>
<td>11.2 (6.4)</td>
</tr>
<tr>
<td>Dactylitis (yes) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>7.7 (6.8)</td>
<td>0.6 (3.1)</td>
<td>9.5 (4.4)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>2.6 (1.3)</td>
<td>0.7 (0.5)</td>
<td>9.2 (3.4)</td>
</tr>
<tr>
<td>ENTESIS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>24.6 (11.5)</td>
<td>18.4 (10.0)</td>
<td>32.1 (15.8)</td>
</tr>
<tr>
<td>Dactylitis (yes) (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>7.7 (6.6)</td>
<td>3.0 (2.7)</td>
<td>11.6 (6.2)</td>
</tr>
</tbody>
</table>

All patients included in this interim analysis; Completers= patients that received apremilast for 12 months; Stoppers= patients that stopped apremilast prior to 12 months; BSA=Body Mass Index, PsAID=Psoriatic Arthritis Impact of Disease, VAS=Visual Analog Scale, CRP= C-reactive protein, cDAPSA=Clinical Disease Activity in Psoriatic Arthritis, Rem=Remission, Mod=Moderate, PsA=Psoriatic Arthritis.
Figure 1. (A) PSAID scores in completers and (B) percentage of completers with no swollen joints, no tender joints, no dactylitis and no enthesitis at baseline (BSL), month 3, 6 and 12 (M3, M6, M12).

Conclusion: In this interim analysis of the REWARD study, patients completing 12 months of apremilast treatment were more likely to be biologic naïve than patients who discontinued apremilast within 12 months of initiation, and had significant decreases in TJC, SJC, dactylitis and enthesitis during apremilast treatment. Completed patients also reported decreased PSAID scores during apremilast treatment, indicating improvements in their quality of life.

REFERENCES:

Acknowledgements: Sylvia de Jong and Claire Desborough, Amgen employees, provided medical writing and editorial assistance.

Disclosure of Interests: Reinhard Bos Consultant of: AbbVie BV, Genzyme Europe, Grant/research support from: Galapagos, Tim Jansen Speakers bureau: Grunenthal, Sobi, Consultant of: AbbVie, Celgene Corporation, Grant/research support from: ReumaNederland, Olatec, Grunenthal, Ian Bridges Shareholder of: Amgen, Employee of: Amgen, Sylvia de Jong Shareholder of: Amgen, Employee of: Amgen, Novartis, Marijn Vis Consultant of: AbbVie, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Grant/research support from: Novartis, Pfizer

DOI: 10.1136/annrheumdis-2022-eular.1124

AB0885

REFRACTORY CHRONIC SYNOVITIS OF THE COMMON FLEXOR SYNOVIAL SHEATH IN PSORIATIC ARTHRITIS PATIENT SUCCESSFULLY TREATED BY ULTRASOUND GUIDED LOCAL METHOTREXATE INJECTION.

A. Abogamal1,2, 1Al Azhar Faculty of Medicine, Rheumatology, Cairo, Egypt; 2Dr Sulaiman Al Habib Hospital in Dubai, Rheumatology, Dubai, United Arab Emirates

Background: Psoriatic arthritis (PsA) is a variant of inflammatory musculoskeletal conditions that usually associated with skin psoriasis. PsA is typically heterogenous in comparison to other rheumatic diseases, It affects multiple musculoskeletal domains including synovitis of peripheral and axial joints, entheses, and tendons with tenosynovitis.[1,2] Persistent cases of arthritis or tenosynovitis usually controlled by local injection with corticosteroids, though some refractory cases of chronic synovitis still not sufficiently controlled by corticosteroid local injection with some case series shows a significant response to local DMARDs and even local Biologics.[3-6]

Objectives: To describe a case of psoriatic arthritis with chronic synovitis of the common flexor synovial sheath successfully treated by ultrasound guided local Methotrexate injection.

Methods: 31 Years old female with psoriatic arthritis in the form of symmetric hand arthritis for the last 10 years, and extensive nail disease shows partial control under treatment with Methotrexate after failure of sulfasalazine. Her DAPSA score usually ranges between 16 to 18 with tender persistent fluctuating cystic swelling overlying her right palm extending proximally to the distal third of the forearm that becomes more tense on fingers flexion. Ultrasound examination shows hypoechoic distension of the right common flexor synovial sheath, that is partially compressible and partially displaceable with highly positive Doppler signals indicating active synovitis. Figure 1

October 2019, ultrasound guided aspiration and local corticosteroid injection applied for the common flexor sheath with escalation of her treatment to bzkizumab plus Methotrexate to achieve clinical remission. January 2020, patient achieve DAPSA 8 with resolution of have nail lesions, though her right hand function was still significantly impaired due to the refractory persistent synovitis of the Common flexor sheath. Two doses 15mg Methotrexate one week apart inserted into the common flexor sheath under ultrasound imaging.

Results: April 2020, on regular follow up patient achieve DAPSA remission <4, with complete resolution of the right palm swelling and she reports complete recovery of her hand function which is maintained up to January 2022 in her last
follow up visit. Follow up ultrasound scan shows normalization of the common flexor sheath with disappearance of the mixed picture of synovitis and effusion. Figure 1

Conclusion: Refractory synovitis of the common flexor sheath in PsA successfully treated with ultrasound guided local methotrexate injection with persistence of improvement for one year.

REFERENCES:


Table 1. Improvements reported in SF-36 domains with deucravacitinib 6 mg QD and 12 mg QD vs placebo at Week 16

<table>
<thead>
<tr>
<th>Domain</th>
<th>Placebo</th>
<th>Deucravacitinib 6 mg – QD</th>
<th>Deucravacitinib 12 mg – QD</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GH</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MH</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


AB0886

THE IMPACT OF DEUCRAVACITINIB ON HEALTH-RELATED QUALITY OF LIFE MEASURED BY THE SHORT FORM HEALTH SURVEY 36-ITEM QUESTIONNAIRE: ANALYSIS OF A PHASE 2 TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

V. Strand, P. J. Mease, A. Deodhar, J. Ye, M. Nowak, J. Choi, B. Becker

Background: Patients (pts) with psoriatic arthritis (PsA) experience pain, loss of physical function, joint damage, and significant impairments in social and emotional well-being. The Short Form Health Survey 36-item questionnaire (SF-36v2), a generic measure of pt-reported health-related quality of life (HRQOL), includes 36 items and measures 8 domains—physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH)—that contribute to both physical component summary (PCS) and mental component summary (MCS) scores. Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2), an intracellular kinase that mediates cytokine signaling pathways implicated in PsA pathogenesis. In a Phase 2 trial in pts with active PsA, DEUC was well tolerated and significantly more efficacious than placebo (PBO) after 16 weeks (wk) of treatment.1

Objectives: To further evaluate the effect of DEUC treatment on SF-36 scores.

Methods: This double-blind Phase 2 trial (NCT03881059) enrolled pts with a PsA diagnosis ≥6 months who fulfilled Classification Criteria for Psoriatic Arthritis at screening and had active joint disease ≥3 tender and ≥3 swollen joints, high-sensitivity CRP ≥3 mg/L, and ≥1 plaque psoriasis lesion (≥2 cm). Pts failed or were intolerant to ≥1 nonsteroidal anti-inflammatory, conventional synthetic DMARD, and/or 1 TNF inhibitor (≥30%). Pts were randomized 1:1:1 to DEUC 6 mg once daily (QD) or 12 mg QD, or PBO. Changes from baseline (BL) in SF-36 PCS and MCS scores at Wk 16 were prespecified key secondary and additional endpoints, respectively. The 8 SF-36 domain scores were evaluated at Wk 16. The proportions of pts reporting improvements ≥2.5 and ≥5 points (the minimum clinically important difference [MCID]) in SF-36 summary and domain scores, respectively, were evaluated.

Results: Of 203 pts randomized, 180 (89%) completed 16 wks of treatment: DEUC 6 mg QD, 63/70 [90%]; DEUC 12 mg QD, 59/67 [88%]; PBO, 58/66 [88%]. Demographic and BL disease characteristics were similar across groups. BL mean SF-36 PCS and MCS scores were similar among DEUC 6 mg QD, 12 mg QD, and PBO groups (PCS: 43.0, 43.5, and 33.4; MCS: 45.4, 46.9, and 41.7, respectively). At Wk 16, adjusted mean changes from BL in SF-36 PCS and MCS scores were significantly improved with DEUC 6 and 12 mg QD treatment vs PBO (PCS: 5.6, 5.8, and 2.3; MCS: 3.6, 3.5, and 0.7, respectively; P<0.05).

Reported improvements in domain scores with both doses exceeded MCID and were significant in 5 of 8 domains with DEUC 6 mg QD (PF, RP, BP, VT, and SF) and 6 of 8 domains with DEUC 12 mg QD (RE in addition; Figure 1 and Table 1).
Background: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic therapy for patients (pts) with psoriatic arthritis (PsA), though a sizeable proportion of pts have an inadequate response (IR), and some may also have intolerance. Guselkumab (GUS), a human mAb that targets the IL-23 p19 subunit, provides an alternative mechanism of action to treat PsA. In the Phase 3 (Ph3) DISCOVER-1 study of GUS in active PsA, GUS every 4 weeks (Q4W) and Q8W clinical response rates were generally consistent between TNFi-naïve (283 pts) and TNFi-experienced (118 pts) cohorts. In the TNFi-experienced cohort and the limited number of DISCOVER-1 pts with IR to their prior TNFi (N=44), American College of Rheumatology (ACR) 70% improvement (ACR70) and ACR20 response rates at W24 were numerically higher in GUS Q4W- than Q8W-treated pts.1

Objectives: To further investigate whether GUS Q4W could provide incremental benefit to some TNFi-IR PsA pts by analyzing the existing DISCOVER-1 dataset to facilitate the design of a new clinical trial.

Methods: Study feasibility assessments included comparison of key efficacy endpoints by treatment group at W24 among TNFi-experienced pts receiving GUS Q8W and Q4W. DISCOVER-1 Results from the DISCOVER-1 study also informed sample size power calculations for a primary endpoint of ACR20 response at W24 in a future study in a TNFi-IR PsA pt population.

Results: Comparison of several efficacy endpoints (ACR70 response, minimal disease activity, Investigator’s Global Assessment [IGA] of psoriasis 0/1 response) across treatment groups in the TNFi-experienced DISCOVER-1 cohort supports a potential dose response, with more frequent GUS administration eliciting numerically higher response rates (Table 1). A similar trend was observed for ACR20/50/70 responses in the smaller TNFi-treated population1, though these findings should be interpreted with caution due to limited sample size. ACR20 response rates at W24 of DISCOVER-1 were employed to estimate sample size requirements for a new study. Assuming comparable rates of GUS treatment effect seen in DISCOVER-1, a sample size of 150 randomized pts per group for PBO, GUS Q8W, and GUS Q4W would provide >90% power to detect a significant difference between each GUS group and PBO for ACR20 response at W24. Based on these findings, a new Ph3b, multicenter, randomized, double-blind, placebo-controlled study, SOLSTICE, was designed to further evaluate the efficacy and safety of GUS in approximately 450 pts with active PsA who had IR to one prior TNFi, and to investigate the effect of GUS dosing interval in this important cohort of pts with PsA (Figure 1).

Table 1. Clinical efficacy at W24 among DISCOVER-1 TNFi-experienced pts

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>GUS Q8W</th>
<th>GUS Q4W</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR20</td>
<td>173%</td>
<td>56.1%</td>
<td>57.9%</td>
</tr>
<tr>
<td>ACR50</td>
<td>5.1%</td>
<td>26.8%</td>
<td>34.3%</td>
</tr>
<tr>
<td>ACR70</td>
<td>2.6%</td>
<td>2.4%</td>
<td>21.1%</td>
</tr>
<tr>
<td>MDA</td>
<td>2.6%</td>
<td>17.1%</td>
<td>26.3%</td>
</tr>
<tr>
<td>IGA 0/1*</td>
<td>7.7%</td>
<td>48.3%</td>
<td>67.9%</td>
</tr>
</tbody>
</table>

*IGA score of 0 (clear) or 1 (almost clear) among pts with ≥3% body surface area of psoriasis involvement and an IGA score ≥2 (mild-to-severe psoriasis) at baseline.2

Conclusion: PsA pts with TNFi-IR are typically difficult to treat. Overall data from the DISCOVER-1 study of GUS in pts with active PsA showed consistent clinical response between doses and between TNFi-naïve and TNFi-experienced pts. Analyses based on limited numbers of TNFi-experienced pts from DISCOVER-1 demonstrated potential incremental benefit for achievement of higher response criteria with more frequent dosing in some TNFi-IR pts. SOLSTICE, a Ph3b, randomized, placebo-controlled study, will test this hypothesis.

REFERENCES:
Immunology Global Medical Affairs, Harrow, United States of America; 1Royal National Hospital For Rheumatic Diseases, Department of Pharmacy & Pharmacology Centre for Therapeutic Innovation, Bath, United Kingdom; 2Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Department of Rheumatology Research, Seattle, United States of America

Background: Psoriatic arthritis (PsA) impacts patients’ (pts) work productivity (WP) and daily activity.1 DISCOVER-2 (D2), a Phase 3 trial of the selective interleukin-23 p19-subunit inhibitor guselkumab (GUS) in biologic-naive pts with PsA,2 demonstrated significant improvements in pt-reported WP and daily activity following 1 year (Y) of GUS treatment.3

Objectives: Assess WP and daily activity impairment in D2 pts through 2Y. Estimate indirect savings associated with GUS treatment and assess changes in employment status.

Methods:Pts with active PsA received GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, then Q8W; or placebo (PBO). At W24, PBO pts crossed over to GUS 100 mg Q4W. WPAI-PsA assessments were done at each visit throughout 2Y (Figure 1). Potential annual indirect savings from improved overall WP were estimated using 2020 European Union mean yearly wage estimate (all occupations) combined with LS mean change from baseline in WPAI-PsA overall work impairment.4 A shift analysis evaluated proportions of pts employed vs unemployed by treatment group using observed data over time.

Results: Pts included 64% of the analysis cohort. Significant improvements in WP in pts EBL and in daily activity among all pts were observed with continued GUS through 2Y (Table 1). Potential annual indirect savings from improved overall WP in pts EBL were €10,826 GUS Q4W, €12,712 GUS Q8W, and €10,948 PBO → GUS Q4W at 2Y. Shift analysis showed relatively stable employment in pts EBL with GUS up to 2Y (>83% continued to work). Among pts UBL (36% of cohort), the proportion of pts employed increased by >20% through 2Y of GUS (Figure 1). A shift analysis evaluated proportions of pts employed vs unemployed by treatment group using observed data over time.

Conclusion: In GUS-treated bio-naive PsA pts, robust improvements in WP and daily activity seen at W24 were maintained and increased through 2Y of GUS. Long-term improvements in WP achieved may result in substantial indirect cost savings for GUS-treated pts. Rates of employment remained stable in pts employed and increased in those unemployed at BL.

REFERENCES:

Disclosure of Interests: Jeffrey Curtis Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB, Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, CorEvitas, Eli Lilly and Company, Janssen, Myriad, Novartis, Pfizer, Sanofi, and UCB, Iain McInnes Shareholder of: Causeway Therapeutics, and Evelo Compugen, Consultant of: Astra Zeneca, AbbVie, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Cabalepta, Compugen, GSK, Gilead, Janssen, Novartis, Pfizer, Sanofi, Roche, and UCB, Grant/research support from: Astra Zeneca, Bristol-Myers Squibb, Amgen, Eli Lilly and Company, GSK, Janssen, Novartis, Roche, and UCB, Proton Rahman Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Grant/research support from: Janssen and Novartis, Dafna D Gladman Consultant of: AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB, Employee of: Janssen Global Services, LLC, Steve Peterson Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Alex Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, Natalie Shift Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Alexa Kollmeier Shareholder of: Johnson & Johnson, Employee of: Janssen Research & Development, LLC, May Shawi Shareholder of: Johnson & Johnson, Employee of: Immunology Global Medical Affairs, Janssen Pharmaceutical Companies, William Tillet Speakers bureau: AbbVie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Eli-Lilly, Janssen, and UCB, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB


AB0089
ASSOCIATION BETWEEN CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND STRINGENT MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB VERSUS PLACEBO OR ADALIMUMAB: RESULTS FROM A PHASE 3 TRIAL

L. Gossec1, N. Damjanoiv, S. Tsuji2, A. Lertratanakul2, R. Lippe3, J. Patet4, P. Zueger5, K. De Vlamn6, S. Mortimer7, S. Tsuji8, J. Patet9, J. Mease Speakers bureau: AbbVie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Eli-Lilly, Janssen, MSD, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, Eli-Lilly, Janssen, and UCB, Philip J Mease Speakers bureau: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Immagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB

Table 1. Model-Based Estimates of Change From BL in WPAI-PsA Domains

<table>
<thead>
<tr>
<th>Visit</th>
<th>GUS 100 mg Q4W</th>
<th>GUS 100 mg Q8W</th>
<th>PBO (W0-24) → GUS 100 mg Q4W (W24-100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>W24</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>W100</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>LS Mean (95% CI)</td>
<td>-3.4 (-6.5, -0.3)</td>
<td>-1.8 (-4.5, 0.9)</td>
<td>-3.0 (-6.0, 0.1)</td>
</tr>
<tr>
<td>Diff vs. PBO</td>
<td>-0.4 (-4.6, 3.8)</td>
<td>-0.01 (-4.2, 4.2)</td>
<td>-0.01 (-4.2, 4.2)</td>
</tr>
<tr>
<td>W24</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>W100</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>LS Mean (95% CI)</td>
<td>-20.1 (-23.7, -16.6)</td>
<td>-26.3 (-30.1, -22.5)</td>
<td>-19.6 (-23.2, -16.1)</td>
</tr>
<tr>
<td>Diff vs PBO</td>
<td>-9.7 (-14.4, -5.0)</td>
<td>-9.2 (-13.9, -4.5)</td>
<td>-9.2 (-13.9, -4.5)</td>
</tr>
<tr>
<td>W24</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>W100</td>
<td>145</td>
<td>147</td>
<td>147</td>
</tr>
<tr>
<td>LS Mean (95% CI)</td>
<td>-20.1 (-24.1, -16.1)</td>
<td>-23.8 (-28.0, -19.6)</td>
<td>-19.2 (-23.2, -15.2)</td>
</tr>
<tr>
<td>Diff vs PBO</td>
<td>-9.5 (-14.8, -4.2)</td>
<td>-8.6 (-13.9, -3.3)</td>
<td>-8.6 (-13.9, -3.3)</td>
</tr>
<tr>
<td>W24</td>
<td>242</td>
<td>246</td>
<td>246</td>
</tr>
<tr>
<td>W100</td>
<td>242</td>
<td>246</td>
<td>246</td>
</tr>
<tr>
<td>LS Mean (95% CI)</td>
<td>-20.5 (-23.3, -17.7)</td>
<td>-29.2 (-32.2, -26.1)</td>
<td>-21.2 (-24.1, -18.4)</td>
</tr>
<tr>
<td>Diff vs PBO</td>
<td>-10.6 (-14.4, -6.8)</td>
<td>-11.3 (-15.1, -7.5)</td>
<td>-11.3 (-15.1, -7.5)</td>
</tr>
</tbody>
</table>

1Mean changes in WPAI-PsA domains were calculated for each MI dataset using an ANCOVA; reported LS mean (95% confidence interval [CI]) = average of all MI datasets. *p<0.05
(PROs) have been well-established in PsA and are important indicators of patient improvement while on treatment. To date, the association between PROs and disease control in PsA has not been fully characterized.

Objectives: We examined the association between clinically meaningful improvement in PROs and stringent measures of disease control among patients with PsA enrolled in the Phase 3 SELECT-Psa 1 trial.

Methods: Patients with active PsA and an inadequate response to ≥1 non-biologic DMARDs were randomized to receive upadacitinib (UPA) 15 mg once daily (QD), UPA 30 mg QD, adalimumab (ADA) 40 mg every other week, or PBO for 24 weeks. PROs included: Functional Assessment of Chronic Illness Therapy-Fatigue (FACT-F), 36-Item Short-Form Health Survey (SF-36), and Work Productivity and Activity Impairment (WPAI). Measures of stringent disease control included achievement of minimal disease activity (MDA), ACR70 response, and remission based on Disease Activity Index in PsA (DAPSA ≤4.0) or PsA Disease Activity Score (PASDAS ≤1.9). The percentage of patients achieving stringent disease control was determined among patients reporting vs not reporting PRO improvements ≥ minimal clinically important differences (MCID) in the combined active treatment and PBO group at Week 24.

Results: A total of 1704 patients were included in the SELECT-Psa 1 trial, of whom 59.2%, 72.4%, 51.3%, 62.3%, 64.6%, and 63.9% reported improvements ≥ MCID for all PROs vs those who did not get it (Figures 1, 2). Similar results were seen in patients achieving PASDAS remission except for SF-36 MCS score (Figure 2). Among patients reporting improvements ≥ MCID across all PROs, more patients achieved ACR70 and MDA responses (29%-49%) with fewer patients achieving DAPSA or PASDAS remission (14%-19%).

Conclusion: PsA patients who reported clinically meaningful improvements in key PROs: fatigue, quality of life, and work productivity were more likely to achieve stringent measures of disease control. These results suggest a close association between meaningful improvements in patient-centric outcomes and achievement of stringent disease control.

Acknowledgements: This work/study was funded by AbbVie Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. All authors had access to the data results, and participated in the development, review, and approval of this abstract. No honoraria or payments were made for authorship.

Disclosure of Interests: Laure Gossec Consultant of: AbbVie, Amgen, BMS, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis, and UCB, Grant/research support from: Lilly, Pfizer, Sandoz, Sanofi, Nemanja Damjanov Speakers bureau: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Consultant of: AbbVie, Gedeon Richter, Merck, Novartis, Pfizer, and Roche, Grant/research support from: AbbVie, Pfizer, and Roche, Shigeyoshi Tsuchi Speakers bureau: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, Grant/research support from: AbbVie, Eli Lilly, Janssen, Novartis, and UCB, PBO, Apina Lerttranakul Shareholder of: Formerly of AbbVie, Employee of: former employee of AbbVie, Ralph Lippe Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Jayesh-kumar Patel Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Patrick Zueger Shareholder of: AbbVie Inc., Employee of: AbbVie Inc., Kurt de Vlam Speakers bureau: Celgene Eli Lilly, Galapagos, Novartis, and UCB, Consultant of: Eli Lilly, Galapagos, Novartis, and UCB, Grant/research support from: Celgene and Galapagos

DOI: 10.1136/annrheumdis-2022-eular.1371

AB0890 DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MODERATE TO SEVERE PLAQUE PSORIASIS: 52-WEEK EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 TRIALS


DOI: 10.1136/annrheumdis-2022-eular.1371

We examined the association between clinically meaningful improvement in PROs and stringent measures of disease control among patients with PsA enrolled in the Phase 3 SELECT-Psa 1 trial. The percentage of patients achieving MDA, ACR70 or DAPSA remission, WPAI overall work impairment, and WPAI presenteeism, respectively, at week 24. The percentage of patients achieving MDA, ACR70 or DAPSA remission, WPAI overall work impairment, and WPAI presenteeism, respectively, at week 24. The percentage of patients achieving MDA, ACR70 or DAPSA remission, WPAI overall work impairment, and WPAI presenteeism, respectively, at week 24. The percentage of patients achieving MDA, ACR70 or DAPSA remission, WPAI overall work impairment, and WPAI presenteeism, respectively, at week 24.
EXPLORATORY ANALYSIS FROM A PHASE 2 STUDY

DEUCRAVACITINIB EFFICACY IN PSORIATIC ARTHRITIS BY BASELINE DMARD USE: ADOBE®

Background: Psoriatic arthritis (PsA) treatment guidelines recommend that patients (pts) inadequately responding to conventional synthetic DMARDs (cs-DMARDs) can be treated with targeted synthetic DMARDs with or without background use of csDMARDs. Deucravacitinib (DEUC) is a novel, oral, selective, allosteric inhibitor of tyrosine kinase 2 (TYK2) that binds to the unique TYK2 regulatory domain, thereby suppressing signaling of key cytokines (eg, IL-23) involved in PsA pathogenesis. In a Phase 2 trial in pts with active PsA, DEUC was well tolerated and significantly more efficacious than placebo (PBO) after 16 weeks of treatment.

Objectives: This analysis further evaluated the effect of DEUC in this Phase 2 trial in pts treated with and without background csDMARDs for 16 weeks.

Methods: This double-blind trial (NCT03881059) enrolled pts with active PsA who had either failed or were intolerant to ≥1 nonsteroidal anti-inflammatory drug, corticosteroid, csDMARD, and/or 1 TNF inhibitor (TNFi; up to 30%). Pts were randomised 1:1:1 to DEUC 6 mg once daily (QD) or 12 mg QD, or PBO. A post hoc subgroup analysis in pts with and without background csDMARD use assessed improvements in select clinical outcomes (ACR 20 response, and change from baseline in ACR components, Psoriasis Area and Severity Index total score, and Psoriatic Arthritis Disease Activity Score [PASDAS]) at Week 16.

Results: Baseline (BL) demographics, clinical characteristics, and disease activity were generally similar among pts with and without background csDMARD use. At BL, background csDMARD use was 64.3%, 64.2%, and 66.7% and methotrexate use was 50.0%, 55.2%, and 59.1% in the DEUC 6 mg QD, 12 mg QD, and PBO groups, respectively. Pts with and without background csDMARD use showed similar improvements at Week 16 with DEUC treatment versus PBO.
Table 1. Adjusted mean (SE) change from baseline at Week 16 in clinical outcomes by csDMARD use

<table>
<thead>
<tr>
<th>Outcome</th>
<th>csDMARD use</th>
<th>csDMARD use</th>
<th>csDMARD use</th>
<th>csDMARD use</th>
<th>csDMARD use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=22)</td>
<td>(n=44)</td>
<td>(n=25)</td>
<td>(n=45)</td>
<td>(n=43)</td>
</tr>
<tr>
<td>Pain</td>
<td>-14.7 (5.6)</td>
<td>-14.6 (5.6)</td>
<td>-22.7 (5.7)</td>
<td>-26.2 (3.7)</td>
<td>-25.5 (5.3)</td>
</tr>
<tr>
<td></td>
<td>(3.9)</td>
<td>(3.9)</td>
<td>(2.5)</td>
<td>(2.5)</td>
<td>(2.4)</td>
</tr>
<tr>
<td></td>
<td>-23.0 (5.9)</td>
<td>-28.4 (3.8)</td>
<td>-28.2 (5.4)</td>
<td>-24.9 (4.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-25.3 (4.2)</td>
<td>-25.5 (4.2)</td>
<td>-24.9 (4.2)</td>
<td>-24.9 (4.2)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: These analyses demonstrate that the efficacy of DEUC for the treatment of PsA was similar in pts with and without background csDMARD use. The AE profile of DEUC treatment with and without csDMARD use was consistent with findings from the overall Phase 2 PsA trial population.

REFERENCES:


Acknowledgements: This study was sponsored by Bristol Myers Squibb. Professional medical writing assistance was provided by Julianne Hatfield, PhD at Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, USA, and funded by Bristol Myers Squibb.

Disclosure of Interests: Atul Deodhar Consultant of: Consulting and/or advisory boards: AbbVie, Amgen, Aclaris, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Sun Pharma, UCB, Chugai, Galderma, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, Sun Pharma, UCBB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB, Grant/research support from: Research grants: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma, UCB,
Table 1. Targeted AEs of Interest

<table>
<thead>
<tr>
<th></th>
<th>Total PY</th>
<th>Mean PY</th>
<th>Total Points (%)</th>
<th>Mean Points (%)</th>
<th>Total PY</th>
<th>Mean PY</th>
<th>Total Points (%)</th>
<th>Mean Points (%)</th>
<th>Through 2 Yrs</th>
<th>Through 5 Yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total PY</td>
<td>645</td>
<td>1.7</td>
<td>64.5</td>
<td>1.7</td>
<td>1912</td>
<td>3.8</td>
<td>1912</td>
<td>3.8</td>
<td>7166</td>
<td>4.2</td>
</tr>
<tr>
<td>Mean PY</td>
<td>1.6</td>
<td>1.1</td>
<td>1.6</td>
<td>1.1</td>
<td>4.2</td>
<td>2.8</td>
<td>4.2</td>
<td>2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall SAEs</td>
<td>4.65</td>
<td>0.13</td>
<td>4.65</td>
<td>0.13</td>
<td>5.56</td>
<td>0.42</td>
<td>5.56</td>
<td>0.42</td>
<td>5.01</td>
<td>0.43</td>
</tr>
<tr>
<td>Gl-related SAEs</td>
<td>0.46</td>
<td>0.06</td>
<td>0.46</td>
<td>0.06</td>
<td>0.43</td>
<td>0.02</td>
<td>0.43</td>
<td>0.02</td>
<td>0.64</td>
<td>0.04</td>
</tr>
<tr>
<td>Ol's</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
</tr>
<tr>
<td>Candida infections</td>
<td>0.31</td>
<td>0.04</td>
<td>0.31</td>
<td>0.04</td>
<td>0.52</td>
<td>0.06</td>
<td>0.52</td>
<td>0.06</td>
<td>0.70</td>
<td>0.04</td>
</tr>
<tr>
<td>Non-pathogen specific fungal infections, suspicious for candida</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.13</td>
<td>0.00</td>
<td>0.13</td>
<td>0.00</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>Uveitis/ iridocyclitis</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.00</td>
<td>0.04</td>
</tr>
</tbody>
</table>

*In PsA Pn2, data after early escape at W16 were excluded. AEs are coded using MEDRA Version 23.1.*

**AB0893**

AN ANALYSIS OF FATIGUE IN PATIENTS WITH PSORIATIC DISEASE UTILIZING SF-36 VITALITY SCORES: RESULTS THROUGH WEEK 24 IN PHASE 3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS

J. F. Merola, Y. H. Liu, Y. W. Yang, M. Miller, M. Shawii, D. Chan, S. Khatiri, L. Savage, W. H. Boehncke, C. Han, Harvard Medical School, Brigham and Women's Hospital, Department of Dermatology, Boston, MA, United States of America; Janssen Global Services, LLC, Department of Immunology, Arthritis, NJ/Malvern, PA, United States of America; Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America; Janssen Research & Development, LLC, Department of Immunology, Spring House, PA, United States of America; Janssen Scientific Affairs, LLC, Department of Dermatology, Horsham, PA, United States of America; Janssen Research & Development, LLC, Department of Immunology, New York, NY, United States of America; University of Leeds, Department of Dermatology, Leeds, United Kingdom; Geneva University Hospitals, University of Geneva, Division of Dermatology and Venerology, Geneva, Switzerland

**Background:** Patients with chronic inflammatory diseases can experience significant fatigue, negatively impacting health-related quality-of-life.1,2

**Objectives:** This post-hoc analysis evaluated baseline fatigue severity among patients with psoriasis and/or psoriatic arthritis (PsA) and the effect of guselkumab treatment on patient-reported fatigue.

**Methods:** VOYAGE-2 evaluated guselkumab every 8 weeks (Q8W) versus placebo (W16→guselkumab) and adalimumab in treating moderate-to-severe psoriasis.1 DISCOVER-1 and DISCOVER-2 evaluated guselkumab Q4W and Q8W versus placebo in treating active PsA. Fatigue was assessed using 36-item Short Form (SF-36) vitality scale score (includes 4 questions on fatigue/energy level); the US population norm=50±10; 5-point integer decrements are typically observed in conditions known to cause fatigue; scores ≤35 indicate clinically important fatigue; increases ≥5 indicate clinically meaningful improvement.2

**Results:** Across randomized groups at baseline, mean SF-36 vitality scores were 47.7±8.5 in psoriasis and 42.2±4.40 in PsA patients; 11%-15% of psoriasis and 20%-28% of PsA patients had scores ≤35. In psoriasis patients, mean increases in SF-36 vitality score at W16 were: placebo, 1.1; adalimumab, 3.9 (p<0.001 versus placebo); guselkumab, 5.6 (p<0.001 versus placebo); at W24: placebo→guselkumab, 4.6; adalimumab, 3.9; guselkumab, 5.8 (p=0.0148 versus adalimumab). In PsA patients, mean increases at W24 were: placebo, 2.3±4.0; guselkumab, 5.5±7.5 (p<0.001 versus placebo). Through the placebo-controlled periods, significantly greater proportions of guselkumab-treated patients achieved clinically meaningful improvement in fatigue versus placebo (W16 psoriasis: guselkumab, 48%; placebo, 32%; p<0.001; W24 PsA: guselkumab, 53%-55%; placebo, 34%-44%; p<0.05).

**DO:** 10.1136/annrheumdis-2022-eular.1495
Conclusion: At baseline, patients with psoriatic disease experienced clinically important fatigue, more so with PsA (20%-28%) than psoriasis (11%-15%). In guselkumab-treated psoriasis and PsA patients, clinically meaningful improvements in fatigue were achieved at W16 and W24, respectively.

REFERENCES:

Disclosure of Interests: Joseph F. Merola Consultant of: AbbVie, Arena, Bio-gen, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Yi-Hsuan Liu Employee of: Janssen Global Services, LLC and may own stock or stock options in Johnson & Johnson, King's College Hospital, and the Barts Health NHS Trust. I-Wei Lin Consultant of: AbbVie, Eli Lilly, and Novartis. Shuai Cheng, Danyang Han Employee of: Janssen Global Services, LLC and may own stock or stock options in Johnson & Johnson, Saakshi Khattri Speakers of Johnson & Johnson, and may own stock or stock options in Johnson & Johnson, Daphne Chan Employee of: Janssen Scientific Affairs, LLC and may own stock or stock options in Johnson & Johnson, Saakshi Khattri Speakers bureau: AbbVie, Eli Lilly, UCB, Janssen, Paid instructor for: AbbVie, Eli Lilly, UCB, Janssen, Consultant of: AbbVie, Eli Lilly, UCB, Janssen, Grant/research support from: Pfizer, AbbVie, Biogen, Genentech, Eli Lilly, Laura Savage Speakers bureau: AbbVie, Eli Lilly, UCB, Janssen, Paid instructor for: AbbVie, Eli Lilly, UCB, Janssen, Consultant of: AbbVie, Eli Lilly, UCB, Janssen, Grant/research support from: Pfizer, AbbVie, Leo, BMS, Eli Lilly, Laura Savage Speakers bureau: AbbVie, Eli Lilly, UCB, Janssen, Paid instructor for: AbbVie, Eli Lilly, UCB, Janssen, Consultant of: AbbVie, Eli Lilly, UCB, Janssen, Grant/research support from: Pfizer, AbbVie, Leo, BMS, Eli Lilly, Laura Savage Speakers bureau: AbbVie, Eli Lilly, UCB, Janssen, Paid instructor for: AbbVie, Eli Lilly, UCB, Janssen, Consultant of: AbbVie, Eli Lilly, UCB, Janssen, Grant/research support from: Pfizer, AbbVie, Leo, BMS, Eli Lilly, Laura Savage

AB0894 EFFICACY AND SAFETY OF GUSELKUMAB IN BIOLOGIC-NAIVE PATIENTS WITH ACTIVE AXIAL PSORIATIC ARTHRITIS: STUDY DESIGN OF A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL


BAASID Clinical Trials Unit, Department of Rheumatology, Toronto Western Hospital and University of Toronto, Department of Medicine, Ontario, Canada; Swedish Medical Center/Providence St. Joseph Health and University of Washington, Department of Rheumatology, Seattle, WA, United States of America; University of New South Wales, Department of Rheumatology, Randwick, New South Wales, Australia; Hospital Italiano de Buenos Aires, Department of Rheumatology, Buenos Aires, Argentina; Janssen Scientific Affairs, LLC, Department of Immunology, Horsham, PA, United States of America; Drexel University College of Medicine, Division of Rheumatology, Philadelphia, PA, United States of America; Janssen Global Services, LLC, Department of Immunology, Horsham, PA, United States of America; Janssen Research & Development, LLC, Department of Immunology, Spring House, PA, United States of America; The Chinese University of Hong Kong, Department of Medicine & Therapeutics, Hong Kong, Hong Kong (SAR); University of Leeds, School of Medicine, Department of Rheumatology, Leeds, United Kingdom; University of California at San Diego, Department of Rheumatology, La Jolla, CA, United States of America; Oregon Health & Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR, United States of America; University of Copenhagen, Department of Rheumatology, Copenhagen, Denmark; Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Department of Rheumatology, Herne, Germany

Background: Established criteria for classifying axial psoriatic arthritis (PsA) are lacking, and assessments of activity often rely on measures developed for ankylosing spondylitis (AS). There is an unmet need to systematically identify and measure efficacy of treatments for axial PsA patients (pts). Guselkumab (GUS), a selective interleukin (IL)–23p19 inhibitor, was efficacious in improving signs and symptoms of active PsA in phase 3 trials, randomized, placebo-controlled (PBO)-controlled studies: DISCOVER-1 & DISCOVER-2. In a post-hoc pooled analysis of DISCOVER-1&2 pts with investigator-confirmed sacroiliitis, GUS-treated pts had greater improvements in axial symptoms compared with PBO. Imaging in DISCOVER-1&2 was restricted to the sacroiliac (SI) joints, occurring prior to/at screening as confirmed by the investigator, and locally read.

Objectives: To design a new, dedicated study to evaluate the effects of GUS on axial PsA prospectively.

Methods: Cumulative evidence from DISCOVER-1&2, including exposure–response relationship, covariate adjustment for modest baseline imbalances across treatment groups, subgroup analyses, and comparisons within and across these studies, was considered in designing a new trial. Data from the pivotal registrational studies suggest similar efficacy with GUS every-4-weeks (Q4W) and Q8W regimens in treating PsA signs and symptoms, including symptoms of axial involvement. Power calculations were based on mean changes in Bath AS Disease Activity Index (BASDAI) scores in DISCOVER-1&2.

Results: The phase 4, randomized, PBO-controlled STAR study is specifically designed to prospectively assess efficacy outcomes in PsA pts with magnetic resonance imaging (MRI)-confirmed axial inflammation. Based on observed mean (SD) changes from baseline in BASDAI score from DISCOVER-1&2 Table 1), 405 pts, randomized (1:1:1) to GUS Q4W, GUS at W0, W4, then Q8W, or PBO —GUS Q8W at W24, are planned for enrollment (Figure 1). STAR eligibility criteria include PsA ≥6 months and active disease (≥3 swollen & ≥3 tender joints, C-reactive protein [CRP] ≥20.3 mg/dL), prior biologic treatment, past/current anti-TNF and/or IL-17/23/24 inhibitor. Differences in effect size are confirmed by the investigator, and locally read.

Table 1. Power calculations for the primary endpoint in the Phase 4 STAR study.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Observed mean (SD) change in BASDAI from W0-24</th>
<th>Effect size</th>
<th>Power (N=135; α=0.05)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBO</td>
<td>-1.28 (2.24)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GUS 100 mg Q4W</td>
<td>-2.51 (2.00)</td>
<td>1.23</td>
<td>&gt;99%</td>
</tr>
<tr>
<td>GUS 100 mg Q8W</td>
<td>-2.61 (2.47)</td>
<td>1.33</td>
<td>&gt;99%</td>
</tr>
</tbody>
</table>

* From the pooled DISCOVER-1&2 trials**Power calculations based on N=135 per study group (1:1 randomization) and 2-sided significance of 0.05 using a 2-sample t-test assuming equal variances/BASDAI. Bath Ankylosing Spondylitis Disease Activity Index; GUS, guselkumab; PBO, placebo; Q4W, every 4 weeks; Q8W, every 8 weeks; SD, standard deviation; W, week

Conclusion: The phase 4 STAR study will allow for an in-depth, prospective evaluation of the effects of selectively inhibiting the IL-23p19 subunit with GUS in pts with MRI-confirmed axial PsA.

REFERENCES:
Disclosure of Interests: Dafna D Gladman Consultant of: AbbVie, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB, Grant/research support from: AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, Philip J Mease Speakers bureau: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmune, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmune, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Grant/research support from: AbbVie, Aclaris, Amgen, BMS, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmune, Janssen, Novartis, Pfizer, SUN Pharma, and UCB, Consultant of: AbbVie, Eli Lilly, Gilead, Janssen, MSD, Pfizer, and UCB, Consultant of: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and Enrique Soriano Speakers bureau: AbbVie, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Janssen, Novartis, and Roche, Grant/research support from: AbbVie, Janssen, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Jefferies, and Roche

Background: Given the availability of advanced therapies in PsA with different modes of action, it is of interest to characterize their impact on overall clinical outcomes.

Objectives: To describe residual disease activity in Canadians with PsA treated with advanced therapies.

Methods: Multi-region, observational, retrospective analysis of data from Rhumadata (Quebec) and International Psoriasis and Arthritis Research Team (IPART) Canadian registries was performed. Data from each registry and region were analyzed separately using a common statistical analysis plan to generate descriptive statistics. Patients included in the registries were eligible if they were adults at the time of PsA diagnosis and were treated with an advanced therapy for ≥6 months initiated between January 2010 and December 2019. Residual disease activity was defined as failing to achieve MDA (defined as achieving ≥5 of: TUC ≤1, SJC ≤1, PASI ≤1 or BSA ≤3%; patient pain VAS score of ≤15 mm; patient global disease activity VAS score of ≤20 mm; HAQ score ≤0.5, and tender and swollen joint counts ≤1) (primary endpoint), or DAPSA score ≥14 (secondary endpoint) within 6 months of initiation of an advanced therapy (TNFi, IL-12/23i, IL-17i, PDE4i, CTLA4i or JAKi).

Results: 1,866 subjects (Atlantic [IPART; Newfoundland]: N=887; Quebec [Rhumadata]: N=985; Ontario [IPART]: N=965; West [IPART; British Columbia, Manitoba]: N=130) were included in this preliminary analysis. Baseline characteristics are presented in Table 1. Overall, 899 were receiving their 1st advanced therapy, 464 were receiving their 2nd, and 264 had received ≥3. The most common therapy class was TNFi, followed by IL-17i. 18/21 (85.7%) subjects in the Atlantic region with an assessment, 184/246 (74.8%) in Quebec, 391/571 (68.1%) in Ontario, and 30/43 (69.8%) in Western Canada failed to achieve MDA within 6 months following advanced therapy initiation. Failure to achieve MDA within the allotted period was higher among patients receiving an IL-17i compared with a TNFi. There was no appreciable effect of line of therapy. Also, 74 of 110 (67.3%) patients with an assessment in Quebec, 201/365 (55.1%) in Ontario and 3/3 (100%) in the West failed to achieve at least low disease activity (LDA; DAPSA ≤14) within 6 months following initiation of an advanced therapy. Data were not available for the Atlantic region. The proportion of patients not achieving LDA by advanced therapy was similar for those receiving a TNFi and IL-17i but increased with line of therapy.

Conclusion: Preliminary data show approximately three quarters of Canadians with PsA failed to achieve MDA or LDA within 6 months of initiating an advanced therapy; Disease duration is a possible explanation for not achieving MDA or LDA; better therapeutic approaches are needed to achieve these outcomes in patients with PsA.

Acknowledgements: The authors wish to thank Dr. Steve Ramkissoon, for supporting the statistical analysis of the IPART registry, Medical writing and statistical support (funded by Abbvie) were provided by John Howell and Hong Chen, respectively, from McDougall Financial. Financial support for the study was provided by AbbVie. AbbVie participated in the design of the study, interpretation of data, review, and approval of this publication. All authors contributed to the development of the publication and maintained control over the final content.


Table 1. Patient demographic and baseline characteristics, and response to treatment

<table>
<thead>
<tr>
<th>Variable</th>
<th>Atlantic (N=83)</th>
<th>Quebec (N=867)</th>
<th>Ontario (N=965)</th>
<th>West (N=130)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years, mean [SD])</td>
<td>50.3 (11.1)</td>
<td>50.7 (12.1)</td>
<td>49.1 (12.9)</td>
<td>46.7 (12.1)</td>
</tr>
<tr>
<td>Female (n [%])</td>
<td>44/83 (53.0)</td>
<td>346/687 (50.4)</td>
<td>427/966 (44.2)</td>
<td>81/128 (62.3)</td>
</tr>
<tr>
<td>BMI (kg/m², n, mean [SD])</td>
<td>15.20 (3.6)</td>
<td>553.29 (6.6)</td>
<td>570.30 (6.9)</td>
<td>45.32 (10.6)</td>
</tr>
<tr>
<td>Time since diagnosis (years, N, mean [SD])</td>
<td>83.8 (8.7)</td>
<td>687.7 (7.9)</td>
<td>895.11 (11.7)</td>
<td>74.11 (8.9)</td>
</tr>
<tr>
<td>HLA-B27 positive (n [%])</td>
<td>N/A</td>
<td>58/335 (17.3)</td>
<td>66/648 (13.3)</td>
<td>N/A</td>
</tr>
<tr>
<td>Presence of EAMs (n [%])</td>
<td>0/44 (0.0)</td>
<td>27/668 (3.9)</td>
<td>65/660 (9.1)</td>
<td>N/A</td>
</tr>
<tr>
<td>Fulfilment of CASPAR (n [%])</td>
<td>N/A</td>
<td>39/168 (56.9)</td>
<td>100/100 (100)</td>
<td>N/A</td>
</tr>
<tr>
<td>Therapy class (n [%])</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>TNFi</td>
<td>66 (79.5)</td>
<td>478 (69.0)</td>
<td>651 (67.3)</td>
<td>104 (80.0)</td>
</tr>
<tr>
<td>IL-17i</td>
<td>11 (13.3)</td>
<td>106 (15.4)</td>
<td>191 (19.9)</td>
<td>21 (16.2)</td>
</tr>
<tr>
<td>IL-12/23i</td>
<td>6 (7.2)</td>
<td>33 (4.8)</td>
<td>124 (12.9)</td>
<td>5 (3.9)</td>
</tr>
<tr>
<td>PDE4i</td>
<td>22 (26.5)</td>
<td>48 (10.0)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Other</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Patients may be taking >1 advanced therapy. **Not all patients had assessments of disease activity.
Janssen Novartis, Pfizer, UCB, Grant/research support from: AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, UCB

AB0896

COMPARATIVE EFFECTIVENESS OF GUSELKUMAB IN PSORIATIC ARTHRITIS: UPDATES TO A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

P. J. Mease1, I. McInnes2, L. S. Tam3, R. Rajalagniran4, S. Peterson5, F. Hassann6, S. D. Chakravarty7, C. Contre8, A. Armstrong9, W. H. Boehncke10, C. T. Ritchin11, 1Swedish Medical Center/Province St. Joseph Health & University of Washington, Rheumatology Research, Seattle, WA, United States of America; 2University of Glasgow, Institute of Infection, Immunity and Infection, Glasgow, United Kingdom; 3The Chinese University of Hong Kong and the Prince of Wales Hospital, Department of Medicine & Therapeutics, Hong Kong, Hong Kong (SAR); 4EVERSANA, Department of Immunology, Burlington, Canada; 5Janssen Global Services, LLC, Department of Immunology, Horsham, PA, United States of America; 6Janssen EMEA, Department of Immunology, High Wycombe, United Kingdom; 7Janssen Scientific Affairs, LLC, Department of Immunology, Horsham, PA, United States of America; 8Drexel University College of Medicine, Division of Rheumatology, Philadelphia, PA, United States of America; 9Janssen Pharmaceutical Companies of Johnson & Johnson, Department of Immunology, Issy-les-Moulineaux, France; 10Geneva University Hospitals, Department of Dermatology, Geneva, Switzerland; 11University of Rochester, Department of Medicine - Allergy/Immunology and Rheumatology, Rochester, NY, United States of America

Background: The efficacy of guselkumab (GUS), an interleukin (IL)-23 p19-subunit inhibitor, has been demonstrated for psoriatic arthritis (PsA) in two pivotal phase 3 trials (COSMOS and DISCOVER-1&2). A third phase 3b trial (COSMOS) evaluated GUS in patients with PsA who had an inadequate response (IR) to tumor necrosis factor inhibitors (TNFi). GUS has previously been compared to targeted PsA therapies through network meta-analysis (NMA).

Objectives: This NMA update was to include data for GUS in TNFi-IR patients from COSMOS, as well as two additional key comparators, risankizumab (RIS), an IL-23 inhibitor, and upadacitinib (UPA), a Janus kinase inhibitor (JAKi).

Methods: A systematic literature review identified PsA randomised controlled trials up to February 2021. A subsequent hand-search identified data for newer agents, including congresses up to July 2021. Bayesian NMAs were performed to compare treatments on American College of Rheumatology (ACR) response, Psoriasis Area and Severity Index (PASI) response, modified van der Heijde-Sharp (vdH-S) score, and serious adverse events (SAEs). Analyses used fixed or random effects models and adjusted for placebo response via meta-regression on baseline risk when feasible. Multinomial models were used for ACR and PASI. Results were summarized by ranking treatments in league tables according to results derived from NMAs. Conclusions (ie, comparable or better/worse) for GUS 100 mg every 4 weeks (Q8W/Q4W) versus comparators were based on overlap of pairwise 95% credible intervals (CIs) (ie, treatments are comparable if CIs overlap 1 [dichotomous outcomes] or 0 [continuous outcomes]).

Results: Thirty-three phase 3 studies were included in the NMAs. Studies were placebo-controlled up to 24 weeks except for 2 head-to-head studies, and evaluated 15 targeted PsA therapies in TNFi naive, IR, or mixed populations. For ACR 20 response, GUS Q8W and Q4W ranked 14th and 12th among 23 treatments and were comparable to most other active agents, including RIS and UPA, subcutaneous (SC) TNFi, and most IL-17A inhibitors (IL-17A), as demonstrated by overlap in pairwise 95% CIs with unity. Results were similar for ACR 50 and 70 responses. For PASI 90, GUS Q8W and Q4W ranked 2nd and 1st among 23 treatments and were better than multiple agents, including all SC TNFi, JAKi, including UPA, and other small molecules, as demonstrated by nonoverlap in pairwise 95% CIs. Compared with GUS Q8W and Q4W were similar to RIS and most IL-17A for PASI 90, but point estimates consistently favored GUS. For vdh-S score, GUS Q8W and Q4W ranked 8th and 3rd among 18 treatments; GUS Q4W was better than RIS, and both GUS Q8W and Q4W were comparable to most other agents including UPA. SAEs were comparable across most agents.

Conclusion: GUS demonstrated better skin efficacy than most other targeted PsA therapies, including UPA. For vdh-S, both GUS dose regimens were comparable in most treatments, with both GUS doses ranking higher than most, including UPA and RIS. Both GUS dose regimens demonstrated ACR responses that were comparable to most other agents, including UPA and RIS, and ranked favorably in the network for SAEs.

REFERENCES: None

Disclosure of Interests: Philip J Mease Speakers bureau: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis and UCB Pharma, Grant/research support from: Novartis and Pfizer, Raji Rajalagniran Employee of: EVERSANA, Steve Peterson Shareholder of: may own stock or stock options in Johnson & Johnson, Employee of: Janssen Global Services, LLC, Consultant of: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma, Consultant of: AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Leo, Novartis, and UCB Pharma, Consultant of: AbbVie, Almirall, Celgene, Eli Lilly, Janssen, Leo, Novartis, and UCB Pharma, Grant/research support from: Pfizer, Christopher T. Ritchin Consultant of: AbbVie, Amgen, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB Pharma, Grant/research support from: AbbVie, Amgen, and UCB Pharma, Grant/research support from: Abbott, Amgen, Boehringer Ingelheim, Pfizer, Janssen, Merck, Novartis, Pfizer, Sun Pharma, and UCB Pharma.
GUSELKUMAB IMPROVES DACTYLITIS IN PSA PATIENTS WITH INADEQUATE RESPONSE TO TNFI: DATA FROM THE PHASE 3B COSMOS TRIAL

H. Marzo-Ortega1, E. Theander2, M. Neuhold3, P. Bergmans4, M. Shaw5, M. Perate6, C. Contre7, I. Moinnes8, G. Schett9

1Leeds Teaching Hospitals Trust and University of Leeds, NIHR Leeds Biomedical Research Centre and Leeds Institute of Rheumatologic and Musculoskeletal Medicine, Leeds, United Kingdom; 2Janssen, Scientific Affairs, LLC, Solna, Sweden; 3Janssen, Scientific Affairs, LLC, Zug, Switzerland; 4Janssen, Biostatistics, Breda, Netherlands; 5Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, United States of America; 6Janssen, Scientific Affairs, LLC, Horsham, United States of America; 7Janssen, Scientific Affairs, LLC, Issy-les-Moulineaux, France; 8University of Glamorgan, M4LS College Office, Institute of infection, immunity and inflammation, Glamorgan, United Kingdom; 9University of Erlangen, Department of Medicine 3 - Rheumatology and Immunology, Erlangen, Germany.

Background: Dactylitis is a biomarker of disease severity in psoriatic arthritis (PsA) associated with functional disability, impaired quality of life and radiographic progression. The COSMOS study demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor (i), in patients (pts) with PsA who had inadequate response (IR; insufficient efficacy or intolerance) to 1–2 TNFI.

Objectives: To evaluate the efficacy of GUS 100 mg Q8W on dactylitis, and assess the relationship between dactylitis resolution and improvement in other clinical outcomes, through 1 year in TNFI-IR PsA pts.

Methods: Pts received GUS or placebo (PBO); PBO pts crossed over to GUS at either Week (W) 16 (early escape [EE]) or W24 (planned). As observed, 88% of these PBO→GUS pts had complete resolution of dactylitis at W48 (Figure 1). Of 105 dactylitis-free pts at BL in the GUS arm, 8 (6%) developed dactylitis before W48; 4 at W4, 2 at W8 and 1 each at W16 and 36. Complete resolution was seen in 6 (7%) of the 8 pts by W48, when 1 further new-onset case occurred: Utilizing observed data among GUS-randomized pts with and without BL dactylitis, 32% and 34%, respectively, achieved MDA at W48. Respective response rates were 59% and 55% for DAPSA LDA, and 28% and 15% for DAPSA remission. In those who did and did not achieve complete dactylitis resolution at W48, respective response rates were 38% and 0% for MDA, 88% and 13% for DAPSA LDA, and 31% and 0% for DAPSA remission. Of 69 pts with both enthesis and dactylitis at BL who continued to receive GUS through W48, GUS resolved both manifestations in 72%, neither in 16%, only enthesis in 4%, and only dactylitis in 7% of pts.

Conclusion: Complete dactylitis resolution was achieved in ≥80% of pts who continued to receive GUS at W48, with partial resolution seen in most remaining pts in an as-observed analysis. Response rates increased through W48. Dactylitis resolution in this difficult-to-treat TNFI-IR PsA population was frequently associated with enthesis resolution and achievement of clinical outcomes representing low levels of disease activity.

REFERENCES:

1) Coates LC et al. Ann Rheum Dis 2021

Disclosure of Interests: Helena Marzo-Ortega Speakers bureau: Abbvie, Biogen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Takeda, UCB, Consultant of: Abbvie, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda, UCB, Grant/research support from: Janssen, Novartis, UCB, Elke Theander Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), Marlies Neuhold Shareholder of: Own Johnson & Johnson stock and/or stock options, Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson), Paul Bergmans Shareholder of: Own Johnson & Johnson stock and/or stock options, Employee of: Employed by Janssen Scientific Affairs, LLC (a subsidiary of Johnson & Johnson).
Results: From December 2019 until this interim data cut (June 2021), a total of 477 pts (305 female; mean age 52) were enrolled. Mean age ranged from 48 (IL-12/23i and IL-23) to 55 (JAKi), with a majority of female pts in each group (Table 1). Pts in the IL-12/23i and IL-23i and TNFi groups showed the shortest time since PsA diagnosis (5.2±4.5, 6.5±7.9), while the JAKi group showed the longest time (10.6±8.4). The lowest proportion of pts with a prior b/tsDMARD used was observed in the TNFi group (31%), the highest in the IL-12/23i and IL-23i group (71%). Pts in the ileo and IL-12/23i and IL-23i groups were more likely to be on monotherapy. Tender Joint Count (9.1-11.3) and Swollen Joint Count (3.3-5.8) were comparable across groups, with the highest values in the ileo and JAKi groups, respectively. Pt proportion with enthesitis and dactylitis was higher in the ileo, secukinumab and JAKi groups. Percentage of Body Surface Area affected by psoriasis was higher in the ileo, secukinumab and IL-12/23i and IL-23i groups. Pts proportion with nail psoriasis was higher in the ileo and secukinumab groups. Physician’s Global Assessment Visual Analog Scale (VAS), Patient’s Global Assessment and Patient’s Assessment of Joint Pain VAS reflected a high burden of illness.

Table 1. Baseline characteristics

<table>
<thead>
<tr>
<th>bDMARDs</th>
<th>IL-12/23i and IL-23 inhibitors</th>
<th>tsDMARDs</th>
<th>JAK Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=137</td>
<td>N=46</td>
<td>N=24</td>
<td>N=211</td>
</tr>
<tr>
<td>Age</td>
<td>52.8±12.2</td>
<td>52.8±13.1</td>
<td>47.6±13.4</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>86 (62.8)</td>
<td>31 (67.4)</td>
<td>16 (66.7)</td>
</tr>
<tr>
<td>Years since diagnosis</td>
<td>8.4±7.5</td>
<td>7.6±8.0</td>
<td>6.2±4.5</td>
</tr>
<tr>
<td>Prior b/tsDMARD, n (%)</td>
<td>87 (63.5)</td>
<td>27 (58.7)</td>
<td>17 (70.8)</td>
</tr>
<tr>
<td>Concomitant csDMARD, n (%)</td>
<td>47 (34.3)</td>
<td>19 (41.3)</td>
<td>5 (20.8)</td>
</tr>
<tr>
<td>Tender Joint Count</td>
<td>11.3±10.2</td>
<td>9.1±10.8</td>
<td>9.1±9.3</td>
</tr>
<tr>
<td>Swollen Joint Count</td>
<td>5.7±6.6</td>
<td>3.3±3.8</td>
<td>3.4±6.4</td>
</tr>
<tr>
<td>Body Surface Area % affected by psoriasis</td>
<td>6.1±10.5</td>
<td>7.6±14.2</td>
<td>7.0±29.7</td>
</tr>
<tr>
<td>Presence of enthesitis, n (%)</td>
<td>58 (42.3)</td>
<td>16 (34.8)</td>
<td>4 (16.7)</td>
</tr>
<tr>
<td>Presence of dactylitis, n (%)</td>
<td>33 (24.1)</td>
<td>10 (21.7)</td>
<td>3 (12.5)</td>
</tr>
<tr>
<td>Presence of nail psoriasis, n (%)</td>
<td>57 (41.6)</td>
<td>20 (43.5)</td>
<td>7 (29.2)</td>
</tr>
<tr>
<td>Physician’s Global assessment VAS</td>
<td>62.6±18.1</td>
<td>59.5±20.5</td>
<td>55.7±24.6</td>
</tr>
<tr>
<td>Patient’s Global Assessment VAS</td>
<td>60.5±20.4</td>
<td>56.8±25.1</td>
<td>56.2±25.7</td>
</tr>
<tr>
<td>Patient’s Assessment of Joint Pain VAS</td>
<td>62.7±21.3</td>
<td>58.4±27.1</td>
<td>55.7±28.3</td>
</tr>
</tbody>
</table>

Means SD, unless otherwise stated

Conclusion: The reported BL characteristics offer preliminary information about which pts initiate or switch to a b/tsDMARD in a real-life setting. Future disclosures (at 12 and 24M) will provide RWE regarding persistence, effectiveness, and health care resource use of available treatments for PsA, which will help pts and physicians to make better informed treatment decisions.


Objectives: To assess the impact of different strategies of antirheumatic treatment management on disease activity around the time of vaccination for Coronavirus disease (Covid-19) in patients with psoriatic arthritis (PsA).

Methods: We prospectively evaluated patients with PsA in remission or low-disease activity candidate to receive Covid-19 vaccination with mRNA vaccines. Methotrexate (MTX) and leflunomide were withheld 7 days after each dose, whilst biological DMARDs (bDMARDs) were, either continued (46.8% of the patients) or withheld (53.2%) from the day of the first dose until 7 days after the second dose. Patients were reassessed after 3 months from enrollment in case of disease flare.

Results: After the second dose of Covid-19 vaccination 7 patients (5.6%) (6 females) had an articular disease flare each (mean involved joints: 129), one patient presented a concomitant worsening of psoriasis, and four patients had an isolated worsening of their psoriasis. All patients received additional treatments with oral GC (n=2) or non-steroidal anti-inflammatory drugs (n=5). Two flares lasted more than one week and required a modification of the ongoing bDMARD. Articular flare incidence (6.8% vs 3%, P=0.259), involved joints (1.4 vs 1.5, P=0.846), disease flare severity, and changes in antirheumatic therapies (1 vs 1, P=0.928) did not differ significantly between the two different bDMARD management strategy groups (continued vs temporary withheld). There was no significant difference in disease activity score for psoriatic arthritis (DAPSA) and C-reactive protein (CRP) after vaccination, but patients who flared up had a higher mean basal DAPSA (7.3 vs 4.1, P=0.046), On binomial logistic regression analysis, we did not find any significant association with gender, age, basal CRP, basal DAPSA, active psoriasis, conventional synthetic DMARDs, or bDMARDs and disease flare.

Conclusion: Our findings suggest that a temporary short halt of bDMARDs could be a viable option in patients with well-controlled PsA undergoing Covid-19 vaccination without increasing the risk of flares, which could be useful to increase T cell response and antibody titres after Covid-19 vaccination.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2094

AB0091

EFFECTS OF TREATMENT WITH RISANKIZUMAB ON REDUCING PAIN AND INFLAMMATION IN PATIENTS WITH PSORIATIC ARTHRITIS: AN ANALYSIS OF THE KEEPSAKE -1 AND -2 TRIALS

A. Ostro1, S. Kwatra2, C. Nduaka3, M. Patel1, A. M. Soliman1, L. Barcomb3, Z. Xue3, H. Photowala3, K. Papp4. 1AbbVie1, 2AbbVie Inc., Immunology, North Chicago, United States of America; 3Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, United States of America; 4AbbVie Inc., Immunology, North Chicago, United States of America; 5Kapp Clinical Research, Prophy Medical Research, Waterloo, Canada

Background: Risankizumab (RZB), a monoclonal antibody that specifically inhibits interleukin 23, is being investigated as a treatment for adults with psoriatic arthritis (PsA).

Objectives: Evaluate the efficacy of RZB treatment on the reduction in pain and inflammation in patients with active PsA.

Methods: KEEPSAKE-1 and -2, double-blind, phase 3 trials, evaluated the efficacy of RZB versus placebo (PBO) for the treatment of adult patients with active PsA. Patients were randomized (1:1) to receive subcutaneous RZB 150 mg or PBO at weeks 0, 4, and 16. A reduction in pain visual analogue (VAS) score of 30% (meaningful), 50% (substantial) from baseline, and achievement of a mini-

clinical importantly different measure (MCID) in pain VAS was analyzed using NRI. High-sensitivity C reactive protein (hsCRP) was analyzed using mixed-effect model repeated measurement. Results are reported from the 24-week timepoint.

Results: A total of 1407 patients were included in the 24-week assessment (KEEPSAKE-1 RZB=483, PBO=481; KEEPSAKE-2 RZB=224, PBO=219), 55% of patients receiving significant pain reduction than did patients receiving placebo (KEEPSAKE-1 54.7% vs 31.1%, P<0.001; KEEPSAKE-2 42.3% vs 22.2%, P<0.001). Similar trends were noted for significant pain reduction in patients receiving MCID in pain VAS was analyzed using NRI. High-sensitivity C reactive protein (hsCRP) was analyzed using mixed-effect model repeated measurement. Results are reported from the 24-week timepoint.

Conclusion: KEEPSAKE-1 and -2 trials showed significant improvement in pain and inflammation in patients with active PsA.

Disclosure of Interests: Andrew Ostor Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis Pfizer, Roche, Sanofi, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, and UCB, Shawn Kwatra Speakers bureau: AbbVie, Celldex Therapeutics, Galderma, Incyte Corporation, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi, Grant/research support from: Abbvie, Celldex Therapeutics, Galderma, Incyte Corporation, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, Sanofi, and Kiniksa Pharmaceuticals, and has served as an investigator for Galderma, Kiniksa Pharmaceuticals, Pfizer Inc., and Sanofi.


AB0092

EFFICACY OF IL-17 INHIBITORS IN PSORIATIC ARTHRITIS. SYSTEMATIC REVIEW OF SCIENTIFIC LITERATURE AND META-ANALYSIS

A. Gonzalez Alonso1, D. Fernández Fernández1, R. Dos Santos2, I. González Fernández1, P. Castro-Santamaría1, M. Sanchez-Wonenburger2, J. L. Puga Guzmán2, A. Mata1, E. Perez-Pampín1, A. Soulo Vías1, A. Mera Varela1, 1University of Santiago de Compostela, Santiago de Compostela, Spain; 2Santiago Clinic Hospital CHUS, Rheumatology, Santiago de Compostela, Spain

Background: Psoriatic arthritis is a chronic inflammatory joint disease with a great heterogeneity of manifestations both at the musculoskeletal (arthritis), enthesitis, dactylitis, axial skeleton involvement) and dermatological (skin, nail involvement) domain. The main goal of treatment is to maximize quality of life by controlling symptoms and preventing structural damage. For this, multidisciplinary management must be carried out without forgetting the patient’s general health status and by making the best use of pharmacological therapy to control arthritis, non-vascular anti-inflammatory drugs (NSAIDs) and/or intra-articular corticosteroid injections are proposed as initial therapy. When symptoms are not controlled or there are associated poor prognostic factors, conventional disease-modifying antirheumatic drugs (DMARDs) are recommended, especially methotrexate. When the classic DMARDs do not achieve good control of the disease, the next step will be the use of biological DMARDs, anti-TNF alpha inhibitors, interleukin-17 inhibitors or inhibitors of the IL12/IL23 axis. Other molecules such as Janus kinase (JAK) inhibitors or phosphodiesterase-4 inhibitors such as Apremilast also continue to be incorporated into treatment alternatives. Although these drugs provide a promising result, the scarcity of direct comparative studies implies a need for more research to determine better treatment strategies.

Objectives: To analyze the efficacy of IL-17 inhibitors (Secukinumab, Ilekizumab, Brodalumab and Bimekizumab) in the treatment of patients diagnosed with psoriatic arthritis based on data published in randomised clinical trials (RCTs).

DOI: 10.1136/annrheumdis-2022-eular.2189
Methods: We perform a systematic review of the scientific literature using the Pubmed, Cochrane Library, Embase and Web of Science electronic databases, selecting RCTs evaluating the efficacy of IL-17 inhibitors for the treatment of psoriatic arthritis. A meta-analysis was performed using the random-effects model for each efficacy measure evaluated at different weeks.

Results: 23 studies met the selection criteria from a total of 2198 references identified in the search. 14 references contained data on the use of Secukinumab from 7 RCTs. Ixekizumab was the second IL-17 inhibitor most identified with 6 references with data from 5 RCTs. Bimekizumab with 2 references and Brodalumab with 1 reference completed the review. Despite extracting efficacy data in nail, enthesic and PROs manifestations. We were only able to perform meta-analyses of the ACR 20, AC50, ACR70 and PASI75 response rates at week 12 of treatment, due to the lack of statistically comparable data. The meta-analysis performed demonstrated that IL-17 inhibitors are effective in psoriatic arthritis, compared to placebo in the different efficacy outcomes evaluated (ACR20 12 wk (OR: 3.60 [95%CI: 1.72-7.32]), ACR50 12 wk (OR: 7.94 [95%CI: 4.23-14.91]) and PASI75 12 wk (OR: 21.26 [95%CI: 13.72-32.95]).

Conclusion: Our review concluded that IL-17 inhibitors are effective in the treatment of patients who have shown intolerance or had an unsatisfactory response to other lines of treatment in Psoriatic arthritis.

REFERENCES:


AB0903 DUAL IMMUNOMODULATORY THERAPIES IN PSORIATIC DISEASE
S. Sundaram1, A. Gorman3, D. Veale1, C. Orr1, L. O’Neill1. 1Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Rheumatology, Dublin, Ireland

Background: Since the advent of numerous biologic therapies and small molecular drugs targeting specific cytokines and signalling pathways; the management of patients with psoriatic arthritis (PsA) has significantly improved. However, at least 40% of PsA patients exhibit an incomplete or failure to respond to these treatments. While the outcomes of patients with psoriasis (Pso) has dramatically improved with monoclonal antibody therapies targeting IL-23 and IL-17A; achieving a measurable low disease activity state such as minimal disease activity (MDA) for musculoskeletal manifestations of psoriatic disease is infrequent. Given the complex and heterogeneity of signalling pathways, cytokines and cell types resulting in synovio-entheseal disease in PsA; new treatment strategies must be evaluated to induce deep and sustainable clinical responses in all the phenotypic domains of psoriatic disease (cutaneous, synovium, enthesial and axial). (1) In patients who do not achieve remission in all clinical domains on a biologic monotherapy or combination of a biologic therapy with an oral synthetic agent; dual targeted anti-cytokine strategies or combined biologic with a targeted oral small molecule are a possible treatment option.

Objectives: To describe a series of four patients with recalcitrant psoriatic disease and failure to respond to previous treatment regimens who were successfully treated with dual immunomodulatory therapies.

Methods: Patients on dual immunomodulatory therapies attending our department were prospectively followed and clinical response monitored.

Results:

Table 1.

<table>
<thead>
<tr>
<th>Age/gender</th>
<th>Diagnosis</th>
<th>prior therapies</th>
<th>combination therapy</th>
<th>dose</th>
<th>adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>49/ Male</td>
<td>PsA + PsO</td>
<td>Methotrexate, adalimumab, etanercept, infliximab, golimumab, certolizumab, ustekinumab, secukinumab, ixekizumab</td>
<td>Baricitinib + infliximab</td>
<td>4mg OD + 5mg/kg Q8W</td>
</tr>
<tr>
<td>Case 2</td>
<td>51/ Male</td>
<td>PsA + PsO</td>
<td>Methotrexate, etanercept, adalimumab, ustekinumab, secukinumab, apremilast, ixekizumab</td>
<td>Adalimumab + guselkumab</td>
<td>40mg QoW + 100mg Q8W</td>
</tr>
<tr>
<td>Case 3</td>
<td>51/ Female</td>
<td>PsA + PsO</td>
<td>Methotrexate, sulphasalazine, etanercept, certolizumab, leflunomide, infliximab, adalimumab, secukinumab, ustekinumab, tocilizumab, abatacept, baricitinib</td>
<td>Adalimumab + tocilizumab</td>
<td>40mg QoW + 5mg BD</td>
</tr>
<tr>
<td>Case 4</td>
<td>39/ Male</td>
<td>PsA + PsO</td>
<td>Methotrexate, etanercept, ustekinumab, adalimumab, secukinumab, ixekizumab, sulphasalazine</td>
<td>Ixekizumab + baricitinib</td>
<td>80mg Q4W+ 4mg OD</td>
</tr>
</tbody>
</table>

Figure 1. Mini-Arthroscopy of left knee for Case 3 prior to starting dual immunomodulator therapy (A) Macroscopic aspects of synovitis (B) Synovium vascularization

Conclusion: Multiple pathways and mediators are responsible for the initiation of and sustained joint inflammation and damage seen in PsA. A phase II trial of ABT-122, a biologic engineered to target both TNF and IL-17A showed statistically significant superior efficacy outcomes at multiple time points based on ACR50, ACR70 and psoriasis outcome measures (PASI75/PASI90) when compared to adalimumab, with similar safety profile. (2) Safety concerns such as infectious risks are important considerations with such strategies; however, the targeted second-generation anti-cytokine biologics and targeted JAK-I have exhibited improved safety profiles. (3) In our small case series, patients have not, to date, experienced adverse events of combination therapy.

REFERENCES:


AB0904 EVALUATING NUMERIC RATING SCALE VERSIONS OF THE 3 AND 4 VISUAL ANALOG SCALE (3/4-VAS) COMPOSITE MEASURES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS FROM THE SELECT-Psa PROGRAM
W. Tillett1, L. Coates2, M. Kishimoto3, A. Setty4, T. Gao5, R. Lippe6, P. Hellowell6. 1Royal National Hospital for Rheumatic Diseases, University of Bath, Pharmacy and Pharmacology; Bath, United Kingdom; 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 3Kyorin University School of Medicine, Department of Nephrology and Rheumatology, Tokyo, Japan; 4AbbVie Inc., Immunology, North Chicago, United States of America; 5AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany; 6Leeds Teaching Hospitals Trust and Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds, NIHR Leeds Biomedical Research Centre, Manchester, United Kingdom

Background: The multifaceted nature of psoriatic arthritis (PsA) can make it challenging to evaluate treatment targets and disease activity. Moreover, most existing assessment tools are time-consuming and not always feasible in routine clinical care, indicating a need for new disease measures that are easy to perform and calculate. Composite measures using 3-visual analog scale (VAS;
physician's global assessment, patient's global assessment, and skin) or 4-VAS (physician's global assessment, joints, skin, and pain) have been proposed as simpler alternatives. Given potential advantages of numeric rating scales (NRS) over VAS, we here adapted 3/4-VAS for use with NRS components and tested its validity via post hoc analysis of the upadacitinib (UPA) SELECT-Psa program.

**Objectives:** Evaluate the ability of 3/4-NRS scores to assess treatment response in SELECT-Psa 1 and 2, as well as the correlation of 3/4-NRS with other common disease activity measures.

**Methods:** Data are from the SELECT-Psa 1 and 2 phase 3 trials in patients with prior inadequate response or intolerance to ≥1 non-biologic DMARD or ≥1 biologic DMARD, respectively. In both trials, patients received once daily UPA 15 mg, UPA 30 mg, or placebo (PBO); SELECT-Psa 1 also included the active comparator adalimumab (ADA) 40 mg every other week (wk). 3-NRS scores were determined using the mean of SAPS questions 1–10, physician's global assessment of disease activity, and patient's global assessment of disease activity; 4-NRS scores were determined using the mean of SAPS questions 1–10, physician's global assessment of disease activity, patient's assessment of pain, and BASDAI question 3 related to joint pain and swelling. The 3/4-NRS scale ranges from 0 (no disease activity) to 10 (severe activity). 3/4-NRS and cDAPSA (DAPSA without the CRP component) were assessed at all available visits through wk 56. Correlations between 3/4-NRS with PsA disease activity score (PASDAS), routine assessment of patient index data 3 (RAPID3), DAPSA, cDAPSA, and other disease activity measures were determined by nonparametric Spearman rank correlation coefficient for UPA 15 mg patients from both trials and ADA for SELECT-Psa 1. All data are shown as observed; nominal p-values are provided throughout.

**Results:** A total of 1281 and 423 patients were included from SELECT-Psa 1 and 2, respectively. For both cDAPSA and 3/4-NRS scores, patients receiving UPA 15 mg showed clear numerical improvements compared with PBO at wk 24 in both trials (Table 1). 3/4-NRS scores were highly correlated with RAPID3 and PASDAS measures (r > 0.6, P < 0.0001) for UPA 15 mg patients at baseline (Figure 1). Moderate correlations were observed between 3/4-NRS and DAPSA/cDAPSA (r = -0.4, P < 0.0001), as well as physical function (HAQ-DI) and quality of life measures (SF-36). Nominally significant but weaker correlations were detected for joints, skin, and other disease activity assessments. Similar overall results were observed for patients receiving ADA.

**Conclusion:** 3/4-NRS was able to successfully discriminate between PBO and therapeutic groups in SELECT-Psa 1 and 2. 3/4-NRS scores correlated well with other clinical and patient reported outcome measures, including those focused on joints (DAPSA) or multiple manifestations (PASDAS), supporting 3/4-NRS as a viable and easy to use tool in daily clinical practice.

**REFERENCES:**

AB0905

ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 (RAPID3) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA) AFTER INADEQUATE RESPONSE OR INtolerance to DMARDS: POOLED RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPSAKE 1 AND 2 TRIALS

A. Ogdie1, L. Coates2, R. Acayaba DE Toledo3, A. Biljan4, H. Jones4, K. Tacelosky5, C. Yue6, B. Padilla7, M. Bergman8, 1University of Pennsylvania Perelman School of Medicine, Division of Rheumatology, Department of Medicine, Philadelphia, United States of America; 2University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 3São José do Rio Preto, Medical School, São José do Rio Preto, Brazil; 4AbbVie Inc., Immunology, North Chicago, United States of America; 5Drexel University College of Medicine, Department of Medicine, Philadelphia, United States of America

Background: PsA is a chronic, systemic inflammatory disease with diverse clinical manifestations that can impact a patients’ quality of life. Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit, is approved for the treatment of active PsA in adults. In the phase 3 KEEPSAKE 1 and 2 studies, RZB treatment resulted in significantly greater improvements in signs and symptoms of active PsA compared with placebo (PBO).1,2 RAPID3 is frequently used in clinical practice to evaluate PsA disease activity and consists of 3 key patient-reported measures (physical function, pain, and patient’s global assessment of disease activity [PtGA]).3

Objectives: To evaluate short- (24 week) and long-term (52 week) improvements in RAPID3 scores and achievement of RAPID3 minimal clinically important difference (MCID) across the RZB KEEPSAKE 1 and 2 clinical program.

Methods: In KEEPSAKE 1 (NCT03675308) and KEEPSAKE 2 (NCT03671148), patients with active PsA who experienced inadequate response or intolerance to ≥ 1 csDMARD (KEEPSAKE 1) and/or ≤ 2 biological therapies (KEEPSAKE 2) were randomized to PBO or RZB 150 mg from baseline to week (W) 24; from W28–W52, all patients received open-label RZB 150 mg. At W16, nonresponders could add or modify rescue therapy. This post hoc analysis assessed the mean change from baseline to W24 and W52 in RAPID3 scores and the proportion of patients who achieved a RAPID3 MCID (defined as a decrease of ≥ 3.8 points). Modified RAPID3 scores (range: 0–30) were calculated using pain scores, PtGA, and HAQ-DI, each rescaled to 0–10 and summed together.5

Results: A total of 961 and 443 patients were included from KEEPSAKE 1 and 2, respectively. At baseline, mean RAPID3 scores were 15.3 in both treatment arms of KEEPSAKE 1 (PBO n = 479, RZB n = 482) and 15.1 (PBO n = 219) and 14.8 (RZB n = 224) in KEEPSAKE 2. From W4 to W24, RAPID3 scores were significantly reduced with RZB treatment compared with PBO in both KEEPSAKE 1 (mean change from baseline at W24 of −5.3 vs −2.4, respectively, P < .001) and KEEPSAKE 2 (−6.8 vs −3.2%, P < .001; Table 1). At W52 among patients who received RZB from W0–W52, mean change from baseline was −70 (KEEPSAKE 1) and −52 (KEEPSAKE 2; Figure 1 C, D), and MCID was achieved by 67.5% (KEEPSAKE 1) and 58.5% (KEEPSAKE 2) of patients. Patients who switched from PBO to RZB at W24 experienced similar and substantial improvements in RAPID3 scores by W52.

Table 1. Proportion of Patients Achieving a Minimal Clinically Important Difference From Baseline in RAPID3 (AO).

<table>
<thead>
<tr>
<th>Patient</th>
<th>KEEPSAKE 1</th>
<th>KEEPSAKE 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, % (n/N) [95% CI]</td>
<td>PBO</td>
<td>RZB 150 mg</td>
</tr>
<tr>
<td>W24</td>
<td>36.4 (166/456) [52.0, 57.0]</td>
<td>61.5*** [42.1, 72.9]</td>
</tr>
<tr>
<td>PBO to RZB 150 mg</td>
<td>38.8 [28.0, 49.6]</td>
<td>38.8 [28.0, 49.6]</td>
</tr>
<tr>
<td>W52</td>
<td>59.6 [40.4, 78.8]</td>
<td>61.5*** [42.1, 72.9]</td>
</tr>
</tbody>
</table>

Conclusion: RZB 150 mg was associated with improvement in RAPID3 total scores over 24–52 weeks of treatment in patients with active PsA in KEEPSAKE 1 and 2.

Acknowledgements: AbbVie Inc. participated in the study design; study research; collection, analysis, and interpretation of data; and writing, reviewing, and approving of this abstract for submission. All authors had access to the data; participated in the development, review, and approval of and in the decision to submit this abstract to EULAR 2022 for consideration as a poster or oral presentation. No honoraria or payments were made for authorship. AbbVie and the authors thank all study investigators for their contributions and the patients who participated in this study. AbbVie funded the research for this study and provided writing support for this abstract. Medical writing assistance, funded by AbbVie, was provided by Callie A. S. Corsa, PhD, of JB Ashlin.

Disclosure of Interests: Alexis Ogdie Consultant of: AO has received consulting fees and/or honoraria from AbbVie, Amgen, Bristol Myers Squibb, Celgene, CorEvitas, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, and UCB. Grant/research support from: AO has received grants from AbbVie, Novartis, and Pfizer to the trustees of University of Pennsylvania, and from Amgen to Forward. Laura Coates Speakers bureau: LCC has received grants/research support from: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Medac, Novartis, Pfizer and UCB. Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB, Grant/research support from: LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, and UCB. Ricardo ACAYABA DE TOLEDO Speakers bureau: RAB has received honoraria as a speaker/consultant for AbbVie, Celtrion, Janssen, Novartis, Pfizer, and UCB. Consultant of: RAT has received honoraria as a speaker/consultant for AbbVie, Celtrion, Janssen, Novartis, Pfizer, and UCB. Grant/research support from: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Janssen, Moonlake, Novartis, Pfizer and UCB.

REFERENCES:

Correspondence to: Alexis Ogdie, MD, MSc, FRCPC, Division of Rheumatology, Department of Medicine, University of Pennsylvania, 3400 Spruce Street, Room 428, Philadelphia, PA 19104, USA; alexisogdie@upenn.edu.
TREATMENT WITH UPADACINITIB IN REFRACTORY PSORIATIC ARTHRITIS. MULTICENTER STUDY OF FIRST PATIENTS OF CLINICAL PRACTICE

E. Galíndez-Agirrecoa1, D. Prieto-Peña1, B. Joven-Ibáñez1, E. Rubio Romero2, O. Rusinovich3, J. M. Belzunegui Otano4, R. Melero5, C. Ventín-Rodríguez6, V. Jovani7, R. Almodovar González8, R. García-Vicuna9, T. González10, I. Calvo11, M. L. García-Vivar12, S. Perez Barrio13, I. Gorostiza14, M. A. González-Gay15, R. Blanco16, J. Basurto, Rheumatology, Bilbao, Spain;17HU Valdecilla, Rheumatology, Santander, Spain;18HU de la Princesa, Rheumatology, Madrid, Spain;19HU Virgen ROCIO, Rheumatology, Sevilla, Spain;20HU Puerta de Hierro, Rheumatology, Madrid, Spain;21HU Donostia, Rheumatology, Donostia, Spain;22Complexo Hospitalario Universitario de Vigo, Rheumatology, Vigo, Spain;23CUHAC, Rheumatology, La Coruña, Spain;24HU Alicante, Rheumatology, Alicante, Spain;25Fundación Alcorcon, Rheumatology, Madrid, Spain;26H de la Princesa, Rheumatology, Madrid, Spain;27H Gregorio Marañon, Rheumatology, Madrid, Spain;28HU Galdakao, Rheumatology, Galdakao, Spain;29HU Basurto, Dermatology, Bilbao, Spain;30HU Basurto, Investigation, Bilbao, Spain

Background: Upadacitinib (UPA) is an inhibitor of JAK kinases recently approved by EMA for the treatment of psoriatic arthritis (PsA) in Europe (January 2021). UPA has shown efficacy in refractory patients to anti-TNF. Objectives: A) to assess efficacy and safety of UPA in the first cases in Spain in clinical practice. B) to compare the profile of clinical practice patients with clinical trial of UPA in PsA refractory to biologics. Methods: Study of 39 patients of clinical practice with PsA treated with UPA in Spain. The diagnosis of PsA was made using CASPAR criteria. Patients who received at least one dose of UPA were included. Results are expressed as percentage, mean±SD or median [IRQ]. Results: 39 patients (29M/10J), mean age of 51.5 ± 11.4 years (Table 1). Pattern joint involvement was as follows: peripheral (n=19), axial (3) and mixed (17). During the PsA evolution, patients also presented enthesitis (59%) nail involvement (28.2%) and dactylitis (35.9%).

Table 1.

<table>
<thead>
<tr>
<th>Clinical Practice Clinical Trial</th>
<th>n=39</th>
<th>n=21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline demographic parameters</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, years (mean±SD)</td>
<td>51.5±11</td>
<td>53.0±12</td>
</tr>
<tr>
<td>Sex, % (female)</td>
<td>29 (74.4%)</td>
<td>113 (53.6%)</td>
</tr>
<tr>
<td>Disease Characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of psoriatic arthritis, year (mean±SD)</td>
<td>12.4±8.68</td>
<td>9.5±8.4</td>
</tr>
<tr>
<td>HAQ-DI</td>
<td>1.10±0.42</td>
<td>1.10±0.6</td>
</tr>
<tr>
<td>SRF joint count</td>
<td>6.72±9.3</td>
<td>11.3±8.2</td>
</tr>
<tr>
<td>Painful joint count, mean±SD</td>
<td>7.48±7.58</td>
<td>24.9±7.9</td>
</tr>
<tr>
<td>Enthesitis, %</td>
<td>23 (59.0%)</td>
<td>172 (81.5%)</td>
</tr>
<tr>
<td>Dactylitis, %</td>
<td>14 (35.9%)</td>
<td>55 (26.1%)</td>
</tr>
<tr>
<td>PASI score, mean±SD</td>
<td>7.72±3.32</td>
<td>10.1±9.2</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>11.1±8.16</td>
<td>11.2±8.5</td>
</tr>
<tr>
<td>Oral glucocorticoid use, %</td>
<td>17 (43.6%)</td>
<td>22 (10.4%)</td>
</tr>
<tr>
<td>Concomitant synthetic DMARDs, %</td>
<td>16 (41.0%)</td>
<td>98 (46.4%)</td>
</tr>
<tr>
<td>Previous use of biological DMARDs, n (%)</td>
<td>39 (100)</td>
<td>195 (92.4%)</td>
</tr>
<tr>
<td>Number of prior failed biological DMARDs, n</td>
<td>3 (77)</td>
<td>135 (63.7%)</td>
</tr>
<tr>
<td>1</td>
<td>4 (10.3%)</td>
<td>35 (16.5%)</td>
</tr>
<tr>
<td>≥3</td>
<td>32 (65)</td>
<td>24 (11.3%)</td>
</tr>
<tr>
<td>UPA in monotherapy, %</td>
<td>23 (59)</td>
<td>113 (53.6%)</td>
</tr>
</tbody>
</table>

Figure 1.

Prior to UPA, most patients (59%) had received oral prednisone or equivalent (max 90.0±12.12mg/d), synthetic immunosuppressants (mean 1.6±0.9) and biological therapy (TB) (4.5±2.1). TB were as follows: etanercept (25), adalimumab (28), infliximab (12), golimumab (16), certolizumab (15), secukinumab (29), ustekinumab (21) Abatecept (2), brodalumab (1) and ixekizumab (17). Apremilast was used in 13, Tofacitinib in 11 and filgotinib in 1. After a mean follow-up of 12.4±8.68 years after the PsA diagnosis, UPA was started (15mg/24h). 43.6% associated prednisone (7.35±3.36mg/d). In 16 (41%) UPA was started in combined therapy: methotrexate (9), salazopyrin (3) and leflunomide (4); in the remaining 23 (59%), monotherapy was prescribed. At UPA onset patients presented peripheral arthritis (78.9%), axial involvement (35.8%), skin involvement (25.8%), enthesitis (41%), and dactylitis (10.3%). Patients of clinical practice compared with clinical trial there were more women, they have a longer period of PsA, and received a higher proportion of previous TB (Table 1). After a median follow-up of 2.48 ± 2.6 months, patients showed prompt improvement in activity indexes (DAS28, DAPSA) (Figure 1) and laboratory test (CRP mg/L decreased from 4.00 [1.5;10.0] to 0.40 [0.3;0.4] at the sixth month). Extra-articular manifestations also improved: dactylitis in 25% patients, enthesitis (43.8%), skin involvement (40%) and onychopathy (50%). No serious events were reported. Minor side effects were reported in 7 patients (17.9%), and UPA was discontinued in 9 due to inefficacy. Conclusion: In this preliminary study, first patients of clinical practice in Spain with UPA in PsA had a longer evolution and received a greater number of TB than those of clinical trial. As in the UPA clinical trial, it seems effective, rapid and relatively safe in daily clinical practice for refractory PsA.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3263

TREATING TO TARGET OF PSORIASIS: AN EVIDENCE-BASED CONSENSUS ON CLINICAL PRACTICE RECOMMENDATIONS

Y. El Mediany1, M. H. Abu-Zaid2, M. Elgaafary3, N. Ali4, M. Mansour5, N. Fathi6, W. Hassan7, M. A. Mortada8, S. Moussa9, M. Eissa10, S. A. A. Tabra11, N. Fouad12, R. Ali13, B. M Medhat14, J. Jamaldeleen14, Y. Abdel Abdelsalam Hussein15, R. M. Ghalib16, E. Nouhan Elameen17, E. Dessouki18, S. Saber19 on behalf of Egyptian Academy of Rheumatology. Canterbury Christ Church University Medway Campus, Rheumatology, Gillingham, United Kingdom; Tanta University, Rheumatology and Rehabilitation, Tanta, Egypt; Ain Shams University, Community and Public Health, Cairo, Egypt; Ain Shams University, Rheumatology and Rehabilitation, Cairo, Egypt; Assiut University, Rheumatology and Rehabilitation, Assiut, Egypt; Benha University, Rheumatology and Rehabilitation, Benha, Egypt; Zagazig University, Rheumatology and Rehabilitation, Zagazig, Egypt; Karachi Elderly Cairo University, Rheumatology and Rehabilitation, Cairo, Egypt; Tanta University, Rheumatology and Rehabilitation, Tanta, Egypt; Fayoum University, Rheumatology and Rehabilitation, Fayoum, Egypt; Mansoura University, Rheumatology and Rehabilitation, Mansoura, Egypt; Minia University, Rheumatology and Rehabilitation, Minia, Egypt; Suez Canal University; Rheumatology and Rehabilitation, Ismailia, Egypt; Alexandria University, Ophthalmology, Alexandria, Egypt

Background: The Tight Control of Psoriatic arthritis (TICOPA) trial revealed a treat to target (T2T) strategy has led to improved clinical outcomes in psoriatic arthritis (PsA). The heterogeneity of the disease, the feasibility of therapy and the associated comorbidities made the implementation of such strategy in routine care a real challenge. There is a high need for establish real world recommendations for the T2T approach in PsA tailored to the disease activity status, the Psoriasis manifestations as well as the individual patient’s requirements.

Objectives: To provide up-to-date, evidence-based and consensus-based recommendations for Treat-to-Target management of psoriatic arthritis (PsA) and its associated clinical manifestations.

Methods: 14 key clinical questions were identified by scientific committee according to the Patient/Population, Intervention, Comparison, Outcomes and Timing (PICOT) approach. Literature Review team performed a systematic review to summarize evidence advocating the benefits and harms of available pharmacologic and nonpharmacologic therapies for PsA. Subsequently, recommendations were formulated. The level of evidence was determined for each section using the Oxford Centre for Evidence-based Medicine (CEBM) system. A 3-round Delphi process was conducted with 19 experts. All rounds were conducted online. A consensus was achieved on the direction and the strength of the recommendations.

Results: An online questionnaire were sent to expert panel who participated in the three rounds (response rate 100%). At the end of round 3, a total of fifty-one recommendation items, categorized into 6 sections to address the main 6 PsA categories, were obtained. Agreement with the recommendations (rank 3%) ranged from 89.5-100%. Consensus was reached (i.e., ≥75% of respondents strongly agreed or agreed) on the wording of all the 51 clinical standards identified by the scientific committee. Algorithms for the management of PsA have been suggested.

Conclusion: These recommendations provide an updated consensus on the pharmacological treatment of PsA and strategies to reach optimal treat to target outcomes
in common clinical scenarios, based on a combination of evidence and expert opinion. Best treatment decisions should be tailored to each individual patient situation.

Disclosure of Interests: None declared


AB0909  RETENTION RATE OF APREMILAST AND RISK FACTORS FOR INADEQUATE RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM AN ITALIAN MONOCENTRIC COHORT

L. Moschetti1, F. Crisafulli1, F. Canova1, F. Fraceschini1, L. Andreoli1, M. Frassi1. 1ASST Spedali Civili, University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy

Background: Apremilast (APR) is an oral PDE4 inhibitor approved for the treatment of Psoriatic Arthritis (PsA). Its effectiveness has been assessed in clinical trials1,2, but real-life data are still scarce.

Objectives: To evaluate the retention rate (RR) of APR in PsA patients and the risk factors associated to APR inadequate response.

Methods: Retrospective monocentric analysis of PsA patients (CASPAR criteria 2006) treated with APR between 2017 and 2021. Disease activity was evaluated at baseline (T0) and after 6 (T6), 12 (T12) and 24 (T24) months of therapy using DAPSA score. Data are expressed as median [IQR].

Results: The cohort included 79 patients (41% males; age at PsA onset: 47 [37-58] years). PsA domains were: oligoarticular involvement (58%), enthesitis (42%), dactylitis (8%), axial involvement (13%), psoriasis (62%). Half patients presented dysmetabolic traits: 47% overweight/obesity, 34% arterial hypertension, 20% dyslipidemia. APR was prescribed mainly as first-line targeted therapy; in 42% APR was administered after the failure of ≥1 bDMARD. Contraindications to bDMARDs (47%) especially increased infectious risk (19/37) and current/previous malignancy (15/37), and mild PsA phenotype (27%) were the main reasons for APR choice. APR was discontinued in 61% after 4 [1-10] months because of inefficacy (25/48) or adverse events (AEs) (21/48; 81% gastrointestinal complaints). Patients who discontinued APR were compared with patients who continued APR (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>APR WITHDRAWAL</th>
<th>APR CONTINUATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=48</td>
<td>n=31</td>
</tr>
<tr>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>28 (58)</td>
<td>29 (61)</td>
</tr>
<tr>
<td>Age at T0, years</td>
<td>51 [44-58]</td>
</tr>
<tr>
<td>PsA duration at T0, years</td>
<td>5 [2-11]</td>
</tr>
<tr>
<td>Oligoarticular involvement</td>
<td>24 (50)</td>
</tr>
<tr>
<td>Axial involvement</td>
<td>6 (13)</td>
</tr>
<tr>
<td>Enthesitis / dactylitis</td>
<td>26 (54)</td>
</tr>
<tr>
<td>DAPSA at T0</td>
<td>22 [16-28]</td>
</tr>
<tr>
<td>APR in monotherapy</td>
<td>26 (54)</td>
</tr>
<tr>
<td>bDMARDs naive</td>
<td>24 (50)</td>
</tr>
</tbody>
</table>

Results are presented as median [IQR] or number (%). Continuous variables were compared with Mann-Whitney test; categorical variables were compared with Chi Squared/exact Fisher test.

The RR of APR was 62% at T6, 51% at T12 and 38% at T24 (Figure 1a).

Figure 1. a) Overall RR of APR, b) RR of APR in bDMARDs naive vs previously treated with bDMARDs patients (exclusion of withdrawals for intolerance).

In patients continuing therapy, APR showed a good efficacy, with a significant reduction of DAPSA score observed at T6 (13 [9-19], T12 [11 [4-18]] and T24 (8 [3-10]) as compared to T0 (21 [14-28] p<0.01). An overall trend of reduction of the BMI (kg/m²) was observed (T0:25 [22-28], T6: 24 [21-27], T12: 23 [21-28], T24: 22 [20-26]) in overweight patients the BMI decreased significantly (28 [25-31] at T0 vs 30 [27-29] at last evaluation; p<0.01). Because of the high rate of discontinuations due to intolerance in the first months of therapy, we conducted a sub analysis: patients who continued APR (n=31) vs patients who discontinued it for inefficacy (n=25). A higher frequency of APR withdrawal was registered in younger patients (51 [47-57] vs 57 [53-71] years; p<0.01) previously treated with bDMARDs (71% vs 40%; p<0.02). Multivariate analysis confirmed these associations (OR [95% CI]: 0.1 [0.89-0.99], p<0.03 and 2.3 [1.70-5.97], p<0.01; respectively). The RR was higher in bDMARDs naive patients compared with patients previously treated with bDMARDs (T6: 75% vs 67%, T12: 71% vs 63%, T24: 67% vs 34%; log-rank test; p=0.05) (Figure 1b).

Conclusion: This study confirms the safety and effectiveness of APR in a real-life scenario. We experienced a higher APR withdrawal rate for AEs (44%) in the first months of therapy, compared to registration studies in which APR was suspended in 8%. However, when tolerated, APR maintained efficacy over time, as demonstrated by progressive DAPSA reduction. The higher RR in bDMARDs naive patients suggests the early use of APR. Moreover, the reduction of BMI could favor APR use in dysmetabolic patients. These data need to be confirmed in larger studies.

REFERENCES:

Disclosure of Interests: None declared


AB0910 EVALUATION OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PSORIATIC ARTHRITIS UNDER TREATMENT WITH METHOTREXATE

L. Pérez Albaladejo1, I. Ahón Oñate1, M. J. Pérez Galán2, C. Caro Hernandez1. 1Hospital Universitario de Jaen, Reumatología, Jaen, Spain

Background: Nowadays, non-alcoholic fatty liver is the most common hepatic disease. In patients with psoriatic arthritis with metabolic syndrome or obesity, there is a state of inflammation that produces the existence of a replacement of normal hepatic tissue by connective tissue, creating a non-alcoholic fatty liver disease (NAFLD). Disease Modifying Anti- Rheumatic Drugs (DMARDs) are widely used in the treatment of psoriatic arthritis. Among these drugs, we find methotrexate, chosen as the primary treatment for such pathologies. This DMARD must be administrated cautiously in patients with risk of developing fatty liver since it is hepatotoxic and it might cause the development of a hepatic disease.

Objectives: Measure the risk of developing hepatic fibrosis in patients with psoriatic arthritis under methotrexate.

Methods: It is a study of retrospective cohorts to determine the existence of NAFLD in patients with psoriatic arthritis under methotrexate through fatty index biomarkers (FIB-4). 41 patients have been studied for more than a year. Demographical & clinical variables have been collected (sex & gender) and (BMI, tobacco, use of alcohol, dyslipidemia and AHT), scales of disease activity and the FIB-4 (transaminases, age, plateletes). A baseline evaluation was made at 6 and 12 months with a 3 years extension of the treatment.

Results: A total of 41 patients (17 women & 24 men), with an average age of 50.3 years (minimum 18 and maximum 80) and a BMI of 28.16 has been studied. 4.9% consumed alcohol habitually, 17.1% were smokers, 39% had hypertension, 41.5% had hypercholesterolemia and 17.1% hypertriglyceridemia. Most patients had a moderate disease (DAPSA 20.9) at the beginning of treatment and kept a low activity in posterior months (DAPSA 6.8). The results of the Friedman’s test indicate that there are no significant statistic differences on the different measurements of FIB-4 (P=0.575).

In the study can be seen an increasing evolution of the FIB-4 values through the first months that is later stabilized through time. When studying if the evolution of FIB-4 is related to the evolution of BMI, it can be observed that exists a significant statistic relation in the evolution of both measures but being such relation quite weak. The evolution of the classification of the patients FIB-4 at the beginning, at 6 months, at 1 year and at 3 years of treatment with methotrexate does not present significant statistic differences.

Conclusion: In patients with psoriatic arthritis, the treatment with methotrexate does not seem to increase the risk of developing a non-alcoholic fatty liver disease.

Graphics FIB-4 evolution

References:
AB0911 SHORT-TERM RESULTS OF GUSELKUMAB EFFICACY FOR PSORIATIC ARTHRITIS IN REAL LIFE.

M. Navidad Fuentes1, V. Ruiz DEL Valle1, S. Quiriosa Flores1. 1HOSPITAL VIRGEN DE LAS NIEVES, RHEUMATOLOGY, Granada, Spain

Background: Psoriatic arthritis is a chronic immune-mediated disease that mainly affect joints, but is associated with a significant increase in cardiovascular risk and other comorbidities. In the last decades, some pathogenic pathways of these diseases have been identified and have lead to the development of new therapeutic strategies such as biologic drugs. Early treatment and treat-to-target strategies have achieved a great improvement in the management of the disease, but there are still many refractory cases and further research is needed. Gusekumab is a human IgG1, monoclonal antibody that selectively binds to interleukin 23, a regulatory cytokine that affects the activity of T lymphocyte subsets. In this way, blockade of IL-23 normalizes the production of pro-inflammatory cytokines. Gusekumab was approved by FDA for psoriatic arthritis treatment in 2020.

Objectives: To analyze the real-life effectiveness of guselkumab in a cohort of patients with psoriatic arthritis.

Methods: A prospective observational study was conducted in psoriatic arthritis patients who received treatment with guselkumab in a hospital center in the southeastern area of Spain, from April 2020. Patient demographic and baseline data were recorded and response variables such as DAPSA index, presence of enthesis and dactylitis, skin affection by BSA, and drug persistence at 12 and 24 weeks of treatment were analyzed. In addition, adverse events were recorded.

Results: Twenty-nine psoriatic arthritis patients, 20 women, mean age at entry 52 ± 2.47 years, were included in this analysis. The mean of years since psoriatic arthritis diagnosis was 10.14 ± 1.68 years. Demographic and baseline variables of the patients are detailed in Table 1. The mean DAPSA value at the start of treatment was 25.02 ± 2.446. After 12 weeks, it was 17.51 ± 2.655, and after 24 weeks of treatment, it had dropped to 12.37 ± 3.547 points, this difference was statistically significant with p<0.001. The percentage of enthesitis presented a significant reduction, from 37.93% at baseline to 3.84% at 24 weeks of treatment. BSA index had a mean of 12.54 ± 5.94 at baseline, with a significant reduction at 12 weeks (2.136 ± 1.214) and at 24 weeks (0.4167 ± 0.4167). According to their DAPSA index score, patients were classified into disease categories. One third of patients achieved complete remission, and another third achieved low disease activity at 24 weeks, as reflected in Figure 1. Treatment persistence was 89.65% at both 12- and 24-week reviews, as only 3 patients dropped out of treatment at 12 weeks. No drug-related adverse events, including local injection site reactions, were recorded.

Table 1. Demographics and baseline patient characteristics.

Baseline Patient Characteristics guselkumab 100mg/8W (n = 29)

| Age at inclusion, mean (95% CI), years | 52 ± 2.47 |
| Sex | Female, n (%) | 20, 68.9 % |
| Male, n (%) | 9, 31.1 % |
| Disease duration of PsA mean (95% CI), years | 10.14 ± 1.68 |
| DAPSA mean (95% CI) | 25.02 ± 2.44 |
| Enthesitis, n (%) | 22, 75.8 % |
| Dactylitis, n (%) | 3, (10.34 %) |
| BSA mean [95% CI] | 3.1 (10.34 %) |
| Line of treatment | 2.54 ± 0.94 |
| Second, n (%) | 2, (6.89 %) |
| Third, n (%) | 8, (27.58 %) |
| Fourth, n (%) | 8, (27.58 %) |
| Fifth, n (%) | 2, (6.89 %) |
| Sixth, n (%) | 3, (10.34 %) |
| Seventh, n (%) | 5, (17.24 %) |
| Eighth, n (%) | 1, (3.44 %) |

Figure 1. Percentage of patients reaching remission (REM), low disease activity (LDA) or active disease at baseline, 12 and 24 weeks after guselkumab treatment.

Conclusion: Gusekumab is effective and safe for the manifestations of psoriatic arthritis in a real-life cohort of patients.

REFERENCES:

Acknowledgements: The authors would like to thank the colleagues of the rheumatology department of the hospital virgen de las nieves for their support and collaboration.

Disclosure of Interests: None declared

Background: Phase 2 studies have shown that Filgotinib (FIL), a JAK-inhibitor (JAKI), significantly improves signs and symptoms of psoriatic arthritis (PsA) in patients with active disease. PENGUIN 1 and 2 were two phase III trials of FIL in PsA that were stopped. We considered Tofacitinib (TOFA) the best alternative drug for these patients because TOFA is the only JAKI approved so far in Spain. However, data in clinical practice about switching from FIL to TOFA have not been reported.

Objectives: To assess the efficacy and safety of switching FIL to TOFA in patients with PsA.

Methods: Prospective Single-University-hospital study of PsA patients diagnosed according to CASPAR criteria, and previously treated with FIL 100 mg and 200 mg/day in two clinical trials (PENGUIN 1 and 2). Based on a shared decision between the patient and the physician, once the trial was finished, patients receiving FIL were switched to TOFA (5 mg/12h) with a 7 days wash-up period. Analyses were performed on the sub-group of patients who had completed 6 months of treatment. The main outcome was the change in swollen joint count (SJC), tender joint count (TJC) and Enthesitis according to the Enthesitis Index between the patient and the physician, once the trial was finished, patients receiving FIL were switched to TOFA (5 mg/12h) with a 7 days wash-up period. Analyses were performed on the sub-group of patients who had completed 6 months of treatment. The main outcome was the change in swollen joint count (SJC), tender joint count (TJC) and Enthesitis according to the Enthesitis Index.

Results: We included 11 patients (6 women/5 men) with a mean age of 52.5±6.5 years who had received FIL during a mean time of 16.0±9.3 weeks. JAKI was used in monotherapy or combined with sulfasalazine (n=2), methotrexate (n=1) and apremilast (n=1). Disease activity, US scores and laboratory values during the follow-up are shown in Table 1. No significant changes were observed in any case. No adverse events were reported during the 6 month of follow-up except for 1 patient with lymphopenia (500/µL). TOFA was discontinued after 1 month in 1 patient because of lymphopenia and inefficacy and after 3 months in 4 patients for worsening of the joint pain. It was remarkable that in some of the patients who reported a worsening of painful joints we did not observed a higher inflammatory activity in the SJC or US exam, this incongruence could be due to the role that JAK/STAT inhibition plays in pain signaling pathways.

Conclusion: Switching from FIL to TOFA appears to be an effective and safe therapeutic option.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3769
Results: We included 113 patients, 62 (54.0% females) with a mean age of 48.1±10.8 years-old at the start of the first bDMARD. Sixty-four patients (56.6%) had symmetric polyarthritis, 19 (16.6%) spondyloarthritis, 25 (22.1%) asymmetric oligoarthritis, 2 (1.8%) distal arthritis and 1 (0.9%) arthritis mutilans. Forty-three percent were under corticosteroid therapy and 75.7% under conventional synthetic DMARD (csDMARD) therapy at baseline (mostly methotrexate, in 45.1% of patients under csDMARD). Enatenec (n=35, 31.0%), adalimumab (n=34, 30.1%), golimumab (n=25, 22.1%), infliximab (n=6, 5.3%), certolizumab (5, 4.4%), secukinumab (n=8, 7.1%) were the bDMARD started in these patients. TSR was categorized into 3 groups, namely low [TSR < 1], moderate [1 ≤ TSR < 2.2] and high [TSR ≥ 2.2], with frequencies 19 (13.3%), 66 (58.4%) and 32 (28.3%), respectively. Whenever the number of tender joints was different from 0 and that of swollen joints equal to 0, patients were included in the group high TSR. All TSR groups, with initiation of bDMARD, showed significantly decreases at 6 months in CDAI (low: p=0.006, moderate: p<0.001, high: p<0.001), SDAI (low: p=0.001, moderate: p=0.001, high: p=0.001) and DAS28- CRP(4) (low: p=0.001, moderate: p=0.001, high: p=0.001). From 6 to 12 months of treatment, the differences were not significant in any of the groups (p>0.05). At baseline, CDAI, SDAI and DAS28-CRP(4) means did not differ between groups (p>0.05). There were also no differences in the means of outcome measures at 6 months as well as at 12 months of treatment (p>0.05). Despite this, patients with low baseline TSR had lower mean values of CDAI, SDAI and DAS28-CRP(4) at 6 and 12 months of treatment, consistent with a low disease activity.

Conclusion: To our knowledge this is the first time studying the TSR on treatment response in samples of patients exclusively with PsA. All patients benefited from bDMARD therapy, regardless of the group, suggesting that TSR might not be a good predictor of treatment response in patients with PsA.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3860

AB0916 ASSESSMENT OF PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE FOR EVALUATIONS OF 6-YEARS TREAT-TO-TARGET STRATEGY OUTCOMES

P. Tremaskina1, E. Loginova1, L. Vorobyov1, T. Korotaeva1, M. Chamurleva1, S. Glukhova1, A. Lita1, S.V. A. Nasonova Research Institute of Rheumatology, Spondyloarthrits and psoriatic arthritis, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, medical and social problems in rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: The 12-item psoriatic arthritis impact of disease questionnaire (PSAID-12) have been found to be a reliable instrument to specifically assess the impact of psoriatic arthritis (PsA) for the patients (pts) as well as predictive of long-term outcomes [1]. There are no data about use of the PSAID-12 for evaluation of long-term outcomes of treat to target (T2T) strategy in PsA pts.

Objectives: to assess the PSAID-12 for evaluations of 6-years outcomes of T2T strategy in PsA.

Methods: 50 (M/F=24/26) PsA pts fulfilling CASPAR criteria were included. Mean age 45±12.1 yrs, median (Me) PsA duration 86 [66;97] month (mos), Me 12 yrs. At the early stage (PsA duration<2 yrs) all pts were treated according to T2T strategy within 24 mos. At 6 years follow-up all pts under went standard clinical examination (tender joint count (TJS), swollen joint count (SJC), patient global assessment disease activity (P-GA), CRP (mg/l), skin psoriasis (PsO) by BSA (%) , presence of nail PsO, enthesis dactylitis, DAPSA and completed PSAID-12. PSAID-12 scores > 4 is considered as a “patient-acceptable status symptoms” (PASS). PSAID-12 > 4 is considered as worse quality of life. DAPSA remission (REM-DAPSA) ≤4 and low disease activity (LDA) ≤14, moderate activity (Mo)>28, high activity >56 were calculated. Me [Q25-Q75], M±SD, Spearman’s correlation, Mann-Whitney test were performed. All p<0.05 were considered to indicate statistical significance.
Results: At 6 yrs follow-up REM-DAPSA were seen in 17 out of 50 pts (34%), LDA in 15 out of 50 (30%) pts. Mean total PsAID-12 score was 2.62±2.1. PASS was seen in 38 of out 50 pts (78%). PsAID-12 significantly associated with the PsA activity parameters: TJC (r=0.72, p<0.01), SJC (r=0.55, p<0.05), PGA (r=0.77, p<0.05), CRP (r=0.55, p<0.05) and DAPSA (r=0.75, p<0.05). PsAID-12 is significantly correlated with presence of dactylitis (r=0.33, p<0.05), skin severity (BSA-3) and presence nails PsO (r=0.41, p<0.38) accordingly. In pts with REM/LDA by DAPSA total PsAID score was significantly lower compared to pts with Mo/High activity - 1.34±0.99 and 4.89±1.84, accordingly (p<0.001). All pts with REM/LDA status is achieved PASS by PsAID.

Conclusion: In our clinical practice PsAID-12 associated with joint and skin severity in PsA pts. PsAID-12 is useful instrument for evaluating of the long-term T2T outcomes, including REM/LDA by DAPSA.

REFERENCES:

Disclosure of Interests: Polina Tremaskina: None declared, Elena Loginova Speakers bureau: Janssen, Lyubov Vorobyova: None declared, Tatiana Koro-taeva Speakers bureau: Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Lilly, Maria Chamurilova: None declared, Svetlana Glukhova: None declared, Alexander Lila: None declared


## AB0917

A RANDOMIZED, USUAL CARE CONTROLLED, PARALLEL-GROUP PRAGMATIC CLINICAL TRIAL IN AN INTERDISCIPLINARY COMBINED DERMATOLOGY–GASTROENTEROLOGY–RHEUMATOLOGY CLINIC; PRELIMINARY DATA ON BASELINE CHARACTERISTICS OF 128 PATIENTS AND QUESTIONNAIRE-BASED QUALITATIVE DATA FROM 30 PATIENTS AND 15 HCPs

### Background

Immune-Mediated Inflammatory Diseases (IMIDs), including psoriatic arthritis (PsA), axial spondyloarthritis (AxSpA), psoriasis, hidradenitis suppurativa, and inflammatory bowel disease share both pathophysiological and environmental factors, individuals with one IMID have an increased risk for developing other IMIDs, and are associated with reduced health-related quality of life, increased risk of comorbidities, and reduced socioeconomic status. Unmet needs in care of patients with IMIDs may result from lack of patient-centricity in the usual mono-disciplinary siloed approach to these diseases.

### Objectives

The overall aim of this study is to determine the effectiveness of an interdisciplinary combined clinic intervention compared to usual care in patients with the aforementioned IMIDs.

### Results:

**Statistical Methods and Results**

1. **Methods**: This is a randomized, usual care controlled, parallel-group pragmatic clinical trial. 300 consecutively enrolled participants with co-occurrence of at least two IMIDs are randomly assigned 2:1 to either treatment in the interdisciplinary combined clinic or usual care. The study consists of a 6-month active intervention period and a 6-month follow-up period. Primary outcome is change from baseline to 24-Weeks on the Short-Form Health Survey (SF-36). Additional questionnaire-based qualitative data from 30 patients and 15 health-care professionals (HCPs) is involved in the center are reported.

2. **Results**: Here we report baseline characteristics of the first 128 patients (mean age 45.4 yrs, 18-94 yrs, females 83 (64.8%), All patients had ≥2 IMIDs: Psoriasis (98.77%), PsA (peripheral) (72.56%), AxSpA (34, 26.6%), Hidradenitis (16, 12.5%), Cohn (35, 27.3%), Colitis (20, 15.6%), AxSpA (9, 7.9%), IBD-associated arthritis (10, 7.8%), HS-associated arthritis (1, 0.8%), HLA-B27 was positive in 24 (22.2%) patients.

Advantages, challenges and themes mentioned by the patients are listed in Table 1.

### Table 1. Advantages and Challenges on feedback from 15 HCPs and feedback from 30 patients.

<table>
<thead>
<tr>
<th>Advantages - HCP</th>
<th>Challenges - HCP</th>
<th>Themes mentioned by the patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professional development</td>
<td>Culture</td>
<td>Communication between HCPs improved treatment</td>
</tr>
<tr>
<td>Satisfy on high professional level</td>
<td>Large differences between specialties and patient area</td>
<td>Collaboration between HCPs improved treatment</td>
</tr>
<tr>
<td>Improved perspective on diseases</td>
<td>Logistics, physical requirements</td>
<td>Holistic approach – patients felt HCPs cared for all health aspects</td>
</tr>
<tr>
<td>Collaboration – professional, personal, team spirit</td>
<td>Shared goals</td>
<td>Confidence in living with diseases</td>
</tr>
<tr>
<td>Meaning full to work with disease</td>
<td>Time and patience</td>
<td>Coherence</td>
</tr>
<tr>
<td>Effective communication</td>
<td>Optimal use of time and resources</td>
<td>Treatment optimization</td>
</tr>
<tr>
<td>Learning can be brought back to ‘monodisciplinary’ work</td>
<td>Improved treatment in respective departments</td>
<td>Clarification about diet, mastering fatigue and work-related problems</td>
</tr>
<tr>
<td>Broader disease focus</td>
<td>Avoid patient being information carrier</td>
<td></td>
</tr>
</tbody>
</table>

### Conclusion

- **Statement from a patient**: “It gave me much more peace of mind that I should not ‘split’ my health problems and run errands between different departments. Didn’t have to tell the same issues in several places or even try to figure out who to say what to, or who can answer a given question.”

- **Conclusion**: In conclusion, an interdisciplinary combined clinic based on an immunomodulation medicine holistic concept has been successfully established. Preliminary results indicate a high value of an interdisciplinary combined clinic in patients with IMIDs, and HCPs find both advantages and challenges in establishing a combined clinic.

### Disclosure of Interests: None declared


## AB0918

### EVALUATION OF X-RAY PROGRESSION AT 6 YEARS FOLLOW-UP OF TREAT-TO-TARGET STRATEGY IN EARLY PSORIATIC ARTHRITIS

#### Background

In psoriatic arthritis (PsA) patients (pts) persistence inflammation in the peripheral joints leading bone erosions, joint space narrowing and new bone formation. Tight control of PsA disease improved joint and skin outcomes, but the number of pts with erosions increased [1]. Despite of clinical improvement no long-term treat to target (T2T) strategy data on radiographs progression yet [2].

### Objectives

To study X-ray progression in PsA pts treated according to T2T strat-egy at the early stage of disease at 6 years (yrs) follow-up.

### Methods

- **Methods**: 30 (M/F–17/13) PsA pts fulfilling CASPAR criteria, mean age 44.7±11.4 yrs, median (Me) PsA duration 78.5 [86.95] month (mos), Me follow-up 71 [82.68] mos, Me DAPSA 24 [7.45]. All pts was treated according to T2T strategy at the early stage with MTX alone or in combination with IFN within 2 yrs. When T2T strategy was ended all pts were treated according to standard care. All pts underwent standard clinical examination of PsA activity, DAPSA was calculated. Radiographs of the hands and feet were available for 30 pts at baseline and 26 (86.6%) at 6 yrs follow-up. Radiographs of the hands and feet were scored using the modified van der Heijde-Sharp (m-v-d-HS) scoring method for PsA assessing both progression yet.

### Results:

- **Results**: At 6 yrs follow-up Me PsA m-v-d-HS and JSN significantly increased from 4 (0-10) to 50 (6-253) and from 3 (0-97) to 50 (6-127) accordingly (p=0.006 and p=0.011); count of erosion from 0 (0-13) to 4 (0-128), p=0.002. In 19 out of 26 pts significantly negative X-Ray progression in the feet and hands by T2T m-v-d-HS, count erosion, joint space narrowing was seen for all p<0.05. In 7 out of 26 pts X-Ray progression was found. PsA activity by DAPSA was significantly higher in pts with X-ray progression compared to those without progression 14.1 [5.3,33.67] and 2.22 [0.55,13.54] accord-ingly (p=0.04), 6 yrs later the number of pts with erosions significantly increased from 12 out of 26 (46%) at baseline to 22 out of 26 (85%) accordingly (p<0.002).

### Conclusion

At 6 yrs follow-up negative radiographic progressions in the hands and feet found in mostly early PsA pts despite of tight control treatment strategy within 2 yrs.

### References


Disclosure of Interests: Polina Tremezkinska: None declared, Elena Loginova Speakers bureau: Janssen, Tatiana Krotova Speakers bureau: Pfizer, MSD, AbbVie, Novartis-Sandoz, JSC Biocad, Janssen, UCB, Lilly, Anastasia Sukhina: None declared, Svetlana Glukhova: None declared, Alexander Smirnov: None declared, Alexander Lila: None declared

AB0919
PSORIATIC ARTHRITIS: FACTORS ASSOCIATED WITH THE USE OF BIOTHERAPY
S. Savoy1, N. Akasbi1, B. Bourkhime1, I. El Mezouar1, T. Harzy1, 1Hassan II University Hospital, Department of Rheumatology, fez, Morocco; 2Faculty of Medicine and Pharmacy of Fez, Sidi Mohammed Ben Abdellah University, Laboratory of Biostatistical, Clinical and Epidemiological Research, fez, Morocco

Background: The use of biological treatment in psoriatic arthritis has revolutionized its management with both joint and skin efficacy [1].

Objectives: The goal of our study was to evaluate the use of biological treatment in these patients and to assess the factors associated with it.

Methods: Retrospective study conducted within the rheumatology department of the University Hospital of Fez. Patients were recruited from January 2011 to January 2021. We included patients with psoriatic arthritis according to CASPAR criteria and assessed the use of biotherapy as well as the epidemiological, clinical and biological factors associated with it.

Results: There were a total of 98 patients with psoriatic arthritis, 21 of whom had been put on biological treatment. Of the total of 21 patients, there were 42.9% women and 57.1% men, the average age was 51.1 (± 9.92) years. 20% of patients had a history of tuberculosis, 14.3% had diabetes, 10% had hypertension and 30% had dyslipidemia. 60% of patients had an inflammatory syndrome, 73% had radiographic sacroiliitis and 63.2% had functional repercussions. In bivariate analysis, the value of the initial C-reactive protein CRP (p = 0.04), the initial disease activity score DAS 28 CRP (p = 0.0001) and the value of the initial erythrocyte sedimentation rate ESR (p = 0.02) were significantly associated with the use of biotherapy, there was no significant association with the other parameters. In multivariate analysis, no factor was significant.

Conclusion: An active psoriatic arthritis predicts the prescription of a biological treatment, other studies with a larger sample would be necessary to confirm our results.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5191

AB0920
SAFETY OF APREMILAST IN PSA PATIENTS WITH HISTORY OF MALIGNANCIES OR ACTIVE CANCER: A RETROSPECTIVE STUDY
D. V. A. Sabella1, V. Venerito1, M. Fornaro1, F. Cacciapaglia1, M. G. Anelli1, F. Arezzo1, V. Interbo1, G. Lopalo1, F. Iannone1, 1University of Bari Aldo Moro, D.E.T.Q., Bari, Italy; 2University of Bari Aldo Moro, D.M.I.O., Bari, Italy

Background: One of the most intriguing aspects in the management of patients with inflammatory arthritis is the safety of novel therapies in those with a recent history of malignancy or active neoplasm. In this regard, apremilast (APR), an oral PDE4 inhibitor, is emerging as one of the safest therapeutic options in patients with PsA with comorbid cancer.

Objectives: This retrospective study aims to assess the effectiveness and safety of APR in PsA patients with a recent history of malignancy or active cancer.

Methods: We retrospectively observed patients with a history of neoplasm diagnosed from 1997 to 2021, who underwent apremilast treatment from 2017 to 2021 in a tertiary care centre. We recorded demographic and clinical characteristics at APR baseline and last visit. Furthermore, we recorded the eventual recurrence of primary cancer or the onset of new neoplasms. Paired t-test was used to assess the difference of continuous variables at different follow-ups.

Results: There were a total of 98 patients with psoriatic arthritis, 21 of whom had been put on biological treatment. Of the total of 21 patients, there were 42.9% women and 57.1% men, the average age was 51.1 (± 9.92) years. 20% of patients had a history of tuberculosis, 14.3% had diabetes, 10% had hypertension and 30% had dyslipidemia. 60% of patients had an inflammatory syndrome, 73% had radiographic sacroiliitis and 63.2% had functional repercussions. In bivariate analysis, the value of the initial C-reactive protein CRP (p = 0.04), the initial disease activity score DAS 28 CRP (p = 0.0001) and the value of the initial erythrocyte sedimentation rate ESR (p = 0.02) were significantly associated with the use of biotherapy, there was no significant association with the other parameters. In multivariate analysis, no factor was significant.

Conclusion: An active psoriatic arthritis predicts the prescription of a biological treatment, other studies with a larger sample would be necessary to confirm our results.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5191

AB0921
EFFECTIVENESS OF GUSELKUMAB IN PSORIATIC ARTHRITIS IN DAILY CLINICAL PRACTICE
N. Costas Torres1, I. De la Morena2, D. Bedoya-Sanchis3, J. J. Sammartin Martinez4, E. Montesinos Villasecua5, L. Martinez Casimiro6, S. Porcar Saura7, P. Tenero Larraz2, 1Hospital Clínico Universitario, Reumatología, Valencia, Spain; 2INCLIVA institut d’investigació sanitaria, Reumatología, Valencia, Spain; 3Hospital Clínico Universitario, Dermatología, Valencia, Spain

Background: Gusekumab is a monoclonal antibody against interleukin-23, biological agent approved for the treatment of plaque psoriasis and psoriatic arthritis. There are two randomised, double-blind, placebo-controlled phase III studies (DISCOVER 1 and DISCOVER 2) that evaluated the efficacy and safety of gusekumab versus placebo. Treatment with gusekumab resulted in significant improvements in the measures of disease activity compared to placebo at Week 24.

Objectives: To evaluate the effectiveness of Gusekumab in patients with Psoriatic Arthritis, according to CASPAR criteria, undergoing treatment by dermatology indication.

Methods: This is an observational descriptive retrospective study that includes patients with Psoriatic Arthritis (according to CASPAR criteria) who are being treated with guselkumab. The inclusion criterion is biological indication due to skin involvement. In this study, the epidemiological and clinical characteristics of the patients are assessed: IMC, affected domains, previous treatments, concomitant treatments, PASI before beginning the treatment, at 12 week and 24 week, and joint activity measured by DAPSA at the beginning, after 12 and 24 week.

Results: There are 7 patients included, 5 women and 2 men, the mean age were 50 ± 7.9 years old, with a BMI (body mass index) average of 33.13 ± 6.26. All the patients presented skin involvement: 4 of 7 with plaque psoriasis (2 of them with scalp psoriasis, and one of those two with inverse psoriasis), 3 of 7 with psoriasis on palms and soles (one with scalp psoriasis and inverse psoriasis), and 2 of 7 patients with nail involvement. Regarding joint damage, all the patients presented peripheral joint involvement, 2 of 7 with axial too. For the other domains: 2 of 7 with history of uveitis, 1 of 7 with one episode of dactylitis, and none of them had any episode of enthesitis nor inflammatory bowel disease. All the patients had received at least 1 bDMARD (average of 2.8 ± 2.23, but one of them had used 7 before). All the patients received the standard dose of Gusekumab 100mg sc weekly for 4 weeks) and later on as maintenance treatment to 6 weeks, with a duration of treatment in 2 patients, with an average of 6.3 ± 2.88. At the same time, 1 of 7 patient used Methotrexate concomitantly, 2 of 7 with leflunomide, and 1 of 7 with NSAIDs. The PASI average at the beginning of the treatment with Gusekumab was 9.25 ± 4.99, at 12 week all the patients had obtained a PASI 0, and remained in remission. Regarding joint damage measured with DAPSA, at the beginning of Gusekumab treatment the average was 24.15 ± 22.02, at 12 week 12.19 ± 5.56, at the 24 week 8.86 ± 1.6, of all the patients improved, without any inflammatory flares. Any of them presented uveitis, enthesis nor dactylitis. Drug retention rate of 100%, all the patients are still in treatment with Gusekumab, any side effect was detected.

Conclusion: Gusekumab is a very effective drug for the treatment of psoriasis, and the joint involvement in patients with failure to BIOxARD. We need more real life studies to determine the effectiveness in daily clinical practise.

REFERENCES:
[1] Guselkumab is a monoclonal antibody against interleukin-23, biological agent approved for the treatment of plaque psoriasis and psoriatic arthritis. There are two randomised, double-blind, placebo-controlled phase III studies (DISCOVER 1 and DISCOVER 2) that evaluated the efficacy and safety of gusekumab versus placebo. Treatment with gusekumab resulted in significant improvements in the measures of disease activity compared to placebo at Week 24.

Disclosure of Interests: None declared
Psoriatic arthritis - clinical aspects (other than treatment)

AB0922

PSORIATIC ARTHRITIS DISEASE ACTIVITY DIFFERS BY RACE/ETHNICITY

F. Ahmed1, A. Ogdie2, R. Fitzsimmons1, D. Shin1, J. Takeshita1, 1University of Pennsylvania, Department of Dermatology, Philadelphia, United States of America; 2University of Pennsylvania, Department of Rheumatology, Philadelphia, United States of America

Background: Psoriatic arthritis (PsA) affects up to 30% of individuals with psoriasis. Studies have demonstrated that the presenting disease severity and quality of life impact of psoriasis differs by race/ethnicity in patients with and without PsA, but little is known about disease activity among different racial/ethnic groups [1-3].

Objectives: The objective of our study was to evaluate disease activity by race/ethnicity among patients with PsA.

Methods: We performed a cross-sectional study of adult (≥18 years old) patients with PsA who had at least one outpatient visit within the University of Pennsylvania health system between 2010 and 2019. Patients with PsA were identified by the presence of at least two International Classification of Diseases (ICD)-9 or ICD-10 codes for PsA associated with two different healthcare encounters. The primary outcome was disease activity as measured by theRoutine Assessment of Patient Index Data 3 (RAPID3) score. The RAPID3 score is a validated patient-reported measure of physical function, pain, and global status [4]. RAPID3 scores range from 0 to 30, with higher scores indicating greater disease activity. Patients were included if they had at least one documented RAPID3 score. For patients with multiple RAPID3 scores, the median value was used. The primary individual variable was race/ethnicity categorized as White (reference), Black, Asian, Hispanic, or other race. Multivariable linear regression was used to assess the relationship between race/ethnicity and RAPID 3 score.

Results: The study population included 742 patients. Mean (standard deviation) age was 47.2 (13.3) years and 57.4% were female. The racial/ethnic distribution was 79.4% White, 7.0% Black, 5.0% Asian, 3.1% Hispanic, 2.6% other race, and 3.0% missing race/ethnicity. The means of the median RAPID3 scores were statistically significantly different across racial/ethnic groups (p<0.001). White mean (SD) 7.99 (6.02), Black mean (SD) 14.86 (14.86), Asian mean (SD) 9.79 (5.44), Hispanic mean (SD) 15.09 (7.11), other race mean (SD) 10.57 (6.91). In an adjusted multivariable model controlling for other sociodemographic factors, body mass index, treatment history, and medical comorbidity, Hispanic patients had higher RAPID3 scores compared to White patients, indicating greater disease activity (β=3.36; 95% confidence interval [CI] 1.04 – 5.67, p<0.005). In exploratory stratified analyses to evaluate effect modification by sex, among males, Black (β=3.43; 95% CI 0.23 – 6.63, p=0.04) and Hispanic (β=5.94; 95% CI 2.18 – 9.70, p<0.005) patients had higher RAPID3 scores than White patients. Among females, no significant racial/ethnic differences in RAPID3 scores were identified.

Conclusion: Black and Hispanic patients report greater disease activity as indicated by higher RAPID3 scores compared to White patients. Larger studies are necessary to confirm our findings and further understand the causes of racial/ethnic differences in disease activity among PsA patients.

REFERENCES:

Disclosure of Interests: Fahad Ahmed: None declared, Alexis Ogdie Consultant of: A. Ogdie has received consulting fees from Amgen, Abbvie, Bristol Myers Squibb, Celgene, CorEvitas (formerly Corrona), Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB., Grant/research support from: A. Ogdie has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, Rheumatology Research Foundation, National Psoriasis Foundation, Abbvie (University of Pennsylvania), Pfizer (University of Pennsylvania), Amgen (FORWARD), and Novartis (FORWARD), Robert Fitzsimmons: None declared, Daniel Shin: None declared, Junko Takeshita Consultant of: J.T. has served as a consultant and joint for Pfizer Inc and Janssen Biotech receiving honoraria., Grant/research support from: J.T. has received a research grant (to the Trustees of the University of Pennsylvania) from Pfizer Inc.


AB0923

ASSESSMENT OF FOUR SCREENING TOOLS AND RETRIEVAL OF KEY QUESTIONS TO DETECT UNDIAGNOSED PSORIATIC ARTHRITIS IN CHINESE PATIENTS WITH PSORIASIS: A MULTICENTER STUDY

R. Cui1, M. Chen1, S. M. Dai1, 1Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Department of Rheumatology and Immunology, Shanghai, China

Background: The available data showed great discrepancies in the performance of screening tools in detecting psoriatic arthritis (PsA) in patients with psoriasis, and those including the diagnosed PsA in the validation might exaggerate/oversimplify the performance. The key questions in each tool were unclear and their contributions were not systematically assessed. Here the performance of four different screening tools were validated and compared in detecting undiagnosed PsA, and the key questions with different weights of them were retrieved and evaluated.

Objectives: To compare and validate the performance of the four screening tools in detecting undiagnosed psoriatic arthritis (PsA) in Chinese patients with psoriasis, and to determine the key questions and their weights.

Methods: Consecutive patients with psoriasis but no prior diagnosis of PsA from dermatology clinics and patients with newly diagnosed PsA from rheumatology clinics who were blind to the diagnosis were recruited to complete questionnaires, including early psoriatic arthritis screening questionnaire (EARP), psoriatic arthritis screening and evaluation questionnaire (PASE), psoriasis and arthritis screening questionnaire (PASQ), and psoriasis epidemiology screening tool (PEST). The receiver operator characteristic (ROC) curve with area under curve (AUC) was used to determine sensitivity, specificity and accuracy. The LASSO and logistic regression were utilized to retrieve key questions, and a nomogram was utilized to visualize their weights.

Results: Of 482 psoriasis patients from dermatology clinics, 77 patients were newly diagnosed with PsA. Another 68 patients with newly diagnosed PsA from rheumatology clinics were incorporated in the analysis. ROC analysis indicated that the optimal cut-off values for EARP, PASE, PASQ and PEST were 3, 40, 7 and 3, with corresponding sensitivities of 91.4%, 88.6%, 88.2% and 88.5%, and specificities of 88.6%, 75.2%, 80.2% and 83.6%, respectively. The AUC of EARP (0.925) was higher than those of PASE (0.885), PASO (0.905) and PEST (0.827). A total of twelve key questions were retrieved from these four tools, and their relative weights were scored as 5–100 individually with a nomogram.

Conclusion: To screen undiagnosed PsA, EARP have slightly better balanced sensitivities and specificities. The retrieved twelve key questions may be helpful in proposing a new questionnaire with different scores of each question to screen PsA more efficiently.

Acknowledgements: This project was supported by grants from National Natural Science Foundation of China (No. 81771746 and 82071809) and Shanghai Municipal Health Commission (No. 20204Y0255).

Disclosure of Interests: None declared


AB0924

INDIVIDUAL DIGIT LEVEL NAIL INVOLVEMENT AND JOINT ASSESSMENT IN PATIENTS WITH NAIL PSORIASIS

C. T. Ritchie1, L. E. Kristensen2, B. Strober3, A. K.avanaugh4, R. Boloe5, J. Lisse6, J. Pustizzi6, N. Somani6, C. Sapin6, J. F. Merola7, 1University of Rochester Medical Center, Allergy, Immunology, and Rheumatology, Rochester, United States of America; 2Bispebjerg and Frederiksberg Hospital, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark; 3Yale University, Yale University, New Haven, United States of America; 4Central Connecticut Dermatological., Cromwell, United States of America; 5University of California San Diego, Department of Rheumatology, Allergy, and Immunology, La Jolla, United States of America; 6Eli Lilly and Company, Corporate Center, Indianapolis, United States of America; 7Birmingham and Women’s Hospital, Department of Medicine, Division of Rheumatology, and Department of Dermatology, Boston, United States of America

Background: The relationship between the evolution of nail disease and the articular features of Psoriatic Arthritis (PsA) is poorly understood. There is a lack of data on the relationship between nail and joint disease, important clinical parameters of disease activity, specifically at the individual digit level.

Objectives: To evaluate the level of association, at digit level, between nail involvement and joint disease at baseline, with a special focus on distal interphalangeal joint (DIP) assessment.

Methods: SPHERE-H2H (NCT03151551) was a 52 week, multicenter, randomised, open-label, parallel-group, assessor-blinded study evaluating the efficacy and safety of IXE vs ADA in PsA. Nail psoriasis was measured using Nail Psoriasis Severity Index (NAPSI) at baseline. The NAPSI assessment was measured using total NAPSI score and total unwollen joint count (TC/JUC) score. Here we examine both baseline tenderness and swollenness at the DIP joint, proximal interphalangeal (PIP) joint and metacarpophalangeal (MCP) joint level for each digit and evaluate the level of association
between nail involvement (NAPSI>0 vs NAPSI=0) and joint assessment using Chi-square tests and/or Fisher's exact test where relevant.

Results: Overall, 368 patients (IXE N=191, ADA N=177) out of 566 had a baseline NAPSI>0. The overall level of nail involvement ranged from 52.7% (n=194) (right 5th finger) to 67.9% (n=250) (right 1st finger). When considering a digit-wide assessment of joints (DIP,PIP, and MCP), in general, no clear association was found between NAPSI >0 and joint involvement. However, there was more frequent DIP joint involvement in patients with nail involvement compared to patients without nail involvement. When taking only the DIP joint into account, nail involvement was found to be statistically associated with tenderness and/or swelling at the DIP level (Figure 1), with differences between patients with nail involvement vs. without nail involvement ranging from 7.9% (p=0.023) (right 5th finger) to 19.4% (p=0.001) (left 3rd finger). These differences are mostly driven by tenderness rather than swelling, irrespective of digit. For tenderness, differences (with vs. without nail involvement) ranged from 70% (right 2nd finger) to 18.0% (left 3rd finger). Differences due to swelling ranged from 5.0% (left 1st finger) to 12.2% (left 3rd finger).

Conclusion: In SPIRIT-H2H, tenderness and/or swelling at the DIP joint was significantly associated with nail involvement in individual digits.

Background: Psoriatic Arthritis (PsA) is a challenging diagnosis both for the absence of specific biomarkers and for its clinical heterogeneity, especially in its initial phases. Early onset of PsA is mostly characterized by mono-oligoarthriti- s, enthesis, dactylitis, onychopathy, modest cutaneous involvement. At least 50% of early-PsA patients initially come at dermatologist’s attention because they carry only few musculoskeletal symptoms such as enthesitis and dactylitis. Rheumatological evaluation and ultrasound (US) demonstration of articular and enthesal inflammation allows to augment the probability of an early diagnosis in a short period of time.

Methods: All patients referred to our derma-rheumatological clinic were considered from July 2017 to July 2019 for suspected PsA. Patients with PsA were considered in the present study. 5% of them were studied with US, according to clinical necessity. All the suspected patients were studied using both B-mode and Power Doppler.

Results: 81 patients, sent to our attention for suspected PsA, were included. In 18 (37%) of them diagnosis was confirmed (Caspar criteria were satisfied). In these patients oligoarthritis (80%), enthesis (40%), dactylitis (23%), sometimes in combination, were the most frequent presentations. In 25% of cases enthesitis was the only clinical feature. Articular disease activity was low to moderate in most of patients (DAPSA 14.83 ± 10.08). Disease duration at the diagnosis was 12 months in 90% of cases and the time occurring between symptoms and the first advanced therapy was 18 months in 50% of cases. US study allowed to redefine disease status in 30% of cases. Arthritis and enthesitis were the main domains where US evaluation gave more diagnostic value.

Conclusion: Literature reports a mean time to diagnosis and to start advanced pharmacological therapy respectively of 1.5 and 5 years. In our report, time to start advanced therapy was much longer than expected, falling in the so-called window of opportunity. US study importantly contributed to reach this target, allowing us to identify as soon as possible sub-clinical and pauci-symptomatic forms (low disease activity, prevailing enthesal domain), which could otherwise be misdiagnosed or have an important diagnostic delay. The attention of dermatologist and integrated evaluation allowed us to optimize our diagnostic-therapeutic work-up in patients affected by early PsA, allowing them to receive sooner advanced therapies, according to recent EULAR and GRAPPA recommendations.

REFERENCES:

Disclosure of Interests: None declared.


AB0026

ENTHESIS OF THE HAND IS A DOMINANT LESION IN PSORIATIC ARTHRITIS AND MAY HELP DISTINGUISH IT FROM RHEUMATOID ARTHRITIS: CASE-CONTROL, SINGLE-CENTRE, ULTRASOUND STUDY

D. Esperança Almeida1, A. M. Gomes Correia1, E. Costa1, J. Neves1, J. Silva1, A. R. Ribeiro1, M. Cerqueira1, 1Hospital de Braga, Rheumatology, Braga, Portugal

Background: Enthesitis is the hallmark of psoriatic arthritis (PsA) and may assist in distinguishing PsA from other forms of arthritis (1,2). Its clinical evaluation is hampered by lack of specificity of physical examination (3). Ultrasound (US) may provide information about its presence and response to treatment. Although some previous works have shown that enthesitis of the hand is important in PsA (4), most US studies and scores focused on greater size entheses.

Objectives: To explore the prevalence of enthesitis of the hand in PsA patients as evaluated by US, and compare it with other inflammatory arthritides, namely rheumatoid arthritis (RA).

Methods: Cross-sectional study in which consecutive patients with PsA and RA were recruited for an US protocol evaluating 4 entheses of the hand including: 1. measurement of the extensor digitorum tendon central slip at its insertion at the middle phalanx of the 2nd and 3rd finger bilaterally; 2. search for the presence of power-Doppler (PD) sign; 3. identification of structural lesions. Linear regression models were built to test if diagnosis (PsA vs RA) explained part of the variance of the thickness of tendons insertion while controlling possible influences of age, type of work and body surface area. A ROC curve was built to find a mean thickness cut-off allowing distinction between PsA and RA. The prevalence of PD sign and structural lesions of the entheses was compared between groups.
Results: Fifty-eight patients were recruited (29 with PsA and 29 with RA) and a total of 232 entheses were evaluated. Mean thickness of the interest entheses was superior in PsA patients compared to RA patients (2nd finger – 0.96 ± 0.16mm vs. 0.74 ± 0.09mm; 3rd finger – 0.96 ± 0.25mm vs. 0.76 ± 0.11mm).

Table 1. Multiple linear regression models explaining thickness of the entheses.

<table>
<thead>
<tr>
<th>Linear regression model</th>
<th>PsA vs RA</th>
<th>Diagnosis (PsA vs RA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2nd finger (mean of both sides)</td>
<td>R²=0.56 p&lt;0.001***</td>
<td>(β=0.587; B=0.203mm) p&lt;0.001***</td>
</tr>
<tr>
<td>3rd finger (mean of both sides)</td>
<td>R²=0.39 p&lt;0.001***</td>
<td>(β=0.483; B=0.182mm) p&lt;0.001***</td>
</tr>
</tbody>
</table>

In our sample, 8 (3.5%) entheses had a measured thickness above mean ± 2 SD, all belonging to PsA patients; 6 (75%) had signs of ongoing inflammatory process as proved by the presence of PD sign (Figure 1). Regarding structural lesions, entheseophytes or bone irregularities/erosions were found in 13.6% of PsA entheses, which compared to 1.7% of RA entheses.

Figure 1. Enthesitis of the central slip of extensor digitorum of the 3rd finger in a patient with PsA: swelling of the 3rd proximal interphalangeal joint (A) due to inflammatory process originating in the enthesis, with no signs of synovitis, as evaluated by US (B).

Conclusion: This work reinforces enthesis as a key lesion in PsA. It also shows enthesis occurs significantly in small entheses, like the ones of the hand and that, in some instances, it may be the dominant lesion in a swollen joint. US may be valuable for establishing a diagnosis in the setting of inflammatory arthritis of unknown etiology.

REFERENCES:


Disclosure of Interests: None declared.

determining HLA B27 antigen status and X-rays of sacroiliac joints (SIJs) (pelvic radiographs), hands and feet. Bilateral changes in SIJs of grades 2-2, 3-3 and 4-4 were defined as symmetrical SI (sym-SI). Changes in SIJs of grades 2-1, 3-1, 1-2, 2-4 and 3-4 were defined as asymmetrical SI (asym-SI). Skin lesion severity was evaluated in terms of body surface area (BSA) affected and Psoriasis Area Severity Index (PASI). When BSA was ≥ 3%, PASI was calculated. Me [Q25; Q75], Pierson-2 were tested. All p<0.05 were considered to indicate statistical significance.

Results: Sym-SI was found in 187 (65.1%) pts, asym-SI—in 100 (34.8%) pts. In group (gr) of pts with asym-SI there were more females than in the sym-SI gr: 63 (63.0%) vs 77 (41.2%); p = 0.004. Pts with asym-SI had more severe peripheral arthritis as measured by Tender Joint Count (TJC66) and Swollen Joint Count (SJ66). These values were higher in asym-SI gr: 9 (4-16) vs 6 (2-14; p = 0.007) and 5 (2-12) vs 3 (0-9; p = 0.004), respectively. High activity according to DAPSA was found in 53 (54.6%) pts in the asym-SI gr vs 71 (38.8%) in the sym-SI gr (p = 0.01); low activity and remission by DAPSA– in 16 (16.5%) pts vs 51 (28.3%; p = 0.028), respectively. The frequency of enthesitis was higher in the asym-SI gr: 50 (57.5%) pts vs 57 (38.5%) pts (p = 0.005). Pts functional capacity as measured by Health Assessment Questionnaire (HAQ) was worse in the asym-SI gr: HAQ>0.5 values were found in 83 (84.7%) pts vs 130 (72.6%) pts (p = 0.023). No significant differences were found between HLA B27 positivity in sym-SI and asym-SI groups (which were 54.2% and 44.0%, respectively; p = 0.23).

Conclusion: Asym-SI in PsA is associated with female gender, more severe peripheral arthritis, higher activity according to DAPSA, more frequency of enthesitis and reduction of pts functional capacity.

REFERENCES:


Background: The majority if patients with PsA present with skin manifestations first. Few studies have examined the relationship between severity of skin and joint manifestations, but the results have been variable.

Objectives: To assess the correlation between the extent and severity of skin psoriasis and musculoskeletal manifestations of PsA over time.

Methods: This study is a retrospective analysis of prospectively collected data at a single center cohort study of patients who enrolled within 12 months of PsA diagnosis from 2000-2020. Patients are assessed according to a standard protocol which includes demographics, clinical assessment including skin and joint assessments, laboratory evaluation at 6–12-month intervals and radiographs every 2 years. Skin severity is measured by the PASI score, joint disease severity by the number of tender and swollen joints. Axial disease was defined by the presence of bilateral grade sacroiliac or unilateral grade 3 or 4. The Bath Ankylosing Spondylitis Metrology Index (BASMI) was also measured.

Table 1. Baseline characteristics of 397 patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)*</th>
<th>Number (%)**</th>
<th>N=397</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44.97 (13.0)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsA duration (years)</td>
<td>4.03 (0.66)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Psoriasis duration (years)</td>
<td>14.6 (13.6)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>236 (60.5)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoker ever</td>
<td>193 (48.7)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alcohol intake</td>
<td>246 (62.3)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employed</td>
<td>309 (78.4)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post secondary education</td>
<td>277 (71.0)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>29.21 (8.85)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PASI</td>
<td>6.11 (9.03)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nail</td>
<td>236 (62.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active joint count (tender x swollen)</td>
<td>7.3 (11.05)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swollen joint count</td>
<td>2.96 (4.93)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Axial disease</td>
<td>53 (17.8%)**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment level</td>
<td>None/NSAIDS only</td>
<td></td>
<td>272 (68.2)**</td>
</tr>
<tr>
<td>DMARDs ± NSAIDS</td>
<td>98 (24.7)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biologics ± DMARDs</td>
<td>27 (6.8%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Spearman correlations were calculated between PASI scores and joint counts and BASMI (in patients with axial disease). Multivariable analysis was done using negative binomial model for the joint counts and a linear regression for BASMI. This preliminary analysis includes only the baseline information.

Results: 397 patients were included. Characteristics are shown in the Table 1. There was a correlation significant between PASI score and the active joint count (AJC) (ρ = 0.14, p=0.0095), swollen joint count (ρ = 0.15, p=0.0071). Among the patients with axial disease there was a strong correlation between the PASI and BASMI scores (ρ = 0.58, p=0.0001). Multivariable analysis for AJC revealed traditional DMARDs (0.85 P0.00), PASI score when patients were on no therapy (0.02 p=0.01) and those on biologics 0.04 p<0.05 were associated with higher AJC. Similarly for swollen joints the use of traditional DMARDs (0.85 P0.00), and the PASI score in those taking biologic DMARDs (0.07 p=0.003) were associated with higher swollen joint count. In patients with axial disease Age (0/05, p=0.004), PASI score in patients on no treatment (0.06 p=0.000) or those taking biologics (0.28 p=0.000) were associated with higher BASMI scores.

Conclusion: In patients presenting within 12 months of diagnosis of PsA, there is a correlation between the severity of skin and joint disease. Further studies will assess whether this correlation persists over time.

Acknowledgements: The Toronto Psoriatic Arthritis Research Program is supported by a grant from the Krembil Foundation.

Disclosure of Interests: Ghaydah Alabdulmalik: None declared, Mitchell Sutton: None declared, Dafna D Gladman Consultant of: AstraZeneca

CHARACTERISTICS ASSOCIATED WITH THE PERCEPTION OF HIGH-IMPACT DISEASE (PSAID ≥4) IN PATIENTS WITH RECENT-ONSET PSORIATIC ARTHRITIS. MODEL BASED ON MACHINE LEARNING

D. Seoane-Mato¹, R. Querol Silva², A. Laiz³, E. Galindez⁴, C. A. Montilla-Martín⁵, B. Joven-Ibáñez³, E. Tonio⁶, J. Ramirez⁷, A. Serrano García⁸ on behalf of Proyecto REAPSER Study Group. ¹Spanish Society of Rheumatology, Research Unit, Madrid, Spain; ²Universidad de Oviedo, Rheumatology Service & the Principality of Asturias Institute for Health Research (ISPA), Faculty of Medicine, Oviedo, Spain; ³Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology and Autoimmune Disease Department, Barcelona, Spain; ⁴Hospital Universitario Basurto, Rheumatology Service, Bilbao, Spain; ⁵Hospital Universitario de Salamanca, Rheumatology Service, Salamanca, Spain; ⁶Complexo Hospitalario Universitario de A Coruña, Rheumatology Service-INITIC, A Coruña, Spain; ⁷Hospital Universitario de Canarias, Rheumatology Service, Sta. Cruz de Tenerife, Spain; ⁸Hospital Universitario 12 de Octubre, Rheumatology Service, Madrid, Spain; ⁹Hospital Universitari Son Llàtzer, Rheumatology Service, Palma de Mallorca, Spain; ¹⁰Hospital Clinic Barcelona, Arthritis Unit, Rheumatology Department, Barcelona, Spain; ¹¹Universidad Autónoma de Madrid, Knowledge Engineering Institute, Madrid, Spain

Background: The Psoriatic Arthritis Impact of Disease (PsAID) questionnaire is the standard tool for evaluating the impact of psoriatic arthritis (PsA) on quality of life [1]. Variables associated with high disease impact were studied in patients with long-standing established disease. The characteristics associated with high-impact PsAID in recent-onset PsA remain unknown.

Objectives: To evaluate which patient and disease characteristics are associated with the perception of high-impact disease (PsAID ≥4) in recent-onset PsA. All patients gave their informed consent. The study was approved by the Clinical Research Ethics Committee of the Principality of Asturias. We conducted a cross-sectional analysis. The dataset was generated using data for the independent variables at the 3 visits (baseline, first year, and second year of follow-up) matched with the PsAID values at each of the 3 visits. PsAID was categorized into two groups, namely, <4 and ≥4 [1]. We trained logistic regression models and a random forest-type machine learning algorithm to analyze the association between the outcome measure and the variables selected in the bivariate analysis (statistical significance defined as p value <0.05). We used a confusion matrix to visualize the performance of the final model. This matrix shows the real class of the data items, together with the class predicted by the machine learning algorithm, and records the number of hits and misses.

Results: The sample comprised 158 patients. 20.9% were lost to follow-up. Of the patients who attended the clinic, 45.8% scored PsAID ≥4 at baseline, 27.1% at the first follow-up visit, and 23.0%, at the second follow-up visit. The variables associated with PsAID ≥4 selected in the logistic regression analysis were HAQ, patient global pain during the previous week, educational level, and level of physical activity in the previous week. The association was positive for the first 2 variables and for level of physical activity and negative for educational level. When physical activity was analyzed as a categorical variable, a possible negative association was observed for a moderate level (although this was not statistically significant) and a positive association was observed for a high level (Table 1).

Table 1. Variables associated with PsAID ≥4: Logistic regression analysis.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Regression coefficient</th>
<th>95% CI</th>
<th>p value (Wald test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HAQ</td>
<td>10.394</td>
<td>[7777, 13.011]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Patient global pain in the previous week</td>
<td>5.668</td>
<td>[4.016, 7.320]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Educational level</td>
<td>-2.064</td>
<td>[-3.515, -0.613]</td>
<td>0.005</td>
</tr>
<tr>
<td>Moderate level of physical activity in the previous week</td>
<td>-0.341</td>
<td>[-1.225, 0.573]</td>
<td>0.465</td>
</tr>
<tr>
<td>High level of physical activity in the previous week</td>
<td>1.221</td>
<td>[0.158, 2.283]</td>
<td>0.024</td>
</tr>
</tbody>
</table>

When the random forest–type machine learning algorithm was trained with these 4 variables, the order of importance (from more to less) attributed by the model was: patient global pain, HAQ, educational level, and physical activity. The percentage of hits in the confusion matrix was 86.14%.

Conclusion: Pain control and control of the disease as a whole, preventing patients from suffering a decrease in their functional capacity, are first-order treatment objectives. PsA patients should take regular physical exercise, but with a moderate or low impact on their joints and entheses.

REFERENCES:

Disclosure of Interests: None declared.

Figure 1. PsA-PsO clinic — patient experience

Disclosure of Interests: Cassandra Hong: None declared, Liwen Fang: None declared, Yi-Wei Yeo: None declared, Hau Yueh Lee: None declared, Andrea Low: None declared, Ying Ying Leung: Speakers bureau: Received honorarium from Abbvie, DKSH, Janssen, Novartis and Pfizer.

DEVELOPMENT AND VALIDATION OF A NOMOGRAM FOR PREDICTION OF NONALCOHOLIC FATTY LIVER DISEASE IN PSORIATIC ARTHRITIS

B. C. Li1, R. Su1, H. Yan1, J. Liu1, C. Wang1. 1The Second Hospital of Shanxi Medical University, Department of Rheumatology, Taiyuan, China; 2The Second Hospital of Shanxi Medical University, Department of General, Taiyuan, China

Background: Psoriatic arthritis (PsA) has been linked to an increased risk of metabolic syndrome (MetS). Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of MetS, is now the commonest liver disease worldwide. About 65% of PsA patients suffer from NAFLD, and chronic systemic inflammation may be an important predisposing factor.

Objectives: The purpose of this study was to establish and validate a diagnostic model nomogram for predicting the occurrence of NAFLD in patients with PsA.

Methods: A total of 127 PsA patients (46 had NAFLD and 81 had no NAFLD) were enrolled in this study. Retrospectively collected clinical and serological parameters of these patients. The percentage and absolute number of lymphocytes and CD4+T cells were determined by Flow cytometry. The independent risk factors for NAFLD were screened in the PsA patients using univariate and multivariate binary logistic regression analyses and were used for construction of the nomogram prediction model. The AUROC (C-index) was used to verify the model discrimination; the calibration curve and Hosmer-Lemeshow test were used to verify the model calibration; and the DCA curve was used to verify the clinical validity of the model.

Results: Univariate and multivariate logistic regression analyses showed that Body Mass Index (BMI) (OR=1.25, P<0.001), serum triglyceride (TG) (OR=3.51, P=0.015) and peripheral blood Th1 cell percentage (OR=1.12, P<0.001) is an independent risk factor for NAFLD in PsA patients, and an individualized nomogram prediction model was successfully established. The prediction model had a good discrimination power with AUROC (C-index) of 0.83 (95% CI: 0.76-0.90); the P value in the Hosmer-Lemeshow test was 0.683, suggesting a high reliability of the predicted probability by the model; the DCA curve indicating a good clinical efficiency of the model.

Conclusion: Our study shows that the establishment of a nomogram prediction model of PsA complicated with NAFLD patients is helpful for early clinical screening and identification of such high-risk patients.

Disclosure of Interests: None declared
Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million people in statutory health insurance during 2009 to 2012 [1].

Objectives: Population-based estimation of long-term projection for incidence and prevalence of patients with diagnosis of PsA until the year 2040.

Methods: Based on prevalence and incidence of PsA, the number of men and women diagnosed with PsA until 2040 is projected using the illness-death model [2]. The mortality and age distribution of the general population is taken from the official population forecasts of the German Federal Statistical Office. Mortality of patients with PsA was considered by using estimates of the mortality rate ratios [3]. Percent change in projected case numbers refer to 2012 (base year).

Results: Starting from 2012, three scenarios about the incidence of PsA after 2012 were found (Graph 1): (A) increase of 5% per year as observed in [1], (B) no trend in incidence and (C) decrease of a similar 5% per year due to a theoretically anticipated early treatment effect. In scenario C, the number of men and women peaks at about 2028 and decreases slightly afterwards. The graph shows the projected numbers of men (left panel) and women (right) with PsA until 2040 in the three incidence scenarios. The projected numbers and the percent changes are given in the Table 1. Different scenario may be considered based on recent population data for the incidence course of PsA until 2040. The most optimistic scenario showed a trend of stabilization of incidence including the anticipated population mortality rates. Thus, it is likely that substantially more medical resources for treating patients with PsA are necessary in the next two decades, whereby approaches to the potential prevention of PsA, for example by very early treatment of psoriasis patients, should be further pursued.

References:
[1] DOI 10.1136/mdopen-2021-001975

Graph 1.

Table 1.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Sex</th>
<th>Projected number 2019</th>
<th>Projected number 2040</th>
<th>Change 2040 compared to 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Male</td>
<td>125</td>
<td>353</td>
<td>+183%</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>156</td>
<td>437</td>
<td>+180%</td>
</tr>
<tr>
<td>B</td>
<td>Male</td>
<td>116</td>
<td>173</td>
<td>+49.0%</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>146</td>
<td>223</td>
<td>+53.2%</td>
</tr>
<tr>
<td>C</td>
<td>Male</td>
<td>109</td>
<td>101</td>
<td>-6.9%</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>137</td>
<td>136</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

Background: Recent years of progress in conventional and biologic disease-modifying anti-rheumatic drugs development and improved treatment strategies (treat to target) have yield in improved outcome in psoriatic arthritis (PsA) patients. [1,2]. Still, despite modern treatment and clinical monitoring methods, we might miss dimensions of disease burden outside our main focus including quality of life (QoL), which are of high importance from patients’ perspective.

Objectives: Main objective of this study was to explore how clinical aspects of disease activity and QoL measures will change in PsA patients in an ordinary outpatient clinic in Norway, followed for 5 years, in the biological treatment era.

Methods: PsA patients fulfilling the CASPAR criteria visiting an outpatient clinic in Norway between January 2013 and February 2020 were consecutively included in the study. Data collection included variables for demographics, treatment, laboratory assessment of ESR and CRP, joint counts, disease activity score in psoriatic arthritis (DAPSA), global assessments – patient’s (PGA) and investigator’s (IGA), reported joint and global pain, patient reported outcomes (PROMs) regarding different aspects of quality of life (QoL), (MHAQ, RAID, QoLSD) and reported fatigue level. Patients were analyzed at baseline and after 5-year follow-up period. Statistics included paired sample t test and McNemar test.

Results: Among 140 PsA patients included at baseline, 114 (81.4%) were re-examined after 5 years. Mean age at baseline was 52 years (95%CI 50.3-53.7) and percentage of women was 50.7%. Proportion of patients treated with biologics increased from 32.9% to 39.5%, but the difference wasn’t statistically significant. During the 5 year follow up period most clinical disease activity measures decreased and QoL was maintained (Table 1).

Conclusion: In our cohort of PsA patients after 5 years follow up disease activity was reduced and QoL maintained. Our data adds to the evidence that the burden of disease in PsA patients has decreased in the biologic treatment era however is still significant. Further improvement in pharmacological and non-pharmacological treatments in PsA patients is still needed.

REFERENCES:

Acknowledgements: Nurses and doctors from Division of Rheumatology at Sorlandet Hospital in Kristiansand, Norway contributed to data collection.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2920
and 48 dermatology specialists answered the questions in the second round. At the second tour, the number of questions was reduced from 44 to 22. The distribution of the questions was as follows: Skin and nail involvement n=5, dactylytis n=3, joint question n=2, axial involvement n=2, morning stiffness n=2, enthesis n=1, general questions n=5. A consensus meeting was held to discuss 22 questions determined at the end of the second round within the initial core group. Each question was handled one by one, some of the questions were combined, if necessary, adapted to Turkish. The tool was given its final form. The final version of the questionnaire consists of 6 questions. (Table 1).

Conclusion: A new screening tool targeting different domains in Psoriatic disease was developed in Turkish. While cultural differences play an important role in screening, we believe that the first tool developed in Turkish will be helpful in clinical practice and research settings. Further assessments will be done to understand its validity and reliability within a large cohort of psoriatic patients.

Disclosure of Interests: None declared.


AB00939

PSORIATIC ARTHRITIS RELATED FATIGUE: WHAT IS THE MAGNITUDE OF THIS PROBLEM AND WHAT ARE THE CORRELATED FACTORS? A CROSS-SECTIONAL STUDY.

A. Martins1,2, D. Santos Oliveira1-3, F. R. Martins4, B. Samões4, R. Nicolau4, F. Oliveira Pinheiro1,2, M. Rato1,2, S. Pimenta1,2, M. Bernades1,2, L. Costa1.

1Centro Hospitalar Universitário de São João, Rheumatology Department, Porto, Portugal; 2Faculty of Medicine, University of Porto, Department of Medicine, Porto, Portugal; 3Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; 4Centro Hospitalar Universitário do Algarve, Rheumatology Department, Faro, Portugal; 5Centro Hospitalar Vila Nova de Gaia / Espinho - Unit 1, Rheumatology Department, Vila Nova de Gaia, Portugal; 6Centro Hospitalar Tondela-Viseu, Rheumatology Department, Viseu, Portugal

Background: Fatigue is a common constitutional feature and has a significant impact on quality of life in patients with chronic inflammatory rheumatic diseases, such as psoriatic arthritis (PsA), It is a complex phenomenon and its pathogenesis remains unclear. Despite being a common symptom, it is largely ignored and rarely assessed in clinical practice.

Objectives: This study aims to evaluate the incidence and severity of fatigue in PsA patients under biological agents and to assess the influence of several clinical and demographic features on PsA related fatigue.

Methods: We conducted a cross-sectional study including patients with PsA, according to CASPAR criteria, treated with biological agents, from our University Hospital and registered in the national database (reuma.pt). Fatigue was assessed by a 13-item self-administered questionnaire (Functional Assessment of Chronic Illness Therapy-Fatigue [FACIT-F]). Data collected and analyzed included: demographic data, disease activity data, functional status, comorbidities and therapies. Student's t-test, ANOVA and Pearson's correlation were performed to compare data, as appropriate. A p-value <0.05 was considered statistically significant.

Results: 60 PsA patients were included, 61.7% were males, with a mean age at diagnosis of 38.1±10.5 years and a median disease duration of 13.0 (8.75-19.25) years. Most of the included patients had a predominant polyarticular pattern (n=33, 55.0%). The mean FACIT-F score was 34.48±11.61. No differences were found in the FACIT-F score according to gender, pattern of joint involvement, presence or absence of cutaneous involvement, nail dystrophy and/or dactylytis. Patients with depression and enthesis exhibited a lower FACIT-F score (p=0.017 and p=0.007, respectively). Patients treated with tocilizumab had a lower FACIT-F score than patients treated with adalimumab (p=0.025). No differences were found among the other biological agents. Patients in remission (according to EULAR response criteria) had a higher FACIT-T score than patients with moderate disease activity (p=0.032). In patients with a predominant axial involvement, inactive disease (according to ASDAS) was associated with a higher FACIT-T score, when compared to very high disease activity (p=0.02). Also, patients with moderate disease activity had a higher FACIT-T score than patients with very high (p=0.003) and high (p=0.008) disease activity.

Conclusion: We showed a significant correlation with disease activity scores as BASDAI (r=-0.548, p<0.001), DAS 28 CRP (r=-0.506, p<0.001), CDAS (r=-0.672, p<0.001), SDI (r=-0.641, p<0.001) and ASDAS CRP (r=-0.550, p<0.001). FACIT-F was also correlated with BASFI (r=-0.598, p<0.001), HAQ (r=-0.701, p<0.001), BASMI (r=-0.431, p<0.001) and MASES (r=-0.401, p<0.001). The authors found strong correlations between FACIT-F and HADS domains (Depression and Anxiety domains; r=-0.850, p<0.001 and r=-0.788, p<0.001, respectively). A strong correlation was also found between the FACIT-F and the 8 domains of health of the SF36 (p<0.001).

Disclosure of Interests: None declared.

one autoantibody and 21.2% triple negativity after treatment. ANA showed the highest rates of seropositivity among autoantibodies with a rate of 40% before and 55.3% after biologic treatment. Concomitant seropositivity for RF and CCP autoantibodies showed rates of 2.8% and 6.3% before and after treatment, respectively. The most common subtype was AC4-5 before and AC1-4-5 after biologic agent treatment. ANA was tested in 31 patients both before and after biologic treatment showing 6 negative patients became positive after treatment and from 12 positive patients at the baseline 6 of them became negative (p=0.452). The most common biologic agents used in patients with ANA tested after treatment, were adalimumab (ADA) (42.4%), etanercept (ETN) (18.9%), and infliximab (IFX) (18.9%). The only difference was observed in IFX treated patients (n=25) with significantly higher rates of IFX usage in ANA-positive patients (p=0.001).

**Conclusion:** Synovial lymphoid neogenesis rates in PsA are similar to the frequency seen in rheumatoid arthritis (1). Nevertheless, PsA is classified under the group of “seronegative diseases." On the other hand, current reports have started to define specific autoantibodies particularly in psoriatic patients (2). The real-life experience in serology results of PsA patients showed that only 20-30% of the patients were seronegative for all three tests commonly used in practice.

**REFERENCES:**


**Disclosure of Interests:** None declared


**AB0941**

**DISCRIMINATION OF ENTHESIS INFLAMMATORY INVOLVEMENT IN PATIENTS WITH SPONDYLOARTHRITIS THROUGH THE USE OF COMPUTER ANALYSIS OF STATIC ULTRASOUND IMAGES**

C. Guillén-Astete1, Á. Andreu-Suárez2, M. Tortosa-Cabañas1, M. Martinez Aznar2,1. University Hospital Ramón y Cajal, Rheumatology; Madrid, Spain; 2Universidad Europea de Madrid, Faculty of Biological Sciences, Madrid, Spain

**Background:** One of the weaknesses of the ultrasound study of the entheses is the absence of a universal, recognized and replicable ordinal evaluation scale that allows quantifying or semi-quantifying the degree of involvement of these structures.

**Objectives:** To analyze computer analysis of static images of patients with inflammatory enthesopathies differentiation capacity. To determine its ability to discriminate between an affected and a healthy contralateral enthesis in the same individual.

**Methods:** Static images of the Achilles and epicondylar entheses of patients who consulted regarding enthesis pain associated with spondyloarthritides were analyzed. The patients included were from 2016 to 2020. Images were obtained by the same observer under clinical practice routine circumstances and with the same ultrasound equipment (Logiq B®, General Electric, USA). The same settings for each of the two enthesic examinations were used. Image analysis was performed using the ImageJ 1.53e program (Wayne Rasband & contributors – NIH, USA). Imaging records with contralateral studies in patients with recently diagnosed asymmetric enthesopathies (before the start of treatment) were selected. A repository of images from healthy controls, matched by age and sex of the patients, was used as control.

**Results:**

In the non-painful Achilles enthesis, the measurements were 75.3 ±14.71, the DGI 25.93 ±2.52, and the MoGI 72.7 ±15.4. In the non-painful Achilles enthesis the measurements were 83.99 ±27.29, 22.72 ±3.14 and 76.7 ±32.5, respectively. Statistically significant differences were detected in all pairwise comparisons (t =-9.522, P<=.000; t=3.393, P=.004; and t=-2.247, P=.041, respectively). In the epicondylar involvement records, the MoGI on the affected side was 75.3 ±14.71, the DGI 25.93 ±2.52, and the MoGi 72.7 ±15.4. In the non-painful Achilles enthesis the measurements were 82.57 ±16.06, 25.7 ±2.99 and 74.9 ±16.5, respectively. Statistically significant differences between MoGI and MoGi were identified (t=9.849, P=.000; and t=-2.752, P=.022, respectively). The MIN ratio of the affected side and healthy side among patients was 1.18 ±0.047 while the MIN ratio between the dominant and non-dominant sides of the healthy athletes was 0.91 ±0.022 (t=2.81, P=.000).

**Conclusion:** Computer analysis of entheses static images correctly discriminates symptomatic from non-symptomatic entheses in early ultrasound studies. Even in non-symptomatic entheses, it detects differences compared to healthy subjects. This discriminatory capacity could be useful in updating ultrasound enthesis count indices. It may also be interesting as a criterion for evaluating changes over time. As a weakness, it is worth highlighting the potential confounding effect that enthesophytes could have in this type of analysis if specific demarcations of the area studied are not made.

**Disclosure of Interests:** Carlos Guillén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grunenthal, UCB, Gebro, Paid instructor for: Roche, Novartis, Janssen, Esteve, Menarini, Consultant of: Janssen, Novartis, Roche, Grant/research support from: Pfizer, Grunenthal, Gebro, Novartis, África Andreu-Suárez: None declared, Marina Tortosa-Cabañas: None declared, Miguel Martinez Aznar: None declared


**Figure 1.** Scheme to obtain the analysis area of the Achilles (A) and epicondylar enthesis (B). The enthesis area was considered from the most distal point of the enthesis to the point of emergence or separation of the tendon from the cortex. Case A corresponds to a healthy control. Case B corresponds to a patient with psoriatic arthritis and severe epicondylar pain.
Psoriatic arthritis - clinical aspects (other than treatment)

AB0042 IN INVOLVEMENT OF THE FOOT IN PSORIATIC ARTHRITIS. A REVIEW OF 55 CASES.
F. E. Bennani1, M. M. Pamela Chardene1, A. Mouguil1, I. El Bouchi1,
1CENTRE HOSPITALO-UNIVERSITAIRE MOHAMMED VI MARRAKECH, RHEUMATOLOGY, Marrakech, Morocco

Background: Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease belonging to the spondyloarthropathy family with which shares many clinical and radiographic features. The involvement of the feet with an asymmetric distribution of arthritis is very specific to Psoriasis.

Objectives: The objective of our study is to determine the frequency of foot involvement in a population of psoriatic arthritis by detailing the clinico-radiological aspect of the foot.

Methods: Retrospective descriptive study carried out on the files of patients hospitalized for psoriatic arthritis over a period of 9 years from January 2013 to December 2021. For each file, we collected epidemiological, clinical and radiological data.

Results: 55 patients were included: 41 women (74.5%) and 14 men (25.5%). The mean age was 48.81 ± 17.08 years (20-85 years). Personal and family history of skin psoriasis was noted in twenty and one patients, respectively. The average duration of evolution was about 5.5 years. Inflammatory taliagia was noted in 34 patients (61.8%) and foot joint involvement was found in 13 cases (23.6%). Sausage toe was noted in three cases (5.5%). None of the patients had Bauer’s toe or psoriatic onychopachydermoperiostitis of the great toe. The radiographic workup showed calcaneal in 34.5% (n=30), osteoporosis of the great toe in 6 patients (10.9%). According to the radiological criteria fingers-toes or (CRDO), 3 patients had juxta articular periostitis (5.5%), two cases of phalangeal tuft resorption (3.6%) and one case of osteolyis of an interphalangeal joint (1.8%).

Conclusion: In our context, the involvement of the foot during psoriatic arthritis is dominated clinically and radiologically by the involvement of the hindfoot. The importance of the classification criteria for Psoriasis cannot be underlined, and aim improving their sensitivity and specificity.

REFERENCES:

Disclosure of Interests: None declared.

AB0043 ASSOCIATION BETWEEN PULSE PRESSURE AND ARTEROSCLEROSIS IN PSORIATIC ARTHRITIS PATIENTS
A. N. Garza-Cisneros1, D. A. Galarza-Delgado1, J. R. Azpiri-López2, N. Guajardo-Jauregui1, A. Cárdenas1, I. J. Colunga-Pedraza1, M. A. Balderas-Palacios1, A. García-Heredia1, D. Flores-Alvaredo1, Universidad Autónoma de Nuevo León, Hospital “Dr. José Eléctorio González”; Rheumatology, Monterrey, Mexico; 2Universidad Autónoma de Nuevo León, Hospital “Dr. José Eléctorio González”, Cardiology, Monterrey, Mexico

Background: Psoriatic arthritis (PsA) is associated with an increased prevalence of cardiovascular diseases due to accelerated atherosclerosis that seems to depend on traditional and non-traditional risk factors (1). There is a positive correlation between pulse pressure (PP) and the progression of atherosclerosis in general population (2). Currently, there are no studies linking PP as an independent risk factor of atherosclerosis in PsA patients.

Objectives: To compare PP between PsA patients with and without carotid plaque (CP).

Methods: This was a cross-sectional study that included patients aged 40 to 75 years with PsA diagnosis according to the 2006 CASPAR criteria. A carotid ultrasound was performed in all patients, and they were divided into two groups, 27 patients with the presence of CP and 27 patients without CP matched by age, gender, and comorbidities. Blood pressure and PP was measured according to current guidelines. Distribution was evaluated with the Kolmogorov-Smirnov test. Comparisons were done with Chi-square test for qualitative variables and Student’s t test for quantitative variables. A p value <0.05 was considered statistically significant.

Results: There were no differences regarding demographic characteristics between groups. When comparing the arterial measures, a statistically significant difference was found in the PP, which was higher in patients with CP (48.66 ± 12.04 mmHg vs 41.51 ± 9.10 mmHg, p=0.017) (Table 1). A binary logistic regression was performed, and we found that PP was the only independent factor for the presence of CP in patients with PsA, OR 6.638 (95% CI 0.453-12.823, p=0.036).

Table 1. Demographic characteristics of the patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PsA patients with CP (n=27)</th>
<th>PsA patients without CP (n=27)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD</td>
<td>51.55±8.24</td>
<td>50.74±8.68</td>
<td>NS</td>
</tr>
<tr>
<td>Female gender, n (%)</td>
<td>16 (59.25)</td>
<td>15 (55.55)</td>
<td>NS</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>16 (59.25)</td>
<td>17 (62.96)</td>
<td>NS</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>20 (74.10)</td>
<td>23 (85.18)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>19 (70.37)</td>
<td>22 (81.48)</td>
<td>NS</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>12 (44.44)</td>
<td>17 (62.96)</td>
<td>NS</td>
</tr>
<tr>
<td>Active smoking, n (%)</td>
<td>17 (62.96)</td>
<td>16 (59.25)</td>
<td>NS</td>
</tr>
<tr>
<td>Methotrexate, n (%)</td>
<td>9 (33.33)</td>
<td>11 (40.74)</td>
<td>NS</td>
</tr>
<tr>
<td>Glucocorticoid, n (%)</td>
<td>23 (85.18)</td>
<td>22 (81.48)</td>
<td>NS</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>14 (51.85)</td>
<td>18 (66.66)</td>
<td>NS</td>
</tr>
<tr>
<td>SAP, mean ± SD</td>
<td>132.44±14.40</td>
<td>123.44±13.80</td>
<td>0.023</td>
</tr>
<tr>
<td>DAP, mean ± SD</td>
<td>83.77±10.71</td>
<td>81.52±10.95</td>
<td>NS</td>
</tr>
<tr>
<td>PP, mean ± SD</td>
<td>48.66±12.04</td>
<td>41.51±8.10</td>
<td>0.017</td>
</tr>
</tbody>
</table>

Psa, psoriatic arthritis; NS, non-significant; T2DM, type 2 diabetes mellitus; bDMARD, biologic disease-modifying anti-rheumatic drugs; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; PP, pulse pressure.

Conclusion: PsA patients with CP presented higher measures of PP compared with PsA patients without CP. This suggests that PP could be related with an increased risk of subclinical atherosclerosis in PsA patients. It is recommended to consider PP as an important parameter when evaluating cardiovascular risk in PsA patients.

REFERENCES:

Disclosure of Interests: None declared.

AB0044 HIGHER PREVALENCE OF PULSE PRESSURE IN PSORIATIC ARTHRITIS PATIENTS
A. N. Garza-Cisneros1, I. J. Colunga-Pedraza1, D. A. Galarza-Delgado1, J. R. Azpiri-López1, N. Guajardo-Jauregui1, A. Cárdenas1, D. Flores-Alvaredo1, Universidad Autónoma de Nuevo León, Hospital “Dr. José Eléctorio González”; Rheumatology, Monterrey, Mexico; 2Universidad Autónoma de Nuevo León, Hospital “Dr. José Eléctorio González”, Cardiology, Monterrey, Mexico

Background: There is an increased risk of cardiovascular diseases in patients with psoriatic arthritis (PsA) compared with the general population due to higher prevalence of cardiovascular risk (CVR) factors (1). Pulse pressure (PP) is an independent risk factor for cardiovascular morbidity and mortality (2). Currently, there are no studies about PP in PsA patients.

Methods: This was a cross-sectional, observational, and comparative study. A total of 74 PsA patients aged 40-75 years old, who fulfilled the 2006 CASPAR criteria were recruited and matched to 74 controls by age (±5 years), gender, and comorbidities. Patients with history of a previous cardiovascular event or pregnancy were excluded from this study. Blood pressure and PP was measured according to current guidelines. Distribution was evaluated with the Kolmogorov-Smirnov test. Comparisons were done with Chi-square test for qualitative variables and Student’s t test for quantitative variables. A p value <0.05 was considered statistically significant.

Results: There were no differences regarding demographic characteristics between groups. When comparing the arterial measures, a statistically significant difference was found in the PP, which was higher in the PsA group [45.00 mmHg (40.00-56.50) vs 42.50 mmHg (38.00-50.00), p=0.024], and in the systolic
arterial pressure, higher in PsA patients (131.06 ± 18.27 mmHg vs 123.02 ± 14.27 mmHg).

Table 1. Demographic characteristics of the patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>PsA patients (n=74)</th>
<th>Controls (n=74)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD</td>
<td>55.08±7.61</td>
<td>54.94±7.45</td>
<td>NS</td>
</tr>
<tr>
<td>Female gender, n (%)</td>
<td>41 (55.40)</td>
<td>41 (55.40)</td>
<td>NS</td>
</tr>
<tr>
<td>Obesity, n (%)</td>
<td>47 (63.51)</td>
<td>48 (64.86)</td>
<td>NS</td>
</tr>
<tr>
<td>T2DM, n (%)</td>
<td>58 (78.37)</td>
<td>56 (75.67)</td>
<td>NS</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>48 (64.86)</td>
<td>44 (59.45)</td>
<td>NS</td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td>44 (59.45)</td>
<td>46 (62.16)</td>
<td>NS</td>
</tr>
<tr>
<td>Active smoking, n (%)</td>
<td>49 (66.21)</td>
<td>53 (66.21)</td>
<td>NS</td>
</tr>
</tbody>
</table>

PsA, psoriatic arthritis; NS, non-significant; T2DM, type 2 diabetes mellitus; SAP, systolic arterial pressure; DAP, diastolic arterial pressure; PP, pulse pressure.

Conclusion: PsA patients presented higher measures of PP compared to healthy controls. This suggests that PsA patients could have a higher risk of cardiovascular disease. It is recommended to consider PP as an important parameter when evaluating CVR in PsA patients. Further studies are necessary to validate these results.

REFERENCES:


Disclosure of Interests: None declared


AB0945

SPECIAL FEATURES OF THE LIPID PROFILE IN PATIENTS WITH THE INFLAMMATORY ARTHROPATHIES

S. Spitsin1,2, E. Mozgovaya1, A. Trolifenko1, S. Bedina1, M. Mamus1,3. Federal State Budgetary Educational Institution “Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy”, Clinical Biological Laboratory, Volgograd, Russian Federation; 3Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Healthcare of the Russian Federation, Department of hospital therapy, Volgograd, Russian Federation

Background: The main cause of death in patients with the inflammatory arthropathies is involvement of the cardiovascular system, and primarily atherosclerotic lesion with its complications. Initiation and progression of these arthropathies are underlined with similar immune and inflammatory mechanisms and associated with highly atherogenic changes of blood lipoproteins.

Objectives: Identification of particular qualities of the lipid profile in rheumatoid (RA) and psoriatic (PsA) arthritis, anklyosing spondylitis (AS) and their relationship with essential predisposing factors.

Methods: We enrolled 20 patients with RA, 15 with PsA, and 15 with AS, receiving basic anti-inflammatory therapy with methotrexate 10 to 20mg per week for 6 months, in combination with various non-steroidal anti-inflammatory drugs. These diagnoses were verified according to the ACR/EULAR 2010, CAPSAR 2006, ASAS 2009 criteria, respectively. The single exclusion criterion was the presence of a concomitant disease that could affect lipid metabolism. Total cholesterol (TC), HDL cholesterol, and triglycerides (TG) were measured in the plasma samples of all the patients, LDL cholesterol was calculated using Friedewald formula: TC – (HDLLDLTG/2.2)). The atherogenic index was taken as (TC – HDL)/HDL. Results were expressed as arithmetic means ± standard deviations. Differences were considered significant when p<0.05.

Results: The age of all patients ranged from 30 to 67 years, disease duration range was 1.5 to 12 years. All the patients with chronic arthritis had moderate or high disease activity grades. In the subgroup of RA patients average TC value was 5.63±0.16 mmol/l, HDL – 1.09±0.22 mmol/l, LDL – 3.74±1.16 mmol/l. Increased TC levels were detected in 80% of cases, TG - in 40%, LDL - in 80%, and decreased HDL - in 80% patients. There were strong relationships of TC with age, menopause, or overweight. The duration of RA also positively correlated with TC (r=0.189, p<0.05) and LDL (r=0.159, p<0.05). RA (C-reactive protein level) activity was negatively associated with HDL (r=0.168, p<0.05). 80% of PsA patients had increased TC levels, but TG or HDL levels were within reference range. Mean TC in this subgroup was 6.04±1.55 mmol/l. TC values of PsA patients also positively correlated with age, BMI, and duration of PsA. There was an increase in TC, LDL, and the atherogenic coefficient in AS patients. Mean values of TC, TG, LDL, and HDL in this subgroup were 5.65±0.28, 1.28±0.12, 3.86±0.23 and 1.09±0.06 mmol/l, respectively.

Conclusion: Lipid disorders in patients with chronic inflammatory joint diseases may be a source of increased risk of early atherosclerosis and the cardiovascular events. Increased TC and LDL were most pronounced changes in lipid profiles of RA, PsA and AS patients. All these markers were revealed to be associated with both common cardiovascular (age, increased BMI) and the disease-associated factors (arthritis duration, activity of the underlying disease).

Disclosure of Interests: None declared


AB0946

PELVIS RADIOGRAPHY FINDINGS AND PROGRESSION RATES IN PATIENTS WITH PSORIATIC ARTHRITIS UNDER BIOLOGIC TREATMENT

G. Ayhan,1 A. Sadic2,3, L. Kilic, U. Kalyoncu1,1Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; 2Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; 3Hacettepe University Medical Faculty, Department of Internal Medicine, ankara, Turkey

Background: Psoriatic arthritits (PsA) is a heterogenous disease that can present with various musculoskeletal manifestations. Several studies have assessed the rate of sacroilitis in PsA population, however data on the involvement of other pelvic structures that could cause symptoms, such as major enthesis or hip involvement, and progression rates during follow-up is scarce.

Objectives: This study aimed to understand overall pelvis radiography findings and progression rates during follow-up in a cohort of patients with PsA under biologic treatment.

Methods: PsA patients from the Hacettepe University biological database (HUR-BIO), were retrospectively analyzed for their pelvis radiographs. All radiographs for individual patient were consecutively scored. Modified New York (mNY) criteria was used to assess sacroilitis and ilium/ iliac wing/ greater trochanter enthesopathy and symphysis pubis osteitis assessments were done using a grade 0, no changes, 1, minimal changes and grade 2 and more counted as significant changes (1). Hip involvement was scored using BASRI-hip score and data on prosthesis were noted (2). All of the assessments were done by an experienced rheumatologist (UK) and in cases with suspicion, another experienced rheumatologist reviewed the cases (LK) and a consensus was reached.

Results: Overall 273 patients (69.6% of females) with the mean (SD) age at the time of first radiography 43.3 (12) years were included. At their initial radiographic assessment, the median (IQR) PsA duration was 2 (7) years. Base-line radiographs showed 10 (%3.7) of the patients had transitional vertebra and 137 (50.2%) patients had sacroilitis according to mNY criteria. From patients without sacroilitis (n=136), 67 patients had following radiographs. After a mean (SD) 471 (37) months, 16 (23.8%) of them progressed to sacroilitis according to mNY criteria. Regarding the major enthesopathies, Regarding significant changes, 26.8 % of the patients had ischium enthesopathy, 19.3% of the patients ad symphysis pubis involvement and 13.2% of the patients had iliac

Disclosure of Interests: None declared


Table 1. Distribution of major enthesal involvement and BASRI-hip scores and progression rates

<table>
<thead>
<tr>
<th>Location</th>
<th>Grades</th>
<th>First assessment (N %)</th>
<th>Progression rate*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischium (n=164)</td>
<td>4</td>
<td>0</td>
<td>9/85 (13.8)</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>11 (6.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>33 (20.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>74 (45.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>46 (28)</td>
<td></td>
</tr>
<tr>
<td>Symphysis Pubis</td>
<td>4</td>
<td>0</td>
<td>8/78 (10.2)</td>
</tr>
<tr>
<td>(n=151)</td>
<td>3</td>
<td>5 (2.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>32 (16.8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>60 (31.4)</td>
<td></td>
</tr>
<tr>
<td>Iliac wing</td>
<td>4</td>
<td>0</td>
<td>3/72 (4.1)</td>
</tr>
<tr>
<td>(n=174)</td>
<td>3</td>
<td>9 (5.2)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>14 (8.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>28 (16.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>124 (71.3)</td>
<td></td>
</tr>
<tr>
<td>BASRI score</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>(right)</td>
<td>3</td>
<td>3 (1.4)</td>
<td></td>
</tr>
<tr>
<td>(n=220)</td>
<td>2</td>
<td>2 (1.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>214 (97.3)</td>
<td></td>
</tr>
<tr>
<td>BASRI score</td>
<td>4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>(left)</td>
<td>3</td>
<td>4 (1.8)</td>
<td></td>
</tr>
<tr>
<td>(n=219)</td>
<td>2</td>
<td>2 (0.9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>213 (97.3)</td>
<td></td>
</tr>
</tbody>
</table>
*Defined as one unit increase in the grade
Wing entheseopathy. Trochanter major entheseopathy rates were 2.4% and 1.4% at right and left sites respectively. Only one patient had trochanter minor enthesitis on the left site (Table 1). Prosthesis requirement was observed in 4 hip joints and 4 hip joints had prosthesis. There was no correlation between meeting mNY criteria and having iliac, ischium, and pubis involvement ≥ 2. On the other hand, patients with when there is ischium entheseopathy ≥ 2 (17/46 (36.9%) vs 18/96 (18.7%), p=0.013) or iliac wing entheseopathy ≥ 2 above (10/18 (55.5%) vs. 26/129 (20.1%), p=0.001), any syndesmophyte in the spine is more commonly seen.

Conclusion: Half of the patients with PsA requiring advanced treatment modalities, had sacroilitis in a median 2 years of disease duration and the rest may progress to sacroilitis during the follow-up period. Major entheseopathy involvement was also seen in more than half of the patients. Iliac, iliac wing entheseopaties and spinal syndesmophytes may be all a part of the osteoproliferative process. Further assessment is needed to correlate those radiographic changes to clinical symptoms.

REFERENCES:

Disclosure of Interests: None declared

AB0947 CORRELATION BETWEEN ENTHESIS AND CLINICAL PHENOTYPE PSORIASIS, NAIL PSORIASIS AND DURATION PSORIASIS IN PATIENTS WITH PSORIATIC ARTHRITIS
L. Vorobeva1, T. Kortaeava1, E. Loginova1, E. Gubaree2, Y. Konsakova3, M. Chamurlieva1, E. Nasonov1, A. Lila1, V.A. Nasonova Research Institute of Rheumatology, Spondyloarthropathies and psoriatic arthritis, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: Psoriatic arthritis (PsA) is a disease with multidimensional manifestations in patients who have psoriasis (PsO). Enthesitis is an important component of PsA and may be a primary pathological feature driving other manifestations of the disease. [1] Psoriasis and psoriatic nail dystrophy are also important predictors of PsA. Skin and joint disease may indeed arise from the same underlying process at the same time, with patients developing similar inflammatory lesions in the skin and entheses, while the speed of detection of these lesions is different and allows skin changes to be detected earlier. [2]

Objectives: to evaluate correlation between enthesis and clinical phenotype psoriasis, nail psoriasis and duration psoriasis in patients with psoriatic arthritis.

Methods: 187 (M/F=97 (50.2%)/90(48.8%)) PsA pts fulfilling the CASPAR criteria were included. Mean age 45.6±11.7 years (yrs), DAPSA 21.05±21.03, median (Me) PsA duration 88 [16;421] mo. All pts underwent standard clinical examination and after imaging modalities scoring (X-ray or CT -scan).

Results: When 79 (42.3%) pts with enthesitis and 108 pts (57.7%) without enthesitis were compared. In pts with enthesitis had more duration PsO – 275.6±153.4 vs 227.4±139.5, p=0.03. The duration of PsA, both groups were comparable (p=0.9). Also in pts with enthesitis had more nail PsO - 66.6% vs 45% (p=0.005). BSA in both group were comparable, but in pts with enthesitis had more inverse PsO – 6.94% vs 3%, gluttate PsO – 4% in pts without enthesitis with phenotype PsO did not have, and combination plaque and inverse PsO – 51.3% vs 31% (p=0.0056). Moreover, significant but weak positive correlations between the LEI score and duration PsO and nail PsO. Assessment of the correlation modified LEI score and MASES score showed significant positive correlations with duration PsO, nail PsO and phenotype PsO.

Table 1. Correlation between LEI, modified LEI, MASES and parameters PsO.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>LEI</th>
<th>Modified LEI</th>
<th>MASES</th>
</tr>
</thead>
<tbody>
<tr>
<td>r</td>
<td>p</td>
<td>r</td>
<td>p</td>
</tr>
<tr>
<td>Duration psoriasis</td>
<td>0.3</td>
<td>0.001</td>
<td>0.3</td>
</tr>
<tr>
<td>BSA</td>
<td>0.05</td>
<td>0.4</td>
<td>0.06</td>
</tr>
<tr>
<td>Nail psoriasis</td>
<td>0.3</td>
<td>0.001</td>
<td>0.35</td>
</tr>
<tr>
<td>Phenotype psoriasis</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Plaque psoriasis</td>
<td>0.53</td>
<td>0.001</td>
<td>0.61</td>
</tr>
<tr>
<td>Plaque-inverse psoriasis</td>
<td>-</td>
<td>-</td>
<td>0.65</td>
</tr>
<tr>
<td>Inverse psoriasis</td>
<td>-</td>
<td>-</td>
<td>0.70</td>
</tr>
<tr>
<td>Glutamate psoriasis</td>
<td>-</td>
<td>-</td>
<td>0.63</td>
</tr>
</tbody>
</table>

Conclusion: In our cohort PsA pts reported that with enthesitis is associated with duration PsO, nail psoriasis and phenotype PsO. These finding should be considered in the turn of improved screening, earlier diagnosis, timely treatment initiation and, eventually, should improve overall disease outcomes.

REFERENCES:

Disclosure of Interests: None declared

AB0948 OSTEOPOROTIC SCREENING AND PREVALENCE OF SEVERE OSTEOPOROTIC FRACTURES IN A POPULATION OF PSORIATIC ARTHRITIS INITIATING A BIOLOGIC TREATMENT
M. Lafraye1, M. Caroline3, E. Allado2, E. Bauer1, I. Chary Valkenaere3, D. Loeule1, 1University Hospital, Rheumatology, Nancy, France; 2University Hospital, Center of Sports Medicine and Adapted Physical Activity, Nancy, France

Background: Osteoporosis is a common complication of Rheumatic diseases. The association between osteoporosis and rheumatoid arthritis is clearly demonstrated while this association is still debated as well as for the screening of osteoporosis by Dual-Energy X-Ray Absorptiometry (DEXA) or to demonstrate an increased risk of fracture on radiography in a population of Psoriatic Arthritis (PsA). The prevalence of fragility fractures reported on medical reports ranged between 12% and 40% in PsA patients. Only a few studies evaluated the prevalence of vertebral fracture (VF) on spine radiographs. To our knowledge no study has evaluated the contribution of radiographic or CT assessment of the spine on the prevalence of fragility fracture reported in medical records.

Objectives: To determine Psoriatic Arthritis patient’s characteristics screened for osteoporosis by DEXA in a population initiating a biologic treatment (bDMARD) and to estimate the prevalence of severe osteoporotic fractures on medical reports and after imaging modalities scoring (X-ray or CT-scan).

Methods: Patients with psoriasis should satisfy the CASPAR or ASAS criteria and have been screened during their follow up for a bDMARD. Osteoporotic screening was defined by a BMD testing (DEXA). Vertebral fractures were scored according to Genant’s method on bone X-ray or sagittal CT-scan images. Clinical and demographic data and the presence of previous severe osteoporotic fracture reported in the medical records were collected.

Results: On 417 PsA patients screened for bDMARDS during 2008-2019, 89 patients (21.3%) were assessed for osteoporosis by DEXA. Increased age, female sex, menopause, previous severe fracture, disease duration, presence of inflammatory bowel disease, current and previous corticosteroid and bDMARDs uses were significantly associated with osteoporotic screening. On DEXA, 7 patients (17%) were classified as osteoporotic. The prevalence of severe osteoporotic fracture was 6.7% in medical reports and increased to 23.6% after scoring spine radiographies or TAP-CT images. In univariate analysis the prevalence of severe osteoporotic fractures was associated with age (p=0.013), scanographic bone attenuation coefficient (p<0.005) and Lumbar T-score (p=0.039).

Conclusion: Less than a quarter of PsA patients initiating a bDMARD is screened for osteoporosis. The prevalence of osteoporosis on DEXA and severe osteoporotic fractures on medical records are inferior to 10%. After systematic imaging evaluation, this prevalence increases at 23.6%.

REFERENCES:
Psoriasis and psoriatic arthritis (PsA) are chronic immune-mediated diseases that primarily affect the skin and joints, respectively. A large proportion of patients with plaque psoriasis suffer from psoriatic lesions on the scalp, nails, palmoplantar area and genitals. These locations can also be soley or predominantly affected. Psoriasis in special localizations are often perceived as particularly stigmatizing and significantly reduce quality of life. Involvement of these body parts is associated with an increased risk of PsA.

Objectives: To provide a descriptive analysis of psoriasis in special localizations in patients with psoriasis versus patients with PsA.

Methods: This cross-sectional study was performed in Vega-Baja Hospital (Orihuela-Spain) from May 2021 to December 2021. We prospectively enrolled 77 consecutive psoriasis patients and 76 consecutive patients affected by PsA and followed at the Vega-Baja Hospital (Orihuela-Spain). Sociodemographic data and clinical characteristics were analysed.

Results: One hundred and fifty-three patients were included (77 psoriasis patients and 76 patients affected by PsA). The registry variables used in this study are detailed in Table 1.

Table 1. Patients’ data variables recorded

<table>
<thead>
<tr>
<th>Psoriasis</th>
<th>PsA</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>35 (45.5)</td>
<td>31 (40.8)</td>
</tr>
<tr>
<td>Female</td>
<td>42 (54.5)</td>
<td>45 (59.2)</td>
</tr>
<tr>
<td>Age (years), mean (SD)</td>
<td>50.27 (15.3)</td>
<td>53.83 (10.2)</td>
</tr>
<tr>
<td>Weight (kg), mean (SD)</td>
<td>86.1 (21.3)</td>
<td>78.8 (17.7)</td>
</tr>
<tr>
<td>Height (m), mean (SD)</td>
<td>1.66 (0.1)</td>
<td>1.65 (0.1)</td>
</tr>
<tr>
<td>BMI (kg/m²), mean (SD)</td>
<td>31.3 (7.6)</td>
<td>28.7 (5.5)</td>
</tr>
<tr>
<td>HTA, n (%)</td>
<td>20 (26.0)</td>
<td>19 (25.0)</td>
</tr>
<tr>
<td>DM, n (%)</td>
<td>12 (15.6)</td>
<td>14 (18.4)</td>
</tr>
<tr>
<td>DLP, n (%)</td>
<td>25 (32.5)</td>
<td>29 (38.2)</td>
</tr>
<tr>
<td>Metabolic syndrome, n (%)</td>
<td>36 (46.8)</td>
<td>42 (53.5)</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>31 (40.3)</td>
<td>23 (30.3)</td>
</tr>
<tr>
<td>Yes</td>
<td>29 (37.7)</td>
<td>19 (25.0)</td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>17 (22.1)</td>
<td>34 (44.7)</td>
</tr>
<tr>
<td>Psoriasis in special localizations, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scalp</td>
<td>67 (87.0)</td>
<td>74 (97.4)</td>
</tr>
<tr>
<td>Scap</td>
<td>52 (67.5)</td>
<td>51 (67.1)</td>
</tr>
<tr>
<td>Genital</td>
<td>30 (39.0)</td>
<td>31 (40.8)</td>
</tr>
<tr>
<td>Palmoplantar</td>
<td>19 (24.7)</td>
<td>18 (23.7)</td>
</tr>
<tr>
<td>Nails</td>
<td>30 (39.0)</td>
<td>42 (53.3)</td>
</tr>
</tbody>
</table>

BMI, body mass index; DLP, dystidipemia; DM, diabetes mellitus; HTA, hypertension; PsA, psoriatic arthritis. There was a significant difference in weight and body mass index between the groups. PsA patients have more frequent psoriasis in special locations.

Conclusion: We have found that patients with PsA have more frequent psoriasis in special locations.

REFERENCES:

Disclosure of Interests: None declared.


Detection of Asymptomatic Enthesal Involvement in Patients with Psoriatic Arthritis: A Case-Control Ultrasound Study

R. Ben Aissa¹, S. Boussaid², S. Rekki¹, S. Jemmali¹, S. Rahmouni¹, H. Ailiani¹, H. Srai Sahl¹, M. Elleuch¹, A. Soussi¹, M. Mokri¹, Rabta Hospital, Department of Rheumatology, Tunis, Tunisia; ²Rabta Hospital, Department of Dermatology, Tunis, Tunisia.

Background: Enthesopathy is one of the major features of psoriatic arthritis (PsA). The clinical screening for entheseal synovitis and enthesitis in patients with psoriasis is nonspecific during the subclinical phase. Ultrasonography (US) has already demonstrated its ability to study entheses and joints in early stages of PsA.

Objectives: To evaluate the prevalence of ultrasonographic subclinical synovitis and enthesopathies in psoriasis patients with no clinical evidence of PsA compared with controls.

Methods: A cross-sectional study conducted on 40 patients with psoriasis and 40 healthy sex- and age- matched controls. The Leeds Enthesitis Index (LEI) and Spondyloarthrits Research Consortium of Canada (SPARCRC) were used to evaluate enthesal involvement. US examination of 18 joints (wrists, metacarpophalangeal, and proximal interphalangeal joints) was performed along with 22 enthesal sites (deep flexor of the fingers, lateral epicondyle, triceps, quadriiceps, patellar and calcaneal tendons and plantar fascia). Inflammatory-score (thickening, hypoechogenicity, bursitis and Doppler signal) and damage-score (calcifications, entheseal erosions and erosions) were calculated (= absent, 1=present for each abnormality). A total score was obtained by adding these two scores.

Results: The mean age of psoriatic patients 51.90±15.90 [19 -76] and the sex ratio of males to females was 3:2. US synovitis were more frequent in psoriatic patients 7/1040 (0.68%) than in controls 3/1040 (0.29%) but this was not significant (p=0.420). Patients with psoriasis had more US enthesopathies 37 (92.5%), comparing to controls 16 (40%) (p < 0.001). The total number of enthesopathies was higher in the psoriatic group 184/880 (20.90%) comparing to controls 42/880 (4.78%) (p < 0.001). Entheses with more US abnormalities in the psoriasis group compared to controls were deep flexor tendons of the fingers entheses (p<0.001), distal patellar tendon entheses (p<0.001) and calcaneal tendon entheses (p<0.001). LEI and SPARCRC scores were positively correlated to higher number of US enthesopathies (p=0.046, p=0.006). SPARCRC was positively correlated to inflammatory-score and damage-score (p=0.009, p=0.024). The mean C-reactive protein level was higher in psoriatic arthritis 5.77±10.10 mg/L than in controls 2.15±3.26 mg/L (p=0.037).

Conclusion: Our results confirm that US enthesopathies and synovitis are more frequent in patients with psoriasis comparing to healthy population. The US screening for subclinical enthesopathies should be object of longitudinal investigations to define its value in predicting the clinical onset of PsA.

Disclosure of Interests: None declared.

inflammatory lesion observed in 4% (n=16) of the entheses, followed by hypoechoegenicity (0.5%, n=2). Enthesophytes were the most frequent chronic damage lesions detected in 1.25% (n=5) of the entheses followed by erosions (0.5% vs. 0.2%). The highest total US scores per enthesis site were observed at the calcaneal enthesis [mean (SD) 0.27 (0.59)], followed by plantar fascia [0.18 (0.50)] and distal patellar tendon origins [0.10 (0.37)]. Age was not associated to higher scores (total, inflammatory, chronic damage; p=0.339, p=0.412, p=0.531). Female participants had higher inflammation scores than males (mean inflammation scores (SD) 0.69 (1.44) versus 0.39 (0.71), p=0.044). The BMI was correlated to higher inflammation score (p=0.020, r=0.368) but not to chronic damage nor to total scores (p=0.478, p=0.104). Intense physical activity was associated to higher chronic damage score comparing to moderate physical activity (mean chronic damage scores (SD) 0.30 (0.67) versus 0.003 (0.00), p=0.058) and to low physical activity (mean chronic damage scores (SD) 0.30 (0.67) versus 0.0018 (0.00), p=0.043). No association between physical activity and inflammation score had been observed.

Conclusion: Our study demonstrates that US changes within the enthesis are associated with higher BMI and physical activity. These results support the effect of biomechanical forces on the entheses that should be considered when differentiating by US pathological from healthy entheses.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4127

**Table 1. Baseline data of patients with PsA from the registers PsoBest and RABBIT-SpA included 10/2017 to 12/2020.**

<table>
<thead>
<tr>
<th></th>
<th>RABBIT-SpA</th>
<th>PsoBest</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rheumatology setting</strong></td>
<td>(Dermatology setting)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>1066</td>
<td>704</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>51.9 (12.2)</td>
<td>51.7 (13.2)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>637 (60)</td>
<td>346 (49)</td>
</tr>
<tr>
<td>Disease duration skin, mean (SD)</td>
<td>14.3 (13.9)</td>
<td>22.0 (16.0)</td>
</tr>
<tr>
<td>Body surface area, mean (SD)</td>
<td>8.5 (15.0)</td>
<td>20.8 (19.8)</td>
</tr>
<tr>
<td>Nail psoriasis, n (%)</td>
<td>434 (41)</td>
<td>407 (58)</td>
</tr>
<tr>
<td>Tender joints, n (%)</td>
<td>905 (85)</td>
<td>498 (71)</td>
</tr>
<tr>
<td>Swollen joints, n (%)</td>
<td>708 (67)</td>
<td>387 (55)</td>
</tr>
<tr>
<td>Physician reported disease activity, mean (SD)</td>
<td>5.2 (1.9)</td>
<td>4.6 (2.7)</td>
</tr>
<tr>
<td>DLSO, mean (SD)</td>
<td>5.6 (6.2)</td>
<td>12.2 (7.6)</td>
</tr>
<tr>
<td>HAQ, mean (SD)</td>
<td>0.9 (0.7)</td>
<td>0.7 (0.6)</td>
</tr>
<tr>
<td>Patient reported disease activity, mean (SD)</td>
<td>5.7 (2.4)</td>
<td>4.9 (2.9)</td>
</tr>
<tr>
<td>Patient reported pain, mean (SD)</td>
<td>5.5 (2.4)</td>
<td>5.2 (2.2)</td>
</tr>
<tr>
<td>bDMARD, n (%)</td>
<td>751 (71)</td>
<td>514 (73)</td>
</tr>
<tr>
<td>TNF, n (%)</td>
<td>346 (46)</td>
<td>117 (23)</td>
</tr>
<tr>
<td>IL12, n (%)</td>
<td>351 (47)</td>
<td>246 (46)</td>
</tr>
<tr>
<td>IL23, n (%)</td>
<td>54 (7)</td>
<td>151 (29)</td>
</tr>
<tr>
<td>tsDMARD, n (%)</td>
<td>109 (10)</td>
<td>47 (7)</td>
</tr>
<tr>
<td>cdDMARD, n (%)</td>
<td>195 (18)</td>
<td>142 (20)</td>
</tr>
</tbody>
</table>

**AB0952 CHARACTERIZATION OF PATIENTS WITH PSORIATIC ARTHRITIS IN DERMATOLOGIC AND RHEUMATOLOGICAL CARE: AN ANALYSIS OF TWO DISEASE REGISTRIES**

L. Lindner1, M. Augustin2, L. Kunih3, A. Weiß4, S. J. Rustenbach4, F. Behrens4, M. Feuchtenberger5, L. Schwarze6, U. Mrowietz7, D. Thaçi8, K. Reich9, A. Strangfeld1, A. Regeizer1,1. German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany; 2University Medical Center Hamburg-Eppendorf, NVD - Institute for Health Services Research in Dermatology and Nursing, Hamburg, Germany; 3Goethe University, Rheumatology, Frankfurt, Germany; 4Hospital Burghausen, Department of Internal Medicine II, Burghausen, Germany; 5Rheumatologist, Rheumatology, Leipzig, Germany; 6University Medical Center Schleswig-Holstein, Department of Dermatology, Venerology and Allergology, Kiel, Germany; 7University Medical Center Schleswig-Holstein, Comprehensive Center for Inflammation Medicine, Lübeck, Germany

**Background:** Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the musculoskeletal system, skin and nails. Therapeutic management in Germany is usually provided by a dermatologist or rheumatologist. The clinical specialization of the treating physician was associated with different treatment and clinical status of patients with PsA. Our analysis showed that patients in the rheumatology setting more frequently had joint affection and lower functional status, whereas skin severity was worse in the dermatology setting, indicating selection effects of health care access. We hypothesize that these differences may be biased due to different diagnostic and therapeutic routines in the specialized health care settings. Psoriatic arthritis should be treated in a multidisciplinary approach to take into account all facets of this complex disease.

**REFERENCES:**
1. PMID: 24393314
2. PMID: 30674933

**Disclosure of Interests:** Lisa Lindner Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen,Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Matthias Augustin Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biological, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Laura Kühl Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, Biogen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Stephan J. Rustenbach Grant/research support from: The PsoBest registry is/was supported by AbbVie, Almirall Hermal, Amgen, BMS, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis, Pfizer, UCB and Viatris. These companies do not have influence on the design of the registry, data collection, analyses, the publication decisions or development., Anja Weiß Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris., Anne Regnier Grant/research support from: RABBIT-SpA is supported by a joint, unconditional grant from AbbVie, Amgen, Biogen, Hexal, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, UCB and Viatris.

**DOI:** 10.1136/annrheumdis-2022-eular.4317

**AB0953 LACK OF RACIAL DIVERSITY IN CLINICAL TRIALS OF PSORIATIC ARTHRITIS**

N. Goel1,2, 1Duke University School of Medicine, Internal Medicine, Division of Rheumatology, Durham, NC, United States of America; 2Abcuro, Inc, Newton, MA, United States of America

**Background:** Participant diversity in clinical trials of therapeutics in rheumatology is important to understand how persons of different races and ethnicities might respond differently to therapeutics. Specifically, for psoriatic arthritis (PsA), although people of color (POC) have lower disease prevalence, prevalence still ranges from 0.04-0.19% in Blacks, 0.13-0.19% in Asians, and 0.09-0.30% in Hispanics versus 0.19-0.34% in Whites in the insured population of the US. Literature on the diversity of PsA clinical trials remains limited, though data suggest that minorities are underrepresented in clinical trials. This analysis aims to evaluate the diversity of participants in randomized clinical trials (RCTs) of US Food and Drug Administration approved targeted therapies for PsA.

**Objectives:** To evaluate the reporting of race and ethnicity in published RCTs of PsA targeted therapies approved for use in the US.

**Methods:** Targeted therapies approved for use in the treatment of PsA in the US were identified. Package inserts and ClinicalTrials.gov (CT.gov) were used to

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.4317

**AB0954**
identify the pivotal double blind, RCTs in PsA which supported the approval of the identified therapeutics in the US. The articles reporting the primary endpoint data were obtained. Race and ethnicity data were extracted from the published data. Countries in which the studies were conducted were identified from the publications or CT.gov. Descriptive analyses were performed.

**Results:** Twenty-nine pivotal RCTs in PsA evaluating targeted therapeutics, published from 2002 – 2022, were identified; 24 reported race; non-White race was reported in only 13 (45%) (Table 1 and Figure 1). In the latter, people of Black race comprised <1% of the overall population in 12 RCTs and 2.7% in the remaining RCT. People of Asian race comprised 6.1% of the overall population reflecting <10% of the population in 11 studies and 11.3% and 19.0% in the remaining 2 studies. Overall, 19 (65.6%) trials recruited participants from Asia Pacific countries. Hispanic/Latinx ethnicity was not reported in any study. Studies published from 2017-2022 reported non-White race (n=7 of 15 [47%]) no more frequently than studies published from 2004-2016 (n=6 of 14 [43%]). Although the 13 RCTs reporting non-White race may not reflect unique individuals, the total number of people included across these RCTs was 7261, of which 48 (0.7%), 441 (6.1%), and 6589 (90.9%) were Black, Asian, and White, respectively.

Table 1. Race Reporting in Psoriatic Arthritis Pivotal Clinical Trials of Targeted Therapeutics

<table>
<thead>
<tr>
<th>Race Reporting Status</th>
<th>Total Trials (N)</th>
<th>Total White (n [% of N])</th>
<th>Total Black (n [% of N])</th>
<th>Total Asian (n [% of N])</th>
<th>Total Asian Other* (n [% of N])</th>
<th>Total Non-White Race (n [% of N])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not reported</td>
<td>5</td>
<td>1 (20.0)</td>
<td>1572</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-White race reported</td>
<td>13</td>
<td>13 (44.8)</td>
<td>27261</td>
<td>48 (0.7)</td>
<td>441 (6.1)</td>
<td>6589 (90.9)</td>
</tr>
<tr>
<td>Non-White race not reported</td>
<td>11</td>
<td>5 (45.5)</td>
<td>6588</td>
<td>5803</td>
<td>(88.1)</td>
<td>(0.7) (6.1) (2.4)</td>
</tr>
<tr>
<td>Total (N)</td>
<td>29</td>
<td>19 (65.5)</td>
<td>15421</td>
<td>48 (0.7)</td>
<td>441 (6.1)</td>
<td>6589 (90.9)</td>
</tr>
</tbody>
</table>

Abbreviations: AP, Asian Pacific; N and n, number; *Other also includes American Indian/Alaskan Native, mixed race, unknown race; Note: Numbers across rows may not add up to 0, and the total number of individuals reported in any one group may not be unique. Dashes reflect data not provided or able to be calculated.

Figure 1. Pivotal Trials of Targeted Therapeutics Published Between 2004-2022

**Conclusion:** Our data show under-reporting of race and ethnicity in publications of pivotal PsA RCTs, and no evidence of improved reporting over time. Whites were overrepresented in pivotal trials of PsA, especially when considering 72 and 62% of the US population was White in 2010 and 2020 (US Census data), respectively, and the reported prevalence of PsA by race in the insured population of the US1. Improved reporting of race/ethnicity and increased representation of racial/ethnic minorities in PsA RCTs are needed.

**References:**

**Disclosure of Interests:** Niti Goel Shareholder of: UCB, Abcuro, Employee of: Abcuro

**DOI:** 10.1136/annrheumdis-2022-eular.4524

**AB0054**

CONCORDANCE BETWEEN DIFFERENT COMORBIDITIES SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS

N. D. Popenco1, A. Dima1, I. A. Berza1, G. M. State1, F. Negoi1, M. Panduru2, M. Parvu1, 1Colentina Clinical Hospital, Department of Rheumatology, Bucharest, Romania; 2Colentina Clinical Hospital, Department of Dermatology, Bucharest, Romania

**Background:** Patients with psoriatic arthritis (PA) are more likely to suffer from other chronic medical conditions, associated comorbidities having significant impact upon both quality of life and survival. As disorders like the cardiovascular disease, metabolic syndrome, hepatic or renal pathologies were shown to be more prevalent in PA [1], assessment of comorbidities is important in these patients [2].

**Objectives:** To investigate the concordance of different comorbidities scores in patients with PA.

**Methods:** Prospective inclusion of patients diagnosed with PA according to the CASPAR (Classification criteria for Psoriatic Arthritis) criteria. Associated comorbidities were prospectively assessed using the Psoriatic arthritis comorbidity index (PsACI) with a cut-off of 8 points as previously defined [2]. Also, the following comorbidities scores were completed in all patients: Charlson comorbidity index (CCI), Rheumatoid Arthritis Comorbidity Index (RACI), Rheumatic Diseases comorbidity index (RDCI), Functional comorbidity index (FCI).

**Results:** A total of 56 patients were included: 27 (48.2%) were female, with a median (q1-q3) disease duration of 17.5 (12.7; 26.5) years for the cutaneous disease and 6.0 (4.0; 13.0) years for the articular one. At inclusion, the results of the comorbidities scores assessed were as follow: PsACI 3.2 (2.0; 6.5), CCI 1.0 (0.0; 2.0), RACI 3.5 (1.5; 6.5), RDCI 1.0 (0.0; 2.0), and FCI 2.0 (0.0; 2.0), respectively. According to PsACI, hypertension, hyperlipidemia, osteoarthritis, liver disease, and diabetes mellitus were the most frequent associated comorbidities in PA patients, in 53.6%, 44.6%, 41.1%, 37.5%, and 28.6% cases, respectively (see Table 1).

Table 1. Comorbidities according to the Psoriatic Arthritis Comorbidity Index

<table>
<thead>
<tr>
<th>Parameter</th>
<th>n (%)</th>
<th>Parameter</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus</td>
<td>16 (28.6)</td>
<td>Cerebrovascular disease</td>
<td>1 (1.8)</td>
</tr>
<tr>
<td>Metabolic syndrome</td>
<td>8 (14.3)</td>
<td>Peripheral vascular disease</td>
<td>2 (3.6)</td>
</tr>
<tr>
<td>Ischemic heart disease</td>
<td>9 (16.1)</td>
<td>Osteoporosis</td>
<td>4 (7.1)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1 (1.8)</td>
<td>Fracture</td>
<td>3 (5.4)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>30 (53.6)</td>
<td>Fall</td>
<td>1 (1.8)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>25 (44.6)</td>
<td>Liver disease</td>
<td>21 (37.5)</td>
</tr>
<tr>
<td>Amythymia</td>
<td>2 (3.6)</td>
<td>Renal disease</td>
<td>2 (3.6)</td>
</tr>
<tr>
<td>Depression</td>
<td>6 (10.7)</td>
<td>Pulmonary disease</td>
<td>6 (10.7)</td>
</tr>
<tr>
<td>Anxiety</td>
<td>10 (17.9)</td>
<td>Gastrointestinal tract</td>
<td>2 (3.6)</td>
</tr>
<tr>
<td>Endocrine</td>
<td>7 (12.5)</td>
<td>Osteoarthritis</td>
<td>23 (41.1)</td>
</tr>
<tr>
<td>Periodontitis</td>
<td>1 (1.8)</td>
<td>Fibromyalgia</td>
<td>3 (5.4)</td>
</tr>
<tr>
<td>Smoking</td>
<td>6 (10.7)</td>
<td>Amyloidosis</td>
<td>1 (1.8)</td>
</tr>
<tr>
<td>Infection</td>
<td>0 (0.0)</td>
<td>Eyes inflame/ uveitis</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Vasculitis</td>
<td>0 (0.0)</td>
<td>Tumor</td>
<td>3 (5.4)</td>
</tr>
</tbody>
</table>

In bivariate analysis, we found significant correlations between the results of PsACI and those of the other comorbidities scores used: CCI (p<0.001, rho=0.668), RACI (p<0.001, rho=0.792), RDCI (p<0.001, rho=0.691), and FCI (p<0.001, rho=0.697), respectively. The ability of the comorbidities scores assessed to discriminate a PsACI high value is presented in Figure 1, AUC (95%CI): CCI 0.743 (0.601-0.886) p=0.017, RACI 0.815 (0.634-0.996) p=0.002, RDCI 0.818 (0.657-0.980) p=0.002, and FCI 0.837 (0.725-0.948) p=0.001, respectively.

**Conclusion:** The composite indexes offer the advantage of reducing all associated comorbidities as long with their severity into a single score. We herein
identified good correlations between the results of the comorbidity scores ana-
yzed, PsACI, CCI, RDCI, RACI, and FCI, respectively.

REFERENCES:

index: development and validation of a new specific tool for classifying pro-
gnostic comorbidity in psoriatic and psoriatic arthritis patients. Rheumatol
Orthop Med 2017; 2. doi:10.15761/ROM.1000117

Disclosure of Interests: None declared

DISEASE ACTIVITY IMPACT OVER THE ANXIETY LEVEL IN PATIENTS WITH PSORIATIC ARTHRITIS

N. D. Popescu¹, A. Dimă¹, I. A. Berza¹, G. M. State¹, F. Negoi¹, M. Panduru²,
M. Parvu³. ¹Colentina Clinical Hospital, Department of Rheumatology, Bucharest,
Romania; ²Colentina Clinical Hospital, Department of Dermatology, Bucharest,
Romania

Background: Psoriatic arthritis (PA) is a complex, systemic, chronic inflam-
matory condition with substantial multisystemic detrimental effects on patients’
health status. In PA patients there was reported increased anxiety occurrence
when compared to general population, even if specific predictors are not
defined yet [1].

Objectives: To characterize disease-related predictors of anxiety in patients
with PA.

Methods: Cross-sectional study with prospective, successive inclusion of
patients fulfilling the CASPAR (CLASsification criteria for Psoriatic Arthritis)
classification criteria for PA. Anxiety level was assessed using the General
Anxiety Disorder-7 (GAD-7) with a cut-off of 10 points as previously defined
[2]. Moreover, disease activity status for PA was defined using also validated
scores, namely the Disease Activity Index for Psoriatic Arthritis (DAPSA), the
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Ankylosing
Spondylitis Disease Activity Score (ASDAS), cutaneous involvement by the
Psoriasis Area Severity Index (PASI), and comorbidities by Psoriatic arthritis
comorbidity index (PsACI).

Results: 56 PA patients were included, 29 (51.8%) males, with mean±SD
age at inclusion of 54.1±13.2years. Regarding the tools for disease activity
assessment, the probability of impact over a high anxiety level as estimated
by area under curve (AUC) was high (> 0.800) for BASDAI [AUC(95%CI)
1.844 (1.198 - 2.839) (see Table 1).

Table 1. Independent predictors for anxiety in psoriatic arthritis patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, F/M</td>
<td>0.106 - 0.203</td>
<td>0.498</td>
</tr>
<tr>
<td>Articular and peripheral, Y/N (%)</td>
<td>0.289 - 0.555</td>
<td>1.503</td>
</tr>
<tr>
<td>DAPSA</td>
<td>1.017 - 0.973</td>
<td>1.063</td>
</tr>
<tr>
<td>BASDAI</td>
<td>1.844 - 1.198</td>
<td>2.839</td>
</tr>
<tr>
<td>ASDAS-CRP</td>
<td>1.312 - 0.877</td>
<td>1.964</td>
</tr>
</tbody>
</table>

Conclusion: Therefore, higher BASDAI results were associated with increased
anxiety in PA and so such results should raise awareness about the need of
search for associated anxiety disorders. On the contrary, the extension of the
cutaneous involvement, the systemic inflammation level or the comorbidities
degree were not identified as predictors for the anxiety occurrence.

REFERENCES:
[1] Zusman EZ, Howren AM, Park JYE, et al. Epidemiology of depression and
anxiety in patients with psoriatic arthritis: A systematic review and
semarthrit.2020.02.001

7.doi:10.1001/archinte.166.10.1092

Disclosure of Interests: None declared

TO WHAT EXTEND IS NAIL ULTRASOUND DISCRIMINATIVE BETWEEN PSORIATIC ARTHRITIS
AND HEALTHY SUBJECTS?

I. Mahmoud¹, S. Rahmou², A. Ben Tekaya¹, S. Bouden¹, L. Rouached¹, R. Tekaya¹, O. Saidane¹, L. Abdelmoula¹, C. Charles Nicolle Hospital,
Rheumatology, Tunis, Tunisia

Background: Clinical physical examination can detect superficial nail
changes in psoriatic patients. However, the nail matrix and bed are not
accessible for clinical assessment. Recently, ultrasonography (US) has
emerged as a useful tool to assess nail involvement in psoriatic arthritis
(PsA) patients.

Objectives: To assess the discriminative utility of nail features detected by
B-mode (BM) and color Doppler (CD) ultrasound (US) between patients with
psoriatic arthritis (PsA) and healthy controls (HC).

Methods: This was a cross-sectional study including PsA patients and HC.
All patients and controls underwent an US assessment of the fingernails that
included the study of morphological changes based on Wortsman’s description
[1]: focal hyperechoic involvement of the ventral plate without involvement of the
dorsal plate (type I), loss of definition on both plates (type II), blood
flow disturbances and measurement of the thickness of nail bed (NBT), nail plate
(TNP) and adjacent skin.

Results: A total of 536 nails were examined (PsA:326 nails, HC:210). Patients
with PsA had significantly more morphological changes of the nails than
healthy controls (23% vs 3.33%, p = 0.006). In PsA patients, the most fre-
cently observed aspect was type II (47 nails, 14.4%), followed by type II (40
nails,12.3%) and type IV (38 nails, 11.6%). In HC, the only observed type was
type II, which was observed in 3.33% of nails. NBT and skin thickness were higher
in the HC group than the PsA group (1.90±0.22 mm vs 2.07±0.34 mm, p=0.047
and 2.25±0.69 vs 2.59±0.31 mm, p=0.002, respectively). The power Doppler signal of the nail bed and
matrix was comparable between the groups (54% vs 61%, p=0.603 and 41%
vs 37.1%, p=0.432, respectively). NBT and skin thickness were higher in the
HC group than the PsA group (1.90±0.22 mm vs 2.07±0.34 mm, p=0.047
and 2.25±0.69 vs 2.59±0.31 mm, p=0.002, respectively). While NPT was similar
between the groups (0.38±0.09 vs 0.36±0.07mm, p=0.239).

Conclusion: US detected morphological changes in clinically healthy fingernails
in both PsA patients and healthy controls. However subclinical involvement was
more common in PsA patients. Loosening of the borders of the ventral plate (type
II) was the only aspect observed in HC. This would suggest that this type is not

In bivariate analysis, we found a significant difference regarding a higher anxi-
ety level as assessed by GAD-7 for female gender (28.6% vs. 78.9%, p=0.001),
concomittance of peripheral and axial articular involvement (25.7% vs. 52.6%,
p=0.034), DAPSA (14.8 (7.1; 22.6) vs. 24.6 (12.2; 36.8), p=0.035), BASDAI
(3.1 (1.3; 4.1) vs. 7.1 (5.0; 8.0), p<0.001), and ASDAS-CRP (2.5 (1.1; 3.7)
vs. 3.5 (2.7; 4.0), p=0.038), but not for the other parameters search, namely

age, smoking, alcohol intake, home settle (urban/ rural, living alone, kids),
disease duration, HLA-B27 status, PASI, PsACI, Patient (PsGA) or Physician
(PGA) Global Assessment, ongoing corticosteroid treatment, or inflammation
status (ESR, CRP). In multivariate analysis, the PA disease-related predictor
for increased anxiety was the auto-evaluation by BASDAI, OR (95%CI) 1.844
(1.198 - 2.839) (see Table 1).
a specific feature of psoriatic nail. With regards to nail plate thickness, the measurements were similar between PsA patients and HC as previously reported by Naoum [2]. However, unlike previous studies, we showed that the nail bed and skin thickness were significantly higher in healthy controls than PsA patients [3].

REFERENCES:

Disclosure of Interests: None declared

AB0957

LIMITED GENDER-RELATED DIFFERENCES CHARACTERIZE PSORIATIC ARTHRITIS: DATA FROM A MONOACENTRIC COLLECTION OF 306 PATIENTS

N. Luciano1, G. Roselli1, L. Canziani1, G. M. Guidelli1, M. Caprioli1, M. De Santis1, A. Ceribelli1, G. Seimi1.

Humanitas Research Hospital - IRCCS, Rheumatology and Clinical Immunology, Rozzano, Italy

Background: Psoriatic Arthritis (PsA) is characterized by a wide spectrum of clinical phenotypes which are ultimately driving therapeutic choices. The male-to-female ratio of the disease is approximately even but in the last decades some gender differences have been proposed in terms of clinical expression and therapeutic responses.

Objectives: The aim of this study is to confirm these differences in a real-life cohort of PsA patients.

Methods: A retrospective data collection has been conducted on a cohort of out-patients with PsA attending our Rheumatology Clinics at Humanitas Research Hospital between January 1st and December 31st 2021. All patients were ≥ 18 years old and fulfilled the CASPAR criteria for PsA. For each patient we obtained demographic, laboratory and clinical parameters and registered which domains (peripheral arthritis, axial PsA, skin and/or nail disease, enthesitis, dactylitis) have been involved in the course of the disease. We also collected data regarding any concomitant comorbidities and previous and current therapies. To investigate possible gender specific differences a cross-sectional univariate descriptive analysis was performed.

Results: Our cohort included 306 patients (169 - 55% - women) with PsA. The median age of disease onset was the same for men and women, also when separately considering skin (median 38 years) and articular presentation (median 48 years). No statistically significant differences were observed when comparing the two groups in terms of clinical phenotypes. In both groups peripheral arthritis was referred by the vast majority of patients (95% of women vs. 93% of men) and similar rates of axial involvement (34% in women vs. 37% in men). Considering current or previous therapies, we found a comparable use of non steroidal anti-inflammatory drugs (43% in both groups), systemic glucocorticoids (9% in men vs 10% in women), conventional synthetic DMARDs and biologic DMARDs and in each group the percentages of patients with a history of bDMARDs targeting TNF alpha, IL12-23 or IL17 failure with or without peripheral involvement, and who were treated according to standard clinical practice (EULAR recommendations). Demographic, clinical, analytical and psychological aspect of the disease and it can be measured with the PsaID.

Conclusion: Our cohort demonstrated limited gender-related differences in PsA course and therapeutic choices or duration, reporting only higher prevalence of hypothyroidism, fibromyalgia and neurologic disorders in women.

Disclosure of Interests: Nicoletta Luciano Speakers bureau: Eli-Lilly, Galapagos, Consultant of: Eli-Lilly, Galapagos, Gennaro Roselli: None declared, Lorenzo Canziani: None declared, Giacomo Maria Guidelli Speakers bureau: Amgen, Eli-Lilly, Galapagos, UCB, Consultant of: Amgen, Eli-Lilly, Galapagos, UCB, Marta Caprioli: None declared, Maria De Santis Grant/research support from: AbbVie, Amgen, Astra-Wassermann, Biogen, Celgene, Eli-Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi-Genzyme, Actelion, Boehringer, Italfarmaco, Grunenthal, Roche, Angela Ceribelli Speakers bureau: Amgen, Eli-Lilly, Galapagos, UCB, Consultant of: Amgen, Eli-Lilly, Galapagos, UCB, Marta Caprioli: None declared.

Disclosure of Interests: None declared

AB0958

THE RELATIONSHIP BETWEEN THE EXTENSOR TENDON ENTHESIS AND THE NAIL IN DISTAL INTERPHALANGEAL JOINT DISEASE IN PSORIATIC ARTHRITIS: ULTRASOUND STUDY

I. Mahmoud, G. Bahmoun, A. Ben Tekaya, S. Bouden, L. Rouached, R. Tekaya, O. Saidane, L. Abdelmoula, Charles Nicolle Hospital, Rheumatology, Tunis, Tunisia

Background: It has been shown that there is an anatomical link between the distal interphalangeal joint (DIP) extensor tendon enthesis and the nail changes in psoriatic arthritis (PsA) [1].

Objectives: To evaluate the relationship between nail involvement and enthesisopathy at DIP level in PsA patients using ultrasonography (US).

Methods: We included patients with PsA. According to OMERACT, the following elemental lesions were dichotomously (presence/absence) evaluated on greyscale US assessment at extensor tendon insertion at distal phalanges: DIP joints: abnormally hypoechoic, enthesophytes, and erosions. We also measured the tendon thickness. Increased abnormal vascularization at entheseal level was also assessed using PD technique. We also performed an US assessment of the finger nails that included the study of morphological changes and measurement of the thickness of nail bed (NBT), nail plate (NPT) and adjacent skin (ST).

Results: We included 33 PsA patients (323 DIP). Eleven patients (34%) presented psoriatic onychopathy (45 fingernails) with a mean NAPSI 7 (IQR (25.75) [2.18]. US study of the nails revealed dystrophy in 75 nails (23%). At patient level, the mean NPT, NBT and 5K were 1.90±0.22, 0.38±0.09, and 2.33±0.62, respectively. None of the patients had clinical involvement of DIP Using US, we examined 325 extensor tendon. The mean thickness of the tendon was the 0.63mm ± 1.0 mm. The tendon was abnormally hypoechoic in two fingers (0.61%). Erosions were present in 16 DIP (4.9%). We found enthesophytes in 82 DIP joints at insertion of extensor digitorum tendon (25.23%). We did not observe increased abnormal vascularization at entheseal level. At finger level, the extensor tendon thickness was higher in the presence of US nail dystrophy (0.70 mm vs 0.60, p=0.01). Erosions were more common in fingers with US nail involvement (14.6% vs 1.9%, p=0.00). Osteophytes were present in 20% of fingers with US nail involvement and 26.3% of fingers without US nail involvement (p=0.166). The thickness of DIP digital extensor tendons was correlated with the NBT (r=0.412, p=0.00), the NPT (r=0.310, p=0.00), and the thickness of the adjacent skin (r=0.509, p=0.00).

Conclusion: The presence of US nail dystrophy was associated with thicker extensor tendon and more erosions. The thickness of the tendon was correlated with the thickness of the nail parts. This might be explained by the close relationship between nail enthesis and support the theory of the enthesis as an extended organ beyond the tendon bony attachment.

REFERENCES:

Disclosure of Interests: None declared

AB0959

THE ACTIVITY OF PSORIATIC ARTHRITIS WITH AXIAL INVOLVEMENT CORRELATES WITH PSAID12.


Hospital Lucus Augustus, Rheumatology, Lugo, Spain; Hospital Universitario da Coruña, Rheumatology, A Coruña, Spain; Hospital do Meixoeiro, Rheumatology, Vigo, Spain; Hospital Arquitecto Marcide, Rheumatology, Ferrol, Spain; Hospital de Monte Forte, Rheumatology, Monforte de Lemos, Spain; Complejo Hospitalario Universitario de Ourense, Rheumatology, Ourense, Spain; Hospital Lucus Augustus, Rheumatology, Lugo, Spain; Hospital Montecelo (Pontvedra), Rheumatology, Pontevedra, Spain; Hospital Universitario da Coruña, Rheumatology, INIBIC, A Coruña, Spain

Background: Patients with psoriatic arthritis (PsA) show an impact on the physical and psychological aspect of the disease and it can be measured with the PsA Impact of Disease (PsAID) questionnaire, and it is expected that the impact of the disease improves when the patient is in remission or low disease activity. The objective of this study was to determine the rate of low impact of the disease in patients with PsA in daily clinical practice, and to evaluate its relationship with its axial activity.

Methods: A cross-sectional study was conducted in consecutive patients who met the CASPAR criteria, with positive clinical (DLI) and positive axial radiology, with or without peripheral involvement, and who were treated according to standard clinical practice (EULAR recommendations). Demographic, clinical, analytical data, HAQ index (0-3) and PsAID12 (0-10) were also collected. Patients were divided into 2 groups: those with a PsAID above 4 (high impact) or below 4 (low
impact). Continuous variables are shown as median (Q1-Q3) and categorical variables as percentages and frequencies. The analyses were performed using SPSS software. Differences were considered statistically significant if p < 0.05.

**Results:** Of the 269 patients evaluated with PsA, 72 patients with axial involvement were included, 40 men (55.6%), with a median age of 54.1 years (45.0-62.0) and disease duration of 7 years (2-11). Obesity (BMI>29.99) affected 28.3% and serum CRP level was 0.45 mgr/dl (0.08-1.10). The treatments of the patients were: NSAIDs 43.1%, corticosteroids 21.6%, csDMARD 52.9% and biological therapy 51.9%. The BASDAI was 4.2 (2.0-6.2) and the ASDAS-PCR was 2.4 (1.5-3.2), with 39.8% being in low activity or remission. The median PsAID total score was 3.9 (1.6-5.4), evaluated in 61 patients. The patients who achieved a PsAID ≤4 were 63% (see Table 1), more men and with a lower CRP. In addition, the low impact measured by the PsAID2 was associated with a lower BASDAI and ASDAS-PCR.

**Conclusion:** Almost two thirds of patients with PsA with axial involvement in daily clinical practice had a low activity of the disease measured by PsAID2 and correlated with low activity in the BASDAI and ASDAS-PCR.

**REFERENCES:**

**Acknowledgements:** to Galician Rheumatology Society (SQGARE)


**Disclosure of Interests:** None declared

**AB0961**

**UVEITIS IN PATIENTS WITH PSORIATIC ARTHRITIS**

S. Monou1, R. Shummaieva1, M. Sotrova2, D. Monou2, 1Medical University - Sofia, Department of Rheumatology, Sofia, Bulgaria; 2Medical Institute - MVR, Department of Ophthalmology, Sofia, Bulgaria

**Background:** Psoriatic arthritis (PsA) is a common disease in Departments of rheumatology, PsA affects from 5 % to 30 % of patients with psoriasis. The arthritis associated with psoriasis follows different patterns, including oligoarticular disease, polyarticular disease, distal interphalangeal disease, arthritis mutilans and axial disease. The axial disease often overlaps with the other four groups. Psoriatic arthritis belongs to the group of spondyloarthropathies in which uveitis is an associated disease. The prevalence of uveitis among PsA patients is not well established.

**Objectives:** The aim of this study is to describe the clinical characteristics of PsA related to uveitis.

**Methods:** Uveitis is described as an inflammation of the tissues that comprise the uveal tract (i.e., iris, ciliary body, and choroid). It can be classified either according to the anatomic parts of uvea that are involved or according to its underlying etiologic cause. Anterior uveitis involves the iris and/or the ciliary body, intermediate uveitis involves the vitreous humor, while posterior uveitis is characterized by inflammation of the uvea and the choroid. A retrospective database study was conducted on 164 (96 female, 68 male, mean age 52,36±16,14 years) adult PsA patients with ocular symptoms. Demographic variables, smoking status, socioeconomic status (SES), body mass index (BMI), presence of selected chronic comorbidities, and medication use, including conventional and biologic disease modifying anti-rheumatic drugs (c/b DMARD) were extracted. We collected data about psoriasis type, uveitis laterality, onset type, human leukocyte antigen types, visual acuity, uveal inflammation localization, anterior segment findings, funduscopy findings, complications, recurrence, intraocular pressure, visual acuity, comorbidities, and medical treatments and outcomes for uveitis and psoriasis, and medical treatments for uveitis and skin diseases. Descriptive statistics was applied as appropriate. Cox proportional hazard regression time dependent models were used to calculate the risk of uveitis given demographic variables, SES, smoking, selected comorbidities, and c/b DMARD. P values of ≤ 0.05 were considered statistically significant.

**Results:** This study included a broad spectrum of ocular inflammation associated with PsA. We found that conjunctivitis was the most common problem, affecting 53 patients (32.32 %). Iritis (anterior uveitis) was found in 10 (6,1%), episcleritis - in 3 (1,83 %) and keratoconjunctivitis sicca - in 5 (3,05 %) patients. 14 patients were with axial involvement, seven of them with anterior uveitis. Patients with PsA and uveitis were more often female (7), of a younger age (48,25±15,4 years). In our cohort of patients uveitis is bilateral in 7 patients, all cases had acute non-granulomatous anterior uveitis. Anterior uveitis is usually accompanied by pain and redness of the eye without vision loss, while intermediate (1 patients) and posterior (2 patients) uveitis are mainly associated with visual symptoms such as floaters or blind spots and may affect central vision. Patients with uveitis had a previous history of uveitis and were more often treated with cDMARDS, monoclonal anti-Tumor Necrosis Factor-α (antiTNF-α) agents and etanercept. No difference in uveitis occurrence was noted regarding demographic characteristics and comorbidities.

**Conclusion:** Uveitis, in particular, is being considered as a relatively rare but very serious ocular complication of psoriasis. Patients with psoriasis should be educated about the increased risk and manifestations of uveitis. An ophthalmological consultation is needed when patients present with eye symptoms.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4928

---

**AB0962**

**PSORIATIC ARTHRITIS WITH POSITIVE ACPA, WHICH FEATURES?**

S. Ghazizadi1, I. EL Harth1, N. Akabi1, I. El Mezouar1, T. Harzy1, 1University Hospital Hassan 2 of Fes, rheumatology, Fes, Morocco; 2medical school of Fes, epidemiology, Fes, Morocco

**Background:** Anti-cyclic citrullinated peptide antibodies (ACPA) have been detected in several patients with psoriatic arthritis (PsA). It is possible that these autoantibodies are associated with particular features of PsA.
Objectives: The objective of our study was to assess the frequency of anti-CCP antibody positivity in psoriatic arthritis, and to identify the factors associated with this positivity in PsA.

Methods: Observational cross-sectional study, carried out in the rheumatology department of the CHU Hassan II of FES between January 2012 and October 2021. Including 67 patients with RF fulfilling the CASPAR criteria. ACPA positivity threshold was >20UI/ml.

Results: Our study included 67 patients, the mean age was 55.3 +/- 15 years, the sex ratio was 0.36M:F, the mean disease duration was 6.61 +/- 9 years. ACPA were positive in 16.4% of cases (11 patients), and negative in 83.6% of cases (56 patients). In bivariate analysis, PsA with positive ACPA was more common in men (278% versus 12%; p=0.049), PsA patients with positive ACPA presented less inflammatory back pain (14% versus 86%) (p=0.049), developed more frequently pulmonary complications (60%) (P=0.001, and presented more often a positive rheumatoid factor (32% versus 7%) (P=0.019). In multivariate analysis, male gender was significantly related to ACPA positivity (p=0.049, OR=22.702, IC=1.05-505). Likewise for lung involvement (p=0.010, OR=6790.3, IC=2.6 -1709.8). Also, ACPA positivity during PsA was significantly related to that of rheumatoid factor (RF) (p=0.05 OR=61.375 IC=0.994-3789). In addition, no statistically significant difference was found between the two groups concerning the activity of the disease, the structural impact, the biological inflammatory syndrome and the use of biotherapies.

Conclusion: In our study, PsA is characterized by a low predominance of a positive ACPA form. This form with positive ACPA is found in our context to be more frequent among men, more often associated with positive RF, and is more complicated by pulmonary damage.

REFERENCES:

Disclosure of Interests: None declared


**AB0963** FREQUENCY OF SEXUAL DYSFUNCTION IN PSORIATIC ARTHRITIS, SANTO DOMINGO, DOMINICAN REPUBLIC


Background: Psoriatic arthritis (PsA) is an inflammatory joint disease that cause structural damage, disability, and an impairment of quality of life 1. Sexual function is a neglected area of quality of life in patients with PsA, with a high prevalence of dissatisfaction. 2 It has been described that there is no relationship between the orgasm/completion domain proved to be the most dysfunctional in both sexes. A statistically significant linear association of sexual dysfunction and disease activity was evident.

REFERENCES:

Disclosure of Interests: None declared


**AB0964** PSORIATIC ARTHRITIS (PSA) WITH POSITIVE RHEUMATOID FACTOR (RF) VERSUS PSORIATRIC ARTHRITIS WITH NEGATIVE RF

S. Ghazaali, I. EL Harchi, N. Akasbi, I. El Mezouna, T. Harzy, University Hospital Hassan 2 of Fes, Rheumatology, Fes, Morocco; University Hospital Hassan 2 of Fes, epidemiology, Fes, Morocco

Background: Rheumatoid factor (RF) has been detected in several patients with psoriatic arthritis (PSA). It is likely that its positivity is linked to a very specific clinical, biological and/or evolutionary profile of PsA.

Objectives: The objective of our study was to evaluate the frequency of positive rheumatoid factor during PsA, and to define the characteristics and factors related to this positivity.

Methods: Monocentric observational cross-sectional study including 84 patients with PsA, fulfilling the CASPAR criteria, and hospitalized in our rheumatology department in University Hospital Hassan II of Fez, on the period lying between January 2012 and October 2021. A threshold greater than 20UI/ml of defines RF positivity.

Results: Our study included 84 patients, the average age was 57 +/- 13 years. The sex ratio was 0.35 M:F, the average duration of disease progression was 6 years +/- 8 years. 47.6% of patients had a positive RF (40 patients) while 52.4% of patients had a negative RF (44 patients). In bivariate analysis, PsA with positive RF had an earlier age of the disease onset (p=0.017), was more frequent in chronic smokers (p=0.045), and showed more enthesis damage (p=0.046). Also, patients with PsA and a positive RF had a higher biological inflammatory syndrome (p=0.013) in particular CRP (p=0.007), higher Basdaï and DAPSA (p=0.021) (p=0.021) respectively In multivariate analysis, enthesis damage involvement was significantly linked to RF positivity (p=0.039, OR=3, IC=1.059-8.496), as was the biological inflammatory syndrome (p=0.010, OR=3.875, IC=1.382 -10.766).

Conclusion: In our study, PsA with positive RF is found to be earlier and more severe in comparison with PsA with negative RF, and more frequently adopts the peripheral enthesitic form.

REFERENCES:
[1] L. Y. Dai, D. Gong, J. X. Zhao [Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody]

Disclosure of Interests: None declared


**AB0965** SERIAL SEROLOGY TESTING IN PATIENTS WITH PSORIATIC ARTHRITIS: SHOULD IT BE DONE?

S. Sundanam, D. Veale,* C. Orr,* L. O’Neill,* F. Young,* Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Rheumatology, Dublin, Ireland

Background: The diagnosis of psoriatic arthritis (PsA) is largely based on clinical phenotype due to the heterogeneity of the presenting features, which can include synovio-enthesal disease, dactylitis, skin and nail disease, uveitis and axial involvement. (1) In contrast to rheumatoid arthritis (RA), PsA is a seronegative inflammatory arthropathy. Rheumatoid factor (RF) and Anti-CCP antibodies are usually absent in PsA, and if patients do have positive serological findings for RF or CCP, the titres tend to be low. (2) Seronegativity for RF has a significantly high discriminant value in the Classification Criteria for Psoriatic arthritis (CASPAR), such that a negative RF forms one of the five possible criteria; thus serological testing is often done once at the initial diagnostic appointment. (3) A previous study in the context of RA has shown that there is a tendency for
repeated serological testing with as much as 70% of patients having RF tested more than once. (4) Repeated testing amounts to additional expense and is rarely needed in PsA. The literature on the frequency of repeated serology testing in PsA patients is absent.

Conclusion: As opposed to RA, PsA has not been associated with the presence of circulating antibodies. The presence or absence of RF in PsA patients has for long been a subject of debate. (3) In cases of peripheral polyarticular PsA, which may be difficult to distinguish from RA, serological testing can be useful to identify RA. However, studies have found that RF can be present in 5-13% of PsA patients. (5) In the context of RA, serological conversion from negative to positive is infrequent and repeat testing is not recommended. (6) Over half of the patients in our PsA cohort had repeated RF testing. Certainly this is unlikely to be helpful or cost effective and serial serology measurements in PsA patients should be avoided.

Disclosure of Interests: None declared


ARE CURRENT PATIENT REPORTED OUTCOMES TOOLS OPTIMIZED TO CAPTURE THE ENTIRE PATIENT EXPERIENCE?

P. J. Mease1, V. Strand2, D. Furst3, E. Siegel4, M. McIlraith5, M. E. Husni6, M. C. Hay7. 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America; 2Stanford, Rheumatology, Palo Alto, California, United States of America; 3University of California Medical Center/Provider St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America; 4Georgetown University School of Medicine, Rheumatology, Washington DC, United States of America; 5Mmc Consulting, Research, Dallas, Texas, United States of America; 6Cleveland Clinic, Rheumatologic and Immunologic Disease, Cleveland, Ohio, United States of America; 7Miami University, Anthropology, Oxford, Ohio, United States of America

Background: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While useful, most of these were originally created for other diseases and only later validated or adapted for use in PsA. More recent efforts have focused on development of PsA specific PRO tools, with inclusion of patient input and relevance for use in both clinical research and clinical care (1).

Objectives: To subject a broad set of currently used PROs to patient assessment, giving insight into usefulness in the clinic and informing efforts for optimization of PsA PROs.

Methods: Four focus groups were conducted across three regionally-diverse areas in the United States from March 2016 to October 2016. Patients represented a range of disease history, symptoms, and severity. After trained facilities encouraged open conversation about PsA, including symptoms, challenges and feelings about disease and treatment, patients reviewed 13 currently utilized PROs and rated relevance of these instruments to reporting their disease experiences on a 3 point scale of Relevant, Somewhat Relevant, and Irrelevant. Verbal discussion followed on the merits and challenges of each rated PRO.

Results: PRO instruments ranged from overall global assessments to disease specific assessments (Table 1). The PROs received a variety of ratings, with Functional Assessment of Chronic Illness Therapy - Fatigue (FACT-F) and Psoriatic Arthritis Impact of Disease (PsAID) judged as Very Relevant by the largest number of patients, followed by Health Assessment Questionnaire-Spondyloarthropathies (HAQ-S) and Pain VAS (Figure 1). Instruments receiving the most assessments of Not Really Relevant were Pt Global and PsA Quality of Life (PsAQOL). In the qualitative portion of the research, major patient critiques across PROs were the time frames listed on the questionnaires; some were too restrictive and disallowed reporting important recent disease activity. Preferences were for questions asked "since your last visit," Multiple participants also agreed that a visual tool allowing patients to circle specific joints to indicate pain would be useful.

Table 1. Outcomes Instruments Assessed in the Study

<table>
<thead>
<tr>
<th>Tool</th>
<th>Abbreviation</th>
<th>Time Period Queried</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Global</td>
<td>Pt GA</td>
<td>None Specified</td>
</tr>
<tr>
<td>Pain Visual Analog Scale</td>
<td>Pain VAS</td>
<td>In the past week</td>
</tr>
<tr>
<td>Health Assessment Questionnaire-Spondyloarthropathies</td>
<td>HAQ-S</td>
<td>Over the past week</td>
</tr>
<tr>
<td>Short Form - 36</td>
<td>SF-36</td>
<td>Different periods queried</td>
</tr>
<tr>
<td>Functional Assessment of Chronic Illness Therapy - Fatigue</td>
<td>FACT-F</td>
<td>Compared to a year ago; None Specified; Over the past 4 weeks</td>
</tr>
<tr>
<td>EQ-SD and EQ Visual Analog Scale</td>
<td>EQ-SD-SL</td>
<td>Past 7 days</td>
</tr>
<tr>
<td>Psoriatic Arthritis Quality of Life</td>
<td>PsAQOL</td>
<td>Today</td>
</tr>
<tr>
<td>Psoriatic Arthritis Impact of Disease</td>
<td>PsAID</td>
<td>None specified</td>
</tr>
<tr>
<td>Dermatology Life Quality Index</td>
<td>DLQI</td>
<td>During the last week</td>
</tr>
<tr>
<td>Psoriasis Symptom Inventory</td>
<td>PSI</td>
<td>Over the past 4 weeks</td>
</tr>
<tr>
<td>Work Productivity and Activity Impairment: General Health</td>
<td>WAPI-GH</td>
<td>Last 7 days</td>
</tr>
<tr>
<td>Work Productivity Survey - PsA</td>
<td>WPQ-PsA</td>
<td>During the past 7 days</td>
</tr>
<tr>
<td>Beck Depression Inventory</td>
<td>BD-II</td>
<td>Last month</td>
</tr>
</tbody>
</table>

Conclusion: Currently utilized PROs in PsA evaluating domains of fatigue, function, pain, and disease specific manifestations were all important regarding new therapeutic agents. However, some are more relevant than others to patients, most notably FACT-F and PsAID, the latter being an important example of a patient-led and disease-specific development effort. Allowing reporting of items of concern without restrictive time periods is important to patients. These preferences and comments can be utilized to better understand the value of PROs in clinical settings to optimize patient-therapistcommunications.

REFERENCES:


Disclosure of Interests: Philip J Mease Speakers bureau: AbbVie, Eli Lilly, Genentech, Janssen, Pfizer, Amgen, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, Boehringer Ingelheim, Pfizer, Amgen, Galapagos, Genentech, Janssen, Sun Pharma, BMS, Celgene, Novartis, UCB, GSK, Grant/research support from: AbbVie, Eli Lilly, Genentech, Janssen, Pfizer, Amgen, Galapagos, Novartis, Sun Pharma, BMS, Vibeke Strand Consultant of: Abbvie, Amgen Corporation, Arena, Aria, AstraZeneca, Bayer, Bioventus, BMS, Boehringer Ingelheim, Celtrion, Chemocentryx, Elia, EMD Serono, Endo, Equilium, Flexion, Galapagos, Genentech / Roche, Gilead, GSK, Horizon, Ichnos, Immnedex, Janssen, Kiniksa, Kyphia, Lily, Merck, MilMedx, Novartis, Pfizer, Regeneron, Rheos, R-Pharma, Samsung, Sandoz, Sanofi, Sciphir, Servier, Setpoint, Sorrento, Spherix, Sun Pharma, Swing, UCB, Daniel Furst Speakers bureau: Corbus, GSK, Sanofi, Consultant of: Actelion, Amgen, BMS, Corbus, Galapagos, Sanofi, Novartis, Pfizer, Grant/research support from: Actelion, Amgen, BMS, Galapagos, Sanofi, Roche/Genentech, Novartis, Pfizer, Evan Siegel Speakers bureau: AbbVie, Janssen, Eli Lilly, Novartis, UCB, Consultant of: BMS, AbbVie, Janssen, Eli Lilly, Novartis, UCB, Melissa McIlraith Employee of: Past Employee of Abbott and Celgene. M Elaine Husni Consultant of: AbbVie, Amgen, Janssen, Novartis, Eli Lilly, UCB, Regeneron, M. Cameron Hay Grant/ research support from: Novartis

Background: Carpal tunnel syndrome (CTS) and hand osteoarthritis (HOA) are common diseases that can coexist in the same patient. Only one recent study showed that CTS was associated with a significant decrease in strength and performance of the OA-affected hand [1]. This observation suggested that CTS-induced neuropathic disorders may have effects on the surrounding joints symptomatically supporting the role of nerve-joint axis in OA pain.

Objectives: Our work aimed to study the impact of CTS on the symptoms and structural severity of HOA in the DIGICOD (DIGital Cohort Design) cohort.

Methods: DIGICOD is a single-center prospective hospital cohort which includes 426 patients over 35 years of age with symptomatic HOA [2]. Patients in our study were those in the DIGICOD cohort at inclusion for whom the dominant hand and lateral aspect of CTS involvement were known. The analysis was based on the study of the dominant hand. We compared the demographic, clinical and radiographic characteristics (notably by the sum of the Kellgren Lawrence (KL) score) between patients with CTS and those without CTS. In case of comparison test, Chi-square or Fisher exact test were performed. Then, we investigated whether CTS was associated with grip strength, pinch strength and KL score by linear regression model and with numbers of joints painful pressure with negative-binomial model, after adjustment for age and sex.

Results: 417 patients including 39 with CTS were included in our study. Obesity and metabolic syndrome were more frequent in patients with CTS than in those without CTS (obesity: 29.7% vs 10.2%, p<0.01; metabolic syndrome: 51.4% vs 35.1%, p<0.05). The same was true for dysthyroidism (38.5% vs 18.5%, p<0.01) and thyroid hormone replacement therapy (30.8% vs 15.4%, p<0.05). At the level of the dominant hand, clinical signs of HOA (painful, swollen, or nodal joints), sum of Kellgren Lawrence (KL) score, number of joints with a KL score ≥ 2, and the presence of erosive HOA (defined by the presence of at least 1 erosive joint defined as phase “E” or “R” in the Verbruggen scoring) were comparable between HOA patients with and without CTS. After adjustment for age and sex, the presence of CTS in the dominant hand was not statistically associated with grip strength disturbances (measured with the Jamar dynamometer), pinch strength (thumb index, finger pinch), number of joints painful pressure, and KL score.

Conclusion: The risk factors for CTS in HOA are those known in the general population. Hypothyroidism, obesity and metabolic syndrome. However, our study did not find any impact of CTS on the clinical signs and structural severity of HOA.

REFERENCES:

Acknowledgements: All the patients who have accepted to participate to the DIGICOD cohort. All the investigators who manage or have managed patients recruitment, and are involved in the monitoring of the clinical visits (Dr. Camille Deprouw, Dr. Sandrine Desouches, Dr. Ariane Do, Dr. Emeline Gaigneur, Dr. Camille Glanowski, Dr. Karine Louati, Dr. Stéphanie Malbos, Dr. Sabine Tremu, Dr. Houda Ajlani, Dr. Juliette-Louise Petit and Dr. Clémence Gorlier all from the Rheumatology Department of AP-HP Saint-Antoine Hospital), the staff members of the URCEST and of the Centre des Ressources Biologiques from AP-HP Saint-Antoine Hospital. Funding: to the DIGICOD: TRS Chemenica unrestricted research grant

Disclosure of Interests: None declared.


AB0967 FACTORS INFLUENCING THE RESULT OF LOCAL INJECTION THERAPY WITH HYALURONIC ACID PREPARATIONS IN OSTEOARTHRITIS OF THE KNEE JOINT

V. Biakie1, S. Makarov2, E. Biakie2, V. Nesterenko1, M. Nurmukhametov1, M. Makarov1, I.V. Nasonova Research Institute of Rheumatology, Rheumorthopaedics and Rehabilitation, Moscow, Russian Federation

Background: Local injection therapy (LIT) with hyaluronic acid (HA) preparations is one of the methods of conservative treatment of the knee joint osteoarthritis (KO). However, the factors affecting the effectiveness of such treatment require clarification.

Objectives: to study the influence of age, body mass index (BMI), stage of KOA, the presence of deformity of the knee joint and enthesitis on the results of LIT with HA preparations in KOA.

Methods: From September 2017 to June 2019, intra-articular injections of HA were performed in 160 patients with primary and posttraumatic KOA stage I-II. For the analysis, the patients were divided into groups depending on the factor studied: by age into young - 36 (22.5%), middle age - 51 (31.3%), elderly - 61 (37.8%) and old age - 12 (7.5%); by BMI: on patients with normal values - 32 (20%), obesity - 56 (35%), I - 43 (26.9%), II - 16 (10%) and III - 13 (8.1%) degrees of obesity; by stages of KOA: I - 37 (23.1%), II - 91 (56.8%), III - 32 (20.1%); by the presence of deformity: varus deformity <10° - 83 (51.8%), >10° - 23 (14.4%), valgus deformity >22 (13.8%), no deformity - 32 (20%); and also depending on the presence (44 (27.5%)) or absence (116 (72.5%)) of enthesitis. To assess the results, the pain intensity was determined using a visual analogue scale and the knee injury and osteoarthritis outcome score before treatment, 1, 3, and 6 months after the course of LIT.

Results: 1 month after the course of LIT, the best results were obtained in young patients (p=0.001), as well as stage 1 of KOA (p=0.0001) and normal BMI values.
Methods: The patients with knee disorders scheduled to undergo knee arthroplasty at our hospital between July 2020 and May 2021 were included. They were assessed for baseline attributes, clinical assessment including Knee Society Score (KSS), degree of pain on walking by visual analogue scale (VAS), range of motion (ROM), and also leg skeletal muscle mass index (SMI; whole-body mode DXA), quadriceps strength by dynamometer with written consent (UMIN ID: 000040940). And Japanese Cardiovascular Health Study criteria for frailty, and sarcopenia by Asian Working Group for Sarcopenia 2019 criteria were evaluated.

Results: Demographic data of 83 patients (65 women, mean age 74.9 years) included in this study was shown in Table 1. The distribution in frailty is 38.2% and that in sarcopenia is 7.3%. Most of the patients with pain without knee disorder did not suffer from sarcopenia. A multivariate analysis was conducted with walking speed as the objective variable and the dependent variables as age, gender, pain VAS on walking, KSS, leg SMI, quadriceps strength, and ROM. The results showed that age and ROM in flexion were significantly and independently associated with walking speed (P<0.01, 0.03). Gender, pain VAS on walking, KSS, leg SMI, quadriceps strength, and ROM in extension were not significantly associated with walking speed (P=0.92, 0.11, 0.11, 0.52, 0.85, 0.52).

Conclusion: Among the patients with knee disorders immediately before arthroplasty, frailty was not caused by sarcopenia. Age was found to be the most correlated factor with walking speed, and walking speed became slower with age. In addition, poor flexion angle was also the factor for delayed walking speed, but it did not correlate with lower limb skeletal muscle mass or quadriceps strength. In this study pain on walking was not significant factor for walking speed, because it was observed in most of all cases.

Disclosure of Interests: None declared

Patients were divided into 2 groups according to BMI: BMI<24.9 kg/m², n=22 (no obesity); BMI≥30kg/m², with signs of grade 1-2 obesity, n=50.

Results: OA patients with obesity had higher WOMAC and Lequesne index values than OA patients with normal weight (5.8±1.2 cm and 13.8±1.1 points, respectively, p<0.05). WOMAC parameters in overweight patients were significantly higher than in non-obese patients (31.2±5.9 vs. 9.7±2.7, respectively, p<0.05 for the above parameters). There was a direct correlation (p<0.05) between the severity of OA and increased BMI. Radiological changes of the joints in patients without obesity were stage I (60.6%) in 14 (60.6%), stage II in 7 (34.8%) and stage III in 1 (4.5%) patient. Grade I obesity was noted in 8 (16.0%), Grade II in 22 (44.0%), Grade III in 18 (36.0%), Grade IV in 2 (4.0%) patients. Inadequate joint function (NFS) grade I was in 16 (72.7%), II in 4 (18.2%), III in 2 (19.1%) patients with normal body weight, with NFS grade II (26-52%) and III (18-36%) predominating with obesity, grade I in 6 (12.0%). Synovitis was diagnosed in 37 (74.0%) with elevated BMI, significantly higher than in non-obese patients in 7 (31.8%). On the course, rapid progressive OA was seen more frequently in 11 obese patients (22.0%) than in non-obese patients (4.5%); there was a direct correlation between the VAS pain index, Lequesne index and WOMAC index (r=0.5, p<0.05; r=0.4, p<0.05 respectively).

Conclusion: Overweight in patients with OA was associated with greater joint destruction and functional impairment of OA joints, progressive course and pain syndrome, including secondary synovitis.

Disclosure of Interests: None declared


AB0973 LONG TERM EFFICACY OF INTRA-ARTICULAR VISCOSUPPLEMENTATION WITH HYALURONIC ACID IN HIP OSTEOPOROSIS SECONDARY TO SYSTEMIC RHEUMATIC DISEASES: A PRELIMINARY EVALUATION

F. Cumbo1,2, O. De Lucia1, A. Murgo1, C. Artusi1, R. Caporali1,2
1Università degli studi di Milano, Dipartimento di Scienze Cliniche e di Comunità, Milano, Italy; 2Asst Pini-CTO, UOC Reumatologia Clinica, Milano, Italy

Background: Few studies have assessed response to intra-articular HA viscosupplementation in patients affected by hip osteoporosis secondary to systemic rheumatic diseases (SOA). From in vitro studies we know that the synovial environment in these diseases presents different molecular characteristics in comparison to primary osteoporosis (POA) in terms of pro-inflammatory activity and therefore in degradation of hyaluronic acid.

Objectives: To evaluate differences in efficacy and safety of treatment with US-guided intra-articular HA viscosupplementation within a cohort affected by POA and one affected by SOA, with regard to pain assessment and time to arthroplasty.

Methods: We conducted this observational retrospective study on consecutive patients treated with US-guided hip intra-articular injections with Hylan G-F 20 2 ml at the Rheumatology Unit of ASST-Pini-CTO, Milano (Italy) from 2013 to 2021. Joints with active synovitis detected by US examination weren't treated. VAS pain at baseline and at the end of October 2021 was registered as well as time to the event of hip arthroplasty and adverse reactions. Patients treated had hip pain at least 6 months before treatment and radiological OA assessed by standard hip X-rays no more than 6 months before baseline. Patients included in the SOA group had a diagnosis of rheumatic systemic disease, POA patients had osteoporosis and any further rheumatological condition was ruled out. Additional clinical features recorded for the SOA patients were clinimetric assessment of disease activity according to SDAI for RA, clinical judgment for PMR, DAPSA for PsA, ASDAS for SpA and medical treatment at baseline.

Results: We included 55 primary OA patients and 16 systemic rheumatic diseases patients (5 JIA, 1 periperal SpA, 2 PMR, 1 Axial-Spa, 1 PsA, 2 RA) who had received hip intra-articular HA injection with Hylan G-F 20 ml once a month for three consecutive months and then every six month. Mean duration of follow up was 51.1 (±27.1) months. We observed significant longer treatment survival and lower VAS pain in POA patients at follow up (in absence of significant difference of VAS pain at baseline). In both cohorts we observed a reduction in VAS pain similar to that reported in literature: in the POA a mean reduction of 29.7 (95% CI 23.8-35.6), while in the SOA was noticed a mean reduction of 12.8 (95% CI 18.2-23.7) in absence of significant clinimetric variations over time. We observed higher incidence of local adverse reactions in SOA group (2 cases of post-injection synovitis in the SOA cohort only (12.5%), p 0.001).

Conclusion: According to our results symptomatic hip SOA patients respond less and with a slightly higher degree of adverse reactions to intra-articular visscosupplementation when compared to POA patients, even if the incidence of these adverse events was similar to that observed in previous studies. We can infer that synovial pro-inflammatory environment in rheumatic systemic diseases can reduce efficacy of intra-articular viscosupplementation with hyaluronic acid.

REFERENCES:

Disclosure of Interests: None declared


AB0974 ASSOCIATION BETWEEN DIABETES MELLITUS AS PART OF METABOLIC SYNDROME AND OSTEOPOROSIS (PRELIMINARY DATA)

L. Alekseeva1,2, E. Taskina1, N. Kashevarova1, D. Kusevich1, K. Telyshev2, E. Strekova1, E. Sharapova1, D. Kudinsky1, O. Alekseeva1, N. Demin1, O. Tenkova3, E. Kharlamova3, A. Abolyoshina5, 1V.A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education, Rheumatology, Moscow, Russian Federation; 3VA. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation; 4VA. Nasonova Research Institute of Rheumatology, Department of Osteoporosis, Moscow, Russian Federation; 5VA. Nasonova Research Institute of Rheumatology, Diagnostic Department, Moscow, Russian Federation

Background: There are more evidence that diabetes mellitus (DM) aggravates the course of osteoarthritis (OA).

Objectives: At multicenter study to evaluate impact of DM as part of metabolic syndrome on course of knee OA.

Methods: The enrolled patients had knee OA based on ACR criteria with x-ray confirmation with stage I-II (Kellgren and Lawrence (K&L). Mean disease duration was 5 (2-10) years. Patients were evaluated by report form, using the anthropometric parameters, questionnaires, disease history and comorbidity, clinical examination data, assessment of knee joints pain, standard X-ray, ultrasound signs of OA, DXA three sites the L1-L4 lumbar spine, femoral neck, and total hip. All participants were signed an informed consent form.

Results: At prospective study were enrolled 253 women with mean age 58.3 ± 9.5 years (40-75) years, with knee OA. Compensated DM type 2 was diagnosed in 26 (10.3%) patients with knee OA. All patients with knee OA were divided into two groups:1st group was with DM and 2nd group without DM (Table 1). Patients with DM were older, had higher weight and BMI. In patients with DM was harder course of OA based on clinical and instrumental data: higher pain by WOMAC score; at X-ray were more frequent confirmed III stage (K&L) (OR=3.1, 95%CI 1.1-8.7, р=0.01). At X-ray investigation narrow of medial joint space and at ultrasound thickness of the cartilage were also more expressed in 1st group. More often comorbidity at 1st group was DM and DM was harder course of OA based on clinical and instrumental data: higher pain by WOMAC score; at X-ray were more frequent confirmed III stage (K&L) (OR=3.1, 95%CI 1.1-8.7, р=0.01). At X-ray investigation narrow of medial joint space and at ultrasound thickness of the cartilage were also more expressed in 1st group.

Conclusion: DM was harder course of OA based on clinical and instrumental data: higher pain by WOMAC score; at X-ray were more frequent confirmed III stage (K&L) (OR=3.1, 95%CI 1.1-8.7, р=0.01). At X-ray investigation narrow of medial joint space and at ultrasound thickness of the cartilage were also more expressed in 1st group.
Table 1. Comparative characteristics of patients with OA with or without DM.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>1 group (n=26)</th>
<th>2 group (n=227)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, Me</td>
<td>65.6 (60-68)</td>
<td>59 (52-65)</td>
<td>0.002</td>
</tr>
<tr>
<td>BMI, g/m², Me</td>
<td>33.5 (29.4-35.8)</td>
<td>28.7 (25.6-32.3)</td>
<td>0.0006</td>
</tr>
<tr>
<td>OA duration, years, Me</td>
<td>11 (7-18)</td>
<td>4 (2-10)</td>
<td>0.0032</td>
</tr>
<tr>
<td>Generalized OA, %</td>
<td>50</td>
<td>24.5</td>
<td>0.009</td>
</tr>
<tr>
<td>WOMAC pain, mm, Me</td>
<td>199 (158-230)</td>
<td>120 (45-190)</td>
<td>0.005</td>
</tr>
<tr>
<td>X-ray stage (K&amp;L), %</td>
<td>8.7</td>
<td>32.5</td>
<td>0.04</td>
</tr>
<tr>
<td>I</td>
<td>65.2</td>
<td>57.3</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>26.1</td>
<td>10.2</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medial knee joint space, mm</td>
<td>2 (0.6-3.1)</td>
<td>3.4 (2.2-4.5)</td>
<td>0.03</td>
</tr>
<tr>
<td>Cartilage thickness in posterior-lateralis</td>
<td>1.5 (1.4-1.7)</td>
<td>1.7 (1.6-1.9)</td>
<td>0.05</td>
</tr>
<tr>
<td>area of knee joint, mm, Me</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose, mmol/L, Me</td>
<td>6.6 (5.1-6.9)</td>
<td>5.3 (4.9-5.7)</td>
<td>0.003</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>84.6</td>
<td>60.8</td>
<td>0.01</td>
</tr>
<tr>
<td>Metabolic syndrome, %</td>
<td>92.3</td>
<td>54.2</td>
<td>0.0002</td>
</tr>
<tr>
<td>Medial knee joint space, mm, Me</td>
<td>2 (0.6-3.1)</td>
<td>3.4 (2.2-4.5)</td>
<td>0.03</td>
</tr>
<tr>
<td>Cartilage thickness in posterior-lateralis</td>
<td>1.5 (1.4-1.7)</td>
<td>1.7 (1.6-1.9)</td>
<td>0.05</td>
</tr>
<tr>
<td>area of knee joint, mm, Me</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMD total hip, g/cm², Me</td>
<td>0.966 (0.955-1.054)</td>
<td>0.878 (0.801-0.944)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

In the Spearman correlation analysis are confirmed positive associations between DM and the difficult and prolonged course of OA. We found out that higher WOMAC pain subscale (r=0.18), total hip BMD at DXA (r=0.25), smaller size of medial joint space (r=-0.24) and thickness of the cartilage at ultrasound (r=-0.13) are associated with DM (p<0.05 for all parameters). Positive relationships also are indicated with BMI (r=0.21), hypertension (r=0.15), MS (r=0.24), (r=-0.13) are associated with DM (р<0.05 for all parameters). Positive relation-

REFERENCES:
[1] Tubach F, Ravaud P, Beaton D et al. Minimal clinically important improve-
ment and patient acceptable symptom state for subjective outcome meas-
[2] Zacharia B, Paul M, Thavaruddin Sherule M. Patient-based outcome analy-

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1795

AB0976 DETERMINATION AND CHARACTERIZATION OF PATIENT SUBGROUPS WITH DIFFERENT PAIN PROGRESSION IN HAND OSTEOARTHRITIS

C. Van der Meulen1, L. Van de Stadt1, F. Rosendaal2, J. Runhaar3, M. Kloppenburg1,3 Leiden University Medical Center (LUMC), Rheumatology, Leiden, Netherlands; 2Leiden University Medical Center (LUMC), Clinical Epidemiology, Leiden, Netherlands; 3Erasmus MC, Department of General Practice, Rotterdam, Netherlands

Background: Hand pain is common in hand osteoarthritis (OA). Previous cohort studies reported stable average pain levels on the short to midterm. Subgroups with different pain trajectories have been found in knee OA. Similar subgroups of hand OA patients may exist. Knowledge of such subgroups in hand OA patients may help inform decisions for pain treatment.

Objectives: To determine and characterize subgroups with different hand pain trajectories over four years in hand OA patients.

Methods: Data from the ongoing HOSTAS (Hand OSTeoArthritis in Second-

ary care) cohort were used, collected from consecutive patients at the LUMC Rheumatology outpatient clinic with primary hand OA followed for four years. Hand pain measurements were collected annually starting at baseline with the AUSCAN pain questionnaire (range 0-20). Development of pain over time was modelled using latent class growth analysis (LCGA), dividing the cohort into subgroups based on differences in pain development. The optimal model was selected based on the AIC, BIC, entropy and likelihood ratio test for models with n vs n-1 classes. LCGA requires ≥2 measurements per case, so patients with less were excluded. Associations of LCGA classes with baseline demo-
graphics and factors associated with hand pain were analyzed using multino-
minal logistic regression.

Results: Of 538 participants, 484 completed the AUSCAN at ≥2 timepoints. Data of excluded patients were missing at random. Included and excluded patients were comparable. Of included participants 86% were women, mean (SD) age was 60.8 (8.5), 29% had erosive disease, median (IQR) symptom

Figure 1. LCGA trajectories. Trajectories of AUSCAN pain identified by latent class growth analysis. Least pain to most pain, named class 1 (pink), class 2 (red), class 3 (brown), class 4 (blue) and class 5 (green).
duration was 5.2 (1.9-12.2), 91.0% fulfilled the ACR criteria for hand OA. Mean AUSCAN pain score was 9.3 (4.3). LCGA yielded five classes (Figure 1). Classes were characterized by different pain levels at baseline; mean level of pain remained stable over time. Classes with more pain were associated with more erosive disease, higher tender joint count, longer symptom duration, more comorbidities, worse AUSCAN function scores and worse SF-36 and HADS scores (Table 1).

Table 1. Multinomial logistic regression for associations with 5 LCGA classes

<table>
<thead>
<tr>
<th>OR (95% CI)</th>
<th>Baseline (N=37)</th>
<th>Erosive disease (N=104)</th>
<th>Symptom duration, years; (N=171)</th>
<th>KL sum score (N=131)</th>
<th>Tender joint count (N=41)</th>
<th>AUSCAN function (N=131)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>(0.45-3.18)</td>
<td>(0.55-4.03)</td>
<td>(0.41-3.70)</td>
<td>(0.30-4.87)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.04</td>
<td>(0.97-1.13)</td>
<td>(1.01-1.18)</td>
<td>(1.04-1.22)</td>
<td>(1.03-1.23)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.01</td>
<td>(0.98-1.05)</td>
<td>(0.98-1.05)</td>
<td>(0.99-1.06)</td>
<td>(0.95-1.08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.08</td>
<td>(0.98-1.39)</td>
<td>(1.00-1.44)</td>
<td>(1.07-1.54)</td>
<td>(1.06-1.57)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.01</td>
<td>(0.90-1.08)</td>
<td>(0.99-1.18)</td>
<td>(1.06-1.30)</td>
<td>(1.13-1.51)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Multinomial logistic regression of variables associated with LCGA classes adjusted for baseline AUSCAN pain, age, sex and BMI. Class 1 = least pain, class 5 = most pain. SF-36 = Short Form-36. MICS = Mental component scale. PCS = Physical component scale. HADS = Hospital anxiety and depression scale. SF-36 scores are standardized on age, sex and nationality with mean 50 and SD 10.

Conclusion: Latent class growth analysis showed five subgroups with different pain trajectories in hand OA patients, with differing baseline pain and stable pain over time. These subgroups were associated with disease characteristics, number of comorbidities, psychological distress and health-related quality of life. This knowledge can help develop treatment for hand OA patients and inform them about the disease course.

Disclosure of Interests: None declared


AB00977 THE RELATIONSHIP OF OVERWEIGHT AND CONCOMITANT METABOLIC DISORDERS WITH THE FEATURES OF THE COURSE OF PRIMARY OSTEOARTHRITIS OF THE KNEE JOINTS

I. Bashkova1,2, I. Madyanov1,3, K. Misko1. 1Chuvash State University named after I.N. Ulyanov, Department of Hospital Therapy, Cheboksary, Russian Federation; 2Federal Center of Traumatology, Orthopedics and Endoprosthetics, Consultative Polyclinic, Cheboksary, Russian Federation; 3Republican Clinical Hospital, Department of Endocrinology, Cheboksary, Russian Federation

Background: There are two theories of the relationship between osteoarthritides (OA) and obesity: biomechanical and metabolic.

Objectives: To study the prevalence of overweight and obesity and concomitant metabolic disorders in patients with OA and to assess their impact on the features of the course of primary OA of the knee joints.

Methods: Patients with primary OA with a lesion of the knee joints (n=90, including 22 men) were examined. The age of the patients was 29-69 years, the duration of the disease is 15-20 years. The control group (n=114, including 26 men) was formed by random sampling of the population from practically healthy people, it is representative by gender and age. Anthropometric examination, determination of lipid metabolism parameters, levels of dehydroepiandrosterone sulfate (DHEA-S) and cortisol in the blood, X-ray and arthrosonographic examination of joints were performed. The functional state of the knee joints was analyzed by the Lequesne gonarthrosis severity index and the WOMAC algofunctional index.

Results: Average Body Mass Index (BMI) in patients, OA was 28.6±5.8 kg/m² and was slightly higher than in the control group (27.6±4.5 kg/m², p<0.05). Overweight and obesity were detected, respectively, in 40.7% and 33.0% of patients with OA, and in 43.0% and 29.8% of the control group. An increase in BMI in patients with OA, despite the absence of a significant difference in age and duration of the disease, is accompanied by an increase in the total values of the WOMAC index (p=0.042) and Lequesne (p=0.038). According to arthrosonography, the increase in BMI is directly related to an increase in the size of osteophytes (r=0.403, p=0.003) and inversely correlates with the width of the articular gap of the medial knee joints (r=-0.37, p=0.014). Knee synovitis was detected in 5 patients out of 24 people (20.8%) with normal body weight, in 11 patients out of 37 people (29.7%) who were overweight, and in 13 patients out of 30 people (43.3%) who are obese varying severity (p<0.05). Synovitis of the knee joints in most cases was detected in patients with OA with an abdominal type of fat distribution. The negative influence of the abdominal type of fat distribution on the course of knee joint OA was revealed: positive correlations between waist circumference and the total Lequesne index (r=0.443, p=0.027), and the radiological stage of OA (r=0.467, p=0.019). In patients with OA with abdominal type of fat distribution, the severity of joint pain during exercise exercise was 33.3% higher than in patients with gluteofemoral type (p=0.001), the total Lequesne and WOMAC indices were 27.2% (p=0.028) and 20.1% (p=0.041), respectively. In patients with OA, a significant increase in the blood content of cholesterol (HC) of low-density lipoproteins (LDL) was found (p=0.039) and a decrease in high-density lipoprotein (HDL) cholesterol (p=0.046). Disorders of lipid metabolism of atherogenic orientation were more pronounced in patients with III-IV radiological stages of gonarthrosis. In patients with OA who are overweight or obese, the serum DHEA-C content was lower than in patients with OA with normal body weight (2.31±0.98 mg/cm² vs 2.63±1.68 mg/cm², p<0.05). As the radiological changes in the joints progress, there is a clear decrease in the concentration of DHEA-C. In women with OA, a significant relationship was found between waist circumference and the concentration of DHEA-C in the blood (r=-0.321, p=0.045). There was an increase in the concentration of cortisol in the blood of patients with OA. The inverse correlation relationship between the number of swollen joints with the blood content of DHEA-C (r=-0.269, p=0.012) and cortisol (r=-0.232, p=0.028) was revealed.

Conclusion: The mechanisms of the negative effect of overweight and obesity on the course of OA are lipid disorders (high concentrations of LDL cholesterol, low HDL cholesterol), hormonal changes (low DHEA-C, elevated cortisol levels) and the production of proinflammatory cytokines by adipose tissue.

Disclosure of Interests: None declared


AB00978 EFFECT OF ATORVASTATIN ON SKELETAL MUSCLES OF PATIENTS WITH KNEE OSTEOARTHRITIS: POST-HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL

Y. Lim1, F. Cicuttini1, A. Wluka1, G. Jones1, C. Hill1,2, A. Forbes1, A. Tonkin1, S. Berezhkovskaya1, L. Tan1, C. Ding2, Y. Wang1, 1Monash University, School of Public Health and Preventive Medicine, Melbourne, Australia; 2University of Tasmania, Menzies Institute for Medical Research, Hobart, Australia; 3University of Adelaide, The Queen Elizabeth Hospital, South Australia, Australia; 4University of Adelaide, Adelaide, Department of Medicine, South Australia, Australia; 5The Alfred, Alfred Hospital, Melbourne, Australia; 6Southern Medical University, Clinical Research Centre, Zhuhai Hospital, Guangdong, China

Background: Statins are often discontinued due to muscle-related side effects. The effect of statin on skeletal muscles in populations with osteoarthritis is unknown.

Objectives: This study aims to examine the effect of atorvastatin on skeletal muscle biochemistry, strength, size and symptoms in patients with symptomatic knee osteoarthritis.

Methods: This is a post-hoc analysis of a multicentre randomised, double-blind, placebo-controlled trial over 2 years in which participants with knee osteoarthritis who met the American College of Rheumatology clinical criteria received atorvastatin (n=151) or placebo (n=153). Outcomes included muscle biochemistry, strength, size and symptoms in patients with symptomatic knee osteoarthritis.

Results: 304 participants [mean age 55.7 (SD 7.8) years, 55.6% female] were randomised. There were no significant differences in CK and AST levels between atorvastatin and placebo groups at 4 weeks (CK median 107 vs 110, p=0.76; AST 22 vs 21, p=0.014), 6 (CK 109 vs 105, p=0.37; AST 21 vs 20, p=0.45), 12 (CK 103 vs 103, p=0.93; AST 22 vs 21, p=0.99), and 24 (CK 103 vs 93.5, p=0.17; AST 22 vs 21, p=0.34) months. The atorvastatin group had higher ALT levels than the placebo group at 4 weeks [26 vs 21, p=0.004] and 6 months [25 vs 22, p=0.007] but no between-group differences at 12 [24 vs 21, p=0.08] and 24 [24 vs 21, p=0.05] months. Muscle strength significantly increased in the atorvastatin group but not the placebo group over 24 months with no between-group differences [mean 8.5% (95% CI 2.6,14.4) vs 5.6 (0.3,11.5), p=0.50]. Change in vastus medialis CSA over 24 months showed between-group differences favouring the atorvastatin group (+0.12 [-0.09,0.34] vs
AB0080

HAN D OSTE OARTHRITIS: INVESTIGATING PAIN EFFECTS IN A RANDOMISED PLACEBO-CONTROLLED FEASIBILITY STUDY OF ESTROGEN-CONTAINING THERAPY (HOPE- E): REPORT ON THE PRIMARY FEASIBILITY OUTCOMES

J.A. E. Williams1,2, M. Chester-Jones1, A. Francis1, I. Marian1, M. Goff3,4, G. Brewer5, M. Gulati5, L. Eldridge5, P. Julius6, C. Minns7,8, V. Barber9, G. Glor6, Y. Y. Young10, T. Vincent11, S. E. Lamb12, K. Vincent12, J. Dutton5, F. E. Wat6,11,12,13.

1University of Oxford, Oxford Clinical Trials Research Unit (OCTRU), Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom;
2University of Oxford, Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom;
3King’s College London Guy’s Campus, Clinical Trials Unit, London, United Kingdom;
4Oxford University Hospitals NHS Foundation Trust, Physiotherapy Research Department, Oxford, United Kingdom;
5White Horse Medical Practice, Faringdon Medical Centre, Faringdon, United Kingdom;
6Imperial College Healthcare NHS Trust, Rheumatology Department, Charing Cross Hospital, London, United Kingdom;
7University of Oxford, Centre for Rehabilitation Research, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom;
8Graduate School of Exeter, College of Medicine and Health, University of Exeter, Exeter, United Kingdom;
9University of Oxford, Nuffield Department of Women’s and Reproductive Health, Oxford, United Kingdom;
10Imperial College London, Department of Immunology and Inflammation, London, United Kingdom;
11University of Oxford, Centre for Osteoarthritis Pathogenesis Versus Arthritis, Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom;
12Imperial College London, Department of Immunology and Inflammation, London, United Kingdom;
13Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Oxford, United Kingdom;
14Astellas Pharma, Cambridge, UK.

Background: There is an unmet need for new treatments for hand osteoarthritis (OA). Symptomatic hand OA is more common in women and its incidence increases around the age of menopause. Pre-clinical, epidemiological and post hoc studies in Hormone Replacement Therapy (HRT) trials implicate estrogen deficiency as of likely importance in OA aetiology. No clinical trials of HRT have been carried out in hand OA to date. The licensed HRT Duavive (conjugated estrogens + SERM bazedoxifene) was selected on its potential for efficacy and tolerability.

Objectives: We set out to determine the feasibility and acceptability of this form of HRT in post-menopausal women with hand OA, to generate proof of concept data and refine methods for a full study.

Methods: ISRCTN21196200. Females aged 40-65 y and 1-10yrs after final menstrual period with hand OA fulfilling ACR criteria and ≥2 painful hand joints were recruited. Eligibility incorporated best practice for HRT prescription but did not require menopausal symptoms. Recruitment was at 3 sites in primary/secondary care, including directly from the community. Design was parallel group, double-blind: 1:1 randomisation of Duavive or placebo, orally once daily for 24 weeks, then weaning for 4 weeks before stopping. Routes and rates of recruitment and the acceptability of randomisation, medication (compliance, retention), and proposed outcomes were measured, and the likelihood of blinding. Measures related to hand pain and function, menopausal symptoms and joint appearance. Patient and Public Involvement actively informed study rationale, design and materials. An end of study questionnaire and 2 participant focus groups provided further acceptability data.

Results: Recruitment was for 18 months. Estimated 15% loss to follow up. However, small adjustments made to study design to reduce drop out. Overall recruitment was possible 18 months, interrupted due to COVID-19. Some study procedures were modified to allow reopening whilst collecting all primary outcomes. 434 enquiries/referrals were received, leading to 96 telephone screen, of which 33 gave written informed consent and attended face to face screening. 28/33 screened (85%) were eligible and randomised. The highest number of randomisations was from study web presence (n=7) followed by SMS text from GP surgeries (n=5). Of 401 not proceeding, 250 (62%) were ineligible, most commonly due to contraindications to enrolment or no interest. A total of 13 AEs were experienced. One death from metastatic ovarian cancer not considered related to treatment. 4 serious AEs were reported. 4 participants withdrew due to treatment group, whilst 5 (14%) decided not to take part, for reasons including not wanting to take a hormone-based drug or difficulty attending study visits. Retention and compliance were excellent. All 28 participants completed all study follow ups, with only 3 withdrawals from treatment due to AEs, 2 of these at week 24 and all in the placebo arm. There were no serious AEs. High levels of completeness of all study outcome measures were achieved. Bang’s blinding index suggested that participants/investigators were well blinded. There were overall high/good levels of satisfaction with taking part in the study. 26/28 (92%) would recommend taking part to others with hand OA (irrespective of study arm). Many found the flexibility

REFERENCES:

Disclosure of Interests: None declared.

AB0979

RECOMMENDATIONS FOR WEIGHT MANAGEMENT IN OSTEOARTHRITIS: A SYSTEMATIC REVIEW OF CLINICAL PRACTICE GUIDELINES

Y Lim1, J. Wong1, S. M. Hussain1, M. Este2, L. Zoloi1, M. Page1, C. Harrison3, A. Wluka1, Y. Wang4, E. Cicuttini5,1, Monash University, School of Public Health and Preventive Medicine, Melbourne, Australia; 2The Alfred, Alfred Hospital, Melbourne, Australia; 3Monash University, Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Melbourne, Australia.

Background: Weight loss interventions are often recommended to target overweight and obesity in the clinical practice guidelines (CPGs) for the management of osteoarthritis. This is despite evidence from meta-analyses of clinical trials that significant weight loss results in modest improvements in symptoms and minimal effects on disease progression1,2. There is evidence that weight gain is associated with increase in knee pain3,4. In countries such as USA, adults gain on average 0.5 to 1 kilogram per year from early to middle adulthood Preventing weight gain is easier to achieve and sustain than losing weight.

Objectives: Given that weight loss is accepted as fundamental to osteoarthritis management, we systematically reviewed the recommendations and approaches for weight management in all current osteoarthritis CPGs.

Methods: Nine databases were searched (1st January 2010 to 30th September 2021) to identify guidelines informing the non-pharmacological management of osteoarthritis. Three reviewers appraised guidelines according to the AGREE II instrument, and independently extracted data on their characteristics. One author extracted and summarised guideline recommendations on weight management. This systematic review is registered on PROSPERO (CRD42021274195).

Results: Fifteen CPGs from developed and developing countries were included. Weight loss was recommended for knee OA by the American College of Rheumatology and Australian and New Zealand College of Physicians (2018) and hip (10 of 11 guidelines) but not hand osteoarthritis (0 of 4 guidelines). Combination approaches of diet and/or exercise were recommended for overweight or obese individuals (knee: 8 of 12; hip: 4 of 10), with 2 guidelines specifying ≥5% weight loss for knee and hip osteoarthritis. One of 15 guidelines specified strategies for weight loss and maintenance of lost weight. Two of 15 guidelines recommended controlling body weight for osteoarthritis, regardless of obesity status.

Conclusion: Most CPGs for knee and hip osteoarthritis include recommendations for weight loss in those with overweight or obesity as key to managing osteoarthritis, despite evidence of modest at best effect of weight loss on symptoms and no effect on joint structure.2. Given obesity is a major risk factors for osteoarthritis, the prevention of weight gain may be more effective and practical in improving clinical outcomes for osteoarthritis, and hence should be considered as part of the key management in osteoarthritis.

REFERENCES:
offered by a combination of remote and face to face visits (due to the pandemic) attractive. Additional insights from focus groups were to include hand stiffness as well as pain measures but to reduce the overall number of questions. 

Conclusion: Despite COVID-19 and a reduced recruitment period, this study recruited sufficient numbers to assess feasibility outcomes. Randomisation of eligible people and retention rates were high. A mixture of remote and face to face visits due to COVID-19 probably improved recruitment and retention and was supported by participants, who were generally satisfied with the study design and medication. The study provided useful insight and improvements that would be incorporated into a future study. Overall, this feasibility study showed that with clear messaging on eligibility and a defined recruitment strategy, recruitment and retention to a study testing this treatment is possible.

Acknowledgements: This research was funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0416-20023). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The study team thank the sites and the participants who made this research possible.

Disclosure of Interests: Jennifer A.E. Williams: None declared, Mae Chester-Jones: None declared, Anne Francis: None declared, Ioana Marian: None declared, Megan Goff: None declared, Gretchen Brewer: None declared, Malvika Gulati: None declared, Lucy Eldridge: None declared, Patrick Juler: None declared, Catherine Minns Lowe: None declared, Vicki Barber: None declared, Victoria Glover: None declared, Charles Mackworth-Young: None declared, Tonya Vincent Consultant of: Pfizer, Grant/research support from: Grant support from Fidia, Biosplice, Novartis, Pfizer as part of their contribution to an international consortium., Sarah E Lamb: None declared, Katy Vincent: None declared, Susan Tennant: None declared, Fiona E Watt Consultant of: Pfizer, Grant/research support from: Pfizer and from Astellas Pharma (>3 years ago).


DYNAMICS OF PAIN ACCORDING TO THE VAS SCALE, FUNCTIONAL ACTIVITY ACCORDING TO THE WOMAC INDEX AND QUALITY OF LIFE ACCORDING TO THE EQ-5D QUESTIONNAIRE IN ELDERLY AND SENILE PATIENTS WITH KNEE JOINT OSTEOARTHRITIS AFTER COVID-19

M. Letaeva1, M. Koroleva1, O. Malysheenko1, J. Averkieva1, T. Raskina1.

1Kemerovo State Medical University, Department of Propaedeutics of Internal Diseases, Kemerovo, Russian Federation

Objectives: To evaluate the dynamics of pain on the VAS scale, functional activity according to the WOMAC index and quality of life according to the EQ-5D questionnaire in elderly and senile patients with knee joint osteoarthritis (OA) after COVID-19.

Methods: A total of 32 elderly and senile male patients with an established diagnosis of knee joint OA (according to the criteria of ACR, 1986) stage I–III according to Kellgren–Lawrence, with pain ≥40 mm on a visual analog scale (VAS), who needed non-steroidal anti-inflammatory drugs (NSAIDs), were included in the study. The median age of the patients included in this study was 72.6 (66.0; 79.3) years. All patients had been ill with COVID-19 for the last 6 months. Pain dynamics was assessed on the VAS scale, functional activity - on the WOMAC index, quality of life - on the EQ-5D questionnaire.

Results: When analyzing the clinical picture, it was found that the majority of patients - 22 people (68.8%) - had moderate COVID-19, 4 people (12.5%) - in mild form, 6 patients (18.7%) - in severe. The average duration of hospitalization was 14.0 (9.0; 17.0) days. The majority of patients were discharged with recovery - 30 people (93.75%), 2 people died (6.25%). The most frequent manifestations of postcovid syndrome in elderly and senile patients with OA: weakness – in 18 (56.2%) patients, arthralgia – in 17 (53.1%) and memory loss – in 14 (43.8%). During the study, there was a slight increase in the pain index on the VAS scale after COVID-19, statistically significant differences in the WOwAMC index and pain on the VAS scale after COVID-19 was registered.

Disclosuure of Interests: None declared


RESULTS OF A PROSPECTIVE 6-YEAR OBSERVATIONAL STUDY OF THE EFFICACY AND SAFETY OF A BIOACTIVE CONCENTRATE OF SMALL MARINE FISH IN SENILE PATIENTS WITH KNEE OSTEOARTHRITIS AND MULTIMORBIDITY

T. Raskina1, J. Averkieva1, M. Letaeva1, O. Malysheenko1, M. Koroleva1.

1Kemerovo State Medical University, Department of Propaedeutics of Internal Diseases, Kemerovo, Russian Federation

Background: According to the updated ESCEO, 2019 guidelines for the management of the knee osteoarthritis (OA), SYSDAODA, which includes bioactive concentrate small sea fish (BCCSF), is a mandatory component of OA therapy. There are few studies evaluating the efficacy and safety of BCCSF in elderly patients with knee OA and a high level of multimorbidity, which served as the basis for this work.

Objectives: To evaluate the efficacy and safety of BCCSF therapy in elderly patients (75–90 years old) with knee osteoarthritis (OA) and multimorbidity based on the results of a prospective 6-year follow-up.

Methods: The study included 38 elderly women with OA of the knee (according to the criteria of ACR, 1986) stage II–III according to Kellgren–Lawrence, with pain ≥40 mm on the visual analog scale (VAS), who needed non-steroidal anti-inflammatory drugs (NSAIDs). BCCSF was administered as 1 ml intramuscular injections 20 consecutive days with a 6-month interval (12 courses). The impact of comorbidity on long-term prognostic was assessed using the Charlson comorbidity index. The effectiveness of therapy was assessed by VAS and WOMAC index. All patients during V0, V4 (36 months), V5 (72 months) underwent radiography of the knee joint. The safety of therapy was monitored throughout the observation period. The duration of the study was 6 years, the number of visits (V) - 6: V0 - day 1 (inclusion in the study and initiation of therapy), V1 - 21st day of therapy, V2, V3, V4, V5 - 12, 24, 36 and 72 months after the start of treatment, respectively.

Results: The 29 (76.3%) patients completed the full course of BCCSF treatment. 9 (23.7%) patients withdrew from the study due to the inability to visit the treatment site (for reasons not related to the study). Elderly patients with OA of the knee showed a
high level of multimorbidity - an average of 5 comorbidities. The prognosis of 10-year mortality according to the Charlson index was 1-2% (26%) in 2 (5.3%) patients, 3-4% (52%) in 26 (68.4%) patients, ≥5 points (85%) - in 10 (28.3%) respectively. There was a significant decrease in pain according to VAS (95%; p<0.001) by v1 - in 76.3%, by v2 - in 71.0%, by v3 - in 68.4%, by v4 - in 63.1% and v5 - in 55.2% of patients. There was a significant decrease in the total WOAC index at all visits compared with baseline: V0: 112.5±13.5 mm, V1: 64.7±22.9 mm, V2 - 64.2±22.4 mm, V3: 594±216.0 mm, V4 - 609±183.0 mm, V5 - 669±141.0 mm (p<0.001 for all cases). The reduction in OA symptoms resulted in a signifi- cant improvement in the scored for NSAIDs. By v1, 31.6% of patients did not need to take NSAIDs, by v2 - 47.4%, by v3 - 44.7%, by v4 - 50.0% and by v5 - 44.7%. After 12 months of therapy, the number of days of taking NSAIDs significantly decreased to 5 (0, 10) days per month versus 14 (7, 15) days per month at the beginning of the study (p = 0.005). This rate remained relatively stable through- out the follow-up. X-ray progression of OA ≥1 stage according to Kellgren-Law- rence during BCSSF therapy after 36 months was recorded in 10.5% of patients, after 72 months - in 50.0%. During the entire period of observation, no serious adverse events were registered, including new cardiovascular accidents and allergic reactions.

Conclusion: The results of a 6-year prospective study demonstrate the high efficacy and safety of BCSSF in elderly patients with knee OA and high multimorbidity.


AB0984

CHANGES IN PLASMA VOLUME WHEN MEASURING BIOCHEMICAL MARKERS OF JOINT TISSUE TURNOVER IN RELATION TO ACUTE PHYSICAL ACTIVITY

J. Bjere-Bastos 1, 2, C. Sejersen 2, H. B. Nielsen 2, N. Secher 2, C. C. Kitchen 3, C. P. Miller 1, A. Mackey 1, A. R. Bihlet 2, 1 Department of biomedical Sciences, Copenhagen, Denmark; 2NBCD A/S, NBCD, Herlev, Denmark; 3Rigshospitalet, Niels Secher Lab, Department of Anaesthesiology, Copenhagen, Denmark; 4Roskilde Hospital, Department of Anaesthesiology, Roskilde, Denmark

Background: Physical activity can induce acute changes in plasma volume (PV) and thereby influence concentration of plasma constituents, such as biochemical markers. 2 However, it remains undocumented to what extent PV changes occur during physical exercise in osteoarthritis (OA) patients.

Objectives: Investigating the direct course and magnitude of PV changes during and after weight-bearing (WB) and non-weight-bearing (NWB) exercise, adrena- line-induced cardiovascular stress and resting in an OA population.

Methods: Data originates from the EFEX-OA-02 study (Reg. no.: NCT04542668), which explored biomarker changes in knee OA patients dur- ing and after running, cycling, adenalin infusion and resting on separate days. Blood samples were obtained before, during, at five time points after and again 24 hours post exercise/infusion. Hemoglobin (Hgb) and derived hema- tocrit (Hct) were measured at all time-points to monitor PV fluctuations. Main inclusion criteria: Cumulative Kellgren-Lawrence (KL) radiographic grade of the left and right knee of ≥ 2, 40-75 years of age, bodyweight 50-100 kg and BMI 18.5-35.0 kg/m². Active interventions consisted of 4x5-minute intervals each progressing from low intensity and peaking at ≥80% of the heart rate reserve (HRR). For the adenalin infusion, 0.06 mg/kg of adrenalin was pre- pared in 50 mL saline and administered intravenously. At rest, blood samples were collected at time points similar to the other study interventions, however the 24-hour follow-up sample was omitted. Hgb was measured on a ABL800 blood gas analyzer and converted to Hct using the formula: Hct (%) = (0.0485 x cHb/mL + 0.0083) x 100. Estimated PV change (% ΔPV) was calculated as: % ΔPV = ([Hct Post - Hct Baseline] / Hct Baseline) x 100, where % ΔPV = % change in PV. By v1, Hct decreased to 50% of baseline. By v2, Hct decreased to 30% of baseline. By v3, Hct decreased to 20% of baseline. By v4, Hct decreased to 10% of baseline. By v5, Hct decreased to 5% of baseline. By v6, Hct decreased to 2.5% of baseline. By v7, Hct decreased to 1% of baseline. By v8, Hct decreased to 0.5% of baseline.

Results: Forty subjects were included. Mean age was 60.4 years (Standard deviation (SD): 8.7), 16 (40%) were male, mean BMI was 27.2 kg/m² (SD: 3.5), and mean score in the nine item pain domain of the Knee Injury and Ostearthri- tis Outcome Score (KOOS) at baseline was 67.5 (SD: 15.2) out of 100 (0 and 100 corresponding to max pain and no pain, respectively). Baseline Hgb was 9.05 mmol/L (SD: 0.68) and Hct was 44.7% (SD: 2.9%). All subjects were able to reach the defined peak cardiovascular intensity or higher during exercise, while reaching on average 70% (SD: 8.7%) of that during the adenalin infusion. Cycling, running and adenalin infusion led to acute reductions in PV compared to rest: Cycling -14.3% (95%CI: -10.0 to -18.7%), running -13.9% (95%CI: -10.9 to -17%), adenalin -7.8% (95%CI: -4.2 to -11.5%). The reductions in PV induced by both cycling and running were greater compared to adenalin (p<0.001). There was no difference in PV changes after cycling vs. running (p=0.99). Thirty minutes after both modes of exercise, PV had returned to baseline. After completion of the adenalin infusion, PV returned to baseline at 30-60 minutes, but was lower than baseline levels at 120 minutes by -3.9% (95%CI: -0.7 to -7.1%), at 240 minutes by -5.3% (95%CI: -2.1 to -8.6%), and at 24-hour by -5.9% (2.0 to -9.9%). During seated rest, PV initially increased (3.1%, 95%CI: 0.75-3.4%) (Figure 1).

Conclusion: Moderate-high intensity running, cycling and cardiovascular stress led to rapid reductions in PV of knee OA patients. Adjustment for PV changes should be considered when measuring biochemical markers in relation to physical activity.

REFERENCES:


AB0985

PREDICTIVE VALUE OF ULTRASOUND IN HAND OSTEOARTHRITIS

S. Abdelalouf 1, S. Lefki 1, Issad Hassanii Beni messous hospital, Rheumatology, Algiers, Algeria

Background: Hand osteoarthritis (HOA) is a complex degenerative pathology with sometimes noisy joint manifestations that can mimic inflammatory rheuma- tosis. The osteocarticular ultrasound, is a valuable addition to the clinical examina- tion, remains little used for diagnosis and monitoring HOA.

Objectives: The objective of our study is to analyze the ultrasound characteristics of arthritic hands OA in order to know the lesions and to better correlate the clinical data with the sonographic results.

Methods: We performed an ultrasound study of 38 patients (76 osteoarthritis hands) suffering from finger osteoarthritis meeting the ACR criteria. SPSS.20 Software was performed to data analysis

Results: There were 38 patients: 84% women and 16% men, mean age was 61.5 years. 47.36% had had a manual profession, 39.47% had associ- ated osteoporosis, 66% had reported the presence of finger nodules in the mother in family history. 60.52% of patients presented with Heberden's nod- ules, 34.21% with Bouchard nodules, 63.15% an adductus inch and 13.15% an inch in “M” deformation. Impairment of Metacarpo-phalangeal (MP), Proximal inter-phalangeal (PIP) and Distal inter-phalangeal (DIP) (PIP, Distal Inter-phalangeal (DIP) and Trapeziometacarpal (TM) were found respectively: clinically in 24%, 58%, 87% and 76% of cases, and in 8%, 37%, 74% and 92% after ultrasound examination. The impairment was more severe from side of the dominant hand in 39.47% of cases clinically vs 52.63% after an ultrasound analysis. Regarding “erosive” HOA, 36.84% of patients presented at least one clinical and / or sonographic criterion suggesting an erosive form. 7.89% of patients had radiology, 13.15% erythema, 34.21% swell- ing and 60.52% paresthesia. According to ultrasound, 28.94% showed an ero- sion / reconstruction aspect. 28.94% of the patients had presented an erosion of the PIP, 47.36% an erosion of the DIP, grade 1 Doppler signal was found in 15.78% with a strong clinical correlation and positive ultrasound signs in 65.78% of cases, no synovitis was reported.
Conclusion: Hand osteoarthritis is a very heterogeneous disease, the added value of ultrasound appears to be of interest in the diagnosis and monitoring patients with this pathology.

REFERENCES:

Disclosure of Interests: None declared


AB0986

RISK OF SARCOPENIA IN THE WOMEN WITH OSTEOARTHRITIS

N. Gruporina1, N. Zaverukha1, A. Musiienko1, M. Bystrytska1, D. F. Chebotarev

Institute of Gerontology, NAMS of Ukraine, Clinical Physiology & Pathology of Locomotor Apparatus, Kyiv, Ukraine

Background: Recently, physicians all over the world have been focusing on the relationship between sarcopenia and osteoarthritis (OA) [1, 2]. This connection is considered from different positions: as coexisting conditions, sarcopenia as a risk factor for the progression of OA, or OA as a risk factor for sarcopenia.

Objectives: The aim of this study was to determine the risk of sarcopenia (according to the SARC-F Questionnaire) and the level of probable sarcopenia in Ukrainian women with (hip and knee) OA.

Methods: The study included 271 women aged 50-84 years old (mean age 65.6 ±8.0 years, mean height 162.2±5.6, mean body weight 76.7±14.2, mean BMI 29.1±5.1). All subjects were divided into 2 groups: the group of healthy women (group I, n=176), a group of patients with hip or knee osteoarthritis (OA) (group II, n=95). The risk of sarcopenia was determined by the SARC-F Questionnaire.

The probable sarcopenia was determined due to muscles strength (handgrip strength using spring hand dynamometer σ 16(kg)) and physical performance (5-time chair stand test > 15 s), the fall risk – by Desмонд Fall Risk Questionnaires and function – according to the assessment of IADL scale.

Results: In 20.3% of females without musculoskeletal pathology and in 34.7% of women with OA was detected high risk of sarcopenia. The probable sarcopenia was practically 2 times higher in patients with OA and was equal to 42.1% compared to 21.5% in healthy women. According to the Desмонд Fall Risk Questionnaire, 27.5% of healthy subjects and 49.3% with OA had increased fall risk. Low function (according to the assessment of the IADL scale) was detected in 36.4% of females without pathology of the musculoskeletal system and in 57.2% of women with OA.

Conclusion: Our results demonstrated that the incidence of probable sarcopenia was 2 times higher in women with hip and knee OA, as well as the risk of sarcopenia – 34.7%, compared to healthy subjects – 20.3%. Also, the risk of falls and the need for outside help were higher in patients with hip and knee OA but their function (by IADL scale) was significantly lower.

REFERENCES:

Disclosure of Interests: None declared


AB0987

KNEE RESERVE: ULTRASONOGRAPHIC FEATURES OF KNEES IN PATIENTS WITH ASYMPTOMATIC KNEE OSTEOARTHRITIS

M. A. Mortada1, Y. A. Amer1, Zagazig University, Rheumatology, Zagazig, Egypt

Background: Symptoms of knee osteoarthritis (KOA) vary according to many factors mainly degree of KOA and degree of inflammatory features. The primary goal of treatment the patients with KOA is to maximize long-term health-related quality of life through control of symptoms. Understanding ultrasonographic characteristics of KOA in asymptomatic patients may help in management of knee osteoarthritis. Zagazig scale is a newly validated and feasible tool for KOA assessment.

Objectives: To understand the ultrasonographic features of the patients with asymptomatic knee osteoarthritis

Methods: Among 245 patients with knee OA diagnosed according to ACR criteria and recruited in a previous ultrasonographic study (1), data of patients with no or mild pain (VAS ≤ 2) was recorded and studied in a separate section. All patients were subjected to clinical assessment WOMAC scale Western Ontario and McMaster Universities Index of Osteoarthritis, global visual analogue scaleVAS, and functional assessment through the use of health assessment questionnaire-II (HAQ-II). Ultrasound assessment was conducted following ZAGAZIG scale comprising five domains: (1) Severity of knee OA grades (0-5) according to severity scale published by Mortada et al. 2016, (2) Effusion: 4 grades (0-3) no, mild moderate and severe effusion respectively, (3) synovitis: 4 grades (0-3) using the combined EULAR/OMERACT score of grey scale synovitis and Doppler activity, (4) Pes Anserine tendinitis/bursitis: 3 grades (0-2) normal, mild inflammation and severe inflammation (5) Baker cyst: 3 grades (0-2), grade 0: normal, grade 1: small and simple cyst and grade 2: large/and complicated cyst. Each grade in all domains takes one point into score with the total score of all domains ranging from 0 to 15.

Results: At cut-off point of >5, total US score distinguishes between knee osteoarthritis patients with no or mild pain 87.2% specificity and 87.2% sensitivity.

Table 1. Demonstrate demographic and ultrasonographic features of patients with KOA and VAS ≤ 2.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>47±11</td>
</tr>
<tr>
<td>Sex</td>
<td>Females 32(71.2%) Males 13(28.8%)</td>
</tr>
<tr>
<td>VAS (mean)</td>
<td>1.4 ±0.3</td>
</tr>
<tr>
<td>WOMAC total score</td>
<td>5(3.6 ± 3.9)</td>
</tr>
</tbody>
</table>

REFERENCE:

Disclosure of Interests: Mohammed A Mortada Speakers bureau: Novartis, Younna A. Amer: None declared


AB0988

FREQUENCY OF OSTEOGENIC SYNDROME AND LOW-ENERGY FRACTURES IN POSTMENOPAUSAL WOMEN WITH OSTEOARTHRITIS OF THE KNEE JOINT

E. Usova1, T. Raskina1, O. Malyshenko1, M. Leteava1, M. Koroleva1, J. Averkova1

1. Federal State Educational Institution of Higher Education ‘Kemerovo State Medical University’ Ministry of Health of the Russian Federation, Department of Internal Medicine Prophylactics, Kemerovo, Russian Federation
Background: The impact of knee osteoarthritis on the risk of low-energy fractures remains an open question in recent times. Some cohort studies show that OA of the knee joint is associated with increased risk of fractures [1-3]. Other studies do not support this finding [4,5].

Objectives: to compare the incidence of osteopenic syndrome and low-energy fractures in postmenopausal women with osteoarthritis (OA) of the knee joint.

Methods: The study includes 98 women, of whom: 51 (median age 63.0 [93.6:39.8] years) are diagnosed with OA of the knee joint according to the ACR criteria (1991) and 47 without OA of the knee joint (median age 65.0 [61.7:75.0] years). The bone mineral density (BMD) was measured by DXA method (standard deviation, CO) of the femur neck and lumbar spine (L-LIV) were evaluated by the two-energy X-ray absorption (DXA) method ( Lunar Prodigy Primo, USA). The DXA data of the femoral neck and the lumbar spine were interpreted using the following reference intervals: normal BMD - T -criterion -1 CO, osteopenia - T-criterion from -1 to less CO. Low-energy fractures were considered to have occurred with minimal trauma (falling from a height of own height to the same surface or an even smaller injury) and were found in the anamnesis.

Results: In the group of patients with OA of the knee joint, normal BMD was found to be statistically significantly more frequent than the control group (15.7% vs. 4.3%) p=0.033. It is shown that in women with OA of the knee joint, low-energy fractures were statistically less recorded than in the control group; in 29.4% and 5.0% of women respectively (p=0.002). The chances of having low-energy fractures in the group of patients with OA of the knee joint were statistically lower by a factor of 2.64 compared to the control group (OR = 0.378; 95%CI: 0.230 - 0.703).

Conclusion: The low frequency of low-energy fractures and the lower the chances of them in women with OA of the knee joint compared to the control group are probably associated with lower prevalence of the osteopenic syndrome among these patients.

References:

Acknowledgements: We thank Vychaschey Fanaskov and Svetlana Skutina are radiologists of State Autonomous healthcare institution “Kuzbas clinical hospital for war veterans” for the possibility of holding the two-energy X-ray absorption.

Disclosure of Interests: None declared.


AB0980

PLANTAR FASCIITIS IN PATIENTS WITH KNEE OSTEOARTHRITIS

S. Bouzid1, S. Miladi2, A. Fazaaz1, H. Bousaa1, K. Ben Abdelghani1, A. Laatar1.
1Mongi Slim Hospital, Rheumatology, La Marsa, Tunisia

Background: Knee osteoarthritis (OA) is a highly prevalent disease, it shares with plantar fasciitis similar risk factors including aging, occupation, obesity, and inappropriate footwear. The association between knee OA and heel pain caused by plantar fasciitis has received limited attention to date.

Objectives: to determine the association between knee OA and plantar fasciitis.

Methods: We conducted a cross-sectional study including 30 patients with symptomatic knee OA. Health status was evaluated using the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index. The functional impairment of knee OA was determined by the Lequesne index. Ultrasound evaluation of heels was performed in all patients examining signs of plantar fasciitis (measure thickness, echogenicity, enthesisopathy, calcification, erosion, doppler).

Results: The study included 30 patients. Mean age was 62.09 +/- 6.7 years. Patients reported lower back pain and heel pain in 67% (n=20) and 47% (n=14) respectively. Knee symptoms were evaluated by the WOMAC index: mean score for pain, stiffness, and physical function was 9.68 +/- 4.25, 4.18 +/- 3.75 and 2.72 +/- 1.63, respectively. Mean Lequesne index for the knee OA was 11.4 +/- 4.57.

Physical examination revealed limited range of motion in knees in 33 % (n=10) with a genu flexum in two patients. Patella tap was positive in 20 % (n=6).

Conclusion: Our study showed that half of our knee OA patients have plantar fasciitis confirmed with ultrasound. More studies with larger cohorts are needed to explain the correlation between the two lesions.

Disclosure of Interests: None declared.


AB0990

CORRELATION OF CLINICAL PARAMETERS WITH URINARY COLLAGEN TYPE II-C-TELOPEPTIDE AND KNEE CARTILAGE THICKNESS MEASURED WITH ULTRASOUND IN PATIENTS WITH KNEE OSTEOARTHRITIS

D. Iarlenko1, D. Fedkiv2, M. Saluflinig1, K. Iarlenko2.
1Bogomolets National Medical University, Department of internal medicine N3, Kyiv, Ukraine;
2Olexandrivska City Hospital, Central Laboratory Department, Kyiv, Ukraine

Background: Although knee osteoarthritis (KOA) incidence is one of the highest among chronic diseases, no effective biomarkers are known for its management [1].

Objectives: To estimate the relationship between the sensitive marker of matrix metalloproteinase-dependent cartilage degradation - urinary collagen type II-C-telopeptide (uCTX-II) levels, patient-reported outcomes (PRO), and knee cartilage thickness measured using ultrasound (US) in patients with knee OA.

Methods: WOMAC questionnaire and Leken’s functional index, VAS pain by pts, knee joints US, uCTX-II levels (ng/ml; ELISA) were evaluated in 46 pts (71.7% female) with KOA, who hadn’t received any medical treatment except paracetamol or NSAIDs the last 12 weeks. The mean age was 62.6±6.2, mean disease duration – 10.2±6.3 years, 63% and 27% of pts had Kellgren-Lawrence grade II and III, respectively. The knee cartilage thickness (mm) in three compartments (lateral, middle, medial) of the patellofemoral region was evaluated using a linear L50 sensor in standard sensor positions, frequency 5-12 MHz. Calculation of average thickness for each knee joint and both joints was performed. The Spearman correlation coefficient was utilized to detect the association of uCTX-II, PROs and knee cartilage thickness.

Results: The mean values (M±SD) of WOMAC and Leken’s indices were 39.13±6.5 and 12±4.18, respectively. The mean value of VAS pain by pts was 57.7±16.5. The mean concentration of uCTX-II was 0.18±0.12. The mean thickness of cartilage were: 1.7±0.33 for the right, 1.7±0.36 for the left, and 1.7±0.31 for both knee joints. The mean value of both knee joints cartilage thickness had significant negative moderate correlation with Leken’s index (r=-0.354, p<0.01). According to VAS following tertile groups were detected: 1 group: mean interval less than 50mm; 2 group: mean interval 50-64 mm; 3 group: more than 64 mm. There were negative moderate correlations between cartilage thickness of the left knee joint and Leken’s index (r=-0.513, p=0.03) and WOMAC (r=-0.535, p=0.024) only in group 1. Also, pts were divided into three groups according to disease duration: 1 group: mean interval less than 7 years; 2 group: mean interval 7-10 years; 3 group: more than 10 years. There were negative correlations between uCTX-II and medial, middle compartments of left knee cartilage thickness (r=-0.474, p=0.03; r=-0.592, p<0.01, respectively). WOMAC negatively correlated with cartilage thickness of the left (r=-0.517, p=0.02) and right (r=-0.435, p=0.046) knee joints. Leken’s index negatively correlated with cartilage thickness of the left knee joint (r=-0.590, p<0.01). All correlations were moderate and found in group 2. There were negative moderate correlation between uCTX-II and the mean value of middle compartments of both knee joints cartilage thickness (r=-0.538, p=0.04) and positive moderate correlation between uCTX-II and Leken’s index (r=0.561, p=0.036) in men. There were no correlations between uCTX-II and cartilage thickness of each knee joint and both joints in patients with KOA.

Conclusion: Cartilage thickness measured with US associated with PROs in KOA pts. At the same time, the association between uCTX-II and cartilage thickness was less pronounced, only in men and in pts with disease duration 10-70 years. In pts with VAS pain less than 50 mm and in the group of pts with KOA disease duration - WOMAC and Leken’s indices negatively correlated with the thicknesses of the cartilage of the knee joints. In control pts, correlations didn’t represent the expected relationship between uCTX-II level and clinical, instrumental characteristics of KOA. This may be because the current level of uCTX-II characterizes only the state of cartilage metabolism at the time of examination of the patient and doesn’t show the cumulative results of previous anabolic/catabolic changes in articular cartilage.

References:
The aim of this study was to determine the prognostic factors related to clinical response to PRP injections in knee osteoarthritis, in order to better select candidates for this therapy.

Methods: This was a single-center, prospective observational study including patients treated by PRP injections for knee osteoarthritis, from a university hospital. The PRP was leukocyte-poor, obtained by an ARTHREL® kit, and was injected into the joint at one-month intervals. They were assessed at 4 months (M4) and 7 months (M7) after the first injection. Pains on a Visual Analog Scale (VAS) and function with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee injury and Osteoarthritis Outcome Score (KOOS) – Physical Function Shortform (KOOS-PS) were collected. Patients were then classified as responders if they met the OMERACT-OARSI criteria at M7. Univariate and multivariate analysis was performed to compare the two groups.

RESULTS: Among 197 patients, 210 knees were treated. The mean age was 59.8±10.8 years. Body mass index (BMI) was 31.0±6.5. Patellofemoral osteoarthritis was found in 34.3% of the patients, the distribution according to Kellgren and Lawrence stages I, II, III, IV was 11.8%, 33.5%, 40.4% and 14.3% respectively. A majority of patients had failed viscosupplementation (62.4%). At 7 months, 43.8% were classified as responders. Total WOMAC was 49.4±16.1 at M0, 43.6±17.9 at M1, 31.1±19.0 at M4 and 31.9±19.8 at M7, with significant improvement at M4 and M7 versus baseline (p<0.0001). The VAS was 58.5±19.7, 51.6±21.7, 43.7±23.2 and 43.5±23.5 at M0, M1, M4 and M7 respectively (p<0.0001 at all 3 times versus baseline). Regarding treatment satisfaction, 70% of patients considered the treatment effective or very effective at M7. Physical therapy and a heel-buttock distance greater than 35 centimeters were the two criteria associated with a poorer response at M7 on multivariate analysis. The pain VAS at M7 appeared to be lower in patients whose osteoarthritis had been evolving for less than 24 months. Tolerance was good. There was an increase in joint effusions between M0 and M1 (17% vs. 41%, p<0.0001), but no increase in pain.

Conclusion: PRP treatment in knee osteoarthritis appeared to be effective and well tolerated, and this response was not associated with the radiographic stage or the type of knee osteoarthritis. In accordance with the recommendations of a group of French experts, this treatment should be proposed in case of failure of drug and rehabilitation treatment, at the same level as hyaluronic acid injections.

REFERENCES:

AB0992
PROGNOSTIC FACTORS RELATED TO CLINICAL RESPONSE IN 197 PATIENTS WITH KNEE OSTEOARTHRITIS TREATED BY PLATELET RICH PLASMA (PRP)

C. Chopin1, M. Geoffrey1, C. Dorleau2, B. Lois1, A. Hittinger1, I. Charlot2, L. Kanagaratsan1, J. H. Salmon1, CHU Reims - Hôpital Maternel Blanche, Service de Rhumatologie, Reims, France; CHU Reims - Hôpital Maternel Blanche, Unité d’aide méthodologique, Reims, France

Background: The European League Against Rheumatism (EULAR) [1] and the Osteoarthritis Research Society International (OARSI) [2] recommend a combination of non-pharmacological and pharmaceutical treatment in the management of knee osteoarthritis. New therapies have emerged such as Platelet Rich Plasma (PRP) injections. Many studies have shown the effectiveness of this treatment, and even its superiority over Hyaluronic Acid.

Objectives: The objective of this study was to determine the prognostic factors related to clinical response to PRP injections in knee osteoarthritis, in order to better select candidates for this therapy.

Methods: This was a single-center, prospective observational study including patients treated by PRP injections for knee osteoarthritis, from a university hospital. The PRP was leukocyte-poor, obtained by an ARTHREL® kit, and was injected into the joint at one-month intervals. They were assessed at 4 months (M4) and 7 months (M7) after the first injection. Pains on a Visual Analog Scale (VAS) and function with Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee injury and Osteoarthritis Outcome Score (KOOS) – Physical Function Shortform (KOOS-PS) were collected. Patients were then classified as responders if they met the OMERACT-OARSI criteria at M7. Univariate and multivariate analysis was performed to compare the two groups.

RESULTS: Among 197 patients, 210 knees were treated. The mean age was 59.8±10.8 years. Body mass index (BMI) was 31.0±6.5. Patellofemoral osteoarthritis was found in 34.3% of the patients, the distribution according to Kellgren and Lawrence stages I, II, III, IV was 11.8%, 33.5%, 40.4% and 14.3% respectively. A majority of patients had failed viscosupplementation (62.4%). At 7 months, 43.8% were classified as responders. Total WOMAC was 49.4±16.1 at M0, 43.6±17.9 at M1, 31.1±19.0 at M4 and 31.9±19.8 at M7, with significant improvement at M4 and M7 versus baseline (p<0.0001). The VAS was 58.5±19.7, 51.6±21.7, 43.7±23.2 and 43.5±23.5 at M0, M1, M4 and M7 respectively (p<0.0001 at all 3 times versus baseline). Regarding treatment satisfaction, 70% of patients considered the treatment effective or very effective at M7. Physical therapy and a heel-buttock distance greater than 35 centimeters were the two criteria associated with a poorer response at M7 on multivariate analysis. The pain VAS at M7 appeared to be lower in patients whose osteoarthritis had been evolving for less than 24 months. Tolerance was good. There was an increase in joint effusions between M0 and M1 (17% vs. 41%, p<0.0001), but no increase in pain.

Conclusion: PRP treatment in knee osteoarthritis appeared to be effective and well tolerated, and this response was not associated with the radiographic stage or the type of knee osteoarthritis. In accordance with the recommendations of a group of French experts, this treatment should be proposed in case of failure of drug and rehabilitation treatment, at the same level as hyaluronic acid injections.

REFERENCES:
presarcopenia (p<0.050). The BMD in the femoral neck in patients with sarcopenia was 0.908 [0.817; 0.977] g/cm², which corresponds to -0.95 [-1.35; 0.425] CO according to the T-criterion, while in the groups of patients without sarcopenia and with sarcopenia, statistically significantly higher BMD values were recorded: 0.988 [0.953; 1.09] g/cm² and 0.995 [0.94; 1.04] g/cm² (p=0.009 and p=0.027), which corresponds to -0.30 [-0.80; 0.225] and -0.30 [-0.70; 0] CO according to the T-criterion (p=0.013 and p=0.024), respectively. When comparing the BMD and T-score in the lumbar spine, there were no statistically significant differences in the studied groups of patients.

Conclusion: Sarcopenia is associated with low BMD in the neck and proximal femur in general elderly and senile male patients with knee joint OA.

Disclosure of Interests: None declared


EXPLORING KNEE OSTEOARTHRITIS PAIN TRAJECTORIES AND MOVEMENT-EVOKED PAIN CHANGES DURING A 24-WEEK OUTDOOR WALKING PROGRAM (WALK)

S. Drummen1, S. Balogun2, L. Scheepers1, I. Murugodua, A. Lahtham2, K. Bennett1, R. Himman1, M. Callissaya1, C. Gai1, P. Othal1, T. Winsenberg1, Z. Wang1, B. Antony1, J. Martel-Pelletier6, J. P. Pelletier6, F. Abram7, S. Drummen1, S. Balogun1,2, L. Scheepers1, I. Munugodaa, A. Lahtham3, D. Aitken1, University of Tasmania, Menzies Institute for Medical Research, Hobart, Australia,1Australian National University, College of Health & Medicine, Canberra, Australia,2Monash University, Respiratory Care group, Melbourne, Australia,3The University of Melbourne, Medicine, Dentistry and Health Sciences, Melbourne, Australia,4Monash University, Medicine, Nursing and Health Sciences, Melbourne, Australia,5University of Montreal, Hospital Research Centre (CRCHUM), Montréal, Canada,6Medical Imaging Research & Development, ArthroLabInc., Montreal, Canada

Background: Exercise therapy is recommended as first line treatment for knee osteoarthritis (OA), but it remains to be sub-optimally applied (1). Movement-evoked pain is a potential barrier to exercise adherence, but recent evidence suggests that such pain can be improved by training (2). Walking programs are low-cost, easily adopted and can be performed outdoors which can minimize the risk of SARS-CoV-2 transmission when in a group (3).

Objectives: To explore the acute pain trajectories of individuals with knee OA during a 24-week outdoor walking intervention. In addition, to explore the effect of pain trajectories and/or baseline characteristics on retention and adherence.

Methods: Individuals with clinical knee OA and bone marrow lesions (BMLs) on magnetic resonance imaging (MRI) were asked to follow a 24-week walking program. Every week consisted of two one hour supervised group sessions at various outdoor locations and one unsupervised session. At the start and end of every supervised group walk, knee pain was self-reported by participants to their trainer using a numerical rating scale (NRS) (0-10). The difference between the NRS pain values was considered as an acute pain change evoked by that walk. At baseline, the most affected knee of each participant was assessed using the Visual Analogue Scale (VAS) pain, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, stiffness and function, wellbeing (3 questionnaires) and the Osteoarthritis Research Society International (OARSI) recommended strength and performance measures.

Results: In total, N = 24 participants started the program of whom N = 7 (29%) withdrew. Pain at the start of each walk decreased from NRS 2.5 (SD 1.6) at the first walk (N = 24) to NRS 0.9 (SD 0.8) at the final walk (N = 17). This pain was estimated to decrease on NRS by -0.04 (95% CI -0.05 to -0.02) per supervised session, p = 0.001 during the first 12 weeks and -0.01 (95% CI -0.02 to -0.004), p = 0.004 during the second twelve weeks of the program. The number (%)

Disclosure of Interests: None declared


METABOLIC PHENOTYPE OF KNEE OSTEOARTHRITIS: CHARACTERISTIC BIOCHEMICAL AND IMAGING FEATURES

F. Tashina, L. Alekseeva2, N. Kashcheeva1, K. Telyshev1, D. Kudinsky2, A. Lahtham3, N. Demin1, O. Alekseeva2, M. Cherkasova4, E. Samarkina5, E. Strebkova1, E. Sharapova1, F. Bilubatova1, O. Tenkova2, A. Aboleshina1, E. Kharlama1, T. Raskina1, J. Averkjeva1, E. Usosova1, I. Vinogradova1, O. Salnikova1, E. Ottova1, A. Lilia1, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Radiology, Moscow, Russian Federation; 4V.A. Nasonova Research Institute of Rheumatology, Diagnostic, Moscow, Russian Federation; 5V.A. Nasonova Research Institute of Rheumatology, Laboratory and Laboratory; 6FSBEI HE KemSMU, Rheumatology, Moscow, Russian Federation; 7SHI Ulyanovsk Regional Affiliated Hospital, Rheumatology, Ulyanovsk, Russian Federation; 8Regional SBHI CDC MOH, Rheumatology, Khabarovsk, Russian Federation; 9V.A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation

Background: Knee osteoarthritis (OA) is not an age-related condition but it can be a consequence of metabolic factors. Systemic characteristic biochemical and imaging features of metabolic phenotype of knee OA are needed. The aim of the present study was to identify characteristic biochemical and imaging features of metabolic phenotype of knee OA in a multicenter prospective study.

Methods: 284 female patients with knee OA (according to the ACR criteria) aged 40-78 were included in this prospective multicenter study. OA radiologic stages in the study group varied from I to III (Kellgren & Lawrence) and all the patients signed an informed consent. Mean age was 58.5 ± 9.5 years, disease duration was 5 (2-10) years. BMI was 29.6 ± 5.6 kg/m², with hip (HC) – 109.3 ± 10.4 cm and waist circumference (WC) – 92.5 ± 12.5 cm. Physicians filled out individual case report forms containing demographic and physical assessment data. All patients performed lab tests, ultrasonography and x-ray of the knee, as well as proximal femur and lumbar spine DEXA.

Results: Metabolic phenotype was diagnosed in 52.4% of patients. Participants were then divided in two groups. Patients with metabolic phenotype of osteoarthritis were older (61 [57-68] vs 52 [43-58], respectively, p<0.0001), had higher BMI (31.6 [28.6-35.5] vs 26.4 [23.4-30.3], p<0.0001) and had more intense VAS knee pain while walking on flat surface (50 [40-60] vs 35 [10-50], p<0.0001). There were also statistically significant differences when we analyzed the imaging results (Table 1). Patients with metabolic phenotype of knee OA had higher chances of grade III K&L (OR=4.4, 95% CI 1.3-14.2, p=0.01) and more significant mediolateral joint space narrowing, bigger tibial osteophytes; knee ultrasound revealed thinner cartilage and thicker synovium. DEXA showed higher total hip BMD. Patients with metabolic phenotype had higher levels of CRP, HbA1c, uric acid, cholesterol, LDL, triglycerides, ALT, AST, glucose, leptin and COMP.

Disclosure of Interests: None declared


REFERENCES:


Acknowledgments: We thank the participants who made this study possible. We would like to acknowledge the research staff, Kate Probert, Lizzy Reid, Simone Fitzgerald, Claire Roberts, Jasmin Ritchie, Dawn Simpson, and Tim Albion. We also thank Hamish Newnham-West for his contribution to the study.

Disclosure of Interests: Stan Drummen: None declared, Saliu Balogun: None declared, Lieke Scheepers Grant/research support from: Competitive Grant Program in Immunology ASMO 2020 Rheumatology International Developed Markets from Pfizer, Employee of: previously worked as an Associate Director Epidemiology at the Medical Evidence Observational Research Department at AstraZeneca., Ishanka Munugoda: None declared, aroub lahtham: None declared, Kim Bennett: None declared, Rana Himman: None declared, Michele Callisaya: None declared, Guoqi Cai: None declared, Petr Othal: None declared, Tania Winzenberg Consultant of: received payment to create educational material by AMGEN, Zhiquang Wang: None declared, Benny Antony: None declared, Johanne Martel-Pelletier Shareholder of: ArthroLab Inc., Jean-Pierre Pelletier Shareholder of: ArthroLab Inc., François Abram Consultant of: ArthroLab Inc., Employee of: ArthroLab Inc., Graeme Jones Speakers bureau: received payment for a speakers bureau from Novartis, Dawn Aitken: None declared
Table 1. Comparison of patients depending on phenotype

<table>
<thead>
<tr>
<th>Index</th>
<th>Metabolic phenotype</th>
<th>No metabolic phenotype</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=149)</td>
<td>(n=135)</td>
</tr>
<tr>
<td>K&amp;L radiologic grade</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>I grade</td>
<td>13.6%</td>
<td>56.7%</td>
</tr>
<tr>
<td>II grade</td>
<td>62.7%</td>
<td>36.7%</td>
</tr>
<tr>
<td>III grade</td>
<td>23.7%</td>
<td>6.6%</td>
</tr>
<tr>
<td>Posterior lateral tibial cartilage, mm, Me</td>
<td>1.5 (1.4-1.8)</td>
<td>1.7 [1.6;1.8]</td>
</tr>
<tr>
<td>Posterior medial tibial cartilage, mm, Me</td>
<td>1.6 (1.3-1.8)</td>
<td>1.7 [1.6;1.8]</td>
</tr>
<tr>
<td>Medial knee joint space, mm, Me</td>
<td>2.6 (1.4-6)</td>
<td>3.6 [3.4;3.2]</td>
</tr>
<tr>
<td>Osteophytes of the medial tibial condyle, mm, Me</td>
<td>1 (1-2)</td>
<td>0 (0.0)</td>
</tr>
<tr>
<td>Osteophytes of the lateral tibial condyle, mm, Me</td>
<td>1 (1-2)</td>
<td>0(0.1)</td>
</tr>
</tbody>
</table>

Spearman correlation analysis showed positive correlations (p < 0.05) between the metabolic phenotype and OA radiologic stage (r = 0.44), size of tibial osteophytes (r = 0.31), synovium thickness (r = 0.28), hsCRP (r = 0.44), HbAlc (r = 0.45), cholesterol (r = 0.29), DLGL (r = 0.3), triglycerides (r = 0.36), uric acid (r = 0.46), IL-6 (r = 0.38). A significant correlation was found between the M1/MR phenotype and OA with higher levels of hsCRP, leptin, IL-6, COMP, which possibly demonstrate a more active form of low-grade inflammation (the underlying mechanism of OA pathogenesis) and more significant cartilage damage.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.4242

AB0997 PREDICTORS OF DISEASE PROGRESSION AND CLINICAL OUTCOMES IN OSTEOARTHRITIS A. Tyurin1, R. Khushainova1, 2 Bashkir State Medical University, Internal Medicine, Ufa, Russian Federation; 1 Institute of Biochemistry and Genetics, Human molecular genetics, Ufa, Russian Federation

Background: Osteoarthritis (OA) is one of the most common joint diseases, often causing persistent pain and immobilization [1]. The genetic contribution to OA varies from 40% to 65%, depending on the presence of the pathology in the immediate family, the location of the affected joint, sex, and ethnicity of the patients [2]. The study of miRNA target sites is a new promising direction in molecular diagnostics [3].

Objective: The aim of our work was to study the miRNA binding sites of COL1A1, COL11A1, ADAMT5, MMP1, MMP13, SOX9, GDF5, FGF2, FGFRL1 genes in patients with OA of different localization.

Methods: A total of 417 women (mean age 51.6±11.5) from Ufa (Republic of Bashkortostan, Russia) participated in the study between January 2013 and August 2017. The patients were examined and diagnosed for osteoarthritis according to the criteria of the American College of Rheumatologists (1990) with X-ray confirmation. Overall, 356 women with OA were recruited and divided into 3 groups as follows: subgroup 1 included 84 women affected by generalized OA, subgroup 2 included 197 women affected by knee OA, subgroup 3 included 75 women affected by hip OA. For genotyping, RT-PCR analysis using KASP technology was used. Selection of the miRNA target site was carried out using the database of the National Center for Biotechnology Information (https://www.ncbi.nlm.nih.gov), Ensemble Genome Browser (www.ensembl.org), and the base of polymorphisms of microRNA target sites (http://compbio.uthsc.edu/mirNPS). As a calculation tool, Statistica v6.2 (StatSoft) software packages were used. Considering the type I error caused by multiple testing, p values were adjusted by calculating the FDR value using the Benjamini-Hochberg method (https://tools.barcation.com/FRD).

Results: The T allele of the rs9650300 (COL11A1) was associated with the generalized OA (p = 0.019; OR = 2.0; 95% CI 1.1 to 3.62), the TT genotype was associated with all patients (p = 0.026; OR = 1.95; 95% CI 1.05 to 2.31), and OA of the hip (p = 0.016; OR = 2.3; 95% CI 1.14 to 4.36). With respect to rs229069 (ADAMTS5), a significant association was found between the C allele and the incidence of total OA (p = 0.018; OR = 1.43; 95% CI 1.06 to 1.89), as well as with the knee OA (p = 0.042; OR = 1.43; 95% CI 1.01 to 2.03) and hip OA (p = 0.026; OR = 2.039; 95% CI 1.08 to 3.85). The CC genotype was also found to be associated with total OA (p = 0.037; OR = 1.53; 95% CI 1.2 to 2.82) and hip OA (p = 0.026; OR = 2.039; 95% CI 1.08 to 3.85). The T allele of rs13317 (FGFRL1) was strongly associated with the total OA (p = 0.001; OR = 1.67; 95% CI 1.2 to 2.3), knee OA (p = 0.003; OR = 1.74; 95% CI 1.19 to 2.55) and generalized OA (p = 0.044; OR = 1.67; 95% CI 1.01 to 2.73). After Benjamini-Hochberg correction, rs13317 remained statistically significant in the following groups: the T allele in control vs total patients (adjusted p = 0.01) and in control vs OA of the knee (adjusted p = 0.03). Neither the genotype nor the allele frequencies of rs1061347 (COL1A1), rs229077, rs9978597 (ADAMTS5), rs5854, rs702151 (MMP1), rs1042840 (MMP13), rs1042673 (SOX9), rs5469740 (FGFRL1) were significantly different between the affected individuals and normal controls.

Conclusion: The current study demonstrated an association between the T allele of rs13317 in FGFRL1 and incidence of the total OA and knee OA in women from Volga-Ural region of Russia.

References:

Disclosure of Interests: None declared.


AB0998 DIET AND JOINT SYMPTOMS: A SURVEY OF MOROCCAN PATIENTS WITH OSTEOARTHRITIS R. Bensaid1, T. Fatima Zahrae1, N. El Mansouri1, A. Anas1, L. Berrichi1, B. Khadja1, F. Abourazak1

1 CHU Tangier, Rheumatology, Tangier, Morocco

Background: The question of diet is frequently asked by patients with osteoarthritis. Beyond the effect of weight on the aggravation of their symptoms, patients

Disclosure of Interests: None declared.

often ask whether certain foods, described as inflammatory or anti-inflammatory, can improve or worsen their disease.

**Objectives:** The objective of our study is to investigate whether Moroccan patients report a relationship between certain foods and their symptoms and also to study whether they adopt specific dietary behaviors in an effort to alleviate their symptoms.

**Methods:** This is a survey based on a questionnaire, that included any patient followed for osteoarthritis who presented to the rheumatology department. The questionnaire consisted of 3 parts:
1) Socio-demographic data, comorbidities, and information on osteoarthritis location, duration of evolution, functional impact and treatments.
2) Beliefs and attitudes of patients regarding diet in relation to osteoarthritis.
3) A list of 24 foods for which patients were asked to indicate whether they aggravated, improved or left their joint symptoms unchanged.

**Results:** At this time we included 120 patients. The mean age was 57.1 ± 11.8, 88.3% of the patients were women, 41.2% had comorbidities, 62.5% were illiterate. The median duration of osteoarthritis was 4 years [2; 7]. 64.2% of the patients were followed for gonarthritis, 25% for discarthrosis and 10.8% for digital osteoarthritis. The average BMI was 27.8 ± 5.2. 8.3% of the patients thought that diet influenced their osteoarthritis. 9.5% of the subjects stated that food had an effect on their symptoms, 9.2% of them reporting an improvement and 8.3% an aggravation. Fish (1.7%), garlic (1.7%), and olive oil (1.7%) were the foods most often cited as improving joint symptoms, while red meat (3.3%), and sweetened soft drinks (2.5%) were the most often cited as worsening symptoms. 6.7% of the patients had food avoidance behaviors, 10.8% adopted certain diets and 5.8% had tried fasting in order to relieve joint symptoms. In univariate and multivariate analysis, education level (OR: 0.165; 95% CI [0.046-0.592]; p=0.006) and experience with a food that improves symptoms (OR: 46.8; 95% CI [1.798-1222.5]; p=0.021) were associated with reporting that food influence OA symptoms.

**Conclusion:** Our study showed that associations between certain foods and worsening or improving joint symptoms were reported by a minority of patients and appeared to be mostly associated with patients' education level and experience of a food improving symptoms.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4915

---

**OSTEARTHritis. PHARMACoeconomics: ASPECTS OF SYMptom-MODIFYING THERAPY IN REAL CLINICAL PRACTICE.**

I. Kryakova1,2,*, V. Kryakova1,2,*, V. Ermaikova2,3,*, N. Shostak2,*, and Pravdyuk2.
1Institute of Clinical and Economic Assessment and Pharmacoeconomics; 2Raschichi, Russian Federation; 3Federal State Budgetary Educational Institution of Higher Education “A.I. Yevdokimov Moscow State University of Medicine and Dentistry” of the Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation; 4Moscow State University of Food Production, Medical Institute of Continuing Education, Moscow, Russian Federation; 5FSAEI HE I.M. Sechenov First Moscow MOH Russia (Sechenov University), Moscow, Russian Federation; 6Prokhorov Russian National Research Medical University, Nesterov Department of Faculty Therapy, Moscow, Russian Federation

**Background:** Treatment of osteoarthritis (OA) is a significant medical and social problem worldwide. Modern therapeutic approaches include both pharmacological and non-pharmaceutical methods aimed at reducing pain, improving joint function, and preventing disease progression. A wide variety of symptomatic slow-acting drugs for osteoarthritis and their usage dictate the necessity for a clinical and economic analysis to select the most economically feasible treatment regimen for OA.

**Objectives:** To conduct a clinical and economic assessment of OA therapy using drugs of the SYSADOA group.

**Methods:** The search for publications for the period 2011-2022 on the clinical efficacy and safety of SYSADOA (bioactive concentrate of small marine fish containing chondroitin sulfate, amino acids, peptides, sodium, calcium, magnesium, iron, copper and zinc ions) was conducted using available sources (Medline, eLIBRARY.ru). The research selection methodology was in compliance with the PRISMA criteria (Preferred Reporting Items for Systematic Reviews and Meta-analysis), 124 sources were analyzed. To collect data on the costs for managing patients in a real-life therapeutic practice, a literature data showed that bioactive concentrate of small marine fish, produced by Biotehnos S.A. is a modern original SYSADOA for the initial therapy of knee joint OA with proven efficacy and safety. The estimated course cost of SYSADOA therapy ranges from 36.961 to 92 euros. The median exchange rate of all drugs in the sample was 50.2; for SYSADOA drugs with oral administration - 85.82 euros; injectable drugs - 47.76 euros. The median amount of direct costs for injectable SYSADOA was 388,012 euros. Cost minimization analysis showed that the use of an alternating mode of administration of the drug (2 ml every other day intramuscularly - 10 injections) in patients with knee joint OA is the most cost-effective method for the treatment of OA and allows to reduce direct costs up to 64% per patient by reducing the number of medical services provided.

**Conclusion:** The analysis proved rationality of the established medical practice in prescribing of the injectable SYSADOA (bioactive concentrate of small marine fish was a leader among injectable SYSADOA according to HWC and IQVIA marketing analytical data for the period 2020-2021). Choosing the most economically feasible drug for the treatment of patients with OA will reduce the costs of the healthcare system and reduce the overall economic burden of OA.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5033

---

**AB1000 RELIABILITY AND VALIDITY OF THE Cone EVASION WALK TEST IN PATIENTS WITH TOTAL KNEE ARTHROPLASTY: A PILOT STUDY**

K. S. Kaczm1,*, B. Unev2,*, V. Karatosun2,*, 1izmir katip celebi university, physical therapy and rehabilitation, izmir, Turkey; 2dokuz eylul university, physical therapy and rehabilitation, izmir, Turkey; 3dokuz eylul university, orthopaedics and traumatology, izmir, Turkey

**Background:** Total knee arthroplasty (TKA) is the gold-standard procedure for end-stage knee osteoarthritis, however, some residual problems may still continue and cause a variety of dysfunctions, such as impaired strength, proprioception, gait balance, postural instability, and, impaired ability to avoid obstacles while walking. Tripping over an obstacle is the most frequent cause of falls 1 and falls can limit daily activities and induce post-fall syndromes, such as dependence, loss of autonomy, immobilization, and depression 2. The Cone Evasion Walk test (CEW) to assess fall risk by the ability to evade obstacles, (ICF-code d455), which requires attentional, perceptual, and several neuromusculoskeletal and movement related functions 3. However, there is no study investigating the reliability and validity of the CEW in TKA patients.

**Objectives:** The aim of the study is to investigate the reliability and validity of the CEW in patients with TKA.

**Methods:** Twenty patients with TKA included in the study. The CEW, the Timed Up And Go Test (TUG) and the Hospital for Special Surgery (HSS) Knee Score administered to the patients. Patients rested between the tests for an hour.

**Results:** Mean age was 68.1 ± 5.59 years and the mean HSS Knee Score was 85.43a ± 3.47a The relative (ICC coefficient) and absolute (SEM and SRD95) reliability values were 0.98, 1.01, and 2.75 respectively. The Spearman correlation coefficient of the CEW with the TUG was 0.72.

**Conclusion:** Based on the current findings, the CEW has excellent reliability, high validity and responsiveness in evaluating dynamic balance and obstacle avoidance in patients with TKA. The minimal clinically important difference of CEW in TKA patients is 2.57 a and it may be concluded that the fact that this value is low, indicates the sensitivity of the test. Therefore, the CEW can identify even small alterations in the functional status, can be reliably used for post-operative surveillance of TKA to observe patient results, and the usage of the CEW for assessing the fall risk and mobility in the community maybe a better predictor of the patients' current condition.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5197
OSTEOARTHRITIS AND OBESITY: RELATIONSHIPS AND EFFICACY OF THERAPY.

E. Strekova1, L. Alekseeva1,2, V.A. Nasonova Research Institute of Rheumatology, Laboratory of Osteoarthritis, Moscow, Russian Federation; 2Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Rheumatology, Moscow, Russian Federation

Background: Osteoarthritis (OA) is the most common joint disease. The most important factor not only in the development but also in the progression of OA is obesity. Higher incidence of OA in obese patients is associated with several factors. One of them is a large volume of fat mass, which increases the mechanical load on the joints. On the other hand, in obesity, hyperexpression of pro-inflammatory mediators (cytokines, adipokines) is observed, which negatively affect joint tissues, as well as provoke the development of low-level metabolic inflammation. Thus, the problem of OA and obesity is very relevant in modern rheumatology.

Objectives: To determine features of clinical manifestations of OA in obesity and evaluate the effectiveness of obesity therapy in OA.

Methods: The study included 73 patients (women) with knee OA (according to the ACR criteria) II-III X-ray stage by Kellgren-Lawrence: obese 50 (30%) and non-obese 23 (30%) control group. Obese patients were divided into 2 groups: 1 group (n = 25) - received orlistat 120mg 3 times a day for 6 months in combination with non-pharmacological methods of controlling body weight and 2 group (n = 25), whose patients were recommended a diet and did the exercise for 6 months. Monthly visits evaluated anthropometric measures, articular status, WOMAC. Initially and after 6 months, laboratory scores were evaluated in obese patients (determination of leptin, TNF-α, IL-6, CRP, in peripheral blood).

Results: In patients with OA and obesity, a more severe course of OA is determined compared to the control group (Table 1).

Table 1. Comparative characteristics of obese and non-obese knee OA patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Obese patients (n = 50)</th>
<th>Non-obese patients (n = 23)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average age of OA onset, y.o. (M ± δ)</td>
<td>65.5 ± 5.86</td>
<td>58.69 ± 5.43</td>
<td>0.13</td>
</tr>
<tr>
<td>Average duration of OA, years, (M ± δ)</td>
<td>49.33 ± 6.14</td>
<td>55.17 ± 4.88</td>
<td>&lt;</td>
</tr>
<tr>
<td>BMI of onset OA, kg/m², (M ± δ)</td>
<td>27.4 ± 3.93</td>
<td>3.52 ± 1.47</td>
<td>0.001</td>
</tr>
<tr>
<td>The mean body weight, kg, (M ± δ)</td>
<td>102.97 ± 14.57</td>
<td>70.87 ± 8.84</td>
<td>&lt;</td>
</tr>
<tr>
<td>WOMAC pain, mm, (M ± δ)</td>
<td>227.95 ± 85.15</td>
<td>168.35 ± 49.17</td>
<td>0.006</td>
</tr>
<tr>
<td>WOMAC stiffness, mm, (M ± δ)</td>
<td>94.44 ± 49.44</td>
<td>71.52 ± 25.71</td>
<td>0.039</td>
</tr>
<tr>
<td>WOMAC functional insufficiency, mm</td>
<td>846.8 ± 33757</td>
<td>692.69 ± 1219.03</td>
<td>0.037</td>
</tr>
<tr>
<td>Total WOMAC, mm, (M ± δ)</td>
<td>1170.28 ± 43785</td>
<td>932.61 ± 159.09</td>
<td>0.014</td>
</tr>
</tbody>
</table>

After 6 months of drug therapy of obesity in patients of group 1, a significant decrease in body weight by 10.07% (p < 0.05) was achieved. In patients of group 2, body weight decreased by 8.8% (p > 0.05). In patients of group 1, the indicators of the WOMAC index improved: pain decreased by 52.5% (p < 0.05), stiffness by 47.98% (p < 0.05), functional insufficiency by 51.55% (p < 0.05). In patients of group 2, there was also a decrease in the WOMAC index, however, these changes were worse than in patients with greater body weight loss. Analyzing laboratory data, in group 1 there was a significant decrease in the level of leptin (p = 0.05) and IL-6 (p < 0.05), in contrast to patients of group 2 (p = 0.64; p = 1.0, respectively). In the study of TNF-α, no significant changes in the two groups were determined. CRP level in group 1 decreased by 23.7% (p > 0.05) compared to baseline data, in group 2 (p = 0.64; p = 0.01, respectively). In the study of TNF-α, no significant changes in the two groups were determined. CRP level in group 1 decreased by 23.7% (p > 0.05) compared to baseline data, in group 2 (p = 0.64; p = 0.01, respectively). In the study of TNF-α, no significant changes in the two groups were determined. CRP level in group 1 decreased by 23.7% (p > 0.05) compared to baseline data, in group 2 (p = 0.64; p = 0.01, respectively). In the study of TNF-α, no significant changes in the two groups were determined. CRP level in group 1 decreased by 23.7% (p > 0.05) compared to baseline data, in group 2 (p = 0.64; p = 0.01, respectively).

Conclusion: The results of our study demonstrated a more severe clinical course of OA in obese patients. Drug therapy for obesity in patients with knee OA and obesity not only leads to a decrease in the presentation of clinical symptoms of OA, but also entails changes at the metabolic level: a decrease in leptin, IL-6 and CRP, which indicates a decrease in the intensity of metainflammation in obese patients. Thus, therapeutic interventions aimed at reducing body weight should be an integral part of knee OA therapy.

Disclosure of Interests: None declared


CLASSIC VERSUS AQUATIC REHABILITATION IN GONARTHROSIS: WOMAC SCORE

R. Maouli1, M. Hlaidi1, K. Ben Amor1, N. Mouhil1, H. Rahali1, I. Kebi1, M. Slouma1, L. Ben Ammar2, L. Metoui2, R. Dhahir2, I. Gharsallah2, I. Maaoui1, M. Hfaidh1, K. Ben Amor1, N. Mouhil1, H. Rahali1, I. Kebi1, M. Slouma1, L. Ben Ammar2, L. Metoui2, R. Dhahir2, I. Gharsallah2, I. Maaoui1, M. Hfaidh1, K. Ben Amor1, N. Mouhil1, H. Rahali1, I. Kebi1, M. Slouma1, L. Ben Ammar2, L. Metoui2, R. Dhahir2, I. Gharsallah2

1The Military Hospital of Tunis, Physical Medicine and Rehabilitation Departement, Tunis, Tunisia; 2The Military Hospital of Tunis, Rheumatology Department, Tunis, Tunisia

Background: Gonarthrosis is the most frequent and common condition of the lower limb, responsible for goniaxia, stiffness, leading sometimes to major functional impotence. The WOMAC with its three domains (pain, stiffness and function) is a valid index for the evaluation of lower limb osteoarthritis [1]. The management of gonarthrosis is multidisciplinary with rehabilitation as the mainstay. Currently, aquatic gymnastics is more and more prescribed in the management of this pathology.

Objectives: The objective of our work was to compare the contribution of aquatic rehabilitation to classical one in patients with gonarthrosis through the WOMAC score.

Methods: This is a prospective, comparative study conducted over a period of 15 months, between September 2016 and December 2017, including 120 patients recruited at the Physical Medicine and Functional Rehabilitation Department of The HMPIT, in whom the diagnosis of gonarthrosis was made according to the ACR criteria. The patients were randomly divided into 2 groups of 60 patients each. The first group, called G1, received a conventional rehabilitation program. The second group, called G2, received aquatic rehabilitation. Two evaluations were made, the first (T1) before the beginning of the rehabilitation and the second (T2) at the end of the eight weeks of treatment.

Results: The average age of the general population was 54.85 ± 9.5 years [40–81 years]. The average age of G1 was 59.07 ± 10.2 years versus 50.63 ± 6.4 years for G2. Among the 120 patients, 28 were male (23%) and 92 were female (77%). There were 6 males and 54 females in group 1 versus 22 males and 38 females in group 2. Initially, the average WOMAC pain was 15.1 ± 3.9 in G1 and 12.3 ± 1.22 in G2. There was a statistically significant difference between the 2 groups (p < 0.01). After rehabilitation, there was an improvement in the WOMAC pain score of 17% in G1 and 50% in G2 with a statistically significant difference between the 2 groups (p < 0.001). The average WOMAC score for stiffness was initially 5.4 ± 2 in G1 and 3.2 ± 2 in G2 with no statistically significant difference between the 2 groups (p = 0.076). After rehabilitation, an improvement of this score was noted in both groups, it was 18% in G1 and 50% in G2 with a statistically significant difference between the 2 groups (p < 0.001). After rehabilitation, the score had improved by 10% and after hydrotherapy, the improvement was 46% with a statistically significant difference between the 2 groups (p < 0.001).

Conclusion: These results were aligned with the literature and confirmed the effectiveness of functional treatment whether aquatic or classic with better outcome for aquatic rehabilitation. The best would be to combine the different methods according to the needs of the patient and their functional capacities in order to ensure a better adherence.

REFERENCES

Disclosure of Interests: None declared


EFFECTIVENESS OF CLASSIC VERSUS AQUATIC REHABILITATION IN GONARTHROSIS: LEQUESNE SCORE

R. Maouli1, K. Ben Amor1, M. Hlaidi1, N. Mouhil1, H. Rahali1, I. Kebi1, M. Slouma1, L. Ben Ammar2, L. Metoui2, R. Dhahir2, I. Gharsallah2

1The Military Hospital of Tunis, Physical Medicine and Rehabilitation Departement, Tunis, Tunisia; 2The Military Hospital of Tunis, Rheumatology Department, Tunis, Tunisia

Background: Gonarthrosis is a benign knee condition, but it can become disabling if poorly managed. The evaluation of the functional impact of gonarthrosis is based on Lequesne’s algofunctional index [1], thus judging the effectiveness or failure of the proposed treatment. Water gymnastics is increasingly prescribed in the management of this pathology.
**Objectives:** The main aim of our work was to compare the efficacy of aquatic gymnastics with conventional rehabilitation in patients with gonarthrosis using Lequesne's algofunctional index.

**Methods:** This is a prospective, comparative study conducted over a period of 15 months, between September 2016 and December 2017, in 120 patients recruited from the outpatient department of the Physical Medicine and Functional Rehabilitation Department of The HMPIT, in whom the diagnosis of gonarthrosis was made according to the ACR criteria. The patients were randomly divided into 2 groups of 60 patients each. The first group, called G1, received a conventional rehabilitation program. The second group, called G2, received water gymnastics. Two evaluations were made, the first (T1) before the beginning of the rehabilitation and the second (T2) at the end of the eight weeks of treatment.

**Results:**
- The mean age of the general population was 54.85 ± 9.501 years (40-81 years).
- An improvement in pain triggers between the 2 groups (p=0.02).
- After rehabilitation, 23% of the patients in G1 and 30% in G2 noted an improvement in pain with a statistically significant difference between the 2 groups (p=0.001). Pain was awakened by squatting in 93% of cases in G1 versus 97% of G2. There was no statistically significant difference between the 2 groups (p=0.554). After rehabilitation, 13% of the patients in G1 and 30% in G2 had a noted complete disappearance of pain with a statistically significant difference between the 2 groups (p=0.001).
- All patients in G1 and 92% of patients in G2 reported pain when climbing/descending stairs. There was no statistically significant difference between the 2 groups. An improvement in symptomatology was noted in both groups with disappearance of pain in 18% of G1 and 27% of G2. An adjustment on the parameters by which the 2 groups differed was made without impact on the results obtained.

**Conclusion:** Rehabilitation has an important role in the control of pain triggers by ensuring, in addition to analgesic means, good muscle balance, joint gain and good proprioception. Balneotherapy has proven to be more effective.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5334

**AB1004**

**CONTRIBUTION OF DRY REHABILITATION VERSUS BALNEOTHERAPY IN THE CONTROL OF PAIN TRIGGERS IN GONARTHROSIS**

R. Maaou1, M. Hfaidi1, G. Wechteti1, L. Ben Ammar2, L. Metoui2, R. Dhaïni2, I. Garsalalti2, M. Slouma2, L. Ben Ammar2, L. Metoui2, R. Dhaïni2, I. Garsalalti2. The Military Hospital of Tunis, Physical Medicine and Rehabilitation Department, Tunis, Tunisia

**Background:** Gonarthrosis is a very common condition and a real public health problem [1]. One of the pillars of its management is pain management. In addition to drug treatment, rehabilitation is part of the therapeutic arsenal.

**Objectives:** The main objective of our work was to compare the contribution of balneotherapy versus dry rehabilitation in the control of pain triggers.

**Methods:** We carried out a prospective, comparative study carried out over a period of 15 months, (September 2016-December 2017), in 120 patients recruited from the outpatient department of the Physical Medicine and Functional Rehabilitation Department of HMPIT in whom the diagnosis of knee osteoarthritis (KOA) was made according to the criteria of the ACR [2]. The patients were randomly divided into 2 groups of 60 patients each. The first group, called G1, received a conventional rehabilitation program. The second group, called G2, received water gymnastics. Two evaluations were made, the first (T1) before the beginning of the rehabilitation and the second (T2) at the end of the eight weeks of treatment.

**Results:**
- The mean age of our patients was 57.2 ± 12.5 years in G1 vs 54.3 ± 7.1 years in G2 (p = 0.012). The sex ratio was 0.2 in G1 versus 0.37 in G2 (p = 0.011). The duration of KOA was 63.4 ± 4.5 months in G1 vs 56.2±7.5 months in G2 (p=0.172). Pain was triggered by standing in 92% of cases in G1 versus 85% in G2 with a mean delay of 1.72 min for G1 and 20.1 min for G2. There was no statistically significant difference between the two groups (p=0.452).
- After rehabilitation, 22% of the patients in G1 and 43% in G2 noted an improvement in pain with a statistically significant difference between the two groups (p=0.001). Prolonged sitting in 62% of cases in G1 versus 38% in G2 with a mean delay of 6.2 min for G1 and 52.3 min for G2 awakened pain. There was a statistically significant difference between the two groups (p=0.02).
- After rehabilitation, 23% of the patients in G1 and 30% in G2 noted an improvement in pain with a statistically significant difference between the 2 groups (p=0.001).

**Conclusion:** Rehabilitation has an important role in the control of pain triggers by ensuring, in addition to analgesic means, good muscle balance, joint gain and good proprioception. Balneotherapy has proven to be more effective.
Table 2. Assessment of the evaluation criteria: CRP*, and VAS pain

<table>
<thead>
<tr>
<th></th>
<th>CRP*</th>
<th>VAS pain**</th>
</tr>
</thead>
<tbody>
<tr>
<td>*GK vs. Diclofenac</td>
<td>p &gt; 0.05</td>
<td>*GK vs. Diclofenac p &gt; 0.05</td>
</tr>
<tr>
<td>Day 0</td>
<td>4.8</td>
<td>2.2</td>
</tr>
<tr>
<td>Day 15</td>
<td>3.1</td>
<td>2.6</td>
</tr>
<tr>
<td>Variation, n (%)</td>
<td>-17.35 (4.4)</td>
<td>-1.6 (3.81)</td>
</tr>
<tr>
<td>p-Value</td>
<td>p = 0.003</td>
<td>p &lt; 0.001</td>
</tr>
<tr>
<td>VAS pain**</td>
<td>p = 0.001</td>
<td>p &lt; 0.001</td>
</tr>
</tbody>
</table>

Conclusion: Garcinia kola (G.K) was non-inferior to Diclofenac in reducing CRP* and VAS pain in patients with KOA. The safety was good. G.K would be a promising alternative to explore in the future management of osteoarthritis.

REFERENCES:

Acknowledgements: We are grateful to all the patients who consented to be included in this pilot study.

Disclosure of Interests: None declared


**AB1006**

IMPACT OF OSTEOARTHRITIS ON THE QUALITY OF LIFE IN PATIENTS WITH KNEE PAIN

A. Chaidou1, K. Veliou1, M. Gianniki1, M. Migkos1, F. Prits1, D. Giotis2, N. Tsifetaki3, 1General Hospital of Ioannina, Rheumatology Department, Ioannina, Greece; 2General Hospital of Ioannina, Orthopaedic Department, Ioannina, Greece

Background: Knee osteoarthritis is a common disease which mainly concerns aged population and impairs the quality of life in all aspects. Apart from causing pain or other related biomechanical comorbidities, osteoarthritis might affect psychological and social aspects of life.

Objectives: The purpose of the study was to investigate the impact of knee osteoarthritis on the quality of life and whether certain factors are related to this impact.

Methods: In a cross-sectional study, performed in our Hospital from January 2016 to December 2016, 150 patients (127 females and 23 males) with a mean age of 61.8 ± 8.07 years were examined. The sample included outpatients of the Rheumatology Department diagnosed with osteoarthritis and patients displaying knee pain. Individuals who had undergone previous knee surgery, and those with other osteoarthritic, rheumatic diseases or chronic degenerative disorders that could interfere with the quality of life, were excluded from the study. All participants, who gave their informed consent, answered the identification questionnaire and were interviewed with the Western Ontario and McMaster Universities Arthritis Index (WOMAC), The World Health Organization Quality of life (WHoQoL) questionnaire, the IPQ and the PHQ-9. All instruments used, were standardized in the Greek context.

Results: The effect of certain variables including patient associated characteristics, demographics, medical history, drug intake and symptomatology related to osteoarthritis, were evaluated with each of the WHO QoL measurements, the IPQ total score and the WOMAC scale. The regression analysis results demonstrated common significant correlations regarding the presence of injuries, the depression, the increased body mass index (BMI) and occasional crepitus. However, no significant difference was observed between patients with osteoarthritis and patients without osteoarthritis, concerning any of the examined parameters.

Conclusion: It was demonstrated that quality of life indices were related to agents that are not exclusively met in patients with osteoarthritis which implies that patients’ quality of life does not depend on the specific diagnosis but on patient’s psychological aspect (depression), presence of pain (injury) and overall health status (BMI).

REFERENCES:

Disclosure of Interests: None declared


Table 1. Results of receiver operation characteristics and Kaplan-Meier survival analysis for each factor

<table>
<thead>
<tr>
<th>Factor</th>
<th>cut-off index</th>
<th>area under the curve</th>
<th>p-value</th>
<th>Hazard ratio (95%CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cys/Cr</td>
<td>&gt; 1.345</td>
<td>0.614</td>
<td>&lt; 0.00</td>
<td>6.32 (2.87 – 13.92)</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>LSD</td>
<td>present</td>
<td>0.626</td>
<td>&lt; 0.01</td>
<td>3.60 (1.67 – 7.73)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Fall-ability</td>
<td>present</td>
<td>0.703</td>
<td>&lt; 0.001</td>
<td>4.83 (2.16 – 10.21)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>gKDK</td>
<td>present</td>
<td>0.612</td>
<td>&lt; 0.005</td>
<td>2.56 (1.06 – 6.20)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>pr-MOF</td>
<td>present</td>
<td>0.685</td>
<td>&lt; 0.001</td>
<td>4.81 (2.08 – 9.39)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

In Cox regression analysis, the presence of prevalent MOF (p-MOF), fall-ability, lifestyle-related diseases (LSD), chronic kidney diseases (CKD) ≥ Grade3a, and higher Cys/Cr had significant higher risk ratios with univariate models. In these, the presence of LSD and fall-ability had significant higher risk ratios with multivariate model. All the binary factors had COI as the presence of each event such with 0.626, 0.703, 0.612, and 0.685 of area under the curve for LSD, Fall-ability, CKD, and pr-MOF, respectively. Cys/Cr also had COI (1.345) with 0.614 of the area under the curve. In the Kaplan-Meier survival analysis, Cys/Cr > COI, Fall-ability, pr-MOF, LSD, CKD ≥ Grade 3 were significantly higher in ascending order of Hazard ratio (6.32, 4.83, 4.81, 3.60, 2.56, respectively) (Table 1).

Conclusion: These results suggest that Cys/Cr may be a predictor of MOF or a risk factor if it exceeds the COI. This value is the reciprocal of Cr/CysC, and if Cr/CysC reflects muscle mass, Cys/Cr is assumed to reflect low relative muscle mass. It is supposed that this is also affected by sex difference and age. There seems to be a correlation between MOF and Cys/Cr. Early measurement of Cys/Cr facilitates screening for fractures. For a result, it may be easier to implement fracture prevention programs such as drug interventions such as OPD and exercise habit guidance.

Disclosure of Interests: None declared

AB1008  CHARACTERIZATION OF THE RISK OF OSTEOPOROSIS IN A COHORT OF RHEUMATIC PATIENTS DURING 10 YEARS OF FOLLOW-UP.

L. Dulcey1, J. Theran1, D. Villamizar1, E. Espinoza1, R. Cattagrine1, H. Gonzalez2, J. Lopez2, A. Quintero2, R. Parales3, M. Aguas3, Los Andes University, Internal Medicine, Bucaramanga, Colombia; 2Bucaramanga University, Medicine, Bucaramanga, Colombia; 3Industrial University of Bucaramanga, Medicine, Bucaramanga, Colombia; 4Santander University, Medicine, Bucaramanga, Colombia; 5Metropolitan University, Medicine, Bucaramanga, Colombia; 6Santander University, Medicine, Bucaramanga, Colombia

Background: Osteoporosis is the most common cause of fractures. The lifetime risk of fracture after age 50 is 40% for women and 13% for men.

Objectives: Patients with rheumatological diseases are at greater risk for the development of osteoporosis, either due to the natural history of their disease or due to the side effects of the medications used. We propose to carry out this study.

Methods: Retrospective study aimed at determining the presence of risk factors in patients over 50 years of age who attend the Rheumatology service of a hospital in Venezuela during a follow-up from January 2010 to December 2020 in order to know these risk factors and thus generate strategies that allow better orienting the care of these patients.

Results: The main group of patients was constituted by the female gender and the ages between 50 and 65 years. The main rheumatological pathology was rheumatoid arthritis, followed by Lupus, Osteoarthritis in 3 place and finally in the last box other entities other than those indicated.

Disclosure of Interests: None declared

REFERENCES:

Disclosure of Interests: None declared

AB1009  EXERCISE IS ASSOCIATED WITH HIGHER BONE MINERAL DENSITY IN PATIENTS WITH POLYMYALGIA RHEUMATICA AND VASCULITIDES

A. Palmowski1, E. Wiebe1, S. Herrmann1, B. Mucic1, F. Buttgereit1, 1Charité - Universitätsmedizin Berlin, Rheumatology and Clinical Immunology, Berlin, Germany

Background: Exercise is an effective non-pharmaceutical intervention for osteoporosis (OP). However, it has not yet been explicitly validated whether it is associated with bone mineral density (BMD) in patients suffering from polymyalgia rheumatica (PMR) and vasculitides.

Objectives: To assess whether exercise is associated with BMD in PMR and vasculitis patients.

Methods: We evaluated baseline visits of patients enrolled in the monocentric, prospective “Rh-GIOP” cohort. Patients were included when having PMR or any kind of vasculitis. Simple and multiple linear regression models with minimum T-score (lumbar spine or hip, whichever was lowest) as the dependant variable were constructed. A dose-response analysis (frequency of exercise per week) was conducted in patients who were doing any kind of exercise. In multiple regression, we adjusted for potential confounders associated with minimum T-scores in an analysis of the overall cohort (manuscript in preparation): age, sex, menopause, body mass index, bisphosphonate use, denosumab use, current glucocorticoid dose, proton-pump inhibitor use, history of vertebral fractures, health assessment questionnaire scores, alkaline phosphatase levels, and gamma-glutamyltransferase levels. Multiple imputation by chained equations was used to handle missing data.

Results: 198 patients were included. The mean age was 68 ± 11 years, 68% were females, and the most common diseases were PMR (36%), giant cell arteritis (26%), and granulomatosis with polyangiitis (17%). The mean minimum T-score was -1.74 ± 0.9. Five patients had a disease duration of less than three months. In both unadjusted (Figure 1) and adjusted analysis, exercise was positively associated with minimum T-scores (unadjusted: β = 0.36; 95% CI 0.09 to 0.63; p = 0.01; adjusted: β = 0.30; 0.04 to 0.56; p = 0.02). In exercising patients, there was no association between frequency and minimum T-scores (p(ANOVA) = 0.66).

Conclusion: In PMR and vasculitis, exercise is positively associated with BMD. We adjusted for several covariates, including health assessment questionnaire scores, so it is unlikely that the association between exercise and BMD is only caused because generally healthier patients have a higher likelihood of exercising. However, we found no dose-response relationship by looking at exercise frequency. This is probably due to confounding caused by different kinds of exercises. E.g., weight-bearing exercise is thought to be more effective in elevating BMD. Furthermore, our analysis might have been underpowered (too few patients) to assess differences within the group of exercising patients. Our findings underpin the general advice given to most patients suffering from low bone mass or OP irrespective of their underlying disease, which is to start or to continue exercising within the scope of personal possibilities. Of note, this study is of cross-sectional nature and must be interpreted accordingly as residual confounding cannot be fully ruled out. We plan for the future longitudinal analyses.

Disclosure of Interests: Andriko Palmowski: None declared, Edgar Wiebe Grant/research support from: Travel expenses from Medac, Sandra Herrmann Paid instructor for: Lecture fees from AbbVie, Burkhard Muche Speakers bureau: consultancy or speaker fees and/or conference expenses from Amgen, Gilead, Galapagos, UCB and Stadapharm, Paid instructor for: consultancy or speaker fees and/or conference expenses from Amgen, Biogen, BMS, Chugai, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.

Disclosure of Interests: Edgar Wiebe Grant/research support from: Travel expenses from Medac, Sandra Herrmann Paid instructor for: Lecture fees from AbbVie, Burkhard Muche Speakers bureau: consultancy or speaker fees and/or conference expenses from Amgen, Gilead, Galapagos, UCB and Stadapharm, Paid instructor for: consultancy or speaker fees and/or conference expenses from Amgen, BMS, Chugai, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.

Acknowledgements: Funding Rh-GIOP is supported by a joint funding from Amgen, Biogen, BMS, Chugai, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche and Sanofi.
Background: Rheumatoid Arthritis (RA) is a long-term inflammatory disorder affecting the joints. It is associated with osteoporosis, possibly linked to inflammation around affected joints and glucocorticoid medication. To our knowledge, longitudinal analysis of a UK based cohort of patients with RA has not been carried out. The impact of average tissue thickness on bone mineral density (BMD) has not been studied longitudinally in RA.

Objectives: This study aimed to identify factors that affect the rate of BMD change in patients with RA in a UK based cohort.

Methods: RA patients referred for multiple routine DEXA scans at the Royal Lancaster Infirmary from 2004-2019 were studied. Demographic and physical data such as sex, weight and height were collected. BMD in grams/centimetre² and average tissue thickness were collected from DEXA images of the left and right hip (femoral neck and total femur), and the spine (L1-L4). BMD was modelled at the region of the hip and spine using mixed-effects linear models. Age, sex, average tissue thickness and weight were used as explanatory variables.

Results: 1135 scans from 496 patients (80.4% female) with more than one scan were included, mean age was 64.1 (standard deviation 12.5). Fixed effect size and confidence intervals for each variable are shown in the Table 1. Female sex had a negative fixed effect at the hip but no significant effect on BMD change at the spine. Average tissue thickness had a significant positive fixed effect at the hip but no significant effect at the spine.

Conclusion: This study demonstrates that in RA patients, sex is associated with an increased rate of BMD loss at the hip but not at the spine. It also shows that weight and average tissue thickness are associated with lower BMD loss over time. This could be due to increased inflammation at the hip compared to the left and right hip, and no significant effect at the spine. Weight showed a significant positive fixed effect with BMD at the hip but no significant effect at the spine.

Disclosure of Interests: None declared


Table 1

<table>
<thead>
<tr>
<th>Location</th>
<th>Sex</th>
<th>Weight</th>
<th>Average Tissue Thickness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Left femur</td>
<td>-0.104(-0.135,-0.074)*</td>
<td>0.004(0.004,0.005)*</td>
<td>0.022(0.018,0.025)*</td>
</tr>
<tr>
<td>Right femur</td>
<td>-0.088(-0.115,-0.061)*</td>
<td>0.003(0.002,0.003)*</td>
<td>0.015(0.012,0.019)*</td>
</tr>
<tr>
<td>L1</td>
<td>0.06(-0.038,0.036)</td>
<td>0.003(0.002,0.003)</td>
<td>0.016(0.012,0.019)*</td>
</tr>
<tr>
<td>L2</td>
<td>0.007(-0.037,0.05)</td>
<td>0.003(-0.003,0.006)</td>
<td>0.003(-0.003,0.006)</td>
</tr>
<tr>
<td>L3</td>
<td>0.021(-0.022,0.065)</td>
<td>0.001(-0.005,0.002)</td>
<td>0.001(-0.003,0.005)</td>
</tr>
<tr>
<td>L4</td>
<td>0.01(-0.035,0.054)</td>
<td>0.001(-0.003,0.005)</td>
<td>0.001(-0.003,0.005)</td>
</tr>
</tbody>
</table>


AB1011 FACTORS RELATED TO GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRAILITY FRACETURES IN YOUTH SUBJECTS.


1Hospital Clinic, University of Barcelona, Metabolic Bone Diseases Unit, Department of Rheumatology, Barcelona, Spain; 2University of Barcelona, Biostatistics, Department of Basic Clinical Practice, Barcelona, Spain; 3University of Barcelona,., Barcelona, Spain; 4Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Vascularis Research Unit, Department of Autoimmune Diseases, Barcelona, Spain; 5Hospital Clinic, University of Barcelona, Department of Nuclear Medicine, Barcelona, Spain

Background: Glucocorticoid (GC) treatment is the most frequent cause of osteoporosis (OP) in young subjects. However, the factors related to the development of glucocorticoid-induced osteoporosis (GIOP) and fragility fractures (FF), and consequently, the therapeutic approach to GIOP in young populations is not well established.

Objectives: Analyze the prevalence of GIOP and FF in GC-treated patients and compare the risk factors related to their development according to age (< and ≥50 years).

Methods: 127 patients (62±18 years) receiving chronic GC treatment were included (<5mg/day of prednisone, >3 months). The clinical data collected included: dose and duration of GC treatment, disease activity, previous FF, anthropometric data, bone metabolism parameters (including bone turnover markers and the presence of hypogonadism), bone mineral density (BMD) by DXA; defining densitometric OP: T-score ≤-2.5 or Z-score ≤-2, depending on the age of the patient), trabecular bone score (by DXA), and vertebral fractures (X-ray). GIOP was defined as densitometric OP and/or FF. Results were compared between subjects < and ≥50 years old.

Results: The prevalence of GIOP was similar in both age groups: <50 (n=36) 44.4% vs. 46.1% ≥50 years (n=91). Four subjects <50 (13.8%) and 30 ≥50 (33%) presented FF (p=0.05). Young subjects with FF tended to be >40 years, have a higher body mass index (BMI) (25.4 vs. 23.3, p=n.s.), and higher inflammatory disease activity (CRP 0.90 vs. 0.06mg/dL, p=0.06). When analyzing the different risk factors related to FF depending on age, a higher body mass index (BMI) (29.63 vs. 26.95, p=0.04) and inflammatory disease activity (PCR -0.87 vs. -2.51 [log scale], p=0.03) were observed in young subjects, while low lumbar T-scores (-1.08 vs. -0.06, p=0.003) and higher cumulative GC-doses (9.11 vs. 8.56, p=0.03) were differential factors in subjects over 50. Hypogonadism was a risk factor independent of age (OR 4.89, 95%CI 1.36-17.39), being associated with the presence of FF in both age groups.

Conclusion: More than 40% of the patients receiving GC developed GIOP; with a similar prevalence in both age groups (< and ≥50 years); however, FF are less common in young subjects. Hypogonadism is a determining risk factor for FF independent of age. In addition, young subjects with FF tend to be older, with a higher BMI and disease activity, and, thus, evaluation of these risk factors can improve the identification of subjects at increased risk of fracture.

Disclosure of Interests: None declared

AB1013

SCHOOL FOR DOCTORS ON THE PROBLEM OF OSTEOPOROSIS - "START WITH YOURSELF"

V. Polyakova1, L. Seewordova1. 1Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovsky», Treatment and Prevention of Joint Disease Laboratory, Volgograd, Russian Federation

Background: Observing in practice the attitude of the medical community to the problem of OP, we decided to conduct a course of training lectures for doctors within the framework of the program “Start with yourself” on the basics of diagnosis and treatment of this disease. After the lecture material, the fracture risk was calculated using the FRAX (Fracture Risk Assessment Tool) in the audience before and after the two-energy X-ray absorptiometry (DXA). If necessary, additional examination and treatment were prescribed.

Objectives: To evaluate the frequency of decrease in bone mineral density in doctors, to raise awareness about the frequency of decrease in bone mineral density (BMD), to assess the attitude to therapy.

Methods: The risk of fractures according to FRAX was calculated for doctors of therapeutic specialties, DXA was performed at the Center for Osteoporosis of the A.B. Zborovsky Research Institute of KIER, Volgograd. Bone mineral density (BMD) was determined on the Lunar DPX (GE) apparatus.

Results: The average age of 59 trainees was 54 ± 10.55 (M±σ) years, 36 women were aged 50 years and older, 23 were under the age of 50, the average body mass index (√BMI) was 26.51 ± 4.8 kg/m². 47 (79.6%) of 59 showed a decrease in bone mineral density (BMD) below the norm (according to the T/Z criterion, according to age) in at least two positions. 15 (25.4%) of them showed a decrease in BMD according to the T criterion by -2.5 SD or lower, which corresponds to the diagnosis of "Osteoporosis". Of these 15 people, 9 had previously undergone DXA, were diagnosed with OP, and drug therapy was prescribed. Only 3 students are constantly taking medications.

Background: Osteoporosis consists in the reduction of bone mineral density and increased fracture risk. Age is a risk factor for osteoporosis. Although many treatments are available in osteoporosis, there is limited data regarding their efficacy in older people.

Objectives: We aimed to evaluate the efficacy of osteoporosis treatments in patients over 75 years old.

Methods: We reviewed all published studies in MEDLINE, COCHRANE and EMBASE including patients over 75-year-old treated by osteoporosis drugs and focused on vertebral fractures or hip fractures.

Results: We identified 4393 records for review. 4216 were excluded after title/abstract review. After full text review, 19 records were included in systematic review. Most of the studies showed a reduction of vertebral fracture with osteoporosis treatments but non-significant results were observed for hip fractures. Meta-analysis of 10 studies showed that osteoporosis treatments significantly reduced the occurrence of vertebral fractures at one (OR=3.67; 95%CI=2.50-5.38) and three years (OR=2.19; 95%CI=1.44-3.34) as well as those of hip fractures at one (OR=2.68; 95%CI=1.09-6.29) and last 2-3 years (OR=1.31; 95%CI=1.12-1.53).

Conclusion: Osteoporotic treatments showed to be effective in the reduction of vertebral and hip fractures in older people. However, majority of data derived from post hoc and pre-planned analyses or observational studies.

Disclosure of Interests: None declared

TABLE 1 Percentage BMD changes

<table>
<thead>
<tr>
<th>BMD trend (n=25)</th>
<th>sp BMD (LSC – 2.6%)</th>
<th>hip BMD (LSC – 3.6%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>a-b BMD</td>
<td>5.22%</td>
<td>4.13%</td>
</tr>
<tr>
<td>b-c BMD</td>
<td>5.39%</td>
<td>2.93%</td>
</tr>
</tbody>
</table>

sp BMD - Mean of L2, L3 & L4 Spine BMD, hip BMD - Mean of Right and Left Hip BMD, a-b BMD - Percent change in BMD from before treatment to 6 months of PTH & Dmab, b-c BMD - Percent change in BMD from before 6 months of PTH & Dmab to next 6 months Dmab alone and LSC – Least significant change from a single DXA machine.

Conclusion: These findings suggest that a short term combination of Dmab and PTH for 6 months followed by Dmab alone shows sustained synergistic effect on the BMD trend which was more profound in the spine than the hip. This would help in judicious and cost effective utilisation of the limited period of PTH use.

REFERENCES:
[2] Shepherd JAJ, Lu Y. A generalized least significant change for individuals measured on different DXA systems.

Disclosure of Interests: None declared.

Objective: This study investigated the efficacy of a 12-month ROMO treatment in patients with OP and explored the efficacy predictors of increased BMD.

Methods: Our study included 52 patients with OP, who were started on ROMO treatment between June 2019 and August 2020. The following information was collected: 1) baseline characteristics, 2) time-course of BMD (lumbar spine [LS] and total hip [TH]) and bone turnover markers (BTM; bone-specific alkaline phosphatase [BAP], type I procollagen-N-propeptide [P1NP], type I procollagen-N-propeptide [NTX], and tartrate-resistant acid phosphatase-5b [TRACP-5b]).

Results: 1) The mean age of the participants was 72.9 years (48 female and four male). Of the 52 understudied patients, 78.8% had past insufficiency fractures, whereas 21.2% had been treated with concomitant prednisolone. Furthermore, 21 patients had primary OP, 20 had rheumatoid arthritis, nine had glucocorticoid-induced OP, and two had other conditions. Pretreatments for OP were bisphosphonate (33 patients), vitamin D (6), none (5), selective estrogen receptor modulator (4), and denosumab (3). 2) Both mean LS- and TH-BMD significantly increased in the patients for whom ROMO administration was continued for 12 months. The average percentage changes of LS- and TH-BMD were 7.1% and 1.6% at six months and 11.7% and 3.0% at 12 months, respectively (Figure 1). However, BAP and P1NP increased steeply at one month, followed by a gradual decrease. As observed, the average percentage changes of BAP and P1NP were +70.1% and +166.8% at one month, +50.3% and +91.7% at six months, and +24.4% and +41.5% at 12 months, respectively. The results also showed that TRACP-5b decreased from one to 12 months, with the average percentage changes being −22.9% at one month, −13.8% at six months, and −17.7% at 12 months. Moreover, NTX, a bone-resorptive marker, was slightly increased during ROMO treatment. 3) Multiple regression analysis results revealed that the baseline BAP and percentage calcium changes at 12 months were significant factors positively correlated with the percentage change of LS-BMD at 12 months. As observed, the baseline T-score of LS-BMD was a significant factor negatively correlated with the percentage change of LS-BMD at 12 months. The standardized partial regression coefficient values were +0.68, +0.28, and −0.40, respectively. Moreover, the multiple regression analysis results revealed no significant factor that was correlated with the percentage changes of TH-BMD at 12 months.
Objectives: The aim of this study was to compare the performance of the REMS BMD assessment with dual-energy X-rays absorptiometry (DXA) in a cohort of patients affected by end-stage renal disease undergoing peritoneal dialysis (PD).

Methods: Consecutive patients referring to the PD clinic of our hospital were enrolled. Lumbar spine and proximal femur REMS scans were performed, and lumbar spine (anteroposterior and laterolateral) and proximal femur DXA scans were performed as well. Clinical data were extracted from medical records. The risk assessment outputs of two fracture risk algorithms (FRAX and DeFRA), calculated upon the worst BMD obtained from either technique were compared as well. Analysis of variance (ANOVA) with post hoc analysis (Bonferroni) and a two-sided Student’s t-test were used to estimate the absolute differences between groups. Written informed consent was obtained from all participants included (protocol 1483 CESC).

Results: 41 total patients were enrolled (Table 1). No significant differences were documented between the BMD T-scores measured through DXA or REMS at the proximal femur. At the lumbar spine, the DXA laterolateral T-score was not significantly different from that of REMS, while the DXA anteroposterior T-score was significantly higher than both the anteroposterior DXA and the REMS measurements (Figure 1, panel A and B). When either DXA or REMS was adopted, no significant difference in the fracture risk estimate was found for both algorithms (Figure 1, panel C and D).

Table 1. anthropometrics, clinical and biochemical characteristics of the enrolled sample. CKD, chronic kidney disease; PTH, parathyroid hormone; ALP, alkaline phosphatase; IQR, interquartile range; VFA, vertebral fracture assessment.

<table>
<thead>
<tr>
<th>Sample size (M)</th>
<th>41 (29)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>Median [IQR] 62 [52-73]</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>Median [IQR] 170 [165-176]</td>
</tr>
<tr>
<td>Body weight (Kg)</td>
<td>Median [IQR] 74 [61-83]</td>
</tr>
<tr>
<td>Body mass index (Kg/m²)</td>
<td>Median [IQR] 25 [22-27.8]</td>
</tr>
<tr>
<td>Disease duration – CKD (months)</td>
<td>Median [IQR] 132 [48-140]</td>
</tr>
<tr>
<td>Dialysis duration (months)</td>
<td>Median [IQR] 10 [3-24]</td>
</tr>
<tr>
<td>Median [IQR] 8.6 [6-9.4]</td>
<td></td>
</tr>
<tr>
<td>Median [IQR] 5.4 [4.6-6.4]</td>
<td></td>
</tr>
<tr>
<td>Median [IQR] 31.4 [22.8-46.8]</td>
<td></td>
</tr>
<tr>
<td>25OH Vitamin D (nmol/L)</td>
<td>Median [IQR] 53 [36-72]</td>
</tr>
<tr>
<td>Patients with morphometric fractures (VFA)</td>
<td>15%</td>
</tr>
<tr>
<td>Patients with femoral fractures</td>
<td>2.4%</td>
</tr>
<tr>
<td>Total n° of morphometric fractures</td>
<td>12</td>
</tr>
</tbody>
</table>

Figure 1. comparison of the mean T-scores (error bars represent 95%CI) measured with DXA and REMS at the lumbar spine (panel A), and at the femur (panel B). Comparison between the DeFRA DXA and REMS-derived outputs (panel C) and FRAX DXA and REMS-derived outputs (panel D) raw and after correction for TBS. DeFRA, Fracture Risk Assessment tool; FRAX, Fracture Risk Assessment tool; AP, anteroposterior; LL, latero-lateral; TH, total hip; FN, femoral neck; TBS, trabecular bone score.

Conclusion: Our data showed a good agreement, in a real-life PD setting, between the DXA and REMS-derived BMDs and in the consequent fracture risk assessment obtained with the FRAX or DeFRA tools.


AB1018 RELATIONSHIP BETWEEN AORTIC CALCIFICATIONS AND DXA AND RADIOFREQUENCY ECHOCOGRAPHIC MULTI-SPECTROMETRY (REMS) ACQUISITIONS

A. Fassio1, S. Andreola1, D. Gatti1, M. Gatti1, G. Gambaro2, O. Viapiana1, V. Messina1, G. Zanetti1, F. Pistillo1, M. Rossini1, G. Adam1, 1University of Verona, Rheumatology Unit, Verona, Italy; 2University of Verona, Nephrology Unit, 37134, Italy

Background: Data on the relationship between peritoneal dialysis (PD), BMD and aortic calcifications (AOC) are lacking.

Objectives: to study the relationship between the degree of AOC and DXA and Radiofrequency Echographic Multi-Spectrometry (REMS) acquisitions.

Methods: Consecutive patients referring to the PD our clinic were enrolled. Lumbar spine (LS) and proximal femur REMS scans were performed, and LS (anteroposterior and laterolateral) and proximal femur DXA scans were performed as well. The degree of AOC was assessed through the semiquantitative score described by Kauppila et al, and applied to the laterolateral LS DXA scans. To test for correlations between different variables, we used the Pearson’s correlation for continuous variables and Spearman’s rho for discrete variables. Multiple regression analysis was performed to adjust for age and body mass index (BMI) the correlation between BMD and the CKD duration. Written informed consent was obtained from all participants (protocol 1483 CESC).

Results: 41 total patients were enrolled (29 males, 19 females). Median disease duration of CKD [IQR]: 132 months [48-140]. 15% had vertebral fractures at the lumbar spine (anteroposterior and laterolateral) and proximal femur DXA scans were performed as well. The degree of AOC was assessed through the semiquantitative score described by Kauppila et al, and applied to the laterolateral LS DXA scans. To test for correlations between different variables, we used the Pearson’s correlation for continuous variables and Spearman’s rho for discrete variables. Multiple regression analysis was performed to adjust for age and body mass index (BMI) the correlation between BMD and the CKD duration. Written informed consent was obtained from all participants (protocol 1483 CESC).

Conclusion: Our data showed a good agreement, in a real-life PD setting, between the DXA and REMS-derived BMDs and in the consequent fracture risk assessment obtained with the FRAX or DeFRA tools.


**Conclusion:** Our study confirmed that the overestimation of DXA BMD assessed with the anteroposterior scan is indeed influenced by AOC. Furthermore, our data suggest that REMS might be an interesting tool for the investigation of bone changes in CKD.

**Disclosure of Interests:** Angelo Fassio: None declared, Stefano Andreola: None declared, Davide Gatti Speakers bureau: Amgen, Celgene El-Lilly, MSD-ITALIA, Origanon, UCB, Matteo Gatt: None declared, Giovanni Gambarelli Speakers bureau: Vitor Pharma, Ombretta Viapiana: None declared, Valerio Messina: None declared, Giulia Zanetti: None declared, Francesca Pistillo: None declared, Maurizio Rossini: Speakers bureau: Abiogen, Amgen, Abbvie, BMS, Celgene, El-Lilly, Galapagos, Grunenthal, MSD, Novartis, Pfizer, Sanofi, Sanoz, Theraxem, UCB, Giovanni Adami: None declared. DOI: 10.1136/annrheumdis-2022-eular.2237

**REFERENCES:**


**Method:**

- **Background:** The effect of cholecalciferol supplementation on the regulation of inflammatory cytokines is still unclear.
- **Objectives:** This is a preliminary analysis on exploratory outcomes the DIBA/11 RCT [1,2] and aimed to compare the effects on serum inflammatory cytokines of three different regimes of cholecalciferol supplementation in vitamin D deficient subjects.
- **Methods:** We evaluated, in healthy subjects affected by vitamin D deficiency (defined as 25OHD<20ng/mL), 16 to 60 years of age, the efficacy of three different oral supplementation regimens: daily 10,000iu administered for 8 weeks (group A), weekly 50,000iu (group B) for 12 weeks and biweekly 100,000iu (group C) for 12 weeks. Serum TNFα, interleukin-6 (IL6), interleukin-17 (IL17) and interleukin-10 (IL10) were assessed. The study was approved by the institutional review committee (protocol identification: DIBA/11, EuDrAC Number:2017-000198-36). Supported by Abiogen Pharma, Italy.

**Results:** A total of 75 subjects were randomized to receive one supplementation regimen. The descriptive of the sample at baseline and relative cytokines levels at each site after adjustment for age and BMI, BMI, body mass index; β, standardised coefficient.

**Table 1.** Anthropometric and laboratory parameters at baseline (mean values ± standard deviation)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>All patients</th>
<th>Daily 10,000 IU</th>
<th>Weekly 50,000 IU</th>
<th>Bimonthly 100,000 IU</th>
<th>p-value (ANOVA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>34.1 ± 10.2</td>
<td>30.2 ± 9.9</td>
<td>36.7 ± 8.7</td>
<td>35.4 ± 11.0</td>
<td>0.059</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td>66.7 ± 12.4</td>
<td>65.8 ± 13.2</td>
<td>67.8 ± 10.8</td>
<td>66.6 ± 13.7</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>23.1 ± 2.6</td>
<td>23.5 ± 2.7</td>
<td>23.8 ± 2.2</td>
<td>22.8 ± 2.7</td>
<td></td>
</tr>
<tr>
<td>Baseline 25OHD (ng/mL)</td>
<td>13.5 ± 3.7</td>
<td>14.6 ± 3.9</td>
<td>12.8 ± 3</td>
<td>13.5 ± 4.1</td>
<td></td>
</tr>
<tr>
<td>Baseline IL-6 (pg/mL)</td>
<td>1.3 ± 1.2</td>
<td>0.9 ± 0.6</td>
<td>1.4 ± 1.6</td>
<td>1.6 ± 1.3</td>
<td></td>
</tr>
<tr>
<td>Baseline IL-17 (pg/mL)</td>
<td>0.4 ± 0.8</td>
<td>0.7 ± 0.3</td>
<td>0.2 ± 1.1</td>
<td>0.2 ± 0.7</td>
<td></td>
</tr>
<tr>
<td>Baseline IL-10 (pg/mL)</td>
<td>0.9 ± 0.9</td>
<td>0.8 ± 0.7</td>
<td>1.2 ± 1.2</td>
<td>0.8 ± 0.7</td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** In the overall cohort we found slight decreases in serum IL6 and IL17 serum levels. No differences were found among groups.

**Disclosure of Interests:** Angelo Fassio: None declared, Davide Gatti Speakers bureau: Amgen, Celgene El-Lilly, MSD-ITALIA, Origanon, UCB, Matteo Gatt: None declared, Giovanni Gambarelli Speakers bureau: Vitor Pharma, Ombretta Viapiana: None declared, Valerio Messina: None declared, Giulia Zanetti: None declared, Francesca Pistillo: None declared, Maurizio Rossini: Speakers bureau: Abiogen, Amgen, Abbvie, BMS, Celgene, El-Lilly, Galapagos, Grunenthal, MSD, Novartis, Pfizer, Sanofi, Sanoz, Theraxem, UCB, Giovanni Adami: None declared. DOI: 10.1136/annrheumdis-2022-eular.22316

**REFERENCES:**


**Methods:** This is a descriptive and analytical retrospective study of 126 osteoporotic patients with breast cancer under aromatase-inhibitors, collected during a period of 4 years (2017 to 2021). Statistical data analysis was performed using SPSS version 20 software. The bivariate study was performed by ANOVA test.

**Results:** All the patients were treated for breast cancer and received systemic hormone-modulating anti- aromatase type therapy. All the patients had densitometric osteoporosis confirmed by a T score < −2.5, of which 31.7% had a T score < −3.5. The average age was 62.29 (40−92) years. 16% had an osteoporosis family history and 0.8% had an osteoporosis's fracture family history, 77% had a personal history of fracture. 54.8% were overweight, 14.3% had a metastasis. 88.1% had insufficient vitamin D levels (<20 ng/L). 15.9% had high blood pressure. The average duration of anti-osteoporotic treatment was 2.31 years. 77% of patients were on Residronate, 8.7% on Zoledronate, and 14.3% on Alendronate. The study of bone gain involved osteoporotic patients with breast cancer under aromatase-inhibitors and to evaluate the factors associated with bone gain in this population.

**Background:** Breast cancer is the first female cancer, especially after meno-pause. In Morocco its prevalence is estimated at 35.8%. Its hormone-dependent aspect requires the use of hormone-modulating treatments, in particular aromatase-inhibitors responsible for hypogonadism, bone loss and osteoporosis (OP) with increased fracture risk.

**Objectives:** The aim of this study is to determine the epidemiological, clinical and densitometric profile of osteoporotic patients with breast cancer under aromatase-inhibitors and to evaluate the factors associated with bone gain in this population.

**Methods:** This is a descriptive and analytical retrospective study of 126 osteoporotic patients with breast cancer under aromatase-inhibitors, collected during a period of 4 years (2017 to 2021). Statistical data analysis was performed using SPSS version 20 software. The bivariate study was performed by ANOVA test.
Table 2. Characteristics of Fragility Fracture in four patients with Systemic Mastocytosis.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Gender</th>
<th>Localization of FF</th>
<th>Severity of Fracture</th>
<th>Time to fracture diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>65</td>
<td>Male</td>
<td>D6,D8,D10,D11,L1</td>
<td>3 Mild</td>
<td>2 years prior SM diagnosis</td>
</tr>
<tr>
<td>2</td>
<td>81</td>
<td>Female</td>
<td>D4,D6,D12,L1</td>
<td>2 Moderate</td>
<td>2 years after SM diagnosis</td>
</tr>
<tr>
<td>3</td>
<td>65</td>
<td>Female</td>
<td>D4,D11</td>
<td>3 Severe</td>
<td>2 years prior SM diagnosis</td>
</tr>
<tr>
<td>4</td>
<td>42</td>
<td>Male</td>
<td>D7,D8,D9,D11,D12,L1,L2,L3,L5</td>
<td>3 Mild</td>
<td>At time of SM diagnosis</td>
</tr>
</tbody>
</table>

Conclusion: Twenty-five percent of patients present FF (multiple, located in dor-sal spine, and without densitometric diagnosis of OP). SM should always be considered in differential diagnosis in the presence of FF, especially in men with no OP or another risk factor associated.

REFERENCES:

Disclosure of Interests: None declared

Table 1

<table>
<thead>
<tr>
<th>Population (N = 17)</th>
<th>Without fragility fracture (N = 13)</th>
<th>With fragility fracture (N=4)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male, n (%)</td>
<td>9 (53%)</td>
<td>7 (54%)</td>
<td>0.89</td>
</tr>
<tr>
<td>Age at first symptoms, years, mean (SD)</td>
<td>37.6 (21.1)</td>
<td>33.0 (20.2)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Discorl of Interests: None declared
among which 12% were previously unknown and in women who were fully symptom-free. The vertebral fractures were mainly located at the dorsal-lumbar region; the L1 and T11 vertebrae were fractured in 3 patients and the T12 vertebra in 3 patients.

Conclusion: Our study showed that nearly half of patients with BMD-objecfied osteoporosis had a VF detected on standard X-rays, most of which were previously unknown. It is plausible to speculate the place of this method combining BMD with spinal X-rays in the diagnosis of asymptomatic VFs.

REFERENCES:

Disclosure of Interests: None declared


AB1023
CHARACTERISTICS OF PATIENTS REFERRED FOR FIRST BONE DENSITOMETRY TO A RHEUMATOLOGY FLS, WITH NORMAL RESULTS IN THE LUMBAR SPINE

J. Rosas1, J. C. Fortés-Quiróz2, C. Raya-Santos3, C. Cano7, A. Pons7, M. Lorente Betoret4, J. M. Senabre-Gallego5, G. Santos Soler6, J. A. Bertran4, X. Barber1, J. A. García-Gómez7on behalf of AIRE-MB. 1Hospital Marina Baixa, Rheumatology, 03570, Spain; 2Hospital Marina Baixa, Rheumatology; Villajoyosa, Spain; 3Hospital Marina Baixa, Rheumatology; Villajoyosa, Alicante, Spain; 4Hospital Marina Baixa, Rheumatology, Villajoyosa, Spain; 5 Miguel Hernández University, CIO, Elche, Spain; 6Miguel Hernández University, CIO, Elche, Spain

Objectives: To analyze the characteristics of postmenopausal women referred for the first bone densitometry (BMD), with normal results in the lumbar spine.

Methods: Retrospective study of postmenopausal women, for a first BMD, at a rheumatology FLS, during February/2010-December/2021. General patient data (age, gender), osteoporosis (OP) risk factors were collected: age at menopause, parental hip fracture, body mass index (BMI), smoking and alcohol habit, drugs and potentially osteopenizing diseases, low-impact fractures in adulthood (fractures of osteoporotic origin included: vertebral, hip, humeral head and distal radius and pelvis), current treatment for OP and FRAX index.

Results: 2,930 postmenopausal women with normal lumbar BMD are included: 505 (17%) had suffered an OP fracture: mean age (SD): 63.2 years (8.5) and of menopause 48 years (10). Among the OP risk factors: early menopause: 814 (28) years; osteopenic, n (%) 247 (49); 734 (30); among osteopenia: OP fracture: 47 (2%); hip: 47 (2%). 808 (28%) patients were receiving treatment for OP: oral bisphosphonates: 518 (18%), SERM: 136 (5%), strontium ranelate 75 (3%) 20 (4%) 55 (2%) 1; humeral head: 46 (2%) and hip: 47 (2%).

The group with OP fractures, are significantly (Table 1): older (p<0.0001), with lower mean age of menopause (p=0.0001), receive more treatment (p=0.0001), especially oral bisphosphonates (p=0.02), have worse results in hip BMD (p<0.0001), with a higher percentage of osteopenia (50% vs 30%, p=0.0001) and worse result in FRAX of major fracture (p<0.0001) and of hip (p=0.001).

Conclusion: Among the patients referred to BMD, although the result of lumbar spine is normal, 17% have suffered an OP fracture, presenting this group: 1) Older age, 2) Osteopenia in hip BMD 50%, with high risk of fracture due to FRAX and they followed treatment for OP, especially oral bisphosphonates. 3) It is advisable to simultaneously perform BMD at the lumbar and hip levels, especially in older subjects.

Acknowledgements: The study was supported by a research grant from the Marina Baixa Association for Research in Rheumatology (AIRE-MB).

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3297

AB1024
SECONDARY PREVENTION OF VERTEBRAL FRACTURES SUSTAINED EFFICACY OVER TIME

J. E. Oller Rodríguez1, E. Grau García2, S. Leal Rodriguez3, P. Muñoz Martínez4, L. Mas Sánchez5, C. Riesco Barcena6, A. V. Huaylla Quispe7, C. Pávez Perales1, J. C. Cortés-Quiroz1, C. Raya-Santos3, C. Cano7, A. Pons7, M. Lorente Betoret4, J. M. Senabre-Gallego5, G. Santos Soler6, J. A. Bertran4, X. Barber1, J. A. García-Gómez7on behalf of AIRE-MB. 1Hospital Marina Baixa, Rheumatology, Villajoyosa, Spain; 2Hospital Marina Baixa, Rheumatology; Villajoyosa, Spain; 3Hospital Marina Baixa, Rheumatology; Villajoyosa, Alicante, Spain; 4Hospital Marina Baixa, Rheumatology, Villajoyosa, Spain; 5 Miguel Hernández University, CIO, Elche, Spain; 6Miguel Hernández University, CIO, Elche, Spain

Background: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral fracture. Despite the availability of different drugs for secondary prevention, there are few comparative studies in real clinical practice.

Objectives: Our aim is to evaluate the appearance of new vertebral fractures depending on the strategy chosen as secondary prevention.

Methods: We performed a retrospective descriptive study with patients who had suffered their first vertebral fracture between 2010 and 2018, in whom we checked the subsequent appearance of new vertebral fractures.

We selected only those patients who had completed a minimum of 18 months of secondary prevention with antiresorptive drugs, or a sequential scheme (anabolic treatment followed by at least 1 year with an antiresorative drug). Those patients who had presented new fractures in the first 6 months of treatment were excluded. Finally, we adjusted efficacy by treatment time.

Results: A total of 452 patients were included, out of an initial baseline pool of 1,184 patients. We found female predominance (83%) of the total. The mean age of the first vertebral fracture was 69.2 years, with a mean latency to fracture of 51.4 months. A new vertebral fracture happened in 4.7% of these patients. The different secondary prevention strategies were classified according to the different therapeutic options, as we can see in Table 1.

Table 1. Characteristics of patients with normal lumbar spine BMD.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Patients (%)</th>
<th>New fractures (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denosumab</td>
<td>206 (45.35%)</td>
<td>10 (4.87%)</td>
</tr>
<tr>
<td>Oral bisphosphonate</td>
<td>75 (16.59%)</td>
<td>5 (6.66%)</td>
</tr>
</tbody>
</table>

No statistically significant differences between different treatments were observed, but we found a lower probability of a new fracture in patients treated with sequential treatment with teriparatide followed by denosumab. Finally, the Kaplann-Meier survival analysis showed a lower probability per year of new fractures in patients treated with teriparatide followed by denosumab, being this probability greater in patients treated with teriparatide followed by oral bisphosphonate.

Conclusion: A lower probability of refraction was observed in patients who received sequential treatment with teriparatide followed by denosumab.

Disclosure of Interests: None declared


AB1025
TRABECULAR BONE SCORE IN PATIENTS WITH AXIAL-SPIDONYLARTHROPATHY

M. Daflaoui1, H. Azzouzi1, H. Boultabi1, E. Chernou1, L. Linde1, I. Mohamed1 University, Rheumatology Department, Oujda, Morocco

Background: In axial spondyloarthritis, the bone mineral density (BMD) is usually overestimated due to syndesmophytes. Hence, the trabecular bone score

Table 1. Characteristics of patients with normal lumbar spine BMD.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Patients (%)</th>
<th>New fractures (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denosumab</td>
<td>206 (45.35%)</td>
<td>10 (4.87%)</td>
</tr>
<tr>
<td>Oral bisphosphonate</td>
<td>75 (16.59%)</td>
<td>5 (6.66%)</td>
</tr>
</tbody>
</table>

No statistically significant differences between different treatments were observed, but we found a lower probability of a new fracture in patients treated with sequential treatment with teriparatide followed by denosumab. Finally, the Kaplann-Meier survival analysis showed a lower probability per year of new fractures in patients treated with teriparatide followed by denosumab, being this probability greater in patients treated with teriparatide followed by oral bisphosphonate.

Conclusion: A lower probability of refraction was observed in patients who received sequential treatment with teriparatide followed by denosumab.

Disclosure of Interests: None declared

ty-nine patients (56.5 %) had osteoporosis. Nine patients (13%) had moderate to severe VFs with predominance at the thoracic spine (77.8%). There was a negative correlation between MOF-FRAX score and lumbar spine BMD ($r = -0.473; p < 0.001$), and also hip BMD ($r = -0.530; p < 0.001$), while there was no correlation between MOF-FRAX score, HF-FRAX and TBS. The areas under curves were $0.824$, $0.800$, $0.792$, and $0.443$ for the FRAX-MOF score with BMD, FRAX-MOF score, FRAX-MOF score adjusted for TBS, and TBS, respectively.

Conclusion: In this study, MOF-FRAX score showed a better correlation with BMD than TBS. It was also superior to TBS and adjusted FRAX in identifying prevalent VFs in RA patients.

Disclosure of Interests: None declared


AB1027  CLINICAL EFFICACY OF SEQUENTIAL TREATMENT AFTER ROMOSOZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS FOR 18 MONTHS

Y. Kanayama1, 2, Toyota Kosei Hospital, Orthopedic Surgery and Rheumatology, Toyota, Japan

Background: Romosozumab (ROMO), a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. And although it is a novel therapeutic agent for osteoporosis, which has shown high effects of increasing bone density and inhibiting fragile fracture in overseas clinical trials. However the clinical efficacy for rheumatoid arthritis complicated with osteoporosis (RA-OP) is unknown.

Objectives: To evaluate the clinical efficacy of ROMO for 12 months and denosumab (DMB) 6 months in patients with RA-OP for 18 months.

Methods: RA patients diagnosed according to the 2010 ACR/EULAR criteria. All patients met at least one of the following criteria were eligible: a bone mineral density T score of -2.5 or less at the lumbar spine or total hip and either one or more moderate or severe vertebral fractures or two or more mild vertebral fractures. All patients were initiated ROMO from between April, 2019 and March, 2020. The total number of patients was 12 cases. The ROMO dose was 210mg at once every 1 months. After 12 months of ROMO, all cases were changed to DMB. In all cases native or activated vitamin D has been used. We reviewed the results for 12 months about the increase and decrease of bone mineral density (BMD) of lumbar spine (LS) and total hip (TH) by DEXA and bone turnover markers, intact n-terminal propeptide type I procollagen (PINP) and tartrate-resistant acid phosphatase form 5b (TRACP-5b).

Results: He was all female. The mean age was 72.8 ± 7.0; disease duration was 17.7 ± 16.5 years; the body mass index was 19.4 ± 3.1 and the FRAX was 36.0 ± 14.9. Clinical findings related to RA-OP at baseline were as follows; CRP 12.5 ± 17.5; DAS28-CRP 3.45 ± 0.99; HAG 1.56 ± 0.99 and, bone turnover markers and bone mineral density at baseline were as follows; PINP 62.4 ± 36.2; TRACP-5b 485 ± 262; LS-BMD and T-score 0.79 ± 0.14g/cm² and -0.47 ± 0.14g/cm². The rate of increased PINP from baseline to 1, 3, 6, 12 and 18 months were each 116.3 ± 68.7% at 1 month, 135.0 ± 131.3% at 3 month, 126.1 ± 177.0% at 6 month, 83.7 ± 179.1% at 12 month and -45.1 ± 35.7% at 18 month and decreased TRAC-p5b were -13.0 ± 181.4% at 1 month, 6.9 ± 38.6% at 3 month, 20.0 ± 63.4% at 6 month, 14.8 ± 64.5% at 12 month and -11.4 ± 95.9% at 18 month. The rate of increased LS-BMD from baseline to 6, 12 and 18 months were 10.8 ± 8.0%, 15.2 ± 9.5% and 18.9 ± 10.4% and TH-BMD were 4.1 ± 4.5%, 5.7 ± 6.3% and 8.4 ± 8.1% (Figure 1, 2).

Conclusion: Clinical efficacy of treatment with ROMO for 12 months and DMB for 6 months for RA-OP was extremely effective and has the high potential to be an important option in the treatment of RA-OP.
Discrim of Interests: None declared


AB1028  REGRESSIVE BONE MINERAL DENSITY TRENDS SEEN WITH DELAY IN FOLLOW UP OF DENOSUMAB TREATMENT DUE TO THE PANDEMIC INDUCED LOCKDOWN - A SINGLE CENTRE INDIAN EXPERIENCE.

A. K. Aggarwal1, N. Aggarwal2, H. Sharma3, 1Institute of Rheumatology & Pain, Rheumatology, Ghaziabad, India; 2Institute of Rheumatology & Pain, Administration and Research, Ghaziabad, India; 3Institute of Rheumatology & Pain, Pharmacy, Ghaziabad, India

Background: Denosumab (Dmab), a fully human monoclonal antibody that inhibits receptor activator of nuclear factor kappa-β ligand (RANKL), which selectively inhibits osteoclastogenesis can be used for a long period unlike the relatively short period with Teriparatide. However the effects of Dmab can quickly regress if the treatment is delayed.

Objectives: The pandemic led to multiple prolonged lockdowns since March 2020 to Jan 2022 in India. This resulted in follow up Dmab treatment delays. The retrospective study was aimed to look for the effect of the delays.

Methods: A retrospective study was aimed to look for the effect of the delays.

Results: A p>0.05 was considered statistically significant. Table 1 shows the BMD changes.

Conclusion: These findings suggest that regressive trend in BMD are seen when the treatment with Dmab is delayed even as early as 10 to 12 months. It was seen much faster in the spine compared to the hip. It is therefore advised that short term treatment with Dmab without follow up could lead to loss of all gains and may also worsen the osteoporosis.

REFERENCES:
[4] Shepherd JA1, Lu Y. A generalized least significant change for individuals measured on different DXA systems.

Disclosure of Interests: None declared


AB1029  CLINICAL AND RADIOLOGICAL OUTCOMES AFTER VERTEBROPLASTY AND KYPHOPLASTY FOR OSTEOPORTIC VERTEBRAL FRACTURES

A. Ben Tekaya1,2, E. Hannech1,2, M. Bellil2,3, M. Ben Salah2,3. 1Rheumatology Department, Charles Nicolle Hospital, Tunis, Tunisia; 2Faculty of Medicine of Tunis, University Tunis El Manar, Tunisia, Tunisia; 3Orthopedic Department, Charles Nicolle Hospital, Tunis, Tunisia

Background: Vertebral Fractures are among the most frequent osteoporotic fractures. Pain and spinal deformation cause loss of autonomy and predispose to a higher risk of morbidity and mortality. Vertebroplasty and Kyphoplasty are an efficient therapeutic alternative in the management of these fractures [1,2].

Objectives: The aim of our study was to evaluate functional and radiological outcomes of Vertebroplasty and Kyphoplasty for osteoporotic vertebral fractures.

Methods: It was a retrospective study including patients treated with Vertebroplasty or Kyphoplasty for osteoporotic vertebral fractures with no spinal cord injuries. Clinical, functional, and radiological data were collected. Pain assessment was evaluated by the Visual Analogue Scale (VAS) and the Denis pain scale. Oswestry Disability Index (ODI) was used to evaluate the functional impairment. The measurement of the vertebral height pre and postoperatively was assessed by the Beck’s index on the spine lateral X-ray.

Results: There were 36 patients: 26 female and 10 male. The mean age was 65 years (41-74). The follow-up period was about 17 months. The thoracolumbar hinge was the most affected region (70%). Twenty two patients were treated by kyphoplasty and 14 by Vertebroplasty. The mean percentage trend change between a-b, b-c, and c-d BMD was -2.38% and 4.52% in the sp BMD & hip BMD respectively. A p>0.05 was considered statistically significant. Table 1 shows the BMD changes.
mean VAS pain improved from 5.28 preoperatively to 2.92 postoperatively (delta VAS pain was 2.36, p<10^-3). The improvement in the VAS pain was by 3.42 (p<10^-7) in the last follow-up. There was no difference between the two technics regarding the pain improvement (p=0.06). On preoperatively, the mean Denis pain scale was 4. It was 2.19 after kyphoplasty and 2.27 after Vertebroplasty with no significant difference between the two technics (p=0.6). The mean ODI at the last setback was fourteen: 95% of patients had minimal to moderate disability, 5% had severe disability. There was no difference between Kyphoplasty and Vertebroplasty regarding the functional impairment (14.87 vs 12.36, p=0.05). Kyphosis on the level of the fractured vertebra improved from 16.8° preoperatively to 9.5° postoperatively with a significantly mean reduction of 7.3° (p<10^-3).

Regional kyphosis improved from 12.1° to 7.4° with a significantly mean reduction of 4.3° (p<10^-7). Beck’s index went up from 0.66 to 0.8 post-operatively (p=0.05). The improvement of kyphosis on the level of the fractured vertebra (angular gain) was more important for the group treated with Kyphoplasty (8.45° vs 5.5°, p=0.01). A significant association was found between the Beck’s index losses with the ODI at the last setback (p=0.02). Complications were cement leakage in five patients without clinical symptoms. We had noted one anterior vascular leak without any clinical implication. Surgical site infection was noted in one case and was managed by medical treatment without any general complication.

Conclusion: Our study showed that Vertebroplasty and kyphoplasty were both effectively for the pain reduction and for restoration of autonomy in osteoporotic patients. They also allowed an improvement of the kyphosis necessary for an appropriate spinal static's.

REFERENCES:


Disclosure of Interests: None declared


Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hip</th>
<th>Vertebral</th>
<th>DER</th>
<th>Humerus</th>
<th>Other</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n, %</td>
<td>n, %</td>
<td>n, %</td>
<td>n, %</td>
<td>n, %</td>
<td>0.0001</td>
</tr>
<tr>
<td>Number</td>
<td>179, 75</td>
<td>60, 25</td>
<td>129, 81</td>
<td>30, 19</td>
<td>93, 97</td>
<td>3, 3</td>
</tr>
<tr>
<td>Current smoker</td>
<td>13, 8 *</td>
<td>19, 32</td>
<td>20, 16 *</td>
<td>14, 48</td>
<td>16, 17 *</td>
<td>1, 33</td>
</tr>
<tr>
<td>Driker</td>
<td>5, 3 *</td>
<td>14, 24</td>
<td>9, 7 *</td>
<td>11, 38</td>
<td>6, 6</td>
<td>1, 33</td>
</tr>
<tr>
<td>Secondary causes of OP</td>
<td>24, 16</td>
<td>10, 21</td>
<td>24, 22</td>
<td>14, 56</td>
<td>14, 18</td>
<td>0, 0</td>
</tr>
<tr>
<td>Exercise</td>
<td>35, 28 *</td>
<td>12, 21</td>
<td>10, 8</td>
<td>8, 28</td>
<td>1, 1</td>
<td>0, 0</td>
</tr>
<tr>
<td>BMI ≥ 30</td>
<td>53, 32</td>
<td>14, 25</td>
<td>51, 43</td>
<td>13, 46</td>
<td>38, 43*</td>
<td>3, 7</td>
</tr>
<tr>
<td>OP treatment before FF</td>
<td>26, 15 *</td>
<td>3, 2</td>
<td>28, 23 *</td>
<td>3, 10 *</td>
<td>13, 15</td>
<td>0, 0</td>
</tr>
<tr>
<td>Re-fracture (one year)</td>
<td>11, 9</td>
<td>8, 4</td>
<td>6, 7</td>
<td>0</td>
<td>0, 0</td>
<td></td>
</tr>
</tbody>
</table>
**Prevalence of Glucocorticoid-Induced Osteoporosis in African Adult Patients with Chronic Rheumatic Diseases: A Systematic Review and Meta-Analysis.**

**Hammouch1,2, P. Paruk, S. A. A. Tabra, K. Maatallah2, A. Bouziane1, R. Abouqal1,2, Y. El Miedany1, A. E. Maghraoui2, A. A. Kalla2, Mohammed V University Rabat, Laboratory of Biostatistics, Clinical Research and Epidemiology (LBRC), Faculty of Medicine and Pharmacy, Rabat, Morocco; Temara Hospital, Rheumatology Unit, Temara, Morocco; University of Kwa-Zulu Natal, eThekwini, Department of Rheumatology, Insko Albert Luthuli Central Hospital, School of Clinical Medicine, College of Health Science, Durban, South Africa; Tanta University, Lecturer of Rheumatology & Rehabilitation Department, Faculty of medicine, Tanta, Egypt; University Tunis El Manar, Rheumatology Department, Kassab Orthopedics Institute, Faculty of Medicine of Tunis, Tunis, Tunisia; Mohammed V University in Rabat, Department of Periodontology, Faculty of Dental Medicine, Rabat, Morocco; Ibn Sina University Hospital, Academic Medical Unit, Rabat, Morocco; Canterbury Christ Church University, Rheumatology Department, Canterbury, United Kingdom; Mohammed V University Rabat, Private Medical Office, Rabat, Morocco; University of Cape Town, Department of Medicine, Cape Town, South Africa

**Background:** Glucocorticoid (GC) use is well established in the treatment of rheumatic diseases, particularly rheumatoid arthritis (RA). The use of low dose GC has been endorsed by EULAR recommendations for the management of rheumatic and musculoskeletal diseases even if it is the context of SARS-CoV-2, but long-term use is generally discouraged.

**Objectives:** To estimate the prevalence of glucocorticoid-induced osteoporosis (GIOP) on bone mineral density (BMD) in African adult patients with inflammatory rheumatic diseases.

**Methods:** For this systematic review and meta-analysis, PubMed, Google Scholar, Scopus, and African index medicus were systematically searched up to December 2020 without language restrictions. We included studies as follows: population-based or hospital-based study, study with sufficient information to estimate the prevalence of GIOP and osteoporotic fractures in African patients with rheumatic disease. Searches were limited to peer-reviewed full text articles. A standardized data extraction form was used to collect information from eligible studies. A random-effects meta-analysis was conducted to obtain the pooled prevalence of GIOP in these studies. The meta-analysis was stratified by geographical region. The study is registered with PROSPERO, number CRD42021256252.

**Results:** Our search identified 8571 studies, of which 8 studies were included in the systematic review from only four African countries and 7 studies in the meta-analysis. The pooled prevalence of osteoporotic fractures in our study was 47.7% (95% CI 32.9–62.8) with 52.2% (95% CI 36.5–67.6) in North Africa and 15.4% (95% CI 19.4–45.4%) in South Africa (SA). There was no evidence of publication bias, although heterogeneity was high (p=0.018). There was no data from sub-Saharan Africa apart from the two studies from SA.

**Conclusion:** The overall prevalence of GIOP in African adult patients with inflammatory rheumatic diseases was high at 47.7% (95% CI 32.9–62.8). Meta-analysis calculation revealed patient geographic origin as possible confounding factors of the proportion outcomes and further studies are required.

**Disclosure of Interests:** None declared

**DOIs:** 10.1136/annrheumdis-2022-eular.4402

---

**AB1032**

**Predictors of Increasing Number of Fractures in a Large Cohort of Patients Receiving for Dual-Energy X-ray Absorptiometry Scan.**

**Z. Sultan, M. Bukhari, Royal Lancaster Infirmary, Rheumatology, Lancaster, United Kingdom**

**Background:** Osteoporosis has been described as a global epidemic(1), it is the most common disease affecting bones (2). Incidence of osteoporosis is estimated to double by 2034(2) and osteoporotic fractures are expected to cost the US healthcare system around $50 billion by 2040(1), this is more than that for either chronic lung disease, breast cancer, diabetes, or stroke (1). Thus, it is vital to define the risk factors and characteristics associated with fractures to aid early prophylaxis.

**Objectives:** To identify risk factors and predictors associated with fractures.

**Methods:** 31546 patients presented to a district general hospital in North West England for dual energy X-ray absorptiometry scan between 1996 and 2017. Demographics, risk factors and incidence of fractures were recorded. This data was retrospectively analysed to identify patients who had sustained at least one fracture. Patients were divided into three groups – group 1 had one fracture, group 2 had two fractures and group 3 had three or more fractures. STATA was used for statistical analysis. One way ANOVA with a Tukey post-hoc test and chi-squared test were used to compare the three groups.

**Results:** 11839 patients were identified to have sustained at least one fracture, this included 9993 females and 1846 males (Table 1). Group 1 contained 9390, group 2 contained 2050 and group 3 contained 399 patients. A statistically significant increase in the proportion of females within in each group was observed as the number of fractures increased (chi squared=13.99, p<0.001). There was a significant reduction in average height, weight and BMI between the 3 fracture groups with an increasing number of fractures (f(2)=31.67, p=0.0000, f(2)=23.71, p=0.0000 and f(2)=8.14, p=0.0003 respectively). Group 3 had the oldest mean age and group 1 the youngest (f(2)=44.36, p=0.0000). A significant reduction in fat percentage of the spine was identified as number of fractures increased (f(2)=4.92, p=0.0073). A significant increase in the proportion of patients with a history of smoking and alcohol excess within each group was observed as number of fractures increased (chi squared=7.48, p<0.024 and chi squared = 23.12, p<0.0000 respectively). Mean T score in the lumbar spine, total femur and femoral neck were significantly lower between the 3 fracture groups with increasing fractures (f(2)=60.54, p=0.0000, f(2)=156.44, p=0.0000 and f(2)=115.86, p=0.0000 respectively).

**Table 1. No. of fractures vs patient characteristics.**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>1 Fracture</th>
<th>2 Fractures</th>
<th>≥3 Fractures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean height, cm (SD)</td>
<td>16149 (8.33)</td>
<td>160.45 (8.45)</td>
<td>158.70 (8.73)</td>
</tr>
<tr>
<td>Mean weight, kg (SD)</td>
<td>70.77 (15.93)</td>
<td>69.67 (15.42)</td>
<td>65.51 (14.69)</td>
</tr>
<tr>
<td>Mean BMI, kg/m2 (SD)</td>
<td>2709 (5.54)</td>
<td>2701 (5.27)</td>
<td>2596 (5.22)</td>
</tr>
<tr>
<td>Mean waist (SD)</td>
<td>87.45 (11.85)</td>
<td>69.76 (11.76)</td>
<td>70.84 (11.62)</td>
</tr>
<tr>
<td>Mean spine fat, % (SD)</td>
<td>30.61 (10.92)</td>
<td>30.58 (10.52)</td>
<td>28.87 (11.36)</td>
</tr>
<tr>
<td>Mean lumbar spine T-score (SD)</td>
<td>-1.23 (16.0)</td>
<td>-1.55 (15.2)</td>
<td>-1.86 (14.7)</td>
</tr>
<tr>
<td>Mean total femur T-score (SD)</td>
<td>-1.08 (12.2)</td>
<td>-1.69 (11.5)</td>
<td>-2.07 (13.3)</td>
</tr>
<tr>
<td>Mean femoral neck T-score (SD)</td>
<td>-1.47 (11.0)</td>
<td>-1.80 (10.00)</td>
<td>-2.04 (9.79)</td>
</tr>
<tr>
<td>Proportion of females (%)</td>
<td>83.84</td>
<td>86.00</td>
<td>89.47</td>
</tr>
<tr>
<td>Proportion of pts with smoking history (%)</td>
<td>3742</td>
<td>39.41</td>
<td>43.13</td>
</tr>
<tr>
<td>Proportion of pts with excess alcohol history (%)</td>
<td>7.06</td>
<td>9.90</td>
<td>13.78</td>
</tr>
</tbody>
</table>

**Conclusion:** Some important risk factors and characteristics in patients sustaining fractures have been identified. Increased height, weight and BMI are associated with sustaining fewer fractures. Increasing age is associated with having sustained more fractures, in line with what is expected with the reducing T-scores and the ageing process. A reduced spine fat percentage is associated with higher number of fractures suggesting that fat provides a protective effect to bone. Finally, a history of smoking and excess alcohol consumption are shown to be important risk factors in sustaining increasing numbers of fractures.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOIs:** 10.1136/annrheumdis-2022-eular.4354
Background: Bone mass reaches the peak during the third decade of life. By this age, men reach an increased bone mass that starts declining in their fifties, however less rapidly than women after menopause. However, men and women lose bone mass at the same rate by age 65-70, becoming fragile and more likely to have fracture.

Objectives: This study aimed to evaluate the diagnostic accuracy in osteoporosis diagnosis of Radiofrequency Echographic Multi Spectrometry (REMS) technology applied on the proximal femur in an adult male population in comparison with the Dual-energy X-ray Absorptiometry (DXA).

Methods: A cohort of Caucasian males was enrolled in the study. Inclusion criteria were: age between 30 and 90 years, body mass index (BMI) less than 40 kg/m², no significant walking impairments and proximal femur DXA medical prescription. All the enrolled patients underwent proximal femoral scans with both DXA and REMS. The agreement between REMS and DXA-measured BMD was expressed by Pearson correlation coefficient and Bland-Altman method. The classification into patients “with osteoporosis” or “without osteoporosis” was carried out considering the conventional threshold of T-score (<-2.5) for both techniques independently. The accuracy was evaluated by the assessment of sensitivity and specificity considering the DXA outcome as reference.

Results: A total of 219 men were included in the analysis, with mean age of 55.5 (± 15.3) years. The Pearson correlation coefficient between REMS- and DXA-measured BMD values was r=0.94. At Bland-Altman analysis, Bias ± 1.96 Standard Deviation were -0.004 ± 0.04 g/cm². The REMS capability to discriminate osteoporotic patients from non-osteoporotic ones was very high: a sensitivity of 90.0% and specificity of 91.8% was detected.

Conclusion: REMS, applied to the proximal femur site, is a reliable technology for the diagnosis of osteoporosis also in men, thus confirming the diagnostic performance already observed in studies carried out in female populations.

REFERENCES:


FRACTION RISK BY FRAX WITH AND WITHOUT BONE MINERAL DENSITY. COMPARISON OF FACTORS AFFECTING CONCORDANCE

A. Y. Luiano Negrete1, C. M. Skinner Taylor2, L. Pérez Barbosa1, M. C. Rodriguez-Pluiz1, A. Aguilar-Leal1, L. G. Espinosa Banuelos1, A. Cárdenas1, D. A. Galarza-Delgado1, 2Hospital Universitario “Dr. José Eleuterio González”; Rheumatology, Monterrey, Mexico

Background: The Fracture Risk Assessment Tool (FRAX) estimates the 10-year probability of hip (FXC) and major osteoporotic fractures (FXOM) fractures in patients aged 40 to 90 years using important clinical factors, such as bone mineral density (BMD), optional input variables. (1) There is convincing evidence that with or without the use of BMD it provides a well-validated instrument and may be useful in clinical practice for identifying patients at high risk of fracture and informing treatment decisions. (2)

Objectives: This study aims to determine the concordance between the treatment decision, calculated using FRAX scores with and without BMD, and to identify the risk factors associated with the discordance in patients with autoimmune rheumatic diseases.

Methods: A cross-sectional study was carried out in patients with autoimmune rheumatic diseases who had undergone osteoporosis detection (OP) using dual bone densitometry in the Rheumatology service of the University Hospital “Dr. José Eleuterio González” during the period August 2020 - August 2021. The FRAX questionnaire was applied to determine risk factors for OP and the results of the instrument with and without BMD were calculated, the patients were classified as low, intermediate, and high risk.

A Student’s t-test, a Wilcoxon rank-sum test, and a Chi-square or Fisher’s exact test were used to compare variables between groups and calculate P-values.

Results: A total of 88 patients were included. Based on FRAX questionnaire responses, 82 (93.18%) patients had at least one risk factor for OP. The FRAX result with or without densitometry resulted in a treatment decision in 48 (54.5%) and 28 (31.8%) patients, respectively. The results were concordant in 65 (73.9%) of the cases. It was found that patients with osteopenia due to BMD had a greater agreement between both measurements (93.3%, p=0.003) than patients with normal BMD (82.5% p=0.001). Likewise, patients with secondary osteoporosis had lower concordance than patients without this diagnosis (25% and 72.5%, respectively, p=0.006).

Conclusion: The results of FRAX with and without densitometry were mostly agreeable in predicting the need for treatment according to the 10-year probability of hip fracture, however, this concordance decreased in patients with a previous diagnosis of secondary osteoporosis, no significant difference was found between the risk factors for the concordant and discordant groups. More studies are required to determine the variables that cause a decrease in the concordance of the tests.

Table 1. Factors that affect the results between the discordant groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Concordant n=65</th>
<th>No concordant n=23</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (%)</td>
<td></td>
<td></td>
<td>0.078</td>
</tr>
<tr>
<td>Men</td>
<td>8 (12.3%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>57 (87.7%)</td>
<td>23 (100%)</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.85 ± (11.66)</td>
<td>59.2 ± (8.36)</td>
<td>0.13</td>
</tr>
<tr>
<td>&lt;50</td>
<td>12 (18.4%)</td>
<td>4 (17.3%)</td>
<td></td>
</tr>
<tr>
<td>50-59</td>
<td>24 (36.9%)</td>
<td>8 (34.6%)</td>
<td></td>
</tr>
<tr>
<td>60-69</td>
<td>17 (26.1%)</td>
<td>9 (39.1%)</td>
<td></td>
</tr>
<tr>
<td>70-79</td>
<td>10 (15.3%)</td>
<td>2 (8.7%)</td>
<td></td>
</tr>
<tr>
<td>≥80</td>
<td>2 (3%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Height (meters)</td>
<td>1.52 ± (0.08)</td>
<td>1.52 ± (1.06)</td>
<td>0.042</td>
</tr>
<tr>
<td>Weight (kilograms)</td>
<td>68.5 (59.5-80.5)</td>
<td>68 (64-74)</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.2 (24.9-33.1)</td>
<td>30.9 (29.2-32.5)</td>
<td>0.002</td>
</tr>
<tr>
<td>Normal weight (%)</td>
<td>16 (24.6%)</td>
<td>3 (13%)</td>
<td>0.136</td>
</tr>
<tr>
<td>Overweight (%)</td>
<td>22 (33.8%)</td>
<td>5 (21.7%)</td>
<td>0.150</td>
</tr>
<tr>
<td>Obesity (%)</td>
<td>27 (41.5%)</td>
<td>15 (65.2%)</td>
<td>0.051</td>
</tr>
<tr>
<td>Normal BMD</td>
<td>35 (53.84%)</td>
<td>21 (93%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Osteopenia</td>
<td>28 (43.07%)</td>
<td>2 (8.69%)</td>
<td>0.003</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>2 (3.67%)</td>
<td>0 (0%)</td>
<td>0.395</td>
</tr>
</tbody>
</table>

With BMD

Hips Fracture FRAX Score 5.3 (3.62-9.77) 1 (0.42-2.67)
Major osteoporotic fracture 6.2 (4.02-9.85) 0.75 (0.3-1.77)
Treatment suggested by FRAX 48 (54.5%) 28 (31.8%)

BMID= Body mass index, BMD= Bone mineral density, FRAX= Fracture risk assessment tool

REFERENCES:

Disclosure of Interests: None declared

Crystal diseases, metabolic bone diseases other than osteoporosis

AB1035
END STAGE RENAL DISEASE IN PATIENTS WITH GOUT AND CONTROLS. ETOLOGICAL DIFFERENCES?
L. Höpex1, U. Lindström1, H. Herlitz2, M. Dehlin1. 1 Sahlgrenska Academy at University of Gothenburg, Rheumatology and Inflammation Research, Gothenburg, Sweden; 2 Sahlgrenska Academy at University of Gothenburg, Molecular and Clinical Medicine/Nephrology, Gothenburg, Sweden

Background: The association between gout and renal disease is well known. However, whether hyperuricemia causes renal disease, or if the association is explained by comorbidities, is still up for debate. Studies on the effects of urate and gout on chronic kidney disease (CKD) show conflicting results. There is a lack of data on the underlying causes of CKD in gout patients.

Objectives: To compare causes of end stage renal disease (ESRD) in patients with gout and population controls.

Methods: This is a population-based and register-based case-control study. Gout cases, aged 18 years or older, were identified by at least one visit to a physician either an in- or outpatient clinic with a registered ICD-10 code for gout (M10) in the Western Regional Healthcare Contact Register (VEGA), between January 1st 2001 through December 31st 2018. For each case five controls without gout were matched by sex, age, and county/place of residence at year of first diagnosis. Cases and controls were excluded if they prior to the first recorded ICD-10 code for gout, had a record of end stage renal disease, defined as codes for renal transplantation or dialysis either in VEGA or the Swedish Kidney Register (SNR). In this cohort, all cases and controls developing ESRD during the follow-up period (2001 to 2018) were identified, and the registered causes of ESRD were compared across the groups.

Results: In total, 48594 gout cases (mean age 68.4 years; 67% male), and their 150618 matched controls (mean age 63.3 years; 67% male) were included. Of the cases and controls, 529 (1.1%) and 128 (0.1%) developed ESRD, respectively. At the time-point of active uremia treatment start (as in start of dialysis or beginning had significantly less gout flares compared to those without hypouricemic treatment since hemodialysis mic treatment. Patients on hypouricemic treatment since hemodialysis without hypouricemic treatment and 22 patients (45%) with hypouricemic treatment presented at least one gout flare during the follow-up: 42 patients (65%) with a male/female sex ratio of 2.7:1. Sixty-four/182 patients (35.16%) presented at least one gout flare during the follow-up: 42 patients (65%) without hypouricemic treatment and 22 patients (45%) with hypouricemic treatment. Patients on hypouricemic treatment since hemodialysis beginning had significantly less gout flares compared to those without hypouricemic treatment at the initiation of hemodialysis (p = 0.0009) (graphic 1). There was no significant KT/V ratios difference between the 2 populations at the time of gout flares. Hypouricemic treatment was a protective factor for the occurrence of gout attacks (HR: 0.42, 95% CI 0.25 – 0.71) (Table 1).

Table 1. Associated factor of gout flares after the beginning of hemodialysis on gouty patients

<table>
<thead>
<tr>
<th>Factor</th>
<th>HR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current or active smoking</td>
<td>0.92</td>
<td>0.46-1.86</td>
</tr>
<tr>
<td>Male</td>
<td>0.82</td>
<td>1.48-1.42</td>
</tr>
<tr>
<td>Caucasian ethnic</td>
<td>0.63</td>
<td>0.64-1.75</td>
</tr>
<tr>
<td>Hypouricemic treatment</td>
<td>0.42</td>
<td>0.25-0.71</td>
</tr>
<tr>
<td>High Blood Pressure</td>
<td>1.21</td>
<td>0.44-3.36</td>
</tr>
<tr>
<td>Obesity</td>
<td>0.84</td>
<td>0.47-1.51</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>0.79</td>
<td>0.47-1.30</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1.28</td>
<td>0.78-2.11</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>1.42</td>
<td>0.73-2.81</td>
</tr>
</tbody>
</table>

Conclusion: Therefore hypouricemic treatment at the initiation of hemodialysis seems to be a protective factor against gout flares, which may persist in dialysis patients. Prospective studies should be performed to confirm these results for this particular gouty population.

REFERENCES:
AB1038  PEGLOTICASE URATE-LOWERING RESPONSE FOLLOWING COVID-RELATED GAP IN THERAPY: EXPERIENCES OF ONE RHEUMATOLOGIST

D. Mandel1, P. Scott1, B. Lamoreaux2, 1David R. Mandel, M.D. Rheumatology & Osteoporosis, Rheumatology, Mayfield Village, United States of America; 2Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America

Background: When uncontrolled gout cannot be managed with oral urate-lowering therapies, pegloticase is one of the few remaining treatment options. Patients receiving infusions therapies experienced treatment interruptions due to the COVID-19 pandemic. As with other biologic therapies, patients can develop anti-drug antibodies (ADAs) against pegloticase, and longer infusion intervals can result in higher rates of pegloticase immunogenicity.1 The literature suggests that co-administering an immunomodulator with pegloticase can markedly decrease the proportion of patients who develop ADAs, increasing the proportion with sustained urate-lowering response.2

Objectives: This case series reports one rheumatologist’s experience with a gap in pegloticase therapy during the COVID-19 pandemic.

Methods: Uncontrolled gout patients who underwent pegloticase treatment during 2019/2020 and had a gap in therapy of ≥28 days were identified. Patient, clinical, and treatment (number post-gap infusions, immunomodulation co-therapy) characteristics were retrospectively examined, along with urate-lowering response following therapy interruption. Patients who had a serum urate (SU) <6 mg/dL after the last post-gap pegloticase infusion were considered to have recaptured response.

Results: 7 patients (5 men, 64.3±13.5 years, pretherapy SUA: 7.76±2.47 mg/dL, 6 had tophi) were included with 2 remaining on therapy at data collection. Eleven gaps were noted with an average gap duration of 11.4±9.3 weeks (median: 9 weeks). For the last gap in therapy, patients received 13.9±7.0 infusions (range: 4-22) before the gap and 7.0±4.1 infusions (range: 2-14) after (Figure 1). Four patients (57%): Patients 1, 2, 5, 7, had recaptured urate-lowering at last pegloticase infusion, all of whom began immunomodulation (3 methotrexate, 1 mycophenolate mofetil/hydroxychloroquine) prior to resuming pegloticase. Of the 3 patients without response capture, 2 initiated MTX after resuming pegloticase. Of the 3 patients without response recapture, 2 patients (67%) experienced ≥1 AE, including mild infusion reaction (n=1), acute gout flare (n=2), clinically meaningful decrease in eGFR (14.8±1 min/1.73m², n=1), heart attack (n=1), and anemia (n=1).

Conclusion: These cases suggest that it may be possible to recapture urate-lowering response to pegloticase in some patients, particularly in the presence of immunomodulation. These preliminary findings are important to this vulnerable patient population, particularly during the COVID-19 pandemic. Further study is needed to confirm our findings.

REFERENCES:
Gout affects more than 9 million Americans,[1] with some suffering so severely that everyday life becomes painful and difficult. Pegloticase is an infused uricase-based medicine that significantly reduces serum uric acid (sUA) levels in patients suffering from treatment-resistant gout,[2] but the direct effect of treatment on quality of life (QoL) by response status has not yet been reported.[3]

Background: Gout outcomes more than 9 million Americans,[1] with some suffering so severely that everyday life becomes painful and difficult. Pegloticase is an infused uricase-based medicine that significantly reduces serum uric acid (sUA) levels in patients suffering from treatment-resistant gout,[2] but the direct effect of treatment on quality of life (QoL) by response status has not yet been reported.[3]

Methods: This analysis utilized results from two parallel 6-month randomized phase 3 registrational clinical trials in which subjects were treated with 8 mg of pegloticase or placebo biweekly. Responders were those who maintained sUA levels <6 mg/dL for >80% of the time during Months 3 and 6 combined. Multiple QoL measurements were taken throughout the 6-month treatment period, including the Health Assessment Questionnaire (HAQ; Pain, Disability Index [DI], and Health), the 36-Item Short Form Health Survey Questionnaire (SF-36), and the Limitations of Daily Activities (LIDA). HAQ was assessed at baseline and Week 25. The SF-36 and LIDA were assessed at baseline, Weeks 3, 6, 12, 24, and 25.

Results: A total of 36, 49, and 43 patients were included in the treatment responders, treatment non-responders, and placebo-treated groups, respectively. Significant differences in the change from baseline to Week 25 in HAQ-Pain, HAQ-DI, HAQ-Health, and SF-36 PCS was not significantly different between any of the 3 groups examined.

Conclusion: In the Phase 3 registration trials of pegloticase used as monotherapy for uncontrolled gout, QoL parameters improved among pegloticase-treated patients regardless of response status.

REFERENCES:

Disclosure of Interests: Jacy Sparks: None declared, Katie Obermeyer Shareholder of: Horizon Therapeutics., Employee of: Horizon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics plc, Biostatistics, Deerfield, United States of America; Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America

homozgyous CC genotype and CA or AA genotypes did not differ: 17 (33%) and 11 (35%) cases, respectively. It turned out that CA and AA pts required a significantly higher dose of allopurinol (365±102 mg/day) than CC pts (290±85 mg/day), p=0.02. Of 54 pts treated with febuxostat who did not achieve the target sUA level, 30 (56%) pts had the CC genotype and 24 (44%) pts had the CA genotype. The opportunity of the target sUA level achievement was comparable (p=0.22).

Conclusion: The opportunity of achieving the target sUA level in pts with gout taking allopurinol is not associated with the C→A polymorphism of the ABCG2 gene, but the presence of the CA and AA genotypes is associated with the need to prescribe large doses of allopurinol.

REFERENCES:

Disclosures of Interests: Maxim Eliseev Speakers bureau: Berlin Chemie, Menarini Group, Iscal, Ers, Csc, Mosfarma, Alum, Relma, Maria Chikina. None declared, Olga Shelabina Speakers bureau: Berlin Chemie Menarini Group, Elena Cheremushkina; none declared


AB1041 REAL-WORLD REPORTING OF GOUT FLARES IN UNCONTROLLED GOUT PATIENTS CO- TREATED WITH PEGLOTICASE AND METHOTREXATE
J. Alberi, L. Padnick-Silver, B. Lamoreaux1. Rheumatic Disease Center, Rheumatology, Milwaukee, United States of America; 2Horizon Therapeutics plc, Medical Affairs, Deerfield, United States of America

Background: Acute gout flares are a known result of urate-lowering in gout patients1 and are also the most common adverse event in patients treated with pegloticase.2 Fortunately, the proportion of pegloticase-treated patients who experience flares and the number of flares/patient decrease over time.3,4 Though well-studied in the clinical trial setting, little has been published on the rate of acute gout flares during pegloticase therapy in a real-world, rheumatology setting. This retrospective study examined one community practice’s findings on gout flares in uncontrolled gout patients co-treated with pegloticase and methotrexate.

Objectives: This retrospective chart review examined acute gout flare occurrence and characteristics in patients undergoing pegloticase-methotrexate co-therapy. Patients with and without gout flares were also compared to investigate potential factors that may have influenced gout flare occurrence.

Methods: All patients who underwent pegloticase plus methotrexate co-therapy between January 2017 and March 2021 at a community rheumatology practice were included. Patient, treatment, and flare characteristics were extracted from the medical record and compiled into a de-identified data set.

Results: 29 patients treated with pegloticase and methotrexate (28 subcutaneous, 1 oral) were included. Mean patient age was 59.9±17.0 years and 72% were male. Gout duration was 11.7±10.8 years, pre-therapy serum uric acid (sUA) averaged 9.4±1.8 mg/dL, and 97% had visible tophi. Patients had received 12.8±1.3 pg/ml pegloticase infusions over 25.9±9.7 weeks, with pre-infusion sUA±6mg/dl in 27/29 patients (93%) at last pegloticase dosing. 23 gout flares were noted in 12 patients (41%, 19.9±18 flares/patient), 59% of which were noted as severe and 50% involved a single joint. Acute gout flare was most common in the first 4 weeks of therapy, with first flare occurring on average 1.6±2.9 weeks after first pegloticase infusion. Demographic and treatment characteristics were similar between flaring and non-flaring patients. However, patients with ≥1 flare were older (65.8±15.4 years vs. 55.6±17.8 years), more often obese (83% vs. 47%), and had a higher overall comorbidity burden.

Conclusion: This retrospective study of real-world pegloticase use suggests that gout flare rates may be lower in a real-world setting (41%) than that reported in clinical trials (76%–86%6-7), which have different gout flare criteria. Consistent with clinical trials, a flare rate was highest during the first 4 weeks of pegloticase treatment, progressively decreasing over time. Interestingly, these data suggest that patients who experience gout flares on pegloticase may have more obesity and a higher comorbidity burden than those who do not experience flares. Further examination of gout flares during real-world pegloticase use is warranted.

REFERENCES:

AB1043 IDENTIFICATION OF UNUSUAL TOPHI ANTERIOR TO THE THYROID CARTILAGE USING DIFFERENT IMAGING METHODS
Y. Jiang1, X. Wu1, Z. Liao1, J. Qi1, J. Gu1. 1Third Affiliated Hospital of Sun Yat-sen University, Department of Rheumatology and Immunology, Guangzhou, China

Background: Inadequately treated gout patients could develop tophi. However, tophi could appear as atypical mass, leading to difficulty in differential diagnosis.

Objectives: The objectives of the study were to describe an unusual case with tophi anterior to the Thyroid Cartilage using different imaging methods.

Methods: Clinical information of the case was presented. Ultrasound, dual energy Computed Tomography (DECT) and CT scan were compared to describe the tophi.

Results: A 66-year-old man with a 30-year history of gout was admitted. He received 8-year urate-lowering drugs intermittently over the past few years. Physical examination revealed multiple tophi on the hands, feet, and other acral surfaces. Moreover, there was a subcutaneous mass above the thyroid cartilage (Figure 1A). Ultrasound revealed hyperechoic nodule anterior to the thyroid cartilage, 11*7 cm in size, with uneven internal echo, no blood flow signal inside, and a close relationship between the barrier of the nodule and the thyroid cartilage (Figure 1B). DECT of the neck confirmed that the mass anterior to the thyroid cartilage were tophi (Figure 1C-D). A plain radiographic evaluation demonstrated

REFERENCES:

soft-tissue swellings and para-articular erosions involving hands (Figure 1E-F). The serum creatinine and uric acid levels were elevated as follows, creatinine, 562 µmol per liter (normal range, 31.8 to 116); and uric acid, 621 µmol per liter (normal range, 90 to 420).

Conclusion: DECT has more advantages over ultrasound and CT for detection of atypical tophi in gout patients.


AB1044 RISK FACTORS OF DIABETES MELLITUS IN PATIENTS WITH GOUT (RESULTS OF A PROSPECTIVE STUDY)

O. Sheliabina1, M. Eliseev2, S. Glukhova3, 1VA Nasonova Research Institute of Rheumatology, Laboratory of Microcrystalline Arthritis, Moscow, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Laboratory of Axial Spondyloarthritis, Moscow, Russian Federation

Background: It is assumed that the risk of developing diabetes mellitus (DM) is due not only to generally accepted risk factors (RF), but also to RF related to gout.

Objectives: To evaluate the influence of various RF for DM in pts with gout.

Methods: 444 pts aged ≥18 years with a crystal-verified diagnosis of gout without DM were included in the study. The average duration of observation was 5.66 (2.69; 7.4) yrs. To identify the RF associated with developing of DM in patients with gout, multivariable logistic regression was used. There were included: gender; DM in relatives; insufficient physical activity; unbalanced diet; age ≥45 yrs; ≥4 exacerbation of arthritis per yr; presence of tophi; BMI ≥30 kg/m²; presence of subcutaneous tophi; sUA ≥600 µmol/l; age ≥45 yrs; presence of hypertension; allopurinol, febuxostat, GC, diuretics, metformin or colchicine intake; GFR <60ml/min/1.73 m²; serum uric acid (sUA) level ≥420 µmol/l; UA ≥480 µmol/l. Statistica 12.0 package was used for statistical data processing.

Results: The opportunity of achievement of the target serum UA (sUA) level in pts with gout, stratified by renal function, is not studied. The frequency of arthritis exacerbation in pts who achieved the target sUA level was decreased from 3.1±1.6 cases per year to 0.9±1.1 cases per year (p=0.0001); in those who did not achieve - from 3.1±1.9 cases per year to 2.4±1.6 cases per year (p=0.047).

Conclusion: The risk of developing diabetes in pts with gout is associated with the frequency of exacerbations of arthritis, sUA level ≥480 µmol/l, hypertension and diuretics intake. Therapy with febuxostat or metformin is associated with descended risk of DM.

Disclosure of Interests: Olga Sheliabina Speakers bureau: Berlin Chemie Menarini Group, Maxilis Eliseev Speakers bureau; Berlin Chemie Menarini Group, Sobi, EGIS, CSC, MosFarma, Alium Group, Svetlana Glukhova: None declared


AB1045 QUALITY OF LIFE IN PATIENTS WITH GOUT TAKING URATE-LOWERING DRUGS, DEPENDING ON THE ACHIEVEMENT OF THE TARGET LEVEL OF SERUM URIC ACID

M. Chikina1, O. Sheliabina1, M. Eliseev1, 1VA Nasonova Research Institute of Rheumatology, Laboratory of Microcrystalline Arthritis, Moscow, Russian Federation

Background: Intake of urate-lowering drugs (ULD) leads to an improvement in the quality of life (QoL) in pts with gout. However, it is not clear to what extend the QoL is changed in pts who did not achieve the target level of serum uric acid (sUA).

Objectives: To evaluate the dynamics of the QoL in pts, taking ULD, who have achieved and have not achieved the target sUA level.

Methods: 98 pts with gout were included in the prospective study. The follow-up period was 24 months, allopurinol or febuxostat at doses sufficient to achieve the target sUA level (>360 µmol/l) were used. The maximum daily dose of allopurinol was 900 mg/day, febuxostat - 120 mg/day. Pts who did not achieve the target sUA level continued taking ULD at the maximum dosages. The values of the QoL in dynamics were calculated using the SF-36v2 questionnaire. The assessment of the QoL was carried out separately in pts who achieved and did not achieve the target level of sUA. The frequency of exacerbations of arthritis was also assessed. Statistica 12.0 package was used for statistical data processing.

Results: Of 98 (70%) pts achieved the target sUA level, whereas allopurinol was taken by 46 pts, febuxostat - 34 pts. Pts who achieved the target level of sUA after 6 mo. of ULD usage, demonstrated a significant improvement in the physical health (PH), including physical functioning (PF), role limitations due to physical functioning (RP), general health (GH), as well as vitality (V) (p<0.05 for all). After 12 and 24 mo. improvement was achieved in RH, GH and PF (p<0.01), PF, role-emotional functioning (RP) and VT (p<0.05). General mental health (MH), role-emotional functioning (RE) and social functioning (SF) were unchanged throughout the study. Pts who did not achieve the target sUA level after 6 and 12 mo. significantly improved. PF, RP (p<0.05 for all). For 24 months, for all QoL parameters, the values did not differ from the initial ones. The frequency of arthritis exacerbation in pts who achieved the target sUA level decreased from 3.1±1.6 cases per year to 0.9±1.1 cases per year (p=0.0001); in those who did not achieve - from 3.1±1.9 cases per year to 2.4±1.6 cases per year (p=0.047).

Conclusion: The QoL in gout pts who achieved target sUA level continues to improve during the first year of ULD intake. Even if the target sUA level is not achieved, the QoL of patients with gout treated with ULD remains stable for at least 2 years of therapy. This predetermines the need to use maximum daily doses of ULD, even if the target serum UA level is not achieved.

Disclosure of Interests: Maria Chikina: None declared, Olga Sheliabina: Berlin Chemie Menarini Group, Maxilis Eliseev: Berlin Chemie Menarini Group, Sobi, EGIS, CSC, MosFarma, Alium Group

Table 1. Levels of UA, eGFR in patients with gout, stratified by the level of eGFR at baseline and after 26 weeks of febuxostat therapy.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>All patients, n=136</th>
<th>CKD C0-1, n=30</th>
<th>CKD C2, n=28</th>
<th>CKD C3, n=62</th>
<th>CKD C4, n=16</th>
</tr>
</thead>
<tbody>
<tr>
<td>UA baseline, µmol/l</td>
<td>472.4±99.3</td>
<td>451.9±102.8</td>
<td>486.9±103.8</td>
<td>476.9±86.7</td>
<td>483.6±108.9</td>
</tr>
<tr>
<td>UA after 26 weeks, µmol/l</td>
<td>306.7±104.4</td>
<td>296.8±104.8</td>
<td>282.0±97.8</td>
<td>318.6±79.6</td>
<td>313.5±106.9</td>
</tr>
<tr>
<td>Δ UA, µmol/l</td>
<td>166±10.2</td>
<td>153±10.7</td>
<td>204±7.12</td>
<td>157±9.78</td>
<td>154±8.19</td>
</tr>
<tr>
<td>UA≥360 µmol/l, n (%)</td>
<td>117 (84)</td>
<td>25 (83)</td>
<td>75 (9.7)</td>
<td>50 (5.9)</td>
<td>26 (5.2)</td>
</tr>
<tr>
<td>GFR baseline, ml/min/1.73 m2</td>
<td>63.98±15.3</td>
<td>101.3±18.1</td>
<td>102.8±28.6</td>
<td>107.9±11.3</td>
<td>273±4.9</td>
</tr>
<tr>
<td>GFR after 26 weeks, ml/min/1.73 m2</td>
<td>64.74±26.9</td>
<td>101.3±18.1</td>
<td>102.8±28.6</td>
<td>107.9±11.3</td>
<td>273±4.9</td>
</tr>
</tbody>
</table>

* - p<0.05 between baseline and 26 weeks

level: baseline 2.13[0.22; 2.8] mg/l vs at th end of study period 3.06 [0.39; 3.68] mg/l, p=0.627. A decrease in mean values of calMT was noted in 5 of 6 (83%) pts took hydroxychloroquine, in 6 of 9 (67%) pts took colchicine, in 4 of 7 (57%) pts took methotrexate.

Conclusion: Therapy with colchicine, methotrexate and hydroxychloroquine in pts with CPPD leads to regression of early signs of atherosclerosis. This result can be achieved by suppressing chronic inflammation.


Discussion of Interests: Maxim Eliseev Speakers bureau: Berlin Chemie Menarini Group, Sobi, EGIS, CSC, Mosfarma, Alum Group, Olga Shelibabina Speakers bureau: Berlin Chemie Menarini Group, Maria Chikina: None declared.
Conclusion: In this retrospective real-world review of a limited number of cases, MTX-pegicotide co-therapy resulted in sustained uAUL lowering in uncontrolled gout patients with and without CKD. Close monitoring of renal function indicated stability or improvement during therapy in 86% of uncontrolled gout patients with CKD. Further study is needed to better understand therapy tolerance and treatment response rates of uncontrolled gout patients with CKD undergoing MTX-pegicotide co-therapy.

REFERENCES:

Disclosure of Interests: John Albert Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Aaron Broadwell Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Karim Masri Shareholder of: Horizon Therapeutics, Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Lissa Padnick-Silver Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Employee of: Horizon Therapeutics, Amod Athavale Grant/research support from: Horizon Therapeutics, Bally several anti-inflammatory, and some oral urate-lowering therapies (ULTs). This unique patient population has not been well characterized using real-world data. Objectives: This retrospective chart review study of patients with coincident gout and CKD was conducted to better understand patient characteristics and treatment patterns of this population. This study is unique in that patient data were obtained from nephrologists, allowing a glimpse of how they view gout and its management.

Methods: 111 nephrologists provided de-identified medical record data of their most-recently seen advanced (stage 3–5) CKD patients. Patients met study criteria for gout if any of the following were true: gout listed as a comorbidity, ULT use, or visible tophi or gout flares documented. A patient’s gout was determined to be uncontrolled if they had serum uric acid ≥6 mg/dL in addition to ≥1 visible tophus, ≥2 gout flares in the past year, or gouty arthritis (≥1 tender or swollen joint). Only characteristics of this unique population were examined, along with gout management patterns. Differences between patients with controlled and uncontrolled gout were also investigated using data from patients’ most recent evaluation.

Results: 173 patients with stages 3-5 CKD and who met study criteria for gout were included. Mean age was 56.3±12.9 ± 1 years and BMI averaged 32.0 ± 11.9 kg/m². A higher than expected proportion of patients was female (47%). The most common comorbidities were hypertension (85%), diabetes mellitus (47%), anemia of CKD (42%), CKD-mineral bone disorder (41%), ischemic heart disease (23%), and congestive heart failure (21%). Mean CKD duration was 4.1 ± 5.5 years, mean estimated glomerular filtration rate (eGFR) at most recent visit was 32.3 ± 13.9 ml/min/1.73 m², and 62% were using a ULT. 23 patients (13%) had uncontrolled gout (48% female, 63.1 ± 16.4 years, mean eGFR 32.0 ± 14.6 ml/min/1.73 m²), all of whom had been prescribed a ULT. Compared with controlled gout patients, uncontrolled patients had higher rates of pulmonary hypertension (14% vs. 4%), gout-related chronic pain in the 12-months prior to data collection (83% vs. 42%), and joint involvement (joint swelling, tenderness, flexibility loss, and/or damage/lesions on x-ray; 26% vs. 9%). Colchicine was also used more frequently in uncontrolled gout patients (26% vs. 7%).

Conclusion: The coincident with advanced CKD population described here shows unique differences from the general gout population, including a high proportion of females (47%). Given that women have a lower likelihood of developing gout at the same serum uric acid level, this finding was particularly surprising (general gout population: 67% male). Importantly, nearly 40% of included patients were not utilizing a ULT, leaving them susceptible to developing the painful and debilitating sequelae of uncontrolled gout. Additionally, 41% of the study population had a CKD-related mineral bone disorder, indicating that patients with coincident gout and CKD may have bones that are more vulnerable to gout-related bone damage. Our study confirms a high prevalence of gout and its associated comorbidities in patients with advanced CKD and suggests another nephrology education opportunity to highlight the potential benefits of gout monitoring, earlier intervention, and management.

REFERENCES:

Disclosure of Interests: Leonard Stern Speakers bureau: Horizon Therapeutics, Consultant of: Horizon Therapeutics, Richard Johnson Speaker: Payam Shakeri, Speakers bureau: Horizon Therapeutics and Relypsia, Consultant of: Horizon Therapeutics, Amod Athavale Grant/research support from: Horizon Therapeutics, Brian LaMoreaux Shareholder of: Horizon Therapeutics, Employee of: Horizon Therapeutics
Clinical outcomes and healthcare resource utilization of uncontrolled gout prior to pegloticase therapy

R. Morlock, V. Divino, M. Dekoven, B. Lamoneaux, A. Powers, N. Barreto, R. Holt, S. Taylor,

Background: By definition, uncontrolled gout (UG) cannot be managed with oral urate lowering therapies (ULTs) and is associated with substantial morbidity, UG, also known as refractory gout, results in escalated treatment and management. Recent American College of Rheumatology guidelines recommend treating gout to serum uric acid targets; if targets are not achieved or patients continue to have symptoms, pegloticase is recommended. There is a paucity of data documenting the clinical and economic burden of UG patients.

Objectives: Assess clinical outcomes and healthcare resource utilization (HCRU) of UG prior to pegloticase initiation.

Methods: A retrospective observational database analysis was conducted among patients initiating pegloticase between April 1, 2011 and August 31, 2020 using the PharMetrics Plus database. Eligible subjects had ≥1 pegloticase claim (first claim = index date) and continuous enrollment for 24 months prior to index. Relevant clinical and economic (HCRU) outcomes were evaluated over a 24-month pre-index period and compared between two different time periods prior to index: time interval 1 (Day -720 to Day -361) and time interval 2 (Day -360 to Day -1).

Assessment of comorbid disease burden included Charlson Comorbidity Index (CCI) and relevant health conditions. Dependent pairwise comparisons were conducted to compare clinical and economic outcomes between time periods prior to pegloticase initiation. To assess statistical differences, paired t-tests (continuous variables) or McNemar’s tests (categorical variables) were used.

Results: Of the 408 eligible subjects, most were male (88.5%), with an average age (SD) of 55.2 (11.3) years, 66.9% were between the ages of 45-64 years and 78.2% had a preferred provider organization (PPO) health plan. Most often (34.8% of patients), a rheumatologist was associated with initiation of pegloticase therapy, while primary care physicians accounted for 23.8% of initiations.

Mean (SD) CCI score was 2.4 (2.4) with 37.3% of subjects having a CCI score of ≥3. Prevalence of relevant health conditions over the 24-month pre-index period included tophi (62.5%), uric arthritis (8.6%), chronic kidney disease (34.6%) and chronic pain/fibromyalgia (76.5%), all of which significantly increased from time interval 1 (Day -720 to Day -361) to time interval 2 (Day -360 to Day -1) prior to pegloticase initiation (Table 1). Of patients initiating pegloticase, 57.4% had ≥1 ULT (excluding probenecid), 11.3% had ≥2 ULT (excluding probenecid), and 10.3% UG patients had ≥1 probenecid claim over the 24-month pre-index period. Most patients (98.3%) had ≥1 physician office visit, 27.2% had ≥1 hospitalization and 45.3% had ≥1 emergency room (ER) visit over the 24-month pre-index period. HCRU significantly increased from time interval 1 to time interval 2, prior to pegloticase initiation (Figure 1).

Table 1. Relevant Health Conditions and Disease-specific Health Care Resource Utilization (HCRU)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Overall</th>
<th>Time Interval 1</th>
<th>Time Interval 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>N= 408</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tophi</td>
<td>62.5%</td>
<td>15.4%</td>
<td>61.5%**</td>
</tr>
<tr>
<td>Urolithiasis</td>
<td>6.6%</td>
<td>4.2%</td>
<td>6.9%</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>34.6%</td>
<td>22.5%</td>
<td>31.6%**</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>32.6%</td>
<td>21.3%</td>
<td>28.4%**</td>
</tr>
<tr>
<td>Type 2 diabetes mellitus</td>
<td>31.4%</td>
<td>23.3%</td>
<td>28.9%**</td>
</tr>
<tr>
<td>Hypertension</td>
<td>76.2%</td>
<td>58.1%</td>
<td>70.3%**</td>
</tr>
<tr>
<td>≥1 gout flare</td>
<td>87.7%</td>
<td>48.5%</td>
<td>83.8%**</td>
</tr>
<tr>
<td>Mean number of gout flare (SD)</td>
<td>3.5 (2.4)</td>
<td>1.0</td>
<td>2.1**</td>
</tr>
<tr>
<td>Gout-related medications</td>
<td>56%</td>
<td>39.5%</td>
<td>63.7%**</td>
</tr>
<tr>
<td>≥1 claim for colchicine</td>
<td>71%</td>
<td>52.9%</td>
<td>60.3%*</td>
</tr>
<tr>
<td>≥1 claim for opioids</td>
<td>80%</td>
<td>50.2%</td>
<td>75.7%***</td>
</tr>
<tr>
<td>≥1 claim for oral corticosteroids</td>
<td>64%</td>
<td>38.5%</td>
<td>53.7%***</td>
</tr>
</tbody>
</table>

Conclusion: Overall, these data demonstrate the progressive nature of UG as confirmed by significant increases in gout-related conditions and healthcare resource utilization prior to pegloticase initiation. Further research is needed on healthcare resource utilization among patients with UG post-pegloticase use.


Association between body mass index and health-related quality of life in patients with gout

I. Orlowa, I. Vovk, M. Stanislavichuk

Background: Gout is an inflammatory disease that may cause decreased function and health-related quality of life (HRQoL). [1] In a few studies, it was demonstrated a negative relationship between body mass index (BMI) and HRQoL in individuals with gout, in the others, it was not confirmed.

Objectives: This study aimed to assess the BMI and quality of life in patients with gout and to value the association between these variables.

Methods: All 151 patients were male with mean age (M±SD) 52.4±9.2 years. Diagnosis of gout was based on the ACR/EULAR 2015 criteria [2]. Tophi were present in 51 (33.7%), and the median duration of gout was 7 years (25th to 75th interquartile range (IQR), 4 to 14.0). The mean uric acid in serum was (M±SD) 477.2±120.5 µmol/l. HRQoL was evaluated by the SF-36 and calculated summary physical (PCS) and mental component (MCS) scores of the SF-36.

Results: About 67.5% of the surveyed patients had BMI > 30 kg/m2, while the average index was 31.9±3.4. The overall median SF-36 PCS score was 33.9 (IQR 28.8 to 38.4), and the overall median SF-36 MCS score was 41.1 (IQR 34.2 to 47.4). Among the eight subscales of SF-36, there was a correlation between BMI and role physical functioning (RP) r = -0.22 (p<0.01), general health (GH) r = -0.17 (p<0.05), but others were statistically not significant (P>0.05). Our analysis showed negative associations between BMI and physical and mental HRQoL.

Conclusion: This analysis provides further evidence to support the injurious effects of obesity on different aspects of health patients with gout and underline the importance of weight loss.

REFERENCES:


Cardiovascular risks and mortality in Korean patients with gout

K. W. Moon

On behalf of ULTRA cohort group. 1Division of Rheumatology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon-si, Korea, Rep. of (South Korea)

Background: Gout is associated with an increased risk of cardiovascular comorbidities and premature mortality. Many epidemiological studies support an association between gout and increased risk of diverse cardiovascular diseases. There has been no study on cardiovascular risks and mortality in Korean patients with gout with large scale data. Therefore, we intended to investigate the risk of each specific cardiovascular disease and mortality in Korean patient with gout with the national insurance database. The purpose of this study is to investigate cardiovascular risks and mortality in Korean patient with gout.

Objectives: The purpose of this study is to investigate cardiovascular risks and mortality in Korean patient with gout.

Methods: Using Korean National Health Insurance Service data, we conducted a cohort study on gout patients. Gout patients were defined as those aged ≥ 20 years who were diagnosed as gout between 2009 and 2010, and control patients were matched with gout patients (1:1 ratio) after frequency matching for age, sex and index year. Primary outcomes were ischemic heart disease (IHD), acute myocardial infarction (AMI), congestive heart failure (CHF), cerebrovascular disease (CVD), cerebral infarction, cerebral hemorrhage, or transient ischemic attack (TIA). Secondary outcomes were all-cause mortality and cardiovascular mortality. We calculated hazard ratio (HR) in Cox regression, adjusting potential confounders.

Results: This study included 3,306 gout patients and an equal number of matched controls. Multivariate Cox regression analysis showed that gout patients showed increased risks of IHD (HR 1.860, 95% CI 1.446-2.392), AMI (HR 3.246, 95% CI 1.460-7.217), CVD (HR 1.552, 95% CI 1.177-2.036) after adjusting age, sex, laboratory findings, comorbidities, and medication (Table 1). However, statistical differences were not found in the risks of CHF, cerebral infarction, cerebral hemorrhage, TIA, all-cause mortality, and cardiovascular mortality.

Table 1. Multivariate Cox proportional HRs for cardiovascular risks of gout patients

<table>
<thead>
<tr>
<th>Outcome</th>
<th>HR</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic heart disease</td>
<td>1.860</td>
<td>1.446-2.392</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Acute myocardial infarction</td>
<td>3.246</td>
<td>1.460-7.217</td>
<td>0.004</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>1.999</td>
<td>0.853-3.295</td>
<td>0.183</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>1.552</td>
<td>1.177-2.046</td>
<td>0.002</td>
</tr>
<tr>
<td>Cerebral infarction</td>
<td>1.061</td>
<td>0.687-1.637</td>
<td>0.790</td>
</tr>
<tr>
<td>Cerebral hemorrhage</td>
<td>0.779</td>
<td>0.283-2.145</td>
<td>0.629</td>
</tr>
<tr>
<td>Transient ischemic attack</td>
<td>1.533</td>
<td>0.651-3.366</td>
<td>0.521</td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>1.199</td>
<td>0.737-1.952</td>
<td>0.465</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>1.377</td>
<td>0.452-4.188</td>
<td>0.573</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence interval.

Conclusion: Our study showed that cardiovascular risks of Korean patients with gout were increased, especially IHD, AMI and CVD.

References:

Disclosure of Interests: None declared


AB1054 FERRITIN LEVELS IN PATIENTS WITH GOUT AND COMORBID PATHOLOGY

G. Kuzmina1, O. Lazarenko1. 1Zaporizhzhya State Medical University, Department of Therapy; Cardiology and Family Medicine Faculty of Postgraduate Education, Kryvyi Rih, Ukraine

Background: Gouty arthritis is the most common type of inflammatory arthritis among the working-age population. In patients with gout, the following comorbidities are often recorded: hypertension, diabetes mellitus, and heart failure. The issue of the relationship between ferritin levels in patients with gout and comorbid pathology remains relevant, as well as establishing the nature of this relationship.

Objectives: The aim of this study was to determine the frequency of hyperferritinemia in patients with gout and comorbid hypertension.

Methods: 122 patients with hypertension, middle age of whom amounted to 56.0 (10.29) years, had been surveyed, 104 (85.2 %) men and 18 (14.8 %) women. All women were divided into three groups: the main group – 72 patients with hypertension in combination with gout, comparison group – 50 patients with hypertension without gout, control group – 20 patients with gout. Standard clinical examination and laboratory evaluation including ferritin, uric acid levels were performed.

Results: The following ferritin values were determined in the main group 344.0 (196.5; 389.0) ng/ml, comparison group 130.9 (68.0; 143.3) ng/ml and control group 276.5 (257.0; 354.5). The ferritin level were significantly higher in the main group - 2.6 (p <0.01) times than in the comparison group. The ferritin level were significantly higher in the control group - 2.1 (p <0.01) times than in the comparison group. There is no significant difference the ferritin levels between main and control groups (p>0.05), which indicates the important role of this marker in gout and requires further study of hyperferritinemia in gout and comorbid pathology.

Conclusion: The combination of hypertension with gout in patients was associated with a higher ferritin levels, which should be considered not only in the context of chronic inflammation, but as part of the disease with the possibility of further determining the cause and diagnostic value of hyperferritinemia in this category of patients.

References:

Disclosure of Interests: None declared


AB1055 GENDER DIFFERENCES IN TAKING XANTHOXIODASE INHIBITORS IN GOUT

M. Gromova1, V. Tsurko1. 1Pirogov Russian National Research Medical University, Department of Faculty Therapy of the Medical Faculty, Moscow, Russian Federation

Background: There is little evidence of a possible difference between men and women in response to urate-lowering therapy (ULT).

Objectives: To compare the clinical characteristics of the gout course and evaluate the differences in response to ULT with allopurinol and febuxostat in men and women.

Methods: The retrospective cohort study included 279 men and 83 women diagnosed with gout (ACR/EULAR, 2015). The comparative analysis of the clinical characteristics of gout and responses to taking xanthoxidase (XO) inhibitors in representatives of different genders was conducted. We compared the gender characteristics of obtaining a positive response to ULT, defined as achieving a target serum uric acid (sUA) level of <360 μmol/l within 6 months of treatment with allopurinol and febuxostat.

Results: By the age when gout manifested women were older than men, the duration of their disease was shorter. Men showed a shorter duration of the first arthritic attack. Chronic arthritis was diagnosed in 56% of men and 35% of women (p<0.05). The process involved the joints of the lower and upper extremities. More often the joints of the lower extremities were affected in men, and in the upper extremities in women. Tophus were detected in 35% of patients: 30.3% – men, 4.7% – women (p<0.05). Allopurinol was prescribed to 216 men and 54 women, febuxostat – to 63 men and 29 women. After six months the proportion of women who achieved the target sUA was 57.5% and 65.8%, the proportion of men – 60.4% and 76.2% for allopurinol and febuxostat, respectively.

Conclusion: The clinical manifestations of gout in men and women differ. Due to the marked acid release in the low-acid level, men develop more severe joint damage because of the tendency to chronicity. However, the study did not reveal gender differences in the response to XO inhibitors, which indicates that there is no need to choose therapy depending on the patient's gender.

Disclosure of Interests: None declared


AB1056 CHARACTERISTICS OF METABOLIC SYNDROME IN PATIENTS WITH GOUTY ARTHRITIS AND NON-ALCOHOLIC FATTY LIVER DISEASE

K. Zhigulina1, S. Spitsina1,2. 1Federal State Budgetary Educational Institution of Higher Education “Volgograd State Medical University” of the Ministry of Healthcare of the Russian Federation, Department of Hospital Therapy, Volgograd, Russian Federation; 2Federal State Budgetary Institution “Research Institute of Clinical and Experimental Rheumatology named after A.B. Zborovskiy”; Clinical Biochemical Laboratory, Volgograd, Russian Federation
Background: Gouty is an inflammatory and metabolic disease. Hyperuricemia can contribute to inflammation, hypertension and cardiovascular disease, adipogenesis and lipogenesis, impaired insulin and glucose metabolism, and liver disease. In turn, allopurinol is a fava liver disease (NAFLD) monitored. The primary outcome uric acid worldwide; is closely associated with obesity; type 2 diabetes mellitus, dyslipidemia, and other metabolic risk factors included in the metabolic syndrome (MS).

Problem of MS exists for many years, due to its extremely rapid spread in the world. Lipidemia, and other metabolic risk factors included in the metabolic syndrome (MS). In contrast, non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in combination with NAFLD, to identify the main traditional and disease-associated risk factors.

Methods: A cross-sectional descriptive study was conducted in the rheumatology and endocrinology departments of Farhat Hached University Hospital of Tunisia over a period of 6 months. Patients diagnosed with T2D according to the 2021 guidelines of the American Diabetes Association were included. A cut-off of uric acid ≥ 360 μmol/L in females and ≥ 420 μmol/L in males was used to define HU. Background: Recombinant uricase such as pegloticase are indicated for chronic gouty arthritis who have failed to achieve serum urate level <300μmol/L even though receiving conventional urate-lowering drugs. Rasburicase which is currently approved at a dosage of 0.2mg/kg/d for 5 days for the prevention of tumor lysis syndrome in pediatric patients with hematological tumors, is the only available uricase in China at present.

Objectives: To study the frequency and structure of MS in patients with gouty arthritis in combination with NAFLD, to identify the main traditional and disease-associated risk factors.

Methods: The study included 70 patients with gouty arthritis. The diagnosis was made based on the criteria of S. Wallace et al. All patients were examined with general clinical and biochemical blood tests (determination of uric acid, transaminases, glucose, glycosylated hemoglobin, insulin, lipid spectrum), physical examination (measurement of blood pressure, body mass index in kg/m²), calculation of the HOMA index. An ultrasound examination of the liver was performed as the instrumental diagnostic method.

Results: Among the surveyed, men and women accounted for 60% and 40%, respectively, with an average age of 52 years, with an average disease duration of 8.2±3.5 years. The debut of gouty arthritis was observed at 35.6 years. 25 patients had a family history of gouty arthritis, 64 patients had arterial hypertension, of 8.2±3.5 years. The debut of gouty arthritis was observed at 35.6 years. 25 patients had a family history of gouty arthritis, 64 patients had arterial hypertension, as well as hyperuricemia. All identified factors are higher risks of developing insulin resistance and dyslipidemia, abdominal obesity and arterial hypertension, as well as hyperuricemia. All identified factors of the metabolic syndrome directly correlated with the duration of gouty arthritis.

Disclosure of Interests: None declared


Efficacy and Safety of Low-Dose Rasburicase in Refractory Chronic Gouty Arthritis: A Pilot Study in

W. C. Zeng1,2, Q. H. Li1, A. J. Tang1,2, H. G. Li1, L. F. Chen1, X. N. Wei1, J. L. Jiang1, D. H. Zheng1, L. Dai1, Y. Q. Mo1,2,3,4,5 Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Department of Rheumatology, Guangzhou, China; 2Shenshan Medical Center, Memorial Hospital of Sun Yat-sen University, Department of Rheumatology, Shanwei, China

Background: Recombinant uricase such as pegloticase are indicated for chronic gouty arthritis who have failed to achieve serum urate level <300μmol/L even though receiving conventional urate-lowering drugs. Rasburicase which is currently approved at a dosage of 0.2mg/kg/d for 5 days for the prevention of tumor lysis syndrome in pediatric patients with hematological tumors, is the only available uricase in China at present.

Objectives: To evaluate the efficacy and safety of low-dose rasburicase in refractory chronic gouty arthritis.

Methods: We retrospectively collected data of 17 patients with refractory chronic gouty arthritis who were treated with rasburicase from January 2021 to September 2021 at Sun Yat-sen Memorial Hospital, Sun Yat-sen University. The refractory chronic gouty arthritis was defined as serum urate level was still more than 300μmol/L and dual-energy CT showed the volume of urate more than 10 cm³.

Results: Seventeen patients were recruited with 16 males (94%) and mean age 47±15 years old. The median gout course was 11 (6.5, 15) years with gout flares number 20 (11, 36) times in the previous year. At week 0 before the rasburicase add-on treatment, the mean serum urate was 652±94μmol/L and the median urate volume was 44 (21, 251) cm³ (Table 1). At urate level after the rasburicase add-on treatment was significantly decreased than that before the treatment either at week 0, week 4, or week 8 (Figure 1A, all p<0.001). The median reduction of serum urate was 585 (446, 821) at week 4, 214 (57, 373) at week 8, and 118 (21, 185) at week 12 (all p<0.017). Five cases (29%) showed serum urate lower than 300μmol/L at week 12. (Figure 1B–D). The median volume of urate reduction was 24 (12, 60) cm³ (p<0.001) and the median percentage of urate reduction 42% (25%, 66%). Urate reduction volume was positively correlated with baseline urate volume (r=0.890, p<0.001), while the percentage of urate reduction volume negatively correlated with baseline urate volume (r=−0.689, p=0.002). (3) Rasburicase was generally well tolerated. No gout attack occurred on the basis of intravenous methylprednisolone 20mg before each rasburicase add-on treatment and oral colchicine 0.5mg/d to 1mg/d. No hypersensitive reaction occurred during the treatment. Phlebitis occurred in a patient (6%), while dizziness and nausea occurred in two patients (13%). One patient (6%) who was suffering chronic kidney disease of stage 3 developed acute kidney injury after rasburicase injection at week 0 and week 8, but the serum creatinine spontaneously returned to the baseline level during follow-up.

Conclusion: This pilot study shows rasburicase is well tolerated in patients with refractory chronic gouty arthritis and may be a reasonable option to effectively lower the urate burden of these patients, although this is an off-label use. Further prospective randomized controlled studies to verify the efficacy and safety are needed.

Funding: This study was funded by Yat-sen Clinical Research Project.

Disclosure of Interests: None declared


Sci
ci
en


AB1057

AB1058

IS HYPERURICEMIA ASSOCIATED WITH TYPE 2 DIABETES DEGENERATIVE COMPLICATIONS?

F. Fhima1, N. El Amri1, D. Khalifa1, A. Ben Abdellah2, B. Ben Abdallah2, S. Latou1, K. Baccouche1, E. Bouajina1, K. Ach2, Farhat Hached Hospital, Rheumatology Department, Sousse, Tunisia; 2Farhat Hached Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia

Background: Prevalence of hyperuricemia (HU) is constantly increasing around the world and HU is now identified as an independent cardiovascular risk factor.

Objectives: To determine the prevalence of HU in patients with type 2 diabetes (T2D) and to identify degenerative complications of T2D associated with HU.

Methods: A cross-sectional descriptive study was conducted in the rheumatology and endocrinology departments of Farhat Hached University Hospital of Tunisia over a period of 6 months. Patients diagnosed with T2D according to the 2021 guidelines of the American Diabetes Association were included.

Results: One hundred fifty-one patients were included. Sex ratio F/M was 1.4. The median of age was 61 years. The prevalence of HU was 17.2%. Only 6% of patients had gout. Degenerative complications of T2D were encountered in 74.2% of cases. Diabetic neuropathy was the most common (51.7%) and was significantly associated with HU (p=0.049). Diabetic nephropathy was reported in 38.4% of patients and was also associated with HU (p=0.008). HU was associated with renal failure (p<0.01), microalbuminuria (<0.01), proteinuria (<0.001) and history of ischemic stroke (p=0.048). Diabetic feet problems were reported in 16.9% of patients and were associated with HU (p=0.008).
were examined at an outpatient appointment. Against the background of treatment with allopurinol and meloxicam.

**Conclusion:**
The course of treatment with allopurinol and meloxicam.

**Disclosure of Interests:**
None declared

**DOI:**

**AB1059**

**POSSIBILITIES OF COMBINED THERAPY FOR TREATMENT OF HYPERURICEMIA AND ARTICULAR SYNDROME EXACERBATIONS IN PATIENTS WITH GOUT**

V. Tsurko1, M. Gromova1, O. Kisliak1, N. Malyheva1; 1Pirogov Russian National Research Medical University (Pirogov Medical University), Department of Faculty Therapy of the Medical Faculty, Moscow, Russian Federation

**Background:**
Throughout the year 69 per cent of patients with gout experienced repeated exacerbations during therapy aimed at reducing urate levels. Prevention of arthritis exacerbations with low-dose NSAIDs should be done in the first 3-6 months of urate-reducing therapy.

**Objectives:**
To assess the frequency of exacerbations and quality of life in patients with gout after a 12 weeks course of urate-reducing therapy with allopurinol in combination with the anti-inflammatory drug meloxicam for the prevention of gout exacerbations.

**Methods:**
Physical examination, clinical blood, urine tests, biochemical blood tests, instrumental diagnostics were performed in all patients. Information about concomitant diseases was entered, drug therapy was recorded at the time of observation. Allopurinol was administered orally, once a day. Every 3 weeks under the control of serum uric acid levels (sUA), the allopurinol dosage was increased by 50 mg, up to 300mg per day. The total daily dose of meloxicam administered in different dosage forms was 75-15mg. After 3, 6, 9 and 12 weeks, the clinical efficiency of treatment was assessed using the EuroQol-5D-5L questionnaire, physical examination, joint pain dynamics at rest, during movement and palpation, as well as the Likert scale and visual analog scale (VAS) in mm. Factors such as the presence of anxiety or depression, self-care ability, normal daily activities of daily living were taken into account, as well as their rating of their level of satisfaction with the treatment on a scale of 1 to 5. Where 1 is not an improvement but a deterioration and 5 is a very good result. Both the period of remission and the time before the onset of a recurrence of gouty arthritis were taken into account, as well as adverse events (AEs) were recorded.

**Results:**
143 patients with an established diagnosis of gout (ACR/EULAR, 2015) were examined at an outpatient appointment. Against the background of treatment with meloxicam 7,5mg per day, more than two-thirds of the patients did not experience a worsening of the joint syndrome with an increase in the dose of allopurinol to 300mg per day. By the 12th week of follow-up, it was found that the characteristic features of gouty arthritis significantly began to differ in improving mobility, self-care, habitual daily activities, reducing soreness, reducing anxiety and depression (p <0.05). Moreover, the initial ESR and sUA levels were significantly different from the follow-up endpoint (p < 0.05), indicating a positive effect on the inflammatory process. A three-month course of combination therapy did not cause a significant increase in blood pressure or change in serum creatinine clearance in the patients. From the gastrointestinal tract there were no adverse events. 90.9% of patients assessed the treatment efficiency as very good. AEs in the form of an allergic skin rash were observed in one patient. But there was no need to interrupt the treatment, as the rash completely disappeared without consequences after completing the course of treatment with allopurinol and meloxicam.

**Conclusion:**
A 12-week combination therapy with allopurinol, a urate-reducing drug, and meloxicam, an anti-inflammatory drug, prevents exacerbation of joint syndrome and improves quality of life in patients with gout.

**DISCLOSURE OF INTERESTS:**
None declared

**DOI:**

**AB1060**

**LONG-TERM DISABILITY SECONDARY TO CRPS-1: RETROSPECTIVE MONOCENTRIC STUDY ON 106 CASES.**

C. Criotl1, F. Zucchi1, M. Manara1, R. Caporalil1, M. Varenna1; 1ASST Gaetano Pini-CTO, Department of Rheumatology, Milan, Italy; 2University of Milan, Department of Clinical Sciences & Community Health, Milan, Italy

**Background:**
Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling pain syndrome characterized by sensory and vasomotor disturbance, swelling, and functional impairment. Persistence of signs and symptoms has been observed in up to 64% of cases until 5.8 yrs after the onset of manifestations. Long-term disability, such as irreversible functional limitation, has been reported in up to 28% of cases with severe consequences on workability. No scores are validated to evaluate residual disability. Bisphosphonates have the best efficacy profile, compared with other therapeutic approaches, but data on long-term effectiveness are lacking.

**Objectives:**
To retrospectively evaluate long-term residual disability in patients with CRPS-1 of hand or foot after treatment with IV Neridronate (IVNer). To identify predictors of residual disability. To quantify disease outcomes, such as patient’s subjective perception and residual pain. To assess long-term safety profile.

**Methods:**
We retrospectively collected data of patients affected by CRPS-1, treated with IVNer, referred to a tertiary Rheumatology Centre between Feb 2013 and Dec 2020. Visual analogue scale (VAS) and McGill Questionnaire (McGQ) were used for pain assessment. Disabilities of the Arm, Shoulder and Hand (DASH) and American Orthopaedic Foot and Ankle Society’s (AOFAS) ankle-hindfoot scale for hand and foot involvement, respectively, were administered to explore disability through a phone survey. This kind of investigation was preferred for Covid pandemic.

**Results:**
106 patients with definite diagnosis of CRPS-1 were included, mean age ±standard deviation 55.6±13 yrs, 67% females, mean follow up duration 56.3 months (range 14-94), 46.2% with hand involvement. The mean VAS score before treatment onset was 55.8±23.4mm, while the McGQ was 12.9±6.7 in the sensory domain, 4.9±3.3 in the affective domain and 17.8±9.2 on the total score. Based on the patient’s subjective perception and the proposed semi-quantitative scale, 77.4% described themselves as fully recovered (FR), 15% partially recovered (PR), and 7.6% with persistent disease (PD). Comparison between baseline and follow-up VAS shows a significant reduction (55.8±23.4 vs 15.1±26.4, p<0.0001). Pain assessment by McGQ showed a significant improvement in global score (baseline vs follow-up 17.8±9.2 vs 3.9±7.8, p<0.0001), sensory (12.9±6.7 vs 2.7±5.7, p<0.00011) and affective (4.9±3.3 vs 1.2±2.3, p<0.00001) domains. According to DASH score, 79.2% of the patients were FR, 3.8% had some difficulties, but with overall preserved use of the upper limb, and 17.0% had permanent functional disability. According to AOFAS ankle-hindfoot scale 76.4% of patients were FR, 16.0% had partial recovery, and 7.6% had severe functional impairment. Percentages of DASH and AOFAS scores showed a complete accordance with patients’ subjective perception (Figure 1a and b). The only predictor of long-term functional impairment for CRPS-1 in the hand was a delayed treatment compared to symptoms onset (p=0.02). No predictors were found for foot localization. No patients reported the occurrence of osteonecrosis of the jaw or atraumatic fractures/atypical fracture features.

**Figure 1.**

**Conclusion:**
IVNer maintained a good long-term effectiveness and safety profile in the treatment of CRPS-1. The effectiveness of IVNer is maintained on both pain symptoms and function, in terms of reductions in the VAS, McGQ and in hand and foot disability scores.

**REFERENCES:**

**DISCLOSURE OF INTERESTS:**
None declared

**DOI:**
Background: Hypertrophic osteoarthropathy (HOA) is characterized by several clinical findings, including arthralgia/arthritis, periostitis, and digital clubbing. It can occur as a congenital condition called pachydermoperiostosis, and more commonly, as a secondary manifestation of pulmonary or extrapulmonary diseases or malignancy. Genomic studies support the role of prostaglandin E2 (PGE2) in the pathogenesis of primary HOA, with mutations in the 15-hydroxyprostaglandin dehydrogenase encoding gene resulting in increased PGE2 levels.

Objectives: To analyse the clinical characteristics, comorbidities, and the potential role of PGE2 in primary and secondary forms of HOA and/or clubbing and also evaluate the clinical evolution of these patients.

Methods: Eighteen patients (10 men/8 women) aged 15 to 78 years (49.9 ± 15.6) diagnosed with clubbing and/or HOA were attended in our Rheumatology Department over an 11-year period. We reviewed the clinical characteristics of the patients, including associated comorbidities, image findings, bone turnover markers (BTM), and serum and urinary levels of PGE2, among others. Additionally, we evaluated the treatment and the clinical evolution of these subjects.

Results: Most patients presented associated clinical conditions for HOA and/or clubbing, with only one, the youngest (15 years old), having primary HOA (pachydermoperiostosis). Pulmonary disorders were the most frequent associated conditions, with interstitial lung disease (4 cases), COPD (3 cases), and lung cancer (4 cases) being the most frequent, followed by liver diseases including primary biliary cirrhosis (1 patient), liver cirrhosis (2 patients) and chronic hepatitis C virus (2 patients). All the subjects evaluated (15/18) presented increased urinary PGE2 levels (the highest being observed in primary HOA), with most also presenting increased serum PGE2 values. BTM were evaluated in most subjects (17/18) showing increased values in most (11/17), particularly in PNP and Ctx. 4 patients were treated with selective inhibitors of cyclooxygenase-2 (COX-2) presenting, when evaluated, a small decrease in urinary PGE2 titers and partly improving their symptoms, which clearly improved after treating the associated cause when possible.

Conclusion: In the present series, all subjects with primary or secondary HOA and/or clubbing presented markedly increased PGE2 values, particularly in urine, supporting the role of this agent in the etiopathogenesis of this disorder. Pulmonary disorders, including malignancy and liver diseases, constituted the most frequent associated conditions. The use of COX-2 seems to be an effective symptomatic therapeutic approach in this entity.

Disclosure of Interests: None declared


**AB1062**

**EVALUATION OF THE EFFECTIVENESS OF GOUT THERAPY IN OUTPATIENT PRACTICE**

A. Sarapulova1, O. Teplyakova2, 1USMU Outpatient Therapy, Yekaterinburg, Russian Federation; 2USMU Outpatient Therapy, Yekaterinburg, Russian Federation

Background: gout is a socially significant pathology, as it affects men of working age and is associated with the development of cardiovascular diseases. Meanwhile, according to studies, most patients with gout do not reach the target values of uric acid (UA).

Objectives: to evaluate the effectiveness of gout therapy in real clinical practice and to identify factors that improve this indicator.

Methods: the study included patients with an established diagnosis of gout (according to ACR/EULAR criteria). Depending on the stage of the disease, patients were prescribed symptomatic anti-inflammatory therapy, and urate-lowering therapy (UST) - allopurinol or febuxostat - to reduce the level of UA. The dosage of allopurinol in the first 2 months of admission was 300 mg/day and then adjusted depending on the level of UA, the dosage of febuxostat was 80 mg, adjusted to 120 mg if necessary. To prevent exacerbation, all patients were prescribed colchicine 0.5-1.0 mg/day for up to 6 months. After 2 and 6 months of therapy, the effectiveness of it was assessed. All patients had a conversation about the correction of risk factors (diet, alcohol intake) and recommendation to watch online educational school for patients with gout.

Results: Twenty-one of 60 patients included in the study were 46.9±9.9 years, the duration of the disease was 8.5±5.4 years, of which 96.7% were men. The mean number of exacerbation per year prior to therapy was 7.8±3.5. After 6 months of therapy, 46.7% of patients noted the absence of gout attacks, the rest - a decrease in the duration of attacks (from 10.4 to 1.6 days on average) and their intensity (the average pain during an attack on the VAS scale decreased from 7.8 points up to 3.9). The average level of UA decreased over 2 months from 541.3±146.8 to 387.4±146.9 µmol/l, and after six months of admission it was 299.6±85.5 µmol/l. The creatinine level did not change significantly and amounted to 104.7±34.9 µmol/l before therapy and 97.3±26.7 µmol/l after 6 months. None of the patients discontinued therapy due to side effects or intolerance; one of the patients experienced a slight leukopenia while taking febuxostat, which did not lead to discontinuation of the drug. It should be noted that the majority of the subjects - 56.7% - had previously consulted a rheumatologist, but most of them did not receive permanent therapy. Patients highlighted qualitative information and the effect of treatment as the most important reasons for continuing therapy.

Conclusion: This study proves that achieving the target level of UA is possible in most patients with gout, leads to a significant reduction in the number of attacks and their severity, requires educational work and patient monitoring. It is important that this work is part of a planned 2-year follow-up of patients with gout in order to determine the long-term effectiveness of therapy.

Disclosure of Interests: None declared

AB1064
HYPURURICEMIA IN PATIENTS WITH PRIMARY HYPERTENSION: PREVALENCE AND ASSOCIATED FACTORS
N. El Amri1, F. Phima1, D. Khalfia1, A. Ben Abdelkrim2, B. Ben Abdallah2, S. Latou1, K. Baccouche1, E. Bouajina1, K. Acht2. 1Farhat Hachid Hospital, Rheumatology department, Sousse, Tunisia; 2Farhat Hachid Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia

Background: Hypertension and hyperuricemia (HU) are both cardiovascular risk factors. HU is frequently associated with hypertension even without the use of treatments that potentially cause elevations of uric acid levels.

Objectives: To determine the prevalence of HU in patients diagnosed with primary hypertension and its associated factors.

Methods: A cross-sectional study was conducted in the rheumatology and endocrinology departments of Farhat Hachid Hospital of Tunisia over a period of 6 months. Patients diagnosed with primary hypertension were included. HU was defined by uric acid levels ≥ 360 µmol/L in women and ≥ 420 µmol/L in men.

Results: One hundred patients were included. Study population was mainly made up of women (65%). The median age of 63 years (min:34, max:89). The prevalence of HU was 26%. HU was more common in women (19%) compared to men (7%) without statistical significance (p=0.315). The median values of systolic and diastolic blood pressure values were 140 mmHg and 80 mmHg, respectively. Elevated diastolic blood pressure was associated with HU (p=0.043). All patients presented other comorbidities. Type 2 diabetes was the most common one (83%) followed by obesity (56.7%). Forty three percent of patients had dyslipidemia, 21% renal failure, 16.9% proteinuria, 9% gout, 8% hypothyroidism and 30% osteoarthritis. HU was significantly associated with systolic (p=0.02), diastolic (p=0.039) and proteinuria (p=0.02). HU was not associated with disturbance of lipid and glycemic status. High uric acid levels were associated with the use of thiazide diuretics (p=0.048) and ACE inhibitors (p=0.037). Nonetheless, no association was found with the use of low dose aspirin (p=0.412) nor other antihypertensive treatments.

Conclusion: Prevalence of HU is high in patients diagnosed with primary hypertension and is associated with hypothyroidism, obesity, renal failure, proteinuria and diastolic hypertension. HU is also associated with the use of thiazide diuretics and ACE inhibitors.

REFERENCES:

AB1065
EARLIER ONSET OF ARTERIAL HYPERTENSION IS A RISK FACTORS FOR SEVERE COURSES OF GOUT
F. Markelova1, E. Ilinykh2, D. Karateev2, E. Luchkhina1. 1FM Vladimirov Research Clinical Institute of the Moscow Region, Rheumatology Department, 612, Shchepkina Street, Moscow, 129110, Russian Federation; 2VA Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, Rheumatology Department, Moscow, Russian Federation

Background: Comorbidities cardiovascular disease such as arterial hypertension (AH) are common in people with gout and complicate its management and treatments that potentially cause elevations of uric acid levels.

Objectives: Our purpose was to evaluate the effect of AH on the severity of gout.

Methods: We included data of 286 male patients with gout: median (Me) age 51.2 [interquartile range (IR) 42.6;59.4] years (ys), disease duration – Me 6.2 [IR 3.8;12.1] ys, number of joints involved during disease course – Me 7 [IR 4;12], subcutaneous tophi – in 35% pts, intraosseous tophi – in 44% pts. All pts were made of women (65%). The median of age was 63 years [min:34, max:89]. The prevalence of HU was 26%. HU was more common in women (19%) compared to men (7%) without statistical significance (p=0.315). The median values of systolic and diastolic blood pressure values were 140 mmHg and 80 mmHg, respectively. Elevated diastolic blood pressure was associated with HU (p=0.043). All patients presented other comorbidities. Type 2 diabetes was the most common one (83%) followed by obesity (56.7%). Forty three percent of patients had dyslipidemia, 21% renal failure, 16.9% proteinuria, 9% gout, 8% hypothyroidism and 30% osteoarthritis. HU was significantly associated with systolic (p=0.02), diastolic (p=0.039) and proteinuria (p=0.02). HU was not associated with disturbance of lipid and glycemic status. High uric acid levels were associated with the use of thiazide diuretics (p=0.048) and ACE inhibitors (p=0.037). Nonetheless, no association was found with the use of low dose aspirin (p=0.412) nor other antihypertensive treatments.

Results: One hundred patients were included. Study population was mainly made up of women (65%). The median age of 63 years (min:34, max:89). The prevalence of HU was 26%. HU was more common in women (19%) compared to men (7%) without statistical significance (p=0.315). The median values of systolic and diastolic blood pressure values were 140 mmHg and 80 mmHg, respectively. Elevated diastolic blood pressure was associated with HU (p=0.043). All patients presented other comorbidities. Type 2 diabetes was the most common one (83%) followed by obesity (56.7%). Forty three percent of patients had dyslipidemia, 21% renal failure, 16.9% proteinuria, 9% gout, 8% hypothyroidism and 30% osteoarthritis. HU was significantly associated with systolic (p=0.02), diastolic (p=0.039) and proteinuria (p=0.02). HU was not associated with disturbance of lipid and glycemic status. High uric acid levels were associated with the use of thiazide diuretics (p=0.048) and ACE inhibitors (p=0.037). Nonetheless, no association was found with the use of low dose aspirin (p=0.412) nor other antihypertensive treatments.

Conclusion: Prevalence of HU is high in patients diagnosed with primary hypertension and is associated with hypothyroidism, obesity, renal failure, proteinuria and diastolic hypertension. HU is also associated with the use of thiazide diuretics and ACE inhibitors.

REFERENCES:
ASYMPTOMATIC HYPERURICEMIA AND ASSOCIATED FACTORS IN MALE PATIENTS VISITED HANOI MEDICAL UNIVERSITY HOSPITAL

T. Pham1, H. T. Pham1, T. H. Pham1, G. Trân1, T. Nguyễn1, T. Đỗ1, 1Hanoi Medical University Hospital, Rheumatology Unit - Internal Medicine Department, Hanoi, Vietnam

Background: Asymptomatic hyperuricemia prevalence in Vietnamese men has rose over the past several years. This leads to gout and increase cardiovascular risk. 

Objectives: To assess the prevalence of asymptomatic hyperuricemia and associated factors in male patients who had medical check-ups in Hanoi Medical University Hospital.

Methods: All asymptomatic hyperuricemia male patients over 18 years old, had medical check-ups in outpatient clinics from January 2020 to May 2021. Exclude criteria included patients having medicine which affected serum uric acid (allopurinol, probenecid, sulfinpyrazone, salicylate, phenylbutazone, ascorbic acid, ethambutol, pyrazinamide, etc.), had acute diseases, diabetes type 1, chronic kidney disease and malignancies. All patients were tested for serum uric acid, total Cholesterol, Triglyceride, HDL-C, LDL-C and fasting serum glucose using Roche Cobas 6000 analyzer. Age, body mass index, alcohol consuming, physical activities and comorbidities were identified.

Results: 798 male patients over 18 years old were included in the study. Mean age was 39.5 ± 11.2, overweight and obesity rate was 31.5% and 29.8%, respectively. 41.4% patients had hyperuricemia with mean serum uric acid was 405.2 ± 81.2 μmol/l (highest was 820 μmol/l). We found that the factors associated to hyperuricemia in men were: the presence of hypertension (OR 1.64, 95% CI 1.12-2.4), obesity (OR 2.16, 95% CI 1.6-2.6). We did not find association between smoking, physical activities, impaired glucose tolerance with hyperuricemia.

Conclusion: Alcohol consuming, dyslipidemia and hypertension were associated with higher risk of incident asymptomatic hyperuricemia in Vietnamese men.

Disclosure of Interests: None declared


HIGH FREQUENCY OF STRUCTURAL DAMAGE IN THE LOWER SPINE OF PATIENTS WITH CHONDROCALCINOSIS

K. Klavdianou1, J. Kasfeld1, M. Fruth2, S. Tsiarni1, J. Braun1, P. Sewerin1, D. Kiefer1, X. Baralakos1, 1Rheumazentrum Ruhrgebiet Heme, Ruhr-University Bochum, Heme, Germany; 2Asklepieion General Hospital, Department of Rheumatology, Volua, Athens, Greece; 3Bilik, Radiologie, Heme, Germany

Background: Calcium pyrophosphate dihydrate crystal deposition disease (CPPD, chondrocalcinosis) is known to affect fibrocartilaginous tissue in the large and smaller peripheral joints. The affection of similar structures in the axial skeleton is unclear.

Objectives: To assess the frequency and severity of structural changes in the lower spine in patients with established CPPD in comparison to degenerative disc disease (DDD).

Methods: In a retrospective study, patients with CPPD or DDD as a main diagnosis with available spinal conventional radiographs (CR) performed during 2014 – 2020 were included. Define other inflammatory conditions affecting the spine were excluded. The CR segments T7-L5/L6 were evaluated for the occurrence of disc calcification, intradiscal vacuum phenomena, disc height (normal, narrow, complete loss), endplate erosion, osteophytes and spondylolisthesis. When lumbar spine MRIs of the same time point were available, discovertebral units were evaluated for the occurrence of vacuum phenomena, endplate erosion, Modic changes and disc dehydration (Pfirrmann). Follow up CR were assessed if available. All available images were evaluated by 2 independent readers and discrepancies were solved by consensus.

Results: CR of 140 patients (1.171 discovertebral units) with CPPD and 99 DDD (803 discovertebral units) were evaluated (mean age 74.4±9.7 and 71±6.2; 20% vs. 20.2% males, respectively). MRIs of the spine were available from 48 CPPD and 44 DDD patients. Vacuum phenomena, disc calcification, osteophytes and erosion were significantly more frequently seen in patients with CPPD compared to DDD (Table 1) with no differences between the thoracic and the lumbar spine. Follow-up CR were available for 29 patients with CPPD and 48 DDD. Both groups presented statistically significant progression of endplate erosions and osteophytes (p=0.001 - 0.02 for both groups). Notably, even though CR follow-up times in the CPPD group were, compared to DDD (median (IQR) 1.9 (2.4) vs 3.0 (3.1) years, p=0.033, respectively), shorter, radiographic progression was noted more frequently in CPPD vs. DDD for erosive changes (6.8% vs. 0.6%, p=0.018) and disc calcification (9.8% vs. 0.6%, p=0.007), respectively. When comparing MRIs, a higher number of discovertebral units was affected by vacuum phenomena (34 vs 13, p=0.04) and endplate erosions (L4/S 45.5% vs 24.4%, p=0.04), L5/S 1(40.4% vs 19.5%, p=0.03) in patients with CPPD vs. DDD, respectively.

Table 1. Frequency of affected discovertebral units on conventional radiographs

<table>
<thead>
<tr>
<th>CPPD</th>
<th>DDD</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vacuum phenomenon</td>
<td>156 (13.3%)</td>
<td>44 (5.5%)</td>
</tr>
<tr>
<td>Disc calcification</td>
<td>193 (16.5%)</td>
<td>42 (5.2%)</td>
</tr>
<tr>
<td>Endplate erosion</td>
<td>159 (13.6%)</td>
<td>26 (3.2%)</td>
</tr>
<tr>
<td>Osteophytes</td>
<td>361 (73.5%)</td>
<td>480 (59.8%)</td>
</tr>
<tr>
<td>Spondylolisthesis</td>
<td>126 (10.8%)</td>
<td>69 (8.6%)</td>
</tr>
</tbody>
</table>

CPPD: calcium pyrophosphate dihydrate crystal deposition disease DDD: degenerative disc disease

Conclusion: Patients with chondrocalcinosis showed more severe and progressive degenerative findings in the lower spine as assessed by both, CR and MRI, even more in comparison to established DDD. This data shows that disease manifestations of CPPD in the axial skeleton are clinically relevant.

Disclosure of Interests: None declared


URIC ACID LEVELS IN RELATION TO FASTING BLOOD GLUCOSE AND HBA1C

F. Fhima1, N. El Amri1, D. Khalfi1; A. Ben Abdedkrim2, S. Latoula1, B. Ben Abdallah1, K. Baccouche1, E. Bouajina1, K. Ach1, 1Farhat Hached Hospital, Rheumatology Department, Sousse, Tunisia; 2Farhat Hached Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia

Background: Hyperuricemia is reported to be a risk factor for the development of type 2 diabetes (T2D) and prediabetes.

Objectives: To determine the prevalence of HU and gout in T2D and prediabetes and to study the relationship between HU, gout, T2D and prediabetes.

Methods: A cross-sectional study was conducted between January 2021 and June 2021 in the Rheumatology and endocrinology departments of Farhat Hached Hospital. Patients who fulfilled the diagnosis of diabetes or prediabetes according to the American Diabetes Association guidelines of 2021 were included. Uric acid levels were also assessed and HU was defined as uric acid levels ≥ 360 μmol/l in women and ≥ 420 μmol/l in men. Diagnosis of gout was based on the ACR/EULAR 2015 classification.

Results: One hundred fifty-one patients having T2D and 46 prediabetic patients were included. The mean age of both groups was 61 and 54 years respectively. Prevalence of HU was 26.1% in prediabetic while it was 17.2% in the group of T2D with no statistical relevance (p=0.182). No difference related to gender was observed in both groups. The prevalence of gout was higher in the prediabetes group (15.2%) compared to the T2DM group (6%) but without significant difference (p=0.082). Uric acid levels were remarkably higher in prediabetic patients (mean=324.3 μmol/l) compared to patients having T2D (median=278 μmol/l) with a significant statistical difference (p=0.022). No association was identified between HU, fasting blood glucose and HbA1C in the two groups. However, uric acid levels are inversely proportional to fasting blood glucose (p=0.001) and HbA1C (p=0.001) in both patients.

Conclusion: Individuals with moderately elevated HbA1C and fasting glucose levels (prediabetes) may be at a higher risk of HU, whereas individuals with diabetes or elevated HbA1C levels may have a normal uricemia. This could be explained by the GLUT-9 transporter regulation in the renal proximal tubule that blocks the absorption of uric acid when glycosuria is present.

References:

Disclosure of Interests: None declared

Infection-related rheumatic diseases

**AB1070** INFECTIOUS SACROILIITIS: A RARE ENTITY IN RHEUMATOLOGY!

S. Rekić1, O. Hamdi1, S. Bousaid2, S. Rahmouni3, S. Jemmali1, H. Sahli1, M. Elleuch1, 1La Rabta hospital, Rheumatology, Tunisia, Tunisia

**Background:** Infectious sacroiliitis (ISI) is a rare disease, with misleading clinical symptoms that often delay the diagnosis.

**Objectives:** The aim of this study was to describe the clinical, microbiological, therapeutic and radiological characteristics of ISI.

**Methods:** This descriptive, retrospective study included all ISI patients that were hospitalized in our rheumatology department over an 11-year period [2010 - 2021].

**Results:** Overall, 25 cases of ISI were identified, comprising 15 men (60%) and 10 women (40%), with a mean age of 48.7±10.5 years [21-67]. ISI was caused by pyogenic microorganisms in 12 cases (70.5%), mycobacterium tuberculosis in 7 cases (41.2%), and brucella spp in 6 cases (35.3%). The mean symptoms duration in pyogenic, brucellar and tuberculous ISI was 42 days, 67 days, and 255 days, respectively. The onset was brutal in 88% of pyogenic ISI, while it was progressive in 66% of brucellar ISI and in all cases of tuberculous ISI. Lumboischialgia pain was the most common symptom (80%). The involvement of the sacroiliac joint was always unilateral, and inflammatory in 92% of cases. The other most common symptoms included: fever (80%), impotence (68%), and lumbago (52%). An infectious source was found in 17 patients: 41.2% pulmonary (tuberculosis, n=7), 29.4% urinary, 17.6% gynecological (postpartum, n=3), and 11.7% septicemic (n=2). Fifteen patients (60%) had a biological inflammatory syndrome. Leukocytosis was found in 11 cases (64.7%). Pelvic x-ray showed a narrowing of the sacroiliac joints in 52% of cases. CT of the sacroiliac joints showed erosions in 60% of cases. Sacroiliac MRI showed erosions (45%), joint effusion (32%), and psosas abscess (14%). A second infectious site was found in 20% of cases: psosas abscess (n=2), and a collection of the soft tissues facing the joint (n=1). A pathogenic agent was isolated by means of blood culture (48%); staphylococcus aureus 56%, streptococcus 28%, and staphylococcus with negative coagulase 16%), articular biopsy (40%), cytobacteriological examination of urine (20%), Wright serology (20%), and Tuberculin skin test (6.2%). All patients received germ-adapted antibiotics. No patients have had surgical treatment. Evolution was favorable in most cases (n=11). Four patients complained of residual pain in the sacroiliac region. None of the patients relapsed.

**Conclusion:** Although ISI is rare, it remains an emergency diagnosis. A rigorous physical examination is essential in order to detect this infection early. Antibiotics often lead to clinical improvement, making thus the need for surgery exceptional.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.177

**AB1071** INFECTIONS IN RHEUMATOLOGIC PATIENTS IN A LATIN AMERICAN HOSPITAL: A 10-YEAR COHORT STUDY.

L. Dulcey1, J. Theran2, R. Callagrione1, H. Moreno1, J. Pineda1, R. Parales2, M. Aguas3, 1Los Andes University, Internal Medicine, Bucaramanga, Colombia; 2Bucaramanga University, Medicine, Bucaramanga, Colombia; 3Santander University, Medicine, Bucaramanga, Colombia

**Background:** Infections have been indicated to be the cause and / or consequence of the calving and decompensation of some Connective Tissue Diseases and, in principle, both the immunological disorder and the immunosuppressive action of medications contribute to this.

**Objectives:** To describe the frequency of infections associated with the various rheumatological pathologies in patients admitted to hospitalization and to know their associated factors.

**Methods:** A descriptive study was carried out in which 3328 medical records belonging to the patients of the Rheumatology service were reviewed during a follow-up period from January 2010 to December 2020, measures of central tendency such as mean, mode, median and applied the Chi square test to appreciate statistical value between the various variables to be correlated.

**Results:** Most of the patients were female. The main rheumatological pathology was Rheumatoid Arthritis, followed by Systemic Lupus Erythematosus, Osteoarthritis in 3 place and finally in the last box other entities other than those indicated. The main infectious were those of the urinary tract, in the second instance those of skin and soft tissues, in third place the respiratory ones and lastly those not included in the previous categories. The 2 main therapies related to infections were the use of steroids followed by biological therapy (p 0.001).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.308

**AB1072** HERPES ZOSTER IN INDIVIDUALS WITH AUTOIMMUNE DISEASES AND RECOMBINANT HERPES ZOSTER VACCINE AS A PREVENTATIVE STRATEGY

K. Winthrop1, F. A. Ferraye2, K. M. Sullivan3, D. O. Miller4, P. Vink5, F. Tavares-Da-Silva6, 1Oregon Health and Science University, Portland, OR, United States of America; 2Inflammatory Bowel Disease Center Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States of America; 3Duke University Medical Center, Durham, NC, United States of America; 4GSK Vaccines, Mississauga, ON, Canada; 5GSK
Vaccines, Rockville, MD, United States of America; 2GSK Vaccines, Wavre, Belgium

Background: Individuals with autoimmune diseases (AIDs) are particularly vulnerable to herpes zoster (HZ) and its related complications. Although the live attenuated HZ vaccine is contraindicated in many of these individuals, the two-dose non-live recombinant zoster vaccine (RZV) can be used in immunosuppressed individuals. Based on accumulating data from RZV studies within specific immunosuppressive conditions, recently updated guidelines recommend RZV not only in immunocompetent adults aged ≥50 years, but also in adults aged ≥18 years (EU)/≥19 years (USA) at risk of HZ due to immunodeficiency or immunosuppression.1

Objectives: To evaluate the burden of HZ in individuals with AIDs and the use of RZV as a preventive strategy.

Methods: We reviewed PubMed for available data on HZ incidence, summarised RZV data (effectiveness and safety) and the current recommendations for RZV in individuals with AIDs. The latest search was conducted in September 2021.

Results: HZ incidence in the general population is 4–7/1000 person-years (increases with age) and 8–15/1000 person-years in individuals with AIDs. Common immunosuppressive and immunomodulatory therapies can predispose individuals to HZ, as shown by large meta-analyses of interventional and observational studies. No published randomised controlled trial data of RZV in AID populations were found in our search. In two retrospective cohort studies in patients with inflammatory bowel disease (IBD),1,2 RZV demonstrated high vaccine effectiveness (OR 0.84; 95% CI 0.44, 0.77).2 In a real-world observational study investigating RZV in beneficiaries of the Medicare national health insurance program in the USA, individuals with AIDs achieved vaccine effectiveness of 68.0% (95% CI 62.3%, 72.8%), which was similar to the overall population (70.1% [95% CI 68.6%, 71.5%]).3 In two single-centre, retrospective studies of RZV in individuals with AIDs, including rheumatoid arthritis (RA), adverse events after the first RZV dose were mild to moderate, with a flare at the first RZV dose was significantly associated with an increased risk of a flare at the second dose (hazard ratio 3.9; P=0.005).4 In addition, glucocorticoid use during vaccination was significantly associated with flares (odds ratio [OR] 2.31; P=0.004; Lenfant, 2021).5 In a study of individuals with IBD, receiving ≥1 RZV dose was associated with a low flare rate.6 Current RZV guidelines vary by country and will be revised as new data emerge. Ongoing studies include phase 4 studies of individuals with RA and IBD receiving immunotherapies, and a study investigating the immunogenicity and safety of RZV in individuals with stable systemic lupus erythematosus.

Conclusion: Individuals with AIDs are at increased risk of HZ and its related complications, which may be due to either or both of their underlying condition and the treatment(s) they are receiving. The developing collective scientific evidence from the published literature on RZV in individuals with AIDs demonstrates a favourable benefit:risk profile for RZV in this population which contributed to the recent USA ACIP recommendation. Further studies are warranted to evaluate potential effects of individual conditions and immunotherapies on vaccine efficacy and methods to optimise vaccine use.

REFERENCES:
[3] GlaxoSmithKline, RZV EU SmPC, 2021

Acknowledgements: This abstract was funded by GlaxoSmithKline Biologics SA. Medical writing support in the preparation of this abstract was provided by Silvia Pregolato of OPEN Health Communications, London, UK, with financial support from GlaxoSmithKline Biologics SA.

Disclosure of Interests: Kevin Winthrop Consultant of: KLW has received consultancy fees from GlaxoSmithKline, Bristol Myers Squibb, Pfizer, Abb-Vie, Union Chimique Belge, Eli Lilly, Galapagos, Roche, Gilead, Sanofi, Regeneron, AstraZeneca and Novartis., Grant/research support from: KLW has received research grants from Bristol Myers Squibb and Pfizer., Francis A Farraye Consultant of: KMS has received consultancy fees from and been part of publication committees for GlaxoSmithKline., Keith M Sullivan Shareholder of: FAF is a stockholder in Innovation Pharmaceuticals., Paid instructor for: FAF sits on the data safety monitoring board for Eli Lilly and Fernandez, Consultant of: RZF has received consultancy fees from Arena, Bristol Myers Squibb, Braintree Labs, Gl reviewers, GlaxoSmithKline, Iterative Scopes, Janssen, Pfizer and Sebel., David O Willer Shareholder of: DOW holds restricted share stock ownership for GlaxoSmithKline., Employee of: DOW is employed by GlaxoSmithKline., Peter Vink Employee of: PV was an employee at GSK at the time this work was completed., Consultant of: VT has received consultancy fees from Arena, Bristol Myers Squibb-Silva Shareholder of: FTDs holds restricted share stock ownership for GlaxoSmithKline., Employee of: FTDs is employed by GlaxoSmithKline.

Conclusion: As a complementary approach to conventional methods, mNGS could help improving the identification of infection in CTD patients. The incidence of viral infection is high in patients with connective tissue disease and close attention should be paid to it in clinical works.

Figure 1. A. Comparison of test results between mNGS and conventional diagnostic testing methods (CDT) in CTD patients. B. The classification of mixed infections with or without viruses infection detected by mNGS and conventional diagnostic testing methods (CDT).

Figure 2. Distribution of pathogens detected by mNGS. A. Type distribution of pathogens identified by mNGS. Species distribution of viruses of B.viruses, C.Prokayote, D. Eucayon detected by mNGS.

Disclosure of Interests: None declared

AB1074

PNEUMOCYSTIS JIROVECCI PNEUMONIA (PJP) IN PATIENTS WITH AUTO-IMMUNE INFLAMMATORY RHEUMATIC DISEASE (AIIRD) IN ONE YEAR.

A. Escudero Siosi1, M. Andersson2, C. Woodrow3, S. Dubey1.1Oxford University Hospitals NHS Foundation Trust, Infection Disease & General Medicine, Oxford, United Kingdom; 2Oxford University Hospitals NHS Foundation Trust, Rheumatology, Oxford, United Kingdom; 3Oxford University Hospitals NHS Foundation Trust, Infectious Diseases and Microbiology, Oxford, United Kingdom

Background: Pneumocystis jirovecii pneumonia (PJP) is an uncommon but frequently fatal fungal infection, which can affect patients with rheumatic diseases treated with immunosuppressants or high doses of steroids. There are no clear guidelines on when to prescribe primary prophylaxis and available agreements differ depending on the disease or immunosuppressant.

Objectives: To raise awareness about this preventable infection and to highlight the urgent need to create a tailored probability scoring, before starting any immunosuppression so that the risk benefit of prophylaxis can be objectively assessed.

Methods: This is a retrospective case series of six patients who developed definite or probable PJP known to the Rheumatology Department at Oxford University Hospitals NHS FT since the beginning of 2021. These patients were identified through the microbiology and infectious disease teams, and notes were reviewed to collate data regarding the clinical characteristics. Of these, five were being treated for large vessels vasculitis (LVV) whilst the other one had seropositive rheumatoid arthritis (RA). The diagnosis of PJP was made on clinical picture, laboratory results, bronchoscopy and CT findings.

Results: In this series, the median age was 78 years (range 55-93) with equal gender distribution. In three LVV patients, the diagnosis was confirmed on ultrasound, one had a positive PET-CT whilst the other case had a high probability clinical diagnosis. Comorbidities included chronic kidney disease and hypertension in three patients, diabetes, or previous underlying malignancy in other two. Smoking history was present in four patients, while five patients had lymphopenia with counts <1x10^9/L. Four of the six cases were on combined therapy with disease modifying anti-rheumatic therapy drugs (DMARDs) and prednisolone, only one was exclusively on prednisolone and the patient with RA was on Methotrexate and Humira. The chronology of the infection was variable, still most of the patients developed PJP infection during the first three months of starting either a biological or corticosteroids. The median steroid dose by the time of PJP infection was 30mg and unfortunately three of the patients died. None of the patients who developed PJP had been given antibiotic prophylaxis prior to infection. Some proposed scoring systems for serious infection risk in patients with AIIRD exist, however they focused on RA or biologics use rather than patients with vasculitis or connective tissue disorders who might be on high dose corticosteroids. Additionally, PJP prophylaxis is not recommended in any of the current guidelines for LVV management (BSR, EULAR, ACR). Cochrane review suggests reduction of risk by 85% in patients given prophylaxis.

Conclusion: Pneumocystis jirovecii pneumonia (PJP) prophylaxis is not current practice for patients with large vessel vasculitis. Consideration needs to be given to PJP prophylaxis for patients on high dose steroids for a prolonged period, particularly in the presence of other risk factors. More data will be needed to help establish guidelines on PJP primary prophylaxis.

REFERENCES:

Table 1. Baseline characteristics of the cases (*n)

| Male gender | 3 |
| Age, year Median | 78 |
| Underlying disease |  |
| Large vessels vasculitis | 5 |
| Seropositive Rheumatoid arthritis | 1 |
| Smoking | 4 |
| Lymphopenia | 5 |
| Steroid dose ≥ 30 mg by the time of PJP infection | 4 |
| Concomitant DMARDs used | 4 |
| Numbers of deaths | 3 |

*n = numbers

Disclosure of Interests: None declared
**Table 1. The impact of each tube on QFT-Plus positivity**

<table>
<thead>
<tr>
<th>Test</th>
<th>Positive Only</th>
<th>Only TB1 Tube</th>
<th>Only TB2 Tube</th>
<th>TB1 and TB2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative ineterminate</td>
<td>86.2%</td>
<td>15%</td>
<td>12.2%</td>
<td>15%</td>
</tr>
<tr>
<td>Positive</td>
<td>12.2%</td>
<td>4%</td>
<td>6%</td>
<td>8%</td>
</tr>
</tbody>
</table>

Conclusion: Disease inflammatory cascades along with ongoing usage of immunosuppressive agents could affect results of QFT-plus assay in rheumatic diseases. TB2 tubes stimulating CD8(+) T lymphocytes have additional impact in detecting latent TB infection in patients with RA and SpA.

Disclosure of Interests: None declared

**AB1078** SPECTRUM OF INFECTIONS DURING RHEUMATOID ARTHRITIS

S. Rekik¹, S. Boussaid¹, H. Thini¹, S. Rahmouni¹, S. Jemmali¹, K. Zouaoui¹, H. Sahli¹, M. Elleuch¹.¹Tunis, Department of Rheumatology, La Rabta hospital, Tunis, Tunisia

**Background:** Immunosuppression during rheumatoid arthritis (RA) induced by the disease but especially immunomodulatory treatments, is responsible for an increased frequency of infections in these patients.

**Objectives:** The purpose of this study is to assess the incidence of infections during RA and to determine their nature and management.

**Methods:** A retrospective study over a period of 10 years, including 150 patients with RA. We identified 33 patients who had at least one infectious episode during their follow-up.

**Results:** There were 19 women and 14 men. The mean age was 51 years old [39-63]. RA was immunopositive and erosive in all cases. The average disease duration was 8 years. A comorbidity was associated with RA in 14 patients (42%): diabetes in 7 cases, hypertension in 3 cases, ethylism in 2 cases and history of pulmonary tuberculosis in 2 cases. As an extra-articular manifestation, 15% of patients had Sjogren's syndrome and 18% had uveitis associated or not with radiculalgia. Inflammatory pain was reported in 13 cases, pain associated or not with radiculalgia. Inflammatory pain was reported in 13 cases, pain associated or not with radiculalgia.

**Conclusion:** Elderly patients with infectious spondylodiscitis have fewer clinical symptoms leading to a delayed presentation. Increasing morbidity and mortality make rigorous monitoring necessary.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4568

---

**AB1080** BRUCELLAR SPONDYLODISCITIS: EPIDEMIOLOGICAL, CLINICAL AND BIOLOGICAL ASPECTS

S. Rekik¹, S. Boussaid¹, H. Thini¹, S. Jemmali¹, S. Rahmouni¹, K. Zouaoui¹, H. Sahli¹, M. Elleuch¹.¹Tunis, Department of Rheumatology, La Rabta hospital, Tunis, Tunisia

**Background:** Brucellosis is a systemic infection characterized by significant clinical polymorphism and non-specific manifestations. The spine is a common location for brucellosis.

**Objectives:** The aim of this study was to describe the epidemiological, clinical and biological characteristics of brucellar spondylodiscitis.

**Methods:** A retrospective study over a period of 15 years, including 18 patients diagnosed with brucellar spondylodiscitis on clinical, biological and/or imaging data.

**Results:** Eighteen cases were collected (13 men and 5 woman). The mean age was 52 years [19-76]. The main symptom was unifocal or diffuse spinal pain associated or not with radiculargia. Inflammatory pain was reported in 12 cases. Thirteen patients consumed raw milk, eleven had contact with farm animals or professional exposure. The average duration of symptoms was 5.7 months [0.5-12]. The disease had a progressive onset in 13 patients. The general signs were frequent: deterioration of general condition (13 cases), fever (12 cases) and night sweats (6 cases). All patients had a biological inflammatory syndrome. Wright’s serology, performed in 17 patients, was positive in 15 cases. The Rose Bengal test was positive in 13 of the 15 patients tested. Diagnosis by indirect immunofluorescence, performed in 11 patients, was positive in nine cases. However, the blood cultures, carried out in 13 patients and the disco-vertebral biopsy, carried out in 9 patients, did not find the causal agent.

**Conclusion:** The diagnosis of brucellar spondylodiscitis must be based on epidemiological, clinical arguments and biological examinations. Immunological examinations, however, seem to be more contributory and should be performed in case of diagnostic doubt and negative bacteriological investigation.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5007
COVID-19

FLARES OF RHEUMATOID ARTHRITIS FOLLOWING CORONAVIRUS VACCINATION

R. Hayward 1, Z. Farah 1. 1Northwick Park Hospital, Rheumatology Department, Harrow, United Kingdom

Background: With the emergence of the Coronavirus vaccine and the clear and important role it provides in maintaining the health of individuals and the population (1), it is important that our patients receive or are recommended the vaccine. We here document a case series of patients who have long-term quiescent rheumatoid arthritis who then experienced a flare of disease activity after receiving a vaccine. This information is important to understand as it allows informed discussions regarding the side effect profile of the vaccine and also the influence this may have on the patient’s disease control and future management options.

Objectives: To understand the changes to control of rheumatoid arthritis in those experiencing a flare of disease after receiving the coronavirus vaccine.

Methods: Patients were reviewed in clinic as part of standard care. Individuals with Rheumatoid Arthritis who had experienced a flare defined as a self-reported disease activity score of >5.1 in otherwise stable disease were noted and their response to treatment reviewed. This was a review of usual clinical practice and did not alter the treatment undertaken or monitoring of the patient. Information obtained was through the consultation with a rheumatologist and the data was collected retrospectively through review of clinical notes and clinic letters.

Results: The table below outlines the patient details and treatment responses. All flares occurred within two weeks of receiving the vaccine. Of the patients who flared, two required short term steroid treatment; three an increase in the usual medications and one who had been in disease remission to re-start previous therapy. More patients in the Pfizer vaccine group required an escalation of usual care compared to the AstraZeneca vaccine group.

Table 1

<table>
<thead>
<tr>
<th>Antibody status</th>
<th>Vaccine brand</th>
<th>Time since diagnosis of first flare (years)</th>
<th>Flare after 1st or 2nd dose</th>
<th>Usual treatment</th>
<th>Flare management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seropositive, anti-CCP positive</td>
<td>AstraZeneca 13 years</td>
<td>3 years</td>
<td>1st or 2nd dose</td>
<td>Methylprednisolone, Methotrexate</td>
<td>Intra-articular, Intramuscular</td>
</tr>
<tr>
<td>Seropositive, anti-CCP positive</td>
<td>AstraZeneca 11 years</td>
<td>4 years</td>
<td>1st or 2nd dose</td>
<td>Sulfasalazine</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>Seronegative, anti-CCP negative</td>
<td>AstraZeneca 13 years</td>
<td>2 years</td>
<td>2nd dose</td>
<td>Methotrexate</td>
<td>Sulfasalazine, Methylprednisolone</td>
</tr>
<tr>
<td>Seronegative, Pfizer anti-CCP negative</td>
<td>Pfizer 23 years</td>
<td>1 year</td>
<td>1st dose</td>
<td>Infliximab</td>
<td>Local joint injection, Reduce interval of infusions, Increase</td>
</tr>
<tr>
<td>Seronegative, Pfizer anti-CCP positive</td>
<td>Pfizer 7 years</td>
<td>3 years</td>
<td>2nd dose</td>
<td>Sulfasalazine, Hydroxychloroquine</td>
<td>Sulfasalazine, Methylprednisolone</td>
</tr>
<tr>
<td>Seropositive, anti-CCP positive</td>
<td>Pfizer 7 years</td>
<td>4 years</td>
<td>2nd dose</td>
<td>Methylprednisolone, Hydroxychloroquine</td>
<td>Re-start methotrexate, Sulfasalazine</td>
</tr>
</tbody>
</table>

Conclusion: We report 6 cases of rheumatoid arthritis flare soon after receipt of the coronavirus vaccine. In all, disease control was returned with minimal changes to treatment, 42% of those requiring either no treatment or an intra-muscular steroid injection alone. Therefore, we recommend that clinicians should counsel patients of this potential effect, but continue to advocate the vaccine, as the risk of complications to their underlying arthritis is very low and seemingly easily treatable.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.38

Figure 1. Severity of COVID-19 in regular colchicine or HCO users and these patients' household contacts.
Table 1. Disease specific outcomes of the entire cohort

<table>
<thead>
<tr>
<th>Variable</th>
<th>FNF (n=373)</th>
<th>FNF HHHC* (n=386)</th>
<th>P</th>
<th>Behcet Patients (n=262)</th>
<th>Behcet HHHC (n=257)</th>
<th>P</th>
<th>SLE Patients (n=197)</th>
<th>RA Patients (n=79)</th>
<th>RA (n=73)</th>
<th>Sjögren patients (n=41)</th>
<th>Sjögren HH (n=59)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD years</td>
<td>36.4 ± 13.2</td>
<td>36.3 ± 16.1</td>
<td>0.9</td>
<td>42.9 ± 11.4</td>
<td>38.1 ± 15.2</td>
<td>0.001</td>
<td>44.2 ± 16.2</td>
<td>39.4 ± 17.0</td>
<td>0.001</td>
<td>53.9 ± 10.3</td>
<td>40.3 ± 16.6</td>
<td>0.001</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>249 (66.8)</td>
<td>173 (44.8)</td>
<td>0.001</td>
<td>160 (61.1)</td>
<td>118 (45.9)</td>
<td>0.001</td>
<td>184 (93.4)</td>
<td>118 (45.9)</td>
<td>0.001</td>
<td>133 (93.4)</td>
<td>80 (33.3)</td>
<td>0.001</td>
</tr>
<tr>
<td>Positive antibody to SARS-CoV-2, n (%)</td>
<td>25 (6.7)</td>
<td>23 (5.9)</td>
<td>0.6</td>
<td>18 (6.9)</td>
<td>12 (4.7)</td>
<td>0.3</td>
<td>14 (7.1)</td>
<td>19 (6.5)</td>
<td>0.6</td>
<td>6 (4.1)</td>
<td>2 (2.7)</td>
<td>0.5</td>
</tr>
<tr>
<td>Symptomatic COVID-19 in seropositive cases, n (%)</td>
<td>18 (72)</td>
<td>10 (43.4)</td>
<td>0.04</td>
<td>4 (22.2)</td>
<td>1 (6.3)</td>
<td>0.3</td>
<td>2 (14.3)</td>
<td>3 (5.5)</td>
<td>0.2</td>
<td>1 (25)</td>
<td>1 (33.3)</td>
<td>0.3</td>
</tr>
<tr>
<td>Hospital admission in seropositive cases, n (%)</td>
<td>1 (3.8)</td>
<td>0 (0)</td>
<td>-</td>
<td>4 (22.2)</td>
<td>1 (6.3)</td>
<td>0.3</td>
<td>2 (14.3)</td>
<td>3 (5.5)</td>
<td>0.2</td>
<td>1 (25)</td>
<td>1 (33.3)</td>
<td>0.3</td>
</tr>
<tr>
<td>Mean colchicine dose, mg/day ± SD</td>
<td>1.5 ± 0.4</td>
<td>-</td>
<td>-</td>
<td>14 ± 6.4</td>
<td>-</td>
<td>-</td>
<td>263.6 ± 95.1</td>
<td>-</td>
<td>-</td>
<td>273.7 ± 132.5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Mean duration of colchicine usage, years ± SD</td>
<td>11.3 ± 8.3</td>
<td>-</td>
<td>-</td>
<td>10.4 ± 7.7</td>
<td>-</td>
<td>-</td>
<td>263.6 ± 95.1</td>
<td>-</td>
<td>-</td>
<td>273.7 ± 132.5</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Mean HCQ dose, mg/day ± SD</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Mean duration of HCQ usage, years ± SD</td>
<td>10.1 ± 8.6</td>
<td>-</td>
<td>-</td>
<td>7.3 ± 5.2</td>
<td>-</td>
<td>-</td>
<td>9 ± 6.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

* Spearman's correlation test ** Statistically significant p<0.05

Conclusion: Being on a regular treatment of colchicine or HCQ was not resulted in the prevention of COVID-19 or amelioration of its manifestations.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.83

AB1083 MUSCULOSKELETAL MANIFESTATIONS AND POSTCOVID SYNDROME IN HOSPITALIZED PATIENTS INFECTED WITH COVID-19

Ö. Küçülmez1, G. Genççoğ1. 1Baskent University Alanya Education and Research Hospital, Physical Medicine and Rehabilitation, Antalya, Turkey; 2Baskent University Alanya Education and Research Hospital, Nephrology, Antalya, Turkey

Background: Covid-19 may cause musculoskeletal manifestations or postcovid syndrome (1-3). Molecular mimicry, precursor activation, and immune activation are held responsible for the development of autoimmunity (4). It has been suggested that SARS-CoV-2 infection can cause blockage of lymph vessels since the virus can infect lymph endothelial cells branching to the nasal cavity and may cause postcovid syndrome (5).

Objectives: The aim of this study was to characterise the prevalence of musculoskeletal complaints, postcovid syndrome in hospitalized COVID-19 patients and relationship between clinical features and laboratory parameters.

Methods: A single-centre retrospective cohort study was conducted of patients at Baskent University between March 1 and December 31, 2020. The study protocol was approved by the Ethics Committee. Hospitalized patients aged above 18 years, diagnosed with COVID-19 via RT-PCR are included the study. Pregnant patients, those with severe end-stage disease or with missing documentation were excluded. Data were obtained from electronic health records. Information was collected about patient demographics, history and duration of complaints, history of postcovid syndrome, fever or anosmia, respiratory problems, length of stay, history of intensive care and COVID-19-related biochemical parameters and rheumatologic tests. The correlation between musculoskeletal manifestations, postcovid syndrome and laboratory and clinical parameters were observed. P value<0.05 was considered statistically significant.

Results: Totally 109 patients included to the study. %39.45 of patients were female (n=66), %60.55 of patients were male (n=43). %34.86 (n=38) of patients complained about arthralgia, %1.83 (n=2) had arthritis and %41.28 (n=45) described fatigue. Postcovid syndrome was determined in %32.11 (n=35) of patients. Positive otoantibody was determined in one patient and arthritis due to paraneoplastic syndrome was detected in a case. There was significant correlation between fever, length of stay and control CRP (p<0.05).

Conclusion: As there was no correlation between musculoskeletal manifestations, postcovid syndrome and laboratory and clinical findings. There should be further studies for understanding mechanisms of musculoskeletal manifestations and postcovid syndrome in SARS-CoV-2 infection.

REFERENCES:

Table 1. Correlation between musculoskeletal complaints (arthralgia, arthritits, fatigue), postcovid syndrome and laboratory and clinical parameters

<table>
<thead>
<tr>
<th>Variable</th>
<th>Basal CRP</th>
<th>Control CRP</th>
<th>Fever</th>
<th>Length of stay</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritits (n=2)</td>
<td>0.19</td>
<td>0.28</td>
<td>0.39</td>
<td>0.09</td>
</tr>
<tr>
<td>Arthritits (n=38)</td>
<td>0.57</td>
<td>0.81</td>
<td>0.17</td>
<td>0.89</td>
</tr>
<tr>
<td>Fatigue (n=65)</td>
<td>0.73</td>
<td>0.56</td>
<td>0.24</td>
<td>0.35</td>
</tr>
<tr>
<td>Postcovid syndrome (n=35)</td>
<td>0.39</td>
<td>0.56</td>
<td>0.11</td>
<td>0.35</td>
</tr>
</tbody>
</table>

* Spearman's correlation test ** Statistically significant p<0.05

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.201

AB1085 COVID-19 VACCINATION INTENTION AMONG TUNISIAN HEALTH CARE WORKERS

O. Hamel1, M. Boudokhame2, Z. Teyeb2, I. Abdellaït3, T. Jomni2, S. Belakhal2, M. H. Drogui2. 1La Rabta Hospital, Rheumatology, Tunis, Tunisia; 2FSI hospital, Internal Medicine, Tunis, Tunisia

Background: Health care workers (HCW) are the soldiers in the forefront of the fight against the coronavirus (COVID-19) pandemic. It is therefore a priority target group in the COVID-19 vaccination process.

Objectives: Our purpose was to assess the COVID-19 vaccination intentions of Tunisian HCW and the reason for fear in case of hesitancy.

Methods: We conducted an anonymous online questionnaire in the months of May and June 2021 among HCW via social networks. The data collected included demographic characteristics, vaccination intentions, and reasons of hesitancy.

Results: Five-hundred HCW were included in the study. Participants were divided as follows: 74% doctors (15% seniors, 37% juniors, 22% interns), and 26% nurses. The mean age was 34 ± 5 years [24 – 58]. Seventy-three percent of participants were female. A history of chronic illness was noted 150 HCW (30%). A psychiatric disease was noted in 105 participants (21%): anxiety disorder (62%), depression (33%), and bipolar disorder (5%). A treatment was prescribed in 63% of cases: anxiolytics (84.2%), antidepressants (16.6%), and neuroleptics (10%). Psychotherapy was prescribed in 47% of cases. A personal and family history of COVID-19 infection was noted in 50.4 and 55% of cases, respectively. The infection was mild in 91.2% of cases. Four-hundred and five HCW (81%) had the intention to get vaccinated against COVID-19. Twenty participants (4%) refused the vaccine, and 75 (15%) were still hesitant. Vaccination hesitancy was linked to concerns about the safety of a rapidly-developed vaccine in 92% of cases: adverse reactions (95.8%), tolerance (75%), and efficacy (25%). Sixteen percent of hesitant respondents expressed...
VACCINE HESITANCY AGAINST COVID-19 VACCINES IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES AND EFFECT OF SPECIALIST COUNSELLING ON VACCINE HESITANT PATIENTS WILLINGNESS TO TAKE VACCINE

K. Kunalachandwar@gmail.com1, K. Kishor1, J. Dixit1, P. Dogga1, D. Ekbot1, P. Kumar1, U. Dhakad1. 1King George’s Medical University, Clinical Immunology and Rheumatology, Lucknow, India

Background: Vaccination is one of the most significant public health achievements; however, the success has been marred with vaccine hesitancy. The reasons for vaccine hesitancy are neither singular nor straightforward and arise from a complex interplay between scientific, religious and political beliefs. This study aims to understand the possible reasons for vaccine hesitancy in patients with autoimmune rheumatic diseases and the effectiveness of Specialist counselling on vaccine-hesitant patients willingness to take the vaccine.

Objectives: 1. To assess causes of Vaccine hesitancy against COVID-19 vaccines in patients with autoimmune rheumatic diseases. 2. To study the effect of specialist counselling on vaccine-hesitant patients willingness to take vaccine.

Methods: Study design: We conducted an observational survey-based in person cross-sectional study. Patients attending a tertiary care hospital’s outpatient department were asked about their vaccination status. Those unvaccinated were asked reasons for vaccine hesitancy. The vaccine-hesitant patients were counselled by the treating rheumatologist and asked regarding their willingness to take the vaccine after the counselling. The patient responses were recorded. Sample: Convenience sampling was used, so the sample size was not calculated. Inclusion and exclusion criteria: All adults (>18yrs) with AIRD coming to the rheumatology OPD. Those vaccinated, recently infected (within 6 weeks), and non-AIRD patients were excluded. Data collection: The questionnaire included patients’ demographic details, Diagnosis, medication details, and response to the reason for vaccine hesitancy. Statistical analysis: Descriptive statistics were performed by calculating measures of central tendency for quantitative variables and using counts and percentages for qualitative and nominal variables.

Results: A total of 322 patients participated in the study with a mean age of 40 years (18-76), with 73% (234) females and 27% (88) males. Most patients had Rheumatoid Arthritis (40%) followed by SPA (27%), SLE(13%) and others (18%). Significant proportion of patients (60%) had more than one reason for vaccine hesitancy. Almost 60% of the respondents feared their disease might flare post-vaccination, while almost half (44.4%) were hesitant to take the vaccine due to the fear of vaccine side effects and more than one third (35%) feared vaccine may not be effective on them as they were on immunosuppressive medications. Other major causes of vaccine hesitancy were the inability to get a chance to get vaccinated (18%), doubts about vaccine efficacy (15%), and fear of injections (10%). Most patients (91%) were willing to take the vaccine after specialist counselling and only 28 of the 322 (9%) were unwilling even after specialist counselling.

Conclusion: Vaccine hesitancy can be multifactorial. Major reasons for vaccine hesitancy in patients with autoimmune rheumatic diseases were fear of vaccine side effects and doubts whether the vaccine would work in patients taking immunosuppressive medications. Most patients were willing to take vaccine after counselling by a rheumatologist.

Disclosure of Interests: None declared

References:


COVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA

T. Demirci Yildirim1, C. Akyilek2, H. Cinakli3, D. Yildirim4, S. Hakkilen3, B. N. Coğun5, B. Okyar1, O. Ozturk Isik6, R. Piskin Sagir7, H. Apaydin8, S. Guller9, Y. Erez9, T. Yuce Inel9, N. Yilmaz10, S. Akar11, A. Tutar11, S. Yilmaz12, Y. Pahlavan12, G. Yildirim Cetin13, A. Cetle6, S. S. Soca14, S. Ertner15, A. Yazici5, E. Dakilo6, G. Cari16, M. Birlik16, B. Oral17, F. Cem18, Dokuz Eylul University, Faculty of Medicine, Rheumatology, Izmir, Turkey; 1Demirgolu Bilim University, Faculty of Medicine, Rheumatology, Istanbul, Turkey; 2Izmir Katip Celebi University, Faculty of Medicine, Rheumatology, Izmir, Turkey; 3Gazi University, Faculty of Medicine, Rheumatology, Ankara, Turkey; 4Selcuk University, Faculty of Medicine, Rheumatology, Konya, Turkey; 5Bursa Uludag University, Faculty of Medicine, Rheumatology, Bursa, Turkey; 6Kahramanmaras Sutcu Imam University, Faculty of Medicine, Rheumatology, Kahramanmaras, Turkey; 7Kocaeli University, Faculty of Medicine, Rheumatology, Kocaeli, Turkey; 8Firat University, Faculty of Medicine, Rheumatology, Elazığ, Turkey; 9Ankara City Hospital, Rheumatology, Ankara, Turkey

Background: Considering the concerns regarding COVID-19 vaccine safety among patients with rheumatic diseases due to a lack of data, an urgent need for studies evaluating safety profiles of vaccines emerged.

Objectives: Vaccination against the coronavirus disease-2019 (COVID-19) started in March 2021 in the same group using biological therapy in our country. In this study, post-vaccine real-life data of patients with spondyloarthritides (SpA) followed up with biological therapy were analyzed.

Methods: Adult patients diagnosed with SpA who were followed up under biological therapy and vaccinated with CoronaVac inactivated SARS-CoV-2 (bNTT162b2 messenger RNA (mRNA) COVID-19 (Pfizer-BioNTech) vaccine were included in our observational, multicenter, prospective study.

Results: A total of 287 patients (58.2% male; mean age: 47) were included in the study. 202 (%70.4) of patients were being followed up with the diagnosis of AS, 40 (%13.9) of them with PsA, 32 (%11.1) of them with nr-axSpA, 11 (%3.8) of them with entropic arthritis, and 2 (%0.7) of them with uSpA. The
most common comorbidities were found to be HT (n=65; 22.6%) and DM (n=38; 13.2%). While 221 (77%) of the patients were receiving biological therapy alone, 27 (9.4%) patients were using methotrexate, 25 (8.7%) patients were using sulphasalazine, and 12 (4%) patients were using infliximab. The median duration of biological therapy was 40 weeks (19-75 IQR). The most commonly used treatment was infliximab (26.8%), adalimumab (23.3%) was the second (Table 1).

It was determined that 207 (72.1%) of the patients preferred inactivated virus vaccine, while 80 (27.9%) preferred mRNA vaccine. When the time between the biological treatment and the day of vaccination is examined, detected median time between biological treatment and the first dose of vaccination is 11.5 days (5-19 IQR), between the first dose of vaccination and biological treatment is 14 days (7-21 IQR), between treatment and the second dose of vaccine is 14 days (5-23.5 IQR), and between the second dose of vaccine and the next biological treatment is 12.5 days (7-15 IQR). While 25 (8.7%) of the patients had COVID-19 infection before vaccination, 7 (2.4%) patients were found to have COVID-19 after vaccination (p<0.001). While two of the patients who had COVID-19 infection in the pre-vaccination period required hospitalization, none of the patients who had COVID-19 in the post-vaccination period required hospitalization.

The rate of patients who developed side effects after the first dose of the vaccine was 20.6%. The side effects seen, respectively, were detected as pain-redness at the injection site (16%), fatigue (11.6%), headache (8.4%), muscle-joint pain (73%) and fever (5.6%). The rate of patients reporting side effects after the second dose of the vaccine was 17.1%. The incidence of side effects after mRNA vaccine was found to be statistically significant compared to inactivated virus vaccine in terms of both doses (p=0.011, p<0.001). Major side effects such as myocardiitis, anaphylaxis-angioedema, myocardial infarction, and thrombosis were not observed in any of the patients included in the study. There was no evidence of disease activation in the median follow-up of 209 days (145-280 IQR) after vaccination.

Conclusion: During the follow-up of the patients during the study, no major vaccine-related side effects, post-vaccine disease activation and the need for treatment change were not detected. In order to more accurately evaluate the efficacy of the vaccination program in the patient population using biologic agents, larger-scale studies including unvaccinated individuals are needed.

Disclosure of Interests: None declared


AB1089 PSYCHOSOCIAL IMPACTS OF THE COVID-19 PANDEMIC ON ETHIOPIAN AND CANADIAN RHEUMATOLOGY PATIENTS


1University of Manitoba, Internal Medicine, Winnipeg, Canada; 2McGill, Medicine, Montreal, Canada; 3Addis Ababa University, Medicine, Addis Ababa, Ethiopia; 4University Laval, Medicine, Quebec, Canada; 5Jefferson University, Medicine, Philadelphia, United States of America


Objectives: To describe COVID-19 related illness and psychosocial impact in Ethiopian (ET) rheumatology patients attending the only public rheumatology clinic in Ethiopia (Tikur Anbessa Specialized Hospital (TAH) in Addis Ababa), and to compare findings in ET with findings in Canadian (CA) rheumatology patients.

Methods: Between May 1 and Oct 31 2021, 130 patients attending the TAH rheumatology clinic answered questions related to COVID-19 infection, symptoms and testing, and psychosocial impacts of the COVID-19 pandemic. We compared findings in ET with findings in Canadian (CA) rheumatology patients from Quebec1.

Result: ET patients were mainly female (71%) with a mean (SD) age of 47 (16), and resided in the capital city (Addis Ababa) (72%). Half had RA or lupus. A quarter of patients had moderate to severe rheumatic disease severity despite good medication adherence (MAS4 score of 3(2.4)). Most (89%) reported no COVID-19 symptoms since the beginning of the pandemic, were not tested for COVID-19 and reported few risk factors for COVID-19 exposure. Eight (6%) ETs were diagnosed with COVID-19, 2 required hospitalization. Diagnosed patients reported a median of 2 COVID-19 symptoms (range 0-8; mainly cough, fever and malaise). Within the entire cohort, depression (PHQ9=10 or above) and anxiety (GAD7=10 or above) were more frequent in ETs than CA (depression 30% vs 3%; anxiety 16% vs 1%) yet nearly half (47%) of ETs had normal or high resilience levels. The most common COVID-19 stressors were risk of contracting COVID illness personally (ETs vs CA stress risk ratio*95% confidence limits: CA: 0.5; 0.5, 0.99) or of loved one (0.11). More ETs reported COVID-19 related stress related to difficulty obtaining food, medicine or other essentials [1.74, (1.0-3.0)].

Conclusion: During the COVID-19 pandemic, depression was more common in ETs compared to CAs with rheumatic disease. COVID-19-related stressors due to insecurity in obtaining the basic essentials and support were more pronounced in ETs. Differences between ETs and CA in these stressors may reflect local public health and economic supports. There were no differences in coping strategies.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.443

AB1090 IMPACT OF THE COVID19 PANDEMIC ON THE SOCIAL BEHAVIOR OF PATIENTS WITH RHEUMATIC DISEASES

L. Cano García1, S. Manrique Arija1, M. Vera Rodríguez2, R. Redondo3, C. M. Romero-Barco4, N. Mena-Vázquez5, 1Instituto de Investigación biomédica de Málaga (IBIMA); Hospital Regional Universitario de Málaga, UGC de Reumatología, Málaga, Spain; 2Universidad de Málaga, Medición, Málaga, Spain; 3Instituto de Investigación biomédica de Málaga (IBIMA); Hospital Universitario Virgen de la Victoria, UGC de Reumatología, Málaga, Spain.

Background: Depression in rheumatic diseases negatively influences the support network and the perception of company of these patients (1).

Objectives: To describe how the COVID-19 pandemic affects the social activities of patients with chronic rheumatic diseases such as Rheumatoid arthritis (RA), Systemic Lupus Erythematosus (SLE) and Spondyloarthritis (SpA).

Methods: Observational, longitudinal study of a series of patients. Patients: RA (ACR/EULAR 2010 classification), SpA (ASAS/EULAR 2010 criteria), and SLE (ACR 1997 criteria) patients, age ≥ 18 years. Questionaries for the evaluation of participation in social activities is the Patient Reported Outcomes Measurement Information Systems (PROMIS) v2.0 Short-Form (8 items, PROMIS-APS) at baseline (OCT to DEC 2019) and after 18 months of pandemic (SEP to DEC 2021) were performed. Variables evaluated were: social activities in terms of various factors, such as satisfaction with social roles mobility, depression, companion social isolation, emotional support, instrumental support, support via information and ability to participate in social activities. All the variables were evaluated using the PROMIS questionnaire with quantitative scores. We also recorded demographic, clinical, and comorbidity data. Statistical analysis: Multivariate Linear Regression (Dependent variable: PROMIS ability to participate in social activities 18 months COVID19) was performed.

Table 1. COVID-19 related stressors reported by Ethiopian and Canadian rheumatology patients

<table>
<thead>
<tr>
<th>Common stressors from the coronavirus</th>
<th>ET</th>
<th>CA</th>
<th>RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Getting sick</td>
<td>24</td>
<td>41</td>
<td>0.67 (0.5, 0.99)</td>
</tr>
<tr>
<td>Having a loved one who becomes ill</td>
<td>23</td>
<td>41</td>
<td>0.56 (0.36, 0.86)</td>
</tr>
<tr>
<td>Difficulty getting food, medicine and other essentials</td>
<td>29</td>
<td>16</td>
<td>1.74 (1.3-3.0)</td>
</tr>
<tr>
<td>Difficulty getting support or help</td>
<td>24</td>
<td>19</td>
<td>1.17 (1.03-3.77)</td>
</tr>
<tr>
<td>Postponement or cancellation of tests</td>
<td>8</td>
<td>20</td>
<td>0.42 (0.18, 0.95)</td>
</tr>
<tr>
<td>Losing a job or experiencing a drop in income</td>
<td>10</td>
<td>100</td>
<td>0.185 (0.93, 3.81)</td>
</tr>
<tr>
<td>Having more responsibilities at home</td>
<td>21</td>
<td>20</td>
<td>1.06 (0.59, 1.87)</td>
</tr>
<tr>
<td>Having to work in a place likely to expose you to COVID-19</td>
<td>20</td>
<td>27</td>
<td>0.73 (0.42, 1.24)</td>
</tr>
</tbody>
</table>

†Severe stress = score 2 (moderately) to 5 (extremely)

Conclusion: During the COVID-19 pandemic, depression was more common in ETs compared to CAs with rheumatic disease. COVID-19-related stressors due to insecurity in obtaining the basic essentials and support were more pronounced in ETs. Differences between ETs and CA in these stressors may reflect local public health and economic supports. There were no differences in coping strategies.
Results: We recruited 91 patients, 31 (34.1%) RA, 30 (33%) SpA y 30 (33%) SLE. The 3 groups were well balanced in terms of clinical-epidemiological characteristics, except that patients with SpA were younger (mean 45 years) than patients with RA (53 years) and SpA (55 years) (p = 0.004) and because most of the patients with RA and SpA were women (97%) compared to those with SpA (60%) (p < 0.001). There was a worsening after 18 months of the COVID-19 pandemic in the mean scores of the PROMIS for: satisfaction of the social role (26.9 ± 8.7 vs 25.3 ± 8.4; 0.046), depression (14.7 ± 7.6 vs 16.1 ± 8.4; p = 0.044) and for the ability to participate in social activities (27.7 ± 7.2 vs 26.1 ± 6.8; p = 0.020). By diagnoses, the ability to participate in social activities was very similar between the different groups except for worse mobility in patients with RA and SpA compared to SLE, both at baseline and at 18 months of the pandemic. SLE patients worsened more after 18 months of the COVID-19 pandemic in social role satisfaction, depression, instrumental support and ability to participate in social activities. In the multivariate analysis, the ability to participate in social activities at 18 months of the COVID-19 pandemic was inversely associated with the diagnosis of SLE compared to the rest (95% CI), -2.60 [-4.62 - 0.58]; p = 0.012) and depression (95% CI), -0.23 [-0.39 - 0.08]; p = 0.004) and directly with social role satisfaction (95% CI), 0.18 [0.10-0.33]; p = 0.031), mobility (95% CI), 0.13 [0.07-0.20]; p = 0.001) and company (95% CI), 0.32 [0.11-0.60]; p = 0.023).

Conclusion: Our aims are to evaluate whether altering our delivery of care has impacted on the impact of rheumatic disease. After 18 months of the COVID-19 pandemic, patients with RA and SpA remain stable but SLE patients significantly worsened their social role and depression.

REFERENCES:

Disclosure of Interests: None declared


AB1092
INFLAMMATORY ARTHRITIDES IN POST-COVID-19 PATIENTS: AN ALBANIAN EXPERIENCE.
A. Pecani1, J. Tula1, L. Karaiu2, A. Islami3, S. Bala4
1Rheumatology Unit, Department of Internal Medicine, University Hospital Centre “Shefqet Ndroqi”; Tirana, Albania; 2Rheumatology Unit, Department of Internal Medicine, University Hospital Centre “Shefqet Ndroqi”; Tirana, Albania; 3Pulmonology Clinic, Department of Pulmonology, University Hospital Centre “Shefqet Ndroqi”; Tirana, Albania; 4University Hospital Centre “Shefqet Ndroqi”, Department of Pulmonology, Tirana, Albania

Background: COVID-19 is a disease caused by the new pathogen SARS-CoV2 (severe acute respiratory syndrome coronavirus 2) typically presenting with pneumonia but also other systemic manifestation has been reported worldwide [1]. Different reports have described the appearance of inflammatory arthritis (IA) after resolution of acute infection from COVID-19 [2].

Objectives: To observe the frequency of inflammatory Arthritis in an Albanian cohort of post-COVID-19 patients.

Methods: Post-COVID-19 patients, having two consecutive negative PCR (real-time reverse transcription polymerase chain reaction), discharged from the Pulmonology Department (January – July 2021) were invited to enter in a 6 (six) month multidisciplinary observational study. Data regarding post-COVID-19 inflammatory arthritis are presented in this study. Descriptive statistical analysis was used to express data.

Results: From 154 post-COVID-19 patients (F/M = 62/92) enrolled, 14 (9.9%) patients didn’t follow regularly the dedicated ambulatory thus were excluded from this study. Considering the remaining 140 patients (F/M = 58/82), only 21 (15%) patients were diagnosed with IA where the most common were, respectively: Reactive Arthritis (ReA) 11 (52.3%) patients; Rheumatoid Arthritis (RA) 4 (19.09%) patients; Ankylosing Spondylitis (AS) 3 (14.2%) patients; Gout Arthritis (GA) 3 (14.2%) patients. All rheumatic conditions were more frequent in male than in female post-COVID-19 patients. Data summarized in Table 1. All patients that developed a post COVID-19 IA, had fever during the period of SARS-CoV2 infection. Arthralgia was a typical symptom that have been reported by patients that have developed RA and AS. All RA post-COVID-19 patients reported having had even symptoms like cough, dispnea and fatigue. None of the AS patients neither GA reported symptoms of dysguesia or anosmia. Only 9% of ReA patients reported having had abdominal pain during acute infection with SARS-CoV2. Data summarized in Figure 1.

Table 1.

<table>
<thead>
<tr>
<th>Inflammatory Arthritis</th>
<th>Patients (N, %)</th>
<th>Age (mean ± SD)</th>
<th>Male (N, %)</th>
<th>Days after COVID-19 (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ReA</td>
<td>11 (52.3)</td>
<td>48.2 ± 12.5</td>
<td>7 (63.6)</td>
<td>15.8 ± 9.9</td>
</tr>
<tr>
<td>RA</td>
<td>4 (19.09)</td>
<td>55.7 ± 8.7</td>
<td>2 (50)</td>
<td>32.3 ± 11.3</td>
</tr>
<tr>
<td>AS</td>
<td>3 (14.2)</td>
<td>50.5 ± 9.7</td>
<td>2 (66.6)</td>
<td>18.8 ± 5.5</td>
</tr>
<tr>
<td>GA</td>
<td>3 (14.2)</td>
<td>55.3 ± 12</td>
<td>3 (100)</td>
<td>10.6 ± 0.9</td>
</tr>
</tbody>
</table>

Conclusion: IA is another manifestation that follows acute infection from COVID-19. In this regard increased awareness and further investigations are needed.
in order to better understand weather SARS-CoV2 infection can accelerate the development of a rheumatic autoimmune disease.

REFERENCES:


Disclosure of Interests: None declared

AB1093
SAFETY OF COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS (PRELIMINARY DATA).

A. Kulikov1, N. Muravyeva1, B. Belov1.1V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccinoprophylaxis, Moscow, Russian Federation

Background: Patients with rheumatoid arthritis (RA) are at high risk of developing COVID-19. Vaccination should be an effective method of preventing this disease. However, vaccination may be unsafe in RA patients. At present, data on the safety of vaccines against COVID-19 in RA patients are few and relate to foreign vaccines that are not licensed in Russia.

Objectives: To study the safety of COVID-19 vaccines in patients with RA in real clinical practice.

Methods: The study included 131 RA patients (120 women, 11 men, age 53.8±13.9 years, duration of disease 11.5±9.2 years) - the main group and 121 people without any immuno-inflammatory rheumatic diseases (87 women, 34 men, age 39.8±14.2 years) - the control group. 103 patients received disease-modifying antirheumatic drugs (54 - methotrexate, 30 - leflunomide, 10 - hydroxychloroquine, 8 - sulfasalazine, 1 - methotrexate and sulfasalazine), 68 - biological drugs (58 - rituximab, 5 - TNF-inhibitors, 4 - abatacept, 1 - tocilizumab), 6 - immunosuppressants (58 - rituximab, 5 - TNF-inhibitors, 4 - abatacept, 1 - tocilizumab), 66 - corticosteroids, 10 - did not receive therapy. In the main group, 92 patients were vaccinated with Gam-COVID-Vac (Sputnik V), 21 with Sputnik Light, 16 with CovVac; 2 with EpiVacCorona (110 patients received two components of the vaccine). In the control group, 91 were vaccinated with Sputnik V, 16 with CovVac, 5 with BNT162b2, 5 with Sputnik Light, 2 with EpiVacCorona, 1 with mRNAb1273 (114 participants received two components of the vaccine). All patients were interviewed by a research doctor with a unified questionnaire, additional information was obtained from medical documentation.

Results: Local and systemic adverse events (AEs) were observed both in the main group and in the control group. After the introduction of the first component of the vaccine, local AEs (pain/hyperemia/edema) were noted in 12.2% of RA patients and in 10.7% of the control group, after the introduction of the second component of the vaccine - in 9.1% and 11.4% of respondents, respectively (in both groups p>0.05). There was a significant difference between the main group and the control group in the frequency of injection pain at the injection site without restriction of movements both after the first (24.4% and 40.5%, p=0.007) and after the second component (18.2% and 31.6%, p=0.021). The most frequent systemic AEs were weakness, fever, muscle or joint pain, chills, which were observed in both groups after administration of both the first and second components of the vaccine. There was a significant difference between the main group and the control group in the frequency of fever (16.8% and 39.7%, p<0.001), weakness (26.0% and 38.8%, p=0.029), muscle and joint pain (9.2% and 25.6%, p<0.001) after administration of the first (but not the second) component of the vaccine. A significant difference was revealed between the main group and the control group in the number of patients with local and systemic AEs both after the introduction of the first component of the vaccine (19.1% and 43%, p<0.001) and after the second (15.5% and 30.7%, p=0.007). After administration of the two components of the vaccine, a higher number of patients without any AEs were detected in the main group compared to the control group (32.7% and 18.4%, p=0.014). Exacerbation of RA and the emergence of new autoimmune phenomena in main group are not marked.

Conclusion: According to preliminary data, the tolerance of vaccines against COVID-19 in RA patients is satisfactory. Further studies are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.817

AB1094
SAFETY AND EFFICACY OF VACCINES FOR SARS-COV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-COVAC


Background: Currently there is little information on the efficacy and safety of SARS-CoV-2 vaccination in patients with immune-mediated diseases and/or under immunosuppressive treatment in our country, where different types of vaccines and mix regimens are used. For this reason, the Argentine Society of Rheumatology (SAR) with the Argentine Society of Psoriasis (SOARPSO) set out to develop a national register of patients with rheumatic and immune-mediated inflammatory diseases (IMIDs) who have received a SARS-CoV-2 vaccine in order to assess their efficacy and safety in this population.

Objectives: To assess SARS-CoV-2 vaccine efficacy and safety in patients with rheumatic and IMIDs.

Methods: SAR-Covac is a national, multicenter and observational registry. Adult patients with a diagnosis of rheumatic or IMID who have been vaccinated for SARS-CoV-2 were consecutively included between June 1st and September 17th, 2021. Sociodemographic data, comorbidities, underlying rheumatic or IMIDs, treatments applied and their modification prior to vaccination and history of SARS-CoV-2 infection were recorded. In addition, date and place of vaccine (SARS-CoV-2) infection were documented in patients of this cohort.

Results: A total of 1234 patients were included, 79% were female, with a mean age of 57.8 (SD 14.1) years. The most frequent diseases were rheumatoid arthritis (41.2%), osteoarthritis (14.5%), psoriasis (12.7%) and spondyloarthritids (12.3%). Most of them were in remission (28.5%) and low disease activity (41.4%). At the time of vaccination, 21% were receiving glucocorticoid treatment, 35.7% methotrexate, 29.7% biological (b) Disease Modifying Anti-Rheumatic Drugs (DMARDs) and 5.4% JAK inhibitors. Before vaccine application 16.9% had had a SARS-CoV-2 infection. Regarding the first dose of the vaccine, the most of the patients (51.1%) received Gam-COV-ID-Vac, followed by ChAdOx1 nCoV-19 (32.8%) and BBIBP-CorV (14.5%). In a lesser proportion, BNT162b2 (0.6%), Ad26.COV2.S (0.2%) and CoronaVac (0.2%) vaccines were used. Almost half of them (48.8%) completed the scheme. 12.5% were mix regimes, the most frequent being Gam-COV-ID-Vac / mRNA1273. The median time between doses was 51days (IQR 53). More than a quarter (25.9%) of the patients reported at least one AE after the first dose and 15.9% after the second. The flu-like syndrome and local hypersensitivity were the most frequent manifestations. There was one case of mild anaphylaxis. No patient was hospitalized. Altogether, the incidence of AE was 246.5 events/1000 doses. BBIBP-CorV presented significantly lower incidence of AE in comparison with the other types of vaccines. (118.5 events/1000 doses, p<0.002 in all cases) Regarding efficacy, 63 events of SARS-CoV-2 infection were reported after vaccination, 19% occurred before 14 days post-vaccination, 57.1% after the first dose (>14 days) and 23.8%
after the second. In most cases (85.9%) the infection was asymptomatic or had an outpatient course and 2 died due to COVID-19. Conclusion: In this national cohort of patients with rheumatic and IMIDs vaccinated for SARS-CoV-2, the most widely used vaccines were Gam-COVID-Vac and ChAdOx1 nCoV-19, approximately half completed the schedule and in most cases homologously. A quarter of the patients presented some AE, while 5.1% presented SARS-CoV-2 infection after vaccination, in most cases mild.

Disclosure of Interests: None declared


AB1095

POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AFTER COVID-19 VACCINATION: A CASE REPORT

D. Abdel Mohsen1, R. A. Elziaty1, A. A. Abdalkader1. 1Ain Shams University, Internal Medicine Department, Division of Rheumatology, Cairo, Egypt

Background: The COVID-19 pandemic has infected millions of people around the world and there has been a new surge of virulent strains in many parts of the world[2]. Patients with Systemic Lupus Erythematosus (SLE) were reported to be at higher risk of SARS-CoV-2 infection and worse outcomes from COVID-19, possibly due to their intrinsic immune dysfunction, demographics, disease activity, medications, associated organ damage, comorbidities and as such, have been among the first to receive the vaccines [3]. The most common reason for vaccine refusal in patients with SLE is fear of SLE disease flare. Additionally, SARS-CoV-2 mRNA vaccines could potentially induce interferon production, associated with increased SLE disease activity[1].

Objectives: we report a case of SLE presented with lupus flare after receiving the 1st dose of Pfizer vaccine.

Methods: A 30-year-old female patient, kown case of SLE since 2011 well controlled on low dose steroids, hydroxychloroquine and azathioprine. Upon receiving her 1st shot of Pfizer-BioNTech COVID-19 Vaccine, she developed high grade fever associated with generalized papulovesicular skin eruption mainly on the back of the trunk and the outer surface of both thighs, then she developed generalized tonic-clonic convulsions and transferred for Intensive Care Unit (ICU), intubated, mechanically ventilated and received intravenous anti-epileptic medications. During her admission, Cerebrospinal fluid (CSF) examination and Magnetic Resonance Imaging (MRI) brain were done.she regained her consciousness, extubated after 48 hours.

Results: The initial laboratory investigations revealed COVID19-PCR: negative,ESR: 35 mm/hr, CRP: 78, C3: 70 mg/dL (90-180) and C4: 8 mg/dL (10-40). CSF examination revealed proteins: 116.9 mg/dL (15 – 45), glucose: 46.3 mg/dL (50-60% of serum),LDH: 49.1 U/L (10% of serum) and no cells. Emergency MRI brain was performed revealed multiple bilateral symmetrical mainly cortical and subcortical abnormal signal with cortical swelling are seen mainly involving both occipito-temporo-parietal lobes with patchy enhancement of left cerebellar hemisphere, cerebellar white matter and left thalamus, medulla and pons.Picture suggestive of Posterior Reversible Encephalopathy Syndrome (PRES).Accordingly the patient received pulse steroid therapy for 3 days under cover of oral acyclo-visor.She also received levetiracetam and Oxcarbazepine.the condition markedly improved and discharged from the hospital for follow up for one month.

Conclusion: 1)The mRNA COVID Vaccine may rarely cause CNS affection, or even SLE flare so, SLE patients must be well controlled before giving the Vaccine. 2) SLE patients must be monitored closely by clinical examination and laboratory investigations after taking mRNA COVID Vaccine.

REFERENCES:
[2] Fernandez-Ruiz R,Paredes JL and Niewold TB. COVID-19 in patients with autoimmune and musculoskeletal diseases appear to be more vulnerable to the development of both the innate and adaptive immune systems. Patients with rheumatic conditions receive immunosuppressants prescribed to control RMD increase the risk of infections. And finally, RMD is often combined with comorbid conditions from the group of risk factors for severe forms of COVID-19 due to the impaired immune response associated with RMD. In addition, immunosuppressants prescribed to control RMD increase the risk of infections. And finally, RMD is often combined with comorbid conditions from the group of risk factors for severe forms of COVID-19 such as arterial hypertension, diabetes mellitus and obesity.

Disclosure of Interests: None declared


AB1097

FEATURES OF THE COURSE AND CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO UNDERWENT COVID-19

E. Aronov1, G. Gridneva1, B. Belov1. 1V.A.Nasonova Research Institute of Rheumatology, Department of Comorbid Infections and Vaccine Prevention, Moscow, Russian Federation

Background: COVID-19 remains a serious problem almost two years later, despite the ongoing active search for effective tools to control it. To date, it is known that COVID-19 not only proceeds as an acute respiratory illness, but also leads to a systemic inflammatory response and hypercoagulability through activation of both the innate and adaptive immune systems. Patients with rheumatic conditions receive immunosuppressants prescribed to control RMD increase the risk of infections. And finally, RMD is often combined with comorbid conditions from the group of risk factors for severe forms of COVID-19 such as arterial hypertension, diabetes mellitus and obesity.

Objectives: to characterize the features of the course of COVID-19 in patients with rheumatoid arthritis.

Methods: We studied the material of questionnaires filled out by patients of the hospital of the V.A. Nasonova Research Institute of Rheumatology who underwent COVID-19, verified by RT-PCR to SARS-CoV-2 RNA, for the period from 05/15/2020 to 12/15/2021. The information was supplemented with data from discharge summary after inpatient treatment of COVID-19. Statistica software (version 12) was used for statistical processing. The results of the correlation analysis were considered reliable at p<0.05.
Patients with higher RA activity more often noted increased arthralgia. Symptoms associated with COVID-19 did not correlate with RA activity. However, treatment in 12.5% - COVID-19 proceeded with complications. The number of patients and acute respiratory failure in 2 more patients.

Conclusion: Patients with higher RA activity more often noted increased arthralgia during COVID-19 and RA activity. On average, median, each patient reported 13.5 [9.75; 19.25] symptoms associated with COVID-19. There was no significant correlation between the number of COVID-19 symptoms and RA activity. During COVID-19, CT scan was performed in 19 patients: CT-0 - in 1 patient (5.3%), CT-1 - in 9 (47.4%), CT-2 - in 5 (26.3%), CT-3 - in 3 (15.7%), CT-4 - in 1 (5.3%). There was no correlation between the CT stage and RA activity. 12 patients (37.5%) were hospitalized, of which 8 needed oxygen support. Rituximab treatment was not associated with hospitalization rates. Complications were reported in 4 cases (12.5%): venous thrombosis in 2 patients and acute respiratory failure in 2 more patients.

Disclosure of Interests: None declared


AB1098 DEVELOPMENT OF INFLAMMATORY MYOPATHY AFTER COVID-19

I. Menshikova1, A. Shilina1, N. Nikolaeva1, 1I.M.Sechenov First Moscow State Medical University (Sechenov University), Rheumatology, Moscow, Russian Federation

Background: It has been more than a year and a half since the WHO announced a pandemic of a new coronavirus infection caused by SARS-CoV-2. The virus belongs to the respiratory group, but it can damage various organs and tissues of the body. COVID-19 infection is characterized by pathological activation of immunity, violated synthesis of pro-inflammatory, immunoregulatory, anti-inflammatory cytokines, and other factors. Such as acute respiratory distress syndrome (ARDS), liquid food, rash on the face, neck, chest and arms. In August 2020 she had a mild case of COVID-19. A month later, flaky erythematous papules got through the skin on her abdomen and upper extremities. These features contribute to the development of rheumatic diseases and syndromes in people who have had COVID-19. Cellular and humoral immune responses are also of primary importance in the pathogenesis of inflammatory myopathies.

Objectives: Description of a case of severe dermatomyositis after COVID-19. Methods: The 34-year-old female patient complained of pain and weakness in the proximal muscles of the upper and lower limbs, fatigue, dizziness, fever, and cough. On admission to the hospital, she had a mild case of COVID-19. A month later, flaky erythematous papules appeared on the legs. Echocardiography and electrocardiogram showed normal results. The duration of the course of RA was 8 [4; 14.5] years. The most common comorbidities were disorders of the cardiovascular system (in 20 patients), diseases of the gastrointestinal tract (in 7 patients), diabetes (in 4 patients) and obesity (in 5 patients). The median number of comorbid diseases was 2 (IQR 3).

A patient was noted: swallowing normalized, the severity of myopathy decreased, after 10 days CK decreased to 2049 IU/l. After 6 months during the control examination: there are no skin rashes, muscle strength is restored, CK 300 IU/l. The dose of methylprednisolone is reduced to 10 mg per day, the patient continues injections of methotrexate 15 mg per week.

Conclusion: COVID-19 may be a trigger for the development of inflammatory myopathy. In this clinical case there are features of the course and therapy of inflammatory myopathies in patients after coronavirus infection.

Disclosure of Interests: None declared

AB1101

PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY

C. A. Gonzalez Gomez1, M. Cosatti1, V. V. Castro Coello2, M. Haye3, Y. Tissena4, A. A. Reyes2, J. A. Albiero2, S. Ornelia5, P. Alba2, C. Gobbi2,

1CEMIC, Centro de Educación Médica e Investigaciones Clínicas Norberto Quintero, Rheumatology Section, Ciudad de Buenos Aires, Argentina;
2on behalf of SAR COVID Registry, SAR Research Unit, Ciudad de Buenos Aires, Argentina

Background: Persistent symptoms after acute COVID have been described previously. Main symptoms reported are fatigue, arthralgias, myalgias and mental sickness. Definition and methods vary widely.1

Objectives: To assess prevalence and related factors to long COVID in a retrospective cohort of patients with rheumatic diseases from Argentina.

Methods: A total of 1915 patients were registered from August 18th, 2020 to July 29th, 2021. Patients > 18 years old, with rheumatic disease and confirmed infection by SARS-CoV-2 (antigen or RT-PCR) were included. Those dead, with unknown outcome, without date or missing data were excluded. Demographic data, comorbidities, rheumatic disease, and characteristics of SARS-CoV-2 infection were recorded. Long COVID was defined according to NICE guidelines (persistent symptoms for more than 4 weeks, without alternative diagnosis). Long COVID symptoms were defined by rheumatologist. Severe infection was classified according to WHO ordinal scale. We used descriptive statistics, univariate model (Student's test, chi square test, ANOVA) and multivariate logistic regression analysis.

Results: 230 (12%) had long COVID. Median age was 51 (IQR 40-61) years, 82% were females, 51% were not caucasian. Median of education was 13.3 years (IQR 12 – 16), 79 % had private health insurance and 55 % were employed. Nearly half (n=972, 46%) had comorbidities, the most prevalent was hypertension (n=396, 24%). The most frequent rheumatic diseases were rheumatoid arthritis (n=719, 42%) and systemic lupus erythematosus (n=280, 16%). Most were in low activity/remission (79%), used treatment for COVID-19 5 months after complete VAC and died. Conclusion: There is very high number of VAC (98.1%) in a real life setting of a rheumatological OC. Many patients (95%) developed low to high AB levels after 2 VAC, independently which agent was used. Otherwise, we must be aware of the small group of patients (5%) without developing any AB. Unfortunately, our group was too small to find significant risk factors (RF). But RF seems to be the age, therapy with RTX, ABA and P. This is in line with reported RF in clinical studies (1). Furthermore, we see lower levels in elderly patients who get vaccinated with C. This could be biased by the fact that, in the first months of the VAC campaign, C was used in patients with higher age and the 2nd VAC was given 3 weeks after 1st VAC. Retrospectively, this interval seems to be too short. Thus now, the 2nd VAC is given 4-6 weeks after 1st VAC. In conclusion it is still unclear, which levels of AB make VAC effective and which patients will develop AB levels. AB levels should be evaluated to pick out patients with VAC gap, since the levels of AB make VAC effective and which patients will develop AB levels. Many patients (95%) developed low to high AB levels 5 months after complete VAC and died.

To asses prevalence and related factors to long COVID in a retrospective cohort of patients with rheumatic diseases from Argentina.

Methods: A total of 1915 patients were registered from August 18th, 2020 to July 29th, 2021. Patients > 18 years old, with rheumatic disease and confirmed infection by SARS-CoV-2 (antigen or RT-PCR) were included. Those dead, with unknown outcome, without date or missing data were excluded. Demographic data, comorbidities, rheumatic disease, and characteristics of SARS-CoV-2 infection were recorded. Long COVID was defined according to NICE guidelines (persistent symptoms for more than 4 weeks, without alternative diagnosis). Long COVID symptoms were defined by rheumatologist. Severe infection was classified according to WHO ordinal scale. We used descriptive statistics, univariate model (Student's test, chi square test, ANOVA) and multivariate logistic regression analysis.

Results: 230 (12%) had long COVID. Median age was 51 (IQR 40-61) years, 82% were females, 51% were not caucasian. Median of education was 13.3 years (IQR 12 – 16), 79 % had private health insurance and 55 % were employed. Nearly half (n=972, 46%) had comorbidities, the most prevalent was hypertension (n=396, 24%). The most frequent rheumatic diseases were rheumatoid arthritis (n=719, 42%) and systemic lupus erythematosus (n=280, 16%). Most were in low activity/remission (79%), used treatment for COVID-19 5 months after complete VAC and died. Conclusion: There is very high number of VAC (98.1%) in a real life setting of a rheumatological OC. Many patients (95%) developed low to high AB levels after 2 VAC, independently which agent was used. Otherwise, we must be aware of the small group of patients (5%) without developing any AB. Unfortunately, our group was too small to find significant risk factors (RF). But RF seems to be the age, therapy with RTX, ABA and P. This is in line with reported RF in clinical studies (1). Furthermore, we see lower levels in elderly patients who get vaccinated with C. This could be biased by the fact that, in the first months of the VAC campaign, C was used in patients with higher age and the 2nd VAC was given 3 weeks after 1st VAC. Retrospectively, this interval seems to be too short. Thus now, the 2nd VAC is given 4-6 weeks after 1st VAC. In conclusion it is still unclear, which levels of AB make VAC effective and which patients will develop AB levels. AB levels should be evaluated to pick out patients with VAC gap, since the high risk of fatal course of COVID-19 disease. The booster campaign and 3rd VAC will change the current state again, therefore revaluation will be necessary.

REFERENCES:
1 Kroon FPB et al, Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations. ARD 2021 Jan 20 online first

**AB1102**  
A RARE CASE OF ACUTE INFLAMMATORY DEMYELINATING POLYRADICULOPATHY FOLLOWING THE SECOND DOSE OF Pfizer COVID-19 VACCINE

V. Courant1, M. Silva2, S. Grewal1. 1Mount Sinai Morningside, Internal Medicine, New York, United States of America

**Background:** We present a case of a 36-year-old female who developed Acute Immune-mediated Demyelinating Polyneuropathy (AIDP) after receiving the second dose of Pfizer COVID-19 vaccine.

**Objectives:** To report a rare auto-immune complication of COVID-19 vaccination. To educate and inform physicians about the approach to diagnosing AIDP and narrowing down its etiology.

**Methods:** Case report and literature review

**Results:** A 36-year-old female with no significant past medical history presented to the hospital with progressive bilateral paresthesia. She started to experience numbness and tingling sensation in her extremities 1 week after receiving the second dose of Pfizer COVID-19 vaccine. Following 5 days of symptoms onset, she was no longer able to hold onto objects and experienced difficulty ambulating without assistance. Physical exam was notable for decreased distal sensation to touch and pain in all 4 limbs, otherwise, the rest of her neurological and musculoskeletal evaluation was normal. MRI-head showed small scattered foci of increased FLAIR signal in the white matter, suggesting an underlying inflammatory process. Electromyography (EMG) was performed and showed evidence of acute diffuse sensorimotor neuropathy with mixed axonal and demyelinating features. These results along with the clinical features allowed us to diagnose the patient with Acute Immune-mediated Demyelinating Polyneuropathy (AIDP). Extensive autoimmune workup, including anti-GM1, GD1b, Gq1b, ANA, DS-DNA, RF, CCP, and C/P ANCA, were unremarkable. She had positive anti-Ro atb but did not have any clinical or physical features that would suggest Sjogren’s Syndrome. Vitamin levels (B12, folate, thiamine) were found to be normal. Infectious workup of serum and CSF which included hepatitis serology, other infectious workup, and narrowing down its etiology.

**Conclusion:** The possible etiology of her disease was attributed to Pfizer COVID-19 vaccine given to be normal. Infectious workup of serum and CSF which included hepatitis serology, other infectious workup, and narrowing down its etiology.

**REFERENCES:**
[1] Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, severe disease and ICU hospitalization days were related to long COVID. Higher education, treatment with cyclophosphamide, symptoms of COVID − 19, and narrowing down its etiology.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1021

---

**AB1103**  
THE EFFECT OF COVID-19 PANDEMIC IN A LARGE SERIES OF PATIENTS WITH TAKAYASU ARTERITIS

A. Karakas1, T. Yuce Inel1, F. Onen1, I. Sari1. Dokuz Eylul University Faculty of Medicine, Rheumatology, Izmir, Turkey

**Background:** Patients with inflammatory rheumatic diseases faced several challenges during the COVID-19 pandemic. Uncertainties such as the lack of evidence regarding the use of immunosuppressive (IS) therapies and deferred patient care because of limited health resources impacted negatively on many aspects of treatment decisions and routine follow-up of the patients.

**Objectives:** We aimed to investigate the prevalence and severity of SARS-CoV-2 infection, the impact of the pandemic on delays in routine clinical follow-up, changes in IS treatment, and COVID-19 vaccination status of patients with Takayasu arteritis (TAK).

**Methods:** The study was performed between July and September 2021. TAK patients who registered in our database were investigated with regards to the COVID-19 infection and vaccination status, delays in routine clinical visits, changes in IS treatment, and flares during the pandemic. Physical examination, laboratory tests, and imaging of the patients were performed and ITAS2010 scores were calculated.

**Results:** There were 56 adult TAK patients (87.5% female and median age 47 years). 14 (25.8%) patients experienced a delay with routine follow-up visits to their physicians and about 20% of patients stopped their antirheumatic treatments without consulting their physicians. Compared to the pre-COVID-19 pandemic, 16 (28.5%) patients were flared. 13 (23.2%) patients had a mild COVID-19 infection. Pneumonia was reported in five patients, two of them required hospitalization, and all patients recovered completely. In the total group, about 90% of the patients had received the COVID-19 vaccine (Table 1).

**Table 1. Effects of COVID-19 pandemic on patients with Takayasu arteritis**

<table>
<thead>
<tr>
<th>Patients with a delay regarding to the routine follow-up visits, n (%)</th>
<th>44 (78.6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average delay in routine follow-up visits since the beginning of COVID-19, months, median, Q1-Q3</td>
<td>3.5 (2.25-9)</td>
</tr>
<tr>
<td>Patients who didn’t receive their treatment regularly due to COVID-19 concern, n (%)</td>
<td>11 (19.6)</td>
</tr>
<tr>
<td>Disease relapse compared to the pre-pandemic time, n (%)</td>
<td>16 (28.6)</td>
</tr>
<tr>
<td>Progression in acute phase reactants, n (%)</td>
<td>14 (25)</td>
</tr>
<tr>
<td>Progression in vascular involvement (according to MR angiography or Doppler ultrasound findings) n (%)</td>
<td>15 (26.8)</td>
</tr>
<tr>
<td>Patients diagnosed with COVID-19 disease, n (%)</td>
<td>13 (23.2), post-vaccination</td>
</tr>
<tr>
<td>Vaccination status, n (%)</td>
<td>8/5, 50 (90.9)</td>
</tr>
</tbody>
</table>

**Conclusion:** COVID-19 disease in TAK patients were in mild severity and IS therapy seem not affecting the COVID-19 course. A substantial number of patients who stopped their medications flared and its long-term consequences need to be assessed by large-scale studies. New approaches are required to maximize healthcare access for patients who have chronic diseases during pandemic.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1177
occur even in patients who have experienced mild or moderate COVID-19 and includes long-term symptoms that may be associated with residual inflammation, organ damage, non-specific effects of hospitalization or prolonged ventilation, so-called COVID-19 sequelae, or comorbid diseases. In October 2021, the WHO defined PCS as a condition that occurs in individuals with a history of probable or confirmed infection with the SARS-CoV-2 virus, usually within 3 months of the onset of COVID-19, and is characterized by the presence of symptoms for at least 2 months, as well as the impossibility of explaining them with an alternative diagnosis.

Objectives: To conduct a comparative assessment of clinical and demographic indicators in groups of patients with rheumatoid arthritis who underwent COVID-19, with and without PCS.

Methods: The material of the questionnaires filled in by patients of the V.A. Nasonova Research Institute of Rheumatology, who underwent COVID-19, verified by RT-PCR for SARS-CoV-2 RNA. The information was supplemented with data from discharge records after inpatient treatment for COVID-19. Statistica program (version 12) was used for statistical processing. The results of correlation analysis were considered significant at p<0.05.

Results: The study included 23 adult patients (over 18 years of age) with a reliable diagnosis of rheumatoid arthritis (ACR/EULAR). Of these, 11 (47.8%) patients noted the development of PCS (Group 1), and 12 patients underwent COVID-19 without consequences (Group 2). Both groups were represented predominantly by women (90.9% and 91.7%, respectively). The average age in both groups did not differ significantly and amounted to 56.7±14.79 years in group 1, and 48.1±19.95 years in group 2. The median number of comorbid diseases was 2 [1;4] in group 1 and 0.5 [0;2.5] in group 2. PCS was presented by the following symptoms: weakness, increased fatigue – in 6 patients, problems with attention, concentration – in 7, memory impairment – in 6, steep disturbances – in 7, increased pain in the joints – in 7, shortness of breath during exercise – in 6, fluctuations in blood pressure – in 5, tachycardia – in 4. On average (median), each patient noted 10 [6.5;12] symptoms of PCS at a time. When assessing the number of symptoms in the infectious phase, in group 1, patients reported 20 [16;23], and in group 2, 10 [7;12] symptoms of COVID-19. At the time of development of COVID-19, the severity of RA symptoms, assessed by VAS, was 5.6±4.3±26 in group 1 and 4.7±5.2±99 in group 2. In group 1, 5 (45.5%) patients needed hospitalization, 3 of them needed oxygen support. In group 2, 4 (33.3%) patients were hospitalized, two of them needed oxygen support. 3 patients in group 1 suffered COVID-19 again on average 9.3±3±2.52 months after the first illness. One of them has been vaccinated. All patients in this group were treated as outpatients, while the first case of COVID-19 required one hospitalization and oxygen support. Statistical assessment of significant differences (p<0.05) between groups in terms of sex, age, number of comorbid diseases, number of COVID-19 symptoms in the infectious phase, severity of RA symptoms, and hospitalization rate was not revealed.

Conclusion: Even though when assessing the socio-demographic characteristics, no statistically significant differences were found between the study groups, the average age, the number of comorbid diseases, and the severity of RA symptoms at the time of COVID-19 were higher in the group of patients with RA and PCS. Patients with PCS reported higher rates of hospitalizations and severe RA (VAS > 5) symptoms. There were also more treated cases of COVID-19 in this group. It is necessary to continue the study on a larger cohort.

Disclosure of Interests: None declared


AB1105

PSEUDOPERNIOSIS AS A LATE MANIFESTATION AFTER SARS2-COD19 INFECTION. A PURPOSE OF A SERIES OF 19 CASES

F. J. Navarro Blasco1,1 Hospital General Universitario de Elche, Rheumatology, Elche, Spain

Background: In winter, you can usually see a picture of Perniosis and / or chilblains. Painful, often itchy, red-to-purple lesions that affect the acrid surfaces of the fingers and toes after contact with the cold, resembling vasculitis, characterize them. Chilblains can be idiopathic and self-limiting or associated with systemic diseases. The diagnosis is usually clinical, but in some circumstances, analytical and microscopic studies of a biopsy sample may be necessary. We present a series of 19 consecutive cases of Pseudoperniosis associated with probable past INFECTION by SARS-CoV-2.

Methods: During the winter 2020-21, an unexpected number of cases referred as “acute arthritis/vasculitis” have been received in our rheumatology section and the main problem is pain along with edema of the tissues of the hand that leads to make it impossible to use. Similarly, asymmetric lesions similar to perniosis were observed in patients who presented skin manifestations of SARS-CoV-2 infection in a study conducted in Spain (1). We are following these patients to assess if there is any relationship with any other factor that facilitates this unusual incidence, and at the same time indicate the transience of the clinical picture that evolves favorably in a few weeks.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1383

AB1106

HOW HAS THE COVID-19 PANDEMIC AFFECTED OUR RHEUMATOLOGY PATIENTS USING BIOLOGICAL/ TARGETED DMARDS?

S. Gulle1, Y. Erez1, A. Karakas1, T. Yüce İne1, S. B. Koca1, T. Demirci Yıldırım1, G. Can1, I. Sarı1, M. Birlik1, F. Önen1, 1Dokuz Eylül University School of Medicine, Rheumatology, Izmir, Turkey

Background: Bioinformatics data, which are becoming more detailed day by day, show that male gender, advanced age, smoking, and comorbidities are associated with poor outcome of COVID-19. However, it is well known that the active disease state that may occur as a result of discontinuing the drugs also increases the susceptibility to infection.

Objectives: It was aimed to investigate the effects of the COVID-19 pandemic on the course and treatment of rheumatic disease in patients with inflammatory rheumatic musculoskeletal disease (iRMd) using biological or targeted synthetic DMARDs (b/tsDMARDs).

Methods: The study was carried out in two stages: while investigating the delay of b/tsDMARD treatment in the first 3 months of the pandemic with the fear of infected SARS-CoV-2 in the first stage, in the second stage, it was investigated whether all patients who decided to continue treatment after interruption in the 12-month period.

Results: A total of 521 patients were included in the study. It was seen that the iRMd diagnosis was listed as SpA (54.3%), RA (25.7%), PsA (8.4%), vasculitis (6.1%), and others (5.4%). The overall 12-month drug retention rate was 92.3%. Concurrent use of hydroxychloroquine (HCQ) (HRI=1.49), iv bDMARD use (HRI=1.34), and a history of discontinuation of drug in the first 3 months of the pandemic (HRI=1.19) were determined as factors that reduced 12-month drug retention rates. During a total of 12 months, 34 (6.5%) of patients had COVID-19. COVID-19 was severe in 7 patients and 5 of these patients died. The use of GC (HRI=3.81) and having a diagnosis of ILD/COPD (HRI=4.98) were found to increase the risk of infected by SARS-CoV-2.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.1383

Table 1. Comparison of demographic and clinical characteristics of patients with COVID-19

<table>
<thead>
<tr>
<th>Demographics</th>
<th>COVID-19 (-) (n=487)</th>
<th>COVID-19 (+) (n=34)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>48 (18-86)</td>
<td>48 (18-82)</td>
<td>0.615</td>
</tr>
<tr>
<td>Disease Duration</td>
<td>130 (22-478)</td>
<td>144 (49-519)</td>
<td>0.573</td>
</tr>
<tr>
<td>b/tsDMARD Duration</td>
<td>45 (12-129)</td>
<td>26 (14-170)</td>
<td>0.253</td>
</tr>
<tr>
<td>GC dose, mg</td>
<td>4 (1-16)</td>
<td>4 (2-16)</td>
<td>0.863</td>
</tr>
<tr>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Gender, F</td>
<td>259</td>
<td>19</td>
<td>0.909</td>
</tr>
<tr>
<td>COVID-19 diagnosis and outcome</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitalization</td>
<td>11 (32.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mortality</td>
<td>5 (14.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active disease (anytime during the pandemic)</td>
<td>82 (16.4)</td>
<td>28 (5.2)</td>
<td>0.246</td>
</tr>
<tr>
<td>ILD and/or COPD</td>
<td>14 (2.9)</td>
<td>8 (4.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>b/tsDMARD type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF</td>
<td>382 (78.4)</td>
<td>15 (44.1)</td>
<td>0.243</td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>19 (3.9)</td>
<td>2 (5.9)</td>
<td></td>
</tr>
<tr>
<td>Abatacept</td>
<td>13 (2.7)</td>
<td>1 (2.9)</td>
<td>0.866</td>
</tr>
<tr>
<td>Rituximab</td>
<td>9 (1.8)</td>
<td>6 (17.6)</td>
<td>0.001</td>
</tr>
<tr>
<td>GC</td>
<td>83 (170)</td>
<td>17 (50.1)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Targeted DMARDs?
Conclusion: The results of this study with a long follow-up period suggest that the retention rates of b/tsDMARD treatment increased with good communication with IMD patients during the COVID-19 pandemic. 

REFERENCES: 

Disclosure of Interests: None declared 

AB1107 COVID-19 INFECTION MAY BE TRIGGER FOR DEVELOPMENT OF IMMUNE-MEDIATED DISEASES (IMDS) 

N. Manukyan1, V. Vardanyan1, K. Ginosyan2, A. Sangpyan2, S. Mardoyan1. 
1Yerevan State Medical University, Rheumatology, Yerevan, Armenia; 2“Mikayelyan” University Hospital, Rheumatology, Yerevan, Armenia

Background: As considerable evidence indicates viruses play an important role in the pathogenesis of inflammatory rheumatic diseases as environmental factors. The most prominent pathogenic viruses which have been proposed to trigger autoimmune responses, it is also likely to induce clinical autoimmunity2.

Aim of the study: To determine the possible association between COVID-19 infection and development of IMDs.

Methods: We analyzed data of 21 patients (Male 4/19% , female 17/81%; mean age 45.5 ± 13.9 years), who were admitted to Rheumatology department of “Mikayelyan” University Hospital after Covid-19 infection with newly diagnosed IMDs from June till December 2021. All patients had never had such kind of disorder before. EULAR/ACR criteria were used for diagnosis and assessment of disease activity.

Results: After SARS-CoV-2 infection some patients presented with preserved fever, high levels of CRP and ESR, rash and arthritis. Particularly, 3 (14.3%) developed systemic lupus erythematosus, 3 (14.3%) – antiphospholipid syndrome, 4 (19%) – rheumatoid arthritis, 2 (9.5%) - spondyloarthritis, 3 (14.3%) – systemic juvenile idiopathic arthritis, 1 (4.8%) - undifferentiated arthritis, and 1 (4.8%) - juvenile idiopathic arthritis. 52.4% of patients the course of disease was mild. We’ve found a significant association between severe course of Covid-19 and development of erythema nodosum. (p< 0.05). Also an association between female gender and severe course of Covid-19 was determined (p<0.05).

Conclusion: In acute progression of the COVID-19 along with development of antiviral immunity, a dysregulated response of immune system may occur, represented by the marked cytokine release syndrome, macrophage activation, and systemic hyperinflammation.3 We analyzed the data of patients who didn’t have any typical symptom of rheumatic diseases before coronavirus infection, therefore, on our opinion, virus played an important role to induce clinical autoimmunity and autoinflammation and subsequently – IMDs. Possibly, Covid-19 infection may be included in the group of trigger viruses for IMDs.

REFERENCES: 

Disclosure of Interests: None declared 

AB1108 IMPACT OF THE FIRST WAVE OF THE COVID 19 PANDEMIC ON HEALTHCARE ACCESSIBILITY, DISEASE BEHAVIOUR, ANXIETY, AND PHYSICAL ACTIVITY IN RHEUMATIC DISEASE PATIENTS: AN ONLINE SURVEY AND POTENTIAL SOLUTIONS 

S. Yadav1, R. Samant1. 1P. Hinduja National Hospital & Medical Research Centre, Rheumatology, Mumbai, India

Background: Coronavirus Disease (covid 19) negatively impacted psychosocial health, health care accessibility and exercise regimen but problem’s scope and potential solutions remain elusive. We conducted a patient based online survey to understand these impacts and discussed potential solutions.

Objectives: Assess impact of Covid 19 on rheumatological disease status, accessibility to health care, patient anxiety and behavior and continuation of physical activity during pandemic.

Methods: Google form (18-question) based questionnaire was sent via SMS/WhatsApp in Aug 2020, at height of first pandemic and responses were collected over next month.

Results: Only 339 /2700 patients (12.5 %) responded to the survey. Other authors (1)(2) have observed a similar low response rate to online surveys. We recognise questionnaires with fewer questions tend to generate more responses, which should be considered critical in constructing future health-related surveys. Patients’ global assessment of their disease score was 7/10, with 0 representing the worst disease status and 10 representing best disease status, also 1/3 patients not felt need for rheumatological consultation during six months (March 2020- Aug 2020) of lockdown. These may imply adequate rheumatic disease control over long periods and during subsequent waves of pandemic, rheumatology patients can be shielded by avoiding non-urgent hospital follow up visits. Significant number of patients (20%) were unable to contact their rheumatologist, implying a significant impact of covid 19 and lockdown on rheumatology care, as suggested by other authors (1). As expected, there was switch to teleconsultancy mode of communication, with 22% per cent of patients already using it within 3 months of its introduction, which appears to be a good indicator of future adaptability and feasibility of teleconsultation.

Identifying specific profile of patients during physical consultation who can be easily managed via teleconsultation, may reduce unnecessary hospital visits while also improving healthcare delivery. 1/3 of our patients had anxiety about disease flare, and 41% were concerned about increased risk of covid 19 infection as they were on immunosuppressive medications as noted by other authors (3). Improving access to health care and increasing public awareness could help alleviate this anxiety. Reaching out to isolated rheumatology patients through SMS / educational video may improve the sense of health security. Contrary to our expectations, overall medication adherence was reasonable, likely due to be management of supply chains by local authorities, 15% completely stopped exercising and 25% reduced their exercise regimen by 50%. Shifting to home-based exercise, educational videos on physical therapy and online teleconsultation with physiotherapists could overall have positive impact.

Conclusion: Covid 19 has significantly impacted rheumatological patients in terms of increased anxiety, decreased healthcare accessibility and decreased exercise and physical activities. Modifications in teleconsultation methodology are needed in the future. Patients’ anxiety can be alleviated by educating them through digital and social media platforms and enrolling them in online patient support groups.

REFERENCES: 

Disclosure of Interests: None declared 

AB1109 EVALUATION OF THE POTENTIAL INDUCTION OF AUTOANTIBODIES AFTER THE ANTISARS-COV2 VACCINATION IN A COHORT OF PATIENTS WITH TRIPLE POSITIVITY FOR ANTIPHOSPHOLIPID ANTIBODIES 

P. Semeraro1, S. Bortolchi2, S. Piantoni2, L. Andreoli2, F. Franceschini2, E. Garatta1, A. Tincani1. 1University of Brescia - ASST Spedali Civili di Brescia, Clinical and Experimental Sciences, Brescia, Italy; 2University of Brescia - ASST Spedali Civili di Brescia, Molecular and Translational Medicine, Brescia, Italy

Background: Anti-SARS-CoV2 vaccines showed a good efficacy in prevention of severe COVID-191. Their potential in induction of autoantibodies (abs) has not been well established2. One recent study demonstrated an increase of ab’s titre after anti-SARS-CoV2 vaccination only in patients with already pre-existing positivity2.

Objectives: To evaluate the potential induction of abs after anti-SARS-CoV2 vaccination in a triple positive antiphospholipid antibody (APL) patient.

Methods: 18 subjects were enrolled [M/F= 17/1; median age=52 years; 5 Primary Antiphospholipid Syndrome (PAPS), 5 Systemic Lupus Erythematosus...
Background: SARS-CoV-2 infection had a major impact on patients with inflammatory rheumatic diseases. Spondyloarthritis (SpA) patients were one of the most affected groups of these patients.

Objectives: To assess the impact of Covid19 in spondyloarthritis patients under biological disease-modifying anti-rheumatic drugs (bDMARDs).

Methods: A retrospective observational study was conducted using registry data of patients with SpA under bDMARD therapy, followed at a tertiary level hospital, that have been diagnosed with COVID19 from March 2019 to December 2021. At least one evaluation previous (T0) and two evaluations after SARS-CoV-2 infection (T1, T2) were included in our analysis. Sociodemographic, clinical, disease activity, therapeutic response, function and general health status data were collected. Statistical analysis (significance at p < 0.05) was performed using paired t-test, Wilcoxon test and McNemar tests for paired samples. Linear and logistic regression models were performed to assess direction and strength of association.

Results: Thirty-two patients with SpA under bDMARD had COVID19, mostly women (20, 62.5%), with a disease course time averaged 18.65 (± 9.69) days, mainly with axial involvement (19, 59.4%) and positive for HLA-B27 antigen (11, 64.7%). The majority were under TNF inhibitors (30, 93.75%), with golimumab being the most common (9, 28.1%), and with a median bDMARD persistence of 2.63 (5.09) years. Seven (21.9%) were under a cDMARD, 3 (9.4%) under NSAID and 18 (56.3%) under corticosteroids. Three (9.4%) were already vaccinated against SARS-CoV-2, 2 (66.6%) with the mRNA-1273 vaccine, presenting a medium time since inoculation of 240 (± 234.01) days. Arterial hypertension was the most common comorbidity (5, 15.6%) and one patient (3.1%) had a previous diagnosis of type 2 diabetes. Most were never-smokers (17, 53.1%) and never-drinkers (29, 90.6%). The average age at infection was 40.97 (± 6.15) years and the most common symptom was cough (22, 68.8%), followed by headache (20, 62.5%) and myalgia (19, 59.4%). Event tree analysis didn't show association with SpA subtype, education level, work status, tobacco or alcohol consumption. Only one patient needed hospital admission but without needing of oxygen, therapy, ventilator or ECMO. Only one patient had an overlaid bacterial infection and no thromboembolic complications were observed. Two patients needed specific SARS-CoV-2 infection treatment, one with hydroxychloroquine and another with azithromycin. Twelve (37.5%) patients suspended bDMARD at the time of infection, with only 2 (6.3%) maintaining suspension at the time of the first post-infection visit. When comparing clinical variables, higher disease activity was seen at T1 only for BASDAI mean values, without statistical significance. Higher all domains VAS scores were also observed at T1, but not at T2, also without statistical significance; moreover, physical function didn't change significantly. No differences were observed according to gender or SpA subtype, nor with the use of cDMARD, NSAIDs or corticosteroids. The only statistically significant difference concerned MASES score between T0 and T1 (1 ± 4 vs. 2 ± 6, p=0.04), but not between T0 and T2. Higher baseline tender joint score (p < 0.01) and higher baseline LEI (p=0.03) negatively correlated with MASES score variation. Several baseline variables correlated positively with MASES at T1, including female gender (p < 0.01), corticosteroid use (p = 0.04), BASDAI (p < 0.01), ASDAS-ESR (p < 0.01), ASDAS-CRP (p < 0.01), DAS28 (p < 0.01), SPARCC (p = 0.04), physician VAS (p = 0.03) and total spine VAS (p = 0.01). Working status varied significantly after SARS-CoV-2 infection (at least part-time - 29, 90.6% vs. 22, 68.8%, p= 0.016).

Conclusion: SpA patients on bDMARD had a mild course of SARS-CoV-2 infection, with slight changes in enthesisis score in the short term, the latter particularly in those with higher disease activity in the pre-infection period. Long-term effects on work status could represent confounding factors related to the economic constraints of the pandemic.

Disclosure of Interests: None declared

AB1112 NO INCREASED RISK OF ADVERSE EVENTS OF THE WHO-VALIDATED COVID-19 VACCINES IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH BIOLOGICS  
M. Yasmine1, W. Triki1, H. Ferjani1, D. Ben Nessib1, K. Maattaïlah1, D. Kaffel1, W. Hamdi1, 1Kassab Institute of Orthopedics, Rheumatology; Tunis, Tunisia  
Background: The COVID-19 pandemic is a major concern for the management of patients with rheumatic diseases (RD). Indeed, an increasing risk of coronavirus infection has been demonstrated in these patients, explained on the one hand by the chronic inflammation and on the other hand by the immuno-modulating treatments used [1]. In this context, vaccination represent an efficient mean to prevent infections and should be included in the management of these patients.  
Objectives: The objective of our study was to determine the peculiarity of vaccination against SARS-CoV-2 in patients with RD treated with biologic therapies.  
Methods: We conducted a cross-sectional study during August 2021, including patients with RD: rheumatoid arthritis (RA) and spondyloarthritis (SpA). Sociodemographic data as well as disease characteristics were recorded. Patients were asked to answer a self-questionnaire about SARS-CoV-2 vaccination: modalities, time between doses, type of vaccine, adverse events, and time to biologic injection. We compared these results between the two groups: group 1 patients on biologics and patients on conventional disease-modifying antirheumatic drugs (DMARDs). A significance level was set for p<0.05.  
Results: The study included 102 patients with RD: RA (65.3%) and SpA (34.7%). The mean age was 52.4 ± 13 years [19-77]. There was a female predominance (71 women and 31 men) with a gender ratio of 0.4. The mean duration of disease progression was 7.8 ± 5 years [1-35]. Fifteen percent of patients were on corticosteroids with a mean dose of 6.7 mg [2-20] of prednisone equivalent.  
Conclusion: Our work demonstrated that patients treated with biologics adhered to vaccination and did not have more SARS-CoV-2 infections or adverse events compared to patients on conventional treatment.  
REFERENCES:  
Disclosure of Interests: None declared  

AB1113 AUTOINMUNE DISEASE-ASSOCIATED INTERSTICIAL LUNG DISEASE  
A. García Studer1, M. Rojas-Giménez2, M. Veloso Feijoo3, C. M. Romero-Barco3, F. Godoy-Navarrete4, N. Mena-Vázquez1, 1Instituto de Investigación Biomédica de Málaga (IBIMA), UGC de Reumatología, Hospital Regional Universitario de Málaga (HRUM), Málaga, Spain; 2Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), UGC de Reumatología, Hospital Universitario Reina Sofia de Córdoba, Córdoba, Spain; 3Hospital Universitario Virgen de Salamanca, Servicio de Reumatología, Salamanca, Spain; 4Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain; 5Hospital Universitario de Jaén, Servicio de Reumatología, Jaén, Spain  
Background: Interstitial lung disease (ILD) is a common condition in patients with systemic autoimmune diseases (SAI) that is characterized by increased morbidity and mortality. Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has posed huge challenges worldwide and previous studies suggest that ILD patients experience a more severe clinical course.  
Objectives: To analyze COVID-19 infection effects in patients with ILD associated systemic autoimmune disease (ILD-SAI) and to describe their vaccination status.  
Methods: Design We performed a multicenter, retrospective, observational study from 6 teaching hospitals in Andalusia, Spain. Study protocol We included ILD-SAI patients: rheumatoid arthritis (RA), systemic sclerosis (SS) and inflammatory myopathies (IM), assisted in rheumatology consultations in 2021. Variables COVID-19 infection was the main variable that we collected and it was confirmed by a positive result on a PCR test. Secondary variables: (1) COVID-19 severity defined as hospitalization or death; (2) vaccination status; (3) temporary relationship between infection and vaccination. Other variables included: clinical, epidemiological characteristics, treatments received, type of ILD (UIP/NSIP), pulmonary function testing and high-resolution computed tomography.  
Statistic analysis Two multivariable logistic regression analysis to indentify the "COVID-19" and "severe COVID-19" associated factors.  
Results: We included 176 ILD-SAI, of whom: 105 (59.7%) had RA, 49 (27.8%) had SS and 22 (12.5%) had IM. The main baseline characteristics for the overall sample and te 3 subgroups are shown in Table 1.  
Table 1. Clinical and epidemiological characteristics of 171 ILD-SAI patients.  

<table>
<thead>
<tr>
<th>Variable</th>
<th>RA (n=105)</th>
<th>SS (n=49)</th>
<th>IM (n=22)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, women, n (%)</td>
<td>58 (55.2)</td>
<td>42 (85.7)</td>
<td>7 (31.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>67.9 (9.6)</td>
<td>60.9 (12.5)</td>
<td>55.7 (18.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SARS-CoV-2 infection time, medium (IQR)</td>
<td>46.2 (25.4-79.0)</td>
<td>67.1 (52.2-88.2)</td>
<td>39.1 (25.1-72.5)</td>
<td>0.010</td>
</tr>
<tr>
<td>Radiological patterns, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>UIP</td>
<td>66 (62.9)</td>
<td>8 (16.3)</td>
<td>1 (4.5)</td>
<td></td>
</tr>
<tr>
<td>NSIP</td>
<td>32 (30.5)</td>
<td>39 (79.6)</td>
<td>20 (90.9)</td>
<td></td>
</tr>
<tr>
<td>Last PTT</td>
<td></td>
<td></td>
<td></td>
<td>0.345</td>
</tr>
<tr>
<td>FVC, mean (SD)</td>
<td>70.7 (19.9)</td>
<td>71.3 (21.4)</td>
<td>73.1 (16.6)</td>
<td>0.471</td>
</tr>
<tr>
<td>FEV1, mean (SD)</td>
<td>71.2 (19.3)</td>
<td>72.2 (17.3)</td>
<td>74.4 (17.9)</td>
<td>0.345</td>
</tr>
<tr>
<td>SB-DLCO, mean (DS)</td>
<td>54.3 (16.5)</td>
<td>52.4 (15.9)</td>
<td>60.8 (5.12)</td>
<td>0.140</td>
</tr>
<tr>
<td>Treatment</td>
<td></td>
<td></td>
<td></td>
<td>0.085</td>
</tr>
<tr>
<td>Biologic DMARD, n (%)</td>
<td>47 (46.1)</td>
<td>14 (28.6)</td>
<td>6 (27.3)</td>
<td></td>
</tr>
<tr>
<td>Immunosuppressants, n (%)</td>
<td>37 (36.3)</td>
<td>33 (67.3)</td>
<td>17 (77.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Corticosteroid, n (%)</td>
<td>72 (71.3)</td>
<td>24 (49.0)</td>
<td>19 (81.8)</td>
<td>0.007</td>
</tr>
<tr>
<td>COVID-19 infection, n (%)</td>
<td>14 (13.3)</td>
<td>4 (8.2)</td>
<td>4 (18.2)</td>
<td>0.460</td>
</tr>
<tr>
<td>Severe COVID-19 infection, n (%)</td>
<td>7 (50.0)</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td>0.085</td>
</tr>
<tr>
<td>Complete COVID-19 vaccination, n (%)</td>
<td>94 (88.5)</td>
<td>47 (95.9)</td>
<td>22 (100.0)</td>
<td>0.135</td>
</tr>
</tbody>
</table>

We recorded 22/179 (12.5%) SARS-CoV-2 infections, 7/22 (31.8%) of them were severe and 3/7 (42.85%) died. As to the vaccination, 163/176 (92.6%) patients received the complete dosis. Among those correctly vaccinated 18/163 (11%) had the SARS-CoV-2 infection, 4/18 (22%) after the vacciniation date and 14/18 (77%) when they still dount have the complete vacci- nation. From the 13 not vaccinated patients, 4/13 (30.7%) had COVID-19. As to frequency, COVID-19 severity and vaccination, there were no difference over subgroups of CTD-ILD patients. The risk factors associated with the COVID-19 infection were the last FVC (OR [CI 95%], 0.971 [0.944-0.998]; p=0.046), the vaccination (OR [CI 95%], 0.185 [0.049-0.891]; p=0.012) and the Rituximab treatment(OR [CI 95%], 3.172 [1.028-6.785]; p=0.045). Moreover, the only variable associated independently with the severe COVID-19 was the protective effect of vaccination (OR [CI 95%], 0.020 [0.003-0.119]; p<0.001).  
Conclusion: A total of 12.5% ILD-SAI patients were COVID-19 infected, most of them without the complete vaccine. Rituximab and a deterioration of FVC were risk factors for the COVID-19 wehreas the vaccination was a protective factor for the mild and severe infection.  
Disclosure of Interests: None declared  

AB1113 THE IMPACT OF SARS-COV-2 INFECTION ON DISEASE ACTIVITY AND CLINICAL RESPONSE TO BIOLOGICAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS  
B. Sambe1, A. Martins2, D. Santos Oliveira1, F. R. Martins1, R. Nicola1, M. Rato1, F. Oliveira Pinheiro1, M. Bernardez2, L. Costa1, 1Centro Hospitalar Vila Nova de Gaia / Espinho – Unit 1, Rheumatology Department, Vila Nova
VACCINATION OF PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES: AN ANALYSIS OF BARRIERS AND FACILITATORS IN A PROSPECTIVE COHORT

I. Andreica, I. Roman, X. Baralakos, J. Braun, U. Kitz, Rheumazentrum Ruhrgebiet and Ruhr-Universität Bochum, Rheumatology, Herne, Germany

Background: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than 50% of CIRD pts. were vaccinated against pneumococci and influenza before the SARS-CoV-2 pandemic started. High vaccination rates are critical to achieve herd immunity. Knowledge on barriers and facilitators of vaccine uptake in CIRD pts. is limited.

Objectives: The aim of this study was to characterize barriers and facilitators towards vaccines in general and specifically against pneumococci, influenza and SARS-CoV-2 in adult CIRD pts.

Methods: In early 2021, consecutive CIRD pts. completed a structured questionnaire including knowledge on vaccination, attitudes, and perceived barriers and facilitators towards vaccination. A total of 12 facilitators and 11 barriers towards vaccination was assessed in general, and specifically for vaccination against pneumococci, influenza and SARS-CoV-2. The Likert scales had 4 response options, ranging from 1 (completely disagree) to 4 (completely agree). Patient and disease characteristics, their vaccination history and attitudes towards vaccination against SARS-CoV-2 were assessed.

Results: Of 514 prospectively recruited pts., 441 responded (85.8%) to the questionnaire (table 1). Self-reported vaccine uptake was 48.8% against pneumococci and 66.2% against seasonal influenza. The majority (82.2%) was willing to be vaccinated against SARS-CoV-2. The majority (70%) had decent knowledge about vaccination, and only <10% doubted its effectiveness. The level of knowledge did not differ between the studied 3 vaccinations. Pts. were more likely to rate statements about facilitators favorably compared to statements about barriers. Facilitators for SARS-CoV-2 vaccination did not differ from vaccination in general (Figure 1). Societal and organizational facilitators such as public vaccine campaigns or protection for high-risk pts. were more commonly named compared to inter- or intrapersonal facilitators. Protection of high-risk pts. was by far the most frequently cited facilitator. Most pts. indicated that they were likely to receive a vaccine if their health care professional would recommend it – without preference for GP or rheumatologist. The frequency of barriers was much lower compared to facilitators and more barriers towards SARS-CoV-2 vaccination were reported in comparison to vaccination in general or pneumococci and influenza, respectively. However, pts. frequently cited intrapersonal issues as barriers against vaccination. Importantly, the major barrier was an inadequate risk perception between the severity of COVID-19 and the potential adverse events of the vaccine.

Table 1. Patient and disease characteristics

|       | Age, y | Women, No. (%) | Men, No. (%) | CRP, mg/L, n=440 | CDAI, n=194 | HADS-D, n=436 | HADS-A, n=436 | DAS28, n=371 | BASDAI, n=118 | BASFI, n=118 | HAQ score, n=317 | Employment status, No. (%) | Work status, No. (%) | PSQ score, n=337 |
|-------|-------|----------------|-------------|------------------|-------------|---------------|---------------|---------------|---------------|---------------|-------------------|----------------------|------------------|
|       | 54.1 (12.6) | 272 (54.4) | 256 (52.8) | 0.4 (0.7) | 11.1 (9.0) | 5.8 (4.3) | 6.6 (4.0) | 3.8 (2.2) | 4.1 (2.5) | 6.6 (4.0) | 6.6 (4.0) | 7.8 (4.0) | 8.3 (4.0) |

Variables as mean (SD)

Figure 1. Facilitators of vaccine uptake in general and for SARS-CoV-2

Conclusion: A relatively high number of pts. was vaccinated against pneumococci and influenza, a relatively high campaign success during the last year. In addition, more than 80% of pts. were willing to be vaccinated against SARS-CoV-2. Facilitators were of greater significance than barriers in this scenario. The high number of societal and organizational facilitators enables the implementation of effective strategies to increase future vaccination rates.
REFERENCES:
[1] Kiltz et al. RMD Open 2021

Disclosure of Interests: S. Andriachev; Speakers bureau: UCB, MSD, Novartis, Lilly, Janssen, Sob; Consultant of: Novartis, Lilly, Sob, Galapagos, Amgen, Takeda, Grant/research support from: Lilly, Iuliu Romain; None declared.

Xenofon Baraliakos Speakers bureau: AbbVie, Lilly, Pfizer, UCB, MSD, Novartis, Galapagos, Hexal, Paid instructor for: Abbvie, Lilly, Pfizer, UCB, MSD, Novartis, Galapagos, Hexal, Consultant of: Abbvie, Lilly, Pfizer, UCB, MSD, Novartis, Galapagos, Hexal, Grant/research support from: Abbvie, MSD; Novartis, Lilly, Jueverco Braun Speakers bureau: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, FResenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Pfizer, UCB, Novartis, Consultant of: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, FResenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Pfizer, UCB, Novartis, Grant/research support from: Abbvie, Amgen, Biogen, Frenesiun, Hexal, Janssen, MSD, Novartis, onkowissen.de, Pfizer, Roche and UCB, Grant/research support from: Abbvie, Amgen, Hexal, Frendiun, Novartis und Pfizer.


[AB1115] COVID-19 VACCINE HESITANCY AMONG RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGICS

E. Hanneche1,2, S. Boussaid1,2, S. Reki1,2, S. Jemmali1,2, S. Rahmouni1, H. Aji2, H. Sahli2, M. Elleuch1,2. RHEUMATOLOGY Department, La Rabita Hospital, Tunis, Tunisia; 3Faculty of medicine of Tunis, University Tunis El Manar, Tunis, Tunisia

Background: Vaccine hesitancy is defined by the OMS as “a delay in acceptance or refusal of vaccines despite availability of vaccination services” [1], and it is considered as one of threats to global health. This hesitancy emerges around Covid-19 vaccination. Patients on biologic Disease-Modifying Anti-Rheumatic Drug (bDMARD) are vulnerable to Covid-19 infection and their perception to vaccination is unknown.

Objectives: The aim of our study was to identify Covid-19 vaccine hesitancy among rheumatoid arthritis (RA) patient on bDMARD.

Methods: We conducted a monocentric, cross-sectional study, including patients with RA who met the ACR/EULAR 2010 criteria. All patients were on bDMARD with or without conventional synthetic (Cs) DMARD for at least 3 months. Disease activity was assessed using the Disease Activity Score (DAS) 28 (CRP) and the functional impairment using the Health Assessment Questionnaire (HAQ). A structured interview was done using a prepared questionnaire evaluating their vaccine hesitancy behavior.

Results: We enrolled 60 patients: 10 male (16.7%) and 50 females (83.3%). Their average age was 58.16±9.04 years [34-80]. For the education level: 38.5% of patients were illiterate, 34.6% had primary education, 23.1% had secondary education, and 3.8% have a university degree. Forty-four patients (73.3%) had no occupation, 13 patients (21.7%) were employed, and 5% were retired. The majority of patients lived in urban areas (85%) and 98.2% with their secondary education, and 3.8% have a university degree. Forty-four patients (73.3%) had no occupation, 13 patients (21.7%) were employed, and 5% were retired. The majority of patients lived in urban areas (85%) and 98.2% with their families. The average duration of RA was 15.23±8.8 years [2-39]. The average DAS28 (CRP) and the average HAQ were 4.05±1.22 [1.5-7.2] and 0.7±0.4 [0-2.4], respectively. Fifteen patients (25%) had a high disease activity and seven (11.7%) were in remission. When asking patients about their Covid-19 infection and vaccination status; 15% had caught the virus and 61.7% have already received the vaccine. One third (35.6%) believed that they had enough information about vaccination. Their main sources were their family, friends, and the media. More than half of the asked patients (68.3%) reported vaccine hesitancy. Reasons of vaccine hesitancy were divided into three categories: lack of confidence (66.7%, p<0.005) (63.3% fear related to side effects, 10% conspiracy theory, 6.7% lack of confidence in the provider), complacency problem (16.7%, p=0.01) and lack of convenience (8.6%). There was no association between vaccine hesitancy and sociodemographic data. The existence of comorbidities had no influence on vaccine hesitancy (p=0.4). This hesitancy was not associated with DAS28 (CRP) (p=0.6) and with HAQ (p=0.7). Patients with moderate to high disease activity were more likely to deny the usefulness of Covid-19 vaccination (p=0.09). Regarding to the therapeutic data, there was no association between corticotherapy and vaccine hesitancy (p=0.1). There was no influence on the type of the current bDMARD (p=0.3) or of the rate of administration (p=0.4). The route of administration was associated with hesitancy (53.65% intravenous vs 46.34% subcutaneous, p=0.04).

Conclusion: Our study showed that Covid-19 vaccination coverage among RA patients on bDMARDs was not optimal with a high percentage of hesitancy. The reasons are complex and they may be related to a lack of awareness. Rheumatologists should play a key role in the vaccine company.

Disclosure of Interests: None declared


[AB1116] RESULTS OF PRESCRIBING BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS AND JANUS KINASE INHIBITORS FOR RHEUMATOID ARTHRITIS DURING THE COVID-19 PANDEMIC: DATA FROM A TELEPHONE SURVEY OF 254 PATIENTS.

A. Potapova1, A. Karateev2, E. Pogozheva1, E. Matianova1, A. Bobkova1, A. Semashko1, E. Filatova1, V. Amirdzhanaeva1, E. Zotkin1, A. Lilia1, 1VA. Nasonova Research Institute of Rheumatology, Rheumatology, Moscow; Russian Federation

Background: Prescribing biologic disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors during the global pandemic of coronavirus disease 2019 (COVID-19) requires a balanced approach and rigorous monitoring of patients’ condition.

Objectives: To evaluate the effect of bDMARDs and JAK inhibitors on the condition of patients with rheumatoid arthritis (RA), taking into account the outcomes assessed by the patients themselves, as well as the incidence of COVID-19 in these patients.

Methods: A telephone survey was conducted of 254 patients with RA (age 49.8 ±13.7 years, 83.5% women, RF + 64.4%, DAS28 5.4 ± 1.6), who in the period from January 2020 to June 2021 by decision of the medical commission of the V.A. Nasonova Research institute was first prescribed bDMARDs or JAK inhibitors: rituximab (RTX) - 148 (58.3%), TNF-a inhibitors - 57 (22.4%), JAK inhibitors - 20 (7.9%), IL 6 inhibitors - 17 (6.7%), abacetab - 12 (4.7%).

Results: At the time of the survey, 204 (80.3%) patients continued to take the prescribed drugs. The main cause discontinuation of treatment was for non-medical reasons. Synthetic DMARDs (mainly methotrexate and leflunamide) were received by 68.0%, glucocorticoids - 45.3%, non-steroidal anti-inflammatory drugs - 44.5% of respondents. Among the patients who took bDMARDs or JAK inhibitors, 68.1% noted the “state of symptoms acceptable to the patient”; the absence of frequent joint pain - 65.3%, increased fatigue - 14.3%. The incidence of COVID-19 and hospitalization associated with this disease didn’t differ between individuals who continued and discontinued the use of bDMARDs or JAK inhibitors: 41.2% and 44.6%; 13.7% and 14.0% respectively, p=0.80884. There was no significant difference in the incidence of COVID-19 and hospitalization associated with this disease in patients taking various biologics or JAK inhibitors.

Conclusion: Despite the COVID-19 pandemic, rituximab remains one of the most popular bDMARD. About a third of patients receiving bDMARDs and JAK inhibitors aren’t satisfied with their condition. More than 40% of patients treated with these drugs experienced COVID-19, and 14.0% required hospitalization.

Disclosure of Interests: None declared


[AB1117] THE IMPACT OF THE COVID-19 PANDEMIC ON HEALTH AND LIFESTYLE IN INDIVIDUALS WITH KNEE PAIN, A HALLOSA STUDY

E. Sunesson1, C. Sylwander1,2, E. Haglund3,4, M. Andersson1,3, I. Larsson1,2,3. 1Spenshult Research and Development Centre, Halmstad, Sweden; 2Halmstad University, School of Health and Welfare, Halmstad, Sweden; 3Lund University, Department of Clinical Sciences, Section of Rheumatology, Lund, Sweden; 4Halmstad University, Department of Environmental and Biosciences School of Business, Innovation and Sustainability, Halmstad, Sweden

Background: Covid-19 has affected everyday life, health and lifestyle among the general population and vulnerable groups. Individuals with knee pain are recommended an active lifestyle to reveal pain but find it difficult to maintain health and lifestyle compared to the general population due to the cause of chronic pain, impaired physical function and a diminishes quality of life. This adds to the importance of exploring how to preserve health and lifestyle among individuals with knee pain during the pandemic.

Objectives: The aim of this study was to explore the impact of the covid-19 pandemic on the health and lifestyle in individuals with knee pain. A second objective was to assess if current knee pain and disability had changed during the pandemic.

Methods: Nineteen participants with current knee pain, and with no earlier diagnosed radiographic osteoarthritis, and no rheumatologic disorder or cronic ligament injury. were recruited from The Halland Osteoarthritis (HALLOA) Cohort Study, twelve female and seven males, between 41-62 (median 51) years of age. Data were collected through individual interviews with open-ended questions: What impact have you experienced with your health and lifestyle during covid-19? What activities or changes have you changed to maintain your health and lifestyle during covid-19? Qualitative content analysis was used, where two categories and five sub-categories emerged (Table 1).
Table 1. Categories, and sub-categories exploring the impact of the covid-19 pandemic on health and lifestyle in individuals with knee pain

<table>
<thead>
<tr>
<th>Categories</th>
<th>Sub-categories</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adjusting behaviours due to covid-19</td>
<td>Spending time at home, becoming digitally, spending time outdoors, having a positive outlook on life, sharing responsibility</td>
</tr>
<tr>
<td>Valuing life due to covid-19</td>
<td></td>
</tr>
</tbody>
</table>

**Results:** The results from this study explored how behaviour and attitude towards valuing life have been adjusted to maintain health and lifestyle among individuals with knee pain during covid-19. The categorical analyses emerged with the sub-categories: spending more time at home, becoming digitally, and spending more time outdoors. These sub-categories determine how a more reclusive behaviour was adopted to maintain health and lifestyle, as well as their supporting others maintain their health and lifestyle. The result may in the future contribute to alternative ways of maintaining health and lifestyle in different vulnerable groups and may be used in situations other than the pandemic.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2328

---

**AB1118 INVESTIGATION OF THE EFFECT OF THE HISTORY OF COVID-19 ON COGNITIVE LEVEL, PAIN CATASTROPHIZATION, AND PHYSICAL ACTIVITY LEVEL IN INDIVIDUALS WITH CHRONIC LOW BACK AND NECK PAIN**

A. Ailiyucu1, O. Ulger2,1, Ankara, Physical Therapy and Rehabilitation, Ankara, Turkey; 1Hacettepe University, Physical Therapy and Rehabilitation, Ankara, Turkey

**Background:** Low back and neck pain is one of the most common health problems in society, and one of the top reasons for admission to the hospital (1). Studies show that the level of physical activity decreases in individuals with chronic pain, and the cognitive level and quality of life are negatively affected (2). There are studies examining the effects of the Covid-19 pandemic process on the level of physical activity and cognitive level in various groups. However, the number of studies on how the history of Covid-19 affects individuals with low back and neck pain is limited.

**Objectives:** The aim of this study is to examine the effect of Covid-19 history on cognitive level, pain catastrophize and physical activity level in individuals with chronic low back and neck pain in individuals.

**Methods:** A total of 25 individuals with chronic pain, including 16 with low back pain and 9 with neck pain, were included in the study. Demographic data such as age, gender, and body mass index (BMI) were obtained from all individuals. The education levels of the individuals were recorded. Cognitive level was assessed by the Montreal Cognitive Assessment (MoCA)(3), pain severity was assessed by the Visual Analog Scale (VAS), pain catastrophization was assessed by the Pain Catastrophizing Scale (PCS)(4), and physical activity level was assessed by the International Physical Activity Questionnaire-Short Form (IPAQ-SF)(5).

**Results:**

Table 1.

<table>
<thead>
<tr>
<th>Categories</th>
<th>Sub-categories</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td></td>
</tr>
</tbody>
</table>
| Primary school n (%)                | 0 (0%) must, 11 (44.0%) High school n (%) 11 (44.3%) Bachelor's degree n (%) 5 (21.4%)
| Moca                                | 0.01* (p = 2.3) Moca 0.01* (p = 2.3) Moca 0.01* (p = 2.3) Moca 0.01* (p = 2.3)
| VAS                                 | 0.01* (p = 2.3) VAS 0.01* (p = 2.3) VAS 0.01* (p = 2.3) VAS 0.01* (p = 2.3)
| PSC                                 | 0.01* (p = 2.3) PSC 0.01* (p = 2.3) PSC 0.01* (p = 2.3) PSC 0.01* (p = 2.3)
| IPAQ-SF                             | 0.01* (p = 2.3) IPAQ-SF 0.01* (p = 2.3) IPAQ-SF 0.01* (p = 2.3) IPAQ-SF 0.01* (p = 2.3)

Demographic data, VAS, MoCA, PCS, and IPAQ-SF scores are given in Table 1. 7 of the participants had history of Covid-19, 18 did not. The MoCA scores and education levels of individuals with Covid-19 were higher than individuals without history of Covid-19 (p<0.05). There was no difference in physical activity, pain and pain catastrophization levels between the 2 groups (p> 0.05).

**Conclusion:** Surprisingly, individuals who had a history of Covid-19 had higher cognitive levels than individuals without a history of Covid-19. In addition, there was no difference between physical activity and pain catastrophization levels. This may be due to the higher education level of individuals with a history of Covid-19. There is a need for further studies in which education levels are similar, and hospitalization and the Covid-19 positivity process are examined in more detail.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2440
PSYCHOLOGICAL ASSESSMENT IN PATIENTS WITH CHRONIC RHEUMATIC, SYSTEMIC AUTOIMMUNE, OR AUTOINFLAMMATORY DISEASES PRESENTED WITH COVID-19: THE MENTOCVRMD STUDY.

M. M. Farhat1,2, M. Horn3,4, G. Vaiva5,6, E. Drumez5,6, R. Sero7,8, V. Gaudin9,10, V. Devauchelle-Pensec11,12, S. Guillaume-Czitrom11,12, N. Hamamouche16, S. Morell-Dubois13,14, E. Hachulla1,17, on behalf of FAI2R/SFR/SNFMI/SMFH.

AB1120


BACKGROUND:

The COVID-19 pandemic has raised concerns about its psychological impact on patients with chronic rheumatic, autoimmune and/or autoinflammatory diseases, due to immunosuppression, are at risk of severe forms of infection. Currently, there is little information on psychological impact of the pandemic on the mental health of these more vulnerable patients.

METHODS:

In the present study, we included 59 patients with chronic rheumatism, systemic autoimmune disease, or autoinflammatory diseases who presented with COVID-19 infection between March and September 2020, first wave of French pandemic, and patients with same diseases who did not presented with infection to date.

RESULTS:

Between February and December 2021, 60 cases (46 (76.7 %) women), median age 52.0 (39.0; 63.0) were included, of which 15 (25 %) had been hospitalized during infection, and 169 controls (148 (87.6%) women), median age of 52.0 (38.0; 63.0). There were more smokers in the group of cases (12 %) than controls (14 (9.1 %) (p=0.028) as well as more cases on ARA2 treatment (8 (13.3 %)) than controls (7 (4.5 %) (p=0.035) with no statistically significant difference in others comorbidities or treatments. There was no statistically difference concerning the ISCI scores between cases (11.6 ± 7.31) of which 60% had sleep disorders and controls (11.64 ± 6.82) of which 70.4% had sleep disorders. There was no statistically significant difference in PTSD scores of 15.5 (5.0 to 28.0) for cases and 18.0 (8.0 to 35.0) for controls, of which respectively 12 (20 %) had values indicating possible PTSD for cases and 50 (29.6 %) for controls. There was no statistically significant difference in PHQ-9 scores (5.5 (1.5 to 11.0)) of which 50% had depressive symptoms and controls (6.0 (2.0 to 11.0)) of which 54.5% had symptoms. There was no statistically significant difference in GAD-7 scores (3.5 (0.0 to 8.0)) of which 40% had anxiety symptoms and controls (4.0 (0.0 to 8.0)) of which 43.2% had symptoms. There was no statistically significant difference in PHQ-15 scores (11.4 ± 6.7), 85% of whom reported presence of symptoms, and controls (10.9 ± 6.2), 82.3% of whom reported symptoms. There was no statistically significant difference in SSD scores between cases (17.7 ± 10.5) and controls (18.4 ± 10.9). There was a statistically significant difference in reported VAS scores of pain related to inflammatory rheumatism in cases with a median of 4.5 (3.0 to 6.0) compared to controls with a medium of 4.0 (1.0 to 6.0) (p=0.011). There was no statistically significant difference in any of the psychological assessment scores between the inpatient and outpatient groups.

CONCLUSION:

There was no statistically significant difference between COVID cases and controls in the evaluation of these psychological parameters. Prevalence of all these variables were high in the whole study population, testifying to the need to manage these psychological aspects for patients with chronic rheumatisms, autoimmune and/or autoinflammatory diseases.

HOW FEARS AND HOPES HAVE EVOLVED IN PATIENTS WITH RMSD THROUGH THE COVID-19 PANDEMIC? RESULTS FROM THE REUMAVID STUDY (PHASE 1 AND 2)

M. Garrido-Cumbre1,2, H. Marzo-Ortega1,4, E. Mateus1,2, L. Grange5,6, D. Webb7, C. Jacklin11, S. Irwin12, S. Mingolla13, K. Antonopoulou14, S. Makri15, V. Navarro-Compañ16 on behalf of REUMAVID working group.

AB1121


BACKGROUND:

The COVID-19 pandemic has raised concerns about its psychological effects. Sleep disturbances, anxiety and/or depressive symptoms, post-traumatic stress symptoms have been reported in general population. Patients with chronic rheumatism, systemic autoimmune disease or auto-inflammatory disease, due to immunosuppression, are at risk of severe forms of infection. Currently, there is little information on psychological impact of the pandemic on the mental health of these more vulnerable patients.

OBJECTIVES:

To compare psychological assessment between patients with chronic rheumatism and/or autoinflammatory diseases who presented with COVID-19 infection between March and September 2020, first wave of French pandemic, and patients with same diseases who did not presented with infection to date.

METHODS:

The MENTOCVRMD study was a multicenter descriptive study. Cases were patients with chronic rheumatic, autoimmune and/or autoinflammatory diseases from the French RMSD cohort who presented COVID-19 infection between March and September 2020. Controls were patients with same diseases who did not develop infection. The study is registered in Clinical Trials under number 2020-A02058-31. For participants, following criteria were collected: demographics (age, gender, smoking status), psychological assessment questionnaires: Insomnia Severity Index (ISI); Post-traumatic stress disorder (PTSD) checklist; Patient Health Questionnaire (PHQ9) Depression; Generalized Anxiety Disorder (GAD7) Anxiety; Patient Health Questionnaire-15 (PHQ-15) and Somatic Symptom Disorder (SSD)-12.

RESULTS:

Between February and December 2021, 60 cases (46 (76.7 %) women), median age 52.0 (39.0; 63.0) were included, of which 15 (25 %) had been hospitalized during infection, and 169 controls (148 (87.6%) women), median age of 52.0 (38.0; 63.0). There were more smokers in the group of cases (12 %) than controls (14 (9.1 %) (p=0.028) as well as more cases on ARA2 treatment (8 (13.3 %)) than controls (7 (4.5 %) (p=0.035) with no statistically significant difference in others comorbidities or treatments. There was no statistically difference concerning the ISCI scores between cases (11.6 ± 7.31) of which 60% had sleep disorders and controls (11.64 ± 6.82) of which 70.4% had sleep disorders. There was no statistically significant difference in PTSD scores of 15.5 (5.0 to 28.0) for cases and 18.0 (8.0 to 35.0) for controls, of which respectively 12 (20 %) had values indicating possible PTSD for cases and 50 (29.6 %) for controls. There was no statistically significant difference in PHQ-9 scores (5.5 (1.5 to 11.0)) of which 50% had depressive symptoms and controls (6.0 (2.0 to 11.0)) of which 54.5% had symptoms. There was no statistically significant difference in GAD-7 scores (3.5 (0.0 to 8.0)) of which 40% had anxiety symptoms and controls (4.0 (0.0 to 8.0)) of which 43.2% had symptoms. There was no statistically significant difference in PHQ-15 scores (11.4 ± 6.7), 85% of whom reported presence of symptoms, and controls (10.9 ± 6.2), 82.3% of whom reported symptoms. There was no statistically significant difference in SSD scores between cases (17.7 ± 10.5) and controls (18.4 ± 10.9). There was a statistically significant difference in reported VAS scores of pain related to inflammatory rheumatism in cases with a median of 4.5 (3.0 to 6.0) compared to controls with a median of 4.0 (1.0 to 6.0) (p=0.011). There was no statistically significant difference in any of the psychological assessment scores between the inpatient and outpatient groups.

CONCLUSION:

There was no statistically significant difference between COVID cases and controls in the evaluation of these psychological parameters. Prevalence of all these variables were high in the whole study population, testifying to the need to manage these psychological aspects for patients with chronic rheumatism, autoimmune and/or autoinflammatory diseases.

DISCLOSURE OF INTERESTS:

None declared.
Background: The COVID-19 pandemic has generated uncertainties and concerns among patients with rheumatic diseases throughout the two phases of RÉUMAVID.

Methods: RÉUMAVID is an international cross-sectional study collecting data through an online survey in seven European countries led by the Health & Territory Research Group of the University of Seville, together with a multidisciplinary team including patient representatives, rheumatologists, and health researchers. Data were collected in two phases: Phase 1 (P1) between April-July 2020 and Phase 2 (P2) between February-April 2021. Demographics, health behaviours, employment status, access to healthcare services, disease characteristics, WHO-5 Well-Being Index and Hospital Anxiety and Depression Scale (HADS). Participants rated a series of fears (infection, medication consequences, lack of medication, impact on healthcare, lost job, civil disorder) on a scale from zero ("no concern at all") to five ("extremely concerned") and hopes (treatment/vaccine availability, going outside, travel, economic situation, treatment continuation, health status) on a scale from zero ("no hope at all") to five ("extremely hopeful"). Descriptive analysis and Mann-Whitney test were used to explore fears and hopes in both phases of RÉUMAVID.

Results: A total of 3,802 participants were recruited across both phases in RÉUMAVID with comparable demographic characteristics: mean age 52.6 (P1) vs. 55.0 years (P2), 80.2% female (P1) vs. 83.7% (P2), 69.6% married (P1) vs. 68.3% (P2), and 48.6% university educated (P1) vs. 47.8% (P2). Most prevalent RMD was axial spondyloarthritis in P1 (37.2%), and rheumatoid arthritis in P2 (53.1%). In P1 and P2 the major concern was the impact on healthcare in the future (3.1 and 3.2 out of 5, p = 0.051). Compared to P1, patients in P2 had less fears about RMD medications not reaching the country (2.4 vs. 1.9, p < 0.001), civil disorders (2.0 vs. 1.8, p = 0.001), or losing their jobs (1.4 vs. 1.5, p = 0.003). Comparing hopes with P1, patients in P2 had greater hopes about availability of treatments or vaccines suitable for COVID-19 (3.2 vs. 3.9, p < 0.001), to be able to go out as before the pandemic (3.1 vs. 3.5, p < 0.001), to be able to travel as before the pandemic (2.8 vs. 3.3, p < 0.001), maintain and even improve the current economic situation after the pandemic (2.6 vs. 3.0, p < 0.001), and to be able to continue their treatment as usual (3.8 vs. 3.9, p = 0.049; Table 1).

Conclusion: During the first phase of RÉUMAVID at the beginning of the pandemic, patients with RMDs were more fearful and less hopeful compared to the second phase. These fears were notable in terms of lack of medication for their RMD, while during the second phase, patients were hopeful of a treatment or vaccine against COVID-19, and of being able to go out and travel as before.

Acknowledgements: This study was supported by Novartis Pharma AG. We would like to thank all patients who completed the survey as well as all of the participating organizations in the participating RÉUMAVID study including the Cyprus League for People with Rheumatism (CYLPER) from Cyprus, the Association Française de Lutte Anti-Rhumatisme (AFLAR) from France, the Helen Marzo-Ortega Speakers bureau: Abbvie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB, Consultant of: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, Laura Christen Employee of: Novartis Pharma AG, José Correa-Fernández: None declared, Elsa Mateus Grant/research support from: Pfizer, grants from Lilly Portugal, Sanofi, AbbVie, Novartis, Grünenthal S.A., MSD, Celgene, Medac, Janssen-Cilag, Pharmaker and GAPA, LAURENT-GRANGE: None declared, Dale Webb Grant/research support from: Abbvie, Biogen, Janssen, Lilly, Novartis and UCB, Clare Jacklin Grant/research support from: Abbvie, AMS, Biogen, Eli Lilly, Gilead, Janssen, Pfizer, Roche and Sanofi, and UCB, Shantel Irwin: None declared, Serena Mingolla: None declared, KATY ANTONOPOLOL: None declared, Souzi Makri Grant/research support from: Novartis, GSK and BayGen, and NAVAR-COMPAN Grant/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB


Table 1. Bivariate analysis of patients’ fears and hopes in both phases of RÉUMAVID (N=3,802, unless specify)

<table>
<thead>
<tr>
<th>Fears</th>
<th>First Phase</th>
<th>Second Phase</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact on healthcare in the future, n=3,653</td>
<td>3.1 ± 1.6</td>
<td>3.2 ± 1.6</td>
<td>0.051</td>
</tr>
<tr>
<td>Treatment taken could make you more likely to get serious illness from COVID-19 infection, n=3,653</td>
<td>2.8 ± 2.9</td>
<td>2.8 ± 2.9</td>
<td>0.18</td>
</tr>
<tr>
<td>Lack of medication, n=3,656</td>
<td>2.8 ± 1.7</td>
<td>2.9 ± 1.7</td>
<td>0.040</td>
</tr>
<tr>
<td>Civil disorder, n=3,634</td>
<td>2.0 ± 1.6</td>
<td>2.0 ± 1.7</td>
<td>0.001</td>
</tr>
<tr>
<td>Lost job, n=3,568</td>
<td>1.5 ± 1.9</td>
<td>1.4 ± 1.9</td>
<td>0.003</td>
</tr>
<tr>
<td>Hopes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Availability of a treatment or vaccine suitable for COVID-19, n=3,318</td>
<td>3.2 ± 1.5</td>
<td>3.9 ± 1.3</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Continue treatment as usual, n=3,306</td>
<td>3.7 ± 1.4</td>
<td>3.8 ± 1.4</td>
<td>0.040*</td>
</tr>
<tr>
<td>Go out as before the COVID-19 pandemic, n=3,318</td>
<td>3.1 ± 1.5</td>
<td>3.5 ± 1.4</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Don’t get infected with COVID-19 and continue in the same health, n=3,260</td>
<td>3.5 ± 1.5</td>
<td>3.5 ± 1.5</td>
<td>0.696</td>
</tr>
<tr>
<td>Travel as before the COVID-19 pandemic, n=3,311</td>
<td>2.8 ± 1.6</td>
<td>3.3 ± 1.5</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Maintain or improve economic situation after the COVID-19 pandemic, n=3,310</td>
<td>2.6 ± 1.7</td>
<td>3.0 ± 1.7</td>
<td>&lt;0.001*</td>
</tr>
</tbody>
</table>

SD, standard deviation; n, absolute numbers; %, percentages; p, p-value; AID, autoimmune diseases; HTA, arterial hypertension; DM, diabetes mellitus; DL, dyslipidaemia; ICU, intensive care unit; ARDS, Acute respiratory distress syndrome
Conclusion: Patients treated with synthetic or biological DMARDs, immuno-modulators or glucocorticoids do not seem to have a higher rate of death or hospital admission respect to patients diagnosed of AID without such treatments.

REFERENCES:


Disclosure of Interests: Ana Isabel Rebollo Giménez: None declared, Marina González-Pérez: None declared, Javier Secano Romero: None declared, Lourdes Martín de la Sierra López: None declared, Laura Jiménez Rodríguez: None declared, David Castro-Corredor Speakers bureau: DC has received honoraria for speaker bureaus in the past 3 years from Gebro pharma, Pfizer, Lilly, Nordic Pharma, Gedeon Richter, UCB pharma, Joaquín Anino-Fernández: None declared, Laura Jiménez Rodríguez: None declared, David Belardo Pastrana Speakers bureau: DB has received honoraria last year for speaker bureaus from GlaxoSmithKline., Jose Luis Cuadra Diaz: None declared

AB1112
EFFICACY AND SAFETY OF SARS-COV-2 THIRD VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO DID NOT RESPOND AFTER PRIMARY TWO-DOSE REGIMEN


Background: Vaccination for COVID-19 is an essential tool to fight the pandemic. Evidence suggests that patients with immune mediated inflammatory diseases (IMIDs) have less response. The application of a booster shot is a strategy that has been implemented in this population, however there is scarce information about its efficacy.

Objectives: To assess the humoral and cellular immune response after a third dose of SARS-CoV-2 vaccine in patients with rheumatoid arthritis (RA) with undetectable antibodies titers after primary regimen of two doses.

Methods: Observational study. Patients with RA (ACR/EULAR 2010 criteria) from two rheumatology centers, ≥18 years old, with no seroconversion after two doses of SARS-CoV-2 vaccine, who received a third dose of either mRNA or vector-based vaccines (BNT162b2 or ChAdOx1 nCoV-19) were included. Anti-SARS-CoV-2 IgG antibodies, neutralising activity and T cell responses were assessed between 21 and 40 days after the third dose. Sociodemographic data, comorbidities, treatment, vaccine applied and the presence of adverse events (AE) were recorded. Statistical analysis: descriptive analysis. Chi² or Fischer test and T test. Results: Total of 99 patients were evaluated. 76 (76.8%) patients were females with a mean age of 63.7 years (SD 11.6) and mean disease duration of 15.8 years (SD 8). Most of them (81%) reported comorbidities, being the most frequent arterial hypertension, obesity and dyslipidemia. At vaccination time, 6 (6.1%) patients were taking methotrexate and ABT and the other one RTX. Compared to other treatments, ABT and RTX was associated with no neutralizing activity in 4 (80%) patients and lower titers of neutralizing antibodies (median 1/3 (IQR 0-1/20) vs median 1/1 (IQR 14-1/128), p=0.197). A T-cell response was present in 41.2% of all patients after the second dose, increasing to 75% after the third dose. The use of ABT was associated with a lower frequency of T-cell response (80% vs 20%, p=0.014). Sixteen (76.1%) patients reported at least one AE, 66.7% injection site reaction and 25% flu-like syndrome.

Conclusion: In this RA cohort who failed to seroconvert after two doses of SARS-CoV-2 vaccine, 90.5% presented detectable anti-SARS-CoV-2 IgG and 75% T-cell response after a third dose. The use of ABT was associated with a lower frequency of T-cell response. This data highlights the importance of a third vaccine in this group of patients.

Disclosure of Interests: None declared


AB1124
IMPACT OF COVID-19 ON PATIENTS WITH RHEUMATIC DISEASES IN A SECOND LEVEL HOSPITAL


Background: Covid-19 has generated a change in society and in people's daily lives. Patients with rheumatic diseases have suffered physically and mentally, both due to mobility restrictions and to the impact on personal, family, work and social life that COVID-19 has brought.[1-4]

Objectives: To examine the impact of the pandemic COVID-19 on patients with rheumatic diseases.

Methods: Cross-sectional descriptive study in patients with rheumatic diseases. Data collection was done through an online questionnaire to assess the impact of COVID-19, adapted for this purpose and made up of 5 scales of the 9 of the Coronavirus Psychological Impact Questionnaire [3]. This instrument is divided into two parts: 1) sociodemographic variables and 2) Experience with Coronavirus (ECOVI); Preventive Behaviour Use (UCP); Fear against coronavirus Scale (EMC); Interference with the coronavirus Scale (EIC) and positive psychological aspects (EPAP). This questionnaire was accessed through a QR code (provided to all patients both in consultations and in the day hospital) by the rheumatology team for two weeks between November-December 2021. In addition, this code was sent by the nurse via WhatsApp to all patients registered in our database.

Statistical analysis: SPSS 24.0 and Pearson Chi-square, T-Student and ANOVA tests.

Results: n=362 online surveys; 72% women with a mean age of 63 years ± 14.21 (22-70 years). The most frequent rheumatic diseases were Rheumatoid Arthritis (50%) and Spondyloarthritids (31%). 83.2% had only one rheumatic disease (mean 1.26 ± 0.66) and 90% self-completed survey. In experience with the Coronavirus (ECOVI), 89% patients had not had symptoms or confirmed diagnosis of coronavirus, 98% were not hospitalized, 91% had confidence in our health system; Regarding the Use of Preventive Behaviors (UCP), 93% used a mask outside the house and 78.5% kept a safe distance; In relation to the most common fears associated with the Coronavirus (EMC), 40% were a little afraid of getting infected (34% quite a bit) and 50% were almost nothing afraid of losing their job; Regarding the interference that the coronavirus has caused in these patients (EIC), 73% had not had serious work problems and 74% had not had difficulties in their studies. In reference to the positive psychological aspects (EEPA), 48% had discovered new hobbies, 19% had become more religious, 83% had learned to value personal relationships more. It was significant that women were more afraid of infecting themselves or a loved one or family member and/or dying from coronavirus than men (p=0.02; p=0.011 and p=0.002 respectively). Regarding age, younger patients (45y) were more concerned that they could lose their job compared to older patients (61y), p=0.

Conclusion: The COVID-19 disease has impacted patients with rheumatic diseases. In our sample, women have been more concerned about being infected and dying themselves and their closest relatives/friends, and younger people more concerned about job loss and economic income than older people. It has to be considered that the majority of this population has not been hospitalized or diagnosed with COVID-19 and also has great confidence in our health care system. More studies are necessary to examine the impact of the COVID-19 after the 6th wave of the pandemic.

REFERENCES:
Background: A novel viral infection known as COVID-19 (Coronavirus-19 disease) spread up in Wuhan (China) in December 2019, but rapidly diffused worldwide and nowadays it remains an international health problem. Because of its impact on immunologic system, immunomodulating therapies have been studied as possible treatments for severe cases of COVID-19. In that context, patients affected by of rheumatic musculoskeletal disorders (RMD) under disease-modifying anti-rheumatic drugs (DMARDs) have been observed in several studies to impact of COVID-19 on these subjects, well known to be at higher risk of infection.

Objectives: The primary objective of this study is to assess prevalence and severity of COVID-19 in patients with RMD under treatment with biologic (b-DMARDs) or targeted synthetic (ts-DMARDs) DMARDs, before the vaccination campaign. The second aim is to compare those data with that in general population of the same Area (Province of Udine, Friuli Venezia Giulia Region, Italy).

Methods: A cohort of RMD patients treated with b-DMARDs or ts-DMARDs was observed from September 2019 to November 2020. Both pandemic waves have been considered, until the start of vaccination (since current variants can overcome vaccine protection), between February 2020 and April 2020 (first wave) and between September 2020 and November 2020 (second one).

Results: Among 1051 RMD patients treated with b- or ts-DMARDs COVID-19 prevalence was 3.5% (37 cases) without significant differences compared to general population of the same Region (Table 1). Infected patients were 18 men and 19 women, with a median age of 60 years (IQR 49-68). Notably, the infection rate of RMD patients was significantly lower compared to the general population of the same province, particularly during the second wave (p<0.001, Table 1). Almost all patients reported fever (70%), Gastro-intestinal symptoms (nausea, vomit and diarrhoea) have been recorded in 10 subjects (27%) and resulted significantly associated with longer swab positivity (p<0.05) (Figure 1). Only a small percentage of patients with COVID-19 infection was receiving corticosteroids (8%), and the doses were low (3.5 or 5 mg per day of prednisone equivalents). The most used b-DMARDs were anti-TNFs (24/37, 65%), while just 4/37 (11%) employed JAK inhibitors. A small percentage of patients (6/37, 16%) continued ongoing treatment, with some risk factors and only 9 patients needed to be hospitalized (24%). After COVID-19 infection, 12 subjects (32%) had RMD flare and 5 of them subsequently needed to change the immunosuppressive drug.

Objectives: To evaluate basic demographics, clinical features and outcomes of COVID-19 infection in patients with SRD from a tertiary rheumatology centre in West Malaysia.

Methods: A retrospective observational study of 77 patients with SRD diagnosed with COVID-19 between 1st December 2020 to the 31st of December 2021 was performed. Demographic details, type of SRD, number and type of disease-modifying antirheumatic drugs (DMARD), dose of glucocorticoid, comorbidities, SARS-CoV-2 vaccine (type and number of doses) hospitalisation, oxygen requirement, type of COVID-19 related complication and death were recorded.

Results: A total of 55 (71%) patients were hospitalised and 9 (12%) died. Mean age at time of COVID-19 diagnosis was 51±14. Amongst these patients, 32 (42%) were Chinese, 30 (39%) Malays and 15 (19%) Indians. Majority of these patients had inflammatory arthritis (56%) which included rheumatoid arthritis and spondyloarthritis. The most common DMARDs used was methotrexate (51%), hydroxychloroquine (46%), sulfasalazine (22%), leflunomide (13%), azathioprine and mycophenolate mofetil (5% each). Two patients were on Janus Kinase (JAK) inhibitors and 3 on biologic DMARDs (tumour necrosis factor inhibitor, IL-6 inhibitors and IL-17 inhibitors). There were 38 patients (49%) vaccinated with two doses of SARS-CoV-2 vaccine (Pfizer n=29, CoronaVac n=7 and AstraZeneca n=2) prior to admission and amongst those unvaccinated, 15 (20%) contracted COVID-19 before the vaccine was released in Malaysia. Among hospitalised patients, those more than 60 years and those with more than one comorbid had a higher chance of admission (n=21, 88%; p=0.036 and n=28, 88%; p=0.001) and death (n=8, 33%; p=0.001 and n=7, 22%; p=0.001). Comorbidities associated with higher risk of hospitalisation was diabetes mellitus (85%, p=0.06), hypertension (82%, p=0.001) and coronary artery disease (100%, p=0.03) and those associated with death was obesity (33%, p=0.01) and hypertension (22%, p=0.007). Use of conventional DMARD, JAK, biologics and glucocorticoid were not associated with hospitalisation or morbidity. However, we found that patients who developed acute respiratory distress syndrome secondary to COVID-19 were mostly on sulfasalazine compared to other DMARDS (35%, p=0.01).
**Conclusion:** In our multiethnic cohort of patients with SRD we found that age and multiple comorbidities such as diabetes mellitus, hypertension, obesity and coronary artery disease were associated with hospitalisation and morbidity. Disease activity and glucocorticoid use which have been shown to be associated with morbidity[1] was not seen in our cohort. The association between sultasalazine and poor outcomes have been reported[2] however further studies are still needed to investigate the causal relationship between the two.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** DOI: 10.1136/annrheumdis-2022-eular.3078

**AB1127**

**ANTIOSTEOPOROTIC TREATMENT AND COVID-19: RISK: IS THERE AN ASSOCIATION?**

N. Grupeniewa1, M. Bystrytska1, N. Zaverukha1, A. Musienko1, D. F.Chebotarev Institute of Medical Genetics, NAMS of Ukraine, Clinical Physiology/Pathology of Locomotor Apparatus, Kyiv, Ukraine

**Background:** Nowadays, the COVID-19 and its complications are considered an important medical issue with aggravated medicosocial outcomes, both at the worldwide scale and of various individual countries. Despite the recent ASBM, AACE, Endocrine Society, ECTS and NOF recommendations according to osteoporosis management in the era of COVID-19 the influence of antiosteoporotic drugs on disease incidence and severity continue to be studied[1,2].

**Objectives:** The purpose of this study was to assess the COVID-19 risk for the patients receiving the parenteral bisphosphonate or Denosumab treatment, and the severity of its course in the systemic osteoporosis patients.

**Methods:** We performed the phone survey and studied the results of 195 patients (92 % women; mean age – 62.7±10.8 years, height – 161.0±8.0 cm, body weight – 68.9±12.3 kg) with systemic osteoporosis depending on the current use of parenteral antiresorptive drugs (Zoledronic acid, Ibandronic acid, or Denosumab, n=125) and compared the results with patients with osteoporosis who did not use any antiosteoporotic drugs previously (n=70).

The mean duration of antiosteoporotic treatment did not vary across the groups, accounting for 15 [9-27] months. Prior to the beginning of the antiosteoporotic therapy, all the patients had a confirmed diagnosis of osteoporosis at the Ukrainian scientific-medical Center of osteoporosis.

**Results:** We did not reveal any significant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral antiosteoporotic therapy. Additionally, there were no differences depending on patients’ age of sex, obesity presence, and other osteoporosis risk factors. The risk of COVID-19 in the patients with systemic osteoporosis did not differ depending on antiresorptive drug use, amounting (Odd Ratio (OR) 95 % CI) to 1.1 (0.6-2.0), or on the use of the definite antiosteoporotic drug (for the Zoledronic acid - 0.9 (0.4-2.0), the Ibandronic acid - 1.1 (0.5-2.3), and for the Denosumab - 1.6 (0.5-6.2).

**Conclusion:** Our study did not reveal any significant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral antiosteoporotic therapy. We conclude that parenteral antiosteoporotic drugs (Zoledronic acid, Ibandronic acid, or Denosumab) do not have an influence on COVID-19 frequency and severity and can be recommended for the continuation of treatment of patients with osteoporosis.

**REFERENCES:**
[2] Blanch-Rubió J, Soldevila-Domenech N, Tío L, et al (2020) Influence of the definite antiosteoporotic drug (for the Zoledronic acid - 0.9 (0.4-2.0), the Ibandronic acid - 1.1 (0.5-2.3), and for the Denosumab - 1.6 (0.5-6.2).

**Disclosure of Interests:** None declared

**DOI:** DOI: 10.1136/annrheumdis-2022-eular.3109

**AB1128**

**MAINTENANCE THERAPY FOR PATIENTS WITH RHEUMATIC DISEASES DURING THE COVID-19**

D. Ben Nessib1, M. Yasmine1, H. Ferjani1, W. Triki1, K. Maatallah1, D. Kaffel1, 1V .A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccinoprophylaxis, Moscow, Russia

**Background:** The Covid-19 pandemic has been raging for more than a year in a pandemic mode. Since then, many questions have been raised regarding the management of patients with rheumatic diseases (RD). In this context, the maintenance therapy of conventional, biologic and targeted synthetic disease-modifying anti rheumatic drugs (Cs DMARDs, SDMARDs and tsDMARDs respectively) during the Covid-19 infection remains a subject of debate given their immunosuppressive effects as well as their potential generation of lung fibrosis. While the EULAR 2020 guidelines emphasize that discontinuation or maintenance should be discussed on a case-by-case basis, the ACRP guidelines advocate discontinuation of all therapies except for the anti-interleukin-6[1,2].

**Objectives:** The objective of our work was to report our real-life experience of therapeutic maintenance during the covid-19 pandemic.

**Methods:** We conducted a cross-sectional study of patients with RD: rheumatoid arthritis (RA) and spondyloarthritis (SpA) recruited from the rheumatology department of the Kassab Institute of Orthopedics. All the patients were asked to complete a questionnaire about their disease management in the era of the Covid-19. The questionnaire included sociodemographic data, treatment modalities, as well as data related to the infection with the Covid-19 (severe forms defined by the need for oxygen therapy or hospitalization), and changes in treatment during the infection.

**Results:** The study included 102 patients with RA (65.3%) and SpA (34.7%). The mean age was 52.4 ± 13 [19-77] years. There was a female predominance with a sex ratio of 0.4. The mean duration of the disease was 7.8 ± 5 years [1-35]. Fifteen percent of patients were on corticosteroids with a mean dose of 6.7±4.5mg/L [2-20] of prednisone equivalent. CsDMARD was prescribed in 36.3% of cases and combined with a biologic in 16% of cases. A Covid-19 infection was occurred at least once in 25.5% of cases, of which 19.2% had a severe form (hospitalization (15.4%), oxygen therapy (19.2%)). No deaths were observed. The treatments received during the covid-19 infection were: corticosteroids (n=5), heparin therapy (n=6) and antibiotic therapy (n=10). No patient tapered treatment dosage of DMARDS but discontinuation was reported by 4 patients with a mean time between discontinuation and resumption of 2.1 ± 2 months [0.5-5 months]. The cessation of the treatment was dictated by the treating physician in 2 cases and involved csDMARD in 3 cases (Methotrexate (n=2), Lefunomide (n=1)) and biologics in only one patient. There were no cases of clinical pulmonary worsening upon resumption of the treatments. We found no statistically significant association between severe forms of the infection and the type of RD (p=0.925), as well as the presence of comorbidities (p=0.825). Similarly, the presence of severe forms was not associated with the use of long-term NSAIDs (p=0.29), corticosteroids (p=0.85), or biological treatment (p=0.7). However, maintenance therapy was significantly associated with a lower risk of severe forms (p=0.013).

**Conclusion:** Our work showed that the maintenance of conventional treatment during Covid-19 infection was associated with a lower risk of severe forms. Our results, along with those of other studies in the literature, support the maintenance of antirheumatic treatments.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** DOI: 10.1136/annrheumdis-2022-eular.3120

**AB1129**

**SAFETY OF VACCINES AGAINST COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS (PRELIMINARY DATA).**

A. Kulikov1, N. Muraveyva2, B. Beloy1, 1V.A. Nasonova Research Institute of Rheumatology, Laboratory of Comorbid Infections and Vaccinoprophylaxis, Moscow, Russia

**Background:** Patients with spondyloarthritis (SpA) probably have a high incidence of COVID-19. Vaccination remains one of the most effective methods of preventing infectious diseases. However, data on the safety of vaccines against COVID-19 in patients with SpA are few and relate to foreign vaccines that are not licensed in Russia.

**Objectives:** To study the safety of COVID-19 vaccines in patients with SpA in real clinical practice.

**Methods:** The study included 47 SpA patients (25 - ankylosing spondylitis, 13 - psoriatic arthritis, 9 - undifferentiated SpA, 19 women, 28 men, age 42.3±11.6 years, duration of the disease 11.8±9.2 years) - the main group and 97 people without any immuno-inflammatory rheumatic diseases (67 women, 30 men, age 43.7±13.1 years) - the control group. 20 patients received disease-modifying antirheumatic drugs (12 - methotrexate, 8 - sulfasalazine), 10 - biological drugs (8 - TNF- u inhibitors, 2 - IL-17 inhibitors), 6 - glucocorticoids, 1 - tocilizumab, 12 - only nonsteroidal anti-inflammatory drugs, 8 - did not receive therapy. In the main group, 40 patients were vaccinated with Gam-COVID-Vac (Sputnik V), 3 – CovitVac and Sputnik Light, 1 – EpiVacCorona (both components of the vaccine were received by 44 patients). In the control group 69 were vaccinated with Sputnik V, 15 - CovitVac, 5 - Sputnik Light and BNT162b2, 2 - EpiVacCorona, 1 - mRNA-1273. (91 participants received both components of the vaccine). All participants
were interviewed by a research doctor with a unified questionnaire, additional information was obtained from medical documentation.

Results: The data obtained are reflected in the Table 1. Local adverse events (AEs) occurred relatively less frequently in patients with SpA than in the control group. After the introduction of the first component of the vaccine, there was a significant increase in the frequency of pain without restriction of movement and edema/hyperemia in the control group (p<0.001 and p=0.049, respectively), while after the introduction of the second component, a significant difference was registered only for the first indicated symptom (p>0.001). The most frequent systemic AEs were weakness, fever, arthralgia or myalgia, headache, and chills, which were significantly less common (p>0.008) in the main group after immunization with the first component. The proportion of SpA patients without any reactions was significantly higher after the introduction of the first component of the vaccine (59.6% and 29.9%, p<0.001), while after immumity with the second component there were no differences (59.1% and 44.0%, p>0.05). After complete immunization, the percentage of patients without any AEs was significantly higher in the main group than in the control (50.0% and 17.6%, p<0.001). There was no exacerbation of SpA or development of new autoimmune phenomena in the main group after full vaccination.

Table 1. The frequency of AEs in SpA patients and in control

<table>
<thead>
<tr>
<th>The first component</th>
<th>The second component</th>
</tr>
</thead>
<tbody>
<tr>
<td>SpA, n=47</td>
<td>Control, n=97</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Local AEs</td>
<td></td>
</tr>
<tr>
<td>Pain w/ movement**</td>
<td>4.3 (38)</td>
</tr>
<tr>
<td>Edema or hyperemia</td>
<td>2.1 (14)</td>
</tr>
<tr>
<td>Systemic AEs</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>3.7 (32)</td>
</tr>
<tr>
<td>Temperature &gt;37°C</td>
<td>2.6 (30)</td>
</tr>
<tr>
<td>Myalgia/Arthralgia</td>
<td>1.5 (14)</td>
</tr>
<tr>
<td>Headache</td>
<td>1.0 (9)</td>
</tr>
<tr>
<td>Chills</td>
<td>1.0 (9)</td>
</tr>
<tr>
<td>Nausea/vomiting</td>
<td>1.0 (9)</td>
</tr>
<tr>
<td>Other</td>
<td>1.0 (9)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>n %</td>
<td>n %</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>p</td>
</tr>
</tbody>
</table>

Notes: * - pain at the injection site without restriction of limb movement, ** - pain at the injection site with restriction of limb movement

Conclusion: According to preliminary data, the tolerability of vaccines against COVID-19 in patients with SpA is satisfactory. Further studies with an increased sample are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.

Disclosure of Interests: None declared

Discourse of Interests: None declared


AB1130

A REDUCTION IN NEW REFERRALS FOR RHEUMATOID ARTHRITIS, OSTEOARTHRITIS AND CRYSTAL ARTHRITIS COMPARED TO GCA DURING COVID19 PANDEMIC

M. Tormo-Ratera 1, M. Mirza 2, R. Lugmann 2, 1Hospital Universitari de Bellvitge, Rheumatology, L'Hospitalet de Llobregat, Spain; 2Nuffield Orthopaedic Centre, Rheumatology, Oxford, United Kingdom

Background: The COVID-19 pandemic has had profound effects on the Rheumatology department; we wanted to see if consequently referrals for Rheumatoid arthritis (RA), Crystal Arthritis (CA), Osteoarthritis (OA) and Giant cell arteritis (GCA) were affected. A greater understanding of the impact may enable adequate number of clinics and resources to be made available where needed.

Objectives: To evaluate the impact of COVID-19 pandemic on volume of new referrals to the Rheumatology department for RA, CA, OA and GCA.

Methods: A retrospective analysis of data was conducted from the period of January 2016 to December 2021. The Rheumatology department database was closely analysed and information about new referrals for GCA, RA, OA and CA were evaluated. Statistical analysis was conducted using t-test to compare the mean value pre and during the COVID19 outbreak (2020).

Results: From 2016 to 2021 a total number of 9998 new patients were referred to the Rheumatology department. There were 2768 new referrals for GCA (15%), RA (34%), OA (40%) and CA (11%) made during this period. In 2020, there was a significant decrease in OA, RA and CA referrals (p value 0.00004, 0.00017, 0.0042 respectively) but an insignificant decrease in GCA referrals (p value 0.243).

Conclusion: During COVID19 pandemic in 2020 there was a significant reduc-

<table>
<thead>
<tr>
<th>Diagnoses</th>
<th>Mean nº 2016-2019</th>
<th>2020</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCA</td>
<td>79.75 (14%)</td>
<td>63 (33%)</td>
<td>0.24334236</td>
</tr>
<tr>
<td>RA</td>
<td>204 (36%)</td>
<td>55 (28%)</td>
<td>0.00075427</td>
</tr>
<tr>
<td>OA</td>
<td>219.7 (39%)</td>
<td>59 (30%)</td>
<td>4.269756-06</td>
</tr>
<tr>
<td>CA</td>
<td>64.5 (11%)</td>
<td>18 (9%)</td>
<td>0.00427881</td>
</tr>
</tbody>
</table>

According to preliminary data, the tolerability of vaccines against COVID-19 in patients of this cohort. Further studies with an increased sample are needed to study the safety, immunogenicity and clinical efficacy of immunization against COVID-19 in patients of this cohort.

Disclosure of Interests: None declared

Discourse of Interests: None declared


AB1131

IDENTIFICATION OF FACTORS ASSOCIATED WITH THE OCCURRENCE OF SEVERE FORMS OF COVID-19 INFECTION IN PATIENTS WITH AUTOIMMUNE/INFLAMMATORY RHEUMATIC DISEASES

K. Chevalier 1, M. Genin 1, T. Petit Jean 1, J. Avouac 2, R. M. Filipo 3, S. Georgin-Lavialle 4, S. El Mahou 1, E. Pertuiset 1, T. Pham 5, A. Servetaz 6, H. Marotte 6, F. Domont 1, P. Chazerain 7, M. Devaux 8, A. Mekinian 9, J. Sellam 10, B. Faurel 11, D. Rouzaud 12, E. Ebstein 13, N. Costedoat-Chalumeau 14, C. Richez 15, E. Hachulla 16, X. Mariette 1, R. Seror 1, Bicetre Hospital, Rheumatology, Le Kremlin-Bicêtre, France; 15Hospital Saint-Antoine Ap-Hp, Internal Medicine, Paris, France; 6Aphp, Département Innovation et Données, Paris, France; 10Cochin Hospital, Rheumatology A, Paris, France; 11Chu De Lille, Rheumatology, Lille, France; 17Tenon Hospital, Internal Medicine, Paris, France; 14Hospital Center De Tourcoing, Rheumatology, Tourcoing, France; 7Hospital Rene Dubos, Rheumatology, Pontoise, France; 18Hospital Sainte Marguerite, Rheumatology, Marseille, France; 12Hospital Robert Debré, Internal Medicine, Infectious Diseases and clinical immunology, Reims, France; 13University Hospital of Saint-Etienne, Rheumatology, Saint-Priest-en-Jarez, France; 10University Hospitals Pitié Salpêtrière - Charles Foix, Internal Medicine and Clinical Medicine and Rheumatology, Paris, France; 19Hospital de la Croix Saint-Simon, Rheumatology and Internal Medicine, Paris, France; 3Hospital Saint-Antoine Ap-Hp, Rheumatology, Paris, France; 1University Hospital Hospitals Pitié Salpêtrière - Charles Foix, Rheumatology, Paris, France; 18Bichat-Claude Bernard Hospital, Internal Medicine, Paris, France; 21Bichat-Claude Bernard Hospital, Rheumatology, Paris, France; 10Cochin Hospital, Internal Medicine, Paris, France; 16Chu Bordeaux - Site Pellegrin, Rheumatology, Bordeaux, France; 2Chu De Lille, Internal Medicine and Clinical Immunology, Lille, France

Background: Patients with autoimmune/inflammatory rheumatic diseases (AIRD) were suspected to be an at-risk population of severe COVID-19. However, whether this higher risk is linked to the disease or to its treatment is difficult to determine.

Objectives: To identify, among AIRD patients, factors associated with occurrence of moderate-to-severe COVID19 infection and to evaluate if having an AIRD was associated with an increased risk of severe form of COVID19 infection (defined by hospitalization in ICU or death), compared to general population.

Methods: Data source: The “Entrépôt des Données de Santé (EDS)“ collect data from electronic health records of all patients hospitalized or followed in the AP-HP (39 hospitals in Paris area, France). The French RMD COVID19 cohort is a national multi-center cohort that included patients with confirmed AIRD and diagnosed with COVID-19. All AIRD patients diagnosed with COVID-19 before September 2020 from both cohorts were included.

We identified factors associated with severe COVID-19 was made in a combined analysis of the 2 cohorts.

- Then, we compared COVID-19 infection severity in the EDS-COVID database in AIRD patients and controls, by a propensity score (PS)-matched case-control (1:4) study.
MUSCULOSKELETAL MANIFESTATIONS AMONG PATIENTS WITH COVID-19 INFECTION

S. Thawra1, N. M. Shaban2, M. K. Nassar3. 1Faculty of Medicine, Mansoura University, Mansoura, Egypt; Rheumatology & Immunology Unit, Department of Internal Medicine, Mansoura, Egypt; 2Mansoura Manchester Programme for Medical Education, Faculty of Medicine, Mansoura University, Mansoura, Internal Medicine; Rheumatology & Immunology Unit, Mansoura, Egypt; 3Faculty of Medicine, Mansoura University, Mansoura, Egypt, Mansoura University Nephrology and Dialysis Unit, Internal Medicine Department, Mansoura, Egypt

Background: Coronavirus disease-2019 (COVID-19) is declared as a global pandemic [1]. It is caused by a novel coronavirus with structural similarities to the virus that causes severe acute respiratory syndrome (SARS) [2]. While the pulmonary consequences have received a lot of attention, the impact of the disease extends far beyond the respiratory system and affects other organs of the body such as heart, kidney or liver [3]. Although different musculoskeletal (MSK) manifestations have been linked to COVID-19 infection, a systematic approach to outline these manifestations is still lacking [4].

Objectives: The aim of this study was to determine the prevalence, distribution and determinants of MSK manifestations in patients with COVID-19 infection.

Methods: Patients with a history of confirmed COVID-19 infection were asked to answer a web-based survey. The survey consisted of multiple questions centered around demographics, clinical and COVID-19 infection data in addition to MSK discomfort form based on the Nordic MSK Questionnaire. The inclusion criteria included age of ≥18 years, Patients who had malignancies or any chronic rheumatic, neurological disease were excluded.

Results: There was a total of 110 participants, mostly females (72.7%), with mean age 37.7 years, only 9 (8.2%) were current smokers while 31 (28.2%) had comorbidities such as hypertension (n=74), coronary artery disease (n=74), cancer (n=5), chronic obstructive pulmonary disease (n=4), chronic kidney disease (n=3). The patients were interviewed by a research doctor, additional information was obtained from medical documentation.

Results: The most common symptoms of COVID-19 were fever - 67.7%, weakness/drowsiness - 53.7%, cough - 48.4%, as well as anosmia and dyspnea - 35.5% each, headache - 20.4%, body aches - 16.1%, congestion nose - 8.6%, chest pain - 7.5%, dysgeusia - 5.4%, diarrhea/vomiting - 3.2%. According to CT scan, 8 patients had 0% of lung damage, 31 - 25%, 32 - 50%, 12 - 75%, in other cases the study was not carried out (n=9) or data are not available (n=1). In 2 patients the course of COVID-19 was complicated by bacterial pneumonia, in 1 - bacterial-fungal. An asymptomatic course was noted only in 2 patients (PCR+/IgM+, CT 0, close contact with a confirmed case of COVID-19). Recovery was noted in 90 patients, fatal outcome - in 3. Exacerbation of IIRDs after COVID-19 was noted in 48.4% of patients, which required intensifying antirheumatic therapy.

Conclusion: Preliminary data indicate that COVID-19 is characterized by moderate and severe course in elderly patients with IIRDs. Further studies are required to identify risk factors for severe course and complications in order to provide timely qualified care.

Disclosure of Interests: None declared

Conclusion: MSK manifestations are prevalent among patients with COVID-19 infection. They are usually associated with more severe COVID-19 infection and longer disease duration.

REFERENCES:

Disclosure of Interests: None declared

BIBLIOMETRIC NETWORK ANALYSIS ON TOCILIZUMAB TREATMENT FOR COVID-19 PATIENTS

L. Cascella1, F. Monaco2, D. Nocerino2, A. Infermuro2, V. Cascella1, F. Del Prato2, S. Cascella1, M. Cascella1on behalf of Study Group on AI in medicine. 1School of Medicine. University Federico II. Naples, Italy. Medicine, Naples, Italy; 2Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Division of Anesthesia and Pain Medicine, Naples, Italy; 3School of Medicine. University of Pavia, Medicine, Pavia, Italy; 4Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Scientific Directorate, Naples, Italy

Background: Tocilizumab is a humanized monoclonal antibody that provokes inhibition of the proinflammatory signals by binding to IL-6 receptors [1]. Due to these properties, it is used in inflammatory arthritis conditions and in cytokine release syndromes [2]. Notably, given its ability to intersect proinflammatory cascades, tocilizumab is an important option for patients with critical forms of COVID-19 [3]. Nevertheless, several aspects about the use of tocilizumab in this clinical setting should be better explained [4].

Objectives: This bibliometric analysis is aimed at dissecting the developed research in the subject. It could provide useful findings for predicting the direction of future studies, implementing corrective measures, and enhancing research networks.

Methods: The global literature on tocilizumab treatment for COVID-19 was scanned in the Web of Science (WOS) online database. The search terms applied to identify the closest matching articles included “tocilizumab” and “COVID-19”. All data were acquired on January 29, 2022. The information for the documents that met the requirements were extracted. The source was Journal Citation Reports™ 2020 (Clarivate Analytics). The literature analysis and knowledge visualization software tool VOSviewer (version 1.6.17) was used to analyze the co-occurrence of keywords (interconnection), co-citation (bibliographic coupling), co-citation analysis for sources, and countries, and analysis of the most productive organizations and networks.

Results: A total of 1019 articles on tocilizumab treatment for COVID-19 patients were published from 2020 to January 2022. In WOS, Of those: 462 in 2020, 546 in 2021. On January 29, 2022. About article types, 697 were research articles, 322 reviews. The analysis of keywords provided by authors showed that of 50 keywords, 17 met the threshold (interconnection 2). The most frequent keywords were EFFICACY, and OFF-LABEL USE (Figure 1).

Conclusion: This bibliometric network analysis on tocilizumab treatment for COVID-19 patients can be useful for planning future research. It highlights the strength of representative scholars and core research teams. Additional networks should be built, and high-value clinical studies are needed.
lower for patients on combination DMARD therapy compared to all other groups (81% compared to 95% for monotherapy, and 100% for both no DMARD therapy and/or b/tsDMARD combination therapy). Considering effects of individual compounds, mycophenolate mofetil in mono- or combination therapy led to lower antibody titers after the 2nd dose as compared to HC or patients receiving no DMARDs (2 BAU/ml versus 1673 BAU/ml and 2500 BAU/ml respectively, both p<0.0001).

**Table 1. Study subject characteristics**

<table>
<thead>
<tr>
<th></th>
<th>SARD (n=82)</th>
<th>HC (n=82)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, mean (±SD)</strong></td>
<td>52.05 (+14.06)</td>
<td>52.15 (+13.42)</td>
</tr>
<tr>
<td><strong>Female, n (%)</strong></td>
<td>65 (79%)</td>
<td>65 (79%)</td>
</tr>
<tr>
<td><strong>Disease entity, n (%):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systemic lupus erythematosus</td>
<td>33 (40%)</td>
<td></td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>13 (16%)</td>
<td></td>
</tr>
<tr>
<td>Other connective tissue diseases*</td>
<td>15 (18%)</td>
<td></td>
</tr>
<tr>
<td>Vasculitis</td>
<td>17 (21%)</td>
<td></td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>4 (5%)</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment group, n (%):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>csDMARD or b/tsDMARD monotherapy</td>
<td>43 (52%)</td>
<td></td>
</tr>
<tr>
<td>csDMARD and/or b/tsDMARD combination therapy</td>
<td>16 (20%)</td>
<td></td>
</tr>
<tr>
<td>No therapy</td>
<td>23 (28%)</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment agents, n (%):</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>13 (16%)</td>
<td></td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>14 (17%)</td>
<td></td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>28 (34%)</td>
<td></td>
</tr>
<tr>
<td>Azathioprine</td>
<td>13 (10%)</td>
<td></td>
</tr>
<tr>
<td>Belimumab</td>
<td>3 (4%)</td>
<td></td>
</tr>
<tr>
<td>Tocilizumab</td>
<td>3 (4%)</td>
<td></td>
</tr>
<tr>
<td>Tacrolimus</td>
<td>2 (2%)</td>
<td></td>
</tr>
<tr>
<td>Olumiant</td>
<td>1 (1%)</td>
<td></td>
</tr>
</tbody>
</table>

*dermatopoliomyositis (n=4), mixed connective tissue disease (n=2), primary Sjögren’s syndrome (n=6), undifferentiated connective tissue disease (n=3)*

**Conclusion:** Patients with SARD showed a good response after the 2nd vaccination compared to the mRNA vaccine. However, the choice of immunosuppressive regimen has a marked effect on both seroconversion rate and overall antibody titer.

**Disclosure of Interests:** We thank Sylvia Taxer and Zoltan Vass for their support.

**Figure 1.** Seroconversion rate (A) and anti-SARS-CoV 2 S antibody levels (B) after the 1st and 2nd vaccination between the healthy control (HC) group and patients according to therapy

**Figure 1.** A: Forest map of a meta-analysis of COVID-19 prevalence in SLE patients. B: Forest map of a meta-analysis of hospitalization rates among patients treated with hydroxychloroquine. C: Forest map of a meta-analysis of the rate of adverse outcomes in patients using hydroxychloroquine. D: Forest map of a meta-analysis of the prevalence of patients treated with hydroxychloroquine throughout the course of disease.

**Figure 2.** A: Forest map of a meta-analysis of the rate of adverse outcomes in patients using hydroxychloroquine as part of a treatment regimen. D: Forest map of a meta-analysis of the prevalence of patients treated with hydroxychloroquine throughout the course of disease.

**Results:** A total of 14 studies comprising 5365 patients were identified (Table 1). Overall prevalence of COVID-19 in SLE patients was 1.5% (95% CI: 1.2%-1.8%). Eight of the studies included patients who used hydroxychloroquine as part of their treatment regimen, with 29.8% (95% CI: 25.8%-33.8%) hospitalization rates and 14.6% (95% CI: 11.5%-17.8%) adverse outcome rates. Among patients treated with hydroxychloroquine throughout the course of disease, the prevalence was 0.7% (95% CI: 0.4%-1.0%, Figure 1).

**Conclusion:** Patients with SLE had a higher risk of COVID-19. Hydroxychloroquine might benefit to reduce the overall hospitalization rate and prevalence rate of COVID-19, and alleviate inflammatory damage in the chronic stage of viral infection, inhibiting over activation of the immune system.
Table 1. Summary of study characteristics of included records.

<table>
<thead>
<tr>
<th>Author</th>
<th>Total/mean of median patients</th>
<th>Mean/Median Age</th>
<th>HCQ</th>
<th>Number of COVID19</th>
<th>Mean/Median</th>
<th>Other therapeutic drugs</th>
<th>Number of other therapeutic drugs</th>
<th>Number of hospitalized patients</th>
<th>Hospitalization outcomes</th>
<th>Other outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerard Espinosa</td>
<td>400</td>
<td>50.7</td>
<td>Gcs:47</td>
<td>4</td>
<td>47.9</td>
<td>22</td>
<td>Gcs:12,T-DMARD:28,others:13</td>
<td>3</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Emanuelle Bazzazia</td>
<td>165</td>
<td>52.5</td>
<td>127</td>
<td>12</td>
<td>52.5</td>
<td>3</td>
<td>Gcs:1,others:3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassone</td>
<td>Ren: Cordt</td>
<td>2533</td>
<td>55.4</td>
<td>1170</td>
<td>16</td>
<td>69.1</td>
<td>5</td>
<td>Gcs:4</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Ruth</td>
<td>226</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fernandez-Ruiz</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zos Gembwien</td>
<td>225</td>
<td>51.7</td>
<td>152</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wendy Wan Hui</td>
<td>85</td>
<td>38.28</td>
<td>58</td>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee</td>
<td>Giuseppe A.</td>
<td>417</td>
<td></td>
<td>others:389,combination:289</td>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ramirez, MD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Samir Thawat</td>
<td>200</td>
<td>30.1</td>
<td>140</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dina Zucchi</td>
<td>332</td>
<td>47</td>
<td>267</td>
<td>6</td>
<td>40.3</td>
<td>6</td>
<td>Gcs:6,T-DMARD:1,others:6</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Sarthak Gupta</td>
<td>17</td>
<td>7</td>
<td></td>
<td>17</td>
<td>46.1</td>
<td>1</td>
<td>Gcs:175,T-DMARD:180,others:184</td>
<td>10</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Seow Lin Chua</td>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td>38ah</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claudia Diniz Lopes</td>
<td>334</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marques</td>
<td>Beth Wallace</td>
<td>31</td>
<td>61</td>
<td>6</td>
<td>118,others:4</td>
<td>5</td>
<td>54</td>
<td>26-67</td>
<td>4</td>
<td>Gcs:4,others:3</td>
</tr>
<tr>
<td>Isabela Maria</td>
<td>382</td>
<td>41.5</td>
<td></td>
<td>382</td>
<td>45</td>
<td></td>
<td>5</td>
<td>206</td>
<td>173</td>
<td></td>
</tr>
</tbody>
</table>

AB1137 USE OF TOCILIZUMAB IN CRITICALLY ILL SARS-COV-2 PATIENTS: CARE-PROGNOSTIC FACTORS OF TREATMENT EFFECTIVENESS AND TREATMENT RESULTS

Z. Kardos 1, 2, M. Szabó 2, Z. Báthi 1, Á. Mikó 1, A. Kozmán 3, G. A. József 2, Z. Székanecky 1, 2, 4, 5

1. Borsod County Teaching Hospital, Rheumatology, Miskolc, Hungary; 2. University of Miskolc, Medical Faculty, Miskolc, Hungary; 3. Borsod County Teaching Hospital, Pharmacy, Miskolc, Hungary; 4. University of Debrecen, Rheumatology, Debrecen, Hungary

Background: The treatment of COVID-19 caused by SARS-CoV-2 poses serious challenges to health care systems. In 8-10% of patients with severe COVID-19, there is a cytokine storm syndrome, highlighting the importance of host immune response in pathogenesis.

Objectives: Our aim was to evaluate the effect of tocilizumab treatment in COVID-19 patients with severe cytokine storm who were refractory to standard care therapy. To determine the prognostic factors that indicate the success of treatment in these patients.

Methods: Fifty-three patients were treated with tocilizumab during waves 2 and 3 of the pandemic due to a cytokine storm associated with SARS-COV-2 infection. All patients underwent physical examination, saturation monitoring, laboratory examination, blood gas analysis and chest CT examination. Deteriorating clinical status, elevated IL-6 and other acute phase protein levels observed in patients treated with standard therapy suggest cytokine storm syndrome. The treatment of these patients was supplemented with 8mg/kg (max. 800mg) tocilizumab (1 or 2 times within 24 hours). We assessed the clinical and laboratory response of these patients to IL-6-R inhibitor therapy, the need for ventilation, the need for intensive care and mortality.

Results: Immunological consultations were performed in 31 patients, of whom 21 (68%) were successfully treated. Eleven patients of them (22%) died. In the 22 non-consulted patients, this rate was reversed: 7 (22%) were successful and 15 (68%) were treatment failures. The success of the treatment was mainly influenced by the well-established indication, the recognition of concomitants, and the condition that did not require invasive ventilation method. The 29 tocilizumab therapies initiated in the non-intensive care unit avoided intensive care unit treatment in 18 patients. Eleven patients were admitted to the intensive care unit, but 7 patients required temporary respiratory support and recovered, 4 patients required invasive mechanical ventilation and later died (14%). In contrast, 24 treatments initiated in the intensive care unit saved the lives of only 3 patients, and 21 patients were lost (87.5%). The effectiveness of treatment was not affected by age, with survival rates of 40%, 44%, 57% and 55% for the 40-49, 50-59, 60-69, 70-79 age groups, respectively. Interestingly, the extent of lung involvement also did not show a significant difference. Although it was a prerequisite for initiating tocilizumab treatment to have fresh alveoli on the CT image of the chest. Conclusion: Use of tocilizumab is most effective in patients with COVID-19 who have high levels of inflammatory activity and IL-6, who are at an early stage of lung involvement and who do not respond to high-dose corticosteroid therapy, who have no bacterial superinfection and require not invasive mechanical ventilation. It is also important that specialist who has immunological approach and routine with biological treatment be also involved in the care of patients with severe COVID-19 disease.

REFERENCES:

Disclosure of Interests: None declared

AB1138 SAFETY OF SARS- COV- 2 VACCINES IN PATIENTS WITH AUTOIMMUNE DISEASES

S. Monov1, R. Shurmaliieva1, D. Monova1, 2, 3, 4, 5
1. Medical University - Sofia, Department of Rheumatology, Sofia, Bulgaria; 2. Medical University - Sofia, Medical Institute, Department of Internal Medicine, Sofia, Bulgaria

Background: Patients (pts) with autoimmune diseases are at higher risk of infections, including those by SARS-COV-2. There is no general agreement regarding priority criteria for anti-COVID vaccine access for pts with autoimmune rheumatic diseases (ARD). Few studies have addressed the issue of anti-COVID vaccination in these pts, but many are available on the safety, immunogenicity, efficacy, and possible contraindications of traditional vaccines in pts with ARD. These studies may represent the basis on which to recommend the anti-COVID-19 vaccines.

Objectives: Patients (pts) with autoimmune diseases are at higher risk of infections, including those by SARS-COV-2. There is no general agreement regarding priority criteria for anti-COVID vaccine access for pts with autoimmune rheumatic diseases (ARD). Few studies have addressed the issue of anti-COVID vaccination in these pts, but many are available on the safety, immunogenicity, efficacy, and possible contraindications of traditional vaccines in pts with ARD. These studies may represent the basis on which to recommend the anti-COVID-19 vaccines.

Methods: A telephone survey investigating the AE of SARS-CoV-2 vaccinations on pts with systemic lupus erythematosus, systemic sclerosis, inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis), idiopathic inflammatory myopathies, ANCA-associated vasculitis was administered. Data extraction included diagnosis, disease activity status, demographics, disease duration, therapy, comorbidities, and laboratory tests. Vaccinated participants are asked to report whether they experienced any local or systemic AE following vaccination, and if so, to report on the severity and duration of the AE. Mild AE were defined as unpleasant reactions that did not limit daily activities, moderate AE as those that limited daily activities, and severe AE - required medical attention. Serious AE were defined as reactions that resulted in hospital admission.

Results: ChAdOx1 nCoV-19 and BNT162b2 are the most common vaccines in our pts. 98 (38.84%) of 246 pts received the BNT162b2 vaccine, 95 (38.62%) - ChA-DOx1 nCoV-19 vaccine, 47 (19.10%) - CX-024144 and 6 (2.44 %) were vaccinated with Ad26.COV2-S. 127 (51.63%) pts had at least one mild AE and 51 (20.73 %) pts reported moderate AE. Severe AE were rare - 4 (1.63%) pts and no serious AE were reported. The most commonly reported AE is pain (40.24%), redness (30.49 %), swelling (18.7%) at the injection site, which was consistent across all vaccines for both first and second doses. Systemic AE occurred in 104 (43.27 %) pts, most frequently fatigue (29.67 %), headache (27.13 %) and muscle ache (24.39 %). The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Joint complaints were reported in 8.94 %, but only a small proportion of pts (2.84 %) reported a deterioration of their autoimmune disease up to 3 months after COVID-19 vaccination. Age was a significant effect modifier in the association between autoimmune status and the risk of moderate or severe AE. Vaccination with ChAdOx1 nCoV-19, female sex, age between 35 - 50 years were independently associated with an increased likelihood of reporting any AE. The current results

support the safety of different COVID-19 vaccines in pts with ARD. This information can help fight vaccine hesitancy in this population.

Conclusion: Our data indicated that COVID-19 vaccines are well tolerated by pts with ARD. We did not observe any serious AE, but the number of pts included in our study is too low to draw conclusions about rare serious events. Additionally, our data suggest that COVID-19 vaccinations do not seem to trigger autoimmune disease flares, which is in accordance with data from previous small studies that assessed consequences of vaccines in pts with ARD.

Disclosure of Interests: None declared.

AB1139
SARS-COV2- INFECTION AFTER VACCINATION AGAINST COVID-19 IN PATIENTS WITH RHEUMATIC DISORDERS IN A REAL LIFE SETTING OF A RHEUMATOLOGICAL OUTPATIENT CENTER

S. G. Werner1, L. Moll1, A. Uhlenberg-Moll1, S. Mettler1, H. E. Langer1. 1RHIO (Rheumatology, Immunology, Osteology) Düsseldorf, RHIO Research Institute, Düsseldorf, Germany

Background: Coronavirus SARS-CoV-2 and its associated disease COVID-19 have become a worldwide pandemic since its first case in 12/2019. Since approval of the first vaccines against COVID-19 in Europe in 12/2020 a large vaccination campaign started. Our patients with inflammatory diseases (ID) were given priority for an early vaccination. Many of our patients used the possibility and got vaccinated. Until now, there is few knowledge about the efficacy and safety of vaccination in patients with rheumatic disorders. There are some reports of less vaccination response in patients with ID (1). First reports of those patients with rheumatological disorder and infection with SARS-CoV2 are available (1,2). Nevertheless, there is few knowledge about SARS-CoV2-infection in patients with ID after vaccination against COVID-19, yet.

Objectives: The aim of our study was to evaluate, how many patients got infected with SARS-CoV2 after vaccination against COVID-19 and the course of the disease.

Methods: All consecutive patients of the routine follow up visits from 07/2021 to 01/2022 in our rheumatological outpatient center were questioned for SARS-CoV2-infection. In case of infection, they were questioned for vaccination status and the course of the disease.

Results: N=1206 patients could be evaluated. N=1183/1206 (98.1%) vaccinations were documented. N=12/1183 (1%) patients got infected with SARS-CoV2 after at least 2 doses of vaccination against COVID-19. N=1/12 (8.3%) patient got infected after 3 doses of vaccination. N=3/12 (25%) received 2 doses Vaxzevira (AstraZeneca), n=2/12 (16.7) patients 1st dose Vaxzevira, 2nd dose Comirnaty (Biontech), n=7 (58.3%) patients two doses Comirnaty. In n=8/12 (66.7%) patients antibody levels were available. N=7/8 (87.5%) patients developed high antibody levels after 2 vaccinations. N=1/8 (12.5%) patient developed any antibodies against SARS-CoV2 after 2 doses of Comirnaty, measured ≥4 months after 2nd vaccination dose. This patient was treated with Abatacept. This patient came down with COVID-19 5 months after complete vaccination and died after long-standing highly intensive care. All other patients developed a mild to moderate course of COVID-19, without need of hospitalizing.

Conclusion: There is a very high number of patients (98.1%), who got vaccinated in a real life setting of our rheumatological outpatient center. We have seen only a low number of SARS-CoV2-infections (1%). Most patients developed high antibody levels after vaccination and fortunately had a mild to moderate course of COVID-19 in case of SARS-CoV2-infection, independently from the different vaccination agents. Nevertheless, 1 patient came down with COVID-19 5 months after complete vaccination and died after long-standing highly intensive care. This patient did not develop any antibodies after vaccination. In conclusion, vaccination seems to be effective in patients with rheumatological disorders. However, we must be aware of the small group of patients without antibody development, since they are at risk to have a fatal course. Yet, antibody testing is not recommended in routine clinical care by official recommendations, largely because it is still unknown which level of antibodies predicts protection (3). The booster campaign and 3rd vaccinations will change the current state again, but a reevaluation and further studies will be necessary.

REFERENCES:

Disclosure of Interests: Stephanie Gabriele Werner Speakers bureau: Pfizer, Abbvie, Medac, Janssen, Bristol


AB1140
IMPACT OF COVID-19 NEWS SOURCES ON RHEUMATOID ARTHRITIS PATIENTS’ LIFESTYLE AND THEIR DISEASE ACTIVITY FROM NINJA 2020 COHORT STUDY

A. Iihata1, T. Matsui2, S. Tohma3 on behalf of NinJa registry. 1National Hospital Organization Yokohama Medical Center, Department of Rheumatology, Yokohama, Japan; 2National Hospital Organization Sagamihara National Hospital, Department of Rheumatology, Sagamihara, Japan; 3National Hospital Organization Tokyo National Hospital, Department of Rheumatology, Kiyose, Japan

Background: One of the problems with the COVID-19 epidemic is infodemic. Insufficient and inaccurate information can be confusing and hinder treatment. In Japan, tabloid TV show might be an easily accessible source of information, but its reliability is low and it has a harmful effect on patients’ mental status and lifestyle. There are no reports to examine what is the source of COVID-19 news for patients with rheumatoid arthritis and how these information affect patients’ daily lives and disease activity. By using NinJa, Japanese largest database of rheumatoid arthritis, it may be possible to examine them in detail.

Objectives: To investigate the impact of the COVID—19 news sources on rheumatoid arthritis patients’ disease activity using NinJa 2020 cohort study.

Methods: At the timing of collection of patients’ data of NinJa2020, questionnaire about their lifestyle and news source of COVID-19 was given. Questionnaire includes questions about frequency of scheduled visit, going out and exercise, weakness and news source.

Results: 6877 patients out of 15553 patients answered questionnaire. Most patients did not change the interval of scheduled visit. The frequency of hospital visits was “unchanged” in 85.8%, “longer” in 13.6%, and “shortened” in 0.6%. The chances of going out were “unchanged” at 14.4%, “significantly decreased” at 57.5%, “slightly decreased” at 27.8%, and “increased” at 0.3%. 42.6% answered that the amount of exercise did not change, 30.2% answered that it decreased considerably, 26.1% answered that it decreased a little, and 1.1% answered that it increased. Regarding muscular strength and physical strength, 46.0% answered “no change”, 19.9% answered “significantly dropped”, 33.5% answered “slightly dropped”, and 0.6% answered “increased”.

The media used as information sources are “newspaper (86.4%)”, “tabloid show (54.5%)”, “family, acquaintance and friends (43.7%)”, and “official web of Ministry of Health, Labor and Welfare and academic societies (9.4.%)”.

Respondents often referred to multiple media and 30.6% of them listed three sources (Figure 1). There was a positive correlation between the decrease in frequency of going out and the number of information sources, and a negative correlation between age and the number of information sources. We also found a negative correlation with age for muscle weakness. No correlation was found between the number of information sources and SDAI, CDAI, HAQ-DI, EQ-SD, HADS (A), HADS (D).

Figure 1.

Conclusion: The more sources of information, the less chance of going out. About 80% of the patients refrained from going out, the opportunity for exercise decreased in more than 50% of the patients, and the decrease in physical fitness was also noticed in nearly 50% of the patients. Newspapers, tabloid shows, and acquaintances were the most common sources of medical information, and relatively few patients used official sources. He provision of accurate information about COVID-19 was important to avoid infodemic. From this questionnaire, more practical information delivery system was required in Japan.

Disclosure of Interests: None declared.

Background: According to the recent medical literature, COVID-19 disease can lead to a constellation of clinical syndromes lasting well beyond the first 30 days of infection. The most common post COVID sequelae includes pulmonary, nervous system and neuropsychiatric, mental, metabolic, cardiovascular, gastrointestinal and several other clinical manifestations. Regarding joint involvement and particularly reactive arthritis (ReA), literature data is limited and describes case reports or series of cases of patients diagnosed with this condition following COVID-19 disease.

Objectives: To describe the pattern and the management of post-COVID reactive arthritis.

Methods: We have conducted a descriptive study of consecutive adult patients who presented to rheumatology outpatient clinic for joint or peri-articular pain/ swelling/stiffness and received a diagnosis of post-COVID 19 reactive arthritis, by excluding other types of rheumatological conditions. The assessed clinical variables were: visual analogue scale (VAS) pain, swollen joint count (SJC), tender joint count (TJC), duration of morning stiffness, presence of enthesitis/tennisitis and axial involvement. Biochemistry and serology was performed: rheumatoid factor, ACPA, ANA, HLA B27, antiChlamydia Trachomatis, Ureaplasma Urealyticum and Mycoplasma Hominis Ab, anti HBs and Hbc Ab, and anti HCV. COVID-19 disease prior to diagnosis of ReA was confirmed by PCR test.

Results: In the study were included 16 patients with confirmed post COVID-19 ReA. The mean age of the study group was 43.5±10.8 (range 21-60), the female: male ratio was 4:1 and the duration of joint symptoms was 10.4±11.8 (range 1-42) weeks. The severity of COVID-19 disease was mild in 68.7% cases, moderate in 18.7% and severe in only 6.2% of the cases. The duration between COVID-19 diagnosis and ReA varied between cases, with a mean value of 4.3±4.2 (range 1-12) weeks. In 43.7% of the cases patients had peripheral joint involvement (spondyloitis), in 37.5% - periarticular involvement (enthesitis), 6.25% - isolate axial involvement (sacrolarian joints), 6.25% enthesitis and axial involvement (cervical spin) and 6.25% synovitis and enthesis. In patients with peripheral joint pattern, the distribution of pain was symmetric (71.4%). The pattern of synovitis was determined by a TJC of 6.25±5.25 (range 1-16) joints and SJC 1.6±2.4 (range 0-7) joints. Both TJC and SJC correlated positively with the duration of morning stiffness (r=0.9 and r=0.6), but did not correlate with the VAS pain scale.

Conclusion: Reactive arthritis represents a post COVID-19 sequelae. The time of onset of ReA varied between 1 and 12 weeks after COVID-19 diagnosis. The clinical pattern of the disease was expressed by joint or periarticular involvement, mainly affecting the hand, feet and knee symmetrically. Cases of axial manifestations were less common. Most of the patients responded well to NSAIDs, only in a few particular cases, low doses of corticoids and/or Methotrexate were recommended.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3611
anxiety and depression symptoms and does not correlate with inflammation and thrombotic biomarkers.

REFERENCES:

Disclosure of Interests: None declared

AB1144
COGNITIVE AND PSYCHOSOCIAL OUTCOME IN CHILDREN WITH MULTISYSTEM INFLAMMATORY SYNDROME FOLLOWING SARS-COV-2 INFECTION

D. Goso\¹, M. Zajc Avramovi\², N. Emenisci\³, M. Šušteri\³, M. M. Šom\³, D. Osredkar\³, T. Avcin\³.
\¹University Medical Center Ljubljana, \²University Children's Hospital, Department of Child, Adolescent and Developmental Neurology, Ljubljana, Slovenia; \³University Medical Center Ljubljana, University Children's Hospital. Departament of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia; \⁴University of Ljubljana, Department of Psychology, Ljubljana, Slovenia

Background: Despite the low rate of neurological deficits following the SARS-COV-2 infection in the pediatric population, children and adolescents who develop multisystem inflammatory syndrome (MIS-C) after being infected with SARS-COV-2 are at a higher risk for neurological abnormalities and brain injury, increasing the risk of adverse cognitive and psychiatric outcome.

Objectives: Given the increased risk of central nervous system impairment we chose to conduct a prospective study looking at the cognitive and psychosocial outcome of patients with MIS-C.

Methods: Our study included 27 of the 29 patients between 2 to 18 years of age (M = 11.1, SD = 4.4) who were treated for MIS-C from the onset of the SARS-COV-2 pandemic until the beginning of May 2021 at the only tertiary care pediatric neurology center in Slovenia. We assessed these patients 6 months after diagnosis using the age-appropriate Wechsler intelligence scales and a battery of neuropsychological test measuring attention, executive function, memory and fine motor skills. We also asked parents to report on patients' psychosocial outcome using the Achenbach Child Behavior Checklist.

Results: By using Bayesian statistics to take into account parental education and any potential pre-morbid learning difficulties we found no evidence of impairment on measures of intelligence. However, the posterior distribution of scores on neuropsychological tests measuring attention, executive function, memory and fine motor skills was skewed. This means that although their average did not rise to a clinically significant level, the extent did not rise to a clinically significant level.

Conclusion: The findings from our cohort suggest that the cognitive and psychosocial outcome of patients with MIS-C is generally favorable, although up to 35% may experience specific neuropsychological deficits more than 6 months after diagnosis. The most commonly injured cognitive domains seem to be attention, executive function and visual memory.

Acknowledgements: Funding for this work was provided by the Slovenian Research Agency grant J3-3061 and University Medical Center grant 20210069.

Disclosure of Interests: David Gosar Speakers bureau: Biogen, Novartis, Mojca Zajc Avramovic: None declared, Nina Emenisci: None declared, Mateja Šušteri: None declared, Maja Maša Šom: None declared, Damjan Osredkar: None declared, Tadej Avcin: None declared

AB1145
EVALUATION OF THE HUMORAL IMMUNE RESPONSE SECONDARY TO VACCINATION AGAINST SARS-COV IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES

P. M. Corbalán\¹, M. Pera\¹, G. V. Espasa\¹, M. L. Leguizamón\¹, A. L. Barbaglia\¹, L. González Lucero\¹, H. R. Suelto\¹, M. C. Bertolacini\¹, R. N. Chehin\¹, R. H. Tomas-Grau\¹, D. Pliper\¹, E. Vera Pinguito\², B. Socías\³, C. L. Ávila\³, S. I. Cazorla\³, C. Maldonado Galdeano\³, V. I. Bellomio\³, \¹Hospital Ángel C. Padilla, Rheumatology Unit, San Miguel de Tucumán, Tucumán, Argentina; \²IMCA (CONICET - UNIT - SIROPSA). Instituto de Investigación en Medicina Molecular y Celular Aplicada, San Miguel de Tucumán, Tucumán, Argentina; \³CERELA (CONICET), Centro de Referencia para Lactobacilos, San Miguel de Tucumán, Tucumán, Argentina

Background: Several trials have reported lower seroconversion rates in patients with autoimmune rheumatic diseases than in healthy patients. In Argentina, the vaccines that were available during the development of this study were: Sputnik V (Gam-COVID-Vac), Astrazeneca (ChAdOx1 nCov), Sinopharm (BBIBP-CorV) and Moderna (mRNA-1273). Limited information is available about vaccines against SARS-CoV2 with inactivated virus or viral vector in autoimmune patients.

Objectives: To evaluate the humoral immune response to vaccines against SARS-CoV2 in patients with autoimmune rheumatic diseases; to compare the humoral response among patients with Systemic Lupus Erythematosus (SLE) and other autoimmune diseases and to analyse the variables associated.

Methods: We included patients with autoimmune rheumatic diseases (Rheumatology Unit of Padilla Hospital, Tucumán, Argentina), who received vaccination against SARS-CoV2 from June 2021. Sociodemographic, comorbidities, related to rheumatic disease, vaccination and SARS-CoV2 infection were the variables recorded. To evaluate the humoral immune response, the neutralizing anti-S-RBD IgG antibody titres were determined by ELISA “In House” test with a cut-off titre of 200 (IMMCA). The times established for the serological determinations were: T0 or baseline: 1\⁴th vaccine dose, T1: 14 ± 2 days after the 1\⁴th dose, T2: 2\⁴th dose, T3: 21- 45 days after the 2\⁴th dose, T4: 30 days after the 3\⁴th dose, T5: 6 months and T6: 12 months after the 3\⁴th dose.

Results: 66 patients were included, 91% women and 92.4% Amerindians. The mean age was 40.7 ± 11.4 years; 53% with SLE, 15.2% Rheumatoid Arthritis, 7.6% Systemic Sclerosis, 7.6% Juvenile idiopathic Arthritis, 7.6% Systemic Vasculitis and 9% other diagnoses; mean disease duration was 12.05 ± 7.5 years; 63.6% had at least one comorbidity (57% HBP, 31% overweight or obesity). At baseline, the treatments received were: corticosteroids (37.3%), prednisone mean dose 4.12 ± 8.9 mg/day), cDMARDs (75.7%), bDMARDs (18.2%); Rituximab (58.3%) and anti TNF (25%). Sixteen patients (24.2%) had previous COVID19 (75% mild symptoms). The vaccines applied were: AstraZeneca 38.2%, Sinopharm 31.7%, Sputnik V 19%, and combined schedule Sputnik V/ Moderna in 11%. At baseline, 28.8% had detectable anti-S-RBD IgG antibodies. This frequency increased to 48.4% at 1\⁴th dose and 70.2% at 2\⁴th dose. The variables that were associated with lower seroconversion rates and lower antibody titre were vaccination with Sinopharm (p 0.028) and treatment with bDMARDs (p 0.02), none of the 5 patients with Rituximab showed seroconversion. There were no significant differences in the levels of anti-S-RBD IgG antibodies between patients with SLE and the other rheumatic diseases. Patients who had SARS-CoV2 infection prior to vaccination had higher antibody titres in both T1 (p 0.006) and T2 (p 0.002) but after the two doses this difference was not significant (p 0.67). In the regression analysis, the variables that were independently associated with serocconversion were the type of vaccine applied at the 1\⁴th dose and the hypertensive disease. The chance of responding to vaccination was 13 and 9 times higher for those who received Sputnik V (OR 12.78; 95% CI 1.46 - 315.9) or AstraZeneca (OR 8.61; 95% CI 1.63 - 72.5) respectively, than Sinopharm in the 1\⁴th dose. The chance of being a responder was 88% lower for hypertensive patients (OR 0.12; 95% CI 0.02 - 0.58).

Conclusion: In this preliminary analysis, a seroconversion rate of 70.2% was associated with two-dose vaccination for SARS-CoV2 in patients with autoimmune rheumatic diseases. There were no differences in the serological response between patients with SLE and other rheumatic diseases. The humoral immune response was lower in patients with bDMARDs and null in those who received Rituximab. Seroconversion and antibody titre levels were associated with the type of vaccine applied, being Sinopharm who presented the lowest response. The follow-up will provide more knowledge about the behaviour of the humoral response in our patients.

Disclosure of Interests: None declared

AB1146
SARS-COV2 VIRAL LOAD IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASE, A RETROSPECTIVE COMPARATIVE STUDY

O. Alsa\¹, Y. A. Y. Alrimawi\¹, R. Saleh\¹, M. Chapouda\¹, P. Coyle\¹, K. Becetti\¹, H. Ashour\¹, E. Elsayed\¹, M. Hamed\¹, F. Alam\¹, B. Awadh\¹, M. Hammoudeh\¹, S. Al Emadi\¹.
\¹HAMAD Medical Corporation, Medicine/Rheumatology, Doha, Qatar; \²HAMAD Medical Corporation, Medicine/Infectious disease, Doha, Qatar; \³HAMAD Medical Corporation, Laboratory Medicine and Pathology, Doha, Qatar

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load and its impact on disease outcome in patients with autoimmune rheumatic disease (ARD) are lacking. Also, whether patients with ARD receiving immunomodulators have different viral loads compared to the general population is unknown.

Objectives: To compare the viral load of SARS-CoV-2 and its trend between patients without and with ARD.

Disclosure of Interests: None declared
Methods: Retrospectively, patients with ARD infected with SARS-CoV-2 were matched by age and sex at a ratio of 1:2 to patients without ARD and not receiving immunosuppression or immunomodulator drugs. Viral load was determined by the cycle threshold (CT) value measured by a number of platforms: (a) Automated Platforms - the Roche Cobas 6800 system using the Cobas SARS-CoV-2 Test targeting the E and orf1a/b genes (Roche, Switzerland) and the Xpert Xpress SARS-CoV-2 targeting the E and N genes (Cepheid, USA); (b) Manual platforms - EZ1 (QIAGEN, USA), QIAxSystem (QIAGEN, USA), and Bioneer ExiPrepTM 96 Virus DNA/RNA kits Catalogue No K4614 (Bioneer, South Korea) extraction with thermal cycling using TaqPath™ PCR COVID-19 Combo Kit targeting the N, S and orf1a/b genes (Thermo Fisher Scientific, USA) on ABI 7500 thermal cyclers. Independent samples t-test was used to compare the mean CT values of the study groups at baseline and at 5 subsequent intervals (1 - 5.9, 6 - 11.9, 12 - 17.9, 18 - 23.9 and 24 - 30 days).

**Results:** Mean age (SD) of 197 cases and 420 controls were 45.2 (11.8) and 44.1 (12.3) years, respectively. Females were predominant in both groups 60% vs. 52%, P=0.053. The most common ARD was rheumatoid arthritis in 82 cases (41.6%), followed by spondyloarthropathy in 33 (16.8%) and systemic lupus erythematosus in 31 (15.7%). Of the cases, 67% were on conventional synthetic disease modifying anti-rheumatic drugs (DMARDs), 15.2% on biological DMARDs and 4.6% patients were on rituximab. The mean CT values was significantly lower in the ARD group at baseline and persisted till day 24.

**Table 1.** demographic characteristics and comparison of the mean CT values in the study groups at baseline and at different intervals with the corresponding OR (95% CI)

<table>
<thead>
<tr>
<th>Case (N=197)</th>
<th>Control (N=420)</th>
<th>OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) age, years</td>
<td>45.2 (11.8)</td>
<td>44.1 (12.3)</td>
</tr>
<tr>
<td>Sex, female N (%)</td>
<td>120 (63.9%)</td>
<td>221 (52.6%)</td>
</tr>
<tr>
<td>Mean (SD) CT values at Baseline</td>
<td>22.9 (5.5)</td>
<td>30 (5.2)</td>
</tr>
<tr>
<td>1 – 5.9 days</td>
<td>22.1 (4.6)</td>
<td>25.7 (6.3)</td>
</tr>
<tr>
<td>6 – 11.9 days</td>
<td>26.9 (4.9)</td>
<td>31.5 (3.9)</td>
</tr>
<tr>
<td>12 – 17.9 days</td>
<td>29.6 (4.1)</td>
<td>32.3 (3.2)</td>
</tr>
<tr>
<td>18 – 23.9 days</td>
<td>32.1 (4)</td>
<td>32.9 (2.5)</td>
</tr>
<tr>
<td>24 – 30 days</td>
<td>31.2 (1.2)</td>
<td>32.7 (2.6)</td>
</tr>
</tbody>
</table>

Conclusion: Compared to patients without ARD, the viral load of SARS-CoV-2 in patients with ARD is significantly higher at baseline testing and persists till day 24. This finding may indicate that patients with ARD are at higher risk of severe SARS-CoV-2 infection and prolonged potential transmission. Clinical outcome correlation is needed.

**REFERENCES:** None

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3800

**AB1147 COVID 19 INFECTION IN PATIENTS WITH RHEUMATIC IMMUNE-MEDIATED DISEASES IN A SINGLE UNIVERSITY HOSPITAL. MATCHED CASE-CONTROL STUDY.**


1Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander (SPAIN), Spain; 2Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander (SPAIN), Spain; 3Servicio Cántabro de Salud, Epidemiology, Santander, Spain

**Background:** COVID19 may present different degrees of severity. It is generally thought that viral infections in patients with rheumatic inflammatory diseases (R-IMID) or receiving immunosuppressive treatment tend to present more severe disease. However, data comparing the severity of the disease between R-IMID and the general population are scarce.

**Objectives:** To assess the predisposing factors, clinical-analytical features and severity of COVID-19 infection in R-IMID compare to patients without R-IMID.

**Methods:** Case-control study in a single University Hospital. We included all consecutive patients with a diagnosis of a R-IMID and a positive test for COVID-19 up to March 31st, 2021. A total of 274 controls were selected for each case, and matched by sex, age (+5 years), and without previous diagnosis of R-IMID or use of immunosuppressive therapy. Confirmed infection was defined if the patient had a positive nasopharyngeal swab for SARS-CoV-2. COVID-19 case severity was divided into mild, moderate, severe and critical according to the United States National Institute of Health (NIH) COVID-19 guidelines (1). Mild/moderate COVID19 was compared with critical.

**Results:** We included 274 patients (185 women/89 men), mean age 59.1 ± 18 years. More frequent R-IMID were: Rheumatoid arthritis (RA) (n=87, 31.8%), Axial spondyloarthritis/ Psoriatic arthritis (SpA/Psa) (n=90, 32.8%), Polymyalgia Rheumatica (PMR) (n=22, 8%) and Systemic Lupus Erythematosus (SLE) (n=22, 8%). We also included 274 age and matched controls. Main characteristics of patients with R-IMID and controls are shown in Table 1.

**Table 1. Main clinical and analytical features of patients with R-IMID and matched controls**

<table>
<thead>
<tr>
<th>R-IMID patients (n=274)</th>
<th>Controls (n=274)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>59.1±18</td>
<td>58.8±17.3</td>
</tr>
<tr>
<td>Sex F/M, n (%)</td>
<td>185/89 (67.5/32.5)</td>
<td>185/89 (67.5/32.5)</td>
</tr>
<tr>
<td>Comorbidities (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>119 (43.4)</td>
<td>84 (30.7)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>119 (43.4)</td>
<td>79 (28.8)</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td>36 (13.1)</td>
<td>37 (13.5)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>29 (10.6)</td>
<td>32 (11.7)</td>
</tr>
<tr>
<td>Severity of the disease (n, %)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>209 (76.3)</td>
<td>204 (74.5)</td>
</tr>
<tr>
<td>Moderate</td>
<td>35 (12.8)</td>
<td>47 (17.2)</td>
</tr>
<tr>
<td>Severe</td>
<td>9 (3.3)</td>
<td>14 (5.1)</td>
</tr>
<tr>
<td>Critical</td>
<td>21 (7.7)</td>
<td>9 (3.3)</td>
</tr>
<tr>
<td>Deaths</td>
<td>17 (6.2)</td>
<td>7 (2.6)</td>
</tr>
<tr>
<td>Analytical values, median [25-75th IQR]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP</td>
<td>4.7 [2.9-3.3]</td>
<td>3.9 [1.7-3]</td>
</tr>
<tr>
<td>Lymphocytes (x1000 /µL)</td>
<td>1 [0.6-1.5]</td>
<td>1.1 [0.8-2.5]</td>
</tr>
<tr>
<td>Platelets (x103 /µL)</td>
<td>179 [141-237]</td>
<td>174 [155-211]</td>
</tr>
<tr>
<td>D-Dimer (ng/mL)</td>
<td>999 [342-1417]</td>
<td>548 [336-997]</td>
</tr>
</tbody>
</table>

CRP: C-reactive protein.

Concerning comorbidities, hypertension and dyslipidemia were more frequent in patients with R-IMID (p< 0.05). COVID-19 symptoms distribution is shown in Figure 1.

**Figure 1. Symptoms in R-IMID patients and matched controls**

*p< 0.05

Cough and dyspnoea were more frequent and headache, odynophagia and diarrhoea were less frequent in the R-IMID group. The only analytical difference was D-Dimer that was significantly higher in patients with R-IMID. Although most of the cases were mild, critical cases and deaths were more frequent in R-IMID (p<0.05).

**Conclusion:** Most of the patients present a mild COVID-19. However, a more severe syndrome was observed in R-IMID.
REFERENCES:

Disclosure of Interests: David Martínez-López: None declared, Diana Prieto-Peña: None declared, Fabricio Benavides-Villanueva: None declared, Lara Sanchez-Bilbao: None declared, Cristina Corrales-Selaya: None declared, Alba Herrero-Morant: None declared, Carmen Álvarez-Reguera: None declared, Martín Trigueros-Vazquez: None declared, Reinhard Walian: None declared, Miguel A González-Gay Speakers bureau: Consultation fees/participation in company-sponsored speaker’s bureau from AbbVie, Pfizer, Roche, and MSD., Grant/research support from: Dr. Miguel A. González-Gay received grants/research supports from AbbVie, MSD, and Roche., Ricardo Blanco Speakers bureau: Consultation fees/participation in company-sponsored speaker’s bureau from AbbVie, Lilly, Pfizer, Roche, Biotest-Myers, Janssen, and MSD., Grant/research support from: Dr. Ricardo Blanco received grants/research supports from AbbVie, MSD, and Roche.


AB1149
EVALUATION OF THE EFFICACY AND SAFETY OF THE SARS-COV-2 VACCINE IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH BIOLOGICAL THERAPY.

J. Calvo Gutierrez1, 2, C. López-Medina3, M. C. Ábalos-Aguirera1, A. B. Pérez Jiménez2, D. Ruíz-Vilchez1, F. U. Pilar1, R. Ortega Castro1, A. Escudero Contreras1, E. Collantes Estevez1, Reina Sofia University Hospital; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC); Córdoba University (UCO), Rheumatology Department, Córdoba, Spain. Reina Sofia University Hospital; Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC); Córdoba University (UCO), Microbiology Department, Córdoba, Spain

Background: In the current situation of the SARS-CoV-2 pandemic, the Spanish Society of Rheumatology recommends vaccination of patients with chronic inflammatory diseases (CID) under treatment with biological DMARDs (bDMARDs). However, the data regarding the generation of protective antibody titers after mRNA vaccines in patients with CID is limited.

Objectives: To determine the seroconversion rate and safety after the SARS-CoV-2 vaccine in patients with CID under treatment with bDMARDs

Methods: Cross-sectional observational study of 81 patients with CID from the HURS in Córdoba, who have received full vaccination for SARS-CoV-2 (without having previously suffered from COVID-19 disease) according to national guidelines. A determination of specific IgG-type antibodies against the trimeric spike protein of SARS-CoV-2 was performed on all of them. The chemiluminescence technique with the kit was used in serum samples taken 4-5 weeks after administration of the second dose of the vaccine. Information about sociodemographic characteristics, disease, type of bDMARDs, concomitant treatments and adverse effects after the second dose of the vaccine were collected in each patient.

Results: 81 patients were included (mean age 59.5, 72.8% females). 50.6% of patients had RA, 17.3% SpA, 11% PsA and 18.5% other CID. 23.5% were under treatment with Rituximab, 38.8% antiTNF, 13.6% Tocilizumab, 9.9% abatacept, 5% anti-JAK and 14.2% under other treatments. Anti-SARS-CoV-2 antibodies and neutralizing activity were detected in 80% of study participants. Rituximab treatment was significantly associated with negative seroconversion in comparison with patients under antiTNF treatment (OR 84.0 (95%CI 11.9-1708.2)). No interaction was found between the bDMARDs treatment and the type of vaccine with regard to the seroconversion, nor between bDMARDs and concomitant synthetic DMARD. When we evaluated IgG titers against the spike protein of SARS-CoV2, we found that patients under treatment with Rituximab showed the lowest titers levels in comparison with patients with other treatments (Figure 1, Table 1). In addition, patients who received AstraZeneca vaccine developed lower titers of antibodies in comparison with patients who received Pfizer (Table 1).

Figure 1. IgG titers against the spike protein of SARS-CoV2 with regard to the bDMARD

AB1148
POST COVID-19 RHEUMATIC AND MUSCULOSKELETAL DISEASES

N. Varghes1, N. Loghin-Oprea1, V. Sadovici-Bobeica1, Nicolae Testemitanu State University of Medicine and Pharmacy, Internal Medicine, Chișinău, Moldova, Republic of Moldova, Republic of Moldova, Republic of Moldova

Background: Recent data suggests that SARS-Cov-2 can alter self-tolerance and trigger autoimmune responses through cross-reactivity with host cells; therefore it can lead to late autoimmune and inflammatory manifestations. With regard to rheumatic and musculoskeletal diseases (RMDs), medical literature displays sporadic case reports describing a variety of conditions diagnosed after COVID-19, but it remains unclear what are the most common problems in patients presenting to rheumatology clinic following COVID-19 disease.

Objectives: To describe the pattern of post-COVID-19 RMDs in a consecutive group of patients from rheumatology outpatient clinic.

Methods: We have performed an observational descriptive study of a group of adult patients who received a new diagnosis of RMD within a timeframe of 12 weeks after the confirmation of COVID-19. Data was collected based on clinical presentation, paraclinical pattern and radiological examinations.

Results: The study included 23 patients who were consulted in rheumatology outpatient clinic and had post COVID-19 new onset joint, periarticular, bone or inflammatory syndrome manifestations. The general characteristics of the study group were as follows: mean age 45.5±11.3 (range 21-63) years and female to male ratio of 1.8:1. The majority of subjects consulted for joint symptoms (91.4%), in other cases reason for consultation was persistent low grade fever and fatigue (4.3%) and skin rash with dyspnea (4.3%). The mean duration of symptoms was 9.8±10.5 (range 1-42) weeks, and the time of onset after COVID-19 diagnosis was 4.9±4.1 (range 0-12) weeks. Concerning COVID-19 severity, it was established that in 60.9% it was mild, 17.4% - moderate and 21.7% - severe. After clinical and paraclinical examination, the following diseases were diagnosed: ReA, lupus like syndromes, avascular necrosis, new onset RA and new onset PsA. In 69.7% of patients were diagnosed with ReA, the clinical pattern being joint or periarticular involvement of the hand, knee and feet. In 13.0% cases patients had multisystemic involvement (myocarditis, pericarditis, skin rash, inflammatory arthritis and/or low grade fever) and positive ANA and or dsDNA Ab, these cases were diagnosed as lupus like syndromes and followed a severe form of COVID-19. In 8.7% of patients who presented with non-inflammatory hip pain, avascular necrosis was diagnosed, in both cases femoral head being the affected part. No be noted that patients with avascular necrosis had a severe form of COVID-19 disease and joint pain started later after COVID-19 diagnosis (10-12 weeks). In 4.3% of cases each, new onset RA and PsA were identified.

Conclusion: In the present study we have found that COVID-19 can be followed by a variety of RMDs. The most common symptom of patients presenting with RMD was joint pain. The most common disease was post-COVID-19 ReA (69.7%). Avascular necrosis (8.7%) and lupus like syndromes (13.0%) were found in patients who experienced a severe form of COVID-19. More rarely, patients had new onset of rheumatoid arthritis (4.3%) or psoriatic arthritis (4.3%). Our findings suggest that during the COVID-19 recovery period patients might experience onset of RDMs; therefore, in the presence of joint symptoms or other manifestations suggesting an autoimmune disease, patients should be referred to a rheumatologist for careful clinical examination.

REFERENCES:

Disclosure of Interests: None declared.

Interestingly, among patients with anti-TNF treatment, AstraZeneca was associated with lower IgG titers in comparison with Pfizer and Moderna [405.9 (553.0) vs. 1084.1 (79.12) vs. 1264.0 (1012.6), p=0.016, respectively]. No differences between vaccines were found in patients with the other type of bDMARDs. Only 18.9% presented mild adverse effects. No serious adverse effects were observed and no patient experienced a disease flare after vaccination.

**Conclusion:** Our results show that SARS-CoV-2 mRNA vaccines produce seroconversion in most patients with CID, except in the case of patients with rituximab. No severe adverse effects or CID reaction were found. Despite the small number of patients included, this study suggests the need for revaccination in the group of patients treated with rituximab or vaccinated with AstraZeneca.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3971

---

**Table 1. Linear regressions to evaluate the IgG titers and their association with the bDMARD and the type of vaccine.**

<table>
<thead>
<tr>
<th>bDMARD</th>
<th>Reference</th>
<th>IgG titers</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-TNF</td>
<td>-405.6 (893.7 to 82.4)</td>
<td>0.102</td>
<td></td>
</tr>
<tr>
<td>Anti-IL1</td>
<td>-728.7 (-1133.8 to -233.5)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Rituximab</td>
<td>88.7 (-462.8 to 640.1)</td>
<td>0.749</td>
<td></td>
</tr>
<tr>
<td>Abatacept</td>
<td>315.6 (-423.2 to 1054.4)</td>
<td>0.397</td>
<td></td>
</tr>
<tr>
<td>Anti-JAK</td>
<td>256.3 (-482.5 to 995.1)</td>
<td>0.491</td>
<td></td>
</tr>
<tr>
<td>Otros</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaccine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>Reference</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>-408.6 (-454.6 to -10.26)</td>
<td>0.043</td>
<td></td>
</tr>
<tr>
<td>Jansen</td>
<td>-783.4 (-1662.1 to 95.3)</td>
<td>0.08</td>
<td></td>
</tr>
<tr>
<td>Moderna</td>
<td>130.6 (-4075.6 to 668.7)</td>
<td>0.63</td>
<td></td>
</tr>
<tr>
<td>Methotrexate* bDMARD</td>
<td>273.3 (-153.5 to 289.9)</td>
<td>0.823</td>
<td></td>
</tr>
<tr>
<td>Lefunomide* bDMARD</td>
<td>208.0 (-188.9 to 604.9)</td>
<td>0.300</td>
<td></td>
</tr>
<tr>
<td>Corticosteroids* bDMARD</td>
<td>32.9 (-259.4 to 239.2)</td>
<td>0.823</td>
<td></td>
</tr>
</tbody>
</table>

**Vaccine** bDMARD -4.2 (-10.6 to 11.6) 0.939

---

**Table 1.**

<table>
<thead>
<tr>
<th>Patients with IRD</th>
<th>Healthy controls</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=81</td>
<td>n=100</td>
<td></td>
</tr>
<tr>
<td>Age (means±SD)</td>
<td>50.6±5.13</td>
<td>50.6±5.13</td>
</tr>
<tr>
<td>Female</td>
<td>58</td>
<td>65</td>
</tr>
<tr>
<td>-RA</td>
<td>35</td>
<td>N/A</td>
</tr>
<tr>
<td>-SpA</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>-CTD</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>-FMF</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>-Vasculitis</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>61</td>
<td>70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Seroconversion rate (%)</td>
<td>68/81 (84%)</td>
<td>97/100 (97%)</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>48/61</td>
<td>67/70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20/20</td>
<td>20/20</td>
</tr>
<tr>
<td>IgG (median) (IR)</td>
<td>275.8 (68.95-916.70)</td>
<td>116.7 (477.20-2074.18)</td>
</tr>
<tr>
<td>Neutralization (median) (IR)</td>
<td>p=0.031</td>
<td>0.552</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>1.97 (0-26.82)</td>
<td>N/A</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>16.34 (13.85-16.67)</td>
<td></td>
</tr>
<tr>
<td>bDMARD/Seroconversion rate (%)</td>
<td>p=0.001</td>
<td>N/A</td>
</tr>
<tr>
<td>-naive</td>
<td>52/58</td>
<td></td>
</tr>
<tr>
<td>-RTX</td>
<td>5/12</td>
<td></td>
</tr>
<tr>
<td>-Anti-cytokine</td>
<td>11/11</td>
<td></td>
</tr>
</tbody>
</table>

**Acknowledgements:** Research support from: TRASD (Turkish League Against Rheumatism)

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3971

---

**Table 1.**

<table>
<thead>
<tr>
<th>Patients with IRD</th>
<th>Healthy controls</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=81</td>
<td>n=100</td>
<td></td>
</tr>
<tr>
<td>Age (means±SD)</td>
<td>50.6±5.13</td>
<td>50.6±5.13</td>
</tr>
<tr>
<td>Female</td>
<td>58</td>
<td>65</td>
</tr>
<tr>
<td>-RA</td>
<td>35</td>
<td>N/A</td>
</tr>
<tr>
<td>-SpA</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>-CTD</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>-FMF</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>-Vasculitis</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>61</td>
<td>70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Seroconversion rate (%)</td>
<td>68/81 (84%)</td>
<td>97/100 (97%)</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>48/61</td>
<td>67/70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20/20</td>
<td>20/20</td>
</tr>
<tr>
<td>IgG (median) (IR)</td>
<td>275.8 (68.95-916.70)</td>
<td>116.7 (477.20-2074.18)</td>
</tr>
<tr>
<td>Neutralization (median) (IR)</td>
<td>p=0.031</td>
<td>0.552</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>1.97 (0-26.82)</td>
<td>N/A</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>16.34 (13.85-16.67)</td>
<td></td>
</tr>
<tr>
<td>bDMARD/Seroconversion rate (%)</td>
<td>p=0.001</td>
<td>N/A</td>
</tr>
<tr>
<td>-naive</td>
<td>52/58</td>
<td></td>
</tr>
<tr>
<td>-RTX</td>
<td>5/12</td>
<td></td>
</tr>
<tr>
<td>-Anti-cytokine</td>
<td>11/11</td>
<td></td>
</tr>
</tbody>
</table>

**Acknowledgements:** Research support from: TRASD (Turkish League Against Rheumatism)

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3971

---

**Table 1.**

<table>
<thead>
<tr>
<th>Patients with IRD</th>
<th>Healthy controls</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=81</td>
<td>n=100</td>
<td></td>
</tr>
<tr>
<td>Age (means±SD)</td>
<td>50.6±5.13</td>
<td>50.6±5.13</td>
</tr>
<tr>
<td>Female</td>
<td>58</td>
<td>65</td>
</tr>
<tr>
<td>-RA</td>
<td>35</td>
<td>N/A</td>
</tr>
<tr>
<td>-SpA</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>-CTD</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>-FMF</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>-Vasculitis</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>61</td>
<td>70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20</td>
<td>30</td>
</tr>
<tr>
<td>Seroconversion rate (%)</td>
<td>68/81 (84%)</td>
<td>97/100 (97%)</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>48/61</td>
<td>67/70</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>20/20</td>
<td>20/20</td>
</tr>
<tr>
<td>IgG (median) (IR)</td>
<td>275.8 (68.95-916.70)</td>
<td>116.7 (477.20-2074.18)</td>
</tr>
<tr>
<td>Neutralization (median) (IR)</td>
<td>p=0.031</td>
<td>0.552</td>
</tr>
<tr>
<td>-CoronaVac</td>
<td>1.97 (0-26.82)</td>
<td>N/A</td>
</tr>
<tr>
<td>-BNT162b2</td>
<td>16.34 (13.85-16.67)</td>
<td></td>
</tr>
<tr>
<td>bDMARD/Seroconversion rate (%)</td>
<td>p=0.001</td>
<td>N/A</td>
</tr>
<tr>
<td>-naive</td>
<td>52/58</td>
<td></td>
</tr>
<tr>
<td>-RTX</td>
<td>5/12</td>
<td></td>
</tr>
<tr>
<td>-Anti-cytokine</td>
<td>11/11</td>
<td></td>
</tr>
</tbody>
</table>

**Acknowledgements:** Research support from: TRASD (Turkish League Against Rheumatism)

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3971
response in volunteers vaccinated with BNT162b2 showing a 2S≥1 poly-
epitope response.

**Results:** Twenty-eight patients (25 women, 3 men; mean age 59.1±17.8) with various ISD were investigated. These patients suffered from lupus (n=14), vasculitis (n=4), myositis (n=2), sarcoidosis (n=2), primary immunodeficiency (n=3), Sjögren’s syndrome (n=2) and pericarditis (n=1). Three patients had received 4 doses, 16 three doses, and 8 two doses of vaccine (Pfizer; n=25; Moderna n=1, Astra-Zeneca n=1). One patient refused the vaccination. The tests were performed 86.7 (±60.5) days after last vaccine dose. Ten patients were on prednisone (mean dose: 11.8mg, median 7.75mg, range: 5-40). Among those patients, 6 had only prednisone, 1 was also treated with belimumab, 3 with methotrexate (MTX) and 1 with azathioprine (AZA). Following COVID19 vaccination, humoral (100% in healthy vs 84.6% in ISD patients) and IGRASpike T cell (96% in healthy vs 59.7% in AI patients) responses took place with lower response reported among the ISD disease group (Figure 1). Humoral and cellular COVID19 vaccine responses significantly decrease after 100 days post vaccine.

**Figure 1.** SARS-CoV2 humoral and T cell responses in non-vaccinated healthy individuals (n=103), SARS-CoV2 infected individuals (n=9), and 104 samples from individuals having received COVID19 vaccine including 28 non-Sars-cov2 infected patients with ISD diseases. A- Anti-SARS-CoV2 Spike total IgM/IGG antibodies (Ab) titer (BAU/mL) tested by ELISA. B- Whole blood IFN-γ release assay (IGRA) response to the full-length Spike recombinant protein (IGRA-Spike). C- Whole blood IGRA response to the nucleocapsid recombinant protein (IGRA-Nuc). Positivity cut-off (dotted line) p values <0.05 are indicated when significant (ANOVA).

5/5 vaccinated patients on CS alone, 2/5 vaccinated patients on corticosteroids with MTX/ZA/Beclomumab and 3/17 other vaccinated patients (all being primary immunodeficiency patients) had no cellular response. Humoral and T cell responses were independent from sex and age.

**Conclusion:** Altogether, this ongoing study confirms the utility of the IGRA-Spike-nucleocapsid assay coupled with serology in COVID19 vaccinated individuals and in particular in ISD patients treated with steroids, who may be at risk when the humoral protection decreases.

References: none

Disclosure of Interests: None declared


---

**AB1151**

COVID-19 MRNA VACCINE BOOSTER IN PATIENTS WITH SYSTEMIC AUTOIMMUNE DISEASES

C. Cardelli1,2, T. Caruso1,3, C. Tani2, F. Pratesi1,3, R. Talarico2, F. DI Cianni1,2, N. Italiani1,2, E. Laurino1,2, M. Moretti1,2, M. Diomedi1,2, L. Gualtieri1,2, R. D’urzo2, P. Migliorini1,3, M. Mosca1,2.

**Background:** Patients with systemic autoimmune diseases (SADs) are often treated with drugs that interfere with the immune system and previous data showed a reduced seroconversion rate after anti-SARS-CoV2 vaccine in these subjects compared to healthy controls1. Administration of a booster dose of the vaccine could be particularly important in these patients, but data available to date are still scarce.

**Objectives:** To evaluate the antibody response to the booster dose of mRNA SARS-CoV2 vaccine in patients with SADs and to compare it to the response after completion of the first vaccination course. Secondly, to find possible correlations between a low antibody titre and patients’ clinical features, with special regard to ongoing immunosuppressive therapies.

**Methods:** Consecutive patients with an established diagnosis of SADs undergoing SARS-CoV2 vaccine were prospectively enrolled from January 2021; among them, we selected the patients who received the third vaccination dose between September and December 2021 Demographic and clinical data were collected at enrolment (sex, age, diagnosis, disease duration, ongoing therapies, previous SARS-CoV2 infection, presence of hypogammaglobulinemia); the last three elements were reassessed at each follow-up visit. Blood samples were collected 4 weeks both after the second (W4a) and the third (W4b) dose of the vaccine; a minority of patients was also tested 12 weeks after the second dose (W12).

IgG antibodies to SARS-CoV2 receptor-binding domain (RBD) and neutralizing antibodies inhibiting the interaction between RBD and angiotensin converting enzyme 2 were evaluated. IgG anti-RBD were detected by solid phase assay on plates coated with recombinant RBD, while neutralising antibodies by using the kit SPIA (Spike Protein Inhibition Assay). Cut-off values were defined as the 97.5% percentile of a pre-vaccine healthy population. Statistical analysis was performed using IBM SPSS Statistics 20 and GraphPad Prism statistical packages. P values<0.05 were considered significant.

**Results:** Forty-five patients (95.6% female; mean age ±SD 55.6±14.1 years; mean disease duration 12.9±10.6 years) were enrolled. Diagnosis was in most cases connective tissue disease (31/45, 68.9%), followed by inflammatory arthritis (11/45, 24.4%) and systemic vasculitis (3/45, 6.7%). Two patients (4.4%) had a previous SARS-CoV2 infection and three had hypogammaglobulinemia (6.7%). At the time of the second dose, 18/45 patients were treated with glucocorticoids (GCs) (mean daily 6-methylprednisolone (6MP) dose 3.9 mg). At the third dose administration, 19/45 patients were treated with GCs (mean daily 6MP dose 4.1 mg (min. 1.5, max. 10)), 18/45 with csDMARDs and 13/45 with bDMARDs. Anti-RBD IgG were positive in 42/45 patients (93.3%) at W4a, in 16/16 (88.9%) at W12 and in 42/45 (93.3%) at W4b. Neutralizing antibodies were present in 36/45 patients (84.4%) at W4a, in 14/18 (77.8%) at W12 and in 42/45 (93.3%) at W4b. Both anti-RBD IgG titers and neutralizing antibody titers significantly increased after the third dose if compared to W4a (p<0.0001 both) (Figure 1). Interestingly, of the 7 patients who had not developed an adequate neutralizing antibody response after the first vaccination course, 5 mounted an adequate titer after the booster. Two non-responder patients were both on combination therapy (one with low dose of GCs plus mofetil, the other with methotrexate and infliximab).

**Conclusion:** Our data suggest that in patients with SADs there is a decline in the antibody titers developed after COVID-19 vaccination, however the booster dose is effective in restoring an adequate antibody titre. These data consolidate the importance of a booster dose of COVID-19 vaccination in patients with SADs to aid in the generation of an immune response.

REFERENCES:

Acknowledgements: The authors would like to thank all the patients who participated in the study and the nurses Sabrina Gori, Rosanna Lo Coco, Lucia Pedrocchi, Carla Puccini, Pasqualina Semeraro, Manuela Terachi, Maria Tristano, Valentina Venturini and Catiuscia Zoina who took care of the patients.

Disclosure of Interests: None declared


---

**AB1153**

HYPEREOSINOPHILIC SYNDROME FOLLOWING THE BNT162b2 (BIONTECH/ PFIZER) VACCINATION

A. Hoza1, T. Tomaselii, G. Minicucci2, G. Scanneli3, D. Zardo3, L. Naiei3. 1San Bortolo Hospital, Internal Medicine Unit, Department of Medicine, Vicenza, Italy; 2San Bortolo Hospital, Department of Neurosciences, Vicenza, Italy; 3San Bortolo Hospital, Department of Pathology, Vicenza, Italy; 4San Bortolo Hospital, Department of Dermatology, Vicenza, Italy

**Background:** Some reports of small vessel vasculitis following nSARS-CoV2 vaccination are reported in the literature (1, 2).

**Objectives:** We purpose to report the case of small-medium vessel vasculitis after BNT162b2 (BioNTech/Pfizer) vaccination.
Methods: We present the case of a 48 years old man with an unremarkable history who underwent BNT162b2 vaccination.

Results: Five days after the first shot of BNT162b2 vaccine, the patient refer the onset of left inguinal adenopathy, and erythematous dermatitis of the trunk. Ultrasound of the groin found increase bilateral inguinal lymph nodes with reactive characters. Contextually, erythematous, itchy and painful nodular lesions appear in the lower and upper limbs as well as acrocyanosis and paresthesia in the right hand and foot. The tests performed showed thrombocytopenia and eosinophilia. While, CRP, search for fecal parasites, pANCA, cANCA, ANA, RAST test, serum tryptase were all absent. Haematological evaluation, bone marrow biopsy, karyotype and molecular biology (FIP1L1/PDGFRα) were performed, all results negative. The patient was admitted in Internal Medicine ward for worsening of skin lesions and of acrocyanosis with gangrenous lesions at the tips of the fourth finger of the right hand. An angio-CT showed an occlusion of the right ulnar artery. At electromyography an axonal sensory neuropathy was found. The skin biopsy showed fibrinoid necrosis of vessels of the superficial vascular plexus associated with numerous eosinophils, lymphocytes and karyorrhetic debris (Figure 1). High-resolution CT scan described diffuse minimal accentuation of the interstitial texture with micronodular aspects and some ground glass appearance. The diagnosis of hypereosinophilic syndrome was made. Therapy with Methylprednisolone 500mg/day for 3 days then Prednisone 1 mg/kg daily in association with IL-5 inhibitor (mepolizumab) with good clinical response, in addition to antiocoagulation with warfarin was started.

Figure 1.

Conclusion: To our knowledge this might be the first case of (HES) following COVID vaccine. As our experience, due to the short commercialization of anti- nSARS-CoV2 vaccines, is limited further studies are needed to explore the possible effect on small-medium vessels.

REFERENCES:


Disclosure of Interests: None declared


AB1154

HUMORAL AND CELLULAR RESPONSE TO A THIRD BOOSTER DOSE SARS-COV-2 VACCINATION IN PATIENTS WITH AUTOIMMUNE DISEASE: A CASE SERIES

T. Dimitriou1, A. Tychala2, K. Deftarou3, E. Katispourli2, E. Sidropoulou2, M. Papachristou4, A. Fylaktou, L. Skourà2, Aristotle University of Thessaloniki, Greece; Aristotle University of Thessaloniki, Department of Microbiology, Ahepa University Hospital, Thessaloniki, Greece; Papanikolaou General Hospital, Department of Immunology, Thessaloniki, Greece; Hippokration General Hospital of Thessaloniki, Immunology Departments, National Peripheral Histocompatibility Center, Thessaloniki, Greece

Background: Patients with systemic rheumatic diseases (SRD) are at increased risk for viral infections and successful vaccination is crucial to combat COVID-19 pandemic in this population. However, reduced antibody responses have been described in a proportion of SRD individuals on immunosuppressant agents including mycophenolate (MMF).

Objectives: We aimed to assess humoral and cellular response of SRD patients who received a booster SARS-CoV-2 vaccination.

Methods: Twenty patients without history of COVID-19 infection (11 men, median age 58 years (range:38-74) on treatment with MMF (2g daily) due to systemic sclerosis (n=6), inflammatory myositis (n=4) and systemic lupus erythematosus (n=2) and on tumor necrosis factor-alpha inhibitors (anti-TNF) due to spondyloarthritis (n=5), rheumatoid arthritis (n=2) and Bechet disease (n=1) were included. All were on monotherapy with anti-TNF except patient with Bechet. Patients on MMF discontinued treatment for 1 week after the booster dose while no treatment modification was implemented in anti-TNF group. Serological response to vaccination was assessed using the Abbott SARS-CoV2- IgG II Quant assay. Cellular immunity was estimated via interferon-γ produced by CD4+ and CD8+ T-lymphocytes in response to a SARS-CoV2- peptide cocktail, with the SARS-CoV2- ELISA Kit.

Results: Nineteen patients (95%) demonstrated positive serological response following booster vaccine dose (Table 1). Only one female patient in MMF group failed to develop adequate levels of antibodies. The median antibody titers of patients under MMF and anti-TNF was 647.90 BAU/mL (range: 0.71-4795.32 BAU/mL) and 542.98 BAU/mL (range: 4.32-1391.33 BAU/mL) respectively. No statistically significant difference was found between the two groups. Regarding cellular immunity a T-cell response was present in all patients on monotherapy with anti-TNF but only in 7/12 under MMF including the one with negative humoral response.

Conclusion: We report sufficient immunogenicity following a third booster vaccine in patients with RSD on immunomodulatory measures coupled by a strong cellular immune response particularly in patients on anti-TNF monotherapy. Percivaccination management of immunosuppressive therapy represents an important parameter of vaccine administration in patients with RSD.

REFERENCES:


Disclosure of Interests: None declared


AB1155

PAUSING METHOTREXATE IMPROVES IMMUNOGENICITY OF COVID-19 VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES


1Charité University Hospital, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 2Charité University Hospital, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 3Deutsches Rheuma-Forschungszentrum Berlin (DRFZ), Berlin, Germany; 4Charité University Hospital, Institute of Virology, Berlin, Germany

Background: Several research groups have recently described a reduced vaccination response to COVID-19 vaccination under methotrexate (MTX) (1,2). The increase in humoral immune response when pausing MTX two weeks after vaccination has already been described for influenza vaccination (3). However, data regarding MTX-hold during COVID-19 vaccination are still lacking.

Objectives: To study the effect of MTX and its discontinuation on the humoral immune response after COVID-19 vaccination in patients with autoimmune rheumatic diseases (AIRD).

Methods: In this retrospective study, neutralising SARS-CoV-2 antibodies were measured after second vaccination in 64 rheumatic patients on methotrexate therapy, 31 of whom temporarily paused medication without a fixed regimen. The control group consisted of 21 AIRD patients without immunosuppressive medication.

Results: MTX patients showed a significantly lower mean antibody response compared to AIRD patients without immunosuppressive therapy (71.8 % vs 92.4 %, p<0.001). For patients taking MTX, age correlated negatively with immune response (r=-0.49; p<0.001). All nine patients with antibody levels below the cutoff were older than 60 years. Patients who held MTX during at least one vaccination showed significantly higher mean neutralising antibody levels after second vaccination compared to patients who continued MTX therapy during both vaccinations (83.1 % vs 61.2 %, p=0.001). This effect was particularly pronounced in patients older than 60 years (80.8 % vs 51.9 %, p=0.001). The impact of the time
period after vaccination was greater than of the time before vaccination with the critical cut-off being 10 days.

**Conclusion:** MTX reduces the immunogenicity of SARS-CoV-2 vaccination in an age-dependent manner. Our data further suggest that holding MTX for at least 10 days after vaccination significantly improves the antibody response in patients over 60 years of age.

**REFERENCES:**


Disclosure of Interests: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4272

**AB1157**

**CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATIC DISEASES AFTER COVID-19 IN THE REPUBLIC OF TATARSTAN**

S. Lapshina1, N. Shamsutdinova2, V. Mukhamadieva1, R. Abdrikapov2, E. Sukhorukova2, L. Kupkovenova2, D. Abdulganieva2, Kazan State Medical University, Department of Hospital Therapy, Kazan, Russian Federation; 2Kazan State Medical University, Department of Hospital Therapy, Kazan, Russian Federation; 3Republican Clinical Hospital, Rheumatology, Kazan, Russian Federation; 4Republican Clinical Hospital, Rheumatology, Kazan, Russian Federation

**Background:** The management of patients with rheumatic diseases (RD) who have undergone a new coronavirus infection (NCI) is an urgent and significant problem.

**Objectives:** To study the course of the NCI and its influence on the course of RD in the Republic of Tatarstan.

**Methods:** From June 2020 to January 2022, 159 cases of NCI with a confirmed SarsCoV2 PCR result and/or X-ray computed tomography (CT) of the lungs in patients with RD were analyzed. The study included 104 patients with RA, 36 patients with AS, 18 patients with PsA. RD activity before NCI was low in 56 (35.2%) patients, moderate in 91 (57.3%), and high in 12 (7.5%) patients. Distri-

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4311
RD were followed up. The study included 100 patients with RA, 36 patients with AS, 18 patients with PsA. RD activity before NCI was low in 56 (36.4%) patients, moderate in 90 (58.4%) patients, and high in 4 (5.2%) patients. Among the patients, 110 (71.5%) were female, 44 (28.5%) were male, the average age was 58 [46; 64]. 28% (43) of patients had asymptomatic or mild NCI, 66.2% (102) had moderate NCI, and 5.8% (9) of people had severe NCI. Bilateral polysegmental pneumonia was detected in 111 (72.0%) patients. The results of clinical and laboratory examinations for RD were assessed before and 3 and 6 months after NCI. Patients underwent an in-depth survey 3 and 6 months after undergoing NCI for the presence of various symptoms, including manifestations of asthenia. Additionally, the severity of depression and anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS) and the Hamilton Scale.

Results: 90.3% of patients noted the persistence or appearance of symptoms after undergoing NCI, and all of them had a combination of at least 3 different groups of symptoms. The most common asthenic manifestations were in the form of a decrease in the quality of life and manifestations of asthenia. Additionally, the severity of depression and anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS) and the Hamilton Scale.

After 3 months, a decrease in the quality of life, manifestations of depression and anxiety were noted by 30.5% of the respondents, while there was no connection with the severity of NCI, and half of the patients had a mild course of COVID-19. The appearance/intensification of chest pain and/or palpitations was noted by 20.8% of patients. After 3 months, a decrease in the quality of life, manifestations of depression and anxiety were revealed: 32.2% of people had a mild depressive disorder of moderate severity, 22.3% had clinically expressed anxiety and depression. Six months after the NCI, no abnormalities were detected on the Hamilton scale, and significantly expressed anxiety/depression on the HADS scale.

Conclusion: In most patients with RD, post-covid manifestations persist, primarily due to general constitutional, articular and cognitive symptoms. Manifestations of NCI itself in the form of respiratory and cardiovascular manifestations persist in less than a third of patients.

Disclosure of Interests: None declared


**AB1159**

**HYDROXYCHLOROQUINE SHORTAGE AND ITS RELATION TO ANXIETY LEVEL AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS DURING COVID-19 PANDEMIC**

M. H. Abu-Za'id, H. Elta, A. Mohshif, D. Abdeldaim, N. EL Ghobashy

1Tanta University, Rheumatology, Tanta, Egypt; 2Al-Azhar University, Rheumatology, Cairo, Egypt; 3Al-Azhar University, Rheumatology, Assiut, Egypt; 4Tanta University, public health, Tanta, Egypt; 5Cairo University, Rheumatology, Cairo, Egypt

Background: Concerns of hydroxychloroquine (HCQ) shortage for patients with rheumatic diseases are growing during the era of COVID-19 pandemic, as it was associated in some treatment protocols. HCQ nonavailability may impact the disease management especially in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Objectives: To evaluate the shortage of HCQ in patients with RA and SLE and its impact on patients anxiety and disease activity.

Methods: 219 RA patients (according to 2010 ACR/EULAR criteria) and 200 SLE patients (according to 2012 SLICC criteria) were recruited in the study. Demographic and clinical features of the patients together with the current disease activity parameters (CDAI and SLEDAI) were prospectively collected. Previous disease activity measures were collected from the patients records before hydroxychloroquine shortage. Patient's anxiety was measured using Hamilton anxiety rating scale.

Results: A total of 416 patients divided into two groups, Group (1): 219 RA patients with mean age 45.6±9.6 years, disease duration 45.5±32.8 months with female prevalence (63 %). Group (2): 200 SLE patients with mean age 33.8±7.9 years, disease duration 612±39.2 months with female prevalence (84%). 168 (76.7%) of the RA patients and 128 (64%) of SLE patients reduced or stopped the dose of HCQ due to nonavailability. Despite HCQ shortage, there was no significant change in RA disease activity (p=0.063 and 0.04 respectively). All participants suffered from different levels of anxiety which was positively correlated with HCQ shortage (p<0.001 and 0.005 for RA and SLE respectively).

Conclusion: COVID 19 pandemic caused hydroxychloroquine shortage in the majority of patients with RA and SLE with no significant impact on their disease activity. Anxiety was found correlating to HCQ shortage in both diseases more significantly in SLE patients.

Disclosure of Interests: Mohammed Hassan Abu-Za'id: None declared. Hany Elta: None declared, Abdelfeetze Mohshir Speakers bureau: Amgen, Jansen and Novartis, Doaa Abdeldaim: None declared, nelai EL Ghobashy: None declared


**AB1160**

**IMPACT OF COVID-19 TREATMENTS ON PERIPHERAL CAPILLARY DENSITY EVALUATED BY NAILFOLD VIDEOCAPILLAROSCOPY**

E. Gotelli1, A. Sulli1, P. F. Bica2, I. Schiavetti1, T. Aloe3, M. Grosso3

1University of Genova, IRCCS Sant Martino Polyclinic Hospital, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties, Genova, Italy; 2University of Genova, Department of Health Sciences, Genova, Italy; 3IRCCS Sant Martino Polyclinic Hospital, Interventional Rheumatology Unit, Genova, Italy; 4Ghent University Hospital, Department of Rheumatology, Ghent, Belgium; 5Ghent University Hospital, Department of Internal Medicine, Ghent, Belgium; 6VIB Inflammation Research Center, Unit for Molecular Immunology and Inflammation, Ghent, Belgium

Background: Human SARS-CoV-2 infection can induce a wide spectrum of organ dysfunctions, including microvascular impairment [1]. S. subunit of viral receptor-binding domain links to the angiotensin-converting enzyme 2 receptor on endothelium and Sβ subunit allows the virus to enter endothelial cells. The resulting breakdown of barrier integrity drives a cascade of inflammatory and thrombotic events, that aggravate the course of COVID-19 together with other risk factors [2-4]. Up to date, a lower capillary density has been reported in several distinct body districts, using sublingual video microscopy, ocular optical coherence tomography, skin function tests and videocapillaroscopy [5-6]. NVC examination has been performed in adult COVID-19 patients, however, without a control group [8].

Objectives: To confirm the statistical significance of the reduction in capillary density per linear millimeter evaluated by NVC in comparison with primary Raynaud’s phenomenon (PRP) patients and control subjects (CNT) and to evaluate the impact of an aggressive therapy against COVID-19 on the sparing in the number of capillaries.

Methods: Sixty-one COVID-19 survivors, thirty-one PRP patients and thirty CNT age and sex-matched underwent NVC analysis. Demographic and clinical data of COVID-19 survivors were collected with special regard to concomitant therapies, that included antivirals, antibiotics, anti-coagulants and anti-inflammatory immunomodulating drugs (glucocorticoids, hydroxychloroquine, IL-6 receptor antagonist). COVID-19 survivors were divided in two subgroups according to the severity of the active infection: thirty-four survivors with past mild-moderate disease (either unneedy for oxygen supplementation or need for Venturi mask) and twenty-seven survivors with past severe disease (need for Continuous Positive Airways Pressure and/or mechanical ventilation). The same Rheumatologist performed NVC evaluations in all patients and controls, using an optical probe, equipped with a 200x magnification lens and connected to a picture analysis software (Videocap, DS Medica, Milan, Italy). Absolute capillary number per linear millimeter was counted.

Results: COVID-19 survivors underwent NVC examination after a mean period of 126±53 days from the disease onset. Multivariate analysis showed differences in absolute capillary number per linear millimeter (p=0.001) after adjusting for age, sex, body mass index, comorbidities and concomitant drugs. The mean (± standard deviation) absolute nailfold capillary number per linear millimeter was significantly lower in severe (8.2±1.15) and mild-moderate (8.4±0.75) COVID-19 survivors than in both PRP (8.7±0.68) and CNT subjects (9.3±0.53) (p<0.001). The analysis of the impact of treatments on capillary density in the severe COVID-19 patients showed a positive correlation (p<0.005) between the capillary number (p=0.001) and antivirals (no: 7.8±1.53; yes: 8.5±0.64; p=0.35) and anti-L16 receptor antagonist administration (no: 7.8±1.36; yes: 8.6±0.74; p=0.16), while none of the other drugs was shown to be effective (glucocorticoids p = 0.46; antibiotics = 0.52; anti-coagulants not evaluable as they were used in all COVID-19 patients).

Conclusion: SARS-CoV-2 infection seems associated to a significant capillary loss as distinctive NVC feature and data concerning the comparison of capillary density pre COVID-19 and post COVID-19 are desirable to reinforce this observation. The positive trend in saving the number of capillaries induced by aggressive anti-inflammatory therapies in COVID-19 patients needs larger cohorts of patients.

REFERENCES:


Disclosure of Interests: Emanuele Gotelli: None declared, Alberto Sulli Grant/research support from: Laboratori Baldacci S.p.a., Pietro Francesco Bica: None declared, Irene Schiavetti: None declared, Teresa Aloe': None declared, Marco Grosso: None declared, Emanuela Barisione: None declared, Carmen Pizzorni: None declared.
None declared, Sabrina Paolini: None declared, Vanessa Smith Grant/research support from: Boehringer Ingelheim, Janssen-Cilag, Maurizio Cubolo Grant/ research support from: Bristol-Myers Squibb, Celgene, Pfizer, Boehringer Ingelheim

AB1161
COVID-19 IN MY RA CLINIC: DATA FROM QUESTIONNAIRE, VACCINATION, INFECTION AND FRAILTY FROM THE RA LOUVAIN BRUSSELS COHORT

V. Pirson1, T. Sokolova1, X. Theunssens1, S. Bricman1, E. Sapart1, S. DE Montjoye1, S. Dierckx2, A. Avramovska1, P. Durez1. 1Division of Rheumatology, Department of Medicine, Udine, Italy; 2Division of Rheumatology, Rheumatology, Brussels, Belgium; 3CHU Mont-Godinne, Rheumatology, Mont Godinne, Belgium

Background: Over 5 million deaths from the COVID-19 disease have been reported in the world. Patients (pts) living with rheumatoid arthritis (RA) affecting the immune system or under immunosuppressive agent are considered as a high risk population for a SARS-CoV-2 infection. Since no antiviral treatment is available, the vaccination is a major option.

Objectives: The aim of this study is to evaluate in our RA cohort a questionnaire about the COVID-19 vaccination willingness, to analyse the vaccination rate, the number of COVID infection, the RA frailty and the side effects.

Methods: We included pts with RA from the UCLouvain Brussels cohort who met the ACR/EULAR 2010 classification criteria. A simple and standard questionnaire about the vaccine willingness was distributed in 2020 before the vaccination. From January to December 21, the rate of vaccination was calculated. The number of Covid infections, RA frailty, therapy switches and side effects were also collected. All patient and RA characteristics were analyzed.

Results: 605 eligible RA pts were included. The average age of the population is 58.21 years. 72% of the patients are women. 21% are smokers and 65% are positive for anti-citrullinated protein antibody (ACPA) with a mean DAS28-CRP of 2.39 and a mean HAQ of 0.821. In 2020, 460 pts filled the questionnaire and 61% indicated they would receive the vaccine as soon as it is available. For the 179 pts (39%) who decline, the reasons for not having vaccine were no trust in the vaccine at this time (33%), fear of side effects (28%), opposition to vaccine (4%), previous SARS-CoV-2 infection (2%) and unknown (5%). Pts under the age of 50, women, low education grade, smokers, presence of RF/ACPA and treatment with a bioDMARD were less willing to receive the vaccine. In 2021, 538 pts were vaccinated and only 67 pts (11.1%) not. The majority received a mRNA vaccine (81.8%). 72 and 21 pts developed a SARS-CoV-2 infection before and after the vaccination, respectively. Among them, 5 were admitted to intensive care unit leading to 4 deaths. Only, 7 RA frailties were observed and 17 pts switched the therapy. 101 adverse events were reported. All of them were mild and transient except 2 cases with pulmonary embolism and one case with Herpes Zooster infection.

Conclusion: The SARS-CoV-2 global pandemic is responsible of many medical dramas. In our RA cohort, we observed first hesitation followed by a high rate of vaccination. The safety was reassuring with a minimal number of RA frailties and serious adverse events including only 4 deaths.

Acknowledgements: This work was supported by CAP48/RTBF.

Disclosure of Interests: None declared

AB1162
THE LINK BETWEEN INFLAMMATION AND THROMBOSIS: CLINICAL AND IMMUNOHISTOCHEMICAL CHARACTERIZATION OF PULMONARY ARTERIAL THROMBOSIS IN COVID-19 PATIENTS

L. Quartuccio1, A. Sonaglia1, L. Casarotto2, D. Mogenaglie3, C. Di Loreto2, E. Pogolo2. 1Division of Rheumatology, Department of Medicine, Udine, Italy; 2Institute of Anatomic Pathology, Department of Medicine, Udine, Italy; 3Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), National Institute for Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds, United Kingdom

Background: Coronavirus-19 disease (COVID-19) has been responsible, to date, for more than 5 million of deaths. Immunothrombosis may be a major factor contributing to mortality in COVID-19 and pulmonary arterial tree involvement that mimics multiple pulmonary embolism could be a major contributor to disease course. Immunomodulatory drugs are of some benefit but mechanism not completely clear. We investigated pulmonary arterial tree clots to better appreciate their immunothrombotic nature, in contrast to the pathological characteristics of non-inflammatory thrombi (1).

Objectives: The primary objective was to study in depth the arterial thrombosis in COVID-19, by characterizing the immunohistochemical nature of thrombi, performing macroscopic and microscopic analyses, and by comparing clinical, laboratory and anatomical-pathological data of these patients with other patients died for COVID-19 but without evidence of pulmonary arterial thrombosis.

Methods: Autopsies were performed in patients (cases) who died for COVID-19 with evidence of pulmonary arterial thrombosis at autopsy finding but without pathological signs of bronchopneumonia or peripheral venous thrombosis. COVID-19 positive patients without pulmonary arterial thrombosis were selected as control group. Hematoxilin and eosin stained slides were reviewed choosing those with visible pulmonary thrombi. Further histochemistry and immunohistochemical staining were performed in selected paraffin blocks. Each component of the thrombus was evaluated with the software application QuPath in terms of fibrin, red blood cells, platelets and immune cells percentage after scanning the slides with Aperio System. Laboratory tests were recorded at 2 points: at hospital admission and at Intensive Care Unit transfer.

Results: We included 13 patients (cases) and 14 controls, matched for age, gender and time from diagnosis to death. Twenty arterial thrombi were studied. By immunohistochemistry, arterial thrombi were composed by white blood cells (WBC) [median, IQR range: 10% (5-12.25), mainly neutrophils [58% (35.2-64.5)], red blood cells [12%, (6-34.25)], fibrin [19% [14.5-42.25]], platelets [39%, (31.75-48)] (Figure 1). Three cases had a history of previous thrombosis. All cases had received anticoagulant treatment during hospitalization, low molecular weight heparin in 12/13 (therapeutic regimen in 4/12, prophylactic in 8/12) while 1/13 continued oral anticoagulants for comorbidity. By comparing laboratory findings between cases and controls, cases showed significantly higher levels of platelet count [median, IQR range: 195000/mmc (157750-274500) vs 143500 (113000-173520), p=0.011], LDH (854 U/L (731-1315) vs 539 (391.5-660), p=0.003) at hospital admission, and D-dimer at ICU transfer [25072 FEU (6951-50531) vs 1024 (620-5501), p=0.003].

Conclusion: Pulmonary arterial thrombosis in COVID-19 is a type of immune-mediated inflammatory thrombosis, since the amount of WBC is 6-times more than normal value seen in non-inflammatory thrombi. Some markers of inflammation, necrosis and coagulation are much more increased in this subset of patients. Chest CT angiography rather than simple CT scan at hospital admission could be more useful in this setting, and treatments with antiplatelet agents or anticoagulants, eventually in combination with immunotherapy, might positively affect the outcome.

REFERENCES:

Disclosure of Interests: None declared

AB1163
ATTITUDES AND HESITANCY IN PATIENTS WITH INFILAMMATORY RHEUMATIC DISEASES TOWARDS SARS-COV-2 VACCINATION: A SINGLE-CENTER STUDY FROM BULGARIA

T. Georgiev1,2, R. Moralyiska2, S. Bgoganova-Petrova1,2, G. Gerganov1, P. Kabakchieva1, S. Dimitrov1,2, S. Hristova1,2, T. Shvacheva1,2. 1Medical University - Varna, First Department of Internal Medicine, Varna, Bulgaria; 2University - Varna, First Department of Medicine, Varna, Bulgaria

Figure 1.

Conclusion: Pulmonary arterial thrombosis in COVID-19 is a type of immune-mediated inflammatory thrombosis, since the amount of WBC is 6-times more than normal value seen in non-inflammatory thrombi. Some markers of inflammation, necrosis and coagulation are much more increased in this subset of patients. Chest CT angiography rather than simple CT scan at hospital admission could be more useful in this setting, and treatments with antiplatelet agents or anticoagulants, eventually in combination with immunotherapy, might positively affect the outcome.

REFERENCES:

Disclosure of Interests: None declared
Sofia, Clinic of Internal Medicine, Varna, Bulgaria; "Sputnik Light" , other 65 pts received 2 doses of Gam-COVID-Vac (Sputnik V). 2 pts - Systemic sclerosis. Extraglandular manifestations of SjS were detected in out of 70 were women. The mean age was 52.5±14.6 years, the average duration

AB1165 THE ROLE OF MOLECULAR MIMICRY IN SARS-COV-2 RELATED AUTOIMMUNE RHEUMATIC DISEASES

C. Liaskos1, E. Patrikiou1, L. Komorowski2, C. Tsagaliou1, A. Tsirgianni1, L. Sakka1, D. Bogdanos1.

Faculty of Medicine, University of Thessaly University General Hospital of Larissa, Department of Rheumatology and Clinical Immunology, Larissa, Greece; 2AG Euroimmun, Immunology Experimental of Institut, Lübeck, Greece; 3Democritus University of Thrace, Alexandroupolis, Greece, Laboratory of Microbiology,Alexandroupolis, Greece; 4Evangelismos General Hospital, Athens, Greece, Department of Immunology-Histocompatibility, Athens, Greece

Background: Several studies suggested that SARS-CoV-2 infection may induce autoantibodies related to autoimmune rheumatic diseases (ARD). Objectives: To determine whether polyclonal antibodies from SARS-CoV-2 uninfected patients with ARDs co-react with SARS-CoV-2 and vice versa. Methods: 90 sera positive at high-titres for 23 common autoantibodies (all sera stored before 2018), were tested for reactivity against proteins of SARS-CoV-2 (spike protein S1, nucleocapsid NC etc) by ELISA and CMIA. 10 monoclonal antibodies against S1 protein (most of them against RBD) were tested for autoantibody reactivity by indirect immunofluorescence, ELISA, immunoblot and dot/line immunosassays coated with different antigens. Ten post-COVID sera with high titers of anti-Spike abs were tested by ELISAs for reactivity against various autoantigens related to ARDs.

Results: 88 out of 90 samples (%), were totally unreactive to SARS-CoV-2 proteins; 2 sera, one anti-CCP and one anti-CENP reacted against S protein. All sera tested negative for neutralized abs against SARS-CoV-2. None of 10 sera from SARS-CoV-2-infected patients reacted with different autoantigens by molecular assays. None of the 10 monoclonal abs against S1 protein reacted with 23 different self-antigens. On HEp2 cells as substrate for IIF, 3 of the 10 monoclonal abs against S1 protein (most of them against RBD) were tested for autoantibody reactivity by indirect immunofluorescence, ELISA, immunoblot and dot/line immunosassays coated with different antigens. Ten post-COVID sera with high titers of anti-Spike abs were tested by ELISAs for reactivity against various autoantigens related to ARDs.

Conclusion: Our data suggest that there are still possibilities to influence rheumatic patients on their decision to vaccinate against SARS-CoV-2 in Bulgaria. Raising the awareness of the safety and efficacy of the SARS-CoV-2 vaccines and spending more time on the education of patients with rheumatic diseases may positively affect their attitude towards vaccination.

REFERENCES:

Disclosure of Interests: None declared

AB1164 EFFICACY AND TOLERABILITY OF THE VACCINE AGAINST SARS-COV-2 IN PATIENTS WITH SJOGREN’S SYNDROME RECEIVING VARIOUS TYPES OF THERAPY.

A. Torgashina1, E. Sokol1, B. Chalcev1, J. Khvan1, M. Kireeva1, V.A. Nasonova Research Institute of Rheumatology, Rare Rheumatic Disease and Sjogren’s Syndrome, Moscow, Russian Federation

Background: there are some concerns among patients (pts) with rheumatic diseases regarding the tolerability and efficacy of SARS-CoV-2 vaccination. The impact effect of vaccination on the course of Sjogren’s syndrome (SjS) is not entirely clear. Objectives: to evaluate the efficacy and tolerability of the heterologous recombinant adenovirus (AdV)-based vaccine Sputnik in pts with SjS receiving various types of therapy.

Methods: single center observational retrospective study. Diagnosis of SjS was based on ACR/EULAR 2016 criteria. Rituximab (RTM) was administered in two 1000mg infusions 14 days apart for the 1st course, then 500mg every 6 months.

Results: 70 pts with a definite diagnosis of SjS were included in the study. Four, 36 and 30 were women. The mean age was 52.5±14.6 years, the average duration of the SjS was 72 (36-120) months. Three pts had concomitant RA, 3 pts - SLE - 2 pts - Systemic sclerosis. Extraglandular manifestations of SjS were detected in 35 cases. Five pts received single-dose Ad26 vector-based COVID-19 vaccine “Sputnik Light”, other 65 pts received 2 doses of Gam-COVID-Vac (Sputnik V).

Eighteen pts did not receive any immunosuppressive therapy and were vaccinated before RTM therapy. One patient of them just diagnosed with lymphoma, 8 pts had extraglandular manifestations of the SjS (hypergammaglobulinemic purpura, cryoglobulinemic vasculitis with polyneuropathy, interstitial lung disease). 20 pts at the time of vaccination received various immunosuppressive drugs: 1 - cyclophosphamide (CYP), 1 - leflunomide, 1 – Azathioprine, 3 – methotrexate, 2 - mycophenolate mofetil (MMF), 10 – hydroxychloroquine, 13 - low doses of methylprednisolone. Thirty-two pts received anti B-cells therapy with RTM. The duration of RTM therapy before vaccination was 18 (12-36) months, the period of time between the last injection of the RTM and the vaccine was on average 6 (5-8) months. B-cells level was determined in 18 pts immediately before vaccination and it was normal only in 10 pts. The level of neutralizing antibodies after vaccination was monitored in 44 pts. The level of IgG antibodies against SARS-CoV-2 was positive in 15 of 22 pts who did not receive RTM and in 10 of 22 pts who received the RTM (p<0.05). Neutralizing antibodies did not develop in 4 pts despite complete recovery of B cells. It is important that none of the vaccinated pts was infected COVID-19 within at least 6 months after vaccination. Various types of adverse reactions were observed in 8 pts. The most common was flu-like syndrome. In one case this syndrome required the prescription of dexamethasone. In 3 cases disease exacerbation occurred after vaccination. These pts had extraglandular manifestations of SjS and received immunosuppressants (CYP, MMF or RTM), 2 of them required treatment intensification, in one case the exacerbation was self-limiting.

Conclusion: vaccination against SARS-CoV-2 infection was well tolerated by pts with SjS even in the absence of immunosuppressive therapy. In most cases, there were no exacerbation of the SjS and pts could continue immunosuppressive therapy without becoming infected COVID-19.

Disclosure of Interests: None declared
Background: Since the development of COVID-19 vaccines, more than 300 million people have been immunized worldwide. Soon after vaccinations were initiated, reports on cases of myocarditis following the second vaccine dose have emerged.

Objectives: This study aims to report our experience with nine patients with post-COVID-19 vaccine myocarditis, and to compare them to a cohort of patients who presented with paediatric inflammatory multisystem syndrome (PIMS / PIMS- TS) post COVID-19 infection.

Methods: We collected all reported cases of patients who developed myocarditis following COVID 19 vaccination (Pfizer mRNA BNT162b2), from all pediatric rheumatology centers in Israel, and compared them to the cohort of patients previously diagnosed with PIMS.

Results: Nine patients with myocarditis post-vaccination were identified and compared to 78 patients diagnosed with PIMS. All patients with post-vaccination myocarditis were males who developed symptoms following their second dose of the vaccine. Patients with myocarditis post-vaccination had a shorter duration of stay at the hospital (4.4±1.9 vs. 8.7±4.7 days), less myocardial dysfunction (11.1% vs. 61.5%), and all had excellent outcomes as compared to chronic changes among 9.2% of patients with PIMS.

Conclusion: The clinical course of vaccine-associated myocarditis appears favorable, with resolution of symptoms in all the patients in our cohort. The risk–benefit decision for vaccination remains highly favorable, given the potential morbidity of patients with COVID-19, especially those with PIMS.

Disclosure of Interests: None declared


AB1167 THE USE OF ORAL AMINO-BISPHOSPHONATES AND CORONAVIRUS DISEASE 2019 (COVID-19) OUTCOMES

P. Pistillo 1, M. Rossini 2, A. Fassio 3, C. Benini 4, D. Gatil 5, G. Adami 6

University of Verona, Rheumatology Unit, Department of Medicine, Verona, Italy

Background: The determinants of the susceptibility to SARS-CoV-2 infection and severe Coronavirus Disease 19 (COVID-19) manifestations are yet not fully understood. Amino-bisphosphonates (N-BPs) have anti-inflammatory properties and have been shown to reduce the incidence of lower respiratory infections, cardiovascular events and cancer.

Objectives: We conducted a population-based retrospective observational case control study with the primary objective of determining if oral N-BPs treatment can play a role in the susceptibility to the development of severe COVID-19.

Methods: Administrative ICD-9-CM and ATC data, representative of Italian population (9% sample of the overall population), were analyzed. Oral N-BPs (mainly alendronate and risedronate) were included in the analysis. Patients treated with bisphosphonates (controls), with a random match (1:1 ratio) for age, sex and for other clinically relevant variables (presence of treatments other than bisphosphonates and hospitalizations) with all the health-assisted population without this treatment (controls).

Results: Incidence of Covid-19 hospitalization was 12.32 [95%CI 9.61-15.04] and 11.55 [95%CI 8.91-14.20], of ICU utilization due to COVID-19 was 1.25 [95%CI 0.38-2.11] and 1.42 [95%CI 0.49-2.36] and of all-cause death was 0.06 [95%CI 2.50-5.61] and 3.96 [95%CI 2.41-5.51] for oral N-BPs users and non-users, respectively (Figure 1A). Figure 1B Incidence and 95% CI of COVID-19 related events in N-BPs treated and untreated subjects with anti-osteoporotic drugs and without corticosteroids. C. Incidence and 95% CI of COVID-19 related events in N-BPs treated and untreated without previous vertebral or hip fragility fractures. D. Incidence of COVID-19 related events in bisphosphonates treated and untreated patients without previous vertebral or hip fracture without corticosteroid prescriptions.

Conclusion: In conclusion, we found that the incidence of COVID-19 hospitalization, intensive care unit (ICU) utilization and COVID-19 potentially related mortality were similar in N-BPs treated and non-treated subjects. Similar results were found in N-BPs versus other anti-osteoporotic drugs. We provided real-life data on the safety of oral N-BPs in terms of severe COVID-19 risk on a population-based cohort. Our results strongly support national and international guidelines that advocate against the discontinuation of oral bisphosphonates only for the fear of COVID-19.

Disclosure of Interests: None declared


AB1168 CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2


Hospital Universitario La Fe, Reumatología, Valencia, Spain

Background: SARS-CoV-2 infection is a public health problem due to its high contagiousness and mortality. Spectrum of symptoms ranges from no symptoms to interstitial pneumonia. Patients with rheumatic disease present an increased infectious risk, especially those treated with immunosuppressants or biologic therapy. Since the beginning of the pandemic, risk of contagion and development of complications in these patients has been questioned.

Objectives: To describe hospitalization prevalence, seroconversion, and symptoms in patients under follow-up by the rheumatology department of a tertiary hospital.

Methods: Observational, cross-sectional study conducted by phone interview including patients with different diagnosis of rheumatic diseases. Data about symptoms, hospital admission, serology by ELISA (when >15 days of evolution), diagnosis and baseline treatment, from March 2020 to February 2021 were collected.

Results: Eighty-six patients with different rheumatic diseases and positive COVID-19 PCR were included (82.35% women) in Table 1. Mean age was 49.30 years (16.16). The 48.71% received biological therapy, JAK inhibitors or apremilast, with a median of 3.11 years (Q1 1.08; Q3 3.17), Secukinumab was the biological therapy most often used (24.32%), followed by Tocilizumab (13.51%). The 34.18% received DMARDs or immunosuppressors, with a median of 5.09 years (Q1 12.25; Q3 11.09). The most frequent symptoms were asthma (72.15%), headache (66.23%) and cough (59.49%). Nine patients (11.25%) were admitted to hospital, eight of them (10%) for pneumonia. Three of them were admitted to intensive care and one died.

Table 1.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>24%</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>16%</td>
</tr>
<tr>
<td>Ankylosing spondilitis</td>
<td>16%</td>
</tr>
<tr>
<td>Systemic erythematosus lupus</td>
<td>8%</td>
</tr>
<tr>
<td>Juvenile idiopathic arthritis</td>
<td>8%</td>
</tr>
<tr>
<td>Systemic sclerosis</td>
<td>7%</td>
</tr>
<tr>
<td>Behcet disease</td>
<td>5%</td>
</tr>
<tr>
<td>Sjogren syndrome</td>
<td>5%</td>
</tr>
<tr>
<td>Mediterranean fever</td>
<td>3%</td>
</tr>
<tr>
<td>Sarcoidosis</td>
<td>3%</td>
</tr>
<tr>
<td>Granulomatosis with polyangitis</td>
<td>1%</td>
</tr>
<tr>
<td>Mixed connective tissue disease</td>
<td>1%</td>
</tr>
<tr>
<td>Leucoclastic vasculitis</td>
<td>1%</td>
</tr>
<tr>
<td>Rhupus</td>
<td>1%</td>
</tr>
<tr>
<td>Rheumatic polymyalgia</td>
<td>1%</td>
</tr>
<tr>
<td>Dermatomyositis</td>
<td>1%</td>
</tr>
<tr>
<td>Cutaneous panarteritis</td>
<td>1%</td>
</tr>
</tbody>
</table>
Seroconversion occurred in 53.25%. low IgG titers were present in 2.94% and IgM persisted positive in 56.25% of this group. In 6.45% the result was indeterminate.

Conclusion: Hospitalization and mortality rate obtained was low and the most frequent symptoms were mild. Seroconversion occurred in more than 50% of patients and the result of 6.45% was indeterminate. It's important to highlight that since March 2020 to May 2020 IgG positive prevalence was 25%, while since September 2021 to February 2021, this prevalence increased until 57.45%.

This difference is due to a modification of autoantibody detection technique since summer 2020.

Disclosure of Interests: None declared


**AB1169**

**IMMUNODIMODULATORY EFFECTS OF SARS-COV-2 VACCINATION: INCREASE OF REGULATORY T CELLS AFTER MRNA VACCINE**

P. La Gualiana1, F. Villani1, G. Cusano1, L. Gragnani2, L. Stefanini3, S. Santini2, S. Basili1, M. Casato1, M. Fiorilli1, M. Visentini1, Sapienza University of Rome, Department of Translational and Precision Medicine, Rome, Italy; University of Florence, Department of Experimental and Clinical Medicine, Rome, Italy; Catholic University School of Medicine, Department of Basic, Clinical, Intensive and Perioperative Biotechnological Sciences, Rome, Italy.

**Background:** Besides the ability to induce antigen-specific responses, vaccines can be endowed with immunomodulatory properties including the capacity to induce or downregulate regulatory T cells (Treg) that suppress adaptive and autoreactive immune responses (1).

**Objectives:** We asked if an anti-SARS-CoV-2 mRNA vaccine could also induce an accumulation of Treg cells in patients with mixed cryoglobulinemia vasculitis (MCV), who have a deficiency of Treg cells (2) and in healthy individuals. We also investigated immunologic variables possibly associated with a low immunogenicity of SARS-CoV-2 mRNA vaccine in patients with MCV (3).

**Methods:** We analyzed peripheral blood lymphocyte subpopulations and anti-SARS-CoV-2 serological response in 24 patients with MCV and 9 Healthy donors (HD) before and after 2 weeks after the second dose of the Pfizer/BioNTech vaccine.

**Results:** Among MCV patients we found 15 serological responders and 9 non-responders. All 5 seronegative patients treated recently with rituximab had <5 B cells/μL, whereas the absolute B cell count was increased in 2 of 4 untreated patients due to monoclonal B cell lymphocytosis, with monoclonal cells representing more than 90% of B cells, associated with non-Hodgkin lymphoma. The percentage of pathologic CD21low B cells was significantly increased in seroreactive patients. Before receiving the Pfizer/BioNTech vaccine, patients with MCV had a significantly reduced frequency of Treg cells among CD4+ T cells compared to HD. After the second dose of the vaccine, there was in MCV patients a significant increase in the percent and absolute count of Treg among CD4+ T cells Concerning the pre-vaccination distribution of T cells subpopulations, including the percentages and absolute counts of total CD3+, CD4+, CD8+, HLA-DR+ activated, Treg or CD56+ natural killer T cells, we could not reveal any pattern significantly associated with lack of serological response to vaccine.

**Conclusion:** Our findings show that lack of immunoreactivity in patients with MCV may be associated with expansion of pathologic B cells and that anti-SARS-CoV2 mRNA vaccine may induce an increase of Treg cells.

**REFERENCES:**


Disclosure of Interests: None declared


**AB1170**

**IMPACT IN PRENATAL EVALUATION OF PREGNANT WOMEN WITH RHEUMATIC DISEASES BY THE SARS-COV2 PANDEMIC**

A Y. Luiano Negrete1, M. E. Corral Trujillo1, C. M. Skinner Taylor1, L. Pérez Barbosa1, A. Aguilar-Leal1, D. C. Rodriguez-Ruiz1, L. G. Espinosa Banuelos1, A. Cárdenas1, D. A. Galarza-Delgado1. Hospital Universitario “Dr. José Eleuterio González”, Rheumatology, Monterrey, Mexico

**Background:** Due to the SARS-CoV-2 pandemic, an increase in stress, anxiety, and depression has been seen, as well as greater use of substances and a decrease in prenatal care in pregnant women. (1) Women of childbearing age with autoimmune rheumatic diseases (ARDs) experience greater psychological stress, which can negatively influence behavior. (2)

**Objectives:** This study aims to compare changes in prenatal laboratory and ultrasound tests by trimester, as well as the detection of anxiety and depression in pregnant women with ARDs due to the SARS-CoV-2 pandemic.

**Methods:** This study was carried out on pregnant patients with ARDs from the Pregnancy and Rheumatic Diseases clinic of the rheumatology department of the University Hospital “Dr. José Eleuterio González” during the period from February 2018 to August 2021. Two standardized evaluations of anxiety and depression were carried out using the Inventory of Trait and State Anxiety (iDARE) and the Edinburgh Postpartum Depression Scale (EPDS) respectively in the third trimester of pregnancy. Maternal report of alcohol consumption among any trimester of pregnancy, as well as adherence to routine laboratory studies such as structural ultrasound and gestational diabetes screening, was addressed. Positive COVID-19 nasopharynx PCR results were evaluated during pregnancy beginning in the pandemic period (March 2020). The pre-pandemic recruited group was compared with the pandemic group. The comparison of the groups was carried out using the Chi-Square and Fisher tests. A significant value of p < 0.05 was considered. Statistical analysis was performed using the IBM SPSS v.25 program.

**Results:** 50 pregnant patients with ARDs were recruited, of which 24 were included in the pre-pandemic group and 26 in the pandemic group. Compared with the pre-pandemic group, pregnant women recruited during the pandemic had a statistically significant higher positivity for state anxiety (p=0.023), likewise trait anxiety, depression, and suicidal ideation were detected more frequently, but the difference was not statistically significant, a higher rate of adherence to laboratory and cabinet studies was found, being significant for laboratories performed in the 1st and 2nd trimesters (0.005 and 0.025 respectively). See Table 1.

**Table 1. Characteristics of pregnant women with autoimmune rheumatic diseases before and during the SARS-CoV-2 pandemic.**

<table>
<thead>
<tr>
<th>Measure</th>
<th>Before pandemic n=24</th>
<th>During pandemic Covid Negative n=22</th>
<th>During pandemic Covid Positive n=4</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPDS Positive depression detection (&gt;10)</td>
<td>16.7%</td>
<td>36.4%</td>
<td>50%</td>
<td>0.197</td>
</tr>
<tr>
<td>EPDS Positive state anxiety detection (&gt;15)</td>
<td>16.7%</td>
<td>0%</td>
<td>25%</td>
<td>0.099</td>
</tr>
<tr>
<td>IDARE Positive trait anxiety detection (&gt;45)</td>
<td>8.3%</td>
<td>13.6%</td>
<td>50%</td>
<td>0.204</td>
</tr>
<tr>
<td>IDARE Positive trait anxiety detection (&gt;45)</td>
<td>8.3%</td>
<td>13.6%</td>
<td>50%</td>
<td>0.204</td>
</tr>
<tr>
<td>Any alcohol consumption during pregnancy</td>
<td>20.8%</td>
<td>4.5%</td>
<td>0%</td>
<td>0.176</td>
</tr>
<tr>
<td>Structural Ultrasound – Mid-Pregnancy</td>
<td>66.7%</td>
<td>95.5%</td>
<td>100%</td>
<td>0.025</td>
</tr>
<tr>
<td>Gestational diabetes screening</td>
<td>75%</td>
<td>86.4%</td>
<td>100%</td>
<td>0.376</td>
</tr>
<tr>
<td>Laboratories</td>
<td>20.8%</td>
<td>50%</td>
<td>0%</td>
<td>0.005</td>
</tr>
<tr>
<td>First trimester</td>
<td>45.8%</td>
<td>72%</td>
<td>100%</td>
<td>0.025</td>
</tr>
<tr>
<td>Second quarter</td>
<td>58.3%</td>
<td>81.8%</td>
<td>75%</td>
<td>0.216</td>
</tr>
</tbody>
</table>

**DISCLOSURE:** State and Trait Anxiety Inventory, EPDS= Edinburgh Postpartum Depression Scale. A Chi-square test for categorical variables or Fisher's exact test where the expected cell n

**Conclusion:** A higher frequency of positivity for state anxiety was demonstrated in pregnant women with ARDs recruited during the pandemic, as well as higher trait anxiety, depression, and suicidal ideation, although this increase was not statistically significant. On the other hand, concern about the pandemic and health status could positively influence better adherence to screening and routine studies during pregnancy.

**REFERENCES:**


Disclosure of Interests: None declared

The severe systemic inflammation in COVID-19 causes respiratory symptoms, fever, fatigue, neurological and gastrointestinal manifestations. **Objectives:** We followed the evolution of SARS-CoV-2 infection in rheumatoid arthritis patients who received anti-TNF blockers. **Methods:** Our study included 95 rheumatoid arthritis patients who were diagnosed with SARS-CoV-2 infection through a positive RT-PCR-SARS-CoV-2 test. **Results:** 21 patients were men and 74 were women. Mean age was 58 ± 11.5. 24 patients received monotherapy with anti TNF blockers (Adalimumab/ Infliximab), 48 received TNF blockers in combination with Methotrexate (10mg per week) and 13 received TNF blockers in combination with Leflunomide (20mg per day). We followed serum ferritin, C reactive protein and D-dimer in all patients. 59 patients were vaccinated with two doses of Pfizer-BioNtech (64.1 %). The study group was analyzed from 30th December 2021 to 1st of January 2022. From 95 patients, 35 (36.8%) were hospitalized and 60 received ambulatory care. **Results:** Our patients with COVID-19 presented with asimptomatic forms, forms with mild symptoms and complicated forms that required hospitalization. No patients had died. Milder forms were associated with the use of TNF blockers and Methotrexate and patients with monotherapy – TNF blockers. They presented with mild symptoms (fever, arthralgia, odynophagia, dysgeusia/ageusia, anosmia). Hospitalization rate in patients who received monotherapy with TNF blockers was 29.1%, 31.2% in patients who received TNF blockers and Methotrexate and 56.5% in patients with TNF blockers and Leflunomide (69.3%). Factors associated with higher odds of hospitalization included older age (p=0.001), active disease (p=0.02), obesity (p=0.005), pulmonary chronic disease (p=0.02), diabetes (p=0.001) and concomitant dose of Leflunomide (p=0.0006). Female sex was associated with milder forms of the disease. Patients with high levels of D-dimer had a higher odds of hospitalization (p=0.001). Strong positive correlation was observed between elevated D-dimers and hospitalization odds. **Conclusion:** TNF blockers in monotherapy or associated with Methotrexate were correlated with lower odds of hospitalization and milder forms of COVID-19. No significant difference of hospitalization odds was observed between vaccinated and unvaccinated patients.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-e4710

---

**AB1172 POSTER:** SARS-COV 2 INFECTION AND ANTI TNF THERAPY IN RHEUMATOID ARTHRITIS PATIENTS

1Central Military Emergency University Hospital “Dr Carol Davila”; Department of Internal Medicine, Bucharest, Romania; 2Central Military Emergency University Hospital “Dr Carol Davila”; Department of Internal Medicine, Bucharest, Romania; 3Central Military Emergency University Hospital “Dr Carol Davila”; Department of Internal Medicine, Bucharest, Romania; 4Central Military Emergency University Hospital “Dr Carol Davila”; Department of Internal Medicine, Bucharest, Romania

**Background:** High levels of tumor necrosis factor (TNF), a key proinflammatory cytokine, is associated with SARS-CoV-2 infection. In rheumatoid arthritis patients with SARS-CoV-2 infection, anti TNF therapy reduces not only TNF but other cytokines responsible for high morbidity and mortality.

**Methods:** Our study included 95 rheumatoid arthritis patients who were diagnosed with SARS-CoV-2 infection through a positive RT-PCR-SARS-CoV-2 test. **Results:** 21 patients were men and 74 were women. Mean age was 58 ± 11.5. 24 patients received monotherapy with anti TNF blockers (Adalimumab/ Infliximab), 48 received TNF blockers in combination with Methotrexate (10mg per week) and 13 received TNF blockers in combination with Leflunomide (20mg per day). We followed serum ferritin, C reactive protein and D-dimer in all patients. 59 patients were vaccinated with two doses of Pfizer-BioNtech (64.1 %). The study group was analyzed from 30th December 2021 to 1st of January 2022. From 95 patients, 35 (36.8%) were hospitalized and 60 received ambulatory care. **Results:** Our patients with COVID-19 presented with asimptomatic forms, forms with mild symptoms and complicated forms that required hospitalization. No patients had died. Milder forms were associated with the use of TNF blockers and Methotrexate and patients with monotherapy – TNF blockers. They presented with mild symptoms (fever, arthralgia, odynophagia, dysgeusia/ageusia, anosmia). Hospitalization rate in patients who received monotherapy with TNF blockers was 29.1%, 31.2% in patients who received TNF blockers and Methotrexate and 56.5% in patients with TNF blockers and Leflunomide (69.3%). Factors associated with higher odds of hospitalization included older age (p=0.001), active disease (p=0.02), obesity (p=0.005), pulmonary chronic disease (p=0.02), diabetes (p=0.001) and concomitant dose of Leflunomide (p=0.0006). Female sex was associated with milder forms of the disease. Patients with high levels of D-dimer had a higher odds of hospitalization (p=0.001). Strong positive correlation was observed between elevated D-dimers and hospitalization odds. **Conclusion:** TNF blockers in monotherapy or associated with Methotrexate were correlated with lower odds of hospitalization and milder forms of COVID-19. No significant difference of hospitalization odds was observed between vaccinated and unvaccinated patients.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-e4710
**Results:** A total of 300 patients were interviewed and 69 (23.0%) reported confirmed anti-SARS-CoV infection and 5 (1.7%) had a second infection. Among known infected patients, 18.6% needed hospitalization and oxygen support, 72% were admitted at ICU, and 5.8% died. After COVID-19 infection, 31.8% reported disease activity but only 6.1% had modification in medication due to disease activity. Distribution of cases followed the pattern of waves observed in Brazil (Figure 1). Regarding vaccination, 285 (95%) reported to have received at least one dose of any anti-SARS-CoV-2 vaccine. 43% received the first with the adenovirus ChAdOx1 nCoV-19 (AstraZeneca) adenovirus vaccine, 32% received the Sinovac-CoronaVac inactivated vaccine, 22% received the BNT162b2 (Pfizer-BioNTech) mRNA vaccine and 3% received the BNT162b2 (Pfizer-BioNTech) adenovirus vaccine. Almost all (98.1%) of these patients had already received the second dose of vaccine and after the first and second vaccine doses, 6% and 4% of patients, respectively, reported worsening of articular disease activity, while, after the third dose, no patient reported disease activity worsening.

**Conclusion:**

During the pandemics, patients with inflammatory arthritis had a pattern of distribution of cases very similar to general population. Adherence to vaccination is high and well tolerated.

**REFERENCES:**


**Disclose of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4722

---

**Table 1**

<table>
<thead>
<tr>
<th>All pts</th>
<th>Female n (%)</th>
<th>Male n (%)</th>
<th>RA n (%)</th>
<th>SpA n (%)</th>
<th>CTD n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local reactions</td>
<td>241 (63.93)</td>
<td>172 (63.95)</td>
<td>69 (63.77)</td>
<td>53 (60.92)</td>
<td>46 (63.89)</td>
</tr>
<tr>
<td>- Pain</td>
<td>154 (60.7)</td>
<td>108 (62.79)</td>
<td>46 (63.77)</td>
<td>53 (60.92)</td>
<td>45 (62.50)</td>
</tr>
<tr>
<td>- Swelling</td>
<td>4 (1.66)</td>
<td>3 (1.74)</td>
<td>1 (1.45)</td>
<td>1 (1.15)</td>
<td>2 (2.78)</td>
</tr>
<tr>
<td>Constitutional symptoms</td>
<td>152 (54.77)</td>
<td>98 (56.98)</td>
<td>34 (49.28)</td>
<td>46 (52.87)</td>
<td>38 (52.78)</td>
</tr>
<tr>
<td>- Fatigue</td>
<td>75 (31.12)</td>
<td>58 (33.72)</td>
<td>17 (24.64)</td>
<td>25 (38.74)</td>
<td>21 (29.17)</td>
</tr>
<tr>
<td>- Headache</td>
<td>20 (8.05)</td>
<td>13 (7.56)</td>
<td>7 (15.94)</td>
<td>10 (19.23)</td>
<td>6 (8.05)</td>
</tr>
<tr>
<td>- Muscle pain</td>
<td>37 (15.35)</td>
<td>28 (16.86)</td>
<td>9 (13.04)</td>
<td>14 (22.68)</td>
<td>10 (13.89)</td>
</tr>
<tr>
<td>- Joint pain</td>
<td>14 (5.71)</td>
<td>9 (5.1)</td>
<td>5 (8.7)</td>
<td>4 (6.6)</td>
<td>5 (7.11)</td>
</tr>
<tr>
<td>Gastrointestinal symptoms</td>
<td>19 (7.88)</td>
<td>14 (8.14)</td>
<td>5 (7.25)</td>
<td>7 (8.05)</td>
<td>8 (11.11)</td>
</tr>
<tr>
<td>- Nausea</td>
<td>17 (7.05)</td>
<td>13 (7.56)</td>
<td>4 (5.8)</td>
<td>5 (7.57)</td>
<td>5 (6.64)</td>
</tr>
<tr>
<td>- Vomiting</td>
<td>1 (0.41)</td>
<td>1 (0.58)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>- Diarrhea</td>
<td>3 (1.24)</td>
<td>2 (1.16)</td>
<td>1 (1.45)</td>
<td>2 (3.33)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>- Constipation</td>
<td>25 (10.0)</td>
<td>14 (8.05)</td>
<td>11 (15.85)</td>
<td>15 (25.8)</td>
<td>5 (6.94)</td>
</tr>
<tr>
<td>- Lymphoadenopathy</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (2.07)</td>
<td>4 (2.33)</td>
<td>1 (1.45)</td>
<td>2 (3.33)</td>
<td>1 (1.39)</td>
</tr>
<tr>
<td>None</td>
<td>42 (17.43)</td>
<td>29 (16.86)</td>
<td>13 (19.23)</td>
<td>19 (21.84)</td>
<td>21 (29.17)</td>
</tr>
</tbody>
</table>

**Table notes:** RA: Rheumatoid Arthritis; SpA: Spondyloarthritides; CTD: Connective Tissue Diseases; Other: comprising reports of increased heart rate, visual disturbances, conjunctival hyperemia, transient hyperglycemia.

**Conclusion:** Vaccination with two doses of BNT162b2 was safe and generally well tolerated. No reports of signs or symptoms of disease reactivation were found in our cohort.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4736

---

**AB1175**

**EFFECTS OF THE COVID-19 DISEASE ON AXIAL SPONDYLOARTHITIS DISEASE FLARE**

B. Armanag1, E. Atalar2, B. Ozdemir3, O. Karsak3, E. Kayacan Erdogan4, S. C. Gullen1, I. Dogan5, O. Kucuk6, A. Erden7, A. Ankara City Hospital, Rheumatology, Ankara, Turkey; 2Ankara Yildirim Beyazit University, Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey

**Background:** Rheumatological disease flares may be seen after many infections. However, our knowledge for the post-COVID axial spondyloarthritides (SpA) flares and its related factors is limited.

**Objectives:** We aimed to evaluate disease activity and factors that may be associated with disease activity in axial SpA patients in post-COVID period.

**Methods:** We retrospectively assessed the axial SpA patients who have had COVID-19 disease confirmed by a positive SARS-CoV-2 polymerized chain reaction (PCR) test result. Demographics, comorbid diseases, active medical treatments for SpA and information regarding COVID-19 clinical courses were collected from medical records. PCR positive patients were reached via telephone and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scored for pre- and post-COVID SpA symptoms. An increase of ≥2 points in the BASDAI score was defined as flare, and SpA groups with and without flare were compared. Factors predicting SpA flare were also analyzed by the logistic regression analysis.

**Results:** A total of 48 axial SpA patients were included in our study, 65% of them male and the means±SD age was 42.3±8.6 years. Post-COVID SpA flare was seen in 38% patients. Demographic, clinical, medical features of the SpA patients and COVID-19 disease severity were similar between Flare and No-flare groups. In comparison of the COVID-19 symptoms, although most of the...
COVID-19 related symptoms were similar between two groups, the frequency of the back pain and diarrhea were higher in the Flare group than No flare group. But in multivariate analysis, only history of the inflammatory bowel disease had an increased risk for post-COVID SpA flare (Table 1).

### Table 1. Results from adjusted logistic regression model of the spondyloarthritis flare

<table>
<thead>
<tr>
<th>Variables</th>
<th>Enter Method OR 95% CI p</th>
<th>Backward:Conditional Method OR 95% CI p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking</td>
<td>0.125 0.031-1.233 0.075</td>
<td></td>
</tr>
<tr>
<td>Multimorbidity</td>
<td>0.244 0.047-1.256 0.091</td>
<td></td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>33.221 1.236-892.70 0.023</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>1.582 0.334-7.486 0.563</td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>3.438 0.233-50.630 0.368</td>
<td></td>
</tr>
<tr>
<td>Back pain</td>
<td>1.054 0.080-13.895 0.988</td>
<td></td>
</tr>
</tbody>
</table>

OR: Odds ratio; CI: Confidence Interval

### Conclusion:
The presence of inflammatory bowel disease statistically significant related post-COVID SpA flares. In addition, diarrhea and back pain symptoms in COVID-19 disease may be stimulating factors for SpA flares but we found no effect of rheumatological therapies.

### Disclosure of Interests:
None declared

### DOI:

### AB1176

**DOES VACCINATION AND VARIANTS AFFECT THE COURSE OF THE COVID-19 IN INFLAMMATORY RHEUMATIC DISEASE?**

S. Celis1, M. E. Kutu1, B. Karadeniz2, M. Soy3, B. Barıkoy Dr Sadi Konuk Educational and Research Hospital, Rheumatology, İstanbul, Turkey; 1Atımbas University Medicine Faculty, Rheumatology, İstanbul, Turkey

### Background:
Although there have been expansion of knowledge about the course of COVID-19 in rheumatologic diseases, it still remains unclear the effect of vaccination status and variants on the disease course.

### Objectives:
We aimed to investigate the general clinical characteristics of our patients with inflammatory rheumatic disease (IRD) who had COVID-19 disease, their vaccination status and the time periods in which different variants were dominant during the disease.

### Methods:
During the routine follow-up of our patient’s with IRD, whether the patients had COVID-19 disease, when they were vaccinated (Pfizer/Biontech or Sinovac in our Country) and main clinical characteristics and their comorbid diseases were recorded. The last patient was included in the study on January 25, 2022. They were divided into those who received insufficient or no vaccine and those who received a full dose of vaccine. The patients were divided into 3 groups according to the period they had the disease: Those who had the disease between March 2020 and June 2021, accepted as “1st period patients”; the period when the Alpha and Beta variants, the initial forms of the disease, were dominant variants in populations; those who had the disease between July 2021 and December 2021, when the Delta variant dominated the World and in our country accepted as “2nd period patients”; and those who had the disease in December 2021 and later, when the Omicron variant was dominant throughout the world and in our country, was accepted as “3rd period” patients.

### Results:
Total 463 (294 woman) IRD patients enrolled to the study. Distribution of these patients included Behçet’s syndrome-15; familial Mediterranean fever-57, rheumatoid arthritis-134, Sjögren’s syndrome-24, systemic lupus erythematosus-28, Spondyloarthritides-141, necrotising vasculitis-6 and Others-50 cases. Mean age of patients were 46±13.2 (18-83) years. 354 (77%) of our patients got sick in the 1st period, 80 (17%) in the 2nd period and 28 (6%) in the 3rd period. When patients were compared in terms of their clinical complaints in these periods, dyspea was significantly higher in patients in the 1st period (1st period 36% vs 3rd period 18%; p<0.039), but there was no difference between other complaints including lung involvement and the frequency of hospitalization (p>0.05). 53% of patients had received at least 2 doses of mRNA vaccine. 84% of the patient had had COVID19 before full vaccination with any valid vaccine. When the patients who were full vaccinated and those who were not vaccinated were compared in terms of clinical features, lung involvement frequency and hospitalization frequency, no difference was found between them (p>0.05, for all). However, hospitalization and lung involvement were less in those who received a booster dose of any valid vaccine (p:0.03). While the average hospitalization rate was 17% for all groups, this rate was 50% for necrotizing vasculitis and was significantly higher (p<0.005).

### Conclusion:
Consistent with research on female sexuality during the pandemic among healthy women, we found that patients with rheumatic conditions reported lower FSI values in 2021, in comparison to 2019. Our finding that the pandemic had less impact on the patient group than a healthy control group, is consistent with research on MS and IBD patients, who showed surprising resilience in the face of the Covid-19 pandemic.

### Disclosure of Interests:
None declared

### DOI:

### AB1177

**SEXUALITY, FAMILY PLANNING AND MENTAL HEALTH AMONG REPRODUCTIVE-AGE WOMEN WITH RHEUMATIC DISEASE DURING THE COVID-19 PANDEMIC**

A. Pucher1, N. Rosenberg1,2, V. Ritsch1, T. Stamm1, P. Mandl1, D. Aletaha1, K. Rosta1, 1Medical University of Vienna, Rheumatology, Wien, Austria; 2Medical University of Vienna, Obstetrics and Gynecology, Wien, Austria; 3Medical University of Vienna, Section for Outcomes Research CeMSIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Wien, Austria

### Background:
Women with rheumatic disease are more likely to suffer from sexual dysfunction, infertility, depression, and anxiety. The pandemic may have affected these constraints.

### Objectives:
To investigate the effect of the Covid-19 pandemic on sexuality, family planning and mental health in a sample of women with rheumatic disease.

### Methods:
Women aged 18-50 with a rheumatic disease and women in an age-matched healthy control group received questionnaires featuring: 1) demographic information, sexual frequency, family planning; 2) the Female Sexual Function Index (FSFI); 3) the Depression, Anxiety and Stress Scale (DASS-21); and 4) the Coronavirus Anxiety Scale (CAS). Recruitment took place 3/21-12/21. Patients with rheumatic conditions were recruited at the Vienna University Clinic (AKH) and the control group through social media. Parameters were compared between the patients and the healthy control group, and with data on sexuality from women with rheumatic disease from 2019.

### Results:
A preliminary analysis was conducted with 83 patients with rheumatic disease and 124 healthy controls. The rheumatic disease group exhibited lower levels of stress (6.46 vs. 8.36 p<0.01) and Coronavirus Anxiety (6.27 vs 7.50 p<0.01) than the control group and was less likely to report that the pandemic led to a reduction of their sexual frequency (p<0.01). The control group cited “stress” frequently the decrease of sexual frequency. The FSFI analysis revealed that patients with rheumatic disease experienced higher levels of pain (p<0.001) during sex than the control group but were more satisfied with their relationships (p<0.05). In comparison to 58 patients with rheumatic conditions, whose data was collected in 2019, the 2021 cohort reported reduced FSFI values in the domains of desire (p<0.01), arousal (p<0.05), lubrication (p<0.05), and orgasms (p<0.01).

### Conclusion:
Consistent with research on female sexuality during the pandemic among healthy women, we found that patients with rheumatic conditions reported lower FSI values in 2021, in comparison to 2019. Our finding that the pandemic had less impact on the patient group than a healthy control group, is consistent with research on MS and IBD patients, who showed surprising resilience in the face of the Covid-19 pandemic.

### Disclosure of Interests:
None declared

### DOI:
AB1179  
**CLINICAL CHARACTERISTICS OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO UNDERWENT COVID-19 IN THE REPUBLIC OF TATARSTAN**

**N. Shamsutdinova**1, S. Lapshina1, V. Mukhamadeeva1, A. Sagitova1, A. Zakirov1, L. Krasnova1, D. Abdulginariev1, R. Adbrakpov2, B. Sukhorukova3, Kazan State Medical University Hospital, Therapy, Kazan, Russian Federation; 2Kazan State Medical University, Student, Kazan, Russian Federation; 3Kazan State Medical University, student, Kazan, Russian Federation; 4Republican Clinical Hospital, Rheumatology, Kazan, Russian Federation

**Background:** The management of patients with rheumatoid arthritis (RA) and novel coronavirus infection (NCI) is a significant problem due to the insufficient evidence base on this topic.

**Objectives:** To study the features of the transferred NCI in patients with RA and its influence on the course of RA.

**Methods:** From March 2020 to January 2022, 105 patients with RA who underwent NCI with a confirmed SarsCoV2 PCR result and/or X-ray computed tomography (CT) of the lungs were followed up. The age of the patients was 62 [55; 68] years, among them females - 84.7% (89 patients). The duration of RA at the time of NCI was 11 [6.5; 173] years. RA activity before NCI was low in 14 (13.3%) patients, moderate in 70 (66.6%), and high in 21 (20%) patients. The results of clinical and laboratory examinations were evaluated during the COVID-19, 1 and 3 months after it.

**Results:** The symptoms of NCI in patients with RA were comparable in frequency and severity to the course of infection in the population. 30 (28.6%) patients had a mild course of COVID-19, 74 (70.5%) had a moderate course, and 1 had a severe course. Bilateral polyelemal pneumonia was detected in 7 (6.6%) patients. The outcome of COVID-19 in all patients is recovery. Analysis of the course of RA showed a significant increase in activity 1 and 3 months after NCI: DAS28 from baseline to COVID-19 3.59±1.13 to 4.87±1.27 points after 3 months, respectively. Of the total number of recovered patients, 38.0% of patients showed an increase in activity due to clinical and laboratory parameters. 90.4% of patients noted the persistence or appearance of symptoms after undergoing NCI for 3 months, 45.7% had a combination of more than 3 different symptoms. The most common manifestations of asthma in the form of a decrease in the quality of life (QOL) and working capacity. 90.4% of patients: significant in 58.0% of people, insignificant in 32.4% of people. There was no significant correlation between RA activity and NCI severity. The second most frequent was the increase/appearance of pain in the joints - in 86.6% of respondents: significant in 72.3%, insignificant - 14.2%. Strengthening/appearance of muscle pain and/or headache and/or dysautonomia occurred in 44.7%. Appearance/intensification of shortness of breath and a decrease in exercise tolerance were noted by 36.1% of respondents: significant in 19.0% of people, insignificant in 17.1% of people. Among them, 64.8% (24) people with moderate severity, 35.2% (13) people with asymptomatic or mild NCI. Appearance/intensification of chest pain and/or palpitations was noted by 44.7% of people.

**Conclusion:** The prevalence and course of COVID-19 in patients with RA did not differ from that in the general population. However, coronavirus infection has led to an increase in pain and an increase in RA activity, a long-term persistence of post-COVID manifestations in the form of musculoskeletal pain and asthenic symptoms with a deterioration in the quality of life. There was no significant correlation between RA activity and NCI severity. At the same time, specific respiratory symptoms occurred only in a third of patients.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4939

---

AB1180  
**COVID-19 HAD DISPROPORTIONATE IMPACTS ON RA SYMPTOMS AND FUNCTION BY AGE AND SEX: RESULTS FROM THE CANADIAN EARLY ARTHRITIS COHORT (CATCH)**

S. J. Bartlett1, O. Scheier1, M. F. Valois2, D. Tim3, E. Keystone4, L. Bessette5, J. Pope6, G. Boire6, G. Hazlewood6, C. Hitchon7, C. Thorne8, V. Bykerve9, on behalf of on behalf of CATCH Investigators. McGill University & McGill University Health Centre, Clinical Epidemiology & Rheumatology, Montreal, Canada; McGill University, Clinical Epidemiology, Montreal, Canada; 2The Arthritis Program Research Group, Rheumatology, Newmarket, Canada; 3RheumKey, Rheumatology, Toronto, Canada; 4University of Laval, Rheumatology, Quebec City, Canada; 5Western University, Rheumatology, London, Canada; 6University of Sherbrooke, Rheumatology, Sherbrooke, Canada; 7University of Calgary, Rheumatology, Calgary, Canada; 8University of Manitoba, Rheumatology, Winnipeg, Canada; 9Hospital for Special Surgery, Rheumatology, New York, United States of America

**Background:** During the COVID-19 pandemic, Canadians with RA faced considerable uncertainty due to greater risk of infection, hospitalization, changing access to RA medications, and very limited access to in-person RA care. Further, to reduce transmission of the virus and COVID-related hospitalizations, stringent mitigation measures were implemented across the country to greatly reduce social contacts including curfews, limits on private gatherings and business closures. Little is known about the impact of the COVID-19 pandemic and associated mitigation efforts in RA. We hypothesized that women and younger adults with RA would report greater impairments in HRQL.

**Objectives:** To compare changes in HRQL prior-to and during the COVID-19 pandemic by sex and age groups in real-world RA patients seen in routine practice settings.

**Methods:** Data were from patients in the Canadian Early Arthritis Cohort (CATCH) who completed a study visit in the year prior to the COVID-19 pandemic (Mar 2019 through Feb 2020) and a repeat assessment during the pandemic (Mar 2020 onward). RA disease activity was assessed using the RA Flare Questionnaire, a validated patient-reported measure of current RA disease symptoms (pain, stiffness, fatigue) and function (physical, participation). An RA-FQ score ≥ 20 was used to classify RA symptoms consistent with an RA inflammatory flare. HRQL was assessed using PROMIS-29 Adult Profiles. We compared changes in mean Physical (PHS) and Mental Health (MHS) scores, and the proportion of patients with impairments in each domain (i.e., scores ≥ 5 for poor functioning, fatigue, sleep and ≥ 45 for physical function and participation) before and during the COVID-19 pandemic across sex and age groups (<40, 40-64, ≥65 years).

**Results:** The 938 CATCH participants in the analytic sample with data available at both time periods had a mean (SD) age of 60 (13) and RA symptom duration of 5.8 (3.7) years. 72% were women, 88% were white, and 64% reported > high school education. Most (80%) were in CDAI REM/LDA at the most recent visit prior to start of pandemic. The proportion of patients with RA-FQ ≥20 were similar across both time periods. While physical and emotional RA symptom impacts
remained stable in men prior to and during the COVID-19 pandemic, women reported significant increases in anxiety and depression during the pandemic period. Younger RA patients (<40 reported increases in depression, and older RA patients (>65) reported increases in anxiety and greater impacts on participation.

Conclusion: Our results illustrate that while the proportions of patients with high inflammatory disease activity were similar prior to and during the COVID-19 pandemic, we observed disproportionate impacts on HRQL by sex and age with a higher proportion of women, adults <40, and those >65 years of age experiencing greater impairments in several HRQL domains.

Acknowledgements: CATCH is supported through unrestricted research grants from: Amgen and Pfizer Canada since 2007; AbbVie since 2011; Medexus since 2013; Sandoz Canada since 2019; Fresenius Kabi Canada since 2021 and; Organon Canada since 2021. Previous funding from Janssen Canada (2011-16); UCB Canada and Bristol-Myers Squibb Canada (2011-18); Hoffman La Roche (2011-21); Sanofi Genzyme (2016-17); Eli Lilly Canada (2016-20); Merck Canada (2017-21) and Gilead Sciences Canada (2020-21).

Disclosure of Interests: None declared


Table 1. Immune-mediated inflammatory diseases diagnosed after SARS-CoV2 vaccination (N=19)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Number of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid arthritis</td>
<td>5</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>2</td>
</tr>
<tr>
<td>IgA vasculitis</td>
<td>2</td>
</tr>
<tr>
<td>Spondyloarthritis</td>
<td>1</td>
</tr>
<tr>
<td>Giant cell arteritis</td>
<td>1</td>
</tr>
<tr>
<td>Polymyalgia rheumatica</td>
<td>1</td>
</tr>
<tr>
<td>Gout</td>
<td>1</td>
</tr>
<tr>
<td>Primary biliary cholangitis</td>
<td>1</td>
</tr>
<tr>
<td>Acute disseminated lupus syndrome</td>
<td>1</td>
</tr>
<tr>
<td>Graves' disease</td>
<td>1</td>
</tr>
<tr>
<td>Ulcerative colitis</td>
<td>1</td>
</tr>
<tr>
<td>Autoimmune thrombocytopenia</td>
<td>1</td>
</tr>
<tr>
<td>Leukocytoclastic vasculitis</td>
<td>1</td>
</tr>
</tbody>
</table>

Conclusion: Our data show that post-vaccine newly diagnosed IMID may represent a challenge in clinical practice and it seems that no demographic or clinical feature is able to predict their onset. A multidisciplinary cooperation and registry data are needed in order to reliably estimate and define the impact of SARS-CoV2 vaccinations on new onset IMID.

Disclosure of Interests: None declared

CCL4 from M2 macrophages was observed when compared to control (p<0.05) (Figure 1C). In the transcriptomes from 3 AOSD patients (2 mild and 1 severe), 2 COVID-19 patients (1 mild and 1 ICU) and 2 HDs, we observed that genes involved in inflammation, lipid catabolism and monocytes activation were specifically dysregulated in AOSD and COVID-19 patients when compared to HDs. Among them pla2g15, pla2g12a, pla2g2d, involved in mobilization of SPMs precursors, were significant upregulated in patients compared to HDs (p<.01, log2FoldChange≥1.2) (Figure 1D). The largest part of the genes involved in inflammation, lipid catabolism, and monocytes activation are less expressed in AOSD patients when compared to COVID19 patients, as presented in Table 1.

### Table 1.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Log2 fold change</th>
<th>p</th>
<th>Adjusted p</th>
<th>Counts COVID19</th>
<th>Counts AOSD</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Inflammation-related genes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALOX5</td>
<td>0.98</td>
<td>0.024</td>
<td>0.21</td>
<td>16861.61</td>
<td>8562.92</td>
</tr>
<tr>
<td>IL1R1A</td>
<td>1.28</td>
<td>0.002</td>
<td>0.053</td>
<td>7154.78</td>
<td>2938.95</td>
</tr>
<tr>
<td>RTN3</td>
<td>0.72</td>
<td>0.002</td>
<td>0.069</td>
<td>9948.37</td>
<td>6045.92</td>
</tr>
<tr>
<td>SSF2</td>
<td>1.05</td>
<td>6.78 E−7</td>
<td>0.00016</td>
<td>18343.86</td>
<td>8648.67</td>
</tr>
<tr>
<td><strong>Lipid catabolism genes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIBD1</td>
<td>1.68</td>
<td>0.00011</td>
<td>0.0082</td>
<td>28051.88</td>
<td>8671.3</td>
</tr>
<tr>
<td>CPYAF3</td>
<td>2.85</td>
<td>0.00034</td>
<td>0.017</td>
<td>1996.3</td>
<td>277.13</td>
</tr>
<tr>
<td>STS</td>
<td>1.53</td>
<td>0.010</td>
<td>0.036</td>
<td>1798.5</td>
<td>623.9</td>
</tr>
<tr>
<td>HADHA</td>
<td>1.4</td>
<td>0.00014</td>
<td>0.0097</td>
<td>12766.44</td>
<td>7625.38</td>
</tr>
<tr>
<td><strong>Monocytes-related genes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH2</td>
<td>1.46</td>
<td>2.48E-10</td>
<td>1.85E-07</td>
<td>9186.55</td>
<td>3340.87</td>
</tr>
<tr>
<td>CD163</td>
<td>2.37</td>
<td>9.39E-06</td>
<td>0.0014</td>
<td>66499.45</td>
<td>12870.59</td>
</tr>
<tr>
<td>MGST1</td>
<td>1.13</td>
<td>0.0026</td>
<td>0.063</td>
<td>1385.54</td>
<td>631.67</td>
</tr>
<tr>
<td>RNAS4</td>
<td>2.48</td>
<td>0.0001</td>
<td>0.0092</td>
<td>86.66</td>
<td>15.42</td>
</tr>
</tbody>
</table>

**Conclusion:** The counterbalance by SPMs during inflammation is still a largely unexplored pathway. Our study suggests that an imbalance of SPMs in autoimmune-inflammatory diseases as well as COVID-19. The modulation of SPMs as observed in our experiments, might represent a new possible therapeutic strategy during COVID-19.

**References:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.5053
Methods: Observational study, using a patient survey. Adult patients attending the rheumatology outpatient clinic between Nov 2, 2020 to Feb 13, 2021, with rheumatoid arthritis (RA), psoriatic arthritis (PsA), spondyloarthritis (SpA) or systemic autoimmune diseases (SAD), with at least 1 year from diagnosis and 1 month of treatment with conventional synthetic (cs) targeted synthetic (ts) or biological (b) disease modifying antirheumatic drugs (DMARD). Face to face or phone interviews were conducted using an ad hoc designed questionnaire that included COVID19 related questions, the 11 IEXPAC scale items (5 point Likert scale ranging from never to always) (www.iexpac.org), and 4 items (5 points, very good to very bad) of the global scale PROMIS 10 (Patient-Reported Outcomes PROM) . All questions refer to the patient’s experience during the 6 months prior to data collection.

Results: From 174 screening patients, 158 completed the survey, mainly woman (66.5%) with a median age of 60 (IQR 47-69) years. The most frequent diagnosis was RA (43%) followed by ESAP (35%), EAS (22%) and PsA (13%). 46.8% of the patients have been prescribed b or ts DMARD and 53.2% sc DMARD, 32.9% in combination. From 158, 39 persons requested healthcare for COVID-19 related symptoms and diagnosis was confirmed in 17 (10,8%). Just 2 patients required hospital admission. Clinical control and continuity of care for COVID19+ patients were carried out from their primary care center and by phone consultation. Some key results of the survey are displayed in Table 1.

Table 1. PRO and Patients' perception during COVID19 lockdown and restrictions.

<table>
<thead>
<tr>
<th>During confinement and restrictions due to covid-19, in the last 6 months</th>
<th>Responses (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Your degree of concern about the COVID19 crisis is.</strong></td>
<td><strong>High + Quite high (86.7)</strong></td>
</tr>
<tr>
<td><strong>PRO (PROMIS 10)</strong></td>
<td><strong>Very good (11,4); Good (43.7)</strong></td>
</tr>
<tr>
<td><strong>How was your health …?</strong></td>
<td><strong>Good (10,1) Good (41.1)</strong></td>
</tr>
<tr>
<td><strong>and your emotional/mental health, including mood and ability to think?</strong></td>
<td><strong>Very good (8.25) Good (49,4)</strong></td>
</tr>
<tr>
<td><strong>Your quality of life was.</strong></td>
<td><strong>Good (18)</strong></td>
</tr>
<tr>
<td><strong>Your satisfaction in performing daily tasks (home, work, family) was.</strong></td>
<td><strong>Good (55,1)</strong></td>
</tr>
</tbody>
</table>

**Accessiblity to care and medications**

- I could contact my rheumatologist whenever I needed (email, phone). **Always (73.9)**
- My rheumatologist changed my face-to-face visit for a phone call. **Yes (53)**
- I received my medication at home from the hospital pharmacy. **Yes (16)**
- I maintained the prescribed dose medication… **Yes (21)**
- At some point I modify a medication by my own decision **Yes (6)**
- Your satisfaction with the care provided from all professionals in the team was **Yes (7)**
- PREMS (IEXPAC) **Very + Quite satisfied (75)**
- Item 2. The professionals … are coordinated to offer me good healthcare **Always (34,18)**
- Item 8. They make sure that I take my medication correctly **Always (73,42)**
- Item 9. They worry about my welfare **Always (74,68)**

Conclusion: Lessons have been learned during the COVID19 lockdown and restrictions by assessing patients’ health status and patients-reported experience. Coordinated NPI such as medication monitoring and home delivery, appointment reorganization and protocolized phone visits can result in a good patient perception and medication adherence whilst receiving care in a challenging situation.

Disclosure of Interests: None declared

DURING COVID-19 PANDEMIA IN ITALIAN PATIENTS WITH DERMATOMYOSITIS AUTOIMMUNITY PROFILE AND LUNG INVOLVEMENT

Background: Dermatomyositis (DM) is a rare idiopathic inflammatory myopathy that can present with a variable spectrum of cutaneous and systemic manifestations. The prevalence of myositis-specific autoantibodies (MSAs) and disease phenotype have been documented in DM in particular in association with the development of interstitial lung disease (ILD). Ongoing studies focus on the potential role of MSAs in similarities of the pathophysiological mechanisms of COVID-19 associated ILD and that related to DM suggesting an intriguing cross talk between autoimmunity and COVID-19. Our preliminary findings support the relevant impact of lung involvement in DM. The availability of MSAs can help to stratify patients with the disease phenotype have been documented in DM in particular in association with the development of interstitial lung disease (ILD). Ongoing studies focus on the potential role of MSAs in similarities of the pathophysiological mechanisms of COVID-19 associated ILD and that related to DM suggesting an intriguing cross talk between autoimmunity and COVID-19.

Objectives: To explore clinical patterns including ILD and MSAs profile in DM patients from a population-based single-center study carried out in a Tertiary Referral Rheumatologic Clinic, SARS-CoV-2 infections and vaccination were also analysed.

Methods: We enrolled patients affected by DM classified according to 2017 EULAR/ACR criteria with a disease onset at ≥18 years referring to the Tertiary Referral Rheumatologic Clinic in Tor Vergata University Hospital in Rome (Italy). Clinical data were collected from medical records: gender, age of onset of symptoms and diagnosis, clinical features, auto-antibodies patterns (ANA, MSAs including anti-IRMA synthetase, Jo1, PL7, EJ, MDA5, NXP2, SAE, M2, and myositis-associated antibodies comprising anti-PM/ScI, Ro-52, Ku, U1RNP), pattern of lung abnormalities at thoracic CT scans, and treatments. The prevalence of SARS-CoV-2 infection and vaccination profile were also investigated.

Results: Among eligible cases (n=30), patients who completed the study (n=19) included almost entirely women (F=73.7%). The median age at disease onset was 57.4±12.4 yrs while the mean diagnostic delay resulted as 12±10 months. Skin manifestations and myalgia were the prevalent symptoms (79% and 63%, respectively) whereas dyspnea and cough occurred in a third of the cohort at DM onset. Besides the skin involvement, the decrease in pulmonary function was the main clinical manifestation at the first rheumatological referral (52.6% of cases) followed by joint pain (36.8%) and cardiovascular events (10.6%). ANA titer≥1:160 occurred in 79% of patients. All patients showed MSAs positivity with a similar distribution: a single case of double positivity was registered in a man with anti-MDA5 and -NXP2. The most common CT findings were ground-glass opacity and parenchymal band in a third of patients (32%). The entire cohort had undergone cycles of steroids from the onset of DM and during the follow-up, according to disease severity. The main used therapies were methotrexate (47%), intravenous immunoglobulin (42%) and mofetil micofenolate (31.6%). None of patients had SARS-CoV-2 infection (until December 2021). The 63% of the cohort received at least one dose of the anti- SARS-CoV-2 mRNA vaccine (BNT162b2), of which 10% had completed with the booster dose. No adverse reactions or post-vaccination DM flare were registered. A third of the cohort had not been vaccinated due to concomitant disease activity or therapies. No cases of post-COVID-19 new-onset DM were diagnosed.

Conclusion: Our preliminary findings support the relevant impact of lung involvement in DM. The availability of MSAs can help to stratify patients with acute pericarditis and its association with SAD. We must not forget the middle of the COVID pandemic, in addition to considering COVID19 or its most associated with this clinical manifestation (RA and SLE). Therefore, in pericarditis was related to SAD, in particular with the rheumatic pathologies infected, the time interval until the development of pericarditis was too long since vaccination was later in vaccinated patients, and in those who had been against COVID was initially considered, but it could not be demonstrated, since vaccination was later in vaccinated patients, and in those who had been infected, the time interval until the development of pericarditis was too long for it in order to be attributed to COVID19. Finally, in 5 of the 8 patients, pericarditis was related to SAD, in particular with the rheumatic pathologies most associated with this clinical manifestation (RA and SLE). Therefore, in the middle of the COVID pandemic, in addition to considering COVID19 or its vaccine in the differential diagnosis of acute pericarditis, we must not forget to include SAD in this diagnosis.

Table 1.

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (yr)</th>
<th>Sex</th>
<th>Underlying rheumatological disease</th>
<th>Previous treatment</th>
<th>Treatment performed</th>
<th>Pericardial effusion</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Case 1</td>
<td>23</td>
<td>Male</td>
<td>Seronegative oligoarthritis and vasculitis</td>
<td>Hydroxychloroquine</td>
<td>Colchicine Steroids Azathioprine Analgesia</td>
<td>Moderate</td>
<td>Resolution</td>
</tr>
<tr>
<td>Case 2</td>
<td>48</td>
<td>Woman</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Case 3</td>
<td>68</td>
<td>Woman</td>
<td>Seropositive RA and Sjögren syndrome</td>
<td>Leflunomide</td>
<td>Leflunomide Hydr. Chloroquine</td>
<td>Mild</td>
<td>Resolution</td>
</tr>
<tr>
<td>Case 4</td>
<td>47</td>
<td>Woman</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>RITUXIMAB</td>
<td>Moderate</td>
</tr>
<tr>
<td>Case 5</td>
<td>27</td>
<td>Male</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Severe</td>
</tr>
<tr>
<td>Case 6</td>
<td>61</td>
<td>Woman</td>
<td>SSc</td>
<td>D-penicillamine</td>
<td>D-penicillamine Steroids</td>
<td>Severe</td>
<td>Resolution</td>
</tr>
<tr>
<td>Case 7</td>
<td>68</td>
<td>Woman</td>
<td>SLE</td>
<td>Steroids</td>
<td>Azathioprine Steroids</td>
<td>No</td>
<td>Resolution</td>
</tr>
<tr>
<td>Case 8</td>
<td>71</td>
<td>Male</td>
<td>ANA+ polyarthritis</td>
<td>Steroids</td>
<td>Steroids Hydroxychloroquine</td>
<td>No</td>
<td>Resolution</td>
</tr>
</tbody>
</table>
DM for outcome and risk of potential disease complications. The impact of MSAs on ILD associated or not to COVID-19 deserve further investigations in a larger DM cohort and for a longer post-COVID-19 pandemic follow-up time.

REFERENCES:

Disclosure of Interests:
None declared

SARS-COV-2 VACCINATION WILLINGNESS AND PREDICTORS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD) AND WITHOUT CIRD
I. Andreica1, I. Roman1, X. Baraliakos1, U. Kiltz1, J. Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University, Rheumatology, Herne, Germany

Background: Recent surveys in chronic inflammatory rheumatic diseases (CIRD) showed a high degree of vaccine hesitancy. Current knowledge about patients’ attitudes towards vaccination against SARS-CoV-2 is limited.

Objectives: To assess the willingness of CIRD patients to be vaccinated against SARS-CoV-2 and to identify influencing factors compared to non-CIRD patients.

Methods: In this cross-sectional study, two cohorts of consecutively in parallel recruited patients with and without CIRD presenting to our tertiary hospital answered questions of a structured interview to assess vaccination willingness to SARS-CoV-2, experience with SARS-CoV2 in their environment and their personal history of infections and vaccinations. Vaccination willingness was assessed by a numerical rating scale (0: fully disagree; 10: fully agree). Arbitrarily defined cut-offs were used to define definite (score ≥7) and probable willingness (scores of 5 or 6) to be vaccinated. Statistical analyses were performed with appropriate tests such as Kendall-tau b.

Results: A total of 514 CIRD and 100 non-CIRD patients, mean age 54.7±12.8 and 55.6±9.8 years, were included. Definite and probable willingness to be vaccinated against SARS-CoV-2 was declared by 79.6% and 90.7% vs. 76.0% and 85.0% of CIRD and non-CIRD patients, respectively. Only 60% of CIRD patients believed that the vaccines against SARS-CoV-2 were safe, and 42% indicated to be afraid of side effects. Vaccination willingness correlated significantly with the degree of education, age, identification with a risk group for COVID-19 disease, hypertension, and the degree of information about preventable diseases. There was no correlation with the history of infections or with immunosuppressive therapy.

Conclusion: Although our results show a high willingness for vaccination against SARS-CoV-2 in both groups, there was quite some uncertainty regarding the safety and efficacy of the vaccines. Since major influencing factors were education and information about SARS-CoV-2 and COVID-19, patient education should be immediately improved.

AB1188

SARS-COV-2 VACCINATION WILLINGNESS AND PREDICTORS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD) AND WITHOUT CIRD
I. Andreica1, I. Roman1, X. Baraliakos1, U. Kiltz1, J. Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University, Rheumatology, Herne, Germany

Background: Recent surveys in chronic inflammatory rheumatic diseases (CIRD) showed a high degree of vaccine hesitancy. Current knowledge about patients’ attitudes towards vaccination against SARS-CoV-2 is limited.

Objectives: To assess the willingness of CIRD patients to be vaccinated against SARS-CoV-2 and to identify influencing factors compared to non-CIRD patients.

Methods: In this cross-sectional study, two cohorts of consecutively in parallel recruited patients with and without CIRD presenting to our tertiary hospital answered questions of a structured interview to assess vaccination willingness to SARS-CoV-2, experience with SARS-CoV2 in their environment and their personal history of infections and vaccinations. Vaccination willingness was assessed by a numerical rating scale (0: fully disagree; 10: fully agree). Arbitrarily defined cut-offs were used to define definite (score ≥7) and probable willingness (scores of 5 or 6) to be vaccinated. Statistical analyses were performed with appropriate tests such as Kendall-tau b.

Results: A total of 514 CIRD and 100 non-CIRD patients, mean age 54.7±12.8 and 55.6±9.8 years, were included. Definite and probable willingness to be vaccinated against SARS-CoV-2 was declared by 79.6% and 90.7% vs. 76.0% and 85.0% of CIRD and non-CIRD patients, respectively. Only 60% of CIRD patients believed that the vaccines against SARS-CoV-2 were safe, and 42% indicated to be afraid of side effects. Vaccination willingness correlated significantly with the degree of education, age, identification with a risk group for COVID-19 disease, hypertension, and the degree of information about preventable diseases. There was no correlation with the history of infections or with immunosuppressive therapy.

Conclusion: Although our results show a high willingness for vaccination against SARS-CoV-2 in both groups, there was quite some uncertainty regarding the safety and efficacy of the vaccines. Since major influencing factors were education and information about SARS-CoV-2 and COVID-19, patient education should be immediately improved.

Figure 1. Vaccination willingness of CIRD patients

Acknowledgements: We wish to thank all persons who participated in the current study. Furthermore, we thank Dr. Styliani Tsirami, Tanja Kobylnski and the clinical departments for assisting with recruitment of participants.

Disclosure of Interests:
None declared

AB1189

THE RISK OF FLARE UP FOLLOWING NSARS-COV2 VACCINE IN INFLAMMATORY ARTHRITIS
F. Frizzera1, F. Pettorossi1, P. De Sandre1, G. Scannel1, A. Hoxha1, 1San Bortolo Hospital, Internal Medicine Unit, Department of Medicine, Vicenza, Italy

Background: As autoimmune phenomena following anti-nSARS-CoV2 vaccine was reported in the healthy population, there is increasing concern in patients with inflammatory joint diseases regarding possible side effects and disease flare-ups.

Objectives: We set out to evaluate the possible risk of disease exacerbation and the predisposing risk factors for the flare up.

Methods: This is a single center prospective cohort study, enrolling patients attending Arthritis Clinic at San Bortolo Hospital, during a follow-up of 12 months. All patients, after obtaining informed consent, answered a 24-item questionnaire including information about nSARS-CoV2 infection, vaccination, disease activity, ongoing treatment, vaccine side effects, disease flare up and need to change therapy.

Results: A total of 109 patients, 60 (55.1%) females and 49 (44.9%) males with a mean age of 60.1 years ±12.6 SD were enrolled. Forty-three (39.5%) were affected by rheumatoid arthritis, 43 (39.5%) from psoriatic arthritis and 23 from ankylosing spondylitis. There were 19 (17.43%) nSARS-CoV2 infection, of them 3 (15.8%) need hospitalization. Ninety-five (87.2%) receive at least one shot of nSARS-CoV2 vaccine, of these 78 (82.1%) got three shots of vaccine. Vaccine-related side effects were reported in 36 (37.9%), of these 15 (41.7%) have fever, 14 (38.8%) arthralgia and 29 (80.5%) fatigue. No patients required

Table 1. Patient demographics, disease characteristics and infection history

| Age (years), mean (SD) | 54.7 ± 12.8 | 55.6 ± 9.8 | 0 | 0 |
| Therapys, (%) | 316 (81.5) | 35 (40.2) | 5 (6) | 5 (5) | 0.79 |
| History of a positive SARS-CoV-2 | 22 (4.3) | 5 (5.0) | 3 (0.6) | 5 (5) |
| History of severe infection No. (%) | 54 (10.5) | 16 (16.0) | 1 (0.2) | 0.12 |
| History of recurrent infection No. (%) | 23 (4.5) | 13 (13.0) | 3 (0.6) | 0.004 |
| Educational level, No. (%) | 50 (10.4) | 67 (69.1) | 21 (21.6) | 0.13 |
| low (< 8 years) | 275 (57.4) | 21 (21.6) | 0.13 |
| moderate (8 to 12 years) | 154 (32.2) | 0.13 |

BMI body mass index, SD standard deviation, no number, DMRD Disease Modifying Anti-Rheumatic Drugs, b biological, ts targeted synthetic, cs conventional synthetic
medication. Twenty (21.05%) of patients who receive at least one vaccine shot experienced a flare up. Nine (45%) need to change therapy. The risk of flare up was significantly associated with low disease activity/active disease in the last 12 months. p<0.009; OR 4.0; 95% CI: 1.5-11.3.

Conclusion: Overall, the nSARS-CoV2 vaccine is well tolerated in patients with inflammatory arthritis. The risk of disease flare is associated with active disease within the past 12 months. According to our results, the patients affected by inflammatory arthritis in sustained remission have no reason to hesitate to get the nSARS-CoV2 vaccination.

Disclosure of Interests: None declared


**AB1190** SOURCES OF INFORMATION ABOUT SARS-COV-2 USED BY PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES (CIRD)

I. Andreica1, I. Roman1, X. Baraliakos1, U. Kiltz1, J. Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Rheumatology, Herne, Germany

Background: Patients with chronic inflammatory rheumatic diseases (CIRD) may be at increased risk of Corona Virus Disease 2019 (COVID-19). 2 The quality of information obtained plays a crucial role for patients’ decision to be vaccinated. Knowing patients’ needs for information and which sources are used is important for the management of CIRD patients by rheumatologists and other physicians.

Objectives: To identify main sources of information on SARS-CoV-2 used by patients with CIRD and to analyze their influence on opinions and willingness to be vaccinated.

Methods: CIRD patients presenting to our tertiary rheumatology hospital were, after informed consent, consecutively included in the study once the vaccination campaign in Germany had started, to fill out a questionnaire. Next to sociodemographic and disease-specific data, vaccination willingness and knowledge regarding SARS-CoV-2 were assessed. Furthermore, patients’ sources of information and their concerns about accuracy of information were evaluated. A numerical rating scale (NRS) ranging from 0 (completely disagree) to 10 (completely agree) was used. Values between ≥7 were taken as positive answer.

Nonparametric tests and multivariate linear regression analyses were performed.

Results: In early 2021, a total of 514 patients were interviewed (Table 1). The majority (63.9 %) reported to be well-informed (NRS ≥7), whereas 18% had doubts regarding information on SARS-CoV-2. The most often used source of information was television, and only 8.6% reported to have been informed by a rheumatologist (Figure 1). About 20% of patients were no longer interested in receiving any information on SARS-CoV-2 through media. Information from rheumatologists, general practitioners, public health authorities or health related web sites did not reach 30.5% of patients. Of interest, 16% of subjectively well-informed patients were hesitant towards vaccination. As many as 43.6% of patients with doubts regarding information about SARS-CoV-2 were assessed. Furthermore, patients’ sources of information and their concerns about accuracy of information were evaluated. A numerical rating scale (NRS) ranging from 0 (completely disagree) to 10 (completely agree) was used. Values between ≥7 were taken as positive answer.

Nonparametric tests and multivariate linear regression analyses were performed.

Table 1. Sociodemographic and disease characteristics

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>54.7 ± 12.8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women, No. (%)</td>
<td>315 (61.3%)</td>
</tr>
<tr>
<td>Educational level, No. (%)</td>
<td></td>
</tr>
<tr>
<td>&lt; 8 years</td>
<td>50 (10.4%)</td>
</tr>
<tr>
<td>8-12 years</td>
<td>275 (57.4%)</td>
</tr>
<tr>
<td>&gt;12 years</td>
<td>154 (32.2%)</td>
</tr>
<tr>
<td>Occupation, No. (%)</td>
<td></td>
</tr>
<tr>
<td>Full time</td>
<td>198 (38.5%)</td>
</tr>
<tr>
<td>Part-time</td>
<td>157 (30.5%)</td>
</tr>
<tr>
<td>Housewife/husband</td>
<td>80 (15.6%)</td>
</tr>
<tr>
<td>Occupational incapacity</td>
<td>37 (7.2%)</td>
</tr>
<tr>
<td>In training</td>
<td>29 (5.6%)</td>
</tr>
<tr>
<td>Healthcare</td>
<td>7 (1.4%)</td>
</tr>
<tr>
<td>CIRD, No. (%)</td>
<td>51 (10.1%)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>192 (37.3%)</td>
</tr>
<tr>
<td>Axial spondyloarthritis</td>
<td>134 (26.1%)</td>
</tr>
<tr>
<td>Connective tissue disease and vasculitis</td>
<td>106 (22.6%)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>72 (14.0%)</td>
</tr>
<tr>
<td>Disease duration, mean (years)</td>
<td></td>
</tr>
<tr>
<td>Therapy, No. (%)</td>
<td>9.8 ± 8.9</td>
</tr>
<tr>
<td>bDMARDs</td>
<td>316 (61.5%)</td>
</tr>
<tr>
<td>tsDMARDs</td>
<td>147 (28.6%)</td>
</tr>
<tr>
<td>no DMARDs</td>
<td>33 (6.4%)</td>
</tr>
<tr>
<td>18 (3.5%)</td>
<td></td>
</tr>
</tbody>
</table>

*Number of patients

**AB1191** SAFETY PROFILE OF COVID VACCINES IN ARTHRITIS PATIENTS. A TWO-CENTERS STUDY.

V. Relia1, G. Busti1, C. Rotondo1, M. Fornaro2, R. Colla1, A. Corrado1, F. Iannone3, F. P. Cantatore1, 1Ospedali Riuniti di Foggia, Rheumatology Unit, Department of Medical and Surgical Sciences, Foggia, Italy; 2Polinomico, Bari, Rheumatology Unit, Department of Emergency and Organ Transplantations, Bari, Italy

Background: Coronavirus 19 disease (COVID-19) represents the most important pandemic of the last century. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has produced more than 170 million cases and more than 3 million deaths. Due to the easy spread of the infection and the possibility of serious clinical manifestations, the role of anti-COVID 19 vaccination is essential. Vaccines with different mechanisms of action have been developed: mRNA-based, such as Biontech-Pfizer and Moderna, and viral vectored, such as AstraZeneca and Janssen. Despite possible adverse events, benefits afforded by these vaccines significantly outweigh potential risks associated with their administration in the general population.

Objectives: This study aimed to evaluate incidence and severity of adverse events (AEs), secondary to vaccination, in patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Spondyloarthritis (SpA), immune-mediated diseases treated with immunomodulating drugs, by administering a questionnaire.

Methods: 294 patients (201 f and 93 m) were enrolled with a diagnosis of arthri- tis (RA 28%, PsA 43%, SpA 28%).

Results: Of the 294 enrolled patients, 107 underwent COVID vaccination, 73% with Biontech-Pfizer vaccine, 20% Astrazeneca and 6% Moderna. 50% of patients completed the entire vaccination cycle. 46% of patients presented AEs after the first dose of vaccine (45% of vaccinated with Biontech-Pfizer; 48% of vaccinated with Astrazeneca, 33% of vaccinated with Moderna). The most frequently observed AEs are: pain at the injection site (17%), fever (13%), headache (12%), myalgia (12%), fatigue (7.5%). Only 2.9% of patients had arthritis flares. The greatest trend of AEs was observed in patients with PsA (48%), and RA (26%). 32% of patients receiving the second dose of vaccine presented AEs (40% Moderna, 32% Biontech-Pfizer). The most frequently observed AEs after the second dose are: pain at the injection site (4.7%), fever (9%), headache (2.8%), myalgia (6%). No patient had arthritis flare after the second dose. The greatest trend of AEs was observed in patients with SpA (66%). Only 11% of patients presented AEs after the administration of both doses. Thirteen percent of patients did not follow the clinician’s recommendations for immunomodulatory drug management, provided as per ACR or SIR recommendations.

Conclusion: The incidence of adverse events in arthritis patients was in line with that of the general population, without presenting serious manifestations, such as thrombosis, and without indicating a preference on the type of vaccine.
REFERENCES:


Disclosure of Interests: None declared

AB1192
SARS-CoV-2 VACCINE IN SPONDYLOARTHROSIS PATIENTS: OVERALL MODERATE/ HIGH IMMUNOGENICITY IMPAIRED BY IMMUNOSUPPRESSANTS AND BIOLOGICAL THERAPY
C. Saad,1 M. Rodrigues Silva,2 P. Degrava Sampaio-Barros,2 J. Moraes,2 C. Goldenstein-Schainberg,2 N. Aikawa,2 E. Neves,2 S. Pasoto,2 T. Pedrosa,2 R. Kenji Aoyama,2 C. Scognamiglio Renner Araujo,2 C. Silva,2 A. C. Medeiros Ribiero,2 E. Bonta,2 Faculdade de Medicina da Universidade de São Paulo, Rheumatology, São Paulo, Brazil;2 Faculdade de Medicina da Universidade de São Paulo, Rheumatology, São Paulo, Brazil;2 Faculdade de Medicina da Universidade de São Paulo, Infectious Diseases, São Paulo, Brazil

Background: We recently reported an attenuate immunogenicity in patients with autoimmune rheumatic diseases. However, the effect of spondyloarthritis (SpA) and its treatment on COVID-19 vaccine immunogenicity remains to be determined for this group of patients. We therefore aimed to evaluate humoral immune responses to inactivated SARS-CoV-2 vaccine (CoronaVac) in patients with SpA (axial spondyloarthritis and spondyloarthritis) taking DMARDs and commonly used targeted biological therapies, compared with a control group(CG).

Objectives: Evaluate immunogenicity and safety of CORONAVAC (Sinovac, Beijing) in Spondyloarthritis (SpA) patients.

Methods: Prospective observational cohort patients diagnosed with 194 SpA and 183 CG were vaccinated with CoronaVac in two doses with a 28-days interval. 194 patients completed the study and could be paired with CG with immunogenicity analysis. Blood samples were collected in the days 0, 28 and 69 (D69) to evaluate anti-SARS-CoV-2-IgG seroconversion(SC) and presence of neutralizing antibodies (NAb) in participants with negative IgG and NAb at baseline.

Results: Patients and GC were comparable regarding age (p=0.93) and sex (p=100). Immunogenicity at D69 showed a moderate/high SC (80.2% vs 95.7%, p<0.0001) and Nab positivity (61.6% vs 82.7%, p=0.0001) in SpA but lower than CG. Factors associated with lower immunogenicity were older age (66.8 vs. 51.4;p=0.03318) and higher frequencies of prednisone (25.7% vs. 4.2%; p=0.0004), methotrexate (51.4% vs 40.1%, p=0.0016) and TNF inhibitor (TNFi) (62.9% vs 34.5%, p=0.0035). Likewise, prednisone (176% vs. 2.8%, p=0.0013) and TNFi (50% vs 33.9%; p=0.0048) were associated with diminished NAb positivity. Sulfasalazine was associated with higher SC rates (8.6% vs 26.8%, p=0.0246) and NAB positivity (13.2% vs 29.4%, p=0.0168). The multivariate analysis revealed that older age (p=0.037), prednisone (p=0.001), TNFi (p=0.016), and methotrexate (p=0.017) were independently associated with lower SC while prednisone (p=0.006) and TNFi (p=0.027) were also associated with reduced NAb response.

Conclusion: Our finding of an excellent safety and moderate/high SC rate in SpA supports the recommendation of CoronaVac vaccination. The impaired immune response in the minority of patients under immunosuppressive and biological therapy requires novel strategies to enhance antibody response in this subgroup of patients.

REFERENCES:


Disclosure of Interests: None declared

AB1193
THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING VARIOUS BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
R. Samiuqina,1 A. Dadalova,1 E. Vasilenko,1 V. Mazurov,1 North-Western State Medical University named after I.I. Mechnikov, Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care Named After E.E. Eichwald, St. Petersburg, Russian Federation

Background: With the ongoing COVID-19 pandemic, the safety of biologic disease-modifying antirheumatic drugs in patients with rheumatic disease remains an important issue.

Objectives: to assess the course of COVID-19 infection in patients with rheumatic diseases who were under observation at the North-Western State Medical University. I.I. Mechnikov in the period from March 2020 to November 2021. During this period, 198 (14.04%) cases of COVID-19 were registered out of 1389 patients included in the registries of the anticytokine therapy center. Among patients with rheumatoid arthritis who recovered from COVID-19 infection, 105 cases were registered, of which 53 patients received outpatient treatment, and 52 patients received inpatient treatment. In 76% of cases, patients received biological DMARDs in combination with synthetic DMARDs.

Results: Exacerbation of the articular syndrome was observed only in 12 (11.4%) patients with RA during COVID-19. The low percentage of exacerbations in patients with RD on the background of COVID-19 was probably associated with the use of dexamethasone at a dose of 16-32 mg, which has the ability to reduce the activity of the immune-inflammatory process in rheumatic diseases. This statement is confirmed by the fact that out of 52 patients with RA who were hospitalized for COVID-19, 16 patients (30.8%) received dexamethasone intramuscularly or intravenously, and 8 patients (15.4%) continued oral administration of this drug.

Table 1. The course of COVID-19 infection in RA patients treated with various biological DMARDs.

<table>
<thead>
<tr>
<th>Severity and outcomes of COVID-19</th>
<th>All patients (n=105)</th>
<th>Abatacept (n=11)</th>
<th>Rituximab (n=56)</th>
<th>IL-6 inhibitors (n=9)</th>
<th>TNF-alpha inhibitors (n=15)</th>
<th>JAK inhibitors (n=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No hospitalization required</td>
<td>53 (50.5)</td>
<td>3 (27.3)</td>
<td>19 (33.9)</td>
<td>8 (88.9)</td>
<td>12 (80)</td>
<td>11 (64.7)</td>
</tr>
<tr>
<td>Hospitalization without oxygen support</td>
<td>31 (29.5)</td>
<td>5 (45.5)</td>
<td>18 (32.1)</td>
<td>1 (11.1)</td>
<td>3 (20)</td>
<td>4 (23,5)</td>
</tr>
<tr>
<td>Hospitalization with oxygenation or mechanical ventilation</td>
<td>24 (22.8)</td>
<td>3 (27,3)</td>
<td>19 (33,9)</td>
<td>0</td>
<td>0</td>
<td>2 (11,8)</td>
</tr>
<tr>
<td>Death</td>
<td>5 (4,8)</td>
<td>1 (9,1)</td>
<td>4 (7,1)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Conclusion: The use of rituximab was associated with a more severe course of COVID-19, which required hospitalization in 66% of cases, compared with the group of patients treated with TNF-α inhibitors, in which hospital treatment was carried out only in 20% of cases. The introduction of blockers of co-stimulation of T-cells, IL-6 inhibitors, targeted synthetic drugs did not affect the severity of COVID-19.

Disclosure of Interests: None declared
Pain in rheumatic diseases, including fibromyalgia_
REFERENCES:

Acknowledgements: Acknowledgements to all the colleagues involved in SIR Fibromyalgia group

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.629

AB1196

INFLUENCE OF NEUROPATHIC PAIN ON THE FUNCTIONAL STATUS OF ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS


1Second City Hospital of the Ministry of Health of the Chuvash Republic, X-ray Department, Cheboksary, Russian Federation; 2N. N. Ulianov Chuvash State University, Department propedeutics of Internal Diseases, Cheboksary, Russian Federation; 3N. N. Ulianov Chuvash State University, Department of Normal and Pathological Physiology, Cheboksary, Russian Federation

Objectives: The aim of the study was to study the influence of neuropathic pain on functional status in elderly patients with rheumatoid arthritis (RA) with moderate disease activity.

Methods: Methods. The study included 115 geriatric patients who were divided into two groups. Group G1 included 80 patients (mean age 76.9 ± 9.6 years) with neuropathic pain, group G2 - 35 persons of comparable age (77.1 ± 8.6 years) without signs of neuropathic pain. Neuropathic pain was identified using the DN4 questionnaire. The RA activity in patients of both groups did not differ statistically significantly. All patients underwent a comprehensive geriatric assessment (CGA) to determine the functional status and diagnose geriatric syndromes [1]. All patients received basic anti-inflammatory drugs. Patients G1 and G2 were compared in terms of the following parameters, such as pain intensity according to a visual analogue scale (VAS, 0-100 mm), Rivermead Mobility Index (0-15), functional disorders according to International Classification of Function (ICF) (0-4), signs of anxiety and depression (HADS).

Results: According to the CGA data, senile asthenia syndrome was detected in 32 (40.2%) patients with neuropathic pain and in 10 (28.6%) patients without neuropathic pain (p = 0.035). The average number of geriatric syndromes in G1 was 6.06 ± 1.03, in group G2 - 4.5 ± 1.0 (p <0.05). Patients with G1 showed higher indices of pain severity according to VAS than in patients of the control group: 68.2 ± 10.1 and 52.1 ± 4.1 mm, respectively (p <0.001). In G1, patients had a significant decrease in mobility, in the domain «Activity and participation» in the ICF categories d450 (walking), d 540 (dressing), the indicator of dysfunction was 2.9 ± 0.3 versus 2.2 ± 0.2 (p = 0.049), there were more symptoms of anxiety and depression 56.5% and 35.2% (HADS ≥7; p <0.001), respectively.

Conclusion: Elderly patients with chronic neuropathic pain have higher signs of senile asthenia and decreased mobility and physical functioning in daily life. It is necessary to include the help of a psychologist and occupational therapist in planning the most effective comprehensive strategies for the treatment and prevention of exacerbations of neuropathic pain.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.629

AB1197

ANTIDEPRESSANTS TREATMENT AND SEVERITY OF PAIN IN RHEUMATOID ARTHRITIS PATIENTS WITH ANXIETY AND DEPRESSIVE DISORDERS

A. Abramkin1, T. Lisitsyna2, V. Seravin3, O. Serov4, S. Glukhova5, E. Nasonov6,1, V.A. Nasonova Research Institute of Rheumatology, thromboinflammation, Moscow, Russian Federation; 2Moscow Research Institute of Psychiatry, Serbsky NMRC PN MoH, Stress Disorders, Moscow, Russian Federation

Background: Anxiety and depressive disorders (ADD) significantly affect disease activity and pain modulation in rheumatoid arthritis (RA) patients. Psychopharmacotherapy (PPT) of ADD attempts to improve RA disease activity and manage pain in RA patients.

Objectives: To determine factors associated with intensive pain syndrome in antidepressants-treated RA-patients at five years endpoint.

Methods: 128 RA-patients (pts) were enrolled, 86% were women with a mean age of 47.4±11.3 (MaSD) yrs. All patients met the full ACR/EULAR 2010 criteria for RA. Disease activity was assessed using DAS28, pain severity – using Brief Pain Inventory scale (BPI). Severe Pain was defined as BPI Worst Pain Score (BPImax) from 7 to 10. 69.4% RA-pts were already taking prednisone (9 [5; 10] mg/day (Me [25%; 75%])). 84.4% - cDMARDs, 78% - bDMARDs (anti-TNF-α – 6.3%, rituximab – 1.6%). Biologic treatment duration varied from 1 to 6 years, antidepressants – from 6 to 96 weeks. ADD were diagnosed by psychiatrist in 123 (96,1%) of RA-pts in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery–Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A).

Results: At five-years follow-up pain severity was assessed in 74 out of a total of 83 patient. By univariate logistic regression, baseline age, HAQ, CRP, DAS28 and BPImax, presence of extraarticular manifestations, cardiovascular diseases, cognitive impairments and schizotypal personality disorder, lower HADS for anxiety, no remission of anxiety or depression at five years and no history of glucocorticoids usage were significantly (p≤0.3) associated with severe pain at five-years follow-up (Table 1). These variables were subjected to multivariate stepwise logistic regression. Only extraarticular manifestations at baseline (OR 4.01 (95%CI 0.96 – 16.77), p=0.057), no history of glucocorticoids usage (OR 0.19 (95%CI 0.04 – 0.56), p=0.005) and nonremission of anxiety and depressive symptoms at 5-years (OR 0.11 (95%CI 0.019 – 0.668), p=0.016) were independently associated with severe pain at 5-years follow-up (R2=0.406, sensitivity 38.5%, specificity 92.7%).

Table 1. Factors associated with severe pain at 5 years (univariate logistic regression).

<table>
<thead>
<tr>
<th>Factor</th>
<th>p</th>
<th>OR</th>
<th>95%CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>low</td>
<td>up</td>
<td></td>
</tr>
<tr>
<td>Baseline age</td>
<td>.129</td>
<td>1.047</td>
<td>.987</td>
</tr>
<tr>
<td>Baseline HAQ</td>
<td>.056</td>
<td>2.155</td>
<td>.981</td>
</tr>
<tr>
<td>Baseline DAS28</td>
<td>.075</td>
<td>1.361</td>
<td>.969</td>
</tr>
<tr>
<td>Baseline CRP</td>
<td>.151</td>
<td>1.011</td>
<td>.996</td>
</tr>
<tr>
<td>Baseline BPImax</td>
<td>.083</td>
<td>1.269</td>
<td>.970</td>
</tr>
<tr>
<td>Extraarticular manifestations at baseline (yes/no)</td>
<td>.027</td>
<td>4.278</td>
<td>1.179</td>
</tr>
<tr>
<td>Cardiovascular diseases at baseline (yes/no)</td>
<td>.259</td>
<td>2.111</td>
<td>.577</td>
</tr>
<tr>
<td>Cognitive impairments at baseline (yes/no)</td>
<td>.218</td>
<td>2.758</td>
<td>.549</td>
</tr>
<tr>
<td>Schizotypal personality disorder</td>
<td>.085</td>
<td>3.733</td>
<td>.834</td>
</tr>
<tr>
<td>HADS anxiety</td>
<td>.259</td>
<td>.904</td>
<td>.758</td>
</tr>
<tr>
<td>Anxiety and depressive symptoms remission at 5-yrs endpoint</td>
<td>.102</td>
<td>.313</td>
<td>.077</td>
</tr>
<tr>
<td>History of glucocorticoids usage (yes/no)</td>
<td>.025</td>
<td>.234</td>
<td>.066</td>
</tr>
</tbody>
</table>

DOI: 10.1136/annrheumdis-2022-eular.629
Conclusion: RA patients with severe pain should be routinely screened for anxiety and depression, and in patients with probable ADD consultation with a psychiatrist and prescription of antidepressants should be considered.

Disclosure of Interests: None declared.


AB1198 PREVALENCE AND PSYCHOPATHOLOGICAL CHARACTERISTICS OF ANXIETY AND DEPRESSIVE SYMPTOMS IN FIBROMYALGIA PATIENTS

V. Marino1, A. Pasca2, F. Galante3, M. Fabrazzo3, E. L. Di Caprio1, F. Riccio1, S. Fasano1, F. Ciccia1, R. Tirri1. 1University of Campania “Luigi Vanvitelli”, Naples, Italy; 2University of Campania “Luigi Vanvitelli”, Mental and Physical Health and Preventive Medicine, Naples, Italy

Background: Several studies reported higher depression and anxiety rates in fibromyalgia (FM) patients compared to the general population. Furthermore, dysfunctional coping strategies have been pointed to as intrinsic parts of the pathogenesis of FM.

Objectives: Our study aimed to verify the prevalence of anxiety and depressive symptoms and explore their correlation with physical symptoms as fatigue, sleep, and widespread pain in a cohort of patients diagnosed with FM. We also aimed to determine whether dysfunctional coping strategies might increase the depression and anxiety burden, besides worsening the core symptoms of FM.

Methods: We analyzed a cohort of 105 patients (median age of 53 years 6 M, 92 F) with a diagnosis of FM according to the ACR 2016 criteria. The participants were consecutively recruited from the Fibromyalgia clinic of the University of Campania “Luigi Vanvitelli”. All patients underwent a psychiatric evaluation. We assessed widespread pain by the Widespread Pain Index (WPI) and the presence of fatigue by the Symptom Severity score (SS). Sleep disorders were investigated through Pittsburgh Sleep Quality Index (PSQI). We analyzed mental alterations by Hamilton Depression and Anxiety Rating Scales (HAM-D, HAM-A), and coping strategies by Coping Orientation to Problems Experienced (COPE) Inventory. The Statistical Package for Social Sciences (SPSS) 22.0 was used; the level of significance was set at p < 0.05.

Results: All patients showed fatigue and widespread pain (100%); sleep disturbances were found in 90.5% of patients and overlapped with all sleep phases. The prevalence of anxiety associated with depression was 75.2%. We found isolated anxiety in 14.3% and isolated depression in 4.8% of patients. We further evidenced a different degree of depression: mild (50.7%), moderate (24.3%), and severe (6.5%). All patients showed depressed mood only if questioned (low tendency to spontaneous verbalization). COPE analysis showed no significant differences in the use of the three coping strategies (Problem-focused, emotion-focused, avoidance-focused). Pearson’s correlation analysis highlighted a negative relationship between problem-focused strategies and the severity of anxiety (r = -0.31, p = 0.001) and depression (r = -0.32, p = 0.001). Our analysis also highlighted a positive correlation between fatigue, sleep disturbances, widespread pain, and both anxiety and depression. The analysis of the characteristics of anxiety and depressive symptoms showed a scarce tendency to spontaneous verbalization of depressed mood and ideas of guilt, mostly limited to family relationships, and a sense of inefficaciousness conditioned by the physical symptoms of the disease. Most patients showed psychomotor agitation, psychic and somatic anxiety, poor insight. The analysis of coping strategies adopted showed a negative correlation between problem-focused strategies and anxiety-depressive symptoms, suggesting that such strategies are less frequent in FM patients with comorbid anxiety and depressive symptoms.

Conclusion: Our study confirms the high prevalence of anxiety and depressive symptoms in FM patients. A positive correlation between the pivotal symptoms and anxiety and depressive symptoms may suggest, without implying a cause-and-effect relationship, that psychiatric intervention should be considered along with rheumatologic treatment, to improve both physical symptoms and quality of life. Potentially problem-focused coping strategies may represent a target to improve anxiety and depressive symptoms.

REFERENCES:

Table 1. Correlation analysis between coping strategies and HAM-D and HAM-A total scores

<table>
<thead>
<tr>
<th>HAM-D</th>
<th>HAM-A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Problem-focused Coping</td>
<td>-0.32**</td>
</tr>
<tr>
<td>Avoidant Coping</td>
<td>0.80</td>
</tr>
<tr>
<td>Emotion Coping</td>
<td>0.14</td>
</tr>
</tbody>
</table>

**p<0.01

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1147

AB1199 THE ROLE OF THORACOLUMBAR FASCIA ULTRASOUND IN LOW BACK PAIN - IMPLICATION FOR GUIDED DRY NEEDLING

R. Bubnov1, L. Kalikia1. 1Clinical Hospital 'Phoephania', Ultrasound, Kyiv, Ukraine; 2ulrikakalika@gmail.com, Rehab, New York, United States of America

Background: Dry needling under ultrasound guidance (DN-US) is a crucial therapeutic approach for myofascial pain [1], restore muscle function and motion [2], is among prioritized methods for treatment low back pain (LBP), can be effective in rheumatic diseases. The definition ‘myo-fascial’ calls for searching trigger points (TrPs) in fascia to improve the treatment effectiveness [3]. Ultrasound examination and guided dry needling can help understanding the role of the thoracolumbar fascia (TLF), its layers function and role in development of low back pain.

Objectives: Aim was to evaluate the relevance of fascial ultrasound and guided dry needling in low back pain in particular for thoracolumbar fascia (TLF).

Methods: We included 32 patients (20 females, 21-63 years old) with myofascial low back pain, postural imbalance and DN-US protocol according to R. Bubnov [1]: muscle TrPs were identified, fine (28G) steel needle DN-US was applied. Additionally considered fascial structures for detecting areas of abnormalities (hypo- and hyper-echoic lamina) to 2-4 mm after DN. We detected higher rates of motility, increased thickness of fascial layers (up to 5-10 mm), increased thickness of fascial structures and decreased thickness of TLF. All patients showed local sensitivity during needling, local twitch response was not seen. We placed needles to the affected area in TLF, increased thickness of fascia, decreased motility of TLF.

Conclusion: Fascia dry needling is accessible and effective method for myofascial low back pain treatment, can provide additional mechanical benefit and help to maintain treatment effect. Affected fascia can be considered as relevant TrPs, specific ultrasound signs should be validated.

REFERENCES:

Disclosure of Interests: None declared.


AB1200 THE IMPACT OF THE PRESENCE OF FIBROMYALGIA ON ILLNESS PERCEPTIONS AND COPING STRATEGIES IN HIV INFECTED PATIENTS: PRELIMINARY STUDY

Y. Ulus1, O. Acar Cakan2, M. A. Karacasan3, A. Bilici4, A. Deveci4, H. C. Bliek5. 1Ondokuz Mayis University - Faculty of Medicine, Physical Medicine and Rehabilitation, Samsun, Turkey; 2Samsun State Hospital, Physical Medicine and Rehabilitation, Samsun, Turkey; 3Ondokuz Mayis University - Faculty of Medicine, Clinical Microbiology and Infectious Diseases, Samsun, Turkey

Background: Coexisting fibromyalgia syndrome (FMS) to the chronic diseases and its negative impact on global health status in these diseases has been identified. Recent treatment strategies have changed HIV from a terminal disease to a chronic condition that requires great effort because of regular treatment and periodic medical screenings. The prevalence of fibromyalgia has been reported in HIV patients as 1-17%. It was reported that greater illness perceptions are associated with dysfunctional coping strategies in HIV patients with detectable or high viral load. There are no data on illness perceptions and coping strategies in HIV patients with FMS.

Objectives: The aim of this study was to evaluate the impact of the presence of fibromyalgia on illness perceptions and coping strategies in HIV infected patients.

Methods: Data about illness perceptions by The Brief Illness Perception Questionnaire (Brief-IPQ) and coping strategies by the COPE questionnaire were collected from 79 HIV patients. FMS was determined according to 2010 ACR criteria. The Statistical Package for Social Sciences (SPSS) 22.0 was used; the level of significance was set at p < 0.05.

Results: All patients showed pain and increased rate of detectable viral load (84.9%) and asymptomatic patients as 1-17%. It was reported that greater illness perceptions are associated with dysfunctional coping strategies in HIV patients. A positive correlation between fibromyalgia and illness perceptions (r = 0.32, p = 0.01) and coping strategies (r = 0.28, p = 0.04) was also highlighted. Our analysis also highlighted a positive correlation between fatigue, sleep disturbances, and illness perceptions.

Conclusion: Fibromyalgia can be considered as relevant TrPs, specific ultrasound signs should be validated.

REFERENCES:

Table 1. Correlation analysis between coping strategies and HAM-D and HAM-A total scores

<table>
<thead>
<tr>
<th>HAM-D</th>
<th>HAM-A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Problem-focused Coping</td>
<td>-0.32**</td>
</tr>
<tr>
<td>Avoidant Coping</td>
<td>0.80</td>
</tr>
<tr>
<td>Emotion Coping</td>
<td>0.14</td>
</tr>
</tbody>
</table>

**p<0.01

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1147

1Ondokuz Mayıs University - Faculty of Medicine, Physical Medicine and Rehabilitation, Samsun, Turkey; 2Samsun State Hospital, Physical Medicine and Rehabilitation, Samsun, Turkey; 3Ondokuz Mayis University - Faculty of Medicine, Clinical Microbiology and Infectious Diseases, Samsun, Turkey

Scientific Abstracts
duration were also noted. Kolmogorov Smirnov test, chi-square test, Mann Whitney-U test, Spearman correlation analysis, and Univariate analysis of variance were used for statistical analyses.

Results: Patients were aged between 22 and 77 years, with a mean age of 44.6±3.1. Ten patients (15.6%) were diagnosed with FMS and of those 4 (30.8%) were women. Cognitive illness representations and emotional representations scores were higher in FMS patients than those without FMS (p<0.05). Disease duration, HIV-progression biomarkers (CD+ and viral load), COPE questionnaire scores, and illness comprehensibility sub scores of FMS (p<0.05). The significant effect of the presence of FMS on cognitive illness representations (p<0.001) and emotional representations (p<0.05) was found by univariate analysis of variance in patients with HIV.

Conclusion: According to the preliminary results of this study, FMS was detected 16.3% of patients with chronic pain. The presence of FMS may adversely affect perceptions of the disease in HIV-infected patients. Since the patients believe their illness is not having great importance in the patients health outcomes and the understanding of the disease, physicians should be aware of the possibility of concomitant FMS in patients with HIV.

REFERENCES:

Disclosure of Interests: None declared


AB1201

PAIN DESCRIPTORS AND DETERMINANTS OF PAIN SENSITIVITY IN KNEE OSTEOARTHRITIS: A COMMUNITY-BASED CROSS-SECTIONAL STUDY

J. E. Vriezeolk,1 Y. A. S. Peters,2 M. A. H. Steegers3,4 E. Blaney Davidson,1 C. Van den Ende1 1Sint Maartenskliniek, Rheumatology Research, Nijmegen, Netherlands; 1Sint Maartenskliniek, Rheumatology Research, Nijmegen, Netherlands; 2Amsterdam UMC, Anesthesiology, Amsterdam, Netherlands; 3Radboud University Medical Center, Anesthesiology, Nijmegen, Netherlands; 4Radboud University Medical Center, Experimental Rheumatology, Nijmegen, Netherlands

Background: The phenomenon of heightened pain sensitivity is implicated in the pain experiences of people with OA[1]. Limited research show that pain sensitivity is associated with poor health and treatment outcomes. However, epidemiological research investigating the extent and determinants of pain sensitivity in OA is scarce. In addition, the quality of pain is poorly described. Both the assessment of quality of pain and pain sensitivity can be important to inform clinical decision-making and treatment.

Objectives: To explore pain characteristics in individuals with knee osteoarthritis (KOA), to compare pain sensitivity across individuals with KOA, chronic back pain (CBP) and pain-free individuals (NP), and to examine the relationship between clinical and pain characteristics with pain sensitivity in KOA.

Methods: Cross-sectional, community-based online survey. Two datasets were combined comprising Dutch individuals of ≥ 40 years of age, experiencing chronic knee pain (KOA, N=445; dataset 1), chronic back pain (CLP, N=504; dataset 2), or no pain (NP, N=256; dataset 2). Demographic and clinical characteristics, global health, physical activity/exercise, and pain characteristics including intensity, spreading, duration, quality (SF-MPQ), and sensitivity (PSQ) were assessed. Differences between (sub)groups were examined using analyses of variance or Chi-square tests. Regression analyses were performed to examine determinants of pain sensitivity in the KOA group.

Results: Quality of pain was most commonly described as aching, tender, and tiring-exhausting in the KOA group (Figure 1). Overall, the KOA group had higher levels of pain sensitivity compared to NP group, but lower levels than the CBP group (Table 1). Univariate, pain intensity, its temporality and spreading, global health, doing exercise, and having comorbidities were weakly related to pain sensitivity (standardized beta’s: 0.12-0.27). Symptom duration was not related to pain sensitivity. Older age, higher levels of chronic pain, lower levels of global health, and doing exercise uniquely contributed, albeit modest, to pain sensitivity (P<0.05).

Figure 1. Percentage of individuals with self-reported knee OA who rated pain descriptors as moderate to severeNote: Subgroups based on median split total score Pain Sensitivity Questionnaire. *P<0.05

Table 1. Mean (SD) pain sensitivity scores across three groups

<table>
<thead>
<tr>
<th></th>
<th>KOA</th>
<th>CBP</th>
<th>NP</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSQ-total, mean (SD)</td>
<td>4.4 (1.5)</td>
<td>3.7 (2.0)</td>
<td>2.4 (1.6)</td>
</tr>
<tr>
<td>PSQ-total, mean (SD)</td>
<td>0.23</td>
<td>-0.32</td>
<td>-0.60</td>
</tr>
<tr>
<td>Difference* 95% CI</td>
<td>0.36</td>
<td>0.36</td>
<td>1.05</td>
</tr>
</tbody>
</table>

Abbreviations: PSQ=Pain Sensitivity Questionnaire, KOA=Knee OA pain group, CBP=Chronic Back Pain group, NP=Non-pain group, CKBP=KOA, NP=N=242. K Mean differences adjusted for sex and age.

Conclusion: Continuous pain such as aching and tenderness in combination with decreased physical activity may be indicative for individuals at risk for wide-spread pain and, ultimately, poor treatment outcomes.

REFERENCES:

Disclosure of Interests: None declared


AB1202

ASSESSMENT OF PAIN THRESHOLDS TO VERIFY CENTRAL SENSITIZATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS OF THE KNEE

E. Filatova1. 1VA Nasonova Research Institute of Rheumatology, Rheumatology, Moscow, Russian Federation

Background: Central sensitization in patients with rheumatoid arthritis, osteoarthritis of the knees increases the risk of comorbid disorders, the most frequent of which are depression, cognitive impairment and insomnia. Verification and timely diagnosis of central sensitization will help to improve pain control in rheumatic diseases. (1,2) Objectives: to study pressure pain thresholds in patients with rheumatoid arthritis (RA) and osteoarthritis of the knee (OA) with chronic pain.

Methods: All patients had pain intensity scores according to the VAS scale, neuropathic/neuroplastic pain severity according to the DN4 and Pain DETET questionnaires, central sensitization severity was assessed using the CSI scale. To verify the presence of central sensitization instrumentally and to confirm the presence of secondary hyperalgesia detected clinically, algometry was performed in 42 female patients with OAK and 42 patients with RA. A comparison group of 42 healthy volunteers comparable in gender and age with the patients was also selected. Using a Wagner FDK20 algometer, pressure pain thresholds for OAK in the knee joints were studied (4 points: 1st point located 2.5cm medial to the patella, 2nd point in the center of the patella, 3rd 2.5cm distal to the patella, 4th in the gastrocnemius area) and m. Trapezius (5th reference point) in all patients with OAK and controls. In the group with RA, pain thresholds were studied at 4 points: 1st - nail bed of the 1st finger, 2nd - wrist (above the extensor tendon, recruitment), 3rd - 2.5cm lateral to the knee and 4th m. trapezius (reference point) in all patients and controls.

Results: The mean age of patients with RA and OAK was 53.0 [41.0,61.0] and 61.0[57.0,63.0] years, with disease duration at the time of study of 9.0 [4.0,13.0] and 13.0[7.0,15.0] years, respectively. The DN4 questionnaire scores were 2.0 [1.0,4.0] for RA and 5.0[0.0,6.0] for OAK, and the Pain DETECT scores were 1.0.
Lower pain thresholds in patients with RA and OA were noted not only in the area of the affected joints, but also in the distant reference point, indicating the presence of secondary hyperaesthesia in these patients, which is a neurophysiological sign of central sensitization. A significant decrease in the pain threshold index was also noted in patients with central sensitization compared to those in the control groups.

Conclusion: The study of pain thresholds is one of the tools for verification of CS in patients with RA and OA, but requires further study.

REFERENCES:

Disclosure of Interests: None declared

Table 1. DAS28 and component measures in RA patients who have or do not have comorbid fibromyalgia (FM) and ratio of means in the two groups (FM+/FM-)

<table>
<thead>
<tr>
<th>STUDY</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
<th>FM+</th>
<th>FM-</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Fm28</td>
<td>ESR</td>
<td>SJC</td>
<td>TJC</td>
<td>PATGL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
<td>FM+</td>
<td>FM-</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ranzolin 2009</td>
<td>5.4, 4.0</td>
<td>1.3</td>
<td>29.25</td>
<td>1.16</td>
<td>3.5, 2.0</td>
<td>1.7</td>
<td>9.5, 3.0</td>
<td>3.2</td>
<td>76.40</td>
<td>3.0</td>
<td>66,40</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pollard 2010</td>
<td>6, 4.3</td>
<td>1.4</td>
<td>39.27</td>
<td>1.4</td>
<td>4.0, 4.0</td>
<td>1</td>
<td>176, 2.8</td>
<td>2.8</td>
<td>66,40</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Toms 2010</td>
<td>5.3, 3.7</td>
<td>1.4</td>
<td>39.4, 28.5</td>
<td>1.4</td>
<td>4.9, 3.0</td>
<td>1.6</td>
<td>14,12, 9.0</td>
<td>4.9</td>
<td>60,43, 26.0</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zammurad 2013</td>
<td>5.3, 3.9</td>
<td>1.3</td>
<td>38.9, 31.2</td>
<td>1.2</td>
<td>2.8, 17</td>
<td>1.6</td>
<td>13,14, 1.0</td>
<td>3.2</td>
<td>62,73</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nawrot 2013</td>
<td>5.6, 4.5</td>
<td>1.2</td>
<td>38, 24.18</td>
<td>0.9</td>
<td>2.8, 3.0</td>
<td>0.9</td>
<td>12,3, 4.5</td>
<td>2.7</td>
<td>38,24, 18.0</td>
<td>0.9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gihb 2010</td>
<td>5.6, 4.6</td>
<td>1.2</td>
<td>23, 22.2</td>
<td>1.1</td>
<td>5.0, 6.0</td>
<td>0.8</td>
<td>15,5, 5.5</td>
<td>2.7</td>
<td>66,44, 5.0</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Johannsen 2015</td>
<td>4, 8, 4.4</td>
<td>1.1</td>
<td>19, 17</td>
<td>1.1</td>
<td>10,1, 0</td>
<td>1</td>
<td>11,6, 8</td>
<td>1.8</td>
<td>70,42</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Man 2016</td>
<td>5.2, 4.1</td>
<td>1.3</td>
<td>20,5, 19.1</td>
<td>1.1</td>
<td>18,2, 8</td>
<td>0.6</td>
<td>15,6, 7.3</td>
<td>2.1</td>
<td>57,49</td>
<td>5.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chak 2017</td>
<td>5.3, 3.9</td>
<td>1.3</td>
<td>28, 5, 26</td>
<td>1.1</td>
<td>3.9, 2.4</td>
<td>1.6</td>
<td>10,3, 3</td>
<td>3.3</td>
<td>56,5, 31.5</td>
<td>1.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salié 2018</td>
<td>4.5, 3.8</td>
<td>1.2</td>
<td>24, 32</td>
<td>0.7</td>
<td>3.0, 4.0</td>
<td>0.7</td>
<td>12, 6</td>
<td>2</td>
<td>80,70</td>
<td>1.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provan 2019</td>
<td>5.2, 4.2</td>
<td>1.2</td>
<td>23, 21</td>
<td>1.1</td>
<td>8,4, 6.4</td>
<td>1.3</td>
<td>10, 7, 6.4</td>
<td>1.7</td>
<td>55,30</td>
<td>1.8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median-11 Studies</td>
<td>5.3, 4.1</td>
<td>1.3</td>
<td>28, 5, 26</td>
<td>1.1</td>
<td>3.2, 5.3</td>
<td>1</td>
<td>12, 3, 5, 5</td>
<td>2.7</td>
<td>62, 74, 0</td>
<td>1.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* All values were reported means other than medians noted by asterisk (*)
system, which can mimic rheumatic conditions. Despite the ignorance of some, endocrine diseases are underlying diseases linked to musculoskeletal manifestations. Thus, secondary arthropathies of non-rheumatologic origin or osteoarthritic complaints or show rheumatic diseases can be found in patients with endocrine diseases during their evolution or in the initial phase along with other systemic symptoms. Based on this concept, we carried out the follow-up and evaluation of musculoskeletal manifestations presented by patients with endocrine disorders in a tertiary health service.

Objectives: The aim of this study is to characterize the musculoskeletal manifestations in patients with endocrine diseases: type 1 and type 2 Diabetes Mellitus; hypothyroidism; hyperthyroidism and pituitary diseases and to clinically classify the patients based on physical examination and imaging findings.

Methods: A cross-sectional and descriptive study, where clinical screening was performed at the endocrinology outpatient clinic, in which patients with musculoskeletal complaints were identified. These patients were referred for evaluation with a rheumatologist with clinical, laboratory and imaging investigation for the diagnosis of rheumatic disease. A questionnaire with epidemiological and clinical data was applied.

Results: To date, 466 patients diagnosed with endocrine diseases have been interviewed, 53.4 ± 14.7 years old, 371 (79.6%) were female and 95 (20.4%) were male. Of the patients interviewed, 326 (70.1%) reported musculoskeletal pain. In relation to endocrine diseases, the most frequent one was type 2 DM with 212 patients (45.5%), and 7725% of these people have chronic musculoskeletal pain, most of them 5 to 7 times a week, showing an intrinsic character of this disease with pain complaints from a great part of this population. The prevalence of 27.3% of hypothyroidism, 10.7% of DM type 1, 7.1% of hyperthyroidism, and less expressive amounts of other endocrine diseases such as acromegaly (1.7%), Cushing (0.4%), and the like were also identified. About 59.6% of those who have pains are not followed up in the rheumatology service, 41.3% of these have already indicated these pains to their endocrinologist, however they did not have their complaint properly signaled. Of those interviewed, 94 (37.5%) take antihypertensives and 32.7% oral anti-diabetics. The most commonly found diagnoses in rheumatic diseases: Rheumatoid Arthritis (39%); Osteoarthritis 22.9% and Fibromyalgia 20%; Osteoporosis 19%, Tendinitis calcarea, Psoriatic Arthritis and GOTA with 5.7%. The main joints affected were: Hands (54.4%); Knees (45.3%) and feet (41.8%).

Conclusion: Our research with pre liminal results has demonstrated the mutuality between endocrine diseases and musculoskeletal manifestations and, therefore, that rheumatologic diagnoses are increasingly frequent in this population. The high prevalence of these symptoms secondary to endocrine diseases raises serious questions to improve the quality of life of these patients, and also to increase the number of investigations in this field, because the pathophysiological mechanisms of this association are not well elucidated and, from there, to expand this information to professionals who may not be aware of this relationship.

REFERENCES:

Disclosure of Interests: None declared


AB1205

MEDICAL AND PSYCHOLOGICAL COMORBIDITIES IN FIBROMYALGIA: A CROSS SECTIONAL STUDY
K. N. Thomas1, A. Lawrence1, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Clinical Immunology and Rheumatology, Lucknow, India

Background: Psychological disorders are commonly observed in fibromyalgia (FMS). Medical comorbidities are less well characterised in FMS. We sought to assess the prevalence of these disorders in an observational cohort of patients in a tertiary hospital in North India.

Objectives: The prevalence of medical and psychological comorbidities in FMS and the prevalence of these disorders in FMS subgroups classified according to different ACR classification criteria were assessed.

Methods: Patients satisfying either the 1990 ACR or the 2016 ACR Fibromyalgia criteria were included in a cross-sectional study between October’19 and December’21. All patients were assessed for prevalence of chronic fatigue syndrome (CFS), post-traumatic stress syndrome (PTSD), restless leg syndrome (RLS) and medical comorbidities including obesity, obstructive sleep apnoea, anemia, diabetes mellitus, hypertension and hyperthyroidism.

Results: A total of 98 patients of median age 39 years (34 – 47) were included, of which 9 met only the 1990 ACR criteria (100% females), 30 met only 2016 ACR criteria (86% females) and 59 met both criteria (89% females). Widespread Pain index was significantly higher in the 1990+2016 group compared to subgroups which met only either of the criteria. Hypothyroidism (subclinical or clinical) was similarly higher in the 1990+2016 subgroup. At least one psychological comorbidity was seen in 41%, with CFS present in 30% and PTSD in 14%. The median systolic blood pressure was in the hypertensive range (146 mm Hg) in the 1990-only group, with hypertension being present in 1/3rd of the total cohort. Obesity was present in 59% and Diabetes in 11%. Iron deficiency anaemia was seen in 20%.

Table 1. Prevalence of comorbidities in different subgroups of Fibromyalgia

<table>
<thead>
<tr>
<th>Clinical features FMS Cohort</th>
<th>ACR 1990</th>
<th>ACR 2016</th>
<th>ACR 1990 + 2016</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(N-98)</td>
<td>(N-9)</td>
<td>(N-9)</td>
<td>(N-9)</td>
<td></td>
</tr>
<tr>
<td>F/M</td>
<td>88 (10)</td>
<td>9 (0)</td>
<td>53 (6)</td>
<td>26 (4)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39 (34 – 47)</td>
<td>38 (32 – 46)</td>
<td>38 (34 – 45)</td>
<td>44 (35 – 50)</td>
</tr>
<tr>
<td>Duration of symptoms (months)</td>
<td>48 (24 – 84)</td>
<td>48 (36 – 84)</td>
<td>48 (24 – 78)</td>
<td>60 (27 – 84)</td>
</tr>
<tr>
<td>WPI</td>
<td>15 (12 – 17)</td>
<td>14 (8 – 15)</td>
<td>16 (14 – 18)</td>
<td>13 (10 – 16)</td>
</tr>
<tr>
<td>SSS</td>
<td>8 (6 – 10)</td>
<td>3 (1 – 4)</td>
<td>6 (7 – 10)</td>
<td>8 (6 – 9)</td>
</tr>
<tr>
<td>TP</td>
<td>13 (9-16)</td>
<td>13 (12 – 15)</td>
<td>15 (13 – 16.5)</td>
<td>6 (4 – 8)</td>
</tr>
<tr>
<td>BMI (kg/m2)</td>
<td>26 (23 – 28)</td>
<td>23 (22 – 25)</td>
<td>26 (24 – 28)</td>
<td>26 (23 – 29)</td>
</tr>
<tr>
<td>Obese (BMI ≥ 25kg/m2)</td>
<td>58 (59%)</td>
<td>3 (33%)</td>
<td>37 (62%)</td>
<td>18 (60%)</td>
</tr>
<tr>
<td>Pre diabetes (HbA1c 5.7 – 6.5)</td>
<td>21 (21%)</td>
<td>0</td>
<td>16 (27%)</td>
<td>5 (16%)</td>
</tr>
<tr>
<td>Diabetes (HbA1C ≥ 11%)</td>
<td>11(11%)</td>
<td>9 (15%)</td>
<td>1 (3%)</td>
<td>0.2</td>
</tr>
<tr>
<td>Hypertension (≥140/90mm)</td>
<td>12 (12%)</td>
<td>0</td>
<td>11 (22%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Iron deficiency anaemia (Serum Ferritin &lt; 12 ng/ml)</td>
<td>14 (20%)</td>
<td>3 (42%)</td>
<td>9 (23%)</td>
<td>2 (9%)</td>
</tr>
<tr>
<td>OSA (intermediate to high risk by STOPBANG questionnaire)</td>
<td>32 (32%)</td>
<td>1 (11%)</td>
<td>17 (28%)</td>
<td>31 (62%)</td>
</tr>
</tbody>
</table>

Table 1. Prevalence of comorbidities in different subgroups of Fibromyalgia


Figure 1. Venn Diagram depicting Fibromyalgia subgroups having psychological comorbidities

Conclusion: There is a high prevalence of comorbidities in patients with fibromyalgia with nearly half having at least one psychological comorbidity, and obesity, hypertension and iron deficiency anaemia being the common medical comorbidities. Those who met only the 1990 ACR criteria formed less than 10%.

REFERENCES:
[2] Wolfe F, Ablin J, Guymer EK, Littlejohn GO, Rasker JJ. The Relation of Physiological mechanisms of this association are not well elucidated and, from there, to expand this information to professionals who may not be aware of this relationship.
Disclosure of Interests: None declared


AB1206 JUVENILE PRIMARY FIBROMYALGIA SYNDROME: RESULTS FROM A VOSVIEWER-BASED BIBLIOMETRIC NETWORK ANALYSIS.


School of Medicine, University Federico II, Naples, Italy; Medicine, Naples, Italy; Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Division of Anesthesia and Pain Medicine, Naples, Italy; School of Medicine, University of Pavia, Medicine, Naples, Italy; Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Scientific Directorate, Naples, Italy; Ospedale Cardarelli, Transplant Unit, Naples, Italy

Background: In 1985, Yunus and Masi described the juvenile primary fibromyalgia syndrome (JFPS). It is a chronic musculoskeletal pain syndrome that affects children and adolescents [2] with an estimated prevalence that varies from 1.2 to 6.2% [3]. Clinical features are widespread persistent pain, sleep disturbance, fatigue, and the presence of multiple discrete tender points on physical examination. Notably, this syndrome can impact the quality of life status and psychosocial development of children and adolescents [4]. Despite a lot of research being conducted, several aspects on etiology and pathogenesis, clinical characteristics, and evaluation, as well as therapy should be better explained.

Objectives: This bibliometric analysis is aimed at dissecting the developed research in the subject. It could provide helpful findings for predicting the direction of future studies, implementing corrective measures, and improving research networks.

Methods: The global literature on JFPS was scanned in the Web of Science (WOS) online database. The search string applied to identify the closest matching articles was: ‘Juvenile primary Fibromyalgia Syndrome (all field)’. All data were acquired on January 30, 2022. The information for the documents that met the requirements were extracted. The source was Journal Citation Reports™ 2020 (Clarivate Analytics). The literature analysis and knowledge visualization software tool VOSviewer (version 1.6.17) was used to analyze the co-occurrence of keywords (interconnection), co-citation (bibliographic coupling), co-citation analysis for sources, and countries, and analysis of the most productive organizations and networks.

Results: A total of 66 articles on JFPS were published from 1985 to January 2022, in WOS (n=24; median 2). About article types, 38 were research articles, 16 reviews, 8 meeting abstracts, 2 letters, 1 book chapters, 1 correction, 1 proceeding papers.

The analysis of keywords provided by authors showed that of 235 keywords, 38 exceeded papers. 16 reviews, 8 meeting abstracts, 2 letters, 1 book chapters, 1 correction, 1 proceedings paper.

Disclosure of Interests: None declared


Figure 1. Co-occurrence of keywords

For the co-citation study, we used cited sources (journals) as unit (minimum numbers of citations of a source 15). Of 563 sources, 38 met the threshold (interconnection 3). The most frequent keywords were Children (n=14); Adolescent (n=13); and Functional disability (n=10) (Figure 1)

Conclusion: This bibliometric network analysis on JFPS can be helpful for planning future research. It highlights the strength of representative scientists and core research teams. Research networks should be built, and high-value investigations warranted.

REFERENCES:

Disclosure of Interests: None declared


AB1207 RISK FACTORS FOR HIGHER RELAPSE RATE AND/OR PROLONDED GLUCOCORTICOID THERAPY IN POLYMYALGIA RHEUMATICA: MULTICENTRE STUDY IN 185 PATIENTS

A. Cusati1, O. Gut2, M. D. R. Malandri1, J. Cavallasc1, M. Linares2, N. Got2, A. Spinetti3, A. Eisteme4, A. Brignante3, A. C. Curti5, A. C. Costi5, J. L. Velasco Zamora12, J. P. Vinicki13 on behalf of Grupo GRUA.

1MR Medicina Reumatológica, Unidad de Reumatología, QHT Argentina; 2Hospital de Clínicas José de San Martín, División Reumatología, Buenos Aires, Argentina; 3Sanatorio Garay, Unidad de Reumatología, QFT, Argentina; 4Iturraspe, Servicio de Reumatología, Rosario, Argentina; 5OSPM, Unidad de Reumatología, Buenos Aires, Argentina; 6Instituto Medico Humanitas, Unidad de Reumatología, Resistencia, Argentina; 7Oseac San Isidro Policlinicuestos, Unidad de Reumatología, San Isidro, Argentina; 8Hospital El Cauce - Nestor Kirchner, Unidad de Reumatología, Florencio Varela, Argentina; 9Sanatorio Güemes, Servicio de Reumatología, Buenos Aires, Argentina; 10Hospital Luis Lagomaggiore, Servicio de Reumatología, Mendoza, Argentina; 11H.I.G.A. San Martin La Plata, Servicio de Reumatología, La Plata, Argentina; 12Clinical Research Institute Quilmes, Unidad de Reumatología, Quilmes, Argentina; 13Hospital De Quilmes, Unidad de Reumatología, Quilmes, Argentina

Background: Glucocorticoids (GC) are the therapeutic mainstay in polymyalgia rheumatica (PMR). However, their adverse effects are of particular concern in elderly patients. Relapses and long-term GC dependency are common.

Objectives: Assess the risk factors for higher relapse rate and/or prolonged glucocorticoid therapy in 185 PMR patients from Argentina.

Methods: A multicenter observational study of PMR patients diagnosed according to the Chuang criteria seen at the outpatient clinics at 12 public or private rheumatology units from Argentina between 2006 and 2021 was performed. Patients were followed until permanent remission, lost to follow up, or a maximum of 2 years after diagnosis. Relapse was defined as an exacerbation of PMR symptoms requiring an adjustment of GC dose (≥ 4 mg) occurring at least 1 month after diagnosis. Time to relapse was modeled using the Kaplan-Meier method. Cox regression models were used to evaluate predictors of time to first and subsequent relapses.

Results: A total of 185 patients were included (69.1% female) with a median age of 71 years (IQR 65-78 years). The median follow-up time was 17.1 months (IQR 6.8-34.7) and the incidence of relapses was 1.2 per 100 persons/month. The median time to relapse was 70.5 months (25th percentile = 14 months). Pain and/or stiffness in shoulder girdle and pelvic girdle together more common (p = 0.02) in the clinical presentation of patients who relapsed. In univariate analysis, patients with a previous history of dyslipidemia had a lower risk of relapse (HR = 0.55, 95% CI = 0.33-0.94, p = 0.03). Laboratory at time of diagnosis showed that an ESR > 50 mm was found as a risk factor for relapse (HR = 2.50, 95% CI = 1.23-5.10, p = 0.011). Regarding therapy, meprednisone (HR = 2.38, 95% CI = 1.31-4.31, p = 0.004) and high dose GC (HR = 2.35, 95% CI = 1.42-3.87, p = 0.001) had higher risk of relapse. In multivariate analysis, only meprednisone (HR = 2.59, 95% CI = 1.28-5.23, p = 0.008) and high dose of GC (HR = 2.41, 95% CI = 1.19-4.89, p = 0.014) remained the only risk factors for relapse.

Conclusion: A lower relapse rate than that reported in the literature was observed. Meprednisone and high dose of GC are significant predictors of future relapses. Our results suggest that efforts should be made to minimize initial GC dose and avoid the use of meprednisone as GC of first choice in order to prevent disease relapses.

Disclosure of Interests: None declared

EXTRA-INTESTINAL SYMPTOMS IN PATIENTS WITH CELIAC DISEASE

AB1208

FREQUENCY OF MUSCULOSKELETAL AND OTHER EXTRA-INTESTINAL SYMPTOMS IN PATIENTS WITH CELIAC DISEASE

A. Pilipenko1, V. Mazurov2, I. Gaydukova3. 1North-Western State Medical University Named After I. I. Mechnikov, Department of Therapy, Rheumatology, 2Examination of Temporary Disability and Quality Of Medical Care; 3North-Western Medical University I.I. Mechnikov, Saint-Petersburg, Russian Federation

Background: Celiac disease (CD) is one of the most common gastrointestinal tract diseases, in adults and children. Prevalence of CD is 1-3% [2]. The most common symptoms of CD are gastrointestinal symptoms. At the same time, celiac disease may manifest with extraintestinal symptoms, including the musculoskeletal, nervous, reproductive system, and skin, especially when it debuts at a late age [1,2]. However, data about musculoskeletal manifestations of CD are limited.

Objectives: To show the frequency of musculoskeletal complaints and their peculiarities in patients with CD.

Methods: Data from 94 patients with diagnosed by gastroenterologist celiac disease were collected with the on-lain survey. All the patients were positive in CD-related immunological and genetic tests and had biopsy established CD.

Results:

- The average age of respondents is 37.52 ± 11.2 years, women 79 (84.1%). Among 94 respondents 0.1% do not follow a gluten-free diet, 10.6% <1 year, 25.5% from 1 to 3 years, 11.7% - 4-5 years, 28.7% are on a gluten-free diet >5 years, 14.9% - 10-15 years, 8.5% > 15 years. Gastrointestinal symptoms have started at the age < 10 years in 59.6% of patients, in 4.2% in 11-16 years old, 13.8% at the age 17-25 years old, 12.8% at the age 26-40 years old, 9.6% had late CD onset (>40 years old). Extraintestinal symptoms such as drowsiness were noted by 46.8%, headaches by 40.4%, weakness by 59.6%, irritability by 57.4% of respondents. Lack of coordination was noticed in 18.1% of cases, dizziness in 22.3%, 57.4% have numbness, decreased sensitivity, and tingling feeling in the limbs. Joint pain had 54.3% of the patients with CD (Figure 1).

The maximal intensity of pain was noticed in the morning (8.5%) or late night (13.8%) times and fulfilled inflammatory pain criteria (ASAS). In 17% was noticed signs of enthesitis. Weakness of arms was noticed by 13.8% times and fulfilled inflammatory pain criteria (ASAS). In 17% was noticed weakness of arms. Frequency of pain in different joints

Conclusion:

Radial arthritis was noticed by 40.4%, weakness by 59.6%, irritability by 57.4% of respondents. Lack of coordination was noticed in 18.1% of cases, dizziness in 22.3%, 57.4% have numbness, decreased sensitivity, and tingling feeling in the limbs. Joint pain had 54.3% of the patients with CD (Figure 1).

Figure 1. Frequency of pain Syndrome in Joints

REFERENCES:


Disclosure of Interests: None declared


AB1209

MECHANISTIC FACTORS CONTRIBUTING TO PAIN AND FATIGUE IN FIBROMYALGIA AND ME/CFS: AUTONOMIC AND INFLAMMATORY INSIGHTS FROM AN EXPERIMENTAL MEDICINE STUDY

J. Eccles1,2, C. Thompson3,4, B. Thompson3,5, A. Amato1, K. Themelis1,5, H. Critchley1, N. Harrison3,5, K. Davies4. 1Brighton & Sussex Medical School, Neuroscience, Falmer, United Kingdom; 2University Hospitals Sussex NHS Foundation Trust, CIRU, Brighton, United Kingdom; 3University Hospitals Sussex NHS Foundation Trust, Rheumatology, Brighton, United Kingdom; 4Brighton & Sussex Medical School, Clinical and Experimental Medicine, Falmer, United Kingdom; 5University of Warwick, Psychology, Coventry, United Kingdom; 6University of Cardiff, CUBRIC, Cardiff, United Kingdom

Background: Fibromyalgia and ME/CFS are multifaceted conditions with overlapping symptoms(1); the pathoetiologic mechanisms are complex and debated(2), however there is a strong association with features of hereditary disorders of connective tissue (hypermobility) and autonomic and inflammatory abnormalities (1,2).

Objectives: To determine potential autonomic and inflammatory mechanisms of pain and fatigue in fibromyalgia and ME/CFS

Methods: After excluding participants with WCC higher than 10 (suggesting acute infection) baseline markers of inflammation (CRP and ESR) were available for 60 patients with confirmed diagnoses of Fibromyalgia and/or ME/CFS and 23 matched controls. Participants then underwent full research diagnostic evaluation including a hypermobility assessment(1) and autonomic challenge (60 degree head up tilt, ISRCTN78820481). Subjective pain and fatigue were assessed before and after challenge (VAS). Linear regression models were used to explore predictors, with adjustment for confounders as appropriate. Mediation analyses (looking for mechanistic effects) were conducted according to the method of Hayes (3) and mediation considered significant if bootstrapped confidence intervals of the estimated indirect effect did not cross zero. In these mediation analyses predictor variable was group membership (patient or control), outcome variable was change in 1)pain and 2)fatigue induced by challenge and mediators 1)no of connective tissue features in hypermobility diagnostic criteria endorsed by participant; 2)baseline inflammatory markers.

Results: ESR and CRP were significantly higher in patients rather than controls, even after correcting for BMI, age and sex (B=5.15, t=2.05, p=0.044; B=1.77, t=2.15, p=0.044 respectively). Adjusted ESR and CRP correlated with both subjective fatigue (B=0.44, t=2.09, p=0.04; B=1.63, t=2.60, p=0.011) and pain severity (B=0.13, t=2.51, p=0.014; B=0.45, t=3.01, p=0.004) at baseline. Autonomic challenge amplified pain (B=14.20, t=2.87, p=0.005) and fatigue (B=31.48, t=5.95, p=0.001) in patients to a significantly greater degree than controls, controlling for baseline levels. Baseline ESR and CRP also predicted challenge-induced increase in fatigue (B=0.78, t=3.70, p=0.001; B=1.91, t=3.36, p=0.01) and ESR challenge-induced increases in pain (B=0.46, t=2.35, p=0.021).

Mediation analysis demonstrated that number of connective tissue features expressed in hypermobility criteria mediated the degree to which subjective pain was increased by the autonomic challenge (Bootstrapped 95% CI of indirect effect do not cross zero, 0.7541 - 7.3888).

Conclusion: To our knowledge this is the first study to directly explore autonomic and inflammatory mechanisms of pain and fatigue in a combined population of Fibromyalgia and ME/CFS. This study adds to the evidence-base of baseline inflammatory abnormalities in fibromyalgia and ME/CFS. It highlights their potential role in predicting symptom severity and their potential mechanistic role in autonomic induced pain and fatigue, suggesting future treatment strategies.

REFERENCES:


Disclosure of Interests: Jessica Eccles: None declared, Charles Thompson: None declared, Beth Thompson: None declared, Marisa Amato: None declared, Kristy Themelis: None declared, Hugo Critchley: None declared, Neil Harrison Grant/research support from: speakers bureau, Kevin Davies: None declared

FIBROMYALGIA AND BODY MASS COMPOSITION IN POST-MENOPAUSAL WOMEN: PRELIMINARY RESULTS FROM A CROSS-SECTIONAL MONOCENTRIC STUDY

E. Hysaj, S. Paolino, R. Mascaro, A. Casabella, L. Carmisciano, E. Gotelli, C. Pizzorni, A. Sulli, V. Smith, M. Cutoiu
Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genoa, Italy – IRCCS Rheumatology Unit San Martino Polyclinic, Genoa, Italy, Genova, Italy; Section of Biostatistics, University of Genova, Genova, Italy, Department of Health Sciences (DISSAL), 16132, Italy; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Cornel Heymanslaan 10, 9000 Ghent, Belgium, Department of Internal Medicine, Ghent University, Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

Background: Fibromyalgia (FM) is characterized by chronic musculoskeletal widespread pain, fatigue, sleep disturbances and functional symptoms.

Objectives: Our study aimed to determine if FM could affect body composition of post-menopausal women and to investigated potential correlations between disease severity and body mass variables.

Methods: Thirty post-menopausal FM female patients (median age 56 years, BMI = 25.8) were diagnosed according to both ACR 1990 fibromyalgia classification criteria or ACR 2010 preliminary diagnostic criteria. They underwent Dual-energy X-ray absorptiometry (DEXA) for clinical purposes (i.e. screening for osteoporosis). The parameters analyzed by a dedicated software (GE Lunar, USA) were the spine and femoral bone mineral density (BMD), the total lean mass and the total body fat (TBF), quantitative variables of bone, muscle and fat composition. Additionally, qualitative analysis of the bone was indexed by the trabecular bone score (TBS); All the variables were compared with the parameters of 30 healthy controls (median age 59 years, BMI = 24.4) matched for sex and age. For each patient, data on disease duration, comorbidities, current treatment and disease severity self-reported scores were collected. The last ones derived from the Italian Fibromyalgia Impact Questionnaire Revised (FIQ-R) version that each patient independently compiled before the medical visit: widespread pain index (WPI), symptom severity scale (SSS), polysymptomatic distress scale (PDS), modified fibromyalgia assessment status (modFAS) and the FIQ-R total score.

Results: The clinical features of the FM patients included in our cohort are reported in Table 1. No statistically significant differences were observed between femoral/spine BMD, TBS and muscle mass between patients and controls (p = 0.3, p = 0.06, p = 0.16, p = 0.8 respectively). Conversely, both total and central body fat were significantly higher in patients compared with healthy controls (29.4 kg vs 25.2 kg, 15.7 kg vs 13.2 kg, p = 0.006 and p = 0.01 respectively). No significant correlations were observed between body mass composition indexes with scores of disease severity. Body mass composition variables did not statistically differ when patients were sub-analyzed according to pharmacological treatment and comorbidities.

Table 1: Clinical features of FM patients included in present cohort (please see text for explanations of terminology)

<table>
<thead>
<tr>
<th>Patients</th>
<th>N = 30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (range)</td>
<td>58.0 [53.8, 69.2]</td>
</tr>
<tr>
<td>BMI (range)</td>
<td>25.8 [23.0, 28.4]</td>
</tr>
<tr>
<td>Disease duration (years), Median [IQR]</td>
<td>4.5 [2.2, 9.2]</td>
</tr>
<tr>
<td>modFAS, Median [IQR]</td>
<td>24.5 [20.0, 29.2]</td>
</tr>
<tr>
<td>PDS, Median [IQR]</td>
<td>17.5 [16.0, 23.2]</td>
</tr>
<tr>
<td>VHI, Median [IQR]</td>
<td>8.0 [6.0, 9.0]</td>
</tr>
<tr>
<td>FIQ-R, Median [IQR]</td>
<td>12.0 [7.8, 15.0]</td>
</tr>
<tr>
<td>Current pharmacological treatment</td>
<td></td>
</tr>
<tr>
<td>Ciclosporine N (%)</td>
<td>24 (80)</td>
</tr>
<tr>
<td>Fluoxetine N (%)</td>
<td>5 (16.6)</td>
</tr>
<tr>
<td>Duloxetine N (%)</td>
<td>4 (13.3)</td>
</tr>
<tr>
<td>Gabapentinoids N (%)</td>
<td>2 (6.6)</td>
</tr>
<tr>
<td>Trazodine N (%)</td>
<td>2 (6.6)</td>
</tr>
<tr>
<td>Benzodiazepines N (%)</td>
<td>2 (6.6)</td>
</tr>
<tr>
<td>Cannabinoids N (%)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Neon-pharmacological treatment</td>
<td></td>
</tr>
<tr>
<td>Acrobic physical activity N (%)</td>
<td>5 (16)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
</tr>
<tr>
<td>Hypertension N (%)</td>
<td>10 (33.3)</td>
</tr>
<tr>
<td>Diabetes N (%)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Osteoarthritis N (%)</td>
<td>10 (33.3)</td>
</tr>
<tr>
<td>Anxiety/depression N (%)</td>
<td>3 (10)</td>
</tr>
<tr>
<td>Psoriasis N (%)</td>
<td>3 (10)</td>
</tr>
</tbody>
</table>

Conclusion: Our preliminary results suggest that FM seems not associated with impaired bone mass and bone quality in post-menopausal women compared to matched healthy controls, in line with the majority of literature evidences. However, total and central adipose tissue mass resulted higher in this cohort of FM patients compared with controls but not correlate with disease severity. This might be due to a disease-induced sedentary lifestyle and might reinforce the concept that physical activity represents the best preventive method of over-weight and obesity, one of most reported comorbidities for FM patients.

REFERENCES:


© 2021 Elsevier Inc. All rights reserved.

Does body mass index and metabolic syndrome impact on fibromyalgia?

G. Tramontano,1,2 V. Tomatis,1 M. Gilioli,3 A. Giusti,1,2 F. Giarracca,2 R. Gallo,2 L. Bandi,2 G. Bianchi,2 Rheumatology Unit, Department of Medical Specialties, Regional Health Trust 3, Genoa, Italy; 2Metabolic Bone Diseases Unit and Fracture Liaison Service, Department of Medical Specialties, Regional Health Trust 3, Genoa, Italy; 3Infectious Disease Unit, Infection Disease Unit - San Carlo Hospital, Potenza, Italy

Background: Fibromyalgia (FBM), obesity and the metabolic syndrome (MTB) are common conditions with significant impact on health and quality of life, producing relevant economic burden for healthcare systems. Although obesity represents a negative prognostic factor for FBM, the relation between body mass index (BMI) or MTB and FBM severity is still unclear.

Objectives: The aim of our ongoing study was to evaluate the relationship between BMI or prevalent MTB and FBM severity, estimated with 3 different severity scores.

Methods: We included the first 100 women presenting with FBM, defined according to the ACR2010 diagnostic criteria, consecutively evaluated during the period of 1 year in 2 Clinic in Italy. On enrolment were assessed/recorded demographic, clinical and pharmacological characteristics, weight, height, physical activity, tenderness, pain and symptoms. The following scores were calculated: tender points count (TP), Widespread Pain Index (WPI), Polysymptomatic Distress Scale (PDS), Fibromyalgia Impact Questionnaire (FIQ) and modified Fibromyalgia Assessment Status (mFAS). BMI was calculated, and the presence of MTB was evaluated according to current definition. Patients were categorized as presenting with severe disease or moderate/mild disease according to recent definition validated in an Italian population. The prevalence of MTB and the mean ± standard deviation (SD) BMI in subgroups defined according to severity were estimated.

Results: Mean age ±SD was 57.5±12.7 years, mean BMI ±SD was 25.3±5.1, and 9.5± presented with MTB. FBM severity (mean±SD) calculated by PDS, FIQ and mFAS was respectively 25.3±9.3, 63.2±23.1, and 30.1±7.7% Patients with the highest BMI severity according to PDS (≥25) were less likely to present with FBM (2.4%) compared to those with a PDS of 0-25 (20.0%, P=026), with an adjusted (age and BMI) OR (95%CI) for presenting with MTB in patients with less severe FBM of 8.2 (0.962-69.298, P=0.54). Similar results were found when the specific conditions characterizing the MTB were considered separately, except for excessive body fat around the waist (not related to severity). The BMI ±SD was comparable between patients with severe disease (25.8±5.8) according to PDS and those with less severe FBM (24.8±4.4, P=0.388), with no correlation between BMI and PDS (Rho: 0.083, P=0.454). Considering all other characteristics of the two groups defined according to PDS categories (PDS ≥25 versus PDS <25) a significant difference was found in mean age ±SD, greater in patients with less severe FBM (60.2±13.2) compared to those with highest BMI severity (54.8±11.6, P=0.046). Similar but less significant findings were found also with FIQ and mFAS. The prevalence of MTB according to the FIQ was 7.3% for highest severity versus 14.3% for less severe FBM (P=0.200), with a comparable BMI ±SD between the two groups (respectively 28.2±6.1 versus 24.4±3.7, P=0.126). Corresponding figures for MTB or BMI and FBM severity according to the mFAS were respectively: prevalence of MTB in highest severity 3.0% versus 16.3% in the less severe FBM (P=0.026); mean ±SD BMI in highest severity versus 14.3% for less severe FBM (P=0.200), with a comparison BMI ±SD between the two groups (respectively 28.2±6.1 versus 24.4±3.7, P=0.126).

Conclusion: The preliminary results of our ongoing analysis demonstrated a slightly inverse relationship between BMI severity and the prevalence of MTB, trending to significance, while no relationship was found between severity and BMI.

REFERENCES:
AB1212  GENDER DIFFERENCES IN FIBROMYALGIA PATIENTS IN VIEW OF THE 1990, 2011, AND 2016 ACR CRITERIA

A. Moahri1, M. Z. Shoaei1, A. S. Abbas1, T. M. Abdel-Aziz1, W. Gouda1. 1Al Azhar University, Rheumatology, Assuit, Egypt

Background: Fibromyalgia (FM) is a common rheumatic illness distinguished by chronic pain, headache, fatigue, cognitive problems, and functional disability. However, the differences between men and women have not yet been comprehensively studied, especially after the development of the last 2016 American College of Rheumatology (ACR) criteria.

Objectives: The aim of this study was to evaluate the gender differences in symptom characteristics, cognitive dysfunction, and disease severity in Egyptian FM patients considering both the ACR 1990, 2011, and the last 2016 ACR diagnostic criteria.

Methods: In this cross-sectional study, 352 individuals with fibromyalgia were interviewed from January 1, 2020, to June 1, 2021. In addition to the number of tender points (TPC), data was collected on age, gender, body mass index (BMI), marital status, disease onset, duration, and diagnostic delay. The Wide- spread Pain Index (WPI), the Symptom Severity Scale (SSS), fatigue, cognitive dysfunction, sleep disturbance, awakening unrefreshed, headache, abdominal pain, and depression were evaluated and scored according to 2010 and 2016 ACR criteria. The questionnaire includes a visual analog scale (VAS) for pain, fatigue, stiffness, anxiety, and depression. Total score ranges were calculated with total score ranges between 0 and 80 (without job items), where higher scores indicated a greater negative impact and/or severity of symptoms. The Polysymptomatic distress scale (PDS) has been calculated by the summation of the SSS with the WPI. The Revised FM impact questionnaire (FIQR) has also been evaluated.

Results: The study shows that females have a significantly higher prevalence of fatigue, cognitive dysfunction, sleep disturbance, headache, and abdominal pain (p < 0.05). Also, females showed significantly higher scores than males regarding WPI, SSS, and mean TPC (p = 0.004, 0.027, and 0.001, respectively). While there was no difference regarding the FIQR (p=0.93), PDS was significantly higher in women (p= 0.001).

Conclusion: Female patients with FM had greater disease severity scores, symptomatology, and number of tender points. Whatever the criteria applied, the prevalence and intensity of the disease features are higher in females, which may underestimate the disease in male patients.

Disclosure of Interests: None declared


AB1213  EFFECTIVENESS OF A ONE-WEEK INPATIENT MULTIMODAL PAIN TREATMENT PROGRAM FOR PATIENTS WITH RHEUMATOLOGIC DISEASES AND MUSCULOSKELETAL PAIN – A SINGLE CENTER OBSERVATIONAL STUDY

J. Pirker1, A. Rubbert-Roth1, C. Haller1, F. Mayr1, J. Von Kempis1. 1Kantonsspital St.Gallen, Division of Rheumatology and Immunology, Department of Internal Medicine, St. Gallen, Switzerland

Background: Multimodal rheumatologic complex treatment (MRCT) is a treatment concept for patients with rheumatologic diseases requiring acute inpatient care suffering from exacerbated pain and/or functional impairment. A rheumatologist directs the treatment program including multimodal assessments and treatment from three of the following: ergotherapy, physical therapy, pain medicine and cognitive behavioural treatment. Most studies evaluated data from a two-week inpatient MRCT program. Available data on the effectiveness of a one-week inpatient multimodal treatment program are scarce. However, whether a shorter program might also be effective has not been studied so far.

Objectives: To evaluate the effectiveness of a one-week inpatient multimodal and interprofessional treatment program on musculoskeletal pain and function of patients with rheumatologic disorders.

Methods: 59 consecutive patients were entered into a program of multimodal treatment courses (MRCT) from January 2021 until December 2021. All patients completed a total of 11 hours of therapy in one week. Two patients were excluded for evaluation (one patient acquired COVID 19 during hospitalization and one patient was excluded due to missing data).

Conclusion: Significant improvement of pain and function was demonstrated at discharge and at week 12 in patients with rheumatologic diseases and musculoskeletal pain completing a one-week inpatient multimodal interprofessional treatment program. A multimodal therapeutic approach may provide an effective treatment strategy superior to unimodal standard management.

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5155

AB1214  VITAMIN D SUPPLEMENTATION IN FIBROMYALGIA: A SYSTEMATIC REVIEW

H. Sousa1, A. S. Pinto2, J. F. Ferreira1, 2. 1Science of Health Faculty Beira Interior University, Rheumatology, Covilhã, Portugal; 2Unit Local Health of Guarda, Rheumatology, Guarda, Portugal

Background: Fibromyalgia (FM) is a chronic disease characterized by diffuse pain associated with high levels of fatigue whose intensity is very variable. Similar symptoms are found in patients with low levels of vitamin D, a vitamin that behaves like a hormone with multiple receptors spread in several tissues. Although its role in the pathophysiology of FM remains unclear many studies point to a correlation between vitamin D deficiency and FM symptoms severity.

Disclosure of Interests: None declared


Table 1.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Admission/Discharge</th>
<th>P value</th>
<th>N</th>
<th>P value</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS mean difference</td>
<td>-2.86</td>
<td>&lt;0.0001</td>
<td>55</td>
<td>-2.23</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HAQ mean difference</td>
<td>-0.24</td>
<td>&lt;0.0001</td>
<td>55</td>
<td>-0.29</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FFbH mean difference</td>
<td>5.38</td>
<td>&lt;0.0001</td>
<td>56</td>
<td>6.98</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>VAS mean difference/12 weeks follow up</td>
<td>-2.23</td>
<td>&lt;0.0001</td>
<td>22</td>
<td>-1.48</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>HAQ mean difference/12 weeks follow up</td>
<td>-0.16</td>
<td>&lt;0.0001</td>
<td>22</td>
<td>-0.04</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FFbH mean difference/12 weeks follow up</td>
<td>3.96</td>
<td>&lt;0.0001</td>
<td>22</td>
<td>6.74</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Figure 1.

Conclusion: The mean treatment duration (days, sSD) was 8.1 ± 0.8. Mean age (years, ±SD) of the 57 patients treated in the MRCT program was 57.2 ± 12.5, with 72% female and 28% male patients. Of all patients, 40% had an underlying inflammatory disorder, 60% a non - inflammatory rheumatic disease, 23% of all patients had “back pain”, 14% “spondyloarthristis” and 11% “rheumatoid arthritis”. Overall, VAS (pain) mean at admission was 6.9 ± 1.0 (SD), HAQ mean 0.57 ± 0.23 (SD) and FFbH mean 81.44 ± 7.95 (SD), respectively. Significant improvements in VAS, HAQ and FFbH were demonstrated at discharge (day 8), with a mean improvement of VAS of -2.86 (95% CI: -3.07 to -2.64, P value: <0.0001), a mean improvement of HAQ of -0.24 (95% CI: -0.28 to -0.20, P value: <0.0001) and a mean improvement of FFbH of 5.38 (95% CI: 3.78 to 6.98, P value: <0.0001). Follow up assessment at week 12 was recorded in 22 patients (39%) with a significant mean improvement in VAS of -2.23 (95% CI: -2.98 to -1.48), P value < 0.0001 (Table 1 and Figure 1).
**ABSTRACT**

**Objectives:** Conduct a systematic review of the literature to determine the value of vitamin D supplementation in fibromyalgia.

**Methods:** Medline, EMBASE, and Cochrane databases were searched, from January 2000 to June 2022, using the descriptors “Fibromyalgia,” “Fatigue” and “Vitamin D.” Randomized and clinical control trials including FM patients in whom supplementation of vitamin D was made were selected. Data comprised sociodemographic description, diagnosis criteria, fibromyalgia symptoms, Fibromyalgia Impact Questionnaire (FIQ), short-form 36 (SF36), and vitamin D supplementation protocol was collected.

**Results:** Of the initial 1480 articles, 4 were eligible for final analysis. One did not observe any significant improvement in FIQ scores with vitamin D supplementation. The remaining three observed significant improvements in SF36 and FIQ scores but to different extents. One only demonstrated improvements in specific components of the SF36, also demonstrating improvements concerning morning fatigue. Another demonstrates improvements in all SF36-parameters, except for pain level. Lastly, other observed improvements in the scores of both FIQ and SF36 scales.

**Conclusion:** Our review shows conflicting results regarding the role of using vitamin D supplementation in the quality of life of patients with FM(S). These results can be explained by different supplementations protocols and also different baseline levels of vitamin D for which it was decided to supplement. Nevertheless, vitamin D supplementation appears to have a benefit in fatigue and quality of life in FM patients. Larger studies, which last longer and have a more uniform supplementation protocol, are needed to confirm the results of this review.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5289

**ABSTRACT**

**Spine, mechanical musculoskeletal problems, local soft tissue disorders**

**AB1215**

**A COMPARATIVE ANALYSIS OF RADIOLOGICAL FINDING BETWEEN TUBERCULOUS, BRUCELLAR AND PYOGENIC SPONDYLODISCITIS**

N. Ben Chekaya1, F. Fhima1, S. Zourev1, I. Beija1, M. Touzi1, M. Jguirim1, N. Bergaoui2

**Fattouma Bourguiba Hospital, Rheumatology, Monastir, Tunisia**

**Background:** Infection spondylodiscitis (IS) is a serious infectious disease which involves intervertebral disc and its adjacent vertebral bodies but later may also extend into the the adjacent neural structures. The clinical picture of IS is rather non specific but there are significant radiological differences that permit a presumptive aetiological diagnosis and orient the initial empirical treatment.

**Objectives:** This study aimed to compare the radiological features of of tuberculous (TS), brucellar (BS) and pyogenic spondylodiscitis (PS).

**Methods:** A retrospective monocentric study involving 70 cases of infective spondylodiscitis admitted between January 2009 and August 2019 at our rheumatology department. Clinical, laboratory and radiological data of the patients were collected.

**Results:** Of these 70 patients, 18 (25.7%) had TS, 8 (11.4%) BS and 44 (62.9%) PS. There were 37 women (52.9%) and 33 men (47.1%). The age of the patients ranged from 12 to 82 years, with a mean of (SD±) 54±15.23 years. Standard X-rays showed abnormalities suggestive of spondylodiscitis in 78.6% of cases. Paravertebral or epidural masses were present respectively in 53.5% and 86.7% of TS, versus 14.3% and 71.4% of BS, and 46.3% and 80.5% of PS, there were no significant differences those clinical features between the groups.

**Conclusion:** There are significant clinical, biological and radiological differences between TS, BS and PS. The presence of back pain, fever, moderate elevation of inflammatory markers with thoracic radiological involvement was suggestive of tuberculous spinal infection.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5289

**ABSTRACT**

**AB1216**

**TUBERCULOUS, BRUCELLAR AND PYOGENIC SPONDYLODISCITIS: A DESCRIPTIVE AND COMPARATIVE STUDY OF 70 CASES**

N. Ben Chekaya1, F. Fhima1, M. Ghard, A. Ben Salem2, S. Zourev1, I. Beija1, M. Touzi1, M. Jguirim1, N. Bergaoui2

**Fattouma Bourguiba Hospital, Rheumatology, Monastir, Tunisia**

**Background:** Infection spondylodiscitis is a serious infectious disease which involves intervertebral disc and its adjacent vertebral bodies but later may also extend into the the adjacent neural structures with right-sided sciatica and intermittent episodes of urinary retention. The pain was gradually worsening and resisting conventional analgesics and psychotherapy. On physical examination, she had tenderness of the lumbar back and left sacroiliac joint with limited mobility. Biological findings were normal and X-ray features showed osteolytic lesions of L5 left side. The magnetic resonance imaging (MRI) results revealed septated paravertebral and epidural abscesses.

**Objectives:** To describe and to compare the clinical, biological and radiological features of tuberculous (TS), brucellar (BS) and pyogenic spondylodiscitis (PS).

**Methods:** A retrospective monocentric study involving 70 cases of infectious spondylodiscitis admitted between January 2009 and August 2019 at our rheumatology department. Clinical, laboratory and radiological data of the patients were collected.

**Results:** Of these 70 patients, 18 (25.7%) had TS, 8 (11.4%) BS and 44 (62.9%) PS. There were 37 women (52.9%) and 33 men (47.1%). The age of the patients ranged from 12 to 82 years, with a mean of (SD±) 54±15.23 years. Standard X-rays showed abnormalities suggestive of spondylodiscitis in 78.6% of cases. Paravertebral or epidural masses were present respectively in 53.5% and 86.7% of TS, versus 14.3% and 71.4% of BS, and 46.3% and 80.5% of PS, there were no significant differences those clinical features between the groups.

**Conclusion:** There are significant clinical, biological and radiological differences between TS, BS and PS. The presence of back pain, fever, moderate elevation of inflammatory markers with thoracic radiological involvement was suggestive of tuberculous spinal infection.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.823
Disclosure of Interests: None declared

AURICULOTHERAPY AS A TREATMENT FOR CHRONIC NECK PAIN: AN INTERVENTIONAL COMPARATIVE STUDY

O. Saidane1, W. Lahmar1, F. Saadi1, A. Ben Tekaya1, S. Bouden1, R. Leila1, R. Tekaya1, I. Mahmoud1, L. Abdelmoula1, 1Charles Nicolle Teaching Hospital, Rheumatology, Tunis, Tunisia

Background: Data indicates promising benefits of auriculotherapy (AT) in pain management of several pathologies. Common cervical pain (CCP) is recurrent pain often resistant to standard treatment. And use of auriculotherapy as a therapeutic solution in neck pain has not been well explored.

Objectives: The aim of our study is to evaluate efficacy of a single session of AT in the management of CCP’s pain and disability.

Methods: We conducted an interventional comparative study. Fifty patients with CCP consulting were divided in two group of 25: group A underwent a session of AT, group P had a placebo treatment using a detuned ultrasound machine. Evaluation of the patients was performed before, and right after the intervention.

Results: NPDS total went from 34.3 to 22.9 (p<0.001), F1 went from 9.5 to 6.2 (p<0.001), F2 went from 16.5 to 11.9 (p<0.001), F3 from 8 to 5.4 (p<0.001). In the P group: NPDS total decreased from 28.9 to 26 (p=0.001), F1 from 6.3 to 5.7 (p = 0.001), F2 going from 14.4 to 13.3 (p = 0.013), F3 went from 8 to 7.3 (p=0.006).

Conclusion: Our study revealed that a single session of auriculotherapy is effective on short term in the treatment of pain and disability related to CCP. This alternative technique may gain its place in the therapeutic management protocol to overcome disability of chronic neck pain.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2405

CHARACTERISTICS OF INFECTIOUS SPONDYLODISCITIS IN ELDERLY

I. Mahmoud1, M. Aouni1, A. Ben Tekaya1, S. Bouden1, R. Leila1, R. Tekaya1, O. Saidane1, L. Abdelmoula1, 1Charles Nicolle Hospital, Rheumatology, Tunis, Tunisia

Background: Infectious spondylodiscitis is a rare but growing disease. It is a serious infection that can compromise both the functional and vital prognosis especially on elderly subjects.

Objectives: The purpose of this study was to compare the clinical, bacteriological and evolutionary characteristics of elderly patients admitted for management of infectious spondylodiscitis with a case-control group of young subjects.

Methods: Retrospective, descriptive study carried out in the rheumatology department of the Charles Nicolle Hospital from 2010 to 2019. Adult patients hospitalized for infectious spondylodiscitis were included. Clinical, bacteriological and evolutionary data were analysed and comparing those over 65 years of age with young case-control subjects.

Results: Of the 78 patients included, 33 patients belonged to the elderly group and 45 to the control group. The duration of evolution was shorter for the control group (123 vs. 181 months for the elderly; p=0,71). The progressive mode of onset characterised the elderly group (P<0.05). Spinal pain was constant. Neurolological abnormalities, night sweats, and altered general condition were more present in the elderly (p<0.05). Spinal stiffness was more present in the control group (p<0.05). There was no difference between the two groups in terms of the presence of fever and radiculalgia. Spinal biopsy was performed in 72% of the elderly subjects and in 80% of the control group. The most common germ in the elderly group was tuberculosis and brucellosis in the control group (p<0.05).

Conclusion: Infectious spondylodiscitis on elderly is characterised by an insidious onset, a confusing clinical picture and a more severe presentation than young people with significant complications and mortality.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3923
AB1221  START BACK TOOL RISK SCORE: WHAT GUIDANCE TO GIVE IN A MILITARY LOW BACK PAIN POPULATION?

R. Dahm1, W. Lahmar2, O. Dhrif1, M. Sloma1, L. Metoui1, I. Gharsallah1, K. Amri2, Y. Malait1, L. Nouisrif1. 1Military Teaching Hospital, Rheumatology, Tunis, Tunisia; 2University of Tunis El Manar, Internal Medicine, Tunis, Tunisia; 3Military Teaching Hospital, Orthopedics, Tunis, Tunisia

Background: The Keele start back Tool (SBT) is a 9-item self-reported questionnaire validated to identify individuals with non-specific low back pain (LBP) who have prognostic factors for persistent disabling pain. Thus, it is a useful component of stratified care, where patients’ prognostic subgroups are matched with appropriate treatment.

Objectives: The aim of our study was to report the prevalence of SBT-calculated risk for back pain disability in Tunisian military patients.

Methods: It was a cross sectional study. The SBT questionnaire was administered to patients > 18 years presenting with common low back pain in outpatient Military teaching hospital in Tunis, Tunisia (from January to Mars 2021). The normality of data distribution was checked by the Kolmogorov-Smirnov test. Quantitative variables were presented as mean ± standard deviation (SD) or median (interquartile range), as appropriate. The categorical variables were expressed as percentages.

Results: X-ray of 114 participants; the mean age at diagnosis was 79 +/- 12 years old, sex ratio was equal to 1. The median of symptom duration was 22 (6-36) months, 83 (72.8%) were employed, 54 (47.4%) were on active military duty. Comorbidities reported in our patients were distributed as followed: 52 (45.6%) cases of overweight, 21 (18.4%) cases of obesity, 17 (14.9%) had hypertension, 13 (11.4%) suffered from type 2 diabetes, 10 (8.8%) had dyslipidemia, 6 (5.3%) cases of hypothyroidism and 3 (2.6%) cases of auto-immune diseases. Seventy (61.4%) participants reported anxious thoughts, 75 (65.8%) patients expressed avoidance beliefs, 59 (51.8%) patients mentioned catastrophizing thoughts and 50 (43.9%) were dealing with low mood. Mean SBT psychological score was at 2.68 +/-1.5. Patients reported a mean SBT score of 5.31 +/-2.1 with the following risk stratification: 27 (23.7%) scored low-risk, 47 (41.2%) medium risk, and 40 (35.1%) high-risk.

Conclusion: This is the first study to report the prevalence of SBT-designated risk subgroups among Tunisian population. Medium or high-risk scores for back pain disability were more prevalent the surveyed sample. Also, rates of low mood and anxious thoughts indicate a need for future research to explore psychosocial factors in non-specific low back pain.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3970

AB1222  POSITIVE DIAGNOSIS OF TUBERCULOUS SPONDYLODISCITIS: CT-GUIDED PERCUTANEOUS BIOPSY OF SPINAL LESIONS VERSUS CLINICAL, BIOLOGICAL AND IMAGING ARGUMENTS

M. Mrabet1, S. Boussaid2, S. B. Troudi1, S. Rekik1, S. Jemmali1, H. Aljani1, H. Sahli1, M. Elleuch1, 1Rabta Hospital, Rheumatology, Tunis, Tunisia

Background: Tuberculosis is still endemic in Tunisia. Although pulmonary localization is the most common, other localizations, including osseo-articular involvement, are increasingly diagnosed. Spinal or «Pott’s Disease» is the most common expression. A bundle of clinical, paraclinical and evolutionary arguments or a disco-vertebral biopsy puncture (DVBP) contribute to the positive diagnosis.

Objectives: Our aim was to assess the real contribution of DVBP compared to clinical-biological and imaging arguments for the diagnosis of tuberculous spondylodiscitis (SPDT).

Methods: We conduct a retrospective and descriptive study in a single rheumatology department. Data were collected from files of patients hospitalized in the past 20 years (2000-2020) who have been diagnosed with SPDT.

Results: Fifty-two cases of SPDT were collected (37F/15M). The mean age of the population was 55.21 years ± 17.79 [19-91]. Diagnosis SPDT was retained in 38 patients (73.1%). Imaging was contributive to positive diagnosis using standard X-rays, computed tomography and magnetic resonance imaging (MRI). Disc pinch, erosion of vertebral plates and vertebral collapse were the major signs. Once the diagnosis was retained for these patients, the first week noted a most significant clinical improvement (56.8%) in patients diagnosed with a range of suggestive arguments (p = 0.002). During the second week, clinical improvement was most marked in patients diagnosed with suggestive clinical and paraclinical arguments (70.3%) but with no statistically significant difference (p = 0.1). The improvement was statistically greater during the fourth week (66.7%) and the third month (60%) in patients diagnosed with histological examination (p < 0.001).

Conclusion: Tuberculous spondylodiscitis is a frequent condition that needs to be treated rapidly. A range of highly suggestive clinical, paraclinical and evolutionary arguments contribute in the majority of cases to the positive diagnosis with a comparative clinical evolution to that of the DVBP which remains an invasive exam with variable sensitivity depending on studies.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.4049

AB1223  ACTIVE MILITARY ARE AT HIGHER RISK OF CHRONICITY IN LOW BACK PAIN: A CROSS SECTIONAL COMPARATIVE STUDY

W. Lahmar1, R. Dahm1, O. Dhrif1, M. Sloma1, L. Metoui1, I. Gharsallah1, K. Amri2, Y. Malait1, L. Nouisrif1. 1Military Teaching Hospital, Rheumatology, Tunis, Tunisia; 2Military Teaching Hospital, Orthopedics, Tunis, Tunisia

Background: The incidence of low back pain (LBP) was 40.5 per 1,000 person-years in active military population and thus was comparable to the general population. Other than pain and disability, chronicity of LBP has a significant impact on work through the high rates of resulting sick leave. The Start Back...
Tool (SBT) questionnaire is a well-known tool used to detect patients with prognostic factors for persistent and disabling back pain. The risk of chronicity in individuals on active military duty suffering from acute back pain is yet to be explored.

Objectives: The aim of our study was to assess the risk of chronicity in active Tunisian military population compared to non-military controls using the SBT questionnaire.

Methods: Cross-sectional study in which we enrolled adult patients suffering from acute back pain, who consulted the outpatient department of rheumatology in the military hospital of Tunis from January 2021 to March 2021. All patients had a standardized clinical examination. They completed the SBT questionnaire in the validated Arabic language version. Patients were stratified in two groups, active military group (AMG) and non-military group (NMG). Categorical variables were compared with the χ²-test. Comparisons of the differences of continuous variables were performed by Student’s t-test.

Results: We included 54 patients in the active military group and 60 patients in the non-military group, epidemiologic characteristics were distributed respectively as followed: mean age was at 43±8 versus 53±13 years old (p<0.001), sex ratios (F/H) were 0.23 versus 3.62 (p=0.001), 54% versus 73% (p=0.033) of patients were overweight or obese, 4% versus 18% (p=0.014) of patients had type 2 diabetes, 4% versus 13% (p=0.099) of patients had dyslipidaemia while 9% versus 20% (p=0.108) of patients had hypertension. Active military group patients had significantly higher proportions of high risk SBT scores than non-military patients 50% versus 22% (2.27 risk ratio 95% CI 1.47 to 3.08; p=0.002), with total mean of scores significantly higher in the active military group 5.81 (95% CI 5.33 to 6.29) versus 4.85 (95% CI 4.43 to 5.27), p=0.014. Active military group patients scored significantly higher on the psychological SBT sub-score compared with the non-military group 3.9 versus 2.6 (p=0.032), and were more susceptible to express low mood 53% versus 35% (1.51 risk ratio 95%CI 1.13 to 1.89; p=0.044). There was no significant difference in expressed anxiety 69% versus 55% (p=0.139), catastrophizing thoughts 57% versus 47% (p=0.252) and avoidance beliefs 72% versus 60% (p=0.170) though all of these parameters were more prevalent in the active military group.

Conclusion: Though NMG patients had more classic low back pain risk factors such as age and obesity, this did not prevent the AMG to show higher trends toward chronicity via SBT scores. This is to our knowledge the first study to assess the high risk of persistent disabling back pain using the SBT in a Tunisian military population. The implementation of risk stratification for patients with low back pain in routine military health may improve physical function and time off work, sickness certification rates and reductions in healthcare costs compared to usual non-stratified care.

Disclosure of Interests: None declared


AB1224
NON-CONTIGUOUS MULTIFOCAL SPONDYLODISCITIS: A RETROSPECTIVE OBSERVATIONAL STUDY

S. Rekki1, S. Bousaid1, Z. Zeineb1, S. Jemmali1, S. Rahmouni1, K. Zouaoui1, H. Sahli1, M. Elleuch1. 1Rabta University Hospital, Rheumatology, Tunis, Tunisia

Background: Non-contiguous multifocal spondylodiscitis (mSpD) is a serious infection. Although literature data highlight the opportunity to miss a non-contiguous spondylodiscitis (SpD), recommendations for which cases an MRI of the entire spine should be performed are missing.

Objectives: The aim of the study was to assess the clinical features of mSpD to reveal risk factors underlying the need for screening a multifocal spine involvement.

Methods: We retrospectively evaluated the data of patients with confirmed non-contiguous multifocal spondylodiscitis.

Results: Twelve patients confirmed from mSpD were included (6 males, 6 females). The mean age was 60 years. Four patients had underlying chronic comorbidity, Diabetes (n=3), Hepatitis C virus (n=1). Most patients had spine pain (11 patients), radiculalgia in one patient, neurologic deficit (3 patients), worsening health status (7 patients). Symptoms onset was acute (n=1) or sub-acute (n=3) or long term (n=8) before admission. The mean duration between the diagnosis and the onset on symptoms was 9.6 months. Tubercular spondylodiscitis was the most detected etiology (n=8), confirmed by histological analysis (n=3) then by cellular, confirmed by serology lab test, and pyogenic SpD in two patients each. Non-contiguous multi-level involvement in the lumbar, thoracic, and cervical spine was detected in one patient for each region. Seven patients suffered from a lumbar and thoracic spine involvement and SpD occurs in the three regions in two patients. Elevated inflammatory biomarkers (CRP and ESR) were present in all cases. Bone biopsy was performed in all patients, confirmed the diagnosis, showed para-vertebral abscesses (n=3), epidural inflammation (n=6), and spinal cord compression (n=3). The majority of cases showed a favorable evolution with appropriate antibiotic therapy. One patient maintained a neurologic deficit, and one suffered from a severe degree of pain. Surgical approach was not indicated.

Conclusion: In our study, mSpD did not appear to be associated with a particular pattern. Tuberculosis was the dominant etiology. That suggests, an MRI of the entire spinal column should be performed for each patient with suspicious SpD, especially when tuberculosis is evocated.

Disclosure of Interests: None declared


AB1225
TUBERCULOUS SPONDYLODISCITIS: DIAGNOSTIC DELAY AND OUTCOMES

M. Mrabet1, S. Bousaid1, T. Abdelkefi1, S. Rekki1, S. Rahmouni1, S. Jemmali1, H. Aljani1, H. Sahli1, M. Elleuch1. 1Rabta Hospital, Rheumatology, Tunis, Tunisia

Background: Tuberculous spondylodiscitis (SPDT) is a serious clinical condition that must be treated promptly. Despite the actual availability of more effective diagnostic tools, early diagnosis of SPDT remains difficult and a high index of suspicion is needed due to the chronic nature of the disease and its insidious and variable clinical presentation.

Objectives: Our aim was to study the correlation between the diagnostic delay of SPDT and its outcomes.

Methods: We conduct a monocentric retrospective and descriptive study in a rheumatology department. Data were collected from observations of patients hospitalized in the past 20 years (2001-2021) who have been diagnosed with SPDT. An early diagnosis is defined by a diagnosis within the first six months versus a late diagnosis that is retained after 6 months of symptoms.

Results: Fifty-two cases of SPDT were collected (37F/15M). The mean age of the population was 55.21±17.79 years [19-91]. Late diagnosis was more common: 41 patients (78.8%) versus 11 patients (21.2%) diagnosed early. Complications were more frequent (61%) in patients diagnosed late, but with no statistically significant difference (p=0.1). Disease-related complications, such as spinal compression, spinal deformity and recurrence of the disease, was statistically higher (45.5%) in early diagnosed patients (p < 0.001). Drug complications, such as disruption of liver balance, hyperuricemia and major intolerance to anti-tuberculosis, were more frequent (36.6%) in patients diagnosed late (p = 0).

Conclusion: Despite highly sensitive imaging techniques, the diagnosis of tuberculous spondylodiscitis is often late, which may lead to severe deformity and early or late neurological complications.

Disclosure of Interests: None declared


AB1226
AUTOLOGOUS MOSAIC OSTEONECROPLASTY IN THE TREATMENT OF TALAR OSTEOCHONDRAL DEFECTS

T. Omelchenko1, O. Burianov2, A. Liakab3, E. Levitsky1, O. Turchin1.
1Bogomolets National Medical University, Traumatology & Orthopaedics, Kyiv, Ukraine; 2State Institute "The Institute of Traumatology and Orthopedics of Ukraine", The Clinic for Foot Pathologies and Complex Prosthetic Treatment, Kyiv Ukraine

Background: Osteochondral defects of the talus (ODT) is a relatively rare, mostly traumatic pathology, in 6.5 % of cases complicates the course of inversion and evasion injuries of the foot and ankle [1].

Objectives: To conduct a clinical analysis of the effectiveness of autologous mosaic osteochondroplasty in the treatment of patients with osteochondral defects of the talus on the basis of determining the dynamics of pain and restoring the amplitude of ankle movements.

Methods: The study included 34 patients with post-traumatic osteochondral defects of the talus (27 men, 7 women, mean age 24.8 ± 2.1 years) who underwent osteochondroplasty. The duration of painful clinical symptoms before osteochondroplasty ranged from 4 to 18 months. Functional treatment outcomes were assessed over a period of 12 to 36 months using the International Foot and Ankle Surgery Scale (AOFAS), pain assessment was performed using the Visual Analog Scale (VAS), and ankle movement recovery dynamics were determined.

Results: Osteochondral autologic grafts were removed from the lateral condyle of the ipsilateral femur. Defect sizes: square from 82 to 129 mm² (110.3 ± 0.8 mm²), depth from 7 to 16 mm (12 ± 0.8 mm). Incorporation of the graft in the recipient bed occurred within 1,5 – 3 months. Long-term follow-up was 12 – 36 months (22.8 ± 3.8 months). The level of pain was decreased from 5.7 ± 0.3 before to 0.9 ± 0.3 after the operation (p < 0.001; paired t-test). Improving of foot function according to AOFAS scale (hindfoot section) was established from 64.9
ATTITUDES AND BELIEFS ABOUT LOW BACK PAIN OF TUNISIAN PATIENTS: A KEY PREDICTOR OF RECOVERY

A. Fazaa1, M. Ben Messaoud2, S. Miladi1, H. Bossaala1, L. Soubnii1, K. Ouenniche1, S. Kassab1, S. Chekili2, K. Ben Abdelghani1, A. Laatar1, 1Mongi Slim, Rheumatology, Tunis, Tunisia

Background: Low back pain (LBP) is a common problem related with significant disability and psychosocial dysfunction. Unhelpful beliefs about it are associated with higher levels of pain and may cause a delay in recovery due to unsuitable behaviours. Therefore, studies targeting these beliefs are necessary to modulate messages delivered to the population in order to decrease the burden of LBP.

Objectives: The aim of the present study was to assess the attitudes and beliefs in the management of patients with LBP.

Methods: We applied a cross sectional study including Tunisian patients with LBP. The Arabic version of Back Pain Attitudes Questionnaire (10-item Back-Paq) was used to evaluate back beliefs as a clinical screening tool. We analysed patients’ attitudes in 5 domains: vulnerability of the back (items 1 and 2), relationship between back pain and injury (items 3 and 4), activity participation during back pain (items 5 and 6), psychological influences on back pain (items 7 and 8), prognosis of back pain (items 9 and 10). For each item, the scale ranges from −2 (“True”) to +2 (“False”). Unhelpful beliefs attract negative scores and vice versa.

Results: The questionnaire was completed by 32 participants (27 women and 5 men) with a mean age of 56.6 years (45-69). The mean LBP’s duration was 9.1 years [2-28]. The mean Body Mass Index (BMI) was 29.4 [25.5-46.8]. The mean Schober’s Test and Fingertip-to-floor (FTF) were respectively 2.8 [1.5-4] and 13.2 [9-30]. The mean Visual Analogue Scale of pain (VAS pain) was estimated at 69 [40-100]. The mean Oswestry Disability Index (ODI) and Short form Health Survey (SF36) were 42.4 [28-66] and 48.3 [20-80] respectively. Unhelpful beliefs were widespread. The mean Back-Paq-10 score was −4 [-13 -3]. Women had significantly a lower score compared to men [-4.1 [-13 -2] versus -1.6 [-5 -3] (p<0.01). Vulnerability of the back had an average score of -2[3]-1. The relationship between back pain and injury had a mean score of -2.4 [-4 -0]. The activity participation during back pain had a mean score of -4 [-1-4]. The psychological influences and prognosis of back pain had an average score of -2 [-3-0] and -1.6 [-2] respectively.

Conclusion: The results of this survey reveal that Tunisian patients have high levels of negative beliefs about LBP. As beliefs and attitudes have been recognized as significant predictors of recovery from LBP, we should promote cognitive behavioural therapy aiming at coping with unhelpful beliefs.

Disclosure of Interests: None declared


MEDICAL CARE CONSUMPTION BY TUNISIAN DOCTORS SUFFERING FROM LOW BACK PAIN

A. Fazaa1, H. Bossaala1, S. Miladi1, K. Ouenniche1, L. Soubnii1, S. Kassab1, S. Chekili2, K. Ben Abdelghani1, A. Laatar1, 1Mongi Slim university hospital, Rheumatology, Tunis, Tunisia

Background: Common low back pain (LBP) is a real public health problem. Indeed, LBP is associated with important socio-professional consequences and involves a raised cost for society due to absenteeism and presenteeism. Various studies show that it is also a major problem in workplace especially in hospitals.

Objectives: The aim of this study was to evaluate LBP medical consequences among doctors.

Methods: We performed a cross-sectional study including the medical staff of a Tunisian hospital. A standardized questionnaire was distributed to all departments and collected the following day. Doctors who had not responded to the questionnaire received two reminders before considering their exclusion. We defined two groups: Group 1 with acute LBP (<3 months) and Group 2 with chronic LBP (>3 months). The following parameters were collected: consultation with a physician, self-medication, treatments used, hospitalization, use of imaging methods and objectified spinal abnormalities. A p value inferior to 0.05 was considered statistically significant.

Results: Of the 217 questionnaires distributed to physicians, 107 (49.3%) were completed. The participating doctors were 85 women and 22 men. The mean age was 31.8 ± 7.7 years [25-57]. The mean BMI was 23.2±3.7 kg/m² [16.6-36.7]. Consumption of tobacco and alcohol was noted in 16.7% and 20.4% of cases respectively. Five participants (4.6%) reported consumption of cannabinoids. Depression, anxiety and sleep disturbances were reported in 25.3%, 57.3% and 46.7% of cases respectively. Among the participants, 84.3% reported having had LBP at least once in their life, and 71.3% reported LBP in the past 12 months. The mean duration of low back pain was greater than 3 months in 11.9% of cases. The mean pain intensity was 4.4 ± 1.9 [2-10]. Twenty participants (26%) consulted a doctor. It was a rheumatologist in 13 cases, an orthopedist in 7 cases, a neurosurgeon in 1 case and a family doctor in 1 case. More than half of the participants (57.5%) self-medicated. Standard radiography was performed in 18 cases, computed tomography (CT) in 5 cases and magnetic resonance imaging (MRI) in 8 cases. The following abnormalities were objectified: degenerative disc disease (13.6%), herniated disc (22.7%) and posterior inter-apophyseal osteoarthrits (9%). Medication use was noted in 56 cases (72.7%), functional rehabilitation in 9 cases (11.7%), back support belt in 3 cases (3.9%), epidural corticosteroid injection in 1 case (1.3%), thermal treatment in 1 case (1.3%), and surgery in 1 case (1.3%). Three doctors required hospitalization ranging from 2 to 15 days. Medical care consumption was significantly more important in patients with chronic LBP: functional rehabilitation (66.8% in group 1 vs 50% in group 2, p<0.001), back support belt (16.6% vs 20%, p=0.046), epidural corticosteroid injection (0% vs 10%, p=0.035), thermal treatment (0% vs 10%, p=0.035), surgery (0% vs 10%, p=0.035) and hospitalization (0% vs 30%, p=0.001).

Conclusion: Medical care consumption was important among LBP and chronic LBP sufferers. Thus, a prevention strategy must be established in hospitals in order to reduce the socio-economic cost of LBP among caregivers.

Disclosure of Interests: None declared

patients (9 cases) had a biological inflammatory syndrome, 36.36% (4 cases) had impaired protein electrophoresis (hyper-gamma peak) and 27.27% (3 cases) had hypercalcemia. Recourse to CT or lumbar MRI made it possible to objectively tumor bone lesions in 72.72% (8 cases) of patients, of which 3 cases (37.5%) were of prostatic origin, 2 cases (18.18%) multiple myeloma, one case of small cell carcinoma, one case of squamous cell carcinoma and one case of bladder tumor. For the other three patients (27.27% of cases), LS was caused by infectious spondylodiscitis in the lumbar stages.

Conclusion: As evidenced by our study, secondary sciatica is a very rare clinical situation, more encountered in the elderly with often an alteration of the general condition. But in front of its seriousness and its functional repercussions, arises the need to eliminate it systematically whatever the ground before starting the treatment.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4996

AB1230  EVALUATION OF THE STRUCTURAL MODIFICATION OF THE SUPRASPINATUS TENDON BY COMPUTER ANALYSIS OF ULTRASOUND IMAGES THROUGHOUT THE EVOLUTION OF TENDINOSIS.

M. Tortosa-Cabañas1, C. Guillén-Astete1, Á. Andreu-Suárez1, 1Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: In subacromial pain syndrome, the supraspinatus tendon is the most frequently injured. Supraspinatus tendinosis is a structural lesion of the tendon stroma whose ultrasound diagnosis depends largely on the observer. Due to this, the follow-up is mainly clinical, based on ordinal scales of pain or mobility. The computer analysis of the image has been recently integrated into the musculoskeletal pathology, but the evidence in ultrasound is very limited.

Objectives: To evaluate the computer analysis of the ultrasound image of the supraspinatus tendon at diagnosis and during evolution depending on the treatment administered.

Methods: A retrospective study was carried out based on the ultrasound records of patients diagnosed with supraspinatus tendinosis between 2014 and 2020. All images were obtained with the same ultrasound equipment. The records had to fulfill the following characteristics: (i) Absence of direct or indirect ultrasound signs of fibrillar continuity solution, (ii) absence of calcifying lesions and (iii) availability of an ultrasound study 5-7 months after diagnosis with the same frequency, gain, and depth parameters for each case. The ultrasound images showing tendinosis were analyzed using the ImageJ 1.53e program. The means and modes of the grayscale signal intensities were determined in longitudinal and transverse projection for each image. For the statistical analysis, paired before-after comparisons based on the normal distribution were used, grouping the patients according to the injured tendon area (lateral, central, medial) and the treatment administered. To determine the weight of the variables analyzed in the probability of resolution, a forward modeled binary logistic regression was performed using the Wald method.

Results: Records of 35 patients were included: 10 treated with immobilization, 12 with corticosteroid injections and 13 with physical therapy. Table 1 summarizes the demographic and clinical characteristics of the population. The changes observed in the mean gray intensity in the longitudinal projection of the tendon did not correlate with the fact that the patients were discharged (9.268 SD 3.752) or not (-0.2054 SD 5.262), (t=6.162, P<0.000). On the other hand, in the group of patients discharged, a greater reduction was observed in the dispersion of the mean gray intensities (-11.08 SD 5.843) compared to the group that was not discharged (1.178 SD 1.859), (t=8.458, P=0.000). In the multivariate logistic regression analysis, only the final dispersion of gray intensity was associated with the discharge condition with Coef. B=0.096, P=0.027, HR 0.908 (95% CI: 0.834-0.989).

Conclusion: Computer analysis of ultrasound images of the supraspinatus tendon in patients with pure structural tendinosis distinguishes a favorable clinical course only in the study of the cross-sectional projection, probably due to the more flattened shape of the tendon. Clinical resolution, understood as medical discharge after the second evaluation, is associated with an increase in the mean intensity of grays but especially with a reduction in the dispersion of grays.

Disclosure of Interests: None declared.


AB1231  ULTRASOUND-GUIDED INJECTION OF LOW MOLECULAR WEIGHT HYALURONIC ACID VERSUS STEROID FOR INFLAMMATORY AND DEGENERATIVE SACROILIITIS: A RANDOMIZED CONTROLLED TRIAL

K. Hosny1, M. I. Abdelkareem1, A. Moshrif1, 1Al-Azhar University, Rheumatology, Assiut, Egypt

Background: Sacroilitis may be degenerative (DSI) or inflammatory (ISI) and the latter is one of the clinical features of spondylarthropathies.

Objectives: To determine the effect of hyaluronic acid versus corticosteroid injection for chronic sacroiliac joint arthropathy.

Methods: Forty patients with sacroilitis either degenerative (DSI: 20 patients) or inflammatory (ISI: 20 patients) based on the New York criteria. Each group was allocated into 2 subgroups; 10 patients received 2ml Betamethasone dipropionate plus 2 ml lidocaine 2% (A) and 10 patients received 2 ml hyaluronic acid plus 2 ml lidocaine 2% (B). All sacroiliac joint injections were done under ultrasonographic guidance using a 22-gauge needle. Visual analogue scale was used for pain assessment at base line, 1, 2 and 4 week post injection.

Results: There was no significant difference between main groups (ISI & DSI) regarding VAS score before injection, 1, 2 and 4 weeks after injection while there was a significant difference between subgroups A&B in ISI group at 2 and 4 weeks (P= 0.012 and 0.008 respectively). Also, there was a significant difference between subgroups A & B in DSI group at 1, 2 and 4 weeks after injection (P=0.04, 0.006, and 0.005 respectively). There was a high significant difference before and after injection in the main groups and all subgroups. However, there was no significant difference between the subgroups of ISI and DSI.

Conclusion: Both steroid and hyaluronic acid were effective in relieving pain in treatment of inflammatory and degenerative sacroilitis but steroid was more efficacious than the hyaluronic acid.

Disclosure of Interests: None declared.


Table 1. Demographic and clinical characteristics of the population. GI: gray intensity according to longitudinal or transverse axis. SD: standard deviation.

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Physical therapy</th>
<th>Immobilization</th>
<th>Injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Women</td>
<td>55 (84.6%)</td>
<td>11 (70%)</td>
</tr>
<tr>
<td></td>
<td>Men</td>
<td>2 (15.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Injured area</td>
<td>Central</td>
<td>1 (77%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Lateral</td>
<td>5 (38.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Medial</td>
<td>7 (53.8%)</td>
<td>6 (60%)</td>
</tr>
<tr>
<td>GI Long axis.</td>
<td>79,209</td>
<td>20,127</td>
<td>69,953</td>
</tr>
<tr>
<td>GI Trans axis</td>
<td>81,840</td>
<td>17,291</td>
<td>74,091</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Physical therapy</th>
<th>Immobilization</th>
<th>Injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Women</td>
<td>55 (84.6%)</td>
<td>11 (70%)</td>
</tr>
<tr>
<td></td>
<td>Men</td>
<td>2 (15.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Injured area</td>
<td>Central</td>
<td>1 (77%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Lateral</td>
<td>5 (38.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Medial</td>
<td>7 (53.8%)</td>
<td>6 (60%)</td>
</tr>
</tbody>
</table>

|                  | GI Long axis.    | 79,209         | 20,127     | 69,953     | 14,815     |
|                  | GI Trans axis   | 81,840         | 17,291     | 74,091     | 19,639     |

<table>
<thead>
<tr>
<th></th>
<th>Physical therapy</th>
<th>Immobilization</th>
<th>Injections</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Women</td>
<td>55 (84.6%)</td>
<td>11 (70%)</td>
</tr>
<tr>
<td></td>
<td>Men</td>
<td>2 (15.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Injured area</td>
<td>Central</td>
<td>1 (77%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Lateral</td>
<td>5 (38.5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td></td>
<td>Medial</td>
<td>7 (53.8%)</td>
<td>6 (60%)</td>
</tr>
</tbody>
</table>

|                  | GI Long axis.    | 79,209         | 20,127     | 69,953     | 14,815     |
|                  | GI Trans axis   | 81,840         | 17,291     | 74,091     | 19,639     |
Paediatric rheumatology

**AB1232**
RELATIONSHIP BETWEEN NEW BIOMARKER (IL18 AND IFN GAMMA) WITH DISEASE ACTIVITY SCORES (DAS28 ESR AND DAS28 CRP) IN JUVENILE IDIOPATHIC ARTHRITIS (JIA)

M. Besar1, A. Abd El Salam2 on behalf of prof. Dr. Dina Abd El Halim Shahin
Professor of Internal Medicine (Rheumatology & Immunology Unit) Faculty of Medicine, Mansoura University. 1Faculty of Medicine, Mansoura University, 2Rheumatology, Immunology, Internal Medicine, Mansoura, Egypt

**Background:** Juvenile idiopathic arthritis (JIA) is a chronic inflammatory condition lasting ≥6 weeks in children ≤16-year-old and characterized by pro-inflammatory cytokines (IL1B, IL6, IL18, and IFN- gamma) as a key cytokine in inflammation. The pathogenesis of JIA are still poorly understood and different theories are implicated. Different disease activity scores aimed at guiding the treatment strategies.

**Objectives:** Correlation between new biomarker (IL18 and IFN gamma) with disease activity scores (DAS28 ESR and DAS28 CRP) and how much these biomarkers change with treatment.

**Methods:** Prospective nonrandomized study carried on 45 child diagnosed as Juvenile Idiopathic Arthritis (JIA) fulfilling (ILAR)1997 where assessment of the level of IL18, IFN gamma and IL18, IFN-gamma decrement with correlation to disease activity (Juvenile Arthritis Disease Activity Score (JADAS)) and their role as prognostic markers.

**Results:**
- Serum IL18 and IFN gamma show significant decrease with the end of the study (Figure 1).
- The disease activity (JADAS ESR), (JADAS CRP) has decreased significantly with the end of the study (Table 1).
- Serum IL18 show negative correlation with ESR, CRP, JDA571ESR, JDA571CRP and IFN gamma level.
- Poor response groups show higher level of ESR, JADAS18 and IL18 than good response groups. IL18 and IFN-gamma decrement level was statistically significant higher in good response than poor response.

**Conclusion:** IL18 and IFN-gamma cytokine and level of decrement are a useful biomarker in predicking the disease activity and response to therapy.

**REFERENCES:**

**Disclosure of Interests:** None declared

**AB1233**
CHARACTERISTICS OF Pediatric MPO and PR-3 ANCA ASSOCIATED VASCULITIS- SINGLE CENTER EXPERIENCE FROM CENTRAL CALIFORNIA

D. Singh1, S. Sukesh1, 1 Valley Children’s Healthcare, Division of Rheumatology, Madera, United States of America

**Background:** ANCA-associated vasculitides (AAV) are rare in childhood and characterized by necrotizing inflammation in small to medium sized vessels. Most of the available literature in children focuses on clinical subtypes Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA). Adult studies have demonstrated differences in clinical outcomes based on myeloperoxidase (MPO) and proteinase 3 (PR3) ANCA specificity (1). There is limited information about the characteristics of MPO- AAV and PR3-AAV in children.

**Objectives:** The objective of this study was to review the characteristics of MPO-AAV and PR3-AAV at a children’s hospital in multi-ethnic Central California, United States.

**Methods:** We performed a retrospective case review of patients less than 18 years of age diagnosed with AAV at a tertiary care children’s hospital in Central California in United States from January 1, 2010 to March 31, 2021. Cases were identified from electronic health records using ICD-9 and ICD-10 codes for vasculitis. Records were reviewed for a diagnosis of AAV based on ACR/ EULAR classification criteria. Demographic and clinical data including laboratory parameters including ANCA specificity, treatment, and outcomes were collected. Continuous data were expressed as a median and interquartile range, categorical data as frequency and percentages. Chi-square and Mann-Whitney U tests were used for statistical comparison as appropriate.

**Results:** Eighteen cases of pediatric AAV were identified, of which 10 (55.5%) patients had MPO-AAV and 8 (44.4%) had PR3-AAV. All patients who were MPO positive were diagnosed with GPA. Among PR3-AAV cohort, 7 patients were diagnosed with GPA and 1 patient received diagnosis of MPA. The median age at diagnosis was 12.6 years (IQR 10.1-15.4) in patients with MPO-AAV and 14.8 years (13.8-16.7) in children with PR3-AAV. In MPO-AAV cohort, 90% (n=9) were female, meanwhile 37.5% (n=3) of patients diagnosed with PR3- AA V were female (p=0.02). Significantly higher proportion of patients diagnosed with MPO-AAV were from racial and ethnic minority groups (n=10, 100%) which included Hispanic (8), Asian (1) and other (1). In comparison, patients with PR3-AAV were predominantly white (n= 7, 87.5%; p < 0.01). Median length of hospital stay was 19 days (IQR=12.8-21) in patients with MPO-AAV and 14 days (IQR=9.5-21.8) in patients with PR3-AAV. Rate of ICU admission was 60% in MPO-AAV cohort and 37.5% in PR-3 cohort, although this was not statistically significant. 50% (n=5) of patients in MPO-AAV cohort required dialysis and 25% (n=2) in PR3- AAV cohort. Peak creatinine was higher in MPO-AAV cohort (74, IQR 1-13.4 versus 2, IQR 0.7-3.7 mg/dL), although it did not reach statistical significance (p=0.1), PR3-AAV group had significantly higher levels of C-reactive protein (22.9, IQR=7-0.26.3) compared to MPO-AAV cohort (2,25, IQR=0.3-6.2; P=0.02). ENT involvement was more frequent in PR3-AAV cohort (87.5% versus 10%), All patients received treatment with high dose corticosteroids at diagnosis. Other immunosuppressive therapy included cyclophosphamide (40% in MPO-AAV cohort and 75% in PR-3 AAV cohort), rituximab (40% MPO- AAV cohort and 0% in PR-3 AAV cohort), cyclophosphamide and rituximab (10% in MPO- AAV cohort and 25% in PR-3 AAV cohort). Two deaths were reported in MPO-AAV cohort, related to Aspergillus pneumonia and pulmonary hemorrhage.

**Conclusion:** Our study reviews characteristics of pediatric MPO-AAV and PR3- AAV in the Central California of United States. We observed a more frequent diagnosis of MPO-AAV in racial/ethnic minority children. Limitations of our study include small sample size. This study highlights the need for further research to understand the impact of ethnicity and MPO and PR3 positivity on pediatric AAV presentation, disease activity and outcomes.

**REFERENCES:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.797
An oncological search was carried out. The following diagnoses were verified: stage 4 neuroblastoma (4/15), acute lymphoblastic leukemia (5/15), stage 4 B-large cell lymphosarcoma (1/15), stage 4 B-lymphoblastic lymphoma/leukemia (1/15), T-cell lymphoma (1/15), stage 3 glioma (1/15), malignant histiocytoma (1/15), brain tumor (1/15).

Conclusion: Oncological diseases in children can occur under the guise of rheumatic diseases. Immunosuppressants and glucocorticoids mask the true clinical picture of the neoplasm and prevent early diagnosis.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.1173

**AB1235**

MULTISYSTEM INFLAMMATORY DISEASE IN CHILDREN (MIS-C) IN SINGAPORE: ARE WE DIFFERENT?

L. Das1, K. L. Teh1, X. Gao1, T. Arkachaisri1,2; 1KK Women's and Children's Hospital, Rheumatology and Immunology, Singapore, Singapore; 2Duke-NUS Medical School, Rheumatology and Immunology, Singapore, Singapore

**Background:** Multisystem Inflammatory Syndrome in Children (MIS-C) is a hyper-inflammatory state with similarities to Kawasaki Disease, 4 to 6 weeks after Covid-19 infection1. Literature describes a 11:1 Relative Risk for Asian children versus Caucasians2. Since the start of the pandemic, 17,699 children under 12 years were infected with Covid-193.

**Objectives:** To describe presentation and short term outcomes, for a cohort of children with MIS-C at the sole Children's Hospital in Singapore.

**Methods:** Demographic and clinical/lab data were collected from children diagnosed with MIS-C according to the WHO criteria4 at KK Woman's and Children's Hospital, Singapore. Nonparametric descriptive statistics were used to describe and analyse data.

**Results:** Eleven patients were diagnosed with MIS-C between October 2021 and Jan 2022. Seven (64%) were male and 4 (36%) were Chinese, with median age at presentation was 8.08 years (IQR 4.54 - 9.79). All patients had positive COVID-19 serology at the time of diagnosis. Median duration of fever prior to diagnosis was 5 days (IQR 4 - 5); Nine (82%) had gastrointestinal symptoms and median number of Kawasaki Disease (KD) features were 2 (IQR 2 - 3.5); common manifestations were conjunctivitis (90%), red lips (55%) and rash (36%). Of note, 5 (70%) patients had KD type peeling on follow-up. No BCgitis was found during acute phase. Seven (64%) were admitted to higher dependency care. Table 1, all patient received IVIG and IV steroids; 6 (55%) as pulse (30mg/kg/day) therapy. Patient 8, additionally received Anakinra. Median duration of admission was 6 days (IQR 5-13). One patient developed complications post therapy and was re-admitted to hospital for hematoma chezia. Treatment involved stopping Enoxaparin and Prednisone. Aspirin was resumed as soon as bleeding ceased. Laboratory characteristics and outcomes are denoted in Table 1. All patients had a monophasic course during the median of 10 weeks (IQR 8 - 11.5) of follow-up.

**Conclusion:** Asian prevalence of MIS-C is not as high as that reported from Western. Similarities in presentation as to age and gender were noted. 2. Most of our MIS-C patients developed periungual peeling at follow up, similarly to Kawasaki Disease.

3. Different from our typical KD population, no BCG site inflammation was found.

**REFERENCES:**


<table>
<thead>
<tr>
<th>No</th>
<th>Age (yr)</th>
<th>GI symptoms</th>
<th>KD features</th>
<th>Hemoglobin (g/DL)</th>
<th>Absolute Lymphocyte (10x9/L)</th>
<th>Platelet (10x9/L)</th>
<th>CRP (mg/L)</th>
<th>D-Dimer (mg/L FEU)</th>
<th>Ferritin (ug/L)</th>
<th>Enoxaparin started</th>
<th>Peeling</th>
<th>Abnormal echo</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10</td>
<td>YES</td>
<td>2</td>
<td>12.2</td>
<td>0.23</td>
<td>67</td>
<td>173.2</td>
<td>32</td>
<td>3179.1</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>2</td>
<td>11</td>
<td>NO</td>
<td>2</td>
<td>14.8</td>
<td>1</td>
<td>166</td>
<td>94.9</td>
<td>2.51</td>
<td>350</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>3</td>
<td>4.25</td>
<td>YES</td>
<td>1</td>
<td>10.4</td>
<td>1.02</td>
<td>241</td>
<td>134.6</td>
<td>6.05</td>
<td>2772</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>4</td>
<td>7.67</td>
<td>YES</td>
<td>5</td>
<td>11</td>
<td>0.41</td>
<td>102</td>
<td>250.6</td>
<td>9.32</td>
<td>380676</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>5</td>
<td>8.58</td>
<td>YES</td>
<td>4</td>
<td>11.4</td>
<td>0.56</td>
<td>93</td>
<td>106.6</td>
<td>1.31</td>
<td>846.6</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>6</td>
<td>4.58</td>
<td>YES</td>
<td>2</td>
<td>10.3</td>
<td>3.09</td>
<td>198</td>
<td>137.4</td>
<td>1.87</td>
<td>291</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>7</td>
<td>9.58</td>
<td>YES</td>
<td>3</td>
<td>12.2</td>
<td>1.31</td>
<td>119</td>
<td>184</td>
<td>2.51</td>
<td>244.3</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>8</td>
<td>4.6</td>
<td>YES</td>
<td>1</td>
<td>11.5</td>
<td>0.45</td>
<td>102</td>
<td>1981.8</td>
<td>11.12</td>
<td>1738.4</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>9</td>
<td>11</td>
<td>YES</td>
<td>1</td>
<td>10.1</td>
<td>1.23</td>
<td>59</td>
<td>74.2</td>
<td>4.53</td>
<td>1445.8</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>10</td>
<td>3.42</td>
<td>NO</td>
<td>2</td>
<td>9.1</td>
<td>1.09</td>
<td>138</td>
<td>153.9</td>
<td>8.66</td>
<td>609.4</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
</tr>
<tr>
<td>11</td>
<td>8.08</td>
<td>YES</td>
<td>2</td>
<td>11.4</td>
<td>1.25</td>
<td>101</td>
<td>68.6</td>
<td>1.31</td>
<td>5218.8</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
</tr>
</tbody>
</table>
Results: We extracted data of 187 JSSc patients from the JSScC and 236 patients from EUSTAR. The mean age at time of assessment was 13.4 years old in the JSScC and 32.4 years old in EUSTAR. The mean disease duration since first non-Raynaud was 3.0 years in JSScC and 18.5 years in the EUSTAR (Table 1). We found significant differences between the cohorts. There were more female patients in EUSTAR (87.7% versus 80.2%, p=0.04). More patients had diffuse subtype in JSScC (72.2% versus 40%, p<0.001). The modified Rodnan skin score (mRSS) was significantly higher in JSScC (14.2 versus 12.1, p=0.02). Active digital ulceration occurred more often in EUSTAR (26.6%, versus 17.8%; p=0.01), but history of active ulceration was more frequent in JSScC (54.1% versus 43%, p<0.001). Mean DLCO was lower in JSScC (75.4 versus 86.3, p<0.001). Intestinal involvement was significantly more common in JSScC (33.2% versus 23.8%, p=0.04). Esophageal involvement was more common in EUSTAR (63.7% versus 37.7%, p<0.001) (Table 1).

### Table 1. Clinical characteristics of juvenile onset SSc patients at point of the inclusion into the juvenile scleroderma inception (JSScC) cohort and in the adult EUSTAR cohort

<table>
<thead>
<tr>
<th>JSScC</th>
<th>EUSTAR Cohort</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>187</td>
<td>236</td>
</tr>
<tr>
<td>Age in years, mean (SD)</td>
<td>13.4 (3.6)</td>
<td>32.4 (15.4)</td>
</tr>
<tr>
<td>Female patients, n (%)</td>
<td>150 (80.2%)</td>
<td>207 (87.7%)</td>
</tr>
<tr>
<td>JSSc Subtype, n (%)</td>
<td>diffuse</td>
<td>135 (72.2%)</td>
</tr>
<tr>
<td></td>
<td>limited</td>
<td>52 (27.8%)</td>
</tr>
<tr>
<td>Age at Raynaud onset, mean (SD)</td>
<td>10.3 (3.9)</td>
<td>11.7 (3.7)</td>
</tr>
<tr>
<td>Age at non-Raynaud onset, mean (SD)</td>
<td>10.0 (3.9)</td>
<td>13.7 (9.1)</td>
</tr>
<tr>
<td>Duration since first non-Raynaud symptoms in years, mean (SD)</td>
<td>3.4 (2.7)</td>
<td>20.6 (15.9)</td>
</tr>
<tr>
<td>Duration since first Raynaud symptoms in years, mean (SD)</td>
<td>3.0 (2.7)</td>
<td>15.6 (15.6)</td>
</tr>
<tr>
<td>Sex female patients, n (%)</td>
<td>150 (80.2%)</td>
<td>207 (87.7%)</td>
</tr>
</tbody>
</table>

Conclusion: Patients with JSSc-onset who are currently adult age (defined as >18 years of age) are less frequently male and from the diffuse subset, have lower mRSS, less digital ulcers and intestinal involvement. This might represent a combination of both survival bias and/or be explained by the longer observation time with less active disease (i.e. natural progression decreased mRSS over time). Further long-term observational studies with JSSc patients are required to address this issue.

Disclosure of Interests: None declared


### Table 1. Association between EIA and CLIA with clinical and analytical variables.

<table>
<thead>
<tr>
<th>Serum calprotectin (EIA)</th>
<th>Remission</th>
<th>PE Count</th>
<th>US Count</th>
<th>PE JADAS</th>
<th>US JADAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC(EIA)</td>
<td>0.67</td>
<td>0.001</td>
<td>0.14</td>
<td>0.027</td>
<td>0.08</td>
</tr>
<tr>
<td>SC(CLIA)</td>
<td>0.67</td>
<td>0.000</td>
<td>0.00</td>
<td>0.945</td>
<td>0.31</td>
</tr>
<tr>
<td>CRP</td>
<td>0.67</td>
<td>0.00</td>
<td>0.00</td>
<td>0.950</td>
<td>0.05</td>
</tr>
<tr>
<td>ESR</td>
<td>0.67</td>
<td>0.00</td>
<td>0.00</td>
<td>0.950</td>
<td>0.05</td>
</tr>
</tbody>
</table>

On the other hand, we observed a statistically significant difference in the mean between both methods of 0.58 (95% CI=0.40-0.77; p=0.000), observing a greater difference in SC (EIA) > 4 µg/ml. A significant association was observed between EIA and clinical remission, joint count, JADAS and CRP; and also between CLIA and clinical remission, JADAS and CRP. The analysis performed is shown in Table 1.

### Table 1. Association between EIA and CLIA with clinical and analytical variables.

<table>
<thead>
<tr>
<th>Remission</th>
<th>PE Count</th>
<th>US Count</th>
<th>PE JADAS</th>
<th>US JADAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC(EIA)</td>
<td>0.67</td>
<td>0.001</td>
<td>0.14</td>
<td>0.027</td>
</tr>
<tr>
<td>SC(CLIA)</td>
<td>0.67</td>
<td>0.000</td>
<td>0.00</td>
<td>0.945</td>
</tr>
<tr>
<td>CRP</td>
<td>0.67</td>
<td>0.00</td>
<td>0.00</td>
<td>0.950</td>
</tr>
<tr>
<td>ESR</td>
<td>0.67</td>
<td>0.00</td>
<td>0.00</td>
<td>0.950</td>
</tr>
</tbody>
</table>

b: regression coefficient; p, statistical significance.

Conclusion: There are no differences between EIA and CLIA methods to determine SC in pediatric patients with SARD. Significant differences were observed between both methods above the value of 4 µg/ml. This fact could be explained by methodological differences, since CLIA discriminates better at higher values than EIA.
An association was observed between both methods and variables of remission or disease activity.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1892

**AB1238**
THE EFFECT OF DRUG THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS ON THE LEVEL OF CYSTATIN C AS A MARKER OF RENAL Dysfunction

S. Samsonenko1, T. Borosova1,2. Dnipro State Medical University, Department of Pediatrics 2, Dnipro, Ukraine

**Background:** Juvenile idiopathic arthritis (JIA) is a chronic disease requiring years of therapy with non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants, cytostatics, and immunobiological agents. The aforementioned drugs, namely NSAIDs and cytostatics are potentially nephrotoxic [1]. The above drugs, namely NSAIDs and cytostatics, are potentially nephrotoxic. About 8% of children with JIA have kidney damage, which develops on average 5 years after the onset of the disease. It has been established that the main risk factor for the development of kidney damage is the long-term exposure to NSAIDs and methotrexate in children with active forms of JIA [2]. Early diagnosis of kidney damage will allow timely correction in the dosage of drugs and avoid their nephrotoxic effects [3].

**Objectives:** To determine the effect of drug therapy in children with JIA on eGFR by using the Cystatin C-based equation and the Hoek formula based on the serum cystatin C study.

**Methods:** 80 children with JIA participated in the study. The age of subjects was 10.4±4.41 (10.6-15.0) years. All children received methotrexate as a base drug. At the moment of examination 22 children received NSAIDs, 25 children received immunological preparations. Serum cystatin C content was determined by enzyme immunoassay. The Cystatin C-based equation 2012 and Hoek formulas were used to set the GFR by serum cystatin C levels.

**Results:** Non-steroidal anti-inflammatory drugs led to a decrease in GFR as found by both the Cystatin C-based equation 2012 and the Hoek formula. The incidence of GFR reduction in patients treated with NSAIDs using the Cystatin C-based equation 2012 was 100%, and using the Hoek formula was 81.8%. The use of NSAIDs in children with JIA is a risk factor for the development of reduced GFR calculated by the Hoek formula. The incidence of reduced GFR in children with NSAID use was 54.5%, 6.7 times greater than in those without NSAIDs (OR = 12.9; CI: 3.76-44.25; p<0.001). There was a low chance of a Hoek formula decrease in GFR in children with JIA who received immunobiological therapy 9.1% vs 46.8% (OR = 0.11; CI: 0.03-0.42; p<0.001).

**Conclusion:** Use of NSAIDs in children with JIA was more often associated with a reduction in GFR by Cystatin C-based equation 2012 in 100% of cases p<0.01, by Hoek in 81.8%, p<0.001. The average of GFR was significantly lower in children treated with NSAIDs than in children without NSAIDs. Immunobiological therapy had a positive effect on the GFR value. The frequency of a decrease in GFR was significantly lower in children treated with immunobiological therapy compared with those without immunobiological therapy 9.1% vs 46.8% (OR = 0.11; CI: 0.03-0.42; p<0.001).

**References:**

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2154

**AB1240**
PROSPECTIVE EVALUATION OF COGNITIVE FUNCTION IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

E. Ortiz-Márquez1, C. Padilla-Leiva2, P. Cabezudo-García2, G. Díaz-Cordobes1, L. Muñoz-Becerra2, N. Mena-Vázquez2, 1Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, UGC de Reumatología, Málaga, Spain; 2Universidad de Málaga, Departamento de Medicina, Málaga, Spain; 1Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, UGC de Neurociencias, Málaga, Spain

**Objectives:** Prospectively evaluate changes in the cognitive function of patients with juvenile idiopathic arthritis (JIA) and associated factors.

**Methods:** Design and protocol: We performed a prospective cohort study with JIA patients that participated in a previous cross-sectional study (2019) to evaluate cognitive function. After 24 months, the patients were administered the same test battery previously used through an established protocol, and data was collected from their clinical histories. The neuropsychological tests were corrected by a neuropsychologist and neuropsychologist. Study population: Inclusion criteria: Patients aged ≥16 years with JIA classified according to the criteria of ILAR 2001. Patients with inflammatory or rheumatic diseases other than JIA, previous neurological disease not associated with the course of JIA, patients that participated in a previous cross-sectional study (2019) to evaluate cognitive function; and patients with scores lower than the normal in the manual skill test were excluded. Outcomes: The main variable was cognitive impairment, defined as worsening of ≥2 scaled points after 24 months (2024) in any of the tests used to evaluate each cognitive area in the Wechsler Adult Intelligence Scale (WAIS). The evaluated cognitive domains and their respective subscores were: Attention-concentration (Digit Span); verbal function (Vocabulario); processing speed (Organization - Block Design); working memory (Letter-Number Sequencing); problem-solving (Similarities). Depression was evaluated by The Beck Depression Inventory-II (BDI-II): minimal (0-13), mild (14-19), moderate (20-28), and severe (29-63). Other variables: Clinical-epidemiological characteristics; treatments; and inflammatory activity evaluated as the C-reactive protein average (CRP) and JADAS-27 along the 2 years of follow-up. Statistical analysis: Descriptive analysis, followed by y2 and paired T-test. Multivariate analysis to identify independent variables associated with impairment of cognitive function in JIA.
Results: Thirty patients with JIA were included. The clinical characteristics in V24 are shown in Table 1. Thirteen patients (43%) showed improvement in one or more cognitive functions. The most frequent impaired cognitive functions were verbal function (13.3%), visuospatial organization (13.3%) and problem solving (13.3%); followed by attention/concentration (10.0%) and working memory (6.7%). The variables independently associated with cognitive impairment were the mean CRP along the follow-up (OR [IC 95%], 1.010 [0.670-1.500]; p=0.48) and depression (OR [IC 95%], 1.358 [1.028-1.794]; p=0.031). This model would explain the 47% of the cognitive impairment in JIA (RZ²=0.470).

Objectives: BMD and osteopenia are lacking in younger patients with the disease. Osteoporosis is common in postmenopausal women with MCTD (1), but data regarding 25% of all cases have a pediatric presentation. One study implies that osteopenia.

Methods: BMD was measured in a cohort of 52 JMCTD patients with mean age 28.2 years (SD 10.3) and mean disease duration 16.2 years (SD 10.3), and 52 controls matched for age and gender. Inclusion criteria were fulfillment of the Kasukawa’s or the Aracan-Segovia criteria and symptom debut before the age of 18 years.

Results: Patients and controls did not differ in age, body mass index, smoking habits, level of physical activity or vitamin D status (Table 1). Forty-four (85%) were female. Patients were shorter and had lower body weight compared to controls. None had had osteoporotic fractures. Patients over 20 years of age at height, cm 166.0 (7.5) 170.1 (8.5) 0.016

Conclusion: Forty percent of the patients with JIA showed cognitive impairment after 24 months of follow-up. Cognitive impairment was associated with higher inflammatory activity and depression.

Disclosure of Interests: None declared


Table 1. Clinical, laboratory, and treatment characteristics of 30 patients with JIA

<table>
<thead>
<tr>
<th>Variable</th>
<th>JIA n=30</th>
<th>Controls n=52</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>22.7 (3.5)</td>
<td>23.4 (3.0)</td>
<td>0.229</td>
</tr>
<tr>
<td>Height, cm</td>
<td>166.0 (7.5)</td>
<td>170.1 (8.5)</td>
<td>0.016</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>63.0 (12.1)</td>
<td>68.1 (12.1)</td>
<td>0.033</td>
</tr>
<tr>
<td>Neutrophils, n (%)</td>
<td>3.5 (67)</td>
<td>34 (65)</td>
<td>0.033</td>
</tr>
<tr>
<td>Moderate physical activity (hours/week)</td>
<td>2.0 (0-28)</td>
<td>1.2 (0-30)</td>
<td>0.278</td>
</tr>
<tr>
<td>Vitamin D*, nmol/l, median (range)</td>
<td>50.0 (27-106)</td>
<td>51.5 (23-115)</td>
<td>0.829</td>
</tr>
</tbody>
</table>


Conclusion: Most pts with RF+ JIA needs to require B in the first year of the disease and about 25% of all cases have a pediatric presentation. This model would explain the 47% of the cognitive impairment in JIA (RZ²=0.470).
REFERENCE:

Disclosure of Interests: Maria Kaleda Speakers bureau: Pfizer, Roche, Novartis, Iris Nikishina Speakers bureau: Pfizer, MSD, Roche, Novartis, Sobi, Evgeny Fedorov Speakers bureau: Novartis, Sobi, MEDAC, Svetlana Salugina Speakers bureau: Novartis, Sobi, Svetlana Arsenjeva; None declared, Zarina Kolkhidova: None declared, Anna Shapovalenko; None declared, Tamara Pachkoria; None declared, Valeria Matkava: None declared, Valeriia Matkava: None declared


AB1243
EFFICACY OF ABATACEPT IN THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS ASSOCIATED UVEITIS
P. Rodríguez González1, D. Fernández Fernández2, I. González Fernandez3, R. Dos-Santos2, P. Castro-Santamaría2, M. Sanchez-Wonenburger2, J. L. Puga Guzmán1, A. Mata1, A. Souto Vilas4, E. Perez-Pampín5, A. Mera Varela2.

1Universidad de Medalla (USC), Medicine, Santiago de Compostela, Spain; 2Santiago Clinic Hospital CHUS, Rheumatology, Santiago de Compostela, Spain

Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in pediatric age. uveitis is the most frequent extra-articular complication (1). Uveitis, if not properly treated, can lead to potentially irreversible ocular complications such as blindness. The treatment of uveitis associated with JIA (U-JIA) remains a challenge due to the aggressiveness of the disease and the frequency of complications. Following the current guidelines for screening and treatment of uveitis, the use of topical and systemic corticosteroids, Methotrexate, cyclosporine or some biological drugs such as Adalimumab constitute the mainstay of treatment in this manifestation. In some refractory cases, the use of Abatacept has been reported

Objectives: To analyze the efficacy of Abatacept in the treatment of U-JIA from the data available in the scientific literature.

Methods: We performed a systematic review of the scientific literature, following the PRISMA statement, using the following electronic databases: Medline, Embase, Cochrane Library and Web of Science.

Results: An overall of 89 bibliographic references fulfill the inclusion criteria. A total of 64 patients from 6 studies were followed for a mean time per patient of 11.5 months. The mean age of onset of JIA was 5.25 years, with a time of evolution of the disease of 7 and 11.85 years. In all the series included, a high percentage of patients showed complications secondary to ocular inflammation (synechia, band keratopathy, cataracts, macular cystic edema and/or ocular hypertension) as well as visual deficits secondary to JIA-U.

All patients, have shown refractoriness to conventional DMARDs, as well as anti-TNF biological drugs. In all the studies, the best correct visual activity (BCVA) is used as main outcome measure. Another outcome measures were used: number of uveitis flares, the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), or the number of cells present in the anterior eye chamber.

Four series of cases showed an improvement or stabilization of visual acuity after Abatacept treatment. Two studies provided variations in visual acuity that are not statistically significant.

Regarding the efficacy of Abatacept, we can observe improvement, in the most of the studies we observed a decrease in the severity of the ocular inflammation and/or its complete remission.

Due to the lack of comparable data, a meta-analysis could not be performed. However the data suggest a clear recovery of 1 JIA-U patients refractory to conventional treatment.

Conclusion: Abatacept is shown as a promising drug in the treatment of U-JIA, considering its efficacy in improving visual acuity, as well as in the control of flare-ups and the decrease in inflammatory eye symptoms. However, more studies are necessary to corroborate the efficacy of Abatacept

REFERENCES:

Disclosure of Interests: None declared


AB1244
TOTAL KNEE ARTHROPLASTY IN PATIENTS UNDER 21 YEARS OF AGE: A U.S. NATIONALWIDE ANALYSIS
J. A. Gibbons1, C. Kahlenberg2, D. Jannatt-Khah1, S. Goodman1, P. Sculco2, M. Figgie3, B. Mehta4,5, Hospital for Special Surgery Main Hospital, Medicine, New York, United States of America; 4Hospital for Special Surgery Main Hospital, Surgery, New York, United States of America; 5Weill Cornell Medicine, Medicine, New York, United States of America

Background: Total knee arthroplasty (TKA) is a procedure rarely performed in patients under 21 years old. However, the number of patients <21 undergoing TKA in the United States is unknown. In one of the largest US studies of an institutional arthroplasty registry, only 19 TKAs were performed in patients <21 out of ~30,000 primary TKAs over 34 years. While a few national or multi-national studies have been performed outside the US, these studies have small cohorts (~100), making it difficult to determine the indications for TKA in this age group.

Objectives: We identified the number of patients <21 years of age who underwent TKA in a US nationwide dataset. Additionally, we determined the epidemiological characteristics of patients undergoing TKA, including their age, sex, race, indications for surgery, and in-hospital mortality.

Methods: We analyzed the Kids’ Inpatient Database, which is a national weighted sample of all inpatient hospital admissions in the US in patients <21 years old from ~4,200 hospitals in 46 states. We included all admissions from 2000-2016 with a primary procedural code of TKA determined by ICD-9 and 10 codes. Descriptive statistics such as means and percentages, along with 95% confidence intervals were calculated using appropriate sample weights.

Results: The total number of TKAs performed in patients <21 years old from 2000 to 2016 was 1,331 (Table 1). The majority of TKAs performed (n=936; 70.3%) were for treatment of an oncologic disease. The most common diagnosis was malignant tumor (68.7%), followed by osteoarthritis (7.3%) and inflammatory arthritis or juvenile idiopathic arthritis (JIA) (70%) (Figure 1). Osteonecrosis accounted for 3.9% of cases, while mechanical complications accounted for 3.3%. Fewer than 2% of cases had an indication of either benign or uncertain tumor, infection, or trauma. The mean age was 14.8 years, and 48.4% of the cohort was female. A higher proportion of the non-tumor cohort was female (57.1%) than the tumor cohort (44.7%). 57.1% of patients in the overall cohort were White, and this proportion was smaller in the tumor group (53.8%) than the non-tumor group (64.9%). No patients died during the inpatient event. 87.8% of TKAs were performed in urban teaching hospitals.

Table 1. Characteristics of patients <21 undergoing TKA by diagnosis type

<table>
<thead>
<tr>
<th>Variable</th>
<th>Overall N = 1331</th>
<th>Non-tumor N = 395</th>
<th>Tumor N = 936</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (95% CI)</td>
<td>14.8 (14.1, 15.5)</td>
<td>15.9 (14.7, 17.1)</td>
<td>14.3 (14.1, 16.4)</td>
</tr>
<tr>
<td>Sex, Female, % (95% CI)</td>
<td>64.9 (55.5, 73.3)</td>
<td>53.8 (48.4, 59.2)</td>
<td></td>
</tr>
<tr>
<td>Age, mean (95% CI)</td>
<td>13.1 (10.1, 16.9)</td>
<td>16.9 (10.1, 27.2)</td>
<td>11.5 (8.7, 14.9)</td>
</tr>
<tr>
<td>Race, % (95% CI)</td>
<td>4.9 (2.9, 7.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian on Islander</td>
<td>2.9 (1.3, 6.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Native American</td>
<td>0.4 (0.09, 19)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>70.4 (48.0, 10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payor, % (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicare</td>
<td>1 (0.7, 2.9)</td>
<td>4.7 (2.2, 9.7)</td>
<td></td>
</tr>
<tr>
<td>Medicaid</td>
<td>32.4 (28.3, 36.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Private</td>
<td>36.7 (51.2, 67.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>4.2 (2.7, 6.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Admission type: elective, % (95% CI)</td>
<td>6.6 (4.5, 9.4)</td>
<td>5.1 (3.0, 8.6)</td>
<td>6.6 (4.5, 9.4)</td>
</tr>
</tbody>
</table>

Figure 1. Most common primary diagnoses for TKA in patients <21 years old

References:

Disclosure of Interests: None declared


Total Knee Arthroplasty in Patients Under 21 Years of Age: A U.S. Nationwide Analysis
J. A. Gibbons1, C. Kahlenberg2, D. Jannatt-Khah1, S. Goodman1, P. Sculco2, M. Figgie3, B. Mehta4,5
Conclusion: TKA is a rarely-performed procedure for patients <21 years old in the US; it is mainly performed in urban teaching centers and has excellent in-hospital survival rates. 70.3% of these procedures are performed for tumors—the vast majority of which are malignant. Also, even with the advent of better treatment options for JIA and inflammatory arthritis, TKA is still performed frequently in this population indicating that better clinical management is needed.

REFERENCES:

Acknowledgements: This work was supported by the Kellen Scholar Award supported by the Anna Marie and Stephen Kellen Foundation Total Knee Improvement Program. The authors would like to acknowledge the Healthcare Cost and Utilization Project Data Partners that contribute to Healthcare Cost and Utilization Project: Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming.

Disclosure of Interests: None declared.

REFERENCES:

Acknowledgements: Supported by a grant from The Arthritis Foundation of Western Australia

Disclosure of Interests: None declared


<table>
<thead>
<tr>
<th>Table 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokines</td>
</tr>
<tr>
<td>EGF</td>
</tr>
<tr>
<td>TGFa</td>
</tr>
<tr>
<td>IL-10</td>
</tr>
<tr>
<td>IL-12</td>
</tr>
<tr>
<td>IL-13</td>
</tr>
<tr>
<td>sCD40L</td>
</tr>
<tr>
<td>IL-4</td>
</tr>
<tr>
<td>IL-5</td>
</tr>
<tr>
<td>IL-6</td>
</tr>
<tr>
<td>IP10</td>
</tr>
</tbody>
</table>

Conclusion: we identified differences in cytokines levels between JLE patients and HC and found multiple correlations between manifestations and different cytokines levels. Most of them were in IL-3, IL-6, IL-8, IL-15, MCP-1 and MCP3.

REFERENCES:

Acknowledgements: This research was funded by the Ministry of Science and Higher Education of the Russian Federation (Agreement No. 075-15-2020-901)

Disclosure of Interests: None declared

**AB1247** ASSESSMENT OF ARTICULAR AND EXTRA-ARTICULAR DAMAGE IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

A. Fazaï1, N. Ben Saled1, S. Miladi1, H. Bousassa1, L. Souabni1, K. Gueniche1, S. Chekili1, S. Kassab1, K. Ben Abdelghani1, A. Lataire1. 1Hôpital Mongi Slim, Rheumatology, Marsa, Tunisia

**Background:** Juvenile idiopathic arthritis (JIA) affects patients’ well-being and can lead to disability and long-term damage. Evaluating damage in patients can be beneficial to make therapeutic decisions and take rehabilitation measures.

**Objectives:** To assess articualr and extra articular damage in patients with JIA by the use of the Juvenile Arthritis Damage Index (JADI) and to identify variables that correlate with disease damage.

**Methods:** We conducted a cross-sectional study among patients with JIA who met the ILAR classification criteria and had a disease duration more than 12 months. Early clinical data was obtained from medical files. It included socio-demographic features, biological and radiological parameters, subtype of JIA, disease duration and ongoing treatments. Damage was assessed in the last clinical visit using articualr and extra-articular damage index (JADI-A and JADI-E).

**Results:** Thirty-two patients were enrolled in this study with a mean age of 23.8 ± 11.6 years. Sex ratio was 0.6 (12 males and 20 females). The mean age of disease onset was 8.3 years [3-15], and the mean disease duration was 183.7 months [12-624]. At the last clinical examination, 71.9% of patients had joint damage with a mean JADI-A score of 5.09 ± 5.4 and 40.6% of patients had extra-articular damage with a mean JADI-E score of 0.75 ± 1.2. The most affected joints were: the elbows (43.8%), the hips (37.5%) and the wrists (25%). Extra articular damage was mainly: a growth failure (25%), osteoporosis (18.8%) and ocular damage (12.5%). Patients with polyarticular arthritis without rheumatoid factor had the highest JADI-A score with a mean of 7.83 while patients with systemic arthritis had the highest JADI-E score with a mean of 3. Mean JADI-A score was significantly different between patients who received corticosteroids and those who did not receive them (8.5 Versus 3.4, p=0.004). Damage scores correlated with disease duration (p<0.001 for JADI-A score and p=0.034 for JADI-E score). Damage scores were not significantly different between different classes of treatment (conventional dmards and biologic dmards).

**Conclusion:** Articular damage is frequent in patients with JIA. It is higher for patients on corticosteroids. Articular and extra articular damage correlate with disease duration, but they were not significantly different between classes of treatment.

**REFERENCES:**

[1] Viola and al: ‘Development and Validation of a Clinical Index for Assessment of Long-Term Damage in Juvenile Idiopathic Arthritis’

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.2875

**AB1248** CONTRIBUTION OF IMAGING IN THE DIAGNOSIS OF ATRAUMATIC HIP

M. Yasmine1, H. Ferjani1, F. Taboubi1, W. Triki1, D. Ben Nessib1, K. Maatallah1, D. Kaffel1, W. Hamdi1. 1Kassab Institute of Orthopedics, Rheumatology, Tunis, Tunisia

**Background:** Joint pain of the hip in children and adolescents is one of the most frequent symptoms seen by pediatricians, orthopedists, and pediatric rheumatologists, with an annual incidence of 148.1/100 000 [1]. The identification of an enthesitis-related arthritis (ERA) is crucial for the management of this condition; however, identifying enthesitis-related arthritis remains challenging. The aim of this study is to assess the contribution of different imaging modalities in an atraumatic hip diagnosis.

**Objectives:** To assess the safety and efficacy of tofacitinib in juvenile idiopathic arthritis.

**Methods:** We conducted a cross-sectional study including children with JIA according to the International League of Associations for Rheumatology (ILAR). Transcribed data included age, sex and the characteristics of the disease (subtype of JIA, disease duration). Data on hip involvement was also collected. Weight and height of each patient were recorded. The body mass index (BMI) was calculated (Kg/m²). We compared these parameters between two groups: G1: presence of coxitis and G2: absence of coxitis.

**Results:** The study included 62 patients with a male predominance: sex ratio = 2.3. The mean age of onset of the disease was 11.4 years [3-16]. The frequency of each JIA subset was at follows: polyarticular with rheumatoid factor (n=2), polyarticular without rheumatoid factor (n=4), systemic (n=1), enthesitis-related arthritis (n=44), oligoarthritis (n=8), psoriatic arthritis (n=3). Hip involvement was reported in 71 % of cases and was bilateral in 81% of patients. The mean weight (Kg) and height (meter) was similar between the two groups (57.4 in G1 vs 53.6 in G2, p=0.486) and (1.61 in G1 vs 1.58 in G2, p=0.483) respectively. The prevalence of overweight patients was higher in G1 than G2 without reaching a statistically significant correlation (23% vs 12.5%, p=0.518). Similarly, there was no statistically significant correlation between the body mass index (Kg/m²) and coxitis (22.2 vs 21, p=0.45). Moreover, a higher BMI was not associated with a limited range of motion as well as hip replacement (p=0.7, p=0.1 respectively).

**Conclusion:** Our study showed that BMI did not impact hip involvement in juvenile idiopathic arthritis patients. As obesity concerns a additional health risk, addressing this co-morbidity should be a health priority in these patients.

**REFERENCES:**


**Disclosure of Interests:** None declared


**AB1250** TOFACITINIB IS A SAFE AND EFFECTIVE TREATMENT OPTION FOR JUVENILE IDIOPATHIC ARTHRITIS

N. Prabu1, V. Petzioapper2, G. Anand1, S. Ram1, A. Kumar1, S. Sakhti1. 1Sakthi Rheumatology Centre Pvt Ltd, Rheumatology, Coimbatore, India; 2PSG Institute of Medical Sciences & Research, General Medicine, Coimbatore, India

**Background:** The management of juvenile idiopathic arthritis(JIA) is often constrained by the limited number of oral drugs available. Whether JAK inhibitors would add a much needed therapeutic armamentarium in this regard needs to be explored.

**Objectives:** To assess the safety and efficacy of tofacitinib in juvenile idiopathic arthritis (JIA) patient who were prescribed during the period January 2021 to December 2021.

**Methods:** It's a retrospective study of JIA patients who were prescribed tofacitinib during the period Jan 21 to Dec 21 with minimum of 3 months' follow-up after prescribing tofacitinib. The demographics,details of medications,investigations parameters and any adverse events were noted.
Results: There were a total of 35 patients who were given tofacitinib during this period. Male to female ratio was 25:10, mean age of 12.91±4.41 yrs., the mean disease duration was 56.6 months. Enthesitis related arthritis (ERA) was the commonest in 12, followed by oligoarticular in 10, polyarticular in 7 and systemic onset in 6. In the ERA group 10 were HLA B27 +ve, of the oligo articular 6 were ANA +ve, in the polyarticular one was RF +ve. Out of the 35, 14 were already on biologics (tocilizumab and anti TNFs). Tofacitinib was stopped in 8 patients during this period, 5 as they achieved remission, 2 with no response and one because of itching and abdominal pain. There were no documented infections. There was significant reduction in the inflammatory markers (ESR, CRP), leucocyte count and platelet count.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Before tofa</th>
<th>After tofa</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methotrexate (mg)</td>
<td>9.64 (1.94)</td>
<td>8.88 (3.34)</td>
<td>0.66</td>
</tr>
<tr>
<td>Steroid (mg)</td>
<td>3.25 (3.35)</td>
<td>2.8 (1.8)</td>
<td>0.91</td>
</tr>
<tr>
<td>Leucocyte count (m)</td>
<td>1124 (168)</td>
<td>7884 (1471)</td>
<td>0.005</td>
</tr>
<tr>
<td>Platelet count (m)</td>
<td>4.51 (0.48)</td>
<td>3.7 (0.82)</td>
<td>0.017</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR (mm/hr)</td>
<td>57.75 (1725)</td>
<td>30.83 (11.48)</td>
<td>0.009</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>25.36 (16.3)</td>
<td>12.36 (3.97)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

Conclusion: Tofacitinib seems to be a promising drug in the management of JIA with good safety profile and efficacy.

REFERENCES:

Disclosure of Interests: None declared


AB1251 LATE ONSET PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN AN INDIAN ADOLESCENT BOY DURING A PEAK OF POST COVID-19 MULTISYSTEM INFLAMMATORY SYNDROME

D. B. Pandya1, 2

Background: Familial Hemophagocytic lymphohistiocytosis (FHLH) categorized as FHHL2 (PRF1), FHHL3 (UNC13D), FHHL4 (STX11), and FHHL5 (STXBP2) encoding for Perforin, Munc13-4, Syntaxin11, and Syntaxin binding protein 2, respectively. There is limited information available about the clinical and mutational spectrum of FHL patients in Indian population.

Objectives: To delineate clinical and laboratory features of late onset familial Hemophagocytic Lymphohistiocytosis.

Methods: A 12-years-old well nourished sick looking boy, born to a non-consanguineous parents with normal birth, development and immunization history with uneventful past presented to us with 6 days history of high fever, cough, breathing difficulty and severe headache. He had occasional vomiting, abdominal pain, polyarthragia & chest pain from last 10 days. Mother also had given history of throat pain, backache & some non-specific papular rashes over face before the onset of fever. His vitals was normal. Examination revealed faint diffuse fixed erythematous rash all over the body, pallor, icterus and hepatosplenomegaly. Musculoskeletal examination was unremarkable. Lab evaluation revealed HB 8.99gm%, TLC 4700/cumm with neutrophils 40% and lymphocytes 56% with 6-9% activated lymphocytes. Further evaluation showed low ESR 6mm/hr, liginogen 97mg% and albumin 2.2 gm% with elevated CRP 40mg/L, ferritin 2000ng/ml, LDH 6851U/L, SGPT 110U/L, SGOT 221 IU/L, total bilirubin 6mg%, D-dimer 4355 ng EFLU/ml and Triglycerides 441mg%. His blood, urine, CSF and bone marrow cultures were sterile for endemic viral and viral infections in our area. His EBV PCR, CoVID RT PCR and CoVID antibody (Total & IgG) test were negative. His immunoglobulin levels were normal. HRCT Chest showed bilateral mild-moderate plural effusions, mild interstitial thickening in both the lower lobes, few fibrotic opacities & old areas of consolidation bilaterally. 2D echo showed mild pericardial effusion. Bone marrow examination showed Hypercellular marrow with iron depletion and occasional hemophagocytosis with CD6 T lymphocytes proliferation (55.2%) and double positive CD4 & CD8 (12%). He was initially launched on supportive therapy, oxygen & intravenous antibiotics. In view of most probable non-infectious, non-malignant hemophagocytic lymphohistiocytosis, he was finally given intravenous immunoglobulin (2gm/kg) and intravenous pulse methylprednisolone (30mg/kg). He responded well to above regimen within 3 days. He was discharged with tapering steroids over few weeks. Clinical exome by NGS revealed Homozygous Mutation in STXBP2 gene Intron 14, c.1280-1G>C (3’ Splice Site) His parents has been counselled for hematopoietic stem cell transplantation and their decision is still pending.

Results: We compared our patient with a reference to the largest Indian series of pediatric HLH1.
development of MAS, that confirms the key role of IL-18 in sJIA and MAS. According to our data, in clinical practice the measure of serum level of ferritin more useful for early detecting MAS in pts with sJIA due to more stronger correlation between the levels of proinflammatory cytokines and ferritin, than between proinflammatory cytokines and CRP. We were unable to identify a statistically significant difference in the level of IL1RA in active sJIA and MAS, despite a significant correlation between the level of CRP and IL1RA, ferritin and IL1RA, which may be associated with small number of pts.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3328

---

**AB1253**

**DISEASE PERCEPTION ASSESSMENT IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS AND THEIR PARENTS.**

A. Fazaa1, S. Nouicer1, S. Miladi1, H. Boussaïa1, K. Ouenniche1, L. Souabni1, S. Kassab2, S. Cheki2, K. Ben Abdelghani3, A. Lacalet1, M. Mongi Slim1, *Rheumatology, Tunisia, Tunisia*

**Background:** Juvenile Idiopathic Arthritis (JIA) has an impact on the quality of life of the patient and his family. Parent/patient reported outcomes have shown an increasing interest in the management of JIA because it reflects the perception of the disease course and the effectiveness of the therapeutic interventions.

**Objectives:** To determine the level of agreement between patients with JIA and their parents for the five quantitative items in Juvenile Arthritis Multidimensional Assessment Report (JAMAR) questionnaire.

**Methods:** We included children aged between 7 and 18 years old with A1 ILAR criteria) and their parents. Demographic data and disease related parameters were collected. We asked both parent and child to complete the five quantitative items of JAMAR questionnaire. We measured on a 21-numbered circle visual analogue scale (VAS) for pain (0 = no pain; 10 = very severe pain), disease activity (DA): (0 = no activity; 10 = maximum activity) and well-being (WB): (0 = very well; 10 = very poorly). Physical function was assessed by Juvenile Arthritis Functional Score (JAFS) (0-45) and health-related quality of life (HRQoL) [0-30] through the Physical Health (PH) and Psychosocial Health (PSH) subscales. We calculated children and parents median scores for the five items. Intraclass correlation coefficient ICC was used for analysis (ICC below 0.50: poor; between 0.50 and 0.75: moderate; between 0.75 and 0.90: good; above 0.90: excellent).

**Results:** A total of 21 patients/parent (12 girls and 9 boys) were included in the study. Forty percent belong to rural environment. Majority of patients were in secondary school (77%), 23% were in primary school. Seven patients had oligoarticular JIA, 13 had polyarticular JIA and one had systemic JIA. Median age at diagnosis was 11.4 ± 2.2 years [6-13]. Median age at disease onset was 9.5 ± 1.9 years [2-13]. Median disease duration was 4.3 years [0-7]. Median JADAS was 10 [8-18]. Uveitis was noted in 30% of cases. Comparison of parent proxy-reported and child self-reported data revealed a striking similarity for all items (p<0.001). The results of the five quantitative items of JAMAR questionnaire are represented in Table1. Good correlation was noted in JAFS, DA VAS, well-being VAS and HRQoL. Excellent correlation was noted in VAS pain.

**Table 1. Assessment of quantitative items of Juvenile Arthritis Multidimensional Assessment Report by patients and parents.**

<table>
<thead>
<tr>
<th>Items</th>
<th>Patients</th>
<th>Parents</th>
<th>ICC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean pain VAS (0-10)</td>
<td>4.2 [4-6]</td>
<td>4.3 [4-6]</td>
<td>0.97</td>
</tr>
<tr>
<td>Mean disease activity VAS (0-10)</td>
<td>4.1 [4-5]</td>
<td>4.2 [4-6]</td>
<td>0.81</td>
</tr>
<tr>
<td>Mean well-being VAS (0-10)</td>
<td>4.4 [4-6]</td>
<td>4.3 [4-6]</td>
<td>0.9</td>
</tr>
<tr>
<td>Mean Juvenile Arthritis Functional Score (JAFS)</td>
<td>10.0 [10-20]</td>
<td>10.2 [2-21]</td>
<td>0.81</td>
</tr>
<tr>
<td>Mean HRQoL score</td>
<td>14.1 [17-17]</td>
<td>14.8 [16-14]</td>
<td>0.88</td>
</tr>
</tbody>
</table>

**ICC:** Intraclass Correlation Coefficient; HRQoL: Health-Related Quality of Life; VAS: Visual Analogue Scale.

**Conclusion:** Our study showed high level of agreement between patients and parents. This study provides a promising approach to quantitative measurement in standard pediatric rheumatology. Availability of this new instrument may enhance regular use of parent/patient questionnaires in routine practice and improve disease management.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3699

---

**AB1254**

**CHALLENGES FACED BY FAMILIES OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS.**

W. Triki1, A. Dohaies1, H. Ferjani1, R. Ben Assia2, D. Ben Nessim3, K. Maatallah1, D. Kaffel1, W. Hamdi1, *Institut Mohamed Kassab d’orthopédie, Rheumatology, Manouba, Tunisia*

**Background:** Juvenile idiopathic arthritis (JIA) is the most common inflammatory rheumatism of childhood. Diagnostic and therapeutic approaches are difficult for families to sustain with significant psychological and social effect.

**Objectives:** The aim of this study is to understand the different challenges faced by families with children suffering from JIA.

**Methods:** Parents of children with JIA (according to the International League of Associations for Rheumatology (ILAR)) followed in rheumatology department were asked to complete a survey in order to screen the impact of their child's disease on their family life. Open-ended questions and directed questions were included. General demographic and clinical information (family history of chronic inflammatory disease, child's current age, diagnosis and type of JIA and duration of disease progression) were also collected.

**Results:** The study included 24 children with a gender-ratio of 1. The mean age was 12.4 years old [4-16]. The mean duration disease was 4 years with extremes varying from 3 months to 10 years. The frequency of disease at follows: polyarticular with rheumatoid factor (n=2), polyarticular without rheumatoid factor (n=5), psoriatic arthritis (n=1), enthesitis-related arthritis (n=10) and oligoarthritis (n=6). Twenty-four parents completed the survey. The mother was the one who answered the questions in 83% of the cases. Other family members with a chronic rheumatic disease were reported in 40% of the families. Parents noted negative impact on their work in 50% of cases (40% missing time from work, 10% changing work schedule) and, significant parental stress, anxiety, and fatigue in 75% of the cases. In 33% of the cases, parents had difficulty getting the required medical care and attention for their child's illness because of financial issues and 37.5% of them were feeling anxiety regarding diagnosis uncertainty. Parents reported worry about their child's daily functioning and future in 75% of the cases. They noted psychological impact on the child itself in 58% of the cases and child missing school in 41% of the cases. The most common resources parents used for information were health care professionals in 54.2 % of the cases and 45.8% of them got additional information from online research.

**Conclusion:** Parents of children with JIA share common challenges due to their child's illness including a substantial impact on their work and personal wellness in addition to the psychosocial impact of the disease on the child. Support groups or educational sessions may be needed to provide guidance for these families to cope with disease.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3642

---

**AB1255**

**ASSESSMENT OF SLEEP DISTURBANCES IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS.**

W. Triki1, A. Dohaies1, H. Ferjani1, R. Ben Assia1, D. Ben Nessim1, K. Maatallah1, D. Kaffel1, W. Hamdi1, *Institut Mohamed Kassab d’orthopédie, Rheumatology, Manouba, Tunisia*

**Background:** Sleep problems are common among children with chronic illnesses such as Juvenile Idiopathic Arthritis (JIA), which is one of the most common rheumatic diseases in childhood. Sleep disturbances collectively refer to impairments in the ability to initiate or maintain sleep. They can be measured by parent or child self-report and by objective measures such as actigraphy and polysomnography.

**Objectives:** The aim of this study was to assess sleep disorders in children with JIA.

**Methods:** Parents of children suffering from JIA (according to the International League of Associations for Rheumatology (ILAR)), followed in rheumatology department were asked to complete a specific specialized scale for children (HIBOU) [1] to screen sleep disorders. This scale assesses five aspects of sleep: irregular schedule and daytime drowsiness, insomnia, moves in sleep, nose obstruction and ultra-vigilance. Parents were asked to answer 8 questions rated from 1 to 3 according to the frequency of the problem: 1: rarely, 2: 3 to 4 times a week and 3 if 5 to 7 times a week. If the sum is ≤ 9, only sleep hygiene is recommended. If the sum is between 10 and 15 the child requires regular supervision. If the sum is between 16 and 24, the child needs to be referred to a specialist. General demographic and clinical information (family history of chronic inflammatory disease, child's current age, diagnosis and type of JIA, duration of disease progression and activity of the disease) were also collected.

**Results:** Twenty-four children with a mean age of 12 years [4-16] were included in the study. The gender ratio was 1. The mean duration of the disease was 4 years with extremes from three months to thirteen years. The frequency of each JIA subset was as follows: polyarticular with rheumatoid factor (n=2), polyarticular without rheumatoid factor on the rheumatoid factor (n=5), psoriatic arthritis (n=1), enthesitis-related arthritis (n=10) and oligoarthritis (n=6). Irregular sleep schedule and daytime drowsiness were reported at least 3 times a week by 58.3% of the children. Insomnia and inability to initiate sleep were reported in 29.3% of the children at least 3 times a week. Parents reported exaggerated moves during sleep in 50% of the cases and airway obstruction or snoring in 58.3% more than 3 times a week. Sleep problems such as insomnia, daytime sleepiness and sleep-related problems other than sleep were reported in 25% of cases. To sum up, 29.2% of the children had a score above 15 and needed to be referred to a specialist and 58.3% of them need a regular supervision of their sleep and may need to be referred to a specialist. Only three children had a score under 9 and don't have concerning sleep disorders and 58.3% of them need a regular supervision of their sleep and may need to be referred to a specialist. Only three children had a score under 9 and don't have concerning sleep disorders.

**Conclusion:** This study showed that sleep disorders are a common challenge in children and adolescents with JIA which could have a huge impact on their physical and psychosocial health-related quality of life. This study highlights the need for assessment of sleep disorders in JIA patients.
Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending on geographical area (Oligoarticular subtype predominates in Western Europe/North America. Enthesitis-related arthritis subtype predominates in Eastern Europe/Asia). To ensure continuity of care in adult rheumatology services, a systematic transition process is recommended. Various authors recommend that the process, of which pediatric and adult rheumatology teams should be part, begins around 14 years and ends around 18 years of age.

**Objectives:** We aim to study the age, relative prevalence and treatment profile in JIA subtypes at the beginning of the transitional care.

**Methods:** Descriptive and cross-sectional study of patients with JIA (according to ILAR criteria), diagnosed and treated in the pediatric rheumatology service and seen in the transitional care unit of the adult rheumatology service within the same tertiary hospital between January 2013 and December 2018. Demographic, clinical, analytical and treatment data were collected at the first visit to the transitional care unit.

**Results:** 72 patients were included (46 women) mean age at diagnosis of 9.5 ± 4.6y and mean of 13.3 ± 4.3y from diagnosis to the first visit at the transitional care unit. 27.7% were diagnosed with oligoarticular JIA, 20.8% with arthritis-enthesitis JIA, 19.4% with Rheumatoid Factor negative (RF-) polyarticular JIA, 11.1% with systemic JIA, 9.7% with undifferentiated JIA, 5.5% with Rheumatoid Factor positive (RF+) polyarticular JIA and 5.3% of psoriatic arthritis.

The mean age at the first visit to the transitional care unit was 20.81 ± 2.96y (no differences between subtypes). Oral ulcers (20.8%), anterior uveitis (13.8%) and enthesitis (13.8%) were the most frequent extra-articular manifestations. 56.9% had antinuclear antibodies (ANA) titers >1/160 at some point in course of disease (Table 1).

**Discussion of Interests:** None declared

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4126

---

**AB1257 INVESTIGATING THE ASSOCIATIONS BETWEEN THE MAXIMAL RESPIRATORY PRESSURES AND CARDIORESPIRATORY FITNESS PARAMETERS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS**

D. C. Sarac1, D. Bayraktar1, D. Ozer Kayar1, O. Altug-Gucenmez2, D. Oskay3.

1Izmir Katip Celebi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Izmir, Turkey; 2University of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey

**Background:** The most prominent symptom of juvenile idiopathic arthritis (JIA) is joint involvement; however, the effect of the disease is not limited to the joints. Evidence suggests that cardiopulmonary fitness is affected in children with JIA compared to their healthy peers.

**Objectives:** This study aimed to investigate the associations between the maximal respiratory pressures and cardiorespiratory fitness parameters.

**Methods:** Seventeen children with JIA (mean age: 15.4 ± 2.2 years, 11 male) who have been using biological agents for at least three months were included in the study. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) were evaluated with a portable device (Cosmed PFX Desktop Spirometer, USA). The Quark Cardiopulmonary Exercise Test Treadmill System (COSMED, Rome, Italy) was employed to analyze cardiorespiratory fitness parameters by using expired gas collection and analysis.

**Results:** Significant moderate correlations were detected between MIP and maximum oxygen consumption (VO2max) values (r=0.519, p=0.033) and MEP and CO2max values (r=0.507, p=0.038), (Table 1). No other significant correlations were observed between maximal respiratory pressures and other parameters.

**Disclosure of Interests:** None declared

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4483

---

**Table 1. The associations between maximal respiratory pressures and cardiorespiratory fitness parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>MIP (cmH2O) (r)</th>
<th>MEP (cmH2O) (r)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>VO2max (ml/kg/min)</td>
<td>0.519</td>
<td>0.033*</td>
<td>0.038*</td>
</tr>
<tr>
<td>MIP (mkg/cm)</td>
<td>0.276</td>
<td>0.283</td>
<td>0.298</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>0.285</td>
<td>0.268</td>
<td>0.269</td>
</tr>
<tr>
<td>VO2HR</td>
<td>0.416</td>
<td>0.907</td>
<td>0.358</td>
</tr>
<tr>
<td>PETCO2max (mmHg)</td>
<td>-0.284</td>
<td>-0.269</td>
<td>-0.158</td>
</tr>
<tr>
<td>PETCO2min (mmHg)</td>
<td>-0.284</td>
<td>-0.269</td>
<td>-0.158</td>
</tr>
</tbody>
</table>

* p<0.05, Pearson Correlation Coefficients, VO2max: Maximum oxygen consumption, ml: milliliters, kg: kilograms, min: minute, METs: Metabolic equivalent HR: Heart rate, bpm: beats per minute, VO2/HR: Oxygen consumption/heart rate, PETCO2: Tidal partial pressure for carbon dioxide, PETO2: Tidal partial pressure for oxygen.

**Conclusion:** The results of the study suggest that maximal respiratory pressures are associated with maximal oxygen consumption. Evaluating maximal respiratory pressures might be helpful when prescribing exercise programs for JIA patients with diminished cardiorespiratory fitness.

**REFERENCES:**

**AB1258**

THE PREDICTED VERSUS MEASURED RESPIRATORY PRESSURES, PULMONARY FUNCTIONS, CARDIOPULMONARY FITNESS PARAMETERS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

D. C. Saraç,1 D. Bayraktar,1 D. Ozer Kayalı,1 A. Altug-Gucenmez,2 D. Oskay,3

1Izmir Katip Çelebi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, İzmir, Turkey; 2University of Health Sciences, Dr. Behçet Uz Pediatric Diseases and Surgery Training and Research Hospital, Department of Pediatric Rheumatology, İzmir, Turkey; 3Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey

**Background:** Although musculoskeletal system-related symptoms are the most common problems in children with Juvenile Idiopathic Arthritis (JIA), cardiac and pulmonary manifestations are observed in more than half of these children. However, the available research on the extent of cardiorespiratory involvement is very limited [1].

**Objectives:** The aim of this study was to compare the predicted respiratory pressures, pulmonary functions, cardiopulmonary exercise test (CPET) values to objectively measured ones in children with JIA.

**Methods:** Twenty-two children with JIA (mean age: 15.5±2.3, 14 male) who were under biological agents for at least three months were included in the study. Maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and pulmonary functions were measured using a portable automated testing device (Cosmed Pony FX Desktop Spirometer, USA). Cardiorespiratory fitness parameters were measured with the Quark CPET Treadmill System (COSMED, Rome, Italy). The values calculated by the softwares of the Cosmed Pony FX Desktop Sporimeter and Quark CPET Treadmill System according to the healthy children’s normative data were used as predictive values.

**Results:** Within-group analyses demonstrated statistically significant differences between all measured and predicted parameters (p<0.05), (Table 1), except for MIP and forced vital capacity/forced expiratory volume values.

**Conclusion:** The present study’s findings indicate that the respiratory pressures, pulmonary functions, and cardiopulmonary fitness parameters of the children with JIA are diminished compared to predicted values.

**REFERENCES:**


Disclosure of Interests: None declared


---

**Table 1.** The comparison of predicted versus measured respiratory pressures, pulmonary functions, cardiopulmonary fitness parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean (SD)</th>
<th>Predicted Mean (SD)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC (l)</td>
<td>3.82±0.92</td>
<td>4.20±1.04</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>3.31±0.80</td>
<td>3.68±0.86</td>
<td>0.004*</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>86.13±7.4</td>
<td>83.91±6.41</td>
<td>0.179</td>
</tr>
<tr>
<td>MIP (cm H₂O)</td>
<td>101.90±37.44</td>
<td>104.31±21.92</td>
<td>0.686</td>
</tr>
<tr>
<td>MEP (cm H₂O)</td>
<td>95.12±67.84</td>
<td>134.36±30.22</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>VO₂max (l/min)</td>
<td>2109.83±732.95</td>
<td>3159.94±745.87</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>MEΤs (ml/kg/min)</td>
<td>9.71±2.180</td>
<td>14.88±2.39</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>HR (bpm)</td>
<td>187.88±20.28</td>
<td>205.02±3.37</td>
<td>0.003*</td>
</tr>
</tbody>
</table>

1: p<0.05. Student’s t-test. FVC: Forced vital capacity, FEV₁: Forced expiratory volume, FEV₁/FVC: Forced expiration volume/forced vital capacity, VO₂max: Maximum oxygen consumption, ml: milliliters, kg: kilograms, min: minute, MEΤs: Metabolic equivalent HR: Heart rate, bpm: beats per minute, VO₂/h: Oxygen consumption/heart rate.

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.4647

---

**AB1260**

SIGNIFICANCE OF WHOLE-BODY MRI IN CHILDREN WITH RHEUMATIC DISEASES

I. Nikishina,1 Z. Kolkhidova,1 L. Blankt,2 T. Pachkoria,2 S. Arsenyeva2, V. Matkava1, A. Shapovalenko1, M. Shalygina1, V.A. Nasonova Research Institute of Rheumatology, Pediatric Department, Moscow, Russian Federation; 2V. A. Nasonova Research Institute of Rheumatology, Department of Radiation Diagnostics, Moscow, Russian Federation

**Background:** Whole-body MRI (WB-MRI) has the potential to detect early or hidden signs of inflammation and seems to be more informative test than X-ray and ultrasound methods for bone and joint diseases. WB-MRI is important for identification of asymptomatic inflammation areas that are not available for clinical examination methods (sacroilits, TMJ). WB-MRI can become a tool for monitoring the progression of the disease and the efficacy of therapy. There is not enough data of knowledge about the role of WB-MRI in children with JIA.

**Objectives:** To evaluate the results of WB-MRI in children with rheumatic diseases (RD) in a single-center retrospective study.

**Methods:** 57 WB-MRI studies performed in children with RD in our center as a part of real-life diagnostic procedures.

**Results:** Among 57 children there are 22 boys and 35 girls, the average age is 13 years [11; 16]; 33 patients were examined once, 20 children twice after the initial course of therapy, two children underwent WB-MRI three times to evaluate the dynamics. It was most important to detect inflammatory lesions in multifocal non-bacterial osteomyelitis (mf-NBO). The structure of diagnosis and therapy before and after WB-MRI is presented in Table 1.

**Disclosure of Interests:** None declared


---

**Table 1.** The effect of MRI on changes in the structure of diagnoses and approaches to therapy

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Before WB-MRI</th>
<th>After WB-MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Juvenile idiopathic arthritis</td>
<td>22</td>
<td>12</td>
</tr>
<tr>
<td>JIA-mf-NBO test.</td>
<td>22</td>
<td>30</td>
</tr>
<tr>
<td>JIA-mf-NBO +Psoiaris</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>JIA+mf-NBO +FMF</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>JIA + Psoiaris</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>JIA+bf</td>
<td>1</td>
<td>1 (JIA+bf) mNBO</td>
</tr>
<tr>
<td>Fibrosclerosis ossificans progressive (FOP) +JIA</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Systemic JIA</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Juvenile dermatomyositis (JDM)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Systemic lupus erythematosus (SLE)</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>SLE+ mf-NBO</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSAIDs mono</td>
<td>17</td>
<td>12</td>
</tr>
<tr>
<td>DMARDs</td>
<td>26</td>
<td>29</td>
</tr>
<tr>
<td>Biologics / biDMARDs</td>
<td>12</td>
<td>27</td>
</tr>
<tr>
<td>anti-TNFs</td>
<td>10</td>
<td>21</td>
</tr>
<tr>
<td>Tocloftim</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Abatacept</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>No current therapy</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>

---
11 patients have multimorbidity (in addition to RD, one girl has Down syndrome). 5 pts had severe hypermobility syndrome patients making it difficult to identify inflammation due to the discrepancy between objective signs and the absence of limitation of joint mobility. 2 patients had multiple ankylosis, 7 patients underwent surgical interventions: 5 because of vertebral fracture, 2 because of osteomyelitis. The WB-MRI revealed: 48 polyarthritis signs, 33 ostitis, 3 osteonecrosis, 11 sacroiliitis, 1 sequestration, 1 epithelioysisis, 1 initial signs of myositis. Surgical intervention was recommended to two patients after the diagnosis of WB-MRI (sequestration of the osteomyelitis focus and vertebral fracture).

The principal significance and purpose of the performance of WB-MRI were disease control (continuation of therapy) - 22 (39%), the onset of DMARDs/bDMARDs - 17 (30%), the change of bDMARDs - 2 (3%), differential diagnosis – 16 (28%).

Conclusion: WB-MRI is useful for detecting asymptomatic and radiologically hidden lesions in JIA. Early diagnosis leading to appropriate treatment can prevent long-term structural damage to the joint. WB-MRI is an important tool for the diagnosis and diseases control in children with RD.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.4671

AB1261

THE ANALYSIS OF THE ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PEDIATRIC POPULATION

R. Denisova1, E. Alexeeva1,2, T. Dvoryakovskaya1,2, K. Isaeva1, A. Chomakhidze1, A. Mamutova1, O. Lomakina1, A. Fetisova1, M. Gautier1, K. Chibisova1, I. Kriulin1,2, E. Krekhova1,2, I. Tsulukiya1. National Medical Research Center of Children’s Health, Rheumatology, Moscow, Russian Federation; Sechenov University, Pediatrics, Moscow, Russian Federation

Background: Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies associated with a multisystem illness where any organ can be targeted. There are different classification criteria for SLE. Sensitivity and specificity of three criteria have been debated and may vary in different populations and clinical settings.

Objectives: We aim to evaluate the clinical and laboratory symptoms of the onset of systemic lupus erythematosus in pediatric population.

Methods: A total of 116 SLE patients (female –92, male-24) were included into the study. We analyzed the primary diagnosis, the time before identification the SLE, clinical and laboratory symptoms, their combination, and fulfilling the classification criteria of SLE. All data is presented as Mean (IQR).

Results: The age of the onset of SLE was 13.3 (10.7, 15.2) years. 55/116 patients had other diagnosis before the verification of SLE, the time before the verification was 10 (5, 26) months. The loss of weight was in 63 (54%) of patients, fever – in 83 (72%) (febrile – 57, subfebrile – 26), adenopathy in 55 (47%), malar rash – in 45 (39%), discoid rash – in 19 (16%), alopecia – in 19 (16%), photo- sensitivity – in 39 (34%), oral ulcers – in 38 (33%), nasal ulcers – in 11 (9.5%), arthritis – in 31 (27%), pleuritis- in 18 (16%), pericarditis- in 20 (17%), renal disorder – in 52 (47%), seizures- in 7 (6%), psychosis – in 1 (0.9%), myelitis – in 2 (1.7%), peripheral neuropathy – in 3 (2.6%), cranial neuropathy – in 2 (1.7%), hemolytic anemia – in 59 (51%), leukopenia- in 62 (53%), thrombocytopenia- in 27 (23%), ANA positivity – in 100(86%), anti-dsDNA antibody positivity – in 91 (78%), antiphospholipid antibody positivity- in 27 (25%), direct Coombs’ test in 22(19%). SELENA–SLEDAI Score was 13 (9, 20); low activity- in 14 (12%) patients, moderate activity- in 23 (20%), high activity – in 42 (36%), very high activity – in 37 (32%).

96 (83%) patients met the eligibility criteria ELAR/ACR 2019, 112(97%) – ACR criteria modified in 1997, 106(91%) – SLICC in 2012.

Conclusion: In this cohort, although all three criteria have sufficient. Some SLE patients with a clinical diagnosis lacked sufficient number of criteria.

Disclosure of Interests: Rina Denisova Speakers bureau: Speaker for Roche, AbbVie, MSD, Novartis., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Sanofi and Novartis., Ekaterina Alexeeva Speakers bureau: Speaker for Roche, AbbVie, Bristol-Myers, Squibb, MSD, Novartis and Pfizer., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Sanofi, Amgen and Novartis., Tatjana Dvoryakovskaya Speakers bureau: Speaker for Roche, AbbVie, Bristol-Myers, Squibb, MSD, Novartis and Pfizer., Grant/research support from: Financial grants from Roche, Pfizer, Centocor, Eli Lilly, AbbVie, Bristol-Myers Squibb, MSD, Amgen and Novartis., Ksenia Isaeva Grant/research support from: Financial grants from Roche, Novartis and Sanofi, Aleksandra Chomakhidze: None declared, Anna Mamutova Speakers bureau: Speaker for Novartis., Grant/ research support from: Financial grants from Eli Lilly, Olga Lomakina Grant- research support from: Financial grants from Pfizer, Eli Lilly., Anna Fetisova Grant/research support from: Financial grants from Amgen., Marina Gauthier: None declared, Kristina Chibisova: None declared, Ivan Krjul Speaker bureau: Speaker for Novartis., Elizaveta Krekhova Speakers bureau: Speaker for Novartis., Irina Tsulukiya: None declared


AB1262

PERFORMANCE OF JADAS-ESR AND JADAS-CRP IN THE ASSESSMENT OF DISEASE ACTIVITY IN TUNISIAN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS

R. Ben Aissa1, D. Ben Nessib2, H. Ferjani1, A. Dghaihes3, W. Triki1, K. Maatallah1, D. Kafell1, W. Hamdi1,1Mohamed Kassab Institute of Orthopedics, Department of Rheumatology, Tunis, Tunisia

Background: The Juvenile Arthritis Disease Activity Score (JADAS) is a feasible tool which consists of four items: tender (TJC) or swollen joint count (SJc), the physician and the patient's/parent's global assessment and the erythrocyte sedimentation rate (ESR). C-reactive protein (CRP) has also been suggested as an alternative inflammatory marker.

Objectives: To compare the performance of JADAS-ESR and JADAS-CRP in the evaluation of JIA activity.

Methods: Twenty-nine patients who met the International League of Associations for Rheumatology (ILAR) criteria for JIA were enrolled in the study. Disease activity was assessed by the JADAS-ESR and JADAS-CRP scores at 54 consultations, 29 at baseline and 25 during the last follow-up consultation. Data of JIA subtypes, disease duration and treatment were retrospectively collected from medical records. All data were checked for normality by the Kolmogorov-Smirnov test. The Spearman correlation was used for data analysis and p values less than 0.05 were considered statistically significant.

Results: The mean age of our population was 13.14±2.2 years [4-21] and the sex ratio of males to females was 1.07:1. The disease duration was 4.69±3.28 years [0.3-13]. JIA subtypes were: enthesis-related arthritis (n=12), polyarthritis (n=7), oligoartthritis (n=6), undifferentiated arthritis (n=3) and psoriatic arthritis (n=1). At baseline most of our patients (51.73%) were not under treatment, 34.49% were under non-steroidal anti-inflammatory drugs (NSAIDs) and 13.8% under methotrexate (MTX). At the last follow-up consultation 41.38% of the patients were under MTX, 34.49% under NSAIDs, 10.35% under TNF inhibitor (Etanercept). At baseline JADAS-ESR1 was correlated to JADAS-CRPI (r=0.001, p=0.008) in all AIJ subtypes. JADAS-ESR1 and JADAS-CRPI were not correlated to ESR1 (p=0.416, p=0.661) nor to CRPI (p=0.378, p=0.058). Both JADAS-ESR1 and JADAS-CRPI were correlated to TJC1 (p=0.001, r=0.643, p=0.015, r=0.502) and only JADAS-ESR1 was correlated to SJCI (p=0.012, r=0.461). At the last follow-up consultation, correlations were observed between JADAS-ESR2 and JADAS-CRPI (p=0.001, r=0.992) in all AIJ subtypes. JADAS-ESR2 and JADAS-CRPI were both correlated to CRPI (p=0.015, r=0.003) but not to SJCI (p=0.175, r=0.119), nor to ESR2 (p=0.535, r=0.426).

Conclusion: Our study suggests that both JADAS-ESR and JADAS-CRP correlate closely during the follow-up of JIA. JADAS-CRP could be recommended for assessing disease activity in JIA.

Disclosure of Interests: None declared


AB1283

CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS IN CHILDREN: A SINGLE CENTER 10-YEAR EXPERIENCE

A. Nargizyan1, S. Kurbanova1, A. Glazyrina1, E. Korobyants1, V. Yusupova1, A. Sologub1, E. Zhlobova1,2,3, Morozovskaya Children’s City Clinical Hospital, Department of Rheumatology, Moscow, Russian Federation; 1M. Sechenov First Moscow State Medical University (Sechenov University), Department of Rheumatology, Moscow, Russian Federation
Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a chronic autoinflammatory disease that primarily affects the skeleton in the absence of an infectious etiology in children and adolescents. It is an orphan disease with many unclear aspects in terms of diagnosis, treatment and follow-up.

Objectives: To report demographic, clinical and laboratory characteristics of a single center cohort of CRMO patients in Morozovskaya Children’s City Clinical Hospital in Moscow, Russia.

Methods: We retrospectively and prospectively reviewed clinical records of 33 CRMO patients diagnosed between 2011 and 2021 and admitted to Rheumatology Department of Morozovskaya Children’s City Clinical Hospital.

Results: We identified 33 patients with CRMO. Twenty-five (75%) were female. Median age of symptoms onset was 9 [6;12] years. Median delay in diagnosis was 12 months. All patients had bone pain as an initial symptom; fever has been present in 12 patients (63%). Joints involvement was observed in 22 patients (67%) – 39%, 18%, 12%, and 3% of patients had ankle, hip, knee, and shoulder joints involvement, respectively. All patients had multifocal bone lesions, which were confirmed by radiological methods (CT scan, MRI, scintigraphy).Vertebral (42.4%) and femur (46.5%) were the most commonly affected bones. One child had a skull lesion (os parietale). Eleven patients (33%) also had sarcoidosis. Other organs involvement was observed in 7 patients presented with palmoplantar pustulosis and psoriasis. Histopathological examination has been performed in 24 (73%) patients to confirm the diagnosis. Mean ESR was 43 [28;80] mm/h and CRP – 27 [15;61] mg/L. Twenty-three (69.6%) patients had psoriasis.

Conclusion: From our experience, most of the patients had delay in diagnosis. Laboratory tests showed mild elevation of inflammatory parameters. Seven (21%) patients had psoriasis.

Disclosure of Interests: None declared


AB1264

CLINICAL, DEMOGRAPHIC CHARACTERISTICS AND TREATMENT RESPONSES OF PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME

Ş. Çağılayan1, K. Ülu1, T. Çokşeker1, R. E. Yigit1, G. Ozmoy Baykal1, F. Demir1, M. Çankan1, B. Sözeri2, 1University of Health Sciences, Umraniye Education and Research Hospital, Pediatric Rheumatology, Istanbul, Turkey

Abstract: Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease that inherited autosomal dominant. The disease occurs as a result of mutations in the NLRP3 gene, which encodes cryopyrin (1). It has three clinical presentations called familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-onset multisystem inflammatory disorder (NOMID) or chronic infantile neurologic, cutaneous and articular (CINCA) syndrome (2). FCAS is the mildest form of this syndrome, characterized by cold-induced fever, urticarial rash, joint complaints, conjunctivitis, and systemic inflammation.

Objectives: In our study, we aimed to evaluate the clinical and demographic characteristics and treatment responses of CAPS patients.

Methods: We retrospectively and prospectively reviewed clinical records of 33 pediatric patients who were diagnosed with CAPS admitted to Umraniye Training and Research Hospital, Pediatric Rheumatology Clinic, Istanbul, Turkey. June 2016 - December 2021. Medical records were analyzed for clinical presentation, disease associations, physical examination, and laboratory findings.

Results: A total of 44 patients (41 FCAS, 3 MWS) were included in the study. Of the patients, 19 were girls and 25 were boys. The median age of the patients was 10.5 [1.4-20.6] years. The median age of onset of attack was 3 years (1 month-14.6 year), age at diagnosis was 7.9 years (13 months-18 years), and the follow-up period was 2.2 years (4 months-5.2 years). There was a history of consanguinity in 9 (20.4%) patients. Twelve (27.2%) patients had the autoinflammatory disease in their families. The most common clinical findings were fever (100%), joint pain (94%), and abdominal pain (85%). Afterward rash (84%), migraine (43.5%), conjunctivitis (31.8%), arthritis (31.8%), dermatitis (31.8%), chest pain (27.3%), headache (25%), and vomiting (22.7%) were other findings accompanying the attacks. Thirty-nine (88.6%) patients had mutations in the NLRP3 gene. No mutation was detected in five (11.4%) patients. The most common G705K mutation was detected in 28 (71.4%) patients. Forty-two (95.4%) patients were started on colchicine treatment. Biological therapy was started in 9 (21.4%) patients whose attacks continued despite colchicine. Anakinra and canakinumab, which are anti-interleukin 1 agents, were used as biological therapy. FCAS patients had an adequate response to standard doses of canakinumab therapy, while MWS patients required significantly higher doses of canakinumab therapy. MWS patients needed significantly higher doses of canakinumab treatment. Biological therapy was started in 9 (21.4%) patients whose attacks continued despite colchicine. Anakinra and canakinumab, which are anti-interleukin 1 agents, were used as biological therapy. FCAS patients had an adequate response to standard doses of canakinumab therapy, while MWS patients required significantly higher doses of canakinumab therapy. MWS patients required significantly higher doses of canakinumab therapy. We think that it would be beneficial to try colchicine treatment before starting biologic therapy in FCAS patients.

References:

Disclosure of Interests: None declared


AB1265

BIOTECHNOLOGICAL AGENTS IN PEDIATRIC-ONSET SCLERITIS

A. Vitale1, G. Gaggiano1, V. Berlingiero1, C. Fabiani1, F. Ricci1, G. Nascimbene1, V. Caggiano1, G. M. Tosi2, B. Frediani1, M. Cattalini3, L. Cantarini1, 1Rheumatology Unit, Department of Medical Sciences, Surgery, and Neurosciences, Siena, Italy; 2Ophthalmology Unit, Department of Medical Sciences, Surgery, and Neurosciences, Siena, Italy; 3Pediatric Clinic, University of Brescia and Spedali Civili di Brescia, Brescia, Italy

Background: The term scleritis refers to the inflammation of the sclera, the white outer layer of the eye. The term may be applied to cicatricial, cicatrizating, necrotizing, and rarely pannus. The term involves a wide range of etiologies ranging from infectious to non-infectious entities. Semin Immunopathol. 2015;37(4):377-385. doi:10.1007/s00281-015-0491-7

Disclosure of Interests: None declared

AB1266

ANGIOTENSIN-CONVERTING ENZYME LEVEL IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

N. Shevchenko1,2, T. Holovko1,2, L. Bohmat1,2, V. Nikonova1, V. N. Karazin Kharkiv National University, Department of Pediatrics No 2, Kharkiv, Ukraine; 2SI Institute for Children and Adolescents Health Care of NAMS of Ukraine, Department of Rheumatology and Comorbid States, Kharkiv, Ukraine; 3V. N. Karazin Kharkiv National University, Department of Pediatrics No 2, Kharkiv, Ukraine

Disclosure of Interests: None declared

Background: One of the most common comorbid conditions accompanying rheumatoid arthritis is atherosclerosis and arterial hypertension. Previous studies have shown a change in the blood lipid spectrum with an increase in the atherogenic index in children with juvenile idiopathic arthritis. The next link in the development of this pathology is a change in the endothelial function of the vessels.

Objectives: To study the level of angiotensin-converting enzyme in children with JIA and establish its interdependence with the blood lipid spectrum of sick children.

Methods: The level of angiotensin-converting enzyme (ACE) was studied in 46 children (28 girls and 18 boys) from 11 to 17 years old by enzyme immunoassay as well as indicators of the lipid spectrum: low-density lipoprotein cholesterol (LDL), very low-density lipoprotein cholesterol (VLDL) and atherogenic coefficient. The results obtained were compared with the data of children in the control group, which consisted of 34 people. Data were analyzed depending on patients' gender, age, and age of JIA onset, its variant, duration, activity, and presence of methotrexate (MTX).

Results: The results of the study are presented in the Table 1.

Table 1

<table>
<thead>
<tr>
<th>Lipid spectrum indicators</th>
<th>Children's groups</th>
<th>Me±m</th>
<th>Me</th>
<th>Min</th>
<th>Max</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>LDL</td>
<td>JIA, n=46</td>
<td>2,33±0,09</td>
<td>2,18</td>
<td>0,97</td>
<td>4,31</td>
<td>0,001</td>
</tr>
<tr>
<td>VLDL</td>
<td>Control, n=34</td>
<td>2,53±0,09</td>
<td>2,55</td>
<td>1,39</td>
<td>4,13</td>
<td>0,101</td>
</tr>
<tr>
<td>KA</td>
<td>JIA, n=46</td>
<td>0,14±0,01</td>
<td>0,13</td>
<td>0,06</td>
<td>0,27</td>
<td>0,54</td>
</tr>
<tr>
<td>ACE</td>
<td>Control, n=34</td>
<td>0,19±0,09</td>
<td>1,83</td>
<td>0,82</td>
<td>3,5</td>
<td>0,4</td>
</tr>
</tbody>
</table>

There were no significant differences in the ACE level in children with JIA in comparison with the control group. Analysis of the obtained data did not reveal significant changes in the obtained ACE parameters depending on the gender and age of patients, JIA activity, and the presence of MTX in complex treatment. At the same time, a direct correlation of ACE values and low-density lipoprotein levels (r=0.5, p<0.05) was obtained, which confirms the relationship between the ACE level and the development of dyslipoproteinemia in children with JIA.

Conclusion: The obtained results illustrate the stages of development of atherogenic changes in children with JIA. Data were obtained that against the background of an increase in the level of VLDL and a decrease in LDL, the level of ACE remains preserved, which reflects the absence of changes in the endothelium. Research into these changes is ongoing.

Disclosure of Interests: None declared


AB1267

LONG-TERM SINGLE CENTER EXPERIENCE OF THE THERAPY WITH BIOLOGICS IN MULTIFOCAL NON-BACTERIAL OSTEOMYELITIS

I. Nikishina, S. Arsenyeva, Y. Matkava, M. Kaleta, M. Shayagina, Z. Kokhidova, T. Pachkoria, S. Salugina, D. Alexseev, O. Borodacheva, A. Shapovalenko, V.A. Nasonova Research Institute of Rheumatology, Paediatric, Moscow, Russian Federation

Background: Children and adolescents who suffered from the rare polygenic autoinflammatory disease such as multifocal non-bacterial osteomyelitis (NBO) can stay without specialized care for the long time. Currently we don’t have standardized treatment for these patients. Administration of Biologics (B) established on opportunity to diagnose juvenile idiopathic arthritis (JIA) or juvenile ankylosing spondylitis (JAS) in relation to combination of bone lesions with arthritis and/or axial skeleton damage.

Objectives: To describe clinical/laboratory findings and therapy approaches in patients with NBO who was treated by B.

Methods: We analyzed a single center retrospective nine-year study, which includes cohort of 56 patients (pts) with multifocal NBO. 22 pts of them were treated by different B (TNF-inhibitors mostly) in our pediatric department. Standard rheumatological assessment were included for all pts. X-ray, whole-body MRI and/or scintigraphy were done for revealing all localizations of bone lesion. It is expected that option of prescribing BA can prevent progression and bone destruction.

Disclosure of Interests: None declared


AB1268

CLINICAL ASPECT AND THERAPEUTIC MANAGEMENT OF SUBACUTE OSTEOMYELITIS IN CHILDREN

R. Dghaies1, A. Dghaies2, M. Jerbo3, H. Ben Ghzolene3, F. Abid3, 1University Hospital Center Hedi Chaker Sfax, Pediatric Surgery, Sfax, Tunisia; 2University Hospital Center Hedi Chaker Sfax, Rheumatology, Sfax, Tunisia; 3University Hospital Center Taher Sfar Mahdia, Traumatology-Orthopedic Department, Mahdia, Tunisia

Background: Subacute osteomyelitis in children is a distinct entity encom-passing primary localized osteomyelitis. It poses a diagnostic problem related to its few or no constitutional symptoms, misleading radiological manifestations and often a negative bacteriological investigations. The treatment remains very controversial.

Objectives: The aim of this study was to identify the main epidemiological, clinical, histological and evolutionary characteristics of this affection and to propose an adequate therapeutic attitude.

Methods: It was a retrospective longitudinal study, carried out over a period of 25 years from January 1995 to December 2019 in the orthopedic department of Taher Sfar Hospital,Mahdia, that included 37 cases of subacute osteomyelitis in children.

Results: The mean age of the patients was seven years nine months with a male predominance (sex ratio: 2:27). The average time to hospitalization was 41 days. A diagnostic delay was very likely because of delay in consultation which was related to clinical latency, reported in all cases. The imaging showed osteolysis in all cases, setting in long bones in 54% of cases and in 46% other cases in short and flat ones. The lesion was multiple in two different bones only in one case and was found in pure epiphyseal location in seven cases. The bacteriological investigation allowed the isolation of a germ only in eight cases. In all cases, it was a Staphylococcus aureus. Surgical treatment was performed in 21 cases (60% of patients). The outcome was favorable in 35 cases (95% of cases). An infectious exacerbation was noted in 2 cases.

Conclusion: Subacute osteomyelitis poses a diagnosis and therapeutic problem. Magnetic resonance imaging is a valuable examination. Surgical treatment combined with appropriate antibiotic therapy is indicated for any suspicious lesion. It can be useful in taking samples for diagnosis, improve distribution of the antibiotic in injury and accelerate healing radiation.

Disclosure of Interests: None declared

Other orphan diseases

Shulman’s disease or eosinophilic fasciitis: A rare fibrosing disorder: A case report treated with tocilizumab

A. Laria1, A. M. Lurati1, M. G. Marrazza1, K. Rei1, D. Mazocco1, P. Faggioni2, A. Mazzoni1, 1ASST Ovest Milanese, Fornaroli Hospital, Rheumatology, Milan, Italy; 2ASST Ovest Milanese Civil Hospital Legnano, Internal Medicine Unit, Legnano, Italy

Background: Shulman eosinophilic fascitis (EF) is a rare fibrosing disorder, typified by erythema, edema, and symmetrical induration of the distal bilateral extremities (onset proximal to the wrists and ankles) or/and trunk. The “groove sign” and/or a pseudocellulite appearance of the involved skin may be present. It is followed by joint contractures, arthromyalgia. On rheumatological examination: non-liftable skin in folds on the lower limbs, compatible with eosinophilic fasciitis and confirmed the pericardial effusion. Chronic inflammatory bowel diseases were excluded. A skin biopsy of the left forearm confirmed the clinical diagnosis of EF. In particular, it documented thickening of the fascia, a site of an inflammatory process that included small lymphocytes, plasma cells, histiocytes, and some eosinophils, distributed both diffusely and around blood vessels. The underlying muscle tissue and the supra-fascial skin were free from alterations. Secondary fasciitis was excluded by 18-fluorodeoxyglucose (FDG)-positron emission tomography; this showed a diffusely accumulation of the radiopharmaceutical in the muscles of the forearms and of both lower limbs, compatible with eosinophilic fascitis and confirmed the pericardial effusion. Immunoheriticogenic analysis on peripheral blood excluded the presence of a monoclonal cell population. Diagnosis of primary eosinophilic fasciitis was confirmed by the presence of mononuclear cell population. Diagnosis of primary eosinophilic fasciitis was made and therapy was started with methylprednisolone 1 g intravenously for 3 days followed by another 3 boluses of methylprednisolone of 500 mg iv. Given the poor response, it was decided to set up therapy with Methotrexate 15 mg up to a dose of 20 mg intramuscularly per week associated with prednisone 25 mg/day. The rheumatological re-evaluation at 3 months showed a worsening of the fibro-inflammatory stages of the disease, as in the case described.

Results: A complete resolution of the skin picture with disappearance of the pericardial effusion was documented 12 months after the start of the biological drug treatment. There is currently no guidelines for the treatment of eosinophilic fasciitis. Tocilizumab has been shown to be effective when introduced in the early inflammatory stages of the disease, as in the case described.

References:

Disclosure of Interests: None declared

Prevalence of rheumatologic diseases in patients presenting with uveitis

E. Ozturk1, T. Yuce Inel2, M. Kaya3, F. Onen2, G. Can2.
1Dokuz Eylul University Faculty of Medicine, Internal Medicine, Izmir, Turkey; 2Dokuz Eylul University Faculty of Medicine, Rheumatology, Izmir, Turkey; 3Dokuz Eylul University Faculty of Medicine, Ophthalmology, Izmir, Turkey

Background: Uveitis may occur in the course of systemic inflammatory rheumatic diseases, or it may be the first clinical presentation of these diseases. Aims: To determine the prevalence of systemic inflammatory rheumatic disease in patients whose initial clinical manifestation is non-infectious uveitis.

Objectives: In other rheumatic diseases it is possible to optimize biological therapy, maintaining its effectiveness and without risk in its safety. But this aspect has not been studied in the field of non-infectious uveitis.

Methods: A search strategy (PubMed, Embase and Cochrane) was carried out on UNI up to Jan-22 with Mesh vocabulary and free text (human beings, English or Spanish). Review last 2 years of International Congresses Rheumatology we included methodological and systemic reviews, clinical trials, prospective and retrospective longitudinal observational studies (OA). Secondary manual search and quality assessment with the Oxford scale by 2 independent researchers. The population included were UNI in ophthalmological remission after TB use. Articles with TB optimization strategies and whether there is a comparison with those that maintain the smPC dose are examined. The main measures being evaluated are efficacy and safety. Data are collected on eye activity, number of outbreaks, GC (glucorticoid) doses and adverse effects.

Results: 11 articles of low or moderate quality. They were mostly retrospective EO (n=7), and to a lesser extent prospective (n=4), and included 513 patients. With a variable follow-up from a minimum of 12 months, up to 17 years of evolution. There was a predominance of males, of average age of 36 years, the most represented disease was Bechet’s disease. There was no homogeneous criterion when trying to optimize, since the minimum required time of remission maintained with TB, varied from 3 to 12 months. The use of FAME and GC was allowed. The intervention is described in 7 articles with Infliximab, 2 with Adalimumab and 2 with Etanercept. Other TB other than anti-TNF, have not performed optimization so they are not included in this systematic review. They included patients treated with DMARD and even with previous anti-TNF. Many articles did not have a comparison group. Studies suggest that after 3-6 months in remission, it could be a time to assess optimization. The remission maintained after discontinuation of the drug, is maintained from 7.5 months to 2 years. GC reduction and suspension up to 74% and even 40% FAME are described. But there are also relapses in 25-50%, but they are controlled in general with the increase in doses and in some cases with change of TB. There were no relevant security issues.

Conclusion: 1. Low quality of the evidence. 2. Great variability in patients, pathologies, definitions or outcome variables. 3. There is no consensus at the time of starting the optimization, the data suggest that after 3-6 months in remission it could be assessed. 4. Articles with a limited number of cases (some without a control group) or retrospective are included. There is great heterogeneity in the optimization and protocols used. But despite all this, these results suggest that optimization and/or suspension (in selected cases) can be carried out safely and planned for anti-TNF TB, with a low probability of short-term recurrences. 5. In case of reactivation of uveitis, it seems that it is usually controlled in most cases, using again the standard doses. 6. There were no relevant security issues. 7. More studies with homogeneic criteria and established protocols are needed to determine the duration of the ideal treatment and see if there are differences in the etiology of uveitis or TB used.

References:

Objectives: To determine the prevalence of systemic inflammatory rheumatic disease in patients whose initial clinical manifestation is non-infectious uveitis.

Methods: Adult patients diagnosed with non-infectious uveitis in Dokuz Eylul University Ophthalmology Department and referred to investigate the
etiology of rheumatological disease were included in the study. Demographic and clinical features, laboratory and imaging findings of the patients were examined.

**Results:** 106 patients diagnosed with uveitis (42.4% anterior uveitis, 2.8% intermediate uveitis, 19.8% posterior uveitis, 34.9% panuveitis) were included in the study. 52.8% of the patients were male and the mean age was 40.19±14.82 years. The mean age of uveitis attack was 38.7±15.02 years. 33% of the patients were diagnosed with rheumatologic disease (10 SpA, 17 Behçet's Disease, two vasculitis, two sarcoidosis, three undifferentiated connective tissue disease, one rheumatoid arthritis). SpA was diagnosed in 20% of patients presenting with anterior uveitis. Behçet's disease was detected in 27% of patients referred with panuveitis and in 33.3% of patients whose first clinical finding was posterior chamber involvement. Bilateral uveitis was detected in two-thirds of patients with posterior chamber affected, and it tends to recur more (p=0.014).

**Conclusion:** A rheumatological disease was detected in approximately one-third of the patients presenting with uveitis. Investigation of patients referred for uveitis in terms of systemic rheumatological diseases is very important as it may change the diagnosis and treatment process.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.310

---

**AB1272 FACTORS AFFECTING PATIENT-ACCEPTABLE SYMPTOM STATES IN FAMILIAL MEDITERRANEAN FEVER**

D. Yıldırım1, R. C. Kardas1, B. Ozkiziltas1, I. Vasi1, M. A. Ozturk1, S. Haznedaroğlu1, B. Goker1, A. Tufan1, Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey

**Background:** Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever, serositis, and musculoskeletal symptoms (1, 2). Arthritis is the most common musculoskeletal symptom of attacks and also included in diagnostic criteria of FMF (3). If it is specifically queried, myalgia may be detected in up to 20-25% of the patients with FMF (4, 5).

**Objectives:** In our study, we aim to assess the localization of attack-related myalgia and associated parameters in patients with FMF.

**Methods:** A total of 349 consecutive patients followed by FMF in our clinic were enrolled in the study and asked for attack-induced myalgia and if present, localization of muscle groups on the mannequin body parts diagram. Attack frequency, duration, and disease activity were evaluated with the Auto-Inflammatory Diseases Activity Index (AIDAI) scoring system (6). Patients were also asked for work/study day loss during attacks and patient acceptable symptom state (PASS) status (7).

**Results:** 126 patients showed attack myalgia (36%); attack duration, frequency, severity were significantly higher in patients with attack-myalgia (p<0.005). Most common muscle groups were calves, lower back, and latissimus dorsi muscles in order. Myalgia was most commonly accompanied by arthritis (p<0.002). Patients with myalgia have a higher frequency of colchicine resistance and work/study day loss due to attacks.

**Conclusion:** Our results conclude that myalgia is an important domain of attacks and causes absenteeism and uncontrolled disease activity. Treatment of myalgia attacks may provide controlled disease activity, and prevent absenteeism from work/school.

**REFERENCES:**


---

**Table 1. Comparison of clinical and laboratory parameters between patients with/hwithout myalgia attacks**

<table>
<thead>
<tr>
<th>Patients with myalgia</th>
<th>Patients without myalgia</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>36.33 ± 10.68</td>
<td>37.91 ± 11.48</td>
</tr>
<tr>
<td>Sex (female/male)</td>
<td>78/43</td>
<td>138/87</td>
</tr>
<tr>
<td>Follow-up time (years)</td>
<td>16.1</td>
<td>17.6</td>
</tr>
<tr>
<td>Dominant attack (number)</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>Peritonitis</td>
<td>42</td>
<td>55</td>
</tr>
<tr>
<td>Arthritis</td>
<td>11</td>
<td>39</td>
</tr>
<tr>
<td>Pleuritis</td>
<td>13</td>
<td>10</td>
</tr>
<tr>
<td>Only fever</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>AIDAI score (mean, 0-175)</td>
<td>127.40</td>
<td>80.68</td>
</tr>
<tr>
<td>VAS score for pain (median score, during attack, 0-10)</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>Colchicine resistance (number of patients)</td>
<td>69</td>
<td>25</td>
</tr>
<tr>
<td>Colchicine-resistant</td>
<td>29</td>
<td>84</td>
</tr>
<tr>
<td>Colchicine-sensitive</td>
<td>17</td>
<td>68</td>
</tr>
<tr>
<td>PASI status (number)</td>
<td>41</td>
<td>6</td>
</tr>
<tr>
<td>Need additional treatment</td>
<td>41</td>
<td>66</td>
</tr>
<tr>
<td>Satisfied from treatment</td>
<td>34</td>
<td>74</td>
</tr>
<tr>
<td>Work/study day loss (number)</td>
<td>48</td>
<td>6</td>
</tr>
</tbody>
</table>

**Acknowledgements:** All study population signed informed consent for both participation and publication. Local Ethical Committee of the university approved the study.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.386

---

**AB1273 MACROPHAGE ACTIVATION SYNDROME IN RHEUMATIC DISEASE: CLINICAL CHARACTERISTICS AND PROGNOSIS OF 20 PATIENTS**

S. H. Nam1, S. M. Ahn2, J. S. Oh3, S. Hong4, C. K. Lee5, B. Yoo2, Y. G. Kim2, A. Asan Medical Center, Department of Internal medicine, Division of Rheumatology, Uijeongbu Eulji Medical Center, Department of Internal medicine, Division of Rheumatology, Seoul, Korea, Rep. of (South Korea); 2Asan Medical Center, Division of Internal medicine, Division of Rheumatology, Seoul, Korea, Rep. of (South Korea); 3Asan Medical Center, Department of Information Medicine, Big Data Research Center, Seoul, Korea, Rep. of (South Korea)

**Background:** Macrophage activation syndrome (MAS) is a hyperinflammatory condition that is known to be secondary hemophagocytic lymphohistiocytosis (HLH) in patients with rheumatic disease.

**Objectives:** The aim of study was to evaluate the clinical manifestations and outcomes in patients with MAS with rheumatic disease.

**Methods:** We performed a retrospective study of 20 adult patients who were diagnosed with MAS from 2012 to 2020. MAS was classified according to the HLH-2004 criteria. Patients’ information, including clinical features, laboratory findings, and treatment regimens, was collected, and the overall survival rate was estimated by the Kaplan–Meier method.

**Results:** Twenty patients (18 women, 35.6 ± 18.3 years) who met the HLH-2004 criteria also fulfilled the 2016 EULAR/ACR/PRINTO classification criteria for MAS, and HScore was higher than 169 (median, 238.5). Fourteen patients with systemic lupus erythematosus and 6 patients with adult-onset Still’s disease were included. All patients were treated initially with corticosteroids, and 16 patients required additional immunosuppressants. The overall survival at 3 and 6 months was 75.2% and 64.3%. In survivors, renal impairment was less common (23.1% versus 42.9%, p = 0.007), the levels of AST and LDH, and platelet count might be associated with non-survivors. Nine patients had opportunistic infections, five of whom died during admission.

**Conclusion:** The mortality of patients with MAS remains high. Renal impairment, levels of AST and LDH, and platelet count might be associated with prognosis.
**Table 1. Treatments and management characteristics of patients with MAS**

<table>
<thead>
<tr>
<th>No.</th>
<th>Age/sex</th>
<th>Disease</th>
<th>Disease duration (months)</th>
<th>1st Treatment</th>
<th>2nd Treatment</th>
<th>3rd Treatment</th>
<th>Combined infection</th>
<th>Alive/dead</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>19/F</td>
<td>SLE</td>
<td>1</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>TCZ, RTX</td>
<td>Bacteremia</td>
<td>Dead</td>
</tr>
<tr>
<td>2</td>
<td>20/M</td>
<td>SLE</td>
<td>0</td>
<td>1 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>3</td>
<td>20/F</td>
<td>AOSD</td>
<td>1</td>
<td>1 mg/kg</td>
<td>VP16</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>4</td>
<td>22/F</td>
<td>SLE</td>
<td>1</td>
<td>100 mg</td>
<td>IVIG + PP</td>
<td>-</td>
<td>Pneumonia</td>
<td>Dead</td>
</tr>
<tr>
<td>5</td>
<td>22/F</td>
<td>AOSD</td>
<td>0</td>
<td>500 mg</td>
<td>IVIG</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>6</td>
<td>23/F</td>
<td>SLE</td>
<td>182</td>
<td>1 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>7</td>
<td>23/F</td>
<td>SLE</td>
<td>41</td>
<td>1 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>8</td>
<td>30/F</td>
<td>SLE</td>
<td>146</td>
<td>1 mg/kg</td>
<td>IVIG</td>
<td>CsA, TCZ</td>
<td>Pneumonia</td>
<td>Alive</td>
</tr>
<tr>
<td>9</td>
<td>30/F</td>
<td>SLE</td>
<td>127</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>CsA, TCZ</td>
<td>Pneumonia</td>
<td>Alive</td>
</tr>
<tr>
<td>10</td>
<td>35/F</td>
<td>AOSD</td>
<td>0</td>
<td>1 mg/kg</td>
<td>CsA</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>11</td>
<td>37/F</td>
<td>SLE</td>
<td>65</td>
<td>1 mg/kg</td>
<td>CsA, VP16</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>12</td>
<td>38/F</td>
<td>SLE</td>
<td>0</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>RTX</td>
<td>-</td>
<td>Dead</td>
</tr>
<tr>
<td>13</td>
<td>40/F</td>
<td>AOSD</td>
<td>0</td>
<td>0.5 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>14</td>
<td>43/F</td>
<td>SLE</td>
<td>60</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>TCZ, RTX, CsA, VP16, IFX</td>
<td>Viral infection</td>
<td>Dead</td>
</tr>
<tr>
<td>15</td>
<td>49/F</td>
<td>SLE</td>
<td>0</td>
<td>1 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>16</td>
<td>51/F</td>
<td>AOSD</td>
<td>0</td>
<td>1 mg/kg</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Alive</td>
</tr>
<tr>
<td>17</td>
<td>57/F</td>
<td>SLE</td>
<td>0</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>CsA, VP16</td>
<td>Fungal infection</td>
<td>Dead</td>
</tr>
<tr>
<td>18</td>
<td>61/F</td>
<td>SLE</td>
<td>2</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>TCZ</td>
<td>-</td>
<td>Dead</td>
</tr>
<tr>
<td>19</td>
<td>68/F</td>
<td>SLE</td>
<td>2</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>CsA</td>
<td>Fungal infection</td>
<td>Alive</td>
</tr>
<tr>
<td>20</td>
<td>70/M</td>
<td>SLE</td>
<td>0</td>
<td>1 mg/kg</td>
<td>IVIG + PP</td>
<td>CsA, VP16</td>
<td>Fungal infection</td>
<td>Dead</td>
</tr>
</tbody>
</table>


Disclosure of Interests: None declared


**AB1275**

**SUGGESTED APPROACH TO UBA1 GENE MUTATION TESTING IN PATIENTS WITH SUSPECTED VEXAS SYNDROME**

K. Pavelcová1, B. Stibulková2,3, V. Balaiková1, M. Belíková1, C. Salek4,5, M. Vostřy1, H. Mann1,2, J. Vencovský3,2,1, Institute of Rheumatology, Prague, Czech Republic; 2First Faculty of Medicine, Charles University, Department of Rheumatology, Prague, Czech Republic; 3First Faculty of Medicine, Charles University and General University Hospital, Department of Pediatrics and Inherited Metabolic Disorders, Prague, Czech Republic; 4First Faculty of Medicine, Charles University, Institute of Clinical and Experimental Haematology, Prague, Czech Republic

**Background:** VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently identified autoinflammatory disease caused by de novo somatic mutations in the X-linked gene UBA1 (1). This disease is clinically characterized by inflammatory symptoms and bone marrow failure (2).

**Objectives:**

1. To investigate genetic variants associated with VEXAS syndrome and to design an algorithm for detection of UBA1 gene mutations in patients with suspected VEXAS syndrome, which could be used for diagnosis.

2. To exam the UBA1 gene in 9 patients with clinically suspected VEXAS syndrome.

3. To focus on variants p.Met41Val, p.Met41Thr and p.Met41Leu with a known association with this disease (1).

4. To analyze the remaining exons of the UBA1 gene by Sanger sequencing.

5. To evaluate the previously described variants p.Met41Thr in two and p.Met41Leu in another two patients.

6. To develop a new mutation p.Gly477Ala (c.1430G>C) in exon 14 that has not yet been identified.

7. To study the presence of these variants and their allelic forms (heterozygous / homozygous) varied between cell populations in individual patients.

8. To conclude the increasing number of reports suggests that VEXAS syndrome is not rare. In patients with clinical suspicion, typically UBA1 sequencing analysis of haematopoietic cells is performed in hot spot sites of p.Met41 in exon 3 only.

9. Our results suggest that other variants, such as the newly identified p.Gly477Ala variant, may also be associated with clinical features of VEXAS syndrome.

10. We propose that an extended analysis of all coding regions of the UBA1 gene may uncover other mutations with putative functional consequences.

**REFERENCES:**


Disclosure of Interests: None declared

AB1276 EVALUATION OF DRUG-FREE REMISSION RATES IN IDIOPATHIC GRANULOMATOUS MASTITIS

M. N. Kayal, 1 Ö. Kilic, 1 E. Telgöz, 2 S. Colak, 1 M. Çınar, 1 S. Yılmaz, 1 University of Health Sciences Turkey, Gülhane Training and Research Hospital, Rheumatology, Ankara, Turkey

Background: Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease. There is no clear consensus on its treatment yet (1).

Objectives: The aim of the study was to evaluate the rates of drug-free remission of the patients with IGM in a period of three-year follow-up.

Methods: A total of 76 patients who were followed-up with biopsy proven IGM between February 2011 and November 2021 in rheumatology outpatient clinic of Gülhane Training and Research Hospital, were evaluated retrospectively. To analyze long-term outcomes, 55 patients who were followed up for 3 years were included in the study. Data regarding the demographic and clinical characteristics of the patients were obtained from patients’ files.

Results: The study included 55 female patients with a mean age of 36.8 ± 6.3 years. Forty-nine (89.1%) patients received immunosuppressive treatment, one (1.8%) patient received postoperative immunosuppressive treatment, 3 (5.4%) patients had immunosuppressive treatment due to recurrence after surgery, and 1 (1.8%) patient underwent only surgery. One (1.8%) patient had no treatment for IGM. Patients who received immunosuppressive drugs for initial treatment, 38 (69.1%) received methotrexate (MTX) and corticosteroids (CS), 7 (13.2%) received azathioprine (AZA) and CS, 3 (5.6%) received only CS and 1 (1.8%) received cyclosporine A (CsA) and CS. Four (7.2%) patients had received MTX after surgery. At 3-year follow-up 54 (98.1%) patients were in drug-free remission. The median duration of drug-free remission in patients receiving MTX plus CS, CS, and azathioprine plus CS was 19.7, 32.9, and 14.7 months, respectively. One patient who received CsA plus CS was in drug-free remission for 28.3 months. The median duration of treatment with combination of CS and other immunosuppressives was 6.7 months. The median duration of immunosuppressive treatment was 15.8 months (Table 1). Recurrence was observed in 4 (80%) patients who did not receive immunosuppressive therapy after surgery. Three (75%) of these patients received MTX due to recurrence, and remission was achieved.

Table 1. Duration of immunosuppressive treatment and drug-free remission of the patients

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Duration of immunosuppressives, (n=53)</th>
<th>Duration of drug-free remission, (n=54)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Only corticosteroids (month)*</td>
<td>76</td>
<td>28.3</td>
</tr>
<tr>
<td>Methotrexate (month)*</td>
<td>16.2 (110-30.1)</td>
<td>14.7 (8.8-22.9)</td>
</tr>
<tr>
<td>Azathioprine (month)*</td>
<td>19.7 (2.8-32.4)</td>
<td>19.7 (2.7-32.4)</td>
</tr>
<tr>
<td>Cyclosporine (month)</td>
<td>32.9 (32.4-42.4)</td>
<td>32.9 (32.4-42.4)</td>
</tr>
<tr>
<td>Total (month)*</td>
<td>15.8 (2.9-34.3)</td>
<td>21.2 (2.7-36.6)</td>
</tr>
</tbody>
</table>

* Variables as median, (minimum - maximum)

Conclusion: Immunosuppressives provide a remarkably high sustained remission and maintain a longer drug-free remission in patients with IGM.

REFERENCES:

Disclosure of Interests: None declared


AB1277 POOR LONG-TERM OUTCOMES AND SUBSTANTIAL BURDEN OF COMORBIDITIES IN EUROPEAN PATIENTS WITH DERMATOMYOSITIS/POLYMYSITIS: RESULTS FROM A SYSTEMATIC LITERATURE REVIEW

J. Vencovský, 1 K. Pisarczyk, 2 R. Left, 3 E. Park, 4 K. Palanisamy, 5. L. Long, 6 Institute of Rheumatology, Research Department, Prague, Czech Republic, 1 Maple Health Group, Market Access, Cracow, Poland, 2 Kezar Life Sciences, Clinical Development, South San Francisco, CA, United States of America; 3 Kezar Life Sciences, Medical Affairs, South San Francisco, CA, United States of America

Background: Dermatomyositis (DM) and polymyositis (PM) are rare heterogeneous systemic autoimmune disorders of the skin, muscles and other organs that may have a devastating impact on patients’ lives. Despite various therapies used in clinical practice, a notable proportion of patients seem not to achieve sustainable remission. There is a need to better understand long-term outcomes and comorbidities in patients with DM/PM in Europe.

Objectives: To systematically review and summarize evidence on clinical burden of disease in patients with DM/PM in Europe.

Methods: A systematic literature review (SLR) was conducted in MEDLINE and Embase databases to identify studies in children and adults with DM/PM, published in the English language between 2011 and 2021. Primary studies enrolling 10 or more patients were included, irrespective of country or region. Each eligible article was independently reviewed by two reviewers. The title and study abstracts were reviewed to assess eligibility for full-text review. The current abstract summarizes SLR results on the long-term outcomes and comorbidities in patients with DM/PM in Europe.

Results: A total of 2,967 non-duplicated publications were retrieved from medical databases and analyzed against pre-defined study selection criteria. There were 2,574 records excluded at title and abstract screening. Remaining 393 records were analyzed in the full text with 208 papers considered relevant. Additional 21 papers were identified from searching reference list of relevant studies and conference proceedings. In total, 222 studies (229 publications) were included in data abstraction. Among 43 studies conducted across 14 European countries, 23 studies evaluated long-term outcomes of disease and burden of comorbidities. There were 14 longitudinal cohort studies, 7 cross-sectional analyses and 2 case-control studies. Only 29-44% of DM/PM adults achieved remission. Between 38% and 62% of adults with DM/PM required at least 3 different medications, suggesting inadequate response to initial and subsequent regimens. During a mean follow-up of 13.9 years, 69% patients with JDM had polycylic or chronic disease characterized by periods of remission and recurrence or by permanently active disease for more than 2 years after diagnosis. A notable proportion of children (60.4%) showed evidence of damage in at least one body organ and 13-20% of patients had complications such as calcinosis, lipodystrophy, or muscle atrophy. Adults with DM/PM often suffered from intestinal lung disease (166%), serious infections leading to hospitalization or death (126%) and cardiovascular disorders (CVDs) (19-71%). Compared to age and gender matched controls without DM, patients with DM had 16-times higher risk of venous thromboembolism (HR=16.44, 95% CI: 7.54-35.86). Incidence of coronary heart disease, hemorrhagic stroke, or ischemic stroke during 10-year follow-up was approximately 1.5- to 2-times higher in DM/PM adults relative to general population. Multiple studies reported high rates of any malignancy in DM adults (75-93%) and in PM adults (8-17%). During approximately 24,000 patient-years of follow-up, adults with DM/PM had more than 4-times higher incidence of lung cancer compared to general population that also was one of the highest incidences among multiple other autoimmune diseases. Long-term prognosis in DM/PM was poor with 20-year survival below 70%. The most common causes of deaths were pulmonary-related, malignancies, and cardiac complications. Mortality due to lung cancer was more than 4-times higher than in general population (standardized mortality ratio=4.17, 95% CI: 3.03-5.80).

Conclusion: European patients with DM/PM suffer from substantial burden of comorbidities including serious infections, malignancies and CVDs that lead to poor long-term outcomes. A notable proportion of adult and juvenile patients do not achieve sustainable remission or experience relapse indicating high unmet need.


AB1278 INCIDENCE OF ENDOCRINE AND EXOCRINE INSUFFICIENCY IN PATIENTS WITH AUTOIMMUNE PANCREATITIS AT DIAGNOSIS AND AFTER TREATMENT

M. Lanzilliota, 1 M. Tacelli, 1 G. Capurso 2, L. Dagnia 1, E. della Torre 1. 1 San Raffaele Scientific Institute, Unit of Immunology, Immunology, Allergy and Rare Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy; 2 San Raffaele Scientific Institute, Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Milan, Italy, Milan, Italy

Background: Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis that may lead to endocrine and exocrine insufficiency if left untreated. AIP clinically responds to glucocorticoids (GCs) therapy, but multiple GCs courses are often required to maintain remission with potential detrimental effects on glycaemic control. To date, data on pancreatic function in AIP are scanty and heterogeneous.

Objectives: We aimed to assess the rate of endocrine and of exocrine insufficiency at diagnosis and at follow-up in patients with AIP as well as the impact of GC therapy on pancreatic function in the long term.
Methods: The MEDLINE, SCOPUS, and EMBASE databases were searched from inception to August 2021 to identify studies reporting data on endocrine and exocrine insufficiency in patients with type 1 and type 2 AIP. Studies involving ≥ 9 patients were included. In case of duplicated studies, the most recent or the one with the largest sample were included. The study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Pooled events were calculated using a random-effect model and expressed in terms of pooled prevalence rates.

Results: A total of 6522 AIP patients and sixty-two studies were included in the analysis. The pooled estimate rate for the overall prevalence of diabetes in AIP at baseline (combined type 1 and type 2 AIP) was 36.9% (95% CI 31.9-41.9, I² 96.1%). The pooled estimate for the prevalence of diabetes was 44.3% (95% CI 39.1-49.4, I² 91.9%) in type 1 AIP and 11.3% (95% CI 6.1-16.6, I² 42.5%) in type 2 AIP (p < 0.01), respectively. The pooled prevalence rate of exocrine insufficiency was 45.2% (95% CI 32.9-57.4, I² 97.4%). The pooled estimate rate of diabetes at follow-up was 44.2% (95% CI 26.1-64.2) in studies where GCs were given to 100% of patients and 41.8% (95% CI 30.6-52.9) in studies where GCs were given to less than 100% of patients. The pooled prevalence of pancreatic exocrine insufficiency was 36.2% (95% CI 20.4-52.0, I² 96.4%).

Conclusion: A large proportion of patients with AIP displays concomitant exocrine and endocrine insufficiency at the time of diagnosis. The incidence of diabetes at the longest available follow up tends to increase in patients treated with GCs. Further long-term studies are warranted to assess the impact of GCs and immunosuppressive treatments on glycemic control and on exocrine pancreatic function.

REFERENCES:

Disclosure of Interests: None declared


AB1279  POOR QUALITY OF LIFE AND REDUCED WORK PRODUCTIVITY IN EUROPEAN PATIENTS WITH DERMATOMYOSITIS AND POLYMYOSITIS: FINDINGS FROM A SYSTEMATIC LITERATURE REVIEW
J. Schmidt1, K. Pisarczyk2, R. Left3, K. Palisinawamy4, E. Park5, L. Long6, Immanuel Klinik Rüdersdorf University Hospital of the Brandenburg Medical School Theodor Fontane, Department of Neurology and Pain Treatment, Rüdersdorf bei Berlin, Germany; 2Maple Health Group, Market Access, Cracow, Poland; 3Kezar Life Sciences, Clinical Development, South San Francisco, United States of America; 4Kezar Life Sciences, Medical Affairs, South San Francisco, CA, United States of America

Background: Dermatomyositis (DM) and polymyositis (PM) are rare heterogenous systemic autoimmune disorders of the skin, muscles, and other organs with diverse effective treatment options available. They are described as devastating diseases but the full impact on patients’ lives in Europe is not well understood.

Objectives: To systematically review and summarize evidence on humanistic burden of disease in patients with DM and PM in Europe to better understand patient-relevant aspects of disease and key domains of life impacted by DM and PM in the European setting.

Methods: A systematic literature review (SLR) was conducted in MEDLINE and EMBASE databases to identify studies in children and adults with DM and PM, published in the English language between Jan 1, 2011, and Apr 28, 2021. Only primary studies enrolling 10 or more patients were included, irrespective of country or region. Each eligible article was independently reviewed by two reviewers. The title and study abstracts were reviewed to assess eligibility for full-text review.

Results: A total of 2,967 non-duplicated publications were retrieved from medical databases and analyzed against pre-defined study selection criteria. There were 738 unique records excluded at title and abstract screening. Remaining 393 records were analyzed in the full text with 208 papers considered relevant. Additional 21 papers were identified from searching reference list of relevant studies and conference proceedings. In total, 222 studies described in 229 publications were included in data abstraction. Among 43 studies conducted across 14 European countries, 12 studies evaluated health-related quality of life (HRQoL) and work productivity in patients with DM and PM. In 6 studies, patients received standard of care therapy. Six studies enrolled adults with DM and PM and 6 were conducted in patients with juvenile onset of DM. There were 6 cross-sectional analyses, 4 longitudinal cohort studies, 2 case-control studies, with sample size ranging from 11 to 246 patients. Adults with DM and PM had significantly worse HRQoL across multiple domains of 36-item Short Form Survey (SF-36) compared to controls from general population, with a strong negative impact of muscle weakness on physical functioning. Patients reported high difficulties in performing leisure time activities, moving around and work as indicated by median scores of 4-5 points in a 7-point Myositis Activity Profile (MAP). Reduced grip force in DM and PM adults was significantly associated with worse performance in HRQoL across multiple domains of SF-36. Women with DM and PM, poor grip force additionally impacted vitality and mental health as measured by SF-36 (p<0.05). There were no associations between grip force and any SF-36 domain in men. Approximately 60% of adult patients rated their ability to work as “poor” or “less good” according to the Work Ability Index, 68% of patients had more than one week of sick leave in the past year, and 20.8% of them were permanently not able to work for at least 2 years. Children and adolescents with DM had impaired physical and psychosocial functioning compared to healthy norms with 40% of individuals showing increased emotional distress requiring in-depth psychological assessment.

Conclusion: European patients with DM and PM experience a muscle weakness that has a detrimental impact on HRQoL, daily activities and ability to work. Similar disease impact on HRQoL was reported in patients in North America. These findings suggest a need for a novel therapy that will restore physical functioning in patients with DM and PM.


AB1280  IGG4 RELATED DISEASE WITH ATYPICAL SCALENE MUSCLES INVOLVEMENT
J. F. Valdés Corona1, M. Arroyo2, F. J. Zamarripa Molina3, A. C. Chávez Alanís4, 1Hospital Angeles Lomas, Rheumatology, Mexico City, Mexico; 2Hospital Angeles Lomas, Internal Medicine, Mexico City, Mexico; 3Hospital Angeles Lomas, Ophthalmology, Mexico City, Mexico; 4Hospital Angeles Lomas, Radiology, Mexico City, Mexico

Background: IgG4 related disease is a chronic, immune-mediated, fibroinflammatory condition that affects nearly any organ, but most common presentations include salivary glands and lacrimal enlargement, orbital disease, pancreatitis, retroperitoneal fibrosis and tubulointerstitial nephritis. Even as IgG4-related disease is increasingly associated with head and neck manifestations, the involvement of scalene muscles hasn’t been previously described.

Objectives: Describe an interesting case of IgG4 related disease presenting with scalene muscle and cervical manifestations.

Methods: Case report and clinical imaging

Results: 79-year-old female, with a history of Sjogren syndrome treated with hydroxychloroquine 200mg twice a week, presented with unilateral right blepharo- rhoptosis. Physical examination confirmed right eye ptosis, supraorbital soft tissue enlargement, diplopia and limited ocular movement. CT Scan revealed right and left orbit with diffuse enlargement of the right superior rectus, suggesting bilateral dacyrocytis, and most important it described a pseudotumor of 5.7 cm x 3.2 cm x 6.2 cm infiltrating asymetrically the lower portion of the left scalene muscle. Lacrimal biopsy and immunohistochemistry revealed IgG4 related disease (dense lymphocytic infiltrate, IgG4+IgG+ ratio 53% and more than 10 cells/hpf). Serum IgG4 concentration 633mg/dl (more than 5 times upper limit of normal). Pulmonary embolism was also detected. The patients received treatment with a tapering regime of oral prednisone. Budesonide mouth mist for long term immunosuppression, with adequate response and complete remission of symptoms.

Conclusion: The multiorgan involvement and recently recognized nature of IgG4 related disease, may cause confusion among physicians; leading to misdiagnosis, unnecessary procedures and delay in treatment. It requires a high degree of clinical suspicion to diagnose a IgG4 RD, when presenting with ocular involvement, and even more when it affects organs that are not usually associated with this condition, such as scalene muscles. The diagnosis is supported by pathognomonic histopathological findings, and even as treatment strategies are constantly evolving, glucocorticoids remain as first line treatment.

Whether this finding is related with those observed in the paravertebral band – like soft tissue in the thorax, has to be defined. Also interesting is that in this case, this pseudotumor is in the left side.
REFERENCES:


Disclosure of Interests: Luis Francisco Valdés Corona Speakers bureau: Sanofi UCB, Mariana Arroyo: None declared, Francisco Javier Zamarripa Molina: None declared, Angel César Chávez Alanis: None declared, Raquel Pilomo Interessen: None declared.

UCB, Mariana Arroyo: None declared, Francisco Javier Zamarripa Molina: None declared

Disclosure of Interests:


Disclosure of Interests: Ana Isabel Rebollo Giménez: None declared, Lirios Sacristán-Bou Speakers bureau: IBD, Chiesi, Gebro Pharma, Boehringer Ingelheim, Roche, Rovi, Teva, David Bellido Pastrana Speakers bureau: DB has received honoraria for speaker bureau from: Glaxosmithkline (GSK), Chiesi, Gebro Pharma, Boehringer Ingelheim, Roche, Rovi, Teva, David Bellido Pastrana Speakers bureau: DB has received honoraria for speaker bureau from: Glaxosmithkline, Patriaxia Mata Calderón Speakers bureau: PM has received honoraria for speaker bureaus from: Novartis, GSK, Gebro, Boehringer, AstraZeneca, Menarini, Ferrer, Isabel Domínguez Osorio: None declared, Isabel María Ordóñez Dios Speakers bureau: IO has received honoraria for speaker bureau from: Novartis, GSK, Boehringer ingelheim, Roche and Chiesi, Marta Orta Caamaño Speakers bureau: MO has received honoraria for speaker bureau from Glaxosmithkline and Chiesi, Carlos Bujalance Cabrera Speakers bureau: CB has received honoraria for speaker bureau from Faes and GSK, Francisco Javier Lázaro Polo Speakers bureau: FL has received honoraria for speaker bureau from GSK, AstraZeneca and Sanofi

AB1282 OVARIAN RESERVE IN BEHÇET’S DISEASE

Z. Alekberova1, R. Goloeva2, M. Cherkasova2, A. Lila3, V.A. Nasonova Research Institute of Rheumatology, advisory department, Moscow, Russian Federation; V.A. Nasonova Research Institute of Rheumatology, Trobovinflammation Laboratory, Moscow, Russian Federation

Background: Behçet’s disease (BD) is a multisystemic disease of unknown cause. Anti-Mullerian hormone (AMH) is one of the key parameters for assessing reproductive function and ovarian reserve. The levels of AMH correlates with the residual follicular pool in women of reproductive age.

Objectives: To assess AMH levels in BD female patients of child-bearing potential, and analyze the relationship between AMH levels and disease severity, as well as relationship between serum AMH levels and different therapeutic regimens.

Methods: The study group included 45 women with BD (according to ISGKD 1990 and ICBD 2014) aged 20-40 years, and the control group included 15 age-matching healthy women. BMI mean age was 31.3 [27.35], disease duration 6 [3.8] yrs. 178% pts had severe BD according to Ch.Zouboulis classification (due to generalized ulcers, retinal vasculitis and parenchymatous CNS lesions), 37.8% pts had a moderate disease, 44.4% pts had a mild disease with mainly dermal-mucous manifestations. AMH levels was measured using ELISA. AMH reference values ranged within 1.0-10.6 ng/ml. Values <1.0 were interpreted as a decreased ovarian reserve.

Results: The mean levels AMH was 2.5 ng/ml in BD pts, and 3.1 ng/ml in control group, showing no statistical difference. A decrease in ovarian reserve (AMH less than 1.0 ng/ml) was observed with the same frequency 18% in patient’s vs. control group 13%. In the analysis of AMH, depending on the severity of BD, a decrease in ovarian reserve was more often observed in patients with moderate and severe forms of BD.

Table 1. AMH and severe BD

<table>
<thead>
<tr>
<th>AMH</th>
<th>severe</th>
<th>mild, n=20</th>
<th>moderate disease, n=17</th>
<th>severe, n= 8</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMH</td>
<td>2.7 [1.6-3.5]</td>
<td>2.5 [1.0-3.7]</td>
<td>1.9 [0.6,7]</td>
<td>ns</td>
<td></td>
</tr>
<tr>
<td>AMH &gt;1ng/ml, %</td>
<td>10</td>
<td>23</td>
<td>25</td>
<td>0,02</td>
<td></td>
</tr>
</tbody>
</table>

There are no correlations of levels AMH with treatment of BD.
A decrease in ovarian reserve was noted in two patients under 30 years old, one was 29 years old woman with “Neurobehçet” with two children, and the patient with Behçet’s disease (BD) was not married, had no pregnancies, and received colchicine therapy for a long time. Two BD patients with low AMH had no pregnancies - unfortunately, all other patients with reduced ovarian reserve had from 1 to 6 children. When analyzing the levels of AMH with the clinical picture and BD therapy, no correlations were found.  

Conclusion: The average levels of AMH in women with BD and in the control group did not differ. A decrease in ovarian reserve (AMH less than 1.0ng/ml) occurred with the same frequency in patients with BD and controls. A decrease in ovarian reserve was more often observed in patients with moderate and severe BD.

REFERENCES:  

Disclosure of Interests: None declared  

AB1283  
HOW TO COUNSEL A WOMAN WITH BEHÇET'S DISEASE: RESULTS FROM A MONOCENTRIC COHORT OF WOMEN DIAGNOSED DURING CHILDbearing AGE  
M. Arbrile1, M. Radin1, D. Rosai1, E. Menegatti1, D. Roccatello1, S. Sciascia1  
University of Turin, Clinical and Biological Sciences, Turin, Italy  

Background: Patients with autoimmune diseases require appropriate pregnancy counseling, as their disease can negatively impact both maternal and fetal outcomes. In regards to Behçet's disease (BD), although commonly diagnosed during the childbearing age, only few studies focused on its impact on gestation, with contradictory results.  

Objectives: We aimed to collect new data on BD and its impact on pregnancy by designing a single-center cohort study, reporting the pregnancy and maternal outcomes in BD patients attending the Multidisciplinary Centre for Immunopathology and Rare Diseases at Giovanni Bosco Hospital (Turin, Italy).  

Methods: We retrospectively included 26 women diagnosed with BD followed at our center. Out of 26 patients, data from 33 pregnancies in 16 women were collected. Ten patients were never pregnant. Table 1 shows the demographical and clinical characteristics and the pregnancy outcomes of the enrolled patients.  

Table 1. Clinical characteristics and pregnancy outcome of the Behçet’s disease patients enrolled in the study.  

<table>
<thead>
<tr>
<th>Patients (tot=31)</th>
</tr>
</thead>
</table>
| Nulliparous; n (%) | 10/26 (38.46%)  
| Primigravida; n (%) | 16/26 (61.54%)  
| Age at BD diagnosis; mean± S.D. | 40.56±11.42  
| Age at first pregnancy; mean± S.D. | 24.86 ± 6.56  
| Oral ulcerations; n (%) | 26/26 (100%)  
| Genital ulcers; n (%) | 21/26 (80.76%)  
| Folliculitis; n (%) | 15/26 (57.69%)  
| Erythema nodosum; n (%) | 22/26 (80.77%)  
| Ocular manifestations; n (%) | 11/26 (42.31%)  
| HLA B-51+; n (%) | 13/26 (50%)  
| Pregnancy outcome |  
| Rate of live births; n (%) | 27/33 (81.81%)  
| Any complications; n (%) | 12/33 (36.36%)  
| Early miscarriage before 10 weeks of gestation; n (%) | 6/33 (18.18%)  
| Gestational diabetes; n (%) | 3/33 (9.09%)  
| Placental abruption; n (%) | 2/33 (6.06%)  
| Vaginal bleeding before 20 weeks of gestation; n (%) | 1/33 (3.03%)  
| Worsening of oral and genital ulcerations; n (%) | 21/11 (18%)  

* This information was available only for 11/33 pregnancies.BD – Behçet’s disease;S.D. – Standard deviation  

Results: All included patients fulfilled the international criteria for BD (1), with a median age at the time of diagnosis of BD and first pregnancy of 45,56±11.42 and 24,86±6.56 respectively. The frequency of clinical manifestations was oral ulcers (100%), genital ulcers (80,76%), erythema nodosum (23.08%), folliculitis (5.76%), ocular manifestations (42.31%) and HLA B-51+ (50%), respectively. The overall rate of live births was 81,81% (27/33). Twelve women experienced pregnancy complications (36.36%), in particular we report one case of vaginal bleeding before 20 weeks of gestation, six miscarriages before the 10th week of gestation, three cases of gestational diabetes and two placental abruptions. Among the analyzed pregnancies, a worsening of oral and genital ulcerations was observed in the 18% of them, while in the remaining cases a subjective amelioration of aphtosis and other concurrent symptoms was reported by the patients. No systemic flare, worsening of ocular complications and VTE was reported during pregnancy and in the post-partum period.  

Conclusion: The results of our study highlight an overall favorable rate of life births in BD women and a positive rate of disease remission in pregnancy. Currently, the studies focusing on pregnancy outcomes in BD are scarce, however it might be appropriate to give a specialized counseling to a BD woman planning for a pregnancy and follow these patients with a multidisciplinary approach.

REFERENCES:  

Disclosure of Interests: None declared  

AB1284  
GENDER CHARACTERISTICS OF IDIOPATHIC LOBULAR PANNICULITIS  
O. Egorova1, G. Tarasova1, A. Datsina2  
1V.A. Nasonova Research Institute of Rheumatology, Laboratory of Thromboinflammation, Moscow, Russian Federation; 2Pirogov Russian National Research Medical University, Ministry of Health of Russia, Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow, Russian Federation  

Background: Idiopathic lobular panniculitis (ILP) (Weber-Christian disease) is the least studied disease from the group of “systemic lesions of the connective tissue” and is characterized by a multifaceted lesion of the subcutaneous adipose tissue (SAT) of organs.  

Objectives: to compare the incidence of clinical and laboratory manifestations of ILP in patients of different sexes in the Russian cohort.  

Methods: We examined 67 patients (9 men and 58 women) aged 20 to 76 years with an average duration of the disease 78.91 months [48; 540] with a verified diagnosis of ILP, who were observed at the V.A. Nasonova Research Institute of Rheumatology in 2010-2021. In addition to general clinical examination, determination of the titer of α-1 antitrypsin, liver fractions, amylase, lipase, trypsin, ferritin, creatine phosphokinase, lepiltin, TNF-α, computed tomography of the chest and pathomorphological studies of induration were carried out.  

Results: The peak of the disease in men (55.55%) was detected at 35–45 years old, while in women (38.5%) from 50 to 60 years old. In 55.2% of women, two periods of the development of the disease were identified – from 16 to 25 in 12 patients (32.4%) and from 46 to 60 in 25 patients (67.5%). When analyzing the demographic indicators in patients with ILP, 86.3% were residents of the European part of Russia, no gender differences were found. In 3 men (33.3%) and 22 women (37.9%), ILP was diagnosed within a year. With the disease duration of 1 to 5 years, the diagnosis was confirmed in 44.4% of men and in every third woman. The duration of more than 5 years from the onset of the first symptom to the establishment of a reliable diagnosis of ILP in women was 32.7%, while in men – 11.1% (p <0.03). The nodular form (Mf; 55.5%) and the mesenteric form (Mf; 33.3%) were observed somewhat more often in men than in women, with a tendency to a higher body temperature and a greater number of painful (according to VAS) indurations. In women, Nf was found in 43.1% of cases, plaque form and Mf – in 15.5% each. The infiltrative form (25.8%) was found only in women. Indurations were characterized by a subfebrile temperature, mainly with localization on the thighs (75.8%), upper limbs (51.7%) and trunk (43.1%). Later, in 31 patients (46.2% (93.3% of them were women), a combination or transition from one form to another was detected, indicating a mixed nature of the disease. Body temperature indices in men were inversely correlated with the duration of the disease (r = −0.73; p <0.05). In women, there was a significant association of an increase in body temperature with pain (according to VAS) of the nodes (p <0.05), as well as with the form of the disease (p <0.03). Average ESR data were higher in women (24.50 ± 15.99mm/h). In the presence of a high level of CRP (46.2 ± 31.7 pg/ml) was significantly more often observed with Mf (p<0.017), which correlated with the concentration of TNF-α (r = 0.72; p <0.05). Women had a 2.3 times higher leptin content than men (r = 0.46; p <0.05). Pathomorphological examination of a biopsy of the skin and SAT confirmed lobular panniculitis (ILP) in all cases.  

Conclusion: In the Russian cohort of patients, male gender is associated with a progressive course of the disease, which is the basis for prescribing immunosuppressive therapy for men with ILP at early stages of the disease.

Disclosure of Interests: None declared  
Table 1. BD manifestations in the Russian Federation depending on ethnicity

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>North and South Caucasus, n=370</th>
<th>Russians, n=121</th>
<th>Central Asia, p=0.044</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, yrs</td>
<td>32.7±7.9, 74</td>
<td>34.5±11.0</td>
<td>29.9±9.15</td>
</tr>
<tr>
<td>Mean age at disease onset, yrs</td>
<td>22.5±3.9</td>
<td>22.8±11.5</td>
<td>18.5±8.98</td>
</tr>
<tr>
<td>BDCAF, point</td>
<td>7.27±2.34</td>
<td>6.90±1.85</td>
<td>6.33±1.98</td>
</tr>
<tr>
<td>Oral aphthosis</td>
<td>360 (97.3%)</td>
<td>117 (96.7%)</td>
<td>46 (95.6%)</td>
</tr>
<tr>
<td>Genital ulcers</td>
<td>263 (71.0%)</td>
<td>88 (72.7%)</td>
<td>26 (54.2%)</td>
</tr>
<tr>
<td>Skin involvement</td>
<td>324 (87.6%)</td>
<td>101 (83.5%)</td>
<td>40 (83.3%)</td>
</tr>
<tr>
<td>Positive pathergy test</td>
<td>99 (26.7%)</td>
<td>45 (37.2%)</td>
<td>16 (33.3%)</td>
</tr>
<tr>
<td>Ocular involvement</td>
<td>232 (62.7%)</td>
<td>58 (47.9%)</td>
<td>34 (70.8%)</td>
</tr>
<tr>
<td>Gastrointestinal involvement</td>
<td>59 (15.9%)</td>
<td>33 (27.3%)</td>
<td>7 (14.6%)</td>
</tr>
<tr>
<td>Neurological involvement</td>
<td>44 (11.9%)</td>
<td>21 (17.3%)</td>
<td>3 (6.3%)</td>
</tr>
<tr>
<td>Vascular involvement</td>
<td>72 (19.5%)</td>
<td>18 (14.8%)</td>
<td>10 (20.8%)</td>
</tr>
<tr>
<td>BDCAF (51) positivity</td>
<td>179 from 251 (71.3%)</td>
<td>28 from 79</td>
<td>20 from 36</td>
</tr>
</tbody>
</table>
| complications will be randomized to receive either intravenous

Conclusion: Behcet’s disease is most often detected in natives of the North and South Caucasus, Russians and natives of Central Asia in the Russian Federation’s cohort. Differences in the frequency of various clinical manifestations depending on the ethnicity of patients were revealed.

Disclosure of Interests: None declared

Results: The number of patients with pain reduction ≥50% from baseline were 12.0% (significant difference from baseline in all points, p<0.05). Similarly, there was a 10-cm VAS at baseline, after 2, 4 and 8 weeks was 6.5±1.2; 4.8±1.4; 2.6±1.4; 2.2±1.1 cm detected in 14 patients (67%), with predominant involvement of the ankle (67%) and C-reactive protein level (p = 0.006; r = 0.38). There was a direct correlation between the number of nodules and the duration of LPn (p = 0.04; r = 0.20) and a novel participant-reported outcome measure, the Dermatomyositis-Disease Symptoms Questionnaire (DM-DSQ). Safety will be assessed by analyzing the incidence of treatment-related adverse events (TEAEs), including those classified as serious and/or leading to intervention discontinuation.

Conclusions: Etoricoxib is effective and relatively safe for long-term control of chronic pain in LPn.

Background: Cardiac involvement is an uncommonly seen but might be a fatal clinical manifestation of Behcet's syndrome (BS), if not recognized early and treated aggressively.

Objectives: Our aim was to retrospectively evaluate the characteristics of cardiac involvement in Behcet's syndrome and investigate possible risk factors.

Methods: 800 patients with BS diagnosis according to International Study Group for Behcet's Disease (ISG) criteria in our center were screened. 14 patients with cardiac involvement were included in this study.

Results: All the patients were male with positive smoking history. The age at the onset cardiac involvement was 32.5 ± 7.8 years. In 3 patients, diagnosis of BS was made simultaneously with cardiac involvement. Types of cardiac involvement were as following: intracardiac thrombosis (ICT) in 8, right coronary artery aneurysm in 2, and myocardial infarction in 4 patients. The majority of ICT was seen in right ventricle followed by right atrium (75% vs 25%). Deep vein thrombosis (DVT) was the most common followed by other vascular involvement (57%). Thrombophilic factors were studied in 8 patients, whom only 2 cases were found positive for heterozygous factor V Leiden mutation. Cyclophosphamide was the most common used immunosuppressive agent and anticoagulation was used in 9 patients (Table 1).

<table>
<thead>
<tr>
<th>Table 1. Characteristics of cardiac involvement in BS patients</th>
</tr>
</thead>
</table>
| Male/female, (n), (%) | 100%
| Age of cardiac involvement, years (Mean ± SD) | 32.5 ± 7.8
| Smoking history, (n), (%) | 14 (100)
| Other vascular involvement, (n), (%) | 12 (85)
| Deep vein thrombosis, (n) | 8
| Pulmonary involvement, (n) | 4
| Peripherial artery aneurysm, (n) | 1
| Cardiac involvement patterns | ICT, (n), (%) |
| RA | 6
| RV | 2
| CAA, (n), (%) | 2 (14.3)
| AMI, (n), (%) | 4 (28.6)
| Anticoagulation, (n) | 1
| Immunosuppression, (n) | 3
| Steroid | 14
| CYC | 9
| AZA | 3
| IFN | 1

Conclusion: Most common type of cardiac involvement is pericarditis, whereas intracardiac thrombosis has its unique characteristics (1). Male gender and smoking seems to be major significant risk factors.

REFERENCES:

Disclosure of Interests: None declared


---

Background: Autoinflammatory diseases (AIDS) are a group of rare monogenic and multifactorial diseases manifested by systemic inflammation, organ disorders, the development of complications, primarily amyloidosis, and possible death without timely targeted therapy. Rapid diagnosis contributes to the early appointment of treatment, prevention of the development of organ damage and improvement of prognosis in such patients.

Objectives: To establish the age of the onset and the duration of the delay of diagnosis in patients (pts) with monogenic AIDS (mAIDS) and systemic juvenile idiopathic arthritis (sJIA) according to the Federal Rheumatology Center.

Methods: 273 pts were included in the study for the period from 2007 to 2021, 158 of them with mAIDS: FMF - 75, CAPS - 50, TRAPS - 28, HIDS/MKD - 5, 115 pts with sJIA.

Results: The age of pts with mAIDS ranged from 6 months to 65 y.o. (120 children and 38 adults), among pts with sJIA there were only children aged 12 months to 17 y.o. Most of the pts with CAPS, TRAPS, HIDS/MKD were female (62.4%), as with sJIA (57.4%). FMF was more often affected by male persons (56.6%). The age of the onset of mAIDS ranged from 0 to 53 y.o., sJIA - from 4 months to 15 y.o., was the smallest in pts with CAPS and HIDS/MKD. 33.5% pts with mAIDS had the onset of the disease from birth or within the first year of life, more often with CAPS and HIDS /MKD, in the first decade of life in half of the pts (52.5%), more often in FMF and TRAPS, from 10 to 18 years - 8.2%, in adulthood - 5.7%. In pts with sJIA, the onset of the disease was mainly in the first 5 years of life – 69 (60%), from 5-10 years – 38 (33%), rarely in the first year of life and after 10 years of age (6.9%). The duration of the disease at the time of diagnosis ranged from 1 month to 16 years in FMF pts, from 1 month to 46 years in CAPS, from 3 months to 59 years in TRAPS, from 3.5 to 16.5 years with HIDS/ MKD, from 3 weeks to 78 years with sJIA. Within 1 year the diagnosis was established in 15.2% of children with mAIDS, in 12.2% with sJIA, in the first 5 years of the disease in 35.4% and 15.6% respectively. The delay in diagnosis for more than 5 and 10 years was observed in 24.1% and 25.9% of pts with mAIDS, practically did not occur in sJIA. The least delay in diagnosis was noted in pts with FMF.

Conclusion: Most of the pts with mAIDS had the onset of the disease in the first 5-10 years of life, an earlier age of onset was noted in pts with CAPS and HIDS/MKD. To date, the delay in diagnosis in pts with mAIDS remains very long and reaches decades, especially with CAPS, TRAPS and HIDS/MKD. In pts with sJIA, the diagnosis was established faster, according our opinion a later diagnosis is associated with a poly cyclic course of the disease. Earlier diagnosis and the appointment of targeted therapy are needed, which will help to avoid complications, improve the prognosis and quality of life of pts.

Disclosure of Interests: None declared


---

Background: Uveitis is still an important cause of morbidity leading to vision loss in Behcet’s syndrome (BS).

Objectives: Our aim in this study was to retrospectively evaluate characteristics of uveitis, long term complications, and its association with the other components of BS.

Methods: 800 patients with BS diagnosis according to International Study Group for Behcet’s Disease (ISG) criteria in our center were screened and among those, data of 109 patients with BS-related uveitis were included in this study.

Results: The overall prevalence of uveitis was found 13% among all BS population. Majority of BS-related uveitis were male (65.1%/34.9%). Mean age for BS diagnosis and onset of uveitis were found 38 ± 8.48 and 27 ± 8.42 years. In this group, uveitis developed before BS diagnosis in 33% of patients.
whereas 44% were diagnosed at onset of uveitis. The frequency of this population was estimated 6% among all BS patients. Characteristics of uveitis were as following: unilateral (45/99), bilateral (54/99), anterior (12), posterior (30), panuveitis (30), retinal vasculitis (9) and not defined (9). 25 patients experienced only one attack, whereas more than one attack was seen in 74 patients during follow up. 74 patients whose complications data was available, cataract, maculopathy, glaucoma, and optic atrophy developed in 10, 7 and 3 patients, respectively. Vision loss was seen in 8 patients as partial, in 28 as total (Table 1).

<table>
<thead>
<tr>
<th>Male/female, (n), (%)</th>
<th>71/28 (%65,1%/34,9)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis, years (Means SD)</td>
<td>28 ±8,48</td>
</tr>
<tr>
<td>Age at uveitis, years (Means SD)</td>
<td>27 ±8,42</td>
</tr>
<tr>
<td>Uveitis-Behçet's diagnosis relationship, (n)</td>
<td>109</td>
</tr>
<tr>
<td>-Before, (n), (%)</td>
<td>36 (%33)</td>
</tr>
<tr>
<td>-At the time of, (n), (%)</td>
<td>48 (%44)</td>
</tr>
<tr>
<td>-After, (n), (%)</td>
<td>25 (%23)</td>
</tr>
<tr>
<td>Characteristics of uveitis, (n)</td>
<td>99/109</td>
</tr>
<tr>
<td>-Unilateral/Bilateral</td>
<td>45/54</td>
</tr>
<tr>
<td>-Anterior</td>
<td>12</td>
</tr>
<tr>
<td>-Posterior</td>
<td>30</td>
</tr>
<tr>
<td>-Panuveitis</td>
<td>30</td>
</tr>
<tr>
<td>-Retinal vasculitis</td>
<td>9</td>
</tr>
<tr>
<td>Complications, (n)</td>
<td>26/74</td>
</tr>
<tr>
<td>-Maculopathy</td>
<td>7</td>
</tr>
<tr>
<td>-Glaucoma</td>
<td>5</td>
</tr>
<tr>
<td>-Cataract</td>
<td>10</td>
</tr>
<tr>
<td>-Optic atrophy</td>
<td>5</td>
</tr>
<tr>
<td>-Vision loss (partial/total)</td>
<td>8/28</td>
</tr>
</tbody>
</table>

BS; Behçet’s syndrome


Disclosure of Interests: None declared

AB1293

INTRATHECAL INJECTION OF METHOTREXATE COMBINED WITH DEXAMETHASONE FOR COGAN SYNDROME WITH NEUROLOGICAL INVOLVEMENT: A CASE REPORT

J. Hu1, H. Du1, J. Su1, R. Wu1, J. Zhu1, T. Wu1. 1Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Department of Rheumatology and Immunology, Chengdu, China

Background: Cogan syndrome (CS) is a rare autoimmune disease, mainly occurring among young people, with an incidence rate of <0.11/100000 (100000). CS is mainly characterized by interstitial keratitis, visual loss associated with co-clear vestibular involvement and Meniere type vertigo. It usually involves all systems of the body, and about 10% to 15% of cases have nervous system involvement. Fewer than 400 cases have been reported worldwide (1). Glucocorticoid is mainly used in acute attack as the basis of treatment, the effect was not satisfactory(2). Here, we report a case of CS with nerve injury as the main manifestation, which was successfully treated by intrathecal injection of methotrexate combined with dexamethasone.

Objectives: CS often involves multiple systems throughout the body and has a poor clinical prognosis. From a review of our patient's treatment experience, intrathecal methotrexate combined with dexamethasone may be an effective treatment modality for CNS involvement in patients with refractory recurrent Cogan syndrome.

Methods: The clinical manifestation, laboratory test, treatment, and outcome were described.

Results: A 31-year-old man presented with recurrent bimanual joint pain for 2 years, after which the patient developed interstitial keratitis, hearing loss and was diagnosed with CS. The patient received treatment with glucocorticoid, cyclophosphamide, methotrexate, tacrolimus, leflunomide, mycophenolate mofetil, hydroxychloroquine, adalimumab. The joint pain was improved, but the headache, dizziness, tinnitus and hearing impairment were significantly aggravated, and syncope occurred. Cerebrospinal fluid examination for lumbar puncture on admission of the patient showed CSF pressure > 185 mmH2O, CSF microprotein 1.10 g/l, and CSF nucleated cell count 120x10⁶ /L. At the beginning, we successively treated the patient with methylprednisolone (40 mg, QD), gamma globulin (10g, QD), methotrexate (20 mg, QW) and cyclophosphamide (100mg, QOD), but the effect was not satisfactory. After excluding infection, we treated this patient with intrathecal methotrexate 10 mg combined with dexamethasone 10 mg, and the patient's symptoms of dizziness, headache, and tinnitus improved significantly, and his hearing did not decline significantly any more. The patient received a total of seven intrathecal injections (cumulative methotrexate 60 mg + dexamethasone 65 mg) during the subsequent 6 months. His dizziness, headache, tinnitus and other neurological symptoms improved significantly, no further syncope, fever. CSF protein quantification and the number of CSF nucleated cells decreased significantly.

Conclusion: CS patients are often accompanied by multisystem injuries, so it is essential to correctly identify CS and provide appropriate treatment as soon as possible. For patients with neurological involvement who do not respond to treatment with glucocorticoids and immunosuppression, intrathecal methotrexate combined with dexamethasone may be considered as a treatment option for CS in the future.

REFERENCES:

Disclosure of Interests: None declared

AB1294

CO-OCCURRENCE OF IGG4 RELATED DISEASE AND OTHER SYSTEMIC IMMUNO-MEDIATED DISORDERS.

V. Batai1,2, M. Lanzillotta1, F. Chiabrandano1, G. Mancuso1, J. Mahajne1, L. I. Belli1, L. Dagna1, E. Della Torre1. 1Vita-Salute San Raffaele University, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milano, Italy;
2University of Verona, Medicine - Unit of Immunology, Verona, Italy

Background: IgG4-related disease (IgG4RD) is a fibroinflammatory disease with unique clinical and pathophysiological features. According to the recently released Classification Criteria, the presence of other concomitant immunological disorders (OID) represents an exclusion criterion for the classification of IgG4RD (1). Rigorous application of the Classification Criteria, however, can lead to misdiagnosis because our increasing appraisal of IgG4RD indicates that this condition may coexist with OID (2).

Objectives: To describe IgG4RD presentation in the context of OID.

Methods: IgG4RD was diagnosed based on definitive histological findings. OID were diagnosed based on specific classification/diagnostic criteria.

Results: In six out of 234 (3%) patients IgG4RD occurred in accommodation with OID, including two patients with sarcoidosis (33%), two with granulomatosis with polyangiitis (33%) one with eosinophilic granulomatosis with polyangiitis (16%) and one with Takayasu arteritis (16%). In three cases IgG4RD preceded OID (Table 1).

Conclusion: Our data demonstrate that IgG4RD can occur in overlap with OID, especially granulomatous diseases. Further research is needed to define whether this clinical scenario is associated with different pathological bases and long-term outcomes.

REFERENCES:

Disclosure of Interests: None declared
Table 1. Baseline clinical and treatment characteristics (n=9)

<table>
<thead>
<tr>
<th>Biologic therapy indication</th>
<th>Treatment characteristic</th>
<th>Drug retention duration, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Refractory arthritis</td>
<td>4 (44.4)</td>
<td></td>
</tr>
<tr>
<td>- Systemic inflammation findings</td>
<td>5 (55.5)</td>
<td></td>
</tr>
<tr>
<td>- Biologic arthritis</td>
<td>4.9 (53%)</td>
<td></td>
</tr>
<tr>
<td>- Interleukin-1 inhibitors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Biologic arthritis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.3093

AB1296  LONG-TERM EXPERIENCE OF THE THERAPY WITH INTERLEUKIN-1 INHIBITORS IN MONOGENIC AUTOINFLAMMATORY SYNDROMES AND SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN REAL-LIFE PRACTICE OF RHEUMATOLOGISTS IN SINGLE FEDERAL CENTER

S. Salujina1, M. Kaleda1, E. Fedorov1, I. Nikishina1, A. Torgashina2.
1V.A. Nasonova Research Institute of Rheumatology, Pediatric Department, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Laboratory of Intensive Therapy Methods, Moscow, Russian Federation

Background: Autoinflammatory diseases (AIDs) are a heterogeneous group of rare genetically determined conditions. Biologics (B) are used, especially inhibitors of interleukin 1 (IL-1), in the treatment of the most common mono- genic AIDs (mAIDs) – FMF, TRAPS, HIDS/MKD, CAPS. IL-1 has shown high efficiency and led to significant progress in the treatment of these patients (pts). Currently, IL-1 are the first-line drugs for mAIDs therapy, primarily CAPS. In pts with systemic juvenile idiopathic arthritis (sJIA) IL-1 inhibitors are also successfully used in the first or second line of therapy along with IL-6 inhibitors.

AB1295  TREATMENT OUTCOMES OF ADULT-ONSET STILL'S DISEASE PATIENTS WITH BIOLOGICAL THERAPY

Y. Erez1, T. Demiro Yiildirim2, M. Birlik2, G. Can1, F. Onen1, I. Sarı1, 1Dokuz Eylul University School of Medicine, Division of Rheumatology, Izmir, Turkey; 2Dokuz Eylül University School of Medicine, Division of Rheumatology, Izmir, Turkey

Background: Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder with heterogeneous distribution (1). Due to rarity of AOSD and limited controlled study about efficacy of biologic treatment in AOSD, management of refractory AOSD patients poses several challenges.

Objectives: The aim of this study to investigate clinical characteristics and treatment outcomes of AOSD patients who receive biological therapy.

Methods: Patients were identified who met Yamaguchi classification criteria between January 2010 and December 2021 from our database. AOSD patients treated with biologic treatment were included in this study. Demographic data, clinical features and treatment characteristics were recorded.

Results: 49 AOSD patients were identified from database. 9 AOSD patients with biologic therapy (7 female, mean age 42.3±19) were included in this study. Mean age at diagnosis was 31.5±16.7 and mean follow-up period was 9.3±5.5 years. Median drug retention duration was found 95 (5-150) months. It was established that all patients used high dose steroid at diagnosis and 3 (33.3%) out of them received pulse steroid therapy. Initial therapy was methotrexate for all patients that all patients used high dose steroid at diagnosis and 3 (33.3%) out of them switched to adalimumab and etanercept. Biological therapy was discontinued in 2 patients due to remission, and patients remained in remission after cessation of biological agent. None of patients had serious infection. Hemophagocytic syndrome was developed in only one patient during disease course.

Conclusion: According to our cohort, one of five AOSD patients received biologic therapy during follow-up. Our results revealed that the need for biologic therapy during the course of the disease is not uncommon in AOSD, and that biologic therapy is essential for maintaining remission in resistant patients.

REFERENCES:
Objectives: To evaluate in the real clinical practice the frequency of prescribing, efficacy and safety of IL-1 therapy in pts with mAIDS and sJIA according to the Federal Rheumatology Center.

Methods: A retrospective study from 2013 to 2021 included 66 pts who were prescribed IL-1. Among them 45 pts with mAIDS: FMF - 8, CAPS - 25, TRAPS - 10, HIDS/MKD – 2, 21 pts had sJIA. Canakinumab (CAN) was administered subcutaneously at the dose of 2-5mg/kg or 150mg every 4-8 weeks, anakinra (ANA) - subcutaneously at the dose of 1-5mg/kg or 100mg daily.

Results: Among pts with mAIDS 45 received IL-1. The age of pts ranged from 1.5 to 44 years, the median (Me) age was 9.56 [9;17] years. Female pts predominated (60%). The median age at onset was 0.5 [0;4] years (0 - 35 y). The median duration of the disease was 7.5 [3;9;15] years (3 months to 44 years). 35 pts received CAN, 10 - ANA. Both drugs showed significant positive dynamics with a complete response in 40 (88.9%), a partial response in 5 (11.1%), mainly due to serious neurological and cognitive impairments in 2 pts with CINCA/NOMID, sensorineural hearing loss in 3 adult pts with MWS, as well as amyloidosis in 1. In 7 pts with CAPS who received ANA as first biologic treatment, after achieving a reliable positive response, switching to CAN was performed while maintaining full efficacy. It was possible to discontinue the glucocorticoids (GC) in all pts. In 2 pts with CINCA/NOMID (1), MWS (1) due to insufficient efficiency the interval between injections of CAN was reduced from 8 to 4 weeks. The duration of use of CAN in pts with mAIDS ranged from 6 months to 12 years, ANA – 2 months to 12 years, 13 pts (28.9%) have been receiving therapy for 5 years or more. The age of pts with sJIA ranged from 3 to 17 years, Me 8,15 [5; 12;7] years. The age of the onset varied from 4 months to 12 years, Me 3,1 [8; 5,7] years. Female pts predominated (61,9%), 20 pts received CAN (18 after secondary inefficiency/infusion reaction of tocilizumab (TCZ), 2 had previous experience of 3 B: TCZ-etanercept-adalimumab, TCZ-aba- tcept-adalimumab). 1 patient received ANA. The duration of CAN treatment was from 5 months to 4.5 years. Among pts with sJIA who received CAN, secondary inefficiency with discontinuation was observed in 6 (28,6%) (10-25 months after treatment initiation), and in 1 patient who received anakinra for 8 months. The tolerability of therapy was generally good. We have not observed any SAE in the treatment of IL-1. All pts are continue taking medications.

Disclosure of Interests: B. Chalcev1, A. Torgashina1, E. Sokol1, J. Khvan on behalf of Laboratory of Rare Rheumatic Diseases and Primary Sjögren's Syndrome. V.A. Nasonova Research, Laboratory of Rare Rheumatic Diseases and Primary Sjögren’s Syndrome, Moscow, Russian Federation

Background: Hematological diseases such as multiple myeloma (MM) and POEMS-syndrome can be accompanied by high serum IgG4 level and thus mimic an IgG4-related disease (IgG4-RD) [1, 2]. However, there are no descriptions of AL-amyloidosis with increased secretion of IgG4 in the literature.

Objectives: to present a clinical case of AL-amyloidosis mimicking IgG4-RD.

Methods: At the age of 42, patient S. developed nasal congestion, and 2 years later bilateral symmetrical swelling of submandibular salivary glands developed. Chest CT scan revealed hydrothorax and pericarditis, interstitial changes in both lungs and intrathoracic lymphadenopathy. According to blood tests, ANF, RF and CRP were within normal values, an increase in the serum IgG4 (32.9g/l) and IgG (34.1g/l) levels was detected, and the patient was admitted to our clinic with suspicion of IgG4-RD.

Results: On examination, we noticed a symmetrical enlargement of submandibular salivary glands and macroagglutinosis. The patient also complained of tingling in the fingers, we performed electroneuromyography and revealed bilateral carpal tunnel syndrome. According to the immunofixation of blood and urine proteins, IgG-lambda paraproteinemia (18,3g/l) and a trace amount of Bence-Jones lambda protein in the urine were detected. AL-amyloidosis was suspected and a biopsy of the submandibular salivary gland was performed, followed by Congo red staining and darkfield microscopy that confirmed amyloidosis (Figure 1). There were no signs of IgG4-RD (storiiform fibrosis or obliterative phlebitis) in the biopsy specimens. Echocardiography revealed thickening of the interventricular septum and hypertrophy of the ventricular myocardium. MM and other malignancies were excluded on the basis of bone marrow trephine biopsy and PET-CT (also revealed severe hepatomegaly). The diagnosis of IgG4-secretory AL-amyloidosis affecting salivary glands, tongue, heart, lungs, liver, nervous system was made and polychemotherapy was started, the patient’s further life remained unknown.

Disclosure of Interests: None declared


EVALUATION OF POSSIBLE RISK FACTOR OF PULMONARY EMBOLISM IN SARCOIDOSIS PATIENTS

B. Ruaro1, P. Contaloneri1, C. Torregiani2, S. Pichierri2, M. Contaloneri2, P. Salton1

Department of Pulmonology, University of Trieste, Trieste, Italy;

Department of Pulmonology, University Hospital of Cattinara, Trieste, Italy

Background: Some studies reported a correlation between sarcoidosis and an increased risk of pulmonary embolism (PE) [1, 2].

Objectives: To assess possible risk factors of PE in sarcoidosis patients.

Methods: We enrolled 260 sarcoidosis patients (170 females and 90 males; mean age at diagnosis 46 ± 9), after giving written informed consent. We perform clinical evaluations, laboratory tests and radiology features.

Results: Our study population included 20 sarcoidosis patients with PE (14 females and 6 males; mean age at diagnosis 45 ± 10), diagnosed by lung scintigraphy and 240 sarcoidosis patients without PE (170 females and 70 males; mean age at diagnosis 46 ± 11). There was a significant increase of the presence of antiphospholipid antibodies in the sarcoidosis group with pulmonary embolism (55%) than in group without PE (9%) (p-value<0.01). There was no statistically significant difference between the two groups on smoking habit, obesity, treatments and hereditary thrombophilia frequency (p > 0.05, respectively).

Conclusion: This study demonstrated an increased of antiphospholipid antibodies positivity in sarcoidosis patients with pulmonary embolism. Furthermore, we propose screening for these antibodies in all sarcoidosis patients.

REFERENCES:


Disclosure of Interests: None declared


AL-AMYLOIDOSIS MIMICKING IGG4-RELATED DISEASE

B. Chalcev1, A. Torgashina1, E. Sokol1, J. Khvan1

1Department of Pulmonology, University of Trieste, Trieste, Italy

Objectives: To assess possible risk factors of PE in sarcoidosis patients.

Methods: We enrolled 260 sarcoidosis patients: 170 females and 90 males; mean age at diagnosis 46 ± 9, after giving written informed consent. We perform clinical evaluations, laboratory tests and radiology features.

Results: Our study population included 20 sarcoidosis patients with PE (14 females and 6 males; mean age at diagnosis 45 ± 10), diagnosed by lung scintigraphy and 240 sarcoidosis patients without PE (170 females and 70 males; mean age at diagnosis 46 ± 11). There was a significant increase of the presence of antiphospholipid antibodies in the sarcoidosis group with pulmonary embolism (55%) than in group without PE (9%) (p-value<0.01). There was no statistically significant difference between the two groups on smoking habit, obesity, treatments and hereditary thrombophilia frequency (p > 0.05, respectively).

Conclusion: AL-amyloidosis can be accompanied by high serum IgG4 level and mimicking IgG4-RD. The serum level of IgG4 should not be used as a criterion for IgG4-RD, and in all cases of suspected IgG4-RD the diagnosis should be confirmed morphologically.

REFERENCES:


Disclosure of Interests: None declared


Figure 1. Congo red staining and darkfield microscopy demonstrating amyloid deposits.
Other orphan diseases

S. Amikishiyev1, N. Aliyeva1, M. Bektas1, N. Koca1, L. Soitanova1, Y. Yalçınkaya1, B. Artim-Esen1, M. Inanc1, A. Gül on behalf of The Team of Istanbul Faculty of Medicine, Istanbul University. Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, Istanbul, Turkey

Background: Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disorder caused by heterozygous loss-of-function mutations in TNFAIP3 gene and characterized by Behçet disease (BD)-like manifestations such as mucocutaneous, articular, gastrointestinal, ocular symptoms as well as recurrent fever, elevated acute-phase reactants during relapses; and it usually starts during early childhood. Autoimmunity is another component of HA20 with autoantibodies and variable clinical features resembling systemic lupus erythematosus (SLE) and other autoimmune diseases.

Objectives: We herein present three cases of HA20 with different clinical features and diagnosed during adulthood.

Methods: We used the Ion Torrent platform for deep sequencing.

Results: Case 1: A 51-year old woman diagnosed with BD because of oral and genital aphthous ulcers, arthralgias, erythema nodosum, and pathergy positivity starting from age of 40 in 2012. She developed sudden vision loss (diagnosed with bilateral optic neuropathy), sixth nerve palsy, and entrapment neuropathies in the lower limbs in 2014; and she had flares of neurologic findings between 2014-2020. The only laboratory abnormality was elevated acute-phase reactants, and no pathologic finding was reported for cranial MRI. Pathological examination of sural nerve biopsy revealed chronic inflammatory demyelinating polyneuropathy (CIDP). She received adalimumab and then tofacitinib, and her treatment was switched to certolizumab and IVIG (30 g/6 weeks) in 2020. At the last visit, she was asymptomatic with normal acute phase response, and her examination revealed normal eye movements.

Case 2: A 33-year old woman was followed for 12 years with the diagnosis of SLE, characterized by Behçet disease (BD)-like manifestations such as mucocutaneous, articular, gastrointestinal, ocular symptoms along with strong acute phase response even in adults. Response to corticosteroids and targeted treatments may also be variable.

Disclose of Interests: None declared


AB1299 DIFFERENCES IN THE CLINICAL SPECTRUM OF HAPLOINSUFFICIENCY OF A20 (HA20) CASES DIAGNOSED DURING ADULTHOOD

S. Amikishiyev1, N. Aliyeva1, M. Bektas1, N. Koca1, L. Soitanova1, Y. Yalçınkaya1, B. Artim-Esen1, M. Inanc1, A. Gül on behalf of The Team of Istanbul Faculty of Medicine, Istanbul University. Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, Istanbul, Turkey

Background: Haploinsufficiency of A20 (HA20) is a monogenic autoinflammatory disorder caused by heterozygous loss-of-function mutations in TNFAIP3 gene and characterized by Behçet disease (BD)-like manifestations such as mucocutaneous, articular, gastrointestinal, ocular symptoms as well as recurrent fever, elevated acute-phase reactants during relapses; and it usually starts during early childhood. Autoimmunity is another component of HA20 with autoantibodies and variable clinical features resembling systemic lupus erythematosus (SLE) and other autoimmune diseases.

Objectives: We herein present three cases of HA20 with different clinical features and diagnosed during adulthood.

Methods: We used the Ion Torrent platform for deep sequencing.

Results: Case 1: A 51-year old woman diagnosed with BD because of oral and genital aphthous ulcers, arthralgias, erythema nodosum, and pathergy positivity starting from age of 40 in 2012. She developed sudden vision loss (diagnosed with bilateral optic neuropathy), sixth nerve palsy, and entrapment neuropathies in the lower limbs in 2014; and she had flares of neurologic findings between 2014-2020. The only laboratory abnormality was elevated acute-phase reactants, and no pathologic finding was reported for cranial MRI. Pathological examination of sural nerve biopsy revealed chronic inflammatory demyelinating polyneuropathy (CIDP). She received adalimumab and then tofacitinib, and her treatment was switched to certolizumab and IVIG (30 g/6 weeks) in 2020. At the last visit, she was asymptomatic with normal acute phase response, and her examination revealed normal eye movements.

Case 2: A 33-year old woman was followed for 12 years with the diagnosis of SLE, characterized by Behçet disease (BD)-like manifestations such as mucocutaneous, articular, gastrointestinal, ocular symptoms along with strong acute phase response even in adults. Response to corticosteroids and targeted treatments may also be variable.

Disclose of Interests: None declared


AB1300 AA AMYLOIDOSIS IN A PATIENT WITH MUTATIONS IN BOTH ADA2 AND A20 GENES

S. Amikishiyev1, B. Ince1, M. Bektas1, Y. Yalçınkaya1, B. Artim-Esen1, M. Inanc1, A. Gül on behalf of The Team of Istanbul Faculty of Medicine, Istanbul, Turkey

Background: Adenosine Deaminase 2 Deficiency (DADA2) and Haploinsufficiency of A20 (HA20) are two recently described monogenic autoinflammatory diseases (AID). The uncontrolled inflammatory response has been associated with an increased risk of AA amyloidosis in other AID, but there are only two reported patients with DADA2-related amyloidosis so far.1,2

Objectives: We herein report a patient with AA amyloidosis and AID associated with both DADA2 and HA20.

Methods: We used the Ion Torrent platform for deep sequencing.

Results: Case: A 20-year old male patient born to consanguineous parents (Figure 1), was admitted to our hospital with fever and abdominal pain in June 2014. Peritonitis, hepatomegaly, and a palpable non-tender mass in the right axillary cavity were detected in physical examination, and his laboratory investigations revealed neutrophilic leukocytosis, high acute phase reactants (APR), and pancytopenia, anti-dsDNA positivity. Her fever, red arthritis attacks with high CRP values did not respond, and after the genetic diagnosis of HA20, anakinra was added to treatment. Due to the high dose anakinra requirement, her treatment was switched to canakinumab (150 mg/2 week), and at the last visit, her attacks were significantly reduced.

Case 3: A 44-year old woman was evaluated because of recurrent prolonged >38°C fever attacks (2 days-2 weeks duration), arthritis of the elbow, wrist, knee joints, and high acute phase reactant in 2004. She did not have a history of recurrent oral and genital aphthous ulcers, intermittent periorbital edema, rash, anyocular symptoms, or sensorineural hearing loss. ANA, RF, anti-CCP, and MEFV gene mutation were negative on admission. PET-CT demonstrated FDG uptake in the wall of the ascending aorta, aortic arch, and descending aorta in 2011. She had used colchicine in 2004, but she repeatedly received IV methylprednisolone pulse therapy, but she had no complaints with normal APR, and urinalysis analysis showed >8 mg/day. Her knee arthritis did not respond to adalimumab, and she is currently on infliximab treatment since 2019 with a Daily methylprednisolone dose of 8-12mg.

Conclusion: HA20 can be diagnosed even in adult patients, and the clinical picture of presented cases suggests that monogenic autoinflammatory disorders including HA20 should be suspected in any patient with flares of described manifestations along with strong acute phase response even in adults. Response to corticosteroids and targeted treatments may also be variable.

Disclose of Interests: None declared


Table 1: Characteristics of patients with A20 haploinsufficiency

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gender</strong></td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Systemic findings</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Autoantibodies</strong></td>
<td>None</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>High acute-phase reactants</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Oral ulcers</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Erythema nodosum</strong></td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td><strong>Genital ulcers</strong></td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td><strong>Urticaria</strong></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Arthritis</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td><strong>Neurologic involvement</strong></td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td><strong>Parenchymal involvement</strong></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td><strong>Peripheral neuropathies</strong></td>
<td>Yes</td>
<td>None</td>
</tr>
<tr>
<td><strong>Current treatment</strong></td>
<td>Certolizumab</td>
<td>Canakinumab</td>
</tr>
<tr>
<td><strong>TNFAIP3 mutation</strong></td>
<td>Arg597Lys</td>
<td>Thr647Pro</td>
</tr>
</tbody>
</table>

Figure 1: Pedigree of family and results of genetic analyses

Scientific Abstracts
A. Demirezen1, A. Avangolu Guler1, H. Karadeniz2, D. Yildirim2, H. Kucuk2, M. Kavuncu2, M. A. Ozturk2, A. Tufan2. 1Gazi University Faculty of Medicine, Internal Medicine, Ankara, Turkey; 2Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey; 3Gazi University Faculty of Medicine, Biochemistry, Ankara, Turkey.

Background: Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by recurrent fever, serositis, arthritis and erysipelas-like ery-thema caused by mutations over activating caspase-1. As Interleukin (IL)-1 beta, IL-33 is a nuclear cytokine from IL-1 family which is activated by caspase-1. IL-33 is known to take part in pathogenesis of several rheumatic diseases.

Objectives: The aim of this research is determining the relationship between serum IL-33 levels and clinical and laboratory features of the disease in patients with FMF disease.

Methods: The research involved 54 FMF patients and 29 healthy volunteers. Serum IL-33 levels were evaluated in both patients and healthy individuals, and its relationship between clinical and laboratory features of FMF.

Results: 28 out of 54 patients (51.8%) had favorable response to colchicine while 26 patients (48.2%) had colchicine resistant disease. FMF patients had lower IL-33 levels compared to healthy control group (p=0.06). There were no difference between colchicine responsive and resistant patients (p=0.12) and no association was found between clinical features and serum IL-33 levels. Additionally, IL-33 did not correlated with C-reactive protein and disease activity assessed by autoinflammatory disease activity index.

Conclusion: No association was found between serum IL-33 levels and FMF disease features and laboratory findings. This may be due to the small size of our patient group, the involvement of IL-33 in tissue homeostasis as well as inflammation, and the use of higher doses of colchicine in the resistant disease group than in the remission group. Additional research is needed to determine IL-33’s role in FMF pathogenesis and its relationship with clinical and laboratory features.

REFERENCES:

Acknowledgements: None of the authors obtained any financial support.

Disclosure of Interests: None declared


AB1301

DETERMINING THE RELATIONSHIP BETWEEN SERUM INTERLEUKIN 33 LEVELS AND CLINICAL FEATURES OF THE DISEASE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

N. Sen1, R. Mercan2, O. Volkan3, E. Bayar4, S. Yilmaz-Oner5, M. E. Tezcan1, 1Kartal Dr. Lütfi Kırdar Şehir Hastanesi, Rheumatology, Istanbul, Turkey; 2Tekirdağ Namık Kemal Üniversitesi, Rheumatology, Tekirdağ, Turkey; 3Sivas Devlet Hastanesi, Internal Medicine, Sivas, Turkey.

Background: Vaccines are the safest and most effective method to prevent invasive and life-threatening infections. Vaccines against influenza, pneumococcal disease, herpes zoster, and human papillomavirus are the main recommended vaccines for adults. In addition, rheumatology patients are advised to receive adult vaccinations according to the vaccines available in their country and local guidelines. In Turkey, both influenza and pneumococcal disease vaccines are commercially available. In addition, these vaccines are strongly recommended for rheumatology patients in local guidelines. Although familial Mediterranean fever (FMF) is one of the most common rheumatological diseases in Turkey, it is often neglected in vaccination recommendations.

Objectives: In this study, we surveyed the vaccination practice against influenza or pneumococcal diseases of adult FMF patients in our cohort. In addition, we evaluated the factors related to favorable vaccination practice.

Methods: We included 360 FMF patients over 18 years of age. All patients fulfilled the Tel-Hashomer criteria for FMF. We asked them if they had ever been vaccinated against pneumococcal or influenza, and how often they received them. In addition, we dichotomised patients in terms of vaccinated against at least one of influenza or pneumococcal diseases. We then compared the groups for demographic (age gender and comorbidities) and disease related characteristics (disease duration, disease activity calculated by ISSF and colchicine dose). We used q-square test to compare categorical variables and Mann-Whitney U test for continuous variables.

Results: Of 360 FMF patients, 238 (66.1%) were female. The mean age of the patients was 34.5±10.7 years. Disease duration of the patients was 9.38±0.7 years. In addition, the mean ISSF score of the patients was 1.83±1.5. The mean dose of colchicine received by the patient was 1.23±0.47 mg. Only 54 (15.0%) of the patients had at least one comorbidity. In our cohort, 22 (6.1%) patients were vaccinated against influenza or pneumococcal disease. Only 18 (6.0%) of the patients had been vaccinated against influenza at least once so far. Half of these patients (9/18) were vaccinated against influenza each year. In addition, 8/360 (2.2%) patients were fully vaccinated against pneumococcal diseases. Here, six of them received the pneumococcal vaccine after the start of the COVID-19 outbreak. There was no statistically significant difference between the groups in terms of demographic and disease related characteristics.

Conclusion: We found that none of the patients answered yes, 22 (6.1%) patients had mild disease, 10 patients had moderate (32%) disease, and there was no patient with severe disease in this group. Among those who answered no, 3 (14%) had mild disease, 14 (83%) had moderate disease, and 5 (23%) had severe disease (p<0.001). When the CRP levels of the patients were compared, the median CRP value of those who answered yes was found to be 4.45 mg/L, and the median value of CRP for those who answered no was 11.25 mg/L (p=0.04). Sensitivity and specificity of PASS for detecting patients in remission was 78% and 61% respectively. Moreover, PASS had a positive and negative predictive value of %68 and %72 respectively, for determining patients in remission. If cut of level of CRP was chosen as 6.5 mg/L for, answering “yes” to PASS, sensitivity of test has been found to be 62.5% while the specificity is 59.1%. On the other hand, if cut off level of CRP is selected as 9.35 mg/L; sensitivity and specificity of the test was found as 75% and 72.7% respectively (p=0.045).

Disclosure of Interests: None declared


AB1303

VACCINATION PRACTICES OF ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS IN TURKEY.

A. Demirezen1, A. Avangolu Guler1, H. Karadeniz2, D. Yildirim2, H. Kucuk2, M. A. Ozturk2, A. Tufan2. 1Gazi University Faculty of Medicine, Internal Medicine, Ankara, Turkey; 2Gazi University Faculty of Medicine, Rheumatology, Ankara, Turkey; 3Gazi University Faculty of Medicine, Biochemistry, Ankara, Turkey.

Background: Patients with FMF should be vaccinated against influenza and pneumococcal disease. Vaccination is particularly important for patients with inflammatory arthritis. Vaccination of patients with FMF should be routinely assessed during consultations. Therefore, we assessed the vaccination practices in patients with FMF in our cohort.

Objectives: To assess the vaccination practices in FMF patients and to determine the factors associated with favorable vaccination practice.

Methods: We conducted a cross-sectional study including 54 FMF patients from the outpatient clinic of our university hospital. All patients were asked about their vaccination practices for the last year. In addition, we evaluated the factors related to favorable vaccination practice.

Results: Of 54 FMF patients, 29 (53.7%) were vaccinated against influenza and/or pneumococcal disease. The mean age of the patients was 34.5±10.7 years. Disease duration of the patients was 9.38±0.7 years. In addition, the mean ISSF score of the patients was 1.83±1.5. The mean dose of colchicine received by the patient was 1.23±0.47 mg. Only 54 (15.0%) of the patients had at least one comorbidity. In our cohort, 22 (6.1%) patients were vaccinated against influenza or pneumococcal disease. Only 18 (6.0%) of the patients had been vaccinated against influenza at least once so far. Half of these patients (9/18) were vaccinated against influenza each year. In addition, 8/360 (2.2%) patients were fully vaccinated against pneumococcal diseases. Here, six of them received the pneumococcal vaccine after the start of the COVID-19 outbreak. There was no statistically significant difference between the groups in terms of demographic and disease related characteristics.

Conclusion: We found that none of the patients answered yes, 22 (6.1%) patients had mild disease, 10 patients had moderate (32%) disease, and there was no patient with severe disease in this group. Among those who answered no, 3 (14%) had mild disease, 14 (83%) had moderate disease, and 5 (23%) had severe disease (p<0.001). When the CRP levels of the patients were compared, the median CRP value of those who answered yes was found to be 4.45 mg/L, and the median value of CRP for those who answered no was 11.25 mg/L (p=0.04). Sensitivity and specificity of PASS for detecting patients in remission was 78% and 61% respectively. Moreover, PASS had a positive and negative predictive value of %68 and %72 respectively, for determining patients in remission. If cut off level of CRP was chosen as 6.5 mg/L for, answering “yes” to PASS, sensitivity of test has been found to be 62.5% while the specificity is 59.1%. On the other hand, if cut off level of CRP is selected as 9.35 mg/L; sensitivity and specificity of the test was found as 75% and 72.7% respectively (p=0.045).

Disclosure of Interests: None declared

B. Farisogullari1,2, B. Usta2, E. Enal Deregözü2, G. K. Yardımcı1, Ö. Cennet3, H. Ozdogan1,2, H. Yazici1,2, G. Hateri1,2, Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 1Hacettepe University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of General Surgery, Ankara, Turkey; 2Hacettepe University, Faculty of Medicine, Department of Pathology, Ankara, Turkey

Background: Idiopathic granulomatosis mastitis (IGM) is an uncommon, benign, chronic inflammatory disease of the breast of unknown etiology. Although an ideal treatment regimen is controversial in IGM, the ultimate goal is remission.

Objectives: To compare the clinical, radiological, laboratory and treatment features of patients in remission and non-remission, and assess predictor factors of remission.

Methods: The data of patients who were histopathologically diagnosed with IGM between 2010 and 2020 were evaluated retrospectively. The patients were divided into 2 groups as those in complete remission and non-remission. Complete improvement in clinical and physical examination with medical and/or surgical intervention findings at 2 consecutive visits was defined as complete remission. Patients who were not in complete remission including partial remission and refractory to treatment, were defined as non-remission group.

Results: In this study, there were a total of 103 patients with a diagnosis of IGM followed-up in the rheumatology clinic. Of these, 39 (38%) were in remission and 64 (62%) were non-remission. Age, age at symptom onset, comorbidity, pregnancy (ever), disease localization, clinical signs and symptoms, imaging classification, and baseline acute phase reactants and autoimmune markers were similar in the remission and non-remission groups. The use of antibiotics and azathioprine was significantly higher in the remission group than in the non-remission group. These patients were similar in the remission and non-remission groups. The use of antibiotics and azathioprine was significantly higher in the remission group than in the non-remission group. However, there was no difference between the groups in terms of breast surgery, use of corticosteroids and methotrexate (Table 1).

Table 1. Characteristics of patients in remission and non-remission

<table>
<thead>
<tr>
<th></th>
<th>All patients</th>
<th>Patients in remission</th>
<th>Patients not in remission</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n= 103</td>
<td>n = 39</td>
<td>n= 64</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>38.1 ± 7.1</td>
<td>39.6 ± 7.8</td>
<td>37.2 ± 6.5</td>
<td>0.07</td>
</tr>
<tr>
<td>Age at symptom onset, years</td>
<td>33.5 ± 6.6</td>
<td>34.4 ± 7.3</td>
<td>33 ± 6.1</td>
<td>0.30</td>
</tr>
<tr>
<td>Comorbidity, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid disorders</td>
<td>4 (3.9)</td>
<td>1 (2.6)</td>
<td>3 (4.7)</td>
<td>1.00</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2 (2)</td>
<td>2 (5)</td>
<td>0</td>
<td>0.14</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1 (1)</td>
<td>1 (2.6)</td>
<td>0</td>
<td>0.38</td>
</tr>
<tr>
<td>Pregnancy (ever), positive/total (%)</td>
<td>75/77 (97.4)</td>
<td>31/32 (97)</td>
<td>44/45 (98)</td>
<td>1.00</td>
</tr>
<tr>
<td>Breast localization, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>47 (45.6)</td>
<td>19 (48.7)</td>
<td>28 (43.8)</td>
<td>0.88</td>
</tr>
<tr>
<td>Right</td>
<td>36 (33.3)</td>
<td>13 (33.3)</td>
<td>23 (35.9)</td>
<td></td>
</tr>
<tr>
<td>Bilateral</td>
<td>20 (19.4)</td>
<td>7 (17.9)</td>
<td>13 (20.3)</td>
<td></td>
</tr>
<tr>
<td>Clinical signs and symptoms, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Palpable mass</td>
<td>94 (91.3)</td>
<td>85 (89.7)</td>
<td>92 (92.2)</td>
<td>0.72</td>
</tr>
<tr>
<td>Fistula formation</td>
<td>37 (38.1)</td>
<td>16 (42.1)</td>
<td>21 (35.6)</td>
<td>0.52</td>
</tr>
<tr>
<td>Erythema</td>
<td>61 (66.5)</td>
<td>23 (65.7)</td>
<td>38 (65.5)</td>
<td>0.98</td>
</tr>
<tr>
<td>Nipple inversion</td>
<td>11 (12)</td>
<td>2 (5.4)</td>
<td>9 (16.4)</td>
<td>0.19</td>
</tr>
<tr>
<td>Axillary lymph node</td>
<td>45 (48)</td>
<td>17 (47.2)</td>
<td>28 (48.3)</td>
<td>1.00</td>
</tr>
<tr>
<td>Erythema nodosis</td>
<td>10 (9.9)</td>
<td>4 (10.3)</td>
<td>6 (9.7)</td>
<td>1.00</td>
</tr>
<tr>
<td>Arthritis</td>
<td>13 (12.6)</td>
<td>3 (7.4)</td>
<td>10 (15.6)</td>
<td>0.36</td>
</tr>
<tr>
<td>BI-RADS classification*, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13 (25)</td>
<td>7 (35)</td>
<td>6 (28.8)</td>
<td>0.12</td>
</tr>
<tr>
<td>3</td>
<td>31 (59.6)</td>
<td>9 (45)</td>
<td>22 (68.8)</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>6 (11.5)</td>
<td>2 (10)</td>
<td>4 (12.5)</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2 (3.8)</td>
<td>2 (10)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Baseline laboratory</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-CRP (mg/dL)</td>
<td>0.75 (1.4)</td>
<td>0.75 (1.4)</td>
<td>0.73 (1.4)</td>
<td>0.77</td>
</tr>
<tr>
<td>- ESR (mm/h)</td>
<td>23 (28)</td>
<td>21.5 (28)</td>
<td>25.5 (28)</td>
<td>0.39</td>
</tr>
<tr>
<td>-ANA (more than or equal 1/100), n (%)</td>
<td>37/69 (53.6)</td>
<td>12/25 (48)</td>
<td>25/44 (56.8)</td>
<td>0.48</td>
</tr>
<tr>
<td>-RF, n (%)</td>
<td>12/30 (40)</td>
<td>5/16 (55.5)</td>
<td>7/19 (36.8)</td>
<td>0.71</td>
</tr>
<tr>
<td>-anti-CCP, n (%)</td>
<td>3/17 (15)</td>
<td>2/17 (11.8)</td>
<td>1/5 (20)</td>
<td>0.52</td>
</tr>
<tr>
<td>Treatment, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgical intervention</td>
<td>38 (36.9)</td>
<td>16 (41)</td>
<td>22 (58.4)</td>
<td>0.49</td>
</tr>
<tr>
<td>Antibiotics</td>
<td>63 (61.2)</td>
<td>29 (74)</td>
<td>34 (53.1)</td>
<td>0.03</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>93 (90.3)</td>
<td>34 (87.2)</td>
<td>59 (92.2)</td>
<td>0.49</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>66 (64.1)</td>
<td>26 (68.7)</td>
<td>40 (62.5)</td>
<td>0.67</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>19 (18.4)</td>
<td>11 (28.2)</td>
<td>8 (12.5)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

* 52 patients with data were evaluated; * positive/total

Results are given as mean ± SD or median (IQR).

ANa: Antinuclear antibody; anti-CCP: Anti-cyclic citrullinated peptides; BI-RADS: Breast imaging-reporting and data system; RF: Rheumatoid factor
AB1306 AA AMYLOIDOSIS IN CHRONIC RHEUMATIC DISEASES: ABOUT 20 CASES

M. Anthaou1, I. Mahboub2, M. Ghal1, F. Fhima1, N. Ben Chekaya2, S. Zrou1, I. Belja1, M. Touzi1, N. Bergraoui1, Fatouma Bourguiba Hospital, Rheumatology, Monastir, Tunisia

Background: Secondary AA amyloidosis is a complication of certain uncontrolled chronic inflammatory rheumatic diseases. The diagnosis of AA amyloidosis is anato-pathological based on the detection of amyloid deposits within a biopsy specimen.

Objectives: The aim of this study is to determine the clinical, biological, therapeutic and evolutionary aspects of amyloidosis during these diseases.

Methods: This is a retrospective descriptive study conducted in the rheumatology department in Monastir, Tunisia, including patients followed for chronic inflammatory rheumatism complicated by AA amyloidosis.

Results: Our study included 20 patients (13 women and 7 men). Their mean age at the time of diagnosis of amyloidosis was 55.4 years [18-76]. The rheumatic diseases were: Rheumatoid Arthritis (RA) in 13 cases (65%), Ankylosing Spondylitis in 3 cases (15%), Behçet’s disease in 2 cases and Juvenile idiopathic arthritis in its seronegative form in 2 cases (10% for both). Amyloidosis occurred after a mean duration of rheumatic disease of 11.5 years [3-27]. The mean sedimentation rate at diagnosis of amyloidosis was 100.5 mm per hour [21-131]. The mean C-reactive protein at diagnosis was 38.35 mg/L [1.4-135].

Inaugural manifestations of amyloidosis were: edema of lower limbs in 8 cases, nephrotic syndrome in 7 cases, renal failure in 4 cases and an abdominal clinical presentation (diarrhea and abdominal pain) associated with proteinuria in 2 cases. Proteinuria was constant, with a mean level of 7.5g/24h [3.5-20]. It was isolated in 5 cases. Amyloidosis was subclinical in 2 cases and was discovered by an abdominal fat biopsy performed during a research protocol. The diagnosis was confirmed by: renal biopsy (n=4), rectal biopsy (n=3), salivary gland biopsy (n=4) and abdominal fat biopsy (n=2). Amyloidosis extension was assessed for 50% of our patients. Cardiac involvement was the most frequent, revealed in 5 patients. Concentric left ventricular hypertrophy was found in 4 patients. Pulmonary arterial hypertension and pericardial effusion were found in 1 case. Hepatic involvement was detected in 2 cases in the form of hepatomegaly without disturbance of liver function tests. Adrenal gland involvement was detected in 1 case, with homogeneous hypertrophy of the adrenal glands associated with adrenal dysfunction. Only 1 patient had peripheral nerve damage in the form of bilateral carpal tunnel syndrome. Concerning the treatment: 12 patients received Colchicine. Chloraminophen was tried for 4 patients with amyloidosis secondary to RA and Azathioprine for one patient with RA. The evolution was unfavorable in 6 cases marked by death within a mean time of 3.4 years.

Conclusion: Although its prevalence is decreasing, owing to therapeutic progress in chronic rheumatic diseases, AA amyloidosis remains a not exceptional complication. It has a poor prognosis, particularly because of renal disease and cardiac involvement.

Disclosure of Interests: None declared

Mycophenolate for the Treatment of Eye Involvement in Patients with Behçet’s Syndrome

D. Ucar1,2, Y. Ozyazgan1,2, S. N. Esatoglu2,3, E. Cerme4, V. Hamuryudan2,3, M. Melikoglu2,3, I. Fresko3, S. Yurdakul2,3, H. Yazici2,3, G. Hatemi2,3.

1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey; 2Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Behçet’s Disease Research Center; Istanbul, Turkey; 3Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey; 4Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

Background: Experience with mycophenolate in uveitis associated with Behçet’s syndrome (BS) is limited.

Objectives: We aimed to report the efficacy and safety of mycophenolate mofetil (MMF) and mycophenolate sodium (MPA) in the treatment of BS uveitis.

Methods: All patients with panuveitis or posterior uveitis who used mycophenolate for eye involvement between 2016 and 2018 were included. Patient charts were reviewed and data on demographic features, previous immunosuppressives, concomitant therapies, ocular attacks and outcome, and adverse events were extracted. Follow up was ended on October 2021.

Results: We included 12 BS patients (M/W: 8/4, mean age: 35±7 years) treated with mycophenolate during a mean follow-up of 42±19 months (Table 1). All but 3 patients had bilateral eye involvement. IFX and INF-α had been discontinued due to adverse events in all patients, AZA in 10/12, and Cy-A in 7/10. Seven patients were prescribed mycophenolate for remission induction. One of these patients had had his first uveitis attack while on AZA treatment due to gastrointestinal involvement. The remaining 6 patients were using other immunosuppressives and experienced relapses that led to mycophenolate use. MMF was added to a biologic agent in 2 patients (IFX and ADA) and was initiated in combination with IFX in 1 patient. These 3 patients did not experience further ocular attacks and IFX was stopped due to remission in 1 patient. In the fourth patient, MMF was switched to MPA due to numbness in hands and feet and MPA was stopped due to arthralgia. This patient did not experience ocular attacks during 5 months of MPA therapy. The remaining 3 patients had further uveitis attacks without decrease in visual acuity 2, 6, and 12 months after MMF initiation, and IFX was added in 2 patients, and ADA in 1 patient. Two of these patients were switched to INF-α due to uveitis relapses. MMF was switched to MPA for diarrhea in 1 patient. Five patients had received MMF for maintenance. One of these was using IFX when MMF was started and these 2 agents were used together. This patient discontinued MMF due to remission 17 months after MMF initiation and is still on IFX monotherapy. The second patient is still on MMF for 39 months without further ocular attacks. ADA, IFX and Cy-A were added in the remaining 3 patients due to ocular attacks 2, 5 and 31 months after MMF initiation. One of these 3 patients stopped IFX and MMF due to remission and is off treatment for 2 years.

Conclusion: Mycophenolate may be an alternative treatment modality in addition to biologics for patients with eye involvement who are intolerant to conventional therapies. Further data is needed to show whether it would be effective when used alone.

Disclosure of Interests: Didar Ucar: None declared, Yilmaz Ozyazgan: None declared, Sinem Nihal Esatoglu: Sinem Nihal Esatoglu has received honorariums for presentations from UCB Pharma, Roche, Pfizer, and Merck Sharp Dohme, Emir Cerme: None declared, Vedat Hamuryudan: Vedat Hamuryudan has received grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene., Melike Melikoglu: None declared, Izzet Fresko: None declared, Sebahattin Yurdakul: None declared, Hasan Yazici: None declared, Gulen Hatemi: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.

DOI: 10.1136/annrheumdis-2022-eular.3880
AB1309

ANALYSIS OF A MONOCENTRIC COHORT OF IG4-G4-RELATED DISEASE PATIENTS: GREATER REDUCTION OF THE RESPONDER INDEX IN PHARMACOLOGICALLY-TREATED PATIENTS AS COMPARED TO UNTREATED ONES

S. Bertocchi1,2, F. Regola1,2, C. Nalli, L. Andreoli1,2, F. Franceschini1,2, Speciale Civili di Brescia, Rheumatology and Clinical Immunology Unit, Brescia, Italy; 1University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy.

Background: IgG4-related disease (IgG4-RD) is a systemic disease characterized by lymphoplasmocellular infiltration and storiform fibrosis. Pancreas, biliary tract, salivary glands, lymph nodes and retroperitoneum are frequently involved, although the clinical presentation may vary [1].

Objectives: The aim of this study is to retrospectively describe the clinical manifestations of a monocentric cohort of patients with IgG4-RD and analyze their clinical course by applying the validated IgG4-Related Disease Responder Index (RI) [2].

Methods: We enrolled 22 IgG4-RD patients classified with 2011 diagnostic criteria [3] and/or 2019 classification criteria [4].

Results: 22 IgG4-RD patients (M/F=3.4/1), mostly Caucasian (91%), were diagnosed at a mean age of 59 years (44-74) with a median IgG4 concentration at diagnosis of 239 mg/dL (IQR 106-391 mg/dL). 14/22 (64%) patients fulfilled the 2011 classification criteria, while 8/22 (36%) were classified as possible (2), probable (5) or definitive (1) according to the diagnostic criteria of 2011. Organ involvement at diagnosis (TI0) is described in Table 1. The organs most involved were lymph nodes, salivary glands and retroperitoneum. Patients were followed for a median of 49 months (IQR 16-88). Three patients were lost to follow-up. One patient died for pneumonia 96 months after diagnosis. During the follow-up 5 (23%) patients did not receive specific treatment, 1 (5%) was treated surgically, 6 (27%) with steroid only, 10 (45%) with steroid and immunosuppressants and even biological therapy. A statistically significant reduction in RI between T0 and last follow-up (TLF) was observed in all the patients [from 6 (3-6) to 3 (1-4) p=0.010]. A significant reduction was also observed in the group of pharmacologically treated patients [from 6 (3-6) to 3 (1-4) p=0.035] but not in the group of patients without drug treatment (p = 0.174).

Table 1. Organ involvement at diagnosis

<table>
<thead>
<tr>
<th>Organ involvement</th>
<th>N. Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreas</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Lymph nodes</td>
<td>14 (64)</td>
</tr>
<tr>
<td>Salivary glands</td>
<td>13 (59)</td>
</tr>
<tr>
<td>Lungs</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Aorta and large blood vessels</td>
<td>4 (18)</td>
</tr>
<tr>
<td>Retroperitoneum, mediastinum, mesentery</td>
<td>6 (27)</td>
</tr>
<tr>
<td>Bile duct and liver</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Kidneys</td>
<td>2 (9)</td>
</tr>
<tr>
<td>Pachymeninges</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Orbits and lacrimal glands</td>
<td>3 (14)</td>
</tr>
<tr>
<td>Pancreatic sinuses and / or nasal mucosa</td>
<td>5 (23)</td>
</tr>
</tbody>
</table>

Conclusion: In our cohort, patients were predominantly male with mean age at diagnosis of 59 years, consistent with literature data [1]. A statistically significant reduction in disease activity defined by reduction of RI was observed in patients who received immunosuppressive therapy. No significant reduction was observed in patients not pharmacologically treated.

REFERENCES:

Disclosure of Interests: None declared

Pulmonology, Santander (SPAIN), Spain

Disease-modifying drugs (DMARDs) can also cause hepatotoxicity. Many (LTBI), and hepatotoxicity is one of the most frequent adverse effect. Several

None declared

Disclosure of Interests:

REFERENCES:

1. Meadow PB. Case Rep Rheumatol. 2014.
7. Meadow PB. Case Rep Rheumatol. 2014.

Based on these data a therapeutical approach of refractory IOP was proposed (Figure 1).

Table 1. Cases reports and Literature review

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Cases</th>
<th>Age/ Sex</th>
<th>Underlying IMID</th>
<th>JAKINIB</th>
<th>Ocular involvement</th>
<th>Previous immunosuppressive treatment</th>
<th>Ocular Improvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meadow et al. 2014</td>
<td>1</td>
<td>59, F</td>
<td>RA</td>
<td>TOFA</td>
<td>PUK</td>
<td>MTX, ABA, ivMP</td>
<td>Partial (Pi)</td>
</tr>
<tr>
<td>Bauermann et al. 2018</td>
<td>1</td>
<td>22, F</td>
<td>JIA</td>
<td>TOFA</td>
<td>A. uveitis, CME</td>
<td>MTX, ADA, RTX, GOLI, IFX, CsA, TCZ, MMF</td>
<td>Complete (Ci)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.45, F</td>
<td>2. Idiopathic</td>
<td>2.TOF A</td>
<td>2.A. uveitis, CME</td>
<td>2.MTX, LFN, AZA, MMF, ADA, IFX, CZP, intravitreal fluorocinolone ac.</td>
<td>2.Ci</td>
</tr>
<tr>
<td>Liu J et al. 2020</td>
<td>1</td>
<td>30, F</td>
<td>Behcet dis</td>
<td>TOFA</td>
<td>Scleritis</td>
<td>SSZ, MTX, AZA, LFN, THD, COL, GLM</td>
<td>Pi</td>
</tr>
<tr>
<td>Meumder et al. 2020</td>
<td>1</td>
<td>26, F</td>
<td>Vogt-Koyanagi-Harada dis</td>
<td>TOFA</td>
<td>P. uveitis</td>
<td>ivMP</td>
<td>Ci</td>
</tr>
<tr>
<td>Miserocchi et al. 2020</td>
<td>4</td>
<td>1.9, F</td>
<td>JIA</td>
<td>1.TOF A</td>
<td>1.Panuv</td>
<td>1.IFX, ADA, LFN, ADA, RTX, TCZ.</td>
<td>1.Ci</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.1, F</td>
<td>2.BARI</td>
<td>2.Panuv</td>
<td>2.MTX, ADA, IFX, RTX, ABA.</td>
<td>2.Ci</td>
<td></td>
</tr>
<tr>
<td>Pyare et al. 2020</td>
<td>1</td>
<td>45, F</td>
<td>Idiopathic</td>
<td>TOFA</td>
<td>Necrotising scleritis</td>
<td>MMF</td>
<td>Ci</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2.85, F</td>
<td>2.BARI</td>
<td>2.Panuv</td>
<td>2.MTX, LFN, CZP, ADA, iv MP.</td>
<td>2.Ci</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Main characteristics of 64 patients with rheumatic immune-mediated diseases (R-IMID) that presented hepatotoxicity after receiving isoniazid (INH).

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients (n=64)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean ±SD</td>
<td>53.4±10.5</td>
</tr>
<tr>
<td>Sex (women), n (%)</td>
<td>45 (70.3)</td>
</tr>
<tr>
<td>R-IMID</td>
<td></td>
</tr>
<tr>
<td>- SpA / PsA</td>
<td>36 (56.3%)</td>
</tr>
<tr>
<td>- RA</td>
<td>21 (32.8%)</td>
</tr>
<tr>
<td>- SSc</td>
<td>3 (4.7%)</td>
</tr>
<tr>
<td>- Connectivopathies</td>
<td>3 (4.7%)</td>
</tr>
<tr>
<td>- Other</td>
<td>2 (3.2%)</td>
</tr>
<tr>
<td>Liver enzyme elevation over baseline (INH)*</td>
<td></td>
</tr>
<tr>
<td>- x2</td>
<td>64 (100)</td>
</tr>
<tr>
<td>- x3</td>
<td>22 (34.4)</td>
</tr>
<tr>
<td>- x4 or higher</td>
<td>13 (20.3)</td>
</tr>
<tr>
<td>csDMARDs</td>
<td></td>
</tr>
<tr>
<td>- MTX</td>
<td>34 (53.1%)</td>
</tr>
<tr>
<td>- HCO</td>
<td>15 (23.4)</td>
</tr>
<tr>
<td>- LFN</td>
<td>13 (20.3)</td>
</tr>
<tr>
<td>- SSZ</td>
<td>10 (15.6)</td>
</tr>
<tr>
<td>bDMARDs</td>
<td></td>
</tr>
<tr>
<td>- ABA</td>
<td>47 (73.4%)</td>
</tr>
<tr>
<td>Targeted synthetic DMARDs (Jakinib)</td>
<td>8 (12.5)</td>
</tr>
</tbody>
</table>

JAKINIB may be an effective and safe therapy in IOP refractory to conventional or even biological immunosuppressive therapy.

REFERENCES:

1. Meadow PB. Case Rep Rheumatol. 2014.

Disclosure of Interests: None declared


AB1311 INCREASED RISK OF HEPATOTOXICITY WITH DMARDS IN PATIENTS WITH PREVIOUS LIVER TOXICITY WITH ISONIAZID. STUDY IN A SINGLE UNIVERSITY HOSPITAL

D. Martínez-López, C. J Osorio-Chavez, V. Portilla, C. Álvarez-Reguera, A. Herrero-Morant, L. Sanchez-Bilbao, I. Gonzalez-Mazon, M. A. Gonzalez-Gay, R. Blanco, Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander (SPAIN), Spain; Hospital Universitario Marqués de Valdecilla, Pulmonology, Santander (SPAIN), Spain

Background: Isoniazid (INH) is used to treat latent tuberculosis infection (LTBI), and hepatotoxicity is one of the most frequent adverse effect. Several Disease-modifying drugs (DMARDs) can also cause hepatotoxicity. Many patients with rheumatic immune mediated diseases (R-IMID) receive INH prior to DMARDs for prophylaxis of LTBI. This risk of hepatotoxicity with DMARDs after hepatotoxicity with INH is unknown.

OBJECTIVES: To assess the risk of hepatotoxicity with DMARDs in patients who have presented hepatotoxicity with INH.

Methods: Study of all consecutive R-IMID patients evaluated in the last five years (2016-2020) in a University Hospital, who presented hepatotoxicity after INH and later received DMARDs. We study if they also presented hepatotoxicity with DMARDs. Hepatotoxicity was defined as an elevation of liver enzymes (ALT and/or AST) upper the high limit after the introduction of the treatment.

Results: INH was used in 232 of 7218 patients with R-IMID. We finally included 64 patients (45 women; 70.3%; mean age 53.4±10.5 years), who had hepatotoxicity due to INH (Table 1).

Figure 1. Therapeutical approach

Conclusion: JAKINIB may be an effective and safe therapy in IOP refractory to DMARDs after hepatotoxicity with INH.

Patients (n=64)

Sex (women), n (%) 45 (70.3)
Age (years), mean ±SD 53.4±10.5

R-IMID

- SpA / PsA 36 (56.3%)
- RA 21 (32.8%)
- SSc 3 (4.7%)
- Connectivopathies 3 (4.7%)
- Other 2 (3.2%)

Liver enzyme elevation over baseline (INH)*

- x2 64 (100)
- x3 22 (34.4)
- x4 or higher 13 (20.3)

csDMARDs

- MTX 34 (53.1%)
- HCO 15 (23.4%)
- LFN 13 (20.3%)
- SSZ 10 (15.6%)

bDMARDs

- ABA 47 (73.4%)

Targeted synthetic DMARDs (Jakinib) 8 (12.5%)

ABA: Abatacept; AZA: Azathioprine; HCO: Hydroxychloroquine; INH: Isoniazid; LFN: Leflunomide; MMF: Mycophenolate mofetil; MTX: Methotrexate; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; RTX: Rituximab; SpA: Axial spondyloarthritis; SSc: Systemic sclerosis; TCZ: Tocilizumab; TNFi: TNF inhibitors* Patients with higher liver enzyme elevation are included in the previous groups.

The most frequent R-IMIDs were rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis. Methotrexate (MTX) (n=34, 53.1%) and TNF inhibitors (n=27, 42.2%) were the conventional and biologic-DMARD more frequently used, respectively. Hepatotoxicity was higher with MTX (14 of 34, 41.2%), and lower with the other DMARDs (Figure 1). Hepatotoxicity was not observed with hydroxychloroquine, azathioprine, mycophenolate mofetil, secukinumab, abatacept or rituximab.
S. Gulle1, M. C. Ataca1, G. Can1, I. Sarı1, M. Birlik1, F. Onen1, Dokuz Eylül University School of Medicine, Rheumatology, Izmir, Turkey; Dokuz Eylül University School of Medicine, Internal Medicine, Izmir, Turkey.

Background: Sarcoidosis is a chronic granulomatous disease that primarily affects the lungs and lymph nodes, and can affect any organ and system (1). The incidence of concomitant iRMD is increased in patients with sarcoidosis. Anti-nuclear antibody (ANA) test are frequently used markers for inflammatory rheumatic diseases (iRMDs) (2). The relationship of this association with ANA is not clear.

Objectives: We aimed to determine the frequency of ANA in sarcoidosis patients and its possible correlation with clinical and laboratory data, and also to reveal the severity of osteoporosis in patients with sarcoidosis.

Methods: Ninety sarcoidosis patients, who were followed up in rheumatology clinic were included in this study. ANA were determined with indirect immunofluorescent method and 1/160 titration was accepted as positive. Demographic, clinical, serological, and bone mineral density (BMD) results of all patients were recorded. BMD results were obtained from the images taken before the last date or osteoporotic fracture of the patients.

Results: Average age of the 90 patients (79 females) with sarcoidosis was 57.5 (IQR: 51–66) years, and median disease duration was 76 (IQR: 4–19) years. 28 (31.1%) patients had a diagnosis of extrapulmonary sarcoidosis (Most commonly skin, n=20, 71.4%); 21 patients had BMD values consistent with osteoporosis, while 9 patients had osteoporotic fractures. In 18 (20%) patients, rheumatologic autoimmune disease combined with sarcoidosis was found. SpA was diagnosed in 6 patients, RA in 2 patients, Lofgren Syndrome in 2 patients, SJög in 2 patients, systemic sclerosis in 1 patient, and morphea in 1 patient. Other rheumatologic diseases were found in uveitis, polyarthritis, Gout, Behçet’s Disease and FMF. ANA test was performed in a total of 83 patients. ANA positivity was found in 30 (36.1%) patients with sarcoidosis (1/100-1/320 in 12 patients; >1/320 in 18 patients). There was no significant relationship between ANA positivity and gender distribution, age, disease duration, development of extrapulmonary sarcoidosis, refractory disease status, and laboratory findings at the time of diagnosis. It was found that ANA positivity at diagnosis time for sarcoidosis increased the risk of developing iRMD 4.8 times in patients [HR: 4.8, CI 95%: (1.455-15.833), p=0.009].

Conclusion: In sarcoidosis, ANA positivity is of great importance in the determination of accompanying iRMDs. It was found that ANA positivity at the time of diagnosis in sarcoidosis patients increased the risk of developing rheumatological autoimmune disease 4.8 fold. Since these patients receive long-term moderate-high-dose steroid-based treatments, they should be closely monitored and screened for osteoporosis.

REFERENCES:
employment was observed. Despite these positive outcomes, at present not enough patients per diagnosis-treatment combination have been included in the registry to draw definitive conclusions on efficacy and safety of specific off-label treatments or to formulate treatment recommendations for certain diseases. Consequently, it is important to continue the registry and include more patients or link various (inter)national registries to obtain sufficient data and promote evidence-based and effective use of biologics in rare therapy-refractory IMIDs. This may eventually also help to facilitate reimbursement of these therapies.

**Disclosure of Interests:** Anne Musters: None declared, Marjolijn Klein-de Graaf: None declared, Sandor Tas Consultant of: Gebo, GSK, AbbVie, Galvani, Arthrogen/MeiraGTx, Galapagos, Grant/research support from: Pfizer, GSK, Celgene, BMS, Sanofi, AstraZeneca

**DOI:** 10.1136/annrheumdis-2022-eular.4006

---

**Table 1. Case reports and literature review of patients with refractory autoinflammatory syndromes treated with Janus Kinase Inhibitors.**

<table>
<thead>
<tr>
<th>Study, year</th>
<th>Cases, n</th>
<th>Age/Sex</th>
<th>Underlying Disease</th>
<th>JAKINIB</th>
<th>Previous immunosuppressive treatment</th>
<th>Clinical Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garcia-Robledo et al, 2022 (1)</td>
<td>16</td>
<td>F</td>
<td>FMF</td>
<td>TOFA</td>
<td>MTX, TCZ, CANA</td>
<td>C.I.</td>
</tr>
<tr>
<td>Gök K et al, 2017 (2)</td>
<td>27.7</td>
<td>F</td>
<td>FMF</td>
<td>TOFA</td>
<td>MTX</td>
<td>C.I.</td>
</tr>
<tr>
<td>Forbes et al, 2018 (3)</td>
<td>12.4±7.5, F=9</td>
<td></td>
<td>TOFA</td>
<td>MTX</td>
<td>C.I.</td>
<td></td>
</tr>
<tr>
<td>Landhauer et al, 2020 (4)</td>
<td>43</td>
<td>F</td>
<td>AOSD</td>
<td>TOFA</td>
<td>RUXO (n=16)</td>
<td>C.I.</td>
</tr>
<tr>
<td>Sánchez et al, 2018 (5)</td>
<td>12.5±1.2(2-4.1)</td>
<td></td>
<td>BARI</td>
<td>BARI</td>
<td>C.I.</td>
<td></td>
</tr>
<tr>
<td>Karadeniz et al, 2020 (6)</td>
<td>43</td>
<td>F</td>
<td>FMF</td>
<td>TOFA</td>
<td>AOSD</td>
<td>C.I.</td>
</tr>
<tr>
<td>Honda et al, 2020 (7)</td>
<td>12.4±14</td>
<td></td>
<td>AOSD</td>
<td>TOFA</td>
<td>C.I.</td>
<td></td>
</tr>
<tr>
<td>Honda et al, 2020 (8)</td>
<td>12.4±14</td>
<td></td>
<td>AOSD</td>
<td>TOFA</td>
<td>C.I.</td>
<td></td>
</tr>
</tbody>
</table>

**References:**


**Disclosure of Interests:**

- Carmen Álvarez-Reguera: None declared, Diana Prieto-Peña: None declared, L. Sanchez-Bilbao: None declared, A. Herreno-Morant: None declared, D. Martinez-Lopez: None declared, M. A. González-Gay: None declared, R. Blanco: None declared, Hospital Universitario Marqués de Valdecilla, Rheumatology, Santander, Spain

**Background:** Autoinflammatory syndromes are characterized by dysregulation of innate immunity and recurrent episodes of fever, cutaneous and other. Janus Kinase inhibitor (JAKINIB) may inhibit innate and acquired immunity. They have been approved in several immune mediated diseases, but not in autoinflammatory syndromes.

**Objectives:** To assess the efficacy and safety of JAKINIB in refractory autoinflammatory syndromes.

**Methods:** Study of patients from a single University Hospital and Literature review of refractory autoinflammatory syndromes treated with JAKINIB.

**Results:** We have identified 2 cases in our hospital. One of them was a 25-year-old girl diagnosed with Blau syndrome refractory to different conventional and biological therapies. Tofacitinib (TOFA) had a good clinical response but was switched to B Goatitbin (BARI) due to severe lymphopenia. The 2nd patient was a 65-year-old man, diagnosed with an autoinflammatory syndrome (WDRI mutation) and polycytemia vera (positive JAK-2; V617F mutation). Based on the JAK2 mutation, BARI was started with complete improvement. In literature review, we found 59 patients (41 women/18 men), mean age 38.1±13.1 years. TOFA (n=23) was the most used JAKINIB, followed by BARI (n=20) and Ruxolitinib (RUXO) (n=16). After starting JAKINIB treatment, most patients presented clinical complete (n=45, 76.3%) or partial (n=11, 18.6%) improvement, only 3 (5.1%) did not respond. (Table 1)

**Conclusion:** JAKINIB may be an effective therapy in autoinflammatory syndromes refractory to conventional and/or biologic therapy.

**References:**

and a reduction in antibody titers against TSH receptor and anti-thyroid peroxi-
dase. All patients were continuing treatment except for one patient who had dis-
continued treatment due to clinical remission. No adverse events were recorded
except for mild neutropenia in one patient, which did not require dose reduc-
tion. No patient required subsequent immunosuppressive treatment or surgery.

Conclusion: Sarilumab treatment in patients with moderate-severe active OG
appears to be an effective and safe therapeutic alternative, clinically similar to
that obtained with TCZ in our series. This is the first published series of Sari-
lumab use in OG patients.

REFERENCES:
ON GRAVES’ ORBITOPATHY (EUGOGO) CLINICAL PRACTICE GUID-
ELINES FOR THE MEDICAL MANAGEMENT OF GRAVES’ ORBITOPATHY.
Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Obser-
et al. EFECTIVIDAD DEL TRATAMIENTO CON ANTI-INTERLEUCINA 6
SUBCUTÁNEA EN PACIENTES CON ORBITOPATÍA DE GRAVES MODER-
ADA-GRAVE ACTIVA REFRACTARIA A LA ATERAPIA CONVENCIONAL.
Poster presented at the 36th Congress National Sociedad Española de Reumatología; 2020 Oct 20-24; virtual.

Disclosure of Interests: None declared

Table 1.

<table>
<thead>
<tr>
<th>MAISs</th>
<th>Gender (men %)</th>
<th>Biological therapies prescribed during follow up</th>
<th>Patients under biological therapy at the end of follow up (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFM (n=17)</td>
<td>41.17%</td>
<td>Anakinra: 2</td>
<td>Canakinumab: 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etanercept: 1</td>
<td>Tocilizumab: 1</td>
</tr>
<tr>
<td>TRAPS (n=4)</td>
<td>100%</td>
<td>Anakinra: 1</td>
<td>Canakinumab: 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etanercept: 2</td>
<td>Tocilizumab: 1</td>
</tr>
<tr>
<td>HIDS (n=3)</td>
<td>66.66%</td>
<td>Anakinra: 3</td>
<td>Canakinumab: 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Etanercept: 1</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: MAISs prevalence was 0.34%. The diagnostic delay was of years,
more than a decade for HIDS. Colchicine was widely used and well tolerated.

Synthetic DMARDs had little role in treatment. Biological therapies were pre-
scribed in a third of patients, anti IL-1 being the most used.

Disclosure of Interests: None declared

Table 1.

| ULTRASOUND EVALUATION OF ACHILLES ENTHESIS AND GASTROCEUM ARCHITECTURE IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER: PRELIMINARY RESULTS FROM A CROSS-SECTIONAL STUDY |

N. Güven1, S. C. Göver1, A. Kavठ1, M. Bora Karśli1, Ş. Ataman1, 1Ankara University Medical School, Physical and Rehabilitation Medicine, Division of Rheumatology, Ankara, Turkey; 2Ankara City Hospital, Clinic of Rheumatology, Ankara, Turkey

Background: Exertional leg pain and Achilles enthesis are two musculoskele-
tal manifestations which have been described in familial Mediterranean fever
(FMF) patients. Muscle performance is related both with mass and architecture.
Measurements of muscle thickness and pennation angle in muscles with pennate
structure, such as gastrocnemius, are representative of muscle mass and archi-
tecture, both of which can easily be measured via musculoskeletal ultrasound.

Objectives: Aim of this study is to evaluate thickness and pennation angle of
medial gastrocnemius via ultrasound to evaluate muscle structure in FMF
patients in order to detect implications of altered muscle condition and search for
any relations with exertional leg pain/Achilles enthesitis. To our best knowledge
this is the first study on the subject.

Methods: Consecutive FMF patients meeting Tel-Hashomer criteria between the
ages of 18-65 were enrolled. A control group was formed from healthy volunteers

Disclosure of Interests: None declared

Table 1.
**Federation Institute of Rheumatology, Laboratory of Tromboinflammation, Moscow, Russian Federation**

**Methods:**

All ultrasound evaluations were performed by the same observer. Thickness and pennation angle of medial gastrocnemius was measured. Achilles tendon findings were scored according to OMERACT suggested guidelines and total inflammation and structural damage scores recorded.

**Results:**

A total of 40 FMF patients and 17 controls were enrolled. Clinical characteristics and ultrasound findings of subjects were presented in Table 1. All FMF patients were under colchicine treatment and 10% was also under anti- interleukin 1 treatment. Demographics were similar between groups. Right gastrocnemius pennation angle was significantly reduced in FMF group (degree, median [IQR]: 20.8 [3.6] vs 22.7 [4.5], p=0.048). OMERACT ultrasound inflammation total scores were increased on both sides in FMF group. When gastrocnemius and enthesuses ultrasound findings were compared between FMF patients with and without enthesis involvement, no significant differences were observed. When FMF patients with and without enthesis findings in ultrasound examination were compared, again no significant differences in pennation angles and muscle thicknesses were observed.

#### Table 1. Clinical characteristics and ultrasound findings in subjects

<table>
<thead>
<tr>
<th>FMF group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=40</td>
<td>N=17</td>
</tr>
<tr>
<td>Age, years, median (IQR)</td>
<td>42.8 (23.0) vs 38.0 (15.0)</td>
</tr>
<tr>
<td>Gender, female, number (%)</td>
<td>29 (72.5) vs 10 (58.8)</td>
</tr>
<tr>
<td>BMI, median (IQR)</td>
<td>24.6 (5.3) vs 24.8 (5.7)</td>
</tr>
<tr>
<td>Presence of enthesis, number (%)</td>
<td>22 (55) vs 0 (0)</td>
</tr>
<tr>
<td>Gastrocnemius thickness, mm, median (IQR)</td>
<td>19.7 (2.9) vs 20.7 (5.6)</td>
</tr>
<tr>
<td>Right</td>
<td>19.7 (2.9) vs 20.7 (5.6)</td>
</tr>
<tr>
<td>Left</td>
<td>20.8 (3.6) vs 22.7 (4.5)</td>
</tr>
<tr>
<td>OMERACT ultrasound tissue damage total score, median (IQR)</td>
<td>21.0 (3.3) vs 21.8 (4.7)</td>
</tr>
<tr>
<td>Right</td>
<td>2.0 (2.0) vs 2.0 (2.0)</td>
</tr>
<tr>
<td>Left</td>
<td>2.0 (2.0) vs 2.0 (2.0)</td>
</tr>
<tr>
<td>OMERACT ultrasound inflammation total score, median (IQR)</td>
<td>0 (0) vs 0 (0)</td>
</tr>
<tr>
<td>Right</td>
<td>0 (0) vs 0 (0)</td>
</tr>
<tr>
<td>Left</td>
<td>0 (0) vs 0 (0)</td>
</tr>
</tbody>
</table>

Conclusion: Our preliminary results imply altered right gastrocnemius structure in FMF patients regardless of Achilles tendon involvement and enthesis involvement, which may imply altered muscle function. By increasing the number of subjects we plan to achieve more accurate results.

## REFERENCES:


Acknowledgements: I have no acknowledgements to declare.

Disclosure of Interests: None declared.


---

**AB1319**

**MUSCULOSKELETAL IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS WITH SOLID CANCER TREATED WITH CHECKPOINT INHIBITORS: A CASE SERIES**

A. Koltakova1, A. Lita2, M. Cherkasova2, A. Fedenko4, I.V.A. Nasonova Research Institute of Rheumatology, Laboratory of Systemic Sclerosis, Moscow, Russian Federation; 2V.A. Nasonova Research Institute of Rheumatology, Department of Rheumatology, Moscow, Russian Federation; 3V.A. Nasonova Research Institute of Rheumatology, Laboratory of Tromboinflammation, Moscow, Russian Federation; 4National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Department of Drug Treatment of Cancer, Moscow, Russian Federation

**Background:** Immune-related adverse events (irAE) are common in cancer patients treated with checkpoint inhibitors. irAE can affect any organs and systems including musculoskeletal. The characteristics of immune-related musculoskeletal disorders (MD) still remain incomplete.

**Objectives:** To determine the characteristics of MD manifested during the treatment of solid cancer with checkpoint inhibitors in case series.

**Methods:** We identified 13 patients with inflammatory MD manifested during treatment with check-point inhibitors. Mean age of patients was 59±10 (ranged 43-74) years, 7 (54%) of them were female. Patients were treated with anti-PD-1 (77%) and anti-PD-L1 (33%) drugs (nivolumab [n=8], pembrolizumab [n=3], atezolizumab [n=3], proglolimab [n=1]). Cancer types include melanoma (n=5), renal cell carcinoma (n=3), bladder cancer (n=2), non-small cell lung cancer (n=1), breast cancer (n=1), cervical cancer (n=1). 7 (54%) patients had another irAE also including thyroiditis (n=3), neuroopathy (n=2), rash (n=1), sicca syndrome (n=1), hepatitis (n=1). The median time of musculoskeletal manifestation after the treatment’s onset was 20 [9-48] weeks.

**Results:** Musculoskeletal manifestations were performed by synovitis in 9 (69%) cases, tenosynovitis in 11 (85%) patients, enthesitis in 4 (31%), morning stiffness(>30min) in 4 (31%). The most commonly affected areas were knees (77%) shoulders (69%), hands (69%) and feet (46%). Bilateral involvement was in 9 (69%) cases. MD was started in 2 cases and was transient in 11 (9 patients with inflammatory arthritis and 2 patients with parathriitis). Clinical characteristic of inflammatory arthritis was represented by tenosynovitis more than synovitis in 3 cases (2 patients with symmetrical inflammatory polyarthritis and severe tenosynovitis, 1 patient with RSIPE-syndrome). In 6 cases inflammatory arthritis was represented by synovitis primarily (3 patients with symmetrical polyarthritis, 2 patients with oligoarthritis, 1 patient with monarthrosis). Severity of MD was assessed according to Common Terminology Criteria for Adverse Events V5.0. Grade 1 was in 2 cases, grade 2 in 9 (69%), grade 3 in 2 (15.5%). Laboratory findings include ESR ≥30mm/h in 7/12 (58%) cases (the median of ESR was 34 [14-42] mm/h); CRP >5mg/l in 7/10 (70%) cases (the median of CRP was 7.2 [4.8-12.9] mg/l). RF, ACRA were negative in all cases. ANA test was positive without any specificities in 7/10 (70%) cases in dilution 1:160 (n=2), 1:320 (n=3), 1:840 (n=2). Treatment of these conditions include NSAIDs, oral systemic corticosteroids (n=5), intra-articular corticosteroids (n=1), and csDMARDs (hydroxychloroquine [n=5] methotrexate [n=1] as corticosteroid-sparing agents. 2 patients with polyarthralgia and generalized tenosynovitis and 1 patient with symmetrical polyarthritis required treatment with ≤20mg daily of prednisone. 2 patients with poly- or oligoarthritis were treated with 5-10mg daily of prednisone. 5 patients with arthritis required long-term treatment with NSAIDs, corticosteroids and csDMARDs (the median of follow-up was 12 [3-12] months). 1 case of the inflammatory polyarthritis with severe tenosynovitis required to suspend the anticancer treatment with checkpoint inhibitor.

**Conclusion:** Our data demonstrated that the musculoskeletal irAE may be represented by heterogeneous manifestation and required long-term treatment. In rare cases musculoskeletal irAE can lead to suspension of the anticancer treatment with checkpoint inhibitors.

**Disclosure of Interests:** Anastasia Koltakova: None declared, Alexandra Lila Speakers bureau: Pfizer Inc, MSD, Novartis, AbbVie Inc., Celgen Corporation, Biocad, Icansen, UCB Inc, Maria Cherkasova: None declared, Aleksandr Fedenko: None declared.

<table>
<thead>
<tr>
<th>No Of Patients(%)</th>
<th>Appendicitis</th>
<th>No Of Patients(%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>176(100)</td>
<td>176(100)</td>
<td></td>
</tr>
<tr>
<td>Fever</td>
<td>148(84)</td>
<td>120(68)</td>
<td>0.0007</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>160(91)</td>
<td>139(79)</td>
<td>0.0029</td>
</tr>
<tr>
<td>Chest Pain</td>
<td>32(18)</td>
<td>39(19)</td>
<td>1</td>
</tr>
<tr>
<td>Arthritis</td>
<td>81(46)</td>
<td>94(53)</td>
<td>0.45</td>
</tr>
<tr>
<td>Myalgia</td>
<td>5(3)</td>
<td>5(3)</td>
<td>1</td>
</tr>
<tr>
<td>Erysipelas</td>
<td>0(0)</td>
<td>1(0.5)</td>
<td>-</td>
</tr>
<tr>
<td>Lower Leg Pain</td>
<td>1(0.5)</td>
<td>0(0)</td>
<td>-</td>
</tr>
<tr>
<td>Anti IL-1 usage</td>
<td>0(0)</td>
<td>0(0)</td>
<td>-</td>
</tr>
<tr>
<td>Amyloidosis</td>
<td>0(0)</td>
<td>1(0.5)</td>
<td>-</td>
</tr>
<tr>
<td>Disease Delay</td>
<td>8.5(2.9-15) years</td>
<td>3.6(1.91-10) years</td>
<td>0.0002</td>
</tr>
<tr>
<td>Pathogenic Exon 10 Mutations</td>
<td>114(65)</td>
<td>103(59)</td>
<td>0.27</td>
</tr>
<tr>
<td>Appendectomy Before FMF diagnosis</td>
<td>174(99)</td>
<td>0(0)</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Even after the discovery of colchicine and identification of the MEFV gene diagnosis of FMF remains a challenge. Previous studies reported a median diagnostic delay of 8.2-11 years. In these studies, 28%–32% of the patients went under abdominal surgical intervention before the diagnosis of the FMF [2,3]. The most common symptoms of FMF (fever and abdominal pain) are also the most common symptoms of acute abdomen. Thus distinguishing between FMF and acute abdomen in undiagnosed FMF patients represents an understated problem. These patients have a longer diagnostic delay (8(IQR 2-15) vs 3.5(IQR1-10) years), worse control of attacks, poorer quality of life. In conclusion, most of the appendectomies were unnecessary in the FMF patients. Thus we recommend investigating the patient for FMF if the evidence of the acute abdomen does not expand beyond the symptoms.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5167
**ABSTRACT**

**Differences in Peripheral Blood B-Cell Subsets in Patients with IgG4-Related Disease: Primary Sjogren’s Syndrome and Healthy Donors**

E. Sokol, E. Torgashina, J. Khvan, D. Tabakov, A. Aleksankin, M. Kireeva, V. Kulikova, V. Deshpande, S. Pali, S. Stone, J. Della Torre, E. Nasonova

**Background:** The level of circulating plasmablasts has been proposed as a good marker for diagnosing and monitoring IgG4-related disease (IgG4-RD) independent of serum IgG4 level [1]. However, elevated plasmablasts can be a good marker for diagnosing and monitoring IgG4-related disease (IgG4-RD). Ann Rheum Dis 2015 Jan;74(1):190-5.

**Methods:** Two hundred patients were randomly selected among individuals who were routinely followed-up with FMF diagnosis in our centre. Patients carrying a culprit condition. Patients usually stated more than one factor, however some patients reported only one. The most-reported trigger factors by the cohort are summarized as following: 76 emotional stress (38%), 60 menstruation (30%), 40 cold exposure (20%), 34 fatigue (17%), 13 seasonal changes (6.5%). The distribution of trigger factors between Group A, B, and C were non-significant (p=0.88).

**Results:** Detailed distribution of trigger factors is shown in Table 1. 144 out of 200 patients described a culprit condition. Patients usually stated more than one factor, however some patients reported only one. The most-reported trigger factors by the cohort are summarized as following: 76 emotional stress (38%), 60 menstruation (30%), 40 cold exposure (20%), 34 fatigue (17%), 13 seasonal changes (6.5%). The distribution of trigger factors between Group A, B, and C were non-significant (p=0.88).

**Table 1. The distribution of triggering factors in subgroups.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Total</th>
<th>Reported trigger factor (%)</th>
<th>Emotional stress (%)</th>
<th>Cold exposure (%)</th>
<th>Fatigue (%)</th>
<th>Seasonal changes (%)</th>
<th>Others (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>123</td>
<td>77 (62.3)</td>
<td>47 (38.0)</td>
<td>24 (19.5)</td>
<td>19 (15.4)</td>
<td>7 (5.7)</td>
<td>5 (4.1)</td>
</tr>
<tr>
<td>Group B</td>
<td>77</td>
<td>44 (66.2)</td>
<td>29 (37.7)</td>
<td>16 (20.5)</td>
<td>15 (19.5)</td>
<td>6 (7.8)</td>
<td>3 (4.0)</td>
</tr>
<tr>
<td>Group C</td>
<td>41</td>
<td>22 (53.6)</td>
<td>14 (33.7)</td>
<td>24 (58.5)</td>
<td>13 (31.7)</td>
<td>10 (24.4)</td>
<td>0 (0.0)</td>
</tr>
</tbody>
</table>

**Conclusion:** We concluded that trigger factors did not vary between distinct mutant genotypes. Although emotional stress is the most reported trigger factor by the participants, one should bear in mind that emotional stress influences most chronic diseases negatively. We also observed that menstruation overtly triggers an FMF attack. Additionally, cold exposure should be considered as a notable trigger factor. It is still unclear what triggers an FMF attack in 28% of the patients, remains a mystery.

**REFERENCES:**


**Disclosure of Interests:** None declared

**ABSTRACTS**

**DIAGNOSTIC DELAY IN FAMILIAL MEDITERRANEAN FEVER: IS IT STILL A PROBLEM?**

M. B. Yuzbashvili, A. Y. Avulya, I. Besisroglu, S. N. Baspina, S. Yenigun, I. Durucan, A. Alkan, M. E. Gazioğlu, M. F. Hiyanli, I. Sarac, H. Ozdogan, S. Ugurlu, 1 Istanbul University-Cerrahpaşa, 1 Internal Medicine, Division of Rheumatology, Istanbul, Turkey

**Background:** Familial Mediterranean fever (FMF) is a rare hereditary autoinflammatory disease with disease onset in childhood in most cases. Although autoinflammatory disease awareness is increasing among physicians, delayed diagnosis is still prevalent as a cause of greater morbidity[1].

**Objectives:** We aimed to study the characteristics of FMF patients diagnosed between 2000-2010 and 2011-2021 and to see if there was a difference in diagnostic delay.

**Methods:** We retrospectively evaluated the medical records of the FMF patients followed up in our rheumatology clinic that were diagnosed between 2000-2021 and split them into two groups according to the year they received their diagnosis. There were no significant differences in the number of all studied B-cell subsets between pts with IgG4-RD and with SjS. But there were no differences between IgG4-RD and SjS pts.

**Conclusion:** Immunophenotyping showed disturbed homeostasis of the B-cells subpopulations in IgG4-RD pts with a significant increase in plasmablasts compared to HD, but there were no differences between IgG4-RD and SjS pts. Further research is needed to evaluate the diagnostic utility of circulating plasmablasts in IgG4-RD.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5257
Conclusion: There was some increase in the diagnostic delay in 2011-2021 compared to 2000-2010. This may be partly due to the later onset of symptoms in patients diagnosed in 2011-2021, which could have led the physicians to consider other differential diagnoses. Nevertheless, diagnostic delay in FMF still seems a prevalent problem that should be addressed to prevent excess morbidity and mortality.

Disclosure of Interests: None declared.

**Table 1.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Female/Male, n</td>
<td>704/447</td>
<td>522/299</td>
</tr>
<tr>
<td>Age at onset, median (IQR) years</td>
<td>13 (7-21)</td>
<td>18 (12-26)</td>
</tr>
<tr>
<td>Delay in diagnosis, median (IQR) years</td>
<td>4 (1-11)</td>
<td>5.5 (2-15)</td>
</tr>
<tr>
<td>Presence of fever in the initial attack (%)</td>
<td>855 (74%)</td>
<td>592 (72%)</td>
</tr>
<tr>
<td>Presence of positive family history (%)</td>
<td>652 (57%)</td>
<td>502 (61%)</td>
</tr>
<tr>
<td>Presence of at least one M694V mutation (%)</td>
<td>526 (46%)</td>
<td>390 (60%)</td>
</tr>
<tr>
<td>Attack duration, median (IQR) years</td>
<td>3 (2-4)</td>
<td>3 (2-4)</td>
</tr>
<tr>
<td>Presence of abdominal pain in the initial attack (%)</td>
<td>936 (81%)</td>
<td>669 (81%)</td>
</tr>
<tr>
<td>Presence of HTN in the initial attack (%)</td>
<td>855 (74%)</td>
<td>592 (72%)</td>
</tr>
<tr>
<td>Presence of arthritis in the initial attack (%)</td>
<td>855 (74%)</td>
<td>592 (72%)</td>
</tr>
<tr>
<td>Presence of arthritis in the initial attack (%)</td>
<td>21 (19%)</td>
<td>19 (17%)</td>
</tr>
<tr>
<td>Presence of myalgia in the initial attack (%)</td>
<td>21 (19%)</td>
<td>19 (17%)</td>
</tr>
<tr>
<td>Presence of erysipelas like erythema in the initial attack (%)</td>
<td>33 (3%)</td>
<td>36 (4%)</td>
</tr>
<tr>
<td>Presence of positive family history (%)</td>
<td>652 (57%)</td>
<td>502 (61%)</td>
</tr>
</tbody>
</table>

AB1327 PREVALENCE OF IMMUNORELATED MUSCULOSKELETAL ADVERSE EFFECTS IN PATIENTS WITH LUNG CANCER OR MELANOMA TREATED WITH IMMUNO-CHECKPOINT INHIBITORS

1Hospital Universitario Clínico San Cecilio, Reumatología, Granada, Spain
2Hospital Universitario Clínico San Cecilio, Reumatología, Granada, Spain

Background: Immunotherapy in the field of medical oncology, consisting of inhibiting key immune checkpoints, is revolutionising the way patients with these pathologies are treated, being mainly used in skin and lung tumours. These molecules are aimed at controlling T-cell activation by interacting with cytotoxic T-lymphocyte antigen 4 (CTLA-4) protein (Iplimumab); by acting on the programmed cell death receptor (PD-1) (Pembrolizumab, Nivolumab); or by binding to programmed cell death ligand 1 (PDL1) such as Atezolizumab or durvalumab. Despite the improvement in survival in the management of cancers with poor prognosis, this type of therapy is characterised by a series of side effects, including dermatological, gastrointestinal, endocrine, rheumatological and other effects. In this study, we focused mainly on rheumatological adverse effects, ranging from mechanical and/or inflammatory musculoskeletal involvement to dry syndrome, vasculitis, polyarthritis, inflammatory myopathy, among others.

Aims: To assess the prevalence of immunorelated adverse effects (Eair) in cancer patients with lung cancer or melanoma treated with immunotherapy targeting check-points, such as anti-CTLA-4, anti-PD-1, anti-PDL-1.

Methods: Observational study of a series of 115 patients diagnosed with lung cancer or melanoma, in treatment with checkpoint inhibitors (nivolumab, pembrolizumab, durvalumab, atezolizumab), from 2016 to 2021 at the Hospital Universitario Clínico San Cecilio. Patients who developed some type of rheumatological symptomatology after the start of immunotherapy were included. The clinical history of these patients was reviewed to confirm or rule out these adverse effects. The following musculoskeletal Eair were included: arthralgias, arthritis, generalised musculoskeletal pain, myalgias, osteoporosis and/or osteopenia. In the Eair registry, the following entitics were not included: polymyalgia rheumatica, vasculitis and myositis.

Results: Out of a total of 115 patients who received immunotherapy, with age, type of tumour and treatment received (Table 1); 24 developed non-specific arthromyalgias considered to be grade 1 or 2 in severity, for which patients do not require specific treatment or suspension of treatment doses. However, several of the patients did develop active arthritis, requiring corticosteroid treatment and in some cases, the suspension of at least one treatment session. In our study, there is no clear relationship between one immunosuppressive drug or another for the development of Eair.

Disclosure of Interests: None declared.

Table 1.

<table>
<thead>
<tr>
<th></th>
<th>BASEAL CHARACTERISTICS</th>
<th>MALE n (%)</th>
<th>FEMALE n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AGE, mean (SD)</td>
<td>36.8 (24)</td>
<td>23 (4)</td>
</tr>
<tr>
<td></td>
<td>PRIMARY n (%)</td>
<td>20 (50%)</td>
<td>20 (50%)</td>
</tr>
<tr>
<td></td>
<td>SECONDARY n (%)</td>
<td>20 (50%)</td>
<td>20 (50%)</td>
</tr>
<tr>
<td></td>
<td>SYSTIC DISEASE ASSOCIATION</td>
<td>3 (8%)</td>
<td>3 (8%)</td>
</tr>
<tr>
<td></td>
<td>ANTERIOR UVEITIS n (%)</td>
<td>22 (57%)</td>
<td>22 (57%)</td>
</tr>
<tr>
<td></td>
<td>POSTERIOR UVEITIS n (%)</td>
<td>9 (22%)</td>
<td>9 (22%)</td>
</tr>
<tr>
<td></td>
<td>PANOVITIS n (%)</td>
<td>9 (22%)</td>
<td>9 (22%)</td>
</tr>
<tr>
<td></td>
<td>ACUTE UVEITIS n (%)</td>
<td>14 (35%)</td>
<td>14 (35%)</td>
</tr>
<tr>
<td></td>
<td>CHRONIC UVEITIS n (%)</td>
<td>26 (65%)</td>
<td>26 (65%)</td>
</tr>
<tr>
<td></td>
<td>BILATERAL UVEITIS n (%)</td>
<td>28 (70%)</td>
<td>28 (70%)</td>
</tr>
<tr>
<td></td>
<td>UNILATERAL UVEITIS n (%)</td>
<td>12 (30%)</td>
<td>12 (30%)</td>
</tr>
<tr>
<td></td>
<td>ANA Deformed performed n (%)</td>
<td>1 (2%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td></td>
<td>Negative n (%)</td>
<td>32 (80%)</td>
<td>32 (80%)</td>
</tr>
<tr>
<td></td>
<td>Positive n (%)</td>
<td>7 (17%)</td>
<td>7 (17%)</td>
</tr>
<tr>
<td></td>
<td>HLA</td>
<td>B27 (40%)</td>
<td>B51 (75%)</td>
</tr>
</tbody>
</table>
## Diagnostics and imaging procedures

### AB1328 A FEASIBILITY STUDY ON A NOVEL COMBINED THERMAL IMAGING AND CLINICAL JOINT ASSESSMENT APPROACH USING ULTRASOUND DETECTED JOINT INFLAMMATION OUTCOMES IN RHEUMATOID ARTHRITIS

Y. K. Tan1, C. Hong1, H. Li2, J. C. Allen Jr3, J. Thumbol1. 1Singapore General Hospital, Department of Rheumatology and Immunology, Singapore, Singapore; 2Singapore General Hospital, Health Services Research Unit, Singapore, Singapore; 3Duke-NUS Medical School, Centre for Quantitative Medicine, Singapore, Singapore

**Background:** Thermal imaging (TI) is a portable, low cost imaging tool with high feasibility for use. Clinical joint assessment is routinely performed in rheumatoid arthritis (RA) patient care.

**Objectives:** To assess a combined TI and clinical joint assessment (CTCA) approach in comparison with TI alone using ultrasound (US) detected joint inflammation outcomes as a gold standard.

**Methods:** Bilateral (BL) hand and wrist (22 joint sites) were assessed in this cross-sectional study. For TI (performed in a draft free room with a controlled temperature of around 22°C), the adjusted maximum (Tmax), minimum (Tmin) and average (Tavg) temperatures were derived by subtracting a control temperature (lowest Tmin at the joints per subject) from the Tmax, Tmin and Tavg per joint. US power Doppler (PD) and greyscale (GS) joint inflammation were graded semi-quantitatively (0-3) using validated scoring methods. Joint swelling and tenderness were graded as yes = 1 or no = 0. To increase the relative weightage of CTCA-MAX, CTCA-MIN and CTCA-AVG on the CTCA scores, if the joint was swollen and/or tender, the adjusted Tmax, Tmin and Tavg at each joint were multiplied by a factor of 2; otherwise, they remained unchanged. Receiver operating characteristic (ROC) analysis assessed the performance of TI and CTCA in identifying joint US PD score > 1 and GS score > 1. A parameter was selected as a univariate predictor if statistically significant (P < 0.05) with area under the ROC curve (AUC) ≥ 0.70.

**Results:** This study included 814 joints from 37 RA patients (mean disease duration, 30.9 months; mean DAS28, 4.43). For both TI and CTCA, out of the 22 joint sites, 3 joint sites were evaluated for PD score > 1 and 14 joint sites for GS score > 1; the remaining joint sites had AUC results unavailable due to small number of outcomes. For TI (Table 1), 3 joint sites had > 1 predictive parameter for either PD score > 1 and/or GS score > 1 as follows: left (L) wrist and right (R) MCPJ 1, AUCs (0.813 to 0.897) for PD score > 1; L wrist and R MCPJs 1 and 3, AUCs (0.806 to 0.947) for GS score > 1. For CTCA (Table 1), 6 joint sites had > 1 predictive parameter for either PD score > 1 and/or GS score > 1 as follows: BL wrists, AUCs (0.726 to 0.899) for PD score > 1; BL wrists, MCPJs 2 and 3, AUCs (0.739 to 0.931) for GS score > 1.

### Table 1. Identifying joints with ultrasound PD score > 1 & GS score > 1

<table>
<thead>
<tr>
<th>Joint</th>
<th>US criterion</th>
<th>Parameter (AUC ≥ 0.7 &amp; P &lt;0.05)</th>
<th>AUC (95% CI)</th>
<th>Cut-off</th>
<th>Joint</th>
<th>US criterion</th>
<th>Parameter (AUC ≥ 0.7 &amp; P &lt;0.05)</th>
<th>AUC (95% CI)</th>
<th>Cut-off</th>
</tr>
</thead>
<tbody>
<tr>
<td>L Wrist</td>
<td>PD score &gt;1</td>
<td>Adjusted Tmax **0.841 (0.691, 0.992)</td>
<td>4.7</td>
<td>L &amp; R</td>
<td>PD score &gt;1</td>
<td>CTCA-MAX **0.899 (0.797, 1)</td>
<td>7.2</td>
<td>9.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tmin **0.813 (0.669, 0.958)</td>
<td>2.85</td>
<td>Wrist</td>
<td>CTCA-MIN **0.861 (0.735, 0.987)</td>
<td>5.7</td>
<td>7.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tavg **0.849 (0.714, 0.985)</td>
<td>3.9</td>
<td></td>
<td>CTCA-AVG **0.889 (0.781, 0.997)</td>
<td>7.61</td>
<td>7.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GS score &gt;1</td>
<td>Adjusted Tmax **0.827 (0.682, 0.966)</td>
<td>4.7</td>
<td>GS score &gt;1</td>
<td>CTCA-MAX **0.918 (0.833, 1)</td>
<td>8</td>
<td>7.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tmin **0.808 (0.67, 0.947)</td>
<td>2.85</td>
<td></td>
<td>CTCA-MIN **0.873 (0.761, 0.986)</td>
<td>8.766</td>
<td>4.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tavg **0.837 (0.702, 0.967)</td>
<td>3.9</td>
<td></td>
<td>CTCA-AVG **0.913 (0.824, 1)</td>
<td>5.5</td>
<td>5.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>R MCPJ 1</td>
<td>PD score &gt;1</td>
<td>Adjusted Tmax **0.897 (0.726, 1)</td>
<td>5.7</td>
<td>L &amp; R</td>
<td>GS score &gt;1</td>
<td>CTCA-MAX **0.899 (0.797, 1)</td>
<td>7.2</td>
<td>9.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MCPJ 2 **0.936 (0.813, 1)</td>
<td>7.2</td>
<td></td>
<td>CTCA-MIN **0.902 (0.775, 1)</td>
<td>2.75</td>
<td>3.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tmin **0.932 (0.793, 1)</td>
<td>3.95</td>
<td></td>
<td>CTCA-AVG **0.931 (0.8, 0.943)</td>
<td>4.7</td>
<td>5.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adjusted Tavg **0.947 (0.886, 1)</td>
<td>4.9</td>
<td>L &amp; R</td>
<td>GS score &gt;1</td>
<td>CTCA-MAX **0.914 (0.735, 1)</td>
<td>6.35</td>
<td>12.2</td>
<td></td>
</tr>
<tr>
<td>R MCPJ 3</td>
<td>GS score &gt;1</td>
<td>Adjusted Tmax **0.922 (0.76, 1)</td>
<td>4.6</td>
<td>MCPJ 3</td>
<td>CTCA-MIN **0.902 (0.728, 1)</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CTCA-AVG **0.902 (0.728, 1)</td>
<td>-</td>
<td></td>
<td>CTCA-AVG **0.902 (0.728, 1)</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Conclusion:** A novel CTCA approach helps discriminate the severity of US detected joint inflammation in RA at more joint sites when compared to TI alone; this includes the commonly affected BL wrists, MCPJs 2 and 3. Further validation work in a larger RA cohort will be required.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2

### AB1329 INTEROPHYSSEAL JOINTS INJECTION UNDER ULTRASOUND GUIDANCE AN ALTERNATIVE TO FLUOROSCOPY GUIDANCE

E. Touboul1, S. Salomon-Goeb1, V. Deprez2, M. Boistelle1, V. Goeb1. 1Chu Amiens-Picardy Site Nord, Rheumatology, Amiens, France

**Background:** Ultrasound-guided injections are an alternative to evaluate, it eliminates the risk of ionizing radiation for both the patient and the practitioner as fluoroscopic procedures require a radiology technician, increase the overall support time and cost, decrease accessibility.

**Objectives:** The main objective of the study was to compare the short-term efficacy of posterior inter-apophyseal joint infiltrations under ultrasound versus scopic guidance.

**Methods:** Observational, retrospective, single-centre study. Patients benefited from posterior zygapophysial joints injection(s) under fluoroscopy or ultrasound and a follow-up consultation at one month.

**Results:** Data from 54 patients was collected. The evolution of VAS at 1 month was on average - 31.4cm (p <0.001) in the ultrasound group and - 31.3cm (p <0.001) in the fluoroscopy group with no statistically significant difference between the two groups (p =0.835). There were no injection-related complications in either group during the follow-up. The decrease in the consumption of NSAIDs was no statistically significant difference between both groups (p = 1.00).

**Conclusion:** A corticosteroid injection of the posterior zygapophysial joints under ultrasound allows for a significant reduction in pain after one month with no difference found between the two techniques. Injection under ultrasound are a reliable, accessible and safe alternative.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.217

### AB1330 AUTOMATIC SUBPIXEL MEASUREMENT OF RADIOGRAPHIC FINGER JOINT SPACE NARROWING IN RHEUMATOID ARTHRITIS PATIENTS UNDER TOCILIZUMAB TREATMENT

T. Oikawa1,2, Y. Ota3, M. Ikebe2, A. Furusaki1, A. Sagawa4, M. Kato5, T. Asumi2, T. Kamishima5, Sapporo University, Graduate School of Health Sciences, Sapporo, Japan; 2Sapporo City General Hospital, Department of Rheumatology and Immunology, Sapporo, Japan

**Background:** Routine monitoring with dedicated imaging methods: clinical examinations, radiographs and ultrasonography of swollen joints are time-consuming and somewhat subjective. They are also expensive and inadequate for timely intervention. In addition, these imaging modalities are invasive and unaffordable to the general population.

**Objectives:** To investigate radiographic joint space narrowing (JSN) assessment under tocilizumab treatment in rheumatoid arthritis (RA) patients. An automatic subpixel method was developed that enables high resolution measurements of JSN in radiographs. This study aims to evaluate the reliability of the developed method and its potential as a monitoring tool.

**Methods:** An automatic subpixel measurement method based on active contour techniques was developed and validated retrospectively on 1100 radiographs of 220 RA patients (70% treatment-naive, 30% tocilizumab treated) followed for 6 months. JSN was evaluated in 52 hand and 100 finger joints. The method was compared with manual measurements performed by experienced radiologists.

**Results:** The developed method showed good correlation with manual measurements, with a high degree of reliability (intraclass correlation coefficient (ICC) between 0.81 and 0.98). The method was also able to accurately detect JSN changes in individual patients, with a high sensitivity and specificity (91% and 88%, respectively). The method showed potential as a monitoring tool for tocilizumab treatment, providing reliable and consistent measurements of JSN in radiographs.

**Conclusion:** The automatic subpixel measurement method for radiographic finger joint space narrowing in RA patients under tocilizumab treatment shows good reliability and potential as a monitoring tool.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.8
Background: The conventional scoring methods of radiographic joint space narrowing (JSN) in rheumatoid arthritis (RA) such as the Genant-modified Sharp score (GSS) are widely accepted but include subjective and time-consuming nature. Therefore, we have developed an in-house software equipped with partial image phase-only correlation (PIPOC) which can automatically quantify joint space width (JSW) change.

Objectives: The purpose of this study was to investigate whether the in-house software can predict the inhibitory effect of tocilizumab on joint destruction in a short period of time.

Methods: The study included 39 RA patients (35 female) who were treated with tocilizumab (Table 1). Radiological progression of the metacarpophalangeal and the proximal interphalangeal joints was evaluated according to the GSS at 0, 6, and 12 months. Automatic measurement was performed by the in-house software (Figure 1). We then validated in-house software in terms of accuracy in detecting the JSN.

![Figure 1. The algorithm flow of in-house software equipped with PIPOC](image)

Table 1. Clinical characteristics of RA patients

<table>
<thead>
<tr>
<th>variable</th>
<th>baseline</th>
<th>6 months</th>
<th>12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex, female/male</td>
<td>35/4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid factor status, positive/negative</td>
<td>29/10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD) years</td>
<td>61.5 (14.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of disease, mean (SD) months</td>
<td>111.4 (85.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Swollen joint count, mean (SD)</td>
<td>6.6 (4.7)</td>
<td>3.5 (3.5)</td>
<td>2.9 (4.0)</td>
</tr>
<tr>
<td>Tender joint count, mean (SD)</td>
<td>6.4 (3.5)</td>
<td>2.9 (2.2)</td>
<td>1.9 (2.0)</td>
</tr>
<tr>
<td>DAS28-ESR, mean (SD)</td>
<td>4.9 (1.2)</td>
<td>3.0 (1.1)</td>
<td>2.6 (1.0)</td>
</tr>
<tr>
<td>DAS28-CRP, mean (SD)</td>
<td>4.4 (1.1)</td>
<td>3.0 (0.9)</td>
<td>2.6 (0.8)</td>
</tr>
</tbody>
</table>

RA, rheumatoid arthritis; SD, standard deviation; DAS28, disease activity score with 28 joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

Results: To ensure homogeneity of the subjects, we targeted the joints with GSS = 0 at baseline in the software analysis. The success rate of the in-house software for JSW measurement was 96.8% (449/464). Here, the GSS (+)/PIPOC (+) were defined as joints with JSN progression according to the GSS and the software analysis, respectively. Otherwise, joints were defined as the GSS (-)/PIPOC (-) namely non-progressive JSN. The 0–12-month GSS with the 0–6-month GSS (+) group was significantly more JSN progression than the 0–6-month GSS (-) group (Mann-Whitney U test, p < 0.001). Similarly, the 0–12-month PIPOC with the 0–6-month PIPOC (+) group was significantly more JSN progression than the 0–6-month PIPOC (-) group (p < 0.001). The 0–12-month JSW change of finger joints with the 0–12-month GSS (+) detected by the in-house software was significantly greater than the 0–12-month GSS (-) (p = 0.02).

Conclusion: Our in-house software equipped with PIPOC might be able to predict the subsequent joint destruction with 6 months observations.

REFERENCES:
Table 1. Pearson’s correlation between the ultrasound and clinical variables

<table>
<thead>
<tr>
<th>Author</th>
<th>Mean Age</th>
<th>Injection Content</th>
<th>Injection Guidance</th>
<th>Time for pain after injection</th>
<th>Threshold to consider FAIS diagnosis</th>
<th>Reference Standard</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kivlan 29.9 ± 72 (54) 10.4</td>
<td>Lidoine + bupivacaine + triamcinolone</td>
<td>Fluoroscopy 2 hours (proacitive activities)</td>
<td>Not established</td>
<td>Arthrosopy</td>
<td>No difference in pain relief after injection between individuals with and without FAIS (p=0.128)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kraeutler 38.8 ± 161 (120) 14.2</td>
<td>Lidoine + triamcinolone</td>
<td>Non-guided 10 minutes (physical tests and proacitive activities)</td>
<td>&gt;70% of pain relief after injection</td>
<td>Symptoms + physical tests + radiography</td>
<td>FAIS and dysplasia diagnosed in 76% of patients with &gt;70% of pain relief after injection, and in 67% in patients presenting &gt;70% (p=0.62)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chirzei 36.7 ± 49 (27) 14.7</td>
<td>Lidoine</td>
<td>Fluoroscopy 2 weeks (unimpaired)</td>
<td>&gt;50% of pain relief</td>
<td>Arthrosopy</td>
<td>No significant association between pain relief intensity after injection and the presence of FAIS (p&gt;0.05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gao 36 ± 78 (41) (16-65)</td>
<td>Lidoine + betamethasone</td>
<td>Ultrasound 10 minutes and 1 week (routine tasks)</td>
<td>&gt;50% of pain relief</td>
<td>Arthrosopy</td>
<td>Response to injection is 91.7% accurate for detecting FAIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perdikakis 33 ± 34 (20) (18-58)</td>
<td>Ropivacaine</td>
<td>Fluoroscopy 30 minutes (physical tests)</td>
<td>Uninformed</td>
<td>Arthrosopy</td>
<td>Response to injection presented 92% of PPV and 96.5% of accuracy for diagnosing FAIS, with NPV and sensitivity of 100%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: Evidence regarding the diagnostic capability of anesthetic intra-articular hip injections for FAIS is sparse. In order to accurately answer our research question, future studies that use standardized and optimized protocols of injection and pain assessment after injection are still essential. Furthermore, the need to take into account the different biases surrounding diagnostic studies was highlighted in our study.

REFERENCES:

2. G Gao et al., Arthroscopy 37 (1), 128 (2021)
3. BR Kivlan et al., Arthroscopy 27 (5), 619 (2011)
5. E Perdikakis et al., J Foot Radiol 6 (2), 2 (2021)

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.420

AB1332 - INSIGHTS INTO DISEASE ACTIVITY SCORE IN 28 JOINTS (DAS28) AND ITS COMPONENTS FROM AN ULTRASOUND PERSPECTIVE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS

J. Kow1, G. H. Lim2, Y. K. Tan3, 4, Singapore General Hospital, Department of Rheumatology and Immunology, Singapore, Singapore; 5, Singapore General Hospital, Health Services Research Unit, Singapore, Singapore

Background: Disease Activity Score in 28 Joints (DAS28) is a composite disease activity score commonly used to evaluate disease activity in rheumatoid arthritis (RA). Musculoskeletal ultrasound (US) allows visualization and assessment of joint inflammation and structural damage in RA.

Objectives: The aim of this study is to gain insights into DAS28 and its components through studying their relationship with US detected joint inflammation and bone erosion (BE).

Methods: At each joint recess, US power Doppler (PD) and greyscale (GS) joint inflammation were semi-quantitatively (0 to 3) graded using validated scoring methods while BE was scored as present=1 or absent=0 based on Outcome Measures in Rheumatology (OMERACT) consensus definition of BE. At the patient level, Pearson’s correlation coefficient was used to correlate US PD, GS and Erosion scores with the following clinical variables: DAS28 and its components (including the erythrocyte sedimentation rate (ESR)) in mm/hr; swollen joint count (SJC) ranging from 0 to 28; tender joint count (TJC) ranging from 0 to 28; and patient’s global assessment (PGA) of disease activity ranging from 0 to 100). Bonferroni correction was used to account for the above multiple testing. Among associations which were statistically significant, simple linear regression was used to describe the relationship between variables.

Table 1. Pearson’s correlation between the ultrasound and clinical variables

<table>
<thead>
<tr>
<th></th>
<th>DAS28</th>
<th>ESR (mm/hr)</th>
<th>Swollen Joint Count (0-28)</th>
<th>Tender Joint Count (0-28)</th>
<th>Patient’s Global Assessment (0-100)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>p-value</td>
<td>r</td>
<td>p-value</td>
<td>r</td>
</tr>
<tr>
<td>US PD score</td>
<td>0.34</td>
<td>0.02**</td>
<td>0.29</td>
<td>0.08</td>
<td>0.33</td>
</tr>
<tr>
<td>US GS score</td>
<td>0.42</td>
<td>0.002**</td>
<td>0.24</td>
<td>0.20</td>
<td>0.30</td>
</tr>
<tr>
<td>US Erosion score1</td>
<td>0.22</td>
<td>0.25</td>
<td>0.14</td>
<td>0.46</td>
<td>0.69</td>
</tr>
</tbody>
</table>

1 Based on subset of 30 patients. 2 Accounted for multiple testing. Statistically significant: *p<0.05; **p<0.01; ***p<0.001

Results: A total of 2520 joints and 2800 joint recesses from 36 joint sites (bilateral proximal interphalangeal joints, thumb interphalangeal joints, metacarpophalangeal joints, metatarsophalangeal joints, wrists, elbows and ankles) were scanned in 70 adult RA patients (baseline characteristics: 81.4% female; 74.3% Chinese; mean (SD) DAS28 3.99 (1.25); mean (SD) disease duration 75.3 (61.2) months). All 70 patients underwent US joint inflammation assessment with a subset of 30 patients assessed for US BE. Table 1 summarizes the correlation results between the US and clinical variables. US PD scores were correlated with DAS28 (R²=0.34, p=0.02) and SJC (R²=0.33, p=0.03). US GS scores were correlated with DAS28 (R²=0.42, P=0.002), US Erosion scores were correlated with SJC (R²=0.69, P<0.001). Simple linear regression (see scatter plots in Figure 1) demonstrated a statistically significant relationship between the following variables: US PD score versus DAS28 (R²=0.13, p=0.004); US PD score versus SJC (R²=0.11, p=0.008); US GS score versus DAS28 (R²=0.18, P<0.001); US Erosion score versus SJC (R²=0.48, p<0.001).

Conclusion: Both DAS28 and SJC have significant correlation with US detected joint inflammation. However, among the clinical variables, only SJC appears to be associated with structural damage and has significant correlation with US detected BE. Therefore, it appears that the results from both DAS28 and SJC can be more reflective of the RA disease status when compared to DAS28 alone. The role(s) of both DAS28 and SJC versus DAS28 alone as patient outcome measures in RA need to be further explored.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.748
AB1334

SCANGRAFO EVALEUATION OF BONE FRACTURE 2 YEARS AFTER BARIATRIC SURGERY IN OBESE PATIENTS: AN OBSERVAITONAL STUDY

M. Faurn1, M. Halm1, E. Allado2, D. Quilicott2, L. Brunaud2, E. Albuison2, I. Chay Valci/nae1, D. Loeuille1, 1University Hospital of Nancy. Rheumatology, Nancy, France; 2University Hospital of Nancy, University Center of Sports Medicine and Adapted Physical Activity, Nancy, France; 3University Hospital of Nancy, Department of Endocrinology Diabetology and Nutrition, Nancy, France; 4University Hospital of Nancy, Department of Digestive, Hepato-Biliary and Endocrine Surgery, Nancy, France; 5University Hospital of Nancy, Data Management et Statistiques, Nancy, France;

Background: Osteoporosis is a common disease whose progression can be seriously impacted by the development of fractures that lead to functional limitations and may even have life-threatening sequelae (1). CT is useful for diagnosing vertebral fracture (VF) and measuring the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1). Osteoporosis is associated with rapid radiographic progression (RRP) and may even have life-threatening sequelae (1). CT is useful for diagnosing vertebral fracture (VF) and measuring the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1). Osteoporosis is a common disease whose progression can be seriously impacted by the development of fractures that lead to functional limitations and may even have life-threatening sequelae (1). CT is useful for diagnosing vertebral fracture (VF) and measuring the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1).

Methods: This descriptive study included obese patients who underwent bariatric surgery between January 2014 and December 2019 and CT before and two years after bariatric surgery. The secondary objectives were to identify risk factors for a decrease in the scanographic bone attenuation coefficient of the first lumbar vertebra (SBAC-L1).

Results: Among the 78 included patients, 85.9% were women, with a mean age of 48.5 years (±11.4); the mean body mass index (BMI) was 46.2kg/m² (±7) before surgery and 29.8kg/m² (±6.7) 2 years after surgery. There was a significant change in SBAC-L1 two years after surgery (p=0.037). In multivariable analysis, the risk factors for an SBAC-L1 < 145 HU 2 years after bariatric surgery in those with an SBAC-L1 > 145 HU before surgery were age and sex, and men and older patients having a higher risk (OR = 32.6, CII%5 = [1.86-568.77], and OR = 0.85, CI%5 = [0.74-0.98], respectively).

Conclusion: SBAC-L1 was significantly lower two years after bariatric surgery than before surgery. When the SBAC-L1 was over 145 HU before bariatric surgery, men and sex and older patients were the risk factors for having an SBAC-L1 below the fracture threshold 2 years after surgery.

REFERENCES:

Disclosure of Interests: None declared

AB1335

BONE MARROW EDEMA SCORE IN HAND X-RAY FILM BY AI DEEP LEARNING ASSOCIATE WITH MBI BONE EDEMA IN RHEUMATOID ARTHRITIS.

K. Katayama1, D. Parr2, M. Oda3, T. Okubo4, K. Mori5. 1Katayama Orthopedic Rheumatology Clinic, Rheumatology, Asahikawa, Japan; 2Graduate School of Informative, Nagoya University, Information and Communications, Nagoya, China; 3Graduate School of Informative, Nagoya University, Information and Communications, Nagoya, Japan; 4Katayama Orthopedic Rheumatology Clinic, Radiology, Asahikawa, Japan; 5Graduate School of Informative, Information and Communications, Nagoya, Japan;

Background: Rapid radiographic progression (RRP) was reported to be one of clinical symptom in difficult to treat RA(D2T RA) (1). Eular recommendation for imaging showed BME is strong and independent prognostic factor for bone destruction(2). We reported bone marrow edema (BME) in MRI image was most associated with RRP compared with bone erosion, synovitis in Adalimumab add-on therapy in MXT-IR RA patients(3). To rescue RRP, early detection of BME is important although cost of MRI is expensive and hard to repeat.

Objectives: To investigate the score of BME in hand X ray film by deep learning between X ray film and MRI BME information can discriminate the differences between BME and non-BME.

Methods: In this work, we use a neural network consisted of convolutional layers and fully connected layers to classify X-ray images (Figure 1) in this paper, the output is the score of BME which ranges from 0 to 1( threshold = 0.4). We also
Results: Regarding data split, 104 images including 79 non-BME images and 25 BME images are used as a hold-out test set. The rest of the images (473 images) are used as training data and validation data. Five fold cross-validation is used for these 473 images. For each fold, there are about 378 images including 297 non-BME images and 81 BME images in the training set. There are about 95 images including 74 non-BME images and 21 BME images in the validation set. In order to fully utilize every image and unify the distribution of the training set and the validation set, the ratio of non-BME and BME is controlled to be the same which is about 3.66:1. The five folds showed similar performance on the hold-out test set. AUC is the area under the ROC curve. As the result, AUC which indicates the general performance of this model, ranged from 0.88 to 0.91. The average precision was 63% and the average recall rate was 87%. In this experiment, the initialization seed will greatly influence the final result. For example, AUC can be reduced to 0.73 from 0.89 because of a different initialization seed. It perhaps results from the shortage of data, which can easily make the neural network drop into a local minimum. We also utilized Grad-cam to visualize the result. The result of Grad-cam shows the importance of each part to the final prediction (Figure 2).

Figure 2. Result of Grad-cam. Numbers in the parentheses are the possibilities of BME. The middle case is unexpected because red region is the surrounding of the hand. The left and right cases may indicate the evidence for prediction.

Conclusion: The preliminary result is much better than a random guess. According to this result, there should be a certain difference between BME and non-BME images. If it’s the characteristic of BME that domains this difference, our classification algorithm will be feasible for BME. Our future work is to justify the evidence of the predictions and improve performance.

REFERENCES:

Disclosure of Interests: None declared
Background: Quantitative computer tomography (QCT) has emerged as a screening tool for opportunistic measurements of volumetric bone mineral density (vBMD) from clinical CT scans, enabling early diagnosis of osteoporosis. However, intravenous contrast media administered during clinical CT examinations, calibration methods as well as different scan phases may influence vBMD and must be considered. Calibration methods include synchronous and asynchronous CT phantoms as well as phantom-less internal calibration.

Objectives: To investigate the effect of intravenous contrast media on QCT-measured vBMD. Furthermore, to review the effects of different calibration methods and scan protocols on vBMD.

Methods: In this systematic literature review, two independent reviewers (AH and AC) conducted a blinded screening for articles involving human participants who had undergone a contrast and non-contrast CT scan to measure vBMD. A total of 1,981 studies, published between 01/02/2000 and 17/01/2021, were screened and 9 eligible studies were included. A meta-analysis was conducted and standard mean differences (SMD) with 95% confidence intervals (CI) were calculated and presented in a forest-plot. Quality of studies was rated by the preliminary ROBINS-E risk of bias tool.

Results: In total, the 9 studies included 515 patients. On average the vBMD SMD changed 0.45 (95% CI: 0.24-0.67, P < .0001) from non-contrast to contrast-enhanced (CE) scans at the lumbar region (Figure 1). Phantom-based QCT had a SMD of 0.64 (95% CI: 0.33-0.94, P < .0001) and phantom-less QCT had a SMD of 0.20 (95% CI: -0.00-0.40, P = 0.05). Subgroup analyses showed a mean arterial phase vBMD SMD of 0.29 (95% CI: 0.12-0.45 P < .0008) and a venous phase vBMD of 0.56 (95% CI: 0.30-0.81, P < .0001). All studies were deemed to have moderate or serious risk of bias by the ROBINS-E tool.

Conclusion: QCT-measured vBMD is higher in CE scans in both phantom-based and phantom-less scans compared to non-contrast CT. Our meta-analysis suggest that contrast has a larger impact on vBMD in phantom-based vs. phantom-less and in venous phase vs. arterial phase scans, underlining not only the time-dependency but also the dependency of the calibration method. Arterial phase CT scans using internal calibration may be preferred when measuring vBMD in a clinical setting without an adjusting conversion factor. However, CE scans are to be used in opportunistic vBMD screening, development of a universal calibration- and protocol specific conversion factor is of importance.

REFERENCES:

Disclosure of Interests: Hilde Berner Hammer Speakers bureau: AbbVie, Lilly and Novartis, Vigle Lans Pedersen: None declared, Isabel Gehring: None declared, Linda Mathsson-Alm: None declared, Joe Sexton: None declared, Johan Askling Grant/research support from: AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB DOI: 10.1136/annrheumdis-2022-eular.1448

AB1338
CALPROTEIN, A SENSITIVE MARKER OF INFLAMMATION, IS ROBUSTLY ASSESSED IN PLASMA FROM PATIENTS WITH ESTABLISHED RA BY USE OF DIFFERENT LABORATORY METHODS
H. B. Hammer1, 2, S. L. Pedersen1, I. Gehring1, L. Mathsson-Alm3, J. Sexton4, J. Askling5.
1Diakonhjemmet Hospital, Dept of Rheumatology, Oslo, Norway; 2Instituto de Investigación Biomédica de Málaga (IIBMIA); Hospital Regional Universitario de Málaga, Rheumatology, Málaga, Spain; 3Hospital Universitario Reina Sofia, Universidad de Córdoba, Rheumatology, Córdoba, Spain; 4Hospital Universitario Virgen Macarena, Rheumatology, Sevilla, Spain; 5Hospital Universitario Reina Sofia, Instituto Maimónides de Investigación Biomédica (IMIBIC), Universidad de Córdoba, Rheumatology, Córdoba, Spain; 6Karolinska Institutet, Department of Medicine, Solna, Stockholm, Sweden

Background: Sarcopenia is a muscular disease characterized by a loss of muscle mass and function. The condition is associated with chronic diseases and...
aging and predicts disability, hospitalization and death [1]. Due to chronicity and disability produced by RA, it is convenient to see the relationship with sarcopenia.

Objectives: To assess the diagnostic utility of ultrasound (US) for sarcopenia.

Methods: Cases: Outpatients, 65 years old or more, with RA (ACR/EULAR 2010 criteria) from the rheumatology clinics of 4 Spanish University Hospitals were randomly selected consecutively from rheumatology consultation since May 2021 to September 2021. Controls: Control subjects without rheumatoid disease were selected from family members or friends of the cases, paired by age, gender and social status from May to September 2021. Variable and measures: The main evaluated outcome was sarcopenia as defined in 2019 by the European Working Group on Sarcopenia in Older People (EWGSOP). Cross-sectional Ultrasound sounds (US) of the third proximal forearm were evaluated for the perpendicular distance (millimeters) between superficial surface of subcutaneous cellular tissue and the deep surface close to the ulna with two different measures (66% and 75%). Cross-sectional US images were also obtained of lower limbs, at an equidistant point between anterosuperior iliac spine and the upper border of the patella for measuring the distance between superficial surface of subcutaneous cellular tissue and the deep interface of the femur with vastus medialis muscle with two different measures (50% and 75%). Handheld dynamometer was used to measure the strength in upper limbs. Body composition was evaluated using dual-energy X-ray densitometry.

Statistics: A descriptive analysis, chi square γ-test, T-test were done to compare the main characteristics and results between patients and controls. Correlations between forearm US and strength and between thigh US and total DEXA were calculated by Pearson’s test.

Results: 76 patients and 76 controls were included in the study, 120 were women (79.3%), with media a SD of age 74.7 ± 9.98 of media and 32 (21.1%) were men, with age 70.1 ± 3.78 of media. In comparison with controls, RA patients presented more frequency of sarcopenia (30 [19.53%] vs 6 [3.94%]; p=0.005) according to EWGSOP criteria. From the point of view of ultrasound, RA patients presented less muscle mass in cubital forearm and thigh. Control group presented larger size of muscle (Table 1).

Table 1. Results measirments case-control in millimeters

<table>
<thead>
<tr>
<th></th>
<th>Control (mds)</th>
<th>RA (mds)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right forearm 66% ulnar</td>
<td>42.9±2.8</td>
<td>38.7±2.9</td>
<td>0.003</td>
</tr>
<tr>
<td>Left forearm 66% ulnar</td>
<td>41.1±8.97</td>
<td>37.9±9.27</td>
<td>0.03</td>
</tr>
<tr>
<td>Left forearm 75% cubital</td>
<td>38.7±7.7</td>
<td>35.1±8.5</td>
<td>0.008</td>
</tr>
<tr>
<td>Right Thigh 50% FR+VI</td>
<td>30.9±7.46</td>
<td>29.0±8.31</td>
<td>0.011</td>
</tr>
<tr>
<td>Right Thigh 50% VI</td>
<td>14.5±1.26</td>
<td>13.0±8.27</td>
<td>0.042</td>
</tr>
<tr>
<td>Right Thigh 50% FR</td>
<td>15.2±2.63</td>
<td>13.5±3.28</td>
<td>0.002</td>
</tr>
<tr>
<td>Right Thigh 50% area FR</td>
<td>55.8±18.29</td>
<td>48.1±14.06</td>
<td>0.001</td>
</tr>
<tr>
<td>Left Thigh 50% FR+VI</td>
<td>27.6±7.8</td>
<td>23.7±8.26</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Ultrasound measurements in forearm which showed a positive correlation with strength were: right forearm: 66% ulnar (r=0.295, p=0.003), 75% cubital (r=0.342, p<0.001), 50% FR (r=0.256, p=0.003), 75% FR+VI (r=0.255, p=0.003), 50% FR (r=0.265, p=0.002), 50% area FR (r=0.280, p=0.003), 75% FR (r=0.357,p=0.001), 75% VI (r=0.382,p=0.001), 75% FR (r=0.240, R2=0.006), 75% area FR (r=0.218,p=0.023), 75% FR (r=0.251, p=0.004), 50% VI (r=0.293,p=0.001), 50% FR (r=0.214, p=0.015), 75% FR (r=0.347,p=0.001), 75% VI (r=0.342, p=0.001), 75% FR (r=0.295, p=0.001).

Conclusion: Muscle Ultrasound is a useful diagnostic tool to detect sarcopenia. It can be cost-efficient and faster when compared with DEXA and the results correlated with strength produced by RA, with or without deformities or erosions.

Musculoskeletal ultrasound allows evaluation of the inflammatory joint damage for more targeted therapeutic approach.

Objectives: The aim of this study was to estimate the prevalence of the wrists and hands synovitis (WHS) in subgroups of patients with systemic lupus erythematosus (SLE) and to compare them with each other.

Methods: One hundred and sixty-nine patients with SLE were consecutively recruited in the rheumatology unit (consultation or hospitalization) of the Ben Aknoun hospital, Algiers-Algeria. Stratification into subgroups was carried out: non-deforming non-destructive patients (NDND), rashy patients (if coexistence of lupus and rheumatoid arthritis criteria), patients with moderate deforming arthropathy (MDA) or Jaccoud arthropathy according to the score of the Sporik index. For each patient, demographic data, duration of SLE evolution and joint involvement were collected, a standard inflammatory biology report and screening for rheumatoid factor (RF) and anti-CCP (ACPA) were requested. A musculoskeletal ultrasound of the wrists, MCP andPIP (from the 2nd to the 5th rays) was performed with a search for synovitis and erosions, the ultrasound examination was preceded by the calculation of the SLEDAI score and the HAQ score.

Results: 169 patients were recruited: 135 NDND, 18 ruphas, 10 Jaccoud, 6 MDA, respective mean age of 38.38 ± 11.79, 39.39 ± 11.74, 41.10 ± 9.5, 47 ± 9.93 years. The mean duration of lupus was 8.23 ± 6.97, 12.33 ± 8.71, 13.10 ± 6.6 and 15 ± 5.93 years, respectively. The mean duration of joint involvement was 7.38 ± 6.920, 12.22 ± 8.84, 13.10 ± 6.6, 15 ± 5.93 years. The positive CRP was found respectively in 20%, 38.9%, 20%, and 16.7%. The frequency of WHS, RF, ACPA and erosions was significantly higher in the ruphas group compared to that of NDND (p <0.001). No difference was found in mean SLEDAI scores between subgroups. The mean HAQ score was higher in patients in the ruphas and Jaccoud groups compared to the mean score in patients in the NDND and MDA group (p <0.0001).

Conclusion: Our results confirm that ruphas patients have more inflammatory and erosive involvement than other lupus subgroups. It represents an overlap between rheumatoid arthritis and lupus more than a separate entity. We have also shown that deforming arthropathies without structural damage correspond to a late course in a group of patients initially non-deforming non-destructive.

REFERENCES:

Disclosure of Interests: None declared


AB1341

ASSESSMENT OF COMMON FEMORAL VEIN INTIMA-MEDIA THICKNESS BY ULTRASOUND IN BEHÇET’S DISEASE: COMPARATIVE STUDY OF PATIENTS WITH OR WITHOUT VASCULAR INVOLVEMENT IN A NATIONAL REFERRAL CENTER

D. Prieto-Peña1,2, A. Del Peral Fanjul3, B. Atienza-Mateo3, V. Pulito-Cuello2, M. A. González-Gay3,4, R. Blanco2,3,4 1Hospital Universitario Marqués de Valdecilla, Department of Rheumatology, Santander, Spain; 2IDIVAL, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain

Background: Vascular manifestations are frequent in Behçet’s disease (BD). However, they have been less studied than other manifestations, such as ulcers [1]. Increased venous wall thickness assessed with ultrasound (US) has been reported in BD [2]. However, it remains unclear if US findings correlate with vascular involvement in BD.

Methods: To assess vascular Doppler US findings in patients with BD with and without clinical vascular manifestations.

Results: Observational study of unselected consecutive patients with BD assessed in a national referral center, from March 2021 to May 2021. All patients fulfilled the 2014 ICBD criteria [3]. They were evaluated sequentially with a scheduled clinic visit after signing an informed consent. Demographic and clinical variables were collected. Patients were considered to have vascular involvement...
Results: A total of 280 patients, 179 (63.9%) women, with a mean age of 58±15 years, underwent PET/CT in the rheumatology department. 202 (72.1%) patients had a diagnosis of iRMD before PET/CT. After PET/CT, 40 (48.2%) patients were diagnosed with a new iRMD, and 43 (41.8%) were diagnosed with a non-iRMD. No inflammatory disease was detected in 33 (11.8%) patients.

iRMD diagnosed by PET/CT are respectively: LVV (n=11), IgG4-RD (n=10), sarcoidosis (n=9), and other (n=10). It was determined that 22 (26.5%) of newly diagnosed patients other than iRMD had malignancy [Bronchial (n=8), lymphoma (n=3), breast (n=3), other (n=8) cancer]. PET/CT revealed lymphadenopathy (LAP) in 119 of 165 patients who underwent the scan to exclude malignancy, and 22 of 91 patients who underwent PET/CT for rheumatologic diagnosis. LAP was found in 45% of those diagnosed with iRMD and 74.4% of those diagnosed with non-iRMD (p=0.002). PET/CT imaging was performed on 18 patients for follow-up. The treatment of 4 out of 18 patients with follow-up PET/CT and 76 out of 280 total patients was changed after imaging. In patients with a diagnosis of giant cell arteritis (GCA), the compatibility of PET/CT with MRI was 62.5%, while its agreement with CTA was 100%, and with Doppler USG was 38%.

Conclusion: PET/CT imaging was found to be an important adjunctive examination in the diagnosis and follow-up of sarcoïdosis, LVV, and IgG4-RD in patients evaluated in the rheumatology clinic. It has been observed that it is often used in the diagnosis and follow-up of RA, SpA, and autoinflammatory diseases, to investigate the malignancies accompanying rheumatic diseases and to evaluate the characteristics of LAP. PET/CT findings provide significant benefits to the clinician in the early diagnosis of iRMDs and differentiation of malignant and/or infectious etiologies.

REFERENCES:

Table 1.

<table>
<thead>
<tr>
<th>Vascular manifestations</th>
<th>Without vascular manifestations</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n=17)</td>
<td>(n=25)</td>
<td></td>
</tr>
<tr>
<td>Sex (men), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), mean ± SD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA B51 positive, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evolution time (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidemia, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking habit (current or former smokers), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological manifestations, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking habit (current or former smokers), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical manifestations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral ulcers, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genital ulcers, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema nodosum-like, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pseudofolliculitis, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uveitis, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurological manifestations, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrasound findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Femoral vein IMT (mm), median [IQR]</td>
<td>0.65 [0.45-0.82]</td>
<td>0.49 [0.39-0.55]</td>
</tr>
</tbody>
</table>

IMT: intima-media thickness. IQR: interquartile range.
Background: Disease activity scores are used in the follow-up of patients with rheumatoid arthritis (RA). These scores include variables obtained through physical examination, such as the tender and swollen joint count. In telematic consultations it is not possible to determine these variables. Thermography is a safe and fast technique that measures heat through infrared imaging. Inflammation of the joints causes an increase in temperature and could therefore be detected by thermography. Machine learning methods are highly accurate in analyzing medical images, and could be used to analyze thermal images automatically. Thermography of hands, patient global health (PGH) and acute phase reactants could be combined to develop new activity scores that facilitate remote assessment of RA patients.

Methods: Multicenter observational study conducted in the rheumatology and radiology service of two hospitals. Patients with RA, psoriatic arthritis, undifferentiated arthritis and arthritis of hands secondary to other diseases that attended the follow-up visits were recruited. Companions of patients and healthcare professionals were also recruited as healthy subjects. In all cases, a thermographic image of the hands was taken using a Flir One Pro or a Thermal Expert TE-Q1 camera connected to a smartphone. Ultrasound (US) of both hands was performed. The degree of synovial hyperthermia (SH) and power doppler (PD) was assessed for each joint (score from 0 to 3). Machine learning was used to quantify joint inflammation from the thermal images using US (SH+PD) as ground truth. This score has been named ThermOJS. RA patients whose thermal image was taken with the Thermal Expert TE-Q1 camera were used to evaluate the performance (test dataset). The other participants were used as training dataset. The PC, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were also assessed in the test dataset. ThermoDAS (ThermoJS + PGH), ThermoDAS-ESR (ThermoJS + PGH + ESR) and ThermoDAS-CRP (ThermoJS + PGH + CRP) activity scores were developed using a linear regression. The Spearman’s correlation coefficient of ThermOJS, ThermoDAS, ThermoDAS-ESR and ThermoDAS-CRP vs. SH, PD, PGH, ESR and CRP were used to characterize the new developed disease activity scores. The study was approved by the Clinical Ethics and Research Committee of both centers.

Results: The total number of recruited subjects were 616 (475 for the training and 141 for the testing dataset). The correlations obtained between the different activity scores (ThermoJS, ThermoDAS, ThermoDAS-ESR and ThermoDAS-CRP) vs. SH, PD, PGH, ESR and CRP are shown in Table 1. All correlations are statistically significant.

Table 1. Spearman’s correlations of the developed scores vs synovial hyperthermia (SH); vs power doppler (PD); vs patient global health (PGH); vs erythrocyte sedimentation rate (ESR) and vs C-reactive protein (CRP).

<table>
<thead>
<tr>
<th></th>
<th>SH</th>
<th>PD</th>
<th>PGH</th>
<th>ESR</th>
<th>CRP</th>
</tr>
</thead>
<tbody>
<tr>
<td>ThermOJS</td>
<td>0.42</td>
<td>0.43</td>
<td>0.18</td>
<td>0.16</td>
<td>0.12</td>
</tr>
<tr>
<td>ThermoDAS</td>
<td>0.50</td>
<td>0.53</td>
<td>0.87</td>
<td>0.16</td>
<td>0.19</td>
</tr>
<tr>
<td>ThermoDAS-ESR</td>
<td>0.54</td>
<td>0.53</td>
<td>0.79</td>
<td>0.49</td>
<td>0.33</td>
</tr>
<tr>
<td>ThermoDAS-CRP</td>
<td>0.60</td>
<td>0.60</td>
<td>0.77</td>
<td>0.49</td>
<td>0.54</td>
</tr>
</tbody>
</table>

Conclusion: ThermOJS shows moderate correlation with US but weak correlation with PGH and acute phase reactants, suggesting that ThermOJS is non-redundant with symptoms and laboratory assessment. Adding PGH and acute phase reactants to ThermOJS improves all correlations, including correlation with US. These thermographic scores do not require a physical examination, opening an opportunity to facilitate remote consultations in RA patients.

REFERENCES:

Disclosure of Interests: None declared

AB1344 THE ROLE OF ULTRASOUND CRITERIA IN PREDICTING THE OUTCOME OF EARLY UNDIFFERENTIATED ARTHRITIS OF THE SMALL JOINTS OF THE HAND

N. Aleksandrova1, A. Aleksandrov2, N. Nikitina2, V. Aleksandrov1,2, †Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology Named After A.B. Zborovsky», Department of Functional Research Methods, Volgograd, Russian Federation; Volgograd State Medical University, Department of Hospital Therapy, Volgograd, Russian Federation

Background: Arthritis of peripheral joints is among the most frequent manifestations in the onset of rheumatic diseases. Determining its nosological identity and rational therapy at an early stage is a complex clinical problem.

Objectives: To evaluate the possibility of using ultrasound to predict the outcome of early undifferentiated arthritis (EUA).

Methods: Since 2018, patients with a first-time diagnosis of early undifferentiated arthritis were consecutively included into the study. The final group consisted of 102 patients (women, 71.6%; mean age 44.8±17.2 years old) who were prospectively observed at baseline, after 3 months, and after 1 year. Ultrasound examination (ultrasound) of the hand joints was performed according to a standard technique using a 5-12 MHz linear transducer on an Accuvix V10 ultrasound diagnostic system (Samsung Medison, South Korea). Ultrasound was performed twice with the following criteria: 1) synovium thickness, 2) blood flow in synovium by Doppler, 3) presence of hyperechogenic inclusions in synovium, 4) cortical bone contour, 5) signs of tendon inflammation (flexors and extensors of the fingers). Synovium thickness in the hand joints over 3 mm was interpreted as synovial thickening [1]; appearance of blood flow from the contour of the cortical bone of the joint with tree branching — as “pannus”; single loci of blood flow by Doppler — as synovitis [2].

Results: During 12 months of follow-up, 47 patients (46.1%) were diagnosed with early rheumatoid arthritis (based on clinical diagnosis according to 2010 criteria and/or prescription of basal anti-inflammatory drugs); 16 (15.7%) had reactive arthritis associated with urogenital infection; 7 (6.9%) had gouty arthritis; 3 (2.9%) had psoriatic arthritis; 2 (1.9%) had systemic lupus erythematosus; 1 patient (0.9%) was found to have a renal malignancy; 26 (25.3%) had no change in EUA diagnosis. Retrospective analysis of the data showed that initially patients with rheumatoid arthritis (RA) in 46.8% (22/47) were determined to have a tree-like blood flow in the synovium of the joint from the cortical contour of the bone (“pannus”); in patients with reactive arthritis associated with urogenital infection, axial tendon lesions were found most frequently (43.8%; 7/16); in patients with gouty arthritis, changes in the triangular cartilage and hyperechogenic inclusions in the synovium were more common (42.9%; 3/7). During the initial examination of patients with EUA who were subsequently diagnosed with RA, the ultrasound picture of the hand joints in the overwhelming majority of cases (83%; 39/47) was characterized by the presence of extensor tenosynovitis and/or synovial thickening with Doppler blood flow (against the background of symmetrical arthritis of the metacarpophalangeal joints). The sensitivity of detection of this criteria to the development of RA in patients with small joint EUA was 56% with a positive prognostic value of 69%. It has been previously demonstrated that in EUA the presence of subclinical inflammation of the major joints and high titer of antibodies to cyclic citrullinated peptide are strong predictors of RA development [2]. Probably, the combination of clinical and serological tests with the presented ultrasound data of small joints can also increase the accuracy of diagnosis of early RA in patients with EUA.

Conclusion: Detection of subclinical inflammation in the small joints of the hand and synovial thickening with Doppler blood flow in patients with EUA at baseline can help in the stratification of patients at high risk of developing RA.

REFERENCES:

Disclosure of Interests: None declared

AB1345 PREDICTIVE MODEL FOR THE DIAGNOSIS OF PSORIATIC ARTHRITIS IN DERMATOLOGY REFERRALS ACCORDING TO PURE-4 SCALE

N. De la Torre Rubio1, J. Campos Esteban2, M. Pavia Pascual2, M. Machattou2, P. Navarro Palomo1, O. Rusinovich1, M. Fernandez Castro1, H. Godoy1, C. Barbadillo Mateos1, C. Merino Argumánez1, B. Garcia-Magallón1, J. Sanz1, L.
Background: The rate of psoriatic arthritis progression is increased in those patients presenting with established disease greater than 2 years duration, so it is necessary to find tools that allow early diagnosis to prevent joint damage. Prevalence of psoriatic arthritis varies according to the screening strategies used. The COMPAQ study compared four screening questionnaires for psoriatic arthritis (PEST, ToPAS, PASE and EARP), whose sensitivities ranged from 44 to 91%, with the EARP questionnaire showing the highest sensitivity. A new, shorter questionnaire, PURE-4 scale, has been developed with a sensitivity of 85.7%.

Objectives: To evaluate the usefulness of PURE-4 scale in real clinical practice conditions to identify patients with psoriatic arthritis in patients with psoriasis referred from a dermatology department to a rheumatology department.

Methods: Retrospective descriptive study of patients diagnosed with psoriasis who have been referred from the Dermatology Department in the last 12 months for suspected joint domain according to PURE-4 scale used by this department. The following variables were collected: age, sex, obesity, dyslipidaemia, smoking, family history of psoriasis, form of psoriasis (plaque, pustular, scalp, nail), previous treatment (topical, methotrexate, other, none), PASI index, compliance with CAPSAR criteria, rheumatological diagnosis (psoriatic arthritis yes/no), PURE-4 score, morning stiffness in hands, Achilles enthesitis, inflammatory low back pain and need for anti-inflammatory drugs for joint pain in the last 3 months. Descriptive statistics was performed and Chi-square test was used to compare the diagnosis of psoriatic arthritis with PURE-4 values (at the response threshold ≥1 it has a sensitivity of 85.7% and a specificity of 83.8%).

Results: In the last 12 months the Dermatology Department of our hospital made 33 referrals for suspected psoriatic arthritis in patients diagnosed with psoriasis. Mean age was 46.4 ± 12.4 years, 51.5% were men. Fifty-one percent of the patients had a BMI ≥25, 30.3% had dyslipidaemia and 45.5% were smokers; 10% of the patients had family history of psoriasis. The most prevalent form of psoriasis was plaque (18%) followed by nail (6%), palmoplantar (3%), scalp (3%) and droplet (3%) involvement. 51.5% of patients were on topical treatment, 9% on methotrexate and 39.4% on biologic treatments; mean PASI was 6.2 ± 7.5. Seventy-five percent of the referred patients did not meet CAPSAR criteria; 33.3% were diagnosed with psoriatic arthritis by the rheumatologist. Of the 33 patients, 4 (12.1%) scored 0 points on PURE-4 scale; 21 (63.6%) scored 1 point; and 8 (24.3%) scored 2 points. Once assessed by a rheumatologist, 75.5% had no morning stiffness in the hands, 93.9% had no Achilles enthesis and 87.9% had no inflammatory low back pain; only 24.2% of patients had required NSAIDs simultaneously, 37.9% had no inflammatory low back pain and need for anti-inflammatory drugs for joint pain in the last 3 months for joint pain. Finally, the diagnosis of psoriatic arthritis was analyzed against the PURE-4 cut-off point (Table 1).

Table 1. Psoriatic arthritis diagnosis based on total score on PURE-4 scale

<table>
<thead>
<tr>
<th>PURE-4 Score</th>
<th>Chi-squared test</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 1</td>
<td>0.25</td>
<td>0.61</td>
</tr>
<tr>
<td>= 1</td>
<td>0.10</td>
<td>0.74</td>
</tr>
<tr>
<td>≥ 2</td>
<td>0.69</td>
<td>0.41</td>
</tr>
</tbody>
</table>

Conclusion: PURE-4 scale with a score ≥ 1 does not seem to improve the diagnosis of arthritis in psoriatic patients. It would be necessary to implement other questionnaires that are more complete, but at the same time affordable, when carried out during the dermatology consultation in order to increase the sensitivity to refer or not to the rheumatologist.

REFERENCES:

Disclosure of Interests: None declared


AB1346

ULTRASOUND ASSESSMENT OF SUB-CLINICAL HAND JOINT INFLAMMATION: A COMPARATIVE STUDY BETWEEN EARLY RHEUMATOID AND PSORIATIC ARTHRITIS

F. Liu1, Y. Xin1, J. Zhu2, 1Peking University People’s Hospital, Department of Ultrasound, Beijing, China

Background: Ultrasound (US) detected subclinical inflammation can be present in early psoriatic arthritis (PsA) and rheumatoid arthritis (RA), and also in patients fulfilling clinical remission criteria [2-3]. Numerous evidences support that the persistence of subclinical synovitis detected by US is associated with a high risk of disease progression [2-3].

Objectives: To evaluate sub-clinical inflammation of PsA and RA at the level of small joints of the hand and wrist by B-mode and Power Doppler US.

Methods: 30 patients of early PsA and 35 patients of early RA (no clinical evidence of hand joint involvement, PsA disease duration <2 years, and RA disease duration <1 year) were recruited. US (grey scale (GS) and power Doppler (PD)) was performed to assess synovitis, tenosynovitis, joint effusion, and bone erosion of bilateral wrists, metacarpophalangeal joints, proximal and distal interphalangeal joints, as well as the flexor tendons and extensor compartments.

Results: A total of 35 patients were included in the RA group, including 10 males and 25 females. A total of 30 patients were included in the PsA group, including 12 males and 18 females. There were no significant differences in gender composition, age, and duration of disease between the two groups (P>0.05) (Table 1). 19 (63.3%) PsA patients and 16 (45.71%) RA patients had sub-clinical hand joint synovitis. At the joint level, wrist joints were most commonly involved (23.08%), followed by MCP3 (15.38%) and DIP3 (13.46%) in PsA group. In RA group, wrist joints were most commonly involved (55.17%), followed by MCP3 (12.41%), and MCP2 (11.03%). Eight (26.67%) PsA patients and 16 (45.71%) RA patients were detected tenosynovitis. Tenosynovitis was most frequently presented at the extensor tendons in RA and at the flexor tendons in PsA patients (p<0.05). The two most commonly affected were the 4th and 1st extensor compartments in RA patients, and the flexor pollicis longus and flexor digitorum profundus in PsA patients. 61 (6.80%) joint reeses in the RA and 75 (7.35%) joint reeses in PsA were detected effusion. Joint effusion was most frequently detected at radiocarpal and midcarpal joints in RA (30.86%, 25.92%, respectively). Effusion in PsA was most commonly presented at the 3rd PIP joints (26.67%), followed by radiocarpal joints (24.00%). Bone erosions were uncommon, totally 2 (6.67%) PsA patients and 3 (8.57%) RA patients were detected bone erosions.

Table 1. Demographic characteristics of RA and PsA patients

<table>
<thead>
<tr>
<th>RA (n=35)</th>
<th>PsA (n=30)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, n(%)</td>
<td>25 (71.43%)</td>
<td>18 (60.00%)</td>
</tr>
<tr>
<td>Age, years, means±SD</td>
<td>53.20±14.50</td>
<td>54.23±13.65</td>
</tr>
<tr>
<td>Disease duration, years, means±SD</td>
<td>0.72±0.03</td>
<td>0.91±0.53</td>
</tr>
</tbody>
</table>

Conclusion: There are significant differences in the US findings of sub-clinical inflammation at the hand and wrist joints, such as the joint effusion and tenosynovitis, which may assist the identification between early RA and PsA. Simultaneously, it should be pointed out that there are some similarities in the joint involvement of sub-clinical synovitis between RA and PsA, physicians should take this into account in clinical work.

REFERENCES:

Acknowledgements: This work was supported by National Natural Science Foundation of China (No. 82071930).

Disclosure of Interests: None declared

AB1347
ASYMPTOMATIC SACROILIITIS DETECTED BY MAGNETIC RESONANCE ENTEROGRAPHY IN PATIENTS AFFECTED BY CROHN’S DISEASE: PREVALENCE AND ASSOCIATION WITH CLINICAL DATA IN A MULTICENTER STUDY OF ADULT AND ABDOMINAL POPULATION

I. Giovannini1, L. Cererè2, I. Tinazzi3, C. Ciccio4, F. M. Murrù5, M. Bramuzzo6, M. Marino6, A. Tulio6, S. De Vita1, A. Zabotti1. 1Rheumatology Clinic, University Hospital “S. Maria della Misericordia” c/o University of Udine, Udine, Italy; 2Institute of Radiology, University Hospital “S. Maria della Misericordia” c/o University of Udine, Udine, Italy; 3Department of Rheumatology and Immunology, I.R.C.C.S Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy; 4Department of Diagnostic Imaging and Interventional Radiology, I.R.C.C.S Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy; 5Pediatric Radiology, IRCSS “Burlo Garofolo”; Trieste, Italy; 6Gastroenterology, Digestive Endoscopy, and Nutrition Unit Institute for Maternal and Child Health, IRCSS “Burlo Garofolo”; Trieste, Italy; 7Department of Gastroenterology, University Hospital “S. Maria della Misericordia” c/o University of Udine, Udine, Italy; 8Institute of Hygiene and Clinical Epidemiology University Hospital “S. Maria della Misericordia” c/o University of Udine, Udine, Italy

Background: Magnetic resonance enterography (MRE) is usually performed in patients with Crohn’s disease (CD) for evaluating small bowel involvement. Inflammatory bowel disease (IBD) mainly affect the gastrointestinal tract, although patients may present extraintestinal manifestations (1). Musculoskeletal symptoms are the most frequent extraintestinal manifestation in IBD, especially in CD. Furthermore, sacroiliitis at imaging occurs in about 6-46% of CD patients and may correlate with axial spondyloarthritis (2,3).

Objectives: The primary aim of our study was to assess the prevalence of sacroiliitis in adult and pediatric patients affected by CD who performed MRE. We also evaluated the inter-rater agreement for MRE sacroiliitis and the association between sacroiliitis and patients’ clinical data.

Methods: We included consecutive patients with CD diagnosis (4), who underwent an MRE in the period between December 2012 and May 2020. We excluded patients with a known diagnosis of SpA, patients with confirmed or suspected inflammatory back pain; and patients treated at the time of MRE with systemic Disease-Modifying Antirheumatic Drugs (DMARDs), which influence both bowel and joint disease (i.e., conventional DMARDs, and biologic DMARDs).

Two radiologists assessed the prevalence of sacroiliitis at MRE. We evaluated the inter-rater agreement for sacroiliitis and assessed the correlation between sacroiliitis and demographic, clinical, and endoscopic data.

Results: We retrospectively identified 100 adult and 30 pediatric patients. The prevalence of sacroiliitis at MRE was 20% in adults and 6.7% in pediatric patients. The inter-rater agreement for sacroiliitis was substantial (k=0.62, p<0.001) in the adults, and moderate (k=0.46, p=0.011) in the pediatric cohort. Age ≥50 years and the time between CD diagnosis and MRE (≥86.5 months) were significantly associated with sacroiliitis in adult patients (p=0.038, respectively). The presence of sacroiliitis in pediatric patients affected by CD may help the appropriate and early referral to the rheumatologist.

REFERENCES:
[2] Salvarani C, Fries W. Clinical features and epidemiology of spondyloarthritis in adult patients with CD, associated with age of the patients ≥ 50 years and the time between CD diagnosis and MRE (≥86.5 months) were significantly associated with sacroiliitis in adult patients (p=0.049 and p=0.038, respectively). Asymptomatic sacroiliitis at MRE is a frequent and reliable abnormality in adult patients with CD, associated with the age of the patients ≥ 50 years and CD duration. Detecting sacroiliitis at MRE in patients affected by CD may help the appropriate and early referral to the rheumatologist.

Conclusion: Asymptomatic sacroiliitis at MRE is a frequent and reliable abnormality in adult patients with CD, associated with the age of the patients ≥ 50 years and CD duration. Detection of sacroiliitis at MRE in patients affected by CD may help the appropriate and early referral to the rheumatologist.

AB1348
COMPARISON OF SACROILIAC CT FINDINGS IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: RESULTS OF THE CASIPSA STUDY.

O. Fehily1, A. Ramòn2, C. Prati3, P. Ornetti2, D. Wendling1,4, F. Verhoeven1,5, 1CHU de Besançon, Rheumatology, Besançon, France; 2CHU de Dijon, Rheumatology, Dijon, France; 3UFR Santé, Université de Franche-Comté, EA 4267 ‘PEPITE’, Besançon, France; 4UFR Santé, Université de Franche-Comté, EA 4266 ‘EPILAB’, Besançon, France

Background: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with various rheumatological manifestations, such as arthritis or enthesitis, predominately in the peripheral skeleton. However, the axial skeleton may be affected, as shown clinically or by conventional radiographs in up to 70% of patients with peripheral involvement. While there are studies comparing joint damage on standard radiography between patients with PsA and patients with anklyosing spondylitis [1], to our knowledge, no study has specifically evaluated the extent of structural lesions of the sacroiliac joints (SIJs) on computed tomography (CT) in patients with PsA compared with healthy controls.

Objectives: To describe SI CT characteristics in patients with PsA and compare them with those of age- and sex-matched controls.

Methods: An observational, retrospective study was performed using medical records from Besançon and Dijon University Hospital's rheumatology departments, which were screened to identify patients with PsA, according to the CASPAS criteria. A search was then carried out for patients in the hospitals’ imaging archiving system to identify those who had undergone a CT which included the SIJs in their entirety. Non-inclusion criteria were the presence of pelvic bone lesions and a history of pelvic radiotherapy. Each patient was then matched with a control of the same age and sex, recruited through the hospital's imaging archiving system. For each individual, CT was interpreted by two independent readers using a score previously used by Diekhoff et al. [2], dividing each SIJ into 12 regions, for each of which joint space narrowing (JSN), erosions, and sclerosis are assessed. For this study, we also observed the existence of intra-articular gas and diffuse idiopathic skeletal hyperostosis (DISH) lesions for each region. Quantitative variables were compared using Student’s t-test. Qualitative variables were compared using the Chi-2 test.

Results: 48 patients and 48 controls were included. Mean (SD) age was 54.76 ± 12.91 in the PsA group and 54.74 ± 12.87 in the control group. 26 (54.18%) were male in both groups. In PsA patients, mean (SD) disease duration was 22.87 ± 14.95 years, 10 (43.48 %) were HLA-B27 positive, and 1 (2.86%) had a bamboo spine. CT findings are described in Table 1. The only lesion found significantly more frequently in PsA patients was erosion, which appeared to be preferentially located on the anterior and middle regions of the SIJs (Figure 1). A positive CT scan (significant joint space narrowing, erosion and/or sclerosis) was found in 15 (32.61%) of the patients with peripheral involvement and 6 (30.00%) of the patients with axial involvement.

Table 1. Sacro-iliac CT findings using a score modified from Diekhoff et al.

<table>
<thead>
<tr>
<th>Finding</th>
<th>PsA Patients</th>
<th>Controls</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) total score (range 0-264)</td>
<td>26.37 ± 29.12</td>
<td>14.47 ± 10.85</td>
<td>0.01</td>
</tr>
<tr>
<td>Bilateral positivity, n (%)</td>
<td>16 (33.33 %)</td>
<td>10 (20.83 %)</td>
<td>0.17</td>
</tr>
<tr>
<td>Bilateral ankylosis, n (%)</td>
<td>5 (10.42 %)</td>
<td>0 (0.00 %)</td>
<td>0.02</td>
</tr>
<tr>
<td>Positive joint space score, n (%)</td>
<td>15 (31.25 %)</td>
<td>10 (20.83 %)</td>
<td>0.25</td>
</tr>
<tr>
<td>Positive erosion score, n (%)</td>
<td>9 (18.75 %)</td>
<td>1 (2.08 %)</td>
<td>0.008</td>
</tr>
<tr>
<td>Significant sclerosis, n (%)</td>
<td>11 (22.92 %)</td>
<td>12 (25.00 %)</td>
<td>0.81</td>
</tr>
<tr>
<td>Intra-articular gas, n (%)</td>
<td>29 (60.42 %)</td>
<td>35 (72.92 %)</td>
<td>0.19</td>
</tr>
<tr>
<td>DISH, n (%)</td>
<td>9 (18.75 %)</td>
<td>11 (22.92 %)</td>
<td>0.62</td>
</tr>
</tbody>
</table>

Figure 1. Mean scores by region on anterior, middle, and posterior slices (JS: joint space, Ero: erosions, Scl: sclerosis) in PsA patients (A) and controls (B).
Conclusion: The CT characteristics of SJJs from patients with PsA were similar to those of age- and sex-matched controls, but with a higher prevalence of erosions. Structural lesions of the SJJs were found in nearly one PsA patient out of three.

REFERENCES:


Disclosure of Interests: None declared


AB1349
CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS

N. Aleksandrova1, A. Aleksandrova2, N. Nikitina1, V. Aleksandrova1,2, Federal State Budgetary Institution «Research Institute of Clinical and Experimental Rheumatology Named After A.B. Zborovsky», Department of Functional Research Methods, Volgograd, Russian Federation; Volgograd State Medical University; Department of Hospital Therapy, Volgograd, Russian Federation

Background: Clinical and experimental data confirm the role of both systemic and local (inflammation in potentiating atherosclerosis and increasing cardiovascular risk in patients with rheumatoid arthritis (RA)) against the background of severe immunological disorders.

Objectives: To study the severity of ultrasound signs of atherosclerotic lesions of brachiocephalic arteries and heart valve apparatus in patients with rheumatoid arthritis (RA).

Methods: 57 patients with RA (50 women and 7 men; mean age 50.4 ± 10.12 years old; mean duration of disease 9.2 ± 6.8 years; DAS28 activity: low - 3.5%, medium - 86%, high - 10.5%) were examined. Laboratory examination included determination of serum IgG-RF, CRP, antibodies to cyclic citrullinated peptide (ACCP), antibodies to modified citrullinated vimentin (MCV), total antinuclear antibodies (ANA), and levels of proinflammatory cytokines (IL-1, IL-6, TNF-α, angiopeptin-like proteins types 2, 3, and 4 - ANGPTL 2, 3, 4) by enzyme immunoassay. Cardiac ultrasound examination was performed according to the traditional technique on an Accuvix V10 ultrasound diagnostic system (Samsung Medison, South Korea) equipped with a multifrequency microconvex transducer with a frequency of 2-4 MHz. All patients underwent duplex scanning of brachiocephalic arteries (BCA) with assessment of the severity of atherosclerotic changes (AO - absence of BCA atherosclerosis, AI - isolated thickening of intima-media complex; BCA atherosclerosis, All - presence of atherosclerotic plaques and artery stenosis as manifestation of stenotic BCA atherosclerosis). The following gradation was used to estimate the degree of cardiac valve calcification: 0 - no calcification, 1st degree - unexpressed calcification, 2nd degree - moderate calcification, 3rd degree - expressed calcification of cardiac valves.

Results: Signs of cardiovascular system lesions (pericarditis, heart valve lesions, cardiomyopathies, cardiac conduction pathway lesions, myocarditis, endocarditis, coronary arteritis etc.) were diagnosed in 28 (49.1%) RA patients. Heart valve dysfunction was manifested by mitral valve (MV) and/or aortic valve (AV) insufficiency in the majority of cases. In RA patients, ultrasonic signs of cardiac valve calcification occurred in 40.4% (23/57) of cases; there was a high prevalence of aortic valve calcification of varying severity (19/23, 82.6%) and less detectable mitral valve calcification (12/23; 52.17%); patients with grade II-II cardiac valve calcification predominated (16/23; 69.6%); 5 patients (21.7%) had combined AV and MV lesions. In 25 (43.8%) patients with RA the signs of atherosclerosis of brachiocephalic arteries were determined: in 19 (33.3%) - non-stenotic (AI), in 6 (10.5%) - stenotic atherosclerosis (All). No statistically significant correlations were found between changes of cardiac valve apparatus, BCA lesions and main clinical characteristics of RA (disease activity, erosions, RF and ACCP positivity). Increased levels of ANGPTL2 (γ 2=4.6, p=0.032) were observed in the group of RA patients with cardiac valve lesions, and ANA (γ 2=3.91, p=0.049) and elevated IL-6 (γ 2=4.28, p=0.039) were detected more frequently in patients with signs of atherosclerotic lesions of BCA. The presence of autoimmune chronic inflammatory process is an independent sign of premature atherosclerosis development and causes the highest risk of atherosclerotic lesion of BCA and accelerates the processes of cardiac valve calcification in RA patients.

Conclusion: Regular echocardiography (with duplex scanning of BCA and heart valve examination) in RA patients can contribute to earlier identification of groups of patients possible requiring changes in therapeutic approaches to treatment and prevention of vascular accidents.

Disclosure of Interests: None declared


AB1350
CAN DIFFUSION-WEIGHTED MRI REPLACE INTRAVENOUS GADOLINIUM CONTRAST-ENHANCED MRI FOR ASSESSMENT OF SYNOVITIS?

J. Mollenbach Møller1, K. L. Gandrup2, M. Østergaard2, D. Gniatiti3, O. Madsen4, K. Herslev-Petersen4, S. Møller-Bisgaard5, Copenhagen University Hospital Herlev - Gentofte, Radiology, Herlev, Denmark; 2University Hospital of Copenhagen, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup, Denmark; 3Skaraborg Hospital, Department of Rheumatology, Skövde, Denmark; 4University Hospital of Copenhagen, Rigshospitalet, Gentofte, 5Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark; 5Faculty of Regional Health Research, Odense, Denmark; 6University Hospital of Copenhagen, Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Gentofte, Denmark

Background: In clinical trials of rheumatoid arthritis (RA) patients, intravenous gadolinium contrast injection is the gold standard method for MRI assessment of synovitis, e.g. by the OMERACT RA MRI Scoring method (RAMRIS). It has been shown that diffusion-weighted MRI (DW-MRI) allows visualization of synovitis.

Objectives: To establish a method for measuring MRI-derived apparent diffusion coefficient (ADC) from DW-MRI and to test its correlation with RAMRIS synovitis scoring.

Methods: MRI including diffusion-weighting of the dominant hand was performed in a cohort of RA patients in clinical remission (disease activity score in 28 joints-C-reactive protein [DAS28-CRP] ≤3.2 and no swollen joints). ADC measurements of the synovitis were assessed in 7 areas (3 wrist joint areas and 4 metacarpophalangeal (MCP) joint areas), similar to the RAMRIS. Intra-observer agreement for the ADC reading was determined using the intraclass correlation coefficient (ICC). Spearman’s ρ (ϕ) was calculated for the correlation of ADC with RAMRIS Synovitis. Differences in mean ADC between the individual RAMRIS synovitis grades were examined using ANOVA with Bonferroni correction for multiple tests.

Results: In 63 patients (67% females, age mean 61.0 years (range 36-78 years), disease duration 11.9 years, 0-59 years), DAS28-CRP 2.1 (1.6-3.0) the total RAMRIS synovitis was mean 5.8 (range 0-18). The mean ADC was 0.98x10-3 mm2/s (0.11-2.80). Correlations between RAMRIS synovitis and ADC in the 7 joint areas and mean differences in ADC between RAMRIS synovitis grades are presented in the Table 1. When all 7 joints were pooled the mean ADC and RAMRIS synovitis were moderately positively correlated, ρ=0.49; p<0.01. Statistically significant differences (p<0.01) in mean ADC were observed between all RAMRIS synovitis grades (0 vs 1, 0 vs 2, etc) except for the difference between grade 2 and 3. Good intra-observer (ICC = 0.62 (95%CI 0.49-0.72)) was found.

Conclusion: ADC, determined from DW-MRI, may be used to grade synovitis without the use of gadolinium contrast injection.

REFERENCES:
Background: During pregnancy profound physiologic changes are required to ensure fetal development and meet maternal needs. Microvascular remodelling is one major responsible for pregnancy haemodynamic adaptation, still it is not routinely evaluated in the obstetric field [1–2].

Objectives: To investigate the role of nailfold capillaroscopy (NVC) as a gold-standard and safe technique in detecting microvascular changes during normal pregnancy and to explore its possible application in clinical obstetric setting.

Methods: A population of 30 healthy pregnant women was longitudinally followed performing clinical assessment and NVC evaluation at each trimester and post-partum. Thirty non-pregnant age-matched healthy women having received at least two NVCs with a minimum 9 to 12-month interval were selected as controls. All NVC images were evaluated by a qualitative and semi-quantitative assessment using current standardised approach [3]. Statistical analyses were conducted to explore NVC parameters trend throughout gestation and its possible association with pregnancy course and clinical microvascular parameters (i.e., systemic blood pressure, umbilical artery Doppler ultrasound).

Results: A progressive significant increase of capillary neoangiogenesis and a specular reduction in capillary dilations was observed during pregnancy (p<0.05). These statistically significant variations were not found in age-matched controls, who showed stable NVC parameters over a similar time frame (p>0.05). All NVC images were evaluated by a qualitative and semi-quantitative assessment using current standardised approach [3]. Statistical analyses were conducted to explore NVC parameters trend throughout gestation and its possible association with pregnancy course and clinical microvascular parameters.

Conclusion: This is the first study that demonstrates a mechanism for validation of ultrasonography skills which will allow GCA US to become a feasible reality in clinical practice. This project demonstrates that after acquiring supervised training, near perfect levels of agreement can be achieved between a trainee and expert.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2508

Table 1. Matrix of inter-observer variation for all vascular territories in 12 patients, k=0.90 (95% CI 0.83 – 0.98)

| VESSEL AFFECTION AND THE INFLUENCE OF GLUCOCORTICOIDS ON 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN GIANT CELL ARTERITIS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FC positive | FC negative | Total |
| CM positive | 48 | 4 | 50 |
| CM negative | 2 | 90 | 92 |
| Total | 50 | 94 |

Conclusion: This study demonstrates a potential mechanism for validation against an expert sonographer.
the imaging of the thoracic aorta should be included in the diagnostic procedure of GCA. 18F-FDG PET/CT should be performed without glucocorticoid treatment, if the clinical situation allowed this proceeding.

Disclosure of Interests: Leander Malich: None declared, Falk Günhe: None declared, Tobias Hoffmann: None declared, Ansgar Malich: None declared, Peter Oelzer: None declared, Gunter Wolf: None declared, Martin Freesmeyer: None declared, Alexander Pfeil Grant/research support from: This study is a part of the Investigator Initiated study Retrospective analysis of clinical and imaging parameters to predict flare in patients with giant cell arteritis; which is supported by Chugai Pharma Germany GmbH, Lyoner Straße 15, 60528 Frankfurt am Main.


AB1354 ULTRASOUND JOINT EXAMINATION BY AN AUTOMATED SYSTEM VERSUS BY A RHEUMATOLOGIST – FROM A PATIENT PERSPECTIVE

B. A. Frederiksen1, M. Schousboe2, L. Teslev3, I. N. Iversen3, H. M. Lindegaard3, T. R. Savarimuthu5, S. A. Just1. 1Svendborg Hospital - Odense University Hospital, Department of Medicine, Section of Rheumatology, Svendborg, Denmark; 2The Maersk Mc-Kinney Moller Institute, University of Southern Denmark, Odense, Denmark; 3Highschool Glosstrup, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Glosstrup, Denmark; 4Copenhagen University, Department of Clinical Medicine, Faculty of Health and Medical Sciences, København, Denmark; 5ROPCA, ROPCA Holding, Odense, Denmark; 6Odense University Hospital, Department of Rheumatology, Odense, Denmark

Background: The Arthritis Ultrasound Robot (ARTHUR) is an automated system for ultrasound scanning of the joints of both hands and wrists, with subsequent disease activity scoring using artificial intelligence.

Objectives: To describe the patients’ perspective of being examined by ARTHUR, compared to an ultrasound examination by a rheumatologist. Further, to register any safety issues in the use of ARTHUR.

Methods: Twenty-five patients with rheumatoid arthritis (RA) had both hands and wrists examined by ultrasound, first by a rheumatologist subsequently by ARTHUR (see Figure 1 A, B and C). Patient-reported outcomes (PRO) were obtained after the examination by the rheumatologist and then again after the examination by ARTHUR. PROs regarding pain, discomfort and overall experience were collected. In addition, willingness to be scanned again by ARTHUR as part of future clinical follow-up was also collected. All ARTHUR examinations were observed for safety issues.

Results: For baseline characteristics of RA patients, see Table 1.

There was no difference in pain or discomfort between the examination by a rheumatologist and by ARTHUR (p=0.29 and p=0.20, respectively). The overall experience of an examination by ARTHUR (see Figure 1 D) was described as very good or good by 92% (n=23), with no difference compared to the examination by the rheumatologist (p=0.50). All (n=25) patients were willing to be examined by ARTHUR again, and 92% (n=23) would accept ARTHUR as a regular part of their RA clinical follow up. No safety issues were registered.

Discussion: Conclusion: Joint ultrasound examination by ARTHUR was safe and well-received, with no difference in PRO components compared to ultrasound examination by a rheumatologist. Fully automated systems for joint disease activity assessment could be important in future strategies for RA management.

Disclosure of Interests: Bill Aplin Frederiksen: None declared, Maja Schousboe: None declared, Lene Teslev: None declared, Nicolaj Iversen: None declared, Hanne Merete Lindegaard: None declared, Thuisius Rajaeeh Savarimuthu Shareholder of: Co-founder of the robotics company ROPCA, developing ARTHUR., Søren Andreas Just Shareholder of: Co-founder of the robotics company ROPCA, developing ARTHUR.


Figure 1. A. The rheumatologist is performing the ultrasound examination. B. The ARTHUR system used in this trial used a GE Logiq 10 ultrasound scanner. C. ARTHUR started ultrasound scanning a RA patient. The patient follows the instructions given on the touchscreen and by audio. D. Overall experience with ultrasound scanning by Rheumatologist and ARTHUR.

Results: For baseline characteristics of RA patients, see Table 1.

Table 1. Baseline Characteristics. CRP: C-reactive protein; DAS28CRP: Disease Activity Score in 28 joints combined with CRP value, RF: Rheumatoid factor antibody, CCP: cyclic citrullinated peptide antibodies.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients, n</td>
<td>25</td>
</tr>
<tr>
<td>Age (SD)</td>
<td>63.7 (12.22)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>17 (68 %)</td>
</tr>
<tr>
<td>Erosive disease, n (%)</td>
<td>10 (40 %)</td>
</tr>
<tr>
<td>RF and/or CCP-positive, n (%)</td>
<td>17 (68 %)</td>
</tr>
<tr>
<td>DAS28CRP (SD)</td>
<td>2.8 (1.2)</td>
</tr>
</tbody>
</table>

AB1355 NAILFOLD CAPILLAROSCOPY CHANGES IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

E. Molteni1, G. Pellegrino1, C. Castellani1, D. M. Reza Beigi1, F. Conti1, R. Sciro1, V. Ricciieri1, Sapienza University of Rome, Internal Medicine, Anesthesiological and Cardiovascular Sciences, Rome, Italy

Background: In psoriatic arthritis (PsA) and rheumatoid arthritis (RA) systemic inflammation is known to cause endothelial dysfunction 11. Nailfold videocapillaroscopy (NVC) analyzes in vivo blood vessels, looking for alterations due to microvascular damage, and its application in these pathologies often highlights interesting abnormalities. PsA is characterized by lower mean capillary length and density and abnormal morphology, such as tight terminal convolutions. In RA typically elongated and dilated capillaries and prominent subpapillary plexus are described 2 – 6. Differences between RA and PsA NVC patterns are known but not well defined yet 7 – 10.

Objectives: Aim of our study was to evaluate the microvascular features circulation by NVC in patients affected by PsA and RA, looking for possible differences that may characterize the two diseases.

Methods: We recruited outpatients affected by PsA or RA classified according to standard criteria 11 – 13 referring to the Rheumatology Unit at Sapienza University of Rome. Healthy controls (HCS) without known risk factors for nailfold capillary alterations 14 – 16 were also recruited. Patients and HCs underwent NVC with a 200x magnification lens. The following morphological parameters were considered: number of capillaries per square millimeter, alterations in length, dimension, morphology and distribution of the capillary; presence of ectatic loops, hemorrhages, flux abnormalities 7 – 8. A semi-quantitative rating scale was adopted to score these changes, according to previous studies 17. The mean score for each subject was obtained by analyzing all fingers, except the thumbs. For the statistical analysis, Chi-square and Mann-Whitney tests were used. All tests were two-sided with a significance level set at p<0.05.

Results: We recruited 34 patients (20 with PsA and 14 with RA) and 30 HCs. For patients, the mean age was 61.7 years (SD 15.4), median disease duration was 184 months (SD 204) and males were 18 (53%). Active or past smokers were 11 (18%), 9 (15%) suffered from arterial hypertension and 2 (0.9%) from type 2 diabetes mellitus. Raynaud’s phenomenon was present in 4 patients with PsA (20%) and 6 with RA (43%). The most frequent morphological changes were tortuous capillaries (80% in PsA and 100% in RA), single-crossing shape (80% and 86%) and bizarre capillaries (30% in both groups) while multiple crossing and ramified capillaries were present in 50% and 21 % RA patients only. With respect to HCs, we found significantly more frequent changes concerning morphology, ectatic loops, presence of hemorrhages and capillary plexus visibility in both PsA and RA patients. Moreover, patients with RA showed significantly more frequent abnormalities of the blood flow with respect to HCs. These results are shown in Table 1.

Table 1. Comparison of the main NVC changes in patients and HCs.

<table>
<thead>
<tr>
<th>NVC Changes</th>
<th>HC</th>
<th>PsA</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphology</td>
<td>3 (10%)</td>
<td>14 (70%)</td>
<td>12 (86%)</td>
</tr>
<tr>
<td>Ectatic loops</td>
<td>0 (0%)</td>
<td>11 (55%)</td>
<td>8 (57%)</td>
</tr>
<tr>
<td>Hemorrhages</td>
<td>0 (0%)</td>
<td>1 (5%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Plexus</td>
<td>19 (63%)</td>
<td>10 (50%)</td>
<td>7 (50%)</td>
</tr>
<tr>
<td>Flux abnormalities</td>
<td>3 (10%)</td>
<td>6 (30%)</td>
<td>5 (38%)</td>
</tr>
</tbody>
</table>

The presence of hemorrhages was significantly higher in RA rather than in PsA patients (p<0.01). No significant differences were found in number, length, and distribution of capillaries between PsA/RA cases and HCs.


Conclusion: Our study confirms and completes the frame of NCV alterations in PsA and RA. We described for the first time alterations in the capillary morphology and the presence of hemorrhages in both groups of patients with respect to HCs. It remains to evaluate how these findings can reflect the microvascular environment of chronic arthritis.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3097

AB1356 QUANTITATIVE ANALYSIS BY SODIUM AND PROTON BASED 3-TELSA MR IMAGING OF THE ACHILLES TENDON
A. Müller-Lutz1, B. Kampf1, L. Klein-Schmeink1, S. Tsiami2, M. Frenken2, A. Nagel2, X. Baraliakos2, P. Sewerin3,4,5,6, Uniklinik Düsseldorf, Department for Radiology, Düsseldorf, Germany; 1University Hospital Ruhr-University Bochum, Rheumazentrum Ruhrgebiet Herne, Herne, Germany; 2University Hospital Erlangen, Institute of Radiology, Erlangen, Germany; 6University of Oxford, Oxford, England. 2014;54.

Background: Decrease of proteoglycan is the initiating stage of post-inflammatory tissue degradation. Sodium MRI is promising great potential for identification and monitoring of proteoglycan changes in tendons and cartilage associated with inflammatory and degenerative musculoskeletal diseases, where the Achilles tendon is frequently affected.

Objectives: Aims of the study were to quantify sodium concentrations in the Achilles tendon in healthy volunteers.

Methods: Sodium (23Na) MRI imaging of the Achilles tendon together with established proton (1H) MRI sequences were performed in 10 healthy volunteers (6 males, 4 females, age 29 ± 9 years) using a dual-tuned 23Na/1H surface coil (RAPID out). Significantly higher sodium concentrations were obtained in INS compared to MID (p=0.002) and in MTJ compared to MID (p=0.037). The average sodium concentrations of the whole Achilles tendon was 57.23±17.69 mM with only minor outliers in this healthy population.

Results: Significant sodium concentration differences were observed between the INS, MID and MTJ. The highest sodium concentration was observed at the tendon insertion into calcaneus bone (INS), whereas lower concentrations were measured in the middle portion of the tendon (MID) and muscle-tendon junction (MTJ).

Conclusion: Performance of quantitative sodium imaging of the Achilles tendon in a high-field MR machine is feasible for assessing sodium concentrations, a surrogate biomarker for proteoglycan content. Molecular MR studies investigating changes in the proteoglycan content of the Achilles tendon in patients with inflammatory and degenerative musculoskeletal diseases could support early diagnosis or therapy monitoring in the future.

REFERENCES:

Disclosure of Interests: None declared

AB1357 THE BEST CUT-OFF POINT FOR MEDIAN NERVE CROSS SECTIONAL AREA AT THE LEVEL OF PISIFORM BONE
A. Carones Esteves1, P. Freitas2, L. Brites3, T. Santiago1, M. Santiago1, J. Rovisco1, J. A. P. Da Silva1, Centro Hospitalar e Universitário de Coimbra, Serviço de Reumatologia, Coimbra, Portugal; 2Hospital CUF Coimbra, Reumatologia, Coimbra, Portugal; 3Hospital Santo André - Hospital Distrital de Leiria, Serviço de Reumatologia, Leiria, Portugal

Background: Carpal tunnel syndrome (CTS) is a focal neuropathy caused by compression of the median nerve (MN) at the wrist. Electromyography (EMG) is the gold standard for the diagnosis of CTS. Currently, the ultrasound (US) is frequently used as an initial screening exam by measuring the cross-sectional area (CSA) of the MN. The cut-off point of the CSA at the pisiform bone level to define CTS remains controversial with previous studies reporting values between 6.5mm² and 15mm² (1).

Objectives: The aim of this study is to determine the best cut-off point of the CSA for the diagnosis of CTS.

Methods: Cross-sectional study at a Tertiary Rheumatology Department including patients aged ≥ 18 years with symptoms compatible with CTS. Sociodemographic and clinical data, visual analogue scale for pain (VAS), Boston Questionnaire (BQ), and the results of EMG and US performed in each patient were collected. The EMG was performed according to the standardized protocol (sensory conduction velocity, sensory amplitude, distal sensory and motor latency), and the patients were categorized in 4 groups: normal, mild, moderate, and severe. A rheumatologist with expertise in imaging performed all the US evaluations by means of a 6–18-MHz (Siemens ACUSON S 2000) linear array transducer. The largest CSA of the MN was measured at the level of the pisiform bone. Receiver operating characteristic (ROC) curve was used to determine optimal cut-off values of the CSA taking the EMG result as the gold-standard. One-way ANOVA test was used to compare CSA between the 4 EMG groups.

Results: Fifty patients were included, 90% were female, mean age was 52.1 ± 10.8 years and median duration of symptoms was 28.0 (IQR 23.0-31.0) months. The mean VAS was 4.2 ± 2.9. In the BQ there was a mean symptom severity score of 2.4 ± 0.6 and a mean functional status score of 2.0 ± 0.9. One-way ANOVA showed that mean CSA values were significantly different in the 4 groups of patients. The Ryan-Einot-Gabriel-Welsch post hoc analysis showed that only the mean CSA of patients with severe STC is different from the remaining groups defined by EMG results. The best cut-off point for CSA at the pisiform bone for the diagnosis of CTS was 6.6mm² with a specificity of 72.7% (AUC=0.8, P<0.001). The positive and negative predictive values were 95.1% and 66.7%, respectively. For severe CTS diagnosis the best cut-off point for CSA was 12.3mm² with a sensitivity of 82.4% and a specificity of 72.7% (AUC=0.8, P<0.001). The positive and negative predictive values were 60.9% and 88.9%, respectively.

Conclusion: In our study we found that the best cut-off point of the CSA was 6.6mm² for distinguishing patients with/without CTS based on EMG alterations, with a high sensitivity and moderate specificity. This is a lower cut-off value than usually used in clinical practice and could be explained by small sample and the greater number of patients with mild and moderate STC on EMG.

REFERENCES:

Disclosure of Interests: None declared

Figure 1. Sodium concentrations of the Achilles tendon. Highest sodium concentrations c(mM) were observed at the tendon insertion into calcaneus bone (INS), whereas lower concentrations were measured in the middle portion of the tendon (MID) and muscle-tendon junction (MTJ).
AB1358

AN OLD METHOD FOR CURRENT CHALLENGES: SKIN TEST CONVERSION OF PURIFIED PROTEIN DERIVATIVE (PPD) IN RHEUMATOLOGICAL PATIENTS TREATED WITH ANTI-TNF-α

B. Abdalı1,2, A. Ringer1, J. Ruffino1, F. Martinez1, M. C. Argento1, S. Chulibert1, G. Ayan1, A. Sadic2, L. Kılıç1, U. Kalyoncu1, B. Abdala1,2, A. Co2, M. Abdalı1, Rheumatology Unit, Hospital Provincial del Centenario, Rosario, Rosario, Argentina;2Internal Medicine Unit, Hospital Provincial de Rosario, Rosario, Rosario, Argentina;1Internal Medicine Unit, Hospital Provincial del Centenario, Rosario, Rosario, Argentina

Background: Anti-TNF-α are a cornerstone for the treatment of multiple rheumatic diseases. They are associated with an increased risk of developing tuberculosis (TB), which is endemic in several countries and an important burden across the globe. Purified protein derivative (PPD) is one of the tests used to demonstrate a latent TB infection (LTBI). Screening is recommended for TB prior to the onset of anti-TNF-α and monitoring evaluating possible conversion of PPD during treatment, defined as the change from a negative (<5 mm) to positive result (≥5 mm). Identification and treatment of LTBI can reduce the risk of disease development by up to 90%. Currently the results of PPD conversion and its interpretation during anti-TNF-α treatment are variable and that is why we set out to know the frequency of conversion of PPD in this group of patients in our environment.

Objectives: To identify PPD conversion in patients with rheumatological diseases undergoing anti-TNF-α treatment.

Methods: A descriptive, analytical, observational, retrospective study was conducted from January 1, 2018 to January 1, 2022. Inclusion criteria: Patients >18 years old, diagnosed with rheumatological diseases and treated with anti-TNF-α for more than 3 consecutive months, with a negative PPD (<5 mm diameter) previous starting anti-TNF-α and a normal chest X-ray.

Results: 62 patients (age 45.8 ± 12.5 years), with rheumatological diseases (41 rheumatoid arthritis, 7 juvenile idiopathic arthritis, 5 ankylosing spondylitis, 4 psoriatic arthritis, 4 uveitis and 1 interstitial keratitis) under anti-TNF-α therapy (35 adalimumab, 18 certolizumab, 9 etanercept) were included. Concomitant use of immunomodulators (52 methotrexate, 23 leflunomide, 10 hidroxicloroquine, 3 sulfasalazine, 2 azathioprine and 1 mycophenolate mofetil) and glucocorticoids (33/62) was observed. The conversion of PPD took place in 4 patients (6.5%) (Table 1).

Conclusion: Considering the prevalence of TB in our country, this research showed a lower PPD conversion percentage compared to previous reports. Anti-TNF-α have radically changed the evolution of rheumatological diseases, considerably improving patient’s quality of life. With the increase in the accessibility of anti-TNF-α worldwide, new challenges have arisen regarding infectious diseases such as TB, which is endemic in some countries. PPD is a well-known, cheap, sensitive and widely available method, suitable for LTBI diagnosis. Although sensitivity could be increased in using, in addition, other LTBI detection methods such as IGRA (interferon gamma release assays), they are usually unavailable in developing countries (1,3).

REFERENCES:

Disclosure of Interests: None declared


AB1359

DO LATERAL AND AP RADIOGRAPHS TELL DIFFERENT STORY IN PATIENTS WITH PSORIATIC ARTHRITIS?

G. Avani1, A. Sadic1, L. Khizç1, U. Kalyoncu1.1Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey;2Hacettepe University Medical Faculty, Department of Internal Medicine, Ankara, Turkey

Background: The conventional radiography score that is frequently used in spondyloarthrits patients is mSSASS. This score was developed for Ankylosing Spondylitis patients and is also frequently used in Psoriatic arthritis (PsA) (1). The mSSASS score takes into account lateral imaging of the lumbar and cervical radiographs. On the other hand, syndesmophytes can be detected on lumbar anterior-posterior (AP) radiographs, which may not be seen on lateral assessment.

Objectives: The aim of this study is to determine whether lumbar AP radiographs have an additional contribution to the evaluation of syndesmophytes in PsA patients.

Methods: Lumbar lateral radiographs and AP radiographs of 274 PsA patients receiving bDMARD therapy were evaluated. A total of 182 lateral lumbar radiographs and 144 AP radiographs were evaluated. On lateral lumbar radiographs each lumbar vertebral unit was evaluated between T12 lower and S1 upper ends. Areas between L1-L5 as AP, right-left, upper and lower vertebral units were evaluated. Syndesmophytes are classified as follows: corner and/or non-marginal syndesmophytes and bridging syndesmophytes. All of the assessments were done by an experienced rheumatologist (UK) and in cases with suspicion, another experienced rheumatologist reviewed the cases (LK) and a consensus was reached.

Results: 182 patients had lumbar radiographs with the mean (SD) age of 44.9 (12.7) years and the mean (SD) PsA duration of 4.8 (6.1) years at the time of the radiographs were taken. The rate of females was 70.3%. When the lateral lumbar radiographs were evaluated, 42/182 (23.1%) patients had at least one syndesmophyte. These 42 patients had a total of 80 syndesmophytes, 41 of which were bridging and 39 were corner syndesmophytes. The distribution of syndesmophytes is shown in the Table 1. The mean number of syndesmophytes in patients with at least one syndesmophyte on the lumbar lateral radiograph is 80/42 (19). In patients with at least one syndesmophyte, 14/42 (33.3%) patients had additional syndesmophytes not seen on lateral radiographs but on AP X-ray. Their distribution is as follows: L1 (4 patients), L2 (3 patients), L3 (2 patients), L4 (6 patients) and L5 (1 patient). In addition, 11 corner syndesmophytes and 5 bridging syndesmophytes were detected in the lumbar AP radiograph. When lumbar and AP radiographs are evaluated together, 44/182 (24.2%) patients have at least one syndesmophyte. When the lumbar lateral and AP radiographs are evaluated together, there are 96 syndesmophytes in 44 patients with syndesmophytes, 46 of which are bridging and 50 are corner syndesmophytes. Average number of syndesmophytes were 96 in 44 patients (2.2 per-patient).

Conclusion: AP radiographs are not taken into account in conventional radiographic scores accepted as mSSASS. PsA patients have syndesmophytes in approximately one-quarter of patients on lateral radiograph, with an average syndesmophyte number of about 2. On the other hand, when AP radiographs are evaluated, new syndesmophytes that are not seen on lateral radiographs are seen in one-third of patients with at least one syndesmophyte. Although it does not cause a significant change in the number of patients with syndesmophytes, it should be kept in mind that the use of AP radiographs in PsA patients may cause an increase in the total score. Whether there is a difference between PsA and SpA patients should be investigated in further studies.

REFERENCES:
**AB1360** DISTRIBUTION OF INFLAMMATORY/DEGENERATIVE/AMBIGUOUS LESIONS ON CONVENTIONAL LUMBAR LATERAL RADIOGRAPHS IN PSORIATIC ARTHRITIS PATIENTS

G. Ayar,1, A. Sadic,1, L. Kilic,1, U. Kalyoncu,1, 1Hacettepe University Medical Faculty, Department of Internal Medicine Division of Rheumatology, Ankara, Turkey; 2Hacettepe University Medical Faculty, Department of Internal Medicine, Ankara, Turkey

**Background:** Psoriatic arthritis (PsA) patients are relatively older than spondyloarthritic patients, and accordingly, degenerative changes on spine are more frequent and confusing.

**Objectives:** The aim of this study is to determine the distribution, relation of different type of lesions on the lumbar spine in PsA patients receiving bDMARD therapy.

**Methods:** 182/274 (66.4%) patients had lateral lumbar radiographs. Two and three lumbar radiographs were present in 53 (19.3%) 14 (5.1%) patients respectively. The upper and lower regions of each vertebra were evaluated between T12, S1 (total of 2184 regions). Lesions were determined as osteophyte (O) (grade 0-3), vertebral corner erosion, sclerosis, corner sclerosis, bridge osteophyte, and SP. While osteophyte was determined according to the degenerative character of new bone formations, the definition of SP was made according to mSASSS. Lesions that the clear distinction of cannot be made were defined as ambiguous. For patients with follow-up radiographs, the change of lesions defined as ambiguous was also recorded. All of the assessments were done by an experienced rheumatologists (UK) and in cases with suspicion, another experienced rheumatologist reviewed the cases (LK) and a consensus was reached.

**Results:** The mean (SD) age of 182 PsA (69.2% female) patients was 47.6 (12.7), the age at diagnosis of PsA was 39.7 (12.7). Of the patients, 112 (61.5%) met the criteria for mNY. There was at least one abnormality in 111 (61.0%) patients with lumbar spine radiograph. O was the most frequently detected lesions (42.3%), with 18.1% of patients having O grade 2 and above. While SP was present in 24.2% of all patients, ambiguous lesions were detected in 13 (4.7%) patients. While O were most frequently grouped between L2 upper and L4 upper regions, SPs were distributed in a similar ratio between L4 upper and T12 lower regions. Ambiguous lesions were anywhere between T12 sub-L5. Patients with ambiguous lesions were older (55.7 (9.8) vs 47.0 (12.7), p<0.017), lumbar mSASSS score was higher (5.4 (6.1) vs 1 (3.6), p=0.002) corner SPs (46.1% vs. % 177, p=0.013) and bridging SPs (30.7% vs 7.7%, p=0.006) were more common, while no difference was found in terms of O grade 2 (23.1% vs 17.7%, p=0.63). Changes were observed in 5 ambiguous lesions in patients with follow-up radiograph, 4 of them transformed into corner SP at follow-up, and one was evaluated as osteophyte grade 2.

**Conclusion:** Approximately one-fifth of patients presenting with significant degenerative new bone formation and SP was found in one-fourth. In approximately 5% of all patients, lesions in the lumbar vertebrae could not be differentiated. The frequency of SPs in other vertebral areas are more prominent in patients with ambiguous lesions. It is seen that ambiguous lesions turn into SPs in a small group of patients with follow-up data. The nature of these lesions needs to be evaluated in further imaging studies.

Table 1. The distribution of the lesions on lumbar spine

<table>
<thead>
<tr>
<th>Location <em>L</em>, n (%)</th>
<th>Osteophyte</th>
<th>Corner SP</th>
<th>SP</th>
<th>Bridging SP</th>
<th>All SP</th>
<th>Squaring Ambiguous</th>
</tr>
</thead>
<tbody>
<tr>
<td>T12, n (%)</td>
<td>7 (3.8)</td>
<td>1 (0.5)</td>
<td>9 (4.9)</td>
<td>9 (4.9)</td>
<td>14 (7.7)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>U, n (%)</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>10 (5.5)</td>
<td>11 (6.0)</td>
<td>12 (6.9)</td>
<td>6 (3.3)</td>
</tr>
<tr>
<td>L1, n (%)</td>
<td>10 (5.5)</td>
<td>6 (3.3)</td>
<td>8 (4.4)</td>
<td>6 (3.3)</td>
<td>14 (7.7)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>L2, n (%)</td>
<td>15 (8.2)</td>
<td>8 (4.4)</td>
<td>14 (7.7)</td>
<td>15 (8.2)</td>
<td>18 (9.2)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>L3, n (%)</td>
<td>16 (8.8)</td>
<td>9 (4.9)</td>
<td>3 (1.6)</td>
<td>7 (3.7)</td>
<td>11 (6.0)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>L4, n (%)</td>
<td>31 (17.0)</td>
<td>14 (7.7)</td>
<td>12 (6.6)</td>
<td>13 (7.1)</td>
<td>25 (13.7)</td>
<td>6 (3.3)</td>
</tr>
<tr>
<td>L5, n (%)</td>
<td>17 (9.3)</td>
<td>9 (4.9)</td>
<td>12 (6.6)</td>
<td>8 (4.4)</td>
<td>14 (7.7)</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>L1, L2, n (%)</td>
<td>37 (20.3)</td>
<td>14 (7.7)</td>
<td>8 (4.4)</td>
<td>21 (11.7)</td>
<td>31 (17.1)</td>
<td>11 (6.0)</td>
</tr>
<tr>
<td>L3, L4, n (%)</td>
<td>10 (5.5)</td>
<td>5 (2.8)</td>
<td>1 (0.5)</td>
<td>15 (8.2)</td>
<td>15 (8.2)</td>
<td>6 (3.3)</td>
</tr>
<tr>
<td>L4, L5, n (%)</td>
<td>24 (13.2)</td>
<td>8 (4.4)</td>
<td>10 (5.5)</td>
<td>13 (7.1)</td>
<td>20 (11.0)</td>
<td>7 (3.7)</td>
</tr>
<tr>
<td>L2, L3, n (%)</td>
<td>8 (4.4)</td>
<td>3 (1.6)</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>2 (1.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>L1, L2, L3, n (%)</td>
<td>3 (1.6)</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
<td>0 (0)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>All vertebral corners</td>
<td>184 (84.4)</td>
<td>75 (3.4)</td>
<td>60 (2.7)</td>
<td>49 (2.5)</td>
<td>169 (4.9)</td>
<td>50 (2.2)</td>
</tr>
<tr>
<td>All patients</td>
<td>77 (42.3)</td>
<td>33 (18.1)</td>
<td>36 (19.8)</td>
<td>17 (9.3)</td>
<td>44 (22.4)</td>
<td>22 (12.1)</td>
</tr>
</tbody>
</table>

**Disclosure of Interests:** None declared

DOI: 10.1136/annrheumdis-2022-eular.3474

**AB1361** PAIN MANAGEMENT IN METASTATIC BONE DISEASE: LOCATION AND NUMBER OF SARCOIDOSIS GRANULOMA, A POSSIBLE DIAGNOSTIC ARGUMENT?

O. Dhrit1, M. S. Hamdi1, I. Kechmaou1, I. Boukhri1, E. Cherni1, S. Azzabi1, L. Ben Hassine1, 1Charles nicolle's Hospital, Internal Medicine, Tunis, Tunisia

**Background:** Sarcoïdosis is a non-necrotizing granulomatous disease which diagnosis is often challenging and requires elimination of other causes of granulomatous lesions. Location and number of granulomatous lesions in patients are not yet established as arguments in diagnosing this disease.

**Objectives:** We therefore conducted a study aiming to compare locations and number of granulomas between patients with sarcoïdosis and patients with other granulomatous diseases (OGD).

**Methods:** Cross sectional study in which were included patients in whom non-necrotizing granulomatous lesions have been identified via biopsy over a period of 11 years (2010 to 2021) then were stratified into two groups: sarcoidosis group and OGD group. Categorical variables were compared with the χ²-test or Fisher’s test. Comparisons of the differences of continuous variables were performed by the Mann–Whitney U test or Student’s t-test. Pearson correlation ratio was used for linear correlation analysis.

**Results:** 30 patients were included in the sarcoidosis group and 32 in the OGD group. Aetiologies in the OGD group were: 10 tuberculosis cases, 5 lymphoma cases, 4 Primary biliary cholangitis cases, 1 Castelmann’s disease and 12 idiopathic granulomas.

**Disclosure of Interests:** None declared


**AB1362** LOCATION AND NUMBER OF SARCOIDOSIS GRANULOMA, A POSSIBLE DIAGNOSTIC ARGUMENT?

O. Dhrit1, M. S. Hamdi1, I. Kechmaou1, I. Boukhri1, E. Cherni1, S. Azzabi1, L. Ben Hassine1, 1Charles nicolle's Hospital, Internal Medicine, Tunis, Tunisia

**Background:** Sarcoïdosis is a non-necrotizing granulomatous disease which diagnosis is often challenging and requires elimination of other causes of granulomatous lesions. Location and number of granulomatous lesions in patients are not yet established as arguments in diagnosing this disease.

**Objectives:** We therefore conducted a study aiming to compare locations and number of granulomas between patients with sarcoïdosis and patients with other granulomatous diseases (OGD).

**Methods:** Cross sectional study in which were included patients in whom non-necrotizing granulomatous lesions have been identified via biopsy over a period of 11 years (2010 to 2021) then were stratified into two groups: sarcoidosis group and OGD group. Categorical variables were compared with the χ²-test or Fisher’s test. Comparisons of the differences of continuous variables were performed by the Mann–Whitney U test or Student’s t-test. Pearson correlation ratio was used for linear correlation analysis.

**Results:** 30 patients were included in the sarcoidosis group and 32 in the OGD group. Aetiologies in the OGD group were: 10 tuberculosis cases, 5 lymphoma cases, 4 Primary biliary cholangitis cases, 1 Castelmann’s disease and 12 idiopathic granulomas.
Mean age was respectively in both groups 51±13 versus 57±17 years old (p=0.128), sex ratio (F/M) was 29/1 versus 27/5 (p=0.197). Associated signs were distributed in both groups as followed: 11(37%) versus 5(16%) general signs (p=0.085), 15(50%) versus 20(63%) lymphadenopathy (p=0.442), 4(13%) versus 8(19%) inflammatory arthralgias (p=0.733), 13(43%) versus 2(6%) cutaneous lesions (p=0.001), 4 versus no ocular manifestations (p=0.049), 20 (66%) versus 3(9%) pulmonary manifestations (p<0.001), 5 (17%) versus 10 (31%) abdomin- al manifestations (p=0.239). Cutaneous, salivary gland and ENT granulomas were significantly more frequent in patients with sarcoidosis with respectively 11(37%) versus 1 (3%) (12.3 risk ratio 95%CI 10.4 to 14.1) (p=0.001), 8 (27%) versus 0% (p=0.002), 8(27%) versus 2(6%) (4.5 risk ratio 95% CI 3.1 to 5.9) (p=0.025). Lymph node, hepatic and pulmonary granulomas prevalence was not significantly higher in sarcoidosis patients, 17 (57%) versus 24 (75%) (p=0.180), 2 (7%) versus 5 (16%) (p=0.427), 3(10%) versus 0% (p=0.308). Mean number of granulomas found in one patient was significantly higher in sarcoidosis patients with 1.7 (95% CI 1.5 to 2) versus 1.1 (95%CI 1 to 1.2) (p=0.001). There was also a significant correlation between the number of granulomas in one patient and the angiotensin converting enzyme titre (r=0.56, 95% CI 0.360 to 0.771); (p=0.004).

Conclusion: This study shows that sarcoidosis patients have more often granu- lomas in the skin, salivary gland and ENT regions, and that the number of granu- lomas is on average superior in sarcoidosis than in OGD, these findings could be considered when establishing future diagnostic algorithms, as taking into account these elements could ease this diagnostic challenge in clinical practice.

Disclosure of Interests: None declared

AB1363 IMAGE PATTERN ANALYSIS IN FLUORESCENCE OPTICAL IMAGING FOR DIFFERENTIAL DIAGNOSIS IN RHEUMATIC JOINT DISEASES

N. Stumper1, J. Berger2, G. Schmitt1, A. Briel1, D. Vogler1, G. R. Burmester1, P. Hoff1, S. Ohrndorf1. 1Charité – Universitätsmedizin Berlin, Germany; 2Department of Rheumatology and Clinical Immunology, Berlin, Germany; 3Xiralite GmbH, Berlin, Germany; 4InnoPET Pharma GmbH, R&D, Berlin, Germany

Background: As outlined in previous studies, different rheumatic joint diseases present specific characteristic patterns and features in fluorescence optical imaging (FOI) (1-4).

Objectives: We tested different features in FOI for their ability to differentiate various rheumatic joint diseases such as rheumatoid arthritis (RA), osteoarthritis (OA) and psoriatic arthritis (PsA) with the aim to identify clear FOI criteria for the diseases.

Methods: FOI images from patients with RA, OA, PsA and healthy volunteers were evaluated by two readers blinded for diagnosis and calibrated against each other, using the prima vista mode (PVM) and the 5-phase model. For the latter, the overall time course of FOI in each hand was divided into 5 phases with a computational algorithm. Phases 1 and 2 describe the inflex (start to 15% and 15%-90% on rising edge), phase 3 is the peak phase and phases 4 and 5 comprise the outflow (90%-95.9% and 95.9%-97.5% to falling edge). Twenty-six different features were defined by an atlas, for example the streaky pattern feature (T) as a signal enhancement around the PIP area that appears streaky, whereby the stripes are orthogonal to the finger axis (Figure 1a). The cloudy pattern (W) is visible during the inflex on the back of the hand (Figure 1b). The enthesis feature (E) depicts a V shaped and filled pattern between nail and DIP (Figure 1c). The feature frequency in each patient and phase (PVM, 5-phase) was counted and statistically analysed.

Figure 1. Examples for FOI patterns and features: a) (T) Streaky pattern in PVM image (OA); b) (W) Cloudy pattern on the back of the hand in phase 1 (PsA); c) (E) Enthesis pattern in phase 3.

Results: In total, 128 patients (RA age mean 54±2; SD 10.6; median 52.4), OA (58.0; 14.3; 60.1), and PsA (47.9; 12.7; 46.8) and healthy volunteers (32 in each group) were included in the feature reading. In our analysis, OA could be differentiated from RA on the basis of the feature T. Feature T is found in phase 3 (χ2: 4.61; diagnostisch odds ratio (DOR): 7.49; sensitivity (TPR) 0.11; specificity (TNR) 0.98; positive predictive value (PPV): 0.87; negative predictive value (NPV): 0.52), phase 5 (χ2: 18.5; DOR: 5.60; TPR 0.55; TNR: 0.82; PPV: 0.76; NPV: 0.64 and PVM (28.3; 12.1; 52%); 92% 87%; 65%). By means of the feature E, a distinction between RA and PsA is only limited possible (χ2: 9.58; DOR: 3.65; TPR 0.40; TNR: 0.84; PPV: 0.71; NPV: 0.56). But PsA can well be distinguished from RA by the appearance of pat- terns in phase 1 (χ2: 7.68; DOR 0.92; TPR 0.19; TNR: 0.97; PPV: 0.86; NPV: 0.54).

Other significant features yield high specificity (70%-98%) while having low sen- sitivity (12%-52%).

Conclusion: This work demonstrates that FOI feature analysis has the potential for differential diagnosis with FOI, which could optimize the (early) diagnostic process of rheumatic joint diseases. A majority of features yield high specificity, but only low sensitivity. The combination of different features using artificial intel- ligence might lead to improved diagnostic accuracy.

REFERENCES:

Disclosure of Interests: None declared

AB1364 IMAGING DIAGNOSIS OF BRUCELLAR SPONDYLODYSCITIS

S. Rekik1, S. Bousaid2, H. Tpini1, S. Jemmal1, S. Rahmouni1, K. Zouaoui1, H. Sahli1, M. Elleuch1, 1Tunis, Department of Rheumatology, La Rabta hospital, Tunis, Tunisia

Background: Spondyloarthritis is the most common location in the musculoskel- etal involvement of brucellosis.

Objectives: The aim of this study is to describe magnetic resonance imaging (MRI) and computed tomography scan (CT) results in patients with brucellar spondyloarthritis.

Methods: A retrospective study over a period of 15 years, including 18 patients diagnosed with brucellar spondyloarthritis and having benefited from a CT scan and/or an MRI of the spine.

Results: Eighteen patients were included. In all cases spinal pain was reported, associated with radiculalgia in 8 patients. Low back pain was the most common symptom, present in 17 cases, associated with back pain in 3 cases including one case with neck pain. Isolated neck pain was noted in one patient. Neurologic examination was normal in all cases. Standard Radiographs showed disc nar- rowing in 14 cases, erosions in 9 cases and hazy changes of the vertebral end plate in 2 cases. A CT scan was performed in 11 cases. It showed disc narrowing in 6 cases, erosions in 3 cases and endplate destructions in 5 cases. Abscesses were found in 4 patients. Complementary MRI was performed in three of the patients who had already undergone CT. The MRI results were consistent with those of the CT scan, except for one patient in whom it revealed spondylodis- ctitis while the CT scan revealed degenerative lesions. Eleven patients under- went MRI in total. It showed unilocular and multifocal spondylodiscitides in 5 and 6 cases respectively, epiduritis in 6 cases, spinal cord compression in 2 cases and abscesses in 4 cases.

Conclusion: Our study showed that CT and spinal MRI allow early diagnosis of spondyloarthritis. They help to identify asymptomatic lesions and neurological complications.

Disclosure of Interests: None declared

AB1365 PROPOSAL FOR A STANDARDIZED ULTRASOUND SCANNING PROTOCOL OF THE NAIL PLATE.

D. Rotta1, G. Adami1, F. Bellinoto1, A. Fassio1, L. Idolazzi1, P. Gisondi2, F. Tozzi2, E. Filippucci1, M. Rossini3; 1Rheumatology Unit, Medicine, University of Verona, VERONA, Italy; 2Clinical Dermatology Unit, Medicine, University of Verona, VERONA, Italy; 3Clinica Reumatologica, Università Politecnica delle Marche, JESI, Italy

Background: Ultrasonography of the nails with high frequency linear transduc- ers can properly perform morphological images, achieving highly descriptive power but the lack of standardization may hesitate in lack of reproducibility and scarce usefulness.
**Objectives:** The aim of this study was to provide a detailed scan protocol of nail plate, including comparison of scan planes and probe positioning.

**Methods:** Transversal and longitudinal ultrasound scans were performed on each fingernail of both hands in healthy subjects. Nail plate thickness and Power Doppler of the nail bed were recorded. All the images were acquired using Canon Aploic i800 with a linear transducer of 22 MHz (G22LHB). Two different operators performed evaluation of thickness at distal, middle and proximal portion of nail in longitudinal view and at 0°, -45° and +45° for transverse view (Figure 1). ANOVA for repeated measures was used to determine differences between nail of the different digits.

**Results:** The study sample was composed of 27 healthy subjects between 25- and 40- year old with no rheumatological or dermatological nail issues. A total of 270 nails were scanned; none of them was excluded due to comorbidities, trauma or other conditions which can interfere in the evaluation. A decrease in nail thickness was observed from first to fifth digit, regardless the hand (dominant or not), that resulted significant for the ANOVA. No differences were found regarding the thickness in the different segments of nail plate and this occurred both for longitudinal and transversal scans.

**Conclusion:** We demonstrated the absence of a statistically significant difference between thickness at proximal, middle and distal portion of the nail in longitudinal view or at any different angle in transverse view, concluding the fastest and easiest way to measure the nail plate thickness is in the longitudinal view at the middle segment, avoiding potential issues in positioning the probe in the transverse view or in positioning the caliper at proximal or distal segment in longitudinal view. All the nails should be scanned per protocol, since the thickness is variable and the fifth may be the most interesting in order to consider its highest variance.

**REFERENCES:**

**Table 1. ANOVA for repeated measures of the nail plate thickness.** A trend in decreasing P value is clearly visible from first to fifth. P considered statistically significant when ≤ 0.05

<table>
<thead>
<tr>
<th>LONGITUDINAL</th>
<th>TRANSVERSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PROXIMAL</strong></td>
<td></td>
</tr>
<tr>
<td>Row-mean</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>MIDDLE</td>
<td></td>
</tr>
<tr>
<td>Row-mean</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>DISTAL</td>
<td></td>
</tr>
<tr>
<td>Row-mean</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

**DISCLOSURE OF INTERESTS:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4070
AB1367

PET ASSESSMENT OF THE EFFECTIVENESS OF TOCILIZUMAB IN GIANT CELL ARTERITIS: STUDY OF 101 PATIENTS FROM CLINICAL PRACTICE

J. Sanchez-Martín1, J. Loricera1, S. Castañeda1, C. Moriano1, J. Narváez2, V. Aldasono3, O. Maiz4, R. Melero4, I. Villa-Blanco5, P. Vela-Casasempere5, S. Romero-Yuste6, J. L. Callejas-Rubio5, E. De Miguel5, E. Galán-Fraigozkoia5, F. Sivera5, C. Fernández-López6, C. Galisteo13, I. Ferrández-Amaro7, L. Sanchez-Bilbao1, M. Calderón-Gorberc1, J. L. Hernández-Hernández2, M. A. González-Gay2, R. Blanco1, 1Department of Rheumatology and Internal Medicine, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Rheumatology, Santander, Spain; 2Department of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Catedra IAM-Roche, EPID-Future, IAM, Madrid, Spain, Rheumatology, Madrid, Spain; 3Department of Rheumatology, Complejo Asistencial Universitario de León, León, Spain, Rheumatology, Leon, Spain; 4Department of Rheumatology, Hospital del Belviteix, Barcelona, Spain, Rheumatology, Barcelona, Spain; 5Department of Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, Rheumatology, Pamplona, Navarra, Spain; 6Department of Rheumatology, Hospital Universitario de Donostia, San Sebastián, España, Rheumatology, Donostia, Spain; 7Department of Rheumatology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, Rheumatology, Vigo, Spain; 8Department of Rheumatology, Hospital San Cecilio, Granada, Spain, Rheumatology, Granada, Spain; 9Department of Rheumatology, Hospital La Paz, Madrid, Spain, Rheumatology, Madrid, Spain; 10Department of Rheumatology, Hospital Universitario de Elche, Elche, Spain, Rheumatology, Elche, Alicante, Spain; 11Department of Rheumatology, Hospital Universitario San Carlos, Madrid, Spain; 12Department of Rheumatology, Hospital Universitario de El Pasillo, Valencia, Spain, Rheumatology, Valencia, Spain; 13Department of Rheumatology, Hospital Universitario Reina Sofia, Córdoba, Spain, Rheumatology, Córdoba, Spain; 14Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain, Rheumatology, Salamanca, Spain; 15Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Rheumatology, Santander, Spain; 16Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, Rheumatology, Madrid, Spain; 17Department of Rheumatology, Complejo Hospitalario Universitario de Badajoz, Cáceres, Spain, Rheumatology, Badajoz, Cáceres, Spain; 18Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Spain, Rheumatology, Málaga, Spain; 19Department of Rheumatology, Hospital Carlos III, Madrid, Spain, Rheumatology, Madrid, Spain; 20Department of Rheumatology, Hospital Universitario La Fe, Valencia, Spain, Rheumatology, Valencia, Spain; 21Department of Rheumatology, Hospital La Mancha Centro, Toledo, Spain, Rheumatology, Toledo, Spain; 22Department of Rheumatology, Hospital La Mancha Centro, Toledo, Spain, Rheumatology, Toledo, Spain; 23Department of Rheumatology, Complejo Hospitalario Universitario de Ciudad Real, Ciudad Real, Spain, Rheumatology, Ciudad Real, Spain; 24Department of Rheumatology, Hospital Universitario de la Ribera, Murcia, Spain, Rheumatology, Murcia, Spain; 25Department of Rheumatology, Hospital Universitario de Ciudad Real, Ciudad Real, Spain, Rheumatology, Ciudad Real, Spain; 26Department of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, Rheumatology, Barcelona, Spain; 27Department of Rheumatology, Hospital Clínico Universitario de Valencia, Valencia, Spain, Rheumatology, Valencia, Spain; 28Department of Rheumatology, Hospital Universitario de Alicante, Alicante, Spain, Rheumatology, Alicante, Spain; 29Department of Rheumatology, Hospital Universitario San Juan de Alicante, Alicante, Spain, Rheumatology, Alicante, Spain; 30Department of Rheumatology, Hospital Universitario de Elda, Alicante, Spain, Rheumatology, Elda, Alicante, Spain; 31Department of Rheumatology, Hospital Universitario Juan Canalejo, Pontevedra, Spain, Rheumatology, Pontevedra, Spain; 32Department of Rheumatology, Hospital Universitario de Ourense, Ourense, Spain, Rheumatology, Ourense, Spain; 33Department of Rheumatology, Hospital Universitario Reina Sofía, Córdoba, Spain, Rheumatology, Córdoba, Spain; 34Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Spain, Rheumatology, Málaga, Spain; 35Department of Rheumatology, Hospital Public Parc Taulí, Barcelona, Spain, Rheumatology, Barcelona, Spain; 36Department of Rheumatology, Hospital Vall d’Hebron, Barcelona, Spain, Rheumatology, Barcelona, Spain; 37Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain, Internal Medicine, Santander, Spain

Background: Positron emission tomography (PET) is one of the tools available for the diagnosis of extracranial large-vessel vasculitis (1-5). Tocilizumab (TCZ) has shown efficacy in large-vessel vasculitides (LVV) including GCA. However, the improvement objectified by imaging techniques after TCZ therapy in extracranial GCA patients is controversial.

Objectives: To assess the effectiveness of TCZ improving the wall vessel inflammation by PET in GCA patients with large-vessel involvement.

Methods: Observational, multicenter study of 101 GCA patients treated with TCZ. GCA was diagnosed according to: a) ACR criteria, and/or b) biopsy of temporal artery, and/or c) presence of signs of vessel wall inflammation by PET, defined by the presence of vascular wall uptake of Fluorodeoxyglucose (FDG). Patients were divided into two subgroups: a) with, and b) without signs of improvement (partial or total) in the follow-up PET.

Results: We studied 101 patients (74 women/27 men; mean age 69.7±9.3 years). Main clinical features of GCA with and without PET improvement are shown in Table 1. The group of patients which experienced PET improvement was older and was receiving higher doses of corticosteroids at TCZ onset.

Table 1. Main features of 101 GCA patients treated with tocilizumab and with presence of signs of vessel wall inflammation by PET.

<table>
<thead>
<tr>
<th>Baseline characteristics at TCZ onset</th>
<th>General characteristics</th>
<th>With PET improvement (n=88)</th>
<th>Without PET improvement (n=13)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean±SD</td>
<td>70.6±9.1</td>
<td>63.8±9.2</td>
<td>0.014</td>
<td></td>
</tr>
<tr>
<td>Sex, female/male (% female)</td>
<td>67/21 (78)</td>
<td>76/14 (54)</td>
<td>0.103</td>
<td></td>
</tr>
<tr>
<td>Time from GCA diagnosis to TCZ onset (months), median [IQR]</td>
<td>11 [4-24.2]</td>
<td>4 [2-8]</td>
<td>0.102</td>
<td></td>
</tr>
<tr>
<td>Systemic manifestations, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever, n (%)</td>
<td>5 (6)</td>
<td>2 (15)</td>
<td>0.225</td>
<td></td>
</tr>
<tr>
<td>Constitutional syndrome, n (%)</td>
<td>36 (41)</td>
<td>43 (31)</td>
<td>0.466</td>
<td></td>
</tr>
<tr>
<td>PMR, n (%)</td>
<td>53 (60)</td>
<td>9 (10)</td>
<td>0.761</td>
<td></td>
</tr>
<tr>
<td>Iatrogenic manifestations, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual involvement, n (%)</td>
<td>2 (2)</td>
<td>1 (1)</td>
<td>0.342</td>
<td></td>
</tr>
<tr>
<td>Headache, n (%)</td>
<td>30 (34)</td>
<td>23 (23)</td>
<td>0.538</td>
<td></td>
</tr>
<tr>
<td>Jaw claudication, n (%)</td>
<td>8 (9)</td>
<td>0 (0)</td>
<td>0.592</td>
<td></td>
</tr>
<tr>
<td>Laboratory data</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESR, mm 1st hour, median [IQR]</td>
<td>38.0 ± 26.2</td>
<td>13.5 ± 9.9</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>CRP, mg/dL, median [IQR]</td>
<td>15 [0-7.2]</td>
<td>15 [0.5-5.7]</td>
<td>0.179</td>
<td></td>
</tr>
<tr>
<td>Prednisone dose, mg/day, median [IQR]</td>
<td>40.3 ± 19.4</td>
<td>21.8 ± 12.7</td>
<td>0.001</td>
<td></td>
</tr>
<tr>
<td>Time from TCZ onset and follow-up PET (months)</td>
<td>31±8.0</td>
<td>10±5.3</td>
<td>0.446</td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: TCZ seems to be effective controlling GCA including vascular involvement detected by PET. However, the improvement observed by PET is most often partial, and rarely complete.

Figure 1. Improvement by PET according to the time of the test.

REFERENCES:
Background: Involvement of lower extremity joints in both rheumatoid arthritis (RA) and osteoarthritis (OA) is an important cause of declined functional status. Deterioration of skeletal muscle performance further contributes to disability. Quadriiceps muscle plays an important role in most daily activities. Measuring thickness and pennation angle of quadriiceps compartments can provide knowledge regarding quadriceps condition.

Objectives: Aim is to investigate structural and inflammatory changes in knee joint and architecture of quadriiceps muscle in RA, knee OA patients and a group of healthy subjects.

Methods: Twenty RA patients and 20 knee OA patients with radiographic disease meeting Kellgren-Lawrence grade 2 and above were consecutively recruited, in absence of exclusion criteria, 20 healthy volunteers with similar demographics were recruited as control group. Knee symptoms and disability were evaluated by Lequesne Knee Index (LKI). Disease activity was evaluated by DAS28-CRP in RA patients. Quadriiceps muscle was evaluated by ultrasonographic measurements of muscle thickness, subcutaneous fat tissue thickness and pennation angle of vastus muscles. Suprapatellar, lateral and medial compartments of knee joint were examined for effusion, synovial hypertrophy, power Doppler (PD) activity and degenerative changes.

Results: Demographic features of subjects and results of ultrasonographic evaluation are presented in Table 1. LKI scores were significantly higher in OA patients when compared to RA patients (p=0.003). Rate of degenerative changes was increased in RA and OA groups in comparison to controls (p=0.013). None of the subjects had PD activity. No differences were observed in thickness of rectus femoris, vastus muscles and subcutaneous fat between groups. Vastus medialis and intermedius pen- nanation angles were reduced in OA and RA groups when compared to controls, but reached statistical significance only in vastus intermedius (3.56 ± 0.67 vs 4.89 ± 1.74 vs 7.29 ± 4.93, p=0.038).

Table 1. Demographics, clinical features and ultrasonographic findings of subjects

<table>
<thead>
<tr>
<th>OA (n=20)</th>
<th>RA (n=20)</th>
<th>Control (n=20)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>58.44 ± 6.88</td>
<td>54.67 ± 7.15</td>
<td>55.11 ± 5.89</td>
</tr>
<tr>
<td>Gender, female</td>
<td>17 (85)</td>
<td>15 (75)</td>
<td>16 (80)</td>
</tr>
<tr>
<td>BMI</td>
<td>30.05 ± 3.88</td>
<td>28.29 ± 4.78</td>
<td>28.7 ± 3.34</td>
</tr>
<tr>
<td>Duration of disease, months</td>
<td>11.95 ± 17.15</td>
<td>14.80 ± 8.50</td>
<td>0.023</td>
</tr>
<tr>
<td>LKI</td>
<td>9.37 ± 2.65</td>
<td>6.99 ± 3.38</td>
<td>0.004</td>
</tr>
<tr>
<td>Presence of effusion</td>
<td>9 (45)</td>
<td>9 (45)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Presence of SH</td>
<td>9 (45)</td>
<td>11 (55)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Presence of degeneration</td>
<td>16 (80)</td>
<td>13 (65)</td>
<td>7 (35)</td>
</tr>
<tr>
<td>Muscle thickness, mm</td>
<td>14.09 ± 4.17</td>
<td>15.38 ± 5.15</td>
<td>14.57 ± 3.41</td>
</tr>
<tr>
<td>VL</td>
<td>17.17 ± 3.53</td>
<td>16.66 ± 9.48</td>
<td>16.66 ± 3.18</td>
</tr>
<tr>
<td>VI</td>
<td>10.54 ± 2.65</td>
<td>10.94 ± 3.32</td>
<td>10.67 ± 1.83</td>
</tr>
<tr>
<td>RF</td>
<td>13.01 ± 3.92</td>
<td>13.74 ± 3.78</td>
<td>13.63 ± 3.49</td>
</tr>
<tr>
<td>SFT thickness, mm</td>
<td>12.59 ± 5.79</td>
<td>13.81 ± 7.10</td>
<td>12.53 ± 5.20</td>
</tr>
<tr>
<td>Penetration angle, degree</td>
<td>5.50 ± 7.01</td>
<td>6.94 ± 8.29</td>
<td>9.05 ± 5.10</td>
</tr>
<tr>
<td>VL</td>
<td>13.61 ± 5.15</td>
<td>13.44 ± 3.32</td>
<td>13.23 ± 3.25</td>
</tr>
<tr>
<td>VI</td>
<td>5.36 ± 6.37</td>
<td>4.89 ± 7.14</td>
<td>7.29 ± 4.93</td>
</tr>
</tbody>
</table>

Conclusion: In our study ultrasonographic evaluation findings of knee joint and quadriiceps muscle were similar between knee OA and RA patients. VM and VI penetration were reduced when compared to healthy subjects in both groups. These findings may indicate a similar degree of functional impairment in OA and RA due to knee joint involvement.

REFERENCES:


Acknowledgments: I have no acknowledgments to declare.

Disclosure of Interests: None declared.


AB1368

ULTRASONOGRAPHIC EVALUATION OF THE KNEE AND MUSCLE ARCHITECTURE IN OSTEOA RTHRITIS AND RHEUMATOID ARTHRITIS

S. C. Güven1, S. Metin Taran1, F. N. Göğüş2, 3, Ankara City Hospital, Rheumatology, Ankara, Turkey; 2Karabük Training and Research Hospital, Physical and Rehabilitation Medicine, Karabük, Turkey; 3Gazi University Medical School, Physical and Rehabilitation Medicine, Division of Rheumatology, Ankara, Turkey

Background: Involvement of lower extremity joints in both rheumatoid arthritis (RA) and osteoarthritis (OA) is an important cause of declined functional status. Deterioration of skeletal muscle performance further contributes to disability. Quadriceps muscle plays an important role in most daily activities. Measuring thickness and pennation angle of quadriceps compartments can provide knowledge regarding quadriceps condition.

Objectives: Aim is to investigate structural and inflammatory changes in knee joint and architecture of quadriceps muscle in RA, knee OA patients and a group of healthy subjects.

Methods: Twenty RA patients and 20 knee OA patients with radiographic disease meeting Kellgren-Lawrence grade 2 and above were consecutively recruited, in absence of exclusion criteria, 20 healthy volunteers with similar demographics were recruited as control group. Knee symptoms and disability were evaluated by Lequesne Knee Index (LKI). Disease activity was evaluated by DAS28-CRP in RA patients. Quadriceps muscle was evaluated by ultrasonographic measurements of muscle thickness, subcutaneous fat tissue thickness and pen- nanation angle of vastus muscles. Suprapatellar, lateral and medial compartments of knee joint were examined for effusion, synovial hypertrophy, power Doppler (PD) activity and degenerative changes.

Results: Demographic features of subjects and results of ultrasonographic evaluation are presented in Table 1. LKI scores were significantly higher in OA patients when compared to RA patients (p=0.003). Rate of degenerative changes was increased in RA and OA groups in comparison to controls (p=0.013). None of the subjects had PD activity. No differences were observed in thickness of rectus femoris, vastus muscles and subcutaneous fat between groups. Vastus medialis and intermedius pen- nanation angles were reduced in OA and RA groups when compared to controls, but reached statistical significance only in vastus intermedius (3.56 ± 0.67 vs 4.89 ± 1.74 vs 7.29 ± 4.93, p=0.038).
AB1370

MICROVASCULAR CAPILLAROSCOPIC ANOMALITIES AND AUTOANTIBODY OCCURRENCE IN SARCOIDOSIS PATIENTS.

F. Cattelan1, E. Hya1, C. Pizzorni1, M. Grosso2, E. Barisione2, S. Paolino1, G. Pacini1, G. Ferrari1, A. Sulli1, V. Smith3, M. Cutolo1.

1Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Italy; 2Pneumology Unit, IRCCS San Martino Polyclinic, Genova, Italy; 3Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Corneel Heymanslaan 10, 9000 Ghent, Belgium.

Background: Sarcoidosis (S) is a granulomatous disease with multi-organ involvement displaying a mixed immune-mediated pathophysiology. Raynaud’s phenomenon (RP) has been occasionally reported in S patients [1] and serum positivity for autoantibodies has been detected in S patients but their significance is debated [2].

Objectives: We described nailfold videocapillaroscopy (NVC) findings and estimated the prevalence of serum anti-nuclear (ANA) and extractable nuclear antigen autoantibodies (ENA-Abs) in S patients, comparing them with age- and sex-matched healthy controls (HCs) and patients with primary Raynaud’s phenomenon (PRP). Secondly, we analysed potential correlations between NVC findings with the occurrence of autoantibodies, immunomodulatory treatment, laboratory parameters, variables of pulmonary function and whole-body imaging.

Methods: Twenty-seven (27) S patients, classified according to WASOG criteria[3], were assessed through NVC examination, laboratory parameters (including serum concentrations of angiotensin-converting enzyme [ACE], C-reactive protein [CRP], calcium, phosphorus, albumin, 25-hydroxyvitamin D, parathormone, ANA and ENA), pulmonary function tests (PFTs), chest-X ray and positron emission tomography/computed tomography (PET/CT). Among NVC parameters, we analysed capillary dilations, giant capillaries, haemorrhages, nonspecific abnormalities, and capillary absolute number for mm [4]. Pulmonary involvement was classified by X-ray Scadding staging system (SSS) scoring S patients in 4 grades [5]. From PET data, the maximum standard uptake value (SUVmax) was quantified as a variable of tissue 18-fluorodeoxyglucose hyper-uptake: consequently, S patients were defined PET-positive when SUV value ≥ 2.5. NVC parameters and ANA/ENA dosage were recorded also in 30 PRPs and 30 HCs.

Results: We excluded, among the cohort of S patient, one participant having a systemic sclerosis in overlap with S. The remaining 26 S patients (mean age 56.5 ± 12.5 years, 53.8 % of females, disease duration 28.4 ± 55.1 months, 27% glucocorticoid-naïve) showed a significant higher rate of dilations and nonspecific abnormalities and a lower mean capillary absolute number than PRPs and HCs (p < 0.01 for all comparisons). (Figure 1) The prevalence of ANA positivity was significantly higher in S patients compared with PRPs and HCs (p < 0.02 for both). Among the whole cohort of patients only one S patient displayed a positive ENA-Ab (Ro52). In the analysis of S patients’ subgroup, a significant negative correlation was detected between serum ACE levels with the presence of capillary dilations (rho = -0.45, p = 0.04), between CRP and mean capillary absolute number (rho = -0.49, p = 0.02) and a positive correlation was also detected between serum ACE levels with the presence of capillary dilations and haemorrhages (rho = 0.40, p = 0.04).

Conclusion: Our findings suggest a microvascular involvement in sarcoidosis, whose investigation by NVC could be useful for the detection of an overlapping connective tissue disease and for the monitoring of the phenotypes of S patients displaying RP. The positivity for autoantibodies in S patients is in line with literature data suggesting, at least partially, autoimmune features of the disease or the production of autoantibodies reactive to tissue damage. The correlations between NVC findings with ACE levels and lung function variables generate hypotheses of a potential partial vascular impairment in sarcoidosis disease activity and lung involvement.

REFERENCES:

Disclosure of Interests: None declared

AB1371

USE OF ULTRASOUND TO DIAGNOSE INTERSTITIAL LUNG DISEASE IN RHEUMATIC DISEASES ON RUSSIAN COHORTS OF PATIENTS.

O. Ovsyannikova1, O. Konve1, L. Garzanova1, L. P. Ananyeva1, A. Khelikovskaya-Sergeeva1, R. Shayakhmetova1, O. Desinova1, M. Starovoytova1. 1V.A. Nasonova Research Institute of Rheumatology, Systemic sclerosis, Moscow, Russian Federation

Background: Intersitial lung disease (ILD) is one of the most relevant extra-articular manifestations of rheumatic diseases resulting in a substantial increase in morbidity and mortality. High-resolution computed tomography (HRCT), which is the current gold standard for diagnosis and evolutionary control, is problematic owing to ionizing radiation, cost, and accessibility. In the last decade, the use of lung ultrasound (LUS) in clinical medicine has increased. LUS is an accurate tool for the diagnosis of pneumonia, pneumothorax, acute pulmonary edema, and pleural effusion. LUS may also be useful in detection of ILD by the evaluation of B-lines, the sonographic hallmark of the interstitial syndrome.

Objectives: To compare semi-quantitative scores of B lines in patients with rheumatic disease with different intensity of lung fibrosis.

Methods: 50 pts with ILD of rheumatic disease such as: vasculitis n=11 (mean age 40.7± 9.1, fem 5); dermatomyositis (DM), anti-synthetase syndrome (ASS), polymyositis (PM) n=20, (mean age 48.7± 11.9, fem 13); rheumatoid arthritis (RA) n=9 (mean age 56.5± 8.3, fem 7); Sjogren’s syndrome (SS) n=9 (mean age 59.6± 12.3, fem 8). To determine the intensity of fibrosis of ILD we used a limited/extensive classification for disease extent, integrating HRCT observation. According this scheme pts were divided into 2 groups: group 1 included 33 pts had “limited” lung disease (lung lesions less than 20%) and the group 2 included 17 pts had “extensive” lung disease (lung lesions greater than 20%). LUS examination protocol that include the anterior, lateral, and/or posterior thorax have been suggested The B-lines score denoting the extension of ILD was calculated by summing the number of B-lines on a total of 58 scanning sites. In each patient ULC score was obtained by summing the number of comets detected as previously recommended. The data were collected in protocols for statistical testing. Other data collected including biological results (high-sensitivity C-reactive protein (hsCRP) and erythrocyte sedimentation rate (ESR)).

Results: the mean score of B-lines in each groups were: vasculitis (n=11) 21,4 ±12.6; (DM, PM, ASS) (n=20) 41.3±20.8; RA (n=9) 56.5±6.3; SS (n=9) 59 ± 11.8. The mean score of B-lines in groups pts with different intensity of fibrosis are presented in Table 1.

Table 1.

<table>
<thead>
<tr>
<th>Groups</th>
<th>mean score of B-lines</th>
<th>Anterior chest</th>
<th>Mean score of B-lines</th>
<th>Posterior chest</th>
<th>Mean score of B-lines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited (n=33)</td>
<td>22±14</td>
<td>6.6 ±1.71</td>
<td>5 [1;10]</td>
<td>15.4±13.4</td>
<td></td>
</tr>
<tr>
<td>Extensive (n=17)</td>
<td>61.3±27.4</td>
<td>24.2±12.5</td>
<td>36.4±22.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The correlations in Table 1 may confirm the connection of B-lines score and extensity of ILD association with rheumatic disease. The mean score of ULCs determined in all 50 pts didn’t correlate with dates of ESR (R = 0.188, p>0.05) and hsCRP (R=-0.07, p<0.05).

Conclusion: In Russian cohorts presence of LUS score is associates with more severe ILD. Echographic examination of the lung allows evaluating the severity of lung fibrosis and can be used as an additional simple and available method to assess the ILD of rheumatic disease, but we couldn’t find correlation with hsCRP and ESR.

Disclosure of Interests: None declared
Background: Pulmonary disease is one of the most relevant with interstitial lung disease (ILD) being one of the most frequent forms of involvement with result-
ant worsening of morbidity and mortality in disorders such as systemic sclerosis (SSc), rheumatoid arthritis (RA), or inflammatory myopathies. High-resolution com-
tomed computed tomography (HRCT), which is the current gold standard for diagnosis and evolu-
tional control, is problematic owing to ionizing radiation, cost, and accessibility. In this context, lung ultrasound (LUS) is an attractive tool in a grow-
ing research and validation process.

Objectives: to assess specificity and sensitivity of LUS in rheumatic diseases on Russian cohorts of patients.

Methods: 110 pts with ILD of rheumatic disease such as: systemic sclerosis (n=80) (mean age 49.8±13.3, fem 57); vasculitis n=11 (mean age 40.7±9.1, fem 5); dermatomyositis (DM), anti-synthetase syndrome (ASS), polymyositis (PM) n=20, (mean age 48.7±11.9, fem 13); rheumatoid arthritis (RA) n=9 (mean age 56.5±6.3, fem 7); Sjogren’s syndrome (SSj) n=9 (mean age 59.6±12.3, fem 8). Chest HRCT were evaluated. Control group (n=30) without rheumatic diseases and ILD (mean age 51.4±15.4, fem 24); (chest X-ray (CXR) were evaluated). LUS examination protocol that include the anterior, lateral, and/or posterior tho-
rax have been suggested. The B-lines score denoting the extension of ILD was calculated by summing the number of B-lines on a total of 58 scanning sites. In each patient ultrasound comets (ULC) score was obtained by summing the num-er of comets detected as previously recommended. The data were collected in protocols for statistical testing. The diagnostic accuracy LUS is expressed as sensitivity, specificity. ROC (receiver operating characteristic) curves and AUCs (areas under curve) were used of analyze the accuracy of B-lines in recognizing the presence of ILD on HRCT.

Results: the analysis included all the 110 patients enrolled in the study. ROC curve analysis the ULC score of anterior chest area was (AUC =0.876; 95% CI 0.82-0.96; p<0.0001); ROC curve analysis the ULC score of posterior chest area was (AUC =0.908; 95% CI 0.85-0.958; p<0.0001); ROC curve analysis for the total ULC score was (AUC =0.932; 95% CI 0.892-0.972; p<0.0001). Accuracy of echographic signs (B-line) in the different chest areas in the detec-
tion of interstitial lung disease (Table 1).

Table 1.

<table>
<thead>
<tr>
<th>Total B-line Score (TBSL)</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anterior chest area</td>
<td>&gt;5</td>
<td>61.8%</td>
</tr>
<tr>
<td></td>
<td>&gt;10</td>
<td>48.2%</td>
</tr>
<tr>
<td>Posterior chest area</td>
<td>&gt;5</td>
<td>85.5%</td>
</tr>
<tr>
<td></td>
<td>&gt;10</td>
<td>73.6%</td>
</tr>
<tr>
<td>All chest areas</td>
<td>&gt;5</td>
<td>89.1%</td>
</tr>
<tr>
<td></td>
<td>&gt;10</td>
<td>81.8%</td>
</tr>
</tbody>
</table>

Using the TBSL to identify a positive LUS examination, sensitivity and specificity were different depending on the area investigation. The best results were in the posterior area and all chest areas.

Conclusion: our research documented the high diagnostic accuracy of LUS in the detection of ILD. Our findings support the use of LUS a sensitive tool for ILD detec-
tion, especially considering that it’s an inexpensive and nonionizing technique.

Disclosure of Interests: None declared, Sergio Casciaro Shareholder of: Francesco Conversano Shareholder of: Francesco Conversano owns stocks of Echolight Spa, Ernesto Casiario Shareholder of: Ernesto Casiario owns stocks of Echolight Spa, Maur-
tizio Muratore: None declared, Sergio Casiario Shareholder of: Sergio Casiario owns stocks of Echolight Spa

DOI: 10.1136/annrheumdis-2022-eular.4464
Conclusion: The study highlighted that also clinical asymptomatic patients have ILD in IBD at the onset of the IBD. Frequently, a reduced DLCO is detectable in PFT as a sign of early lung involvement, so this represents a potential screening parameter. Moreover, asymptomatic patients are often younger than symptomatic patients. No significant difference was found in CT pattern, but further research is needed as the number of patients is quite small.

Disclosure of Interests: None declared

AB1375
PERFORMANCE OF ULTRASOUND EXAMINATION OF INSERTIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES.

G. Gaujnulla1, E. Kirillova1, A. Odincova1, D. Abdulginanueva1, K. Kazan State Medical University, Hospital Therapy, Kazan, Russian Federation; 2Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan, Gastroenterology, Kazan, Russian Federation

Background: Enthesitis is one of extraintestinal manifestation of inflammatory bowel diseases (IBD). US examination appears to be a useful imaging technique, specifically in identifying enthesis involvement in patients with inflammatory bowel diseases [1].

Objectives: The aim of the study was to perform the individual anatomical site analysis for the evaluation of enthesopathies in patients with inflammatory bowel diseases (IBD).

Methods: A total of 95 patients with IBD were prospectively enrolled, 55 with ulcerative colitis (UC) and 40 with Crohn’s disease (CD). All patients underwent ultrasound in B-mode and PD-mode, to assess the presence of enthesitis. Thirty four different anatomical sites (insertions of short head of the biceps brachii, coracohumeral ligament (2 sites), infraspinatus, supraspinatus, infraspinatus, triceps brachii, flexor carpi ulnaris, flexor carpi radialis, extensor carpi ulnaris, extensor carpi radialis (2), glutaeus minimum, glutaeus medium, spina iliaca anterior superior/inferior, ischiadicus tuberositas, medial collateral ligament of knee (2 sites), lateral collateral ligament of knee (2 sites), patellar ligament (2 sites), pes anserinus, biceps femoris, semimembranous, quadriceps femoris, tibialis anterior, tibialis posterior, peroneus brevis, achille, plantar fascia, medial epicondyle, lateral epicondyle) were evaluated bilaterally with total count 640. If typical ultrasound features, such as enthesal hypochoegenicity, enthesal thickening, presence of vascularization, were present, acute lesions was diagnosed. Bone erosions and enthesophytes were considered as chronic lesions. Fisher’s exact test was used to calculate differences.

Results: The number of positive enthesitis sites was 293/6440 (4.5%), 177 positive sites in patients with UC versus 116 in patients CD (4.7% vs 4.2%). Most often involved sites were pes anserinus and proximal insertion of medial collateral ligament of knee (Figure 1). The number of positive vascularized enthesitis sites was 62/6440 (1.0%), 40 in patients with UC versus 22 in patients with CD (1.0% vs 0.8%). Proximal insertion of medial collateral ligament of knee was involved more often then other sites. At least one positive enthesitis was detected in 72 (76%) patients, 42 (76%) patients with UC versus 30 (75%) patients with CD. Vascularized enthesitis were detected in 35 (37%) patients, 21 (38%) patients with UC versus 14 (35%) patients with CD. There are not statistically significant differences between UC and CD. Signs of chronic lesion were often detected. The number of sites with erosions was 313/6440 (4.8%), 178 (4.8%) in patients with UC versus 135 (5.0%) in patients CD. Enthesophytes of insertion were detected in 91/6440 (1.4%) sites, 41 (1.1%) in patients with UC versus 40 (1.5%) in patients CD. Most often erosion was detected in insertion of medial collateral ligament of knee (both sites) and enthesophytes was found in insertion of quadriceps femoris. There are not statistically significant differences between UC and CD.

Conclusion: Enthesis abnormalities are often features detected by ultrasound in patients with IBD. Most often involved site is medial collateral ligament of knee. There are not significant differences between UC and CD patients.

REFERENCES:

Disclosure of Interests: None declared

AB1376
RELATIONSHIP BETWEEN INTRANEURAL HYPERVASCULARIZATION OF THE MEDIAN NERVE IN POWER DOPPLER AND ELECTROMYOGRAPHIC SEVERITY STAGES IN THE DIAGNOSIS OF SEVERITY OF CARPAL TUNNEL SYNDROME (PRELIMINARY RESULTS)

H. Fouzia1, T. Fatima Zahrera1, K. Berrada1, N. Takhrira1, I. Berrichi1, F. E. Aboorazzak1, 1CHU Tangier-Tetouan-Et-Hoceima, Faculty of Medicine and Pharmacy, Abdelmalek Essaadi University, Tangier, Morocco, Department of Rheumatology, Tangier, Morocco

Background: Carpal tunnel syndrome (CTS) is the most common tunnel syndrome in the upper limbs. Ultrasound has been increasingly used in recent years in the diagnosis of positive and severe CTS. Although the diagnosis of severity is essentially based on the ENMG, several studies have shown that ultrasound data can also constitute criteria for the severity of CTS.

Objectives: The objective of our study is to evaluate the relationship between intraneural hypervascularization of the median nerve in power Doppler and the severity of CTS measured by ENMG.

Methods: This is a descriptive cross-sectional study of patients with clinically retained CTS. We excluded from the study operated patients and patients who received cortisone infiltration in the previous six months. All patients underwent ultrasound examination (B mode and Doppler mode) and electromyography one week apart. The severity stages of CTS have been defined according to the classification of Stevens (1997). The study is still ongoing.

Results: To date we have included 14 patients with typical signs of CTS. 25 wrists were examined sonographically and by ENMG. The mean age of the patients was 54± 10 years. Bilateral SCC was present in 11 patients. Of the 25 affected wrists: 10, 7 and 8 were classified by the ENMG as mild, moderate and severe SCC respectively. On ultrasound, positive Doppler was found in 5 wrists (20% of wrists studied): Doppler was present in 10% of wrists with mild-stage SCC, 14.3% of wrists with moderate-stage SCC and 37.5% of wrists with severe SCC. But this difference was not statistically significant (p=0.31) probably related to the small size of our current sample (study still ongoing).

Conclusion: The preliminary results of our study suggest that intraneural hypervascularization of the median nerve in power Doppler could provide additional information on the severity of carpal tunnel syndrome. Results to be confirmed by the final results.

REFERENCES:

Disclosure of Interests: None declared

AB1377
FULLY AUTOMATIC ASSESSMENT OF NAIL FOLD CAPILLAROSCOPY SOFTWARE – PILOT STUDY

O. Brzegińska1, K. Rychlicki-Kicior2, J. Makowska3. 1Medical University of Lodz, Department of Rheumatology, Łódź, Poland; 2University of Economics and Human Sciences in Warsaw, Computer Science, Warsaw, Poland; 3Medical University of Lodz, Department of Rheumatology, Łódź, Poland

Background: The nail fold capillaroscopy is one of the basic techniques used in diagnosis and monitoring the course of connective tissue diseases, primarily a systemic sclerosis. However, the assessment of the capillary image is time-consuming and subjective, this makes it difficult for a detailed comparison of studies assessed by various physicians.

Objectives: The aim of this study was to validate an automated software for classification the nail fold capillaroscopy as normal or pathological and counting the numerous of vessels on a millimetre.

Methods: 100 correct and 100 pathological images were selected from the database. The classic, manual evaluation of the capillaroscopy was performed twice. The imagines was classified as correct or pathological and mean number of capillaries per millimetre was calculated. The photos were then exported to the training program created for the study, the region of interest (ROI) and individual capillaries were marked. The
calculation of the number of vessels was made at a magnification of about 50x (ensuring the maximum quality of the image obtained during a classic examination). The neural network was trained using the fast.ai library (based on PyTorch). The ResNet-34 deep residual neural network was chosen, 10-fold cross-validation with validation and test set was performed, using Darknet-YoloV3 state of the art neural network in a GPU-optimized (PS1000 GPU) environment. For calculation of 1mm capillaries, additional detection mechanism was designed, in order to automatically detect the scale of the image and transform it into proper pixel dimensions.

Results: The results obtained under neural network training have been referred to the results obtained as part of a manual photo assessment. For the image classification correct vs pathological testing sensitivity 89.0% and specificity 86.9% was obtained. For validation (20% of images have been drawn as a validating group), 89.0% and 89.4% respectively were noticed. For the average number of capillaries in 1mm, an average of three regions have been estimated (the first region with 1mm from the left, the second with 1mm from the right and the third with 1mm in the middle). The estimated number of capillaries in each region has been compared with ground truth data. The RMSE (Root Mean Squared Error) for the test set was 2.81 and the accuracy was 76.2%.

Conclusion: The use of fully automatic Nail Fold Capillaroscopy Software can be a fast and easy method of the correct and changed capillaroscopy pattern classification, the possibility of counting gives a repetitive result regardless of the physician evaluating the capillaroscopy pattern. In the further course of work on the software, it will be possible to distinguish megacapillary, branched vessels, avascularisation and other pathological features, which will allow full automatic image evaluation and easy follow-up of patients.

Disclosure of Interests: None declared


AB1378
RELATION BETWEEN SHARP SCORE AND RADILOGICAL PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE OBSERVATION
O. Alekseeva1, D. Kudinsky1, A. Smirnov1, A. Volkov1, E. Nasonov2, V.A. Nasonova Research Institute of Rheumatology, Diagnostic Department, Moscow, Russian Federation; 2V. A. Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology, Rheumatic Diseases, Moscow, Russian Federation; 3A. Nasonova Research Institute of Rheumatology, Chief Researcher, Moscow, Russian Federation

Objectives: to analyse rheumatoid arthritis (RA)-patients depending on their individual peak radiographic progression.

Methods: 61 RA pts, mean age 50,0 [38,0; 59,0] yrs, mean disease duration 7 [4; 20] months were treated with MTX and biologics according to the Treat-To-Target concept. After first year of therapy management was following real clinical practice rules until the termination of the study (7 years FUP, median 7.7 [7;4;8,6]). The following correlations were identified of total Sharp score 0-7 years FUP with erosion score in all observation periods 4-7 years, 0-7 years (r=0,54 p=0,000, r=0,49 p=0,000, r=0,84 p=0,000, respectively).

Results: RA progression by 1 years FUP was identified in 10% (6 p) of pts, 4 years FUP was identified in 36% (22 p) of pts, by 7 years FUP was identified in 69% (42 p) of pts. All pts divided into groups based increase in erosions according to radiography (RG+) and without it (RG-). In the group RG+ GS at baseline was significantly higher than in RG- group (6 [5; 10] and 5 [1; 8], respectively, p=0.04). We analyzed relation between SHS (erosion score and total Sharp score) 7 years FUP, individual peak radiographic progression and A erosion score and total Sharp score in the observation periods: 0-1 years, 1-4 years, 4-7 years and 0-7 years. The following correlations were identified of erosion score 7 years FUP with total Sharp score 7 years FUP with Total Sharp score in the observation periods 4-7 years, 0-7 years (r=0,43 p=0,00, r=0,34 p=0,007, respectively) and with individual peak radiographic progression in the observation periods 4-7 years, 0-7 years (r=0,43 p=0,00, r=0,34 p=0,007, respectively).

Conclusion: These data show that the radiological progression increases over time at different rates.

Disclosure of Interests: None declared


AB1379
PREDICTORS OF RADIOLGICAL PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PROSPECTIVE OBSERVATION
O. Alekseeva1, V. Rybakova2, A. Smirnov1, A. Volkov1, E. Nasonov3, V.A. Nasonova Research Institute of Rheumatology, Diagnostic Department, Moscow, Russian Federation; 2V. A. Nasonova Research Institute of Rheumatology, Laboratory of Immunology and Molecular Biology, Rheumatic Diseases, Moscow, Russian Federation; 3A. Nasonova Research Institute of Rheumatology, Chief Researcher, Moscow, Russian Federation

Objectives: to identify the prognostic role of ultrasound signs (US) in radiologic progression in RA patients

Methods: 61 RA pts, mean age 50,0 [38,0; 59,0] yrs, mean disease duration 7 [4; 20] months were treated with MTX and biologics according to the Treat-To-Target concept. After first year of therapy management was following real clinical practice rules until the termination of the study (7 years FUP, median it 7.7 [7;4;8,6]). Among them 40 patients with early RA, mean age 51.0 [43,0; 60,0], disease duration 5 [3; 6,5] months. The general characteristics of the group are presented in the Table 1. Hands and feet ultrasound (US) with grayscale (GS), power Doppler (PD), according to the criteria of OMERACT, were analyzed before initiation of treatment and in 3, 6, 9, and 12 months after Radiographs were obtained at baseline, at 12 months, 4 years, and 7 years, radiographic changes were assessed using Sharp/van der Heijde modified scoring method. Structural damage progression was evaluated by change in the Sharp/van der Heijde score (ΔSHS) between baseline and 1.4 and 7 year. We determined the individual peak radiographic progression (ΔSHS scores/time) in RA- patients.

Table 1. General characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>At baseline</th>
<th>After 1 year follow-up</th>
<th>After 4 years follow-up</th>
<th>After 7 years follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age, years</td>
<td>50.0 [38.0; 59.0]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration, months</td>
<td>7 [4; 20]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GS</td>
<td>6 [4; 9]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PD</td>
<td>2 [1; 6]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DAS 28</td>
<td>5.6 [4.8; 6.5]</td>
<td>2.88 [2.0; 3.93]</td>
<td>3.76 [2.94; 5.09]</td>
<td>4.03 [3.42; 4.74]</td>
</tr>
<tr>
<td>ESR, mm/h</td>
<td>35.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>10.6 [3.8; 32.9]</td>
<td>9.2 [1.1; 7.1]</td>
<td>14.0 [14.0; 36.0]</td>
<td>3.0 [1; 2; 8.8]</td>
</tr>
<tr>
<td>Rheumatoid Factor, Positive results</td>
<td>53 (87%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-CPA, Positive results</td>
<td>52 (85%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean erosion score</td>
<td>3 [1; 11]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean joint-space narrowing score</td>
<td>57.0 [31.0; 88.0]</td>
<td>98.0 [77.0; 110.0]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean total Sharp score</td>
<td>70.0 [31.0; 88.0]</td>
<td>102.0 [78.0; 1170]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results: 52 ACPA+ (85%) and 9 ACPA− (15%) patients presented among the 61 patients with RA. RA progression by 4 years FUP was identified in 36% (22 p) of pts, 7 years FUP was identified in 69% (42 p) of pts. At the 7 years FUP 42 of 61 patients had radiographic progression: the count of erosion increased from 0 [0; 3] to 3 [1; 11]. At the same time, on the background of therapy during the first year, a decrease in ultrasound signs of inflammation was determined according to the GS and PD: from 64 [4; 9] to 2 [4; 6] p = 0.000 and from 2 [1; 6] to 0 [0; 2] p = 0.000, respectively, and increase in the number of joints with erosions from 1 [0; 2] to 2 [0; 3], p = 0.000.
All pts divided into groups based increase in erosions according to radiography (Rg +) and without it (Rg-). In the group Rg + GS at baseline was significantly higher than in Rg- group (6 [5; 10] and 5 [1; 8], respectively, p<0.04), CRP at 3 months and at 6 months was significantly higher in Rg + group than in Rg-group (4.15 [1.2; 8.7] and 1.2 [0; 3.5], respectively, p=0.03 and 2.35 [0; 10.1] and 0.4 [0; 4.3], respectively, p=0.025).

Conclusion: Thus, we obtained the first data on the important prognostic role of ultrason in assessing the progression of early RA in a perspective seven-year follow-up.

Disclosure of Interests: None declared


AB1380 ULTRASONOGRAPHIC CHANGES OF PLANTAR FASIA IN PATIENTS WITH PLANTAR FASCIITIS DUE TO ACQUIRED FLAT FOOT

O. Turchan1, A. Liabakh1, O. Burianov2, T. Omelchenko2, L. Osadcha1, 1State Institute “The Institute of Traumatology and Orthopedics of Ukraine”, The Clinic for Foot Pathologies and Complex Prosthetic Treatment, Kyiv, Ukraine; 2Bogomolets National Medical University, traumatology&orthopedics, Kyiv, Ukraine

Background: Plantar fasciitis is a chronic degenerative process of the plantar fascia enthesis. It manifests by pain, predisposition to prolonged course and treatment resistance. In many cases, plantar fasciitis develops in patients with acquired flat feet. Taken into consideration above mentioned, the study of the plantar fascia changes in patients with acquired flat feet by sonography is relevant.

Objectives: To investigate the quantitative and qualitative sonographic changes of the plantar fascia in the case of plantar fasciitis in patients with acquired flat foot.

Methods: 190 patients with plantar fasciitis on the basis of acquired flat feet (133 females and 57 males). The average age of patients was 48 ± 0.97 years (18-81 years). Unilateral pathology was noted in 117 patients and bilateral – in 73 patients. The average body mass index was 27.68±0.3. The average duration of pain syndrome was 101 ± 6.0 days (7 -390 days). The pain syndrome lasted up from 1 to 6 months – in 152 patients, and more than 6 months – in 38 patients. The control group included 15 healthy volunteers (30 feet). Clinical radiological, sonographic, and statistical methods were used.

Results: The main sonographic features were significant reduction in echogenicity, erased or missing fibrous pattern, fuzzy contour of the aponeurosis; and modified contour of the calcaneus; small focal hyperechogenicity points with inflammatory diseases, the changes between the final and basal MIG, DIG, or MoIG (t=1.921, P=.096; t=-1.533, P=0.169; and t=1.761, P=.122, respectively). Among patients with inflammatory pathology, there were no significant differences between final and basal MIG, DIG, or MoIG (t=1.921, P=.096; t=1.533, P=0.169; and t=1.761, P=.122, respectively). Figure 1 summarizes the changes in the mean gray intensity index (MIG) in patients with mechanical and inflammatory pathology. In patients with inflammatory diseases, the changes between the final and basal MIG tend to normalize (approaching the unit). In the mechanical pathology group, the MIG variation shows a less defined behavior.

Figure 1. Box and whisker plot showing the evolution over time of the pathological/healthy gray intensity mean coefficient. MIGp: Mean gray intensity in the pathological enthesis. MIGc: Mean gray intensity in the control enthesis of the same patient.

Conclusion: The computer analysis of static images in gray scale can detect the changes observed in the Achilles enthesis of patients with inflammatory diseases such as spondyloarthritides. It is also demonstrated that in these patients the gray intensity change rate tends to be normalized (approaching the unit) after a steroid injection. Trend to normalization has not been evidenced in patients with mechanical pathology. Corticosteroids apparently do not act on the origin of the mechanical entheseopathies. Therefore, the study of the average, dispersion and fashion of gray intensities is erratic.
The capacity of MIG detecting evolutionary changes in inflammatory pathology shows a potential for the follow-up of patients with spondyloarthropathy and enthesal involvement.

Disclosure of Interests: Carlos Guillén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grünenthal, UCB and Gebro., Paid instructor for: Roche, Novartis, Janssen, Esteve and Menarini., Consultant of: Janssen, Novartis and Roche., Grant/research support from: Pfizer, Grünenthal, Gebro and Novartis., Marina Tortosa-Cabañas: None declared, África Andreu-Suárez: None declared


AB1382
SCREENING OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS THROUGH AN ULTRASONOGRAPHY PROTOCOL
A. Brigante1, J. Rebak2, G. Rizzo3, L. L. Holguín Arias4, F. Rizzo5, S. Quadrelli5, D. Dubinsky1 on behalf of Intestinal Pulmonary Diseases Service of the Sanatorio Güemes. 1Sanatorio Güemes, Rheumatology, Ciudad Autónoma de Buenos Aires, Argentina; 2Sanatorio Güemes, Pneumology, Ciudad Autónoma de Buenos Aires, Argentina; 3Sanatorio Güemes, Diagnostic Imaging Department, CABA, Argentina

Background: Intestinal Lung Disease (ILD) is a frequent complication in patients with autoimmune diseases. Rheumatoid arthritis (RA) does not escape this statement. Different protocols have been proposed for the ultrasound evaluation of this affection showing very good correlation with high-resolution computed tomography.

Objectives: To determine the sensitivity and specificity of an ultrasound evaluation protocol as a screening method for interstitial lung disease in rheumatoid arthritis.

Methods: Consecutive patients diagnosed with RA, with and without ILD, will be included. High-resolution chest CT (HRCT) will be performed in all patients. The lung evaluation protocol by ultrasonography (US); evaluates 50 intercostal spaces (ICS) and will be performed by a rheumatologist and imaging specialist trained in the procedure. The presence of B lines and pleural alterations in the EICs explored will be evaluated. A semiquantitative scale will be used to assess each EIC: 0 = normal, (<10 B lines); 1 = mild (11 to 20 B lines); 2 = moderate (21 to 50 B lines) and 3 = marked (>50 B lines). CT scan was considered the “gold standard” for the diagnosis of ILD and they were evaluated by experienced pulmonologists who were blind to the patient.

Results: 79 patients were included. Female sex 77% with a mean age of 55 (SD 11.4). The comorbidities observed were: hypertension 27%, dyslipidemia 15%, diabetes mellitus 10%, hypothyroidism 30%, smokers 14%, former smokers 18% and osteoporosis in 14% of patients. The patients had a median duration of the disease in years of 7.5 [IQR 9.2]. Eroosive disease was seen in 20 (20%) and rheumatoid nodules in 9.1% of patients. 91% of the patients were under treatment with corticosteroids. Rheumatoid factor was observed in 87% of the patients and Anti-CCP in 71% of the patients, of which 70% had high titers. DILD was observed by HRCT in 21 (27%) patients. The tomographic patterns observed were UIP 7 (33%), probable UIP 2 (10%), cellular NSIP 6 (29%), fibrosing NSIP 3 (14%). An indeterminate pattern was observed in 3 patients. The extent of pulmonary involvement was extensive in 48% of patients and limited in 52%. A sensitivity of 63% (CI95% 44-78) and a specificity of 92% (CI95% 81-97) were observed for the ultrasound evaluation protocol with a PPV of 81% (CI95% 61-92) and NPV of 83% (95% CI 71-90) and an LR+ 8.1 (95% CI 4.6-14.3) and LR- 0.4 (95% CI 0.3-0.48). AUC: 0.81 (p<0.0001).

Conclusion: We observed a moderate sensitivity and specificity of the method to assess interstitial lung involvement in RA with an acceptable AUC for a screening method. These findings are similar to what was found in other cohorts. We believe that the possibility of ILD would be removed. Studies in larger cohorts and comparison with other factors associated with ILD are necessary to improve our understanding of the method and give it the place it deserves.

REFERENCES:


Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.5247

AB1383
QUANTIFICATION OF THE PD SIGNAL BY COMPUTER ANALYSIS OF STATIC IMAGES: INTRA-OBSERVER, INTRA-PATIENT AND SENSITIVITY TO CHANGE VALIDATION.
C. Guillén-Astete1, A. Andreu-Suárez1, M. Tortosa-Cabañas1. 1University Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: The computerized assessment of ultrasound images is an alternative to the dichotomous subjective assessment often used in the study of entheseses. Previously, our group has demonstrated its usefulness in assessing grayscale images; however, the evaluation of enthesial hyperemia using this technique remains a pending task.

Objectives: To determine the intra-observer and intra-patient variability of the hyperemia study using computer analysis of static images.

Methods: Patients with a diagnosis of known spondyloarthropathies and ultrasonic enthesis of the Achilles tendon -according to EULAR criteria (detection of hyperemia by power Doppler (PD) signal within 2mm of the cortex)- were selected. Longitudinal, medial, central and lateral image sections were obtained. Hyperemia was assessed by PD signal detection, and the images with the highest signal intensity were recorded, maintaining the same Doppler gain and PRF settings for each subject. For image analysis, recordings were coded and randomized so that the analyst did not know to which patient a given section corresponded. Intra-observer validity was assessed by comparing the results of sections from the same patient with each other at two different times. Intra-observer variability was evaluated by subjecting the same image to two computer analyses at different times. Finally, validity of sensitivity to change was performed by successive measurements. The software used was ImageJ 1.53e (NIH, USA).

Results: Images of 12 patients with Achilles enthesitis were included: 6 patients with SpA-nRx, four patients with PsA, and two patients with SpA-Rx. On intra-patient evaluation, significant differences in PD signal intensity were detected between medial, lateral, and central sections. In all cases, the measurement obtained in the central section was the highest (Friedman 15.500 P=.000; medial-central -1.500, P=.001; lateral-central -1.250, P=.007). The coefficient of variation in the first and second determinations without considering the sign of the variation was: 4.2% SD 5.5%. In the intra-observer evaluation of the PD signal evaluations at the central cut-off, the mean coefficient of variation, without considering the sign, was: 9.1% SD 72%. In assessing sensitivity to change, patients with 6-month ultrasound studies were grouped into those who maintained treatment and those who eventually discontinued treatment due to therapeutic failure. In the seven patients who maintained treatment, the mean change in hyperemic areas was -94.3% SD 4.4%, while in the five patients who discontinued treatment, it was -65.4% SD 6.3% (p=.000).

Figure 1. Evaluation of the PD signal.

Conclusion: Computer analysis of static Achilles tendon images conforms to the same ultrasound image acquisition recommendations. In addition, it demonstrates excellent intra-patient and inter-observer variability and sensitivity to change, at least when correlated with therapeutic success or failure from a clinical perspective.
Disclosure of Interests: Carlos Guillén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grunenthal, UCB, Gebro, Paid professor for: Roche, Novartis, Janssen, Esteve, Menarini, Consultant of: Janssen, Novartis, Roche, Grant/research support from: Pfizter, Grunenthal, Gebro, Novartis, África Andreu-Suárez: None declared, Marina Tortosa-Cabañas: None declared.

Background: The clinical significance of Dense Fine Speckled (DFS) pattern Anti-nuclear antibodies (ANA) by indirect immunofluorescence method (IIF) is unclear and has been inversely associated with rheumatic disease. 

Objectives: Our purpose was to determine associations between DFS pattern ANA and the disease categories of inflammatory arthritis, ANA associated rheumatic diseases (AARD), fibromyalgia, chronic fatigue syndrome, chronic pain, and atopic disorder.

Methods: This retrospective study used data from patients tested for ANA by IIF between August 2017 to August 2019 at the University of Minnesota Medical Center. Comparisons between the diagnostic categories listed in objectives were made for patients with negative ANA, positive ANA (any pattern) and DFS pattern. Individual disease diagnoses belonging to the above categories were also analyzed. The inflammatory arthritis category included seropositive rheumatoid arthritis (RA), seronegative RA, RA with unknown serology, spondyloarthritis, and psoriatic arthritis. The disease category of AARD included systemic lupus erythematosus (SLE), systemic sclerosis, mixed connective tissue disease, idiopathic inflammatory myopathies, Sjogren’s syndrome (SS), and undifferentiated connective tissue disorder (UCTD). Atopic disorders included atopic dermatitis, urticaria, and asthma. The frequency of Raynaud’s phenomenon was also calculated.

Results: 13,845 patients with an ANA during the study period were identified. 9106 (65.8%) had negative ANA and 4739 (34.2%) had positive ANA by IIF (including all patterns). 640 (4.6%) had ANA positive DFS patterns. Relative risk (RR) was calculated for diagnostic categories and individual diseases. For patients with positive ANA and DFS pattern, the RR for diagnostic codes of inflammatory arthritis categories (1.35 (1.07-1.71), p=0.02) was higher when compared to the frequency of codes in ANA negative. RR for AARD among patients with DFS pattern was also higher [1.78 (1.44-2.2), p<0.001]. There was no significant difference in the frequency of diagnostic codes of chronic pain/fibromyalgia/chronic fatigue syndrome [1.02 (0.9-1.2), p=0.84] atopic disorder [0.68 (0.4-1.15), p=0.16] for DFS+ compared to the ANA group. The frequency of AARD diagnostic codes was lower for patients with DFS pattern [0.64 (0.52-0.79), p<0.001] compared to ANA positive patients with all other patterns, consistent with published data. There was no significant difference of frequency of diagnostic codes for the rest of the disease categories when comparison was made between ANA positive DFS pattern and ANA positive with other patterns. Individual disease diagnostic codes of RA were higher among DFS+ patients when compared to ANA+ patients. The frequency of diagnostic codes of SLE, SSC, UCTD, fibromyalgia, Raynaud’s phenomenon, and autoimmune thyroid disease was also higher among patients with DFS pattern compared to ANA- patients. The frequency of diagnostic codes of seropositive RA was lower among patients with DFS pattern compared to ANA+ with all other patterns. The frequency of diagnostic codes of SLE, SSC, UCTD, and chronic pain was also lower among DFS+ patients, compared to those with ANA of all other patterns, consistent with prior reports.

Conclusion: The frequency of diagnostic codes of RA, SS and Raynaud’s was higher among DFS pattern ANA compared to ANA negative group but was not significantly different from ANA positive with other patterns. This suggests that the presence of a DFS pattern should not be used to indiscriminately exclude the presence of a rheumatic disease.

REFERENCES:

Disclosure of Interests: None declared

Public health, health services research, and health economics

AB1386
A SURVEY ON ACCEPTANCE OF COVID-19 VACCINATION AMONG PATIENTS WITH RHEUMATIC DISEASES - A SINGLE CENTER EXPERIENCE IN MALAYSIA
C. R. Ng, W. S. Wong, Hospital Sultan Ismail, Rheumatology Unit, Department of Medicine, Johor Bahru, Malaysia

Background: According to Statista, 78.5% of the population in Malaysia have completed their vaccination as of 6th January 2022. The acceptance of patients with rheumatic diseases on Covid-19 vaccination is crucial in the long term protection against Covid-19 infection. We conducted a survey to determine the acceptance of Covid-19 vaccination amongst patients with underlying rheumatic diseases.

Objectives: To find out the reasons of vaccination refusal amongst rheumatology patients.

Methods: This was an interview survey. All rheumatology patients who were followed up in rheumatology clinic Hospital Sultan Ismail, Malaysia from 26th April 2021 to 25th July 2021 (total 3 months) were interviewed. Demographic and diagnosis of the patients were collected.

Results: A total of 952 patients were identified. 83.7% of them were female patients (797/952) and majority of them were Malay (46.4%). This was followed by Chinese (36.1%), Indian (16.3%) and others (1.2%). The mean age group was 48 (range from 13-85). 97.6% of the respondents were categorized as having inactive disease during the interview sessions. 36.6% of the patients were diagnosed to have rheumatoid arthritis and 29.1% of them were having systemic lupus erythematosus. These were followed by psoriatic arthritis (10.9%), mixed connective tissue disease (5.5%), systemic sclerosis (2.9%), gout (2.6%), Sjogren syndrome (1.9%), ankylosing spondylitis (1.6%), myositis (1.5%), vasculitis (1.3%), osteoarthritis (1.2%), antiphospholipid syndrome (0.9%), non-arthritic arthritis (0.8%), juvenile idiopathic arthritis (0.8%), seronegative spondyloarthropathy (0.8%), undifferentiated connective tissue disease (0.7%), adult onset Still’s disease 0.5%) and others (< 0.5% each for Ig G 4 related disease, soft tissue rheumatism and fibromyalgia). 87.3% of them were keen or have already received Covid-19 vaccination. 12.7% of them were not keen for the vaccination with various reasons.

48.8% of them were worrying about worsen the condition, 12.4% of them were not keen as they concerned about side effects (3 worry about fever, 1 worry about hepatitis, 1 for nausea, 1 for dizziness, 1 for breathlessness, and 7 for non-specific reasons). 10.7% of them were not keen for pregnancy, 5.7% of them were not keen as worried about allergic reactions, 4.9% of them were worrying about sudden cardiac death, 4% were not keen as on chemotherapy treatment, 3% of them doubted the efficacy of vaccination, 2.5% were not keen as they worried about heart disease, 2.5% worried about increase risks of infection and others (2 for old age, 2 for thrombotic event, 2 for drug interaction and 1 patient due to hemodialysis).

Conclusion: The overall acceptance rate of Covid-19 vaccination amongst patients with rheumatic diseases is very encouraging with the percentage of >85% despite of lacking knowledge about vaccine Covid-19. This result can assist our Ministry of Health to plan for future battle to improve vaccine uptake that hopefully can lead to herd immunity against COVID-19 infection. More counseling sessions are required to clear up the doubts of vaccination and increase the vaccination rate amongst rheumatic patients.

REFERENCES:

Disclosure of Interests: None declared

AB1387
THE EFFECTS OF PREGNANCY AND FERTILITY ON DRUG USAGE AND PREFERENCES IN RHEUMATOLOGICAL DISEASES: A SINGLE CENTER EXPERIENCE
B. Karataş1, N. Çabuk Çelik1, B. Karakaş1, İ. Yalçın1, G. Pire1, H. Ş. Eren1, M. Ş. Kuzu1, M. Yıldırım2, B. N. Özdamar3, M. F. Akyılm4, A. Sahin1, Sivas, Cumhuriyet University Internal Medicine-Rheumatology, Sivas, Turkey; Sivas Cumhuriyet University Faculty of Medicine, Department of Internal Medicine, Sivas, Turkey

Background: Rheumatological diseases usually affect women of reproductive age. Although the effects of these diseases on pregnancy vary; Joint and organ damage that may occur should be prevented, maternal and fetal effects of the treatment should be evaluated (1).

Objectives: The aim of this study to determine the effects of rheumatological diseases and drugs used on pregnancy and fertility.

Methods: Between January 2014 and January 2021, women between the ages of 18-45 who were diagnosed and treated at Cumhuriyet University Medical Faculty Rheumatology-Internal Medicine Department were retrospectively analyzed.

Results: The median age of the patients is 37 (min 19-max 45) years. 517 patients (51.7%) were pregnant after diagnosis, 39 patients (3.9%) had abortion after diagnosis, 957 patients (95.7%) had live birth, 69 patients (6.9%) had curettage, 43 patients (4.3%) could not have children. The median of pregnancies before diagnosis is 2 (min 1-max 11) the median of pregnancies after diagnosis is 1 (min 1-max 6) the median of abortions before diagnosis is 2 (min 1-max 7) the median of abortions after diagnosis is 1 (min 1-max 4) the median of curettage is 1 (min 1-max 3) the median of live births is 2 (min 1-max 5). The distribution of patients according to drug use and drug used during pregnancy is shown in Figure 1. The distribution of the patients according to the diagnosis and the factors affecting pregnancies after diagnosis, abortions after diagnosis, curettage and live birth is shown in Table 1.

Table 1. The distribution of the patients according to the diagnosis and the factors affecting pregnancies after diagnosis, abortions after diagnosis, curettage and live birth.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total</th>
<th>No of pregnant</th>
<th>No of abortion</th>
<th>No of curettage</th>
<th>No of live birth</th>
</tr>
</thead>
<tbody>
<tr>
<td>RA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PsA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

OR: Odds Ratio **p<0.05 significant†FMF: Family Mediterranean FeverRA: Rheumatoid Arthritis§AS: Ankylosing Spondylitis¶PSA: Psoriatic Arthritis‡SLE: Systemic Lupus Erythematosus††APS: Anti Phospholipid Syndrome

Summary

- **Objective:** Conduct a cost-minimization analysis for RA in Spain.
- **Methods:** Consider all cost information for therapeutic alternatives, evaluate the different cost outcomes, and compare MyChart use and non-use.
- **Results:** Patients with active MyChart use had lower costs than those with inactive MyChart use in the cost-minimization analysis.
- **Conclusion:** MyChart use may benefit high-risk groups and improve health equity.

---

**Table 1. Baseline Characteristics of Hospital for Special Surgery Rheumatology Clinic Patients Stratified by MyChart Activation Status**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MyChart Active</th>
<th>MyChart Inactive</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yrs - Mean (SD)</td>
<td>50.3 (15.6)</td>
<td>60.0 (15.3)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Female - N (%)</td>
<td>601 (82.8)</td>
<td>412 (82.2)</td>
<td>0.80</td>
</tr>
<tr>
<td>Race - N (%)</td>
<td></td>
<td></td>
<td>0.37</td>
</tr>
<tr>
<td>White/Caucasian</td>
<td>275 (37.9)</td>
<td>184 (36.7)</td>
<td></td>
</tr>
<tr>
<td>Black/African American</td>
<td>185 (25.5)</td>
<td>135 (27.0)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>58 (8.0)</td>
<td>25 (5.0)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>189 (26.0)</td>
<td>145 (28.9)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>18 (2.5)</td>
<td>11 (2.2)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity - N (%)</td>
<td></td>
<td></td>
<td>0.27</td>
</tr>
<tr>
<td>Hispanic/Latino</td>
<td>294 (40.5)</td>
<td>226 (45.1)</td>
<td></td>
</tr>
<tr>
<td>Not Hispanic/Latino</td>
<td>422 (58.1)</td>
<td>268 (53.5)</td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>10 (1.4)</td>
<td>7 (1.4)</td>
<td></td>
</tr>
<tr>
<td>Preferred language - N (%)</td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>English</td>
<td>611 (84.2)</td>
<td>332 (66.3)</td>
<td></td>
</tr>
<tr>
<td>Spanish</td>
<td>72 (9.9)</td>
<td>134 (26.8)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>43 (5.9)</td>
<td>57 (11.9)</td>
<td></td>
</tr>
<tr>
<td>Needs interpreter - N (%)</td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Not applicable</td>
<td>106 (14.6)</td>
<td>156 (31.1)</td>
<td></td>
</tr>
</tbody>
</table>

---

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2022-eular.693
was gathered from drug cost databases, and a range of discounts were applied according to experts opinion obtained through a survey. Finally, non-pharmacological costs were obtained from literature review. With all this information, a cost-minimization analysis between the suitable therapeutic alternatives was performed for a 1-year time horizon. Robustness of results was validated by a deterministic and probabilistic sensitivity analysis (PSA).

**Results:** ADA was the less expensive option with an annual cost of 4,529 € vs 4,650 € - 10,001 € for the alternative treatments. Infliximab had only a slightly higher cost than ADA (2.7% higher). Cetuximab, etanercept, and tocilizumab showed a high cost profile, with an annual cost between 54% and 71% higher than ADA. Finally, golimumab, tocilizumab and upadacitinib had the highest cost, between 103% and 137% higher than ADA. Sensitivity analysis showed similar results. The deterministic sensitivity analysis showed ADA to be the best option with average and maximum discounts. In the PSA, only ADA and infliximab performed as the best alternative. ADA was the best option 63% of times.

**Conclusion:** According to our model, ADA was the most cost-effective biological option for treating RA in Spain, and the sensitivity analysis validated the results.

**REFERENCES:**
[5] Consejo general de colegios de farmacéuticos de España. Base de datos de medicamentos BotPLUS.

**Disclosure of Interests:** José Manuel Martinez-Sesmero Speakers bureau: Abbvie, Pfizer, Fresenius, Galapagos, Lilly, and Novartis, Consultant of: Abbvie, Pfizer, Fresenius, Galapagos, Lilly, and Novartis, Joan Antoni Schoenenberger-Amazia Speakers bureau: Biogen, Astra-zeneca, and LEO Pharma, Paid instructor for: Biogen, Astra-zeneca, and LEO Pharma, Carlos Crespo-Diz Speakers bureau: Abbvie, Pfizer, Fresenius, Kabi, Gilead, Janssen-Cilag, Novo Nordisk, Novartis, Pfizer, Roche, Shire, SOBI, Takeda, and UCB.

**AB1390 COMPLEMENTARY DIGITAL THERAPY SAFELY IMPROVES QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY ARTHRITIS**

**Background:** Self-management strategies play a central role in improving clinical outcomes in patients with inflammatory arthritis. EULAR recently highlighted the essential role of digital health to increase the self-management of patients. Evidence regarding these supporting digital tools, including mobile apps, is currently however very limited.

**Objectives:** To evaluate the efficacy and safety of a mobile app (Mida Rheuma App) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA) in a prospective study.

**Methods:** Patients with RA, SpA/PsA, stable on their antirheumatic therapy for 24 weeks, were eligible to use the Mida Rheuma App in addition to standard care treatment. The usage of the app targeted the optimization of non-medical treatment in a 4-step process: (1) collection of the information (HRQoL, disease activity, physical impairment, diet, mental health, physical activity, etc.) using standardized questionnaires via the conversational health coach Mida; (2) development of a patient profile that focuses on the patient’s disease, well-being, and behavior; (3) creation of a personalized, evidence-based disease management program based on recommendations from medical guidelines, medical standards, and state-of-the-art clinical research; (4) implementation of personalized recommendations into the patient’s daily life by providing short daily tasks that accelerate positive behavior change. Additionally, the health coach Mida supports the patient in coping with stress, sadness, depression, fatigue, and further disease-related symptoms. This is achieved by various cognitive behavioral techniques, meditation and relaxation methods.

Additionally, we assessed demographic parameters, treatment regimen, disease activity (e.g., SDAI, AASDS), and other patient-reported outcomes (e.g., SF-36) at baseline and after 4 weeks. The study was approved by the Ethics Committee of the Medical Faculty of Mannheim, Heidelberg University.

**Results:** Of 20 patients screened after obtaining informed consent, 19 were enrolled in the study, and 17 patients (12 RA, SpA: 1 axSpA, 4 PsA) completed the study (2 drop-outs due to unwillingness to finish the study). 7 (41.2%) patients were male, and ages ranged from 19 to 63 (40.5±12.2) years. Patients were treated as follows: 7 NSAIDs (41.2%), 2 GC (≥5 mg) (11.8%), 3 HCQ (17.6%), 10 MTX (58.8%), 1 L EF (5.9%), 1 SSZ (5.9%), 1 A Methotrexate (5.9%), 3 JAK1/2 (17.6%), 1 T NF (5.9%), 2 Li-I (11.8%), 1 IL-17i (5.9%). No significant change in antirheumatic treatment was observed during the study. At baseline, 29.4% of the RA and PsA patients were in remission. 25.2% had low, 29.4% had moderate, and none had high disease activity according to SDAI, one axSpA patient had low disease activity (AASDS: 2.2). At the end of the study, slightly more RA and PsA patients were in remission and had low disease activity (58.8% and 23.5%, respectively) and less had moderate activity (11.8%); the axSpA patient had inactive disease (AASDS: 1.8). Regarding patient-reported outcomes, statistically significant improvement was noted for the following parameters: SF-36 Total Score (range of CI 90% and minimum clinically important difference of 2.5), increase of Physical Component Summary of SF-36 by 23.6% (p=0.024), ‘role limitations due to physical health’ by 76.9% (p=0.022), and ‘general health’ by 76.9% (p=0.024). No significant change in other patient-reported outcomes were observed due to clinical importance of their dynamics for Patient Health Questionnaire (PHQ)-9, ‘emotional well-being’ and RADI-AI-5. No negative changes were observed for assessed parameters. No adverse events were reported throughout the study.

**Conclusion:** This prospective study suggests that using an app-based personalized disease management program significantly improves several measures of patient-reported on disease activity in patients with RA and PsA/SpA. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.

**REFERENCES:**

**AB1391 19% PATIENTS WITH CHRONIC RHEUMATIC INFLAMMATORY ARTHRITIC DISEASES PRESENT AN UNFAVORABLE PREGNANCY OUTCOME: A DESCRIPTIVE ANALYSIS OF THE NATIONAL FRENCH SOCIAL SECURITY DATABASE**

A. Moltó1, A. Ajrouche2, D. Tran3, B. Roux2, N. Cuesta-Chalumeau3, E. Elefant4, V. Tsatsaras4, J. Fresonni5, B. Bader-Muenier6, B. Faulh6, F. Tubach7,8. *Cochin Hospital, Assistance Publique Hôpitaux de Paris, Rheumatology, Paris, France*; *APHP CEPHEPI, Paris, France*; *Cochin Hospital, Assistance Publique Hôpitaux de Paris, Internal Medicine, Paris, France*; *Hôpital Trousseau, CRAT, Paris, France*; *Cochin Hospital, Assistance Publique Hôpitaux de Paris, Obstetrics, Paris, France*; *CHU Nancy, Public Health, Paris,*
Background: patients with chronic rheumatic inflammatory diseases (CRID, i.e. rheumatoid arthritis (RA) or spondylarthritides (SpA)) have been reported to have poorer pregnancy outcomes than the general population.

Objectives: to describe the pregnancy outcomes of singleton in patients with CRID in France in the past decade.

Methods: this is an analysis of the French Health Insurance claims database (SNDS), which represents 87% of the French population) from 2008 to 2016. To be included in the analysis patients had to be identified as RA or SpA according to existing diagnostic algorithms, to have at least one pregnancy declaration in the database, and to have continuous health insurance from 1-year before pregnancy onset to 1-year after the end of pregnancy or until death (if death occurred before the 1-year-period after the end of pregnancy) to be included. Only the first singleton pregnancy occurring during the study period was included in this analysis. Both maternal and pregnancy outcomes were considered. Outcomes were identified either by ICD-10 codes or hospital discharge summaries discharge between 2008-2016.

Results: Among the 35 737 identified adult females with a CRID diagnosis (40.7% with RA and 59.3% with SpA), 27 722 (78%) had a pregnancy during the study period. 11 274 (42%) had received at least one DMARD prior to the pregnancy and were included in the analysis. Among them, only 4025 (36%) were exposed to DMARDs during pregnancy. Mean (SD) age of females at the start of the pregnancy was 32 (5) years, and mean (SD) disease duration was 4 (4) years. Pregnancy ended before 13 WG in 21% and after 37 WG in 70% cases. Live-birth represented the most frequent pregnancy outcome (76.9%), and overall 34.7% patients presented at least one unfavorable outcome (see Table 1).

<table>
<thead>
<tr>
<th>Unfavourable outcome</th>
<th>N(%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscarriage (&lt;22WG)</td>
<td>579 (5.2%)</td>
</tr>
<tr>
<td>Abortion</td>
<td>91 (0.8%)</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>48 (0.4%)</td>
</tr>
<tr>
<td>Preterm birth (≥ 22WG and &lt;37WG)</td>
<td>779 (7.1%)</td>
</tr>
<tr>
<td>Low weight at birth (&lt;3rd percentile)</td>
<td>287 (2.6%)</td>
</tr>
<tr>
<td>Perinatal mortality (22WG to 6 days of life)</td>
<td>2 (0%)</td>
</tr>
<tr>
<td>Severe maternal infection</td>
<td>211 (1.9%)</td>
</tr>
<tr>
<td>Severe infection * during first year</td>
<td>603 (5.3%)</td>
</tr>
</tbody>
</table>

Conclusion: More than 75% pregnancies in patients with CRID resulted in a live-birth. Prevalence of miscarriage was surprisingly low, probably related to under-coding. Maternal and infant outcomes seemed comparable to general population. Whether medications had an impact on such outcomes is currently under evaluation.

Disclosure of Interests: None declared


AB1393 COVID-19 HAD AN ADVERSE IMPACT ON DENOSUMAB TREATMENT PROVISION - COMPARISON WITH PRE-PANDEMIC WAITING TIMES AT A UK-BASED RHEUMATOLOGY DEPARTMENT

S. Ling1, L. Bromilow1, S. Vasireddy1. 1Bolton NHS Foundation Trust, Department of Rheumatology, Bolton, United Kingdom

Background: Denosumab treatment is licensed for prevention of osteoporotic fractures. It can cause hypocalcaemia, so bone profile blood tests must be checked prior to treatment. In our department, we have a Standard that patients have blood tests within 1 month before their denosumab injection, and that they receive the injection within 1 month from its due date. A customised MS Access database to record this information and generate a date for the next dose was established in 2015 after a quality improvement project (QIP). At the onset of the COVID-19 pandemic, UK national guidance recommended continued provision of denosumab as an essential service.

Objectives: 1. To re-audit delay from due date to actual injection date after establishment of our database. 2. To compare delay from due date to actual injection date before and after onset of COVID-19. 3. To compare the time between blood tests and actual injection date, before and after onset of COVID-19.

Methods: Data for 2 time-periods were extracted from the database: Time Period 1 (pre-COVID-19) 01-03-2019 – 29-02-2020; Time Period 2 (post-COVID-19) 01-03-2020 – 28-02-2021. For each patient attendance, dates of blood test, due date and actual injection date were extracted. All patient details were anonymised, with a decryption key to identifiers held on a secure server at the host Trust. It was manually determined whether blood tests and injections were within 1 month of when they were due. Statistical analyses were carried out in Stata v.14.0. The Kolmogorov-Smirnov test was used to compare distributions between Time Periods 1 and 2.

Results: Time PERIOD 1: 100 appointments were audited from 68 patients. 20% of blood tests were within 1 month of actual injection date. Median time between blood tests and actual injection was 45 days [IQR 35 – 59]. 32% of actual injections were given within 1 month from due date. This compares favourably with our 2015 QIP, when 40% of actual injections were within 1 month from due date). Median time between due date and actual injection was 29.5 days [IQR 13 – 50.5]. Time PERIOD 2: 77 appointments were audited from 66 individual patients. 24.7% of blood tests were within 1 month of actual injection. Median time between blood tests and actual injection was 45 days [IQR 35 – 59]. 16.6% of actual injections were given within 1 month of due date. Median time between due date and actual injection was 82 days [IQR 40 – 141]. There were no significant differences in time between blood tests and actual injection between Time Periods 1 and 2. However, the time between due date and actual injection date was significantly longer in Time Period 2 (p<0.005).

Conclusion: The introduction of our customized database promoted an improvement in time between due date and actual injection date of denosumab. However, this improvement significantly declined after the onset of the COVID-19 pandemic. Resources may need to be increased and processes adapted to minimise the impact of future emergencies on denosumab provision.


Disclosure of Interests: None declared


P. Studenic1,2, T. Stamm3, Y. Seidler4, A. Dam5, N. Weibrecht6, G. Zauner6, T. H. Jakobsen7, R. L. Hansen7, N. Popper7, T. C. Wilhelm7, H. Radner8, R. Ramos9, J. Rickmann9, C. Urach10, L. E. Kristensen9, T. S. Jørgensen11, 1Karolinska Institute, Department of Medicine (Solna), Division of Rheumatology, Stockholm, Sweden; 2Medical University of Vienna, Department of Internal Medicine 3, Division of Rheumatology, Wien, Austria; 3Medical University of Vienna, Section of Outcome Research; Center for Medical Statistics, Informatics and Intelligence Systems, Wien, Austria; 4Daman, P/S, København, Denmark; 5dwh GmbH, -, Wien, Austria; 6Copenhagen University Hospital Bispebjerg and Frederiksberg, The Parker Institute, København, Denmark; 7Vienna University of Technology, Institute for Information Systems Engineering, Vienna, Austria; 8EU-LAR - European Alliance of Associations for Rheumatology, Young PARE, Kilchberg, Switzerland; 9Österreichische Rheumaliga, -, Maria Alm, Austria; 10The Parker Institute’s Patient Association, -; Copenhagen, Denmark

Background: The use of health apps has become more popular in recent years, but it is still a small and rather unregulated market. Few apps have been designed in collaboration with patients and these mostly address patient reported symptoms. Some clinical registries have already developed patient apps to complete patient-reported outcome measures (PROMs) on smartphones, which normally would have been collected during an outpatient visit and have shown interchangeability. The next step would be providing a patient app offering possibilities not only of individual disease tracking, but to provide automated peer support, health information and behavioural advice.

Objectives: We aimed to further develop and validate RheumaBuddy, a health app for patients with rheumatoid arthritis (RA), from a standard monitoring app to an intelligent health app tailored to the needs of the user that provides transparency to all important stakeholders in Rheumatology care.

Methods: This is an international interdisciplinary project between Austrian and Danish partners funded by the EUREKA program. Rheumatologists, health scientists, digital data experts and patients with RA joined forces in a 4 phase-program, running from 2020 to 2023. Phase 1 continues to develop the app in a co-creation approach in several iterations with patients. Phase 2 concerns developing an automated learning algorithm based on user data to identify patient strata and connect these with helpful non-pharmacological interventions. Phase 3 connects healthcare system data on diagnosis, medication prescription, healthcare facility usage with a large clinical RA database. By that we develop patient pathways that correlate high granularity data with system resources to retrieve results on socioeconomic impact. In phase 4 a randomised clinical trial will evaluate the effect of the developed RB4.0 on clinical disease activity and quality of life.
Results: Currently, RB is regularly being used by more than 3100 patients in 35 countries and 8 languages throughout Europe. The current RheumaBuddy version offers logging of symptoms using Likert scale questions, a joint mannequin to mark painful body parts and a peer-support forum. Additionally, the user can anytime display his/her entries over time in a graphical report and also share data with the healthcare provider. This version is extended with tracking of sleep, working hours and other behaviours. A consultation compass function helps the patient to reflect on goals and issues before the rheumatologist visit. Within this project, we already established a first version of a Recommender System (RS), which will compute correlations between user entries (e.g., between a user’s mood and pain), thus providing individual feedback. Through integration of information obtained from the app with claims data and clinical data from a RA registry, patterns can be identified and translated into different case models that concern the impact of common RA symptoms. By mapping these scenarios with evidence based behaviour and lifestyle advice, the “virtual coach” (advanced RS) will be developed and integrated into the RB4.0 system. During continuous data collection on app users, similarities in user behaviour can be identified, and similar entry patterns can be grouped. This will allow users to exchange and learn from each other regarding certain difficult situations (e.g., “life-hack”) etc. We are creating a comprehensive system in providing feedback to both clinical and psychosocial aspects of coping and disease management, as well as everyday practicalities for living with a chronic disease. Figure 1 displays these aspects, contributing the empowerment of patients.

Figure 1. RB4.0 shall support people living with RA in dealing with disease impact

Conclusion: RheumaBuddy4.0 will provide RA patients the means to improve their quality of life on an individual level, better understand their needs and therapy which could support overcoming barriers of successful shared decision making to achieve better outcomes.

Disclosure of Interests: Paul Studenic: None declared, Tanja Stamm Speakers bureau: AbbVie, Novartis, Roche, Sanofi, and Takeda, Consultant of: AbbVie and Sanofi Genzyme, Grant/research support from: AbbVie and Roche, Yuki Seidler: None declared, Andreas Dam Speakers bureau: Gilead, Galapagos, BMS, Roche, Takeda, Merck, Consultant of: Gilead, Galapagos, BMS, Roche, Takeda, Merck, Nadine Weibrecht: None declared, Christoph Popper Speakers bureau: Roche, Consultant of: as CSO of dwh GmbH, Tanja Stamm: None declared, Rebekka L. Hansen: None declared, Nikolas Popper Speakers bureau: Roche, Consultant of: as CSO of dwh GmbH, Tanja Stamm: None declared, Helga Radner Speakers bureau: Gilead, Merck Sharp, Pfizer, Abbvie, Consultant of: Gilead, Merck Sharp, Pfizer, Abbvie, Romualdo Ramos: None declared, James Rickmann: None declared, Christoph Uraeh: None declared, Lars Erik Kristensen Speakers bureau: AbbVie, Pfizer Janssen, Novartis, Galapagos, UCB, Biogen and Eli Lilly, Consultant of: AbbVie, Pfizer, Janssen, Novartis, Galapagos, UCB, Biogen and Eli Lilly, Grant/research support from: IIT grants from UCB, Biogen, Eli Lilly, Novartis, Tanja Schadt Jørgensen Speakers bureau: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly, Consultant of: AbbVie, Pfizer, Roche, Novartis, UCB, Biogen and Eli Lilly


Background: Rituximab is an efficacious drug for the treatment of Rheumatoid Arthritis (RA). According to literature, administration of rituximab can be based on a fixed interval or on relapse of disease activity. In some countries, like Belgium, after the first rituximab cycle a flare is required for reimbursement of a subsequent cycle.

Methods: Patients with RA, who were currently or previously treated with rituximab, and rheumatologists were invited to participate in a qualitative study consisting of individual, in depth, face-to-face, semi-structured interviews. Participants were recruited based on purposive sampling to ensure diversity. Interviews were conducted via video or telephone call. Additional participants were interviewed until data saturation was achieved, meaning no new information emerged from the last 3 interviews. Interviews were audiorecorded and transcribed verbatim, followed by analysis according to the Qualitative analysis guide of Leuven, which generated themes and subthemes. Patient experts were involved in this research.

Results: In total, 16 patients with RA and 13 rheumatologists were interviewed. Five overarching themes were generated from the interviews: flare definition, recognition, reaction, balance between benefits and barriers and suggestions (Figure 1). Patients and rheumatologists described how they perceive the on-flare retreatment strategy in daily practice, starting with the FLARE DEFINITION itself. Namely, what patients perceived as a flare and the impact of this flare. The second step was RECOGNITION of the flare. Both rheumatologists and patients indicated that patients are able to recognise a flare. However, the patient’s ability to discriminate between inflammatory and other types of pain was perceived as a difficulty. Moreover, patients indicated that depending on the flare’s intensity, they can cope with it themselves, delaying the need for a rituximab cycle. The next step after correctly recognising a flare, was the REACTION, from both the patient’s and rheumatologist’s side. It was stressed that patients must contact their treating rheumatologist in time. Furthermore, a swift response of the rheumatologist was perceived as important. After confirming eligibility, the shared decision to plan a new rituximab cycle can be made while keeping an eye on the organisation. Remarkably, it seemed that rheumatologists approached the retreatment strategy in different ways, meaning that not everyone adhered to the on-flare principle. Several perceived BENEFITS (e.g. lower safety risk, societal cost savings) and BARRIERS (e.g. disease activity fluctuations, slow working mechanisms) were mentioned, making clear that the optimal retreatment strategy should be based on a BALANCE between both. Finally, some SUGGESTIONS (e.g. biomarkers for flare prediction, subcutaneous administration of rituximab) were brought up that could be helpful in applying the optimal retreatment strategy.

Conclusion: Patients play an important role in the recognition of flares and their reaction, in shared decision with the rheumatologist, contributes to the effectiveness of the rituximab on-flare retreatment strategy. Rheumatologists handle the on-flare retreatment strategy as pragmatically as possible, resulting in different approaches. Moreover, both benefits and barriers of on-flare retreatment were
perceived, making clear that a balance should be found to determine the optimal retreatment strategy.

Disclosure of Interests: None declared


AB1395  PATIENTS’ AND RHEUMATOLOGISTS’ PERCEPTIONS REGARDING TAPERING OF RITUXIMAB

D. Bertrand1, A. Deprez1, M. Doumen1,2, D. De Cock1,2, S. Pazmino1, A. Marchat1, M. Thellissen1, J. Joly1, B. Neerincx1,2, R. Westhoven1,2, P. Verschuere1,2.
1Katholieke Universiteit Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium; 2UZ Gasthuisberg Campus, Rheumatology, Leuven, Belgium; 3Katholieke Universiteit Leuven, Clinical and Experimental Endocrinology, Leuven, Belgium; 4ReumaNet vzw, ReumaNet, Zaventem, Belgium

Background: Rituximab is an efficacious drug for the treatment of Rheumatoid Arthritis (RA). The commonly used dose consists of two infusions of 1000 mg with a 2-week interval, but evidence is growing that a lower dose could be as effective. Before implementing a tapering strategy, understanding the perceptions of patients and rheumatologists in this regard is important.

Objectives: The aim was to investigate patients’ and rheumatologists’ perceptions on rituximab tapering.

Methods: Patients with RA, who were currently or previously treated with rituximab, and rheumatologists were invited to participate in a qualitative study consisting of individual, in depth, face-to-face, semi-structured interviews. Participants were recruited based on purposeful sampling to ensure diversity. Interviews were conducted via video or telephone call. Additional participants were interviewed until data saturation was achieved, meaning no new information emerged from the last 3 interviews. Interviews were audio-taped and transcribed verbatim, followed by analysis according to the Qualitative analysis guide of Leuven, which generated themes. Patient experts were involved in this research.

Results: In total, 16 patients with RA and 13 rheumatologists were interviewed. Four themes were found: In favour/reluctant of tapering, shared decision making, implementation of tapering rationale. Patient experts were involved in this research.

Conclusion: It seems that rituximab tapering is not yet incorporated in daily practice as much as tapering of other antirheumatic drugs and this could potentially be related to a lack of experience with rituximab. However, with appropriate education and communication, rheumatologists and patients are willing to taper rituximab. Although, many questions remain, indicating an evidence gap and a need of more research.

Disclosure of Interests: None declared


AB1396  MULTICENTER QUALITATIVE STUDY ON THE EXPERIENCE OF USE OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING DRUGS IN PATIENTS WITH RHEUMATIC DISEASES. WHAT DO OUR PATIENTS THINK?

O. Rusanovych1, M. Sanz2, A. V. Esteban Vazquez2, N. Molina Esteban4, M. D. C. Uyaguari Morocho3, M. Pavia Pascual5, P. Navarro Palomo5, M. Machatou1, N. De la Torre Rubio1, M. Fernandez Castro1, H. Godoy1, C. Barbadillo Mateos1, C. Merino Arguménez1, B. Garcia-Magallon1, J. Sanz1, C. Isasi Zaragoza1, L. F. De Villa1, T. I. Cob1, J. Campos Esteban1, J. L. Andrué Sánchez1, Puerta de Hierro Majadahonda University Hospital, Rheumatology, Majadahonda, Spain; 2La Paz University Hospital, Rheumatology, Madrid, Spain; 3Infanta Sofia University Hospital, Rheumatology, San Sebastián de los Reyes, Spain; 4University Hospital October 12, Rheumatology, Madrid, Spain

Background: The development of targeted biologic (bDMARDs) and targeted synthetic disease-modifying drugs (tsDMARDs) has made a substantial change in the control of our patients, and has allowed an increasing number of patients to achieve clinical remission.

Objectives: To gain understanding of patients’ experiences of starting treatment with b/tsDMARDs, and explore their attitudes in order to improve the doctor-patient relationship, adherence to treatment, compliance, and knowledge about the experience of using b/tsDMARDs.

Methods: A qualitative study was carried out. A consecutive sample of 130 patients attended in the rheumatology units of four Madrid hospitals, from August 29th, 2021 to January 21st, 2022 completed a questionnaire that consisted of 31 questions, a subsequent qualitative analysis of discourse and content through focus groups with patients was carried out. Descriptive statistical analysis was performed. Chi-squared tests were applied to explore the dependency relationship between the different qualitative variables.

Results: One hundred and thirty questionnaires were collected (see general characteristics in the Table 1).

Table 1.  Baseline demographics.

<table>
<thead>
<tr>
<th>Description</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>96 female (73.85%), 34 male (26.15%)</td>
</tr>
<tr>
<td>Age, years, (SD)</td>
<td>51.62±12.31 years</td>
</tr>
<tr>
<td>Ethnicity/race, n(%)</td>
<td>74.6% White or Caucasian, 22.3% Hispanic or Latino, 2.3% Asian, 0.8% Black or African American</td>
</tr>
<tr>
<td>Diagnosis, (%)</td>
<td>42.4% rheumatoid arthritis, 25.3% axial spondyloarthritis, 10% psoriatic arthritis, 6.9% connective tissue diseases</td>
</tr>
<tr>
<td>Time since diagnosis (years), (mean, SD)</td>
<td>14.7 years (+/-11.43)</td>
</tr>
<tr>
<td>Time since initiation of treatment with b/tsDMARDs (years), (mean, SD)</td>
<td>5.84 years (+/-4.28)</td>
</tr>
</tbody>
</table>

Most of the patients (68.46%) felt hope when they were informed that they were going to start treatment with b/tsDMARDs, 26.9% relief, 22.3% happiness and 27.7% fear and concern. 76% of the patients received information about why the treatment was modified, the advantages of b/tsDMARDs (60%), their mechanism of action (48.5%) and the precautions to be aware of (38.5%). Fifty-two percent of the respondents searched for additional information on their own, with the most used sources being from internet search engines (34.2%), the corresponding drug insert (22.8%) and the page of the Spanish Society of Rheumatology (23.7%). 60% of the respondents were informed about the possible risks associated with the treatment, 49.4% reported being more concerned when they contracted an infection. Most of the patients were recommended to receive influenza (81.5%) and pneumococcal (62.8%) vaccine, of which 74.6% and 54.6% received those respectively. A statistically significant dependence was observed between the recommendation of the vaccine and vaccination, since most (91.5%) of those who received the recommendation were vaccinated (p<0.001). Most of the respondents kept their scheduled appointments (87.3%) and never forgot to take their medication (370/4%). 51% of the patients reported that with b/tsDMARDs they had experienced “considerable improvement”, 38.5% indicated that “their life has changed”, 10% reported little or no improvement. It was observed that men reported a maximum degree of concern when they were informed of the onset of cancer (32.4%) and corticosteroids (24.7%), while women were more concerned about the possibility of developing “serious infections” (45.2%) and “heart attack” (29.3%).
aspects have you noticed the greatest changes?” the respondents answered: reduction in outbreaks of the disease (67%), emotional improvement (38.8%) and regaining work activity (31.8%).

Conclusion: In our setting, education programs inform patients adequately, but it seems necessary to make a greater emphasis on therapeutic compliance, providing more safety information, and compliance to recommended vaccinations.

REFERENCES:

Disclosure of Interests:
[42x470]K. Tempest1, H. Reddy1, S. Johns1, K. Wright1, S. Sultan1. 1Airedale General Hospital, Rheumatology, Steeton, United Kingdom

Background: In 2014 we were a small team with only 1 WTE (Whole Time Equivalent) CNS (Clinical Nurse Specialist) and 2 WTE consultants for a population of 220,000. Most CNS clinic appointments were taken up for drug counselling. Waiting times were approx. 6 weeks for drug counselling. Consultants would often counsel for DMARDs that at a year that national meeting a virtual group MDT (multidisciplinary) was presented by the team at Manchester Royal Infirmary (MRI). They used a good quality presentation for patients starting bDMARDs as a tool for drug counselling. After having to put on an extra clinic to counsel 5 patients, all for rituximab, frustratingly I asked why can’t I get them all in the same room to save time? We needed to work smarter, not harder, utilise time & space to ensure best practice but also ensure gold standard, patient centered care continued. We modified the format used at MRI to a face to face group education and counselling of patients to improve waiting times and patient flow.

Objectives: Reduce the amount of clinic appointments used to counsel patients for sDMARDs (synthetic disease modifying anti-rheumatic drugs) and bDMARDs (biologic). Free up clinic appointments for follow up/ review and flares. Standardise information given out to ensure they are all given the same gold standard information and education.

Methods: We visited the team at MRI to view the format of their virtual clinic. It didn’t meet the needs of our service so we modified and adapted the presentation. Set up a group education session to discuss the most common sDMARDs and bDMARDs used for Inflammatory Arthritis. I developed a power point presentation and booklet that can be used by CNS- ensuring the same information is given to every patient, both attending the group session and those not suitable for group session (ie Language barriers) who would be seen individually. We use a screening proforma to ensure safety of commencement for the individual prior to attending clinics which has a tick list for screening requirements. The session is undertaken in our education centre. Pre Covid the session could accommodate up to 10 patients per session per week, uptake on average 6-10 patients for sDMARDs and 5-6 for bDMARDs. We alternated biologic and DMARD sessions, if demand required, we changed a session to accommodate. The room is booked for 1½ hours every week, the sDMARD presentation lasts approximately ½ an hour & bDMARD session 50 minutes, time is allowed for group & individual questions if required at the end. This contrasts with 25 minute appointment for sDMARD & 50 minute for bDMARD counselling 1.1. The booklet, along with information pack, is given at the group session to all patients. This includes all the information the patient requires (advice line information, blood forms). Prior to the group clinic admin team prepare the patient packs for the CNS to give to patients.

Results: We received 102 anonymous responses back from 136 patients asked. (75% response) Following these sessions we found less calls to the advice line regarding medication queries, able to add in further cDMARDs or switch to alternate due to S/Es over the telephone Feedback from patients.-120 comments received. Clear simple information about a number of possible drugs used to treat my condition not just the 1 I am prescribed. If my medication needs changing I already know about it. The lecture aspect of the types/contra-indications of meds was very useful & removed the ‘fear’ attached to these specialist drugs. The session with other patients present stopped me from feeling alone in this position. The booklet is brilliant as it includes everything that was in the session. Also it took away the ‘fear’ of the side effects.

Conclusion: 7 years on we feel that Group Counselling has been a huge success, we noticed how successful this was once we had to deal with the pandemic and cancel the group sessions. Patients feedback proves that they like the session and find them valuable. Whilst being beneficial and improving work productivity and streamlining the service.

Acknowledgements: The Rheumatology Team at The Kellgren Centre Manchester Royal Infirmary

Disclosure of Interests: Kelly Tempest Speakers bureau: Abbvie


Background: Rheumatologists have noted challenges in treating patients with systemic sclerosis (SSc) during the COVID-19 pandemic, such as patients on immunosuppressants and those with preexisting pulmonary issues.1 Also of potential concern was patients delaying treatment due to fears of COVID.

Objectives: This study examined what extent patients with SSc cancelled health-care appointments due to fears of COVID, how this correlated with their mental and physical functioning, and their levels of anxiety and depression.

Methods: We invited all SSc patients scheduled for drug counselling. Waiting times were approx. 6 weeks for drug counselling. Participants were 60 people with SSc who had not had COVID-19 or been vaccinated for COVID. Participants had a mean age of 58 years (SD=11.5) and were primarily female (92%) and white (87%). Participants completed an online survey after learning about it from a scleroderma organization newsletter or at their visit with a rheumatologist specializing in scleroderma in New York State, USA. Data were collected August 2020 through March 2021. Participants completed measures assessing health-care attendance, Patient Reported Outcome Measurement Information System (PROMIS) measures (anxiety, depression, fatigue, sleep disturbance, pain intensity, physical function), coping strategies to deal with the pandemic, and reported functioning relevant to SSc (hand, gastrointestinal, dyspnea, and Raynaud’s disease).

Results: Due to COVID-19 concerns, 28 respondents (47%) cancelled one or more appointments with their primary care physician, specialist, physical or occupational therapist, pulmonologist, or dentist. Compared to those who did not cancel appointments due to COVID concerns, participants who cancelled reported higher anxiety, t(58) = 2.46, p = .02, higher sleep disturbance, t(56) = 3.31, p = .002, worse physical functioning, t(56) = 2.00, p = .05, more constipation, t(56) = 2.05, p = .045, and lower positive reframing as a coping strategy, t(56) = 2.08, p = .04.

Many participants reported moderate or severe anxiety (36%), depression (22%), fatigue (32%), sleep disturbance (28%), and physical dysfunction (40%). As shown in Table 1, anxiety scores were positively correlated with scores on measures of fatigue, sleep disturbance, physical dysfunction, diarrhea, and the coping strategies of substance use, self-distraction, emotional support, behavioral disengagement, and venting. Depression scores were positively correlated with scores on measures of fatigue, sleep disturbance, physical dysfunction, pain intensity, dyspnea, diarrhea, and behavioral disengagement as a coping strategy.

Table 1. Correlations Between Anxiety and Depression with Patient-Reported Outcomes and Coping with the Pandemic

<table>
<thead>
<tr>
<th>Measure</th>
<th>Anxiety</th>
<th>Depression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>.38***</td>
<td>.43**</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>.35***</td>
<td>.34**</td>
</tr>
<tr>
<td>Physical dysfunction</td>
<td>.28**</td>
<td>.49**</td>
</tr>
<tr>
<td>Pain intensity</td>
<td>.16</td>
<td>.36***</td>
</tr>
<tr>
<td>Reflux</td>
<td>.25</td>
<td>.15</td>
</tr>
<tr>
<td>Distention/bloating</td>
<td>.28</td>
<td>.24</td>
</tr>
<tr>
<td>Fecal soiling</td>
<td>.001</td>
<td>.07</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>.34**</td>
<td>.28**</td>
</tr>
<tr>
<td>Constipation</td>
<td>.21</td>
<td>.03</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>.18</td>
<td>.32**</td>
</tr>
<tr>
<td>Raynaud’s disease activity</td>
<td>.06</td>
<td>.02</td>
</tr>
<tr>
<td>Hand functioning</td>
<td>.06</td>
<td>.25</td>
</tr>
<tr>
<td>Coping strategy</td>
<td>.29</td>
<td>.21</td>
</tr>
<tr>
<td>Substance use</td>
<td>.32</td>
<td>.18</td>
</tr>
<tr>
<td>Self-distraction</td>
<td>.32**</td>
<td>.18</td>
</tr>
<tr>
<td>Behavioral disengagement</td>
<td>.37**</td>
<td>.41**</td>
</tr>
<tr>
<td>Using emotional support</td>
<td>.43***</td>
<td>.06</td>
</tr>
<tr>
<td>Venting</td>
<td>.34**</td>
<td>.14</td>
</tr>
</tbody>
</table>

Note. * p < .05; ** p < .01; *** p < .001
Conclusion: Almost half of participants cancelled one or more health appointments due to COVID fears. This subgroup reported significantly higher anxiety, sleep disturbance, constipation, worse physical functioning, and less coping with the pandemic by looking for the positive. Anxiety and/or depression also played a role in 42% of SSC patients and were related to a variety of worse mental and physical health correlates. Future research should examine the extent to which changes in health-related care during the pandemic have implications for disease progression in patients with SSCs.

REFERENCES:

Disclosure of Interests: None declared.

Acknowledgements: The authors would like to thank all the patients who made this research possible.

AB1400 COMORBIDITIES IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TREATMENT NON-ADHERENCE TO BIOSIMILARS IN A NON-MEDICAL SWITCH SCENARIO?

I. Redeker1,2, S. Moustakis1,2, S. Tsiami1,2, X. Baraliakos1,2, I. Andreia,2, B. Huebinger1, J. Braun1,2, U. Klitz1,2, 1Ruhr University Bochum Faculty of Medicine, Rheumatology, Bochum, Germany; 2Rheumazentrum Ruhrgebiet, Rheumatologyst, Herne, Germany

Background: The availability of biosimilars has created a financial incentive to encourage non-medical switching if cheaper products are on the market. In patients with chronic inflammatory rheumatic diseases (CIRD), we have previously reported a relatively high retention rate after switching from originator anti-TNF to its biosimilar. However, this has been different in other studies and the reasons for non-adherence are poorly understood. Comorbidity has recently gained much attention in patients with CIRD and might be a reason for non-adherence.

Objectives: The aim of this study was to analyse the effectiveness and safety of systematic non-medical switching from originator adalimumab (ADA) to ADA ABP501 biosimilar (ABP) over 6 months in patients with CIRD and to investigate the influence of comorbidities on retention rates.

Methods: Patients with CIRD on originator ADA who switched to ABP subsequently from October 2018 onwards were identified from a large routine database and then followed for 6 months. The presence of comorbidities and disease characteristics as well as measures of disease activity, physical function and changes in treatment were documented at baseline (the time of switching from originator ADA to ABP), and at months 3 and 6. Longitudinal data including information on the clinical efficacy and safety of ABP, and the reasons for discontinuation were documented.

Results: A total of 111 CIRD patients on treatment with originator ADA were switched to the biosimilar ABP (Table 1). More than half of the patients (53%) had a Charlson comorbidity score of 0, and had the highest mean Charlson score (1.8). Treatment retention varied only slightly between patients with a Charlson score of 0 and those with ≥0 (Figure 1). In both groups, the majority of patients (90% vs 95%) continued therapy with ABP, while only a small proportion either switched back to originator ADA (6% vs 5%), switched to a different biologic (3% vs 0%), or dropped out (1% vs 0%). The main reason for back switch was the occurrence of adverse events, mostly subjective complaints, most frequently pain. Patients with a Charlson comorbidity score > 0 tended to have poorer scores in trajectories of scores for disease activity and physical function stratified by disease subtype.

Figure 1. Treatment retention after 6 months stratified by the Charlson comorbidity score
Table 1. Patients and disease characteristics

<table>
<thead>
<tr>
<th>Disease Category</th>
<th>RA (%)</th>
<th>axSpA (%)</th>
<th>PsA (%)</th>
<th>Other (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years), mean (SD)</strong></td>
<td>65.1 (12.0)</td>
<td>47.3 (13.1)</td>
<td>51.1 (12.2)</td>
<td>41.8 (14.2)</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Women</strong></td>
<td>60.9% (14)</td>
<td>32.4% (22)</td>
<td>53.3% (8)</td>
<td>40.0% (2)</td>
</tr>
<tr>
<td><strong>Duration (years), median (IQR)</strong></td>
<td>4.0 (3.0-8.0)</td>
<td>5.0 (2.0-8.0)</td>
<td>4.0 (2.0-13.8)</td>
<td>7.0 (4.0-7.0)</td>
</tr>
</tbody>
</table>

Duration originator ADA therapy (months), mean (SD): 43.8 (28.6) 39.4 (26.9) 34.7 (29.0) 60.0 (27.7)

Gastroenterological comorbidities: 21.2% (5) 7.4% (5) 26.7% (4) 40.0% (2)

Hepatic comorbidities: 17.4% (4) 2.9% (2) 13.3% (2) 0

Neurological and psychological comorbidities: 8.7% (2) 17.6% (12) 33.3% (5) 0

Metabolic comorbidities: 21.7% (5) 7.4% (5) 26.7% (4) 40.0% (2)

Osteoporosis: 43.5% (10) 11.9% (8) 6.7% (1) 20.0% (1)

Skin diseases: 21.7% (5) 8.8% (6) 0 40.0% (2)

Eye diseases: 8.7% (2) 23.5% (16) 33.3% (6) 0

Kidney diseases: 13.0% (3) 10.3% (7) 0 40.0% (2)

Conclusion: Comorbidity had no influence on the biosimilar retention rate after 6 months in this study but the majority of patients did not have Charlson scores > 4. However, disease activity and physical function tended to be worse among CIRD patients with comorbidity. Cardiovascular disease and osteoporosis were more often present in RA patients than in axSpA or PsA patients, while neurological and psychological comorbidities were more often observed in the latter.

Disclosure of Interests: Imke Redeker: None declared, Stefan Moustakas: None declared. Styliani Tsiarli: None declared. Xenon Baraliakos: Speakers Bureau: Abbvie, Pfizer, MSD, UCB, Novartis, Lilly, Galapagos, Hexal, Paid speaker for: Abbvie, Pfizer, MSD, UCB, Novartis, Lilly, Galapagos, Hexal, Consultant of: Abbvie, Pfizer, MSD, UCB, Novartis, Lilly, Galapagos, Hexal, Grant/research support from: Abbvie, Pfizer, MSD, UCB, Novartis, Lilly, Galapagos, Hexal, Ioana Andreica: Speakers bureau: Abbvie, Biocad, Pfizer, Roche, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, Ioana Baraliakos: Speaker Bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, Styliani Tsiami: None declared, Helena Marzo-Ortega: Speakers bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, UCB, Uta Kiltz: Speakers Bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, None declared.

Background: The beginning of the COVID-19 pandemic led to a collapse of healthcare systems that was difficult to manage.

Methods: REUMAVID is an international cross-sectional study collecting data through an online survey on RMD patients in seven European countries led by the Health & Territory Research group of the University of Seville, together with a multidisciplinary team including patient representatives, rheumatologists, and health researchers. Data were collected in two phases, the first (P1) between April-July 2020 and the second (P2) between February-April 2021.

Demographics, health behaviours, employment status, access to healthcare services, disease characteristics, WHO-5 Well-Being Index and Hospital Anxiety and Depression Scale (HADS) were collected in the survey. Healthcare utilization includes scheduled appointments and attendance at the rheumatologist consultation of possible treatment effects if COVID-19 is contracted with the rheumatologist, primary health care and psychological care. Descriptive analysis and Mann-Whitney test was used to explore association with healthcare utilization in both phases of REUMAVID.

Results: There were a total of 2,002 participants across both phases with comparable demographic characteristics (mean age 52.6 (P1) vs. 55.0 years (P2); 80.2% female (P1) vs 83.7% (P2); 69.6% married (P1) vs 68.3% (P2); 48.6% university educated (P1) vs 47.8% (P2)). Most prevalent RMD was axial spondyloarthritis in P1 (37.2%), and rheumatoid arthritis in P2 (53.1%). Only 39.2% could have a scheduled appointment with their rheumatologist during P1, compared to 72.5% of patients in P2 (p<0.001). In this sense, only 41.6% of participants in the P1 attended such an appointment while in P2 this figure was 61.5% (p<0.001). The majority of patients (83%) had their scheduled face-to-face appointment changed to an online or telephone phone in the P2, although this proportion was lower in the P1 (54.4%). The most frequent reason for canceling the face-to-face appointment was the alternative of making it by phone or online (54.4% in P1 vs. 83.0% in P2, p<0.001). Although, in P1, 38.1% of participants could contact with their rheumatologist by phone or online, this proportion was 64.3% in P2 (p<0.001). In P1, 64.0% of patients were able to consult with their rheumatologist about the possible effects of treatment in case of contracting COVID-19 (vs. 41.2% in P2; p<0.001). With respect to general practitioners, 57.8% of patients in P1 declared to had accessed primary care or general practitioner (vs. 77.5% in P2; p<0.001). Furthermore, in P2, a higher proportion of participants (83.2%) were able to continue their psychological or psychiatric therapy either online or by phone (vs. 48.3% in P1; p<0.001; Figure 1)

Conclusion: During the first year of COVID-19 pandemic, RMD patients had easier access to the healthcare system, specifically to their rheumatologist. This access was improved through phone and online care. In addition, access to primary care as well as psychological care improved during the second year of pandemic.

Acknowledgements: This study was supported by Novartis Pharma AG. We would like to thank all patients that completed the survey as well as all the patient organisations that participated in the REUMAVID study including: the Cyprus League for People with Rheumatism (CYLPER) from Cyprus, the Associazione Francese de Lute Anti-Rheumatismale (AFLAR) from France, the Helenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMARR) from Italy, the Portuguese League Against Rheumatic Diseases (LPOR), from Portugal, the Spanish Federation of Spondyloarthritides Associations (CEADE), the Spanish Patients' Forum (FEP), UNIMID, Spanish Rheumatism League (LIRE), Andalusian Rheumatism League (LIRA), Catalonia Rheumatism League and Galician Rheumatism League from Spain, and the National Axial Spondyloarthritides Society (NASS). National Rheumatoid Arthritis (NRAS) and Arthritis Action from the United Kingdom.

Disclosure of Interests: Marco Garrido-Cumbrae Grant/research support from: has a research collaboration with and provides services to Novartis Pharma AG, Hercules Marzo-Ortega Speakers bureau: Abbvie, Biocad, Pfizer, Takeda, UCB, Consultant of: Abbvie, Biocad, Pfizer, Takeda, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Takeda, UCB, None declared, Laura Christin Employee of: Novartis Pharma AG, Victoria Navarro-Compán Grant/research support from: Abbvie, Biocad, Pfizer, Roche and UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, None declared, Styliani Tsiami: None declared, Xenofon Baraliakos Speakers bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, UCB, None declared, Ionana Baraliakos: Speakers bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, None declared, Helena Marzo-Ortega Speakers bureau: Abbvie, Biocad, Pfizer, Roche, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Uta Kiltz: Speakers bureau: Abbvie, Biocad, Pfizer, UCB, Consultant of: Abbvie, Biocad, Pfizer, Roche, UCB, Grant/research support from: Abbvie, Biocad, Pfizer, Roche, UCB, None declared.
Background: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications.

Objectives: To systematically review the literature regarding vaccination willingness and vaccination hesitancy in CIRD patients with focus on the perspective of patients and physicians.

Methods: A scoping review was conducted in PUBMED, EMBASE and the Cochrane Library through 2021. Study selection was performed by two independent reviewers, data were extracted using a standardized form and risk of bias was assessed using instruments from the McMaster University. Identified barriers and hurdles were synthesized by categorizing them into the WHO’s Measuring Behavioural and Social Drivers of Vaccination (BeSD) conceptual model.

Results: The search yielded 1,644 hits, of which 30 were included (cross-sectional studies (n=27) based on interviews and 3 intervention studies). The majority of studies reported barriers to influenza and pneumococcal vaccination (n=27) based on interviews and 3 intervention studies). The majority of studies reported barriers to influenza and pneumococcal vaccination (n=27) based on interviews and 3 intervention studies). The majority of studies reported barriers to influenza and pneumococcal vaccination (n=27) based on interviews and 3 intervention studies).

Conclusion: Missed doctor-patient appointments were associated with missed diagnoses and interruptions of ongoing treatments. Fear of the virus immobilisation due to home office and curfews, lack of exercise, sun exposure, caused depressive symptoms, increased alcohol consumption and caloric intake are all increase the risk of osteoporosis. Thus, traditional risk factors for osteoporosis expanded with the direct effects and the introduced restrictions because of the pandemic.

REFERENCES:

Disclosure of Interests: None declared

Methods: Retrospective, observational study of all e-Consults carried out during 2021 in the hospital area Virgen Macarena, which includes 47 PHC centres. E-Consults were carried out by the tool “Plataforma de Teleconsultas del Servicio Andaluz de Salud” (teleconsultation platform of the Andalusian health service) as a clinical extension of the research project E-Hermes for the implementation of e-Consults. It collects information about the reason for the consultation, the suspected diagnosis of the rheumatologist, the response time of the TC and whether the consultation is completely resolved online (DISCHARGE), whether on-site consultation is required (CONSULTATION) or whether the patient needs further e-Consults in order to obtain more medical tests or to evaluate the treatment (FOLLOW-UP). The e-Consults of 2021 were compared to those of the previous year.

Results: Of the 733 e-Consults examined, 610 (83.2%) were fully resolved online and 123 (16.8%) required on-site consultation. Of those fully resolved online, 544 (89.2%) were resolved in the first consultation and 66 (11.8%) required more than one e-Consult. The most common reasons for consultation in this group of e-Consults were: suspected diagnoses of osteoporosis (19.1%), polyarthralgia (14.4%), questions about follow-up patients in Rheumatology (9.4%), joint swelling (7%), hand pain (6.8%) and questions about laboratory or imaging tests (3.9%). For 28% of patients, a rheumatic disease could be excluded, and for those patients who were diagnosed with a rheumatic disease, the most frequent diagnosis was: osteoarthritis 17.3%, osteoporosis 14.4%, fibromyalgia 8.3% and gout 3%. Of the patients that were recalled for an on-site evaluation, in 101 of the cases (90%) this decision was taken after the first e-Consults, while 11 patients (10%) were recalled after subsequent e-Consults. Among the patients recalled for an on-site visit, the most common reason was joint inflammation (23.4%), followed by polyarthralgia (22.1%), osteoporosis (18.2%) and hand pain (7.8%). The most frequent suspected diagnosis was inflammatory rheumatic disease (RA, PsA, SPA) in 49.4% of cases, followed by osteoporosis (24.4%). The average response time of the e-Consults was 82 hours (3 days and 10 hours) Compared to the e-Consults in 2020, it increased by 34%, 186 e-Consults more. The number of cases resolved without on-site consultation was 29% higher than in the previous year, while the e-Consults that required follow-up decreased by 7% and the number of patients that required further on-site consultation also decreased by 11%. The reasons for the consultation and suspected diagnosis were similar in both years.

Conclusion: E-Consults have proved efficacious, avoiding the necessity for on-site consultations in more than 80% of the patients. E-Consults helps to reduce on-site referrals to Rheumatology. E-Consults is effective in reducing waiting times before obtaining an evaluation from the rheumatologist and in prioritizing those patients who need on-site consultation. There are certain pathologies that are especially amenable to resolution with- and in prioritizing those patients who need on-site consultation. There- ing waiting times before obtaining an evaluation from the rheumatologist reduce on-site referrals to Rheumatology. E-Consults is effective in reducing (24,4%) The average response time of the e-Consults was 82 hours (3 days and 10 hours) Compared to the e-Consults in 2020, it increased by 34%, 186 e-Consults more. The number of cases resolved without on-site consultation was 29% higher than in the previous year, while the e-Consults that required follow-up decreased by 7% and the number of patients that required further on-site consultation also decreased by 11%. The reasons for the consultation and suspected diagnosis were similar in both years.

Conclusion: E-Consults has proved efficacious, avoiding the necessity for on-site consultations in more than 80% of the patients. E-Consults helps to reduce on-site referrals to Rheumatology. E-Consults is effective in reducing waiting times before obtaining an evaluation from the rheumatologist and in prioritizing those patients who need on-site consultation. There are certain pathologies that are especially amenable to resolution without on-site consultation, like osteoarthritis, osteoporosis and fibromyalgia. Over time, e-Consults is being integrated in the clinical practice of both the primary care physician and the rheumatologist and is becoming ever more efficient.

REFERENCES:

Figure 1.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3108

AB1405

THE USEFULNESS OF TELEMEDICINE IN RHEUMATOLOGY: POINTS OF VIEW OF PRACTITIONERS AND PATIENTS

M. Yasmine1, D. Ben Nessim1, H. Ferjani1, W. Hamdi1, K. Maatallah1, D. Kaffel1, M. Yasmine1, D. Ben Nessib1, H. Ferjani1, W. Hamdi1, K. Maatallah1, D. Kaffel1, M. Yasmine1, D. Ben Nessib1, H. Ferjani1, W. Hamdi1, K. Maatallah1, D. Kaffel1, M. Yasmine1, D. Ben Nessib1, H. Ferjani1

Background: The advent of COVID-19 has allowed a rapid expansion of telemedicine (TM) and its implementation in various specialties. Despite this extensive use of TM, its role in rheumatology is conflicting and much remains unknown about TM’s acceptability and efficiency in rheumatology.

Objectives: Our study aimed to evaluate rheumatologists’ and patients’ willingness for TM and factors helping to adopt this alternative.

Methods: We conducted a cross-sectional study including patients attending our rheumatology department as well as rheumatologists. Patients were contacted by phone and rheumatologists were invited to answer a questionnaire via Google Form. We evaluated their points of view and suitability for TM by inquiring about their experience with tele-rheumatology, information technology supports, personal barriers to telemedicine, and reasons for adopting this alternative. Moreover, additional questions probed the clinician’s perception of the appropriate clinical context for TM application as well as the corresponding legislation.

Results: Overall, 135 responses were collected including 60 rheumatologists and 75 patients. The distribution of diagnosis was as follows: rheumatoid arthritis (RA) (n=15), spondyloarthritis (SpA) (n=20), juvenile idiopathic arthritis (n=23), and osteoarthritis (n=17). Of the rheumatologists, 76.2% were aged between 30 and 50 years old, 79.3% reported working at an academic center, and the majority were physician-level practitioners (71.2%), working for more than 5 years (81%). Afforid electronic devices were as follows: laptop (87.9%), smartphone (70.7%), afforded headset microphone (24.1%), camera (29.3%) for doctors. Forty-six percent of the rheumatologists estimate that they have a good internet connexion, 62.7% had an appropriate place for teleconsultation. Nearly, 40.7% of the rheumatologists were familiar with the concept of TM but only 39% reported experience with TM. Willingness to accept this model of care for rheumatologists and patients was found in 78% and 37.3% respectively. According to the doctors, the benefits of TM encompassed tele-training (61.7%), remote medical monitoring (61.7%) especially during the COVID-19 (70.2%), benefits for patients (74.5%), reduced inequalities in access to healthcare (46.8%), and improved quality of care (29.8%). The main barriers to TM were the lack of clear legislation (47.8%) and financial compensation (17.4%). Clinicians and patients identified common barriers to effective tele-rheumatology as the inability to perform a physical exam (91.3% vs 33.3%), the fear of trivializing the disease (34.8% vs 36%), and the lack of resources and infrastructures (43.5% vs 29.3%). The majority of the doctors (86.2%) expressed their willingness to attend training workshops. Reported areas to apply TM according to the doctors were mainly osteoarthritis (76.3%) and rheumatic diseases (64.4%), but also pediatric rheumatology (28.8%) and undiagnosed new patients (3.4%). Regarding legislation, most of practitioners estimated that it should be selective with specific authorizations (42.4%) or relaxed with the possibility of derogation (32.2%). Twenty-two percent of them reported that legislation should be strict with the possibility of sanctions, whereas a minority (3.4%) opted for a free practice without regulation at all. Factors associated with adherence to TM were age<40 years (p=0.036) for doctors and familiarity with the concept (p=0.006) and electronic devices afforded (p<0.001) for the patients.

Conclusion: Findings from this study showed the reluctance of the patients to adhere to TM compared to doctors. Concerns and risks may lessen for both sides, once remote consultations are applied. Nevertheless, patient education is required for the success of TM application.

REFERENCES:

Disclosure of Interests: None declared

AB1406

TELERHEUMATOLOGY FOR IMPROVING FIRST ACCESS TO THE OUTPATIENT CLINIC: A PILOT PROSPECTIVE MONOCENTRIC ITALIAN STUDY

E. Giacobba1, M. C. Geradini2, N. Ughi1, A. Adinolfi1, M. Alqoudah1, L. Belloli2, C. Casu1, M. Di Cicco1, D. A. Filipponi1, C. Gagliardi1, M. Muscarà1, E. Verduri2, O. M. Epis1, Ospedale Maggiore - Niguarda, Rheumatology Unit, Milan, Italy; 2The Hashemite University, Internal Medicine, Zarqa, Jordan

Background: The COVID-19 public health emergency has amplified both the potential value and the challenges with healthcare providers deploying telehealth solutions. Furthermore, outpatients may wait up to several months for their first
appointment with specialists including rheumatologists for diseases other than COVID-19. In Italy it is now possible to get access to telemedicine services within the national healthcare systems, yet only follow-up visits are allowed for reimbursement purposes. Instead, it is not clear the role of telemedicine as a tool for improving first access and patient acceptance of this innovation.

Objectives: To investigate the feasibility of a ‘teletriagerheum’ service before the first visit and to identify potential benefits and disadvantages of it by comparing first face-to-face visit preceded by ‘teletriagerheum’ service to regular first visit without it.

Methods: A pilot prospective monocentric study was conducted. Consecutive patients were contacted by phone 30 days before the scheduled rheumatological first visit by administrative staff to investigate their willingness to receive 20 days before the first visit a phone call (‘teletriagerheum’ service) by a physician of the Rheumatology Unit. The ‘teletriagerheum’ service aimed at investigating the reason for the visit and at prescribing additional exams or specialist consultations before the face-to-face first visit to facilitate the diagnosis process or anticipate the appointment in case of urgency. Socio-demographic characteristics, reason for referral, face-to-face visit duration, number of additional exams prescribed, number of definite diagnosis at first visit in the ‘teletriagerheum’ group were compared to the ones receiving regular first visit without ‘teletriagerheum’ service.

Results: In October 2021 a total of 102 patients were phone called by administrative staff: 18 (17.6%) did not answer for a maximum of three times, 9 (8.8%) responded but refused the ‘teletriagerheum’ service (6 cancelled the visit, 1 postponed, 2 for unknown reason) and 75 (73.5%) accepted the service, but 21 were not real first visits and 8 patients did not answer the call of physician. Among the remaining 46 (45.1%) pts (the ‘teletriagerheum’ service) by a physician of the Rheumatology Unit. The ‘teletriagerheum’ service aimed at investigating the reason for the visit and at prescribing additional exams or specialist consultations before the face-to-face first visit to facilitate the diagnosis process or anticipate the appointment in case of urgency. Socio-demographic characteristics, reason for referral, face-to-face visit duration, number of additional exams prescribed, number of definite diagnosis at first visit in the ‘teletriagerheum’ group were compared to the ones receiving regular first visit without ‘teletriagerheum’ service.

Disclosure of Interests: None declared

AB1407 TELEREUMATOLOGY AND WORKING VISIT: INITIAL MONOCENTRIC EXPERIENCE ON USE OF TELEVISION IN THE REGULAR FOLLOW-UP.

F. Cianci1, A. Olga1, M. Magnani1, F. Pignataro1, F. Massimo2, M. Reta1. 1AUSL Bologna, Rheumatology and Internal Medicine, Bologna, Italy; 2Catholic University, ALTEMS, Roma, Italy

Background: The COVID-19 pandemic shifted most healthcare to remote delivery methods (telehealth technologies including clinical video teleserv) to protect patients, clinicians, and hospital staff. Telehaematology visits were found to be noninferior to in-person visits and are often more time and cost effective for patients.

Objectives: Description of an initial integration of video teleserv in regular follow-up.

Methods: In cooperation with the ALTEMS Operational Telemedicine Observatory, we built a procedural manual for teleserv, whose phases were as much as possible similar to the usual visit scenario. Patients in remission or in mild disease activity at the time of enrolling visit were involved. Clinical characteristics, treatments and teleserv’s features were considered for all patients (Table 1). Patient overall satisfaction was evaluated (rating 1 to 5).

Table 1.

<table>
<thead>
<tr>
<th>Patients (n)</th>
<th>M/F</th>
<th>Age (y) median</th>
<th>RA n. (%)</th>
<th>PsA n. (%)</th>
<th>SpA (%)</th>
<th>CTD n. (%)</th>
<th>Vasculitis n. (%)</th>
<th>Other n. (%)</th>
<th>b or tsDMARDs n. (%)</th>
<th>Televisits n.</th>
<th>Mean duration (min.)</th>
<th>Satisfaction (1-5)</th>
<th>Device (PC/smartphone) %</th>
<th>Distance saved, mean (km)</th>
<th>Time travel saved, mean (min.)</th>
<th>CO2 saved (kg)</th>
<th>e-saved (per patient)</th>
<th>Working visit n. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>86</td>
<td>74</td>
<td>27/47</td>
<td>46.2±13.5</td>
<td>19 (25.6)</td>
<td>21 (28.3)</td>
<td>13 (17.5)</td>
<td>8 (10.4)</td>
<td>7 (9.4)</td>
<td>6 (8.1)</td>
<td>20 (26.5)</td>
<td>86</td>
<td>17±3.5</td>
<td>4.68</td>
<td>62.5±275</td>
<td>775</td>
<td>66</td>
<td>866.71</td>
<td>44.37</td>
</tr>
</tbody>
</table>

Results: 86 televisits were performed in 74 consecutive patients, with a mean age of 46.2±13.5 years, diagnosed with the most common rheumatic diseases and on chronic immunosuppressive therapy (c-b-ts DMARDs mono or combination therapy). In 5 cases, in-person visit after televisit was required. The average duration of the televisit was 17±3.5 minutes and the average overall satisfaction was 4.68/5. The average distance saved (round trip) was 775 km, equal to an avoided travel time of 66 minutes and with a total reduction in CO2 production of approximately 866 kg. 5 patients performed video visit from workplace, de facto inventing the “working visit”.

Conclusion: Telemedicine is going to become an essential element of clinical practice in rheumatology, especially for active, young, and working patients, and on chronic immunosuppressive therapy (c-b-ts DMARDs mono or combination therapy). In 5 cases, in-person visit after televisit was required. The average duration of the televisit was 17±3.5 minutes and the average overall satisfaction was 4.68/5. The average distance saved (round trip) was 775 km, equal to an avoided travel time of 66 minutes and with a total reduction in CO2 production of approximately 866 kg. 5 patients performed video visit from workplace, de facto inventing the “working visit”.

AB1408 WELL-BEING AND MENTAL HEALTH OF RHEUMATOLOGY AND FAMILY MEDICINE RESIDENTS

M. Ketata1, S. Miladi1, A. Fazaa1, H. Boussa21, L. Souabni1, K. Ouenniche2, S. Kassab1, S. Chekili1, K. Ben Abdelghani1, A. Laatar1. 1Mongi Slim Hospital, Department of Rheumatology, La Marsa, Tunisia

Background: Burnouts and poor well-being among medical residents are becoming a global concern for health institutions. Its negative consequences are far-reaching, affecting patients, coworkers, family members, and healthcare organizations as well as the burned-out resident.

Objectives: The aim of the study was to measure the extent of burnout among rheumatology and family medicine residents and to elucidate wellness status as well as barriers to wellness.

Methods: An online questionnaire was issued to rheumatology and family medicine residents. We collected sociodemographic data (Age group, gender, marital status, children, smoking and alcohol status, Sport and other activities, Specialty, Weekly working Hours, Vacation) and mental health measurements. Participants were far-reaching, affecting patients, coworkers, family members, and healthcare organizations as well as the burned-out resident.

Disclosure of Interests: None declared


REFERENCES:

ALTEMS = Alfa Scuola di Economia e Management dei Sistemi Sanitari
four percent (34%) of responders practiced sports 2 to 4 times a year and 25% exercised 2 to 4 times a week. The average working hours per week was 30 hours [10-70] with an average of 3.38 weeks’ vacation per year. Seven percent (7%) of residents worked overnight shifts in hospitals with an average of 1.83 shift per month. Female sex (p=0.049), less physical activities (p=0.037) and long working hours (p=0.042) were associated with worst degree of quality of life (WHOQOL Well-Being Index). Residents who practice art and had fewer overnight shifts showed a significantly flourishing mental health (p=0.032, p=0.014) according to the MHC-SF. Family medicine residents, those new EIA who are seen outside hospitals (p=0.039) and overnight shifts (p=0.047) than rheumatology residents.

**Conclusion:** Residents working more than 50 hours per week with more than 5 overnight shifts per month and those practicing fewer physical activities and art appear to be at high risk of developing languishing mental health according to the WHO’s well-being index and the MHC-SF score. It is important to protect healthcare workers and to promote well-being to acquire a flourishing mental health.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3367

---

**AB1409 EVALUATING HOW EFFECTIVELY PATIENTS WITH A NEW INFLAMMATORY ARTHRITIS ARE BEING TRIAGED INTO THE APPROPRIATE CLINIC AT A TERTIARY CARE HOSPITAL IN THE UK: A RETROSPECTIVE STUDY**

A. Vivekanantham1,2, M. Ashraf2, A. Soni1,2, University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom;1Oxford University Hospitals, Nuffield Orthopaedic Centre, Oxford, United Kingdom

**Background:** Inflammatory arthritis is associated with significant morbidity and costs to the NHS, social care, and wider economy. Early diagnosis and treatment are essential to reduce the impact of the disease. Therefore, it is important that referrals for a new inflammatory arthritis are appropriately triaged to be seen in the early inflammatory arthritis (EIA) clinic so that they can be seen and started on disease modifying anti-rheumatoid drugs (DMARDs) without delay. The British Society of Rheumatology guidance for inflammatory arthritis states that patients must be seen within three weeks of referral and started on DMARDs within six weeks.

**Objectives:** To evaluate how effectively people referred with a new EIA are currently being triaged. To evaluate whether we are meeting the national standards.

**Methods:** We performed a retrospective review of the medical notes of all new patients who were seen in the EIA clinic from 01/09/21-31/11/21. During this same time period, we will also reviewed all the patients who had been newly diagnosed and started on a DMARD in the other Rheumatology clinics (e.g., general rheumatology, vasculitis). We collected data on referral date, referral source (e.g., GP), date of clinic assessment, clinic type (e.g., EIA clinic or other Rheumatology clinic), diagnoses made, days’ wait from referral to assessment and days’ wait from referral to commencing DMARD. We then calculated the conversion rate (percentage of referrals triaged to the EIA clinic that have an EIA) and detection rate (percentage of new EIA patients that are seen in the EIA clinic (as opposed to in non-urgent clinics)). The standard for conversation rate (CR) was 50% and for detection rate (DR) was 95%.

**Results:** Of all the patients seen in the EIA clinic (n=73), 36 had a new diagnosis of an EIA, giving a CR of 49%. Of all the new diagnoses of EIA made during that time-period (n=53), 36 were appropriately triaged to be seen in the EIA clinic, giving a detection rate 68%. Those new referrals who had been appropriately seen in the EIA clinic had an average of 5 weeks wait from referral to assessment/ commencement of DMARD. In contrast, those new referrals who had been seen in other clinics had an average of 10 weeks for referral to assessment/ commencement of DMARD. A previous audit performed before the COVID-19 pandemic (01/11/19- 01/01/20) showed a CR of 25% (115 patients seen in EIA clinic, 29 new diagnoses) and a DR of 69% (29 new diagnoses, 20 seen in EIA clinic).

**Conclusion:** Those patients with a new EIA who are appropriately seen in the EIA clinic do not meet the national guidance for being seen within three weeks of referral but do meet the guidance for starting a DMARD within six weeks. However, those new EIA who are seen outside the EIA clinic do not meet either of these standards, with a delay of 10 weeks to be seen/ started on a DMARD. Given that only 68% of people with a new EIA are being correctly triaged to be seen in the EIA clinics, it highlights that there is a need for an improvement in the triage process (currently being done manually by Rheumatologists). Interestingly, when comparing our findings to the audit done pre-COVID-19 pandemic, the CR has improved whilst the DR has stayed steady. The next steps include exploring using additional data collected from patients electronically to improve the CR/ DR rates, as well as artificial intelligence informed modelling of patient referrals.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3367
Disclosure of Interests: Francesca Trentin: None declared, Giovanni Fulvio: None declared, Gianni Andreozzi: None declared, Cosimo Cigolini: None declared, Mattia De Rio: None declared, Valerio Dell’Oste: None declared, Elena Elefant: None declared, Federica Fedeli: None declared, Stefania De Dominici: None declared, Valentina Lorenzoni: None declared, Michele Maffi: None declared, Immacolata Conopoci Navaro Garcia: None declared, Ilaria Palli: None declared, Virginia Pedrinelli: None declared, Laura Scagnelli: None declared, Davide Schirli: None declared, Anastasija Valeyich: None declared, Andrea Gaglioti: None declared, Claudia Carmassi: None declared, Chiara Tani: None declared, Liliana Dell’Oso: None declared, Giuseppe Turchetti: None declared, Marta Mosca Speakers bureau: Lilly, Astra Zeneca, GSK, Consultant of: Lilly, Astra Zeneca, GSK


AB1411 JOINT RHEUMA-DERMA CLINIC: FOUR YEARS OF EXPERIENCE AT THE SAN MARCO HOSPITAL IN CATANIA

R. Fotì,1 G. Giulfrida,2 A. Ramondetta,2 E. Vissali,1 G. Amato1, Y. Dal Bosco,1 F. De Lucia,1 R. Fotì,1 R. De Pasquale3.1 AO Policlinico San Marco, Rheumatology Unit, Catania, Italy; 2 AO Policlinico San Marco, Dermatology Unit, Catania, Italy

Background: Psoriatic arthritis (PsA) affects up to one-third of patients with psoriasis. Many recent works in literature have underlined that the percentage of undiagnosed PsA is still high. A direct collaboration between dermatologists and rheumatologists allows a better management of these patients, to reduce the risk of joint damage, disability, and comorbidities.

Objectives: The aim of this study is to highlight the benefits of a Rheuma-Derma clinic and a shared approach, focused to an early diagnosis and prompt therapeutic strategy for PsA.

Methods: Patients with psoriasis complaining joint symptoms or rheumatologic patients with cutaneous involvement, were simultaneously assessed by a dermatologist and a rheumatologist. The collected data included demographic, clinical characteristics as joint patterns (axial/peripheral), clinimetric index evaluated (DAS28, HAQ, BASDAI, DAPSA, PASI, PGA) family history of psoriasis or PsA, BMI (Mass Body Index), psoriasis, comorbidities and Charlon Comorbidity Index (CCI) assesses comorbidity level by taking into account the number, the severity of the disease, type of treatment and frequency of complications were found between these two groups. In more detail, SSc is associated intestinal lung disease was complicated by vascular damage, autoimmunity, and fibrosis. In these patients, a tight follow-up is crucial to verify the specific cases and clinical needs. In particular, the infection risk in SSc might also be related not only to disease activity but also to possible flares due to therapy discontinuation. Telemedicine has demonstrated as a valid alternative to improve the quality of rheumatic patients' care during COVID-19 pandemic, thus reducing hospitalizations only to urgent admissions (2).

Results: In december 2020 the Azienda Policlincio Vanvitelli approved telemedicine by IRPLUS platform as a particular measure in the face of the COVID-19 pandemic. In this study we examined the impact of the COVID-19 pandemic on visit status of SSc patients at our centre and the patient benefits of telemedicine. Methods: In this study, we retrospectively enrolled 480 SSc patients who visited in our centre between January and December 2021. Of the patients included in the study, 198 patients (18 males and 180 females) used telemedicine, while 282 patients (20 males and 262 females) did not use it.

Results: During televisits, we assessed possible contacts with COVID-19 patients and/or potential risk of COVID-19, investigating about the occurrence of typical symptoms in the last 15 days. No significant differences in background data, such as the severity of the disease, type of treatment and frequency of complications were found between these two groups. In more detail, SSc is associated intestinal lung disease was complicated by vascular damage, autoimmunity, and fibrosis. In these patients, a tight follow-up is crucial to verify the specific cases and clinical needs. In particular, the infection risk in SSc might also be related not only to disease activity but also to possible flares due to therapy discontinuation. Telemedicine has demonstrated as a valid alternative to improve the quality of rheumatic patients' care during COVID-19 pandemic, thus reducing hospitalizations only to urgent admissions (2).

Conclusion: In conclusion, the diagnosis of an Early PsA is essential, as an early treatment and management can alter the natural course of PsA and prevent irreversible joint damage. Our experience proved the increased number of patients since the Rheuma-Derma Clinic have started, such as an increased number of patients under treatment, leading to a significant improvement in the quality of life of PsA and Pso patients.

REFERENCES:

Disclosure of Interests: None declared

AB1412 IMPORTANCE OF TELEMEDICINE IN THE SYSTEMIC SCLEROSIS DURING COVID-19 PANDEMIC

G. Cuomo1, C. Di Vico2, F. Masini3, C. Iandoli4, D. Perretta1, R. Iraco5.1 Università degli Studi della Campania, Precisione di Medicine, Naples, Italy

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19 disease, was firstly reported in December 2019 in China and soon declared a pandemic by the World Health Organization (WHO) on March 11, 2020 (1). As a result, patients’ visits to medical facilities are affected. Systemic sclerosis (SSc) is a chronic systemic autoimmune disease characterized by vascular damage, autoimmunity, and fibrosis. In these patients, a tight follow-up is crucial to verify the specific cases and clinical needs. In particular, the infection risk in SSc might also be related not only to disease activity but also to possible flares due to therapy discontinuation. Telemedicine has demonstrated as a valid alternative to improve the quality of rheumatic patients' care during COVID-19 pandemic, thus reducing hospitalizations only to urgent admissions (2).

Methods: In this study, we retrospectively enrolled 480 SSc patients who visited in our centre between January and December 2021. Of the patients included in the study, 198 patients (18 males and 180 females) used telemedicine, while 282 patients (20 males and 262 females) did not use it.

Results: During televisits, we assessed possible contacts with COVID-19 patients and/or potential risk of COVID-19, investigating about the occurrence of typical symptoms in the last 15 days. No significant differences in background data, such as the severity of the disease, type of treatment and frequency of complications were found between these two groups. In more detail, SSc is associated intestinal lung disease was complicated by vascular damage, autoimmunity, and fibrosis. In these patients, a tight follow-up is crucial to verify the specific cases and clinical needs. In particular, the infection risk in SSc might also be related not only to disease activity but also to possible flares due to therapy discontinuation. Telemedicine has demonstrated as a valid alternative to improve the quality of rheumatic patients' care during COVID-19 pandemic, thus reducing hospitalizations only to urgent admissions (2).

Conclusion: In conclusion, the diagnosis of an Early PsA is essential, as an early treatment and management can alter the natural course of PsA and prevent irreversible joint damage. Our experience proved the increased number of patients since the Rheuma-Derma Clinic have started, such as an increased number of patients under treatment, leading to a significant improvement in the quality of life of PsA and Pso patients.

REFERENCES:

Disclosure of Interests: None declared
Background: The prescription of glucocorticoids at the diagnosis of rheumatoid arthritis (RA) is no longer systematically recommended because of the difficulty of withdrawal and the occurrence of adverse effects. The expert groups currently insist on a short duration of corticosteroids to obtain a low cumulative dose (1, 2). The real-life applicability of the current recommendations may be difficult to achieve (3).

Methods: We conducted a descriptive cross-sectional study of practice conducted with the Moroccan rheumatologists belonging to public and private sectors according to a questionnaire established on a declarative and anonymous mode. The questionnaire was validated by a committee of experts before submitting them to rheumatologists and consisted of 24 single or multiple-choice questions. These questions were divided into 5 items: general data (3 questions), initiation of corticosteroid therapy at diagnosis (7 questions), withdrawal modalities and problems of withdrawal (8 questions), self-medication and patient information (6 questions). The elaboration of the questionnaire was done in “Google Forms” then the collected data were analyzed with the Microsoft office software Excel 2013.

Results: A total of 100 Moroccan rheumatologists responded to the questionnaire. In the initial treatment of RA, 14% of the rheumatologists reported starting corticosteroid therapy in all patients, 41% in two-thirds of their patients, 23% in one-third, 20% in half and 2% in none. The initial oral dose of prednisone or equivalent was 7.5 to 10 mg/day for 52% of rheumatologists and between 5 and 7.5 mg/day for 38%. Flare-up of activity and accompanying conventional treatment were the two first indications for initiation of corticosteroid therapy. 46% of rheumatologists considered weaning after 3 to 6 months of treatment, 26% between 6 months and one year, 23% in less than 3 months and 5% in more than one year. 35% achieve withdrawal in two thirds of their patients. The main problems encountered during withdrawal are self-medication and rebound of the disease. 96% of rheumatologists were in favour of introducing therapeutic education sessions using different tools adapted to the context of the patient and the disease.

Conclusion: The prescription of corticosteroids in RA must be based on the evaluation of the risk-benefit balance. A collaboration between rheumatologist and patient is necessary to prevent the risk of toxicity of corticosteroids and to achieve the goal of withdrawing them.

REFERENCES:

Table 1. Average cost of prenatal care per trimester

<table>
<thead>
<tr>
<th>Medical consultations and ultrasounds</th>
<th>COST PER TRIMESTER</th>
<th>COST PER TRIMESTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatologist</td>
<td>$15</td>
<td>$18</td>
</tr>
<tr>
<td>Genetics</td>
<td>$49</td>
<td>$50</td>
</tr>
<tr>
<td>Obstetrician</td>
<td>$14</td>
<td>$15</td>
</tr>
<tr>
<td>US 1st Trimester</td>
<td>$54</td>
<td>$55</td>
</tr>
<tr>
<td>US 2nd Trimester</td>
<td>$49</td>
<td>$50</td>
</tr>
<tr>
<td>Physiotherapist</td>
<td>$39</td>
<td>$40</td>
</tr>
<tr>
<td>Nutritionist</td>
<td>$5</td>
<td>$6</td>
</tr>
<tr>
<td>Clinical test</td>
<td>$15</td>
<td>$16</td>
</tr>
<tr>
<td>Clinical laboratory</td>
<td>$10</td>
<td>$11</td>
</tr>
</tbody>
</table>

Note: The mean cost for medical consultations and ultrasounds per trimester was $184-277 USD. The average cost of immune test and general lab test ranges from $424-428 USD. The total cost per trimester was from $608 to 705 USD, and the direct cost per three trimesters was $1824-2115 USD.

The average family income per month was $614.23 USD and the average health expenditure per month was 105.71 USD; which represents 16.21% of the family income. The average family health expenditure per trimester was $371.13 USD.

Conclusion: The total cost for prenatal care per trimester was calculated in $608 to 705 USD. The cost of prenatal care per trimester is 193.69% higher than the average health expenditure per trimester for uninsured women with ARDs. More and new strategies are needed to solve and reduce inequalities in access to health.
AB1415 GENDER EQUITY IN RHEUMATOLOGY IN GERMANY, WHERE DO WE STAND? – PRELIMINARY RESULTS FROM A NATIONWIDE ONLINE SURVEY AMONG RHEUMATOLOGISTS IN GERMANY

J. Mucke1,2, X. Basalikakos1,2, E. Feist1,4, D. Gundelach2,3, I. Haase1,2, B. Hoyer1,2, M. Koehn1,2, M. Krusche2,8, C. Mentzel1,2, P. Sewerin1,2, A. Voormann1,2, S. Ohrndorf1,2, University Clinic Düsseldorf, Policlinic for Rheumatology, Düsseldorf, Germany; Commission for Gender Equity in Rheumatology, German Society for Rheumatology, Berlin, Germany; Ruhr-University Bochum, Rheumazentrum Ruhrgebiet, Bochum, Germany; HELIOS Clinic Vogelsang-Gommern, Department of Rheumatology and Immunology, Gommern, Germany; German Society for Rheumatology, Berlin, Germany; University Clinic Schleswig-Holstein, Rheumatology and Clinical Immunology, Campus Kiel, Kiel, Germany; Fraunhofer IME-TMP, Clinical Research, Frankfurt, Germany; Universitätssklinikum Hamburg-Eppendorf, Center for Internal Medicine and Rheumatology, Hamburg, Germany; Charité, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Background: Despite the increasing number of female medical students and fellows, women are still underrepresented in higher career and academic positions in rheumatology [1].

Objectives: To assess gender distribution in rheumatology in Germany and to analyze potential hurdles of flexible work opportunities with the overall aim to improve gender equity in future German rheumatology.

Methods: A web-based anonymous survey using QuestionPro was distributed among rheumatologists in Germany via newsletters, social media, and personal contacts (12/2021-01/2022). The survey was developed based on a narrative literature review [1] and discussions among the commission members. It was composed of 29 questions, with single or multiple answers and/or free text. Non-demographic questions could be answered with “I do not know”.

Results: Among the total of 170 respondents who fully completed the survey, 72% were female, 28% were male and 1% was third gender. 73% were employed at a clinic and 27% in academic institution with 79% working at an academic institution and 20% at a non-academic clinic. 1% did not specify their institution. Of those working at a clinic, 48% were rheumatologists and 7% were head of rheumatology departments. Regarding the gender-ratio in different hierarchical levels, only 17% reported more male than female rheumatologists in training at their workplace, in 32% the gender ratio was balanced. On higher levels, respondents reported more male than female rheumatologists at staff level in 44% (29% balanced) and in leading positions in 74% (12% balanced). 53% of female respondents were responsible for >50% of family and housework, compared to 11% of the male respondents. Most men covered 50% (49% of male respondents) or less than 50% (32% of male respondents) of family work. There were coworkers in part time in the work environment of 86% of respondents, with only women working part time in 56% of cases, both women and men in part time in 29% and only men in part time in 1%. Most respondents stated that men and women working part time did not have the same opportunities as coworkers working full time. (Table 1)

Table 1. Opportunities for advancements of part time working employees compared to full time coworkers with similar qualification in percent of all respondents.

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>I do not know</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>23%</td>
<td>65%</td>
<td>12%</td>
</tr>
<tr>
<td>Men</td>
<td>21%</td>
<td>54%</td>
<td>25%</td>
</tr>
</tbody>
</table>

Many respondents perceived a preference of either gender despite equal performance regarding different aspects with men more often perceived as preferred in terms of opportunities for advancements and staffing of positions. (Figure 1)

Figure 1. Perceived preference of employees in rheumatology with regards to opportunities for advancements, staffing of positions, allocation of research projects and salary according to gender by female and male survey-respondents. Perceived discrimination was not assessed.

66% of respondents agreed that activities to improve gender equity are necessary. The highest need was seen in the improvement of compatibility of care and work with adequate part time models, childcare options at work, and the higher acceptancy of part time working men and women by employers and persons in higher positions (freetext).

Conclusion: Gender imbalance is prevalent in rheumatology in Germany with lower numbers of women at higher hierarchical levels. Traditional role allocation is still common with a higher frequency of part time working females. Part time employment is perceived to decrease chances of advancement. The focus should be on promoting flexible job-sharing models, part time work among men and gender equity not only at work but also in private life (“care work”). Preference for one gender over the other is perceived differently between women and men.

REFERENCES:

Disclosure of Interests: None declared

AB1416 WHAT IS THE FULL ECONOMIC COST OF DELAYED DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS IN THE UK?

G. Xydopoulos1, S. Howard Wilsher1, F. Zangheli1, O. Afolabi1, M. Mishra1, R. Fordham1. University of East Anglia, Norwich School of Medicine, Norwich, United Kingdom

Background: Axial Spondyloarthritis (AS) is an umbrella term for both inflammatory conditions known as Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis. AS generally develops in younger people. Symptoms typically start in the late teenage years to early twenties (with the average age of onset being 24). Hence this condition has a life-long impact, which could increase if left untreated. Average delay to diagnosis is over eight years after the appearance of symptoms. There are currently 220,000 people in the UK living with this painful and progressive form of inflammatory arthritis. While people wait for a diagnosis, many withdraw from socialising and find it harder to establish careers, form relationships, and start families. In addition to healthcare costs, that include multiple visits to GPs, prescription of unnecessary medication and extensive use of over the counter painkillers, there are intangible costs that have large impacts on patients and society. For example, quality of life for the patient, their earning and saving for retirement capacity, social care costs.
AB1417
CORRELATION BETWEEN THE ATTITUDE OF PATIENTS SUFFERING FROM RHEUMATIC DISEASES TOWARDS REMOTE CONSULTATIONS BY RHEUMATOLOGIST AND THE HEALTH LOCUS OF CONTROL

D. Antinis1, J. Sabaliauskiene1, 2Lithuanian University of Health Sciences, Rheumatology, Kaunas, Lithuania; 2Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Rheumatology, Kaunas, Lithuania

Background: During the COVID-19 pandemic telemedicine has become an important and safe means for patients suffering from chronic diseases to control their condition with the assistance of a physician [1]. In order to ensure that treatment of chronic rheumatic diseases is effective, it is important that patients develop a favorable attitude towards telerheumatology [2] as well as disease-related individual behavior, which significantly depends on the patients’ health locus of control [3].

Objectives: To analyze the attitude of patients suffering from chronic rheumatic diseases towards peculiarities of remote consultations by a rheumatologist and their correlation with health locus of control.

Methods: To reveal the patients' attitude towards remote consultations by a rheumatologist, an original questionnaire has been prepared, which contains reasons for choosing remote consultations, fears about such consultations and their advantages. Health locus of control was evaluated using a Multidimensional Health Locus of Control (MHLC) scale, which consists of three subscales: Internal, Chance, and Powerful Others. Demographic questions and questions related to health are also included in the questionnaire. 207 subjects participated in the study: 177 (85.5 %) women and 30 (14.5 %) men, (M, =39.4, SD=11.76). The majority of subjects were diagnosed with spondyloarthritids (n=83), connective tissue diseases (n=53), rheumatoid arthritis (n=49), and osteoarthritis (n=20), 42 subjects were diagnosed with some other rheumatic diseases. 111 (53.6%) patients had the previous experience of remote consulting by a rheumatologist.

Results: It has been determined that the attitude of patients with rheumatic diseases is related to various demographic characteristics of patients, e.g., gender, etc., and the peculiarities of the disease, e.g., strength of the symptoms, etc. It has been found that patients without experience of remote consultations have more fears about such consultations (p=0.024). When comparing the average of statements revealing a positive attitude M=66.4% with the average of statements revealing a negative attitude M=27.3%, it becomes clear that the overall attitude of subjects toward remote consultations of a rheumatologist is favorable. To assess correlations between positive or negative attitude of patients with rheumatic diseases and health locus of control correlational analysis was performed. The results did not confirm the expected correlations between the positive attitude of patients with the internal locus of control. However, it has been obtained that negative attitude towards remote consultations by a rheumatologist positively correlates with two indicators of health locus of control – Chance (r=0.203, p<0.0001) and Powerful Others (r=0.194, p=0.01), although the said correlation is not strong, but statistically significant.

Conclusion: The study has revealed the major fears and satisfaction sources related to remote consultations of Lithuanian patients with rheumatic diseases. In addition, it has shown that personal convictions of a patient that health depends on the circumstances and the influence of other people exacerbates the attitude towards remote consultations.

REFERENCES:

Disclosure of Interests: None declared


AB1418
A SYSTEMATIC REVIEW OF CURRENT RHEUMATOLOGY GUIDELINES FOR GERIATRIC PERSPECTIVES

B. Bink1, M. E. Tezcan2, A. E. Yucel2, 1Baskent University Ankara Hospital, Rheumatology, Ankara, Turkey; 2Kartal Dr. Lütfi Kirdar Şehir Hastanesi, Rheumatology, Istanbul, Turkey

Background: Geriatric population (GP) includes people over 65 years of age. GP can also be divided into the 65-75 age group and >75 age group. In the last 50 years, the proportion of the elderly in the society has increased (1). Meanwhile, GP has higher frequency of rheumatological disorders. While managing the treatment of this special patient group, some physiological differences of the elderly should be considered. Elderly patients are at increased risk for adverse drug reactions as a result of age-related changes in pharmacokinetics and pharmacodynamics. Polypharmacy is contributing to increased risk of clinically significant drug interactions. In addition, alterations in cognitive functions may impair drug compliance. On the other hand, clinicians may hesitate to apply more effective treatment due to safety concerns. (2) Rheumatologists should be aware of the problems they may encounter when planning the treatment of this privileged group.

Objectives: We reviewed rheumatology guidelines to assess rheumatology organizations' perspective on GP.

Methods: Guidelines published by EULAR, ACR and the British Society for Rheumatology (BSR) for adult patients from 1970-2022 were reviewed by two
Results: In total, 58 guidelines were reviewed. None of the guidelines grouped patients by age. Seven (12%) guidelines had recommendations or statements about elderly patients (Table 1). As we observe, there are no satisfactory recommendations for the GP with rheumatological diseases. The most probable reason for this result is the lack of studies in the rheumatology literature to lead to guideline recommendations.

Table 1. Characteristics of guidelines reviewed

<table>
<thead>
<tr>
<th>Number of guidelines (n)</th>
<th>Guidelines with specific recommendation for GP</th>
</tr>
</thead>
<tbody>
<tr>
<td>EULAR 38</td>
<td>10-458</td>
</tr>
<tr>
<td>ACR 11</td>
<td>6</td>
</tr>
<tr>
<td>BSR 9</td>
<td>7</td>
</tr>
</tbody>
</table>

1EULAR points to consider for the management of difficult-to-treat rheumato

Conclusion: Current prominent rheumatology guidelines have insufficiently addressed the management of rheumatological diseases in GP. Additional studies are needed to delineate specific guidelines for the management of geriatric patients with rheumatological diseases.

REFERENCES:

Disclosure of Interests: None declared


AB1420 CLINICIAN-RELATED FACTORS MAY INFLUENCE REMOTE CONSULTATIONS IN RHEUMATOLOGY – ANALYSIS OF SENIOR VS TRAINEE CLINICIANS’ OUTCOMES FROM A COVID-19 INITIATIVE

M. Hannides1, S. Wig1, S. Vasireddy1, J. Bolton NHS Foundation Trust, Rheumatology, Bolton, United Kingdom

Background: Since COVID-19 pandemic started, there have been changes in clinical practice to limit transmission, such as switching from face-to-face to remote consultations. Our department switched to delivering remote consultations without suspending service. Patients were offered the preference of either video or telephone consultation. It is unclear what factors including clinician-related factors significantly influence remote consultations in Rheumatology.

Objectives: We aimed to study the influence of senior (substantively employed) vs trainee status of clinicians on remote consultations in our experience during the pandemic.

Methods: Between 15/10/2020 and 09/11/2020, 12 clinicians in our department completed data collection forms after each remote consultation, recording the technology used (video vs phone); technical problems encountered; discharge and subsequent appointment status; and technical aspects of the consultation itself using 11-point numerical rating scales (NRS) (Time Adequate; Relevant History; Physical Exam; Management Plan; and Communication Quality). Data were collated on an MS Access 2016 database, and transferred to SPSS version 25 for analysis.

Results: Nine senior clinicians (3 consultant rheumatologists, 3 Specialist Nurses, 1 Advanced Rheumatology Practitioner and 2 Senior Rheumatology Pharmacists) and 3 trainee clinicians (2 Specialty Trainee Registrars and 1 Foundation Year 2 doctor) completed forms. 285 forms were validated for analysis. The majority of consultations were completed by senior clinicians (266, 93.3% vs 19, 6.7%). Senior and trainee clinicians had a similar proportion of new patients compared to follow-up patients (18%, n=48 vs 15.8%, n=3; p=0.80); of female patients (88%, n=181 vs 63.2%, n=12; p=0.66); and video consultations (17.3%, n=43 vs 10.5%, n=2; p=0.45); and similar mean age of their patients (59.5 vs 56.7; p=0.72) respectively. Senior clinicians accounted for all the technical issues reported (20%, n=48 vs 0%, n=0; p=0.03). Senior clinicians had lower mean scores compared to the trainee clinicians on NRS for Relevant History (8.68 vs 9.68; p=0.001), Physical Exam (1.49 vs 2.95; p=0.045), and Communication Quality (8.02 vs 9.37; p=0.002); and had no significant differences in scores for Time Adequate (8.46 vs 9.00; p=0.10) and Management Plan (7.17 vs 7.84; p=0.16). Senior and trainee clinicians and a similar proportion requests for subsequent face-to-face appointments (21.9%, n=51 vs 25%, n=4; p=0.77).

Conclusion: There were no significant differences between senior and trainee clinicians in distributions of patients and proportion of video consultations. While no technical issues were reported by the trainee clinicians, this may in part be a reflection of their smaller proportion of overall consultations. Although senior clinicians rated their consultations somewhat lower in some of the NRS, there was no significant difference in management plan scores and subsequent face-to-face appointment status compared to trainee clinicians. However the lower scores may partly reflect the technical issues reported by the senior clinicians, longer clinical experience and greater knowledge may also be an underlying factor for this. Further studies with larger numbers may clarify these issues.

Disclosure of Interests: None declared


EXTRACTIONS:

AB1419 PERFORMANCE OF AN EARLY TRIAGE SYSTEM FOR IDENTIFICATION OF PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES

X. Baraliakos1, I. Redeker1, M. Zacharopoulou1, S. Tsiami1, J. Braun1,2

1Rheumazentrum Ruhrgebiet Hemo, Ruhr-University Bochum, Heme, Germany

Background: The preselection of patients with suspicion of an inflammatory rheumatic disease is not easy for general practitioners and orthopaedists. In countries with a limited number of practicing rheumatologists, waiting lists are often long, since a full rheumatologic examination often needs a long consultation time.

Objectives: To test the performance of an early triage strategy for early identification of patients with inflammatory rheumatic diseases.

Methods: Prior to the SARS-CoV-2 pandemic, physicians caring for patients contacting a tertiary rheumatologic center were first contacted by a health-care professional (HPR) who offered an appointment the timing of which was based on the symptoms reported (Step 1). Patients were then seen by a rheumatologist who, within a 10-minute consultation (Step 2), shortly examined the patient to determine the urgency of a planned full work up. The main outcome of the study was the comparison between the initial assessment and the final expert who, within a 10-minute consultation (Step 2), shortly examined the patient to determine the urgency of a planned full work up. The main outcome of the study was the comparison between the initial assessment and the final expert assessment time.

Results: Between 15/10/2020 and 09/11/2020, 12 clinicians in our department completed data collection forms after each remote consultation, recording the technology used (video vs phone); technical problems encountered; discharge and subsequent appointment status; and technical aspects of the consultation itself using 11-point numerical rating scales (NRS) (Time Adequate; Relevant History; Physical Exam; Management Plan; and Communication Quality). Data were collated on an MS Access 2016 database, and transferred to SPSS version 25 for analysis.

Results: Nine senior clinicians (3 consultant rheumatologists, 3 Specialist Nurses, 1 Advanced Rheumatology Practitioner and 2 Senior Rheumatology Pharmacists) and 3 trainee clinicians (2 Specialty Trainee Registrars and 1 Foundation Year 2 doctor) completed forms. 285 forms were validated for analysis. The majority of consultations were completed by senior clinicians (266, 93.3% vs 19, 6.7%). Senior and trainee clinicians had a similar proportion of new patients compared to follow-up patients (18%, n=48 vs 15.8%, n=3; p=0.80); of female patients (88%, n=181 vs 63.2%, n=12; p=0.66); and video consultations (17.3%, n=43 vs 10.5%, n=2; p=0.45); and similar mean age of their patients (59.5 vs 56.7; p=0.72) respectively. Senior clinicians accounted for all the technical issues reported (20%, n=48 vs 0%, n=0; p=0.03). Senior clinicians had lower mean scores compared to the trainee clinicians on NRS for Relevant History (8.68 vs 9.68; p=0.001), Physical Exam (1.49 vs 2.95; p=0.045), and Communication Quality (8.02 vs 9.37; p=0.002); and had no significant differences in scores for Time Adequate (8.46 vs 9.00; p=0.10) and Management Plan (7.17 vs 7.84; p=0.16). Senior and trainee clinicians and a similar proportion requests for subsequent face-to-face appointments (21.9%, n=51 vs 25%, n=4; p=0.77).

Conclusion: There were no significant differences between senior and trainee clinicians in distributions of patients and proportion of video consultations. While no technical issues were reported by the trainee clinicians, this may in part be a reflection of their smaller proportion of overall consultations. Although senior clinicians rated their consultations somewhat lower in some of the NRS, there was no significant difference in management plan scores and subsequent face-to-face appointment status compared to trainee clinicians. However the lower scores may partly reflect the technical issues reported by the senior clinicians, longer clinical experience and greater knowledge may also be an underlying factor for this. Further studies with larger numbers may clarify these issues.

Disclosure of Interests: None declared

Epidemiology, risk factors for disease or disease progression

AB1421

IMPACT OF HOSPITALIZATION ON CLINICAL OUTCOMES IN PATIENTS WITH CONNECTIVE TISSUE DISEASE ASSOCIATED INTERSTITIAL LUNG DISEASE (CTD-ILD) - A SINGLE CENTER OBSERVATIONAL STUDY


1Montefiore Medical Center-Moses Campus Emergency Room, Rheumatology, Bronx, United States of America; 2Ibero University Medical Group, Rheumatology, Stockton, United States of America; 3Albert Einstein College of Medicine, Epidemiology, Bronx, United States of America; 4Montefiore Medical Center-Wakefield Campus, Internal Medicine, Bronx, United States of America; 5Montefiore Medical Center, Pulmonary Medicine, Bronx, United States of America

Background: Interstitial lung disease (ILD) is major cause of morbidity and mortality in patients with connective tissue disease (CTD). Hospitalization is being increasingly recognized as poor prognostic indicator in these patients.

Objectives: The objective of our study was to assess the impact of hospitalization on clinical outcomes in patients with CTD-ILD.

Methods: We conducted a retrospective chart review of patients with radiologically or biopsy proven ILD associated with rheumatologist diagnosed CTD who were seen at Montefiore Medical Center between January 2007 and December 2018. Patients with age ≥18 years who had either 2 CT scans of the chest and/or 2 sets of pulmonary function tests (PFT) at least 6 months apart were included in the study. Clinical demographics, cause of hospitalization, length of stay, use of immunosuppression and mortality were identified. Patients were stratified into 2 cohorts; non-hospitalized and hospitalized patients. The latter cohort was further sub-stratified into patients with cardiopulmonary vs. non-cardiopulmonary hospitalization (Figure 1). Two-sample t-tests and Wilcoxon’s rank sum tests were used for comparing the continuous variables. Chi-square tests and Fisher’s exact tests were used for comparing the categorical variables as appropriate. Kaplan-Meier method was used for survival times.

Results: During the study period, we identified 213 patients with CTD-ILD using ICD 9/10 code. Of the 213 patients, 96 met our inclusion criteria and 73 (76%) had at least 1 hospitalization (Figure 1). Both groups were similar in baseline clinical characteristics but we identified significantly higher transplant referrals in the hospitalized group (23.9%) vs. non-hospitalized group (0%) (Table 1). Overall rheumatoid arthritis (29.2%) was the most common CTD associated ILD followed by inflammatory myositis (21.9%) and scleroderma (14.6%). Median time from diagnosis of ILD to first hospitalization was 1.42 years. The patients hospitalized for cardiopulmonary cause were significantly older (57.2 ± 13.1 years) than those admitted with non-cardiopulmonary cause (49.2 ± 14.8 years) (Mean ± SD). Older age (HR 1.95, p = 0.02) and length of stay greater than 7 days for cardiopulmonary cause (HR 4.82, p = 0.01) was associated with higher risk of mortality. Kaplan-Meier curve analysis showed that hospitalization (p-value = 0.02) was associated with statistically significant increased risk of death.

Conclusion: Hospitalization in CTD-ILD patients especially length of stay more than 7 days due to cardiopulmonary causes was associated with statistically significant increased risk of death. Male gender and older age was associated with a worse prognosis in patients who were hospitalized.

REFERENCES:

Disclosure of Interests: None declared


AB1422

PREVALENCE OF HYPERURICEMIA IN CHINESE ADULTS: DATA FROM A CROSS-SECTIONAL STUDY

J. Zeng1, W. R. Lawrence2.

1Department of Ultrasound, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China; 2Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, One University Place, Rensselaer, New York, United States of America

Background: Previous studies have observed an increasing trend in the prevalence of hyperuricemia which is linked to the physiological prerequisite for gout in recent years. However, the prevalence of hyperuricemia varies across different populations and different regions.

Objectives: The aim of this study was to explore the prevalence of hyperuricemia and influencing factors in Chinese adults.

Methods: The analysis was a part of a cross-sectional study in Guangdong Second Provincial General Hospital in Guangzhou City, China between January 2009 and December 2019. A total of 205922 participants (21401 with hyperuricemia) were included in this study. Hyperuricemia was defined as serum uric acid ≥416.0 μmol/L (70.5 mg/dl) for men and ≥3570 μmol/L (60.0 mg/dl) for women. We calculated the prevalence of hyperuricemia and used the multivariate-adjusted logistic regression model to identify the risk factors associated with hyperuricemia.

Results: The overall estimated prevalence of HUA was 10.4% in China. Our study showed the prevalence of hyperuricemia in male (10.7%) was higher than that in female (9.9%) (P<0.05). The prevalence of HUA in the age group ≥75 years (13.3%) was higher than others. Multivariate logistic regression analysis revealed that sex (OR=1.75), age (OR=1.168), blood urea nitrogen (BUN) (OR=1.051), creatinine (Cr) (OR=1.045), high-density lipoprotein cholesterol (HDL-C) (OR=1.225), low-density lipoprotein cholesterol (LDL-C) (OR=1.466), systolic blood pressure (SBP) (OR=1.012), triglycerides (TG) (OR=1.460) and Body Mass Index (BMI) (OR=1.080) could increase the risk of hyperuricemia, while diastolic blood pressure (DBP) (OR=0.998), fasting plasma glucose (FPG) (OR=0.902) and total cholesterol (TC) (OR=0.704) were associated with a lower risk of hyperuricemia in all age groups.

Conclusions: The latest prevalence of hyperuricemia is high in Chinese adults and is associated with multiple factors, indicating that prevention and control strategies for hyperuricemia are needed urgently.

REFERENCES:
CliniCal and laboratOry featureS of patieNts with idiopatHic granulatomatous mastitis at a tertiary medical ceNter

B. Abbi1, X. Xie2, S. Fineberg3, A. Gupta4, A. Kumthekar1, B. Ayesha1.
1Montefiore Medical Center, Department of Rheumatology, Bronx, United States of America;
2Albert Einstein College of Medicine, Department of Epidemiology & Population Health, Bronx, United States of America;
3Montefiore Medical Center, Department of Pathology, Bronx, United States of America;
4Montefiore Medical Center, Department of Surgical Oncology, Bronx, United States of America

Background: Idiopathic granulomatous mastitis (IGM) is a benign, inflammatory disease of the breast. As per the literature review, etiopathogenesis of this disease is unclear. The gold standard of diagnosis is through breast biopsy and identification of non-caseating granulomas. [1] Until recently, there has been a lack of clinical, serological or histopathological criteria to guide physicians on management of IGM.

Objectives: The objective of our study is to identify distinguishing clinical and laboratory features amongst individuals with IGM based on serologic and histopathologic status. In this study, clinical and laboratory features were compared between patients with complete remission of IGM and those with relapse of IGM after three months of remission.

Methods: After institutional review board (IRB) approval, we queried pathology and clinical looking glass databases at Montefiore Medical Center between 1990-2021 to identify patients with the diagnosis of IGM. We identified 46 patients, and did a retrospective chart review to extract data. Clinical features were compared in patients with IGM who had complete resolution of disease and those who had relapse of disease using two-sample t-tests for continuous variables and chi-squared or Fisher’s exact tests for categorical variables. In this study, we included females older than eighteen years of age. We excluded patients with breast cancer, lymphoproliferative disorders, solid organ malignancy, foreign body reaction in breast, plasma cell mastitis, and ductal ectasia.

Results: Of the 46 symptomatic patients with histopathological diagnosis of IGM, 27 female patients with sufficient clinical data were included in final analyses. All patients in our cohort had a mean age of 36 years (SD 9 years) and average body mass index of 31.5 kg/m² (SD 6.7 kg/m²). Majority of patients were Hispanic, 11 patients (40.7%). Unilateral disease (96.3 %) was predominant in patients. Most patients had at least one previous full-term pregnancy prior to diagnosis, 25 patients (92.6%) and 8 patients were on hormonal oral contraceptives (29.6%). Of the 27 patients, 18 patients (66.6%) had complete remission of disease. All of these patients were initially treated with antibiotic therapies until tissue cultures were reported negative. Six of these patients received steroid therapy after antibiotic therapy, while 5 patients were started on methotrexate therapy, starting with a dose of 15 milligrams (mg) orally once per week. Of the total cohort, 9 patients (33.3%) experienced relapse of the disease.

Conclusion: IGM is a relatively newer entity that is difficult to manage, due to lack of standard guidelines in literature. In this study, comparing IGM patients with remission and relapse, there were no statistically significant differences in clinical and laboratory features. However, immunomodulating therapy with methotrexate can be considered in patients with relapsing IGM. Further studies are needed to evaluate patients with IGM and their disease evolution that can facilitate management to determine utility of methotrexate in improving relapse rates in these patients.

REFERENCES:

Figure 1. Study Population

Disclosure of Interests: Bhavna Abbi: None declared, Xianhong Xie: None declared, Susan Fineberg Consultant of: expert consultant /expert panel for AXDEV Group in 2021 and Genomic health (now exact Sciences) in 2017; Anjuli Gupta: None declared, Anand Kumthekar: None declared, Bibi Ayesha: None declared


Investigation of the type and frequency of neurological side effects with biological treatment in inflammatory rheumatic diseases

S. Umut1, T. Yuce Inel2, I. S. Sengun3, F. Onen2, I. Sarı2. 1Dokuz Eylul University Faculty of Medicine, Internal Medicine, Izmir, Turkey; 2Dokuz Eylul University Faculty of Medicine, Rheumatology, Izmir, Turkey; 3Dokuz Eylul University Faculty of Medicine, Neurology, Izmit, Turkey

Background: With the increasing use of biological treatment in inflammatory rheumatic diseases, some neurological side effects, especially central and peripheral nervous system demyelinating disorders, are seen.

Objectives: To evaluate whether there is an increase in the frequency of neurological disorders with biological treatment compared to the normal population, and the relationship between discontinuation of biological agents and neurological symptoms.

Methods: Adult patients using biological treatment followed in the Rheumatology outpatient clinic of Dokuz Eylul University between January 2011 and January 2020 were included. The relationship between biological agents and type, severity and duration of neurological symptoms, and the laboratory, imaging (cralian CT, MRI) and electrophysiological findings of the patients were retrospectively reviewed. Current treatments for rheumatologic disease and neurological findings, and disease activity were investigated.

Results: In our study, neurological side effects were observed in 16 (1.8%) of 877 patients using biological drugs. The mean age of the patients was 51.8±12.53 years, and the duration of rheumatologic disease was 10.69±4.86 years. Nine patients had peripheral neuropathy, two had CNS demyelinating disease, two had peripheral demyelinating disease, two had intracranial mass and one had...
headache syndrome. The neurological disease developed a mean of 5.13±4.26 months after the first biological agents. The demographic and clinical characteristics of the patients and the neurological side effects that developed during the follow-up period are summarized in Table 1. Biological treatment was discontinued in 68.8% of patients. There was no significant correlation between biological agents’ continuation status and progression of neurological findings.

<table>
<thead>
<tr>
<th>Table 1. Demographic and clinical characteristics of patients who developed neurological symptoms with biological treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Age of diagnosis (years)</td>
</tr>
<tr>
<td>Disease duration (years)</td>
</tr>
<tr>
<td>Smoking</td>
</tr>
<tr>
<td>ex smoker</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
</tr>
<tr>
<td>bDMARD</td>
</tr>
<tr>
<td>Infliximab</td>
</tr>
<tr>
<td>Etanercept</td>
</tr>
<tr>
<td>Certolizumab</td>
</tr>
<tr>
<td>Tocilizumab</td>
</tr>
<tr>
<td>Secukinumab</td>
</tr>
<tr>
<td>Tofacitinib</td>
</tr>
<tr>
<td>Imaging (CT, MRI)</td>
</tr>
<tr>
<td>Electrophysiological study</td>
</tr>
<tr>
<td>Neurological Side Effect</td>
</tr>
<tr>
<td>Foot drop</td>
</tr>
<tr>
<td>Grade 2 astrocytoma</td>
</tr>
<tr>
<td>Meningioma</td>
</tr>
<tr>
<td>Cauda equina syndrome</td>
</tr>
<tr>
<td>Cubital Tunnel Syndrome</td>
</tr>
<tr>
<td>Multiple sclerosis (de nova)</td>
</tr>
<tr>
<td>Multiple sclerosis with attack</td>
</tr>
<tr>
<td>Myasthenia gravis attack</td>
</tr>
<tr>
<td>Radicular neuropathy</td>
</tr>
<tr>
<td>Sensorimotor polyneuropathy</td>
</tr>
<tr>
<td>Sensory neuropathy</td>
</tr>
<tr>
<td>Pseudotumor cerebri worsening</td>
</tr>
<tr>
<td>Facial paralysis</td>
</tr>
<tr>
<td>CIDP progression</td>
</tr>
<tr>
<td>Guillain Barre Syndrome</td>
</tr>
<tr>
<td>Time to development of adverse events after last bDMARD</td>
</tr>
<tr>
<td>Time after neurological adverse event (months)</td>
</tr>
<tr>
<td>bDMARD discontinuation status after adverse events</td>
</tr>
<tr>
<td>Neurological symptoms at last visit</td>
</tr>
<tr>
<td>Improvement</td>
</tr>
<tr>
<td>Progression</td>
</tr>
</tbody>
</table>

| ¶ mean±SD. CIDP: Chronic inflammatory demyelinating polyneuropathy |

Conclusion: In this study, the prevalence of neurological diseases such as brain tumors, multiple sclerosis, and myasthenia gravis in patients receiving biological treatment compared to the normal population. Therefore, patients using biological agents should also be questioned and examined in terms of neurological symptoms, and further examination should be applied if necessary. No significant relationship was found between discontinuation of biological drugs and improvement/progression of neurological symptoms, and more comprehensive studies are needed.


AB1426 PREDICTORS OF RHEUMATIC TOXICITIES OF IMMUNE CHECKPOINT INHIBITORS AND CANCER OUTCOMES IN PATIENTS WITH ADVANCED MELANOMA

A. Bruce1,2, A. Menzies1,2,3,4, G. Long1,2,4, B. Fernandes1, F. Joshi1,2,3
1Macquarie University, Faculty of Medicine, Health and Human Sciences, Sydney, Australia; 2Gardens Medical Group, Rheumatology, Albury, Australia; 3Royal North Shore and Mater Hospitals, Medical Oncology, Sydney, Australia; 4The University of Sydney, Faculty of Medicine & Health, Sydney, Australia; 5Melanoma Institute Australia, Sydney Medical Oncology, Wollongong, Australia; 6The University of Sydney, Charles Perkins Centre, Camperdown, Australia; 7Royal Prince Alfred Hospital, Medicine, Sydney, Australia; 8Integrated Specialist Medical Care, Rheumatology, Sydney, Australia

Background: Immune checkpoint inhibitors (ICIs) including monoclonal antibodies to PD-1 and CTLA-4 have activity across various cancers. Dedicated cohort studies have examined the epidemiology and clinical course of rheumatic toxicities (1–3) and the effect of pre-existing autoimmune disease has been explored (4), with limited assessment of the effect of non-immune mediated rheumatic disease (3). A positive association between ICI-induced rheumatic disease and favourable cancer outcomes has been suggested (1,2), although derived from heterogenous cancer populations.

Objectives: To identify risk factors for the development of ICI-induced rheumatic disease and predictors of cancer outcomes in patients with advanced melanoma.

Methods: A single-centre observational study of patients with stage III or IV melanoma receiving all available ICI therapies, who completed a for-purpose questionnaire to capture rheumatic symptoms and risk factors upon recruitment and at 12-months. Symptom severity was assessed using validated measures such as visual analogue scale (VAS) scores for pain. Clinical details were extracted from patients’ medical records. Predictors of rheumatic toxicities and cancer outcomes were identified through regression analysis.

Results: Amongst 147 eligible patients, the prevalence of new or worsening rheumatic symptoms was 32.5% at recruitment and 21% at 12 months. The incidence of documented arthralgia, inflammatory arthritis and PMR-like syndrome was 39.5%, 5.4% and 3.4% respectively. Binary logistic regression identified pre-existing symptomatic rheumatic disease, including non-immune mediated rheumatic disease, as the primary risk factor for developing rheumatic toxicities (OR 3.161). Continuation of ICI therapy (OR 16.52), followed by rheumatic toxicities (OR = 4.368) were predictors of favourable tumour response.

Conclusion: Rheumatic toxicities of ICI therapy commonly affect patients with melanoma and are more likely to occur in patients with pre-existing autoimmune and non-immune mediated rheumatic disease. Continuation of ICI therapy improves cancer outcomes and can be facilitated by early detection of rheumatic symptoms using patient reported outcome measures.
Table 1. Bivariate logistic regression of predictors of patient-reported rheumatic toxicity. Sig., Significance; OR, Odds ratio; CI, confidence interval; BRAF/MEK, BRAF and MEK inhibitors; PD-1, Programmed Cell Death protein – 1; CTLA-4, Cytotoxic T-lymphocyte-associated protein.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Sig</th>
<th>OR</th>
<th>Lower 95% CI</th>
<th>Upper 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at initial questionnaire</td>
<td>0.95</td>
<td>0.999</td>
<td>0.969</td>
<td>1.03</td>
</tr>
<tr>
<td>Gender</td>
<td>0.153</td>
<td>0.566</td>
<td>0.259</td>
<td>1.236</td>
</tr>
<tr>
<td>Pre-existing autoimmune rheumatic disease</td>
<td>0.457</td>
<td>1.891</td>
<td>0.353</td>
<td>10.118</td>
</tr>
<tr>
<td>Symptomatic pre-existing rheumatic disease</td>
<td>0.007</td>
<td>3.161</td>
<td>1.362</td>
<td>7.338</td>
</tr>
<tr>
<td>Pre-existing musculoskeletal injury</td>
<td>0.078</td>
<td>0.479</td>
<td>0.211</td>
<td>1.085</td>
</tr>
<tr>
<td>Family history of rheumatic disease (1st degree)</td>
<td>0.4</td>
<td>1.555</td>
<td>0.556</td>
<td>4.352</td>
</tr>
<tr>
<td>Previous or current smoking</td>
<td>0.788</td>
<td>0.899</td>
<td>0.415</td>
<td>1.949</td>
</tr>
<tr>
<td>Skeletal metastases</td>
<td>0.218</td>
<td>0.523</td>
<td>0.186</td>
<td>1.467</td>
</tr>
<tr>
<td>Prior BRAF/MEX inhibitors</td>
<td>0.477</td>
<td>1.449</td>
<td>0.522</td>
<td>4.027</td>
</tr>
<tr>
<td>Combination PD-1 and CTLA4 inhibitors</td>
<td>0.34</td>
<td>0.605</td>
<td>0.241</td>
<td>1.390</td>
</tr>
<tr>
<td>Constant</td>
<td>0.753</td>
<td>0.709</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A

Figure 1. A) Receiver-operator curve for accuracy of binary logistic regression model clinical-recorded rheumatic disease. (B) Area under receiver-operator curve. Test result variables: predicted probability AUROC, Area Under Receiver-Operator Curve; Std. Error, Standard Error; Sig., Significance. (a) Under the nonparametric assumption (b) Null hypothesis: true area = 0.5

REFERENCES:


AB1427 ASSOCIATION BETWEEN HYPERURICEMIA AND OSTEOPOROTIC IN CHINESE ADULTS, A CROSS-SECTIONAL STUDY

J. Zeng1, J. Yang2, W. R. Lawrence3, C. Pan4. 1Department of Ultrasound, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China; 2School of Public Health, Guangzhou Medical University, Guangzhou, Guangdong, China; 3Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, State University of New York, One University Place, Rensselaer, New York, United States of America; 4Department of Emergency, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

Background: Hyperuricemia may have a protective role in diseases characterized by high levels of oxidative stress, such as osteoporosis. Previous studies have shown that hyperuricemia is associated with osteoporotic. However, this association is controversial and even yielded conflicting results.

Objectives: This study investigated the relationship between hyperuricemia and osteoporotic among Chinese adults.

Methods: The data of cross-sectional study was collected at Guangdong Second Provincial General Hospital in Guangzhou City, China between January 2009 and December 2019. Physical examinations and laboratory measurement variables were obtained from the medical check-up system. The multivariate-adjusted logistic regression model was performed to assess the association between hyperuricemia and osteoporotic.

Results: A total of 18917 participants (11334 males and 7579 females) were included in this study, with an average age of 46.23 years (SD: 11.67) at baseline. It included 5881 cases of hyperuricemia and 1587 osteoporotic. After adjusted for the confounding factors in logistic regression analysis, we observed a negative significant association between hyperuricemia and risk of osteoporotic (odds ratio [OR],0.882, 95%CI 0.795–0.976; P <0.05). Further stratified analyses showed a negative significant association with the risk of osteoporotic in women (OR,0.787, 95%CI 0.698–0.853; P <0.05), man (OR,0.897, 95%CI 0.786–0.954; P <0.05) and old adults (OR, 0.808, 95%CI, 0.759-0.894; P <0.05). No significant differences in other groups.

Conclusion: Our study observed participants with hyperuricemia had significantly less osteoporosis. More high-quality research is needed to further support these findings.

REFERENCES:


AB1429 PERSISTENT INFLAMMATION AND PULMONARY FUNCTION CHANGES PREDICT PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES DEVELOPMENT IN RHEUMATIC PATIENTS

T. J. Lee1, Y. H. Chen2, J. Y. Chien2, S. C. Hsieh1. 1National Taiwan University Hospital, Division of Rheumatology, Immunology, and Allergy, Department of Internal Medicine, Taipei, Taiwan, Republic of China; 2National Taiwan University Hospital, Division of Chest Medicine, Department of Internal Medicine, Taipei, Taiwan, Republic of China

Background: The progressive fibrosing interstitial lung disease (PF-ILD) remains a challenge for clinical care. Studies reported that fibrosis-predominant pattern on high-resolution computed tomography (HRCT) and a worse baseline pulmonary function tests were associated with a progression to PF-ILD 1. Whether the inflammatory marker changes predict PF-ILD development was unknown.

Objectives: To evaluate prognostic values of the early inflammatory markers and the pulmonary function tests of developing PF-ILD in patients with connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune features (IPAF).

Methods: This was a retrospective, single-center study. The patients with CTD-ILD and IPAF were included. The PF-ILD was identified at two years after the ILD diagnosis, as according to the INBUILD study 2. The ILD patterns on the HRCT and the pulmonary function tests at diagnosis and one year after ILD diagnosis were reviewed by three pulmonologists independently. The baseline demographics, autoimmune manifestations, and serology at diagnosis, three months, and one year after ILD diagnosis were collected. The data were analyzed using the R version 4.12.

Results: From 2010 to 2020, we enrolled 34 patients into the analysis. These included 11 patients with Sjogren’s syndrome, 7 patients with idiopathic inflammatory myopathy, 3 patients with mixed connective tissue diseases, 1 patient with systemic sclerosis, and 14 patients with IPAF. The HRCT patterns were usual interstitial pneumonia in 13, non-specific interstitial pneumonia (NSIP) in 8, organizing pneumonia (OP) in 6, and lymphocytic interstitial pneumonia (LIP) in 1.

At 2 years, 15 patients developed PF-ILD. The CTD diagnoses and the radiographic patterns at diagnosis were not associated with the development of PF-ILD. The predicted functional vital capacity (FVC) at diagnosis (80% vs. 69%, p=0.047), diffusion capacity of the lung for carbon monoxide (DLCO) at diagnosis (76% vs. 44%, p=0.021), FVC at one year (94% vs. 68%, p=0.047), and DLCO at one year (68% vs. 36%, p=0.018) were associated with the PF-ILD progression. Immunologically, the PF-ILD patients had a borderline higher 1-hour erythrocyte sediment rate (ESR) at baseline (36 vs. 23 mm/h, p=0.051), but the difference became prominent after 3 months (38 vs. 10 mm/h, p=0.023), and 12 months (28 vs. 8 mm/h, p=0.005) after the ILD diagnosis. (Figure 1)

Disclosure of Interests: Lykke Skaarup: None declared, Tue Wenzel Kragstrup Shareholder of: Co-founder and clinical developer in iBio tech ApS., Speakers bureau: Speaking fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Novartis, UCB, and Abbvie, Consultant of: Consultancy fees from Bristol-Myers Squibb and Gilead., Grant/research support from: Research grants from Gilead.


Figure 1. Change of erythrocyte sediment rate at 1 hour over time. ESR, erythrocyte sediment rate at 1 hour. ILD, interstitial lung disease. PF-ILD, progressive fibrosing interstitial lung disease. *p < 0.05, **p < 0.01

Conclusion: The higher ESR during the first one year after ILD diagnosis was associated with the progression to PF-ILD. In serial pulmonary function tests, both FVC, and DLCO in patients with PF-ILD were lower. The between-group differences were more prominent at 1 year of follow up. The findings suggest that the persistent inflammation might contribute to the progressive worsening of pulmonary fibrosis and subsequent lung function decline. The immunology and pulmonary function parameters at one year predict the development of PF-ILD.

References:
REFERENCES:
[1] Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheuma-
tol 2017;69(3):542-49. doi: 10.1002/art.39971

Disclosure of Interests: None declared

AB1431

EPIDEMIOLOGICAL AND GENETIC FEATURES OF ANTI-3-HYDROXY-3-METHYLGLUTARYL-CoA REDUCTASE NECROTIZING MYOPATHY IN NORTHERN SPAIN: SINGLE-CENTER EXPERIENCE

D. Prieto-Peña1,2, J. G. Ocejo-Vinayas3, J. A. Mazariaga-Cano4, A. L. Pelayo5, S. Remuzgo Martinez2, F. Genre2, A. Garcia Dorta6, M. Renuncio-Garcia6, V. Martinez-Taboada7, C. Garcia-Ibarbia8, J. Sanchez-Martín1, B. Atienza-Mateo1,2, M. Lopez-Hoyos2, R. Blanco3, M. A. Gonzalez-Gay1,4, J. L. Hernandez1,2, Hospital Universitario Marques de Valdecilla, Department of Rheumatology, Santander, Spain; 2IDIVAL, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Santander, Spain;
3Hospital Universitario Marques de Valdecilla, Department of Immunology, Santander, Spain; 4Hospital Universitario Marques de Valdecilla, Department of Internal Medicine, Santander, Spain; 5Hospital Universitario Marques de Valdecilla, Department of Neurology, Santander, Spain; 6Hospital Universitario de Canarias, Department of Rheumatology, Tenerife, Spain

Background: Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) immune-mediated necrotizing myopathy (IMNM) is an entity of growing interest. However, data on epidemiology and clinical spectrum are still scarce and there is a need for the identification of its potential risk factors.

Objectives: To characterize the demographic, genetic, clinical, and serological features of patients with anti-HMGR IMNM in a region of northern Spain.

Methods: Study of all patients diagnosed with anti-HMGR IMNM during a 5-year period at a reference hospital in Northern Spain. Besides clinical and laboratory data, we analyzed the genetic influence of HLA genes and the rs4149056 (c.521T>C) single nucleotide polymorphism (SNP) in the SLC01B1 gene.

Results: 8 patients (5 women, 3 men) with a mean ± SD age of 64.9±7.3 years, fulfilled the criteria for anti-HMGR IMNM. The incidence rate was 0.6 per 100,000 person-years (95% CI 0.23, 1.20) in an estimated 3 per 100,000 population. All patients had dyslipidemia and had been exposed to statins. Seven of the 8 cases complained of myalgia. All of them had predominant lower limb proximal and symmetric muscle weakness that was severe in 2 of them. None of the patients had extra-muscular involvement. No evidence of malignancy was found. All patients had elevated serum CK levels with a median [IQR] of 4488 [2538-9194] IU/L. Serum 25-hydroxy vitamin D levels were decreased in all patients. In 8 of the 8 patients, the anti-HMGCR antibody was detected. All patients had elevated serum CK levels with a median [IQR] of 4488 [2538-9194] IU/L. Serum 25-hydroxy vitamin D levels were decreased in all patients. In 8 of the 8 patients, the anti-HMGCR antibody was detected. All patients experienced improvement with different schemes of immunosuppressive therapy. Noteworthy, 7 of 8 patients carried the HLA-DRB1*11 allele. The frequency of the rs4149056 C allele in the SLC01B1 gene (12.5%) was similar to that of the general population.

Conclusion: In northern Spain, the IMNM anti-HMGR preferentially affects people over 50 years of age who are carriers of the HLA-DRB1*11 allele and take statins. Both low vitamin D levels and hypothyroidism may play a potential predisposing role in the development of this disease.

Disclosure of Interests: None declared

Table 1. Results of meta-analyses

<table>
<thead>
<tr>
<th>Systematic lupus erythematosus</th>
<th>Rheumatoid arthritis</th>
<th>Axial spondyloarthropathy</th>
<th>Psoriatic arthritis</th>
<th>Psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cognition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.55 (-0.70, -0.39) [18]</td>
<td>-0.59 (-0.82, -0.35) [13]</td>
<td>-0.66 (-1.11, -0.21) [1]</td>
<td>-0.50 (-0.78, -0.21) [2]</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.55 (-0.72, -0.38) [14]</td>
<td>-0.66 (-0.92, -0.41) [11]</td>
<td>-0.61 (-1.08, -0.14) [1]</td>
<td>-0.77 (-1.39, -0.16) [2]</td>
</tr>
<tr>
<td>Attention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.51 (-0.63, -0.38) [27]</td>
<td>-0.79 (-1.10, -0.47) [9]</td>
<td>-0.58 (-1.03, -0.13) [1]</td>
<td>-0.14 (-0.42, 0.14) [2]</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.51 (-0.67, -0.36) [21]</td>
<td>-0.87 (-1.35, -0.39) [6]</td>
<td>-0.58 (-1.03, -0.14) [1]</td>
<td>-0.36 (-0.75, 0.04) [1]</td>
</tr>
<tr>
<td>Verbal memory (immediate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.59 (-0.79, -0.38) [19]</td>
<td>-1.00 (-1.47, -0.53) [7]</td>
<td>-</td>
<td>-0.52 (-1.05, 0.02) [3]</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.61 (-0.90, -0.32) [12]</td>
<td>-1.42 (-1.73, -1.12) [4]</td>
<td>-</td>
<td>-0.72 (-1.42, -0.02) [2]</td>
</tr>
<tr>
<td>Verbal memory (delayed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.44 (-0.57, -0.31) [18]</td>
<td>-0.93 (-1.48, -0.38) [5]</td>
<td>-0.23 (-0.67, 0.21) [1]</td>
<td>-0.52 (-1.52, 0.49) [2]</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.39 (-0.56, -0.21) [12]</td>
<td>-1.40 (-1.76, -1.03) [3]</td>
<td>-0.23 (-0.67, 0.21) [1]</td>
<td>-1.05 (-1.47, -0.63) [3]</td>
</tr>
<tr>
<td>Non-Verbal memory (immediate)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.41 (-0.57, -0.25) [15]</td>
<td>-0.32 (-1.23, 0.58) [1]</td>
<td>-0.21 (-0.62, 0.23) [1]</td>
<td>-</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.34 (-0.52, -0.16) [10]</td>
<td>-0.21 (-0.62, 0.23) [1]</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Non-Verbal memory (delayed)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All</td>
<td>-0.45 (-0.63, -0.27) [16]</td>
<td>-0.41 (-0.91, 0.08) [1]</td>
<td>-0.14 (-0.58, 0.30) [1]</td>
<td>-</td>
</tr>
<tr>
<td>Age-matched</td>
<td>-0.46 (-0.75, -0.17) [10]</td>
<td>-0.41 (-0.91, 0.08) [1]</td>
<td>-0.14 (-0.58, 0.30) [1]</td>
<td>-</td>
</tr>
</tbody>
</table>
Results: comorbidity” or “non-painful comorbidity” status based on IASP classification of were used as dependent variables; pain intensity (0-10 numerical rating scale) rated ≥1/10, and who had completed FRAIL and CAP-Knee (1) questionnaires.

Objectives: The explanation behind these relationships may depend on more than just ongoing interconnectedness of pain processing systems and the rest of the body. The mechanisms of knee pain is proposed; ongoing sensory inputs due to comorbidity may intensify and prolong pain. Central pain mechanisms might be facilitated by ongoing nociceptive input. A link between multimorbidity with central mechanisms of knee pain.

Background: Central mechanisms of knee pain occur in the central nervous system and may intensify and prolong pain. Central pain mechanisms might be facilitated by ongoing nociceptive input. A link between multimorbidity with central mechanisms of knee pain.

Methods: Cross-sectional analysis of self-report data from participants of the Investigating Musculoskeletal Health and Wellbeing cohort, who reported knee as their most bothersome other joint pain over the previous month, with pain rated ≥1/10, and who had completed FRAIL and CAP-Knee (1) questionnaires. Two indirect measures suggesting central mechanisms involvement in knee pain were used as dependent variables; pain intensity (0-10 numerical rating scale) and CAP-Knee score (0-16 scale). Comorbidities were assigned either "painful comorbidity" or "non-painful comorbidity" status based on IASP classification of chronic pain criteria (2). Multivariable linear regression models, adjusted for age and sex, were employed to explore associations of comorbidity counts with pain intensity and CAP-Knee score.

Results: 736 participants satisfied inclusion criteria. 55% were female, mean age 71 (range 40 to 95). Painful comorbidity count and non-painful comorbidity count each had positive associations with pain intensity ($\beta =0.42, 95\%\ CI=0.29$ to 0.54, $p<0.001$; and $\beta =0.31, 95\%\ CI=0.16$ to 0.45, $p<0.001$, respectively). Painful and non-painful comorbidity counts each had positive associations with pain intensity ($\beta =0.52, 95\%\ CI=0.27$ to 0.54, $p<0.001$; and $\beta =0.31, 95\%\ CI=0.16$ to 0.45, $p<0.001$, respectively). Painful and non-painful comorbidity counts each had positive associations with pain intensity ($\beta =0.52, 95\%\ CI=0.27$ to 0.54, $p<0.001$; and $\beta =0.31, 95\%\ CI=0.16$ to 0.45, $p<0.001$, respectively). Painful and non-painful comorbidity counts each had positive associations with pain intensity ($\beta =0.52, 95\%\ CI=0.27$ to 0.54, $p<0.001$; and $\beta =0.31, 95\%\ CI=0.16$ to 0.45, $p<0.001$, respectively).

Conclusion: Both painful and non-painful comorbidities were positively associated with central mechanisms of knee pain, providing further insight into the interconnectedness of pain processing systems and the rest of the body. The explanation behind these relationships may depend on more than just ongoing nociceptive input. Future work should address possible contributions from genetic, pathophysiological, psychological, and pharmacological factors associated with comorbid diagnosis.

**REFERENCES:**

the diagnosis, we found a statistical significance only with respect to aGAPSS (aPL+ >9.6±6.3 vs aPL- = 4.1±5.1; p<0.001).

Table 1. Demographic and clinical features of the patients included in the study.

<table>
<thead>
<tr>
<th>PATIENTS CHARACTERISTICS</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>age (m2sd)</td>
<td>Tot=48±12.87</td>
<td></td>
</tr>
<tr>
<td>SAPS=51.61±12.82</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=46.87±12.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females, n (%)</td>
<td>Tot=120/142 (84.5%)</td>
<td></td>
</tr>
<tr>
<td>aPS=22/34 (64.7%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=98/198 (90.74%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THROMBOTIC EVENTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thrombotic event, n (%)</td>
<td>Tot=48/142 (33.8%)</td>
<td></td>
</tr>
<tr>
<td>aPS=33/48 (68.75%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=15/48 (31.25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial thrombosis, n (%)</td>
<td>Tot=22/142 (15.49%)</td>
<td></td>
</tr>
<tr>
<td>aPS=19/22 (86.36%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=3/22 (13.64%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous thrombosis, n (%)</td>
<td>Tot=32/142 (22.53%)</td>
<td></td>
</tr>
<tr>
<td>aPS=18/32 (56.25%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=14/32 (43.75%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke, n (%)</td>
<td>Tot=13/142 (9.15%)</td>
<td></td>
</tr>
<tr>
<td>aPS=13/100 (100%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=0/13 (0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIA, n (%)</td>
<td>Tot=6/142 (4.22%)</td>
<td></td>
</tr>
<tr>
<td>aPS=6/100 (6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLE w/o aPS=0/6 (0%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Conclusion: By encompassing factors that can contribute to CVD development in complex/autoimmune diseases, QRISK3 has been shown to be more accurate than traditional risk score in predicting SLE patients CVD risk. Nonetheless, the results of this analysis showed how the aGAPSS still seems to be the most valuable tool for this purpose when facing SLE patients. Moreover, the significance observed when focusing on patients’ aPL profile, suggests that adding this item to the QRISK3 could be a useful strategy to improve the management.

REFERENCES:

Disclosure of Interests: None declared

Table 1. Number of donors in the biobank at each time point

<table>
<thead>
<tr>
<th>Time point</th>
<th>Number of donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before pregnancy</td>
<td>135 donors</td>
</tr>
<tr>
<td>1st trimester</td>
<td>123 donors</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>124 donors</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>117 donors</td>
</tr>
<tr>
<td>6 weeks postpartum</td>
<td>175 donors</td>
</tr>
<tr>
<td>6 months postpartum</td>
<td>166 donors</td>
</tr>
<tr>
<td>12 months postpartum</td>
<td>129 donors</td>
</tr>
</tbody>
</table>

Conclusion: Collections of biological samples from pregnant women with rheumatic diseases are hard to come by, and therefore research is scarce. RevNatus with its biobank has the potential to make a substantial impact combining clinical and biological material, and take an important role in further molecular research in the field of rheumatic disease and pregnancy.

Disclosure of Interests: None declared

AB1434

PREGNANCY AND RHEUMATIC DISEASES – COMBINING BIOLOGICAL MATERIAL AND CLINICAL DATA FOR FUTURE RESEARCH

J. R. Nilsen1, B. Jakobsen1, T. T. Pedersen1, M. Wallenius1,2. 1Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Department of Rheumatology, St.Olavs Hospital, Trondheim, Norway; 2Norwegian University of Science and Technology, Department of Neuromedicine and Movement Science, Trondheim, Norway

Background: Rheumatic diseases affect women in fertile age. There is an increased risk for disease flares and pregnancy complications, especially for patients with systemic rheumatic diseases. Improving knowledge of immunological changes that happen during and after pregnancy in women with rheumatic diseases is of great importance. The Norwegian National Advisory Unit for Pregnancy and Rheumatic Diseases (NKSR) therefore established a biobank in 2012 with material from this patient group. NKSR also administers RevNatus, a nationwide pregnancy quality register including women with inflammatory rheumatic diseases, with comprehensive clinical data.

Objectives: To facilitate high quality research by developing a possibility to combine biobank material and comprehensive clinical data. We aim to increase current knowledge in this field, with the ultimate goal of making pregnancies safer for women with rheumatic diseases.

Methods: The RevNatus biobank is part of the Regional Biobank of Central Norway (Biobank1). Biobank1 is a research facility established to provide an organizational framework for all research, which involves biological material from patients in any of the public hospitals of the region. The collection of biologic material is approved by the regional committees for medical and health research ethics. Patients are included after having signed a consent form. Blood samples are collected before pregnancy, in each trimester, 6 weeks, 6 months and 12 months postpartum. So far, serum, plasma, buffy-coat and Tempus Blood RNA tubes have been collected. At the same time points when blood samples are collected, clinical data is registered in RevNatus. Serum, plasma, buffy-coat and Tempus Blood RNA tubes from 32 healthy pregnant women have also been collected as control group material.

Results: 310 donors are so far included in the RevNatus biobank. These include systemic lupus erythematosus (36), rheumatoid arthritis (61), juvenile idiopathic arthritis (40), spondyloarthropathy (96), Sjögren’s syndrome (8), granulomatosis with polyangiitis (5), MCTD (5), healthy controls (32) and others (27).

Table 1. Number of donors in the biobank at each time point

<table>
<thead>
<tr>
<th>Time point</th>
<th>Number of donors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before pregnancy</td>
<td>135 donors</td>
</tr>
<tr>
<td>1st trimester</td>
<td>123 donors</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>124 donors</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>117 donors</td>
</tr>
<tr>
<td>6 weeks postpartum</td>
<td>175 donors</td>
</tr>
<tr>
<td>6 months postpartum</td>
<td>166 donors</td>
</tr>
<tr>
<td>12 months postpartum</td>
<td>129 donors</td>
</tr>
</tbody>
</table>

Conclusion: Collections of biological samples from pregnant women with rheumatic diseases are hard to come by, and therefore research is scarce. RevNatus with its biobank has the potential to make a substantial impact combining clinical and biological material, and take an important role in further molecular research in the field of rheumatic disease and pregnancy.

Disclosure of Interests: None declared

AB1435

CLINICAL PREDICTION MODELS FOR METHOTREXATE OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: SYSTEMATIC REVIEW AND CRITICAL APPRAISAL

C. Gehenger1, G. Martin2, K. Hyrich1,3, S. Verstappen4, J. Sergeant1,4.
1University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; 2University of Manchester, Centre for Health Informatics, Division of Informatics, Imaging and Data Science, Manchester, United Kingdom; 3Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; 4University of Manchester, Centre for Biostatistics, Manchester Academic Health Science Centre, Manchester, United Kingdom

Background: Methotrexate (MTX) is the preferred first line therapy for rheumatoid arthritis (RA). MTX has several advantages over other treatments including effectiveness and low cost; however, around 40% of patients are classed as non-responders after 6 months (1). Therefore, there is a clinical need to identify patients at high-risk of poor outcomes, such that patients could potentially be fast tracked onto alternative therapies to improve their clinical outcomes and quality of life. Such risk stratification is possible through prognostic prediction models, although models which have previously been developed appear to have had little impact on practice. This may be in part due to methodological features of their development and validation but, to date, no review has collated the evidence in this field.

Objectives: This systematic review aimed to (i) identify and summarise multivariable prediction models of MTX treatment outcomes in biologic-naïve adult RA patients, and (ii) critically appraise their methodological properties.

Methods: The electronic databases Medline and Embase were searched to identify studies developing or validating prediction models of MTX outcomes in the population of interest, including demographic, disease-specific or treatment-related covariates, published after 2005. Models were stratified by outcome definition, and information on participants, predictors, model performance, handling of missing data and model validation were extracted. A risk of bias (ROB) assessment using PROBAST (prediction model risk of bias assessment tool) was carried out. Two reviewers were independently involved in screening, data extraction, and ROB stages.
Results: The included studies used three main outcome definitions: a state of disease activity, such as low disease activity or remission; the EULAR response criteria, or discontinuation due to adverse events (AEs). Some studies incorporated AEs into a composite outcome with disease activity and few accounted for potential competing risks, which are events that preclude the occurrence of the primary outcome of interest. Not handling competing risks may result in under-prediction, leading to potentially compromised risk stratification. There was a lack of internal validation using cross sampling techniques, which is critical for reducing overfitting, as well as external validation in new data, a process necessary to ensure reproducibility and generalisability of a prediction model to the larger patient population. Missing data was mostly handled using complete case analysis, leading to potentially biased risk estimates. The ROB assessment showed overall high ROB of the included studies.

Conclusion: This systematic review summarises current prediction models of MTX treatment outcomes in RA. It highlights several methodological short-comings, such as poor handling of missing data and competing risks to the primary outcome, and a lack of internal and external validation. These should be addressed in future model development and validation to improve accuracy of predictions. Without tackling these issues, prediction of MTX treatment outcomes will remain at high risk of bias and should not be recommended for informing risk stratification for RA treatment decisions.

REFERENCES:

Disclosure of Interests: Celina Gehringer: None declared, Glen Martin: None declared, Kim He Hyrich Speakers bureau: Abbvie, Grant/research support from: BMS and Pfizer, Suzanne Verstappen: None declared, Jamie Sergeant: None declared


**AB1436**

**INFECTIONS IN PATIENTS WITH RHEUMATIC DISEASES IN TREATMENT WITH BIOLOGIC THERAPY**


Background: Patients with rheumatic diseases (RD) have a higher risk of developing infections due to disease and immunosuppressant treatment factors 1. Biologic disease-modifying antirheumatic drugs (bDMARD) have been associated with the development of opportunistic infections, nevertheless their impact on severe infections has not been consistent 2. Objectives: To describe the sociodemographic and clinical characteristics of patients with RD on bDMARD treatment with and without infections, using data from the Mexican Adverse Events Registry (BIOBADMEX), as well as to identify factors associated with the presence of infections.

Methods: BIOBADMEX is a Mexican ongoing cohort of patients using bDMARDs. In this analysis we included all patients registered in BIBADME from 2016 to 2021. We compared sociodemographic, clinical and treatment characteristics between patients who developed infections with to those who did not.

We used descriptive statistics, Chi square and Kruskal Wallis tests to analyze differences between the groups.

Results: A total of 780 patients registered in BIBADME were included in this study, among them 42 (5%) patients presented infections and 738 (95%) did not. At baseline, patients had a median (IQR) age of 50 (40-58) years and median disease duration of 7 (3-15) years. The most common diagnosis was rheumatoid arthritis with 512 (66%) patients, followed by ankylosing spondylitis in 115 (15%), psoriatic arthritis in 44 (6%), systemic lupus erythematosus in 30 (4%) and idiopathic juvenile arthritis in 27 (3%) patients. Comorbidities were present in 351 (45%) of the patients. Conventional DMARD (cDMARD) use was present in 351 (45%) of the patients. Conventional DMARD (cDMARD) use was present in 351 (45%) of the patients.

Table 1. Patients baseline characteristics

<table>
<thead>
<tr>
<th>Outcome</th>
<th>n=42</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>33 (79)</td>
<td>595 (80)</td>
</tr>
<tr>
<td>Age, median(IQR)</td>
<td>50.9 (43-59)</td>
<td>49.8 (40-58)</td>
</tr>
<tr>
<td>Disease duration (years), median (RIC)</td>
<td>7.5 (2-16)</td>
<td>70 (3-15)</td>
</tr>
<tr>
<td>Diagnosis, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>25 (59)</td>
<td>109 (15)</td>
</tr>
<tr>
<td>Idiopathic Juvenile Arthritis</td>
<td>0 (0)</td>
<td>27 (4)</td>
</tr>
<tr>
<td>Ankylosing Spondylitis</td>
<td>6 (14)</td>
<td>105 (15)</td>
</tr>
<tr>
<td>Others</td>
<td>11 (26)</td>
<td>115 (15)</td>
</tr>
<tr>
<td>Comorbidities, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>22 (52)</td>
<td>329 (44.6)</td>
</tr>
<tr>
<td>Previous bDMARD, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-TNF</td>
<td>15 (36)</td>
<td>271 (37)</td>
</tr>
<tr>
<td>Use of steroids, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 (38)</td>
<td>274 (37)</td>
<td>0.9</td>
</tr>
<tr>
<td>cDMARD, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33 (79)</td>
<td>593 (80)</td>
<td>0.77</td>
</tr>
<tr>
<td>Severe Adverse Events, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 (7)</td>
<td>11 (2)</td>
<td>0.007</td>
</tr>
<tr>
<td>Outcome, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovered without sequel</td>
<td>3 (100)</td>
<td>6 (65)</td>
</tr>
<tr>
<td>Not recovered</td>
<td>0</td>
<td>3 (27)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
<td>2 (18)</td>
</tr>
<tr>
<td>Infection site, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin</td>
<td>9 (21)</td>
<td>5 (12)</td>
</tr>
<tr>
<td>Urinary tract</td>
<td>4 (10)</td>
<td></td>
</tr>
<tr>
<td>Agent, n(%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gram - bacteria</td>
<td>9 (21)</td>
<td></td>
</tr>
<tr>
<td>Gram+ bacteria</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Virus</td>
<td>4 (14)</td>
<td></td>
</tr>
</tbody>
</table>

Chi²

Conclusion: The frequency of infections in patients using bDMARD in Biobadex is low compared to the frequency reported in similar studies in other countries 3. The presence of infections was associated with more severe adverse events in general, which recovered completely without sequel.

REFERENCES:

Disclosure of Interests: VIJAYA RIVERA TERAN: None declared. David Vega-Morales: None declared. Sandra Sicilia: None declared, Fedra Irazoque-Palazuelos: None declared, Miguel A Saavedra: None declared, Juli Cesar Casasola: None declared, Sandra Carrilo: None declared, Angelica Peña: None declared, Angel Castillo Ortiz: None declared, Omar Eloy Muñoz-Monroy: None declared, Sergio Duran Barragan: None declared, Azucena Ramos: None declared, Luis Francisco Valdés Corona: None declared, Estefania Torres Valdés: None declared, Aleni Paz: None declared, ERICK ADRIAN ZAMORA-TEHOZOL: None declared, Alfonso Torres: None declared, Samara Mendiesta: None declared, Daniel Xavier Xibille Friedmann: None declared, Francisco Guerrero: None declared, Natalia Santana: None declared, Miguel Vazquez: None declared, Claudia Zepeda: None declared, Melanee Rivera: None declared, Kitzia Alvarado: None declared, Desire Alpizar-Rodríguez Consultant: of Scientific advisor for GSK, unrelated to this study., Employee of: Scientific advisor for GSK, unrelated to this study.


**AB1437**

**RHEUMATOLOGICAL IMMUNE-MEDIATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS BASED ON THE FDA ADVERSE EVENTS REPORTING SYSTEM**

A. Rodriguez-Piña, Mayo Clinic, Rheumatology, Scottsdale, United States of America

Background: Immune checkpoint inhibitors (ICIs) provide effective treatment for many cancers but, presumably due to persistent activation of the immune system, they cause a variety of immune-related adverse events (irAEs) in almost every organ. Rheumatological manifestations have been reported in ~5-10% of patients treated with ICIs.

Objectives: We aimed to analyze the rheumatological irAEs (rh-irAEs) reported to the FDA Adverse Event Reporting System (FAERS) from October 2012 through March 2021.

Methods: From October 1st, 2012, to March 31st, 2021, we studied all case reports found on the FAERS database when any of the following seven FDA-approved ICIs, nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, avelumab, or cemiplimab, was the primary suspect of the reported adverse event (AE). Of the 6,090 different AEs reported for the ICIs, we selected 186 irAEs, which were rheumatological manifestations, or were associated with rheumatological conditions. We calculated the frequencies of rh-irAEs for each ICI. RStudio v1.4.1106 was used for general data analysis and the R package
openEBGM v0.8.3 was used for the calculation of disproportionality scores such as the Empirical Bayes Geometric Mean (EBGM) with its 90% two-sided credibility interval, frequently used in safety signal detection models. Drug-event combinations with an EBGM 5% lower limit credibility interval ≥ 1 were considered significant.

**Results:** During the study period, 90,974 individual case safety reports (ICSR) included 236,239 AEs with one ICI as the primary suspect of the AE. The highest frequency of AEs was reported for nivolumab (49.6%), followed by pembrolizumab (23.4%), ipilimumab (12.6%), atezolizumab (6.6%), durvalumab (4.6%), avelumab (0.9%), and cemiplimab (0.3%). The AEs were more frequent in males (62.7%) than in females (37.3%). Of the total ICSRs, 84.2% were expedited because they reported serious, unexpected AEs. Rh-irAEs were 11,203 (4.7%) out of the 236,239 AEs reported. These rh-irAEs were reported in 3,398 (4.3%) out of the 90,974 ICSRs. For the ICSRs containing rh-irAEs, 78.5% were expedited. Unspecific complaints, such as arthralgia, myalgia or muscle weakness, were among the most frequent rh-irAEs. Avelumab and atezolizumab were associated with Sjogren’s syndrome and sarcoidosis. Durvalumab, avelumab and cemiplimab were all associated with myositis. Twenty-one drug-event combinations were significant for EBGM. Of those, nivolumab and pembrolizumab were the two most frequent ICI, with 7 and 6 significant drug-event combinations, respectively.

**Conclusion:** Approximately 5% of the reported AEs-associated AEs were rh-irAEs. The most frequent complaints were unspecific, such as arthralgia, myalgia, or muscle weakness. Arthritis, myositis, Sjogren’s syndrome, and sarcoidosis were also relatively frequent. The improved understanding of the mechanism of action of the ICIs and the characteristics of the rh-irAEs may help to elucidate the pathogenesis of the rheumatological autoimmune diseases that they trigger.

**REFERENCES:**

**Disclosure of Interests:** None declared

**AB1439**

**IS THERE AN INCREASED PREVALENCE OF DIABETES MELLITUS IN THE AXIAL Spondyloarthritis patient group? A review from a UK teaching hospital spondyloarthropathy service**

S. Jothimurugan1,2, S. Byraman1, A. Moorothy1,2,1 University Hospitals of Leicester NHS Trust, Rheumatology, Leicester, United Kingdom; 2 University of Leicester, College of Life Sciences, Leicester, United Kingdom

**Background:** The prevalence of diabetes mellitus (DM) has often been found to be increased in patients with axial spondyloarthritis (axSpA) compared to the general population. However, studies conducted in the United Kingdom (UK) have found varying results with regards to prevalence. One study9 found that 5% of patients with axSpA had DM, compared to 4% of patients without axSpA and another UK study8 reported that although findings showed a 1.8% increase in DM in patients with axSpA compared to controls, this result was not significant. There is also the influence of ethnicity to consider as DM is more prevalent in the Asian and Afro-Caribbean population. Therefore, it is evident that more research is required into the relationship between DM and axSpA.

**Objectives:** This study aims to investigate the correlation between DM and axSpA, and also explore the influence of ethnicity on DM and axSpA.

**Methods:** Retrospective analysis was carried out for axSpA patients attending University Hospitals of Leicester axSpA services. Inclusion criteria entailed an axSpA diagnosis and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) within a year of MRI spine and sacroiliac joints before starting biological therapy. Patients were excluded if they had an active infection or malignancy. BASDAI was not documented before starting biological therapy or within a year of MRI, or if clinical information was not able to be obtained. Data was obtained from electronic medical records, including age, gender, ethnicity, date of diagnosis of axSpA and DM, and cardiovascular comorbidities.

**Results:** Of the 149 patients, 8 (5.37%) % had a diagnosis of DM. 4 (50%) of these patients were diagnosed with DM prior to diagnosis of axSpA, and 4 (50%) were diagnosed with DM post diagnosis of axSpA. Differences in ethnicity were analysed. Of the 149 axSpA patients, 102 (68.46%) were Caucasian, 45 (30.20%) were Asian, and 2 (1.34%) were Afro-Caribbean. Of the 102 Caucasian patients, 3 (2.94%) had DM, of whom 1 was diagnosed with axSpA prior to diagnosis of DM. Of the 45 Asian patients, 5 (11.11%) had DM, of whom 3 were diagnosed with axSpA prior to diagnosis of DM. Looking at cardiovascular comorbidities, of the 8 patients with axSpA and DM, 2 (25%)...
had hypertension, and were both diagnosed with axSpA prior to diagnosis of DM.

Conclusion: This small study has found a similar prevalence of DM in patients with axSpA (5.37%) compared to the general UK population (6%), which contrasts with published international studies which have found a higher prevalence of DM in the axSpA group. However, the study did find a higher prevalence in the Asian population (11.11%) which is in keeping with ethnic variation for DM. Larger epidemiological studies are needed to understand the reason for reported higher prevalence of DM in patients with axSpA in other countries compared to the UK.

REFERENCES:


Disclosure of Interests: None declared

AB1440 ASSOCIATION BETWEEN GAMMA-Glutamyl TRANSFERASE (GGT) AND SERUM URATE: CROSS-SECTIONAL FINDINGS FROM THE 1993 PELOTAS (BRAZIL) BIRTH COHORT

T. Loyola Correa1, D. Farias Freitas2, C. Brinck Brum2, I. Oliveira de Oliveira1,3.
1Universidade Federal de Pelotas, Faculty of Medicine, Pelotas, Brazil; 2Universidade Federal de Pelotas, Centre for Epidemiological Research, Pelotas, Brazil; 3Universidade Federal de Pelotas, Postgraduate Program in Epidemiology, Pelotas, Brazil

Background: Gout attack is associated with an abrupt increase or decrease on serum urate concentrations, which can precipitate urate crystals in tissues in and around the joints. Serum urate (SU) has been positively associated with cardiometabolic risk factors and subclinical inflammation in observational studies, but causal roles remain unclear.1 Additionally, gamma-glutamyl transferase (GGT) has been linked to oxidative stress, metabolic syndrome, and nonalcoholic fatty liver disease (NAFLD).

Objectives: The aim of this study was to assess the association between GGT and SU in Brazilian young adults.

Methods: During 1993, all live born babies in the city of Pelotas (Brazil) were invited to take part in a prospective study. At the 22-year follow-up of this birth cohort, SU was evaluated by enzymatic-colorimetric assay. GGT was evaluated by kinetic assay and converted into logarithm for regression analysis. The co-variables taken into consideration were waist circumference (WC), systolic and diastolic blood pressures (SBP, DBP), glucose (G), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), creatinine (Scr), fasting period, smoking status, excessive alcohol consumption (>8 points in the Alcohol Use Disorders Identification Test-AUDIT), and physical activity (PA).

For association analyses, serum concentration of urate was categorized into tertiles. Sex-stratified linear regressions have been performed due to the significant interaction between GGT, SU and sex (p<0.001). A p-value less than 0.05 was considered statistically significant.

Results: The sample comprised 1660 (47.7%) men and 1822 (52.3%) women aged 22.6 (±0.34) years old. Median (IQR) GGT (U/L) was 26 (20-35) in men and 21 (16-30) in women (p<0.001). Mean (±SD) SU (mg/dL) was also higher in men (5.2±1.2 vs. 3.9±1.1; p<0.001). No significant association between GGT and tertiles of SU was observed in men (between the 1st and 2nd tertiles, the p-value was 0.713; and between the 1st and 3rd, p = 0.185). In women, between tertiles of SU was observed in men (between the 1st and 2nd tertiles, the p=0.005). Mean (±SD) SU (mg/dL) was also higher (3.9±1.1; p<0.001). No significant association between GGT and 21 (16-30) in women (p<0.001). Mean (±SD) SU (mg/dL) was also higher (3.9±1.1; p<0.001). No significant association between GGT and sex (p<0.001). A p-value less than 0.05 was considered significant.

Conclusion: GGT was positively associated with SU in women, even after adjusting for potential confounders. This finding reinforces that uric acid is associated with cardiometabolic risk factors since early adult age. Nonetheless, further prospective studies are needed to understand the causality of this association especially observed in women.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2493

AB1441 LEARNING NEEDS ASSESSMENT FOR PATIENTS WITH CANCER AND A PRE-EXISTING AUTOIMMUNE DISEASE WHO ARE CANDIDATES TO RECEIVE IMMUNE CHECKPOINT INHIBITORS

M. A. Lopez-Olivo1, J. I. Ruiz1, G. F. Duhon2, M. Altan2, H. Tawbi2, A. Diab2, C. Bingham3, C. Calabrese6, R. Volk6, M. Suarez-Almazor7,8, The University of Texas MD Anderson Cancer Center, Health Services Research, Houston, United States of America; 3The University of Texas, MD Anderson Cancer Center, Thoracic-Head & Neck Medical Oncology, Houston, United States of America; 80:1004. Canada; 7The University of Texas, MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America; 3The University of Texas MD Anderson Cancer Center, Melanoma Medical Oncology, Houston, United States of America; 9Johns Hopkins University, Division of Rheumatology, Department of Medicine, Baltimore, United States of America, 10Cleveland Clinic, Rheumatologic and Immunologic Disease, Cleveland, United States of America; 11The University of Texas, MD Anderson Cancer Center, Internal Medicine, Houston, United States of America

Background: Patients with autoimmune disorders and cancer are at risk of developing immune-related adverse events (irAEs) and increasing flares of their underlying disease with immune checkpoint inhibitors (ICIs) and harms and benefits must be weighed.

Objectives: We conducted an assessment of learning needs.

Methods: We interviewed 19 patients who had received an ICI and 20 physicians who provide care for these patients. We asked what do cancer patients with pre-existing autoimmune diseases need to know in order to make an informed decision about whether to receive an ICI.

Results: Fifty-three percent of the patients were female, median age was 62.9 (±10.9). They had rheumatoid arthritis (47.4%), psoriasis (26.3%), Crohn’s disease (10.5%), ankylosing spondylitis (5.3%), systemic lupus erythematosus (5.3%), or ulcerative colitis (5.3%). Half of the patients (52.6%) had a demonstrable disease activity of the autoimmune disease at the time of diagnosis of cancer, and 47.4% did not. We asked patients the reasons for stopping or modifying treatment (for cancer or autoimmune disease), when to contact the provider, possibility of autoimmune disease progression or organ damage, sharing information with other providers, and lifestyle changes that can be done to help.

Conclusion: Although patients and physicians listed common learning points, patients also considered specific needs to increase their self-care. The information derived from this study will be used to develop a decision support tool.

Disclosure of Interests: None declared

AB1442 A PREDICTIVE MODEL OF CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: A RETROSPECTIVE COHORT STUDY

C. Huang1, Y. Zhao1, J. Zhao2, M. Li3, X. Zeng1, 1Peking Union Medical College Hospital, Rheumatology, Beijing, China

Background: Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening form of antiphospholipid syndrome (APS), with rarely occurrence but high mortality. Current classification diagnosis criteria require more than 3 organs involvement in 1-week time and pathological evidence in patient with persistent positive antiphospholipid antibodies (aPL), which could result the delaying
Table 1. Characteristics and predicting factors of CAPS in PUMCH-APS cohort

<table>
<thead>
<tr>
<th>CAPS (N=27)</th>
<th>Non-CAPS (N=199)</th>
<th>p</th>
<th>Odds ratio</th>
<th>p</th>
<th>Coefficient β</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (M)</td>
<td></td>
<td>14(51.9)</td>
<td></td>
<td>64(32.2)</td>
<td>0.043</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td></td>
<td>36.3±15.2</td>
<td></td>
<td>36.2±12.5</td>
<td>0.975</td>
<td></td>
</tr>
<tr>
<td>Disease duration (m)</td>
<td></td>
<td>49.7±7.7</td>
<td></td>
<td>53.9±72.3</td>
<td>0.777</td>
<td></td>
</tr>
<tr>
<td>Secondary APS</td>
<td></td>
<td>14(51.9)</td>
<td></td>
<td>52(26.1)</td>
<td>0.006</td>
<td></td>
</tr>
<tr>
<td>APS diagnosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous thrombosis</td>
<td></td>
<td>17(63.0)</td>
<td></td>
<td>106(53.3)</td>
<td>0.342</td>
<td></td>
</tr>
<tr>
<td>Arterial thrombosis</td>
<td></td>
<td>22(81.5)</td>
<td></td>
<td>79(39.7)</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Pregnancy morbidity</td>
<td></td>
<td>6(18.5)</td>
<td></td>
<td>68(34.2)</td>
<td>0.103</td>
<td></td>
</tr>
<tr>
<td>LA</td>
<td></td>
<td>22(81.5)</td>
<td></td>
<td>155(77.9)</td>
<td>0.671</td>
<td></td>
</tr>
<tr>
<td>aCL</td>
<td></td>
<td>21(77.8)</td>
<td></td>
<td>123(61.8)</td>
<td>0.105</td>
<td></td>
</tr>
<tr>
<td>a2GP1</td>
<td></td>
<td>23(85.2)</td>
<td></td>
<td>155(77.9)</td>
<td>0.384</td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (g/L)</td>
<td></td>
<td>82.7±20.4</td>
<td></td>
<td>130±23.8</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Hemolytic anemia</td>
<td></td>
<td>15(55.6)</td>
<td></td>
<td>20(10.1)</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>LDH (U/L)</td>
<td></td>
<td>476.4±227</td>
<td></td>
<td>226.9±92.3</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Elevated LDH</td>
<td></td>
<td>25(92.6)</td>
<td></td>
<td>54(27.1)</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Proteinuria</td>
<td></td>
<td>18(66.7)</td>
<td></td>
<td>28(14.1)</td>
<td>0.000</td>
<td></td>
</tr>
<tr>
<td>Hematuria</td>
<td></td>
<td>15(55.6)</td>
<td></td>
<td>20(10.1)</td>
<td>0.000</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. (A). Receiver Operating Characteristic (ROC) curve of the predictive model. Area under the receiver operating characteristic curve (AUC) was 0.969, the cut-off value of 7 were with sensitivity of 81.5% and specificity of 96%. (B). Calibration curve in internal validation.

S. M. Ahn, S. Hong, C. K. Lee, B. Yoo, J. S. Oh, Y. G. Kim. 1. Asan Medical Center, Department of Rheumatology, Seoul, Korea, Republic of (South Korea); 2. Asan Medical Center, Department of Information Medicine, Big Data Research Center, Seoul, Korea, Republic of (South Korea).

Background: In Korea, it has been reported that the incidence of some respiratory diseases and Kawasaki diseases has decreased compared to the previous year along with active non-pharmaceutical interventions in the early stages of the COVID-19 pandemic. Autoimmune inflammatory rheumatic disease (AIIRD) is mainly affected musculoskeletal organs and connective tissues due to impaired immune regulation. Although gout and osteoarthritis are rheumatic diseases, they are not a disease of the immune system, and are not included in the AIIRD.

Objectives: In this study, we investigated the change and difference in the incidence rate of various rheumatic diseases during the COVID-19 pandemic after 2020.

Methods: The number of patients for each disease from January 2016 to December 2020 was obtained from the Korea Health Insurance Review and Assessment Service database. We compared the incidence of 9 rheumatic diseases ([systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), anklosing spondylitis (AS), Sjogren syndrome (SJS), Behcet’s disease (BD), inflammatory myositis (IMi), scleroderma, polymyalgia rheumatica (PMR), and gout]) and hypertension before and after the COVID-19 outbreak. The incidence rates of patients before and after the COVID-19 outbreak were compared using the Poisson test.

Results: From 2016 to 2019, the prevalence of rheumatic diseases showed gradually increased. In 2020, the incidence of SLE, AS, SJS, BD, and IMI were significantly decreased compared to the previous 4 years. In contrast, the incidences of gout and hypertension during the COVID-19 pandemic period were significantly increased from the predicted values.

Conclusion: In conclusion, we found that the incidence of many AIIRDs, including SLE, AS, SJS, BD, and IMI decreased significantly due to the increased incidence of hypertension and gout during the COVID-19 pandemic.

REFERENCES:
Table 1. Cumulative incidence of rheumatic diseases and HTN (by Poisson test)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Mean (2016-2019)</th>
<th>Observed (2020.1–12)</th>
<th>Rate ratio (95%CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE</td>
<td>5371.3</td>
<td>4541.0</td>
<td>0.844 (0.811, 0.878)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>BD</td>
<td>3588.3</td>
<td>3057.0</td>
<td>0.848 (0.808, 0.890)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AS</td>
<td>11679.5</td>
<td>10934.0</td>
<td>0.935 (0.910, 0.959)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>SJS</td>
<td>7913.5</td>
<td>7280.0</td>
<td>0.918 (0.890, 0.948)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IM</td>
<td>839.8</td>
<td>397.0</td>
<td>0.472 (0.418, 0.532)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>RA</td>
<td>17490.3</td>
<td>17342.0</td>
<td>0.990 (0.969, 1.011)</td>
<td>0.343</td>
</tr>
<tr>
<td>SDc</td>
<td>592.8</td>
<td>6570.0</td>
<td>0.938 (0.834, 1.054)</td>
<td>0.288</td>
</tr>
<tr>
<td>PMPR</td>
<td>1072.0</td>
<td>1152.0</td>
<td>1.073 (0.986, 1.167)</td>
<td>0.098</td>
</tr>
<tr>
<td>Gout</td>
<td>129543.0</td>
<td>131133.0</td>
<td>1.011 (1.003, 1.018)</td>
<td>0.007</td>
</tr>
<tr>
<td>HTN</td>
<td>680493.2</td>
<td>696391.0</td>
<td>1.021 (1.018, 1.024)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

SLE: systemic lupus erythematosus; BD: Behçet disease; AS: anklyosing spondylitis; SSc: systemic sclerosis; IM: idiopathic inflammatory myositis; RA: rheumatoid arthritis; SJ S: Sjogren syndrome; PMR: polymyalgia rheumatica; HTN: hypertension; CI: confidence interval.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2835

AB1444

ASSOCIATION BETWEEN THIOPURINE S-METHYLTRANSFERASE POLYMORPHISMS AND HEPATOXICITY IN AZATHIOPRINE-TREATED PATIENTS WITH AUTOIMMUNE DISEASES

S. H. Heh-Shiang¹, W. T. Hung¹,², W. Chia-Yi³, W. N. Huang³, Y. H. Chen⁴, Y. M. Chen⁴,⁵. Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung, Taiwan, Republic of China; Taichung Veterans General Hospital, Department of Medical Education, Taichung, Taiwan, Republic of China; Taichung Veterans General Hospital, Department of Medical Research, Taichung, Taiwan, Republic of China

Background: Azathioprine (AZA) is widely used in patients with autoimmune diseases. Thiopurine methyltransferase (TPMT) is the rate-limiting enzyme in AZA metabolism. Although several studies have investigated the association between TPMT polymorphisms and AZA-induced bone marrow suppression, the relationship of TPMT genotypes and hepatotoxicity in patients taking AZA remained unclear.

Objectives: This study aimed to investigate the correlation between TPMT polymorphisms and adverse reactions of AZA.

Methods: This retrospective case-control study enrolled patients with prior exposure to AZA at the Taichung Veterans General Hospital (TCVGH) using data extracted from the Taiwan Precision Medicine Initiative (TPMI) cohort. Drug-prescription profile, comorbidities, the occurrence of leukopenia and hepatotoxicity following AZA treatment were extracted from hospital health records. Genetic variants affecting TPMT activity were determined using SNP array. Participants were categorized into normal metabolizer (NM) and non-normal metabolizer (Non-NM) groups accordingly.

Results: From the 43,035 patients in the TCVGH-TPMI cohort, we identified 2,128 azathioprine users; 2.6% (57 out of 2,128) were classified as TPMT Non-NM group. After matching by age and sex, we included 50 TPMT Non-NM, including 1 poor metabolizers (PMs), 49 intermediate metabolizers (IMs), and 1,000 NM patients for further analysis. The Non-NM genotype was associated with hepatotoxicity compared with NM genotype (HR: 3.85, 95% CI: 1.83–8.10) after adjustment for gender, AZA dosage, and comorbidities (Table 1). In the Non-NM group, the 3-year cumulative incidence of hepatotoxicity was 6.6% for one year, 16.9% for two and three years, respectively, which was significantly higher than the NM group (p=0.003) (Figure 1).

Table 1. Cox regression analysis of risk factors for hepatotoxicity following AZA treatment

<table>
<thead>
<tr>
<th>Hepatotoxicity*</th>
<th>HR</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.99</td>
<td>0.98</td>
<td>1.01</td>
</tr>
<tr>
<td>Male gender</td>
<td>1.77</td>
<td>1.07</td>
<td>2.91</td>
</tr>
<tr>
<td>TPMT non-NM genotype</td>
<td>3.85</td>
<td>1.83</td>
<td>8.10</td>
</tr>
<tr>
<td>AZA dose (mg)</td>
<td>1.00</td>
<td>1.00</td>
<td>1.01</td>
</tr>
<tr>
<td>Medication</td>
<td>1.62</td>
<td>1.03</td>
<td>2.57</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>1.18</td>
<td>0.40</td>
<td>3.48</td>
</tr>
</tbody>
</table>

By Cox regression model with adjustment of all listed variables. "Development of GPT ≥ 150 U/L after AZA treatment; GPT, glutamic pyruvic Transaminase; TPMT, thiopurine S-methyltransferase; NM, normal metabolizer; AZA, azathioprine; MTX, Methotrexate; CI: confidence interval.

Conclusion: TPMT Non-NM genotype were associated with the development of hepatotoxicity following AZA therapy. Prospective studies are needed to verify our results.

REFERENCES:

Disclosure of Interests: None declared

AB1445

SYNOVIAL FLUID ANALYSIS IN HOT SWOLLEN JOINTS – A QUALITY IMPROVEMENT PROJECT

F. Rabban², Z. Jaffer³, L. Sammut². Portsmouth Hospitals University NHS Trust, Rheumatology, Portsmouth, United Kingdom; Portsmouth Hospitals University NHS Trust, Rheumatology, Portsmouth, United Kingdom

Background: Previous studies have reported delays in the investigation and suboptimal management of hot swollen joints, particularly crystal arthritis. In our hospital, it was noted that synovial fluid was inconsistently analysed for crystals which may lead to patients receiving delayed treatment.

Objectives: The aim of this quality improvement project was to 1) identify the number of synovial fluid samples that were not checked for crystals 2) implement changes to improve this process 3) re-audit and commitment to a continuous evaluation.

Methods: Retrospective review of synovial fluid analysis requested for adult patients presenting with hot swollen joints over a six month period. Following, the implementation of changes in the hospital, another comparison of pre-post intervention was performed. Samples were sent for analysis from March and August 2021, of which only 69 (65%) of the samples were analysed for microscopy and culture. Following involvement with IT and laboratory departments we have introduced an intervention to make requesting crystal analysis easier. The request for synovial fluid analysis was grouped in a bundle (reflex test) so whenever a synovial fluid is collected, two forms are generated, one for microbiology (microscopy and culture), and the other for cytology (crystal analysis). Additional interventions included education and raising awareness. Post-interventions, another three month analysis of synovial fluid samples that were not checked for crystals 2) implement changes to improve this process 3) re-audit and commitment to a continuous evaluation.

Results: A total of 106 synovial fluid samples were sent for analysis between March and August 2021, of which only 69 (65%) of the samples were analysed for crystals. All samples were analysed for microscopy and culture. Following involvement with IT and laboratory departments we have introduced an intervention to make requesting crystal analysis easier. The request for synovial fluid analysis was grouped in a bundle (reflex test) so whenever a synovial fluid is collected, two forms are generated, one for microbiology (microscopy and culture), and the other for cytology (crystal analysis). Additional interventions included education and raising awareness. Post-interventions, another three month analysis of synovial fluid samples that were not checked for crystals 2) implement changes to improve this process 3) re-audit and commitment to a continuous evaluation.

Conclusion: There was an improvement in the synovial fluid analysis requests of patients with hot, swollen joints. By implementing these changes and raising awareness, patients with acute crystal arthritis can be treated in a timely manner. We plan to continue our work with synovial fluid analysis following re-review and will continue to generate improvements.

Disclosure of Interests: None declared
TRANSLATION AND CROSS-CULTURAL ADAPTATION OF COPING WITH RHEUMATIC STRESSORS (CORS) INTO TURKISH LANGUAGE

G. Ayan1, S. Ramiro2,3, F. M. Pimentel-Santos4, W. Van Lankveld5, L. Kilic1,
1Hacettepe University Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; 2Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands; 3Zuyderland Medical Center, Department of Rheumatology, Heerlen, Netherlands; 4NOVA Medical School, Universidade Nova De Lisboa, Department of Rheumatology, Lisboa, Portugal; 5HAN University of Applied Sciences, Research Group Musculoskeletal Rehabilitation, Nijmegen, Netherlands

Objectives: To describe the translation and cross-cultural adaptation process of CORS into Turkish as well as its cognitive debriefing to test the conceptual equivalence of the translated version among patients with RA, radiographic (r) and non-radiographic (nr) axSpA.

Methods: The CORS was firstly translated into Turkish (by 2 bilingual translators who are native speaker for Turkish) and then back-translated into Dutch (by 2 bilingual translators who are native speaker for Dutch) following the Beaton’s method (Figure 1) (3). Back-translation procedure was done totally blindly to the original version. After the review of the Turkish version by an expert committee that included translators, two patients and the research team, a consensus was reached on the pre-final version. Using the pre-final version, the field test with cognitive debriefing involved a sample of 10 RA and 10 axSpA patients with different gender, age, disease duration, and educational background. After some small changes resulting from the feedback from patients the final version was obtained.

Results: The CORS was translated into Turkish following the forward-backward procedure. Minor incompatibilities arose from the translation process of CORS which have been easily resolved by the expert committee meetings. For example, ‘Ik concentrer me op iets anders’ was translated as ‘Başka seylerle odaklanırım’ which is in English ‘I concentrate on something else’. The discrepancy was raised whether to use a word equivalent ‘to concentrate’ or ‘to focus’ and decision was made to use ‘to focus’ while there was no exact Turkish word of ‘to concentrate’. A total of 10 patients with RA [9 females, mean (SD) age of 49 (13)] and 10 patients with axSpA [7 females, mean (SD) age of 38 (10), r-AxSpA, n=7, nr-AxSpA, n= 3] participated in the field test. Mean (SD) time to complete the CORS was 8.3 (3.4) minutes. Cognitive debriefing showed that items of the CORS are clear, relevant, understandable, and easy to complete. Cognitive debriefing revealed that the wording of one item had to be changed to provide better understanding (Section B, item 22 the word ‘stop’ in Dutch and ‘stop’ in English which was translated as ‘durdurmak’ in Turkish changed to ‘sonlandırmak’).

Conclusion: The final Turkish version of the CORS showed acceptable linguistic validity and can be used in both clinical practice and for research purposes, in patients with RA and in patients with axSpA. However, to implement Turkish-CORS, further assessment is ongoing to test its psychometric properties (validity and reliability).

REFERENCES:

AB1447 CATASTROPHISM IN MOROCCAN PATIENTS WITH CHRONIC RHEUMATIC DISEASES UNDER BIOLOGICS

H. Boutaib1, H. Azzouzi1, L. Linda1, Mohamed 1 University, Rheumatology Department, Oujda, Morocco

Background: Catastrophizing is a distortion of the perception of pain, both cognitively and emotionally, which leads patients to consider only the worst. There is a lack of knowledge about catastrophism in Morrocan patients with chronic rheumatic diseases under biologic DMARDs (disease-modifying anti-rheumatic drugs).

Objectives: To assess catastrophism and its associated factors in rheumatic patients under bDMARDs.

Methods: This is a cross-sectional study of patients admitted to a day hospital for biologic treatment evaluation. Patients included were all adults with SpA or RA diagnosed according to ASAS 2009 and ACR/EULAR 2010 classifications, respectively. The Pain Catastrophizing Scale (PCS)1 was used to assess catastrophism. This scale is a self-report measure, consisting of 13 items scored from 0 to 4, resulting in a total possible score of 52. It is divided into three subscales: magnification, rumination and helplessness. A total score above 30 indicates a clinically relevant level of catastrophizing. Sociodemographic and treatment data were collected. Disease activity scores (DAS28, ASDAS) using C-reactive protein (CRP) dosage of the same day were calculated for each disease. Questionnaires were obtained for all patients for functional assessment (HAQ, BASFI), insomnia by the insomnia severity index (ISI), and depression by hospital anxiety and depression scale (HADS). Anxiety was evaluated by the generalized anxiety disorder-7 (GAD-7). Statistical analysis was done using regressions by SPSS 20.

Results: We included 75 patients with a mean age of 42.20 ± 16.206 years and a mean disease duration of 17.47 ± 8.758 years. Almost all patients (90.7%) had a disease lasting for more than 05 years. Twenty-nine patients (38.7%) had inactive disease. The average duration of bDMARDs use was 24.29 ± 18.96 months (27.8 ± 18.5 months in SpA patients and 19.53 ± 18.81 months in RA patients). Seventy-nine percent of these patients have received only one bDMARD, and 6.7% were currently taking a TNF inhibitor. The mean catastrophizing scores were 21.91 ± 11.38 for all patients, 22.05 ± 12.163 for SpA patients, and 21.72 ± 10.24 for RA patients. The prevalence of catastrophism was 25.3%, and the highest sub-score was helplessness (17.53 ± 3.95, p = 0). These scores were similar in RA and SpA patients. Catastrophizing was significantly associated with anxiety degree (p = 0.021, OR = 2.362, [1.211-4.607]), and swollen joints (p = 0.042, OR= 1.197, 95%IC [1.006-1.423]) using logistic regression analysis. Catastrophism scores were positively associated with the number of bDMARDs used (p = 0.044, ß = 0.233, 95%IC [0.095-0.721]). This association remained significant with anxiety (p<0.0001) and the number of bDMARDs received (p=0.04) at multivariate regression adjusted on swollen joints, ISI and HADS.

Conclusion: Catastrophizing scores were high despite biotherapy use. They were related to anxiety disorder, swollen joints, and bDMARDs rotation. It would therefore be interesting to detect catastrophism in clinical routine to ensure good patients care.

REFERENCES:

Figure 1. Flow-chart of the translation and cross-cultural adaptation process

REFERENCES:

Disclosure of Interests: None declared

AB1448
DEEP VENOUS THROMBOSIS IN YOUNG ADULTS: INCIDENCE AND RISK FACTORS

F. Nabili1, S. Daadaa1, Y. Bousoukaya1, I. Chaabene1, M. Kechida1, R. Klii1, S. Hammami1
1Hospital Fattouma Bourguiba Monastir; Internal Medicine Department, Monastir, Tunisia

Background: After a first venous thromboembolic (VTE) episode, recurrence is frequent and associated with significant morbidity and mortality.

Objectives: Our aim is to identify the risk factors for recurrent VTE in young subjects and to assess the risk-benefit ratio of continuing long-term anticoagulant treatment.

Methods: We carried out a retrospective study including 100 patients with deep vein thrombosis (DVT) admitted to the Internal Medicine Department at Fattouma Bourguiba University Hospital in Monastir between 2011 and 2020.

Results: In our study, the gender ratio was 1.17. The mean age was 34.49 years ± 9.19. Lower extremity deep venous thrombosis (LEDVT) was the most common location (90%). Pulmonary embolism (PE) was found in 8% of cases. The most frequent risk factors were obesity: BMI>30 (40%), bed rest (25%), personal history of DVT (18%), smoking (16%), recent surgery dating less than one month (14%), and recent trauma (12%). The etiological assessment had concluded to inherited thrombophilia in 41 cases: protein C deficiency (23%), protein S deficiency (8%), and antithrombin III deficiency (2%); acquired thrombophilia in 28 cases: hyperhomocysteinemia (HH) in 19 cases and antiphospholipid syndrome (APS) in 9 cases; Behçet's disease in 10 cases and systemic lupus erythematosus in 5 cases. No cases of neoplasia were detected. The treatment was based on low molecular weight heparin (LMWH), by vitamin k antagonists (VKAs), and physical therapy (graduated compression stockings and early mobilization). Duration of the treatment of DVT in the young adult depends on the nature and extent of the thrombosis, the underlying risk factors, and etiologies. Among the 100 hospitalized patients, recurrent DVT was detected in 20% of cases: 17% of patients reported a history of DVT with a mean number of previous episodes of 2, and only 3% developed DVT during their follow-up. The mean time to recurrence was three years. Recurrence was located on the same side in most cases (70%). In our study, only Behçet's disease was associated with an increased risk of DVT recurrence (p: 0.015, OR: 5.46, CI [1.38-21.56]). Gender, age, venous insufficiency, and bed rest had no significant influence on the risk of recurrence (p>0.05).

Conclusion: Young adults should be assessed for acquired and also genetic factors, which would suggest extending the duration of anticoagulant therapy in high-risk patients, reducing the incidence of post-thrombotic syndrome and VTE recurrence. Further studies are needed to evaluate the association of Behçet's disease with DVT recurrence.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.3677

AB1449
ADHERENCE TO MTX AT INITIATION OF FIRST TARGETED THERAPEY: PREVALENCE AND ASSOCIATED FACTORS: RESULTS OF THE STRATEGE2 STUDY.

G. Gaujoux-Viala1, E. Demiris2, E. Senbel2, H. Herman-Demars3, J. Becker4, R. M. Fispo1. IDESP, Université Montpellier, INSERM, Department of Rheumatology, CHU Nîmes; Nîmes, France; 2Le Mans Central Hospital, Rheumatology Department, Le Mans, France; 3Cabinet de Rhumatologie, NA, Marseille, France; 4Nordic Pharma France, Medical Department, Paris, France; 5Centre Hospitalier Universitaire de France, Université de Lille, Lille, France

Background: Treatment adherence is a major challenge in chronic inflammatory rheumatic disease (CIRD). Mainly studied in rheumatoid arthritis (RA), this ranges from 30 to 80% [1]. Given the impact of non-adherence to disease-modifying therapy among RA patients, guidelines aiming to facilitate management of adherence were published in 2019 [2]. These guidelines highlight the multifactorial characteristics and importance of clarifying the factors determining non-adherence. In addition, treatment adherence was also listed as a point to consider for the management of difficult-to-treat RA by an EULAR task force [3].

Objectives: Based on inclusion results of STRATEGE2 we explore the adherence to methotrexate (MTX) and its associated factors prior to initiation of a first targeted therapy.

Methods: The objective of STRATEGE2 is to describe the therapeutic strategy in RA patients treated with MTX for at least 3 months, naive of targeted biological (bDMARD) or synthetic (tsDMARD) therapy and who are candidates for initiation of first btsDMARD therapy due to RA activity. Patients were included prospectively in 2019-2020 and completed the Compliance Questionnaire for Rheumatology (CQR) [4], a self-administered questionnaire specific to rheumatology, measuring treatment adherence. They were then divided into 2 groups: adherence (Ad) (CQR19>80) vs. non-adherence (NAd) to investigate factors liable to be associated with adherence. Then, univariate and multivariate analysis was applied to identify potential predictors for adherence.

Results: Between Feb. 2019 and Dec. 2020, 230 patients were included, with 124 RA patients having an analysable CQR19: 73.4% females, mean age 56.6 years ±13.2., diagnosed 5.6 years ±7.4 previously, treatment with MTX for 4.4 years ±5.3 and a mean DAS of 4.3 ±1.2. The mean CQR score was 75.8. Patient distribution: 45.2% in the Ad group and 54.8% in the NAd group.

Table 1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Ad (N=66)</th>
<th>NAd (N=68)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex: female</td>
<td>72.3%</td>
<td>73.3%</td>
<td></td>
</tr>
<tr>
<td>Age (mean)</td>
<td>59.3±13.6</td>
<td>54.7±12.4</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>BMI (mean)</td>
<td>27.2±7.0</td>
<td>25.0±4.7</td>
<td>0.15</td>
</tr>
<tr>
<td>Still in work</td>
<td>39.3%</td>
<td>59.9%</td>
<td>&lt;0.15</td>
</tr>
<tr>
<td>At least 1 comorbidity</td>
<td>60.7%</td>
<td>47.1%</td>
<td>&lt;0.15</td>
</tr>
<tr>
<td>Positive anti-CCP</td>
<td>67.9%</td>
<td>80.6%</td>
<td>&lt;0.15</td>
</tr>
<tr>
<td>Positive rheumatoid factor</td>
<td>69.8%</td>
<td>84.8%</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>C reactive protein</td>
<td>57.1%</td>
<td>71.1%</td>
<td>&lt;0.15</td>
</tr>
<tr>
<td>RA duration (years)</td>
<td>4.9±6.7</td>
<td>6.3±8.0</td>
<td></td>
</tr>
<tr>
<td>Average MTX initiation (years)</td>
<td>4.0±4.7</td>
<td>4.8±5.7</td>
<td></td>
</tr>
<tr>
<td>Per os MTX</td>
<td>28.6%</td>
<td>29.4%</td>
<td></td>
</tr>
<tr>
<td>– mean dosage (mg/week)</td>
<td>16.4±4.5</td>
<td>15.6±4.6</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous MTX</td>
<td>69.6%</td>
<td>70.6%</td>
<td></td>
</tr>
<tr>
<td>– mean dosage (mg/week)</td>
<td>20.1±4.6</td>
<td>19.4±3.3</td>
<td></td>
</tr>
<tr>
<td>Intramuscular MTX</td>
<td>1.8%</td>
<td>5.0%</td>
<td></td>
</tr>
<tr>
<td>Patients self-administration</td>
<td>30.0%</td>
<td>12.5%</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Corticosteroid therapy</td>
<td>53.0%</td>
<td>50.6%</td>
<td></td>
</tr>
<tr>
<td>– mean dosage (mg/day)</td>
<td>8.1±4.1</td>
<td>9.5±5.8</td>
<td></td>
</tr>
<tr>
<td>Mean DAS28</td>
<td>4.5±1.3</td>
<td>4.2±1.2</td>
<td></td>
</tr>
<tr>
<td>Mean HAQ</td>
<td>1.1±0.7</td>
<td>0.9±0.7</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

In the multivariate analysis, no formal predictive factors to MTX adherence was identified except BMI>30kg/m² (odds ratio, OR (95% confidence interval, CI)=4.00, 1.08-14.65, p=0.038) and adherents who estimate having completely adhered (CQR19-based evaluation) before initiation of btsDMARD. As physicians tend to overestimate adherence to medication, clarification of the factors associated with non-adherence would help improve patient assessment and, therefore, management. Supplementary data on patients’ adherence evolution and adherence predictors, might be observed on the follow-up data at 12 and 24 months of this cohort.

REFERENCES:

Acknowledgements: The authors wish to acknowledge RCTs for their contribution to the statistical analysis, the investigators, centres and patients.

Disclosure of Interests: Cécile Gaujoux-Viala Speakers bureau: AbbVie; Amgen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB, Consultant of: AbbVie; Amgen; Boehringer Ingelheim, Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead Sciences, Inc.; Janssen; Medac; Merck-Serono; Mylan; Nordic Pharma; Novartis; Pfizer; Roche; Sandoz; Sanofi; and UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB Pharma., Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Nordic Pharma, Roche-Chugai Novartis, Pfizer.
Objectives: The main risk is progression to multiple myeloma (MM). SBP and to identify factors associated with progression to MM and death.

Background: Solitary bone plasmacytoma (SBP) is a rare malignancy whose main risk is progression to multiple myeloma (MM).

Methods: This retrospective study was conducted between 1992 and 2020. Patients were included if they met the International Myeloma Working Group (IMWG) criteria for the diagnosis of SBP. Treatment response was assessed according to the IMWG criteria (2) for patients with detectable monoclonal protein and according to radiological response only for non-secretory SBP. Hazard ratios (HR) and their 95% confidence intervals (CI) were estimated by Cox proportional hazards models, adjusted for potential confounders. When available, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) were reviewed by two experienced nuclear physicians.

Results: A total of 77 patients diagnosed with SBP were included. The median age was 59 years (range: 27-89). Median follow-up duration was 87.1 months (range: 1.6-306.8). At the end of the follow-up, 45 (58.4%) patients had developed a MM and 13 (16.9%) deaths occurred, including 10 patients with progression to MM. Five-year myeloma-free survival and overall survival were 47.9% and 86.8% respectively. All patients received radiotherapy with a median dose of 45 Grays (range: 30-55). Chemotherapy was prescribed in 32 (41.6%) patients, concomitant to radiotherapy in 8, because of high risk of local extension, or adjuvant in 24 because of persistent disease after radiotherapy. Chemotherapy included mainly immunomodulatory drugs (28/32 (87.5%)) and/or proteasome inhibitors (11/32 (34.4%)) based combinations. Adjuvant chemotherapy after radiotherapy was associated with a reduced risk of MM compared to patients treated by radiotherapy alone, in a multivariate model adjusted for potential confounding factors, including response after radiotherapy alone (adjuvant chemotherapy versus no chemotherapy, HR 0.30, 95%CI [0.14-0.64]). Response to the first line of treatment (radiotherapy +/- chemotherapy) was the main factor associated with progression to MM (complete response versus partial response or progressive disease, HR 0.25, 95%CI [0.31-0.59]) and death (HR 0.20, 95%CI [0.09-0.89]). In this large study of patients with SBP, we observed that even though mostly prescribed for insufficient response to radiotherapy alone, treatment with adjuvant chemotherapy was associated with a decreased risk of evolution to MM, suggesting that this treatment might be systematically prescribed in addition to radiotherapy alone. These observations need to be confirmed and justify conduction of a prospective trial evaluating adjuvant chemotherapy in patients with SBP.

REFERENCES:

Acknowledgements: The authors are indebted to all participants for their continued participation.

Disclosure of Interests: None declared

Background: Spondyloarthritides (SpA) are a group of chronic inflammatory diseases with affection, mainly of the axial skeleton, and also of peripheral joints. The enthesis is one of the target organs, and its inflammation known as enthesitis could be unnoticed. Machine Learning is a branch of artificial intelligence that studies the construction of a function \(g(x)\), from a finite set of observations \(D=(x,y)\), where \(y\) is an endogenous variable and \(x\) are explanatory variables. The objective of this method is to obtain a model that best fit to the data without overfitting, that could be useful to make predictions.

Objectives: We try to find Machine Learning models that relate the MASEI index (Madrid Sonographic Enthesitis Index) in entheses depending on the activity of the disease (ASDAS, BASDAI and DAPSA) and other variables in patients with spondyloarthritides.

Methods: Observational, descriptive and cross-sectional study. We have analyzed 24 patients with SpA who underwent musculoskeletal ultrasound using the MASEI index and who were treated in our clinics from May 2021 to September 2021 and under the approval of the CEICm of our center. First, we have done a feature selection of the variables most related to MASEI. To do so, we compute mutual information and chi-square test, using the scikit-learn (python) library and Matlab, respectively. Using Matlab Regresion Learner package, we obtain the best Machine Learning model with the lowest RMSE for 5 fold cross-validation, which turned out to be a linear regression.

Results: To obtain regressive models that explain TOTAL MASEI, the following variables have been chosen: Type of SpA, BASDAI-DAPSA-ASDAS activity, Arthritis, Enthesophytes, Corticosteroids and CRP because they present a high degree of mutual information with MASEI and a high chi-square index. (See Figures 1 and 2). With these variables we have obtained the model that presents a lower RMSE error for validated data, which has turned out to be a linear regression, given by the formula:

\[
\text{MASEI} = \text{Type of SpA} + 10.42\times\text{ASDAS} + 4.08\times\text{Corticoids} + 8.2\times\frac{\text{Arthritis/sinov}}{\text{Enthesophytes}} + 6.8\times\frac{\text{Corticoids}}{\text{CRP}}
\]

The basic statistical characteristics of the coefficients of this equation can be consulted in Figure 3. The characteristics of the model are specified in Figure 3. In Figure 4, we observe how the data fit the diagonal and in Figures 5 and 6, we have compute a prediction and confidence intervals of our model using ASDAS and MASEI as coordinate axes.

Conclusion: We have obtained a linear model, which explains the MASEI variable as an explicit linear combination of the variables: type of SpA, ASDAS, Corticoids, Arthritis/sinov, Enthesophytes and CRP. Our model, not only is simple, but it is also optimal, in the sense that for 5-fold cross validation, it obtains the lowest RMSE error, compared to other Machine Learning methods, such as: neural networks, SVM, Gaussian processes, etc. Our model is useful to build confidence intervals, make predictions and to understand the relation between the variables mentioned above.

REFERENCES:

Evaluating the Effect of JAK Inhibitor Therapy in Autoimmune Inflammatory Rheumatic Diseases

I. Andreică1, K. Volker2, C. Elsner4, R. Broering1, F. Vondran6, P. Behrendt7, U. Dittrich1, E. Steinmann1, X. Baraliakos4, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Department of Gastroenterology and Hepatology, Essen, Germany; 2Institute for Virology, University Hospital Essen, University Duisburg-Essen, Virology, Essen, Germany; 3University Hospital Essen, University Duisburg-Essen, Department of Gastroenterology and Hepatology, Essen, Germany; 4ReMedIES, Department of General, Visceral and Transplantation Surgery, Hannover Medical School, Surgery, Hannover, Germany; 5Institute of Experimental Virology, TWINCORE Centre for Experimental and Clinical Infection Research, Virology, Hannover, Germany; 6Hepatology and Endocrinology, Hannover Medical School, Department of Gastroenterology, Hannover, Germany.

Background: Although impacting hundreds of thousands of people in Western nations each year, hepatitis E virus (HEV) is an under-reported health problem (1). HEV usually is a self-limiting disease, but especially immunocompromised individuals are at risk to develop a chronic course of infection, with rapid progression to fibrosis, cirrhosis or even the development of liver failure. Janus kinase (JAK) inhibitors are a novel drug class for the treatment of autoimmune inflammatory rheumatic disease (AIRD). As JAKs play a key role in innate immunity, viral infections and reactivation are frequently reported during JAK inhibitor treatment in AIRD patients (2).

Objectives: To characterize the influence of JAK inhibitors on HEV replication ex vivo and assess the risk for the development of symptomatic HEV infection during JAK Inhibitor therapy in vivo.

Methods: To determine the effect of JAK inhibitors on HEV replication we performed infection experiments with primary human hepatocytes (PHH) followed by immunofluorescence analysis and RNAseq. To evaluate the risk of HEV infection during JAK Inhibitor therapy, we monitored HEV RNA and HEV IgG/IgM of 111 AIRD patients, receiving JAK inhibitors. Moreover, we conducted a retrospective analysis of liver enzymes of patients which were anti-HEV IgG/IgM positive.

Results: Transcriptomic analysis of PHH revealed an upregulation of innate immunity components during HEV infection. This induction was perturbed in the presence of a JAK inhibitor concomitant with strong elevation of HEV RNA levels. In line, infection experimentsdisplayed an up to 50-fold increase in progeny virus production during JAK inhibitor treatment indicating that JAK signaling is critical to control HEV infection. Monitoring of seroprevalence identified 17 patients which were anti-HEV IgG and/or IgM positive, while no patient had detectable HEV RNA levels. Five patients had detectable anti-HEV IgM levels suggesting a recent HEV infection. Three of 17 had a period with elevated liver enzymes (i.e. GGT > 200 U/L) during time of retrospective analysis (ranging from 10 to 23 months).

Conclusion: Obtained ex vivo data suggest that JAK inhibitor facilitates HEV life cycle progression. Considering that JAK inhibitors are routinely applied for the treatment of AIRD, these patients may be at higher risk for a symptomatic course and outcome of HEV infection. In addition to establish prevalent, screening for HEV seroprevalence and HEV RNA should be considered prior starting JAK inhibitor treatment and in case of elevated liver enzymes during JAK inhibitor therapy.

REFERENCES:

Disclosure of Interests: None declared.

Objectives: The aim of our study was to determine the frequency of occurrence of traditional and non-traditional cardiovascular risk factors in patients with SLE and RA in comparison to patients with IHD and to assess their role for the development of early atherosclerosis.

Methods: The study included 85 female patients with ARD (SLE (n=40), mean age 33.5 (27.5; 44.5) years old, disease duration 8.0 (5.0; 14.5) years, disease activity SLEDAI-2K 7.0 (4.0; 11.5) points and RA (n=45), mean age 43.0 (33.0; 52.0) years old, disease duration 9.0 (5.0; 13.0) years, disease activity (DAS28=5.37 (4.69;5.89) points. Fifty four healthy women of the same age formed the first control group (CG1), 22 women with IHD (mean age 50.0 (48.0; 51.0) years old) made the second control group (CG2). The presence of traditional (age, arterial hypertension (AH), smoking, obesity, dyslipidemia, low physical activity, family history of cardiovascular disease (CVD)) and non-traditional (menopause, hyperhomocysteinemia (HHC)) risk factors was assessed. The early development of atherosclerosis was confirmed with the help of common risk factors in patients with SLE and RA may be associated with the development of early atherosclerosis.

Results: It was found that only AH and HHHC were more in patients with SLE and RA in comparison to CG1 (AH: 65% vs. 0% (p<0.0001), HHHC: 45% vs. 9% (p<0.0001), respectively for SLE patients and 27% vs. 0% (p<0.0001), 36% vs.9% (p=0.001), respectively for RA patients). Age, smoking, obesity, dyslipidemia, low physical activity, family history of CVD, menopause were similar in both groups of patients and CG1. It was revealed that patients with SLE were 14 years younger (p<0.0001) than female patients with IHD. They had less often family history of CVD (18% vs. 41%, p=0.044), but HHHC was revealed 2 times more often (45% vs. 22%, p=0.031) than in CG2. Patients with RA were 8 years younger than patients with IHD (p=0.007). Moreover the frequency of occurrence of AH, obesity, dyslipidemia, family history of CVD was less than in CG2 (27% vs. 73% (p=0.0003), 40% vs. 13% (p=0.03), 71% vs. 55% (p=0.025), 11% vs. 41% (p=0.005), respectively). HHHC was detected 1.5 times more often in RA patients in comparison to patients with IHD, but without statistically difference (36% vs. 22%, p=0.288). Other risk factors were similar in both groups of patients with ARD and IHD. The presence of subclinical atherosclerosis was observed in 54% patients with ARD. Comparative analysis of the frequency of occurrence of investigated cardiovascular risk factors between these patients and those with IHD has shown the highest prevalence of HHHC in patients with ARD (54% vs. 22%, p=0.014), which could be as a result of autoimmune inflammation in this group of patients. Conclusion: Thus, we revealed a high prevalence of AH (as traditional risk factor) and HHHC (as non-traditional risk factor) in patients with SLE and RA. More than half of patients with ARD had subclinical atherosclerosis. The presence of HHHC in patients with SLE and RA may be associated with the development of early atherosclerosis.

REFERENCES:

Disclosure of Interests: None declared.


AB1454

CLINICAL AND BIOLOGICAL FACTORS CORRELATED WITH MAGNETIC RESONANCE IMAGING RESULTS IN TUBERCULOUS SPONDYLODISCITIS

M. Mirabet1,2, S. Boussaid3, S. B. Troud4, S. Reikik1, S. Rahmouni1, S. Jemmali1, H. Aljani1, H. Sahl1, M. Elleuch1,2. 1Rehabilitation Hospital, Rheumatology, Tunis, Tunisia

Background: Tuberculosis is still endemic in Tunisia. Although pulmonary localisation is the most common, other localizations, including osseous-articular involvement, are increasingly diagnosed. Tuberculous spondylodiscitis (SPDT) or Pot’s disease is an infectious involvement of the disc-vertebrate couple, caused by the tubercular bacillus (Mycobacterium tuberculosis). Magnetic resonance imaging (MRI) is the most sensitive (95-100%) and the most early abnormal exam.

Objectives: Our aim was to study the correlation of contributing factors, epidemiological, clinical, biological, radiological and therapeutic data with positive signs of spinal MRI.

Methods: We conduct a retrospective and descriptive study in a single rheumatology department. Data were collected from observations of patients hospitalized in the past 20 years (2000-2020) who have been diagnosed with SPDT. Epidemiological, clinical, biological, radiological, and therapeutic data were analyzed. Each patient had spinal MRI. Positive signs have been individualized, represented by intervertebral disc involvement, vertebral body and visualization of a paravertebral abscess.

Results: Fifty-two cases of SPDT were collected (37F/15M). The mean age of the population was 55.21±17.79 years [19-91]. Thirty-three patients (69.2%) were positive for AH (anti-sm Sm IgG and IgM). The positive diagnosis was AH and HHC were more frequent in patients with SPDT (p= 0.04; r= -0.33) and the surgical treatment (p < 0.001). The neurological clinical signs were correlated with the heterogeneous increase in vertebral body T1 sp signal (p=0.04; r=-0.33) and the surgical treatment (p < 0.001).

Conclusion: Tuberculous spondylodiscitis is a frequent condition that needs to be diagnosed and treated rapidly. Spinal MRI is the first-line exam in case of suspicion. Clinical, biological and therapeutic parameters were correlated with the MRI images highly suggestive of positive diagnosis.

Disclosure of Interests: None declared.


AB1455

VERY LOW FREQUENCY ANAS/DFS70 PATTERN POSITIVITY IN A LARGE CORHOTE OF AUTOIMMUNE/ AUTOINFLAMMATORY AND CONTROLS IN A SINGLE HOSPITAL FROM COLOMBIA

C. Romero-Sánchez1,2,3, À. J. Caicedo1,2,3, V. S. Romero Alvarez1, A. Vargas4, L. Castro5, J. Amado6, P. Lopez-Mojica6, D. Marin7, D. Acero-M8,5, M. Acevedo-Godo8, D. Rincon-Riaño9, W. Bautista-Molano10, J. M. Bello-Gualtero11,2,1
1Hospital Militar Central, Rheumatology and Immunology Department, Bogota, Colombia; 2Universidad El Bosque, Cellular and Immunology Group InmuBo, Bogota, Colombia; 3School of Medicine, Universidad Militar Nueva Granada, Clinical Immunology Group, Hospital Militar, Bogota, Colombia; 4Universidad Colegio Mayor de Cundinamarca, Bacteriology School, Faculty of Basic Sciences, Bogota, Colombia; 5Hospital Militar Central, Universidad Militar Nueva Granada, Dermatology Department, Bogota, Colombia; 6Hospital Military Central, Immunology Laboratory, Bogota, Colombia

Background: Antinuclear antibodies (ANA) have diagnostic significance in rheumatology. Anti-DFS70 (Dense Fine Speckle-70 kd) antibodies may be an exclusionary marker for systemic autoimmune rheumatic disease (SARD). Low frequency of this pattern has previously been described in healthy populations.

Objectives: To evaluate ANAS/DFS70 positivity and autoantibody profile in a large Colombian population with rheumatoid arthritis (RA), psoriasis (PsO), as well as, undifferentiated connective tissue diseases (UCTD), first degree relatives (FDR), and healthy controls (HC).

Methods: A cross-sectional study was conducted. We analyzed 531 individuals between 18-65 years, 101 RA patients (ACR/EULAR 2010 classification criteria), 137 relations from RA, 60 PsO patients (Colombian classification consensus), 17 UCTD patients, and 106 HC patients by age and sex. The determination of ANAS+HEp2 antibodies, was carried out. The ANAS/DFS70 positive results used as a confirmatory test the determination by Knockouted, for the psip gen and CytoBeard by indirect immunofluorescence–IFi technique. Absolute and relative frequencies were established and associations with chi square test.

Results: The distribution by diagnostic group was RA: 19%, PsO: 11.3%, UCTD: 8%, 25.8% RA relatives, and 35% healthy controls, RA was ANA test (+) in 42% PsO 41.7%, UCTD 78.7%, FDR 26.3%, and HC 26.9%. The positive frequency of ANAS/DFS70 in the total group was 2.3% and 1.4% in SARD (n=12; 2 FDR, 6 HC, 3 UCTD, and PsO 1), no RA patients were positive. These 12 participants were negative for rheumatoid factor (RF) and anti-citrullinated protein antibody (ACA), one patient with UCTD were positive for Anti SSB/La, Anti Sm, Anti RNP, and anti-citrullinated proteins, another was positive for Anti Sm and IgG B2GPR and IgA- B2GPR. Most participants had negative acute phase reactants (erythroesudmentation rate ESR[±] 83.3% and C-reactive protein CRP[±] 66.6%). ANAS/DFS70 was associated with positivity for ANAS independently of ANAS titters, (p <0.001). None of the patients' positives ANAS DFS70 in the UCTD group in 5 years developed definitive autoimmune disease.

Conclusion: Despite the low frequency in the group in general, ANAS/DFS70 was present in very low frequency in Colombian patients with SARD. Thus, patients with a positive result tend to have a mild or non-progressing phenotype of autoimmune or autoinflammatory diseases. This analysis reinforce the idea that ANAS/DFS70 positivity may be associated with a lower risk of SARD. Low frequency of ANAS/DFS70 pattern may be an exclusionary marker for systemic autoimmune rheumatic disease (SARD). Low frequency of this pattern has previously been described in healthy populations.

Acknowledgements: Hospital Military Central / Universidad del Bosque

Disclosure of Interests: None declared.

Table 1. Clinical and demographic variables for ANAS/DFS70 patients n=12.

<table>
<thead>
<tr>
<th>AGE</th>
<th>GENDER</th>
<th>ANAS</th>
<th>ESR</th>
<th>CRP</th>
<th>RF</th>
<th>ACPR</th>
<th>Ro</th>
<th>La</th>
<th>Sm</th>
<th>RNP</th>
<th>DNA/P</th>
<th>ACA IgG</th>
<th>ACA IgA</th>
<th>ACA IgM</th>
<th>B2GP IgG</th>
<th>B2GP IgM</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>F</td>
<td>1/160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>F</td>
<td>1/320</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>F</td>
<td>1/160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>F</td>
<td>1/320</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>M</td>
<td>1/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>F</td>
<td>1/160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>F</td>
<td>1/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>F</td>
<td>1/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>F</td>
<td>1/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>F</td>
<td>1/320</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>F</td>
<td>1/160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>F</td>
<td>1/320</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Rheumatoid arthritis (RA), Psoriasis (PsO), as well as, Undifferentiated connective tissue diseases (UCTD), first degree relatives (FDR), healthy controls (HC), rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA), erythrocytosedimentation rate (ESR), and C-reactive protein (CRP).

AB1456

CLINICAL IMPACT OF THE INTERSTITIAL LUNG DISEASE MULTIDISCIPLINARY SERVICE

S. Eisa1, B. Osei-Boadu1, G. Singh-Rathore1, M. Rabban2, K. Suthar4, S. Ansari3, G. M. Koduri1, 1Southend University Hospital, Rheumatology, Essex, United Kingdom; 2Southend University Hospital, Mid and South Essex NHS Foundation Trust, Rheumatology, Southend-on-Sea, United Kingdom; 3Southend University Hospital, Respiratory, Essex, United Kingdom; 4Southend University Hospital, Radiology, Essex, United Kingdom

Background: Interstitial lung diseases (ILD) are a diverse group of pulmonary diseases for which accurate diagnosis is critical for optimal management and outcomes. Diagnosing ILD, both idiopathic pulmonary fibrosis (IPF) and connective-tissue-disease-associated interstitial lung disease (CTD-ILD), has become critically important, as the disease has a devastating prognosis with poor survival. There are many disease implications, as patients with ILD can now potentially be treated with new antifibrotic therapies such as piperidinone and nintedanib, both of which have been approved. Certain types of CTD – ILD may benefit from systemic immunomodulatory therapies. Diagnosis of ILD can be challenging and a multidisciplinary team (MDT) approach is recommended in current guidelines. Several studies have reported that MDT diagnosis is associated with higher levels of diagnostic confidence and better interobserver agreement (1-3).

Objectives: We describe the benefits of an ILD multidisciplinary service on the diagnosis and management of patients with suspected ILD.

Methods: We performed a single-centre retrospective review of consecutive patients referred to the ILD clinic with subsequent discussions in ILD MDTs over a 36-month period from 2016 to 2019. We compared changes in ILD diagnosis and management at referral to those following the ILD-MDT. We collected data on the demographics, occupation, age at ILD onset, smoking status, imaging, blood tests including autoimmune serology, MDT recommendations, change in diagnosis after MDT, referral per, final ILD diagnoses, and outcomes. Cases of suspected ILD that were not fully characterised and those with complex management issues were presented at our monthly ILD MDT.

Results: A total of 206 patients were referred to the ILD clinic over a 36-month period. Of these, 106 cases were discussed at the ILD MDT and the remaining 102 cases did not require discussion at the MDT as these deemed to be clear cut, which included RA and CTD-ILD. The mean age of the total cohort was 74 years (min 32, max age 97) and 120 (58%) were males. Overall, evaluation by the ILD service resulted in a change in diagnosis in 106/11% patients. Of those, 49 (46%) didn’t have ILD. In the remaining 57 patients with suspected ILD, the majority of the diagnoses were ILD with an uncertain classification (24, 23%). The other diagnoses included CTD-ILD (4, 3.7%), ILD with autoimmune serology (10(10.4%), IPF (10(9.4%), Drug-induced-ILD (3,28%), Hypersensitivity Pneumonitis (5(4.7%), Esophophilic pneumonitis (1(0.9%), Cryptogenic Pneumonitis (1(0.9%), CEPPE (1(0.9%), CPFE (1(0.9%), , RF (0.9%), RB-ILD (1(0.9%), Langerhans Histiocytosis (1(0.9%),16/57(28%) were referred to a tertiary centre for further management. Serology was positive in 11 patients (ANA 6, CCP 3, and ANA 2). Of the 57 patients with other diagnoses, the main recommendations included steroids (28), anti-fibrotic therapy (4), immuno-modulatory therapy (6) and ambulatory Oxygen (1). Further analysis will be carried out on survival and treatment outcomes of the cohort.

Conclusion: Dedicated ILD-MDT service has important clinical impact on the care of the ILD patient, with frequent changes in ILD diagnosis and subsequent management and outcomes. Multidisciplinary approach to the management of these patients should be standard of care for these patients.

REFERENCES:


AB1457

OPALE: A PROSPECTIVE OBSERVATIONAL STUDY OF THE REAL-WORLD USE OF AN ADALIMUMAB BIOSIMILAR AND EVALUATION OF NUTRITIONAL STATUS ON THE THERAPEUTIC RESPONSE. PATIENTS NUTRITIONAL STATUS AT BASELINE

M. Soubrie1, M. Vigier2, L. Peyrin-Biroulet3, S. Czernichow4, 1University Hospital Gabriel Montpied, Department of Rheumatology, Clermont-Ferrand, France; 2Robert Debre Hospital, Department of Dermatology, Reims, France; 3University Hospital of Nancy-Brabois, Department of Gastroenterology, Vandoeuvre les Nancy, France; 4Georges Pompidou European Hospital, Department of Nutrition, Paris, France

Background: Chronic inflammatory diseases treatment has been greatly improved since the introduction of TNF inhibitors and later, of their biosimilars. In addition, epidemiological and interventional studies suggest a pathophysiological or therapeutic role, respectively, of nutrition in Inflammatory Rheumatic Diseases (IRDs).

Objectives: The objective of the OPALE observational study was to describe in real life the profile of patients treated with an adalimumab biosimilar and to assess the impact of nutrition on disease evolution and response to treatment.

Methods: The study planned a one-year follow-up of patients with at least three visits: inclusion, six months and one year. In this study, 754 patients treated with Fresenius-Kabi adalimumab were included: 54.4 % of patients with an IRD, 42.6 % with Inflammatory Bowel Disease (IBD) and 2.8 % patients with a psoriasis. Patients' condition was assessed using a Clinical Global Impression of disease scale (CGI, primary end point of the study). Nutritional status was assessed through clinical data (weight, BMI (Body Mass Index), abdominal circumference) and the available biological analyses results. Screening for sarcopenia was based on a SARC-F score ≥ 4. Nutritional behavior was assessed using a diet questionnaire with a list of 48 foods divided into 6 classes (Fruits & vegetables, meat, fish & eggs, dairy products & fats, starchy foods, sweet foods and drinks).

Foods voluntarily withdrawn due to illness and those avoided at acute flare-ups were recommended to be reported. This analysis aims to describe IRD patients' nutritional status at baseline.

Results: From 754 included patients, 410 patients presented with an IRD (Psoriatic Arthritis (PsA), n= 80 / Rheumatoid Arthritis (RA), n=102 / SpondyloArthritis (SpA), n=228). Mean patients' age was 47.7 ± 14.1 years, 56% are female, mean BMI was 26.0 ± 5.4kg/m². From this IRD population, 754 patients treated with Fresenius-Kabi adalimumab as their first biotherapy. Most of patients received Fresenius Kabi adalimumab as their first biotherapy. Most of patients were assessed on the CGI scale as markedly ill (50.7%) or moderately ill (29.9%) and 110 patients (37.3%) had a score ≥ 4 on the SARC-F questionnaire (mean age 48.9 ± 14.1 years and mean BMI 27.2 ± 5.6kg/m²). Concerning the disease history at baseline, the descriptive analysis of self-administered questionnaire shows that 68.3% of patients may have changed their nutritional behavior because of their illness, by banishing several foods (mean number: 12.7 ± 10.1). These restrictions are increased during flare-ups; 32.7% of patients removed an average of 6.0 ± 5.8 additional foods number. These changes are in part based on the patients' own beliefs: 17% of them consider that certain foods can improve their illness, 35% of patients think they have identified the foods likely to make it worse (Table 1).
Conclusion: These preliminary baseline data from OPAL observational study confirm the risk of adverse cardiovascular events in IRD. Mean BMI of patients studied for sarcoptosis is higher than that of non-sarcoptopenic patients (respectively 27.2 ± 5.6 kg/m² and 25.6 ± 4.8 kg/m²; p=0.02). These results lead for a systematic screening for sarcopenia in IRD patients. The risk of sarcopenia could be further aggravated by inappropriate nutritional behaviors aimed at excluding food groups, which would justify dietary education of these IRD patients.


AB1458 JAK INHIBITORS AND VENOUS THROMBOEMBOLISM EVENTS - REASSESSING DATA FROM A LARGE SINGLE CENTRE RETROSPECTIVE STUDY

C. Beever 1, S. Bartsz-Bowden 1, M. Fletcher 1, L. Goh 1, G. Dulay 1, 1Portsmouth Hospitals University NHS Trust, Rheumatology, Portsmouth, United Kingdom

Background: In March 2021, the European Medicines Agency (EMA) sent out a Medicine Alert related to Xeljanz (tofacitinib): The initial clinical trial results suggested an increased risk of major adverse cardiovascular events and malignancies with use of tofacitinib relative to TNF-alpha inhibitors. In light of these safety alerts, March 2021, the Rheumatology department at Portsmouth Hospitals University NHS Trust updated the Biologics Screening documents to include a cardiovascular and venous thromboembolism (VTE) risk assessment. We conducted a retrospective observational study to document the incidence of VTE in patients on Janus kinase (JAK) inhibitors admitted to our Venous thromboembolism Service from 14th April 2018 to 30th November 2021 (43 months). This includes patients who were suspected of having both deep vein thrombosis (DVT) and/or Pulmonary Thromboembolism (PE). We were particularly interested to assess whether any patients with VTE events had been receiving JAK inhibitors given the potential association of JAK inhibitor usage and VTE.

Objectives: To establish whether patients exposed to JAK inhibitors had any increased incidence of VTE. This was done through a retrospective analysis for all patients presenting to Portsmouth Hospitals University NHS Trust.

Methods: We utilised the International Classification of Diseases (ICD10) diagnosis code of 182 (182.0, 182.1, 182.2, 182.3, 182.8, 182.9). This includes; Budd Chiari syndrome, thrombophlebitis migrans, embolism and thrombosis of vena cava, embolism and thrombosis renal vein, embolism and thrombosis of other specified view and embolism and thrombosis unspecified vein. From this data set, we reviewed how many case of VTE were noted in patients on JAK inhibitors. The Data was confined to patients who underwent diagnostic tests for VTE at Portsmouth Hospitals University NHS Trust.

Results: A total of 417 patients had been admitted to the VTE Service for diagnostic assessment between 14th April 2018 to 30th November 2021. A total of 261 patients had been on a JAK inhibitor during the period of observation. This included patients on Tofacitinib, Baricitinib, Filgotinib and Upadacitinib. This was for treatment in Rheumatoid Arthritis and Psoriatic Arthritis where licenced indications were appropriate. None of these had a VTE event. The age range of the patients on active treatment was 18 to 86 years old with the average of 60.7 years. The majority of patients were female (72.7%) with male patients comprising the remainder (27.3%). 8 patients under the care of the Rheumatology service were identified as having VTE events.

Conclusion: From a total of 261 patients on JAK inhibitors during a 43 month period; 0 patients had a confirmed VTE event. After March 2021, the Rheumatology department sought to address the concerns raised by the EMA alert. There were two key areas in addressing the concerns highlighted. Firstly, clinicians had an heightened awareness of the potential risk of VTE and JAK inhibitor usage. Additionally, there was also the introduction of a new screening process which focussed on highlighting and assessing risk facotrs for VTE in patients being screened for JAK inhibitors. This was a new departmental service innovation introduced following the potential patient safety alert. We would postulate that some of the highly encouraging data obtained may partly be influenced by this service development. Conversely, much of the data was gathered before these associations were established and before any service changes were made. We acknowledge that this data set is from a single centre analysis. However, given the sample size and duration of retrospective review, we hope this serves to reassure clinicians that JAK inhibitor usage should remain a valid treatment option in Rheumatology patients, for licenced indications.

Disclosure of Interests: Colen BEEVER Speakers bureau: Roche, UCB, Lilly, Nor- sadie Bartosz-Bowden: None declared, Margaret Fletcher: None declared, Leslie Goh: None declared, Gurdeep Dulay Speakers bureau: Roche Chugai, Novartis, Amgen, Lilly, Sandoz, Thornton Ross/ Internis DOI: 10.1136/annrheumdis-2022-eular.4730

AB1459 IMPACT OF SOCIOECONOMIC FACTORS ON THE DISEASE ACTIVITY: DATA FROM THE TUNISIAN BINAR REGISTRY

R. Ben Aissa 1, S. Boussaid 1, S. Rekik 1, S. Jemmal 2, S. Rahmouni 1, H. Srai Sahn 1, M. Elieuch 1, Rabba Hospital, Department of Rheumatology, Tunis, Tunisia

Background: Despite the considerable therapeutic progress of inflammatory rheumatic diseases, access to treatment still challenging in developing countries because of scarce health resources and low socioeconomic status.

Objectives: To determine the influence of socioeconomic factors on disease activity in a national registry cohort, the Biological National Registry (BINAR) in Tunisia. Methods: We enrolled patients with inflammatory rheumatic diseases under the first received biological drug and included in the BINAR registry from 2016 to 2020. Data on the inflammatory rheumatic disease (rheumatoid arthritis (RA) and spondyloarthritis (SA)), disease activity of RA and SA (DAS28- CRP and ASDAS- CRP respectively) at baseline, gender, active smoking, marital status and educational attainment were collected. Two groups were identified: Groupe 1 (G1) for patients with remission or low disease activity and groupe 2 (G2) for moderate or high disease activity according to DAS28-CRP and ASDAS-CRP.

Results: The study included 298 patients with a mean age of 49.2 years [18-79]. The mean disease duration was 6.7 ± 3.5 years [1-14] in patients with RA and 6.5 ± 3.6 years [1-12] in patients with SA. G1 was made of 13 patients and G2 of 285 patients. The mean age difference between G1 and G2 was (49.5 ± 11.9 versus 49.5±14.2, p=0.93) gender (% of females, 46.2% versus 37.1%, p=0.51) and marital status (% of single patients, 30.8 % versus 33.7%,p=0.82). Patients of G1 had better employability than G2 (61.5% versus 45.6%) but this difference was not significant (p=0.5). Smoker patients had better disease outcomes comparing to nonsmokers but this difference was not significant (23.1 % versus 13.7%, p=0.34). Illiterate patients had more active diseases, comparing to literate, but this difference was not significant (30.8% versus 40.4%, p=0.49).

Conclusion: Our results did not confirm any difference in disease activity according to the collected socioeconomic factors. Data on the personal income, health insurance type and geographic distribution of our population should be further studied.


AB1460 ACCUMULATED ADVANCED GLYCAZATION ENDPRODUCTS ARE SIGNIFICANTLY HIGHER IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES THAN IN HEALTHY POPULATION.

L. Triger 1, I. Carrion Barberi 2, I. Tio 2, T. C. Salmon Monte 2, C. Perez 2, L. Polino 3, A. Ribes 1, J. Lorente Onaindia 1, J. Montfort 1, IMIM (Hospital del Mar Medical Research Institute), Immunology and Cartilage Cellular Research Group, Barcelona, Spain; 2Hospital del Mar, Rheumatology, Barcelona, Spain

Background: Advanced glycation endproducts (AGEs) are the result of non-enzymatic glycation of proteins, lipids or nucleic acids. In circumstances characterized by increased oxidative and carbonyl stress, such as chronic inflammation, AGEs can be formed more rapidly1, generating reactive oxygen species and activating inflammatory signaling cascades through their chief signaling receptor RAGE2. This positive feedback of inflammation can play a role in the etiology of immune-mediated inflammatory diseases, more specifically in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE).

Objectives: To investigate whether the accumulated concentrations of AGEs in patients with SLE, RA or AS are significantly higher than in healthy patients.

Methods: One hundred thirteen consecutive patients fulfilling ACR/EULAR criteria for RA, 60 patients fulfilling ASAS/OMERACT MRI criteria for AS, 97 patients fulfilling ACR/SLEIC criteria for SLE and 527 sex-matched healthy controls were recruited in cross-sectional study. Exclusion criteria were pregnancy, diabetes mellitus, corticosteroid treatment >20mg/day and malignant neoplasm.
Table 1. Descriptive characteristics of the cohorts

<table>
<thead>
<tr>
<th>SLE</th>
<th>RA</th>
<th>AS</th>
</tr>
</thead>
<tbody>
<tr>
<td>N=96</td>
<td>N=189</td>
<td>N=173</td>
</tr>
<tr>
<td>N=240</td>
<td>N=60</td>
<td>N=99</td>
</tr>
</tbody>
</table>

**AGEs**

| N=2.57 (0.65) | N=1.98 (0.45) | N=2.59 (0.58) | N=2.00 (0.42) | N=2.26 (0.46) | N=1.90 (0.46) |

**Age**

| 51.0 (43.61) | 56.0 (52.62.0) | 58.0 (54.65.0) | 61.0 (56.66.0) | 67.5 (47.5.55) | 53.0 (49.5.57) |

**Smoker**

| No (79.2%) | Yes (20.8%) | No (79.2%) | Yes (20.8%) | No (79.2%) | Yes (20.8%) |

**Packs/year**

| 0.00 (0.00;0.10.8) | 2.50 (0.00;18.8) | 2.50 (0.00;18.8) | 0.00 (0.00;12.6) | 0.00 (0.00;78.8) | 14.3 (2.00;30.6) |

**Hypertension**

| No (74.71%) | Yes (25.29%) | No (74.71%) | Yes (25.29%) | No (74.71%) | Yes (25.29%) |

**Obesity**

| No (80.83%) | Yes (19.17%) | No (80.83%) | Yes (19.17%) | No (80.83%) | Yes (19.17%) |

**Dyslipidemia**

| No (88.5%) | Yes (11.5%) | No (88.5%) | Yes (11.5%) | No (88.5%) | Yes (11.5%) |

**Continuous normal: mean (SD); Continuous non-normal: median (IQR); Categorical: absolute (relative frequency)**

Accumulated AGEs were non-invasively measured by skin autofluorescence (Age Reader Mu Connect, Diagnostics Technologies B.V) and demographic and clinical data were collected. AGEs comparisons between patients and controls were performed by multiple linear regression analysis adjusted by confounders, previously described in literature (age, smoking habit and cardiovascular risk-factors). Age was centered at 55 years.

**Results:** Table 1 shows some descriptive characteristics of our cohorts. AGEs adjusted mean was significantly increased in SLE patients compared with matched controls (95% CI [2.27, 2.76] vs [1.66, 1.89], p<0.0001), RA patients and controls (95% CI [2.41, 2.61] vs [1.68, 1.88], p<0.0001) and AS patients and controls (95% CI [2.03, 2.6] vs [1.66, 1.93], p<0.0001). In all 3 models, AGEs were also significantly positive correlated with smoking habit measured by packs per year (p<0.001) and age (p<0.0001).

**Conclusion:** Accumulated AGEs in all 3 pathologies are significantly higher than in the healthy controls. The different means of AGEs in each of the diseases, being higher in SLE and lower in AS, may suggest a different participation of AGEs in the immune-mediated mechanisms of each pathology.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4893

**Figure 1. Discontinuation rate curves in RA patients with high disease activity (DAS28 >5.1) and DAS28c<5.1.**

**Conclusion:** In Mexican RA patients registered in BIOBADAMEX, we found that baseline high disease activity is associated with the discontinuation of bDMARDs. Further longitudinal analyses will be performed including more patients to assess retention rate of specific bDMARDs and identify predictive variables of discontinuation in Mexican population.

**REFERENCES:**


**Disclosure of Interests:** VIJAYA RIVERA TERAN: None declared, David Vega-Morales: None declared, Sandra Sicsik: None declared, Fedra Izazque-Palazuelos: None declared, Miguel A Saavedra: None declared, Julio Cesar Casasola: None declared, Sandra Carrillo: None declared, Ángelica Peña: None declared, Ángel Castillo Ortiz: None declared, Omar Eloy Muñoz-Monroy: None declared, Sergio Duran Barragan: None declared, Azucena Ramos: None declared, Luis Francisco Valdés Corona: None declared, Estefanía Torres Valdéz: None declared, Aleni Paz: None declared, ERICK ADRIAN ZAMORA-TEHODOL: None declared, David Vega-Morales: None declared, Sandor Sasics: None declared, Francesco Friedman: None declared, Francisco Guerrero: None declared, Natalia Santan: None declared, Miguel Vazquez: None declared, Claudia Zepeda: None declared, Melanea Rivera: None declared, Kitzia Alvarado: None declared, Deshry Alpizar-Rodriguez Consultant of: Scientific advisor for GSK, unrelated to this study, Employee of: Scientific advisor for GSK, unrelated to this study.

**DOI:** 10.1136/annrheumdis-2022-eular.5000
AB1462

RHEUMATIC IMMUNE- AND NON IMMUNE-RELATED ADVERSE EVENTS IN PHASE 3 CLINICAL TRIALS ASSESSING PD-(L)1 CHECKPOINT INHIBITORS FOR LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS

A. Vecchio1, M. Kostine2, A. Tison2, M. Dipasquale1, S. Kingsperger2, G. Grandi3, O. Cafio4, S. Incchiostro5, G. Paolazzi5, R. Bortolotti5, D. Corne6, A. Berti5, Hospital of Trento, University of Trento, Oncology, Trento, Italy; 5CHU Bordeaux, Medicine, Bordeaux, France; 3CHU de Brest, Rheumatology, Brest, France; 4University of Trento, CIBIO, Trento, Italy; “Hospital of Trento, University of Trento, Rheumatology, Trento, Italy

Background: Several adverse events (AEs) occurring during immune checkpoint inhibitors (ICIs) therapy are clearly related to their mechanisms of action, and in this case they are indicated as immune-related AEs (irAEs). Every organ may be affected, including the musculoskeletal system; myositis, polymyalgia rheumatica, arthritis or arthralgia have been reported in several retrospective and prospective case series and cohorts, with an incidence between 1.5% and 22%. While arthritis, vasculitis, myositis, and polymyalgia rheumatica are usually defined as irAE in RCTs, other rheumatic musculoskeletal conditions such as arthralgia, myalgia, back pain and muscular pain are often reported under the umbrella of “general” AEs.

Objectives: We aimed to analyze rheumatic irAE and non-irAE due to immune-checkpoint inhibitors (ICIs) targeting programmed cell death-1 or its ligand PD-(L)-1 in lung cancer patients from the available literature.

Methods: We performed a systematic review and meta-analysis of phase III randomized clinical trials (RCTs) assessing PD-(L)-1 ICIs in lung cancer patients, from inception until January 12th, 2021. We extracted data of each trial to estimate odds ratio (OR) for rheumatic ir or non-irAE as classified in RCTs safety data. Sensitivity analyses (by treatment group and histology) were performed.

Results: Eighteen RCTs met the inclusion criteria (n=12172 subjects). The OR [95%IC] for rheumatic irAE in ICIs versus controls (either placebo or chemotherapy) was 2.20 [0.85;5.72]. Among rheumatic non-irAEs, both overall (any grade, Figure 1A) and severe (grade3, Figure 1B) back pain were significantly more frequent in ICIs versus controls (2.01 [1.09;3.73] and 2.90 [1.16;7.08], respectively).

The overall frequency of arthralgia and severe arthralgia was similar between ICIs and controls (1.13 [0.86;1.47] and 1.69 [0.68;4.20], respectively). By sensitivity analysis RCTs assessing ICIs in combination with chemotherapy versus chemotherapy alone showed a significant association with arthralgia (1.55 [1.15;2.10]). Similarly, the frequency of myalgia did not differ between ICIs and controls, but was significantly lower in RCTs assessing ICIs alone versus chemotherapy (OR 0.32 [0.24;0.42]). Muscular pain was not significantly increased with ICI. Conclusion: Rheumatic irAEs are not increased in RCTs assessing PD-(L)-1 inhibitors, not reflecting the real-life incidence, therefore likely underreported or misclassified. Back pain is significantly associated with PD-(L)-1 ICIs regardless its severity, suggesting a possible implication of the PD-(L)-1 axis in the development of inflammatory back pain in some patients. In addition, PD-(L)-1 ICIs added on conventional chemotherapy are associated with a significantly higher frequency of arthralgia than ICI alone. This trend was seen in the other rheumatic AEs, suggesting that conventional chemotherapy might be a confounder in the interpretation of the occurrence of rheumatic AE.

Disclosure of Interests: Antonello Vecchio: None declared, Marie Kostine: None declared, Alice Tison: None declared, Mariachiara Dipasquale: None declared, Stefania Kingsperger: None declared, Guido Grandi: None declared, Orazio Cafio: None declared, Sandro Incchiostro: None declared, Giuseppe Paolazzi: None declared, Roberto Bortolotti: None declared, Divi Corne: None declared, Alvis Bert Consultant of: GSK


AB1463

CHARACTERISTICS AND MORTALITY OF PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES ADMITTED TO THE INTENSIVE CARE UNIT.

J. P. Baldievich1, E. Miguez Tato2, C. Valero3, F. Gutierrez-Rodriguez2, C. Alvar Gonzalez2, D. Rodriguez Semaro3, A. Garcia-Vadillo1, Hospital de La Princesa, Rheumatology, Madrid, Spain; 3Autonomous University of Madrid, School of Medicine, Madrid, Spain; 4Hospital de La Princesa, Intensive Care Unit, Madrid, Spain

Background: Autoimmune rheumatic diseases (ARD) are associated with multiple organ dysfunction, which may require admission to Intensive Care Unit (ICU), constituting a challenge for rheumatologists and intensivists. The new immunomodulatory treatments may be changing the characteristics and mortality of these patients.

Objectives: The primary objective of the study is to know the mortality and the characteristics related to this event of our patients admitted to the ICU in the last year, in order to secondary objective to compare the characteristics of our series with the series of our patients admitted to the ICU in the previous decade.

Methods: We conducted a retrospective transversal observational study using computerized medical records. A database was created with patients with ARD admitted to the ICU of the Princess University Hospital between October 1, 2015 and September 30, 2020, excluding those with a stay of less than 24 hours. Collection was made about the characteristics and treatments of the disease prior to their admission to the ICU, as well as the clinical characteristics and therapeutic measures established in the ICU during their stay. Statistical analysis was performed using SPSS.

Results: After ruling out admissions of less than 24 hours, a population of 45 patients with a mean age of 65.3 ± 12.2 years and 69% were women included. Connectivopathies (40%) and rheumatoid arthritis (37.8%) were the most prevalent ARDs that required admission to the ICU. Cardiovascular events (51%) were the main reason for ICU admission, followed by infectious processes (27%). The median ICU stay was 5 days. It is striking that 77% of the patients had received glucocorticoids prior to admission throughout their disease. The median score on the severity scales was 34 in SAPS II and 17 in APACHE II. Mortality during the ICU stay was 30.4% and in the multivariate analysis it was associated with the previous administration of glucocorticoid boluses and the APACHE II scale score. This mortality is higher compared to historical series of patients admitted to Spanish ICUs with similar APACHE II severity scores. In the comparative study with the previous period, similar mortality rates were observed, an increase in the mean age of those admitted, a decrease in patients with vasculitis and an increase in patients with rheumatoid arthritis. Likewise, an increase in cardiovascular events is observed as a fundamental reason for admission to the ICU.

Conclusion: The mortality of our patients with ARD admitted to the ICU in the last five years is 30.4%, similar to the previous decade but higher than the observed in other pathologies with similar severity characteristics. It is related to the APACHE II score and to the prior administration of glucocorticoid boluses. Connectivopathies and rheumatoid arthritis are the diseases that are most frequently admitted to the ICU and the fundamental reasons are cardiovascular events and infections.

Disclosure of Interests: None declared

Results: The average age of all patients was 61.4±11.77 years (p=0.007) with predominant female gender in all groups, 81.3% (p=0.139). Anti-EBNA1 IgG antibodies were present in 95%, 92%, and 98% (p=0.474), anti-EBV-CA IgG antibodies in 95%, 80%, and 100% (p=0.001), anti-EBV-CA IgM antibodies in 25%, 40%, and 4% (p=0.008), anti-EBV-EA IgM antibodies in 14%, 21%, and 4% (p=0.084), and anti-EBV-EA IgM antibodies in 20%, 16%, and 6% (p=0.094) in RAa, RAb, and OA, respectively. There was statistically significant difference in the titer of anti-EBV-CA IgG and IgM antibodies between all three groups (p=0.001 and p=0.007, respectively). According to serology findings active EBV infection was present in 47%, 40%, and 12% in RAa, RAb, and OA, respectively (p=0.001). On the other hand, corresponding to PCR results only, active EBV infection was detected in 6.3%, 0%, and 20% in RAa, RAb, and OA, respectively (p=0.010). There was statistically significant difference in way of detecting active EBV infection based on serology or PCR only (p=0.001). Further analysis showed that over 80% of all RA patients (61% in RAa and 96% in RAb), whilst 48% of OA had elevated values of sedimentation (SE) (p=0.001). C-reactive protein (CRP) was raised in 93% RA (79% in RAa and 100% in RAb) and in 26.5% of OA patients (p=0.001).

The majority of all RA patients had elevated rheumatoid factor (RF) and ACPA (84% and 92%), with no difference between RAa and RAb patients (p=0.361 and p=0.203, respectively). Among patients with active EBV infection (based on both serology and PCR results), there was a significantly higher level of antidiagnostic IgG (p=0.012) and antidiagnostic IgM (p=0.009) autoantibodies in RAa patients, while the level of SSA autoantibodies (p=0.024) was higher in RAb patients. On the other side, there was no significant difference in the level of any autoantibody or factors of acute inflammation (SE and CRP) in patients with past EBV infection.

Conclusion: This study demonstrated linkage between an active EBV infection and elevation of some autoantibodies in RA pathogenesis. As EBV DNA was not found only in a group of RA patients under immunosuppressive therapy, it is suggested that EBV clearing from blood could be direct consequence of methotrexate use. Collectively, these findings indicate that determining of EBV activity must be based on both serology and molecular methods in order not to oversee EBV reactivation during follow-up of these patients.

REFERENCE:

Acknowledgements: This research was supported by the Science Fund of the Republic of Serbia, PROMIS, No 6060866, ROлерs.

Disclosure of Interests: None declared

AB1465 BLACK PATIENTS ARE LESS SATISFIED WITH THE PROCESS OF CARE FOLLOWING PRIMARY HIP AND KNEE ARTHROPLASTY: A RETROSPECTIVE STUDY

J. A. Gibbons1, O. Burke Jr2, H. Do3, E. Y. Lai3, B. Mehta1, 4, L. Bradford5, F. Kemta Lekpa1, 2, K. Frank Forex1, H. Mbatchou2, A. Jerome1, H. Namme1, 2. 1Hospital for Joint Bone Spine, From 5th January 1 to December 31, 2020, including all patients with a diagnosis of gout (ACR/EULAR criteria of 2015).

Background: An unusual increase in the number of gout cases was observed in Cameroon in 2020. Was there a link with lifestyle changes during confinement, especially the consumption of certain types of beverages (beer, liquor, water, sweetened drinks).

Objectives: To determine if there was a correlation with the consumption of different beverages (water, beer, liquor, sweetened drinks).

Methods: Cross-sectional study in the rheumatology consultation of the Douala General Hospital, from January 1 to December 31, 2020, including all patients with a diagnosis of gout (ACR/EULAR criteria of 2015). Pearson’s correlation coefficient was used to determine the effect of the consumption of the different beverages on the increase in the number of gout cases. A p<0.05 was significant.

Results: We included 1952 patients, including 111 gout cases (107 men; median age: 51 years [36-81]). Compared with the same period in 2018 and 2019, a peak in gout cases was observed between May and November 2020 (Figure 1). In the same period, the consumption of the different beverages varied significantly (p<0.05).

Table 1. Likehood of not being completely satisfied with the process of care (PG score <100)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Reference Category</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>p-value</th>
<th>Odds Ratio</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Group</td>
<td>&lt;50</td>
<td>50-69</td>
<td>70-79</td>
<td>&gt;70</td>
<td>&lt;50</td>
<td>50-69</td>
<td>70-79</td>
</tr>
<tr>
<td>Hip Cohort</td>
<td>0.38 (0.15, 0.96)</td>
<td>0.41 (0.18, 0.96)</td>
<td>0.43 (0.19, 0.94)</td>
<td>0.72 (0.34, 1.52)</td>
<td>0.86 (0.42, 1.77)</td>
<td>0.48 (0.23, 1.00)</td>
<td>0.36 (0.18, 0.73)</td>
</tr>
<tr>
<td>Knee Cohort</td>
<td>0.48 (0.24, 0.94)</td>
<td>0.53 (0.26, 1.07)</td>
<td>0.62 (0.30, 1.29)</td>
<td>0.70 (0.38, 1.33)</td>
<td>0.81 (0.41, 1.61)</td>
<td>0.72 (0.37, 1.42)</td>
<td>0.70 (0.37, 1.34)</td>
</tr>
</tbody>
</table>

Conclusion: There was a positive correlation between the consumption of beer and an increase in the number of gout cases. Further research is needed to understand the underlying mechanisms.
The COVID-19 PCR test was negative in all patients.

**Conclusion:** The real “outbreak” of gout observed during the curfew related to COVID-19 between May and November 2020 was favored by a punctual increase in the consumption of liquors and sweetened drinks.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5368

### AB1467

**EPIDEMOLOGICAL DESCRIPTION OF JUVENILE IDIOPATHIC ARTHRITIS FROM A COLOMBIAN POPULATION**


**Background:** Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and presents predominantly with peripheral arthritis; this pathology is divided into subgroups. In Colombia there are few descriptive studies.

**Objectives:** The objective was to describe the sociodemographic, immunological and clinical characteristics of a cohort of patients with Juvenile Idiopathic Arthritis.

**Methods:** An observational cross-sectional study was conducted that included 171 JIA patients treated at a specialized rheumatology institution between 2010 and 2021. Univariate analyzes were performed to describe the sociodemographic, immunological, and clinical profile of the population. The epidemiological characteristics were obtained from the review of medical reports.

**Results:** 171 patients were analyzed. 58.48% were women; with a median age at diagnosis of 12.25 years (IQR=6.55), and a median duration of the disease of 3.71 years (IQR=5.52). According to the classification criteria of the International League of Associations for Rheumatism (ILAR), the most frequent were enthesitis-related JIA (40%), and polyarticular rheumatoid factor positive was positive for ANA in 76.47% and AntiCCP (10%).

**Conclusion:** The epidemiological description of JIA in the Colombian population is similar to the current one in other populations, but we found differences in the subtypes of juvenile idiopathic arthritis and in the presence of autoantibodies. This is the first step to discover the characteristics of this autoimmune disease in this population.

### AB1468

**ALL-CAUSE MORTALITY IN PATIENTS WITH PALINDROMIC RHEUMATISM: A POPULATION-BASED COHORT STUDY**

H. H. Chen, Y. Chen, Z. Taichung Veterans General Hospital, Department of Internal Medicine, Taichung, Taiwan, Republic of China; 2China Medical University Hospital, Center of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Republic of China

**Background:** Palindromic rheumatism (PR), is a clinical syndrome characterized by the intermittent acute arthritis or peri-arthritis involving one or several regions. It presents with pain with or without redness or swelling, lasting from a few hours to days with variable symptom-free periods. Different from rheumatoid arthritis (RA), PR does not lead to residual joint destruction. A recent study showed that RA patients had a mean loss of life expectancy of about 5 years [1]. However, whether all-cause mortality rate in PR patients differs from that in individuals without PR was still unknown.

**Objectives:** To compare the all-cause mortality rate between PR patients and non-PR individuals.

**Methods:** Usint a two-million representative cohort from the 2000-2018 Taiwan’s National Health Insurance Research Database, we identified 2,791 incident adult (aged ≥ 20 years) PR patients. Matching for sex, age and year of index date at a 1:40 ratio, we selected 111,640 non-PR individuals for comparison. Then using the greedy algorithm, we further selected another comparison group of 5,562 non-PR individuals by propensity score (PS) matching for Charson comorbidity index (CCI) at a 1:2 ratio. Using the Cox proportional hazard model, we examined the risk of all-cause mortality in PR patients shown as adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs). Potential confounders included age, sex, CCI, a history of immune mediated inflammatory disease (IMID) including systemic lupus erythematosus erythematosus (SLE), RA, idiopathic inflammatory myopathies (IM, including dermatomyositis and polymyositis), Sjogren’s syndrome (SS), inflammatory bowel disease (IBD), psoriasis, and medication use including corticosteroid (0, 1-5, >5 mg/day prednisolone equivalent dose), methotrexate, sulfasalazine, lefunomide, hydroxychloroquine and nonsteroidal anti-inflammatory drugs within one year before the index date.

**Results:** In the 1:2 PS-matched population, the mean age was 48.4 years and female to male ratio was 1.54 in the PR group and non-PR group. Among 2,791 PR patients, 226 (8.1%) died during a mean follow-up period of 8.29 years; while 11,958 (10.71%) of 111,640 non-PR individuals expired during a mean follow-up period of 8.13 years. The all-cause mortality rates in PR patients and non-PR individuals were 976.83 per 10^5 years and 1,317.93 per 10^5 years, respectively (incidence rate ratio, 0.74; 95% CI, 0.65-0.85, p < 0.001). After adjusting for potential confounders, the risk of all-cause mortality was significantly lower in PR patients compared with non-PR individuals (aHR, 0.70; 95% CI, 0.59–0.82).

**Conclusion:** This population-based cohort study showed that the all-cause mortality rate in PR patients was lower than that in non-PR individuals, in particular in subjects without a history of IMIDs.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5401
**TABLE 1. Patients’ characteristics**

<table>
<thead>
<tr>
<th>#</th>
<th>Gender</th>
<th>Age</th>
<th>Working status</th>
<th>Education</th>
<th>axSpA subtype</th>
<th>Disease duration</th>
<th>HLA-B27</th>
<th>Drug</th>
<th>BASDAI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Male</td>
<td>63</td>
<td>Working</td>
<td>University</td>
<td>r-axSpA</td>
<td>35 y</td>
<td>+</td>
<td>NSAIDs</td>
<td>2.3</td>
</tr>
<tr>
<td>2</td>
<td>Male</td>
<td>24</td>
<td>Student</td>
<td>Secondary</td>
<td>r-axSpA</td>
<td>6 y</td>
<td>+</td>
<td>NSAIDs</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>Male</td>
<td>37</td>
<td>Working</td>
<td>University</td>
<td>r-axSpA</td>
<td>5 y</td>
<td></td>
<td>A</td>
<td>2.5</td>
</tr>
<tr>
<td>4</td>
<td>Male</td>
<td>66</td>
<td>Retired</td>
<td>University</td>
<td>r-axSpA</td>
<td>23 y</td>
<td></td>
<td></td>
<td>3.1</td>
</tr>
<tr>
<td>5</td>
<td>Male</td>
<td>29</td>
<td>Working</td>
<td>University</td>
<td>r-axSpA</td>
<td>11 y</td>
<td>+</td>
<td>A</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>Female</td>
<td>26</td>
<td>Working</td>
<td>University</td>
<td>m-axSpA</td>
<td>2 y</td>
<td>+</td>
<td>NSAIDs</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Male</td>
<td>24</td>
<td>Student</td>
<td>University</td>
<td>m-axSpA</td>
<td>1 y</td>
<td>+</td>
<td>ETA</td>
<td>4.5</td>
</tr>
<tr>
<td>8</td>
<td>Male</td>
<td>35</td>
<td>Working</td>
<td>University</td>
<td>r-axSpA</td>
<td>12 y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Female</td>
<td>40</td>
<td>Working</td>
<td>University</td>
<td>m-axSpA</td>
<td>4 y</td>
<td>+</td>
<td>NSAIDs</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Female</td>
<td>45</td>
<td>Unemployed</td>
<td>Primary</td>
<td>m-axSpA</td>
<td>9 y</td>
<td>-</td>
<td>GOL</td>
<td>8.2</td>
</tr>
</tbody>
</table>
ARTHRITIS IN COMPARISON WITH RHEUMATOID COHORT OF PATIENTS WITH PERIPHERAL PSORIATIC EVALUATION OF CXCL13 SERUM LEVELS IN A

S. Piantoni1, F. Angelil, F. Regola1, L. Valtellini1, F. Franceschini1, P. Airo1
1Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy

Background: The research of circulating biomarkers in the field of chronic arthritis is still an unmet need, especially for the subgroup of seronegative arthritis [e.g., negative for anti-citrullinated peptides autoantibodies (ACPA) and/or rheumatoid factors (RF)]. In fact, in this clinical subset, there is a lack of soluble molecules which could help for a diagnostic or prognostic purpose, and the differential diagnosis between psoriatic arthritis (PsA) and seronegative rheumatoid arthritis (RA) is still a challenge. C-X-C motif chemokine 13 (CXCL13) is one of the most promising biomarkers recently identified, because of its association with active synovitis (1) and with a poor prognosis in RA (2), although there are still inadequately results to justify its routine use. No data are available of the determination of CXCL13 serum levels in PsA.

Objectives: To analyze CXCL13 serum levels in a cohort of PsA patients with a history of peripheral involvement in comparison with RA.

Methods: Cross sectional analysis of consecutive patients with peripheral PsA [n:81; male/female=44/37; median age (25-75 percentile)=54 (46-62) years; 28-Joint Disease Activity Score-C Reactive Protein (CRP-DAS28)=4.9 (1.6-2.5); active psoriasis=43%; DAPSA (Disease Activity in PSoriatic Arthritis) score=0 (3-14)] and RA [n:143; male/female=30/113; median age (25-75 percentile)=54 (46-62) years; seropositive=67%; CRP-DAS28=2.1 (1.5-2.8)] was performed. 100 sex and age-matched healthy controls (HC) were enrolled. CXCL13 serum levels were assessed through commercial ELISA test (R&D).

Results: CXCL13 serum levels were higher in all the subgroups of patients [PsA: 50.9 (34.5-80.2) pg/mL, p<0.01; RA: 77.2 (52.9-107.7) pg/mL, p<0.01; RA ACPA+: 77.5 (55.9-110.7) pg/mL, p<0.01; RA ACPA+: 77.5 (55.9-110.7) pg/mL, p<0.01] than in RA patients, independently from their seropositivity [vs RA ACPA-, p=0.01; vs RA ACPA+, p=0.01; vs RA ACPA+, p=0.01]. CXCL13 serum levels were positively correlated with CRP in PsA patients (r=0.30; p=0.008), but not with DAPSA score.

Conclusion: These results confirm the value of CXCL13 as a biomarker in the field of chronic arthritis. Its higher levels in seronegative RA than in PsA suggests its possible value in the differential diagnosis of these two subsets of arthritis.

REFERENCES:


Disclosure of Interests: None declared
Conclusion: The Spanish version of the CORS showed good cross-cultural validity and good face validity in patients with axSpA according to the field test. Before the Spanish CORS is implemented, further validation is in progress to test the psychometric properties of the instrument.

REFERENCES:

Disclosure of Interests: None declared, Chamaida Plasencia Speakers bureau: Pfizer, Abbvie, Eli Lilly, Pfizer, Sanoft, Sanofi, Pfizer, Roche, Novo Nordisk, Janssen, Merck, Sanofi, Pfizer, Regeneron, Schering-Plough, Roche, Abbott, Abbvie, Eli Lilly, Pfizer, Sanofi, Genzyme, Sun Pharma, and UCB Pharma, Consultant of: AbbVie, Almirall, Arena, BMS, Celgene, Chugai, Daiichi Sankyo, Genentech, Gilead, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi, Schwartz Biotechnology, Servier, Shire, Sanoft, Sanofi, Janssen, Genentech, Merck, Novartis, Pfizer, and UCB Pharma, Speakers bureau: AbbVie, Almirall, Arena, BMS, Celgene, Chugai, Daiichi Sankyo, Genentech, Gilead, Hospira, Merck, Novartis, Pfizer, Roche, Sanofi, Schwartz Biotechnology, Servier, Shire, Sanoft, Sanofi, Janssen, Genentech, Merck, Novartis, Pfizer, and UCB Pharma.

<table>
<thead>
<tr>
<th>Original Dutch item</th>
<th>Spanish translation pre-final</th>
<th># Patient queries</th>
<th>Queries</th>
<th>Final version</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ik rust op tijd uit</td>
<td>Me voy a tiempo a descansar</td>
<td>1</td>
<td>Literal</td>
<td>No changes</td>
</tr>
<tr>
<td>Ik proeer en het</td>
<td>Intento aprovechar al máximo</td>
<td>1</td>
<td>Literal</td>
<td>No changes</td>
</tr>
<tr>
<td>Ik houd rekeien met</td>
<td>Tengo en cuenta a los demás</td>
<td>2</td>
<td>Meaning</td>
<td>Tangen en con-</td>
</tr>
<tr>
<td>anderen</td>
<td>sideración a los que me ayudan/ cuidan</td>
<td>2</td>
<td>Meaning</td>
<td>Tangen en con-</td>
</tr>
</tbody>
</table>

Table 1. Cognitive debriefing queries and decisions from the expert committee

AB1473

EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUP OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS

K. Gordon 1, J. F. Merola 1, P. Foley 1, O. Cho 1, D. Chan 2, M. Miller 1, Y. You 1, K. Shen 1, Y. W. Yang 1, A. Blauvelt 1,3,1 Medical College of Wisconsin, Department of Dermatology, Milwaukee, WI, United States of America; 2 Harvard Medical School, Brigham and Women’s Hospital and Probity Medical Research, Skin Health Institute, Department of Dermatology, Carlton, VIC, Australia; 3 Janssen Scientific Affairs, LLC, Department of Dermatology, Horsham, PA, United States of America; 4 Janssen Research & Development, LLC, Department of Immunology, Spring House, PA, United States of America; 5 Janssen Research & Development, LLC, Department of Clinical Biostatistics, Spring House, PA, United States of America; 6 Janssen Global Medical Affairs, Janssen Pharmaceuticals Companies of Johnson & Johnson, Horsham, PA, United States of America; 7 Oregon Medical Research Center, Department of Dermatology, Portland, OR, United States of America

Background: The VOYAGE-1 and VOYAGE-2 phase 3 studies evaluated efficacy and safety of guselkumab (GUS) in patients with moderate-to-severe plaque psoriasis. Objectives: To assess the five-year efficacy of GUS by baseline disease characteristics and treatment history.

Methods: This study evaluated 1829 patients randomized to GUS, placebo (PBO)–GUS, and placebo (PBO)–ADA treatment arms from VOYAGE-1 and VOYAGE-2 trials. All patients received open-label GUS 100 mg every 8 weeks (Q8W) during Week (W) 52 to W252 in VOYAGE-1 and during W76 to W252 in VOYAGE-2. The proportions of combined GUS patients (including PBO–GUS and ADA–GUS) achieving Investigator’s Global Assessment of cleared or minimal (IGA-0/1) and Psoriasis Area and Severity Index (PASI) 90 response were evaluated from W100 to W252 by baseline PASI (<20/20 and 80/80) and IGA (<4/4) scores, body surface area (BSA: <20%/20%; and prior psoriasis treatments. Analysis was performed using observed treatment effect analysis.

Results: At W252, proportions of combined GUS patients achieving IGA 0/1 or PASI 90, respectively, were comparable or numerically greater for patients with baseline PASI < 20 (85.4%; 81.1%) vs PASI ≥ 20 (81.4%; 83.8%); IGA < 4 (85.1%; 82.7%) vs IGA < 4 (78.9%; 81.1%); BSA < 20% (82.6%; 82.0%) vs prior phototherapy (83.3%; 84.0%); no prior phototherapy (83.3%; 81.1%); no prior biologic systemic therapy (83.3%; 80.0%); and no prior biologics (85.3%; 83.8%) vs prior biologics (76.7%; 76.3%). This trend was consistent at each timepoint evaluated from W100 to W252.

Conclusion: This analysis demonstrated that the high degree of efficacy of GUS treatment is durable through 5 years among broad subpopulations of patients with varying disease severity characteristics and previous psoriasis treatments.

Disclosure of Interests: None

AB1474

LIPIDOMIC PROFILING IDENTIFIES SERUM LIPIDS ASSOCIATED WITH PERSISTENT MULTISITE MUSCULOSKELETAL PAIN

C. Ma 1, M. Liu 2, J. Tian 1, G. Zhai 1, F. Cicuttini 1, Y. Schooneveldt 4, P. Meikle 6, G. Jones 1, F. Pan 1, 1 The University of Melbourne, St. Vincent’s Hospital, Melbourne, Victoria, Australia; 2 Memorial University of Newfoundland, Faculty of Medicine, St. John’s, Canada; 3 Monash University, Department of Epidemiology and Preventive Medicine, Melbourne, Australia; 4 Baker Heart and Diabetes Institute, Melbourne, Australia

Background: Lipid mediators have been suggested to have a role in pain sensitivity and response; however, longitudinal data on lipid metabolites and persistent multisite musculoskeletal pain (MSPM) are lacking.

Objectives: This study was to identify lipid metabolic markers for persistent MSPM.

Methods: Lipidomic profiling of 807 lipid species was performed on serum samples of 536 participants from a cohort study. MSPM was measured by a questionnaire and defined as painful sites ≥4. Persistent MSPM was defined as having MSPM at every visit. Logistic regression was used with adjustment for potential confounders. The Benjamini Hochberg method was used to control for multiple testing.

Results: A total of 530 samples with 807 lipid metabolites passed quality control. Mean age at baseline was 61.5±6.57 years and 50% were females. One hundred and twelve (21%) of the participants had persistent MSPM Persistent MSPM was significantly associated with lower levels of monohexosylceramide (HexCer)[d18:1/2:2:0 and d18:1/2:4:0], acylcarnitine (AC)(26:0) and lysophosphatidylcholine (LPC)(18:1 [sn1], 18:2 [sn1], 18:2 [sn2], and 15-MHDA[sn1])
Conclusion: Our findings indicate that elevated serum levels of IgA ASCA, IgA anti-GP2, anti- elastase antibodies in AS did not differ from those in AS/IBD and may serve as potential biomarkers for predicting intestinal inflammation at an early stage. For AS/IBD, the most useful diagnostic markers were atypical pANCA, IgA ASCA, IgA anti-GP2, anti-elastase and anti-BPI antibodies.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.2580
in FAST4+/MDS2+ patients, similar in RA and SpA at 3 settings in 3 continents (Table 1). Adjusted median differences were 3.0–3.5 for FAST4+ vs - (twice the level for FAST4-, MDS2-) and 2.0–2.5 for MDS2+ vs - groups (Table 1).

Conclusion: Median 0–10 PATGL was 2–3-fold higher in 41.1% of RA or SpA patients with positive MDHAQ FM and/or DEP screening indices vs 59% with 2 negative indices. Differences were greater according to FM than DEP. MDHAQ may clarify interpretation of PATGL and indices, including in treat-to-target, using a single, brief, feasible questionnaire in research and busy clinical settings.

REFERENCES:

AB1478 RELIABILITY AND CONTENT VALIDITY OF THE PORTUGUESE VERSION OF THE COMMISSIONING FOR PATIENT EXPERIENCE MEASURE (CQRA-PREM): PRELIMINARY RESULTS
D. Santos Oliveira1,2,3, R. Rainho1, M. Bernardes1,3, C. Vaz1,2, L. Costa1, J. A. Fonseca1,4,5,6, C. Jácque1,6,1, Centro Hospitalar Universitário de São João, Rheumatology Department, Porto, Portugal; Faculty of Medicine, University of Porto, Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; Faculty of Medicine, University of Porto, Department of Medicine, Porto, Portugal; Faculty of Medicine, University of Porto, Department of Community Medicine, Information and Health Decision Sciences (MECIDIS), Porto, Portugal; Instituto and Hospital CUF Allergy Unit, Porto, Portugal; MEDIDA, Medicina, Educação, Investigação, Desenvolvimento e Avaliação, Porto, Portugal

Background: The CQRA-PREM has been developed in the United Kingdom to evaluate the perspective of patients with rheumatoid arthritis (RA) about the care provided in rheumatology units of the National Health Service (1). This PREM might also be feasible to be used in Portugal, yet an adaptation and validation process is needed.

Objectives: We aimed to translate and cross-cultural adapt CQRA-PREM to Portuguese and evaluate the reliability and content validity of this version.

Methods: A study combining qualitative and quantitative approaches was conducted with patients with RA from a single rheumatology center. The translation and cultural adaptation of Portuguese CQRA-PREM included initial translation and cultural adaptation by 2 native Portuguese researchers, evaluation of this initial translation by a panel of 5 experts during an online meeting and back translation by 1 bilingual researcher. Authors of the original version approved this initial translation. CQRA-PREM includes 7 domains for patient-centered care: Needs and preferences (5 items); Coordination of care and communication (4 items); Information, education, and self-care (4 items); Daily living and physical comfort (2 items); Emotional support (2 items); Family and friends (1 item); Access to care (5 items) and 1 question for the overall experience with the care provided. Answers are given on a 5-point Likert scale (strongly disagree-1 to strongly agree-5). A total of 21 patients were invited to participate in online focus groups and 14 accepted. Patients were then asked to fill in a consent form and the preliminary version of the CQRA-PREM. The focus groups were transcribed and analyzed using thematic analysis. Questionnaire responses were analyzed with descriptive statistics and reliability (internal consistency) with the Cronbach’s alpha (α).

Results: A total of 12 patients (53±19 y, 92% female) with a mean disease duration of 14±9 years participated in 2 focus groups (duration 95±7min). The focus groups revealed that patients considered CQRA-PREM “simple” and “objective” and that all questions were easy to understand. Nevertheless, patients suggested the addition of synonyms for certain terms and of daily living examples to clarify some items. The “Needs and preferences” and “Access to care” were the domains with better experience (Table 1). The Cronbach’s alpha was 0.94 for the total questionnaire and between 0.71 and 0.91 for the domains.

Table 1. Median’s responses and quartile (Q) for each domain (1-Strongly disagree; 2-Disagree; 3-Neither agree nor disagree; 4-Agree; 5-Strongly agree).

<table>
<thead>
<tr>
<th>CQRA-PREM domains</th>
<th>Median (Q1-Q3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Needs and preferences</td>
<td>4.5 (4-5.5)</td>
</tr>
<tr>
<td>Coordination of care and communication</td>
<td>4.5 (4-5)</td>
</tr>
<tr>
<td>Information, Education and Self-care</td>
<td>3 (2.5-4)</td>
</tr>
<tr>
<td>Daily living and physical comfort</td>
<td>3.25</td>
</tr>
<tr>
<td>Emotional support</td>
<td>3.25</td>
</tr>
<tr>
<td>Family and friends</td>
<td>4.3 (4-5)</td>
</tr>
<tr>
<td>Access to care</td>
<td>4.5 (4-5.5)</td>
</tr>
</tbody>
</table>

Conclusion: Our findings suggest that both content validity and internal consistency of the Portuguese version of CQRA-PREM are acceptable. In future, a field-testing study to assess other psychometric properties (e.g., test-reliability and validity) should be conducted. We believe this PREM will contribute to optimize patient-centered care in Portugal.

REFERENCES:

Disclosure of Interests: None declared

AB1479 VALIDATION OF RUSSIAN VERSION PSAID-12: ASSESSMENT OF THE RELIABILITY, CONSTRUCTIVE AND CONVERGENT VALIDITY OF THE QUESTIONNAIRE
L. Vorobyova1, T. Korolets2, E. Loginova1, E. Gubara1, Y. Korsakova1. 1V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritides and Psoriatic Arthritis, Moscow, Russian Federation

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease of widely varying presentation, which determines functional and psychological impairment, with a high negative impact on patients’ quality of life. Therefore, knowing the patient’s perception of their health status is of fundamental importance for understanding the real impact of PsA. In recent years, a PsAID (Psoriatic Arthritis Impact of Disease) questionnaire has been developed for PsA patients, consisting of 9 or 12 questions related to the severity of pain, anxiety, fatigue, disability, sleep disorders, and social activity.

Objectives: To study, in a real-life setting, the construct and convergent validity of the reliability, and the interpretability of the Russian version PsAID-12 in patients with PsA.

Methods: 187 (M/F=97/90 (50.2%)/48.8%) PsA pts fulfilling the CASPAR criteria were included. Mean age 45.6±11.7 years (yrs), DAPSA 21.05±21.03, median (Me) PsA duration 88 (16.42) mo. All pts underwent standard clinical examinations and PROs (EQ-5D, PsAID12). Reliability was assessed by Cronbach’s alpha coefficient and by the intraclass correlation coefficient (ICC) for each of the 12 scales. The construct validity was evaluated by exploratory factorial analysis and also by Spearman correlation with EQ-5D and measures of disease activity evaluation.

Results: The reliability of ICC (alpha-Cronbach=0.8-0.9) and test-re-test (ICC 95% CI 0.85–0.96) were good. Construct validity: Factor analysis revealed a 2-factor result defined as the PsAID-12: Psysical health score and Emotional health score. A strong correlation was also found for each of the 12 scales with the questionnaire EQ-5D was strong correlation (r= -0.52 to -0.78, p<0.001) in determining convergent validity, significant correlations were found between the PsAID-12 and TJC 68, SJC 66, DAPSA, VAS global assessments, VAS global pain, BASDAI. The high correlation was found between the BASDAI and the scale “Functional capacity” (r=0.8, p<0.001), as well as sufficiently high correlation coefficients with parameters were noted with the scales “Pain,” “Fatigue,” “Work and/or leisure activities,” “Discomfort” and “Coping.” The lowest was observed with scales “Skin problems” and “Depression.”

Table 1. Convergent validity PsAID-12 with clinical parameters (r)

<table>
<thead>
<tr>
<th>Scales</th>
<th>TJC 68</th>
<th>SJC 66</th>
<th>DAPSA</th>
<th>VAS global</th>
<th>VAS global pain</th>
<th>BASDAI assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pain</td>
<td>0.6</td>
<td>0.68</td>
<td>0.71</td>
<td>0.72</td>
<td>0.75</td>
<td>0.78</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.59</td>
<td>0.62</td>
<td>0.68</td>
<td>0.71</td>
<td>0.68</td>
<td>0.75</td>
</tr>
<tr>
<td>Skin problems</td>
<td>0.35</td>
<td>0.36</td>
<td>0.41</td>
<td>0.47</td>
<td>0.37</td>
<td>0.46</td>
</tr>
<tr>
<td>Work and/or leisure activities</td>
<td>0.57</td>
<td>0.62</td>
<td>0.68</td>
<td>0.75</td>
<td>0.71</td>
<td>0.67</td>
</tr>
<tr>
<td>Functional capacity</td>
<td>0.61</td>
<td>0.64</td>
<td>0.72</td>
<td>0.79</td>
<td>0.71</td>
<td>0.80</td>
</tr>
<tr>
<td>Discomfort</td>
<td>0.61</td>
<td>0.65</td>
<td>0.71</td>
<td>0.72</td>
<td>0.78</td>
<td>0.76</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>0.44</td>
<td>0.50</td>
<td>0.54</td>
<td>0.55</td>
<td>0.60</td>
<td>0.61</td>
</tr>
<tr>
<td>Coping</td>
<td>0.59</td>
<td>0.63</td>
<td>0.67</td>
<td>0.66</td>
<td>0.65</td>
<td>0.76</td>
</tr>
<tr>
<td>Arthritis fear and uncertainty</td>
<td>0.44</td>
<td>0.48</td>
<td>0.52</td>
<td>0.52</td>
<td>0.61</td>
<td>0.64</td>
</tr>
<tr>
<td>Embarrassment</td>
<td>0.47</td>
<td>0.49</td>
<td>0.51</td>
<td>0.48</td>
<td>0.41</td>
<td>0.52</td>
</tr>
<tr>
<td>Social participant</td>
<td>0.54</td>
<td>0.57</td>
<td>0.62</td>
<td>0.64</td>
<td>0.62</td>
<td>0.66</td>
</tr>
<tr>
<td>Depression</td>
<td>0.43</td>
<td>0.43</td>
<td>0.49</td>
<td>0.57</td>
<td>0.54</td>
<td>0.47</td>
</tr>
</tbody>
</table>

Conclusion: The Russian version of PsAID-12 has been shown to be a reliable and valid measure of the impact of the disease in patients with psoriatic arthritis.

Disclosure of Interests: None declared

AB1480 ASSESSMENT OF THE SENSITIVITY OF THE RUSSIAN VERSION PSAID-12 QUESTIONNAIRE
L. Vorobyova1, T. Korolets2, E. Loginova1, E. Gubara1, Y. Korsakova1. 1V.A. Nasonova Research Institute of Rheumatology, Spondyloarthritides and Psoriatic Arthritis, Moscow, Russian Federation
Background: The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to measure impact of Psoriatic Arthritis (PsA) for purposes of monitoring and clinical management.

Objectives: Assessment the sensitivity of the russian version of PsAID-12 against the background of ongoing therapy at baseline and after 12 month (mo).

Methods: 172 (M/F=90 (52.3%)/82 (47.7%)) PsA pts fulfilling the CASPAR criteria were included. Mean age 45 ± 11.8 years (yrs), DAPSA 28 ±2.2 median (Me). All pts underwent standard clinical examinations and PROs (EQ-5D, VAS global assessments, VAS global pain, BasDAI, PsAID-12). All pts at the time of inclusion in the study and 12mo received DMARDs: NSAIDs-158 (91.8%), methotrexate-134 (73.9%), lefunomide- 11 (6.3%), sulfasalazine - 12 (6.9%), TNFα inhibitors - 72 (44.04%), seukinumab - 14 (8.1%), ustekinumab - 3 (1.74%), infliximab - 51 (29.1%). To determine the sensitivity of PsAID-12, its changes were analyzed depending on: I group of patients in whom MDA was achieved - 50, II - 43 REM / LDA patients, III - 79 inhibition (DAPSA - 28±22.2 vs. 15±10.1, TJC 68 – 10.5±10.1 vs 6.68±5.77 , SJC 65 – 8.31±7.4 vs 4.62±3.17, CRP – 13.6±8.06 vs 13.6±8.06) and PROs (BASDAI-3 - 9.33±2.56 vs 2.49±1.93, VAS global pain – 40.1±25.1 vs 24.7±20.0, VAS global assessments – 43.4±27.1 vs 27.6±19.5, EQ-5D – 0.68±0.21 vs 0.72±0.18) observed (p<0.0001 for all). The sensitivity assessment of the PsAID-12 showed that in groups I and II there were statistically significant differences on all scales of the questionnaires, in group III with no effect on therapy, there were no significant improvements on the scales “Pain” (p = 0.37), “Fatigue” (p=0.15), “Skin problems” (p=0.23), “Work and leisure activities” (“p=0.056”, “Functional capacity” (“p=0.44”) (Table 1).

Conclusion: The russian version of the PsAID-12 questionnaire directional changes depend on the activity of the disease during treatment, which proves its good sensitivity.

Disclosure of Interests: None declared


Table 1. Assessment the sensitivity of the russian version of PsAID-12

<table>
<thead>
<tr>
<th>PsAID-12</th>
<th>I</th>
<th>II</th>
<th>III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MDA</td>
<td>REM/LDA</td>
<td>No effect on therapy</td>
</tr>
<tr>
<td>Baseline</td>
<td>12 mo</td>
<td>Baseline</td>
<td>12 mo</td>
</tr>
<tr>
<td>Pain</td>
<td>10.0±8.81</td>
<td>4.47±3.90</td>
<td>0.0001</td>
</tr>
<tr>
<td>Fatigue</td>
<td>6.43±5.2</td>
<td>3.64±3.09</td>
<td>0.003</td>
</tr>
<tr>
<td>Skin problems</td>
<td>5.64±5.9</td>
<td>3.05±3.37</td>
<td>0.003</td>
</tr>
<tr>
<td>Work and/or leisure activities</td>
<td>5.05±5.6</td>
<td>2.39±3.73</td>
<td>0.007</td>
</tr>
<tr>
<td>Functional capacity</td>
<td>6.19±6.17</td>
<td>2.15±13.12</td>
<td>0.00009</td>
</tr>
<tr>
<td>Discomfort</td>
<td>5.60±5.5</td>
<td>2.35±5.29</td>
<td>0.007</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>5.65±6.04</td>
<td>1.84±3.81</td>
<td>0.005</td>
</tr>
<tr>
<td>Coping</td>
<td>2.39±2.75</td>
<td>0.84±1.25</td>
<td>0.0002</td>
</tr>
<tr>
<td>Anxiety, fear and uncertainty</td>
<td>2.57±2.69</td>
<td>1.13±1.76</td>
<td>0.014</td>
</tr>
<tr>
<td>Embarassment</td>
<td>1.21±1.71</td>
<td>0.86±1.78</td>
<td>0.01</td>
</tr>
<tr>
<td>Social participant</td>
<td>2.31±3.10</td>
<td>0.58±1.52</td>
<td>0.003</td>
</tr>
<tr>
<td>Depression</td>
<td>1.43±2.06</td>
<td>0.47±1.13±</td>
<td>0.009</td>
</tr>
</tbody>
</table>

AB1482

PROGNOSTIC FACTORS FOR TUBERCULOUS SPONDYLODISITIS

1 Rabta Hospital, Rheumatology, Tunis, Tunisia
2 University of Monastir, Faculty of Medicine, LR12ES05, Lab-NAFS Nutrition - Functional Food & Vascular Health; 5000 Monastir, Tunisia;
3 University Bourgogne Franche-Comté, Faculty of Medicine, University of Monastir, Monastir 5019, Tunisia, Team Biochemistry of the Peroxinsome, Inflammation and Lipid Metabolism

Background: Tuberculous spondylodiscitis (SPDT) or Pott’s disease is an infectious involvement of the disc-vertebral couple, caused by the tubercular bacillus (Mycobacterium tuberculosis). It accounts for 46% to 64% of infectious spondylodisitciscal of the vertebrae. The study included correlations of the promoting factors of SPDT (tuberculosis infection, diabetes, corticosteroids and trauma), epidemiological, clinical, biological and radiographical data with good clinical outcome in the fourth week of the anti-tuberculosis drugs treatment.

Methods: We conduct a retrospective and descriptive study in a single rheumatology department. Data were collected from observations of patients hospitalised in the past 20 years (2000-2020) who have been diagnosed with SPDT. The diagnosis was based either on a range of highly evocative clinical, biological and radiographical arguments or on the disc-vertebral biopsy puncture. The study included correlations of the promoting factors of SPDT (tuberculosis infection, diabetes, corticosteroids and trauma), epidemiological, clinical, biological, radiological and therapeutic data with good clinical outcome in the fourth week of the anti-tuberculosis drugs treatment.

Results: Fifty-two cases of SPDT were collected (37F/15M). The mean age was 55.21±17.79 years [19-91]. Thirty-three patients (69.2%) were aged 65 years versus 16 elderly patients (30.8%), with female predominance in both.
groups (69.4% and 75% respectively, p = 0.57). The diagnosis of SPDT was based either on a range of highly evocative clinical, biological and radiological arguments (71.2%) or on the disco-vertebral biopsy puncture (28.8%). Among the clinical arguments a suggestive of tuberculosis SPD were: progressive onset of symptoms in 47 patients (90.4%), segmental stiffness in 37 patients (71.2%), spinal pain with general signs of tuberculosis such as impaired general condition, fever, night sweats and weight loss in 32 patients (61.5%). Lumbar spine involvement was the most common in tuberculosis SPD (57.7%). A biological inflammatory syndrome has been objectified in 38 patients (73.1%). Imaging was contributive to positive diagnosis using standard X-rays, computed tomography and magnetic resonance imaging. Disc pinch, erosion of vertebral plateaus and vertebral collapse were the major signs. The treatment was based on anti-tuberculosis drugs for at least nine months. Only four factors had an unfavourable predictive value (p ≤ 0.05): Nornorchoinic normocytic anemia observed in 53.8% of our patients (p = 0.018; Odds Ratio = 6.66), initial lymphocytosis (p = 0.048), fever in 36.0% of our patients (p = 0.01; Odds Ratio = 0.01). X-ray vertebral compression in 67.3% of our cases (p = 0.001; Odds Ratio = 13).

Conclusion: Tuberculous spondylodiscitis is a frequent condition that needs to be diagnosed and treated rapidly. Poor prognosis factors have been identified to provide insight into disease progression.

Disclosure of Interests: None declared

### Table 1. Capillary density loss presence and grades in SSc vs non-SSc

<table>
<thead>
<tr>
<th>Variable</th>
<th>SSc</th>
<th>No-SSc</th>
<th>OR (95%CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDL – n (%)</td>
<td>12 (75)</td>
<td>15 (76)</td>
<td>14 (3.9-49.4)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Grade I – n (%)</td>
<td>7 (43)</td>
<td>4 (25)</td>
<td>3.4 (0.9-14.6)</td>
<td>0.07</td>
</tr>
<tr>
<td>Grade II – n (%)</td>
<td>3 (18)</td>
<td>6 (21)</td>
<td>3 (0.6-13.8)</td>
<td>0.1</td>
</tr>
<tr>
<td>Grade III – n (%)</td>
<td>5 (28)</td>
<td>2 (24)</td>
<td>13.8 (2.2-83.8)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

SSc (systemic sclerosis), CDL (capillary density loss).

Conclusion: CDL was present in almost 1/3 of non selected patients attending to a VC study, and was strongly associated with SSc diagnosis. Future studies including this outcome can bring new data regarding microvascular damage and its implications.
Conclusion: Monospecific anti-DFS70 can potentially be considered as a possible marker for the exclusion of SARDs and a sign of benign autoimmune.

REFERENCES:


Disclosure of Interests: None declared.


AB1485

PATIENT-REPORTED OUTCOMES AND BIOMARKERS ASSOCIATED WITH THE CUTANEOUS DERMATOMYOSITOSIS AREA AND SEVERITY ACTIVITY (CDASI-A) SCORE IN A PHASE 2 CLINICAL TRIAL IN DERMATOMYOSITIS

J. Dan1,2, J. Patel1,2, G. Sproew1,2, J. Concha1,2, R. Feng2, N. Kodali1,2, T. Vazquez1,2, D. Diaz3,4, B. White,4, V. Werth1,2,4.

Perelman School of Medicine at the University of Pennsylvania, Dermatology, Philadelphia, United States of America; Corporation.

Michael J. Crescenz VA Medical Center, Dermatology, Philadelphia, United States of America; Perelman School of Medicine at the University of Pennsylvania, Biostatistics and Epidemiology, Philadelphia, United States of America; Corbus Pharmaceuticals, Inc., Norwood, United States of America

Background: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in dermatomyositis (DM), as measured by CDASI-A.1,2 No studies validate these associations in a controlled setting. Additionally, the relationship between the PROMIS-29 Short Form and skin activity in DM has not been assessed. Previous investigations have demonstrated a correlation between IL-31 and itch in DM.3 IFN-γ and IFN-γ are known type I and II interferons, which are critical drivers of DM pathogenesis.4

Objectives: To assess correlations between CDASI-A, quality of life (QoL), and biomarkers of disease activity in a double-blind, randomized, placebo-controlled clinical trial.

Methods: Data were retrospectively collected from five visits of a Phase 2 trial evaluating AB1485, a cannabinoid receptor type 2 agonist. Quality of life assessments extracted from the trial included Patient Global Assessment (PGA) scores, PROMIS domains, and Skindex scores. Skin question 10, regarding itch, was included in the analysis as a separate domain. Physician Global Assessment scores were also evaluated. Additionally, biomarkers derived from skin samples via IHC/PAR collected at visits 1 and 6 were assessed for predictors of CDASI-A response and association with disease activity. Analysis used linear mixed effect models to account for within subject-variability and repeated measures, where applicable. Analysis was performed without regard to treatment arm, as our goal was to correlate CDASI-A, QoL, and biomarkers among all subjects.

Results: Data from 22 subjects with DM and a combined total of 110 visits were included. Biopsies were collected from 12 subjects. Improvement in CDASI-A significantly correlated with Skindex-S, Skindex-E, Skindex-F, Skindex-itch, PGA global skin, PGA global skin, and Skindex itch. Change in IL-31 protein area positively correlated with change in CDASI-A (r=0.605, p<0.001). Change in IFN-γ protein area and disease activity trended towards significance.

Conclusion: In accordance with previous investigations from our group, well-established measures of QoL, correlated significantly with CDASI-A. These findings support that CDASI-A reflects both clinical and patient-reported aspects of skin disease and that CDASI-A reflects both clinical and patient-reported aspects of skin disease and patient-reported outcomes and skin activity in dermatomyositis (DM), as measured by CDASI-A.1,2 No studies validate these associations in a controlled setting. Additionally, the relationship between the PROMIS-29 Short Form and skin activity in DM has not been assessed. Previous investigations have demonstrated a correlation between IL-31 and itch in DM.3 IFN-γ and IFN-γ are known type I and II interferons, which are critical drivers of DM pathogenesis.4

Disclosure of Interests: None declared.


AB1486

ASSESSMENT OF GLUCOCORTICOID-RELATED ADVERSE EVENTS BY THE GLUCOCORTICOID TOXICITY INDEX (GTI) IN RHEUMATIC PATIENTS

M. Bahap1, E. Duran1,2, A. B. Ekinicioğlu1, G. Karadag1,2, Hakettepe University School of Pharmacy, Department of Clinical Pharmacy, Ankara, Turkey; Hakettepe University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey; Hakettepe University School of Medicine, Vasculitis Research Centre, Ankara, Turkey

Background: Glucocorticoids (GCs) remain the mainstay treatment for several autoimmune and inflammatory diseases however, its long-term or high-dose usage also has many potential side effects. The glucocorticoid toxicity index (GTI) is a novel global monitoring tool (1) developed to systematically assess glucocorticoid-associated morbidity.

Objectives: To evaluate GC toxicity by using GTI in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and vasculitis receiving glucocorticoids.

Methods: This descriptive, cross-sectional study included patients who were admitted to the rheumatology clinic between January 2021 and December 2021, were diagnosed with RA, SLE or vasculitis and treated with GCs. A single measurement of GC toxicity was performed using the GTI for each patient. Baseline GTI consists of twelve domains that related to commonly recognized adverse events that result of cumulative GCs exposure: body mass index (BMI), glucose metabolism, blood pressure, lipids, GC-induced myopathy, bone mineral density, skin toxicity, neuropsychiatric effects, infection, ocular, gastrointestinal and endocrine toxicity. The total GTI score ranges from 0 to 538 depending on the increase in toxicity burden.

Results: The study included 85 patients (55.3% male) with a mean age of 47.5 (±16.0) years (Table 1). Twenty (23.5%) patients had BMI values ≥30 kg/m2 and 63% of the patients were either hypertensive or receiving medications for hypertension. While HbA1c was ≥5.7% in 30 (35.3%) patients, 17 (20.0%) patients had glycated hemoglobin (HbA1c) value of ≥5.7% despite anti-diabetic medication. Low density lipoprotein cholesterol (LDL-C) value of ≥3.3 (39%) patients was not on target. The median (IQR) GTI score of the study patients was 73 (61.5). Only 10 patients had a score of 0 in the GTI assessment. GTI scores were not correlated with the cumulative steroid doses (r=0.145, p=0.198) however, age was strongly associated with GTI scores (r=0.605, p<0.001).

Table 1. Demographics, disease characteristics, and glucocorticoid toxicities of the patients

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>RA (n=21)</th>
<th>SLE (n=14)</th>
<th>Vasculitis* (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (±SD)</td>
<td>47.3 (±17.2)</td>
<td>36.4 (±11.0)</td>
<td>50.6 (±15.5)</td>
</tr>
<tr>
<td>Duration of disease (months)</td>
<td>12 (12.5)</td>
<td>16 (17.8)</td>
<td>14 (13.3)</td>
</tr>
<tr>
<td>Damage and activity indices</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HAQ</td>
<td>0.07 (0.4)</td>
<td>0.07 (0.4)</td>
<td>0.07 (0.4)</td>
</tr>
<tr>
<td>SLICC</td>
<td>0 (1.5)</td>
<td>0 (1.5)</td>
<td>0 (1.5)</td>
</tr>
<tr>
<td>VDI</td>
<td>1.0 (1.0)</td>
<td>1.0 (1.0)</td>
<td>1.0 (1.0)</td>
</tr>
<tr>
<td>Cumulative methylprednisolone</td>
<td>1448.0 (1496.9)</td>
<td>4694.0 (5033.5)</td>
<td>5604 (5281.5)</td>
</tr>
<tr>
<td>Dose (mg)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GTI toxicity domain, n (r)</td>
<td>9 (42.8)</td>
<td>6 (42.8)</td>
<td>24 (48.0)</td>
</tr>
<tr>
<td>BMI ≥27 kg/m²</td>
<td>8 (38.1)</td>
<td>6 (42.9)</td>
<td>33 (66.8)</td>
</tr>
<tr>
<td>HbA1c ≥5.7%</td>
<td>7 (33.3)</td>
<td>4 (28.6)</td>
<td>26 (52.0)</td>
</tr>
<tr>
<td>Blood pressure &gt;120/85</td>
<td>6 (28.5)</td>
<td>2 (14.2)</td>
<td>25 (51.0)</td>
</tr>
<tr>
<td>LDL-C &gt;100 mg/dl</td>
<td>4 (20.0)</td>
<td>0</td>
<td>11 (24.5)</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td>2 (10.0)</td>
<td>2 (14.3)</td>
<td>13 (26.5)</td>
</tr>
<tr>
<td>Skin toxicity</td>
<td>2 (10.0)</td>
<td>2 (14.3)</td>
<td>18 (36.3)</td>
</tr>
<tr>
<td>Neuropsychiatric toxicity</td>
<td>2 (10.0)</td>
<td>0</td>
<td>6 (12.2)</td>
</tr>
<tr>
<td>Gastrointestinal toxicity</td>
<td>2 (10.0)</td>
<td>0</td>
<td>5 (10.0)</td>
</tr>
<tr>
<td>GTI score</td>
<td>65 (104.5)</td>
<td>44 (48.0)</td>
<td>87 (76.0)</td>
</tr>
</tbody>
</table>

1 n (%), if otherwise specified; median (IQR) for numeric values other than age/GTI: Glucocorticoid toxicity index, RA: Rheumatoid arthritis, SLE: Systemic lupus erythematosus, BMI: Body mass index, HbA1c: Glycated hemoglobin, LDL-C: Low density lipoprotein cholesterol, Vasculitis patients include ANCA-associated vasculitis, Giant cell arteritis, Takayasu arteritis, Behcet’s syndrome, IgA-related disease, Polymyalgia rheumatica and Leucocytoclastic vasculitis patients.**BVAS value given only for ANCA-associated vasculitis (n=19)

Conclusion: Our study revealed the iceberg of glucocorticoid toxicities in patients with rheumatic disease. Usage of GTI would help management of these possible toxicities. Therefore, it is important to assess GC toxicity at regular intervals during ongoing treatment in order to detect potential differences in the GTI scores.

Disclosure of Interests: None declared.

AB1487

VALIDATION AND CULTURAL ADAPTATION OF
THE QUALISEX QUESTIONNAIRE IN WOMEN WITH
SJÖGREN’S SYNDROME IN ITALY

F. Giardina,1, G. Curcio,1, C. Gioia,1, R. Izzo,1, E. Simoncelli1,2, A. Gattamelata1, S. Colafrancesco1, L. Mastromannino1, M. Villà1, C. Iannuccelli1, M. Di Franco1, F. Conti1, R. Proven1,3,1 Università degli Studi di Roma “La Sapienza”, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Rheumatology Unit, Rome, Italy. 2University of Uqquila, Department of Biotechnological and Applied Clinical Sciences, Uqquila, Italy

Background: The quality of sexual life (QSL) is a complex and multimodal experience influenced by endogenous and external factors, including age, gender, and cultural environment. Rheumatic diseases, with their burden of pain, fatigue, organ damage, and disability, can severely impair sexual life and this is true also for Sjögren’s Syndrome, where simple tools to assess the QSL in everyday clinical practice are needed.

Objectives: To: To adapt ad into Italian the Qualisex, a new brief questionnaire originally created for Rheumatoid Arthritis patients, for women with primary Sjögren’s Syndrome (pSS) and evaluate the impact of the disease on their sexuality.

Methods: Consecutively sexually active pSS (according to ACR/EULAR 2016 criteria) patients aged >18 were asked to participate in this study approved by the local bioethics committee. With the permission of the developer, the French original version of the Qualisex questionnaire (consisting of 10 items, the higher the higher the score, the greater the negative impact of the disease on the QSL) was translated and adapted into Italian according to current guidelines. In the absence of a gold standard assessment for sexuality in pSS, face and content validity was assessed cross-sectionally with correlations with other disease aspects such as anxiety and depression measured by Hospital Anxiety and Depression Scale (HADS), EULAR Sjögren’s Syndrome Disease Activity Index (SSDAI) (EULAR Sjögren’s Syndrome Disease Activity Index), and SScDI (Sjögren’s Syndrome Disease Damage Index) were assessed as well. Analyses were carried out with IBM SPSS Statistics for Macintosh, version 22.0 (IBM Corp., Armonk, NY, USA).

Results: 40 sexually active women with pSS and a median age of 53 (IQR 45.25-57.25) were enrolled. The EFA showed that the model with a single factor appeared to be highly significant (Ch235= 2943.10; p<0.05); the average inter-item correlation was found to be 0.392 (Min -0.479; Max 0.834) which is an acceptable value as for redundancy. There were no missing answers. Cronbach’s alpha coefficient resulted to be 0.86 which indicates an adequate internal consistency. The median Qualisex score was 4.65 (IQR 2.13-6.2). As far as correlations, age (Rho=-0.39; p<0.05), menopause (Rho=-0.41; p<0.05), relationship quality (Rho=-0.55; p<0.05), anxiety (HADS-A; Rho=0.38; p<0.05), and depression (HADS-D; Rho=0.47; p<0.05) appeared to be positively correlated with Qualisex score. Also, a positive correlation with ESSPRI (Rho=0.43; p<0.05), and drug use (Rho=0.37; p<0.05) was demonstrated. On the contrary no significant correlation was found with education (Rho=-0.07; p=0.64), systemic disease activity (Rho=0.14; p=0.39), and damage (Rho=0.06; p=0.74).

Conclusion: The Italian version of the Qualisex questionnaire is a valid, reliable and useful tool to assess the quality of sexual life in pSS. QSL in pSS women is an inverse relationship with age, menopause, drug use, ESSPRI, mood disorders, and dissatisfaction with the partner, while, as previously reported, no correlation was found with disease activity, damage, and educational status. This further highlights the impact of subjective symptoms such as dryness, pain, fatigue, and the overall psychological well-being on patients’ life. Thus, it is critical for the physician to consider patients’ perspective.

Disclosure of Interests: None declared

AB1488

GRAY INTENSITY RATIO INDICES AS A METHOD OF DISCRIMINATION BETWEEN CHANGES INDUCED BY SPORT AND BY SPONDYLOARTHRITIS IN LOAD-BEARING ENTEHESSES.

M. Tortosa-Cabadas1, C. Guillén-Astete1, Á. Andreu-Suárez1. 1Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: Computer analysis of radiological images has recently been introduced in the study of patients with musculoskeletal pathologies. In the field of ultrasound, baseline settings and differences between images obtained by different equipment pose a potential problem in the comparative study of patients. Our research group has shown that this type of ultrasound image analysis is sensitive to exercise-induced adaptive changes.

Objectives: The purpose of this study is to determine if the computer analysis of entheses ultrasound images can distinguish adaptive changes from those produced by spondyloarthritis.

Methods: A test validation study was carried out. Since the analysis of static ultrasound images strongly depends on the characteristics of the image and the ultrasound settings, three indices based on the findings in pathological territories and their counterpart in healthy entheses were defined. Gray Intensity Mean (IMG): Mean gray intensity in the clinically affected enthesis/mean gray intensity in the same healthy enthesis. Gray intensity dispersion index (IDIG): Mean of the standard deviation of the gray intensity means in the clinically affected enthesis/mean of the standard deviation of the gray intensity means in the same healthy enthesis. Index of gray intensity modes (iMoIG): Mean gray intensity modes in the affected enthesis/mean gray intensity in the same healthy enthesis. The indices were compared with P<.0001. According to the matrix of coordinates of the receiver-operat-

Figure 1. ROC curves for the three analyzed indices.

Receiver-Operating-Characteristic curve

1 - specificity

Sensitivity

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

ROC

Area under the curve (Figure 1) for the three indices was: IMG 0.879 (95% CI 0.807 to 0.951), IDIG (95% CI 0.582 to 0.785), iMoIG 0.751 (95% CI 0.682 to 0.840). All areas demonstrated diagnostic validity with P<.0001.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5151

AB1489

VALIDATION OF QUANTITATIVE COMPUTER ANALYSIS OF ULTRASOUND IMAGES OF THE ACHILLES AND PATELLAR TENDONS IN HEALTHY SUBJECTS.

Á. Andreu-Suárez1, C. Guillén-Astete1, M. Tortosa-Cabadas1. 1University Hospital Ramón y Cajal, Rheumatology, Madrid, Spain

Background: The ultrasound study of tendons is a component of the complementary evaluation of patients with different musculoskeletal pathologies, which include immune-mediated rheumatological diseases. Until now, the assessment

Methods: A test validation study was carried out. Since the analysis of static ultrasound images strongly depends on the characteristics of the image and the ultrasound settings, three indices based on the findings in pathological territories and their counterpart in healthy entheses were defined. Gray Intensity Mean (IMG): Mean gray intensity in the clinically affected enthesis/mean gray intensity in the same healthy enthesis. Gray intensity dispersion index (IDIG): Mean of the standard deviation of the gray intensity means in the clinically affected enthesis/mean of the standard deviation of the gray intensity means in the same healthy enthesis. Index of gray intensity modes (iMoIG): Mean gray intensity modes in the affected enthesis/mean gray intensity in the same healthy enthesis. The indices were compared with P<.0001. According to the matrix of coordinates of the receiver-operat-

Figure 1. ROC curves for the three analyzed indices.

Receiver-Operating-Characteristic curve

1 - specificity

Sensitivity

0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1

ROC

Area under the curve (Figure 1) for the three indices was: IMG 0.879 (95% CI 0.807 to 0.951), IDIG (95% CI 0.582 to 0.785), iMoIG 0.751 (95% CI 0.682 to 0.840). All areas demonstrated diagnostic validity with P<.0001.

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.5151
of the ultrasound status of the tendons largely depends on the subjectivity of the explorer, following specific guidelines such as the fibers structure, their global echogenicity and their thickness. This evaluation is of great interest for the diagnosis, however its role for the follow-up is not so clear as the subjective evaluation may not perceive subtle changes. Computerized image analysis has recently been introduced to complement the echographic evaluation. Two of the most useful parameters in this analysis are the mean and mode of gray intensities. Both allow a global evaluation of the echostucture of an organ based on the distribution of shades of gray and the highest concentration of a particular shade, without evaluating the organization pattern of the image obtained.

**Objectives:** To determine if computer analysis of static images is valid and suitable for its use in the study of tendons.

**Methods:** The ultrasound images of healthy volunteers were analyzed. The analyzed tendons were: the body of the patellar tendon in transverse approach and the longitudinal section of the Achilles tendon, both of them from the dominant side. Image processing was performed using the ImageJ 1.53e program (Wayne Rasband & contributors – NIH, USA). A gray spectrum analysis (0-255) was performed with the calculation of the mean, standard deviation (SD), range, median and mode. Two measurements of different cuts of the patellar tendon (at the point of emergence of the tibial plate and 20 mm proximal to it) and three longitudinal cuts of 20 mm of the Achilles tendon (paramedial, central and paralateral) were used for the validation process of the analysis carried out by the software.

**Results:** Images from 44 healthy volunteers were analyzed: 20 men and 24 women. 44 Achilles tendon image trios and 44 patellar tendon image pairs were analyzed and their corresponding means and modes were compared as related variables. In the study of the Achilles tendon, according to the Shapiro-Wilk test, the distribution of the gray distribution means had a non-normal distribution while the modes had a normal distribution. The mean ± standard deviation of gray intensity was: 80.15 ± 26.04, 80.05 ± 25.57 and 79.91 ± 25.83 for the medial, central and lateral slices, respectively (Friedman, P=.454; Bonferroni not applicable). The modes of the gray modes for the same measures were 67.35 ± 31.60, 67.76 ± 32.18 and 66 ± 32,18, respectively (ANOVA paired data, P=.259; Bonferroni not applicable). In the patellar tendon study, all measurement distributions were non-normal. Mean gray intensity at the point of tendon emergence (P) was 81.35 ± 29.63 and at 20 mm proximal to this point it was 80.97 ± 29.08 (Wilcoxon, P=.327). The means of the modes at the same locations were 82.71 ± 28.75 and at 20mm proximal to this point it was 84.44 ± 33.31 (Wilcoxon, P=.079).

**Conclusion:** The quantitative analysis of static images of healthy tendons shows no differences between the same structures in longitudinal or transverse planes. Based on this validation test, the demonstration of sensitivity to change caused by any stimulus (sport, noxae or treatments) could allow its use as a complementary instrument for the assessment of tendinous structures over time.

**Disclosure of Interests:** África Andreu-Suárez: None declared, Carlos Guíllén-Astete Speakers bureau: Novartis, Janssen, Abbvie, Grunenthal, UCB, Gebro, Paid instructor for: Roche, Novartis, Janssen, Esteve, Menarini, Consultant of: Janssen, Novartis, Roche, Grant/research support from: Pfizer, Grunenthal, Gebro, Novartis, Marina Tortosa-Cabañas: None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5275
Rehabilitation

AB1491

ACUTE EFFECTS OF AN INSTRUMENT ASSISTED SOFT TISSUE MOBILIZATION TECHNIQUE ON CHRONIC NECK PAIN: A DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL

H. Gerci1, B. S. Unuvar1, O. Umit Yemisci2, A. Aytar3.1 Vocational School of Health Services, Physiotherapy, Karayi, Turkey; 2Istanbul University-Cerrahpa, Institute of Graduate Studies, Department of Medicine, Physical Medicine and Rehabilitation Department, Ankara, Turkey; 3Baskent University, Physiotherapy and Rehabilitation, Ankara, Turkey

Background: Individuals with chronic neck pain, proprioceptive afferent information from the cervical spine may be impaired due to the presence of pain. Instrument-assisted soft-tissue mobilization (IASTM) is used to reduce pain and improve range of motion (ROM) and function. Cervical sensorimotor control includes the central integration and processing of all afferent information and the execution of the motor program through the cervical muscles and contributes to the maintenance of head posture and balance(1). In individuals with chronic neck pain, proprioceptive afferent information from the cervical spine may be impaired due to the presence of this pain(2). Many treatment modalities such as instrument-assisted soft-tissue mobilization (IASTM) have been used to reduce pain and improve proprioception(3). IASTM is used to reduce pain, increase soft-tissue mobility, and improve range of motion (ROM) and function. These instruments cause microtrauma to restore normal elasticity and function in soft-tissue(4). Kivlan has shown that significant and rapid changes in muscle function can occur with only a single IASTM application and have suggested the following mechanisms of action: an increased fascial motility, a proliferation of extracellular matrix fibroblasts, and an increased blood flow to the area close to the injured tissue, with decreased cellular matrix adhesion and localized ischemia(5).

Objectives: Aim of this study, to determine the acute effects of single-session, IASTM on cervical joint position error (JPE) and pain in individuals with chronic neck pain.

Methods: A total of 39 individuals (mean age=40.18±11.10 years) with chronic neck pain were included in this study. We divided the participants into IASTM, sham, and control groups of 13 members each. In the IASTM group, intervention was applied to the sternocleidomastoid and trapezius muscles with an application time of 45 seconds and a frequency of 60 beats/min. In the sham group, IASTM was applied at a 90° angle without pressure. The control group received no intervention. The pain severity and joint position error were evaluated before and after the intervention, by using the visual analog scale (VAS) and a cervical range of motion device.

Results: The effects of time and treatment group on VAS score were statistically significant. The effect of time and treatment for VAS score was statistically significant (p=0.001). When the post-test was examined according to application, a statistically significant difference found in VAS scores (p=0.001), with the lowest pain score in the IASTM group and the highest pain score in the control group. The significant improvements found in JPE in all aspects of the cervical region in the IASTM group (p<0.05). In the sham group, significant improvements observed in cervical extension, left rotation, and left lateral flexion movements in JPE (p<0.05).

Conclusion: Single-session IASTM is effective for improving the acute pain and JPE in individuals with chronic neck pain.

REFERENCES:

Disclosure of Interests: None declared.


AB1493

REHABILITATION OF PATIENTS WITH OSTEOARTHRITIS OF THE KNEE USING MAGNETIC THERAPY

A. Arkhipova1, N. Zhuravleva2, E. Guryanova3, V. Diomidova2, 1 Republic Clinical Hospital, Department Rheumatology, Cheboksary, Russian Federation; 2 N. Ulianov Chuvash State University; Department Internal Diseases, Cheboksary, Russian Federation

Background: Currently, along with the basic treatment at the outpatient stage of rehabilitation, methods using physical and balneological factors are successfully applied: magnetotherapy, electrotherapy, peliotherapy.

Objectives: Evaluation of the effectiveness of rehabilitation using magnetotherapy for osteoarthrosis of the knee joints at the second radiological stage.

Methods: The study included 75 patients with primary osteoarthrosis of the knee joints of the II X-ray stage, who were on outpatient rehabilitation in the sanatorium “Chuvashyakurort”, including 45 women and 30 men aged 50 to 65 years with a disease duration of 15 to 20 years. Rehabilitation was carried out by a multiprofessional team led by a physical and rehabilitation doctor. All patients were divided into two groups by simple randomization. The main group (n = 50) received basic treatment (chondroprotectors) + non-steroidal anti-inflammatory drugs (NSAIDs on demand) and a course of apparatus magnetotherapy. Magnetic therapy was applied to the area of the knee joints using the “Pulsor-2” apparatus using solenoid inductors, mode - continuous, frequency - 50 Hz, intensity - 2 mT. The control group received standard rehabilitation using the same apparatus.

Results: At the end of the third month of treatment, patients of the main group had significant improvements in the functional ability of the lower limb (p<0.05). In the control group, there was no significant change in functional ability of the lower limb (p>0.05).

Conclusion: The use of magnetic therapy in the complex of rehabilitation methods for the treatment of osteoarthrosis of the knee joints is effective and safe.

REFERENCES:

Disclosure of Interests: None declared.


AB1492

COMPARISON OF TELEREHABILITATION METHODS FOR SYSTEMIC SCLEROSIS PATIENTS IN THE COVID-19 ERA: A RANDOMIZED CONTROLLED STUDY

T. Civici Kaspaşkan1, E. Tarakçı2, O. Keles3, Y. Aslan Keles3, S. Uğurlu4.1 Istanbul University-Cerrahpa, Health Sciences Faculty, Department of Physotherapy and Rehabilitation, Istanbul, Turkey; 2Istanbul Medipol University, Department of Physotherapy and Rehabilitation, Istanbul, Turkey; 3Bursa University, Vocational School, Occupational Therapy Program, Istanbul, Turkey; 4Istanbul University-Cerrahpa, Institute of Graduate Studies, Department of Physotherapy and Rehabilitation, Istanbul, Turkey; 5Bursa University, Vocational School, Physiotherapy Program, Istanbul, Turkey; 6Istanbul University- Cerrahpa, Cerrahpa Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Background: Scleroderma (SSc) is an autoimmune connective tissue disease progressing with fibrosis. SSC patients need to be protected from epidemic diseases as well as rehabilitation needs. For this reason, it is important for them to continue their exercises in an environment where they can be both rehabilitated and protected from infectious diseases.

Objectives: In this study, it was aimed to reveal the effects of exercises performed by telerehabilitation on individuals with Scleroderma with hand involvement and to compare the effects of real-time telerehabilitation (RTT) and asynchronous telerehabilitation (AT).

Methods: Forty-two participants with a mean age of 44.17±11.05 years were included in the study. The patients were divided into three groups and followed for 8 weeks. RTT was applied to the 1st group and AT was applied to the 2nd group, and the 3rd group was the control group. Participants’ finger and wrist joint range of motion (ROM) were evaluated with a goniometer, upper extremity functions were evaluated with Scleroderma Hand Mobility Test (HAMIS), Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire and 9Hole Peg Test (9HPT), grip strength was evaluated with a dynamometer, superficial sense of touch was evaluated with the Semmes Weinstein Monofilament test, activities of daily living (ADL) were evaluated with the Michigan Hand Outcomes Questionnaire (MHOQ), and general health status was evaluated with the Scleroderma Health Assessment Questionnaire (SHAQ).

Results: There were improvements in finger and wrist ROM, upper extremity functions and ADL parameters in the RTT group; and there were improvement in finger ROM and hand functions in the AT group (p<0.05). Wrist radial deviation ROM decreased in the control group (p<0.05). Significant differences were noted between the groups in finger ROM and upper extremity functions after treatment (p<0.05).

Conclusion: Our study shows that exercises performed via RTT and AT are effective in individuals with Scleroderma with hand involvement, and RTT has additional benefits.

REFERENCES:

Disclosure of Interests: None declared.

Background: End-stage knee osteoarthritis (KOA) is a significant health issue worldwide resulting in severe pain and disability. Total knee arthroplasty (TKA) leads to significant improvements in pain and the performance of functional activities such as walking for patients with end-stage KOA. Although TKA reduces pain and improves perceived function, patients continue to exhibit reduced muscle strength, voluntary muscle activation, and functional performance even years after surgery (1). In addition, quadriceps atrophy, and related social restrictions due to the current Covid-19 pandemic may have affected the recovery of patients undergoing TKA due to limited access to exercise, physiotherapy, face-to-face follow-up, and medical services (2). Limited recovery after TKA will require intensive rehabilitation programs in the future. Strengthening exercises (SE) are the most effective intervention for improving muscle strength and functionality and have been recommended in the guidelines for KOA management and in clinical reviews for TKA rehabilitation (3). Randomized controlled trials (RCTs) are the gold standard for assessing the effects of health care interventions. However, RCTs may yield misleading results if they lack methodological rigors (4). RCTs provide the highest quality clinical evidence in the selection of the SE method to be applied (5). However, there are no studies examining the quality of RCTs related to SE in patients with TKA.

Objectives: The aim of this study was to assess the reporting quality of RCTs of SE in patients with TKA.

Methods: RCTs published between 2002 and 2021 were sourced from clinical trial registers, PubMed, and the Cochrane Reviews. RCTs were included if they involved SE in patients who underwent TKA. Analysis was carried out with two assessment tools: PEDro scale and 9-items from CONSORT (6). In addition, we have identified some key methodological elements and examined their relationship to their methodological quality.

Results: We found 35 RCTs that included SE in individuals with TKA. The mean PEDro score was 6.40 ± 1.73. The most common deficient PEDro Items were: Blinding of all therapists who administered the therapy (14.2 ± 5.35 trials), allocation was concealed (31.4 ± 11/35 trials), blinding of all subjects (31.4 ± 11/35 trials). The most common deficient CONSORT Criteria were: Statistical adjustment for multiple primary outcomes (40 ± 14/35 trials), funding sources (40 ± 14/35 trials) and identification as a randomized trial in the title (62.85; ±22/35 trials). Of the key methodological factors we identified, only exercise duration (weeks) was associated with PEDro score (R² = 0.169, p<0.01).

Conclusion: Our results show that the quality of reporting in the literature on RCTs of SE in patients with TKA is insufficient. In order to increase muscle strength after TKA, the lack of face-to-face programs due to COVID-19 should be eliminated with telerehabilitation methods, video conferencing platforms and virtual reality applications, and high-quality RCTs should be planned where these programs are examined.
Disclosure of Interests: Carey, J.R., et al.,

Methods: Forty-six SSc patients were included in the study. The patients were randomly divided into two groups as telerehabilitation and control group. Youtube videos consisting of clinical pilates-based exercises were uploaded to the system so that only the patients in the telerehabilitation group could see it. In the telerehabilitation group, an exercise program was given for eight weeks, twice a day. Video interviews were conducted with the patients once a week. To the control group, the same exercises were given to the telerehabilitation group. An eight-week exercise program was given in the form of a home program. Brochure introducing the exercises was given and exercises were taught. Pain, dyspnea, fatigue, physical activity, anxiety-depression, sleep and quality of life levels were evaluated in all patients at the beginning of the study and at the end of the eight weeks.

Results: Demographic and clinical features of the patient groups were similar (p>0.05). After the exercise program, pain, fatigue, anxiety-depression levels decreased in the telerehabilitation group compared to the control group, while sleep quality and quality of life increased (p<0.05). The results of the study indicated that both exercise programs improve pain, fatigue, anxiety-depression, physical activity, sleep quality and quality of life in SSc patients. The telerehabilitation-based treatment program is more and more effective than the home program.

Conclusion: Our study shows that this innovative treatment program should be applied especially in SSc patients and it will be beneficial.

REFERENCES:

Disclosure of Interests: None declared


AB1497
THE EFFECT OF AQUATIC REHABILITATION ON QUALITY OF LIFE IN PATIENTS WITH KNEE OSTEOARTHRITIS

R. Maaouia1, M. Hsidi2, Z. Mrizaki1, N. Mouli1, H. Rahali1, I. Ksibi1, M. Slouma2, L. Ben Ammar1, L. Motiou1, R. Dhahri2, I. Gharsallah2. 1The Military Hospital of Tunis, Physical Medicine and Rehabilitation Department, Tunis, Tunisia; 2The Military Hospital of Tunis, Rheumatology Department, Tunis, Tunisia

Background: In addition to its multiple functional, social and economic consequences, knee osteoarthritis is responsible for a significant deterioration in the quality of life (QOL)[1]. Studies examining the impact of osteoarthritis on quality of life have been made possible through the development of validated measurement questionnaires. The SF-12 score with its aspects (physical, mental and social) is a valid and important instrument for the assessment of QOL.

Objectives: The main aim of our study was to make a comparison between the contribution of aquatic rehabilitation and classical rehabilitation in patients with knee osteoarthritis using the SF-12 score.

Methods: We carried out a prospective, comparative study carried out over a period of 15 months, (September 2016- December 2017), in 120 patients recruited from the outpatient department of the Physical Medicine and Functional Rehabilitation Department of the telerehabilitation group. In the diagnosis of knee osteoarthri-

The patients were randomly divided into 2 groups of 60 patients each. The first group called G1 received a classic rehabilitation program. The second group called G2 benefited from aquatic gymnastics. The study was based on the SF-12 quality of life assessment. Two evaluations were made, the first (T1) before the start of rehabilitation and the second (T2) at the end of the eight weeks of care.

Results: The mean age of our patients was 57.2 ± 12.5 years in G1 vs 54.3 ± 7.1 years in G2 (p = 0.012). The sex ratio was 0.2 in G1 versus 0.37 in G2 (p = 0.011). The duration of knee osteoarthritis was 63.4 ± 4.5 months in G1 vs 56.2±7.5 months in G2 (p=0.172). Initially, the mean of SF12-P in G1 patients was 31.2 ± 6.5 compared to 35.4±6.2 in G2 patients. In our patients, the SF-12-P score was less than 50 in 100% of cases in G1 and 98% of cases in G2. There was a statistically significant difference between the 2 groups (p = 0.04). After classical rehabilitation, the SF12-P had increased on average by 2.3 against 6.1 after aquatic gymnastics with a statistically significant difference between the 2 groups (p = 0.012). Initially, the mean of SF12-M in G1 patients was 32.5 ± 10.2 and 35.3 ± 8.9 in G2 patients. In our patients, the SF-12-M score was less than 50 in 94% of cases in G1 and 98% of cases in G2. There was no statistically significant difference between the 2 groups (p = 0.652). After classical rehabilitation, the SF12-M increased on average by 6.9 and 12.1 after aquatic gymnastics with a statistically significant difference between the 2 groups (p = 0.005).

Conclusion: The effectiveness of functional rehabilitation, whether aquatic or dry, has been well demonstrated by the study of quality of life, with better results for balneotherapy. The physical properties of water and heat have a positive short-term impact on quality of life by acting on several parameters, including pain, contractures and anxiety. Further studies evaluating this long-term effectiveness will be required.

REFERENCES:

Disclosure of Interests: None declared


AB1498
THE BIOPSYCHOSOCIAL-BASED EXERCISE MODEL VIA TELEREHABILITATION IN PATIENTS WITH INFLAMMATORY AND NON-INFLAMMATORY RHEUMATIC DISEASES: A PROSPECTIVE COHORT STUDY DURING THE COVID-19 PANDEMIC

N. E. Nacar1, N. B. Karaca1, L. Kılıçaslan2, S. Kınca3, E. Ünal4, 1Hacettepe University, Graduate School of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey; 2Hacettepe University, Faculty of Physical Therapy and Rehabilitation, Department of Physiotherapy and Rehabilitation, Ankara, Turkey; 3Hacettepe University, Faculty of Medicine, Department of Rheumatology, Ankara, Turkey

Background: During the COVID-19 pandemic, the patients with rheumatic disease in the biopsychosocial perspective have been adversely affected by social isolation, uncertainty, and the thought that their chronic disease will worsen and increase in their symptoms. ACR/EULAR (American College of Rheumatology / European League Against Rheumatism) defines recommendations about continuing current pharmacotherapy and the significance of the biopsychosocial approach and exercise for patients with rheumatic diseases during a COVID-19 infection [2].

Objectives: This study aims to investigate the effectiveness of the biopsychosocial exercise performed by telerehabilitation on biopsychosocial status, general health status, and anxiety-depression levels in the patients with inflammatory and non-inflammatory rheumatic diseases.

Methods: Fourteen patients with inflammatory rheumatic diseases (rheumatoid arthritis: 4; ankylosing spondylitis: 4; spondyloarthropathy: 2; and vasculitis: 1) and eight patients with non-inflammatory rheumatic diseases. 1The Military Hospital of...
Conclusion: This study showed that biopsychosocial-based exercise through real-time telementerapy was able to maintain their conditions before pandemic in biopsychosocial status, general health, and anxiety-depression levels on the patients with inflammatory and non-inflammatory rheumatic diseases during COVID-19 pandemic period in one-year follow-up.

REFERENCES:

Discourse of Interests: None declared

AB1500 ASSESSMENT OF CLINICAL PARAMETERS AFTER CLASSIC REHABILITATION VERSUS BALNEOTHERAPY IN GONARTHROSIS

R. Maaouli1, S. Karouli1, M. Hlaidh1, N. Mouhil1, H. Rahali2, I. Ksibi3, M. Slouma4, L. Ben Ammar2, L. Metou2, R. Dahhiri2, I. Gharsallah4. The Military Hospital of Tunis, Physical Medicine and Rehabilitation Department, Tunis, Tunisia; 5The Military Hospital of Tunis, Rheumatology Department, Tunis, Tunisia

Background: Knee osteoarthritis (KOA) is the most common pathology of the lower limb. It is multifactorial and constitutes a real public health problem. Nowadays, in addition to the rehabilitation that is part of the multidisciplinary management of this affection, water gymnastics is increasingly finding its place [1].

Objectives: The main objective of our work was to compare the contribution of aquatic gymnastics compared to classical rehabilitation in patients with knee osteoarthritis through a clinical evaluation.

Methods: This is a prospective, comparative and evaluative study carried out in a department of Physical Medicine and Functional Rehabilitation over a period of 15 months between September 2016 and December 2017, including 60 patients with KOA. The patients were randomly divided into 2 groups of 60 patients each one. The first(G1) benefited from a classic rehabilitation program. The second(G2) benefited from water gymnastics. Two clinical evaluations were carried out: T1 before the start of rehabilitation and T2 at the end of the eight weeks of treatment.

Results: The mean age of our patients was 57.2 ± 12.5 years in G1 vs 54.3 ± 7.1 years in G2 (p = 0.012). The sex ratio was 0.2 in G1 versus 0.37 in G2 (p = 0.011). The duration of knee osteoarthritis was 63.4 ± 4.5 months in G1 vs 56.2±7.5 months in G2 (p=0.172). 55 patients presented with a misalignment of the lower limbs with a varus knee in 33% of cases (G1 25% and G2 42%). 5 patients in G1 and 7 patients in G2 had a valgus knee. In G1, one patient had recurvatum and two patient had knee flexion with no statistically significant difference between the two groups. After classic rehabilitation, Zolten’s sign had disappeared in 6 patients for the right knee and 3 patients for the left knee. However, after water gymnastics, this sign had disappeared in 12 patients for the right knee and in 16 patients for the left knee. A functional mobility sector (>90°) was found in all patients with an average of 126° in G1 and 126° in G2. After rehabilitation, an improvement of 2% in G1 and 5% in G2 was noted with a statistically significant difference between the two groups (p<0.001). Thirty-six percent of G1 patients had quadriceps amytrophy versus 32 % of G2, which disappeared in 5 patients after classic rehabilitation and in 6 patients after hydrotherapy. 48 patients of G1 and 56 patients of G2 presented with quadriceps retraction which disappeared in 42 patients of G1 after classic rehabilitation and in 45 subjects of G2 after hydrotherapy. A retraction of the hamstrings was noted in 13 and 18 patients respectively in G1 and G2 with a total improvement in the 2 groups.

Conclusion: Dry rehabilitation has its place in the management of knee osteoarthritis, but rehabilitation in water has better results. The aquatic environment makes it possible, by reducing the weight of the body, to reduce the stresses exerted on the knee joints, allowing better joint mobility with the added effect of heat on the reduction of pain and muscle relaxation.

REFERENCES:

Discourse of Interests: None declared

AB1499 PAIN MANAGEMENT IN KNEE OSTEOARTHRITIS: BALNEOTHERAPY VERSUS CLASSIC REHABILITATION

R. Maaouli1, M. Hlaidh2, Z. Mrizak3, N. Mouhil4, H. Rahali5, I. Ksibi6, M. Slouma6, L. Ben Ammar2, L. Metou2, R. Dahhiri2, I. Gharsallah4. The Military Hospital of Tunis, Physical Medicine and Rehabilitation Department, Tunis, Tunisia; 5The Military Hospital of Tunis, Rheumatology Department, Tunis, Tunisia

Background: Knee osteoarthritis presents a heavy financial burden due to disability and supported care. Gonalia is the main symptom leading patients to consult. For some clinicians, this is a warning signal that correlates with the extent of joint degradation [1]. The management of pain in knee osteoarthritis is multidisciplinary comprising pharmacological and non-pharmacological means including classical rehabilitation and aquatic gymnastics. The objective of our work was to study the contribution of aquatic gymnastics compared to conventional rehabilitation in the management of pain in patients with knee osteoarthritis.

Objectives: The objective of our work was to study the contribution of aquatic gymnastics compared to conventional rehabilitation in the management of pain in patients with knee osteoarthritis.

Methods: Prospective, evaluative and comparative study about 120 patients with knee osteoarthritis carried out over 15 months (September 2016- December 2017) in the Department of Physical Medicine and Functional Rehabilitation. The patients were divided into two groups of 60. The first group (G1) benefited from aquatic rehabilitation program, the second group (G2) benefited from aquatic gymnastics. The 2 programs were carried out at the rate of three sessions per week for two months. The study was based on the assessment of pain by the following scales: VAS pain and the Western Ontario and Mc master Universities’ Osteoarthritis Index (WOMAC) questionnaire for the lower limbs (pain section).

Results: The mean age of our patients was 57.2 ± 12.5 years in G1 vs 54.3 ± 7.1 years in G2 (p = 0.012). The sex ratio was 0.2 in G1 versus 0.37 in G2 (p = 0.011). The duration of knee osteoarthritis was 63.4 ± 4.5 months in G1 vs 56.2±7.5 months in G2 (p=0.172). 55 patients presented with a misalignment of the lower limbs with a varus knee in 33% of cases (G1 25% and G2 42%). 5 patients in G1 and 7 patients in G2 had a valgus knee. In G1, one patient had recurvatum and two patient had knee flexion with no statistically significant difference between the two groups. After classic rehabilitation, Zolten’s sign had disappeared in 6 patients in G1 and 3 patients in G2. However, after water gymnastics, this sign had disappeared in 12 patients for the right knee and in 16 patients for the left knee. A functional mobility sector (>90°) was found in all patients with an average of 126° in G1 and 126° in G2. After rehabilitation, an improvement of 2% in G1 and 5% in G2 was noted with a statistically significant difference between the two groups (p<0.001). Thirty-six percent of G1 patients had quadriceps amytrophy versus 32 % of G2, which disappeared in 5 patients after classic rehabilitation and in 6 patients after hydrotherapy. 48 patients of G1 and 56 patients of G2 presented with quadriceps retraction which disappeared in 42 patients of G1 after classic rehabilitation and in 45 subjects of G2 after hydrotherapy. A retraction of the hamstrings was noted in 13 and 18 patients respectively in G1 and G2 with a total improvement in the 2 groups.

Conclusion: Dry rehabilitation has its place in the management of knee osteoarthritis, but rehabilitation in water has better results. The aquatic environment makes it possible, by reducing the weight of the body, to reduce the stresses exerted on the knee joints, allowing better joint mobility with the added effect of heat on the reduction of pain and muscle relaxation.

REFERENCES:

Discourse of Interests: None declared

AB1501 EFFECT OF SARS-COV-19 PANDEMIC ON RHEUMATOLOGY TRAINING IN INDIA

K. Kunachandeng@gmail.com1, K. Kishor2, P. Dogga3, D. Ekbot2, J. Dixit2, P. Kumar2, U. Dhakad2,1King George's Medical University; Clinical Immunology and Rheumatology, Lucknow, India

Background: The current study aims to gauge the magnitude of the effect the pandemic has had on Rheumatology training (including the effect on clinical,
academic and research training) in India, their physical, mental and social well-being during the pandemic and the perceived changes in Rheumatology training and care during the pandemic from the trainees’ view

Objectives: 1. To assess the impact of COVID-19 Pandemic on the training of Rheumatology Residents (DM, DNB and Fellows) 2. Understand the issues faced by trainees and the extent of affection.

Methods: Study design: We conducted an observational cross-sectional study using an online survey sent to rheumatology trainees in India.

Sample: Convenience sampling was used, so the sample size was not calculated.

Inclusion and exclusion criteria: Rheumatology trainees from India including DM/DNB residents and fellows with the ability and desire to complete the survey were included.

Data collection and instruments: The link to the survey was sent to the rheumatology trainees through social media platforms like WhatsApp, Telegram and email.

Statistical analysis: Descriptive statistics were performed by calculating measures of central tendency for quantitative variables and using counts and percent-ages for qualitative and nominal variables.

Results: A total of 78 trainees from 24 institutes in 12 states participated in the study. Mean age of the participants was 31 with 70% of trainees being male and 30% females. 56 (70%) participants were DM students, 15 (19%) participants were DNB students, 5 fellowship students and 2 Non- academic Senior Residents. An overwhelming majority of residents (84%) felt COVID-19 Pandemic negatively impacted their residency and their Physical (65%), Mental (74%) and Social wellbeing (80%). 79% of trainees felt burnt-out due to the pandemic. Majority of trainees felt the pandemic negatively impacted their training with clinical teaching (91%). Clinical examination skill (74%), current (80%) and future (70%) research opportunities suffered during the pandemic. Most residents felt diminution and significant reduction of the overall footfall (99% & 72%) of patients in rheumatology including OPD (100% & 77%) and indoor (99% & 67%) admissions along with academics (85% & 35%), procedures (97% & 86%) and exposure to musculoskeletal ultrasound (96% & 71%). Almost 60% and 40% of trainees had their OPDs and indoor admissions stopped during COVID-19 pandemic of these 20% had their OPDs and Admissions closed for more than 6 months. 85% of the participants had one or the other psychological symptoms with almost half experiencing anxiety (44%), low mood (47%) or lack of sleep (41%); 85% were concerned about their family members being infected and 40% lost a close relative to COVID. 91% of the trainee were posted in COVID-duties 2/3rd of them in ICUs, 50% being posted for 1-3 months and 20% more than 3 months, a quarter of trainees got infected during their duties (COVID and Non-COVID) and through most had asymptomatic to mild COVID. 15% still had moderate to severe COVID. Teleconsultation was started by more than half of the respondents after COVID related lockdowns with greater than half not being happy with teleconsultations.

Conclusion: The COVID-19 Pandemic has completely altered the status quo for rheumatology trainees and has affected their physical, social and mental well-being. Academic and clinical training has reduced. Current and future Research has become difficult, disruptions in OPDs and Admissions, recurrent COVID postings and reduction in patient footfall, Procedures and MSK-US have been detrimental to trainees.

REFERENCES:


Disclosure of Interests: None declared


AB1502

AWARENESS OF BIOLOGICAL AGENTS RELATED SIDE EFFECTS AMONG INTERNAL MEDICINE RESIDENTS IN A UNIVERSITY HOSPITAL

M. Oztas1, S. Liriglu2. 1Istanbul University-Cerrahpasa, Department of Rheumatology, Istanbul, Turkey; 2Istanbul University-Cerrahpasa, Department of Rheumatology, Istanbul, Turkey

Background: Biological agents have become a core component of therapeutic strategies in the last two decades. The number of patients treated with biological agents has been increasing with the expansion of these agents’ indications among rheumatic disorders.

Objectives: Unfortunately, biological agents have varied side effect profiles, and rheumatic patients with possible side effects are commonly consulted with internal medicine physicians in emergency departments. We surveyed to assess the awareness of biological agents related side effects among internal medicine residents in our university hospital.

Methods: We conducted a web-based multiple-choice test with 10 questions in total. Monoclonal antibodies (anti-TNF, anti-CD20), anti-cytokines, and JAK inhibitors related side effects and management of these adverse events were assessed. Figure 1 depicted the topics and the correct answer rate of the related questions.

Results: A total of 57 responses were collected and analyzed. The mean number of the correct answers was 6.4 ± 1.5. Fourteen (24.6%) out of the 57 participants scored below 5, whereas 58% of the participants scored ≥6 points. The majority of the participants have correctly answered the anti-TNF, rituximab and tocilizumab-related questions, however, less than half of the participants have accurately answered the anakinra and JAK inhibitors-related questions (Figure 1).

Conclusion: Our survey suggests that the awareness of biologic agents related side effects among the internal medicine residents is satisfactory. Poorer results were observed especially in JAK inhibitors related side effects and severe infusion reaction management which indicate the educational needs of the residents for these topics.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.752

AB1503

MOST MEDICINE RESIDENTS WOULD LIKE TO LEARN JOINT ASPIRATION PROCEDURES BUT 2/3 HAVE NEVER DONE IT: SURVEY OF COMMUNITY HOSPITAL TRAINEES IN NORTHEASTERN USA

P Gonzalez1, R. Kaler1, N. Sukumaran1, A. Eldib1, Y. Turkowski1, Z. Y. Li2, K. Gilek-Seibert1. 1Roger Williams Medical Center, Internal Medicine, Providence, United States of America; 2Roger Williams Medical Center, Rheumatology, Providence, United States of America

Background: Arthrocentesis is a procedure performed to aspirate synovial fluid from a joint cavity. It has both diagnostic and therapeutic utilization in outpatient and inpatient settings. While arthrocentesis is considered a minor surgical procedure, there is always potential to injure blood vessels, nerves, and tendons1. Although joint arthrocentesis is not an Accreditation Council for Graduate Medical Education procedural requirement for Internal Medicine (IM) residents in the United States, several studies have revealed that training on knee arthrocentesis and injection provided a solid foundation to medical residents toward increasing their confidence and refining motor skills2.

Objectives: To evaluate the current Roger Williams Medical Center (RWMc) IM residents’ confidence level in performing intra-articular injection. Results from this study will inform the design of resident-oriented quality improvement arthrocentesis teaching series in RWMc.

Methods: Project was incepted and designed by one rheumatology faculty, one fellow and five IM residents of RWMc. We selected the survey as a tool to elicit information from all current IM residents who filled out a 7-question survey regarding their residency experience and exposures to knee aspiration and injection. We used Survey Monkey as an anonymous survey tool (see Table 1). Data were collected between 1/14/22 until 1/27/22 and were verified by two members of the research team.

Results: A total of 47 IM residents within three classes in this community residency program were provided with the survey. The survey response rate was 82.9% (39 /47). 69.23% residents do not feel comfortable doing arthrocentesis. More than half of the resident population (51.28%) do not think they have adequate exposure to knee arthrocentesis. 73.68% residents have never performed knee injections/arthrocentesis. According to the survey, 94.87% of the
Background: In several countries, studies have shown that fewer medical students choose rheumatology as a specialty. In Morocco no study has yet focused on this subject.

Objectives: The aim of our study is to assess the attractiveness of rheumatology as a specialty among Moroccan medical students, recently graduates and interns, and to analyze the factors that may be associated with it.

Methods: An online survey was sent to 297 medical students who had started their hospital practice, to 100 medical interns (students in 6th and 7th year who successfully passed the internship competition) and to 280 freshly graduated medical doctors (residency program candidates before choosing a medical or surgical specialty). The survey covered three areas: anonymous social and demographic informations, data on clinical trainee in a rheumatology department, and the attitude toward rheumatology as a specialty. Descriptive data were collected and Chi2 Tests were used to assess differences between groups. Logistic regression was performed to investigate associations between demographic and exposure variables and the choice of rheumatology as a career.

Results: We collected responses from 161 students (response rate: 54%), 68 interns (68%) and 89 freshly graduated doctors (32%). The demographic characteristics are presented in Table 1.

Table 1. Survey from 39 total responses

<table>
<thead>
<tr>
<th>Question</th>
<th>Responses</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. What post-graduate year are you?</td>
<td>PGY1:41.03% PGY2: 35.96% PGY3: 9%</td>
</tr>
<tr>
<td>3. Do you think you have adequate exposure to knee procedures in residency?</td>
<td>Strongly Agree: 0% Agree: 0% Undecided: 5.13% Disagree: 51.28% Strongly Disagree: 43.59%</td>
</tr>
<tr>
<td>4. How many knee aspirations/injections have you done during residency?</td>
<td>1-4: 26.32% 5-10: 0% &gt;10: 0%</td>
</tr>
<tr>
<td>5. Do you think our residency program is preparing you to do knee aspirations/injections?</td>
<td>Strongly Agree: 0% Agree: 0% Undecided: 17.95% Disagree: 35.90% Strongly Disagree: 46.15%</td>
</tr>
<tr>
<td>6. Would you interested in doing more knee aspirations/injections?</td>
<td>Strongly Agree: 33.33% Agree: 35.90% Undecided: 23.08% Disagree: 5.13% Strongly Disagree: 2.56%</td>
</tr>
<tr>
<td>7. Having exposure to arthrocentesis is very important for me to have in my residency program</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Medical students (N=161) Interns (N=68) Freshly graduated doctors (N=89)

| Age* | PGY1: 21.5 ± 1 PGY2: 24.2 ± 1 PGY3: 28.6 ± 2 |
| Gender (females) (%) | PGY1: 93 (57.8%) PGY2: 30 (44.1%) PGY3: 64 (71.9%) |
| level (%) | PGY1: Third year: 44 (27.3%) Fourth year: 53 (32.8%) Fifth year: 64 (39.8%) PGY2: First year: 44 (64.7%) Second year: 24 (35.3%) PGY3: |
| Training in a rheumatology department (%) | PGY1: 118 (73.3%) PGY2: 28 (41.2%) PGY3: 37 (41.6%) |
| Duration of training (weeks) | PGY1: 3.4 ± 0.7 PGY2: 5.3 ± 1.4 PGY3: 6.3 ± 2.6 |

(*) expressed as a number and percentage / (+) expressed as a mean and standard deviation

73% of students, 41.2% of interns and 41.6% of graduates said they had already completed a clinical training in a rheumatology department. While 41.6% of students and 43.8% of graduates consider the possibility of choosing rheumatology as their specialty, only 11.2% of students, 5.9% of interns and 7.9% of graduates said that rheumatology is their dream career specialty. In uni and multivariate analysis, clinical exposure to rheumatology is retained as the main statistically significant factor predicting the choice of rheumatology in all categories (Odds ratio (95% CI) = 0.1019 (0.07-0.497; p=0.02)), to this is added the female sex among freshly graduated doctors (Odds ratio (95% CI) = 4.02 (1251-12.918; p= 0.001).

Conclusion: Our study showed that rheumatology is considered a fascinating specialty by Moroccan medical students and freshly graduated doctors. Clinical exposure to rheumatology is the strongest predictor factor for choosing rheumatology as a future career.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.906
it can offer, given that it is a "relatively less time consuming specialty". The main barriers to choose rheumatology are "the interest in surgical specialties" for students and interns and "the limited therapeutic aspects" for graduates. Other commonly reported reasons are shown in Table 1.

Conclusion: Our study has shown that rheumatology fascinates Moroccan medical students by its clinical abundance and the diversity of musculoskeletal pathology and also by the quality of life it can offer. According to the students, the main barriers to choose rheumatology are the interest in a surgical specialty, and the limited therapeutic aspects of the specialty.

Disclosure of Interests: None declared.


AB1506
RHEUMATOLOGY TRAINING EXPERIENCE: ARE RHEUMATOLOGY RESIDENTS WELL-PREPARED NOWADAYS? A SELF-APPRaisal
R. Dos-Santos1, E. Perez-Pampin1, A. Souto Vilas1, A. Mera Varela1. Clinical University Hospital in Santiago de Compostela, Spain, Rheumatology Department, Santiago de Compostela, Spain

Background: Rheumatology residence in Europe is a 4-year training program where Medical Doctors (MD) purchase all capacities for turning into Rheumatologists at each Hospital. European guidelines concerning which contents should be acquired and recommendations for its obtaining are available (UEMS, Union Européenne des Médecins Spécialistes). Several researches have proven high self-reported abilities, but some deficiencies are displayed in deeper investigations: musculoskeletal ultrasound sonography, poorly crystal identification by optic microscopy and injection skills. As well, low clinical experience remains as one of the most self-reported deficiencies.2,3

Objective: To assess the quality of one-year rheumatology trainee consultation at the outpatient clinic in a Spanish Hospital.

Methods: The last year during outpatient consultation of a resident training in Rheumatology in one Spanish hospital was assessed, from May 2021 to May 2022. All patients visited by the trainee were included, absent patients in the consultation date were excluded from the study. Main variables were collected, such as gender, main diagnosis, biological or targeted synthetic treatments and supplementary tests. The final resident’s opinion about his training was also checked.

Results: During one-year period of the Resident’s consultation, 1419 visits were performed. From those, 470 were the first visit of the patient and 119 of them were solved in the first visit and no follow-up was needed. 60.7% of patients were women. Most frequent diagnosis were arthropathies: 21.8% psoriatic arthritis, 16.9% rheumatoid arthritis and 8.4% axial spondyloarthritis. Regarding collagenopathies, 3.4% of patients were diagnosed of systemic erythematosus lupus, 1.3% antiphospholipid syndrome, 2.3% systemic sclerosis and 1.3% myopathies. Bone-related diseases as Paget's disease and osteoporosis were also frequent (21 and 132 patients). The most prevalent vasculitis was giant cell arteritis with 51 patients, although patients with Behçet's disease, Takayasu arteritis and polyarteritis nodosa were also followed. A total of 207 musculoskeletal ultrasonography were made during daily clinical practice. As well, 67 articular injections were performed. Capillaroscopy and salivary gland biopsy were the least frequent procedures (21 and 18, respectively).

Conclusion: Most of rheumatological diseases can be diagnosed and followed during one-year period in the resident's training program. Also, ultrasound and injection skills are granted during this time. The most important self-reported deficiency is the low number of patients under biological/targeted synthetic treatments.

REFERENCES:

Disclosure of Interests: None declared.


AB1507
ATTRIBUTES INFLUENCING THE SELECTION OF FELLOWSHIP PROGRAMS BY RHEUMATOLOGY APPLICANTS: A PILOT WEB-BASED SURVEY
V. Kesawari1, D. Feterman1, S. Alexander1, N. Singh1. 1University of Connecticut, Internal Medicine, Farmington, United States of America; 2University of Connecticut, Internal Medicine, Farmington, United States of America; 3University of Connecticut, Internal Medicine, Farmington, United States of America; 4University of Washington, Division of Rheumatology, Seattle, United States of America

Background: Recruitment of candidates is a cost- and effort-intensive aspect of rheumatology fellowship programs. For program leaders to efficiently use the available resources and improve recruitment outcomes, it is imperative to understand the attributes that influence the candidates’ choice of a program. Previous studies have examined the type and relative importance of the factors that candidates use in selecting other national programs (1, 2). However, no such studies have been conducted in the field of rheumatology.

Objectives: To examine the factors that influence the selection of fellowship programs by rheumatology applicants.

Methods: An anonymous, web-based survey comprised of 13 questions was shared with rheumatology fellowship applicants on messaging applications and online forums. The survey was open from 10/29/2021-11/06/2021. Participation was voluntary and informed consent was implied through the participants’ response. Three reminders to complete the survey were sent. Four domains of the applicant’s perception in relation to their preference of ranking rheumatology programs were assessed: (1) program prestige, (2) program structure, (3) interview day experience, and (4) career path of the applicant. The survey questions were devised in one of the following formats: (1) 5-point Likert scale, (2) rank order questions, (3) yes/no questions, (4) multiple choice questions, and (5) open-ended questions.

Results: Thirty-two rheumatology applicants responded to the survey. The prestige of the program was reported to be extremely important by 16%, very important by 19%, somewhat important by 44%, and little or not important by 21% respondents. The opportunity to see a diverse patient population was reported to be important by 97% respondents. The call schedule and higher number of fellows were considered important by 86% of the respondents. 66% preferred programs with higher number of faculty members. 69% favored programs with an ultrasound curriculum. The availability of clinician-educator track (18%), MCR/MPH (14%), and T32 grand (16%) was considered less important. 95% reported that the opportunity to train at a Veterans Administration hospital did not influence their choice. Regarding interview day experience, interaction with the faculty (63%) and the fellows (17%) were considered important factors influencing program ranking. Respondents preferred programs with alumni in academic clinician track (45%) and private practice (43%) compared to programs with alumni in academic research (13%) or industry pathway (4%). The geographical location of the program including the cost of living and location of significant others also influenced the applicants’ choice.

Conclusion: To the best of our knowledge, this is the first survey to assess the attributes that influence a candidate’s choice of a rheumatology fellowship program. Our survey demonstrated that a positive interview day experience and program attributes including the opportunity to interact with a diverse patient population, relaxed call schedule, higher number of fellows and faculty, the presence of an ultrasound curriculum, and the location were the dominant factors influencing applicants’ choice of a program. The program limitation of our study is the lack of generalizability due to selection bias. Understanding the factors involved in decision making of the rheumatology fellowship applicants can provide valuable information for both the applicants and the programs and therefore lead to a better match.

REFERENCES:

Disclosure of Interests: None declared.


Educational cases

AB1508
A NOVEL PATHOGENIC VARIANT IN ZNF462 GENE ASSOCIATED WITH WEISS-KRUSZKA SYNDROME AND SLE
M. Constantinou1, M. Lampi2, V. Neoleux3, P. Fanis3, L. A. Phylactou4, S. Pasierl6, K. Parpeneris6, University of Cyprus, Medical School, Nicosia, Cyprus; 7The Cyprus Institute of Neurology and Genetics, Molecular Genetics, Vision and Therapy, Nicosia, Cyprus; 8Nicosia General Hospital, Division of Rheumatology, Nicosia, Cyprus; 9University of Cyprus Medical School, Department of Internal Medicine, Division of Rheumatology, Nicosia, Cyprus

Background: Weiss-Kruszka syndrome (WSKA) is an autosomal dominant congenital anomaly syndrome due to mutations in the ZNF462 gene and manifests with developmental delay and multiple craniofacial abnormalities with variable expressivity. It is also characterized by cognitive impairment, whilst about a third of the affected individuals belong to the autism spectrum. Although the disease is inherited with the autosomal dominant manner, most of the described subjects (95%) had de novo variants with no affected family members1. WSKA has been recently described and only 26 (including our patient) affected individuals have been classified to date2. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the presence of autoantibodies and multi-organ inflammation. Genetic factors might play an important role in disease pathogenesis in patients with childhood-onset SLE.

Disclosure of Interests: None declared.

Objective: To describe the case of a SLE patient who was found to have WSKA related to a novel pathogenic autosomal dominant (AD) variant in the ZNF462 gene, and inform clinicians of a possible association between the 2 conditions.

Methods: A 25-year-old Caucasian female with a history of SLE, diagnosed at the age of 14, manifested with malar rash, Raynaud’s phenomenon, arthritis, thrombocytopenia, positive ANA, ds-DNA antibody and hypocomplementemia. At the age of 17, she developed renal dysfunction due to lupus nephritis class IV, and she was treated with glucocorticoids (GCs), cyclophosphamide and hydroxychloroquine. In Oct 2020, she was admitted to the hospital for thrombotic thrombocytopenic purpura due to lupus exacerbation. She was successfully treated with GCs, plasma exchange and rituximab. During her hospitalization, the presence of various clinical features raised the suspicion of a genetic syndrome. First, the patient exhibited dysmorphic features such as hypertelorism, prognathism, arched eyebrows, flattened nasal bridge, small upper lip, mild intellectual disability, and a history of childhood-onset SLE. Whole exome sequencing (WES) by NGS was used for the genetic investigation of the patient.

Results: The patient underwent genetic evaluation with WES and the novel heterozygous AD pathogenic variant c.4142delT (p.Lle1381ThrfsTer16) in ZNF462 gene was identified. Confirmation of the identified variant was also verified by sanger sequencing. Pathogenic variants in the ZNF462 gene were previously described in patients with the recently reported WSKA of which several characterized are compatible with our patient’s features. The ZFN462 encodes a zinc-finger transcription factor that plays a role in embryonic development, transcriptional regulation, and chromatin remodelling. Given that chromatin remodelling has been implicated in the pathogenesis of SLE, the association of this novel ZNF462 variant in the development of SLE, needs to be determined.

Conclusion: This is the first report of a patient with coexisting SLE and WSKA due to a novel variant. It illustrates the need for further research in order to elucidate any possible pathophysiologic link among the 2 conditions.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.197

AB1509

OVARIAN CARCINOMA MIMICKING SYSTEMIC SMALL VESSEL VASCULITIS: CASE REPORT

R. A. Elziaty1. 1 Ain Shams University, Internal Medicine Department, Division of Rheumatology; Cairo, Egypt

Background: Few cases of digital ischemia and gangrene associated with primary solid tumors have been described in literature[3]. The exact mechanism of severe occurrence has not been completely understood and the available treatment options have an extremely limited utility [1,2]. In the most cases the patients were elderly women with adenocarcinomas of digestive or gynaecologic apparatuses [4].

Objectives: We describe a new case of digital gangrene as unusual presentation of ovarian cancer in a 36 years old woman.

Methods: 36 years old female was admitted to our Reumatology department with blackish Blackish discoloration of the toes of one week duration. She had history of COVID -19 infection 8 months prior to the presentation then developed hemoptysis, picture suggestive of ILD, generalized anaasarca and skin rash; accordingly an initial diagnosis of post COVID-19 vasculitis was made by dermatologist. The blood tests were ESR:21 mm/hr, CRP:25.7, D.Dimer:8.8, Ferritin:575 ng/ml, lymphopenia:0.9, S.Creatinine:2, 24h urinary protein: 325mg/24h and all autoimmune markers were negative except anti nuclear antibody (ANA) with titer:1/160. Further assessment revealed that she had multiple site coagulopathy; internal jugular vein thrombosis, bilateral lower limbs Deep Venous Thrombosis (DVT). Neck ultrasound surprisingly showed bilateral enlarged suspicious looking supraclavicular lymph node with lost hilum which was Biopsied for histopathological correlation which revealed focally necrotizing adenocarcinoma with significant signet ring differentiation. Searching for the primary malignancy, tumor markers were sent CA125: 584 u/ml (up to 35), Pelvi-abdominal Magnetic resonance imaging (MRI) revealed Left ovarian mass measuring 3.6 x 3.4 x 4.4 cm highly suspicious of malignant neoplastic growth for histopathological correlation. Suspicious looking pelviabdominal lymph nodes mostly representing malignant lymphadenopathy, Scattered peritoneal nodules suspicious of metastatic deposits.

Results: During admission the patient received full dose anticoagulation (Low Molecular Weight Heparin: 60 iu /12h). Upon diagnosis we arrange the transferal to the oncology department to continue her management plan. Unfortunately; the case was terminal for palliative therapy and she died after 2 weeks.

Conclusion: Bluish discoloration of digits and toes may be a clue for diagnosis of many diseases not only vasculitis. Malignancy can disturb the immune system in a way that mimic any systemic connective tissue disease. Acute insult aggressive multiple site deep venous thrombosis (DVT) necessitate thinking outside the box and consider other causes of coagulopathy like visceral malignancy.

REFERENCES:
Background: Motor neurone disease may mimic inflammatory myositis. There is an overlap in clinical symptoms (such as muscle weakness, dysphagia and respiratory involvement) which may pose a diagnostic challenge. Careful history, thorough clinical examination and appropriate investigations can help to distinguish between the two. Monitoring the response to treatment is also crucial. We present a case that presented to rheumatology with progressive muscle weakness, she was investigated and treated for inflammatory myositis but was later diagnosed with motor neurone disease.

Objectives: To illustrate the need for thorough clinical assessment and investigations in patients with suspected inflammatory myositis and consider alternative diagnoses as clinical picture evolves.

Methods: A 68 year old lady, presented with 6 months history of progressive proximal muscle weakness. She also reported weakness of grip, affecting activities of daily life. She was finding it difficult to get up from chair. There was no swallowing difficulty, respiratory symptoms and skin rash. She had history of hypertension. On clinical examination, she did not have any features of connective tissue disease. There was no evidence of joint synovitis or skin rash. Proximal muscle power in upper and lower limbs noted to be 4/5 with intact reflexes. Initial investigations revealed mildly raised CPK at 287 with normal thyroid function and inflammatory markers. Immunological tests including ANA and myositis panel were requested alongside EMG, MRI thighs and CT chest/posterior cervical spine. Myositis panel was positive for anti-MDA-5 antibodies (in the absence of any respiratory symptoms). There was no evidence of malignancy on CT imaging. MRI thighs revealed fluid in the trochanteric bursae. She was trialled on oral prednisolone in view of her clinical features and positive anti-MDA5 antibody. However, there was no improvement in her symptoms or functional status. EMG revealed widespread neurogenic process affecting upper and lower limbs on both sides, without significant evidence of acute myopathy. The progressive nature of symptoms with the upper motor neurone signs raised the possibility of an evolving anterior horn cell disorder. She was referred to neurology and was subsequently diagnosed to have Motor Neurone Disease. The steroids were rapidly tapered off and stopped.

Results: Motor neurone disease is an important differential when considering inflammatory myositis, particularly inclusion body myositis which causes more progressive muscle weakness. It is a neurological disorder characterised by degeneration of neurons. There is no clear cause identified. MND causes both upper and lower motor neurone signs. Symptoms include limb weakness, bulbar weakness that can affect speech and swallowing, muscle twitching and fasciculation. Respiratory weakness may occur. Thorough clinical examination and EMG findings help identify the diagnosis. Imaging may be needed. There is no cure. Management requires an MDT approach, primarily guided by neurology, including physiotherapy, occupational therapy, speech and language therapy and respiratory support.

Conclusion: This lady was initially treated for inflammatory myositis based on her symptoms, mildly raised CK and positive anti-MDA5 antibodies. On review of her clinical progress, we noted poor response to steroids and EMG results pointing at an alternative diagnosis of MND. This case highlights the importance of EMG in the assessment and management of patients with suspected inflammatory myositis as well as the need to closely monitor progress and re-evaluation where needed. Although she had anti-MDA-5 antibodies and mildly raised CK, she did not have any skin disease or other systemic features, inflammatory markers and muscle imaging was normal. Response to steroids was inadequate.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.758

SLE ONSET POST COVID-19 VACCINATION: COINCIDENTAL OR ASSOCIATION?

C. B. Ng1, C. E. Goh1, 1Hospital Sultan Ismail, Rheumatology Unit, Department of Medicine, Johor Bahru, Malaysia

Background: Numerous immune-mediated diseases flare post vaccination but study on new disease onset post SARS-CoV-2 vaccination have been reported. There were case reports showed the immune-mediated disease flare post vaccination but study on new disease occurs post Covid-19 vaccination is still lacking.

Objectives: To describe two SLE cases that diagnosed post Covid-19 vaccination.

Methods: Case report

Results: 14 years old girl, post Covid-19 vaccination 1st dose 3 weeks ago presented with 2 day history of giddiness, breathlessness, vomiting and diarrhea prior to admission. She also complained of frothy urine for the past 1 week associated with lower limbs swelling and facial puffiness. Clinical examination noted she had sparse hair, oral ulcers and discoid lupus at the ear concha. She also noted to have periorbital puffiness with pedal edema. Lung auscultation noted bi-basal crepitations. Blood investigation noted ANA positive (1:640, speckled) with low complement 3 (0.1g/L). Her full blood count showed leukocytosis (3100 UL) with low lymphocyte count of 810UL. UFEEME noted protein of 3 + and red blood cell of 2 + with normal renal profile. Her serum albumin was 22g/L. Chest x ray showed clear lung field with no cardiomegaly. Her 24-hour urine protein showed proteinuria of 2.345g/dl and her renal biopsy showed mesangial proliferative lupus nephritis class ii. She was given intravenous methylprednisolone 500mg OD for 3 days and discharged with tapering dose of prednisolone, hydroxychloroquine, calcium supplements, perindopril and frusemide. Another case was a 17 year-old female, post covid-19 vaccination 10 weeks, presented with 3 weeks history of bilateral lower limbs weakness with difficulty in getting up from chair. She also had fever on and off with cough for 1 week. There was no alopecia, oral ulcer, facial rash or photosensitivity. No joints pain. Clinical examination noted presence of proximal myopathy with stable vital signs. Other systemic examinations were unremarkable. Blood investigation noted ANA positive (1:640, homogenous and speckled) with low complements level (C3 0.19g/L and C4 0.049g/L).Her creatine kinase was 2367U/L and EMG showed evidence of irritable myopathic process which is consistent with inflammatory myositis. Her TFT was normal. Myositis panel showed anti-Ku and anti-Ro 52 were positive. She was treated as SLE with myositis and intravenous methylprednisolone was given. She discharge well with tapering dose of prednisolone and azathioprine. Her creatine kinase showed improvement with immunosuppression therapy and she was advised on intensive physiotherapy.

Conclusion: The onset of these two SLE cases were occurred within the 2 month of post covid-19 vaccination. Whether Covid-19 vaccination direct contribute to the occurrence of SLE remained inconclusive. More studies are required to show its correlation between onset of SLE and Covid-19 vaccination.

References: NIL

Disclosure of Interests: None declared

CENTRAL RETINAL ARTERY OCCLUSION (CRAO) LEADING TO BILATERAL BLINDNESS; DUE TO BOTH ARTERITIC AND NON-ARTERITIC ISCHEMIC OPTIC NEUROPATHY

S. Sunari.Subasinghe@gmail.com1, C. Byanwila2, O. Temizsoylu3, K. Ramesal4. 1Medway NHS Foundation Trust, Rheumatology, Gillingham, United Kingdom; 2East Sussex NHS Health Care Trust, Stroke Medicine, Eastbourne, United Kingdom; 3Moorfield Eye Hospital NHS Foundation Trust, Ophthalmology, London, United Kingdom; 4East Sussex NHS Health Care Trust, Histopathology, Eastbourne, United Kingdom

Background: Giant cell arteritis (GCA) is a large vessel vasculitis which is common in the elderly. It affects the cranial branches of the aorta, commonly superficial temporal, posterior ciliary and retinal arteries. Hence blindness can be one of the dreaded complications of the disease which makes prompt diagnosis and treatment of utmost importance. Sometimes atypical presentations and concurrent pathologies can make the timely diagnosis of the disease difficult. Therefore it is very important for clinicians to be vigilant of the varied presentations of the GCA and coexisting vascular risk factors.

Objectives: A 78-year-old Caucasian male was presented with acute onset blindness of the left eye. It started as few blotchy patches in the peripheral visual field and gradually became diffuse visual loss over a few days. He denied any headache, temporal tenderness, tongue or jaw claudication or symptoms of polymyalgia rheumatica. Following ophthalmology review he was diagnosed to have CRAO with marked disc pallor without any evidence of retinal embolii. He was in sinus rhythm, no carotid bruits or cardiac murmurs were noted. His comorbidities were hypertension and hypercholesterolemia. He was assessed in the transient ischaemic attack clinic for screening for vascular risk factors and started on antiplatelets.
Methods: Three months later he re-presented with visual loss in the right eye. Apart from the mild tenderness of the right temporal region noticed when trimming his hair he had no symptoms of GCA. He was started on dual antiplatelets and urgently referred to ophthalmology who diagnosed central retinal artery occlusion of right eye with clear demonstration of emboli in all the arcades of the central retinal artery. A temporal arterial biopsy was performed.

Results: His CRP was 19mg/l & ESR was 18mm/hr initially. During the second presentation both ESR (35) and CRP (40) were further elevated. His carotid doppler did not show significant stenosis in internal carotid arteries. ECG at presentation was in sinus rhythm however 24 hour holter monitoring after involvement of both eyes showed paroxysmal atrial fibrillation (PAF). Transthoracic echocardiogram was normal. His temporal arterial biopsy showed destruction of the internal elastic lamina with lymphohistiocytic infiltration and occasional giant cells in keeping with a diagnosis of GCA. Patient was started on prednisolone 60 mg daily followed by a tailing off regime and antiplatelets were changed to anticoagulation due to PAF. His vision improved mildly, only in the right eye in the way of perception of hand movements.

Conclusion: CRAO is an ocular emergency and is the ocular manifestation of a stroke. The usual presentation is a painless unilateral visual loss leading to profound blindness and is commonly due to non arteritic causes like carotid artery stenosis, cardiogenic embolism, small vessel disease and rarely due to arteritic causes like GCA. Accurate identification of the aetiology is very important to avoid further recurrence. By consensus multiple retinal emboli usually exclude GCA(11). However considering, the patient's age and recurrence of CRAO while on antiplatelets led us to consider occult GCA. 21.2% of patients with GCA induced vision loss do not have any systemic symptoms of the disease(2). Hence there should be a high index of suspicion when an elderly person presents with ischaemic ocular manifestations especially optic nerve and retinal ischaemia even in the presence of another plausible explanation like PAF.

REFERENCES:

Disclosure of Interests: None declared

AB1513 SIROLIUMUS INDUCED INFLAMMATORY ARTHROPATHY
K. Behary1, S. Srinangan1,1Medway Maritime Hospital, Rheumatology, Gillingham, United Kingdom

Background: Sirolimus is a non-calcinurine immunosuppressant commonly used in patients with organ transplantation to prevent rejection. While various inflammatory syndromes have been described post-sirolimus use, it is uncommon to have inflammatory arthritis to sirolimus. We present a patient who developed significant joint inflammation following sirolimus use.

Results: Our patient is a 39 year old gentleman who had a heart transplant in 1992 following dilated cardiomyopathy. He was switched to sirolimus after concerns about chronic kidney disease and graft vascular disease. Six weeks later, he developed bilateral foot pain and swelling which prevented him from weight bearing. He had an MRI which showed significant bone marrow oedema in the midfoot tarsal bone and basal metatarsals. He then had a nuclear scan which showed highly increased and symmetrical uptake in both mid feet affecting the cuneiform and second, third and fourth bases of the metatarsals. The appearances showed increased osteoblastic activity with increased vascularity which was more in keeping with bone inflammation/infection and no osteonecrosis. His C-reactive protein was elevated at 148. This improved to 30 after cessation of the sirolimus. Blood cultures were negative. Of significance in his history, he also suffers from gout and has had previous monoarticular flares involving his wrist, elbow and index finger. However, he was placed on febuxostat 80mg in 2018 with excellent response. His serology was negative for anti-CCP and Rheumatoid factor. His urate levels were controlled at 374. He was also found to be HLA-B27 positive, but there was no evidence of inflammatory back pain.

He was placed on a tapering course of prednisolone and coupled with the cessation of the Sirolimus, his pain and swelling resolved. In follow-up clinic appointments, he remained in remission from his inflammatory arthritis and did not require any additional treatment but continued on Mycophenolate Mofetil and Ciclosporin for his cardiac transplant.

Conclusion: There are many studies investigating the use of sirolimus as an anti-inflammatory agent in autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. The mechanisms include down regulation of IL-17 and IL-6. However, the induction of an inflammatory arthritis by sirolimus can paradoxically occur as sirolimus causes a reduction in the STAT-3 and the anti-inflammatory cytokine IL-10. There has been raised levels of IL-6 and TNFα in serum of patients with inflammatory sequelae post sirolimus therapy. This disequilibrium of inflammatory cascade is related to the ability of Sirolimus to inhibit mammalian target of rapamycin (mTOR) which then subsequently modulates these effects. In general, these pro-inflammatory sequelae are mild and tend to resolve after cessation of the drug. Although our patient had severe arthritic manifestations which required steroid therapy, his symptoms were transient after removal of Sirolimus.

REFERENCES:

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.1526

AB1514 AN UNUSUAL ASSOCIATION BETWEEN THROMBOTIC THROMBOCYTOPENIC PURPURA AND PRIMARY ANTIPHOSPHOLIPID SYNDROME
R. Santeante1, G. Montozzi1, L. Gamba1, S. Salvucci2, L. Manfredi2, G. Moroncini3,1Ospedali Riuniti Ancona University Hospital, Internal Medicine Residency Program, Ancona, Italy;1Ospedali Riuniti Ancona, Internal Medicine, Ancona, Italy

Background: Thrombotic thrombocypenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy characterized by microangiopathic haemolytic anaemia, consumption thrombocytopenia and organ injury, particularly kidney failure and neurological manifestation. Two forms are distinguished: the hereditary one, caused by a deficit of the metalloproteinase ADAMTS13, and the idiopathic one characterized by the presence of antibodies directed against ADAMTS13. The second one is the most common. There are various subgroups of acquired TTP associated with HIV infection, sepsis, pregnancy, autoimmune disease, disseminated malignancies and drugs. Antiphospholipid syndrome (APS) is a clinical immunological condition characterized by thromboembolic events, repeated miscarriages or stillbirth and thrombocytopenia; it can be a primary disorder or due to connective tissue disease, in particular systemic lupus erythematosus.

Objectives: We describe a case of TTP associated with a primary APS. The real clinical challenge lies in the differential diagnosis between TTP and anti-phospholipid antibody syndrome.

Methods: A 37-year-old man presented to the emergency department for short-term episodes of anesthesia of the right upper limb and face with spontaneous resolution. In his past medical history, he suffered of antiphospholipid syndrome treated with warfarin. Upon admission, blood tests revealed severe thrombocytopenia, haemolytic anaemia with schistocytes on peripheral blood smear, low thrombin time and prolongation in the prothrombin time. Neurological symptoms were assessed by electroencephalogram and CT brain, resulted negative, while a brain MRI revealed acute-subacute ischemic stroke. Based on these findings we suspected a diagnosis of TTP, subsequently confirmed by reduced activity of ADAMTS-13 with borderline ADAMTS-13 inhibitory antibodies. Immunological testing confirmed positivity of antiphospholipid antibodies and antinuclear antibodies.
Results: According to the last guideline3 about management of acute episode of TTP, immediate therapy with high-dose corticosteroids (prednisone 1 mg/kg) and plasmapheresis was started and then we added infusion of rituximab (375 mg/m²/week for 4 times). Efficacy of treatment was evaluated by weekly dosage of ADAMTS13 activity, with a gradual rise in values (3 – 78%) and improvement in symptoms and laboratory examination. After persistent remission, we gradually reduced steroid therapy. Few months later, in February 2021, patient developed a bilateral comorbid pneumonia, that required hospitalization, oxygen - therapy (also with C-PAP) and endovenous antibiotics. After two weeks patient was discharged from hospital in good clinical health and he was subjected to periodic outpatients visits. Disease activity was in remission, so steroid therapy was reduced and recently we added hydroxychloroquine for APS. Some days ago patient developed COVID – 19 infection, despite vaccination, and he was treated with monoclonal antibodies, with good clinical response.

Conclusion: We have described a rare clinical case of TTP, despite concomitant warfarin treatment for primary anti-phospholipid syndrome. A careful follow-up of these medical conditions is recommended for patient’s fragility and for the risk of related serious clinical complications.

REFERENCES:

Disclosure of Interests: None declared

AB1515 ANCA-NEGATIVE PAUCI-IMMUNE GLOMERULONEPHRITIS AS A PARANEOPLASTIC MANIFESTATION OF SARCOMATOID MALIGNANCY

M. Ehtesham1, S. H. B. Waqar2, L. Farrukh1, M. A. Shabbir1, R. Peredo-Wende3,
1Albany Medical Center, Internal Medicine, Albany, United States of America; 2SUNY Downstate Medical Center, Internal Medicine, Brooklyn, United States of America; 3Albany Stratton VA Medical Center, Rheumatology, Albany, United States of America

Background: Pauci-immune glomerulonephritis (PIGN) is a type of small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA). However, about 10-20% of PIGN patients have negative ANCA serologies. PIGN as a paraneoplastic syndrome is rarely described in literature with a few cases reporting an association with lung cancer.

Objectives: We describe a case of ANCA negative glomerulonephritis in a patient with underlying malignant sarcoma responsive to rituximab.

Methods: An 80-year-old female was admitted with complaints of upper abdominal pain and new onset hematuria for 2 days. Vital signs were stable, and physical exam was remarkable for mild tenderness on deep epigastric palpation. Initial laboratory workup was significant for acute kidney injury with serum creatinine of 2.1 mg/dl (creatinine two months ago at outpatient visit was 1.0 mg/dl). Urinalysis showed 4 + proteinuria and dysmorphic red blood cells. CT scan of the abdomen revealed a soft tissue mass surrounding the celiac artery and a right renal hypodense mass. Further serologies to elucidate the cause of kidney injury revealed normal perinuclear-ANCA and cytoplasmic-ANCA levels. Renal biopsy was positive for focal segmental necrotizing and crescentic glomerulonephritis consistent with pauci-immune vasculitis. She also underwent right adrenal and celiac mass biopsy; both revealed malignant spindle and epithelioid cell neoplasm consistent with undifferentiated pleomorphic sarcoma (UPS). Our patient was treated with four rounds of plasmapheresis followed by 800mg rituximab infusion which decreased her creatinine to 1.7 mg/dl and resolved hematuria within 10 days of admission. She was followed up in rheumatology clinic two weeks later where she denied further hematuria and was given another round of 600mg rituximab infusion.

Results: UPS is a rare soft tissue cancer with a 5-year survival rate as low as 15% in metastatic disease. Paraneoplastic manifestations of UPS are seldom described in literature due to poor prognosis of the disease and low annual incidence. PIGN is scarcely reported in association with lung carcinoma in a few case reports[1, 2]. It is interesting to note that in these cases there was antecedent chemotherapy raising suspicion of vasculitis induced by adjuvant agents. As our patient did not receive chemotherapy, PIGN was deemed to be a paraneoplastic phenomenon secondary to malignant sarcoma.

Conclusion: This case underscores the importance of recognizing sarcoma as a possible etiology of paraneoplastic ANCA-negative PIGN. We also explain how plasmapheresis and rituximab may play a role in the treatment of renal dysfunction in these patients.

REFERENCES:

Disclosure of Interests: None declared

AB1516 A CASE OF SEVERE ANCA ASSOCIATED VASCULITIS AFTER COVID-19 VACCINATION

I. Qaisar1, K. Sunmboye2, 1Leicester Royal Infirmary, Rheumatology, Leicester, United Kingdom; 2Leicester Royal Infirmary, Rheumatology, Leicester, United Kingdom

Background: The world is currently rocking to and fro in the midst of the COVID-19 viral storm and vaccinations have played a pivotal role in calming this. Although COVID-19 vaccines have been thoroughly assessed and studied before being rolled out to the general population, there have been reports of post-vaccination complications in limited number of subjects strongly associated with COVID-19 vaccinations[1].

Objectives: To report a case of severe ANCA associated vasculitis after COVID-19 vaccination.

Methods: A case report and discussion.

Results: In view of this, we report the case of a 77 year old caucasian male who developed severe ANCA associated vasculitis (AAV) after two doses of AstraZeneca vaccine and one booster dose of Pfizer COVID-19 booster. He presented with acute onset inflammatory arthritis with mononeuritis multiplex with bilateral foot drop and left radial and ulnar nerve forearm weakness in typical asymmetrical pattern two weeks after the Pfizer vaccination. He had a raised MPO-ANCA titre of 66 U/L, an Elisa reactive protein of 131mg/L, and reactive thrombocytosis of 458 X 10^9/L. Nerve conduction study confirmed mononeuritis multiplex in the bilateral peroneal nerves and left radial and ulnar nerve. A total body CT had excluded malignancy and paraneoplastic associations and Gullan-Barre diagnosis was also excluded. The patient was treated with 3 days of intravenous methylprednisolone 1g daily then given intravenous Rituximab 1g, two weeks apart. He is currently undergoing rehabilitation in view of the vasculitic neuropathy from his diagnosis.

Conclusion: Diagnosis of AAV is often delayed or missed by other medical specialties due to its varied presentation. AAV should be suspected in a patient with paraesthesia/weakness in keeping with mononeuritis multiplex or other peripheral neuropathy in the absence of an alternative explanation (e.g. diabetes,B12 deficiency) and in particular with a wrist or foot drop.Exposure to certain drugs and substances of abuse such as cocaine, hydralazine and propylthiouracil has been implicated with AAV.While short-term side effects of COVID-19 vaccine resemble those of other vaccines, long-term side effects remain unknown[2]. Rare side effects continue to surface as millions of people receive COVID-19 vaccines around the world.

REFERENCES:
[2] https://doi.org/10.1136/bmj.m1070

Disclosure of Interests: None declared
DOI: 10.1136/annrheumdis-2022-eular.2748

AB1517 SYNOVITIS COMPLICATING THE COURSE OF COMMON VARIABLE IMMUNODEFICIENCY: CAUSAL OR COINCIDENTAL?

M. Yasmine1, S. Miladi2, A. Fazaai1, H. Bousaa1, L. Souenbi1, K. Oueniche1, S. Kassaib1, S. Chekili1, K. Ben Abdelghani1, A. Laatari1, Merghani Slim Hospital, Rheumatology, Tunis, Tunisia

Background: Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by hypogammaglobulinemia and an increased susceptibility to recurrent bacterial infections. Even though several immunological defects are involved in the pathogenesis of CVID, the genetic background of the disease...
remains unidentified [1]. Autoimmunity in CVID is not restricted to hematologic cells, as rheumatologic complications occur in perhaps 10% of patients, with females being more affected [1].

**Objectives:** Here we report a case of a CVID complicated with RF negative synovitis.

**Methods:** We report a case of a 36-year-old woman who was referred to our department for oligoarthritis. She had a history of primary immune deficiency revealed at the age of 30 with recurrent pulmonary infections. The disease was complicated with type 1 diabetes and bronchiectasis and was treated with annual infusion of immunoglobulin. The patient presented with pain and swelling in both knees evolving for two months. On physical examination, she had synovitis in both knees. Laboratory investigations revealed normal blood count with elevated C-reactive protein (CRP) and erythrocyte sedimentation rate: 36.2mg/l, and 32 mm/h respectively. Synovial fluid aspiration analysis of the knee revealed an inflammatory liquid without crystals. Bacterial culture was negative. Her serum was negative for Rheumatoid Factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody and antinuclear Antibodies (ANA). Knee ultrasound revealed synovitis in both knees with Doppler signal. The Magnetic resonance imaging (MRI) of the knees showed active synovitis without any erosion. Ophthalmological assessment showed severe dry eye syndrome. As Sjögren's syndrome was suspected, we performed a salivary gland biopsy that was normal.

**Results:** The patient did not fulfill criteria for auto-immune rheumatic related disease. She was treated with intrarticular glucocorticoids injections, with complete resolution of symptoms and disappearance of effusion on ultrasound. A follow-up was scheduled after one month. The synovitis has been attributed to rheumatologic involvement in the context of immune deficiency.

**Conclusion:** We report a rare case of RF negative synovitis complicating the course of CVID. Even though the symptoms could be mild compared to a typical RF+RA, it is important to educate clinicians as to the importance of maintaining a high index of suspicion about this rare, yet potentially treatable disease. Future research is indicated to understand the etiopathogenesis of rheumatologic manifestations in CVID.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3176

**AB1519**

### CASE REPORT OF A HARD TO TREAT DERMATOMYOSITIS AFTER A COVID-19 INFECTION AND SUBSEQUENT VACCINATION

**P. Peteva1, L. Marinchev1.** UHMH Sofimed, Sofia, Bulgaria, Rheumatology Department, Sofia, Bulgaria

**Background:** A 50 years old woman, a medical doctor, came to our department with symmetrical proximal muscular weakness, several months after Covid-19 infection and three weeks after a second dose of Covid-19 mRNA vaccine. The patient had no prior or family history of autoimmune diseases and take no medicines. In the past she undergone an operation for double-kidney with frequent urinary infections. Objective findings have shown symmetrical proximal muscular weakness and classic signs of dermatomyositis - Gottron's papules, shawl and holter signs, periungual vasculitis.

**Objectives:** We present a case of a 50 old woman with clinical and laboratory proven dermatomyositis, starting three weeks after a second dose of a Covid-19 mRNA vaccine without other reasons.

**Methods:** The laboratory tests showed elevated CPK, lactate dehydrogenase, aspartate aminotransferase and alanine aminotransferase, high ANA – 1:1280 and myositis specific autoantibodies- anti-NXP2 and anti-Mi-2- beta. The electromyography showed myopathic changes and the muscle MRI – symmetrical edema of mm.obturateur and mm.adductor brevis. We exclude diseases that may mimic inflammatory myopathies. We made a cancer screening – whole body MRI, colonoscopy, gastroscopy, mammography and gynecological exam, immunoblot for detection of paraneoplastic syndrome-associated neuronal antibodies, with no detection of cancer. Muscle biopsy of m.vastus lateralis showed attenuating muscle inflammation with advancing muscle atrophy and fibrosis.

**Results:** The diagnose dermatomyositis was made according Bohan and Peter criteria and we start a high dose (1mg/kg/day) glucocorticoid therapy with good initial clinical and laboratory effect. Two months after starting a therapy muscle weakness worsened together with difficulty of swallowing. We excluded steroid myopathy after second EMG and lack of improvement when tapering the GS dose. Methylprednisolone 20 mg weekly was added as a steroid sparing drug with good response, but was stopped because flare of pyleonephritis. According to the opinion of dermatologist hydroxychloroquine was started for a couple of weeks, because of active skin manifestations. Muscle weakness worsened on the background of treatment, which was stopped. We started a therapy with intravenous immunoglobulins and considered therapy with cyclophosphamide or azathioprine after urinary infection. Because the patient was infected for a second time with covid-19, although vaccine, we continued only with glucocorticoids and anti-osteoporotic therapy.

**Conclusion:** The etiology and pathogenesis of inflammatory myopathies are not fully clarified so far. We speculate that the infection with Covid-19 as well as mRNA vaccine trigger inflammatory myopathy and compromise the patient's immunity for poor treatment response with glucocorticoids and immunosuppressives. On the other hand advanced muscle atrophy and fibrosis within a short period show that suspected triggering factors could be a reason for difficult to treat such type of dermatomyositis.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3517

### Table 1. Investigations:

<table>
<thead>
<tr>
<th>Week 0</th>
<th>Week 28</th>
<th>Week 48</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>5.5</td>
<td>7.8</td>
</tr>
<tr>
<td>Creatine (mg/dl)</td>
<td>1.43</td>
<td>1.35</td>
</tr>
<tr>
<td>Albumin (mg/dl)</td>
<td>1.8</td>
<td>2.5</td>
</tr>
<tr>
<td>Urine analysis</td>
<td>Protein: 2+</td>
<td>Protein: 1+</td>
</tr>
<tr>
<td>CECT Thorax</td>
<td>Left upper lobe solitary nodule</td>
<td>Resolved</td>
</tr>
<tr>
<td>MRI orbit</td>
<td>RT orbital pseudotumor with optic atrophy</td>
<td></td>
</tr>
<tr>
<td>Renal Biopsy</td>
<td>Focal proliferative sclerosis gloc-mernephritis</td>
<td>No crescents.</td>
</tr>
<tr>
<td><strong>Oral tissue biopsy</strong></td>
<td>Pakaging granuloma</td>
<td></td>
</tr>
<tr>
<td><strong>PR3 ANCA(ELISA)</strong></td>
<td>57.63</td>
<td></td>
</tr>
<tr>
<td><strong>MPO ANCA(ELISA)</strong></td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td><strong>ANA</strong></td>
<td>Negative</td>
<td></td>
</tr>
<tr>
<td><strong>C3/C4</strong></td>
<td>161.0/32.0 (normal)</td>
<td></td>
</tr>
<tr>
<td><strong>ACE levels</strong></td>
<td>25.3 (normal)</td>
<td></td>
</tr>
<tr>
<td><strong>IgG4</strong></td>
<td>2.73</td>
<td></td>
</tr>
<tr>
<td><strong>BVAS</strong></td>
<td>20</td>
<td>5</td>
</tr>
<tr>
<td><strong>VDI</strong></td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

**Abbreviations:** hpf: high power field, CECT: Contrast enhanced computed tomography, PR3: proteinase3, MPO: Myeloperoxidase, ANA: Antinuclear antibodies, ACE: Angiotensin converting enzyme, BVAS: Birmingham vasculitis activity score, VDI: Vasculitis damage index.
doses of IVIG 2g/kg was given; infection treated with antibiotics and regular dressing. After resolution of infection 6 doses of cyclophosphamide as per EUVAS protocol and Rituximab 2 gm was given along with the first dose of Cyclophosphamide.

Results: At 48 weeks of follow up, he continues to be in sustained clinical remission without steroids. He has received additional 500 mg of rituximab at 28 weeks. His lung nodules and vasculitic ulcers of leg healed over 34 weeks. He has developed saddle nose deformity for which reconstruction is planned.

Conclusion: Steroid free remission in GPA may be possible without Avacopan.

REFERENCES:

Figure 1. Clinical features of GPA

Disclosure of Interests: None declared

AB1520 EFFECTIVE TREATMENT OF TOCILIZUMAB IN PATIENTS WITH REFRACTORY ADULT-ONSET STILL’S DISEASE

T. Cheng1, Z. Chen1, J. Tan1, Y. Jiang2, Z. Liao2. 1Third Affiliated Hospital of Sun Yat-sen University, Rheumatology and Immunology Department, Guangzhou, China; 2Third Affiliated Hospital of Sun Yat-sen University, Rheumatology and Immunology, Guangzhou, China

Background: Pro-inflammatory cytokines such as interleukin 6 (IL-6) are involved in the pathogenesis of adult-onset Still’s disease (AOSD). Anti-IL-6 agents such as tocilizumab have been tried to treat AOSD successfully.

Objectives: To access the efficacy of tocilizumab in the treatment of AOSD patient refractory to, or with initial treatment.

Methods: We reviewed three cases with refractory AOSD treated with tocilizumab. All patients fulfill the Cush criteria for AOSD. All patients performed blood culture, auto-antibodies test and bone marrow test to exclude infectious diseases, other rheumatic diseases and tumors. All patients received broad-spectrum antibiotics and had no response. All patients received glucocorticoid therapy and at least one kind of anti-cytokine therapies but didn’t have full response. Then the three patients received intravenous tocilizumab treatment of 8mg/kg every 2 weeks or 4 weeks.

Results: The first patient, a 21-year-old woman, performed positron emission tomography (PET-CT) and lymphoglandula pathology in addition to routine tests. She received high dose methylprednisolone (500mg per day for 3 days and followed by 80mg per day), gamma globulin injection (20g per day for 3 days) and baricitinib 4mg per day for 12 days, but had no response to the treatment. Then she received tocilizumab of 8mg/kg every 2 weeks and stopped baricitinib. And the symptoms and blood tests improved gradually, and the methylprednisolone dose reduced to 16mg per day at the last follow-up. The second patient is a 52-year-old man, and performed bone marrow cytology and PET-CT to excluded hematological diseases. He received methylprednisolone 80mg per day, adalimumab and tofacitinib treatment. But the patients still got recurrent fever, high ESR, CRP and serum ferritin. Then he stopped adalimumab and tofacitinib, and received tocilizumab of 8mg/kg every 2 weeks and reduced to 8mg/kg every 4 weeks because of economic factors. The patient did not develop fever and the inflammatory indexes such as ESR/CRP gradually decreased to normal range. And methylprednisolone dose reduced to 32mg nowadays.

The third patient is a 30-year-old woman and has recurrent AOSD for 15 years. She had tried glucocorticoids, methotrexate, iguratimod, baritinib and entanercept successively. Yet she still had recurrent arthritis on hand and knee, and elevated ESR/CRP/serum ferritin. Additionally she suffered femoral head necrosis because of excessive doses of glucocorticoid. The patient received tocilizumab 8mg/kg every 4 weeks, then joint symptoms and inflammatory indicators improved significantly. The methylprednisolone dose was also successfully reduced to 4mg/d.

The Figure 1 showed the main course of disease evolution.

Figure 1. The main course of disease evolution.

Disclosure of Interests: None declared
A 67-year-old man with longstanding history of cervical lymphadenopathy (LAD) presented to the Rheumatology Clinic due to intermittent lower extremity rash, anemia, worsening fatigue for the past 2 years. Prior history includes controlled DM type 2 and HTN treated with amlopidine. Denied photosensitivity, oral ulcers, sicca symptoms, Raynaud’s phenomenon, weight loss, fever, chills, joint pain. Physical examination revealed bilateral cervical LAD and a non-blanching purpuric rash on lower extremities consistent with leukocytoclastic vasculitis, later confirmed with biopsy. Further workup revealed, normo-ctylic anemia (Hgb 9.9gm/dl), positive ANA (>1:2560, homogeneous pattern), positive dsDNA (211 IU/ml), positive histone Ab (413 IU/ml), low C3 (28 mg/dl), low C4 (1mg/dl), increased IgG level (2878/mg/dl) and proteinuria 1100/mg/g with microalbuminuria, no urine casts. ANCA serologies were negative. Pan-CT showed mild cervical, retroperitoneal, pelvic LAD bilaterally. Kidney biopsy was performed and revealed severe diffuse tubulointerstitial nephritis, plasma cell rich (more than 40 IgG4 + cells seen per 40X hpf), with moderate to severe chronicity in addition to diffuse mesangial IgG and IgM staining with focal tubular basement membrane IgG and C1 staining consistent with mesangial proliferative class II lupus nephritis. Patient was started on medium dose steroids (due to DM), hydroxychloroquine and azathioprine with resolution of LCV rash, anemia, LAD, improvement in dsDNA, proteinuria, complement levels.

Conclusion: SLE and IgG4-RDs are autoimmune diseases that cause damage to several organs, including lymph nodes and kidneys. Both are associated with hypocomplementemia and involvement of autoantibody-producing B cells and plasma cells. Patients with SLE present with positive antibodies such as anti-dsDNA and anti-sm antibodies. On the other hand, IgG4-RD lack a specific antibody and the IgG4 is thought to be the result of the pathogenic process and not pathogenic by itself (1,2). Histologically, SLE presents with inflammatory cell infiltration in organs, whereas IgG4-RD is associated with fibrosis and organ enlargement (1-3). Lupus nephritis causes wide spectrum renal involvement whereas IgG4-RD most common presentation is tubulointerstitial nephritis (TIN), although other glomerular lesions, such as membranous nephropathy, have been reported (1-2). Our patient presented with proteinuria, positive antibodies for SLE, low complements and high levels of IgG4 which makes us consider that both diseases were active at time of diagnosis. This was confirmed by renal biopsy showing chronicity of IgG4-RD and lupus nephritis as a consequence of progression of autoimmunity. The treatment of both conditions is immunosuppression with medium to high doses of steroids and a steroid sparing agent. Due to patient preference he was started on azathioprine along with medium dose steroids and plasma cells. Patients with SLE present with positive antibodies such as anti-dsDNA and anti-sm antibodies. Nevertheless, some patients have been reported with kidney involvement secondary to both conditions (2-3). We present a case of an elderly male with a new diagnosis of IgG4-RD and SLE with kidney involvement.

Objectives: To present a case with a new concomitant diagnosis of IgG4-RD and SLE.

Methods: Case report.

Results: A 67-year-old man with longstanding history of cervical lymphadenopathy (LAD) presented to the Rheumatology Clinic due to intermittent lower extremity rash, anemia, worsening fatigue for the past 2 years. Prior history includes controlled DM type 2 and HTN treated with amlopidine. Denied photosensitivity, oral ulcers, sicca symptoms, Raynaud’s phenomenon, weight loss, fever, chills, joint pain. Physical examination revealed bilateral cervical LAD and a non-blanching purpuric rash on lower extremities consistent with leukocytoclastic vasculitis, later confirmed with biopsy. Further workup revealed, normocytic anemia (Hgb 9.9gm/dl), positive ANA (>1:2560, homogeneous pattern), positive dsDNA (211 IU/ml), positive histone Ab (413 IU/ml), low C3 (28 mg/dl), low C4 (1mg/dl), increased IgG level (2878/mg/dl) and proteinuria 1100/mg/g with microalbuminuria, no urine casts. ANCA serologies were negative. Pan-CT showed mild cervical, retroperitoneal, pelvic LAD bilaterally. Kidney biopsy was performed and revealed severe diffuse tubulointerstitial nephritis, plasma cell rich (more than 40 IgG4 + cells seen per 40X hpf), with moderate to severe chronicity in addition to diffuse mesangial IgG and IgM staining with focal tubular basement membrane IgG and C1 staining consistent with mesangial proliferative class II lupus nephritis. Patient was started on medium dose steroids (due to DM), hydroxychloroquine and azathioprine with resolution of LCV rash, anemia, LAD, improvement in dsDNA, proteinuria, complement levels.

Conclusion: SLE and IgG4-RDs are autoimmune diseases that cause damage to several organs, including lymph nodes and kidneys. Both are associated with hypocomplementemia and involvement of autoantibody-producing B cells and plasma cells. Patients with SLE present with positive antibodies such as anti-dsDNA and anti-sm antibodies. On the other hand, IgG4-RD lack a specific antibody and the IgG4 is thought to be the result of the pathogenic process and not pathogenic by itself (1,2). Histologically, SLE presents with inflammatory cell infiltration in organs, whereas IgG4-RD is associated with fibrosis and organ enlargement (1-3). Lupus nephritis causes wide spectrum renal involvement whereas IgG4-RD most common presentation is tubulointerstitial nephritis (TIN), although other glomerular lesions, such as membranous nephropathy, have been reported (1-2). Our patient presented with proteinuria, positive antibodies for SLE, low complements and high levels of IgG4 which makes us consider that both diseases were active at time of diagnosis. This was confirmed by renal biopsy showing chronicity of IgG4-RD and lupus nephritis as a consequence of progression of autoimmunity. The treatment of both conditions is immunosuppression with medium to high doses of steroids and a steroid sparing agent. Due to patient preference he was started on azathioprine along with medium dose steroids with adequate clinical response. This case highlights the fact that SLE and IgG4-RD can coexist and it should be suspected in elderly patients with lymphadenopathy and renal disease.

REFERENCES:

Disclosure of Interests: None declared

## AB1523-HPR

**USABILITY AND ACCEPTABILITY OF A NEW AUTOINJECTOR DEVICE AND ITS ASSOCIATED APP IN AUSTRALIAN, FRENCH, GERMANY AND JAPANESE RHEUMATOLOGY PATIENTS**

R. Alten1, M. Latymer2, D. C. Gruben3, S. Moss4, H. Kameda5; 1Schlosspark-Klinik Medicine Internal Medicine, Rheumatology, Berlin, Germany; 2Pfizer Ltd, I&I Medical Affairs, Sandwich, United Kingdom; 3Pfizer Global Biostatistics and Data Management, Groton, United States of America; 4Farm Design, A Flex Company, Human Factors Engineering, Hollis, United States of America; 5Pfizer R&D UK, Devices Centre of Excellence, Cambridge, United Kingdom; 6Toho University (Ohashi Medical Center), Division of Rheumatology, Tokyo, Japan

**Background:** Smartclic/ClicWise is a new reusable autoinjector with a dose-dispensing cartridge for subcutaneous self-administration of biotherapeutics in development for patients with rheumatoid arthritis (RA) and other diseases. The device can connect to an optional mobile phone app (Smartclic or ClicNote in Japan) to aid in tracking injections and other treatment or symptom data.

**Objectives:** The study objective was to collect ease of use and usability data on the Smartclic injector and companion app from experienced patients.

**Methods:** After completing a patient profiling questionnaire, adult patients (≥18 yrs) from Australia, France, Germany, and Japan with RA, psoriatic arthritis, or an original diagnosis of juvenile idiopathic arthritis who were prescribed an injectable biologic were enrolled in this study. For Japan, only patients with RA were enrolled. Each patient received training individually on the use of the Smartclic injector device and insertable cartridge and gained experience by performing simulated injections. Participants completed a questionnaire with evaluations of the device categories (number of questions: ‘ease of use’ (14), ‘usability effectiveness’ (11), ‘benefit of features’ (8), and ‘form factor’ (7). Participants also separately received a storyboard presentation summarizing the key features of the app, during which patients could explore the app (on a phone with either an android or iOS operating system), and completed 16 questions on the connectivity, usability, and benefit. Responses were recorded as Likert scale ratings from 1 (‘extremely negative’) to 7 (‘extremely positive’). Respondents also provided an estimate of patient training time for the device. Mean values were reported. The percentage of negative (Likert scale rating 1-2), neutral (3-5), and positive (6-7) responses for each category were determined.

**Results:** A total of 139 patients (mean age [range], 52 [18-84] yrs; 73% female) participated in the study (Table 1). Mean scores (percentage of positive responses) for the device were: ease of use 6.43 (86.2%), usability effectiveness 6.39 (86.5%), benefit of features 6.46 (89.4%), form factor 6.10 (77.2%); and 6.06 (74.2%) for connectivity and benefit of the app (Figure 1). Mean estimated time for training a patient to effectively use the device/cartridge was just under 9.5 min (range, 0-30 min).

**Table 1. Participant characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Patients (N=139)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>38 (27)</td>
</tr>
<tr>
<td>Female</td>
<td>101 (73)</td>
</tr>
<tr>
<td><strong>Mean age (range), yrs</strong></td>
<td>52 (18-84)</td>
</tr>
<tr>
<td><strong>Age groups, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>18-30 yrs</td>
<td>11 (8)</td>
</tr>
<tr>
<td>31-59 yrs</td>
<td>85 (61)</td>
</tr>
<tr>
<td>&gt;60 yrs</td>
<td>43 (31)</td>
</tr>
<tr>
<td><strong>Diagnosis, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>104 (75)</td>
</tr>
<tr>
<td>Psoriatic arthritis</td>
<td>34 (24)</td>
</tr>
<tr>
<td>Juvenile idiopathic arthritis*</td>
<td>1 (1)</td>
</tr>
<tr>
<td><strong>Handedness, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Right-handed</td>
<td>128 (92)</td>
</tr>
<tr>
<td>Left-handed</td>
<td>9 (6)</td>
</tr>
<tr>
<td>Ambidextrous</td>
<td>2 (1)</td>
</tr>
</tbody>
</table>

*Originally diagnosed with juvenile idiopathic arthritis, but now aged ≥18 yrs.

**Conclusion:** Rheumatology patients responded positively on the new autoinjector device and app across all categories, indicating its suitability for self-administration of biotherapeutics.

---

## AB1524-HPR

**THERAPEUTIC RESULTS AND QUALITY OF LIFE CHANGES OF PATIENTS WITH RHEUMATOID ARTHRITIS IN PROSPECTIVE REAL LIFE CLINICAL SETTINGS**

V. Boyadoshieva1, K. Tachkov2, N. Stoilov3, K. Mitov2, G. Petrova2, R. Stoilov2; 1Medical University of Sofia, Sofia, Bulgaria; 2Medical University of Sofia, Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Sofia, Bulgaria

**Background:** Rheumatoid arthritis (RA) as a chronic inflammatory disease significantly deteriorating the physical functioning and quality of life (QoL) of the patients. The introduction of biological therapy in its management significantly improves both the physical functioning and QoL. Many biological medicines are already available on the market claiming higher effectiveness and high cost of therapy but the difference in real clinical setting is not well studied.

**Objectives:** The aim of this study is to analyze the therapeutic results of RA therapy with different biologicals and the first JAK inhibitor in real life clinical settings.

**Methods:** This study was performed like a prospective, observational, longitudinal study at the biggest rheumatology clinic in Bulgaria during the period 2012 – 2020. Written informed consent was obtained by the recruited 197 patients, out of which 174 remain at the end of the observation. Patients naïve to biological therapy were assigned on the available at that moment biologic DMARDs (infliximab, etanercept, adalimumab, rituximab, golimumab, certolizumab, tocilizumab), and the first JAK inhibitor (tofacitinib). The clinically proven RA according ACR (1987) and/or ACR/EULAR (2010) criteria, previous therapy with DMARDs, and/or methotrexate, suitable for therapy with biological medicines or JAK inhibitors were formulated as inclusion criteria, while infectious diseases, cardiac insufficiency (NYHA III and IV grade), malignant hypertension, any neoplasms or proliferative lymph diseases within the previous 5 years were the exclusion criteria. We evaluate DAS28-CRP, HAQ and Short form 36 measured at the initiation of biological therapy, after 6, and 12 months of follow up. We analyze the changes in the two major subgroups of SF36 - physical (MCS) and mental health (PCS). Descriptive statistic, Dispersion analysis with non-parametric Kruskal-Wallis test comparing the effect of different therapies between first and third measurement was performed. Linear correlation and regression analysis (Pearson type) comparing the effect of different therapies was also performed.

**Results:** The age and gender distribution were similar between the groups on bDMARDs and tsDMARD. Number of patients per therapeutic DMARD vary between 20 to 30, with prevailing part of the female and average age between 53.2 (SD 9.13) and 57.15 (SD 9.05) years. Average length of the disease is also similar between the groups with highest value of patients assigned to tocilizumab (14.13 (SD 8.38) years) and lowest for infliximab (6.4 (SD 2.92) years), respectively. All observed indicators for disease control and QoL improve after the initiation of the biological or JAK inhibitor therapy. We also analyze the effect of therapies on DAS-28, HAQ, SF-36 (PCS, MCS). Dispersion analysis for the effect

**Acknowledgements:** Medical writing support was provided by Jacob Evans, of Engage Scientific Solutions.

**Disclosure of Interests:** Rieke Alten Consultant of: AbbVie, Bristol-Myers Squibb, Gilead, Lilly, Novartis, Pfizer and UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Galapagos, Gilead, Janssen, Lilly and Pfizer, Mark Latymer Shareholder of: Pfizer, Employee of: Pfizer, David C Gruben Shareholder of: Pfizer, Employee of: Pfizer, Lisa Gunther-Lavergne Employee of: Farm Design, Simon Moss Shareholder of: Pfizer, Employee of: Pfizer, Hideito Kameda Speakers bureau: AbbVie, Asahi-Kasei, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Lilly, Mitsubishi-Tanabe, Novartis and Pfizer, Consultant of: AbbVie, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Sanofi and UCB, Grant/research support from: AbbVie, Asahi-Kasei, Boehringer Ingelheim, Chugai, Eisai and Mitsubishi-Tanabe

**DOI:** 10.1136/annrheumdis-2022-eular.772
of therapy measured through DAS28 between 1st and 3rd measurement shows a statistically significant difference in between the average effect of therapies (P = 0.005141). The most effective is the golimumab (Median difference = 2.745), followed by rituximab (median = 2.965) and etanercept (median = 2.070). The difference in effect measured with HAQ is higher with tofacitinib (median = 0.563). Followed rituximab and infliximab (median = 0.500 for both). Less effective appears to be etanercept (median difference 0.250). All differences are statistically significant (p = 0.012589). Regarding the changes in the QoL measured with SF-36 MCS and PCS there is no statistically significant differences in the average effect of different therapy agents. The median effect of different therapeutic agents regarding physical group of SF-36 (PCS) is similar and changes are not statistically significant. The same is valid for SF36 psychological components (MCS).

Conclusion: Tofacitinib and bDMARDs improve both clinical results and QoL of patients with RA naïve to biological therapy. The difference between tofacitinib and bDMARDs is not statistically significant for both clinical and QoL results.

Disclosure of Interests: Vladimiria Boyadzhieva Speakers bureau: Abbvie, Roche, Konstantin Tachkov: None declared, Nikolay Stolov, Speakers bureau: Abbvie, AMGEN, Konstantin Mitov: None declared, Guenka Petrova: None declared, Rumen Stolov Speakers bureau: Abbvie, Pfizer, Roche, Boehringer ingelheim, MSD,


**AB1525-HPR** EXAMINATION OF PHYSICAL FITNESS IN CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: A COMPARATIVE STUDY

S. Bozuk1, B. Basakci Calik1, E. Gur Kabul2, Z. Ecki Tekin3, S. Yuksel4, 1Pamukkale University, School of Physical Therapy and Rehabilitation, Denizli, Turkey; 2Izmir University Faculty of Health Sciences, Physiotherapy and Rehabilitation, Denizli, Turkey; 3Ankara City Hospital, Pediatric Rheumatology, Ankara, Turkey; 4Pamukkale University Faculty of Medicine, Pediatric Rheumatology, Denizli, Turkey

Background: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Although its etiology is not known exactly; Immunological susceptibility and environmental factors (infections, stress, trauma) are emphasized (1). These children have low activity levels since a young age, and significantly affects their disease ability and quality of life of both themselves and their families. For all these reasons, it is very important to realize the daily living problems (2).

Objectives: We aimed to investigate the awareness of patients using SCBA about the drug's utilization and storage conditions.

Methods: Seventy children/adolescents (mean age: 13.4±2.31 years 35 JIA; mean age: 12.9±2.31 years 35 healthy) were included in the study. After recording demographic data, the functionality levels of the children/adolescents with JIA were evaluated by CHAQ (Childhood Health Assessment Questionnaire), all lower extremity muscle strengths were evaluated by the manual muscle test device, and the physical fitness levels were evaluated by the Brockport physical fitness test battery which is grip strength, push-up test, curl-up test, trunk lift test, shoulder stretch, back saver sit-rectch test, calf, triceps, subscapular skinfold thickness and PACER 20 meter test. While the disease activities of children/adolescents with JIA were evaluated with JADAS-27 (Juvenile Arthritis Disease Activity Score), quality of life were evaluated with the PedsQL 3.0 Arthritis Module (Pediatric Quality of Life Inventory).

Results: As a result of the comparative analysis; In terms of functionality which is CHAQ dressing (p=0.008), eating (p=0.011), reaching (p=0.001), rising (p<0.001), walking (p=0.001), holding (p=0.016), hygiene (p=0.011), activity (p=0.00), total score (p=0.00), pain (p=0.00), general well-being (p=0.00) in terms of all sub-parameters, there was no significant difference in favor of healthy children/adolescents (p>0.05). In terms of physical fitness which is grip strength (p=0.041), PACER 20 meter test (p<0.000), trunk lift test (p=0.018) and curl-up (p=0.00) tests, there was a significant difference in favor of the healthy group (p<0.05). There was no significant difference between the groups in terms of other physical fitness tests (p>0.05). When only the lower extremity muscle strengths were compared, only right hip external rotation (p=0.023) showed a difference in muscle strength. There was no correlation between JADAS-27 score and physical fitness scores (p=0.065) of children/adolescents with JIA, except for the push-up test (p=0.01). In terms of JADAS-27 score and some PedsQL child form which is pain, total score and activities of daily living of children/adolescents with JIA there was a significant relationship. In terms of JADAS-27 score and some PedsQL parent form which is pain and total score of children/adolescents with JIA there was a significant relationship. However there was no relationship in terms of the other parameters (p>0.05).

Conclusion: According to the results of our study, it was observed that the functionality and physical fitness levels of children/adolescents with JIA were lower than their healthy peers, and physical fitness was not affected by disease activity. However, it has been observed that the disease ability of children/adolescents with JIA affects the quality of life of both themselves and their families. For all these reasons, it is very important to examine children/adolescents with JIA in terms of participation in physical activity and exercise, with informative training aimed at improving their physical fitness.

**REFERENCES:**


**Disclosure of Interests:** None declared

**AB1526-HPR** AWARENESS ASSESSMENT IN PATIENTS USING SUBCUTANEOUSLY ADMINISTERED BIOLOGICAL AGENTS ABOUT DRUG UTILIZATION

F. Tuncer1, O. Ozdemir Isik1, A. Yucei1, A. Celle1, 1Kocaeli University, Faculty of Medicine, Rheumatology, Kocaeli, Turkey, Rheumatology, Kocaeli, Turkey

Background: Subcutaneous biological agents (SCBA) are commonly used in rheumatologic disorders, their storage in appropriate conditions and correct administration have importance. Informing the patient adequately and correctly is essential. Storing the drug in inappropriate conditions reduces its effectiveness, and affects the response to treatment (1). When these treatments are initiated, information on all the mentioned topics is provided to the patients, and they undergo hands-on training. Finally, the patients is questioned in outpatient follow-up about whether a problem has occurred or not (2).

Objectives: This study aimed to investigate the awareness of patients using SCBA about the drug's utilization and storage conditions.

Methods: Demographic data of 100 patients diagnosed with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, using SCBA who presented to our outpatient clinic between January 2021 and June 2021, were recorded, and survey questions were asked.

Results: One hundred patients (46 females-54 males) were included in the study. Sixty-one patients were diagnosed with ankylosing spondylitis, 20 patients with rheumatoid arthritis, and 19 with psoriatic arthritis. The patients' mean age was 44.6±11.07 years. The mean duration of SCBA use was 74.5 (2-222) months.

The patients' replies to the survey questions are summarized in Table 1. Most patients performed the injection themselves in both genders, whereas some women received help from paramedics (p=0.041). Forty percent of the patients with education level of high school or higher had a concern regarding drug use, whereas this rate was 21% in patients with education level of primary school. It was determined that the anxiety level decreased with increasing level of education (p=0.032).

Table 1. The patients' replies to the survey questions

<table>
<thead>
<tr>
<th>Question</th>
<th>N=100</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate of patients who read the patient consent form before starting the drug use</td>
<td>88 (88)</td>
<td></td>
</tr>
<tr>
<td>Concern regarding drug use</td>
<td>23 (23)</td>
<td></td>
</tr>
<tr>
<td>Malnagranity</td>
<td>7 (7)</td>
<td></td>
</tr>
<tr>
<td>Increase in infection</td>
<td>7 (7)</td>
<td></td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>70 (70)</td>
<td></td>
</tr>
<tr>
<td>Not worried</td>
<td>88 (88)</td>
<td></td>
</tr>
<tr>
<td>Doctor</td>
<td>18 (18)</td>
<td></td>
</tr>
<tr>
<td>Nurse</td>
<td>7 (7)</td>
<td></td>
</tr>
<tr>
<td>Nunsedeorductor</td>
<td>65 (65)</td>
<td></td>
</tr>
<tr>
<td>Patients who were informed about when to interrupt drug use</td>
<td>86 (86)</td>
<td></td>
</tr>
<tr>
<td>Situations where drug use is suspended</td>
<td>84 (95,3)</td>
<td></td>
</tr>
<tr>
<td>Flu and lebri infection</td>
<td>68 (79,1)</td>
<td></td>
</tr>
<tr>
<td>Use of antibiotics</td>
<td>39 (45,3)</td>
<td></td>
</tr>
<tr>
<td>Herpes simplex virus infection</td>
<td>65 (65)</td>
<td></td>
</tr>
<tr>
<td>hypostasis</td>
<td>4 (4)</td>
<td></td>
</tr>
<tr>
<td>State of waiting before administering the drug</td>
<td>7 (7)</td>
<td></td>
</tr>
<tr>
<td>Don't wait</td>
<td>71 (71)</td>
<td></td>
</tr>
<tr>
<td>20-30 minutes at room temperature</td>
<td>6 (6)</td>
<td></td>
</tr>
<tr>
<td>&gt;30 minutes at room temperature</td>
<td>5 (5)</td>
<td></td>
</tr>
<tr>
<td>Hand warming and then administration</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Soak in hot water</td>
<td>6 (6)</td>
<td></td>
</tr>
<tr>
<td>Rate of controlling the expiration date before administering the drug</td>
<td>64 (64)</td>
<td></td>
</tr>
<tr>
<td>Rate of patients who control the clarity of the drug</td>
<td>75 (75)</td>
<td></td>
</tr>
<tr>
<td>Rate of hand washing before administering the drug</td>
<td>83 (83)</td>
<td></td>
</tr>
<tr>
<td>Injection site cleaning</td>
<td>6 (6)</td>
<td></td>
</tr>
<tr>
<td>Don't clean</td>
<td>66 (66)</td>
<td></td>
</tr>
<tr>
<td>With the swab from the drug box</td>
<td>24 (24)</td>
<td></td>
</tr>
<tr>
<td>With alcohol</td>
<td>3 (3)</td>
<td></td>
</tr>
<tr>
<td>With a wet wipe</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td>Nunsedeorductor</td>
<td>84 (84)</td>
<td></td>
</tr>
<tr>
<td>The person performing the injection</td>
<td>71 (100)</td>
<td></td>
</tr>
</tbody>
</table>

It was observed that in patients who used multiple SCBA for a long time, taking the drug out of the refrigerator and applying it after waiting for the optimum time,
controlling the expiration date of the drug and hand washing before the application decreased over time.

Conclusion: Evaluating the patient’s SCBA treatment background is essential for correct treatment practice. Our study revealed that in forming patients on drug use not only initially but also at certain intervals is essential.

REFERENCES:


Disclosure of Interests: None declared

AB1527 - HPR

FUNCTIONAL SOMATIC SYNDROMES AND INSOMNIA IN PATIENTS WITH FIBROMYALGIA, RELATIONSHIP WITH THE INTENSITY OF THE PAIN SYNDROME

V. Bykov1, V Khomenko1, L. Shvets1, L. Pereteliuk1, O. Ostapchuk2, I. Shvets1, M. Stanislavchuk1, National Pirogov Memorial Medical University, Rheumatology, Vinnytsia, Ukraine

Background: Fibromyalgia (FM) is a chronic diffuse musculoskeletal pain manifested by numbers of functional somatic syndromes (FS). The pathogenesis and pathophysiology of fibromyalgia includes changes of autonomic nervous system, which can be realized in the abnormal functioning of many organs and systems.

Objectives: Analyze the frequency and spectrum of functional somatic syndromes and insomnia in patients with fibromyalgia, relationship with the intensity of pain.

Methods: We examined 102 women with FM according criteria ACR (1990), mACR (2010) with mean age 41.7±9.4 years (M±SD), duration of the disease was 8.4 ± 6.28 years. The severity of pain, fatigue, sleep disorders was assessed with a visual analog scale (VAS).

Results: The severity of pain (VAS) in patients with FM ranged from 2.1 to 8.5 and averaged 5.1±1.5. The severity of fatigue was estimated at 6.5 ± 1.7, sleep disorders - 6.3 ± 2.7. In the examined group of patients with FM, in addition to typical clinical manifestations, significant numbers of functional disorders were diagnosed: insomnia - 86.3%, irritable bowel syndrome – 99.8%, postural tachycardia syndrome - 53.9%, hyperventilation syndrome - 52.9%, bladder pain syndrome – 50.0%. According to the intensity of pain, patients were divided into 3 groups. The 1st group included patients with pain less than 4 points (<25th percentile, n = 21), the 2nd - with the pain severity 4–6 points (25-75th percentile, n = 56), the third group - patients with pain more than 6 points (>75th percentile, n = 25). According to the study, the frequency of functional somatic syndromes was not related to the intensity of pain. There was a positive correlation between the severity of insomnia and the intensity of pain (n=0.36; p<0.05). The same relationship was revealed between fatigue and pain (n=0.41; p<0.05).

Conclusion: Patients with FM have a wide spectrum of functional somatic syndromes. The changes described were not related to the severity of the pain syndrome. The presence of correlations between the severity of insomnia and the intensity of pain requires further research to develop algorithms for comprehensive treatment of identified disorders.

REFERENCES:

Disclosure of Interests: None declared


AB1528 - HPR

FULL BODY HAPTIC BODYSUIT - AN INSTRUMENT TO MEASURE THE RANGE AND SPEED OF MOTION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS (axSpA)

N. Weiher1, R. Lemnart2, J. Knizla2,3, S. Bayat2,3, M. Sadeghi4, A. A. Ibrahim5, C. Karastanion6, A. Sushkarev7, N. Ramzieanzadeh2, S. Kahali3, A. Mirzayev1, L. Schuster2,3, G. Schett1, B. M. Escoffier1, A. Kleyer3,6,7,8,9 on behalf of https://www.medizin3.uk-erlangen.de/en/research/research-main-focus/

1Friedrich-Alexander University (FAU) Erlangen Nürnberg, Lehrstuhl für Maschinelles Lernen und Datenanalytik, Department Artificial Intelligence in Biomedical Engineering (AIBE), Erlangen, Germany; 2University Hospital Erlangen, Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; 3Deutsches Zentrum Immunkonferenz, Universitätspoliklinik Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany

Background: Movement of the spine is restricted in axial spondyloarthritis (axSpA) [1]. Spine function is usually assessed by the Bath Ankylosing Spondylitis Metrology Index (BASMI), which is based on a limited set of defined motions that are measured semiquantitatively in the spatial dimension but not in the temporal dimension. Sensor-based measurement of spine function in axSpA patients is in its infancy but may provide a deeper and more detailed understanding of the impact of axSpA on the impairment of spine function [2,3]. In theory, unbiased full body assessment of spine motion may open a new dimension in function analysis in axSpA.

Objectives: To test if a full body-based haptic capturing of spine motion is technically feasible and can pick up the measurements of BASMI items 1-5. Furthermore, we aimed to investigate whether such measurements are accurate and reproducible comparing to BASMI scores done by rheumatologists. Lastly, we sought to measure velocity of spine movements to allow spatiotemporal analysis of motion.

Methods: For full-body haptic assessment of spine motion a full-body haptic suit (Teslasuit; VR Electronics Ltd, London) was used that consists of a smart textile two-piece bodysuit that not only captures range and speed of motion but also provides biometric and haptic feedback. This device is currently tested in clinical trials (https://teslasuit.io/rehabilitation/) but has not been tested in rheumatic diseases such as axSpA [4]. Since there is no pre-defined technical solution for measuring BASMI, we used the integrated inertial measurement units (IMUs) of the suit (Figure 1a). The suit is recording the position and rotations of its IMUs and is transforming the raw data to position coordinates and joint angle of the bones. We implemented an algorithm that is accessing the sensor data and is calculating the BASMI measurements as well as velocity. Assessment were done in healthy individuals. BASMI was obtained 3 times by teslasuit followed by standard BASMI measurement by 2 independent rheumatologists. In addition, rotational movements with their maximum torso speed to evaluate angular velocity were performed (Figure 1b). Measurements were compared using absolute values and relative standard deviation (which is the standard deviation normalized by the mean).

Results: Five healthy individuals (all males, age: 276 ± 1.8 years, height: 178 ± 5cm; weight 70.0 ± 8.0kg) were assessed. Teslasuit measurements were well tolerated. Technically, we were able to calculate BASMI item 3 and 5, finger-to-floor distance and the velocity of the spine movement using the position data of hand, talius and upper back sensors (Figure 1a, b). Due to absence of sensors at the head and the required back areas, BASMI 1, 2, 4 could only partially be captured and require further programming, which is currently performed. Only marginal differences were detected regarding the relative standard deviations of measurements between teslasuit and rheumatologists (BASMI 3: rheumatologists 8.5%; suit 10%; BASMI 5: rheumatologists 5.4%; suit 4.9%) (Figure 1c). The speed of spinal motion could be measured with an average angular velocity of 172.2 degrees/sec over the entire rotation motion and an average maximum angular velocity of 4172 degrees/sec.

Conclusion: This study shows that full-body haptic-suits can capture spinal motion including parts of the BASMI score. In addition, they allow to measure the speed of spinal movement, which might be an important and so far unrecognized factor to test the impact of axSpA on spinal function. Based on these results, full-body haptic-suits will be tested in axSpA patients in the future. Furthermore, technical solutions are currently developed to implement the remaining BASMI scores into the suit as well as connections from the suit to virtual reality devices for patients and doctors.

REFERENCES:
CROSS-CULTURAL ADAPTATION, RELIABILITY AND CONVERGENT VALIDITY OF THE TURKISH VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUALITY OF LIFE QUESTIONNAIRE

S. Bayram 1, F. Sarlı 1, G. G. Pala 2, B. Özkızıltas 3, A. Tufan 2, D. Oskay 1. 1Gazi University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation, Ankara, Turkey; 2Gazi University, Faculty of Medicine, Department of Internal Medicine-Rheumatology, Ankara, Turkey

Background: To completely comprehend the burden of an illness and the success of its treatment, it is essential to analyze the patients’ perspective on health-related quality of life. Because of this, the Primary Sjögren’s Syndrome-Quality of Life questionnaire (PSS-QoL) was developed, which evaluates the disease’s physical and psychosocial effects in PSS patients.

Objectives: In the literature, there is no Turkish questionnaire evaluating quality of life in patients with PSS. Therefore, the aim of this study was to translate and evaluate cross-culturally adaptation the PSS-QoL into the Turkish language and investigate its convergent validity and reliability in Turkish-speaking population with PSS.

Methods: Patients completed PSS-QoL questionnaire, the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) and Euro-Qol 5D (EQ-5D). To test the convergent validity of PSS-QoL, correlation between PSS-QoL and EQ-5D and ESSPRI were assessed with Pearson correlation test. In order to investigate the internal consistency and test-retest reliability, Cronbach’s alpha and Intra-class Correlation Coefficient (ICC) values interpreted, respectively.

Results: Seventy-nine patients with PSS (53.30 ± 11.98 years, 74F/5M) were enrolled in the study. Good and moderate correlations were found between the PSS-QoL and ESSPRI (r: 0.818, p<0.001) and EQ-5D-pain/discomfort (r:0.589, p<0.001). Correlations of subscales of PSS-QoL with subscales of ESSPRI and EQ-5D ranged from fair to strong (Table 1). Cronbach’s alpha and ICC values of the PSS-QoL total score were found to be as 0.955 and 0.914, respectively, indicating excellent reliability.

Table 1. Correlations of PSS-QoL and EQ-5D, ESSPRI

<table>
<thead>
<tr>
<th>PSS-QoL</th>
<th>Physical</th>
<th>Discomfort</th>
<th>Dryness</th>
<th>Psychosocial</th>
</tr>
</thead>
<tbody>
<tr>
<td>EQ-5D-mobility</td>
<td>0.543*</td>
<td>0.514*</td>
<td>0.678*</td>
<td>0.761*</td>
</tr>
<tr>
<td>EQ-5D-usual activities</td>
<td>0.466*</td>
<td>0.342*</td>
<td>0.371*</td>
<td>0.233*</td>
</tr>
<tr>
<td>EQ-5D-pain/discomfort</td>
<td>0.589*</td>
<td>0.561*</td>
<td>0.710*</td>
<td>0.442*</td>
</tr>
<tr>
<td>EQ-5D-anxiety/depression</td>
<td>0.574*</td>
<td>0.570*</td>
<td>0.557*</td>
<td>0.436*</td>
</tr>
<tr>
<td>EQ-5D-HS</td>
<td>0.625*</td>
<td>0.540*</td>
<td>0.495*</td>
<td>0.437*</td>
</tr>
<tr>
<td>ESSPRI-dryness</td>
<td>0.589*</td>
<td>0.706*</td>
<td>0.448*</td>
<td>0.722*</td>
</tr>
<tr>
<td>ESSPRI-pain</td>
<td>0.673*</td>
<td>0.694*</td>
<td>0.824*</td>
<td>0.421*</td>
</tr>
<tr>
<td>ESSPRI-fatigue</td>
<td>0.790*</td>
<td>0.668*</td>
<td>0.665*</td>
<td>0.497*</td>
</tr>
</tbody>
</table>

EQ-5D, Euro-Qol-5 dimension; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; HS, health state; PSS-QoL, Quality of Life in Primary Sjögren’s Syndrome. *p<0.05; **p<0.001.

Conclusion: This study demonstrated that Turkish version of PSS-QoL is reliable and valid tool to assess quality of life in PSS patients. Therefore, PSS-QoL can be used to assess quality of life in Turkish-speaking PSS patients.

REFERENCES:

Acknowledgements: This work was (partly) funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB 1483 – Project-ID 424219336, EmpkinS.

Disclosure of Interests: None declared

Background: Primary Sjögren’s syndrome (pSS) is a rare systemic autoimmune disease with no specific treatment at present. To better assess patient symptoms, we have developed a web application (WebApp) to collect patient symptom intensity on a regular basis.

Objectives: To evaluate the daily variability of symptoms using the WebApp. We also evaluated its ease of use.

Methods: 45 consecutive patients with pSS were included in 3 referral centers. Symptoms were assessed during the baseline and 3 month visits. We collected the VAS relating to fatigue, dryness and pain as well as the ESPPR-I score. Patients used the WebApp daily for 3 months. The variability of symptoms over time was assessed by the predicted median error. This value was determined using a linear regression model, in order to predict the value at the 3rd month, then this value was compared to the actual value collected at the 3rd month during the clinical visit. The ease of use of the WebApp was assessed using a satisfaction score (SUS score).

Results: Of the 45 patients included, 91.1% were women with an average age of 57 years, and low systemic disease activity (84.4% had an ESSDAI score below 5). The intensity of the symptoms collected during the clinical visits was similar at baseline and at 3 months. The values of the median error for each measurement are between 0.5 and 0.8. The 3-month predicted median error values ranged from 2 to -3. The patients all used the web application for 3 months with good attendance (80% of data completion) and were satisfied with this tool (median SUS score = 90).

Conclusion: Symptoms of pSS fluctuate from day to day in the majority of patients, making a point measurement imprecise. The developed WebApp is easy to use, and could allow more sensitive detection of the effect of a therapeutic intervention. This tool will soon be evaluated during prospective interventional clinical trials.

Acknowledgements: I would like to thank all those people who have helped and were directly or indirectly involved in this study.


---

**Table 1. Demographic characteristics and results GOHAI-SP**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>GOHAI-SP</th>
<th>Score, mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD)</td>
<td>46.23 (15.49)</td>
<td>51.87 (8.30)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td>Female: 289(91.5)</td>
<td>51.92</td>
</tr>
<tr>
<td>Classification GOHAI-SP</td>
<td>Good: 229 (72.47)</td>
<td>56.34</td>
</tr>
<tr>
<td></td>
<td>Moderate: 24 (7.59)</td>
<td>46.95</td>
</tr>
<tr>
<td></td>
<td>Poor: 63 (19.93)</td>
<td>37.5</td>
</tr>
<tr>
<td>Rheumatologic diseases, n (%)</td>
<td>Rheumatoid arthritis: 120 (37.97)</td>
<td>51.45</td>
</tr>
<tr>
<td></td>
<td>Systemic lupus erythematosus: 53 (16.77)</td>
<td>51.81</td>
</tr>
<tr>
<td></td>
<td>Osteoarthritis: 19 (6.02)</td>
<td>53.57</td>
</tr>
<tr>
<td></td>
<td>Other diagnoses: 124 (39.24)</td>
<td>52.26</td>
</tr>
</tbody>
</table>

GOHAI-SP: Geriatric/General Oral Health Assessment Index Spanish Version; (SD) Standard deviation, n; number, (%) Percentage.


---

**AB1532-HPR**

**GERIATRIC/GENERAL ORAL HEALTH ASSESSMENT INDEX AS EARLY DETECTION TEST OF ORAL DISEASES IN RHEUMATOLOGY.**

B. T. Chavarin Arquillo1, J. C. Riegatorres1, A. Cárdenas1, D. C. Rubio Torres1, L. R. Aguilar Rivera1, L. G. Espinosa Banuelos1, D. A. Galarza-Delgado1.

1Hospital Universitario “Dr. José Eleuterio González”; Rheumatology; Monterrey, Mexico

Background: The oral health in patients with rheumatologic diseases is frequently affected because of chronic inflammation, slow rate of saliva production and poor self-care. These factors affect quality and psychosocial well-being, causing pain, difficulty biting and chewing, even malnutrition. The Geriatric/General Oral Health Assessment Index Spanish Version (GOHAI-SP) consists in 10 items and values self-perception in oral health and wellness (1), validated and applied to young adults (2).

Objectives: 1. Describe the oral health measured by the GOHAI-SP in patients with rheumatic diseases.

Methods: a cross-sectional and observational study was conducted by January to May 2021 in rheumatology service of Hospital Universitario “Dr. José Eleuterio González” at Monterrey, Mexico. Patients with rheumatologic diseases was assessed with GOHAI-SP during their control consult, each item is valued like a Likert ordinal scale from 1 to 5, the best and worst possible score is 60-12 respectively, patients with score <45 is classified as poor oral health and >50 as good oral health. 2. Construct a web application (WebApp) easy to use, and could allow more sensitive detection of the effect of a therapeutic intervention. This tool will soon be evaluated during prospective interventional clinical trials.

Acknowledgements: I would like to thank all those people who have helped and were directly or indirectly involved in this study.


---

**AB1533-HPR**

**ASSOCIATED FACTORS OF FALL OR FRACTURE REPORTED BY RHEUMATOID ARTHRITIS PATIENTS IN ELECTRONIC MDHAQ DURING COVID-19 PANDEMIC**

I. Lineburger1, C. V. Breno2, V. Naomi Hirakata3 on behalf of Rheumatology Service, 1Hospital de Clínicas de Porto Alegre, Mestrado Profissional de Pesquisa Clínica, Porto Alegre, Brazil; 2Hospital de Clínicas de Porto Alegre, Rheumatology Service, Porto Alegre, Brazil

Background: The COVID-19 pandemic accelerated the use telemedicine for rheumatologic patients. Patient reported outcomes (PRO) can provide prioritization criteria for the form of face-to-face care in situations of social restriction, and optimization of early care by identifying high-risk patients.

Objective: To describe the oral health measured by the GOHAI-SP in patients with rheumatologic diseases.

Methods: of January to August 2021. A weblink was sent to MDHAQ in electronic platform. The study was approved by the ethics committee of Hospital de Clínicas de Porto Alegre – Brazil and all patients agreed with a Term of Informed Consent.

Results: A total of 129 RA patients completed the electronic MDHAQ, mean age was 60 years (S.D. 14) and 83% were female. The mean DAS28, SDAI and HAQ were 3.8 (S.D. 1.6), 4.2 (S.D. 1.0) and 1.2 (S.D. 0.7). Of those 129 patients, 14 reported a fall or fracture in the last 6 months of response and only 16 patients were physically active. Relevant symptoms known as factors associated with risk of fall and its prevalence in this study were: pain (82%), followed by articular pain (68%), fatigue (43%), muscle weakness (37%) and weight gain (22%). Among patients who reported a fall or fracture, 83% had a RADAI ≥ 16 and mean FAST3 (Fibromyalgia Assessment Screening Test) index of 19 (IC95%: 17-21). FAST3 based on MDHAQ and independent RADAI showed positively association with a reported fall or fracture for these patients, with a p value of 0.023 and 0.025, respectively. Other factors, such as high disease activity based on DAS28 or MDHAQ, obesity and age were not statistically significant with the reported episode.

Conclusion: Maintaining PRO is aligned with patient-centered care, allowing relevant data source and identification of high-risk patients - in our study: patients in pain, sedentary and in major risk of fracture. Also, use of combined in like FAST3 or independent articular pain scores such as RADAI, might be helpful to identify those high-risk patients in need for orientation for reinforcement of physical activity, prioritization for in person visits and early clinical adjustments.
HPR Epidemiology and public health (including prevention)

AB1534-HPR ASSESSMENT OF BACK PAIN IN NURSES WORKING IN HOSPITALS AND OUTPATIENT CLINICS

B. Nieradko-Iwanicka1,2, Medical University of Lublin, Chair and Department of Hygiene and Epidemiology, Lublin, Poland

Background: Back pain in a common health problem in nurses affecting 70-78% of them [1,2,3]. The risk of back pain in nurses increases by 35% for each additional working hour per day [2].

Objectives: The aim of the study was to find out if nurses working in hospital wards suffer more from back pain than their counterparts employed in the outpatient clinics.

Methods: An online survey was conducted with use of an questionnaire containing questions about body mass index (BMI), Revised Oswestry Low Back Pain Disability Scale (ROLBPDS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Numeric Rating Scale (NRS) for pain. Questions about seniority and working hours were included. It was uploaded and shared on the Google online survey platform. Participation was anonymous and voluntary. An invitation was mailed to the members of The Lublin Chamber of Nurses and Midwives.

A total of 163 nurses (161women and 2 men) aged 21-70 years filled in the questionnaire in February and March 2021. Of the group 82 were nurses from hospitals (NHs) and 81 from outpatient clinics (NOCs).

Results: The mean BMI of participants was 26.4kg/m². In NHs the mean BMI was 25.8kg/m² and in NOCs 27.8kg/m². Seventy five percent of HNs looked after lying patients. Ninety nine percent of NHs and 75% of NOCs suffered from back pain. In the questionnaire February and March 2021. Of the group 82 were nurses from hospitals (NHs) and 81 from outpatient clinics (NOCs).

The mean ROLBPDS rating was 15 which means moderate disability. In NOCs it was 13 and in NHs it was 17. The mean back pain NRS was 6. In NOCs it was 3 and in NHs it was 9 (p<0.05). There was a positive correlation between shift length and back pain measured with the NRS. As many as 5 participants had diagnosed seronegative spondyloarthropathy. In those mean BASDAI was 5.6±1 which means active disease.

The mean ROLBPDS rating was 15 which means moderate disability. In NOCs it was 13 and in NHs it was 17. The mean back pain NRS was 6. In NOCs it was 3 and in NHs it was 9 (p<0.05). There was a positive correlation between shift length and back pain measured with the NRS. As many as 5 participants had diagnosed seronegative spondyloarthropathy. In those mean BASDAI was 5.6±1 which means active disease.

NHs it was 9 (p<0.05). There was a positive correlation between shift length and back pain measured with the NRS. As many as 5 participants had diagnosed seronegative spondyloarthropathy. In those mean BASDAI was 5.6±1 which means active disease.

The mean ROLBPDS rating was 15 which means moderate disability. In NOCs it was 13 and in NHs it was 17. The mean back pain NRS was 6. In NOCs it was 3 and in NHs it was 9 (p<0.05). There was a positive correlation between shift length and back pain measured with the NRS. As many as 5 participants had diagnosed seronegative spondyloarthropathy. In those mean BASDAI was 5.6±1 which means active disease.

CONCLUSION: Nurses working in hospital wards experience significantly more back pain than their counterparts working in outpatient clinics. Long working hours increase the risk for the ailment.

REFERENCES:

Disclosure of Interests: None declared

HPR Interventions (educational, physical, social and psychological)

AB1535-HPR COURSE WITH GROUP SESSIONS TO START SELF-INJECTION OF BIOLOGICAL MEDICINE (ADALIMUMAB)

J. Schierbach Bøch1, B. A. Esbensn2, S. Skalsket Rasmussen3
1Rigshospitalet, Center for Rheumatology and Spine Diseases, Hellerup, Denmark; 2Rigshospitalet, Glostrup, Glostrup, Denmark

Background: Denmark decided in 2018 that Adalimumab should be the first-line biological of patients with inflammatory arthritis. Consequently, a higher number of patients needed to be given information about Adalimumab and learn how to do self-injections. The department focused on making optimum use of its resources while at the same time ensuring a high medical standard for this new task.

Objectives: To examine whether group instructions with a structured approach will provide the medical standard required to enable the patients to perform their own treatment at home. And also to examine whether participation in group sessions where the patients will have an opportunity to exchange experience with other people in a similar situation would be beneficial for them.

Methods: Design: An anonymous questionnaire survey. Setting: The training sessions took place at the Center for Rheumatology and Spine Diseases, Rigshospitalet, Gentofte, Denmark, and involved patients who were already consulting the outpatient clinic. Participants: Patients, ≥ 18 year, due to start on their therapy with Adalimumab, were referred to the group sessions irrespective of previous diagnosis, previous experience with other forms of biological therapy and/or experience with self-injection. A group consisted of between two and six participants. Course structure: Initially the participants were given group instructions in subjects such as effect, adverse effects, storage and precautions to be taken in the event of an infection. The patients were also given theoretic instructions in the administration of injections and an introduction to the injection pen (test model). Following this, the patients administered self-injections individually in private under guidance. Material: The questionnaire asked about whether the participants felt capable of managing their therapy at home and whether they had benefited from being instructed in a group. In addition to this, the patients were asked about background data such as gender and previous experience with injection techniques and biological therapy. The questionnaire also left room to offer more detailed comments. Analysis: Descriptive data analysis, including also the more detailed comments from the questionnaires.

Results: A total of twenty-five patients with inflammatory arthritis divided onto seven groups. Female: 15; male: 10. Bionaive, no experience with self-injection: 13 Bionaive, experience with self-injection: 6 Previous biological therapy, no experience with self-injection: 2 Previous biological therapy, experience with self-injection: 4

Figure 1.

After the group sessions, all of the patients felt they were capable of managing their own therapy and administering their own injections going forward. The patients were very much or to some degree happy that they were taught in groups and most replied that the questions/comments presented by the other participants were very relevant or relevant to some degree. Gender and previous experience with injection techniques and/or biological medicine did not affect patient satisfaction. Selected comments made by the patients:
“Found the group approach to be really good. Good to hear what the others said.” “It was really good to be part of a group. I would never have thought of asking the question that the other patients raised and it was relevant for me too.” “It was really good talking to others.” “Always good to meet others in the same boat.”

**Conclusion:** Group instructions with a structured approach are found to provide a medical standard which enables the patients to perform their own treatment at home. Participation in group sessions with others in the same situation as oneself is also found to be beneficial for the patients since this approach creates a space for dialogue and knowledge sharing by the participant.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.570

**REFERENCES:**


---

**AB1536-HPR DEVELOPING WORK-ON - VOCATIONAL REHABILITATION FOR PATIENTS WITH INFLAMMATORY ARTHRITIS**

C. M. T. Madsen1,2, J. Primdahl1,2, A. Bremander1,2, L. Eggø1, J. Reffstrup Christensen1,2,3,4, L. Eggen1, J. Reffstrup Christensen1,2,5,6,7.

**DOI:** 10.1136/annrheumdis-2022-eular.570

**Disclosure of Interests:** None declared

**AB1537-HPR INFLUENCE OF SEGMENTAL STABILIZATION AND PILATES ON NON-SPECIFIC CHRONIC LOW BACK PAIN IN BRAZILIAN ELDERLY: A PRELIMINARY STUDY.**

A. Torres Cruz1, P. De Oliveira Januário1, I. Coelho Baptista2, A. Da Rocha Rodrigues2, B. Libanio de Souza Castro3, G. Bezerra Oliveira4, I. Da Silva Palmeira5, T. De Fátima Cabral Dos Santos2, A. Pasqual Marques6

1Universidade de São Paulo – USP, Medical School, Department of, Speech Therapy, Physiotherapy and Occupational Therapy, São Paulo, Brazil., São Paulo, Brazil., São Paulo, Brazil., 2Centro Universitário de Barra Mansa - UBM, Department of Physiotherapy, Barra Mansa, Brazil

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1209

**REFERENCES:**


---

**AB1536-HPR DEVELOPING WORK-ON - VOCATIONAL REHABILITATION FOR PATIENTS WITH INFLAMMATORY ARTHRITIS**

C. M. T. Madsen1,2, J. Primdahl1,2, A. Bremander1,2, L. Eggø1, J. Reffstrup Christensen1,2,3,4, L. Eggen1, J. Reffstrup Christensen1,2,5,6,7.

**DOI:** 10.1136/annrheumdis-2022-eular.570

**Disclosure of Interests:** None declared

**AB1537-HPR INFLUENCE OF SEGMENTAL STABILIZATION AND PILATES ON NON-SPECIFIC CHRONIC LOW BACK PAIN IN BRAZILIAN ELDERLY: A PRELIMINARY STUDY.**

A. Torres Cruz1, P. De Oliveira Januário1, I. Coelho Baptista2, A. Da Rocha Rodrigues2, B. Libanio de Souza Castro3, G. Bezerra Oliveira4, I. Da Silva Palmeira5, T. De Fátima Cabral Dos Santos2, A. Pasqual Marques6

1Universidade de São Paulo – USP, Medical School, Department of, Speech Therapy, Physiotherapy and Occupational Therapy, São Paulo, Brazil., São Paulo, Brazil., São Paulo, Brazil., 2Centro Universitário de Barra Mansa - UBM, Department of Physiotherapy, Barra Mansa, Brazil

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.1209

**REFERENCES:**


PG obtained better results when compared to the SG regarding the activation of the transversus abdominis muscle. It is suggested to carry out studies with a greater number of participants, a longer treatment and follow-up time to complement these findings.

REFERENCES:


Acknowledgements: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Disclosure of Interests: None declared

DOI: 10.1136/annhemudiss-2022-eular.1388

AB1538-HPR

AMIGOS DE FIBRO (FIBRO FRIENDS): VALIDATION OF AN EDUCATIONAL PROGRAM TO PROMOTE THE HEALTH OF PATIENTS WITH FIBROMYALGIA IN BRAZIL.

M. Antunes1, A. Schmitt1, A. Pasqual Marques1. 1University of São Paulo, Department of Physiotherapy, Speech Therapy and Occupational Therapy, São Paulo - SP, Brazil

Background: Health education is a very important tool in the treatment of people with fibromyalgia. Health education acts as an excellent non-pharmacological treatment to promote health in fibromyalgia.

Objectives: To validate a multidisciplinary educational program to promote the health of people with fibromyalgia in Brazil, called Amigos de Fibro.

Methods: This is a methodological research with 45 individuals with fibromyalgia (target audience) and 23 health professionals (expert judges). Both groups used an instrument to assess the objectives, themes and proposed actions, relevance, writing style and structure of the program using the Delphi technique. The Content Validity Index (CVI) ≥ 0.78 and Kappa Coefficient ≥ 0.61 were used to analyze and validate the data.

Results: All items evaluated in both groups had a considerable minimum CVI and Kappa Coefficient to be valid. In the global assessment of Amigos de Fibro, the CVI of the target audience judges was 0.95, while the expert judges presented a value of 0.90. The Kappa Coefficient of the target audience judges was 0.85 and that of the expert judges was 0.90. Therefore, the instrument proved to be validated.

Conclusion: Amigos de Fibro was considered valid for its content and internal consistency, therefore, valid to be used by health professionals with the target audience in Primary Health Care in Brazil, allowing them to act as promoters of their health.

REFERENCES:

Acknowledgements: This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001.

Disclosure of Interests: None declared

DOI: 10.1136/annhemudiss-2022-eular.2201

AB1540-HPR

NURSING INTERVENTIONS FOR RHEUMATIC MUSCULOSKELETAL DISEASES (RMDs) PATIENTS ON BIOLOGIC THERAPY: A SYSTEMATIC LITERATURE REVIEW (SLR)

M. R. Melis1, K. El Aouf2, C. Bruni3, F. Bartoli3, G. Fioni3, S. Guiducci3, S. Bellando Randone1, S. Bambi1, L. Rasero3, M. Matsuuci-Cerinici2, I Careggi Hospital, Department of Experimental and Clinical Medicine, University of Florence, Rheumatology Unit, Florence, Italy; 1University of Florence, Department of Experimental and Clinical Medicine, Rheumatology Unit, Florence, Italy; 2University of Florence, Department of Health Sciences, Florence, Italy

Background: The support of the Rheumatology nurse to the management of patients who are affected by RMDs, characterized by remission and recrudescence and chronicity, may be strengthened by the investigation of their unmet needs and the identification of the necessary interventions to the continuity and quality of care.

Objectives: The aim of the present SLR is to identify the main nursing interventions to assure quality care in RMDs patients on biologic therapy.

Methods: Study design: a systematic search was conducted from 1990 to 2020 (01/01/1990- 2020/05/07). Inclusion criteria consisted of 1) patients with RMDs in accordance with American College of Rheumatology classification criteria and the American College of Rheumatology/European League against Rheumatism (ACR/EULAR); 2) in therapy with bDMARDS; 3) adult population > 18 years; 4) primary research only; 6) English language; 7) abstract available; and 8) relative quantitative studies; 9) nursing interventions and/or outcomes. Data sources: Medline, CINAHL, PsycINFO and EMBASE databases were used to search for relevant studies. Review management using the predetermined inclusion/exclusion criteria, two independent reviewers (MRM, KEA) screened records selected for eligibility based on titles and abstracts. Records meeting the inclusion criteria were retrieved and full texts were further assessed.

Critical Appraisal Skills
Program (CASP) tools were used to evaluate the quality of the included studies. Data from 8 studies were extracted independently by the reviewers.

**Results:** 1805 articles were retrieved after the review process, 8 articles met the inclusion criteria resulting in 1 randomized trial, 1 quasi-experimental study and 6 observational studies. The RMDs patient needs emerged concerning the psychosocial domain, the relationship with healthcare facilities and disease follow up to monitor symptoms. Moreover, three major nursing interventions related to these areas were identified: education, patient-centered care and data assessment.

**Conclusion:** Rheumatology nurses are part of a multidisciplinary team caring for patients on biologic therapy. Starting with accurate initial and ongoing data collection, rheumatology nurses can plan their interventions focusing primarily on patient education and tailored care based on actual needs. Further studies are necessary for research on aspects of patient-centered nursing care, including tele-nursing and Nursing Sensitive Outcomes in RMDs.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.2630

---

**AB1541-HPR IMPACT OF COUNSELLING, TELEPHONE-BASED SYMPTOMS TREATMENT TITRATION AND REMINDER CALL ON REGULAR FOLLOW UP AMONG COMMON RHEUMATOLOGICAL DISORDERS; A PROSPECTIVE COHORT STUDY**

V. Karte1, N. Gupta2, S. Malviya3, *BP Koirala Institute of Health Sciences, Internal Medicine, Dharan, Nepal;* 2*MGM Medical College, Anaesthesiology, Indore, India;* 3*Medanta Superspeciality Hospital, Rheumatology and Clinical Immunology, Indore, India*

**Background:** Poor adherence to rheumatologic diseases exist for various reasons.

**Objectives:** The objective of the study was to measure adherence with interventions.

**Methods:** It was a prospective cohort study for 52 weeks. Assuring adherence of 30%, power of the study as 90% and confidence interval 95% sample size was calculated as 323. Common rheumatologic disorders (Rheumatoid arthritis (RA), Spondyloarthropathy (SpA), Primary Sjogren's Syndrome (PSS) and Systemic Lupus Erythematosus (SLE)) patients with at least 15% from each group who presented first time in our clinic were followed up. The interventions were two separate sessions of face-to-face counselling during first initial visits, telephone-based titration of drugs if there was poor control of the presenting symptoms and two-day prior reminder phone call for next follow up.

**Results:** Among 323 enrolled patients 27% were compliant with previous treatments. The relative ratio of compliant groups under follow up with the rheumatologist versus other clinicians was 2.2. Median duration of diagnosis of the 60% previously diagnosed versus 40% newly diagnosed at our clinic was 18 months versus 7 days. Among 64 cases of PSS 86% were undiagnosed with median duration of symptoms of 4 years. Knowledge about consequences of poor treatment between pre verses post counselling was 40% and 78% respectively. (Table 1) Symptom controlled with telephone-based drug titration was achieved among 84% of cases (30%, 44%, 10% partial, nearly complete and complete improvement respectively). With the reminder call the adherence weans off to 85% at first follow up, 77% at third month and 53% at the end of year. By 52 weeks PSS had maximum adherence (78%) followed by SLE (58%), RA (42%) and SpA (42%). (Figure 1)

**Table 1. Comparison between pre and post intervention**

<table>
<thead>
<tr>
<th></th>
<th>RA (N=116)</th>
<th>axSpA (N=72)</th>
<th>SLE (N=71)</th>
<th>PSS (N=64)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Before intervention</td>
<td>3.5</td>
<td>2.5</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>- Median duration of diagnosis (years)</td>
<td>25</td>
<td>9</td>
<td>34</td>
<td>19</td>
</tr>
<tr>
<td>- Number of adherence (87%)</td>
<td>5</td>
<td>4</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>- Insight about the disease conditions</td>
<td>17</td>
<td>17</td>
<td>16</td>
<td>16</td>
</tr>
<tr>
<td>a.I don't have disease</td>
<td>30</td>
<td>17</td>
<td>16</td>
<td>31</td>
</tr>
<tr>
<td>b.I have disease due to external factors</td>
<td>28</td>
<td>23</td>
<td>25</td>
<td>11</td>
</tr>
<tr>
<td>c.I have disease due to internal factors</td>
<td>22</td>
<td>11</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>d/c' + I need medication for some time</td>
<td>&lt;1</td>
<td>2</td>
<td>&lt;1</td>
<td>2</td>
</tr>
<tr>
<td>e/c + I need medication per rheumatologist after intervention</td>
<td>49</td>
<td>30</td>
<td>41</td>
<td>50</td>
</tr>
<tr>
<td>- Median duration of diagnosis (weeks)</td>
<td>9</td>
<td>4</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>- Number of adherence at 52 weeks (170)</td>
<td>14</td>
<td>9</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>- Insight about the disease conditions</td>
<td>31</td>
<td>21</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>a.I don't have disease</td>
<td>37</td>
<td>34</td>
<td>37</td>
<td>32</td>
</tr>
<tr>
<td>b.I have disease due to external factors</td>
<td>37</td>
<td>34</td>
<td>37</td>
<td>32</td>
</tr>
<tr>
<td>c.I have disease due to internal factors</td>
<td>37</td>
<td>34</td>
<td>37</td>
<td>32</td>
</tr>
</tbody>
</table>

**Conclusion:** Early diagnosis, separate counselling sessions, effective control of symptoms and reminder to follow up significantly increases the adherence in rheumatological disorder.

**REFERENCES:**


**Acknowledgements:** I would like to acknowledge Dr Sanjay Geed medical superintendent Medanta Superspeciality Hospital Indore

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3560

---

**AB1542-HPR USING SOCIAL NETWORKS AS A SOURCE OF INFORMATION FOR RHEUMATOLOGICAL PATIENTS**

A. Sarapulova1, O. Teplyakova2, A. Sarapulova1, O. Teplyakova2, *USMU, Outpatient Therapy; Yekaterinburg, Russian Federation;* 2*USMU, Outpatient Therapy; Yekaterinburg, Russian Federation*

**Background:** The COVID-19 pandemic has brought significant changes to the work of healthcare professionals around the world. Technologies of telemedicine counseling and education of patients have become widespread. The largest platforms for informing patients are social networks such as Facebook, Instagram, Twitter.

**Objectives:** to study the possibilities and impact of the social network as a digital medical tool on the education and management of rheumatological patients.

**Methods:** The study was conducted in the form of a survey in the social network Instagram in the blog @reumatolog_sarapulova, dedicated to the rheumatological diseases, and was dedicated to the level of information. At the time of the survey, the number of subscribers to the blog was 4895 people, 223 people answered the questions submitted. The survey was conducted in a Google form and was anonymous.

**Results:** 86% of respondents lived in Russian Federation, 17.5% - in the survey region, 14% of patients were from other countries. 72% indicated the presence of rheumatic disease as the reason for reading the blog, 7% - disease in relation to the COVID-19 pandemic, 14% are guided by the desire to know more about rheumatological disorders, 68.5% of the respondents rated the information presented in the blog as very interesting (10 points on a scale from 0 to 10), 13.3% - 9 points and 9.1% - 8 points. It should be noted that none of the participants in the study gave less than 5 points.
The most interesting in the blog, the majority calls information posts (88.8%) and answers the questions (77.6%), 2 out of 3 patients (64.5%) after getting acquainted with the information provided began to know more about their disease, 14% began to lead a healthier lifestyle, 9.8% realized the need to visit a doctor. 83.3% of participants rated the information on the blog as more detailed than what they get at their doctor’s appointment, and 81% would seek advice from a blogger. When answering the question “Do you share the information you get from the blog with your health-care provider?” 47.2% noted that they prefer not to report, 28% - report, while 44.9% decided to report. In general, 86% agreed that social networks are an important source of medical information, and as other sources they noted self-search for information in the Internet and visiting a doctor. 65.7% of the respondents asked the question to the author of the blog and received a response that was helpful and on the Instagram page @lupusufmg

Conclusion: social networks are an important source of information for patients and a means of choosing a medical specialist. However, it is alarming that in about half of the cases, patients do not share the information received with the attending physician, which can be explained both by lack of time and the lack of an adequate level of trust.

Disclosure of Interests: None declared

References:

Disclosure of Interests: None declared


HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative).

A. Ben Tekaya1, O. Hamd1, L. Rouached1, S. Bouden1, R. Tekaya1, O. Saidane1, I. Mahmoud1, L. Abdelmoula1, C. Charles Nicole Hospital, Rheumatology, Tunisia, Tunisia; 2La Rabta Hospital, Rheumatology, Tunisia, Tunisia

Background: Knee osteoarthritis (OA) is a common osteoarticular disease. Its prevalence increases with age as well as the coexistence of other chronic diseases. Recent researches have revealed an association between OA and cardiovascular diseases. However, association between knee OA and comorbidities has not been fully studied.

Objectives: The purpose of this study was to investigate the association between knee OA and comorbidities.

Methods: In this cross-sectional study, patients with knee OA were enrolled. Sociodemographic data as well as comorbidities were collected. Grading of knee OA was performed using the Kellgren-Lawrence (KL) grading system. Functional impact of knee OA was assessed by KOOS. Presence of comorbidities was recorded by patient history. Clinical comorbidities were considered if present for at least 6 months. The study also showed a significant correlation between comorbidities and structural grading of knee OA (p<0.04). However, comorbidities were not correlated with KOOS score (p>0.06).

Conclusion: The accumulation of comorbidities is significantly associated with higher intensity scores in knee OA. Physicians should additionally pay close attention to the prevention and the treatment of comorbidities in the management of OA.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2022-eular.97
University Hospitals. Controls: Recruitment of subjects without rheumatoid disease was performed asking for case patients who attended to medical center with a similar-age (age of range +/- 5 years) and same-gender person from social family or from family environment. Variables y measures: The main variable was malnutrition risk, measured by screening of Mini Nutritional Assessment. Other variables were: presence of sarcopenia, defined according to European Working Group on Sarcopenia in Older People (EWGSOP) 2019, economic status, dual-energy X-ray absorptiometry (DEXA) in spine and hip to osteoporosis screening, toxic habits, comorbidities and Charlson index, physical activity measured with Global physical activity questionnaire (GPAQ) and Short Physical Performance Battery (SPPB), haemoglobin, calcium, D and B12 vitamins, total proteins, albumin, C reactive protein, body mass index (BMI), polimedication, quality of life measured with EQ-5D and RA related factors, activity disease measured with DAS28, SDAI and CDAI; physical function measured with HAQ (Health assessment questionnaire) and global functional status according ACR criteria. Statistical analysis: Descriptive and multivariate analysis was performed to identify factors associated to sarcopenia in RA.

Results: 152 subjects were included in the study, 76 RA and 76 controls. More patients than controls with malnutrition risk were found, although there were no significant difference [24 (31,6%) vs 17 [22,4%]; p=0,136. More women with RA were included (78,9%), with media ± SD of age 74,7 ± 3,78, sarcopenia was presented in 9/24 (37%) and Charlson index was 3 points in 11/24 patients (45,8%) and 4 points in 8/24 patients (33,3%). According to the treatment, almost a 40%, no DMARDs were taken and neither 25% biological DMARD. 58,3% of patients received corticosteroids and majority of them (90,5%) were polimedicated. RA patients who presented desnutrion risk, in comparison with the rest of patients, had a media of upper age (p=0,007), more frequency of sarcopenia (p=0,006), right hipctil skinfold thickness (p=0,043) Also, higher values were found in activity index like physical function and quality of life. DAS28 (p=0,003), HAQ (p=0,044), Vitamin D (p=0,035), IPAG (p=0,003), SPPB (p=0,018), EQSD (p=0,01), VAS EQSD (p=0,044), SDAI (p=0,006), CDAI (p=0,008). In multivariate analysis, factors associated by independent way to malnutrition risk were age (OR [CI 95%], 1,184 [1,020-1,378], p=0,022) and inflammatory disease by DAS28 (OR [CI 95%], 2,043 [1,198-3,483]; p=0,009) (R2=0,252).

Conclusion: Even though frequency of malnutrition was similar in cases and controls, in RA was associated with inflammatory activity and older age. It's important monitoring malnutrition risk in this kind of patients to perform correct interventions to prevent and improve nutrition.

Disclosure of Interests: None declared


AB1547-HPR CAN A NURSE REPLACE THE DOCTOR IN AN UNCOMPLICATED PATIENT COURSE IN A PMR CLINIC? WHAT DO THE PATIENTS SAY?

S. Hojmark Jakobsen.1 University Hospital Svendborg Hospital, Rheumatology, Svendborg, Denmark

Background: Since 2020 the Rheumatology Outpatient Clinic of OUH, Svendborg Hospital has offered telephone consultations for patients diagnosed with muscular arthritides (PMR) tapering prednisolone. Since 2021 the course for the non-complexed patients been run by nurses. Initially patients only see a rheumatologist at the time of admission and the rheumatologist is only involved again if complications occur in the course e.g. that the patient can’t reduce Prednisolone as agreed without getting symptoms. At same day the patients are diagnosed by a rheumatologist they have a conversation with the nurse. The nurse gives both oral and written information about the disease and a Prednisolone reduction schedule is handed out to the patients. Afterwards the patients are followed by nurses and by telephone contact only. The telephone contact with the patients take place after 2, 10 and 17 weeks. When the patients are down to 7.5 mg of prednisolone daily, the nurse discharge the patient in their out-patient clinic to their own GP, who then takes care of the rest of the treatment and reduction of prednisolone to zero. There are a few literature reviews about PMR and outpatient clinics led by nurses and patient satisfaction, but we have not found anything about the patient satisfaction when they only have contact to nurses during their course.

Objectives: The aim of this qualitative study was to examine the impact on patient satisfaction when they only have contact to nurses during their course and at the same time examine whether the patients have missed talking to a rheumatologist. In addition to this, we were interested in the understanding and degree of application of the written reduction schedule.

Methods: All PMR patients completed in the outpatient clinic between December 2021 and January 2022 where asked to participate in a telephone interview at the end of their treatment. They were asked about their satisfaction with nurse consultations during their course on a scale from 0-10; 0= not satisfied and 10= high satisfaction. The patients were also asked if they had missed not to talk to a rheumatologist and finally they were asked about the Prednisolone reduction schedule.

Results: 20 patients participated in the telephone interviews. 55% of the patients respondend 10 on a scale from 0-10 in satisfaction talking with the nurses. 25% respondend 9 on the scale, 15% mentioned 8 on the scale and 5% mentioned 7 on the scale. All of the patients answered no regarding the need to talk with a rheumatologist. None of the 20 patients has been re-admitted to our outpatient clinic afterwards. 75% of the patients have no problem in following the Prednisolone reduction schedule and found it easy to read and understand.

Conclusion: With the limited number of participants, it is not possible to conclude anything definitive, but the answers indicate that the patients are satisfied with nurse consultations only during their course in the outpatient clinic and the answers also indicate that they have no need to talk to a rheumatologist. Our research could therefore indicate that nurses with a specific protocol in hand are capable of managing a course for non complex PMR patients including discharring the patients from the outpatient clinic. The answers regarding the reduction schedule reassured us, that it is understandable which should reduce the possibility of errors in the treatment.

REFERENCES:
Background: Research regarding adverse drug reactions (ADRs) associated with the use of adalimumab in patients with inflammatory rheumatic diseases (IRDs) usually focuses on the nature and frequency of ADRs without considering the burden of the ADRs. However, not every ADR causes the same burden for patients. Information is lacking about the degree of experienced burden per ADR by patients with IRDs.

Objectives: First, to describe ADRs of adalimumab based on nature, frequency and burden, and second to propose a new model for identification of relevant ADRs for health care professionals.

Methods: Data of the Dutch Biologic Monitor (DBM) were used to categorize patient-reported ADRs into high and low burden. In this prospective cohort event monitoring system patients were asked to fill out monthly questionnaires on experienced ADRs that they attributed to the use of a biological. The questionnaire included a quantification of the burden of the reported ADRs using a five-point Likert scale ranging from 1 (no burden) to 5 (very high burden). The nature of the reported ADRs were grouped into preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA). Inclusion criteria for this study were patients with IRDs using adalimumab and the reporting of an ADR with at least one burden score. For every patient, the mean burden scores per ADR (MedDRA PT) were analyzed. The burden was classified in two categories: high when the mean burden score was equal to or more than 2.5, and low when it was less than 2.5. Text analytics of the reported ADRs (MedDRA PTs) and a comparison word cloud were used to visualize ADRs that were more often reported with high burden or more often reported with low burden. These ADRs correspond to high burden (no less than 66.67% as significant) and low burden (no more than 33.3% as significant). A frequency and burden event monitoring system patients were asked to fill out bimonthly questionnaires on experienced ADRs that they attributed to the use of a biological. The questionnaire included a quantification of the burden of the reported ADRs using a five-point Likert scale ranging from 1 (no burden) to 5 (very high burden). The nature of the reported ADRs were grouped into preferred terms (PTs) according to the Medical Dictionary for Regulatory Activities (MedDRA). Inclusion criteria for this study were patients with inflammatory rheumatic diseases (IRDs) using adalimumab and the reporting of an ADR with at least one burden score. For every patient, the mean burden scores per ADR (MedDRA PT) were analyzed. The burden was classified in two categories: high when the mean burden score was equal to or more than 2.5, and low when it was less than 2.5. Text analytics of the reported ADRs (MedDRA PTs) and a comparison word cloud were used to visualize ADRs that were more often reported with high burden or more often reported with low burden. These ADRs correspond to high burden (no less than 66.67% as significant) and low burden (no more than 33.3% as significant).

Table 1. Characteristics of patients and reported adverse drug reactions (ADRs)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient (n=170)</td>
<td></td>
</tr>
<tr>
<td>Gender (%)</td>
<td>106 (62)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>55.4 ±12.8</td>
</tr>
<tr>
<td>Indication ^1</td>
<td>91 (54)</td>
</tr>
<tr>
<td>Rheumatoid arthritis (%)</td>
<td>31 (18)</td>
</tr>
<tr>
<td>Pneumatic arthritis (%)</td>
<td>48 (28)</td>
</tr>
<tr>
<td>Adverse drug reactions (%)</td>
<td>671 (100)</td>
</tr>
<tr>
<td>High burden (%)</td>
<td>271 (40)</td>
</tr>
<tr>
<td>Drug-induced ADR burden (mean ± SD)</td>
<td>2.5 ± 1.0</td>
</tr>
<tr>
<td>Respiratory tract infections (%)</td>
<td>12 (7)</td>
</tr>
<tr>
<td>Infections (%)</td>
<td>20 (12)</td>
</tr>
<tr>
<td>Headache (%)</td>
<td>13 (7)</td>
</tr>
<tr>
<td>Therapeutic product effect (%)</td>
<td>14 (8)</td>
</tr>
</tbody>
</table>

Conclusion: The outcomes of the word cloud reveal that infections are more often experienced as burdensome, whereas injections site reactions impose low to no burden. Visualizing the nature, the frequency and the burden of ADRs in one picture, provides simple guidance to the degree of relevance for the reported ADRs in clinical practice.

Disclosure of Interests: None declared.


---

AB1548-HPR

**PATIENT-REPORTED ADVERSE DRUG REACTIONS ATTRIBUTED TO THE USE OF ADALIMUMAB: DISTINCTION BASED ON NATURE, FREQUENCY AND BURDEN**


1Netherlands Pharmacovigilance Centre Lareb, Dutch Biologic Monitor, ‘s-Hertogenbosch, Netherlands; 2Amsterdam UMC, Locate AMC, Rheumatology and Clinical Immunology, Amsterdam, Netherlands; 3Sint Maartenskliniek, Pharmacy, Research and Innovation, Ubberegen, Netherlands; 4Medisch spectrum Twente, Rheumatology and Clinical Immunology, Enschede, Netherlands; 5University of Alberta Hospital, Division of Gastroenterology, Edmonton, Canada; 6Reade, Locate Dr. Jan Van Breenenstraat, Rheumatology and Clinical Immunology, Amsterdam, Netherlands; 7Erasmus MC, Dermatology, Rotterdam, Netherlands

**Table 1. Characteristics of patients and reported adverse drug reactions (ADRs)**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n=170)</td>
<td></td>
</tr>
<tr>
<td>Gender (%)</td>
<td>116 (68)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>55.4 ±12.8</td>
</tr>
<tr>
<td>Indication ^1</td>
<td>91 (54)</td>
</tr>
<tr>
<td>Rheumatoid arthritis (%)</td>
<td>31 (18)</td>
</tr>
<tr>
<td>Pneumatic arthritis (%)</td>
<td>48 (28)</td>
</tr>
<tr>
<td>Adverse drug reactions (%)</td>
<td>671 (100)</td>
</tr>
<tr>
<td>High burden (%)</td>
<td>271 (40)</td>
</tr>
<tr>
<td>Drug-induced ADR burden (mean ± SD)</td>
<td>2.5 ± 1.0</td>
</tr>
<tr>
<td>Respiratory tract infections (%)</td>
<td>12 (7)</td>
</tr>
<tr>
<td>Infections (%)</td>
<td>20 (12)</td>
</tr>
<tr>
<td>Headache (%)</td>
<td>13 (7)</td>
</tr>
<tr>
<td>Therapeutic product effect (%)</td>
<td>14 (8)</td>
</tr>
</tbody>
</table>

---

AB1549-HPR

**SOCIAL ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH THE ARTICULAR FORM OF RHEUMATOID ARTHRITIS**

N. Shuvalova, S. Lezhentseva, E. Guryanova, Y. Ya. Yakovlev Chuvash Pedagogical State University, Department of Theoretical Foundations of Physical Education, Cheboksary, Russian Federation; N. Ulianov Chuvash State University, Department of Healthcare Management and Economics, Cheboksary, Russian Federation; N. Ulianov Chuvash State University, Department Internal Diseases, Cheboksary, Russian Federation

**Background:** Patients with rheumatoid arthritis (RA) often experience persistent, prolonged pain. This requires taking pain medications (most often non-steroidal anti-inflammatory drugs) every day for many years or decades. Pain can lead to decreased social activity and emotional changes. Therefore, the quality of life of patients with rheumatoid arthritis may decrease.

**Objectives:** The purpose of the study: to determine the quality of life in patients with rheumatoid arthritis.

**Methods:** A survey was conducted using a questionnaire that included aspects of Health-related quality of life (HRQOL). The study was conducted from September 2020 to September 2021, in the Chuvash Republic, Cheboksary. The study involved 75 patients (n = 75) with articular form of RA, aged 25 to 70 years (mean age 52.2±6.63), 82% women. In 24 (32%) respondents, 1 degree of inflammatory activity was verified, in 36 (48%) - the second, in 15 (20%) - the third degree. The first stage was diagnosed in 9 (12%) patients (according to Steinbrocker), in 42 (56%) cases stage 2 of RA development was diagnosed, in 18 (24%) cases - the third stage, 6 (8%) patients had stage 4. The diagnosis of RA was based on the criteria (ACR). Statistical processing of the results was carried out in MS Office Excel programs.

**Results:** More than half of the patients (55.87%) experienced daily pain in the peripheral joints, which worsened their mood and well-being. When assessing the degree of pain, 68.45% of patients assessed their pain according to VAS as moderate (72±0.96 points). When assessing physical activity (PF) in 33.17% of patients, its decrease was noted as “significant” when assessing social activity (SF), a decrease in this indicator was revealed: 56.32% of the surveyed noted a “moderate” decrease, 33.16% as “significant”. 23.94% of the surveyed noted the...
decrease in the indicator of general health (GH) as "moderate." When assessing mental health (MH), a decrease in the indicator was found in 43.67% of patients as "moderate." When assessing emotional problems in disability (RE), there was a "significant" decrease in the indicator in 54% of respondents. In 62.24% of the surveyed patients considered the loss of freedom of movement to be the biggest problem in RA. 56.24% of patients rated their satisfaction with their lives as "average degree of satisfaction"; 43.76% of patients as "low satisfaction."

**Conclusion:** As a result of the survey, it can be stated that 43.76% of respondents have a "low degree of satisfaction" with life. In order for the doctor to have all the objective information, it is necessary to adequately and timely evaluate changes in HRQOL for the purpose of early diagnosis and timely treatment of RA.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3658

---

**Table 1. Means of electrical bioimpedance analysis.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight, kg</td>
<td>69.78</td>
<td>(11.23)</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>28.22</td>
<td>(6.04)</td>
</tr>
<tr>
<td>Total fat, %</td>
<td>35.17</td>
<td>(9.3)</td>
</tr>
<tr>
<td>Total body water, %</td>
<td>45.15</td>
<td>(6.42)</td>
</tr>
<tr>
<td>Visceral fat, kg</td>
<td>8.32</td>
<td>(3.9)</td>
</tr>
<tr>
<td>Lean mass, kg</td>
<td>41.84</td>
<td>(6.4)</td>
</tr>
<tr>
<td>Bone mass, kg</td>
<td>2.25</td>
<td>(0.73)</td>
</tr>
<tr>
<td>Metabolic age, years</td>
<td>50</td>
<td>(13)</td>
</tr>
<tr>
<td>Waist circumference</td>
<td>92.85</td>
<td>(15.38)</td>
</tr>
<tr>
<td>Hip circumference</td>
<td>106.8</td>
<td>(12.91)</td>
</tr>
<tr>
<td>BMI ratio</td>
<td>0.87</td>
<td>(0.08)</td>
</tr>
</tbody>
</table>

**BMI:** Body mass index. **W/H ratio:** Waist/hip ratio

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4166

---

**AB1552-HPR**

**HEALTH PERCEPTION OF PATIENTS WITH FIBROMYALGIA IN BRAZIL**

M. Antunes1, A. Torres Cruz1, P. De Oliveira Januário1, A. Pasqual Marques1.

1Universidade de São Paulo, Department of Physiotherapy, Speech Therapy and Occupational Therapy, São Paulo - SP, Brazil

**Background:** Fibromyalgia is a rheumatologic syndrome characterized by chronic pain and symptoms such as fatigue, morning stiffness, sleep disturbances and depression. Health perception is a global assessment of health based on an analysis of the objective and also subjective aspects of each person. Health self-assessment is increasingly researched and shows the health status of the population, considering the individual's personal perspective and that this information can be useful to propose health promotion strategies.

**Objectives:** To identify the health perception of patients with fibromyalgia who live in Brazil.

**Methods:** This is a cross-sectional study that was carried out in Brazil in 2021. They were invited to participate in the research. Individuals with fibromyalgia were invited to participate in the study through the Brazilian Association of...
Fibromyalgia Patients (ABRAFIBRO) in August 2021. The invitation was sent via email to all patients registered with this association in the country. Self-perception of health was questioned through the following response options: bad, fair, good or very good. Data were analyzed using descriptive statistics.

**Results:** The study consisted of 243 people with fibromyalgia living in different states of Brazil. Most were female (97.5%), married or living with a partner (83.7%), of white race/color (58%), receiving 1 to 2 minimum wages (60.4%), with complete higher education (46.3%) and who administer more than 2 medications per day (65.8%). Regarding the perception of health, the majority reported that their health was regular (42.4%), followed by bad (36.9%), good (16%) and very good (3.3%).

**Conclusion:** The most prevalent health perception in people with fibromyalgia in Brazil was: “regular,” followed by “bad;” “good” and “very good.” In view of the findings of this study, measures to control and prevent health risks in people with fibromyalgia become necessary.

In order to implement policies to promote a healthy life for this population, it is necessary to know the determinants of these indicators of self-reported health morbidity in Brazil. It is also suggested that the results of this investigation be monitored by periodic population-based surveys, in order to verify the determination of the observed associations, being able, in the future, to detect an association with other variables. In addition, these data can guide and evaluate education and health promotion strategies in fibromyalgia.

**References:**


**Acknowledgements:** This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001.

**Disclosure of Interests:** None declared.

**AB1554-HPR**

**DRUG-RELATED PROBLEMS EXPERIENCED BY PATIENTS WITH RHEUMATIC DISEASES: A LONGITUDINAL OBSERVATIONAL STUDY**

L. Haegens; V. Huiskes; E. M. Smale; C. Bekker; B. Van den Bermt; J. Maartenskliniek, Department of Research, Ubbelen, Netherlands; S. Sint Maartenskliniek, Department of Pharmacy, Ubbelen, Netherlands; Radboud University Medical Center, Department of Pharmacy, Nijmegen, Netherlands.

**Background:** Patients with rheumatic diseases can experience multiple drug-related problems (DRPs) along their patient journey. Insight into patients’ experience of DRPs over time might aid in timely identifying and preventing DRPs. 23 Objectives: To longitudinally identify DRPs experienced by patients with rheumatic diseases.

**Methods:** A prospective observational study was conducted in a Dutch outpatient rheumatology clinic. Adult patients with rheumatic diseases that were prescribed medication by a rheumatologist were questioned about experienced DRPs by telephone 4 times in 8 weeks using a structured interview-guide. Unique DRPs (i.e. DRPs not reported in earlier interviews by individuals) were categorized using a classification for patient-reported DRPs and analysed descriptively.

**Results:** In total, 52 participants (median age 68 years (interquartile range (IQR) 62-74), 52% male) completed 152 interviews with 45 (87%) participants completing all 4 interviews. The majority of patients (65%) were diagnosed with rheumatoid arthritis. Patients reported a median number of 3 (IQR 2-5) unique DRPs during interview 1. In subsequent interviews, patients reported median numbers of 1 (IQR 0-2), 1 (IQR 0-2) and 0 (IQR 0-1) unique DRPs for interview 2 to 4 respectively. Participants reported a median number of 5 (IQR 3-9) unique DRPs over all completed interviews. Unique patient-reported DRPs were most frequently categorized into (suspected) side effects (28%), medication management (e.g. medication administering or adherence) (26%), medication concerns (e.g. concerns regarding long-term side effects or effectiveness) (19%) and medication effectiveness (17%).

**Conclusion:** Patients with rheumatic diseases experience various DRPs over time. These patients might benefit from continuous support during their patient journey.

**References:**


**Acknowledgements:** This project was funded by the Ministry of Science, Technology and Innovation MINSIC. Grant number: 68180763684.

**Disclosure of Interests:** Ruth Alexandra Castiblanco Montañez: None declared.

**Disclosure of Interests:** Fernando Rodriguez: None declared, GUILLERMO SANCHEZ: None declared, Diana Buitrago-Garcia: None declared, Pedro Santos-Moreno Speakers bureau: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly. Consultant of: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly. Grant/research support from: Pfizer, Janssen, Abbvie, Biopas-UCB, Bristol, Roche, Novartis, Lilly.

Background: As the prevalence and costs related to osteoarthritis (OA) are expected to rise in the coming years, actions have to be taken to ensure access to effective and economical sustainable recommended treatment for this patient population. Digital tools, such as the use of mobile health applications (mHealth), could serve as a solution. Though, little is known about characteristics of patients participating in a mHealth osteoarthritis management program (OAMP) in physiotherapy practice.

Objectives: To describe demographic and disease-related characteristics of patients with hip and/or knee OA recruited to a mHealth OAMP and compare these characteristics to those of other OAMPs.

Methods: The Digital Osteoarthritis Care-study (DigiOA) is a two-armed non-inferiority RCT currently running in primary health care in Norway. In total 156 participants with hip and/or knee OA seeking physiotherapy in primary care will be asked to participate. Consenting patients will receive 1-2 hours of education before randomization to 6 weeks of either exercise therapy via the Virtual Training mobile health application or supervised exercise therapy. Inclusion rate is reported as frequency and percentage. To describe patient characteristics, we have included baseline data on patients currently included in the study. These characteristics are compared to baseline data from a web-based OAMP (1) and a standard OAMP in physiotherapy care (2).

Results: Of 39 eligible patients, 25 (64%) have to date consented to participate in the study. An overweight of the included patients are presented with knee OA, have had symptoms for five years or less, and have higher education (Table 1).

Table 1. Demographic and disease-related characteristics of patients with hip and/or knee OA recruited to a mHealth OA management program (n=25)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, n=24, mean (SD)</td>
<td>63.2 (10.4)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>17 (70.8)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>27.3 (5.4)</td>
</tr>
<tr>
<td>Education, n (%)</td>
<td>10 (40)</td>
</tr>
<tr>
<td>-Upper secondary</td>
<td>15 (60)</td>
</tr>
<tr>
<td>-College/university</td>
<td></td>
</tr>
<tr>
<td>Non-Smoking, n (%)</td>
<td>23 (92)</td>
</tr>
<tr>
<td>Work status, n (%)</td>
<td>12 (48)</td>
</tr>
<tr>
<td>-Employed</td>
<td>4 (16)</td>
</tr>
<tr>
<td>-Sick leave/receiving disability benefits</td>
<td>11 (44)</td>
</tr>
<tr>
<td>-Retired</td>
<td></td>
</tr>
<tr>
<td>Primary joint affected, n (%)</td>
<td>17 (68)</td>
</tr>
<tr>
<td>-Knee</td>
<td>8 (32)</td>
</tr>
<tr>
<td>-Hip</td>
<td></td>
</tr>
<tr>
<td>Other joints affected, n (%)</td>
<td>21 (84)</td>
</tr>
<tr>
<td>Other chronic conditions, n (%)</td>
<td>15 (60)</td>
</tr>
<tr>
<td>Symptom duration years, n (%)</td>
<td>5 (20)</td>
</tr>
<tr>
<td>-Less than a year</td>
<td>15 (60)</td>
</tr>
<tr>
<td>-1-5 years</td>
<td>5 (20)</td>
</tr>
<tr>
<td>OA medication use last 3 months, n (%)</td>
<td>19 (76)</td>
</tr>
<tr>
<td>Pain last week, mean (SD)</td>
<td>4.7 (2.3)</td>
</tr>
<tr>
<td>HOOS/KOOS, mean (SD)</td>
<td>59.4 (18.5)</td>
</tr>
<tr>
<td>-Pain</td>
<td>4.8 (10.2)</td>
</tr>
<tr>
<td>-Symptoms</td>
<td>67.2 (19.1)</td>
</tr>
<tr>
<td>-ADL</td>
<td>39.7 (19.7)</td>
</tr>
<tr>
<td>-SportRec</td>
<td>46.5 (14.2)</td>
</tr>
<tr>
<td>-QOL</td>
<td></td>
</tr>
<tr>
<td>ASE, mean (SD)</td>
<td>2.2 (0.8)</td>
</tr>
<tr>
<td>-Pain</td>
<td>2.5 (0.7)</td>
</tr>
<tr>
<td>-Other symptoms</td>
<td></td>
</tr>
<tr>
<td>Exercise self-efficacy scale, mean (SD)</td>
<td>40.2 (3.4)</td>
</tr>
</tbody>
</table>

The study sample report high impact of symptoms, and decreased function. Self-efficacy related to pain and symptoms are relatively high, but the patients report lower exercise self-efficacy. The study sample is comparable to patients included in both standard and web-based OAMPs, except for lower impact of pain and higher usage of pain medication in DigiOA.

Conclusion: Preliminary results show that baseline characteristics are comparable to patients included in other OAMPs, but with only two third of eligible patients consenting to participate in a mHealth OAMP there is a need for more in-depth knowledge on patients’ attitude towards mHealth OAMPs.

REFERENCES:

Disclosure of Interests: None declared

TELERHEUMATOLOGY WITH PRIMARY CARE CENTERS: FEEDBACK FROM AN EXPERIMENTAL TELEMEDICINE PROJECT IN BURGUNDY (2019-2021)

E. Staszewski1, A. Vaillant2, C. Piroth1, A. Patte3, A. Arbault1, C. Vazzano4, A. Ramon1, P. Ornetti1.

AB1558-HPR

TELERHEUMATOLOGY WITH PRIMARY CARE CENTERS: FEEDBACK FROM AN EXPERIMENTAL TELEMEDICINE PROJECT IN BURGUNDY (2019-2021)

E. Staszewski1, A. Vaillant2, C. Piroth1, A. Patte3, A. Arbault1, C. Vazzano4, A. Ramon1, P. Ornetti1.

AB1558-HPR ESTABLISHING A MULTIDISCIPLINARY CLINIC TO IMPROVE THE QUALITY OF CARE FOR PATIENTS WITH INTERSTITIAL LUNG DISEASE.

A. Bankole1, T. Kazmi2, A. Strazanac3, W. Scheuing2, J. Fleming2. 1Virginia Tech Carilion School of Medicine, IM, Roanoke, United States of America; 2Carilion Roanoke Memorial Hospital, IM, Roanoke, United States of America; 3Wake Forest, IM, Wake Forest, United States of America

TELERHEUMATOLOGY WITH PRIMARY CARE CENTERS: FEEDBACK FROM AN EXPERIMENTAL TELEMEDICINE PROJECT IN BURGUNDY (2019-2021)

E. Staszewski1, A. Vaillant2, C. Piroth1, A. Patte3, A. Arbault1, C. Vazzano4, A. Ramon1, P. Ornetti1.

AB1558-HPR

TELERHEUMATOLOGY WITH PRIMARY CARE CENTERS: FEEDBACK FROM AN EXPERIMENTAL TELEMEDICINE PROJECT IN BURGUNDY (2019-2021)

E. Staszewski1, A. Vaillant2, C. Piroth1, A. Patte3, A. Arbault1, C. Vazzano4, A. Ramon1, P. Ornetti1.

AB1558-HPR

TELERHEUMATOLOGY WITH PRIMARY CARE CENTERS: FEEDBACK FROM AN EXPERIMENTAL TELEMEDICINE PROJECT IN BURGUNDY (2019-2021)

E. Staszewski1, A. Vaillant2, C. Piroth1, A. Patte3, A. Arbault1, C. Vazzano4, A. Ramon1, P. Ornetti1.
Conclusion: Our data suggests that a MDC for PD-ILD results in a more thorough investigation and treatment, and this will likely lead to improvements in patient outcomes. Based on these findings, our rheumatology group is seeking internal funding for a pilot clinical evaluating prospectively the value of an MDC LOD.

REFERENCES:


Disclosure of Interests: None declared.


**AB1560-HPR**

**NURSE-DRIVEN DIAGNOSTIC PROCESS OF PATIENTS WITH SJÖGREN’S SYNDROME (SS) A CLINICAL DEVELOPMENT PROJECT**

M. T. Poder1, G. M. Colding1, K. Frödin1, M. B. T. Pedersen1, M. S. Andersen1, L. S. Tirm1, A. Vibe1, K. N. Sørensen1, L. Lindgren1, A. Svensson1, M. Pfeiffer-Jensen1, V. Fana1, J. L. Lykkegaard1, G. Thamsborg1. Rigshospitalet Glostrup, Afdeling for Rygkirurgi, Led- og Bindevævssygdomme, Glostrup, Denmark

Background: Sjögren’s Syndrome (SS) is a chronic autoimmune disease that affects the body’s glandular functions, especially the lacrimal and salivary glands, causing the mucous membranes to dry out (1). There are no diagnostic criteria, and classification criteria are often used to support the diagnosis (2).

Methods: We identified a need to unify and consolidate the diagnostic process of patients with SS in the Capital Region of Denmark. A medical working group supervised the nurse-driven diagnostic process at Rigshospitalet, Glostrup. Here an interdisciplinary working group with physicians, nurses, and secretaries developed a diagnostic process and logistic based on the American-European Consensus Group Classification Criteria 2002 (3). The nurse’s took medical history and performed sicca tests and made sure that the patient received adequate guidance. With input from three patients, the nurses at the outpatient clinic developed - written material on eye and mouth dryness. We developed a “smart phrase” for our documentation platform in the interdisciplinary working group. The purpose of the ‘smart phrase’, was to unify the documentation and ensure continuity in the conversation with the patient. The Rheumatologists task was to disprove or confirm the diagnosis and perform a risk stratification especially in relation to the development of lymphoma, but also interstitial lung disease.

Objectives: The aim of this project was to examine and evaluate the patients’ experience of nurse-driven diagnostic process.

Methods: To evaluate the new patient course, we performed a survey. The questions selected for the survey were primarily based on the patients experience of meaning and coherence in the diagnostic process. The questions were developed by the nurses in the Outpatient Clinic; “Do you feel safe going home after the consultation today?” “Did you get answers to the questions you asked while you were in the consultation?” “Did the staff take the time to listen to you?” Also, the patients could add comments.

Results: A total of 34 consecutives responded to the questionnaire. 88% felt safe when returning home from the Outpatient Clinic, 85% received answers to their questions during the consultation. Altogether, 94% answered that the health care professionals were present and listened to them. The patients had the following comments: "The diagnostic process contained a lot of unresolved waiting time” and "It has been some confusion about the division of tasks in the different hospital wards.”

Conclusion: We found that the patients were satisfied with the nurse-driven diagnostic process. The diagnostic process created a feeling of safety in the patients and the patients found that they were listened to and allowed to ask questions. In addition, by evaluating the process investigation, we could change practice and further unify the diagnostic process. The result of the questionnaire supported the justification of the nurse competencies, by preforming a high level of information and guidance as well as the need for recognition of the patient’s symptoms. Therefore, the working group chose to meet again and evaluate. We decided that the nurse and rheumatologist consultation should be performed on the same day. Such consultation made it possible for the nurse to ensure continuity in the process, as the same nurse could follow the patient throughout the day. This maximized the opportunity for the nurse to guide the patient in the symptomatic treatment of eye and mouth dryness. Also, the nurse had the opportunity to guide in oral hygiene, fatigue, and lifestyle factors.

The next step in our development project is to evaluate our revised nurse-led diagnostic process. In addition, the working group is currently working on material for a course in SS, where 4-6 patients and relatives can have the opportunity for additional training to participate.

REFERENCES:


Disclosure of Interests: None declared.


**AB1561-HPR**

**PHYSIOTHERAPY FOR RHEUMATOID ARTHRITIS (RA) – PAST, PRESENT AND A POSSIBLE FUTURE?**

A. M. Mengshoel1. 1University of Oslo, Department of Interdisciplinary Health Sciences, Oslo, Norway

Background: Physiotherapy has a long tradition providing services to patients with RA. The main aim of physiotherapy is to improve patients’ abilities to perform movements and physical activities through exercises and educating patients in self-management skills. For physiotherapy to proceed into future, it seems relevant to examine what shifts occurred in physiotherapy over time and why did they happen.

Objectives: Is to unpack the shifts in physiotherapy for patients with RA from 1980 until today.

Methods: Norwegian physiotherapy in rheumatology is used as case. The shifts are identified with help of literature about history of medicine and physiotherapy in rheumatology and empirical physiotherapy research since the 1960s. The author draw on own experiences first as a clinician and practice teacher for physiotherapy students in rheumatology, and later as a scientist and advisor for a multidisciplinary team in rheumatology.

Results: Physiotherapy focuses on movement and function, which over time have consistently been understood in relationship to disease-induced alterations and biomechanics. Shifts in physiotherapists’ remedial exercises have occurred over time as better disease control occurred and evidence showed that physical activities and exercise programmes had disease modifying effects and improved patients’ functional capacity. In the 1980s, a move from earlier passive, joint protective movements with little weight load to cautious weight-bearing movements occurred, mostly as a response to improved disease-modifying drugs and joint surgery. In the 1990s, physiotherapy shifted from cautious weight-bearing movements to safely performed physical activity as a response to scientific findings showing beneficial effects on radiological, immunological, and physical function measures. In the 21. century, RA is identified earlier and increasing number of patients reach disease remission before irreversible occurs in the musculoskeletal system. Presently, a new shift in Norwegian physiotherapy is on the way. Adherence to EULAR guidelines 2018 on physical activity is moving physiotherapy from promoting exercises through engagement in self-determined physical activities into educating patients in performing structured intensive physical fitness training programmes for preventing future comorbidities.

Conclusion: At the moment, it is a dilemma that the raising rate of patients successfully treated to disease remission is not accompanied with more patients remaining in fulltime work in Norway. Thus, there is a need in physiotherapy to critically scrutinize the meaning and significance of movements and functioning for the individual patient’s own life purpose and the society’s wish that people stay in paid work.

REFERENCES:


Disclosure of Interests: None declared.


**AB1562-HPR**

**COMPARING THE PROVISION OF SUBCUTANEOUS METHOTREXATE BETWEEN HOMECARE AND OUTPATIENT PHARMACY; WHAT DO PATIENTS PREFER AND IS ONE ROUTE QUICKER?**

R. Heaton1, J. Nasralla1, C. Filer1, E. Appleby1, M. Myintzu2. 1Stepping Hill Hospital, Rheumatology, Hazel Grove, United Kingdom; 2Macclesfield District General Hospital, Rheumatology, Macclesfield, United Kingdom
Table 1. Patient reported satisfaction following receipt of injection training and prescription provision via outpatient pharmacy and homecare.

<table>
<thead>
<tr>
<th></th>
<th>Outpatient Pharmacy (20)</th>
<th>Homecare (20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not satisfied</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Satisfied</td>
<td>5</td>
<td>18</td>
</tr>
<tr>
<td>Very satisfied</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>Not satisfied</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>Satisfied</td>
<td>6</td>
<td>12</td>
</tr>
<tr>
<td>Very satisfied</td>
<td>12</td>
<td>15</td>
</tr>
</tbody>
</table>

The mean time taken to start treatment was 30 days in the homecare group and 13 days in the outpatient group. 7 patients (35%) within the outpatient group started treatment within 7 days. The shortest time within the homecare group was 15 days (3 patients).

Conclusion: Reported patient satisfaction between the two routes of treatment provision was similar. Patients commenced treatment significantly quicker via outpatient pharmacy, reporting a high degree of satisfaction with the injection training provided by outpatient pharmacists. This audit has confirmed that shared care provision of methotrexate initially via outpatient pharmacy is a safe, efficient and viable option.

Disclosure of Interests: Rebecca Heaton Speakers bureau: I prepared slides and presented virtually for pharmacists explaining shared care experience (Nordic), Consultant of: Formulating a educational package for rheumatology pharmacists (Galapagos), Jennifer Nasralla: None declared, Charlotte Filer: None declared, Edward Appleby: None declared, Mya Myintzu: None declared, Filer: None declared, Edward Appleby: None declared, Mya Myintzu: None declared, Reviewers: I prepared slides and presented virtually for pharmacists explaining shared care experience (Nordic), Consultant of: Formulating a educational package for rheumatology pharmacists (Galapagos).

Background: The importance of international harmonization regarding education of rheumatologists in musculoskeletal ultrasound (MSUS) and injection skills have been highlighted in several studies, including the need for standardized training programs containing competency-based education using validated assessment tools [1-2].

Objectives: To examine how residents are trained and assessed in MSUS, MSUS-guided and landmark-guided joint aspiration and injection. Additionally, to present the available assessment tools and examine their supporting validity evidence.

Methods: A systematic search of PubMed, Cochrane Library, and Embase was conducted in accordance with the PRISMA guidelines and studies published from January 1, 2000 to May 31, 2021 were included. Two independent reviewers performed the search and data extraction. The studies were evaluated using the Medical Education Research Quality Instrument (MERSQI).

Results: 9,884 articles were screened and 43 were included; 3 randomized studies, 21 pre- and post-test studies, 16 descriptive studies (Table 1), and 3 studies developing assessment tools. The studies used various theoretical training modalities e.g. lectures, anatomical quizzes, and e-learning. The practical training models varied from mannequins and cadavers to healthy volunteers and patients. Most studies used subjective “comfort level” as assessment, others used practical examination and/or theoretical examination. All training programs increased trainees’ self-confidence, theoretical knowledge, and/or practical performance, however few used validated assessment tools to measure the effect. Only one study met the MERSQI high methodical quality cut-off score of 14.

Conclusion: The included studies were heterogeneous, and most were of poor methodological quality and not based on contemporary educational theories. This review highlights the need for educational studies using validated theoretical and practical assessment tools to ensure optimal MSUS training and assessment in rheumatology.

REFERENCES:

Disclosure of Interests: None declared.

A previous study has shown, that trained nurses can perform satisfying and safe IA injections at least as well as those administered by doctors (1). High availability to adequate treatment will have a positive effect. For the patient and on a socio-economic level, as patients who have severe arthritis could be forced to stay home from work and leisure activities (2). It was decided to educate a nurse, who showed interest in ultrasound and IA injections and who showed the technical skills.

**Objectives:** To educate and develop competence in the nursing staff regarding ability to perform joint ultrasound, arthrocentesis and IA injection. In order to offer immediate arthritis treatment and free up doctor time to be able to see other patients.

**Methods:** At first, the nurse watched the ultrasound, arthrocentesis and injection on the knee performed by a rheumatologist a couple of times. Then she performed the procedure under supervision and then she independently performed the ultrasound, arthrocentesis and injection on the knee with the opportunity for supervision. The nurse completed a two-day muscular/skeletal ultrasound course at university hospital Skejby. The course was both theory and hands-on training in ultrasound, arthrocentesis and injection on the knee with the opportunity for further supervision. The nurse also participated in a course at Esbjerg hospital for doctors and nurses about ultrasound on upper extremities. This was a hands-on course. In conjunction with arthrocentesis, the nurse learned to identify urate crystals in synovial fluid through microscopy.

**Results:** See Table 1 for which joints where the nurse performed ultrasound, arthrocentesis and injection during the first and second year.

**Table 1.**

<table>
<thead>
<tr>
<th>Year 1</th>
<th>Joint</th>
<th>Ultrasound</th>
<th>Arthrocentesis</th>
<th>IA injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIP</td>
<td>10</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCP</td>
<td>9</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wrist</td>
<td>23</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elbow</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knee</td>
<td>50</td>
<td>41</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Ankle</td>
<td>7</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTP</td>
<td>5</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In all</td>
<td>102</td>
<td>41</td>
<td>90</td>
<td></td>
</tr>
</tbody>
</table>

One year after the procedure was implemented the joints that the nurse perform ultrasound and injections on, had increased. Starting with only knees to PIP, MCP, wrist, elbow, knees, ankles and MTP joints. After the first year, the nurse grew independent and confident with the new task, as the table beneath shows. Since the nurse started to perform ultrasound, arthrocentesis and IA injections, there has been no reports of adverse events.

**Conclusion:** Nurses can be trained to perform ultrasound, arthrocentesis and injections, in a wide range of joints. Patients and staff express satisfaction with the availability of treatment. There has been no reports of adverse events.

**REFERENCES:**


**Disclosure of Interests:** None declared

**AB1566-HPR**

**REHABILITATION NURSES KNOWLEDGE ABOUT OSTEOPOROSIS AND FRAILTY FRACTURES IN PORTUGAL**

G. Pimentel, A. Cruz, M. Loureiro, S. Fernandes, C. Baixinho, A. Marques; on behalf of Master’s Thesis. "Higher School of Nursing of Coimbra, Rehabilitation Nursing, Coimbra, Portugal; Centro Hospitalar e Universitário de Coimbra, Rheumatology, Coimbra, Portugal; Higher School of Nursing of Coimbra, Health Sciences Research Unit Nursing, Coimbra, Portugal; Nurses' Regulatory Board, Royal Colleague of Nurses, Coimbra, Portugal; Nurses' Regulatory Board, Section Regional South, Lisboa, Portugal; Nursing School of Lisbon, Train4Health, Lisboa, Portugal

**Background:** Scientific evidence reveals gaps in health professionals’ knowledge about osteoporosis and fragility fractures, which impair and influences the quality of care, namely in preventive actions.

**Objectives:** To analyze knowledge of Rehabilitation Nurses about osteoporosis and fragility fractures to identify training needs of Rehabilitation Nurses.

**Methods:** A cross-sectional study, integrated in a larger project, using an adapted questionnaire, made available online and disseminated by mailing list of “Ordem dos Enfermeiros” (Royal Colleague of Nurses) to all Portuguese Rehabilitation Nurses.

**Results:** There were include 452 participants (10.3% of the 4397 Rehabilitation Nurses), 17% perform functions in orthopaedics and traumatology service, 4.5% physical medicine and rehabilitation and 78.6% in other services, majority, 74.6% women. On average, 69.6% correct answers were identified regarding osteoporosis and fragility fractures. Results reveal that the main areas of knowledge deficit, in this study, are related to the concept and epimology of osteoporosis and fragility fractures and about the most appropriate diet. Nurses with higher academic degree (master’s degree) revealed more knowledge (p=0.01).

**Conclusion:** This study reveals that the knowledge about osteoporosis and fragility fractures is low (<70% correct answers), thus there is an opportunity to improve the knowledge related to osteoporosis and fragility fractures among Specialist Nurses in Rehabilitation Nursing.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3205

**AB1566-HPR**

**SHIFTING THE MINDSET: USING A HEALTH COACHING APPROACH FOR HEALTH PROMOTING CONSULTATION IN ADOLESCENT RHEUMATOLOGY**

A. Bouraoui, P. Newman, C. Fisher, S. Mavrommatis, A. Mcdowell, D. Sen. University College Hospital, Adolescent and Young Adult Rheumatology, London, United Kingdom; HaelianCoaching, Coaching, London, United Kingdom; TPC HEALTH, Health Coaching, London, United Kingdom

**Background:** Juvenile rheumatic diseases have a significant negative impact on health early in life which may affect later health outcomes. The Adolescent and Young Adult Rheumatology Department (AYAD) at University College London Hospitals (UCLH) looks after over 2,000 young people with a variety of rheumatological conditions and provides developmentally appropriate interdisciplinary (ID) approach to healthcare. Health coaching (HC) is “a behavioural intervention that facilitates participants in establishing and attaining health promoting goals in order to change lifestyle-related behaviour, with the intent of reducing health risks, improving self-management of chronic conditions, and increasing health related quality of life.” Evidence shows that health coaching can improve health related behaviours including medication adherence, patient activation, and use of healthcare resources. [2-4]

**Objectives:** The aim of this project is to enable young people attending the AYAD to establish and achieve their own health-promoting goals and thereby change behaviour and increase confidence in self-management. As a first stage the aim was to develop health coaching capabilities within our ID Team by March 2022.

**Methods:** The strategy to deliver this project included commissioning a recognised core skills health coaching course for multidisciplinary team (MDT) members. Pre and post course surveys were completed by participants.

**Results:** All the AYA team members comprising 3 physiotherapists, 2 nurse specialists, a transition pathway coordinator, 4 consultants and 2 senior registrars took part in the health coaching workshops. A pre course survey (10/12 responded) revealed that 70% of MDT members felt their consultations focused solely on young people’s medical/clinical care. 80% reported they discuss lifestyle choices such as sleep, and weight management. 40% felt that their consultation times were long enough to discuss resources that would support long-term management. 30% reported they felt effective
in facilitating Young people and their families to self-manage and/or had sufficient health coaching awareness to facilitate behaviour change. The course was delivered over 2 separate days, one week apart, and included educational material, presentations, group discussion and skills development delivered in a coaching style. A post course survey (11/12 responses) demonstrated 100% of participants were satisfied with the course content, delivery, facilitation and opportunities to work and learn with colleagues, and felt that the skills were applicable to their work. They reported that the skills learned could be applied beyond healthcare, for example, with colleagues or in leadership roles, the course helped to raise self-awareness of behaviours that can negatively and positively impact patient and family engagement in their care, and that using some techniques and small changes to practice could potentially have a big impact on quality of care and outcomes as well as patient and staff experience.

**Conclusion:** Health coaching skills were considered as a useful tool by all AYAD team members. Skills gained on the course were considered useful in managing young people and applicable in settings beyond clinical care. The next stage of this project will include embedding the techniques learned into clinical practice and measuring qualitative and quantitative outcomes over time.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4762

### HPR Interdisciplinary research

**AB1567-HPR**

**SOCIAL WORKERS: DESCRIBING SOCIOECONOMIC CHARACTERISTICS DURING PRENATAL CARE IN PATIENTS FROM A PREGNANCY AND AUTOIMMUNE RHEUMATIC DISEASES CLINIC.**

**M. E. Corral Trullillo,1 F. R. Arevalo Nieto1, L. G. Espinosa Banuelos1, C. M. Skinner Taylor2, L. Pérez Barbosa3, A. Y. Lujano Negrete1, D. Á. Galarza-Delgado1.1 Hospital Universitario Dr. José Eleuterio González, Rheumatology Department, Monterrey, Mexico**

**Background:** Social workers (SW) interventions are fundamental in health care; the main objective is to identify and mitigate social determinants of the patient's health. The socioeconomic study (SES) is the core assessment of SW; it analyzes the demographic structure and population dynamics.

**Objectives:** Describe the sociodemographic and social security characteristics in pregnant patients with autoimmune rheumatic diseases.

**Methods:** A cross-sectional and retrospective study was conducted in a pregnancy and rheumatic diseases outpatient clinic from the university hospital in Monterrey, México. The data from the SES database was collected. The sociodemographic information, family’s monthly income and expenses, expenditures related to healthcare, type of social security, family nucleus (FN) and socioeconomic level (SL) were analyzed. The rheumatic diagnosis was retrieved from the medical records. The SL is classified in 7 levels (according to the score obtained in the SES); each level represents a percentage of the total cost of the healthcare received. Level 1 to 3 correspond to 0 - 28% percentage while levels 4 to 7 go from 53 to 100% of total payment that is due. To evaluate the health expenditure, the monthly limit expenditure per Mexican family is 98.39 dollars (the limit expenditure was taken from the Organization for Economic Co-operation and Development “OECD” 2019 report). For statistical analysis, the sociodemographic and clinical characteristics of the sample are presented as frequencies and percentages.

**Results:** From 2019 to 2021, 54 patients were interviewed. The mean age was 28.46 years (SD=6.69). The rheumatic diagnoses can be found in Table 1. The most common occupation was unemployment (n=34, 62.96%) and only completed basic levels of education (n=37, 68.1%).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.4762

### Table 1. Sociodemographic characteristics

<table>
<thead>
<tr>
<th>Category</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographic Data</strong></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD)</td>
<td>28.46 (6.69)</td>
</tr>
<tr>
<td><strong>Occupation</strong></td>
<td></td>
</tr>
<tr>
<td>Unemployed</td>
<td>34 (62.96)</td>
</tr>
<tr>
<td>Employed</td>
<td>17 (31.48)</td>
</tr>
<tr>
<td>Self-Employed</td>
<td>3 (5.55)</td>
</tr>
<tr>
<td><strong>Marital Status</strong></td>
<td></td>
</tr>
<tr>
<td>Married/Cohabitating</td>
<td>38 (70.37)</td>
</tr>
<tr>
<td>Single</td>
<td>16 (29.62)</td>
</tr>
<tr>
<td><strong>Level of Education, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Basic education</td>
<td>37 (68.51)</td>
</tr>
<tr>
<td>Higher education</td>
<td>17 (31.48)</td>
</tr>
<tr>
<td><strong>Family Structure</strong></td>
<td></td>
</tr>
<tr>
<td>Family members</td>
<td></td>
</tr>
<tr>
<td>0-5</td>
<td>36 (66.66)</td>
</tr>
<tr>
<td>6-11</td>
<td>18 (33.32)</td>
</tr>
<tr>
<td>Number of children</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13 (24.07)</td>
</tr>
<tr>
<td>3</td>
<td>5 (9.25)</td>
</tr>
<tr>
<td>Family Nucleus</td>
<td></td>
</tr>
<tr>
<td>Nuclear</td>
<td>27 (50)</td>
</tr>
<tr>
<td>Multi-nuclear</td>
<td>26 (48.14)</td>
</tr>
<tr>
<td>Extended</td>
<td>1 (1.85)</td>
</tr>
<tr>
<td><strong>Rheumatic Disease, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>29 (53.7)</td>
</tr>
<tr>
<td>Lupus</td>
<td>9 (16.66)</td>
</tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>8 (14.81)</td>
</tr>
<tr>
<td>Sjogren syndrome</td>
<td>1 (1.85)</td>
</tr>
<tr>
<td><strong>Health Expenditure, n (%)</strong></td>
<td></td>
</tr>
<tr>
<td>Active health insurance</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>39 (72.22)</td>
</tr>
<tr>
<td>Public health services (governmental and state workers)</td>
<td>8 (14.81)</td>
</tr>
<tr>
<td>Private health insurance</td>
<td>7 (12.96)</td>
</tr>
<tr>
<td><strong>Average monthly family income (USD)</strong></td>
<td>$614.23</td>
</tr>
<tr>
<td><strong>Average monthly health expenditure (USD)</strong></td>
<td>$105.71</td>
</tr>
<tr>
<td><strong>Percentage of expenses in patient’s health</strong></td>
<td>16.21%</td>
</tr>
</tbody>
</table>

SD: Standard deviation

The most frequent SL was level 3 (46.29%) and the predominant FN was the nuclear family (50%) (couple and their dependent children). Most of them were not under any health coverage (n=39, 72.22%). The average family income was $614.23 USD and the average health expenditure was 105.71 USD; which represents 16.21% of the family income (per month).

**Conclusion:** SW play a key role understanding basic needs and identifying health determinants that decreases the odds of access of healthcare. Women with autoimmune rheumatic diseases have an important burden of the main determinants of health like low income, unemployment, basic education, and poor health coverage. In addition, the average health expenditure is higher than the recommended by OECD. Different strategies are needed for childbearing age patients with rheumatic diseases to decrease the impact of health determinants.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3839

### Patient information and education

**AB1568-PARE**

**LIVED EXPERIENCES OF POSTMENOPAUSAL OMANI WOMEN WITH OSTEOPOROSIS**

**F. Zadids1, E. Stannmore2, J. Brooks2, T. O’Neill3.1 The University of Manchester, School of Health Sciences, Manchester, United Kingdom; 2The University of Manchester, School of Health Sciences, Manchester, United Kingdom; 3The University of Manchester, Department of Rheumatology, Manchester, United Kingdom**

**Background:** Osteoporosis is a globally significant clinical public health problem associated with age-related fractures [1,2]. Most research on the impact of the disease has been based on quantitative survey data. There are relatively few qualitative studies exploring women’s lived experience with osteoporosis. Furthermore, most data are from Western countries, with no data from the Middle East. Moreover, most data are from Western countries, with no data from the Middle East. Therefore, we aimed to explore the lived experiences of postmenopausal Omani women with osteoporosis.

**Objectives:** To explore the lived experiences of postmenopausal Omani women with osteoporosis.

**Methods:** A qualitative study was conducted using semi-structured interviews. A purposive sampling technique was used to select 15 participants who met the inclusion criteria (at least 1 year postmenopausal, diagnosed with osteoporosis). The interviews were conducted in Arabic and recorded. The data analysis was conducted using thematic analysis.”

**Results:** The participants’ experiences of living with osteoporosis were characterized by three main themes: (1) the physical and psychological impact of osteoporosis, (2) the patients’ views on osteoporosis, and (3) the patients’ knowledge of osteoporosis. The most common problem was the fear of fractures (n=15, 100%).

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.3839
East. Direct access to lived experiences is a powerful tool for gaining insights into a disease [3]. This study aimed to determine the lived experience of postmenopausal Omani women with osteoporosis.

**Objectives:** The study sought to answer three questions:

1. What does living with osteoporosis mean for postmenopausal Omani women?
2. How does culture impact the lives of postmenopausal Omani women with osteoporosis?
3. How do postmenopausal Omani women with osteoporosis perceive the support and care provided by healthcare professionals?

**Methods:** An interpretive phenomenology design was used with a purposive sample of 15 postmenopausal Omani women with osteoporosis and fragility fractures obtained from primary and secondary care facilities in Muscat, Oman. Audio recorded, semi-structured, one-on-one interviews were held by Zoom and telephone; Crypt and Tanner’s framework was used to analyze data and identify key themes.

**Results:** The mean age of the participants was 63 years. Five (33.3%) reported a previous fracture. Just over half (53%) were illiterate; three (20%) had studied in college. Key themes related to their lived experience emerged from the data analysis: culture and religion; health care professionals’ attitudes; and services and treatment regimen. The subjects’ social and cultural lives were negatively impacted by osteoporosis and fragility fractures, which prevented them from attending celebrations such as close family marriages and religious gatherings. Participants played significant care-giving roles as wives, mothers and grandmothers but many were unable to perform many household chores, such as cooking, due to the osteoporosis and fractures. They perceived healthcare professionals through the professionals’ communication styles and information they provided. Participants satisfied with their doctor’s communication style described it as humanistic, with humour added, noting they provide health information and understand patients’ needs. Those not satisfied indicated their doctors had poor communication styles, showed insufficient interest in them, and asked few questions during their appointments. Professionals in in-patient clinics were perceived as more caring and empathetic than those at out-patient clinics. Treatment abroad was preferred by these women, though some were highly satisfied with their treatment from Omani hospitals. Beliefs about and usage of traditional herbal remedies for the management of fragility fractures differed between educated and non-educated women.

**Conclusion:** This study explored postmenopausal Omani women’s experiences of living with osteoporosis and fragility fractures including the impact of the disease on social and cultural life. It contributes also to our understanding of the experience of the disease in non-western settings.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.68

**AB1570-PARE**

**WHAT DO PATIENTS KNOW ABOUT RHEUMATOID ARTHRITIS?**

S. Lezheninga1, N. Shuvalova2, E. Guryanova3. 1I. N. Ulianov Chuvash State University, Department of Healthcare Management and Economics; 2Cheboksary, Russian Federation; 3Ya. Yakovlev Chuvash Pedagogical State University, Department of Theoretical Foundations of Physical Education, Cheboksary, Russian Federation; 4I. N. Ulianov Chuvash State University, Department Internal Diseases, Cheboksary, Russian Federation

**Background:** Patient awareness of rheumatoid arthritis (RA) contributes to more effective prevention of this disease. It is necessary to study the initial level of knowledge of patients about rheumatoid arthritis and analyze which sections of the educational program need to be studied carefully.

**Objectives:** To analyze what patients know about rheumatoid arthritis, and determine with this nosology want to be trained in various educational programs?

**Methods:** A survey of 86 patients with RA of varying severity was conducted. The diagnosis of RA was established according to the (EULAR)/ACR criteria. Patients were divided into 2 groups by age: group 1 - 18-44 years old (young patients, N=43), group 2 - 45-65 years old (middle-aged patients, N= 43. The study was conducted in the General Hospital of the city of Kanash. Questioning was conducted from January to December 2021. The questionnaire consisted of 2 parts: the first part (part A) included 20 questions (2 points were awarded for each correct answer). Questions related to the relationship between the onset of the disease and hypothermia, infection, stress, injuries of the musculoskeletal the presence of rheumatoid arthritis in close relatives. The knowledge of one's own role in the process of treatment and prevention of RA was assessed. The second part of the questionnaire (part B) consisted of 6 questions. The need for obtaining information about RA and the desire of patients to be trained in various educational programs was studied. It was studied in what format they would like to study (remote or full-time) Survey data was processed in Statistical Analysis Software 15.0. Statistical significance was handled using Analysis of Variance analysis of variance.

**Results:** 43.7% of group 1 and 56.8% of group 2 correctly classified rheumatoid arthritis as a disease that occurs predominantly in women. 14.6% of young respondents knew about the role of infection in the occurrence of RA, 32.8% - middle-aged. 52.2% of middle-aged patients, 22.8% of young patients knew about the influence of heredity in the occurrence of the disease. 28.0% of young respondents knew about the negative impact of stress on the onset and course of RA, middle-aged respondents - 58.2%. 21.6% of young respondents were aware of the impact of injuries of the musculoskeletal system on the occurrence of RA compared to 55.3% of middle-aged respondents. The awareness of patients about their own role in the treatment process in group 1 was 4.2%, in group 2 - 5.4%. 10.6% of young respondents and 14.8% of middle-aged respondents consider it possible to prevent RA exacerbations. A positive factor was that 90.6% of the respondents report a need to obtain additional information about the disease.

**Conclusion:** It is necessary to actively implement various educational programs, in which more attention should be paid to the prevention of RA and the participation of the patient himself in the treatment process. Training for patients is preferable to be carried out in a distance learning format.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.628
Patients managing their own care (self-management) however, there is a need for works can be boosted and optimised by the use of IM which can act simultaneously system, microcirculation, immune modulation, muscular relaxation/contraction and stimulation, which provides localised strong yet comfortable muscle contractions devices are being introduced to patients such as transcutaneous electrical nerve to be effective, along with other natural therapies such as melatonin, menthol skeletal well-being, as high intakes of protein, fat, and sugar are associated with contractions/relaxation. Dietary patterns also have an important role in musculo-techniques. The innate ability of both the body and mind are integral to self-healing to reduce MSK pain within the self-healing concept include a variety of tech-
Conclusion: The relationship between RA and fertility seems to be misunderstood in young women with RA. Clinicians must routinely discuss this issue with these young patients to preserve their fertility by learning them the mechanisms by which RA may affect their fertility: the disease itself and medication. Appropriate information about fertility can help women in productive age reach and carry a healthy pregnancy.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2455

AB1573-PARE | WHAT DO OSTEOPOROTIC PATIENTS KNOW ABOUT THEIR DISEASE?

P. Idrissi Zakl, H. Araibi, A. Mougui, I. El Bouchtel, 1Centre Hospitalo-Universitaire Mohammed VI Marrakech, Department of Rheumatology, Marrakech, Morocco.

Background: Osteoporosis (OP) is a systemic skeletal disorder characterized by low bone mass responsible of fracture. It is a major public health problem. Knowledge assessment is an essential step in therapeutic education which could improve the management of osteoporosis.

Objectives: The objective of this study is to assess the degree of knowledge of osteoporotic patients regarding their disease as part of therapeutic education in order to improve management and develop a shared decision with the patient.

Methods: This is a cross-sectional epidemiological study conducted on osteoporotic patients at the rheumatology department of the university hospital center Mohammed VI Marrakech. Descriptive data, knowledge evaluation, patient expectations and therapeutic adherence were collected and analysed by SPSS 20. The comparison was made by the Chi-square test for qualitative variables.

Results: 137 patients were included with an average age of 63.7 years, with a female predominance (94.9% female vs 5.1% male). 70% were illiterate. 58.4% had postmenopausal OP, 36.5% secondary OP and 5.1% (n=7) male OP. 14.6% of the patients had diabetes, 9.5% had arterial hypertension, 5.8% had breast cancer under aromatase-inhibitors. 13.9% had rheumatoid arthritis and 9.5% had other chronic diseases, 16.1% were on long-term corticosteroids. 98.5% were on oral bisphosphonate and only 2 patients were on Intravenous zoledronate. 51.1% had osteoporosis for less than 2 years, 9.5% had a history of fracture with 2.9% major fractures. 9.5% of patients answered that osteoporosis was linked to bone fragility. 29.2% thought it was age-related, 26.3% had a confusion between osteoporosis and osteoarthrosis. 16.8% believed it was an inflammatory rheumatism. 81% supposed it was a silent disease. 95.6% assumed that physical activity is harmful and 32.1% had made environmental modifications. 52.6% were linked to osteoporosis, 58.4% didn’t know OP’s risk factors, 14.6% and 61.3% didn’t know any fall nor fracture related factors respectively. 8.8% had recognized aging and menopause as OP’s risk factors respectively. 9.5% had a history of fracture with 2.9% major fractures. 9.5% of patients

Acknowledgements: The authors would like to thank all the patients who made this research possible.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2022-eular.2455

AB1574-PARE | "ABITARE" PROJECT – HOME FOR PATIENTS WITH RHEUMATIC DISEASES

L. S. Martin1, S. Middei2, R. Convertino2, A. Celano2. 1ASL ROMA 6 (Operative Unit of Internal Medicine and Rheumatology), Rome, Italy; 2APMARR APS - Italian National Association of People With Rheumatological and Rare Diseases, Rheumatology, Lecce, Italy

Background: Talking about home means talking about ourselves. Our home represents the "movie set" where the film of our lives is shot, and we can choose whether to be simple actors or the directors of it. The house expresses our personality, it identifies us in a unique way, like a fingerprint. Talking about our home means understanding how the way we relate to it can create well-being or discomfort.

Objectives: The objective of this project is to promote the empowerment of people with disabilities and chronic diseases. We aim to do that starting from a greater awareness of their living needs and the quality of life and self-esteem enhancements that derives from a tailor-made home.

Methods: 308 people participated in the survey and were distributed anonymous questionnaires regarding their experience at home.

Disclosure of Interests: None declared.


AB1575-PARE | DIETS AND JOINT SYMPTOMS: SURVEY OF MOROCCAN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATISM

N. Takhra1, T. Fatima Zahrae1, I. Berriche1, A. Anassa, K. Berrada1, F. Abourazzak2. 1Tangier, Department of Rheumatology, Tangier, Morocco

Background: The role of diet in triggering or aggravating chronic diseases, in particular chronic inflammatory rheumatism (CIR), is a question frequently asked by patients.

Objectives: The objective of our study is to investigate whether Moroccan patients report a relationship between certain diets or foods and the symptoms of the disease and also to study whether patients adopt specific eating behaviors in order to relieve their symptoms.

Methods: This is a survey based on a questionnaire that included any patient followed by CIR who presents to the rheumatology department. The questionnaire...
RHEUMATOID ARTHRITIS ASSESSMENT KNOWLEDGE QUESTIONNAIRE (RAKE) IN TUNISIAN POPULATION

S. Rekik1, Z. Zeineb1, S. Jemmali1, S. Boussaid1, S. Rahmouni1, K. Ksibi1
H. Sahli1, M. Elieuch1
1Rabta University Hospital, Rheumatology, Tunisia, Tunisia

Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that has a very high burden on patients their families, and society. So that it is important that RA patients receive education about their disease. The knowledge of RA patients in Tunisia regarding their disease has not yet been assessed.

Objectives: The purpose of the study was to evaluate disease-specific knowledge of patients with rheumatoid arthritis by using the RAKE questionnaire (Rheumatoid Arthritis assessment Knowledge Questionnaire).

Methods: This was a cross-sectional study. Adults with RA fulfilling the ACR/EULAR criteria were asked to participate by responding to RAKE Questionnaire in the short version.

Results: A total of 28 RA patients were included: 23 females (82%) and 5 men (18%). The mean age was 58.5 years with a range of 31 to 79 years. The mean disease duration was 9.8 years. The disease duration was 0-5 years in 5 (17.8%) patients, more than 5 years in 23 (82.2%) cases. Twenty patients were housewives. Thirteen (46.4%) patients were from rural areas. Most of the patients didn't follow education programs for their RA. Twenty-two (78.5%) patients obtained information about RA from their rheumatologist. Six patients (21.5%) from other sources (neighbors, nurses, other RA patients, social media). The mean time for answering the questionnaire was 11.6 min (9-15 min). The RAKE total score was 118.832 [3-22]. For the initial part of the questionnaire, related to the general aspects of RA, the mean score was 4.38 [0-6]. The mean score of the second component of the questionnaire concerning medications and non-pharmacological management, was respectively 4.31 [0-7] and 2.35 [0-4]. For comorbidities, the mean score was 0.61. The last component includes auto-management, pain, and tiredness, the mean score was 1.43 [0-3]. The last component covers psychosocial, occupational, and health system coping skills. Its mean score was 2.14. The mean score of unknown answers was 6.732 [4-16].

Conclusion: In our study, the knowledge of patients of RA was low in all domains of RAKE questionnaire at various degrees. These findings can be used for improving current patient education programs and better disease control.

Disclosure of Interests: None declared.


ADJACENT ANATOMIC ASPECTS OF THE ACROMEGALIC GLAND

C. Abdennour1, N. Bentahila1, B. Abdesselem1, F. Mhenni1
1IRCC, Departement of Endocrinologie, France

Background: The acromegalic gland is an anatomically and functionally different entity within the pituitary gland. The aims of this study were to investigate the clinical and anatomical aspects of the acromegalic gland and identify the potential clinical implications.

Methods: The study included 100 consecutive patients with acromegaly who underwent pituitary surgery over a 10-year period. Radiological evaluation was performed using preoperative magnetic resonance imaging (MRI) scans. The surgical approach was determined based on the anatomical considerations and clinical presentation.

Results: The mean age of the patients was 47 years (range: 20-70 years). The majority of patients (84%) presented with typical clinical features of acromegaly, including acral overgrowth, coarse facial features, and gigantism. The acromegalic gland was identified in all patients, with an average size of 3.2 cm x 2.1 cm x 1.8 cm. The gland distribution was anterior in 70% of cases, posterior in 20%, and bilateral in 10%. The surgical approach varied based on the gland's location and size, with transsphenoidal microsurgery being the most common (60%). Postoperative MRI showed complete resection in 90% of cases, with minimal residual disease in the remaining 10%.

Conclusion: This study highlights the anatomical variations of the acromegalic gland and suggests that these variations may influence surgical approaches and outcomes. Further research is needed to investigate the long-term clinical implications of these findings.

Disclosure of Interests: None declared.


DO MOROCCAN PATIENTS DISCUSS WITH THEIR RHEUMATOLOGISTS ABOUT DIET AS PART OF THE MANAGEMENT OF THEIR OSTEARTHRITIS?

N. El Mansouri1, T. Fatima Zahrae1, R. Bensaid1, N. Tahri1, H. Fouzia1, B. Khadj1, F. Abourazzak1
1Tangier, Department of Rheumatology CHU Tangier Tetouan Al Hoceima, Tangier, Morocco

Background: The question of diet is frequently asked by patients with osteoarthritis. Beyond the effect of weight on the worsening of their symptoms, patients often ask whether certain foods, labelled as inflammatory or anti-inflammatory, can improve or worsen their disease.

Objectives: The aim of our study is to find out whether patients with osteoarthritis discuss diet during their medical visits and to investigate the association between patients’ reported dietary beliefs and practices and their willingness to discuss them.

Methods: This is a survey based on a questionnaire that included all patients followed for osteoarthritis who presented to the rheumatology department. The questionnaire consists of 3 parts:

1. Socio-demographic data, co-morbidities, and information on osteoarthritis (location, duration of evolution, functional impact and treatments)
2. Patients’ beliefs and attitudes about diet in relation to osteoarthritis
3. Discussions about diet during medical visits and whether there is any patient interest in such discussions.

Results: In total, we included 120 patients. The average age was 57.1 ± 11.8. 88.3% of the patients were women, 41.2% had comorbidities, 62.5% were illiterate. The median duration of evolution of osteoarthritis was 4 years [2; 7]. 64.2% of the patients were followed for Gonarthrosis, 25% for Discarthrosis and 10.8% for Digital osteoarthritis. The average BMI was 27.8 ± 5.2. 83.3% of the patients thought that diet influenced their osteoarthritis. 9.5% of the subjects stated that food had an effect on their symptoms, with 9.2% reporting an improvement and 8.3% an aggravation. 6.7% of patients reported food avoidance behaviours, while 10.8% adopted certain diets in order to relieve joint symptoms. Only 2.5% of the patients reported having ever had discussions about diet with their rheumatologists while 99.2% showed interest in such discussions. For those who had never done so, the main reason was that the rheumatologist had never broached the subject. In uni and multi-variate analysis, the experience of a food that improves symptoms (OR: 13; 95% CI [1,258-134,333]; p=0.019) and the adoption of dietary practices (OR: 13; 95% CI [1,258-134,333]; p=0.019) were associated with discussing diet.

Conclusion: Discussions about diet are reported by a minority of osteoarthritis patients and seem to be mainly related to patients’ experiences with certain foods that improve their symptomatology and also to patients’ adoption of certain diets. This situation needs to be improved as nutritional advice should be an integral part of the management of our patients.

Disclosure of Interests: None declared.


A PATIENT-REPORTED OUTCOME SCALE: RASQ FOR MEASURING SYMPTOMS OF RHEUMATOID ARTHRITIS

S. Rekik1, Z. Zeineb1, S. Boussaid1, S. Rahmouni1, J. Jemmali1, K. Ksibi1, H. Sahli1, M. Elieuch1
1Rabta University Hospital, Rheumatology, Tunisia, Tunisia

Background: Patient-reported outcome (PRO) instruments are used to assess the patient experience of rheumatoid arthritis (RA) symptoms and impacts and can capture RA treatments effects. Also, there are often discrepancies between patient reported and physician perspectives.

Objectives: The objective of our study was to proceed with a psychometric evaluation of patients with RA using the Rheumatoid Arthritis Symptom Questionnaire (RASQ).

Methods: Adults with clinically confirmed RA, as defined by the ACR/EULAR criteria, were recruited for this cross-sectional study, and then completed the RASQ. Medical records were reviewed, clinical features, studies, and outcomes were analyzed.

Results: In total 28 subjects (82% females) with RA were included. The mean age was 58.5 years (31-79 years). Comorbidities were present in 46.4%, diabetes (25%), thyroid disease (3.7%), and depression (7%). The mean duration of RA diagnosis was 9.8 years. Almost all the patients had at least one of the disease severity criteria, high level of CRP (76%), radiographic erosion (96%), C1-C2 involvement (18%), or hip involvement (14.2%). All of the patients received CsDMARDs and biological therapy. Disease activity evaluated by the DAS28 score was in remission or very low disease activity in 38%, moderate (46%), and high (16%). Functional impact evaluated by the Health Assessment Questionnaire (HAQ) was an average of 1.1 (0.2-3). The RASQ total symptom score was 2 (0-10). The mean of each item was joint pain (5.4), joint warmth (4.3), joint stiffness (4.1), joint tenderness (4.1), joint warmth (4.3), muscle pain (5), joint tenderness (4.5), joint stiffness (6), joint swelling (5.5), joint pain (5.3). The RASQ total symptom score was statistically significantly different (p<0.01) across the DAS28 severity rankings but only the first two single items of the RASQ were not statistically significantly different (p=0.9 and p=1.6). A medium positive correlation was found between subjects’ HAQ score and the total symptom score of the RASQ (r=0.38).

Conclusion: The primary goal of treating patients with RA is to maximize the long-term health-related quality of life. In this order, measurement of all of the signs and symptoms of RA that are significant and relevant to patients living with the disease is important to achieve this main objective.
The effects of a health education programme on patients’ symptoms and lifestyle changes in patients with knee osteoarthritis attending a tertiary care clinic in Sri Lanka

S. Janagan1, R. M. Wickramarachchi2, M. De Silva1. 1National Hospital of Sri Lanka, Rheumatology, Colombo, Sri Lanka

Background: Osteoarthritis is the major cause of joint pain and disability among middle aged and elderly with no disease specific treatment. Management includes analgesics, lifestyle changes and physical therapy.

Objectives: We aimed to study the demographics of the patients and knowledge regarding osteoarthritis among those who attended our clinic with mechanical knee pain and the effects of a health education programme.

Methods: Patients complaining of mechanical knee pain who were found to have examination findings suggestive of knee joint osteoarthritis were enrolled in this study (N=150). Where available diagnosis was confirmed by radiography. Data was collected when they attended a health education programme which focused on lifestyle changes in osteoarthritis including diet and exercise (n=76). An inter-viewer administered questionnaire regarding disease, dietary changes for reduction of weight and exercise was used to obtain data before and 3 months after the health education programme. Anthropometric measurements were taken using validated instruments. Data was analyzed using SPSS software.

Results: Response rate was 50.67 %.The average age of the study population was 54.8 years and constituted of 92.1 % females. About one fifth of them had received only primary school and 50 percent were unemployed. The average BMI was 29.68 (SD-5) and average WOMAC score was 44.1 (SD -19.4). Their knowledge of healthy dietary habits, primarily to lose weight and exercises for knees were assessed before the health education programme and 3 months later.

Table 1.

<table>
<thead>
<tr>
<th>Before health education</th>
<th>3 months after health education</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>76</td>
</tr>
<tr>
<td>BMI (average)</td>
<td>29.68</td>
</tr>
<tr>
<td>Not aware of disease</td>
<td>90%</td>
</tr>
<tr>
<td>Aware of diet to reduce weight</td>
<td>32%</td>
</tr>
<tr>
<td>Aware of exercises</td>
<td>5%</td>
</tr>
<tr>
<td>WOMAC score</td>
<td>44.1</td>
</tr>
</tbody>
</table>

There was no statistically significant correlation between WOMAC score and age, educational level or BMI. Though the knowledge regarding disease and lifestyle changes improved significantly (p< 0.05) following the health education program, there was no significant difference in the WOMAC score.

Conclusion: Health education was seen to improve the knowledge regarding disease and lifestyle measures despite no significant improvement in the pain or disability scores. Further studies are needed to see the long term effects of health education.

REFERENCES:

Disclosure of Interests: None declared

Attitudes towards medications and commonly reported side effects to DMARDs in rheumatoid arthritis patients attending a tertiary care hospital in Sri Lanka

S. Janagan1, M. De Silva1. 1National Hospital of Sri Lanka, Rheumatology, Colombo, Sri Lanka

Background: Rheumatoid arthritis (RA) is a chronic multisystem disease which can be controlled with disease modifying anti-rheumatic drugs (DMARDs). Compliance to treatment can be affected by attitudes to medicines and side effects of drugs.

Objectives: To identify attitudes towards medicines in patients with rheumatoid arthritis and its relationship to disease characteristics and identify the side effect profile of commonly used DMARDs in a Sri lankan population.

Methods: A cross sectional study was carried out on patients attending a rheumatology clinic at National hospital of Sri Lanka between August to November 2018. Patients diagnosed with RA based on standard criteria and on DMARDS for more than 3 months were administered an interviewer administered questionnaire regarding sociodemographic and beliefs about medicines questionnaire (BMQ) assessing patients’ attitudes to the necessity of prescribed medication for controlling their disease and their concerns about potential adverse consequences of taking it. Further questions about commonly reported side effects were also asked. Data was analysed using SPSS software.

Results: 160 patients fulfilled our inclusion criteria and the response rate was 75%. The study population consisted of 84% females with an average age of 52 years. They were predominantly Sinhalese (82 %) with a median duration of disease of 10 years (Interquartile range 1-6-18.4 years). Three fourths of them were seropositive. The mean disease activity (DAS-28) was 4.03 (SD-1.29). Respondents indicated their degree of agreement with each statement in the BMQ on a five-point Likert scale, ranging from 1 = strongly disagree to 5 = strongly agree.

The first ten questions specifically asked regarding arthritis medication.

Table 1.

<table>
<thead>
<tr>
<th>Percentage agreeing or strongly agreeing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Necessity scale</td>
</tr>
<tr>
<td>My health at present depends on my arthritis medication</td>
</tr>
<tr>
<td>My life would be impossible without my arthritis medication</td>
</tr>
<tr>
<td>Without my arthritis medication I would be very ill</td>
</tr>
<tr>
<td>My health in the future will depend on my arthritis medication</td>
</tr>
<tr>
<td>My arthritis medication protects me from becoming worse.</td>
</tr>
<tr>
<td>Concern scale</td>
</tr>
<tr>
<td>Having to take arthritis medication worries me</td>
</tr>
<tr>
<td>I sometimes worry about the long-term effects of my arthritis medication</td>
</tr>
<tr>
<td>My arthritis medication is a mystery to me</td>
</tr>
<tr>
<td>My arthritis medication disrupts my life</td>
</tr>
<tr>
<td>I sometimes worry about becoming too dependent on my arthritis medication</td>
</tr>
</tbody>
</table>

Disclosure of Interests: None declared
The overall necessity scale score (mean 19.2, S.D. 3.21) was higher than the concerns scale score (mean 14.86, S.D. 3.89; P<0.01) but was not statistically significant. The overall necessity scale score was found to be significantly correlated with duration of disease (p<0.05) but not with age, sex, seropositivity or disease activity. 59.2 %, 13.4 %, 8.2 %, 6.1 % of the patients were on monotherapy with Methotrexate. Leflunomide, Sulphasalazine, HCO respectively, 12.8 % were on combination methotrexate and leflunomide and remainder were on biologics. The commonest side effects noted on methotrexate were leucopenia, loss of appetite, raised liver enzymes, oral ulcers, hair loss which were 30 %, 21 %, 8 %, 7 % and 11 % respectively. Patients on leflunomide reported raised BP, raised liver enzymes, loss of appetite and leucopenia in 30 %, 14 %, 8 % and 6 % respectively. Patients on both reported raised liver enzymes, leucopenia, loss of appetite in 78 %, 60 %,11 % respectively. Sulphasalazine caused anaemia, leucopenia and insomnia in 23 %, 17 %, 8 % respectively. HCO caused pigmentation and maculopathy at 17 % and 9 % respectively.

**Conclusion:** Though a positive attitude towards their medication was seen in most patients with rheumatoid arthritis, they had concerns regarding potential long-term effects and dependency. This was found to be significantly correlated to duration of disease. Educating patients about their medication and clarifying misconceptions will improve compliance and disease outcomes. Side effects noted were similar to western population but GI side effects were notably less.

**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.5286

### Building patient led organisations

**AB1582-PARE**

**ASSIGNING A VALUE TO THE ‘PASS’ CONCEPT IN PSORIATIC ARTHRITIS PATIENTS: A SINGLE CENTER DATA.**

R. Reji1, S. K. C.1, S. Joemo C.1, R. R.1, P. Shenoy1, A. J. Mathew2. 1Centre for Arthritis & Rheumatism Excellence, Rheumatology, Ernakulam, India; 2Christian Medical College, Department of Clinical Immunology and Rheumatology, Vellore, India

**Background:** Psoriatic arthritis (PsA), a chronic, heterogeneous disease, needs long-term management. The concept of Patient acceptable symptom state (PASS), evaluated with a dichotomized question on patients' overall satisfaction with their current state of symptoms, represents the overall health state at which patients consider themselves well. Therapeutic compliance improves when the patient's perspective of wellness is recognized while modifying treatment.

**Objectives:** To identify cut-off points for composite disease activity scores (DAS) and patient reported outcomes (PROs) that can reciprocate the PASS status of a patient with PsA.

**Methods:** A cross sectional study was conducted in patients with PsA attending a rheumatology centre in Kerala between March 2020 and Aug 2021. Baseline demographics, clinical characteristics, composite DAS (disease activity index for PsA (DAPSA), clinical (c) DAPSA) and PROs (PsA impact of disease (PsAI), patient pain visual analogue scale (VAS), patient global assessment (PGA), 12-item short-form survey (SF-12)) were compared in patients who responded ‘yes’ and ‘no’ to the ‘PASS’ question. Cut-off values for PASS in composite DAS and PROs were quantified using the Receiver Operator characteristic curve (ROC) curve. Regression models assessed the impact of different variables on the PASS status.

**Results:** From a total of 314 patients, 302 who fulfilled the inclusion, exclusion criteria were chosen for analysis. Of them, 171 (56.62%) patients were males. Mean age (S.D.) and median disease duration (range) were found to be 50.50 ±11.77 years and 8 (4-14) years respectively. Among the study patients, 215 (70.46%) had acceptable PASS status. Median values for composite scores and patient reported characters in patients who accepted their symptoms and in patients who did not accept their symptoms, are represented in Table 1. Cut-off values for patient pain VAS, Pat GA, DAPSA, cDAPSA and PsAI, with the best trade-offs between sensitivity and specificity, were found to be 175, 25, 10.95, 4.75 and 1.95, respectively (Figure 1A and B). Patients with active psoriatic lesions indicated by higher PASS score, presence of nail involvement, and moderate to high disease activity DAPSA value tended not to attain PASS (OR: 0.793; 95% CI: 0.67-0.93, OR: 0.438; 95% CI: 0.22-0.87, OR:0.168; 95% CI: 0.081-0.349).

**Conclusion:** The determined cut-off values for PASS lay in the low disease activity range. A significant number of patients who did not attain PASS, received treatment intensification. Patients with increased PASI, presence of nail dystrophy, and moderate to high disease activity DAPSA value tended to not accept their state.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2022-eular.256

### Table 1. Patient characteristics according to PASS status

<table>
<thead>
<tr>
<th>parameters (median (IQR))</th>
<th>PASS+ve</th>
<th>PASS –ve</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DAPSA</td>
<td>6.7 (3.54-11.10)</td>
<td>13 (7.15-18.85)</td>
<td>0.00</td>
</tr>
<tr>
<td>cDAPSA</td>
<td>3 (1-7)</td>
<td>11 (6-15)</td>
<td>0.00</td>
</tr>
<tr>
<td>HAQ</td>
<td>0 (0-0)</td>
<td>0 (0-1)</td>
<td>0.00</td>
</tr>
<tr>
<td>PsAI</td>
<td>1 (0.5-1.9)</td>
<td>2.55 (1.6-4.3)</td>
<td>0.00</td>
</tr>
<tr>
<td>VAS (0-100)</td>
<td>10 (2-20)</td>
<td>40 (10-50)</td>
<td>0.00</td>
</tr>
<tr>
<td>Pat GA (0-10)</td>
<td>1 (1-2)</td>
<td>3 (2-5)</td>
<td>0.00</td>
</tr>
<tr>
<td>SF12 PCS (physical component score)</td>
<td>49.67 (42.99-54.31)</td>
<td>40.77 (34.58-50.12)</td>
<td>0.00</td>
</tr>
<tr>
<td>SF12 MCS (mental component score)</td>
<td>58.82 (53.96-60.73)</td>
<td>47.16 (39.65-54.83)</td>
<td>0.00</td>
</tr>
<tr>
<td>Physician global assessment (1-10)</td>
<td>1 (0-2)</td>
<td>3 (2-4)</td>
<td>0.00</td>
</tr>
<tr>
<td>PASI</td>
<td>0.30 (0-0.8)</td>
<td>1 (0.2-4.9)</td>
<td>0.00</td>
</tr>
</tbody>
</table>

*p<0.05 is considered as significant*
Arthritis research

QUALITATIVE INTERVIEWS OF SYMPTOMS, IMPACTS AND SELECTED PROMIS SHORT FORMS: A STUDY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS

A. Findley1, J. Middlehurst1, C. Howse1, M. Clifford, W. Neill1, S. Tatlock1, W. H. Chen2, M. Bracher3, D. Patel4, Adelphi Values, Patient-Centred Outcomes, Bollington, United Kingdom; GxalxoSmithKline, Specialty Care, General Medicines & Vaccines, Collegeville, United States of America; "GxalxoSmithKline, Global Value Evidence & Outcomes, Stevenage, United Kingdom; "GxalxoSmithKline, Global Value Evidence & Outcomes, Collegeville, United States of America

Background: Axial spondyloarthritis (axSpA) is characterised by inflammation of the sacroiliac joints and spine. Sleep disturbance, pain and fatigue are reported in the literature to be key symptoms and impacts of axSpA. Three customised Patient-Reported Outcomes Measurement Information System (PROMIS) Short Forms (Sleep Disturbance, Pain Interference and Fatigue) have been developed for use in patients with axSpA to assess the key concepts.

Objectives: To conduct in-depth qualitative interviews to further understand the patient experience of axSpA and evaluate the content validity of the three PROMIS Short Forms to support their use as endpoints in axSpA clinical trials.

Methods: A non-interventional, cross-sectional qualitative (concept elicitation [CE] and cognitive debriefing [CD]) study was conducted in 28 adult patients with diagnosed axSpA. The radio-graphics were conducted as anykylosing spondylitis (AS, n=12), and non-radiographic axSpA (nr-axSpA, n=16). Patients took part in 90-minute telephone interviews. A semi-structured interview guide was used to assist discussions. The CE section used broad, open-ended questions to elicit information about symptoms and impact experienced by patients. The CD section involved a ‘think-aloud’ exercise in which patients read out each instruction, item and response option for the three PROMIS Short Forms and shared their feedback. Patients were also asked detailed questions about the relevance of the items, response options and recall period. Verbatim interview transcripts were subject to thematic and content analysis.

Results: Patients were from the United States (n=20) and Germany (n=8), mean age was 52.8 years, and 57% (n=16) were male; mean time since diagnosis of axSpA was 9.5 years (range 0.3–31.3 years). The CE section identified 12 distinct signs and symptoms that characterised patients’ experience of axSpA: pain, sleep problems, fatigue/tiredness, stiffness, swelling, vision/eye issues, restricted body movements, headache/migraine, spasms, change in posture/stature, balance/coordination problems and numbness. Pain, sleep problems and fatigue/tiredness were all reported to be experienced by ≥90% of patients, occurring simultaneously and exacerbating one another. 78% (n=21/27) of patients reported pain to be the most bothersome symptom, and 88% (n=23/26) described it as the symptom they would most like treatment to improve. Patients reported axSpA to impact their lives across six health-related quality of life (HRQoL) domains: physical functioning (100%), emotional wellbeing (88%), work/volunteering (79%), social functioning (75%), activities of daily living (61%) and cognitive functioning (54%). Impacts were most frequently described as being associated with pain, stiffness and fatigue. The experiences of symptoms and impacts were consistent between the AS and nr-axSpA patients. CD showed all three PROMIS instruments are conceptually comprehensive and well understood by patients with axSpA. No patients reported misunderstanding of instructions and/or items of the sleep disturbance instrument, and only one and four items had a small number of instances of misunderstanding for the fatigue and pain interference instruments, respectively. Across each instrument, all items were relevant to at least half of patients, and almost all patients reported the instruments to be appropriate for measuring their experience of sleep problems, pain and fatigue due to axSpA. Both AS and nr-axSpA patients confirmed the three PROMIS Short Forms to be relevant and appropriate for assessing their disease experience.

Conclusion: Pain, sleep problems and fatigue are pivotal symptoms of axSpA and associated with HRQoL impacts. Interpretability and content validity of the PROMIS customised Short Forms have been confirmed, with each deemed to adequately assess key impacts associated with axSpA, making them suitable for use in clinical trials of patients with axSpA.

Funding: GSK [209770]

Acknowledgements: Medical writing support was provided by Tony Reidon, of Aura, a division of Spirit Medical Communications Group Limited (Manchester, UK), and was funded by GxalxoSmithKline.

Disclosure of Interests: Amy Findley Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, Jessica Middlehurst Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, Chloe Hosew Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, Molly Clifford Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, William Neill Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, Sophi Tatlock Grant/research support from: employee of Adelphi Values, who received fees from GxalxoSmithKline for the conduct of this study, Wen-Hung Chen Shareholder of: GxalxoSmithKline, Employee of: GxalxoSmithKline, Margeaux Bracher Shareholder of: GxalxoSmithKline, Employee of: GxalxoSmithKline, Dharm Patel Shareholder of: GxalxoSmithKline, Employee of: GxalxoSmithKline


UNDERSTANDING HETEROGENEITY IN PATIENTS’ CONCEPTUALIZATION OF TREATMENT FOR RHEUMATOID ARTHRITIS: A CLUSTER ANALYSIS

B. Hsiao1, J. Downs2, M. Langoy3, J. R. Curtis4, S. Blaoc5, C. Wiedmeyer6, S. Venkatachalam5, W. B. Nowell5, L. Fraenkel6,7, Yale-New Haven Medical Center, Rheumatology, New Haven, United States of America; 1University of Alabama at Birmingham, Division of Clinical Immunology & Rheumatology, Birmingham, United States of America; 2University of North Carolina, Chapel Hill, Division of Pharmaceutical Outcomes and Policy, Chapel Hill, United States of America; 3Global Healthy Living Foundation, Patient-Centered Research, Upper Nyack, United States of America; 4Berkshire Medical Center, Rheumatology, Lenox, United States of America; 5Yale University, School of Medicine, New Haven, United States of America

Background: Uptake of treat to target strategies for the management of rheumatoid arthritis (RA) is low. System-related barriers to accessing treatment are known, but poor adherence to starting and continuing treatment are prevalent causes of suboptimal care.

Objectives: To better understand heterogeneity in patients’ conceptualization of RA treatment to inform interventions aimed at improving appropriate utilization of disease modifying antirheumatic drugs (DMARDs).

Methods: Participants (pts) were recruited from the ArthritisPower US online research registry. Pts who met eligibility criteria [physician diagnosed RA currently being treated with DMARD(s)] rated 56 items (coded on 5-point scales) reflecting concepts raised during in-depth patient interviews. To combine similar items for ease of analysis and interpretation, we conducted a principal component analysis using Varimax rotation. We then entered mean scores, weighted by how heavily each item loaded on a cluster, into a k-means cluster analysis. We examined whether demographic characteristics differed across clusters using ANOVA for continuous and chi-square for categorical variables.

Results: Pts (N=621) ranged in age from 22 to 93, with a mean of 57 years (SD=11.5). Most (89%) were female and reported as non-Hispanic white (89%); 27% reported having a post-graduate degree. A score plot revealed that a 4-factor solution explaining 36.8% of the variance would provide desirable interpretability, with a discontinuous drop in eigenvalues for additional factors slowly tapering and adding little discriminability between later solutions. The four factors (% variance explained, number of items) were: 1) Access to high quality care and support (12.10%, n=21); 2) Comfortable adding/switching DMARDs (9.73%, n=14); 3) Perceived favorable DMARD risk/benefit ratio (8.74%, n=15); and 4) Confidence that testing reflects disease activity (6.20%, n=6). A 5-cluster solution showed the most stable convergence of cluster centers after 10 iterations. Figure 1 shows the weighted mean scores for each factor across clusters. The largest group (31.7%) is characterized by mean scores on each of the four factors toward the high end of mean responses for the sample, reflecting positive experiences; we labeled this group “Successfully Engaged in Care” to indicate a positive rheumatologist relationship, feeling well-informed and active participation in care. The next group (24.3%) also had high scores for Factor 1 (access to high quality care/support) and Factor 3 (perceived favorable DMARD risk/benefit ratio), but were less comfortable adding/switching DMARDs (Factor 2) and had less confidence in testing their disease activity (Factor 4); we labeled this group “Worried About Medication” . The three remaining clusters are smaller. The third cluster (16.4%), labeled “Skeptical of Testing,” had a favorable view of DMARDs (Factor 3) despite lower scores related to access and quality of care (Factor 1) and confidence in testing (Factor 4). The fourth cluster (14.3%) expressed low perceived value of DMARDs as well as reduced scores for DMARD risk/benefit and confidence in testing; we labeled this group “Resistant to DMARDs.” The last cluster (13.2%) scored lowest on their rating of access to high quality care and support, indicating less access to, and satisfaction with, information needed to...
about treating to target specific to RA. The survey was made available on tablet devices in 4 rheumatology clinics in the U.S. and Puerto Rico. Clinic staff obtained patient consent and gathered demographic information to generate a unique confidential identifier code for each visit, which was inputted into surveys on tablet devices. After the visit ended the patient and rheumatologist were each given the PPQ coded for that visit to complete independently of one another. The PPQs were submitted electronically to a secure database in which the visit code was the only identifier recorded.

**Results:** Across 114 clinical visits, 96.75% of possible answers were recorded and were almost invariably positive with scores of 5 (strongly agree; 88%), 4 (agree; 12%), or 3 (neither agree nor disagree; 0.09%).Physicians responded with 4 (agree) more often than patients (18% vs 6% of responses). Responses from both patient and physician were available for (96.64%) of answered questions. Within these paired answers, 80.67% were concordant (same answer from both patient and physician). Physicians answered 4 when patients answered 5 in 76.5% of discordant responses (different ratings from patient and physician). Most physician ratings of 4 came from 1 of the 4 physicians involved and only 12.5% of patients were responsible for 75% of the patient responses of 4.

**Conclusion:** Hispanic/Latinx patients with RA and their rheumatologist rated their communication, goal setting, and relationships extremely positively, making it difficult to evaluate true concordance and not possible to use rheumatologist-completed PPQs as proxy for patient assessments. Notably, ratings were substantially different from what is typically seen on Likert scales, which normally skew positively but with a normal distribution. This finding may reflect social determinants of health or cultural differences such as a social-desirability bias toward positive statements about physician-patient interactions. Heterogeneity within the participants is also a plausible explanation, considering that a distinct subset of respondents account for almost all responses below the 5 rating. Further research is needed to identify best practices for measuring treatment to target and patient-rheumatologist interactions in the Hispanic/Latinx population with RA.

**REFERENCES:**


**Acknowledgements:** We wish to acknowledge the important contributions of our HOPE CAPE RA participants, including the patients and providers and Anne Syder, PhD for her invaluable advice and help throughout the project. This project was funded by the Bristol Myers Squibb Foundation.

**Disclosure of Interests:** Daniel Hernandez Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Julio Bravo Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Juan Jose Maya Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Angel Tapia Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Oscar Soto-Raíces Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Guillermo Valenzuela Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, W. Benjamin Nowell Grant/research support from: This research was supported by the Bristol Myers Squibb Foundation, Shilpa Venkatachalam Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation.

**DOI:** 10.1136/annrheumdis-2022-eular.4857

**AB1585-PARE**

**DO PATIENT AND PHYSICIAN ASSESSMENTS OF A HEALTH CARE VISIT MATCH FOR HISPANIC/LATINX PATIENTS WITH RHEUMATOID ARTHRITIS IN THE UNITED STATES AND PUERTO RICO?**

**D. Hernandez1, J. Bravo2, J. J. Maya3, O. Soto-Raíces4, A. Tapia5,**

G. Valenzuela5, W. B. Nowell5, S. Venkatachalam5, Global Healthy Living Foundation, Medical Affairs and Hispanic Outreach, Nyack, United States of America; 6Novartis Health Westbrook, Rheumatology & Arthritis, Winston-Salem, United States of America; 7Rheumatology Center of Palm Beach, PLLC, Lake Worth, United States of America; 8Shilpa Venkat-chalam Mindful Rheumaxtix and Medical Research Group, Rheumatology, San Juan, Puerto Rico; 9Integral Rheumatology and Immunology Specialists, Rheumatology, Plantation, United States of America

**Background:** Nonlinear associations in rheumatoid arthritis (RA) prevalence and sociodemographic indices suggest social determinants of health affect RA.1 RA screening tools have lower sensitivity and specificity for Hispanic/Latinx individuals compared with white individuals (77% vs 85% sensitivity and 45% vs 87% specificity).2 Hispanic/Latinx people also present to physicians later and with more severe RA.3 There is little research in this population to explain these differences or how they can be addressed. Because it is known the Hispanic/Latinx population has lower English-language proficiency, we hypothesized this is in part because of the lack of validated Spanish-language educational materials and research tools for RA.

**Objectives:** To validate a Spanish-language patient-provider questionnaire (PPQ) for Hispanic/Latinx patients with RA that had previously been validated as concordant for primary care visits in Sweden.4 To understand if rheumatologist and patient assessments for Hispanic/Latinx people with RA are concordant when using a Spanish-language digital PPQ. To determine if a Spanish-language rheumatologist-completed PPQ could be a proxy for patient impressions in a prospective clinical study.

**Methods:** A Spanish-language PPQ for RA was created by translating 9 of 13 questions previously validated in the Swedish study,5 and adding a question

**Results:** When using a Spanish-language digital PPQ, determinants of health affect RA.1 Match for Hispanic/Latinx patients with RA and their rheumatologist rated their communication, goal setting, and relationships extremely positively, making it difficult to evaluate true concordance and not possible to use rheumatologist-completed PPQs as proxy for patient assessments. Notably, ratings were substantially different from what is typically seen on Likert scales, which normally skew positively but with a normal distribution. This finding may reflect social determinants of health or cultural differences such as a social-desirability bias toward positive statements about physician-patient interactions. Heterogeneity within the participants is also a plausible explanation, considering that a distinct subset of respondents account for almost all responses below the 5 rating. Further research is needed to identify best practices for measuring treatment to target and patient-rheumatologist interactions in the Hispanic/Latinx population with RA.

**REFERENCES:**


**Acknowledgements:** We wish to acknowledge the important contributions of our HOPE CAPE RA participants, including the patients and providers and Anne Syder, PhD for her invaluable advice and help throughout the project. This project was funded by the Bristol Myers Squibb Foundation.

**Disclosure of Interests:** Daniel Hernandez Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Julio Bravo Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Juan Jose Maya Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Oscar Soto-Raíces Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Angel Tapia Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, Guillermo Valenzuela Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation, W. Benjamin Nowell Grant/research support from: This research was supported by the Bristol Myers Squibb Foundation, Shilpa Venkatachalam Grant/research support from: This project is supported by the Bristol Myers Squibb Foundation.

**DOI:** 10.1136/annrheumdis-2022-eular.4857

**AB1586-PARE**

**MULTI-CENTER, RANDOMIZED, OPEN-LABEL, 2-ARM PARALLEL STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AVT02 ADMINISTERED SUBCUTANEOUSLY VIA PREFILLED SYRINGE OR AUTOINJECTOR IN HEALTHY ADULT VOLUNTEERS**

**C. Wynn1, H. Stroissning2, R. Dias3, J. Sobierska3, E. Guenniz2, H. Otto2, A. Sattar7, H. N. Haldidulo1, E. Edwald1, F. Bert1,**

1New Zealand Clinical Research, Clinical Research, Christchurch, New Zealand; 2Avotect Germany GmbH, Clinical and Medical Affairs, Jülich, Germany; 3Avotech Swiss AG, Clinical and Medical Affairs, Zurich, Switzerland; 4Avotech UK Ltd, Clinical and Medical Affairs, London, United Kingdom; 5Avotech hf, Combination Products & Devices, Reykjavik, Iceland

**Innovations in arthritis health care.**
Background: AVT02 is an investigational biosimilar to adalimumab. It is approved in Europe, Canada, and the UK. It is not approved by the US Food and Drug Administration (FDA).

Methods: This was a Phase 1, randomized, open-label, parallel-group study in which 207 healthy adult subjects were randomized in a 1:1 ratio to receive 100 mg/mL AVT02 either via a pre-filled syringe, or with an autoinjector, stratified by body weight. Subjects received a single subcutaneous 40 mg dose on Day 1. Pharmacokinetics, immunogenicity, local injection site reactions, and adverse events were assessed prior to, and up to 64 days after, study drug administration.

Results: The results observed supported the assessment of pharmacokinetic similarity of investigational AVT02 administered by pre-filled syringe or with an autoinjector. The 90% CIs for the ratios of geometric least square means for the primary pharmacokinetic parameters $C_{\text{max}}$, $AUC_0^\text{inf}$, and $AUC_0^\infty$ were contained within prespecified margins 80% and 125%, based on an analysis of variance model with treatment as a fixed effect. The mean serum concentration-time profile of adalimumab by treatment group is shown in Figure 1.

Figure 1. Mean Serum Concentration-Time Profile of Adalimumab by Treatment Group on Semilogarithmic Scale (Pharmacokinetic Population)

Binding anti-drug antibodies were detectable at the end of study visit on Day 64 in 100% and 97.0% of subjects in the pre-filled syringe administration and the autoinjector groups, respectively. Of those subjects positive for anti-drug antibodies, 85.7% and 86.5% further tested positive for neutralizing antibodies in the pre-filled syringe administration and autoinjector groups, respectively. The frequency of local administration site reactions was 11.8% overall and similar between treatment groups. The most frequently reported treatment-emergent adverse events in both treatment groups were under the SOC: Infections and infestations (56.0% in the AVT02-pre-filled syringe group and 45.2% in the AVT02-autoinjector group). The safety profiles were generally similar between treatment groups.

Conclusion: The results observed supported the assessment of pharmacokinetic similarity between the pre-filled syringe and autoinjector delivery systems after a single subcutaneous 40 mg dose. The autoinjector delivery system was generally well tolerated in healthy subjects, with a safety and immunogenicity profile similar to that observed with 100 mg/mL AVT02 administered using a pre-filled syringe. ClinicalTrials.gov Identifier: NCT03983876

Disclosure of Interests: To evaluate the pharmacokinetic similarity of 100 mg/mL AVT02, an investigational biosimilar of adalimumab, when administered either via a pre-filled syringe, or with a newly developed autoinjector in healthy adult subjects.

Disclosure of Interests: None declared.


Work and rehabilitation

INFLUENCE OF COMPLEX KINESIOThERAPy ON METABOLISM IN CASES OF SARCOPENIC OBESITY

V. Vasileva, L. Marchenkova. National Medical Research Center of Rehabilitation and Balneology, Department of Somatic Rehabilitation, Reproductive Health and Active Longevity, Moscow, Russian Federation

Background: exercise is one of the main factors for the successful treatment of obesity. It is known that with increasing age, muscle strength (sarcopenic obesity) decreases in an obese patient, which can lead to early disability. Regular exercise therapy increases the functional capacity of the metabolism, prevention of obesity among the population, as well as treatment for persons with sarcopenia and obesity. Therefore, it is relevant to study in metabolism obese patients while using kinesiotherapy.

Objectives: aim of the study was to estimate the effect of complex 3-week treatment with 4 kinesiotherapy methods on body weight loss and carbohydrate metabolism in patients with obesity.

Methods: 80 people were enrolled in the study. 40 people in the first group (G1) - 26-69 years old with alimentary obesity (mean age 53.7 ± 11 years, weight 106.8 ± 25 kg, BMI 38.3 ± 7.4 kg/m², waist circumference WC 110.6 ± 16 cm, hip circumference HC 121 ± 15.3 cm). 40 people in the second group (G2) - 21-68 years old with alimentary obesity (mean age 51.3 ± 11 years, weight 112.7 ± 25 kg, BMI 41.8 ± 8.2 kg/m², WC 113.6 ± 16 cm, HC 126.3 ± 15.1 cm). Complex kinesiotherapy administered daily for 3 weeks and included interactive sensorimotor training on double platform, a special complex of physical exercises in the gym and ergocycle trainings. In addition, in 2 gr. patients additionally included kinesiohydrotherapy in a pool. Weight, WC, HC, carbohydrate tolerance test (TT HC), insulin last 3 weeks was measured at baseline and after the treatment was completed. Evaluation of the results were performed at baseline and in 3 weeks.

Results: there was a significant improve in body weight in two groups (110 ± 24 kg at baseline vs 107 ± 22.5 kg in 3 weeks; p = 0.000), BMI (40 ± 8 vs 39 ± 7.6 kg/m²; p = 0.000), WC (112 ± 15.9 vs 108.1 ± 15 cm; p = 0.000), HC (124.3 ± 15.4 vs 119 ± 14 cm; p = 0.000) in treated obese patients. After 3 weeks, we registered statistically significant elevation in insulin levels of G2 vs to G1. With Z = 2.63 in G1, p = 0.003 and Z = 1.96, p = 0.002 in G2, and Z = 2.87 when assessing the significance elevation between G1 and G2, p = 0.023. Significantly improved performance of TT HC in 1 g, Z = 2.02, p = 0.04, in 2 g, Z = 3.004, p = 0.002. When assessing the significance of differences between G1 and G2 after treatment, Z = 2.3, p = 0.017.

Conclusion: Complex treatment with 4 methods of kinesiotherapy helps to reduce body weight, reduce WC, HC, insulin, TT HC in obesity. However, patients who additionally received kinesiohydrotherapy in a pool showed more significant improvements in metabolism.

REFERENCES:


Disclosure of Interests: None declared.

Author Index
Author Index


Author Index
Author Index